diff --git a/exercicios/para-casa/exercicioCrisPereiraS11/MaternalMortality_HealthIndicators.csv b/exercicios/para-casa/exercicioCrisPereiraS11/MaternalMortality_HealthIndicators.csv
new file mode 100644
index 0000000..ce842c3
--- /dev/null
+++ b/exercicios/para-casa/exercicioCrisPereiraS11/MaternalMortality_HealthIndicators.csv
@@ -0,0 +1,34194 @@
+,Country,Year,Indicator:Maternal mortality ratio (per 100 000 live births),Type_of_Medicine,Measure,Total_Sales_Value
+0,Australia,2016,6,B-Blood and blood forming organs,Million of national currency units,667.0
+1,Australia,2016,6,M-Musculo-skeletal system,Million US$ at exchange rate,316.7
+2,Australia,2016,6,M-Musculo-skeletal system,Million of national currency units,426.0
+3,Australia,2016,6,R03-Drugs for obstructive airway diseases,Million of national currency units,629.0
+4,Australia,2016,6,B-Blood and blood forming organs,Million US$ at exchange rate,495.8
+5,Australia,2016,6,B-Blood and blood forming organs,"Million US$, purchasing power parity",460.0
+6,Australia,2016,6,R03-Drugs for obstructive airway diseases,Million US$ at exchange rate,467.6
+7,Australia,2016,6,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million US$ at exchange rate,361.3
+8,Australia,2016,6,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ exchange rate",14.9
+9,Australia,2016,6,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"Million US$, purchasing power parity",335.1
+10,Australia,2016,6,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million of national currency units,486.0
+11,Australia,2016,6,M-Musculo-skeletal system,"/capita, US$ exchange rate",13.1
+12,Australia,2016,6,M-Musculo-skeletal system,"Million US$, purchasing power parity",293.8
+13,Australia,2016,6,M-Musculo-skeletal system,"/capita, US$ purchasing power parity",12.1
+14,Australia,2016,6,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ purchasing power parity",18.1
+15,Australia,2016,6,C09-Agents acting on the Renin-Angiotensin system,% of total sales,4.2
+16,Australia,2016,6,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ exchange rate",19.5
+17,Australia,2016,6,B-Blood and blood forming organs,"/capita, US$ purchasing power parity",19.0
+18,Australia,2016,6,B-Blood and blood forming organs,% of total sales,4.4
+19,Australia,2016,6,B-Blood and blood forming organs,"/capita, US$ exchange rate",20.5
+20,Australia,2016,6,C09-Agents acting on the Renin-Angiotensin system,"Million US$, purchasing power parity",438.6
+21,Australia,2016,6,R03-Drugs for obstructive airway diseases,"/capita, US$ exchange rate",19.3
+22,Australia,2016,6,R03-Drugs for obstructive airway diseases,"/capita, US$ purchasing power parity",17.9
+23,Australia,2016,6,R03-Drugs for obstructive airway diseases,"Million US$, purchasing power parity",433.7
+24,Australia,2016,6,C09-Agents acting on the Renin-Angiotensin system,Million US$ at exchange rate,472.8
+25,Australia,2016,6,R03-Drugs for obstructive airway diseases,% of total sales,4.1
+26,Australia,2016,6,C09-Agents acting on the Renin-Angiotensin system,Million of national currency units,636.0
+27,Australia,2016,6,R-Respiratory system,"Million US$, purchasing power parity",489.6
+28,Australia,2016,6,R-Respiratory system,"/capita, US$ exchange rate",21.8
+29,Australia,2016,6,R-Respiratory system,Million US$ at exchange rate,527.8
+30,Australia,2016,6,C08-Calcium channel blockers,Million of national currency units,133.0
+31,Australia,2016,6,R-Respiratory system,"/capita, US$ purchasing power parity",20.2
+32,Australia,2016,6,R-Respiratory system,% of total sales,4.6
+33,Australia,2016,6,C07-Beta blocking agents,"Million US$, purchasing power parity",105.5
+34,Australia,2016,6,C07-Beta blocking agents,Million US$ at exchange rate,113.7
+35,Australia,2016,6,C07-Beta blocking agents,Million of national currency units,153.0
+36,Australia,2016,6,C07-Beta blocking agents,% of total sales,1.0
+37,Australia,2016,6,R-Respiratory system,Million of national currency units,710.0
+38,Australia,2016,6,C07-Beta blocking agents,"/capita, US$ exchange rate",4.7
+39,Australia,2016,6,C07-Beta blocking agents,"/capita, US$ purchasing power parity",4.4
+40,Australia,2016,6,A-Alimentary tract and metabolism,"/capita, US$ exchange rate",42.5
+41,Australia,2016,6,A-Alimentary tract and metabolism,Million US$ at exchange rate,1028.1
+42,Australia,2016,6,A-Alimentary tract and metabolism,"Million US$, purchasing power parity",953.7
+43,Australia,2016,6,A-Alimentary tract and metabolism,"/capita, US$ purchasing power parity",39.4
+44,Australia,2016,6,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),% of total sales,3.2
+45,Australia,2016,6,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ purchasing power parity",13.9
+46,Australia,2016,6,A-Alimentary tract and metabolism,% of total sales,9.0
+47,Australia,2016,6,C08-Calcium channel blockers,"/capita, US$ exchange rate",4.1
+48,Australia,2016,6,C08-Calcium channel blockers,Million US$ at exchange rate,98.9
+49,Australia,2016,6,C08-Calcium channel blockers,"Million US$, purchasing power parity",91.7
+50,Australia,2016,6,C08-Calcium channel blockers,"/capita, US$ purchasing power parity",3.8
+51,Australia,2016,6,A-Alimentary tract and metabolism,Million of national currency units,1383.0
+52,Australia,2016,6,M-Musculo-skeletal system,% of total sales,2.8
+53,Australia,2016,6,C08-Calcium channel blockers,% of total sales,0.9
+54,Australia,2016,6,A02A-Antacids,% of total sales,0.0
+55,Australia,2016,6,G-Genito urinary system and sex hormones,"/capita, US$ purchasing power parity",10.2
+56,Australia,2016,6,G-Genito urinary system and sex hormones,% of total sales,2.3
+57,Australia,2016,6,A02A-Antacids,"Million US$, purchasing power parity",0.0
+58,Australia,2016,6,A02A-Antacids,Million US$ at exchange rate,0.0
+59,Australia,2016,6,A02A-Antacids,"/capita, US$ purchasing power parity",0.0
+60,Australia,2016,6,A02A-Antacids,"/capita, US$ exchange rate",0.0
+61,Australia,2016,6,J-Antiinfectives for systemic use,Million of national currency units,3422.0
+62,Australia,2016,6,C-Cardiovascular system,Million of national currency units,1860.0
+63,Australia,2016,6,J-Antiinfectives for systemic use,Million US$ at exchange rate,2543.8
+64,Australia,2016,6,G-Genito urinary system and sex hormones,Million of national currency units,359.0
+65,Australia,2016,6,G-Genito urinary system and sex hormones,"Million US$, purchasing power parity",247.6
+66,Australia,2016,6,G-Genito urinary system and sex hormones,"/capita, US$ exchange rate",11.0
+67,Australia,2016,6,G-Genito urinary system and sex hormones,Million US$ at exchange rate,266.9
+68,Australia,2016,6,G03-Sex hormones and modulators of the genital system,"Million US$, purchasing power parity",191.7
+69,Australia,2016,6,G03-Sex hormones and modulators of the genital system,"/capita, US$ exchange rate",8.5
+70,Australia,2016,6,G03-Sex hormones and modulators of the genital system,Million US$ at exchange rate,206.7
+71,Australia,2016,6,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million of national currency units,224.0
+72,Australia,2016,6,G03-Sex hormones and modulators of the genital system,% of total sales,1.8
+73,Australia,2016,6,G03-Sex hormones and modulators of the genital system,"/capita, US$ purchasing power parity",7.9
+74,Australia,2016,6,G03-Sex hormones and modulators of the genital system,Million of national currency units,278.0
+75,Australia,2016,6,"H-Systemic hormonal preparations, excluding sex hormones and insulins",% of total sales,1.5
+76,Australia,2016,6,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ purchasing power parity",6.4
+77,Australia,2016,6,A02A-Antacids,Million of national currency units,0.0
+78,Australia,2016,6,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million US$ at exchange rate,166.5
+79,Australia,2016,6,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ exchange rate",6.9
+80,Australia,2016,6,"H-Systemic hormonal preparations, excluding sex hormones and insulins","Million US$, purchasing power parity",154.5
+81,Australia,2016,6,C10-Lipid modifying agents,"/capita, US$ purchasing power parity",20.2
+82,Australia,2016,6,C10-Lipid modifying agents,"Million US$, purchasing power parity",488.9
+83,Australia,2016,6,C10-Lipid modifying agents,"/capita, US$ exchange rate",21.8
+84,Australia,2016,6,J01-Antibacterials for systemic use,% of total sales,2.6
+85,Australia,2016,6,C10-Lipid modifying agents,% of total sales,4.6
+86,Australia,2016,6,Products not elsewhere classified,% of total sales,28.5
+87,Australia,2016,6,J01-Antibacterials for systemic use,"/capita, US$ purchasing power parity",11.2
+88,Australia,2016,6,Products not elsewhere classified,"Million US$, purchasing power parity",3003.8
+89,Australia,2016,6,Products not elsewhere classified,Million of national currency units,4356.0
+90,Australia,2016,6,Products not elsewhere classified,Million US$ at exchange rate,3238.1
+91,Australia,2016,6,Products not elsewhere classified,"/capita, US$ exchange rate",133.9
+92,Australia,2016,6,C10-Lipid modifying agents,Million of national currency units,709.0
+93,Australia,2016,6,C10-Lipid modifying agents,Million US$ at exchange rate,527.1
+94,Australia,2016,6,Products not elsewhere classified,"/capita, US$ purchasing power parity",124.2
+95,Australia,2016,6,C-Cardiovascular system,% of total sales,12.2
+96,Australia,2016,6,J-Antiinfectives for systemic use,"Million US$, purchasing power parity",2359.7
+97,Australia,2016,6,C-Cardiovascular system,"/capita, US$ purchasing power parity",53.0
+98,Australia,2016,6,C-Cardiovascular system,"Million US$, purchasing power parity",1282.6
+99,Australia,2016,6,C-Cardiovascular system,Million US$ at exchange rate,1382.7
+100,Australia,2016,6,C-Cardiovascular system,"/capita, US$ exchange rate",57.2
+101,Australia,2016,6,J-Antiinfectives for systemic use,"/capita, US$ exchange rate",105.2
+102,Australia,2016,6,J01-Antibacterials for systemic use,"Million US$, purchasing power parity",270.3
+103,Australia,2016,6,J01-Antibacterials for systemic use,Million US$ at exchange rate,291.4
+104,Australia,2016,6,J01-Antibacterials for systemic use,"/capita, US$ exchange rate",12.0
+105,Australia,2016,6,J-Antiinfectives for systemic use,"/capita, US$ purchasing power parity",97.5
+106,Australia,2016,6,J01-Antibacterials for systemic use,Million of national currency units,392.0
+107,Australia,2016,6,J-Antiinfectives for systemic use,% of total sales,22.4
+108,Australia,2016,6,C01A-Cardiac glycosides,"Million US$, purchasing power parity",3.4
+109,Australia,2016,6,C01A-Cardiac glycosides,"/capita, US$ exchange rate",0.2
+110,Australia,2016,6,"C01B-Antiarrhythmics, Class I and III",Million US$ at exchange rate,14.9
+111,Australia,2016,6,"C01B-Antiarrhythmics, Class I and III","Million US$, purchasing power parity",13.8
+112,Australia,2016,6,C01A-Cardiac glycosides,"/capita, US$ purchasing power parity",0.1
+113,Australia,2016,6,"C01B-Antiarrhythmics, Class I and III","/capita, US$ exchange rate",0.6
+114,Australia,2016,6,A10-Drugs used in diabetes,"/capita, US$ purchasing power parity",18.5
+115,Australia,2016,6,C01A-Cardiac glycosides,% of total sales,0.0
+116,Australia,2016,6,C03-Diuretics,Million of national currency units,46.0
+117,Australia,2016,6,C03-Diuretics,Million US$ at exchange rate,34.2
+118,Australia,2016,6,C02-Antihypertensives,"/capita, US$ exchange rate",3.0
+119,Australia,2016,6,C02-Antihypertensives,"/capita, US$ purchasing power parity",2.8
+120,Australia,2016,6,C01A-Cardiac glycosides,Million of national currency units,5.0
+121,Australia,2016,6,C01A-Cardiac glycosides,Million US$ at exchange rate,3.7
+122,Australia,2016,6,"C01B-Antiarrhythmics, Class I and III",Million of national currency units,20.0
+123,Australia,2016,6,C02-Antihypertensives,% of total sales,0.6
+124,Australia,2016,6,A10-Drugs used in diabetes,"/capita, US$ exchange rate",19.9
+125,Australia,2016,6,A10-Drugs used in diabetes,"Million US$, purchasing power parity",446.8
+126,Australia,2016,6,"C01B-Antiarrhythmics, Class I and III","/capita, US$ purchasing power parity",0.6
+127,Australia,2016,6,N-Nervous system,Million US$ at exchange rate,1411.7
+128,Australia,2016,6,N-Nervous system,"Million US$, purchasing power parity",1309.5
+129,Australia,2016,6,N05C-Hypnotics and sedatives,Million US$ at exchange rate,20.8
+130,Australia,2016,6,N05C-Hypnotics and sedatives,Million of national currency units,28.0
+131,Australia,2016,6,N-Nervous system,Million of national currency units,1899.0
+132,Australia,2016,6,N05B-Anxiolytics,% of total sales,0.3
+133,Australia,2016,6,A10-Drugs used in diabetes,% of total sales,4.2
+134,Australia,2016,6,N05B-Anxiolytics,Million of national currency units,45.0
+135,Australia,2016,6,N05B-Anxiolytics,"/capita, US$ purchasing power parity",1.3
+136,Australia,2016,6,N-Nervous system,"/capita, US$ purchasing power parity",54.1
+137,Australia,2016,6,N-Nervous system,"/capita, US$ exchange rate",58.4
+138,Australia,2016,6,N-Nervous system,% of total sales,12.4
+139,Australia,2016,6,"C01B-Antiarrhythmics, Class I and III",% of total sales,0.1
+140,Australia,2016,6,N05C-Hypnotics and sedatives,"/capita, US$ exchange rate",0.9
+141,Australia,2016,6,N05C-Hypnotics and sedatives,"Million US$, purchasing power parity",19.3
+142,Australia,2016,6,N05C-Hypnotics and sedatives,"/capita, US$ purchasing power parity",0.8
+143,Australia,2016,6,N05C-Hypnotics and sedatives,% of total sales,0.2
+144,Australia,2016,6,Total pharmaceutical sales,"/capita, US$ purchasing power parity",436.3
+145,Australia,2016,6,N06A-Antidepressants,Million of national currency units,441.0
+146,Australia,2016,6,Total pharmaceutical sales,"Million US$, purchasing power parity",10554.0
+147,Australia,2016,6,Total pharmaceutical sales,"/capita, US$ exchange rate",470.3
+148,Australia,2016,6,M01A-Antiinflammatory and antirheumatic products non-steroids,"Million US$, purchasing power parity",79.3
+149,Australia,2016,6,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ exchange rate",3.5
+150,Australia,2016,6,M01A-Antiinflammatory and antirheumatic products non-steroids,Million of national currency units,115.0
+151,Australia,2016,6,M01A-Antiinflammatory and antirheumatic products non-steroids,Million US$ at exchange rate,85.5
+152,Australia,2016,6,Total pharmaceutical sales,Million of national currency units,15305.0
+153,Australia,2016,6,Total pharmaceutical sales,Million US$ at exchange rate,11377.4
+154,Australia,2016,6,A10-Drugs used in diabetes,Million of national currency units,648.0
+155,Australia,2016,6,N05B-Anxiolytics,Million US$ at exchange rate,33.5
+156,Australia,2016,6,N06A-Antidepressants,"/capita, US$ exchange rate",13.6
+157,Australia,2016,6,N06A-Antidepressants,"Million US$, purchasing power parity",304.1
+158,Australia,2016,6,N06A-Antidepressants,Million US$ at exchange rate,327.8
+159,Australia,2016,6,N06A-Antidepressants,% of total sales,2.9
+160,Australia,2016,6,N06A-Antidepressants,"/capita, US$ purchasing power parity",12.6
+161,Australia,2016,6,N05B-Anxiolytics,"/capita, US$ exchange rate",1.4
+162,Australia,2016,6,C03-Diuretics,% of total sales,0.3
+163,Australia,2016,6,M01A-Antiinflammatory and antirheumatic products non-steroids,% of total sales,0.8
+164,Australia,2016,6,A10-Drugs used in diabetes,Million US$ at exchange rate,481.7
+165,Australia,2016,6,C03-Diuretics,"/capita, US$ exchange rate",1.4
+166,Australia,2016,6,C03-Diuretics,"Million US$, purchasing power parity",31.7
+167,Australia,2016,6,C03-Diuretics,"/capita, US$ purchasing power parity",1.3
+168,Australia,2016,6,C02-Antihypertensives,Million of national currency units,98.0
+169,Australia,2016,6,N02-Analgesics,"Million US$, purchasing power parity",342.7
+170,Australia,2016,6,N02-Analgesics,"/capita, US$ exchange rate",15.3
+171,Australia,2016,6,N02-Analgesics,Million US$ at exchange rate,369.5
+172,Australia,2016,6,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ purchasing power parity",3.3
+173,Australia,2016,6,N02-Analgesics,Million of national currency units,497.0
+174,Australia,2016,6,C02-Antihypertensives,Million US$ at exchange rate,72.9
+175,Australia,2016,6,C02-Antihypertensives,"Million US$, purchasing power parity",67.6
+176,Australia,2016,6,N05B-Anxiolytics,"Million US$, purchasing power parity",31.0
+177,Australia,2016,6,N02-Analgesics,"/capita, US$ purchasing power parity",14.2
+178,Australia,2016,6,N02-Analgesics,% of total sales,3.2
+179,Australia,2015,6,B-Blood and blood forming organs,Million of national currency units,617.0
+180,Australia,2015,6,M-Musculo-skeletal system,Million of national currency units,401.0
+181,Australia,2015,6,M-Musculo-skeletal system,Million US$ at exchange rate,301.3
+182,Australia,2015,6,R03-Drugs for obstructive airway diseases,Million of national currency units,618.0
+183,Australia,2015,6,R03-Drugs for obstructive airway diseases,Million US$ at exchange rate,464.3
+184,Australia,2015,6,B-Blood and blood forming organs,Million US$ at exchange rate,463.5
+185,Australia,2015,6,B-Blood and blood forming organs,"Million US$, purchasing power parity",418.7
+186,Australia,2015,6,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million US$ at exchange rate,369.6
+187,Australia,2015,6,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"Million US$, purchasing power parity",333.9
+188,Australia,2015,6,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ exchange rate",15.5
+189,Australia,2015,6,M-Musculo-skeletal system,"/capita, US$ exchange rate",12.6
+190,Australia,2015,6,M-Musculo-skeletal system,"Million US$, purchasing power parity",272.1
+191,Australia,2015,6,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million of national currency units,492.0
+192,Australia,2015,6,M-Musculo-skeletal system,"/capita, US$ purchasing power parity",11.4
+193,Australia,2015,6,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ purchasing power parity",19.3
+194,Australia,2015,6,C09-Agents acting on the Renin-Angiotensin system,% of total sales,5.5
+195,Australia,2015,6,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ exchange rate",21.4
+196,Australia,2015,6,B-Blood and blood forming organs,% of total sales,5.0
+197,Australia,2015,6,B-Blood and blood forming organs,"/capita, US$ purchasing power parity",17.6
+198,Australia,2015,6,B-Blood and blood forming organs,"/capita, US$ exchange rate",19.5
+199,Australia,2015,6,C09-Agents acting on the Renin-Angiotensin system,"Million US$, purchasing power parity",460.7
+200,Australia,2015,6,R03-Drugs for obstructive airway diseases,"/capita, US$ exchange rate",19.5
+201,Australia,2015,6,R03-Drugs for obstructive airway diseases,"/capita, US$ purchasing power parity",17.6
+202,Australia,2015,6,R03-Drugs for obstructive airway diseases,"Million US$, purchasing power parity",419.4
+203,Australia,2015,6,C09-Agents acting on the Renin-Angiotensin system,Million US$ at exchange rate,510.1
+204,Australia,2015,6,R03-Drugs for obstructive airway diseases,% of total sales,5.0
+205,Australia,2015,6,C09-Agents acting on the Renin-Angiotensin system,Million of national currency units,679.0
+206,Australia,2015,6,R-Respiratory system,"/capita, US$ exchange rate",22.0
+207,Australia,2015,6,R-Respiratory system,"Million US$, purchasing power parity",473.0
+208,Australia,2015,6,R-Respiratory system,Million US$ at exchange rate,523.6
+209,Australia,2015,6,C08-Calcium channel blockers,Million of national currency units,124.0
+210,Australia,2015,6,R-Respiratory system,"/capita, US$ purchasing power parity",19.9
+211,Australia,2015,6,R-Respiratory system,% of total sales,5.7
+212,Australia,2015,6,C07-Beta blocking agents,"Million US$, purchasing power parity",97.7
+213,Australia,2015,6,C07-Beta blocking agents,Million of national currency units,144.0
+214,Australia,2015,6,C07-Beta blocking agents,Million US$ at exchange rate,108.2
+215,Australia,2015,6,C07-Beta blocking agents,"/capita, US$ exchange rate",4.5
+216,Australia,2015,6,C07-Beta blocking agents,% of total sales,1.2
+217,Australia,2015,6,R-Respiratory system,Million of national currency units,697.0
+218,Australia,2015,6,C07-Beta blocking agents,"/capita, US$ purchasing power parity",4.1
+219,Australia,2015,6,A-Alimentary tract and metabolism,"/capita, US$ exchange rate",42.7
+220,Australia,2015,6,A-Alimentary tract and metabolism,"/capita, US$ purchasing power parity",38.5
+221,Australia,2015,6,A-Alimentary tract and metabolism,Million US$ at exchange rate,1016.5
+222,Australia,2015,6,A-Alimentary tract and metabolism,"Million US$, purchasing power parity",918.1
+223,Australia,2015,6,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),% of total sales,4.0
+224,Australia,2015,6,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ purchasing power parity",14.0
+225,Australia,2015,6,A-Alimentary tract and metabolism,% of total sales,11.0
+226,Australia,2015,6,C08-Calcium channel blockers,"/capita, US$ exchange rate",3.9
+227,Australia,2015,6,C08-Calcium channel blockers,"/capita, US$ purchasing power parity",3.5
+228,Australia,2015,6,C08-Calcium channel blockers,Million US$ at exchange rate,93.2
+229,Australia,2015,6,C08-Calcium channel blockers,"Million US$, purchasing power parity",84.1
+230,Australia,2015,6,A-Alimentary tract and metabolism,Million of national currency units,1353.0
+231,Australia,2015,6,C08-Calcium channel blockers,% of total sales,1.0
+232,Australia,2015,6,A02A-Antacids,% of total sales,0.0
+233,Australia,2015,6,G-Genito urinary system and sex hormones,% of total sales,2.4
+234,Australia,2015,6,G-Genito urinary system and sex hormones,"/capita, US$ purchasing power parity",8.5
+235,Australia,2015,6,A02A-Antacids,"Million US$, purchasing power parity",1.4
+236,Australia,2015,6,A02A-Antacids,"/capita, US$ purchasing power parity",0.1
+237,Australia,2015,6,A02A-Antacids,"/capita, US$ exchange rate",0.1
+238,Australia,2015,6,A02A-Antacids,Million US$ at exchange rate,1.5
+239,Australia,2015,6,J-Antiinfectives for systemic use,Million of national currency units,822.0
+240,Australia,2015,6,C-Cardiovascular system,Million of national currency units,1992.0
+241,Australia,2015,6,J-Antiinfectives for systemic use,Million US$ at exchange rate,617.5
+242,Australia,2015,6,G-Genito urinary system and sex hormones,Million of national currency units,298.0
+243,Australia,2015,6,G-Genito urinary system and sex hormones,"Million US$, purchasing power parity",202.2
+244,Australia,2015,6,G-Genito urinary system and sex hormones,"/capita, US$ exchange rate",9.4
+245,Australia,2015,6,G-Genito urinary system and sex hormones,Million US$ at exchange rate,223.9
+246,Australia,2015,6,G03-Sex hormones and modulators of the genital system,"Million US$, purchasing power parity",149.3
+247,Australia,2015,6,G03-Sex hormones and modulators of the genital system,"/capita, US$ exchange rate",6.9
+248,Australia,2015,6,G03-Sex hormones and modulators of the genital system,Million US$ at exchange rate,165.3
+249,Australia,2015,6,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million of national currency units,191.0
+250,Australia,2015,6,G03-Sex hormones and modulators of the genital system,% of total sales,1.8
+251,Australia,2015,6,G03-Sex hormones and modulators of the genital system,"/capita, US$ purchasing power parity",6.3
+252,Australia,2015,6,G03-Sex hormones and modulators of the genital system,Million of national currency units,220.0
+253,Australia,2015,6,"H-Systemic hormonal preparations, excluding sex hormones and insulins",% of total sales,1.6
+254,Australia,2015,6,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ purchasing power parity",5.4
+255,Australia,2015,6,A02A-Antacids,Million of national currency units,2.0
+256,Australia,2015,6,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million US$ at exchange rate,143.5
+257,Australia,2015,6,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ exchange rate",6.0
+258,Australia,2015,6,"H-Systemic hormonal preparations, excluding sex hormones and insulins","Million US$, purchasing power parity",129.6
+259,Australia,2015,6,C10-Lipid modifying agents,"/capita, US$ purchasing power parity",23.4
+260,Australia,2015,6,C10-Lipid modifying agents,"/capita, US$ exchange rate",25.9
+261,Australia,2015,6,C10-Lipid modifying agents,"Million US$, purchasing power parity",556.4
+262,Australia,2015,6,J01-Antibacterials for systemic use,% of total sales,3.0
+263,Australia,2015,6,C10-Lipid modifying agents,% of total sales,6.7
+264,Australia,2015,6,Products not elsewhere classified,% of total sales,32.5
+265,Australia,2015,6,Products not elsewhere classified,"Million US$, purchasing power parity",2705.5
+266,Australia,2015,6,Products not elsewhere classified,Million of national currency units,3987.0
+267,Australia,2015,6,Products not elsewhere classified,Million US$ at exchange rate,2995.3
+268,Australia,2015,6,Products not elsewhere classified,"/capita, US$ exchange rate",125.8
+269,Australia,2015,6,C10-Lipid modifying agents,Million of national currency units,820.0
+270,Australia,2015,6,C10-Lipid modifying agents,Million US$ at exchange rate,616.0
+271,Australia,2015,6,Products not elsewhere classified,"/capita, US$ purchasing power parity",113.6
+272,Australia,2015,6,J01-Antibacterials for systemic use,"/capita, US$ purchasing power parity",10.3
+273,Australia,2015,6,C-Cardiovascular system,% of total sales,16.2
+274,Australia,2015,6,J-Antiinfectives for systemic use,"Million US$, purchasing power parity",557.8
+275,Australia,2015,6,C-Cardiovascular system,"/capita, US$ purchasing power parity",56.8
+276,Australia,2015,6,C-Cardiovascular system,"Million US$, purchasing power parity",1351.7
+277,Australia,2015,6,C-Cardiovascular system,Million US$ at exchange rate,1496.5
+278,Australia,2015,6,C-Cardiovascular system,"/capita, US$ exchange rate",62.8
+279,Australia,2015,6,J-Antiinfectives for systemic use,"/capita, US$ exchange rate",25.9
+280,Australia,2015,6,J01-Antibacterials for systemic use,"Million US$, purchasing power parity",246.3
+281,Australia,2015,6,J01-Antibacterials for systemic use,Million US$ at exchange rate,272.7
+282,Australia,2015,6,J01-Antibacterials for systemic use,"/capita, US$ exchange rate",11.5
+283,Australia,2015,6,J-Antiinfectives for systemic use,"/capita, US$ purchasing power parity",23.4
+284,Australia,2015,6,J01-Antibacterials for systemic use,Million of national currency units,363.0
+285,Australia,2015,6,J-Antiinfectives for systemic use,% of total sales,6.7
+286,Australia,2015,6,M-Musculo-skeletal system,% of total sales,3.3
+287,Australia,2015,6,C01A-Cardiac glycosides,"/capita, US$ exchange rate",0.2
+288,Australia,2015,6,C01A-Cardiac glycosides,"Million US$, purchasing power parity",3.4
+289,Australia,2015,6,"C01B-Antiarrhythmics, Class I and III",Million US$ at exchange rate,14.3
+290,Australia,2015,6,"C01B-Antiarrhythmics, Class I and III","Million US$, purchasing power parity",12.9
+291,Australia,2015,6,C01A-Cardiac glycosides,"/capita, US$ purchasing power parity",0.1
+292,Australia,2015,6,"C01B-Antiarrhythmics, Class I and III","/capita, US$ exchange rate",0.6
+293,Australia,2015,6,A10-Drugs used in diabetes,"/capita, US$ purchasing power parity",17.6
+294,Australia,2015,6,C01A-Cardiac glycosides,% of total sales,0.0
+295,Australia,2015,6,C03-Diuretics,Million of national currency units,43.0
+296,Australia,2015,6,C03-Diuretics,Million US$ at exchange rate,32.3
+297,Australia,2015,6,A10-Drugs used in diabetes,"/capita, US$ exchange rate",19.5
+298,Australia,2015,6,C02-Antihypertensives,"/capita, US$ exchange rate",2.9
+299,Australia,2015,6,C02-Antihypertensives,"/capita, US$ purchasing power parity",2.6
+300,Australia,2015,6,C01A-Cardiac glycosides,Million US$ at exchange rate,3.8
+301,Australia,2015,6,"C01B-Antiarrhythmics, Class I and III",Million of national currency units,19.0
+302,Australia,2015,6,C01A-Cardiac glycosides,Million of national currency units,5.0
+303,Australia,2015,6,"C01B-Antiarrhythmics, Class I and III","/capita, US$ purchasing power parity",0.5
+304,Australia,2015,6,C02-Antihypertensives,% of total sales,0.7
+305,Australia,2015,6,N-Nervous system,"Million US$, purchasing power parity",1306.9
+306,Australia,2015,6,N-Nervous system,Million US$ at exchange rate,1446.9
+307,Australia,2015,6,N05C-Hypnotics and sedatives,Million US$ at exchange rate,18.0
+308,Australia,2015,6,N05C-Hypnotics and sedatives,Million of national currency units,24.0
+309,Australia,2015,6,N-Nervous system,Million of national currency units,1926.0
+310,Australia,2015,6,N05B-Anxiolytics,% of total sales,0.3
+311,Australia,2015,6,A10-Drugs used in diabetes,% of total sales,5.0
+312,Australia,2015,6,N05B-Anxiolytics,Million of national currency units,39.0
+313,Australia,2015,6,N05B-Anxiolytics,"/capita, US$ purchasing power parity",1.1
+314,Australia,2015,6,N-Nervous system,"/capita, US$ purchasing power parity",54.9
+315,Australia,2015,6,N-Nervous system,% of total sales,15.7
+316,Australia,2015,6,"C01B-Antiarrhythmics, Class I and III",% of total sales,0.2
+317,Australia,2015,6,N-Nervous system,"/capita, US$ exchange rate",60.8
+318,Australia,2015,6,N05C-Hypnotics and sedatives,"/capita, US$ exchange rate",0.8
+319,Australia,2015,6,N05C-Hypnotics and sedatives,"Million US$, purchasing power parity",16.3
+320,Australia,2015,6,N05C-Hypnotics and sedatives,% of total sales,0.2
+321,Australia,2015,6,N05C-Hypnotics and sedatives,"/capita, US$ purchasing power parity",0.7
+322,Australia,2015,6,A10-Drugs used in diabetes,"Million US$, purchasing power parity",418.7
+323,Australia,2015,6,Total pharmaceutical sales,"/capita, US$ purchasing power parity",350.0
+324,Australia,2015,6,N06A-Antidepressants,Million of national currency units,438.0
+325,Australia,2015,6,Total pharmaceutical sales,"Million US$, purchasing power parity",8335.5
+326,Australia,2015,6,Total pharmaceutical sales,"/capita, US$ exchange rate",387.5
+327,Australia,2015,6,M01A-Antiinflammatory and antirheumatic products non-steroids,"Million US$, purchasing power parity",80.7
+328,Australia,2015,6,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ exchange rate",3.8
+329,Australia,2015,6,M01A-Antiinflammatory and antirheumatic products non-steroids,Million of national currency units,119.0
+330,Australia,2015,6,M01A-Antiinflammatory and antirheumatic products non-steroids,Million US$ at exchange rate,89.4
+331,Australia,2015,6,N06A-Antidepressants,Million US$ at exchange rate,329.1
+332,Australia,2015,6,N05B-Anxiolytics,"Million US$, purchasing power parity",26.5
+333,Australia,2015,6,Total pharmaceutical sales,Million of national currency units,12284.0
+334,Australia,2015,6,Total pharmaceutical sales,Million US$ at exchange rate,9228.5
+335,Australia,2015,6,A10-Drugs used in diabetes,Million of national currency units,617.0
+336,Australia,2015,6,N05B-Anxiolytics,Million US$ at exchange rate,29.3
+337,Australia,2015,6,N06A-Antidepressants,"/capita, US$ exchange rate",13.8
+338,Australia,2015,6,N06A-Antidepressants,"Million US$, purchasing power parity",297.2
+339,Australia,2015,6,N06A-Antidepressants,% of total sales,3.6
+340,Australia,2015,6,N06A-Antidepressants,"/capita, US$ purchasing power parity",12.5
+341,Australia,2015,6,C03-Diuretics,% of total sales,0.4
+342,Australia,2015,6,N05B-Anxiolytics,"/capita, US$ exchange rate",1.2
+343,Australia,2015,6,M01A-Antiinflammatory and antirheumatic products non-steroids,% of total sales,1.0
+344,Australia,2015,6,C03-Diuretics,"/capita, US$ purchasing power parity",1.2
+345,Australia,2015,6,A10-Drugs used in diabetes,Million US$ at exchange rate,463.5
+346,Australia,2015,6,C03-Diuretics,"Million US$, purchasing power parity",29.2
+347,Australia,2015,6,C03-Diuretics,"/capita, US$ exchange rate",1.4
+348,Australia,2015,6,N02-Analgesics,"Million US$, purchasing power parity",375.9
+349,Australia,2015,6,C02-Antihypertensives,Million of national currency units,91.0
+350,Australia,2015,6,N02-Analgesics,"/capita, US$ exchange rate",17.5
+351,Australia,2015,6,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ purchasing power parity",3.4
+352,Australia,2015,6,N02-Analgesics,Million of national currency units,554.0
+353,Australia,2015,6,N02-Analgesics,Million US$ at exchange rate,416.2
+354,Australia,2015,6,C02-Antihypertensives,"Million US$, purchasing power parity",61.7
+355,Australia,2015,6,C02-Antihypertensives,Million US$ at exchange rate,68.4
+356,Australia,2015,6,N02-Analgesics,"/capita, US$ purchasing power parity",15.8
+357,Australia,2015,6,N02-Analgesics,% of total sales,4.5
+358,Australia,2014,6,M-Musculo-skeletal system,Million of national currency units,383.0
+359,Australia,2014,6,B-Blood and blood forming organs,Million of national currency units,545.0
+360,Australia,2014,6,M-Musculo-skeletal system,Million US$ at exchange rate,345.2
+361,Australia,2014,6,R03-Drugs for obstructive airway diseases,Million of national currency units,634.0
+362,Australia,2014,6,R03-Drugs for obstructive airway diseases,Million US$ at exchange rate,571.5
+363,Australia,2014,6,B-Blood and blood forming organs,Million US$ at exchange rate,491.3
+364,Australia,2014,6,B-Blood and blood forming organs,"Million US$, purchasing power parity",375.2
+365,Australia,2014,6,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million US$ at exchange rate,479.6
+366,Australia,2014,6,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ exchange rate",20.4
+367,Australia,2014,6,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"Million US$, purchasing power parity",366.3
+368,Australia,2014,6,M-Musculo-skeletal system,"/capita, US$ exchange rate",14.7
+369,Australia,2014,6,M-Musculo-skeletal system,"Million US$, purchasing power parity",263.7
+370,Australia,2014,6,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million of national currency units,532.0
+371,Australia,2014,6,M-Musculo-skeletal system,"/capita, US$ purchasing power parity",11.2
+372,Australia,2014,6,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ purchasing power parity",20.7
+373,Australia,2014,6,C09-Agents acting on the Renin-Angiotensin system,% of total sales,5.9
+374,Australia,2014,6,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ exchange rate",27.1
+375,Australia,2014,6,B-Blood and blood forming organs,% of total sales,4.6
+376,Australia,2014,6,B-Blood and blood forming organs,"/capita, US$ purchasing power parity",16.0
+377,Australia,2014,6,B-Blood and blood forming organs,"/capita, US$ exchange rate",20.9
+378,Australia,2014,6,R03-Drugs for obstructive airway diseases,"/capita, US$ purchasing power parity",18.6
+379,Australia,2014,6,R03-Drugs for obstructive airway diseases,"/capita, US$ exchange rate",24.3
+380,Australia,2014,6,R03-Drugs for obstructive airway diseases,"Million US$, purchasing power parity",436.5
+381,Australia,2014,6,C09-Agents acting on the Renin-Angiotensin system,Million US$ at exchange rate,636.4
+382,Australia,2014,6,R03-Drugs for obstructive airway diseases,% of total sales,5.3
+383,Australia,2014,6,C09-Agents acting on the Renin-Angiotensin system,Million of national currency units,706.0
+384,Australia,2014,6,C09-Agents acting on the Renin-Angiotensin system,"Million US$, purchasing power parity",486.1
+385,Australia,2014,6,R-Respiratory system,"/capita, US$ exchange rate",25.3
+386,Australia,2014,6,R-Respiratory system,Million US$ at exchange rate,594.0
+387,Australia,2014,6,R-Respiratory system,"Million US$, purchasing power parity",453.7
+388,Australia,2014,6,C08-Calcium channel blockers,Million of national currency units,119.0
+389,Australia,2014,6,R-Respiratory system,"/capita, US$ purchasing power parity",19.3
+390,Australia,2014,6,R-Respiratory system,% of total sales,5.5
+391,Australia,2014,6,C07-Beta blocking agents,"Million US$, purchasing power parity",97.8
+392,Australia,2014,6,C07-Beta blocking agents,Million of national currency units,142.0
+393,Australia,2014,6,C07-Beta blocking agents,Million US$ at exchange rate,128.0
+394,Australia,2014,6,C07-Beta blocking agents,"/capita, US$ exchange rate",5.5
+395,Australia,2014,6,C07-Beta blocking agents,% of total sales,1.2
+396,Australia,2014,6,R-Respiratory system,Million of national currency units,659.0
+397,Australia,2014,6,C07-Beta blocking agents,"/capita, US$ purchasing power parity",4.2
+398,Australia,2014,6,C08-Calcium channel blockers,Million US$ at exchange rate,107.3
+399,Australia,2014,6,A-Alimentary tract and metabolism,"/capita, US$ exchange rate",51.9
+400,Australia,2014,6,A-Alimentary tract and metabolism,"/capita, US$ purchasing power parity",39.6
+401,Australia,2014,6,A-Alimentary tract and metabolism,"Million US$, purchasing power parity",930.1
+402,Australia,2014,6,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),% of total sales,4.5
+403,Australia,2014,6,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ purchasing power parity",15.6
+404,Australia,2014,6,A-Alimentary tract and metabolism,% of total sales,11.4
+405,Australia,2014,6,A-Alimentary tract and metabolism,Million US$ at exchange rate,1217.8
+406,Australia,2014,6,C08-Calcium channel blockers,"/capita, US$ exchange rate",4.6
+407,Australia,2014,6,C08-Calcium channel blockers,"/capita, US$ purchasing power parity",3.5
+408,Australia,2014,6,C08-Calcium channel blockers,"Million US$, purchasing power parity",81.9
+409,Australia,2014,6,A-Alimentary tract and metabolism,Million of national currency units,1351.0
+410,Australia,2014,6,M-Musculo-skeletal system,% of total sales,3.2
+411,Australia,2014,6,C08-Calcium channel blockers,% of total sales,1.0
+412,Australia,2014,6,A02A-Antacids,% of total sales,0.0
+413,Australia,2014,6,G-Genito urinary system and sex hormones,"/capita, US$ purchasing power parity",7.0
+414,Australia,2014,6,G-Genito urinary system and sex hormones,% of total sales,2.0
+415,Australia,2014,6,A02A-Antacids,"Million US$, purchasing power parity",0.7
+416,Australia,2014,6,A02A-Antacids,"/capita, US$ purchasing power parity",0.0
+417,Australia,2014,6,A02A-Antacids,"/capita, US$ exchange rate",0.0
+418,Australia,2014,6,J-Antiinfectives for systemic use,Million of national currency units,801.0
+419,Australia,2014,6,G-Genito urinary system and sex hormones,Million of national currency units,240.0
+420,Australia,2014,6,C-Cardiovascular system,Million of national currency units,2200.0
+421,Australia,2014,6,J-Antiinfectives for systemic use,Million US$ at exchange rate,722.0
+422,Australia,2014,6,G-Genito urinary system and sex hormones,"Million US$, purchasing power parity",165.2
+423,Australia,2014,6,G-Genito urinary system and sex hormones,"/capita, US$ exchange rate",9.2
+424,Australia,2014,6,G-Genito urinary system and sex hormones,Million US$ at exchange rate,216.3
+425,Australia,2014,6,A02A-Antacids,Million US$ at exchange rate,0.9
+426,Australia,2014,6,G03-Sex hormones and modulators of the genital system,"Million US$, purchasing power parity",115.0
+427,Australia,2014,6,G03-Sex hormones and modulators of the genital system,"/capita, US$ exchange rate",6.4
+428,Australia,2014,6,G03-Sex hormones and modulators of the genital system,Million US$ at exchange rate,150.5
+429,Australia,2014,6,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million of national currency units,168.0
+430,Australia,2014,6,G03-Sex hormones and modulators of the genital system,% of total sales,1.4
+431,Australia,2014,6,G03-Sex hormones and modulators of the genital system,"/capita, US$ purchasing power parity",4.9
+432,Australia,2014,6,"H-Systemic hormonal preparations, excluding sex hormones and insulins",% of total sales,1.4
+433,Australia,2014,6,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ purchasing power parity",4.9
+434,Australia,2014,6,A02A-Antacids,Million of national currency units,1.0
+435,Australia,2014,6,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million US$ at exchange rate,151.4
+436,Australia,2014,6,"H-Systemic hormonal preparations, excluding sex hormones and insulins","Million US$, purchasing power parity",115.7
+437,Australia,2014,6,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ exchange rate",6.5
+438,Australia,2014,6,G03-Sex hormones and modulators of the genital system,Million of national currency units,167.0
+439,Australia,2014,6,C10-Lipid modifying agents,"/capita, US$ purchasing power parity",30.1
+440,Australia,2014,6,C10-Lipid modifying agents,"Million US$, purchasing power parity",707.8
+441,Australia,2014,6,C10-Lipid modifying agents,"/capita, US$ exchange rate",39.5
+442,Australia,2014,6,C10-Lipid modifying agents,% of total sales,8.6
+443,Australia,2014,6,J01-Antibacterials for systemic use,% of total sales,2.7
+444,Australia,2014,6,Products not elsewhere classified,% of total sales,30.4
+445,Australia,2014,6,Products not elsewhere classified,"Million US$, purchasing power parity",2489.5
+446,Australia,2014,6,Products not elsewhere classified,Million of national currency units,3616.0
+447,Australia,2014,6,Products not elsewhere classified,Million US$ at exchange rate,3259.5
+448,Australia,2014,6,Products not elsewhere classified,"/capita, US$ exchange rate",138.8
+449,Australia,2014,6,C10-Lipid modifying agents,Million of national currency units,1028.0
+450,Australia,2014,6,C10-Lipid modifying agents,Million US$ at exchange rate,926.7
+451,Australia,2014,6,Products not elsewhere classified,"/capita, US$ purchasing power parity",106.0
+452,Australia,2014,6,J01-Antibacterials for systemic use,"/capita, US$ purchasing power parity",9.4
+453,Australia,2014,6,C-Cardiovascular system,% of total sales,18.5
+454,Australia,2014,6,J-Antiinfectives for systemic use,"/capita, US$ exchange rate",30.8
+455,Australia,2014,6,J-Antiinfectives for systemic use,"Million US$, purchasing power parity",551.5
+456,Australia,2014,6,C-Cardiovascular system,"Million US$, purchasing power parity",1514.6
+457,Australia,2014,6,C-Cardiovascular system,Million US$ at exchange rate,1983.1
+458,Australia,2014,6,C-Cardiovascular system,"/capita, US$ purchasing power parity",64.5
+459,Australia,2014,6,C-Cardiovascular system,"/capita, US$ exchange rate",84.5
+460,Australia,2014,6,J01-Antibacterials for systemic use,"Million US$, purchasing power parity",220.3
+461,Australia,2014,6,J01-Antibacterials for systemic use,Million US$ at exchange rate,288.5
+462,Australia,2014,6,J01-Antibacterials for systemic use,"/capita, US$ exchange rate",12.3
+463,Australia,2014,6,J-Antiinfectives for systemic use,"/capita, US$ purchasing power parity",23.5
+464,Australia,2014,6,J-Antiinfectives for systemic use,% of total sales,6.7
+465,Australia,2014,6,J01-Antibacterials for systemic use,Million of national currency units,320.0
+466,Australia,2014,6,C01A-Cardiac glycosides,"/capita, US$ exchange rate",0.2
+467,Australia,2014,6,C01A-Cardiac glycosides,"/capita, US$ purchasing power parity",0.1
+468,Australia,2014,6,C01A-Cardiac glycosides,"Million US$, purchasing power parity",2.8
+469,Australia,2014,6,"C01B-Antiarrhythmics, Class I and III",Million US$ at exchange rate,17.1
+470,Australia,2014,6,"C01B-Antiarrhythmics, Class I and III","Million US$, purchasing power parity",13.1
+471,Australia,2014,6,"C01B-Antiarrhythmics, Class I and III","/capita, US$ exchange rate",0.7
+472,Australia,2014,6,"C01B-Antiarrhythmics, Class I and III","/capita, US$ purchasing power parity",0.6
+473,Australia,2014,6,A10-Drugs used in diabetes,"/capita, US$ purchasing power parity",17.3
+474,Australia,2014,6,C01A-Cardiac glycosides,% of total sales,0.0
+475,Australia,2014,6,C03-Diuretics,Million US$ at exchange rate,34.3
+476,Australia,2014,6,C03-Diuretics,Million of national currency units,38.0
+477,Australia,2014,6,A10-Drugs used in diabetes,"/capita, US$ exchange rate",22.6
+478,Australia,2014,6,C02-Antihypertensives,"/capita, US$ exchange rate",3.2
+479,Australia,2014,6,C02-Antihypertensives,"/capita, US$ purchasing power parity",2.4
+480,Australia,2014,6,C01A-Cardiac glycosides,Million US$ at exchange rate,3.6
+481,Australia,2014,6,"C01B-Antiarrhythmics, Class I and III",Million of national currency units,19.0
+482,Australia,2014,6,C01A-Cardiac glycosides,Million of national currency units,4.0
+483,Australia,2014,6,C02-Antihypertensives,% of total sales,0.7
+484,Australia,2014,6,N-Nervous system,"Million US$, purchasing power parity",1324.6
+485,Australia,2014,6,N-Nervous system,Million US$ at exchange rate,1734.3
+486,Australia,2014,6,N05C-Hypnotics and sedatives,Million US$ at exchange rate,18.9
+487,Australia,2014,6,N05C-Hypnotics and sedatives,Million of national currency units,21.0
+488,Australia,2014,6,N05B-Anxiolytics,% of total sales,0.3
+489,Australia,2014,6,A10-Drugs used in diabetes,% of total sales,5.0
+490,Australia,2014,6,N05B-Anxiolytics,Million of national currency units,33.0
+491,Australia,2014,6,N05B-Anxiolytics,"/capita, US$ purchasing power parity",1.0
+492,Australia,2014,6,N-Nervous system,Million of national currency units,1924.0
+493,Australia,2014,6,N-Nervous system,% of total sales,16.2
+494,Australia,2014,6,N-Nervous system,"/capita, US$ purchasing power parity",56.4
+495,Australia,2014,6,"C01B-Antiarrhythmics, Class I and III",% of total sales,0.2
+496,Australia,2014,6,N-Nervous system,"/capita, US$ exchange rate",73.9
+497,Australia,2014,6,N05C-Hypnotics and sedatives,"/capita, US$ exchange rate",0.8
+498,Australia,2014,6,N05C-Hypnotics and sedatives,"Million US$, purchasing power parity",14.5
+499,Australia,2014,6,N05C-Hypnotics and sedatives,"/capita, US$ purchasing power parity",0.6
+500,Australia,2014,6,N05C-Hypnotics and sedatives,% of total sales,0.2
+501,Australia,2014,6,Total pharmaceutical sales,"/capita, US$ purchasing power parity",348.6
+502,Australia,2014,6,Total pharmaceutical sales,"Million US$, purchasing power parity",8184.6
+503,Australia,2014,6,Total pharmaceutical sales,"/capita, US$ exchange rate",456.5
+504,Australia,2014,6,N06A-Antidepressants,Million of national currency units,464.0
+505,Australia,2014,6,M01A-Antiinflammatory and antirheumatic products non-steroids,"Million US$, purchasing power parity",84.0
+506,Australia,2014,6,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ exchange rate",4.7
+507,Australia,2014,6,A10-Drugs used in diabetes,"Million US$, purchasing power parity",405.5
+508,Australia,2014,6,N06A-Antidepressants,Million US$ at exchange rate,418.3
+509,Australia,2014,6,M01A-Antiinflammatory and antirheumatic products non-steroids,Million of national currency units,122.0
+510,Australia,2014,6,M01A-Antiinflammatory and antirheumatic products non-steroids,Million US$ at exchange rate,110.0
+511,Australia,2014,6,Total pharmaceutical sales,Million of national currency units,11888.0
+512,Australia,2014,6,N05B-Anxiolytics,"Million US$, purchasing power parity",22.7
+513,Australia,2014,6,Total pharmaceutical sales,Million US$ at exchange rate,10716.1
+514,Australia,2014,6,A10-Drugs used in diabetes,Million of national currency units,589.0
+515,Australia,2014,6,N05B-Anxiolytics,Million US$ at exchange rate,29.7
+516,Australia,2014,6,N06A-Antidepressants,"/capita, US$ exchange rate",17.8
+517,Australia,2014,6,N06A-Antidepressants,"Million US$, purchasing power parity",319.5
+518,Australia,2014,6,N06A-Antidepressants,% of total sales,3.9
+519,Australia,2014,6,N06A-Antidepressants,"/capita, US$ purchasing power parity",13.6
+520,Australia,2014,6,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ purchasing power parity",3.6
+521,Australia,2014,6,C03-Diuretics,% of total sales,0.3
+522,Australia,2014,6,N05B-Anxiolytics,"/capita, US$ exchange rate",1.3
+523,Australia,2014,6,M01A-Antiinflammatory and antirheumatic products non-steroids,% of total sales,1.0
+524,Australia,2014,6,A10-Drugs used in diabetes,Million US$ at exchange rate,530.9
+525,Australia,2014,6,C03-Diuretics,"Million US$, purchasing power parity",26.2
+526,Australia,2014,6,C03-Diuretics,"/capita, US$ purchasing power parity",1.1
+527,Australia,2014,6,C03-Diuretics,"/capita, US$ exchange rate",1.5
+528,Australia,2014,6,C02-Antihypertensives,Million of national currency units,83.0
+529,Australia,2014,6,N02-Analgesics,"Million US$, purchasing power parity",355.3
+530,Australia,2014,6,N02-Analgesics,Million of national currency units,516.0
+531,Australia,2014,6,N02-Analgesics,Million US$ at exchange rate,465.1
+532,Australia,2014,6,N02-Analgesics,"/capita, US$ exchange rate",19.8
+533,Australia,2014,6,C02-Antihypertensives,"Million US$, purchasing power parity",57.1
+534,Australia,2014,6,C02-Antihypertensives,Million US$ at exchange rate,74.8
+535,Australia,2014,6,N02-Analgesics,"/capita, US$ purchasing power parity",15.1
+536,Australia,2014,6,N02-Analgesics,% of total sales,4.3
+537,Australia,2013,6,M-Musculo-skeletal system,Million of national currency units,378.0
+538,Australia,2013,6,B-Blood and blood forming organs,Million of national currency units,481.0
+539,Australia,2013,6,M-Musculo-skeletal system,Million US$ at exchange rate,364.9
+540,Australia,2013,6,B-Blood and blood forming organs,Million US$ at exchange rate,464.4
+541,Australia,2013,6,R03-Drugs for obstructive airway diseases,Million of national currency units,617.0
+542,Australia,2013,6,R03-Drugs for obstructive airway diseases,Million US$ at exchange rate,595.7
+543,Australia,2013,6,B-Blood and blood forming organs,"Million US$, purchasing power parity",332.4
+544,Australia,2013,6,M-Musculo-skeletal system,"Million US$, purchasing power parity",261.2
+545,Australia,2013,6,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million US$ at exchange rate,568.6
+546,Australia,2013,6,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"Million US$, purchasing power parity",407.0
+547,Australia,2013,6,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ exchange rate",24.6
+548,Australia,2013,6,M-Musculo-skeletal system,"/capita, US$ exchange rate",15.8
+549,Australia,2013,6,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million of national currency units,589.0
+550,Australia,2013,6,M-Musculo-skeletal system,"/capita, US$ purchasing power parity",11.3
+551,Australia,2013,6,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ purchasing power parity",22.1
+552,Australia,2013,6,C09-Agents acting on the Renin-Angiotensin system,% of total sales,6.3
+553,Australia,2013,6,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ exchange rate",30.9
+554,Australia,2013,6,B-Blood and blood forming organs,% of total sales,4.1
+555,Australia,2013,6,B-Blood and blood forming organs,"/capita, US$ purchasing power parity",14.4
+556,Australia,2013,6,B-Blood and blood forming organs,"/capita, US$ exchange rate",20.1
+557,Australia,2013,6,C09-Agents acting on the Renin-Angiotensin system,"Million US$, purchasing power parity",511.4
+558,Australia,2013,6,R03-Drugs for obstructive airway diseases,"/capita, US$ purchasing power parity",18.4
+559,Australia,2013,6,R03-Drugs for obstructive airway diseases,"Million US$, purchasing power parity",426.4
+560,Australia,2013,6,R03-Drugs for obstructive airway diseases,"/capita, US$ exchange rate",25.8
+561,Australia,2013,6,C09-Agents acting on the Renin-Angiotensin system,Million US$ at exchange rate,714.4
+562,Australia,2013,6,R03-Drugs for obstructive airway diseases,% of total sales,5.2
+563,Australia,2013,6,C09-Agents acting on the Renin-Angiotensin system,Million of national currency units,740.0
+564,Australia,2013,6,R-Respiratory system,"/capita, US$ exchange rate",26.6
+565,Australia,2013,6,R-Respiratory system,"Million US$, purchasing power parity",440.9
+566,Australia,2013,6,R-Respiratory system,Million US$ at exchange rate,615.9
+567,Australia,2013,6,C08-Calcium channel blockers,Million of national currency units,131.0
+568,Australia,2013,6,R-Respiratory system,"/capita, US$ purchasing power parity",19.1
+569,Australia,2013,6,R-Respiratory system,% of total sales,5.4
+570,Australia,2013,6,C07-Beta blocking agents,"Million US$, purchasing power parity",104.3
+571,Australia,2013,6,C07-Beta blocking agents,Million of national currency units,151.0
+572,Australia,2013,6,C07-Beta blocking agents,Million US$ at exchange rate,145.8
+573,Australia,2013,6,C07-Beta blocking agents,"/capita, US$ exchange rate",6.3
+574,Australia,2013,6,C07-Beta blocking agents,% of total sales,1.3
+575,Australia,2013,6,R-Respiratory system,Million of national currency units,638.0
+576,Australia,2013,6,C07-Beta blocking agents,"/capita, US$ purchasing power parity",4.5
+577,Australia,2013,6,A-Alimentary tract and metabolism,"/capita, US$ exchange rate",58.4
+578,Australia,2013,6,A-Alimentary tract and metabolism,"/capita, US$ purchasing power parity",41.8
+579,Australia,2013,6,A-Alimentary tract and metabolism,"Million US$, purchasing power parity",966.7
+580,Australia,2013,6,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),% of total sales,5.0
+581,Australia,2013,6,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ purchasing power parity",17.6
+582,Australia,2013,6,A-Alimentary tract and metabolism,% of total sales,11.8
+583,Australia,2013,6,C08-Calcium channel blockers,Million US$ at exchange rate,126.5
+584,Australia,2013,6,A-Alimentary tract and metabolism,Million US$ at exchange rate,1350.6
+585,Australia,2013,6,C08-Calcium channel blockers,"/capita, US$ exchange rate",5.5
+586,Australia,2013,6,C08-Calcium channel blockers,"/capita, US$ purchasing power parity",3.9
+587,Australia,2013,6,C08-Calcium channel blockers,"Million US$, purchasing power parity",90.5
+588,Australia,2013,6,A-Alimentary tract and metabolism,Million of national currency units,1399.0
+589,Australia,2013,6,M-Musculo-skeletal system,% of total sales,3.2
+590,Australia,2013,6,C08-Calcium channel blockers,% of total sales,1.1
+591,Australia,2013,6,A02A-Antacids,% of total sales,0.0
+592,Australia,2013,6,G-Genito urinary system and sex hormones,"/capita, US$ purchasing power parity",6.7
+593,Australia,2013,6,G-Genito urinary system and sex hormones,% of total sales,1.9
+594,Australia,2013,6,A02A-Antacids,"Million US$, purchasing power parity",1.4
+595,Australia,2013,6,A02A-Antacids,"/capita, US$ purchasing power parity",0.1
+596,Australia,2013,6,A02A-Antacids,"/capita, US$ exchange rate",0.1
+597,Australia,2013,6,G-Genito urinary system and sex hormones,Million of national currency units,225.0
+598,Australia,2013,6,J-Antiinfectives for systemic use,Million of national currency units,790.0
+599,Australia,2013,6,J-Antiinfectives for systemic use,Million US$ at exchange rate,762.7
+600,Australia,2013,6,C-Cardiovascular system,Million of national currency units,2516.0
+601,Australia,2013,6,G-Genito urinary system and sex hormones,"/capita, US$ exchange rate",9.4
+602,Australia,2013,6,G-Genito urinary system and sex hormones,"Million US$, purchasing power parity",155.5
+603,Australia,2013,6,G-Genito urinary system and sex hormones,Million US$ at exchange rate,217.2
+604,Australia,2013,6,G03-Sex hormones and modulators of the genital system,"Million US$, purchasing power parity",110.6
+605,Australia,2013,6,G03-Sex hormones and modulators of the genital system,"/capita, US$ exchange rate",6.7
+606,Australia,2013,6,G03-Sex hormones and modulators of the genital system,Million US$ at exchange rate,154.5
+607,Australia,2013,6,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million of national currency units,156.0
+608,Australia,2013,6,G03-Sex hormones and modulators of the genital system,"/capita, US$ purchasing power parity",4.8
+609,Australia,2013,6,G03-Sex hormones and modulators of the genital system,% of total sales,1.4
+610,Australia,2013,6,A02A-Antacids,Million US$ at exchange rate,1.9
+611,Australia,2013,6,G03-Sex hormones and modulators of the genital system,Million of national currency units,160.0
+612,Australia,2013,6,"H-Systemic hormonal preparations, excluding sex hormones and insulins",% of total sales,1.3
+613,Australia,2013,6,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ purchasing power parity",4.7
+614,Australia,2013,6,A02A-Antacids,Million of national currency units,2.0
+615,Australia,2013,6,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million US$ at exchange rate,150.6
+616,Australia,2013,6,"H-Systemic hormonal preparations, excluding sex hormones and insulins","Million US$, purchasing power parity",107.8
+617,Australia,2013,6,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ exchange rate",6.5
+618,Australia,2013,6,C-Cardiovascular system,Million US$ at exchange rate,2428.9
+619,Australia,2013,6,C10-Lipid modifying agents,"/capita, US$ purchasing power parity",38.5
+620,Australia,2013,6,C10-Lipid modifying agents,"Million US$, purchasing power parity",890.0
+621,Australia,2013,6,C10-Lipid modifying agents,"/capita, US$ exchange rate",53.8
+622,Australia,2013,6,C10-Lipid modifying agents,% of total sales,10.9
+623,Australia,2013,6,J01-Antibacterials for systemic use,% of total sales,2.7
+624,Australia,2013,6,Products not elsewhere classified,% of total sales,27.4
+625,Australia,2013,6,Products not elsewhere classified,"Million US$, purchasing power parity",2238.2
+626,Australia,2013,6,Products not elsewhere classified,"/capita, US$ exchange rate",135.2
+627,Australia,2013,6,Products not elsewhere classified,Million of national currency units,3239.0
+628,Australia,2013,6,Products not elsewhere classified,Million US$ at exchange rate,3126.9
+629,Australia,2013,6,C10-Lipid modifying agents,Million US$ at exchange rate,1243.4
+630,Australia,2013,6,C10-Lipid modifying agents,Million of national currency units,1288.0
+631,Australia,2013,6,Products not elsewhere classified,"/capita, US$ purchasing power parity",96.8
+632,Australia,2013,6,J01-Antibacterials for systemic use,"/capita, US$ purchasing power parity",9.6
+633,Australia,2013,6,C-Cardiovascular system,% of total sales,21.3
+634,Australia,2013,6,J-Antiinfectives for systemic use,"/capita, US$ exchange rate",33.0
+635,Australia,2013,6,J-Antiinfectives for systemic use,"Million US$, purchasing power parity",545.9
+636,Australia,2013,6,C-Cardiovascular system,"Million US$, purchasing power parity",1738.6
+637,Australia,2013,6,C-Cardiovascular system,"/capita, US$ purchasing power parity",75.2
+638,Australia,2013,6,C-Cardiovascular system,"/capita, US$ exchange rate",105.0
+639,Australia,2013,6,J01-Antibacterials for systemic use,"Million US$, purchasing power parity",221.1
+640,Australia,2013,6,J01-Antibacterials for systemic use,Million US$ at exchange rate,308.9
+641,Australia,2013,6,J01-Antibacterials for systemic use,"/capita, US$ exchange rate",13.4
+642,Australia,2013,6,J-Antiinfectives for systemic use,"/capita, US$ purchasing power parity",23.6
+643,Australia,2013,6,J-Antiinfectives for systemic use,% of total sales,6.7
+644,Australia,2013,6,J01-Antibacterials for systemic use,Million of national currency units,320.0
+645,Australia,2013,6,C01A-Cardiac glycosides,"/capita, US$ exchange rate",0.2
+646,Australia,2013,6,C01A-Cardiac glycosides,"/capita, US$ purchasing power parity",0.1
+647,Australia,2013,6,C01A-Cardiac glycosides,"Million US$, purchasing power parity",2.8
+648,Australia,2013,6,"C01B-Antiarrhythmics, Class I and III",Million US$ at exchange rate,17.4
+649,Australia,2013,6,"C01B-Antiarrhythmics, Class I and III","Million US$, purchasing power parity",12.4
+650,Australia,2013,6,"C01B-Antiarrhythmics, Class I and III","/capita, US$ exchange rate",0.8
+651,Australia,2013,6,"C01B-Antiarrhythmics, Class I and III","/capita, US$ purchasing power parity",0.5
+652,Australia,2013,6,C01A-Cardiac glycosides,% of total sales,0.0
+653,Australia,2013,6,A10-Drugs used in diabetes,"/capita, US$ purchasing power parity",17.7
+654,Australia,2013,6,C03-Diuretics,Million US$ at exchange rate,35.7
+655,Australia,2013,6,C03-Diuretics,Million of national currency units,37.0
+656,Australia,2013,6,C02-Antihypertensives,"/capita, US$ purchasing power parity",2.6
+657,Australia,2013,6,A10-Drugs used in diabetes,"/capita, US$ exchange rate",24.8
+658,Australia,2013,6,C02-Antihypertensives,"/capita, US$ exchange rate",3.7
+659,Australia,2013,6,C01A-Cardiac glycosides,Million US$ at exchange rate,3.9
+660,Australia,2013,6,"C01B-Antiarrhythmics, Class I and III",Million of national currency units,18.0
+661,Australia,2013,6,C02-Antihypertensives,% of total sales,0.7
+662,Australia,2013,6,C01A-Cardiac glycosides,Million of national currency units,4.0
+663,Australia,2013,6,N-Nervous system,"Million US$, purchasing power parity",1380.7
+664,Australia,2013,6,N-Nervous system,Million US$ at exchange rate,1928.9
+665,Australia,2013,6,N05C-Hypnotics and sedatives,Million US$ at exchange rate,20.3
+666,Australia,2013,6,N05C-Hypnotics and sedatives,Million of national currency units,21.0
+667,Australia,2013,6,N-Nervous system,Million of national currency units,1998.0
+668,Australia,2013,6,N05B-Anxiolytics,% of total sales,0.3
+669,Australia,2013,6,A10-Drugs used in diabetes,% of total sales,5.0
+670,Australia,2013,6,N05B-Anxiolytics,Million of national currency units,34.0
+671,Australia,2013,6,N05B-Anxiolytics,"/capita, US$ purchasing power parity",1.0
+672,Australia,2013,6,N05C-Hypnotics and sedatives,"Million US$, purchasing power parity",14.5
+673,Australia,2013,6,N-Nervous system,% of total sales,16.9
+674,Australia,2013,6,N-Nervous system,"/capita, US$ purchasing power parity",59.7
+675,Australia,2013,6,"C01B-Antiarrhythmics, Class I and III",% of total sales,0.2
+676,Australia,2013,6,N-Nervous system,"/capita, US$ exchange rate",83.4
+677,Australia,2013,6,N05C-Hypnotics and sedatives,"/capita, US$ exchange rate",0.9
+678,Australia,2013,6,N05C-Hypnotics and sedatives,"/capita, US$ purchasing power parity",0.6
+679,Australia,2013,6,N05C-Hypnotics and sedatives,% of total sales,0.2
+680,Australia,2013,6,A10-Drugs used in diabetes,"Million US$, purchasing power parity",410.5
+681,Australia,2013,6,Total pharmaceutical sales,"/capita, US$ purchasing power parity",353.2
+682,Australia,2013,6,N06A-Antidepressants,Million US$ at exchange rate,505.9
+683,Australia,2013,6,Total pharmaceutical sales,"Million US$, purchasing power parity",8167.9
+684,Australia,2013,6,Total pharmaceutical sales,"/capita, US$ exchange rate",493.4
+685,Australia,2013,6,N06A-Antidepressants,Million of national currency units,524.0
+686,Australia,2013,6,M01A-Antiinflammatory and antirheumatic products non-steroids,"Million US$, purchasing power parity",88.5
+687,Australia,2013,6,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ exchange rate",5.3
+688,Australia,2013,6,M01A-Antiinflammatory and antirheumatic products non-steroids,Million of national currency units,128.0
+689,Australia,2013,6,M01A-Antiinflammatory and antirheumatic products non-steroids,Million US$ at exchange rate,123.6
+690,Australia,2013,6,Total pharmaceutical sales,Million of national currency units,11820.0
+691,Australia,2013,6,Total pharmaceutical sales,Million US$ at exchange rate,11411.0
+692,Australia,2013,6,N05B-Anxiolytics,"Million US$, purchasing power parity",23.5
+693,Australia,2013,6,A10-Drugs used in diabetes,Million of national currency units,594.0
+694,Australia,2013,6,N05B-Anxiolytics,Million US$ at exchange rate,32.8
+695,Australia,2013,6,N06A-Antidepressants,"/capita, US$ exchange rate",21.9
+696,Australia,2013,6,N06A-Antidepressants,"Million US$, purchasing power parity",362.1
+697,Australia,2013,6,N06A-Antidepressants,% of total sales,4.4
+698,Australia,2013,6,N06A-Antidepressants,"/capita, US$ purchasing power parity",15.7
+699,Australia,2013,6,C03-Diuretics,% of total sales,0.3
+700,Australia,2013,6,N05B-Anxiolytics,"/capita, US$ exchange rate",1.4
+701,Australia,2013,6,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ purchasing power parity",3.8
+702,Australia,2013,6,M01A-Antiinflammatory and antirheumatic products non-steroids,% of total sales,1.1
+703,Australia,2013,6,C02-Antihypertensives,Million of national currency units,88.0
+704,Australia,2013,6,A10-Drugs used in diabetes,Million US$ at exchange rate,573.4
+705,Australia,2013,6,C03-Diuretics,"Million US$, purchasing power parity",25.6
+706,Australia,2013,6,C03-Diuretics,"/capita, US$ purchasing power parity",1.1
+707,Australia,2013,6,C03-Diuretics,"/capita, US$ exchange rate",1.5
+708,Australia,2013,6,N02-Analgesics,"Million US$, purchasing power parity",347.6
+709,Australia,2013,6,N02-Analgesics,"/capita, US$ exchange rate",21.0
+710,Australia,2013,6,N02-Analgesics,Million of national currency units,503.0
+711,Australia,2013,6,N02-Analgesics,Million US$ at exchange rate,485.6
+712,Australia,2013,6,C02-Antihypertensives,"Million US$, purchasing power parity",60.8
+713,Australia,2013,6,C02-Antihypertensives,Million US$ at exchange rate,85.0
+714,Australia,2013,6,N02-Analgesics,"/capita, US$ purchasing power parity",15.0
+715,Australia,2013,6,N02-Analgesics,% of total sales,4.3
+716,Australia,2012,6,M-Musculo-skeletal system,Million of national currency units,312.0
+717,Australia,2012,6,B-Blood and blood forming organs,Million of national currency units,405.0
+718,Australia,2012,6,M-Musculo-skeletal system,Million US$ at exchange rate,323.0
+719,Australia,2012,6,B-Blood and blood forming organs,Million US$ at exchange rate,419.3
+720,Australia,2012,6,R03-Drugs for obstructive airway diseases,Million of national currency units,586.0
+721,Australia,2012,6,R03-Drugs for obstructive airway diseases,Million US$ at exchange rate,606.8
+722,Australia,2012,6,B-Blood and blood forming organs,"Million US$, purchasing power parity",263.0
+723,Australia,2012,6,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"Million US$, purchasing power parity",325.9
+724,Australia,2012,6,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million US$ at exchange rate,519.8
+725,Australia,2012,6,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ exchange rate",22.9
+726,Australia,2012,6,M-Musculo-skeletal system,"/capita, US$ exchange rate",14.2
+727,Australia,2012,6,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million of national currency units,502.0
+728,Australia,2012,6,M-Musculo-skeletal system,"/capita, US$ purchasing power parity",8.9
+729,Australia,2012,6,M-Musculo-skeletal system,"Million US$, purchasing power parity",202.6
+730,Australia,2012,6,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ purchasing power parity",16.1
+731,Australia,2012,6,C09-Agents acting on the Renin-Angiotensin system,% of total sales,5.4
+732,Australia,2012,6,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ exchange rate",25.6
+733,Australia,2012,6,B-Blood and blood forming organs,% of total sales,3.9
+734,Australia,2012,6,B-Blood and blood forming organs,"/capita, US$ exchange rate",18.4
+735,Australia,2012,6,B-Blood and blood forming organs,"/capita, US$ purchasing power parity",11.6
+736,Australia,2012,6,R03-Drugs for obstructive airway diseases,"/capita, US$ purchasing power parity",16.7
+737,Australia,2012,6,R03-Drugs for obstructive airway diseases,"/capita, US$ exchange rate",26.7
+738,Australia,2012,6,R03-Drugs for obstructive airway diseases,"Million US$, purchasing power parity",380.5
+739,Australia,2012,6,C09-Agents acting on the Renin-Angiotensin system,Million US$ at exchange rate,581.9
+740,Australia,2012,6,C09-Agents acting on the Renin-Angiotensin system,"Million US$, purchasing power parity",364.9
+741,Australia,2012,6,R03-Drugs for obstructive airway diseases,% of total sales,5.7
+742,Australia,2012,6,C09-Agents acting on the Renin-Angiotensin system,Million of national currency units,562.0
+743,Australia,2012,6,R-Respiratory system,"/capita, US$ exchange rate",27.2
+744,Australia,2012,6,R-Respiratory system,Million US$ at exchange rate,619.2
+745,Australia,2012,6,R-Respiratory system,"Million US$, purchasing power parity",388.3
+746,Australia,2012,6,R-Respiratory system,"/capita, US$ purchasing power parity",17.1
+747,Australia,2012,6,C08-Calcium channel blockers,Million of national currency units,118.0
+748,Australia,2012,6,R-Respiratory system,% of total sales,5.8
+749,Australia,2012,6,C07-Beta blocking agents,"Million US$, purchasing power parity",89.0
+750,Australia,2012,6,C07-Beta blocking agents,"/capita, US$ exchange rate",6.2
+751,Australia,2012,6,C07-Beta blocking agents,Million of national currency units,137.0
+752,Australia,2012,6,C07-Beta blocking agents,Million US$ at exchange rate,141.9
+753,Australia,2012,6,C07-Beta blocking agents,% of total sales,1.3
+754,Australia,2012,6,R-Respiratory system,Million of national currency units,598.0
+755,Australia,2012,6,C07-Beta blocking agents,"/capita, US$ purchasing power parity",3.9
+756,Australia,2012,6,C08-Calcium channel blockers,Million US$ at exchange rate,122.2
+757,Australia,2012,6,A-Alimentary tract and metabolism,"/capita, US$ exchange rate",55.3
+758,Australia,2012,6,A-Alimentary tract and metabolism,"/capita, US$ purchasing power parity",34.7
+759,Australia,2012,6,A-Alimentary tract and metabolism,"Million US$, purchasing power parity",788.3
+760,Australia,2012,6,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),% of total sales,4.8
+761,Australia,2012,6,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ purchasing power parity",14.3
+762,Australia,2012,6,A-Alimentary tract and metabolism,% of total sales,11.7
+763,Australia,2012,6,C08-Calcium channel blockers,"/capita, US$ exchange rate",5.4
+764,Australia,2012,6,C08-Calcium channel blockers,"/capita, US$ purchasing power parity",3.4
+765,Australia,2012,6,C08-Calcium channel blockers,"Million US$, purchasing power parity",76.6
+766,Australia,2012,6,A-Alimentary tract and metabolism,Million of national currency units,1214.0
+767,Australia,2012,6,M-Musculo-skeletal system,% of total sales,3.0
+768,Australia,2012,6,C08-Calcium channel blockers,% of total sales,1.1
+769,Australia,2012,6,A-Alimentary tract and metabolism,Million US$ at exchange rate,1257.0
+770,Australia,2012,6,Products not elsewhere classified,Million of national currency units,2822.0
+771,Australia,2012,6,A02A-Antacids,% of total sales,0.0
+772,Australia,2012,6,G-Genito urinary system and sex hormones,"/capita, US$ purchasing power parity",4.4
+773,Australia,2012,6,G-Genito urinary system and sex hormones,% of total sales,1.5
+774,Australia,2012,6,A02A-Antacids,"Million US$, purchasing power parity",1.3
+775,Australia,2012,6,A02A-Antacids,"/capita, US$ purchasing power parity",0.1
+776,Australia,2012,6,A02A-Antacids,"/capita, US$ exchange rate",0.1
+777,Australia,2012,6,J-Antiinfectives for systemic use,Million of national currency units,446.0
+778,Australia,2012,6,G-Genito urinary system and sex hormones,Million of national currency units,155.0
+779,Australia,2012,6,J-Antiinfectives for systemic use,Million US$ at exchange rate,461.8
+780,Australia,2012,6,C-Cardiovascular system,Million of national currency units,2538.0
+781,Australia,2012,6,G-Genito urinary system and sex hormones,"/capita, US$ exchange rate",7.1
+782,Australia,2012,6,G-Genito urinary system and sex hormones,"Million US$, purchasing power parity",100.6
+783,Australia,2012,6,G-Genito urinary system and sex hormones,Million US$ at exchange rate,160.5
+784,Australia,2012,6,A02A-Antacids,Million US$ at exchange rate,2.1
+785,Australia,2012,6,G03-Sex hormones and modulators of the genital system,"Million US$, purchasing power parity",66.9
+786,Australia,2012,6,G03-Sex hormones and modulators of the genital system,"/capita, US$ exchange rate",4.7
+787,Australia,2012,6,G03-Sex hormones and modulators of the genital system,Million US$ at exchange rate,106.6
+788,Australia,2012,6,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million of national currency units,98.0
+789,Australia,2012,6,G03-Sex hormones and modulators of the genital system,"/capita, US$ purchasing power parity",2.9
+790,Australia,2012,6,G03-Sex hormones and modulators of the genital system,% of total sales,1.0
+791,Australia,2012,6,"H-Systemic hormonal preparations, excluding sex hormones and insulins",% of total sales,0.9
+792,Australia,2012,6,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ purchasing power parity",2.8
+793,Australia,2012,6,A02A-Antacids,Million of national currency units,2.0
+794,Australia,2012,6,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million US$ at exchange rate,101.5
+795,Australia,2012,6,G03-Sex hormones and modulators of the genital system,Million of national currency units,103.0
+796,Australia,2012,6,"H-Systemic hormonal preparations, excluding sex hormones and insulins","Million US$, purchasing power parity",63.6
+797,Australia,2012,6,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ exchange rate",4.5
+798,Australia,2012,6,C-Cardiovascular system,Million US$ at exchange rate,2627.9
+799,Australia,2012,6,C10-Lipid modifying agents,"/capita, US$ purchasing power parity",43.9
+800,Australia,2012,6,C10-Lipid modifying agents,"Million US$, purchasing power parity",998.6
+801,Australia,2012,6,C10-Lipid modifying agents,"/capita, US$ exchange rate",70.0
+802,Australia,2012,6,C10-Lipid modifying agents,% of total sales,14.9
+803,Australia,2012,6,J01-Antibacterials for systemic use,% of total sales,1.8
+804,Australia,2012,6,Products not elsewhere classified,% of total sales,27.3
+805,Australia,2012,6,Products not elsewhere classified,"Million US$, purchasing power parity",1832.3
+806,Australia,2012,6,Products not elsewhere classified,"/capita, US$ exchange rate",128.5
+807,Australia,2012,6,Products not elsewhere classified,Million US$ at exchange rate,2921.9
+808,Australia,2012,6,C10-Lipid modifying agents,Million US$ at exchange rate,1592.5
+809,Australia,2012,6,C10-Lipid modifying agents,Million of national currency units,1538.0
+810,Australia,2012,6,Products not elsewhere classified,"/capita, US$ purchasing power parity",80.6
+811,Australia,2012,6,C-Cardiovascular system,% of total sales,24.5
+812,Australia,2012,6,J-Antiinfectives for systemic use,"/capita, US$ exchange rate",20.3
+813,Australia,2012,6,J-Antiinfectives for systemic use,"Million US$, purchasing power parity",289.6
+814,Australia,2012,6,C-Cardiovascular system,"Million US$, purchasing power parity",1647.9
+815,Australia,2012,6,C-Cardiovascular system,"/capita, US$ purchasing power parity",72.5
+816,Australia,2012,6,C-Cardiovascular system,"/capita, US$ exchange rate",115.6
+817,Australia,2012,6,J01-Antibacterials for systemic use,"Million US$, purchasing power parity",119.5
+818,Australia,2012,6,J01-Antibacterials for systemic use,Million US$ at exchange rate,190.5
+819,Australia,2012,6,J01-Antibacterials for systemic use,"/capita, US$ purchasing power parity",5.3
+820,Australia,2012,6,J01-Antibacterials for systemic use,"/capita, US$ exchange rate",8.4
+821,Australia,2012,6,J-Antiinfectives for systemic use,"/capita, US$ purchasing power parity",12.7
+822,Australia,2012,6,J-Antiinfectives for systemic use,% of total sales,4.3
+823,Australia,2012,6,J01-Antibacterials for systemic use,Million of national currency units,184.0
+824,Australia,2012,6,C01A-Cardiac glycosides,"/capita, US$ exchange rate",0.2
+825,Australia,2012,6,C01A-Cardiac glycosides,"/capita, US$ purchasing power parity",0.1
+826,Australia,2012,6,"C01B-Antiarrhythmics, Class I and III",Million US$ at exchange rate,17.6
+827,Australia,2012,6,"C01B-Antiarrhythmics, Class I and III","Million US$, purchasing power parity",11.0
+828,Australia,2012,6,C01A-Cardiac glycosides,"Million US$, purchasing power parity",2.6
+829,Australia,2012,6,"C01B-Antiarrhythmics, Class I and III","/capita, US$ exchange rate",0.8
+830,Australia,2012,6,"C01B-Antiarrhythmics, Class I and III","/capita, US$ purchasing power parity",0.5
+831,Australia,2012,6,C01A-Cardiac glycosides,% of total sales,0.0
+832,Australia,2012,6,A10-Drugs used in diabetes,"/capita, US$ purchasing power parity",14.8
+833,Australia,2012,6,C03-Diuretics,Million US$ at exchange rate,31.1
+834,Australia,2012,6,C03-Diuretics,Million of national currency units,30.0
+835,Australia,2012,6,C02-Antihypertensives,"/capita, US$ purchasing power parity",2.2
+836,Australia,2012,6,A10-Drugs used in diabetes,"/capita, US$ exchange rate",23.6
+837,Australia,2012,6,C02-Antihypertensives,"/capita, US$ exchange rate",3.6
+838,Australia,2012,6,C01A-Cardiac glycosides,Million US$ at exchange rate,4.1
+839,Australia,2012,6,"C01B-Antiarrhythmics, Class I and III",Million of national currency units,17.0
+840,Australia,2012,6,C01A-Cardiac glycosides,Million of national currency units,4.0
+841,Australia,2012,6,C02-Antihypertensives,% of total sales,0.8
+842,Australia,2012,6,N-Nervous system,"Million US$, purchasing power parity",1148.0
+843,Australia,2012,6,N-Nervous system,Million US$ at exchange rate,1830.6
+844,Australia,2012,6,N05C-Hypnotics and sedatives,Million US$ at exchange rate,17.6
+845,Australia,2012,6,N05C-Hypnotics and sedatives,Million of national currency units,17.0
+846,Australia,2012,6,N05B-Anxiolytics,% of total sales,0.3
+847,Australia,2012,6,A10-Drugs used in diabetes,% of total sales,5.0
+848,Australia,2012,6,N-Nervous system,Million of national currency units,1768.0
+849,Australia,2012,6,N05B-Anxiolytics,Million of national currency units,27.0
+850,Australia,2012,6,N05C-Hypnotics and sedatives,"Million US$, purchasing power parity",11.0
+851,Australia,2012,6,N-Nervous system,% of total sales,17.1
+852,Australia,2012,6,N-Nervous system,"/capita, US$ purchasing power parity",50.5
+853,Australia,2012,6,"C01B-Antiarrhythmics, Class I and III",% of total sales,0.2
+854,Australia,2012,6,N05B-Anxiolytics,"/capita, US$ purchasing power parity",0.8
+855,Australia,2012,6,N-Nervous system,"/capita, US$ exchange rate",80.5
+856,Australia,2012,6,N05C-Hypnotics and sedatives,"/capita, US$ purchasing power parity",0.5
+857,Australia,2012,6,N05C-Hypnotics and sedatives,"/capita, US$ exchange rate",0.8
+858,Australia,2012,6,N05C-Hypnotics and sedatives,% of total sales,0.2
+859,Australia,2012,6,Total pharmaceutical sales,"/capita, US$ purchasing power parity",295.8
+860,Australia,2012,6,N06A-Antidepressants,Million US$ at exchange rate,461.8
+861,Australia,2012,6,Total pharmaceutical sales,"Million US$, purchasing power parity",6723.5
+862,Australia,2012,6,Total pharmaceutical sales,"/capita, US$ exchange rate",471.6
+863,Australia,2012,6,N06A-Antidepressants,Million of national currency units,446.0
+864,Australia,2012,6,M01A-Antiinflammatory and antirheumatic products non-steroids,"Million US$, purchasing power parity",55.2
+865,Australia,2012,6,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ exchange rate",3.9
+866,Australia,2012,6,M01A-Antiinflammatory and antirheumatic products non-steroids,Million of national currency units,85.0
+867,Australia,2012,6,M01A-Antiinflammatory and antirheumatic products non-steroids,Million US$ at exchange rate,88.0
+868,Australia,2012,6,Total pharmaceutical sales,Million of national currency units,10355.0
+869,Australia,2012,6,Total pharmaceutical sales,Million US$ at exchange rate,10721.7
+870,Australia,2012,6,N05B-Anxiolytics,"Million US$, purchasing power parity",17.5
+871,Australia,2012,6,A10-Drugs used in diabetes,Million of national currency units,519.0
+872,Australia,2012,6,N05B-Anxiolytics,Million US$ at exchange rate,28.0
+873,Australia,2012,6,N06A-Antidepressants,"/capita, US$ exchange rate",20.3
+874,Australia,2012,6,N06A-Antidepressants,"Million US$, purchasing power parity",289.6
+875,Australia,2012,6,N06A-Antidepressants,% of total sales,4.3
+876,Australia,2012,6,N06A-Antidepressants,"/capita, US$ purchasing power parity",12.7
+877,Australia,2012,6,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ purchasing power parity",2.4
+878,Australia,2012,6,C03-Diuretics,% of total sales,0.3
+879,Australia,2012,6,C02-Antihypertensives,Million of national currency units,78.0
+880,Australia,2012,6,M01A-Antiinflammatory and antirheumatic products non-steroids,% of total sales,0.8
+881,Australia,2012,6,N05B-Anxiolytics,"/capita, US$ exchange rate",1.2
+882,Australia,2012,6,A10-Drugs used in diabetes,Million US$ at exchange rate,537.4
+883,Australia,2012,6,C03-Diuretics,"Million US$, purchasing power parity",19.5
+884,Australia,2012,6,A10-Drugs used in diabetes,"Million US$, purchasing power parity",337.0
+885,Australia,2012,6,C03-Diuretics,"/capita, US$ purchasing power parity",0.9
+886,Australia,2012,6,C03-Diuretics,"/capita, US$ exchange rate",1.4
+887,Australia,2012,6,N02-Analgesics,"Million US$, purchasing power parity",281.1
+888,Australia,2012,6,N02-Analgesics,"/capita, US$ exchange rate",19.7
+889,Australia,2012,6,N02-Analgesics,Million of national currency units,433.0
+890,Australia,2012,6,N02-Analgesics,Million US$ at exchange rate,448.3
+891,Australia,2012,6,C02-Antihypertensives,Million US$ at exchange rate,80.8
+892,Australia,2012,6,C02-Antihypertensives,"Million US$, purchasing power parity",50.6
+893,Australia,2012,6,N02-Analgesics,"/capita, US$ purchasing power parity",12.4
+894,Australia,2012,6,N02-Analgesics,% of total sales,4.2
+895,Australia,2011,6,M-Musculo-skeletal system,Million of national currency units,309.0
+896,Australia,2011,6,B-Blood and blood forming organs,Million of national currency units,417.0
+897,Australia,2011,6,M-Musculo-skeletal system,Million US$ at exchange rate,318.7
+898,Australia,2011,6,B-Blood and blood forming organs,Million US$ at exchange rate,430.1
+899,Australia,2011,6,R03-Drugs for obstructive airway diseases,Million of national currency units,562.0
+900,Australia,2011,6,R03-Drugs for obstructive airway diseases,Million US$ at exchange rate,579.7
+901,Australia,2011,6,B-Blood and blood forming organs,"Million US$, purchasing power parity",276.0
+902,Australia,2011,6,M-Musculo-skeletal system,"Million US$, purchasing power parity",204.5
+903,Australia,2011,6,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"Million US$, purchasing power parity",375.2
+904,Australia,2011,6,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million US$ at exchange rate,584.9
+905,Australia,2011,6,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ exchange rate",26.2
+906,Australia,2011,6,M-Musculo-skeletal system,"/capita, US$ exchange rate",14.3
+907,Australia,2011,6,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million of national currency units,567.0
+908,Australia,2011,6,M-Musculo-skeletal system,"/capita, US$ purchasing power parity",9.2
+909,Australia,2011,6,C09-Agents acting on the Renin-Angiotensin system,% of total sales,5.9
+910,Australia,2011,6,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ purchasing power parity",18.0
+911,Australia,2011,6,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ exchange rate",28.1
+912,Australia,2011,6,B-Blood and blood forming organs,% of total sales,4.1
+913,Australia,2011,6,B-Blood and blood forming organs,"/capita, US$ exchange rate",19.3
+914,Australia,2011,6,B-Blood and blood forming organs,"/capita, US$ purchasing power parity",12.4
+915,Australia,2011,6,R03-Drugs for obstructive airway diseases,"/capita, US$ purchasing power parity",16.6
+916,Australia,2011,6,R03-Drugs for obstructive airway diseases,"Million US$, purchasing power parity",371.9
+917,Australia,2011,6,R03-Drugs for obstructive airway diseases,"/capita, US$ exchange rate",25.9
+918,Australia,2011,6,R03-Drugs for obstructive airway diseases,% of total sales,5.5
+919,Australia,2011,6,C09-Agents acting on the Renin-Angiotensin system,Million US$ at exchange rate,628.2
+920,Australia,2011,6,C09-Agents acting on the Renin-Angiotensin system,"Million US$, purchasing power parity",403.0
+921,Australia,2011,6,C09-Agents acting on the Renin-Angiotensin system,Million of national currency units,609.0
+922,Australia,2011,6,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ purchasing power parity",16.8
+923,Australia,2011,6,R-Respiratory system,"/capita, US$ exchange rate",26.4
+924,Australia,2011,6,R-Respiratory system,Million US$ at exchange rate,590.0
+925,Australia,2011,6,R-Respiratory system,"Million US$, purchasing power parity",378.5
+926,Australia,2011,6,R-Respiratory system,"/capita, US$ purchasing power parity",16.9
+927,Australia,2011,6,C08-Calcium channel blockers,Million of national currency units,142.0
+928,Australia,2011,6,R-Respiratory system,% of total sales,5.6
+929,Australia,2011,6,C08-Calcium channel blockers,Million US$ at exchange rate,146.5
+930,Australia,2011,6,C07-Beta blocking agents,"Million US$, purchasing power parity",93.3
+931,Australia,2011,6,C07-Beta blocking agents,"/capita, US$ exchange rate",6.5
+932,Australia,2011,6,C07-Beta blocking agents,Million US$ at exchange rate,145.4
+933,Australia,2011,6,R-Respiratory system,Million of national currency units,572.0
+934,Australia,2011,6,C07-Beta blocking agents,% of total sales,1.4
+935,Australia,2011,6,C07-Beta blocking agents,"/capita, US$ purchasing power parity",4.2
+936,Australia,2011,6,A-Alimentary tract and metabolism,"/capita, US$ exchange rate",56.2
+937,Australia,2011,6,A-Alimentary tract and metabolism,"/capita, US$ purchasing power parity",36.1
+938,Australia,2011,6,A-Alimentary tract and metabolism,"Million US$, purchasing power parity",806.1
+939,Australia,2011,6,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),% of total sales,5.5
+940,Australia,2011,6,A-Alimentary tract and metabolism,% of total sales,11.9
+941,Australia,2011,6,A-Alimentary tract and metabolism,Million US$ at exchange rate,1256.4
+942,Australia,2011,6,C08-Calcium channel blockers,"/capita, US$ exchange rate",6.6
+943,Australia,2011,6,C08-Calcium channel blockers,"/capita, US$ purchasing power parity",4.2
+944,Australia,2011,6,C08-Calcium channel blockers,"Million US$, purchasing power parity",94.0
+945,Australia,2011,6,M-Musculo-skeletal system,% of total sales,3.0
+946,Australia,2011,6,A-Alimentary tract and metabolism,Million of national currency units,1218.0
+947,Australia,2011,6,C08-Calcium channel blockers,% of total sales,1.4
+948,Australia,2011,6,Products not elsewhere classified,Million of national currency units,2515.0
+949,Australia,2011,6,A02A-Antacids,% of total sales,0.0
+950,Australia,2011,6,G-Genito urinary system and sex hormones,"/capita, US$ purchasing power parity",4.2
+951,Australia,2011,6,G-Genito urinary system and sex hormones,% of total sales,1.4
+952,Australia,2011,6,A02A-Antacids,"Million US$, purchasing power parity",1.3
+953,Australia,2011,6,A02A-Antacids,"/capita, US$ exchange rate",0.1
+954,Australia,2011,6,A02A-Antacids,"/capita, US$ purchasing power parity",0.1
+955,Australia,2011,6,J-Antiinfectives for systemic use,Million of national currency units,386.0
+956,Australia,2011,6,G-Genito urinary system and sex hormones,Million of national currency units,143.0
+957,Australia,2011,6,J-Antiinfectives for systemic use,Million US$ at exchange rate,398.2
+958,Australia,2011,6,C-Cardiovascular system,Million of national currency units,2825.0
+959,Australia,2011,6,G-Genito urinary system and sex hormones,"/capita, US$ exchange rate",6.6
+960,Australia,2011,6,G-Genito urinary system and sex hormones,"Million US$, purchasing power parity",94.6
+961,Australia,2011,6,G-Genito urinary system and sex hormones,Million US$ at exchange rate,147.5
+962,Australia,2011,6,G03-Sex hormones and modulators of the genital system,"/capita, US$ exchange rate",4.6
+963,Australia,2011,6,G03-Sex hormones and modulators of the genital system,"Million US$, purchasing power parity",66.2
+964,Australia,2011,6,G03-Sex hormones and modulators of the genital system,Million US$ at exchange rate,103.1
+965,Australia,2011,6,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million of national currency units,86.0
+966,Australia,2011,6,G03-Sex hormones and modulators of the genital system,"/capita, US$ purchasing power parity",3.0
+967,Australia,2011,6,G03-Sex hormones and modulators of the genital system,% of total sales,1.0
+968,Australia,2011,6,"H-Systemic hormonal preparations, excluding sex hormones and insulins",% of total sales,0.8
+969,Australia,2011,6,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ purchasing power parity",2.5
+970,Australia,2011,6,A02A-Antacids,Million US$ at exchange rate,2.1
+971,Australia,2011,6,A02A-Antacids,Million of national currency units,2.0
+972,Australia,2011,6,"H-Systemic hormonal preparations, excluding sex hormones and insulins","Million US$, purchasing power parity",56.9
+973,Australia,2011,6,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million US$ at exchange rate,88.7
+974,Australia,2011,6,G03-Sex hormones and modulators of the genital system,Million of national currency units,100.0
+975,Australia,2011,6,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ exchange rate",4.0
+976,Australia,2011,6,C-Cardiovascular system,Million US$ at exchange rate,2914.0
+977,Australia,2011,6,C10-Lipid modifying agents,"/capita, US$ purchasing power parity",52.0
+978,Australia,2011,6,C10-Lipid modifying agents,% of total sales,17.1
+979,Australia,2011,6,C10-Lipid modifying agents,"Million US$, purchasing power parity",1162.1
+980,Australia,2011,6,C10-Lipid modifying agents,"/capita, US$ exchange rate",81.1
+981,Australia,2011,6,J01-Antibacterials for systemic use,% of total sales,1.9
+982,Australia,2011,6,Products not elsewhere classified,% of total sales,24.5
+983,Australia,2011,6,Products not elsewhere classified,"Million US$, purchasing power parity",1664.4
+984,Australia,2011,6,Products not elsewhere classified,"/capita, US$ exchange rate",116.1
+985,Australia,2011,6,Products not elsewhere classified,Million US$ at exchange rate,2594.2
+986,Australia,2011,6,C10-Lipid modifying agents,Million US$ at exchange rate,1811.3
+987,Australia,2011,6,C10-Lipid modifying agents,Million of national currency units,1756.0
+988,Australia,2011,6,Products not elsewhere classified,"/capita, US$ purchasing power parity",74.5
+989,Australia,2011,6,C-Cardiovascular system,% of total sales,27.5
+990,Australia,2011,6,J-Antiinfectives for systemic use,"/capita, US$ exchange rate",17.8
+991,Australia,2011,6,J-Antiinfectives for systemic use,"Million US$, purchasing power parity",255.5
+992,Australia,2011,6,C-Cardiovascular system,"Million US$, purchasing power parity",1869.6
+993,Australia,2011,6,C-Cardiovascular system,"/capita, US$ purchasing power parity",83.7
+994,Australia,2011,6,C-Cardiovascular system,"/capita, US$ exchange rate",130.4
+995,Australia,2011,6,J01-Antibacterials for systemic use,"Million US$, purchasing power parity",131.0
+996,Australia,2011,6,J01-Antibacterials for systemic use,"/capita, US$ purchasing power parity",5.9
+997,Australia,2011,6,J01-Antibacterials for systemic use,"/capita, US$ exchange rate",9.1
+998,Australia,2011,6,J01-Antibacterials for systemic use,Million US$ at exchange rate,204.2
+999,Australia,2011,6,C07-Beta blocking agents,Million of national currency units,141.0
+1000,Australia,2011,6,J-Antiinfectives for systemic use,% of total sales,3.8
+1001,Australia,2011,6,J-Antiinfectives for systemic use,"/capita, US$ purchasing power parity",11.4
+1002,Australia,2011,6,J01-Antibacterials for systemic use,Million of national currency units,198.0
+1003,Australia,2011,6,C01A-Cardiac glycosides,"/capita, US$ exchange rate",0.2
+1004,Australia,2011,6,C01A-Cardiac glycosides,"/capita, US$ purchasing power parity",0.1
+1005,Australia,2011,6,"C01B-Antiarrhythmics, Class I and III",Million US$ at exchange rate,17.5
+1006,Australia,2011,6,"C01B-Antiarrhythmics, Class I and III","Million US$, purchasing power parity",11.3
+1007,Australia,2011,6,C01A-Cardiac glycosides,"Million US$, purchasing power parity",2.6
+1008,Australia,2011,6,"C01B-Antiarrhythmics, Class I and III","/capita, US$ exchange rate",0.8
+1009,Australia,2011,6,"C01B-Antiarrhythmics, Class I and III","/capita, US$ purchasing power parity",0.5
+1010,Australia,2011,6,C01A-Cardiac glycosides,% of total sales,0.0
+1011,Australia,2011,6,A10-Drugs used in diabetes,"/capita, US$ purchasing power parity",13.9
+1012,Australia,2011,6,C03-Diuretics,Million US$ at exchange rate,30.9
+1013,Australia,2011,6,C03-Diuretics,Million of national currency units,30.0
+1014,Australia,2011,6,C02-Antihypertensives,"/capita, US$ purchasing power parity",2.1
+1015,Australia,2011,6,A10-Drugs used in diabetes,"/capita, US$ exchange rate",21.7
+1016,Australia,2011,6,C02-Antihypertensives,"/capita, US$ exchange rate",3.3
+1017,Australia,2011,6,C01A-Cardiac glycosides,Million US$ at exchange rate,4.1
+1018,Australia,2011,6,C02-Antihypertensives,% of total sales,0.7
+1019,Australia,2011,6,"C01B-Antiarrhythmics, Class I and III",Million of national currency units,17.0
+1020,Australia,2011,6,C01A-Cardiac glycosides,Million of national currency units,4.0
+1021,Australia,2011,6,N-Nervous system,"Million US$, purchasing power parity",1184.6
+1022,Australia,2011,6,N-Nervous system,Million US$ at exchange rate,1846.4
+1023,Australia,2011,6,N05C-Hypnotics and sedatives,Million US$ at exchange rate,18.6
+1024,Australia,2011,6,N05C-Hypnotics and sedatives,Million of national currency units,18.0
+1025,Australia,2011,6,N05B-Anxiolytics,% of total sales,0.3
+1026,Australia,2011,6,A10-Drugs used in diabetes,% of total sales,4.6
+1027,Australia,2011,6,N-Nervous system,Million of national currency units,1790.0
+1028,Australia,2011,6,N05B-Anxiolytics,Million of national currency units,28.0
+1029,Australia,2011,6,N05C-Hypnotics and sedatives,"Million US$, purchasing power parity",11.9
+1030,Australia,2011,6,N-Nervous system,% of total sales,17.4
+1031,Australia,2011,6,N-Nervous system,"/capita, US$ purchasing power parity",53.0
+1032,Australia,2011,6,"C01B-Antiarrhythmics, Class I and III",% of total sales,0.2
+1033,Australia,2011,6,N05C-Hypnotics and sedatives,"/capita, US$ purchasing power parity",0.5
+1034,Australia,2011,6,N05C-Hypnotics and sedatives,"/capita, US$ exchange rate",0.8
+1035,Australia,2011,6,N-Nervous system,"/capita, US$ exchange rate",82.6
+1036,Australia,2011,6,N05C-Hypnotics and sedatives,% of total sales,0.2
+1037,Australia,2011,6,Total pharmaceutical sales,"/capita, US$ purchasing power parity",304.0
+1038,Australia,2011,6,N02-Analgesics,Million of national currency units,408.0
+1039,Australia,2011,6,N06A-Antidepressants,Million US$ at exchange rate,503.4
+1040,Australia,2011,6,Total pharmaceutical sales,"Million US$, purchasing power parity",6790.6
+1041,Australia,2011,6,Total pharmaceutical sales,"/capita, US$ exchange rate",473.8
+1042,Australia,2011,6,N06A-Antidepressants,Million of national currency units,488.0
+1043,Australia,2011,6,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ exchange rate",4.3
+1044,Australia,2011,6,M01A-Antiinflammatory and antirheumatic products non-steroids,"Million US$, purchasing power parity",61.5
+1045,Australia,2011,6,M01A-Antiinflammatory and antirheumatic products non-steroids,Million of national currency units,93.0
+1046,Australia,2011,6,M01A-Antiinflammatory and antirheumatic products non-steroids,Million US$ at exchange rate,95.9
+1047,Australia,2011,6,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ purchasing power parity",2.8
+1048,Australia,2011,6,Total pharmaceutical sales,Million of national currency units,10261.0
+1049,Australia,2011,6,Total pharmaceutical sales,Million US$ at exchange rate,10584.2
+1050,Australia,2011,6,N05B-Anxiolytics,"Million US$, purchasing power parity",18.5
+1051,Australia,2011,6,A10-Drugs used in diabetes,Million of national currency units,470.0
+1052,Australia,2011,6,N05B-Anxiolytics,Million US$ at exchange rate,28.9
+1053,Australia,2011,6,N06A-Antidepressants,"/capita, US$ exchange rate",22.5
+1054,Australia,2011,6,N06A-Antidepressants,"Million US$, purchasing power parity",323.0
+1055,Australia,2011,6,N06A-Antidepressants,% of total sales,4.8
+1056,Australia,2011,6,N06A-Antidepressants,"/capita, US$ purchasing power parity",14.5
+1057,Australia,2011,6,N05B-Anxiolytics,"/capita, US$ purchasing power parity",0.8
+1058,Australia,2011,6,C03-Diuretics,% of total sales,0.3
+1059,Australia,2011,6,C02-Antihypertensives,Million of national currency units,72.0
+1060,Australia,2011,6,M01A-Antiinflammatory and antirheumatic products non-steroids,% of total sales,0.9
+1061,Australia,2011,6,N05B-Anxiolytics,"/capita, US$ exchange rate",1.3
+1062,Australia,2011,6,C03-Diuretics,"Million US$, purchasing power parity",19.9
+1063,Australia,2011,6,A10-Drugs used in diabetes,Million US$ at exchange rate,484.8
+1064,Australia,2011,6,A10-Drugs used in diabetes,"Million US$, purchasing power parity",311.0
+1065,Australia,2011,6,C03-Diuretics,"/capita, US$ purchasing power parity",0.9
+1066,Australia,2011,6,C03-Diuretics,"/capita, US$ exchange rate",1.4
+1067,Australia,2011,6,N02-Analgesics,"Million US$, purchasing power parity",270.0
+1068,Australia,2011,6,N02-Analgesics,"/capita, US$ exchange rate",18.8
+1069,Australia,2011,6,N02-Analgesics,Million US$ at exchange rate,420.9
+1070,Australia,2011,6,C02-Antihypertensives,"Million US$, purchasing power parity",47.6
+1071,Australia,2011,6,C02-Antihypertensives,Million US$ at exchange rate,74.3
+1072,Australia,2011,6,N02-Analgesics,"/capita, US$ purchasing power parity",12.1
+1073,Australia,2011,6,N02-Analgesics,% of total sales,4.0
+1074,Australia,2010,5,Total pharmaceutical sales,Million of national currency units,9795.0
+1075,Australia,2010,5,M-Musculo-skeletal system,Million of national currency units,324.0
+1076,Australia,2010,5,B-Blood and blood forming organs,Million of national currency units,406.0
+1077,Australia,2010,5,B-Blood and blood forming organs,Million US$ at exchange rate,372.4
+1078,Australia,2010,5,M-Musculo-skeletal system,Million US$ at exchange rate,297.2
+1079,Australia,2010,5,R03-Drugs for obstructive airway diseases,Million US$ at exchange rate,497.2
+1080,Australia,2010,5,R03-Drugs for obstructive airway diseases,Million of national currency units,542.0
+1081,Australia,2010,5,B-Blood and blood forming organs,"Million US$, purchasing power parity",270.0
+1082,Australia,2010,5,M-Musculo-skeletal system,"Million US$, purchasing power parity",215.5
+1083,Australia,2010,5,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"Million US$, purchasing power parity",417.7
+1084,Australia,2010,5,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million US$ at exchange rate,576.1
+1085,Australia,2010,5,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ exchange rate",26.1
+1086,Australia,2010,5,M-Musculo-skeletal system,"/capita, US$ exchange rate",13.5
+1087,Australia,2010,5,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million of national currency units,628.0
+1088,Australia,2010,5,M-Musculo-skeletal system,"/capita, US$ purchasing power parity",9.8
+1089,Australia,2010,5,C09-Agents acting on the Renin-Angiotensin system,% of total sales,6.0
+1090,Australia,2010,5,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ exchange rate",24.6
+1091,Australia,2010,5,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ purchasing power parity",17.9
+1092,Australia,2010,5,B-Blood and blood forming organs,% of total sales,4.1
+1093,Australia,2010,5,B-Blood and blood forming organs,"/capita, US$ exchange rate",16.9
+1094,Australia,2010,5,B-Blood and blood forming organs,"/capita, US$ purchasing power parity",12.3
+1095,Australia,2010,5,R03-Drugs for obstructive airway diseases,"/capita, US$ purchasing power parity",16.4
+1096,Australia,2010,5,R03-Drugs for obstructive airway diseases,"Million US$, purchasing power parity",360.5
+1097,Australia,2010,5,R03-Drugs for obstructive airway diseases,"/capita, US$ exchange rate",22.6
+1098,Australia,2010,5,R03-Drugs for obstructive airway diseases,% of total sales,5.5
+1099,Australia,2010,5,C09-Agents acting on the Renin-Angiotensin system,Million US$ at exchange rate,543.0
+1100,Australia,2010,5,C09-Agents acting on the Renin-Angiotensin system,"Million US$, purchasing power parity",393.7
+1101,Australia,2010,5,C09-Agents acting on the Renin-Angiotensin system,Million of national currency units,592.0
+1102,Australia,2010,5,R-Respiratory system,"/capita, US$ exchange rate",22.9
+1103,Australia,2010,5,R-Respiratory system,Million US$ at exchange rate,505.4
+1104,Australia,2010,5,R-Respiratory system,"Million US$, purchasing power parity",366.4
+1105,Australia,2010,5,R-Respiratory system,"/capita, US$ purchasing power parity",16.6
+1106,Australia,2010,5,C08-Calcium channel blockers,Million of national currency units,159.0
+1107,Australia,2010,5,C08-Calcium channel blockers,Million US$ at exchange rate,145.9
+1108,Australia,2010,5,R-Respiratory system,% of total sales,5.6
+1109,Australia,2010,5,C07-Beta blocking agents,"Million US$, purchasing power parity",94.4
+1110,Australia,2010,5,C07-Beta blocking agents,"/capita, US$ exchange rate",5.9
+1111,Australia,2010,5,C07-Beta blocking agents,Million US$ at exchange rate,130.3
+1112,Australia,2010,5,R-Respiratory system,Million of national currency units,551.0
+1113,Australia,2010,5,C07-Beta blocking agents,% of total sales,1.4
+1114,Australia,2010,5,C07-Beta blocking agents,"/capita, US$ purchasing power parity",4.3
+1115,Australia,2010,5,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ purchasing power parity",19.0
+1116,Australia,2010,5,A-Alimentary tract and metabolism,"/capita, US$ exchange rate",51.1
+1117,Australia,2010,5,A-Alimentary tract and metabolism,"/capita, US$ purchasing power parity",37.0
+1118,Australia,2010,5,A-Alimentary tract and metabolism,"Million US$, purchasing power parity",816.0
+1119,Australia,2010,5,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),% of total sales,6.4
+1120,Australia,2010,5,A-Alimentary tract and metabolism,% of total sales,12.5
+1121,Australia,2010,5,C08-Calcium channel blockers,"/capita, US$ exchange rate",6.6
+1122,Australia,2010,5,C08-Calcium channel blockers,"/capita, US$ purchasing power parity",4.8
+1123,Australia,2010,5,C08-Calcium channel blockers,"Million US$, purchasing power parity",105.7
+1124,Australia,2010,5,M-Musculo-skeletal system,% of total sales,3.3
+1125,Australia,2010,5,A-Alimentary tract and metabolism,Million of national currency units,1227.0
+1126,Australia,2010,5,A-Alimentary tract and metabolism,Million US$ at exchange rate,1125.5
+1127,Australia,2010,5,C08-Calcium channel blockers,% of total sales,1.6
+1128,Australia,2010,5,Products not elsewhere classified,Million of national currency units,2266.0
+1129,Australia,2010,5,A02A-Antacids,% of total sales,0.0
+1130,Australia,2010,5,G-Genito urinary system and sex hormones,% of total sales,1.4
+1131,Australia,2010,5,A02A-Antacids,"Million US$, purchasing power parity",1.3
+1132,Australia,2010,5,A02A-Antacids,"/capita, US$ exchange rate",0.1
+1133,Australia,2010,5,A02A-Antacids,"/capita, US$ purchasing power parity",0.1
+1134,Australia,2010,5,G-Genito urinary system and sex hormones,"/capita, US$ purchasing power parity",4.2
+1135,Australia,2010,5,J-Antiinfectives for systemic use,Million US$ at exchange rate,324.7
+1136,Australia,2010,5,J-Antiinfectives for systemic use,Million of national currency units,354.0
+1137,Australia,2010,5,G-Genito urinary system and sex hormones,Million of national currency units,138.0
+1138,Australia,2010,5,C-Cardiovascular system,Million of national currency units,2744.0
+1139,Australia,2010,5,G-Genito urinary system and sex hormones,"/capita, US$ exchange rate",5.7
+1140,Australia,2010,5,G-Genito urinary system and sex hormones,Million US$ at exchange rate,126.6
+1141,Australia,2010,5,G-Genito urinary system and sex hormones,"Million US$, purchasing power parity",91.8
+1142,Australia,2010,5,C-Cardiovascular system,Million US$ at exchange rate,2517.1
+1143,Australia,2010,5,G03-Sex hormones and modulators of the genital system,"/capita, US$ exchange rate",4.2
+1144,Australia,2010,5,G03-Sex hormones and modulators of the genital system,Million US$ at exchange rate,91.7
+1145,Australia,2010,5,G03-Sex hormones and modulators of the genital system,"Million US$, purchasing power parity",66.5
+1146,Australia,2010,5,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million of national currency units,79.0
+1147,Australia,2010,5,G03-Sex hormones and modulators of the genital system,"/capita, US$ purchasing power parity",3.0
+1148,Australia,2010,5,G03-Sex hormones and modulators of the genital system,% of total sales,1.0
+1149,Australia,2010,5,"H-Systemic hormonal preparations, excluding sex hormones and insulins",% of total sales,0.8
+1150,Australia,2010,5,A02A-Antacids,Million US$ at exchange rate,1.8
+1151,Australia,2010,5,A02A-Antacids,Million of national currency units,2.0
+1152,Australia,2010,5,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ purchasing power parity",2.4
+1153,Australia,2010,5,"H-Systemic hormonal preparations, excluding sex hormones and insulins","Million US$, purchasing power parity",52.5
+1154,Australia,2010,5,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million US$ at exchange rate,72.5
+1155,Australia,2010,5,G03-Sex hormones and modulators of the genital system,Million of national currency units,100.0
+1156,Australia,2010,5,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ exchange rate",3.3
+1157,Australia,2010,5,C10-Lipid modifying agents,"/capita, US$ purchasing power parity",50.7
+1158,Australia,2010,5,C10-Lipid modifying agents,% of total sales,17.2
+1159,Australia,2010,5,C10-Lipid modifying agents,"/capita, US$ exchange rate",69.9
+1160,Australia,2010,5,J01-Antibacterials for systemic use,% of total sales,2.0
+1161,Australia,2010,5,Products not elsewhere classified,% of total sales,23.1
+1162,Australia,2010,5,C10-Lipid modifying agents,"Million US$, purchasing power parity",1117.3
+1163,Australia,2010,5,Products not elsewhere classified,"Million US$, purchasing power parity",1507.0
+1164,Australia,2010,5,Products not elsewhere classified,"/capita, US$ exchange rate",94.3
+1165,Australia,2010,5,Products not elsewhere classified,Million US$ at exchange rate,2078.6
+1166,Australia,2010,5,C10-Lipid modifying agents,Million US$ at exchange rate,1541.1
+1167,Australia,2010,5,Products not elsewhere classified,"/capita, US$ purchasing power parity",68.4
+1168,Australia,2010,5,C10-Lipid modifying agents,Million of national currency units,1680.0
+1169,Australia,2010,5,C-Cardiovascular system,% of total sales,28.0
+1170,Australia,2010,5,J-Antiinfectives for systemic use,"Million US$, purchasing power parity",235.4
+1171,Australia,2010,5,J-Antiinfectives for systemic use,"/capita, US$ exchange rate",14.7
+1172,Australia,2010,5,C-Cardiovascular system,"Million US$, purchasing power parity",1824.9
+1173,Australia,2010,5,C-Cardiovascular system,"/capita, US$ purchasing power parity",82.8
+1174,Australia,2010,5,C-Cardiovascular system,"/capita, US$ exchange rate",114.2
+1175,Australia,2010,5,J01-Antibacterials for systemic use,"Million US$, purchasing power parity",129.0
+1176,Australia,2010,5,J01-Antibacterials for systemic use,"/capita, US$ purchasing power parity",5.9
+1177,Australia,2010,5,J01-Antibacterials for systemic use,"/capita, US$ exchange rate",8.1
+1178,Australia,2010,5,J01-Antibacterials for systemic use,Million US$ at exchange rate,178.0
+1179,Australia,2010,5,J-Antiinfectives for systemic use,% of total sales,3.6
+1180,Australia,2010,5,J-Antiinfectives for systemic use,"/capita, US$ purchasing power parity",10.7
+1181,Australia,2010,5,J01-Antibacterials for systemic use,Million of national currency units,194.0
+1182,Australia,2010,5,C07-Beta blocking agents,Million of national currency units,142.0
+1183,Australia,2010,5,C01A-Cardiac glycosides,Million of national currency units,4.0
+1184,Australia,2010,5,C01A-Cardiac glycosides,"/capita, US$ exchange rate",0.2
+1185,Australia,2010,5,C01A-Cardiac glycosides,"/capita, US$ purchasing power parity",0.1
+1186,Australia,2010,5,"C01B-Antiarrhythmics, Class I and III","Million US$, purchasing power parity",11.3
+1187,Australia,2010,5,C01A-Cardiac glycosides,"Million US$, purchasing power parity",2.7
+1188,Australia,2010,5,"C01B-Antiarrhythmics, Class I and III",Million US$ at exchange rate,15.6
+1189,Australia,2010,5,"C01B-Antiarrhythmics, Class I and III","/capita, US$ exchange rate",0.7
+1190,Australia,2010,5,"C01B-Antiarrhythmics, Class I and III","/capita, US$ purchasing power parity",0.5
+1191,Australia,2010,5,C01A-Cardiac glycosides,% of total sales,0.0
+1192,Australia,2010,5,A10-Drugs used in diabetes,"/capita, US$ purchasing power parity",12.8
+1193,Australia,2010,5,C03-Diuretics,Million US$ at exchange rate,28.4
+1194,Australia,2010,5,C03-Diuretics,Million of national currency units,31.0
+1195,Australia,2010,5,C02-Antihypertensives,"/capita, US$ purchasing power parity",1.9
+1196,Australia,2010,5,A10-Drugs used in diabetes,"/capita, US$ exchange rate",17.7
+1197,Australia,2010,5,C02-Antihypertensives,"/capita, US$ exchange rate",2.7
+1198,Australia,2010,5,C01A-Cardiac glycosides,Million US$ at exchange rate,3.7
+1199,Australia,2010,5,C02-Antihypertensives,% of total sales,0.7
+1200,Australia,2010,5,"C01B-Antiarrhythmics, Class I and III",Million of national currency units,17.0
+1201,Australia,2010,5,A10-Drugs used in diabetes,Million of national currency units,424.0
+1202,Australia,2010,5,N-Nervous system,"Million US$, purchasing power parity",1135.3
+1203,Australia,2010,5,N-Nervous system,Million US$ at exchange rate,1565.8
+1204,Australia,2010,5,N05C-Hypnotics and sedatives,Million of national currency units,19.0
+1205,Australia,2010,5,N05C-Hypnotics and sedatives,Million US$ at exchange rate,17.4
+1206,Australia,2010,5,N05C-Hypnotics and sedatives,"Million US$, purchasing power parity",12.6
+1207,Australia,2010,5,A10-Drugs used in diabetes,% of total sales,4.3
+1208,Australia,2010,5,N05B-Anxiolytics,% of total sales,0.3
+1209,Australia,2010,5,N-Nervous system,Million of national currency units,1707.0
+1210,Australia,2010,5,N05B-Anxiolytics,Million of national currency units,29.0
+1211,Australia,2010,5,N05B-Anxiolytics,Million US$ at exchange rate,26.6
+1212,Australia,2010,5,N-Nervous system,% of total sales,17.4
+1213,Australia,2010,5,N-Nervous system,"/capita, US$ purchasing power parity",51.5
+1214,Australia,2010,5,"C01B-Antiarrhythmics, Class I and III",% of total sales,0.2
+1215,Australia,2010,5,N05C-Hypnotics and sedatives,"/capita, US$ purchasing power parity",0.6
+1216,Australia,2010,5,N05C-Hypnotics and sedatives,"/capita, US$ exchange rate",0.8
+1217,Australia,2010,5,N-Nervous system,"/capita, US$ exchange rate",71.1
+1218,Australia,2010,5,N05C-Hypnotics and sedatives,% of total sales,0.2
+1219,Australia,2010,5,Total pharmaceutical sales,"/capita, US$ purchasing power parity",295.7
+1220,Australia,2010,5,N02-Analgesics,Million of national currency units,378.0
+1221,Australia,2010,5,N06A-Antidepressants,Million US$ at exchange rate,429.3
+1222,Australia,2010,5,Total pharmaceutical sales,"Million US$, purchasing power parity",6514.3
+1223,Australia,2010,5,Total pharmaceutical sales,"/capita, US$ exchange rate",407.8
+1224,Australia,2010,5,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ exchange rate",4.2
+1225,Australia,2010,5,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ purchasing power parity",3.1
+1226,Australia,2010,5,M01A-Antiinflammatory and antirheumatic products non-steroids,"Million US$, purchasing power parity",67.8
+1227,Australia,2010,5,N06A-Antidepressants,Million of national currency units,468.0
+1228,Australia,2010,5,M01A-Antiinflammatory and antirheumatic products non-steroids,Million of national currency units,102.0
+1229,Australia,2010,5,M01A-Antiinflammatory and antirheumatic products non-steroids,Million US$ at exchange rate,93.6
+1230,Australia,2010,5,Total pharmaceutical sales,Million US$ at exchange rate,8984.9
+1231,Australia,2010,5,N05B-Anxiolytics,"Million US$, purchasing power parity",19.3
+1232,Australia,2010,5,N06A-Antidepressants,"/capita, US$ exchange rate",19.5
+1233,Australia,2010,5,N06A-Antidepressants,"Million US$, purchasing power parity",311.2
+1234,Australia,2010,5,N06A-Antidepressants,% of total sales,4.8
+1235,Australia,2010,5,N06A-Antidepressants,"/capita, US$ purchasing power parity",14.1
+1236,Australia,2010,5,N05B-Anxiolytics,"/capita, US$ purchasing power parity",0.9
+1237,Australia,2010,5,C03-Diuretics,% of total sales,0.3
+1238,Australia,2010,5,C02-Antihypertensives,Million of national currency units,64.0
+1239,Australia,2010,5,N05B-Anxiolytics,"/capita, US$ exchange rate",1.2
+1240,Australia,2010,5,A10-Drugs used in diabetes,Million US$ at exchange rate,388.9
+1241,Australia,2010,5,C03-Diuretics,"Million US$, purchasing power parity",20.6
+1242,Australia,2010,5,A10-Drugs used in diabetes,"Million US$, purchasing power parity",282.0
+1243,Australia,2010,5,C03-Diuretics,"/capita, US$ purchasing power parity",0.9
+1244,Australia,2010,5,C03-Diuretics,"/capita, US$ exchange rate",1.3
+1245,Australia,2010,5,M01A-Antiinflammatory and antirheumatic products non-steroids,% of total sales,1.0
+1246,Australia,2010,5,N02-Analgesics,"Million US$, purchasing power parity",251.4
+1247,Australia,2010,5,N02-Analgesics,"/capita, US$ exchange rate",15.7
+1248,Australia,2010,5,N02-Analgesics,Million US$ at exchange rate,346.7
+1249,Australia,2010,5,C02-Antihypertensives,"Million US$, purchasing power parity",42.6
+1250,Australia,2010,5,C02-Antihypertensives,Million US$ at exchange rate,58.7
+1251,Australia,2010,5,N02-Analgesics,"/capita, US$ purchasing power parity",11.4
+1252,Australia,2010,5,N02-Analgesics,% of total sales,3.9
+1253,Australia,2017,6,B-Blood and blood forming organs,Million of national currency units,748.0
+1254,Australia,2017,6,M-Musculo-skeletal system,Million of national currency units,429.0
+1255,Australia,2017,6,M-Musculo-skeletal system,Million US$ at exchange rate,328.8
+1256,Australia,2017,6,R03-Drugs for obstructive airway diseases,Million of national currency units,650.0
+1257,Australia,2017,6,B-Blood and blood forming organs,Million US$ at exchange rate,573.3
+1258,Australia,2017,6,B-Blood and blood forming organs,"Million US$, purchasing power parity",506.2
+1259,Australia,2017,6,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million US$ at exchange rate,346.4
+1260,Australia,2017,6,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ exchange rate",14.1
+1261,Australia,2017,6,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"Million US$, purchasing power parity",305.9
+1262,Australia,2017,6,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million of national currency units,452.0
+1263,Australia,2017,6,M-Musculo-skeletal system,"/capita, US$ exchange rate",13.4
+1264,Australia,2017,6,M-Musculo-skeletal system,"Million US$, purchasing power parity",290.3
+1265,Australia,2017,6,M-Musculo-skeletal system,"/capita, US$ purchasing power parity",11.8
+1266,Australia,2017,6,R03-Drugs for obstructive airway diseases,Million US$ at exchange rate,498.2
+1267,Australia,2017,6,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ purchasing power parity",16.5
+1268,Australia,2017,6,C09-Agents acting on the Renin-Angiotensin system,% of total sales,4.0
+1269,Australia,2017,6,C09-Agents acting on the Renin-Angiotensin system,"Million US$, purchasing power parity",404.7
+1270,Australia,2017,6,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ exchange rate",18.6
+1271,Australia,2017,6,B-Blood and blood forming organs,"/capita, US$ purchasing power parity",20.6
+1272,Australia,2017,6,B-Blood and blood forming organs,% of total sales,5.1
+1273,Australia,2017,6,B-Blood and blood forming organs,"/capita, US$ exchange rate",23.3
+1274,Australia,2017,6,R03-Drugs for obstructive airway diseases,"/capita, US$ exchange rate",20.3
+1275,Australia,2017,6,R03-Drugs for obstructive airway diseases,"/capita, US$ purchasing power parity",17.9
+1276,Australia,2017,6,R03-Drugs for obstructive airway diseases,"Million US$, purchasing power parity",439.9
+1277,Australia,2017,6,C09-Agents acting on the Renin-Angiotensin system,Million US$ at exchange rate,458.3
+1278,Australia,2017,6,C09-Agents acting on the Renin-Angiotensin system,Million of national currency units,598.0
+1279,Australia,2017,6,R03-Drugs for obstructive airway diseases,% of total sales,4.4
+1280,Australia,2017,6,R-Respiratory system,"Million US$, purchasing power parity",493.4
+1281,Australia,2017,6,R-Respiratory system,"/capita, US$ exchange rate",22.7
+1282,Australia,2017,6,R-Respiratory system,Million US$ at exchange rate,558.7
+1283,Australia,2017,6,C08-Calcium channel blockers,Million of national currency units,130.0
+1284,Australia,2017,6,R-Respiratory system,"/capita, US$ purchasing power parity",20.1
+1285,Australia,2017,6,R-Respiratory system,% of total sales,4.9
+1286,Australia,2017,6,R-Respiratory system,Million of national currency units,729.0
+1287,Australia,2017,6,C07-Beta blocking agents,"Million US$, purchasing power parity",103.5
+1288,Australia,2017,6,C07-Beta blocking agents,Million of national currency units,153.0
+1289,Australia,2017,6,C07-Beta blocking agents,Million US$ at exchange rate,117.3
+1290,Australia,2017,6,C07-Beta blocking agents,% of total sales,1.0
+1291,Australia,2017,6,C07-Beta blocking agents,"/capita, US$ exchange rate",4.8
+1292,Australia,2017,6,C07-Beta blocking agents,"/capita, US$ purchasing power parity",4.2
+1293,Australia,2017,6,A-Alimentary tract and metabolism,"/capita, US$ exchange rate",44.4
+1294,Australia,2017,6,A-Alimentary tract and metabolism,Million US$ at exchange rate,1091.4
+1295,Australia,2017,6,A-Alimentary tract and metabolism,"Million US$, purchasing power parity",963.8
+1296,Australia,2017,6,A-Alimentary tract and metabolism,"/capita, US$ purchasing power parity",39.2
+1297,Australia,2017,6,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ purchasing power parity",12.4
+1298,Australia,2017,6,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),% of total sales,3.1
+1299,Australia,2017,6,A-Alimentary tract and metabolism,% of total sales,9.6
+1300,Australia,2017,6,C08-Calcium channel blockers,"/capita, US$ exchange rate",4.1
+1301,Australia,2017,6,C08-Calcium channel blockers,Million US$ at exchange rate,99.6
+1302,Australia,2017,6,C08-Calcium channel blockers,"Million US$, purchasing power parity",88.0
+1303,Australia,2017,6,C08-Calcium channel blockers,"/capita, US$ purchasing power parity",3.6
+1304,Australia,2017,6,A-Alimentary tract and metabolism,Million of national currency units,1424.0
+1305,Australia,2017,6,C08-Calcium channel blockers,% of total sales,0.9
+1306,Australia,2017,6,M-Musculo-skeletal system,% of total sales,2.9
+1307,Australia,2017,6,A02A-Antacids,% of total sales,0.0
+1308,Australia,2017,6,G-Genito urinary system and sex hormones,% of total sales,2.5
+1309,Australia,2017,6,G-Genito urinary system and sex hormones,"/capita, US$ purchasing power parity",10.0
+1310,Australia,2017,6,A02A-Antacids,"/capita, US$ purchasing power parity",0.0
+1311,Australia,2017,6,A02A-Antacids,"Million US$, purchasing power parity",0.0
+1312,Australia,2017,6,A02A-Antacids,Million US$ at exchange rate,0.0
+1313,Australia,2017,6,A02A-Antacids,"/capita, US$ exchange rate",0.0
+1314,Australia,2017,6,J-Antiinfectives for systemic use,Million of national currency units,2540.0
+1315,Australia,2017,6,C-Cardiovascular system,Million of national currency units,1798.0
+1316,Australia,2017,6,J-Antiinfectives for systemic use,Million US$ at exchange rate,1946.7
+1317,Australia,2017,6,G-Genito urinary system and sex hormones,Million of national currency units,362.0
+1318,Australia,2017,6,G-Genito urinary system and sex hormones,"Million US$, purchasing power parity",245.0
+1319,Australia,2017,6,G-Genito urinary system and sex hormones,"/capita, US$ exchange rate",11.3
+1320,Australia,2017,6,G-Genito urinary system and sex hormones,Million US$ at exchange rate,277.4
+1321,Australia,2017,6,G03-Sex hormones and modulators of the genital system,"Million US$, purchasing power parity",183.4
+1322,Australia,2017,6,G03-Sex hormones and modulators of the genital system,"/capita, US$ exchange rate",8.4
+1323,Australia,2017,6,G03-Sex hormones and modulators of the genital system,Million of national currency units,271.0
+1324,Australia,2017,6,G03-Sex hormones and modulators of the genital system,Million US$ at exchange rate,207.7
+1325,Australia,2017,6,G03-Sex hormones and modulators of the genital system,% of total sales,1.8
+1326,Australia,2017,6,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million of national currency units,237.0
+1327,Australia,2017,6,G03-Sex hormones and modulators of the genital system,"/capita, US$ purchasing power parity",7.5
+1328,Australia,2017,6,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ purchasing power parity",6.5
+1329,Australia,2017,6,"H-Systemic hormonal preparations, excluding sex hormones and insulins",% of total sales,1.6
+1330,Australia,2017,6,A02A-Antacids,Million of national currency units,0.0
+1331,Australia,2017,6,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million US$ at exchange rate,181.6
+1332,Australia,2017,6,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ exchange rate",7.4
+1333,Australia,2017,6,"H-Systemic hormonal preparations, excluding sex hormones and insulins","Million US$, purchasing power parity",160.4
+1334,Australia,2017,6,C10-Lipid modifying agents,"/capita, US$ purchasing power parity",18.5
+1335,Australia,2017,6,C10-Lipid modifying agents,"/capita, US$ exchange rate",21.0
+1336,Australia,2017,6,C10-Lipid modifying agents,"Million US$, purchasing power parity",456.2
+1337,Australia,2017,6,J01-Antibacterials for systemic use,% of total sales,2.7
+1338,Australia,2017,6,J01-Antibacterials for systemic use,"/capita, US$ purchasing power parity",10.9
+1339,Australia,2017,6,C10-Lipid modifying agents,% of total sales,4.6
+1340,Australia,2017,6,Products not elsewhere classified,% of total sales,31.0
+1341,Australia,2017,6,Products not elsewhere classified,"Million US$, purchasing power parity",3104.5
+1342,Australia,2017,6,Products not elsewhere classified,Million US$ at exchange rate,3515.6
+1343,Australia,2017,6,Products not elsewhere classified,Million of national currency units,4587.0
+1344,Australia,2017,6,C10-Lipid modifying agents,Million of national currency units,674.0
+1345,Australia,2017,6,C10-Lipid modifying agents,Million US$ at exchange rate,516.6
+1346,Australia,2017,6,Products not elsewhere classified,"/capita, US$ exchange rate",142.9
+1347,Australia,2017,6,Products not elsewhere classified,"/capita, US$ purchasing power parity",126.2
+1348,Australia,2017,6,C-Cardiovascular system,% of total sales,12.2
+1349,Australia,2017,6,J-Antiinfectives for systemic use,"Million US$, purchasing power parity",1719.1
+1350,Australia,2017,6,C-Cardiovascular system,"/capita, US$ purchasing power parity",49.5
+1351,Australia,2017,6,C-Cardiovascular system,"Million US$, purchasing power parity",1216.9
+1352,Australia,2017,6,C-Cardiovascular system,Million US$ at exchange rate,1378.0
+1353,Australia,2017,6,C-Cardiovascular system,"/capita, US$ exchange rate",56.0
+1354,Australia,2017,6,J-Antiinfectives for systemic use,"/capita, US$ exchange rate",79.2
+1355,Australia,2017,6,J01-Antibacterials for systemic use,Million US$ at exchange rate,302.7
+1356,Australia,2017,6,J01-Antibacterials for systemic use,"Million US$, purchasing power parity",267.3
+1357,Australia,2017,6,J01-Antibacterials for systemic use,"/capita, US$ exchange rate",12.3
+1358,Australia,2017,6,J-Antiinfectives for systemic use,"/capita, US$ purchasing power parity",69.9
+1359,Australia,2017,6,J01-Antibacterials for systemic use,Million of national currency units,395.0
+1360,Australia,2017,6,J-Antiinfectives for systemic use,% of total sales,17.2
+1361,Australia,2017,6,C01A-Cardiac glycosides,"Million US$, purchasing power parity",3.4
+1362,Australia,2017,6,C01A-Cardiac glycosides,"/capita, US$ exchange rate",0.2
+1363,Australia,2017,6,"C01B-Antiarrhythmics, Class I and III",Million US$ at exchange rate,15.3
+1364,Australia,2017,6,A10-Drugs used in diabetes,"/capita, US$ purchasing power parity",19.8
+1365,Australia,2017,6,"C01B-Antiarrhythmics, Class I and III","/capita, US$ exchange rate",0.6
+1366,Australia,2017,6,C01A-Cardiac glycosides,% of total sales,0.0
+1367,Australia,2017,6,"C01B-Antiarrhythmics, Class I and III","Million US$, purchasing power parity",13.5
+1368,Australia,2017,6,C01A-Cardiac glycosides,"/capita, US$ purchasing power parity",0.1
+1369,Australia,2017,6,C03-Diuretics,Million of national currency units,48.0
+1370,Australia,2017,6,A10-Drugs used in diabetes,"Million US$, purchasing power parity",485.9
+1371,Australia,2017,6,C02-Antihypertensives,"/capita, US$ exchange rate",3.3
+1372,Australia,2017,6,C02-Antihypertensives,"/capita, US$ purchasing power parity",2.9
+1373,Australia,2017,6,C01A-Cardiac glycosides,Million of national currency units,5.0
+1374,Australia,2017,6,C01A-Cardiac glycosides,Million US$ at exchange rate,3.8
+1375,Australia,2017,6,"C01B-Antiarrhythmics, Class I and III",Million of national currency units,20.0
+1376,Australia,2017,6,C02-Antihypertensives,% of total sales,0.7
+1377,Australia,2017,6,A10-Drugs used in diabetes,"/capita, US$ exchange rate",22.4
+1378,Australia,2017,6,N-Nervous system,Million US$ at exchange rate,1471.5
+1379,Australia,2017,6,N-Nervous system,Million of national currency units,1920.0
+1380,Australia,2017,6,N-Nervous system,"Million US$, purchasing power parity",1299.4
+1381,Australia,2017,6,N05C-Hypnotics and sedatives,Million US$ at exchange rate,21.5
+1382,Australia,2017,6,N05C-Hypnotics and sedatives,Million of national currency units,28.0
+1383,Australia,2017,6,N05B-Anxiolytics,% of total sales,0.3
+1384,Australia,2017,6,A10-Drugs used in diabetes,% of total sales,4.9
+1385,Australia,2017,6,N05B-Anxiolytics,Million of national currency units,48.0
+1386,Australia,2017,6,N05B-Anxiolytics,"/capita, US$ purchasing power parity",1.3
+1387,Australia,2017,6,N-Nervous system,"/capita, US$ purchasing power parity",52.8
+1388,Australia,2017,6,N-Nervous system,"/capita, US$ exchange rate",59.8
+1389,Australia,2017,6,N-Nervous system,% of total sales,13.0
+1390,Australia,2017,6,"C01B-Antiarrhythmics, Class I and III",% of total sales,0.1
+1391,Australia,2017,6,N05C-Hypnotics and sedatives,"/capita, US$ exchange rate",0.9
+1392,Australia,2017,6,N05C-Hypnotics and sedatives,"Million US$, purchasing power parity",19.0
+1393,Australia,2017,6,"C01B-Antiarrhythmics, Class I and III","/capita, US$ purchasing power parity",0.6
+1394,Australia,2017,6,N05C-Hypnotics and sedatives,% of total sales,0.2
+1395,Australia,2017,6,N05C-Hypnotics and sedatives,"/capita, US$ purchasing power parity",0.8
+1396,Australia,2017,6,Total pharmaceutical sales,"/capita, US$ purchasing power parity",406.6
+1397,Australia,2017,6,N06A-Antidepressants,Million of national currency units,433.0
+1398,Australia,2017,6,Total pharmaceutical sales,"/capita, US$ exchange rate",460.4
+1399,Australia,2017,6,Total pharmaceutical sales,"Million US$, purchasing power parity",9999.0
+1400,Australia,2017,6,M01A-Antiinflammatory and antirheumatic products non-steroids,"Million US$, purchasing power parity",70.4
+1401,Australia,2017,6,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ exchange rate",3.2
+1402,Australia,2017,6,M01A-Antiinflammatory and antirheumatic products non-steroids,Million of national currency units,104.0
+1403,Australia,2017,6,M01A-Antiinflammatory and antirheumatic products non-steroids,Million US$ at exchange rate,79.7
+1404,Australia,2017,6,N06A-Antidepressants,Million US$ at exchange rate,331.9
+1405,Australia,2017,6,Total pharmaceutical sales,Million of national currency units,14774.0
+1406,Australia,2017,6,Total pharmaceutical sales,Million US$ at exchange rate,11323.2
+1407,Australia,2017,6,A10-Drugs used in diabetes,Million of national currency units,718.0
+1408,Australia,2017,6,N05B-Anxiolytics,Million US$ at exchange rate,36.8
+1409,Australia,2017,6,N06A-Antidepressants,"Million US$, purchasing power parity",293.1
+1410,Australia,2017,6,N06A-Antidepressants,"/capita, US$ exchange rate",13.5
+1411,Australia,2017,6,N06A-Antidepressants,% of total sales,2.9
+1412,Australia,2017,6,N06A-Antidepressants,"/capita, US$ purchasing power parity",11.9
+1413,Australia,2017,6,N05B-Anxiolytics,"/capita, US$ exchange rate",1.5
+1414,Australia,2017,6,C03-Diuretics,% of total sales,0.3
+1415,Australia,2017,6,M01A-Antiinflammatory and antirheumatic products non-steroids,% of total sales,0.7
+1416,Australia,2017,6,N05B-Anxiolytics,"Million US$, purchasing power parity",32.5
+1417,Australia,2017,6,C03-Diuretics,"/capita, US$ purchasing power parity",1.3
+1418,Australia,2017,6,C03-Diuretics,Million US$ at exchange rate,36.8
+1419,Australia,2017,6,A10-Drugs used in diabetes,Million US$ at exchange rate,550.3
+1420,Australia,2017,6,C03-Diuretics,"/capita, US$ exchange rate",1.5
+1421,Australia,2017,6,C03-Diuretics,"Million US$, purchasing power parity",32.5
+1422,Australia,2017,6,N02-Analgesics,"Million US$, purchasing power parity",346.5
+1423,Australia,2017,6,N02-Analgesics,"/capita, US$ exchange rate",16.0
+1424,Australia,2017,6,N02-Analgesics,Million US$ at exchange rate,392.4
+1425,Australia,2017,6,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ purchasing power parity",2.9
+1426,Australia,2017,6,N02-Analgesics,Million of national currency units,512.0
+1427,Australia,2017,6,C02-Antihypertensives,Million US$ at exchange rate,82.0
+1428,Australia,2017,6,C02-Antihypertensives,Million of national currency units,107.0
+1429,Australia,2017,6,C02-Antihypertensives,"Million US$, purchasing power parity",72.4
+1430,Australia,2017,6,N02-Analgesics,"/capita, US$ purchasing power parity",14.1
+1431,Australia,2017,6,N02-Analgesics,% of total sales,3.5
+1432,Austria,2016,5,N-Nervous system,% of total sales,14.8
+1433,Austria,2016,5,N-Nervous system,"Million US$, purchasing power parity",571.1
+1434,Austria,2016,5,N-Nervous system,"/capita, US$ purchasing power parity",65.4
+1435,Austria,2016,5,N-Nervous system,"/capita, US$ exchange rate",56.2
+1436,Austria,2016,5,J01-Antibacterials for systemic use,Million US$ at exchange rate,69.3
+1437,Austria,2016,5,J01-Antibacterials for systemic use,Million of national currency units,62.6
+1438,Austria,2016,5,J-Antiinfectives for systemic use,Million US$ at exchange rate,288.4
+1439,Austria,2016,5,J-Antiinfectives for systemic use,"Million US$, purchasing power parity",335.4
+1440,Austria,2016,5,J-Antiinfectives for systemic use,Million of national currency units,260.6
+1441,Austria,2016,5,J-Antiinfectives for systemic use,"/capita, US$ purchasing power parity",38.4
+1442,Austria,2016,5,J-Antiinfectives for systemic use,% of total sales,8.7
+1443,Austria,2016,5,J-Antiinfectives for systemic use,"/capita, US$ exchange rate",33.0
+1444,Austria,2016,5,"H-Systemic hormonal preparations, excluding sex hormones and insulins",% of total sales,1.8
+1445,Austria,2016,5,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ purchasing power parity",8.1
+1446,Austria,2016,5,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ exchange rate",7.0
+1447,Austria,2016,5,N02-Analgesics,"/capita, US$ exchange rate",8.3
+1448,Austria,2016,5,N02-Analgesics,Million US$ at exchange rate,72.7
+1449,Austria,2016,5,N02-Analgesics,"Million US$, purchasing power parity",84.5
+1450,Austria,2016,5,G03-Sex hormones and modulators of the genital system,% of total sales,0.4
+1451,Austria,2016,5,N02-Analgesics,Million of national currency units,65.7
+1452,Austria,2016,5,G03-Sex hormones and modulators of the genital system,"/capita, US$ purchasing power parity",2.0
+1453,Austria,2016,5,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million US$ at exchange rate,60.9
+1454,Austria,2016,5,"H-Systemic hormonal preparations, excluding sex hormones and insulins","Million US$, purchasing power parity",70.8
+1455,Austria,2016,5,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million of national currency units,55.0
+1456,Austria,2016,5,A10-Drugs used in diabetes,"/capita, US$ purchasing power parity",22.1
+1457,Austria,2016,5,A10-Drugs used in diabetes,"/capita, US$ exchange rate",19.0
+1458,Austria,2016,5,A02A-Antacids,"/capita, US$ purchasing power parity",0.1
+1459,Austria,2016,5,A02A-Antacids,% of total sales,0.0
+1460,Austria,2016,5,A10-Drugs used in diabetes,Million of national currency units,149.7
+1461,Austria,2016,5,A10-Drugs used in diabetes,Million US$ at exchange rate,165.8
+1462,Austria,2016,5,A10-Drugs used in diabetes,"Million US$, purchasing power parity",192.7
+1463,Austria,2016,5,N02-Analgesics,% of total sales,2.2
+1464,Austria,2016,5,A10-Drugs used in diabetes,% of total sales,5.0
+1465,Austria,2016,5,A02A-Antacids,Million of national currency units,0.6
+1466,Austria,2016,5,N02-Analgesics,"/capita, US$ purchasing power parity",9.7
+1467,Austria,2016,5,A02A-Antacids,"/capita, US$ exchange rate",0.1
+1468,Austria,2016,5,A02A-Antacids,"Million US$, purchasing power parity",0.8
+1469,Austria,2016,5,A02A-Antacids,Million US$ at exchange rate,0.6
+1470,Austria,2016,5,J01-Antibacterials for systemic use,"Million US$, purchasing power parity",80.6
+1471,Austria,2016,5,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"Million US$, purchasing power parity",66.6
+1472,Austria,2016,5,M01A-Antiinflammatory and antirheumatic products non-steroids,"Million US$, purchasing power parity",53.5
+1473,Austria,2016,5,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ exchange rate",5.3
+1474,Austria,2016,5,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ exchange rate",6.6
+1475,Austria,2016,5,M01A-Antiinflammatory and antirheumatic products non-steroids,Million US$ at exchange rate,46.0
+1476,Austria,2016,5,M01A-Antiinflammatory and antirheumatic products non-steroids,Million of national currency units,41.6
+1477,Austria,2016,5,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),% of total sales,1.7
+1478,Austria,2016,5,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ purchasing power parity",7.6
+1479,Austria,2016,5,R-Respiratory system,% of total sales,5.7
+1480,Austria,2016,5,R-Respiratory system,"/capita, US$ purchasing power parity",25.4
+1481,Austria,2016,5,N05C-Hypnotics and sedatives,"Million US$, purchasing power parity",3.5
+1482,Austria,2016,5,N05C-Hypnotics and sedatives,"/capita, US$ exchange rate",0.3
+1483,Austria,2016,5,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million of national currency units,51.7
+1484,Austria,2016,5,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million US$ at exchange rate,57.3
+1485,Austria,2016,5,N05C-Hypnotics and sedatives,"/capita, US$ purchasing power parity",0.4
+1486,Austria,2016,5,N05C-Hypnotics and sedatives,% of total sales,0.1
+1487,Austria,2016,5,N06A-Antidepressants,% of total sales,2.8
+1488,Austria,2016,5,N06A-Antidepressants,"/capita, US$ purchasing power parity",12.6
+1489,Austria,2016,5,M-Musculo-skeletal system,"/capita, US$ purchasing power parity",15.1
+1490,Austria,2016,5,M-Musculo-skeletal system,% of total sales,3.4
+1491,Austria,2016,5,N06A-Antidepressants,"Million US$, purchasing power parity",110.0
+1492,Austria,2016,5,N06A-Antidepressants,Million US$ at exchange rate,94.6
+1493,Austria,2016,5,N06A-Antidepressants,Million of national currency units,85.5
+1494,Austria,2016,5,N06A-Antidepressants,"/capita, US$ exchange rate",10.8
+1495,Austria,2016,5,R-Respiratory system,Million of national currency units,172.2
+1496,Austria,2016,5,M-Musculo-skeletal system,"Million US$, purchasing power parity",132.3
+1497,Austria,2016,5,M-Musculo-skeletal system,"/capita, US$ exchange rate",13.0
+1498,Austria,2016,5,M-Musculo-skeletal system,Million of national currency units,102.8
+1499,Austria,2016,5,M-Musculo-skeletal system,Million US$ at exchange rate,113.7
+1500,Austria,2016,5,R-Respiratory system,Million US$ at exchange rate,190.6
+1501,Austria,2016,5,R-Respiratory system,"Million US$, purchasing power parity",221.6
+1502,Austria,2016,5,R-Respiratory system,"/capita, US$ exchange rate",21.8
+1503,Austria,2016,5,N-Nervous system,Million of national currency units,443.7
+1504,Austria,2016,5,B-Blood and blood forming organs,% of total sales,9.3
+1505,Austria,2016,5,Products not elsewhere classified,Million of national currency units,920.3
+1506,Austria,2016,5,N-Nervous system,Million US$ at exchange rate,491.2
+1507,Austria,2016,5,B-Blood and blood forming organs,"Million US$, purchasing power parity",360.9
+1508,Austria,2016,5,B-Blood and blood forming organs,Million US$ at exchange rate,310.3
+1509,Austria,2016,5,B-Blood and blood forming organs,"/capita, US$ purchasing power parity",41.3
+1510,Austria,2016,5,B-Blood and blood forming organs,"/capita, US$ exchange rate",35.5
+1511,Austria,2016,5,J01-Antibacterials for systemic use,% of total sales,2.1
+1512,Austria,2016,5,Products not elsewhere classified,% of total sales,30.6
+1513,Austria,2016,5,J01-Antibacterials for systemic use,"/capita, US$ purchasing power parity",9.2
+1514,Austria,2016,5,J01-Antibacterials for systemic use,"/capita, US$ exchange rate",7.9
+1515,Austria,2016,5,Products not elsewhere classified,"Million US$, purchasing power parity",1184.5
+1516,Austria,2016,5,Products not elsewhere classified,Million US$ at exchange rate,1018.7
+1517,Austria,2016,5,Products not elsewhere classified,"/capita, US$ purchasing power parity",135.6
+1518,Austria,2016,5,Products not elsewhere classified,"/capita, US$ exchange rate",116.6
+1519,Austria,2016,5,R03-Drugs for obstructive airway diseases,Million of national currency units,146.7
+1520,Austria,2016,5,N05B-Anxiolytics,"/capita, US$ purchasing power parity",1.0
+1521,Austria,2016,5,R03-Drugs for obstructive airway diseases,Million US$ at exchange rate,162.3
+1522,Austria,2016,5,N05B-Anxiolytics,"/capita, US$ exchange rate",0.8
+1523,Austria,2016,5,N05C-Hypnotics and sedatives,Million of national currency units,2.7
+1524,Austria,2016,5,N05C-Hypnotics and sedatives,Million US$ at exchange rate,3.0
+1525,Austria,2016,5,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ purchasing power parity",6.1
+1526,Austria,2016,5,M01A-Antiinflammatory and antirheumatic products non-steroids,% of total sales,1.4
+1527,Austria,2016,5,N05B-Anxiolytics,% of total sales,0.2
+1528,Austria,2016,5,R03-Drugs for obstructive airway diseases,"/capita, US$ purchasing power parity",21.6
+1529,Austria,2016,5,R03-Drugs for obstructive airway diseases,"/capita, US$ exchange rate",18.6
+1530,Austria,2016,5,B-Blood and blood forming organs,Million of national currency units,280.4
+1531,Austria,2016,5,R03-Drugs for obstructive airway diseases,% of total sales,4.9
+1532,Austria,2016,5,R03-Drugs for obstructive airway diseases,"Million US$, purchasing power parity",188.8
+1533,Austria,2016,5,N05B-Anxiolytics,Million US$ at exchange rate,7.2
+1534,Austria,2016,5,N05B-Anxiolytics,"Million US$, purchasing power parity",8.4
+1535,Austria,2016,5,N05B-Anxiolytics,Million of national currency units,6.5
+1536,Austria,2016,5,G03-Sex hormones and modulators of the genital system,"/capita, US$ exchange rate",1.7
+1537,Austria,2016,5,A-Alimentary tract and metabolism,Million US$ at exchange rate,328.7
+1538,Austria,2016,5,A-Alimentary tract and metabolism,"Million US$, purchasing power parity",382.2
+1539,Austria,2016,5,A-Alimentary tract and metabolism,Million of national currency units,296.9
+1540,Austria,2016,5,A-Alimentary tract and metabolism,% of total sales,9.9
+1541,Austria,2016,5,C08-Calcium channel blockers,"/capita, US$ purchasing power parity",1.6
+1542,Austria,2016,5,A-Alimentary tract and metabolism,"/capita, US$ exchange rate",37.6
+1543,Austria,2016,5,A-Alimentary tract and metabolism,"/capita, US$ purchasing power parity",43.7
+1544,Austria,2016,5,C08-Calcium channel blockers,"/capita, US$ exchange rate",1.4
+1545,Austria,2016,5,C07-Beta blocking agents,"/capita, US$ purchasing power parity",6.4
+1546,Austria,2016,5,C07-Beta blocking agents,% of total sales,1.5
+1547,Austria,2016,5,C07-Beta blocking agents,"Million US$, purchasing power parity",56.1
+1548,Austria,2016,5,C07-Beta blocking agents,"/capita, US$ exchange rate",5.5
+1549,Austria,2016,5,C08-Calcium channel blockers,"Million US$, purchasing power parity",14.0
+1550,Austria,2016,5,C08-Calcium channel blockers,Million US$ at exchange rate,12.0
+1551,Austria,2016,5,C08-Calcium channel blockers,Million of national currency units,10.9
+1552,Austria,2016,5,C10-Lipid modifying agents,"/capita, US$ exchange rate",12.9
+1553,Austria,2016,5,C10-Lipid modifying agents,"/capita, US$ purchasing power parity",15.1
+1554,Austria,2016,5,C10-Lipid modifying agents,Million US$ at exchange rate,113.1
+1555,Austria,2016,5,C10-Lipid modifying agents,"Million US$, purchasing power parity",131.5
+1556,Austria,2016,5,C-Cardiovascular system,"/capita, US$ purchasing power parity",63.0
+1557,Austria,2016,5,C-Cardiovascular system,"/capita, US$ exchange rate",54.2
+1558,Austria,2016,5,C10-Lipid modifying agents,% of total sales,3.4
+1559,Austria,2016,5,C-Cardiovascular system,% of total sales,14.2
+1560,Austria,2016,5,C09-Agents acting on the Renin-Angiotensin system,Million US$ at exchange rate,176.2
+1561,Austria,2016,5,C09-Agents acting on the Renin-Angiotensin system,"Million US$, purchasing power parity",204.9
+1562,Austria,2016,5,C08-Calcium channel blockers,% of total sales,0.4
+1563,Austria,2016,5,C09-Agents acting on the Renin-Angiotensin system,Million of national currency units,159.2
+1564,Austria,2016,5,C09-Agents acting on the Renin-Angiotensin system,% of total sales,5.3
+1565,Austria,2016,5,C10-Lipid modifying agents,Million of national currency units,102.2
+1566,Austria,2016,5,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ exchange rate",20.2
+1567,Austria,2016,5,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ purchasing power parity",23.5
+1568,Austria,2016,5,"C01B-Antiarrhythmics, Class I and III",% of total sales,0.2
+1569,Austria,2016,5,"C01B-Antiarrhythmics, Class I and III","/capita, US$ purchasing power parity",1.0
+1570,Austria,2016,5,"C01B-Antiarrhythmics, Class I and III","/capita, US$ exchange rate",0.9
+1571,Austria,2016,5,C02-Antihypertensives,Million of national currency units,48.7
+1572,Austria,2016,5,C02-Antihypertensives,"/capita, US$ exchange rate",6.2
+1573,Austria,2016,5,C02-Antihypertensives,"Million US$, purchasing power parity",62.7
+1574,Austria,2016,5,C02-Antihypertensives,Million US$ at exchange rate,53.9
+1575,Austria,2016,5,Total pharmaceutical sales,"Million US$, purchasing power parity",3869.5
+1576,Austria,2016,5,Total pharmaceutical sales,"/capita, US$ exchange rate",380.9
+1577,Austria,2016,5,Total pharmaceutical sales,Million of national currency units,3006.4
+1578,Austria,2016,5,Total pharmaceutical sales,Million US$ at exchange rate,3327.8
+1579,Austria,2016,5,"C01B-Antiarrhythmics, Class I and III",Million US$ at exchange rate,7.5
+1580,Austria,2016,5,"C01B-Antiarrhythmics, Class I and III",Million of national currency units,6.8
+1581,Austria,2016,5,Total pharmaceutical sales,"/capita, US$ purchasing power parity",442.9
+1582,Austria,2016,5,"C01B-Antiarrhythmics, Class I and III","Million US$, purchasing power parity",8.8
+1583,Austria,2016,5,C03-Diuretics,"Million US$, purchasing power parity",21.7
+1584,Austria,2016,5,C03-Diuretics,"/capita, US$ exchange rate",2.1
+1585,Austria,2016,5,C03-Diuretics,Million of national currency units,16.9
+1586,Austria,2016,5,C03-Diuretics,Million US$ at exchange rate,18.7
+1587,Austria,2016,5,C07-Beta blocking agents,Million of national currency units,43.6
+1588,Austria,2016,5,C07-Beta blocking agents,Million US$ at exchange rate,48.3
+1589,Austria,2016,5,C03-Diuretics,"/capita, US$ purchasing power parity",2.5
+1590,Austria,2016,5,C03-Diuretics,% of total sales,0.6
+1591,Austria,2016,5,C01A-Cardiac glycosides,% of total sales,0.0
+1592,Austria,2016,5,C01A-Cardiac glycosides,"/capita, US$ purchasing power parity",0.1
+1593,Austria,2016,5,C02-Antihypertensives,"/capita, US$ purchasing power parity",7.2
+1594,Austria,2016,5,C02-Antihypertensives,% of total sales,1.6
+1595,Austria,2016,5,C01A-Cardiac glycosides,Million US$ at exchange rate,0.5
+1596,Austria,2016,5,C01A-Cardiac glycosides,Million of national currency units,0.5
+1597,Austria,2016,5,C01A-Cardiac glycosides,"/capita, US$ exchange rate",0.1
+1598,Austria,2016,5,C01A-Cardiac glycosides,"Million US$, purchasing power parity",0.6
+1599,Austria,2016,5,G-Genito urinary system and sex hormones,Million of national currency units,46.6
+1600,Austria,2016,5,G-Genito urinary system and sex hormones,Million US$ at exchange rate,51.6
+1601,Austria,2016,5,G03-Sex hormones and modulators of the genital system,Million of national currency units,13.4
+1602,Austria,2016,5,G-Genito urinary system and sex hormones,"/capita, US$ purchasing power parity",6.9
+1603,Austria,2016,5,G-Genito urinary system and sex hormones,% of total sales,1.5
+1604,Austria,2016,5,G-Genito urinary system and sex hormones,"Million US$, purchasing power parity",60.0
+1605,Austria,2016,5,G-Genito urinary system and sex hormones,"/capita, US$ exchange rate",5.9
+1606,Austria,2016,5,G03-Sex hormones and modulators of the genital system,"Million US$, purchasing power parity",17.3
+1607,Austria,2016,5,C-Cardiovascular system,Million of national currency units,427.9
+1608,Austria,2016,5,G03-Sex hormones and modulators of the genital system,Million US$ at exchange rate,14.9
+1609,Austria,2016,5,C-Cardiovascular system,"Million US$, purchasing power parity",550.8
+1610,Austria,2016,5,C-Cardiovascular system,Million US$ at exchange rate,473.7
+1611,Austria,2015,5,N-Nervous system,% of total sales,15.9
+1612,Austria,2015,5,N-Nervous system,"Million US$, purchasing power parity",582.2
+1613,Austria,2015,5,N-Nervous system,"/capita, US$ exchange rate",59.7
+1614,Austria,2015,5,N-Nervous system,"/capita, US$ purchasing power parity",67.4
+1615,Austria,2015,5,J01-Antibacterials for systemic use,Million US$ at exchange rate,72.3
+1616,Austria,2015,5,J01-Antibacterials for systemic use,Million of national currency units,65.2
+1617,Austria,2015,5,J-Antiinfectives for systemic use,Million US$ at exchange rate,326.8
+1618,Austria,2015,5,J-Antiinfectives for systemic use,"Million US$, purchasing power parity",368.8
+1619,Austria,2015,5,J-Antiinfectives for systemic use,Million of national currency units,294.6
+1620,Austria,2015,5,J-Antiinfectives for systemic use,% of total sales,10.1
+1621,Austria,2015,5,J-Antiinfectives for systemic use,"/capita, US$ purchasing power parity",42.7
+1622,Austria,2015,5,J-Antiinfectives for systemic use,"/capita, US$ exchange rate",37.8
+1623,Austria,2015,5,"H-Systemic hormonal preparations, excluding sex hormones and insulins",% of total sales,1.8
+1624,Austria,2015,5,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ exchange rate",6.8
+1625,Austria,2015,5,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ purchasing power parity",7.6
+1626,Austria,2015,5,N02-Analgesics,Million US$ at exchange rate,70.2
+1627,Austria,2015,5,N02-Analgesics,"/capita, US$ exchange rate",8.1
+1628,Austria,2015,5,N02-Analgesics,"Million US$, purchasing power parity",79.2
+1629,Austria,2015,5,G03-Sex hormones and modulators of the genital system,% of total sales,0.4
+1630,Austria,2015,5,N02-Analgesics,Million of national currency units,63.3
+1631,Austria,2015,5,G03-Sex hormones and modulators of the genital system,"/capita, US$ purchasing power parity",1.9
+1632,Austria,2015,5,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million US$ at exchange rate,58.3
+1633,Austria,2015,5,"H-Systemic hormonal preparations, excluding sex hormones and insulins","Million US$, purchasing power parity",65.8
+1634,Austria,2015,5,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million of national currency units,52.6
+1635,Austria,2015,5,A10-Drugs used in diabetes,"/capita, US$ purchasing power parity",19.4
+1636,Austria,2015,5,A10-Drugs used in diabetes,"/capita, US$ exchange rate",17.2
+1637,Austria,2015,5,A02A-Antacids,"/capita, US$ purchasing power parity",0.0
+1638,Austria,2015,5,A02A-Antacids,% of total sales,0.0
+1639,Austria,2015,5,A10-Drugs used in diabetes,Million US$ at exchange rate,148.7
+1640,Austria,2015,5,A10-Drugs used in diabetes,Million of national currency units,134.0
+1641,Austria,2015,5,A10-Drugs used in diabetes,"Million US$, purchasing power parity",167.8
+1642,Austria,2015,5,N02-Analgesics,% of total sales,2.2
+1643,Austria,2015,5,A10-Drugs used in diabetes,% of total sales,4.6
+1644,Austria,2015,5,A02A-Antacids,Million of national currency units,0.2
+1645,Austria,2015,5,J01-Antibacterials for systemic use,"Million US$, purchasing power parity",81.6
+1646,Austria,2015,5,N02-Analgesics,"/capita, US$ purchasing power parity",9.2
+1647,Austria,2015,5,A02A-Antacids,"/capita, US$ exchange rate",0.0
+1648,Austria,2015,5,A02A-Antacids,Million US$ at exchange rate,0.2
+1649,Austria,2015,5,A02A-Antacids,"Million US$, purchasing power parity",0.3
+1650,Austria,2015,5,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"Million US$, purchasing power parity",95.7
+1651,Austria,2015,5,M01A-Antiinflammatory and antirheumatic products non-steroids,"Million US$, purchasing power parity",52.4
+1652,Austria,2015,5,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ exchange rate",5.4
+1653,Austria,2015,5,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ exchange rate",9.8
+1654,Austria,2015,5,M01A-Antiinflammatory and antirheumatic products non-steroids,Million US$ at exchange rate,46.4
+1655,Austria,2015,5,M01A-Antiinflammatory and antirheumatic products non-steroids,Million of national currency units,41.8
+1656,Austria,2015,5,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),% of total sales,2.6
+1657,Austria,2015,5,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ purchasing power parity",11.1
+1658,Austria,2015,5,R-Respiratory system,% of total sales,5.8
+1659,Austria,2015,5,N05C-Hypnotics and sedatives,"Million US$, purchasing power parity",3.2
+1660,Austria,2015,5,N05C-Hypnotics and sedatives,"/capita, US$ exchange rate",0.3
+1661,Austria,2015,5,R-Respiratory system,"/capita, US$ purchasing power parity",24.4
+1662,Austria,2015,5,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million of national currency units,76.5
+1663,Austria,2015,5,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million US$ at exchange rate,84.8
+1664,Austria,2015,5,N05C-Hypnotics and sedatives,"/capita, US$ purchasing power parity",0.4
+1665,Austria,2015,5,N05C-Hypnotics and sedatives,% of total sales,0.1
+1666,Austria,2015,5,N06A-Antidepressants,% of total sales,3.3
+1667,Austria,2015,5,N06A-Antidepressants,"/capita, US$ purchasing power parity",13.8
+1668,Austria,2015,5,M-Musculo-skeletal system,"/capita, US$ purchasing power parity",14.5
+1669,Austria,2015,5,M-Musculo-skeletal system,% of total sales,3.4
+1670,Austria,2015,5,N06A-Antidepressants,Million of national currency units,95.3
+1671,Austria,2015,5,N06A-Antidepressants,"Million US$, purchasing power parity",119.3
+1672,Austria,2015,5,N06A-Antidepressants,Million US$ at exchange rate,105.7
+1673,Austria,2015,5,N06A-Antidepressants,"/capita, US$ exchange rate",12.2
+1674,Austria,2015,5,R-Respiratory system,Million of national currency units,168.4
+1675,Austria,2015,5,M-Musculo-skeletal system,"Million US$, purchasing power parity",125.4
+1676,Austria,2015,5,M-Musculo-skeletal system,"/capita, US$ exchange rate",12.9
+1677,Austria,2015,5,M-Musculo-skeletal system,Million of national currency units,100.2
+1678,Austria,2015,5,M-Musculo-skeletal system,Million US$ at exchange rate,111.1
+1679,Austria,2015,5,R-Respiratory system,Million US$ at exchange rate,186.9
+1680,Austria,2015,5,R-Respiratory system,"Million US$, purchasing power parity",210.9
+1681,Austria,2015,5,R-Respiratory system,"/capita, US$ exchange rate",21.6
+1682,Austria,2015,5,N-Nervous system,Million of national currency units,465.1
+1683,Austria,2015,5,B-Blood and blood forming organs,% of total sales,8.4
+1684,Austria,2015,5,Products not elsewhere classified,Million of national currency units,832.2
+1685,Austria,2015,5,N-Nervous system,Million US$ at exchange rate,516.0
+1686,Austria,2015,5,B-Blood and blood forming organs,"Million US$, purchasing power parity",308.3
+1687,Austria,2015,5,B-Blood and blood forming organs,Million US$ at exchange rate,273.2
+1688,Austria,2015,5,B-Blood and blood forming organs,"/capita, US$ purchasing power parity",35.7
+1689,Austria,2015,5,B-Blood and blood forming organs,"/capita, US$ exchange rate",31.6
+1690,Austria,2015,5,J01-Antibacterials for systemic use,% of total sales,2.2
+1691,Austria,2015,5,J01-Antibacterials for systemic use,"/capita, US$ exchange rate",8.4
+1692,Austria,2015,5,J01-Antibacterials for systemic use,"/capita, US$ purchasing power parity",9.4
+1693,Austria,2015,5,Products not elsewhere classified,% of total sales,28.4
+1694,Austria,2015,5,Products not elsewhere classified,"Million US$, purchasing power parity",1041.8
+1695,Austria,2015,5,Products not elsewhere classified,Million US$ at exchange rate,923.3
+1696,Austria,2015,5,Products not elsewhere classified,"/capita, US$ purchasing power parity",120.5
+1697,Austria,2015,5,Products not elsewhere classified,"/capita, US$ exchange rate",106.8
+1698,Austria,2015,5,R03-Drugs for obstructive airway diseases,Million of national currency units,146.9
+1699,Austria,2015,5,N05B-Anxiolytics,"/capita, US$ purchasing power parity",1.0
+1700,Austria,2015,5,R03-Drugs for obstructive airway diseases,Million US$ at exchange rate,162.9
+1701,Austria,2015,5,N05B-Anxiolytics,% of total sales,0.2
+1702,Austria,2015,5,N05C-Hypnotics and sedatives,Million of national currency units,2.6
+1703,Austria,2015,5,N05C-Hypnotics and sedatives,Million US$ at exchange rate,2.9
+1704,Austria,2015,5,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ purchasing power parity",6.1
+1705,Austria,2015,5,M01A-Antiinflammatory and antirheumatic products non-steroids,% of total sales,1.4
+1706,Austria,2015,5,N05B-Anxiolytics,"/capita, US$ exchange rate",0.9
+1707,Austria,2015,5,R03-Drugs for obstructive airway diseases,"/capita, US$ purchasing power parity",21.3
+1708,Austria,2015,5,R03-Drugs for obstructive airway diseases,"/capita, US$ exchange rate",18.9
+1709,Austria,2015,5,B-Blood and blood forming organs,Million of national currency units,246.3
+1710,Austria,2015,5,R03-Drugs for obstructive airway diseases,% of total sales,5.0
+1711,Austria,2015,5,N05B-Anxiolytics,"Million US$, purchasing power parity",8.5
+1712,Austria,2015,5,N05B-Anxiolytics,Million US$ at exchange rate,7.6
+1713,Austria,2015,5,R03-Drugs for obstructive airway diseases,"Million US$, purchasing power parity",183.8
+1714,Austria,2015,5,N05B-Anxiolytics,Million of national currency units,6.8
+1715,Austria,2015,5,A-Alimentary tract and metabolism,Million US$ at exchange rate,329.7
+1716,Austria,2015,5,A-Alimentary tract and metabolism,"Million US$, purchasing power parity",372.0
+1717,Austria,2015,5,A-Alimentary tract and metabolism,Million of national currency units,297.1
+1718,Austria,2015,5,A-Alimentary tract and metabolism,% of total sales,10.1
+1719,Austria,2015,5,C08-Calcium channel blockers,"/capita, US$ purchasing power parity",3.0
+1720,Austria,2015,5,A-Alimentary tract and metabolism,"/capita, US$ exchange rate",38.1
+1721,Austria,2015,5,G03-Sex hormones and modulators of the genital system,"/capita, US$ exchange rate",1.7
+1722,Austria,2015,5,A-Alimentary tract and metabolism,"/capita, US$ purchasing power parity",43.0
+1723,Austria,2015,5,C08-Calcium channel blockers,"/capita, US$ exchange rate",2.6
+1724,Austria,2015,5,C07-Beta blocking agents,"/capita, US$ purchasing power parity",6.4
+1725,Austria,2015,5,C07-Beta blocking agents,% of total sales,1.5
+1726,Austria,2015,5,C07-Beta blocking agents,"Million US$, purchasing power parity",55.7
+1727,Austria,2015,5,C07-Beta blocking agents,"/capita, US$ exchange rate",5.7
+1728,Austria,2015,5,C08-Calcium channel blockers,"Million US$, purchasing power parity",25.8
+1729,Austria,2015,5,C08-Calcium channel blockers,Million of national currency units,20.6
+1730,Austria,2015,5,C08-Calcium channel blockers,Million US$ at exchange rate,22.9
+1731,Austria,2015,5,C10-Lipid modifying agents,"/capita, US$ exchange rate",12.2
+1732,Austria,2015,5,C10-Lipid modifying agents,"/capita, US$ purchasing power parity",13.8
+1733,Austria,2015,5,C10-Lipid modifying agents,Million US$ at exchange rate,105.3
+1734,Austria,2015,5,C10-Lipid modifying agents,"Million US$, purchasing power parity",118.8
+1735,Austria,2015,5,C-Cardiovascular system,"/capita, US$ purchasing power parity",61.8
+1736,Austria,2015,5,C-Cardiovascular system,"/capita, US$ exchange rate",54.8
+1737,Austria,2015,5,C10-Lipid modifying agents,% of total sales,3.2
+1738,Austria,2015,5,C-Cardiovascular system,% of total sales,14.6
+1739,Austria,2015,5,C09-Agents acting on the Renin-Angiotensin system,Million US$ at exchange rate,174.8
+1740,Austria,2015,5,C09-Agents acting on the Renin-Angiotensin system,"Million US$, purchasing power parity",197.2
+1741,Austria,2015,5,C08-Calcium channel blockers,% of total sales,0.7
+1742,Austria,2015,5,C09-Agents acting on the Renin-Angiotensin system,Million of national currency units,157.5
+1743,Austria,2015,5,C09-Agents acting on the Renin-Angiotensin system,% of total sales,5.4
+1744,Austria,2015,5,C10-Lipid modifying agents,Million of national currency units,94.9
+1745,Austria,2015,5,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ exchange rate",20.2
+1746,Austria,2015,5,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ purchasing power parity",22.8
+1747,Austria,2015,5,"C01B-Antiarrhythmics, Class I and III",% of total sales,0.2
+1748,Austria,2015,5,"C01B-Antiarrhythmics, Class I and III","/capita, US$ exchange rate",0.9
+1749,Austria,2015,5,"C01B-Antiarrhythmics, Class I and III","/capita, US$ purchasing power parity",1.0
+1750,Austria,2015,5,C02-Antihypertensives,Million of national currency units,45.7
+1751,Austria,2015,5,C02-Antihypertensives,"/capita, US$ exchange rate",5.9
+1752,Austria,2015,5,C02-Antihypertensives,"Million US$, purchasing power parity",57.2
+1753,Austria,2015,5,C02-Antihypertensives,Million US$ at exchange rate,50.7
+1754,Austria,2015,5,"C01B-Antiarrhythmics, Class I and III","Million US$, purchasing power parity",8.8
+1755,Austria,2015,5,Total pharmaceutical sales,"Million US$, purchasing power parity",3666.5
+1756,Austria,2015,5,Total pharmaceutical sales,"/capita, US$ exchange rate",376.0
+1757,Austria,2015,5,Total pharmaceutical sales,Million of national currency units,2928.9
+1758,Austria,2015,5,Total pharmaceutical sales,Million US$ at exchange rate,3249.6
+1759,Austria,2015,5,"C01B-Antiarrhythmics, Class I and III",Million US$ at exchange rate,7.8
+1760,Austria,2015,5,Total pharmaceutical sales,"/capita, US$ purchasing power parity",424.2
+1761,Austria,2015,5,"C01B-Antiarrhythmics, Class I and III",Million of national currency units,7.0
+1762,Austria,2015,5,C02-Antihypertensives,"/capita, US$ purchasing power parity",6.6
+1763,Austria,2015,5,C03-Diuretics,"Million US$, purchasing power parity",20.6
+1764,Austria,2015,5,C03-Diuretics,"/capita, US$ exchange rate",2.1
+1765,Austria,2015,5,C03-Diuretics,Million of national currency units,16.5
+1766,Austria,2015,5,C03-Diuretics,Million US$ at exchange rate,18.3
+1767,Austria,2015,5,C07-Beta blocking agents,Million of national currency units,44.5
+1768,Austria,2015,5,C07-Beta blocking agents,Million US$ at exchange rate,49.4
+1769,Austria,2015,5,C03-Diuretics,"/capita, US$ purchasing power parity",2.4
+1770,Austria,2015,5,C03-Diuretics,% of total sales,0.6
+1771,Austria,2015,5,C01A-Cardiac glycosides,% of total sales,0.0
+1772,Austria,2015,5,C01A-Cardiac glycosides,"/capita, US$ purchasing power parity",0.1
+1773,Austria,2015,5,C02-Antihypertensives,% of total sales,1.6
+1774,Austria,2015,5,C01A-Cardiac glycosides,Million US$ at exchange rate,0.6
+1775,Austria,2015,5,C01A-Cardiac glycosides,Million of national currency units,0.5
+1776,Austria,2015,5,C01A-Cardiac glycosides,"/capita, US$ exchange rate",0.1
+1777,Austria,2015,5,C01A-Cardiac glycosides,"Million US$, purchasing power parity",0.7
+1778,Austria,2015,5,G-Genito urinary system and sex hormones,Million of national currency units,45.5
+1779,Austria,2015,5,G-Genito urinary system and sex hormones,Million US$ at exchange rate,50.5
+1780,Austria,2015,5,G03-Sex hormones and modulators of the genital system,Million of national currency units,13.0
+1781,Austria,2015,5,C-Cardiovascular system,Million of national currency units,426.9
+1782,Austria,2015,5,G-Genito urinary system and sex hormones,"/capita, US$ purchasing power parity",6.6
+1783,Austria,2015,5,G-Genito urinary system and sex hormones,% of total sales,1.6
+1784,Austria,2015,5,G-Genito urinary system and sex hormones,"Million US$, purchasing power parity",57.0
+1785,Austria,2015,5,G-Genito urinary system and sex hormones,"/capita, US$ exchange rate",5.8
+1786,Austria,2015,5,G03-Sex hormones and modulators of the genital system,"Million US$, purchasing power parity",16.3
+1787,Austria,2015,5,G03-Sex hormones and modulators of the genital system,Million US$ at exchange rate,14.4
+1788,Austria,2015,5,C-Cardiovascular system,"Million US$, purchasing power parity",534.4
+1789,Austria,2015,5,C-Cardiovascular system,Million US$ at exchange rate,473.6
+1790,Austria,2014,5,N-Nervous system,% of total sales,17.1
+1791,Austria,2014,5,N-Nervous system,"/capita, US$ exchange rate",74.2
+1792,Austria,2014,5,N-Nervous system,"Million US$, purchasing power parity",597.9
+1793,Austria,2014,5,N-Nervous system,"/capita, US$ purchasing power parity",70.0
+1794,Austria,2014,5,J01-Antibacterials for systemic use,Million US$ at exchange rate,87.8
+1795,Austria,2014,5,J01-Antibacterials for systemic use,"Million US$, purchasing power parity",82.7
+1796,Austria,2014,5,J01-Antibacterials for systemic use,Million of national currency units,66.1
+1797,Austria,2014,5,J-Antiinfectives for systemic use,"Million US$, purchasing power parity",302.3
+1798,Austria,2014,5,J-Antiinfectives for systemic use,Million US$ at exchange rate,320.8
+1799,Austria,2014,5,J-Antiinfectives for systemic use,Million of national currency units,241.5
+1800,Austria,2014,5,J-Antiinfectives for systemic use,% of total sales,8.7
+1801,Austria,2014,5,J-Antiinfectives for systemic use,"/capita, US$ purchasing power parity",35.4
+1802,Austria,2014,5,J-Antiinfectives for systemic use,"/capita, US$ exchange rate",37.5
+1803,Austria,2014,5,"H-Systemic hormonal preparations, excluding sex hormones and insulins",% of total sales,1.8
+1804,Austria,2014,5,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ exchange rate",7.9
+1805,Austria,2014,5,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ purchasing power parity",7.5
+1806,Austria,2014,5,N02-Analgesics,"/capita, US$ exchange rate",9.6
+1807,Austria,2014,5,N02-Analgesics,"/capita, US$ purchasing power parity",9.0
+1808,Austria,2014,5,N02-Analgesics,Million US$ at exchange rate,81.9
+1809,Austria,2014,5,N02-Analgesics,"Million US$, purchasing power parity",77.1
+1810,Austria,2014,5,G03-Sex hormones and modulators of the genital system,% of total sales,0.5
+1811,Austria,2014,5,N02-Analgesics,Million of national currency units,61.6
+1812,Austria,2014,5,G03-Sex hormones and modulators of the genital system,"/capita, US$ purchasing power parity",1.9
+1813,Austria,2014,5,"H-Systemic hormonal preparations, excluding sex hormones and insulins","Million US$, purchasing power parity",64.0
+1814,Austria,2014,5,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million US$ at exchange rate,67.9
+1815,Austria,2014,5,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million of national currency units,51.1
+1816,Austria,2014,5,A02A-Antacids,Million of national currency units,0.1
+1817,Austria,2014,5,A10-Drugs used in diabetes,"/capita, US$ purchasing power parity",18.1
+1818,Austria,2014,5,A02A-Antacids,"/capita, US$ purchasing power parity",0.0
+1819,Austria,2014,5,A10-Drugs used in diabetes,"/capita, US$ exchange rate",19.2
+1820,Austria,2014,5,A02A-Antacids,% of total sales,0.0
+1821,Austria,2014,5,A10-Drugs used in diabetes,Million US$ at exchange rate,164.5
+1822,Austria,2014,5,A10-Drugs used in diabetes,Million of national currency units,123.8
+1823,Austria,2014,5,A10-Drugs used in diabetes,"Million US$, purchasing power parity",155.0
+1824,Austria,2014,5,A10-Drugs used in diabetes,% of total sales,4.4
+1825,Austria,2014,5,N02-Analgesics,% of total sales,2.2
+1826,Austria,2014,5,A02A-Antacids,"/capita, US$ exchange rate",0.0
+1827,Austria,2014,5,A02A-Antacids,"Million US$, purchasing power parity",0.2
+1828,Austria,2014,5,A02A-Antacids,Million US$ at exchange rate,0.2
+1829,Austria,2014,5,M01A-Antiinflammatory and antirheumatic products non-steroids,"Million US$, purchasing power parity",53.3
+1830,Austria,2014,5,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ exchange rate",12.4
+1831,Austria,2014,5,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"Million US$, purchasing power parity",99.7
+1832,Austria,2014,5,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ exchange rate",6.6
+1833,Austria,2014,5,M01A-Antiinflammatory and antirheumatic products non-steroids,Million US$ at exchange rate,56.5
+1834,Austria,2014,5,M01A-Antiinflammatory and antirheumatic products non-steroids,Million of national currency units,42.6
+1835,Austria,2014,5,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ purchasing power parity",11.7
+1836,Austria,2014,5,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),% of total sales,2.9
+1837,Austria,2014,5,N05C-Hypnotics and sedatives,"/capita, US$ purchasing power parity",0.4
+1838,Austria,2014,5,R-Respiratory system,% of total sales,5.9
+1839,Austria,2014,5,N05C-Hypnotics and sedatives,"Million US$, purchasing power parity",3.5
+1840,Austria,2014,5,N05C-Hypnotics and sedatives,"/capita, US$ exchange rate",0.4
+1841,Austria,2014,5,R-Respiratory system,"/capita, US$ purchasing power parity",24.0
+1842,Austria,2014,5,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million of national currency units,79.6
+1843,Austria,2014,5,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million US$ at exchange rate,105.8
+1844,Austria,2014,5,N05C-Hypnotics and sedatives,% of total sales,0.1
+1845,Austria,2014,5,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ purchasing power parity",6.2
+1846,Austria,2014,5,N06A-Antidepressants,% of total sales,3.9
+1847,Austria,2014,5,M-Musculo-skeletal system,% of total sales,3.6
+1848,Austria,2014,5,N06A-Antidepressants,Million of national currency units,109.5
+1849,Austria,2014,5,N06A-Antidepressants,"Million US$, purchasing power parity",137.1
+1850,Austria,2014,5,N06A-Antidepressants,Million US$ at exchange rate,145.5
+1851,Austria,2014,5,N06A-Antidepressants,"/capita, US$ purchasing power parity",16.0
+1852,Austria,2014,5,N06A-Antidepressants,"/capita, US$ exchange rate",17.0
+1853,Austria,2014,5,R-Respiratory system,Million of national currency units,163.8
+1854,Austria,2014,5,M-Musculo-skeletal system,"Million US$, purchasing power parity",125.9
+1855,Austria,2014,5,M-Musculo-skeletal system,"/capita, US$ exchange rate",15.6
+1856,Austria,2014,5,M-Musculo-skeletal system,Million of national currency units,100.5
+1857,Austria,2014,5,M-Musculo-skeletal system,Million US$ at exchange rate,133.6
+1858,Austria,2014,5,R-Respiratory system,"Million US$, purchasing power parity",205.0
+1859,Austria,2014,5,R-Respiratory system,Million US$ at exchange rate,217.5
+1860,Austria,2014,5,M-Musculo-skeletal system,"/capita, US$ purchasing power parity",14.7
+1861,Austria,2014,5,R-Respiratory system,"/capita, US$ exchange rate",25.5
+1862,Austria,2014,5,N-Nervous system,Million of national currency units,477.6
+1863,Austria,2014,5,B-Blood and blood forming organs,% of total sales,7.9
+1864,Austria,2014,5,Products not elsewhere classified,Million of national currency units,767.7
+1865,Austria,2014,5,N-Nervous system,Million US$ at exchange rate,634.5
+1866,Austria,2014,5,B-Blood and blood forming organs,"Million US$, purchasing power parity",275.5
+1867,Austria,2014,5,B-Blood and blood forming organs,Million US$ at exchange rate,292.4
+1868,Austria,2014,5,B-Blood and blood forming organs,"/capita, US$ purchasing power parity",32.2
+1869,Austria,2014,5,B-Blood and blood forming organs,"/capita, US$ exchange rate",34.2
+1870,Austria,2014,5,Products not elsewhere classified,Million US$ at exchange rate,1020.0
+1871,Austria,2014,5,J01-Antibacterials for systemic use,% of total sales,2.4
+1872,Austria,2014,5,J01-Antibacterials for systemic use,"/capita, US$ exchange rate",10.3
+1873,Austria,2014,5,J01-Antibacterials for systemic use,"/capita, US$ purchasing power parity",9.7
+1874,Austria,2014,5,Products not elsewhere classified,% of total sales,27.5
+1875,Austria,2014,5,Products not elsewhere classified,"Million US$, purchasing power parity",961.1
+1876,Austria,2014,5,Products not elsewhere classified,"/capita, US$ exchange rate",119.3
+1877,Austria,2014,5,Products not elsewhere classified,"/capita, US$ purchasing power parity",112.5
+1878,Austria,2014,5,R03-Drugs for obstructive airway diseases,Million of national currency units,141.9
+1879,Austria,2014,5,N05B-Anxiolytics,"/capita, US$ purchasing power parity",1.0
+1880,Austria,2014,5,R03-Drugs for obstructive airway diseases,Million US$ at exchange rate,188.5
+1881,Austria,2014,5,N05B-Anxiolytics,% of total sales,0.3
+1882,Austria,2014,5,N05C-Hypnotics and sedatives,Million of national currency units,2.8
+1883,Austria,2014,5,N05C-Hypnotics and sedatives,Million US$ at exchange rate,3.7
+1884,Austria,2014,5,M01A-Antiinflammatory and antirheumatic products non-steroids,% of total sales,1.5
+1885,Austria,2014,5,R03-Drugs for obstructive airway diseases,"/capita, US$ purchasing power parity",20.8
+1886,Austria,2014,5,R03-Drugs for obstructive airway diseases,"/capita, US$ exchange rate",22.1
+1887,Austria,2014,5,B-Blood and blood forming organs,Million of national currency units,220.1
+1888,Austria,2014,5,R03-Drugs for obstructive airway diseases,% of total sales,5.1
+1889,Austria,2014,5,N05B-Anxiolytics,"/capita, US$ exchange rate",1.1
+1890,Austria,2014,5,N05B-Anxiolytics,"Million US$, purchasing power parity",8.8
+1891,Austria,2014,5,N05B-Anxiolytics,Million US$ at exchange rate,9.4
+1892,Austria,2014,5,R03-Drugs for obstructive airway diseases,"Million US$, purchasing power parity",177.7
+1893,Austria,2014,5,N05B-Anxiolytics,Million of national currency units,7.1
+1894,Austria,2014,5,G03-Sex hormones and modulators of the genital system,"/capita, US$ exchange rate",2.0
+1895,Austria,2014,5,A-Alimentary tract and metabolism,Million US$ at exchange rate,381.4
+1896,Austria,2014,5,A-Alimentary tract and metabolism,"Million US$, purchasing power parity",359.4
+1897,Austria,2014,5,C08-Calcium channel blockers,"/capita, US$ purchasing power parity",4.0
+1898,Austria,2014,5,A-Alimentary tract and metabolism,Million of national currency units,287.1
+1899,Austria,2014,5,A-Alimentary tract and metabolism,% of total sales,10.3
+1900,Austria,2014,5,A-Alimentary tract and metabolism,"/capita, US$ exchange rate",44.6
+1901,Austria,2014,5,A-Alimentary tract and metabolism,"/capita, US$ purchasing power parity",42.0
+1902,Austria,2014,5,C07-Beta blocking agents,"/capita, US$ purchasing power parity",6.8
+1903,Austria,2014,5,C07-Beta blocking agents,% of total sales,1.7
+1904,Austria,2014,5,C07-Beta blocking agents,"Million US$, purchasing power parity",57.8
+1905,Austria,2014,5,C07-Beta blocking agents,"/capita, US$ exchange rate",7.2
+1906,Austria,2014,5,C08-Calcium channel blockers,"Million US$, purchasing power parity",34.5
+1907,Austria,2014,5,C08-Calcium channel blockers,"/capita, US$ exchange rate",4.3
+1908,Austria,2014,5,C08-Calcium channel blockers,Million of national currency units,27.6
+1909,Austria,2014,5,C08-Calcium channel blockers,Million US$ at exchange rate,36.7
+1910,Austria,2014,5,C08-Calcium channel blockers,% of total sales,1.0
+1911,Austria,2014,5,C10-Lipid modifying agents,"/capita, US$ exchange rate",14.3
+1912,Austria,2014,5,C10-Lipid modifying agents,"/capita, US$ purchasing power parity",13.5
+1913,Austria,2014,5,C10-Lipid modifying agents,Million US$ at exchange rate,122.0
+1914,Austria,2014,5,C10-Lipid modifying agents,"Million US$, purchasing power parity",115.0
+1915,Austria,2014,5,C-Cardiovascular system,"/capita, US$ purchasing power parity",63.4
+1916,Austria,2014,5,C10-Lipid modifying agents,% of total sales,3.3
+1917,Austria,2014,5,C-Cardiovascular system,% of total sales,15.5
+1918,Austria,2014,5,C09-Agents acting on the Renin-Angiotensin system,Million US$ at exchange rate,213.4
+1919,Austria,2014,5,C09-Agents acting on the Renin-Angiotensin system,"Million US$, purchasing power parity",201.1
+1920,Austria,2014,5,C09-Agents acting on the Renin-Angiotensin system,Million of national currency units,160.7
+1921,Austria,2014,5,C09-Agents acting on the Renin-Angiotensin system,% of total sales,5.8
+1922,Austria,2014,5,C10-Lipid modifying agents,Million of national currency units,91.8
+1923,Austria,2014,5,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ exchange rate",25.0
+1924,Austria,2014,5,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ purchasing power parity",23.5
+1925,Austria,2014,5,"C01B-Antiarrhythmics, Class I and III",% of total sales,0.3
+1926,Austria,2014,5,"C01B-Antiarrhythmics, Class I and III","/capita, US$ purchasing power parity",1.1
+1927,Austria,2014,5,"C01B-Antiarrhythmics, Class I and III","/capita, US$ exchange rate",1.1
+1928,Austria,2014,5,C02-Antihypertensives,Million of national currency units,42.7
+1929,Austria,2014,5,C02-Antihypertensives,"/capita, US$ exchange rate",6.6
+1930,Austria,2014,5,C02-Antihypertensives,"Million US$, purchasing power parity",53.4
+1931,Austria,2014,5,C02-Antihypertensives,Million US$ at exchange rate,56.7
+1932,Austria,2014,5,Total pharmaceutical sales,"Million US$, purchasing power parity",3489.5
+1933,Austria,2014,5,Total pharmaceutical sales,"/capita, US$ exchange rate",433.3
+1934,Austria,2014,5,Total pharmaceutical sales,Million of national currency units,2787.4
+1935,Austria,2014,5,Total pharmaceutical sales,Million US$ at exchange rate,3703.1
+1936,Austria,2014,5,"C01B-Antiarrhythmics, Class I and III",Million US$ at exchange rate,9.6
+1937,Austria,2014,5,"C01B-Antiarrhythmics, Class I and III","Million US$, purchasing power parity",9.0
+1938,Austria,2014,5,Total pharmaceutical sales,"/capita, US$ purchasing power parity",408.3
+1939,Austria,2014,5,"C01B-Antiarrhythmics, Class I and III",Million of national currency units,7.2
+1940,Austria,2014,5,C-Cardiovascular system,"/capita, US$ exchange rate",67.3
+1941,Austria,2014,5,C03-Diuretics,"Million US$, purchasing power parity",20.6
+1942,Austria,2014,5,C03-Diuretics,"/capita, US$ exchange rate",2.6
+1943,Austria,2014,5,C03-Diuretics,Million of national currency units,16.5
+1944,Austria,2014,5,C03-Diuretics,Million US$ at exchange rate,21.9
+1945,Austria,2014,5,C07-Beta blocking agents,Million of national currency units,46.2
+1946,Austria,2014,5,C07-Beta blocking agents,Million US$ at exchange rate,61.3
+1947,Austria,2014,5,C03-Diuretics,"/capita, US$ purchasing power parity",2.4
+1948,Austria,2014,5,C03-Diuretics,% of total sales,0.6
+1949,Austria,2014,5,C02-Antihypertensives,"/capita, US$ purchasing power parity",6.3
+1950,Austria,2014,5,C01A-Cardiac glycosides,% of total sales,0.0
+1951,Austria,2014,5,C01A-Cardiac glycosides,"/capita, US$ purchasing power parity",0.1
+1952,Austria,2014,5,C02-Antihypertensives,% of total sales,1.5
+1953,Austria,2014,5,C01A-Cardiac glycosides,Million US$ at exchange rate,0.8
+1954,Austria,2014,5,C01A-Cardiac glycosides,Million of national currency units,0.6
+1955,Austria,2014,5,C01A-Cardiac glycosides,"/capita, US$ exchange rate",0.1
+1956,Austria,2014,5,C01A-Cardiac glycosides,"Million US$, purchasing power parity",0.7
+1957,Austria,2014,5,G-Genito urinary system and sex hormones,Million US$ at exchange rate,60.2
+1958,Austria,2014,5,G-Genito urinary system and sex hormones,Million of national currency units,45.3
+1959,Austria,2014,5,G03-Sex hormones and modulators of the genital system,Million of national currency units,13.1
+1960,Austria,2014,5,C-Cardiovascular system,Million of national currency units,432.8
+1961,Austria,2014,5,G-Genito urinary system and sex hormones,"/capita, US$ purchasing power parity",6.6
+1962,Austria,2014,5,G-Genito urinary system and sex hormones,% of total sales,1.6
+1963,Austria,2014,5,G-Genito urinary system and sex hormones,"Million US$, purchasing power parity",56.7
+1964,Austria,2014,5,G-Genito urinary system and sex hormones,"/capita, US$ exchange rate",7.0
+1965,Austria,2014,5,G03-Sex hormones and modulators of the genital system,"Million US$, purchasing power parity",16.4
+1966,Austria,2014,5,G03-Sex hormones and modulators of the genital system,Million US$ at exchange rate,17.4
+1967,Austria,2014,5,C-Cardiovascular system,"Million US$, purchasing power parity",541.8
+1968,Austria,2014,5,C-Cardiovascular system,Million US$ at exchange rate,574.9
+1969,Austria,2013,5,N-Nervous system,% of total sales,18.0
+1970,Austria,2013,5,N-Nervous system,"/capita, US$ exchange rate",74.2
+1971,Austria,2013,5,N-Nervous system,"Million US$, purchasing power parity",594.4
+1972,Austria,2013,5,N-Nervous system,"/capita, US$ purchasing power parity",70.1
+1973,Austria,2013,5,J01-Antibacterials for systemic use,Million US$ at exchange rate,92.6
+1974,Austria,2013,5,J01-Antibacterials for systemic use,"Million US$, purchasing power parity",87.5
+1975,Austria,2013,5,J01-Antibacterials for systemic use,Million of national currency units,69.7
+1976,Austria,2013,5,J-Antiinfectives for systemic use,"Million US$, purchasing power parity",229.4
+1977,Austria,2013,5,J-Antiinfectives for systemic use,Million of national currency units,182.9
+1978,Austria,2013,5,J-Antiinfectives for systemic use,Million US$ at exchange rate,242.9
+1979,Austria,2013,5,J-Antiinfectives for systemic use,% of total sales,6.9
+1980,Austria,2013,5,J-Antiinfectives for systemic use,"/capita, US$ purchasing power parity",27.1
+1981,Austria,2013,5,J-Antiinfectives for systemic use,"/capita, US$ exchange rate",28.6
+1982,Austria,2013,5,"H-Systemic hormonal preparations, excluding sex hormones and insulins",% of total sales,1.9
+1983,Austria,2013,5,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ exchange rate",7.9
+1984,Austria,2013,5,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ purchasing power parity",7.4
+1985,Austria,2013,5,N02-Analgesics,Million US$ at exchange rate,78.1
+1986,Austria,2013,5,N02-Analgesics,"/capita, US$ exchange rate",9.2
+1987,Austria,2013,5,N02-Analgesics,"/capita, US$ purchasing power parity",8.7
+1988,Austria,2013,5,N02-Analgesics,"Million US$, purchasing power parity",73.8
+1989,Austria,2013,5,N02-Analgesics,Million of national currency units,58.8
+1990,Austria,2013,5,G03-Sex hormones and modulators of the genital system,% of total sales,0.5
+1991,Austria,2013,5,G03-Sex hormones and modulators of the genital system,"/capita, US$ purchasing power parity",2.1
+1992,Austria,2013,5,"H-Systemic hormonal preparations, excluding sex hormones and insulins","Million US$, purchasing power parity",63.0
+1993,Austria,2013,5,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million of national currency units,50.2
+1994,Austria,2013,5,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million US$ at exchange rate,66.6
+1995,Austria,2013,5,A02A-Antacids,Million of national currency units,0.1
+1996,Austria,2013,5,A10-Drugs used in diabetes,"/capita, US$ purchasing power parity",17.0
+1997,Austria,2013,5,A02A-Antacids,% of total sales,0.0
+1998,Austria,2013,5,A10-Drugs used in diabetes,"/capita, US$ exchange rate",18.0
+1999,Austria,2013,5,A10-Drugs used in diabetes,Million US$ at exchange rate,152.9
+2000,Austria,2013,5,A10-Drugs used in diabetes,Million of national currency units,115.2
+2001,Austria,2013,5,A02A-Antacids,"/capita, US$ purchasing power parity",0.0
+2002,Austria,2013,5,A10-Drugs used in diabetes,"Million US$, purchasing power parity",144.5
+2003,Austria,2013,5,A10-Drugs used in diabetes,% of total sales,4.4
+2004,Austria,2013,5,N02-Analgesics,% of total sales,2.2
+2005,Austria,2013,5,A02A-Antacids,"/capita, US$ exchange rate",0.0
+2006,Austria,2013,5,A02A-Antacids,Million US$ at exchange rate,0.2
+2007,Austria,2013,5,A02A-Antacids,"Million US$, purchasing power parity",0.2
+2008,Austria,2013,5,M01A-Antiinflammatory and antirheumatic products non-steroids,"Million US$, purchasing power parity",54.5
+2009,Austria,2013,5,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ exchange rate",13.0
+2010,Austria,2013,5,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"Million US$, purchasing power parity",104.2
+2011,Austria,2013,5,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ exchange rate",6.8
+2012,Austria,2013,5,M01A-Antiinflammatory and antirheumatic products non-steroids,Million US$ at exchange rate,57.6
+2013,Austria,2013,5,M01A-Antiinflammatory and antirheumatic products non-steroids,Million of national currency units,43.4
+2014,Austria,2013,5,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ purchasing power parity",12.3
+2015,Austria,2013,5,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),% of total sales,3.2
+2016,Austria,2013,5,N05C-Hypnotics and sedatives,"/capita, US$ purchasing power parity",0.4
+2017,Austria,2013,5,R-Respiratory system,% of total sales,6.2
+2018,Austria,2013,5,N05C-Hypnotics and sedatives,"Million US$, purchasing power parity",3.2
+2019,Austria,2013,5,N05C-Hypnotics and sedatives,"/capita, US$ exchange rate",0.4
+2020,Austria,2013,5,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million of national currency units,83.0
+2021,Austria,2013,5,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million US$ at exchange rate,110.3
+2022,Austria,2013,5,N05C-Hypnotics and sedatives,% of total sales,0.1
+2023,Austria,2013,5,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ purchasing power parity",6.4
+2024,Austria,2013,5,R-Respiratory system,"/capita, US$ purchasing power parity",24.4
+2025,Austria,2013,5,N06A-Antidepressants,% of total sales,4.1
+2026,Austria,2013,5,R-Respiratory system,Million of national currency units,164.6
+2027,Austria,2013,5,M-Musculo-skeletal system,% of total sales,3.8
+2028,Austria,2013,5,N06A-Antidepressants,Million of national currency units,107.2
+2029,Austria,2013,5,N06A-Antidepressants,"Million US$, purchasing power parity",134.5
+2030,Austria,2013,5,N06A-Antidepressants,Million US$ at exchange rate,142.4
+2031,Austria,2013,5,N06A-Antidepressants,"/capita, US$ purchasing power parity",15.9
+2032,Austria,2013,5,N06A-Antidepressants,"/capita, US$ exchange rate",16.8
+2033,Austria,2013,5,M-Musculo-skeletal system,"Million US$, purchasing power parity",127.0
+2034,Austria,2013,5,M-Musculo-skeletal system,"/capita, US$ exchange rate",15.9
+2035,Austria,2013,5,M-Musculo-skeletal system,Million of national currency units,101.2
+2036,Austria,2013,5,M-Musculo-skeletal system,Million US$ at exchange rate,134.4
+2037,Austria,2013,5,R-Respiratory system,"Million US$, purchasing power parity",206.5
+2038,Austria,2013,5,R-Respiratory system,Million US$ at exchange rate,218.6
+2039,Austria,2013,5,M-Musculo-skeletal system,"/capita, US$ purchasing power parity",15.0
+2040,Austria,2013,5,R-Respiratory system,"/capita, US$ exchange rate",25.8
+2041,Austria,2013,5,N-Nervous system,Million of national currency units,473.8
+2042,Austria,2013,5,B-Blood and blood forming organs,% of total sales,7.3
+2043,Austria,2013,5,Products not elsewhere classified,Million of national currency units,712.5
+2044,Austria,2013,5,N-Nervous system,Million US$ at exchange rate,629.3
+2045,Austria,2013,5,B-Blood and blood forming organs,"Million US$, purchasing power parity",240.2
+2046,Austria,2013,5,B-Blood and blood forming organs,Million US$ at exchange rate,254.2
+2047,Austria,2013,5,B-Blood and blood forming organs,"/capita, US$ purchasing power parity",28.3
+2048,Austria,2013,5,B-Blood and blood forming organs,"/capita, US$ exchange rate",30.0
+2049,Austria,2013,5,Products not elsewhere classified,Million US$ at exchange rate,946.3
+2050,Austria,2013,5,J01-Antibacterials for systemic use,% of total sales,2.6
+2051,Austria,2013,5,J01-Antibacterials for systemic use,"/capita, US$ exchange rate",10.9
+2052,Austria,2013,5,J01-Antibacterials for systemic use,"/capita, US$ purchasing power parity",10.3
+2053,Austria,2013,5,Products not elsewhere classified,"Million US$, purchasing power parity",893.9
+2054,Austria,2013,5,Products not elsewhere classified,"/capita, US$ exchange rate",111.6
+2055,Austria,2013,5,Products not elsewhere classified,"/capita, US$ purchasing power parity",105.4
+2056,Austria,2013,5,Products not elsewhere classified,% of total sales,27.0
+2057,Austria,2013,5,R03-Drugs for obstructive airway diseases,Million of national currency units,143.5
+2058,Austria,2013,5,N05B-Anxiolytics,"/capita, US$ purchasing power parity",1.0
+2059,Austria,2013,5,N05B-Anxiolytics,% of total sales,0.3
+2060,Austria,2013,5,R03-Drugs for obstructive airway diseases,Million US$ at exchange rate,190.6
+2061,Austria,2013,5,N05C-Hypnotics and sedatives,Million of national currency units,2.6
+2062,Austria,2013,5,N05C-Hypnotics and sedatives,Million US$ at exchange rate,3.4
+2063,Austria,2013,5,M01A-Antiinflammatory and antirheumatic products non-steroids,% of total sales,1.6
+2064,Austria,2013,5,N05B-Anxiolytics,"/capita, US$ exchange rate",1.1
+2065,Austria,2013,5,R03-Drugs for obstructive airway diseases,"/capita, US$ purchasing power parity",21.2
+2066,Austria,2013,5,R03-Drugs for obstructive airway diseases,"/capita, US$ exchange rate",22.5
+2067,Austria,2013,5,B-Blood and blood forming organs,Million of national currency units,191.4
+2068,Austria,2013,5,R03-Drugs for obstructive airway diseases,% of total sales,5.4
+2069,Austria,2013,5,N05B-Anxiolytics,"Million US$, purchasing power parity",8.5
+2070,Austria,2013,5,N05B-Anxiolytics,Million US$ at exchange rate,9.0
+2071,Austria,2013,5,R03-Drugs for obstructive airway diseases,"Million US$, purchasing power parity",180.1
+2072,Austria,2013,5,N05B-Anxiolytics,Million of national currency units,6.8
+2073,Austria,2013,5,A-Alimentary tract and metabolism,Million US$ at exchange rate,365.9
+2074,Austria,2013,5,A-Alimentary tract and metabolism,"Million US$, purchasing power parity",345.6
+2075,Austria,2013,5,C08-Calcium channel blockers,"/capita, US$ purchasing power parity",4.2
+2076,Austria,2013,5,A-Alimentary tract and metabolism,Million of national currency units,275.5
+2077,Austria,2013,5,A-Alimentary tract and metabolism,% of total sales,10.5
+2078,Austria,2013,5,A-Alimentary tract and metabolism,"/capita, US$ exchange rate",43.1
+2079,Austria,2013,5,A-Alimentary tract and metabolism,"/capita, US$ purchasing power parity",40.8
+2080,Austria,2013,5,C07-Beta blocking agents,"/capita, US$ purchasing power parity",6.9
+2081,Austria,2013,5,C07-Beta blocking agents,% of total sales,1.8
+2082,Austria,2013,5,C07-Beta blocking agents,"Million US$, purchasing power parity",58.4
+2083,Austria,2013,5,C07-Beta blocking agents,"/capita, US$ exchange rate",7.3
+2084,Austria,2013,5,C08-Calcium channel blockers,"Million US$, purchasing power parity",35.7
+2085,Austria,2013,5,C08-Calcium channel blockers,"/capita, US$ exchange rate",4.5
+2086,Austria,2013,5,C08-Calcium channel blockers,Million of national currency units,28.4
+2087,Austria,2013,5,C08-Calcium channel blockers,Million US$ at exchange rate,37.8
+2088,Austria,2013,5,C08-Calcium channel blockers,% of total sales,1.1
+2089,Austria,2013,5,C10-Lipid modifying agents,"/capita, US$ exchange rate",14.1
+2090,Austria,2013,5,C10-Lipid modifying agents,"/capita, US$ purchasing power parity",13.3
+2091,Austria,2013,5,C10-Lipid modifying agents,Million US$ at exchange rate,119.6
+2092,Austria,2013,5,C10-Lipid modifying agents,"Million US$, purchasing power parity",113.0
+2093,Austria,2013,5,C-Cardiovascular system,"/capita, US$ purchasing power parity",64.8
+2094,Austria,2013,5,C-Cardiovascular system,% of total sales,16.6
+2095,Austria,2013,5,C10-Lipid modifying agents,% of total sales,3.4
+2096,Austria,2013,5,C09-Agents acting on the Renin-Angiotensin system,"Million US$, purchasing power parity",209.6
+2097,Austria,2013,5,C09-Agents acting on the Renin-Angiotensin system,Million US$ at exchange rate,221.9
+2098,Austria,2013,5,C09-Agents acting on the Renin-Angiotensin system,Million of national currency units,167.1
+2099,Austria,2013,5,C09-Agents acting on the Renin-Angiotensin system,% of total sales,6.3
+2100,Austria,2013,5,C10-Lipid modifying agents,Million of national currency units,90.0
+2101,Austria,2013,5,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ exchange rate",26.2
+2102,Austria,2013,5,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ purchasing power parity",24.7
+2103,Austria,2013,5,"C01B-Antiarrhythmics, Class I and III",% of total sales,0.3
+2104,Austria,2013,5,C02-Antihypertensives,Million of national currency units,42.1
+2105,Austria,2013,5,"C01B-Antiarrhythmics, Class I and III","/capita, US$ exchange rate",1.1
+2106,Austria,2013,5,"C01B-Antiarrhythmics, Class I and III","/capita, US$ purchasing power parity",1.1
+2107,Austria,2013,5,C02-Antihypertensives,"/capita, US$ exchange rate",6.6
+2108,Austria,2013,5,C02-Antihypertensives,"Million US$, purchasing power parity",52.8
+2109,Austria,2013,5,C02-Antihypertensives,Million US$ at exchange rate,55.9
+2110,Austria,2013,5,Total pharmaceutical sales,"Million US$, purchasing power parity",3306.0
+2111,Austria,2013,5,Total pharmaceutical sales,"/capita, US$ exchange rate",412.7
+2112,Austria,2013,5,Total pharmaceutical sales,Million of national currency units,2635.2
+2113,Austria,2013,5,Total pharmaceutical sales,Million US$ at exchange rate,3499.8
+2114,Austria,2013,5,"C01B-Antiarrhythmics, Class I and III",Million US$ at exchange rate,9.7
+2115,Austria,2013,5,"C01B-Antiarrhythmics, Class I and III","Million US$, purchasing power parity",9.1
+2116,Austria,2013,5,Total pharmaceutical sales,"/capita, US$ purchasing power parity",389.9
+2117,Austria,2013,5,"C01B-Antiarrhythmics, Class I and III",Million of national currency units,7.3
+2118,Austria,2013,5,C02-Antihypertensives,"/capita, US$ purchasing power parity",6.2
+2119,Austria,2013,5,C03-Diuretics,"Million US$, purchasing power parity",19.3
+2120,Austria,2013,5,C03-Diuretics,"/capita, US$ exchange rate",2.4
+2121,Austria,2013,5,C03-Diuretics,Million of national currency units,15.4
+2122,Austria,2013,5,C03-Diuretics,Million US$ at exchange rate,20.5
+2123,Austria,2013,5,C07-Beta blocking agents,Million of national currency units,46.5
+2124,Austria,2013,5,C07-Beta blocking agents,Million US$ at exchange rate,61.8
+2125,Austria,2013,5,C03-Diuretics,"/capita, US$ purchasing power parity",2.3
+2126,Austria,2013,5,C03-Diuretics,% of total sales,0.6
+2127,Austria,2013,5,C01A-Cardiac glycosides,% of total sales,0.0
+2128,Austria,2013,5,C01A-Cardiac glycosides,"/capita, US$ purchasing power parity",0.1
+2129,Austria,2013,5,C02-Antihypertensives,% of total sales,1.6
+2130,Austria,2013,5,C01A-Cardiac glycosides,Million US$ at exchange rate,0.7
+2131,Austria,2013,5,C01A-Cardiac glycosides,Million of national currency units,0.6
+2132,Austria,2013,5,C01A-Cardiac glycosides,"/capita, US$ exchange rate",0.1
+2133,Austria,2013,5,C01A-Cardiac glycosides,"Million US$, purchasing power parity",0.7
+2134,Austria,2013,5,C-Cardiovascular system,"/capita, US$ exchange rate",68.6
+2135,Austria,2013,5,G-Genito urinary system and sex hormones,Million US$ at exchange rate,60.2
+2136,Austria,2013,5,G-Genito urinary system and sex hormones,Million of national currency units,45.4
+2137,Austria,2013,5,G03-Sex hormones and modulators of the genital system,Million of national currency units,14.0
+2138,Austria,2013,5,C-Cardiovascular system,Million of national currency units,437.7
+2139,Austria,2013,5,G-Genito urinary system and sex hormones,"Million US$, purchasing power parity",56.9
+2140,Austria,2013,5,G-Genito urinary system and sex hormones,"/capita, US$ purchasing power parity",6.7
+2141,Austria,2013,5,G-Genito urinary system and sex hormones,% of total sales,1.7
+2142,Austria,2013,5,G-Genito urinary system and sex hormones,"/capita, US$ exchange rate",7.1
+2143,Austria,2013,5,G03-Sex hormones and modulators of the genital system,"/capita, US$ exchange rate",2.2
+2144,Austria,2013,5,G03-Sex hormones and modulators of the genital system,"Million US$, purchasing power parity",17.5
+2145,Austria,2013,5,G03-Sex hormones and modulators of the genital system,Million US$ at exchange rate,18.6
+2146,Austria,2013,5,C-Cardiovascular system,"Million US$, purchasing power parity",549.1
+2147,Austria,2013,5,C-Cardiovascular system,Million US$ at exchange rate,581.3
+2148,Austria,2012,5,N-Nervous system,% of total sales,18.6
+2149,Austria,2012,5,N-Nervous system,"/capita, US$ exchange rate",74.2
+2150,Austria,2012,5,N-Nervous system,"Million US$, purchasing power parity",598.7
+2151,Austria,2012,5,N-Nervous system,"/capita, US$ purchasing power parity",71.0
+2152,Austria,2012,5,J01-Antibacterials for systemic use,Million US$ at exchange rate,87.6
+2153,Austria,2012,5,J01-Antibacterials for systemic use,"Million US$, purchasing power parity",83.8
+2154,Austria,2012,5,J01-Antibacterials for systemic use,Million of national currency units,68.2
+2155,Austria,2012,5,J-Antiinfectives for systemic use,"Million US$, purchasing power parity",218.4
+2156,Austria,2012,5,J-Antiinfectives for systemic use,Million US$ at exchange rate,228.4
+2157,Austria,2012,5,J-Antiinfectives for systemic use,Million of national currency units,177.7
+2158,Austria,2012,5,J-Antiinfectives for systemic use,% of total sales,6.8
+2159,Austria,2012,5,J-Antiinfectives for systemic use,"/capita, US$ exchange rate",27.1
+2160,Austria,2012,5,J-Antiinfectives for systemic use,"/capita, US$ purchasing power parity",25.9
+2161,Austria,2012,5,"H-Systemic hormonal preparations, excluding sex hormones and insulins",% of total sales,1.8
+2162,Austria,2012,5,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ exchange rate",7.3
+2163,Austria,2012,5,N02-Analgesics,Million US$ at exchange rate,77.4
+2164,Austria,2012,5,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ purchasing power parity",7.0
+2165,Austria,2012,5,N02-Analgesics,"/capita, US$ exchange rate",9.2
+2166,Austria,2012,5,N02-Analgesics,"/capita, US$ purchasing power parity",8.8
+2167,Austria,2012,5,N02-Analgesics,"Million US$, purchasing power parity",74.1
+2168,Austria,2012,5,N02-Analgesics,Million of national currency units,60.3
+2169,Austria,2012,5,G03-Sex hormones and modulators of the genital system,% of total sales,0.5
+2170,Austria,2012,5,G03-Sex hormones and modulators of the genital system,"/capita, US$ purchasing power parity",2.0
+2171,Austria,2012,5,"H-Systemic hormonal preparations, excluding sex hormones and insulins","Million US$, purchasing power parity",59.1
+2172,Austria,2012,5,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million US$ at exchange rate,61.8
+2173,Austria,2012,5,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million of national currency units,48.1
+2174,Austria,2012,5,A10-Drugs used in diabetes,"/capita, US$ purchasing power parity",16.1
+2175,Austria,2012,5,A02A-Antacids,% of total sales,0.0
+2176,Austria,2012,5,A10-Drugs used in diabetes,"/capita, US$ exchange rate",16.8
+2177,Austria,2012,5,A10-Drugs used in diabetes,Million US$ at exchange rate,142.0
+2178,Austria,2012,5,A10-Drugs used in diabetes,Million of national currency units,110.5
+2179,Austria,2012,5,A10-Drugs used in diabetes,"Million US$, purchasing power parity",135.8
+2180,Austria,2012,5,A02A-Antacids,"/capita, US$ purchasing power parity",0.0
+2181,Austria,2012,5,A10-Drugs used in diabetes,% of total sales,4.2
+2182,Austria,2012,5,N02-Analgesics,% of total sales,2.3
+2183,Austria,2012,5,A02A-Antacids,"/capita, US$ exchange rate",0.0
+2184,Austria,2012,5,A02A-Antacids,Million US$ at exchange rate,0.2
+2185,Austria,2012,5,A02A-Antacids,"Million US$, purchasing power parity",0.2
+2186,Austria,2012,5,M01A-Antiinflammatory and antirheumatic products non-steroids,"Million US$, purchasing power parity",53.3
+2187,Austria,2012,5,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ exchange rate",13.5
+2188,Austria,2012,5,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ exchange rate",6.6
+2189,Austria,2012,5,M01A-Antiinflammatory and antirheumatic products non-steroids,Million US$ at exchange rate,55.7
+2190,Austria,2012,5,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ purchasing power parity",12.9
+2191,Austria,2012,5,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),% of total sales,3.4
+2192,Austria,2012,5,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"Million US$, purchasing power parity",108.5
+2193,Austria,2012,5,N05C-Hypnotics and sedatives,"/capita, US$ purchasing power parity",0.4
+2194,Austria,2012,5,R-Respiratory system,% of total sales,6.2
+2195,Austria,2012,5,N05C-Hypnotics and sedatives,"Million US$, purchasing power parity",3.2
+2196,Austria,2012,5,N05C-Hypnotics and sedatives,"/capita, US$ exchange rate",0.4
+2197,Austria,2012,5,M01A-Antiinflammatory and antirheumatic products non-steroids,Million of national currency units,43.4
+2198,Austria,2012,5,R-Respiratory system,"/capita, US$ purchasing power parity",23.5
+2199,Austria,2012,5,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million of national currency units,88.3
+2200,Austria,2012,5,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million US$ at exchange rate,113.4
+2201,Austria,2012,5,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ purchasing power parity",6.3
+2202,Austria,2012,5,N05C-Hypnotics and sedatives,% of total sales,0.1
+2203,Austria,2012,5,N06A-Antidepressants,% of total sales,3.9
+2204,Austria,2012,5,N06A-Antidepressants,Million of national currency units,103.2
+2205,Austria,2012,5,R-Respiratory system,Million of national currency units,161.4
+2206,Austria,2012,5,M-Musculo-skeletal system,% of total sales,4.1
+2207,Austria,2012,5,N06A-Antidepressants,"Million US$, purchasing power parity",126.8
+2208,Austria,2012,5,N06A-Antidepressants,Million US$ at exchange rate,132.6
+2209,Austria,2012,5,N06A-Antidepressants,"/capita, US$ purchasing power parity",15.0
+2210,Austria,2012,5,N06A-Antidepressants,"/capita, US$ exchange rate",15.7
+2211,Austria,2012,5,M-Musculo-skeletal system,"Million US$, purchasing power parity",132.4
+2212,Austria,2012,5,M-Musculo-skeletal system,"/capita, US$ exchange rate",16.4
+2213,Austria,2012,5,M-Musculo-skeletal system,Million of national currency units,107.7
+2214,Austria,2012,5,M-Musculo-skeletal system,Million US$ at exchange rate,138.4
+2215,Austria,2012,5,R-Respiratory system,"Million US$, purchasing power parity",198.4
+2216,Austria,2012,5,R-Respiratory system,Million US$ at exchange rate,207.4
+2217,Austria,2012,5,M-Musculo-skeletal system,"/capita, US$ purchasing power parity",15.7
+2218,Austria,2012,5,R-Respiratory system,"/capita, US$ exchange rate",24.6
+2219,Austria,2012,5,N-Nervous system,Million of national currency units,487.1
+2220,Austria,2012,5,B-Blood and blood forming organs,% of total sales,6.3
+2221,Austria,2012,5,N-Nervous system,Million US$ at exchange rate,625.9
+2222,Austria,2012,5,Products not elsewhere classified,Million of national currency units,664.5
+2223,Austria,2012,5,B-Blood and blood forming organs,"Million US$, purchasing power parity",202.5
+2224,Austria,2012,5,B-Blood and blood forming organs,Million US$ at exchange rate,211.7
+2225,Austria,2012,5,B-Blood and blood forming organs,"/capita, US$ purchasing power parity",24.0
+2226,Austria,2012,5,B-Blood and blood forming organs,"/capita, US$ exchange rate",25.1
+2227,Austria,2012,5,Products not elsewhere classified,Million US$ at exchange rate,853.7
+2228,Austria,2012,5,J01-Antibacterials for systemic use,% of total sales,2.6
+2229,Austria,2012,5,J01-Antibacterials for systemic use,"/capita, US$ exchange rate",10.4
+2230,Austria,2012,5,J01-Antibacterials for systemic use,"/capita, US$ purchasing power parity",9.9
+2231,Austria,2012,5,Products not elsewhere classified,% of total sales,25.4
+2232,Austria,2012,5,Products not elsewhere classified,"Million US$, purchasing power parity",816.7
+2233,Austria,2012,5,Products not elsewhere classified,"/capita, US$ exchange rate",101.3
+2234,Austria,2012,5,Products not elsewhere classified,"/capita, US$ purchasing power parity",96.9
+2235,Austria,2012,5,R03-Drugs for obstructive airway diseases,Million of national currency units,139.9
+2236,Austria,2012,5,N05B-Anxiolytics,"/capita, US$ purchasing power parity",0.9
+2237,Austria,2012,5,N05B-Anxiolytics,% of total sales,0.2
+2238,Austria,2012,5,R03-Drugs for obstructive airway diseases,Million US$ at exchange rate,179.7
+2239,Austria,2012,5,N05C-Hypnotics and sedatives,Million of national currency units,2.6
+2240,Austria,2012,5,N05C-Hypnotics and sedatives,Million US$ at exchange rate,3.3
+2241,Austria,2012,5,M01A-Antiinflammatory and antirheumatic products non-steroids,% of total sales,1.7
+2242,Austria,2012,5,R03-Drugs for obstructive airway diseases,"/capita, US$ purchasing power parity",20.4
+2243,Austria,2012,5,R03-Drugs for obstructive airway diseases,"/capita, US$ exchange rate",21.3
+2244,Austria,2012,5,B-Blood and blood forming organs,Million of national currency units,164.8
+2245,Austria,2012,5,R03-Drugs for obstructive airway diseases,% of total sales,5.4
+2246,Austria,2012,5,N05B-Anxiolytics,"Million US$, purchasing power parity",8.0
+2247,Austria,2012,5,N05B-Anxiolytics,"/capita, US$ exchange rate",1.0
+2248,Austria,2012,5,R03-Drugs for obstructive airway diseases,"Million US$, purchasing power parity",171.9
+2249,Austria,2012,5,N05B-Anxiolytics,Million of national currency units,6.5
+2250,Austria,2012,5,N05B-Anxiolytics,Million US$ at exchange rate,8.3
+2251,Austria,2012,5,A02A-Antacids,Million of national currency units,0.1
+2252,Austria,2012,5,A-Alimentary tract and metabolism,"Million US$, purchasing power parity",335.6
+2253,Austria,2012,5,A-Alimentary tract and metabolism,Million US$ at exchange rate,350.8
+2254,Austria,2012,5,C08-Calcium channel blockers,"/capita, US$ purchasing power parity",4.3
+2255,Austria,2012,5,A-Alimentary tract and metabolism,Million of national currency units,273.0
+2256,Austria,2012,5,A-Alimentary tract and metabolism,% of total sales,10.4
+2257,Austria,2012,5,A-Alimentary tract and metabolism,"/capita, US$ exchange rate",41.6
+2258,Austria,2012,5,A-Alimentary tract and metabolism,"/capita, US$ purchasing power parity",39.8
+2259,Austria,2012,5,C07-Beta blocking agents,"/capita, US$ purchasing power parity",7.5
+2260,Austria,2012,5,C07-Beta blocking agents,% of total sales,2.0
+2261,Austria,2012,5,C07-Beta blocking agents,"Million US$, purchasing power parity",63.0
+2262,Austria,2012,5,C07-Beta blocking agents,"/capita, US$ exchange rate",7.8
+2263,Austria,2012,5,C08-Calcium channel blockers,"Million US$, purchasing power parity",36.2
+2264,Austria,2012,5,C08-Calcium channel blockers,"/capita, US$ exchange rate",4.5
+2265,Austria,2012,5,C08-Calcium channel blockers,Million of national currency units,29.5
+2266,Austria,2012,5,C08-Calcium channel blockers,Million US$ at exchange rate,37.8
+2267,Austria,2012,5,C08-Calcium channel blockers,% of total sales,1.1
+2268,Austria,2012,5,C10-Lipid modifying agents,"/capita, US$ exchange rate",15.6
+2269,Austria,2012,5,C10-Lipid modifying agents,"/capita, US$ purchasing power parity",14.9
+2270,Austria,2012,5,C10-Lipid modifying agents,Million US$ at exchange rate,131.1
+2271,Austria,2012,5,C10-Lipid modifying agents,"Million US$, purchasing power parity",125.4
+2272,Austria,2012,5,C-Cardiovascular system,"/capita, US$ purchasing power parity",70.4
+2273,Austria,2012,5,C-Cardiovascular system,% of total sales,18.5
+2274,Austria,2012,5,C10-Lipid modifying agents,% of total sales,3.9
+2275,Austria,2012,5,C09-Agents acting on the Renin-Angiotensin system,"Million US$, purchasing power parity",239.2
+2276,Austria,2012,5,C09-Agents acting on the Renin-Angiotensin system,Million US$ at exchange rate,250.0
+2277,Austria,2012,5,C09-Agents acting on the Renin-Angiotensin system,Million of national currency units,194.6
+2278,Austria,2012,5,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ exchange rate",29.7
+2279,Austria,2012,5,C10-Lipid modifying agents,Million of national currency units,102.1
+2280,Austria,2012,5,C09-Agents acting on the Renin-Angiotensin system,% of total sales,7.4
+2281,Austria,2012,5,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ purchasing power parity",28.4
+2282,Austria,2012,5,"C01B-Antiarrhythmics, Class I and III",% of total sales,0.3
+2283,Austria,2012,5,C02-Antihypertensives,Million of national currency units,41.4
+2284,Austria,2012,5,"C01B-Antiarrhythmics, Class I and III","/capita, US$ exchange rate",1.1
+2285,Austria,2012,5,"C01B-Antiarrhythmics, Class I and III","/capita, US$ purchasing power parity",1.1
+2286,Austria,2012,5,C02-Antihypertensives,"/capita, US$ exchange rate",6.3
+2287,Austria,2012,5,C02-Antihypertensives,Million US$ at exchange rate,53.2
+2288,Austria,2012,5,C02-Antihypertensives,"Million US$, purchasing power parity",50.9
+2289,Austria,2012,5,C02-Antihypertensives,"/capita, US$ purchasing power parity",6.0
+2290,Austria,2012,5,Total pharmaceutical sales,"Million US$, purchasing power parity",3211.4
+2291,Austria,2012,5,Total pharmaceutical sales,"/capita, US$ exchange rate",398.2
+2292,Austria,2012,5,Total pharmaceutical sales,Million of national currency units,2613.0
+2293,Austria,2012,5,Total pharmaceutical sales,Million US$ at exchange rate,3357.1
+2294,Austria,2012,5,"C01B-Antiarrhythmics, Class I and III",Million US$ at exchange rate,9.4
+2295,Austria,2012,5,"C01B-Antiarrhythmics, Class I and III","Million US$, purchasing power parity",9.0
+2296,Austria,2012,5,Total pharmaceutical sales,"/capita, US$ purchasing power parity",381.0
+2297,Austria,2012,5,"C01B-Antiarrhythmics, Class I and III",Million of national currency units,7.3
+2298,Austria,2012,5,C03-Diuretics,"Million US$, purchasing power parity",19.2
+2299,Austria,2012,5,C03-Diuretics,"/capita, US$ exchange rate",2.4
+2300,Austria,2012,5,C03-Diuretics,Million US$ at exchange rate,20.1
+2301,Austria,2012,5,C07-Beta blocking agents,Million of national currency units,51.3
+2302,Austria,2012,5,C07-Beta blocking agents,Million US$ at exchange rate,65.9
+2303,Austria,2012,5,C03-Diuretics,"/capita, US$ purchasing power parity",2.3
+2304,Austria,2012,5,C03-Diuretics,Million of national currency units,15.6
+2305,Austria,2012,5,C03-Diuretics,% of total sales,0.6
+2306,Austria,2012,5,C01A-Cardiac glycosides,% of total sales,0.0
+2307,Austria,2012,5,C01A-Cardiac glycosides,"/capita, US$ purchasing power parity",0.1
+2308,Austria,2012,5,C02-Antihypertensives,% of total sales,1.6
+2309,Austria,2012,5,C01A-Cardiac glycosides,Million US$ at exchange rate,0.8
+2310,Austria,2012,5,C01A-Cardiac glycosides,Million of national currency units,0.6
+2311,Austria,2012,5,C01A-Cardiac glycosides,"/capita, US$ exchange rate",0.1
+2312,Austria,2012,5,C01A-Cardiac glycosides,"Million US$, purchasing power parity",0.8
+2313,Austria,2012,5,G-Genito urinary system and sex hormones,Million US$ at exchange rate,58.3
+2314,Austria,2012,5,G03-Sex hormones and modulators of the genital system,Million of national currency units,13.7
+2315,Austria,2012,5,C-Cardiovascular system,Million of national currency units,483.2
+2316,Austria,2012,5,C-Cardiovascular system,"/capita, US$ exchange rate",73.6
+2317,Austria,2012,5,G-Genito urinary system and sex hormones,Million of national currency units,45.4
+2318,Austria,2012,5,G-Genito urinary system and sex hormones,% of total sales,1.7
+2319,Austria,2012,5,G-Genito urinary system and sex hormones,"/capita, US$ purchasing power parity",6.6
+2320,Austria,2012,5,G-Genito urinary system and sex hormones,"Million US$, purchasing power parity",55.8
+2321,Austria,2012,5,G-Genito urinary system and sex hormones,"/capita, US$ exchange rate",6.9
+2322,Austria,2012,5,G03-Sex hormones and modulators of the genital system,"/capita, US$ exchange rate",2.1
+2323,Austria,2012,5,G03-Sex hormones and modulators of the genital system,"Million US$, purchasing power parity",16.8
+2324,Austria,2012,5,G03-Sex hormones and modulators of the genital system,Million US$ at exchange rate,17.6
+2325,Austria,2012,5,C-Cardiovascular system,"Million US$, purchasing power parity",593.9
+2326,Austria,2012,5,C-Cardiovascular system,Million US$ at exchange rate,620.8
+2327,Austria,2011,5,N-Nervous system,% of total sales,19.2
+2328,Austria,2011,5,N06A-Antidepressants,Million US$ at exchange rate,138.3
+2329,Austria,2011,5,N-Nervous system,"/capita, US$ exchange rate",81.3
+2330,Austria,2011,5,N-Nervous system,"Million US$, purchasing power parity",589.6
+2331,Austria,2011,5,N-Nervous system,"/capita, US$ purchasing power parity",70.3
+2332,Austria,2011,5,J01-Antibacterials for systemic use,"Million US$, purchasing power parity",86.4
+2333,Austria,2011,5,J01-Antibacterials for systemic use,Million US$ at exchange rate,100.0
+2334,Austria,2011,5,J01-Antibacterials for systemic use,Million of national currency units,71.8
+2335,Austria,2011,5,J-Antiinfectives for systemic use,"Million US$, purchasing power parity",200.3
+2336,Austria,2011,5,J-Antiinfectives for systemic use,Million of national currency units,166.5
+2337,Austria,2011,5,J-Antiinfectives for systemic use,Million US$ at exchange rate,231.8
+2338,Austria,2011,5,J-Antiinfectives for systemic use,% of total sales,6.5
+2339,Austria,2011,5,J-Antiinfectives for systemic use,"/capita, US$ exchange rate",27.6
+2340,Austria,2011,5,J-Antiinfectives for systemic use,"/capita, US$ purchasing power parity",23.9
+2341,Austria,2011,5,"H-Systemic hormonal preparations, excluding sex hormones and insulins",% of total sales,1.9
+2342,Austria,2011,5,N02-Analgesics,Million US$ at exchange rate,82.8
+2343,Austria,2011,5,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ purchasing power parity",6.9
+2344,Austria,2011,5,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ exchange rate",8.0
+2345,Austria,2011,5,N02-Analgesics,"/capita, US$ purchasing power parity",8.5
+2346,Austria,2011,5,N02-Analgesics,"/capita, US$ exchange rate",9.9
+2347,Austria,2011,5,N02-Analgesics,"Million US$, purchasing power parity",71.5
+2348,Austria,2011,5,N02-Analgesics,Million of national currency units,59.5
+2349,Austria,2011,5,G03-Sex hormones and modulators of the genital system,% of total sales,0.5
+2350,Austria,2011,5,G03-Sex hormones and modulators of the genital system,"/capita, US$ purchasing power parity",2.0
+2351,Austria,2011,5,"H-Systemic hormonal preparations, excluding sex hormones and insulins","Million US$, purchasing power parity",57.7
+2352,Austria,2011,5,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million of national currency units,47.9
+2353,Austria,2011,5,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million US$ at exchange rate,66.7
+2354,Austria,2011,5,A02A-Antacids,Million of national currency units,0.1
+2355,Austria,2011,5,A10-Drugs used in diabetes,"/capita, US$ purchasing power parity",14.9
+2356,Austria,2011,5,A02A-Antacids,% of total sales,0.0
+2357,Austria,2011,5,A10-Drugs used in diabetes,"/capita, US$ exchange rate",17.3
+2358,Austria,2011,5,A10-Drugs used in diabetes,Million US$ at exchange rate,144.9
+2359,Austria,2011,5,A10-Drugs used in diabetes,Million of national currency units,104.1
+2360,Austria,2011,5,A10-Drugs used in diabetes,"Million US$, purchasing power parity",125.2
+2361,Austria,2011,5,A10-Drugs used in diabetes,% of total sales,4.1
+2362,Austria,2011,5,N02-Analgesics,% of total sales,2.3
+2363,Austria,2011,5,A02A-Antacids,"/capita, US$ exchange rate",0.0
+2364,Austria,2011,5,A02A-Antacids,"/capita, US$ purchasing power parity",0.0
+2365,Austria,2011,5,A02A-Antacids,Million US$ at exchange rate,0.2
+2366,Austria,2011,5,A02A-Antacids,"Million US$, purchasing power parity",0.2
+2367,Austria,2011,5,M01A-Antiinflammatory and antirheumatic products non-steroids,"Million US$, purchasing power parity",51.2
+2368,Austria,2011,5,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ exchange rate",16.0
+2369,Austria,2011,5,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ purchasing power parity",6.1
+2370,Austria,2011,5,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ exchange rate",7.1
+2371,Austria,2011,5,M01A-Antiinflammatory and antirheumatic products non-steroids,Million US$ at exchange rate,59.2
+2372,Austria,2011,5,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ purchasing power parity",13.8
+2373,Austria,2011,5,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),% of total sales,3.8
+2374,Austria,2011,5,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"Million US$, purchasing power parity",115.8
+2375,Austria,2011,5,R-Respiratory system,% of total sales,6.3
+2376,Austria,2011,5,N05C-Hypnotics and sedatives,"/capita, US$ purchasing power parity",0.4
+2377,Austria,2011,5,N05C-Hypnotics and sedatives,"/capita, US$ exchange rate",0.4
+2378,Austria,2011,5,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million US$ at exchange rate,134.0
+2379,Austria,2011,5,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million of national currency units,96.2
+2380,Austria,2011,5,N05C-Hypnotics and sedatives,% of total sales,0.1
+2381,Austria,2011,5,N05C-Hypnotics and sedatives,"Million US$, purchasing power parity",3.2
+2382,Austria,2011,5,M01A-Antiinflammatory and antirheumatic products non-steroids,Million of national currency units,42.6
+2383,Austria,2011,5,N06A-Antidepressants,% of total sales,3.9
+2384,Austria,2011,5,N06A-Antidepressants,Million of national currency units,99.3
+2385,Austria,2011,5,R-Respiratory system,Million of national currency units,159.6
+2386,Austria,2011,5,M-Musculo-skeletal system,% of total sales,4.3
+2387,Austria,2011,5,N06A-Antidepressants,"Million US$, purchasing power parity",119.5
+2388,Austria,2011,5,N06A-Antidepressants,"/capita, US$ exchange rate",16.5
+2389,Austria,2011,5,N06A-Antidepressants,"/capita, US$ purchasing power parity",14.2
+2390,Austria,2011,5,M-Musculo-skeletal system,"Million US$, purchasing power parity",131.7
+2391,Austria,2011,5,M-Musculo-skeletal system,"/capita, US$ exchange rate",18.2
+2392,Austria,2011,5,M-Musculo-skeletal system,Million of national currency units,109.5
+2393,Austria,2011,5,M-Musculo-skeletal system,Million US$ at exchange rate,152.4
+2394,Austria,2011,5,M-Musculo-skeletal system,"/capita, US$ purchasing power parity",15.7
+2395,Austria,2011,5,R-Respiratory system,"Million US$, purchasing power parity",192.0
+2396,Austria,2011,5,R-Respiratory system,Million US$ at exchange rate,222.2
+2397,Austria,2011,5,R-Respiratory system,"/capita, US$ purchasing power parity",22.9
+2398,Austria,2011,5,R-Respiratory system,"/capita, US$ exchange rate",26.5
+2399,Austria,2011,5,N-Nervous system,Million of national currency units,490.1
+2400,Austria,2011,5,B-Blood and blood forming organs,% of total sales,5.7
+2401,Austria,2011,5,Products not elsewhere classified,Million of national currency units,617.8
+2402,Austria,2011,5,N-Nervous system,Million US$ at exchange rate,682.3
+2403,Austria,2011,5,B-Blood and blood forming organs,"Million US$, purchasing power parity",175.4
+2404,Austria,2011,5,B-Blood and blood forming organs,Million US$ at exchange rate,203.0
+2405,Austria,2011,5,B-Blood and blood forming organs,"/capita, US$ purchasing power parity",20.9
+2406,Austria,2011,5,B-Blood and blood forming organs,"/capita, US$ exchange rate",24.2
+2407,Austria,2011,5,Products not elsewhere classified,Million US$ at exchange rate,859.9
+2408,Austria,2011,5,J01-Antibacterials for systemic use,% of total sales,2.8
+2409,Austria,2011,5,J01-Antibacterials for systemic use,"/capita, US$ exchange rate",11.9
+2410,Austria,2011,5,J01-Antibacterials for systemic use,"/capita, US$ purchasing power parity",10.3
+2411,Austria,2011,5,Products not elsewhere classified,"/capita, US$ exchange rate",102.5
+2412,Austria,2011,5,Products not elsewhere classified,"Million US$, purchasing power parity",743.1
+2413,Austria,2011,5,Products not elsewhere classified,% of total sales,24.2
+2414,Austria,2011,5,Products not elsewhere classified,"/capita, US$ purchasing power parity",88.6
+2415,Austria,2011,5,R03-Drugs for obstructive airway diseases,Million of national currency units,136.9
+2416,Austria,2011,5,N05B-Anxiolytics,% of total sales,0.3
+2417,Austria,2011,5,N05B-Anxiolytics,"/capita, US$ purchasing power parity",0.9
+2418,Austria,2011,5,R03-Drugs for obstructive airway diseases,Million US$ at exchange rate,190.6
+2419,Austria,2011,5,N05C-Hypnotics and sedatives,Million of national currency units,2.6
+2420,Austria,2011,5,N05C-Hypnotics and sedatives,Million US$ at exchange rate,3.7
+2421,Austria,2011,5,M01A-Antiinflammatory and antirheumatic products non-steroids,% of total sales,1.7
+2422,Austria,2011,5,R03-Drugs for obstructive airway diseases,"/capita, US$ purchasing power parity",19.6
+2423,Austria,2011,5,R03-Drugs for obstructive airway diseases,"/capita, US$ exchange rate",22.7
+2424,Austria,2011,5,B-Blood and blood forming organs,Million of national currency units,145.8
+2425,Austria,2011,5,R03-Drugs for obstructive airway diseases,% of total sales,5.4
+2426,Austria,2011,5,N05B-Anxiolytics,"Million US$, purchasing power parity",7.8
+2427,Austria,2011,5,N05B-Anxiolytics,"/capita, US$ exchange rate",1.1
+2428,Austria,2011,5,R03-Drugs for obstructive airway diseases,"Million US$, purchasing power parity",164.7
+2429,Austria,2011,5,N05B-Anxiolytics,Million of national currency units,6.5
+2430,Austria,2011,5,N05B-Anxiolytics,Million US$ at exchange rate,9.0
+2431,Austria,2011,5,A-Alimentary tract and metabolism,"Million US$, purchasing power parity",327.7
+2432,Austria,2011,5,A-Alimentary tract and metabolism,Million US$ at exchange rate,379.2
+2433,Austria,2011,5,C08-Calcium channel blockers,"/capita, US$ purchasing power parity",4.4
+2434,Austria,2011,5,A-Alimentary tract and metabolism,Million of national currency units,272.4
+2435,Austria,2011,5,A-Alimentary tract and metabolism,"/capita, US$ exchange rate",45.2
+2436,Austria,2011,5,A-Alimentary tract and metabolism,% of total sales,10.7
+2437,Austria,2011,5,A-Alimentary tract and metabolism,"/capita, US$ purchasing power parity",39.0
+2438,Austria,2011,5,C07-Beta blocking agents,"/capita, US$ purchasing power parity",8.2
+2439,Austria,2011,5,C07-Beta blocking agents,% of total sales,2.3
+2440,Austria,2011,5,C07-Beta blocking agents,"Million US$, purchasing power parity",69.0
+2441,Austria,2011,5,C07-Beta blocking agents,"/capita, US$ exchange rate",9.5
+2442,Austria,2011,5,C08-Calcium channel blockers,"Million US$, purchasing power parity",36.7
+2443,Austria,2011,5,C08-Calcium channel blockers,"/capita, US$ exchange rate",5.1
+2444,Austria,2011,5,C08-Calcium channel blockers,Million of national currency units,30.5
+2445,Austria,2011,5,C08-Calcium channel blockers,% of total sales,1.2
+2446,Austria,2011,5,C08-Calcium channel blockers,Million US$ at exchange rate,42.5
+2447,Austria,2011,5,C10-Lipid modifying agents,"/capita, US$ exchange rate",17.0
+2448,Austria,2011,5,C10-Lipid modifying agents,"/capita, US$ purchasing power parity",14.7
+2449,Austria,2011,5,C10-Lipid modifying agents,"Million US$, purchasing power parity",123.4
+2450,Austria,2011,5,C-Cardiovascular system,"/capita, US$ purchasing power parity",71.1
+2451,Austria,2011,5,C-Cardiovascular system,% of total sales,19.5
+2452,Austria,2011,5,C10-Lipid modifying agents,% of total sales,4.0
+2453,Austria,2011,5,C10-Lipid modifying agents,Million US$ at exchange rate,142.8
+2454,Austria,2011,5,C09-Agents acting on the Renin-Angiotensin system,"Million US$, purchasing power parity",237.0
+2455,Austria,2011,5,C09-Agents acting on the Renin-Angiotensin system,Million of national currency units,197.0
+2456,Austria,2011,5,C09-Agents acting on the Renin-Angiotensin system,Million US$ at exchange rate,274.2
+2457,Austria,2011,5,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ exchange rate",32.7
+2458,Austria,2011,5,C10-Lipid modifying agents,Million of national currency units,102.6
+2459,Austria,2011,5,C09-Agents acting on the Renin-Angiotensin system,% of total sales,7.7
+2460,Austria,2011,5,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ purchasing power parity",28.2
+2461,Austria,2011,5,"C01B-Antiarrhythmics, Class I and III",% of total sales,0.3
+2462,Austria,2011,5,C02-Antihypertensives,Million of national currency units,39.6
+2463,Austria,2011,5,"C01B-Antiarrhythmics, Class I and III","/capita, US$ exchange rate",1.3
+2464,Austria,2011,5,"C01B-Antiarrhythmics, Class I and III","/capita, US$ purchasing power parity",1.1
+2465,Austria,2011,5,C02-Antihypertensives,"/capita, US$ exchange rate",6.6
+2466,Austria,2011,5,C02-Antihypertensives,"/capita, US$ purchasing power parity",5.7
+2467,Austria,2011,5,C02-Antihypertensives,Million US$ at exchange rate,55.2
+2468,Austria,2011,5,C02-Antihypertensives,"Million US$, purchasing power parity",47.7
+2469,Austria,2011,5,Total pharmaceutical sales,"Million US$, purchasing power parity",3066.7
+2470,Austria,2011,5,Total pharmaceutical sales,"/capita, US$ exchange rate",422.9
+2471,Austria,2011,5,Total pharmaceutical sales,Million of national currency units,2549.6
+2472,Austria,2011,5,Total pharmaceutical sales,Million US$ at exchange rate,3548.9
+2473,Austria,2011,5,"C01B-Antiarrhythmics, Class I and III",Million US$ at exchange rate,10.6
+2474,Austria,2011,5,"C01B-Antiarrhythmics, Class I and III","Million US$, purchasing power parity",9.2
+2475,Austria,2011,5,Total pharmaceutical sales,"/capita, US$ purchasing power parity",365.4
+2476,Austria,2011,5,"C01B-Antiarrhythmics, Class I and III",Million of national currency units,7.6
+2477,Austria,2011,5,C03-Diuretics,"/capita, US$ exchange rate",2.6
+2478,Austria,2011,5,C03-Diuretics,"Million US$, purchasing power parity",18.5
+2479,Austria,2011,5,C03-Diuretics,Million US$ at exchange rate,21.4
+2480,Austria,2011,5,C07-Beta blocking agents,Million of national currency units,57.4
+2481,Austria,2011,5,C07-Beta blocking agents,Million US$ at exchange rate,79.9
+2482,Austria,2011,5,C03-Diuretics,"/capita, US$ purchasing power parity",2.2
+2483,Austria,2011,5,C03-Diuretics,% of total sales,0.6
+2484,Austria,2011,5,C03-Diuretics,Million of national currency units,15.4
+2485,Austria,2011,5,C01A-Cardiac glycosides,% of total sales,0.0
+2486,Austria,2011,5,C01A-Cardiac glycosides,"/capita, US$ purchasing power parity",0.1
+2487,Austria,2011,5,C02-Antihypertensives,% of total sales,1.6
+2488,Austria,2011,5,C01A-Cardiac glycosides,Million US$ at exchange rate,0.9
+2489,Austria,2011,5,C01A-Cardiac glycosides,Million of national currency units,0.7
+2490,Austria,2011,5,C01A-Cardiac glycosides,"/capita, US$ exchange rate",0.1
+2491,Austria,2011,5,C01A-Cardiac glycosides,"Million US$, purchasing power parity",0.8
+2492,Austria,2011,5,C-Cardiovascular system,"/capita, US$ exchange rate",82.3
+2493,Austria,2011,5,G-Genito urinary system and sex hormones,Million US$ at exchange rate,61.1
+2494,Austria,2011,5,G-Genito urinary system and sex hormones,Million of national currency units,43.9
+2495,Austria,2011,5,G03-Sex hormones and modulators of the genital system,Million of national currency units,13.9
+2496,Austria,2011,5,C-Cardiovascular system,Million of national currency units,495.9
+2497,Austria,2011,5,G-Genito urinary system and sex hormones,"Million US$, purchasing power parity",52.8
+2498,Austria,2011,5,G-Genito urinary system and sex hormones,% of total sales,1.7
+2499,Austria,2011,5,G-Genito urinary system and sex hormones,"/capita, US$ purchasing power parity",6.3
+2500,Austria,2011,5,G-Genito urinary system and sex hormones,"/capita, US$ exchange rate",7.3
+2501,Austria,2011,5,G03-Sex hormones and modulators of the genital system,"/capita, US$ exchange rate",2.3
+2502,Austria,2011,5,G03-Sex hormones and modulators of the genital system,Million US$ at exchange rate,19.3
+2503,Austria,2011,5,G03-Sex hormones and modulators of the genital system,"Million US$, purchasing power parity",16.7
+2504,Austria,2011,5,C-Cardiovascular system,"Million US$, purchasing power parity",596.5
+2505,Austria,2011,5,C-Cardiovascular system,Million US$ at exchange rate,690.3
+2506,Austria,2010,5,N-Nervous system,"/capita, US$ exchange rate",74.1
+2507,Austria,2010,5,N-Nervous system,"/capita, US$ purchasing power parity",66.3
+2508,Austria,2010,5,N-Nervous system,"Million US$, purchasing power parity",554.9
+2509,Austria,2010,5,J01-Antibacterials for systemic use,"Million US$, purchasing power parity",88.2
+2510,Austria,2010,5,J01-Antibacterials for systemic use,Million of national currency units,74.3
+2511,Austria,2010,5,J01-Antibacterials for systemic use,Million US$ at exchange rate,98.5
+2512,Austria,2010,5,J-Antiinfectives for systemic use,"Million US$, purchasing power parity",193.3
+2513,Austria,2010,5,J-Antiinfectives for systemic use,Million of national currency units,162.8
+2514,Austria,2010,5,J-Antiinfectives for systemic use,Million US$ at exchange rate,215.8
+2515,Austria,2010,5,J-Antiinfectives for systemic use,% of total sales,6.5
+2516,Austria,2010,5,J-Antiinfectives for systemic use,"/capita, US$ exchange rate",25.8
+2517,Austria,2010,5,J-Antiinfectives for systemic use,"/capita, US$ purchasing power parity",23.1
+2518,Austria,2010,5,N-Nervous system,% of total sales,18.7
+2519,Austria,2010,5,A10-Drugs used in diabetes,Million of national currency units,96.6
+2520,Austria,2010,5,"H-Systemic hormonal preparations, excluding sex hormones and insulins",% of total sales,1.9
+2521,Austria,2010,5,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ purchasing power parity",6.8
+2522,Austria,2010,5,N02-Analgesics,"/capita, US$ purchasing power parity",8.8
+2523,Austria,2010,5,N02-Analgesics,"/capita, US$ exchange rate",9.8
+2524,Austria,2010,5,N02-Analgesics,"Million US$, purchasing power parity",73.4
+2525,Austria,2010,5,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ exchange rate",7.5
+2526,Austria,2010,5,N02-Analgesics,Million of national currency units,61.9
+2527,Austria,2010,5,G03-Sex hormones and modulators of the genital system,% of total sales,0.6
+2528,Austria,2010,5,G03-Sex hormones and modulators of the genital system,"/capita, US$ purchasing power parity",2.1
+2529,Austria,2010,5,"H-Systemic hormonal preparations, excluding sex hormones and insulins","Million US$, purchasing power parity",56.5
+2530,Austria,2010,5,A02A-Antacids,Million of national currency units,0.2
+2531,Austria,2010,5,N02-Analgesics,Million US$ at exchange rate,82.0
+2532,Austria,2010,5,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million of national currency units,47.6
+2533,Austria,2010,5,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million US$ at exchange rate,63.0
+2534,Austria,2010,5,A10-Drugs used in diabetes,"/capita, US$ purchasing power parity",13.7
+2535,Austria,2010,5,A02A-Antacids,% of total sales,0.0
+2536,Austria,2010,5,A10-Drugs used in diabetes,Million US$ at exchange rate,128.1
+2537,Austria,2010,5,A10-Drugs used in diabetes,"/capita, US$ exchange rate",15.3
+2538,Austria,2010,5,A10-Drugs used in diabetes,"Million US$, purchasing power parity",114.7
+2539,Austria,2010,5,A02A-Antacids,"/capita, US$ purchasing power parity",0.0
+2540,Austria,2010,5,A10-Drugs used in diabetes,% of total sales,3.9
+2541,Austria,2010,5,A02A-Antacids,Million US$ at exchange rate,0.3
+2542,Austria,2010,5,N02-Analgesics,% of total sales,2.5
+2543,Austria,2010,5,A02A-Antacids,"/capita, US$ exchange rate",0.0
+2544,Austria,2010,5,A02A-Antacids,"Million US$, purchasing power parity",0.2
+2545,Austria,2010,5,M01A-Antiinflammatory and antirheumatic products non-steroids,"Million US$, purchasing power parity",50.0
+2546,Austria,2010,5,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ exchange rate",17.1
+2547,Austria,2010,5,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ purchasing power parity",6.0
+2548,Austria,2010,5,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ exchange rate",6.7
+2549,Austria,2010,5,M01A-Antiinflammatory and antirheumatic products non-steroids,Million US$ at exchange rate,55.8
+2550,Austria,2010,5,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ purchasing power parity",15.3
+2551,Austria,2010,5,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),% of total sales,4.3
+2552,Austria,2010,5,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"Million US$, purchasing power parity",127.9
+2553,Austria,2010,5,R-Respiratory system,% of total sales,6.2
+2554,Austria,2010,5,N05C-Hypnotics and sedatives,"/capita, US$ purchasing power parity",0.4
+2555,Austria,2010,5,N05C-Hypnotics and sedatives,"/capita, US$ exchange rate",0.4
+2556,Austria,2010,5,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million US$ at exchange rate,142.8
+2557,Austria,2010,5,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million of national currency units,107.7
+2558,Austria,2010,5,N05C-Hypnotics and sedatives,% of total sales,0.1
+2559,Austria,2010,5,M-Musculo-skeletal system,Million of national currency units,109.6
+2560,Austria,2010,5,N06A-Antidepressants,Million of national currency units,94.0
+2561,Austria,2010,5,N06A-Antidepressants,% of total sales,3.8
+2562,Austria,2010,5,R-Respiratory system,Million of national currency units,154.8
+2563,Austria,2010,5,M-Musculo-skeletal system,% of total sales,4.4
+2564,Austria,2010,5,N06A-Antidepressants,"Million US$, purchasing power parity",111.6
+2565,Austria,2010,5,N06A-Antidepressants,"/capita, US$ exchange rate",14.9
+2566,Austria,2010,5,N06A-Antidepressants,"/capita, US$ purchasing power parity",13.3
+2567,Austria,2010,5,M-Musculo-skeletal system,"/capita, US$ exchange rate",17.4
+2568,Austria,2010,5,M-Musculo-skeletal system,"Million US$, purchasing power parity",130.1
+2569,Austria,2010,5,M-Musculo-skeletal system,Million US$ at exchange rate,145.2
+2570,Austria,2010,5,M01A-Antiinflammatory and antirheumatic products non-steroids,Million of national currency units,42.1
+2571,Austria,2010,5,R-Respiratory system,"Million US$, purchasing power parity",183.8
+2572,Austria,2010,5,R-Respiratory system,Million US$ at exchange rate,205.3
+2573,Austria,2010,5,R-Respiratory system,"/capita, US$ purchasing power parity",22.0
+2574,Austria,2010,5,R-Respiratory system,"/capita, US$ exchange rate",24.5
+2575,Austria,2010,5,M-Musculo-skeletal system,"/capita, US$ purchasing power parity",15.6
+2576,Austria,2010,5,N05C-Hypnotics and sedatives,"Million US$, purchasing power parity",3.0
+2577,Austria,2010,5,N-Nervous system,Million of national currency units,467.4
+2578,Austria,2010,5,B-Blood and blood forming organs,% of total sales,6.1
+2579,Austria,2010,5,Products not elsewhere classified,Million US$ at exchange rate,773.7
+2580,Austria,2010,5,Products not elsewhere classified,Million of national currency units,583.6
+2581,Austria,2010,5,N-Nervous system,Million US$ at exchange rate,619.6
+2582,Austria,2010,5,N06A-Antidepressants,Million US$ at exchange rate,124.6
+2583,Austria,2010,5,B-Blood and blood forming organs,"Million US$, purchasing power parity",179.5
+2584,Austria,2010,5,B-Blood and blood forming organs,Million US$ at exchange rate,200.4
+2585,Austria,2010,5,B-Blood and blood forming organs,"/capita, US$ purchasing power parity",21.5
+2586,Austria,2010,5,B-Blood and blood forming organs,"/capita, US$ exchange rate",24.0
+2587,Austria,2010,5,J01-Antibacterials for systemic use,% of total sales,3.0
+2588,Austria,2010,5,J01-Antibacterials for systemic use,"/capita, US$ exchange rate",11.8
+2589,Austria,2010,5,J01-Antibacterials for systemic use,"/capita, US$ purchasing power parity",10.6
+2590,Austria,2010,5,Products not elsewhere classified,"/capita, US$ exchange rate",92.5
+2591,Austria,2010,5,Products not elsewhere classified,"Million US$, purchasing power parity",693.0
+2592,Austria,2010,5,Products not elsewhere classified,% of total sales,23.4
+2593,Austria,2010,5,Products not elsewhere classified,"/capita, US$ purchasing power parity",82.9
+2594,Austria,2010,5,R03-Drugs for obstructive airway diseases,Million of national currency units,132.5
+2595,Austria,2010,5,N05B-Anxiolytics,% of total sales,0.2
+2596,Austria,2010,5,N05B-Anxiolytics,"/capita, US$ purchasing power parity",0.9
+2597,Austria,2010,5,R03-Drugs for obstructive airway diseases,Million US$ at exchange rate,175.7
+2598,Austria,2010,5,N05C-Hypnotics and sedatives,Million US$ at exchange rate,3.3
+2599,Austria,2010,5,N05C-Hypnotics and sedatives,Million of national currency units,2.5
+2600,Austria,2010,5,M01A-Antiinflammatory and antirheumatic products non-steroids,% of total sales,1.7
+2601,Austria,2010,5,R03-Drugs for obstructive airway diseases,"/capita, US$ purchasing power parity",18.8
+2602,Austria,2010,5,R03-Drugs for obstructive airway diseases,"/capita, US$ exchange rate",21.0
+2603,Austria,2010,5,B-Blood and blood forming organs,Million of national currency units,151.2
+2604,Austria,2010,5,R03-Drugs for obstructive airway diseases,% of total sales,5.3
+2605,Austria,2010,5,N05B-Anxiolytics,"Million US$, purchasing power parity",7.3
+2606,Austria,2010,5,N05B-Anxiolytics,"/capita, US$ exchange rate",1.0
+2607,Austria,2010,5,R03-Drugs for obstructive airway diseases,"Million US$, purchasing power parity",157.3
+2608,Austria,2010,5,N05B-Anxiolytics,Million of national currency units,6.2
+2609,Austria,2010,5,N05B-Anxiolytics,Million US$ at exchange rate,8.2
+2610,Austria,2010,5,A-Alimentary tract and metabolism,"Million US$, purchasing power parity",325.9
+2611,Austria,2010,5,C08-Calcium channel blockers,"/capita, US$ purchasing power parity",4.9
+2612,Austria,2010,5,A-Alimentary tract and metabolism,Million of national currency units,274.4
+2613,Austria,2010,5,A-Alimentary tract and metabolism,Million US$ at exchange rate,363.8
+2614,Austria,2010,5,C08-Calcium channel blockers,% of total sales,1.4
+2615,Austria,2010,5,A-Alimentary tract and metabolism,% of total sales,11.0
+2616,Austria,2010,5,A-Alimentary tract and metabolism,"/capita, US$ exchange rate",43.5
+2617,Austria,2010,5,A-Alimentary tract and metabolism,"/capita, US$ purchasing power parity",39.0
+2618,Austria,2010,5,C07-Beta blocking agents,"/capita, US$ purchasing power parity",9.0
+2619,Austria,2010,5,C07-Beta blocking agents,% of total sales,2.6
+2620,Austria,2010,5,C07-Beta blocking agents,"Million US$, purchasing power parity",75.7
+2621,Austria,2010,5,C07-Beta blocking agents,"/capita, US$ exchange rate",10.1
+2622,Austria,2010,5,C08-Calcium channel blockers,"Million US$, purchasing power parity",40.9
+2623,Austria,2010,5,C08-Calcium channel blockers,"/capita, US$ exchange rate",5.5
+2624,Austria,2010,5,C08-Calcium channel blockers,Million of national currency units,34.5
+2625,Austria,2010,5,C08-Calcium channel blockers,Million US$ at exchange rate,45.7
+2626,Austria,2010,5,C10-Lipid modifying agents,"/capita, US$ purchasing power parity",13.7
+2627,Austria,2010,5,C10-Lipid modifying agents,"/capita, US$ exchange rate",15.3
+2628,Austria,2010,5,C10-Lipid modifying agents,"Million US$, purchasing power parity",114.5
+2629,Austria,2010,5,C-Cardiovascular system,"/capita, US$ purchasing power parity",70.7
+2630,Austria,2010,5,C-Cardiovascular system,% of total sales,20.0
+2631,Austria,2010,5,C10-Lipid modifying agents,% of total sales,3.9
+2632,Austria,2010,5,C10-Lipid modifying agents,Million US$ at exchange rate,127.8
+2633,Austria,2010,5,C09-Agents acting on the Renin-Angiotensin system,"Million US$, purchasing power parity",232.0
+2634,Austria,2010,5,C09-Agents acting on the Renin-Angiotensin system,Million US$ at exchange rate,259.1
+2635,Austria,2010,5,C09-Agents acting on the Renin-Angiotensin system,Million of national currency units,195.4
+2636,Austria,2010,5,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ exchange rate",31.0
+2637,Austria,2010,5,C10-Lipid modifying agents,Million of national currency units,96.4
+2638,Austria,2010,5,C09-Agents acting on the Renin-Angiotensin system,% of total sales,7.8
+2639,Austria,2010,5,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ purchasing power parity",27.7
+2640,Austria,2010,5,"C01B-Antiarrhythmics, Class I and III",% of total sales,0.3
+2641,Austria,2010,5,C02-Antihypertensives,Million of national currency units,39.3
+2642,Austria,2010,5,"C01B-Antiarrhythmics, Class I and III","/capita, US$ exchange rate",1.1
+2643,Austria,2010,5,"C01B-Antiarrhythmics, Class I and III","/capita, US$ purchasing power parity",1.0
+2644,Austria,2010,5,C02-Antihypertensives,"/capita, US$ exchange rate",6.2
+2645,Austria,2010,5,C02-Antihypertensives,"/capita, US$ purchasing power parity",5.6
+2646,Austria,2010,5,C02-Antihypertensives,Million US$ at exchange rate,52.1
+2647,Austria,2010,5,C02-Antihypertensives,"Million US$, purchasing power parity",46.6
+2648,Austria,2010,5,Total pharmaceutical sales,"Million US$, purchasing power parity",2959.9
+2649,Austria,2010,5,Total pharmaceutical sales,"/capita, US$ exchange rate",395.2
+2650,Austria,2010,5,Total pharmaceutical sales,Million of national currency units,2493.0
+2651,Austria,2010,5,Total pharmaceutical sales,Million US$ at exchange rate,3305.0
+2652,Austria,2010,5,"C01B-Antiarrhythmics, Class I and III",Million US$ at exchange rate,9.0
+2653,Austria,2010,5,"C01B-Antiarrhythmics, Class I and III","Million US$, purchasing power parity",8.1
+2654,Austria,2010,5,Total pharmaceutical sales,"/capita, US$ purchasing power parity",353.9
+2655,Austria,2010,5,"C01B-Antiarrhythmics, Class I and III",Million of national currency units,6.8
+2656,Austria,2010,5,C03-Diuretics,"/capita, US$ exchange rate",2.5
+2657,Austria,2010,5,C03-Diuretics,"Million US$, purchasing power parity",18.8
+2658,Austria,2010,5,C03-Diuretics,Million US$ at exchange rate,21.0
+2659,Austria,2010,5,C03-Diuretics,"/capita, US$ purchasing power parity",2.2
+2660,Austria,2010,5,C07-Beta blocking agents,Million US$ at exchange rate,84.5
+2661,Austria,2010,5,C07-Beta blocking agents,Million of national currency units,63.7
+2662,Austria,2010,5,C03-Diuretics,% of total sales,0.6
+2663,Austria,2010,5,C01A-Cardiac glycosides,Million of national currency units,0.7
+2664,Austria,2010,5,C01A-Cardiac glycosides,% of total sales,0.0
+2665,Austria,2010,5,C01A-Cardiac glycosides,"/capita, US$ purchasing power parity",0.1
+2666,Austria,2010,5,C02-Antihypertensives,% of total sales,1.6
+2667,Austria,2010,5,C01A-Cardiac glycosides,Million US$ at exchange rate,1.0
+2668,Austria,2010,5,C01A-Cardiac glycosides,"/capita, US$ exchange rate",0.1
+2669,Austria,2010,5,C03-Diuretics,Million of national currency units,15.8
+2670,Austria,2010,5,C01A-Cardiac glycosides,"Million US$, purchasing power parity",0.9
+2671,Austria,2010,5,G-Genito urinary system and sex hormones,Million US$ at exchange rate,57.9
+2672,Austria,2010,5,G-Genito urinary system and sex hormones,"Million US$, purchasing power parity",51.8
+2673,Austria,2010,5,G03-Sex hormones and modulators of the genital system,Million of national currency units,14.5
+2674,Austria,2010,5,C-Cardiovascular system,Million of national currency units,498.0
+2675,Austria,2010,5,G-Genito urinary system and sex hormones,Million of national currency units,43.7
+2676,Austria,2010,5,G-Genito urinary system and sex hormones,% of total sales,1.8
+2677,Austria,2010,5,G-Genito urinary system and sex hormones,"/capita, US$ exchange rate",6.9
+2678,Austria,2010,5,G-Genito urinary system and sex hormones,"/capita, US$ purchasing power parity",6.2
+2679,Austria,2010,5,G03-Sex hormones and modulators of the genital system,"/capita, US$ exchange rate",2.3
+2680,Austria,2010,5,G03-Sex hormones and modulators of the genital system,"Million US$, purchasing power parity",17.3
+2681,Austria,2010,5,G03-Sex hormones and modulators of the genital system,Million US$ at exchange rate,19.3
+2682,Austria,2010,5,C-Cardiovascular system,"/capita, US$ exchange rate",78.9
+2683,Austria,2010,5,C-Cardiovascular system,"Million US$, purchasing power parity",591.3
+2684,Austria,2010,5,C-Cardiovascular system,Million US$ at exchange rate,660.2
+2685,Austria,2017,5,N-Nervous system,% of total sales,14.1
+2686,Austria,2017,5,N-Nervous system,"Million US$, purchasing power parity",567.4
+2687,Austria,2017,5,N-Nervous system,"/capita, US$ exchange rate",56.5
+2688,Austria,2017,5,N-Nervous system,"/capita, US$ purchasing power parity",64.5
+2689,Austria,2017,5,J01-Antibacterials for systemic use,Million US$ at exchange rate,67.6
+2690,Austria,2017,5,N-Nervous system,Million US$ at exchange rate,496.7
+2691,Austria,2017,5,J01-Antibacterials for systemic use,Million of national currency units,59.8
+2692,Austria,2017,5,J-Antiinfectives for systemic use,Million US$ at exchange rate,300.3
+2693,Austria,2017,5,J-Antiinfectives for systemic use,"Million US$, purchasing power parity",343.1
+2694,Austria,2017,5,J-Antiinfectives for systemic use,Million of national currency units,265.9
+2695,Austria,2017,5,J-Antiinfectives for systemic use,"/capita, US$ purchasing power parity",39.0
+2696,Austria,2017,5,J-Antiinfectives for systemic use,% of total sales,8.5
+2697,Austria,2017,5,J-Antiinfectives for systemic use,"/capita, US$ exchange rate",34.1
+2698,Austria,2017,5,"H-Systemic hormonal preparations, excluding sex hormones and insulins",% of total sales,1.8
+2699,Austria,2017,5,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ purchasing power parity",8.3
+2700,Austria,2017,5,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ exchange rate",7.3
+2701,Austria,2017,5,N02-Analgesics,"/capita, US$ exchange rate",8.7
+2702,Austria,2017,5,N02-Analgesics,Million US$ at exchange rate,76.4
+2703,Austria,2017,5,N02-Analgesics,"Million US$, purchasing power parity",87.2
+2704,Austria,2017,5,G03-Sex hormones and modulators of the genital system,% of total sales,0.4
+2705,Austria,2017,5,N02-Analgesics,Million of national currency units,67.6
+2706,Austria,2017,5,G03-Sex hormones and modulators of the genital system,"/capita, US$ purchasing power parity",2.0
+2707,Austria,2017,5,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million US$ at exchange rate,63.9
+2708,Austria,2017,5,"H-Systemic hormonal preparations, excluding sex hormones and insulins","Million US$, purchasing power parity",73.0
+2709,Austria,2017,5,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million of national currency units,56.5
+2710,Austria,2017,5,A10-Drugs used in diabetes,"/capita, US$ purchasing power parity",24.3
+2711,Austria,2017,5,A10-Drugs used in diabetes,"/capita, US$ exchange rate",21.3
+2712,Austria,2017,5,A02A-Antacids,"/capita, US$ purchasing power parity",0.1
+2713,Austria,2017,5,A02A-Antacids,% of total sales,0.0
+2714,Austria,2017,5,A10-Drugs used in diabetes,Million of national currency units,165.7
+2715,Austria,2017,5,A10-Drugs used in diabetes,"Million US$, purchasing power parity",213.8
+2716,Austria,2017,5,A10-Drugs used in diabetes,Million US$ at exchange rate,187.2
+2717,Austria,2017,5,N02-Analgesics,% of total sales,2.2
+2718,Austria,2017,5,A10-Drugs used in diabetes,% of total sales,5.3
+2719,Austria,2017,5,A02A-Antacids,Million of national currency units,0.9
+2720,Austria,2017,5,N02-Analgesics,"/capita, US$ purchasing power parity",9.9
+2721,Austria,2017,5,A02A-Antacids,"Million US$, purchasing power parity",1.1
+2722,Austria,2017,5,A02A-Antacids,"/capita, US$ exchange rate",0.1
+2723,Austria,2017,5,A02A-Antacids,Million US$ at exchange rate,1.0
+2724,Austria,2017,5,M01A-Antiinflammatory and antirheumatic products non-steroids,Million US$ at exchange rate,45.7
+2725,Austria,2017,5,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"Million US$, purchasing power parity",49.7
+2726,Austria,2017,5,M01A-Antiinflammatory and antirheumatic products non-steroids,"Million US$, purchasing power parity",52.2
+2727,Austria,2017,5,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ exchange rate",5.2
+2728,Austria,2017,5,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ exchange rate",4.9
+2729,Austria,2017,5,G03-Sex hormones and modulators of the genital system,"/capita, US$ exchange rate",1.7
+2730,Austria,2017,5,M01A-Antiinflammatory and antirheumatic products non-steroids,Million of national currency units,40.5
+2731,Austria,2017,5,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),% of total sales,1.2
+2732,Austria,2017,5,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ purchasing power parity",5.7
+2733,Austria,2017,5,R-Respiratory system,% of total sales,5.7
+2734,Austria,2017,5,R-Respiratory system,"/capita, US$ purchasing power parity",26.0
+2735,Austria,2017,5,N05C-Hypnotics and sedatives,"Million US$, purchasing power parity",3.8
+2736,Austria,2017,5,N05C-Hypnotics and sedatives,"/capita, US$ exchange rate",0.4
+2737,Austria,2017,5,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million of national currency units,38.5
+2738,Austria,2017,5,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million US$ at exchange rate,43.5
+2739,Austria,2017,5,N05C-Hypnotics and sedatives,"/capita, US$ purchasing power parity",0.4
+2740,Austria,2017,5,N05C-Hypnotics and sedatives,% of total sales,0.1
+2741,Austria,2017,5,N06A-Antidepressants,% of total sales,2.6
+2742,Austria,2017,5,N06A-Antidepressants,"/capita, US$ purchasing power parity",11.7
+2743,Austria,2017,5,M-Musculo-skeletal system,"/capita, US$ purchasing power parity",15.5
+2744,Austria,2017,5,M-Musculo-skeletal system,% of total sales,3.4
+2745,Austria,2017,5,N06A-Antidepressants,"Million US$, purchasing power parity",103.3
+2746,Austria,2017,5,N06A-Antidepressants,Million US$ at exchange rate,90.4
+2747,Austria,2017,5,N06A-Antidepressants,Million of national currency units,80.1
+2748,Austria,2017,5,N06A-Antidepressants,"/capita, US$ exchange rate",10.3
+2749,Austria,2017,5,R-Respiratory system,Million of national currency units,177.4
+2750,Austria,2017,5,M-Musculo-skeletal system,"Million US$, purchasing power parity",136.1
+2751,Austria,2017,5,M-Musculo-skeletal system,"/capita, US$ exchange rate",13.5
+2752,Austria,2017,5,M-Musculo-skeletal system,Million of national currency units,105.5
+2753,Austria,2017,5,M-Musculo-skeletal system,Million US$ at exchange rate,119.2
+2754,Austria,2017,5,R-Respiratory system,Million US$ at exchange rate,200.4
+2755,Austria,2017,5,R-Respiratory system,"Million US$, purchasing power parity",228.9
+2756,Austria,2017,5,R-Respiratory system,"/capita, US$ exchange rate",22.8
+2757,Austria,2017,5,N-Nervous system,Million of national currency units,439.7
+2758,Austria,2017,5,B-Blood and blood forming organs,% of total sales,9.9
+2759,Austria,2017,5,Products not elsewhere classified,Million of national currency units,987.4
+2760,Austria,2017,5,B-Blood and blood forming organs,"Million US$, purchasing power parity",399.7
+2761,Austria,2017,5,B-Blood and blood forming organs,Million US$ at exchange rate,350.0
+2762,Austria,2017,5,B-Blood and blood forming organs,"/capita, US$ purchasing power parity",45.4
+2763,Austria,2017,5,B-Blood and blood forming organs,"/capita, US$ exchange rate",39.8
+2764,Austria,2017,5,J01-Antibacterials for systemic use,% of total sales,1.9
+2765,Austria,2017,5,Products not elsewhere classified,% of total sales,31.6
+2766,Austria,2017,5,J01-Antibacterials for systemic use,"/capita, US$ purchasing power parity",8.8
+2767,Austria,2017,5,J01-Antibacterials for systemic use,"/capita, US$ exchange rate",7.7
+2768,Austria,2017,5,Products not elsewhere classified,"Million US$, purchasing power parity",1274.1
+2769,Austria,2017,5,Products not elsewhere classified,Million US$ at exchange rate,1115.5
+2770,Austria,2017,5,Products not elsewhere classified,"/capita, US$ purchasing power parity",144.8
+2771,Austria,2017,5,Products not elsewhere classified,"/capita, US$ exchange rate",126.8
+2772,Austria,2017,5,B-Blood and blood forming organs,Million of national currency units,309.8
+2773,Austria,2017,5,N05B-Anxiolytics,"/capita, US$ purchasing power parity",1.0
+2774,Austria,2017,5,R03-Drugs for obstructive airway diseases,Million of national currency units,148.3
+2775,Austria,2017,5,N05B-Anxiolytics,"/capita, US$ exchange rate",0.8
+2776,Austria,2017,5,R03-Drugs for obstructive airway diseases,Million US$ at exchange rate,167.5
+2777,Austria,2017,5,N05B-Anxiolytics,% of total sales,0.2
+2778,Austria,2017,5,N05C-Hypnotics and sedatives,Million of national currency units,2.9
+2779,Austria,2017,5,N05C-Hypnotics and sedatives,Million US$ at exchange rate,3.3
+2780,Austria,2017,5,M01A-Antiinflammatory and antirheumatic products non-steroids,% of total sales,1.3
+2781,Austria,2017,5,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ purchasing power parity",5.9
+2782,Austria,2017,5,J01-Antibacterials for systemic use,"Million US$, purchasing power parity",77.2
+2783,Austria,2017,5,R03-Drugs for obstructive airway diseases,"/capita, US$ exchange rate",19.0
+2784,Austria,2017,5,R03-Drugs for obstructive airway diseases,"/capita, US$ purchasing power parity",21.8
+2785,Austria,2017,5,R03-Drugs for obstructive airway diseases,% of total sales,4.7
+2786,Austria,2017,5,N05B-Anxiolytics,Million US$ at exchange rate,7.3
+2787,Austria,2017,5,N05B-Anxiolytics,"Million US$, purchasing power parity",8.4
+2788,Austria,2017,5,N05B-Anxiolytics,Million of national currency units,6.5
+2789,Austria,2017,5,R03-Drugs for obstructive airway diseases,"Million US$, purchasing power parity",191.4
+2790,Austria,2017,5,A-Alimentary tract and metabolism,Million US$ at exchange rate,343.6
+2791,Austria,2017,5,A-Alimentary tract and metabolism,"Million US$, purchasing power parity",392.5
+2792,Austria,2017,5,A-Alimentary tract and metabolism,Million of national currency units,304.2
+2793,Austria,2017,5,A-Alimentary tract and metabolism,% of total sales,9.7
+2794,Austria,2017,5,C08-Calcium channel blockers,"/capita, US$ purchasing power parity",1.5
+2795,Austria,2017,5,A-Alimentary tract and metabolism,"/capita, US$ exchange rate",39.1
+2796,Austria,2017,5,A-Alimentary tract and metabolism,"/capita, US$ purchasing power parity",44.6
+2797,Austria,2017,5,C08-Calcium channel blockers,"/capita, US$ exchange rate",1.3
+2798,Austria,2017,5,C07-Beta blocking agents,"/capita, US$ purchasing power parity",6.0
+2799,Austria,2017,5,C07-Beta blocking agents,"/capita, US$ exchange rate",5.3
+2800,Austria,2017,5,C07-Beta blocking agents,"Million US$, purchasing power parity",53.0
+2801,Austria,2017,5,C07-Beta blocking agents,% of total sales,1.3
+2802,Austria,2017,5,C08-Calcium channel blockers,"Million US$, purchasing power parity",13.0
+2803,Austria,2017,5,C08-Calcium channel blockers,Million US$ at exchange rate,11.4
+2804,Austria,2017,5,C08-Calcium channel blockers,Million of national currency units,10.1
+2805,Austria,2017,5,C10-Lipid modifying agents,"/capita, US$ exchange rate",14.2
+2806,Austria,2017,5,C10-Lipid modifying agents,"/capita, US$ purchasing power parity",16.2
+2807,Austria,2017,5,C10-Lipid modifying agents,Million US$ at exchange rate,125.0
+2808,Austria,2017,5,C10-Lipid modifying agents,"Million US$, purchasing power parity",142.8
+2809,Austria,2017,5,C-Cardiovascular system,"/capita, US$ purchasing power parity",63.8
+2810,Austria,2017,5,C-Cardiovascular system,"/capita, US$ exchange rate",55.8
+2811,Austria,2017,5,C10-Lipid modifying agents,% of total sales,3.5
+2812,Austria,2017,5,C-Cardiovascular system,% of total sales,13.9
+2813,Austria,2017,5,C09-Agents acting on the Renin-Angiotensin system,Million US$ at exchange rate,181.3
+2814,Austria,2017,5,C09-Agents acting on the Renin-Angiotensin system,"Million US$, purchasing power parity",207.0
+2815,Austria,2017,5,C08-Calcium channel blockers,% of total sales,0.3
+2816,Austria,2017,5,C09-Agents acting on the Renin-Angiotensin system,Million of national currency units,160.5
+2817,Austria,2017,5,C09-Agents acting on the Renin-Angiotensin system,% of total sales,5.1
+2818,Austria,2017,5,C10-Lipid modifying agents,Million of national currency units,110.6
+2819,Austria,2017,5,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ exchange rate",20.6
+2820,Austria,2017,5,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ purchasing power parity",23.5
+2821,Austria,2017,5,"C01B-Antiarrhythmics, Class I and III",% of total sales,0.2
+2822,Austria,2017,5,"C01B-Antiarrhythmics, Class I and III","/capita, US$ purchasing power parity",1.0
+2823,Austria,2017,5,"C01B-Antiarrhythmics, Class I and III","/capita, US$ exchange rate",0.8
+2824,Austria,2017,5,C02-Antihypertensives,"Million US$, purchasing power parity",64.0
+2825,Austria,2017,5,C02-Antihypertensives,"/capita, US$ exchange rate",6.4
+2826,Austria,2017,5,C02-Antihypertensives,Million of national currency units,49.6
+2827,Austria,2017,5,C02-Antihypertensives,Million US$ at exchange rate,56.0
+2828,Austria,2017,5,"C01B-Antiarrhythmics, Class I and III","Million US$, purchasing power parity",8.5
+2829,Austria,2017,5,Total pharmaceutical sales,"Million US$, purchasing power parity",4035.1
+2830,Austria,2017,5,Total pharmaceutical sales,Million US$ at exchange rate,3532.8
+2831,Austria,2017,5,Total pharmaceutical sales,Million of national currency units,3127.2
+2832,Austria,2017,5,Total pharmaceutical sales,"/capita, US$ exchange rate",401.6
+2833,Austria,2017,5,"C01B-Antiarrhythmics, Class I and III",Million US$ at exchange rate,7.4
+2834,Austria,2017,5,"C01B-Antiarrhythmics, Class I and III",Million of national currency units,6.6
+2835,Austria,2017,5,Total pharmaceutical sales,"/capita, US$ purchasing power parity",458.7
+2836,Austria,2017,5,C03-Diuretics,"Million US$, purchasing power parity",23.6
+2837,Austria,2017,5,C03-Diuretics,"/capita, US$ exchange rate",2.4
+2838,Austria,2017,5,C03-Diuretics,Million of national currency units,18.3
+2839,Austria,2017,5,C03-Diuretics,Million US$ at exchange rate,20.7
+2840,Austria,2017,5,C07-Beta blocking agents,Million of national currency units,41.1
+2841,Austria,2017,5,C07-Beta blocking agents,Million US$ at exchange rate,46.4
+2842,Austria,2017,5,C03-Diuretics,"/capita, US$ purchasing power parity",2.7
+2843,Austria,2017,5,C03-Diuretics,% of total sales,0.6
+2844,Austria,2017,5,C01A-Cardiac glycosides,"/capita, US$ purchasing power parity",0.1
+2845,Austria,2017,5,C01A-Cardiac glycosides,% of total sales,0.0
+2846,Austria,2017,5,C02-Antihypertensives,"/capita, US$ purchasing power parity",7.3
+2847,Austria,2017,5,C02-Antihypertensives,% of total sales,1.6
+2848,Austria,2017,5,C01A-Cardiac glycosides,Million US$ at exchange rate,0.5
+2849,Austria,2017,5,C01A-Cardiac glycosides,Million of national currency units,0.4
+2850,Austria,2017,5,C01A-Cardiac glycosides,"/capita, US$ exchange rate",0.1
+2851,Austria,2017,5,C01A-Cardiac glycosides,"Million US$, purchasing power parity",0.6
+2852,Austria,2017,5,G-Genito urinary system and sex hormones,Million of national currency units,46.1
+2853,Austria,2017,5,G-Genito urinary system and sex hormones,Million US$ at exchange rate,52.1
+2854,Austria,2017,5,G03-Sex hormones and modulators of the genital system,Million of national currency units,13.4
+2855,Austria,2017,5,G-Genito urinary system and sex hormones,"/capita, US$ purchasing power parity",6.8
+2856,Austria,2017,5,G-Genito urinary system and sex hormones,% of total sales,1.5
+2857,Austria,2017,5,G-Genito urinary system and sex hormones,"Million US$, purchasing power parity",59.5
+2858,Austria,2017,5,G-Genito urinary system and sex hormones,"/capita, US$ exchange rate",5.9
+2859,Austria,2017,5,G03-Sex hormones and modulators of the genital system,"Million US$, purchasing power parity",17.3
+2860,Austria,2017,5,G03-Sex hormones and modulators of the genital system,Million US$ at exchange rate,15.2
+2861,Austria,2017,5,C-Cardiovascular system,Million of national currency units,434.7
+2862,Austria,2017,5,C-Cardiovascular system,"Million US$, purchasing power parity",560.8
+2863,Austria,2017,5,C-Cardiovascular system,Million US$ at exchange rate,491.0
+2864,Belgium,2010,6,C03-Diuretics,Million US$ at exchange rate,50.5
+2865,Belgium,2010,6,Total pharmaceutical sales,Million of national currency units,5881.5
+2866,Belgium,2010,6,C03-Diuretics,"Million US$, purchasing power parity",45.6
+2867,Belgium,2010,6,C03-Diuretics,"/capita, US$ exchange rate",4.6
+2868,Belgium,2010,6,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million of national currency units,122.5
+2869,Belgium,2010,6,G-Genito urinary system and sex hormones,Million US$ at exchange rate,317.7
+2870,Belgium,2010,6,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million US$ at exchange rate,162.4
+2871,Belgium,2010,6,C03-Diuretics,Million of national currency units,38.1
+2872,Belgium,2010,6,"H-Systemic hormonal preparations, excluding sex hormones and insulins","Million US$, purchasing power parity",146.4
+2873,Belgium,2010,6,N06A-Antidepressants,Million of national currency units,186.8
+2874,Belgium,2010,6,N06A-Antidepressants,"Million US$, purchasing power parity",223.2
+2875,Belgium,2010,6,N06A-Antidepressants,Million US$ at exchange rate,247.6
+2876,Belgium,2010,6,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ exchange rate",14.9
+2877,Belgium,2010,6,C03-Diuretics,"/capita, US$ purchasing power parity",4.2
+2878,Belgium,2010,6,C03-Diuretics,% of total sales,0.6
+2879,Belgium,2010,6,N05C-Hypnotics and sedatives,Million of national currency units,67.6
+2880,Belgium,2010,6,N05C-Hypnotics and sedatives,"Million US$, purchasing power parity",80.9
+2881,Belgium,2010,6,N05C-Hypnotics and sedatives,Million US$ at exchange rate,89.7
+2882,Belgium,2010,6,G-Genito urinary system and sex hormones,% of total sales,4.1
+2883,Belgium,2010,6,C01A-Cardiac glycosides,Million US$ at exchange rate,1.8
+2884,Belgium,2010,6,C01A-Cardiac glycosides,"Million US$, purchasing power parity",1.6
+2885,Belgium,2010,6,C01A-Cardiac glycosides,Million of national currency units,1.3
+2886,Belgium,2010,6,G-Genito urinary system and sex hormones,"/capita, US$ purchasing power parity",26.3
+2887,Belgium,2010,6,G-Genito urinary system and sex hormones,"/capita, US$ exchange rate",29.2
+2888,Belgium,2010,6,G-Genito urinary system and sex hormones,"Million US$, purchasing power parity",286.5
+2889,Belgium,2010,6,N05C-Hypnotics and sedatives,"/capita, US$ exchange rate",8.2
+2890,Belgium,2010,6,N05C-Hypnotics and sedatives,% of total sales,1.2
+2891,Belgium,2010,6,N05C-Hypnotics and sedatives,"/capita, US$ purchasing power parity",7.4
+2892,Belgium,2010,6,C07-Beta blocking agents,% of total sales,1.8
+2893,Belgium,2010,6,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),% of total sales,3.0
+2894,Belgium,2010,6,C07-Beta blocking agents,"Million US$, purchasing power parity",129.6
+2895,Belgium,2010,6,C07-Beta blocking agents,"/capita, US$ purchasing power parity",11.9
+2896,Belgium,2010,6,C07-Beta blocking agents,"/capita, US$ exchange rate",13.2
+2897,Belgium,2010,6,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million of national currency units,177.4
+2898,Belgium,2010,6,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million US$ at exchange rate,235.2
+2899,Belgium,2010,6,G03-Sex hormones and modulators of the genital system,Million of national currency units,135.6
+2900,Belgium,2010,6,G-Genito urinary system and sex hormones,Million of national currency units,239.7
+2901,Belgium,2010,6,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ purchasing power parity",19.5
+2902,Belgium,2010,6,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ exchange rate",21.6
+2903,Belgium,2010,6,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"Million US$, purchasing power parity",212.0
+2904,Belgium,2010,6,C07-Beta blocking agents,Million US$ at exchange rate,143.7
+2905,Belgium,2010,6,M-Musculo-skeletal system,% of total sales,4.3
+2906,Belgium,2010,6,M-Musculo-skeletal system,"/capita, US$ purchasing power parity",27.5
+2907,Belgium,2010,6,N06A-Antidepressants,"/capita, US$ exchange rate",22.7
+2908,Belgium,2010,6,N06A-Antidepressants,% of total sales,3.2
+2909,Belgium,2010,6,N06A-Antidepressants,"/capita, US$ purchasing power parity",20.5
+2910,Belgium,2010,6,"H-Systemic hormonal preparations, excluding sex hormones and insulins",% of total sales,2.1
+2911,Belgium,2010,6,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ purchasing power parity",13.4
+2912,Belgium,2010,6,C07-Beta blocking agents,Million of national currency units,108.4
+2913,Belgium,2010,6,M-Musculo-skeletal system,"Million US$, purchasing power parity",299.2
+2914,Belgium,2010,6,M-Musculo-skeletal system,"/capita, US$ exchange rate",30.5
+2915,Belgium,2010,6,M-Musculo-skeletal system,Million of national currency units,250.3
+2916,Belgium,2010,6,M-Musculo-skeletal system,Million US$ at exchange rate,331.9
+2917,Belgium,2010,6,"C01B-Antiarrhythmics, Class I and III","Million US$, purchasing power parity",19.1
+2918,Belgium,2010,6,"C01B-Antiarrhythmics, Class I and III","/capita, US$ exchange rate",1.9
+2919,Belgium,2010,6,"C01B-Antiarrhythmics, Class I and III","/capita, US$ purchasing power parity",1.8
+2920,Belgium,2010,6,G03-Sex hormones and modulators of the genital system,% of total sales,2.3
+2921,Belgium,2010,6,G03-Sex hormones and modulators of the genital system,"/capita, US$ purchasing power parity",14.9
+2922,Belgium,2010,6,"C01B-Antiarrhythmics, Class I and III",Million US$ at exchange rate,21.2
+2923,Belgium,2010,6,"C01B-Antiarrhythmics, Class I and III",Million of national currency units,16.0
+2924,Belgium,2010,6,N02-Analgesics,"/capita, US$ exchange rate",29.9
+2925,Belgium,2010,6,N02-Analgesics,"/capita, US$ purchasing power parity",26.9
+2926,Belgium,2010,6,N02-Analgesics,% of total sales,4.2
+2927,Belgium,2010,6,N02-Analgesics,Million of national currency units,245.6
+2928,Belgium,2010,6,"C01B-Antiarrhythmics, Class I and III",% of total sales,0.3
+2929,Belgium,2010,6,N02-Analgesics,"Million US$, purchasing power parity",293.5
+2930,Belgium,2010,6,N02-Analgesics,Million US$ at exchange rate,325.6
+2931,Belgium,2010,6,Total pharmaceutical sales,"/capita, US$ purchasing power parity",645.2
+2932,Belgium,2010,6,G03-Sex hormones and modulators of the genital system,"/capita, US$ exchange rate",16.5
+2933,Belgium,2010,6,Total pharmaceutical sales,Million US$ at exchange rate,7797.2
+2934,Belgium,2010,6,Total pharmaceutical sales,"/capita, US$ exchange rate",715.6
+2935,Belgium,2010,6,Total pharmaceutical sales,"Million US$, purchasing power parity",7030.2
+2936,Belgium,2010,6,A10-Drugs used in diabetes,"Million US$, purchasing power parity",166.8
+2937,Belgium,2010,6,A10-Drugs used in diabetes,"/capita, US$ exchange rate",17.0
+2938,Belgium,2010,6,A10-Drugs used in diabetes,Million of national currency units,139.5
+2939,Belgium,2010,6,A10-Drugs used in diabetes,Million US$ at exchange rate,184.9
+2940,Belgium,2010,6,N-Nervous system,% of total sales,17.3
+2941,Belgium,2010,6,A10-Drugs used in diabetes,"/capita, US$ purchasing power parity",15.3
+2942,Belgium,2010,6,A10-Drugs used in diabetes,% of total sales,2.4
+2943,Belgium,2010,6,M01A-Antiinflammatory and antirheumatic products non-steroids,% of total sales,1.9
+2944,Belgium,2010,6,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ purchasing power parity",12.3
+2945,Belgium,2010,6,N05B-Anxiolytics,"/capita, US$ exchange rate",7.8
+2946,Belgium,2010,6,N05B-Anxiolytics,"Million US$, purchasing power parity",76.9
+2947,Belgium,2010,6,N05B-Anxiolytics,% of total sales,1.1
+2948,Belgium,2010,6,N05B-Anxiolytics,"/capita, US$ purchasing power parity",7.1
+2949,Belgium,2010,6,C01A-Cardiac glycosides,% of total sales,0.0
+2950,Belgium,2010,6,C01A-Cardiac glycosides,"/capita, US$ purchasing power parity",0.1
+2951,Belgium,2010,6,C01A-Cardiac glycosides,"/capita, US$ exchange rate",0.2
+2952,Belgium,2010,6,M01A-Antiinflammatory and antirheumatic products non-steroids,"Million US$, purchasing power parity",133.9
+2953,Belgium,2010,6,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ exchange rate",13.6
+2954,Belgium,2010,6,M01A-Antiinflammatory and antirheumatic products non-steroids,Million of national currency units,112.0
+2955,Belgium,2010,6,M01A-Antiinflammatory and antirheumatic products non-steroids,Million US$ at exchange rate,148.5
+2956,Belgium,2010,6,N-Nervous system,Million of national currency units,1019.6
+2957,Belgium,2010,6,G03-Sex hormones and modulators of the genital system,"Million US$, purchasing power parity",162.1
+2958,Belgium,2010,6,N-Nervous system,Million US$ at exchange rate,1351.7
+2959,Belgium,2010,6,C02-Antihypertensives,Million US$ at exchange rate,23.5
+2960,Belgium,2010,6,C02-Antihypertensives,Million of national currency units,17.7
+2961,Belgium,2010,6,N-Nervous system,"/capita, US$ purchasing power parity",111.9
+2962,Belgium,2010,6,N-Nervous system,"/capita, US$ exchange rate",124.1
+2963,Belgium,2010,6,N-Nervous system,"Million US$, purchasing power parity",1218.7
+2964,Belgium,2010,6,C02-Antihypertensives,% of total sales,0.3
+2965,Belgium,2010,6,G03-Sex hormones and modulators of the genital system,Million US$ at exchange rate,179.8
+2966,Belgium,2010,6,N05B-Anxiolytics,Million of national currency units,64.4
+2967,Belgium,2010,6,N05B-Anxiolytics,Million US$ at exchange rate,85.3
+2968,Belgium,2010,6,C02-Antihypertensives,"Million US$, purchasing power parity",21.2
+2969,Belgium,2010,6,C02-Antihypertensives,"/capita, US$ exchange rate",2.2
+2970,Belgium,2010,6,C02-Antihypertensives,"/capita, US$ purchasing power parity",1.9
+2971,Belgium,2010,6,R03-Drugs for obstructive airway diseases,"Million US$, purchasing power parity",299.4
+2972,Belgium,2010,6,R03-Drugs for obstructive airway diseases,"/capita, US$ exchange rate",30.5
+2973,Belgium,2010,6,A02A-Antacids,"/capita, US$ exchange rate",1.3
+2974,Belgium,2010,6,R03-Drugs for obstructive airway diseases,Million of national currency units,250.5
+2975,Belgium,2010,6,R03-Drugs for obstructive airway diseases,Million US$ at exchange rate,332.1
+2976,Belgium,2010,6,A02A-Antacids,"/capita, US$ purchasing power parity",1.2
+2977,Belgium,2010,6,J01-Antibacterials for systemic use,Million US$ at exchange rate,333.3
+2978,Belgium,2010,6,C09-Agents acting on the Renin-Angiotensin system,Million of national currency units,234.8
+2979,Belgium,2010,6,R03-Drugs for obstructive airway diseases,"/capita, US$ purchasing power parity",27.5
+2980,Belgium,2010,6,J01-Antibacterials for systemic use,Million of national currency units,251.4
+2981,Belgium,2010,6,R03-Drugs for obstructive airway diseases,% of total sales,4.3
+2982,Belgium,2010,6,C10-Lipid modifying agents,Million US$ at exchange rate,416.1
+2983,Belgium,2010,6,C08-Calcium channel blockers,% of total sales,1.2
+2984,Belgium,2010,6,C10-Lipid modifying agents,"/capita, US$ purchasing power parity",34.4
+2985,Belgium,2010,6,C08-Calcium channel blockers,"/capita, US$ exchange rate",8.8
+2986,Belgium,2010,6,C08-Calcium channel blockers,"/capita, US$ purchasing power parity",7.9
+2987,Belgium,2010,6,A02A-Antacids,Million US$ at exchange rate,14.2
+2988,Belgium,2010,6,A02A-Antacids,"Million US$, purchasing power parity",12.8
+2989,Belgium,2010,6,C10-Lipid modifying agents,"/capita, US$ exchange rate",38.2
+2990,Belgium,2010,6,C10-Lipid modifying agents,"Million US$, purchasing power parity",375.1
+2991,Belgium,2010,6,A02A-Antacids,Million of national currency units,10.7
+2992,Belgium,2010,6,Products not elsewhere classified,"/capita, US$ purchasing power parity",131.1
+2993,Belgium,2010,6,A02A-Antacids,% of total sales,0.2
+2994,Belgium,2010,6,B-Blood and blood forming organs,"/capita, US$ exchange rate",54.6
+2995,Belgium,2010,6,Products not elsewhere classified,% of total sales,20.3
+2996,Belgium,2010,6,Products not elsewhere classified,"/capita, US$ exchange rate",145.5
+2997,Belgium,2010,6,Products not elsewhere classified,Million of national currency units,1195.5
+2998,Belgium,2010,6,Products not elsewhere classified,Million US$ at exchange rate,1584.9
+2999,Belgium,2010,6,Products not elsewhere classified,"Million US$, purchasing power parity",1428.9
+3000,Belgium,2010,6,C10-Lipid modifying agents,% of total sales,5.3
+3001,Belgium,2010,6,C10-Lipid modifying agents,Million of national currency units,313.8
+3002,Belgium,2010,6,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ purchasing power parity",25.8
+3003,Belgium,2010,6,C09-Agents acting on the Renin-Angiotensin system,% of total sales,4.0
+3004,Belgium,2010,6,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ exchange rate",28.6
+3005,Belgium,2010,6,C09-Agents acting on the Renin-Angiotensin system,Million US$ at exchange rate,311.3
+3006,Belgium,2010,6,C09-Agents acting on the Renin-Angiotensin system,"Million US$, purchasing power parity",280.7
+3007,Belgium,2010,6,B-Blood and blood forming organs,% of total sales,7.6
+3008,Belgium,2010,6,B-Blood and blood forming organs,"/capita, US$ purchasing power parity",49.3
+3009,Belgium,2010,6,B-Blood and blood forming organs,Million of national currency units,448.9
+3010,Belgium,2010,6,B-Blood and blood forming organs,Million US$ at exchange rate,595.2
+3011,Belgium,2010,6,B-Blood and blood forming organs,"Million US$, purchasing power parity",536.6
+3012,Belgium,2010,6,R-Respiratory system,"/capita, US$ purchasing power parity",56.2
+3013,Belgium,2010,6,R-Respiratory system,% of total sales,8.7
+3014,Belgium,2010,6,A-Alimentary tract and metabolism,"/capita, US$ purchasing power parity",68.8
+3015,Belgium,2010,6,R-Respiratory system,"Million US$, purchasing power parity",612.9
+3016,Belgium,2010,6,R-Respiratory system,Million US$ at exchange rate,679.7
+3017,Belgium,2010,6,R-Respiratory system,"/capita, US$ exchange rate",62.4
+3018,Belgium,2010,6,J-Antiinfectives for systemic use,% of total sales,9.7
+3019,Belgium,2010,6,C08-Calcium channel blockers,Million of national currency units,72.4
+3020,Belgium,2010,6,J-Antiinfectives for systemic use,"/capita, US$ purchasing power parity",62.7
+3021,Belgium,2010,6,J-Antiinfectives for systemic use,"/capita, US$ exchange rate",69.5
+3022,Belgium,2010,6,A-Alimentary tract and metabolism,% of total sales,10.7
+3023,Belgium,2010,6,A-Alimentary tract and metabolism,"Million US$, purchasing power parity",749.5
+3024,Belgium,2010,6,A-Alimentary tract and metabolism,"/capita, US$ exchange rate",76.3
+3025,Belgium,2010,6,R-Respiratory system,Million of national currency units,512.7
+3026,Belgium,2010,6,A-Alimentary tract and metabolism,Million of national currency units,627.0
+3027,Belgium,2010,6,C-Cardiovascular system,Million US$ at exchange rate,1184.9
+3028,Belgium,2010,6,C-Cardiovascular system,Million of national currency units,893.8
+3029,Belgium,2010,6,A-Alimentary tract and metabolism,Million US$ at exchange rate,831.3
+3030,Belgium,2010,6,J-Antiinfectives for systemic use,Million US$ at exchange rate,757.6
+3031,Belgium,2010,6,J-Antiinfectives for systemic use,"Million US$, purchasing power parity",683.1
+3032,Belgium,2010,6,J-Antiinfectives for systemic use,Million of national currency units,571.5
+3033,Belgium,2010,6,C-Cardiovascular system,"Million US$, purchasing power parity",1068.3
+3034,Belgium,2010,6,C-Cardiovascular system,"/capita, US$ exchange rate",108.7
+3035,Belgium,2010,6,J01-Antibacterials for systemic use,% of total sales,4.3
+3036,Belgium,2010,6,C08-Calcium channel blockers,Million US$ at exchange rate,95.9
+3037,Belgium,2010,6,C08-Calcium channel blockers,"Million US$, purchasing power parity",86.5
+3038,Belgium,2010,6,C-Cardiovascular system,"/capita, US$ purchasing power parity",98.1
+3039,Belgium,2010,6,J01-Antibacterials for systemic use,"Million US$, purchasing power parity",300.5
+3040,Belgium,2010,6,J01-Antibacterials for systemic use,"/capita, US$ exchange rate",30.6
+3041,Belgium,2010,6,J01-Antibacterials for systemic use,"/capita, US$ purchasing power parity",27.6
+3042,Belgium,2010,6,C-Cardiovascular system,% of total sales,15.2
+3043,Belgium,2011,6,C03-Diuretics,Million US$ at exchange rate,51.3
+3044,Belgium,2011,6,C03-Diuretics,"/capita, US$ exchange rate",4.6
+3045,Belgium,2011,6,C03-Diuretics,"Million US$, purchasing power parity",44.3
+3046,Belgium,2011,6,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million of national currency units,125.4
+3047,Belgium,2011,6,G-Genito urinary system and sex hormones,Million US$ at exchange rate,336.1
+3048,Belgium,2011,6,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million US$ at exchange rate,174.6
+3049,Belgium,2011,6,C03-Diuretics,Million of national currency units,36.9
+3050,Belgium,2011,6,"H-Systemic hormonal preparations, excluding sex hormones and insulins","Million US$, purchasing power parity",150.8
+3051,Belgium,2011,6,N06A-Antidepressants,Million of national currency units,188.6
+3052,Belgium,2011,6,N06A-Antidepressants,"Million US$, purchasing power parity",226.7
+3053,Belgium,2011,6,N06A-Antidepressants,Million US$ at exchange rate,262.5
+3054,Belgium,2011,6,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ exchange rate",15.8
+3055,Belgium,2011,6,C03-Diuretics,"/capita, US$ purchasing power parity",4.0
+3056,Belgium,2011,6,C03-Diuretics,% of total sales,0.6
+3057,Belgium,2011,6,N05C-Hypnotics and sedatives,Million of national currency units,71.2
+3058,Belgium,2011,6,N05C-Hypnotics and sedatives,"Million US$, purchasing power parity",85.5
+3059,Belgium,2011,6,N05C-Hypnotics and sedatives,Million US$ at exchange rate,99.1
+3060,Belgium,2011,6,G-Genito urinary system and sex hormones,% of total sales,4.0
+3061,Belgium,2011,6,C01A-Cardiac glycosides,Million US$ at exchange rate,2.0
+3062,Belgium,2011,6,C01A-Cardiac glycosides,Million of national currency units,1.5
+3063,Belgium,2011,6,G-Genito urinary system and sex hormones,"/capita, US$ purchasing power parity",26.3
+3064,Belgium,2011,6,G-Genito urinary system and sex hormones,"/capita, US$ exchange rate",30.5
+3065,Belgium,2011,6,G-Genito urinary system and sex hormones,"Million US$, purchasing power parity",290.3
+3066,Belgium,2011,6,N05C-Hypnotics and sedatives,"/capita, US$ exchange rate",9.0
+3067,Belgium,2011,6,N05C-Hypnotics and sedatives,"/capita, US$ purchasing power parity",7.7
+3068,Belgium,2011,6,N05C-Hypnotics and sedatives,% of total sales,1.2
+3069,Belgium,2011,6,C07-Beta blocking agents,% of total sales,1.7
+3070,Belgium,2011,6,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),% of total sales,2.9
+3071,Belgium,2011,6,C07-Beta blocking agents,"Million US$, purchasing power parity",119.6
+3072,Belgium,2011,6,C07-Beta blocking agents,"/capita, US$ purchasing power parity",10.8
+3073,Belgium,2011,6,C07-Beta blocking agents,"/capita, US$ exchange rate",12.5
+3074,Belgium,2011,6,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million of national currency units,176.7
+3075,Belgium,2011,6,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million US$ at exchange rate,246.0
+3076,Belgium,2011,6,G03-Sex hormones and modulators of the genital system,Million of national currency units,132.5
+3077,Belgium,2011,6,G-Genito urinary system and sex hormones,Million of national currency units,241.5
+3078,Belgium,2011,6,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ purchasing power parity",19.2
+3079,Belgium,2011,6,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ exchange rate",22.3
+3080,Belgium,2011,6,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"Million US$, purchasing power parity",212.4
+3081,Belgium,2011,6,C07-Beta blocking agents,Million US$ at exchange rate,138.5
+3082,Belgium,2011,6,M-Musculo-skeletal system,% of total sales,4.2
+3083,Belgium,2011,6,M-Musculo-skeletal system,"/capita, US$ purchasing power parity",27.3
+3084,Belgium,2011,6,N06A-Antidepressants,"/capita, US$ exchange rate",23.8
+3085,Belgium,2011,6,N06A-Antidepressants,"/capita, US$ purchasing power parity",20.5
+3086,Belgium,2011,6,N06A-Antidepressants,% of total sales,3.1
+3087,Belgium,2011,6,C01A-Cardiac glycosides,"Million US$, purchasing power parity",1.8
+3088,Belgium,2011,6,M-Musculo-skeletal system,"/capita, US$ exchange rate",31.6
+3089,Belgium,2011,6,"H-Systemic hormonal preparations, excluding sex hormones and insulins",% of total sales,2.1
+3090,Belgium,2011,6,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ purchasing power parity",13.7
+3091,Belgium,2011,6,C07-Beta blocking agents,Million of national currency units,99.5
+3092,Belgium,2011,6,M-Musculo-skeletal system,Million of national currency units,250.8
+3093,Belgium,2011,6,M-Musculo-skeletal system,"Million US$, purchasing power parity",301.5
+3094,Belgium,2011,6,M-Musculo-skeletal system,Million US$ at exchange rate,349.2
+3095,Belgium,2011,6,"C01B-Antiarrhythmics, Class I and III","Million US$, purchasing power parity",18.1
+3096,Belgium,2011,6,"C01B-Antiarrhythmics, Class I and III","/capita, US$ exchange rate",1.9
+3097,Belgium,2011,6,"C01B-Antiarrhythmics, Class I and III","/capita, US$ purchasing power parity",1.6
+3098,Belgium,2011,6,G03-Sex hormones and modulators of the genital system,% of total sales,2.2
+3099,Belgium,2011,6,G03-Sex hormones and modulators of the genital system,"/capita, US$ purchasing power parity",14.4
+3100,Belgium,2011,6,"C01B-Antiarrhythmics, Class I and III",Million US$ at exchange rate,21.0
+3101,Belgium,2011,6,"C01B-Antiarrhythmics, Class I and III",Million of national currency units,15.1
+3102,Belgium,2011,6,N02-Analgesics,"/capita, US$ exchange rate",32.2
+3103,Belgium,2011,6,N02-Analgesics,"/capita, US$ purchasing power parity",27.8
+3104,Belgium,2011,6,N02-Analgesics,% of total sales,4.3
+3105,Belgium,2011,6,N02-Analgesics,Million of national currency units,255.3
+3106,Belgium,2011,6,"C01B-Antiarrhythmics, Class I and III",% of total sales,0.3
+3107,Belgium,2011,6,N02-Analgesics,"Million US$, purchasing power parity",306.9
+3108,Belgium,2011,6,N02-Analgesics,Million US$ at exchange rate,355.3
+3109,Belgium,2011,6,Total pharmaceutical sales,"/capita, US$ purchasing power parity",652.7
+3110,Belgium,2011,6,G03-Sex hormones and modulators of the genital system,"/capita, US$ exchange rate",16.7
+3111,Belgium,2011,6,Total pharmaceutical sales,Million US$ at exchange rate,8342.4
+3112,Belgium,2011,6,Total pharmaceutical sales,Million of national currency units,5993.3
+3113,Belgium,2011,6,Total pharmaceutical sales,"/capita, US$ exchange rate",755.8
+3114,Belgium,2011,6,Total pharmaceutical sales,"Million US$, purchasing power parity",7204.3
+3115,Belgium,2011,6,A10-Drugs used in diabetes,"Million US$, purchasing power parity",180.8
+3116,Belgium,2011,6,A10-Drugs used in diabetes,"/capita, US$ exchange rate",19.0
+3117,Belgium,2011,6,A10-Drugs used in diabetes,Million of national currency units,150.4
+3118,Belgium,2011,6,A10-Drugs used in diabetes,Million US$ at exchange rate,209.4
+3119,Belgium,2011,6,N-Nervous system,% of total sales,17.5
+3120,Belgium,2011,6,A10-Drugs used in diabetes,% of total sales,2.5
+3121,Belgium,2011,6,A10-Drugs used in diabetes,"/capita, US$ purchasing power parity",16.4
+3122,Belgium,2011,6,M01A-Antiinflammatory and antirheumatic products non-steroids,% of total sales,2.0
+3123,Belgium,2011,6,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ purchasing power parity",12.8
+3124,Belgium,2011,6,N05B-Anxiolytics,"/capita, US$ exchange rate",8.2
+3125,Belgium,2011,6,N05B-Anxiolytics,"Million US$, purchasing power parity",78.2
+3126,Belgium,2011,6,N05B-Anxiolytics,% of total sales,1.1
+3127,Belgium,2011,6,N05B-Anxiolytics,"/capita, US$ purchasing power parity",7.1
+3128,Belgium,2011,6,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ exchange rate",14.8
+3129,Belgium,2011,6,C01A-Cardiac glycosides,"/capita, US$ purchasing power parity",0.2
+3130,Belgium,2011,6,C01A-Cardiac glycosides,% of total sales,0.0
+3131,Belgium,2011,6,C01A-Cardiac glycosides,"/capita, US$ exchange rate",0.2
+3132,Belgium,2011,6,M01A-Antiinflammatory and antirheumatic products non-steroids,"Million US$, purchasing power parity",141.3
+3133,Belgium,2011,6,M01A-Antiinflammatory and antirheumatic products non-steroids,Million of national currency units,117.5
+3134,Belgium,2011,6,M01A-Antiinflammatory and antirheumatic products non-steroids,Million US$ at exchange rate,163.6
+3135,Belgium,2011,6,G03-Sex hormones and modulators of the genital system,"Million US$, purchasing power parity",159.3
+3136,Belgium,2011,6,N-Nervous system,Million of national currency units,1050.7
+3137,Belgium,2011,6,C02-Antihypertensives,Million US$ at exchange rate,28.8
+3138,Belgium,2011,6,C02-Antihypertensives,Million of national currency units,20.7
+3139,Belgium,2011,6,N-Nervous system,Million US$ at exchange rate,1462.5
+3140,Belgium,2011,6,N-Nervous system,"/capita, US$ purchasing power parity",114.4
+3141,Belgium,2011,6,N-Nervous system,"/capita, US$ exchange rate",132.5
+3142,Belgium,2011,6,N-Nervous system,"Million US$, purchasing power parity",1263.0
+3143,Belgium,2011,6,C02-Antihypertensives,% of total sales,0.3
+3144,Belgium,2011,6,G03-Sex hormones and modulators of the genital system,Million US$ at exchange rate,184.5
+3145,Belgium,2011,6,N05B-Anxiolytics,Million of national currency units,65.0
+3146,Belgium,2011,6,N05B-Anxiolytics,Million US$ at exchange rate,90.5
+3147,Belgium,2011,6,C02-Antihypertensives,"Million US$, purchasing power parity",24.9
+3148,Belgium,2011,6,C02-Antihypertensives,"/capita, US$ purchasing power parity",2.3
+3149,Belgium,2011,6,C02-Antihypertensives,"/capita, US$ exchange rate",2.6
+3150,Belgium,2011,6,R03-Drugs for obstructive airway diseases,"Million US$, purchasing power parity",306.7
+3151,Belgium,2011,6,R03-Drugs for obstructive airway diseases,"/capita, US$ exchange rate",32.2
+3152,Belgium,2011,6,R03-Drugs for obstructive airway diseases,Million US$ at exchange rate,355.1
+3153,Belgium,2011,6,J01-Antibacterials for systemic use,Million of national currency units,244.6
+3154,Belgium,2011,6,R03-Drugs for obstructive airway diseases,Million of national currency units,255.1
+3155,Belgium,2011,6,A02A-Antacids,"/capita, US$ purchasing power parity",1.3
+3156,Belgium,2011,6,J01-Antibacterials for systemic use,Million US$ at exchange rate,340.5
+3157,Belgium,2011,6,C09-Agents acting on the Renin-Angiotensin system,Million of national currency units,233.0
+3158,Belgium,2011,6,R03-Drugs for obstructive airway diseases,"/capita, US$ purchasing power parity",27.8
+3159,Belgium,2011,6,R03-Drugs for obstructive airway diseases,% of total sales,4.3
+3160,Belgium,2011,6,A02A-Antacids,"/capita, US$ exchange rate",1.4
+3161,Belgium,2011,6,C08-Calcium channel blockers,% of total sales,1.1
+3162,Belgium,2011,6,C10-Lipid modifying agents,"/capita, US$ purchasing power parity",35.7
+3163,Belgium,2011,6,C08-Calcium channel blockers,"/capita, US$ exchange rate",8.5
+3164,Belgium,2011,6,C08-Calcium channel blockers,"/capita, US$ purchasing power parity",7.4
+3165,Belgium,2011,6,A02A-Antacids,Million US$ at exchange rate,16.0
+3166,Belgium,2011,6,A02A-Antacids,"Million US$, purchasing power parity",13.8
+3167,Belgium,2011,6,C10-Lipid modifying agents,"/capita, US$ exchange rate",41.4
+3168,Belgium,2011,6,C10-Lipid modifying agents,Million US$ at exchange rate,456.5
+3169,Belgium,2011,6,C10-Lipid modifying agents,"Million US$, purchasing power parity",394.3
+3170,Belgium,2011,6,A02A-Antacids,Million of national currency units,11.5
+3171,Belgium,2011,6,A02A-Antacids,% of total sales,0.2
+3172,Belgium,2011,6,Products not elsewhere classified,"/capita, US$ purchasing power parity",134.5
+3173,Belgium,2011,6,B-Blood and blood forming organs,"/capita, US$ exchange rate",56.0
+3174,Belgium,2011,6,Products not elsewhere classified,% of total sales,20.6
+3175,Belgium,2011,6,Products not elsewhere classified,"/capita, US$ exchange rate",155.7
+3176,Belgium,2011,6,Products not elsewhere classified,Million of national currency units,1234.9
+3177,Belgium,2011,6,Products not elsewhere classified,Million US$ at exchange rate,1719.0
+3178,Belgium,2011,6,Products not elsewhere classified,"Million US$, purchasing power parity",1484.5
+3179,Belgium,2011,6,C10-Lipid modifying agents,% of total sales,5.5
+3180,Belgium,2011,6,C10-Lipid modifying agents,Million of national currency units,328.0
+3181,Belgium,2011,6,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ purchasing power parity",25.4
+3182,Belgium,2011,6,C09-Agents acting on the Renin-Angiotensin system,% of total sales,3.9
+3183,Belgium,2011,6,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ exchange rate",29.4
+3184,Belgium,2011,6,C09-Agents acting on the Renin-Angiotensin system,Million US$ at exchange rate,324.3
+3185,Belgium,2011,6,C09-Agents acting on the Renin-Angiotensin system,"Million US$, purchasing power parity",280.0
+3186,Belgium,2011,6,B-Blood and blood forming organs,% of total sales,7.4
+3187,Belgium,2011,6,B-Blood and blood forming organs,"/capita, US$ purchasing power parity",48.4
+3188,Belgium,2011,6,B-Blood and blood forming organs,Million of national currency units,444.1
+3189,Belgium,2011,6,B-Blood and blood forming organs,Million US$ at exchange rate,618.2
+3190,Belgium,2011,6,B-Blood and blood forming organs,"Million US$, purchasing power parity",533.9
+3191,Belgium,2011,6,R-Respiratory system,"/capita, US$ purchasing power parity",56.9
+3192,Belgium,2011,6,R-Respiratory system,% of total sales,8.7
+3193,Belgium,2011,6,A-Alimentary tract and metabolism,"/capita, US$ purchasing power parity",70.5
+3194,Belgium,2011,6,R-Respiratory system,Million US$ at exchange rate,726.9
+3195,Belgium,2011,6,R-Respiratory system,"Million US$, purchasing power parity",627.7
+3196,Belgium,2011,6,R-Respiratory system,"/capita, US$ exchange rate",65.8
+3197,Belgium,2011,6,J-Antiinfectives for systemic use,% of total sales,9.8
+3198,Belgium,2011,6,C08-Calcium channel blockers,Million of national currency units,67.8
+3199,Belgium,2011,6,J-Antiinfectives for systemic use,"/capita, US$ purchasing power parity",63.8
+3200,Belgium,2011,6,J-Antiinfectives for systemic use,"/capita, US$ exchange rate",73.9
+3201,Belgium,2011,6,A-Alimentary tract and metabolism,% of total sales,10.8
+3202,Belgium,2011,6,A-Alimentary tract and metabolism,"Million US$, purchasing power parity",778.6
+3203,Belgium,2011,6,A-Alimentary tract and metabolism,"/capita, US$ exchange rate",81.7
+3204,Belgium,2011,6,R-Respiratory system,Million of national currency units,522.2
+3205,Belgium,2011,6,C-Cardiovascular system,Million of national currency units,889.8
+3206,Belgium,2011,6,A-Alimentary tract and metabolism,Million of national currency units,647.7
+3207,Belgium,2011,6,C-Cardiovascular system,Million US$ at exchange rate,1238.6
+3208,Belgium,2011,6,A-Alimentary tract and metabolism,Million US$ at exchange rate,901.6
+3209,Belgium,2011,6,J-Antiinfectives for systemic use,Million US$ at exchange rate,815.8
+3210,Belgium,2011,6,J-Antiinfectives for systemic use,"Million US$, purchasing power parity",704.5
+3211,Belgium,2011,6,C-Cardiovascular system,"Million US$, purchasing power parity",1069.6
+3212,Belgium,2011,6,J-Antiinfectives for systemic use,Million of national currency units,586.1
+3213,Belgium,2011,6,C-Cardiovascular system,"/capita, US$ exchange rate",112.2
+3214,Belgium,2011,6,J01-Antibacterials for systemic use,% of total sales,4.1
+3215,Belgium,2011,6,C08-Calcium channel blockers,Million US$ at exchange rate,94.4
+3216,Belgium,2011,6,C08-Calcium channel blockers,"Million US$, purchasing power parity",81.5
+3217,Belgium,2011,6,C-Cardiovascular system,"/capita, US$ purchasing power parity",96.9
+3218,Belgium,2011,6,J01-Antibacterials for systemic use,"/capita, US$ exchange rate",30.8
+3219,Belgium,2011,6,J01-Antibacterials for systemic use,"/capita, US$ purchasing power parity",26.6
+3220,Belgium,2011,6,J01-Antibacterials for systemic use,"Million US$, purchasing power parity",294.1
+3221,Belgium,2011,6,C-Cardiovascular system,% of total sales,14.8
+3222,Belgium,2012,6,C03-Diuretics,Million US$ at exchange rate,45.8
+3223,Belgium,2012,6,C03-Diuretics,"/capita, US$ exchange rate",4.1
+3224,Belgium,2012,6,C03-Diuretics,"Million US$, purchasing power parity",43.4
+3225,Belgium,2012,6,C03-Diuretics,Million of national currency units,35.7
+3226,Belgium,2012,6,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million of national currency units,124.4
+3227,Belgium,2012,6,G-Genito urinary system and sex hormones,Million US$ at exchange rate,303.9
+3228,Belgium,2012,6,"H-Systemic hormonal preparations, excluding sex hormones and insulins","Million US$, purchasing power parity",151.3
+3229,Belgium,2012,6,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million US$ at exchange rate,159.8
+3230,Belgium,2012,6,N06A-Antidepressants,Million of national currency units,185.6
+3231,Belgium,2012,6,N06A-Antidepressants,"Million US$, purchasing power parity",225.7
+3232,Belgium,2012,6,N06A-Antidepressants,Million US$ at exchange rate,238.4
+3233,Belgium,2012,6,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ exchange rate",14.4
+3234,Belgium,2012,6,C03-Diuretics,"/capita, US$ purchasing power parity",3.9
+3235,Belgium,2012,6,C03-Diuretics,% of total sales,0.6
+3236,Belgium,2012,6,N05C-Hypnotics and sedatives,Million of national currency units,70.2
+3237,Belgium,2012,6,N05C-Hypnotics and sedatives,"Million US$, purchasing power parity",85.4
+3238,Belgium,2012,6,N05C-Hypnotics and sedatives,Million US$ at exchange rate,90.2
+3239,Belgium,2012,6,C01A-Cardiac glycosides,Million US$ at exchange rate,1.8
+3240,Belgium,2012,6,G-Genito urinary system and sex hormones,% of total sales,4.0
+3241,Belgium,2012,6,C01A-Cardiac glycosides,Million of national currency units,1.4
+3242,Belgium,2012,6,G-Genito urinary system and sex hormones,"/capita, US$ exchange rate",27.4
+3243,Belgium,2012,6,G-Genito urinary system and sex hormones,"/capita, US$ purchasing power parity",25.9
+3244,Belgium,2012,6,G-Genito urinary system and sex hormones,"Million US$, purchasing power parity",287.7
+3245,Belgium,2012,6,N05C-Hypnotics and sedatives,"/capita, US$ exchange rate",8.1
+3246,Belgium,2012,6,N05C-Hypnotics and sedatives,% of total sales,1.2
+3247,Belgium,2012,6,N05C-Hypnotics and sedatives,"/capita, US$ purchasing power parity",7.7
+3248,Belgium,2012,6,C07-Beta blocking agents,% of total sales,1.6
+3249,Belgium,2012,6,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),% of total sales,2.7
+3250,Belgium,2012,6,C07-Beta blocking agents,"Million US$, purchasing power parity",119.0
+3251,Belgium,2012,6,C07-Beta blocking agents,"/capita, US$ purchasing power parity",10.7
+3252,Belgium,2012,6,C07-Beta blocking agents,"/capita, US$ exchange rate",11.3
+3253,Belgium,2012,6,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million of national currency units,158.3
+3254,Belgium,2012,6,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million US$ at exchange rate,203.4
+3255,Belgium,2012,6,G03-Sex hormones and modulators of the genital system,Million of national currency units,124.1
+3256,Belgium,2012,6,G-Genito urinary system and sex hormones,Million of national currency units,236.6
+3257,Belgium,2012,6,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ exchange rate",18.3
+3258,Belgium,2012,6,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ purchasing power parity",17.3
+3259,Belgium,2012,6,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"Million US$, purchasing power parity",192.6
+3260,Belgium,2012,6,C07-Beta blocking agents,Million US$ at exchange rate,125.7
+3261,Belgium,2012,6,M-Musculo-skeletal system,% of total sales,4.2
+3262,Belgium,2012,6,M-Musculo-skeletal system,"/capita, US$ purchasing power parity",27.3
+3263,Belgium,2012,6,N06A-Antidepressants,"/capita, US$ exchange rate",21.5
+3264,Belgium,2012,6,N06A-Antidepressants,% of total sales,3.1
+3265,Belgium,2012,6,N06A-Antidepressants,"/capita, US$ purchasing power parity",20.3
+3266,Belgium,2012,6,M-Musculo-skeletal system,"/capita, US$ exchange rate",28.9
+3267,Belgium,2012,6,"H-Systemic hormonal preparations, excluding sex hormones and insulins",% of total sales,2.1
+3268,Belgium,2012,6,C07-Beta blocking agents,Million of national currency units,97.8
+3269,Belgium,2012,6,M-Musculo-skeletal system,"Million US$, purchasing power parity",303.7
+3270,Belgium,2012,6,M-Musculo-skeletal system,Million of national currency units,249.7
+3271,Belgium,2012,6,M-Musculo-skeletal system,Million US$ at exchange rate,320.8
+3272,Belgium,2012,6,C01A-Cardiac glycosides,"Million US$, purchasing power parity",1.7
+3273,Belgium,2012,6,"C01B-Antiarrhythmics, Class I and III","Million US$, purchasing power parity",18.4
+3274,Belgium,2012,6,"C01B-Antiarrhythmics, Class I and III","/capita, US$ purchasing power parity",1.7
+3275,Belgium,2012,6,"C01B-Antiarrhythmics, Class I and III","/capita, US$ exchange rate",1.7
+3276,Belgium,2012,6,"C01B-Antiarrhythmics, Class I and III",Million US$ at exchange rate,19.4
+3277,Belgium,2012,6,G03-Sex hormones and modulators of the genital system,% of total sales,2.1
+3278,Belgium,2012,6,G03-Sex hormones and modulators of the genital system,"/capita, US$ purchasing power parity",13.6
+3279,Belgium,2012,6,"C01B-Antiarrhythmics, Class I and III",Million of national currency units,15.1
+3280,Belgium,2012,6,N02-Analgesics,"/capita, US$ exchange rate",28.9
+3281,Belgium,2012,6,N02-Analgesics,% of total sales,4.2
+3282,Belgium,2012,6,N02-Analgesics,"/capita, US$ purchasing power parity",27.4
+3283,Belgium,2012,6,N02-Analgesics,"Million US$, purchasing power parity",304.4
+3284,Belgium,2012,6,N02-Analgesics,Million of national currency units,250.3
+3285,Belgium,2012,6,"C01B-Antiarrhythmics, Class I and III",% of total sales,0.3
+3286,Belgium,2012,6,N02-Analgesics,Million US$ at exchange rate,321.5
+3287,Belgium,2012,6,Total pharmaceutical sales,"/capita, US$ purchasing power parity",650.4
+3288,Belgium,2012,6,G03-Sex hormones and modulators of the genital system,"/capita, US$ exchange rate",14.4
+3289,Belgium,2012,6,Total pharmaceutical sales,Million US$ at exchange rate,7630.9
+3290,Belgium,2012,6,Total pharmaceutical sales,Million of national currency units,5939.4
+3291,Belgium,2012,6,Total pharmaceutical sales,"/capita, US$ exchange rate",687.0
+3292,Belgium,2012,6,Total pharmaceutical sales,"Million US$, purchasing power parity",7224.3
+3293,Belgium,2012,6,A10-Drugs used in diabetes,"Million US$, purchasing power parity",188.8
+3294,Belgium,2012,6,A10-Drugs used in diabetes,Million of national currency units,155.2
+3295,Belgium,2012,6,A10-Drugs used in diabetes,Million US$ at exchange rate,199.4
+3296,Belgium,2012,6,A10-Drugs used in diabetes,"/capita, US$ exchange rate",18.0
+3297,Belgium,2012,6,N-Nervous system,% of total sales,16.9
+3298,Belgium,2012,6,A10-Drugs used in diabetes,% of total sales,2.6
+3299,Belgium,2012,6,A10-Drugs used in diabetes,"/capita, US$ purchasing power parity",17.0
+3300,Belgium,2012,6,M01A-Antiinflammatory and antirheumatic products non-steroids,% of total sales,2.0
+3301,Belgium,2012,6,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ purchasing power parity",12.8
+3302,Belgium,2012,6,N05B-Anxiolytics,% of total sales,1.1
+3303,Belgium,2012,6,N05B-Anxiolytics,"/capita, US$ exchange rate",7.4
+3304,Belgium,2012,6,N05B-Anxiolytics,"Million US$, purchasing power parity",77.6
+3305,Belgium,2012,6,N05B-Anxiolytics,"/capita, US$ purchasing power parity",7.0
+3306,Belgium,2012,6,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ exchange rate",13.6
+3307,Belgium,2012,6,C01A-Cardiac glycosides,"/capita, US$ purchasing power parity",0.2
+3308,Belgium,2012,6,C01A-Cardiac glycosides,% of total sales,0.0
+3309,Belgium,2012,6,C01A-Cardiac glycosides,"/capita, US$ exchange rate",0.2
+3310,Belgium,2012,6,M01A-Antiinflammatory and antirheumatic products non-steroids,"Million US$, purchasing power parity",142.5
+3311,Belgium,2012,6,M01A-Antiinflammatory and antirheumatic products non-steroids,Million of national currency units,117.2
+3312,Belgium,2012,6,M01A-Antiinflammatory and antirheumatic products non-steroids,Million US$ at exchange rate,150.6
+3313,Belgium,2012,6,G03-Sex hormones and modulators of the genital system,"Million US$, purchasing power parity",151.0
+3314,Belgium,2012,6,N-Nervous system,Million of national currency units,1005.5
+3315,Belgium,2012,6,C02-Antihypertensives,Million of national currency units,19.6
+3316,Belgium,2012,6,N-Nervous system,Million US$ at exchange rate,1291.9
+3317,Belgium,2012,6,N-Nervous system,"/capita, US$ exchange rate",116.3
+3318,Belgium,2012,6,N-Nervous system,"/capita, US$ purchasing power parity",110.1
+3319,Belgium,2012,6,C02-Antihypertensives,Million US$ at exchange rate,25.2
+3320,Belgium,2012,6,N-Nervous system,"Million US$, purchasing power parity",1223.1
+3321,Belgium,2012,6,C02-Antihypertensives,% of total sales,0.3
+3322,Belgium,2012,6,N05B-Anxiolytics,Million of national currency units,63.8
+3323,Belgium,2012,6,N05B-Anxiolytics,Million US$ at exchange rate,82.0
+3324,Belgium,2012,6,G03-Sex hormones and modulators of the genital system,Million US$ at exchange rate,159.5
+3325,Belgium,2012,6,C02-Antihypertensives,"Million US$, purchasing power parity",23.9
+3326,Belgium,2012,6,C02-Antihypertensives,"/capita, US$ exchange rate",2.3
+3327,Belgium,2012,6,C02-Antihypertensives,"/capita, US$ purchasing power parity",2.1
+3328,Belgium,2012,6,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ purchasing power parity",13.6
+3329,Belgium,2012,6,R03-Drugs for obstructive airway diseases,"Million US$, purchasing power parity",308.6
+3330,Belgium,2012,6,R03-Drugs for obstructive airway diseases,"/capita, US$ exchange rate",29.4
+3331,Belgium,2012,6,R03-Drugs for obstructive airway diseases,Million US$ at exchange rate,326.0
+3332,Belgium,2012,6,J01-Antibacterials for systemic use,Million of national currency units,225.8
+3333,Belgium,2012,6,R03-Drugs for obstructive airway diseases,Million of national currency units,253.7
+3334,Belgium,2012,6,A02A-Antacids,"/capita, US$ purchasing power parity",1.3
+3335,Belgium,2012,6,J01-Antibacterials for systemic use,Million US$ at exchange rate,290.2
+3336,Belgium,2012,6,C09-Agents acting on the Renin-Angiotensin system,Million of national currency units,226.4
+3337,Belgium,2012,6,A02A-Antacids,"/capita, US$ exchange rate",1.3
+3338,Belgium,2012,6,R03-Drugs for obstructive airway diseases,"/capita, US$ purchasing power parity",27.8
+3339,Belgium,2012,6,R03-Drugs for obstructive airway diseases,% of total sales,4.3
+3340,Belgium,2012,6,C10-Lipid modifying agents,Million US$ at exchange rate,379.9
+3341,Belgium,2012,6,C08-Calcium channel blockers,% of total sales,1.1
+3342,Belgium,2012,6,C10-Lipid modifying agents,"/capita, US$ purchasing power parity",32.4
+3343,Belgium,2012,6,C08-Calcium channel blockers,"/capita, US$ exchange rate",7.4
+3344,Belgium,2012,6,C08-Calcium channel blockers,"/capita, US$ purchasing power parity",7.0
+3345,Belgium,2012,6,A02A-Antacids,Million US$ at exchange rate,14.9
+3346,Belgium,2012,6,A02A-Antacids,"Million US$, purchasing power parity",14.1
+3347,Belgium,2012,6,C10-Lipid modifying agents,"/capita, US$ exchange rate",34.2
+3348,Belgium,2012,6,C10-Lipid modifying agents,"Million US$, purchasing power parity",359.7
+3349,Belgium,2012,6,A02A-Antacids,Million of national currency units,11.6
+3350,Belgium,2012,6,A02A-Antacids,% of total sales,0.2
+3351,Belgium,2012,6,Products not elsewhere classified,"/capita, US$ purchasing power parity",140.7
+3352,Belgium,2012,6,B-Blood and blood forming organs,"/capita, US$ exchange rate",52.1
+3353,Belgium,2012,6,Products not elsewhere classified,% of total sales,21.6
+3354,Belgium,2012,6,Products not elsewhere classified,"/capita, US$ exchange rate",148.6
+3355,Belgium,2012,6,Products not elsewhere classified,Million of national currency units,1284.3
+3356,Belgium,2012,6,Products not elsewhere classified,Million US$ at exchange rate,1650.1
+3357,Belgium,2012,6,Products not elsewhere classified,"Million US$, purchasing power parity",1562.2
+3358,Belgium,2012,6,C10-Lipid modifying agents,% of total sales,5.0
+3359,Belgium,2012,6,C10-Lipid modifying agents,Million of national currency units,295.7
+3360,Belgium,2012,6,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ purchasing power parity",24.8
+3361,Belgium,2012,6,C09-Agents acting on the Renin-Angiotensin system,% of total sales,3.8
+3362,Belgium,2012,6,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ exchange rate",26.2
+3363,Belgium,2012,6,C09-Agents acting on the Renin-Angiotensin system,Million US$ at exchange rate,290.9
+3364,Belgium,2012,6,C09-Agents acting on the Renin-Angiotensin system,"Million US$, purchasing power parity",275.4
+3365,Belgium,2012,6,B-Blood and blood forming organs,% of total sales,7.6
+3366,Belgium,2012,6,B-Blood and blood forming organs,"/capita, US$ purchasing power parity",49.3
+3367,Belgium,2012,6,B-Blood and blood forming organs,"Million US$, purchasing power parity",548.0
+3368,Belgium,2012,6,B-Blood and blood forming organs,Million of national currency units,450.6
+3369,Belgium,2012,6,B-Blood and blood forming organs,Million US$ at exchange rate,578.9
+3370,Belgium,2012,6,R-Respiratory system,"/capita, US$ purchasing power parity",56.6
+3371,Belgium,2012,6,R-Respiratory system,% of total sales,8.7
+3372,Belgium,2012,6,A-Alimentary tract and metabolism,"/capita, US$ purchasing power parity",70.9
+3373,Belgium,2012,6,R-Respiratory system,Million US$ at exchange rate,664.4
+3374,Belgium,2012,6,R-Respiratory system,"Million US$, purchasing power parity",629.0
+3375,Belgium,2012,6,R-Respiratory system,"/capita, US$ exchange rate",59.8
+3376,Belgium,2012,6,J-Antiinfectives for systemic use,% of total sales,9.8
+3377,Belgium,2012,6,C08-Calcium channel blockers,Million of national currency units,63.9
+3378,Belgium,2012,6,J-Antiinfectives for systemic use,"/capita, US$ exchange rate",67.5
+3379,Belgium,2012,6,A-Alimentary tract and metabolism,% of total sales,10.9
+3380,Belgium,2012,6,A-Alimentary tract and metabolism,"Million US$, purchasing power parity",787.5
+3381,Belgium,2012,6,A-Alimentary tract and metabolism,"/capita, US$ exchange rate",74.9
+3382,Belgium,2012,6,R-Respiratory system,Million of national currency units,517.1
+3383,Belgium,2012,6,C-Cardiovascular system,Million of national currency units,840.1
+3384,Belgium,2012,6,A-Alimentary tract and metabolism,Million of national currency units,647.4
+3385,Belgium,2012,6,A-Alimentary tract and metabolism,Million US$ at exchange rate,831.8
+3386,Belgium,2012,6,C-Cardiovascular system,Million US$ at exchange rate,1079.3
+3387,Belgium,2012,6,J-Antiinfectives for systemic use,Million US$ at exchange rate,750.0
+3388,Belgium,2012,6,J-Antiinfectives for systemic use,"Million US$, purchasing power parity",710.0
+3389,Belgium,2012,6,J-Antiinfectives for systemic use,Million of national currency units,583.7
+3390,Belgium,2012,6,C-Cardiovascular system,"Million US$, purchasing power parity",1021.8
+3391,Belgium,2012,6,C-Cardiovascular system,"/capita, US$ exchange rate",97.2
+3392,Belgium,2012,6,J-Antiinfectives for systemic use,"/capita, US$ purchasing power parity",63.9
+3393,Belgium,2012,6,C08-Calcium channel blockers,Million US$ at exchange rate,82.0
+3394,Belgium,2012,6,J01-Antibacterials for systemic use,% of total sales,3.8
+3395,Belgium,2012,6,C08-Calcium channel blockers,"Million US$, purchasing power parity",77.7
+3396,Belgium,2012,6,J01-Antibacterials for systemic use,"Million US$, purchasing power parity",274.7
+3397,Belgium,2012,6,C-Cardiovascular system,"/capita, US$ purchasing power parity",92.0
+3398,Belgium,2012,6,J01-Antibacterials for systemic use,"/capita, US$ purchasing power parity",24.7
+3399,Belgium,2012,6,J01-Antibacterials for systemic use,"/capita, US$ exchange rate",26.1
+3400,Belgium,2012,6,C-Cardiovascular system,% of total sales,14.1
+3401,Belgium,2016,5,C03-Diuretics,Million US$ at exchange rate,36.5
+3402,Belgium,2016,5,C03-Diuretics,Million of national currency units,33.0
+3403,Belgium,2016,5,C03-Diuretics,"Million US$, purchasing power parity",42.2
+3404,Belgium,2016,5,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million of national currency units,126.2
+3405,Belgium,2016,5,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million US$ at exchange rate,139.7
+3406,Belgium,2016,5,N06A-Antidepressants,Million of national currency units,130.1
+3407,Belgium,2016,5,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ exchange rate",12.3
+3408,Belgium,2016,5,N06A-Antidepressants,Million US$ at exchange rate,144.0
+3409,Belgium,2016,5,C03-Diuretics,"/capita, US$ purchasing power parity",3.7
+3410,Belgium,2016,5,C03-Diuretics,"/capita, US$ exchange rate",3.2
+3411,Belgium,2016,5,"H-Systemic hormonal preparations, excluding sex hormones and insulins","Million US$, purchasing power parity",161.6
+3412,Belgium,2016,5,C03-Diuretics,% of total sales,0.5
+3413,Belgium,2016,5,G-Genito urinary system and sex hormones,Million US$ at exchange rate,249.6
+3414,Belgium,2016,5,N05C-Hypnotics and sedatives,Million of national currency units,77.6
+3415,Belgium,2016,5,G-Genito urinary system and sex hormones,"/capita, US$ purchasing power parity",25.5
+3416,Belgium,2016,5,N05C-Hypnotics and sedatives,Million US$ at exchange rate,85.9
+3417,Belgium,2016,5,C01A-Cardiac glycosides,Million US$ at exchange rate,1.0
+3418,Belgium,2016,5,C01A-Cardiac glycosides,Million of national currency units,0.9
+3419,Belgium,2016,5,G-Genito urinary system and sex hormones,% of total sales,3.6
+3420,Belgium,2016,5,N05C-Hypnotics and sedatives,"Million US$, purchasing power parity",99.4
+3421,Belgium,2016,5,G-Genito urinary system and sex hormones,"/capita, US$ exchange rate",22.0
+3422,Belgium,2016,5,G-Genito urinary system and sex hormones,"Million US$, purchasing power parity",288.7
+3423,Belgium,2016,5,N05C-Hypnotics and sedatives,% of total sales,1.2
+3424,Belgium,2016,5,N05C-Hypnotics and sedatives,"/capita, US$ exchange rate",7.6
+3425,Belgium,2016,5,N05C-Hypnotics and sedatives,"/capita, US$ purchasing power parity",8.8
+3426,Belgium,2016,5,N06A-Antidepressants,"Million US$, purchasing power parity",166.5
+3427,Belgium,2016,5,C07-Beta blocking agents,% of total sales,1.4
+3428,Belgium,2016,5,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),% of total sales,2.6
+3429,Belgium,2016,5,C07-Beta blocking agents,"/capita, US$ purchasing power parity",9.7
+3430,Belgium,2016,5,C07-Beta blocking agents,"Million US$, purchasing power parity",110.3
+3431,Belgium,2016,5,C07-Beta blocking agents,Million US$ at exchange rate,95.3
+3432,Belgium,2016,5,C07-Beta blocking agents,"/capita, US$ exchange rate",8.4
+3433,Belgium,2016,5,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ purchasing power parity",18.4
+3434,Belgium,2016,5,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million of national currency units,163.2
+3435,Belgium,2016,5,G-Genito urinary system and sex hormones,Million of national currency units,225.5
+3436,Belgium,2016,5,G03-Sex hormones and modulators of the genital system,Million of national currency units,109.3
+3437,Belgium,2016,5,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million US$ at exchange rate,180.7
+3438,Belgium,2016,5,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ exchange rate",15.9
+3439,Belgium,2016,5,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"Million US$, purchasing power parity",209.0
+3440,Belgium,2016,5,M-Musculo-skeletal system,% of total sales,4.1
+3441,Belgium,2016,5,M-Musculo-skeletal system,"/capita, US$ exchange rate",24.8
+3442,Belgium,2016,5,M-Musculo-skeletal system,"/capita, US$ purchasing power parity",28.7
+3443,Belgium,2016,5,N06A-Antidepressants,% of total sales,2.1
+3444,Belgium,2016,5,N06A-Antidepressants,"/capita, US$ exchange rate",12.7
+3445,Belgium,2016,5,N06A-Antidepressants,"/capita, US$ purchasing power parity",14.7
+3446,Belgium,2016,5,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ purchasing power parity",14.3
+3447,Belgium,2016,5,"H-Systemic hormonal preparations, excluding sex hormones and insulins",% of total sales,2.0
+3448,Belgium,2016,5,C07-Beta blocking agents,Million of national currency units,86.1
+3449,Belgium,2016,5,M-Musculo-skeletal system,"Million US$, purchasing power parity",325.6
+3450,Belgium,2016,5,M-Musculo-skeletal system,Million US$ at exchange rate,281.5
+3451,Belgium,2016,5,M-Musculo-skeletal system,Million of national currency units,254.3
+3452,Belgium,2016,5,"C01B-Antiarrhythmics, Class I and III","Million US$, purchasing power parity",19.0
+3453,Belgium,2016,5,"C01B-Antiarrhythmics, Class I and III",Million US$ at exchange rate,16.4
+3454,Belgium,2016,5,"C01B-Antiarrhythmics, Class I and III","/capita, US$ purchasing power parity",1.7
+3455,Belgium,2016,5,"C01B-Antiarrhythmics, Class I and III","/capita, US$ exchange rate",1.4
+3456,Belgium,2016,5,G03-Sex hormones and modulators of the genital system,"/capita, US$ purchasing power parity",12.4
+3457,Belgium,2016,5,G03-Sex hormones and modulators of the genital system,% of total sales,1.8
+3458,Belgium,2016,5,"C01B-Antiarrhythmics, Class I and III",Million of national currency units,14.8
+3459,Belgium,2016,5,N02-Analgesics,"/capita, US$ exchange rate",24.1
+3460,Belgium,2016,5,N02-Analgesics,"Million US$, purchasing power parity",316.0
+3461,Belgium,2016,5,N02-Analgesics,% of total sales,4.0
+3462,Belgium,2016,5,N02-Analgesics,"/capita, US$ purchasing power parity",27.9
+3463,Belgium,2016,5,"C01B-Antiarrhythmics, Class I and III",% of total sales,0.2
+3464,Belgium,2016,5,N02-Analgesics,Million of national currency units,246.8
+3465,Belgium,2016,5,N02-Analgesics,Million US$ at exchange rate,273.2
+3466,Belgium,2016,5,Total pharmaceutical sales,"/capita, US$ purchasing power parity",705.4
+3467,Belgium,2016,5,G03-Sex hormones and modulators of the genital system,"Million US$, purchasing power parity",140.0
+3468,Belgium,2016,5,G03-Sex hormones and modulators of the genital system,"/capita, US$ exchange rate",10.7
+3469,Belgium,2016,5,Total pharmaceutical sales,"/capita, US$ exchange rate",609.8
+3470,Belgium,2016,5,N-Nervous system,% of total sales,14.6
+3471,Belgium,2016,5,Total pharmaceutical sales,Million US$ at exchange rate,6910.0
+3472,Belgium,2016,5,Total pharmaceutical sales,Million of national currency units,6242.6
+3473,Belgium,2016,5,Total pharmaceutical sales,"Million US$, purchasing power parity",7993.0
+3474,Belgium,2016,5,A10-Drugs used in diabetes,"Million US$, purchasing power parity",245.6
+3475,Belgium,2016,5,A10-Drugs used in diabetes,Million US$ at exchange rate,212.4
+3476,Belgium,2016,5,A10-Drugs used in diabetes,Million of national currency units,191.8
+3477,Belgium,2016,5,A10-Drugs used in diabetes,% of total sales,3.1
+3478,Belgium,2016,5,A10-Drugs used in diabetes,"/capita, US$ exchange rate",18.7
+3479,Belgium,2016,5,A10-Drugs used in diabetes,"/capita, US$ purchasing power parity",21.7
+3480,Belgium,2016,5,M01A-Antiinflammatory and antirheumatic products non-steroids,% of total sales,1.7
+3481,Belgium,2016,5,N05B-Anxiolytics,% of total sales,1.2
+3482,Belgium,2016,5,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ exchange rate",10.6
+3483,Belgium,2016,5,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ purchasing power parity",12.3
+3484,Belgium,2016,5,N05B-Anxiolytics,"Million US$, purchasing power parity",92.8
+3485,Belgium,2016,5,N05B-Anxiolytics,"/capita, US$ exchange rate",7.1
+3486,Belgium,2016,5,N05B-Anxiolytics,"/capita, US$ purchasing power parity",8.2
+3487,Belgium,2016,5,C01A-Cardiac glycosides,"/capita, US$ purchasing power parity",0.1
+3488,Belgium,2016,5,C01A-Cardiac glycosides,% of total sales,0.0
+3489,Belgium,2016,5,C01A-Cardiac glycosides,"Million US$, purchasing power parity",1.1
+3490,Belgium,2016,5,C01A-Cardiac glycosides,"/capita, US$ exchange rate",0.1
+3491,Belgium,2016,5,M01A-Antiinflammatory and antirheumatic products non-steroids,"Million US$, purchasing power parity",139.6
+3492,Belgium,2016,5,M01A-Antiinflammatory and antirheumatic products non-steroids,Million US$ at exchange rate,120.7
+3493,Belgium,2016,5,M01A-Antiinflammatory and antirheumatic products non-steroids,Million of national currency units,109.0
+3494,Belgium,2016,5,N-Nervous system,Million of national currency units,910.9
+3495,Belgium,2016,5,C02-Antihypertensives,Million of national currency units,25.9
+3496,Belgium,2016,5,G03-Sex hormones and modulators of the genital system,Million US$ at exchange rate,121.0
+3497,Belgium,2016,5,N-Nervous system,"/capita, US$ exchange rate",89.0
+3498,Belgium,2016,5,N-Nervous system,"/capita, US$ purchasing power parity",102.9
+3499,Belgium,2016,5,N-Nervous system,Million US$ at exchange rate,1008.3
+3500,Belgium,2016,5,N-Nervous system,"Million US$, purchasing power parity",1166.3
+3501,Belgium,2016,5,C02-Antihypertensives,% of total sales,0.4
+3502,Belgium,2016,5,N05B-Anxiolytics,Million US$ at exchange rate,80.2
+3503,Belgium,2016,5,N05B-Anxiolytics,Million of national currency units,72.5
+3504,Belgium,2016,5,C02-Antihypertensives,"Million US$, purchasing power parity",33.2
+3505,Belgium,2016,5,C02-Antihypertensives,Million US$ at exchange rate,28.7
+3506,Belgium,2016,5,C02-Antihypertensives,"/capita, US$ purchasing power parity",2.9
+3507,Belgium,2016,5,C02-Antihypertensives,"/capita, US$ exchange rate",2.5
+3508,Belgium,2016,5,R03-Drugs for obstructive airway diseases,Million US$ at exchange rate,269.6
+3509,Belgium,2016,5,R03-Drugs for obstructive airway diseases,"Million US$, purchasing power parity",311.9
+3510,Belgium,2016,5,R03-Drugs for obstructive airway diseases,"/capita, US$ exchange rate",23.8
+3511,Belgium,2016,5,J01-Antibacterials for systemic use,Million of national currency units,197.1
+3512,Belgium,2016,5,A02A-Antacids,"Million US$, purchasing power parity",12.5
+3513,Belgium,2016,5,R03-Drugs for obstructive airway diseases,Million of national currency units,243.6
+3514,Belgium,2016,5,A02A-Antacids,"/capita, US$ exchange rate",1.0
+3515,Belgium,2016,5,A02A-Antacids,"/capita, US$ purchasing power parity",1.1
+3516,Belgium,2016,5,R03-Drugs for obstructive airway diseases,"/capita, US$ purchasing power parity",27.5
+3517,Belgium,2016,5,R03-Drugs for obstructive airway diseases,% of total sales,3.9
+3518,Belgium,2016,5,C08-Calcium channel blockers,% of total sales,0.7
+3519,Belgium,2016,5,C10-Lipid modifying agents,"/capita, US$ purchasing power parity",24.6
+3520,Belgium,2016,5,C08-Calcium channel blockers,"/capita, US$ exchange rate",4.5
+3521,Belgium,2016,5,C08-Calcium channel blockers,"/capita, US$ purchasing power parity",5.2
+3522,Belgium,2016,5,A02A-Antacids,Million US$ at exchange rate,10.8
+3523,Belgium,2016,5,C10-Lipid modifying agents,Million US$ at exchange rate,241.4
+3524,Belgium,2016,5,A02A-Antacids,Million of national currency units,9.8
+3525,Belgium,2016,5,C10-Lipid modifying agents,"/capita, US$ exchange rate",21.3
+3526,Belgium,2016,5,C10-Lipid modifying agents,"Million US$, purchasing power parity",279.3
+3527,Belgium,2016,5,C09-Agents acting on the Renin-Angiotensin system,Million of national currency units,190.4
+3528,Belgium,2016,5,A02A-Antacids,% of total sales,0.2
+3529,Belgium,2016,5,Products not elsewhere classified,"/capita, US$ purchasing power parity",187.2
+3530,Belgium,2016,5,Products not elsewhere classified,"/capita, US$ exchange rate",161.8
+3531,Belgium,2016,5,B-Blood and blood forming organs,"/capita, US$ exchange rate",54.7
+3532,Belgium,2016,5,Products not elsewhere classified,% of total sales,26.5
+3533,Belgium,2016,5,Products not elsewhere classified,Million of national currency units,1656.3
+3534,Belgium,2016,5,Products not elsewhere classified,Million US$ at exchange rate,1833.4
+3535,Belgium,2016,5,C10-Lipid modifying agents,Million of national currency units,218.1
+3536,Belgium,2016,5,Products not elsewhere classified,"Million US$, purchasing power parity",2120.7
+3537,Belgium,2016,5,C10-Lipid modifying agents,% of total sales,3.5
+3538,Belgium,2016,5,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ exchange rate",18.6
+3539,Belgium,2016,5,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ purchasing power parity",21.5
+3540,Belgium,2016,5,C09-Agents acting on the Renin-Angiotensin system,Million US$ at exchange rate,210.7
+3541,Belgium,2016,5,C09-Agents acting on the Renin-Angiotensin system,% of total sales,3.0
+3542,Belgium,2016,5,C09-Agents acting on the Renin-Angiotensin system,"Million US$, purchasing power parity",243.7
+3543,Belgium,2016,5,B-Blood and blood forming organs,"Million US$, purchasing power parity",716.6
+3544,Belgium,2016,5,B-Blood and blood forming organs,% of total sales,9.0
+3545,Belgium,2016,5,B-Blood and blood forming organs,"/capita, US$ purchasing power parity",63.2
+3546,Belgium,2016,5,B-Blood and blood forming organs,Million of national currency units,559.7
+3547,Belgium,2016,5,B-Blood and blood forming organs,Million US$ at exchange rate,619.5
+3548,Belgium,2016,5,R-Respiratory system,"/capita, US$ purchasing power parity",57.7
+3549,Belgium,2016,5,R-Respiratory system,% of total sales,8.2
+3550,Belgium,2016,5,R-Respiratory system,Million US$ at exchange rate,565.2
+3551,Belgium,2016,5,R-Respiratory system,"/capita, US$ exchange rate",49.9
+3552,Belgium,2016,5,R-Respiratory system,"Million US$, purchasing power parity",653.8
+3553,Belgium,2016,5,J-Antiinfectives for systemic use,% of total sales,10.2
+3554,Belgium,2016,5,C08-Calcium channel blockers,Million of national currency units,45.9
+3555,Belgium,2016,5,A-Alimentary tract and metabolism,% of total sales,10.9
+3556,Belgium,2016,5,J-Antiinfectives for systemic use,"/capita, US$ exchange rate",62.0
+3557,Belgium,2016,5,C-Cardiovascular system,% of total sales,11.0
+3558,Belgium,2016,5,A-Alimentary tract and metabolism,"/capita, US$ purchasing power parity",76.6
+3559,Belgium,2016,5,J-Antiinfectives for systemic use,"/capita, US$ purchasing power parity",71.7
+3560,Belgium,2016,5,A-Alimentary tract and metabolism,"Million US$, purchasing power parity",867.6
+3561,Belgium,2016,5,A-Alimentary tract and metabolism,"/capita, US$ exchange rate",66.2
+3562,Belgium,2016,5,C-Cardiovascular system,Million of national currency units,686.7
+3563,Belgium,2016,5,A-Alimentary tract and metabolism,Million US$ at exchange rate,750.1
+3564,Belgium,2016,5,A-Alimentary tract and metabolism,Million of national currency units,677.6
+3565,Belgium,2016,5,J-Antiinfectives for systemic use,Million of national currency units,634.8
+3566,Belgium,2016,5,J-Antiinfectives for systemic use,Million US$ at exchange rate,702.6
+3567,Belgium,2016,5,R-Respiratory system,Million of national currency units,510.7
+3568,Belgium,2016,5,J-Antiinfectives for systemic use,"Million US$, purchasing power parity",812.7
+3569,Belgium,2016,5,C-Cardiovascular system,"Million US$, purchasing power parity",879.3
+3570,Belgium,2016,5,C-Cardiovascular system,Million US$ at exchange rate,760.2
+3571,Belgium,2016,5,C-Cardiovascular system,"/capita, US$ exchange rate",67.1
+3572,Belgium,2016,5,C08-Calcium channel blockers,Million US$ at exchange rate,50.9
+3573,Belgium,2016,5,J01-Antibacterials for systemic use,% of total sales,3.2
+3574,Belgium,2016,5,C08-Calcium channel blockers,"Million US$, purchasing power parity",58.8
+3575,Belgium,2016,5,J01-Antibacterials for systemic use,"Million US$, purchasing power parity",252.4
+3576,Belgium,2016,5,J01-Antibacterials for systemic use,Million US$ at exchange rate,218.2
+3577,Belgium,2016,5,J01-Antibacterials for systemic use,"/capita, US$ purchasing power parity",22.3
+3578,Belgium,2016,5,J01-Antibacterials for systemic use,"/capita, US$ exchange rate",19.3
+3579,Belgium,2016,5,C-Cardiovascular system,"/capita, US$ purchasing power parity",77.6
+3580,Belgium,2014,6,C03-Diuretics,Million US$ at exchange rate,46.1
+3581,Belgium,2014,6,C03-Diuretics,"Million US$, purchasing power parity",43.4
+3582,Belgium,2014,6,C03-Diuretics,Million of national currency units,34.7
+3583,Belgium,2014,6,C03-Diuretics,"/capita, US$ exchange rate",4.1
+3584,Belgium,2014,6,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million of national currency units,123.1
+3585,Belgium,2014,6,"H-Systemic hormonal preparations, excluding sex hormones and insulins","Million US$, purchasing power parity",153.8
+3586,Belgium,2014,6,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million US$ at exchange rate,163.6
+3587,Belgium,2014,6,N06A-Antidepressants,Million of national currency units,179.1
+3588,Belgium,2014,6,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ exchange rate",14.6
+3589,Belgium,2014,6,N06A-Antidepressants,Million US$ at exchange rate,238.0
+3590,Belgium,2014,6,C03-Diuretics,"/capita, US$ purchasing power parity",3.9
+3591,Belgium,2014,6,C03-Diuretics,% of total sales,0.6
+3592,Belgium,2014,6,G-Genito urinary system and sex hormones,Million US$ at exchange rate,301.1
+3593,Belgium,2014,6,N05C-Hypnotics and sedatives,Million of national currency units,75.3
+3594,Belgium,2014,6,G-Genito urinary system and sex hormones,"/capita, US$ purchasing power parity",25.3
+3595,Belgium,2014,6,N05C-Hypnotics and sedatives,Million US$ at exchange rate,100.0
+3596,Belgium,2014,6,C01A-Cardiac glycosides,Million US$ at exchange rate,1.5
+3597,Belgium,2014,6,G-Genito urinary system and sex hormones,% of total sales,3.8
+3598,Belgium,2014,6,C01A-Cardiac glycosides,Million of national currency units,1.1
+3599,Belgium,2014,6,N05C-Hypnotics and sedatives,"Million US$, purchasing power parity",94.0
+3600,Belgium,2014,6,G-Genito urinary system and sex hormones,"/capita, US$ exchange rate",26.9
+3601,Belgium,2014,6,G-Genito urinary system and sex hormones,"Million US$, purchasing power parity",283.2
+3602,Belgium,2014,6,N05C-Hypnotics and sedatives,"/capita, US$ exchange rate",8.9
+3603,Belgium,2014,6,N05C-Hypnotics and sedatives,% of total sales,1.3
+3604,Belgium,2014,6,N05C-Hypnotics and sedatives,"/capita, US$ purchasing power parity",8.4
+3605,Belgium,2014,6,N06A-Antidepressants,"Million US$, purchasing power parity",223.8
+3606,Belgium,2014,6,C07-Beta blocking agents,% of total sales,1.5
+3607,Belgium,2014,6,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),% of total sales,2.4
+3608,Belgium,2014,6,C07-Beta blocking agents,"/capita, US$ purchasing power parity",10.2
+3609,Belgium,2014,6,C07-Beta blocking agents,"Million US$, purchasing power parity",114.8
+3610,Belgium,2014,6,C07-Beta blocking agents,Million US$ at exchange rate,122.1
+3611,Belgium,2014,6,C07-Beta blocking agents,"/capita, US$ exchange rate",10.9
+3612,Belgium,2014,6,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million of national currency units,144.1
+3613,Belgium,2014,6,G03-Sex hormones and modulators of the genital system,Million of national currency units,113.7
+3614,Belgium,2014,6,G-Genito urinary system and sex hormones,Million of national currency units,226.7
+3615,Belgium,2014,6,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million US$ at exchange rate,191.4
+3616,Belgium,2014,6,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ exchange rate",17.1
+3617,Belgium,2014,6,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ purchasing power parity",16.1
+3618,Belgium,2014,6,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"Million US$, purchasing power parity",180.0
+3619,Belgium,2014,6,M-Musculo-skeletal system,% of total sales,4.3
+3620,Belgium,2014,6,M-Musculo-skeletal system,"/capita, US$ purchasing power parity",28.4
+3621,Belgium,2014,6,N06A-Antidepressants,"/capita, US$ exchange rate",21.2
+3622,Belgium,2014,6,M-Musculo-skeletal system,"/capita, US$ exchange rate",30.2
+3623,Belgium,2014,6,N06A-Antidepressants,% of total sales,3.0
+3624,Belgium,2014,6,N06A-Antidepressants,"/capita, US$ purchasing power parity",20.0
+3625,Belgium,2014,6,"H-Systemic hormonal preparations, excluding sex hormones and insulins",% of total sales,2.1
+3626,Belgium,2014,6,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ purchasing power parity",13.7
+3627,Belgium,2014,6,C07-Beta blocking agents,Million of national currency units,91.9
+3628,Belgium,2014,6,M-Musculo-skeletal system,"Million US$, purchasing power parity",318.5
+3629,Belgium,2014,6,M-Musculo-skeletal system,Million of national currency units,254.9
+3630,Belgium,2014,6,M-Musculo-skeletal system,Million US$ at exchange rate,338.6
+3631,Belgium,2014,6,C01A-Cardiac glycosides,"Million US$, purchasing power parity",1.4
+3632,Belgium,2014,6,"C01B-Antiarrhythmics, Class I and III","Million US$, purchasing power parity",19.4
+3633,Belgium,2014,6,"C01B-Antiarrhythmics, Class I and III","/capita, US$ purchasing power parity",1.7
+3634,Belgium,2014,6,"C01B-Antiarrhythmics, Class I and III","/capita, US$ exchange rate",1.8
+3635,Belgium,2014,6,"C01B-Antiarrhythmics, Class I and III",Million US$ at exchange rate,20.6
+3636,Belgium,2014,6,G03-Sex hormones and modulators of the genital system,% of total sales,1.9
+3637,Belgium,2014,6,G03-Sex hormones and modulators of the genital system,"/capita, US$ purchasing power parity",12.7
+3638,Belgium,2014,6,"C01B-Antiarrhythmics, Class I and III",Million of national currency units,15.5
+3639,Belgium,2014,6,N02-Analgesics,"/capita, US$ exchange rate",28.0
+3640,Belgium,2014,6,N02-Analgesics,% of total sales,4.0
+3641,Belgium,2014,6,N02-Analgesics,"/capita, US$ purchasing power parity",26.3
+3642,Belgium,2014,6,N02-Analgesics,"Million US$, purchasing power parity",295.3
+3643,Belgium,2014,6,N02-Analgesics,Million of national currency units,236.3
+3644,Belgium,2014,6,"C01B-Antiarrhythmics, Class I and III",% of total sales,0.3
+3645,Belgium,2014,6,N02-Analgesics,Million US$ at exchange rate,314.0
+3646,Belgium,2014,6,Total pharmaceutical sales,"/capita, US$ purchasing power parity",663.1
+3647,Belgium,2014,6,G03-Sex hormones and modulators of the genital system,"/capita, US$ exchange rate",13.5
+3648,Belgium,2014,6,Total pharmaceutical sales,Million US$ at exchange rate,7901.2
+3649,Belgium,2014,6,Total pharmaceutical sales,Million of national currency units,5947.5
+3650,Belgium,2014,6,Total pharmaceutical sales,"Million US$, purchasing power parity",7432.3
+3651,Belgium,2014,6,Total pharmaceutical sales,"/capita, US$ exchange rate",704.9
+3652,Belgium,2014,6,N-Nervous system,% of total sales,16.1
+3653,Belgium,2014,6,A10-Drugs used in diabetes,"Million US$, purchasing power parity",214.2
+3654,Belgium,2014,6,A10-Drugs used in diabetes,Million of national currency units,171.4
+3655,Belgium,2014,6,A10-Drugs used in diabetes,Million US$ at exchange rate,227.7
+3656,Belgium,2014,6,A10-Drugs used in diabetes,"/capita, US$ exchange rate",20.3
+3657,Belgium,2014,6,A10-Drugs used in diabetes,% of total sales,2.9
+3658,Belgium,2014,6,A10-Drugs used in diabetes,"/capita, US$ purchasing power parity",19.1
+3659,Belgium,2014,6,M01A-Antiinflammatory and antirheumatic products non-steroids,% of total sales,1.9
+3660,Belgium,2014,6,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ purchasing power parity",12.4
+3661,Belgium,2014,6,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ exchange rate",13.1
+3662,Belgium,2014,6,N05B-Anxiolytics,% of total sales,1.2
+3663,Belgium,2014,6,N05B-Anxiolytics,"/capita, US$ exchange rate",8.3
+3664,Belgium,2014,6,N05B-Anxiolytics,"Million US$, purchasing power parity",87.8
+3665,Belgium,2014,6,N05B-Anxiolytics,"/capita, US$ purchasing power parity",7.8
+3666,Belgium,2014,6,C01A-Cardiac glycosides,"/capita, US$ purchasing power parity",0.1
+3667,Belgium,2014,6,C01A-Cardiac glycosides,% of total sales,0.0
+3668,Belgium,2014,6,C01A-Cardiac glycosides,"/capita, US$ exchange rate",0.1
+3669,Belgium,2014,6,M01A-Antiinflammatory and antirheumatic products non-steroids,"Million US$, purchasing power parity",138.5
+3670,Belgium,2014,6,M01A-Antiinflammatory and antirheumatic products non-steroids,Million US$ at exchange rate,147.2
+3671,Belgium,2014,6,M01A-Antiinflammatory and antirheumatic products non-steroids,Million of national currency units,110.8
+3672,Belgium,2014,6,G03-Sex hormones and modulators of the genital system,"Million US$, purchasing power parity",142.0
+3673,Belgium,2014,6,N-Nervous system,Million of national currency units,958.5
+3674,Belgium,2014,6,C02-Antihypertensives,Million of national currency units,20.2
+3675,Belgium,2014,6,N-Nervous system,Million US$ at exchange rate,1273.4
+3676,Belgium,2014,6,N-Nervous system,"/capita, US$ exchange rate",113.6
+3677,Belgium,2014,6,N-Nervous system,"/capita, US$ purchasing power parity",106.9
+3678,Belgium,2014,6,N-Nervous system,"Million US$, purchasing power parity",1197.8
+3679,Belgium,2014,6,C02-Antihypertensives,% of total sales,0.3
+3680,Belgium,2014,6,N05B-Anxiolytics,Million US$ at exchange rate,93.4
+3681,Belgium,2014,6,N05B-Anxiolytics,Million of national currency units,70.3
+3682,Belgium,2014,6,G03-Sex hormones and modulators of the genital system,Million US$ at exchange rate,151.0
+3683,Belgium,2014,6,C02-Antihypertensives,"Million US$, purchasing power parity",25.2
+3684,Belgium,2014,6,C02-Antihypertensives,Million US$ at exchange rate,26.8
+3685,Belgium,2014,6,C02-Antihypertensives,"/capita, US$ purchasing power parity",2.2
+3686,Belgium,2014,6,C02-Antihypertensives,"/capita, US$ exchange rate",2.4
+3687,Belgium,2014,6,R03-Drugs for obstructive airway diseases,Million US$ at exchange rate,333.1
+3688,Belgium,2014,6,R03-Drugs for obstructive airway diseases,"Million US$, purchasing power parity",313.3
+3689,Belgium,2014,6,R03-Drugs for obstructive airway diseases,"/capita, US$ exchange rate",29.7
+3690,Belgium,2014,6,J01-Antibacterials for systemic use,Million of national currency units,213.6
+3691,Belgium,2014,6,R03-Drugs for obstructive airway diseases,Million of national currency units,250.7
+3692,Belgium,2014,6,A02A-Antacids,"/capita, US$ purchasing power parity",1.2
+3693,Belgium,2014,6,A02A-Antacids,"/capita, US$ exchange rate",1.2
+3694,Belgium,2014,6,R03-Drugs for obstructive airway diseases,"/capita, US$ purchasing power parity",28.0
+3695,Belgium,2014,6,R03-Drugs for obstructive airway diseases,% of total sales,4.2
+3696,Belgium,2014,6,C09-Agents acting on the Renin-Angiotensin system,Million of national currency units,199.3
+3697,Belgium,2014,6,C08-Calcium channel blockers,% of total sales,1.0
+3698,Belgium,2014,6,C10-Lipid modifying agents,"/capita, US$ purchasing power parity",25.2
+3699,Belgium,2014,6,C08-Calcium channel blockers,"/capita, US$ exchange rate",6.8
+3700,Belgium,2014,6,C08-Calcium channel blockers,"/capita, US$ purchasing power parity",6.4
+3701,Belgium,2014,6,A02A-Antacids,Million US$ at exchange rate,13.9
+3702,Belgium,2014,6,A02A-Antacids,"Million US$, purchasing power parity",13.1
+3703,Belgium,2014,6,C10-Lipid modifying agents,Million US$ at exchange rate,300.6
+3704,Belgium,2014,6,A02A-Antacids,Million of national currency units,10.5
+3705,Belgium,2014,6,C10-Lipid modifying agents,"/capita, US$ exchange rate",26.8
+3706,Belgium,2014,6,C10-Lipid modifying agents,"Million US$, purchasing power parity",282.8
+3707,Belgium,2014,6,A02A-Antacids,% of total sales,0.2
+3708,Belgium,2014,6,Products not elsewhere classified,"/capita, US$ purchasing power parity",160.9
+3709,Belgium,2014,6,Products not elsewhere classified,"/capita, US$ exchange rate",171.1
+3710,Belgium,2014,6,B-Blood and blood forming organs,"/capita, US$ exchange rate",59.4
+3711,Belgium,2014,6,Products not elsewhere classified,% of total sales,24.3
+3712,Belgium,2014,6,Products not elsewhere classified,Million of national currency units,1443.5
+3713,Belgium,2014,6,Products not elsewhere classified,Million US$ at exchange rate,1917.7
+3714,Belgium,2014,6,C10-Lipid modifying agents,Million of national currency units,226.3
+3715,Belgium,2014,6,Products not elsewhere classified,"Million US$, purchasing power parity",1803.9
+3716,Belgium,2014,6,C10-Lipid modifying agents,% of total sales,3.8
+3717,Belgium,2014,6,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ exchange rate",23.6
+3718,Belgium,2014,6,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ purchasing power parity",22.2
+3719,Belgium,2014,6,C09-Agents acting on the Renin-Angiotensin system,% of total sales,3.4
+3720,Belgium,2014,6,C09-Agents acting on the Renin-Angiotensin system,Million US$ at exchange rate,264.8
+3721,Belgium,2014,6,C09-Agents acting on the Renin-Angiotensin system,"Million US$, purchasing power parity",249.1
+3722,Belgium,2014,6,B-Blood and blood forming organs,% of total sales,8.4
+3723,Belgium,2014,6,B-Blood and blood forming organs,"/capita, US$ purchasing power parity",55.9
+3724,Belgium,2014,6,B-Blood and blood forming organs,"Million US$, purchasing power parity",626.5
+3725,Belgium,2014,6,B-Blood and blood forming organs,Million of national currency units,501.4
+3726,Belgium,2014,6,B-Blood and blood forming organs,Million US$ at exchange rate,666.1
+3727,Belgium,2014,6,R-Respiratory system,"/capita, US$ purchasing power parity",56.4
+3728,Belgium,2014,6,R-Respiratory system,% of total sales,8.5
+3729,Belgium,2014,6,R-Respiratory system,Million US$ at exchange rate,671.6
+3730,Belgium,2014,6,A-Alimentary tract and metabolism,"/capita, US$ purchasing power parity",70.6
+3731,Belgium,2014,6,R-Respiratory system,"Million US$, purchasing power parity",631.7
+3732,Belgium,2014,6,R-Respiratory system,"/capita, US$ exchange rate",59.9
+3733,Belgium,2014,6,J-Antiinfectives for systemic use,% of total sales,9.7
+3734,Belgium,2014,6,C08-Calcium channel blockers,Million of national currency units,57.1
+3735,Belgium,2014,6,A-Alimentary tract and metabolism,% of total sales,10.6
+3736,Belgium,2014,6,J-Antiinfectives for systemic use,"/capita, US$ exchange rate",68.3
+3737,Belgium,2014,6,J-Antiinfectives for systemic use,"/capita, US$ purchasing power parity",64.3
+3738,Belgium,2014,6,A-Alimentary tract and metabolism,"Million US$, purchasing power parity",791.5
+3739,Belgium,2014,6,R-Respiratory system,Million of national currency units,505.5
+3740,Belgium,2014,6,A-Alimentary tract and metabolism,"/capita, US$ exchange rate",75.1
+3741,Belgium,2014,6,C-Cardiovascular system,Million of national currency units,724.2
+3742,Belgium,2014,6,A-Alimentary tract and metabolism,Million of national currency units,633.4
+3743,Belgium,2014,6,A-Alimentary tract and metabolism,Million US$ at exchange rate,841.4
+3744,Belgium,2014,6,C-Cardiovascular system,Million US$ at exchange rate,962.1
+3745,Belgium,2014,6,J-Antiinfectives for systemic use,Million US$ at exchange rate,765.8
+3746,Belgium,2014,6,J-Antiinfectives for systemic use,Million of national currency units,576.4
+3747,Belgium,2014,6,J-Antiinfectives for systemic use,"Million US$, purchasing power parity",720.3
+3748,Belgium,2014,6,C-Cardiovascular system,"Million US$, purchasing power parity",905.0
+3749,Belgium,2014,6,C-Cardiovascular system,"/capita, US$ exchange rate",85.8
+3750,Belgium,2014,6,J01-Antibacterials for systemic use,% of total sales,3.6
+3751,Belgium,2014,6,C08-Calcium channel blockers,Million US$ at exchange rate,75.9
+3752,Belgium,2014,6,C-Cardiovascular system,"/capita, US$ purchasing power parity",80.7
+3753,Belgium,2014,6,C08-Calcium channel blockers,"Million US$, purchasing power parity",71.4
+3754,Belgium,2014,6,J01-Antibacterials for systemic use,Million US$ at exchange rate,283.7
+3755,Belgium,2014,6,J01-Antibacterials for systemic use,"Million US$, purchasing power parity",266.9
+3756,Belgium,2014,6,J01-Antibacterials for systemic use,"/capita, US$ purchasing power parity",23.8
+3757,Belgium,2014,6,J01-Antibacterials for systemic use,"/capita, US$ exchange rate",25.3
+3758,Belgium,2014,6,C-Cardiovascular system,% of total sales,12.2
+3759,Belgium,2015,5,C03-Diuretics,Million US$ at exchange rate,37.2
+3760,Belgium,2015,5,C03-Diuretics,Million of national currency units,33.5
+3761,Belgium,2015,5,C03-Diuretics,"Million US$, purchasing power parity",41.9
+3762,Belgium,2015,5,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million of national currency units,126.9
+3763,Belgium,2015,5,"H-Systemic hormonal preparations, excluding sex hormones and insulins","Million US$, purchasing power parity",158.6
+3764,Belgium,2015,5,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million US$ at exchange rate,140.8
+3765,Belgium,2015,5,C03-Diuretics,"/capita, US$ exchange rate",3.3
+3766,Belgium,2015,5,N06A-Antidepressants,Million of national currency units,155.6
+3767,Belgium,2015,5,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ exchange rate",12.5
+3768,Belgium,2015,5,N06A-Antidepressants,Million US$ at exchange rate,172.7
+3769,Belgium,2015,5,C03-Diuretics,"/capita, US$ purchasing power parity",3.7
+3770,Belgium,2015,5,C03-Diuretics,% of total sales,0.5
+3771,Belgium,2015,5,N05C-Hypnotics and sedatives,Million of national currency units,78.0
+3772,Belgium,2015,5,G-Genito urinary system and sex hormones,"/capita, US$ purchasing power parity",24.9
+3773,Belgium,2015,5,N05C-Hypnotics and sedatives,Million US$ at exchange rate,86.6
+3774,Belgium,2015,5,C01A-Cardiac glycosides,Million US$ at exchange rate,1.1
+3775,Belgium,2015,5,G-Genito urinary system and sex hormones,% of total sales,3.6
+3776,Belgium,2015,5,C01A-Cardiac glycosides,Million of national currency units,1.0
+3777,Belgium,2015,5,N05C-Hypnotics and sedatives,"Million US$, purchasing power parity",97.6
+3778,Belgium,2015,5,G-Genito urinary system and sex hormones,"/capita, US$ exchange rate",22.1
+3779,Belgium,2015,5,G-Genito urinary system and sex hormones,"Million US$, purchasing power parity",280.9
+3780,Belgium,2015,5,G-Genito urinary system and sex hormones,Million US$ at exchange rate,249.3
+3781,Belgium,2015,5,N05C-Hypnotics and sedatives,"/capita, US$ exchange rate",7.7
+3782,Belgium,2015,5,N05C-Hypnotics and sedatives,% of total sales,1.3
+3783,Belgium,2015,5,N05C-Hypnotics and sedatives,"/capita, US$ purchasing power parity",8.7
+3784,Belgium,2015,5,C07-Beta blocking agents,% of total sales,1.4
+3785,Belgium,2015,5,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),% of total sales,2.5
+3786,Belgium,2015,5,C07-Beta blocking agents,"/capita, US$ purchasing power parity",9.7
+3787,Belgium,2015,5,C07-Beta blocking agents,"Million US$, purchasing power parity",109.2
+3788,Belgium,2015,5,C07-Beta blocking agents,Million US$ at exchange rate,96.9
+3789,Belgium,2015,5,C07-Beta blocking agents,"/capita, US$ exchange rate",8.6
+3790,Belgium,2015,5,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million of national currency units,154.7
+3791,Belgium,2015,5,G03-Sex hormones and modulators of the genital system,Million of national currency units,111.0
+3792,Belgium,2015,5,G-Genito urinary system and sex hormones,Million of national currency units,224.7
+3793,Belgium,2015,5,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million US$ at exchange rate,171.7
+3794,Belgium,2015,5,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ exchange rate",15.2
+3795,Belgium,2015,5,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ purchasing power parity",17.2
+3796,Belgium,2015,5,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"Million US$, purchasing power parity",193.4
+3797,Belgium,2015,5,M-Musculo-skeletal system,% of total sales,4.1
+3798,Belgium,2015,5,M-Musculo-skeletal system,"/capita, US$ exchange rate",25.2
+3799,Belgium,2015,5,M-Musculo-skeletal system,"/capita, US$ purchasing power parity",28.4
+3800,Belgium,2015,5,N06A-Antidepressants,"/capita, US$ exchange rate",15.3
+3801,Belgium,2015,5,N06A-Antidepressants,% of total sales,2.5
+3802,Belgium,2015,5,N06A-Antidepressants,"/capita, US$ purchasing power parity",17.3
+3803,Belgium,2015,5,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ purchasing power parity",14.1
+3804,Belgium,2015,5,"H-Systemic hormonal preparations, excluding sex hormones and insulins",% of total sales,2.0
+3805,Belgium,2015,5,C07-Beta blocking agents,Million of national currency units,87.3
+3806,Belgium,2015,5,N06A-Antidepressants,"Million US$, purchasing power parity",194.5
+3807,Belgium,2015,5,M-Musculo-skeletal system,"Million US$, purchasing power parity",320.4
+3808,Belgium,2015,5,M-Musculo-skeletal system,Million of national currency units,256.3
+3809,Belgium,2015,5,M-Musculo-skeletal system,Million US$ at exchange rate,284.4
+3810,Belgium,2015,5,G03-Sex hormones and modulators of the genital system,"Million US$, purchasing power parity",138.8
+3811,Belgium,2015,5,"C01B-Antiarrhythmics, Class I and III","Million US$, purchasing power parity",19.1
+3812,Belgium,2015,5,"C01B-Antiarrhythmics, Class I and III","/capita, US$ purchasing power parity",1.7
+3813,Belgium,2015,5,"C01B-Antiarrhythmics, Class I and III","/capita, US$ exchange rate",1.5
+3814,Belgium,2015,5,"C01B-Antiarrhythmics, Class I and III",Million US$ at exchange rate,16.9
+3815,Belgium,2015,5,G03-Sex hormones and modulators of the genital system,% of total sales,1.8
+3816,Belgium,2015,5,G03-Sex hormones and modulators of the genital system,"/capita, US$ purchasing power parity",12.3
+3817,Belgium,2015,5,"C01B-Antiarrhythmics, Class I and III",Million of national currency units,15.3
+3818,Belgium,2015,5,N02-Analgesics,"/capita, US$ exchange rate",23.6
+3819,Belgium,2015,5,N02-Analgesics,% of total sales,3.9
+3820,Belgium,2015,5,N02-Analgesics,"/capita, US$ purchasing power parity",26.6
+3821,Belgium,2015,5,N02-Analgesics,"Million US$, purchasing power parity",299.9
+3822,Belgium,2015,5,"C01B-Antiarrhythmics, Class I and III",% of total sales,0.2
+3823,Belgium,2015,5,N02-Analgesics,Million of national currency units,239.9
+3824,Belgium,2015,5,N02-Analgesics,Million US$ at exchange rate,266.2
+3825,Belgium,2015,5,Total pharmaceutical sales,"/capita, US$ purchasing power parity",686.5
+3826,Belgium,2015,5,G03-Sex hormones and modulators of the genital system,"/capita, US$ exchange rate",10.9
+3827,Belgium,2015,5,Total pharmaceutical sales,"/capita, US$ exchange rate",609.3
+3828,Belgium,2015,5,Total pharmaceutical sales,Million US$ at exchange rate,6869.7
+3829,Belgium,2015,5,Total pharmaceutical sales,Million of national currency units,6191.6
+3830,Belgium,2015,5,Total pharmaceutical sales,"Million US$, purchasing power parity",7739.6
+3831,Belgium,2015,5,N-Nervous system,% of total sales,15.2
+3832,Belgium,2015,5,A10-Drugs used in diabetes,"Million US$, purchasing power parity",223.5
+3833,Belgium,2015,5,A10-Drugs used in diabetes,Million of national currency units,178.8
+3834,Belgium,2015,5,A10-Drugs used in diabetes,Million US$ at exchange rate,198.4
+3835,Belgium,2015,5,A10-Drugs used in diabetes,"/capita, US$ exchange rate",17.6
+3836,Belgium,2015,5,A10-Drugs used in diabetes,% of total sales,2.9
+3837,Belgium,2015,5,A10-Drugs used in diabetes,"/capita, US$ purchasing power parity",19.8
+3838,Belgium,2015,5,M01A-Antiinflammatory and antirheumatic products non-steroids,% of total sales,1.8
+3839,Belgium,2015,5,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ exchange rate",10.8
+3840,Belgium,2015,5,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ purchasing power parity",12.2
+3841,Belgium,2015,5,N05B-Anxiolytics,% of total sales,1.1
+3842,Belgium,2015,5,N05B-Anxiolytics,"/capita, US$ exchange rate",6.9
+3843,Belgium,2015,5,N05B-Anxiolytics,"Million US$, purchasing power parity",87.1
+3844,Belgium,2015,5,N05B-Anxiolytics,"/capita, US$ purchasing power parity",7.7
+3845,Belgium,2015,5,C01A-Cardiac glycosides,"/capita, US$ purchasing power parity",0.1
+3846,Belgium,2015,5,C01A-Cardiac glycosides,% of total sales,0.0
+3847,Belgium,2015,5,C01A-Cardiac glycosides,"Million US$, purchasing power parity",1.2
+3848,Belgium,2015,5,C01A-Cardiac glycosides,"/capita, US$ exchange rate",0.1
+3849,Belgium,2015,5,M01A-Antiinflammatory and antirheumatic products non-steroids,"Million US$, purchasing power parity",137.2
+3850,Belgium,2015,5,M01A-Antiinflammatory and antirheumatic products non-steroids,Million of national currency units,109.7
+3851,Belgium,2015,5,M01A-Antiinflammatory and antirheumatic products non-steroids,Million US$ at exchange rate,121.7
+3852,Belgium,2015,5,N-Nervous system,Million of national currency units,940.8
+3853,Belgium,2015,5,C02-Antihypertensives,Million of national currency units,24.3
+3854,Belgium,2015,5,N-Nervous system,"/capita, US$ exchange rate",92.6
+3855,Belgium,2015,5,N-Nervous system,"/capita, US$ purchasing power parity",104.3
+3856,Belgium,2015,5,N-Nervous system,Million US$ at exchange rate,1043.8
+3857,Belgium,2015,5,N-Nervous system,"Million US$, purchasing power parity",1176.0
+3858,Belgium,2015,5,C02-Antihypertensives,Million US$ at exchange rate,27.0
+3859,Belgium,2015,5,C02-Antihypertensives,% of total sales,0.4
+3860,Belgium,2015,5,N05B-Anxiolytics,Million US$ at exchange rate,77.3
+3861,Belgium,2015,5,N05B-Anxiolytics,Million of national currency units,69.7
+3862,Belgium,2015,5,G03-Sex hormones and modulators of the genital system,Million US$ at exchange rate,123.2
+3863,Belgium,2015,5,C02-Antihypertensives,"Million US$, purchasing power parity",30.4
+3864,Belgium,2015,5,C02-Antihypertensives,"/capita, US$ purchasing power parity",2.7
+3865,Belgium,2015,5,C02-Antihypertensives,"/capita, US$ exchange rate",2.4
+3866,Belgium,2015,5,R03-Drugs for obstructive airway diseases,Million US$ at exchange rate,274.9
+3867,Belgium,2015,5,R03-Drugs for obstructive airway diseases,"Million US$, purchasing power parity",309.7
+3868,Belgium,2015,5,R03-Drugs for obstructive airway diseases,"/capita, US$ exchange rate",24.4
+3869,Belgium,2015,5,J01-Antibacterials for systemic use,Million of national currency units,215.7
+3870,Belgium,2015,5,R03-Drugs for obstructive airway diseases,Million of national currency units,247.8
+3871,Belgium,2015,5,A02A-Antacids,"/capita, US$ purchasing power parity",1.1
+3872,Belgium,2015,5,A02A-Antacids,"/capita, US$ exchange rate",1.0
+3873,Belgium,2015,5,R03-Drugs for obstructive airway diseases,"/capita, US$ purchasing power parity",27.5
+3874,Belgium,2015,5,R03-Drugs for obstructive airway diseases,% of total sales,4.0
+3875,Belgium,2015,5,C08-Calcium channel blockers,% of total sales,0.8
+3876,Belgium,2015,5,C10-Lipid modifying agents,"/capita, US$ purchasing power parity",24.4
+3877,Belgium,2015,5,C08-Calcium channel blockers,"/capita, US$ exchange rate",4.8
+3878,Belgium,2015,5,C08-Calcium channel blockers,"/capita, US$ purchasing power parity",5.4
+3879,Belgium,2015,5,A02A-Antacids,Million US$ at exchange rate,11.1
+3880,Belgium,2015,5,A02A-Antacids,"Million US$, purchasing power parity",12.5
+3881,Belgium,2015,5,C10-Lipid modifying agents,Million US$ at exchange rate,243.8
+3882,Belgium,2015,5,A02A-Antacids,Million of national currency units,10.0
+3883,Belgium,2015,5,C10-Lipid modifying agents,"/capita, US$ exchange rate",21.6
+3884,Belgium,2015,5,C10-Lipid modifying agents,"Million US$, purchasing power parity",274.7
+3885,Belgium,2015,5,C09-Agents acting on the Renin-Angiotensin system,Million of national currency units,196.5
+3886,Belgium,2015,5,A02A-Antacids,% of total sales,0.2
+3887,Belgium,2015,5,Products not elsewhere classified,"/capita, US$ purchasing power parity",173.0
+3888,Belgium,2015,5,Products not elsewhere classified,"/capita, US$ exchange rate",153.6
+3889,Belgium,2015,5,B-Blood and blood forming organs,"/capita, US$ exchange rate",51.4
+3890,Belgium,2015,5,Products not elsewhere classified,% of total sales,25.2
+3891,Belgium,2015,5,Products not elsewhere classified,Million of national currency units,1560.4
+3892,Belgium,2015,5,Products not elsewhere classified,Million US$ at exchange rate,1731.3
+3893,Belgium,2015,5,C10-Lipid modifying agents,Million of national currency units,219.7
+3894,Belgium,2015,5,Products not elsewhere classified,"Million US$, purchasing power parity",1950.5
+3895,Belgium,2015,5,C10-Lipid modifying agents,% of total sales,3.5
+3896,Belgium,2015,5,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ exchange rate",19.3
+3897,Belgium,2015,5,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ purchasing power parity",21.8
+3898,Belgium,2015,5,C09-Agents acting on the Renin-Angiotensin system,% of total sales,3.2
+3899,Belgium,2015,5,C09-Agents acting on the Renin-Angiotensin system,Million US$ at exchange rate,218.0
+3900,Belgium,2015,5,C09-Agents acting on the Renin-Angiotensin system,"Million US$, purchasing power parity",245.6
+3901,Belgium,2015,5,B-Blood and blood forming organs,% of total sales,8.4
+3902,Belgium,2015,5,B-Blood and blood forming organs,"/capita, US$ purchasing power parity",58.0
+3903,Belgium,2015,5,B-Blood and blood forming organs,"Million US$, purchasing power parity",653.4
+3904,Belgium,2015,5,B-Blood and blood forming organs,Million of national currency units,522.8
+3905,Belgium,2015,5,B-Blood and blood forming organs,Million US$ at exchange rate,580.0
+3906,Belgium,2015,5,C-Cardiovascular system,% of total sales,11.3
+3907,Belgium,2015,5,R-Respiratory system,"/capita, US$ purchasing power parity",58.3
+3908,Belgium,2015,5,R-Respiratory system,% of total sales,8.5
+3909,Belgium,2015,5,R-Respiratory system,Million US$ at exchange rate,583.5
+3910,Belgium,2015,5,R-Respiratory system,"/capita, US$ exchange rate",51.8
+3911,Belgium,2015,5,R-Respiratory system,"Million US$, purchasing power parity",657.4
+3912,Belgium,2015,5,J-Antiinfectives for systemic use,% of total sales,11.0
+3913,Belgium,2015,5,C08-Calcium channel blockers,Million of national currency units,48.6
+3914,Belgium,2015,5,A-Alimentary tract and metabolism,% of total sales,10.5
+3915,Belgium,2015,5,J-Antiinfectives for systemic use,"/capita, US$ exchange rate",67.0
+3916,Belgium,2015,5,J-Antiinfectives for systemic use,"/capita, US$ purchasing power parity",75.5
+3917,Belgium,2015,5,A-Alimentary tract and metabolism,"/capita, US$ purchasing power parity",72.2
+3918,Belgium,2015,5,A-Alimentary tract and metabolism,"Million US$, purchasing power parity",814.2
+3919,Belgium,2015,5,R-Respiratory system,Million of national currency units,525.9
+3920,Belgium,2015,5,A-Alimentary tract and metabolism,"/capita, US$ exchange rate",64.1
+3921,Belgium,2015,5,C-Cardiovascular system,Million of national currency units,701.7
+3922,Belgium,2015,5,A-Alimentary tract and metabolism,Million US$ at exchange rate,722.7
+3923,Belgium,2015,5,A-Alimentary tract and metabolism,Million of national currency units,651.4
+3924,Belgium,2015,5,J-Antiinfectives for systemic use,Million US$ at exchange rate,755.4
+3925,Belgium,2015,5,J-Antiinfectives for systemic use,Million of national currency units,680.8
+3926,Belgium,2015,5,J-Antiinfectives for systemic use,"Million US$, purchasing power parity",851.0
+3927,Belgium,2015,5,C-Cardiovascular system,"Million US$, purchasing power parity",877.1
+3928,Belgium,2015,5,C-Cardiovascular system,Million US$ at exchange rate,778.5
+3929,Belgium,2015,5,C-Cardiovascular system,"/capita, US$ exchange rate",69.1
+3930,Belgium,2015,5,C08-Calcium channel blockers,Million US$ at exchange rate,53.9
+3931,Belgium,2015,5,J01-Antibacterials for systemic use,% of total sales,3.5
+3932,Belgium,2015,5,C08-Calcium channel blockers,"Million US$, purchasing power parity",60.7
+3933,Belgium,2015,5,J01-Antibacterials for systemic use,"Million US$, purchasing power parity",269.6
+3934,Belgium,2015,5,J01-Antibacterials for systemic use,Million US$ at exchange rate,239.3
+3935,Belgium,2015,5,C-Cardiovascular system,"/capita, US$ purchasing power parity",77.8
+3936,Belgium,2015,5,J01-Antibacterials for systemic use,"/capita, US$ purchasing power parity",23.9
+3937,Belgium,2015,5,J01-Antibacterials for systemic use,"/capita, US$ exchange rate",21.2
+3938,Belgium,2013,6,C03-Diuretics,Million US$ at exchange rate,46.8
+3939,Belgium,2013,6,C03-Diuretics,"/capita, US$ exchange rate",4.2
+3940,Belgium,2013,6,C03-Diuretics,"Million US$, purchasing power parity",43.7
+3941,Belgium,2013,6,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million of national currency units,124.8
+3942,Belgium,2013,6,C03-Diuretics,Million of national currency units,35.2
+3943,Belgium,2013,6,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million US$ at exchange rate,165.8
+3944,Belgium,2013,6,"H-Systemic hormonal preparations, excluding sex hormones and insulins","Million US$, purchasing power parity",154.8
+3945,Belgium,2013,6,N06A-Antidepressants,Million of national currency units,181.3
+3946,Belgium,2013,6,N06A-Antidepressants,Million US$ at exchange rate,240.8
+3947,Belgium,2013,6,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ exchange rate",14.9
+3948,Belgium,2013,6,C03-Diuretics,"/capita, US$ purchasing power parity",3.9
+3949,Belgium,2013,6,G-Genito urinary system and sex hormones,Million US$ at exchange rate,308.1
+3950,Belgium,2013,6,C03-Diuretics,% of total sales,0.6
+3951,Belgium,2013,6,N05C-Hypnotics and sedatives,Million of national currency units,75.4
+3952,Belgium,2013,6,G-Genito urinary system and sex hormones,"/capita, US$ purchasing power parity",25.8
+3953,Belgium,2013,6,N05C-Hypnotics and sedatives,Million US$ at exchange rate,100.2
+3954,Belgium,2013,6,C01A-Cardiac glycosides,Million US$ at exchange rate,1.6
+3955,Belgium,2013,6,N05C-Hypnotics and sedatives,"Million US$, purchasing power parity",93.6
+3956,Belgium,2013,6,G-Genito urinary system and sex hormones,% of total sales,3.9
+3957,Belgium,2013,6,C01A-Cardiac glycosides,Million of national currency units,1.2
+3958,Belgium,2013,6,G-Genito urinary system and sex hormones,"/capita, US$ exchange rate",27.6
+3959,Belgium,2013,6,N06A-Antidepressants,"Million US$, purchasing power parity",224.9
+3960,Belgium,2013,6,G-Genito urinary system and sex hormones,"Million US$, purchasing power parity",287.7
+3961,Belgium,2013,6,N05C-Hypnotics and sedatives,"/capita, US$ exchange rate",9.0
+3962,Belgium,2013,6,N05C-Hypnotics and sedatives,% of total sales,1.3
+3963,Belgium,2013,6,N05C-Hypnotics and sedatives,"/capita, US$ purchasing power parity",8.4
+3964,Belgium,2013,6,C07-Beta blocking agents,% of total sales,1.6
+3965,Belgium,2013,6,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),% of total sales,2.4
+3966,Belgium,2013,6,C07-Beta blocking agents,"/capita, US$ purchasing power parity",10.8
+3967,Belgium,2013,6,C07-Beta blocking agents,"Million US$, purchasing power parity",120.4
+3968,Belgium,2013,6,C07-Beta blocking agents,"/capita, US$ exchange rate",11.6
+3969,Belgium,2013,6,C07-Beta blocking agents,Million US$ at exchange rate,128.9
+3970,Belgium,2013,6,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million of national currency units,142.9
+3971,Belgium,2013,6,G03-Sex hormones and modulators of the genital system,Million of national currency units,118.0
+3972,Belgium,2013,6,G-Genito urinary system and sex hormones,Million of national currency units,232.0
+3973,Belgium,2013,6,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million US$ at exchange rate,189.8
+3974,Belgium,2013,6,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ exchange rate",17.0
+3975,Belgium,2013,6,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ purchasing power parity",15.9
+3976,Belgium,2013,6,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"Million US$, purchasing power parity",177.2
+3977,Belgium,2013,6,M-Musculo-skeletal system,% of total sales,4.2
+3978,Belgium,2013,6,M-Musculo-skeletal system,"/capita, US$ purchasing power parity",28.0
+3979,Belgium,2013,6,N06A-Antidepressants,"/capita, US$ exchange rate",21.6
+3980,Belgium,2013,6,N06A-Antidepressants,% of total sales,3.0
+3981,Belgium,2013,6,N06A-Antidepressants,"/capita, US$ purchasing power parity",20.2
+3982,Belgium,2013,6,M-Musculo-skeletal system,"/capita, US$ exchange rate",30.0
+3983,Belgium,2013,6,"H-Systemic hormonal preparations, excluding sex hormones and insulins",% of total sales,2.1
+3984,Belgium,2013,6,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ purchasing power parity",13.9
+3985,Belgium,2013,6,C07-Beta blocking agents,Million of national currency units,97.1
+3986,Belgium,2013,6,M-Musculo-skeletal system,"Million US$, purchasing power parity",312.5
+3987,Belgium,2013,6,M-Musculo-skeletal system,Million of national currency units,251.9
+3988,Belgium,2013,6,M-Musculo-skeletal system,Million US$ at exchange rate,334.6
+3989,Belgium,2013,6,"C01B-Antiarrhythmics, Class I and III","Million US$, purchasing power parity",19.1
+3990,Belgium,2013,6,"C01B-Antiarrhythmics, Class I and III","/capita, US$ purchasing power parity",1.7
+3991,Belgium,2013,6,"C01B-Antiarrhythmics, Class I and III","/capita, US$ exchange rate",1.8
+3992,Belgium,2013,6,G03-Sex hormones and modulators of the genital system,% of total sales,2.0
+3993,Belgium,2013,6,G03-Sex hormones and modulators of the genital system,"/capita, US$ purchasing power parity",13.1
+3994,Belgium,2013,6,"C01B-Antiarrhythmics, Class I and III",Million of national currency units,15.4
+3995,Belgium,2013,6,"C01B-Antiarrhythmics, Class I and III",Million US$ at exchange rate,20.5
+3996,Belgium,2013,6,N02-Analgesics,"/capita, US$ exchange rate",29.2
+3997,Belgium,2013,6,N02-Analgesics,% of total sales,4.1
+3998,Belgium,2013,6,N02-Analgesics,"/capita, US$ purchasing power parity",27.3
+3999,Belgium,2013,6,N02-Analgesics,"Million US$, purchasing power parity",304.5
+4000,Belgium,2013,6,N02-Analgesics,Million of national currency units,245.5
+4001,Belgium,2013,6,"C01B-Antiarrhythmics, Class I and III",% of total sales,0.3
+4002,Belgium,2013,6,N02-Analgesics,Million US$ at exchange rate,326.1
+4003,Belgium,2013,6,Total pharmaceutical sales,"/capita, US$ purchasing power parity",661.1
+4004,Belgium,2013,6,G03-Sex hormones and modulators of the genital system,"/capita, US$ exchange rate",14.0
+4005,Belgium,2013,6,Total pharmaceutical sales,"/capita, US$ exchange rate",707.9
+4006,Belgium,2013,6,Total pharmaceutical sales,Million US$ at exchange rate,7899.5
+4007,Belgium,2013,6,Total pharmaceutical sales,Million of national currency units,5947.9
+4008,Belgium,2013,6,Total pharmaceutical sales,"Million US$, purchasing power parity",7378.0
+4009,Belgium,2013,6,N-Nervous system,% of total sales,16.5
+4010,Belgium,2013,6,A10-Drugs used in diabetes,"Million US$, purchasing power parity",202.5
+4011,Belgium,2013,6,A10-Drugs used in diabetes,Million of national currency units,163.2
+4012,Belgium,2013,6,A10-Drugs used in diabetes,Million US$ at exchange rate,216.8
+4013,Belgium,2013,6,A10-Drugs used in diabetes,"/capita, US$ exchange rate",19.4
+4014,Belgium,2013,6,A10-Drugs used in diabetes,% of total sales,2.7
+4015,Belgium,2013,6,A10-Drugs used in diabetes,"/capita, US$ purchasing power parity",18.1
+4016,Belgium,2013,6,M01A-Antiinflammatory and antirheumatic products non-steroids,% of total sales,1.9
+4017,Belgium,2013,6,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ purchasing power parity",12.7
+4018,Belgium,2013,6,N05B-Anxiolytics,"/capita, US$ exchange rate",8.1
+4019,Belgium,2013,6,N05B-Anxiolytics,"Million US$, purchasing power parity",84.5
+4020,Belgium,2013,6,N05B-Anxiolytics,"/capita, US$ purchasing power parity",7.6
+4021,Belgium,2013,6,N05B-Anxiolytics,% of total sales,1.1
+4022,Belgium,2013,6,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ exchange rate",13.6
+4023,Belgium,2013,6,C01A-Cardiac glycosides,"/capita, US$ purchasing power parity",0.1
+4024,Belgium,2013,6,C01A-Cardiac glycosides,% of total sales,0.0
+4025,Belgium,2013,6,C01A-Cardiac glycosides,"/capita, US$ exchange rate",0.1
+4026,Belgium,2013,6,M01A-Antiinflammatory and antirheumatic products non-steroids,"Million US$, purchasing power parity",141.9
+4027,Belgium,2013,6,M01A-Antiinflammatory and antirheumatic products non-steroids,Million of national currency units,114.4
+4028,Belgium,2013,6,M01A-Antiinflammatory and antirheumatic products non-steroids,Million US$ at exchange rate,151.9
+4029,Belgium,2013,6,G03-Sex hormones and modulators of the genital system,"Million US$, purchasing power parity",146.4
+4030,Belgium,2013,6,N-Nervous system,Million of national currency units,978.6
+4031,Belgium,2013,6,C02-Antihypertensives,Million of national currency units,19.3
+4032,Belgium,2013,6,N-Nervous system,Million US$ at exchange rate,1299.7
+4033,Belgium,2013,6,N-Nervous system,"/capita, US$ exchange rate",116.5
+4034,Belgium,2013,6,N-Nervous system,"/capita, US$ purchasing power parity",108.8
+4035,Belgium,2013,6,N-Nervous system,"Million US$, purchasing power parity",1213.9
+4036,Belgium,2013,6,C01A-Cardiac glycosides,"Million US$, purchasing power parity",1.5
+4037,Belgium,2013,6,C02-Antihypertensives,Million US$ at exchange rate,25.7
+4038,Belgium,2013,6,C02-Antihypertensives,% of total sales,0.3
+4039,Belgium,2013,6,N05B-Anxiolytics,Million US$ at exchange rate,90.4
+4040,Belgium,2013,6,N05B-Anxiolytics,Million of national currency units,68.1
+4041,Belgium,2013,6,G03-Sex hormones and modulators of the genital system,Million US$ at exchange rate,156.7
+4042,Belgium,2013,6,C02-Antihypertensives,"Million US$, purchasing power parity",24.0
+4043,Belgium,2013,6,C02-Antihypertensives,"/capita, US$ purchasing power parity",2.1
+4044,Belgium,2013,6,C02-Antihypertensives,"/capita, US$ exchange rate",2.3
+4045,Belgium,2013,6,R03-Drugs for obstructive airway diseases,Million US$ at exchange rate,340.5
+4046,Belgium,2013,6,R03-Drugs for obstructive airway diseases,"Million US$, purchasing power parity",318.0
+4047,Belgium,2013,6,R03-Drugs for obstructive airway diseases,"/capita, US$ exchange rate",30.5
+4048,Belgium,2013,6,J01-Antibacterials for systemic use,Million of national currency units,218.9
+4049,Belgium,2013,6,R03-Drugs for obstructive airway diseases,Million of national currency units,256.4
+4050,Belgium,2013,6,A02A-Antacids,"/capita, US$ purchasing power parity",1.2
+4051,Belgium,2013,6,C09-Agents acting on the Renin-Angiotensin system,Million of national currency units,218.2
+4052,Belgium,2013,6,A02A-Antacids,"/capita, US$ exchange rate",1.3
+4053,Belgium,2013,6,R03-Drugs for obstructive airway diseases,"/capita, US$ purchasing power parity",28.5
+4054,Belgium,2013,6,R03-Drugs for obstructive airway diseases,% of total sales,4.3
+4055,Belgium,2013,6,C08-Calcium channel blockers,% of total sales,1.0
+4056,Belgium,2013,6,C08-Calcium channel blockers,"/capita, US$ exchange rate",6.9
+4057,Belgium,2013,6,C08-Calcium channel blockers,"/capita, US$ purchasing power parity",6.4
+4058,Belgium,2013,6,A02A-Antacids,Million US$ at exchange rate,14.7
+4059,Belgium,2013,6,A02A-Antacids,"Million US$, purchasing power parity",13.8
+4060,Belgium,2013,6,C10-Lipid modifying agents,Million US$ at exchange rate,337.2
+4061,Belgium,2013,6,C10-Lipid modifying agents,"/capita, US$ exchange rate",30.2
+4062,Belgium,2013,6,C10-Lipid modifying agents,"Million US$, purchasing power parity",314.9
+4063,Belgium,2013,6,A02A-Antacids,Million of national currency units,11.1
+4064,Belgium,2013,6,A02A-Antacids,% of total sales,0.2
+4065,Belgium,2013,6,Products not elsewhere classified,"/capita, US$ purchasing power parity",147.2
+4066,Belgium,2013,6,Products not elsewhere classified,"/capita, US$ exchange rate",157.7
+4067,Belgium,2013,6,B-Blood and blood forming organs,"/capita, US$ exchange rate",58.5
+4068,Belgium,2013,6,Products not elsewhere classified,% of total sales,22.3
+4069,Belgium,2013,6,Products not elsewhere classified,Million of national currency units,1324.7
+4070,Belgium,2013,6,Products not elsewhere classified,Million US$ at exchange rate,1759.4
+4071,Belgium,2013,6,C10-Lipid modifying agents,Million of national currency units,253.9
+4072,Belgium,2013,6,Products not elsewhere classified,"Million US$, purchasing power parity",1643.2
+4073,Belgium,2013,6,C10-Lipid modifying agents,% of total sales,4.3
+4074,Belgium,2013,6,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ exchange rate",26.0
+4075,Belgium,2013,6,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ purchasing power parity",24.2
+4076,Belgium,2013,6,C09-Agents acting on the Renin-Angiotensin system,% of total sales,3.7
+4077,Belgium,2013,6,C09-Agents acting on the Renin-Angiotensin system,Million US$ at exchange rate,289.7
+4078,Belgium,2013,6,C09-Agents acting on the Renin-Angiotensin system,"Million US$, purchasing power parity",270.6
+4079,Belgium,2013,6,B-Blood and blood forming organs,% of total sales,8.3
+4080,Belgium,2013,6,B-Blood and blood forming organs,"/capita, US$ purchasing power parity",54.6
+4081,Belgium,2013,6,B-Blood and blood forming organs,"Million US$, purchasing power parity",609.2
+4082,Belgium,2013,6,B-Blood and blood forming organs,Million of national currency units,491.1
+4083,Belgium,2013,6,B-Blood and blood forming organs,Million US$ at exchange rate,652.3
+4084,Belgium,2013,6,C10-Lipid modifying agents,"/capita, US$ purchasing power parity",28.2
+4085,Belgium,2013,6,R-Respiratory system,"/capita, US$ purchasing power parity",59.0
+4086,Belgium,2013,6,A-Alimentary tract and metabolism,"/capita, US$ purchasing power parity",72.2
+4087,Belgium,2013,6,R-Respiratory system,% of total sales,8.9
+4088,Belgium,2013,6,R-Respiratory system,Million US$ at exchange rate,705.1
+4089,Belgium,2013,6,R-Respiratory system,"/capita, US$ exchange rate",63.2
+4090,Belgium,2013,6,R-Respiratory system,"Million US$, purchasing power parity",658.5
+4091,Belgium,2013,6,J-Antiinfectives for systemic use,% of total sales,9.8
+4092,Belgium,2013,6,C08-Calcium channel blockers,Million of national currency units,57.9
+4093,Belgium,2013,6,A-Alimentary tract and metabolism,% of total sales,10.9
+4094,Belgium,2013,6,J-Antiinfectives for systemic use,"/capita, US$ exchange rate",69.2
+4095,Belgium,2013,6,J-Antiinfectives for systemic use,"/capita, US$ purchasing power parity",64.6
+4096,Belgium,2013,6,A-Alimentary tract and metabolism,"Million US$, purchasing power parity",805.9
+4097,Belgium,2013,6,R-Respiratory system,Million of national currency units,530.9
+4098,Belgium,2013,6,A-Alimentary tract and metabolism,"/capita, US$ exchange rate",77.3
+4099,Belgium,2013,6,C-Cardiovascular system,Million of national currency units,782.9
+4100,Belgium,2013,6,A-Alimentary tract and metabolism,Million US$ at exchange rate,862.9
+4101,Belgium,2013,6,A-Alimentary tract and metabolism,Million of national currency units,649.7
+4102,Belgium,2013,6,C-Cardiovascular system,Million US$ at exchange rate,1039.8
+4103,Belgium,2013,6,J-Antiinfectives for systemic use,Million US$ at exchange rate,772.0
+4104,Belgium,2013,6,J-Antiinfectives for systemic use,Million of national currency units,581.3
+4105,Belgium,2013,6,J-Antiinfectives for systemic use,"Million US$, purchasing power parity",721.0
+4106,Belgium,2013,6,C-Cardiovascular system,"Million US$, purchasing power parity",971.2
+4107,Belgium,2013,6,C-Cardiovascular system,"/capita, US$ exchange rate",93.2
+4108,Belgium,2013,6,J01-Antibacterials for systemic use,% of total sales,3.7
+4109,Belgium,2013,6,C08-Calcium channel blockers,Million US$ at exchange rate,76.9
+4110,Belgium,2013,6,C-Cardiovascular system,"/capita, US$ purchasing power parity",87.0
+4111,Belgium,2013,6,C08-Calcium channel blockers,"Million US$, purchasing power parity",71.8
+4112,Belgium,2013,6,J01-Antibacterials for systemic use,Million US$ at exchange rate,290.7
+4113,Belgium,2013,6,J01-Antibacterials for systemic use,"Million US$, purchasing power parity",271.5
+4114,Belgium,2013,6,J01-Antibacterials for systemic use,"/capita, US$ exchange rate",26.1
+4115,Belgium,2013,6,J01-Antibacterials for systemic use,"/capita, US$ purchasing power parity",24.3
+4116,Belgium,2013,6,C-Cardiovascular system,% of total sales,13.2
+4117,Belgium,2017,5,C03-Diuretics,Million US$ at exchange rate,37.1
+4118,Belgium,2017,5,C03-Diuretics,Million of national currency units,32.8
+4119,Belgium,2017,5,C03-Diuretics,"Million US$, purchasing power parity",42.3
+4120,Belgium,2017,5,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million of national currency units,128.1
+4121,Belgium,2017,5,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million US$ at exchange rate,144.7
+4122,Belgium,2017,5,C03-Diuretics,"/capita, US$ exchange rate",3.3
+4123,Belgium,2017,5,N06A-Antidepressants,Million of national currency units,125.3
+4124,Belgium,2017,5,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ exchange rate",12.7
+4125,Belgium,2017,5,N06A-Antidepressants,Million US$ at exchange rate,141.6
+4126,Belgium,2017,5,C03-Diuretics,"/capita, US$ purchasing power parity",3.7
+4127,Belgium,2017,5,"H-Systemic hormonal preparations, excluding sex hormones and insulins","Million US$, purchasing power parity",165.2
+4128,Belgium,2017,5,C03-Diuretics,% of total sales,0.5
+4129,Belgium,2017,5,N05C-Hypnotics and sedatives,Million of national currency units,77.2
+4130,Belgium,2017,5,G-Genito urinary system and sex hormones,"/capita, US$ purchasing power parity",25.3
+4131,Belgium,2017,5,N05C-Hypnotics and sedatives,Million US$ at exchange rate,87.2
+4132,Belgium,2017,5,C01A-Cardiac glycosides,Million US$ at exchange rate,1.0
+4133,Belgium,2017,5,G-Genito urinary system and sex hormones,% of total sales,3.4
+4134,Belgium,2017,5,C01A-Cardiac glycosides,Million of national currency units,0.8
+4135,Belgium,2017,5,G-Genito urinary system and sex hormones,"/capita, US$ exchange rate",22.2
+4136,Belgium,2017,5,G-Genito urinary system and sex hormones,Million US$ at exchange rate,252.5
+4137,Belgium,2017,5,G-Genito urinary system and sex hormones,"Million US$, purchasing power parity",288.2
+4138,Belgium,2017,5,N05C-Hypnotics and sedatives,"/capita, US$ exchange rate",7.7
+4139,Belgium,2017,5,N05C-Hypnotics and sedatives,"Million US$, purchasing power parity",99.5
+4140,Belgium,2017,5,N05C-Hypnotics and sedatives,% of total sales,1.2
+4141,Belgium,2017,5,N05C-Hypnotics and sedatives,"/capita, US$ purchasing power parity",8.7
+4142,Belgium,2017,5,C07-Beta blocking agents,% of total sales,1.3
+4143,Belgium,2017,5,C07-Beta blocking agents,"/capita, US$ purchasing power parity",9.4
+4144,Belgium,2017,5,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),% of total sales,2.4
+4145,Belgium,2017,5,C07-Beta blocking agents,"Million US$, purchasing power parity",106.6
+4146,Belgium,2017,5,C07-Beta blocking agents,Million US$ at exchange rate,93.4
+4147,Belgium,2017,5,C07-Beta blocking agents,"/capita, US$ exchange rate",8.2
+4148,Belgium,2017,5,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million of national currency units,155.3
+4149,Belgium,2017,5,G-Genito urinary system and sex hormones,Million of national currency units,223.5
+4150,Belgium,2017,5,G03-Sex hormones and modulators of the genital system,Million of national currency units,108.0
+4151,Belgium,2017,5,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ exchange rate",15.4
+4152,Belgium,2017,5,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ purchasing power parity",17.6
+4153,Belgium,2017,5,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million US$ at exchange rate,175.4
+4154,Belgium,2017,5,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"Million US$, purchasing power parity",200.2
+4155,Belgium,2017,5,M-Musculo-skeletal system,% of total sales,3.8
+4156,Belgium,2017,5,M-Musculo-skeletal system,"/capita, US$ exchange rate",24.6
+4157,Belgium,2017,5,M-Musculo-skeletal system,"/capita, US$ purchasing power parity",28.1
+4158,Belgium,2017,5,N06A-Antidepressants,% of total sales,1.9
+4159,Belgium,2017,5,N06A-Antidepressants,"/capita, US$ exchange rate",12.4
+4160,Belgium,2017,5,N06A-Antidepressants,"Million US$, purchasing power parity",161.5
+4161,Belgium,2017,5,N06A-Antidepressants,"/capita, US$ purchasing power parity",14.2
+4162,Belgium,2017,5,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ purchasing power parity",14.5
+4163,Belgium,2017,5,C07-Beta blocking agents,Million of national currency units,82.7
+4164,Belgium,2017,5,"H-Systemic hormonal preparations, excluding sex hormones and insulins",% of total sales,2.0
+4165,Belgium,2017,5,M-Musculo-skeletal system,"Million US$, purchasing power parity",319.3
+4166,Belgium,2017,5,M-Musculo-skeletal system,Million of national currency units,247.7
+4167,Belgium,2017,5,M-Musculo-skeletal system,Million US$ at exchange rate,279.8
+4168,Belgium,2017,5,"C01B-Antiarrhythmics, Class I and III","Million US$, purchasing power parity",19.2
+4169,Belgium,2017,5,"C01B-Antiarrhythmics, Class I and III",Million US$ at exchange rate,16.8
+4170,Belgium,2017,5,"C01B-Antiarrhythmics, Class I and III","/capita, US$ purchasing power parity",1.7
+4171,Belgium,2017,5,"C01B-Antiarrhythmics, Class I and III","/capita, US$ exchange rate",1.5
+4172,Belgium,2017,5,G03-Sex hormones and modulators of the genital system,"/capita, US$ purchasing power parity",12.2
+4173,Belgium,2017,5,G03-Sex hormones and modulators of the genital system,% of total sales,1.7
+4174,Belgium,2017,5,"C01B-Antiarrhythmics, Class I and III",Million of national currency units,14.9
+4175,Belgium,2017,5,N02-Analgesics,"/capita, US$ exchange rate",24.5
+4176,Belgium,2017,5,N02-Analgesics,"Million US$, purchasing power parity",318.0
+4177,Belgium,2017,5,N02-Analgesics,% of total sales,3.8
+4178,Belgium,2017,5,N02-Analgesics,"/capita, US$ purchasing power parity",28.0
+4179,Belgium,2017,5,"C01B-Antiarrhythmics, Class I and III",% of total sales,0.2
+4180,Belgium,2017,5,N02-Analgesics,Million US$ at exchange rate,278.6
+4181,Belgium,2017,5,N02-Analgesics,Million of national currency units,246.6
+4182,Belgium,2017,5,Total pharmaceutical sales,"/capita, US$ purchasing power parity",741.6
+4183,Belgium,2017,5,Total pharmaceutical sales,"/capita, US$ exchange rate",649.8
+4184,Belgium,2017,5,G03-Sex hormones and modulators of the genital system,"Million US$, purchasing power parity",139.2
+4185,Belgium,2017,5,N-Nervous system,% of total sales,13.8
+4186,Belgium,2017,5,G03-Sex hormones and modulators of the genital system,"/capita, US$ exchange rate",10.7
+4187,Belgium,2017,5,Total pharmaceutical sales,Million of national currency units,6543.2
+4188,Belgium,2017,5,Total pharmaceutical sales,Million US$ at exchange rate,7391.7
+4189,Belgium,2017,5,Total pharmaceutical sales,"Million US$, purchasing power parity",8435.9
+4190,Belgium,2017,5,A10-Drugs used in diabetes,"Million US$, purchasing power parity",259.9
+4191,Belgium,2017,5,A10-Drugs used in diabetes,Million US$ at exchange rate,227.8
+4192,Belgium,2017,5,A10-Drugs used in diabetes,Million of national currency units,201.6
+4193,Belgium,2017,5,A10-Drugs used in diabetes,% of total sales,3.1
+4194,Belgium,2017,5,N-Nervous system,"/capita, US$ purchasing power parity",102.1
+4195,Belgium,2017,5,A10-Drugs used in diabetes,"/capita, US$ exchange rate",20.0
+4196,Belgium,2017,5,A10-Drugs used in diabetes,"/capita, US$ purchasing power parity",22.9
+4197,Belgium,2017,5,M01A-Antiinflammatory and antirheumatic products non-steroids,% of total sales,1.6
+4198,Belgium,2017,5,N05B-Anxiolytics,% of total sales,1.1
+4199,Belgium,2017,5,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ exchange rate",10.4
+4200,Belgium,2017,5,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ purchasing power parity",11.8
+4201,Belgium,2017,5,N05B-Anxiolytics,"Million US$, purchasing power parity",88.7
+4202,Belgium,2017,5,N05B-Anxiolytics,"/capita, US$ exchange rate",6.8
+4203,Belgium,2017,5,N05B-Anxiolytics,"/capita, US$ purchasing power parity",7.8
+4204,Belgium,2017,5,C01A-Cardiac glycosides,"/capita, US$ purchasing power parity",0.1
+4205,Belgium,2017,5,C01A-Cardiac glycosides,"Million US$, purchasing power parity",1.1
+4206,Belgium,2017,5,C01A-Cardiac glycosides,"/capita, US$ exchange rate",0.1
+4207,Belgium,2017,5,C01A-Cardiac glycosides,% of total sales,0.0
+4208,Belgium,2017,5,M01A-Antiinflammatory and antirheumatic products non-steroids,"Million US$, purchasing power parity",134.8
+4209,Belgium,2017,5,M01A-Antiinflammatory and antirheumatic products non-steroids,Million US$ at exchange rate,118.1
+4210,Belgium,2017,5,M01A-Antiinflammatory and antirheumatic products non-steroids,Million of national currency units,104.5
+4211,Belgium,2017,5,N-Nervous system,Million of national currency units,901.0
+4212,Belgium,2017,5,C02-Antihypertensives,Million of national currency units,26.1
+4213,Belgium,2017,5,G03-Sex hormones and modulators of the genital system,Million US$ at exchange rate,122.0
+4214,Belgium,2017,5,N-Nervous system,"/capita, US$ exchange rate",89.5
+4215,Belgium,2017,5,N-Nervous system,Million US$ at exchange rate,1017.8
+4216,Belgium,2017,5,N-Nervous system,"Million US$, purchasing power parity",1161.6
+4217,Belgium,2017,5,C02-Antihypertensives,% of total sales,0.4
+4218,Belgium,2017,5,N05B-Anxiolytics,Million US$ at exchange rate,77.7
+4219,Belgium,2017,5,N05B-Anxiolytics,Million of national currency units,68.8
+4220,Belgium,2017,5,C02-Antihypertensives,"Million US$, purchasing power parity",33.6
+4221,Belgium,2017,5,C02-Antihypertensives,Million US$ at exchange rate,29.5
+4222,Belgium,2017,5,C02-Antihypertensives,"/capita, US$ purchasing power parity",3.0
+4223,Belgium,2017,5,C02-Antihypertensives,"/capita, US$ exchange rate",2.6
+4224,Belgium,2017,5,R03-Drugs for obstructive airway diseases,Million US$ at exchange rate,283.9
+4225,Belgium,2017,5,R03-Drugs for obstructive airway diseases,"Million US$, purchasing power parity",324.0
+4226,Belgium,2017,5,J01-Antibacterials for systemic use,Million of national currency units,189.6
+4227,Belgium,2017,5,A02A-Antacids,"Million US$, purchasing power parity",12.3
+4228,Belgium,2017,5,R03-Drugs for obstructive airway diseases,Million of national currency units,251.3
+4229,Belgium,2017,5,R03-Drugs for obstructive airway diseases,"/capita, US$ exchange rate",25.0
+4230,Belgium,2017,5,A02A-Antacids,"/capita, US$ exchange rate",0.9
+4231,Belgium,2017,5,A02A-Antacids,"/capita, US$ purchasing power parity",1.1
+4232,Belgium,2017,5,R03-Drugs for obstructive airway diseases,"/capita, US$ purchasing power parity",28.5
+4233,Belgium,2017,5,R03-Drugs for obstructive airway diseases,% of total sales,3.8
+4234,Belgium,2017,5,C08-Calcium channel blockers,% of total sales,0.7
+4235,Belgium,2017,5,C10-Lipid modifying agents,"/capita, US$ purchasing power parity",24.1
+4236,Belgium,2017,5,C08-Calcium channel blockers,"/capita, US$ purchasing power parity",4.9
+4237,Belgium,2017,5,C08-Calcium channel blockers,"/capita, US$ exchange rate",4.3
+4238,Belgium,2017,5,A02A-Antacids,Million US$ at exchange rate,10.8
+4239,Belgium,2017,5,C10-Lipid modifying agents,Million US$ at exchange rate,240.3
+4240,Belgium,2017,5,A02A-Antacids,Million of national currency units,9.5
+4241,Belgium,2017,5,C10-Lipid modifying agents,"/capita, US$ exchange rate",21.1
+4242,Belgium,2017,5,C10-Lipid modifying agents,"Million US$, purchasing power parity",274.2
+4243,Belgium,2017,5,C09-Agents acting on the Renin-Angiotensin system,Million of national currency units,175.5
+4244,Belgium,2017,5,A02A-Antacids,% of total sales,0.1
+4245,Belgium,2017,5,Products not elsewhere classified,"/capita, US$ purchasing power parity",216.6
+4246,Belgium,2017,5,Products not elsewhere classified,"/capita, US$ exchange rate",189.8
+4247,Belgium,2017,5,B-Blood and blood forming organs,"/capita, US$ exchange rate",59.1
+4248,Belgium,2017,5,Products not elsewhere classified,% of total sales,29.2
+4249,Belgium,2017,5,C10-Lipid modifying agents,Million of national currency units,212.7
+4250,Belgium,2017,5,Products not elsewhere classified,Million of national currency units,1910.8
+4251,Belgium,2017,5,Products not elsewhere classified,Million US$ at exchange rate,2158.6
+4252,Belgium,2017,5,Products not elsewhere classified,"Million US$, purchasing power parity",2463.6
+4253,Belgium,2017,5,C10-Lipid modifying agents,% of total sales,3.3
+4254,Belgium,2017,5,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ exchange rate",17.4
+4255,Belgium,2017,5,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ purchasing power parity",19.9
+4256,Belgium,2017,5,C09-Agents acting on the Renin-Angiotensin system,Million US$ at exchange rate,198.3
+4257,Belgium,2017,5,C09-Agents acting on the Renin-Angiotensin system,"Million US$, purchasing power parity",226.3
+4258,Belgium,2017,5,C09-Agents acting on the Renin-Angiotensin system,% of total sales,2.7
+4259,Belgium,2017,5,B-Blood and blood forming organs,"Million US$, purchasing power parity",767.1
+4260,Belgium,2017,5,B-Blood and blood forming organs,% of total sales,9.1
+4261,Belgium,2017,5,B-Blood and blood forming organs,"/capita, US$ purchasing power parity",67.4
+4262,Belgium,2017,5,B-Blood and blood forming organs,Million of national currency units,595.0
+4263,Belgium,2017,5,B-Blood and blood forming organs,Million US$ at exchange rate,672.1
+4264,Belgium,2017,5,C-Cardiovascular system,% of total sales,10.0
+4265,Belgium,2017,5,R-Respiratory system,"/capita, US$ purchasing power parity",57.8
+4266,Belgium,2017,5,R-Respiratory system,% of total sales,7.8
+4267,Belgium,2017,5,R-Respiratory system,"/capita, US$ exchange rate",50.6
+4268,Belgium,2017,5,R-Respiratory system,Million US$ at exchange rate,575.9
+4269,Belgium,2017,5,R-Respiratory system,"Million US$, purchasing power parity",657.2
+4270,Belgium,2017,5,A-Alimentary tract and metabolism,% of total sales,10.7
+4271,Belgium,2017,5,J-Antiinfectives for systemic use,% of total sales,10.3
+4272,Belgium,2017,5,C08-Calcium channel blockers,Million of national currency units,43.1
+4273,Belgium,2017,5,J-Antiinfectives for systemic use,"/capita, US$ exchange rate",66.9
+4274,Belgium,2017,5,A-Alimentary tract and metabolism,"/capita, US$ purchasing power parity",79.1
+4275,Belgium,2017,5,J-Antiinfectives for systemic use,"/capita, US$ purchasing power parity",76.4
+4276,Belgium,2017,5,A-Alimentary tract and metabolism,"Million US$, purchasing power parity",899.3
+4277,Belgium,2017,5,A-Alimentary tract and metabolism,"/capita, US$ exchange rate",69.3
+4278,Belgium,2017,5,A-Alimentary tract and metabolism,Million US$ at exchange rate,788.0
+4279,Belgium,2017,5,C-Cardiovascular system,Million of national currency units,655.8
+4280,Belgium,2017,5,A-Alimentary tract and metabolism,Million of national currency units,697.5
+4281,Belgium,2017,5,J-Antiinfectives for systemic use,Million of national currency units,674.1
+4282,Belgium,2017,5,J-Antiinfectives for systemic use,Million US$ at exchange rate,761.5
+4283,Belgium,2017,5,R-Respiratory system,Million of national currency units,509.8
+4284,Belgium,2017,5,J-Antiinfectives for systemic use,"Million US$, purchasing power parity",869.1
+4285,Belgium,2017,5,C-Cardiovascular system,Million US$ at exchange rate,740.9
+4286,Belgium,2017,5,C-Cardiovascular system,"Million US$, purchasing power parity",845.5
+4287,Belgium,2017,5,C-Cardiovascular system,"/capita, US$ exchange rate",65.1
+4288,Belgium,2017,5,C08-Calcium channel blockers,Million US$ at exchange rate,48.7
+4289,Belgium,2017,5,J01-Antibacterials for systemic use,% of total sales,2.9
+4290,Belgium,2017,5,C08-Calcium channel blockers,"Million US$, purchasing power parity",55.6
+4291,Belgium,2017,5,J01-Antibacterials for systemic use,"Million US$, purchasing power parity",244.4
+4292,Belgium,2017,5,J01-Antibacterials for systemic use,Million US$ at exchange rate,214.2
+4293,Belgium,2017,5,J01-Antibacterials for systemic use,"/capita, US$ purchasing power parity",21.5
+4294,Belgium,2017,5,J01-Antibacterials for systemic use,"/capita, US$ exchange rate",18.8
+4295,Belgium,2017,5,C-Cardiovascular system,"/capita, US$ purchasing power parity",74.3
+4296,Canada,2017,10,C-Cardiovascular system,Million of national currency units,3999.3
+4297,Canada,2017,10,N-Nervous system,"/capita, US$ purchasing power parity",128.8
+4298,Canada,2017,10,C-Cardiovascular system,"Million US$, purchasing power parity",3298.9
+4299,Canada,2017,10,C-Cardiovascular system,Million US$ at exchange rate,3081.3
+4300,Canada,2017,10,"C01B-Antiarrhythmics, Class I and III",Million US$ at exchange rate,22.7
+4301,Canada,2017,10,N-Nervous system,% of total sales,19.2
+4302,Canada,2017,10,"C01B-Antiarrhythmics, Class I and III","/capita, US$ purchasing power parity",0.7
+4303,Canada,2017,10,"C01B-Antiarrhythmics, Class I and III","/capita, US$ exchange rate",0.6
+4304,Canada,2017,10,"C01B-Antiarrhythmics, Class I and III","Million US$, purchasing power parity",24.3
+4305,Canada,2017,10,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ purchasing power parity",7.0
+4306,Canada,2017,10,G03-Sex hormones and modulators of the genital system,% of total sales,2.7
+4307,Canada,2017,10,G03-Sex hormones and modulators of the genital system,"/capita, US$ purchasing power parity",18.4
+4308,Canada,2017,10,C-Cardiovascular system,"/capita, US$ exchange rate",84.3
+4309,Canada,2017,10,G-Genito urinary system and sex hormones,"/capita, US$ purchasing power parity",34.3
+4310,Canada,2017,10,G-Genito urinary system and sex hormones,% of total sales,5.1
+4311,Canada,2017,10,M01A-Antiinflammatory and antirheumatic products non-steroids,% of total sales,1.0
+4312,Canada,2017,10,"C01B-Antiarrhythmics, Class I and III",% of total sales,0.1
+4313,Canada,2017,10,G03-Sex hormones and modulators of the genital system,"/capita, US$ exchange rate",17.2
+4314,Canada,2017,10,G03-Sex hormones and modulators of the genital system,"Million US$, purchasing power parity",671.0
+4315,Canada,2017,10,B-Blood and blood forming organs,"/capita, US$ exchange rate",24.5
+4316,Canada,2017,10,B-Blood and blood forming organs,"/capita, US$ purchasing power parity",26.2
+4317,Canada,2017,10,B-Blood and blood forming organs,% of total sales,3.9
+4318,Canada,2017,10,J-Antiinfectives for systemic use,"Million US$, purchasing power parity",1920.3
+4319,Canada,2017,10,J-Antiinfectives for systemic use,Million US$ at exchange rate,1793.6
+4320,Canada,2017,10,B-Blood and blood forming organs,"Million US$, purchasing power parity",958.4
+4321,Canada,2017,10,N-Nervous system,"Million US$, purchasing power parity",4706.2
+4322,Canada,2017,10,J-Antiinfectives for systemic use,Million of national currency units,2328.0
+4323,Canada,2017,10,N-Nervous system,Million of national currency units,5705.3
+4324,Canada,2017,10,N-Nervous system,Million US$ at exchange rate,4395.7
+4325,Canada,2017,10,C-Cardiovascular system,"/capita, US$ purchasing power parity",90.3
+4326,Canada,2017,10,C-Cardiovascular system,% of total sales,13.4
+4327,Canada,2017,10,B-Blood and blood forming organs,Million of national currency units,1161.9
+4328,Canada,2017,10,G03-Sex hormones and modulators of the genital system,Million of national currency units,813.5
+4329,Canada,2017,10,G03-Sex hormones and modulators of the genital system,Million US$ at exchange rate,626.8
+4330,Canada,2017,10,N-Nervous system,"/capita, US$ exchange rate",120.3
+4331,Canada,2017,10,J-Antiinfectives for systemic use,"/capita, US$ exchange rate",49.1
+4332,Canada,2017,10,"C01B-Antiarrhythmics, Class I and III",Million of national currency units,29.5
+4333,Canada,2017,10,J-Antiinfectives for systemic use,"/capita, US$ purchasing power parity",52.5
+4334,Canada,2017,10,B-Blood and blood forming organs,Million US$ at exchange rate,895.2
+4335,Canada,2017,10,J-Antiinfectives for systemic use,% of total sales,7.8
+4336,Canada,2017,10,M-Musculo-skeletal system,"/capita, US$ exchange rate",19.6
+4337,Canada,2017,10,J01-Antibacterials for systemic use,Million of national currency units,694.6
+4338,Canada,2017,10,C03-Diuretics,% of total sales,0.8
+4339,Canada,2017,10,C03-Diuretics,"/capita, US$ purchasing power parity",5.1
+4340,Canada,2017,10,M-Musculo-skeletal system,Million of national currency units,929.4
+4341,Canada,2017,10,J01-Antibacterials for systemic use,Million US$ at exchange rate,535.2
+4342,Canada,2017,10,M-Musculo-skeletal system,"Million US$, purchasing power parity",766.6
+4343,Canada,2017,10,M-Musculo-skeletal system,Million US$ at exchange rate,716.1
+4344,Canada,2017,10,J01-Antibacterials for systemic use,"Million US$, purchasing power parity",573.0
+4345,Canada,2017,10,M-Musculo-skeletal system,"/capita, US$ purchasing power parity",21.0
+4346,Canada,2017,10,C08-Calcium channel blockers,Million of national currency units,531.6
+4347,Canada,2017,10,C08-Calcium channel blockers,Million US$ at exchange rate,409.6
+4348,Canada,2017,10,M-Musculo-skeletal system,% of total sales,3.1
+4349,Canada,2017,10,C03-Diuretics,"Million US$, purchasing power parity",187.0
+4350,Canada,2017,10,C03-Diuretics,"/capita, US$ exchange rate",4.8
+4351,Canada,2017,10,C03-Diuretics,Million of national currency units,226.7
+4352,Canada,2017,10,C03-Diuretics,Million US$ at exchange rate,174.7
+4353,Canada,2017,10,C07-Beta blocking agents,"/capita, US$ purchasing power parity",7.4
+4354,Canada,2017,10,C07-Beta blocking agents,"/capita, US$ exchange rate",6.9
+4355,Canada,2017,10,C07-Beta blocking agents,Million US$ at exchange rate,251.8
+4356,Canada,2017,10,C07-Beta blocking agents,"Million US$, purchasing power parity",269.6
+4357,Canada,2017,10,C10-Lipid modifying agents,"/capita, US$ purchasing power parity",27.8
+4358,Canada,2017,10,C10-Lipid modifying agents,% of total sales,4.1
+4359,Canada,2017,10,"H-Systemic hormonal preparations, excluding sex hormones and insulins","Million US$, purchasing power parity",430.0
+4360,Canada,2017,10,C07-Beta blocking agents,% of total sales,1.1
+4361,Canada,2017,10,C10-Lipid modifying agents,"/capita, US$ exchange rate",25.9
+4362,Canada,2017,10,J01-Antibacterials for systemic use,% of total sales,2.3
+4363,Canada,2017,10,C10-Lipid modifying agents,Million US$ at exchange rate,947.3
+4364,Canada,2017,10,J01-Antibacterials for systemic use,"/capita, US$ exchange rate",14.6
+4365,Canada,2017,10,J01-Antibacterials for systemic use,"/capita, US$ purchasing power parity",15.7
+4366,Canada,2017,10,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million US$ at exchange rate,401.6
+4367,Canada,2017,10,C07-Beta blocking agents,Million of national currency units,326.8
+4368,Canada,2017,10,C10-Lipid modifying agents,"Million US$, purchasing power parity",1014.2
+4369,Canada,2017,10,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million of national currency units,521.3
+4370,Canada,2017,10,C08-Calcium channel blockers,"Million US$, purchasing power parity",438.5
+4371,Canada,2017,10,C09-Agents acting on the Renin-Angiotensin system,% of total sales,4.4
+4372,Canada,2017,10,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ exchange rate",11.0
+4373,Canada,2017,10,"H-Systemic hormonal preparations, excluding sex hormones and insulins",% of total sales,1.8
+4374,Canada,2017,10,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ purchasing power parity",29.6
+4375,Canada,2017,10,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ purchasing power parity",11.8
+4376,Canada,2017,10,M01A-Antiinflammatory and antirheumatic products non-steroids,"Million US$, purchasing power parity",254.6
+4377,Canada,2017,10,M01A-Antiinflammatory and antirheumatic products non-steroids,Million US$ at exchange rate,237.8
+4378,Canada,2017,10,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ exchange rate",27.6
+4379,Canada,2017,10,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ exchange rate",6.5
+4380,Canada,2017,10,C02-Antihypertensives,"Million US$, purchasing power parity",106.9
+4381,Canada,2017,10,C01A-Cardiac glycosides,% of total sales,0.1
+4382,Canada,2017,10,C02-Antihypertensives,Million of national currency units,129.6
+4383,Canada,2017,10,C02-Antihypertensives,Million US$ at exchange rate,99.9
+4384,Canada,2017,10,C01A-Cardiac glycosides,"Million US$, purchasing power parity",13.7
+4385,Canada,2017,10,C01A-Cardiac glycosides,Million US$ at exchange rate,12.8
+4386,Canada,2017,10,C10-Lipid modifying agents,Million of national currency units,1229.5
+4387,Canada,2017,10,C01A-Cardiac glycosides,"/capita, US$ purchasing power parity",0.4
+4388,Canada,2017,10,C01A-Cardiac glycosides,"/capita, US$ exchange rate",0.3
+4389,Canada,2017,10,C02-Antihypertensives,"/capita, US$ purchasing power parity",2.9
+4390,Canada,2017,10,C02-Antihypertensives,% of total sales,0.4
+4391,Canada,2017,10,G-Genito urinary system and sex hormones,Million of national currency units,1517.6
+4392,Canada,2017,10,C02-Antihypertensives,"/capita, US$ exchange rate",2.7
+4393,Canada,2017,10,C08-Calcium channel blockers,"/capita, US$ exchange rate",11.2
+4394,Canada,2017,10,C08-Calcium channel blockers,"/capita, US$ purchasing power parity",12.0
+4395,Canada,2017,10,C08-Calcium channel blockers,% of total sales,1.8
+4396,Canada,2017,10,G-Genito urinary system and sex hormones,Million US$ at exchange rate,1169.2
+4397,Canada,2017,10,C09-Agents acting on the Renin-Angiotensin system,Million US$ at exchange rate,1009.3
+4398,Canada,2017,10,C09-Agents acting on the Renin-Angiotensin system,Million of national currency units,1310.0
+4399,Canada,2017,10,M01A-Antiinflammatory and antirheumatic products non-steroids,Million of national currency units,308.6
+4400,Canada,2017,10,C09-Agents acting on the Renin-Angiotensin system,"Million US$, purchasing power parity",1080.6
+4401,Canada,2017,10,G-Genito urinary system and sex hormones,"/capita, US$ exchange rate",32.0
+4402,Canada,2017,10,G-Genito urinary system and sex hormones,"Million US$, purchasing power parity",1251.8
+4403,Canada,2017,10,C01A-Cardiac glycosides,Million of national currency units,16.6
+4404,Canada,2017,10,A-Alimentary tract and metabolism,"Million US$, purchasing power parity",3337.3
+4405,Canada,2017,10,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),% of total sales,3.3
+4406,Canada,2017,10,N06A-Antidepressants,% of total sales,4.7
+4407,Canada,2017,10,A-Alimentary tract and metabolism,Million of national currency units,4045.8
+4408,Canada,2017,10,A-Alimentary tract and metabolism,Million US$ at exchange rate,3117.1
+4409,Canada,2017,10,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million US$ at exchange rate,765.8
+4410,Canada,2017,10,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million of national currency units,994.0
+4411,Canada,2017,10,R-Respiratory system,Million of national currency units,1991.3
+4412,Canada,2017,10,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ purchasing power parity",22.4
+4413,Canada,2017,10,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ exchange rate",21.0
+4414,Canada,2017,10,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"Million US$, purchasing power parity",819.9
+4415,Canada,2017,10,N05C-Hypnotics and sedatives,"/capita, US$ exchange rate",4.3
+4416,Canada,2017,10,N05C-Hypnotics and sedatives,"/capita, US$ purchasing power parity",4.6
+4417,Canada,2017,10,N05C-Hypnotics and sedatives,"Million US$, purchasing power parity",167.3
+4418,Canada,2017,10,N05C-Hypnotics and sedatives,Million of national currency units,202.8
+4419,Canada,2017,10,N05C-Hypnotics and sedatives,Million US$ at exchange rate,156.2
+4420,Canada,2017,10,N06A-Antidepressants,"Million US$, purchasing power parity",1148.0
+4421,Canada,2017,10,N06A-Antidepressants,"/capita, US$ exchange rate",29.3
+4422,Canada,2017,10,N06A-Antidepressants,"/capita, US$ purchasing power parity",31.4
+4423,Canada,2017,10,N05C-Hypnotics and sedatives,% of total sales,0.7
+4424,Canada,2017,10,N06A-Antidepressants,Million of national currency units,1391.7
+4425,Canada,2017,10,N06A-Antidepressants,Million US$ at exchange rate,1072.2
+4426,Canada,2017,10,Products not elsewhere classified,Million US$ at exchange rate,5837.3
+4427,Canada,2017,10,Products not elsewhere classified,"Million US$, purchasing power parity",6249.7
+4428,Canada,2017,10,R03-Drugs for obstructive airway diseases,"/capita, US$ purchasing power parity",36.0
+4429,Canada,2017,10,R03-Drugs for obstructive airway diseases,% of total sales,5.4
+4430,Canada,2017,10,Products not elsewhere classified,Million of national currency units,7576.5
+4431,Canada,2017,10,Products not elsewhere classified,"/capita, US$ exchange rate",159.7
+4432,Canada,2017,10,A02A-Antacids,Million US$ at exchange rate,1.2
+4433,Canada,2017,10,A02A-Antacids,"Million US$, purchasing power parity",1.3
+4434,Canada,2017,10,A02A-Antacids,"/capita, US$ exchange rate",0.0
+4435,Canada,2017,10,A02A-Antacids,"/capita, US$ purchasing power parity",0.0
+4436,Canada,2017,10,A02A-Antacids,Million of national currency units,1.6
+4437,Canada,2017,10,Products not elsewhere classified,"/capita, US$ purchasing power parity",171.0
+4438,Canada,2017,10,Products not elsewhere classified,% of total sales,25.4
+4439,Canada,2017,10,R-Respiratory system,"/capita, US$ purchasing power parity",44.9
+4440,Canada,2017,10,A-Alimentary tract and metabolism,"/capita, US$ exchange rate",85.3
+4441,Canada,2017,10,A-Alimentary tract and metabolism,"/capita, US$ purchasing power parity",91.3
+4442,Canada,2017,10,R-Respiratory system,Million US$ at exchange rate,1534.2
+4443,Canada,2017,10,R-Respiratory system,"/capita, US$ exchange rate",42.0
+4444,Canada,2017,10,R-Respiratory system,"Million US$, purchasing power parity",1642.6
+4445,Canada,2017,10,R03-Drugs for obstructive airway diseases,Million US$ at exchange rate,1227.6
+4446,Canada,2017,10,R03-Drugs for obstructive airway diseases,"Million US$, purchasing power parity",1314.4
+4447,Canada,2017,10,R03-Drugs for obstructive airway diseases,"/capita, US$ exchange rate",33.6
+4448,Canada,2017,10,A-Alimentary tract and metabolism,% of total sales,13.6
+4449,Canada,2017,10,R-Respiratory system,% of total sales,6.7
+4450,Canada,2017,10,R03-Drugs for obstructive airway diseases,Million of national currency units,1593.4
+4451,Canada,2017,10,N05B-Anxiolytics,% of total sales,0.5
+4452,Canada,2017,10,A02A-Antacids,% of total sales,0.0
+4453,Canada,2017,10,N02-Analgesics,"/capita, US$ exchange rate",22.7
+4454,Canada,2017,10,A10-Drugs used in diabetes,"Million US$, purchasing power parity",1794.7
+4455,Canada,2017,10,N02-Analgesics,"/capita, US$ purchasing power parity",24.3
+4456,Canada,2017,10,N02-Analgesics,% of total sales,3.6
+4457,Canada,2017,10,N02-Analgesics,Million of national currency units,1077.1
+4458,Canada,2017,10,N02-Analgesics,Million US$ at exchange rate,829.9
+4459,Canada,2017,10,A10-Drugs used in diabetes,Million US$ at exchange rate,1676.3
+4460,Canada,2017,10,A10-Drugs used in diabetes,Million of national currency units,2175.7
+4461,Canada,2017,10,Total pharmaceutical sales,Million of national currency units,29776.2
+4462,Canada,2017,10,A10-Drugs used in diabetes,"/capita, US$ exchange rate",45.9
+4463,Canada,2017,10,A10-Drugs used in diabetes,% of total sales,7.3
+4464,Canada,2017,10,A10-Drugs used in diabetes,"/capita, US$ purchasing power parity",49.1
+4465,Canada,2017,10,Total pharmaceutical sales,"/capita, US$ purchasing power parity",672.1
+4466,Canada,2017,10,Total pharmaceutical sales,Million US$ at exchange rate,22941.2
+4467,Canada,2017,10,Total pharmaceutical sales,"Million US$, purchasing power parity",24561.7
+4468,Canada,2017,10,Total pharmaceutical sales,"/capita, US$ exchange rate",627.7
+4469,Canada,2017,10,N05B-Anxiolytics,"Million US$, purchasing power parity",132.1
+4470,Canada,2017,10,N05B-Anxiolytics,Million US$ at exchange rate,123.4
+4471,Canada,2017,10,N05B-Anxiolytics,"/capita, US$ purchasing power parity",3.6
+4472,Canada,2017,10,N05B-Anxiolytics,"/capita, US$ exchange rate",3.4
+4473,Canada,2017,10,N05B-Anxiolytics,Million of national currency units,160.2
+4474,Canada,2017,10,N02-Analgesics,"Million US$, purchasing power parity",888.5
+4475,Canada,2016,10,N-Nervous system,"/capita, US$ purchasing power parity",128.7
+4476,Canada,2016,10,C-Cardiovascular system,Million of national currency units,3942.4
+4477,Canada,2016,10,C-Cardiovascular system,"Million US$, purchasing power parity",3266.2
+4478,Canada,2016,10,C-Cardiovascular system,Million US$ at exchange rate,2974.0
+4479,Canada,2016,10,"C01B-Antiarrhythmics, Class I and III",Million US$ at exchange rate,21.9
+4480,Canada,2016,10,N-Nervous system,% of total sales,19.8
+4481,Canada,2016,10,"C01B-Antiarrhythmics, Class I and III","Million US$, purchasing power parity",24.0
+4482,Canada,2016,10,"C01B-Antiarrhythmics, Class I and III","/capita, US$ purchasing power parity",0.7
+4483,Canada,2016,10,"C01B-Antiarrhythmics, Class I and III","/capita, US$ exchange rate",0.6
+4484,Canada,2016,10,C-Cardiovascular system,"/capita, US$ exchange rate",82.4
+4485,Canada,2016,10,G03-Sex hormones and modulators of the genital system,% of total sales,2.8
+4486,Canada,2016,10,G03-Sex hormones and modulators of the genital system,"/capita, US$ purchasing power parity",18.5
+4487,Canada,2016,10,G-Genito urinary system and sex hormones,"/capita, US$ purchasing power parity",34.1
+4488,Canada,2016,10,G-Genito urinary system and sex hormones,% of total sales,5.2
+4489,Canada,2016,10,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ purchasing power parity",7.4
+4490,Canada,2016,10,M01A-Antiinflammatory and antirheumatic products non-steroids,% of total sales,1.1
+4491,Canada,2016,10,"C01B-Antiarrhythmics, Class I and III",% of total sales,0.1
+4492,Canada,2016,10,G03-Sex hormones and modulators of the genital system,"/capita, US$ exchange rate",16.8
+4493,Canada,2016,10,G03-Sex hormones and modulators of the genital system,"Million US$, purchasing power parity",666.8
+4494,Canada,2016,10,B-Blood and blood forming organs,"/capita, US$ exchange rate",22.2
+4495,Canada,2016,10,B-Blood and blood forming organs,"/capita, US$ purchasing power parity",24.4
+4496,Canada,2016,10,B-Blood and blood forming organs,% of total sales,3.8
+4497,Canada,2016,10,J-Antiinfectives for systemic use,"Million US$, purchasing power parity",1901.4
+4498,Canada,2016,10,J-Antiinfectives for systemic use,Million US$ at exchange rate,1731.3
+4499,Canada,2016,10,B-Blood and blood forming organs,"Million US$, purchasing power parity",881.7
+4500,Canada,2016,10,N-Nervous system,"/capita, US$ exchange rate",117.2
+4501,Canada,2016,10,N-Nervous system,"Million US$, purchasing power parity",4646.5
+4502,Canada,2016,10,J-Antiinfectives for systemic use,Million of national currency units,2295.1
+4503,Canada,2016,10,N-Nervous system,Million of national currency units,5608.5
+4504,Canada,2016,10,N-Nervous system,Million US$ at exchange rate,4230.9
+4505,Canada,2016,10,C-Cardiovascular system,% of total sales,13.9
+4506,Canada,2016,10,C-Cardiovascular system,"/capita, US$ purchasing power parity",90.5
+4507,Canada,2016,10,B-Blood and blood forming organs,Million of national currency units,1064.2
+4508,Canada,2016,10,G03-Sex hormones and modulators of the genital system,Million of national currency units,804.9
+4509,Canada,2016,10,G03-Sex hormones and modulators of the genital system,Million US$ at exchange rate,607.2
+4510,Canada,2016,10,J-Antiinfectives for systemic use,"/capita, US$ exchange rate",47.9
+4511,Canada,2016,10,J-Antiinfectives for systemic use,"/capita, US$ purchasing power parity",52.7
+4512,Canada,2016,10,"C01B-Antiarrhythmics, Class I and III",Million of national currency units,29.0
+4513,Canada,2016,10,B-Blood and blood forming organs,Million US$ at exchange rate,802.8
+4514,Canada,2016,10,J-Antiinfectives for systemic use,% of total sales,8.1
+4515,Canada,2016,10,M-Musculo-skeletal system,"/capita, US$ exchange rate",19.0
+4516,Canada,2016,10,J01-Antibacterials for systemic use,Million of national currency units,687.1
+4517,Canada,2016,10,C03-Diuretics,% of total sales,0.8
+4518,Canada,2016,10,M-Musculo-skeletal system,Million of national currency units,910.8
+4519,Canada,2016,10,J01-Antibacterials for systemic use,Million US$ at exchange rate,518.3
+4520,Canada,2016,10,J01-Antibacterials for systemic use,"Million US$, purchasing power parity",569.2
+4521,Canada,2016,10,M-Musculo-skeletal system,"Million US$, purchasing power parity",754.6
+4522,Canada,2016,10,M-Musculo-skeletal system,Million US$ at exchange rate,687.1
+4523,Canada,2016,10,C03-Diuretics,"/capita, US$ purchasing power parity",4.9
+4524,Canada,2016,10,M-Musculo-skeletal system,"/capita, US$ purchasing power parity",20.9
+4525,Canada,2016,10,C08-Calcium channel blockers,Million of national currency units,546.9
+4526,Canada,2016,10,C08-Calcium channel blockers,Million US$ at exchange rate,412.6
+4527,Canada,2016,10,M-Musculo-skeletal system,% of total sales,3.2
+4528,Canada,2016,10,C03-Diuretics,"/capita, US$ exchange rate",4.5
+4529,Canada,2016,10,C03-Diuretics,"Million US$, purchasing power parity",177.5
+4530,Canada,2016,10,C03-Diuretics,Million of national currency units,214.3
+4531,Canada,2016,10,C03-Diuretics,Million US$ at exchange rate,161.7
+4532,Canada,2016,10,C07-Beta blocking agents,"/capita, US$ purchasing power parity",7.4
+4533,Canada,2016,10,C07-Beta blocking agents,"/capita, US$ exchange rate",6.7
+4534,Canada,2016,10,C07-Beta blocking agents,Million US$ at exchange rate,241.9
+4535,Canada,2016,10,C07-Beta blocking agents,"Million US$, purchasing power parity",265.7
+4536,Canada,2016,10,C07-Beta blocking agents,% of total sales,1.1
+4537,Canada,2016,10,C10-Lipid modifying agents,"/capita, US$ purchasing power parity",28.4
+4538,Canada,2016,10,C10-Lipid modifying agents,% of total sales,4.4
+4539,Canada,2016,10,"H-Systemic hormonal preparations, excluding sex hormones and insulins","Million US$, purchasing power parity",412.9
+4540,Canada,2016,10,C10-Lipid modifying agents,"/capita, US$ exchange rate",25.9
+4541,Canada,2016,10,J01-Antibacterials for systemic use,% of total sales,2.4
+4542,Canada,2016,10,C10-Lipid modifying agents,Million US$ at exchange rate,934.8
+4543,Canada,2016,10,J01-Antibacterials for systemic use,"/capita, US$ exchange rate",14.4
+4544,Canada,2016,10,J01-Antibacterials for systemic use,"/capita, US$ purchasing power parity",15.8
+4545,Canada,2016,10,C10-Lipid modifying agents,"Million US$, purchasing power parity",1026.6
+4546,Canada,2016,10,C07-Beta blocking agents,Million of national currency units,320.7
+4547,Canada,2016,10,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million US$ at exchange rate,376.0
+4548,Canada,2016,10,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million of national currency units,498.4
+4549,Canada,2016,10,C08-Calcium channel blockers,"Million US$, purchasing power parity",453.1
+4550,Canada,2016,10,C09-Agents acting on the Renin-Angiotensin system,% of total sales,4.5
+4551,Canada,2016,10,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ exchange rate",10.4
+4552,Canada,2016,10,"H-Systemic hormonal preparations, excluding sex hormones and insulins",% of total sales,1.8
+4553,Canada,2016,10,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ purchasing power parity",11.4
+4554,Canada,2016,10,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ purchasing power parity",29.2
+4555,Canada,2016,10,M01A-Antiinflammatory and antirheumatic products non-steroids,"Million US$, purchasing power parity",266.7
+4556,Canada,2016,10,M01A-Antiinflammatory and antirheumatic products non-steroids,Million US$ at exchange rate,242.8
+4557,Canada,2016,10,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ exchange rate",26.6
+4558,Canada,2016,10,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ exchange rate",6.7
+4559,Canada,2016,10,C02-Antihypertensives,"Million US$, purchasing power parity",98.8
+4560,Canada,2016,10,C02-Antihypertensives,Million of national currency units,119.2
+4561,Canada,2016,10,C01A-Cardiac glycosides,% of total sales,0.1
+4562,Canada,2016,10,C02-Antihypertensives,Million US$ at exchange rate,89.9
+4563,Canada,2016,10,C01A-Cardiac glycosides,"Million US$, purchasing power parity",14.6
+4564,Canada,2016,10,C10-Lipid modifying agents,Million of national currency units,1239.2
+4565,Canada,2016,10,C01A-Cardiac glycosides,"/capita, US$ purchasing power parity",0.4
+4566,Canada,2016,10,C01A-Cardiac glycosides,"/capita, US$ exchange rate",0.4
+4567,Canada,2016,10,C02-Antihypertensives,"/capita, US$ purchasing power parity",2.7
+4568,Canada,2016,10,C02-Antihypertensives,% of total sales,0.4
+4569,Canada,2016,10,G-Genito urinary system and sex hormones,Million of national currency units,1485.0
+4570,Canada,2016,10,C02-Antihypertensives,"/capita, US$ exchange rate",2.5
+4571,Canada,2016,10,C08-Calcium channel blockers,"/capita, US$ exchange rate",11.4
+4572,Canada,2016,10,C08-Calcium channel blockers,"/capita, US$ purchasing power parity",12.5
+4573,Canada,2016,10,C08-Calcium channel blockers,% of total sales,1.9
+4574,Canada,2016,10,G-Genito urinary system and sex hormones,Million US$ at exchange rate,1120.2
+4575,Canada,2016,10,C09-Agents acting on the Renin-Angiotensin system,Million US$ at exchange rate,959.6
+4576,Canada,2016,10,C09-Agents acting on the Renin-Angiotensin system,Million of national currency units,1272.1
+4577,Canada,2016,10,M01A-Antiinflammatory and antirheumatic products non-steroids,Million of national currency units,321.9
+4578,Canada,2016,10,C09-Agents acting on the Renin-Angiotensin system,"Million US$, purchasing power parity",1053.9
+4579,Canada,2016,10,G-Genito urinary system and sex hormones,"/capita, US$ exchange rate",31.0
+4580,Canada,2016,10,G-Genito urinary system and sex hormones,"Million US$, purchasing power parity",1230.3
+4581,Canada,2016,10,C01A-Cardiac glycosides,Million US$ at exchange rate,13.3
+4582,Canada,2016,10,C01A-Cardiac glycosides,Million of national currency units,17.6
+4583,Canada,2016,10,A-Alimentary tract and metabolism,"Million US$, purchasing power parity",3166.9
+4584,Canada,2016,10,A02A-Antacids,% of total sales,0.0
+4585,Canada,2016,10,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),% of total sales,3.7
+4586,Canada,2016,10,N06A-Antidepressants,% of total sales,5.0
+4587,Canada,2016,10,A-Alimentary tract and metabolism,Million US$ at exchange rate,2883.6
+4588,Canada,2016,10,A-Alimentary tract and metabolism,Million of national currency units,3822.6
+4589,Canada,2016,10,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million US$ at exchange rate,782.4
+4590,Canada,2016,10,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million of national currency units,1037.1
+4591,Canada,2016,10,R-Respiratory system,Million of national currency units,1936.0
+4592,Canada,2016,10,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ purchasing power parity",23.8
+4593,Canada,2016,10,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ exchange rate",21.7
+4594,Canada,2016,10,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"Million US$, purchasing power parity",859.2
+4595,Canada,2016,10,N05C-Hypnotics and sedatives,"/capita, US$ exchange rate",4.3
+4596,Canada,2016,10,N05C-Hypnotics and sedatives,"/capita, US$ purchasing power parity",4.7
+4597,Canada,2016,10,N05C-Hypnotics and sedatives,"Million US$, purchasing power parity",168.6
+4598,Canada,2016,10,N05C-Hypnotics and sedatives,Million of national currency units,203.5
+4599,Canada,2016,10,N05C-Hypnotics and sedatives,Million US$ at exchange rate,153.5
+4600,Canada,2016,10,N06A-Antidepressants,"Million US$, purchasing power parity",1174.8
+4601,Canada,2016,10,N06A-Antidepressants,"/capita, US$ exchange rate",29.6
+4602,Canada,2016,10,N06A-Antidepressants,"/capita, US$ purchasing power parity",32.5
+4603,Canada,2016,10,N05C-Hypnotics and sedatives,% of total sales,0.7
+4604,Canada,2016,10,N06A-Antidepressants,Million of national currency units,1418.0
+4605,Canada,2016,10,N06A-Antidepressants,Million US$ at exchange rate,1069.7
+4606,Canada,2016,10,Products not elsewhere classified,Million US$ at exchange rate,5108.0
+4607,Canada,2016,10,Products not elsewhere classified,"Million US$, purchasing power parity",5609.8
+4608,Canada,2016,10,R03-Drugs for obstructive airway diseases,"/capita, US$ purchasing power parity",35.3
+4609,Canada,2016,10,Products not elsewhere classified,"/capita, US$ exchange rate",141.5
+4610,Canada,2016,10,R03-Drugs for obstructive airway diseases,% of total sales,5.4
+4611,Canada,2016,10,Products not elsewhere classified,Million of national currency units,6771.3
+4612,Canada,2016,10,A02A-Antacids,Million US$ at exchange rate,1.1
+4613,Canada,2016,10,A02A-Antacids,"Million US$, purchasing power parity",1.2
+4614,Canada,2016,10,A02A-Antacids,"/capita, US$ exchange rate",0.0
+4615,Canada,2016,10,A02A-Antacids,"/capita, US$ purchasing power parity",0.0
+4616,Canada,2016,10,A02A-Antacids,Million of national currency units,1.5
+4617,Canada,2016,10,Products not elsewhere classified,"/capita, US$ purchasing power parity",155.4
+4618,Canada,2016,10,Products not elsewhere classified,% of total sales,23.9
+4619,Canada,2016,10,R-Respiratory system,"/capita, US$ purchasing power parity",44.4
+4620,Canada,2016,10,A-Alimentary tract and metabolism,"/capita, US$ exchange rate",79.9
+4621,Canada,2016,10,A-Alimentary tract and metabolism,"/capita, US$ purchasing power parity",87.7
+4622,Canada,2016,10,R-Respiratory system,Million US$ at exchange rate,1460.5
+4623,Canada,2016,10,R-Respiratory system,"Million US$, purchasing power parity",1603.9
+4624,Canada,2016,10,R-Respiratory system,"/capita, US$ exchange rate",40.4
+4625,Canada,2016,10,R03-Drugs for obstructive airway diseases,Million US$ at exchange rate,1161.7
+4626,Canada,2016,10,R03-Drugs for obstructive airway diseases,"Million US$, purchasing power parity",1275.8
+4627,Canada,2016,10,R03-Drugs for obstructive airway diseases,"/capita, US$ exchange rate",32.2
+4628,Canada,2016,10,A-Alimentary tract and metabolism,% of total sales,13.5
+4629,Canada,2016,10,R-Respiratory system,% of total sales,6.8
+4630,Canada,2016,10,R03-Drugs for obstructive airway diseases,Million of national currency units,1540.0
+4631,Canada,2016,10,A10-Drugs used in diabetes,"Million US$, purchasing power parity",1613.1
+4632,Canada,2016,10,N02-Analgesics,"/capita, US$ exchange rate",23.3
+4633,Canada,2016,10,N02-Analgesics,"/capita, US$ purchasing power parity",25.6
+4634,Canada,2016,10,N02-Analgesics,% of total sales,3.9
+4635,Canada,2016,10,Total pharmaceutical sales,Million of national currency units,28334.3
+4636,Canada,2016,10,N02-Analgesics,Million of national currency units,1117.2
+4637,Canada,2016,10,N02-Analgesics,Million US$ at exchange rate,842.8
+4638,Canada,2016,10,A10-Drugs used in diabetes,Million US$ at exchange rate,1468.8
+4639,Canada,2016,10,A10-Drugs used in diabetes,Million of national currency units,1947.1
+4640,Canada,2016,10,A10-Drugs used in diabetes,"/capita, US$ exchange rate",40.7
+4641,Canada,2016,10,A10-Drugs used in diabetes,"/capita, US$ purchasing power parity",44.7
+4642,Canada,2016,10,A10-Drugs used in diabetes,% of total sales,6.9
+4643,Canada,2016,10,Total pharmaceutical sales,"Million US$, purchasing power parity",23474.1
+4644,Canada,2016,10,Total pharmaceutical sales,Million US$ at exchange rate,21374.5
+4645,Canada,2016,10,Total pharmaceutical sales,"/capita, US$ purchasing power parity",650.1
+4646,Canada,2016,10,Total pharmaceutical sales,"/capita, US$ exchange rate",591.9
+4647,Canada,2016,10,N05B-Anxiolytics,"/capita, US$ exchange rate",3.4
+4648,Canada,2016,10,N05B-Anxiolytics,"Million US$, purchasing power parity",135.4
+4649,Canada,2016,10,N05B-Anxiolytics,Million US$ at exchange rate,123.3
+4650,Canada,2016,10,N05B-Anxiolytics,% of total sales,0.6
+4651,Canada,2016,10,N05B-Anxiolytics,"/capita, US$ purchasing power parity",3.7
+4652,Canada,2016,10,N02-Analgesics,"Million US$, purchasing power parity",925.6
+4653,Canada,2016,10,N05B-Anxiolytics,Million of national currency units,163.4
+4654,Canada,2015,11,N-Nervous system,"/capita, US$ purchasing power parity",122.0
+4655,Canada,2015,11,C-Cardiovascular system,Million of national currency units,3888.7
+4656,Canada,2015,11,C-Cardiovascular system,"Million US$, purchasing power parity",3115.8
+4657,Canada,2015,11,C-Cardiovascular system,Million US$ at exchange rate,3040.9
+4658,Canada,2015,11,"C01B-Antiarrhythmics, Class I and III",Million US$ at exchange rate,22.1
+4659,Canada,2015,11,N-Nervous system,% of total sales,20.0
+4660,Canada,2015,11,"C01B-Antiarrhythmics, Class I and III","Million US$, purchasing power parity",22.7
+4661,Canada,2015,11,"C01B-Antiarrhythmics, Class I and III","/capita, US$ purchasing power parity",0.6
+4662,Canada,2015,11,"C01B-Antiarrhythmics, Class I and III","/capita, US$ exchange rate",0.6
+4663,Canada,2015,11,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ purchasing power parity",7.6
+4664,Canada,2015,11,C-Cardiovascular system,"/capita, US$ exchange rate",85.2
+4665,Canada,2015,11,G03-Sex hormones and modulators of the genital system,% of total sales,3.0
+4666,Canada,2015,11,G03-Sex hormones and modulators of the genital system,"/capita, US$ purchasing power parity",18.2
+4667,Canada,2015,11,G-Genito urinary system and sex hormones,"/capita, US$ purchasing power parity",33.9
+4668,Canada,2015,11,G-Genito urinary system and sex hormones,% of total sales,5.6
+4669,Canada,2015,11,M01A-Antiinflammatory and antirheumatic products non-steroids,% of total sales,1.2
+4670,Canada,2015,11,"C01B-Antiarrhythmics, Class I and III",% of total sales,0.1
+4671,Canada,2015,11,G03-Sex hormones and modulators of the genital system,"/capita, US$ exchange rate",17.7
+4672,Canada,2015,11,B-Blood and blood forming organs,"/capita, US$ purchasing power parity",21.4
+4673,Canada,2015,11,B-Blood and blood forming organs,"/capita, US$ exchange rate",20.9
+4674,Canada,2015,11,B-Blood and blood forming organs,% of total sales,3.5
+4675,Canada,2015,11,J-Antiinfectives for systemic use,"Million US$, purchasing power parity",1960.8
+4676,Canada,2015,11,J-Antiinfectives for systemic use,Million US$ at exchange rate,1913.7
+4677,Canada,2015,11,N-Nervous system,"/capita, US$ exchange rate",119.1
+4678,Canada,2015,11,J-Antiinfectives for systemic use,Million of national currency units,2447.2
+4679,Canada,2015,11,N-Nervous system,"Million US$, purchasing power parity",4355.4
+4680,Canada,2015,11,N-Nervous system,Million of national currency units,5435.7
+4681,Canada,2015,11,N-Nervous system,Million US$ at exchange rate,4250.7
+4682,Canada,2015,11,C-Cardiovascular system,% of total sales,14.3
+4683,Canada,2015,11,B-Blood and blood forming organs,Million of national currency units,954.8
+4684,Canada,2015,11,C-Cardiovascular system,"/capita, US$ purchasing power parity",87.3
+4685,Canada,2015,11,G03-Sex hormones and modulators of the genital system,"Million US$, purchasing power parity",648.5
+4686,Canada,2015,11,G03-Sex hormones and modulators of the genital system,Million of national currency units,809.3
+4687,Canada,2015,11,G03-Sex hormones and modulators of the genital system,Million US$ at exchange rate,632.9
+4688,Canada,2015,11,J-Antiinfectives for systemic use,"/capita, US$ purchasing power parity",54.9
+4689,Canada,2015,11,J-Antiinfectives for systemic use,"/capita, US$ exchange rate",53.6
+4690,Canada,2015,11,"C01B-Antiarrhythmics, Class I and III",Million of national currency units,28.3
+4691,Canada,2015,11,B-Blood and blood forming organs,Million US$ at exchange rate,746.6
+4692,Canada,2015,11,B-Blood and blood forming organs,"Million US$, purchasing power parity",765.0
+4693,Canada,2015,11,J-Antiinfectives for systemic use,% of total sales,9.0
+4694,Canada,2015,11,M-Musculo-skeletal system,"/capita, US$ exchange rate",19.9
+4695,Canada,2015,11,C03-Diuretics,% of total sales,0.8
+4696,Canada,2015,11,J01-Antibacterials for systemic use,Million of national currency units,678.2
+4697,Canada,2015,11,M-Musculo-skeletal system,Million of national currency units,907.0
+4698,Canada,2015,11,J01-Antibacterials for systemic use,Million US$ at exchange rate,530.4
+4699,Canada,2015,11,J01-Antibacterials for systemic use,"Million US$, purchasing power parity",543.4
+4700,Canada,2015,11,M-Musculo-skeletal system,"Million US$, purchasing power parity",726.7
+4701,Canada,2015,11,M-Musculo-skeletal system,Million US$ at exchange rate,709.3
+4702,Canada,2015,11,M-Musculo-skeletal system,"/capita, US$ purchasing power parity",20.4
+4703,Canada,2015,11,C08-Calcium channel blockers,Million US$ at exchange rate,426.7
+4704,Canada,2015,11,C08-Calcium channel blockers,Million of national currency units,545.6
+4705,Canada,2015,11,M-Musculo-skeletal system,% of total sales,3.3
+4706,Canada,2015,11,C03-Diuretics,"/capita, US$ purchasing power parity",4.6
+4707,Canada,2015,11,C03-Diuretics,"/capita, US$ exchange rate",4.5
+4708,Canada,2015,11,C03-Diuretics,"Million US$, purchasing power parity",165.9
+4709,Canada,2015,11,C03-Diuretics,Million of national currency units,207.0
+4710,Canada,2015,11,C03-Diuretics,Million US$ at exchange rate,161.9
+4711,Canada,2015,11,C07-Beta blocking agents,"/capita, US$ purchasing power parity",7.1
+4712,Canada,2015,11,C07-Beta blocking agents,"/capita, US$ exchange rate",6.9
+4713,Canada,2015,11,C07-Beta blocking agents,% of total sales,1.2
+4714,Canada,2015,11,C07-Beta blocking agents,"Million US$, purchasing power parity",253.6
+4715,Canada,2015,11,C07-Beta blocking agents,Million US$ at exchange rate,247.5
+4716,Canada,2015,11,C10-Lipid modifying agents,"/capita, US$ purchasing power parity",27.8
+4717,Canada,2015,11,C10-Lipid modifying agents,% of total sales,4.6
+4718,Canada,2015,11,C10-Lipid modifying agents,"/capita, US$ exchange rate",27.1
+4719,Canada,2015,11,J01-Antibacterials for systemic use,% of total sales,2.5
+4720,Canada,2015,11,J01-Antibacterials for systemic use,"/capita, US$ exchange rate",14.9
+4721,Canada,2015,11,J01-Antibacterials for systemic use,"/capita, US$ purchasing power parity",15.2
+4722,Canada,2015,11,C10-Lipid modifying agents,"Million US$, purchasing power parity",991.4
+4723,Canada,2015,11,"H-Systemic hormonal preparations, excluding sex hormones and insulins","Million US$, purchasing power parity",379.8
+4724,Canada,2015,11,C07-Beta blocking agents,Million of national currency units,316.5
+4725,Canada,2015,11,C08-Calcium channel blockers,"Million US$, purchasing power parity",437.2
+4726,Canada,2015,11,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million US$ at exchange rate,370.7
+4727,Canada,2015,11,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million of national currency units,474.0
+4728,Canada,2015,11,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ exchange rate",10.4
+4729,Canada,2015,11,C09-Agents acting on the Renin-Angiotensin system,% of total sales,4.5
+4730,Canada,2015,11,"H-Systemic hormonal preparations, excluding sex hormones and insulins",% of total sales,1.7
+4731,Canada,2015,11,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ purchasing power parity",10.6
+4732,Canada,2015,11,M01A-Antiinflammatory and antirheumatic products non-steroids,"Million US$, purchasing power parity",270.8
+4733,Canada,2015,11,M01A-Antiinflammatory and antirheumatic products non-steroids,Million US$ at exchange rate,264.3
+4734,Canada,2015,11,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ purchasing power parity",27.6
+4735,Canada,2015,11,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ exchange rate",7.4
+4736,Canada,2015,11,C02-Antihypertensives,"Million US$, purchasing power parity",83.6
+4737,Canada,2015,11,C10-Lipid modifying agents,Million of national currency units,1237.3
+4738,Canada,2015,11,C02-Antihypertensives,Million of national currency units,104.3
+4739,Canada,2015,11,C02-Antihypertensives,Million US$ at exchange rate,81.6
+4740,Canada,2015,11,C01A-Cardiac glycosides,% of total sales,0.1
+4741,Canada,2015,11,C01A-Cardiac glycosides,"Million US$, purchasing power parity",15.2
+4742,Canada,2015,11,C01A-Cardiac glycosides,"/capita, US$ purchasing power parity",0.4
+4743,Canada,2015,11,C01A-Cardiac glycosides,"/capita, US$ exchange rate",0.4
+4744,Canada,2015,11,C02-Antihypertensives,"/capita, US$ purchasing power parity",2.3
+4745,Canada,2015,11,C02-Antihypertensives,% of total sales,0.4
+4746,Canada,2015,11,C02-Antihypertensives,"/capita, US$ exchange rate",2.3
+4747,Canada,2015,11,G-Genito urinary system and sex hormones,Million of national currency units,1511.3
+4748,Canada,2015,11,G-Genito urinary system and sex hormones,Million US$ at exchange rate,1181.8
+4749,Canada,2015,11,C08-Calcium channel blockers,"/capita, US$ purchasing power parity",12.2
+4750,Canada,2015,11,C08-Calcium channel blockers,"/capita, US$ exchange rate",12.0
+4751,Canada,2015,11,C10-Lipid modifying agents,Million US$ at exchange rate,967.6
+4752,Canada,2015,11,C08-Calcium channel blockers,% of total sales,2.0
+4753,Canada,2015,11,C09-Agents acting on the Renin-Angiotensin system,Million US$ at exchange rate,961.1
+4754,Canada,2015,11,C09-Agents acting on the Renin-Angiotensin system,"Million US$, purchasing power parity",984.7
+4755,Canada,2015,11,M01A-Antiinflammatory and antirheumatic products non-steroids,Million of national currency units,338.0
+4756,Canada,2015,11,C09-Agents acting on the Renin-Angiotensin system,Million of national currency units,1229.0
+4757,Canada,2015,11,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ exchange rate",26.9
+4758,Canada,2015,11,G-Genito urinary system and sex hormones,"/capita, US$ exchange rate",33.1
+4759,Canada,2015,11,G-Genito urinary system and sex hormones,"Million US$, purchasing power parity",1210.9
+4760,Canada,2015,11,C01A-Cardiac glycosides,Million US$ at exchange rate,14.9
+4761,Canada,2015,11,C01A-Cardiac glycosides,Million of national currency units,19.0
+4762,Canada,2015,11,A-Alimentary tract and metabolism,"/capita, US$ exchange rate",83.8
+4763,Canada,2015,11,A-Alimentary tract and metabolism,"Million US$, purchasing power parity",3064.8
+4764,Canada,2015,11,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),% of total sales,4.2
+4765,Canada,2015,11,N06A-Antidepressants,% of total sales,5.3
+4766,Canada,2015,11,A-Alimentary tract and metabolism,Million of national currency units,3825.0
+4767,Canada,2015,11,A-Alimentary tract and metabolism,Million US$ at exchange rate,2991.1
+4768,Canada,2015,11,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million US$ at exchange rate,896.9
+4769,Canada,2015,11,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million of national currency units,1146.9
+4770,Canada,2015,11,R-Respiratory system,Million of national currency units,1874.5
+4771,Canada,2015,11,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ purchasing power parity",25.7
+4772,Canada,2015,11,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ exchange rate",25.1
+4773,Canada,2015,11,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"Million US$, purchasing power parity",919.0
+4774,Canada,2015,11,N05C-Hypnotics and sedatives,"/capita, US$ exchange rate",4.5
+4775,Canada,2015,11,N05C-Hypnotics and sedatives,"/capita, US$ purchasing power parity",4.6
+4776,Canada,2015,11,N05C-Hypnotics and sedatives,"Million US$, purchasing power parity",163.6
+4777,Canada,2015,11,N05C-Hypnotics and sedatives,Million of national currency units,204.2
+4778,Canada,2015,11,N05C-Hypnotics and sedatives,Million US$ at exchange rate,159.7
+4779,Canada,2015,11,N05C-Hypnotics and sedatives,% of total sales,0.8
+4780,Canada,2015,11,N06A-Antidepressants,"Million US$, purchasing power parity",1148.1
+4781,Canada,2015,11,N06A-Antidepressants,"/capita, US$ exchange rate",31.4
+4782,Canada,2015,11,N06A-Antidepressants,"/capita, US$ purchasing power parity",32.2
+4783,Canada,2015,11,N06A-Antidepressants,Million of national currency units,1432.9
+4784,Canada,2015,11,N06A-Antidepressants,Million US$ at exchange rate,1120.5
+4785,Canada,2015,11,Products not elsewhere classified,Million US$ at exchange rate,4788.3
+4786,Canada,2015,11,Products not elsewhere classified,"Million US$, purchasing power parity",4906.2
+4787,Canada,2015,11,Products not elsewhere classified,"/capita, US$ exchange rate",134.1
+4788,Canada,2015,11,R03-Drugs for obstructive airway diseases,"/capita, US$ purchasing power parity",33.6
+4789,Canada,2015,11,Products not elsewhere classified,Million of national currency units,6123.2
+4790,Canada,2015,11,R03-Drugs for obstructive airway diseases,% of total sales,5.5
+4791,Canada,2015,11,A02A-Antacids,Million US$ at exchange rate,1.1
+4792,Canada,2015,11,A02A-Antacids,"Million US$, purchasing power parity",1.1
+4793,Canada,2015,11,A02A-Antacids,"/capita, US$ exchange rate",0.0
+4794,Canada,2015,11,A02A-Antacids,"/capita, US$ purchasing power parity",0.0
+4795,Canada,2015,11,A02A-Antacids,% of total sales,0.0
+4796,Canada,2015,11,A02A-Antacids,Million of national currency units,1.4
+4797,Canada,2015,11,Products not elsewhere classified,"/capita, US$ purchasing power parity",137.4
+4798,Canada,2015,11,Products not elsewhere classified,% of total sales,22.6
+4799,Canada,2015,11,R-Respiratory system,"/capita, US$ purchasing power parity",42.1
+4800,Canada,2015,11,A-Alimentary tract and metabolism,"/capita, US$ purchasing power parity",85.8
+4801,Canada,2015,11,R-Respiratory system,Million US$ at exchange rate,1465.8
+4802,Canada,2015,11,R-Respiratory system,"Million US$, purchasing power parity",1502.0
+4803,Canada,2015,11,R-Respiratory system,"/capita, US$ exchange rate",41.1
+4804,Canada,2015,11,R03-Drugs for obstructive airway diseases,Million US$ at exchange rate,1171.9
+4805,Canada,2015,11,R03-Drugs for obstructive airway diseases,"Million US$, purchasing power parity",1200.8
+4806,Canada,2015,11,R03-Drugs for obstructive airway diseases,"/capita, US$ exchange rate",32.8
+4807,Canada,2015,11,A-Alimentary tract and metabolism,% of total sales,14.1
+4808,Canada,2015,11,R-Respiratory system,% of total sales,6.9
+4809,Canada,2015,11,R03-Drugs for obstructive airway diseases,Million of national currency units,1498.6
+4810,Canada,2015,11,N05B-Anxiolytics,% of total sales,0.6
+4811,Canada,2015,11,N02-Analgesics,"/capita, US$ purchasing power parity",25.1
+4812,Canada,2015,11,N02-Analgesics,"/capita, US$ exchange rate",24.5
+4813,Canada,2015,11,A10-Drugs used in diabetes,"Million US$, purchasing power parity",1363.8
+4814,Canada,2015,11,Total pharmaceutical sales,Million of national currency units,27126.4
+4815,Canada,2015,11,N02-Analgesics,% of total sales,4.1
+4816,Canada,2015,11,N02-Analgesics,Million of national currency units,1117.2
+4817,Canada,2015,11,N02-Analgesics,Million US$ at exchange rate,873.6
+4818,Canada,2015,11,A10-Drugs used in diabetes,Million US$ at exchange rate,1331.0
+4819,Canada,2015,11,A10-Drugs used in diabetes,Million of national currency units,1702.1
+4820,Canada,2015,11,A10-Drugs used in diabetes,"/capita, US$ exchange rate",37.3
+4821,Canada,2015,11,A10-Drugs used in diabetes,"/capita, US$ purchasing power parity",38.2
+4822,Canada,2015,11,A10-Drugs used in diabetes,% of total sales,6.3
+4823,Canada,2015,11,Total pharmaceutical sales,"Million US$, purchasing power parity",21735.2
+4824,Canada,2015,11,Total pharmaceutical sales,Million US$ at exchange rate,21212.6
+4825,Canada,2015,11,Total pharmaceutical sales,"/capita, US$ purchasing power parity",608.8
+4826,Canada,2015,11,Total pharmaceutical sales,"/capita, US$ exchange rate",594.1
+4827,Canada,2015,11,N05B-Anxiolytics,"Million US$, purchasing power parity",130.7
+4828,Canada,2015,11,N05B-Anxiolytics,Million US$ at exchange rate,127.5
+4829,Canada,2015,11,N05B-Anxiolytics,"/capita, US$ purchasing power parity",3.7
+4830,Canada,2015,11,N05B-Anxiolytics,"/capita, US$ exchange rate",3.6
+4831,Canada,2015,11,N02-Analgesics,"Million US$, purchasing power parity",895.2
+4832,Canada,2015,11,N05B-Anxiolytics,Million of national currency units,163.1
+4833,Canada,2014,11,C-Cardiovascular system,Million of national currency units,3973.2
+4834,Canada,2014,11,C-Cardiovascular system,"Million US$, purchasing power parity",3229.3
+4835,Canada,2014,11,C-Cardiovascular system,Million US$ at exchange rate,3596.5
+4836,Canada,2014,11,"C01B-Antiarrhythmics, Class I and III","Million US$, purchasing power parity",23.5
+4837,Canada,2014,11,"C01B-Antiarrhythmics, Class I and III",Million US$ at exchange rate,26.2
+4838,Canada,2014,11,N-Nervous system,% of total sales,20.9
+4839,Canada,2014,11,"C01B-Antiarrhythmics, Class I and III","/capita, US$ purchasing power parity",0.7
+4840,Canada,2014,11,"C01B-Antiarrhythmics, Class I and III","/capita, US$ exchange rate",0.7
+4841,Canada,2014,11,C-Cardiovascular system,"/capita, US$ exchange rate",101.5
+4842,Canada,2014,11,G03-Sex hormones and modulators of the genital system,% of total sales,3.1
+4843,Canada,2014,11,G-Genito urinary system and sex hormones,"/capita, US$ purchasing power parity",34.7
+4844,Canada,2014,11,G-Genito urinary system and sex hormones,% of total sales,5.9
+4845,Canada,2014,11,G03-Sex hormones and modulators of the genital system,"/capita, US$ purchasing power parity",18.3
+4846,Canada,2014,11,"C01B-Antiarrhythmics, Class I and III",% of total sales,0.1
+4847,Canada,2014,11,M01A-Antiinflammatory and antirheumatic products non-steroids,% of total sales,1.8
+4848,Canada,2014,11,G03-Sex hormones and modulators of the genital system,"/capita, US$ exchange rate",20.4
+4849,Canada,2014,11,B-Blood and blood forming organs,"/capita, US$ purchasing power parity",20.0
+4850,Canada,2014,11,B-Blood and blood forming organs,% of total sales,3.4
+4851,Canada,2014,11,B-Blood and blood forming organs,"/capita, US$ exchange rate",22.2
+4852,Canada,2014,11,J-Antiinfectives for systemic use,"Million US$, purchasing power parity",1363.9
+4853,Canada,2014,11,J-Antiinfectives for systemic use,Million US$ at exchange rate,1519.0
+4854,Canada,2014,11,N-Nervous system,"/capita, US$ exchange rate",135.9
+4855,Canada,2014,11,N-Nervous system,"/capita, US$ purchasing power parity",122.1
+4856,Canada,2014,11,N-Nervous system,Million of national currency units,5321.8
+4857,Canada,2014,11,J-Antiinfectives for systemic use,Million of national currency units,1678.1
+4858,Canada,2014,11,N-Nervous system,"Million US$, purchasing power parity",4325.4
+4859,Canada,2014,11,N-Nervous system,Million US$ at exchange rate,4817.2
+4860,Canada,2014,11,C-Cardiovascular system,% of total sales,15.6
+4861,Canada,2014,11,B-Blood and blood forming organs,Million of national currency units,870.2
+4862,Canada,2014,11,G03-Sex hormones and modulators of the genital system,Million of national currency units,798.1
+4863,Canada,2014,11,C-Cardiovascular system,"/capita, US$ purchasing power parity",91.1
+4864,Canada,2014,11,G03-Sex hormones and modulators of the genital system,Million US$ at exchange rate,722.4
+4865,Canada,2014,11,G03-Sex hormones and modulators of the genital system,"Million US$, purchasing power parity",648.7
+4866,Canada,2014,11,J-Antiinfectives for systemic use,"/capita, US$ purchasing power parity",38.5
+4867,Canada,2014,11,J-Antiinfectives for systemic use,"/capita, US$ exchange rate",42.9
+4868,Canada,2014,11,"C01B-Antiarrhythmics, Class I and III",Million of national currency units,28.9
+4869,Canada,2014,11,B-Blood and blood forming organs,Million US$ at exchange rate,787.7
+4870,Canada,2014,11,B-Blood and blood forming organs,"Million US$, purchasing power parity",707.3
+4871,Canada,2014,11,J-Antiinfectives for systemic use,% of total sales,6.6
+4872,Canada,2014,11,J01-Antibacterials for systemic use,Million US$ at exchange rate,618.4
+4873,Canada,2014,11,M-Musculo-skeletal system,"/capita, US$ purchasing power parity",22.7
+4874,Canada,2014,11,M-Musculo-skeletal system,"/capita, US$ exchange rate",25.2
+4875,Canada,2014,11,C03-Diuretics,% of total sales,0.8
+4876,Canada,2014,11,J01-Antibacterials for systemic use,Million of national currency units,683.2
+4877,Canada,2014,11,M-Musculo-skeletal system,Million of national currency units,988.0
+4878,Canada,2014,11,J01-Antibacterials for systemic use,"Million US$, purchasing power parity",555.3
+4879,Canada,2014,11,M-Musculo-skeletal system,"Million US$, purchasing power parity",803.0
+4880,Canada,2014,11,M-Musculo-skeletal system,Million US$ at exchange rate,894.3
+4881,Canada,2014,11,C03-Diuretics,"/capita, US$ purchasing power parity",4.6
+4882,Canada,2014,11,C08-Calcium channel blockers,Million US$ at exchange rate,495.6
+4883,Canada,2014,11,C08-Calcium channel blockers,Million of national currency units,547.5
+4884,Canada,2014,11,C08-Calcium channel blockers,"Million US$, purchasing power parity",445.0
+4885,Canada,2014,11,M-Musculo-skeletal system,% of total sales,3.9
+4886,Canada,2014,11,C03-Diuretics,Million of national currency units,201.9
+4887,Canada,2014,11,C03-Diuretics,"/capita, US$ exchange rate",5.2
+4888,Canada,2014,11,C03-Diuretics,"Million US$, purchasing power parity",164.1
+4889,Canada,2014,11,C03-Diuretics,Million US$ at exchange rate,182.8
+4890,Canada,2014,11,C07-Beta blocking agents,"/capita, US$ purchasing power parity",7.1
+4891,Canada,2014,11,C07-Beta blocking agents,% of total sales,1.2
+4892,Canada,2014,11,C07-Beta blocking agents,"/capita, US$ exchange rate",8.0
+4893,Canada,2014,11,C07-Beta blocking agents,"Million US$, purchasing power parity",253.3
+4894,Canada,2014,11,C10-Lipid modifying agents,"/capita, US$ purchasing power parity",31.4
+4895,Canada,2014,11,C10-Lipid modifying agents,% of total sales,5.4
+4896,Canada,2014,11,C10-Lipid modifying agents,"/capita, US$ exchange rate",35.0
+4897,Canada,2014,11,C07-Beta blocking agents,Million US$ at exchange rate,282.1
+4898,Canada,2014,11,J01-Antibacterials for systemic use,% of total sales,2.7
+4899,Canada,2014,11,J01-Antibacterials for systemic use,"/capita, US$ exchange rate",17.5
+4900,Canada,2014,11,J01-Antibacterials for systemic use,"/capita, US$ purchasing power parity",15.7
+4901,Canada,2014,11,C10-Lipid modifying agents,"Million US$, purchasing power parity",1113.6
+4902,Canada,2014,11,"H-Systemic hormonal preparations, excluding sex hormones and insulins","Million US$, purchasing power parity",368.9
+4903,Canada,2014,11,C07-Beta blocking agents,Million of national currency units,311.6
+4904,Canada,2014,11,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million US$ at exchange rate,410.9
+4905,Canada,2014,11,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million of national currency units,453.9
+4906,Canada,2014,11,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ exchange rate",11.6
+4907,Canada,2014,11,C09-Agents acting on the Renin-Angiotensin system,% of total sales,4.7
+4908,Canada,2014,11,"H-Systemic hormonal preparations, excluding sex hormones and insulins",% of total sales,1.8
+4909,Canada,2014,11,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ purchasing power parity",10.4
+4910,Canada,2014,11,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ purchasing power parity",27.7
+4911,Canada,2014,11,M01A-Antiinflammatory and antirheumatic products non-steroids,"Million US$, purchasing power parity",365.9
+4912,Canada,2014,11,M01A-Antiinflammatory and antirheumatic products non-steroids,Million US$ at exchange rate,407.5
+4913,Canada,2014,11,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ exchange rate",11.5
+4914,Canada,2014,11,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ purchasing power parity",10.3
+4915,Canada,2014,11,C02-Antihypertensives,"Million US$, purchasing power parity",74.8
+4916,Canada,2014,11,C10-Lipid modifying agents,Million of national currency units,1370.1
+4917,Canada,2014,11,C02-Antihypertensives,Million of national currency units,92.0
+4918,Canada,2014,11,C02-Antihypertensives,Million US$ at exchange rate,83.3
+4919,Canada,2014,11,C01A-Cardiac glycosides,% of total sales,0.1
+4920,Canada,2014,11,C01A-Cardiac glycosides,"Million US$, purchasing power parity",16.7
+4921,Canada,2014,11,C01A-Cardiac glycosides,"/capita, US$ exchange rate",0.5
+4922,Canada,2014,11,C01A-Cardiac glycosides,"/capita, US$ purchasing power parity",0.5
+4923,Canada,2014,11,C02-Antihypertensives,"/capita, US$ purchasing power parity",2.1
+4924,Canada,2014,11,C02-Antihypertensives,% of total sales,0.4
+4925,Canada,2014,11,G-Genito urinary system and sex hormones,Million US$ at exchange rate,1369.1
+4926,Canada,2014,11,G-Genito urinary system and sex hormones,Million of national currency units,1512.5
+4927,Canada,2014,11,C02-Antihypertensives,"/capita, US$ exchange rate",2.3
+4928,Canada,2014,11,C08-Calcium channel blockers,"/capita, US$ purchasing power parity",12.6
+4929,Canada,2014,11,C08-Calcium channel blockers,"/capita, US$ exchange rate",14.0
+4930,Canada,2014,11,C10-Lipid modifying agents,Million US$ at exchange rate,1240.2
+4931,Canada,2014,11,C08-Calcium channel blockers,% of total sales,2.1
+4932,Canada,2014,11,C09-Agents acting on the Renin-Angiotensin system,Million US$ at exchange rate,1094.1
+4933,Canada,2014,11,C09-Agents acting on the Renin-Angiotensin system,"Million US$, purchasing power parity",982.4
+4934,Canada,2014,11,M01A-Antiinflammatory and antirheumatic products non-steroids,Million of national currency units,450.2
+4935,Canada,2014,11,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ exchange rate",30.9
+4936,Canada,2014,11,C09-Agents acting on the Renin-Angiotensin system,Million of national currency units,1208.7
+4937,Canada,2014,11,G-Genito urinary system and sex hormones,"/capita, US$ exchange rate",38.6
+4938,Canada,2014,11,G-Genito urinary system and sex hormones,"Million US$, purchasing power parity",1229.3
+4939,Canada,2014,11,C01A-Cardiac glycosides,Million US$ at exchange rate,18.6
+4940,Canada,2014,11,C01A-Cardiac glycosides,Million of national currency units,20.5
+4941,Canada,2014,11,A-Alimentary tract and metabolism,"Million US$, purchasing power parity",2745.1
+4942,Canada,2014,11,A-Alimentary tract and metabolism,"/capita, US$ exchange rate",86.3
+4943,Canada,2014,11,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),% of total sales,4.4
+4944,Canada,2014,11,N06A-Antidepressants,% of total sales,5.9
+4945,Canada,2014,11,A-Alimentary tract and metabolism,Million of national currency units,3377.5
+4946,Canada,2014,11,A-Alimentary tract and metabolism,Million US$ at exchange rate,3057.3
+4947,Canada,2014,11,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million US$ at exchange rate,1027.3
+4948,Canada,2014,11,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million of national currency units,1134.9
+4949,Canada,2014,11,R-Respiratory system,Million of national currency units,1794.4
+4950,Canada,2014,11,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ purchasing power parity",26.0
+4951,Canada,2014,11,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"Million US$, purchasing power parity",922.4
+4952,Canada,2014,11,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ exchange rate",29.0
+4953,Canada,2014,11,N05C-Hypnotics and sedatives,"/capita, US$ exchange rate",5.1
+4954,Canada,2014,11,N05C-Hypnotics and sedatives,"/capita, US$ purchasing power parity",4.6
+4955,Canada,2014,11,N05C-Hypnotics and sedatives,"Million US$, purchasing power parity",162.4
+4956,Canada,2014,11,N05C-Hypnotics and sedatives,Million of national currency units,199.8
+4957,Canada,2014,11,N05C-Hypnotics and sedatives,Million US$ at exchange rate,180.9
+4958,Canada,2014,11,N06A-Antidepressants,"/capita, US$ exchange rate",38.2
+4959,Canada,2014,11,N06A-Antidepressants,"/capita, US$ purchasing power parity",34.3
+4960,Canada,2014,11,N06A-Antidepressants,"Million US$, purchasing power parity",1216.3
+4961,Canada,2014,11,N06A-Antidepressants,Million of national currency units,1496.5
+4962,Canada,2014,11,N05C-Hypnotics and sedatives,% of total sales,0.8
+4963,Canada,2014,11,N06A-Antidepressants,Million US$ at exchange rate,1354.6
+4964,Canada,2014,11,Products not elsewhere classified,Million US$ at exchange rate,5021.1
+4965,Canada,2014,11,Products not elsewhere classified,"Million US$, purchasing power parity",4508.4
+4966,Canada,2014,11,Products not elsewhere classified,"/capita, US$ exchange rate",141.7
+4967,Canada,2014,11,R03-Drugs for obstructive airway diseases,"/capita, US$ purchasing power parity",33.6
+4968,Canada,2014,11,R03-Drugs for obstructive airway diseases,% of total sales,5.7
+4969,Canada,2014,11,Products not elsewhere classified,Million of national currency units,5547.0
+4970,Canada,2014,11,A02A-Antacids,Million US$ at exchange rate,1.2
+4971,Canada,2014,11,A02A-Antacids,"Million US$, purchasing power parity",1.1
+4972,Canada,2014,11,A02A-Antacids,"/capita, US$ exchange rate",0.0
+4973,Canada,2014,11,A02A-Antacids,"/capita, US$ purchasing power parity",0.0
+4974,Canada,2014,11,A02A-Antacids,% of total sales,0.0
+4975,Canada,2014,11,Products not elsewhere classified,"/capita, US$ purchasing power parity",127.2
+4976,Canada,2014,11,Products not elsewhere classified,% of total sales,21.7
+4977,Canada,2014,11,A02A-Antacids,Million of national currency units,1.3
+4978,Canada,2014,11,R-Respiratory system,"/capita, US$ purchasing power parity",41.2
+4979,Canada,2014,11,A-Alimentary tract and metabolism,"/capita, US$ purchasing power parity",77.5
+4980,Canada,2014,11,R-Respiratory system,Million US$ at exchange rate,1624.3
+4981,Canada,2014,11,R-Respiratory system,"Million US$, purchasing power parity",1458.4
+4982,Canada,2014,11,R-Respiratory system,"/capita, US$ exchange rate",45.8
+4983,Canada,2014,11,R03-Drugs for obstructive airway diseases,Million US$ at exchange rate,1325.2
+4984,Canada,2014,11,R03-Drugs for obstructive airway diseases,"Million US$, purchasing power parity",1189.9
+4985,Canada,2014,11,R03-Drugs for obstructive airway diseases,"/capita, US$ exchange rate",37.4
+4986,Canada,2014,11,A-Alimentary tract and metabolism,% of total sales,13.2
+4987,Canada,2014,11,R-Respiratory system,% of total sales,7.0
+4988,Canada,2014,11,R03-Drugs for obstructive airway diseases,Million of national currency units,1464.0
+4989,Canada,2014,11,N02-Analgesics,"/capita, US$ purchasing power parity",25.4
+4990,Canada,2014,11,N02-Analgesics,"/capita, US$ exchange rate",28.3
+4991,Canada,2014,11,A10-Drugs used in diabetes,"Million US$, purchasing power parity",1230.6
+4992,Canada,2014,11,Total pharmaceutical sales,Million of national currency units,25517.0
+4993,Canada,2014,11,N02-Analgesics,% of total sales,4.3
+4994,Canada,2014,11,N02-Analgesics,Million US$ at exchange rate,1002.9
+4995,Canada,2014,11,N02-Analgesics,Million of national currency units,1107.9
+4996,Canada,2014,11,A10-Drugs used in diabetes,Million US$ at exchange rate,1370.5
+4997,Canada,2014,11,A10-Drugs used in diabetes,Million of national currency units,1514.1
+4998,Canada,2014,11,A10-Drugs used in diabetes,"/capita, US$ exchange rate",38.7
+4999,Canada,2014,11,A10-Drugs used in diabetes,"/capita, US$ purchasing power parity",34.7
+5000,Canada,2014,11,A10-Drugs used in diabetes,% of total sales,5.9
+5001,Canada,2014,11,Total pharmaceutical sales,"Million US$, purchasing power parity",20739.5
+5002,Canada,2014,11,Total pharmaceutical sales,Million US$ at exchange rate,23097.6
+5003,Canada,2014,11,Total pharmaceutical sales,"/capita, US$ purchasing power parity",585.2
+5004,Canada,2014,11,Total pharmaceutical sales,"/capita, US$ exchange rate",651.8
+5005,Canada,2014,11,N05B-Anxiolytics,"Million US$, purchasing power parity",133.1
+5006,Canada,2014,11,N05B-Anxiolytics,Million US$ at exchange rate,148.3
+5007,Canada,2014,11,N05B-Anxiolytics,"/capita, US$ purchasing power parity",3.8
+5008,Canada,2014,11,N05B-Anxiolytics,"/capita, US$ exchange rate",4.2
+5009,Canada,2014,11,N05B-Anxiolytics,% of total sales,0.6
+5010,Canada,2014,11,N02-Analgesics,"Million US$, purchasing power parity",900.5
+5011,Canada,2014,11,N05B-Anxiolytics,Million of national currency units,163.8
+5012,Canada,2013,11,C-Cardiovascular system,Million of national currency units,4082.7
+5013,Canada,2013,11,C-Cardiovascular system,"Million US$, purchasing power parity",3335.5
+5014,Canada,2013,11,C-Cardiovascular system,Million US$ at exchange rate,3963.3
+5015,Canada,2013,11,"C01B-Antiarrhythmics, Class I and III","Million US$, purchasing power parity",23.3
+5016,Canada,2013,11,N-Nervous system,% of total sales,21.3
+5017,Canada,2013,11,"C01B-Antiarrhythmics, Class I and III","/capita, US$ purchasing power parity",0.7
+5018,Canada,2013,11,"C01B-Antiarrhythmics, Class I and III","/capita, US$ exchange rate",0.8
+5019,Canada,2013,11,G03-Sex hormones and modulators of the genital system,% of total sales,3.2
+5020,Canada,2013,11,G-Genito urinary system and sex hormones,% of total sales,6.0
+5021,Canada,2013,11,"C01B-Antiarrhythmics, Class I and III",% of total sales,0.1
+5022,Canada,2013,11,M01A-Antiinflammatory and antirheumatic products non-steroids,% of total sales,1.9
+5023,Canada,2013,11,G03-Sex hormones and modulators of the genital system,"/capita, US$ purchasing power parity",18.3
+5024,Canada,2013,11,C-Cardiovascular system,"/capita, US$ exchange rate",113.0
+5025,Canada,2013,11,G03-Sex hormones and modulators of the genital system,"/capita, US$ exchange rate",21.7
+5026,Canada,2013,11,B-Blood and blood forming organs,"/capita, US$ purchasing power parity",18.0
+5027,Canada,2013,11,B-Blood and blood forming organs,% of total sales,3.1
+5028,Canada,2013,11,"C01B-Antiarrhythmics, Class I and III",Million US$ at exchange rate,27.7
+5029,Canada,2013,11,J-Antiinfectives for systemic use,"Million US$, purchasing power parity",1210.9
+5030,Canada,2013,11,B-Blood and blood forming organs,"/capita, US$ exchange rate",21.4
+5031,Canada,2013,11,J-Antiinfectives for systemic use,Million US$ at exchange rate,1438.8
+5032,Canada,2013,11,N-Nervous system,"/capita, US$ exchange rate",144.6
+5033,Canada,2013,11,N-Nervous system,"/capita, US$ purchasing power parity",121.7
+5034,Canada,2013,11,J-Antiinfectives for systemic use,Million of national currency units,1482.2
+5035,Canada,2013,11,N-Nervous system,Million of national currency units,5224.8
+5036,Canada,2013,11,N-Nervous system,Million US$ at exchange rate,5071.9
+5037,Canada,2013,11,N-Nervous system,"Million US$, purchasing power parity",4268.6
+5038,Canada,2013,11,C-Cardiovascular system,% of total sales,16.6
+5039,Canada,2013,11,B-Blood and blood forming organs,Million of national currency units,774.2
+5040,Canada,2013,11,C-Cardiovascular system,"/capita, US$ purchasing power parity",95.1
+5041,Canada,2013,11,G03-Sex hormones and modulators of the genital system,Million of national currency units,784.7
+5042,Canada,2013,11,G03-Sex hormones and modulators of the genital system,"Million US$, purchasing power parity",641.1
+5043,Canada,2013,11,G03-Sex hormones and modulators of the genital system,Million US$ at exchange rate,761.7
+5044,Canada,2013,11,B-Blood and blood forming organs,Million US$ at exchange rate,751.6
+5045,Canada,2013,11,J-Antiinfectives for systemic use,"/capita, US$ purchasing power parity",34.5
+5046,Canada,2013,11,"C01B-Antiarrhythmics, Class I and III",Million of national currency units,28.5
+5047,Canada,2013,11,J-Antiinfectives for systemic use,"/capita, US$ exchange rate",41.0
+5048,Canada,2013,11,B-Blood and blood forming organs,"Million US$, purchasing power parity",632.5
+5049,Canada,2013,11,J-Antiinfectives for systemic use,% of total sales,6.0
+5050,Canada,2013,11,C10-Lipid modifying agents,Million of national currency units,1484.4
+5051,Canada,2013,11,J01-Antibacterials for systemic use,Million US$ at exchange rate,658.8
+5052,Canada,2013,11,M-Musculo-skeletal system,"/capita, US$ purchasing power parity",23.0
+5053,Canada,2013,11,M-Musculo-skeletal system,"/capita, US$ exchange rate",27.4
+5054,Canada,2013,11,C03-Diuretics,% of total sales,0.8
+5055,Canada,2013,11,J01-Antibacterials for systemic use,Million of national currency units,678.7
+5056,Canada,2013,11,M-Musculo-skeletal system,Million of national currency units,989.4
+5057,Canada,2013,11,J01-Antibacterials for systemic use,"Million US$, purchasing power parity",554.5
+5058,Canada,2013,11,M-Musculo-skeletal system,"Million US$, purchasing power parity",808.3
+5059,Canada,2013,11,M-Musculo-skeletal system,Million US$ at exchange rate,960.5
+5060,Canada,2013,11,C08-Calcium channel blockers,Million US$ at exchange rate,545.8
+5061,Canada,2013,11,C08-Calcium channel blockers,Million of national currency units,562.3
+5062,Canada,2013,11,C08-Calcium channel blockers,"Million US$, purchasing power parity",459.4
+5063,Canada,2013,11,M-Musculo-skeletal system,% of total sales,4.0
+5064,Canada,2013,11,C03-Diuretics,"/capita, US$ exchange rate",5.5
+5065,Canada,2013,11,C03-Diuretics,"/capita, US$ purchasing power parity",4.7
+5066,Canada,2013,11,C03-Diuretics,"Million US$, purchasing power parity",163.5
+5067,Canada,2013,11,C03-Diuretics,Million of national currency units,200.1
+5068,Canada,2013,11,C03-Diuretics,Million US$ at exchange rate,194.2
+5069,Canada,2013,11,C07-Beta blocking agents,"/capita, US$ purchasing power parity",7.2
+5070,Canada,2013,11,C07-Beta blocking agents,% of total sales,1.3
+5071,Canada,2013,11,C07-Beta blocking agents,"Million US$, purchasing power parity",252.0
+5072,Canada,2013,11,C07-Beta blocking agents,"/capita, US$ exchange rate",8.5
+5073,Canada,2013,11,C10-Lipid modifying agents,% of total sales,6.0
+5074,Canada,2013,11,C10-Lipid modifying agents,"/capita, US$ purchasing power parity",34.6
+5075,Canada,2013,11,C10-Lipid modifying agents,"/capita, US$ exchange rate",41.1
+5076,Canada,2013,11,C07-Beta blocking agents,Million US$ at exchange rate,299.5
+5077,Canada,2013,11,J01-Antibacterials for systemic use,% of total sales,2.8
+5078,Canada,2013,11,J01-Antibacterials for systemic use,"/capita, US$ exchange rate",18.8
+5079,Canada,2013,11,C10-Lipid modifying agents,"Million US$, purchasing power parity",1212.7
+5080,Canada,2013,11,J01-Antibacterials for systemic use,"/capita, US$ purchasing power parity",15.8
+5081,Canada,2013,11,"H-Systemic hormonal preparations, excluding sex hormones and insulins","Million US$, purchasing power parity",355.5
+5082,Canada,2013,11,C07-Beta blocking agents,Million of national currency units,308.5
+5083,Canada,2013,11,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million of national currency units,435.1
+5084,Canada,2013,11,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million US$ at exchange rate,422.4
+5085,Canada,2013,11,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ exchange rate",12.0
+5086,Canada,2013,11,C09-Agents acting on the Renin-Angiotensin system,% of total sales,4.9
+5087,Canada,2013,11,"H-Systemic hormonal preparations, excluding sex hormones and insulins",% of total sales,1.8
+5088,Canada,2013,11,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ purchasing power parity",10.1
+5089,Canada,2013,11,M01A-Antiinflammatory and antirheumatic products non-steroids,"Million US$, purchasing power parity",371.8
+5090,Canada,2013,11,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ exchange rate",12.6
+5091,Canada,2013,11,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ purchasing power parity",28.1
+5092,Canada,2013,11,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ purchasing power parity",10.6
+5093,Canada,2013,11,C02-Antihypertensives,"Million US$, purchasing power parity",62.5
+5094,Canada,2013,11,C02-Antihypertensives,"/capita, US$ exchange rate",2.1
+5095,Canada,2013,11,C02-Antihypertensives,Million of national currency units,76.5
+5096,Canada,2013,11,C02-Antihypertensives,Million US$ at exchange rate,74.3
+5097,Canada,2013,11,C01A-Cardiac glycosides,% of total sales,0.1
+5098,Canada,2013,11,C01A-Cardiac glycosides,"Million US$, purchasing power parity",17.7
+5099,Canada,2013,11,M01A-Antiinflammatory and antirheumatic products non-steroids,Million US$ at exchange rate,441.8
+5100,Canada,2013,11,C01A-Cardiac glycosides,"/capita, US$ exchange rate",0.6
+5101,Canada,2013,11,C01A-Cardiac glycosides,"/capita, US$ purchasing power parity",0.5
+5102,Canada,2013,11,C02-Antihypertensives,"/capita, US$ purchasing power parity",1.8
+5103,Canada,2013,11,C02-Antihypertensives,% of total sales,0.3
+5104,Canada,2013,11,G-Genito urinary system and sex hormones,Million US$ at exchange rate,1430.8
+5105,Canada,2013,11,G-Genito urinary system and sex hormones,Million of national currency units,1473.9
+5106,Canada,2013,11,C08-Calcium channel blockers,"/capita, US$ purchasing power parity",13.1
+5107,Canada,2013,11,C08-Calcium channel blockers,"/capita, US$ exchange rate",15.6
+5108,Canada,2013,11,C10-Lipid modifying agents,Million US$ at exchange rate,1441.0
+5109,Canada,2013,11,C08-Calcium channel blockers,% of total sales,2.3
+5110,Canada,2013,11,C09-Agents acting on the Renin-Angiotensin system,Million US$ at exchange rate,1172.3
+5111,Canada,2013,11,C09-Agents acting on the Renin-Angiotensin system,"Million US$, purchasing power parity",986.6
+5112,Canada,2013,11,M01A-Antiinflammatory and antirheumatic products non-steroids,Million of national currency units,455.1
+5113,Canada,2013,11,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ exchange rate",33.4
+5114,Canada,2013,11,C09-Agents acting on the Renin-Angiotensin system,Million of national currency units,1207.6
+5115,Canada,2013,11,G-Genito urinary system and sex hormones,"/capita, US$ exchange rate",40.8
+5116,Canada,2013,11,G-Genito urinary system and sex hormones,"Million US$, purchasing power parity",1204.2
+5117,Canada,2013,11,C01A-Cardiac glycosides,Million US$ at exchange rate,21.1
+5118,Canada,2013,11,C01A-Cardiac glycosides,Million of national currency units,21.7
+5119,Canada,2013,11,G-Genito urinary system and sex hormones,"/capita, US$ purchasing power parity",34.3
+5120,Canada,2013,11,A-Alimentary tract and metabolism,"Million US$, purchasing power parity",2651.3
+5121,Canada,2013,11,A-Alimentary tract and metabolism,"/capita, US$ exchange rate",89.8
+5122,Canada,2013,11,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),% of total sales,4.9
+5123,Canada,2013,11,N06A-Antidepressants,% of total sales,5.9
+5124,Canada,2013,11,A-Alimentary tract and metabolism,Million of national currency units,3245.2
+5125,Canada,2013,11,A-Alimentary tract and metabolism,Million US$ at exchange rate,3150.3
+5126,Canada,2013,11,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million US$ at exchange rate,1160.7
+5127,Canada,2013,11,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million of national currency units,1195.7
+5128,Canada,2013,11,R-Respiratory system,Million of national currency units,1729.2
+5129,Canada,2013,11,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ purchasing power parity",27.8
+5130,Canada,2013,11,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ exchange rate",33.1
+5131,Canada,2013,11,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"Million US$, purchasing power parity",976.9
+5132,Canada,2013,11,N05C-Hypnotics and sedatives,"/capita, US$ exchange rate",5.3
+5133,Canada,2013,11,N05C-Hypnotics and sedatives,"/capita, US$ purchasing power parity",4.5
+5134,Canada,2013,11,N05C-Hypnotics and sedatives,Million of national currency units,193.2
+5135,Canada,2013,11,N05C-Hypnotics and sedatives,Million US$ at exchange rate,187.5
+5136,Canada,2013,11,N05C-Hypnotics and sedatives,"Million US$, purchasing power parity",157.8
+5137,Canada,2013,11,N05C-Hypnotics and sedatives,% of total sales,0.8
+5138,Canada,2013,11,N06A-Antidepressants,"/capita, US$ exchange rate",40.3
+5139,Canada,2013,11,N06A-Antidepressants,"/capita, US$ purchasing power parity",33.9
+5140,Canada,2013,11,N06A-Antidepressants,"Million US$, purchasing power parity",1189.9
+5141,Canada,2013,11,N06A-Antidepressants,Million of national currency units,1456.4
+5142,Canada,2013,11,N06A-Antidepressants,Million US$ at exchange rate,1413.8
+5143,Canada,2013,11,R-Respiratory system,Million US$ at exchange rate,1678.6
+5144,Canada,2013,11,Products not elsewhere classified,Million US$ at exchange rate,4992.5
+5145,Canada,2013,11,Products not elsewhere classified,"Million US$, purchasing power parity",4201.8
+5146,Canada,2013,11,Products not elsewhere classified,"/capita, US$ exchange rate",142.3
+5147,Canada,2013,11,R03-Drugs for obstructive airway diseases,"/capita, US$ purchasing power parity",32.6
+5148,Canada,2013,11,R03-Drugs for obstructive airway diseases,% of total sales,5.7
+5149,Canada,2013,11,Products not elsewhere classified,Million of national currency units,5143.0
+5150,Canada,2013,11,A02A-Antacids,Million US$ at exchange rate,1.3
+5151,Canada,2013,11,A02A-Antacids,"Million US$, purchasing power parity",1.1
+5152,Canada,2013,11,A02A-Antacids,"/capita, US$ exchange rate",0.0
+5153,Canada,2013,11,A02A-Antacids,"/capita, US$ purchasing power parity",0.0
+5154,Canada,2013,11,A02A-Antacids,% of total sales,0.0
+5155,Canada,2013,11,Products not elsewhere classified,"/capita, US$ purchasing power parity",119.8
+5156,Canada,2013,11,Products not elsewhere classified,% of total sales,20.9
+5157,Canada,2013,11,A02A-Antacids,Million of national currency units,1.3
+5158,Canada,2013,11,R-Respiratory system,"/capita, US$ purchasing power parity",40.3
+5159,Canada,2013,11,A-Alimentary tract and metabolism,"/capita, US$ purchasing power parity",75.6
+5160,Canada,2013,11,R-Respiratory system,"Million US$, purchasing power parity",1412.7
+5161,Canada,2013,11,R-Respiratory system,"/capita, US$ exchange rate",47.8
+5162,Canada,2013,11,A-Alimentary tract and metabolism,% of total sales,13.2
+5163,Canada,2013,11,R03-Drugs for obstructive airway diseases,"Million US$, purchasing power parity",1143.6
+5164,Canada,2013,11,R03-Drugs for obstructive airway diseases,"/capita, US$ exchange rate",38.7
+5165,Canada,2013,11,R03-Drugs for obstructive airway diseases,Million US$ at exchange rate,1358.8
+5166,Canada,2013,11,R-Respiratory system,% of total sales,7.0
+5167,Canada,2013,11,R03-Drugs for obstructive airway diseases,Million of national currency units,1399.8
+5168,Canada,2013,11,N02-Analgesics,"/capita, US$ purchasing power parity",25.5
+5169,Canada,2013,11,N02-Analgesics,"/capita, US$ exchange rate",30.3
+5170,Canada,2013,11,A10-Drugs used in diabetes,"Million US$, purchasing power parity",1118.5
+5171,Canada,2013,11,Total pharmaceutical sales,Million of national currency units,24579.2
+5172,Canada,2013,11,N02-Analgesics,% of total sales,4.4
+5173,Canada,2013,11,N02-Analgesics,Million US$ at exchange rate,1061.6
+5174,Canada,2013,11,A10-Drugs used in diabetes,Million US$ at exchange rate,1328.9
+5175,Canada,2013,11,N02-Analgesics,Million of national currency units,1093.6
+5176,Canada,2013,11,A10-Drugs used in diabetes,Million of national currency units,1369.0
+5177,Canada,2013,11,A10-Drugs used in diabetes,"/capita, US$ exchange rate",37.9
+5178,Canada,2013,11,A10-Drugs used in diabetes,"/capita, US$ purchasing power parity",31.9
+5179,Canada,2013,11,A10-Drugs used in diabetes,% of total sales,5.6
+5180,Canada,2013,11,Total pharmaceutical sales,"Million US$, purchasing power parity",20081.0
+5181,Canada,2013,11,Total pharmaceutical sales,Million US$ at exchange rate,23860.1
+5182,Canada,2013,11,Total pharmaceutical sales,"/capita, US$ purchasing power parity",572.4
+5183,Canada,2013,11,Total pharmaceutical sales,"/capita, US$ exchange rate",680.1
+5184,Canada,2013,11,N02-Analgesics,"Million US$, purchasing power parity",893.5
+5185,Canada,2013,11,N05B-Anxiolytics,"Million US$, purchasing power parity",134.2
+5186,Canada,2013,11,N05B-Anxiolytics,"/capita, US$ purchasing power parity",3.8
+5187,Canada,2013,11,N05B-Anxiolytics,"/capita, US$ exchange rate",4.5
+5188,Canada,2013,11,N05B-Anxiolytics,Million US$ at exchange rate,159.4
+5189,Canada,2013,11,N05B-Anxiolytics,% of total sales,0.7
+5190,Canada,2013,11,N05B-Anxiolytics,Million of national currency units,164.2
+5191,Canada,2012,11,C-Cardiovascular system,Million of national currency units,4627.3
+5192,Canada,2012,11,"C01B-Antiarrhythmics, Class I and III",% of total sales,0.1
+5193,Canada,2012,11,C-Cardiovascular system,"Million US$, purchasing power parity",3717.9
+5194,Canada,2012,11,C-Cardiovascular system,Million US$ at exchange rate,4630.2
+5195,Canada,2012,11,"C01B-Antiarrhythmics, Class I and III","Million US$, purchasing power parity",24.6
+5196,Canada,2012,11,N-Nervous system,% of total sales,21.4
+5197,Canada,2012,11,"C01B-Antiarrhythmics, Class I and III","/capita, US$ purchasing power parity",0.7
+5198,Canada,2012,11,"C01B-Antiarrhythmics, Class I and III","/capita, US$ exchange rate",0.9
+5199,Canada,2012,11,G03-Sex hormones and modulators of the genital system,% of total sales,3.1
+5200,Canada,2012,11,G-Genito urinary system and sex hormones,% of total sales,5.9
+5201,Canada,2012,11,G03-Sex hormones and modulators of the genital system,"/capita, US$ purchasing power parity",17.4
+5202,Canada,2012,11,M01A-Antiinflammatory and antirheumatic products non-steroids,% of total sales,1.9
+5203,Canada,2012,11,G03-Sex hormones and modulators of the genital system,"/capita, US$ exchange rate",21.7
+5204,Canada,2012,11,C-Cardiovascular system,"/capita, US$ exchange rate",133.4
+5205,Canada,2012,11,C-Cardiovascular system,"/capita, US$ purchasing power parity",107.1
+5206,Canada,2012,11,B-Blood and blood forming organs,"/capita, US$ purchasing power parity",17.2
+5207,Canada,2012,11,B-Blood and blood forming organs,% of total sales,3.1
+5208,Canada,2012,11,B-Blood and blood forming organs,"/capita, US$ exchange rate",21.4
+5209,Canada,2012,11,"C01B-Antiarrhythmics, Class I and III",Million US$ at exchange rate,30.6
+5210,Canada,2012,11,J-Antiinfectives for systemic use,"Million US$, purchasing power parity",1158.4
+5211,Canada,2012,11,J-Antiinfectives for systemic use,Million US$ at exchange rate,1442.7
+5212,Canada,2012,11,N-Nervous system,"/capita, US$ exchange rate",149.9
+5213,Canada,2012,11,N-Nervous system,"/capita, US$ purchasing power parity",120.4
+5214,Canada,2012,11,N-Nervous system,Million of national currency units,5200.6
+5215,Canada,2012,11,N-Nervous system,Million US$ at exchange rate,5203.9
+5216,Canada,2012,11,N-Nervous system,"Million US$, purchasing power parity",4178.5
+5217,Canada,2012,11,J-Antiinfectives for systemic use,Million of national currency units,1441.8
+5218,Canada,2012,11,C-Cardiovascular system,% of total sales,19.0
+5219,Canada,2012,11,B-Blood and blood forming organs,Million of national currency units,742.9
+5220,Canada,2012,11,G03-Sex hormones and modulators of the genital system,Million of national currency units,751.1
+5221,Canada,2012,11,G03-Sex hormones and modulators of the genital system,Million US$ at exchange rate,751.6
+5222,Canada,2012,11,G03-Sex hormones and modulators of the genital system,"Million US$, purchasing power parity",603.5
+5223,Canada,2012,11,B-Blood and blood forming organs,Million US$ at exchange rate,743.4
+5224,Canada,2012,11,J-Antiinfectives for systemic use,"/capita, US$ purchasing power parity",33.4
+5225,Canada,2012,11,J-Antiinfectives for systemic use,"/capita, US$ exchange rate",41.6
+5226,Canada,2012,11,"C01B-Antiarrhythmics, Class I and III",Million of national currency units,30.6
+5227,Canada,2012,11,B-Blood and blood forming organs,"Million US$, purchasing power parity",596.9
+5228,Canada,2012,11,J-Antiinfectives for systemic use,% of total sales,5.9
+5229,Canada,2012,11,J01-Antibacterials for systemic use,Million US$ at exchange rate,694.6
+5230,Canada,2012,11,M-Musculo-skeletal system,"/capita, US$ purchasing power parity",22.7
+5231,Canada,2012,11,C03-Diuretics,% of total sales,0.8
+5232,Canada,2012,11,M-Musculo-skeletal system,"/capita, US$ exchange rate",28.3
+5233,Canada,2012,11,J01-Antibacterials for systemic use,Million of national currency units,694.2
+5234,Canada,2012,11,M-Musculo-skeletal system,Million of national currency units,980.8
+5235,Canada,2012,11,J01-Antibacterials for systemic use,"Million US$, purchasing power parity",557.8
+5236,Canada,2012,11,M-Musculo-skeletal system,"Million US$, purchasing power parity",788.0
+5237,Canada,2012,11,M-Musculo-skeletal system,Million US$ at exchange rate,981.4
+5238,Canada,2012,11,C08-Calcium channel blockers,Million US$ at exchange rate,613.8
+5239,Canada,2012,11,M-Musculo-skeletal system,% of total sales,4.0
+5240,Canada,2012,11,C08-Calcium channel blockers,"Million US$, purchasing power parity",492.8
+5241,Canada,2012,11,C08-Calcium channel blockers,Million of national currency units,613.4
+5242,Canada,2012,11,C03-Diuretics,Million of national currency units,198.4
+5243,Canada,2012,11,C03-Diuretics,"/capita, US$ exchange rate",5.7
+5244,Canada,2012,11,C03-Diuretics,"/capita, US$ purchasing power parity",4.6
+5245,Canada,2012,11,C03-Diuretics,Million US$ at exchange rate,198.5
+5246,Canada,2012,11,C03-Diuretics,"Million US$, purchasing power parity",159.4
+5247,Canada,2012,11,C07-Beta blocking agents,"/capita, US$ purchasing power parity",7.4
+5248,Canada,2012,11,C07-Beta blocking agents,% of total sales,1.3
+5249,Canada,2012,11,C07-Beta blocking agents,"Million US$, purchasing power parity",258.3
+5250,Canada,2012,11,C07-Beta blocking agents,"/capita, US$ exchange rate",9.3
+5251,Canada,2012,11,C10-Lipid modifying agents,% of total sales,7.5
+5252,Canada,2012,11,C10-Lipid modifying agents,"/capita, US$ purchasing power parity",42.2
+5253,Canada,2012,11,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ exchange rate",11.9
+5254,Canada,2012,11,C07-Beta blocking agents,Million US$ at exchange rate,321.7
+5255,Canada,2012,11,J01-Antibacterials for systemic use,% of total sales,2.9
+5256,Canada,2012,11,C10-Lipid modifying agents,"Million US$, purchasing power parity",1465.0
+5257,Canada,2012,11,J01-Antibacterials for systemic use,"/capita, US$ exchange rate",20.0
+5258,Canada,2012,11,J01-Antibacterials for systemic use,"/capita, US$ purchasing power parity",16.1
+5259,Canada,2012,11,"H-Systemic hormonal preparations, excluding sex hormones and insulins","Million US$, purchasing power parity",332.5
+5260,Canada,2012,11,C07-Beta blocking agents,Million of national currency units,321.5
+5261,Canada,2012,11,C10-Lipid modifying agents,"/capita, US$ exchange rate",52.6
+5262,Canada,2012,11,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million of national currency units,413.8
+5263,Canada,2012,11,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million US$ at exchange rate,414.1
+5264,Canada,2012,11,C09-Agents acting on the Renin-Angiotensin system,% of total sales,5.6
+5265,Canada,2012,11,"H-Systemic hormonal preparations, excluding sex hormones and insulins",% of total sales,1.7
+5266,Canada,2012,11,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ purchasing power parity",9.6
+5267,Canada,2012,11,M01A-Antiinflammatory and antirheumatic products non-steroids,"Million US$, purchasing power parity",364.9
+5268,Canada,2012,11,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ exchange rate",13.1
+5269,Canada,2012,11,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ purchasing power parity",31.5
+5270,Canada,2012,11,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ purchasing power parity",10.5
+5271,Canada,2012,11,C02-Antihypertensives,"Million US$, purchasing power parity",59.0
+5272,Canada,2012,11,C02-Antihypertensives,"/capita, US$ exchange rate",2.1
+5273,Canada,2012,11,C02-Antihypertensives,Million of national currency units,73.4
+5274,Canada,2012,11,C02-Antihypertensives,Million US$ at exchange rate,73.4
+5275,Canada,2012,11,C01A-Cardiac glycosides,"Million US$, purchasing power parity",17.9
+5276,Canada,2012,11,C01A-Cardiac glycosides,"/capita, US$ exchange rate",0.6
+5277,Canada,2012,11,C01A-Cardiac glycosides,% of total sales,0.1
+5278,Canada,2012,11,C01A-Cardiac glycosides,"/capita, US$ purchasing power parity",0.5
+5279,Canada,2012,11,C10-Lipid modifying agents,Million of national currency units,1823.4
+5280,Canada,2012,11,M01A-Antiinflammatory and antirheumatic products non-steroids,Million US$ at exchange rate,454.4
+5281,Canada,2012,11,C02-Antihypertensives,% of total sales,0.3
+5282,Canada,2012,11,C02-Antihypertensives,"/capita, US$ purchasing power parity",1.7
+5283,Canada,2012,11,G-Genito urinary system and sex hormones,Million US$ at exchange rate,1431.5
+5284,Canada,2012,11,G-Genito urinary system and sex hormones,Million of national currency units,1430.6
+5285,Canada,2012,11,C08-Calcium channel blockers,"/capita, US$ purchasing power parity",14.2
+5286,Canada,2012,11,C08-Calcium channel blockers,"/capita, US$ exchange rate",17.7
+5287,Canada,2012,11,C10-Lipid modifying agents,Million US$ at exchange rate,1824.6
+5288,Canada,2012,11,C08-Calcium channel blockers,% of total sales,2.5
+5289,Canada,2012,11,C09-Agents acting on the Renin-Angiotensin system,Million US$ at exchange rate,1363.6
+5290,Canada,2012,11,C09-Agents acting on the Renin-Angiotensin system,"Million US$, purchasing power parity",1094.9
+5291,Canada,2012,11,M01A-Antiinflammatory and antirheumatic products non-steroids,Million of national currency units,454.1
+5292,Canada,2012,11,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ exchange rate",39.3
+5293,Canada,2012,11,C09-Agents acting on the Renin-Angiotensin system,Million of national currency units,1362.7
+5294,Canada,2012,11,G-Genito urinary system and sex hormones,"/capita, US$ exchange rate",41.2
+5295,Canada,2012,11,G-Genito urinary system and sex hormones,"Million US$, purchasing power parity",1149.4
+5296,Canada,2012,11,C01A-Cardiac glycosides,Million US$ at exchange rate,22.3
+5297,Canada,2012,11,C01A-Cardiac glycosides,Million of national currency units,22.3
+5298,Canada,2012,11,G-Genito urinary system and sex hormones,"/capita, US$ purchasing power parity",33.1
+5299,Canada,2012,11,A-Alimentary tract and metabolism,"Million US$, purchasing power parity",2570.7
+5300,Canada,2012,11,A-Alimentary tract and metabolism,"/capita, US$ exchange rate",92.2
+5301,Canada,2012,11,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),% of total sales,5.3
+5302,Canada,2012,11,A-Alimentary tract and metabolism,Million of national currency units,3199.5
+5303,Canada,2012,11,A-Alimentary tract and metabolism,Million US$ at exchange rate,3201.5
+5304,Canada,2012,11,N06A-Antidepressants,% of total sales,5.9
+5305,Canada,2012,11,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million US$ at exchange rate,1299.0
+5306,Canada,2012,11,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million of national currency units,1298.2
+5307,Canada,2012,11,R-Respiratory system,Million of national currency units,1676.3
+5308,Canada,2012,11,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ purchasing power parity",30.0
+5309,Canada,2012,11,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ exchange rate",37.4
+5310,Canada,2012,11,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"Million US$, purchasing power parity",1043.1
+5311,Canada,2012,11,N05C-Hypnotics and sedatives,"/capita, US$ exchange rate",5.4
+5312,Canada,2012,11,N05C-Hypnotics and sedatives,"/capita, US$ purchasing power parity",4.3
+5313,Canada,2012,11,N05C-Hypnotics and sedatives,Million of national currency units,187.0
+5314,Canada,2012,11,N05C-Hypnotics and sedatives,% of total sales,0.8
+5315,Canada,2012,11,N05C-Hypnotics and sedatives,Million US$ at exchange rate,187.1
+5316,Canada,2012,11,N05C-Hypnotics and sedatives,"Million US$, purchasing power parity",150.2
+5317,Canada,2012,11,N06A-Antidepressants,"/capita, US$ exchange rate",41.6
+5318,Canada,2012,11,N06A-Antidepressants,"/capita, US$ purchasing power parity",33.4
+5319,Canada,2012,11,N06A-Antidepressants,"Million US$, purchasing power parity",1160.4
+5320,Canada,2012,11,N06A-Antidepressants,Million of national currency units,1444.2
+5321,Canada,2012,11,N06A-Antidepressants,Million US$ at exchange rate,1445.1
+5322,Canada,2012,11,Products not elsewhere classified,Million US$ at exchange rate,4586.9
+5323,Canada,2012,11,Products not elsewhere classified,"Million US$, purchasing power parity",3683.1
+5324,Canada,2012,11,Products not elsewhere classified,"/capita, US$ exchange rate",132.1
+5325,Canada,2012,11,R03-Drugs for obstructive airway diseases,"/capita, US$ purchasing power parity",31.3
+5326,Canada,2012,11,R03-Drugs for obstructive airway diseases,% of total sales,5.6
+5327,Canada,2012,11,Products not elsewhere classified,Million of national currency units,4584.0
+5328,Canada,2012,11,A02A-Antacids,"Million US$, purchasing power parity",1.1
+5329,Canada,2012,11,A02A-Antacids,"/capita, US$ exchange rate",0.0
+5330,Canada,2012,11,A02A-Antacids,"/capita, US$ purchasing power parity",0.0
+5331,Canada,2012,11,A02A-Antacids,% of total sales,0.0
+5332,Canada,2012,11,A02A-Antacids,Million US$ at exchange rate,1.4
+5333,Canada,2012,11,Products not elsewhere classified,"/capita, US$ purchasing power parity",106.1
+5334,Canada,2012,11,A02A-Antacids,Million of national currency units,1.4
+5335,Canada,2012,11,Products not elsewhere classified,% of total sales,18.9
+5336,Canada,2012,11,R-Respiratory system,Million US$ at exchange rate,1677.4
+5337,Canada,2012,11,R-Respiratory system,% of total sales,6.9
+5338,Canada,2012,11,A-Alimentary tract and metabolism,"/capita, US$ purchasing power parity",74.1
+5339,Canada,2012,11,R-Respiratory system,"/capita, US$ purchasing power parity",38.8
+5340,Canada,2012,11,R-Respiratory system,"Million US$, purchasing power parity",1346.9
+5341,Canada,2012,11,R-Respiratory system,"/capita, US$ exchange rate",48.3
+5342,Canada,2012,11,R03-Drugs for obstructive airway diseases,"Million US$, purchasing power parity",1085.0
+5343,Canada,2012,11,R03-Drugs for obstructive airway diseases,"/capita, US$ exchange rate",38.9
+5344,Canada,2012,11,R03-Drugs for obstructive airway diseases,Million US$ at exchange rate,1351.3
+5345,Canada,2012,11,A-Alimentary tract and metabolism,% of total sales,13.2
+5346,Canada,2012,11,R03-Drugs for obstructive airway diseases,Million of national currency units,1350.4
+5347,Canada,2012,11,N02-Analgesics,"/capita, US$ purchasing power parity",25.8
+5348,Canada,2012,11,A10-Drugs used in diabetes,"Million US$, purchasing power parity",991.2
+5349,Canada,2012,11,N02-Analgesics,% of total sales,4.6
+5350,Canada,2012,11,Total pharmaceutical sales,Million of national currency units,24297.8
+5351,Canada,2012,11,N02-Analgesics,Million US$ at exchange rate,1116.2
+5352,Canada,2012,11,N02-Analgesics,Million of national currency units,1115.5
+5353,Canada,2012,11,A10-Drugs used in diabetes,Million of national currency units,1233.7
+5354,Canada,2012,11,A10-Drugs used in diabetes,"/capita, US$ exchange rate",35.6
+5355,Canada,2012,11,A10-Drugs used in diabetes,"/capita, US$ purchasing power parity",28.6
+5356,Canada,2012,11,A10-Drugs used in diabetes,% of total sales,5.1
+5357,Canada,2012,11,Total pharmaceutical sales,"Million US$, purchasing power parity",19522.5
+5358,Canada,2012,11,Total pharmaceutical sales,Million US$ at exchange rate,24313.2
+5359,Canada,2012,11,Total pharmaceutical sales,"/capita, US$ purchasing power parity",562.4
+5360,Canada,2012,11,Total pharmaceutical sales,"/capita, US$ exchange rate",700.4
+5361,Canada,2012,11,N02-Analgesics,"Million US$, purchasing power parity",896.3
+5362,Canada,2012,11,A10-Drugs used in diabetes,Million US$ at exchange rate,1234.5
+5363,Canada,2012,11,N05B-Anxiolytics,"Million US$, purchasing power parity",132.4
+5364,Canada,2012,11,N05B-Anxiolytics,Million US$ at exchange rate,164.9
+5365,Canada,2012,11,N05B-Anxiolytics,"/capita, US$ exchange rate",4.8
+5366,Canada,2012,11,N05B-Anxiolytics,"/capita, US$ purchasing power parity",3.8
+5367,Canada,2012,11,N05B-Anxiolytics,% of total sales,0.7
+5368,Canada,2012,11,N02-Analgesics,"/capita, US$ exchange rate",32.2
+5369,Canada,2012,11,N05B-Anxiolytics,Million of national currency units,164.8
+5370,Chile,2015,14,B-Blood and blood forming organs,Million of national currency units,92673.7
+5371,Chile,2015,14,B-Blood and blood forming organs,Million US$ at exchange rate,141.7
+5372,Chile,2015,14,G-Genito urinary system and sex hormones,Million of national currency units,165236.3
+5373,Chile,2015,14,C10-Lipid modifying agents,"Million US$, purchasing power parity",101.3
+5374,Chile,2015,14,G-Genito urinary system and sex hormones,Million US$ at exchange rate,252.6
+5375,Chile,2015,14,G-Genito urinary system and sex hormones,"Million US$, purchasing power parity",422.4
+5376,Chile,2015,14,C10-Lipid modifying agents,"/capita, US$ purchasing power parity",5.6
+5377,Chile,2015,14,B-Blood and blood forming organs,"/capita, US$ purchasing power parity",13.2
+5378,Chile,2015,14,B-Blood and blood forming organs,% of total sales,5.1
+5379,Chile,2015,14,B-Blood and blood forming organs,"Million US$, purchasing power parity",236.9
+5380,Chile,2015,14,B-Blood and blood forming organs,"/capita, US$ exchange rate",7.9
+5381,Chile,2015,14,C10-Lipid modifying agents,"/capita, US$ exchange rate",3.4
+5382,Chile,2015,14,C10-Lipid modifying agents,% of total sales,2.2
+5383,Chile,2015,14,A-Alimentary tract and metabolism,% of total sales,17.4
+5384,Chile,2015,14,C01A-Cardiac glycosides,"Million US$, purchasing power parity",0.4
+5385,Chile,2015,14,C01A-Cardiac glycosides,Million US$ at exchange rate,0.3
+5386,Chile,2015,14,A-Alimentary tract and metabolism,"Million US$, purchasing power parity",812.4
+5387,Chile,2015,14,A-Alimentary tract and metabolism,"/capita, US$ purchasing power parity",45.2
+5388,Chile,2015,14,A-Alimentary tract and metabolism,"/capita, US$ exchange rate",27.0
+5389,Chile,2015,14,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ purchasing power parity",6.2
+5390,Chile,2015,14,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ exchange rate",3.7
+5391,Chile,2015,14,"H-Systemic hormonal preparations, excluding sex hormones and insulins",% of total sales,2.4
+5392,Chile,2015,14,C01A-Cardiac glycosides,Million of national currency units,173.5
+5393,Chile,2015,14,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million of national currency units,43736.2
+5394,Chile,2015,14,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million US$ at exchange rate,66.9
+5395,Chile,2015,14,"H-Systemic hormonal preparations, excluding sex hormones and insulins","Million US$, purchasing power parity",111.8
+5396,Chile,2015,14,G-Genito urinary system and sex hormones,"/capita, US$ exchange rate",14.1
+5397,Chile,2015,14,G-Genito urinary system and sex hormones,"/capita, US$ purchasing power parity",23.5
+5398,Chile,2015,14,G03-Sex hormones and modulators of the genital system,Million of national currency units,117332.5
+5399,Chile,2015,14,G-Genito urinary system and sex hormones,% of total sales,9.1
+5400,Chile,2015,14,C10-Lipid modifying agents,Million US$ at exchange rate,60.6
+5401,Chile,2015,14,C01A-Cardiac glycosides,% of total sales,0.0
+5402,Chile,2015,14,C01A-Cardiac glycosides,"/capita, US$ exchange rate",0.0
+5403,Chile,2015,14,C01A-Cardiac glycosides,"/capita, US$ purchasing power parity",0.0
+5404,Chile,2015,14,G03-Sex hormones and modulators of the genital system,% of total sales,6.4
+5405,Chile,2015,14,G03-Sex hormones and modulators of the genital system,"/capita, US$ purchasing power parity",16.7
+5406,Chile,2015,14,A-Alimentary tract and metabolism,Million of national currency units,317777.7
+5407,Chile,2015,14,G03-Sex hormones and modulators of the genital system,Million US$ at exchange rate,179.4
+5408,Chile,2015,14,A-Alimentary tract and metabolism,Million US$ at exchange rate,485.8
+5409,Chile,2015,14,G03-Sex hormones and modulators of the genital system,"Million US$, purchasing power parity",299.9
+5410,Chile,2015,14,G03-Sex hormones and modulators of the genital system,"/capita, US$ exchange rate",10.0
+5411,Chile,2015,14,Total pharmaceutical sales,"/capita, US$ purchasing power parity",259.4
+5412,Chile,2015,14,C07-Beta blocking agents,Million of national currency units,16311.0
+5413,Chile,2015,14,C07-Beta blocking agents,Million US$ at exchange rate,24.9
+5414,Chile,2015,14,Total pharmaceutical sales,Million US$ at exchange rate,2788.0
+5415,Chile,2015,14,Total pharmaceutical sales,"Million US$, purchasing power parity",4662.0
+5416,Chile,2015,14,Total pharmaceutical sales,"/capita, US$ exchange rate",155.1
+5417,Chile,2015,14,C02-Antihypertensives,"/capita, US$ purchasing power parity",0.5
+5418,Chile,2015,14,C02-Antihypertensives,"/capita, US$ exchange rate",0.3
+5419,Chile,2015,14,C02-Antihypertensives,"Million US$, purchasing power parity",9.1
+5420,Chile,2015,14,C-Cardiovascular system,% of total sales,7.6
+5421,Chile,2015,14,C07-Beta blocking agents,"Million US$, purchasing power parity",41.7
+5422,Chile,2015,14,C02-Antihypertensives,% of total sales,0.2
+5423,Chile,2015,14,C-Cardiovascular system,Million of national currency units,138496.2
+5424,Chile,2015,14,C03-Diuretics,Million US$ at exchange rate,10.4
+5425,Chile,2015,14,C03-Diuretics,Million of national currency units,6793.5
+5426,Chile,2015,14,C-Cardiovascular system,Million US$ at exchange rate,211.7
+5427,Chile,2015,14,C-Cardiovascular system,"/capita, US$ exchange rate",11.8
+5428,Chile,2015,14,C-Cardiovascular system,"Million US$, purchasing power parity",354.0
+5429,Chile,2015,14,C03-Diuretics,"/capita, US$ purchasing power parity",1.0
+5430,Chile,2015,14,C03-Diuretics,% of total sales,0.4
+5431,Chile,2015,14,Total pharmaceutical sales,Million of national currency units,1823693.1
+5432,Chile,2015,14,C-Cardiovascular system,"/capita, US$ purchasing power parity",19.7
+5433,Chile,2015,14,C03-Diuretics,"Million US$, purchasing power parity",17.4
+5434,Chile,2015,14,C03-Diuretics,"/capita, US$ exchange rate",0.6
+5435,Chile,2015,14,C08-Calcium channel blockers,% of total sales,0.4
+5436,Chile,2015,14,C08-Calcium channel blockers,"/capita, US$ purchasing power parity",1.0
+5437,Chile,2015,14,C09-Agents acting on the Renin-Angiotensin system,Million of national currency units,49040.7
+5438,Chile,2015,14,C08-Calcium channel blockers,"Million US$, purchasing power parity",17.2
+5439,Chile,2015,14,C08-Calcium channel blockers,Million US$ at exchange rate,10.3
+5440,Chile,2015,14,C08-Calcium channel blockers,"/capita, US$ exchange rate",0.6
+5441,Chile,2015,14,C09-Agents acting on the Renin-Angiotensin system,% of total sales,2.7
+5442,Chile,2015,14,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ purchasing power parity",7.0
+5443,Chile,2015,14,C10-Lipid modifying agents,Million of national currency units,39621.5
+5444,Chile,2015,14,C09-Agents acting on the Renin-Angiotensin system,"Million US$, purchasing power parity",125.4
+5445,Chile,2015,14,C09-Agents acting on the Renin-Angiotensin system,Million US$ at exchange rate,75.0
+5446,Chile,2015,14,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ exchange rate",4.2
+5447,Chile,2015,14,C02-Antihypertensives,Million US$ at exchange rate,5.4
+5448,Chile,2015,14,C02-Antihypertensives,Million of national currency units,3557.7
+5449,Chile,2015,14,"C01B-Antiarrhythmics, Class I and III",% of total sales,0.1
+5450,Chile,2015,14,C07-Beta blocking agents,"/capita, US$ exchange rate",1.4
+5451,Chile,2015,14,C07-Beta blocking agents,% of total sales,0.9
+5452,Chile,2015,14,C07-Beta blocking agents,"/capita, US$ purchasing power parity",2.3
+5453,Chile,2015,14,"C01B-Antiarrhythmics, Class I and III",Million US$ at exchange rate,2.6
+5454,Chile,2015,14,"C01B-Antiarrhythmics, Class I and III",Million of national currency units,1679.1
+5455,Chile,2015,14,C08-Calcium channel blockers,Million of national currency units,6710.2
+5456,Chile,2015,14,"C01B-Antiarrhythmics, Class I and III","/capita, US$ purchasing power parity",0.2
+5457,Chile,2015,14,"C01B-Antiarrhythmics, Class I and III","/capita, US$ exchange rate",0.1
+5458,Chile,2015,14,"C01B-Antiarrhythmics, Class I and III","Million US$, purchasing power parity",4.3
+5459,Chile,2015,14,N-Nervous system,"/capita, US$ purchasing power parity",40.3
+5460,Chile,2015,14,J01-Antibacterials for systemic use,"/capita, US$ purchasing power parity",11.3
+5461,Chile,2015,14,J01-Antibacterials for systemic use,"/capita, US$ exchange rate",6.8
+5462,Chile,2015,14,J01-Antibacterials for systemic use,"Million US$, purchasing power parity",202.9
+5463,Chile,2015,14,N06A-Antidepressants,% of total sales,3.1
+5464,Chile,2015,14,J01-Antibacterials for systemic use,% of total sales,4.4
+5465,Chile,2015,14,A10-Drugs used in diabetes,"/capita, US$ exchange rate",7.4
+5466,Chile,2015,14,A10-Drugs used in diabetes,% of total sales,4.8
+5467,Chile,2015,14,A10-Drugs used in diabetes,"/capita, US$ purchasing power parity",12.4
+5468,Chile,2015,14,A10-Drugs used in diabetes,Million of national currency units,87238.4
+5469,Chile,2015,14,A10-Drugs used in diabetes,Million US$ at exchange rate,133.4
+5470,Chile,2015,14,A10-Drugs used in diabetes,"Million US$, purchasing power parity",223.0
+5471,Chile,2015,14,N06A-Antidepressants,Million of national currency units,56272.0
+5472,Chile,2015,14,N06A-Antidepressants,"Million US$, purchasing power parity",143.9
+5473,Chile,2015,14,N06A-Antidepressants,Million US$ at exchange rate,86.0
+5474,Chile,2015,14,M-Musculo-skeletal system,Million of national currency units,123321.4
+5475,Chile,2015,14,N05C-Hypnotics and sedatives,% of total sales,0.5
+5476,Chile,2015,14,N06A-Antidepressants,"/capita, US$ purchasing power parity",8.0
+5477,Chile,2015,14,Products not elsewhere classified,"Million US$, purchasing power parity",616.7
+5478,Chile,2015,14,Products not elsewhere classified,"/capita, US$ exchange rate",20.5
+5479,Chile,2015,14,N06A-Antidepressants,"/capita, US$ exchange rate",4.8
+5480,Chile,2015,14,Products not elsewhere classified,% of total sales,13.2
+5481,Chile,2015,14,Products not elsewhere classified,"/capita, US$ purchasing power parity",34.3
+5482,Chile,2015,14,R-Respiratory system,% of total sales,9.6
+5483,Chile,2015,14,R-Respiratory system,"/capita, US$ purchasing power parity",25.0
+5484,Chile,2015,14,A02A-Antacids,"Million US$, purchasing power parity",28.9
+5485,Chile,2015,14,R03-Drugs for obstructive airway diseases,Million of national currency units,46814.6
+5486,Chile,2015,14,R03-Drugs for obstructive airway diseases,Million US$ at exchange rate,71.6
+5487,Chile,2015,14,A02A-Antacids,Million of national currency units,11322.5
+5488,Chile,2015,14,R-Respiratory system,Million of national currency units,175733.0
+5489,Chile,2015,14,A02A-Antacids,Million US$ at exchange rate,17.3
+5490,Chile,2015,14,R-Respiratory system,"Million US$, purchasing power parity",449.2
+5491,Chile,2015,14,R-Respiratory system,Million US$ at exchange rate,268.7
+5492,Chile,2015,14,R-Respiratory system,"/capita, US$ exchange rate",14.9
+5493,Chile,2015,14,A02A-Antacids,"/capita, US$ purchasing power parity",1.6
+5494,Chile,2015,14,Products not elsewhere classified,Million US$ at exchange rate,368.8
+5495,Chile,2015,14,A02A-Antacids,% of total sales,0.6
+5496,Chile,2015,14,J01-Antibacterials for systemic use,Million US$ at exchange rate,121.4
+5497,Chile,2015,14,J01-Antibacterials for systemic use,Million of national currency units,79384.9
+5498,Chile,2015,14,R03-Drugs for obstructive airway diseases,"/capita, US$ exchange rate",4.0
+5499,Chile,2015,14,A02A-Antacids,"/capita, US$ exchange rate",1.0
+5500,Chile,2015,14,R03-Drugs for obstructive airway diseases,"Million US$, purchasing power parity",119.7
+5501,Chile,2015,14,M-Musculo-skeletal system,Million US$ at exchange rate,188.5
+5502,Chile,2015,14,R03-Drugs for obstructive airway diseases,"/capita, US$ purchasing power parity",6.7
+5503,Chile,2015,14,Products not elsewhere classified,Million of national currency units,241259.0
+5504,Chile,2015,14,R03-Drugs for obstructive airway diseases,% of total sales,2.6
+5505,Chile,2015,14,N02-Analgesics,"Million US$, purchasing power parity",193.2
+5506,Chile,2015,14,N02-Analgesics,"/capita, US$ exchange rate",6.4
+5507,Chile,2015,14,N02-Analgesics,"/capita, US$ purchasing power parity",10.7
+5508,Chile,2015,14,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million of national currency units,30504.0
+5509,Chile,2015,14,N02-Analgesics,Million US$ at exchange rate,115.5
+5510,Chile,2015,14,M01A-Antiinflammatory and antirheumatic products non-steroids,"Million US$, purchasing power parity",166.2
+5511,Chile,2015,14,J-Antiinfectives for systemic use,Million of national currency units,241797.7
+5512,Chile,2015,14,M01A-Antiinflammatory and antirheumatic products non-steroids,Million US$ at exchange rate,99.4
+5513,Chile,2015,14,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ purchasing power parity",9.2
+5514,Chile,2015,14,M01A-Antiinflammatory and antirheumatic products non-steroids,% of total sales,3.6
+5515,Chile,2015,14,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ exchange rate",5.5
+5516,Chile,2015,14,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million US$ at exchange rate,46.6
+5517,Chile,2015,14,N-Nervous system,Million of national currency units,283661.8
+5518,Chile,2015,14,N-Nervous system,Million US$ at exchange rate,433.7
+5519,Chile,2015,14,N-Nervous system,% of total sales,15.6
+5520,Chile,2015,14,N-Nervous system,"/capita, US$ exchange rate",24.1
+5521,Chile,2015,14,N-Nervous system,"Million US$, purchasing power parity",725.1
+5522,Chile,2015,14,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ exchange rate",2.6
+5523,Chile,2015,14,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"Million US$, purchasing power parity",78.0
+5524,Chile,2015,14,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ purchasing power parity",4.3
+5525,Chile,2015,14,N02-Analgesics,Million of national currency units,75558.7
+5526,Chile,2015,14,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),% of total sales,1.7
+5527,Chile,2015,14,N05B-Anxiolytics,% of total sales,0.7
+5528,Chile,2015,14,N05C-Hypnotics and sedatives,Million of national currency units,9241.4
+5529,Chile,2015,14,N05C-Hypnotics and sedatives,Million US$ at exchange rate,14.1
+5530,Chile,2015,14,N05B-Anxiolytics,"Million US$, purchasing power parity",32.5
+5531,Chile,2015,14,N05B-Anxiolytics,Million US$ at exchange rate,19.4
+5532,Chile,2015,14,N05B-Anxiolytics,"/capita, US$ purchasing power parity",1.8
+5533,Chile,2015,14,N05B-Anxiolytics,"/capita, US$ exchange rate",1.1
+5534,Chile,2015,14,M-Musculo-skeletal system,"/capita, US$ exchange rate",10.5
+5535,Chile,2015,14,M-Musculo-skeletal system,"/capita, US$ purchasing power parity",17.5
+5536,Chile,2015,14,M-Musculo-skeletal system,"Million US$, purchasing power parity",315.3
+5537,Chile,2015,14,N05C-Hypnotics and sedatives,"/capita, US$ exchange rate",0.8
+5538,Chile,2015,14,N05C-Hypnotics and sedatives,"Million US$, purchasing power parity",23.6
+5539,Chile,2015,14,M-Musculo-skeletal system,% of total sales,6.8
+5540,Chile,2015,14,N05C-Hypnotics and sedatives,"/capita, US$ purchasing power parity",1.3
+5541,Chile,2015,14,N02-Analgesics,% of total sales,4.1
+5542,Chile,2015,14,J-Antiinfectives for systemic use,"/capita, US$ purchasing power parity",34.4
+5543,Chile,2015,14,M01A-Antiinflammatory and antirheumatic products non-steroids,Million of national currency units,65023.8
+5544,Chile,2015,14,J-Antiinfectives for systemic use,% of total sales,13.3
+5545,Chile,2015,14,J-Antiinfectives for systemic use,Million US$ at exchange rate,369.7
+5546,Chile,2015,14,J-Antiinfectives for systemic use,"/capita, US$ exchange rate",20.6
+5547,Chile,2015,14,N05B-Anxiolytics,Million of national currency units,12721.9
+5548,Chile,2015,14,J-Antiinfectives for systemic use,"Million US$, purchasing power parity",618.1
+5549,Chile,2014,15,B-Blood and blood forming organs,Million US$ at exchange rate,120.2
+5550,Chile,2014,15,G-Genito urinary system and sex hormones,Million of national currency units,145380.0
+5551,Chile,2014,15,B-Blood and blood forming organs,Million of national currency units,68583.3
+5552,Chile,2014,15,C10-Lipid modifying agents,"Million US$, purchasing power parity",91.7
+5553,Chile,2014,15,G-Genito urinary system and sex hormones,Million US$ at exchange rate,254.9
+5554,Chile,2014,15,G-Genito urinary system and sex hormones,"Million US$, purchasing power parity",395.9
+5555,Chile,2014,15,B-Blood and blood forming organs,"/capita, US$ purchasing power parity",10.5
+5556,Chile,2014,15,B-Blood and blood forming organs,% of total sales,4.4
+5557,Chile,2014,15,B-Blood and blood forming organs,"Million US$, purchasing power parity",186.8
+5558,Chile,2014,15,B-Blood and blood forming organs,"/capita, US$ exchange rate",6.8
+5559,Chile,2014,15,C10-Lipid modifying agents,"/capita, US$ exchange rate",3.3
+5560,Chile,2014,15,C10-Lipid modifying agents,"/capita, US$ purchasing power parity",5.2
+5561,Chile,2014,15,C10-Lipid modifying agents,% of total sales,2.2
+5562,Chile,2014,15,G-Genito urinary system and sex hormones,"/capita, US$ exchange rate",14.3
+5563,Chile,2014,15,A-Alimentary tract and metabolism,% of total sales,16.8
+5564,Chile,2014,15,C01A-Cardiac glycosides,"Million US$, purchasing power parity",0.7
+5565,Chile,2014,15,C01A-Cardiac glycosides,Million US$ at exchange rate,0.4
+5566,Chile,2014,15,A-Alimentary tract and metabolism,"Million US$, purchasing power parity",708.1
+5567,Chile,2014,15,A-Alimentary tract and metabolism,"/capita, US$ purchasing power parity",39.8
+5568,Chile,2014,15,A-Alimentary tract and metabolism,"/capita, US$ exchange rate",25.6
+5569,Chile,2014,15,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ purchasing power parity",5.8
+5570,Chile,2014,15,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ exchange rate",3.8
+5571,Chile,2014,15,"H-Systemic hormonal preparations, excluding sex hormones and insulins",% of total sales,2.5
+5572,Chile,2014,15,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million of national currency units,38190.1
+5573,Chile,2014,15,C01A-Cardiac glycosides,Million of national currency units,247.9
+5574,Chile,2014,15,"H-Systemic hormonal preparations, excluding sex hormones and insulins","Million US$, purchasing power parity",104.0
+5575,Chile,2014,15,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million US$ at exchange rate,67.0
+5576,Chile,2014,15,A-Alimentary tract and metabolism,Million US$ at exchange rate,455.9
+5577,Chile,2014,15,G-Genito urinary system and sex hormones,"/capita, US$ purchasing power parity",22.3
+5578,Chile,2014,15,G03-Sex hormones and modulators of the genital system,Million of national currency units,102222.0
+5579,Chile,2014,15,G-Genito urinary system and sex hormones,% of total sales,9.4
+5580,Chile,2014,15,C01A-Cardiac glycosides,% of total sales,0.0
+5581,Chile,2014,15,C01A-Cardiac glycosides,"/capita, US$ exchange rate",0.0
+5582,Chile,2014,15,C01A-Cardiac glycosides,"/capita, US$ purchasing power parity",0.0
+5583,Chile,2014,15,G03-Sex hormones and modulators of the genital system,% of total sales,6.6
+5584,Chile,2014,15,G03-Sex hormones and modulators of the genital system,"/capita, US$ purchasing power parity",15.6
+5585,Chile,2014,15,A-Alimentary tract and metabolism,Million of national currency units,260015.0
+5586,Chile,2014,15,G03-Sex hormones and modulators of the genital system,"Million US$, purchasing power parity",278.4
+5587,Chile,2014,15,G03-Sex hormones and modulators of the genital system,Million US$ at exchange rate,179.2
+5588,Chile,2014,15,G03-Sex hormones and modulators of the genital system,"/capita, US$ exchange rate",10.1
+5589,Chile,2014,15,C10-Lipid modifying agents,Million US$ at exchange rate,59.0
+5590,Chile,2014,15,Total pharmaceutical sales,"/capita, US$ purchasing power parity",236.8
+5591,Chile,2014,15,C07-Beta blocking agents,Million of national currency units,15358.9
+5592,Chile,2014,15,C07-Beta blocking agents,Million US$ at exchange rate,26.9
+5593,Chile,2014,15,Total pharmaceutical sales,Million US$ at exchange rate,2711.4
+5594,Chile,2014,15,Total pharmaceutical sales,"Million US$, purchasing power parity",4211.3
+5595,Chile,2014,15,Total pharmaceutical sales,"/capita, US$ exchange rate",152.4
+5596,Chile,2014,15,C02-Antihypertensives,"/capita, US$ purchasing power parity",0.5
+5597,Chile,2014,15,C02-Antihypertensives,"/capita, US$ exchange rate",0.3
+5598,Chile,2014,15,C02-Antihypertensives,"Million US$, purchasing power parity",8.5
+5599,Chile,2014,15,C-Cardiovascular system,% of total sales,8.0
+5600,Chile,2014,15,C07-Beta blocking agents,"Million US$, purchasing power parity",41.8
+5601,Chile,2014,15,C02-Antihypertensives,% of total sales,0.2
+5602,Chile,2014,15,C-Cardiovascular system,Million of national currency units,124399.3
+5603,Chile,2014,15,C03-Diuretics,Million US$ at exchange rate,7.9
+5604,Chile,2014,15,C03-Diuretics,Million of national currency units,4497.4
+5605,Chile,2014,15,C-Cardiovascular system,"/capita, US$ exchange rate",12.3
+5606,Chile,2014,15,C-Cardiovascular system,Million US$ at exchange rate,218.1
+5607,Chile,2014,15,C-Cardiovascular system,"Million US$, purchasing power parity",338.8
+5608,Chile,2014,15,C03-Diuretics,"/capita, US$ purchasing power parity",0.7
+5609,Chile,2014,15,C03-Diuretics,% of total sales,0.3
+5610,Chile,2014,15,Total pharmaceutical sales,Million of national currency units,1546451.1
+5611,Chile,2014,15,C-Cardiovascular system,"/capita, US$ purchasing power parity",19.0
+5612,Chile,2014,15,C03-Diuretics,"/capita, US$ exchange rate",0.4
+5613,Chile,2014,15,C03-Diuretics,"Million US$, purchasing power parity",12.2
+5614,Chile,2014,15,C08-Calcium channel blockers,% of total sales,0.4
+5615,Chile,2014,15,C08-Calcium channel blockers,"/capita, US$ purchasing power parity",1.0
+5616,Chile,2014,15,C09-Agents acting on the Renin-Angiotensin system,Million of national currency units,44854.1
+5617,Chile,2014,15,C08-Calcium channel blockers,"Million US$, purchasing power parity",18.0
+5618,Chile,2014,15,C08-Calcium channel blockers,Million US$ at exchange rate,11.6
+5619,Chile,2014,15,C08-Calcium channel blockers,"/capita, US$ exchange rate",0.7
+5620,Chile,2014,15,C09-Agents acting on the Renin-Angiotensin system,% of total sales,2.9
+5621,Chile,2014,15,C10-Lipid modifying agents,Million of national currency units,33677.0
+5622,Chile,2014,15,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ purchasing power parity",6.9
+5623,Chile,2014,15,C09-Agents acting on the Renin-Angiotensin system,"Million US$, purchasing power parity",122.1
+5624,Chile,2014,15,C09-Agents acting on the Renin-Angiotensin system,Million US$ at exchange rate,78.6
+5625,Chile,2014,15,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ exchange rate",4.4
+5626,Chile,2014,15,C02-Antihypertensives,Million US$ at exchange rate,5.5
+5627,Chile,2014,15,C02-Antihypertensives,Million of national currency units,3129.0
+5628,Chile,2014,15,"C01B-Antiarrhythmics, Class I and III",% of total sales,0.1
+5629,Chile,2014,15,C07-Beta blocking agents,"/capita, US$ exchange rate",1.5
+5630,Chile,2014,15,C07-Beta blocking agents,"/capita, US$ purchasing power parity",2.4
+5631,Chile,2014,15,C07-Beta blocking agents,% of total sales,1.0
+5632,Chile,2014,15,"C01B-Antiarrhythmics, Class I and III",Million US$ at exchange rate,3.0
+5633,Chile,2014,15,"C01B-Antiarrhythmics, Class I and III",Million of national currency units,1688.5
+5634,Chile,2014,15,C08-Calcium channel blockers,Million of national currency units,6613.0
+5635,Chile,2014,15,"C01B-Antiarrhythmics, Class I and III","/capita, US$ purchasing power parity",0.3
+5636,Chile,2014,15,"C01B-Antiarrhythmics, Class I and III","Million US$, purchasing power parity",4.6
+5637,Chile,2014,15,"C01B-Antiarrhythmics, Class I and III","/capita, US$ exchange rate",0.2
+5638,Chile,2014,15,J01-Antibacterials for systemic use,"/capita, US$ purchasing power parity",11.1
+5639,Chile,2014,15,J01-Antibacterials for systemic use,"Million US$, purchasing power parity",196.9
+5640,Chile,2014,15,J01-Antibacterials for systemic use,"/capita, US$ exchange rate",7.1
+5641,Chile,2014,15,N06A-Antidepressants,% of total sales,3.2
+5642,Chile,2014,15,J01-Antibacterials for systemic use,% of total sales,4.7
+5643,Chile,2014,15,A10-Drugs used in diabetes,"/capita, US$ exchange rate",6.5
+5644,Chile,2014,15,A10-Drugs used in diabetes,"/capita, US$ purchasing power parity",10.1
+5645,Chile,2014,15,A10-Drugs used in diabetes,% of total sales,4.3
+5646,Chile,2014,15,A10-Drugs used in diabetes,Million of national currency units,66175.6
+5647,Chile,2014,15,A10-Drugs used in diabetes,Million US$ at exchange rate,116.0
+5648,Chile,2014,15,A10-Drugs used in diabetes,"Million US$, purchasing power parity",180.2
+5649,Chile,2014,15,N06A-Antidepressants,"/capita, US$ purchasing power parity",7.5
+5650,Chile,2014,15,N06A-Antidepressants,Million of national currency units,48805.4
+5651,Chile,2014,15,N06A-Antidepressants,Million US$ at exchange rate,85.6
+5652,Chile,2014,15,N06A-Antidepressants,"Million US$, purchasing power parity",132.9
+5653,Chile,2014,15,M-Musculo-skeletal system,Million of national currency units,107902.8
+5654,Chile,2014,15,M-Musculo-skeletal system,Million US$ at exchange rate,189.2
+5655,Chile,2014,15,N05C-Hypnotics and sedatives,% of total sales,0.6
+5656,Chile,2014,15,Products not elsewhere classified,"Million US$, purchasing power parity",594.8
+5657,Chile,2014,15,Products not elsewhere classified,"/capita, US$ exchange rate",21.5
+5658,Chile,2014,15,N06A-Antidepressants,"/capita, US$ exchange rate",4.8
+5659,Chile,2014,15,Products not elsewhere classified,% of total sales,14.1
+5660,Chile,2014,15,Products not elsewhere classified,"/capita, US$ purchasing power parity",33.4
+5661,Chile,2014,15,R-Respiratory system,% of total sales,9.9
+5662,Chile,2014,15,R-Respiratory system,"/capita, US$ purchasing power parity",23.5
+5663,Chile,2014,15,R03-Drugs for obstructive airway diseases,Million of national currency units,37615.6
+5664,Chile,2014,15,A02A-Antacids,"Million US$, purchasing power parity",28.3
+5665,Chile,2014,15,R03-Drugs for obstructive airway diseases,Million US$ at exchange rate,66.0
+5666,Chile,2014,15,R-Respiratory system,"/capita, US$ exchange rate",15.2
+5667,Chile,2014,15,A02A-Antacids,Million of national currency units,10396.9
+5668,Chile,2014,15,R-Respiratory system,Million of national currency units,153706.6
+5669,Chile,2014,15,A02A-Antacids,Million US$ at exchange rate,18.2
+5670,Chile,2014,15,R-Respiratory system,"Million US$, purchasing power parity",418.6
+5671,Chile,2014,15,R-Respiratory system,Million US$ at exchange rate,269.5
+5672,Chile,2014,15,A02A-Antacids,"/capita, US$ purchasing power parity",1.6
+5673,Chile,2014,15,A02A-Antacids,% of total sales,0.7
+5674,Chile,2014,15,Products not elsewhere classified,Million US$ at exchange rate,383.0
+5675,Chile,2014,15,J01-Antibacterials for systemic use,Million US$ at exchange rate,126.8
+5676,Chile,2014,15,J01-Antibacterials for systemic use,Million of national currency units,72295.7
+5677,Chile,2014,15,R03-Drugs for obstructive airway diseases,"/capita, US$ exchange rate",3.7
+5678,Chile,2014,15,A02A-Antacids,"/capita, US$ exchange rate",1.0
+5679,Chile,2014,15,R03-Drugs for obstructive airway diseases,"Million US$, purchasing power parity",102.4
+5680,Chile,2014,15,Products not elsewhere classified,Million of national currency units,218422.5
+5681,Chile,2014,15,R03-Drugs for obstructive airway diseases,% of total sales,2.4
+5682,Chile,2014,15,R03-Drugs for obstructive airway diseases,"/capita, US$ purchasing power parity",5.8
+5683,Chile,2014,15,N02-Analgesics,"/capita, US$ exchange rate",6.6
+5684,Chile,2014,15,N02-Analgesics,"Million US$, purchasing power parity",181.0
+5685,Chile,2014,15,N02-Analgesics,"/capita, US$ purchasing power parity",10.2
+5686,Chile,2014,15,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million of national currency units,26581.9
+5687,Chile,2014,15,N02-Analgesics,Million US$ at exchange rate,116.6
+5688,Chile,2014,15,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million US$ at exchange rate,46.6
+5689,Chile,2014,15,M01A-Antiinflammatory and antirheumatic products non-steroids,"Million US$, purchasing power parity",157.6
+5690,Chile,2014,15,M01A-Antiinflammatory and antirheumatic products non-steroids,Million US$ at exchange rate,101.5
+5691,Chile,2014,15,J-Antiinfectives for systemic use,Million of national currency units,180250.2
+5692,Chile,2014,15,M01A-Antiinflammatory and antirheumatic products non-steroids,% of total sales,3.7
+5693,Chile,2014,15,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ purchasing power parity",8.9
+5694,Chile,2014,15,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ exchange rate",5.7
+5695,Chile,2014,15,N-Nervous system,Million US$ at exchange rate,437.6
+5696,Chile,2014,15,N-Nervous system,Million of national currency units,249601.3
+5697,Chile,2014,15,N-Nervous system,% of total sales,16.1
+5698,Chile,2014,15,N-Nervous system,"/capita, US$ exchange rate",24.6
+5699,Chile,2014,15,N-Nervous system,"/capita, US$ purchasing power parity",38.2
+5700,Chile,2014,15,N-Nervous system,"Million US$, purchasing power parity",679.7
+5701,Chile,2014,15,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ exchange rate",2.6
+5702,Chile,2014,15,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"Million US$, purchasing power parity",72.4
+5703,Chile,2014,15,N02-Analgesics,Million of national currency units,66475.8
+5704,Chile,2014,15,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),% of total sales,1.7
+5705,Chile,2014,15,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ purchasing power parity",4.1
+5706,Chile,2014,15,N05B-Anxiolytics,% of total sales,0.8
+5707,Chile,2014,15,N05C-Hypnotics and sedatives,Million of national currency units,8655.6
+5708,Chile,2014,15,N05C-Hypnotics and sedatives,Million US$ at exchange rate,15.2
+5709,Chile,2014,15,N05B-Anxiolytics,"Million US$, purchasing power parity",32.0
+5710,Chile,2014,15,N05B-Anxiolytics,"/capita, US$ purchasing power parity",1.8
+5711,Chile,2014,15,N05B-Anxiolytics,"/capita, US$ exchange rate",1.2
+5712,Chile,2014,15,N05B-Anxiolytics,Million US$ at exchange rate,20.6
+5713,Chile,2014,15,M-Musculo-skeletal system,"/capita, US$ purchasing power parity",16.5
+5714,Chile,2014,15,M-Musculo-skeletal system,"/capita, US$ exchange rate",10.6
+5715,Chile,2014,15,M-Musculo-skeletal system,"Million US$, purchasing power parity",293.8
+5716,Chile,2014,15,N05C-Hypnotics and sedatives,"/capita, US$ exchange rate",0.9
+5717,Chile,2014,15,N05C-Hypnotics and sedatives,"Million US$, purchasing power parity",23.6
+5718,Chile,2014,15,M-Musculo-skeletal system,% of total sales,7.0
+5719,Chile,2014,15,N05C-Hypnotics and sedatives,"/capita, US$ purchasing power parity",1.3
+5720,Chile,2014,15,N02-Analgesics,% of total sales,4.3
+5721,Chile,2014,15,J-Antiinfectives for systemic use,"/capita, US$ purchasing power parity",27.6
+5722,Chile,2014,15,M01A-Antiinflammatory and antirheumatic products non-steroids,Million of national currency units,57880.5
+5723,Chile,2014,15,J-Antiinfectives for systemic use,% of total sales,11.7
+5724,Chile,2014,15,J-Antiinfectives for systemic use,"/capita, US$ exchange rate",17.8
+5725,Chile,2014,15,N05B-Anxiolytics,Million of national currency units,11744.7
+5726,Chile,2014,15,J-Antiinfectives for systemic use,Million US$ at exchange rate,316.0
+5727,Chile,2014,15,J-Antiinfectives for systemic use,"Million US$, purchasing power parity",490.9
+5728,Chile,2013,16,B-Blood and blood forming organs,Million US$ at exchange rate,151.7
+5729,Chile,2013,16,B-Blood and blood forming organs,Million of national currency units,75138.6
+5730,Chile,2013,16,G-Genito urinary system and sex hormones,Million of national currency units,134181.4
+5731,Chile,2013,16,G-Genito urinary system and sex hormones,Million US$ at exchange rate,270.9
+5732,Chile,2013,16,C10-Lipid modifying agents,"Million US$, purchasing power parity",85.8
+5733,Chile,2013,16,G-Genito urinary system and sex hormones,"Million US$, purchasing power parity",383.7
+5734,Chile,2013,16,B-Blood and blood forming organs,"/capita, US$ purchasing power parity",12.2
+5735,Chile,2013,16,G-Genito urinary system and sex hormones,"/capita, US$ exchange rate",15.4
+5736,Chile,2013,16,B-Blood and blood forming organs,% of total sales,5.2
+5737,Chile,2013,16,B-Blood and blood forming organs,"/capita, US$ exchange rate",8.6
+5738,Chile,2013,16,C10-Lipid modifying agents,"/capita, US$ purchasing power parity",4.9
+5739,Chile,2013,16,C10-Lipid modifying agents,"/capita, US$ exchange rate",3.4
+5740,Chile,2013,16,B-Blood and blood forming organs,"Million US$, purchasing power parity",214.9
+5741,Chile,2013,16,C10-Lipid modifying agents,% of total sales,2.1
+5742,Chile,2013,16,A-Alimentary tract and metabolism,% of total sales,15.2
+5743,Chile,2013,16,C01A-Cardiac glycosides,"Million US$, purchasing power parity",0.4
+5744,Chile,2013,16,C01A-Cardiac glycosides,Million US$ at exchange rate,0.3
+5745,Chile,2013,16,A-Alimentary tract and metabolism,"Million US$, purchasing power parity",630.8
+5746,Chile,2013,16,A-Alimentary tract and metabolism,"/capita, US$ purchasing power parity",35.8
+5747,Chile,2013,16,A-Alimentary tract and metabolism,"/capita, US$ exchange rate",25.3
+5748,Chile,2013,16,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ purchasing power parity",3.9
+5749,Chile,2013,16,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ exchange rate",2.7
+5750,Chile,2013,16,C01A-Cardiac glycosides,Million of national currency units,136.0
+5751,Chile,2013,16,"H-Systemic hormonal preparations, excluding sex hormones and insulins",% of total sales,1.6
+5752,Chile,2013,16,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million of national currency units,23741.8
+5753,Chile,2013,16,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million US$ at exchange rate,47.9
+5754,Chile,2013,16,"H-Systemic hormonal preparations, excluding sex hormones and insulins","Million US$, purchasing power parity",67.9
+5755,Chile,2013,16,G-Genito urinary system and sex hormones,"/capita, US$ purchasing power parity",21.8
+5756,Chile,2013,16,G03-Sex hormones and modulators of the genital system,Million of national currency units,95808.5
+5757,Chile,2013,16,G-Genito urinary system and sex hormones,% of total sales,9.3
+5758,Chile,2013,16,C01A-Cardiac glycosides,% of total sales,0.0
+5759,Chile,2013,16,C01A-Cardiac glycosides,"/capita, US$ exchange rate",0.0
+5760,Chile,2013,16,C01A-Cardiac glycosides,"/capita, US$ purchasing power parity",0.0
+5761,Chile,2013,16,G03-Sex hormones and modulators of the genital system,% of total sales,6.6
+5762,Chile,2013,16,A-Alimentary tract and metabolism,Million US$ at exchange rate,445.4
+5763,Chile,2013,16,G03-Sex hormones and modulators of the genital system,"/capita, US$ purchasing power parity",15.6
+5764,Chile,2013,16,A-Alimentary tract and metabolism,Million of national currency units,220594.0
+5765,Chile,2013,16,G03-Sex hormones and modulators of the genital system,"Million US$, purchasing power parity",274.0
+5766,Chile,2013,16,G03-Sex hormones and modulators of the genital system,Million US$ at exchange rate,193.4
+5767,Chile,2013,16,G03-Sex hormones and modulators of the genital system,"/capita, US$ exchange rate",11.0
+5768,Chile,2013,16,Total pharmaceutical sales,"/capita, US$ purchasing power parity",235.0
+5769,Chile,2013,16,C07-Beta blocking agents,Million of national currency units,12752.7
+5770,Chile,2013,16,C07-Beta blocking agents,Million US$ at exchange rate,25.7
+5771,Chile,2013,16,Total pharmaceutical sales,Million US$ at exchange rate,2921.6
+5772,Chile,2013,16,Total pharmaceutical sales,"Million US$, purchasing power parity",4138.0
+5773,Chile,2013,16,Total pharmaceutical sales,"/capita, US$ exchange rate",165.9
+5774,Chile,2013,16,C02-Antihypertensives,"/capita, US$ purchasing power parity",0.5
+5775,Chile,2013,16,C02-Antihypertensives,"/capita, US$ exchange rate",0.3
+5776,Chile,2013,16,C02-Antihypertensives,"Million US$, purchasing power parity",8.2
+5777,Chile,2013,16,C-Cardiovascular system,% of total sales,7.3
+5778,Chile,2013,16,C07-Beta blocking agents,"Million US$, purchasing power parity",36.5
+5779,Chile,2013,16,C02-Antihypertensives,% of total sales,0.2
+5780,Chile,2013,16,C-Cardiovascular system,Million of national currency units,105559.0
+5781,Chile,2013,16,C03-Diuretics,Million of national currency units,3467.2
+5782,Chile,2013,16,C03-Diuretics,Million US$ at exchange rate,7.0
+5783,Chile,2013,16,C-Cardiovascular system,Million US$ at exchange rate,213.1
+5784,Chile,2013,16,C-Cardiovascular system,"/capita, US$ exchange rate",12.1
+5785,Chile,2013,16,C-Cardiovascular system,"Million US$, purchasing power parity",301.9
+5786,Chile,2013,16,C03-Diuretics,"/capita, US$ purchasing power parity",0.6
+5787,Chile,2013,16,C03-Diuretics,% of total sales,0.2
+5788,Chile,2013,16,Total pharmaceutical sales,Million of national currency units,1446986.6
+5789,Chile,2013,16,C-Cardiovascular system,"/capita, US$ purchasing power parity",17.1
+5790,Chile,2013,16,C03-Diuretics,"Million US$, purchasing power parity",9.9
+5791,Chile,2013,16,C03-Diuretics,"/capita, US$ exchange rate",0.4
+5792,Chile,2013,16,C08-Calcium channel blockers,% of total sales,0.4
+5793,Chile,2013,16,C08-Calcium channel blockers,"/capita, US$ purchasing power parity",0.9
+5794,Chile,2013,16,C09-Agents acting on the Renin-Angiotensin system,Million of national currency units,36639.5
+5795,Chile,2013,16,C08-Calcium channel blockers,"Million US$, purchasing power parity",16.2
+5796,Chile,2013,16,C08-Calcium channel blockers,"/capita, US$ exchange rate",0.7
+5797,Chile,2013,16,C09-Agents acting on the Renin-Angiotensin system,Million US$ at exchange rate,74.0
+5798,Chile,2013,16,C09-Agents acting on the Renin-Angiotensin system,% of total sales,2.5
+5799,Chile,2013,16,C10-Lipid modifying agents,Million of national currency units,30013.4
+5800,Chile,2013,16,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ purchasing power parity",5.9
+5801,Chile,2013,16,C09-Agents acting on the Renin-Angiotensin system,"Million US$, purchasing power parity",104.8
+5802,Chile,2013,16,C08-Calcium channel blockers,Million US$ at exchange rate,11.5
+5803,Chile,2013,16,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ exchange rate",4.2
+5804,Chile,2013,16,C02-Antihypertensives,Million US$ at exchange rate,5.8
+5805,Chile,2013,16,"C01B-Antiarrhythmics, Class I and III",% of total sales,0.1
+5806,Chile,2013,16,C02-Antihypertensives,Million of national currency units,2861.8
+5807,Chile,2013,16,C07-Beta blocking agents,"/capita, US$ purchasing power parity",2.1
+5808,Chile,2013,16,C07-Beta blocking agents,"/capita, US$ exchange rate",1.5
+5809,Chile,2013,16,C07-Beta blocking agents,% of total sales,0.9
+5810,Chile,2013,16,C10-Lipid modifying agents,Million US$ at exchange rate,60.6
+5811,Chile,2013,16,"C01B-Antiarrhythmics, Class I and III",Million US$ at exchange rate,3.3
+5812,Chile,2013,16,"C01B-Antiarrhythmics, Class I and III",Million of national currency units,1625.7
+5813,Chile,2013,16,C08-Calcium channel blockers,Million of national currency units,5672.3
+5814,Chile,2013,16,"C01B-Antiarrhythmics, Class I and III","/capita, US$ purchasing power parity",0.3
+5815,Chile,2013,16,"C01B-Antiarrhythmics, Class I and III","/capita, US$ exchange rate",0.2
+5816,Chile,2013,16,"C01B-Antiarrhythmics, Class I and III","Million US$, purchasing power parity",4.6
+5817,Chile,2013,16,J01-Antibacterials for systemic use,"/capita, US$ purchasing power parity",11.5
+5818,Chile,2013,16,J01-Antibacterials for systemic use,"/capita, US$ exchange rate",8.1
+5819,Chile,2013,16,N06A-Antidepressants,% of total sales,2.1
+5820,Chile,2013,16,J01-Antibacterials for systemic use,% of total sales,4.9
+5821,Chile,2013,16,J01-Antibacterials for systemic use,"Million US$, purchasing power parity",202.3
+5822,Chile,2013,16,A10-Drugs used in diabetes,"/capita, US$ exchange rate",5.8
+5823,Chile,2013,16,A10-Drugs used in diabetes,% of total sales,3.5
+5824,Chile,2013,16,A10-Drugs used in diabetes,"/capita, US$ purchasing power parity",8.2
+5825,Chile,2013,16,A10-Drugs used in diabetes,Million US$ at exchange rate,101.6
+5826,Chile,2013,16,A10-Drugs used in diabetes,Million of national currency units,50330.5
+5827,Chile,2013,16,A10-Drugs used in diabetes,"Million US$, purchasing power parity",143.9
+5828,Chile,2013,16,N06A-Antidepressants,Million of national currency units,30007.6
+5829,Chile,2013,16,N06A-Antidepressants,"Million US$, purchasing power parity",85.8
+5830,Chile,2013,16,N06A-Antidepressants,Million US$ at exchange rate,60.6
+5831,Chile,2013,16,M-Musculo-skeletal system,Million of national currency units,87138.2
+5832,Chile,2013,16,M-Musculo-skeletal system,Million US$ at exchange rate,175.9
+5833,Chile,2013,16,N05C-Hypnotics and sedatives,% of total sales,0.5
+5834,Chile,2013,16,Products not elsewhere classified,"/capita, US$ exchange rate",27.0
+5835,Chile,2013,16,Products not elsewhere classified,"Million US$, purchasing power parity",673.1
+5836,Chile,2013,16,N06A-Antidepressants,"/capita, US$ purchasing power parity",4.9
+5837,Chile,2013,16,N06A-Antidepressants,"/capita, US$ exchange rate",3.4
+5838,Chile,2013,16,Products not elsewhere classified,% of total sales,16.3
+5839,Chile,2013,16,Products not elsewhere classified,"/capita, US$ purchasing power parity",38.2
+5840,Chile,2013,16,R-Respiratory system,% of total sales,9.7
+5841,Chile,2013,16,R-Respiratory system,"/capita, US$ purchasing power parity",22.8
+5842,Chile,2013,16,R03-Drugs for obstructive airway diseases,Million of national currency units,30901.9
+5843,Chile,2013,16,A02A-Antacids,"Million US$, purchasing power parity",27.9
+5844,Chile,2013,16,R03-Drugs for obstructive airway diseases,Million US$ at exchange rate,62.4
+5845,Chile,2013,16,A02A-Antacids,Million of national currency units,9763.4
+5846,Chile,2013,16,R-Respiratory system,Million of national currency units,140586.0
+5847,Chile,2013,16,A02A-Antacids,Million US$ at exchange rate,19.7
+5848,Chile,2013,16,R-Respiratory system,"Million US$, purchasing power parity",402.0
+5849,Chile,2013,16,R-Respiratory system,"/capita, US$ exchange rate",16.1
+5850,Chile,2013,16,R-Respiratory system,Million US$ at exchange rate,283.9
+5851,Chile,2013,16,A02A-Antacids,"/capita, US$ purchasing power parity",1.6
+5852,Chile,2013,16,A02A-Antacids,% of total sales,0.7
+5853,Chile,2013,16,J01-Antibacterials for systemic use,Million US$ at exchange rate,142.8
+5854,Chile,2013,16,J01-Antibacterials for systemic use,Million of national currency units,70741.0
+5855,Chile,2013,16,Products not elsewhere classified,Million US$ at exchange rate,475.2
+5856,Chile,2013,16,R03-Drugs for obstructive airway diseases,"/capita, US$ exchange rate",3.5
+5857,Chile,2013,16,A02A-Antacids,"/capita, US$ exchange rate",1.1
+5858,Chile,2013,16,R03-Drugs for obstructive airway diseases,"Million US$, purchasing power parity",88.4
+5859,Chile,2013,16,R03-Drugs for obstructive airway diseases,"/capita, US$ purchasing power parity",5.0
+5860,Chile,2013,16,Products not elsewhere classified,Million of national currency units,235364.6
+5861,Chile,2013,16,R03-Drugs for obstructive airway diseases,% of total sales,2.1
+5862,Chile,2013,16,N02-Analgesics,"/capita, US$ exchange rate",7.3
+5863,Chile,2013,16,N02-Analgesics,"Million US$, purchasing power parity",183.0
+5864,Chile,2013,16,N02-Analgesics,"/capita, US$ purchasing power parity",10.4
+5865,Chile,2013,16,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million of national currency units,24042.2
+5866,Chile,2013,16,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million US$ at exchange rate,48.5
+5867,Chile,2013,16,N02-Analgesics,Million US$ at exchange rate,129.2
+5868,Chile,2013,16,M01A-Antiinflammatory and antirheumatic products non-steroids,"Million US$, purchasing power parity",154.6
+5869,Chile,2013,16,J-Antiinfectives for systemic use,Million of national currency units,209955.4
+5870,Chile,2013,16,M01A-Antiinflammatory and antirheumatic products non-steroids,Million US$ at exchange rate,109.2
+5871,Chile,2013,16,M01A-Antiinflammatory and antirheumatic products non-steroids,% of total sales,3.7
+5872,Chile,2013,16,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ purchasing power parity",8.8
+5873,Chile,2013,16,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ exchange rate",6.2
+5874,Chile,2013,16,N-Nervous system,Million US$ at exchange rate,433.6
+5875,Chile,2013,16,N-Nervous system,% of total sales,14.8
+5876,Chile,2013,16,N-Nervous system,Million of national currency units,214727.7
+5877,Chile,2013,16,N-Nervous system,"/capita, US$ exchange rate",24.6
+5878,Chile,2013,16,N-Nervous system,"/capita, US$ purchasing power parity",34.9
+5879,Chile,2013,16,N-Nervous system,"Million US$, purchasing power parity",614.1
+5880,Chile,2013,16,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ exchange rate",2.8
+5881,Chile,2013,16,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"Million US$, purchasing power parity",68.8
+5882,Chile,2013,16,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ purchasing power parity",3.9
+5883,Chile,2013,16,N02-Analgesics,Million of national currency units,63983.2
+5884,Chile,2013,16,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),% of total sales,1.7
+5885,Chile,2013,16,N05B-Anxiolytics,% of total sales,0.8
+5886,Chile,2013,16,N05C-Hypnotics and sedatives,Million of national currency units,7153.9
+5887,Chile,2013,16,N05C-Hypnotics and sedatives,Million US$ at exchange rate,14.4
+5888,Chile,2013,16,N05B-Anxiolytics,"Million US$, purchasing power parity",31.6
+5889,Chile,2013,16,N05B-Anxiolytics,"/capita, US$ purchasing power parity",1.8
+5890,Chile,2013,16,N05B-Anxiolytics,"/capita, US$ exchange rate",1.3
+5891,Chile,2013,16,M-Musculo-skeletal system,"/capita, US$ purchasing power parity",14.1
+5892,Chile,2013,16,M-Musculo-skeletal system,"/capita, US$ exchange rate",10.0
+5893,Chile,2013,16,M-Musculo-skeletal system,"Million US$, purchasing power parity",249.2
+5894,Chile,2013,16,N05C-Hypnotics and sedatives,"/capita, US$ exchange rate",0.8
+5895,Chile,2013,16,N05C-Hypnotics and sedatives,"Million US$, purchasing power parity",20.5
+5896,Chile,2013,16,M-Musculo-skeletal system,% of total sales,6.0
+5897,Chile,2013,16,N05C-Hypnotics and sedatives,"/capita, US$ purchasing power parity",1.2
+5898,Chile,2013,16,N05B-Anxiolytics,Million US$ at exchange rate,22.3
+5899,Chile,2013,16,J-Antiinfectives for systemic use,"/capita, US$ purchasing power parity",34.1
+5900,Chile,2013,16,N02-Analgesics,% of total sales,4.4
+5901,Chile,2013,16,M01A-Antiinflammatory and antirheumatic products non-steroids,Million of national currency units,54075.4
+5902,Chile,2013,16,J-Antiinfectives for systemic use,% of total sales,14.5
+5903,Chile,2013,16,N05B-Anxiolytics,Million of national currency units,11038.7
+5904,Chile,2013,16,J-Antiinfectives for systemic use,Million US$ at exchange rate,423.9
+5905,Chile,2013,16,J-Antiinfectives for systemic use,"/capita, US$ exchange rate",24.1
+5906,Chile,2013,16,J-Antiinfectives for systemic use,"Million US$, purchasing power parity",600.4
+5907,Chile,2012,17,B-Blood and blood forming organs,Million US$ at exchange rate,135.8
+5908,Chile,2012,17,B-Blood and blood forming organs,Million of national currency units,66082.9
+5909,Chile,2012,17,G-Genito urinary system and sex hormones,Million of national currency units,122348.3
+5910,Chile,2012,17,B-Blood and blood forming organs,"Million US$, purchasing power parity",190.3
+5911,Chile,2012,17,C10-Lipid modifying agents,"Million US$, purchasing power parity",79.6
+5912,Chile,2012,17,G-Genito urinary system and sex hormones,"/capita, US$ exchange rate",14.4
+5913,Chile,2012,17,G-Genito urinary system and sex hormones,Million US$ at exchange rate,251.5
+5914,Chile,2012,17,G-Genito urinary system and sex hormones,"Million US$, purchasing power parity",352.4
+5915,Chile,2012,17,B-Blood and blood forming organs,"/capita, US$ purchasing power parity",10.9
+5916,Chile,2012,17,B-Blood and blood forming organs,% of total sales,5.3
+5917,Chile,2012,17,B-Blood and blood forming organs,"/capita, US$ exchange rate",7.8
+5918,Chile,2012,17,C10-Lipid modifying agents,"/capita, US$ purchasing power parity",4.6
+5919,Chile,2012,17,C10-Lipid modifying agents,"/capita, US$ exchange rate",3.3
+5920,Chile,2012,17,C10-Lipid modifying agents,% of total sales,2.2
+5921,Chile,2012,17,A-Alimentary tract and metabolism,% of total sales,16.3
+5922,Chile,2012,17,C01A-Cardiac glycosides,Million US$ at exchange rate,0.4
+5923,Chile,2012,17,C01A-Cardiac glycosides,"Million US$, purchasing power parity",0.5
+5924,Chile,2012,17,A-Alimentary tract and metabolism,"Million US$, purchasing power parity",586.3
+5925,Chile,2012,17,A-Alimentary tract and metabolism,"/capita, US$ exchange rate",24.0
+5926,Chile,2012,17,A-Alimentary tract and metabolism,"/capita, US$ purchasing power parity",33.6
+5927,Chile,2012,17,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ purchasing power parity",4.5
+5928,Chile,2012,17,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ exchange rate",3.2
+5929,Chile,2012,17,C01A-Cardiac glycosides,Million of national currency units,185.5
+5930,Chile,2012,17,"H-Systemic hormonal preparations, excluding sex hormones and insulins",% of total sales,2.2
+5931,Chile,2012,17,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million US$ at exchange rate,55.7
+5932,Chile,2012,17,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million of national currency units,27115.2
+5933,Chile,2012,17,"H-Systemic hormonal preparations, excluding sex hormones and insulins","Million US$, purchasing power parity",78.1
+5934,Chile,2012,17,G-Genito urinary system and sex hormones,"/capita, US$ purchasing power parity",20.2
+5935,Chile,2012,17,G-Genito urinary system and sex hormones,% of total sales,9.8
+5936,Chile,2012,17,G03-Sex hormones and modulators of the genital system,Million of national currency units,87798.2
+5937,Chile,2012,17,C01A-Cardiac glycosides,"/capita, US$ exchange rate",0.0
+5938,Chile,2012,17,C01A-Cardiac glycosides,% of total sales,0.0
+5939,Chile,2012,17,C01A-Cardiac glycosides,"/capita, US$ purchasing power parity",0.0
+5940,Chile,2012,17,G03-Sex hormones and modulators of the genital system,% of total sales,7.0
+5941,Chile,2012,17,A-Alimentary tract and metabolism,Million US$ at exchange rate,418.5
+5942,Chile,2012,17,A-Alimentary tract and metabolism,Million of national currency units,203569.3
+5943,Chile,2012,17,G03-Sex hormones and modulators of the genital system,"/capita, US$ purchasing power parity",14.5
+5944,Chile,2012,17,G03-Sex hormones and modulators of the genital system,"Million US$, purchasing power parity",252.9
+5945,Chile,2012,17,G03-Sex hormones and modulators of the genital system,Million US$ at exchange rate,180.5
+5946,Chile,2012,17,G03-Sex hormones and modulators of the genital system,"/capita, US$ exchange rate",10.3
+5947,Chile,2012,17,C10-Lipid modifying agents,Million US$ at exchange rate,56.8
+5948,Chile,2012,17,Total pharmaceutical sales,"/capita, US$ purchasing power parity",206.1
+5949,Chile,2012,17,C07-Beta blocking agents,Million of national currency units,11971.2
+5950,Chile,2012,17,C07-Beta blocking agents,Million US$ at exchange rate,24.6
+5951,Chile,2012,17,Total pharmaceutical sales,Million US$ at exchange rate,2565.9
+5952,Chile,2012,17,Total pharmaceutical sales,"Million US$, purchasing power parity",3594.9
+5953,Chile,2012,17,Total pharmaceutical sales,"/capita, US$ exchange rate",147.1
+5954,Chile,2012,17,C02-Antihypertensives,"/capita, US$ purchasing power parity",0.4
+5955,Chile,2012,17,C02-Antihypertensives,"Million US$, purchasing power parity",7.3
+5956,Chile,2012,17,C02-Antihypertensives,"/capita, US$ exchange rate",0.3
+5957,Chile,2012,17,C-Cardiovascular system,% of total sales,8.1
+5958,Chile,2012,17,C07-Beta blocking agents,"Million US$, purchasing power parity",34.5
+5959,Chile,2012,17,C02-Antihypertensives,% of total sales,0.2
+5960,Chile,2012,17,C-Cardiovascular system,Million of national currency units,100837.7
+5961,Chile,2012,17,C03-Diuretics,Million of national currency units,3547.9
+5962,Chile,2012,17,C03-Diuretics,Million US$ at exchange rate,7.3
+5963,Chile,2012,17,C-Cardiovascular system,Million US$ at exchange rate,207.3
+5964,Chile,2012,17,C-Cardiovascular system,"/capita, US$ exchange rate",11.9
+5965,Chile,2012,17,C-Cardiovascular system,"Million US$, purchasing power parity",290.4
+5966,Chile,2012,17,C03-Diuretics,"/capita, US$ purchasing power parity",0.6
+5967,Chile,2012,17,C03-Diuretics,% of total sales,0.3
+5968,Chile,2012,17,Total pharmaceutical sales,Million of national currency units,1248234.6
+5969,Chile,2012,17,C03-Diuretics,"Million US$, purchasing power parity",10.2
+5970,Chile,2012,17,C-Cardiovascular system,"/capita, US$ purchasing power parity",16.6
+5971,Chile,2012,17,C03-Diuretics,"/capita, US$ exchange rate",0.4
+5972,Chile,2012,17,C08-Calcium channel blockers,% of total sales,0.5
+5973,Chile,2012,17,C09-Agents acting on the Renin-Angiotensin system,Million of national currency units,35202.9
+5974,Chile,2012,17,C08-Calcium channel blockers,"/capita, US$ purchasing power parity",1.0
+5975,Chile,2012,17,C08-Calcium channel blockers,"Million US$, purchasing power parity",17.0
+5976,Chile,2012,17,C08-Calcium channel blockers,"/capita, US$ exchange rate",0.7
+5977,Chile,2012,17,C09-Agents acting on the Renin-Angiotensin system,Million US$ at exchange rate,72.4
+5978,Chile,2012,17,C09-Agents acting on the Renin-Angiotensin system,% of total sales,2.8
+5979,Chile,2012,17,C10-Lipid modifying agents,Million of national currency units,27634.2
+5980,Chile,2012,17,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ purchasing power parity",5.8
+5981,Chile,2012,17,C09-Agents acting on the Renin-Angiotensin system,"Million US$, purchasing power parity",101.4
+5982,Chile,2012,17,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ exchange rate",4.1
+5983,Chile,2012,17,C08-Calcium channel blockers,Million US$ at exchange rate,12.2
+5984,Chile,2012,17,C02-Antihypertensives,Million US$ at exchange rate,5.2
+5985,Chile,2012,17,"C01B-Antiarrhythmics, Class I and III",% of total sales,0.1
+5986,Chile,2012,17,C02-Antihypertensives,Million of national currency units,2551.3
+5987,Chile,2012,17,C07-Beta blocking agents,"/capita, US$ purchasing power parity",2.0
+5988,Chile,2012,17,C07-Beta blocking agents,"/capita, US$ exchange rate",1.4
+5989,Chile,2012,17,C07-Beta blocking agents,% of total sales,1.0
+5990,Chile,2012,17,"C01B-Antiarrhythmics, Class I and III",Million US$ at exchange rate,3.0
+5991,Chile,2012,17,C08-Calcium channel blockers,Million of national currency units,5913.9
+5992,Chile,2012,17,"C01B-Antiarrhythmics, Class I and III",Million of national currency units,1457.1
+5993,Chile,2012,17,"C01B-Antiarrhythmics, Class I and III","/capita, US$ purchasing power parity",0.2
+5994,Chile,2012,17,"C01B-Antiarrhythmics, Class I and III","Million US$, purchasing power parity",4.2
+5995,Chile,2012,17,"C01B-Antiarrhythmics, Class I and III","/capita, US$ exchange rate",0.2
+5996,Chile,2012,17,J01-Antibacterials for systemic use,"/capita, US$ purchasing power parity",11.2
+5997,Chile,2012,17,J01-Antibacterials for systemic use,"/capita, US$ exchange rate",8.0
+5998,Chile,2012,17,N06A-Antidepressants,% of total sales,2.3
+5999,Chile,2012,17,J01-Antibacterials for systemic use,% of total sales,5.4
+6000,Chile,2012,17,J01-Antibacterials for systemic use,"Million US$, purchasing power parity",195.7
+6001,Chile,2012,17,A10-Drugs used in diabetes,"/capita, US$ exchange rate",4.9
+6002,Chile,2012,17,A10-Drugs used in diabetes,"/capita, US$ purchasing power parity",6.9
+6003,Chile,2012,17,A10-Drugs used in diabetes,% of total sales,3.3
+6004,Chile,2012,17,A10-Drugs used in diabetes,Million US$ at exchange rate,85.8
+6005,Chile,2012,17,A10-Drugs used in diabetes,Million of national currency units,41736.2
+6006,Chile,2012,17,A10-Drugs used in diabetes,"Million US$, purchasing power parity",120.2
+6007,Chile,2012,17,N06A-Antidepressants,Million of national currency units,28119.5
+6008,Chile,2012,17,N06A-Antidepressants,Million US$ at exchange rate,57.8
+6009,Chile,2012,17,N06A-Antidepressants,"Million US$, purchasing power parity",81.0
+6010,Chile,2012,17,M-Musculo-skeletal system,Million US$ at exchange rate,177.1
+6011,Chile,2012,17,M-Musculo-skeletal system,Million of national currency units,86133.7
+6012,Chile,2012,17,N05C-Hypnotics and sedatives,% of total sales,0.5
+6013,Chile,2012,17,Products not elsewhere classified,"/capita, US$ exchange rate",20.0
+6014,Chile,2012,17,N06A-Antidepressants,"/capita, US$ exchange rate",3.3
+6015,Chile,2012,17,N06A-Antidepressants,"/capita, US$ purchasing power parity",4.6
+6016,Chile,2012,17,Products not elsewhere classified,% of total sales,13.6
+6017,Chile,2012,17,Products not elsewhere classified,"/capita, US$ purchasing power parity",28.1
+6018,Chile,2012,17,R-Respiratory system,% of total sales,10.7
+6019,Chile,2012,17,R-Respiratory system,"/capita, US$ purchasing power parity",22.1
+6020,Chile,2012,17,R03-Drugs for obstructive airway diseases,Million of national currency units,29207.1
+6021,Chile,2012,17,R03-Drugs for obstructive airway diseases,"Million US$, purchasing power parity",84.1
+6022,Chile,2012,17,A02A-Antacids,"Million US$, purchasing power parity",26.5
+6023,Chile,2012,17,R03-Drugs for obstructive airway diseases,Million US$ at exchange rate,60.0
+6024,Chile,2012,17,A02A-Antacids,Million of national currency units,9204.3
+6025,Chile,2012,17,R-Respiratory system,Million of national currency units,133945.9
+6026,Chile,2012,17,A02A-Antacids,Million US$ at exchange rate,18.9
+6027,Chile,2012,17,R-Respiratory system,"Million US$, purchasing power parity",385.8
+6028,Chile,2012,17,R-Respiratory system,"/capita, US$ exchange rate",15.8
+6029,Chile,2012,17,R-Respiratory system,Million US$ at exchange rate,275.3
+6030,Chile,2012,17,A02A-Antacids,"/capita, US$ purchasing power parity",1.5
+6031,Chile,2012,17,A02A-Antacids,% of total sales,0.7
+6032,Chile,2012,17,Products not elsewhere classified,"Million US$, purchasing power parity",489.5
+6033,Chile,2012,17,J01-Antibacterials for systemic use,Million US$ at exchange rate,139.7
+6034,Chile,2012,17,J01-Antibacterials for systemic use,Million of national currency units,67944.0
+6035,Chile,2012,17,Products not elsewhere classified,Million US$ at exchange rate,349.4
+6036,Chile,2012,17,R03-Drugs for obstructive airway diseases,"/capita, US$ exchange rate",3.4
+6037,Chile,2012,17,A02A-Antacids,"/capita, US$ exchange rate",1.1
+6038,Chile,2012,17,R03-Drugs for obstructive airway diseases,"/capita, US$ purchasing power parity",4.8
+6039,Chile,2012,17,Products not elsewhere classified,Million of national currency units,169953.3
+6040,Chile,2012,17,R03-Drugs for obstructive airway diseases,% of total sales,2.3
+6041,Chile,2012,17,N02-Analgesics,"/capita, US$ exchange rate",7.5
+6042,Chile,2012,17,N02-Analgesics,"Million US$, purchasing power parity",184.5
+6043,Chile,2012,17,N02-Analgesics,"/capita, US$ purchasing power parity",10.6
+6044,Chile,2012,17,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million of national currency units,22320.2
+6045,Chile,2012,17,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million US$ at exchange rate,45.9
+6046,Chile,2012,17,N02-Analgesics,Million US$ at exchange rate,131.7
+6047,Chile,2012,17,M01A-Antiinflammatory and antirheumatic products non-steroids,"Million US$, purchasing power parity",145.8
+6048,Chile,2012,17,J-Antiinfectives for systemic use,Million of national currency units,132266.7
+6049,Chile,2012,17,M01A-Antiinflammatory and antirheumatic products non-steroids,Million US$ at exchange rate,104.1
+6050,Chile,2012,17,M01A-Antiinflammatory and antirheumatic products non-steroids,% of total sales,4.1
+6051,Chile,2012,17,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ purchasing power parity",8.4
+6052,Chile,2012,17,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ exchange rate",6.0
+6053,Chile,2012,17,N-Nervous system,Million US$ at exchange rate,423.4
+6054,Chile,2012,17,N-Nervous system,Million of national currency units,205981.7
+6055,Chile,2012,17,N-Nervous system,% of total sales,16.5
+6056,Chile,2012,17,N-Nervous system,"/capita, US$ purchasing power parity",34.0
+6057,Chile,2012,17,N-Nervous system,"/capita, US$ exchange rate",24.3
+6058,Chile,2012,17,N-Nervous system,"Million US$, purchasing power parity",593.2
+6059,Chile,2012,17,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ exchange rate",2.6
+6060,Chile,2012,17,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"Million US$, purchasing power parity",64.3
+6061,Chile,2012,17,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ purchasing power parity",3.7
+6062,Chile,2012,17,N02-Analgesics,Million of national currency units,64056.5
+6063,Chile,2012,17,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),% of total sales,1.8
+6064,Chile,2012,17,N05C-Hypnotics and sedatives,Million of national currency units,5909.7
+6065,Chile,2012,17,N05B-Anxiolytics,% of total sales,0.9
+6066,Chile,2012,17,N05C-Hypnotics and sedatives,Million US$ at exchange rate,12.1
+6067,Chile,2012,17,N05B-Anxiolytics,"Million US$, purchasing power parity",30.6
+6068,Chile,2012,17,N05B-Anxiolytics,"/capita, US$ purchasing power parity",1.8
+6069,Chile,2012,17,N05B-Anxiolytics,"/capita, US$ exchange rate",1.3
+6070,Chile,2012,17,N05C-Hypnotics and sedatives,"Million US$, purchasing power parity",17.0
+6071,Chile,2012,17,M-Musculo-skeletal system,"/capita, US$ purchasing power parity",14.2
+6072,Chile,2012,17,M-Musculo-skeletal system,"/capita, US$ exchange rate",10.2
+6073,Chile,2012,17,M-Musculo-skeletal system,"Million US$, purchasing power parity",248.1
+6074,Chile,2012,17,N05C-Hypnotics and sedatives,"/capita, US$ exchange rate",0.7
+6075,Chile,2012,17,M-Musculo-skeletal system,% of total sales,6.9
+6076,Chile,2012,17,N05C-Hypnotics and sedatives,"/capita, US$ purchasing power parity",1.0
+6077,Chile,2012,17,N05B-Anxiolytics,Million US$ at exchange rate,21.9
+6078,Chile,2012,17,M01A-Antiinflammatory and antirheumatic products non-steroids,Million of national currency units,50640.7
+6079,Chile,2012,17,J-Antiinfectives for systemic use,% of total sales,10.6
+6080,Chile,2012,17,J-Antiinfectives for systemic use,"/capita, US$ purchasing power parity",21.8
+6081,Chile,2012,17,N02-Analgesics,% of total sales,5.1
+6082,Chile,2012,17,N05B-Anxiolytics,Million of national currency units,10633.1
+6083,Chile,2012,17,J-Antiinfectives for systemic use,Million US$ at exchange rate,271.9
+6084,Chile,2012,17,J-Antiinfectives for systemic use,"/capita, US$ exchange rate",15.6
+6085,Chile,2012,17,J-Antiinfectives for systemic use,"Million US$, purchasing power parity",380.9
+6086,Chile,2011,18,B-Blood and blood forming organs,Million US$ at exchange rate,114.1
+6087,Chile,2011,18,B-Blood and blood forming organs,Million of national currency units,55202.5
+6088,Chile,2011,18,G-Genito urinary system and sex hormones,Million of national currency units,111351.6
+6089,Chile,2011,18,G-Genito urinary system and sex hormones,Million US$ at exchange rate,230.2
+6090,Chile,2011,18,C10-Lipid modifying agents,"Million US$, purchasing power parity",71.9
+6091,Chile,2011,18,G-Genito urinary system and sex hormones,"/capita, US$ exchange rate",13.3
+6092,Chile,2011,18,G-Genito urinary system and sex hormones,"Million US$, purchasing power parity",320.0
+6093,Chile,2011,18,B-Blood and blood forming organs,"/capita, US$ purchasing power parity",9.2
+6094,Chile,2011,18,B-Blood and blood forming organs,% of total sales,4.7
+6095,Chile,2011,18,B-Blood and blood forming organs,"/capita, US$ exchange rate",6.6
+6096,Chile,2011,18,C10-Lipid modifying agents,"/capita, US$ purchasing power parity",4.2
+6097,Chile,2011,18,C10-Lipid modifying agents,"/capita, US$ exchange rate",3.0
+6098,Chile,2011,18,B-Blood and blood forming organs,"Million US$, purchasing power parity",158.6
+6099,Chile,2011,18,C10-Lipid modifying agents,% of total sales,2.1
+6100,Chile,2011,18,C01A-Cardiac glycosides,% of total sales,0.0
+6101,Chile,2011,18,A-Alimentary tract and metabolism,% of total sales,15.7
+6102,Chile,2011,18,C01A-Cardiac glycosides,Million US$ at exchange rate,0.2
+6103,Chile,2011,18,C01A-Cardiac glycosides,"Million US$, purchasing power parity",0.3
+6104,Chile,2011,18,A-Alimentary tract and metabolism,"Million US$, purchasing power parity",530.5
+6105,Chile,2011,18,A-Alimentary tract and metabolism,"/capita, US$ exchange rate",22.1
+6106,Chile,2011,18,A-Alimentary tract and metabolism,"/capita, US$ purchasing power parity",30.7
+6107,Chile,2011,18,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ purchasing power parity",3.1
+6108,Chile,2011,18,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ exchange rate",2.2
+6109,Chile,2011,18,"H-Systemic hormonal preparations, excluding sex hormones and insulins",% of total sales,1.6
+6110,Chile,2011,18,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million US$ at exchange rate,38.2
+6111,Chile,2011,18,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million of national currency units,18495.4
+6112,Chile,2011,18,"H-Systemic hormonal preparations, excluding sex hormones and insulins","Million US$, purchasing power parity",53.1
+6113,Chile,2011,18,G-Genito urinary system and sex hormones,"/capita, US$ purchasing power parity",18.5
+6114,Chile,2011,18,G-Genito urinary system and sex hormones,% of total sales,9.4
+6115,Chile,2011,18,G03-Sex hormones and modulators of the genital system,Million of national currency units,80168.5
+6116,Chile,2011,18,C01A-Cardiac glycosides,"/capita, US$ exchange rate",0.0
+6117,Chile,2011,18,C01A-Cardiac glycosides,"/capita, US$ purchasing power parity",0.0
+6118,Chile,2011,18,G03-Sex hormones and modulators of the genital system,% of total sales,6.8
+6119,Chile,2011,18,A-Alimentary tract and metabolism,Million US$ at exchange rate,381.7
+6120,Chile,2011,18,A-Alimentary tract and metabolism,Million of national currency units,184612.6
+6121,Chile,2011,18,G03-Sex hormones and modulators of the genital system,"/capita, US$ purchasing power parity",13.4
+6122,Chile,2011,18,G03-Sex hormones and modulators of the genital system,"Million US$, purchasing power parity",230.4
+6123,Chile,2011,18,G03-Sex hormones and modulators of the genital system,Million US$ at exchange rate,165.8
+6124,Chile,2011,18,G03-Sex hormones and modulators of the genital system,"/capita, US$ exchange rate",9.6
+6125,Chile,2011,18,C07-Beta blocking agents,Million of national currency units,10586.3
+6126,Chile,2011,18,Total pharmaceutical sales,"/capita, US$ purchasing power parity",196.4
+6127,Chile,2011,18,C07-Beta blocking agents,Million US$ at exchange rate,21.9
+6128,Chile,2011,18,Total pharmaceutical sales,"Million US$, purchasing power parity",3388.6
+6129,Chile,2011,18,Total pharmaceutical sales,Million US$ at exchange rate,2438.2
+6130,Chile,2011,18,Total pharmaceutical sales,"/capita, US$ exchange rate",141.3
+6131,Chile,2011,18,C02-Antihypertensives,"/capita, US$ purchasing power parity",0.4
+6132,Chile,2011,18,C02-Antihypertensives,"Million US$, purchasing power parity",6.7
+6133,Chile,2011,18,C02-Antihypertensives,"/capita, US$ exchange rate",0.3
+6134,Chile,2011,18,C-Cardiovascular system,% of total sales,7.8
+6135,Chile,2011,18,C07-Beta blocking agents,"Million US$, purchasing power parity",30.4
+6136,Chile,2011,18,C02-Antihypertensives,% of total sales,0.2
+6137,Chile,2011,18,C-Cardiovascular system,Million of national currency units,91532.1
+6138,Chile,2011,18,C-Cardiovascular system,Million US$ at exchange rate,189.2
+6139,Chile,2011,18,C03-Diuretics,Million of national currency units,2756.0
+6140,Chile,2011,18,C03-Diuretics,Million US$ at exchange rate,5.7
+6141,Chile,2011,18,C-Cardiovascular system,"/capita, US$ exchange rate",11.0
+6142,Chile,2011,18,C-Cardiovascular system,"/capita, US$ purchasing power parity",15.2
+6143,Chile,2011,18,C-Cardiovascular system,"Million US$, purchasing power parity",263.0
+6144,Chile,2011,18,C03-Diuretics,% of total sales,0.2
+6145,Chile,2011,18,C03-Diuretics,"/capita, US$ purchasing power parity",0.5
+6146,Chile,2011,18,Total pharmaceutical sales,Million of national currency units,1179279.0
+6147,Chile,2011,18,C03-Diuretics,"Million US$, purchasing power parity",7.9
+6148,Chile,2011,18,C03-Diuretics,"/capita, US$ exchange rate",0.3
+6149,Chile,2011,18,C08-Calcium channel blockers,% of total sales,0.5
+6150,Chile,2011,18,C09-Agents acting on the Renin-Angiotensin system,Million of national currency units,32614.1
+6151,Chile,2011,18,C08-Calcium channel blockers,"Million US$, purchasing power parity",16.9
+6152,Chile,2011,18,C08-Calcium channel blockers,"/capita, US$ purchasing power parity",1.0
+6153,Chile,2011,18,C08-Calcium channel blockers,"/capita, US$ exchange rate",0.7
+6154,Chile,2011,18,C09-Agents acting on the Renin-Angiotensin system,Million US$ at exchange rate,67.4
+6155,Chile,2011,18,C09-Agents acting on the Renin-Angiotensin system,% of total sales,2.8
+6156,Chile,2011,18,C10-Lipid modifying agents,Million US$ at exchange rate,51.7
+6157,Chile,2011,18,C10-Lipid modifying agents,Million of national currency units,25005.3
+6158,Chile,2011,18,C09-Agents acting on the Renin-Angiotensin system,"Million US$, purchasing power parity",93.7
+6159,Chile,2011,18,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ purchasing power parity",5.4
+6160,Chile,2011,18,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ exchange rate",3.9
+6161,Chile,2011,18,C08-Calcium channel blockers,Million US$ at exchange rate,12.2
+6162,Chile,2011,18,C02-Antihypertensives,Million US$ at exchange rate,4.8
+6163,Chile,2011,18,"C01B-Antiarrhythmics, Class I and III",% of total sales,0.1
+6164,Chile,2011,18,C02-Antihypertensives,Million of national currency units,2317.9
+6165,Chile,2011,18,C07-Beta blocking agents,"/capita, US$ purchasing power parity",1.8
+6166,Chile,2011,18,C07-Beta blocking agents,"/capita, US$ exchange rate",1.3
+6167,Chile,2011,18,C07-Beta blocking agents,% of total sales,0.9
+6168,Chile,2011,18,"C01B-Antiarrhythmics, Class I and III",Million US$ at exchange rate,2.8
+6169,Chile,2011,18,C08-Calcium channel blockers,Million of national currency units,5881.7
+6170,Chile,2011,18,"C01B-Antiarrhythmics, Class I and III",Million of national currency units,1341.3
+6171,Chile,2011,18,"C01B-Antiarrhythmics, Class I and III","/capita, US$ purchasing power parity",0.2
+6172,Chile,2011,18,"C01B-Antiarrhythmics, Class I and III","Million US$, purchasing power parity",3.9
+6173,Chile,2011,18,"C01B-Antiarrhythmics, Class I and III","/capita, US$ exchange rate",0.2
+6174,Chile,2011,18,J01-Antibacterials for systemic use,"/capita, US$ purchasing power parity",10.0
+6175,Chile,2011,18,J01-Antibacterials for systemic use,"/capita, US$ exchange rate",7.2
+6176,Chile,2011,18,N06A-Antidepressants,% of total sales,2.2
+6177,Chile,2011,18,J01-Antibacterials for systemic use,% of total sales,5.1
+6178,Chile,2011,18,A10-Drugs used in diabetes,Million of national currency units,34618.4
+6179,Chile,2011,18,A10-Drugs used in diabetes,"/capita, US$ purchasing power parity",5.8
+6180,Chile,2011,18,A10-Drugs used in diabetes,"/capita, US$ exchange rate",4.1
+6181,Chile,2011,18,A10-Drugs used in diabetes,% of total sales,2.9
+6182,Chile,2011,18,A10-Drugs used in diabetes,Million US$ at exchange rate,71.6
+6183,Chile,2011,18,A10-Drugs used in diabetes,"Million US$, purchasing power parity",99.5
+6184,Chile,2011,18,N06A-Antidepressants,Million US$ at exchange rate,53.2
+6185,Chile,2011,18,N06A-Antidepressants,Million of national currency units,25714.6
+6186,Chile,2011,18,N06A-Antidepressants,"Million US$, purchasing power parity",73.9
+6187,Chile,2011,18,M-Musculo-skeletal system,Million US$ at exchange rate,127.2
+6188,Chile,2011,18,M-Musculo-skeletal system,Million of national currency units,61502.0
+6189,Chile,2011,18,N05C-Hypnotics and sedatives,% of total sales,0.4
+6190,Chile,2011,18,Products not elsewhere classified,"/capita, US$ exchange rate",20.0
+6191,Chile,2011,18,N06A-Antidepressants,"/capita, US$ purchasing power parity",4.3
+6192,Chile,2011,18,N06A-Antidepressants,"/capita, US$ exchange rate",3.1
+6193,Chile,2011,18,Products not elsewhere classified,% of total sales,14.1
+6194,Chile,2011,18,Products not elsewhere classified,"/capita, US$ purchasing power parity",27.8
+6195,Chile,2011,18,R-Respiratory system,% of total sales,10.6
+6196,Chile,2011,18,R03-Drugs for obstructive airway diseases,Million of national currency units,26263.5
+6197,Chile,2011,18,R-Respiratory system,"/capita, US$ purchasing power parity",20.8
+6198,Chile,2011,18,R03-Drugs for obstructive airway diseases,"Million US$, purchasing power parity",75.5
+6199,Chile,2011,18,R03-Drugs for obstructive airway diseases,Million US$ at exchange rate,54.3
+6200,Chile,2011,18,A02A-Antacids,Million of national currency units,9337.8
+6201,Chile,2011,18,R-Respiratory system,Million of national currency units,124669.7
+6202,Chile,2011,18,A02A-Antacids,Million US$ at exchange rate,19.3
+6203,Chile,2011,18,R-Respiratory system,"/capita, US$ exchange rate",14.9
+6204,Chile,2011,18,R-Respiratory system,"Million US$, purchasing power parity",358.2
+6205,Chile,2011,18,R-Respiratory system,Million US$ at exchange rate,257.8
+6206,Chile,2011,18,A02A-Antacids,"/capita, US$ exchange rate",1.1
+6207,Chile,2011,18,A02A-Antacids,% of total sales,0.8
+6208,Chile,2011,18,A02A-Antacids,"/capita, US$ purchasing power parity",1.6
+6209,Chile,2011,18,Products not elsewhere classified,"Million US$, purchasing power parity",479.3
+6210,Chile,2011,18,J01-Antibacterials for systemic use,"Million US$, purchasing power parity",173.3
+6211,Chile,2011,18,J01-Antibacterials for systemic use,Million US$ at exchange rate,124.7
+6212,Chile,2011,18,J01-Antibacterials for systemic use,Million of national currency units,60319.9
+6213,Chile,2011,18,Products not elsewhere classified,Million US$ at exchange rate,344.9
+6214,Chile,2011,18,R03-Drugs for obstructive airway diseases,"/capita, US$ exchange rate",3.1
+6215,Chile,2011,18,R03-Drugs for obstructive airway diseases,"/capita, US$ purchasing power parity",4.4
+6216,Chile,2011,18,Products not elsewhere classified,Million of national currency units,166797.1
+6217,Chile,2011,18,R03-Drugs for obstructive airway diseases,% of total sales,2.2
+6218,Chile,2011,18,N02-Analgesics,"/capita, US$ exchange rate",7.1
+6219,Chile,2011,18,N02-Analgesics,"/capita, US$ purchasing power parity",9.8
+6220,Chile,2011,18,N02-Analgesics,"Million US$, purchasing power parity",169.5
+6221,Chile,2011,18,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million US$ at exchange rate,43.7
+6222,Chile,2011,18,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million of national currency units,21124.4
+6223,Chile,2011,18,N02-Analgesics,Million US$ at exchange rate,122.0
+6224,Chile,2011,18,M01A-Antiinflammatory and antirheumatic products non-steroids,"Million US$, purchasing power parity",136.3
+6225,Chile,2011,18,J-Antiinfectives for systemic use,Million of national currency units,177900.9
+6226,Chile,2011,18,M01A-Antiinflammatory and antirheumatic products non-steroids,Million US$ at exchange rate,98.1
+6227,Chile,2011,18,M01A-Antiinflammatory and antirheumatic products non-steroids,% of total sales,4.0
+6228,Chile,2011,18,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ exchange rate",5.7
+6229,Chile,2011,18,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ purchasing power parity",7.9
+6230,Chile,2011,18,N-Nervous system,Million US$ at exchange rate,387.1
+6231,Chile,2011,18,N-Nervous system,% of total sales,15.9
+6232,Chile,2011,18,N-Nervous system,Million of national currency units,187215.0
+6233,Chile,2011,18,N-Nervous system,"/capita, US$ purchasing power parity",31.2
+6234,Chile,2011,18,N-Nervous system,"/capita, US$ exchange rate",22.4
+6235,Chile,2011,18,N-Nervous system,"Million US$, purchasing power parity",537.9
+6236,Chile,2011,18,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ exchange rate",2.5
+6237,Chile,2011,18,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ purchasing power parity",3.5
+6238,Chile,2011,18,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"Million US$, purchasing power parity",60.7
+6239,Chile,2011,18,N02-Analgesics,Million of national currency units,58995.7
+6240,Chile,2011,18,C01A-Cardiac glycosides,Million of national currency units,91.5
+6241,Chile,2011,18,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),% of total sales,1.8
+6242,Chile,2011,18,N05C-Hypnotics and sedatives,Million of national currency units,5170.6
+6243,Chile,2011,18,N05B-Anxiolytics,% of total sales,0.8
+6244,Chile,2011,18,N05C-Hypnotics and sedatives,Million US$ at exchange rate,10.7
+6245,Chile,2011,18,N05B-Anxiolytics,"Million US$, purchasing power parity",28.1
+6246,Chile,2011,18,N05B-Anxiolytics,"/capita, US$ purchasing power parity",1.6
+6247,Chile,2011,18,N05B-Anxiolytics,"/capita, US$ exchange rate",1.2
+6248,Chile,2011,18,M-Musculo-skeletal system,"/capita, US$ purchasing power parity",10.2
+6249,Chile,2011,18,M-Musculo-skeletal system,"Million US$, purchasing power parity",176.7
+6250,Chile,2011,18,M-Musculo-skeletal system,"/capita, US$ exchange rate",7.4
+6251,Chile,2011,18,N05C-Hypnotics and sedatives,"Million US$, purchasing power parity",14.9
+6252,Chile,2011,18,M-Musculo-skeletal system,% of total sales,5.2
+6253,Chile,2011,18,N05C-Hypnotics and sedatives,"/capita, US$ exchange rate",0.6
+6254,Chile,2011,18,N05C-Hypnotics and sedatives,"/capita, US$ purchasing power parity",0.9
+6255,Chile,2011,18,A02A-Antacids,"Million US$, purchasing power parity",26.8
+6256,Chile,2011,18,N05B-Anxiolytics,Million US$ at exchange rate,20.2
+6257,Chile,2011,18,J-Antiinfectives for systemic use,% of total sales,15.1
+6258,Chile,2011,18,J-Antiinfectives for systemic use,"/capita, US$ purchasing power parity",29.6
+6259,Chile,2011,18,N02-Analgesics,% of total sales,5.0
+6260,Chile,2011,18,M01A-Antiinflammatory and antirheumatic products non-steroids,Million of national currency units,47430.8
+6261,Chile,2011,18,N05B-Anxiolytics,Million of national currency units,9773.0
+6262,Chile,2011,18,J-Antiinfectives for systemic use,Million US$ at exchange rate,367.8
+6263,Chile,2011,18,J-Antiinfectives for systemic use,"/capita, US$ exchange rate",21.3
+6264,Chile,2011,18,J-Antiinfectives for systemic use,"Million US$, purchasing power parity",511.2
+6265,Chile,2010,20,B-Blood and blood forming organs,Million of national currency units,19663.6
+6266,Chile,2010,20,G-Genito urinary system and sex hormones,Million US$ at exchange rate,159.7
+6267,Chile,2010,20,B-Blood and blood forming organs,Million US$ at exchange rate,38.5
+6268,Chile,2010,20,G-Genito urinary system and sex hormones,Million of national currency units,81496.5
+6269,Chile,2010,20,C10-Lipid modifying agents,"Million US$, purchasing power parity",54.0
+6270,Chile,2010,20,G-Genito urinary system and sex hormones,"/capita, US$ exchange rate",9.4
+6271,Chile,2010,20,G-Genito urinary system and sex hormones,"Million US$, purchasing power parity",226.5
+6272,Chile,2010,20,B-Blood and blood forming organs,% of total sales,2.4
+6273,Chile,2010,20,B-Blood and blood forming organs,"/capita, US$ purchasing power parity",3.2
+6274,Chile,2010,20,B-Blood and blood forming organs,"/capita, US$ exchange rate",2.3
+6275,Chile,2010,20,C10-Lipid modifying agents,"/capita, US$ purchasing power parity",3.2
+6276,Chile,2010,20,C10-Lipid modifying agents,"/capita, US$ exchange rate",2.2
+6277,Chile,2010,20,B-Blood and blood forming organs,"Million US$, purchasing power parity",54.6
+6278,Chile,2010,20,C10-Lipid modifying agents,% of total sales,2.4
+6279,Chile,2010,20,A-Alimentary tract and metabolism,% of total sales,18.3
+6280,Chile,2010,20,C01A-Cardiac glycosides,Million US$ at exchange rate,0.1
+6281,Chile,2010,20,C01A-Cardiac glycosides,"Million US$, purchasing power parity",0.1
+6282,Chile,2010,20,A-Alimentary tract and metabolism,"Million US$, purchasing power parity",420.5
+6283,Chile,2010,20,A-Alimentary tract and metabolism,"/capita, US$ exchange rate",17.4
+6284,Chile,2010,20,A-Alimentary tract and metabolism,"/capita, US$ purchasing power parity",24.6
+6285,Chile,2010,20,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ purchasing power parity",2.1
+6286,Chile,2010,20,"H-Systemic hormonal preparations, excluding sex hormones and insulins",% of total sales,1.5
+6287,Chile,2010,20,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ exchange rate",1.5
+6288,Chile,2010,20,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million US$ at exchange rate,25.1
+6289,Chile,2010,20,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million of national currency units,12798.0
+6290,Chile,2010,20,"H-Systemic hormonal preparations, excluding sex hormones and insulins","Million US$, purchasing power parity",35.6
+6291,Chile,2010,20,G-Genito urinary system and sex hormones,"/capita, US$ purchasing power parity",13.3
+6292,Chile,2010,20,G-Genito urinary system and sex hormones,% of total sales,9.9
+6293,Chile,2010,20,G03-Sex hormones and modulators of the genital system,Million of national currency units,64724.6
+6294,Chile,2010,20,C01A-Cardiac glycosides,"/capita, US$ exchange rate",0.0
+6295,Chile,2010,20,C01A-Cardiac glycosides,% of total sales,0.0
+6296,Chile,2010,20,C01A-Cardiac glycosides,"/capita, US$ purchasing power parity",0.0
+6297,Chile,2010,20,G03-Sex hormones and modulators of the genital system,% of total sales,7.8
+6298,Chile,2010,20,A-Alimentary tract and metabolism,Million US$ at exchange rate,296.5
+6299,Chile,2010,20,A-Alimentary tract and metabolism,Million of national currency units,151311.4
+6300,Chile,2010,20,G03-Sex hormones and modulators of the genital system,"/capita, US$ purchasing power parity",10.5
+6301,Chile,2010,20,G03-Sex hormones and modulators of the genital system,"Million US$, purchasing power parity",179.9
+6302,Chile,2010,20,G03-Sex hormones and modulators of the genital system,Million US$ at exchange rate,126.8
+6303,Chile,2010,20,G03-Sex hormones and modulators of the genital system,"/capita, US$ exchange rate",7.4
+6304,Chile,2010,20,C07-Beta blocking agents,Million of national currency units,8640.2
+6305,Chile,2010,20,Total pharmaceutical sales,"/capita, US$ purchasing power parity",134.5
+6306,Chile,2010,20,C07-Beta blocking agents,Million US$ at exchange rate,16.9
+6307,Chile,2010,20,Total pharmaceutical sales,"Million US$, purchasing power parity",2295.8
+6308,Chile,2010,20,Total pharmaceutical sales,Million US$ at exchange rate,1619.0
+6309,Chile,2010,20,Total pharmaceutical sales,"/capita, US$ exchange rate",94.9
+6310,Chile,2010,20,C02-Antihypertensives,"/capita, US$ purchasing power parity",0.3
+6311,Chile,2010,20,C02-Antihypertensives,"Million US$, purchasing power parity",4.7
+6312,Chile,2010,20,C02-Antihypertensives,"/capita, US$ exchange rate",0.2
+6313,Chile,2010,20,C07-Beta blocking agents,"Million US$, purchasing power parity",24.0
+6314,Chile,2010,20,C02-Antihypertensives,% of total sales,0.2
+6315,Chile,2010,20,C-Cardiovascular system,Million of national currency units,74875.9
+6316,Chile,2010,20,C-Cardiovascular system,Million US$ at exchange rate,146.7
+6317,Chile,2010,20,C03-Diuretics,Million of national currency units,1770.5
+6318,Chile,2010,20,C03-Diuretics,Million US$ at exchange rate,3.5
+6319,Chile,2010,20,C-Cardiovascular system,"/capita, US$ exchange rate",8.6
+6320,Chile,2010,20,C-Cardiovascular system,"/capita, US$ purchasing power parity",12.2
+6321,Chile,2010,20,C-Cardiovascular system,"Million US$, purchasing power parity",208.1
+6322,Chile,2010,20,C03-Diuretics,% of total sales,0.2
+6323,Chile,2010,20,C03-Diuretics,"/capita, US$ purchasing power parity",0.3
+6324,Chile,2010,20,Total pharmaceutical sales,Million of national currency units,826115.8
+6325,Chile,2010,20,C03-Diuretics,"Million US$, purchasing power parity",4.9
+6326,Chile,2010,20,C-Cardiovascular system,% of total sales,9.1
+6327,Chile,2010,20,C03-Diuretics,"/capita, US$ exchange rate",0.2
+6328,Chile,2010,20,C08-Calcium channel blockers,% of total sales,0.6
+6329,Chile,2010,20,C09-Agents acting on the Renin-Angiotensin system,Million of national currency units,28108.5
+6330,Chile,2010,20,C09-Agents acting on the Renin-Angiotensin system,Million US$ at exchange rate,55.1
+6331,Chile,2010,20,C08-Calcium channel blockers,"/capita, US$ purchasing power parity",0.8
+6332,Chile,2010,20,C08-Calcium channel blockers,"Million US$, purchasing power parity",13.8
+6333,Chile,2010,20,C08-Calcium channel blockers,"/capita, US$ exchange rate",0.6
+6334,Chile,2010,20,C09-Agents acting on the Renin-Angiotensin system,% of total sales,3.4
+6335,Chile,2010,20,C10-Lipid modifying agents,Million US$ at exchange rate,38.1
+6336,Chile,2010,20,C10-Lipid modifying agents,Million of national currency units,19420.8
+6337,Chile,2010,20,C09-Agents acting on the Renin-Angiotensin system,"Million US$, purchasing power parity",78.1
+6338,Chile,2010,20,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ purchasing power parity",4.6
+6339,Chile,2010,20,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ exchange rate",3.2
+6340,Chile,2010,20,C08-Calcium channel blockers,Million US$ at exchange rate,9.8
+6341,Chile,2010,20,C02-Antihypertensives,Million US$ at exchange rate,3.3
+6342,Chile,2010,20,C02-Antihypertensives,Million of national currency units,1699.3
+6343,Chile,2010,20,C07-Beta blocking agents,"/capita, US$ purchasing power parity",1.4
+6344,Chile,2010,20,C07-Beta blocking agents,"/capita, US$ exchange rate",1.0
+6345,Chile,2010,20,"C01B-Antiarrhythmics, Class I and III",% of total sales,0.1
+6346,Chile,2010,20,C07-Beta blocking agents,% of total sales,1.0
+6347,Chile,2010,20,"C01B-Antiarrhythmics, Class I and III",Million US$ at exchange rate,2.3
+6348,Chile,2010,20,C08-Calcium channel blockers,Million of national currency units,4975.3
+6349,Chile,2010,20,"C01B-Antiarrhythmics, Class I and III",Million of national currency units,1169.2
+6350,Chile,2010,20,"C01B-Antiarrhythmics, Class I and III","/capita, US$ purchasing power parity",0.2
+6351,Chile,2010,20,"C01B-Antiarrhythmics, Class I and III","Million US$, purchasing power parity",3.2
+6352,Chile,2010,20,"C01B-Antiarrhythmics, Class I and III","/capita, US$ exchange rate",0.1
+6353,Chile,2010,20,C01A-Cardiac glycosides,Million of national currency units,49.0
+6354,Chile,2010,20,J01-Antibacterials for systemic use,"/capita, US$ purchasing power parity",6.3
+6355,Chile,2010,20,J01-Antibacterials for systemic use,"/capita, US$ exchange rate",4.4
+6356,Chile,2010,20,J01-Antibacterials for systemic use,% of total sales,4.7
+6357,Chile,2010,20,N06A-Antidepressants,% of total sales,3.9
+6358,Chile,2010,20,A02A-Antacids,"Million US$, purchasing power parity",23.2
+6359,Chile,2010,20,A10-Drugs used in diabetes,"/capita, US$ purchasing power parity",3.5
+6360,Chile,2010,20,A10-Drugs used in diabetes,"/capita, US$ exchange rate",2.5
+6361,Chile,2010,20,A10-Drugs used in diabetes,% of total sales,2.6
+6362,Chile,2010,20,A10-Drugs used in diabetes,Million US$ at exchange rate,42.3
+6363,Chile,2010,20,A10-Drugs used in diabetes,"Million US$, purchasing power parity",60.0
+6364,Chile,2010,20,A10-Drugs used in diabetes,Million of national currency units,21597.9
+6365,Chile,2010,20,N06A-Antidepressants,Million US$ at exchange rate,62.6
+6366,Chile,2010,20,N06A-Antidepressants,Million of national currency units,31955.1
+6367,Chile,2010,20,N06A-Antidepressants,"Million US$, purchasing power parity",88.8
+6368,Chile,2010,20,M-Musculo-skeletal system,Million US$ at exchange rate,134.1
+6369,Chile,2010,20,M-Musculo-skeletal system,Million of national currency units,68438.5
+6370,Chile,2010,20,N05C-Hypnotics and sedatives,% of total sales,0.4
+6371,Chile,2010,20,Products not elsewhere classified,"/capita, US$ exchange rate",11.0
+6372,Chile,2010,20,N06A-Antidepressants,"/capita, US$ purchasing power parity",5.2
+6373,Chile,2010,20,N06A-Antidepressants,"/capita, US$ exchange rate",3.7
+6374,Chile,2010,20,Products not elsewhere classified,% of total sales,11.6
+6375,Chile,2010,20,Products not elsewhere classified,"/capita, US$ purchasing power parity",15.6
+6376,Chile,2010,20,R-Respiratory system,% of total sales,13.1
+6377,Chile,2010,20,R03-Drugs for obstructive airway diseases,Million of national currency units,15206.7
+6378,Chile,2010,20,R-Respiratory system,"/capita, US$ purchasing power parity",17.6
+6379,Chile,2010,20,R03-Drugs for obstructive airway diseases,"Million US$, purchasing power parity",42.3
+6380,Chile,2010,20,R03-Drugs for obstructive airway diseases,Million US$ at exchange rate,29.8
+6381,Chile,2010,20,R-Respiratory system,Million of national currency units,108206.7
+6382,Chile,2010,20,A02A-Antacids,Million of national currency units,8337.3
+6383,Chile,2010,20,A02A-Antacids,Million US$ at exchange rate,16.3
+6384,Chile,2010,20,R-Respiratory system,"/capita, US$ exchange rate",12.4
+6385,Chile,2010,20,R-Respiratory system,"Million US$, purchasing power parity",300.7
+6386,Chile,2010,20,R-Respiratory system,Million US$ at exchange rate,212.1
+6387,Chile,2010,20,A02A-Antacids,"/capita, US$ exchange rate",1.0
+6388,Chile,2010,20,A02A-Antacids,% of total sales,1.0
+6389,Chile,2010,20,A02A-Antacids,"/capita, US$ purchasing power parity",1.4
+6390,Chile,2010,20,Products not elsewhere classified,"Million US$, purchasing power parity",265.7
+6391,Chile,2010,20,J01-Antibacterials for systemic use,"Million US$, purchasing power parity",106.9
+6392,Chile,2010,20,J01-Antibacterials for systemic use,Million US$ at exchange rate,75.4
+6393,Chile,2010,20,J01-Antibacterials for systemic use,Million of national currency units,38463.8
+6394,Chile,2010,20,Products not elsewhere classified,Million US$ at exchange rate,187.4
+6395,Chile,2010,20,R03-Drugs for obstructive airway diseases,"/capita, US$ exchange rate",1.7
+6396,Chile,2010,20,R03-Drugs for obstructive airway diseases,"/capita, US$ purchasing power parity",2.5
+6397,Chile,2010,20,Products not elsewhere classified,Million of national currency units,95614.1
+6398,Chile,2010,20,R03-Drugs for obstructive airway diseases,% of total sales,1.8
+6399,Chile,2010,20,N02-Analgesics,"/capita, US$ exchange rate",6.2
+6400,Chile,2010,20,N02-Analgesics,"/capita, US$ purchasing power parity",8.8
+6401,Chile,2010,20,N02-Analgesics,"Million US$, purchasing power parity",150.1
+6402,Chile,2010,20,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million US$ at exchange rate,31.7
+6403,Chile,2010,20,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million of national currency units,16183.9
+6404,Chile,2010,20,N02-Analgesics,Million US$ at exchange rate,105.8
+6405,Chile,2010,20,M01A-Antiinflammatory and antirheumatic products non-steroids,"Million US$, purchasing power parity",98.3
+6406,Chile,2010,20,J-Antiinfectives for systemic use,Million of national currency units,58760.8
+6407,Chile,2010,20,M01A-Antiinflammatory and antirheumatic products non-steroids,Million US$ at exchange rate,69.3
+6408,Chile,2010,20,M01A-Antiinflammatory and antirheumatic products non-steroids,% of total sales,4.3
+6409,Chile,2010,20,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ exchange rate",4.1
+6410,Chile,2010,20,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ purchasing power parity",5.8
+6411,Chile,2010,20,N-Nervous system,Million US$ at exchange rate,303.7
+6412,Chile,2010,20,N-Nervous system,% of total sales,18.8
+6413,Chile,2010,20,N-Nervous system,Million of national currency units,154950.4
+6414,Chile,2010,20,N-Nervous system,"/capita, US$ purchasing power parity",25.2
+6415,Chile,2010,20,N-Nervous system,"/capita, US$ exchange rate",17.8
+6416,Chile,2010,20,N-Nervous system,"Million US$, purchasing power parity",430.6
+6417,Chile,2010,20,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ exchange rate",1.9
+6418,Chile,2010,20,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ purchasing power parity",2.6
+6419,Chile,2010,20,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"Million US$, purchasing power parity",45.0
+6420,Chile,2010,20,N02-Analgesics,Million of national currency units,54002.2
+6421,Chile,2010,20,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),% of total sales,2.0
+6422,Chile,2010,20,N05C-Hypnotics and sedatives,Million of national currency units,3361.7
+6423,Chile,2010,20,N05B-Anxiolytics,% of total sales,1.0
+6424,Chile,2010,20,N05C-Hypnotics and sedatives,Million US$ at exchange rate,6.6
+6425,Chile,2010,20,N05B-Anxiolytics,"Million US$, purchasing power parity",23.9
+6426,Chile,2010,20,N05B-Anxiolytics,"/capita, US$ purchasing power parity",1.4
+6427,Chile,2010,20,N05B-Anxiolytics,"/capita, US$ exchange rate",1.0
+6428,Chile,2010,20,N05C-Hypnotics and sedatives,"Million US$, purchasing power parity",9.3
+6429,Chile,2010,20,M-Musculo-skeletal system,"/capita, US$ purchasing power parity",11.1
+6430,Chile,2010,20,M-Musculo-skeletal system,"Million US$, purchasing power parity",190.2
+6431,Chile,2010,20,M-Musculo-skeletal system,"/capita, US$ exchange rate",7.9
+6432,Chile,2010,20,N05C-Hypnotics and sedatives,"/capita, US$ exchange rate",0.4
+6433,Chile,2010,20,N05C-Hypnotics and sedatives,"/capita, US$ purchasing power parity",0.5
+6434,Chile,2010,20,M-Musculo-skeletal system,% of total sales,8.3
+6435,Chile,2010,20,J-Antiinfectives for systemic use,% of total sales,7.1
+6436,Chile,2010,20,J-Antiinfectives for systemic use,"/capita, US$ purchasing power parity",9.6
+6437,Chile,2010,20,M01A-Antiinflammatory and antirheumatic products non-steroids,Million of national currency units,35363.2
+6438,Chile,2010,20,N02-Analgesics,% of total sales,6.5
+6439,Chile,2010,20,N05B-Anxiolytics,Million of national currency units,8596.0
+6440,Chile,2010,20,J-Antiinfectives for systemic use,Million US$ at exchange rate,115.2
+6441,Chile,2010,20,J-Antiinfectives for systemic use,"/capita, US$ exchange rate",6.7
+6442,Chile,2010,20,J-Antiinfectives for systemic use,"Million US$, purchasing power parity",163.3
+6443,Chile,2010,20,N05B-Anxiolytics,Million US$ at exchange rate,16.8
+6444,Chile,2017,13,B-Blood and blood forming organs,Million US$ at exchange rate,143.7
+6445,Chile,2017,13,G-Genito urinary system and sex hormones,Million of national currency units,178137.8
+6446,Chile,2017,13,B-Blood and blood forming organs,Million of national currency units,93218.1
+6447,Chile,2017,13,C10-Lipid modifying agents,"Million US$, purchasing power parity",90.0
+6448,Chile,2017,13,C10-Lipid modifying agents,Million US$ at exchange rate,55.1
+6449,Chile,2017,13,G-Genito urinary system and sex hormones,Million US$ at exchange rate,274.6
+6450,Chile,2017,13,G-Genito urinary system and sex hormones,"Million US$, purchasing power parity",447.9
+6451,Chile,2017,13,B-Blood and blood forming organs,"/capita, US$ purchasing power parity",12.7
+6452,Chile,2017,13,B-Blood and blood forming organs,"Million US$, purchasing power parity",234.4
+6453,Chile,2017,13,B-Blood and blood forming organs,"/capita, US$ exchange rate",7.8
+6454,Chile,2017,13,B-Blood and blood forming organs,% of total sales,4.5
+6455,Chile,2017,13,C10-Lipid modifying agents,"/capita, US$ exchange rate",3.0
+6456,Chile,2017,13,C10-Lipid modifying agents,"/capita, US$ purchasing power parity",4.9
+6457,Chile,2017,13,C10-Lipid modifying agents,% of total sales,1.7
+6458,Chile,2017,13,C01A-Cardiac glycosides,"Million US$, purchasing power parity",0.5
+6459,Chile,2017,13,A-Alimentary tract and metabolism,% of total sales,18.6
+6460,Chile,2017,13,C01A-Cardiac glycosides,Million US$ at exchange rate,0.3
+6461,Chile,2017,13,A-Alimentary tract and metabolism,"Million US$, purchasing power parity",968.8
+6462,Chile,2017,13,A-Alimentary tract and metabolism,"/capita, US$ purchasing power parity",52.6
+6463,Chile,2017,13,A-Alimentary tract and metabolism,"/capita, US$ exchange rate",32.2
+6464,Chile,2017,13,C01A-Cardiac glycosides,Million of national currency units,198.3
+6465,Chile,2017,13,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ exchange rate",4.6
+6466,Chile,2017,13,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ purchasing power parity",7.6
+6467,Chile,2017,13,"H-Systemic hormonal preparations, excluding sex hormones and insulins",% of total sales,2.7
+6468,Chile,2017,13,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million of national currency units,55462.8
+6469,Chile,2017,13,A-Alimentary tract and metabolism,Million US$ at exchange rate,593.8
+6470,Chile,2017,13,"H-Systemic hormonal preparations, excluding sex hormones and insulins","Million US$, purchasing power parity",139.5
+6471,Chile,2017,13,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million US$ at exchange rate,85.5
+6472,Chile,2017,13,G-Genito urinary system and sex hormones,"/capita, US$ purchasing power parity",24.3
+6473,Chile,2017,13,G03-Sex hormones and modulators of the genital system,Million of national currency units,124650.7
+6474,Chile,2017,13,G-Genito urinary system and sex hormones,% of total sales,8.6
+6475,Chile,2017,13,C01A-Cardiac glycosides,% of total sales,0.0
+6476,Chile,2017,13,G-Genito urinary system and sex hormones,"/capita, US$ exchange rate",14.9
+6477,Chile,2017,13,C01A-Cardiac glycosides,"/capita, US$ exchange rate",0.0
+6478,Chile,2017,13,C01A-Cardiac glycosides,"/capita, US$ purchasing power parity",0.0
+6479,Chile,2017,13,G03-Sex hormones and modulators of the genital system,% of total sales,6.0
+6480,Chile,2017,13,G03-Sex hormones and modulators of the genital system,"/capita, US$ purchasing power parity",17.0
+6481,Chile,2017,13,A-Alimentary tract and metabolism,Million of national currency units,385291.1
+6482,Chile,2017,13,G03-Sex hormones and modulators of the genital system,Million US$ at exchange rate,192.1
+6483,Chile,2017,13,G03-Sex hormones and modulators of the genital system,"Million US$, purchasing power parity",313.4
+6484,Chile,2017,13,G03-Sex hormones and modulators of the genital system,"/capita, US$ exchange rate",10.4
+6485,Chile,2017,13,Total pharmaceutical sales,"/capita, US$ purchasing power parity",282.3
+6486,Chile,2017,13,C07-Beta blocking agents,Million US$ at exchange rate,28.9
+6487,Chile,2017,13,C07-Beta blocking agents,Million of national currency units,18779.6
+6488,Chile,2017,13,Total pharmaceutical sales,Million US$ at exchange rate,3187.0
+6489,Chile,2017,13,Total pharmaceutical sales,"/capita, US$ exchange rate",173.0
+6490,Chile,2017,13,Total pharmaceutical sales,"Million US$, purchasing power parity",5199.6
+6491,Chile,2017,13,C02-Antihypertensives,"/capita, US$ exchange rate",0.4
+6492,Chile,2017,13,C02-Antihypertensives,"/capita, US$ purchasing power parity",0.7
+6493,Chile,2017,13,C02-Antihypertensives,"Million US$, purchasing power parity",12.4
+6494,Chile,2017,13,C07-Beta blocking agents,"Million US$, purchasing power parity",47.2
+6495,Chile,2017,13,C-Cardiovascular system,% of total sales,7.1
+6496,Chile,2017,13,C02-Antihypertensives,% of total sales,0.2
+6497,Chile,2017,13,C-Cardiovascular system,Million of national currency units,146723.5
+6498,Chile,2017,13,C03-Diuretics,Million of national currency units,5534.7
+6499,Chile,2017,13,C03-Diuretics,Million US$ at exchange rate,8.5
+6500,Chile,2017,13,C-Cardiovascular system,"/capita, US$ exchange rate",12.3
+6501,Chile,2017,13,C-Cardiovascular system,Million US$ at exchange rate,226.1
+6502,Chile,2017,13,C-Cardiovascular system,"Million US$, purchasing power parity",368.9
+6503,Chile,2017,13,C03-Diuretics,"/capita, US$ purchasing power parity",0.8
+6504,Chile,2017,13,Total pharmaceutical sales,Million of national currency units,2067820.4
+6505,Chile,2017,13,C03-Diuretics,% of total sales,0.3
+6506,Chile,2017,13,C-Cardiovascular system,"/capita, US$ purchasing power parity",20.0
+6507,Chile,2017,13,C03-Diuretics,"/capita, US$ exchange rate",0.5
+6508,Chile,2017,13,C03-Diuretics,"Million US$, purchasing power parity",13.9
+6509,Chile,2017,13,C08-Calcium channel blockers,"/capita, US$ purchasing power parity",1.2
+6510,Chile,2017,13,C08-Calcium channel blockers,% of total sales,0.4
+6511,Chile,2017,13,C09-Agents acting on the Renin-Angiotensin system,Million of national currency units,55530.1
+6512,Chile,2017,13,C08-Calcium channel blockers,Million US$ at exchange rate,13.1
+6513,Chile,2017,13,C08-Calcium channel blockers,"Million US$, purchasing power parity",21.3
+6514,Chile,2017,13,C08-Calcium channel blockers,"/capita, US$ exchange rate",0.7
+6515,Chile,2017,13,C09-Agents acting on the Renin-Angiotensin system,% of total sales,2.7
+6516,Chile,2017,13,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ purchasing power parity",7.6
+6517,Chile,2017,13,C10-Lipid modifying agents,Million of national currency units,35776.7
+6518,Chile,2017,13,C09-Agents acting on the Renin-Angiotensin system,"Million US$, purchasing power parity",139.6
+6519,Chile,2017,13,C09-Agents acting on the Renin-Angiotensin system,Million US$ at exchange rate,85.6
+6520,Chile,2017,13,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ exchange rate",4.6
+6521,Chile,2017,13,C02-Antihypertensives,Million US$ at exchange rate,7.6
+6522,Chile,2017,13,C02-Antihypertensives,Million of national currency units,4932.3
+6523,Chile,2017,13,"C01B-Antiarrhythmics, Class I and III",% of total sales,0.1
+6524,Chile,2017,13,C07-Beta blocking agents,"/capita, US$ exchange rate",1.6
+6525,Chile,2017,13,C07-Beta blocking agents,% of total sales,0.9
+6526,Chile,2017,13,C07-Beta blocking agents,"/capita, US$ purchasing power parity",2.6
+6527,Chile,2017,13,"C01B-Antiarrhythmics, Class I and III",Million of national currency units,2149.5
+6528,Chile,2017,13,"C01B-Antiarrhythmics, Class I and III",Million US$ at exchange rate,3.3
+6529,Chile,2017,13,C08-Calcium channel blockers,Million of national currency units,8473.5
+6530,Chile,2017,13,"C01B-Antiarrhythmics, Class I and III","/capita, US$ exchange rate",0.2
+6531,Chile,2017,13,"C01B-Antiarrhythmics, Class I and III","/capita, US$ purchasing power parity",0.3
+6532,Chile,2017,13,"C01B-Antiarrhythmics, Class I and III","Million US$, purchasing power parity",5.4
+6533,Chile,2017,13,J01-Antibacterials for systemic use,"/capita, US$ purchasing power parity",10.9
+6534,Chile,2017,13,J01-Antibacterials for systemic use,"/capita, US$ exchange rate",6.7
+6535,Chile,2017,13,J01-Antibacterials for systemic use,"Million US$, purchasing power parity",200.6
+6536,Chile,2017,13,N06A-Antidepressants,% of total sales,3.0
+6537,Chile,2017,13,J01-Antibacterials for systemic use,% of total sales,3.9
+6538,Chile,2017,13,N06A-Antidepressants,"/capita, US$ purchasing power parity",8.6
+6539,Chile,2017,13,A10-Drugs used in diabetes,"/capita, US$ exchange rate",9.3
+6540,Chile,2017,13,A10-Drugs used in diabetes,"/capita, US$ purchasing power parity",15.2
+6541,Chile,2017,13,A10-Drugs used in diabetes,Million of national currency units,111563.3
+6542,Chile,2017,13,A10-Drugs used in diabetes,"Million US$, purchasing power parity",280.5
+6543,Chile,2017,13,A10-Drugs used in diabetes,Million US$ at exchange rate,171.9
+6544,Chile,2017,13,N06A-Antidepressants,Million of national currency units,62830.3
+6545,Chile,2017,13,N06A-Antidepressants,Million US$ at exchange rate,96.8
+6546,Chile,2017,13,M-Musculo-skeletal system,Million of national currency units,116144.0
+6547,Chile,2017,13,N05C-Hypnotics and sedatives,% of total sales,0.6
+6548,Chile,2017,13,N05C-Hypnotics and sedatives,"/capita, US$ purchasing power parity",1.7
+6549,Chile,2017,13,N06A-Antidepressants,"Million US$, purchasing power parity",158.0
+6550,Chile,2017,13,Products not elsewhere classified,"Million US$, purchasing power parity",820.0
+6551,Chile,2017,13,N06A-Antidepressants,"/capita, US$ exchange rate",5.3
+6552,Chile,2017,13,Products not elsewhere classified,"/capita, US$ exchange rate",27.3
+6553,Chile,2017,13,Products not elsewhere classified,% of total sales,15.8
+6554,Chile,2017,13,Products not elsewhere classified,"/capita, US$ purchasing power parity",44.5
+6555,Chile,2017,13,A10-Drugs used in diabetes,% of total sales,5.4
+6556,Chile,2017,13,R-Respiratory system,% of total sales,9.7
+6557,Chile,2017,13,R-Respiratory system,"/capita, US$ purchasing power parity",27.4
+6558,Chile,2017,13,A02A-Antacids,"Million US$, purchasing power parity",29.2
+6559,Chile,2017,13,R03-Drugs for obstructive airway diseases,Million US$ at exchange rate,86.4
+6560,Chile,2017,13,R03-Drugs for obstructive airway diseases,Million of national currency units,56041.0
+6561,Chile,2017,13,R-Respiratory system,"/capita, US$ exchange rate",16.8
+6562,Chile,2017,13,A02A-Antacids,Million of national currency units,11617.0
+6563,Chile,2017,13,A02A-Antacids,Million US$ at exchange rate,17.9
+6564,Chile,2017,13,R-Respiratory system,Million of national currency units,200656.9
+6565,Chile,2017,13,R-Respiratory system,"Million US$, purchasing power parity",504.6
+6566,Chile,2017,13,R-Respiratory system,Million US$ at exchange rate,309.3
+6567,Chile,2017,13,A02A-Antacids,"/capita, US$ purchasing power parity",1.6
+6568,Chile,2017,13,Products not elsewhere classified,Million US$ at exchange rate,502.6
+6569,Chile,2017,13,A02A-Antacids,% of total sales,0.6
+6570,Chile,2017,13,J01-Antibacterials for systemic use,Million US$ at exchange rate,123.0
+6571,Chile,2017,13,J01-Antibacterials for systemic use,Million of national currency units,79791.6
+6572,Chile,2017,13,R03-Drugs for obstructive airway diseases,"/capita, US$ exchange rate",4.7
+6573,Chile,2017,13,A02A-Antacids,"/capita, US$ exchange rate",1.0
+6574,Chile,2017,13,R03-Drugs for obstructive airway diseases,"Million US$, purchasing power parity",140.9
+6575,Chile,2017,13,Products not elsewhere classified,Million of national currency units,326087.2
+6576,Chile,2017,13,R03-Drugs for obstructive airway diseases,"/capita, US$ purchasing power parity",7.7
+6577,Chile,2017,13,R03-Drugs for obstructive airway diseases,% of total sales,2.7
+6578,Chile,2017,13,N02-Analgesics,"Million US$, purchasing power parity",200.3
+6579,Chile,2017,13,M-Musculo-skeletal system,Million US$ at exchange rate,179.0
+6580,Chile,2017,13,N02-Analgesics,"/capita, US$ exchange rate",6.7
+6581,Chile,2017,13,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million of national currency units,31943.0
+6582,Chile,2017,13,N02-Analgesics,Million US$ at exchange rate,122.8
+6583,Chile,2017,13,M01A-Antiinflammatory and antirheumatic products non-steroids,% of total sales,2.8
+6584,Chile,2017,13,M01A-Antiinflammatory and antirheumatic products non-steroids,Million US$ at exchange rate,87.9
+6585,Chile,2017,13,M01A-Antiinflammatory and antirheumatic products non-steroids,"Million US$, purchasing power parity",143.4
+6586,Chile,2017,13,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ purchasing power parity",7.8
+6587,Chile,2017,13,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ exchange rate",4.8
+6588,Chile,2017,13,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million US$ at exchange rate,49.2
+6589,Chile,2017,13,N-Nervous system,Million of national currency units,310804.0
+6590,Chile,2017,13,N-Nervous system,Million US$ at exchange rate,479.0
+6591,Chile,2017,13,N-Nervous system,"/capita, US$ purchasing power parity",42.4
+6592,Chile,2017,13,N-Nervous system,"/capita, US$ exchange rate",26.0
+6593,Chile,2017,13,N-Nervous system,"Million US$, purchasing power parity",781.5
+6594,Chile,2017,13,N-Nervous system,% of total sales,15.0
+6595,Chile,2017,13,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ exchange rate",2.7
+6596,Chile,2017,13,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"Million US$, purchasing power parity",80.3
+6597,Chile,2017,13,J-Antiinfectives for systemic use,Million of national currency units,255295.0
+6598,Chile,2017,13,N02-Analgesics,Million of national currency units,79662.9
+6599,Chile,2017,13,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ purchasing power parity",4.4
+6600,Chile,2017,13,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),% of total sales,1.5
+6601,Chile,2017,13,N05B-Anxiolytics,% of total sales,0.8
+6602,Chile,2017,13,N05C-Hypnotics and sedatives,Million US$ at exchange rate,18.8
+6603,Chile,2017,13,N05C-Hypnotics and sedatives,Million of national currency units,12193.6
+6604,Chile,2017,13,N05B-Anxiolytics,"Million US$, purchasing power parity",39.2
+6605,Chile,2017,13,N05B-Anxiolytics,Million US$ at exchange rate,24.0
+6606,Chile,2017,13,N05B-Anxiolytics,"/capita, US$ exchange rate",1.3
+6607,Chile,2017,13,N05B-Anxiolytics,"/capita, US$ purchasing power parity",2.1
+6608,Chile,2017,13,M-Musculo-skeletal system,"/capita, US$ exchange rate",9.7
+6609,Chile,2017,13,M-Musculo-skeletal system,"/capita, US$ purchasing power parity",15.9
+6610,Chile,2017,13,M-Musculo-skeletal system,"Million US$, purchasing power parity",292.0
+6611,Chile,2017,13,N05C-Hypnotics and sedatives,"/capita, US$ exchange rate",1.0
+6612,Chile,2017,13,N05C-Hypnotics and sedatives,"Million US$, purchasing power parity",30.7
+6613,Chile,2017,13,M-Musculo-skeletal system,% of total sales,5.6
+6614,Chile,2017,13,J-Antiinfectives for systemic use,"/capita, US$ purchasing power parity",34.9
+6615,Chile,2017,13,M01A-Antiinflammatory and antirheumatic products non-steroids,Million of national currency units,57012.2
+6616,Chile,2017,13,J-Antiinfectives for systemic use,% of total sales,12.3
+6617,Chile,2017,13,N02-Analgesics,"/capita, US$ purchasing power parity",10.9
+6618,Chile,2017,13,J-Antiinfectives for systemic use,"/capita, US$ exchange rate",21.4
+6619,Chile,2017,13,J-Antiinfectives for systemic use,Million US$ at exchange rate,393.5
+6620,Chile,2017,13,N05B-Anxiolytics,Million of national currency units,15592.8
+6621,Chile,2017,13,N02-Analgesics,% of total sales,3.9
+6622,Chile,2017,13,J-Antiinfectives for systemic use,"Million US$, purchasing power parity",641.9
+6623,Chile,2016,13,B-Blood and blood forming organs,Million US$ at exchange rate,147.5
+6624,Chile,2016,13,G-Genito urinary system and sex hormones,Million of national currency units,191680.8
+6625,Chile,2016,13,B-Blood and blood forming organs,Million of national currency units,99840.0
+6626,Chile,2016,13,C10-Lipid modifying agents,"Million US$, purchasing power parity",108.0
+6627,Chile,2016,13,C10-Lipid modifying agents,Million US$ at exchange rate,63.4
+6628,Chile,2016,13,G-Genito urinary system and sex hormones,Million US$ at exchange rate,283.2
+6629,Chile,2016,13,G-Genito urinary system and sex hormones,"Million US$, purchasing power parity",482.5
+6630,Chile,2016,13,B-Blood and blood forming organs,"/capita, US$ purchasing power parity",13.8
+6631,Chile,2016,13,B-Blood and blood forming organs,% of total sales,4.9
+6632,Chile,2016,13,B-Blood and blood forming organs,"Million US$, purchasing power parity",251.3
+6633,Chile,2016,13,B-Blood and blood forming organs,"/capita, US$ exchange rate",8.1
+6634,Chile,2016,13,N-Nervous system,"/capita, US$ purchasing power parity",42.0
+6635,Chile,2016,13,C10-Lipid modifying agents,"/capita, US$ exchange rate",3.5
+6636,Chile,2016,13,C10-Lipid modifying agents,"/capita, US$ purchasing power parity",5.9
+6637,Chile,2016,13,C10-Lipid modifying agents,% of total sales,2.1
+6638,Chile,2016,13,G-Genito urinary system and sex hormones,"/capita, US$ exchange rate",15.6
+6639,Chile,2016,13,A-Alimentary tract and metabolism,% of total sales,17.8
+6640,Chile,2016,13,C01A-Cardiac glycosides,"Million US$, purchasing power parity",0.8
+6641,Chile,2016,13,C01A-Cardiac glycosides,Million US$ at exchange rate,0.5
+6642,Chile,2016,13,A-Alimentary tract and metabolism,"Million US$, purchasing power parity",909.1
+6643,Chile,2016,13,A-Alimentary tract and metabolism,"/capita, US$ purchasing power parity",50.0
+6644,Chile,2016,13,A-Alimentary tract and metabolism,"/capita, US$ exchange rate",29.4
+6645,Chile,2016,13,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ exchange rate",4.1
+6646,Chile,2016,13,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ purchasing power parity",7.1
+6647,Chile,2016,13,"H-Systemic hormonal preparations, excluding sex hormones and insulins",% of total sales,2.5
+6648,Chile,2016,13,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million of national currency units,50996.5
+6649,Chile,2016,13,C01A-Cardiac glycosides,Million of national currency units,335.1
+6650,Chile,2016,13,"H-Systemic hormonal preparations, excluding sex hormones and insulins","Million US$, purchasing power parity",128.4
+6651,Chile,2016,13,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million US$ at exchange rate,75.3
+6652,Chile,2016,13,A-Alimentary tract and metabolism,Million US$ at exchange rate,533.5
+6653,Chile,2016,13,G-Genito urinary system and sex hormones,"/capita, US$ purchasing power parity",26.6
+6654,Chile,2016,13,G03-Sex hormones and modulators of the genital system,Million of national currency units,139368.4
+6655,Chile,2016,13,G-Genito urinary system and sex hormones,% of total sales,9.5
+6656,Chile,2016,13,C01A-Cardiac glycosides,% of total sales,0.0
+6657,Chile,2016,13,C01A-Cardiac glycosides,"/capita, US$ exchange rate",0.0
+6658,Chile,2016,13,C01A-Cardiac glycosides,"/capita, US$ purchasing power parity",0.0
+6659,Chile,2016,13,G03-Sex hormones and modulators of the genital system,% of total sales,6.9
+6660,Chile,2016,13,G03-Sex hormones and modulators of the genital system,"/capita, US$ purchasing power parity",19.3
+6661,Chile,2016,13,A-Alimentary tract and metabolism,Million of national currency units,361148.7
+6662,Chile,2016,13,G03-Sex hormones and modulators of the genital system,Million US$ at exchange rate,205.9
+6663,Chile,2016,13,G03-Sex hormones and modulators of the genital system,"/capita, US$ exchange rate",11.3
+6664,Chile,2016,13,G03-Sex hormones and modulators of the genital system,"Million US$, purchasing power parity",350.8
+6665,Chile,2016,13,Total pharmaceutical sales,"/capita, US$ purchasing power parity",280.4
+6666,Chile,2016,13,C07-Beta blocking agents,Million US$ at exchange rate,28.2
+6667,Chile,2016,13,C07-Beta blocking agents,Million of national currency units,19105.1
+6668,Chile,2016,13,Total pharmaceutical sales,Million US$ at exchange rate,2989.7
+6669,Chile,2016,13,Total pharmaceutical sales,"/capita, US$ exchange rate",164.6
+6670,Chile,2016,13,Total pharmaceutical sales,"Million US$, purchasing power parity",5094.7
+6671,Chile,2016,13,C02-Antihypertensives,"/capita, US$ purchasing power parity",0.6
+6672,Chile,2016,13,C02-Antihypertensives,"/capita, US$ exchange rate",0.4
+6673,Chile,2016,13,C02-Antihypertensives,"Million US$, purchasing power parity",11.2
+6674,Chile,2016,13,C-Cardiovascular system,% of total sales,7.5
+6675,Chile,2016,13,C07-Beta blocking agents,"Million US$, purchasing power parity",48.1
+6676,Chile,2016,13,C02-Antihypertensives,% of total sales,0.2
+6677,Chile,2016,13,C-Cardiovascular system,Million of national currency units,152031.5
+6678,Chile,2016,13,C03-Diuretics,Million US$ at exchange rate,8.9
+6679,Chile,2016,13,C03-Diuretics,Million of national currency units,6034.4
+6680,Chile,2016,13,C-Cardiovascular system,"/capita, US$ exchange rate",12.4
+6681,Chile,2016,13,C-Cardiovascular system,Million US$ at exchange rate,224.6
+6682,Chile,2016,13,C-Cardiovascular system,"Million US$, purchasing power parity",382.7
+6683,Chile,2016,13,C03-Diuretics,"/capita, US$ purchasing power parity",0.8
+6684,Chile,2016,13,Total pharmaceutical sales,Million of national currency units,2023878.4
+6685,Chile,2016,13,C03-Diuretics,% of total sales,0.3
+6686,Chile,2016,13,C-Cardiovascular system,"/capita, US$ purchasing power parity",21.1
+6687,Chile,2016,13,C03-Diuretics,"/capita, US$ exchange rate",0.5
+6688,Chile,2016,13,C03-Diuretics,"Million US$, purchasing power parity",15.2
+6689,Chile,2016,13,C08-Calcium channel blockers,"/capita, US$ purchasing power parity",1.0
+6690,Chile,2016,13,C08-Calcium channel blockers,% of total sales,0.3
+6691,Chile,2016,13,C09-Agents acting on the Renin-Angiotensin system,Million of national currency units,54643.5
+6692,Chile,2016,13,C08-Calcium channel blockers,Million US$ at exchange rate,10.3
+6693,Chile,2016,13,C08-Calcium channel blockers,"Million US$, purchasing power parity",17.6
+6694,Chile,2016,13,C08-Calcium channel blockers,"/capita, US$ exchange rate",0.6
+6695,Chile,2016,13,C09-Agents acting on the Renin-Angiotensin system,% of total sales,2.7
+6696,Chile,2016,13,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ purchasing power parity",7.6
+6697,Chile,2016,13,C10-Lipid modifying agents,Million of national currency units,42911.6
+6698,Chile,2016,13,C09-Agents acting on the Renin-Angiotensin system,"Million US$, purchasing power parity",137.6
+6699,Chile,2016,13,C09-Agents acting on the Renin-Angiotensin system,Million US$ at exchange rate,80.7
+6700,Chile,2016,13,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ exchange rate",4.4
+6701,Chile,2016,13,C02-Antihypertensives,Million US$ at exchange rate,6.6
+6702,Chile,2016,13,C02-Antihypertensives,Million of national currency units,4456.9
+6703,Chile,2016,13,"C01B-Antiarrhythmics, Class I and III",% of total sales,0.1
+6704,Chile,2016,13,C07-Beta blocking agents,"/capita, US$ exchange rate",1.6
+6705,Chile,2016,13,C07-Beta blocking agents,"/capita, US$ purchasing power parity",2.6
+6706,Chile,2016,13,C07-Beta blocking agents,% of total sales,0.9
+6707,Chile,2016,13,"C01B-Antiarrhythmics, Class I and III",Million US$ at exchange rate,3.3
+6708,Chile,2016,13,"C01B-Antiarrhythmics, Class I and III",Million of national currency units,2214.9
+6709,Chile,2016,13,C08-Calcium channel blockers,Million of national currency units,6996.6
+6710,Chile,2016,13,"C01B-Antiarrhythmics, Class I and III","/capita, US$ exchange rate",0.2
+6711,Chile,2016,13,"C01B-Antiarrhythmics, Class I and III","/capita, US$ purchasing power parity",0.3
+6712,Chile,2016,13,"C01B-Antiarrhythmics, Class I and III","Million US$, purchasing power parity",5.6
+6713,Chile,2016,13,J01-Antibacterials for systemic use,"/capita, US$ purchasing power parity",11.6
+6714,Chile,2016,13,J01-Antibacterials for systemic use,"Million US$, purchasing power parity",210.0
+6715,Chile,2016,13,J01-Antibacterials for systemic use,"/capita, US$ exchange rate",6.8
+6716,Chile,2016,13,N06A-Antidepressants,% of total sales,3.0
+6717,Chile,2016,13,J01-Antibacterials for systemic use,% of total sales,4.1
+6718,Chile,2016,13,A10-Drugs used in diabetes,"/capita, US$ exchange rate",7.9
+6719,Chile,2016,13,A10-Drugs used in diabetes,"/capita, US$ purchasing power parity",13.4
+6720,Chile,2016,13,A10-Drugs used in diabetes,Million of national currency units,96716.5
+6721,Chile,2016,13,A10-Drugs used in diabetes,Million US$ at exchange rate,142.9
+6722,Chile,2016,13,A10-Drugs used in diabetes,"Million US$, purchasing power parity",243.5
+6723,Chile,2016,13,A10-Drugs used in diabetes,% of total sales,4.8
+6724,Chile,2016,13,N06A-Antidepressants,"/capita, US$ purchasing power parity",8.3
+6725,Chile,2016,13,N06A-Antidepressants,Million of national currency units,60183.9
+6726,Chile,2016,13,N06A-Antidepressants,Million US$ at exchange rate,88.9
+6727,Chile,2016,13,M-Musculo-skeletal system,Million of national currency units,120374.3
+6728,Chile,2016,13,N05C-Hypnotics and sedatives,% of total sales,0.5
+6729,Chile,2016,13,N06A-Antidepressants,"Million US$, purchasing power parity",151.5
+6730,Chile,2016,13,Products not elsewhere classified,"Million US$, purchasing power parity",686.4
+6731,Chile,2016,13,Products not elsewhere classified,"/capita, US$ exchange rate",22.2
+6732,Chile,2016,13,N06A-Antidepressants,"/capita, US$ exchange rate",4.9
+6733,Chile,2016,13,Products not elsewhere classified,% of total sales,13.5
+6734,Chile,2016,13,Products not elsewhere classified,"/capita, US$ purchasing power parity",37.8
+6735,Chile,2016,13,R-Respiratory system,% of total sales,9.4
+6736,Chile,2016,13,R-Respiratory system,"/capita, US$ purchasing power parity",26.4
+6737,Chile,2016,13,A02A-Antacids,"Million US$, purchasing power parity",28.4
+6738,Chile,2016,13,R03-Drugs for obstructive airway diseases,Million of national currency units,52879.3
+6739,Chile,2016,13,R03-Drugs for obstructive airway diseases,Million US$ at exchange rate,78.1
+6740,Chile,2016,13,R-Respiratory system,"/capita, US$ exchange rate",15.5
+6741,Chile,2016,13,A02A-Antacids,Million of national currency units,11264.6
+6742,Chile,2016,13,R-Respiratory system,Million of national currency units,190353.2
+6743,Chile,2016,13,A02A-Antacids,Million US$ at exchange rate,16.6
+6744,Chile,2016,13,R-Respiratory system,"Million US$, purchasing power parity",479.2
+6745,Chile,2016,13,R-Respiratory system,Million US$ at exchange rate,281.2
+6746,Chile,2016,13,A02A-Antacids,"/capita, US$ purchasing power parity",1.6
+6747,Chile,2016,13,Products not elsewhere classified,Million US$ at exchange rate,402.8
+6748,Chile,2016,13,A02A-Antacids,% of total sales,0.6
+6749,Chile,2016,13,J01-Antibacterials for systemic use,Million US$ at exchange rate,123.2
+6750,Chile,2016,13,J01-Antibacterials for systemic use,Million of national currency units,83434.7
+6751,Chile,2016,13,R03-Drugs for obstructive airway diseases,"/capita, US$ exchange rate",4.3
+6752,Chile,2016,13,A02A-Antacids,"/capita, US$ exchange rate",0.9
+6753,Chile,2016,13,R03-Drugs for obstructive airway diseases,"Million US$, purchasing power parity",133.1
+6754,Chile,2016,13,Products not elsewhere classified,Million of national currency units,272690.5
+6755,Chile,2016,13,R03-Drugs for obstructive airway diseases,"/capita, US$ purchasing power parity",7.3
+6756,Chile,2016,13,R03-Drugs for obstructive airway diseases,% of total sales,2.6
+6757,Chile,2016,13,M-Musculo-skeletal system,Million US$ at exchange rate,177.8
+6758,Chile,2016,13,N02-Analgesics,"Million US$, purchasing power parity",216.1
+6759,Chile,2016,13,N02-Analgesics,"/capita, US$ purchasing power parity",11.9
+6760,Chile,2016,13,N02-Analgesics,"/capita, US$ exchange rate",7.0
+6761,Chile,2016,13,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million of national currency units,27671.1
+6762,Chile,2016,13,N02-Analgesics,Million US$ at exchange rate,126.8
+6763,Chile,2016,13,M01A-Antiinflammatory and antirheumatic products non-steroids,"Million US$, purchasing power parity",154.1
+6764,Chile,2016,13,M01A-Antiinflammatory and antirheumatic products non-steroids,Million US$ at exchange rate,90.4
+6765,Chile,2016,13,J-Antiinfectives for systemic use,Million of national currency units,281371.0
+6766,Chile,2016,13,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ purchasing power parity",8.5
+6767,Chile,2016,13,M01A-Antiinflammatory and antirheumatic products non-steroids,% of total sales,3.0
+6768,Chile,2016,13,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ exchange rate",5.0
+6769,Chile,2016,13,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million US$ at exchange rate,40.9
+6770,Chile,2016,13,N-Nervous system,Million of national currency units,303392.0
+6771,Chile,2016,13,N-Nervous system,Million US$ at exchange rate,448.2
+6772,Chile,2016,13,N-Nervous system,"/capita, US$ exchange rate",24.7
+6773,Chile,2016,13,N-Nervous system,"Million US$, purchasing power parity",763.7
+6774,Chile,2016,13,N-Nervous system,% of total sales,15.0
+6775,Chile,2016,13,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ exchange rate",2.2
+6776,Chile,2016,13,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"Million US$, purchasing power parity",69.7
+6777,Chile,2016,13,N02-Analgesics,Million of national currency units,85860.4
+6778,Chile,2016,13,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ purchasing power parity",3.8
+6779,Chile,2016,13,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),% of total sales,1.4
+6780,Chile,2016,13,N05B-Anxiolytics,% of total sales,0.7
+6781,Chile,2016,13,N05C-Hypnotics and sedatives,Million US$ at exchange rate,16.0
+6782,Chile,2016,13,N05C-Hypnotics and sedatives,Million of national currency units,10849.8
+6783,Chile,2016,13,N05B-Anxiolytics,"/capita, US$ purchasing power parity",1.9
+6784,Chile,2016,13,N05B-Anxiolytics,"Million US$, purchasing power parity",35.2
+6785,Chile,2016,13,N05B-Anxiolytics,Million US$ at exchange rate,20.6
+6786,Chile,2016,13,N05B-Anxiolytics,"/capita, US$ exchange rate",1.1
+6787,Chile,2016,13,M-Musculo-skeletal system,"/capita, US$ exchange rate",9.8
+6788,Chile,2016,13,M-Musculo-skeletal system,"/capita, US$ purchasing power parity",16.7
+6789,Chile,2016,13,M-Musculo-skeletal system,"Million US$, purchasing power parity",303.0
+6790,Chile,2016,13,N05C-Hypnotics and sedatives,"/capita, US$ exchange rate",0.9
+6791,Chile,2016,13,N05C-Hypnotics and sedatives,"Million US$, purchasing power parity",27.3
+6792,Chile,2016,13,M-Musculo-skeletal system,% of total sales,5.9
+6793,Chile,2016,13,N05C-Hypnotics and sedatives,"/capita, US$ purchasing power parity",1.5
+6794,Chile,2016,13,J-Antiinfectives for systemic use,"/capita, US$ purchasing power parity",39.0
+6795,Chile,2016,13,M01A-Antiinflammatory and antirheumatic products non-steroids,Million of national currency units,61219.5
+6796,Chile,2016,13,J-Antiinfectives for systemic use,% of total sales,13.9
+6797,Chile,2016,13,J-Antiinfectives for systemic use,"/capita, US$ exchange rate",22.9
+6798,Chile,2016,13,N05B-Anxiolytics,Million of national currency units,13974.1
+6799,Chile,2016,13,N02-Analgesics,% of total sales,4.2
+6800,Chile,2016,13,J-Antiinfectives for systemic use,Million US$ at exchange rate,415.6
+6801,Chile,2016,13,J-Antiinfectives for systemic use,"Million US$, purchasing power parity",708.3
+6802,Costa Rica,2016,28,C-Cardiovascular system,"/capita, US$ purchasing power parity",3.3
+6803,Costa Rica,2016,28,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ purchasing power parity",1.0
+6804,Costa Rica,2016,28,C02-Antihypertensives,Million US$ at exchange rate,1.0
+6805,Costa Rica,2016,28,R03-Drugs for obstructive airway diseases,Million US$ at exchange rate,5.7
+6806,Costa Rica,2016,28,N05C-Hypnotics and sedatives,Million US$ at exchange rate,0.4
+6807,Costa Rica,2016,28,C07-Beta blocking agents,"Million US$, purchasing power parity",2.5
+6808,Costa Rica,2016,28,N05C-Hypnotics and sedatives,"/capita, US$ purchasing power parity",0.1
+6809,Costa Rica,2016,28,J01-Antibacterials for systemic use,Million US$ at exchange rate,9.4
+6810,Costa Rica,2016,28,C01A-Cardiac glycosides,"/capita, US$ exchange rate",0.1
+6811,Costa Rica,2016,28,A10-Drugs used in diabetes,"/capita, US$ exchange rate",1.6
+6812,Costa Rica,2016,28,"C01B-Antiarrhythmics, Class I and III","Million US$, purchasing power parity",0.2
+6813,Costa Rica,2016,28,J01-Antibacterials for systemic use,"/capita, US$ purchasing power parity",3.0
+6814,Costa Rica,2016,28,B-Blood and blood forming organs,"Million US$, purchasing power parity",46.6
+6815,Costa Rica,2016,28,C08-Calcium channel blockers,Million of national currency units,298.2
+6816,Costa Rica,2016,28,N02-Analgesics,"/capita, US$ exchange rate",1.0
+6817,Costa Rica,2016,28,C03-Diuretics,"/capita, US$ exchange rate",0.2
+6818,Costa Rica,2016,28,C08-Calcium channel blockers,Million US$ at exchange rate,0.5
+6819,Costa Rica,2016,28,N06A-Antidepressants,"/capita, US$ exchange rate",0.6
+6820,Costa Rica,2016,28,C-Cardiovascular system,Million of national currency units,5484.2
+6821,Costa Rica,2016,28,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million of national currency units,1689.2
+6822,Costa Rica,2016,28,C-Cardiovascular system,Million US$ at exchange rate,10.1
+6823,Costa Rica,2016,28,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ exchange rate",0.9
+6824,Costa Rica,2016,28,G03-Sex hormones and modulators of the genital system,"/capita, US$ purchasing power parity",1.1
+6825,Costa Rica,2016,28,M01A-Antiinflammatory and antirheumatic products non-steroids,"Million US$, purchasing power parity",5.5
+6826,Costa Rica,2016,28,N05B-Anxiolytics,"Million US$, purchasing power parity",1.0
+6827,Costa Rica,2016,28,C02-Antihypertensives,Million of national currency units,539.3
+6828,Costa Rica,2016,28,M01A-Antiinflammatory and antirheumatic products non-steroids,Million of national currency units,1877.2
+6829,Costa Rica,2016,28,J-Antiinfectives for systemic use,Million of national currency units,19042.5
+6830,Costa Rica,2016,28,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ exchange rate",0.6
+6831,Costa Rica,2016,28,N02-Analgesics,"Million US$, purchasing power parity",7.7
+6832,Costa Rica,2016,28,R03-Drugs for obstructive airway diseases,"/capita, US$ purchasing power parity",1.9
+6833,Costa Rica,2016,28,J-Antiinfectives for systemic use,Million US$ at exchange rate,35.0
+6834,Costa Rica,2016,28,B-Blood and blood forming organs,"/capita, US$ exchange rate",6.0
+6835,Costa Rica,2016,28,M01A-Antiinflammatory and antirheumatic products non-steroids,Million US$ at exchange rate,3.4
+6836,Costa Rica,2016,28,N05C-Hypnotics and sedatives,"/capita, US$ exchange rate",0.1
+6837,Costa Rica,2016,28,N05B-Anxiolytics,Million US$ at exchange rate,0.7
+6838,Costa Rica,2016,28,C02-Antihypertensives,"/capita, US$ exchange rate",0.2
+6839,Costa Rica,2016,28,C-Cardiovascular system,"/capita, US$ exchange rate",2.1
+6840,Costa Rica,2016,28,C10-Lipid modifying agents,Million US$ at exchange rate,3.1
+6841,Costa Rica,2016,28,C10-Lipid modifying agents,"/capita, US$ purchasing power parity",1.0
+6842,Costa Rica,2016,28,C07-Beta blocking agents,"/capita, US$ purchasing power parity",0.5
+6843,Costa Rica,2016,28,N06A-Antidepressants,"Million US$, purchasing power parity",4.4
+6844,Costa Rica,2016,28,N06A-Antidepressants,"/capita, US$ purchasing power parity",0.9
+6845,Costa Rica,2016,28,"H-Systemic hormonal preparations, excluding sex hormones and insulins","Million US$, purchasing power parity",6.8
+6846,Costa Rica,2016,28,B-Blood and blood forming organs,"/capita, US$ purchasing power parity",9.5
+6847,Costa Rica,2016,28,J-Antiinfectives for systemic use,"/capita, US$ exchange rate",7.1
+6848,Costa Rica,2016,28,C10-Lipid modifying agents,"Million US$, purchasing power parity",4.9
+6849,Costa Rica,2016,28,A02A-Antacids,"/capita, US$ purchasing power parity",0.6
+6850,Costa Rica,2016,28,"C01B-Antiarrhythmics, Class I and III","/capita, US$ purchasing power parity",0.0
+6851,Costa Rica,2016,28,C01A-Cardiac glycosides,Million US$ at exchange rate,0.4
+6852,Costa Rica,2016,28,"C01B-Antiarrhythmics, Class I and III",Million US$ at exchange rate,0.1
+6853,Costa Rica,2016,28,C07-Beta blocking agents,Million US$ at exchange rate,1.6
+6854,Costa Rica,2016,28,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million of national currency units,2333.1
+6855,Costa Rica,2016,28,J01-Antibacterials for systemic use,"/capita, US$ exchange rate",1.9
+6856,Costa Rica,2016,28,R03-Drugs for obstructive airway diseases,Million of national currency units,3104.4
+6857,Costa Rica,2016,28,C10-Lipid modifying agents,Million of national currency units,1683.6
+6858,Costa Rica,2016,28,A02A-Antacids,Million of national currency units,927.7
+6859,Costa Rica,2016,28,B-Blood and blood forming organs,Million of national currency units,15990.6
+6860,Costa Rica,2016,28,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ exchange rate",0.5
+6861,Costa Rica,2016,28,G03-Sex hormones and modulators of the genital system,"/capita, US$ exchange rate",0.7
+6862,Costa Rica,2016,28,"C01B-Antiarrhythmics, Class I and III",Million of national currency units,75.6
+6863,Costa Rica,2016,28,A02A-Antacids,Million US$ at exchange rate,1.7
+6864,Costa Rica,2016,28,A10-Drugs used in diabetes,"/capita, US$ purchasing power parity",2.6
+6865,Costa Rica,2016,28,B-Blood and blood forming organs,Million US$ at exchange rate,29.4
+6866,Costa Rica,2016,28,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ purchasing power parity",1.4
+6867,Costa Rica,2016,28,N05B-Anxiolytics,"/capita, US$ purchasing power parity",0.2
+6868,Costa Rica,2016,28,A02A-Antacids,"/capita, US$ exchange rate",0.3
+6869,Costa Rica,2016,28,C-Cardiovascular system,"Million US$, purchasing power parity",16.0
+6870,Costa Rica,2016,28,C07-Beta blocking agents,Million of national currency units,868.6
+6871,Costa Rica,2016,28,C03-Diuretics,"Million US$, purchasing power parity",1.2
+6872,Costa Rica,2016,28,C01A-Cardiac glycosides,"Million US$, purchasing power parity",0.6
+6873,Costa Rica,2016,28,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ purchasing power parity",1.1
+6874,Costa Rica,2016,28,J-Antiinfectives for systemic use,"/capita, US$ purchasing power parity",11.4
+6875,Costa Rica,2016,28,A10-Drugs used in diabetes,"Million US$, purchasing power parity",12.5
+6876,Costa Rica,2016,28,C08-Calcium channel blockers,"/capita, US$ purchasing power parity",0.2
+6877,Costa Rica,2016,28,C07-Beta blocking agents,"/capita, US$ exchange rate",0.3
+6878,Costa Rica,2016,28,N06A-Antidepressants,Million of national currency units,1494.7
+6879,Costa Rica,2016,28,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million US$ at exchange rate,3.1
+6880,Costa Rica,2016,28,N02-Analgesics,Million of national currency units,2631.2
+6881,Costa Rica,2016,28,N05C-Hypnotics and sedatives,"Million US$, purchasing power parity",0.6
+6882,Costa Rica,2016,28,R03-Drugs for obstructive airway diseases,"Million US$, purchasing power parity",9.1
+6883,Costa Rica,2016,28,"C01B-Antiarrhythmics, Class I and III","/capita, US$ exchange rate",0.0
+6884,Costa Rica,2016,28,N02-Analgesics,Million US$ at exchange rate,4.8
+6885,Costa Rica,2016,28,C08-Calcium channel blockers,"/capita, US$ exchange rate",0.1
+6886,Costa Rica,2016,28,A10-Drugs used in diabetes,Million US$ at exchange rate,7.9
+6887,Costa Rica,2016,28,G03-Sex hormones and modulators of the genital system,"Million US$, purchasing power parity",5.3
+6888,Costa Rica,2016,28,J01-Antibacterials for systemic use,"Million US$, purchasing power parity",14.9
+6889,Costa Rica,2016,28,C09-Agents acting on the Renin-Angiotensin system,"Million US$, purchasing power parity",4.0
+6890,Costa Rica,2016,28,C10-Lipid modifying agents,"/capita, US$ exchange rate",0.6
+6891,Costa Rica,2016,28,N06A-Antidepressants,Million US$ at exchange rate,2.7
+6892,Costa Rica,2016,28,R03-Drugs for obstructive airway diseases,"/capita, US$ exchange rate",1.2
+6893,Costa Rica,2016,28,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million US$ at exchange rate,4.3
+6894,Costa Rica,2016,28,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ purchasing power parity",0.8
+6895,Costa Rica,2016,28,G03-Sex hormones and modulators of the genital system,Million of national currency units,1812.8
+6896,Costa Rica,2016,28,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ exchange rate",0.7
+6897,Costa Rica,2016,28,C09-Agents acting on the Renin-Angiotensin system,Million of national currency units,1357.8
+6898,Costa Rica,2016,28,C03-Diuretics,Million US$ at exchange rate,0.8
+6899,Costa Rica,2016,28,C02-Antihypertensives,"/capita, US$ purchasing power parity",0.3
+6900,Costa Rica,2016,28,N05C-Hypnotics and sedatives,Million of national currency units,213.0
+6901,Costa Rica,2016,28,J01-Antibacterials for systemic use,Million of national currency units,5106.3
+6902,Costa Rica,2016,28,J-Antiinfectives for systemic use,"Million US$, purchasing power parity",55.5
+6903,Costa Rica,2016,28,C01A-Cardiac glycosides,"/capita, US$ purchasing power parity",0.1
+6904,Costa Rica,2016,28,C03-Diuretics,"/capita, US$ purchasing power parity",0.3
+6905,Costa Rica,2016,28,C01A-Cardiac glycosides,Million of national currency units,201.9
+6906,Costa Rica,2016,28,A02A-Antacids,"Million US$, purchasing power parity",2.7
+6907,Costa Rica,2016,28,C09-Agents acting on the Renin-Angiotensin system,Million US$ at exchange rate,2.5
+6908,Costa Rica,2016,28,N05B-Anxiolytics,"/capita, US$ exchange rate",0.1
+6909,Costa Rica,2016,28,G03-Sex hormones and modulators of the genital system,Million US$ at exchange rate,3.3
+6910,Costa Rica,2016,28,C03-Diuretics,Million of national currency units,427.5
+6911,Costa Rica,2016,28,A10-Drugs used in diabetes,Million of national currency units,4281.7
+6912,Costa Rica,2016,28,N05B-Anxiolytics,Million of national currency units,355.5
+6913,Costa Rica,2016,28,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"Million US$, purchasing power parity",4.9
+6914,Costa Rica,2016,28,C08-Calcium channel blockers,"Million US$, purchasing power parity",0.9
+6915,Costa Rica,2016,28,C02-Antihypertensives,"Million US$, purchasing power parity",1.6
+6916,Costa Rica,2016,28,N02-Analgesics,"/capita, US$ purchasing power parity",1.6
+6917,Costa Rica,2015,28,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ purchasing power parity",1.0
+6918,Costa Rica,2015,28,C02-Antihypertensives,Million US$ at exchange rate,1.0
+6919,Costa Rica,2015,28,R03-Drugs for obstructive airway diseases,Million US$ at exchange rate,6.9
+6920,Costa Rica,2015,28,N05C-Hypnotics and sedatives,Million US$ at exchange rate,0.4
+6921,Costa Rica,2015,28,C07-Beta blocking agents,"Million US$, purchasing power parity",2.3
+6922,Costa Rica,2015,28,N05C-Hypnotics and sedatives,"/capita, US$ purchasing power parity",0.1
+6923,Costa Rica,2015,28,C01A-Cardiac glycosides,"/capita, US$ exchange rate",0.1
+6924,Costa Rica,2015,28,A10-Drugs used in diabetes,"/capita, US$ exchange rate",1.6
+6925,Costa Rica,2015,28,J01-Antibacterials for systemic use,Million US$ at exchange rate,9.2
+6926,Costa Rica,2015,28,"C01B-Antiarrhythmics, Class I and III","Million US$, purchasing power parity",0.2
+6927,Costa Rica,2015,28,J01-Antibacterials for systemic use,"/capita, US$ purchasing power parity",2.9
+6928,Costa Rica,2015,28,B-Blood and blood forming organs,"Million US$, purchasing power parity",47.2
+6929,Costa Rica,2015,28,C08-Calcium channel blockers,Million of national currency units,362.9
+6930,Costa Rica,2015,28,N02-Analgesics,"/capita, US$ exchange rate",1.0
+6931,Costa Rica,2015,28,C03-Diuretics,"/capita, US$ exchange rate",0.2
+6932,Costa Rica,2015,28,C08-Calcium channel blockers,Million US$ at exchange rate,0.7
+6933,Costa Rica,2015,28,N06A-Antidepressants,"/capita, US$ exchange rate",0.5
+6934,Costa Rica,2015,28,C-Cardiovascular system,Million of national currency units,5719.1
+6935,Costa Rica,2015,28,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million of national currency units,1648.5
+6936,Costa Rica,2015,28,C-Cardiovascular system,Million US$ at exchange rate,10.7
+6937,Costa Rica,2015,28,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ exchange rate",0.9
+6938,Costa Rica,2015,28,G03-Sex hormones and modulators of the genital system,"/capita, US$ purchasing power parity",1.0
+6939,Costa Rica,2015,28,C02-Antihypertensives,Million of national currency units,519.3
+6940,Costa Rica,2015,28,M01A-Antiinflammatory and antirheumatic products non-steroids,"Million US$, purchasing power parity",5.3
+6941,Costa Rica,2015,28,N05B-Anxiolytics,"Million US$, purchasing power parity",1.0
+6942,Costa Rica,2015,28,M01A-Antiinflammatory and antirheumatic products non-steroids,Million of national currency units,1858.9
+6943,Costa Rica,2015,28,J-Antiinfectives for systemic use,Million of national currency units,17281.8
+6944,Costa Rica,2015,28,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ exchange rate",0.6
+6945,Costa Rica,2015,28,R03-Drugs for obstructive airway diseases,"/capita, US$ purchasing power parity",2.1
+6946,Costa Rica,2015,28,N02-Analgesics,"Million US$, purchasing power parity",7.4
+6947,Costa Rica,2015,28,J-Antiinfectives for systemic use,Million US$ at exchange rate,32.3
+6948,Costa Rica,2015,28,N05C-Hypnotics and sedatives,"/capita, US$ exchange rate",0.1
+6949,Costa Rica,2015,28,M01A-Antiinflammatory and antirheumatic products non-steroids,Million US$ at exchange rate,3.5
+6950,Costa Rica,2015,28,B-Blood and blood forming organs,"/capita, US$ exchange rate",6.5
+6951,Costa Rica,2015,28,C02-Antihypertensives,"/capita, US$ exchange rate",0.2
+6952,Costa Rica,2015,28,C-Cardiovascular system,"/capita, US$ exchange rate",2.2
+6953,Costa Rica,2015,28,C10-Lipid modifying agents,Million US$ at exchange rate,3.2
+6954,Costa Rica,2015,28,C10-Lipid modifying agents,"/capita, US$ purchasing power parity",1.0
+6955,Costa Rica,2015,28,C07-Beta blocking agents,"/capita, US$ purchasing power parity",0.5
+6956,Costa Rica,2015,28,N06A-Antidepressants,"Million US$, purchasing power parity",3.6
+6957,Costa Rica,2015,28,N06A-Antidepressants,"/capita, US$ purchasing power parity",0.7
+6958,Costa Rica,2015,28,B-Blood and blood forming organs,"/capita, US$ purchasing power parity",9.8
+6959,Costa Rica,2015,28,"H-Systemic hormonal preparations, excluding sex hormones and insulins","Million US$, purchasing power parity",6.5
+6960,Costa Rica,2015,28,J-Antiinfectives for systemic use,"/capita, US$ exchange rate",6.7
+6961,Costa Rica,2015,28,C10-Lipid modifying agents,"Million US$, purchasing power parity",4.8
+6962,Costa Rica,2015,28,"C01B-Antiarrhythmics, Class I and III","/capita, US$ purchasing power parity",0.0
+6963,Costa Rica,2015,28,A02A-Antacids,"/capita, US$ purchasing power parity",0.5
+6964,Costa Rica,2015,28,C01A-Cardiac glycosides,Million US$ at exchange rate,0.4
+6965,Costa Rica,2015,28,"C01B-Antiarrhythmics, Class I and III",Million US$ at exchange rate,0.1
+6966,Costa Rica,2015,28,C07-Beta blocking agents,Million US$ at exchange rate,1.6
+6967,Costa Rica,2015,28,A02A-Antacids,Million US$ at exchange rate,1.7
+6968,Costa Rica,2015,28,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million of national currency units,2298.6
+6969,Costa Rica,2015,28,A02A-Antacids,Million of national currency units,882.4
+6970,Costa Rica,2015,28,J01-Antibacterials for systemic use,"/capita, US$ exchange rate",1.9
+6971,Costa Rica,2015,28,B-Blood and blood forming organs,Million of national currency units,16694.8
+6972,Costa Rica,2015,28,C10-Lipid modifying agents,Million of national currency units,1710.2
+6973,Costa Rica,2015,28,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ exchange rate",0.6
+6974,Costa Rica,2015,28,R03-Drugs for obstructive airway diseases,Million of national currency units,3675.4
+6975,Costa Rica,2015,28,"C01B-Antiarrhythmics, Class I and III",Million of national currency units,64.5
+6976,Costa Rica,2015,28,G03-Sex hormones and modulators of the genital system,"/capita, US$ exchange rate",0.7
+6977,Costa Rica,2015,28,A10-Drugs used in diabetes,"/capita, US$ purchasing power parity",2.3
+6978,Costa Rica,2015,28,B-Blood and blood forming organs,Million US$ at exchange rate,31.2
+6979,Costa Rica,2015,28,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ purchasing power parity",1.3
+6980,Costa Rica,2015,28,N05B-Anxiolytics,Million US$ at exchange rate,0.7
+6981,Costa Rica,2015,28,N05B-Anxiolytics,"/capita, US$ purchasing power parity",0.2
+6982,Costa Rica,2015,28,A02A-Antacids,"/capita, US$ exchange rate",0.3
+6983,Costa Rica,2015,28,C07-Beta blocking agents,Million of national currency units,830.8
+6984,Costa Rica,2015,28,C-Cardiovascular system,"Million US$, purchasing power parity",16.2
+6985,Costa Rica,2015,28,C03-Diuretics,"Million US$, purchasing power parity",1.2
+6986,Costa Rica,2015,28,C01A-Cardiac glycosides,"Million US$, purchasing power parity",0.6
+6987,Costa Rica,2015,28,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ purchasing power parity",1.1
+6988,Costa Rica,2015,28,J-Antiinfectives for systemic use,"/capita, US$ purchasing power parity",10.1
+6989,Costa Rica,2015,28,A10-Drugs used in diabetes,"Million US$, purchasing power parity",11.4
+6990,Costa Rica,2015,28,C-Cardiovascular system,"/capita, US$ purchasing power parity",3.3
+6991,Costa Rica,2015,28,C08-Calcium channel blockers,"/capita, US$ purchasing power parity",0.2
+6992,Costa Rica,2015,28,C07-Beta blocking agents,"/capita, US$ exchange rate",0.3
+6993,Costa Rica,2015,28,N06A-Antidepressants,Million of national currency units,1278.7
+6994,Costa Rica,2015,28,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million US$ at exchange rate,3.1
+6995,Costa Rica,2015,28,N02-Analgesics,Million of national currency units,2634.7
+6996,Costa Rica,2015,28,N05C-Hypnotics and sedatives,"Million US$, purchasing power parity",0.6
+6997,Costa Rica,2015,28,R03-Drugs for obstructive airway diseases,"Million US$, purchasing power parity",10.4
+6998,Costa Rica,2015,28,"C01B-Antiarrhythmics, Class I and III","/capita, US$ exchange rate",0.0
+6999,Costa Rica,2015,28,N02-Analgesics,Million US$ at exchange rate,4.9
+7000,Costa Rica,2015,28,C08-Calcium channel blockers,"/capita, US$ exchange rate",0.1
+7001,Costa Rica,2015,28,A10-Drugs used in diabetes,Million US$ at exchange rate,7.5
+7002,Costa Rica,2015,28,G03-Sex hormones and modulators of the genital system,"Million US$, purchasing power parity",5.0
+7003,Costa Rica,2015,28,J01-Antibacterials for systemic use,"Million US$, purchasing power parity",13.9
+7004,Costa Rica,2015,28,C09-Agents acting on the Renin-Angiotensin system,"Million US$, purchasing power parity",4.5
+7005,Costa Rica,2015,28,C10-Lipid modifying agents,"/capita, US$ exchange rate",0.7
+7006,Costa Rica,2015,28,N06A-Antidepressants,Million US$ at exchange rate,2.4
+7007,Costa Rica,2015,28,R03-Drugs for obstructive airway diseases,"/capita, US$ exchange rate",1.4
+7008,Costa Rica,2015,28,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million US$ at exchange rate,4.3
+7009,Costa Rica,2015,28,G03-Sex hormones and modulators of the genital system,Million of national currency units,1760.3
+7010,Costa Rica,2015,28,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ exchange rate",0.7
+7011,Costa Rica,2015,28,C09-Agents acting on the Renin-Angiotensin system,Million of national currency units,1579.9
+7012,Costa Rica,2015,28,C03-Diuretics,Million US$ at exchange rate,0.8
+7013,Costa Rica,2015,28,C02-Antihypertensives,"/capita, US$ purchasing power parity",0.3
+7014,Costa Rica,2015,28,N05C-Hypnotics and sedatives,Million of national currency units,195.8
+7015,Costa Rica,2015,28,J01-Antibacterials for systemic use,Million of national currency units,4904.9
+7016,Costa Rica,2015,28,J-Antiinfectives for systemic use,"Million US$, purchasing power parity",48.8
+7017,Costa Rica,2015,28,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ purchasing power parity",0.9
+7018,Costa Rica,2015,28,C01A-Cardiac glycosides,"/capita, US$ purchasing power parity",0.1
+7019,Costa Rica,2015,28,C01A-Cardiac glycosides,Million of national currency units,200.6
+7020,Costa Rica,2015,28,C03-Diuretics,"/capita, US$ purchasing power parity",0.2
+7021,Costa Rica,2015,28,A02A-Antacids,"Million US$, purchasing power parity",2.5
+7022,Costa Rica,2015,28,C09-Agents acting on the Renin-Angiotensin system,Million US$ at exchange rate,3.0
+7023,Costa Rica,2015,28,N05B-Anxiolytics,"/capita, US$ exchange rate",0.1
+7024,Costa Rica,2015,28,G03-Sex hormones and modulators of the genital system,Million US$ at exchange rate,3.3
+7025,Costa Rica,2015,28,C03-Diuretics,Million of national currency units,413.6
+7026,Costa Rica,2015,28,A10-Drugs used in diabetes,Million of national currency units,4018.0
+7027,Costa Rica,2015,28,N05B-Anxiolytics,Million of national currency units,348.3
+7028,Costa Rica,2015,28,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"Million US$, purchasing power parity",4.7
+7029,Costa Rica,2015,28,C08-Calcium channel blockers,"Million US$, purchasing power parity",1.0
+7030,Costa Rica,2015,28,C02-Antihypertensives,"Million US$, purchasing power parity",1.5
+7031,Costa Rica,2015,28,N02-Analgesics,"/capita, US$ purchasing power parity",1.5
+7032,Costa Rica,2014,29,R03-Drugs for obstructive airway diseases,Million US$ at exchange rate,7.9
+7033,Costa Rica,2014,29,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ purchasing power parity",1.0
+7034,Costa Rica,2014,29,C02-Antihypertensives,Million US$ at exchange rate,0.9
+7035,Costa Rica,2014,29,N05C-Hypnotics and sedatives,Million US$ at exchange rate,0.3
+7036,Costa Rica,2014,29,C07-Beta blocking agents,"Million US$, purchasing power parity",1.9
+7037,Costa Rica,2014,29,N05C-Hypnotics and sedatives,"/capita, US$ purchasing power parity",0.1
+7038,Costa Rica,2014,29,C01A-Cardiac glycosides,"/capita, US$ exchange rate",0.1
+7039,Costa Rica,2014,29,J01-Antibacterials for systemic use,Million US$ at exchange rate,10.7
+7040,Costa Rica,2014,29,A10-Drugs used in diabetes,"/capita, US$ exchange rate",1.7
+7041,Costa Rica,2014,29,"C01B-Antiarrhythmics, Class I and III","Million US$, purchasing power parity",0.2
+7042,Costa Rica,2014,29,J01-Antibacterials for systemic use,"/capita, US$ purchasing power parity",3.4
+7043,Costa Rica,2014,29,B-Blood and blood forming organs,"Million US$, purchasing power parity",52.6
+7044,Costa Rica,2014,29,C08-Calcium channel blockers,Million of national currency units,319.1
+7045,Costa Rica,2014,29,N02-Analgesics,"/capita, US$ exchange rate",1.1
+7046,Costa Rica,2014,29,C03-Diuretics,"/capita, US$ exchange rate",0.2
+7047,Costa Rica,2014,29,C08-Calcium channel blockers,Million US$ at exchange rate,0.6
+7048,Costa Rica,2014,29,N06A-Antidepressants,"/capita, US$ exchange rate",0.4
+7049,Costa Rica,2014,29,C-Cardiovascular system,Million of national currency units,6768.8
+7050,Costa Rica,2014,29,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million of national currency units,1732.8
+7051,Costa Rica,2014,29,C-Cardiovascular system,Million US$ at exchange rate,12.6
+7052,Costa Rica,2014,29,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ exchange rate",1.1
+7053,Costa Rica,2014,29,G03-Sex hormones and modulators of the genital system,"/capita, US$ purchasing power parity",1.0
+7054,Costa Rica,2014,29,C02-Antihypertensives,Million of national currency units,481.8
+7055,Costa Rica,2014,29,M01A-Antiinflammatory and antirheumatic products non-steroids,"Million US$, purchasing power parity",4.7
+7056,Costa Rica,2014,29,N05B-Anxiolytics,"Million US$, purchasing power parity",1.0
+7057,Costa Rica,2014,29,C-Cardiovascular system,"/capita, US$ purchasing power parity",4.0
+7058,Costa Rica,2014,29,M01A-Antiinflammatory and antirheumatic products non-steroids,Million of national currency units,1674.9
+7059,Costa Rica,2014,29,J-Antiinfectives for systemic use,Million of national currency units,16847.2
+7060,Costa Rica,2014,29,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ exchange rate",0.7
+7061,Costa Rica,2014,29,R03-Drugs for obstructive airway diseases,"/capita, US$ purchasing power parity",2.5
+7062,Costa Rica,2014,29,J-Antiinfectives for systemic use,Million US$ at exchange rate,31.3
+7063,Costa Rica,2014,29,N02-Analgesics,"Million US$, purchasing power parity",8.0
+7064,Costa Rica,2014,29,M01A-Antiinflammatory and antirheumatic products non-steroids,Million US$ at exchange rate,3.1
+7065,Costa Rica,2014,29,N05C-Hypnotics and sedatives,"/capita, US$ exchange rate",0.1
+7066,Costa Rica,2014,29,C-Cardiovascular system,"/capita, US$ exchange rate",2.6
+7067,Costa Rica,2014,29,B-Blood and blood forming organs,"/capita, US$ exchange rate",7.2
+7068,Costa Rica,2014,29,C02-Antihypertensives,"/capita, US$ exchange rate",0.2
+7069,Costa Rica,2014,29,C10-Lipid modifying agents,Million US$ at exchange rate,5.5
+7070,Costa Rica,2014,29,C10-Lipid modifying agents,"/capita, US$ purchasing power parity",1.7
+7071,Costa Rica,2014,29,C07-Beta blocking agents,"/capita, US$ purchasing power parity",0.4
+7072,Costa Rica,2014,29,N06A-Antidepressants,"Million US$, purchasing power parity",3.2
+7073,Costa Rica,2014,29,N06A-Antidepressants,"/capita, US$ purchasing power parity",0.7
+7074,Costa Rica,2014,29,J-Antiinfectives for systemic use,"/capita, US$ exchange rate",6.6
+7075,Costa Rica,2014,29,B-Blood and blood forming organs,"/capita, US$ purchasing power parity",11.0
+7076,Costa Rica,2014,29,"H-Systemic hormonal preparations, excluding sex hormones and insulins","Million US$, purchasing power parity",7.6
+7077,Costa Rica,2014,29,C10-Lipid modifying agents,"Million US$, purchasing power parity",8.4
+7078,Costa Rica,2014,29,A02A-Antacids,"/capita, US$ purchasing power parity",0.5
+7079,Costa Rica,2014,29,"C01B-Antiarrhythmics, Class I and III","/capita, US$ purchasing power parity",0.0
+7080,Costa Rica,2014,29,C01A-Cardiac glycosides,Million US$ at exchange rate,0.4
+7081,Costa Rica,2014,29,"C01B-Antiarrhythmics, Class I and III",Million US$ at exchange rate,0.1
+7082,Costa Rica,2014,29,A02A-Antacids,Million US$ at exchange rate,1.6
+7083,Costa Rica,2014,29,C07-Beta blocking agents,Million US$ at exchange rate,1.2
+7084,Costa Rica,2014,29,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million of national currency units,2700.8
+7085,Costa Rica,2014,29,A02A-Antacids,Million of national currency units,864.0
+7086,Costa Rica,2014,29,J01-Antibacterials for systemic use,"/capita, US$ exchange rate",2.2
+7087,Costa Rica,2014,29,B-Blood and blood forming organs,Million of national currency units,18566.0
+7088,Costa Rica,2014,29,C10-Lipid modifying agents,Million of national currency units,2949.9
+7089,Costa Rica,2014,29,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ exchange rate",0.6
+7090,Costa Rica,2014,29,R03-Drugs for obstructive airway diseases,Million of national currency units,4275.6
+7091,Costa Rica,2014,29,"C01B-Antiarrhythmics, Class I and III",Million of national currency units,71.7
+7092,Costa Rica,2014,29,A10-Drugs used in diabetes,"/capita, US$ purchasing power parity",2.5
+7093,Costa Rica,2014,29,G03-Sex hormones and modulators of the genital system,"/capita, US$ exchange rate",0.7
+7094,Costa Rica,2014,29,B-Blood and blood forming organs,Million US$ at exchange rate,34.5
+7095,Costa Rica,2014,29,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ purchasing power parity",1.6
+7096,Costa Rica,2014,29,N05B-Anxiolytics,"/capita, US$ purchasing power parity",0.2
+7097,Costa Rica,2014,29,N05B-Anxiolytics,Million US$ at exchange rate,0.7
+7098,Costa Rica,2014,29,A02A-Antacids,"/capita, US$ exchange rate",0.3
+7099,Costa Rica,2014,29,C-Cardiovascular system,"Million US$, purchasing power parity",19.2
+7100,Costa Rica,2014,29,C07-Beta blocking agents,Million of national currency units,656.4
+7101,Costa Rica,2014,29,C03-Diuretics,"Million US$, purchasing power parity",1.2
+7102,Costa Rica,2014,29,C01A-Cardiac glycosides,"Million US$, purchasing power parity",0.6
+7103,Costa Rica,2014,29,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ purchasing power parity",1.0
+7104,Costa Rica,2014,29,A10-Drugs used in diabetes,"Million US$, purchasing power parity",12.1
+7105,Costa Rica,2014,29,J-Antiinfectives for systemic use,"/capita, US$ purchasing power parity",10.0
+7106,Costa Rica,2014,29,C08-Calcium channel blockers,"/capita, US$ purchasing power parity",0.2
+7107,Costa Rica,2014,29,C07-Beta blocking agents,"/capita, US$ exchange rate",0.3
+7108,Costa Rica,2014,29,N06A-Antidepressants,Million of national currency units,1118.1
+7109,Costa Rica,2014,29,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million US$ at exchange rate,3.2
+7110,Costa Rica,2014,29,N02-Analgesics,Million of national currency units,2811.6
+7111,Costa Rica,2014,29,N05C-Hypnotics and sedatives,"Million US$, purchasing power parity",0.5
+7112,Costa Rica,2014,29,R03-Drugs for obstructive airway diseases,"Million US$, purchasing power parity",12.1
+7113,Costa Rica,2014,29,"C01B-Antiarrhythmics, Class I and III","/capita, US$ exchange rate",0.0
+7114,Costa Rica,2014,29,N02-Analgesics,Million US$ at exchange rate,5.2
+7115,Costa Rica,2014,29,C08-Calcium channel blockers,"/capita, US$ exchange rate",0.1
+7116,Costa Rica,2014,29,A10-Drugs used in diabetes,Million US$ at exchange rate,7.9
+7117,Costa Rica,2014,29,G03-Sex hormones and modulators of the genital system,"Million US$, purchasing power parity",5.0
+7118,Costa Rica,2014,29,J01-Antibacterials for systemic use,"Million US$, purchasing power parity",16.3
+7119,Costa Rica,2014,29,C09-Agents acting on the Renin-Angiotensin system,"Million US$, purchasing power parity",4.6
+7120,Costa Rica,2014,29,C10-Lipid modifying agents,"/capita, US$ exchange rate",1.1
+7121,Costa Rica,2014,29,N06A-Antidepressants,Million US$ at exchange rate,2.1
+7122,Costa Rica,2014,29,R03-Drugs for obstructive airway diseases,"/capita, US$ exchange rate",1.7
+7123,Costa Rica,2014,29,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million US$ at exchange rate,5.0
+7124,Costa Rica,2014,29,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ purchasing power parity",1.0
+7125,Costa Rica,2014,29,G03-Sex hormones and modulators of the genital system,Million of national currency units,1766.7
+7126,Costa Rica,2014,29,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ exchange rate",0.7
+7127,Costa Rica,2014,29,C09-Agents acting on the Renin-Angiotensin system,Million of national currency units,1623.3
+7128,Costa Rica,2014,29,C03-Diuretics,Million US$ at exchange rate,0.8
+7129,Costa Rica,2014,29,N05C-Hypnotics and sedatives,Million of national currency units,176.3
+7130,Costa Rica,2014,29,C02-Antihypertensives,"/capita, US$ purchasing power parity",0.3
+7131,Costa Rica,2014,29,J01-Antibacterials for systemic use,Million of national currency units,5751.6
+7132,Costa Rica,2014,29,J-Antiinfectives for systemic use,"Million US$, purchasing power parity",47.7
+7133,Costa Rica,2014,29,C01A-Cardiac glycosides,"/capita, US$ purchasing power parity",0.1
+7134,Costa Rica,2014,29,C01A-Cardiac glycosides,Million of national currency units,227.2
+7135,Costa Rica,2014,29,A02A-Antacids,"Million US$, purchasing power parity",2.4
+7136,Costa Rica,2014,29,C03-Diuretics,"/capita, US$ purchasing power parity",0.3
+7137,Costa Rica,2014,29,C09-Agents acting on the Renin-Angiotensin system,Million US$ at exchange rate,3.0
+7138,Costa Rica,2014,29,N05B-Anxiolytics,"/capita, US$ exchange rate",0.1
+7139,Costa Rica,2014,29,G03-Sex hormones and modulators of the genital system,Million US$ at exchange rate,3.3
+7140,Costa Rica,2014,29,C03-Diuretics,Million of national currency units,427.6
+7141,Costa Rica,2014,29,A10-Drugs used in diabetes,Million of national currency units,4269.6
+7142,Costa Rica,2014,29,N05B-Anxiolytics,Million of national currency units,351.2
+7143,Costa Rica,2014,29,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"Million US$, purchasing power parity",4.9
+7144,Costa Rica,2014,29,C08-Calcium channel blockers,"Million US$, purchasing power parity",0.9
+7145,Costa Rica,2014,29,C02-Antihypertensives,"Million US$, purchasing power parity",1.4
+7146,Costa Rica,2014,29,N02-Analgesics,"/capita, US$ purchasing power parity",1.7
+7147,Costa Rica,2013,29,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ purchasing power parity",0.8
+7148,Costa Rica,2013,29,R03-Drugs for obstructive airway diseases,Million US$ at exchange rate,7.3
+7149,Costa Rica,2013,29,N05C-Hypnotics and sedatives,Million US$ at exchange rate,0.3
+7150,Costa Rica,2013,29,C02-Antihypertensives,Million US$ at exchange rate,0.8
+7151,Costa Rica,2013,29,C07-Beta blocking agents,"Million US$, purchasing power parity",1.8
+7152,Costa Rica,2013,29,N05C-Hypnotics and sedatives,"/capita, US$ purchasing power parity",0.1
+7153,Costa Rica,2013,29,C01A-Cardiac glycosides,"/capita, US$ exchange rate",0.1
+7154,Costa Rica,2013,29,A10-Drugs used in diabetes,"/capita, US$ exchange rate",1.5
+7155,Costa Rica,2013,29,J01-Antibacterials for systemic use,Million US$ at exchange rate,10.2
+7156,Costa Rica,2013,29,"C01B-Antiarrhythmics, Class I and III","Million US$, purchasing power parity",0.3
+7157,Costa Rica,2013,29,J01-Antibacterials for systemic use,"/capita, US$ purchasing power parity",3.1
+7158,Costa Rica,2013,29,B-Blood and blood forming organs,"Million US$, purchasing power parity",42.6
+7159,Costa Rica,2013,29,C08-Calcium channel blockers,Million of national currency units,276.6
+7160,Costa Rica,2013,29,N02-Analgesics,"/capita, US$ exchange rate",0.8
+7161,Costa Rica,2013,29,C03-Diuretics,"/capita, US$ exchange rate",0.2
+7162,Costa Rica,2013,29,C08-Calcium channel blockers,Million US$ at exchange rate,0.6
+7163,Costa Rica,2013,29,N06A-Antidepressants,"/capita, US$ exchange rate",0.4
+7164,Costa Rica,2013,29,C-Cardiovascular system,Million of national currency units,5356.4
+7165,Costa Rica,2013,29,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million of national currency units,1381.1
+7166,Costa Rica,2013,29,C-Cardiovascular system,Million US$ at exchange rate,10.7
+7167,Costa Rica,2013,29,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ exchange rate",1.0
+7168,Costa Rica,2013,29,G03-Sex hormones and modulators of the genital system,"/capita, US$ purchasing power parity",1.0
+7169,Costa Rica,2013,29,C02-Antihypertensives,Million of national currency units,394.0
+7170,Costa Rica,2013,29,M01A-Antiinflammatory and antirheumatic products non-steroids,"Million US$, purchasing power parity",5.5
+7171,Costa Rica,2013,29,N05B-Anxiolytics,"Million US$, purchasing power parity",0.9
+7172,Costa Rica,2013,29,M01A-Antiinflammatory and antirheumatic products non-steroids,Million of national currency units,1915.9
+7173,Costa Rica,2013,29,J-Antiinfectives for systemic use,Million of national currency units,14080.5
+7174,Costa Rica,2013,29,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ exchange rate",0.6
+7175,Costa Rica,2013,29,R03-Drugs for obstructive airway diseases,"/capita, US$ purchasing power parity",2.2
+7176,Costa Rica,2013,29,R03-Drugs for obstructive airway diseases,Million of national currency units,3657.2
+7177,Costa Rica,2013,29,N02-Analgesics,"Million US$, purchasing power parity",5.5
+7178,Costa Rica,2013,29,J-Antiinfectives for systemic use,Million US$ at exchange rate,28.2
+7179,Costa Rica,2013,29,N05C-Hypnotics and sedatives,"/capita, US$ exchange rate",0.1
+7180,Costa Rica,2013,29,M01A-Antiinflammatory and antirheumatic products non-steroids,Million US$ at exchange rate,3.8
+7181,Costa Rica,2013,29,B-Blood and blood forming organs,"/capita, US$ exchange rate",6.3
+7182,Costa Rica,2013,29,C-Cardiovascular system,"/capita, US$ exchange rate",2.3
+7183,Costa Rica,2013,29,C02-Antihypertensives,"/capita, US$ exchange rate",0.2
+7184,Costa Rica,2013,29,C10-Lipid modifying agents,Million US$ at exchange rate,3.9
+7185,Costa Rica,2013,29,C10-Lipid modifying agents,"/capita, US$ purchasing power parity",1.2
+7186,Costa Rica,2013,29,J-Antiinfectives for systemic use,"/capita, US$ exchange rate",6.0
+7187,Costa Rica,2013,29,C07-Beta blocking agents,"/capita, US$ purchasing power parity",0.4
+7188,Costa Rica,2013,29,N06A-Antidepressants,"/capita, US$ purchasing power parity",0.6
+7189,Costa Rica,2013,29,N06A-Antidepressants,"Million US$, purchasing power parity",3.0
+7190,Costa Rica,2013,29,"H-Systemic hormonal preparations, excluding sex hormones and insulins","Million US$, purchasing power parity",6.9
+7191,Costa Rica,2013,29,C10-Lipid modifying agents,"Million US$, purchasing power parity",5.7
+7192,Costa Rica,2013,29,"C01B-Antiarrhythmics, Class I and III","/capita, US$ purchasing power parity",0.1
+7193,Costa Rica,2013,29,A02A-Antacids,"/capita, US$ purchasing power parity",0.6
+7194,Costa Rica,2013,29,C01A-Cardiac glycosides,Million US$ at exchange rate,0.3
+7195,Costa Rica,2013,29,"C01B-Antiarrhythmics, Class I and III",Million US$ at exchange rate,0.2
+7196,Costa Rica,2013,29,B-Blood and blood forming organs,"/capita, US$ purchasing power parity",9.0
+7197,Costa Rica,2013,29,A02A-Antacids,Million US$ at exchange rate,2.0
+7198,Costa Rica,2013,29,C07-Beta blocking agents,Million US$ at exchange rate,1.2
+7199,Costa Rica,2013,29,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million of national currency units,2416.6
+7200,Costa Rica,2013,29,A02A-Antacids,Million of national currency units,975.1
+7201,Costa Rica,2013,29,J01-Antibacterials for systemic use,"/capita, US$ exchange rate",2.2
+7202,Costa Rica,2013,29,B-Blood and blood forming organs,Million of national currency units,14811.2
+7203,Costa Rica,2013,29,C10-Lipid modifying agents,Million of national currency units,1969.3
+7204,Costa Rica,2013,29,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ exchange rate",0.6
+7205,Costa Rica,2013,29,"C01B-Antiarrhythmics, Class I and III",Million of national currency units,114.0
+7206,Costa Rica,2013,29,G03-Sex hormones and modulators of the genital system,"/capita, US$ exchange rate",0.7
+7207,Costa Rica,2013,29,A10-Drugs used in diabetes,"/capita, US$ purchasing power parity",2.2
+7208,Costa Rica,2013,29,B-Blood and blood forming organs,Million US$ at exchange rate,29.6
+7209,Costa Rica,2013,29,N05B-Anxiolytics,"/capita, US$ purchasing power parity",0.2
+7210,Costa Rica,2013,29,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ purchasing power parity",1.5
+7211,Costa Rica,2013,29,N05B-Anxiolytics,Million US$ at exchange rate,0.6
+7212,Costa Rica,2013,29,A02A-Antacids,"/capita, US$ exchange rate",0.4
+7213,Costa Rica,2013,29,C07-Beta blocking agents,Million of national currency units,622.3
+7214,Costa Rica,2013,29,C-Cardiovascular system,"Million US$, purchasing power parity",15.4
+7215,Costa Rica,2013,29,C01A-Cardiac glycosides,"Million US$, purchasing power parity",0.4
+7216,Costa Rica,2013,29,C03-Diuretics,"Million US$, purchasing power parity",1.2
+7217,Costa Rica,2013,29,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ purchasing power parity",1.2
+7218,Costa Rica,2013,29,A10-Drugs used in diabetes,"Million US$, purchasing power parity",10.2
+7219,Costa Rica,2013,29,C08-Calcium channel blockers,"/capita, US$ purchasing power parity",0.2
+7220,Costa Rica,2013,29,J-Antiinfectives for systemic use,"/capita, US$ purchasing power parity",8.6
+7221,Costa Rica,2013,29,C02-Antihypertensives,"Million US$, purchasing power parity",1.1
+7222,Costa Rica,2013,29,C07-Beta blocking agents,"/capita, US$ exchange rate",0.3
+7223,Costa Rica,2013,29,N06A-Antidepressants,Million of national currency units,1043.0
+7224,Costa Rica,2013,29,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million US$ at exchange rate,2.8
+7225,Costa Rica,2013,29,N02-Analgesics,Million of national currency units,1924.0
+7226,Costa Rica,2013,29,R03-Drugs for obstructive airway diseases,"Million US$, purchasing power parity",10.5
+7227,Costa Rica,2013,29,N05C-Hypnotics and sedatives,"Million US$, purchasing power parity",0.4
+7228,Costa Rica,2013,29,"C01B-Antiarrhythmics, Class I and III","/capita, US$ exchange rate",0.0
+7229,Costa Rica,2013,29,N02-Analgesics,Million US$ at exchange rate,3.8
+7230,Costa Rica,2013,29,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ purchasing power parity",0.9
+7231,Costa Rica,2013,29,C08-Calcium channel blockers,"/capita, US$ exchange rate",0.1
+7232,Costa Rica,2013,29,A10-Drugs used in diabetes,Million US$ at exchange rate,7.1
+7233,Costa Rica,2013,29,G03-Sex hormones and modulators of the genital system,"Million US$, purchasing power parity",4.8
+7234,Costa Rica,2013,29,J01-Antibacterials for systemic use,"Million US$, purchasing power parity",14.6
+7235,Costa Rica,2013,29,C09-Agents acting on the Renin-Angiotensin system,"Million US$, purchasing power parity",4.1
+7236,Costa Rica,2013,29,N06A-Antidepressants,Million US$ at exchange rate,2.1
+7237,Costa Rica,2013,29,R03-Drugs for obstructive airway diseases,"/capita, US$ exchange rate",1.6
+7238,Costa Rica,2013,29,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million US$ at exchange rate,4.8
+7239,Costa Rica,2013,29,G03-Sex hormones and modulators of the genital system,Million of national currency units,1682.6
+7240,Costa Rica,2013,29,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ exchange rate",0.8
+7241,Costa Rica,2013,29,C09-Agents acting on the Renin-Angiotensin system,Million of national currency units,1436.0
+7242,Costa Rica,2013,29,C03-Diuretics,Million US$ at exchange rate,0.8
+7243,Costa Rica,2013,29,J01-Antibacterials for systemic use,Million of national currency units,5081.9
+7244,Costa Rica,2013,29,N05C-Hypnotics and sedatives,Million of national currency units,138.7
+7245,Costa Rica,2013,29,C-Cardiovascular system,"/capita, US$ purchasing power parity",3.3
+7246,Costa Rica,2013,29,C02-Antihypertensives,"/capita, US$ purchasing power parity",0.2
+7247,Costa Rica,2013,29,J-Antiinfectives for systemic use,"Million US$, purchasing power parity",40.5
+7248,Costa Rica,2013,29,C01A-Cardiac glycosides,"/capita, US$ purchasing power parity",0.1
+7249,Costa Rica,2013,29,C01A-Cardiac glycosides,Million of national currency units,137.7
+7250,Costa Rica,2013,29,A02A-Antacids,"Million US$, purchasing power parity",2.8
+7251,Costa Rica,2013,29,C03-Diuretics,"/capita, US$ purchasing power parity",0.2
+7252,Costa Rica,2013,29,C09-Agents acting on the Renin-Angiotensin system,Million US$ at exchange rate,2.9
+7253,Costa Rica,2013,29,N05B-Anxiolytics,"/capita, US$ exchange rate",0.1
+7254,Costa Rica,2013,29,G03-Sex hormones and modulators of the genital system,Million US$ at exchange rate,3.4
+7255,Costa Rica,2013,29,C03-Diuretics,Million of national currency units,406.6
+7256,Costa Rica,2013,29,A10-Drugs used in diabetes,Million of national currency units,3557.3
+7257,Costa Rica,2013,29,N05B-Anxiolytics,Million of national currency units,314.0
+7258,Costa Rica,2013,29,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"Million US$, purchasing power parity",4.0
+7259,Costa Rica,2013,29,C10-Lipid modifying agents,"/capita, US$ exchange rate",0.8
+7260,Costa Rica,2013,29,C08-Calcium channel blockers,"Million US$, purchasing power parity",0.8
+7261,Costa Rica,2013,29,N02-Analgesics,"/capita, US$ purchasing power parity",1.2
+7262,Costa Rica,2012,29,R03-Drugs for obstructive airway diseases,Million US$ at exchange rate,6.4
+7263,Costa Rica,2012,29,N05C-Hypnotics and sedatives,Million US$ at exchange rate,0.3
+7264,Costa Rica,2012,29,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ purchasing power parity",0.6
+7265,Costa Rica,2012,29,C02-Antihypertensives,Million US$ at exchange rate,0.8
+7266,Costa Rica,2012,29,J01-Antibacterials for systemic use,Million US$ at exchange rate,9.7
+7267,Costa Rica,2012,29,C07-Beta blocking agents,"Million US$, purchasing power parity",1.7
+7268,Costa Rica,2012,29,N05C-Hypnotics and sedatives,"/capita, US$ purchasing power parity",0.1
+7269,Costa Rica,2012,29,C01A-Cardiac glycosides,"/capita, US$ exchange rate",0.1
+7270,Costa Rica,2012,29,A10-Drugs used in diabetes,"/capita, US$ exchange rate",1.4
+7271,Costa Rica,2012,29,"C01B-Antiarrhythmics, Class I and III","Million US$, purchasing power parity",0.2
+7272,Costa Rica,2012,29,J01-Antibacterials for systemic use,"/capita, US$ purchasing power parity",3.0
+7273,Costa Rica,2012,29,B-Blood and blood forming organs,"Million US$, purchasing power parity",35.5
+7274,Costa Rica,2012,29,C08-Calcium channel blockers,Million of national currency units,204.0
+7275,Costa Rica,2012,29,C08-Calcium channel blockers,Million US$ at exchange rate,0.4
+7276,Costa Rica,2012,29,C03-Diuretics,"/capita, US$ exchange rate",0.2
+7277,Costa Rica,2012,29,N02-Analgesics,"/capita, US$ exchange rate",0.7
+7278,Costa Rica,2012,29,N06A-Antidepressants,"/capita, US$ exchange rate",0.4
+7279,Costa Rica,2012,29,C-Cardiovascular system,Million of national currency units,5057.2
+7280,Costa Rica,2012,29,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million of national currency units,1000.3
+7281,Costa Rica,2012,29,C-Cardiovascular system,Million US$ at exchange rate,10.1
+7282,Costa Rica,2012,29,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ exchange rate",0.9
+7283,Costa Rica,2012,29,G03-Sex hormones and modulators of the genital system,"/capita, US$ purchasing power parity",1.0
+7284,Costa Rica,2012,29,C02-Antihypertensives,Million of national currency units,379.8
+7285,Costa Rica,2012,29,M01A-Antiinflammatory and antirheumatic products non-steroids,"Million US$, purchasing power parity",5.1
+7286,Costa Rica,2012,29,N05B-Anxiolytics,"Million US$, purchasing power parity",0.8
+7287,Costa Rica,2012,29,M01A-Antiinflammatory and antirheumatic products non-steroids,Million of national currency units,1763.9
+7288,Costa Rica,2012,29,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ exchange rate",0.4
+7289,Costa Rica,2012,29,J-Antiinfectives for systemic use,Million of national currency units,13948.3
+7290,Costa Rica,2012,29,R03-Drugs for obstructive airway diseases,"/capita, US$ purchasing power parity",2.0
+7291,Costa Rica,2012,29,J-Antiinfectives for systemic use,Million US$ at exchange rate,27.7
+7292,Costa Rica,2012,29,N02-Analgesics,"Million US$, purchasing power parity",4.9
+7293,Costa Rica,2012,29,N05C-Hypnotics and sedatives,"/capita, US$ exchange rate",0.1
+7294,Costa Rica,2012,29,M01A-Antiinflammatory and antirheumatic products non-steroids,Million US$ at exchange rate,3.5
+7295,Costa Rica,2012,29,C-Cardiovascular system,"/capita, US$ exchange rate",2.2
+7296,Costa Rica,2012,29,C02-Antihypertensives,"/capita, US$ exchange rate",0.2
+7297,Costa Rica,2012,29,B-Blood and blood forming organs,"/capita, US$ exchange rate",5.2
+7298,Costa Rica,2012,29,C10-Lipid modifying agents,Million US$ at exchange rate,4.2
+7299,Costa Rica,2012,29,C10-Lipid modifying agents,"/capita, US$ purchasing power parity",1.3
+7300,Costa Rica,2012,29,J-Antiinfectives for systemic use,"/capita, US$ exchange rate",6.0
+7301,Costa Rica,2012,29,C07-Beta blocking agents,"/capita, US$ purchasing power parity",0.4
+7302,Costa Rica,2012,29,N06A-Antidepressants,"/capita, US$ purchasing power parity",0.6
+7303,Costa Rica,2012,29,"H-Systemic hormonal preparations, excluding sex hormones and insulins","Million US$, purchasing power parity",6.4
+7304,Costa Rica,2012,29,C10-Lipid modifying agents,"Million US$, purchasing power parity",6.1
+7305,Costa Rica,2012,29,"C01B-Antiarrhythmics, Class I and III","/capita, US$ purchasing power parity",0.0
+7306,Costa Rica,2012,29,A02A-Antacids,"/capita, US$ purchasing power parity",0.5
+7307,Costa Rica,2012,29,C01A-Cardiac glycosides,Million US$ at exchange rate,0.3
+7308,Costa Rica,2012,29,B-Blood and blood forming organs,"/capita, US$ purchasing power parity",7.6
+7309,Costa Rica,2012,29,J01-Antibacterials for systemic use,"/capita, US$ exchange rate",2.1
+7310,Costa Rica,2012,29,"C01B-Antiarrhythmics, Class I and III",Million US$ at exchange rate,0.1
+7311,Costa Rica,2012,29,A02A-Antacids,Million US$ at exchange rate,1.5
+7312,Costa Rica,2012,29,C07-Beta blocking agents,Million US$ at exchange rate,1.2
+7313,Costa Rica,2012,29,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million of national currency units,2194.5
+7314,Costa Rica,2012,29,A02A-Antacids,Million of national currency units,765.2
+7315,Costa Rica,2012,29,B-Blood and blood forming organs,Million of national currency units,12208.2
+7316,Costa Rica,2012,29,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ exchange rate",0.5
+7317,Costa Rica,2012,29,"C01B-Antiarrhythmics, Class I and III",Million of national currency units,74.5
+7318,Costa Rica,2012,29,C10-Lipid modifying agents,Million of national currency units,2104.9
+7319,Costa Rica,2012,29,G03-Sex hormones and modulators of the genital system,"/capita, US$ exchange rate",0.7
+7320,Costa Rica,2012,29,B-Blood and blood forming organs,Million US$ at exchange rate,24.3
+7321,Costa Rica,2012,29,N05B-Anxiolytics,"/capita, US$ purchasing power parity",0.2
+7322,Costa Rica,2012,29,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ purchasing power parity",1.4
+7323,Costa Rica,2012,29,N05B-Anxiolytics,Million US$ at exchange rate,0.6
+7324,Costa Rica,2012,29,A10-Drugs used in diabetes,"/capita, US$ purchasing power parity",2.1
+7325,Costa Rica,2012,29,C07-Beta blocking agents,Million of national currency units,591.5
+7326,Costa Rica,2012,29,A02A-Antacids,"/capita, US$ exchange rate",0.3
+7327,Costa Rica,2012,29,C-Cardiovascular system,"Million US$, purchasing power parity",14.7
+7328,Costa Rica,2012,29,C01A-Cardiac glycosides,"Million US$, purchasing power parity",0.4
+7329,Costa Rica,2012,29,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ purchasing power parity",1.1
+7330,Costa Rica,2012,29,C03-Diuretics,"Million US$, purchasing power parity",1.1
+7331,Costa Rica,2012,29,A10-Drugs used in diabetes,"Million US$, purchasing power parity",9.7
+7332,Costa Rica,2012,29,J-Antiinfectives for systemic use,"/capita, US$ purchasing power parity",8.7
+7333,Costa Rica,2012,29,C08-Calcium channel blockers,"/capita, US$ purchasing power parity",0.1
+7334,Costa Rica,2012,29,C07-Beta blocking agents,"/capita, US$ exchange rate",0.3
+7335,Costa Rica,2012,29,N06A-Antidepressants,Million of national currency units,933.3
+7336,Costa Rica,2012,29,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million US$ at exchange rate,2.0
+7337,Costa Rica,2012,29,N02-Analgesics,Million of national currency units,1696.3
+7338,Costa Rica,2012,29,"C01B-Antiarrhythmics, Class I and III","/capita, US$ exchange rate",0.0
+7339,Costa Rica,2012,29,R03-Drugs for obstructive airway diseases,"Million US$, purchasing power parity",9.3
+7340,Costa Rica,2012,29,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ purchasing power parity",0.8
+7341,Costa Rica,2012,29,N05C-Hypnotics and sedatives,"Million US$, purchasing power parity",0.4
+7342,Costa Rica,2012,29,N02-Analgesics,Million US$ at exchange rate,3.4
+7343,Costa Rica,2012,29,C08-Calcium channel blockers,"/capita, US$ exchange rate",0.1
+7344,Costa Rica,2012,29,A10-Drugs used in diabetes,Million US$ at exchange rate,6.6
+7345,Costa Rica,2012,29,G03-Sex hormones and modulators of the genital system,"Million US$, purchasing power parity",4.6
+7346,Costa Rica,2012,29,J01-Antibacterials for systemic use,"Million US$, purchasing power parity",14.1
+7347,Costa Rica,2012,29,C09-Agents acting on the Renin-Angiotensin system,"Million US$, purchasing power parity",3.5
+7348,Costa Rica,2012,29,N06A-Antidepressants,Million US$ at exchange rate,1.9
+7349,Costa Rica,2012,29,R03-Drugs for obstructive airway diseases,"/capita, US$ exchange rate",1.4
+7350,Costa Rica,2012,29,C02-Antihypertensives,"Million US$, purchasing power parity",1.1
+7351,Costa Rica,2012,29,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million US$ at exchange rate,4.4
+7352,Costa Rica,2012,29,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ exchange rate",0.8
+7353,Costa Rica,2012,29,G03-Sex hormones and modulators of the genital system,Million of national currency units,1597.4
+7354,Costa Rica,2012,29,C09-Agents acting on the Renin-Angiotensin system,Million of national currency units,1212.1
+7355,Costa Rica,2012,29,C03-Diuretics,Million US$ at exchange rate,0.7
+7356,Costa Rica,2012,29,J01-Antibacterials for systemic use,Million of national currency units,4854.0
+7357,Costa Rica,2012,29,N05C-Hypnotics and sedatives,Million of national currency units,141.2
+7358,Costa Rica,2012,29,C-Cardiovascular system,"/capita, US$ purchasing power parity",3.2
+7359,Costa Rica,2012,29,C02-Antihypertensives,"/capita, US$ purchasing power parity",0.2
+7360,Costa Rica,2012,29,J-Antiinfectives for systemic use,"Million US$, purchasing power parity",40.6
+7361,Costa Rica,2012,29,C01A-Cardiac glycosides,"/capita, US$ purchasing power parity",0.1
+7362,Costa Rica,2012,29,C01A-Cardiac glycosides,Million of national currency units,126.1
+7363,Costa Rica,2012,29,A02A-Antacids,"Million US$, purchasing power parity",2.2
+7364,Costa Rica,2012,29,C03-Diuretics,"/capita, US$ purchasing power parity",0.2
+7365,Costa Rica,2012,29,C09-Agents acting on the Renin-Angiotensin system,Million US$ at exchange rate,2.4
+7366,Costa Rica,2012,29,N05B-Anxiolytics,"/capita, US$ exchange rate",0.1
+7367,Costa Rica,2012,29,G03-Sex hormones and modulators of the genital system,Million US$ at exchange rate,3.2
+7368,Costa Rica,2012,29,C03-Diuretics,Million of national currency units,364.4
+7369,Costa Rica,2012,29,R03-Drugs for obstructive airway diseases,Million of national currency units,3202.7
+7370,Costa Rica,2012,29,N06A-Antidepressants,"Million US$, purchasing power parity",2.7
+7371,Costa Rica,2012,29,A10-Drugs used in diabetes,Million of national currency units,3318.6
+7372,Costa Rica,2012,29,N05B-Anxiolytics,Million of national currency units,282.2
+7373,Costa Rica,2012,29,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"Million US$, purchasing power parity",2.9
+7374,Costa Rica,2012,29,C10-Lipid modifying agents,"/capita, US$ exchange rate",0.9
+7375,Costa Rica,2012,29,C08-Calcium channel blockers,"Million US$, purchasing power parity",0.6
+7376,Costa Rica,2012,29,N02-Analgesics,"/capita, US$ purchasing power parity",1.1
+7377,Costa Rica,2011,30,R03-Drugs for obstructive airway diseases,Million US$ at exchange rate,6.1
+7378,Costa Rica,2011,30,C02-Antihypertensives,Million US$ at exchange rate,0.7
+7379,Costa Rica,2011,30,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ purchasing power parity",0.6
+7380,Costa Rica,2011,30,N05C-Hypnotics and sedatives,Million US$ at exchange rate,0.3
+7381,Costa Rica,2011,30,C01A-Cardiac glycosides,"/capita, US$ exchange rate",0.1
+7382,Costa Rica,2011,30,C07-Beta blocking agents,"Million US$, purchasing power parity",1.5
+7383,Costa Rica,2011,30,N05C-Hypnotics and sedatives,"/capita, US$ purchasing power parity",0.1
+7384,Costa Rica,2011,30,A10-Drugs used in diabetes,"/capita, US$ exchange rate",1.2
+7385,Costa Rica,2011,30,J01-Antibacterials for systemic use,Million US$ at exchange rate,10.9
+7386,Costa Rica,2011,30,J01-Antibacterials for systemic use,"/capita, US$ purchasing power parity",3.6
+7387,Costa Rica,2011,30,"C01B-Antiarrhythmics, Class I and III","Million US$, purchasing power parity",0.2
+7388,Costa Rica,2011,30,C08-Calcium channel blockers,Million of national currency units,177.2
+7389,Costa Rica,2011,30,B-Blood and blood forming organs,"Million US$, purchasing power parity",35.4
+7390,Costa Rica,2011,30,C03-Diuretics,"/capita, US$ exchange rate",0.3
+7391,Costa Rica,2011,30,N02-Analgesics,"/capita, US$ exchange rate",0.7
+7392,Costa Rica,2011,30,N06A-Antidepressants,"/capita, US$ exchange rate",0.6
+7393,Costa Rica,2011,30,C08-Calcium channel blockers,Million US$ at exchange rate,0.4
+7394,Costa Rica,2011,30,C-Cardiovascular system,Million of national currency units,4872.5
+7395,Costa Rica,2011,30,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million of national currency units,886.3
+7396,Costa Rica,2011,30,C-Cardiovascular system,Million US$ at exchange rate,9.6
+7397,Costa Rica,2011,30,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ exchange rate",1.0
+7398,Costa Rica,2011,30,G03-Sex hormones and modulators of the genital system,"/capita, US$ purchasing power parity",1.1
+7399,Costa Rica,2011,30,C02-Antihypertensives,Million of national currency units,347.1
+7400,Costa Rica,2011,30,M01A-Antiinflammatory and antirheumatic products non-steroids,"Million US$, purchasing power parity",5.0
+7401,Costa Rica,2011,30,N05B-Anxiolytics,"Million US$, purchasing power parity",0.8
+7402,Costa Rica,2011,30,C09-Agents acting on the Renin-Angiotensin system,"Million US$, purchasing power parity",3.0
+7403,Costa Rica,2011,30,M01A-Antiinflammatory and antirheumatic products non-steroids,Million of national currency units,1662.2
+7404,Costa Rica,2011,30,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ exchange rate",0.4
+7405,Costa Rica,2011,30,J-Antiinfectives for systemic use,Million of national currency units,14773.7
+7406,Costa Rica,2011,30,R03-Drugs for obstructive airway diseases,"/capita, US$ purchasing power parity",2.0
+7407,Costa Rica,2011,30,J-Antiinfectives for systemic use,Million US$ at exchange rate,29.2
+7408,Costa Rica,2011,30,N02-Analgesics,"Million US$, purchasing power parity",4.6
+7409,Costa Rica,2011,30,C02-Antihypertensives,"/capita, US$ exchange rate",0.1
+7410,Costa Rica,2011,30,N05C-Hypnotics and sedatives,"/capita, US$ exchange rate",0.1
+7411,Costa Rica,2011,30,M01A-Antiinflammatory and antirheumatic products non-steroids,Million US$ at exchange rate,3.3
+7412,Costa Rica,2011,30,C-Cardiovascular system,"/capita, US$ exchange rate",2.1
+7413,Costa Rica,2011,30,B-Blood and blood forming organs,"/capita, US$ exchange rate",5.1
+7414,Costa Rica,2011,30,C10-Lipid modifying agents,Million US$ at exchange rate,3.9
+7415,Costa Rica,2011,30,C10-Lipid modifying agents,"/capita, US$ purchasing power parity",1.3
+7416,Costa Rica,2011,30,J-Antiinfectives for systemic use,"/capita, US$ exchange rate",6.4
+7417,Costa Rica,2011,30,C07-Beta blocking agents,"/capita, US$ purchasing power parity",0.3
+7418,Costa Rica,2011,30,N06A-Antidepressants,"/capita, US$ purchasing power parity",0.9
+7419,Costa Rica,2011,30,"H-Systemic hormonal preparations, excluding sex hormones and insulins","Million US$, purchasing power parity",6.6
+7420,Costa Rica,2011,30,C10-Lipid modifying agents,"Million US$, purchasing power parity",5.9
+7421,Costa Rica,2011,30,"C01B-Antiarrhythmics, Class I and III","/capita, US$ purchasing power parity",0.0
+7422,Costa Rica,2011,30,A02A-Antacids,"/capita, US$ purchasing power parity",0.5
+7423,Costa Rica,2011,30,B-Blood and blood forming organs,"/capita, US$ purchasing power parity",7.7
+7424,Costa Rica,2011,30,C01A-Cardiac glycosides,Million US$ at exchange rate,0.3
+7425,Costa Rica,2011,30,"C01B-Antiarrhythmics, Class I and III",Million US$ at exchange rate,0.1
+7426,Costa Rica,2011,30,J01-Antibacterials for systemic use,"/capita, US$ exchange rate",2.4
+7427,Costa Rica,2011,30,A02A-Antacids,Million US$ at exchange rate,1.5
+7428,Costa Rica,2011,30,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million of national currency units,2218.4
+7429,Costa Rica,2011,30,C07-Beta blocking agents,Million US$ at exchange rate,1.0
+7430,Costa Rica,2011,30,A02A-Antacids,Million of national currency units,749.2
+7431,Costa Rica,2011,30,B-Blood and blood forming organs,Million of national currency units,11848.0
+7432,Costa Rica,2011,30,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ exchange rate",0.4
+7433,Costa Rica,2011,30,R03-Drugs for obstructive airway diseases,Million of national currency units,3103.4
+7434,Costa Rica,2011,30,"C01B-Antiarrhythmics, Class I and III",Million of national currency units,73.6
+7435,Costa Rica,2011,30,C10-Lipid modifying agents,Million of national currency units,1973.1
+7436,Costa Rica,2011,30,G03-Sex hormones and modulators of the genital system,"/capita, US$ exchange rate",0.7
+7437,Costa Rica,2011,30,B-Blood and blood forming organs,Million US$ at exchange rate,23.4
+7438,Costa Rica,2011,30,N05B-Anxiolytics,"/capita, US$ purchasing power parity",0.2
+7439,Costa Rica,2011,30,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ purchasing power parity",1.4
+7440,Costa Rica,2011,30,N05B-Anxiolytics,Million US$ at exchange rate,0.5
+7441,Costa Rica,2011,30,A10-Drugs used in diabetes,"/capita, US$ purchasing power parity",1.8
+7442,Costa Rica,2011,30,C07-Beta blocking agents,Million of national currency units,501.3
+7443,Costa Rica,2011,30,A02A-Antacids,"/capita, US$ exchange rate",0.3
+7444,Costa Rica,2011,30,C-Cardiovascular system,"Million US$, purchasing power parity",14.5
+7445,Costa Rica,2011,30,C01A-Cardiac glycosides,"Million US$, purchasing power parity",0.4
+7446,Costa Rica,2011,30,C03-Diuretics,"Million US$, purchasing power parity",2.0
+7447,Costa Rica,2011,30,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ purchasing power parity",1.1
+7448,Costa Rica,2011,30,A10-Drugs used in diabetes,"Million US$, purchasing power parity",8.5
+7449,Costa Rica,2011,30,C08-Calcium channel blockers,"/capita, US$ purchasing power parity",0.1
+7450,Costa Rica,2011,30,J-Antiinfectives for systemic use,"/capita, US$ purchasing power parity",9.6
+7451,Costa Rica,2011,30,C02-Antihypertensives,"Million US$, purchasing power parity",1.0
+7452,Costa Rica,2011,30,N06A-Antidepressants,Million of national currency units,1440.9
+7453,Costa Rica,2011,30,C07-Beta blocking agents,"/capita, US$ exchange rate",0.2
+7454,Costa Rica,2011,30,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million US$ at exchange rate,1.8
+7455,Costa Rica,2011,30,N02-Analgesics,Million of national currency units,1540.2
+7456,Costa Rica,2011,30,"C01B-Antiarrhythmics, Class I and III","/capita, US$ exchange rate",0.0
+7457,Costa Rica,2011,30,R03-Drugs for obstructive airway diseases,"Million US$, purchasing power parity",9.3
+7458,Costa Rica,2011,30,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ purchasing power parity",0.6
+7459,Costa Rica,2011,30,N05C-Hypnotics and sedatives,"Million US$, purchasing power parity",0.4
+7460,Costa Rica,2011,30,N02-Analgesics,Million US$ at exchange rate,3.0
+7461,Costa Rica,2011,30,C08-Calcium channel blockers,"/capita, US$ exchange rate",0.1
+7462,Costa Rica,2011,30,A10-Drugs used in diabetes,Million US$ at exchange rate,5.6
+7463,Costa Rica,2011,30,G03-Sex hormones and modulators of the genital system,"Million US$, purchasing power parity",5.0
+7464,Costa Rica,2011,30,J01-Antibacterials for systemic use,"Million US$, purchasing power parity",16.5
+7465,Costa Rica,2011,30,N06A-Antidepressants,Million US$ at exchange rate,2.8
+7466,Costa Rica,2011,30,R03-Drugs for obstructive airway diseases,"/capita, US$ exchange rate",1.3
+7467,Costa Rica,2011,30,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million US$ at exchange rate,4.4
+7468,Costa Rica,2011,30,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ exchange rate",0.7
+7469,Costa Rica,2011,30,G03-Sex hormones and modulators of the genital system,Million of national currency units,1661.5
+7470,Costa Rica,2011,30,C09-Agents acting on the Renin-Angiotensin system,Million of national currency units,996.1
+7471,Costa Rica,2011,30,C03-Diuretics,Million US$ at exchange rate,1.3
+7472,Costa Rica,2011,30,J01-Antibacterials for systemic use,Million of national currency units,5512.1
+7473,Costa Rica,2011,30,N05C-Hypnotics and sedatives,Million of national currency units,129.2
+7474,Costa Rica,2011,30,C-Cardiovascular system,"/capita, US$ purchasing power parity",3.2
+7475,Costa Rica,2011,30,J-Antiinfectives for systemic use,"Million US$, purchasing power parity",44.1
+7476,Costa Rica,2011,30,C02-Antihypertensives,"/capita, US$ purchasing power parity",0.2
+7477,Costa Rica,2011,30,C01A-Cardiac glycosides,"/capita, US$ purchasing power parity",0.1
+7478,Costa Rica,2011,30,C01A-Cardiac glycosides,Million of national currency units,132.1
+7479,Costa Rica,2011,30,A02A-Antacids,"Million US$, purchasing power parity",2.2
+7480,Costa Rica,2011,30,C03-Diuretics,"/capita, US$ purchasing power parity",0.4
+7481,Costa Rica,2011,30,C09-Agents acting on the Renin-Angiotensin system,Million US$ at exchange rate,2.0
+7482,Costa Rica,2011,30,N05B-Anxiolytics,"/capita, US$ exchange rate",0.1
+7483,Costa Rica,2011,30,G03-Sex hormones and modulators of the genital system,Million US$ at exchange rate,3.3
+7484,Costa Rica,2011,30,C03-Diuretics,Million of national currency units,671.9
+7485,Costa Rica,2011,30,N06A-Antidepressants,"Million US$, purchasing power parity",4.3
+7486,Costa Rica,2011,30,A10-Drugs used in diabetes,Million of national currency units,2834.0
+7487,Costa Rica,2011,30,N05B-Anxiolytics,Million of national currency units,277.6
+7488,Costa Rica,2011,30,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"Million US$, purchasing power parity",2.6
+7489,Costa Rica,2011,30,C10-Lipid modifying agents,"/capita, US$ exchange rate",0.8
+7490,Costa Rica,2011,30,C08-Calcium channel blockers,"Million US$, purchasing power parity",0.5
+7491,Costa Rica,2011,30,N02-Analgesics,"/capita, US$ purchasing power parity",1.0
+7492,Costa Rica,2010,32,R03-Drugs for obstructive airway diseases,Million US$ at exchange rate,6.3
+7493,Costa Rica,2010,32,C02-Antihypertensives,Million US$ at exchange rate,0.5
+7494,Costa Rica,2010,32,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ purchasing power parity",0.6
+7495,Costa Rica,2010,32,N05C-Hypnotics and sedatives,Million US$ at exchange rate,0.3
+7496,Costa Rica,2010,32,C07-Beta blocking agents,"Million US$, purchasing power parity",1.0
+7497,Costa Rica,2010,32,N05C-Hypnotics and sedatives,"/capita, US$ purchasing power parity",0.1
+7498,Costa Rica,2010,32,C09-Agents acting on the Renin-Angiotensin system,"Million US$, purchasing power parity",4.4
+7499,Costa Rica,2010,32,C01A-Cardiac glycosides,"/capita, US$ exchange rate",0.1
+7500,Costa Rica,2010,32,A10-Drugs used in diabetes,"/capita, US$ exchange rate",1.1
+7501,Costa Rica,2010,32,J01-Antibacterials for systemic use,Million US$ at exchange rate,11.5
+7502,Costa Rica,2010,32,J01-Antibacterials for systemic use,"/capita, US$ purchasing power parity",4.1
+7503,Costa Rica,2010,32,"C01B-Antiarrhythmics, Class I and III","Million US$, purchasing power parity",0.2
+7504,Costa Rica,2010,32,C08-Calcium channel blockers,Million of national currency units,175.2
+7505,Costa Rica,2010,32,C08-Calcium channel blockers,Million US$ at exchange rate,0.3
+7506,Costa Rica,2010,32,C03-Diuretics,"/capita, US$ exchange rate",0.2
+7507,Costa Rica,2010,32,N02-Analgesics,"/capita, US$ exchange rate",0.6
+7508,Costa Rica,2010,32,N06A-Antidepressants,"/capita, US$ exchange rate",0.7
+7509,Costa Rica,2010,32,B-Blood and blood forming organs,"Million US$, purchasing power parity",35.0
+7510,Costa Rica,2010,32,C-Cardiovascular system,Million of national currency units,4821.9
+7511,Costa Rica,2010,32,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million of national currency units,924.5
+7512,Costa Rica,2010,32,C-Cardiovascular system,Million US$ at exchange rate,9.2
+7513,Costa Rica,2010,32,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ exchange rate",1.0
+7514,Costa Rica,2010,32,G03-Sex hormones and modulators of the genital system,"/capita, US$ purchasing power parity",1.0
+7515,Costa Rica,2010,32,C02-Antihypertensives,Million of national currency units,286.8
+7516,Costa Rica,2010,32,M01A-Antiinflammatory and antirheumatic products non-steroids,"Million US$, purchasing power parity",4.7
+7517,Costa Rica,2010,32,N05B-Anxiolytics,"Million US$, purchasing power parity",0.8
+7518,Costa Rica,2010,32,M01A-Antiinflammatory and antirheumatic products non-steroids,Million of national currency units,1530.3
+7519,Costa Rica,2010,32,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ exchange rate",0.4
+7520,Costa Rica,2010,32,J-Antiinfectives for systemic use,Million of national currency units,17239.8
+7521,Costa Rica,2010,32,R03-Drugs for obstructive airway diseases,"/capita, US$ purchasing power parity",2.2
+7522,Costa Rica,2010,32,J-Antiinfectives for systemic use,Million US$ at exchange rate,32.8
+7523,Costa Rica,2010,32,N02-Analgesics,"Million US$, purchasing power parity",4.4
+7524,Costa Rica,2010,32,C02-Antihypertensives,"/capita, US$ exchange rate",0.1
+7525,Costa Rica,2010,32,N05C-Hypnotics and sedatives,"/capita, US$ exchange rate",0.1
+7526,Costa Rica,2010,32,M01A-Antiinflammatory and antirheumatic products non-steroids,Million US$ at exchange rate,2.9
+7527,Costa Rica,2010,32,C-Cardiovascular system,"/capita, US$ exchange rate",2.0
+7528,Costa Rica,2010,32,B-Blood and blood forming organs,"/capita, US$ exchange rate",4.8
+7529,Costa Rica,2010,32,C10-Lipid modifying agents,Million US$ at exchange rate,3.6
+7530,Costa Rica,2010,32,"C01B-Antiarrhythmics, Class I and III","/capita, US$ purchasing power parity",0.0
+7531,Costa Rica,2010,32,C10-Lipid modifying agents,"/capita, US$ purchasing power parity",1.3
+7532,Costa Rica,2010,32,C07-Beta blocking agents,"/capita, US$ purchasing power parity",0.2
+7533,Costa Rica,2010,32,J-Antiinfectives for systemic use,"/capita, US$ exchange rate",7.2
+7534,Costa Rica,2010,32,N06A-Antidepressants,"/capita, US$ purchasing power parity",1.1
+7535,Costa Rica,2010,32,"H-Systemic hormonal preparations, excluding sex hormones and insulins","Million US$, purchasing power parity",7.1
+7536,Costa Rica,2010,32,C10-Lipid modifying agents,"Million US$, purchasing power parity",5.8
+7537,Costa Rica,2010,32,A02A-Antacids,"/capita, US$ purchasing power parity",0.4
+7538,Costa Rica,2010,32,C01A-Cardiac glycosides,Million US$ at exchange rate,0.3
+7539,Costa Rica,2010,32,B-Blood and blood forming organs,"/capita, US$ purchasing power parity",7.7
+7540,Costa Rica,2010,32,J01-Antibacterials for systemic use,"/capita, US$ exchange rate",2.5
+7541,Costa Rica,2010,32,"C01B-Antiarrhythmics, Class I and III",Million US$ at exchange rate,0.1
+7542,Costa Rica,2010,32,A02A-Antacids,Million US$ at exchange rate,1.2
+7543,Costa Rica,2010,32,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million of national currency units,2333.6
+7544,Costa Rica,2010,32,C07-Beta blocking agents,Million US$ at exchange rate,0.6
+7545,Costa Rica,2010,32,A02A-Antacids,Million of national currency units,649.4
+7546,Costa Rica,2010,32,B-Blood and blood forming organs,Million of national currency units,11435.7
+7547,Costa Rica,2010,32,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ exchange rate",0.6
+7548,Costa Rica,2010,32,"C01B-Antiarrhythmics, Class I and III",Million of national currency units,55.7
+7549,Costa Rica,2010,32,R03-Drugs for obstructive airway diseases,Million of national currency units,3327.3
+7550,Costa Rica,2010,32,C10-Lipid modifying agents,Million of national currency units,1900.8
+7551,Costa Rica,2010,32,G03-Sex hormones and modulators of the genital system,"/capita, US$ exchange rate",0.6
+7552,Costa Rica,2010,32,B-Blood and blood forming organs,Million US$ at exchange rate,21.7
+7553,Costa Rica,2010,32,N05B-Anxiolytics,"/capita, US$ purchasing power parity",0.2
+7554,Costa Rica,2010,32,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ purchasing power parity",1.6
+7555,Costa Rica,2010,32,N05B-Anxiolytics,Million US$ at exchange rate,0.5
+7556,Costa Rica,2010,32,A10-Drugs used in diabetes,"/capita, US$ purchasing power parity",1.8
+7557,Costa Rica,2010,32,C07-Beta blocking agents,Million of national currency units,314.6
+7558,Costa Rica,2010,32,A02A-Antacids,"/capita, US$ exchange rate",0.3
+7559,Costa Rica,2010,32,C-Cardiovascular system,"Million US$, purchasing power parity",14.8
+7560,Costa Rica,2010,32,C02-Antihypertensives,"Million US$, purchasing power parity",0.9
+7561,Costa Rica,2010,32,C01A-Cardiac glycosides,"Million US$, purchasing power parity",0.5
+7562,Costa Rica,2010,32,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ purchasing power parity",1.0
+7563,Costa Rica,2010,32,C03-Diuretics,"Million US$, purchasing power parity",1.5
+7564,Costa Rica,2010,32,A10-Drugs used in diabetes,"Million US$, purchasing power parity",8.3
+7565,Costa Rica,2010,32,C08-Calcium channel blockers,"/capita, US$ purchasing power parity",0.1
+7566,Costa Rica,2010,32,J-Antiinfectives for systemic use,"/capita, US$ purchasing power parity",11.6
+7567,Costa Rica,2010,32,N06A-Antidepressants,Million of national currency units,1617.5
+7568,Costa Rica,2010,32,C07-Beta blocking agents,"/capita, US$ exchange rate",0.1
+7569,Costa Rica,2010,32,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million US$ at exchange rate,1.8
+7570,Costa Rica,2010,32,N02-Analgesics,Million of national currency units,1450.0
+7571,Costa Rica,2010,32,"C01B-Antiarrhythmics, Class I and III","/capita, US$ exchange rate",0.0
+7572,Costa Rica,2010,32,R03-Drugs for obstructive airway diseases,"Million US$, purchasing power parity",10.2
+7573,Costa Rica,2010,32,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ purchasing power parity",1.0
+7574,Costa Rica,2010,32,N02-Analgesics,Million US$ at exchange rate,2.8
+7575,Costa Rica,2010,32,N05C-Hypnotics and sedatives,"Million US$, purchasing power parity",0.5
+7576,Costa Rica,2010,32,C08-Calcium channel blockers,"/capita, US$ exchange rate",0.1
+7577,Costa Rica,2010,32,A10-Drugs used in diabetes,Million US$ at exchange rate,5.2
+7578,Costa Rica,2010,32,J01-Antibacterials for systemic use,"Million US$, purchasing power parity",18.5
+7579,Costa Rica,2010,32,G03-Sex hormones and modulators of the genital system,"Million US$, purchasing power parity",4.5
+7580,Costa Rica,2010,32,N06A-Antidepressants,Million US$ at exchange rate,3.1
+7581,Costa Rica,2010,32,R03-Drugs for obstructive airway diseases,"/capita, US$ exchange rate",1.4
+7582,Costa Rica,2010,32,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million US$ at exchange rate,4.4
+7583,Costa Rica,2010,32,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ exchange rate",0.6
+7584,Costa Rica,2010,32,G03-Sex hormones and modulators of the genital system,Million of national currency units,1471.6
+7585,Costa Rica,2010,32,J01-Antibacterials for systemic use,Million of national currency units,6059.1
+7586,Costa Rica,2010,32,C03-Diuretics,Million US$ at exchange rate,0.9
+7587,Costa Rica,2010,32,N05C-Hypnotics and sedatives,Million of national currency units,166.7
+7588,Costa Rica,2010,32,C-Cardiovascular system,"/capita, US$ purchasing power parity",3.3
+7589,Costa Rica,2010,32,C09-Agents acting on the Renin-Angiotensin system,Million of national currency units,1443.7
+7590,Costa Rica,2010,32,J-Antiinfectives for systemic use,"Million US$, purchasing power parity",52.7
+7591,Costa Rica,2010,32,C02-Antihypertensives,"/capita, US$ purchasing power parity",0.2
+7592,Costa Rica,2010,32,C01A-Cardiac glycosides,"/capita, US$ purchasing power parity",0.1
+7593,Costa Rica,2010,32,C01A-Cardiac glycosides,Million of national currency units,157.0
+7594,Costa Rica,2010,32,A02A-Antacids,"Million US$, purchasing power parity",2.0
+7595,Costa Rica,2010,32,C03-Diuretics,"/capita, US$ purchasing power parity",0.3
+7596,Costa Rica,2010,32,C09-Agents acting on the Renin-Angiotensin system,Million US$ at exchange rate,2.7
+7597,Costa Rica,2010,32,N05B-Anxiolytics,"/capita, US$ exchange rate",0.1
+7598,Costa Rica,2010,32,G03-Sex hormones and modulators of the genital system,Million US$ at exchange rate,2.8
+7599,Costa Rica,2010,32,C03-Diuretics,Million of national currency units,488.0
+7600,Costa Rica,2010,32,N05B-Anxiolytics,Million of national currency units,272.4
+7601,Costa Rica,2010,32,N06A-Antidepressants,"Million US$, purchasing power parity",4.9
+7602,Costa Rica,2010,32,A10-Drugs used in diabetes,Million of national currency units,2715.6
+7603,Costa Rica,2010,32,C08-Calcium channel blockers,"Million US$, purchasing power parity",0.5
+7604,Costa Rica,2010,32,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"Million US$, purchasing power parity",2.8
+7605,Costa Rica,2010,32,C10-Lipid modifying agents,"/capita, US$ exchange rate",0.8
+7606,Costa Rica,2010,32,N02-Analgesics,"/capita, US$ purchasing power parity",1.0
+7607,Costa Rica,2017,27,C-Cardiovascular system,"/capita, US$ purchasing power parity",3.8
+7608,Costa Rica,2017,27,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ purchasing power parity",1.1
+7609,Costa Rica,2017,27,R03-Drugs for obstructive airway diseases,Million US$ at exchange rate,5.3
+7610,Costa Rica,2017,27,N05C-Hypnotics and sedatives,Million US$ at exchange rate,0.4
+7611,Costa Rica,2017,27,C07-Beta blocking agents,"Million US$, purchasing power parity",2.8
+7612,Costa Rica,2017,27,N05C-Hypnotics and sedatives,"/capita, US$ purchasing power parity",0.1
+7613,Costa Rica,2017,27,C01A-Cardiac glycosides,"/capita, US$ exchange rate",0.1
+7614,Costa Rica,2017,27,J01-Antibacterials for systemic use,Million US$ at exchange rate,7.7
+7615,Costa Rica,2017,27,A10-Drugs used in diabetes,"/capita, US$ exchange rate",1.6
+7616,Costa Rica,2017,27,C02-Antihypertensives,Million US$ at exchange rate,1.1
+7617,Costa Rica,2017,27,C-Cardiovascular system,Million US$ at exchange rate,11.4
+7618,Costa Rica,2017,27,"C01B-Antiarrhythmics, Class I and III","Million US$, purchasing power parity",0.2
+7619,Costa Rica,2017,27,J01-Antibacterials for systemic use,"/capita, US$ purchasing power parity",2.6
+7620,Costa Rica,2017,27,B-Blood and blood forming organs,"Million US$, purchasing power parity",45.0
+7621,Costa Rica,2017,27,C08-Calcium channel blockers,Million of national currency units,364.0
+7622,Costa Rica,2017,27,N02-Analgesics,"/capita, US$ exchange rate",1.0
+7623,Costa Rica,2017,27,C03-Diuretics,"/capita, US$ exchange rate",0.1
+7624,Costa Rica,2017,27,C08-Calcium channel blockers,Million US$ at exchange rate,0.6
+7625,Costa Rica,2017,27,N06A-Antidepressants,"/capita, US$ exchange rate",0.5
+7626,Costa Rica,2017,27,C-Cardiovascular system,Million of national currency units,6494.7
+7627,Costa Rica,2017,27,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million of national currency units,1838.9
+7628,Costa Rica,2017,27,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ exchange rate",0.9
+7629,Costa Rica,2017,27,G03-Sex hormones and modulators of the genital system,"/capita, US$ purchasing power parity",1.2
+7630,Costa Rica,2017,27,C02-Antihypertensives,Million of national currency units,625.9
+7631,Costa Rica,2017,27,M01A-Antiinflammatory and antirheumatic products non-steroids,"Million US$, purchasing power parity",5.6
+7632,Costa Rica,2017,27,N05B-Anxiolytics,"Million US$, purchasing power parity",1.2
+7633,Costa Rica,2017,27,J-Antiinfectives for systemic use,Million of national currency units,19558.1
+7634,Costa Rica,2017,27,M01A-Antiinflammatory and antirheumatic products non-steroids,Million of national currency units,1901.9
+7635,Costa Rica,2017,27,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ exchange rate",0.7
+7636,Costa Rica,2017,27,N02-Analgesics,"Million US$, purchasing power parity",8.2
+7637,Costa Rica,2017,27,R03-Drugs for obstructive airway diseases,"/capita, US$ purchasing power parity",1.8
+7638,Costa Rica,2017,27,J-Antiinfectives for systemic use,Million US$ at exchange rate,34.5
+7639,Costa Rica,2017,27,M01A-Antiinflammatory and antirheumatic products non-steroids,Million US$ at exchange rate,3.4
+7640,Costa Rica,2017,27,B-Blood and blood forming organs,"/capita, US$ exchange rate",5.5
+7641,Costa Rica,2017,27,N05C-Hypnotics and sedatives,"/capita, US$ exchange rate",0.1
+7642,Costa Rica,2017,27,N05B-Anxiolytics,Million US$ at exchange rate,0.7
+7643,Costa Rica,2017,27,C02-Antihypertensives,"/capita, US$ exchange rate",0.2
+7644,Costa Rica,2017,27,C-Cardiovascular system,"/capita, US$ exchange rate",2.3
+7645,Costa Rica,2017,27,C10-Lipid modifying agents,Million US$ at exchange rate,3.4
+7646,Costa Rica,2017,27,C10-Lipid modifying agents,"/capita, US$ purchasing power parity",1.1
+7647,Costa Rica,2017,27,N06A-Antidepressants,"Million US$, purchasing power parity",4.2
+7648,Costa Rica,2017,27,C07-Beta blocking agents,"/capita, US$ purchasing power parity",0.6
+7649,Costa Rica,2017,27,N06A-Antidepressants,"/capita, US$ purchasing power parity",0.8
+7650,Costa Rica,2017,27,B-Blood and blood forming organs,"/capita, US$ purchasing power parity",9.1
+7651,Costa Rica,2017,27,"H-Systemic hormonal preparations, excluding sex hormones and insulins","Million US$, purchasing power parity",7.2
+7652,Costa Rica,2017,27,J-Antiinfectives for systemic use,"/capita, US$ exchange rate",7.0
+7653,Costa Rica,2017,27,A02A-Antacids,"/capita, US$ purchasing power parity",0.6
+7654,Costa Rica,2017,27,C10-Lipid modifying agents,"Million US$, purchasing power parity",5.6
+7655,Costa Rica,2017,27,"C01B-Antiarrhythmics, Class I and III","/capita, US$ purchasing power parity",0.0
+7656,Costa Rica,2017,27,C01A-Cardiac glycosides,Million US$ at exchange rate,0.3
+7657,Costa Rica,2017,27,"C01B-Antiarrhythmics, Class I and III",Million US$ at exchange rate,0.1
+7658,Costa Rica,2017,27,C07-Beta blocking agents,Million US$ at exchange rate,1.7
+7659,Costa Rica,2017,27,C10-Lipid modifying agents,Million of national currency units,1908.2
+7660,Costa Rica,2017,27,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million of national currency units,2446.5
+7661,Costa Rica,2017,27,J01-Antibacterials for systemic use,"/capita, US$ exchange rate",1.6
+7662,Costa Rica,2017,27,B-Blood and blood forming organs,Million of national currency units,15352.6
+7663,Costa Rica,2017,27,A02A-Antacids,Million of national currency units,1006.5
+7664,Costa Rica,2017,27,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ exchange rate",0.7
+7665,Costa Rica,2017,27,G03-Sex hormones and modulators of the genital system,"/capita, US$ exchange rate",0.7
+7666,Costa Rica,2017,27,"C01B-Antiarrhythmics, Class I and III",Million of national currency units,76.7
+7667,Costa Rica,2017,27,R03-Drugs for obstructive airway diseases,Million of national currency units,3015.6
+7668,Costa Rica,2017,27,A02A-Antacids,Million US$ at exchange rate,1.8
+7669,Costa Rica,2017,27,A10-Drugs used in diabetes,"/capita, US$ purchasing power parity",2.7
+7670,Costa Rica,2017,27,B-Blood and blood forming organs,Million US$ at exchange rate,27.1
+7671,Costa Rica,2017,27,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ purchasing power parity",1.5
+7672,Costa Rica,2017,27,N05B-Anxiolytics,"/capita, US$ purchasing power parity",0.2
+7673,Costa Rica,2017,27,A02A-Antacids,"/capita, US$ exchange rate",0.4
+7674,Costa Rica,2017,27,C-Cardiovascular system,"Million US$, purchasing power parity",19.0
+7675,Costa Rica,2017,27,C07-Beta blocking agents,Million of national currency units,941.0
+7676,Costa Rica,2017,27,C03-Diuretics,"Million US$, purchasing power parity",1.2
+7677,Costa Rica,2017,27,C01A-Cardiac glycosides,"Million US$, purchasing power parity",0.5
+7678,Costa Rica,2017,27,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ purchasing power parity",1.1
+7679,Costa Rica,2017,27,J-Antiinfectives for systemic use,"/capita, US$ purchasing power parity",11.6
+7680,Costa Rica,2017,27,A10-Drugs used in diabetes,"Million US$, purchasing power parity",13.5
+7681,Costa Rica,2017,27,C08-Calcium channel blockers,"/capita, US$ purchasing power parity",0.2
+7682,Costa Rica,2017,27,C07-Beta blocking agents,"/capita, US$ exchange rate",0.3
+7683,Costa Rica,2017,27,N06A-Antidepressants,Million of national currency units,1423.3
+7684,Costa Rica,2017,27,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million US$ at exchange rate,3.2
+7685,Costa Rica,2017,27,N02-Analgesics,Million of national currency units,2796.1
+7686,Costa Rica,2017,27,N05C-Hypnotics and sedatives,"Million US$, purchasing power parity",0.6
+7687,Costa Rica,2017,27,R03-Drugs for obstructive airway diseases,"Million US$, purchasing power parity",8.8
+7688,Costa Rica,2017,27,"C01B-Antiarrhythmics, Class I and III","/capita, US$ exchange rate",0.0
+7689,Costa Rica,2017,27,N02-Analgesics,Million US$ at exchange rate,4.9
+7690,Costa Rica,2017,27,C08-Calcium channel blockers,"/capita, US$ exchange rate",0.1
+7691,Costa Rica,2017,27,A10-Drugs used in diabetes,Million US$ at exchange rate,8.1
+7692,Costa Rica,2017,27,G03-Sex hormones and modulators of the genital system,"Million US$, purchasing power parity",6.0
+7693,Costa Rica,2017,27,J01-Antibacterials for systemic use,"Million US$, purchasing power parity",12.9
+7694,Costa Rica,2017,27,C09-Agents acting on the Renin-Angiotensin system,"Million US$, purchasing power parity",5.7
+7695,Costa Rica,2017,27,C10-Lipid modifying agents,"/capita, US$ exchange rate",0.7
+7696,Costa Rica,2017,27,N06A-Antidepressants,Million US$ at exchange rate,2.5
+7697,Costa Rica,2017,27,R03-Drugs for obstructive airway diseases,"/capita, US$ exchange rate",1.1
+7698,Costa Rica,2017,27,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million US$ at exchange rate,4.3
+7699,Costa Rica,2017,27,G03-Sex hormones and modulators of the genital system,Million of national currency units,2033.8
+7700,Costa Rica,2017,27,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ exchange rate",0.7
+7701,Costa Rica,2017,27,C09-Agents acting on the Renin-Angiotensin system,Million of national currency units,1954.6
+7702,Costa Rica,2017,27,C03-Diuretics,Million US$ at exchange rate,0.7
+7703,Costa Rica,2017,27,C02-Antihypertensives,"/capita, US$ purchasing power parity",0.4
+7704,Costa Rica,2017,27,N05C-Hypnotics and sedatives,Million of national currency units,212.0
+7705,Costa Rica,2017,27,J01-Antibacterials for systemic use,Million of national currency units,4383.7
+7706,Costa Rica,2017,27,J-Antiinfectives for systemic use,"Million US$, purchasing power parity",57.4
+7707,Costa Rica,2017,27,C01A-Cardiac glycosides,"/capita, US$ purchasing power parity",0.1
+7708,Costa Rica,2017,27,C03-Diuretics,"/capita, US$ purchasing power parity",0.2
+7709,Costa Rica,2017,27,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ purchasing power parity",1.2
+7710,Costa Rica,2017,27,A02A-Antacids,"Million US$, purchasing power parity",3.0
+7711,Costa Rica,2017,27,C01A-Cardiac glycosides,Million of national currency units,185.4
+7712,Costa Rica,2017,27,C09-Agents acting on the Renin-Angiotensin system,Million US$ at exchange rate,3.4
+7713,Costa Rica,2017,27,N05B-Anxiolytics,"/capita, US$ exchange rate",0.1
+7714,Costa Rica,2017,27,G03-Sex hormones and modulators of the genital system,Million US$ at exchange rate,3.6
+7715,Costa Rica,2017,27,C03-Diuretics,Million of national currency units,405.0
+7716,Costa Rica,2017,27,A10-Drugs used in diabetes,Million of national currency units,4591.0
+7717,Costa Rica,2017,27,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"Million US$, purchasing power parity",5.4
+7718,Costa Rica,2017,27,N05B-Anxiolytics,Million of national currency units,399.9
+7719,Costa Rica,2017,27,C02-Antihypertensives,"Million US$, purchasing power parity",1.8
+7720,Costa Rica,2017,27,C08-Calcium channel blockers,"Million US$, purchasing power parity",1.1
+7721,Costa Rica,2017,27,N02-Analgesics,"/capita, US$ purchasing power parity",1.7
+7722,Croatia,2016,7,C07-Beta blocking agents,Million US$ at exchange rate,94.1
+7723,Croatia,2016,7,N05C-Hypnotics and sedatives,Million US$ at exchange rate,36.5
+7724,Croatia,2016,7,A10-Drugs used in diabetes,"Million US$, purchasing power parity",859.9
+7725,Croatia,2016,7,N-Nervous system,"/capita, US$ exchange rate",225.3
+7726,Croatia,2016,7,G-Genito urinary system and sex hormones,"Million US$, purchasing power parity",383.2
+7727,Croatia,2016,7,A02A-Antacids,"/capita, US$ exchange rate",2.7
+7728,Croatia,2016,7,C08-Calcium channel blockers,"Million US$, purchasing power parity",218.3
+7729,Croatia,2016,7,B-Blood and blood forming organs,"/capita, US$ exchange rate",118.3
+7730,Croatia,2016,7,A-Alimentary tract and metabolism,"Million US$, purchasing power parity",1724.3
+7731,Croatia,2016,7,"C01B-Antiarrhythmics, Class I and III","/capita, US$ exchange rate",4.2
+7732,Croatia,2016,7,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million US$ at exchange rate,116.2
+7733,Croatia,2016,7,C02-Antihypertensives,"/capita, US$ purchasing power parity",23.0
+7734,Croatia,2016,7,"C01B-Antiarrhythmics, Class I and III",Million of national currency units,16.0
+7735,Croatia,2016,7,C07-Beta blocking agents,Million of national currency units,85.0
+7736,Croatia,2016,7,J-Antiinfectives for systemic use,"/capita, US$ purchasing power parity",260.0
+7737,Croatia,2016,7,A02A-Antacids,Million of national currency units,10.0
+7738,Croatia,2016,7,R-Respiratory system,"Million US$, purchasing power parity",802.0
+7739,Croatia,2016,7,R03-Drugs for obstructive airway diseases,"/capita, US$ exchange rate",58.1
+7740,Croatia,2016,7,Total pharmaceutical sales,Million US$ at exchange rate,6424.2
+7741,Croatia,2016,7,N02-Analgesics,Million US$ at exchange rate,203.7
+7742,Croatia,2016,7,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million US$ at exchange rate,124.0
+7743,Croatia,2016,7,N05B-Anxiolytics,"Million US$, purchasing power parity",205.0
+7744,Croatia,2016,7,C10-Lipid modifying agents,"/capita, US$ exchange rate",39.0
+7745,Croatia,2016,7,C-Cardiovascular system,Million of national currency units,777.0
+7746,Croatia,2016,7,M01A-Antiinflammatory and antirheumatic products non-steroids,"Million US$, purchasing power parity",294.1
+7747,Croatia,2016,7,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million of national currency units,112.0
+7748,Croatia,2016,7,N05C-Hypnotics and sedatives,Million of national currency units,33.0
+7749,Croatia,2016,7,J-Antiinfectives for systemic use,"Million US$, purchasing power parity",1084.9
+7750,Croatia,2016,7,N-Nervous system,Million of national currency units,849.0
+7751,Croatia,2016,7,B-Blood and blood forming organs,Million of national currency units,446.0
+7752,Croatia,2016,7,G-Genito urinary system and sex hormones,"/capita, US$ purchasing power parity",91.8
+7753,Croatia,2016,7,C08-Calcium channel blockers,"/capita, US$ purchasing power parity",52.3
+7754,Croatia,2016,7,N06A-Antidepressants,"/capita, US$ purchasing power parity",43.8
+7755,Croatia,2016,7,N02-Analgesics,Million of national currency units,184.0
+7756,Croatia,2016,7,N06A-Antidepressants,Million of national currency units,82.0
+7757,Croatia,2016,7,C02-Antihypertensives,Million of national currency units,43.0
+7758,Croatia,2016,7,C09-Agents acting on the Renin-Angiotensin system,"Million US$, purchasing power parity",728.5
+7759,Croatia,2016,7,C10-Lipid modifying agents,Million of national currency units,147.0
+7760,Croatia,2016,7,R03-Drugs for obstructive airway diseases,Million of national currency units,219.0
+7761,Croatia,2016,7,C01A-Cardiac glycosides,"/capita, US$ purchasing power parity",2.7
+7762,Croatia,2016,7,B-Blood and blood forming organs,Million US$ at exchange rate,493.7
+7763,Croatia,2016,7,G03-Sex hormones and modulators of the genital system,"Million US$, purchasing power parity",135.9
+7764,Croatia,2016,7,M-Musculo-skeletal system,"/capita, US$ exchange rate",57.6
+7765,Croatia,2016,7,N06A-Antidepressants,Million US$ at exchange rate,90.8
+7766,Croatia,2016,7,C03-Diuretics,"Million US$, purchasing power parity",115.8
+7767,Croatia,2016,7,N05B-Anxiolytics,"/capita, US$ purchasing power parity",49.1
+7768,Croatia,2016,7,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ exchange rate",86.8
+7769,Croatia,2016,7,A02A-Antacids,Million US$ at exchange rate,11.1
+7770,Croatia,2016,7,Total pharmaceutical sales,"/capita, US$ purchasing power parity",3098.4
+7771,Croatia,2016,7,"C01B-Antiarrhythmics, Class I and III",Million US$ at exchange rate,17.7
+7772,Croatia,2016,7,M-Musculo-skeletal system,Million of national currency units,217.0
+7773,Croatia,2016,7,C02-Antihypertensives,"Million US$, purchasing power parity",95.8
+7774,Croatia,2016,7,N-Nervous system,Million US$ at exchange rate,939.9
+7775,Croatia,2016,7,G03-Sex hormones and modulators of the genital system,"/capita, US$ exchange rate",16.2
+7776,Croatia,2016,7,N05C-Hypnotics and sedatives,"/capita, US$ exchange rate",8.8
+7777,Croatia,2016,7,A10-Drugs used in diabetes,"/capita, US$ purchasing power parity",206.1
+7778,Croatia,2016,7,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ exchange rate",27.9
+7779,Croatia,2016,7,N02-Analgesics,"/capita, US$ purchasing power parity",98.2
+7780,Croatia,2016,7,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ purchasing power parity",70.5
+7781,Croatia,2016,7,C02-Antihypertensives,Million US$ at exchange rate,47.6
+7782,Croatia,2016,7,R-Respiratory system,"/capita, US$ purchasing power parity",192.2
+7783,Croatia,2016,7,A-Alimentary tract and metabolism,"/capita, US$ purchasing power parity",413.3
+7784,Croatia,2016,7,C-Cardiovascular system,Million US$ at exchange rate,860.2
+7785,Croatia,2016,7,Total pharmaceutical sales,"/capita, US$ exchange rate",1539.7
+7786,Croatia,2016,7,M-Musculo-skeletal system,"/capita, US$ purchasing power parity",115.9
+7787,Croatia,2016,7,R03-Drugs for obstructive airway diseases,Million US$ at exchange rate,242.4
+7788,Croatia,2016,7,C-Cardiovascular system,"/capita, US$ purchasing power parity",414.9
+7789,Croatia,2016,7,C10-Lipid modifying agents,Million US$ at exchange rate,162.7
+7790,Croatia,2016,7,Total pharmaceutical sales,Million of national currency units,5803.0
+7791,Croatia,2016,7,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ purchasing power parity",59.8
+7792,Croatia,2016,7,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million of national currency units,105.0
+7793,Croatia,2016,7,J01-Antibacterials for systemic use,"/capita, US$ exchange rate",79.9
+7794,Croatia,2016,7,B-Blood and blood forming organs,"/capita, US$ purchasing power parity",238.1
+7795,Croatia,2016,7,C10-Lipid modifying agents,"Million US$, purchasing power parity",327.5
+7796,Croatia,2016,7,C09-Agents acting on the Renin-Angiotensin system,Million US$ at exchange rate,362.0
+7797,Croatia,2016,7,A02A-Antacids,"/capita, US$ purchasing power parity",5.3
+7798,Croatia,2016,7,C03-Diuretics,Million US$ at exchange rate,57.6
+7799,Croatia,2016,7,A10-Drugs used in diabetes,"/capita, US$ exchange rate",102.4
+7800,Croatia,2016,7,C09-Agents acting on the Renin-Angiotensin system,% of total sales,5.6
+7801,Croatia,2016,7,A10-Drugs used in diabetes,% of total sales,6.7
+7802,Croatia,2016,7,G03-Sex hormones and modulators of the genital system,% of total sales,1.1
+7803,Croatia,2016,7,J-Antiinfectives for systemic use,"/capita, US$ exchange rate",129.2
+7804,Croatia,2016,7,R03-Drugs for obstructive airway diseases,"/capita, US$ purchasing power parity",116.9
+7805,Croatia,2016,7,C01A-Cardiac glycosides,Million US$ at exchange rate,5.5
+7806,Croatia,2016,7,A-Alimentary tract and metabolism,"/capita, US$ exchange rate",205.4
+7807,Croatia,2016,7,N02-Analgesics,"Million US$, purchasing power parity",409.9
+7808,Croatia,2016,7,C08-Calcium channel blockers,Million of national currency units,98.0
+7809,Croatia,2016,7,C03-Diuretics,"/capita, US$ exchange rate",13.8
+7810,Croatia,2016,7,C07-Beta blocking agents,"/capita, US$ purchasing power parity",45.4
+7811,Croatia,2016,7,C-Cardiovascular system,"Million US$, purchasing power parity",1731.0
+7812,Croatia,2016,7,J01-Antibacterials for systemic use,Million US$ at exchange rate,333.2
+7813,Croatia,2016,7,"C01B-Antiarrhythmics, Class I and III","/capita, US$ purchasing power parity",8.5
+7814,Croatia,2016,7,"H-Systemic hormonal preparations, excluding sex hormones and insulins","Million US$, purchasing power parity",233.9
+7815,Croatia,2016,7,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ exchange rate",35.0
+7816,Croatia,2016,7,N05B-Anxiolytics,"/capita, US$ exchange rate",24.4
+7817,Croatia,2016,7,G-Genito urinary system and sex hormones,Million of national currency units,172.0
+7818,Croatia,2016,7,N05C-Hypnotics and sedatives,"/capita, US$ purchasing power parity",17.6
+7819,Croatia,2016,7,M-Musculo-skeletal system,% of total sales,3.7
+7820,Croatia,2016,7,C10-Lipid modifying agents,% of total sales,2.5
+7821,Croatia,2016,7,"H-Systemic hormonal preparations, excluding sex hormones and insulins",% of total sales,1.8
+7822,Croatia,2016,7,C-Cardiovascular system,% of total sales,13.4
+7823,Croatia,2016,7,N06A-Antidepressants,% of total sales,1.4
+7824,Croatia,2016,7,N02-Analgesics,% of total sales,3.2
+7825,Croatia,2016,7,C02-Antihypertensives,% of total sales,0.7
+7826,Croatia,2016,7,C08-Calcium channel blockers,% of total sales,1.7
+7827,Croatia,2016,7,G-Genito urinary system and sex hormones,% of total sales,3.0
+7828,Croatia,2016,7,M01A-Antiinflammatory and antirheumatic products non-steroids,% of total sales,2.3
+7829,Croatia,2016,7,A-Alimentary tract and metabolism,% of total sales,13.3
+7830,Croatia,2016,7,J-Antiinfectives for systemic use,% of total sales,8.4
+7831,Croatia,2016,7,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),% of total sales,1.9
+7832,Croatia,2016,7,R-Respiratory system,% of total sales,6.2
+7833,Croatia,2016,7,B-Blood and blood forming organs,% of total sales,7.7
+7834,Croatia,2016,7,"C01B-Antiarrhythmics, Class I and III",% of total sales,0.3
+7835,Croatia,2016,7,N05B-Anxiolytics,% of total sales,1.6
+7836,Croatia,2016,7,C01A-Cardiac glycosides,% of total sales,0.1
+7837,Croatia,2016,7,C03-Diuretics,% of total sales,0.9
+7838,Croatia,2016,7,N05C-Hypnotics and sedatives,% of total sales,0.6
+7839,Croatia,2016,7,J01-Antibacterials for systemic use,% of total sales,5.2
+7840,Croatia,2016,7,N-Nervous system,% of total sales,14.6
+7841,Croatia,2016,7,C07-Beta blocking agents,% of total sales,1.5
+7842,Croatia,2016,7,R03-Drugs for obstructive airway diseases,% of total sales,3.8
+7843,Croatia,2016,7,N05B-Anxiolytics,Million of national currency units,92.0
+7844,Croatia,2016,7,A02A-Antacids,% of total sales,0.2
+7845,Croatia,2016,7,"C01B-Antiarrhythmics, Class I and III","Million US$, purchasing power parity",35.6
+7846,Croatia,2016,7,C08-Calcium channel blockers,"/capita, US$ exchange rate",26.0
+7847,Croatia,2016,7,N05C-Hypnotics and sedatives,"Million US$, purchasing power parity",73.5
+7848,Croatia,2016,7,G03-Sex hormones and modulators of the genital system,"/capita, US$ purchasing power parity",32.6
+7849,Croatia,2016,7,G-Genito urinary system and sex hormones,"/capita, US$ exchange rate",45.6
+7850,Croatia,2016,7,B-Blood and blood forming organs,"Million US$, purchasing power parity",993.6
+7851,Croatia,2016,7,N05B-Anxiolytics,Million US$ at exchange rate,101.8
+7852,Croatia,2016,7,G-Genito urinary system and sex hormones,Million US$ at exchange rate,190.4
+7853,Croatia,2016,7,N06A-Antidepressants,"/capita, US$ exchange rate",21.8
+7854,Croatia,2016,7,N02-Analgesics,"/capita, US$ exchange rate",48.8
+7855,Croatia,2016,7,M01A-Antiinflammatory and antirheumatic products non-steroids,Million US$ at exchange rate,146.1
+7856,Croatia,2016,7,C02-Antihypertensives,"/capita, US$ exchange rate",11.4
+7857,Croatia,2016,7,A10-Drugs used in diabetes,Million US$ at exchange rate,427.3
+7858,Croatia,2016,7,N-Nervous system,"/capita, US$ purchasing power parity",453.3
+7859,Croatia,2016,7,C09-Agents acting on the Renin-Angiotensin system,Million of national currency units,327.0
+7860,Croatia,2016,7,R03-Drugs for obstructive airway diseases,"Million US$, purchasing power parity",487.9
+7861,Croatia,2016,7,C07-Beta blocking agents,"/capita, US$ exchange rate",22.6
+7862,Croatia,2016,7,M-Musculo-skeletal system,Million US$ at exchange rate,240.2
+7863,Croatia,2016,7,C01A-Cardiac glycosides,"Million US$, purchasing power parity",11.1
+7864,Croatia,2016,7,R-Respiratory system,Million US$ at exchange rate,398.5
+7865,Croatia,2016,7,J01-Antibacterials for systemic use,"/capita, US$ purchasing power parity",160.7
+7866,Croatia,2016,7,J01-Antibacterials for systemic use,Million of national currency units,301.0
+7867,Croatia,2016,7,A-Alimentary tract and metabolism,Million US$ at exchange rate,856.8
+7868,Croatia,2016,7,C07-Beta blocking agents,"Million US$, purchasing power parity",189.4
+7869,Croatia,2016,7,G03-Sex hormones and modulators of the genital system,Million of national currency units,61.0
+7870,Croatia,2016,7,Total pharmaceutical sales,"Million US$, purchasing power parity",12928.0
+7871,Croatia,2016,7,J-Antiinfectives for systemic use,Million of national currency units,487.0
+7872,Croatia,2016,7,A-Alimentary tract and metabolism,Million of national currency units,774.0
+7873,Croatia,2016,7,N06A-Antidepressants,"Million US$, purchasing power parity",182.7
+7874,Croatia,2016,7,G03-Sex hormones and modulators of the genital system,Million US$ at exchange rate,67.5
+7875,Croatia,2016,7,C01A-Cardiac glycosides,"/capita, US$ exchange rate",1.3
+7876,Croatia,2016,7,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ purchasing power parity",56.1
+7877,Croatia,2016,7,C10-Lipid modifying agents,"/capita, US$ purchasing power parity",78.5
+7878,Croatia,2016,7,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"Million US$, purchasing power parity",249.5
+7879,Croatia,2016,7,M-Musculo-skeletal system,"Million US$, purchasing power parity",483.4
+7880,Croatia,2016,7,A10-Drugs used in diabetes,Million of national currency units,386.0
+7881,Croatia,2016,7,M01A-Antiinflammatory and antirheumatic products non-steroids,Million of national currency units,132.0
+7882,Croatia,2016,7,J01-Antibacterials for systemic use,"Million US$, purchasing power parity",670.6
+7883,Croatia,2016,7,A02A-Antacids,"Million US$, purchasing power parity",22.3
+7884,Croatia,2016,7,C01A-Cardiac glycosides,Million of national currency units,5.0
+7885,Croatia,2016,7,C-Cardiovascular system,"/capita, US$ exchange rate",206.2
+7886,Croatia,2016,7,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ exchange rate",29.7
+7887,Croatia,2016,7,C08-Calcium channel blockers,Million US$ at exchange rate,108.5
+7888,Croatia,2016,7,C03-Diuretics,"/capita, US$ purchasing power parity",27.8
+7889,Croatia,2016,7,C03-Diuretics,Million of national currency units,52.0
+7890,Croatia,2016,7,R-Respiratory system,"/capita, US$ exchange rate",95.5
+7891,Croatia,2016,7,R-Respiratory system,Million of national currency units,360.0
+7892,Croatia,2016,7,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ purchasing power parity",174.6
+7893,Croatia,2016,7,J-Antiinfectives for systemic use,Million US$ at exchange rate,539.1
+7894,Croatia,2016,7,N-Nervous system,"Million US$, purchasing power parity",1891.4
+7895,Croatia,2015,8,C07-Beta blocking agents,Million US$ at exchange rate,97.8
+7896,Croatia,2015,8,C02-Antihypertensives,"/capita, US$ purchasing power parity",25.0
+7897,Croatia,2015,8,A10-Drugs used in diabetes,"Million US$, purchasing power parity",737.9
+7898,Croatia,2015,8,N-Nervous system,"/capita, US$ exchange rate",212.0
+7899,Croatia,2015,8,G-Genito urinary system and sex hormones,"Million US$, purchasing power parity",353.9
+7900,Croatia,2015,8,A02A-Antacids,"/capita, US$ exchange rate",2.6
+7901,Croatia,2015,8,C08-Calcium channel blockers,"Million US$, purchasing power parity",218.8
+7902,Croatia,2015,8,B-Blood and blood forming organs,"/capita, US$ exchange rate",92.7
+7903,Croatia,2015,8,A-Alimentary tract and metabolism,"Million US$, purchasing power parity",1544.5
+7904,Croatia,2015,8,"C01B-Antiarrhythmics, Class I and III","/capita, US$ exchange rate",4.4
+7905,Croatia,2015,8,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million US$ at exchange rate,106.6
+7906,Croatia,2015,8,"C01B-Antiarrhythmics, Class I and III",Million of national currency units,17.0
+7907,Croatia,2015,8,C07-Beta blocking agents,Million of national currency units,89.0
+7908,Croatia,2015,8,J-Antiinfectives for systemic use,"/capita, US$ purchasing power parity",209.5
+7909,Croatia,2015,8,A02A-Antacids,Million of national currency units,10.0
+7910,Croatia,2015,8,R03-Drugs for obstructive airway diseases,"/capita, US$ exchange rate",56.7
+7911,Croatia,2015,8,R-Respiratory system,"Million US$, purchasing power parity",746.5
+7912,Croatia,2015,8,Total pharmaceutical sales,Million US$ at exchange rate,5786.3
+7913,Croatia,2015,8,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million US$ at exchange rate,125.2
+7914,Croatia,2015,8,C10-Lipid modifying agents,"/capita, US$ exchange rate",43.3
+7915,Croatia,2015,8,C-Cardiovascular system,Million of national currency units,782.0
+7916,Croatia,2015,8,N05B-Anxiolytics,"Million US$, purchasing power parity",195.2
+7917,Croatia,2015,8,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million of national currency units,114.0
+7918,Croatia,2015,8,M01A-Antiinflammatory and antirheumatic products non-steroids,"Million US$, purchasing power parity",276.7
+7919,Croatia,2015,8,J-Antiinfectives for systemic use,"Million US$, purchasing power parity",881.6
+7920,Croatia,2015,8,N-Nervous system,Million of national currency units,812.0
+7921,Croatia,2015,8,B-Blood and blood forming organs,Million of national currency units,355.0
+7922,Croatia,2015,8,N02-Analgesics,Million US$ at exchange rate,205.4
+7923,Croatia,2015,8,C08-Calcium channel blockers,"/capita, US$ purchasing power parity",52.0
+7924,Croatia,2015,8,G-Genito urinary system and sex hormones,"/capita, US$ purchasing power parity",84.1
+7925,Croatia,2015,8,N06A-Antidepressants,"/capita, US$ purchasing power parity",41.3
+7926,Croatia,2015,8,N02-Analgesics,Million of national currency units,187.0
+7927,Croatia,2015,8,N06A-Antidepressants,Million of national currency units,81.0
+7928,Croatia,2015,8,C02-Antihypertensives,Million of national currency units,49.0
+7929,Croatia,2015,8,C09-Agents acting on the Renin-Angiotensin system,"Million US$, purchasing power parity",682.2
+7930,Croatia,2015,8,C10-Lipid modifying agents,Million of national currency units,166.0
+7931,Croatia,2015,8,C01A-Cardiac glycosides,"/capita, US$ purchasing power parity",2.5
+7932,Croatia,2015,8,B-Blood and blood forming organs,Million US$ at exchange rate,390.0
+7933,Croatia,2015,8,R03-Drugs for obstructive airway diseases,Million of national currency units,217.0
+7934,Croatia,2015,8,G03-Sex hormones and modulators of the genital system,"Million US$, purchasing power parity",135.1
+7935,Croatia,2015,8,N06A-Antidepressants,Million US$ at exchange rate,89.0
+7936,Croatia,2015,8,M-Musculo-skeletal system,"/capita, US$ exchange rate",53.3
+7937,Croatia,2015,8,C03-Diuretics,"Million US$, purchasing power parity",103.0
+7938,Croatia,2015,8,N05B-Anxiolytics,"/capita, US$ purchasing power parity",46.4
+7939,Croatia,2015,8,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ exchange rate",83.0
+7940,Croatia,2015,8,A02A-Antacids,Million US$ at exchange rate,11.0
+7941,Croatia,2015,8,"C01B-Antiarrhythmics, Class I and III",Million US$ at exchange rate,18.7
+7942,Croatia,2015,8,N05C-Hypnotics and sedatives,Million US$ at exchange rate,34.1
+7943,Croatia,2015,8,Total pharmaceutical sales,"/capita, US$ purchasing power parity",2685.0
+7944,Croatia,2015,8,M-Musculo-skeletal system,Million of national currency units,204.0
+7945,Croatia,2015,8,C02-Antihypertensives,"Million US$, purchasing power parity",105.1
+7946,Croatia,2015,8,N-Nervous system,Million US$ at exchange rate,892.1
+7947,Croatia,2015,8,G03-Sex hormones and modulators of the genital system,"/capita, US$ exchange rate",16.4
+7948,Croatia,2015,8,A10-Drugs used in diabetes,"/capita, US$ purchasing power parity",175.4
+7949,Croatia,2015,8,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ exchange rate",25.3
+7950,Croatia,2015,8,N02-Analgesics,"/capita, US$ purchasing power parity",95.3
+7951,Croatia,2015,8,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ purchasing power parity",65.8
+7952,Croatia,2015,8,A-Alimentary tract and metabolism,"/capita, US$ purchasing power parity",367.0
+7953,Croatia,2015,8,C02-Antihypertensives,Million US$ at exchange rate,53.8
+7954,Croatia,2015,8,R-Respiratory system,"/capita, US$ purchasing power parity",177.4
+7955,Croatia,2015,8,C-Cardiovascular system,Million US$ at exchange rate,859.1
+7956,Croatia,2015,8,Total pharmaceutical sales,"/capita, US$ exchange rate",1375.1
+7957,Croatia,2015,8,M-Musculo-skeletal system,"/capita, US$ purchasing power parity",104.0
+7958,Croatia,2015,8,R03-Drugs for obstructive airway diseases,Million US$ at exchange rate,238.4
+7959,Croatia,2015,8,C10-Lipid modifying agents,Million US$ at exchange rate,182.4
+7960,Croatia,2015,8,N05C-Hypnotics and sedatives,"/capita, US$ exchange rate",8.1
+7961,Croatia,2015,8,C-Cardiovascular system,"/capita, US$ purchasing power parity",398.6
+7962,Croatia,2015,8,Total pharmaceutical sales,Million of national currency units,5267.0
+7963,Croatia,2015,8,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ purchasing power parity",58.1
+7964,Croatia,2015,8,J01-Antibacterials for systemic use,"/capita, US$ exchange rate",77.5
+7965,Croatia,2015,8,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million of national currency units,97.0
+7966,Croatia,2015,8,B-Blood and blood forming organs,"/capita, US$ purchasing power parity",181.0
+7967,Croatia,2015,8,C10-Lipid modifying agents,"Million US$, purchasing power parity",356.1
+7968,Croatia,2015,8,C09-Agents acting on the Renin-Angiotensin system,Million US$ at exchange rate,349.4
+7969,Croatia,2015,8,A02A-Antacids,"/capita, US$ purchasing power parity",5.1
+7970,Croatia,2015,8,C03-Diuretics,Million US$ at exchange rate,52.7
+7971,Croatia,2015,8,A10-Drugs used in diabetes,"/capita, US$ exchange rate",89.8
+7972,Croatia,2015,8,J-Antiinfectives for systemic use,"/capita, US$ exchange rate",107.3
+7973,Croatia,2015,8,C09-Agents acting on the Renin-Angiotensin system,% of total sales,6.0
+7974,Croatia,2015,8,A10-Drugs used in diabetes,% of total sales,6.5
+7975,Croatia,2015,8,G03-Sex hormones and modulators of the genital system,% of total sales,1.2
+7976,Croatia,2015,8,C01A-Cardiac glycosides,Million US$ at exchange rate,5.5
+7977,Croatia,2015,8,R03-Drugs for obstructive airway diseases,"/capita, US$ purchasing power parity",110.6
+7978,Croatia,2015,8,A-Alimentary tract and metabolism,"/capita, US$ exchange rate",188.0
+7979,Croatia,2015,8,N02-Analgesics,"Million US$, purchasing power parity",401.1
+7980,Croatia,2015,8,C03-Diuretics,"/capita, US$ exchange rate",12.5
+7981,Croatia,2015,8,C08-Calcium channel blockers,Million of national currency units,102.0
+7982,Croatia,2015,8,C-Cardiovascular system,"Million US$, purchasing power parity",1677.5
+7983,Croatia,2015,8,C07-Beta blocking agents,"/capita, US$ purchasing power parity",45.4
+7984,Croatia,2015,8,N05B-Anxiolytics,Million of national currency units,91.0
+7985,Croatia,2015,8,J01-Antibacterials for systemic use,Million US$ at exchange rate,326.3
+7986,Croatia,2015,8,"C01B-Antiarrhythmics, Class I and III","/capita, US$ purchasing power parity",8.7
+7987,Croatia,2015,8,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ exchange rate",33.7
+7988,Croatia,2015,8,"H-Systemic hormonal preparations, excluding sex hormones and insulins","Million US$, purchasing power parity",208.1
+7989,Croatia,2015,8,N05B-Anxiolytics,"/capita, US$ exchange rate",23.8
+7990,Croatia,2015,8,G-Genito urinary system and sex hormones,Million of national currency units,165.0
+7991,Croatia,2015,8,N05C-Hypnotics and sedatives,"/capita, US$ purchasing power parity",15.8
+7992,Croatia,2015,8,M-Musculo-skeletal system,% of total sales,3.9
+7993,Croatia,2015,8,C10-Lipid modifying agents,% of total sales,3.2
+7994,Croatia,2015,8,"H-Systemic hormonal preparations, excluding sex hormones and insulins",% of total sales,1.8
+7995,Croatia,2015,8,N06A-Antidepressants,% of total sales,1.5
+7996,Croatia,2015,8,C-Cardiovascular system,% of total sales,14.8
+7997,Croatia,2015,8,N02-Analgesics,% of total sales,3.6
+7998,Croatia,2015,8,C02-Antihypertensives,% of total sales,0.9
+7999,Croatia,2015,8,C08-Calcium channel blockers,% of total sales,1.9
+8000,Croatia,2015,8,G-Genito urinary system and sex hormones,% of total sales,3.1
+8001,Croatia,2015,8,M01A-Antiinflammatory and antirheumatic products non-steroids,% of total sales,2.4
+8002,Croatia,2015,8,J-Antiinfectives for systemic use,% of total sales,7.8
+8003,Croatia,2015,8,A-Alimentary tract and metabolism,% of total sales,13.7
+8004,Croatia,2015,8,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),% of total sales,2.2
+8005,Croatia,2015,8,R-Respiratory system,% of total sales,6.6
+8006,Croatia,2015,8,"C01B-Antiarrhythmics, Class I and III",% of total sales,0.3
+8007,Croatia,2015,8,B-Blood and blood forming organs,% of total sales,6.7
+8008,Croatia,2015,8,N05B-Anxiolytics,% of total sales,1.7
+8009,Croatia,2015,8,C03-Diuretics,% of total sales,0.9
+8010,Croatia,2015,8,C01A-Cardiac glycosides,% of total sales,0.1
+8011,Croatia,2015,8,N05C-Hypnotics and sedatives,% of total sales,0.6
+8012,Croatia,2015,8,J01-Antibacterials for systemic use,% of total sales,5.6
+8013,Croatia,2015,8,N-Nervous system,% of total sales,15.4
+8014,Croatia,2015,8,R03-Drugs for obstructive airway diseases,% of total sales,4.1
+8015,Croatia,2015,8,C07-Beta blocking agents,% of total sales,1.7
+8016,Croatia,2015,8,A02A-Antacids,% of total sales,0.2
+8017,Croatia,2015,8,"C01B-Antiarrhythmics, Class I and III","Million US$, purchasing power parity",36.5
+8018,Croatia,2015,8,G03-Sex hormones and modulators of the genital system,"/capita, US$ purchasing power parity",32.1
+8019,Croatia,2015,8,C08-Calcium channel blockers,"/capita, US$ exchange rate",26.6
+8020,Croatia,2015,8,G-Genito urinary system and sex hormones,"/capita, US$ exchange rate",43.1
+8021,Croatia,2015,8,B-Blood and blood forming organs,"Million US$, purchasing power parity",761.5
+8022,Croatia,2015,8,N05B-Anxiolytics,Million US$ at exchange rate,100.0
+8023,Croatia,2015,8,N05C-Hypnotics and sedatives,"Million US$, purchasing power parity",66.5
+8024,Croatia,2015,8,G-Genito urinary system and sex hormones,Million US$ at exchange rate,181.3
+8025,Croatia,2015,8,N02-Analgesics,"/capita, US$ exchange rate",48.8
+8026,Croatia,2015,8,N06A-Antidepressants,"/capita, US$ exchange rate",21.1
+8027,Croatia,2015,8,M01A-Antiinflammatory and antirheumatic products non-steroids,Million US$ at exchange rate,141.7
+8028,Croatia,2015,8,C02-Antihypertensives,"/capita, US$ exchange rate",12.8
+8029,Croatia,2015,8,A10-Drugs used in diabetes,Million US$ at exchange rate,377.9
+8030,Croatia,2015,8,N-Nervous system,"/capita, US$ purchasing power parity",413.9
+8031,Croatia,2015,8,C09-Agents acting on the Renin-Angiotensin system,Million of national currency units,318.0
+8032,Croatia,2015,8,R03-Drugs for obstructive airway diseases,"Million US$, purchasing power parity",465.5
+8033,Croatia,2015,8,M-Musculo-skeletal system,Million US$ at exchange rate,224.1
+8034,Croatia,2015,8,C07-Beta blocking agents,"/capita, US$ exchange rate",23.2
+8035,Croatia,2015,8,C01A-Cardiac glycosides,"Million US$, purchasing power parity",10.7
+8036,Croatia,2015,8,J01-Antibacterials for systemic use,"/capita, US$ purchasing power parity",151.4
+8037,Croatia,2015,8,R-Respiratory system,Million US$ at exchange rate,382.3
+8038,Croatia,2015,8,J01-Antibacterials for systemic use,Million of national currency units,297.0
+8039,Croatia,2015,8,A-Alimentary tract and metabolism,Million US$ at exchange rate,791.0
+8040,Croatia,2015,8,C07-Beta blocking agents,"Million US$, purchasing power parity",190.9
+8041,Croatia,2015,8,G03-Sex hormones and modulators of the genital system,Million of national currency units,63.0
+8042,Croatia,2015,8,N05C-Hypnotics and sedatives,Million of national currency units,31.0
+8043,Croatia,2015,8,Total pharmaceutical sales,"Million US$, purchasing power parity",11298.4
+8044,Croatia,2015,8,A-Alimentary tract and metabolism,Million of national currency units,720.0
+8045,Croatia,2015,8,J-Antiinfectives for systemic use,Million of national currency units,411.0
+8046,Croatia,2015,8,N06A-Antidepressants,"Million US$, purchasing power parity",173.8
+8047,Croatia,2015,8,G03-Sex hormones and modulators of the genital system,Million US$ at exchange rate,69.2
+8048,Croatia,2015,8,C01A-Cardiac glycosides,"/capita, US$ exchange rate",1.3
+8049,Croatia,2015,8,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ purchasing power parity",49.4
+8050,Croatia,2015,8,C10-Lipid modifying agents,"/capita, US$ purchasing power parity",84.6
+8051,Croatia,2015,8,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"Million US$, purchasing power parity",244.5
+8052,Croatia,2015,8,M-Musculo-skeletal system,"Million US$, purchasing power parity",437.6
+8053,Croatia,2015,8,A10-Drugs used in diabetes,Million of national currency units,344.0
+8054,Croatia,2015,8,M01A-Antiinflammatory and antirheumatic products non-steroids,Million of national currency units,129.0
+8055,Croatia,2015,8,J01-Antibacterials for systemic use,"Million US$, purchasing power parity",637.1
+8056,Croatia,2015,8,A02A-Antacids,"Million US$, purchasing power parity",21.5
+8057,Croatia,2015,8,C01A-Cardiac glycosides,Million of national currency units,5.0
+8058,Croatia,2015,8,C-Cardiovascular system,"/capita, US$ exchange rate",204.2
+8059,Croatia,2015,8,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ exchange rate",29.8
+8060,Croatia,2015,8,C08-Calcium channel blockers,Million US$ at exchange rate,112.1
+8061,Croatia,2015,8,C03-Diuretics,Million of national currency units,48.0
+8062,Croatia,2015,8,R-Respiratory system,"/capita, US$ exchange rate",90.9
+8063,Croatia,2015,8,R-Respiratory system,Million of national currency units,348.0
+8064,Croatia,2015,8,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ purchasing power parity",162.1
+8065,Croatia,2015,8,J-Antiinfectives for systemic use,Million US$ at exchange rate,451.5
+8066,Croatia,2015,8,C03-Diuretics,"/capita, US$ purchasing power parity",24.5
+8067,Croatia,2015,8,N-Nervous system,"Million US$, purchasing power parity",1741.8
+8068,Croatia,2014,8,C07-Beta blocking agents,Million US$ at exchange rate,119.3
+8069,Croatia,2014,8,C02-Antihypertensives,"/capita, US$ purchasing power parity",26.1
+8070,Croatia,2014,8,A10-Drugs used in diabetes,"Million US$, purchasing power parity",674.0
+8071,Croatia,2014,8,N-Nervous system,"/capita, US$ exchange rate",246.0
+8072,Croatia,2014,8,G-Genito urinary system and sex hormones,"Million US$, purchasing power parity",340.2
+8073,Croatia,2014,8,B-Blood and blood forming organs,"/capita, US$ exchange rate",93.8
+8074,Croatia,2014,8,A-Alimentary tract and metabolism,"Million US$, purchasing power parity",1471.4
+8075,Croatia,2014,8,"C01B-Antiarrhythmics, Class I and III","/capita, US$ exchange rate",5.0
+8076,Croatia,2014,8,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million US$ at exchange rate,118.0
+8077,Croatia,2014,8,"C01B-Antiarrhythmics, Class I and III",Million of national currency units,16.0
+8078,Croatia,2014,8,C07-Beta blocking agents,Million of national currency units,91.0
+8079,Croatia,2014,8,J-Antiinfectives for systemic use,"/capita, US$ purchasing power parity",204.8
+8080,Croatia,2014,8,A02A-Antacids,Million of national currency units,10.0
+8081,Croatia,2014,8,R-Respiratory system,"Million US$, purchasing power parity",686.8
+8082,Croatia,2014,8,R03-Drugs for obstructive airway diseases,"/capita, US$ exchange rate",65.3
+8083,Croatia,2014,8,Total pharmaceutical sales,Million US$ at exchange rate,6561.7
+8084,Croatia,2014,8,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million US$ at exchange rate,165.2
+8085,Croatia,2014,8,C10-Lipid modifying agents,"/capita, US$ exchange rate",45.8
+8086,Croatia,2014,8,C-Cardiovascular system,Million of national currency units,778.0
+8087,Croatia,2014,8,N-Nervous system,Million of national currency units,795.0
+8088,Croatia,2014,8,N05B-Anxiolytics,"Million US$, purchasing power parity",191.4
+8089,Croatia,2014,8,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million of national currency units,126.0
+8090,Croatia,2014,8,A02A-Antacids,"/capita, US$ exchange rate",3.1
+8091,Croatia,2014,8,M01A-Antiinflammatory and antirheumatic products non-steroids,"Million US$, purchasing power parity",267.9
+8092,Croatia,2014,8,J-Antiinfectives for systemic use,"Million US$, purchasing power parity",867.5
+8093,Croatia,2014,8,C08-Calcium channel blockers,"/capita, US$ purchasing power parity",57.2
+8094,Croatia,2014,8,B-Blood and blood forming organs,Million of national currency units,303.0
+8095,Croatia,2014,8,N02-Analgesics,Million US$ at exchange rate,242.5
+8096,Croatia,2014,8,G-Genito urinary system and sex hormones,"/capita, US$ purchasing power parity",80.3
+8097,Croatia,2014,8,N06A-Antidepressants,"/capita, US$ purchasing power parity",41.2
+8098,Croatia,2014,8,N02-Analgesics,Million of national currency units,185.0
+8099,Croatia,2014,8,N06A-Antidepressants,Million of national currency units,82.0
+8100,Croatia,2014,8,C02-Antihypertensives,Million of national currency units,52.0
+8101,Croatia,2014,8,R-Respiratory system,"/capita, US$ purchasing power parity",162.1
+8102,Croatia,2014,8,C09-Agents acting on the Renin-Angiotensin system,"Million US$, purchasing power parity",686.8
+8103,Croatia,2014,8,C10-Lipid modifying agents,Million of national currency units,148.0
+8104,Croatia,2014,8,B-Blood and blood forming organs,Million US$ at exchange rate,397.2
+8105,Croatia,2014,8,C01A-Cardiac glycosides,"/capita, US$ purchasing power parity",2.5
+8106,Croatia,2014,8,R03-Drugs for obstructive airway diseases,Million of national currency units,211.0
+8107,Croatia,2014,8,G03-Sex hormones and modulators of the genital system,"Million US$, purchasing power parity",129.7
+8108,Croatia,2014,8,M-Musculo-skeletal system,"/capita, US$ exchange rate",61.6
+8109,Croatia,2014,8,C03-Diuretics,"Million US$, purchasing power parity",95.7
+8110,Croatia,2014,8,N05B-Anxiolytics,"/capita, US$ purchasing power parity",45.2
+8111,Croatia,2014,8,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ exchange rate",99.9
+8112,Croatia,2014,8,A02A-Antacids,Million US$ at exchange rate,13.1
+8113,Croatia,2014,8,N05C-Hypnotics and sedatives,Million US$ at exchange rate,39.3
+8114,Croatia,2014,8,"C01B-Antiarrhythmics, Class I and III",Million US$ at exchange rate,21.0
+8115,Croatia,2014,8,Total pharmaceutical sales,"/capita, US$ purchasing power parity",2512.8
+8116,Croatia,2014,8,M-Musculo-skeletal system,Million of national currency units,199.0
+8117,Croatia,2014,8,C02-Antihypertensives,"Million US$, purchasing power parity",110.6
+8118,Croatia,2014,8,N-Nervous system,Million US$ at exchange rate,1042.1
+8119,Croatia,2014,8,G03-Sex hormones and modulators of the genital system,"/capita, US$ exchange rate",18.9
+8120,Croatia,2014,8,A10-Drugs used in diabetes,"/capita, US$ purchasing power parity",159.1
+8121,Croatia,2014,8,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ exchange rate",27.8
+8122,Croatia,2014,8,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ purchasing power parity",63.2
+8123,Croatia,2014,8,N02-Analgesics,"/capita, US$ purchasing power parity",92.9
+8124,Croatia,2014,8,C08-Calcium channel blockers,"Million US$, purchasing power parity",242.4
+8125,Croatia,2014,8,A-Alimentary tract and metabolism,"/capita, US$ purchasing power parity",347.3
+8126,Croatia,2014,8,C02-Antihypertensives,Million US$ at exchange rate,68.2
+8127,Croatia,2014,8,C-Cardiovascular system,Million US$ at exchange rate,1019.8
+8128,Croatia,2014,8,Total pharmaceutical sales,"/capita, US$ exchange rate",1549.0
+8129,Croatia,2014,8,M-Musculo-skeletal system,"/capita, US$ purchasing power parity",99.9
+8130,Croatia,2014,8,R03-Drugs for obstructive airway diseases,Million US$ at exchange rate,276.6
+8131,Croatia,2014,8,N05C-Hypnotics and sedatives,"/capita, US$ exchange rate",9.3
+8132,Croatia,2014,8,C10-Lipid modifying agents,Million US$ at exchange rate,194.0
+8133,Croatia,2014,8,C-Cardiovascular system,"/capita, US$ purchasing power parity",390.5
+8134,Croatia,2014,8,Total pharmaceutical sales,Million of national currency units,5006.0
+8135,Croatia,2014,8,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ purchasing power parity",63.2
+8136,Croatia,2014,8,N06A-Antidepressants,Million US$ at exchange rate,107.5
+8137,Croatia,2014,8,J01-Antibacterials for systemic use,"/capita, US$ exchange rate",89.1
+8138,Croatia,2014,8,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million of national currency units,90.0
+8139,Croatia,2014,8,N05C-Hypnotics and sedatives,Million of national currency units,30.0
+8140,Croatia,2014,8,B-Blood and blood forming organs,"/capita, US$ purchasing power parity",152.1
+8141,Croatia,2014,8,C10-Lipid modifying agents,"Million US$, purchasing power parity",314.7
+8142,Croatia,2014,8,C09-Agents acting on the Renin-Angiotensin system,Million US$ at exchange rate,423.4
+8143,Croatia,2014,8,A02A-Antacids,"/capita, US$ purchasing power parity",5.0
+8144,Croatia,2014,8,A10-Drugs used in diabetes,"/capita, US$ exchange rate",98.1
+8145,Croatia,2014,8,C03-Diuretics,Million US$ at exchange rate,59.0
+8146,Croatia,2014,8,C09-Agents acting on the Renin-Angiotensin system,% of total sales,6.5
+8147,Croatia,2014,8,G03-Sex hormones and modulators of the genital system,% of total sales,1.2
+8148,Croatia,2014,8,R03-Drugs for obstructive airway diseases,"/capita, US$ purchasing power parity",105.9
+8149,Croatia,2014,8,C01A-Cardiac glycosides,Million US$ at exchange rate,6.6
+8150,Croatia,2014,8,J-Antiinfectives for systemic use,"/capita, US$ exchange rate",126.2
+8151,Croatia,2014,8,A-Alimentary tract and metabolism,"/capita, US$ exchange rate",214.1
+8152,Croatia,2014,8,A10-Drugs used in diabetes,% of total sales,6.3
+8153,Croatia,2014,8,N02-Analgesics,"Million US$, purchasing power parity",393.4
+8154,Croatia,2014,8,C-Cardiovascular system,"Million US$, purchasing power parity",1654.3
+8155,Croatia,2014,8,C03-Diuretics,"/capita, US$ exchange rate",13.9
+8156,Croatia,2014,8,C07-Beta blocking agents,"/capita, US$ purchasing power parity",45.7
+8157,Croatia,2014,8,N05B-Anxiolytics,Million of national currency units,90.0
+8158,Croatia,2014,8,J01-Antibacterials for systemic use,Million US$ at exchange rate,377.5
+8159,Croatia,2014,8,C08-Calcium channel blockers,Million of national currency units,114.0
+8160,Croatia,2014,8,"C01B-Antiarrhythmics, Class I and III","/capita, US$ purchasing power parity",8.0
+8161,Croatia,2014,8,"H-Systemic hormonal preparations, excluding sex hormones and insulins","Million US$, purchasing power parity",191.4
+8162,Croatia,2014,8,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ exchange rate",39.0
+8163,Croatia,2014,8,N05B-Anxiolytics,"/capita, US$ exchange rate",27.8
+8164,Croatia,2014,8,G-Genito urinary system and sex hormones,Million of national currency units,160.0
+8165,Croatia,2014,8,N05C-Hypnotics and sedatives,"/capita, US$ purchasing power parity",15.1
+8166,Croatia,2014,8,M-Musculo-skeletal system,% of total sales,4.0
+8167,Croatia,2014,8,C10-Lipid modifying agents,% of total sales,3.0
+8168,Croatia,2014,8,"H-Systemic hormonal preparations, excluding sex hormones and insulins",% of total sales,1.8
+8169,Croatia,2014,8,C-Cardiovascular system,% of total sales,15.5
+8170,Croatia,2014,8,N06A-Antidepressants,% of total sales,1.6
+8171,Croatia,2014,8,N02-Analgesics,% of total sales,3.7
+8172,Croatia,2014,8,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),% of total sales,2.5
+8173,Croatia,2014,8,C02-Antihypertensives,% of total sales,1.0
+8174,Croatia,2014,8,G-Genito urinary system and sex hormones,% of total sales,3.2
+8175,Croatia,2014,8,C08-Calcium channel blockers,% of total sales,2.3
+8176,Croatia,2014,8,M01A-Antiinflammatory and antirheumatic products non-steroids,% of total sales,2.5
+8177,Croatia,2014,8,A-Alimentary tract and metabolism,% of total sales,13.8
+8178,Croatia,2014,8,J-Antiinfectives for systemic use,% of total sales,8.2
+8179,Croatia,2014,8,R-Respiratory system,% of total sales,6.5
+8180,Croatia,2014,8,B-Blood and blood forming organs,% of total sales,6.1
+8181,Croatia,2014,8,"C01B-Antiarrhythmics, Class I and III",% of total sales,0.3
+8182,Croatia,2014,8,N05B-Anxiolytics,% of total sales,1.8
+8183,Croatia,2014,8,C03-Diuretics,% of total sales,0.9
+8184,Croatia,2014,8,C01A-Cardiac glycosides,% of total sales,0.1
+8185,Croatia,2014,8,N05C-Hypnotics and sedatives,% of total sales,0.6
+8186,Croatia,2014,8,J01-Antibacterials for systemic use,% of total sales,5.8
+8187,Croatia,2014,8,N-Nervous system,% of total sales,15.9
+8188,Croatia,2014,8,R03-Drugs for obstructive airway diseases,% of total sales,4.2
+8189,Croatia,2014,8,C07-Beta blocking agents,% of total sales,1.8
+8190,Croatia,2014,8,A02A-Antacids,% of total sales,0.2
+8191,Croatia,2014,8,"C01B-Antiarrhythmics, Class I and III","Million US$, purchasing power parity",34.0
+8192,Croatia,2014,8,G03-Sex hormones and modulators of the genital system,"/capita, US$ purchasing power parity",30.6
+8193,Croatia,2014,8,C08-Calcium channel blockers,"/capita, US$ exchange rate",35.3
+8194,Croatia,2014,8,G-Genito urinary system and sex hormones,"/capita, US$ exchange rate",49.5
+8195,Croatia,2014,8,B-Blood and blood forming organs,"Million US$, purchasing power parity",644.3
+8196,Croatia,2014,8,N05B-Anxiolytics,Million US$ at exchange rate,118.0
+8197,Croatia,2014,8,G-Genito urinary system and sex hormones,Million US$ at exchange rate,209.7
+8198,Croatia,2014,8,N02-Analgesics,"/capita, US$ exchange rate",57.2
+8199,Croatia,2014,8,N06A-Antidepressants,"/capita, US$ exchange rate",25.4
+8200,Croatia,2014,8,N05C-Hypnotics and sedatives,"Million US$, purchasing power parity",63.8
+8201,Croatia,2014,8,C02-Antihypertensives,"/capita, US$ exchange rate",16.1
+8202,Croatia,2014,8,M01A-Antiinflammatory and antirheumatic products non-steroids,Million US$ at exchange rate,165.2
+8203,Croatia,2014,8,A10-Drugs used in diabetes,Million US$ at exchange rate,415.5
+8204,Croatia,2014,8,N-Nervous system,"/capita, US$ purchasing power parity",399.0
+8205,Croatia,2014,8,C09-Agents acting on the Renin-Angiotensin system,Million of national currency units,323.0
+8206,Croatia,2014,8,R03-Drugs for obstructive airway diseases,"Million US$, purchasing power parity",448.6
+8207,Croatia,2014,8,C07-Beta blocking agents,"/capita, US$ exchange rate",28.2
+8208,Croatia,2014,8,M-Musculo-skeletal system,Million US$ at exchange rate,260.8
+8209,Croatia,2014,8,C01A-Cardiac glycosides,"Million US$, purchasing power parity",10.6
+8210,Croatia,2014,8,J01-Antibacterials for systemic use,"/capita, US$ purchasing power parity",144.6
+8211,Croatia,2014,8,R-Respiratory system,Million US$ at exchange rate,423.4
+8212,Croatia,2014,8,J01-Antibacterials for systemic use,Million of national currency units,288.0
+8213,Croatia,2014,8,A-Alimentary tract and metabolism,Million US$ at exchange rate,907.0
+8214,Croatia,2014,8,G03-Sex hormones and modulators of the genital system,Million of national currency units,61.0
+8215,Croatia,2014,8,C07-Beta blocking agents,"Million US$, purchasing power parity",193.5
+8216,Croatia,2014,8,Total pharmaceutical sales,"Million US$, purchasing power parity",10644.2
+8217,Croatia,2014,8,J-Antiinfectives for systemic use,Million of national currency units,408.0
+8218,Croatia,2014,8,A-Alimentary tract and metabolism,Million of national currency units,692.0
+8219,Croatia,2014,8,N06A-Antidepressants,"Million US$, purchasing power parity",174.4
+8220,Croatia,2014,8,G03-Sex hormones and modulators of the genital system,Million US$ at exchange rate,80.0
+8221,Croatia,2014,8,C01A-Cardiac glycosides,"/capita, US$ exchange rate",1.5
+8222,Croatia,2014,8,C10-Lipid modifying agents,"/capita, US$ purchasing power parity",74.3
+8223,Croatia,2014,8,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ purchasing power parity",45.2
+8224,Croatia,2014,8,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"Million US$, purchasing power parity",267.9
+8225,Croatia,2014,8,M-Musculo-skeletal system,"Million US$, purchasing power parity",423.1
+8226,Croatia,2014,8,M01A-Antiinflammatory and antirheumatic products non-steroids,Million of national currency units,126.0
+8227,Croatia,2014,8,A10-Drugs used in diabetes,Million of national currency units,317.0
+8228,Croatia,2014,8,R-Respiratory system,"/capita, US$ exchange rate",99.9
+8229,Croatia,2014,8,A02A-Antacids,"Million US$, purchasing power parity",21.3
+8230,Croatia,2014,8,J01-Antibacterials for systemic use,"Million US$, purchasing power parity",612.4
+8231,Croatia,2014,8,C01A-Cardiac glycosides,Million of national currency units,5.0
+8232,Croatia,2014,8,C-Cardiovascular system,"/capita, US$ exchange rate",240.7
+8233,Croatia,2014,8,C08-Calcium channel blockers,Million US$ at exchange rate,149.4
+8234,Croatia,2014,8,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ exchange rate",39.0
+8235,Croatia,2014,8,C03-Diuretics,Million of national currency units,45.0
+8236,Croatia,2014,8,R-Respiratory system,Million of national currency units,323.0
+8237,Croatia,2014,8,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ purchasing power parity",162.1
+8238,Croatia,2014,8,J-Antiinfectives for systemic use,Million US$ at exchange rate,534.8
+8239,Croatia,2014,8,C03-Diuretics,"/capita, US$ purchasing power parity",22.6
+8240,Croatia,2014,8,N-Nervous system,"Million US$, purchasing power parity",1690.4
+8241,Croatia,2013,9,C07-Beta blocking agents,Million US$ at exchange rate,124.1
+8242,Croatia,2013,9,C02-Antihypertensives,"/capita, US$ purchasing power parity",26.3
+8243,Croatia,2013,9,A10-Drugs used in diabetes,"Million US$, purchasing power parity",636.5
+8244,Croatia,2013,9,N-Nervous system,"/capita, US$ exchange rate",251.8
+8245,Croatia,2013,9,G-Genito urinary system and sex hormones,"Million US$, purchasing power parity",339.3
+8246,Croatia,2013,9,B-Blood and blood forming organs,"/capita, US$ exchange rate",89.1
+8247,Croatia,2013,9,A-Alimentary tract and metabolism,"Million US$, purchasing power parity",1502.6
+8248,Croatia,2013,9,"C01B-Antiarrhythmics, Class I and III","/capita, US$ exchange rate",5.6
+8249,Croatia,2013,9,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million US$ at exchange rate,117.5
+8250,Croatia,2013,9,"C01B-Antiarrhythmics, Class I and III",Million of national currency units,18.0
+8251,Croatia,2013,9,C07-Beta blocking agents,Million of national currency units,94.0
+8252,Croatia,2013,9,R-Respiratory system,"Million US$, purchasing power parity",699.7
+8253,Croatia,2013,9,J-Antiinfectives for systemic use,"/capita, US$ purchasing power parity",212.5
+8254,Croatia,2013,9,A02A-Antacids,Million of national currency units,9.0
+8255,Croatia,2013,9,R03-Drugs for obstructive airway diseases,"/capita, US$ exchange rate",63.6
+8256,Croatia,2013,9,Total pharmaceutical sales,Million US$ at exchange rate,6845.2
+8257,Croatia,2013,9,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million US$ at exchange rate,215.3
+8258,Croatia,2013,9,C10-Lipid modifying agents,"/capita, US$ exchange rate",69.5
+8259,Croatia,2013,9,C-Cardiovascular system,Million of national currency units,946.0
+8260,Croatia,2013,9,N-Nervous system,Million of national currency units,811.0
+8261,Croatia,2013,9,N05B-Anxiolytics,"Million US$, purchasing power parity",185.5
+8262,Croatia,2013,9,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million of national currency units,163.0
+8263,Croatia,2013,9,A02A-Antacids,"/capita, US$ exchange rate",2.8
+8264,Croatia,2013,9,M01A-Antiinflammatory and antirheumatic products non-steroids,"Million US$, purchasing power parity",248.7
+8265,Croatia,2013,9,J-Antiinfectives for systemic use,"Million US$, purchasing power parity",904.1
+8266,Croatia,2013,9,B-Blood and blood forming organs,Million of national currency units,287.0
+8267,Croatia,2013,9,C08-Calcium channel blockers,"/capita, US$ purchasing power parity",60.9
+8268,Croatia,2013,9,N02-Analgesics,Million US$ at exchange rate,249.6
+8269,Croatia,2013,9,G-Genito urinary system and sex hormones,"/capita, US$ purchasing power parity",79.8
+8270,Croatia,2013,9,N06A-Antidepressants,"/capita, US$ purchasing power parity",41.6
+8271,Croatia,2013,9,N02-Analgesics,Million of national currency units,189.0
+8272,Croatia,2013,9,N06A-Antidepressants,Million of national currency units,84.0
+8273,Croatia,2013,9,C02-Antihypertensives,Million of national currency units,53.0
+8274,Croatia,2013,9,C09-Agents acting on the Renin-Angiotensin system,"Million US$, purchasing power parity",687.0
+8275,Croatia,2013,9,C10-Lipid modifying agents,Million of national currency units,224.0
+8276,Croatia,2013,9,C01A-Cardiac glycosides,"/capita, US$ purchasing power parity",2.0
+8277,Croatia,2013,9,B-Blood and blood forming organs,Million US$ at exchange rate,379.0
+8278,Croatia,2013,9,R03-Drugs for obstructive airway diseases,Million of national currency units,205.0
+8279,Croatia,2013,9,G03-Sex hormones and modulators of the genital system,"Million US$, purchasing power parity",130.7
+8280,Croatia,2013,9,M-Musculo-skeletal system,"/capita, US$ exchange rate",64.6
+8281,Croatia,2013,9,C03-Diuretics,"Million US$, purchasing power parity",92.7
+8282,Croatia,2013,9,N05B-Anxiolytics,"/capita, US$ purchasing power parity",43.6
+8283,Croatia,2013,9,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ exchange rate",101.2
+8284,Croatia,2013,9,A02A-Antacids,Million US$ at exchange rate,11.9
+8285,Croatia,2013,9,"C01B-Antiarrhythmics, Class I and III",Million US$ at exchange rate,23.8
+8286,Croatia,2013,9,N05C-Hypnotics and sedatives,Million US$ at exchange rate,38.3
+8287,Croatia,2013,9,Total pharmaceutical sales,"/capita, US$ purchasing power parity",2567.4
+8288,Croatia,2013,9,M-Musculo-skeletal system,Million of national currency units,208.0
+8289,Croatia,2013,9,C02-Antihypertensives,"Million US$, purchasing power parity",111.7
+8290,Croatia,2013,9,N-Nervous system,Million US$ at exchange rate,1071.1
+8291,Croatia,2013,9,G03-Sex hormones and modulators of the genital system,"/capita, US$ exchange rate",19.2
+8292,Croatia,2013,9,R-Respiratory system,"/capita, US$ purchasing power parity",164.5
+8293,Croatia,2013,9,A10-Drugs used in diabetes,"/capita, US$ purchasing power parity",149.6
+8294,Croatia,2013,9,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ exchange rate",27.6
+8295,Croatia,2013,9,N02-Analgesics,"/capita, US$ purchasing power parity",93.6
+8296,Croatia,2013,9,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ purchasing power parity",58.5
+8297,Croatia,2013,9,C08-Calcium channel blockers,"Million US$, purchasing power parity",259.2
+8298,Croatia,2013,9,A-Alimentary tract and metabolism,"/capita, US$ purchasing power parity",353.2
+8299,Croatia,2013,9,C02-Antihypertensives,Million US$ at exchange rate,70.0
+8300,Croatia,2013,9,C-Cardiovascular system,Million US$ at exchange rate,1249.4
+8301,Croatia,2013,9,Total pharmaceutical sales,"/capita, US$ exchange rate",1609.0
+8302,Croatia,2013,9,M-Musculo-skeletal system,"/capita, US$ purchasing power parity",103.0
+8303,Croatia,2013,9,R03-Drugs for obstructive airway diseases,Million US$ at exchange rate,270.7
+8304,Croatia,2013,9,C10-Lipid modifying agents,Million US$ at exchange rate,295.8
+8305,Croatia,2013,9,N05C-Hypnotics and sedatives,"/capita, US$ exchange rate",9.0
+8306,Croatia,2013,9,C-Cardiovascular system,"/capita, US$ purchasing power parity",468.6
+8307,Croatia,2013,9,Total pharmaceutical sales,Million of national currency units,5183.0
+8308,Croatia,2013,9,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ purchasing power parity",80.7
+8309,Croatia,2013,9,N06A-Antidepressants,Million US$ at exchange rate,110.9
+8310,Croatia,2013,9,J01-Antibacterials for systemic use,"/capita, US$ exchange rate",91.6
+8311,Croatia,2013,9,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million of national currency units,89.0
+8312,Croatia,2013,9,C10-Lipid modifying agents,"Million US$, purchasing power parity",472.1
+8313,Croatia,2013,9,B-Blood and blood forming organs,"/capita, US$ purchasing power parity",142.2
+8314,Croatia,2013,9,C09-Agents acting on the Renin-Angiotensin system,Million US$ at exchange rate,430.6
+8315,Croatia,2013,9,A02A-Antacids,"/capita, US$ purchasing power parity",4.5
+8316,Croatia,2013,9,A10-Drugs used in diabetes,"/capita, US$ exchange rate",93.7
+8317,Croatia,2013,9,C09-Agents acting on the Renin-Angiotensin system,% of total sales,6.3
+8318,Croatia,2013,9,R03-Drugs for obstructive airway diseases,"/capita, US$ purchasing power parity",101.5
+8319,Croatia,2013,9,G03-Sex hormones and modulators of the genital system,% of total sales,1.2
+8320,Croatia,2013,9,C01A-Cardiac glycosides,Million US$ at exchange rate,5.3
+8321,Croatia,2013,9,J-Antiinfectives for systemic use,"/capita, US$ exchange rate",133.2
+8322,Croatia,2013,9,A-Alimentary tract and metabolism,"/capita, US$ exchange rate",221.3
+8323,Croatia,2013,9,N02-Analgesics,"Million US$, purchasing power parity",398.3
+8324,Croatia,2013,9,C-Cardiovascular system,"Million US$, purchasing power parity",1993.7
+8325,Croatia,2013,9,C03-Diuretics,"/capita, US$ exchange rate",13.7
+8326,Croatia,2013,9,C07-Beta blocking agents,"/capita, US$ purchasing power parity",46.6
+8327,Croatia,2013,9,N05B-Anxiolytics,Million of national currency units,88.0
+8328,Croatia,2013,9,J01-Antibacterials for systemic use,Million US$ at exchange rate,389.6
+8329,Croatia,2013,9,"C01B-Antiarrhythmics, Class I and III","/capita, US$ purchasing power parity",8.9
+8330,Croatia,2013,9,"H-Systemic hormonal preparations, excluding sex hormones and insulins","Million US$, purchasing power parity",187.6
+8331,Croatia,2013,9,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ exchange rate",36.6
+8332,Croatia,2013,9,C08-Calcium channel blockers,Million of national currency units,123.0
+8333,Croatia,2013,9,G-Genito urinary system and sex hormones,Million of national currency units,161.0
+8334,Croatia,2013,9,N05B-Anxiolytics,"/capita, US$ exchange rate",27.3
+8335,Croatia,2013,9,N05C-Hypnotics and sedatives,"/capita, US$ purchasing power parity",14.4
+8336,Croatia,2013,9,A10-Drugs used in diabetes,% of total sales,5.8
+8337,Croatia,2013,9,M-Musculo-skeletal system,% of total sales,4.0
+8338,Croatia,2013,9,"H-Systemic hormonal preparations, excluding sex hormones and insulins",% of total sales,1.7
+8339,Croatia,2013,9,C10-Lipid modifying agents,% of total sales,4.3
+8340,Croatia,2013,9,N06A-Antidepressants,% of total sales,1.6
+8341,Croatia,2013,9,C-Cardiovascular system,% of total sales,18.3
+8342,Croatia,2013,9,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),% of total sales,3.1
+8343,Croatia,2013,9,N02-Analgesics,% of total sales,3.6
+8344,Croatia,2013,9,C02-Antihypertensives,% of total sales,1.0
+8345,Croatia,2013,9,C08-Calcium channel blockers,% of total sales,2.4
+8346,Croatia,2013,9,G-Genito urinary system and sex hormones,% of total sales,3.1
+8347,Croatia,2013,9,M01A-Antiinflammatory and antirheumatic products non-steroids,% of total sales,2.3
+8348,Croatia,2013,9,A-Alimentary tract and metabolism,% of total sales,13.8
+8349,Croatia,2013,9,J-Antiinfectives for systemic use,% of total sales,8.3
+8350,Croatia,2013,9,R-Respiratory system,% of total sales,6.4
+8351,Croatia,2013,9,"C01B-Antiarrhythmics, Class I and III",% of total sales,0.3
+8352,Croatia,2013,9,B-Blood and blood forming organs,% of total sales,5.5
+8353,Croatia,2013,9,N05B-Anxiolytics,% of total sales,1.7
+8354,Croatia,2013,9,C03-Diuretics,% of total sales,0.8
+8355,Croatia,2013,9,C01A-Cardiac glycosides,% of total sales,0.1
+8356,Croatia,2013,9,N05C-Hypnotics and sedatives,% of total sales,0.6
+8357,Croatia,2013,9,J01-Antibacterials for systemic use,% of total sales,5.7
+8358,Croatia,2013,9,N-Nervous system,% of total sales,15.6
+8359,Croatia,2013,9,R03-Drugs for obstructive airway diseases,% of total sales,4.0
+8360,Croatia,2013,9,C07-Beta blocking agents,% of total sales,1.8
+8361,Croatia,2013,9,A02A-Antacids,% of total sales,0.2
+8362,Croatia,2013,9,"C01B-Antiarrhythmics, Class I and III","Million US$, purchasing power parity",37.9
+8363,Croatia,2013,9,G03-Sex hormones and modulators of the genital system,"/capita, US$ purchasing power parity",30.7
+8364,Croatia,2013,9,C08-Calcium channel blockers,"/capita, US$ exchange rate",38.2
+8365,Croatia,2013,9,B-Blood and blood forming organs,"Million US$, purchasing power parity",604.8
+8366,Croatia,2013,9,G-Genito urinary system and sex hormones,"/capita, US$ exchange rate",50.0
+8367,Croatia,2013,9,N05B-Anxiolytics,Million US$ at exchange rate,116.2
+8368,Croatia,2013,9,N05C-Hypnotics and sedatives,"Million US$, purchasing power parity",61.1
+8369,Croatia,2013,9,G-Genito urinary system and sex hormones,Million US$ at exchange rate,212.6
+8370,Croatia,2013,9,N02-Analgesics,"/capita, US$ exchange rate",58.7
+8371,Croatia,2013,9,N06A-Antidepressants,"/capita, US$ exchange rate",26.1
+8372,Croatia,2013,9,M01A-Antiinflammatory and antirheumatic products non-steroids,Million US$ at exchange rate,155.8
+8373,Croatia,2013,9,C02-Antihypertensives,"/capita, US$ exchange rate",16.5
+8374,Croatia,2013,9,A10-Drugs used in diabetes,Million US$ at exchange rate,398.9
+8375,Croatia,2013,9,N-Nervous system,"/capita, US$ purchasing power parity",401.7
+8376,Croatia,2013,9,R03-Drugs for obstructive airway diseases,"Million US$, purchasing power parity",432.0
+8377,Croatia,2013,9,C09-Agents acting on the Renin-Angiotensin system,Million of national currency units,326.0
+8378,Croatia,2013,9,M-Musculo-skeletal system,Million US$ at exchange rate,274.7
+8379,Croatia,2013,9,C07-Beta blocking agents,"/capita, US$ exchange rate",29.2
+8380,Croatia,2013,9,N05C-Hypnotics and sedatives,Million of national currency units,29.0
+8381,Croatia,2013,9,C01A-Cardiac glycosides,"Million US$, purchasing power parity",8.4
+8382,Croatia,2013,9,J01-Antibacterials for systemic use,"/capita, US$ purchasing power parity",146.1
+8383,Croatia,2013,9,J01-Antibacterials for systemic use,Million of national currency units,295.0
+8384,Croatia,2013,9,R-Respiratory system,Million US$ at exchange rate,438.5
+8385,Croatia,2013,9,A-Alimentary tract and metabolism,Million US$ at exchange rate,941.7
+8386,Croatia,2013,9,G03-Sex hormones and modulators of the genital system,Million of national currency units,62.0
+8387,Croatia,2013,9,C07-Beta blocking agents,"Million US$, purchasing power parity",198.1
+8388,Croatia,2013,9,Total pharmaceutical sales,"Million US$, purchasing power parity",10923.1
+8389,Croatia,2013,9,J-Antiinfectives for systemic use,Million of national currency units,429.0
+8390,Croatia,2013,9,A-Alimentary tract and metabolism,Million of national currency units,713.0
+8391,Croatia,2013,9,G03-Sex hormones and modulators of the genital system,Million US$ at exchange rate,81.9
+8392,Croatia,2013,9,N06A-Antidepressants,"Million US$, purchasing power parity",177.0
+8393,Croatia,2013,9,C01A-Cardiac glycosides,"/capita, US$ exchange rate",1.2
+8394,Croatia,2013,9,C10-Lipid modifying agents,"/capita, US$ purchasing power parity",111.0
+8395,Croatia,2013,9,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ purchasing power parity",44.1
+8396,Croatia,2013,9,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"Million US$, purchasing power parity",343.5
+8397,Croatia,2013,9,M-Musculo-skeletal system,"Million US$, purchasing power parity",438.4
+8398,Croatia,2013,9,A10-Drugs used in diabetes,Million of national currency units,302.0
+8399,Croatia,2013,9,M01A-Antiinflammatory and antirheumatic products non-steroids,Million of national currency units,118.0
+8400,Croatia,2013,9,R-Respiratory system,"/capita, US$ exchange rate",103.1
+8401,Croatia,2013,9,A02A-Antacids,"Million US$, purchasing power parity",19.0
+8402,Croatia,2013,9,J01-Antibacterials for systemic use,"Million US$, purchasing power parity",621.7
+8403,Croatia,2013,9,C01A-Cardiac glycosides,Million of national currency units,4.0
+8404,Croatia,2013,9,C-Cardiovascular system,"/capita, US$ exchange rate",293.7
+8405,Croatia,2013,9,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ exchange rate",50.6
+8406,Croatia,2013,9,C08-Calcium channel blockers,Million US$ at exchange rate,162.4
+8407,Croatia,2013,9,C03-Diuretics,Million of national currency units,44.0
+8408,Croatia,2013,9,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ purchasing power parity",161.5
+8409,Croatia,2013,9,R-Respiratory system,Million of national currency units,332.0
+8410,Croatia,2013,9,J-Antiinfectives for systemic use,Million US$ at exchange rate,566.6
+8411,Croatia,2013,9,C03-Diuretics,"/capita, US$ purchasing power parity",21.8
+8412,Croatia,2013,9,N-Nervous system,"Million US$, purchasing power parity",1709.2
+8413,Croatia,2013,9,C03-Diuretics,Million US$ at exchange rate,58.1
+8414,Croatia,2012,8,C07-Beta blocking agents,Million US$ at exchange rate,124.9
+8415,Croatia,2012,8,A10-Drugs used in diabetes,"Million US$, purchasing power parity",571.6
+8416,Croatia,2012,8,C02-Antihypertensives,"/capita, US$ purchasing power parity",24.6
+8417,Croatia,2012,8,N-Nervous system,"/capita, US$ exchange rate",246.2
+8418,Croatia,2012,8,G-Genito urinary system and sex hormones,"Million US$, purchasing power parity",335.2
+8419,Croatia,2012,8,B-Blood and blood forming organs,"/capita, US$ exchange rate",85.1
+8420,Croatia,2012,8,A-Alimentary tract and metabolism,"Million US$, purchasing power parity",1455.8
+8421,Croatia,2012,8,A02A-Antacids,Million of national currency units,8.0
+8422,Croatia,2012,8,"C01B-Antiarrhythmics, Class I and III","/capita, US$ exchange rate",5.1
+8423,Croatia,2012,8,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million US$ at exchange rate,96.6
+8424,Croatia,2012,8,"C01B-Antiarrhythmics, Class I and III",Million of national currency units,17.0
+8425,Croatia,2012,8,C07-Beta blocking agents,Million of national currency units,97.0
+8426,Croatia,2012,8,R-Respiratory system,"Million US$, purchasing power parity",664.2
+8427,Croatia,2012,8,J-Antiinfectives for systemic use,"/capita, US$ purchasing power parity",206.2
+8428,Croatia,2012,8,R03-Drugs for obstructive airway diseases,"/capita, US$ exchange rate",60.6
+8429,Croatia,2012,8,Total pharmaceutical sales,Million US$ at exchange rate,6536.0
+8430,Croatia,2012,8,C10-Lipid modifying agents,"/capita, US$ exchange rate",74.5
+8431,Croatia,2012,8,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million US$ at exchange rate,258.9
+8432,Croatia,2012,8,C-Cardiovascular system,Million of national currency units,1005.0
+8433,Croatia,2012,8,N-Nervous system,Million of national currency units,816.0
+8434,Croatia,2012,8,N05B-Anxiolytics,"Million US$, purchasing power parity",183.0
+8435,Croatia,2012,8,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million of national currency units,201.0
+8436,Croatia,2012,8,A02A-Antacids,"/capita, US$ exchange rate",2.4
+8437,Croatia,2012,8,J-Antiinfectives for systemic use,"Million US$, purchasing power parity",880.1
+8438,Croatia,2012,8,M01A-Antiinflammatory and antirheumatic products non-steroids,"Million US$, purchasing power parity",232.4
+8439,Croatia,2012,8,B-Blood and blood forming organs,Million of national currency units,282.0
+8440,Croatia,2012,8,C08-Calcium channel blockers,"/capita, US$ purchasing power parity",66.0
+8441,Croatia,2012,8,N02-Analgesics,Million US$ at exchange rate,246.0
+8442,Croatia,2012,8,G-Genito urinary system and sex hormones,"/capita, US$ purchasing power parity",78.5
+8443,Croatia,2012,8,N06A-Antidepressants,"/capita, US$ purchasing power parity",41.4
+8444,Croatia,2012,8,N02-Analgesics,Million of national currency units,191.0
+8445,Croatia,2012,8,N06A-Antidepressants,Million of national currency units,86.0
+8446,Croatia,2012,8,C02-Antihypertensives,Million of national currency units,51.0
+8447,Croatia,2012,8,R-Respiratory system,"/capita, US$ purchasing power parity",155.6
+8448,Croatia,2012,8,C01A-Cardiac glycosides,"/capita, US$ purchasing power parity",2.4
+8449,Croatia,2012,8,C09-Agents acting on the Renin-Angiotensin system,"Million US$, purchasing power parity",738.2
+8450,Croatia,2012,8,C10-Lipid modifying agents,Million of national currency units,247.0
+8451,Croatia,2012,8,B-Blood and blood forming organs,Million US$ at exchange rate,363.2
+8452,Croatia,2012,8,R03-Drugs for obstructive airway diseases,Million of national currency units,201.0
+8453,Croatia,2012,8,G03-Sex hormones and modulators of the genital system,"Million US$, purchasing power parity",129.5
+8454,Croatia,2012,8,M-Musculo-skeletal system,"/capita, US$ exchange rate",61.8
+8455,Croatia,2012,8,C03-Diuretics,"Million US$, purchasing power parity",88.4
+8456,Croatia,2012,8,N05B-Anxiolytics,"/capita, US$ purchasing power parity",42.9
+8457,Croatia,2012,8,"C01B-Antiarrhythmics, Class I and III",Million US$ at exchange rate,21.9
+8458,Croatia,2012,8,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ exchange rate",108.3
+8459,Croatia,2012,8,A02A-Antacids,Million US$ at exchange rate,10.3
+8460,Croatia,2012,8,N05C-Hypnotics and sedatives,Million US$ at exchange rate,33.5
+8461,Croatia,2012,8,Total pharmaceutical sales,"/capita, US$ purchasing power parity",2444.5
+8462,Croatia,2012,8,M-Musculo-skeletal system,Million of national currency units,205.0
+8463,Croatia,2012,8,C02-Antihypertensives,"Million US$, purchasing power parity",104.9
+8464,Croatia,2012,8,N-Nervous system,Million US$ at exchange rate,1050.9
+8465,Croatia,2012,8,G03-Sex hormones and modulators of the genital system,"/capita, US$ exchange rate",19.0
+8466,Croatia,2012,8,A10-Drugs used in diabetes,"/capita, US$ purchasing power parity",133.9
+8467,Croatia,2012,8,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ exchange rate",22.6
+8468,Croatia,2012,8,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ purchasing power parity",54.4
+8469,Croatia,2012,8,N02-Analgesics,"/capita, US$ purchasing power parity",92.0
+8470,Croatia,2012,8,C08-Calcium channel blockers,"Million US$, purchasing power parity",281.7
+8471,Croatia,2012,8,A-Alimentary tract and metabolism,"/capita, US$ purchasing power parity",341.0
+8472,Croatia,2012,8,C02-Antihypertensives,Million US$ at exchange rate,65.7
+8473,Croatia,2012,8,C-Cardiovascular system,Million US$ at exchange rate,1294.3
+8474,Croatia,2012,8,Total pharmaceutical sales,"/capita, US$ exchange rate",1531.0
+8475,Croatia,2012,8,M-Musculo-skeletal system,"/capita, US$ purchasing power parity",98.7
+8476,Croatia,2012,8,C10-Lipid modifying agents,Million US$ at exchange rate,318.1
+8477,Croatia,2012,8,R03-Drugs for obstructive airway diseases,Million US$ at exchange rate,258.9
+8478,Croatia,2012,8,N05C-Hypnotics and sedatives,"/capita, US$ exchange rate",7.8
+8479,Croatia,2012,8,C-Cardiovascular system,"/capita, US$ purchasing power parity",484.1
+8480,Croatia,2012,8,Total pharmaceutical sales,Million of national currency units,5075.0
+8481,Croatia,2012,8,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ purchasing power parity",96.8
+8482,Croatia,2012,8,N06A-Antidepressants,Million US$ at exchange rate,110.8
+8483,Croatia,2012,8,J01-Antibacterials for systemic use,"/capita, US$ exchange rate",88.4
+8484,Croatia,2012,8,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million of national currency units,75.0
+8485,Croatia,2012,8,C10-Lipid modifying agents,"Million US$, purchasing power parity",507.9
+8486,Croatia,2012,8,B-Blood and blood forming organs,"/capita, US$ purchasing power parity",135.8
+8487,Croatia,2012,8,C09-Agents acting on the Renin-Angiotensin system,Million US$ at exchange rate,462.4
+8488,Croatia,2012,8,A02A-Antacids,"/capita, US$ purchasing power parity",3.9
+8489,Croatia,2012,8,C03-Diuretics,Million US$ at exchange rate,55.4
+8490,Croatia,2012,8,A10-Drugs used in diabetes,"/capita, US$ exchange rate",83.9
+8491,Croatia,2012,8,C09-Agents acting on the Renin-Angiotensin system,% of total sales,7.1
+8492,Croatia,2012,8,R03-Drugs for obstructive airway diseases,"/capita, US$ purchasing power parity",96.8
+8493,Croatia,2012,8,G03-Sex hormones and modulators of the genital system,% of total sales,1.2
+8494,Croatia,2012,8,C01A-Cardiac glycosides,Million US$ at exchange rate,6.4
+8495,Croatia,2012,8,J-Antiinfectives for systemic use,"/capita, US$ exchange rate",129.1
+8496,Croatia,2012,8,A-Alimentary tract and metabolism,"/capita, US$ exchange rate",213.6
+8497,Croatia,2012,8,N02-Analgesics,"Million US$, purchasing power parity",392.7
+8498,Croatia,2012,8,C-Cardiovascular system,"Million US$, purchasing power parity",2066.6
+8499,Croatia,2012,8,C03-Diuretics,"/capita, US$ exchange rate",13.0
+8500,Croatia,2012,8,N05B-Anxiolytics,Million of national currency units,89.0
+8501,Croatia,2012,8,C07-Beta blocking agents,"/capita, US$ purchasing power parity",46.7
+8502,Croatia,2012,8,J01-Antibacterials for systemic use,Million US$ at exchange rate,377.4
+8503,Croatia,2012,8,C08-Calcium channel blockers,Million of national currency units,137.0
+8504,Croatia,2012,8,"C01B-Antiarrhythmics, Class I and III","/capita, US$ purchasing power parity",8.2
+8505,Croatia,2012,8,"H-Systemic hormonal preparations, excluding sex hormones and insulins","Million US$, purchasing power parity",154.2
+8506,Croatia,2012,8,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ exchange rate",34.1
+8507,Croatia,2012,8,N05B-Anxiolytics,"/capita, US$ exchange rate",26.8
+8508,Croatia,2012,8,G-Genito urinary system and sex hormones,Million of national currency units,163.0
+8509,Croatia,2012,8,N05C-Hypnotics and sedatives,"/capita, US$ purchasing power parity",12.5
+8510,Croatia,2012,8,A10-Drugs used in diabetes,% of total sales,5.5
+8511,Croatia,2012,8,M-Musculo-skeletal system,% of total sales,4.0
+8512,Croatia,2012,8,N06A-Antidepressants,% of total sales,1.7
+8513,Croatia,2012,8,"H-Systemic hormonal preparations, excluding sex hormones and insulins",% of total sales,1.5
+8514,Croatia,2012,8,C-Cardiovascular system,% of total sales,19.8
+8515,Croatia,2012,8,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),% of total sales,4.0
+8516,Croatia,2012,8,N02-Analgesics,% of total sales,3.8
+8517,Croatia,2012,8,C10-Lipid modifying agents,% of total sales,4.9
+8518,Croatia,2012,8,C02-Antihypertensives,% of total sales,1.0
+8519,Croatia,2012,8,G-Genito urinary system and sex hormones,% of total sales,3.2
+8520,Croatia,2012,8,C08-Calcium channel blockers,% of total sales,2.7
+8521,Croatia,2012,8,M01A-Antiinflammatory and antirheumatic products non-steroids,% of total sales,2.2
+8522,Croatia,2012,8,A-Alimentary tract and metabolism,% of total sales,14.0
+8523,Croatia,2012,8,J-Antiinfectives for systemic use,% of total sales,8.4
+8524,Croatia,2012,8,R-Respiratory system,% of total sales,6.4
+8525,Croatia,2012,8,"C01B-Antiarrhythmics, Class I and III",% of total sales,0.3
+8526,Croatia,2012,8,B-Blood and blood forming organs,% of total sales,5.6
+8527,Croatia,2012,8,C03-Diuretics,% of total sales,0.8
+8528,Croatia,2012,8,N05B-Anxiolytics,% of total sales,1.8
+8529,Croatia,2012,8,C01A-Cardiac glycosides,% of total sales,0.1
+8530,Croatia,2012,8,J01-Antibacterials for systemic use,% of total sales,5.8
+8531,Croatia,2012,8,N05C-Hypnotics and sedatives,% of total sales,0.5
+8532,Croatia,2012,8,N-Nervous system,% of total sales,16.1
+8533,Croatia,2012,8,R03-Drugs for obstructive airway diseases,% of total sales,4.0
+8534,Croatia,2012,8,C07-Beta blocking agents,% of total sales,1.9
+8535,Croatia,2012,8,A02A-Antacids,% of total sales,0.2
+8536,Croatia,2012,8,"C01B-Antiarrhythmics, Class I and III","Million US$, purchasing power parity",35.0
+8537,Croatia,2012,8,G03-Sex hormones and modulators of the genital system,"/capita, US$ purchasing power parity",30.3
+8538,Croatia,2012,8,C08-Calcium channel blockers,"/capita, US$ exchange rate",41.3
+8539,Croatia,2012,8,B-Blood and blood forming organs,"Million US$, purchasing power parity",579.9
+8540,Croatia,2012,8,G-Genito urinary system and sex hormones,"/capita, US$ exchange rate",49.2
+8541,Croatia,2012,8,N05B-Anxiolytics,Million US$ at exchange rate,114.6
+8542,Croatia,2012,8,G-Genito urinary system and sex hormones,Million US$ at exchange rate,209.9
+8543,Croatia,2012,8,N06A-Antidepressants,"/capita, US$ exchange rate",25.9
+8544,Croatia,2012,8,C02-Antihypertensives,"/capita, US$ exchange rate",15.4
+8545,Croatia,2012,8,M01A-Antiinflammatory and antirheumatic products non-steroids,Million US$ at exchange rate,145.5
+8546,Croatia,2012,8,N05C-Hypnotics and sedatives,"Million US$, purchasing power parity",53.5
+8547,Croatia,2012,8,A10-Drugs used in diabetes,Million US$ at exchange rate,358.0
+8548,Croatia,2012,8,N-Nervous system,"/capita, US$ purchasing power parity",393.0
+8549,Croatia,2012,8,M-Musculo-skeletal system,Million US$ at exchange rate,264.0
+8550,Croatia,2012,8,R03-Drugs for obstructive airway diseases,"Million US$, purchasing power parity",413.3
+8551,Croatia,2012,8,C07-Beta blocking agents,"/capita, US$ exchange rate",29.3
+8552,Croatia,2012,8,N05C-Hypnotics and sedatives,Million of national currency units,26.0
+8553,Croatia,2012,8,C01A-Cardiac glycosides,"Million US$, purchasing power parity",10.3
+8554,Croatia,2012,8,C09-Agents acting on the Renin-Angiotensin system,Million of national currency units,359.0
+8555,Croatia,2012,8,J01-Antibacterials for systemic use,"/capita, US$ purchasing power parity",141.1
+8556,Croatia,2012,8,R-Respiratory system,Million US$ at exchange rate,416.0
+8557,Croatia,2012,8,J01-Antibacterials for systemic use,Million of national currency units,293.0
+8558,Croatia,2012,8,A-Alimentary tract and metabolism,Million US$ at exchange rate,911.8
+8559,Croatia,2012,8,G03-Sex hormones and modulators of the genital system,Million of national currency units,63.0
+8560,Croatia,2012,8,N02-Analgesics,"/capita, US$ exchange rate",57.6
+8561,Croatia,2012,8,C07-Beta blocking agents,"Million US$, purchasing power parity",199.5
+8562,Croatia,2012,8,Total pharmaceutical sales,"Million US$, purchasing power parity",10435.6
+8563,Croatia,2012,8,J-Antiinfectives for systemic use,Million of national currency units,428.0
+8564,Croatia,2012,8,A-Alimentary tract and metabolism,Million of national currency units,708.0
+8565,Croatia,2012,8,N06A-Antidepressants,"Million US$, purchasing power parity",176.8
+8566,Croatia,2012,8,G03-Sex hormones and modulators of the genital system,Million US$ at exchange rate,81.1
+8567,Croatia,2012,8,C01A-Cardiac glycosides,"/capita, US$ exchange rate",1.5
+8568,Croatia,2012,8,C10-Lipid modifying agents,"/capita, US$ purchasing power parity",119.0
+8569,Croatia,2012,8,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"Million US$, purchasing power parity",413.3
+8570,Croatia,2012,8,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ purchasing power parity",36.1
+8571,Croatia,2012,8,M-Musculo-skeletal system,"Million US$, purchasing power parity",421.5
+8572,Croatia,2012,8,M01A-Antiinflammatory and antirheumatic products non-steroids,Million of national currency units,113.0
+8573,Croatia,2012,8,A10-Drugs used in diabetes,Million of national currency units,278.0
+8574,Croatia,2012,8,R-Respiratory system,"/capita, US$ exchange rate",97.4
+8575,Croatia,2012,8,A02A-Antacids,"Million US$, purchasing power parity",16.5
+8576,Croatia,2012,8,C01A-Cardiac glycosides,Million of national currency units,5.0
+8577,Croatia,2012,8,J01-Antibacterials for systemic use,"Million US$, purchasing power parity",602.5
+8578,Croatia,2012,8,C-Cardiovascular system,"/capita, US$ exchange rate",303.2
+8579,Croatia,2012,8,C08-Calcium channel blockers,Million US$ at exchange rate,176.4
+8580,Croatia,2012,8,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ exchange rate",60.6
+8581,Croatia,2012,8,C03-Diuretics,Million of national currency units,43.0
+8582,Croatia,2012,8,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ purchasing power parity",172.9
+8583,Croatia,2012,8,R-Respiratory system,Million of national currency units,323.0
+8584,Croatia,2012,8,C03-Diuretics,"/capita, US$ purchasing power parity",20.7
+8585,Croatia,2012,8,J-Antiinfectives for systemic use,Million US$ at exchange rate,551.2
+8586,Croatia,2012,8,N-Nervous system,"Million US$, purchasing power parity",1677.9
+8587,Croatia,2011,9,C07-Beta blocking agents,Million US$ at exchange rate,133.9
+8588,Croatia,2011,9,A10-Drugs used in diabetes,"Million US$, purchasing power parity",520.0
+8589,Croatia,2011,9,C02-Antihypertensives,"/capita, US$ purchasing power parity",22.5
+8590,Croatia,2011,9,N-Nervous system,"/capita, US$ exchange rate",267.0
+8591,Croatia,2011,9,G-Genito urinary system and sex hormones,"Million US$, purchasing power parity",333.3
+8592,Croatia,2011,9,B-Blood and blood forming organs,"/capita, US$ exchange rate",85.3
+8593,Croatia,2011,9,A-Alimentary tract and metabolism,"Million US$, purchasing power parity",1385.4
+8594,Croatia,2011,9,"C01B-Antiarrhythmics, Class I and III","/capita, US$ exchange rate",6.3
+8595,Croatia,2011,9,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million US$ at exchange rate,98.7
+8596,Croatia,2011,9,"C01B-Antiarrhythmics, Class I and III",Million of national currency units,19.0
+8597,Croatia,2011,9,C07-Beta blocking agents,Million of national currency units,95.0
+8598,Croatia,2011,9,R-Respiratory system,"Million US$, purchasing power parity",668.6
+8599,Croatia,2011,9,J-Antiinfectives for systemic use,"/capita, US$ purchasing power parity",217.1
+8600,Croatia,2011,9,A02A-Antacids,Million of national currency units,9.0
+8601,Croatia,2011,9,R03-Drugs for obstructive airway diseases,"/capita, US$ exchange rate",64.5
+8602,Croatia,2011,9,Total pharmaceutical sales,Million US$ at exchange rate,7145.5
+8603,Croatia,2011,9,C10-Lipid modifying agents,"/capita, US$ exchange rate",82.3
+8604,Croatia,2011,9,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million US$ at exchange rate,282.0
+8605,Croatia,2011,9,C-Cardiovascular system,Million of national currency units,984.0
+8606,Croatia,2011,9,N-Nervous system,Million of national currency units,811.0
+8607,Croatia,2011,9,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million of national currency units,200.0
+8608,Croatia,2011,9,A02A-Antacids,"/capita, US$ exchange rate",3.0
+8609,Croatia,2011,9,N05B-Anxiolytics,"Million US$, purchasing power parity",174.7
+8610,Croatia,2011,9,J-Antiinfectives for systemic use,"Million US$, purchasing power parity",929.6
+8611,Croatia,2011,9,M01A-Antiinflammatory and antirheumatic products non-steroids,"Million US$, purchasing power parity",220.9
+8612,Croatia,2011,9,B-Blood and blood forming organs,Million of national currency units,259.0
+8613,Croatia,2011,9,C08-Calcium channel blockers,"/capita, US$ purchasing power parity",68.0
+8614,Croatia,2011,9,N02-Analgesics,Million US$ at exchange rate,273.5
+8615,Croatia,2011,9,G-Genito urinary system and sex hormones,"/capita, US$ purchasing power parity",77.8
+8616,Croatia,2011,9,R-Respiratory system,"/capita, US$ purchasing power parity",156.1
+8617,Croatia,2011,9,N06A-Antidepressants,"/capita, US$ purchasing power parity",40.8
+8618,Croatia,2011,9,N02-Analgesics,Million of national currency units,194.0
+8619,Croatia,2011,9,N06A-Antidepressants,Million of national currency units,87.0
+8620,Croatia,2011,9,C02-Antihypertensives,Million of national currency units,48.0
+8621,Croatia,2011,9,C01A-Cardiac glycosides,"/capita, US$ purchasing power parity",1.9
+8622,Croatia,2011,9,C09-Agents acting on the Renin-Angiotensin system,"Million US$, purchasing power parity",704.7
+8623,Croatia,2011,9,C10-Lipid modifying agents,Million of national currency units,250.0
+8624,Croatia,2011,9,B-Blood and blood forming organs,Million US$ at exchange rate,365.2
+8625,Croatia,2011,9,R03-Drugs for obstructive airway diseases,Million of national currency units,196.0
+8626,Croatia,2011,9,G03-Sex hormones and modulators of the genital system,"Million US$, purchasing power parity",120.5
+8627,Croatia,2011,9,M-Musculo-skeletal system,"/capita, US$ exchange rate",68.5
+8628,Croatia,2011,9,C03-Diuretics,"Million US$, purchasing power parity",82.3
+8629,Croatia,2011,9,N05B-Anxiolytics,"/capita, US$ purchasing power parity",40.8
+8630,Croatia,2011,9,"C01B-Antiarrhythmics, Class I and III",Million US$ at exchange rate,26.8
+8631,Croatia,2011,9,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ exchange rate",115.5
+8632,Croatia,2011,9,A02A-Antacids,Million US$ at exchange rate,12.7
+8633,Croatia,2011,9,N05C-Hypnotics and sedatives,Million US$ at exchange rate,33.8
+8634,Croatia,2011,9,Total pharmaceutical sales,"/capita, US$ purchasing power parity",2375.8
+8635,Croatia,2011,9,M-Musculo-skeletal system,Million of national currency units,208.0
+8636,Croatia,2011,9,C02-Antihypertensives,"Million US$, purchasing power parity",96.4
+8637,Croatia,2011,9,N-Nervous system,Million US$ at exchange rate,1143.5
+8638,Croatia,2011,9,G03-Sex hormones and modulators of the genital system,"/capita, US$ exchange rate",19.8
+8639,Croatia,2011,9,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ purchasing power parity",51.6
+8640,Croatia,2011,9,A10-Drugs used in diabetes,"/capita, US$ purchasing power parity",121.4
+8641,Croatia,2011,9,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ exchange rate",23.0
+8642,Croatia,2011,9,C08-Calcium channel blockers,"Million US$, purchasing power parity",291.1
+8643,Croatia,2011,9,N02-Analgesics,"/capita, US$ purchasing power parity",90.9
+8644,Croatia,2011,9,A-Alimentary tract and metabolism,"/capita, US$ purchasing power parity",323.5
+8645,Croatia,2011,9,C02-Antihypertensives,Million US$ at exchange rate,67.7
+8646,Croatia,2011,9,C-Cardiovascular system,Million US$ at exchange rate,1387.4
+8647,Croatia,2011,9,Total pharmaceutical sales,"/capita, US$ exchange rate",1668.4
+8648,Croatia,2011,9,C10-Lipid modifying agents,Million US$ at exchange rate,352.5
+8649,Croatia,2011,9,M-Musculo-skeletal system,"/capita, US$ purchasing power parity",97.5
+8650,Croatia,2011,9,R03-Drugs for obstructive airway diseases,Million US$ at exchange rate,276.3
+8651,Croatia,2011,9,N05C-Hypnotics and sedatives,"/capita, US$ exchange rate",7.9
+8652,Croatia,2011,9,C-Cardiovascular system,"/capita, US$ purchasing power parity",461.3
+8653,Croatia,2011,9,Total pharmaceutical sales,Million of national currency units,5068.0
+8654,Croatia,2011,9,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ purchasing power parity",93.8
+8655,Croatia,2011,9,J01-Antibacterials for systemic use,"/capita, US$ exchange rate",95.1
+8656,Croatia,2011,9,N06A-Antidepressants,Million US$ at exchange rate,122.7
+8657,Croatia,2011,9,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million of national currency units,70.0
+8658,Croatia,2011,9,C10-Lipid modifying agents,"Million US$, purchasing power parity",501.9
+8659,Croatia,2011,9,C09-Agents acting on the Renin-Angiotensin system,Million US$ at exchange rate,494.9
+8660,Croatia,2011,9,B-Blood and blood forming organs,"/capita, US$ purchasing power parity",121.4
+8661,Croatia,2011,9,A02A-Antacids,"/capita, US$ purchasing power parity",4.2
+8662,Croatia,2011,9,A10-Drugs used in diabetes,"/capita, US$ exchange rate",85.3
+8663,Croatia,2011,9,C03-Diuretics,Million US$ at exchange rate,57.8
+8664,Croatia,2011,9,C09-Agents acting on the Renin-Angiotensin system,% of total sales,6.9
+8665,Croatia,2011,9,R03-Drugs for obstructive airway diseases,"/capita, US$ purchasing power parity",91.9
+8666,Croatia,2011,9,G03-Sex hormones and modulators of the genital system,% of total sales,1.2
+8667,Croatia,2011,9,J-Antiinfectives for systemic use,"/capita, US$ exchange rate",152.4
+8668,Croatia,2011,9,C01A-Cardiac glycosides,Million US$ at exchange rate,5.6
+8669,Croatia,2011,9,A-Alimentary tract and metabolism,"/capita, US$ exchange rate",227.1
+8670,Croatia,2011,9,"H-Systemic hormonal preparations, excluding sex hormones and insulins","Million US$, purchasing power parity",140.5
+8671,Croatia,2011,9,N02-Analgesics,"Million US$, purchasing power parity",389.5
+8672,Croatia,2011,9,C-Cardiovascular system,"Million US$, purchasing power parity",1975.7
+8673,Croatia,2011,9,C03-Diuretics,"/capita, US$ exchange rate",13.5
+8674,Croatia,2011,9,N05B-Anxiolytics,Million of national currency units,87.0
+8675,Croatia,2011,9,C07-Beta blocking agents,"/capita, US$ purchasing power parity",44.5
+8676,Croatia,2011,9,J01-Antibacterials for systemic use,Million US$ at exchange rate,407.5
+8677,Croatia,2011,9,"C01B-Antiarrhythmics, Class I and III","/capita, US$ purchasing power parity",8.9
+8678,Croatia,2011,9,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ exchange rate",36.2
+8679,Croatia,2011,9,G-Genito urinary system and sex hormones,Million of national currency units,166.0
+8680,Croatia,2011,9,N05B-Anxiolytics,"/capita, US$ exchange rate",28.6
+8681,Croatia,2011,9,C08-Calcium channel blockers,Million of national currency units,145.0
+8682,Croatia,2011,9,N05C-Hypnotics and sedatives,"/capita, US$ purchasing power parity",11.3
+8683,Croatia,2011,9,A10-Drugs used in diabetes,% of total sales,5.1
+8684,Croatia,2011,9,M-Musculo-skeletal system,% of total sales,4.1
+8685,Croatia,2011,9,N06A-Antidepressants,% of total sales,1.7
+8686,Croatia,2011,9,"H-Systemic hormonal preparations, excluding sex hormones and insulins",% of total sales,1.4
+8687,Croatia,2011,9,C-Cardiovascular system,% of total sales,19.4
+8688,Croatia,2011,9,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),% of total sales,3.9
+8689,Croatia,2011,9,N02-Analgesics,% of total sales,3.8
+8690,Croatia,2011,9,C02-Antihypertensives,% of total sales,0.9
+8691,Croatia,2011,9,G-Genito urinary system and sex hormones,% of total sales,3.3
+8692,Croatia,2011,9,C08-Calcium channel blockers,% of total sales,2.9
+8693,Croatia,2011,9,C10-Lipid modifying agents,% of total sales,4.9
+8694,Croatia,2011,9,A-Alimentary tract and metabolism,% of total sales,13.6
+8695,Croatia,2011,9,M01A-Antiinflammatory and antirheumatic products non-steroids,% of total sales,2.2
+8696,Croatia,2011,9,J-Antiinfectives for systemic use,% of total sales,9.1
+8697,Croatia,2011,9,R-Respiratory system,% of total sales,6.6
+8698,Croatia,2011,9,"C01B-Antiarrhythmics, Class I and III",% of total sales,0.4
+8699,Croatia,2011,9,B-Blood and blood forming organs,% of total sales,5.1
+8700,Croatia,2011,9,N05B-Anxiolytics,% of total sales,1.7
+8701,Croatia,2011,9,C03-Diuretics,% of total sales,0.8
+8702,Croatia,2011,9,C01A-Cardiac glycosides,% of total sales,0.1
+8703,Croatia,2011,9,J01-Antibacterials for systemic use,% of total sales,5.7
+8704,Croatia,2011,9,N05C-Hypnotics and sedatives,% of total sales,0.5
+8705,Croatia,2011,9,N-Nervous system,% of total sales,16.0
+8706,Croatia,2011,9,R03-Drugs for obstructive airway diseases,% of total sales,3.9
+8707,Croatia,2011,9,A02A-Antacids,% of total sales,0.2
+8708,Croatia,2011,9,C07-Beta blocking agents,% of total sales,1.9
+8709,Croatia,2011,9,G03-Sex hormones and modulators of the genital system,"/capita, US$ purchasing power parity",28.1
+8710,Croatia,2011,9,"C01B-Antiarrhythmics, Class I and III","Million US$, purchasing power parity",38.1
+8711,Croatia,2011,9,C08-Calcium channel blockers,"/capita, US$ exchange rate",47.7
+8712,Croatia,2011,9,B-Blood and blood forming organs,"Million US$, purchasing power parity",520.0
+8713,Croatia,2011,9,N05B-Anxiolytics,Million US$ at exchange rate,122.7
+8714,Croatia,2011,9,G-Genito urinary system and sex hormones,"/capita, US$ exchange rate",54.6
+8715,Croatia,2011,9,G-Genito urinary system and sex hormones,Million US$ at exchange rate,234.0
+8716,Croatia,2011,9,C02-Antihypertensives,"/capita, US$ exchange rate",15.8
+8717,Croatia,2011,9,N06A-Antidepressants,"/capita, US$ exchange rate",28.6
+8718,Croatia,2011,9,M01A-Antiinflammatory and antirheumatic products non-steroids,Million US$ at exchange rate,155.1
+8719,Croatia,2011,9,N05C-Hypnotics and sedatives,"Million US$, purchasing power parity",48.2
+8720,Croatia,2011,9,A10-Drugs used in diabetes,Million US$ at exchange rate,365.2
+8721,Croatia,2011,9,N-Nervous system,"/capita, US$ purchasing power parity",380.2
+8722,Croatia,2011,9,M-Musculo-skeletal system,Million US$ at exchange rate,293.3
+8723,Croatia,2011,9,R03-Drugs for obstructive airway diseases,"Million US$, purchasing power parity",393.5
+8724,Croatia,2011,9,C07-Beta blocking agents,"/capita, US$ exchange rate",31.3
+8725,Croatia,2011,9,N05C-Hypnotics and sedatives,Million of national currency units,24.0
+8726,Croatia,2011,9,C01A-Cardiac glycosides,"Million US$, purchasing power parity",8.0
+8727,Croatia,2011,9,C09-Agents acting on the Renin-Angiotensin system,Million of national currency units,351.0
+8728,Croatia,2011,9,J01-Antibacterials for systemic use,"/capita, US$ purchasing power parity",135.5
+8729,Croatia,2011,9,J01-Antibacterials for systemic use,Million of national currency units,289.0
+8730,Croatia,2011,9,R-Respiratory system,Million US$ at exchange rate,469.5
+8731,Croatia,2011,9,A-Alimentary tract and metabolism,Million US$ at exchange rate,972.9
+8732,Croatia,2011,9,G03-Sex hormones and modulators of the genital system,Million of national currency units,60.0
+8733,Croatia,2011,9,C07-Beta blocking agents,"Million US$, purchasing power parity",190.7
+8734,Croatia,2011,9,N02-Analgesics,"/capita, US$ exchange rate",63.9
+8735,Croatia,2011,9,Total pharmaceutical sales,"Million US$, purchasing power parity",10175.5
+8736,Croatia,2011,9,A-Alimentary tract and metabolism,Million of national currency units,690.0
+8737,Croatia,2011,9,J-Antiinfectives for systemic use,Million of national currency units,463.0
+8738,Croatia,2011,9,G03-Sex hormones and modulators of the genital system,Million US$ at exchange rate,84.6
+8739,Croatia,2011,9,N06A-Antidepressants,"Million US$, purchasing power parity",174.7
+8740,Croatia,2011,9,C01A-Cardiac glycosides,"/capita, US$ exchange rate",1.3
+8741,Croatia,2011,9,R-Respiratory system,"/capita, US$ exchange rate",109.6
+8742,Croatia,2011,9,C10-Lipid modifying agents,"/capita, US$ purchasing power parity",117.2
+8743,Croatia,2011,9,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ purchasing power parity",32.8
+8744,Croatia,2011,9,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"Million US$, purchasing power parity",401.6
+8745,Croatia,2011,9,M-Musculo-skeletal system,"Million US$, purchasing power parity",417.6
+8746,Croatia,2011,9,M01A-Antiinflammatory and antirheumatic products non-steroids,Million of national currency units,110.0
+8747,Croatia,2011,9,A10-Drugs used in diabetes,Million of national currency units,259.0
+8748,Croatia,2011,9,A02A-Antacids,"Million US$, purchasing power parity",18.1
+8749,Croatia,2011,9,J01-Antibacterials for systemic use,"Million US$, purchasing power parity",580.3
+8750,Croatia,2011,9,C01A-Cardiac glycosides,Million of national currency units,4.0
+8751,Croatia,2011,9,C-Cardiovascular system,"/capita, US$ exchange rate",323.9
+8752,Croatia,2011,9,C08-Calcium channel blockers,Million US$ at exchange rate,204.4
+8753,Croatia,2011,9,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ exchange rate",65.8
+8754,Croatia,2011,9,C03-Diuretics,Million of national currency units,41.0
+8755,Croatia,2011,9,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ purchasing power parity",164.5
+8756,Croatia,2011,9,R-Respiratory system,Million of national currency units,333.0
+8757,Croatia,2011,9,C03-Diuretics,"/capita, US$ purchasing power parity",19.2
+8758,Croatia,2011,9,J-Antiinfectives for systemic use,Million US$ at exchange rate,652.8
+8759,Croatia,2011,9,N-Nervous system,"Million US$, purchasing power parity",1628.3
+8760,Croatia,2010,9,C07-Beta blocking agents,Million US$ at exchange rate,126.1
+8761,Croatia,2010,9,A10-Drugs used in diabetes,"Million US$, purchasing power parity",468.8
+8762,Croatia,2010,9,N-Nervous system,"/capita, US$ exchange rate",250.1
+8763,Croatia,2010,9,C02-Antihypertensives,"/capita, US$ purchasing power parity",19.5
+8764,Croatia,2010,9,G-Genito urinary system and sex hormones,"Million US$, purchasing power parity",317.1
+8765,Croatia,2010,9,A-Alimentary tract and metabolism,"Million US$, purchasing power parity",1244.9
+8766,Croatia,2010,9,B-Blood and blood forming organs,"/capita, US$ exchange rate",85.2
+8767,Croatia,2010,9,A02A-Antacids,Million of national currency units,9.0
+8768,Croatia,2010,9,"C01B-Antiarrhythmics, Class I and III","/capita, US$ exchange rate",5.7
+8769,Croatia,2010,9,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million US$ at exchange rate,82.2
+8770,Croatia,2010,9,C07-Beta blocking agents,Million of national currency units,92.0
+8771,Croatia,2010,9,R-Respiratory system,"/capita, US$ purchasing power parity",152.6
+8772,Croatia,2010,9,"C01B-Antiarrhythmics, Class I and III",Million of national currency units,18.0
+8773,Croatia,2010,9,R-Respiratory system,"Million US$, purchasing power parity",655.5
+8774,Croatia,2010,9,J-Antiinfectives for systemic use,"/capita, US$ purchasing power parity",215.5
+8775,Croatia,2010,9,R03-Drugs for obstructive airway diseases,"/capita, US$ exchange rate",59.0
+8776,Croatia,2010,9,Total pharmaceutical sales,Million US$ at exchange rate,6628.7
+8777,Croatia,2010,9,C10-Lipid modifying agents,"/capita, US$ exchange rate",77.2
+8778,Croatia,2010,9,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million US$ at exchange rate,270.0
+8779,Croatia,2010,9,N-Nervous system,Million of national currency units,784.0
+8780,Croatia,2010,9,J-Antiinfectives for systemic use,"Million US$, purchasing power parity",925.9
+8781,Croatia,2010,9,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million of national currency units,197.0
+8782,Croatia,2010,9,A02A-Antacids,"/capita, US$ exchange rate",2.9
+8783,Croatia,2010,9,C-Cardiovascular system,Million of national currency units,975.0
+8784,Croatia,2010,9,N05B-Anxiolytics,"Million US$, purchasing power parity",167.3
+8785,Croatia,2010,9,M01A-Antiinflammatory and antirheumatic products non-steroids,"Million US$, purchasing power parity",215.9
+8786,Croatia,2010,9,B-Blood and blood forming organs,Million of national currency units,267.0
+8787,Croatia,2010,9,C08-Calcium channel blockers,"/capita, US$ purchasing power parity",66.1
+8788,Croatia,2010,9,N02-Analgesics,Million US$ at exchange rate,254.9
+8789,Croatia,2010,9,G-Genito urinary system and sex hormones,"/capita, US$ purchasing power parity",73.8
+8790,Croatia,2010,9,N06A-Antidepressants,"/capita, US$ purchasing power parity",39.8
+8791,Croatia,2010,9,N02-Analgesics,Million of national currency units,186.0
+8792,Croatia,2010,9,N06A-Antidepressants,Million of national currency units,88.0
+8793,Croatia,2010,9,C02-Antihypertensives,Million of national currency units,43.0
+8794,Croatia,2010,9,C01A-Cardiac glycosides,"/capita, US$ purchasing power parity",2.3
+8795,Croatia,2010,9,C09-Agents acting on the Renin-Angiotensin system,"Million US$, purchasing power parity",663.3
+8796,Croatia,2010,9,B-Blood and blood forming organs,Million US$ at exchange rate,365.9
+8797,Croatia,2010,9,R03-Drugs for obstructive airway diseases,Million of national currency units,185.0
+8798,Croatia,2010,9,C10-Lipid modifying agents,Million of national currency units,242.0
+8799,Croatia,2010,9,G03-Sex hormones and modulators of the genital system,"Million US$, purchasing power parity",120.6
+8800,Croatia,2010,9,M-Musculo-skeletal system,"/capita, US$ exchange rate",67.3
+8801,Croatia,2010,9,C03-Diuretics,"Million US$, purchasing power parity",75.9
+8802,Croatia,2010,9,N05B-Anxiolytics,"/capita, US$ purchasing power parity",38.9
+8803,Croatia,2010,9,"C01B-Antiarrhythmics, Class I and III",Million US$ at exchange rate,24.7
+8804,Croatia,2010,9,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ exchange rate",108.8
+8805,Croatia,2010,9,N05C-Hypnotics and sedatives,Million US$ at exchange rate,31.5
+8806,Croatia,2010,9,Total pharmaceutical sales,"/capita, US$ purchasing power parity",2189.9
+8807,Croatia,2010,9,A02A-Antacids,Million US$ at exchange rate,12.3
+8808,Croatia,2010,9,M-Musculo-skeletal system,Million of national currency units,211.0
+8809,Croatia,2010,9,C02-Antihypertensives,"Million US$, purchasing power parity",83.6
+8810,Croatia,2010,9,N-Nervous system,Million US$ at exchange rate,1074.4
+8811,Croatia,2010,9,G03-Sex hormones and modulators of the genital system,"/capita, US$ exchange rate",19.8
+8812,Croatia,2010,9,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ purchasing power parity",50.3
+8813,Croatia,2010,9,A10-Drugs used in diabetes,"/capita, US$ purchasing power parity",109.1
+8814,Croatia,2010,9,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ exchange rate",19.1
+8815,Croatia,2010,9,C08-Calcium channel blockers,"Million US$, purchasing power parity",284.0
+8816,Croatia,2010,9,A-Alimentary tract and metabolism,"/capita, US$ purchasing power parity",289.8
+8817,Croatia,2010,9,C02-Antihypertensives,Million US$ at exchange rate,58.9
+8818,Croatia,2010,9,C-Cardiovascular system,Million US$ at exchange rate,1336.1
+8819,Croatia,2010,9,Total pharmaceutical sales,"/capita, US$ exchange rate",1542.9
+8820,Croatia,2010,9,N02-Analgesics,"/capita, US$ purchasing power parity",84.2
+8821,Croatia,2010,9,C10-Lipid modifying agents,Million US$ at exchange rate,331.6
+8822,Croatia,2010,9,M-Musculo-skeletal system,"/capita, US$ purchasing power parity",95.5
+8823,Croatia,2010,9,R03-Drugs for obstructive airway diseases,Million US$ at exchange rate,253.5
+8824,Croatia,2010,9,N05C-Hypnotics and sedatives,"/capita, US$ exchange rate",7.3
+8825,Croatia,2010,9,C-Cardiovascular system,"/capita, US$ purchasing power parity",441.4
+8826,Croatia,2010,9,Total pharmaceutical sales,Million of national currency units,4837.0
+8827,Croatia,2010,9,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ purchasing power parity",89.2
+8828,Croatia,2010,9,J01-Antibacterials for systemic use,"/capita, US$ exchange rate",90.6
+8829,Croatia,2010,9,N06A-Antidepressants,Million US$ at exchange rate,120.6
+8830,Croatia,2010,9,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million of national currency units,60.0
+8831,Croatia,2010,9,C-Cardiovascular system,"/capita, US$ exchange rate",311.0
+8832,Croatia,2010,9,C10-Lipid modifying agents,"Million US$, purchasing power parity",470.7
+8833,Croatia,2010,9,B-Blood and blood forming organs,"/capita, US$ purchasing power parity",120.9
+8834,Croatia,2010,9,C09-Agents acting on the Renin-Angiotensin system,Million US$ at exchange rate,467.3
+8835,Croatia,2010,9,A02A-Antacids,"/capita, US$ purchasing power parity",4.1
+8836,Croatia,2010,9,A10-Drugs used in diabetes,"/capita, US$ exchange rate",76.9
+8837,Croatia,2010,9,C03-Diuretics,Million US$ at exchange rate,53.4
+8838,Croatia,2010,9,C09-Agents acting on the Renin-Angiotensin system,% of total sales,7.0
+8839,Croatia,2010,9,R03-Drugs for obstructive airway diseases,"/capita, US$ purchasing power parity",83.8
+8840,Croatia,2010,9,G03-Sex hormones and modulators of the genital system,% of total sales,1.3
+8841,Croatia,2010,9,J-Antiinfectives for systemic use,"/capita, US$ exchange rate",151.8
+8842,Croatia,2010,9,C01A-Cardiac glycosides,Million US$ at exchange rate,6.9
+8843,Croatia,2010,9,A-Alimentary tract and metabolism,"/capita, US$ exchange rate",204.1
+8844,Croatia,2010,9,C-Cardiovascular system,"Million US$, purchasing power parity",1896.5
+8845,Croatia,2010,9,N02-Analgesics,"Million US$, purchasing power parity",361.8
+8846,Croatia,2010,9,C03-Diuretics,"/capita, US$ exchange rate",12.4
+8847,Croatia,2010,9,N05B-Anxiolytics,Million of national currency units,86.0
+8848,Croatia,2010,9,J01-Antibacterials for systemic use,Million US$ at exchange rate,389.2
+8849,Croatia,2010,9,C07-Beta blocking agents,"/capita, US$ purchasing power parity",41.7
+8850,Croatia,2010,9,"H-Systemic hormonal preparations, excluding sex hormones and insulins","Million US$, purchasing power parity",116.7
+8851,Croatia,2010,9,"C01B-Antiarrhythmics, Class I and III","/capita, US$ purchasing power parity",8.1
+8852,Croatia,2010,9,G-Genito urinary system and sex hormones,Million of national currency units,163.0
+8853,Croatia,2010,9,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ exchange rate",35.4
+8854,Croatia,2010,9,N05B-Anxiolytics,"/capita, US$ exchange rate",27.4
+8855,Croatia,2010,9,C08-Calcium channel blockers,Million of national currency units,146.0
+8856,Croatia,2010,9,N05C-Hypnotics and sedatives,"/capita, US$ purchasing power parity",10.4
+8857,Croatia,2010,9,M-Musculo-skeletal system,% of total sales,4.4
+8858,Croatia,2010,9,N06A-Antidepressants,% of total sales,1.8
+8859,Croatia,2010,9,"H-Systemic hormonal preparations, excluding sex hormones and insulins",% of total sales,1.2
+8860,Croatia,2010,9,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),% of total sales,4.1
+8861,Croatia,2010,9,C-Cardiovascular system,% of total sales,20.2
+8862,Croatia,2010,9,N02-Analgesics,% of total sales,3.8
+8863,Croatia,2010,9,C10-Lipid modifying agents,% of total sales,5.0
+8864,Croatia,2010,9,C02-Antihypertensives,% of total sales,0.9
+8865,Croatia,2010,9,G-Genito urinary system and sex hormones,% of total sales,3.4
+8866,Croatia,2010,9,C08-Calcium channel blockers,% of total sales,3.0
+8867,Croatia,2010,9,M01A-Antiinflammatory and antirheumatic products non-steroids,% of total sales,2.3
+8868,Croatia,2010,9,A-Alimentary tract and metabolism,% of total sales,13.2
+8869,Croatia,2010,9,J-Antiinfectives for systemic use,% of total sales,9.8
+8870,Croatia,2010,9,R-Respiratory system,% of total sales,7.0
+8871,Croatia,2010,9,B-Blood and blood forming organs,% of total sales,5.5
+8872,Croatia,2010,9,"C01B-Antiarrhythmics, Class I and III",% of total sales,0.4
+8873,Croatia,2010,9,C03-Diuretics,% of total sales,0.8
+8874,Croatia,2010,9,N05B-Anxiolytics,% of total sales,1.8
+8875,Croatia,2010,9,A10-Drugs used in diabetes,% of total sales,5.0
+8876,Croatia,2010,9,C01A-Cardiac glycosides,% of total sales,0.1
+8877,Croatia,2010,9,J01-Antibacterials for systemic use,% of total sales,5.9
+8878,Croatia,2010,9,N-Nervous system,% of total sales,16.2
+8879,Croatia,2010,9,N05C-Hypnotics and sedatives,% of total sales,0.5
+8880,Croatia,2010,9,R03-Drugs for obstructive airway diseases,% of total sales,3.8
+8881,Croatia,2010,9,A02A-Antacids,% of total sales,0.2
+8882,Croatia,2010,9,C07-Beta blocking agents,% of total sales,1.9
+8883,Croatia,2010,9,G03-Sex hormones and modulators of the genital system,"/capita, US$ purchasing power parity",28.1
+8884,Croatia,2010,9,"C01B-Antiarrhythmics, Class I and III","Million US$, purchasing power parity",35.0
+8885,Croatia,2010,9,C08-Calcium channel blockers,"/capita, US$ exchange rate",46.6
+8886,Croatia,2010,9,B-Blood and blood forming organs,"Million US$, purchasing power parity",519.3
+8887,Croatia,2010,9,G-Genito urinary system and sex hormones,"/capita, US$ exchange rate",52.0
+8888,Croatia,2010,9,N05B-Anxiolytics,Million US$ at exchange rate,117.9
+8889,Croatia,2010,9,G-Genito urinary system and sex hormones,Million US$ at exchange rate,223.4
+8890,Croatia,2010,9,C02-Antihypertensives,"/capita, US$ exchange rate",13.7
+8891,Croatia,2010,9,N06A-Antidepressants,"/capita, US$ exchange rate",28.1
+8892,Croatia,2010,9,M01A-Antiinflammatory and antirheumatic products non-steroids,Million US$ at exchange rate,152.1
+8893,Croatia,2010,9,N05C-Hypnotics and sedatives,"Million US$, purchasing power parity",44.7
+8894,Croatia,2010,9,A10-Drugs used in diabetes,Million US$ at exchange rate,330.3
+8895,Croatia,2010,9,N-Nervous system,"/capita, US$ purchasing power parity",354.9
+8896,Croatia,2010,9,M-Musculo-skeletal system,Million US$ at exchange rate,289.2
+8897,Croatia,2010,9,R03-Drugs for obstructive airway diseases,"Million US$, purchasing power parity",359.8
+8898,Croatia,2010,9,N05C-Hypnotics and sedatives,Million of national currency units,23.0
+8899,Croatia,2010,9,C07-Beta blocking agents,"/capita, US$ exchange rate",29.3
+8900,Croatia,2010,9,C01A-Cardiac glycosides,"Million US$, purchasing power parity",9.7
+8901,Croatia,2010,9,C09-Agents acting on the Renin-Angiotensin system,Million of national currency units,341.0
+8902,Croatia,2010,9,J01-Antibacterials for systemic use,"/capita, US$ purchasing power parity",128.6
+8903,Croatia,2010,9,J01-Antibacterials for systemic use,Million of national currency units,284.0
+8904,Croatia,2010,9,R-Respiratory system,Million US$ at exchange rate,461.8
+8905,Croatia,2010,9,G03-Sex hormones and modulators of the genital system,Million of national currency units,62.0
+8906,Croatia,2010,9,A-Alimentary tract and metabolism,Million US$ at exchange rate,877.1
+8907,Croatia,2010,9,C07-Beta blocking agents,"Million US$, purchasing power parity",179.0
+8908,Croatia,2010,9,Total pharmaceutical sales,"Million US$, purchasing power parity",9408.5
+8909,Croatia,2010,9,G03-Sex hormones and modulators of the genital system,Million US$ at exchange rate,85.0
+8910,Croatia,2010,9,A-Alimentary tract and metabolism,Million of national currency units,640.0
+8911,Croatia,2010,9,N06A-Antidepressants,"Million US$, purchasing power parity",171.2
+8912,Croatia,2010,9,R-Respiratory system,"/capita, US$ exchange rate",107.5
+8913,Croatia,2010,9,C01A-Cardiac glycosides,"/capita, US$ exchange rate",1.6
+8914,Croatia,2010,9,J-Antiinfectives for systemic use,Million of national currency units,476.0
+8915,Croatia,2010,9,C10-Lipid modifying agents,"/capita, US$ purchasing power parity",109.6
+8916,Croatia,2010,9,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"Million US$, purchasing power parity",383.2
+8917,Croatia,2010,9,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ purchasing power parity",27.2
+8918,Croatia,2010,9,M-Musculo-skeletal system,"Million US$, purchasing power parity",410.4
+8919,Croatia,2010,9,M01A-Antiinflammatory and antirheumatic products non-steroids,Million of national currency units,111.0
+8920,Croatia,2010,9,A10-Drugs used in diabetes,Million of national currency units,241.0
+8921,Croatia,2010,9,A02A-Antacids,"Million US$, purchasing power parity",17.5
+8922,Croatia,2010,9,C01A-Cardiac glycosides,Million of national currency units,5.0
+8923,Croatia,2010,9,J01-Antibacterials for systemic use,"Million US$, purchasing power parity",552.4
+8924,Croatia,2010,9,C08-Calcium channel blockers,Million US$ at exchange rate,200.1
+8925,Croatia,2010,9,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ exchange rate",62.8
+8926,Croatia,2010,9,C03-Diuretics,Million of national currency units,39.0
+8927,Croatia,2010,9,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ purchasing power parity",154.4
+8928,Croatia,2010,9,R-Respiratory system,Million of national currency units,337.0
+8929,Croatia,2010,9,C03-Diuretics,"/capita, US$ purchasing power parity",17.7
+8930,Croatia,2010,9,J-Antiinfectives for systemic use,Million US$ at exchange rate,652.3
+8931,Croatia,2010,9,N-Nervous system,"Million US$, purchasing power parity",1525.0
+8932,Croatia,2010,9,N02-Analgesics,"/capita, US$ exchange rate",59.3
+8933,Croatia,2017,8,C07-Beta blocking agents,Million US$ at exchange rate,99.0
+8934,Croatia,2017,8,A10-Drugs used in diabetes,"Million US$, purchasing power parity",924.6
+8935,Croatia,2017,8,N-Nervous system,"/capita, US$ exchange rate",229.7
+8936,Croatia,2017,8,G-Genito urinary system and sex hormones,"Million US$, purchasing power parity",405.7
+8937,Croatia,2017,8,A02A-Antacids,"/capita, US$ exchange rate",2.5
+8938,Croatia,2017,8,B-Blood and blood forming organs,"/capita, US$ exchange rate",136.6
+8939,Croatia,2017,8,A-Alimentary tract and metabolism,"Million US$, purchasing power parity",1810.7
+8940,Croatia,2017,8,"C01B-Antiarrhythmics, Class I and III","/capita, US$ exchange rate",4.4
+8941,Croatia,2017,8,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million US$ at exchange rate,129.7
+8942,Croatia,2017,8,"C01B-Antiarrhythmics, Class I and III",Million of national currency units,16.0
+8943,Croatia,2017,8,C07-Beta blocking agents,Million of national currency units,87.0
+8944,Croatia,2017,8,R03-Drugs for obstructive airway diseases,"/capita, US$ exchange rate",60.6
+8945,Croatia,2017,8,J-Antiinfectives for systemic use,"/capita, US$ purchasing power parity",334.2
+8946,Croatia,2017,8,A02A-Antacids,Million of national currency units,9.0
+8947,Croatia,2017,8,Total pharmaceutical sales,Million US$ at exchange rate,6975.1
+8948,Croatia,2017,8,R-Respiratory system,"Million US$, purchasing power parity",811.3
+8949,Croatia,2017,8,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million US$ at exchange rate,131.9
+8950,Croatia,2017,8,N05B-Anxiolytics,"Million US$, purchasing power parity",204.0
+8951,Croatia,2017,8,C-Cardiovascular system,Million of national currency units,785.0
+8952,Croatia,2017,8,C10-Lipid modifying agents,"/capita, US$ exchange rate",41.0
+8953,Croatia,2017,8,M01A-Antiinflammatory and antirheumatic products non-steroids,"Million US$, purchasing power parity",315.0
+8954,Croatia,2017,8,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million of national currency units,116.0
+8955,Croatia,2017,8,N05C-Hypnotics and sedatives,Million of national currency units,35.0
+8956,Croatia,2017,8,J-Antiinfectives for systemic use,"Million US$, purchasing power parity",1380.1
+8957,Croatia,2017,8,N02-Analgesics,Million US$ at exchange rate,208.2
+8958,Croatia,2017,8,N-Nervous system,Million of national currency units,834.0
+8959,Croatia,2017,8,C08-Calcium channel blockers,"Million US$, purchasing power parity",188.1
+8960,Croatia,2017,8,B-Blood and blood forming organs,Million of national currency units,496.0
+8961,Croatia,2017,8,G-Genito urinary system and sex hormones,"/capita, US$ purchasing power parity",98.2
+8962,Croatia,2017,8,C08-Calcium channel blockers,"/capita, US$ purchasing power parity",45.5
+8963,Croatia,2017,8,N06A-Antidepressants,"/capita, US$ purchasing power parity",43.9
+8964,Croatia,2017,8,N02-Analgesics,Million of national currency units,183.0
+8965,Croatia,2017,8,C02-Antihypertensives,Million of national currency units,47.0
+8966,Croatia,2017,8,N06A-Antidepressants,Million of national currency units,80.0
+8967,Croatia,2017,8,C09-Agents acting on the Renin-Angiotensin system,"Million US$, purchasing power parity",713.9
+8968,Croatia,2017,8,C10-Lipid modifying agents,Million of national currency units,149.0
+8969,Croatia,2017,8,R03-Drugs for obstructive airway diseases,Million of national currency units,220.0
+8970,Croatia,2017,8,C01A-Cardiac glycosides,"/capita, US$ purchasing power parity",2.7
+8971,Croatia,2017,8,M-Musculo-skeletal system,"/capita, US$ exchange rate",62.8
+8972,Croatia,2017,8,G03-Sex hormones and modulators of the genital system,"Million US$, purchasing power parity",140.5
+8973,Croatia,2017,8,C03-Diuretics,"Million US$, purchasing power parity",120.1
+8974,Croatia,2017,8,N05B-Anxiolytics,"/capita, US$ purchasing power parity",49.4
+8975,Croatia,2017,8,B-Blood and blood forming organs,Million US$ at exchange rate,564.2
+8976,Croatia,2017,8,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ exchange rate",86.8
+8977,Croatia,2017,8,A02A-Antacids,Million US$ at exchange rate,10.2
+8978,Croatia,2017,8,Total pharmaceutical sales,"/capita, US$ purchasing power parity",3364.9
+8979,Croatia,2017,8,"C01B-Antiarrhythmics, Class I and III",Million US$ at exchange rate,18.2
+8980,Croatia,2017,8,M-Musculo-skeletal system,Million of national currency units,228.0
+8981,Croatia,2017,8,C02-Antihypertensives,"Million US$, purchasing power parity",106.5
+8982,Croatia,2017,8,N-Nervous system,Million US$ at exchange rate,948.7
+8983,Croatia,2017,8,G03-Sex hormones and modulators of the genital system,"/capita, US$ exchange rate",17.1
+8984,Croatia,2017,8,A10-Drugs used in diabetes,"/capita, US$ purchasing power parity",223.9
+8985,Croatia,2017,8,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ exchange rate",31.4
+8986,Croatia,2017,8,N02-Analgesics,"/capita, US$ purchasing power parity",100.4
+8987,Croatia,2017,8,C02-Antihypertensives,"/capita, US$ purchasing power parity",25.8
+8988,Croatia,2017,8,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ purchasing power parity",76.3
+8989,Croatia,2017,8,N05C-Hypnotics and sedatives,Million US$ at exchange rate,39.8
+8990,Croatia,2017,8,C02-Antihypertensives,Million US$ at exchange rate,53.5
+8991,Croatia,2017,8,R-Respiratory system,"/capita, US$ purchasing power parity",196.5
+8992,Croatia,2017,8,C-Cardiovascular system,Million US$ at exchange rate,892.9
+8993,Croatia,2017,8,A-Alimentary tract and metabolism,"/capita, US$ purchasing power parity",438.4
+8994,Croatia,2017,8,Total pharmaceutical sales,"/capita, US$ exchange rate",1688.9
+8995,Croatia,2017,8,N05C-Hypnotics and sedatives,"/capita, US$ exchange rate",9.6
+8996,Croatia,2017,8,M-Musculo-skeletal system,"/capita, US$ purchasing power parity",125.1
+8997,Croatia,2017,8,R03-Drugs for obstructive airway diseases,Million US$ at exchange rate,250.2
+8998,Croatia,2017,8,C-Cardiovascular system,"/capita, US$ purchasing power parity",430.8
+8999,Croatia,2017,8,C10-Lipid modifying agents,Million US$ at exchange rate,169.5
+9000,Croatia,2017,8,Total pharmaceutical sales,Million of national currency units,6132.0
+9001,Croatia,2017,8,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ purchasing power parity",63.7
+9002,Croatia,2017,8,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million of national currency units,114.0
+9003,Croatia,2017,8,J01-Antibacterials for systemic use,"/capita, US$ exchange rate",85.9
+9004,Croatia,2017,8,N06A-Antidepressants,Million US$ at exchange rate,91.0
+9005,Croatia,2017,8,B-Blood and blood forming organs,"/capita, US$ purchasing power parity",272.2
+9006,Croatia,2017,8,C10-Lipid modifying agents,"Million US$, purchasing power parity",337.7
+9007,Croatia,2017,8,C09-Agents acting on the Renin-Angiotensin system,Million US$ at exchange rate,358.3
+9008,Croatia,2017,8,C03-Diuretics,Million US$ at exchange rate,60.3
+9009,Croatia,2017,8,A02A-Antacids,"/capita, US$ purchasing power parity",4.9
+9010,Croatia,2017,8,A10-Drugs used in diabetes,"/capita, US$ exchange rate",112.4
+9011,Croatia,2017,8,J-Antiinfectives for systemic use,"/capita, US$ exchange rate",167.7
+9012,Croatia,2017,8,C09-Agents acting on the Renin-Angiotensin system,% of total sales,5.1
+9013,Croatia,2017,8,A10-Drugs used in diabetes,% of total sales,6.7
+9014,Croatia,2017,8,G03-Sex hormones and modulators of the genital system,% of total sales,1.0
+9015,Croatia,2017,8,C01A-Cardiac glycosides,Million US$ at exchange rate,5.7
+9016,Croatia,2017,8,R03-Drugs for obstructive airway diseases,"/capita, US$ purchasing power parity",120.7
+9017,Croatia,2017,8,A-Alimentary tract and metabolism,"/capita, US$ exchange rate",220.1
+9018,Croatia,2017,8,N02-Analgesics,"Million US$, purchasing power parity",414.7
+9019,Croatia,2017,8,C08-Calcium channel blockers,Million of national currency units,83.0
+9020,Croatia,2017,8,C03-Diuretics,"/capita, US$ exchange rate",14.6
+9021,Croatia,2017,8,C-Cardiovascular system,"Million US$, purchasing power parity",1779.0
+9022,Croatia,2017,8,C07-Beta blocking agents,"/capita, US$ purchasing power parity",47.7
+9023,Croatia,2017,8,J01-Antibacterials for systemic use,Million US$ at exchange rate,354.9
+9024,Croatia,2017,8,"C01B-Antiarrhythmics, Class I and III","/capita, US$ purchasing power parity",8.8
+9025,Croatia,2017,8,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ exchange rate",38.3
+9026,Croatia,2017,8,"H-Systemic hormonal preparations, excluding sex hormones and insulins","Million US$, purchasing power parity",258.4
+9027,Croatia,2017,8,N05B-Anxiolytics,"/capita, US$ exchange rate",24.8
+9028,Croatia,2017,8,N05C-Hypnotics and sedatives,"/capita, US$ purchasing power parity",19.2
+9029,Croatia,2017,8,G-Genito urinary system and sex hormones,Million of national currency units,179.0
+9030,Croatia,2017,8,M-Musculo-skeletal system,% of total sales,3.7
+9031,Croatia,2017,8,"H-Systemic hormonal preparations, excluding sex hormones and insulins",% of total sales,1.9
+9032,Croatia,2017,8,C10-Lipid modifying agents,% of total sales,2.4
+9033,Croatia,2017,8,C-Cardiovascular system,% of total sales,12.8
+9034,Croatia,2017,8,N06A-Antidepressants,% of total sales,1.3
+9035,Croatia,2017,8,N02-Analgesics,% of total sales,3.0
+9036,Croatia,2017,8,C08-Calcium channel blockers,% of total sales,1.4
+9037,Croatia,2017,8,C02-Antihypertensives,% of total sales,0.8
+9038,Croatia,2017,8,G-Genito urinary system and sex hormones,% of total sales,2.9
+9039,Croatia,2017,8,M01A-Antiinflammatory and antirheumatic products non-steroids,% of total sales,2.3
+9040,Croatia,2017,8,J-Antiinfectives for systemic use,% of total sales,9.9
+9041,Croatia,2017,8,A-Alimentary tract and metabolism,% of total sales,13.0
+9042,Croatia,2017,8,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),% of total sales,1.9
+9043,Croatia,2017,8,R-Respiratory system,% of total sales,5.8
+9044,Croatia,2017,8,B-Blood and blood forming organs,% of total sales,8.1
+9045,Croatia,2017,8,"C01B-Antiarrhythmics, Class I and III",% of total sales,0.3
+9046,Croatia,2017,8,N05B-Anxiolytics,% of total sales,1.5
+9047,Croatia,2017,8,C03-Diuretics,% of total sales,0.9
+9048,Croatia,2017,8,C01A-Cardiac glycosides,% of total sales,0.1
+9049,Croatia,2017,8,N05C-Hypnotics and sedatives,% of total sales,0.6
+9050,Croatia,2017,8,N-Nervous system,% of total sales,13.6
+9051,Croatia,2017,8,J01-Antibacterials for systemic use,% of total sales,5.1
+9052,Croatia,2017,8,C07-Beta blocking agents,% of total sales,1.4
+9053,Croatia,2017,8,R03-Drugs for obstructive airway diseases,% of total sales,3.6
+9054,Croatia,2017,8,A02A-Antacids,% of total sales,0.1
+9055,Croatia,2017,8,N05B-Anxiolytics,Million of national currency units,90.0
+9056,Croatia,2017,8,"C01B-Antiarrhythmics, Class I and III","Million US$, purchasing power parity",36.3
+9057,Croatia,2017,8,N05C-Hypnotics and sedatives,"Million US$, purchasing power parity",79.3
+9058,Croatia,2017,8,C08-Calcium channel blockers,"/capita, US$ exchange rate",22.9
+9059,Croatia,2017,8,G-Genito urinary system and sex hormones,"/capita, US$ exchange rate",49.3
+9060,Croatia,2017,8,G03-Sex hormones and modulators of the genital system,"/capita, US$ purchasing power parity",34.0
+9061,Croatia,2017,8,N05B-Anxiolytics,Million US$ at exchange rate,102.4
+9062,Croatia,2017,8,B-Blood and blood forming organs,"Million US$, purchasing power parity",1124.1
+9063,Croatia,2017,8,G-Genito urinary system and sex hormones,Million US$ at exchange rate,203.6
+9064,Croatia,2017,8,N02-Analgesics,"/capita, US$ exchange rate",50.4
+9065,Croatia,2017,8,N06A-Antidepressants,"/capita, US$ exchange rate",22.0
+9066,Croatia,2017,8,M01A-Antiinflammatory and antirheumatic products non-steroids,Million US$ at exchange rate,158.1
+9067,Croatia,2017,8,C02-Antihypertensives,"/capita, US$ exchange rate",12.9
+9068,Croatia,2017,8,A10-Drugs used in diabetes,Million US$ at exchange rate,464.1
+9069,Croatia,2017,8,N-Nervous system,"/capita, US$ purchasing power parity",457.7
+9070,Croatia,2017,8,R03-Drugs for obstructive airway diseases,"Million US$, purchasing power parity",498.6
+9071,Croatia,2017,8,C09-Agents acting on the Renin-Angiotensin system,Million of national currency units,315.0
+9072,Croatia,2017,8,C07-Beta blocking agents,"/capita, US$ exchange rate",24.0
+9073,Croatia,2017,8,M-Musculo-skeletal system,Million US$ at exchange rate,259.3
+9074,Croatia,2017,8,C01A-Cardiac glycosides,"Million US$, purchasing power parity",11.3
+9075,Croatia,2017,8,R-Respiratory system,Million US$ at exchange rate,407.2
+9076,Croatia,2017,8,J01-Antibacterials for systemic use,"/capita, US$ purchasing power parity",171.2
+9077,Croatia,2017,8,J01-Antibacterials for systemic use,Million of national currency units,312.0
+9078,Croatia,2017,8,A-Alimentary tract and metabolism,Million US$ at exchange rate,908.8
+9079,Croatia,2017,8,C07-Beta blocking agents,"Million US$, purchasing power parity",197.2
+9080,Croatia,2017,8,G03-Sex hormones and modulators of the genital system,Million of national currency units,62.0
+9081,Croatia,2017,8,Total pharmaceutical sales,"Million US$, purchasing power parity",13896.6
+9082,Croatia,2017,8,A-Alimentary tract and metabolism,Million of national currency units,799.0
+9083,Croatia,2017,8,J-Antiinfectives for systemic use,Million of national currency units,609.0
+9084,Croatia,2017,8,N06A-Antidepressants,"Million US$, purchasing power parity",181.3
+9085,Croatia,2017,8,C01A-Cardiac glycosides,"/capita, US$ exchange rate",1.4
+9086,Croatia,2017,8,G03-Sex hormones and modulators of the genital system,Million US$ at exchange rate,70.5
+9087,Croatia,2017,8,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ purchasing power parity",62.6
+9088,Croatia,2017,8,C10-Lipid modifying agents,"/capita, US$ purchasing power parity",81.8
+9089,Croatia,2017,8,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"Million US$, purchasing power parity",262.9
+9090,Croatia,2017,8,A10-Drugs used in diabetes,Million of national currency units,408.0
+9091,Croatia,2017,8,M-Musculo-skeletal system,"Million US$, purchasing power parity",516.7
+9092,Croatia,2017,8,M01A-Antiinflammatory and antirheumatic products non-steroids,Million of national currency units,139.0
+9093,Croatia,2017,8,J01-Antibacterials for systemic use,"Million US$, purchasing power parity",707.1
+9094,Croatia,2017,8,A02A-Antacids,"Million US$, purchasing power parity",20.4
+9095,Croatia,2017,8,C01A-Cardiac glycosides,Million of national currency units,5.0
+9096,Croatia,2017,8,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ exchange rate",31.9
+9097,Croatia,2017,8,C-Cardiovascular system,"/capita, US$ exchange rate",216.2
+9098,Croatia,2017,8,C08-Calcium channel blockers,Million US$ at exchange rate,94.4
+9099,Croatia,2017,8,C03-Diuretics,"/capita, US$ purchasing power parity",29.1
+9100,Croatia,2017,8,C03-Diuretics,Million of national currency units,53.0
+9101,Croatia,2017,8,R-Respiratory system,"/capita, US$ exchange rate",98.6
+9102,Croatia,2017,8,R-Respiratory system,Million of national currency units,358.0
+9103,Croatia,2017,8,J-Antiinfectives for systemic use,Million US$ at exchange rate,692.7
+9104,Croatia,2017,8,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ purchasing power parity",172.9
+9105,Croatia,2017,8,N-Nervous system,"Million US$, purchasing power parity",1890.0
+9106,Denmark,2011,5,Total pharmaceutical sales,Million US$ at exchange rate,3825.9
+9107,Denmark,2011,5,R-Respiratory system,"/capita, US$ purchasing power parity",46.0
+9108,Denmark,2011,5,M-Musculo-skeletal system,Million US$ at exchange rate,120.3
+9109,Denmark,2011,5,Total pharmaceutical sales,Million of national currency units,20540.2
+9110,Denmark,2011,5,Total pharmaceutical sales,"Million US$, purchasing power parity",2751.0
+9111,Denmark,2011,5,C-Cardiovascular system,Million US$ at exchange rate,264.2
+9112,Denmark,2011,5,M-Musculo-skeletal system,"Million US$, purchasing power parity",86.5
+9113,Denmark,2011,5,C-Cardiovascular system,Million of national currency units,1418.5
+9114,Denmark,2011,5,R-Respiratory system,% of total sales,9.3
+9115,Denmark,2011,5,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ purchasing power parity",12.0
+9116,Denmark,2011,5,"H-Systemic hormonal preparations, excluding sex hormones and insulins",% of total sales,2.4
+9117,Denmark,2011,5,M-Musculo-skeletal system,Million of national currency units,646.0
+9118,Denmark,2011,5,J-Antiinfectives for systemic use,Million of national currency units,2036.3
+9119,Denmark,2011,5,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ exchange rate",16.6
+9120,Denmark,2011,5,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million of national currency units,497.6
+9121,Denmark,2011,5,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million US$ at exchange rate,92.7
+9122,Denmark,2011,5,"H-Systemic hormonal preparations, excluding sex hormones and insulins","Million US$, purchasing power parity",66.6
+9123,Denmark,2011,5,J-Antiinfectives for systemic use,"Million US$, purchasing power parity",272.7
+9124,Denmark,2011,5,J-Antiinfectives for systemic use,Million US$ at exchange rate,379.3
+9125,Denmark,2011,5,R-Respiratory system,Million of national currency units,1913.4
+9126,Denmark,2011,5,J-Antiinfectives for systemic use,"/capita, US$ exchange rate",68.1
+9127,Denmark,2011,5,R-Respiratory system,"/capita, US$ exchange rate",64.0
+9128,Denmark,2011,5,Total pharmaceutical sales,"/capita, US$ purchasing power parity",493.8
+9129,Denmark,2011,5,R-Respiratory system,Million US$ at exchange rate,356.4
+9130,Denmark,2011,5,C-Cardiovascular system,% of total sales,6.9
+9131,Denmark,2011,5,R-Respiratory system,"Million US$, purchasing power parity",256.3
+9132,Denmark,2011,5,M-Musculo-skeletal system,"/capita, US$ exchange rate",21.6
+9133,Denmark,2011,5,M-Musculo-skeletal system,"/capita, US$ purchasing power parity",15.5
+9134,Denmark,2011,5,C-Cardiovascular system,"Million US$, purchasing power parity",190.0
+9135,Denmark,2011,5,C-Cardiovascular system,"/capita, US$ exchange rate",47.4
+9136,Denmark,2011,5,J-Antiinfectives for systemic use,"/capita, US$ purchasing power parity",49.0
+9137,Denmark,2011,5,C-Cardiovascular system,"/capita, US$ purchasing power parity",34.1
+9138,Denmark,2011,5,J-Antiinfectives for systemic use,% of total sales,9.9
+9139,Denmark,2011,5,M-Musculo-skeletal system,% of total sales,3.1
+9140,Denmark,2011,5,Total pharmaceutical sales,"/capita, US$ exchange rate",686.8
+9141,Denmark,2011,5,B-Blood and blood forming organs,"/capita, US$ exchange rate",40.3
+9142,Denmark,2011,5,B-Blood and blood forming organs,"Million US$, purchasing power parity",161.5
+9143,Denmark,2011,5,Products not elsewhere classified,Million of national currency units,5610.0
+9144,Denmark,2011,5,Products not elsewhere classified,Million US$ at exchange rate,1044.9
+9145,Denmark,2011,5,G-Genito urinary system and sex hormones,"/capita, US$ purchasing power parity",22.7
+9146,Denmark,2011,5,G-Genito urinary system and sex hormones,% of total sales,4.6
+9147,Denmark,2011,5,A-Alimentary tract and metabolism,"/capita, US$ exchange rate",56.3
+9148,Denmark,2011,5,A-Alimentary tract and metabolism,Million US$ at exchange rate,313.5
+9149,Denmark,2011,5,B-Blood and blood forming organs,"/capita, US$ purchasing power parity",29.0
+9150,Denmark,2011,5,A-Alimentary tract and metabolism,Million of national currency units,1682.9
+9151,Denmark,2011,5,N-Nervous system,"/capita, US$ exchange rate",153.3
+9152,Denmark,2011,5,B-Blood and blood forming organs,% of total sales,5.9
+9153,Denmark,2011,5,A-Alimentary tract and metabolism,"Million US$, purchasing power parity",225.4
+9154,Denmark,2011,5,N-Nervous system,% of total sales,22.3
+9155,Denmark,2011,5,N-Nervous system,"/capita, US$ purchasing power parity",110.2
+9156,Denmark,2011,5,G-Genito urinary system and sex hormones,"/capita, US$ exchange rate",31.6
+9157,Denmark,2011,5,N-Nervous system,Million US$ at exchange rate,853.7
+9158,Denmark,2011,5,G-Genito urinary system and sex hormones,Million of national currency units,946.1
+9159,Denmark,2011,5,G-Genito urinary system and sex hormones,Million US$ at exchange rate,176.2
+9160,Denmark,2011,5,A-Alimentary tract and metabolism,% of total sales,8.2
+9161,Denmark,2011,5,N-Nervous system,Million of national currency units,4583.4
+9162,Denmark,2011,5,N-Nervous system,"Million US$, purchasing power parity",613.9
+9163,Denmark,2011,5,A-Alimentary tract and metabolism,"/capita, US$ purchasing power parity",40.5
+9164,Denmark,2011,5,Products not elsewhere classified,"Million US$, purchasing power parity",751.4
+9165,Denmark,2011,5,Products not elsewhere classified,"/capita, US$ exchange rate",187.6
+9166,Denmark,2011,5,B-Blood and blood forming organs,Million US$ at exchange rate,224.6
+9167,Denmark,2011,5,B-Blood and blood forming organs,Million of national currency units,1206.0
+9168,Denmark,2011,5,Products not elsewhere classified,"/capita, US$ purchasing power parity",134.9
+9169,Denmark,2011,5,G-Genito urinary system and sex hormones,"Million US$, purchasing power parity",126.7
+9170,Denmark,2011,5,Products not elsewhere classified,% of total sales,27.3
+9171,Denmark,2012,5,Total pharmaceutical sales,Million US$ at exchange rate,3532.1
+9172,Denmark,2012,5,R-Respiratory system,"/capita, US$ purchasing power parity",46.8
+9173,Denmark,2012,5,Total pharmaceutical sales,Million of national currency units,20459.8
+9174,Denmark,2012,5,M-Musculo-skeletal system,Million US$ at exchange rate,93.9
+9175,Denmark,2012,5,Total pharmaceutical sales,"Million US$, purchasing power parity",2704.8
+9176,Denmark,2012,5,C-Cardiovascular system,Million US$ at exchange rate,219.8
+9177,Denmark,2012,5,C-Cardiovascular system,Million of national currency units,1273.3
+9178,Denmark,2012,5,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ purchasing power parity",11.4
+9179,Denmark,2012,5,"H-Systemic hormonal preparations, excluding sex hormones and insulins",% of total sales,2.4
+9180,Denmark,2012,5,M-Musculo-skeletal system,Million of national currency units,543.8
+9181,Denmark,2012,5,J-Antiinfectives for systemic use,Million of national currency units,2015.8
+9182,Denmark,2012,5,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ exchange rate",14.9
+9183,Denmark,2012,5,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million of national currency units,482.7
+9184,Denmark,2012,5,"H-Systemic hormonal preparations, excluding sex hormones and insulins","Million US$, purchasing power parity",63.8
+9185,Denmark,2012,5,R-Respiratory system,% of total sales,9.7
+9186,Denmark,2012,5,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million US$ at exchange rate,83.3
+9187,Denmark,2012,5,J-Antiinfectives for systemic use,"Million US$, purchasing power parity",266.5
+9188,Denmark,2012,5,J-Antiinfectives for systemic use,Million US$ at exchange rate,348.0
+9189,Denmark,2012,5,R-Respiratory system,Million of national currency units,1977.5
+9190,Denmark,2012,5,C-Cardiovascular system,% of total sales,6.2
+9191,Denmark,2012,5,J-Antiinfectives for systemic use,"/capita, US$ exchange rate",62.2
+9192,Denmark,2012,5,R-Respiratory system,"/capita, US$ exchange rate",61.1
+9193,Denmark,2012,5,Total pharmaceutical sales,"/capita, US$ purchasing power parity",483.7
+9194,Denmark,2012,5,R-Respiratory system,Million US$ at exchange rate,341.4
+9195,Denmark,2012,5,R-Respiratory system,"Million US$, purchasing power parity",261.4
+9196,Denmark,2012,5,M-Musculo-skeletal system,"/capita, US$ exchange rate",16.8
+9197,Denmark,2012,5,M-Musculo-skeletal system,"/capita, US$ purchasing power parity",12.9
+9198,Denmark,2012,5,C-Cardiovascular system,"Million US$, purchasing power parity",168.3
+9199,Denmark,2012,5,C-Cardiovascular system,"/capita, US$ exchange rate",39.3
+9200,Denmark,2012,5,M-Musculo-skeletal system,"Million US$, purchasing power parity",71.9
+9201,Denmark,2012,5,Total pharmaceutical sales,"/capita, US$ exchange rate",631.7
+9202,Denmark,2012,5,J-Antiinfectives for systemic use,"/capita, US$ purchasing power parity",47.7
+9203,Denmark,2012,5,C-Cardiovascular system,"/capita, US$ purchasing power parity",30.1
+9204,Denmark,2012,5,J-Antiinfectives for systemic use,% of total sales,9.9
+9205,Denmark,2012,5,M-Musculo-skeletal system,% of total sales,2.7
+9206,Denmark,2012,5,B-Blood and blood forming organs,"/capita, US$ exchange rate",41.5
+9207,Denmark,2012,5,B-Blood and blood forming organs,"Million US$, purchasing power parity",177.7
+9208,Denmark,2012,5,Products not elsewhere classified,Million of national currency units,5976.8
+9209,Denmark,2012,5,Products not elsewhere classified,Million US$ at exchange rate,1031.8
+9210,Denmark,2012,5,G-Genito urinary system and sex hormones,"/capita, US$ purchasing power parity",23.1
+9211,Denmark,2012,5,G-Genito urinary system and sex hormones,% of total sales,4.8
+9212,Denmark,2012,5,A-Alimentary tract and metabolism,"/capita, US$ exchange rate",54.9
+9213,Denmark,2012,5,A-Alimentary tract and metabolism,Million US$ at exchange rate,306.8
+9214,Denmark,2012,5,A-Alimentary tract and metabolism,Million of national currency units,1777.0
+9215,Denmark,2012,5,N-Nervous system,"/capita, US$ exchange rate",126.3
+9216,Denmark,2012,5,B-Blood and blood forming organs,"/capita, US$ purchasing power parity",31.8
+9217,Denmark,2012,5,B-Blood and blood forming organs,% of total sales,6.6
+9218,Denmark,2012,5,A-Alimentary tract and metabolism,"Million US$, purchasing power parity",234.9
+9219,Denmark,2012,5,N-Nervous system,% of total sales,20.0
+9220,Denmark,2012,5,N-Nervous system,"/capita, US$ purchasing power parity",96.7
+9221,Denmark,2012,5,G-Genito urinary system and sex hormones,"/capita, US$ exchange rate",30.2
+9222,Denmark,2012,5,N-Nervous system,Million US$ at exchange rate,706.2
+9223,Denmark,2012,5,G-Genito urinary system and sex hormones,Million of national currency units,978.0
+9224,Denmark,2012,5,G-Genito urinary system and sex hormones,Million US$ at exchange rate,168.8
+9225,Denmark,2012,5,A-Alimentary tract and metabolism,% of total sales,8.7
+9226,Denmark,2012,5,N-Nervous system,Million of national currency units,4090.7
+9227,Denmark,2012,5,N-Nervous system,"Million US$, purchasing power parity",540.8
+9228,Denmark,2012,5,A-Alimentary tract and metabolism,"/capita, US$ purchasing power parity",42.0
+9229,Denmark,2012,5,Products not elsewhere classified,"Million US$, purchasing power parity",790.2
+9230,Denmark,2012,5,Products not elsewhere classified,"/capita, US$ exchange rate",184.5
+9231,Denmark,2012,5,B-Blood and blood forming organs,Million US$ at exchange rate,232.0
+9232,Denmark,2012,5,B-Blood and blood forming organs,Million of national currency units,1344.1
+9233,Denmark,2012,5,G-Genito urinary system and sex hormones,"Million US$, purchasing power parity",129.3
+9234,Denmark,2012,5,Products not elsewhere classified,% of total sales,29.2
+9235,Denmark,2012,5,Products not elsewhere classified,"/capita, US$ purchasing power parity",141.3
+9236,Denmark,2013,4,Total pharmaceutical sales,Million US$ at exchange rate,3636.2
+9237,Denmark,2013,4,Total pharmaceutical sales,Million of national currency units,20422.2
+9238,Denmark,2013,4,R-Respiratory system,"/capita, US$ purchasing power parity",46.2
+9239,Denmark,2013,4,Total pharmaceutical sales,"Million US$, purchasing power parity",2776.7
+9240,Denmark,2013,4,C-Cardiovascular system,Million US$ at exchange rate,200.9
+9241,Denmark,2013,4,M-Musculo-skeletal system,Million US$ at exchange rate,98.2
+9242,Denmark,2013,4,C-Cardiovascular system,Million of national currency units,1128.6
+9243,Denmark,2013,4,R-Respiratory system,% of total sales,9.3
+9244,Denmark,2013,4,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ purchasing power parity",10.6
+9245,Denmark,2013,4,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ exchange rate",13.9
+9246,Denmark,2013,4,M-Musculo-skeletal system,Million of national currency units,551.8
+9247,Denmark,2013,4,J-Antiinfectives for systemic use,Million of national currency units,2066.2
+9248,Denmark,2013,4,"H-Systemic hormonal preparations, excluding sex hormones and insulins",% of total sales,2.1
+9249,Denmark,2013,4,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million of national currency units,437.0
+9250,Denmark,2013,4,"H-Systemic hormonal preparations, excluding sex hormones and insulins","Million US$, purchasing power parity",59.4
+9251,Denmark,2013,4,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million US$ at exchange rate,77.8
+9252,Denmark,2013,4,J-Antiinfectives for systemic use,"Million US$, purchasing power parity",280.9
+9253,Denmark,2013,4,J-Antiinfectives for systemic use,Million US$ at exchange rate,367.9
+9254,Denmark,2013,4,Total pharmaceutical sales,"/capita, US$ exchange rate",647.6
+9255,Denmark,2013,4,C-Cardiovascular system,% of total sales,5.5
+9256,Denmark,2013,4,J-Antiinfectives for systemic use,"/capita, US$ exchange rate",65.5
+9257,Denmark,2013,4,R-Respiratory system,Million of national currency units,1909.3
+9258,Denmark,2013,4,R-Respiratory system,"/capita, US$ exchange rate",60.5
+9259,Denmark,2013,4,Total pharmaceutical sales,"/capita, US$ purchasing power parity",494.5
+9260,Denmark,2013,4,R-Respiratory system,Million US$ at exchange rate,340.0
+9261,Denmark,2013,4,R-Respiratory system,"Million US$, purchasing power parity",259.6
+9262,Denmark,2013,4,M-Musculo-skeletal system,"/capita, US$ exchange rate",17.5
+9263,Denmark,2013,4,M-Musculo-skeletal system,"/capita, US$ purchasing power parity",13.4
+9264,Denmark,2013,4,M-Musculo-skeletal system,"Million US$, purchasing power parity",75.0
+9265,Denmark,2013,4,C-Cardiovascular system,"Million US$, purchasing power parity",153.4
+9266,Denmark,2013,4,C-Cardiovascular system,"/capita, US$ exchange rate",35.8
+9267,Denmark,2013,4,J-Antiinfectives for systemic use,"/capita, US$ purchasing power parity",50.0
+9268,Denmark,2013,4,C-Cardiovascular system,"/capita, US$ purchasing power parity",27.3
+9269,Denmark,2013,4,M-Musculo-skeletal system,% of total sales,2.7
+9270,Denmark,2013,4,J-Antiinfectives for systemic use,% of total sales,10.1
+9271,Denmark,2013,4,B-Blood and blood forming organs,"/capita, US$ exchange rate",44.6
+9272,Denmark,2013,4,B-Blood and blood forming organs,"Million US$, purchasing power parity",191.1
+9273,Denmark,2013,4,Products not elsewhere classified,Million of national currency units,6538.7
+9274,Denmark,2013,4,Products not elsewhere classified,Million US$ at exchange rate,1164.2
+9275,Denmark,2013,4,G-Genito urinary system and sex hormones,"/capita, US$ purchasing power parity",21.1
+9276,Denmark,2013,4,A-Alimentary tract and metabolism,"/capita, US$ exchange rate",57.9
+9277,Denmark,2013,4,G-Genito urinary system and sex hormones,% of total sales,4.3
+9278,Denmark,2013,4,A-Alimentary tract and metabolism,Million of national currency units,1825.1
+9279,Denmark,2013,4,N-Nervous system,"/capita, US$ exchange rate",117.0
+9280,Denmark,2013,4,B-Blood and blood forming organs,"/capita, US$ purchasing power parity",34.0
+9281,Denmark,2013,4,B-Blood and blood forming organs,% of total sales,6.9
+9282,Denmark,2013,4,A-Alimentary tract and metabolism,"Million US$, purchasing power parity",248.2
+9283,Denmark,2013,4,N-Nervous system,% of total sales,18.1
+9284,Denmark,2013,4,N-Nervous system,"/capita, US$ purchasing power parity",89.3
+9285,Denmark,2013,4,A-Alimentary tract and metabolism,Million US$ at exchange rate,325.0
+9286,Denmark,2013,4,G-Genito urinary system and sex hormones,"/capita, US$ exchange rate",27.6
+9287,Denmark,2013,4,N-Nervous system,Million US$ at exchange rate,657.0
+9288,Denmark,2013,4,G-Genito urinary system and sex hormones,Million US$ at exchange rate,155.0
+9289,Denmark,2013,4,G-Genito urinary system and sex hormones,Million of national currency units,870.4
+9290,Denmark,2013,4,A-Alimentary tract and metabolism,% of total sales,8.9
+9291,Denmark,2013,4,N-Nervous system,Million of national currency units,3689.7
+9292,Denmark,2013,4,N-Nervous system,"Million US$, purchasing power parity",501.7
+9293,Denmark,2013,4,A-Alimentary tract and metabolism,"/capita, US$ purchasing power parity",44.2
+9294,Denmark,2013,4,Products not elsewhere classified,% of total sales,32.0
+9295,Denmark,2013,4,Products not elsewhere classified,"Million US$, purchasing power parity",889.0
+9296,Denmark,2013,4,Products not elsewhere classified,"/capita, US$ exchange rate",207.3
+9297,Denmark,2013,4,B-Blood and blood forming organs,Million US$ at exchange rate,250.2
+9298,Denmark,2013,4,B-Blood and blood forming organs,Million of national currency units,1405.3
+9299,Denmark,2013,4,G-Genito urinary system and sex hormones,"Million US$, purchasing power parity",118.3
+9300,Denmark,2013,4,Products not elsewhere classified,"/capita, US$ purchasing power parity",158.3
+9301,Denmark,2017,4,Total pharmaceutical sales,Million of national currency units,22941.5
+9302,Denmark,2017,4,M-Musculo-skeletal system,Million of national currency units,598.1
+9303,Denmark,2017,4,R-Respiratory system,"/capita, US$ purchasing power parity",48.6
+9304,Denmark,2017,4,R-Respiratory system,"/capita, US$ exchange rate",50.6
+9305,Denmark,2017,4,Total pharmaceutical sales,"Million US$, purchasing power parity",3338.6
+9306,Denmark,2017,4,C-Cardiovascular system,Million US$ at exchange rate,163.5
+9307,Denmark,2017,4,Total pharmaceutical sales,Million US$ at exchange rate,3474.5
+9308,Denmark,2017,4,M-Musculo-skeletal system,Million US$ at exchange rate,90.6
+9309,Denmark,2017,4,C-Cardiovascular system,Million of national currency units,1079.3
+9310,Denmark,2017,4,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ purchasing power parity",12.1
+9311,Denmark,2017,4,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ exchange rate",12.6
+9312,Denmark,2017,4,J-Antiinfectives for systemic use,Million of national currency units,1983.3
+9313,Denmark,2017,4,"H-Systemic hormonal preparations, excluding sex hormones and insulins",% of total sales,2.1
+9314,Denmark,2017,4,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million of national currency units,477.8
+9315,Denmark,2017,4,R-Respiratory system,% of total sales,8.4
+9316,Denmark,2017,4,"H-Systemic hormonal preparations, excluding sex hormones and insulins","Million US$, purchasing power parity",69.5
+9317,Denmark,2017,4,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million US$ at exchange rate,72.4
+9318,Denmark,2017,4,Total pharmaceutical sales,"/capita, US$ exchange rate",602.7
+9319,Denmark,2017,4,J-Antiinfectives for systemic use,"Million US$, purchasing power parity",288.6
+9320,Denmark,2017,4,J-Antiinfectives for systemic use,Million US$ at exchange rate,300.4
+9321,Denmark,2017,4,C-Cardiovascular system,% of total sales,4.7
+9322,Denmark,2017,4,J-Antiinfectives for systemic use,"/capita, US$ exchange rate",52.1
+9323,Denmark,2017,4,Total pharmaceutical sales,"/capita, US$ purchasing power parity",579.1
+9324,Denmark,2017,4,R-Respiratory system,"Million US$, purchasing power parity",280.2
+9325,Denmark,2017,4,R-Respiratory system,Million of national currency units,1925.4
+9326,Denmark,2017,4,R-Respiratory system,Million US$ at exchange rate,291.6
+9327,Denmark,2017,4,M-Musculo-skeletal system,"Million US$, purchasing power parity",87.0
+9328,Denmark,2017,4,M-Musculo-skeletal system,"/capita, US$ exchange rate",15.7
+9329,Denmark,2017,4,C-Cardiovascular system,"Million US$, purchasing power parity",157.1
+9330,Denmark,2017,4,C-Cardiovascular system,"/capita, US$ exchange rate",28.4
+9331,Denmark,2017,4,M-Musculo-skeletal system,"/capita, US$ purchasing power parity",15.1
+9332,Denmark,2017,4,C-Cardiovascular system,"/capita, US$ purchasing power parity",27.2
+9333,Denmark,2017,4,M-Musculo-skeletal system,% of total sales,2.6
+9334,Denmark,2017,4,J-Antiinfectives for systemic use,% of total sales,8.6
+9335,Denmark,2017,4,J-Antiinfectives for systemic use,"/capita, US$ purchasing power parity",50.1
+9336,Denmark,2017,4,B-Blood and blood forming organs,"/capita, US$ exchange rate",52.4
+9337,Denmark,2017,4,B-Blood and blood forming organs,"Million US$, purchasing power parity",290.1
+9338,Denmark,2017,4,Products not elsewhere classified,Million of national currency units,8416.3
+9339,Denmark,2017,4,G-Genito urinary system and sex hormones,"/capita, US$ purchasing power parity",21.0
+9340,Denmark,2017,4,G-Genito urinary system and sex hormones,"/capita, US$ exchange rate",21.8
+9341,Denmark,2017,4,G-Genito urinary system and sex hormones,% of total sales,3.6
+9342,Denmark,2017,4,A-Alimentary tract and metabolism,Million of national currency units,2320.4
+9343,Denmark,2017,4,B-Blood and blood forming organs,% of total sales,8.7
+9344,Denmark,2017,4,B-Blood and blood forming organs,"/capita, US$ purchasing power parity",50.3
+9345,Denmark,2017,4,N-Nervous system,"/capita, US$ exchange rate",87.1
+9346,Denmark,2017,4,A-Alimentary tract and metabolism,"Million US$, purchasing power parity",337.7
+9347,Denmark,2017,4,N-Nervous system,% of total sales,14.5
+9348,Denmark,2017,4,N-Nervous system,"/capita, US$ purchasing power parity",83.7
+9349,Denmark,2017,4,A-Alimentary tract and metabolism,Million US$ at exchange rate,351.4
+9350,Denmark,2017,4,A-Alimentary tract and metabolism,"/capita, US$ exchange rate",61.0
+9351,Denmark,2017,4,N-Nervous system,Million US$ at exchange rate,502.3
+9352,Denmark,2017,4,Products not elsewhere classified,% of total sales,36.7
+9353,Denmark,2017,4,G-Genito urinary system and sex hormones,Million of national currency units,830.2
+9354,Denmark,2017,4,N-Nervous system,Million of national currency units,3316.9
+9355,Denmark,2017,4,A-Alimentary tract and metabolism,% of total sales,10.1
+9356,Denmark,2017,4,A-Alimentary tract and metabolism,"/capita, US$ purchasing power parity",58.6
+9357,Denmark,2017,4,N-Nervous system,"Million US$, purchasing power parity",482.7
+9358,Denmark,2017,4,Products not elsewhere classified,"Million US$, purchasing power parity",1224.8
+9359,Denmark,2017,4,Products not elsewhere classified,"/capita, US$ exchange rate",221.1
+9360,Denmark,2017,4,B-Blood and blood forming organs,Million US$ at exchange rate,302.0
+9361,Denmark,2017,4,B-Blood and blood forming organs,Million of national currency units,1993.8
+9362,Denmark,2017,4,Products not elsewhere classified,Million US$ at exchange rate,1274.6
+9363,Denmark,2017,4,Products not elsewhere classified,"/capita, US$ purchasing power parity",212.5
+9364,Denmark,2017,4,G-Genito urinary system and sex hormones,"Million US$, purchasing power parity",120.8
+9365,Denmark,2017,4,G-Genito urinary system and sex hormones,Million US$ at exchange rate,125.7
+9366,Denmark,2015,4,Total pharmaceutical sales,Million US$ at exchange rate,3254.8
+9367,Denmark,2015,4,M-Musculo-skeletal system,Million of national currency units,578.9
+9368,Denmark,2015,4,Total pharmaceutical sales,Million of national currency units,21897.7
+9369,Denmark,2015,4,R-Respiratory system,"/capita, US$ purchasing power parity",47.4
+9370,Denmark,2015,4,Total pharmaceutical sales,"Million US$, purchasing power parity",2997.5
+9371,Denmark,2015,4,C-Cardiovascular system,Million US$ at exchange rate,171.3
+9372,Denmark,2015,4,M-Musculo-skeletal system,Million US$ at exchange rate,86.0
+9373,Denmark,2015,4,C-Cardiovascular system,Million of national currency units,1152.3
+9374,Denmark,2015,4,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ purchasing power parity",11.1
+9375,Denmark,2015,4,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ exchange rate",12.0
+9376,Denmark,2015,4,J-Antiinfectives for systemic use,Million of national currency units,2220.3
+9377,Denmark,2015,4,"H-Systemic hormonal preparations, excluding sex hormones and insulins",% of total sales,2.1
+9378,Denmark,2015,4,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million of national currency units,459.2
+9379,Denmark,2015,4,R-Respiratory system,% of total sales,9.0
+9380,Denmark,2015,4,"H-Systemic hormonal preparations, excluding sex hormones and insulins","Million US$, purchasing power parity",62.9
+9381,Denmark,2015,4,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million US$ at exchange rate,68.2
+9382,Denmark,2015,4,J-Antiinfectives for systemic use,"Million US$, purchasing power parity",303.9
+9383,Denmark,2015,4,J-Antiinfectives for systemic use,Million US$ at exchange rate,330.0
+9384,Denmark,2015,4,Total pharmaceutical sales,"/capita, US$ exchange rate",572.7
+9385,Denmark,2015,4,C-Cardiovascular system,% of total sales,5.3
+9386,Denmark,2015,4,J-Antiinfectives for systemic use,"/capita, US$ exchange rate",58.1
+9387,Denmark,2015,4,R-Respiratory system,Million of national currency units,1968.7
+9388,Denmark,2015,4,R-Respiratory system,"/capita, US$ exchange rate",51.5
+9389,Denmark,2015,4,Total pharmaceutical sales,"/capita, US$ purchasing power parity",527.4
+9390,Denmark,2015,4,R-Respiratory system,Million US$ at exchange rate,292.6
+9391,Denmark,2015,4,R-Respiratory system,"Million US$, purchasing power parity",269.5
+9392,Denmark,2015,4,M-Musculo-skeletal system,"/capita, US$ exchange rate",15.1
+9393,Denmark,2015,4,M-Musculo-skeletal system,"/capita, US$ purchasing power parity",13.9
+9394,Denmark,2015,4,M-Musculo-skeletal system,"Million US$, purchasing power parity",79.2
+9395,Denmark,2015,4,C-Cardiovascular system,"Million US$, purchasing power parity",157.7
+9396,Denmark,2015,4,C-Cardiovascular system,"/capita, US$ exchange rate",30.1
+9397,Denmark,2015,4,J-Antiinfectives for systemic use,"/capita, US$ purchasing power parity",53.5
+9398,Denmark,2015,4,C-Cardiovascular system,"/capita, US$ purchasing power parity",27.8
+9399,Denmark,2015,4,M-Musculo-skeletal system,% of total sales,2.6
+9400,Denmark,2015,4,J-Antiinfectives for systemic use,% of total sales,10.1
+9401,Denmark,2015,4,B-Blood and blood forming organs,"/capita, US$ exchange rate",45.0
+9402,Denmark,2015,4,B-Blood and blood forming organs,"Million US$, purchasing power parity",235.6
+9403,Denmark,2015,4,Products not elsewhere classified,Million of national currency units,7278.8
+9404,Denmark,2015,4,Products not elsewhere classified,Million US$ at exchange rate,1081.9
+9405,Denmark,2015,4,G-Genito urinary system and sex hormones,"/capita, US$ purchasing power parity",20.1
+9406,Denmark,2015,4,G-Genito urinary system and sex hormones,"/capita, US$ exchange rate",21.8
+9407,Denmark,2015,4,A-Alimentary tract and metabolism,"/capita, US$ exchange rate",54.6
+9408,Denmark,2015,4,G-Genito urinary system and sex hormones,% of total sales,3.8
+9409,Denmark,2015,4,A-Alimentary tract and metabolism,Million of national currency units,2086.5
+9410,Denmark,2015,4,B-Blood and blood forming organs,% of total sales,7.9
+9411,Denmark,2015,4,B-Blood and blood forming organs,"/capita, US$ purchasing power parity",41.5
+9412,Denmark,2015,4,N-Nervous system,"/capita, US$ exchange rate",94.1
+9413,Denmark,2015,4,A-Alimentary tract and metabolism,"Million US$, purchasing power parity",285.6
+9414,Denmark,2015,4,N-Nervous system,% of total sales,16.4
+9415,Denmark,2015,4,N-Nervous system,"/capita, US$ purchasing power parity",86.6
+9416,Denmark,2015,4,A-Alimentary tract and metabolism,Million US$ at exchange rate,310.1
+9417,Denmark,2015,4,N-Nervous system,Million US$ at exchange rate,534.6
+9418,Denmark,2015,4,G-Genito urinary system and sex hormones,Million of national currency units,834.9
+9419,Denmark,2015,4,N-Nervous system,Million of national currency units,3596.9
+9420,Denmark,2015,4,A-Alimentary tract and metabolism,% of total sales,9.5
+9421,Denmark,2015,4,A-Alimentary tract and metabolism,"/capita, US$ purchasing power parity",50.3
+9422,Denmark,2015,4,N-Nervous system,"Million US$, purchasing power parity",492.4
+9423,Denmark,2015,4,Products not elsewhere classified,% of total sales,33.2
+9424,Denmark,2015,4,Products not elsewhere classified,"Million US$, purchasing power parity",996.4
+9425,Denmark,2015,4,Products not elsewhere classified,"/capita, US$ exchange rate",190.4
+9426,Denmark,2015,4,B-Blood and blood forming organs,Million US$ at exchange rate,255.8
+9427,Denmark,2015,4,B-Blood and blood forming organs,Million of national currency units,1721.2
+9428,Denmark,2015,4,Products not elsewhere classified,"/capita, US$ purchasing power parity",175.3
+9429,Denmark,2015,4,G-Genito urinary system and sex hormones,"Million US$, purchasing power parity",114.3
+9430,Denmark,2015,4,G-Genito urinary system and sex hormones,Million US$ at exchange rate,124.1
+9431,Denmark,2016,4,M-Musculo-skeletal system,Million of national currency units,593.4
+9432,Denmark,2016,4,Total pharmaceutical sales,Million of national currency units,22110.0
+9433,Denmark,2016,4,Total pharmaceutical sales,Million US$ at exchange rate,3284.5
+9434,Denmark,2016,4,R-Respiratory system,"/capita, US$ purchasing power parity",48.2
+9435,Denmark,2016,4,R-Respiratory system,"/capita, US$ exchange rate",50.7
+9436,Denmark,2016,4,Total pharmaceutical sales,"Million US$, purchasing power parity",3122.9
+9437,Denmark,2016,4,C-Cardiovascular system,Million US$ at exchange rate,161.1
+9438,Denmark,2016,4,M-Musculo-skeletal system,Million US$ at exchange rate,88.1
+9439,Denmark,2016,4,C-Cardiovascular system,Million of national currency units,1084.4
+9440,Denmark,2016,4,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ purchasing power parity",11.5
+9441,Denmark,2016,4,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ exchange rate",12.1
+9442,Denmark,2016,4,J-Antiinfectives for systemic use,Million of national currency units,2066.0
+9443,Denmark,2016,4,"H-Systemic hormonal preparations, excluding sex hormones and insulins",% of total sales,2.1
+9444,Denmark,2016,4,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million of national currency units,466.9
+9445,Denmark,2016,4,R-Respiratory system,% of total sales,8.8
+9446,Denmark,2016,4,"H-Systemic hormonal preparations, excluding sex hormones and insulins","Million US$, purchasing power parity",66.0
+9447,Denmark,2016,4,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million US$ at exchange rate,69.4
+9448,Denmark,2016,4,J-Antiinfectives for systemic use,"Million US$, purchasing power parity",291.8
+9449,Denmark,2016,4,J-Antiinfectives for systemic use,Million US$ at exchange rate,306.9
+9450,Denmark,2016,4,Total pharmaceutical sales,"/capita, US$ exchange rate",573.4
+9451,Denmark,2016,4,C-Cardiovascular system,% of total sales,4.9
+9452,Denmark,2016,4,J-Antiinfectives for systemic use,"/capita, US$ exchange rate",53.6
+9453,Denmark,2016,4,Total pharmaceutical sales,"/capita, US$ purchasing power parity",545.2
+9454,Denmark,2016,4,R-Respiratory system,"Million US$, purchasing power parity",276.1
+9455,Denmark,2016,4,R-Respiratory system,Million of national currency units,1954.6
+9456,Denmark,2016,4,R-Respiratory system,Million US$ at exchange rate,290.4
+9457,Denmark,2016,4,M-Musculo-skeletal system,"/capita, US$ exchange rate",15.4
+9458,Denmark,2016,4,M-Musculo-skeletal system,"Million US$, purchasing power parity",83.8
+9459,Denmark,2016,4,C-Cardiovascular system,"Million US$, purchasing power parity",153.2
+9460,Denmark,2016,4,M-Musculo-skeletal system,"/capita, US$ purchasing power parity",14.6
+9461,Denmark,2016,4,C-Cardiovascular system,"/capita, US$ exchange rate",28.1
+9462,Denmark,2016,4,J-Antiinfectives for systemic use,"/capita, US$ purchasing power parity",50.9
+9463,Denmark,2016,4,C-Cardiovascular system,"/capita, US$ purchasing power parity",26.7
+9464,Denmark,2016,4,M-Musculo-skeletal system,% of total sales,2.7
+9465,Denmark,2016,4,J-Antiinfectives for systemic use,% of total sales,9.3
+9466,Denmark,2016,4,B-Blood and blood forming organs,"/capita, US$ exchange rate",48.0
+9467,Denmark,2016,4,B-Blood and blood forming organs,"Million US$, purchasing power parity",261.6
+9468,Denmark,2016,4,Products not elsewhere classified,Million of national currency units,7562.7
+9469,Denmark,2016,4,G-Genito urinary system and sex hormones,"/capita, US$ purchasing power parity",20.5
+9470,Denmark,2016,4,G-Genito urinary system and sex hormones,"/capita, US$ exchange rate",21.6
+9471,Denmark,2016,4,G-Genito urinary system and sex hormones,% of total sales,3.8
+9472,Denmark,2016,4,A-Alimentary tract and metabolism,Million of national currency units,2214.3
+9473,Denmark,2016,4,B-Blood and blood forming organs,% of total sales,8.4
+9474,Denmark,2016,4,B-Blood and blood forming organs,"/capita, US$ purchasing power parity",45.7
+9475,Denmark,2016,4,N-Nervous system,"/capita, US$ exchange rate",90.4
+9476,Denmark,2016,4,A-Alimentary tract and metabolism,"Million US$, purchasing power parity",312.8
+9477,Denmark,2016,4,N-Nervous system,% of total sales,15.8
+9478,Denmark,2016,4,N-Nervous system,"/capita, US$ purchasing power parity",85.9
+9479,Denmark,2016,4,A-Alimentary tract and metabolism,Million US$ at exchange rate,328.9
+9480,Denmark,2016,4,A-Alimentary tract and metabolism,"/capita, US$ exchange rate",57.4
+9481,Denmark,2016,4,N-Nervous system,Million US$ at exchange rate,517.6
+9482,Denmark,2016,4,G-Genito urinary system and sex hormones,Million of national currency units,831.7
+9483,Denmark,2016,4,Products not elsewhere classified,% of total sales,34.2
+9484,Denmark,2016,4,A-Alimentary tract and metabolism,% of total sales,10.0
+9485,Denmark,2016,4,A-Alimentary tract and metabolism,"/capita, US$ purchasing power parity",54.6
+9486,Denmark,2016,4,N-Nervous system,"Million US$, purchasing power parity",492.1
+9487,Denmark,2016,4,N-Nervous system,Million of national currency units,3484.1
+9488,Denmark,2016,4,Products not elsewhere classified,"Million US$, purchasing power parity",1068.2
+9489,Denmark,2016,4,Products not elsewhere classified,"/capita, US$ exchange rate",196.1
+9490,Denmark,2016,4,Products not elsewhere classified,Million US$ at exchange rate,1123.4
+9491,Denmark,2016,4,B-Blood and blood forming organs,Million US$ at exchange rate,275.1
+9492,Denmark,2016,4,B-Blood and blood forming organs,Million of national currency units,1851.8
+9493,Denmark,2016,4,Products not elsewhere classified,"/capita, US$ purchasing power parity",186.5
+9494,Denmark,2016,4,G-Genito urinary system and sex hormones,"Million US$, purchasing power parity",117.5
+9495,Denmark,2016,4,G-Genito urinary system and sex hormones,Million US$ at exchange rate,123.5
+9496,Denmark,2010,5,Total pharmaceutical sales,Million US$ at exchange rate,3764.4
+9497,Denmark,2010,5,M-Musculo-skeletal system,Million US$ at exchange rate,109.9
+9498,Denmark,2010,5,R-Respiratory system,"/capita, US$ purchasing power parity",45.5
+9499,Denmark,2010,5,Total pharmaceutical sales,Million of national currency units,21171.2
+9500,Denmark,2010,5,Total pharmaceutical sales,"Million US$, purchasing power parity",2788.9
+9501,Denmark,2010,5,Total pharmaceutical sales,"/capita, US$ exchange rate",678.6
+9502,Denmark,2010,5,R-Respiratory system,% of total sales,9.1
+9503,Denmark,2010,5,M-Musculo-skeletal system,"Million US$, purchasing power parity",81.5
+9504,Denmark,2010,5,C-Cardiovascular system,Million of national currency units,1722.0
+9505,Denmark,2010,5,C-Cardiovascular system,Million US$ at exchange rate,306.2
+9506,Denmark,2010,5,"H-Systemic hormonal preparations, excluding sex hormones and insulins",% of total sales,2.4
+9507,Denmark,2010,5,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ purchasing power parity",11.8
+9508,Denmark,2010,5,M-Musculo-skeletal system,Million of national currency units,618.3
+9509,Denmark,2010,5,J-Antiinfectives for systemic use,Million of national currency units,2056.7
+9510,Denmark,2010,5,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ exchange rate",15.9
+9511,Denmark,2010,5,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million of national currency units,497.6
+9512,Denmark,2010,5,J-Antiinfectives for systemic use,Million US$ at exchange rate,365.7
+9513,Denmark,2010,5,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million US$ at exchange rate,88.5
+9514,Denmark,2010,5,"H-Systemic hormonal preparations, excluding sex hormones and insulins","Million US$, purchasing power parity",65.6
+9515,Denmark,2010,5,J-Antiinfectives for systemic use,"Million US$, purchasing power parity",270.9
+9516,Denmark,2010,5,R-Respiratory system,Million of national currency units,1917.9
+9517,Denmark,2010,5,J-Antiinfectives for systemic use,"/capita, US$ exchange rate",65.9
+9518,Denmark,2010,5,R-Respiratory system,"/capita, US$ exchange rate",61.5
+9519,Denmark,2010,5,Total pharmaceutical sales,"/capita, US$ purchasing power parity",502.7
+9520,Denmark,2010,5,R-Respiratory system,Million US$ at exchange rate,341.0
+9521,Denmark,2010,5,R-Respiratory system,"Million US$, purchasing power parity",252.7
+9522,Denmark,2010,5,C-Cardiovascular system,% of total sales,8.1
+9523,Denmark,2010,5,M-Musculo-skeletal system,"/capita, US$ exchange rate",19.8
+9524,Denmark,2010,5,M-Musculo-skeletal system,"/capita, US$ purchasing power parity",14.7
+9525,Denmark,2010,5,C-Cardiovascular system,"Million US$, purchasing power parity",226.8
+9526,Denmark,2010,5,C-Cardiovascular system,"/capita, US$ exchange rate",55.2
+9527,Denmark,2010,5,J-Antiinfectives for systemic use,"/capita, US$ purchasing power parity",48.8
+9528,Denmark,2010,5,C-Cardiovascular system,"/capita, US$ purchasing power parity",40.9
+9529,Denmark,2010,5,J-Antiinfectives for systemic use,% of total sales,9.7
+9530,Denmark,2010,5,M-Musculo-skeletal system,% of total sales,2.9
+9531,Denmark,2010,5,B-Blood and blood forming organs,"/capita, US$ exchange rate",39.9
+9532,Denmark,2010,5,Products not elsewhere classified,Million US$ at exchange rate,1011.3
+9533,Denmark,2010,5,B-Blood and blood forming organs,"/capita, US$ purchasing power parity",29.5
+9534,Denmark,2010,5,B-Blood and blood forming organs,"Million US$, purchasing power parity",163.8
+9535,Denmark,2010,5,Products not elsewhere classified,Million of national currency units,5687.4
+9536,Denmark,2010,5,G-Genito urinary system and sex hormones,"/capita, US$ purchasing power parity",24.7
+9537,Denmark,2010,5,G-Genito urinary system and sex hormones,% of total sales,4.9
+9538,Denmark,2010,5,A-Alimentary tract and metabolism,"/capita, US$ exchange rate",55.8
+9539,Denmark,2010,5,A-Alimentary tract and metabolism,Million US$ at exchange rate,309.4
+9540,Denmark,2010,5,A-Alimentary tract and metabolism,Million of national currency units,1740.0
+9541,Denmark,2010,5,B-Blood and blood forming organs,% of total sales,5.9
+9542,Denmark,2010,5,A-Alimentary tract and metabolism,"Million US$, purchasing power parity",229.2
+9543,Denmark,2010,5,N-Nervous system,% of total sales,21.9
+9544,Denmark,2010,5,N-Nervous system,"/capita, US$ purchasing power parity",110.3
+9545,Denmark,2010,5,A-Alimentary tract and metabolism,"/capita, US$ purchasing power parity",41.3
+9546,Denmark,2010,5,N-Nervous system,Million US$ at exchange rate,826.1
+9547,Denmark,2010,5,G-Genito urinary system and sex hormones,Million of national currency units,1041.8
+9548,Denmark,2010,5,G-Genito urinary system and sex hormones,Million US$ at exchange rate,185.2
+9549,Denmark,2010,5,A-Alimentary tract and metabolism,% of total sales,8.2
+9550,Denmark,2010,5,N-Nervous system,"/capita, US$ exchange rate",148.9
+9551,Denmark,2010,5,N-Nervous system,Million of national currency units,4646.0
+9552,Denmark,2010,5,N-Nervous system,"Million US$, purchasing power parity",612.0
+9553,Denmark,2010,5,Products not elsewhere classified,"Million US$, purchasing power parity",749.2
+9554,Denmark,2010,5,Products not elsewhere classified,"/capita, US$ exchange rate",182.3
+9555,Denmark,2010,5,G-Genito urinary system and sex hormones,"/capita, US$ exchange rate",33.4
+9556,Denmark,2010,5,B-Blood and blood forming organs,Million US$ at exchange rate,221.1
+9557,Denmark,2010,5,B-Blood and blood forming organs,Million of national currency units,1243.4
+9558,Denmark,2010,5,Products not elsewhere classified,% of total sales,26.9
+9559,Denmark,2010,5,Products not elsewhere classified,"/capita, US$ purchasing power parity",135.0
+9560,Denmark,2010,5,G-Genito urinary system and sex hormones,"Million US$, purchasing power parity",137.2
+9561,Denmark,2014,4,Total pharmaceutical sales,Million US$ at exchange rate,3816.2
+9562,Denmark,2014,4,M-Musculo-skeletal system,Million of national currency units,534.2
+9563,Denmark,2014,4,R-Respiratory system,"/capita, US$ purchasing power parity",47.0
+9564,Denmark,2014,4,Total pharmaceutical sales,Million of national currency units,21418.1
+9565,Denmark,2014,4,M-Musculo-skeletal system,Million US$ at exchange rate,95.2
+9566,Denmark,2014,4,Total pharmaceutical sales,"Million US$, purchasing power parity",2922.5
+9567,Denmark,2014,4,C-Cardiovascular system,Million US$ at exchange rate,205.5
+9568,Denmark,2014,4,C-Cardiovascular system,Million of national currency units,1153.2
+9569,Denmark,2014,4,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ purchasing power parity",11.3
+9570,Denmark,2014,4,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ exchange rate",14.7
+9571,Denmark,2014,4,"H-Systemic hormonal preparations, excluding sex hormones and insulins",% of total sales,2.2
+9572,Denmark,2014,4,J-Antiinfectives for systemic use,Million of national currency units,2107.4
+9573,Denmark,2014,4,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million of national currency units,465.8
+9574,Denmark,2014,4,R-Respiratory system,% of total sales,9.1
+9575,Denmark,2014,4,"H-Systemic hormonal preparations, excluding sex hormones and insulins","Million US$, purchasing power parity",63.6
+9576,Denmark,2014,4,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million US$ at exchange rate,83.0
+9577,Denmark,2014,4,J-Antiinfectives for systemic use,"Million US$, purchasing power parity",287.6
+9578,Denmark,2014,4,J-Antiinfectives for systemic use,Million US$ at exchange rate,375.5
+9579,Denmark,2014,4,Total pharmaceutical sales,"/capita, US$ exchange rate",676.2
+9580,Denmark,2014,4,C-Cardiovascular system,% of total sales,5.4
+9581,Denmark,2014,4,J-Antiinfectives for systemic use,"/capita, US$ exchange rate",66.5
+9582,Denmark,2014,4,R-Respiratory system,Million of national currency units,1944.7
+9583,Denmark,2014,4,R-Respiratory system,"/capita, US$ exchange rate",61.4
+9584,Denmark,2014,4,Total pharmaceutical sales,"/capita, US$ purchasing power parity",517.9
+9585,Denmark,2014,4,R-Respiratory system,Million US$ at exchange rate,346.5
+9586,Denmark,2014,4,R-Respiratory system,"Million US$, purchasing power parity",265.4
+9587,Denmark,2014,4,M-Musculo-skeletal system,"/capita, US$ exchange rate",16.9
+9588,Denmark,2014,4,M-Musculo-skeletal system,"/capita, US$ purchasing power parity",12.9
+9589,Denmark,2014,4,M-Musculo-skeletal system,"Million US$, purchasing power parity",72.9
+9590,Denmark,2014,4,C-Cardiovascular system,"Million US$, purchasing power parity",157.4
+9591,Denmark,2014,4,C-Cardiovascular system,"/capita, US$ exchange rate",36.4
+9592,Denmark,2014,4,J-Antiinfectives for systemic use,"/capita, US$ purchasing power parity",51.0
+9593,Denmark,2014,4,C-Cardiovascular system,"/capita, US$ purchasing power parity",27.9
+9594,Denmark,2014,4,M-Musculo-skeletal system,% of total sales,2.5
+9595,Denmark,2014,4,J-Antiinfectives for systemic use,% of total sales,9.8
+9596,Denmark,2014,4,B-Blood and blood forming organs,"/capita, US$ exchange rate",50.3
+9597,Denmark,2014,4,B-Blood and blood forming organs,"Million US$, purchasing power parity",217.5
+9598,Denmark,2014,4,Products not elsewhere classified,Million of national currency units,7193.0
+9599,Denmark,2014,4,Products not elsewhere classified,Million US$ at exchange rate,1281.6
+9600,Denmark,2014,4,G-Genito urinary system and sex hormones,"/capita, US$ purchasing power parity",19.7
+9601,Denmark,2014,4,A-Alimentary tract and metabolism,"/capita, US$ exchange rate",61.7
+9602,Denmark,2014,4,G-Genito urinary system and sex hormones,% of total sales,3.8
+9603,Denmark,2014,4,A-Alimentary tract and metabolism,Million of national currency units,1954.7
+9604,Denmark,2014,4,B-Blood and blood forming organs,"/capita, US$ purchasing power parity",38.5
+9605,Denmark,2014,4,B-Blood and blood forming organs,% of total sales,7.4
+9606,Denmark,2014,4,N-Nervous system,"/capita, US$ exchange rate",115.5
+9607,Denmark,2014,4,A-Alimentary tract and metabolism,"Million US$, purchasing power parity",266.7
+9608,Denmark,2014,4,N-Nervous system,% of total sales,17.1
+9609,Denmark,2014,4,G-Genito urinary system and sex hormones,"/capita, US$ exchange rate",25.7
+9610,Denmark,2014,4,N-Nervous system,"/capita, US$ purchasing power parity",88.5
+9611,Denmark,2014,4,A-Alimentary tract and metabolism,Million US$ at exchange rate,348.3
+9612,Denmark,2014,4,N-Nervous system,Million US$ at exchange rate,651.8
+9613,Denmark,2014,4,G-Genito urinary system and sex hormones,Million US$ at exchange rate,144.9
+9614,Denmark,2014,4,G-Genito urinary system and sex hormones,Million of national currency units,813.1
+9615,Denmark,2014,4,A-Alimentary tract and metabolism,% of total sales,9.1
+9616,Denmark,2014,4,N-Nervous system,Million of national currency units,3658.3
+9617,Denmark,2014,4,N-Nervous system,"Million US$, purchasing power parity",499.2
+9618,Denmark,2014,4,A-Alimentary tract and metabolism,"/capita, US$ purchasing power parity",47.3
+9619,Denmark,2014,4,Products not elsewhere classified,"Million US$, purchasing power parity",981.5
+9620,Denmark,2014,4,Products not elsewhere classified,"/capita, US$ exchange rate",227.1
+9621,Denmark,2014,4,B-Blood and blood forming organs,Million US$ at exchange rate,284.0
+9622,Denmark,2014,4,B-Blood and blood forming organs,Million of national currency units,1593.7
+9623,Denmark,2014,4,Products not elsewhere classified,% of total sales,33.6
+9624,Denmark,2014,4,Products not elsewhere classified,"/capita, US$ purchasing power parity",173.9
+9625,Denmark,2014,4,G-Genito urinary system and sex hormones,"Million US$, purchasing power parity",110.9
+9626,Estonia,2016,11,C02-Antihypertensives,"Million US$, purchasing power parity",1.4
+9627,Estonia,2016,11,C02-Antihypertensives,"/capita, US$ exchange rate",0.6
+9628,Estonia,2016,11,N05B-Anxiolytics,"/capita, US$ purchasing power parity",2.0
+9629,Estonia,2016,11,N05B-Anxiolytics,% of total sales,0.5
+9630,Estonia,2016,11,C02-Antihypertensives,Million US$ at exchange rate,0.8
+9631,Estonia,2016,11,"H-Systemic hormonal preparations, excluding sex hormones and insulins",% of total sales,1.3
+9632,Estonia,2016,11,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ purchasing power parity",5.6
+9633,Estonia,2016,11,N02-Analgesics,"Million US$, purchasing power parity",14.1
+9634,Estonia,2016,11,"H-Systemic hormonal preparations, excluding sex hormones and insulins","Million US$, purchasing power parity",7.4
+9635,Estonia,2016,11,N02-Analgesics,Million US$ at exchange rate,8.3
+9636,Estonia,2016,11,N05B-Anxiolytics,Million US$ at exchange rate,1.5
+9637,Estonia,2016,11,N05B-Anxiolytics,Million of national currency units,1.4
+9638,Estonia,2016,11,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million US$ at exchange rate,4.3
+9639,Estonia,2016,11,N02-Analgesics,"/capita, US$ purchasing power parity",10.7
+9640,Estonia,2016,11,N02-Analgesics,"/capita, US$ exchange rate",6.3
+9641,Estonia,2016,11,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million of national currency units,3.9
+9642,Estonia,2016,11,N02-Analgesics,% of total sales,2.6
+9643,Estonia,2016,11,N05B-Anxiolytics,"Million US$, purchasing power parity",2.6
+9644,Estonia,2016,11,C-Cardiovascular system,"/capita, US$ exchange rate",25.9
+9645,Estonia,2016,11,C-Cardiovascular system,"Million US$, purchasing power parity",58.3
+9646,Estonia,2016,11,C02-Antihypertensives,"/capita, US$ purchasing power parity",1.1
+9647,Estonia,2016,11,C02-Antihypertensives,% of total sales,0.3
+9648,Estonia,2016,11,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ exchange rate",3.3
+9649,Estonia,2016,11,C-Cardiovascular system,Million US$ at exchange rate,34.1
+9650,Estonia,2016,11,N05B-Anxiolytics,"/capita, US$ exchange rate",1.2
+9651,Estonia,2016,11,N02-Analgesics,Million of national currency units,7.5
+9652,Estonia,2016,11,C-Cardiovascular system,Million of national currency units,30.8
+9653,Estonia,2016,11,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million of national currency units,3.7
+9654,Estonia,2016,11,B-Blood and blood forming organs,"/capita, US$ exchange rate",21.3
+9655,Estonia,2016,11,B-Blood and blood forming organs,"/capita, US$ purchasing power parity",36.5
+9656,Estonia,2016,11,B-Blood and blood forming organs,Million US$ at exchange rate,28.1
+9657,Estonia,2016,11,B-Blood and blood forming organs,% of total sales,8.7
+9658,Estonia,2016,11,B-Blood and blood forming organs,"Million US$, purchasing power parity",48.0
+9659,Estonia,2016,11,R-Respiratory system,"Million US$, purchasing power parity",40.4
+9660,Estonia,2016,11,R-Respiratory system,"/capita, US$ exchange rate",17.9
+9661,Estonia,2016,11,R-Respiratory system,Million of national currency units,21.3
+9662,Estonia,2016,11,R-Respiratory system,Million US$ at exchange rate,23.6
+9663,Estonia,2016,11,C10-Lipid modifying agents,% of total sales,1.1
+9664,Estonia,2016,11,C10-Lipid modifying agents,"/capita, US$ purchasing power parity",4.4
+9665,Estonia,2016,11,A02A-Antacids,Million of national currency units,0.4
+9666,Estonia,2016,11,A02A-Antacids,"Million US$, purchasing power parity",0.7
+9667,Estonia,2016,11,A02A-Antacids,Million US$ at exchange rate,0.4
+9668,Estonia,2016,11,C10-Lipid modifying agents,Million US$ at exchange rate,3.4
+9669,Estonia,2016,11,C10-Lipid modifying agents,Million of national currency units,3.1
+9670,Estonia,2016,11,B-Blood and blood forming organs,Million of national currency units,25.4
+9671,Estonia,2016,11,C10-Lipid modifying agents,"/capita, US$ exchange rate",2.6
+9672,Estonia,2016,11,C10-Lipid modifying agents,"Million US$, purchasing power parity",5.8
+9673,Estonia,2016,11,R-Respiratory system,"/capita, US$ purchasing power parity",30.7
+9674,Estonia,2016,11,C09-Agents acting on the Renin-Angiotensin system,Million US$ at exchange rate,13.6
+9675,Estonia,2016,11,C09-Agents acting on the Renin-Angiotensin system,Million of national currency units,12.3
+9676,Estonia,2016,11,C09-Agents acting on the Renin-Angiotensin system,"Million US$, purchasing power parity",23.2
+9677,Estonia,2016,11,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ purchasing power parity",17.7
+9678,Estonia,2016,11,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ exchange rate",10.3
+9679,Estonia,2016,11,R03-Drugs for obstructive airway diseases,"/capita, US$ exchange rate",7.5
+9680,Estonia,2016,11,R03-Drugs for obstructive airway diseases,"Million US$, purchasing power parity",16.8
+9681,Estonia,2016,11,R03-Drugs for obstructive airway diseases,"/capita, US$ purchasing power parity",12.8
+9682,Estonia,2016,11,R03-Drugs for obstructive airway diseases,Million of national currency units,8.9
+9683,Estonia,2016,11,R03-Drugs for obstructive airway diseases,Million US$ at exchange rate,9.8
+9684,Estonia,2016,11,C08-Calcium channel blockers,Million US$ at exchange rate,2.3
+9685,Estonia,2016,11,C08-Calcium channel blockers,"Million US$, purchasing power parity",4.0
+9686,Estonia,2016,11,R-Respiratory system,% of total sales,7.4
+9687,Estonia,2016,11,C08-Calcium channel blockers,Million of national currency units,2.1
+9688,Estonia,2016,11,R03-Drugs for obstructive airway diseases,% of total sales,3.1
+9689,Estonia,2016,11,C09-Agents acting on the Renin-Angiotensin system,% of total sales,4.2
+9690,Estonia,2016,11,C08-Calcium channel blockers,"/capita, US$ exchange rate",1.8
+9691,Estonia,2016,11,C08-Calcium channel blockers,"/capita, US$ purchasing power parity",3.0
+9692,Estonia,2016,11,C08-Calcium channel blockers,% of total sales,0.7
+9693,Estonia,2016,11,N05C-Hypnotics and sedatives,Million of national currency units,1.8
+9694,Estonia,2016,11,N05C-Hypnotics and sedatives,Million US$ at exchange rate,2.0
+9695,Estonia,2016,11,G03-Sex hormones and modulators of the genital system,Million US$ at exchange rate,6.4
+9696,Estonia,2016,11,N05C-Hypnotics and sedatives,"Million US$, purchasing power parity",3.4
+9697,Estonia,2016,11,G03-Sex hormones and modulators of the genital system,Million of national currency units,5.8
+9698,Estonia,2016,11,N05C-Hypnotics and sedatives,% of total sales,0.6
+9699,Estonia,2016,11,G-Genito urinary system and sex hormones,% of total sales,4.0
+9700,Estonia,2016,11,N05C-Hypnotics and sedatives,"/capita, US$ exchange rate",1.5
+9701,Estonia,2016,11,N05C-Hypnotics and sedatives,"/capita, US$ purchasing power parity",2.6
+9702,Estonia,2016,11,C03-Diuretics,"/capita, US$ exchange rate",1.6
+9703,Estonia,2016,11,C03-Diuretics,"/capita, US$ purchasing power parity",2.7
+9704,Estonia,2016,11,C03-Diuretics,"Million US$, purchasing power parity",3.6
+9705,Estonia,2016,11,C03-Diuretics,Million of national currency units,1.9
+9706,Estonia,2016,11,C03-Diuretics,Million US$ at exchange rate,2.1
+9707,Estonia,2016,11,G03-Sex hormones and modulators of the genital system,"/capita, US$ purchasing power parity",8.3
+9708,Estonia,2016,11,G03-Sex hormones and modulators of the genital system,"/capita, US$ exchange rate",4.9
+9709,Estonia,2016,11,G03-Sex hormones and modulators of the genital system,"Million US$, purchasing power parity",11.0
+9710,Estonia,2016,11,C03-Diuretics,% of total sales,0.7
+9711,Estonia,2016,11,G03-Sex hormones and modulators of the genital system,% of total sales,2.0
+9712,Estonia,2016,11,G-Genito urinary system and sex hormones,"/capita, US$ purchasing power parity",16.7
+9713,Estonia,2016,11,C07-Beta blocking agents,Million US$ at exchange rate,6.0
+9714,Estonia,2016,11,C07-Beta blocking agents,"Million US$, purchasing power parity",10.3
+9715,Estonia,2016,11,N06A-Antidepressants,% of total sales,1.1
+9716,Estonia,2016,11,C07-Beta blocking agents,Million of national currency units,5.4
+9717,Estonia,2016,11,A02A-Antacids,% of total sales,0.1
+9718,Estonia,2016,11,A02A-Antacids,"/capita, US$ purchasing power parity",0.5
+9719,Estonia,2016,11,A02A-Antacids,"/capita, US$ exchange rate",0.3
+9720,Estonia,2016,11,C07-Beta blocking agents,% of total sales,1.9
+9721,Estonia,2016,11,C07-Beta blocking agents,"/capita, US$ exchange rate",4.6
+9722,Estonia,2016,11,C07-Beta blocking agents,"/capita, US$ purchasing power parity",7.8
+9723,Estonia,2016,11,G-Genito urinary system and sex hormones,Million US$ at exchange rate,12.8
+9724,Estonia,2016,11,G-Genito urinary system and sex hormones,Million of national currency units,11.6
+9725,Estonia,2016,11,G-Genito urinary system and sex hormones,"/capita, US$ exchange rate",9.8
+9726,Estonia,2016,11,G-Genito urinary system and sex hormones,"Million US$, purchasing power parity",22.0
+9727,Estonia,2016,11,N06A-Antidepressants,"/capita, US$ exchange rate",2.7
+9728,Estonia,2016,11,N06A-Antidepressants,"/capita, US$ purchasing power parity",4.7
+9729,Estonia,2016,11,N06A-Antidepressants,Million of national currency units,3.3
+9730,Estonia,2016,11,N06A-Antidepressants,Million US$ at exchange rate,3.6
+9731,Estonia,2016,11,N06A-Antidepressants,"Million US$, purchasing power parity",6.2
+9732,Estonia,2016,11,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),% of total sales,1.3
+9733,Estonia,2016,11,A-Alimentary tract and metabolism,Million US$ at exchange rate,38.0
+9734,Estonia,2016,11,A-Alimentary tract and metabolism,"/capita, US$ exchange rate",28.9
+9735,Estonia,2016,11,A-Alimentary tract and metabolism,"Million US$, purchasing power parity",65.1
+9736,Estonia,2016,11,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ purchasing power parity",5.3
+9737,Estonia,2016,11,A10-Drugs used in diabetes,% of total sales,6.0
+9738,Estonia,2016,11,A-Alimentary tract and metabolism,Million of national currency units,34.3
+9739,Estonia,2016,11,A10-Drugs used in diabetes,"/capita, US$ purchasing power parity",24.8
+9740,Estonia,2016,11,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ exchange rate",3.1
+9741,Estonia,2016,11,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"Million US$, purchasing power parity",7.0
+9742,Estonia,2016,11,N-Nervous system,% of total sales,8.7
+9743,Estonia,2016,11,"C01B-Antiarrhythmics, Class I and III",Million of national currency units,1.0
+9744,Estonia,2016,11,N-Nervous system,"/capita, US$ purchasing power parity",36.4
+9745,Estonia,2016,11,N-Nervous system,"Million US$, purchasing power parity",47.9
+9746,Estonia,2016,11,N-Nervous system,"/capita, US$ exchange rate",21.3
+9747,Estonia,2016,11,"C01B-Antiarrhythmics, Class I and III",% of total sales,0.3
+9748,Estonia,2016,11,"C01B-Antiarrhythmics, Class I and III","/capita, US$ purchasing power parity",1.4
+9749,Estonia,2016,11,A-Alimentary tract and metabolism,% of total sales,11.8
+9750,Estonia,2016,11,"C01B-Antiarrhythmics, Class I and III","Million US$, purchasing power parity",1.8
+9751,Estonia,2016,11,"C01B-Antiarrhythmics, Class I and III",Million US$ at exchange rate,1.1
+9752,Estonia,2016,11,A-Alimentary tract and metabolism,"/capita, US$ purchasing power parity",49.4
+9753,Estonia,2016,11,"C01B-Antiarrhythmics, Class I and III","/capita, US$ exchange rate",0.8
+9754,Estonia,2016,11,C01A-Cardiac glycosides,"Million US$, purchasing power parity",0.2
+9755,Estonia,2016,11,C01A-Cardiac glycosides,"/capita, US$ exchange rate",0.1
+9756,Estonia,2016,11,C01A-Cardiac glycosides,"/capita, US$ purchasing power parity",0.2
+9757,Estonia,2016,11,C01A-Cardiac glycosides,Million of national currency units,0.1
+9758,Estonia,2016,11,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ exchange rate",8.0
+9759,Estonia,2016,11,C01A-Cardiac glycosides,Million US$ at exchange rate,0.1
+9760,Estonia,2016,11,Total pharmaceutical sales,Million US$ at exchange rate,320.9
+9761,Estonia,2016,11,Total pharmaceutical sales,Million of national currency units,289.9
+9762,Estonia,2016,11,M01A-Antiinflammatory and antirheumatic products non-steroids,% of total sales,3.3
+9763,Estonia,2016,11,C01A-Cardiac glycosides,% of total sales,0.0
+9764,Estonia,2016,11,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ purchasing power parity",13.7
+9765,Estonia,2016,11,M-Musculo-skeletal system,"/capita, US$ purchasing power parity",23.6
+9766,Estonia,2016,11,M-Musculo-skeletal system,% of total sales,5.6
+9767,Estonia,2016,11,M-Musculo-skeletal system,"/capita, US$ exchange rate",13.8
+9768,Estonia,2016,11,A10-Drugs used in diabetes,"/capita, US$ exchange rate",14.5
+9769,Estonia,2016,11,A10-Drugs used in diabetes,"Million US$, purchasing power parity",32.7
+9770,Estonia,2016,11,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million US$ at exchange rate,4.1
+9771,Estonia,2016,11,M01A-Antiinflammatory and antirheumatic products non-steroids,Million of national currency units,9.5
+9772,Estonia,2016,11,M01A-Antiinflammatory and antirheumatic products non-steroids,Million US$ at exchange rate,10.5
+9773,Estonia,2016,11,M01A-Antiinflammatory and antirheumatic products non-steroids,"Million US$, purchasing power parity",18.0
+9774,Estonia,2016,11,M-Musculo-skeletal system,"Million US$, purchasing power parity",31.0
+9775,Estonia,2016,11,M-Musculo-skeletal system,Million US$ at exchange rate,18.1
+9776,Estonia,2016,11,M-Musculo-skeletal system,Million of national currency units,16.4
+9777,Estonia,2016,11,J-Antiinfectives for systemic use,Million US$ at exchange rate,49.1
+9778,Estonia,2016,11,J01-Antibacterials for systemic use,"Million US$, purchasing power parity",13.0
+9779,Estonia,2016,11,A10-Drugs used in diabetes,Million US$ at exchange rate,19.1
+9780,Estonia,2016,11,J-Antiinfectives for systemic use,"/capita, US$ purchasing power parity",63.8
+9781,Estonia,2016,11,J-Antiinfectives for systemic use,"Million US$, purchasing power parity",84.0
+9782,Estonia,2016,11,J-Antiinfectives for systemic use,"/capita, US$ exchange rate",37.3
+9783,Estonia,2016,11,J01-Antibacterials for systemic use,Million US$ at exchange rate,7.6
+9784,Estonia,2016,11,Total pharmaceutical sales,"/capita, US$ exchange rate",243.9
+9785,Estonia,2016,11,Total pharmaceutical sales,"/capita, US$ purchasing power parity",417.4
+9786,Estonia,2016,11,J-Antiinfectives for systemic use,Million of national currency units,44.3
+9787,Estonia,2016,11,J01-Antibacterials for systemic use,Million of national currency units,6.9
+9788,Estonia,2016,11,A10-Drugs used in diabetes,Million of national currency units,17.3
+9789,Estonia,2016,11,N-Nervous system,Million of national currency units,25.3
+9790,Estonia,2016,11,N-Nervous system,Million US$ at exchange rate,28.0
+9791,Estonia,2016,11,J-Antiinfectives for systemic use,% of total sales,15.3
+9792,Estonia,2016,11,C-Cardiovascular system,"/capita, US$ purchasing power parity",44.3
+9793,Estonia,2016,11,J01-Antibacterials for systemic use,"/capita, US$ purchasing power parity",9.9
+9794,Estonia,2016,11,C02-Antihypertensives,Million of national currency units,0.8
+9795,Estonia,2016,11,Total pharmaceutical sales,"Million US$, purchasing power parity",549.2
+9796,Estonia,2016,11,J01-Antibacterials for systemic use,"/capita, US$ exchange rate",5.8
+9797,Estonia,2016,11,J01-Antibacterials for systemic use,% of total sales,2.4
+9798,Estonia,2016,11,C-Cardiovascular system,% of total sales,10.6
+9799,Estonia,2015,10,C02-Antihypertensives,"Million US$, purchasing power parity",1.5
+9800,Estonia,2015,10,C02-Antihypertensives,"/capita, US$ exchange rate",0.7
+9801,Estonia,2015,10,N05B-Anxiolytics,"/capita, US$ purchasing power parity",2.0
+9802,Estonia,2015,10,N05B-Anxiolytics,% of total sales,0.5
+9803,Estonia,2015,10,C02-Antihypertensives,Million US$ at exchange rate,0.9
+9804,Estonia,2015,10,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ purchasing power parity",5.0
+9805,Estonia,2015,10,"H-Systemic hormonal preparations, excluding sex hormones and insulins",% of total sales,1.3
+9806,Estonia,2015,10,N02-Analgesics,"Million US$, purchasing power parity",12.7
+9807,Estonia,2015,10,"H-Systemic hormonal preparations, excluding sex hormones and insulins","Million US$, purchasing power parity",6.6
+9808,Estonia,2015,10,N05B-Anxiolytics,Million US$ at exchange rate,1.6
+9809,Estonia,2015,10,N05B-Anxiolytics,Million of national currency units,1.4
+9810,Estonia,2015,10,N02-Analgesics,Million US$ at exchange rate,7.6
+9811,Estonia,2015,10,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million US$ at exchange rate,3.9
+9812,Estonia,2015,10,N02-Analgesics,"/capita, US$ exchange rate",5.8
+9813,Estonia,2015,10,N02-Analgesics,"/capita, US$ purchasing power parity",9.7
+9814,Estonia,2015,10,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million of national currency units,3.5
+9815,Estonia,2015,10,N02-Analgesics,% of total sales,2.6
+9816,Estonia,2015,10,N05B-Anxiolytics,"Million US$, purchasing power parity",2.6
+9817,Estonia,2015,10,C-Cardiovascular system,"/capita, US$ exchange rate",26.5
+9818,Estonia,2015,10,C-Cardiovascular system,"Million US$, purchasing power parity",58.5
+9819,Estonia,2015,10,C02-Antihypertensives,"/capita, US$ purchasing power parity",1.1
+9820,Estonia,2015,10,C02-Antihypertensives,% of total sales,0.3
+9821,Estonia,2015,10,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ exchange rate",3.0
+9822,Estonia,2015,10,N05B-Anxiolytics,"/capita, US$ exchange rate",1.2
+9823,Estonia,2015,10,N02-Analgesics,Million of national currency units,6.8
+9824,Estonia,2015,10,C-Cardiovascular system,Million US$ at exchange rate,34.9
+9825,Estonia,2015,10,C-Cardiovascular system,Million of national currency units,31.5
+9826,Estonia,2015,10,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million of national currency units,3.5
+9827,Estonia,2015,10,B-Blood and blood forming organs,"/capita, US$ exchange rate",17.9
+9828,Estonia,2015,10,B-Blood and blood forming organs,"/capita, US$ purchasing power parity",30.1
+9829,Estonia,2015,10,B-Blood and blood forming organs,% of total sales,8.0
+9830,Estonia,2015,10,B-Blood and blood forming organs,Million US$ at exchange rate,23.6
+9831,Estonia,2015,10,B-Blood and blood forming organs,"Million US$, purchasing power parity",39.6
+9832,Estonia,2015,10,R-Respiratory system,"Million US$, purchasing power parity",37.9
+9833,Estonia,2015,10,R-Respiratory system,"/capita, US$ exchange rate",17.2
+9834,Estonia,2015,10,R-Respiratory system,Million of national currency units,20.4
+9835,Estonia,2015,10,R-Respiratory system,Million US$ at exchange rate,22.6
+9836,Estonia,2015,10,C10-Lipid modifying agents,% of total sales,1.2
+9837,Estonia,2015,10,C10-Lipid modifying agents,"/capita, US$ purchasing power parity",4.6
+9838,Estonia,2015,10,A02A-Antacids,Million of national currency units,0.4
+9839,Estonia,2015,10,A02A-Antacids,"Million US$, purchasing power parity",0.7
+9840,Estonia,2015,10,A02A-Antacids,Million US$ at exchange rate,0.4
+9841,Estonia,2015,10,C10-Lipid modifying agents,Million US$ at exchange rate,3.6
+9842,Estonia,2015,10,B-Blood and blood forming organs,Million of national currency units,21.3
+9843,Estonia,2015,10,C10-Lipid modifying agents,Million of national currency units,3.2
+9844,Estonia,2015,10,R-Respiratory system,"/capita, US$ purchasing power parity",28.8
+9845,Estonia,2015,10,C10-Lipid modifying agents,"/capita, US$ exchange rate",2.7
+9846,Estonia,2015,10,C10-Lipid modifying agents,"Million US$, purchasing power parity",6.0
+9847,Estonia,2015,10,C09-Agents acting on the Renin-Angiotensin system,Million US$ at exchange rate,13.7
+9848,Estonia,2015,10,C09-Agents acting on the Renin-Angiotensin system,Million of national currency units,12.3
+9849,Estonia,2015,10,C09-Agents acting on the Renin-Angiotensin system,"Million US$, purchasing power parity",23.0
+9850,Estonia,2015,10,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ purchasing power parity",17.5
+9851,Estonia,2015,10,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ exchange rate",10.4
+9852,Estonia,2015,10,R03-Drugs for obstructive airway diseases,"/capita, US$ exchange rate",7.3
+9853,Estonia,2015,10,R03-Drugs for obstructive airway diseases,"/capita, US$ purchasing power parity",12.2
+9854,Estonia,2015,10,R03-Drugs for obstructive airway diseases,"Million US$, purchasing power parity",16.0
+9855,Estonia,2015,10,R03-Drugs for obstructive airway diseases,Million of national currency units,8.6
+9856,Estonia,2015,10,R03-Drugs for obstructive airway diseases,Million US$ at exchange rate,9.6
+9857,Estonia,2015,10,C08-Calcium channel blockers,Million US$ at exchange rate,2.6
+9858,Estonia,2015,10,C08-Calcium channel blockers,"Million US$, purchasing power parity",4.4
+9859,Estonia,2015,10,R-Respiratory system,% of total sales,7.7
+9860,Estonia,2015,10,C08-Calcium channel blockers,Million of national currency units,2.3
+9861,Estonia,2015,10,C08-Calcium channel blockers,"/capita, US$ exchange rate",2.0
+9862,Estonia,2015,10,R03-Drugs for obstructive airway diseases,% of total sales,3.3
+9863,Estonia,2015,10,C09-Agents acting on the Renin-Angiotensin system,% of total sales,4.7
+9864,Estonia,2015,10,C08-Calcium channel blockers,"/capita, US$ purchasing power parity",3.3
+9865,Estonia,2015,10,C08-Calcium channel blockers,% of total sales,0.9
+9866,Estonia,2015,10,N05C-Hypnotics and sedatives,Million of national currency units,1.8
+9867,Estonia,2015,10,N05C-Hypnotics and sedatives,Million US$ at exchange rate,1.9
+9868,Estonia,2015,10,N05C-Hypnotics and sedatives,"Million US$, purchasing power parity",3.3
+9869,Estonia,2015,10,G03-Sex hormones and modulators of the genital system,Million US$ at exchange rate,6.6
+9870,Estonia,2015,10,G03-Sex hormones and modulators of the genital system,Million of national currency units,6.0
+9871,Estonia,2015,10,N05C-Hypnotics and sedatives,% of total sales,0.7
+9872,Estonia,2015,10,G-Genito urinary system and sex hormones,% of total sales,4.4
+9873,Estonia,2015,10,N05C-Hypnotics and sedatives,"/capita, US$ exchange rate",1.5
+9874,Estonia,2015,10,N05C-Hypnotics and sedatives,"/capita, US$ purchasing power parity",2.5
+9875,Estonia,2015,10,C03-Diuretics,"/capita, US$ exchange rate",1.5
+9876,Estonia,2015,10,C03-Diuretics,"/capita, US$ purchasing power parity",2.6
+9877,Estonia,2015,10,C03-Diuretics,"Million US$, purchasing power parity",3.4
+9878,Estonia,2015,10,C03-Diuretics,Million of national currency units,1.8
+9879,Estonia,2015,10,C03-Diuretics,Million US$ at exchange rate,2.0
+9880,Estonia,2015,10,G03-Sex hormones and modulators of the genital system,"/capita, US$ purchasing power parity",8.5
+9881,Estonia,2015,10,G03-Sex hormones and modulators of the genital system,"Million US$, purchasing power parity",11.1
+9882,Estonia,2015,10,G03-Sex hormones and modulators of the genital system,"/capita, US$ exchange rate",5.1
+9883,Estonia,2015,10,C03-Diuretics,% of total sales,0.7
+9884,Estonia,2015,10,G03-Sex hormones and modulators of the genital system,% of total sales,2.3
+9885,Estonia,2015,10,G-Genito urinary system and sex hormones,"/capita, US$ purchasing power parity",16.4
+9886,Estonia,2015,10,C07-Beta blocking agents,Million US$ at exchange rate,6.2
+9887,Estonia,2015,10,C07-Beta blocking agents,"Million US$, purchasing power parity",10.4
+9888,Estonia,2015,10,N06A-Antidepressants,% of total sales,1.2
+9889,Estonia,2015,10,A02A-Antacids,% of total sales,0.1
+9890,Estonia,2015,10,C07-Beta blocking agents,Million of national currency units,5.6
+9891,Estonia,2015,10,A02A-Antacids,"/capita, US$ purchasing power parity",0.5
+9892,Estonia,2015,10,A02A-Antacids,"/capita, US$ exchange rate",0.3
+9893,Estonia,2015,10,C07-Beta blocking agents,"/capita, US$ exchange rate",4.7
+9894,Estonia,2015,10,C07-Beta blocking agents,% of total sales,2.1
+9895,Estonia,2015,10,C07-Beta blocking agents,"/capita, US$ purchasing power parity",7.9
+9896,Estonia,2015,10,G-Genito urinary system and sex hormones,Million US$ at exchange rate,12.9
+9897,Estonia,2015,10,G-Genito urinary system and sex hormones,Million of national currency units,11.6
+9898,Estonia,2015,10,G-Genito urinary system and sex hormones,"/capita, US$ exchange rate",9.8
+9899,Estonia,2015,10,G-Genito urinary system and sex hormones,"Million US$, purchasing power parity",21.6
+9900,Estonia,2015,10,N06A-Antidepressants,Million of national currency units,3.2
+9901,Estonia,2015,10,N06A-Antidepressants,"/capita, US$ exchange rate",2.7
+9902,Estonia,2015,10,N06A-Antidepressants,"/capita, US$ purchasing power parity",4.6
+9903,Estonia,2015,10,N06A-Antidepressants,Million US$ at exchange rate,3.6
+9904,Estonia,2015,10,N06A-Antidepressants,"Million US$, purchasing power parity",6.0
+9905,Estonia,2015,10,A-Alimentary tract and metabolism,Million US$ at exchange rate,36.3
+9906,Estonia,2015,10,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),% of total sales,1.3
+9907,Estonia,2015,10,A-Alimentary tract and metabolism,"/capita, US$ exchange rate",27.6
+9908,Estonia,2015,10,A-Alimentary tract and metabolism,"Million US$, purchasing power parity",60.9
+9909,Estonia,2015,10,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ purchasing power parity",4.9
+9910,Estonia,2015,10,A-Alimentary tract and metabolism,Million of national currency units,32.7
+9911,Estonia,2015,10,A10-Drugs used in diabetes,% of total sales,6.2
+9912,Estonia,2015,10,A10-Drugs used in diabetes,"/capita, US$ purchasing power parity",23.1
+9913,Estonia,2015,10,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ exchange rate",2.9
+9914,Estonia,2015,10,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"Million US$, purchasing power parity",6.4
+9915,Estonia,2015,10,A-Alimentary tract and metabolism,"/capita, US$ purchasing power parity",46.3
+9916,Estonia,2015,10,N-Nervous system,% of total sales,9.4
+9917,Estonia,2015,10,"C01B-Antiarrhythmics, Class I and III",Million of national currency units,1.0
+9918,Estonia,2015,10,N-Nervous system,"/capita, US$ purchasing power parity",35.3
+9919,Estonia,2015,10,N-Nervous system,"Million US$, purchasing power parity",46.4
+9920,Estonia,2015,10,N-Nervous system,"/capita, US$ exchange rate",21.1
+9921,Estonia,2015,10,"C01B-Antiarrhythmics, Class I and III",% of total sales,0.4
+9922,Estonia,2015,10,"C01B-Antiarrhythmics, Class I and III","/capita, US$ purchasing power parity",1.4
+9923,Estonia,2015,10,A-Alimentary tract and metabolism,% of total sales,12.3
+9924,Estonia,2015,10,"C01B-Antiarrhythmics, Class I and III","Million US$, purchasing power parity",1.9
+9925,Estonia,2015,10,"C01B-Antiarrhythmics, Class I and III",Million US$ at exchange rate,1.1
+9926,Estonia,2015,10,"C01B-Antiarrhythmics, Class I and III","/capita, US$ exchange rate",0.8
+9927,Estonia,2015,10,C01A-Cardiac glycosides,"Million US$, purchasing power parity",0.3
+9928,Estonia,2015,10,C01A-Cardiac glycosides,"/capita, US$ exchange rate",0.1
+9929,Estonia,2015,10,C01A-Cardiac glycosides,"/capita, US$ purchasing power parity",0.2
+9930,Estonia,2015,10,C01A-Cardiac glycosides,Million of national currency units,0.1
+9931,Estonia,2015,10,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ exchange rate",7.8
+9932,Estonia,2015,10,C01A-Cardiac glycosides,Million US$ at exchange rate,0.2
+9933,Estonia,2015,10,Total pharmaceutical sales,Million US$ at exchange rate,294.2
+9934,Estonia,2015,10,Total pharmaceutical sales,Million of national currency units,265.2
+9935,Estonia,2015,10,M01A-Antiinflammatory and antirheumatic products non-steroids,% of total sales,3.5
+9936,Estonia,2015,10,C01A-Cardiac glycosides,% of total sales,0.1
+9937,Estonia,2015,10,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ purchasing power parity",13.1
+9938,Estonia,2015,10,M-Musculo-skeletal system,% of total sales,5.9
+9939,Estonia,2015,10,M-Musculo-skeletal system,"/capita, US$ purchasing power parity",22.1
+9940,Estonia,2015,10,M-Musculo-skeletal system,"/capita, US$ exchange rate",13.2
+9941,Estonia,2015,10,A10-Drugs used in diabetes,"/capita, US$ exchange rate",13.8
+9942,Estonia,2015,10,A10-Drugs used in diabetes,"Million US$, purchasing power parity",30.4
+9943,Estonia,2015,10,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million US$ at exchange rate,3.8
+9944,Estonia,2015,10,M01A-Antiinflammatory and antirheumatic products non-steroids,Million of national currency units,9.2
+9945,Estonia,2015,10,M01A-Antiinflammatory and antirheumatic products non-steroids,Million US$ at exchange rate,10.2
+9946,Estonia,2015,10,M01A-Antiinflammatory and antirheumatic products non-steroids,"Million US$, purchasing power parity",17.2
+9947,Estonia,2015,10,M-Musculo-skeletal system,"Million US$, purchasing power parity",29.1
+9948,Estonia,2015,10,M-Musculo-skeletal system,Million of national currency units,15.6
+9949,Estonia,2015,10,M-Musculo-skeletal system,Million US$ at exchange rate,17.3
+9950,Estonia,2015,10,J-Antiinfectives for systemic use,Million US$ at exchange rate,35.3
+9951,Estonia,2015,10,J01-Antibacterials for systemic use,"Million US$, purchasing power parity",12.9
+9952,Estonia,2015,10,J-Antiinfectives for systemic use,"Million US$, purchasing power parity",59.2
+9953,Estonia,2015,10,J-Antiinfectives for systemic use,"/capita, US$ purchasing power parity",45.0
+9954,Estonia,2015,10,J-Antiinfectives for systemic use,"/capita, US$ exchange rate",26.8
+9955,Estonia,2015,10,J01-Antibacterials for systemic use,Million US$ at exchange rate,7.7
+9956,Estonia,2015,10,Total pharmaceutical sales,"/capita, US$ purchasing power parity",375.0
+9957,Estonia,2015,10,Total pharmaceutical sales,"/capita, US$ exchange rate",223.6
+9958,Estonia,2015,10,J-Antiinfectives for systemic use,Million of national currency units,31.8
+9959,Estonia,2015,10,J01-Antibacterials for systemic use,Million of national currency units,6.9
+9960,Estonia,2015,10,A10-Drugs used in diabetes,Million of national currency units,16.4
+9961,Estonia,2015,10,A10-Drugs used in diabetes,Million US$ at exchange rate,18.2
+9962,Estonia,2015,10,N-Nervous system,Million of national currency units,25.0
+9963,Estonia,2015,10,N-Nervous system,Million US$ at exchange rate,27.7
+9964,Estonia,2015,10,C-Cardiovascular system,"/capita, US$ purchasing power parity",44.5
+9965,Estonia,2015,10,J-Antiinfectives for systemic use,% of total sales,12.0
+9966,Estonia,2015,10,J01-Antibacterials for systemic use,"/capita, US$ purchasing power parity",9.8
+9967,Estonia,2015,10,C02-Antihypertensives,Million of national currency units,0.8
+9968,Estonia,2015,10,Total pharmaceutical sales,"Million US$, purchasing power parity",493.2
+9969,Estonia,2015,10,J01-Antibacterials for systemic use,% of total sales,2.6
+9970,Estonia,2015,10,C-Cardiovascular system,% of total sales,11.9
+9971,Estonia,2015,10,J01-Antibacterials for systemic use,"/capita, US$ exchange rate",5.9
+9972,Estonia,2014,11,C02-Antihypertensives,"Million US$, purchasing power parity",1.6
+9973,Estonia,2014,11,C02-Antihypertensives,"/capita, US$ exchange rate",0.8
+9974,Estonia,2014,11,N05B-Anxiolytics,"/capita, US$ purchasing power parity",2.0
+9975,Estonia,2014,11,N05B-Anxiolytics,% of total sales,0.6
+9976,Estonia,2014,11,C02-Antihypertensives,Million US$ at exchange rate,1.1
+9977,Estonia,2014,11,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ purchasing power parity",5.2
+9978,Estonia,2014,11,"H-Systemic hormonal preparations, excluding sex hormones and insulins",% of total sales,1.4
+9979,Estonia,2014,11,N02-Analgesics,"Million US$, purchasing power parity",12.0
+9980,Estonia,2014,11,"H-Systemic hormonal preparations, excluding sex hormones and insulins","Million US$, purchasing power parity",6.8
+9981,Estonia,2014,11,N05B-Anxiolytics,Million US$ at exchange rate,1.9
+9982,Estonia,2014,11,N05B-Anxiolytics,Million of national currency units,1.4
+9983,Estonia,2014,11,N05B-Anxiolytics,"Million US$, purchasing power parity",2.7
+9984,Estonia,2014,11,N02-Analgesics,"/capita, US$ exchange rate",6.4
+9985,Estonia,2014,11,N02-Analgesics,"/capita, US$ purchasing power parity",9.1
+9986,Estonia,2014,11,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million of national currency units,3.6
+9987,Estonia,2014,11,N02-Analgesics,% of total sales,2.5
+9988,Estonia,2014,11,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million US$ at exchange rate,4.7
+9989,Estonia,2014,11,C-Cardiovascular system,"/capita, US$ exchange rate",32.4
+9990,Estonia,2014,11,C-Cardiovascular system,"Million US$, purchasing power parity",60.8
+9991,Estonia,2014,11,C02-Antihypertensives,"/capita, US$ purchasing power parity",1.2
+9992,Estonia,2014,11,C02-Antihypertensives,% of total sales,0.3
+9993,Estonia,2014,11,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ exchange rate",3.6
+9994,Estonia,2014,11,N02-Analgesics,Million US$ at exchange rate,8.4
+9995,Estonia,2014,11,N05B-Anxiolytics,"/capita, US$ exchange rate",1.4
+9996,Estonia,2014,11,C-Cardiovascular system,Million US$ at exchange rate,42.5
+9997,Estonia,2014,11,C-Cardiovascular system,Million of national currency units,32.0
+9998,Estonia,2014,11,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million of national currency units,3.4
+9999,Estonia,2014,11,N02-Analgesics,Million of national currency units,6.3
+10000,Estonia,2014,11,B-Blood and blood forming organs,"/capita, US$ purchasing power parity",25.1
+10001,Estonia,2014,11,B-Blood and blood forming organs,% of total sales,7.0
+10002,Estonia,2014,11,B-Blood and blood forming organs,"/capita, US$ exchange rate",17.6
+10003,Estonia,2014,11,B-Blood and blood forming organs,Million US$ at exchange rate,23.1
+10004,Estonia,2014,11,B-Blood and blood forming organs,"Million US$, purchasing power parity",33.0
+10005,Estonia,2014,11,R-Respiratory system,"Million US$, purchasing power parity",37.5
+10006,Estonia,2014,11,R-Respiratory system,"/capita, US$ exchange rate",20.0
+10007,Estonia,2014,11,R-Respiratory system,"/capita, US$ purchasing power parity",28.5
+10008,Estonia,2014,11,R-Respiratory system,Million of national currency units,19.7
+10009,Estonia,2014,11,R-Respiratory system,Million US$ at exchange rate,26.2
+10010,Estonia,2014,11,A02A-Antacids,Million of national currency units,0.4
+10011,Estonia,2014,11,C10-Lipid modifying agents,% of total sales,1.3
+10012,Estonia,2014,11,C10-Lipid modifying agents,"/capita, US$ purchasing power parity",4.7
+10013,Estonia,2014,11,A02A-Antacids,"Million US$, purchasing power parity",0.7
+10014,Estonia,2014,11,A02A-Antacids,Million US$ at exchange rate,0.5
+10015,Estonia,2014,11,C10-Lipid modifying agents,Million US$ at exchange rate,4.3
+10016,Estonia,2014,11,C10-Lipid modifying agents,Million of national currency units,3.2
+10017,Estonia,2014,11,B-Blood and blood forming organs,Million of national currency units,17.4
+10018,Estonia,2014,11,C10-Lipid modifying agents,"/capita, US$ exchange rate",3.3
+10019,Estonia,2014,11,C10-Lipid modifying agents,"Million US$, purchasing power parity",6.1
+10020,Estonia,2014,11,C09-Agents acting on the Renin-Angiotensin system,Million US$ at exchange rate,17.1
+10021,Estonia,2014,11,C09-Agents acting on the Renin-Angiotensin system,Million of national currency units,12.9
+10022,Estonia,2014,11,C09-Agents acting on the Renin-Angiotensin system,"Million US$, purchasing power parity",24.4
+10023,Estonia,2014,11,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ purchasing power parity",18.6
+10024,Estonia,2014,11,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ exchange rate",13.0
+10025,Estonia,2014,11,R03-Drugs for obstructive airway diseases,"/capita, US$ exchange rate",8.8
+10026,Estonia,2014,11,R03-Drugs for obstructive airway diseases,"/capita, US$ purchasing power parity",12.6
+10027,Estonia,2014,11,R03-Drugs for obstructive airway diseases,Million of national currency units,8.7
+10028,Estonia,2014,11,R03-Drugs for obstructive airway diseases,"Million US$, purchasing power parity",16.6
+10029,Estonia,2014,11,R03-Drugs for obstructive airway diseases,Million US$ at exchange rate,11.6
+10030,Estonia,2014,11,C08-Calcium channel blockers,Million US$ at exchange rate,3.4
+10031,Estonia,2014,11,C08-Calcium channel blockers,"Million US$, purchasing power parity",4.9
+10032,Estonia,2014,11,R-Respiratory system,% of total sales,7.9
+10033,Estonia,2014,11,C08-Calcium channel blockers,Million of national currency units,2.6
+10034,Estonia,2014,11,C08-Calcium channel blockers,"/capita, US$ exchange rate",2.6
+10035,Estonia,2014,11,R03-Drugs for obstructive airway diseases,% of total sales,3.5
+10036,Estonia,2014,11,C09-Agents acting on the Renin-Angiotensin system,% of total sales,5.2
+10037,Estonia,2014,11,C08-Calcium channel blockers,"/capita, US$ purchasing power parity",3.7
+10038,Estonia,2014,11,C08-Calcium channel blockers,% of total sales,1.0
+10039,Estonia,2014,11,N05C-Hypnotics and sedatives,Million US$ at exchange rate,2.2
+10040,Estonia,2014,11,N05C-Hypnotics and sedatives,"Million US$, purchasing power parity",3.2
+10041,Estonia,2014,11,N05C-Hypnotics and sedatives,Million of national currency units,1.7
+10042,Estonia,2014,11,G03-Sex hormones and modulators of the genital system,Million US$ at exchange rate,8.2
+10043,Estonia,2014,11,G03-Sex hormones and modulators of the genital system,Million of national currency units,6.2
+10044,Estonia,2014,11,N05C-Hypnotics and sedatives,% of total sales,0.7
+10045,Estonia,2014,11,G-Genito urinary system and sex hormones,% of total sales,4.6
+10046,Estonia,2014,11,N05C-Hypnotics and sedatives,"/capita, US$ exchange rate",1.7
+10047,Estonia,2014,11,N05C-Hypnotics and sedatives,"/capita, US$ purchasing power parity",2.4
+10048,Estonia,2014,11,G03-Sex hormones and modulators of the genital system,"Million US$, purchasing power parity",11.7
+10049,Estonia,2014,11,C03-Diuretics,"/capita, US$ exchange rate",1.8
+10050,Estonia,2014,11,C03-Diuretics,"/capita, US$ purchasing power parity",2.5
+10051,Estonia,2014,11,C03-Diuretics,"Million US$, purchasing power parity",3.3
+10052,Estonia,2014,11,C03-Diuretics,Million of national currency units,1.8
+10053,Estonia,2014,11,C03-Diuretics,Million US$ at exchange rate,2.3
+10054,Estonia,2014,11,G03-Sex hormones and modulators of the genital system,"/capita, US$ purchasing power parity",8.9
+10055,Estonia,2014,11,G03-Sex hormones and modulators of the genital system,"/capita, US$ exchange rate",6.2
+10056,Estonia,2014,11,C03-Diuretics,% of total sales,0.7
+10057,Estonia,2014,11,G03-Sex hormones and modulators of the genital system,% of total sales,2.5
+10058,Estonia,2014,11,C07-Beta blocking agents,Million US$ at exchange rate,7.4
+10059,Estonia,2014,11,C07-Beta blocking agents,"Million US$, purchasing power parity",10.5
+10060,Estonia,2014,11,A02A-Antacids,% of total sales,0.1
+10061,Estonia,2014,11,C07-Beta blocking agents,Million of national currency units,5.5
+10062,Estonia,2014,11,A02A-Antacids,"/capita, US$ purchasing power parity",0.5
+10063,Estonia,2014,11,A02A-Antacids,"/capita, US$ exchange rate",0.4
+10064,Estonia,2014,11,N06A-Antidepressants,% of total sales,1.2
+10065,Estonia,2014,11,C07-Beta blocking agents,"/capita, US$ exchange rate",5.6
+10066,Estonia,2014,11,C07-Beta blocking agents,"/capita, US$ purchasing power parity",8.0
+10067,Estonia,2014,11,C07-Beta blocking agents,% of total sales,2.2
+10068,Estonia,2014,11,G-Genito urinary system and sex hormones,Million US$ at exchange rate,15.3
+10069,Estonia,2014,11,G-Genito urinary system and sex hormones,Million of national currency units,11.5
+10070,Estonia,2014,11,G-Genito urinary system and sex hormones,"/capita, US$ purchasing power parity",16.6
+10071,Estonia,2014,11,G-Genito urinary system and sex hormones,"/capita, US$ exchange rate",11.6
+10072,Estonia,2014,11,G-Genito urinary system and sex hormones,"Million US$, purchasing power parity",21.8
+10073,Estonia,2014,11,N06A-Antidepressants,Million of national currency units,3.0
+10074,Estonia,2014,11,N06A-Antidepressants,"/capita, US$ exchange rate",3.1
+10075,Estonia,2014,11,N06A-Antidepressants,"/capita, US$ purchasing power parity",4.4
+10076,Estonia,2014,11,N06A-Antidepressants,Million US$ at exchange rate,4.1
+10077,Estonia,2014,11,N06A-Antidepressants,"Million US$, purchasing power parity",5.8
+10078,Estonia,2014,11,A-Alimentary tract and metabolism,Million US$ at exchange rate,40.8
+10079,Estonia,2014,11,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),% of total sales,1.3
+10080,Estonia,2014,11,A-Alimentary tract and metabolism,"/capita, US$ exchange rate",31.1
+10081,Estonia,2014,11,A-Alimentary tract and metabolism,"Million US$, purchasing power parity",58.3
+10082,Estonia,2014,11,A-Alimentary tract and metabolism,Million of national currency units,30.7
+10083,Estonia,2014,11,A10-Drugs used in diabetes,% of total sales,6.2
+10084,Estonia,2014,11,A10-Drugs used in diabetes,"/capita, US$ purchasing power parity",22.2
+10085,Estonia,2014,11,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ exchange rate",3.4
+10086,Estonia,2014,11,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ purchasing power parity",4.8
+10087,Estonia,2014,11,A-Alimentary tract and metabolism,"/capita, US$ purchasing power parity",44.4
+10088,Estonia,2014,11,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"Million US$, purchasing power parity",6.4
+10089,Estonia,2014,11,N-Nervous system,% of total sales,9.6
+10090,Estonia,2014,11,"C01B-Antiarrhythmics, Class I and III",Million of national currency units,1.0
+10091,Estonia,2014,11,N-Nervous system,"Million US$, purchasing power parity",45.3
+10092,Estonia,2014,11,N-Nervous system,"/capita, US$ exchange rate",24.1
+10093,Estonia,2014,11,N-Nervous system,"/capita, US$ purchasing power parity",34.5
+10094,Estonia,2014,11,"C01B-Antiarrhythmics, Class I and III",Million US$ at exchange rate,1.3
+10095,Estonia,2014,11,"C01B-Antiarrhythmics, Class I and III",% of total sales,0.4
+10096,Estonia,2014,11,A-Alimentary tract and metabolism,% of total sales,12.3
+10097,Estonia,2014,11,"C01B-Antiarrhythmics, Class I and III","/capita, US$ purchasing power parity",1.4
+10098,Estonia,2014,11,"C01B-Antiarrhythmics, Class I and III","Million US$, purchasing power parity",1.8
+10099,Estonia,2014,11,"C01B-Antiarrhythmics, Class I and III","/capita, US$ exchange rate",1.0
+10100,Estonia,2014,11,C01A-Cardiac glycosides,"/capita, US$ exchange rate",0.2
+10101,Estonia,2014,11,C01A-Cardiac glycosides,"Million US$, purchasing power parity",0.3
+10102,Estonia,2014,11,C01A-Cardiac glycosides,"/capita, US$ purchasing power parity",0.2
+10103,Estonia,2014,11,C01A-Cardiac glycosides,Million of national currency units,0.2
+10104,Estonia,2014,11,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ exchange rate",8.8
+10105,Estonia,2014,11,C01A-Cardiac glycosides,Million US$ at exchange rate,0.2
+10106,Estonia,2014,11,Total pharmaceutical sales,Million of national currency units,249.4
+10107,Estonia,2014,11,Total pharmaceutical sales,Million US$ at exchange rate,331.4
+10108,Estonia,2014,11,M01A-Antiinflammatory and antirheumatic products non-steroids,% of total sales,3.5
+10109,Estonia,2014,11,C01A-Cardiac glycosides,% of total sales,0.1
+10110,Estonia,2014,11,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ purchasing power parity",12.5
+10111,Estonia,2014,11,M-Musculo-skeletal system,% of total sales,5.8
+10112,Estonia,2014,11,M-Musculo-skeletal system,"/capita, US$ purchasing power parity",20.7
+10113,Estonia,2014,11,M-Musculo-skeletal system,"/capita, US$ exchange rate",14.5
+10114,Estonia,2014,11,A10-Drugs used in diabetes,"/capita, US$ exchange rate",15.5
+10115,Estonia,2014,11,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million US$ at exchange rate,4.5
+10116,Estonia,2014,11,A10-Drugs used in diabetes,"Million US$, purchasing power parity",29.2
+10117,Estonia,2014,11,M01A-Antiinflammatory and antirheumatic products non-steroids,Million of national currency units,8.7
+10118,Estonia,2014,11,M01A-Antiinflammatory and antirheumatic products non-steroids,Million US$ at exchange rate,11.5
+10119,Estonia,2014,11,M01A-Antiinflammatory and antirheumatic products non-steroids,"Million US$, purchasing power parity",16.5
+10120,Estonia,2014,11,M-Musculo-skeletal system,"Million US$, purchasing power parity",27.2
+10121,Estonia,2014,11,M-Musculo-skeletal system,Million US$ at exchange rate,19.1
+10122,Estonia,2014,11,M-Musculo-skeletal system,Million of national currency units,14.3
+10123,Estonia,2014,11,J-Antiinfectives for systemic use,Million US$ at exchange rate,37.2
+10124,Estonia,2014,11,J01-Antibacterials for systemic use,"Million US$, purchasing power parity",13.4
+10125,Estonia,2014,11,J-Antiinfectives for systemic use,"/capita, US$ purchasing power parity",40.5
+10126,Estonia,2014,11,J-Antiinfectives for systemic use,"Million US$, purchasing power parity",53.2
+10127,Estonia,2014,11,J-Antiinfectives for systemic use,"/capita, US$ exchange rate",28.3
+10128,Estonia,2014,11,J01-Antibacterials for systemic use,Million US$ at exchange rate,9.4
+10129,Estonia,2014,11,Total pharmaceutical sales,"/capita, US$ purchasing power parity",360.1
+10130,Estonia,2014,11,Total pharmaceutical sales,"/capita, US$ exchange rate",252.1
+10131,Estonia,2014,11,J-Antiinfectives for systemic use,Million of national currency units,28.0
+10132,Estonia,2014,11,J01-Antibacterials for systemic use,Million of national currency units,7.0
+10133,Estonia,2014,11,A10-Drugs used in diabetes,Million US$ at exchange rate,20.4
+10134,Estonia,2014,11,A10-Drugs used in diabetes,Million of national currency units,15.4
+10135,Estonia,2014,11,N-Nervous system,Million of national currency units,23.9
+10136,Estonia,2014,11,N-Nervous system,Million US$ at exchange rate,31.7
+10137,Estonia,2014,11,C-Cardiovascular system,"/capita, US$ purchasing power parity",46.2
+10138,Estonia,2014,11,J-Antiinfectives for systemic use,% of total sales,11.2
+10139,Estonia,2014,11,C-Cardiovascular system,% of total sales,12.8
+10140,Estonia,2014,11,J01-Antibacterials for systemic use,"/capita, US$ purchasing power parity",10.2
+10141,Estonia,2014,11,C02-Antihypertensives,Million of national currency units,0.8
+10142,Estonia,2014,11,J01-Antibacterials for systemic use,% of total sales,2.8
+10143,Estonia,2014,11,Total pharmaceutical sales,"Million US$, purchasing power parity",473.4
+10144,Estonia,2014,11,J01-Antibacterials for systemic use,"/capita, US$ exchange rate",7.1
+10145,Estonia,2013,10,C02-Antihypertensives,"Million US$, purchasing power parity",1.6
+10146,Estonia,2013,10,C02-Antihypertensives,"/capita, US$ exchange rate",0.9
+10147,Estonia,2013,10,N05B-Anxiolytics,"/capita, US$ purchasing power parity",1.9
+10148,Estonia,2013,10,N05B-Anxiolytics,% of total sales,0.6
+10149,Estonia,2013,10,C02-Antihypertensives,Million US$ at exchange rate,1.1
+10150,Estonia,2013,10,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ purchasing power parity",4.8
+10151,Estonia,2013,10,"H-Systemic hormonal preparations, excluding sex hormones and insulins",% of total sales,1.4
+10152,Estonia,2013,10,C02-Antihypertensives,"/capita, US$ purchasing power parity",1.2
+10153,Estonia,2013,10,N02-Analgesics,"Million US$, purchasing power parity",11.3
+10154,Estonia,2013,10,"H-Systemic hormonal preparations, excluding sex hormones and insulins","Million US$, purchasing power parity",6.3
+10155,Estonia,2013,10,N05B-Anxiolytics,"Million US$, purchasing power parity",2.5
+10156,Estonia,2013,10,N05B-Anxiolytics,Million US$ at exchange rate,1.8
+10157,Estonia,2013,10,N05B-Anxiolytics,Million of national currency units,1.3
+10158,Estonia,2013,10,N02-Analgesics,"/capita, US$ exchange rate",6.0
+10159,Estonia,2013,10,N02-Analgesics,"/capita, US$ purchasing power parity",8.6
+10160,Estonia,2013,10,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million US$ at exchange rate,4.4
+10161,Estonia,2013,10,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million of national currency units,3.3
+10162,Estonia,2013,10,N02-Analgesics,% of total sales,2.6
+10163,Estonia,2013,10,C-Cardiovascular system,"/capita, US$ exchange rate",31.9
+10164,Estonia,2013,10,C-Cardiovascular system,"Million US$, purchasing power parity",60.7
+10165,Estonia,2013,10,C02-Antihypertensives,% of total sales,0.4
+10166,Estonia,2013,10,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ exchange rate",3.3
+10167,Estonia,2013,10,N02-Analgesics,Million US$ at exchange rate,7.8
+10168,Estonia,2013,10,N05B-Anxiolytics,"/capita, US$ exchange rate",1.3
+10169,Estonia,2013,10,N02-Analgesics,Million of national currency units,5.9
+10170,Estonia,2013,10,C-Cardiovascular system,Million US$ at exchange rate,42.1
+10171,Estonia,2013,10,C-Cardiovascular system,Million of national currency units,31.7
+10172,Estonia,2013,10,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million of national currency units,3.5
+10173,Estonia,2013,10,B-Blood and blood forming organs,"/capita, US$ purchasing power parity",20.5
+10174,Estonia,2013,10,B-Blood and blood forming organs,% of total sales,6.1
+10175,Estonia,2013,10,B-Blood and blood forming organs,"/capita, US$ exchange rate",14.2
+10176,Estonia,2013,10,B-Blood and blood forming organs,Million US$ at exchange rate,18.7
+10177,Estonia,2013,10,B-Blood and blood forming organs,"Million US$, purchasing power parity",27.0
+10178,Estonia,2013,10,R-Respiratory system,"/capita, US$ exchange rate",18.8
+10179,Estonia,2013,10,R-Respiratory system,"/capita, US$ purchasing power parity",27.1
+10180,Estonia,2013,10,R-Respiratory system,"Million US$, purchasing power parity",35.7
+10181,Estonia,2013,10,R-Respiratory system,Million of national currency units,18.6
+10182,Estonia,2013,10,R-Respiratory system,Million US$ at exchange rate,24.8
+10183,Estonia,2013,10,A02A-Antacids,Million of national currency units,0.3
+10184,Estonia,2013,10,C10-Lipid modifying agents,% of total sales,1.5
+10185,Estonia,2013,10,A02A-Antacids,"Million US$, purchasing power parity",0.6
+10186,Estonia,2013,10,C10-Lipid modifying agents,"/capita, US$ purchasing power parity",5.0
+10187,Estonia,2013,10,A02A-Antacids,Million US$ at exchange rate,0.4
+10188,Estonia,2013,10,C10-Lipid modifying agents,Million US$ at exchange rate,4.6
+10189,Estonia,2013,10,C10-Lipid modifying agents,Million of national currency units,3.4
+10190,Estonia,2013,10,B-Blood and blood forming organs,Million of national currency units,14.1
+10191,Estonia,2013,10,C10-Lipid modifying agents,"/capita, US$ exchange rate",3.5
+10192,Estonia,2013,10,C10-Lipid modifying agents,"Million US$, purchasing power parity",6.6
+10193,Estonia,2013,10,C09-Agents acting on the Renin-Angiotensin system,"Million US$, purchasing power parity",23.8
+10194,Estonia,2013,10,C09-Agents acting on the Renin-Angiotensin system,Million US$ at exchange rate,16.5
+10195,Estonia,2013,10,C09-Agents acting on the Renin-Angiotensin system,Million of national currency units,12.4
+10196,Estonia,2013,10,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ purchasing power parity",18.1
+10197,Estonia,2013,10,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ exchange rate",12.5
+10198,Estonia,2013,10,R03-Drugs for obstructive airway diseases,"/capita, US$ exchange rate",8.4
+10199,Estonia,2013,10,R03-Drugs for obstructive airway diseases,"/capita, US$ purchasing power parity",12.1
+10200,Estonia,2013,10,R03-Drugs for obstructive airway diseases,"Million US$, purchasing power parity",16.0
+10201,Estonia,2013,10,R03-Drugs for obstructive airway diseases,Million of national currency units,8.3
+10202,Estonia,2013,10,R03-Drugs for obstructive airway diseases,Million US$ at exchange rate,11.1
+10203,Estonia,2013,10,C08-Calcium channel blockers,Million US$ at exchange rate,3.9
+10204,Estonia,2013,10,C08-Calcium channel blockers,"Million US$, purchasing power parity",5.6
+10205,Estonia,2013,10,R-Respiratory system,% of total sales,8.1
+10206,Estonia,2013,10,C08-Calcium channel blockers,Million of national currency units,2.9
+10207,Estonia,2013,10,C08-Calcium channel blockers,"/capita, US$ exchange rate",3.0
+10208,Estonia,2013,10,R03-Drugs for obstructive airway diseases,% of total sales,3.6
+10209,Estonia,2013,10,C09-Agents acting on the Renin-Angiotensin system,% of total sales,5.4
+10210,Estonia,2013,10,C08-Calcium channel blockers,"/capita, US$ purchasing power parity",4.3
+10211,Estonia,2013,10,C08-Calcium channel blockers,% of total sales,1.3
+10212,Estonia,2013,10,N05C-Hypnotics and sedatives,Million US$ at exchange rate,2.1
+10213,Estonia,2013,10,N05C-Hypnotics and sedatives,"Million US$, purchasing power parity",3.0
+10214,Estonia,2013,10,N05C-Hypnotics and sedatives,Million of national currency units,1.5
+10215,Estonia,2013,10,G03-Sex hormones and modulators of the genital system,Million US$ at exchange rate,8.5
+10216,Estonia,2013,10,G03-Sex hormones and modulators of the genital system,Million of national currency units,6.4
+10217,Estonia,2013,10,N05C-Hypnotics and sedatives,% of total sales,0.7
+10218,Estonia,2013,10,G-Genito urinary system and sex hormones,% of total sales,5.0
+10219,Estonia,2013,10,N05C-Hypnotics and sedatives,"/capita, US$ exchange rate",1.6
+10220,Estonia,2013,10,N05C-Hypnotics and sedatives,"/capita, US$ purchasing power parity",2.2
+10221,Estonia,2013,10,G03-Sex hormones and modulators of the genital system,"Million US$, purchasing power parity",12.2
+10222,Estonia,2013,10,C03-Diuretics,"/capita, US$ exchange rate",1.7
+10223,Estonia,2013,10,C03-Diuretics,"/capita, US$ purchasing power parity",2.4
+10224,Estonia,2013,10,C03-Diuretics,Million of national currency units,1.6
+10225,Estonia,2013,10,C03-Diuretics,"Million US$, purchasing power parity",3.2
+10226,Estonia,2013,10,C03-Diuretics,Million US$ at exchange rate,2.2
+10227,Estonia,2013,10,G03-Sex hormones and modulators of the genital system,"/capita, US$ purchasing power parity",9.3
+10228,Estonia,2013,10,G03-Sex hormones and modulators of the genital system,"/capita, US$ exchange rate",6.4
+10229,Estonia,2013,10,C03-Diuretics,% of total sales,0.7
+10230,Estonia,2013,10,G03-Sex hormones and modulators of the genital system,% of total sales,2.8
+10231,Estonia,2013,10,C07-Beta blocking agents,Million US$ at exchange rate,7.1
+10232,Estonia,2013,10,C07-Beta blocking agents,"Million US$, purchasing power parity",10.2
+10233,Estonia,2013,10,A02A-Antacids,% of total sales,0.1
+10234,Estonia,2013,10,C07-Beta blocking agents,Million of national currency units,5.3
+10235,Estonia,2013,10,C07-Beta blocking agents,"/capita, US$ exchange rate",5.4
+10236,Estonia,2013,10,A02A-Antacids,"/capita, US$ purchasing power parity",0.5
+10237,Estonia,2013,10,A02A-Antacids,"/capita, US$ exchange rate",0.3
+10238,Estonia,2013,10,C07-Beta blocking agents,"/capita, US$ purchasing power parity",7.7
+10239,Estonia,2013,10,C07-Beta blocking agents,% of total sales,2.3
+10240,Estonia,2013,10,N06A-Antidepressants,% of total sales,1.3
+10241,Estonia,2013,10,G-Genito urinary system and sex hormones,Million US$ at exchange rate,15.2
+10242,Estonia,2013,10,G-Genito urinary system and sex hormones,Million of national currency units,11.4
+10243,Estonia,2013,10,G-Genito urinary system and sex hormones,"/capita, US$ purchasing power parity",16.6
+10244,Estonia,2013,10,G-Genito urinary system and sex hormones,"Million US$, purchasing power parity",21.9
+10245,Estonia,2013,10,G-Genito urinary system and sex hormones,"/capita, US$ exchange rate",11.5
+10246,Estonia,2013,10,N06A-Antidepressants,Million of national currency units,2.9
+10247,Estonia,2013,10,N06A-Antidepressants,"/capita, US$ exchange rate",2.9
+10248,Estonia,2013,10,N06A-Antidepressants,"/capita, US$ purchasing power parity",4.2
+10249,Estonia,2013,10,N06A-Antidepressants,Million US$ at exchange rate,3.9
+10250,Estonia,2013,10,N06A-Antidepressants,"Million US$, purchasing power parity",5.6
+10251,Estonia,2013,10,A-Alimentary tract and metabolism,Million US$ at exchange rate,38.1
+10252,Estonia,2013,10,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),% of total sales,1.5
+10253,Estonia,2013,10,A-Alimentary tract and metabolism,"/capita, US$ exchange rate",28.9
+10254,Estonia,2013,10,A-Alimentary tract and metabolism,"/capita, US$ purchasing power parity",41.7
+10255,Estonia,2013,10,A-Alimentary tract and metabolism,"Million US$, purchasing power parity",54.9
+10256,Estonia,2013,10,A-Alimentary tract and metabolism,Million of national currency units,28.7
+10257,Estonia,2013,10,A10-Drugs used in diabetes,% of total sales,6.1
+10258,Estonia,2013,10,A10-Drugs used in diabetes,"/capita, US$ purchasing power parity",20.5
+10259,Estonia,2013,10,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ exchange rate",3.6
+10260,Estonia,2013,10,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ purchasing power parity",5.1
+10261,Estonia,2013,10,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"Million US$, purchasing power parity",6.8
+10262,Estonia,2013,10,N-Nervous system,% of total sales,10.0
+10263,Estonia,2013,10,"C01B-Antiarrhythmics, Class I and III",Million of national currency units,0.9
+10264,Estonia,2013,10,N-Nervous system,"/capita, US$ purchasing power parity",33.6
+10265,Estonia,2013,10,N-Nervous system,"Million US$, purchasing power parity",44.3
+10266,Estonia,2013,10,N-Nervous system,"/capita, US$ exchange rate",23.3
+10267,Estonia,2013,10,"C01B-Antiarrhythmics, Class I and III",Million US$ at exchange rate,1.2
+10268,Estonia,2013,10,"C01B-Antiarrhythmics, Class I and III",% of total sales,0.4
+10269,Estonia,2013,10,A-Alimentary tract and metabolism,% of total sales,12.4
+10270,Estonia,2013,10,"C01B-Antiarrhythmics, Class I and III","/capita, US$ purchasing power parity",1.3
+10271,Estonia,2013,10,"C01B-Antiarrhythmics, Class I and III","Million US$, purchasing power parity",1.7
+10272,Estonia,2013,10,C01A-Cardiac glycosides,"/capita, US$ exchange rate",0.2
+10273,Estonia,2013,10,C01A-Cardiac glycosides,"Million US$, purchasing power parity",0.3
+10274,Estonia,2013,10,C01A-Cardiac glycosides,"/capita, US$ purchasing power parity",0.2
+10275,Estonia,2013,10,C01A-Cardiac glycosides,Million of national currency units,0.2
+10276,Estonia,2013,10,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ exchange rate",8.0
+10277,Estonia,2013,10,C01A-Cardiac glycosides,Million US$ at exchange rate,0.2
+10278,Estonia,2013,10,Total pharmaceutical sales,Million of national currency units,231.0
+10279,Estonia,2013,10,Total pharmaceutical sales,Million US$ at exchange rate,306.7
+10280,Estonia,2013,10,C01A-Cardiac glycosides,% of total sales,0.1
+10281,Estonia,2013,10,M01A-Antiinflammatory and antirheumatic products non-steroids,% of total sales,3.4
+10282,Estonia,2013,10,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ purchasing power parity",11.5
+10283,Estonia,2013,10,M-Musculo-skeletal system,% of total sales,5.7
+10284,Estonia,2013,10,M-Musculo-skeletal system,"/capita, US$ purchasing power parity",19.2
+10285,Estonia,2013,10,M-Musculo-skeletal system,"/capita, US$ exchange rate",13.3
+10286,Estonia,2013,10,A10-Drugs used in diabetes,"/capita, US$ exchange rate",14.3
+10287,Estonia,2013,10,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million US$ at exchange rate,4.7
+10288,Estonia,2013,10,A10-Drugs used in diabetes,"Million US$, purchasing power parity",27.1
+10289,Estonia,2013,10,M01A-Antiinflammatory and antirheumatic products non-steroids,Million US$ at exchange rate,10.6
+10290,Estonia,2013,10,M01A-Antiinflammatory and antirheumatic products non-steroids,Million of national currency units,7.9
+10291,Estonia,2013,10,M01A-Antiinflammatory and antirheumatic products non-steroids,"Million US$, purchasing power parity",15.2
+10292,Estonia,2013,10,M-Musculo-skeletal system,"Million US$, purchasing power parity",25.3
+10293,Estonia,2013,10,M-Musculo-skeletal system,Million of national currency units,13.2
+10294,Estonia,2013,10,M-Musculo-skeletal system,Million US$ at exchange rate,17.5
+10295,Estonia,2013,10,"C01B-Antiarrhythmics, Class I and III","/capita, US$ exchange rate",0.9
+10296,Estonia,2013,10,J-Antiinfectives for systemic use,Million US$ at exchange rate,31.8
+10297,Estonia,2013,10,J01-Antibacterials for systemic use,"Million US$, purchasing power parity",14.0
+10298,Estonia,2013,10,J-Antiinfectives for systemic use,"Million US$, purchasing power parity",45.8
+10299,Estonia,2013,10,J-Antiinfectives for systemic use,"/capita, US$ purchasing power parity",34.7
+10300,Estonia,2013,10,J-Antiinfectives for systemic use,"/capita, US$ exchange rate",24.1
+10301,Estonia,2013,10,Total pharmaceutical sales,"/capita, US$ purchasing power parity",335.4
+10302,Estonia,2013,10,Total pharmaceutical sales,"/capita, US$ exchange rate",232.7
+10303,Estonia,2013,10,J-Antiinfectives for systemic use,Million of national currency units,23.9
+10304,Estonia,2013,10,J01-Antibacterials for systemic use,Million of national currency units,7.3
+10305,Estonia,2013,10,J01-Antibacterials for systemic use,Million US$ at exchange rate,9.7
+10306,Estonia,2013,10,A10-Drugs used in diabetes,Million US$ at exchange rate,18.8
+10307,Estonia,2013,10,A10-Drugs used in diabetes,Million of national currency units,14.1
+10308,Estonia,2013,10,N-Nervous system,Million of national currency units,23.2
+10309,Estonia,2013,10,N-Nervous system,Million US$ at exchange rate,30.8
+10310,Estonia,2013,10,C-Cardiovascular system,"/capita, US$ purchasing power parity",46.0
+10311,Estonia,2013,10,C-Cardiovascular system,% of total sales,13.7
+10312,Estonia,2013,10,J-Antiinfectives for systemic use,% of total sales,10.4
+10313,Estonia,2013,10,C02-Antihypertensives,Million of national currency units,0.9
+10314,Estonia,2013,10,J01-Antibacterials for systemic use,"/capita, US$ purchasing power parity",10.6
+10315,Estonia,2013,10,J01-Antibacterials for systemic use,% of total sales,3.2
+10316,Estonia,2013,10,Total pharmaceutical sales,"Million US$, purchasing power parity",442.1
+10317,Estonia,2013,10,J01-Antibacterials for systemic use,"/capita, US$ exchange rate",7.4
+10318,Estonia,2012,12,C02-Antihypertensives,"Million US$, purchasing power parity",1.8
+10319,Estonia,2012,12,C02-Antihypertensives,"/capita, US$ exchange rate",0.9
+10320,Estonia,2012,12,N05B-Anxiolytics,"/capita, US$ purchasing power parity",1.8
+10321,Estonia,2012,12,N05B-Anxiolytics,% of total sales,0.6
+10322,Estonia,2012,12,C02-Antihypertensives,Million US$ at exchange rate,1.2
+10323,Estonia,2012,12,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ purchasing power parity",4.4
+10324,Estonia,2012,12,"H-Systemic hormonal preparations, excluding sex hormones and insulins",% of total sales,1.4
+10325,Estonia,2012,12,N02-Analgesics,"Million US$, purchasing power parity",10.6
+10326,Estonia,2012,12,"H-Systemic hormonal preparations, excluding sex hormones and insulins","Million US$, purchasing power parity",5.8
+10327,Estonia,2012,12,N05B-Anxiolytics,"Million US$, purchasing power parity",2.4
+10328,Estonia,2012,12,N05B-Anxiolytics,Million US$ at exchange rate,1.6
+10329,Estonia,2012,12,N05B-Anxiolytics,Million of national currency units,1.3
+10330,Estonia,2012,12,N02-Analgesics,"/capita, US$ exchange rate",5.4
+10331,Estonia,2012,12,N02-Analgesics,"/capita, US$ purchasing power parity",8.0
+10332,Estonia,2012,12,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million of national currency units,3.0
+10333,Estonia,2012,12,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million US$ at exchange rate,3.9
+10334,Estonia,2012,12,N02-Analgesics,% of total sales,2.5
+10335,Estonia,2012,12,C-Cardiovascular system,"/capita, US$ exchange rate",31.6
+10336,Estonia,2012,12,C-Cardiovascular system,"Million US$, purchasing power parity",62.5
+10337,Estonia,2012,12,C02-Antihypertensives,% of total sales,0.4
+10338,Estonia,2012,12,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ exchange rate",2.9
+10339,Estonia,2012,12,N02-Analgesics,Million US$ at exchange rate,7.1
+10340,Estonia,2012,12,N05B-Anxiolytics,"/capita, US$ exchange rate",1.2
+10341,Estonia,2012,12,C02-Antihypertensives,"/capita, US$ purchasing power parity",1.3
+10342,Estonia,2012,12,C-Cardiovascular system,Million US$ at exchange rate,41.8
+10343,Estonia,2012,12,C-Cardiovascular system,Million of national currency units,32.6
+10344,Estonia,2012,12,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million of national currency units,3.4
+10345,Estonia,2012,12,N02-Analgesics,Million of national currency units,5.5
+10346,Estonia,2012,12,B-Blood and blood forming organs,"/capita, US$ purchasing power parity",19.1
+10347,Estonia,2012,12,B-Blood and blood forming organs,% of total sales,5.9
+10348,Estonia,2012,12,B-Blood and blood forming organs,"/capita, US$ exchange rate",12.8
+10349,Estonia,2012,12,B-Blood and blood forming organs,Million US$ at exchange rate,16.9
+10350,Estonia,2012,12,B-Blood and blood forming organs,"Million US$, purchasing power parity",25.2
+10351,Estonia,2012,12,R-Respiratory system,"/capita, US$ exchange rate",16.2
+10352,Estonia,2012,12,R-Respiratory system,"/capita, US$ purchasing power parity",24.2
+10353,Estonia,2012,12,R-Respiratory system,"Million US$, purchasing power parity",32.0
+10354,Estonia,2012,12,R-Respiratory system,Million of national currency units,16.7
+10355,Estonia,2012,12,R-Respiratory system,Million US$ at exchange rate,21.4
+10356,Estonia,2012,12,A02A-Antacids,Million of national currency units,0.3
+10357,Estonia,2012,12,C10-Lipid modifying agents,% of total sales,1.8
+10358,Estonia,2012,12,A02A-Antacids,"Million US$, purchasing power parity",0.6
+10359,Estonia,2012,12,A02A-Antacids,Million US$ at exchange rate,0.4
+10360,Estonia,2012,12,C10-Lipid modifying agents,"/capita, US$ purchasing power parity",5.7
+10361,Estonia,2012,12,C10-Lipid modifying agents,Million US$ at exchange rate,5.1
+10362,Estonia,2012,12,C10-Lipid modifying agents,Million of national currency units,4.0
+10363,Estonia,2012,12,B-Blood and blood forming organs,Million of national currency units,13.1
+10364,Estonia,2012,12,C10-Lipid modifying agents,"/capita, US$ exchange rate",3.8
+10365,Estonia,2012,12,C10-Lipid modifying agents,"Million US$, purchasing power parity",7.6
+10366,Estonia,2012,12,C09-Agents acting on the Renin-Angiotensin system,"Million US$, purchasing power parity",22.8
+10367,Estonia,2012,12,C09-Agents acting on the Renin-Angiotensin system,Million US$ at exchange rate,15.2
+10368,Estonia,2012,12,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ purchasing power parity",17.2
+10369,Estonia,2012,12,C09-Agents acting on the Renin-Angiotensin system,Million of national currency units,11.9
+10370,Estonia,2012,12,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ exchange rate",11.5
+10371,Estonia,2012,12,R03-Drugs for obstructive airway diseases,"/capita, US$ exchange rate",7.2
+10372,Estonia,2012,12,R03-Drugs for obstructive airway diseases,"/capita, US$ purchasing power parity",10.7
+10373,Estonia,2012,12,R03-Drugs for obstructive airway diseases,Million of national currency units,7.4
+10374,Estonia,2012,12,R03-Drugs for obstructive airway diseases,"Million US$, purchasing power parity",14.2
+10375,Estonia,2012,12,R03-Drugs for obstructive airway diseases,Million US$ at exchange rate,9.5
+10376,Estonia,2012,12,C08-Calcium channel blockers,Million US$ at exchange rate,4.5
+10377,Estonia,2012,12,C08-Calcium channel blockers,"Million US$, purchasing power parity",6.7
+10378,Estonia,2012,12,R-Respiratory system,% of total sales,7.5
+10379,Estonia,2012,12,C08-Calcium channel blockers,"/capita, US$ exchange rate",3.4
+10380,Estonia,2012,12,C08-Calcium channel blockers,Million of national currency units,3.5
+10381,Estonia,2012,12,R03-Drugs for obstructive airway diseases,% of total sales,3.3
+10382,Estonia,2012,12,C09-Agents acting on the Renin-Angiotensin system,% of total sales,5.4
+10383,Estonia,2012,12,C08-Calcium channel blockers,"/capita, US$ purchasing power parity",5.1
+10384,Estonia,2012,12,C08-Calcium channel blockers,% of total sales,1.6
+10385,Estonia,2012,12,N05C-Hypnotics and sedatives,Million US$ at exchange rate,2.0
+10386,Estonia,2012,12,N05C-Hypnotics and sedatives,"Million US$, purchasing power parity",2.9
+10387,Estonia,2012,12,N05C-Hypnotics and sedatives,Million of national currency units,1.5
+10388,Estonia,2012,12,G03-Sex hormones and modulators of the genital system,Million US$ at exchange rate,8.5
+10389,Estonia,2012,12,G03-Sex hormones and modulators of the genital system,Million of national currency units,6.6
+10390,Estonia,2012,12,G-Genito urinary system and sex hormones,% of total sales,5.0
+10391,Estonia,2012,12,N05C-Hypnotics and sedatives,% of total sales,0.7
+10392,Estonia,2012,12,N05C-Hypnotics and sedatives,"/capita, US$ exchange rate",1.5
+10393,Estonia,2012,12,N05C-Hypnotics and sedatives,"/capita, US$ purchasing power parity",2.2
+10394,Estonia,2012,12,G03-Sex hormones and modulators of the genital system,"Million US$, purchasing power parity",12.7
+10395,Estonia,2012,12,C03-Diuretics,"/capita, US$ exchange rate",1.7
+10396,Estonia,2012,12,C03-Diuretics,"/capita, US$ purchasing power parity",2.5
+10397,Estonia,2012,12,C03-Diuretics,Million of national currency units,1.7
+10398,Estonia,2012,12,C03-Diuretics,Million US$ at exchange rate,2.2
+10399,Estonia,2012,12,C03-Diuretics,"Million US$, purchasing power parity",3.3
+10400,Estonia,2012,12,G03-Sex hormones and modulators of the genital system,"/capita, US$ purchasing power parity",9.6
+10401,Estonia,2012,12,G03-Sex hormones and modulators of the genital system,"/capita, US$ exchange rate",6.4
+10402,Estonia,2012,12,C03-Diuretics,% of total sales,0.8
+10403,Estonia,2012,12,G03-Sex hormones and modulators of the genital system,% of total sales,3.0
+10404,Estonia,2012,12,C07-Beta blocking agents,Million US$ at exchange rate,6.8
+10405,Estonia,2012,12,C07-Beta blocking agents,"Million US$, purchasing power parity",10.2
+10406,Estonia,2012,12,A02A-Antacids,% of total sales,0.1
+10407,Estonia,2012,12,C07-Beta blocking agents,Million of national currency units,5.3
+10408,Estonia,2012,12,C07-Beta blocking agents,"/capita, US$ exchange rate",5.2
+10409,Estonia,2012,12,A02A-Antacids,"/capita, US$ exchange rate",0.3
+10410,Estonia,2012,12,A02A-Antacids,"/capita, US$ purchasing power parity",0.5
+10411,Estonia,2012,12,C07-Beta blocking agents,"/capita, US$ purchasing power parity",7.7
+10412,Estonia,2012,12,C07-Beta blocking agents,% of total sales,2.4
+10413,Estonia,2012,12,G-Genito urinary system and sex hormones,Million US$ at exchange rate,14.4
+10414,Estonia,2012,12,G-Genito urinary system and sex hormones,Million of national currency units,11.2
+10415,Estonia,2012,12,G-Genito urinary system and sex hormones,"Million US$, purchasing power parity",21.5
+10416,Estonia,2012,12,G-Genito urinary system and sex hormones,"/capita, US$ purchasing power parity",16.2
+10417,Estonia,2012,12,N06A-Antidepressants,Million of national currency units,2.9
+10418,Estonia,2012,12,G-Genito urinary system and sex hormones,"/capita, US$ exchange rate",10.9
+10419,Estonia,2012,12,N06A-Antidepressants,"/capita, US$ exchange rate",2.9
+10420,Estonia,2012,12,N06A-Antidepressants,"/capita, US$ purchasing power parity",4.3
+10421,Estonia,2012,12,N06A-Antidepressants,% of total sales,1.3
+10422,Estonia,2012,12,N06A-Antidepressants,Million US$ at exchange rate,3.8
+10423,Estonia,2012,12,N06A-Antidepressants,"Million US$, purchasing power parity",5.6
+10424,Estonia,2012,12,A-Alimentary tract and metabolism,Million US$ at exchange rate,34.5
+10425,Estonia,2012,12,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),% of total sales,1.5
+10426,Estonia,2012,12,A-Alimentary tract and metabolism,"/capita, US$ exchange rate",26.1
+10427,Estonia,2012,12,A-Alimentary tract and metabolism,"/capita, US$ purchasing power parity",39.0
+10428,Estonia,2012,12,A-Alimentary tract and metabolism,"Million US$, purchasing power parity",51.6
+10429,Estonia,2012,12,A-Alimentary tract and metabolism,Million of national currency units,26.9
+10430,Estonia,2012,12,A10-Drugs used in diabetes,"/capita, US$ purchasing power parity",19.4
+10431,Estonia,2012,12,A10-Drugs used in diabetes,% of total sales,6.0
+10432,Estonia,2012,12,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ purchasing power parity",5.0
+10433,Estonia,2012,12,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ exchange rate",3.3
+10434,Estonia,2012,12,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"Million US$, purchasing power parity",6.6
+10435,Estonia,2012,12,N-Nervous system,% of total sales,10.3
+10436,Estonia,2012,12,"C01B-Antiarrhythmics, Class I and III",Million of national currency units,0.9
+10437,Estonia,2012,12,N-Nervous system,"Million US$, purchasing power parity",43.9
+10438,Estonia,2012,12,N-Nervous system,"/capita, US$ purchasing power parity",33.2
+10439,Estonia,2012,12,N-Nervous system,"/capita, US$ exchange rate",22.2
+10440,Estonia,2012,12,"C01B-Antiarrhythmics, Class I and III",Million US$ at exchange rate,1.1
+10441,Estonia,2012,12,"C01B-Antiarrhythmics, Class I and III",% of total sales,0.4
+10442,Estonia,2012,12,A-Alimentary tract and metabolism,% of total sales,12.1
+10443,Estonia,2012,12,"C01B-Antiarrhythmics, Class I and III","/capita, US$ purchasing power parity",1.3
+10444,Estonia,2012,12,"C01B-Antiarrhythmics, Class I and III","Million US$, purchasing power parity",1.7
+10445,Estonia,2012,12,"C01B-Antiarrhythmics, Class I and III","/capita, US$ exchange rate",0.8
+10446,Estonia,2012,12,C01A-Cardiac glycosides,"/capita, US$ exchange rate",0.2
+10447,Estonia,2012,12,C01A-Cardiac glycosides,"/capita, US$ purchasing power parity",0.2
+10448,Estonia,2012,12,C01A-Cardiac glycosides,"Million US$, purchasing power parity",0.3
+10449,Estonia,2012,12,C01A-Cardiac glycosides,Million of national currency units,0.2
+10450,Estonia,2012,12,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ exchange rate",6.9
+10451,Estonia,2012,12,C01A-Cardiac glycosides,Million US$ at exchange rate,0.2
+10452,Estonia,2012,12,Total pharmaceutical sales,Million of national currency units,221.7
+10453,Estonia,2012,12,Total pharmaceutical sales,Million US$ at exchange rate,284.9
+10454,Estonia,2012,12,C01A-Cardiac glycosides,% of total sales,0.1
+10455,Estonia,2012,12,M01A-Antiinflammatory and antirheumatic products non-steroids,% of total sales,3.2
+10456,Estonia,2012,12,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ purchasing power parity",10.3
+10457,Estonia,2012,12,M-Musculo-skeletal system,% of total sales,5.5
+10458,Estonia,2012,12,M-Musculo-skeletal system,"/capita, US$ exchange rate",11.9
+10459,Estonia,2012,12,M-Musculo-skeletal system,"/capita, US$ purchasing power parity",17.7
+10460,Estonia,2012,12,A10-Drugs used in diabetes,"/capita, US$ exchange rate",13.0
+10461,Estonia,2012,12,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million US$ at exchange rate,4.4
+10462,Estonia,2012,12,A10-Drugs used in diabetes,"Million US$, purchasing power parity",25.7
+10463,Estonia,2012,12,M01A-Antiinflammatory and antirheumatic products non-steroids,Million US$ at exchange rate,9.1
+10464,Estonia,2012,12,M01A-Antiinflammatory and antirheumatic products non-steroids,Million of national currency units,7.1
+10465,Estonia,2012,12,M01A-Antiinflammatory and antirheumatic products non-steroids,"Million US$, purchasing power parity",13.6
+10466,Estonia,2012,12,M-Musculo-skeletal system,"Million US$, purchasing power parity",23.4
+10467,Estonia,2012,12,M-Musculo-skeletal system,Million of national currency units,12.2
+10468,Estonia,2012,12,M-Musculo-skeletal system,Million US$ at exchange rate,15.7
+10469,Estonia,2012,12,J-Antiinfectives for systemic use,Million US$ at exchange rate,31.5
+10470,Estonia,2012,12,J-Antiinfectives for systemic use,"Million US$, purchasing power parity",47.1
+10471,Estonia,2012,12,J01-Antibacterials for systemic use,"Million US$, purchasing power parity",15.2
+10472,Estonia,2012,12,J-Antiinfectives for systemic use,"/capita, US$ purchasing power parity",35.6
+10473,Estonia,2012,12,J-Antiinfectives for systemic use,"/capita, US$ exchange rate",23.8
+10474,Estonia,2012,12,Total pharmaceutical sales,"/capita, US$ purchasing power parity",321.7
+10475,Estonia,2012,12,Total pharmaceutical sales,"/capita, US$ exchange rate",215.4
+10476,Estonia,2012,12,J-Antiinfectives for systemic use,Million of national currency units,24.5
+10477,Estonia,2012,12,J01-Antibacterials for systemic use,Million of national currency units,7.9
+10478,Estonia,2012,12,J01-Antibacterials for systemic use,Million US$ at exchange rate,10.2
+10479,Estonia,2012,12,A10-Drugs used in diabetes,Million of national currency units,13.4
+10480,Estonia,2012,12,A10-Drugs used in diabetes,Million US$ at exchange rate,17.2
+10481,Estonia,2012,12,N-Nervous system,Million of national currency units,22.9
+10482,Estonia,2012,12,C-Cardiovascular system,"/capita, US$ purchasing power parity",47.2
+10483,Estonia,2012,12,N-Nervous system,Million US$ at exchange rate,29.4
+10484,Estonia,2012,12,C-Cardiovascular system,% of total sales,14.7
+10485,Estonia,2012,12,C02-Antihypertensives,Million of national currency units,0.9
+10486,Estonia,2012,12,J01-Antibacterials for systemic use,"/capita, US$ purchasing power parity",11.5
+10487,Estonia,2012,12,J01-Antibacterials for systemic use,% of total sales,3.6
+10488,Estonia,2012,12,Total pharmaceutical sales,"Million US$, purchasing power parity",425.5
+10489,Estonia,2012,12,J-Antiinfectives for systemic use,% of total sales,11.1
+10490,Estonia,2012,12,J01-Antibacterials for systemic use,"/capita, US$ exchange rate",7.7
+10491,Estonia,2011,13,C02-Antihypertensives,"Million US$, purchasing power parity",1.7
+10492,Estonia,2011,13,C02-Antihypertensives,"/capita, US$ exchange rate",0.9
+10493,Estonia,2011,13,N05B-Anxiolytics,"/capita, US$ purchasing power parity",1.7
+10494,Estonia,2011,13,N05B-Anxiolytics,% of total sales,0.6
+10495,Estonia,2011,13,C02-Antihypertensives,Million US$ at exchange rate,1.2
+10496,Estonia,2011,13,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ purchasing power parity",4.1
+10497,Estonia,2011,13,"H-Systemic hormonal preparations, excluding sex hormones and insulins",% of total sales,1.4
+10498,Estonia,2011,13,C02-Antihypertensives,"/capita, US$ purchasing power parity",1.3
+10499,Estonia,2011,13,N02-Analgesics,"Million US$, purchasing power parity",10.5
+10500,Estonia,2011,13,"H-Systemic hormonal preparations, excluding sex hormones and insulins","Million US$, purchasing power parity",5.5
+10501,Estonia,2011,13,N05B-Anxiolytics,"Million US$, purchasing power parity",2.3
+10502,Estonia,2011,13,N05B-Anxiolytics,Million US$ at exchange rate,1.6
+10503,Estonia,2011,13,N05B-Anxiolytics,Million of national currency units,1.2
+10504,Estonia,2011,13,N02-Analgesics,"/capita, US$ exchange rate",5.6
+10505,Estonia,2011,13,N02-Analgesics,"/capita, US$ purchasing power parity",7.9
+10506,Estonia,2011,13,N02-Analgesics,% of total sales,2.6
+10507,Estonia,2011,13,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million of national currency units,2.8
+10508,Estonia,2011,13,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million US$ at exchange rate,3.9
+10509,Estonia,2011,13,C-Cardiovascular system,"/capita, US$ exchange rate",32.7
+10510,Estonia,2011,13,C-Cardiovascular system,"Million US$, purchasing power parity",60.9
+10511,Estonia,2011,13,C02-Antihypertensives,% of total sales,0.4
+10512,Estonia,2011,13,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ exchange rate",2.9
+10513,Estonia,2011,13,N02-Analgesics,Million US$ at exchange rate,7.5
+10514,Estonia,2011,13,N05B-Anxiolytics,"/capita, US$ exchange rate",1.2
+10515,Estonia,2011,13,C-Cardiovascular system,Million US$ at exchange rate,43.4
+10516,Estonia,2011,13,C-Cardiovascular system,Million of national currency units,31.2
+10517,Estonia,2011,13,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million of national currency units,3.2
+10518,Estonia,2011,13,N02-Analgesics,Million of national currency units,5.4
+10519,Estonia,2011,13,C03-Diuretics,Million of national currency units,1.6
+10520,Estonia,2011,13,B-Blood and blood forming organs,"/capita, US$ purchasing power parity",16.7
+10521,Estonia,2011,13,B-Blood and blood forming organs,% of total sales,5.6
+10522,Estonia,2011,13,B-Blood and blood forming organs,"/capita, US$ exchange rate",11.9
+10523,Estonia,2011,13,B-Blood and blood forming organs,Million US$ at exchange rate,15.8
+10524,Estonia,2011,13,B-Blood and blood forming organs,"Million US$, purchasing power parity",22.2
+10525,Estonia,2011,13,R-Respiratory system,"/capita, US$ exchange rate",15.8
+10526,Estonia,2011,13,R-Respiratory system,"/capita, US$ purchasing power parity",22.2
+10527,Estonia,2011,13,R-Respiratory system,"Million US$, purchasing power parity",29.5
+10528,Estonia,2011,13,R-Respiratory system,Million of national currency units,15.1
+10529,Estonia,2011,13,R-Respiratory system,Million US$ at exchange rate,21.0
+10530,Estonia,2011,13,A02A-Antacids,Million of national currency units,0.3
+10531,Estonia,2011,13,C10-Lipid modifying agents,% of total sales,1.9
+10532,Estonia,2011,13,A02A-Antacids,"Million US$, purchasing power parity",0.6
+10533,Estonia,2011,13,A02A-Antacids,Million US$ at exchange rate,0.4
+10534,Estonia,2011,13,C10-Lipid modifying agents,"/capita, US$ purchasing power parity",5.8
+10535,Estonia,2011,13,C10-Lipid modifying agents,Million US$ at exchange rate,5.5
+10536,Estonia,2011,13,C10-Lipid modifying agents,Million of national currency units,3.9
+10537,Estonia,2011,13,B-Blood and blood forming organs,Million of national currency units,11.4
+10538,Estonia,2011,13,C10-Lipid modifying agents,"/capita, US$ exchange rate",4.1
+10539,Estonia,2011,13,C10-Lipid modifying agents,"Million US$, purchasing power parity",7.7
+10540,Estonia,2011,13,C09-Agents acting on the Renin-Angiotensin system,"Million US$, purchasing power parity",21.7
+10541,Estonia,2011,13,C09-Agents acting on the Renin-Angiotensin system,Million US$ at exchange rate,15.5
+10542,Estonia,2011,13,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ purchasing power parity",16.4
+10543,Estonia,2011,13,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ exchange rate",11.7
+10544,Estonia,2011,13,C09-Agents acting on the Renin-Angiotensin system,Million of national currency units,11.1
+10545,Estonia,2011,13,R03-Drugs for obstructive airway diseases,"/capita, US$ exchange rate",7.0
+10546,Estonia,2011,13,R03-Drugs for obstructive airway diseases,"/capita, US$ purchasing power parity",9.8
+10547,Estonia,2011,13,R03-Drugs for obstructive airway diseases,Million of national currency units,6.7
+10548,Estonia,2011,13,R03-Drugs for obstructive airway diseases,Million US$ at exchange rate,9.3
+10549,Estonia,2011,13,R03-Drugs for obstructive airway diseases,"Million US$, purchasing power parity",13.1
+10550,Estonia,2011,13,C08-Calcium channel blockers,Million US$ at exchange rate,5.2
+10551,Estonia,2011,13,C08-Calcium channel blockers,"Million US$, purchasing power parity",7.2
+10552,Estonia,2011,13,C08-Calcium channel blockers,"/capita, US$ exchange rate",3.9
+10553,Estonia,2011,13,R-Respiratory system,% of total sales,7.4
+10554,Estonia,2011,13,C08-Calcium channel blockers,Million of national currency units,3.7
+10555,Estonia,2011,13,R03-Drugs for obstructive airway diseases,% of total sales,3.3
+10556,Estonia,2011,13,C09-Agents acting on the Renin-Angiotensin system,% of total sales,5.4
+10557,Estonia,2011,13,C08-Calcium channel blockers,"/capita, US$ purchasing power parity",5.4
+10558,Estonia,2011,13,C08-Calcium channel blockers,% of total sales,1.8
+10559,Estonia,2011,13,A02A-Antacids,"/capita, US$ exchange rate",0.3
+10560,Estonia,2011,13,N05C-Hypnotics and sedatives,Million US$ at exchange rate,2.0
+10561,Estonia,2011,13,N05C-Hypnotics and sedatives,"Million US$, purchasing power parity",2.8
+10562,Estonia,2011,13,N05C-Hypnotics and sedatives,Million of national currency units,1.4
+10563,Estonia,2011,13,G03-Sex hormones and modulators of the genital system,Million US$ at exchange rate,9.1
+10564,Estonia,2011,13,G03-Sex hormones and modulators of the genital system,Million of national currency units,6.5
+10565,Estonia,2011,13,G03-Sex hormones and modulators of the genital system,"Million US$, purchasing power parity",12.8
+10566,Estonia,2011,13,G-Genito urinary system and sex hormones,% of total sales,5.3
+10567,Estonia,2011,13,N05C-Hypnotics and sedatives,% of total sales,0.7
+10568,Estonia,2011,13,N05C-Hypnotics and sedatives,"/capita, US$ exchange rate",1.5
+10569,Estonia,2011,13,N05C-Hypnotics and sedatives,"/capita, US$ purchasing power parity",2.1
+10570,Estonia,2011,13,C03-Diuretics,"/capita, US$ exchange rate",1.6
+10571,Estonia,2011,13,C03-Diuretics,"/capita, US$ purchasing power parity",2.3
+10572,Estonia,2011,13,C03-Diuretics,Million US$ at exchange rate,2.2
+10573,Estonia,2011,13,C03-Diuretics,"Million US$, purchasing power parity",3.1
+10574,Estonia,2011,13,G03-Sex hormones and modulators of the genital system,"/capita, US$ purchasing power parity",9.6
+10575,Estonia,2011,13,G03-Sex hormones and modulators of the genital system,"/capita, US$ exchange rate",6.9
+10576,Estonia,2011,13,C03-Diuretics,% of total sales,0.8
+10577,Estonia,2011,13,G03-Sex hormones and modulators of the genital system,% of total sales,3.2
+10578,Estonia,2011,13,C07-Beta blocking agents,Million US$ at exchange rate,6.6
+10579,Estonia,2011,13,C07-Beta blocking agents,"Million US$, purchasing power parity",9.3
+10580,Estonia,2011,13,A02A-Antacids,% of total sales,0.1
+10581,Estonia,2011,13,C07-Beta blocking agents,Million of national currency units,4.8
+10582,Estonia,2011,13,C07-Beta blocking agents,"/capita, US$ exchange rate",5.0
+10583,Estonia,2011,13,A02A-Antacids,"/capita, US$ purchasing power parity",0.4
+10584,Estonia,2011,13,C07-Beta blocking agents,"/capita, US$ purchasing power parity",7.0
+10585,Estonia,2011,13,C07-Beta blocking agents,% of total sales,2.3
+10586,Estonia,2011,13,N06A-Antidepressants,% of total sales,1.4
+10587,Estonia,2011,13,G-Genito urinary system and sex hormones,Million US$ at exchange rate,15.0
+10588,Estonia,2011,13,G-Genito urinary system and sex hormones,Million of national currency units,10.8
+10589,Estonia,2011,13,N06A-Antidepressants,Million of national currency units,2.9
+10590,Estonia,2011,13,G-Genito urinary system and sex hormones,"Million US$, purchasing power parity",21.1
+10591,Estonia,2011,13,G-Genito urinary system and sex hormones,"/capita, US$ purchasing power parity",15.9
+10592,Estonia,2011,13,G-Genito urinary system and sex hormones,"/capita, US$ exchange rate",11.3
+10593,Estonia,2011,13,N06A-Antidepressants,"/capita, US$ exchange rate",3.1
+10594,Estonia,2011,13,N06A-Antidepressants,"/capita, US$ purchasing power parity",4.3
+10595,Estonia,2011,13,N06A-Antidepressants,Million US$ at exchange rate,4.1
+10596,Estonia,2011,13,N06A-Antidepressants,"Million US$, purchasing power parity",5.8
+10597,Estonia,2011,13,A-Alimentary tract and metabolism,Million US$ at exchange rate,33.9
+10598,Estonia,2011,13,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),% of total sales,1.6
+10599,Estonia,2011,13,A-Alimentary tract and metabolism,"/capita, US$ purchasing power parity",35.8
+10600,Estonia,2011,13,A-Alimentary tract and metabolism,"/capita, US$ exchange rate",25.5
+10601,Estonia,2011,13,A-Alimentary tract and metabolism,"Million US$, purchasing power parity",47.6
+10602,Estonia,2011,13,A-Alimentary tract and metabolism,Million of national currency units,24.3
+10603,Estonia,2011,13,A10-Drugs used in diabetes,"/capita, US$ purchasing power parity",17.6
+10604,Estonia,2011,13,A10-Drugs used in diabetes,% of total sales,5.8
+10605,Estonia,2011,13,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ purchasing power parity",4.7
+10606,Estonia,2011,13,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ exchange rate",3.4
+10607,Estonia,2011,13,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"Million US$, purchasing power parity",6.3
+10608,Estonia,2011,13,N-Nervous system,% of total sales,10.8
+10609,Estonia,2011,13,"C01B-Antiarrhythmics, Class I and III",Million of national currency units,0.8
+10610,Estonia,2011,13,"C01B-Antiarrhythmics, Class I and III",Million US$ at exchange rate,1.1
+10611,Estonia,2011,13,N-Nervous system,"Million US$, purchasing power parity",43.3
+10612,Estonia,2011,13,N-Nervous system,"/capita, US$ purchasing power parity",32.6
+10613,Estonia,2011,13,N-Nervous system,"/capita, US$ exchange rate",23.2
+10614,Estonia,2011,13,"C01B-Antiarrhythmics, Class I and III",% of total sales,0.4
+10615,Estonia,2011,13,A-Alimentary tract and metabolism,% of total sales,11.9
+10616,Estonia,2011,13,"C01B-Antiarrhythmics, Class I and III","/capita, US$ purchasing power parity",1.2
+10617,Estonia,2011,13,"C01B-Antiarrhythmics, Class I and III","Million US$, purchasing power parity",1.5
+10618,Estonia,2011,13,"C01B-Antiarrhythmics, Class I and III","/capita, US$ exchange rate",0.8
+10619,Estonia,2011,13,C01A-Cardiac glycosides,"/capita, US$ exchange rate",0.2
+10620,Estonia,2011,13,C01A-Cardiac glycosides,"/capita, US$ purchasing power parity",0.2
+10621,Estonia,2011,13,C01A-Cardiac glycosides,"Million US$, purchasing power parity",0.3
+10622,Estonia,2011,13,C01A-Cardiac glycosides,Million of national currency units,0.2
+10623,Estonia,2011,13,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ exchange rate",6.6
+10624,Estonia,2011,13,C01A-Cardiac glycosides,Million US$ at exchange rate,0.2
+10625,Estonia,2011,13,Total pharmaceutical sales,"Million US$, purchasing power parity",399.5
+10626,Estonia,2011,13,Total pharmaceutical sales,Million of national currency units,204.4
+10627,Estonia,2011,13,Total pharmaceutical sales,Million US$ at exchange rate,284.5
+10628,Estonia,2011,13,C01A-Cardiac glycosides,% of total sales,0.1
+10629,Estonia,2011,13,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ purchasing power parity",9.3
+10630,Estonia,2011,13,M01A-Antiinflammatory and antirheumatic products non-steroids,% of total sales,3.1
+10631,Estonia,2011,13,M-Musculo-skeletal system,% of total sales,5.4
+10632,Estonia,2011,13,M-Musculo-skeletal system,"/capita, US$ exchange rate",11.6
+10633,Estonia,2011,13,M-Musculo-skeletal system,"/capita, US$ purchasing power parity",16.3
+10634,Estonia,2011,13,A10-Drugs used in diabetes,"/capita, US$ exchange rate",12.5
+10635,Estonia,2011,13,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million US$ at exchange rate,4.5
+10636,Estonia,2011,13,M01A-Antiinflammatory and antirheumatic products non-steroids,Million US$ at exchange rate,8.7
+10637,Estonia,2011,13,M01A-Antiinflammatory and antirheumatic products non-steroids,"Million US$, purchasing power parity",12.3
+10638,Estonia,2011,13,M01A-Antiinflammatory and antirheumatic products non-steroids,Million of national currency units,6.3
+10639,Estonia,2011,13,M-Musculo-skeletal system,Million of national currency units,11.1
+10640,Estonia,2011,13,M-Musculo-skeletal system,"Million US$, purchasing power parity",21.6
+10641,Estonia,2011,13,M-Musculo-skeletal system,Million US$ at exchange rate,15.4
+10642,Estonia,2011,13,J-Antiinfectives for systemic use,Million US$ at exchange rate,31.1
+10643,Estonia,2011,13,J-Antiinfectives for systemic use,"Million US$, purchasing power parity",43.7
+10644,Estonia,2011,13,J01-Antibacterials for systemic use,"Million US$, purchasing power parity",15.8
+10645,Estonia,2011,13,J-Antiinfectives for systemic use,"/capita, US$ purchasing power parity",32.9
+10646,Estonia,2011,13,J-Antiinfectives for systemic use,"/capita, US$ exchange rate",23.4
+10647,Estonia,2011,13,Total pharmaceutical sales,"/capita, US$ purchasing power parity",301.0
+10648,Estonia,2011,13,A10-Drugs used in diabetes,"Million US$, purchasing power parity",23.3
+10649,Estonia,2011,13,J-Antiinfectives for systemic use,Million of national currency units,22.4
+10650,Estonia,2011,13,Total pharmaceutical sales,"/capita, US$ exchange rate",214.3
+10651,Estonia,2011,13,J01-Antibacterials for systemic use,Million of national currency units,8.1
+10652,Estonia,2011,13,J01-Antibacterials for systemic use,Million US$ at exchange rate,11.2
+10653,Estonia,2011,13,A10-Drugs used in diabetes,Million US$ at exchange rate,16.6
+10654,Estonia,2011,13,A10-Drugs used in diabetes,Million of national currency units,11.9
+10655,Estonia,2011,13,J01-Antibacterials for systemic use,"/capita, US$ exchange rate",8.5
+10656,Estonia,2011,13,C-Cardiovascular system,"/capita, US$ purchasing power parity",45.9
+10657,Estonia,2011,13,N-Nervous system,Million of national currency units,22.1
+10658,Estonia,2011,13,N-Nervous system,Million US$ at exchange rate,30.8
+10659,Estonia,2011,13,C-Cardiovascular system,% of total sales,15.3
+10660,Estonia,2011,13,J-Antiinfectives for systemic use,% of total sales,10.9
+10661,Estonia,2011,13,J01-Antibacterials for systemic use,% of total sales,3.9
+10662,Estonia,2011,13,C02-Antihypertensives,Million of national currency units,0.9
+10663,Estonia,2011,13,J01-Antibacterials for systemic use,"/capita, US$ purchasing power parity",11.9
+10664,Estonia,2010,11,C02-Antihypertensives,"Million US$, purchasing power parity",1.7
+10665,Estonia,2010,11,C02-Antihypertensives,"/capita, US$ exchange rate",0.9
+10666,Estonia,2010,11,N05B-Anxiolytics,% of total sales,0.6
+10667,Estonia,2010,11,N05B-Anxiolytics,"/capita, US$ purchasing power parity",1.7
+10668,Estonia,2010,11,C02-Antihypertensives,"/capita, US$ purchasing power parity",1.3
+10669,Estonia,2010,11,C02-Antihypertensives,Million US$ at exchange rate,1.2
+10670,Estonia,2010,11,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ purchasing power parity",3.7
+10671,Estonia,2010,11,"H-Systemic hormonal preparations, excluding sex hormones and insulins",% of total sales,1.3
+10672,Estonia,2010,11,N02-Analgesics,"Million US$, purchasing power parity",10.2
+10673,Estonia,2010,11,"H-Systemic hormonal preparations, excluding sex hormones and insulins","Million US$, purchasing power parity",4.9
+10674,Estonia,2010,11,N05B-Anxiolytics,"Million US$, purchasing power parity",2.2
+10675,Estonia,2010,11,N05B-Anxiolytics,Million US$ at exchange rate,1.5
+10676,Estonia,2010,11,N02-Analgesics,"/capita, US$ exchange rate",5.2
+10677,Estonia,2010,11,N02-Analgesics,"/capita, US$ purchasing power parity",7.6
+10678,Estonia,2010,11,N02-Analgesics,% of total sales,2.7
+10679,Estonia,2010,11,N05B-Anxiolytics,Million of national currency units,1.1
+10680,Estonia,2010,11,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million of national currency units,2.5
+10681,Estonia,2010,11,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million US$ at exchange rate,3.3
+10682,Estonia,2010,11,C-Cardiovascular system,"/capita, US$ exchange rate",34.8
+10683,Estonia,2010,11,C-Cardiovascular system,"Million US$, purchasing power parity",68.3
+10684,Estonia,2010,11,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ exchange rate",2.5
+10685,Estonia,2010,11,C02-Antihypertensives,% of total sales,0.5
+10686,Estonia,2010,11,N02-Analgesics,Million US$ at exchange rate,6.9
+10687,Estonia,2010,11,N05B-Anxiolytics,"/capita, US$ exchange rate",1.1
+10688,Estonia,2010,11,C-Cardiovascular system,Million US$ at exchange rate,46.3
+10689,Estonia,2010,11,C-Cardiovascular system,Million of national currency units,35.0
+10690,Estonia,2010,11,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million of national currency units,3.6
+10691,Estonia,2010,11,N02-Analgesics,Million of national currency units,5.2
+10692,Estonia,2010,11,B-Blood and blood forming organs,"/capita, US$ purchasing power parity",15.2
+10693,Estonia,2010,11,B-Blood and blood forming organs,% of total sales,5.3
+10694,Estonia,2010,11,B-Blood and blood forming organs,Million US$ at exchange rate,13.7
+10695,Estonia,2010,11,B-Blood and blood forming organs,"/capita, US$ exchange rate",10.3
+10696,Estonia,2010,11,B-Blood and blood forming organs,"Million US$, purchasing power parity",20.2
+10697,Estonia,2010,11,R-Respiratory system,"/capita, US$ exchange rate",14.4
+10698,Estonia,2010,11,R-Respiratory system,"/capita, US$ purchasing power parity",21.2
+10699,Estonia,2010,11,R-Respiratory system,"Million US$, purchasing power parity",28.2
+10700,Estonia,2010,11,R-Respiratory system,Million of national currency units,14.5
+10701,Estonia,2010,11,R-Respiratory system,Million US$ at exchange rate,19.2
+10702,Estonia,2010,11,A02A-Antacids,Million of national currency units,0.3
+10703,Estonia,2010,11,C10-Lipid modifying agents,% of total sales,2.7
+10704,Estonia,2010,11,A02A-Antacids,"Million US$, purchasing power parity",0.5
+10705,Estonia,2010,11,A02A-Antacids,Million US$ at exchange rate,0.4
+10706,Estonia,2010,11,C10-Lipid modifying agents,"/capita, US$ purchasing power parity",7.8
+10707,Estonia,2010,11,C10-Lipid modifying agents,Million US$ at exchange rate,7.1
+10708,Estonia,2010,11,C10-Lipid modifying agents,Million of national currency units,5.3
+10709,Estonia,2010,11,B-Blood and blood forming organs,Million of national currency units,10.3
+10710,Estonia,2010,11,C10-Lipid modifying agents,"/capita, US$ exchange rate",5.3
+10711,Estonia,2010,11,C10-Lipid modifying agents,"Million US$, purchasing power parity",10.4
+10712,Estonia,2010,11,C09-Agents acting on the Renin-Angiotensin system,"Million US$, purchasing power parity",22.8
+10713,Estonia,2010,11,C09-Agents acting on the Renin-Angiotensin system,Million US$ at exchange rate,15.5
+10714,Estonia,2010,11,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ purchasing power parity",17.1
+10715,Estonia,2010,11,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ exchange rate",11.6
+10716,Estonia,2010,11,C09-Agents acting on the Renin-Angiotensin system,Million of national currency units,11.7
+10717,Estonia,2010,11,R03-Drugs for obstructive airway diseases,Million of national currency units,6.4
+10718,Estonia,2010,11,R03-Drugs for obstructive airway diseases,"/capita, US$ exchange rate",6.4
+10719,Estonia,2010,11,R03-Drugs for obstructive airway diseases,"/capita, US$ purchasing power parity",9.4
+10720,Estonia,2010,11,R03-Drugs for obstructive airway diseases,Million US$ at exchange rate,8.5
+10721,Estonia,2010,11,R03-Drugs for obstructive airway diseases,"Million US$, purchasing power parity",12.5
+10722,Estonia,2010,11,C09-Agents acting on the Renin-Angiotensin system,% of total sales,6.0
+10723,Estonia,2010,11,C08-Calcium channel blockers,"Million US$, purchasing power parity",9.7
+10724,Estonia,2010,11,C08-Calcium channel blockers,"/capita, US$ exchange rate",4.9
+10725,Estonia,2010,11,C08-Calcium channel blockers,Million US$ at exchange rate,6.6
+10726,Estonia,2010,11,R-Respiratory system,% of total sales,7.5
+10727,Estonia,2010,11,C08-Calcium channel blockers,Million of national currency units,4.9
+10728,Estonia,2010,11,R03-Drugs for obstructive airway diseases,% of total sales,3.3
+10729,Estonia,2010,11,C08-Calcium channel blockers,"/capita, US$ purchasing power parity",7.3
+10730,Estonia,2010,11,C08-Calcium channel blockers,% of total sales,2.6
+10731,Estonia,2010,11,C03-Diuretics,Million of national currency units,1.6
+10732,Estonia,2010,11,N05C-Hypnotics and sedatives,Million US$ at exchange rate,1.8
+10733,Estonia,2010,11,N05C-Hypnotics and sedatives,"Million US$, purchasing power parity",2.7
+10734,Estonia,2010,11,G03-Sex hormones and modulators of the genital system,"Million US$, purchasing power parity",12.7
+10735,Estonia,2010,11,G03-Sex hormones and modulators of the genital system,Million US$ at exchange rate,8.6
+10736,Estonia,2010,11,G03-Sex hormones and modulators of the genital system,Million of national currency units,6.5
+10737,Estonia,2010,11,N05C-Hypnotics and sedatives,Million of national currency units,1.4
+10738,Estonia,2010,11,G-Genito urinary system and sex hormones,% of total sales,5.5
+10739,Estonia,2010,11,N05C-Hypnotics and sedatives,% of total sales,0.7
+10740,Estonia,2010,11,N05C-Hypnotics and sedatives,"/capita, US$ exchange rate",1.4
+10741,Estonia,2010,11,N05C-Hypnotics and sedatives,"/capita, US$ purchasing power parity",2.0
+10742,Estonia,2010,11,C03-Diuretics,"/capita, US$ exchange rate",1.6
+10743,Estonia,2010,11,C03-Diuretics,"/capita, US$ purchasing power parity",2.3
+10744,Estonia,2010,11,C03-Diuretics,Million US$ at exchange rate,2.1
+10745,Estonia,2010,11,C03-Diuretics,"Million US$, purchasing power parity",3.1
+10746,Estonia,2010,11,G03-Sex hormones and modulators of the genital system,"/capita, US$ purchasing power parity",9.5
+10747,Estonia,2010,11,G03-Sex hormones and modulators of the genital system,"/capita, US$ exchange rate",6.5
+10748,Estonia,2010,11,C03-Diuretics,% of total sales,0.8
+10749,Estonia,2010,11,G03-Sex hormones and modulators of the genital system,% of total sales,3.4
+10750,Estonia,2010,11,C07-Beta blocking agents,Million US$ at exchange rate,7.2
+10751,Estonia,2010,11,C07-Beta blocking agents,"Million US$, purchasing power parity",10.7
+10752,Estonia,2010,11,C07-Beta blocking agents,"/capita, US$ exchange rate",5.4
+10753,Estonia,2010,11,C07-Beta blocking agents,Million of national currency units,5.5
+10754,Estonia,2010,11,A02A-Antacids,% of total sales,0.1
+10755,Estonia,2010,11,A02A-Antacids,"/capita, US$ purchasing power parity",0.4
+10756,Estonia,2010,11,C07-Beta blocking agents,"/capita, US$ purchasing power parity",8.0
+10757,Estonia,2010,11,C07-Beta blocking agents,% of total sales,2.8
+10758,Estonia,2010,11,A02A-Antacids,"/capita, US$ exchange rate",0.3
+10759,Estonia,2010,11,G-Genito urinary system and sex hormones,Million US$ at exchange rate,14.1
+10760,Estonia,2010,11,G-Genito urinary system and sex hormones,Million of national currency units,10.6
+10761,Estonia,2010,11,N06A-Antidepressants,Million of national currency units,3.0
+10762,Estonia,2010,11,G-Genito urinary system and sex hormones,"Million US$, purchasing power parity",20.7
+10763,Estonia,2010,11,G-Genito urinary system and sex hormones,"/capita, US$ purchasing power parity",15.6
+10764,Estonia,2010,11,G-Genito urinary system and sex hormones,"/capita, US$ exchange rate",10.6
+10765,Estonia,2010,11,N06A-Antidepressants,"/capita, US$ exchange rate",3.0
+10766,Estonia,2010,11,N06A-Antidepressants,% of total sales,1.6
+10767,Estonia,2010,11,N06A-Antidepressants,"/capita, US$ purchasing power parity",4.4
+10768,Estonia,2010,11,N06A-Antidepressants,Million US$ at exchange rate,4.0
+10769,Estonia,2010,11,N06A-Antidepressants,"Million US$, purchasing power parity",5.9
+10770,Estonia,2010,11,A-Alimentary tract and metabolism,Million US$ at exchange rate,31.2
+10771,Estonia,2010,11,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),% of total sales,1.9
+10772,Estonia,2010,11,A-Alimentary tract and metabolism,"/capita, US$ purchasing power parity",34.5
+10773,Estonia,2010,11,A-Alimentary tract and metabolism,"/capita, US$ exchange rate",23.4
+10774,Estonia,2010,11,A-Alimentary tract and metabolism,"Million US$, purchasing power parity",46.0
+10775,Estonia,2010,11,A-Alimentary tract and metabolism,Million of national currency units,23.5
+10776,Estonia,2010,11,A10-Drugs used in diabetes,% of total sales,5.9
+10777,Estonia,2010,11,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ purchasing power parity",5.3
+10778,Estonia,2010,11,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"Million US$, purchasing power parity",7.1
+10779,Estonia,2010,11,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ exchange rate",3.6
+10780,Estonia,2010,11,A10-Drugs used in diabetes,"/capita, US$ purchasing power parity",16.8
+10781,Estonia,2010,11,N-Nervous system,% of total sales,11.1
+10782,Estonia,2010,11,"C01B-Antiarrhythmics, Class I and III",Million US$ at exchange rate,1.0
+10783,Estonia,2010,11,"C01B-Antiarrhythmics, Class I and III",Million of national currency units,0.8
+10784,Estonia,2010,11,N-Nervous system,"Million US$, purchasing power parity",42.0
+10785,Estonia,2010,11,N-Nervous system,"/capita, US$ exchange rate",21.4
+10786,Estonia,2010,11,N-Nervous system,"/capita, US$ purchasing power parity",31.5
+10787,Estonia,2010,11,"C01B-Antiarrhythmics, Class I and III",% of total sales,0.4
+10788,Estonia,2010,11,A-Alimentary tract and metabolism,% of total sales,12.1
+10789,Estonia,2010,11,"C01B-Antiarrhythmics, Class I and III","Million US$, purchasing power parity",1.5
+10790,Estonia,2010,11,"C01B-Antiarrhythmics, Class I and III","/capita, US$ purchasing power parity",1.1
+10791,Estonia,2010,11,"C01B-Antiarrhythmics, Class I and III","/capita, US$ exchange rate",0.7
+10792,Estonia,2010,11,C01A-Cardiac glycosides,"/capita, US$ exchange rate",0.2
+10793,Estonia,2010,11,C01A-Cardiac glycosides,"/capita, US$ purchasing power parity",0.2
+10794,Estonia,2010,11,C01A-Cardiac glycosides,Million of national currency units,0.2
+10795,Estonia,2010,11,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ exchange rate",6.1
+10796,Estonia,2010,11,C01A-Cardiac glycosides,Million US$ at exchange rate,0.2
+10797,Estonia,2010,11,C01A-Cardiac glycosides,"Million US$, purchasing power parity",0.3
+10798,Estonia,2010,11,C01A-Cardiac glycosides,% of total sales,0.1
+10799,Estonia,2010,11,Total pharmaceutical sales,"Million US$, purchasing power parity",379.0
+10800,Estonia,2010,11,Total pharmaceutical sales,Million of national currency units,194.1
+10801,Estonia,2010,11,Total pharmaceutical sales,Million US$ at exchange rate,257.2
+10802,Estonia,2010,11,M01A-Antiinflammatory and antirheumatic products non-steroids,% of total sales,3.2
+10803,Estonia,2010,11,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ purchasing power parity",9.0
+10804,Estonia,2010,11,M-Musculo-skeletal system,% of total sales,5.6
+10805,Estonia,2010,11,M-Musculo-skeletal system,"/capita, US$ purchasing power parity",15.8
+10806,Estonia,2010,11,M-Musculo-skeletal system,"/capita, US$ exchange rate",10.7
+10807,Estonia,2010,11,A10-Drugs used in diabetes,"/capita, US$ exchange rate",11.4
+10808,Estonia,2010,11,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million US$ at exchange rate,4.8
+10809,Estonia,2010,11,M01A-Antiinflammatory and antirheumatic products non-steroids,Million US$ at exchange rate,8.1
+10810,Estonia,2010,11,M01A-Antiinflammatory and antirheumatic products non-steroids,"Million US$, purchasing power parity",11.9
+10811,Estonia,2010,11,M01A-Antiinflammatory and antirheumatic products non-steroids,Million of national currency units,6.1
+10812,Estonia,2010,11,M-Musculo-skeletal system,Million of national currency units,10.8
+10813,Estonia,2010,11,M-Musculo-skeletal system,"Million US$, purchasing power parity",21.1
+10814,Estonia,2010,11,M-Musculo-skeletal system,Million US$ at exchange rate,14.3
+10815,Estonia,2010,11,J-Antiinfectives for systemic use,Million US$ at exchange rate,26.3
+10816,Estonia,2010,11,J-Antiinfectives for systemic use,"Million US$, purchasing power parity",38.7
+10817,Estonia,2010,11,J01-Antibacterials for systemic use,"Million US$, purchasing power parity",15.3
+10818,Estonia,2010,11,J-Antiinfectives for systemic use,"/capita, US$ purchasing power parity",29.1
+10819,Estonia,2010,11,J-Antiinfectives for systemic use,"/capita, US$ exchange rate",19.7
+10820,Estonia,2010,11,Total pharmaceutical sales,"/capita, US$ purchasing power parity",284.6
+10821,Estonia,2010,11,A10-Drugs used in diabetes,"Million US$, purchasing power parity",22.4
+10822,Estonia,2010,11,J-Antiinfectives for systemic use,Million of national currency units,19.8
+10823,Estonia,2010,11,J01-Antibacterials for systemic use,Million of national currency units,7.9
+10824,Estonia,2010,11,J01-Antibacterials for systemic use,Million US$ at exchange rate,10.4
+10825,Estonia,2010,11,A10-Drugs used in diabetes,Million of national currency units,11.5
+10826,Estonia,2010,11,A10-Drugs used in diabetes,Million US$ at exchange rate,15.2
+10827,Estonia,2010,11,C-Cardiovascular system,"/capita, US$ purchasing power parity",51.3
+10828,Estonia,2010,11,N-Nervous system,Million of national currency units,21.5
+10829,Estonia,2010,11,N-Nervous system,Million US$ at exchange rate,28.5
+10830,Estonia,2010,11,C-Cardiovascular system,% of total sales,18.0
+10831,Estonia,2010,11,J-Antiinfectives for systemic use,% of total sales,10.2
+10832,Estonia,2010,11,J01-Antibacterials for systemic use,"/capita, US$ exchange rate",7.8
+10833,Estonia,2010,11,Total pharmaceutical sales,"/capita, US$ exchange rate",193.2
+10834,Estonia,2010,11,J01-Antibacterials for systemic use,% of total sales,4.0
+10835,Estonia,2010,11,C02-Antihypertensives,Million of national currency units,0.9
+10836,Estonia,2010,11,J01-Antibacterials for systemic use,"/capita, US$ purchasing power parity",11.5
+10837,Estonia,2017,9,C02-Antihypertensives,"Million US$, purchasing power parity",1.7
+10838,Estonia,2017,9,C02-Antihypertensives,"/capita, US$ exchange rate",0.8
+10839,Estonia,2017,9,C02-Antihypertensives,Million US$ at exchange rate,1.0
+10840,Estonia,2017,9,N05B-Anxiolytics,"/capita, US$ purchasing power parity",2.0
+10841,Estonia,2017,9,N05B-Anxiolytics,% of total sales,0.5
+10842,Estonia,2017,9,"H-Systemic hormonal preparations, excluding sex hormones and insulins",% of total sales,1.4
+10843,Estonia,2017,9,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ purchasing power parity",6.1
+10844,Estonia,2017,9,N02-Analgesics,"/capita, US$ purchasing power parity",11.3
+10845,Estonia,2017,9,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million US$ at exchange rate,4.9
+10846,Estonia,2017,9,"H-Systemic hormonal preparations, excluding sex hormones and insulins","Million US$, purchasing power parity",8.1
+10847,Estonia,2017,9,N02-Analgesics,Million US$ at exchange rate,9.0
+10848,Estonia,2017,9,N05B-Anxiolytics,Million US$ at exchange rate,1.6
+10849,Estonia,2017,9,N05B-Anxiolytics,Million of national currency units,1.4
+10850,Estonia,2017,9,N02-Analgesics,"Million US$, purchasing power parity",14.9
+10851,Estonia,2017,9,N02-Analgesics,"/capita, US$ exchange rate",6.8
+10852,Estonia,2017,9,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million of national currency units,4.3
+10853,Estonia,2017,9,N02-Analgesics,% of total sales,2.6
+10854,Estonia,2017,9,N05B-Anxiolytics,"Million US$, purchasing power parity",2.6
+10855,Estonia,2017,9,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million of national currency units,3.7
+10856,Estonia,2017,9,C-Cardiovascular system,"/capita, US$ exchange rate",25.7
+10857,Estonia,2017,9,C-Cardiovascular system,"Million US$, purchasing power parity",56.0
+10858,Estonia,2017,9,C02-Antihypertensives,"/capita, US$ purchasing power parity",1.3
+10859,Estonia,2017,9,C02-Antihypertensives,% of total sales,0.3
+10860,Estonia,2017,9,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ exchange rate",3.7
+10861,Estonia,2017,9,C-Cardiovascular system,Million US$ at exchange rate,33.8
+10862,Estonia,2017,9,N02-Analgesics,Million of national currency units,7.9
+10863,Estonia,2017,9,N05B-Anxiolytics,"/capita, US$ exchange rate",1.2
+10864,Estonia,2017,9,C-Cardiovascular system,Million of national currency units,29.9
+10865,Estonia,2017,9,B-Blood and blood forming organs,"/capita, US$ exchange rate",25.2
+10866,Estonia,2017,9,B-Blood and blood forming organs,"/capita, US$ purchasing power parity",41.7
+10867,Estonia,2017,9,B-Blood and blood forming organs,Million US$ at exchange rate,33.2
+10868,Estonia,2017,9,B-Blood and blood forming organs,"Million US$, purchasing power parity",54.9
+10869,Estonia,2017,9,B-Blood and blood forming organs,% of total sales,9.8
+10870,Estonia,2017,9,R-Respiratory system,"Million US$, purchasing power parity",41.3
+10871,Estonia,2017,9,R-Respiratory system,"/capita, US$ exchange rate",18.9
+10872,Estonia,2017,9,R-Respiratory system,Million of national currency units,22.1
+10873,Estonia,2017,9,R-Respiratory system,Million US$ at exchange rate,25.0
+10874,Estonia,2017,9,C10-Lipid modifying agents,% of total sales,1.0
+10875,Estonia,2017,9,C10-Lipid modifying agents,"/capita, US$ purchasing power parity",4.5
+10876,Estonia,2017,9,A02A-Antacids,Million of national currency units,0.4
+10877,Estonia,2017,9,A02A-Antacids,"Million US$, purchasing power parity",0.7
+10878,Estonia,2017,9,A02A-Antacids,Million US$ at exchange rate,0.4
+10879,Estonia,2017,9,C10-Lipid modifying agents,Million of national currency units,3.1
+10880,Estonia,2017,9,C10-Lipid modifying agents,Million US$ at exchange rate,3.5
+10881,Estonia,2017,9,B-Blood and blood forming organs,Million of national currency units,29.4
+10882,Estonia,2017,9,C10-Lipid modifying agents,"/capita, US$ exchange rate",2.7
+10883,Estonia,2017,9,C10-Lipid modifying agents,"Million US$, purchasing power parity",5.9
+10884,Estonia,2017,9,R-Respiratory system,"/capita, US$ purchasing power parity",31.4
+10885,Estonia,2017,9,C09-Agents acting on the Renin-Angiotensin system,Million US$ at exchange rate,13.3
+10886,Estonia,2017,9,C09-Agents acting on the Renin-Angiotensin system,Million of national currency units,11.7
+10887,Estonia,2017,9,C09-Agents acting on the Renin-Angiotensin system,"Million US$, purchasing power parity",21.9
+10888,Estonia,2017,9,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ purchasing power parity",16.7
+10889,Estonia,2017,9,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ exchange rate",10.1
+10890,Estonia,2017,9,R03-Drugs for obstructive airway diseases,"Million US$, purchasing power parity",17.2
+10891,Estonia,2017,9,R03-Drugs for obstructive airway diseases,"/capita, US$ exchange rate",7.9
+10892,Estonia,2017,9,R03-Drugs for obstructive airway diseases,"/capita, US$ purchasing power parity",13.1
+10893,Estonia,2017,9,R03-Drugs for obstructive airway diseases,Million of national currency units,9.2
+10894,Estonia,2017,9,R03-Drugs for obstructive airway diseases,Million US$ at exchange rate,10.4
+10895,Estonia,2017,9,C08-Calcium channel blockers,Million US$ at exchange rate,2.1
+10896,Estonia,2017,9,C08-Calcium channel blockers,"Million US$, purchasing power parity",3.5
+10897,Estonia,2017,9,R-Respiratory system,% of total sales,7.3
+10898,Estonia,2017,9,C08-Calcium channel blockers,Million of national currency units,1.9
+10899,Estonia,2017,9,R03-Drugs for obstructive airway diseases,% of total sales,3.1
+10900,Estonia,2017,9,C09-Agents acting on the Renin-Angiotensin system,% of total sales,3.9
+10901,Estonia,2017,9,C08-Calcium channel blockers,"/capita, US$ exchange rate",1.6
+10902,Estonia,2017,9,C08-Calcium channel blockers,% of total sales,0.6
+10903,Estonia,2017,9,C08-Calcium channel blockers,"/capita, US$ purchasing power parity",2.7
+10904,Estonia,2017,9,N05C-Hypnotics and sedatives,Million of national currency units,2.0
+10905,Estonia,2017,9,N05C-Hypnotics and sedatives,Million US$ at exchange rate,2.2
+10906,Estonia,2017,9,G03-Sex hormones and modulators of the genital system,Million US$ at exchange rate,6.1
+10907,Estonia,2017,9,G03-Sex hormones and modulators of the genital system,Million of national currency units,5.4
+10908,Estonia,2017,9,N05C-Hypnotics and sedatives,"Million US$, purchasing power parity",3.7
+10909,Estonia,2017,9,N05C-Hypnotics and sedatives,% of total sales,0.7
+10910,Estonia,2017,9,G-Genito urinary system and sex hormones,% of total sales,3.8
+10911,Estonia,2017,9,N05C-Hypnotics and sedatives,"/capita, US$ exchange rate",1.7
+10912,Estonia,2017,9,N05C-Hypnotics and sedatives,"/capita, US$ purchasing power parity",2.8
+10913,Estonia,2017,9,C03-Diuretics,"/capita, US$ exchange rate",1.6
+10914,Estonia,2017,9,C03-Diuretics,"/capita, US$ purchasing power parity",2.7
+10915,Estonia,2017,9,C03-Diuretics,"Million US$, purchasing power parity",3.6
+10916,Estonia,2017,9,C03-Diuretics,Million of national currency units,1.9
+10917,Estonia,2017,9,C03-Diuretics,Million US$ at exchange rate,2.2
+10918,Estonia,2017,9,G03-Sex hormones and modulators of the genital system,"/capita, US$ exchange rate",4.6
+10919,Estonia,2017,9,G03-Sex hormones and modulators of the genital system,"/capita, US$ purchasing power parity",7.6
+10920,Estonia,2017,9,G03-Sex hormones and modulators of the genital system,"Million US$, purchasing power parity",10.1
+10921,Estonia,2017,9,C03-Diuretics,% of total sales,0.6
+10922,Estonia,2017,9,G03-Sex hormones and modulators of the genital system,% of total sales,1.8
+10923,Estonia,2017,9,G-Genito urinary system and sex hormones,"/capita, US$ purchasing power parity",16.4
+10924,Estonia,2017,9,C07-Beta blocking agents,Million US$ at exchange rate,6.2
+10925,Estonia,2017,9,C07-Beta blocking agents,"Million US$, purchasing power parity",10.2
+10926,Estonia,2017,9,N06A-Antidepressants,% of total sales,1.1
+10927,Estonia,2017,9,A02A-Antacids,% of total sales,0.1
+10928,Estonia,2017,9,C07-Beta blocking agents,Million of national currency units,5.5
+10929,Estonia,2017,9,A02A-Antacids,"/capita, US$ purchasing power parity",0.6
+10930,Estonia,2017,9,A02A-Antacids,"/capita, US$ exchange rate",0.3
+10931,Estonia,2017,9,C07-Beta blocking agents,"/capita, US$ exchange rate",4.7
+10932,Estonia,2017,9,C07-Beta blocking agents,% of total sales,1.8
+10933,Estonia,2017,9,C07-Beta blocking agents,"/capita, US$ purchasing power parity",7.7
+10934,Estonia,2017,9,G-Genito urinary system and sex hormones,Million US$ at exchange rate,13.0
+10935,Estonia,2017,9,G-Genito urinary system and sex hormones,Million of national currency units,11.5
+10936,Estonia,2017,9,G-Genito urinary system and sex hormones,"/capita, US$ exchange rate",9.9
+10937,Estonia,2017,9,G-Genito urinary system and sex hormones,"Million US$, purchasing power parity",21.6
+10938,Estonia,2017,9,N06A-Antidepressants,"/capita, US$ exchange rate",2.8
+10939,Estonia,2017,9,N06A-Antidepressants,"/capita, US$ purchasing power parity",4.6
+10940,Estonia,2017,9,N06A-Antidepressants,Million of national currency units,3.2
+10941,Estonia,2017,9,N06A-Antidepressants,"Million US$, purchasing power parity",6.0
+10942,Estonia,2017,9,N06A-Antidepressants,Million US$ at exchange rate,3.6
+10943,Estonia,2017,9,"C01B-Antiarrhythmics, Class I and III",% of total sales,0.3
+10944,Estonia,2017,9,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),% of total sales,1.2
+10945,Estonia,2017,9,A-Alimentary tract and metabolism,Million US$ at exchange rate,40.2
+10946,Estonia,2017,9,A-Alimentary tract and metabolism,"/capita, US$ exchange rate",30.5
+10947,Estonia,2017,9,A-Alimentary tract and metabolism,"Million US$, purchasing power parity",66.5
+10948,Estonia,2017,9,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ purchasing power parity",5.3
+10949,Estonia,2017,9,A10-Drugs used in diabetes,% of total sales,6.0
+10950,Estonia,2017,9,A-Alimentary tract and metabolism,Million of national currency units,35.6
+10951,Estonia,2017,9,A10-Drugs used in diabetes,"/capita, US$ purchasing power parity",25.5
+10952,Estonia,2017,9,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million US$ at exchange rate,4.2
+10953,Estonia,2017,9,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ exchange rate",3.2
+10954,Estonia,2017,9,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"Million US$, purchasing power parity",7.0
+10955,Estonia,2017,9,A-Alimentary tract and metabolism,"/capita, US$ purchasing power parity",50.5
+10956,Estonia,2017,9,N-Nervous system,% of total sales,8.7
+10957,Estonia,2017,9,N-Nervous system,"/capita, US$ purchasing power parity",37.2
+10958,Estonia,2017,9,"C01B-Antiarrhythmics, Class I and III",Million of national currency units,0.8
+10959,Estonia,2017,9,N-Nervous system,"Million US$, purchasing power parity",49.0
+10960,Estonia,2017,9,N-Nervous system,"/capita, US$ exchange rate",22.5
+10961,Estonia,2017,9,"C01B-Antiarrhythmics, Class I and III","/capita, US$ purchasing power parity",1.1
+10962,Estonia,2017,9,A-Alimentary tract and metabolism,% of total sales,11.8
+10963,Estonia,2017,9,"C01B-Antiarrhythmics, Class I and III",Million US$ at exchange rate,0.9
+10964,Estonia,2017,9,"C01B-Antiarrhythmics, Class I and III","Million US$, purchasing power parity",1.5
+10965,Estonia,2017,9,"C01B-Antiarrhythmics, Class I and III","/capita, US$ exchange rate",0.7
+10966,Estonia,2017,9,C01A-Cardiac glycosides,"Million US$, purchasing power parity",0.2
+10967,Estonia,2017,9,C01A-Cardiac glycosides,"/capita, US$ exchange rate",0.1
+10968,Estonia,2017,9,C01A-Cardiac glycosides,"/capita, US$ purchasing power parity",0.2
+10969,Estonia,2017,9,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ exchange rate",8.1
+10970,Estonia,2017,9,C01A-Cardiac glycosides,Million of national currency units,0.1
+10971,Estonia,2017,9,C01A-Cardiac glycosides,Million US$ at exchange rate,0.1
+10972,Estonia,2017,9,Total pharmaceutical sales,Million US$ at exchange rate,340.0
+10973,Estonia,2017,9,Total pharmaceutical sales,Million of national currency units,301.0
+10974,Estonia,2017,9,M01A-Antiinflammatory and antirheumatic products non-steroids,% of total sales,3.2
+10975,Estonia,2017,9,C01A-Cardiac glycosides,% of total sales,0.0
+10976,Estonia,2017,9,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ purchasing power parity",13.5
+10977,Estonia,2017,9,M-Musculo-skeletal system,"/capita, US$ purchasing power parity",23.9
+10978,Estonia,2017,9,M-Musculo-skeletal system,% of total sales,5.6
+10979,Estonia,2017,9,M-Musculo-skeletal system,"/capita, US$ exchange rate",14.4
+10980,Estonia,2017,9,A10-Drugs used in diabetes,"/capita, US$ exchange rate",15.4
+10981,Estonia,2017,9,A10-Drugs used in diabetes,"Million US$, purchasing power parity",33.6
+10982,Estonia,2017,9,M01A-Antiinflammatory and antirheumatic products non-steroids,Million of national currency units,9.5
+10983,Estonia,2017,9,M01A-Antiinflammatory and antirheumatic products non-steroids,"Million US$, purchasing power parity",17.8
+10984,Estonia,2017,9,M01A-Antiinflammatory and antirheumatic products non-steroids,Million US$ at exchange rate,10.7
+10985,Estonia,2017,9,M-Musculo-skeletal system,"Million US$, purchasing power parity",31.5
+10986,Estonia,2017,9,M-Musculo-skeletal system,Million US$ at exchange rate,19.0
+10987,Estonia,2017,9,M-Musculo-skeletal system,Million of national currency units,16.8
+10988,Estonia,2017,9,J-Antiinfectives for systemic use,Million US$ at exchange rate,49.4
+10989,Estonia,2017,9,J01-Antibacterials for systemic use,"Million US$, purchasing power parity",12.4
+10990,Estonia,2017,9,J-Antiinfectives for systemic use,Million of national currency units,43.8
+10991,Estonia,2017,9,J01-Antibacterials for systemic use,Million US$ at exchange rate,7.5
+10992,Estonia,2017,9,J-Antiinfectives for systemic use,"/capita, US$ purchasing power parity",62.1
+10993,Estonia,2017,9,J-Antiinfectives for systemic use,"Million US$, purchasing power parity",81.8
+10994,Estonia,2017,9,J-Antiinfectives for systemic use,"/capita, US$ exchange rate",37.5
+10995,Estonia,2017,9,Total pharmaceutical sales,"/capita, US$ exchange rate",258.1
+10996,Estonia,2017,9,Total pharmaceutical sales,"/capita, US$ purchasing power parity",427.1
+10997,Estonia,2017,9,A10-Drugs used in diabetes,Million US$ at exchange rate,20.3
+10998,Estonia,2017,9,J01-Antibacterials for systemic use,Million of national currency units,6.6
+10999,Estonia,2017,9,A10-Drugs used in diabetes,Million of national currency units,18.0
+11000,Estonia,2017,9,N-Nervous system,Million of national currency units,26.2
+11001,Estonia,2017,9,J-Antiinfectives for systemic use,% of total sales,14.5
+11002,Estonia,2017,9,C-Cardiovascular system,"/capita, US$ purchasing power parity",42.5
+11003,Estonia,2017,9,N-Nervous system,Million US$ at exchange rate,29.6
+11004,Estonia,2017,9,J01-Antibacterials for systemic use,"/capita, US$ purchasing power parity",9.4
+11005,Estonia,2017,9,C02-Antihypertensives,Million of national currency units,0.9
+11006,Estonia,2017,9,Total pharmaceutical sales,"Million US$, purchasing power parity",562.6
+11007,Estonia,2017,9,J01-Antibacterials for systemic use,"/capita, US$ exchange rate",5.7
+11008,Estonia,2017,9,J01-Antibacterials for systemic use,% of total sales,2.2
+11009,Estonia,2017,9,C-Cardiovascular system,% of total sales,9.9
+11010,Finland,2016,3,C01A-Cardiac glycosides,% of total sales,0.1
+11011,Finland,2016,3,C01A-Cardiac glycosides,"/capita, US$ purchasing power parity",0.2
+11012,Finland,2016,3,C07-Beta blocking agents,"Million US$, purchasing power parity",30.1
+11013,Finland,2016,3,C07-Beta blocking agents,Million US$ at exchange rate,29.3
+11014,Finland,2016,3,C07-Beta blocking agents,Million of national currency units,26.5
+11015,Finland,2016,3,C01A-Cardiac glycosides,Million of national currency units,1.2
+11016,Finland,2016,3,C02-Antihypertensives,Million of national currency units,7.6
+11017,Finland,2016,3,C01A-Cardiac glycosides,"/capita, US$ exchange rate",0.2
+11018,Finland,2016,3,C01A-Cardiac glycosides,"Million US$, purchasing power parity",1.4
+11019,Finland,2016,3,C01A-Cardiac glycosides,Million US$ at exchange rate,1.3
+11020,Finland,2016,3,A-Alimentary tract and metabolism,"/capita, US$ purchasing power parity",62.5
+11021,Finland,2016,3,A-Alimentary tract and metabolism,"/capita, US$ exchange rate",60.9
+11022,Finland,2016,3,A-Alimentary tract and metabolism,% of total sales,13.2
+11023,Finland,2016,3,A-Alimentary tract and metabolism,Million US$ at exchange rate,334.7
+11024,Finland,2016,3,A-Alimentary tract and metabolism,Million of national currency units,302.4
+11025,Finland,2016,3,A-Alimentary tract and metabolism,"Million US$, purchasing power parity",343.3
+11026,Finland,2016,3,N05C-Hypnotics and sedatives,"Million US$, purchasing power parity",13.7
+11027,Finland,2016,3,N05C-Hypnotics and sedatives,Million US$ at exchange rate,13.4
+11028,Finland,2016,3,N-Nervous system,Million of national currency units,307.0
+11029,Finland,2016,3,N05C-Hypnotics and sedatives,"/capita, US$ exchange rate",2.4
+11030,Finland,2016,3,N05C-Hypnotics and sedatives,% of total sales,0.5
+11031,Finland,2016,3,N05C-Hypnotics and sedatives,"/capita, US$ purchasing power parity",2.5
+11032,Finland,2016,3,G-Genito urinary system and sex hormones,"Million US$, purchasing power parity",130.2
+11033,Finland,2016,3,G-Genito urinary system and sex hormones,Million US$ at exchange rate,127.0
+11034,Finland,2016,3,C02-Antihypertensives,Million US$ at exchange rate,8.4
+11035,Finland,2016,3,C02-Antihypertensives,"Million US$, purchasing power parity",8.6
+11036,Finland,2016,3,G-Genito urinary system and sex hormones,% of total sales,5.0
+11037,Finland,2016,3,G-Genito urinary system and sex hormones,"/capita, US$ exchange rate",23.1
+11038,Finland,2016,3,G-Genito urinary system and sex hormones,"/capita, US$ purchasing power parity",23.7
+11039,Finland,2016,3,N-Nervous system,Million US$ at exchange rate,339.8
+11040,Finland,2016,3,N-Nervous system,"Million US$, purchasing power parity",348.5
+11041,Finland,2016,3,G-Genito urinary system and sex hormones,Million of national currency units,114.7
+11042,Finland,2016,3,N-Nervous system,% of total sales,13.4
+11043,Finland,2016,3,N-Nervous system,"/capita, US$ purchasing power parity",63.4
+11044,Finland,2016,3,N-Nervous system,"/capita, US$ exchange rate",61.8
+11045,Finland,2016,3,N06A-Antidepressants,"Million US$, purchasing power parity",35.0
+11046,Finland,2016,3,N06A-Antidepressants,Million US$ at exchange rate,34.1
+11047,Finland,2016,3,N06A-Antidepressants,Million of national currency units,30.8
+11048,Finland,2016,3,N06A-Antidepressants,% of total sales,1.3
+11049,Finland,2016,3,N06A-Antidepressants,"/capita, US$ purchasing power parity",6.4
+11050,Finland,2016,3,N06A-Antidepressants,"/capita, US$ exchange rate",6.2
+11051,Finland,2016,3,A10-Drugs used in diabetes,Million of national currency units,153.5
+11052,Finland,2016,3,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ exchange rate",7.1
+11053,Finland,2016,3,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"Million US$, purchasing power parity",40.1
+11054,Finland,2016,3,A10-Drugs used in diabetes,"Million US$, purchasing power parity",174.3
+11055,Finland,2016,3,A10-Drugs used in diabetes,"/capita, US$ exchange rate",30.9
+11056,Finland,2016,3,A10-Drugs used in diabetes,Million US$ at exchange rate,169.9
+11057,Finland,2016,3,R-Respiratory system,"/capita, US$ exchange rate",30.3
+11058,Finland,2016,3,M-Musculo-skeletal system,% of total sales,4.3
+11059,Finland,2016,3,R-Respiratory system,Million of national currency units,150.2
+11060,Finland,2016,3,M-Musculo-skeletal system,"Million US$, purchasing power parity",111.0
+11061,Finland,2016,3,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),% of total sales,1.5
+11062,Finland,2016,3,M-Musculo-skeletal system,"/capita, US$ purchasing power parity",20.2
+11063,Finland,2016,3,M-Musculo-skeletal system,"/capita, US$ exchange rate",19.7
+11064,Finland,2016,3,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ purchasing power parity",7.3
+11065,Finland,2016,3,R-Respiratory system,Million US$ at exchange rate,166.3
+11066,Finland,2016,3,A10-Drugs used in diabetes,"/capita, US$ purchasing power parity",31.7
+11067,Finland,2016,3,R-Respiratory system,"Million US$, purchasing power parity",170.5
+11068,Finland,2016,3,C08-Calcium channel blockers,% of total sales,0.8
+11069,Finland,2016,3,A10-Drugs used in diabetes,% of total sales,6.7
+11070,Finland,2016,3,C08-Calcium channel blockers,"/capita, US$ purchasing power parity",4.0
+11071,Finland,2016,3,M-Musculo-skeletal system,Million US$ at exchange rate,108.3
+11072,Finland,2016,3,M-Musculo-skeletal system,Million of national currency units,97.8
+11073,Finland,2016,3,G03-Sex hormones and modulators of the genital system,% of total sales,2.5
+11074,Finland,2016,3,"C01B-Antiarrhythmics, Class I and III","/capita, US$ purchasing power parity",0.9
+11075,Finland,2016,3,"C01B-Antiarrhythmics, Class I and III",% of total sales,0.2
+11076,Finland,2016,3,"C01B-Antiarrhythmics, Class I and III","/capita, US$ exchange rate",0.8
+11077,Finland,2016,3,C07-Beta blocking agents,% of total sales,1.2
+11078,Finland,2016,3,C07-Beta blocking agents,"/capita, US$ exchange rate",5.3
+11079,Finland,2016,3,C07-Beta blocking agents,"/capita, US$ purchasing power parity",5.5
+11080,Finland,2016,3,"C01B-Antiarrhythmics, Class I and III",Million of national currency units,4.2
+11081,Finland,2016,3,"C01B-Antiarrhythmics, Class I and III","Million US$, purchasing power parity",4.8
+11082,Finland,2016,3,"C01B-Antiarrhythmics, Class I and III",Million US$ at exchange rate,4.6
+11083,Finland,2016,3,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million of national currency units,35.3
+11084,Finland,2016,3,C08-Calcium channel blockers,"/capita, US$ exchange rate",3.9
+11085,Finland,2016,3,C08-Calcium channel blockers,"Million US$, purchasing power parity",22.0
+11086,Finland,2016,3,C02-Antihypertensives,"/capita, US$ exchange rate",1.5
+11087,Finland,2016,3,R-Respiratory system,% of total sales,6.6
+11088,Finland,2016,3,R-Respiratory system,"/capita, US$ purchasing power parity",31.0
+11089,Finland,2016,3,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million US$ at exchange rate,39.1
+11090,Finland,2016,3,G03-Sex hormones and modulators of the genital system,"Million US$, purchasing power parity",65.5
+11091,Finland,2016,3,G03-Sex hormones and modulators of the genital system,Million US$ at exchange rate,63.9
+11092,Finland,2016,3,G03-Sex hormones and modulators of the genital system,"/capita, US$ exchange rate",11.6
+11093,Finland,2016,3,C08-Calcium channel blockers,Million of national currency units,19.4
+11094,Finland,2016,3,C08-Calcium channel blockers,Million US$ at exchange rate,21.5
+11095,Finland,2016,3,G03-Sex hormones and modulators of the genital system,"/capita, US$ purchasing power parity",11.9
+11096,Finland,2016,3,G03-Sex hormones and modulators of the genital system,Million of national currency units,57.7
+11097,Finland,2016,3,J-Antiinfectives for systemic use,"/capita, US$ exchange rate",37.1
+11098,Finland,2016,3,J-Antiinfectives for systemic use,"Million US$, purchasing power parity",209.0
+11099,Finland,2016,3,J-Antiinfectives for systemic use,"/capita, US$ purchasing power parity",38.0
+11100,Finland,2016,3,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ exchange rate",10.5
+11101,Finland,2016,3,A02A-Antacids,% of total sales,0.1
+11102,Finland,2016,3,J-Antiinfectives for systemic use,Million of national currency units,184.1
+11103,Finland,2016,3,J-Antiinfectives for systemic use,Million US$ at exchange rate,203.8
+11104,Finland,2016,3,C09-Agents acting on the Renin-Angiotensin system,Million of national currency units,54.2
+11105,Finland,2016,3,C09-Agents acting on the Renin-Angiotensin system,Million US$ at exchange rate,60.0
+11106,Finland,2016,3,C09-Agents acting on the Renin-Angiotensin system,"Million US$, purchasing power parity",61.5
+11107,Finland,2016,3,J-Antiinfectives for systemic use,% of total sales,8.0
+11108,Finland,2016,3,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ purchasing power parity",10.8
+11109,Finland,2016,3,C-Cardiovascular system,% of total sales,9.2
+11110,Finland,2016,3,M01A-Antiinflammatory and antirheumatic products non-steroids,% of total sales,2.3
+11111,Finland,2016,3,R03-Drugs for obstructive airway diseases,"/capita, US$ exchange rate",18.2
+11112,Finland,2016,3,R03-Drugs for obstructive airway diseases,% of total sales,4.0
+11113,Finland,2016,3,R03-Drugs for obstructive airway diseases,"/capita, US$ purchasing power parity",18.7
+11114,Finland,2016,3,R03-Drugs for obstructive airway diseases,"Million US$, purchasing power parity",102.7
+11115,Finland,2016,3,R03-Drugs for obstructive airway diseases,Million of national currency units,90.5
+11116,Finland,2016,3,R03-Drugs for obstructive airway diseases,Million US$ at exchange rate,100.2
+11117,Finland,2016,3,A02A-Antacids,"Million US$, purchasing power parity",3.6
+11118,Finland,2016,3,A02A-Antacids,"/capita, US$ exchange rate",0.6
+11119,Finland,2016,3,A02A-Antacids,"/capita, US$ purchasing power parity",0.7
+11120,Finland,2016,3,M01A-Antiinflammatory and antirheumatic products non-steroids,"Million US$, purchasing power parity",59.4
+11121,Finland,2016,3,A02A-Antacids,Million US$ at exchange rate,3.5
+11122,Finland,2016,3,A02A-Antacids,Million of national currency units,3.2
+11123,Finland,2016,3,B-Blood and blood forming organs,"Million US$, purchasing power parity",222.4
+11124,Finland,2016,3,B-Blood and blood forming organs,Million US$ at exchange rate,216.8
+11125,Finland,2016,3,B-Blood and blood forming organs,"/capita, US$ exchange rate",39.5
+11126,Finland,2016,3,B-Blood and blood forming organs,"/capita, US$ purchasing power parity",40.5
+11127,Finland,2016,3,N05B-Anxiolytics,Million US$ at exchange rate,8.0
+11128,Finland,2016,3,N05B-Anxiolytics,Million of national currency units,7.2
+11129,Finland,2016,3,N02-Analgesics,% of total sales,3.2
+11130,Finland,2016,3,Total pharmaceutical sales,"Million US$, purchasing power parity",2598.3
+11131,Finland,2016,3,Total pharmaceutical sales,Million US$ at exchange rate,2533.5
+11132,Finland,2016,3,Total pharmaceutical sales,Million of national currency units,2288.8
+11133,Finland,2016,3,B-Blood and blood forming organs,% of total sales,8.6
+11134,Finland,2016,3,Total pharmaceutical sales,"/capita, US$ exchange rate",461.0
+11135,Finland,2016,3,Total pharmaceutical sales,"/capita, US$ purchasing power parity",472.8
+11136,Finland,2016,3,C03-Diuretics,"/capita, US$ purchasing power parity",1.7
+11137,Finland,2016,3,C03-Diuretics,"Million US$, purchasing power parity",9.1
+11138,Finland,2016,3,C03-Diuretics,"/capita, US$ exchange rate",1.6
+11139,Finland,2016,3,C03-Diuretics,% of total sales,0.3
+11140,Finland,2016,3,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ purchasing power parity",11.2
+11141,Finland,2016,3,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ exchange rate",10.9
+11142,Finland,2016,3,C09-Agents acting on the Renin-Angiotensin system,% of total sales,2.4
+11143,Finland,2016,3,N05B-Anxiolytics,"/capita, US$ purchasing power parity",1.5
+11144,Finland,2016,3,N05B-Anxiolytics,"/capita, US$ exchange rate",1.5
+11145,Finland,2016,3,N05B-Anxiolytics,"Million US$, purchasing power parity",8.2
+11146,Finland,2016,3,C03-Diuretics,Million US$ at exchange rate,8.9
+11147,Finland,2016,3,C03-Diuretics,Million of national currency units,8.0
+11148,Finland,2016,3,N05B-Anxiolytics,% of total sales,0.3
+11149,Finland,2016,3,B-Blood and blood forming organs,Million of national currency units,195.9
+11150,Finland,2016,3,N02-Analgesics,Million US$ at exchange rate,79.9
+11151,Finland,2016,3,N02-Analgesics,"Million US$, purchasing power parity",82.0
+11152,Finland,2016,3,N05C-Hypnotics and sedatives,Million of national currency units,12.1
+11153,Finland,2016,3,C10-Lipid modifying agents,Million of national currency units,66.8
+11154,Finland,2016,3,C10-Lipid modifying agents,Million US$ at exchange rate,73.9
+11155,Finland,2016,3,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million US$ at exchange rate,50.1
+11156,Finland,2016,3,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million of national currency units,45.3
+11157,Finland,2016,3,N02-Analgesics,"/capita, US$ exchange rate",14.5
+11158,Finland,2016,3,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ exchange rate",9.1
+11159,Finland,2016,3,"H-Systemic hormonal preparations, excluding sex hormones and insulins","Million US$, purchasing power parity",51.4
+11160,Finland,2016,3,J01-Antibacterials for systemic use,"Million US$, purchasing power parity",62.7
+11161,Finland,2016,3,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ purchasing power parity",9.4
+11162,Finland,2016,3,J01-Antibacterials for systemic use,Million US$ at exchange rate,61.1
+11163,Finland,2016,3,J01-Antibacterials for systemic use,Million of national currency units,55.2
+11164,Finland,2016,3,J01-Antibacterials for systemic use,"/capita, US$ purchasing power parity",11.4
+11165,Finland,2016,3,J01-Antibacterials for systemic use,"/capita, US$ exchange rate",11.1
+11166,Finland,2016,3,N02-Analgesics,Million of national currency units,72.2
+11167,Finland,2016,3,J01-Antibacterials for systemic use,% of total sales,2.4
+11168,Finland,2016,3,C10-Lipid modifying agents,"/capita, US$ exchange rate",13.5
+11169,Finland,2016,3,C-Cardiovascular system,"/capita, US$ exchange rate",42.3
+11170,Finland,2016,3,C-Cardiovascular system,"/capita, US$ purchasing power parity",43.4
+11171,Finland,2016,3,C02-Antihypertensives,% of total sales,0.3
+11172,Finland,2016,3,C02-Antihypertensives,"/capita, US$ purchasing power parity",1.6
+11173,Finland,2016,3,C10-Lipid modifying agents,"/capita, US$ purchasing power parity",13.8
+11174,Finland,2016,3,C10-Lipid modifying agents,% of total sales,2.9
+11175,Finland,2016,3,"H-Systemic hormonal preparations, excluding sex hormones and insulins",% of total sales,2.0
+11176,Finland,2016,3,C10-Lipid modifying agents,"Million US$, purchasing power parity",75.8
+11177,Finland,2016,3,M01A-Antiinflammatory and antirheumatic products non-steroids,Million US$ at exchange rate,57.9
+11178,Finland,2016,3,M01A-Antiinflammatory and antirheumatic products non-steroids,Million of national currency units,52.3
+11179,Finland,2016,3,N02-Analgesics,"/capita, US$ purchasing power parity",14.9
+11180,Finland,2016,3,C-Cardiovascular system,Million of national currency units,210.1
+11181,Finland,2016,3,C-Cardiovascular system,Million US$ at exchange rate,232.6
+11182,Finland,2016,3,C-Cardiovascular system,"Million US$, purchasing power parity",238.5
+11183,Finland,2015,3,C01A-Cardiac glycosides,% of total sales,0.1
+11184,Finland,2015,3,C01A-Cardiac glycosides,"/capita, US$ purchasing power parity",0.3
+11185,Finland,2015,3,C07-Beta blocking agents,"Million US$, purchasing power parity",30.4
+11186,Finland,2015,3,C07-Beta blocking agents,Million US$ at exchange rate,30.6
+11187,Finland,2015,3,C07-Beta blocking agents,Million of national currency units,27.6
+11188,Finland,2015,3,C01A-Cardiac glycosides,Million of national currency units,1.3
+11189,Finland,2015,3,C02-Antihypertensives,Million of national currency units,7.1
+11190,Finland,2015,3,C01A-Cardiac glycosides,Million US$ at exchange rate,1.4
+11191,Finland,2015,3,C01A-Cardiac glycosides,"/capita, US$ exchange rate",0.3
+11192,Finland,2015,3,C01A-Cardiac glycosides,"Million US$, purchasing power parity",1.4
+11193,Finland,2015,3,A-Alimentary tract and metabolism,"/capita, US$ purchasing power parity",58.9
+11194,Finland,2015,3,A-Alimentary tract and metabolism,% of total sales,13.3
+11195,Finland,2015,3,A-Alimentary tract and metabolism,"/capita, US$ exchange rate",59.3
+11196,Finland,2015,3,A-Alimentary tract and metabolism,Million US$ at exchange rate,325.1
+11197,Finland,2015,3,A-Alimentary tract and metabolism,Million of national currency units,293.0
+11198,Finland,2015,3,A-Alimentary tract and metabolism,"Million US$, purchasing power parity",322.8
+11199,Finland,2015,3,N-Nervous system,Million of national currency units,319.8
+11200,Finland,2015,3,N05C-Hypnotics and sedatives,"Million US$, purchasing power parity",13.8
+11201,Finland,2015,3,C02-Antihypertensives,"/capita, US$ exchange rate",1.4
+11202,Finland,2015,3,N05C-Hypnotics and sedatives,Million US$ at exchange rate,13.9
+11203,Finland,2015,3,N05C-Hypnotics and sedatives,% of total sales,0.6
+11204,Finland,2015,3,N05C-Hypnotics and sedatives,"/capita, US$ exchange rate",2.5
+11205,Finland,2015,3,N05C-Hypnotics and sedatives,"/capita, US$ purchasing power parity",2.5
+11206,Finland,2015,3,G-Genito urinary system and sex hormones,"Million US$, purchasing power parity",123.4
+11207,Finland,2015,3,G-Genito urinary system and sex hormones,Million US$ at exchange rate,124.3
+11208,Finland,2015,3,C02-Antihypertensives,"Million US$, purchasing power parity",7.8
+11209,Finland,2015,3,C02-Antihypertensives,Million US$ at exchange rate,7.9
+11210,Finland,2015,3,G-Genito urinary system and sex hormones,% of total sales,5.1
+11211,Finland,2015,3,G-Genito urinary system and sex hormones,"/capita, US$ purchasing power parity",22.5
+11212,Finland,2015,3,G-Genito urinary system and sex hormones,"/capita, US$ exchange rate",22.7
+11213,Finland,2015,3,N-Nervous system,Million US$ at exchange rate,354.8
+11214,Finland,2015,3,N-Nervous system,"Million US$, purchasing power parity",352.3
+11215,Finland,2015,3,G-Genito urinary system and sex hormones,Million of national currency units,112.0
+11216,Finland,2015,3,N-Nervous system,% of total sales,14.5
+11217,Finland,2015,3,N-Nervous system,"/capita, US$ purchasing power parity",64.3
+11218,Finland,2015,3,N-Nervous system,"/capita, US$ exchange rate",64.8
+11219,Finland,2015,3,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),% of total sales,1.6
+11220,Finland,2015,3,N06A-Antidepressants,"Million US$, purchasing power parity",35.4
+11221,Finland,2015,3,N06A-Antidepressants,Million of national currency units,32.1
+11222,Finland,2015,3,N06A-Antidepressants,Million US$ at exchange rate,35.6
+11223,Finland,2015,3,N06A-Antidepressants,% of total sales,1.5
+11224,Finland,2015,3,N06A-Antidepressants,"/capita, US$ exchange rate",6.5
+11225,Finland,2015,3,N06A-Antidepressants,"/capita, US$ purchasing power parity",6.5
+11226,Finland,2015,3,A10-Drugs used in diabetes,Million of national currency units,148.2
+11227,Finland,2015,3,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ exchange rate",7.2
+11228,Finland,2015,3,A10-Drugs used in diabetes,"/capita, US$ exchange rate",30.0
+11229,Finland,2015,3,A10-Drugs used in diabetes,"Million US$, purchasing power parity",163.3
+11230,Finland,2015,3,A10-Drugs used in diabetes,Million US$ at exchange rate,164.4
+11231,Finland,2015,3,M-Musculo-skeletal system,% of total sales,4.5
+11232,Finland,2015,3,R-Respiratory system,Million of national currency units,144.4
+11233,Finland,2015,3,M-Musculo-skeletal system,"Million US$, purchasing power parity",108.2
+11234,Finland,2015,3,M-Musculo-skeletal system,"/capita, US$ exchange rate",19.9
+11235,Finland,2015,3,M-Musculo-skeletal system,"/capita, US$ purchasing power parity",19.7
+11236,Finland,2015,3,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ purchasing power parity",7.1
+11237,Finland,2015,3,R-Respiratory system,Million US$ at exchange rate,160.2
+11238,Finland,2015,3,A10-Drugs used in diabetes,"/capita, US$ purchasing power parity",29.8
+11239,Finland,2015,3,R-Respiratory system,"/capita, US$ exchange rate",29.2
+11240,Finland,2015,3,R-Respiratory system,"Million US$, purchasing power parity",159.1
+11241,Finland,2015,3,C08-Calcium channel blockers,% of total sales,0.9
+11242,Finland,2015,3,A10-Drugs used in diabetes,% of total sales,6.7
+11243,Finland,2015,3,C08-Calcium channel blockers,"/capita, US$ purchasing power parity",3.8
+11244,Finland,2015,3,R-Respiratory system,"/capita, US$ purchasing power parity",29.0
+11245,Finland,2015,3,M-Musculo-skeletal system,Million US$ at exchange rate,109.0
+11246,Finland,2015,3,M-Musculo-skeletal system,Million of national currency units,98.2
+11247,Finland,2015,3,G03-Sex hormones and modulators of the genital system,% of total sales,2.7
+11248,Finland,2015,3,"C01B-Antiarrhythmics, Class I and III","/capita, US$ purchasing power parity",0.8
+11249,Finland,2015,3,"C01B-Antiarrhythmics, Class I and III",% of total sales,0.2
+11250,Finland,2015,3,"C01B-Antiarrhythmics, Class I and III","/capita, US$ exchange rate",0.8
+11251,Finland,2015,3,C07-Beta blocking agents,% of total sales,1.3
+11252,Finland,2015,3,C07-Beta blocking agents,"/capita, US$ exchange rate",5.6
+11253,Finland,2015,3,C07-Beta blocking agents,"/capita, US$ purchasing power parity",5.5
+11254,Finland,2015,3,"C01B-Antiarrhythmics, Class I and III",Million of national currency units,4.0
+11255,Finland,2015,3,"C01B-Antiarrhythmics, Class I and III","Million US$, purchasing power parity",4.4
+11256,Finland,2015,3,"C01B-Antiarrhythmics, Class I and III",Million US$ at exchange rate,4.4
+11257,Finland,2015,3,G03-Sex hormones and modulators of the genital system,"/capita, US$ purchasing power parity",11.7
+11258,Finland,2015,3,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million of national currency units,35.4
+11259,Finland,2015,3,C08-Calcium channel blockers,"Million US$, purchasing power parity",20.9
+11260,Finland,2015,3,C08-Calcium channel blockers,"/capita, US$ exchange rate",3.8
+11261,Finland,2015,3,R-Respiratory system,% of total sales,6.6
+11262,Finland,2015,3,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"Million US$, purchasing power parity",39.0
+11263,Finland,2015,3,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million US$ at exchange rate,39.3
+11264,Finland,2015,3,G03-Sex hormones and modulators of the genital system,"Million US$, purchasing power parity",64.3
+11265,Finland,2015,3,G03-Sex hormones and modulators of the genital system,"/capita, US$ exchange rate",11.8
+11266,Finland,2015,3,G03-Sex hormones and modulators of the genital system,Million US$ at exchange rate,64.8
+11267,Finland,2015,3,C08-Calcium channel blockers,Million US$ at exchange rate,21.1
+11268,Finland,2015,3,C08-Calcium channel blockers,Million of national currency units,19.0
+11269,Finland,2015,3,G03-Sex hormones and modulators of the genital system,Million of national currency units,58.4
+11270,Finland,2015,3,J-Antiinfectives for systemic use,"/capita, US$ exchange rate",36.9
+11271,Finland,2015,3,J-Antiinfectives for systemic use,"Million US$, purchasing power parity",200.6
+11272,Finland,2015,3,J-Antiinfectives for systemic use,"/capita, US$ purchasing power parity",36.6
+11273,Finland,2015,3,A02A-Antacids,% of total sales,0.1
+11274,Finland,2015,3,J-Antiinfectives for systemic use,Million of national currency units,182.1
+11275,Finland,2015,3,J-Antiinfectives for systemic use,Million US$ at exchange rate,202.0
+11276,Finland,2015,3,J-Antiinfectives for systemic use,% of total sales,8.3
+11277,Finland,2015,3,C09-Agents acting on the Renin-Angiotensin system,Million of national currency units,55.0
+11278,Finland,2015,3,C09-Agents acting on the Renin-Angiotensin system,Million US$ at exchange rate,61.0
+11279,Finland,2015,3,C09-Agents acting on the Renin-Angiotensin system,"Million US$, purchasing power parity",60.6
+11280,Finland,2015,3,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ purchasing power parity",10.6
+11281,Finland,2015,3,C-Cardiovascular system,% of total sales,9.2
+11282,Finland,2015,3,M01A-Antiinflammatory and antirheumatic products non-steroids,% of total sales,2.4
+11283,Finland,2015,3,R03-Drugs for obstructive airway diseases,"/capita, US$ exchange rate",17.7
+11284,Finland,2015,3,R03-Drugs for obstructive airway diseases,% of total sales,4.0
+11285,Finland,2015,3,R03-Drugs for obstructive airway diseases,"/capita, US$ purchasing power parity",17.6
+11286,Finland,2015,3,R03-Drugs for obstructive airway diseases,Million of national currency units,87.5
+11287,Finland,2015,3,R03-Drugs for obstructive airway diseases,"Million US$, purchasing power parity",96.4
+11288,Finland,2015,3,R03-Drugs for obstructive airway diseases,Million US$ at exchange rate,97.1
+11289,Finland,2015,3,A02A-Antacids,"Million US$, purchasing power parity",3.5
+11290,Finland,2015,3,A02A-Antacids,"/capita, US$ exchange rate",0.6
+11291,Finland,2015,3,A02A-Antacids,"/capita, US$ purchasing power parity",0.6
+11292,Finland,2015,3,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ exchange rate",10.7
+11293,Finland,2015,3,M01A-Antiinflammatory and antirheumatic products non-steroids,"Million US$, purchasing power parity",57.9
+11294,Finland,2015,3,A02A-Antacids,Million of national currency units,3.2
+11295,Finland,2015,3,A02A-Antacids,Million US$ at exchange rate,3.6
+11296,Finland,2015,3,B-Blood and blood forming organs,"Million US$, purchasing power parity",195.4
+11297,Finland,2015,3,B-Blood and blood forming organs,"/capita, US$ purchasing power parity",35.7
+11298,Finland,2015,3,B-Blood and blood forming organs,"/capita, US$ exchange rate",35.9
+11299,Finland,2015,3,B-Blood and blood forming organs,Million US$ at exchange rate,196.8
+11300,Finland,2015,3,N05B-Anxiolytics,Million US$ at exchange rate,8.7
+11301,Finland,2015,3,N05B-Anxiolytics,Million of national currency units,7.8
+11302,Finland,2015,3,N02-Analgesics,% of total sales,3.3
+11303,Finland,2015,3,Total pharmaceutical sales,"Million US$, purchasing power parity",2423.7
+11304,Finland,2015,3,Total pharmaceutical sales,Million US$ at exchange rate,2441.0
+11305,Finland,2015,3,Total pharmaceutical sales,Million of national currency units,2200.1
+11306,Finland,2015,3,B-Blood and blood forming organs,% of total sales,8.1
+11307,Finland,2015,3,Total pharmaceutical sales,"/capita, US$ exchange rate",445.5
+11308,Finland,2015,3,Total pharmaceutical sales,"/capita, US$ purchasing power parity",442.3
+11309,Finland,2015,3,C03-Diuretics,"/capita, US$ purchasing power parity",1.8
+11310,Finland,2015,3,C03-Diuretics,% of total sales,0.4
+11311,Finland,2015,3,C03-Diuretics,"/capita, US$ exchange rate",1.8
+11312,Finland,2015,3,C03-Diuretics,"Million US$, purchasing power parity",9.7
+11313,Finland,2015,3,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ purchasing power parity",11.1
+11314,Finland,2015,3,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ exchange rate",11.1
+11315,Finland,2015,3,C09-Agents acting on the Renin-Angiotensin system,% of total sales,2.5
+11316,Finland,2015,3,N05B-Anxiolytics,"/capita, US$ purchasing power parity",1.6
+11317,Finland,2015,3,N05B-Anxiolytics,"Million US$, purchasing power parity",8.6
+11318,Finland,2015,3,N05B-Anxiolytics,"/capita, US$ exchange rate",1.6
+11319,Finland,2015,3,C03-Diuretics,Million US$ at exchange rate,9.8
+11320,Finland,2015,3,N05B-Anxiolytics,% of total sales,0.4
+11321,Finland,2015,3,C03-Diuretics,Million of national currency units,8.8
+11322,Finland,2015,3,B-Blood and blood forming organs,Million of national currency units,177.4
+11323,Finland,2015,3,N02-Analgesics,"/capita, US$ exchange rate",14.6
+11324,Finland,2015,3,N02-Analgesics,Million US$ at exchange rate,79.8
+11325,Finland,2015,3,N02-Analgesics,"Million US$, purchasing power parity",79.2
+11326,Finland,2015,3,"H-Systemic hormonal preparations, excluding sex hormones and insulins",% of total sales,1.9
+11327,Finland,2015,3,C10-Lipid modifying agents,Million of national currency units,58.7
+11328,Finland,2015,3,C10-Lipid modifying agents,Million US$ at exchange rate,65.1
+11329,Finland,2015,3,N05C-Hypnotics and sedatives,Million of national currency units,12.5
+11330,Finland,2015,3,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million US$ at exchange rate,46.8
+11331,Finland,2015,3,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million of national currency units,42.2
+11332,Finland,2015,3,N02-Analgesics,Million of national currency units,71.9
+11333,Finland,2015,3,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ exchange rate",8.5
+11334,Finland,2015,3,"H-Systemic hormonal preparations, excluding sex hormones and insulins","Million US$, purchasing power parity",46.5
+11335,Finland,2015,3,J01-Antibacterials for systemic use,"Million US$, purchasing power parity",57.1
+11336,Finland,2015,3,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ purchasing power parity",8.5
+11337,Finland,2015,3,J01-Antibacterials for systemic use,Million US$ at exchange rate,57.5
+11338,Finland,2015,3,J01-Antibacterials for systemic use,Million of national currency units,51.8
+11339,Finland,2015,3,J01-Antibacterials for systemic use,"/capita, US$ purchasing power parity",10.4
+11340,Finland,2015,3,J01-Antibacterials for systemic use,"/capita, US$ exchange rate",10.5
+11341,Finland,2015,3,J01-Antibacterials for systemic use,% of total sales,2.4
+11342,Finland,2015,3,C10-Lipid modifying agents,"/capita, US$ exchange rate",11.9
+11343,Finland,2015,3,C-Cardiovascular system,"/capita, US$ exchange rate",41.1
+11344,Finland,2015,3,C-Cardiovascular system,"/capita, US$ purchasing power parity",40.9
+11345,Finland,2015,3,C02-Antihypertensives,% of total sales,0.3
+11346,Finland,2015,3,C02-Antihypertensives,"/capita, US$ purchasing power parity",1.4
+11347,Finland,2015,3,C10-Lipid modifying agents,"/capita, US$ purchasing power parity",11.8
+11348,Finland,2015,3,C10-Lipid modifying agents,% of total sales,2.7
+11349,Finland,2015,3,C10-Lipid modifying agents,"Million US$, purchasing power parity",64.7
+11350,Finland,2015,3,C-Cardiovascular system,Million of national currency units,203.2
+11351,Finland,2015,3,M01A-Antiinflammatory and antirheumatic products non-steroids,Million US$ at exchange rate,58.4
+11352,Finland,2015,3,M01A-Antiinflammatory and antirheumatic products non-steroids,Million of national currency units,52.6
+11353,Finland,2015,3,N02-Analgesics,"/capita, US$ purchasing power parity",14.5
+11354,Finland,2015,3,C-Cardiovascular system,Million US$ at exchange rate,225.5
+11355,Finland,2015,3,C-Cardiovascular system,"Million US$, purchasing power parity",223.9
+11356,Finland,2014,3,C01A-Cardiac glycosides,% of total sales,0.1
+11357,Finland,2014,3,C01A-Cardiac glycosides,"/capita, US$ purchasing power parity",0.2
+11358,Finland,2014,3,C07-Beta blocking agents,"Million US$, purchasing power parity",30.4
+11359,Finland,2014,3,C07-Beta blocking agents,Million US$ at exchange rate,36.7
+11360,Finland,2014,3,C07-Beta blocking agents,Million of national currency units,27.6
+11361,Finland,2014,3,C01A-Cardiac glycosides,Million of national currency units,1.1
+11362,Finland,2014,3,C02-Antihypertensives,Million of national currency units,6.2
+11363,Finland,2014,3,C01A-Cardiac glycosides,"/capita, US$ exchange rate",0.3
+11364,Finland,2014,3,C01A-Cardiac glycosides,"Million US$, purchasing power parity",1.2
+11365,Finland,2014,3,C01A-Cardiac glycosides,Million US$ at exchange rate,1.5
+11366,Finland,2014,3,G-Genito urinary system and sex hormones,% of total sales,5.3
+11367,Finland,2014,3,A-Alimentary tract and metabolism,"/capita, US$ purchasing power parity",56.4
+11368,Finland,2014,3,A-Alimentary tract and metabolism,% of total sales,13.3
+11369,Finland,2014,3,A-Alimentary tract and metabolism,Million US$ at exchange rate,371.1
+11370,Finland,2014,3,A-Alimentary tract and metabolism,"/capita, US$ exchange rate",67.9
+11371,Finland,2014,3,A-Alimentary tract and metabolism,"Million US$, purchasing power parity",307.9
+11372,Finland,2014,3,A-Alimentary tract and metabolism,Million of national currency units,279.3
+11373,Finland,2014,3,N05C-Hypnotics and sedatives,"Million US$, purchasing power parity",14.1
+11374,Finland,2014,3,C02-Antihypertensives,"/capita, US$ exchange rate",1.5
+11375,Finland,2014,3,N05C-Hypnotics and sedatives,Million US$ at exchange rate,17.0
+11376,Finland,2014,3,N05C-Hypnotics and sedatives,"/capita, US$ exchange rate",3.1
+11377,Finland,2014,3,N05C-Hypnotics and sedatives,% of total sales,0.6
+11378,Finland,2014,3,N-Nervous system,Million of national currency units,335.5
+11379,Finland,2014,3,N05C-Hypnotics and sedatives,"/capita, US$ purchasing power parity",2.6
+11380,Finland,2014,3,G-Genito urinary system and sex hormones,"Million US$, purchasing power parity",122.8
+11381,Finland,2014,3,C02-Antihypertensives,"Million US$, purchasing power parity",6.8
+11382,Finland,2014,3,C02-Antihypertensives,Million US$ at exchange rate,8.2
+11383,Finland,2014,3,G-Genito urinary system and sex hormones,"/capita, US$ exchange rate",27.1
+11384,Finland,2014,3,G-Genito urinary system and sex hormones,"/capita, US$ purchasing power parity",22.5
+11385,Finland,2014,3,N-Nervous system,"Million US$, purchasing power parity",369.8
+11386,Finland,2014,3,N-Nervous system,Million US$ at exchange rate,445.7
+11387,Finland,2014,3,G-Genito urinary system and sex hormones,Million US$ at exchange rate,148.0
+11388,Finland,2014,3,G-Genito urinary system and sex hormones,Million of national currency units,111.4
+11389,Finland,2014,3,N-Nervous system,% of total sales,16.0
+11390,Finland,2014,3,N-Nervous system,"/capita, US$ purchasing power parity",67.7
+11391,Finland,2014,3,N-Nervous system,"/capita, US$ exchange rate",81.6
+11392,Finland,2014,3,C07-Beta blocking agents,"/capita, US$ exchange rate",6.7
+11393,Finland,2014,3,N06A-Antidepressants,"Million US$, purchasing power parity",36.3
+11394,Finland,2014,3,N06A-Antidepressants,Million US$ at exchange rate,43.7
+11395,Finland,2014,3,N06A-Antidepressants,Million of national currency units,32.9
+11396,Finland,2014,3,N06A-Antidepressants,% of total sales,1.6
+11397,Finland,2014,3,N06A-Antidepressants,"/capita, US$ exchange rate",8.0
+11398,Finland,2014,3,N06A-Antidepressants,"/capita, US$ purchasing power parity",6.6
+11399,Finland,2014,3,A10-Drugs used in diabetes,Million of national currency units,140.0
+11400,Finland,2014,3,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ exchange rate",8.0
+11401,Finland,2014,3,A10-Drugs used in diabetes,"/capita, US$ exchange rate",34.1
+11402,Finland,2014,3,A10-Drugs used in diabetes,"Million US$, purchasing power parity",154.3
+11403,Finland,2014,3,A10-Drugs used in diabetes,Million US$ at exchange rate,186.0
+11404,Finland,2014,3,M-Musculo-skeletal system,% of total sales,4.7
+11405,Finland,2014,3,R-Respiratory system,Million of national currency units,148.8
+11406,Finland,2014,3,M-Musculo-skeletal system,"/capita, US$ purchasing power parity",20.0
+11407,Finland,2014,3,M-Musculo-skeletal system,"/capita, US$ exchange rate",24.1
+11408,Finland,2014,3,R-Respiratory system,Million US$ at exchange rate,197.7
+11409,Finland,2014,3,A10-Drugs used in diabetes,"/capita, US$ purchasing power parity",28.3
+11410,Finland,2014,3,R-Respiratory system,"/capita, US$ exchange rate",36.2
+11411,Finland,2014,3,R-Respiratory system,"Million US$, purchasing power parity",164.0
+11412,Finland,2014,3,C08-Calcium channel blockers,% of total sales,0.9
+11413,Finland,2014,3,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ purchasing power parity",6.7
+11414,Finland,2014,3,A10-Drugs used in diabetes,% of total sales,6.7
+11415,Finland,2014,3,C08-Calcium channel blockers,"/capita, US$ purchasing power parity",3.7
+11416,Finland,2014,3,R-Respiratory system,"/capita, US$ purchasing power parity",30.0
+11417,Finland,2014,3,M-Musculo-skeletal system,Million US$ at exchange rate,131.4
+11418,Finland,2014,3,M-Musculo-skeletal system,"Million US$, purchasing power parity",109.0
+11419,Finland,2014,3,M-Musculo-skeletal system,Million of national currency units,98.9
+11420,Finland,2014,3,"C01B-Antiarrhythmics, Class I and III","/capita, US$ purchasing power parity",0.7
+11421,Finland,2014,3,G03-Sex hormones and modulators of the genital system,% of total sales,2.8
+11422,Finland,2014,3,"C01B-Antiarrhythmics, Class I and III",% of total sales,0.2
+11423,Finland,2014,3,C07-Beta blocking agents,% of total sales,1.3
+11424,Finland,2014,3,C07-Beta blocking agents,"/capita, US$ purchasing power parity",5.6
+11425,Finland,2014,3,"C01B-Antiarrhythmics, Class I and III",Million of national currency units,3.6
+11426,Finland,2014,3,"C01B-Antiarrhythmics, Class I and III","Million US$, purchasing power parity",4.0
+11427,Finland,2014,3,"C01B-Antiarrhythmics, Class I and III","/capita, US$ exchange rate",0.9
+11428,Finland,2014,3,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),% of total sales,1.6
+11429,Finland,2014,3,"C01B-Antiarrhythmics, Class I and III",Million US$ at exchange rate,4.8
+11430,Finland,2014,3,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million of national currency units,33.0
+11431,Finland,2014,3,C08-Calcium channel blockers,"/capita, US$ exchange rate",4.4
+11432,Finland,2014,3,C08-Calcium channel blockers,"Million US$, purchasing power parity",20.0
+11433,Finland,2014,3,R-Respiratory system,% of total sales,7.1
+11434,Finland,2014,3,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million US$ at exchange rate,43.8
+11435,Finland,2014,3,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"Million US$, purchasing power parity",36.4
+11436,Finland,2014,3,G03-Sex hormones and modulators of the genital system,"Million US$, purchasing power parity",63.6
+11437,Finland,2014,3,G03-Sex hormones and modulators of the genital system,"/capita, US$ purchasing power parity",11.6
+11438,Finland,2014,3,G03-Sex hormones and modulators of the genital system,"/capita, US$ exchange rate",14.0
+11439,Finland,2014,3,G03-Sex hormones and modulators of the genital system,Million US$ at exchange rate,76.7
+11440,Finland,2014,3,C08-Calcium channel blockers,Million US$ at exchange rate,24.0
+11441,Finland,2014,3,C08-Calcium channel blockers,Million of national currency units,18.1
+11442,Finland,2014,3,G03-Sex hormones and modulators of the genital system,Million of national currency units,57.7
+11443,Finland,2014,3,J-Antiinfectives for systemic use,"/capita, US$ exchange rate",35.4
+11444,Finland,2014,3,J-Antiinfectives for systemic use,"Million US$, purchasing power parity",160.6
+11445,Finland,2014,3,J-Antiinfectives for systemic use,"/capita, US$ purchasing power parity",29.4
+11446,Finland,2014,3,J-Antiinfectives for systemic use,% of total sales,7.0
+11447,Finland,2014,3,J-Antiinfectives for systemic use,Million of national currency units,145.7
+11448,Finland,2014,3,J-Antiinfectives for systemic use,Million US$ at exchange rate,193.6
+11449,Finland,2014,3,A02A-Antacids,% of total sales,0.1
+11450,Finland,2014,3,C09-Agents acting on the Renin-Angiotensin system,Million of national currency units,54.5
+11451,Finland,2014,3,C09-Agents acting on the Renin-Angiotensin system,Million US$ at exchange rate,72.4
+11452,Finland,2014,3,C09-Agents acting on the Renin-Angiotensin system,"Million US$, purchasing power parity",60.1
+11453,Finland,2014,3,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ purchasing power parity",10.9
+11454,Finland,2014,3,M01A-Antiinflammatory and antirheumatic products non-steroids,% of total sales,2.6
+11455,Finland,2014,3,R03-Drugs for obstructive airway diseases,"/capita, US$ exchange rate",22.1
+11456,Finland,2014,3,R03-Drugs for obstructive airway diseases,% of total sales,4.3
+11457,Finland,2014,3,R03-Drugs for obstructive airway diseases,"/capita, US$ purchasing power parity",18.3
+11458,Finland,2014,3,R03-Drugs for obstructive airway diseases,"Million US$, purchasing power parity",100.2
+11459,Finland,2014,3,R03-Drugs for obstructive airway diseases,Million of national currency units,90.9
+11460,Finland,2014,3,M01A-Antiinflammatory and antirheumatic products non-steroids,"Million US$, purchasing power parity",59.5
+11461,Finland,2014,3,C-Cardiovascular system,% of total sales,9.1
+11462,Finland,2014,3,R03-Drugs for obstructive airway diseases,Million US$ at exchange rate,120.8
+11463,Finland,2014,3,A02A-Antacids,"/capita, US$ exchange rate",0.8
+11464,Finland,2014,3,A02A-Antacids,"Million US$, purchasing power parity",3.4
+11465,Finland,2014,3,A02A-Antacids,"/capita, US$ purchasing power parity",0.6
+11466,Finland,2014,3,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ exchange rate",13.1
+11467,Finland,2014,3,A02A-Antacids,Million US$ at exchange rate,4.1
+11468,Finland,2014,3,A02A-Antacids,Million of national currency units,3.1
+11469,Finland,2014,3,B-Blood and blood forming organs,"Million US$, purchasing power parity",178.7
+11470,Finland,2014,3,B-Blood and blood forming organs,"/capita, US$ purchasing power parity",32.7
+11471,Finland,2014,3,B-Blood and blood forming organs,"/capita, US$ exchange rate",39.4
+11472,Finland,2014,3,N05B-Anxiolytics,Million US$ at exchange rate,10.5
+11473,Finland,2014,3,N05B-Anxiolytics,Million of national currency units,7.9
+11474,Finland,2014,3,N02-Analgesics,% of total sales,3.4
+11475,Finland,2014,3,B-Blood and blood forming organs,Million US$ at exchange rate,215.4
+11476,Finland,2014,3,Total pharmaceutical sales,"Million US$, purchasing power parity",2307.6
+11477,Finland,2014,3,Total pharmaceutical sales,Million US$ at exchange rate,2781.2
+11478,Finland,2014,3,Total pharmaceutical sales,Million of national currency units,2093.5
+11479,Finland,2014,3,B-Blood and blood forming organs,% of total sales,7.7
+11480,Finland,2014,3,Total pharmaceutical sales,"/capita, US$ exchange rate",509.2
+11481,Finland,2014,3,Total pharmaceutical sales,"/capita, US$ purchasing power parity",422.5
+11482,Finland,2014,3,C03-Diuretics,"/capita, US$ purchasing power parity",1.7
+11483,Finland,2014,3,C03-Diuretics,% of total sales,0.4
+11484,Finland,2014,3,C03-Diuretics,"/capita, US$ exchange rate",2.1
+11485,Finland,2014,3,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ purchasing power parity",11.0
+11486,Finland,2014,3,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ exchange rate",13.3
+11487,Finland,2014,3,C09-Agents acting on the Renin-Angiotensin system,% of total sales,2.6
+11488,Finland,2014,3,C03-Diuretics,"Million US$, purchasing power parity",9.4
+11489,Finland,2014,3,N05B-Anxiolytics,"/capita, US$ purchasing power parity",1.6
+11490,Finland,2014,3,N05B-Anxiolytics,"Million US$, purchasing power parity",8.7
+11491,Finland,2014,3,N05B-Anxiolytics,"/capita, US$ exchange rate",1.9
+11492,Finland,2014,3,N05B-Anxiolytics,% of total sales,0.4
+11493,Finland,2014,3,C03-Diuretics,Million US$ at exchange rate,11.3
+11494,Finland,2014,3,C03-Diuretics,Million of national currency units,8.5
+11495,Finland,2014,3,B-Blood and blood forming organs,Million of national currency units,162.1
+11496,Finland,2014,3,N02-Analgesics,"/capita, US$ exchange rate",17.1
+11497,Finland,2014,3,N02-Analgesics,Million US$ at exchange rate,93.5
+11498,Finland,2014,3,N02-Analgesics,"Million US$, purchasing power parity",77.6
+11499,Finland,2014,3,C10-Lipid modifying agents,Million of national currency units,49.1
+11500,Finland,2014,3,C10-Lipid modifying agents,Million US$ at exchange rate,65.2
+11501,Finland,2014,3,N05C-Hypnotics and sedatives,Million of national currency units,12.8
+11502,Finland,2014,3,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million US$ at exchange rate,54.5
+11503,Finland,2014,3,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million of national currency units,41.0
+11504,Finland,2014,3,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ exchange rate",10.0
+11505,Finland,2014,3,J01-Antibacterials for systemic use,"Million US$, purchasing power parity",55.4
+11506,Finland,2014,3,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ purchasing power parity",8.3
+11507,Finland,2014,3,"H-Systemic hormonal preparations, excluding sex hormones and insulins",% of total sales,2.0
+11508,Finland,2014,3,J01-Antibacterials for systemic use,Million US$ at exchange rate,66.8
+11509,Finland,2014,3,J01-Antibacterials for systemic use,Million of national currency units,50.3
+11510,Finland,2014,3,N02-Analgesics,Million of national currency units,70.4
+11511,Finland,2014,3,J01-Antibacterials for systemic use,"/capita, US$ purchasing power parity",10.2
+11512,Finland,2014,3,J01-Antibacterials for systemic use,"/capita, US$ exchange rate",12.2
+11513,Finland,2014,3,"H-Systemic hormonal preparations, excluding sex hormones and insulins","Million US$, purchasing power parity",45.2
+11514,Finland,2014,3,J01-Antibacterials for systemic use,% of total sales,2.4
+11515,Finland,2014,3,C10-Lipid modifying agents,"/capita, US$ exchange rate",11.9
+11516,Finland,2014,3,C-Cardiovascular system,"/capita, US$ exchange rate",46.4
+11517,Finland,2014,3,C-Cardiovascular system,"/capita, US$ purchasing power parity",38.5
+11518,Finland,2014,3,C02-Antihypertensives,% of total sales,0.3
+11519,Finland,2014,3,C02-Antihypertensives,"/capita, US$ purchasing power parity",1.3
+11520,Finland,2014,3,C10-Lipid modifying agents,"/capita, US$ purchasing power parity",9.9
+11521,Finland,2014,3,C10-Lipid modifying agents,% of total sales,2.3
+11522,Finland,2014,3,C10-Lipid modifying agents,"Million US$, purchasing power parity",54.1
+11523,Finland,2014,3,C-Cardiovascular system,Million of national currency units,190.9
+11524,Finland,2014,3,M01A-Antiinflammatory and antirheumatic products non-steroids,Million US$ at exchange rate,71.7
+11525,Finland,2014,3,M01A-Antiinflammatory and antirheumatic products non-steroids,Million of national currency units,54.0
+11526,Finland,2014,3,C-Cardiovascular system,Million US$ at exchange rate,253.6
+11527,Finland,2014,3,C-Cardiovascular system,"Million US$, purchasing power parity",210.4
+11528,Finland,2014,3,N02-Analgesics,"/capita, US$ purchasing power parity",14.2
+11529,Finland,2013,4,C01A-Cardiac glycosides,% of total sales,0.0
+11530,Finland,2013,4,C07-Beta blocking agents,Million of national currency units,27.1
+11531,Finland,2013,4,C07-Beta blocking agents,"Million US$, purchasing power parity",29.9
+11532,Finland,2013,4,C07-Beta blocking agents,Million US$ at exchange rate,36.0
+11533,Finland,2013,4,C01A-Cardiac glycosides,"/capita, US$ purchasing power parity",0.1
+11534,Finland,2013,4,C01A-Cardiac glycosides,Million of national currency units,0.6
+11535,Finland,2013,4,C02-Antihypertensives,Million of national currency units,5.7
+11536,Finland,2013,4,C01A-Cardiac glycosides,Million US$ at exchange rate,0.8
+11537,Finland,2013,4,C01A-Cardiac glycosides,"/capita, US$ exchange rate",0.1
+11538,Finland,2013,4,C01A-Cardiac glycosides,"Million US$, purchasing power parity",0.7
+11539,Finland,2013,4,A-Alimentary tract and metabolism,"/capita, US$ purchasing power parity",53.8
+11540,Finland,2013,4,A-Alimentary tract and metabolism,% of total sales,13.2
+11541,Finland,2013,4,A-Alimentary tract and metabolism,"/capita, US$ exchange rate",64.7
+11542,Finland,2013,4,A-Alimentary tract and metabolism,Million US$ at exchange rate,352.0
+11543,Finland,2013,4,A-Alimentary tract and metabolism,"Million US$, purchasing power parity",292.7
+11544,Finland,2013,4,N05C-Hypnotics and sedatives,"Million US$, purchasing power parity",13.9
+11545,Finland,2013,4,N05C-Hypnotics and sedatives,"/capita, US$ exchange rate",3.1
+11546,Finland,2013,4,C02-Antihypertensives,"/capita, US$ exchange rate",1.4
+11547,Finland,2013,4,N05C-Hypnotics and sedatives,Million US$ at exchange rate,16.7
+11548,Finland,2013,4,N05C-Hypnotics and sedatives,% of total sales,0.6
+11549,Finland,2013,4,N-Nervous system,Million of national currency units,341.2
+11550,Finland,2013,4,N05C-Hypnotics and sedatives,"/capita, US$ purchasing power parity",2.6
+11551,Finland,2013,4,A-Alimentary tract and metabolism,Million of national currency units,265.0
+11552,Finland,2013,4,G-Genito urinary system and sex hormones,"Million US$, purchasing power parity",120.3
+11553,Finland,2013,4,C02-Antihypertensives,"Million US$, purchasing power parity",6.3
+11554,Finland,2013,4,C02-Antihypertensives,Million US$ at exchange rate,7.6
+11555,Finland,2013,4,G-Genito urinary system and sex hormones,% of total sales,5.4
+11556,Finland,2013,4,G-Genito urinary system and sex hormones,"/capita, US$ exchange rate",26.6
+11557,Finland,2013,4,G-Genito urinary system and sex hormones,"/capita, US$ purchasing power parity",22.1
+11558,Finland,2013,4,N-Nervous system,"Million US$, purchasing power parity",376.9
+11559,Finland,2013,4,N-Nervous system,Million US$ at exchange rate,453.2
+11560,Finland,2013,4,G-Genito urinary system and sex hormones,Million of national currency units,108.9
+11561,Finland,2013,4,G-Genito urinary system and sex hormones,Million US$ at exchange rate,144.6
+11562,Finland,2013,4,N-Nervous system,% of total sales,17.0
+11563,Finland,2013,4,N-Nervous system,"/capita, US$ exchange rate",83.3
+11564,Finland,2013,4,N-Nervous system,"/capita, US$ purchasing power parity",69.3
+11565,Finland,2013,4,N06A-Antidepressants,"Million US$, purchasing power parity",34.0
+11566,Finland,2013,4,N06A-Antidepressants,Million of national currency units,30.8
+11567,Finland,2013,4,N06A-Antidepressants,Million US$ at exchange rate,40.9
+11568,Finland,2013,4,N06A-Antidepressants,% of total sales,1.5
+11569,Finland,2013,4,N06A-Antidepressants,"/capita, US$ exchange rate",7.5
+11570,Finland,2013,4,N06A-Antidepressants,"/capita, US$ purchasing power parity",6.3
+11571,Finland,2013,4,C08-Calcium channel blockers,"/capita, US$ purchasing power parity",3.4
+11572,Finland,2013,4,A10-Drugs used in diabetes,Million of national currency units,131.0
+11573,Finland,2013,4,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ exchange rate",7.8
+11574,Finland,2013,4,A10-Drugs used in diabetes,"/capita, US$ exchange rate",32.0
+11575,Finland,2013,4,A10-Drugs used in diabetes,Million US$ at exchange rate,174.0
+11576,Finland,2013,4,A10-Drugs used in diabetes,"Million US$, purchasing power parity",144.7
+11577,Finland,2013,4,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),% of total sales,1.6
+11578,Finland,2013,4,M-Musculo-skeletal system,% of total sales,4.8
+11579,Finland,2013,4,R-Respiratory system,Million of national currency units,146.3
+11580,Finland,2013,4,R-Respiratory system,Million US$ at exchange rate,194.3
+11581,Finland,2013,4,M-Musculo-skeletal system,"/capita, US$ exchange rate",23.6
+11582,Finland,2013,4,M-Musculo-skeletal system,"/capita, US$ purchasing power parity",19.6
+11583,Finland,2013,4,A10-Drugs used in diabetes,"/capita, US$ purchasing power parity",26.6
+11584,Finland,2013,4,R-Respiratory system,"/capita, US$ exchange rate",35.7
+11585,Finland,2013,4,R-Respiratory system,"Million US$, purchasing power parity",161.6
+11586,Finland,2013,4,C08-Calcium channel blockers,% of total sales,0.8
+11587,Finland,2013,4,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ purchasing power parity",6.5
+11588,Finland,2013,4,A10-Drugs used in diabetes,% of total sales,6.5
+11589,Finland,2013,4,R-Respiratory system,"/capita, US$ purchasing power parity",29.7
+11590,Finland,2013,4,M-Musculo-skeletal system,"Million US$, purchasing power parity",106.8
+11591,Finland,2013,4,M-Musculo-skeletal system,Million US$ at exchange rate,128.4
+11592,Finland,2013,4,M-Musculo-skeletal system,Million of national currency units,96.7
+11593,Finland,2013,4,G03-Sex hormones and modulators of the genital system,% of total sales,2.8
+11594,Finland,2013,4,"C01B-Antiarrhythmics, Class I and III","/capita, US$ purchasing power parity",0.8
+11595,Finland,2013,4,"C01B-Antiarrhythmics, Class I and III",% of total sales,0.2
+11596,Finland,2013,4,C07-Beta blocking agents,% of total sales,1.3
+11597,Finland,2013,4,"C01B-Antiarrhythmics, Class I and III",Million of national currency units,3.7
+11598,Finland,2013,4,C07-Beta blocking agents,"/capita, US$ purchasing power parity",5.5
+11599,Finland,2013,4,"C01B-Antiarrhythmics, Class I and III","Million US$, purchasing power parity",4.1
+11600,Finland,2013,4,"C01B-Antiarrhythmics, Class I and III","/capita, US$ exchange rate",0.9
+11601,Finland,2013,4,"C01B-Antiarrhythmics, Class I and III",Million US$ at exchange rate,4.9
+11602,Finland,2013,4,C07-Beta blocking agents,"/capita, US$ exchange rate",6.6
+11603,Finland,2013,4,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million of national currency units,32.0
+11604,Finland,2013,4,C08-Calcium channel blockers,"Million US$, purchasing power parity",18.7
+11605,Finland,2013,4,C08-Calcium channel blockers,"/capita, US$ exchange rate",4.1
+11606,Finland,2013,4,R-Respiratory system,% of total sales,7.3
+11607,Finland,2013,4,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million US$ at exchange rate,42.5
+11608,Finland,2013,4,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"Million US$, purchasing power parity",35.3
+11609,Finland,2013,4,G03-Sex hormones and modulators of the genital system,"Million US$, purchasing power parity",62.8
+11610,Finland,2013,4,G03-Sex hormones and modulators of the genital system,"/capita, US$ purchasing power parity",11.6
+11611,Finland,2013,4,G03-Sex hormones and modulators of the genital system,"/capita, US$ exchange rate",13.9
+11612,Finland,2013,4,G03-Sex hormones and modulators of the genital system,Million US$ at exchange rate,75.6
+11613,Finland,2013,4,C08-Calcium channel blockers,Million US$ at exchange rate,22.4
+11614,Finland,2013,4,C08-Calcium channel blockers,Million of national currency units,16.9
+11615,Finland,2013,4,G03-Sex hormones and modulators of the genital system,Million of national currency units,56.9
+11616,Finland,2013,4,J-Antiinfectives for systemic use,"/capita, US$ exchange rate",35.2
+11617,Finland,2013,4,J-Antiinfectives for systemic use,% of total sales,7.2
+11618,Finland,2013,4,J-Antiinfectives for systemic use,"/capita, US$ purchasing power parity",29.3
+11619,Finland,2013,4,J-Antiinfectives for systemic use,"Million US$, purchasing power parity",159.2
+11620,Finland,2013,4,J-Antiinfectives for systemic use,Million of national currency units,144.1
+11621,Finland,2013,4,J-Antiinfectives for systemic use,Million US$ at exchange rate,191.4
+11622,Finland,2013,4,C09-Agents acting on the Renin-Angiotensin system,Million US$ at exchange rate,75.8
+11623,Finland,2013,4,C09-Agents acting on the Renin-Angiotensin system,Million of national currency units,57.1
+11624,Finland,2013,4,C09-Agents acting on the Renin-Angiotensin system,"Million US$, purchasing power parity",63.1
+11625,Finland,2013,4,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ purchasing power parity",10.9
+11626,Finland,2013,4,M01A-Antiinflammatory and antirheumatic products non-steroids,% of total sales,2.7
+11627,Finland,2013,4,A02A-Antacids,% of total sales,0.1
+11628,Finland,2013,4,R03-Drugs for obstructive airway diseases,"/capita, US$ exchange rate",22.6
+11629,Finland,2013,4,R03-Drugs for obstructive airway diseases,% of total sales,4.6
+11630,Finland,2013,4,R03-Drugs for obstructive airway diseases,"/capita, US$ purchasing power parity",18.8
+11631,Finland,2013,4,R03-Drugs for obstructive airway diseases,Million of national currency units,92.4
+11632,Finland,2013,4,M01A-Antiinflammatory and antirheumatic products non-steroids,"Million US$, purchasing power parity",59.5
+11633,Finland,2013,4,C-Cardiovascular system,% of total sales,9.0
+11634,Finland,2013,4,R03-Drugs for obstructive airway diseases,"Million US$, purchasing power parity",102.1
+11635,Finland,2013,4,R03-Drugs for obstructive airway diseases,Million US$ at exchange rate,122.7
+11636,Finland,2013,4,A02A-Antacids,"/capita, US$ exchange rate",0.7
+11637,Finland,2013,4,A02A-Antacids,"Million US$, purchasing power parity",3.3
+11638,Finland,2013,4,A02A-Antacids,"/capita, US$ purchasing power parity",0.6
+11639,Finland,2013,4,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ exchange rate",13.2
+11640,Finland,2013,4,A02A-Antacids,Million of national currency units,3.0
+11641,Finland,2013,4,A02A-Antacids,Million US$ at exchange rate,4.0
+11642,Finland,2013,4,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ exchange rate",13.9
+11643,Finland,2013,4,B-Blood and blood forming organs,"Million US$, purchasing power parity",172.5
+11644,Finland,2013,4,B-Blood and blood forming organs,"/capita, US$ purchasing power parity",31.7
+11645,Finland,2013,4,B-Blood and blood forming organs,"/capita, US$ exchange rate",38.1
+11646,Finland,2013,4,N05B-Anxiolytics,Million US$ at exchange rate,10.5
+11647,Finland,2013,4,N05B-Anxiolytics,Million of national currency units,7.9
+11648,Finland,2013,4,N02-Analgesics,% of total sales,3.5
+11649,Finland,2013,4,Total pharmaceutical sales,"Million US$, purchasing power parity",2223.1
+11650,Finland,2013,4,Total pharmaceutical sales,Million of national currency units,2012.7
+11651,Finland,2013,4,Total pharmaceutical sales,Million US$ at exchange rate,2673.1
+11652,Finland,2013,4,B-Blood and blood forming organs,% of total sales,7.8
+11653,Finland,2013,4,Total pharmaceutical sales,"/capita, US$ exchange rate",491.5
+11654,Finland,2013,4,Total pharmaceutical sales,"/capita, US$ purchasing power parity",408.7
+11655,Finland,2013,4,C03-Diuretics,"/capita, US$ purchasing power parity",1.7
+11656,Finland,2013,4,C03-Diuretics,% of total sales,0.4
+11657,Finland,2013,4,C03-Diuretics,"/capita, US$ exchange rate",2.0
+11658,Finland,2013,4,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ purchasing power parity",11.6
+11659,Finland,2013,4,C09-Agents acting on the Renin-Angiotensin system,% of total sales,2.8
+11660,Finland,2013,4,C03-Diuretics,"Million US$, purchasing power parity",9.2
+11661,Finland,2013,4,N05B-Anxiolytics,"/capita, US$ purchasing power parity",1.6
+11662,Finland,2013,4,N05B-Anxiolytics,"Million US$, purchasing power parity",8.7
+11663,Finland,2013,4,N05B-Anxiolytics,"/capita, US$ exchange rate",1.9
+11664,Finland,2013,4,N05B-Anxiolytics,% of total sales,0.4
+11665,Finland,2013,4,C03-Diuretics,Million US$ at exchange rate,11.0
+11666,Finland,2013,4,C03-Diuretics,Million of national currency units,8.3
+11667,Finland,2013,4,N02-Analgesics,"/capita, US$ exchange rate",17.0
+11668,Finland,2013,4,B-Blood and blood forming organs,Million of national currency units,156.2
+11669,Finland,2013,4,B-Blood and blood forming organs,Million US$ at exchange rate,207.5
+11670,Finland,2013,4,N02-Analgesics,Million US$ at exchange rate,92.6
+11671,Finland,2013,4,N02-Analgesics,"Million US$, purchasing power parity",77.0
+11672,Finland,2013,4,C10-Lipid modifying agents,Million of national currency units,41.9
+11673,Finland,2013,4,C10-Lipid modifying agents,Million US$ at exchange rate,55.6
+11674,Finland,2013,4,N05C-Hypnotics and sedatives,Million of national currency units,12.6
+11675,Finland,2013,4,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million US$ at exchange rate,51.9
+11676,Finland,2013,4,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million of national currency units,39.1
+11677,Finland,2013,4,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ exchange rate",9.5
+11678,Finland,2013,4,J01-Antibacterials for systemic use,"Million US$, purchasing power parity",59.4
+11679,Finland,2013,4,"H-Systemic hormonal preparations, excluding sex hormones and insulins",% of total sales,1.9
+11680,Finland,2013,4,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ purchasing power parity",7.9
+11681,Finland,2013,4,J01-Antibacterials for systemic use,Million US$ at exchange rate,71.5
+11682,Finland,2013,4,J01-Antibacterials for systemic use,Million of national currency units,53.8
+11683,Finland,2013,4,N02-Analgesics,Million of national currency units,69.7
+11684,Finland,2013,4,J01-Antibacterials for systemic use,"/capita, US$ exchange rate",13.1
+11685,Finland,2013,4,"H-Systemic hormonal preparations, excluding sex hormones and insulins","Million US$, purchasing power parity",43.2
+11686,Finland,2013,4,J01-Antibacterials for systemic use,"/capita, US$ purchasing power parity",10.9
+11687,Finland,2013,4,J01-Antibacterials for systemic use,% of total sales,2.7
+11688,Finland,2013,4,C10-Lipid modifying agents,"/capita, US$ exchange rate",10.2
+11689,Finland,2013,4,C-Cardiovascular system,"/capita, US$ exchange rate",44.4
+11690,Finland,2013,4,C-Cardiovascular system,"/capita, US$ purchasing power parity",36.9
+11691,Finland,2013,4,C02-Antihypertensives,% of total sales,0.3
+11692,Finland,2013,4,C02-Antihypertensives,"/capita, US$ purchasing power parity",1.2
+11693,Finland,2013,4,C10-Lipid modifying agents,"/capita, US$ purchasing power parity",8.5
+11694,Finland,2013,4,C10-Lipid modifying agents,% of total sales,2.1
+11695,Finland,2013,4,M01A-Antiinflammatory and antirheumatic products non-steroids,Million US$ at exchange rate,71.6
+11696,Finland,2013,4,C-Cardiovascular system,Million of national currency units,181.9
+11697,Finland,2013,4,C10-Lipid modifying agents,"Million US$, purchasing power parity",46.3
+11698,Finland,2013,4,M01A-Antiinflammatory and antirheumatic products non-steroids,Million of national currency units,53.9
+11699,Finland,2013,4,C-Cardiovascular system,"Million US$, purchasing power parity",200.9
+11700,Finland,2013,4,C-Cardiovascular system,Million US$ at exchange rate,241.6
+11701,Finland,2013,4,N02-Analgesics,"/capita, US$ purchasing power parity",14.2
+11702,Finland,2012,4,C01A-Cardiac glycosides,% of total sales,0.0
+11703,Finland,2012,4,C07-Beta blocking agents,"Million US$, purchasing power parity",28.8
+11704,Finland,2012,4,C07-Beta blocking agents,Million US$ at exchange rate,33.7
+11705,Finland,2012,4,C07-Beta blocking agents,Million of national currency units,26.2
+11706,Finland,2012,4,C01A-Cardiac glycosides,"/capita, US$ purchasing power parity",0.1
+11707,Finland,2012,4,C01A-Cardiac glycosides,Million of national currency units,0.4
+11708,Finland,2012,4,C02-Antihypertensives,Million of national currency units,5.4
+11709,Finland,2012,4,C01A-Cardiac glycosides,Million US$ at exchange rate,0.5
+11710,Finland,2012,4,C01A-Cardiac glycosides,"/capita, US$ exchange rate",0.1
+11711,Finland,2012,4,C01A-Cardiac glycosides,"Million US$, purchasing power parity",0.4
+11712,Finland,2012,4,A-Alimentary tract and metabolism,"/capita, US$ purchasing power parity",51.8
+11713,Finland,2012,4,A-Alimentary tract and metabolism,% of total sales,13.0
+11714,Finland,2012,4,A-Alimentary tract and metabolism,Million US$ at exchange rate,327.2
+11715,Finland,2012,4,A-Alimentary tract and metabolism,"/capita, US$ exchange rate",60.4
+11716,Finland,2012,4,A-Alimentary tract and metabolism,"Million US$, purchasing power parity",280.4
+11717,Finland,2012,4,N05C-Hypnotics and sedatives,"Million US$, purchasing power parity",13.4
+11718,Finland,2012,4,N05C-Hypnotics and sedatives,"/capita, US$ exchange rate",2.9
+11719,Finland,2012,4,C02-Antihypertensives,"/capita, US$ exchange rate",1.3
+11720,Finland,2012,4,N05C-Hypnotics and sedatives,Million US$ at exchange rate,15.7
+11721,Finland,2012,4,N05C-Hypnotics and sedatives,% of total sales,0.6
+11722,Finland,2012,4,N-Nervous system,Million of national currency units,350.6
+11723,Finland,2012,4,N05C-Hypnotics and sedatives,"/capita, US$ purchasing power parity",2.5
+11724,Finland,2012,4,A-Alimentary tract and metabolism,Million of national currency units,254.7
+11725,Finland,2012,4,G-Genito urinary system and sex hormones,"Million US$, purchasing power parity",115.7
+11726,Finland,2012,4,C02-Antihypertensives,Million US$ at exchange rate,6.9
+11727,Finland,2012,4,C02-Antihypertensives,"Million US$, purchasing power parity",5.9
+11728,Finland,2012,4,G-Genito urinary system and sex hormones,% of total sales,5.3
+11729,Finland,2012,4,G-Genito urinary system and sex hormones,"/capita, US$ exchange rate",24.9
+11730,Finland,2012,4,G-Genito urinary system and sex hormones,"/capita, US$ purchasing power parity",21.4
+11731,Finland,2012,4,N-Nervous system,"Million US$, purchasing power parity",385.9
+11732,Finland,2012,4,G-Genito urinary system and sex hormones,Million of national currency units,105.1
+11733,Finland,2012,4,G-Genito urinary system and sex hormones,Million US$ at exchange rate,135.0
+11734,Finland,2012,4,N-Nervous system,Million US$ at exchange rate,450.4
+11735,Finland,2012,4,N-Nervous system,% of total sales,17.8
+11736,Finland,2012,4,N-Nervous system,"/capita, US$ exchange rate",83.2
+11737,Finland,2012,4,N-Nervous system,"/capita, US$ purchasing power parity",71.3
+11738,Finland,2012,4,C07-Beta blocking agents,"/capita, US$ exchange rate",6.2
+11739,Finland,2012,4,N06A-Antidepressants,"Million US$, purchasing power parity",32.5
+11740,Finland,2012,4,N06A-Antidepressants,Million of national currency units,29.5
+11741,Finland,2012,4,N06A-Antidepressants,Million US$ at exchange rate,37.9
+11742,Finland,2012,4,N06A-Antidepressants,"/capita, US$ exchange rate",7.0
+11743,Finland,2012,4,N06A-Antidepressants,% of total sales,1.5
+11744,Finland,2012,4,N06A-Antidepressants,"/capita, US$ purchasing power parity",6.0
+11745,Finland,2012,4,C08-Calcium channel blockers,"/capita, US$ purchasing power parity",3.1
+11746,Finland,2012,4,A10-Drugs used in diabetes,Million of national currency units,127.2
+11747,Finland,2012,4,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ exchange rate",7.3
+11748,Finland,2012,4,A10-Drugs used in diabetes,"/capita, US$ exchange rate",30.2
+11749,Finland,2012,4,A10-Drugs used in diabetes,"Million US$, purchasing power parity",140.0
+11750,Finland,2012,4,A10-Drugs used in diabetes,Million US$ at exchange rate,163.4
+11751,Finland,2012,4,R-Respiratory system,Million of national currency units,154.4
+11752,Finland,2012,4,M-Musculo-skeletal system,% of total sales,4.9
+11753,Finland,2012,4,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),% of total sales,1.6
+11754,Finland,2012,4,R-Respiratory system,Million US$ at exchange rate,198.4
+11755,Finland,2012,4,M-Musculo-skeletal system,"/capita, US$ exchange rate",22.8
+11756,Finland,2012,4,M-Musculo-skeletal system,"/capita, US$ purchasing power parity",19.5
+11757,Finland,2012,4,A10-Drugs used in diabetes,"/capita, US$ purchasing power parity",25.9
+11758,Finland,2012,4,R-Respiratory system,"Million US$, purchasing power parity",170.0
+11759,Finland,2012,4,R-Respiratory system,"/capita, US$ exchange rate",36.6
+11760,Finland,2012,4,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ purchasing power parity",6.2
+11761,Finland,2012,4,C08-Calcium channel blockers,% of total sales,0.8
+11762,Finland,2012,4,A10-Drugs used in diabetes,% of total sales,6.5
+11763,Finland,2012,4,R-Respiratory system,"/capita, US$ purchasing power parity",31.4
+11764,Finland,2012,4,M-Musculo-skeletal system,"Million US$, purchasing power parity",105.8
+11765,Finland,2012,4,M-Musculo-skeletal system,Million US$ at exchange rate,123.5
+11766,Finland,2012,4,M-Musculo-skeletal system,Million of national currency units,96.1
+11767,Finland,2012,4,"C01B-Antiarrhythmics, Class I and III","/capita, US$ purchasing power parity",0.8
+11768,Finland,2012,4,G03-Sex hormones and modulators of the genital system,% of total sales,2.8
+11769,Finland,2012,4,"C01B-Antiarrhythmics, Class I and III",% of total sales,0.2
+11770,Finland,2012,4,C07-Beta blocking agents,% of total sales,1.3
+11771,Finland,2012,4,"C01B-Antiarrhythmics, Class I and III",Million of national currency units,3.8
+11772,Finland,2012,4,C07-Beta blocking agents,"/capita, US$ purchasing power parity",5.3
+11773,Finland,2012,4,"C01B-Antiarrhythmics, Class I and III","Million US$, purchasing power parity",4.2
+11774,Finland,2012,4,"C01B-Antiarrhythmics, Class I and III","/capita, US$ exchange rate",0.9
+11775,Finland,2012,4,"C01B-Antiarrhythmics, Class I and III",Million US$ at exchange rate,4.9
+11776,Finland,2012,4,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million of national currency units,30.7
+11777,Finland,2012,4,C08-Calcium channel blockers,"Million US$, purchasing power parity",16.8
+11778,Finland,2012,4,C08-Calcium channel blockers,"/capita, US$ exchange rate",3.6
+11779,Finland,2012,4,R-Respiratory system,% of total sales,7.9
+11780,Finland,2012,4,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million US$ at exchange rate,39.4
+11781,Finland,2012,4,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"Million US$, purchasing power parity",33.8
+11782,Finland,2012,4,G03-Sex hormones and modulators of the genital system,"Million US$, purchasing power parity",61.2
+11783,Finland,2012,4,G03-Sex hormones and modulators of the genital system,"/capita, US$ purchasing power parity",11.3
+11784,Finland,2012,4,G03-Sex hormones and modulators of the genital system,"/capita, US$ exchange rate",13.2
+11785,Finland,2012,4,C08-Calcium channel blockers,Million US$ at exchange rate,19.7
+11786,Finland,2012,4,C08-Calcium channel blockers,Million of national currency units,15.3
+11787,Finland,2012,4,G03-Sex hormones and modulators of the genital system,Million US$ at exchange rate,71.4
+11788,Finland,2012,4,G03-Sex hormones and modulators of the genital system,Million of national currency units,55.6
+11789,Finland,2012,4,J-Antiinfectives for systemic use,"/capita, US$ exchange rate",33.4
+11790,Finland,2012,4,J-Antiinfectives for systemic use,% of total sales,7.2
+11791,Finland,2012,4,J-Antiinfectives for systemic use,"/capita, US$ purchasing power parity",28.6
+11792,Finland,2012,4,J-Antiinfectives for systemic use,Million of national currency units,140.8
+11793,Finland,2012,4,J-Antiinfectives for systemic use,"Million US$, purchasing power parity",155.0
+11794,Finland,2012,4,J-Antiinfectives for systemic use,Million US$ at exchange rate,180.9
+11795,Finland,2012,4,C09-Agents acting on the Renin-Angiotensin system,Million US$ at exchange rate,80.9
+11796,Finland,2012,4,C09-Agents acting on the Renin-Angiotensin system,Million of national currency units,63.0
+11797,Finland,2012,4,C09-Agents acting on the Renin-Angiotensin system,"Million US$, purchasing power parity",69.3
+11798,Finland,2012,4,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ purchasing power parity",11.3
+11799,Finland,2012,4,M01A-Antiinflammatory and antirheumatic products non-steroids,% of total sales,2.8
+11800,Finland,2012,4,A02A-Antacids,% of total sales,0.2
+11801,Finland,2012,4,R03-Drugs for obstructive airway diseases,"/capita, US$ exchange rate",22.8
+11802,Finland,2012,4,R03-Drugs for obstructive airway diseases,"/capita, US$ purchasing power parity",19.5
+11803,Finland,2012,4,R03-Drugs for obstructive airway diseases,% of total sales,4.9
+11804,Finland,2012,4,R03-Drugs for obstructive airway diseases,Million of national currency units,95.9
+11805,Finland,2012,4,M01A-Antiinflammatory and antirheumatic products non-steroids,"Million US$, purchasing power parity",61.2
+11806,Finland,2012,4,C-Cardiovascular system,% of total sales,9.0
+11807,Finland,2012,4,R03-Drugs for obstructive airway diseases,"Million US$, purchasing power parity",105.6
+11808,Finland,2012,4,R03-Drugs for obstructive airway diseases,Million US$ at exchange rate,123.2
+11809,Finland,2012,4,A02A-Antacids,"/capita, US$ exchange rate",0.7
+11810,Finland,2012,4,A02A-Antacids,"Million US$, purchasing power parity",3.3
+11811,Finland,2012,4,A02A-Antacids,"/capita, US$ purchasing power parity",0.6
+11812,Finland,2012,4,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ exchange rate",13.2
+11813,Finland,2012,4,A02A-Antacids,Million of national currency units,3.0
+11814,Finland,2012,4,A02A-Antacids,Million US$ at exchange rate,3.9
+11815,Finland,2012,4,B-Blood and blood forming organs,"Million US$, purchasing power parity",167.7
+11816,Finland,2012,4,B-Blood and blood forming organs,"/capita, US$ purchasing power parity",31.0
+11817,Finland,2012,4,B-Blood and blood forming organs,"/capita, US$ exchange rate",36.2
+11818,Finland,2012,4,N05B-Anxiolytics,Million US$ at exchange rate,10.4
+11819,Finland,2012,4,N05B-Anxiolytics,Million of national currency units,8.1
+11820,Finland,2012,4,N02-Analgesics,% of total sales,3.6
+11821,Finland,2012,4,Total pharmaceutical sales,"Million US$, purchasing power parity",2162.7
+11822,Finland,2012,4,Total pharmaceutical sales,Million of national currency units,1964.8
+11823,Finland,2012,4,Total pharmaceutical sales,Million US$ at exchange rate,2524.4
+11824,Finland,2012,4,Total pharmaceutical sales,"/capita, US$ exchange rate",466.3
+11825,Finland,2012,4,B-Blood and blood forming organs,% of total sales,7.8
+11826,Finland,2012,4,Total pharmaceutical sales,"/capita, US$ purchasing power parity",399.5
+11827,Finland,2012,4,C03-Diuretics,"/capita, US$ purchasing power parity",1.7
+11828,Finland,2012,4,C03-Diuretics,% of total sales,0.4
+11829,Finland,2012,4,C03-Diuretics,"/capita, US$ exchange rate",1.9
+11830,Finland,2012,4,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ purchasing power parity",12.8
+11831,Finland,2012,4,C09-Agents acting on the Renin-Angiotensin system,% of total sales,3.2
+11832,Finland,2012,4,C03-Diuretics,"Million US$, purchasing power parity",9.0
+11833,Finland,2012,4,N05B-Anxiolytics,"/capita, US$ purchasing power parity",1.6
+11834,Finland,2012,4,N05B-Anxiolytics,"Million US$, purchasing power parity",8.9
+11835,Finland,2012,4,N05B-Anxiolytics,"/capita, US$ exchange rate",1.9
+11836,Finland,2012,4,N05B-Anxiolytics,% of total sales,0.4
+11837,Finland,2012,4,C03-Diuretics,Million US$ at exchange rate,10.5
+11838,Finland,2012,4,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ exchange rate",15.0
+11839,Finland,2012,4,C03-Diuretics,Million of national currency units,8.2
+11840,Finland,2012,4,N02-Analgesics,"/capita, US$ exchange rate",16.8
+11841,Finland,2012,4,B-Blood and blood forming organs,Million of national currency units,152.4
+11842,Finland,2012,4,B-Blood and blood forming organs,Million US$ at exchange rate,195.8
+11843,Finland,2012,4,N02-Analgesics,Million US$ at exchange rate,91.0
+11844,Finland,2012,4,N02-Analgesics,"Million US$, purchasing power parity",77.9
+11845,Finland,2012,4,C10-Lipid modifying agents,Million of national currency units,35.2
+11846,Finland,2012,4,C10-Lipid modifying agents,Million US$ at exchange rate,45.2
+11847,Finland,2012,4,C10-Lipid modifying agents,"Million US$, purchasing power parity",38.7
+11848,Finland,2012,4,N05C-Hypnotics and sedatives,Million of national currency units,12.2
+11849,Finland,2012,4,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million US$ at exchange rate,54.9
+11850,Finland,2012,4,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million of national currency units,42.7
+11851,Finland,2012,4,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ exchange rate",10.1
+11852,Finland,2012,4,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ purchasing power parity",8.7
+11853,Finland,2012,4,"H-Systemic hormonal preparations, excluding sex hormones and insulins",% of total sales,2.2
+11854,Finland,2012,4,J01-Antibacterials for systemic use,"Million US$, purchasing power parity",60.5
+11855,Finland,2012,4,J01-Antibacterials for systemic use,Million US$ at exchange rate,70.7
+11856,Finland,2012,4,J01-Antibacterials for systemic use,Million of national currency units,55.0
+11857,Finland,2012,4,N02-Analgesics,Million of national currency units,70.8
+11858,Finland,2012,4,J01-Antibacterials for systemic use,"/capita, US$ exchange rate",13.1
+11859,Finland,2012,4,"H-Systemic hormonal preparations, excluding sex hormones and insulins","Million US$, purchasing power parity",47.0
+11860,Finland,2012,4,J01-Antibacterials for systemic use,"/capita, US$ purchasing power parity",11.2
+11861,Finland,2012,4,C10-Lipid modifying agents,"/capita, US$ exchange rate",8.4
+11862,Finland,2012,4,J01-Antibacterials for systemic use,% of total sales,2.8
+11863,Finland,2012,4,C-Cardiovascular system,"/capita, US$ exchange rate",41.8
+11864,Finland,2012,4,C-Cardiovascular system,"/capita, US$ purchasing power parity",35.8
+11865,Finland,2012,4,C02-Antihypertensives,% of total sales,0.3
+11866,Finland,2012,4,C02-Antihypertensives,"/capita, US$ purchasing power parity",1.1
+11867,Finland,2012,4,C10-Lipid modifying agents,"/capita, US$ purchasing power parity",7.2
+11868,Finland,2012,4,C10-Lipid modifying agents,% of total sales,1.8
+11869,Finland,2012,4,C-Cardiovascular system,Million of national currency units,176.2
+11870,Finland,2012,4,M01A-Antiinflammatory and antirheumatic products non-steroids,Million US$ at exchange rate,71.4
+11871,Finland,2012,4,M01A-Antiinflammatory and antirheumatic products non-steroids,Million of national currency units,55.6
+11872,Finland,2012,4,C-Cardiovascular system,"Million US$, purchasing power parity",193.9
+11873,Finland,2012,4,C-Cardiovascular system,Million US$ at exchange rate,226.4
+11874,Finland,2012,4,N02-Analgesics,"/capita, US$ purchasing power parity",14.4
+11875,Finland,2011,4,C01A-Cardiac glycosides,% of total sales,0.0
+11876,Finland,2011,4,C07-Beta blocking agents,Million of national currency units,25.0
+11877,Finland,2011,4,C07-Beta blocking agents,"Million US$, purchasing power parity",27.8
+11878,Finland,2011,4,C01A-Cardiac glycosides,Million US$ at exchange rate,0.6
+11879,Finland,2011,4,C01A-Cardiac glycosides,Million of national currency units,0.4
+11880,Finland,2011,4,C07-Beta blocking agents,Million US$ at exchange rate,34.8
+11881,Finland,2011,4,C02-Antihypertensives,Million of national currency units,5.3
+11882,Finland,2011,4,C01A-Cardiac glycosides,"/capita, US$ purchasing power parity",0.1
+11883,Finland,2011,4,C01A-Cardiac glycosides,"/capita, US$ exchange rate",0.1
+11884,Finland,2011,4,C01A-Cardiac glycosides,"Million US$, purchasing power parity",0.4
+11885,Finland,2011,4,A-Alimentary tract and metabolism,Million of national currency units,241.9
+11886,Finland,2011,4,A-Alimentary tract and metabolism,"/capita, US$ purchasing power parity",50.0
+11887,Finland,2011,4,A-Alimentary tract and metabolism,% of total sales,12.5
+11888,Finland,2011,4,N-Nervous system,Million US$ at exchange rate,492.5
+11889,Finland,2011,4,A-Alimentary tract and metabolism,Million US$ at exchange rate,336.7
+11890,Finland,2011,4,A-Alimentary tract and metabolism,"/capita, US$ exchange rate",62.5
+11891,Finland,2011,4,A-Alimentary tract and metabolism,"Million US$, purchasing power parity",269.4
+11892,Finland,2011,4,N05C-Hypnotics and sedatives,"Million US$, purchasing power parity",11.7
+11893,Finland,2011,4,N05C-Hypnotics and sedatives,"/capita, US$ exchange rate",2.7
+11894,Finland,2011,4,C02-Antihypertensives,"/capita, US$ exchange rate",1.4
+11895,Finland,2011,4,N05C-Hypnotics and sedatives,Million US$ at exchange rate,14.6
+11896,Finland,2011,4,N-Nervous system,Million of national currency units,353.8
+11897,Finland,2011,4,N05C-Hypnotics and sedatives,% of total sales,0.5
+11898,Finland,2011,4,N05C-Hypnotics and sedatives,"/capita, US$ purchasing power parity",2.2
+11899,Finland,2011,4,G-Genito urinary system and sex hormones,"Million US$, purchasing power parity",116.9
+11900,Finland,2011,4,C02-Antihypertensives,"Million US$, purchasing power parity",5.9
+11901,Finland,2011,4,C02-Antihypertensives,Million US$ at exchange rate,7.4
+11902,Finland,2011,4,G-Genito urinary system and sex hormones,"/capita, US$ exchange rate",27.1
+11903,Finland,2011,4,G-Genito urinary system and sex hormones,% of total sales,5.4
+11904,Finland,2011,4,C07-Beta blocking agents,"/capita, US$ exchange rate",6.5
+11905,Finland,2011,4,G-Genito urinary system and sex hormones,"/capita, US$ purchasing power parity",21.7
+11906,Finland,2011,4,N-Nervous system,"Million US$, purchasing power parity",394.0
+11907,Finland,2011,4,G-Genito urinary system and sex hormones,Million of national currency units,105.0
+11908,Finland,2011,4,G-Genito urinary system and sex hormones,Million US$ at exchange rate,146.2
+11909,Finland,2011,4,N-Nervous system,% of total sales,18.4
+11910,Finland,2011,4,N-Nervous system,"/capita, US$ exchange rate",91.4
+11911,Finland,2011,4,N-Nervous system,"/capita, US$ purchasing power parity",73.1
+11912,Finland,2011,4,N06A-Antidepressants,"Million US$, purchasing power parity",32.7
+11913,Finland,2011,4,N06A-Antidepressants,Million of national currency units,29.4
+11914,Finland,2011,4,N06A-Antidepressants,Million US$ at exchange rate,40.9
+11915,Finland,2011,4,N06A-Antidepressants,% of total sales,1.5
+11916,Finland,2011,4,N06A-Antidepressants,"/capita, US$ exchange rate",7.6
+11917,Finland,2011,4,N06A-Antidepressants,"/capita, US$ purchasing power parity",6.1
+11918,Finland,2011,4,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ purchasing power parity",6.1
+11919,Finland,2011,4,C08-Calcium channel blockers,"/capita, US$ purchasing power parity",3.1
+11920,Finland,2011,4,A10-Drugs used in diabetes,Million of national currency units,117.1
+11921,Finland,2011,4,R-Respiratory system,"/capita, US$ purchasing power parity",30.7
+11922,Finland,2011,4,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ exchange rate",7.6
+11923,Finland,2011,4,A10-Drugs used in diabetes,"/capita, US$ exchange rate",30.3
+11924,Finland,2011,4,A10-Drugs used in diabetes,Million US$ at exchange rate,163.0
+11925,Finland,2011,4,A10-Drugs used in diabetes,"Million US$, purchasing power parity",130.4
+11926,Finland,2011,4,R-Respiratory system,Million of national currency units,148.7
+11927,Finland,2011,4,M-Musculo-skeletal system,% of total sales,4.7
+11928,Finland,2011,4,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),% of total sales,1.5
+11929,Finland,2011,4,R-Respiratory system,Million US$ at exchange rate,207.0
+11930,Finland,2011,4,M-Musculo-skeletal system,"/capita, US$ exchange rate",23.5
+11931,Finland,2011,4,M-Musculo-skeletal system,"/capita, US$ purchasing power parity",18.8
+11932,Finland,2011,4,A10-Drugs used in diabetes,"/capita, US$ purchasing power parity",24.2
+11933,Finland,2011,4,R-Respiratory system,"/capita, US$ exchange rate",38.4
+11934,Finland,2011,4,R-Respiratory system,"Million US$, purchasing power parity",165.6
+11935,Finland,2011,4,C08-Calcium channel blockers,% of total sales,0.8
+11936,Finland,2011,4,A10-Drugs used in diabetes,% of total sales,6.1
+11937,Finland,2011,4,M-Musculo-skeletal system,"Million US$, purchasing power parity",101.3
+11938,Finland,2011,4,"C01B-Antiarrhythmics, Class I and III","/capita, US$ purchasing power parity",0.9
+11939,Finland,2011,4,M-Musculo-skeletal system,Million of national currency units,91.0
+11940,Finland,2011,4,M-Musculo-skeletal system,Million US$ at exchange rate,126.7
+11941,Finland,2011,4,G03-Sex hormones and modulators of the genital system,% of total sales,2.9
+11942,Finland,2011,4,"C01B-Antiarrhythmics, Class I and III",% of total sales,0.2
+11943,Finland,2011,4,C07-Beta blocking agents,% of total sales,1.3
+11944,Finland,2011,4,"C01B-Antiarrhythmics, Class I and III",Million of national currency units,4.2
+11945,Finland,2011,4,C07-Beta blocking agents,"/capita, US$ purchasing power parity",5.2
+11946,Finland,2011,4,"C01B-Antiarrhythmics, Class I and III","/capita, US$ exchange rate",1.1
+11947,Finland,2011,4,"C01B-Antiarrhythmics, Class I and III","Million US$, purchasing power parity",4.7
+11948,Finland,2011,4,"C01B-Antiarrhythmics, Class I and III",Million US$ at exchange rate,5.8
+11949,Finland,2011,4,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million of national currency units,29.4
+11950,Finland,2011,4,C08-Calcium channel blockers,"Million US$, purchasing power parity",16.9
+11951,Finland,2011,4,C08-Calcium channel blockers,"/capita, US$ exchange rate",3.9
+11952,Finland,2011,4,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million US$ at exchange rate,40.9
+11953,Finland,2011,4,R-Respiratory system,% of total sales,7.7
+11954,Finland,2011,4,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"Million US$, purchasing power parity",32.7
+11955,Finland,2011,4,G03-Sex hormones and modulators of the genital system,"Million US$, purchasing power parity",62.0
+11956,Finland,2011,4,G03-Sex hormones and modulators of the genital system,"/capita, US$ exchange rate",14.4
+11957,Finland,2011,4,G03-Sex hormones and modulators of the genital system,"/capita, US$ purchasing power parity",11.5
+11958,Finland,2011,4,C08-Calcium channel blockers,Million US$ at exchange rate,21.2
+11959,Finland,2011,4,G03-Sex hormones and modulators of the genital system,Million US$ at exchange rate,77.5
+11960,Finland,2011,4,G03-Sex hormones and modulators of the genital system,Million of national currency units,55.7
+11961,Finland,2011,4,C08-Calcium channel blockers,Million of national currency units,15.2
+11962,Finland,2011,4,J-Antiinfectives for systemic use,"/capita, US$ exchange rate",39.5
+11963,Finland,2011,4,J-Antiinfectives for systemic use,% of total sales,7.9
+11964,Finland,2011,4,J-Antiinfectives for systemic use,"/capita, US$ purchasing power parity",31.6
+11965,Finland,2011,4,J-Antiinfectives for systemic use,"Million US$, purchasing power parity",170.3
+11966,Finland,2011,4,J-Antiinfectives for systemic use,Million of national currency units,152.9
+11967,Finland,2011,4,J-Antiinfectives for systemic use,Million US$ at exchange rate,212.8
+11968,Finland,2011,4,C09-Agents acting on the Renin-Angiotensin system,Million US$ at exchange rate,99.4
+11969,Finland,2011,4,C09-Agents acting on the Renin-Angiotensin system,Million of national currency units,71.4
+11970,Finland,2011,4,C09-Agents acting on the Renin-Angiotensin system,"Million US$, purchasing power parity",79.5
+11971,Finland,2011,4,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ purchasing power parity",11.0
+11972,Finland,2011,4,M01A-Antiinflammatory and antirheumatic products non-steroids,% of total sales,2.8
+11973,Finland,2011,4,A02A-Antacids,% of total sales,0.1
+11974,Finland,2011,4,R03-Drugs for obstructive airway diseases,"/capita, US$ exchange rate",24.2
+11975,Finland,2011,4,R03-Drugs for obstructive airway diseases,"/capita, US$ purchasing power parity",19.4
+11976,Finland,2011,4,R03-Drugs for obstructive airway diseases,% of total sales,4.9
+11977,Finland,2011,4,R03-Drugs for obstructive airway diseases,Million of national currency units,93.8
+11978,Finland,2011,4,M01A-Antiinflammatory and antirheumatic products non-steroids,"Million US$, purchasing power parity",59.2
+11979,Finland,2011,4,R03-Drugs for obstructive airway diseases,"Million US$, purchasing power parity",104.4
+11980,Finland,2011,4,R03-Drugs for obstructive airway diseases,Million US$ at exchange rate,130.6
+11981,Finland,2011,4,A02A-Antacids,"/capita, US$ exchange rate",0.7
+11982,Finland,2011,4,A02A-Antacids,"Million US$, purchasing power parity",3.1
+11983,Finland,2011,4,A02A-Antacids,"/capita, US$ purchasing power parity",0.6
+11984,Finland,2011,4,A02A-Antacids,Million of national currency units,2.8
+11985,Finland,2011,4,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ exchange rate",13.7
+11986,Finland,2011,4,A02A-Antacids,Million US$ at exchange rate,3.9
+11987,Finland,2011,4,C-Cardiovascular system,% of total sales,9.2
+11988,Finland,2011,4,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ exchange rate",18.4
+11989,Finland,2011,4,B-Blood and blood forming organs,"Million US$, purchasing power parity",154.2
+11990,Finland,2011,4,B-Blood and blood forming organs,"/capita, US$ exchange rate",35.8
+11991,Finland,2011,4,B-Blood and blood forming organs,"/capita, US$ purchasing power parity",28.6
+11992,Finland,2011,4,N05B-Anxiolytics,Million US$ at exchange rate,11.4
+11993,Finland,2011,4,N02-Analgesics,% of total sales,3.5
+11994,Finland,2011,4,N05B-Anxiolytics,Million of national currency units,8.2
+11995,Finland,2011,4,Total pharmaceutical sales,"Million US$, purchasing power parity",2146.4
+11996,Finland,2011,4,Total pharmaceutical sales,Million of national currency units,1927.6
+11997,Finland,2011,4,Total pharmaceutical sales,Million US$ at exchange rate,2683.1
+11998,Finland,2011,4,B-Blood and blood forming organs,% of total sales,7.2
+11999,Finland,2011,4,Total pharmaceutical sales,"/capita, US$ exchange rate",498.0
+12000,Finland,2011,4,Total pharmaceutical sales,"/capita, US$ purchasing power parity",398.3
+12001,Finland,2011,4,N05B-Anxiolytics,"Million US$, purchasing power parity",9.1
+12002,Finland,2011,4,C03-Diuretics,% of total sales,0.5
+12003,Finland,2011,4,C03-Diuretics,"/capita, US$ purchasing power parity",1.8
+12004,Finland,2011,4,C03-Diuretics,"/capita, US$ exchange rate",2.3
+12005,Finland,2011,4,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ purchasing power parity",14.8
+12006,Finland,2011,4,C09-Agents acting on the Renin-Angiotensin system,% of total sales,3.7
+12007,Finland,2011,4,N05B-Anxiolytics,"/capita, US$ purchasing power parity",1.7
+12008,Finland,2011,4,N05B-Anxiolytics,% of total sales,0.4
+12009,Finland,2011,4,N05B-Anxiolytics,"/capita, US$ exchange rate",2.1
+12010,Finland,2011,4,C03-Diuretics,Million US$ at exchange rate,12.2
+12011,Finland,2011,4,C03-Diuretics,"Million US$, purchasing power parity",9.8
+12012,Finland,2011,4,C03-Diuretics,Million of national currency units,8.8
+12013,Finland,2011,4,N02-Analgesics,"/capita, US$ exchange rate",17.5
+12014,Finland,2011,4,B-Blood and blood forming organs,Million of national currency units,138.5
+12015,Finland,2011,4,B-Blood and blood forming organs,Million US$ at exchange rate,192.8
+12016,Finland,2011,4,N02-Analgesics,Million US$ at exchange rate,94.5
+12017,Finland,2011,4,N02-Analgesics,"Million US$, purchasing power parity",75.6
+12018,Finland,2011,4,C10-Lipid modifying agents,Million US$ at exchange rate,41.3
+12019,Finland,2011,4,C10-Lipid modifying agents,"Million US$, purchasing power parity",33.1
+12020,Finland,2011,4,C10-Lipid modifying agents,Million of national currency units,29.7
+12021,Finland,2011,4,N05C-Hypnotics and sedatives,Million of national currency units,10.5
+12022,Finland,2011,4,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million US$ at exchange rate,57.8
+12023,Finland,2011,4,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million of national currency units,41.5
+12024,Finland,2011,4,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ purchasing power parity",8.6
+12025,Finland,2011,4,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ exchange rate",10.7
+12026,Finland,2011,4,"H-Systemic hormonal preparations, excluding sex hormones and insulins",% of total sales,2.2
+12027,Finland,2011,4,J01-Antibacterials for systemic use,"Million US$, purchasing power parity",73.0
+12028,Finland,2011,4,J01-Antibacterials for systemic use,Million US$ at exchange rate,91.3
+12029,Finland,2011,4,J01-Antibacterials for systemic use,Million of national currency units,65.6
+12030,Finland,2011,4,N02-Analgesics,Million of national currency units,67.9
+12031,Finland,2011,4,J01-Antibacterials for systemic use,"/capita, US$ exchange rate",16.9
+12032,Finland,2011,4,"H-Systemic hormonal preparations, excluding sex hormones and insulins","Million US$, purchasing power parity",46.2
+12033,Finland,2011,4,J01-Antibacterials for systemic use,"/capita, US$ purchasing power parity",13.6
+12034,Finland,2011,4,J01-Antibacterials for systemic use,% of total sales,3.4
+12035,Finland,2011,4,C10-Lipid modifying agents,"/capita, US$ exchange rate",7.7
+12036,Finland,2011,4,C-Cardiovascular system,"/capita, US$ exchange rate",46.0
+12037,Finland,2011,4,C-Cardiovascular system,"/capita, US$ purchasing power parity",36.8
+12038,Finland,2011,4,C02-Antihypertensives,% of total sales,0.3
+12039,Finland,2011,4,C02-Antihypertensives,"/capita, US$ purchasing power parity",1.1
+12040,Finland,2011,4,C10-Lipid modifying agents,"/capita, US$ purchasing power parity",6.1
+12041,Finland,2011,4,C10-Lipid modifying agents,% of total sales,1.5
+12042,Finland,2011,4,C-Cardiovascular system,Million of national currency units,178.2
+12043,Finland,2011,4,M01A-Antiinflammatory and antirheumatic products non-steroids,Million of national currency units,53.2
+12044,Finland,2011,4,M01A-Antiinflammatory and antirheumatic products non-steroids,Million US$ at exchange rate,74.1
+12045,Finland,2011,4,C-Cardiovascular system,"Million US$, purchasing power parity",198.4
+12046,Finland,2011,4,C-Cardiovascular system,Million US$ at exchange rate,248.0
+12047,Finland,2011,4,N02-Analgesics,"/capita, US$ purchasing power parity",14.0
+12048,Finland,2010,4,C01A-Cardiac glycosides,% of total sales,0.0
+12049,Finland,2010,4,C07-Beta blocking agents,"/capita, US$ exchange rate",7.4
+12050,Finland,2010,4,C07-Beta blocking agents,"Million US$, purchasing power parity",33.1
+12051,Finland,2010,4,C07-Beta blocking agents,Million of national currency units,29.8
+12052,Finland,2010,4,C01A-Cardiac glycosides,"/capita, US$ purchasing power parity",0.1
+12053,Finland,2010,4,C01A-Cardiac glycosides,Million US$ at exchange rate,0.7
+12054,Finland,2010,4,C01A-Cardiac glycosides,Million of national currency units,0.5
+12055,Finland,2010,4,C07-Beta blocking agents,Million US$ at exchange rate,39.5
+12056,Finland,2010,4,C02-Antihypertensives,Million of national currency units,4.9
+12057,Finland,2010,4,C02-Antihypertensives,Million US$ at exchange rate,6.5
+12058,Finland,2010,4,C01A-Cardiac glycosides,"/capita, US$ exchange rate",0.1
+12059,Finland,2010,4,C01A-Cardiac glycosides,"Million US$, purchasing power parity",0.6
+12060,Finland,2010,4,A-Alimentary tract and metabolism,"/capita, US$ purchasing power parity",47.1
+12061,Finland,2010,4,N-Nervous system,Million US$ at exchange rate,456.0
+12062,Finland,2010,4,A-Alimentary tract and metabolism,% of total sales,12.1
+12063,Finland,2010,4,A-Alimentary tract and metabolism,Million US$ at exchange rate,301.6
+12064,Finland,2010,4,A-Alimentary tract and metabolism,"/capita, US$ exchange rate",56.2
+12065,Finland,2010,4,A-Alimentary tract and metabolism,"Million US$, purchasing power parity",252.6
+12066,Finland,2010,4,N05C-Hypnotics and sedatives,"Million US$, purchasing power parity",10.9
+12067,Finland,2010,4,N05C-Hypnotics and sedatives,"/capita, US$ exchange rate",2.4
+12068,Finland,2010,4,C02-Antihypertensives,"/capita, US$ exchange rate",1.2
+12069,Finland,2010,4,N-Nervous system,Million of national currency units,344.0
+12070,Finland,2010,4,N05C-Hypnotics and sedatives,% of total sales,0.5
+12071,Finland,2010,4,N05C-Hypnotics and sedatives,"/capita, US$ purchasing power parity",2.0
+12072,Finland,2010,4,G-Genito urinary system and sex hormones,Million of national currency units,108.1
+12073,Finland,2010,4,G-Genito urinary system and sex hormones,"Million US$, purchasing power parity",120.0
+12074,Finland,2010,4,C02-Antihypertensives,"Million US$, purchasing power parity",5.4
+12075,Finland,2010,4,G-Genito urinary system and sex hormones,% of total sales,5.7
+12076,Finland,2010,4,G-Genito urinary system and sex hormones,"/capita, US$ exchange rate",26.7
+12077,Finland,2010,4,G-Genito urinary system and sex hormones,"/capita, US$ purchasing power parity",22.4
+12078,Finland,2010,4,N-Nervous system,"Million US$, purchasing power parity",382.0
+12079,Finland,2010,4,G-Genito urinary system and sex hormones,Million US$ at exchange rate,143.3
+12080,Finland,2010,4,N-Nervous system,% of total sales,18.3
+12081,Finland,2010,4,N-Nervous system,"/capita, US$ exchange rate",85.0
+12082,Finland,2010,4,A-Alimentary tract and metabolism,Million of national currency units,227.5
+12083,Finland,2010,4,N-Nervous system,"/capita, US$ purchasing power parity",71.2
+12084,Finland,2010,4,N06A-Antidepressants,"Million US$, purchasing power parity",35.2
+12085,Finland,2010,4,N06A-Antidepressants,Million US$ at exchange rate,42.0
+12086,Finland,2010,4,N06A-Antidepressants,Million of national currency units,31.7
+12087,Finland,2010,4,N06A-Antidepressants,"/capita, US$ exchange rate",7.8
+12088,Finland,2010,4,N06A-Antidepressants,% of total sales,1.7
+12089,Finland,2010,4,N06A-Antidepressants,"/capita, US$ purchasing power parity",6.6
+12090,Finland,2010,4,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ purchasing power parity",6.9
+12091,Finland,2010,4,C08-Calcium channel blockers,"/capita, US$ purchasing power parity",3.5
+12092,Finland,2010,4,A10-Drugs used in diabetes,Million of national currency units,104.6
+12093,Finland,2010,4,R-Respiratory system,"/capita, US$ purchasing power parity",30.6
+12094,Finland,2010,4,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ exchange rate",8.2
+12095,Finland,2010,4,A10-Drugs used in diabetes,"/capita, US$ exchange rate",25.9
+12096,Finland,2010,4,A10-Drugs used in diabetes,Million US$ at exchange rate,138.7
+12097,Finland,2010,4,A10-Drugs used in diabetes,"Million US$, purchasing power parity",116.2
+12098,Finland,2010,4,R-Respiratory system,Million of national currency units,147.6
+12099,Finland,2010,4,M-Musculo-skeletal system,% of total sales,4.8
+12100,Finland,2010,4,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),% of total sales,1.8
+12101,Finland,2010,4,R-Respiratory system,Million US$ at exchange rate,195.7
+12102,Finland,2010,4,M-Musculo-skeletal system,"/capita, US$ exchange rate",22.5
+12103,Finland,2010,4,M-Musculo-skeletal system,"/capita, US$ purchasing power parity",18.8
+12104,Finland,2010,4,A10-Drugs used in diabetes,"/capita, US$ purchasing power parity",21.7
+12105,Finland,2010,4,R-Respiratory system,"Million US$, purchasing power parity",163.9
+12106,Finland,2010,4,R-Respiratory system,"/capita, US$ exchange rate",36.5
+12107,Finland,2010,4,C08-Calcium channel blockers,% of total sales,0.9
+12108,Finland,2010,4,A10-Drugs used in diabetes,% of total sales,5.6
+12109,Finland,2010,4,M-Musculo-skeletal system,"Million US$, purchasing power parity",101.1
+12110,Finland,2010,4,C08-Calcium channel blockers,Million of national currency units,17.0
+12111,Finland,2010,4,"C01B-Antiarrhythmics, Class I and III","/capita, US$ purchasing power parity",0.7
+12112,Finland,2010,4,M-Musculo-skeletal system,Million US$ at exchange rate,120.6
+12113,Finland,2010,4,M-Musculo-skeletal system,Million of national currency units,91.0
+12114,Finland,2010,4,G03-Sex hormones and modulators of the genital system,% of total sales,2.9
+12115,Finland,2010,4,"C01B-Antiarrhythmics, Class I and III",% of total sales,0.2
+12116,Finland,2010,4,C07-Beta blocking agents,% of total sales,1.6
+12117,Finland,2010,4,"C01B-Antiarrhythmics, Class I and III",Million of national currency units,3.2
+12118,Finland,2010,4,C07-Beta blocking agents,"/capita, US$ purchasing power parity",6.2
+12119,Finland,2010,4,"C01B-Antiarrhythmics, Class I and III","/capita, US$ exchange rate",0.8
+12120,Finland,2010,4,"C01B-Antiarrhythmics, Class I and III","Million US$, purchasing power parity",3.6
+12121,Finland,2010,4,"C01B-Antiarrhythmics, Class I and III",Million US$ at exchange rate,4.2
+12122,Finland,2010,4,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million of national currency units,33.2
+12123,Finland,2010,4,C08-Calcium channel blockers,"/capita, US$ exchange rate",4.2
+12124,Finland,2010,4,C08-Calcium channel blockers,"Million US$, purchasing power parity",18.9
+12125,Finland,2010,4,R-Respiratory system,% of total sales,7.9
+12126,Finland,2010,4,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million US$ at exchange rate,44.0
+12127,Finland,2010,4,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"Million US$, purchasing power parity",36.9
+12128,Finland,2010,4,G03-Sex hormones and modulators of the genital system,"Million US$, purchasing power parity",60.7
+12129,Finland,2010,4,G03-Sex hormones and modulators of the genital system,"/capita, US$ purchasing power parity",11.3
+12130,Finland,2010,4,G03-Sex hormones and modulators of the genital system,"/capita, US$ exchange rate",13.5
+12131,Finland,2010,4,C08-Calcium channel blockers,Million US$ at exchange rate,22.5
+12132,Finland,2010,4,G03-Sex hormones and modulators of the genital system,Million US$ at exchange rate,72.5
+12133,Finland,2010,4,G03-Sex hormones and modulators of the genital system,Million of national currency units,54.7
+12134,Finland,2010,4,J-Antiinfectives for systemic use,% of total sales,7.9
+12135,Finland,2010,4,J-Antiinfectives for systemic use,"/capita, US$ purchasing power parity",30.8
+12136,Finland,2010,4,J-Antiinfectives for systemic use,Million of national currency units,148.9
+12137,Finland,2010,4,J-Antiinfectives for systemic use,"Million US$, purchasing power parity",165.3
+12138,Finland,2010,4,J-Antiinfectives for systemic use,Million US$ at exchange rate,197.4
+12139,Finland,2010,4,C09-Agents acting on the Renin-Angiotensin system,Million US$ at exchange rate,103.1
+12140,Finland,2010,4,C09-Agents acting on the Renin-Angiotensin system,Million of national currency units,77.8
+12141,Finland,2010,4,C09-Agents acting on the Renin-Angiotensin system,"Million US$, purchasing power parity",86.4
+12142,Finland,2010,4,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ purchasing power parity",10.6
+12143,Finland,2010,4,M01A-Antiinflammatory and antirheumatic products non-steroids,% of total sales,2.7
+12144,Finland,2010,4,R03-Drugs for obstructive airway diseases,"/capita, US$ exchange rate",23.6
+12145,Finland,2010,4,R03-Drugs for obstructive airway diseases,"/capita, US$ purchasing power parity",19.8
+12146,Finland,2010,4,R03-Drugs for obstructive airway diseases,% of total sales,5.1
+12147,Finland,2010,4,R03-Drugs for obstructive airway diseases,Million of national currency units,95.5
+12148,Finland,2010,4,R03-Drugs for obstructive airway diseases,"Million US$, purchasing power parity",106.0
+12149,Finland,2010,4,R03-Drugs for obstructive airway diseases,Million US$ at exchange rate,126.6
+12150,Finland,2010,4,A02A-Antacids,"/capita, US$ exchange rate",0.7
+12151,Finland,2010,4,A02A-Antacids,% of total sales,0.1
+12152,Finland,2010,4,A02A-Antacids,"/capita, US$ purchasing power parity",0.6
+12153,Finland,2010,4,A02A-Antacids,"Million US$, purchasing power parity",3.0
+12154,Finland,2010,4,A02A-Antacids,Million of national currency units,2.7
+12155,Finland,2010,4,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ exchange rate",12.7
+12156,Finland,2010,4,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ exchange rate",19.2
+12157,Finland,2010,4,A02A-Antacids,Million US$ at exchange rate,3.6
+12158,Finland,2010,4,B-Blood and blood forming organs,"Million US$, purchasing power parity",145.8
+12159,Finland,2010,4,B-Blood and blood forming organs,"/capita, US$ exchange rate",32.5
+12160,Finland,2010,4,B-Blood and blood forming organs,"/capita, US$ purchasing power parity",27.2
+12161,Finland,2010,4,N05B-Anxiolytics,Million US$ at exchange rate,11.0
+12162,Finland,2010,4,N02-Analgesics,% of total sales,3.5
+12163,Finland,2010,4,N05B-Anxiolytics,Million of national currency units,8.3
+12164,Finland,2010,4,Total pharmaceutical sales,"Million US$, purchasing power parity",2087.9
+12165,Finland,2010,4,Total pharmaceutical sales,Million of national currency units,1880.2
+12166,Finland,2010,4,Total pharmaceutical sales,Million US$ at exchange rate,2492.6
+12167,Finland,2010,4,Total pharmaceutical sales,"/capita, US$ exchange rate",464.7
+12168,Finland,2010,4,B-Blood and blood forming organs,% of total sales,7.0
+12169,Finland,2010,4,Total pharmaceutical sales,"/capita, US$ purchasing power parity",389.3
+12170,Finland,2010,4,N05B-Anxiolytics,"Million US$, purchasing power parity",9.2
+12171,Finland,2010,4,C03-Diuretics,% of total sales,0.5
+12172,Finland,2010,4,C03-Diuretics,"/capita, US$ purchasing power parity",1.9
+12173,Finland,2010,4,C03-Diuretics,"/capita, US$ exchange rate",2.2
+12174,Finland,2010,4,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ purchasing power parity",16.1
+12175,Finland,2010,4,C09-Agents acting on the Renin-Angiotensin system,% of total sales,4.1
+12176,Finland,2010,4,N05B-Anxiolytics,"/capita, US$ purchasing power parity",1.7
+12177,Finland,2010,4,N05B-Anxiolytics,% of total sales,0.4
+12178,Finland,2010,4,N05B-Anxiolytics,"/capita, US$ exchange rate",2.1
+12179,Finland,2010,4,C03-Diuretics,Million US$ at exchange rate,11.9
+12180,Finland,2010,4,C03-Diuretics,"Million US$, purchasing power parity",10.0
+12181,Finland,2010,4,C03-Diuretics,Million of national currency units,9.0
+12182,Finland,2010,4,C-Cardiovascular system,% of total sales,10.4
+12183,Finland,2010,4,J-Antiinfectives for systemic use,"/capita, US$ exchange rate",36.8
+12184,Finland,2010,4,J01-Antibacterials for systemic use,"/capita, US$ purchasing power parity",13.9
+12185,Finland,2010,4,B-Blood and blood forming organs,Million of national currency units,131.3
+12186,Finland,2010,4,N02-Analgesics,"/capita, US$ exchange rate",16.3
+12187,Finland,2010,4,B-Blood and blood forming organs,Million US$ at exchange rate,174.1
+12188,Finland,2010,4,N05C-Hypnotics and sedatives,Million US$ at exchange rate,13.0
+12189,Finland,2010,4,N02-Analgesics,Million US$ at exchange rate,87.6
+12190,Finland,2010,4,N02-Analgesics,"Million US$, purchasing power parity",73.4
+12191,Finland,2010,4,C10-Lipid modifying agents,Million US$ at exchange rate,46.1
+12192,Finland,2010,4,C10-Lipid modifying agents,"Million US$, purchasing power parity",38.6
+12193,Finland,2010,4,C10-Lipid modifying agents,Million of national currency units,34.8
+12194,Finland,2010,4,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million of national currency units,38.7
+12195,Finland,2010,4,N05C-Hypnotics and sedatives,Million of national currency units,9.8
+12196,Finland,2010,4,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million US$ at exchange rate,51.3
+12197,Finland,2010,4,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ purchasing power parity",8.0
+12198,Finland,2010,4,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ exchange rate",9.6
+12199,Finland,2010,4,"H-Systemic hormonal preparations, excluding sex hormones and insulins",% of total sales,2.1
+12200,Finland,2010,4,J01-Antibacterials for systemic use,"Million US$, purchasing power parity",74.5
+12201,Finland,2010,4,J01-Antibacterials for systemic use,Million US$ at exchange rate,89.0
+12202,Finland,2010,4,J01-Antibacterials for systemic use,Million of national currency units,67.1
+12203,Finland,2010,4,N02-Analgesics,Million of national currency units,66.1
+12204,Finland,2010,4,J01-Antibacterials for systemic use,"/capita, US$ exchange rate",16.6
+12205,Finland,2010,4,"H-Systemic hormonal preparations, excluding sex hormones and insulins","Million US$, purchasing power parity",43.0
+12206,Finland,2010,4,J01-Antibacterials for systemic use,% of total sales,3.6
+12207,Finland,2010,4,C10-Lipid modifying agents,"/capita, US$ exchange rate",8.6
+12208,Finland,2010,4,C-Cardiovascular system,"/capita, US$ exchange rate",48.2
+12209,Finland,2010,4,C-Cardiovascular system,"/capita, US$ purchasing power parity",40.4
+12210,Finland,2010,4,C02-Antihypertensives,% of total sales,0.3
+12211,Finland,2010,4,C02-Antihypertensives,"/capita, US$ purchasing power parity",1.0
+12212,Finland,2010,4,C10-Lipid modifying agents,"/capita, US$ purchasing power parity",7.2
+12213,Finland,2010,4,C10-Lipid modifying agents,% of total sales,1.9
+12214,Finland,2010,4,M01A-Antiinflammatory and antirheumatic products non-steroids,Million US$ at exchange rate,68.1
+12215,Finland,2010,4,M01A-Antiinflammatory and antirheumatic products non-steroids,"Million US$, purchasing power parity",57.1
+12216,Finland,2010,4,C-Cardiovascular system,Million of national currency units,195.0
+12217,Finland,2010,4,C-Cardiovascular system,"Million US$, purchasing power parity",216.5
+12218,Finland,2010,4,M01A-Antiinflammatory and antirheumatic products non-steroids,Million of national currency units,51.4
+12219,Finland,2010,4,C-Cardiovascular system,Million US$ at exchange rate,258.5
+12220,Finland,2010,4,N02-Analgesics,"/capita, US$ purchasing power parity",13.7
+12221,Finland,2017,3,C07-Beta blocking agents,Million of national currency units,23.5
+12222,Finland,2017,3,C01A-Cardiac glycosides,"/capita, US$ purchasing power parity",0.3
+12223,Finland,2017,3,C01A-Cardiac glycosides,% of total sales,0.1
+12224,Finland,2017,3,C07-Beta blocking agents,"Million US$, purchasing power parity",27.2
+12225,Finland,2017,3,C07-Beta blocking agents,Million US$ at exchange rate,26.5
+12226,Finland,2017,3,C01A-Cardiac glycosides,Million of national currency units,1.2
+12227,Finland,2017,3,C02-Antihypertensives,Million of national currency units,6.5
+12228,Finland,2017,3,C01A-Cardiac glycosides,"/capita, US$ exchange rate",0.2
+12229,Finland,2017,3,C01A-Cardiac glycosides,"Million US$, purchasing power parity",1.4
+12230,Finland,2017,3,C01A-Cardiac glycosides,Million US$ at exchange rate,1.4
+12231,Finland,2017,3,A-Alimentary tract and metabolism,"/capita, US$ purchasing power parity",62.0
+12232,Finland,2017,3,A-Alimentary tract and metabolism,"/capita, US$ exchange rate",60.5
+12233,Finland,2017,3,A-Alimentary tract and metabolism,% of total sales,12.8
+12234,Finland,2017,3,A-Alimentary tract and metabolism,Million US$ at exchange rate,333.4
+12235,Finland,2017,3,A-Alimentary tract and metabolism,Million of national currency units,295.1
+12236,Finland,2017,3,A-Alimentary tract and metabolism,"Million US$, purchasing power parity",341.7
+12237,Finland,2017,3,N-Nervous system,Million of national currency units,297.2
+12238,Finland,2017,3,N05C-Hypnotics and sedatives,"Million US$, purchasing power parity",14.8
+12239,Finland,2017,3,N05C-Hypnotics and sedatives,Million US$ at exchange rate,14.5
+12240,Finland,2017,3,N05C-Hypnotics and sedatives,% of total sales,0.6
+12241,Finland,2017,3,N05C-Hypnotics and sedatives,"/capita, US$ exchange rate",2.6
+12242,Finland,2017,3,N05C-Hypnotics and sedatives,"/capita, US$ purchasing power parity",2.7
+12243,Finland,2017,3,G-Genito urinary system and sex hormones,Million US$ at exchange rate,127.2
+12244,Finland,2017,3,G-Genito urinary system and sex hormones,"Million US$, purchasing power parity",130.4
+12245,Finland,2017,3,C02-Antihypertensives,Million US$ at exchange rate,7.3
+12246,Finland,2017,3,G-Genito urinary system and sex hormones,% of total sales,4.9
+12247,Finland,2017,3,G-Genito urinary system and sex hormones,"/capita, US$ purchasing power parity",23.7
+12248,Finland,2017,3,G-Genito urinary system and sex hormones,"/capita, US$ exchange rate",23.1
+12249,Finland,2017,3,C02-Antihypertensives,"Million US$, purchasing power parity",7.5
+12250,Finland,2017,3,N-Nervous system,Million US$ at exchange rate,335.7
+12251,Finland,2017,3,N-Nervous system,"Million US$, purchasing power parity",344.1
+12252,Finland,2017,3,G-Genito urinary system and sex hormones,Million of national currency units,112.6
+12253,Finland,2017,3,N-Nervous system,% of total sales,12.8
+12254,Finland,2017,3,N-Nervous system,"/capita, US$ purchasing power parity",62.5
+12255,Finland,2017,3,N-Nervous system,"/capita, US$ exchange rate",61.0
+12256,Finland,2017,3,N06A-Antidepressants,"Million US$, purchasing power parity",35.1
+12257,Finland,2017,3,N06A-Antidepressants,Million US$ at exchange rate,34.2
+12258,Finland,2017,3,N06A-Antidepressants,Million of national currency units,30.3
+12259,Finland,2017,3,N06A-Antidepressants,% of total sales,1.3
+12260,Finland,2017,3,N06A-Antidepressants,"/capita, US$ exchange rate",6.2
+12261,Finland,2017,3,N06A-Antidepressants,"/capita, US$ purchasing power parity",6.4
+12262,Finland,2017,3,A10-Drugs used in diabetes,Million of national currency units,148.0
+12263,Finland,2017,3,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"Million US$, purchasing power parity",39.7
+12264,Finland,2017,3,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ exchange rate",7.0
+12265,Finland,2017,3,A10-Drugs used in diabetes,"Million US$, purchasing power parity",171.4
+12266,Finland,2017,3,A10-Drugs used in diabetes,"/capita, US$ exchange rate",30.4
+12267,Finland,2017,3,A10-Drugs used in diabetes,Million US$ at exchange rate,167.2
+12268,Finland,2017,3,R-Respiratory system,"/capita, US$ exchange rate",30.8
+12269,Finland,2017,3,M-Musculo-skeletal system,% of total sales,4.2
+12270,Finland,2017,3,R-Respiratory system,Million of national currency units,150.1
+12271,Finland,2017,3,M-Musculo-skeletal system,"Million US$, purchasing power parity",111.3
+12272,Finland,2017,3,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),% of total sales,1.5
+12273,Finland,2017,3,M-Musculo-skeletal system,"/capita, US$ purchasing power parity",20.2
+12274,Finland,2017,3,M-Musculo-skeletal system,"/capita, US$ exchange rate",19.7
+12275,Finland,2017,3,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ purchasing power parity",7.2
+12276,Finland,2017,3,R-Respiratory system,Million US$ at exchange rate,169.6
+12277,Finland,2017,3,A10-Drugs used in diabetes,"/capita, US$ purchasing power parity",31.1
+12278,Finland,2017,3,R-Respiratory system,"Million US$, purchasing power parity",173.8
+12279,Finland,2017,3,C08-Calcium channel blockers,% of total sales,0.8
+12280,Finland,2017,3,A10-Drugs used in diabetes,% of total sales,6.4
+12281,Finland,2017,3,C08-Calcium channel blockers,"/capita, US$ purchasing power parity",3.8
+12282,Finland,2017,3,M-Musculo-skeletal system,Million US$ at exchange rate,108.6
+12283,Finland,2017,3,M-Musculo-skeletal system,Million of national currency units,96.1
+12284,Finland,2017,3,G03-Sex hormones and modulators of the genital system,% of total sales,2.5
+12285,Finland,2017,3,"C01B-Antiarrhythmics, Class I and III","/capita, US$ purchasing power parity",0.9
+12286,Finland,2017,3,"C01B-Antiarrhythmics, Class I and III",% of total sales,0.2
+12287,Finland,2017,3,"C01B-Antiarrhythmics, Class I and III","/capita, US$ exchange rate",0.9
+12288,Finland,2017,3,C07-Beta blocking agents,% of total sales,1.0
+12289,Finland,2017,3,C07-Beta blocking agents,"/capita, US$ exchange rate",4.8
+12290,Finland,2017,3,C07-Beta blocking agents,"/capita, US$ purchasing power parity",4.9
+12291,Finland,2017,3,"C01B-Antiarrhythmics, Class I and III","Million US$, purchasing power parity",4.9
+12292,Finland,2017,3,"C01B-Antiarrhythmics, Class I and III",Million of national currency units,4.2
+12293,Finland,2017,3,"C01B-Antiarrhythmics, Class I and III",Million US$ at exchange rate,4.7
+12294,Finland,2017,3,G03-Sex hormones and modulators of the genital system,"/capita, US$ purchasing power parity",12.1
+12295,Finland,2017,3,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million of national currency units,34.3
+12296,Finland,2017,3,C08-Calcium channel blockers,"/capita, US$ exchange rate",3.7
+12297,Finland,2017,3,C08-Calcium channel blockers,"Million US$, purchasing power parity",21.1
+12298,Finland,2017,3,R-Respiratory system,% of total sales,6.5
+12299,Finland,2017,3,R-Respiratory system,"/capita, US$ purchasing power parity",31.6
+12300,Finland,2017,3,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million US$ at exchange rate,38.7
+12301,Finland,2017,3,G03-Sex hormones and modulators of the genital system,"Million US$, purchasing power parity",66.8
+12302,Finland,2017,3,G03-Sex hormones and modulators of the genital system,Million US$ at exchange rate,65.2
+12303,Finland,2017,3,G03-Sex hormones and modulators of the genital system,"/capita, US$ exchange rate",11.8
+12304,Finland,2017,3,C08-Calcium channel blockers,Million of national currency units,18.2
+12305,Finland,2017,3,C08-Calcium channel blockers,Million US$ at exchange rate,20.6
+12306,Finland,2017,3,G03-Sex hormones and modulators of the genital system,Million of national currency units,57.7
+12307,Finland,2017,3,C02-Antihypertensives,"/capita, US$ exchange rate",1.3
+12308,Finland,2017,3,J-Antiinfectives for systemic use,"/capita, US$ exchange rate",40.4
+12309,Finland,2017,3,J-Antiinfectives for systemic use,"Million US$, purchasing power parity",228.0
+12310,Finland,2017,3,J-Antiinfectives for systemic use,"/capita, US$ purchasing power parity",41.4
+12311,Finland,2017,3,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ exchange rate",10.1
+12312,Finland,2017,3,A02A-Antacids,% of total sales,0.1
+12313,Finland,2017,3,J-Antiinfectives for systemic use,Million of national currency units,196.9
+12314,Finland,2017,3,J-Antiinfectives for systemic use,Million US$ at exchange rate,222.4
+12315,Finland,2017,3,J-Antiinfectives for systemic use,% of total sales,8.5
+12316,Finland,2017,3,C09-Agents acting on the Renin-Angiotensin system,Million of national currency units,50.5
+12317,Finland,2017,3,C09-Agents acting on the Renin-Angiotensin system,Million US$ at exchange rate,57.0
+12318,Finland,2017,3,C09-Agents acting on the Renin-Angiotensin system,"Million US$, purchasing power parity",58.5
+12319,Finland,2017,3,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ purchasing power parity",10.3
+12320,Finland,2017,3,C-Cardiovascular system,% of total sales,8.5
+12321,Finland,2017,3,M01A-Antiinflammatory and antirheumatic products non-steroids,% of total sales,2.1
+12322,Finland,2017,3,R03-Drugs for obstructive airway diseases,"/capita, US$ exchange rate",19.0
+12323,Finland,2017,3,R03-Drugs for obstructive airway diseases,"Million US$, purchasing power parity",107.0
+12324,Finland,2017,3,R03-Drugs for obstructive airway diseases,"/capita, US$ purchasing power parity",19.4
+12325,Finland,2017,3,R03-Drugs for obstructive airway diseases,% of total sales,4.0
+12326,Finland,2017,3,R03-Drugs for obstructive airway diseases,Million of national currency units,92.4
+12327,Finland,2017,3,R03-Drugs for obstructive airway diseases,Million US$ at exchange rate,104.4
+12328,Finland,2017,3,A02A-Antacids,"Million US$, purchasing power parity",3.9
+12329,Finland,2017,3,A02A-Antacids,"/capita, US$ exchange rate",0.7
+12330,Finland,2017,3,A02A-Antacids,"/capita, US$ purchasing power parity",0.7
+12331,Finland,2017,3,M01A-Antiinflammatory and antirheumatic products non-steroids,"Million US$, purchasing power parity",57.0
+12332,Finland,2017,3,A02A-Antacids,Million US$ at exchange rate,3.8
+12333,Finland,2017,3,A02A-Antacids,Million of national currency units,3.4
+12334,Finland,2017,3,B-Blood and blood forming organs,"Million US$, purchasing power parity",251.8
+12335,Finland,2017,3,B-Blood and blood forming organs,Million US$ at exchange rate,245.7
+12336,Finland,2017,3,B-Blood and blood forming organs,"/capita, US$ exchange rate",44.6
+12337,Finland,2017,3,N05B-Anxiolytics,Million of national currency units,6.6
+12338,Finland,2017,3,N05B-Anxiolytics,Million US$ at exchange rate,7.5
+12339,Finland,2017,3,N02-Analgesics,% of total sales,2.9
+12340,Finland,2017,3,B-Blood and blood forming organs,"/capita, US$ purchasing power parity",45.7
+12341,Finland,2017,3,Total pharmaceutical sales,"Million US$, purchasing power parity",2679.0
+12342,Finland,2017,3,Total pharmaceutical sales,Million US$ at exchange rate,2613.7
+12343,Finland,2017,3,Total pharmaceutical sales,Million of national currency units,2313.7
+12344,Finland,2017,3,B-Blood and blood forming organs,% of total sales,9.4
+12345,Finland,2017,3,Total pharmaceutical sales,"/capita, US$ purchasing power parity",486.4
+12346,Finland,2017,3,Total pharmaceutical sales,"/capita, US$ exchange rate",474.5
+12347,Finland,2017,3,C03-Diuretics,"/capita, US$ purchasing power parity",1.7
+12348,Finland,2017,3,C03-Diuretics,"Million US$, purchasing power parity",9.1
+12349,Finland,2017,3,C03-Diuretics,"/capita, US$ exchange rate",1.6
+12350,Finland,2017,3,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ exchange rate",10.4
+12351,Finland,2017,3,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ purchasing power parity",10.6
+12352,Finland,2017,3,C03-Diuretics,% of total sales,0.3
+12353,Finland,2017,3,C09-Agents acting on the Renin-Angiotensin system,% of total sales,2.2
+12354,Finland,2017,3,N05B-Anxiolytics,"/capita, US$ purchasing power parity",1.4
+12355,Finland,2017,3,N05B-Anxiolytics,"/capita, US$ exchange rate",1.4
+12356,Finland,2017,3,N05B-Anxiolytics,"Million US$, purchasing power parity",7.6
+12357,Finland,2017,3,C03-Diuretics,Million US$ at exchange rate,8.9
+12358,Finland,2017,3,N05B-Anxiolytics,% of total sales,0.3
+12359,Finland,2017,3,C03-Diuretics,Million of national currency units,7.9
+12360,Finland,2017,3,N02-Analgesics,"/capita, US$ purchasing power parity",14.0
+12361,Finland,2017,3,B-Blood and blood forming organs,Million of national currency units,217.5
+12362,Finland,2017,3,N02-Analgesics,Million US$ at exchange rate,75.2
+12363,Finland,2017,3,N02-Analgesics,"Million US$, purchasing power parity",77.1
+12364,Finland,2017,3,C10-Lipid modifying agents,Million of national currency units,65.1
+12365,Finland,2017,3,C10-Lipid modifying agents,Million US$ at exchange rate,73.5
+12366,Finland,2017,3,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million US$ at exchange rate,49.9
+12367,Finland,2017,3,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million of national currency units,44.2
+12368,Finland,2017,3,N02-Analgesics,Million of national currency units,66.6
+12369,Finland,2017,3,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ exchange rate",9.1
+12370,Finland,2017,3,"H-Systemic hormonal preparations, excluding sex hormones and insulins","Million US$, purchasing power parity",51.2
+12371,Finland,2017,3,J01-Antibacterials for systemic use,"Million US$, purchasing power parity",60.9
+12372,Finland,2017,3,"H-Systemic hormonal preparations, excluding sex hormones and insulins",% of total sales,1.9
+12373,Finland,2017,3,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ purchasing power parity",9.3
+12374,Finland,2017,3,J01-Antibacterials for systemic use,Million US$ at exchange rate,59.4
+12375,Finland,2017,3,J01-Antibacterials for systemic use,Million of national currency units,52.6
+12376,Finland,2017,3,J01-Antibacterials for systemic use,"/capita, US$ exchange rate",10.8
+12377,Finland,2017,3,N02-Analgesics,"/capita, US$ exchange rate",13.7
+12378,Finland,2017,3,N05C-Hypnotics and sedatives,Million of national currency units,12.8
+12379,Finland,2017,3,J01-Antibacterials for systemic use,% of total sales,2.3
+12380,Finland,2017,3,J01-Antibacterials for systemic use,"/capita, US$ purchasing power parity",11.1
+12381,Finland,2017,3,C-Cardiovascular system,"/capita, US$ exchange rate",40.5
+12382,Finland,2017,3,C-Cardiovascular system,"/capita, US$ purchasing power parity",41.6
+12383,Finland,2017,3,C10-Lipid modifying agents,"/capita, US$ exchange rate",13.4
+12384,Finland,2017,3,C02-Antihypertensives,% of total sales,0.3
+12385,Finland,2017,3,C02-Antihypertensives,"/capita, US$ purchasing power parity",1.4
+12386,Finland,2017,3,C10-Lipid modifying agents,"/capita, US$ purchasing power parity",13.7
+12387,Finland,2017,3,C10-Lipid modifying agents,% of total sales,2.8
+12388,Finland,2017,3,C10-Lipid modifying agents,"Million US$, purchasing power parity",75.4
+12389,Finland,2017,3,C-Cardiovascular system,Million of national currency units,197.7
+12390,Finland,2017,3,M01A-Antiinflammatory and antirheumatic products non-steroids,Million of national currency units,49.2
+12391,Finland,2017,3,M01A-Antiinflammatory and antirheumatic products non-steroids,Million US$ at exchange rate,55.6
+12392,Finland,2017,3,C-Cardiovascular system,Million US$ at exchange rate,223.3
+12393,Finland,2017,3,C-Cardiovascular system,"Million US$, purchasing power parity",228.9
+12394,France,2013,9,Total pharmaceutical sales,Million of national currency units,26800.0
+12395,France,2013,9,Total pharmaceutical sales,Million US$ at exchange rate,35593.6
+12396,France,2013,9,Total pharmaceutical sales,"/capita, US$ purchasing power parity",502.0
+12397,France,2013,9,Total pharmaceutical sales,"/capita, US$ exchange rate",541.2
+12398,France,2013,9,Total pharmaceutical sales,"Million US$, purchasing power parity",33019.4
+12399,France,2012,9,Total pharmaceutical sales,Million of national currency units,27200.0
+12400,France,2012,9,Total pharmaceutical sales,Million US$ at exchange rate,34946.3
+12401,France,2012,9,Total pharmaceutical sales,"/capita, US$ purchasing power parity",492.3
+12402,France,2012,9,Total pharmaceutical sales,"/capita, US$ exchange rate",534.0
+12403,France,2012,9,Total pharmaceutical sales,"Million US$, purchasing power parity",32216.0
+12404,France,2011,9,B-Blood and blood forming organs,% of total sales,7.7
+12405,France,2011,9,N-Nervous system,"Million US$, purchasing power parity",4634.0
+12406,France,2011,9,N-Nervous system,Million US$ at exchange rate,5427.1
+12407,France,2011,9,N-Nervous system,"/capita, US$ exchange rate",83.3
+12408,France,2011,9,N-Nervous system,"/capita, US$ purchasing power parity",71.2
+12409,France,2011,9,N-Nervous system,% of total sales,14.1
+12410,France,2011,9,M-Musculo-skeletal system,% of total sales,3.4
+12411,France,2011,9,C-Cardiovascular system,"/capita, US$ exchange rate",84.1
+12412,France,2011,9,M-Musculo-skeletal system,"/capita, US$ purchasing power parity",17.1
+12413,France,2011,9,M-Musculo-skeletal system,"/capita, US$ exchange rate",20.0
+12414,France,2011,9,M-Musculo-skeletal system,"Million US$, purchasing power parity",1111.1
+12415,France,2011,9,M-Musculo-skeletal system,Million of national currency units,934.8
+12416,France,2011,9,N-Nervous system,Million of national currency units,3898.9
+12417,France,2011,9,C-Cardiovascular system,"/capita, US$ purchasing power parity",71.8
+12418,France,2011,9,M-Musculo-skeletal system,Million US$ at exchange rate,1301.2
+12419,France,2011,9,B-Blood and blood forming organs,"/capita, US$ exchange rate",45.5
+12420,France,2011,9,Total pharmaceutical sales,Million of national currency units,27600.0
+12421,France,2011,9,B-Blood and blood forming organs,Million US$ at exchange rate,2963.3
+12422,France,2011,9,B-Blood and blood forming organs,Million of national currency units,2128.9
+12423,France,2011,9,A-Alimentary tract and metabolism,% of total sales,10.7
+12424,France,2011,9,"H-Systemic hormonal preparations, excluding sex hormones and insulins",% of total sales,1.8
+12425,France,2011,9,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ purchasing power parity",9.2
+12426,France,2011,9,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ exchange rate",10.7
+12427,France,2011,9,"H-Systemic hormonal preparations, excluding sex hormones and insulins","Million US$, purchasing power parity",597.7
+12428,France,2011,9,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million US$ at exchange rate,700.0
+12429,France,2011,9,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million of national currency units,502.9
+12430,France,2011,9,A-Alimentary tract and metabolism,Million of national currency units,2952.3
+12431,France,2011,9,A-Alimentary tract and metabolism,Million US$ at exchange rate,4109.5
+12432,France,2011,9,A-Alimentary tract and metabolism,"Million US$, purchasing power parity",3509.0
+12433,France,2011,9,A-Alimentary tract and metabolism,"/capita, US$ exchange rate",63.1
+12434,France,2011,9,A-Alimentary tract and metabolism,"/capita, US$ purchasing power parity",53.9
+12435,France,2011,9,Total pharmaceutical sales,Million US$ at exchange rate,38418.0
+12436,France,2011,9,B-Blood and blood forming organs,"Million US$, purchasing power parity",2530.3
+12437,France,2011,9,G-Genito urinary system and sex hormones,% of total sales,3.7
+12438,France,2011,9,G-Genito urinary system and sex hormones,"/capita, US$ purchasing power parity",18.9
+12439,France,2011,9,G-Genito urinary system and sex hormones,"/capita, US$ exchange rate",22.1
+12440,France,2011,9,G-Genito urinary system and sex hormones,"Million US$, purchasing power parity",1228.5
+12441,France,2011,9,G-Genito urinary system and sex hormones,Million US$ at exchange rate,1438.7
+12442,France,2011,9,G-Genito urinary system and sex hormones,Million of national currency units,1033.6
+12443,France,2011,9,B-Blood and blood forming organs,"/capita, US$ purchasing power parity",38.9
+12444,France,2011,9,Total pharmaceutical sales,"/capita, US$ exchange rate",589.9
+12445,France,2011,9,Total pharmaceutical sales,"Million US$, purchasing power parity",32804.0
+12446,France,2011,9,Total pharmaceutical sales,"/capita, US$ purchasing power parity",503.7
+12447,France,2011,9,C-Cardiovascular system,"Million US$, purchasing power parity",4679.3
+12448,France,2011,9,C-Cardiovascular system,Million of national currency units,3937.0
+12449,France,2011,9,R-Respiratory system,% of total sales,7.3
+12450,France,2011,9,C-Cardiovascular system,% of total sales,14.3
+12451,France,2011,9,J-Antiinfectives for systemic use,Million of national currency units,3056.5
+12452,France,2011,9,J-Antiinfectives for systemic use,Million US$ at exchange rate,4254.5
+12453,France,2011,9,R-Respiratory system,Million of national currency units,2016.0
+12454,France,2011,9,R-Respiratory system,Million US$ at exchange rate,2806.2
+12455,France,2011,9,R-Respiratory system,"/capita, US$ exchange rate",43.1
+12456,France,2011,9,J-Antiinfectives for systemic use,"Million US$, purchasing power parity",3632.8
+12457,France,2011,9,J-Antiinfectives for systemic use,"/capita, US$ exchange rate",65.3
+12458,France,2011,9,J-Antiinfectives for systemic use,"/capita, US$ purchasing power parity",55.8
+12459,France,2011,9,J-Antiinfectives for systemic use,% of total sales,11.1
+12460,France,2011,9,R-Respiratory system,"Million US$, purchasing power parity",2396.1
+12461,France,2011,9,C-Cardiovascular system,Million US$ at exchange rate,5480.1
+12462,France,2011,9,R-Respiratory system,"/capita, US$ purchasing power parity",36.8
+12463,France,2010,9,Total pharmaceutical sales,Million US$ at exchange rate,36508.9
+12464,France,2010,9,Total pharmaceutical sales,"Million US$, purchasing power parity",32221.6
+12465,France,2010,9,Total pharmaceutical sales,"/capita, US$ purchasing power parity",497.1
+12466,France,2010,9,Total pharmaceutical sales,"/capita, US$ exchange rate",563.2
+12467,France,2010,9,Total pharmaceutical sales,Million of national currency units,27539.0
+12468,Germany,2017,7,C-Cardiovascular system,"Million US$, purchasing power parity",5949.9
+12469,Germany,2017,7,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ exchange rate",22.0
+12470,Germany,2017,7,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ purchasing power parity",9.0
+12471,Germany,2017,7,C-Cardiovascular system,Million US$ at exchange rate,5006.1
+12472,Germany,2017,7,C08-Calcium channel blockers,Million of national currency units,287.2
+12473,Germany,2017,7,M01A-Antiinflammatory and antirheumatic products non-steroids,% of total sales,1.5
+12474,Germany,2017,7,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ purchasing power parity",26.1
+12475,Germany,2017,7,C09-Agents acting on the Renin-Angiotensin system,% of total sales,4.3
+12476,Germany,2017,7,C-Cardiovascular system,Million of national currency units,4431.4
+12477,Germany,2017,7,N-Nervous system,% of total sales,13.5
+12478,Germany,2017,7,R03-Drugs for obstructive airway diseases,Million US$ at exchange rate,2006.7
+12479,Germany,2017,7,N-Nervous system,"/capita, US$ exchange rate",68.4
+12480,Germany,2017,7,N-Nervous system,"/capita, US$ purchasing power parity",81.3
+12481,Germany,2017,7,R03-Drugs for obstructive airway diseases,"/capita, US$ purchasing power parity",28.9
+12482,Germany,2017,7,R03-Drugs for obstructive airway diseases,% of total sales,4.8
+12483,Germany,2017,7,R03-Drugs for obstructive airway diseases,"Million US$, purchasing power parity",2385.0
+12484,Germany,2017,7,R03-Drugs for obstructive airway diseases,"/capita, US$ exchange rate",24.3
+12485,Germany,2017,7,N-Nervous system,Million of national currency units,5004.2
+12486,Germany,2017,7,Products not elsewhere classified,Million US$ at exchange rate,13284.1
+12487,Germany,2017,7,Products not elsewhere classified,Million of national currency units,11759.2
+12488,Germany,2017,7,N-Nervous system,Million US$ at exchange rate,5653.1
+12489,Germany,2017,7,C-Cardiovascular system,"/capita, US$ purchasing power parity",72.0
+12490,Germany,2017,7,R03-Drugs for obstructive airway diseases,Million of national currency units,1776.3
+12491,Germany,2017,7,N-Nervous system,"Million US$, purchasing power parity",6719.0
+12492,Germany,2017,7,C-Cardiovascular system,"/capita, US$ exchange rate",60.6
+12493,Germany,2017,7,R-Respiratory system,Million of national currency units,2146.1
+12494,Germany,2017,7,C10-Lipid modifying agents,"/capita, US$ purchasing power parity",11.9
+12495,Germany,2017,7,R-Respiratory system,"/capita, US$ exchange rate",29.3
+12496,Germany,2017,7,R-Respiratory system,"Million US$, purchasing power parity",2881.5
+12497,Germany,2017,7,R-Respiratory system,Million US$ at exchange rate,2424.4
+12498,Germany,2017,7,M01A-Antiinflammatory and antirheumatic products non-steroids,Million of national currency units,556.5
+12499,Germany,2017,7,Total pharmaceutical sales,"/capita, US$ purchasing power parity",604.1
+12500,Germany,2017,7,M01A-Antiinflammatory and antirheumatic products non-steroids,Million US$ at exchange rate,628.7
+12501,Germany,2017,7,C10-Lipid modifying agents,"/capita, US$ exchange rate",10.0
+12502,Germany,2017,7,C10-Lipid modifying agents,Million US$ at exchange rate,828.7
+12503,Germany,2017,7,C10-Lipid modifying agents,"Million US$, purchasing power parity",985.0
+12504,Germany,2017,7,C10-Lipid modifying agents,% of total sales,2.0
+12505,Germany,2017,7,"C01B-Antiarrhythmics, Class I and III",% of total sales,0.2
+12506,Germany,2017,7,M-Musculo-skeletal system,% of total sales,3.7
+12507,Germany,2017,7,"C01B-Antiarrhythmics, Class I and III","/capita, US$ purchasing power parity",1.2
+12508,Germany,2017,7,"C01B-Antiarrhythmics, Class I and III","Million US$, purchasing power parity",95.6
+12509,Germany,2017,7,"C01B-Antiarrhythmics, Class I and III","/capita, US$ exchange rate",1.0
+12510,Germany,2017,7,M-Musculo-skeletal system,"/capita, US$ purchasing power parity",22.6
+12511,Germany,2017,7,"C01B-Antiarrhythmics, Class I and III",Million of national currency units,71.2
+12512,Germany,2017,7,M01A-Antiinflammatory and antirheumatic products non-steroids,"Million US$, purchasing power parity",747.2
+12513,Germany,2017,7,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ exchange rate",7.6
+12514,Germany,2017,7,R-Respiratory system,% of total sales,5.8
+12515,Germany,2017,7,"C01B-Antiarrhythmics, Class I and III",Million US$ at exchange rate,80.4
+12516,Germany,2017,7,R-Respiratory system,"/capita, US$ purchasing power parity",34.9
+12517,Germany,2017,7,C08-Calcium channel blockers,"/capita, US$ purchasing power parity",4.7
+12518,Germany,2017,7,C08-Calcium channel blockers,"/capita, US$ exchange rate",3.9
+12519,Germany,2017,7,C08-Calcium channel blockers,% of total sales,0.8
+12520,Germany,2017,7,M-Musculo-skeletal system,Million of national currency units,1390.3
+12521,Germany,2017,7,C09-Agents acting on the Renin-Angiotensin system,Million of national currency units,1609.5
+12522,Germany,2017,7,Products not elsewhere classified,"Million US$, purchasing power parity",15788.8
+12523,Germany,2017,7,C08-Calcium channel blockers,Million US$ at exchange rate,324.4
+12524,Germany,2017,7,Products not elsewhere classified,"/capita, US$ exchange rate",160.7
+12525,Germany,2017,7,C08-Calcium channel blockers,"Million US$, purchasing power parity",385.6
+12526,Germany,2017,7,C09-Agents acting on the Renin-Angiotensin system,"Million US$, purchasing power parity",2161.0
+12527,Germany,2017,7,C09-Agents acting on the Renin-Angiotensin system,Million US$ at exchange rate,1818.2
+12528,Germany,2017,7,Total pharmaceutical sales,Million US$ at exchange rate,42011.2
+12529,Germany,2017,7,Total pharmaceutical sales,Million of national currency units,37188.6
+12530,Germany,2017,7,Total pharmaceutical sales,"Million US$, purchasing power parity",49932.1
+12531,Germany,2017,7,C-Cardiovascular system,% of total sales,11.9
+12532,Germany,2017,7,Total pharmaceutical sales,"/capita, US$ exchange rate",508.3
+12533,Germany,2017,7,C10-Lipid modifying agents,Million of national currency units,733.6
+12534,Germany,2017,7,M-Musculo-skeletal system,"/capita, US$ exchange rate",19.0
+12535,Germany,2017,7,M-Musculo-skeletal system,Million US$ at exchange rate,1570.6
+12536,Germany,2017,7,M-Musculo-skeletal system,"Million US$, purchasing power parity",1866.7
+12537,Germany,2017,7,Products not elsewhere classified,% of total sales,31.6
+12538,Germany,2017,7,Products not elsewhere classified,"/capita, US$ purchasing power parity",191.0
+12539,Germany,2017,7,C07-Beta blocking agents,Million of national currency units,654.9
+12540,Germany,2017,7,C01A-Cardiac glycosides,% of total sales,0.1
+12541,Germany,2017,7,C01A-Cardiac glycosides,"/capita, US$ purchasing power parity",0.4
+12542,Germany,2017,7,J-Antiinfectives for systemic use,% of total sales,7.9
+12543,Germany,2017,7,C07-Beta blocking agents,Million US$ at exchange rate,739.8
+12544,Germany,2017,7,J-Antiinfectives for systemic use,"/capita, US$ exchange rate",39.9
+12545,Germany,2017,7,J-Antiinfectives for systemic use,"/capita, US$ purchasing power parity",47.5
+12546,Germany,2017,7,C01A-Cardiac glycosides,"/capita, US$ exchange rate",0.3
+12547,Germany,2017,7,J-Antiinfectives for systemic use,"Million US$, purchasing power parity",3924.2
+12548,Germany,2017,7,J-Antiinfectives for systemic use,Million of national currency units,2922.7
+12549,Germany,2017,7,J-Antiinfectives for systemic use,Million US$ at exchange rate,3301.7
+12550,Germany,2017,7,C01A-Cardiac glycosides,"Million US$, purchasing power parity",29.1
+12551,Germany,2017,7,C01A-Cardiac glycosides,Million of national currency units,21.7
+12552,Germany,2017,7,C01A-Cardiac glycosides,Million US$ at exchange rate,24.5
+12553,Germany,2017,7,C07-Beta blocking agents,"Million US$, purchasing power parity",879.3
+12554,Germany,2017,7,C03-Diuretics,"/capita, US$ exchange rate",6.1
+12555,Germany,2017,7,C03-Diuretics,"Million US$, purchasing power parity",602.2
+12556,Germany,2017,7,C03-Diuretics,% of total sales,1.2
+12557,Germany,2017,7,C03-Diuretics,"/capita, US$ purchasing power parity",7.3
+12558,Germany,2017,7,G03-Sex hormones and modulators of the genital system,% of total sales,1.0
+12559,Germany,2017,7,G03-Sex hormones and modulators of the genital system,"/capita, US$ purchasing power parity",6.3
+12560,Germany,2017,7,C03-Diuretics,Million of national currency units,448.5
+12561,Germany,2017,7,C03-Diuretics,Million US$ at exchange rate,506.7
+12562,Germany,2017,7,C07-Beta blocking agents,% of total sales,1.8
+12563,Germany,2017,7,C07-Beta blocking agents,"/capita, US$ purchasing power parity",10.6
+12564,Germany,2017,7,N05B-Anxiolytics,"/capita, US$ purchasing power parity",1.1
+12565,Germany,2017,7,C07-Beta blocking agents,"/capita, US$ exchange rate",9.0
+12566,Germany,2017,7,N05B-Anxiolytics,Million US$ at exchange rate,74.1
+12567,Germany,2017,7,N05B-Anxiolytics,"Million US$, purchasing power parity",88.1
+12568,Germany,2017,7,N05B-Anxiolytics,"/capita, US$ exchange rate",0.9
+12569,Germany,2017,7,J01-Antibacterials for systemic use,"/capita, US$ exchange rate",10.0
+12570,Germany,2017,7,J01-Antibacterials for systemic use,"/capita, US$ purchasing power parity",11.9
+12571,Germany,2017,7,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million of national currency units,1132.0
+12572,Germany,2017,7,J01-Antibacterials for systemic use,"Million US$, purchasing power parity",983.9
+12573,Germany,2017,7,C02-Antihypertensives,% of total sales,1.1
+12574,Germany,2017,7,C02-Antihypertensives,"/capita, US$ purchasing power parity",6.4
+12575,Germany,2017,7,J01-Antibacterials for systemic use,% of total sales,2.0
+12576,Germany,2017,7,N05B-Anxiolytics,% of total sales,0.2
+12577,Germany,2017,7,"H-Systemic hormonal preparations, excluding sex hormones and insulins",% of total sales,3.0
+12578,Germany,2017,7,J01-Antibacterials for systemic use,Million of national currency units,732.8
+12579,Germany,2017,7,J01-Antibacterials for systemic use,Million US$ at exchange rate,827.8
+12580,Germany,2017,7,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ purchasing power parity",18.4
+12581,Germany,2017,7,"H-Systemic hormonal preparations, excluding sex hormones and insulins","Million US$, purchasing power parity",1519.9
+12582,Germany,2017,7,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million US$ at exchange rate,1278.8
+12583,Germany,2017,7,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ exchange rate",15.5
+12584,Germany,2017,7,N05C-Hypnotics and sedatives,"Million US$, purchasing power parity",120.6
+12585,Germany,2017,7,N05C-Hypnotics and sedatives,"/capita, US$ exchange rate",1.2
+12586,Germany,2017,7,N05C-Hypnotics and sedatives,Million US$ at exchange rate,101.4
+12587,Germany,2017,7,B-Blood and blood forming organs,"Million US$, purchasing power parity",4254.1
+12588,Germany,2017,7,B-Blood and blood forming organs,Million US$ at exchange rate,3579.3
+12589,Germany,2017,7,N05C-Hypnotics and sedatives,"/capita, US$ purchasing power parity",1.5
+12590,Germany,2017,7,N05C-Hypnotics and sedatives,% of total sales,0.2
+12591,Germany,2017,7,B-Blood and blood forming organs,"/capita, US$ exchange rate",43.3
+12592,Germany,2017,7,C02-Antihypertensives,Million US$ at exchange rate,442.0
+12593,Germany,2017,7,C02-Antihypertensives,Million of national currency units,391.3
+12594,Germany,2017,7,C02-Antihypertensives,"/capita, US$ exchange rate",5.3
+12595,Germany,2017,7,C02-Antihypertensives,"Million US$, purchasing power parity",525.4
+12596,Germany,2017,7,B-Blood and blood forming organs,"/capita, US$ purchasing power parity",51.5
+12597,Germany,2017,7,B-Blood and blood forming organs,% of total sales,8.5
+12598,Germany,2017,7,N05C-Hypnotics and sedatives,Million of national currency units,89.8
+12599,Germany,2017,7,A10-Drugs used in diabetes,"Million US$, purchasing power parity",3359.4
+12600,Germany,2017,7,A10-Drugs used in diabetes,"/capita, US$ exchange rate",34.2
+12601,Germany,2017,7,A10-Drugs used in diabetes,Million US$ at exchange rate,2826.5
+12602,Germany,2017,7,G-Genito urinary system and sex hormones,% of total sales,2.0
+12603,Germany,2017,7,A10-Drugs used in diabetes,% of total sales,6.7
+12604,Germany,2017,7,A10-Drugs used in diabetes,"/capita, US$ purchasing power parity",40.6
+12605,Germany,2017,7,A10-Drugs used in diabetes,Million of national currency units,2502.0
+12606,Germany,2017,7,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ exchange rate",9.5
+12607,Germany,2017,7,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ purchasing power parity",11.3
+12608,Germany,2017,7,N02-Analgesics,"/capita, US$ exchange rate",24.1
+12609,Germany,2017,7,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million of national currency units,695.7
+12610,Germany,2017,7,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"Million US$, purchasing power parity",934.1
+12611,Germany,2017,7,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million US$ at exchange rate,785.9
+12612,Germany,2017,7,G-Genito urinary system and sex hormones,"/capita, US$ purchasing power parity",12.2
+12613,Germany,2017,7,A-Alimentary tract and metabolism,"/capita, US$ purchasing power parity",72.8
+12614,Germany,2017,7,A-Alimentary tract and metabolism,"/capita, US$ exchange rate",61.3
+12615,Germany,2017,7,N02-Analgesics,"/capita, US$ purchasing power parity",28.7
+12616,Germany,2017,7,A-Alimentary tract and metabolism,% of total sales,12.1
+12617,Germany,2017,7,A-Alimentary tract and metabolism,Million US$ at exchange rate,5064.7
+12618,Germany,2017,7,A-Alimentary tract and metabolism,Million of national currency units,4483.3
+12619,Germany,2017,7,A-Alimentary tract and metabolism,"Million US$, purchasing power parity",6019.6
+12620,Germany,2017,7,N02-Analgesics,% of total sales,4.7
+12621,Germany,2017,7,B-Blood and blood forming organs,Million of national currency units,3168.4
+12622,Germany,2017,7,G-Genito urinary system and sex hormones,"/capita, US$ exchange rate",10.3
+12623,Germany,2017,7,G-Genito urinary system and sex hormones,Million US$ at exchange rate,848.4
+12624,Germany,2017,7,G-Genito urinary system and sex hormones,Million of national currency units,751.0
+12625,Germany,2017,7,G-Genito urinary system and sex hormones,"Million US$, purchasing power parity",1008.3
+12626,Germany,2017,7,A02A-Antacids,Million US$ at exchange rate,21.6
+12627,Germany,2017,7,A02A-Antacids,"Million US$, purchasing power parity",25.6
+12628,Germany,2017,7,G03-Sex hormones and modulators of the genital system,"Million US$, purchasing power parity",521.4
+12629,Germany,2017,7,A02A-Antacids,% of total sales,0.1
+12630,Germany,2017,7,A02A-Antacids,"/capita, US$ purchasing power parity",0.3
+12631,Germany,2017,7,N06A-Antidepressants,Million of national currency units,702.5
+12632,Germany,2017,7,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),% of total sales,1.9
+12633,Germany,2017,7,N02-Analgesics,Million of national currency units,1763.8
+12634,Germany,2017,7,N02-Analgesics,Million US$ at exchange rate,1992.5
+12635,Germany,2017,7,G03-Sex hormones and modulators of the genital system,Million US$ at exchange rate,438.7
+12636,Germany,2017,7,A02A-Antacids,"/capita, US$ exchange rate",0.3
+12637,Germany,2017,7,G03-Sex hormones and modulators of the genital system,Million of national currency units,388.3
+12638,Germany,2017,7,N06A-Antidepressants,"/capita, US$ purchasing power parity",11.4
+12639,Germany,2017,7,N06A-Antidepressants,"/capita, US$ exchange rate",9.6
+12640,Germany,2017,7,N02-Analgesics,"Million US$, purchasing power parity",2368.2
+12641,Germany,2017,7,N06A-Antidepressants,% of total sales,1.9
+12642,Germany,2017,7,A02A-Antacids,Million of national currency units,19.1
+12643,Germany,2017,7,N06A-Antidepressants,"Million US$, purchasing power parity",943.2
+12644,Germany,2017,7,N05B-Anxiolytics,Million of national currency units,65.6
+12645,Germany,2017,7,N06A-Antidepressants,Million US$ at exchange rate,793.6
+12646,Germany,2017,7,G03-Sex hormones and modulators of the genital system,"/capita, US$ exchange rate",5.3
+12647,Germany,2015,5,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ exchange rate",21.6
+12648,Germany,2015,5,C-Cardiovascular system,"Million US$, purchasing power parity",5492.2
+12649,Germany,2015,5,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ purchasing power parity",9.5
+12650,Germany,2015,5,C-Cardiovascular system,"/capita, US$ exchange rate",58.0
+12651,Germany,2015,5,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ purchasing power parity",25.0
+12652,Germany,2015,5,C-Cardiovascular system,Million US$ at exchange rate,4741.6
+12653,Germany,2015,5,C08-Calcium channel blockers,Million of national currency units,284.9
+12654,Germany,2015,5,M01A-Antiinflammatory and antirheumatic products non-steroids,% of total sales,1.7
+12655,Germany,2015,5,C09-Agents acting on the Renin-Angiotensin system,% of total sales,4.5
+12656,Germany,2015,5,C-Cardiovascular system,Million of national currency units,4273.6
+12657,Germany,2015,5,N-Nervous system,% of total sales,15.3
+12658,Germany,2015,5,R03-Drugs for obstructive airway diseases,Million US$ at exchange rate,1883.2
+12659,Germany,2015,5,N-Nervous system,"/capita, US$ exchange rate",73.4
+12660,Germany,2015,5,N-Nervous system,"/capita, US$ purchasing power parity",85.0
+12661,Germany,2015,5,R03-Drugs for obstructive airway diseases,"/capita, US$ purchasing power parity",26.7
+12662,Germany,2015,5,R03-Drugs for obstructive airway diseases,% of total sales,4.8
+12663,Germany,2015,5,R03-Drugs for obstructive airway diseases,"Million US$, purchasing power parity",2181.3
+12664,Germany,2015,5,R03-Drugs for obstructive airway diseases,"/capita, US$ exchange rate",23.1
+12665,Germany,2015,5,N-Nervous system,Million of national currency units,5401.9
+12666,Germany,2015,5,N-Nervous system,Million US$ at exchange rate,5993.5
+12667,Germany,2015,5,Products not elsewhere classified,Million of national currency units,9719.6
+12668,Germany,2015,5,Products not elsewhere classified,Million US$ at exchange rate,10784.0
+12669,Germany,2015,5,C-Cardiovascular system,"/capita, US$ purchasing power parity",67.2
+12670,Germany,2015,5,R03-Drugs for obstructive airway diseases,Million of national currency units,1697.3
+12671,Germany,2015,5,N-Nervous system,"Million US$, purchasing power parity",6942.2
+12672,Germany,2015,5,R-Respiratory system,Million of national currency units,2054.6
+12673,Germany,2015,5,C10-Lipid modifying agents,"/capita, US$ purchasing power parity",9.4
+12674,Germany,2015,5,R-Respiratory system,Million US$ at exchange rate,2279.6
+12675,Germany,2015,5,R-Respiratory system,"/capita, US$ exchange rate",27.9
+12676,Germany,2015,5,R-Respiratory system,"Million US$, purchasing power parity",2640.5
+12677,Germany,2015,5,M01A-Antiinflammatory and antirheumatic products non-steroids,Million of national currency units,606.3
+12678,Germany,2015,5,M01A-Antiinflammatory and antirheumatic products non-steroids,Million US$ at exchange rate,672.7
+12679,Germany,2015,5,C10-Lipid modifying agents,"/capita, US$ exchange rate",8.1
+12680,Germany,2015,5,C10-Lipid modifying agents,"Million US$, purchasing power parity",767.1
+12681,Germany,2015,5,C10-Lipid modifying agents,Million US$ at exchange rate,662.3
+12682,Germany,2015,5,Total pharmaceutical sales,"/capita, US$ purchasing power parity",556.1
+12683,Germany,2015,5,C10-Lipid modifying agents,% of total sales,1.7
+12684,Germany,2015,5,"C01B-Antiarrhythmics, Class I and III",% of total sales,0.2
+12685,Germany,2015,5,M-Musculo-skeletal system,% of total sales,4.0
+12686,Germany,2015,5,"C01B-Antiarrhythmics, Class I and III","Million US$, purchasing power parity",100.1
+12687,Germany,2015,5,"C01B-Antiarrhythmics, Class I and III","/capita, US$ exchange rate",1.1
+12688,Germany,2015,5,"C01B-Antiarrhythmics, Class I and III","/capita, US$ purchasing power parity",1.2
+12689,Germany,2015,5,"C01B-Antiarrhythmics, Class I and III",Million of national currency units,77.9
+12690,Germany,2015,5,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ exchange rate",8.2
+12691,Germany,2015,5,R-Respiratory system,% of total sales,5.8
+12692,Germany,2015,5,R-Respiratory system,"/capita, US$ purchasing power parity",32.3
+12693,Germany,2015,5,"C01B-Antiarrhythmics, Class I and III",Million US$ at exchange rate,86.4
+12694,Germany,2015,5,C08-Calcium channel blockers,% of total sales,0.8
+12695,Germany,2015,5,C08-Calcium channel blockers,"/capita, US$ purchasing power parity",4.5
+12696,Germany,2015,5,C08-Calcium channel blockers,"/capita, US$ exchange rate",3.9
+12697,Germany,2015,5,M-Musculo-skeletal system,Million of national currency units,1397.1
+12698,Germany,2015,5,C09-Agents acting on the Renin-Angiotensin system,Million of national currency units,1590.0
+12699,Germany,2015,5,Products not elsewhere classified,"/capita, US$ exchange rate",132.0
+12700,Germany,2015,5,Products not elsewhere classified,"Million US$, purchasing power parity",12491.1
+12701,Germany,2015,5,C08-Calcium channel blockers,"Million US$, purchasing power parity",366.1
+12702,Germany,2015,5,C08-Calcium channel blockers,Million US$ at exchange rate,316.1
+12703,Germany,2015,5,C09-Agents acting on the Renin-Angiotensin system,Million US$ at exchange rate,1764.1
+12704,Germany,2015,5,C09-Agents acting on the Renin-Angiotensin system,"Million US$, purchasing power parity",2043.4
+12705,Germany,2015,5,Total pharmaceutical sales,"Million US$, purchasing power parity",45429.5
+12706,Germany,2015,5,Total pharmaceutical sales,Million US$ at exchange rate,39221.0
+12707,Germany,2015,5,Total pharmaceutical sales,Million of national currency units,35349.7
+12708,Germany,2015,5,C-Cardiovascular system,% of total sales,12.1
+12709,Germany,2015,5,Total pharmaceutical sales,"/capita, US$ exchange rate",480.1
+12710,Germany,2015,5,M-Musculo-skeletal system,"/capita, US$ exchange rate",19.0
+12711,Germany,2015,5,M-Musculo-skeletal system,"Million US$, purchasing power parity",1795.5
+12712,Germany,2015,5,M-Musculo-skeletal system,Million US$ at exchange rate,1550.1
+12713,Germany,2015,5,C10-Lipid modifying agents,Million of national currency units,596.9
+12714,Germany,2015,5,Products not elsewhere classified,% of total sales,27.5
+12715,Germany,2015,5,Products not elsewhere classified,"/capita, US$ purchasing power parity",152.9
+12716,Germany,2015,5,M-Musculo-skeletal system,"/capita, US$ purchasing power parity",22.0
+12717,Germany,2015,5,M01A-Antiinflammatory and antirheumatic products non-steroids,"Million US$, purchasing power parity",779.2
+12718,Germany,2015,5,C07-Beta blocking agents,Million of national currency units,668.9
+12719,Germany,2015,5,C01A-Cardiac glycosides,% of total sales,0.1
+12720,Germany,2015,5,C01A-Cardiac glycosides,"/capita, US$ purchasing power parity",0.4
+12721,Germany,2015,5,C07-Beta blocking agents,Million US$ at exchange rate,742.2
+12722,Germany,2015,5,J-Antiinfectives for systemic use,% of total sales,10.6
+12723,Germany,2015,5,C07-Beta blocking agents,"Million US$, purchasing power parity",859.6
+12724,Germany,2015,5,J-Antiinfectives for systemic use,"/capita, US$ purchasing power parity",58.9
+12725,Germany,2015,5,J-Antiinfectives for systemic use,"Million US$, purchasing power parity",4811.3
+12726,Germany,2015,5,J-Antiinfectives for systemic use,Million of national currency units,3743.8
+12727,Germany,2015,5,J-Antiinfectives for systemic use,Million US$ at exchange rate,4153.8
+12728,Germany,2015,5,J-Antiinfectives for systemic use,"/capita, US$ exchange rate",50.9
+12729,Germany,2015,5,C01A-Cardiac glycosides,"Million US$, purchasing power parity",33.9
+12730,Germany,2015,5,C01A-Cardiac glycosides,"/capita, US$ exchange rate",0.4
+12731,Germany,2015,5,C01A-Cardiac glycosides,Million of national currency units,26.4
+12732,Germany,2015,5,C01A-Cardiac glycosides,Million US$ at exchange rate,29.3
+12733,Germany,2015,5,C03-Diuretics,"/capita, US$ exchange rate",6.0
+12734,Germany,2015,5,C03-Diuretics,% of total sales,1.3
+12735,Germany,2015,5,C03-Diuretics,"/capita, US$ purchasing power parity",7.0
+12736,Germany,2015,5,C03-Diuretics,"Million US$, purchasing power parity",569.7
+12737,Germany,2015,5,G03-Sex hormones and modulators of the genital system,% of total sales,1.2
+12738,Germany,2015,5,C03-Diuretics,Million of national currency units,443.3
+12739,Germany,2015,5,C03-Diuretics,Million US$ at exchange rate,491.8
+12740,Germany,2015,5,C07-Beta blocking agents,% of total sales,1.9
+12741,Germany,2015,5,C07-Beta blocking agents,"/capita, US$ exchange rate",9.1
+12742,Germany,2015,5,C07-Beta blocking agents,"/capita, US$ purchasing power parity",10.5
+12743,Germany,2015,5,N05B-Anxiolytics,"/capita, US$ purchasing power parity",1.2
+12744,Germany,2015,5,N05B-Anxiolytics,Million US$ at exchange rate,81.3
+12745,Germany,2015,5,N05B-Anxiolytics,"Million US$, purchasing power parity",94.2
+12746,Germany,2015,5,N05B-Anxiolytics,"/capita, US$ exchange rate",1.0
+12747,Germany,2015,5,J01-Antibacterials for systemic use,"/capita, US$ exchange rate",10.5
+12748,Germany,2015,5,J01-Antibacterials for systemic use,"/capita, US$ purchasing power parity",12.1
+12749,Germany,2015,5,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million of national currency units,1111.7
+12750,Germany,2015,5,J01-Antibacterials for systemic use,"Million US$, purchasing power parity",989.2
+12751,Germany,2015,5,C02-Antihypertensives,% of total sales,1.1
+12752,Germany,2015,5,C02-Antihypertensives,"/capita, US$ purchasing power parity",5.8
+12753,Germany,2015,5,J01-Antibacterials for systemic use,% of total sales,2.2
+12754,Germany,2015,5,N05B-Anxiolytics,% of total sales,0.2
+12755,Germany,2015,5,"H-Systemic hormonal preparations, excluding sex hormones and insulins",% of total sales,3.1
+12756,Germany,2015,5,J01-Antibacterials for systemic use,Million of national currency units,769.7
+12757,Germany,2015,5,J01-Antibacterials for systemic use,Million US$ at exchange rate,854.0
+12758,Germany,2015,5,"H-Systemic hormonal preparations, excluding sex hormones and insulins","Million US$, purchasing power parity",1428.7
+12759,Germany,2015,5,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million US$ at exchange rate,1233.4
+12760,Germany,2015,5,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ purchasing power parity",17.5
+12761,Germany,2015,5,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ exchange rate",15.1
+12762,Germany,2015,5,N05C-Hypnotics and sedatives,"/capita, US$ exchange rate",1.3
+12763,Germany,2015,5,B-Blood and blood forming organs,"/capita, US$ exchange rate",34.8
+12764,Germany,2015,5,N05C-Hypnotics and sedatives,Million US$ at exchange rate,104.8
+12765,Germany,2015,5,N05C-Hypnotics and sedatives,"Million US$, purchasing power parity",121.4
+12766,Germany,2015,5,N05C-Hypnotics and sedatives,"/capita, US$ purchasing power parity",1.5
+12767,Germany,2015,5,B-Blood and blood forming organs,"Million US$, purchasing power parity",3295.4
+12768,Germany,2015,5,B-Blood and blood forming organs,Million US$ at exchange rate,2845.0
+12769,Germany,2015,5,N05C-Hypnotics and sedatives,% of total sales,0.3
+12770,Germany,2015,5,C02-Antihypertensives,Million US$ at exchange rate,412.3
+12771,Germany,2015,5,C02-Antihypertensives,"/capita, US$ exchange rate",5.0
+12772,Germany,2015,5,C02-Antihypertensives,"Million US$, purchasing power parity",477.6
+12773,Germany,2015,5,C02-Antihypertensives,Million of national currency units,371.6
+12774,Germany,2015,5,G03-Sex hormones and modulators of the genital system,"/capita, US$ purchasing power parity",6.4
+12775,Germany,2015,5,B-Blood and blood forming organs,"/capita, US$ purchasing power parity",40.3
+12776,Germany,2015,5,B-Blood and blood forming organs,% of total sales,7.3
+12777,Germany,2015,5,N05C-Hypnotics and sedatives,Million of national currency units,94.5
+12778,Germany,2015,5,A10-Drugs used in diabetes,"Million US$, purchasing power parity",2960.3
+12779,Germany,2015,5,A10-Drugs used in diabetes,"/capita, US$ exchange rate",31.3
+12780,Germany,2015,5,A10-Drugs used in diabetes,Million US$ at exchange rate,2555.8
+12781,Germany,2015,5,G-Genito urinary system and sex hormones,% of total sales,2.3
+12782,Germany,2015,5,A10-Drugs used in diabetes,"/capita, US$ purchasing power parity",36.2
+12783,Germany,2015,5,A10-Drugs used in diabetes,% of total sales,6.5
+12784,Germany,2015,5,A10-Drugs used in diabetes,Million of national currency units,2303.5
+12785,Germany,2015,5,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ exchange rate",10.8
+12786,Germany,2015,5,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ purchasing power parity",12.5
+12787,Germany,2015,5,N02-Analgesics,"/capita, US$ exchange rate",23.0
+12788,Germany,2015,5,B-Blood and blood forming organs,Million of national currency units,2564.2
+12789,Germany,2015,5,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million of national currency units,796.2
+12790,Germany,2015,5,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"Million US$, purchasing power parity",1023.2
+12791,Germany,2015,5,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million US$ at exchange rate,883.4
+12792,Germany,2015,5,A-Alimentary tract and metabolism,"/capita, US$ purchasing power parity",66.9
+12793,Germany,2015,5,A-Alimentary tract and metabolism,% of total sales,12.0
+12794,Germany,2015,5,A-Alimentary tract and metabolism,"/capita, US$ exchange rate",57.8
+12795,Germany,2015,5,A-Alimentary tract and metabolism,Million US$ at exchange rate,4719.0
+12796,Germany,2015,5,A-Alimentary tract and metabolism,Million of national currency units,4253.2
+12797,Germany,2015,5,A-Alimentary tract and metabolism,"Million US$, purchasing power parity",5466.0
+12798,Germany,2015,5,G-Genito urinary system and sex hormones,Million of national currency units,829.9
+12799,Germany,2015,5,N02-Analgesics,% of total sales,4.8
+12800,Germany,2015,5,G-Genito urinary system and sex hormones,"/capita, US$ purchasing power parity",13.1
+12801,Germany,2015,5,G-Genito urinary system and sex hormones,"/capita, US$ exchange rate",11.3
+12802,Germany,2015,5,G-Genito urinary system and sex hormones,Million US$ at exchange rate,920.8
+12803,Germany,2015,5,N02-Analgesics,"/capita, US$ purchasing power parity",26.6
+12804,Germany,2015,5,G-Genito urinary system and sex hormones,"Million US$, purchasing power parity",1066.5
+12805,Germany,2015,5,A02A-Antacids,Million US$ at exchange rate,19.7
+12806,Germany,2015,5,A02A-Antacids,"Million US$, purchasing power parity",22.9
+12807,Germany,2015,5,G03-Sex hormones and modulators of the genital system,"Million US$, purchasing power parity",523.6
+12808,Germany,2015,5,A02A-Antacids,% of total sales,0.1
+12809,Germany,2015,5,A02A-Antacids,"/capita, US$ purchasing power parity",0.3
+12810,Germany,2015,5,N06A-Antidepressants,Million of national currency units,805.8
+12811,Germany,2015,5,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),% of total sales,2.3
+12812,Germany,2015,5,N02-Analgesics,Million US$ at exchange rate,1877.3
+12813,Germany,2015,5,G03-Sex hormones and modulators of the genital system,Million US$ at exchange rate,452.0
+12814,Germany,2015,5,A02A-Antacids,"/capita, US$ exchange rate",0.2
+12815,Germany,2015,5,G03-Sex hormones and modulators of the genital system,Million of national currency units,407.4
+12816,Germany,2015,5,N06A-Antidepressants,"/capita, US$ purchasing power parity",12.7
+12817,Germany,2015,5,N06A-Antidepressants,"/capita, US$ exchange rate",10.9
+12818,Germany,2015,5,N02-Analgesics,"Million US$, purchasing power parity",2174.5
+12819,Germany,2015,5,N06A-Antidepressants,% of total sales,2.3
+12820,Germany,2015,5,N02-Analgesics,Million of national currency units,1692.0
+12821,Germany,2015,5,N05B-Anxiolytics,Million of national currency units,73.3
+12822,Germany,2015,5,A02A-Antacids,Million of national currency units,17.8
+12823,Germany,2015,5,N06A-Antidepressants,Million US$ at exchange rate,894.0
+12824,Germany,2015,5,N06A-Antidepressants,"Million US$, purchasing power parity",1035.6
+12825,Germany,2015,5,G03-Sex hormones and modulators of the genital system,"/capita, US$ exchange rate",5.5
+12826,Germany,2014,5,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ exchange rate",28.5
+12827,Germany,2014,5,C-Cardiovascular system,"Million US$, purchasing power parity",5721.8
+12828,Germany,2014,5,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ purchasing power parity",10.0
+12829,Germany,2014,5,C-Cardiovascular system,"/capita, US$ exchange rate",72.2
+12830,Germany,2014,5,C08-Calcium channel blockers,Million of national currency units,284.7
+12831,Germany,2014,5,C-Cardiovascular system,Million US$ at exchange rate,5845.0
+12832,Germany,2014,5,M01A-Antiinflammatory and antirheumatic products non-steroids,% of total sales,1.8
+12833,Germany,2014,5,C09-Agents acting on the Renin-Angiotensin system,% of total sales,5.2
+12834,Germany,2014,5,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ purchasing power parity",27.9
+12835,Germany,2014,5,C-Cardiovascular system,Million of national currency units,4399.7
+12836,Germany,2014,5,N-Nervous system,% of total sales,16.9
+12837,Germany,2014,5,R03-Drugs for obstructive airway diseases,Million US$ at exchange rate,2270.1
+12838,Germany,2014,5,N-Nervous system,"/capita, US$ exchange rate",93.1
+12839,Germany,2014,5,N-Nervous system,"/capita, US$ purchasing power parity",91.1
+12840,Germany,2014,5,R03-Drugs for obstructive airway diseases,"/capita, US$ purchasing power parity",27.4
+12841,Germany,2014,5,R03-Drugs for obstructive airway diseases,% of total sales,5.1
+12842,Germany,2014,5,R03-Drugs for obstructive airway diseases,"Million US$, purchasing power parity",2222.3
+12843,Germany,2014,5,R03-Drugs for obstructive airway diseases,"/capita, US$ exchange rate",28.0
+12844,Germany,2014,5,N-Nervous system,Million of national currency units,5672.9
+12845,Germany,2014,5,N-Nervous system,Million US$ at exchange rate,7536.5
+12846,Germany,2014,5,Products not elsewhere classified,Million of national currency units,8741.3
+12847,Germany,2014,5,Products not elsewhere classified,Million US$ at exchange rate,11612.8
+12848,Germany,2014,5,Products not elsewhere classified,"Million US$, purchasing power parity",11368.0
+12849,Germany,2014,5,C-Cardiovascular system,"/capita, US$ purchasing power parity",70.7
+12850,Germany,2014,5,C-Cardiovascular system,% of total sales,13.1
+12851,Germany,2014,5,R03-Drugs for obstructive airway diseases,Million of national currency units,1708.8
+12852,Germany,2014,5,N-Nervous system,"Million US$, purchasing power parity",7377.6
+12853,Germany,2014,5,R-Respiratory system,Million of national currency units,2047.5
+12854,Germany,2014,5,C10-Lipid modifying agents,% of total sales,1.7
+12855,Germany,2014,5,C10-Lipid modifying agents,"/capita, US$ purchasing power parity",9.4
+12856,Germany,2014,5,R-Respiratory system,Million US$ at exchange rate,2720.1
+12857,Germany,2014,5,R-Respiratory system,"/capita, US$ exchange rate",33.6
+12858,Germany,2014,5,R-Respiratory system,"Million US$, purchasing power parity",2662.8
+12859,Germany,2014,5,M01A-Antiinflammatory and antirheumatic products non-steroids,Million of national currency units,620.4
+12860,Germany,2014,5,M01A-Antiinflammatory and antirheumatic products non-steroids,Million US$ at exchange rate,824.2
+12861,Germany,2014,5,C10-Lipid modifying agents,"/capita, US$ exchange rate",9.6
+12862,Germany,2014,5,C10-Lipid modifying agents,"Million US$, purchasing power parity",763.4
+12863,Germany,2014,5,"C01B-Antiarrhythmics, Class I and III",% of total sales,0.2
+12864,Germany,2014,5,M-Musculo-skeletal system,% of total sales,4.1
+12865,Germany,2014,5,"C01B-Antiarrhythmics, Class I and III","Million US$, purchasing power parity",104.6
+12866,Germany,2014,5,"C01B-Antiarrhythmics, Class I and III","/capita, US$ exchange rate",1.3
+12867,Germany,2014,5,"C01B-Antiarrhythmics, Class I and III","/capita, US$ purchasing power parity",1.3
+12868,Germany,2014,5,"C01B-Antiarrhythmics, Class I and III",Million of national currency units,80.4
+12869,Germany,2014,5,M01A-Antiinflammatory and antirheumatic products non-steroids,"Million US$, purchasing power parity",806.8
+12870,Germany,2014,5,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ exchange rate",10.2
+12871,Germany,2014,5,R-Respiratory system,% of total sales,6.1
+12872,Germany,2014,5,R-Respiratory system,"/capita, US$ purchasing power parity",32.9
+12873,Germany,2014,5,"C01B-Antiarrhythmics, Class I and III",Million US$ at exchange rate,106.8
+12874,Germany,2014,5,C10-Lipid modifying agents,Million US$ at exchange rate,779.8
+12875,Germany,2014,5,C08-Calcium channel blockers,% of total sales,0.8
+12876,Germany,2014,5,C08-Calcium channel blockers,"/capita, US$ purchasing power parity",4.6
+12877,Germany,2014,5,C08-Calcium channel blockers,"/capita, US$ exchange rate",4.7
+12878,Germany,2014,5,M-Musculo-skeletal system,Million of national currency units,1386.0
+12879,Germany,2014,5,C09-Agents acting on the Renin-Angiotensin system,Million of national currency units,1739.9
+12880,Germany,2014,5,Products not elsewhere classified,"/capita, US$ exchange rate",143.4
+12881,Germany,2014,5,C08-Calcium channel blockers,"Million US$, purchasing power parity",370.3
+12882,Germany,2014,5,C08-Calcium channel blockers,Million US$ at exchange rate,378.2
+12883,Germany,2014,5,C09-Agents acting on the Renin-Angiotensin system,Million US$ at exchange rate,2311.5
+12884,Germany,2014,5,C09-Agents acting on the Renin-Angiotensin system,"Million US$, purchasing power parity",2262.7
+12885,Germany,2014,5,M-Musculo-skeletal system,Million US$ at exchange rate,1841.3
+12886,Germany,2014,5,Total pharmaceutical sales,"Million US$, purchasing power parity",43650.9
+12887,Germany,2014,5,Total pharmaceutical sales,Million US$ at exchange rate,44590.9
+12888,Germany,2014,5,Total pharmaceutical sales,Million of national currency units,33564.8
+12889,Germany,2014,5,Total pharmaceutical sales,"/capita, US$ purchasing power parity",539.0
+12890,Germany,2014,5,Total pharmaceutical sales,"/capita, US$ exchange rate",550.6
+12891,Germany,2014,5,M-Musculo-skeletal system,"/capita, US$ exchange rate",22.7
+12892,Germany,2014,5,M-Musculo-skeletal system,"Million US$, purchasing power parity",1802.5
+12893,Germany,2014,5,C10-Lipid modifying agents,Million of national currency units,587.0
+12894,Germany,2014,5,Products not elsewhere classified,% of total sales,26.0
+12895,Germany,2014,5,Products not elsewhere classified,"/capita, US$ purchasing power parity",140.4
+12896,Germany,2014,5,M-Musculo-skeletal system,"/capita, US$ purchasing power parity",22.3
+12897,Germany,2014,5,C07-Beta blocking agents,Million of national currency units,669.8
+12898,Germany,2014,5,C01A-Cardiac glycosides,"/capita, US$ purchasing power parity",0.5
+12899,Germany,2014,5,C01A-Cardiac glycosides,% of total sales,0.1
+12900,Germany,2014,5,C07-Beta blocking agents,Million US$ at exchange rate,889.8
+12901,Germany,2014,5,J-Antiinfectives for systemic use,% of total sales,8.8
+12902,Germany,2014,5,C07-Beta blocking agents,"Million US$, purchasing power parity",871.1
+12903,Germany,2014,5,J-Antiinfectives for systemic use,"/capita, US$ purchasing power parity",47.6
+12904,Germany,2014,5,J-Antiinfectives for systemic use,"Million US$, purchasing power parity",3857.4
+12905,Germany,2014,5,J-Antiinfectives for systemic use,"/capita, US$ exchange rate",48.7
+12906,Germany,2014,5,J-Antiinfectives for systemic use,Million of national currency units,2966.1
+12907,Germany,2014,5,J-Antiinfectives for systemic use,Million US$ at exchange rate,3940.5
+12908,Germany,2014,5,C01A-Cardiac glycosides,"Million US$, purchasing power parity",37.3
+12909,Germany,2014,5,C01A-Cardiac glycosides,"/capita, US$ exchange rate",0.5
+12910,Germany,2014,5,C01A-Cardiac glycosides,Million of national currency units,28.7
+12911,Germany,2014,5,C01A-Cardiac glycosides,Million US$ at exchange rate,38.1
+12912,Germany,2014,5,C03-Diuretics,"/capita, US$ exchange rate",7.2
+12913,Germany,2014,5,C03-Diuretics,"/capita, US$ purchasing power parity",7.1
+12914,Germany,2014,5,C03-Diuretics,% of total sales,1.3
+12915,Germany,2014,5,C03-Diuretics,"Million US$, purchasing power parity",572.9
+12916,Germany,2014,5,C03-Diuretics,Million of national currency units,440.5
+12917,Germany,2014,5,G03-Sex hormones and modulators of the genital system,% of total sales,1.2
+12918,Germany,2014,5,C03-Diuretics,Million US$ at exchange rate,585.2
+12919,Germany,2014,5,C07-Beta blocking agents,% of total sales,2.0
+12920,Germany,2014,5,C07-Beta blocking agents,"/capita, US$ purchasing power parity",10.8
+12921,Germany,2014,5,C07-Beta blocking agents,"/capita, US$ exchange rate",11.0
+12922,Germany,2014,5,N05B-Anxiolytics,"/capita, US$ purchasing power parity",1.2
+12923,Germany,2014,5,N05B-Anxiolytics,"Million US$, purchasing power parity",99.9
+12924,Germany,2014,5,N05B-Anxiolytics,Million US$ at exchange rate,102.0
+12925,Germany,2014,5,N05B-Anxiolytics,"/capita, US$ exchange rate",1.3
+12926,Germany,2014,5,B-Blood and blood forming organs,Million US$ at exchange rate,3079.2
+12927,Germany,2014,5,J01-Antibacterials for systemic use,"/capita, US$ exchange rate",12.8
+12928,Germany,2014,5,J01-Antibacterials for systemic use,"/capita, US$ purchasing power parity",12.6
+12929,Germany,2014,5,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million of national currency units,1085.5
+12930,Germany,2014,5,J01-Antibacterials for systemic use,"Million US$, purchasing power parity",1017.9
+12931,Germany,2014,5,C02-Antihypertensives,% of total sales,1.1
+12932,Germany,2014,5,C02-Antihypertensives,"/capita, US$ purchasing power parity",5.7
+12933,Germany,2014,5,J01-Antibacterials for systemic use,% of total sales,2.3
+12934,Germany,2014,5,N05B-Anxiolytics,% of total sales,0.2
+12935,Germany,2014,5,J01-Antibacterials for systemic use,Million of national currency units,782.7
+12936,Germany,2014,5,"H-Systemic hormonal preparations, excluding sex hormones and insulins",% of total sales,3.2
+12937,Germany,2014,5,J01-Antibacterials for systemic use,Million US$ at exchange rate,1039.8
+12938,Germany,2014,5,"H-Systemic hormonal preparations, excluding sex hormones and insulins","Million US$, purchasing power parity",1411.7
+12939,Germany,2014,5,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million US$ at exchange rate,1442.1
+12940,Germany,2014,5,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ purchasing power parity",17.4
+12941,Germany,2014,5,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ exchange rate",17.8
+12942,Germany,2014,5,N05C-Hypnotics and sedatives,"/capita, US$ exchange rate",1.6
+12943,Germany,2014,5,N05C-Hypnotics and sedatives,"Million US$, purchasing power parity",126.9
+12944,Germany,2014,5,B-Blood and blood forming organs,"/capita, US$ exchange rate",38.0
+12945,Germany,2014,5,N05C-Hypnotics and sedatives,Million US$ at exchange rate,129.7
+12946,Germany,2014,5,N05C-Hypnotics and sedatives,"/capita, US$ purchasing power parity",1.6
+12947,Germany,2014,5,B-Blood and blood forming organs,"Million US$, purchasing power parity",3014.3
+12948,Germany,2014,5,N05C-Hypnotics and sedatives,% of total sales,0.3
+12949,Germany,2014,5,C02-Antihypertensives,Million US$ at exchange rate,473.6
+12950,Germany,2014,5,C02-Antihypertensives,"/capita, US$ exchange rate",5.8
+12951,Germany,2014,5,C02-Antihypertensives,"Million US$, purchasing power parity",463.6
+12952,Germany,2014,5,C02-Antihypertensives,Million of national currency units,356.5
+12953,Germany,2014,5,B-Blood and blood forming organs,% of total sales,6.9
+12954,Germany,2014,5,B-Blood and blood forming organs,"/capita, US$ purchasing power parity",37.2
+12955,Germany,2014,5,N05C-Hypnotics and sedatives,Million of national currency units,97.6
+12956,Germany,2014,5,G03-Sex hormones and modulators of the genital system,"/capita, US$ purchasing power parity",6.3
+12957,Germany,2014,5,A10-Drugs used in diabetes,"Million US$, purchasing power parity",2899.6
+12958,Germany,2014,5,A10-Drugs used in diabetes,"/capita, US$ exchange rate",36.6
+12959,Germany,2014,5,A10-Drugs used in diabetes,Million US$ at exchange rate,2962.0
+12960,Germany,2014,5,G-Genito urinary system and sex hormones,% of total sales,2.4
+12961,Germany,2014,5,A10-Drugs used in diabetes,"/capita, US$ purchasing power parity",35.8
+12962,Germany,2014,5,A10-Drugs used in diabetes,% of total sales,6.6
+12963,Germany,2014,5,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ purchasing power parity",12.8
+12964,Germany,2014,5,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ exchange rate",13.1
+12965,Germany,2014,5,N02-Analgesics,"/capita, US$ exchange rate",27.5
+12966,Germany,2014,5,B-Blood and blood forming organs,Million of national currency units,2317.8
+12967,Germany,2014,5,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million of national currency units,795.5
+12968,Germany,2014,5,A10-Drugs used in diabetes,Million of national currency units,2229.6
+12969,Germany,2014,5,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"Million US$, purchasing power parity",1034.5
+12970,Germany,2014,5,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million US$ at exchange rate,1056.8
+12971,Germany,2014,5,A-Alimentary tract and metabolism,"/capita, US$ purchasing power parity",66.4
+12972,Germany,2014,5,A-Alimentary tract and metabolism,% of total sales,12.3
+12973,Germany,2014,5,A-Alimentary tract and metabolism,"/capita, US$ exchange rate",67.8
+12974,Germany,2014,5,A-Alimentary tract and metabolism,Million US$ at exchange rate,5489.8
+12975,Germany,2014,5,A-Alimentary tract and metabolism,Million of national currency units,4132.3
+12976,Germany,2014,5,A-Alimentary tract and metabolism,"Million US$, purchasing power parity",5374.0
+12977,Germany,2014,5,G-Genito urinary system and sex hormones,Million of national currency units,815.7
+12978,Germany,2014,5,N02-Analgesics,% of total sales,5.0
+12979,Germany,2014,5,G-Genito urinary system and sex hormones,"/capita, US$ purchasing power parity",13.1
+12980,Germany,2014,5,G-Genito urinary system and sex hormones,"/capita, US$ exchange rate",13.4
+12981,Germany,2014,5,G-Genito urinary system and sex hormones,Million US$ at exchange rate,1083.7
+12982,Germany,2014,5,N02-Analgesics,"/capita, US$ purchasing power parity",26.9
+12983,Germany,2014,5,G-Genito urinary system and sex hormones,"Million US$, purchasing power parity",1060.8
+12984,Germany,2014,5,A02A-Antacids,"Million US$, purchasing power parity",22.2
+12985,Germany,2014,5,A02A-Antacids,Million US$ at exchange rate,22.7
+12986,Germany,2014,5,A02A-Antacids,"/capita, US$ purchasing power parity",0.3
+12987,Germany,2014,5,G03-Sex hormones and modulators of the genital system,"Million US$, purchasing power parity",513.8
+12988,Germany,2014,5,A02A-Antacids,% of total sales,0.1
+12989,Germany,2014,5,N06A-Antidepressants,Million of national currency units,832.6
+12990,Germany,2014,5,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),% of total sales,2.4
+12991,Germany,2014,5,N02-Analgesics,Million US$ at exchange rate,2226.3
+12992,Germany,2014,5,G03-Sex hormones and modulators of the genital system,Million US$ at exchange rate,524.9
+12993,Germany,2014,5,A02A-Antacids,"/capita, US$ exchange rate",0.3
+12994,Germany,2014,5,G03-Sex hormones and modulators of the genital system,Million of national currency units,395.1
+12995,Germany,2014,5,N06A-Antidepressants,"/capita, US$ purchasing power parity",13.4
+12996,Germany,2014,5,N06A-Antidepressants,"/capita, US$ exchange rate",13.7
+12997,Germany,2014,5,N02-Analgesics,"Million US$, purchasing power parity",2179.4
+12998,Germany,2014,5,N06A-Antidepressants,% of total sales,2.5
+12999,Germany,2014,5,N02-Analgesics,Million of national currency units,1675.8
+13000,Germany,2014,5,N05B-Anxiolytics,Million of national currency units,76.8
+13001,Germany,2014,5,A02A-Antacids,Million of national currency units,17.1
+13002,Germany,2014,5,G03-Sex hormones and modulators of the genital system,"/capita, US$ exchange rate",6.5
+13003,Germany,2014,5,N06A-Antidepressants,Million US$ at exchange rate,1106.1
+13004,Germany,2014,5,N06A-Antidepressants,"Million US$, purchasing power parity",1082.8
+13005,Germany,2013,5,M01A-Antiinflammatory and antirheumatic products non-steroids,% of total sales,2.0
+13006,Germany,2013,5,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ exchange rate",30.6
+13007,Germany,2013,5,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ purchasing power parity",9.9
+13008,Germany,2013,5,C-Cardiovascular system,"/capita, US$ exchange rate",73.4
+13009,Germany,2013,5,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ purchasing power parity",29.8
+13010,Germany,2013,5,C-Cardiovascular system,Million US$ at exchange rate,5918.0
+13011,Germany,2013,5,C08-Calcium channel blockers,Million of national currency units,283.4
+13012,Germany,2013,5,C-Cardiovascular system,"Million US$, purchasing power parity",5751.2
+13013,Germany,2013,5,C09-Agents acting on the Renin-Angiotensin system,% of total sales,5.9
+13014,Germany,2013,5,C-Cardiovascular system,Million of national currency units,4455.9
+13015,Germany,2013,5,Products not elsewhere classified,"Million US$, purchasing power parity",10354.8
+13016,Germany,2013,5,N-Nervous system,% of total sales,17.1
+13017,Germany,2013,5,R03-Drugs for obstructive airway diseases,Million US$ at exchange rate,2241.3
+13018,Germany,2013,5,N-Nervous system,"/capita, US$ exchange rate",88.6
+13019,Germany,2013,5,N-Nervous system,"/capita, US$ purchasing power parity",86.1
+13020,Germany,2013,5,R03-Drugs for obstructive airway diseases,"/capita, US$ purchasing power parity",27.0
+13021,Germany,2013,5,R03-Drugs for obstructive airway diseases,% of total sales,5.4
+13022,Germany,2013,5,R03-Drugs for obstructive airway diseases,"Million US$, purchasing power parity",2178.2
+13023,Germany,2013,5,R03-Drugs for obstructive airway diseases,"/capita, US$ exchange rate",27.8
+13024,Germany,2013,5,N-Nervous system,Million of national currency units,5380.2
+13025,Germany,2013,5,N-Nervous system,Million US$ at exchange rate,7145.5
+13026,Germany,2013,5,Products not elsewhere classified,Million of national currency units,8022.7
+13027,Germany,2013,5,Products not elsewhere classified,Million US$ at exchange rate,10655.1
+13028,Germany,2013,5,C-Cardiovascular system,"/capita, US$ purchasing power parity",71.3
+13029,Germany,2013,5,C-Cardiovascular system,% of total sales,14.1
+13030,Germany,2013,5,R03-Drugs for obstructive airway diseases,Million of national currency units,1687.6
+13031,Germany,2013,5,N-Nervous system,"Million US$, purchasing power parity",6944.1
+13032,Germany,2013,5,R-Respiratory system,Million of national currency units,2036.5
+13033,Germany,2013,5,C10-Lipid modifying agents,% of total sales,1.9
+13034,Germany,2013,5,C10-Lipid modifying agents,"/capita, US$ purchasing power parity",9.5
+13035,Germany,2013,5,R-Respiratory system,Million US$ at exchange rate,2704.7
+13036,Germany,2013,5,R-Respiratory system,"/capita, US$ exchange rate",33.5
+13037,Germany,2013,5,R-Respiratory system,"Million US$, purchasing power parity",2628.5
+13038,Germany,2013,5,M01A-Antiinflammatory and antirheumatic products non-steroids,Million US$ at exchange rate,820.5
+13039,Germany,2013,5,M01A-Antiinflammatory and antirheumatic products non-steroids,Million of national currency units,617.8
+13040,Germany,2013,5,M01A-Antiinflammatory and antirheumatic products non-steroids,"Million US$, purchasing power parity",797.4
+13041,Germany,2013,5,C10-Lipid modifying agents,"/capita, US$ exchange rate",9.8
+13042,Germany,2013,5,C10-Lipid modifying agents,"Million US$, purchasing power parity",766.7
+13043,Germany,2013,5,"C01B-Antiarrhythmics, Class I and III",% of total sales,0.3
+13044,Germany,2013,5,M-Musculo-skeletal system,% of total sales,4.3
+13045,Germany,2013,5,"C01B-Antiarrhythmics, Class I and III","Million US$, purchasing power parity",102.1
+13046,Germany,2013,5,"C01B-Antiarrhythmics, Class I and III","/capita, US$ purchasing power parity",1.3
+13047,Germany,2013,5,"C01B-Antiarrhythmics, Class I and III","/capita, US$ exchange rate",1.3
+13048,Germany,2013,5,"C01B-Antiarrhythmics, Class I and III",Million of national currency units,79.1
+13049,Germany,2013,5,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ exchange rate",10.2
+13050,Germany,2013,5,R-Respiratory system,% of total sales,6.5
+13051,Germany,2013,5,R-Respiratory system,"/capita, US$ purchasing power parity",32.6
+13052,Germany,2013,5,"C01B-Antiarrhythmics, Class I and III",Million US$ at exchange rate,105.1
+13053,Germany,2013,5,C08-Calcium channel blockers,% of total sales,0.9
+13054,Germany,2013,5,C08-Calcium channel blockers,"/capita, US$ purchasing power parity",4.5
+13055,Germany,2013,5,C08-Calcium channel blockers,"/capita, US$ exchange rate",4.7
+13056,Germany,2013,5,M-Musculo-skeletal system,Million of national currency units,1361.5
+13057,Germany,2013,5,Products not elsewhere classified,"/capita, US$ purchasing power parity",128.4
+13058,Germany,2013,5,C09-Agents acting on the Renin-Angiotensin system,Million of national currency units,1860.4
+13059,Germany,2013,5,Products not elsewhere classified,"/capita, US$ exchange rate",132.1
+13060,Germany,2013,5,C08-Calcium channel blockers,Million US$ at exchange rate,376.4
+13061,Germany,2013,5,C08-Calcium channel blockers,"Million US$, purchasing power parity",365.8
+13062,Germany,2013,5,C09-Agents acting on the Renin-Angiotensin system,Million US$ at exchange rate,2470.8
+13063,Germany,2013,5,C09-Agents acting on the Renin-Angiotensin system,"Million US$, purchasing power parity",2401.2
+13064,Germany,2013,5,C10-Lipid modifying agents,Million US$ at exchange rate,788.9
+13065,Germany,2013,5,Total pharmaceutical sales,"Million US$, purchasing power parity",40687.6
+13066,Germany,2013,5,Total pharmaceutical sales,Million US$ at exchange rate,41867.7
+13067,Germany,2013,5,Total pharmaceutical sales,Million of national currency units,31524.1
+13068,Germany,2013,5,Total pharmaceutical sales,"/capita, US$ purchasing power parity",504.5
+13069,Germany,2013,5,Total pharmaceutical sales,"/capita, US$ exchange rate",519.2
+13070,Germany,2013,5,M-Musculo-skeletal system,"/capita, US$ exchange rate",22.4
+13071,Germany,2013,5,M-Musculo-skeletal system,"Million US$, purchasing power parity",1757.3
+13072,Germany,2013,5,M-Musculo-skeletal system,Million US$ at exchange rate,1808.2
+13073,Germany,2013,5,C10-Lipid modifying agents,Million of national currency units,594.0
+13074,Germany,2013,5,M-Musculo-skeletal system,"/capita, US$ purchasing power parity",21.8
+13075,Germany,2013,5,Products not elsewhere classified,% of total sales,25.4
+13076,Germany,2013,5,C07-Beta blocking agents,Million of national currency units,661.4
+13077,Germany,2013,5,C07-Beta blocking agents,Million US$ at exchange rate,878.4
+13078,Germany,2013,5,C01A-Cardiac glycosides,"/capita, US$ purchasing power parity",0.5
+13079,Germany,2013,5,C01A-Cardiac glycosides,% of total sales,0.1
+13080,Germany,2013,5,J-Antiinfectives for systemic use,% of total sales,7.6
+13081,Germany,2013,5,C07-Beta blocking agents,"Million US$, purchasing power parity",853.7
+13082,Germany,2013,5,J-Antiinfectives for systemic use,"/capita, US$ purchasing power parity",38.3
+13083,Germany,2013,5,J-Antiinfectives for systemic use,"Million US$, purchasing power parity",3091.6
+13084,Germany,2013,5,J-Antiinfectives for systemic use,"/capita, US$ exchange rate",39.4
+13085,Germany,2013,5,J-Antiinfectives for systemic use,Million of national currency units,2395.3
+13086,Germany,2013,5,J-Antiinfectives for systemic use,Million US$ at exchange rate,3181.2
+13087,Germany,2013,5,C01A-Cardiac glycosides,"Million US$, purchasing power parity",39.8
+13088,Germany,2013,5,C01A-Cardiac glycosides,"/capita, US$ exchange rate",0.5
+13089,Germany,2013,5,C01A-Cardiac glycosides,Million of national currency units,30.8
+13090,Germany,2013,5,C01A-Cardiac glycosides,Million US$ at exchange rate,40.9
+13091,Germany,2013,5,C03-Diuretics,"/capita, US$ exchange rate",6.9
+13092,Germany,2013,5,C03-Diuretics,% of total sales,1.3
+13093,Germany,2013,5,C03-Diuretics,"/capita, US$ purchasing power parity",6.7
+13094,Germany,2013,5,C03-Diuretics,"Million US$, purchasing power parity",540.7
+13095,Germany,2013,5,G03-Sex hormones and modulators of the genital system,% of total sales,1.2
+13096,Germany,2013,5,C03-Diuretics,Million US$ at exchange rate,556.3
+13097,Germany,2013,5,C07-Beta blocking agents,% of total sales,2.1
+13098,Germany,2013,5,C07-Beta blocking agents,"/capita, US$ exchange rate",10.9
+13099,Germany,2013,5,C07-Beta blocking agents,"/capita, US$ purchasing power parity",10.6
+13100,Germany,2013,5,N05B-Anxiolytics,"Million US$, purchasing power parity",99.4
+13101,Germany,2013,5,N05B-Anxiolytics,Million US$ at exchange rate,102.3
+13102,Germany,2013,5,N05B-Anxiolytics,"/capita, US$ purchasing power parity",1.2
+13103,Germany,2013,5,N05B-Anxiolytics,"/capita, US$ exchange rate",1.3
+13104,Germany,2013,5,J01-Antibacterials for systemic use,"/capita, US$ exchange rate",13.6
+13105,Germany,2013,5,J01-Antibacterials for systemic use,"/capita, US$ purchasing power parity",13.3
+13106,Germany,2013,5,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million of national currency units,1046.4
+13107,Germany,2013,5,J01-Antibacterials for systemic use,"Million US$, purchasing power parity",1068.9
+13108,Germany,2013,5,C02-Antihypertensives,% of total sales,1.0
+13109,Germany,2013,5,C02-Antihypertensives,"/capita, US$ purchasing power parity",5.2
+13110,Germany,2013,5,N05B-Anxiolytics,% of total sales,0.2
+13111,Germany,2013,5,J01-Antibacterials for systemic use,% of total sales,2.6
+13112,Germany,2013,5,J01-Antibacterials for systemic use,Million of national currency units,828.2
+13113,Germany,2013,5,"H-Systemic hormonal preparations, excluding sex hormones and insulins",% of total sales,3.3
+13114,Germany,2013,5,J01-Antibacterials for systemic use,Million US$ at exchange rate,1099.9
+13115,Germany,2013,5,"H-Systemic hormonal preparations, excluding sex hormones and insulins","Million US$, purchasing power parity",1350.6
+13116,Germany,2013,5,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million US$ at exchange rate,1389.7
+13117,Germany,2013,5,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ purchasing power parity",16.7
+13118,Germany,2013,5,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ exchange rate",17.2
+13119,Germany,2013,5,N05C-Hypnotics and sedatives,"/capita, US$ exchange rate",1.6
+13120,Germany,2013,5,N05C-Hypnotics and sedatives,Million US$ at exchange rate,129.4
+13121,Germany,2013,5,N05C-Hypnotics and sedatives,"Million US$, purchasing power parity",125.7
+13122,Germany,2013,5,N05C-Hypnotics and sedatives,"/capita, US$ purchasing power parity",1.6
+13123,Germany,2013,5,B-Blood and blood forming organs,"Million US$, purchasing power parity",2598.8
+13124,Germany,2013,5,N05C-Hypnotics and sedatives,% of total sales,0.3
+13125,Germany,2013,5,B-Blood and blood forming organs,"/capita, US$ exchange rate",33.2
+13126,Germany,2013,5,C02-Antihypertensives,Million US$ at exchange rate,433.0
+13127,Germany,2013,5,C02-Antihypertensives,"Million US$, purchasing power parity",420.8
+13128,Germany,2013,5,C02-Antihypertensives,"/capita, US$ exchange rate",5.4
+13129,Germany,2013,5,B-Blood and blood forming organs,% of total sales,6.4
+13130,Germany,2013,5,B-Blood and blood forming organs,"/capita, US$ purchasing power parity",32.2
+13131,Germany,2013,5,N05C-Hypnotics and sedatives,Million of national currency units,97.4
+13132,Germany,2013,5,C02-Antihypertensives,Million of national currency units,326.0
+13133,Germany,2013,5,G03-Sex hormones and modulators of the genital system,"/capita, US$ purchasing power parity",6.0
+13134,Germany,2013,5,A10-Drugs used in diabetes,"/capita, US$ exchange rate",36.3
+13135,Germany,2013,5,A10-Drugs used in diabetes,"Million US$, purchasing power parity",2843.4
+13136,Germany,2013,5,A10-Drugs used in diabetes,Million US$ at exchange rate,2925.8
+13137,Germany,2013,5,G-Genito urinary system and sex hormones,% of total sales,2.5
+13138,Germany,2013,5,A10-Drugs used in diabetes,"/capita, US$ purchasing power parity",35.3
+13139,Germany,2013,5,A10-Drugs used in diabetes,% of total sales,7.0
+13140,Germany,2013,5,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ purchasing power parity",12.5
+13141,Germany,2013,5,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ exchange rate",12.8
+13142,Germany,2013,5,N02-Analgesics,"/capita, US$ exchange rate",27.2
+13143,Germany,2013,5,B-Blood and blood forming organs,Million of national currency units,2013.5
+13144,Germany,2013,5,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million of national currency units,778.8
+13145,Germany,2013,5,A10-Drugs used in diabetes,Million of national currency units,2203.0
+13146,Germany,2013,5,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"Million US$, purchasing power parity",1005.2
+13147,Germany,2013,5,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million US$ at exchange rate,1034.3
+13148,Germany,2013,5,A-Alimentary tract and metabolism,"/capita, US$ purchasing power parity",64.5
+13149,Germany,2013,5,A-Alimentary tract and metabolism,% of total sales,12.8
+13150,Germany,2013,5,A-Alimentary tract and metabolism,Million US$ at exchange rate,5354.4
+13151,Germany,2013,5,A-Alimentary tract and metabolism,Million of national currency units,4031.6
+13152,Germany,2013,5,A-Alimentary tract and metabolism,"/capita, US$ exchange rate",66.4
+13153,Germany,2013,5,A-Alimentary tract and metabolism,"Million US$, purchasing power parity",5203.5
+13154,Germany,2013,5,G-Genito urinary system and sex hormones,Million of national currency units,780.3
+13155,Germany,2013,5,N02-Analgesics,% of total sales,5.2
+13156,Germany,2013,5,G-Genito urinary system and sex hormones,"/capita, US$ purchasing power parity",12.5
+13157,Germany,2013,5,G-Genito urinary system and sex hormones,"/capita, US$ exchange rate",12.9
+13158,Germany,2013,5,B-Blood and blood forming organs,Million US$ at exchange rate,2674.2
+13159,Germany,2013,5,G-Genito urinary system and sex hormones,Million US$ at exchange rate,1036.3
+13160,Germany,2013,5,N02-Analgesics,"/capita, US$ purchasing power parity",26.5
+13161,Germany,2013,5,G-Genito urinary system and sex hormones,"Million US$, purchasing power parity",1007.1
+13162,Germany,2013,5,A02A-Antacids,"Million US$, purchasing power parity",19.5
+13163,Germany,2013,5,A02A-Antacids,Million US$ at exchange rate,20.1
+13164,Germany,2013,5,A02A-Antacids,"/capita, US$ purchasing power parity",0.2
+13165,Germany,2013,5,G03-Sex hormones and modulators of the genital system,"/capita, US$ exchange rate",6.2
+13166,Germany,2013,5,G03-Sex hormones and modulators of the genital system,"Million US$, purchasing power parity",487.7
+13167,Germany,2013,5,A02A-Antacids,% of total sales,0.0
+13168,Germany,2013,5,N06A-Antidepressants,Million of national currency units,791.7
+13169,Germany,2013,5,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),% of total sales,2.5
+13170,Germany,2013,5,N02-Analgesics,Million US$ at exchange rate,2197.1
+13171,Germany,2013,5,G03-Sex hormones and modulators of the genital system,Million US$ at exchange rate,501.9
+13172,Germany,2013,5,A02A-Antacids,"/capita, US$ exchange rate",0.2
+13173,Germany,2013,5,G03-Sex hormones and modulators of the genital system,Million of national currency units,377.9
+13174,Germany,2013,5,N06A-Antidepressants,"/capita, US$ purchasing power parity",12.7
+13175,Germany,2013,5,N06A-Antidepressants,"/capita, US$ exchange rate",13.0
+13176,Germany,2013,5,N02-Analgesics,"Million US$, purchasing power parity",2135.2
+13177,Germany,2013,5,N06A-Antidepressants,% of total sales,2.5
+13178,Germany,2013,5,N02-Analgesics,Million of national currency units,1654.3
+13179,Germany,2013,5,N05B-Anxiolytics,Million of national currency units,77.0
+13180,Germany,2013,5,N06A-Antidepressants,Million US$ at exchange rate,1051.5
+13181,Germany,2013,5,N06A-Antidepressants,"Million US$, purchasing power parity",1021.8
+13182,Germany,2013,5,C03-Diuretics,Million of national currency units,418.9
+13183,Germany,2013,5,A02A-Antacids,Million of national currency units,15.1
+13184,Germany,2012,5,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ exchange rate",30.7
+13185,Germany,2012,5,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ purchasing power parity",9.3
+13186,Germany,2012,5,M01A-Antiinflammatory and antirheumatic products non-steroids,% of total sales,1.9
+13187,Germany,2012,5,C-Cardiovascular system,"/capita, US$ exchange rate",72.4
+13188,Germany,2012,5,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ purchasing power parity",30.3
+13189,Germany,2012,5,C-Cardiovascular system,"Million US$, purchasing power parity",5753.2
+13190,Germany,2012,5,C08-Calcium channel blockers,Million of national currency units,289.6
+13191,Germany,2012,5,C-Cardiovascular system,Million US$ at exchange rate,5819.1
+13192,Germany,2012,5,C09-Agents acting on the Renin-Angiotensin system,% of total sales,6.3
+13193,Germany,2012,5,C-Cardiovascular system,Million of national currency units,4529.2
+13194,Germany,2012,5,N-Nervous system,% of total sales,17.9
+13195,Germany,2012,5,R03-Drugs for obstructive airway diseases,Million US$ at exchange rate,2088.7
+13196,Germany,2012,5,N-Nervous system,"/capita, US$ purchasing power parity",85.9
+13197,Germany,2012,5,R03-Drugs for obstructive airway diseases,"Million US$, purchasing power parity",2065.0
+13198,Germany,2012,5,R03-Drugs for obstructive airway diseases,% of total sales,5.3
+13199,Germany,2012,5,R03-Drugs for obstructive airway diseases,"/capita, US$ purchasing power parity",25.7
+13200,Germany,2012,5,R03-Drugs for obstructive airway diseases,"/capita, US$ exchange rate",26.0
+13201,Germany,2012,5,N-Nervous system,Million of national currency units,5439.9
+13202,Germany,2012,5,Products not elsewhere classified,Million of national currency units,7344.1
+13203,Germany,2012,5,N-Nervous system,Million US$ at exchange rate,6989.1
+13204,Germany,2012,5,Products not elsewhere classified,"Million US$, purchasing power parity",9328.9
+13205,Germany,2012,5,Products not elsewhere classified,Million US$ at exchange rate,9435.6
+13206,Germany,2012,5,C-Cardiovascular system,"/capita, US$ purchasing power parity",71.5
+13207,Germany,2012,5,C-Cardiovascular system,% of total sales,14.9
+13208,Germany,2012,5,R03-Drugs for obstructive airway diseases,Million of national currency units,1625.7
+13209,Germany,2012,5,N-Nervous system,"Million US$, purchasing power parity",6910.0
+13210,Germany,2012,5,N-Nervous system,"/capita, US$ exchange rate",86.9
+13211,Germany,2012,5,R-Respiratory system,Million US$ at exchange rate,2476.9
+13212,Germany,2012,5,R-Respiratory system,Million of national currency units,1927.9
+13213,Germany,2012,5,C10-Lipid modifying agents,% of total sales,2.1
+13214,Germany,2012,5,R-Respiratory system,"/capita, US$ exchange rate",30.8
+13215,Germany,2012,5,C10-Lipid modifying agents,"/capita, US$ purchasing power parity",10.1
+13216,Germany,2012,5,R-Respiratory system,"Million US$, purchasing power parity",2448.9
+13217,Germany,2012,5,M01A-Antiinflammatory and antirheumatic products non-steroids,Million US$ at exchange rate,759.8
+13218,Germany,2012,5,M01A-Antiinflammatory and antirheumatic products non-steroids,"Million US$, purchasing power parity",751.2
+13219,Germany,2012,5,M01A-Antiinflammatory and antirheumatic products non-steroids,Million of national currency units,591.4
+13220,Germany,2012,5,C10-Lipid modifying agents,"/capita, US$ exchange rate",10.3
+13221,Germany,2012,5,C10-Lipid modifying agents,"Million US$, purchasing power parity",815.4
+13222,Germany,2012,5,"C01B-Antiarrhythmics, Class I and III",% of total sales,0.3
+13223,Germany,2012,5,M-Musculo-skeletal system,% of total sales,4.4
+13224,Germany,2012,5,"C01B-Antiarrhythmics, Class I and III","Million US$, purchasing power parity",100.7
+13225,Germany,2012,5,"C01B-Antiarrhythmics, Class I and III","/capita, US$ exchange rate",1.3
+13226,Germany,2012,5,"C01B-Antiarrhythmics, Class I and III","/capita, US$ purchasing power parity",1.3
+13227,Germany,2012,5,"C01B-Antiarrhythmics, Class I and III",Million of national currency units,79.3
+13228,Germany,2012,5,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ exchange rate",9.4
+13229,Germany,2012,5,R-Respiratory system,% of total sales,6.3
+13230,Germany,2012,5,R-Respiratory system,"/capita, US$ purchasing power parity",30.4
+13231,Germany,2012,5,"C01B-Antiarrhythmics, Class I and III",Million US$ at exchange rate,101.9
+13232,Germany,2012,5,C10-Lipid modifying agents,Million US$ at exchange rate,824.7
+13233,Germany,2012,5,C08-Calcium channel blockers,% of total sales,1.0
+13234,Germany,2012,5,C08-Calcium channel blockers,"/capita, US$ purchasing power parity",4.6
+13235,Germany,2012,5,C08-Calcium channel blockers,"/capita, US$ exchange rate",4.6
+13236,Germany,2012,5,M-Musculo-skeletal system,Million of national currency units,1338.2
+13237,Germany,2012,5,C09-Agents acting on the Renin-Angiotensin system,Million of national currency units,1919.1
+13238,Germany,2012,5,Products not elsewhere classified,"/capita, US$ purchasing power parity",116.0
+13239,Germany,2012,5,Products not elsewhere classified,"/capita, US$ exchange rate",117.3
+13240,Germany,2012,5,C08-Calcium channel blockers,"Million US$, purchasing power parity",367.9
+13241,Germany,2012,5,C08-Calcium channel blockers,Million US$ at exchange rate,372.1
+13242,Germany,2012,5,C09-Agents acting on the Renin-Angiotensin system,Million US$ at exchange rate,2465.6
+13243,Germany,2012,5,C09-Agents acting on the Renin-Angiotensin system,"Million US$, purchasing power parity",2437.7
+13244,Germany,2012,5,M-Musculo-skeletal system,Million US$ at exchange rate,1719.3
+13245,Germany,2012,5,Total pharmaceutical sales,"Million US$, purchasing power parity",38669.0
+13246,Germany,2012,5,Total pharmaceutical sales,Million US$ at exchange rate,39111.5
+13247,Germany,2012,5,Total pharmaceutical sales,Million of national currency units,30442.0
+13248,Germany,2012,5,Total pharmaceutical sales,"/capita, US$ purchasing power parity",480.8
+13249,Germany,2012,5,Total pharmaceutical sales,"/capita, US$ exchange rate",486.3
+13250,Germany,2012,5,M-Musculo-skeletal system,"/capita, US$ exchange rate",21.4
+13251,Germany,2012,5,M-Musculo-skeletal system,"Million US$, purchasing power parity",1699.8
+13252,Germany,2012,5,M-Musculo-skeletal system,"/capita, US$ purchasing power parity",21.1
+13253,Germany,2012,5,C10-Lipid modifying agents,Million of national currency units,641.9
+13254,Germany,2012,5,Products not elsewhere classified,% of total sales,24.1
+13255,Germany,2012,5,A-Alimentary tract and metabolism,Million of national currency units,3894.1
+13256,Germany,2012,5,C07-Beta blocking agents,Million of national currency units,654.5
+13257,Germany,2012,5,C07-Beta blocking agents,Million US$ at exchange rate,840.9
+13258,Germany,2012,5,C01A-Cardiac glycosides,"/capita, US$ purchasing power parity",0.5
+13259,Germany,2012,5,C01A-Cardiac glycosides,% of total sales,0.1
+13260,Germany,2012,5,J-Antiinfectives for systemic use,% of total sales,7.9
+13261,Germany,2012,5,C07-Beta blocking agents,"Million US$, purchasing power parity",831.4
+13262,Germany,2012,5,J-Antiinfectives for systemic use,"/capita, US$ purchasing power parity",38.1
+13263,Germany,2012,5,J-Antiinfectives for systemic use,"Million US$, purchasing power parity",3062.8
+13264,Germany,2012,5,J-Antiinfectives for systemic use,"/capita, US$ exchange rate",38.5
+13265,Germany,2012,5,J-Antiinfectives for systemic use,Million of national currency units,2411.2
+13266,Germany,2012,5,J-Antiinfectives for systemic use,Million US$ at exchange rate,3097.9
+13267,Germany,2012,5,C01A-Cardiac glycosides,"Million US$, purchasing power parity",42.7
+13268,Germany,2012,5,C01A-Cardiac glycosides,"/capita, US$ exchange rate",0.5
+13269,Germany,2012,5,C01A-Cardiac glycosides,Million of national currency units,33.6
+13270,Germany,2012,5,C01A-Cardiac glycosides,Million US$ at exchange rate,43.2
+13271,Germany,2012,5,A02A-Antacids,Million of national currency units,14.9
+13272,Germany,2012,5,C03-Diuretics,"/capita, US$ exchange rate",6.4
+13273,Germany,2012,5,C03-Diuretics,"/capita, US$ purchasing power parity",6.3
+13274,Germany,2012,5,C03-Diuretics,% of total sales,1.3
+13275,Germany,2012,5,G03-Sex hormones and modulators of the genital system,% of total sales,1.3
+13276,Germany,2012,5,C03-Diuretics,"Million US$, purchasing power parity",509.8
+13277,Germany,2012,5,C03-Diuretics,Million US$ at exchange rate,515.6
+13278,Germany,2012,5,C07-Beta blocking agents,% of total sales,2.1
+13279,Germany,2012,5,N05B-Anxiolytics,% of total sales,0.3
+13280,Germany,2012,5,C07-Beta blocking agents,"/capita, US$ exchange rate",10.5
+13281,Germany,2012,5,C07-Beta blocking agents,"/capita, US$ purchasing power parity",10.3
+13282,Germany,2012,5,N05B-Anxiolytics,"Million US$, purchasing power parity",100.2
+13283,Germany,2012,5,N05B-Anxiolytics,Million US$ at exchange rate,101.4
+13284,Germany,2012,5,N05B-Anxiolytics,"/capita, US$ purchasing power parity",1.2
+13285,Germany,2012,5,N05B-Anxiolytics,"/capita, US$ exchange rate",1.3
+13286,Germany,2012,5,J01-Antibacterials for systemic use,"/capita, US$ exchange rate",12.3
+13287,Germany,2012,5,J01-Antibacterials for systemic use,"/capita, US$ purchasing power parity",12.2
+13288,Germany,2012,5,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million of national currency units,1019.3
+13289,Germany,2012,5,J01-Antibacterials for systemic use,"Million US$, purchasing power parity",981.8
+13290,Germany,2012,5,C02-Antihypertensives,% of total sales,1.0
+13291,Germany,2012,5,J01-Antibacterials for systemic use,% of total sales,2.5
+13292,Germany,2012,5,C02-Antihypertensives,"/capita, US$ purchasing power parity",4.9
+13293,Germany,2012,5,J01-Antibacterials for systemic use,Million of national currency units,772.9
+13294,Germany,2012,5,"H-Systemic hormonal preparations, excluding sex hormones and insulins",% of total sales,3.3
+13295,Germany,2012,5,J01-Antibacterials for systemic use,Million US$ at exchange rate,993.0
+13296,Germany,2012,5,"H-Systemic hormonal preparations, excluding sex hormones and insulins","Million US$, purchasing power parity",1294.8
+13297,Germany,2012,5,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million US$ at exchange rate,1309.6
+13298,Germany,2012,5,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ purchasing power parity",16.1
+13299,Germany,2012,5,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ exchange rate",16.3
+13300,Germany,2012,5,N05C-Hypnotics and sedatives,"/capita, US$ exchange rate",1.6
+13301,Germany,2012,5,N05C-Hypnotics and sedatives,"/capita, US$ purchasing power parity",1.6
+13302,Germany,2012,5,N05C-Hypnotics and sedatives,Million US$ at exchange rate,127.6
+13303,Germany,2012,5,N05C-Hypnotics and sedatives,"Million US$, purchasing power parity",126.1
+13304,Germany,2012,5,B-Blood and blood forming organs,"Million US$, purchasing power parity",2233.2
+13305,Germany,2012,5,B-Blood and blood forming organs,"/capita, US$ exchange rate",28.1
+13306,Germany,2012,5,N05C-Hypnotics and sedatives,% of total sales,0.3
+13307,Germany,2012,5,C02-Antihypertensives,Million US$ at exchange rate,399.4
+13308,Germany,2012,5,C02-Antihypertensives,"Million US$, purchasing power parity",394.9
+13309,Germany,2012,5,C02-Antihypertensives,"/capita, US$ exchange rate",5.0
+13310,Germany,2012,5,C02-Antihypertensives,Million of national currency units,310.9
+13311,Germany,2012,5,B-Blood and blood forming organs,% of total sales,5.8
+13312,Germany,2012,5,B-Blood and blood forming organs,"/capita, US$ purchasing power parity",27.8
+13313,Germany,2012,5,N05C-Hypnotics and sedatives,Million of national currency units,99.3
+13314,Germany,2012,5,G03-Sex hormones and modulators of the genital system,"/capita, US$ purchasing power parity",6.1
+13315,Germany,2012,5,A10-Drugs used in diabetes,"/capita, US$ exchange rate",33.0
+13316,Germany,2012,5,A10-Drugs used in diabetes,Million US$ at exchange rate,2658.0
+13317,Germany,2012,5,A10-Drugs used in diabetes,"Million US$, purchasing power parity",2627.9
+13318,Germany,2012,5,G-Genito urinary system and sex hormones,% of total sales,2.6
+13319,Germany,2012,5,A10-Drugs used in diabetes,"/capita, US$ purchasing power parity",32.7
+13320,Germany,2012,5,A10-Drugs used in diabetes,% of total sales,6.8
+13321,Germany,2012,5,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ purchasing power parity",12.7
+13322,Germany,2012,5,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ exchange rate",12.9
+13323,Germany,2012,5,N02-Analgesics,"/capita, US$ exchange rate",26.0
+13324,Germany,2012,5,B-Blood and blood forming organs,Million of national currency units,1758.1
+13325,Germany,2012,5,A10-Drugs used in diabetes,Million of national currency units,2068.8
+13326,Germany,2012,5,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million of national currency units,805.4
+13327,Germany,2012,5,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million US$ at exchange rate,1034.8
+13328,Germany,2012,5,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"Million US$, purchasing power parity",1023.1
+13329,Germany,2012,5,A-Alimentary tract and metabolism,"/capita, US$ purchasing power parity",61.5
+13330,Germany,2012,5,A-Alimentary tract and metabolism,% of total sales,12.8
+13331,Germany,2012,5,A-Alimentary tract and metabolism,Million US$ at exchange rate,5003.1
+13332,Germany,2012,5,A-Alimentary tract and metabolism,"/capita, US$ exchange rate",62.2
+13333,Germany,2012,5,A-Alimentary tract and metabolism,"Million US$, purchasing power parity",4946.5
+13334,Germany,2012,5,G-Genito urinary system and sex hormones,Million of national currency units,779.7
+13335,Germany,2012,5,N02-Analgesics,% of total sales,5.4
+13336,Germany,2012,5,B-Blood and blood forming organs,Million US$ at exchange rate,2258.8
+13337,Germany,2012,5,G-Genito urinary system and sex hormones,"/capita, US$ purchasing power parity",12.3
+13338,Germany,2012,5,G-Genito urinary system and sex hormones,"/capita, US$ exchange rate",12.5
+13339,Germany,2012,5,G-Genito urinary system and sex hormones,Million US$ at exchange rate,1001.7
+13340,Germany,2012,5,N02-Analgesics,"/capita, US$ purchasing power parity",25.7
+13341,Germany,2012,5,G-Genito urinary system and sex hormones,"Million US$, purchasing power parity",990.4
+13342,Germany,2012,5,A02A-Antacids,"Million US$, purchasing power parity",18.9
+13343,Germany,2012,5,G03-Sex hormones and modulators of the genital system,"/capita, US$ exchange rate",6.1
+13344,Germany,2012,5,A02A-Antacids,% of total sales,0.0
+13345,Germany,2012,5,N06A-Antidepressants,Million of national currency units,746.5
+13346,Germany,2012,5,G03-Sex hormones and modulators of the genital system,"Million US$, purchasing power parity",487.1
+13347,Germany,2012,5,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),% of total sales,2.6
+13348,Germany,2012,5,N02-Analgesics,Million US$ at exchange rate,2093.0
+13349,Germany,2012,5,A02A-Antacids,"/capita, US$ exchange rate",0.2
+13350,Germany,2012,5,G03-Sex hormones and modulators of the genital system,Million US$ at exchange rate,492.7
+13351,Germany,2012,5,G03-Sex hormones and modulators of the genital system,Million of national currency units,383.5
+13352,Germany,2012,5,N06A-Antidepressants,"/capita, US$ purchasing power parity",11.8
+13353,Germany,2012,5,N06A-Antidepressants,"/capita, US$ exchange rate",11.9
+13354,Germany,2012,5,N06A-Antidepressants,% of total sales,2.5
+13355,Germany,2012,5,N02-Analgesics,"Million US$, purchasing power parity",2069.4
+13356,Germany,2012,5,A02A-Antacids,Million US$ at exchange rate,19.1
+13357,Germany,2012,5,N05B-Anxiolytics,Million of national currency units,78.9
+13358,Germany,2012,5,N02-Analgesics,Million of national currency units,1629.1
+13359,Germany,2012,5,A02A-Antacids,"/capita, US$ purchasing power parity",0.2
+13360,Germany,2012,5,N06A-Antidepressants,Million US$ at exchange rate,959.1
+13361,Germany,2012,5,C03-Diuretics,Million of national currency units,401.3
+13362,Germany,2012,5,N06A-Antidepressants,"Million US$, purchasing power parity",948.2
+13363,Germany,2011,6,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ exchange rate",37.3
+13364,Germany,2011,6,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ purchasing power parity",34.0
+13365,Germany,2011,6,M01A-Antiinflammatory and antirheumatic products non-steroids,% of total sales,1.9
+13366,Germany,2011,6,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ purchasing power parity",8.8
+13367,Germany,2011,6,C-Cardiovascular system,"/capita, US$ exchange rate",83.1
+13368,Germany,2011,6,C-Cardiovascular system,"Million US$, purchasing power parity",6078.4
+13369,Germany,2011,6,C08-Calcium channel blockers,Million of national currency units,292.0
+13370,Germany,2011,6,C-Cardiovascular system,Million US$ at exchange rate,6673.5
+13371,Germany,2011,6,C09-Agents acting on the Renin-Angiotensin system,% of total sales,7.2
+13372,Germany,2011,6,C-Cardiovascular system,Million of national currency units,4794.3
+13373,Germany,2011,6,N-Nervous system,% of total sales,19.1
+13374,Germany,2011,6,R03-Drugs for obstructive airway diseases,Million US$ at exchange rate,2325.3
+13375,Germany,2011,6,N-Nervous system,"/capita, US$ purchasing power parity",89.7
+13376,Germany,2011,6,R03-Drugs for obstructive airway diseases,"Million US$, purchasing power parity",2117.9
+13377,Germany,2011,6,R03-Drugs for obstructive airway diseases,% of total sales,5.6
+13378,Germany,2011,6,R03-Drugs for obstructive airway diseases,"/capita, US$ purchasing power parity",26.4
+13379,Germany,2011,6,R03-Drugs for obstructive airway diseases,"/capita, US$ exchange rate",29.0
+13380,Germany,2011,6,Products not elsewhere classified,Million of national currency units,6791.6
+13381,Germany,2011,6,N-Nervous system,Million of national currency units,5679.2
+13382,Germany,2011,6,N-Nervous system,Million US$ at exchange rate,7905.2
+13383,Germany,2011,6,Products not elsewhere classified,"Million US$, purchasing power parity",8610.7
+13384,Germany,2011,6,Products not elsewhere classified,Million US$ at exchange rate,9453.6
+13385,Germany,2011,6,C-Cardiovascular system,% of total sales,16.1
+13386,Germany,2011,6,C-Cardiovascular system,"/capita, US$ purchasing power parity",75.7
+13387,Germany,2011,6,N-Nervous system,"Million US$, purchasing power parity",7200.4
+13388,Germany,2011,6,N-Nervous system,"/capita, US$ exchange rate",98.5
+13389,Germany,2011,6,R-Respiratory system,Million US$ at exchange rate,2766.2
+13390,Germany,2011,6,R-Respiratory system,Million of national currency units,1987.3
+13391,Germany,2011,6,C10-Lipid modifying agents,% of total sales,2.3
+13392,Germany,2011,6,R-Respiratory system,"/capita, US$ exchange rate",34.5
+13393,Germany,2011,6,R-Respiratory system,"Million US$, purchasing power parity",2519.6
+13394,Germany,2011,6,C10-Lipid modifying agents,"/capita, US$ purchasing power parity",10.6
+13395,Germany,2011,6,M01A-Antiinflammatory and antirheumatic products non-steroids,Million US$ at exchange rate,772.5
+13396,Germany,2011,6,M01A-Antiinflammatory and antirheumatic products non-steroids,"Million US$, purchasing power parity",703.7
+13397,Germany,2011,6,R-Respiratory system,"/capita, US$ purchasing power parity",31.4
+13398,Germany,2011,6,C10-Lipid modifying agents,"/capita, US$ exchange rate",11.7
+13399,Germany,2011,6,M01A-Antiinflammatory and antirheumatic products non-steroids,Million of national currency units,555.0
+13400,Germany,2011,6,C10-Lipid modifying agents,"Million US$, purchasing power parity",852.8
+13401,Germany,2011,6,"C01B-Antiarrhythmics, Class I and III",% of total sales,0.3
+13402,Germany,2011,6,M-Musculo-skeletal system,% of total sales,4.3
+13403,Germany,2011,6,"C01B-Antiarrhythmics, Class I and III","Million US$, purchasing power parity",111.2
+13404,Germany,2011,6,"C01B-Antiarrhythmics, Class I and III","/capita, US$ exchange rate",1.5
+13405,Germany,2011,6,"C01B-Antiarrhythmics, Class I and III","/capita, US$ purchasing power parity",1.4
+13406,Germany,2011,6,"C01B-Antiarrhythmics, Class I and III",Million of national currency units,87.7
+13407,Germany,2011,6,R03-Drugs for obstructive airway diseases,Million of national currency units,1670.5
+13408,Germany,2011,6,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ exchange rate",9.6
+13409,Germany,2011,6,R-Respiratory system,% of total sales,6.7
+13410,Germany,2011,6,"C01B-Antiarrhythmics, Class I and III",Million US$ at exchange rate,122.1
+13411,Germany,2011,6,C08-Calcium channel blockers,% of total sales,1.0
+13412,Germany,2011,6,C08-Calcium channel blockers,"/capita, US$ purchasing power parity",4.6
+13413,Germany,2011,6,M-Musculo-skeletal system,Million of national currency units,1285.2
+13414,Germany,2011,6,C08-Calcium channel blockers,"/capita, US$ exchange rate",5.1
+13415,Germany,2011,6,Products not elsewhere classified,"/capita, US$ purchasing power parity",107.3
+13416,Germany,2011,6,C09-Agents acting on the Renin-Angiotensin system,Million of national currency units,2149.7
+13417,Germany,2011,6,Products not elsewhere classified,"/capita, US$ exchange rate",117.8
+13418,Germany,2011,6,C08-Calcium channel blockers,"Million US$, purchasing power parity",370.2
+13419,Germany,2011,6,C08-Calcium channel blockers,Million US$ at exchange rate,406.5
+13420,Germany,2011,6,M-Musculo-skeletal system,Million US$ at exchange rate,1788.9
+13421,Germany,2011,6,C09-Agents acting on the Renin-Angiotensin system,Million US$ at exchange rate,2992.3
+13422,Germany,2011,6,C09-Agents acting on the Renin-Angiotensin system,"Million US$, purchasing power parity",2725.5
+13423,Germany,2011,6,Total pharmaceutical sales,"Million US$, purchasing power parity",37675.6
+13424,Germany,2011,6,Total pharmaceutical sales,Million US$ at exchange rate,41363.6
+13425,Germany,2011,6,Total pharmaceutical sales,Million of national currency units,29716.2
+13426,Germany,2011,6,C10-Lipid modifying agents,Million US$ at exchange rate,936.2
+13427,Germany,2011,6,Total pharmaceutical sales,"/capita, US$ purchasing power parity",469.3
+13428,Germany,2011,6,Total pharmaceutical sales,"/capita, US$ exchange rate",515.3
+13429,Germany,2011,6,M-Musculo-skeletal system,"/capita, US$ exchange rate",22.3
+13430,Germany,2011,6,M-Musculo-skeletal system,"Million US$, purchasing power parity",1629.4
+13431,Germany,2011,6,C10-Lipid modifying agents,Million of national currency units,672.6
+13432,Germany,2011,6,M-Musculo-skeletal system,"/capita, US$ purchasing power parity",20.3
+13433,Germany,2011,6,Products not elsewhere classified,% of total sales,22.9
+13434,Germany,2011,6,C07-Beta blocking agents,Million of national currency units,647.2
+13435,Germany,2011,6,C07-Beta blocking agents,Million US$ at exchange rate,900.9
+13436,Germany,2011,6,C01A-Cardiac glycosides,"/capita, US$ purchasing power parity",0.6
+13437,Germany,2011,6,C01A-Cardiac glycosides,% of total sales,0.1
+13438,Germany,2011,6,J-Antiinfectives for systemic use,% of total sales,7.1
+13439,Germany,2011,6,C07-Beta blocking agents,"Million US$, purchasing power parity",820.6
+13440,Germany,2011,6,J-Antiinfectives for systemic use,"/capita, US$ purchasing power parity",33.1
+13441,Germany,2011,6,J-Antiinfectives for systemic use,"Million US$, purchasing power parity",2661.1
+13442,Germany,2011,6,J-Antiinfectives for systemic use,"/capita, US$ exchange rate",36.4
+13443,Germany,2011,6,J-Antiinfectives for systemic use,Million of national currency units,2098.9
+13444,Germany,2011,6,J-Antiinfectives for systemic use,Million US$ at exchange rate,2921.6
+13445,Germany,2011,6,C01A-Cardiac glycosides,Million of national currency units,35.8
+13446,Germany,2011,6,C01A-Cardiac glycosides,"Million US$, purchasing power parity",45.4
+13447,Germany,2011,6,C01A-Cardiac glycosides,"/capita, US$ exchange rate",0.6
+13448,Germany,2011,6,C01A-Cardiac glycosides,Million US$ at exchange rate,49.8
+13449,Germany,2011,6,C03-Diuretics,"/capita, US$ purchasing power parity",6.1
+13450,Germany,2011,6,C03-Diuretics,"/capita, US$ exchange rate",6.7
+13451,Germany,2011,6,C03-Diuretics,% of total sales,1.3
+13452,Germany,2011,6,G03-Sex hormones and modulators of the genital system,% of total sales,1.3
+13453,Germany,2011,6,C03-Diuretics,"Million US$, purchasing power parity",493.3
+13454,Germany,2011,6,C03-Diuretics,Million US$ at exchange rate,541.6
+13455,Germany,2011,6,C07-Beta blocking agents,% of total sales,2.2
+13456,Germany,2011,6,N05B-Anxiolytics,% of total sales,0.3
+13457,Germany,2011,6,C07-Beta blocking agents,"/capita, US$ exchange rate",11.2
+13458,Germany,2011,6,C07-Beta blocking agents,"/capita, US$ purchasing power parity",10.2
+13459,Germany,2011,6,N05B-Anxiolytics,"Million US$, purchasing power parity",101.6
+13460,Germany,2011,6,N05B-Anxiolytics,Million US$ at exchange rate,111.5
+13461,Germany,2011,6,N05B-Anxiolytics,"/capita, US$ purchasing power parity",1.3
+13462,Germany,2011,6,N05B-Anxiolytics,"/capita, US$ exchange rate",1.4
+13463,Germany,2011,6,A02A-Antacids,Million of national currency units,14.7
+13464,Germany,2011,6,J01-Antibacterials for systemic use,"/capita, US$ purchasing power parity",11.2
+13465,Germany,2011,6,J01-Antibacterials for systemic use,"/capita, US$ exchange rate",12.4
+13466,Germany,2011,6,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million of national currency units,994.0
+13467,Germany,2011,6,C02-Antihypertensives,% of total sales,1.0
+13468,Germany,2011,6,J01-Antibacterials for systemic use,% of total sales,2.4
+13469,Germany,2011,6,J01-Antibacterials for systemic use,Million of national currency units,712.3
+13470,Germany,2011,6,"H-Systemic hormonal preparations, excluding sex hormones and insulins",% of total sales,3.3
+13471,Germany,2011,6,J01-Antibacterials for systemic use,"Million US$, purchasing power parity",903.1
+13472,Germany,2011,6,J01-Antibacterials for systemic use,Million US$ at exchange rate,991.5
+13473,Germany,2011,6,"H-Systemic hormonal preparations, excluding sex hormones and insulins","Million US$, purchasing power parity",1260.2
+13474,Germany,2011,6,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million US$ at exchange rate,1383.6
+13475,Germany,2011,6,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ purchasing power parity",15.7
+13476,Germany,2011,6,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ exchange rate",17.2
+13477,Germany,2011,6,C02-Antihypertensives,"/capita, US$ purchasing power parity",4.7
+13478,Germany,2011,6,N05C-Hypnotics and sedatives,"/capita, US$ exchange rate",1.8
+13479,Germany,2011,6,N05C-Hypnotics and sedatives,"/capita, US$ purchasing power parity",1.6
+13480,Germany,2011,6,N05C-Hypnotics and sedatives,Million US$ at exchange rate,144.3
+13481,Germany,2011,6,N05C-Hypnotics and sedatives,"Million US$, purchasing power parity",131.5
+13482,Germany,2011,6,B-Blood and blood forming organs,"Million US$, purchasing power parity",2019.3
+13483,Germany,2011,6,B-Blood and blood forming organs,"/capita, US$ exchange rate",27.6
+13484,Germany,2011,6,N05C-Hypnotics and sedatives,% of total sales,0.3
+13485,Germany,2011,6,C02-Antihypertensives,Million US$ at exchange rate,416.5
+13486,Germany,2011,6,C02-Antihypertensives,"Million US$, purchasing power parity",379.3
+13487,Germany,2011,6,C02-Antihypertensives,"/capita, US$ exchange rate",5.2
+13488,Germany,2011,6,B-Blood and blood forming organs,% of total sales,5.4
+13489,Germany,2011,6,A-Alimentary tract and metabolism,Million of national currency units,3704.0
+13490,Germany,2011,6,B-Blood and blood forming organs,"/capita, US$ purchasing power parity",25.2
+13491,Germany,2011,6,C02-Antihypertensives,Million of national currency units,299.2
+13492,Germany,2011,6,N05C-Hypnotics and sedatives,Million of national currency units,103.7
+13493,Germany,2011,6,A10-Drugs used in diabetes,"/capita, US$ exchange rate",33.8
+13494,Germany,2011,6,A10-Drugs used in diabetes,"Million US$, purchasing power parity",2468.6
+13495,Germany,2011,6,A10-Drugs used in diabetes,Million US$ at exchange rate,2710.3
+13496,Germany,2011,6,G-Genito urinary system and sex hormones,% of total sales,2.7
+13497,Germany,2011,6,A10-Drugs used in diabetes,"/capita, US$ purchasing power parity",30.8
+13498,Germany,2011,6,A10-Drugs used in diabetes,% of total sales,6.6
+13499,Germany,2011,6,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ purchasing power parity",12.6
+13500,Germany,2011,6,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ exchange rate",13.8
+13501,Germany,2011,6,N02-Analgesics,"/capita, US$ exchange rate",27.3
+13502,Germany,2011,6,B-Blood and blood forming organs,Million of national currency units,1592.7
+13503,Germany,2011,6,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million of national currency units,796.7
+13504,Germany,2011,6,A10-Drugs used in diabetes,Million of national currency units,1947.1
+13505,Germany,2011,6,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million US$ at exchange rate,1109.0
+13506,Germany,2011,6,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"Million US$, purchasing power parity",1010.1
+13507,Germany,2011,6,A-Alimentary tract and metabolism,"/capita, US$ purchasing power parity",58.5
+13508,Germany,2011,6,A-Alimentary tract and metabolism,% of total sales,12.5
+13509,Germany,2011,6,G-Genito urinary system and sex hormones,Million of national currency units,788.7
+13510,Germany,2011,6,A-Alimentary tract and metabolism,Million US$ at exchange rate,5155.8
+13511,Germany,2011,6,A-Alimentary tract and metabolism,"/capita, US$ exchange rate",64.2
+13512,Germany,2011,6,A-Alimentary tract and metabolism,"Million US$, purchasing power parity",4696.1
+13513,Germany,2011,6,N02-Analgesics,% of total sales,5.3
+13514,Germany,2011,6,B-Blood and blood forming organs,Million US$ at exchange rate,2217.0
+13515,Germany,2011,6,G-Genito urinary system and sex hormones,"/capita, US$ purchasing power parity",12.5
+13516,Germany,2011,6,G-Genito urinary system and sex hormones,"/capita, US$ exchange rate",13.7
+13517,Germany,2011,6,G-Genito urinary system and sex hormones,Million US$ at exchange rate,1097.8
+13518,Germany,2011,6,G-Genito urinary system and sex hormones,"Million US$, purchasing power parity",1000.0
+13519,Germany,2011,6,N02-Analgesics,"/capita, US$ purchasing power parity",24.9
+13520,Germany,2011,6,A02A-Antacids,"Million US$, purchasing power parity",18.6
+13521,Germany,2011,6,G03-Sex hormones and modulators of the genital system,"/capita, US$ exchange rate",6.9
+13522,Germany,2011,6,A02A-Antacids,% of total sales,0.0
+13523,Germany,2011,6,N06A-Antidepressants,Million US$ at exchange rate,1065.4
+13524,Germany,2011,6,N06A-Antidepressants,Million of national currency units,765.4
+13525,Germany,2011,6,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),% of total sales,2.7
+13526,Germany,2011,6,N02-Analgesics,Million US$ at exchange rate,2192.2
+13527,Germany,2011,6,G03-Sex hormones and modulators of the genital system,"Million US$, purchasing power parity",501.3
+13528,Germany,2011,6,A02A-Antacids,"/capita, US$ exchange rate",0.3
+13529,Germany,2011,6,G03-Sex hormones and modulators of the genital system,Million of national currency units,395.4
+13530,Germany,2011,6,G03-Sex hormones and modulators of the genital system,Million US$ at exchange rate,550.4
+13531,Germany,2011,6,A02A-Antacids,"/capita, US$ purchasing power parity",0.2
+13532,Germany,2011,6,N06A-Antidepressants,"/capita, US$ purchasing power parity",12.1
+13533,Germany,2011,6,N06A-Antidepressants,"/capita, US$ exchange rate",13.3
+13534,Germany,2011,6,N06A-Antidepressants,% of total sales,2.6
+13535,Germany,2011,6,N02-Analgesics,"Million US$, purchasing power parity",1996.7
+13536,Germany,2011,6,G03-Sex hormones and modulators of the genital system,"/capita, US$ purchasing power parity",6.2
+13537,Germany,2011,6,A02A-Antacids,Million US$ at exchange rate,20.5
+13538,Germany,2011,6,N02-Analgesics,Million of national currency units,1574.9
+13539,Germany,2011,6,N05B-Anxiolytics,Million of national currency units,80.1
+13540,Germany,2011,6,N06A-Antidepressants,"Million US$, purchasing power parity",970.4
+13541,Germany,2011,6,C03-Diuretics,Million of national currency units,389.1
+13542,Germany,2010,6,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ exchange rate",34.8
+13543,Germany,2010,6,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ purchasing power parity",32.6
+13544,Germany,2010,6,M01A-Antiinflammatory and antirheumatic products non-steroids,% of total sales,1.9
+13545,Germany,2010,6,C-Cardiovascular system,"/capita, US$ exchange rate",78.9
+13546,Germany,2010,6,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ purchasing power parity",8.4
+13547,Germany,2010,6,C-Cardiovascular system,"Million US$, purchasing power parity",6048.6
+13548,Germany,2010,6,C08-Calcium channel blockers,Million of national currency units,308.0
+13549,Germany,2010,6,C-Cardiovascular system,Million US$ at exchange rate,6455.7
+13550,Germany,2010,6,C09-Agents acting on the Renin-Angiotensin system,% of total sales,7.2
+13551,Germany,2010,6,C-Cardiovascular system,Million of national currency units,4869.6
+13552,Germany,2010,6,N-Nervous system,% of total sales,19.1
+13553,Germany,2010,6,R03-Drugs for obstructive airway diseases,Million US$ at exchange rate,2284.2
+13554,Germany,2010,6,N-Nervous system,"/capita, US$ purchasing power parity",86.4
+13555,Germany,2010,6,R03-Drugs for obstructive airway diseases,"Million US$, purchasing power parity",2140.2
+13556,Germany,2010,6,R03-Drugs for obstructive airway diseases,% of total sales,5.8
+13557,Germany,2010,6,R03-Drugs for obstructive airway diseases,"/capita, US$ purchasing power parity",26.2
+13558,Germany,2010,6,R03-Drugs for obstructive airway diseases,"/capita, US$ exchange rate",27.9
+13559,Germany,2010,6,Products not elsewhere classified,Million of national currency units,6585.2
+13560,Germany,2010,6,N-Nervous system,Million of national currency units,5688.1
+13561,Germany,2010,6,N-Nervous system,Million US$ at exchange rate,7540.8
+13562,Germany,2010,6,Products not elsewhere classified,"Million US$, purchasing power parity",8179.5
+13563,Germany,2010,6,Products not elsewhere classified,Million US$ at exchange rate,8730.1
+13564,Germany,2010,6,C-Cardiovascular system,% of total sales,16.4
+13565,Germany,2010,6,C-Cardiovascular system,"/capita, US$ purchasing power parity",74.0
+13566,Germany,2010,6,N-Nervous system,"Million US$, purchasing power parity",7065.3
+13567,Germany,2010,6,N-Nervous system,"/capita, US$ exchange rate",92.2
+13568,Germany,2010,6,C08-Calcium channel blockers,Million US$ at exchange rate,408.3
+13569,Germany,2010,6,R-Respiratory system,Million US$ at exchange rate,2719.7
+13570,Germany,2010,6,R-Respiratory system,Million of national currency units,2051.5
+13571,Germany,2010,6,C10-Lipid modifying agents,% of total sales,2.4
+13572,Germany,2010,6,R-Respiratory system,"/capita, US$ purchasing power parity",31.2
+13573,Germany,2010,6,R-Respiratory system,"/capita, US$ exchange rate",33.3
+13574,Germany,2010,6,R-Respiratory system,"Million US$, purchasing power parity",2548.2
+13575,Germany,2010,6,C10-Lipid modifying agents,"/capita, US$ purchasing power parity",10.8
+13576,Germany,2010,6,M01A-Antiinflammatory and antirheumatic products non-steroids,Million US$ at exchange rate,735.9
+13577,Germany,2010,6,M01A-Antiinflammatory and antirheumatic products non-steroids,"Million US$, purchasing power parity",689.5
+13578,Germany,2010,6,M01A-Antiinflammatory and antirheumatic products non-steroids,Million of national currency units,555.1
+13579,Germany,2010,6,C10-Lipid modifying agents,"/capita, US$ exchange rate",11.5
+13580,Germany,2010,6,C10-Lipid modifying agents,"Million US$, purchasing power parity",880.3
+13581,Germany,2010,6,"C01B-Antiarrhythmics, Class I and III",% of total sales,0.3
+13582,Germany,2010,6,M-Musculo-skeletal system,% of total sales,4.5
+13583,Germany,2010,6,"C01B-Antiarrhythmics, Class I and III","Million US$, purchasing power parity",94.5
+13584,Germany,2010,6,"C01B-Antiarrhythmics, Class I and III","/capita, US$ exchange rate",1.2
+13585,Germany,2010,6,"C01B-Antiarrhythmics, Class I and III","/capita, US$ purchasing power parity",1.2
+13586,Germany,2010,6,"C01B-Antiarrhythmics, Class I and III",Million of national currency units,76.1
+13587,Germany,2010,6,R03-Drugs for obstructive airway diseases,Million of national currency units,1723.0
+13588,Germany,2010,6,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ exchange rate",9.0
+13589,Germany,2010,6,"C01B-Antiarrhythmics, Class I and III",Million US$ at exchange rate,100.9
+13590,Germany,2010,6,R-Respiratory system,% of total sales,6.9
+13591,Germany,2010,6,C08-Calcium channel blockers,% of total sales,1.0
+13592,Germany,2010,6,C08-Calcium channel blockers,"/capita, US$ purchasing power parity",4.7
+13593,Germany,2010,6,M-Musculo-skeletal system,Million US$ at exchange rate,1771.4
+13594,Germany,2010,6,M-Musculo-skeletal system,Million of national currency units,1336.2
+13595,Germany,2010,6,Products not elsewhere classified,"/capita, US$ purchasing power parity",100.0
+13596,Germany,2010,6,C09-Agents acting on the Renin-Angiotensin system,Million of national currency units,2144.2
+13597,Germany,2010,6,C08-Calcium channel blockers,"/capita, US$ exchange rate",5.0
+13598,Germany,2010,6,Products not elsewhere classified,"/capita, US$ exchange rate",106.8
+13599,Germany,2010,6,C08-Calcium channel blockers,"Million US$, purchasing power parity",382.6
+13600,Germany,2010,6,C09-Agents acting on the Renin-Angiotensin system,Million US$ at exchange rate,2842.6
+13601,Germany,2010,6,C09-Agents acting on the Renin-Angiotensin system,"Million US$, purchasing power parity",2663.3
+13602,Germany,2010,6,Total pharmaceutical sales,"Million US$, purchasing power parity",36921.4
+13603,Germany,2010,6,Total pharmaceutical sales,Million US$ at exchange rate,39406.5
+13604,Germany,2010,6,C10-Lipid modifying agents,Million US$ at exchange rate,939.5
+13605,Germany,2010,6,Total pharmaceutical sales,Million of national currency units,29724.7
+13606,Germany,2010,6,Total pharmaceutical sales,"/capita, US$ exchange rate",481.9
+13607,Germany,2010,6,Total pharmaceutical sales,"/capita, US$ purchasing power parity",451.5
+13608,Germany,2010,6,M-Musculo-skeletal system,"/capita, US$ exchange rate",21.7
+13609,Germany,2010,6,M-Musculo-skeletal system,"Million US$, purchasing power parity",1659.7
+13610,Germany,2010,6,M-Musculo-skeletal system,"/capita, US$ purchasing power parity",20.3
+13611,Germany,2010,6,C10-Lipid modifying agents,Million of national currency units,708.7
+13612,Germany,2010,6,Products not elsewhere classified,% of total sales,22.2
+13613,Germany,2010,6,A-Alimentary tract and metabolism,Million of national currency units,3714.8
+13614,Germany,2010,6,C07-Beta blocking agents,Million of national currency units,666.0
+13615,Germany,2010,6,C07-Beta blocking agents,Million US$ at exchange rate,882.9
+13616,Germany,2010,6,C01A-Cardiac glycosides,"/capita, US$ purchasing power parity",0.6
+13617,Germany,2010,6,C01A-Cardiac glycosides,% of total sales,0.1
+13618,Germany,2010,6,J-Antiinfectives for systemic use,% of total sales,6.8
+13619,Germany,2010,6,C07-Beta blocking agents,"Million US$, purchasing power parity",827.2
+13620,Germany,2010,6,J-Antiinfectives for systemic use,"/capita, US$ purchasing power parity",30.8
+13621,Germany,2010,6,J-Antiinfectives for systemic use,"Million US$, purchasing power parity",2520.2
+13622,Germany,2010,6,J-Antiinfectives for systemic use,"/capita, US$ exchange rate",32.9
+13623,Germany,2010,6,J-Antiinfectives for systemic use,Million of national currency units,2029.0
+13624,Germany,2010,6,J-Antiinfectives for systemic use,Million US$ at exchange rate,2689.9
+13625,Germany,2010,6,C01A-Cardiac glycosides,Million of national currency units,39.3
+13626,Germany,2010,6,C01A-Cardiac glycosides,"Million US$, purchasing power parity",48.8
+13627,Germany,2010,6,C01A-Cardiac glycosides,"/capita, US$ exchange rate",0.6
+13628,Germany,2010,6,C01A-Cardiac glycosides,Million US$ at exchange rate,52.1
+13629,Germany,2010,6,C03-Diuretics,"/capita, US$ purchasing power parity",6.0
+13630,Germany,2010,6,C03-Diuretics,"/capita, US$ exchange rate",6.4
+13631,Germany,2010,6,C03-Diuretics,% of total sales,1.3
+13632,Germany,2010,6,G03-Sex hormones and modulators of the genital system,% of total sales,1.4
+13633,Germany,2010,6,C03-Diuretics,"Million US$, purchasing power parity",487.5
+13634,Germany,2010,6,C03-Diuretics,Million US$ at exchange rate,520.3
+13635,Germany,2010,6,C07-Beta blocking agents,% of total sales,2.2
+13636,Germany,2010,6,N05B-Anxiolytics,% of total sales,0.3
+13637,Germany,2010,6,C07-Beta blocking agents,"/capita, US$ exchange rate",10.8
+13638,Germany,2010,6,C07-Beta blocking agents,"/capita, US$ purchasing power parity",10.1
+13639,Germany,2010,6,N05B-Anxiolytics,"Million US$, purchasing power parity",105.6
+13640,Germany,2010,6,N05B-Anxiolytics,Million US$ at exchange rate,112.7
+13641,Germany,2010,6,N05B-Anxiolytics,"/capita, US$ purchasing power parity",1.3
+13642,Germany,2010,6,N05B-Anxiolytics,"/capita, US$ exchange rate",1.4
+13643,Germany,2010,6,A02A-Antacids,Million of national currency units,14.5
+13644,Germany,2010,6,J01-Antibacterials for systemic use,"/capita, US$ purchasing power parity",11.2
+13645,Germany,2010,6,J01-Antibacterials for systemic use,"/capita, US$ exchange rate",12.0
+13646,Germany,2010,6,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million of national currency units,987.2
+13647,Germany,2010,6,J01-Antibacterials for systemic use,% of total sales,2.5
+13648,Germany,2010,6,C02-Antihypertensives,% of total sales,1.0
+13649,Germany,2010,6,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million US$ at exchange rate,1308.7
+13650,Germany,2010,6,J01-Antibacterials for systemic use,Million of national currency units,740.2
+13651,Germany,2010,6,"H-Systemic hormonal preparations, excluding sex hormones and insulins",% of total sales,3.3
+13652,Germany,2010,6,J01-Antibacterials for systemic use,"Million US$, purchasing power parity",919.4
+13653,Germany,2010,6,J01-Antibacterials for systemic use,Million US$ at exchange rate,981.3
+13654,Germany,2010,6,"H-Systemic hormonal preparations, excluding sex hormones and insulins","Million US$, purchasing power parity",1226.2
+13655,Germany,2010,6,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ purchasing power parity",15.0
+13656,Germany,2010,6,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ exchange rate",16.0
+13657,Germany,2010,6,C02-Antihypertensives,"/capita, US$ purchasing power parity",4.7
+13658,Germany,2010,6,N05C-Hypnotics and sedatives,"/capita, US$ exchange rate",1.8
+13659,Germany,2010,6,N05C-Hypnotics and sedatives,"/capita, US$ purchasing power parity",1.7
+13660,Germany,2010,6,N05C-Hypnotics and sedatives,"Million US$, purchasing power parity",137.0
+13661,Germany,2010,6,B-Blood and blood forming organs,"Million US$, purchasing power parity",2050.1
+13662,Germany,2010,6,B-Blood and blood forming organs,"/capita, US$ exchange rate",26.8
+13663,Germany,2010,6,N05C-Hypnotics and sedatives,% of total sales,0.4
+13664,Germany,2010,6,C02-Antihypertensives,"Million US$, purchasing power parity",381.0
+13665,Germany,2010,6,C02-Antihypertensives,Million US$ at exchange rate,406.6
+13666,Germany,2010,6,C02-Antihypertensives,"/capita, US$ exchange rate",5.0
+13667,Germany,2010,6,B-Blood and blood forming organs,% of total sales,5.6
+13668,Germany,2010,6,B-Blood and blood forming organs,"/capita, US$ purchasing power parity",25.1
+13669,Germany,2010,6,C02-Antihypertensives,Million of national currency units,306.7
+13670,Germany,2010,6,N05C-Hypnotics and sedatives,Million of national currency units,110.3
+13671,Germany,2010,6,N05C-Hypnotics and sedatives,Million US$ at exchange rate,146.2
+13672,Germany,2010,6,A10-Drugs used in diabetes,Million US$ at exchange rate,2504.1
+13673,Germany,2010,6,A10-Drugs used in diabetes,"Million US$, purchasing power parity",2346.2
+13674,Germany,2010,6,A10-Drugs used in diabetes,"/capita, US$ purchasing power parity",28.7
+13675,Germany,2010,6,G-Genito urinary system and sex hormones,% of total sales,2.7
+13676,Germany,2010,6,A10-Drugs used in diabetes,% of total sales,6.4
+13677,Germany,2010,6,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ purchasing power parity",13.9
+13678,Germany,2010,6,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ exchange rate",14.8
+13679,Germany,2010,6,N02-Analgesics,"/capita, US$ exchange rate",25.3
+13680,Germany,2010,6,B-Blood and blood forming organs,Million of national currency units,1650.5
+13681,Germany,2010,6,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million of national currency units,912.0
+13682,Germany,2010,6,A10-Drugs used in diabetes,Million of national currency units,1888.9
+13683,Germany,2010,6,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million US$ at exchange rate,1209.1
+13684,Germany,2010,6,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"Million US$, purchasing power parity",1132.8
+13685,Germany,2010,6,A-Alimentary tract and metabolism,% of total sales,12.5
+13686,Germany,2010,6,A-Alimentary tract and metabolism,"/capita, US$ purchasing power parity",56.4
+13687,Germany,2010,6,G-Genito urinary system and sex hormones,Million of national currency units,812.2
+13688,Germany,2010,6,N02-Analgesics,% of total sales,5.3
+13689,Germany,2010,6,A-Alimentary tract and metabolism,Million US$ at exchange rate,4924.8
+13690,Germany,2010,6,A-Alimentary tract and metabolism,"/capita, US$ exchange rate",60.2
+13691,Germany,2010,6,A-Alimentary tract and metabolism,"Million US$, purchasing power parity",4614.2
+13692,Germany,2010,6,B-Blood and blood forming organs,Million US$ at exchange rate,2188.1
+13693,Germany,2010,6,G-Genito urinary system and sex hormones,"/capita, US$ purchasing power parity",12.3
+13694,Germany,2010,6,N02-Analgesics,"/capita, US$ purchasing power parity",23.7
+13695,Germany,2010,6,G-Genito urinary system and sex hormones,Million US$ at exchange rate,1076.7
+13696,Germany,2010,6,G-Genito urinary system and sex hormones,"Million US$, purchasing power parity",1008.8
+13697,Germany,2010,6,G-Genito urinary system and sex hormones,"/capita, US$ exchange rate",13.2
+13698,Germany,2010,6,A10-Drugs used in diabetes,"/capita, US$ exchange rate",30.6
+13699,Germany,2010,6,A02A-Antacids,"Million US$, purchasing power parity",18.0
+13700,Germany,2010,6,G03-Sex hormones and modulators of the genital system,"/capita, US$ exchange rate",6.8
+13701,Germany,2010,6,A02A-Antacids,% of total sales,0.0
+13702,Germany,2010,6,N06A-Antidepressants,Million of national currency units,798.5
+13703,Germany,2010,6,N06A-Antidepressants,Million US$ at exchange rate,1058.6
+13704,Germany,2010,6,G03-Sex hormones and modulators of the genital system,"Million US$, purchasing power parity",521.4
+13705,Germany,2010,6,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),% of total sales,3.1
+13706,Germany,2010,6,A02A-Antacids,"/capita, US$ purchasing power parity",0.2
+13707,Germany,2010,6,N02-Analgesics,Million US$ at exchange rate,2069.6
+13708,Germany,2010,6,A02A-Antacids,"/capita, US$ exchange rate",0.2
+13709,Germany,2010,6,G03-Sex hormones and modulators of the genital system,Million US$ at exchange rate,556.5
+13710,Germany,2010,6,G03-Sex hormones and modulators of the genital system,Million of national currency units,419.8
+13711,Germany,2010,6,N06A-Antidepressants,"/capita, US$ purchasing power parity",12.1
+13712,Germany,2010,6,N06A-Antidepressants,"/capita, US$ exchange rate",12.9
+13713,Germany,2010,6,N06A-Antidepressants,% of total sales,2.7
+13714,Germany,2010,6,N02-Analgesics,"Million US$, purchasing power parity",1939.1
+13715,Germany,2010,6,G03-Sex hormones and modulators of the genital system,"/capita, US$ purchasing power parity",6.4
+13716,Germany,2010,6,A02A-Antacids,Million US$ at exchange rate,19.2
+13717,Germany,2010,6,N02-Analgesics,Million of national currency units,1561.1
+13718,Germany,2010,6,N05B-Anxiolytics,Million of national currency units,85.0
+13719,Germany,2010,6,N06A-Antidepressants,"Million US$, purchasing power parity",991.8
+13720,Germany,2010,6,C03-Diuretics,Million of national currency units,392.5
+13721,Germany,2016,5,C-Cardiovascular system,"Million US$, purchasing power parity",5802.0
+13722,Germany,2016,5,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ exchange rate",21.6
+13723,Germany,2016,5,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ purchasing power parity",9.5
+13724,Germany,2016,5,C-Cardiovascular system,"/capita, US$ exchange rate",58.7
+13725,Germany,2016,5,C-Cardiovascular system,Million US$ at exchange rate,4833.4
+13726,Germany,2016,5,C08-Calcium channel blockers,Million of national currency units,285.0
+13727,Germany,2016,5,M01A-Antiinflammatory and antirheumatic products non-steroids,% of total sales,1.6
+13728,Germany,2016,5,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ purchasing power parity",25.9
+13729,Germany,2016,5,C09-Agents acting on the Renin-Angiotensin system,% of total sales,4.4
+13730,Germany,2016,5,C-Cardiovascular system,Million of national currency units,4366.6
+13731,Germany,2016,5,N-Nervous system,% of total sales,14.6
+13732,Germany,2016,5,R03-Drugs for obstructive airway diseases,Million US$ at exchange rate,1929.4
+13733,Germany,2016,5,N-Nervous system,"/capita, US$ exchange rate",70.7
+13734,Germany,2016,5,N-Nervous system,"/capita, US$ purchasing power parity",84.9
+13735,Germany,2016,5,R03-Drugs for obstructive airway diseases,"/capita, US$ purchasing power parity",28.1
+13736,Germany,2016,5,R03-Drugs for obstructive airway diseases,% of total sales,4.8
+13737,Germany,2016,5,R03-Drugs for obstructive airway diseases,"Million US$, purchasing power parity",2316.1
+13738,Germany,2016,5,R03-Drugs for obstructive airway diseases,"/capita, US$ exchange rate",23.4
+13739,Germany,2016,5,N-Nervous system,Million of national currency units,5260.4
+13740,Germany,2016,5,Products not elsewhere classified,Million US$ at exchange rate,11702.7
+13741,Germany,2016,5,Products not elsewhere classified,Million of national currency units,10572.5
+13742,Germany,2016,5,N-Nervous system,Million US$ at exchange rate,5822.8
+13743,Germany,2016,5,C-Cardiovascular system,"/capita, US$ purchasing power parity",70.5
+13744,Germany,2016,5,R03-Drugs for obstructive airway diseases,Million of national currency units,1743.1
+13745,Germany,2016,5,N-Nervous system,"Million US$, purchasing power parity",6989.6
+13746,Germany,2016,5,R-Respiratory system,Million of national currency units,2134.3
+13747,Germany,2016,5,C10-Lipid modifying agents,"/capita, US$ purchasing power parity",10.7
+13748,Germany,2016,5,R-Respiratory system,Million US$ at exchange rate,2362.5
+13749,Germany,2016,5,R-Respiratory system,"/capita, US$ exchange rate",28.7
+13750,Germany,2016,5,R-Respiratory system,"Million US$, purchasing power parity",2835.9
+13751,Germany,2016,5,M01A-Antiinflammatory and antirheumatic products non-steroids,Million of national currency units,588.8
+13752,Germany,2016,5,M01A-Antiinflammatory and antirheumatic products non-steroids,Million US$ at exchange rate,651.7
+13753,Germany,2016,5,Total pharmaceutical sales,"/capita, US$ purchasing power parity",582.8
+13754,Germany,2016,5,C10-Lipid modifying agents,"/capita, US$ exchange rate",8.9
+13755,Germany,2016,5,C10-Lipid modifying agents,"Million US$, purchasing power parity",884.4
+13756,Germany,2016,5,C10-Lipid modifying agents,Million US$ at exchange rate,736.8
+13757,Germany,2016,5,"C01B-Antiarrhythmics, Class I and III",% of total sales,0.2
+13758,Germany,2016,5,M-Musculo-skeletal system,% of total sales,3.9
+13759,Germany,2016,5,"C01B-Antiarrhythmics, Class I and III","/capita, US$ purchasing power parity",1.2
+13760,Germany,2016,5,"C01B-Antiarrhythmics, Class I and III","Million US$, purchasing power parity",100.3
+13761,Germany,2016,5,"C01B-Antiarrhythmics, Class I and III","/capita, US$ exchange rate",1.0
+13762,Germany,2016,5,M-Musculo-skeletal system,"/capita, US$ purchasing power parity",22.7
+13763,Germany,2016,5,"C01B-Antiarrhythmics, Class I and III",Million of national currency units,75.5
+13764,Germany,2016,5,M01A-Antiinflammatory and antirheumatic products non-steroids,"Million US$, purchasing power parity",782.3
+13765,Germany,2016,5,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ exchange rate",7.9
+13766,Germany,2016,5,C10-Lipid modifying agents,% of total sales,1.8
+13767,Germany,2016,5,R-Respiratory system,% of total sales,5.9
+13768,Germany,2016,5,R-Respiratory system,"/capita, US$ purchasing power parity",34.4
+13769,Germany,2016,5,"C01B-Antiarrhythmics, Class I and III",Million US$ at exchange rate,83.6
+13770,Germany,2016,5,C08-Calcium channel blockers,% of total sales,0.8
+13771,Germany,2016,5,C08-Calcium channel blockers,"/capita, US$ purchasing power parity",4.6
+13772,Germany,2016,5,C08-Calcium channel blockers,"/capita, US$ exchange rate",3.8
+13773,Germany,2016,5,M-Musculo-skeletal system,Million of national currency units,1405.1
+13774,Germany,2016,5,C09-Agents acting on the Renin-Angiotensin system,Million of national currency units,1604.2
+13775,Germany,2016,5,Products not elsewhere classified,"Million US$, purchasing power parity",14047.8
+13776,Germany,2016,5,Products not elsewhere classified,"/capita, US$ exchange rate",142.1
+13777,Germany,2016,5,C08-Calcium channel blockers,Million US$ at exchange rate,315.5
+13778,Germany,2016,5,C08-Calcium channel blockers,"Million US$, purchasing power parity",378.7
+13779,Germany,2016,5,C09-Agents acting on the Renin-Angiotensin system,Million US$ at exchange rate,1775.7
+13780,Germany,2016,5,C09-Agents acting on the Renin-Angiotensin system,"Million US$, purchasing power parity",2131.5
+13781,Germany,2016,5,Total pharmaceutical sales,Million US$ at exchange rate,39979.8
+13782,Germany,2016,5,Total pharmaceutical sales,Million of national currency units,36118.6
+13783,Germany,2016,5,Total pharmaceutical sales,"Million US$, purchasing power parity",47991.3
+13784,Germany,2016,5,C-Cardiovascular system,% of total sales,12.1
+13785,Germany,2016,5,Total pharmaceutical sales,"/capita, US$ exchange rate",485.5
+13786,Germany,2016,5,M-Musculo-skeletal system,"/capita, US$ exchange rate",18.9
+13787,Germany,2016,5,M-Musculo-skeletal system,"Million US$, purchasing power parity",1867.0
+13788,Germany,2016,5,M-Musculo-skeletal system,Million US$ at exchange rate,1555.3
+13789,Germany,2016,5,C10-Lipid modifying agents,Million of national currency units,665.6
+13790,Germany,2016,5,Products not elsewhere classified,% of total sales,29.3
+13791,Germany,2016,5,Products not elsewhere classified,"/capita, US$ purchasing power parity",170.6
+13792,Germany,2016,5,C07-Beta blocking agents,Million of national currency units,659.7
+13793,Germany,2016,5,C01A-Cardiac glycosides,"/capita, US$ purchasing power parity",0.4
+13794,Germany,2016,5,C01A-Cardiac glycosides,% of total sales,0.1
+13795,Germany,2016,5,C07-Beta blocking agents,Million US$ at exchange rate,730.2
+13796,Germany,2016,5,J-Antiinfectives for systemic use,% of total sales,9.0
+13797,Germany,2016,5,J-Antiinfectives for systemic use,"/capita, US$ exchange rate",43.5
+13798,Germany,2016,5,J-Antiinfectives for systemic use,"/capita, US$ purchasing power parity",52.3
+13799,Germany,2016,5,C07-Beta blocking agents,"Million US$, purchasing power parity",876.6
+13800,Germany,2016,5,J-Antiinfectives for systemic use,"Million US$, purchasing power parity",4302.8
+13801,Germany,2016,5,J-Antiinfectives for systemic use,Million US$ at exchange rate,3584.5
+13802,Germany,2016,5,J-Antiinfectives for systemic use,Million of national currency units,3238.3
+13803,Germany,2016,5,C01A-Cardiac glycosides,"Million US$, purchasing power parity",31.4
+13804,Germany,2016,5,C01A-Cardiac glycosides,"/capita, US$ exchange rate",0.3
+13805,Germany,2016,5,C01A-Cardiac glycosides,Million of national currency units,23.6
+13806,Germany,2016,5,C01A-Cardiac glycosides,Million US$ at exchange rate,26.1
+13807,Germany,2016,5,C03-Diuretics,"/capita, US$ exchange rate",6.0
+13808,Germany,2016,5,C03-Diuretics,"Million US$, purchasing power parity",597.8
+13809,Germany,2016,5,C03-Diuretics,% of total sales,1.2
+13810,Germany,2016,5,C03-Diuretics,"/capita, US$ purchasing power parity",7.3
+13811,Germany,2016,5,G03-Sex hormones and modulators of the genital system,% of total sales,1.1
+13812,Germany,2016,5,G03-Sex hormones and modulators of the genital system,"/capita, US$ purchasing power parity",6.5
+13813,Germany,2016,5,C03-Diuretics,Million of national currency units,449.9
+13814,Germany,2016,5,C03-Diuretics,Million US$ at exchange rate,498.0
+13815,Germany,2016,5,C07-Beta blocking agents,% of total sales,1.8
+13816,Germany,2016,5,C07-Beta blocking agents,"/capita, US$ purchasing power parity",10.6
+13817,Germany,2016,5,C07-Beta blocking agents,"/capita, US$ exchange rate",8.9
+13818,Germany,2016,5,N05B-Anxiolytics,"/capita, US$ purchasing power parity",1.1
+13819,Germany,2016,5,N05B-Anxiolytics,Million US$ at exchange rate,76.2
+13820,Germany,2016,5,N05B-Anxiolytics,"/capita, US$ exchange rate",0.9
+13821,Germany,2016,5,J01-Antibacterials for systemic use,"/capita, US$ exchange rate",10.1
+13822,Germany,2016,5,J01-Antibacterials for systemic use,"/capita, US$ purchasing power parity",12.2
+13823,Germany,2016,5,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million of national currency units,1115.3
+13824,Germany,2016,5,J01-Antibacterials for systemic use,"Million US$, purchasing power parity",1002.6
+13825,Germany,2016,5,C02-Antihypertensives,% of total sales,1.1
+13826,Germany,2016,5,C02-Antihypertensives,"/capita, US$ purchasing power parity",6.3
+13827,Germany,2016,5,J01-Antibacterials for systemic use,% of total sales,2.1
+13828,Germany,2016,5,N05B-Anxiolytics,% of total sales,0.2
+13829,Germany,2016,5,"H-Systemic hormonal preparations, excluding sex hormones and insulins",% of total sales,3.1
+13830,Germany,2016,5,J01-Antibacterials for systemic use,Million US$ at exchange rate,835.3
+13831,Germany,2016,5,J01-Antibacterials for systemic use,Million of national currency units,754.6
+13832,Germany,2016,5,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ purchasing power parity",18.0
+13833,Germany,2016,5,"H-Systemic hormonal preparations, excluding sex hormones and insulins","Million US$, purchasing power parity",1481.9
+13834,Germany,2016,5,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million US$ at exchange rate,1234.5
+13835,Germany,2016,5,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ exchange rate",15.0
+13836,Germany,2016,5,N05C-Hypnotics and sedatives,"/capita, US$ exchange rate",1.2
+13837,Germany,2016,5,N05C-Hypnotics and sedatives,"Million US$, purchasing power parity",120.2
+13838,Germany,2016,5,B-Blood and blood forming organs,"/capita, US$ exchange rate",38.1
+13839,Germany,2016,5,N05C-Hypnotics and sedatives,Million US$ at exchange rate,100.2
+13840,Germany,2016,5,B-Blood and blood forming organs,"Million US$, purchasing power parity",3770.0
+13841,Germany,2016,5,B-Blood and blood forming organs,Million US$ at exchange rate,3140.6
+13842,Germany,2016,5,N05C-Hypnotics and sedatives,"/capita, US$ purchasing power parity",1.5
+13843,Germany,2016,5,N05C-Hypnotics and sedatives,% of total sales,0.3
+13844,Germany,2016,5,C02-Antihypertensives,Million US$ at exchange rate,431.8
+13845,Germany,2016,5,C02-Antihypertensives,Million of national currency units,390.1
+13846,Germany,2016,5,C02-Antihypertensives,"/capita, US$ exchange rate",5.2
+13847,Germany,2016,5,C02-Antihypertensives,"Million US$, purchasing power parity",518.3
+13848,Germany,2016,5,B-Blood and blood forming organs,"/capita, US$ purchasing power parity",45.8
+13849,Germany,2016,5,B-Blood and blood forming organs,% of total sales,7.9
+13850,Germany,2016,5,N05C-Hypnotics and sedatives,Million of national currency units,90.5
+13851,Germany,2016,5,N05B-Anxiolytics,"Million US$, purchasing power parity",91.4
+13852,Germany,2016,5,A10-Drugs used in diabetes,"Million US$, purchasing power parity",3211.4
+13853,Germany,2016,5,A10-Drugs used in diabetes,"/capita, US$ exchange rate",32.5
+13854,Germany,2016,5,A10-Drugs used in diabetes,Million US$ at exchange rate,2675.3
+13855,Germany,2016,5,G-Genito urinary system and sex hormones,% of total sales,2.2
+13856,Germany,2016,5,A10-Drugs used in diabetes,% of total sales,6.7
+13857,Germany,2016,5,A10-Drugs used in diabetes,"/capita, US$ purchasing power parity",39.0
+13858,Germany,2016,5,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ exchange rate",10.4
+13859,Germany,2016,5,N02-Analgesics,"/capita, US$ exchange rate",23.3
+13860,Germany,2016,5,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ purchasing power parity",12.5
+13861,Germany,2016,5,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million of national currency units,772.4
+13862,Germany,2016,5,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"Million US$, purchasing power parity",1026.3
+13863,Germany,2016,5,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million US$ at exchange rate,855.0
+13864,Germany,2016,5,A10-Drugs used in diabetes,Million of national currency units,2416.9
+13865,Germany,2016,5,G-Genito urinary system and sex hormones,"/capita, US$ purchasing power parity",12.7
+13866,Germany,2016,5,A-Alimentary tract and metabolism,"/capita, US$ purchasing power parity",71.1
+13867,Germany,2016,5,A-Alimentary tract and metabolism,% of total sales,12.2
+13868,Germany,2016,5,A-Alimentary tract and metabolism,"/capita, US$ exchange rate",59.2
+13869,Germany,2016,5,A-Alimentary tract and metabolism,Million US$ at exchange rate,4875.1
+13870,Germany,2016,5,A-Alimentary tract and metabolism,Million of national currency units,4404.3
+13871,Germany,2016,5,A-Alimentary tract and metabolism,"Million US$, purchasing power parity",5852.1
+13872,Germany,2016,5,N02-Analgesics,% of total sales,4.8
+13873,Germany,2016,5,B-Blood and blood forming organs,Million of national currency units,2837.3
+13874,Germany,2016,5,G-Genito urinary system and sex hormones,"/capita, US$ exchange rate",10.5
+13875,Germany,2016,5,G-Genito urinary system and sex hormones,Million US$ at exchange rate,868.3
+13876,Germany,2016,5,G-Genito urinary system and sex hormones,Million of national currency units,784.4
+13877,Germany,2016,5,N02-Analgesics,"/capita, US$ purchasing power parity",28.0
+13878,Germany,2016,5,G-Genito urinary system and sex hormones,"Million US$, purchasing power parity",1042.2
+13879,Germany,2016,5,A02A-Antacids,Million US$ at exchange rate,21.1
+13880,Germany,2016,5,G03-Sex hormones and modulators of the genital system,"Million US$, purchasing power parity",533.1
+13881,Germany,2016,5,A02A-Antacids,"Million US$, purchasing power parity",25.4
+13882,Germany,2016,5,N02-Analgesics,Million of national currency units,1735.8
+13883,Germany,2016,5,A02A-Antacids,"/capita, US$ purchasing power parity",0.3
+13884,Germany,2016,5,A02A-Antacids,% of total sales,0.1
+13885,Germany,2016,5,N06A-Antidepressants,Million of national currency units,759.1
+13886,Germany,2016,5,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),% of total sales,2.1
+13887,Germany,2016,5,N02-Analgesics,Million US$ at exchange rate,1921.4
+13888,Germany,2016,5,A02A-Antacids,"/capita, US$ exchange rate",0.3
+13889,Germany,2016,5,G03-Sex hormones and modulators of the genital system,Million US$ at exchange rate,444.1
+13890,Germany,2016,5,G03-Sex hormones and modulators of the genital system,Million of national currency units,401.2
+13891,Germany,2016,5,N06A-Antidepressants,"/capita, US$ purchasing power parity",12.2
+13892,Germany,2016,5,N06A-Antidepressants,"/capita, US$ exchange rate",10.2
+13893,Germany,2016,5,N02-Analgesics,"Million US$, purchasing power parity",2306.4
+13894,Germany,2016,5,N06A-Antidepressants,% of total sales,2.1
+13895,Germany,2016,5,N06A-Antidepressants,"Million US$, purchasing power parity",1008.6
+13896,Germany,2016,5,A02A-Antacids,Million of national currency units,19.1
+13897,Germany,2016,5,N05B-Anxiolytics,Million of national currency units,68.8
+13898,Germany,2016,5,N06A-Antidepressants,Million US$ at exchange rate,840.3
+13899,Germany,2016,5,G03-Sex hormones and modulators of the genital system,"/capita, US$ exchange rate",5.4
+13900,Greece,2016,3,N02-Analgesics,Million of national currency units,143.3
+13901,Greece,2016,3,N05B-Anxiolytics,Million US$ at exchange rate,23.7
+13902,Greece,2016,3,N05B-Anxiolytics,Million of national currency units,21.4
+13903,Greece,2016,3,M01A-Antiinflammatory and antirheumatic products non-steroids,Million of national currency units,66.5
+13904,Greece,2016,3,M01A-Antiinflammatory and antirheumatic products non-steroids,Million US$ at exchange rate,73.6
+13905,Greece,2016,3,N05B-Anxiolytics,"/capita, US$ purchasing power parity",3.4
+13906,Greece,2016,3,N05B-Anxiolytics,"Million US$, purchasing power parity",36.4
+13907,Greece,2016,3,N05B-Anxiolytics,"/capita, US$ exchange rate",2.2
+13908,Greece,2016,3,J-Antiinfectives for systemic use,"/capita, US$ exchange rate",65.1
+13909,Greece,2016,3,J-Antiinfectives for systemic use,"Million US$, purchasing power parity",1076.6
+13910,Greece,2016,3,R03-Drugs for obstructive airway diseases,Million US$ at exchange rate,288.1
+13911,Greece,2016,3,R03-Drugs for obstructive airway diseases,Million of national currency units,260.3
+13912,Greece,2016,3,J-Antiinfectives for systemic use,"/capita, US$ purchasing power parity",99.9
+13913,Greece,2016,3,N02-Analgesics,"/capita, US$ exchange rate",14.7
+13914,Greece,2016,3,N02-Analgesics,"/capita, US$ purchasing power parity",22.6
+13915,Greece,2016,3,J-Antiinfectives for systemic use,Million US$ at exchange rate,701.4
+13916,Greece,2016,3,J-Antiinfectives for systemic use,Million of national currency units,633.7
+13917,Greece,2016,3,N02-Analgesics,"Million US$, purchasing power parity",243.4
+13918,Greece,2016,3,B-Blood and blood forming organs,Million US$ at exchange rate,1883.7
+13919,Greece,2016,3,B-Blood and blood forming organs,"Million US$, purchasing power parity",2891.3
+13920,Greece,2016,3,B-Blood and blood forming organs,"/capita, US$ purchasing power parity",268.3
+13921,Greece,2016,3,B-Blood and blood forming organs,"/capita, US$ exchange rate",174.8
+13922,Greece,2016,3,N02-Analgesics,Million US$ at exchange rate,158.6
+13923,Greece,2016,3,R03-Drugs for obstructive airway diseases,"Million US$, purchasing power parity",442.2
+13924,Greece,2016,3,B-Blood and blood forming organs,Million of national currency units,1701.7
+13925,Greece,2016,3,R03-Drugs for obstructive airway diseases,"/capita, US$ exchange rate",26.7
+13926,Greece,2016,3,R03-Drugs for obstructive airway diseases,"/capita, US$ purchasing power parity",41.0
+13927,Greece,2016,3,M-Musculo-skeletal system,Million of national currency units,215.5
+13928,Greece,2016,3,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ purchasing power parity",26.3
+13929,Greece,2016,3,M-Musculo-skeletal system,"Million US$, purchasing power parity",366.1
+13930,Greece,2016,3,M-Musculo-skeletal system,Million US$ at exchange rate,238.5
+13931,Greece,2016,3,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million US$ at exchange rate,184.6
+13932,Greece,2016,3,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ exchange rate",17.1
+13933,Greece,2016,3,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"Million US$, purchasing power parity",283.4
+13934,Greece,2016,3,R-Respiratory system,Million of national currency units,405.5
+13935,Greece,2016,3,G03-Sex hormones and modulators of the genital system,"/capita, US$ purchasing power parity",5.9
+13936,Greece,2016,3,R-Respiratory system,"Million US$, purchasing power parity",688.9
+13937,Greece,2016,3,R-Respiratory system,Million US$ at exchange rate,448.8
+13938,Greece,2016,3,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million of national currency units,166.8
+13939,Greece,2016,3,G03-Sex hormones and modulators of the genital system,Million US$ at exchange rate,41.3
+13940,Greece,2016,3,G03-Sex hormones and modulators of the genital system,Million of national currency units,37.3
+13941,Greece,2016,3,G03-Sex hormones and modulators of the genital system,"/capita, US$ exchange rate",3.8
+13942,Greece,2016,3,G03-Sex hormones and modulators of the genital system,"Million US$, purchasing power parity",63.3
+13943,Greece,2016,3,G-Genito urinary system and sex hormones,Million of national currency units,155.4
+13944,Greece,2016,3,N-Nervous system,"/capita, US$ purchasing power parity",107.3
+13945,Greece,2016,3,G-Genito urinary system and sex hormones,"Million US$, purchasing power parity",264.1
+13946,Greece,2016,3,G-Genito urinary system and sex hormones,Million US$ at exchange rate,172.1
+13947,Greece,2016,3,N-Nervous system,Million US$ at exchange rate,753.0
+13948,Greece,2016,3,N-Nervous system,"/capita, US$ exchange rate",69.9
+13949,Greece,2016,3,N-Nervous system,"Million US$, purchasing power parity",1155.8
+13950,Greece,2016,3,N-Nervous system,Million of national currency units,680.3
+13951,Greece,2016,3,N06A-Antidepressants,"Million US$, purchasing power parity",182.8
+13952,Greece,2016,3,N06A-Antidepressants,Million of national currency units,107.6
+13953,Greece,2016,3,N06A-Antidepressants,"/capita, US$ exchange rate",11.1
+13954,Greece,2016,3,N06A-Antidepressants,Million US$ at exchange rate,119.1
+13955,Greece,2016,3,G-Genito urinary system and sex hormones,"/capita, US$ exchange rate",16.0
+13956,Greece,2016,3,G-Genito urinary system and sex hormones,"/capita, US$ purchasing power parity",24.5
+13957,Greece,2016,3,N06A-Antidepressants,"/capita, US$ purchasing power parity",17.0
+13958,Greece,2016,3,J01-Antibacterials for systemic use,"Million US$, purchasing power parity",393.4
+13959,Greece,2016,3,J01-Antibacterials for systemic use,"/capita, US$ exchange rate",23.8
+13960,Greece,2016,3,J01-Antibacterials for systemic use,Million of national currency units,231.5
+13961,Greece,2016,3,J01-Antibacterials for systemic use,Million US$ at exchange rate,256.3
+13962,Greece,2016,3,A10-Drugs used in diabetes,"/capita, US$ exchange rate",40.9
+13963,Greece,2016,3,A10-Drugs used in diabetes,"Million US$, purchasing power parity",676.5
+13964,Greece,2016,3,J01-Antibacterials for systemic use,"/capita, US$ purchasing power parity",36.5
+13965,Greece,2016,3,A10-Drugs used in diabetes,"/capita, US$ purchasing power parity",62.8
+13966,Greece,2016,3,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ purchasing power parity",10.5
+13967,Greece,2016,3,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ purchasing power parity",19.3
+13968,Greece,2016,3,M01A-Antiinflammatory and antirheumatic products non-steroids,"Million US$, purchasing power parity",112.9
+13969,Greece,2016,3,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ exchange rate",6.8
+13970,Greece,2016,3,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million US$ at exchange rate,135.8
+13971,Greece,2016,3,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million of national currency units,122.7
+13972,Greece,2016,3,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ exchange rate",12.6
+13973,Greece,2016,3,"H-Systemic hormonal preparations, excluding sex hormones and insulins","Million US$, purchasing power parity",208.4
+13974,Greece,2016,3,C10-Lipid modifying agents,"/capita, US$ exchange rate",35.4
+13975,Greece,2016,3,C10-Lipid modifying agents,"/capita, US$ purchasing power parity",54.4
+13976,Greece,2016,3,C10-Lipid modifying agents,Million US$ at exchange rate,381.6
+13977,Greece,2016,3,C10-Lipid modifying agents,"Million US$, purchasing power parity",585.7
+13978,Greece,2016,3,R-Respiratory system,"/capita, US$ purchasing power parity",63.9
+13979,Greece,2016,3,R-Respiratory system,"/capita, US$ exchange rate",41.7
+13980,Greece,2016,3,M-Musculo-skeletal system,"/capita, US$ purchasing power parity",34.0
+13981,Greece,2016,3,M-Musculo-skeletal system,"/capita, US$ exchange rate",22.1
+13982,Greece,2016,3,N05C-Hypnotics and sedatives,Million of national currency units,8.2
+13983,Greece,2016,3,N05C-Hypnotics and sedatives,Million US$ at exchange rate,9.1
+13984,Greece,2016,3,A10-Drugs used in diabetes,Million US$ at exchange rate,440.7
+13985,Greece,2016,3,A10-Drugs used in diabetes,Million of national currency units,398.2
+13986,Greece,2016,3,N05C-Hypnotics and sedatives,"/capita, US$ purchasing power parity",1.3
+13987,Greece,2016,3,C10-Lipid modifying agents,Million of national currency units,344.7
+13988,Greece,2016,3,N05C-Hypnotics and sedatives,"Million US$, purchasing power parity",13.9
+13989,Greece,2016,3,N05C-Hypnotics and sedatives,"/capita, US$ exchange rate",0.8
+13990,Greece,2016,3,C-Cardiovascular system,Million US$ at exchange rate,1039.8
+13991,Greece,2016,3,C-Cardiovascular system,"Million US$, purchasing power parity",1596.1
+13992,Greece,2016,3,C-Cardiovascular system,"/capita, US$ exchange rate",96.5
+13993,Greece,2016,3,C09-Agents acting on the Renin-Angiotensin system,Million of national currency units,362.6
+13994,Greece,2016,3,C-Cardiovascular system,Million of national currency units,939.4
+13995,Greece,2016,3,C01A-Cardiac glycosides,"/capita, US$ exchange rate",0.1
+13996,Greece,2016,3,C03-Diuretics,"/capita, US$ purchasing power parity",5.4
+13997,Greece,2016,3,C-Cardiovascular system,"/capita, US$ purchasing power parity",148.1
+13998,Greece,2016,3,C01A-Cardiac glycosides,"/capita, US$ purchasing power parity",0.1
+13999,Greece,2016,3,"C01B-Antiarrhythmics, Class I and III","Million US$, purchasing power parity",12.5
+14000,Greece,2016,3,"C01B-Antiarrhythmics, Class I and III","/capita, US$ exchange rate",0.8
+14001,Greece,2016,3,A-Alimentary tract and metabolism,Million of national currency units,749.2
+14002,Greece,2016,3,"C01B-Antiarrhythmics, Class I and III",Million US$ at exchange rate,8.2
+14003,Greece,2016,3,"C01B-Antiarrhythmics, Class I and III","/capita, US$ purchasing power parity",1.2
+14004,Greece,2016,3,C09-Agents acting on the Renin-Angiotensin system,"Million US$, purchasing power parity",616.1
+14005,Greece,2016,3,C09-Agents acting on the Renin-Angiotensin system,Million US$ at exchange rate,401.4
+14006,Greece,2016,3,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ purchasing power parity",57.2
+14007,Greece,2016,3,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ exchange rate",37.2
+14008,Greece,2016,3,C03-Diuretics,"/capita, US$ exchange rate",3.5
+14009,Greece,2016,3,A02A-Antacids,"/capita, US$ purchasing power parity",0.7
+14010,Greece,2016,3,A-Alimentary tract and metabolism,Million US$ at exchange rate,829.3
+14011,Greece,2016,3,A-Alimentary tract and metabolism,"Million US$, purchasing power parity",1272.9
+14012,Greece,2016,3,C07-Beta blocking agents,Million of national currency units,59.7
+14013,Greece,2016,3,C02-Antihypertensives,Million of national currency units,26.0
+14014,Greece,2016,3,C01A-Cardiac glycosides,Million of national currency units,0.7
+14015,Greece,2016,3,C01A-Cardiac glycosides,Million US$ at exchange rate,0.8
+14016,Greece,2016,3,C07-Beta blocking agents,"Million US$, purchasing power parity",101.5
+14017,Greece,2016,3,C01A-Cardiac glycosides,"Million US$, purchasing power parity",1.2
+14018,Greece,2016,3,C07-Beta blocking agents,Million US$ at exchange rate,66.1
+14019,Greece,2016,3,C02-Antihypertensives,"Million US$, purchasing power parity",44.2
+14020,Greece,2016,3,C02-Antihypertensives,Million US$ at exchange rate,28.8
+14021,Greece,2016,3,C02-Antihypertensives,"/capita, US$ purchasing power parity",4.1
+14022,Greece,2016,3,C02-Antihypertensives,"/capita, US$ exchange rate",2.7
+14023,Greece,2016,3,A02A-Antacids,"Million US$, purchasing power parity",7.3
+14024,Greece,2016,3,A02A-Antacids,Million US$ at exchange rate,4.8
+14025,Greece,2016,3,A02A-Antacids,Million of national currency units,4.3
+14026,Greece,2016,3,A02A-Antacids,"/capita, US$ exchange rate",0.4
+14027,Greece,2016,3,A-Alimentary tract and metabolism,"/capita, US$ exchange rate",77.0
+14028,Greece,2016,3,C03-Diuretics,"Million US$, purchasing power parity",58.6
+14029,Greece,2016,3,C03-Diuretics,Million US$ at exchange rate,38.2
+14030,Greece,2016,3,C08-Calcium channel blockers,"/capita, US$ purchasing power parity",7.9
+14031,Greece,2016,3,"C01B-Antiarrhythmics, Class I and III",Million of national currency units,7.4
+14032,Greece,2016,3,C07-Beta blocking agents,"/capita, US$ exchange rate",6.1
+14033,Greece,2016,3,C03-Diuretics,Million of national currency units,34.5
+14034,Greece,2016,3,A-Alimentary tract and metabolism,"/capita, US$ purchasing power parity",118.1
+14035,Greece,2016,3,C07-Beta blocking agents,"/capita, US$ purchasing power parity",9.4
+14036,Greece,2016,3,C08-Calcium channel blockers,Million US$ at exchange rate,55.6
+14037,Greece,2016,3,C08-Calcium channel blockers,Million of national currency units,50.2
+14038,Greece,2016,3,C08-Calcium channel blockers,"Million US$, purchasing power parity",85.3
+14039,Greece,2016,3,C08-Calcium channel blockers,"/capita, US$ exchange rate",5.2
+14040,Greece,2015,3,N02-Analgesics,Million of national currency units,84.1
+14041,Greece,2015,3,N05B-Anxiolytics,Million US$ at exchange rate,23.0
+14042,Greece,2015,3,N05B-Anxiolytics,Million of national currency units,20.7
+14043,Greece,2015,3,M01A-Antiinflammatory and antirheumatic products non-steroids,Million of national currency units,62.4
+14044,Greece,2015,3,M01A-Antiinflammatory and antirheumatic products non-steroids,Million US$ at exchange rate,69.3
+14045,Greece,2015,3,N05B-Anxiolytics,"/capita, US$ purchasing power parity",3.1
+14046,Greece,2015,3,N05B-Anxiolytics,"Million US$, purchasing power parity",34.0
+14047,Greece,2015,3,N05B-Anxiolytics,"/capita, US$ exchange rate",2.1
+14048,Greece,2015,3,J-Antiinfectives for systemic use,"/capita, US$ exchange rate",55.2
+14049,Greece,2015,3,J-Antiinfectives for systemic use,"Million US$, purchasing power parity",883.7
+14050,Greece,2015,3,J-Antiinfectives for systemic use,"/capita, US$ purchasing power parity",81.7
+14051,Greece,2015,3,R03-Drugs for obstructive airway diseases,Million US$ at exchange rate,234.7
+14052,Greece,2015,3,R03-Drugs for obstructive airway diseases,Million of national currency units,211.5
+14053,Greece,2015,3,N02-Analgesics,"Million US$, purchasing power parity",138.1
+14054,Greece,2015,3,N02-Analgesics,"/capita, US$ exchange rate",8.6
+14055,Greece,2015,3,N02-Analgesics,"/capita, US$ purchasing power parity",12.8
+14056,Greece,2015,3,J-Antiinfectives for systemic use,Million US$ at exchange rate,597.2
+14057,Greece,2015,3,J-Antiinfectives for systemic use,Million of national currency units,538.2
+14058,Greece,2015,3,B-Blood and blood forming organs,Million US$ at exchange rate,498.4
+14059,Greece,2015,3,B-Blood and blood forming organs,"Million US$, purchasing power parity",737.5
+14060,Greece,2015,3,N02-Analgesics,Million US$ at exchange rate,93.4
+14061,Greece,2015,3,B-Blood and blood forming organs,"/capita, US$ purchasing power parity",68.2
+14062,Greece,2015,3,B-Blood and blood forming organs,"/capita, US$ exchange rate",46.1
+14063,Greece,2015,3,R03-Drugs for obstructive airway diseases,"Million US$, purchasing power parity",347.3
+14064,Greece,2015,3,B-Blood and blood forming organs,Million of national currency units,449.2
+14065,Greece,2015,3,R03-Drugs for obstructive airway diseases,"/capita, US$ exchange rate",21.7
+14066,Greece,2015,3,R03-Drugs for obstructive airway diseases,"/capita, US$ purchasing power parity",32.1
+14067,Greece,2015,3,M-Musculo-skeletal system,Million of national currency units,187.1
+14068,Greece,2015,3,R-Respiratory system,Million of national currency units,331.4
+14069,Greece,2015,3,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ purchasing power parity",23.5
+14070,Greece,2015,3,M-Musculo-skeletal system,"Million US$, purchasing power parity",307.1
+14071,Greece,2015,3,M-Musculo-skeletal system,Million US$ at exchange rate,207.5
+14072,Greece,2015,3,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million US$ at exchange rate,172.0
+14073,Greece,2015,3,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"Million US$, purchasing power parity",254.6
+14074,Greece,2015,3,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ exchange rate",15.9
+14075,Greece,2015,3,G03-Sex hormones and modulators of the genital system,"/capita, US$ purchasing power parity",5.1
+14076,Greece,2015,3,R-Respiratory system,Million US$ at exchange rate,367.7
+14077,Greece,2015,3,R-Respiratory system,"Million US$, purchasing power parity",544.2
+14078,Greece,2015,3,G03-Sex hormones and modulators of the genital system,Million US$ at exchange rate,37.5
+14079,Greece,2015,3,G03-Sex hormones and modulators of the genital system,Million of national currency units,33.8
+14080,Greece,2015,3,G03-Sex hormones and modulators of the genital system,"/capita, US$ exchange rate",3.5
+14081,Greece,2015,3,G03-Sex hormones and modulators of the genital system,"Million US$, purchasing power parity",55.5
+14082,Greece,2015,3,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million of national currency units,155.1
+14083,Greece,2015,3,G-Genito urinary system and sex hormones,Million of national currency units,125.6
+14084,Greece,2015,3,N-Nervous system,"/capita, US$ purchasing power parity",85.7
+14085,Greece,2015,3,G-Genito urinary system and sex hormones,"Million US$, purchasing power parity",206.2
+14086,Greece,2015,3,G-Genito urinary system and sex hormones,Million US$ at exchange rate,139.4
+14087,Greece,2015,3,N-Nervous system,Million US$ at exchange rate,626.3
+14088,Greece,2015,3,N-Nervous system,"Million US$, purchasing power parity",926.8
+14089,Greece,2015,3,N-Nervous system,"/capita, US$ exchange rate",57.9
+14090,Greece,2015,3,N-Nervous system,Million of national currency units,564.5
+14091,Greece,2015,3,N06A-Antidepressants,"Million US$, purchasing power parity",172.9
+14092,Greece,2015,3,N06A-Antidepressants,"/capita, US$ exchange rate",10.8
+14093,Greece,2015,3,N06A-Antidepressants,Million of national currency units,105.3
+14094,Greece,2015,3,N06A-Antidepressants,Million US$ at exchange rate,116.8
+14095,Greece,2015,3,G-Genito urinary system and sex hormones,"/capita, US$ purchasing power parity",19.1
+14096,Greece,2015,3,G-Genito urinary system and sex hormones,"/capita, US$ exchange rate",12.9
+14097,Greece,2015,3,N06A-Antidepressants,"/capita, US$ purchasing power parity",16.0
+14098,Greece,2015,3,R-Respiratory system,"/capita, US$ exchange rate",34.0
+14099,Greece,2015,3,J01-Antibacterials for systemic use,"Million US$, purchasing power parity",375.1
+14100,Greece,2015,3,J01-Antibacterials for systemic use,"/capita, US$ exchange rate",23.4
+14101,Greece,2015,3,J01-Antibacterials for systemic use,Million of national currency units,228.5
+14102,Greece,2015,3,J01-Antibacterials for systemic use,Million US$ at exchange rate,253.5
+14103,Greece,2015,3,A10-Drugs used in diabetes,"/capita, US$ exchange rate",29.1
+14104,Greece,2015,3,A10-Drugs used in diabetes,"Million US$, purchasing power parity",465.9
+14105,Greece,2015,3,J01-Antibacterials for systemic use,"/capita, US$ purchasing power parity",34.7
+14106,Greece,2015,3,A10-Drugs used in diabetes,"/capita, US$ purchasing power parity",43.1
+14107,Greece,2015,3,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ purchasing power parity",9.5
+14108,Greece,2015,3,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ purchasing power parity",15.1
+14109,Greece,2015,3,M01A-Antiinflammatory and antirheumatic products non-steroids,"Million US$, purchasing power parity",102.5
+14110,Greece,2015,3,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ exchange rate",6.4
+14111,Greece,2015,3,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million US$ at exchange rate,110.3
+14112,Greece,2015,3,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million of national currency units,99.5
+14113,Greece,2015,3,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ exchange rate",10.2
+14114,Greece,2015,3,"H-Systemic hormonal preparations, excluding sex hormones and insulins","Million US$, purchasing power parity",163.3
+14115,Greece,2015,3,C10-Lipid modifying agents,"/capita, US$ exchange rate",31.2
+14116,Greece,2015,3,C10-Lipid modifying agents,"/capita, US$ purchasing power parity",46.2
+14117,Greece,2015,3,C10-Lipid modifying agents,Million US$ at exchange rate,337.8
+14118,Greece,2015,3,C10-Lipid modifying agents,"Million US$, purchasing power parity",499.9
+14119,Greece,2015,3,R-Respiratory system,"/capita, US$ purchasing power parity",50.3
+14120,Greece,2015,3,M-Musculo-skeletal system,"/capita, US$ purchasing power parity",28.4
+14121,Greece,2015,3,M-Musculo-skeletal system,"/capita, US$ exchange rate",19.2
+14122,Greece,2015,3,N05C-Hypnotics and sedatives,Million of national currency units,7.4
+14123,Greece,2015,3,N05C-Hypnotics and sedatives,Million US$ at exchange rate,8.3
+14124,Greece,2015,3,A10-Drugs used in diabetes,Million US$ at exchange rate,314.8
+14125,Greece,2015,3,A10-Drugs used in diabetes,Million of national currency units,283.8
+14126,Greece,2015,3,N05C-Hypnotics and sedatives,"/capita, US$ purchasing power parity",1.1
+14127,Greece,2015,3,C10-Lipid modifying agents,Million of national currency units,304.5
+14128,Greece,2015,3,N05C-Hypnotics and sedatives,"Million US$, purchasing power parity",12.2
+14129,Greece,2015,3,N05C-Hypnotics and sedatives,"/capita, US$ exchange rate",0.8
+14130,Greece,2015,3,C-Cardiovascular system,"Million US$, purchasing power parity",1454.5
+14131,Greece,2015,3,C-Cardiovascular system,"/capita, US$ exchange rate",90.8
+14132,Greece,2015,3,C-Cardiovascular system,Million US$ at exchange rate,982.9
+14133,Greece,2015,3,C09-Agents acting on the Renin-Angiotensin system,Million of national currency units,331.1
+14134,Greece,2015,3,C-Cardiovascular system,Million of national currency units,885.9
+14135,Greece,2015,3,C01A-Cardiac glycosides,"/capita, US$ exchange rate",0.1
+14136,Greece,2015,3,C03-Diuretics,"/capita, US$ purchasing power parity",4.7
+14137,Greece,2015,3,C-Cardiovascular system,"/capita, US$ purchasing power parity",134.4
+14138,Greece,2015,3,C01A-Cardiac glycosides,"/capita, US$ purchasing power parity",0.1
+14139,Greece,2015,3,"C01B-Antiarrhythmics, Class I and III","Million US$, purchasing power parity",10.9
+14140,Greece,2015,3,"C01B-Antiarrhythmics, Class I and III","/capita, US$ exchange rate",0.7
+14141,Greece,2015,3,"C01B-Antiarrhythmics, Class I and III",Million US$ at exchange rate,7.3
+14142,Greece,2015,3,A-Alimentary tract and metabolism,Million of national currency units,594.7
+14143,Greece,2015,3,C09-Agents acting on the Renin-Angiotensin system,"Million US$, purchasing power parity",543.6
+14144,Greece,2015,3,C09-Agents acting on the Renin-Angiotensin system,Million US$ at exchange rate,367.4
+14145,Greece,2015,3,"C01B-Antiarrhythmics, Class I and III","/capita, US$ purchasing power parity",1.0
+14146,Greece,2015,3,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ exchange rate",34.0
+14147,Greece,2015,3,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ purchasing power parity",50.2
+14148,Greece,2015,3,A-Alimentary tract and metabolism,Million US$ at exchange rate,659.8
+14149,Greece,2015,3,A-Alimentary tract and metabolism,"Million US$, purchasing power parity",976.4
+14150,Greece,2015,3,C07-Beta blocking agents,Million of national currency units,57.5
+14151,Greece,2015,3,C07-Beta blocking agents,Million US$ at exchange rate,63.8
+14152,Greece,2015,3,C01A-Cardiac glycosides,Million US$ at exchange rate,0.8
+14153,Greece,2015,3,C02-Antihypertensives,Million of national currency units,25.1
+14154,Greece,2015,3,C01A-Cardiac glycosides,Million of national currency units,0.7
+14155,Greece,2015,3,C07-Beta blocking agents,"Million US$, purchasing power parity",94.4
+14156,Greece,2015,3,C01A-Cardiac glycosides,"Million US$, purchasing power parity",1.2
+14157,Greece,2015,3,A02A-Antacids,Million of national currency units,5.2
+14158,Greece,2015,3,C02-Antihypertensives,"Million US$, purchasing power parity",41.3
+14159,Greece,2015,3,C02-Antihypertensives,Million US$ at exchange rate,27.9
+14160,Greece,2015,3,A02A-Antacids,"/capita, US$ purchasing power parity",0.8
+14161,Greece,2015,3,C02-Antihypertensives,"/capita, US$ purchasing power parity",3.8
+14162,Greece,2015,3,C02-Antihypertensives,"/capita, US$ exchange rate",2.6
+14163,Greece,2015,3,A02A-Antacids,"Million US$, purchasing power parity",8.5
+14164,Greece,2015,3,A02A-Antacids,Million US$ at exchange rate,5.7
+14165,Greece,2015,3,A02A-Antacids,"/capita, US$ exchange rate",0.5
+14166,Greece,2015,3,C03-Diuretics,"/capita, US$ exchange rate",3.2
+14167,Greece,2015,3,A-Alimentary tract and metabolism,"/capita, US$ exchange rate",61.0
+14168,Greece,2015,3,C03-Diuretics,"Million US$, purchasing power parity",50.6
+14169,Greece,2015,3,C08-Calcium channel blockers,"/capita, US$ purchasing power parity",7.6
+14170,Greece,2015,3,"C01B-Antiarrhythmics, Class I and III",Million of national currency units,6.6
+14171,Greece,2015,3,C03-Diuretics,Million US$ at exchange rate,34.2
+14172,Greece,2015,3,C07-Beta blocking agents,"/capita, US$ exchange rate",5.9
+14173,Greece,2015,3,C03-Diuretics,Million of national currency units,30.8
+14174,Greece,2015,3,C07-Beta blocking agents,"/capita, US$ purchasing power parity",8.7
+14175,Greece,2015,3,A-Alimentary tract and metabolism,"/capita, US$ purchasing power parity",90.2
+14176,Greece,2015,3,C08-Calcium channel blockers,Million US$ at exchange rate,55.9
+14177,Greece,2015,3,C08-Calcium channel blockers,Million of national currency units,50.4
+14178,Greece,2015,3,C08-Calcium channel blockers,"Million US$, purchasing power parity",82.7
+14179,Greece,2015,3,C08-Calcium channel blockers,"/capita, US$ exchange rate",5.2
+14180,Greece,2014,3,N02-Analgesics,Million of national currency units,89.8
+14181,Greece,2014,3,N05B-Anxiolytics,Million US$ at exchange rate,26.8
+14182,Greece,2014,3,N05B-Anxiolytics,Million of national currency units,20.2
+14183,Greece,2014,3,M01A-Antiinflammatory and antirheumatic products non-steroids,Million of national currency units,66.0
+14184,Greece,2014,3,M01A-Antiinflammatory and antirheumatic products non-steroids,Million US$ at exchange rate,87.7
+14185,Greece,2014,3,N05B-Anxiolytics,"Million US$, purchasing power parity",33.1
+14186,Greece,2014,3,N05B-Anxiolytics,"/capita, US$ exchange rate",2.5
+14187,Greece,2014,3,N05B-Anxiolytics,"/capita, US$ purchasing power parity",3.0
+14188,Greece,2014,3,J-Antiinfectives for systemic use,"/capita, US$ exchange rate",66.9
+14189,Greece,2014,3,J-Antiinfectives for systemic use,"Million US$, purchasing power parity",897.0
+14190,Greece,2014,3,J-Antiinfectives for systemic use,"/capita, US$ purchasing power parity",82.4
+14191,Greece,2014,3,R03-Drugs for obstructive airway diseases,Million US$ at exchange rate,328.5
+14192,Greece,2014,3,R03-Drugs for obstructive airway diseases,Million of national currency units,247.3
+14193,Greece,2014,3,N02-Analgesics,"Million US$, purchasing power parity",146.9
+14194,Greece,2014,3,N02-Analgesics,"/capita, US$ exchange rate",10.9
+14195,Greece,2014,3,N02-Analgesics,"/capita, US$ purchasing power parity",13.5
+14196,Greece,2014,3,J-Antiinfectives for systemic use,Million US$ at exchange rate,728.3
+14197,Greece,2014,3,J-Antiinfectives for systemic use,Million of national currency units,548.2
+14198,Greece,2014,3,B-Blood and blood forming organs,"Million US$, purchasing power parity",805.1
+14199,Greece,2014,3,B-Blood and blood forming organs,Million US$ at exchange rate,653.6
+14200,Greece,2014,3,N02-Analgesics,Million US$ at exchange rate,119.2
+14201,Greece,2014,3,B-Blood and blood forming organs,"/capita, US$ purchasing power parity",73.9
+14202,Greece,2014,3,B-Blood and blood forming organs,"/capita, US$ exchange rate",60.0
+14203,Greece,2014,3,R03-Drugs for obstructive airway diseases,"Million US$, purchasing power parity",404.6
+14204,Greece,2014,3,B-Blood and blood forming organs,Million of national currency units,492.0
+14205,Greece,2014,3,R03-Drugs for obstructive airway diseases,"/capita, US$ exchange rate",30.2
+14206,Greece,2014,3,R03-Drugs for obstructive airway diseases,"/capita, US$ purchasing power parity",37.1
+14207,Greece,2014,3,M-Musculo-skeletal system,Million of national currency units,211.4
+14208,Greece,2014,3,R-Respiratory system,Million of national currency units,365.1
+14209,Greece,2014,3,M-Musculo-skeletal system,"Million US$, purchasing power parity",345.8
+14210,Greece,2014,3,M-Musculo-skeletal system,Million US$ at exchange rate,280.8
+14211,Greece,2014,3,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ purchasing power parity",24.3
+14212,Greece,2014,3,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million US$ at exchange rate,214.6
+14213,Greece,2014,3,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"Million US$, purchasing power parity",264.3
+14214,Greece,2014,3,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ exchange rate",19.7
+14215,Greece,2014,3,G03-Sex hormones and modulators of the genital system,"/capita, US$ purchasing power parity",6.1
+14216,Greece,2014,3,R-Respiratory system,Million US$ at exchange rate,485.1
+14217,Greece,2014,3,R-Respiratory system,"Million US$, purchasing power parity",597.5
+14218,Greece,2014,3,G03-Sex hormones and modulators of the genital system,Million US$ at exchange rate,53.9
+14219,Greece,2014,3,G03-Sex hormones and modulators of the genital system,Million of national currency units,40.6
+14220,Greece,2014,3,G03-Sex hormones and modulators of the genital system,"/capita, US$ exchange rate",4.9
+14221,Greece,2014,3,G03-Sex hormones and modulators of the genital system,"Million US$, purchasing power parity",66.4
+14222,Greece,2014,3,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million of national currency units,161.5
+14223,Greece,2014,3,G-Genito urinary system and sex hormones,Million of national currency units,152.6
+14224,Greece,2014,3,N-Nervous system,"/capita, US$ purchasing power parity",99.9
+14225,Greece,2014,3,G-Genito urinary system and sex hormones,"Million US$, purchasing power parity",249.7
+14226,Greece,2014,3,G-Genito urinary system and sex hormones,Million US$ at exchange rate,202.7
+14227,Greece,2014,3,N-Nervous system,Million US$ at exchange rate,883.7
+14228,Greece,2014,3,N-Nervous system,"Million US$, purchasing power parity",1088.5
+14229,Greece,2014,3,N-Nervous system,"/capita, US$ exchange rate",81.1
+14230,Greece,2014,3,N-Nervous system,Million of national currency units,665.2
+14231,Greece,2014,3,N06A-Antidepressants,"Million US$, purchasing power parity",195.1
+14232,Greece,2014,3,N06A-Antidepressants,"/capita, US$ exchange rate",14.5
+14233,Greece,2014,3,N06A-Antidepressants,Million of national currency units,119.2
+14234,Greece,2014,3,G-Genito urinary system and sex hormones,"/capita, US$ purchasing power parity",22.9
+14235,Greece,2014,3,G-Genito urinary system and sex hormones,"/capita, US$ exchange rate",18.6
+14236,Greece,2014,3,N06A-Antidepressants,"/capita, US$ purchasing power parity",17.9
+14237,Greece,2014,3,R-Respiratory system,"/capita, US$ exchange rate",44.5
+14238,Greece,2014,3,J01-Antibacterials for systemic use,"Million US$, purchasing power parity",385.9
+14239,Greece,2014,3,J01-Antibacterials for systemic use,"/capita, US$ exchange rate",28.8
+14240,Greece,2014,3,J01-Antibacterials for systemic use,Million of national currency units,235.9
+14241,Greece,2014,3,J01-Antibacterials for systemic use,Million US$ at exchange rate,313.3
+14242,Greece,2014,3,A10-Drugs used in diabetes,"/capita, US$ exchange rate",37.3
+14243,Greece,2014,3,A10-Drugs used in diabetes,"Million US$, purchasing power parity",500.8
+14244,Greece,2014,3,A10-Drugs used in diabetes,"/capita, US$ purchasing power parity",46.0
+14245,Greece,2014,3,J01-Antibacterials for systemic use,"/capita, US$ purchasing power parity",35.4
+14246,Greece,2014,3,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ purchasing power parity",9.9
+14247,Greece,2014,3,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ purchasing power parity",17.4
+14248,Greece,2014,3,M01A-Antiinflammatory and antirheumatic products non-steroids,"Million US$, purchasing power parity",108.1
+14249,Greece,2014,3,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ exchange rate",8.1
+14250,Greece,2014,3,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million US$ at exchange rate,153.7
+14251,Greece,2014,3,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million of national currency units,115.7
+14252,Greece,2014,3,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ exchange rate",14.1
+14253,Greece,2014,3,"H-Systemic hormonal preparations, excluding sex hormones and insulins","Million US$, purchasing power parity",189.3
+14254,Greece,2014,3,C10-Lipid modifying agents,"/capita, US$ exchange rate",42.5
+14255,Greece,2014,3,C10-Lipid modifying agents,"/capita, US$ purchasing power parity",52.4
+14256,Greece,2014,3,C10-Lipid modifying agents,Million US$ at exchange rate,463.0
+14257,Greece,2014,3,C10-Lipid modifying agents,"Million US$, purchasing power parity",570.3
+14258,Greece,2014,3,R-Respiratory system,"/capita, US$ purchasing power parity",54.9
+14259,Greece,2014,3,M-Musculo-skeletal system,"/capita, US$ purchasing power parity",31.7
+14260,Greece,2014,3,M-Musculo-skeletal system,"/capita, US$ exchange rate",25.8
+14261,Greece,2014,3,N05C-Hypnotics and sedatives,Million US$ at exchange rate,11.9
+14262,Greece,2014,3,N05C-Hypnotics and sedatives,Million of national currency units,8.9
+14263,Greece,2014,3,A10-Drugs used in diabetes,Million US$ at exchange rate,406.6
+14264,Greece,2014,3,A10-Drugs used in diabetes,Million of national currency units,306.1
+14265,Greece,2014,3,N05C-Hypnotics and sedatives,"/capita, US$ purchasing power parity",1.3
+14266,Greece,2014,3,C10-Lipid modifying agents,Million of national currency units,348.5
+14267,Greece,2014,3,N05C-Hypnotics and sedatives,"Million US$, purchasing power parity",14.6
+14268,Greece,2014,3,N05C-Hypnotics and sedatives,"/capita, US$ exchange rate",1.1
+14269,Greece,2014,3,N06A-Antidepressants,Million US$ at exchange rate,158.4
+14270,Greece,2014,3,C-Cardiovascular system,"Million US$, purchasing power parity",1560.8
+14271,Greece,2014,3,C-Cardiovascular system,"/capita, US$ exchange rate",116.3
+14272,Greece,2014,3,C09-Agents acting on the Renin-Angiotensin system,Million of national currency units,364.8
+14273,Greece,2014,3,C-Cardiovascular system,Million US$ at exchange rate,1267.2
+14274,Greece,2014,3,C-Cardiovascular system,Million of national currency units,953.9
+14275,Greece,2014,3,C01A-Cardiac glycosides,"/capita, US$ exchange rate",0.1
+14276,Greece,2014,3,C03-Diuretics,"/capita, US$ purchasing power parity",5.5
+14277,Greece,2014,3,C-Cardiovascular system,"/capita, US$ purchasing power parity",143.3
+14278,Greece,2014,3,C01A-Cardiac glycosides,"/capita, US$ purchasing power parity",0.1
+14279,Greece,2014,3,"C01B-Antiarrhythmics, Class I and III","Million US$, purchasing power parity",10.4
+14280,Greece,2014,3,"C01B-Antiarrhythmics, Class I and III","/capita, US$ exchange rate",0.8
+14281,Greece,2014,3,"C01B-Antiarrhythmics, Class I and III",Million US$ at exchange rate,8.4
+14282,Greece,2014,3,A-Alimentary tract and metabolism,Million of national currency units,634.9
+14283,Greece,2014,3,"C01B-Antiarrhythmics, Class I and III","/capita, US$ purchasing power parity",1.0
+14284,Greece,2014,3,C09-Agents acting on the Renin-Angiotensin system,"Million US$, purchasing power parity",596.9
+14285,Greece,2014,3,C09-Agents acting on the Renin-Angiotensin system,Million US$ at exchange rate,484.6
+14286,Greece,2014,3,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ exchange rate",44.5
+14287,Greece,2014,3,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ purchasing power parity",54.8
+14288,Greece,2014,3,A-Alimentary tract and metabolism,"Million US$, purchasing power parity",1038.9
+14289,Greece,2014,3,A-Alimentary tract and metabolism,Million US$ at exchange rate,843.5
+14290,Greece,2014,3,C07-Beta blocking agents,Million of national currency units,58.7
+14291,Greece,2014,3,C07-Beta blocking agents,Million US$ at exchange rate,78.0
+14292,Greece,2014,3,C01A-Cardiac glycosides,Million US$ at exchange rate,1.2
+14293,Greece,2014,3,C01A-Cardiac glycosides,Million of national currency units,0.9
+14294,Greece,2014,3,C02-Antihypertensives,Million of national currency units,25.2
+14295,Greece,2014,3,C07-Beta blocking agents,"Million US$, purchasing power parity",96.0
+14296,Greece,2014,3,C01A-Cardiac glycosides,"Million US$, purchasing power parity",1.5
+14297,Greece,2014,3,C02-Antihypertensives,"Million US$, purchasing power parity",41.2
+14298,Greece,2014,3,C02-Antihypertensives,Million US$ at exchange rate,33.5
+14299,Greece,2014,3,A02A-Antacids,"/capita, US$ purchasing power parity",0.8
+14300,Greece,2014,3,C02-Antihypertensives,"/capita, US$ purchasing power parity",3.8
+14301,Greece,2014,3,C02-Antihypertensives,"/capita, US$ exchange rate",3.1
+14302,Greece,2014,3,A02A-Antacids,Million of national currency units,5.5
+14303,Greece,2014,3,A02A-Antacids,"Million US$, purchasing power parity",8.9
+14304,Greece,2014,3,A02A-Antacids,Million US$ at exchange rate,7.2
+14305,Greece,2014,3,A02A-Antacids,"/capita, US$ exchange rate",0.7
+14306,Greece,2014,3,A-Alimentary tract and metabolism,"/capita, US$ exchange rate",77.4
+14307,Greece,2014,3,C03-Diuretics,"Million US$, purchasing power parity",59.5
+14308,Greece,2014,3,C08-Calcium channel blockers,"/capita, US$ purchasing power parity",8.4
+14309,Greece,2014,3,"C01B-Antiarrhythmics, Class I and III",Million of national currency units,6.4
+14310,Greece,2014,3,C03-Diuretics,Million US$ at exchange rate,48.3
+14311,Greece,2014,3,C07-Beta blocking agents,"/capita, US$ exchange rate",7.2
+14312,Greece,2014,3,C03-Diuretics,"/capita, US$ exchange rate",4.4
+14313,Greece,2014,3,C03-Diuretics,Million of national currency units,36.3
+14314,Greece,2014,3,C07-Beta blocking agents,"/capita, US$ purchasing power parity",8.8
+14315,Greece,2014,3,A-Alimentary tract and metabolism,"/capita, US$ purchasing power parity",95.4
+14316,Greece,2014,3,C08-Calcium channel blockers,Million US$ at exchange rate,74.3
+14317,Greece,2014,3,C08-Calcium channel blockers,"Million US$, purchasing power parity",91.6
+14318,Greece,2014,3,C08-Calcium channel blockers,"/capita, US$ exchange rate",6.8
+14319,Greece,2014,3,C08-Calcium channel blockers,Million of national currency units,56.0
+14320,Greece,2013,3,N02-Analgesics,Million of national currency units,82.9
+14321,Greece,2013,3,N05B-Anxiolytics,Million of national currency units,21.8
+14322,Greece,2013,3,N05B-Anxiolytics,Million US$ at exchange rate,29.0
+14323,Greece,2013,3,M01A-Antiinflammatory and antirheumatic products non-steroids,Million of national currency units,67.6
+14324,Greece,2013,3,M01A-Antiinflammatory and antirheumatic products non-steroids,Million US$ at exchange rate,89.8
+14325,Greece,2013,3,N05B-Anxiolytics,"/capita, US$ purchasing power parity",3.2
+14326,Greece,2013,3,N05B-Anxiolytics,"Million US$, purchasing power parity",34.6
+14327,Greece,2013,3,N05B-Anxiolytics,"/capita, US$ exchange rate",2.6
+14328,Greece,2013,3,J-Antiinfectives for systemic use,"/capita, US$ purchasing power parity",74.9
+14329,Greece,2013,3,J-Antiinfectives for systemic use,"/capita, US$ exchange rate",62.8
+14330,Greece,2013,3,J-Antiinfectives for systemic use,"Million US$, purchasing power parity",821.3
+14331,Greece,2013,3,R03-Drugs for obstructive airway diseases,Million US$ at exchange rate,328.4
+14332,Greece,2013,3,R03-Drugs for obstructive airway diseases,Million of national currency units,247.3
+14333,Greece,2013,3,N02-Analgesics,"Million US$, purchasing power parity",131.4
+14334,Greece,2013,3,N02-Analgesics,"/capita, US$ exchange rate",10.0
+14335,Greece,2013,3,N02-Analgesics,"/capita, US$ purchasing power parity",12.0
+14336,Greece,2013,3,J-Antiinfectives for systemic use,Million US$ at exchange rate,688.6
+14337,Greece,2013,3,J-Antiinfectives for systemic use,Million of national currency units,518.5
+14338,Greece,2013,3,B-Blood and blood forming organs,"Million US$, purchasing power parity",734.5
+14339,Greece,2013,3,B-Blood and blood forming organs,Million US$ at exchange rate,615.8
+14340,Greece,2013,3,N02-Analgesics,Million US$ at exchange rate,110.1
+14341,Greece,2013,3,B-Blood and blood forming organs,"/capita, US$ purchasing power parity",67.0
+14342,Greece,2013,3,B-Blood and blood forming organs,"/capita, US$ exchange rate",56.2
+14343,Greece,2013,3,R03-Drugs for obstructive airway diseases,"Million US$, purchasing power parity",391.7
+14344,Greece,2013,3,B-Blood and blood forming organs,Million of national currency units,463.7
+14345,Greece,2013,3,R03-Drugs for obstructive airway diseases,"/capita, US$ exchange rate",29.9
+14346,Greece,2013,3,R03-Drugs for obstructive airway diseases,"/capita, US$ purchasing power parity",35.7
+14347,Greece,2013,3,M-Musculo-skeletal system,Million of national currency units,221.0
+14348,Greece,2013,3,R-Respiratory system,Million of national currency units,359.2
+14349,Greece,2013,3,M-Musculo-skeletal system,Million US$ at exchange rate,293.6
+14350,Greece,2013,3,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ purchasing power parity",26.0
+14351,Greece,2013,3,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million US$ at exchange rate,239.0
+14352,Greece,2013,3,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"Million US$, purchasing power parity",285.1
+14353,Greece,2013,3,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ exchange rate",21.8
+14354,Greece,2013,3,G03-Sex hormones and modulators of the genital system,"/capita, US$ purchasing power parity",5.6
+14355,Greece,2013,3,R-Respiratory system,Million US$ at exchange rate,477.0
+14356,Greece,2013,3,R-Respiratory system,"Million US$, purchasing power parity",568.9
+14357,Greece,2013,3,G03-Sex hormones and modulators of the genital system,Million US$ at exchange rate,51.3
+14358,Greece,2013,3,G03-Sex hormones and modulators of the genital system,Million of national currency units,38.6
+14359,Greece,2013,3,G03-Sex hormones and modulators of the genital system,"/capita, US$ exchange rate",4.7
+14360,Greece,2013,3,G03-Sex hormones and modulators of the genital system,"Million US$, purchasing power parity",61.2
+14361,Greece,2013,3,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million of national currency units,180.0
+14362,Greece,2013,3,G-Genito urinary system and sex hormones,Million of national currency units,149.0
+14363,Greece,2013,3,N-Nervous system,"/capita, US$ purchasing power parity",102.1
+14364,Greece,2013,3,G-Genito urinary system and sex hormones,"Million US$, purchasing power parity",236.0
+14365,Greece,2013,3,G-Genito urinary system and sex hormones,Million US$ at exchange rate,197.9
+14366,Greece,2013,3,N-Nervous system,Million US$ at exchange rate,938.7
+14367,Greece,2013,3,N-Nervous system,"Million US$, purchasing power parity",1119.6
+14368,Greece,2013,3,N-Nervous system,"/capita, US$ exchange rate",85.6
+14369,Greece,2013,3,N-Nervous system,Million of national currency units,706.8
+14370,Greece,2013,3,N06A-Antidepressants,"Million US$, purchasing power parity",213.8
+14371,Greece,2013,3,N06A-Antidepressants,"/capita, US$ exchange rate",16.3
+14372,Greece,2013,3,N06A-Antidepressants,Million of national currency units,134.9
+14373,Greece,2013,3,N06A-Antidepressants,Million US$ at exchange rate,179.2
+14374,Greece,2013,3,G-Genito urinary system and sex hormones,"/capita, US$ purchasing power parity",21.5
+14375,Greece,2013,3,G-Genito urinary system and sex hormones,"/capita, US$ exchange rate",18.0
+14376,Greece,2013,3,N06A-Antidepressants,"/capita, US$ purchasing power parity",19.5
+14377,Greece,2013,3,R-Respiratory system,"/capita, US$ exchange rate",43.5
+14378,Greece,2013,3,J01-Antibacterials for systemic use,"Million US$, purchasing power parity",360.1
+14379,Greece,2013,3,J01-Antibacterials for systemic use,"/capita, US$ exchange rate",27.5
+14380,Greece,2013,3,J01-Antibacterials for systemic use,Million of national currency units,227.4
+14381,Greece,2013,3,J01-Antibacterials for systemic use,Million US$ at exchange rate,301.9
+14382,Greece,2013,3,A10-Drugs used in diabetes,"/capita, US$ exchange rate",34.7
+14383,Greece,2013,3,A10-Drugs used in diabetes,"Million US$, purchasing power parity",453.7
+14384,Greece,2013,3,A10-Drugs used in diabetes,"/capita, US$ purchasing power parity",41.4
+14385,Greece,2013,3,J01-Antibacterials for systemic use,"/capita, US$ purchasing power parity",32.8
+14386,Greece,2013,3,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ purchasing power parity",9.8
+14387,Greece,2013,3,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ purchasing power parity",16.6
+14388,Greece,2013,3,M01A-Antiinflammatory and antirheumatic products non-steroids,"Million US$, purchasing power parity",107.1
+14389,Greece,2013,3,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ exchange rate",8.2
+14390,Greece,2013,3,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million US$ at exchange rate,152.3
+14391,Greece,2013,3,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million of national currency units,114.7
+14392,Greece,2013,3,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ exchange rate",13.9
+14393,Greece,2013,3,"H-Systemic hormonal preparations, excluding sex hormones and insulins","Million US$, purchasing power parity",181.7
+14394,Greece,2013,3,C10-Lipid modifying agents,"/capita, US$ exchange rate",43.8
+14395,Greece,2013,3,C10-Lipid modifying agents,"/capita, US$ purchasing power parity",52.3
+14396,Greece,2013,3,C10-Lipid modifying agents,Million US$ at exchange rate,480.8
+14397,Greece,2013,3,C10-Lipid modifying agents,"Million US$, purchasing power parity",573.4
+14398,Greece,2013,3,R-Respiratory system,"/capita, US$ purchasing power parity",51.9
+14399,Greece,2013,3,M-Musculo-skeletal system,"/capita, US$ purchasing power parity",31.9
+14400,Greece,2013,3,M-Musculo-skeletal system,"/capita, US$ exchange rate",26.8
+14401,Greece,2013,3,N05C-Hypnotics and sedatives,Million US$ at exchange rate,10.9
+14402,Greece,2013,3,N05C-Hypnotics and sedatives,Million of national currency units,8.2
+14403,Greece,2013,3,A10-Drugs used in diabetes,Million US$ at exchange rate,380.4
+14404,Greece,2013,3,A10-Drugs used in diabetes,Million of national currency units,286.4
+14405,Greece,2013,3,N05C-Hypnotics and sedatives,"/capita, US$ purchasing power parity",1.2
+14406,Greece,2013,3,C10-Lipid modifying agents,Million of national currency units,362.0
+14407,Greece,2013,3,N05C-Hypnotics and sedatives,"Million US$, purchasing power parity",13.0
+14408,Greece,2013,3,N05C-Hypnotics and sedatives,"/capita, US$ exchange rate",1.0
+14409,Greece,2013,3,M-Musculo-skeletal system,"Million US$, purchasing power parity",350.1
+14410,Greece,2013,3,C-Cardiovascular system,"Million US$, purchasing power parity",1612.5
+14411,Greece,2013,3,C-Cardiovascular system,"/capita, US$ exchange rate",123.3
+14412,Greece,2013,3,C-Cardiovascular system,Million US$ at exchange rate,1352.0
+14413,Greece,2013,3,C09-Agents acting on the Renin-Angiotensin system,Million of national currency units,400.1
+14414,Greece,2013,3,C-Cardiovascular system,Million of national currency units,1018.0
+14415,Greece,2013,3,C01A-Cardiac glycosides,"/capita, US$ exchange rate",0.1
+14416,Greece,2013,3,C03-Diuretics,"/capita, US$ purchasing power parity",5.5
+14417,Greece,2013,3,C-Cardiovascular system,"/capita, US$ purchasing power parity",147.1
+14418,Greece,2013,3,C01A-Cardiac glycosides,"/capita, US$ purchasing power parity",0.1
+14419,Greece,2013,3,"C01B-Antiarrhythmics, Class I and III","Million US$, purchasing power parity",10.3
+14420,Greece,2013,3,"C01B-Antiarrhythmics, Class I and III","/capita, US$ exchange rate",0.8
+14421,Greece,2013,3,"C01B-Antiarrhythmics, Class I and III","/capita, US$ purchasing power parity",0.9
+14422,Greece,2013,3,"C01B-Antiarrhythmics, Class I and III",Million US$ at exchange rate,8.6
+14423,Greece,2013,3,A-Alimentary tract and metabolism,Million of national currency units,630.1
+14424,Greece,2013,3,C09-Agents acting on the Renin-Angiotensin system,"Million US$, purchasing power parity",633.7
+14425,Greece,2013,3,C09-Agents acting on the Renin-Angiotensin system,Million US$ at exchange rate,531.3
+14426,Greece,2013,3,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ exchange rate",48.5
+14427,Greece,2013,3,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ purchasing power parity",57.8
+14428,Greece,2013,3,A-Alimentary tract and metabolism,"Million US$, purchasing power parity",998.1
+14429,Greece,2013,3,C08-Calcium channel blockers,Million of national currency units,61.0
+14430,Greece,2013,3,C07-Beta blocking agents,Million of national currency units,64.2
+14431,Greece,2013,3,A-Alimentary tract and metabolism,Million US$ at exchange rate,836.8
+14432,Greece,2013,3,C07-Beta blocking agents,Million US$ at exchange rate,85.2
+14433,Greece,2013,3,C01A-Cardiac glycosides,Million US$ at exchange rate,1.3
+14434,Greece,2013,3,C02-Antihypertensives,Million of national currency units,27.0
+14435,Greece,2013,3,C01A-Cardiac glycosides,Million of national currency units,1.0
+14436,Greece,2013,3,C07-Beta blocking agents,"Million US$, purchasing power parity",101.7
+14437,Greece,2013,3,C01A-Cardiac glycosides,"Million US$, purchasing power parity",1.5
+14438,Greece,2013,3,A02A-Antacids,Million of national currency units,5.6
+14439,Greece,2013,3,C02-Antihypertensives,"Million US$, purchasing power parity",42.8
+14440,Greece,2013,3,C02-Antihypertensives,Million US$ at exchange rate,35.9
+14441,Greece,2013,3,A02A-Antacids,"/capita, US$ purchasing power parity",0.8
+14442,Greece,2013,3,C02-Antihypertensives,"/capita, US$ purchasing power parity",3.9
+14443,Greece,2013,3,C02-Antihypertensives,"/capita, US$ exchange rate",3.3
+14444,Greece,2013,3,A02A-Antacids,"Million US$, purchasing power parity",8.9
+14445,Greece,2013,3,A02A-Antacids,Million US$ at exchange rate,7.4
+14446,Greece,2013,3,A02A-Antacids,"/capita, US$ exchange rate",0.7
+14447,Greece,2013,3,C03-Diuretics,"/capita, US$ exchange rate",4.6
+14448,Greece,2013,3,C03-Diuretics,"Million US$, purchasing power parity",60.5
+14449,Greece,2013,3,A-Alimentary tract and metabolism,"/capita, US$ exchange rate",76.3
+14450,Greece,2013,3,C08-Calcium channel blockers,"/capita, US$ purchasing power parity",8.8
+14451,Greece,2013,3,"C01B-Antiarrhythmics, Class I and III",Million of national currency units,6.5
+14452,Greece,2013,3,C03-Diuretics,Million US$ at exchange rate,50.7
+14453,Greece,2013,3,C07-Beta blocking agents,"/capita, US$ exchange rate",7.8
+14454,Greece,2013,3,C03-Diuretics,Million of national currency units,38.2
+14455,Greece,2013,3,C07-Beta blocking agents,"/capita, US$ purchasing power parity",9.3
+14456,Greece,2013,3,A-Alimentary tract and metabolism,"/capita, US$ purchasing power parity",91.0
+14457,Greece,2013,3,C08-Calcium channel blockers,Million US$ at exchange rate,81.0
+14458,Greece,2013,3,C08-Calcium channel blockers,"Million US$, purchasing power parity",96.7
+14459,Greece,2013,3,C08-Calcium channel blockers,"/capita, US$ exchange rate",7.4
+14460,Greece,2012,3,N05B-Anxiolytics,Million of national currency units,21.1
+14461,Greece,2012,3,N02-Analgesics,Million of national currency units,84.3
+14462,Greece,2012,3,N05B-Anxiolytics,Million US$ at exchange rate,27.1
+14463,Greece,2012,3,M01A-Antiinflammatory and antirheumatic products non-steroids,Million of national currency units,74.2
+14464,Greece,2012,3,M01A-Antiinflammatory and antirheumatic products non-steroids,Million US$ at exchange rate,95.3
+14465,Greece,2012,3,N05B-Anxiolytics,"Million US$, purchasing power parity",30.8
+14466,Greece,2012,3,N05B-Anxiolytics,"/capita, US$ purchasing power parity",2.8
+14467,Greece,2012,3,N05B-Anxiolytics,"/capita, US$ exchange rate",2.5
+14468,Greece,2012,3,J-Antiinfectives for systemic use,"/capita, US$ purchasing power parity",79.4
+14469,Greece,2012,3,J-Antiinfectives for systemic use,"/capita, US$ exchange rate",69.9
+14470,Greece,2012,3,J-Antiinfectives for systemic use,"Million US$, purchasing power parity",877.1
+14471,Greece,2012,3,R03-Drugs for obstructive airway diseases,Million US$ at exchange rate,356.9
+14472,Greece,2012,3,R03-Drugs for obstructive airway diseases,Million of national currency units,277.8
+14473,Greece,2012,3,N02-Analgesics,"Million US$, purchasing power parity",123.2
+14474,Greece,2012,3,N02-Analgesics,"/capita, US$ exchange rate",9.8
+14475,Greece,2012,3,N02-Analgesics,"/capita, US$ purchasing power parity",11.2
+14476,Greece,2012,3,J-Antiinfectives for systemic use,Million US$ at exchange rate,771.6
+14477,Greece,2012,3,J-Antiinfectives for systemic use,Million of national currency units,600.5
+14478,Greece,2012,3,B-Blood and blood forming organs,"Million US$, purchasing power parity",744.8
+14479,Greece,2012,3,B-Blood and blood forming organs,Million US$ at exchange rate,655.1
+14480,Greece,2012,3,N02-Analgesics,Million US$ at exchange rate,108.4
+14481,Greece,2012,3,B-Blood and blood forming organs,"/capita, US$ purchasing power parity",67.4
+14482,Greece,2012,3,B-Blood and blood forming organs,"/capita, US$ exchange rate",59.3
+14483,Greece,2012,3,B-Blood and blood forming organs,Million of national currency units,509.9
+14484,Greece,2012,3,R03-Drugs for obstructive airway diseases,"Million US$, purchasing power parity",405.7
+14485,Greece,2012,3,R03-Drugs for obstructive airway diseases,"/capita, US$ exchange rate",32.3
+14486,Greece,2012,3,R03-Drugs for obstructive airway diseases,"/capita, US$ purchasing power parity",36.7
+14487,Greece,2012,3,A10-Drugs used in diabetes,Million US$ at exchange rate,361.1
+14488,Greece,2012,3,M01A-Antiinflammatory and antirheumatic products non-steroids,"Million US$, purchasing power parity",108.4
+14489,Greece,2012,3,M-Musculo-skeletal system,Million of national currency units,245.0
+14490,Greece,2012,3,R-Respiratory system,Million of national currency units,398.3
+14491,Greece,2012,3,M-Musculo-skeletal system,"Million US$, purchasing power parity",357.8
+14492,Greece,2012,3,M-Musculo-skeletal system,Million US$ at exchange rate,314.8
+14493,Greece,2012,3,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ purchasing power parity",29.5
+14494,Greece,2012,3,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million US$ at exchange rate,286.4
+14495,Greece,2012,3,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"Million US$, purchasing power parity",325.6
+14496,Greece,2012,3,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ exchange rate",25.9
+14497,Greece,2012,3,G03-Sex hormones and modulators of the genital system,"/capita, US$ purchasing power parity",6.6
+14498,Greece,2012,3,R-Respiratory system,Million US$ at exchange rate,511.7
+14499,Greece,2012,3,R-Respiratory system,"Million US$, purchasing power parity",581.7
+14500,Greece,2012,3,G03-Sex hormones and modulators of the genital system,Million US$ at exchange rate,64.5
+14501,Greece,2012,3,G03-Sex hormones and modulators of the genital system,Million of national currency units,50.2
+14502,Greece,2012,3,G03-Sex hormones and modulators of the genital system,"/capita, US$ exchange rate",5.8
+14503,Greece,2012,3,G03-Sex hormones and modulators of the genital system,"Million US$, purchasing power parity",73.3
+14504,Greece,2012,3,G-Genito urinary system and sex hormones,Million of national currency units,161.3
+14505,Greece,2012,3,N-Nervous system,"/capita, US$ purchasing power parity",104.5
+14506,Greece,2012,3,G-Genito urinary system and sex hormones,"Million US$, purchasing power parity",235.6
+14507,Greece,2012,3,G-Genito urinary system and sex hormones,Million US$ at exchange rate,207.3
+14508,Greece,2012,3,N-Nervous system,Million US$ at exchange rate,1015.0
+14509,Greece,2012,3,N-Nervous system,"Million US$, purchasing power parity",1153.9
+14510,Greece,2012,3,N-Nervous system,"/capita, US$ exchange rate",91.9
+14511,Greece,2012,3,N-Nervous system,Million of national currency units,790.0
+14512,Greece,2012,3,R-Respiratory system,"/capita, US$ exchange rate",46.3
+14513,Greece,2012,3,N06A-Antidepressants,"Million US$, purchasing power parity",200.0
+14514,Greece,2012,3,N06A-Antidepressants,"/capita, US$ exchange rate",15.9
+14515,Greece,2012,3,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million of national currency units,222.9
+14516,Greece,2012,3,N06A-Antidepressants,Million of national currency units,137.0
+14517,Greece,2012,3,N06A-Antidepressants,Million US$ at exchange rate,176.0
+14518,Greece,2012,3,G-Genito urinary system and sex hormones,"/capita, US$ purchasing power parity",21.3
+14519,Greece,2012,3,G-Genito urinary system and sex hormones,"/capita, US$ exchange rate",18.8
+14520,Greece,2012,3,N06A-Antidepressants,"/capita, US$ purchasing power parity",18.1
+14521,Greece,2012,3,A10-Drugs used in diabetes,Million of national currency units,281.1
+14522,Greece,2012,3,J01-Antibacterials for systemic use,"/capita, US$ exchange rate",34.2
+14523,Greece,2012,3,J01-Antibacterials for systemic use,"Million US$, purchasing power parity",429.6
+14524,Greece,2012,3,J01-Antibacterials for systemic use,Million US$ at exchange rate,377.9
+14525,Greece,2012,3,J01-Antibacterials for systemic use,Million of national currency units,294.1
+14526,Greece,2012,3,A10-Drugs used in diabetes,"/capita, US$ exchange rate",32.7
+14527,Greece,2012,3,A10-Drugs used in diabetes,"/capita, US$ purchasing power parity",37.2
+14528,Greece,2012,3,J01-Antibacterials for systemic use,"/capita, US$ purchasing power parity",38.9
+14529,Greece,2012,3,A10-Drugs used in diabetes,"Million US$, purchasing power parity",410.6
+14530,Greece,2012,3,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ purchasing power parity",18.0
+14531,Greece,2012,3,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ purchasing power parity",9.8
+14532,Greece,2012,3,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ exchange rate",8.6
+14533,Greece,2012,3,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million US$ at exchange rate,175.2
+14534,Greece,2012,3,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million of national currency units,136.4
+14535,Greece,2012,3,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ exchange rate",15.9
+14536,Greece,2012,3,"H-Systemic hormonal preparations, excluding sex hormones and insulins","Million US$, purchasing power parity",199.2
+14537,Greece,2012,3,C10-Lipid modifying agents,"/capita, US$ exchange rate",50.6
+14538,Greece,2012,3,C10-Lipid modifying agents,"/capita, US$ purchasing power parity",57.5
+14539,Greece,2012,3,C10-Lipid modifying agents,Million US$ at exchange rate,558.8
+14540,Greece,2012,3,C10-Lipid modifying agents,"Million US$, purchasing power parity",635.2
+14541,Greece,2012,3,R-Respiratory system,"/capita, US$ purchasing power parity",52.7
+14542,Greece,2012,3,M-Musculo-skeletal system,"/capita, US$ purchasing power parity",32.4
+14543,Greece,2012,3,M-Musculo-skeletal system,"/capita, US$ exchange rate",28.5
+14544,Greece,2012,3,N05C-Hypnotics and sedatives,Million US$ at exchange rate,11.4
+14545,Greece,2012,3,N05C-Hypnotics and sedatives,Million of national currency units,8.9
+14546,Greece,2012,3,N05C-Hypnotics and sedatives,"/capita, US$ purchasing power parity",1.2
+14547,Greece,2012,3,C10-Lipid modifying agents,Million of national currency units,434.9
+14548,Greece,2012,3,N05C-Hypnotics and sedatives,"Million US$, purchasing power parity",13.0
+14549,Greece,2012,3,N05C-Hypnotics and sedatives,"/capita, US$ exchange rate",1.0
+14550,Greece,2012,3,C08-Calcium channel blockers,Million of national currency units,68.8
+14551,Greece,2012,3,C-Cardiovascular system,"Million US$, purchasing power parity",1748.1
+14552,Greece,2012,3,C-Cardiovascular system,"/capita, US$ exchange rate",139.2
+14553,Greece,2012,3,C09-Agents acting on the Renin-Angiotensin system,Million of national currency units,473.3
+14554,Greece,2012,3,C-Cardiovascular system,Million of national currency units,1196.9
+14555,Greece,2012,3,C-Cardiovascular system,Million US$ at exchange rate,1537.7
+14556,Greece,2012,3,C01A-Cardiac glycosides,"/capita, US$ exchange rate",0.1
+14557,Greece,2012,3,C03-Diuretics,"/capita, US$ purchasing power parity",4.9
+14558,Greece,2012,3,C-Cardiovascular system,"/capita, US$ purchasing power parity",158.3
+14559,Greece,2012,3,C01A-Cardiac glycosides,"/capita, US$ purchasing power parity",0.2
+14560,Greece,2012,3,"C01B-Antiarrhythmics, Class I and III","Million US$, purchasing power parity",8.5
+14561,Greece,2012,3,"C01B-Antiarrhythmics, Class I and III","/capita, US$ exchange rate",0.7
+14562,Greece,2012,3,"C01B-Antiarrhythmics, Class I and III","/capita, US$ purchasing power parity",0.8
+14563,Greece,2012,3,"C01B-Antiarrhythmics, Class I and III",Million US$ at exchange rate,7.5
+14564,Greece,2012,3,A-Alimentary tract and metabolism,Million of national currency units,678.3
+14565,Greece,2012,3,C09-Agents acting on the Renin-Angiotensin system,"Million US$, purchasing power parity",691.2
+14566,Greece,2012,3,C09-Agents acting on the Renin-Angiotensin system,Million US$ at exchange rate,608.0
+14567,Greece,2012,3,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ exchange rate",55.1
+14568,Greece,2012,3,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ purchasing power parity",62.6
+14569,Greece,2012,3,A-Alimentary tract and metabolism,"Million US$, purchasing power parity",990.7
+14570,Greece,2012,3,A-Alimentary tract and metabolism,Million US$ at exchange rate,871.5
+14571,Greece,2012,3,C07-Beta blocking agents,Million of national currency units,79.9
+14572,Greece,2012,3,C07-Beta blocking agents,Million US$ at exchange rate,102.6
+14573,Greece,2012,3,A02A-Antacids,Million of national currency units,5.3
+14574,Greece,2012,3,C01A-Cardiac glycosides,Million US$ at exchange rate,1.5
+14575,Greece,2012,3,C02-Antihypertensives,Million of national currency units,32.3
+14576,Greece,2012,3,C01A-Cardiac glycosides,Million of national currency units,1.2
+14577,Greece,2012,3,C07-Beta blocking agents,"Million US$, purchasing power parity",116.7
+14578,Greece,2012,3,C01A-Cardiac glycosides,"Million US$, purchasing power parity",1.7
+14579,Greece,2012,3,C02-Antihypertensives,"Million US$, purchasing power parity",47.2
+14580,Greece,2012,3,C02-Antihypertensives,Million US$ at exchange rate,41.5
+14581,Greece,2012,3,A02A-Antacids,"/capita, US$ purchasing power parity",0.7
+14582,Greece,2012,3,C02-Antihypertensives,"/capita, US$ purchasing power parity",4.3
+14583,Greece,2012,3,C02-Antihypertensives,"/capita, US$ exchange rate",3.8
+14584,Greece,2012,3,A02A-Antacids,"Million US$, purchasing power parity",7.8
+14585,Greece,2012,3,A02A-Antacids,Million US$ at exchange rate,6.9
+14586,Greece,2012,3,A02A-Antacids,"/capita, US$ exchange rate",0.6
+14587,Greece,2012,3,C03-Diuretics,"Million US$, purchasing power parity",53.9
+14588,Greece,2012,3,A-Alimentary tract and metabolism,"/capita, US$ exchange rate",78.9
+14589,Greece,2012,3,"C01B-Antiarrhythmics, Class I and III",Million of national currency units,5.8
+14590,Greece,2012,3,C07-Beta blocking agents,"/capita, US$ purchasing power parity",10.6
+14591,Greece,2012,3,C03-Diuretics,Million of national currency units,36.9
+14592,Greece,2012,3,C07-Beta blocking agents,"/capita, US$ exchange rate",9.3
+14593,Greece,2012,3,C03-Diuretics,Million US$ at exchange rate,47.4
+14594,Greece,2012,3,A-Alimentary tract and metabolism,"/capita, US$ purchasing power parity",89.7
+14595,Greece,2012,3,C08-Calcium channel blockers,"/capita, US$ purchasing power parity",9.1
+14596,Greece,2012,3,C08-Calcium channel blockers,Million US$ at exchange rate,88.4
+14597,Greece,2012,3,C08-Calcium channel blockers,"Million US$, purchasing power parity",100.5
+14598,Greece,2012,3,C08-Calcium channel blockers,"/capita, US$ exchange rate",8.0
+14599,Greece,2012,3,C03-Diuretics,"/capita, US$ exchange rate",4.3
+14600,Greece,2011,3,N02-Analgesics,Million of national currency units,80.9
+14601,Greece,2011,3,N05B-Anxiolytics,Million US$ at exchange rate,31.4
+14602,Greece,2011,3,N05B-Anxiolytics,Million of national currency units,22.6
+14603,Greece,2011,3,M01A-Antiinflammatory and antirheumatic products non-steroids,Million of national currency units,83.3
+14604,Greece,2011,3,M01A-Antiinflammatory and antirheumatic products non-steroids,Million US$ at exchange rate,115.9
+14605,Greece,2011,3,N05B-Anxiolytics,"Million US$, purchasing power parity",31.7
+14606,Greece,2011,3,N05B-Anxiolytics,"/capita, US$ purchasing power parity",2.9
+14607,Greece,2011,3,N05B-Anxiolytics,"/capita, US$ exchange rate",2.8
+14608,Greece,2011,3,N02-Analgesics,Million US$ at exchange rate,112.7
+14609,Greece,2011,3,J-Antiinfectives for systemic use,"/capita, US$ purchasing power parity",87.6
+14610,Greece,2011,3,J-Antiinfectives for systemic use,"/capita, US$ exchange rate",86.9
+14611,Greece,2011,3,R03-Drugs for obstructive airway diseases,Million US$ at exchange rate,438.4
+14612,Greece,2011,3,R03-Drugs for obstructive airway diseases,Million of national currency units,315.0
+14613,Greece,2011,3,N02-Analgesics,"Million US$, purchasing power parity",113.5
+14614,Greece,2011,3,J-Antiinfectives for systemic use,"Million US$, purchasing power parity",972.4
+14615,Greece,2011,3,N02-Analgesics,"/capita, US$ exchange rate",10.1
+14616,Greece,2011,3,N02-Analgesics,"/capita, US$ purchasing power parity",10.2
+14617,Greece,2011,3,J-Antiinfectives for systemic use,Million US$ at exchange rate,965.3
+14618,Greece,2011,3,J-Antiinfectives for systemic use,Million of national currency units,693.5
+14619,Greece,2011,3,B-Blood and blood forming organs,"Million US$, purchasing power parity",812.5
+14620,Greece,2011,3,B-Blood and blood forming organs,Million US$ at exchange rate,806.5
+14621,Greece,2011,3,B-Blood and blood forming organs,"/capita, US$ purchasing power parity",73.2
+14622,Greece,2011,3,B-Blood and blood forming organs,"/capita, US$ exchange rate",72.6
+14623,Greece,2011,3,R03-Drugs for obstructive airway diseases,"/capita, US$ exchange rate",39.5
+14624,Greece,2011,3,B-Blood and blood forming organs,Million of national currency units,579.4
+14625,Greece,2011,3,R03-Drugs for obstructive airway diseases,"Million US$, purchasing power parity",441.7
+14626,Greece,2011,3,R03-Drugs for obstructive airway diseases,"/capita, US$ purchasing power parity",39.8
+14627,Greece,2011,3,M-Musculo-skeletal system,Million of national currency units,275.8
+14628,Greece,2011,3,R-Respiratory system,Million of national currency units,451.6
+14629,Greece,2011,3,M-Musculo-skeletal system,"Million US$, purchasing power parity",386.7
+14630,Greece,2011,3,M-Musculo-skeletal system,Million US$ at exchange rate,383.9
+14631,Greece,2011,3,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"Million US$, purchasing power parity",371.2
+14632,Greece,2011,3,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million US$ at exchange rate,368.5
+14633,Greece,2011,3,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ purchasing power parity",33.4
+14634,Greece,2011,3,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ exchange rate",33.2
+14635,Greece,2011,3,R-Respiratory system,Million US$ at exchange rate,628.6
+14636,Greece,2011,3,G03-Sex hormones and modulators of the genital system,"/capita, US$ purchasing power parity",8.2
+14637,Greece,2011,3,R-Respiratory system,"/capita, US$ exchange rate",56.6
+14638,Greece,2011,3,R-Respiratory system,"Million US$, purchasing power parity",633.2
+14639,Greece,2011,3,G03-Sex hormones and modulators of the genital system,Million US$ at exchange rate,90.9
+14640,Greece,2011,3,G03-Sex hormones and modulators of the genital system,Million of national currency units,65.3
+14641,Greece,2011,3,G03-Sex hormones and modulators of the genital system,"/capita, US$ exchange rate",8.2
+14642,Greece,2011,3,G03-Sex hormones and modulators of the genital system,"Million US$, purchasing power parity",91.6
+14643,Greece,2011,3,G-Genito urinary system and sex hormones,Million of national currency units,191.1
+14644,Greece,2011,3,N-Nervous system,"/capita, US$ purchasing power parity",115.4
+14645,Greece,2011,3,G-Genito urinary system and sex hormones,"Million US$, purchasing power parity",268.0
+14646,Greece,2011,3,G-Genito urinary system and sex hormones,Million US$ at exchange rate,266.0
+14647,Greece,2011,3,N-Nervous system,Million US$ at exchange rate,1272.3
+14648,Greece,2011,3,N-Nervous system,"Million US$, purchasing power parity",1281.7
+14649,Greece,2011,3,N-Nervous system,"/capita, US$ exchange rate",114.6
+14650,Greece,2011,3,N-Nervous system,Million of national currency units,914.1
+14651,Greece,2011,3,N06A-Antidepressants,"Million US$, purchasing power parity",218.9
+14652,Greece,2011,3,N06A-Antidepressants,"/capita, US$ exchange rate",19.6
+14653,Greece,2011,3,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million of national currency units,264.7
+14654,Greece,2011,3,N06A-Antidepressants,Million of national currency units,156.1
+14655,Greece,2011,3,N06A-Antidepressants,Million US$ at exchange rate,217.3
+14656,Greece,2011,3,G-Genito urinary system and sex hormones,"/capita, US$ purchasing power parity",24.1
+14657,Greece,2011,3,G-Genito urinary system and sex hormones,"/capita, US$ exchange rate",24.0
+14658,Greece,2011,3,N06A-Antidepressants,"/capita, US$ purchasing power parity",19.7
+14659,Greece,2011,3,A10-Drugs used in diabetes,Million of national currency units,277.3
+14660,Greece,2011,3,J01-Antibacterials for systemic use,"/capita, US$ exchange rate",42.7
+14661,Greece,2011,3,J01-Antibacterials for systemic use,"Million US$, purchasing power parity",477.7
+14662,Greece,2011,3,J01-Antibacterials for systemic use,Million US$ at exchange rate,474.2
+14663,Greece,2011,3,A10-Drugs used in diabetes,"/capita, US$ exchange rate",34.8
+14664,Greece,2011,3,A10-Drugs used in diabetes,"/capita, US$ purchasing power parity",35.0
+14665,Greece,2011,3,J01-Antibacterials for systemic use,"/capita, US$ purchasing power parity",43.0
+14666,Greece,2011,3,J01-Antibacterials for systemic use,Million of national currency units,340.7
+14667,Greece,2011,3,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ purchasing power parity",19.8
+14668,Greece,2011,3,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ purchasing power parity",10.5
+14669,Greece,2011,3,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ exchange rate",10.4
+14670,Greece,2011,3,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million US$ at exchange rate,218.8
+14671,Greece,2011,3,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million of national currency units,157.2
+14672,Greece,2011,3,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ exchange rate",19.7
+14673,Greece,2011,3,"H-Systemic hormonal preparations, excluding sex hormones and insulins","Million US$, purchasing power parity",220.4
+14674,Greece,2011,3,M01A-Antiinflammatory and antirheumatic products non-steroids,"Million US$, purchasing power parity",116.8
+14675,Greece,2011,3,A10-Drugs used in diabetes,"Million US$, purchasing power parity",388.9
+14676,Greece,2011,3,C10-Lipid modifying agents,"/capita, US$ exchange rate",60.2
+14677,Greece,2011,3,C10-Lipid modifying agents,"/capita, US$ purchasing power parity",60.6
+14678,Greece,2011,3,C10-Lipid modifying agents,Million US$ at exchange rate,668.5
+14679,Greece,2011,3,C10-Lipid modifying agents,"Million US$, purchasing power parity",673.5
+14680,Greece,2011,3,R-Respiratory system,"/capita, US$ purchasing power parity",57.0
+14681,Greece,2011,3,M-Musculo-skeletal system,"/capita, US$ exchange rate",34.6
+14682,Greece,2011,3,M-Musculo-skeletal system,"/capita, US$ purchasing power parity",34.8
+14683,Greece,2011,3,N05C-Hypnotics and sedatives,Million US$ at exchange rate,14.2
+14684,Greece,2011,3,N05C-Hypnotics and sedatives,Million of national currency units,10.2
+14685,Greece,2011,3,A10-Drugs used in diabetes,Million US$ at exchange rate,386.1
+14686,Greece,2011,3,N05C-Hypnotics and sedatives,"/capita, US$ purchasing power parity",1.3
+14687,Greece,2011,3,C10-Lipid modifying agents,Million of national currency units,480.3
+14688,Greece,2011,3,N05C-Hypnotics and sedatives,"Million US$, purchasing power parity",14.3
+14689,Greece,2011,3,N05C-Hypnotics and sedatives,"/capita, US$ exchange rate",1.3
+14690,Greece,2011,3,C-Cardiovascular system,"Million US$, purchasing power parity",1843.2
+14691,Greece,2011,3,C-Cardiovascular system,"/capita, US$ exchange rate",164.8
+14692,Greece,2011,3,C09-Agents acting on the Renin-Angiotensin system,Million of national currency units,523.1
+14693,Greece,2011,3,C-Cardiovascular system,Million of national currency units,1314.5
+14694,Greece,2011,3,C-Cardiovascular system,Million US$ at exchange rate,1829.7
+14695,Greece,2011,3,C03-Diuretics,"/capita, US$ purchasing power parity",4.5
+14696,Greece,2011,3,C01A-Cardiac glycosides,"/capita, US$ purchasing power parity",0.1
+14697,Greece,2011,3,C-Cardiovascular system,"/capita, US$ purchasing power parity",166.0
+14698,Greece,2011,3,"C01B-Antiarrhythmics, Class I and III","/capita, US$ exchange rate",0.8
+14699,Greece,2011,3,"C01B-Antiarrhythmics, Class I and III","/capita, US$ purchasing power parity",0.8
+14700,Greece,2011,3,"C01B-Antiarrhythmics, Class I and III","Million US$, purchasing power parity",8.7
+14701,Greece,2011,3,"C01B-Antiarrhythmics, Class I and III",Million US$ at exchange rate,8.7
+14702,Greece,2011,3,A-Alimentary tract and metabolism,Million of national currency units,743.9
+14703,Greece,2011,3,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ exchange rate",65.6
+14704,Greece,2011,3,C09-Agents acting on the Renin-Angiotensin system,"Million US$, purchasing power parity",733.5
+14705,Greece,2011,3,C09-Agents acting on the Renin-Angiotensin system,Million US$ at exchange rate,728.2
+14706,Greece,2011,3,A-Alimentary tract and metabolism,"Million US$, purchasing power parity",1043.1
+14707,Greece,2011,3,A-Alimentary tract and metabolism,"/capita, US$ exchange rate",93.2
+14708,Greece,2011,3,A02A-Antacids,Million of national currency units,6.0
+14709,Greece,2011,3,C07-Beta blocking agents,Million of national currency units,81.7
+14710,Greece,2011,3,C07-Beta blocking agents,Million US$ at exchange rate,113.7
+14711,Greece,2011,3,A-Alimentary tract and metabolism,Million US$ at exchange rate,1035.5
+14712,Greece,2011,3,C01A-Cardiac glycosides,Million US$ at exchange rate,1.6
+14713,Greece,2011,3,C02-Antihypertensives,Million of national currency units,39.3
+14714,Greece,2011,3,C01A-Cardiac glycosides,Million of national currency units,1.2
+14715,Greece,2011,3,C07-Beta blocking agents,"Million US$, purchasing power parity",114.5
+14716,Greece,2011,3,C01A-Cardiac glycosides,"Million US$, purchasing power parity",1.6
+14717,Greece,2011,3,C02-Antihypertensives,"Million US$, purchasing power parity",55.1
+14718,Greece,2011,3,C02-Antihypertensives,Million US$ at exchange rate,54.7
+14719,Greece,2011,3,A02A-Antacids,"/capita, US$ purchasing power parity",0.8
+14720,Greece,2011,3,C02-Antihypertensives,"/capita, US$ exchange rate",4.9
+14721,Greece,2011,3,C02-Antihypertensives,"/capita, US$ purchasing power parity",5.0
+14722,Greece,2011,3,A02A-Antacids,"Million US$, purchasing power parity",8.4
+14723,Greece,2011,3,A02A-Antacids,Million US$ at exchange rate,8.4
+14724,Greece,2011,3,A02A-Antacids,"/capita, US$ exchange rate",0.8
+14725,Greece,2011,3,C01A-Cardiac glycosides,"/capita, US$ exchange rate",0.1
+14726,Greece,2011,3,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ purchasing power parity",66.1
+14727,Greece,2011,3,A-Alimentary tract and metabolism,"/capita, US$ purchasing power parity",93.9
+14728,Greece,2011,3,C03-Diuretics,"Million US$, purchasing power parity",50.1
+14729,Greece,2011,3,C08-Calcium channel blockers,Million of national currency units,77.7
+14730,Greece,2011,3,"C01B-Antiarrhythmics, Class I and III",Million of national currency units,6.2
+14731,Greece,2011,3,C07-Beta blocking agents,"/capita, US$ purchasing power parity",10.3
+14732,Greece,2011,3,C07-Beta blocking agents,"/capita, US$ exchange rate",10.2
+14733,Greece,2011,3,C03-Diuretics,Million of national currency units,35.7
+14734,Greece,2011,3,C03-Diuretics,Million US$ at exchange rate,49.7
+14735,Greece,2011,3,C08-Calcium channel blockers,"/capita, US$ purchasing power parity",9.8
+14736,Greece,2011,3,C08-Calcium channel blockers,"/capita, US$ exchange rate",9.7
+14737,Greece,2011,3,C08-Calcium channel blockers,Million US$ at exchange rate,108.1
+14738,Greece,2011,3,C08-Calcium channel blockers,"Million US$, purchasing power parity",108.9
+14739,Greece,2011,3,C03-Diuretics,"/capita, US$ exchange rate",4.5
+14740,Greece,2010,3,N02-Analgesics,Million of national currency units,76.5
+14741,Greece,2010,3,N05B-Anxiolytics,Million US$ at exchange rate,29.5
+14742,Greece,2010,3,N05B-Anxiolytics,Million of national currency units,22.3
+14743,Greece,2010,3,M01A-Antiinflammatory and antirheumatic products non-steroids,Million of national currency units,101.4
+14744,Greece,2010,3,M01A-Antiinflammatory and antirheumatic products non-steroids,Million US$ at exchange rate,134.5
+14745,Greece,2010,3,N05B-Anxiolytics,"Million US$, purchasing power parity",30.8
+14746,Greece,2010,3,N05B-Anxiolytics,"/capita, US$ exchange rate",2.7
+14747,Greece,2010,3,N05B-Anxiolytics,"/capita, US$ purchasing power parity",2.8
+14748,Greece,2010,3,J-Antiinfectives for systemic use,"/capita, US$ purchasing power parity",93.2
+14749,Greece,2010,3,J-Antiinfectives for systemic use,"/capita, US$ exchange rate",89.2
+14750,Greece,2010,3,R03-Drugs for obstructive airway diseases,Million US$ at exchange rate,427.1
+14751,Greece,2010,3,R03-Drugs for obstructive airway diseases,Million of national currency units,322.2
+14752,Greece,2010,3,N02-Analgesics,"Million US$, purchasing power parity",106.0
+14753,Greece,2010,3,N02-Analgesics,"/capita, US$ exchange rate",9.1
+14754,Greece,2010,3,N02-Analgesics,"/capita, US$ purchasing power parity",9.5
+14755,Greece,2010,3,J-Antiinfectives for systemic use,"Million US$, purchasing power parity",1036.8
+14756,Greece,2010,3,J-Antiinfectives for systemic use,Million US$ at exchange rate,992.4
+14757,Greece,2010,3,J-Antiinfectives for systemic use,Million of national currency units,748.6
+14758,Greece,2010,3,B-Blood and blood forming organs,"Million US$, purchasing power parity",891.6
+14759,Greece,2010,3,B-Blood and blood forming organs,Million US$ at exchange rate,853.4
+14760,Greece,2010,3,N02-Analgesics,Million US$ at exchange rate,101.4
+14761,Greece,2010,3,B-Blood and blood forming organs,"/capita, US$ purchasing power parity",80.2
+14762,Greece,2010,3,B-Blood and blood forming organs,"/capita, US$ exchange rate",76.7
+14763,Greece,2010,3,R03-Drugs for obstructive airway diseases,"/capita, US$ exchange rate",38.4
+14764,Greece,2010,3,B-Blood and blood forming organs,Million of national currency units,643.7
+14765,Greece,2010,3,R03-Drugs for obstructive airway diseases,"Million US$, purchasing power parity",446.2
+14766,Greece,2010,3,R03-Drugs for obstructive airway diseases,"/capita, US$ purchasing power parity",40.1
+14767,Greece,2010,3,M01A-Antiinflammatory and antirheumatic products non-steroids,"Million US$, purchasing power parity",140.5
+14768,Greece,2010,3,M-Musculo-skeletal system,Million of national currency units,317.4
+14769,Greece,2010,3,R-Respiratory system,Million of national currency units,459.6
+14770,Greece,2010,3,M-Musculo-skeletal system,"Million US$, purchasing power parity",439.6
+14771,Greece,2010,3,M-Musculo-skeletal system,Million US$ at exchange rate,420.8
+14772,Greece,2010,3,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"Million US$, purchasing power parity",444.8
+14773,Greece,2010,3,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million US$ at exchange rate,425.8
+14774,Greece,2010,3,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ purchasing power parity",40.0
+14775,Greece,2010,3,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ exchange rate",38.3
+14776,Greece,2010,3,G03-Sex hormones and modulators of the genital system,Million of national currency units,67.5
+14777,Greece,2010,3,R-Respiratory system,Million US$ at exchange rate,609.3
+14778,Greece,2010,3,G03-Sex hormones and modulators of the genital system,"/capita, US$ purchasing power parity",8.4
+14779,Greece,2010,3,R-Respiratory system,"/capita, US$ exchange rate",54.8
+14780,Greece,2010,3,R-Respiratory system,"Million US$, purchasing power parity",636.5
+14781,Greece,2010,3,G03-Sex hormones and modulators of the genital system,Million US$ at exchange rate,89.4
+14782,Greece,2010,3,G03-Sex hormones and modulators of the genital system,"/capita, US$ exchange rate",8.0
+14783,Greece,2010,3,G03-Sex hormones and modulators of the genital system,"Million US$, purchasing power parity",93.4
+14784,Greece,2010,3,G-Genito urinary system and sex hormones,Million of national currency units,211.3
+14785,Greece,2010,3,N-Nervous system,"/capita, US$ purchasing power parity",130.0
+14786,Greece,2010,3,G-Genito urinary system and sex hormones,"Million US$, purchasing power parity",292.6
+14787,Greece,2010,3,G-Genito urinary system and sex hormones,Million US$ at exchange rate,280.1
+14788,Greece,2010,3,N-Nervous system,Million US$ at exchange rate,1383.9
+14789,Greece,2010,3,N-Nervous system,"Million US$, purchasing power parity",1445.8
+14790,Greece,2010,3,N-Nervous system,"/capita, US$ exchange rate",124.4
+14791,Greece,2010,3,N-Nervous system,Million of national currency units,1043.9
+14792,Greece,2010,3,N06A-Antidepressants,"Million US$, purchasing power parity",258.4
+14793,Greece,2010,3,N06A-Antidepressants,"/capita, US$ exchange rate",22.2
+14794,Greece,2010,3,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million of national currency units,321.2
+14795,Greece,2010,3,N06A-Antidepressants,Million of national currency units,186.6
+14796,Greece,2010,3,N06A-Antidepressants,Million US$ at exchange rate,247.4
+14797,Greece,2010,3,G-Genito urinary system and sex hormones,"/capita, US$ purchasing power parity",26.3
+14798,Greece,2010,3,G-Genito urinary system and sex hormones,"/capita, US$ exchange rate",25.2
+14799,Greece,2010,3,N06A-Antidepressants,"/capita, US$ purchasing power parity",23.2
+14800,Greece,2010,3,A10-Drugs used in diabetes,Million of national currency units,303.2
+14801,Greece,2010,3,J01-Antibacterials for systemic use,"/capita, US$ exchange rate",43.6
+14802,Greece,2010,3,J01-Antibacterials for systemic use,"Million US$, purchasing power parity",507.1
+14803,Greece,2010,3,J01-Antibacterials for systemic use,Million US$ at exchange rate,485.4
+14804,Greece,2010,3,A10-Drugs used in diabetes,"/capita, US$ exchange rate",36.1
+14805,Greece,2010,3,J01-Antibacterials for systemic use,"/capita, US$ purchasing power parity",45.6
+14806,Greece,2010,3,A10-Drugs used in diabetes,"/capita, US$ purchasing power parity",37.8
+14807,Greece,2010,3,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million of national currency units,169.2
+14808,Greece,2010,3,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ purchasing power parity",21.1
+14809,Greece,2010,3,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ purchasing power parity",12.6
+14810,Greece,2010,3,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ exchange rate",12.1
+14811,Greece,2010,3,J01-Antibacterials for systemic use,Million of national currency units,366.1
+14812,Greece,2010,3,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million US$ at exchange rate,224.2
+14813,Greece,2010,3,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ exchange rate",20.2
+14814,Greece,2010,3,"H-Systemic hormonal preparations, excluding sex hormones and insulins","Million US$, purchasing power parity",234.3
+14815,Greece,2010,3,C10-Lipid modifying agents,"/capita, US$ exchange rate",64.8
+14816,Greece,2010,3,C10-Lipid modifying agents,"/capita, US$ purchasing power parity",67.7
+14817,Greece,2010,3,C10-Lipid modifying agents,Million US$ at exchange rate,720.2
+14818,Greece,2010,3,C10-Lipid modifying agents,"Million US$, purchasing power parity",752.5
+14819,Greece,2010,3,R-Respiratory system,"/capita, US$ purchasing power parity",57.2
+14820,Greece,2010,3,M-Musculo-skeletal system,"/capita, US$ exchange rate",37.8
+14821,Greece,2010,3,M-Musculo-skeletal system,"/capita, US$ purchasing power parity",39.5
+14822,Greece,2010,3,A10-Drugs used in diabetes,"Million US$, purchasing power parity",419.9
+14823,Greece,2010,3,N05C-Hypnotics and sedatives,Million US$ at exchange rate,14.2
+14824,Greece,2010,3,A10-Drugs used in diabetes,Million US$ at exchange rate,401.9
+14825,Greece,2010,3,N05C-Hypnotics and sedatives,Million of national currency units,10.7
+14826,Greece,2010,3,N05C-Hypnotics and sedatives,"/capita, US$ purchasing power parity",1.3
+14827,Greece,2010,3,C10-Lipid modifying agents,Million of national currency units,543.3
+14828,Greece,2010,3,N05C-Hypnotics and sedatives,"Million US$, purchasing power parity",14.8
+14829,Greece,2010,3,N05C-Hypnotics and sedatives,"/capita, US$ exchange rate",1.3
+14830,Greece,2010,3,C-Cardiovascular system,"Million US$, purchasing power parity",1974.4
+14831,Greece,2010,3,C-Cardiovascular system,"/capita, US$ exchange rate",169.9
+14832,Greece,2010,3,C09-Agents acting on the Renin-Angiotensin system,Million of national currency units,539.5
+14833,Greece,2010,3,C-Cardiovascular system,Million of national currency units,1425.5
+14834,Greece,2010,3,C-Cardiovascular system,Million US$ at exchange rate,1889.8
+14835,Greece,2010,3,C03-Diuretics,"/capita, US$ purchasing power parity",4.6
+14836,Greece,2010,3,C-Cardiovascular system,"/capita, US$ purchasing power parity",177.5
+14837,Greece,2010,3,C01A-Cardiac glycosides,"/capita, US$ purchasing power parity",0.2
+14838,Greece,2010,3,C09-Agents acting on the Renin-Angiotensin system,Million US$ at exchange rate,715.2
+14839,Greece,2010,3,"C01B-Antiarrhythmics, Class I and III","/capita, US$ exchange rate",0.7
+14840,Greece,2010,3,"C01B-Antiarrhythmics, Class I and III","/capita, US$ purchasing power parity",0.7
+14841,Greece,2010,3,"C01B-Antiarrhythmics, Class I and III","Million US$, purchasing power parity",7.6
+14842,Greece,2010,3,A-Alimentary tract and metabolism,Million of national currency units,856.0
+14843,Greece,2010,3,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ exchange rate",64.3
+14844,Greece,2010,3,C09-Agents acting on the Renin-Angiotensin system,"Million US$, purchasing power parity",747.1
+14845,Greece,2010,3,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ purchasing power parity",67.2
+14846,Greece,2010,3,A-Alimentary tract and metabolism,"Million US$, purchasing power parity",1185.5
+14847,Greece,2010,3,A-Alimentary tract and metabolism,"/capita, US$ exchange rate",102.0
+14848,Greece,2010,3,C07-Beta blocking agents,"/capita, US$ exchange rate",9.7
+14849,Greece,2010,3,A02A-Antacids,Million of national currency units,5.8
+14850,Greece,2010,3,C07-Beta blocking agents,Million of national currency units,81.2
+14851,Greece,2010,3,C07-Beta blocking agents,Million US$ at exchange rate,107.7
+14852,Greece,2010,3,A-Alimentary tract and metabolism,Million US$ at exchange rate,1134.8
+14853,Greece,2010,3,C01A-Cardiac glycosides,Million US$ at exchange rate,1.6
+14854,Greece,2010,3,C02-Antihypertensives,Million of national currency units,41.5
+14855,Greece,2010,3,C01A-Cardiac glycosides,Million of national currency units,1.2
+14856,Greece,2010,3,C07-Beta blocking agents,"Million US$, purchasing power parity",112.5
+14857,Greece,2010,3,C01A-Cardiac glycosides,"Million US$, purchasing power parity",1.7
+14858,Greece,2010,3,C02-Antihypertensives,"Million US$, purchasing power parity",57.5
+14859,Greece,2010,3,A02A-Antacids,"/capita, US$ purchasing power parity",0.7
+14860,Greece,2010,3,C02-Antihypertensives,"/capita, US$ exchange rate",5.0
+14861,Greece,2010,3,C02-Antihypertensives,"/capita, US$ purchasing power parity",5.2
+14862,Greece,2010,3,A02A-Antacids,"Million US$, purchasing power parity",8.0
+14863,Greece,2010,3,A02A-Antacids,Million US$ at exchange rate,7.7
+14864,Greece,2010,3,A02A-Antacids,"/capita, US$ exchange rate",0.7
+14865,Greece,2010,3,C02-Antihypertensives,Million US$ at exchange rate,55.1
+14866,Greece,2010,3,C01A-Cardiac glycosides,"/capita, US$ exchange rate",0.1
+14867,Greece,2010,3,A-Alimentary tract and metabolism,"/capita, US$ purchasing power parity",106.6
+14868,Greece,2010,3,C03-Diuretics,"Million US$, purchasing power parity",50.8
+14869,Greece,2010,3,"C01B-Antiarrhythmics, Class I and III",Million US$ at exchange rate,7.3
+14870,Greece,2010,3,"C01B-Antiarrhythmics, Class I and III",Million of national currency units,5.5
+14871,Greece,2010,3,C07-Beta blocking agents,"/capita, US$ purchasing power parity",10.1
+14872,Greece,2010,3,C03-Diuretics,Million of national currency units,36.7
+14873,Greece,2010,3,C03-Diuretics,Million US$ at exchange rate,48.7
+14874,Greece,2010,3,C08-Calcium channel blockers,Million of national currency units,94.3
+14875,Greece,2010,3,C08-Calcium channel blockers,"/capita, US$ exchange rate",11.2
+14876,Greece,2010,3,C08-Calcium channel blockers,Million US$ at exchange rate,125.0
+14877,Greece,2010,3,C08-Calcium channel blockers,"Million US$, purchasing power parity",130.6
+14878,Greece,2010,3,C08-Calcium channel blockers,"/capita, US$ purchasing power parity",11.7
+14879,Greece,2010,3,C03-Diuretics,"/capita, US$ exchange rate",4.4
+14880,Greece,2017,3,N02-Analgesics,Million of national currency units,141.8
+14881,Greece,2017,3,N05B-Anxiolytics,Million of national currency units,22.2
+14882,Greece,2017,3,N05B-Anxiolytics,"/capita, US$ purchasing power parity",3.6
+14883,Greece,2017,3,M01A-Antiinflammatory and antirheumatic products non-steroids,Million of national currency units,64.2
+14884,Greece,2017,3,M01A-Antiinflammatory and antirheumatic products non-steroids,Million US$ at exchange rate,72.5
+14885,Greece,2017,3,N05B-Anxiolytics,Million US$ at exchange rate,25.1
+14886,Greece,2017,3,N05B-Anxiolytics,"Million US$, purchasing power parity",38.7
+14887,Greece,2017,3,N05B-Anxiolytics,"/capita, US$ exchange rate",2.3
+14888,Greece,2017,3,J-Antiinfectives for systemic use,"/capita, US$ exchange rate",68.6
+14889,Greece,2017,3,J-Antiinfectives for systemic use,"Million US$, purchasing power parity",1135.8
+14890,Greece,2017,3,J-Antiinfectives for systemic use,"/capita, US$ purchasing power parity",105.6
+14891,Greece,2017,3,R03-Drugs for obstructive airway diseases,Million of national currency units,267.2
+14892,Greece,2017,3,R03-Drugs for obstructive airway diseases,Million US$ at exchange rate,301.8
+14893,Greece,2017,3,N02-Analgesics,"/capita, US$ exchange rate",14.9
+14894,Greece,2017,3,N02-Analgesics,"/capita, US$ purchasing power parity",22.9
+14895,Greece,2017,3,J-Antiinfectives for systemic use,Million US$ at exchange rate,737.8
+14896,Greece,2017,3,J-Antiinfectives for systemic use,Million of national currency units,653.1
+14897,Greece,2017,3,N02-Analgesics,"Million US$, purchasing power parity",246.7
+14898,Greece,2017,3,B-Blood and blood forming organs,Million US$ at exchange rate,1157.5
+14899,Greece,2017,3,B-Blood and blood forming organs,"/capita, US$ purchasing power parity",165.7
+14900,Greece,2017,3,B-Blood and blood forming organs,"/capita, US$ exchange rate",107.6
+14901,Greece,2017,3,B-Blood and blood forming organs,"Million US$, purchasing power parity",1781.9
+14902,Greece,2017,3,N02-Analgesics,Million US$ at exchange rate,160.2
+14903,Greece,2017,3,R03-Drugs for obstructive airway diseases,"Million US$, purchasing power parity",464.6
+14904,Greece,2017,3,B-Blood and blood forming organs,Million of national currency units,1024.6
+14905,Greece,2017,3,R03-Drugs for obstructive airway diseases,"/capita, US$ purchasing power parity",43.2
+14906,Greece,2017,3,R03-Drugs for obstructive airway diseases,"/capita, US$ exchange rate",28.1
+14907,Greece,2017,3,M-Musculo-skeletal system,Million of national currency units,212.1
+14908,Greece,2017,3,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ purchasing power parity",24.7
+14909,Greece,2017,3,M-Musculo-skeletal system,"Million US$, purchasing power parity",368.9
+14910,Greece,2017,3,M-Musculo-skeletal system,Million US$ at exchange rate,239.6
+14911,Greece,2017,3,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million US$ at exchange rate,172.3
+14912,Greece,2017,3,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million of national currency units,152.5
+14913,Greece,2017,3,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ exchange rate",16.0
+14914,Greece,2017,3,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"Million US$, purchasing power parity",265.3
+14915,Greece,2017,3,R-Respiratory system,Million of national currency units,410.4
+14916,Greece,2017,3,G03-Sex hormones and modulators of the genital system,"/capita, US$ purchasing power parity",6.1
+14917,Greece,2017,3,R-Respiratory system,"Million US$, purchasing power parity",713.8
+14918,Greece,2017,3,R-Respiratory system,Million US$ at exchange rate,463.7
+14919,Greece,2017,3,G03-Sex hormones and modulators of the genital system,Million US$ at exchange rate,42.9
+14920,Greece,2017,3,G03-Sex hormones and modulators of the genital system,Million of national currency units,38.0
+14921,Greece,2017,3,G03-Sex hormones and modulators of the genital system,"/capita, US$ exchange rate",4.0
+14922,Greece,2017,3,G03-Sex hormones and modulators of the genital system,"Million US$, purchasing power parity",66.1
+14923,Greece,2017,3,N-Nervous system,"/capita, US$ purchasing power parity",104.6
+14924,Greece,2017,3,G-Genito urinary system and sex hormones,Million of national currency units,166.8
+14925,Greece,2017,3,G-Genito urinary system and sex hormones,Million US$ at exchange rate,188.4
+14926,Greece,2017,3,G-Genito urinary system and sex hormones,"Million US$, purchasing power parity",290.0
+14927,Greece,2017,3,N-Nervous system,Million US$ at exchange rate,730.9
+14928,Greece,2017,3,N-Nervous system,Million of national currency units,647.0
+14929,Greece,2017,3,N-Nervous system,"/capita, US$ exchange rate",68.0
+14930,Greece,2017,3,N-Nervous system,"Million US$, purchasing power parity",1125.1
+14931,Greece,2017,3,N06A-Antidepressants,"Million US$, purchasing power parity",173.8
+14932,Greece,2017,3,N06A-Antidepressants,Million US$ at exchange rate,112.9
+14933,Greece,2017,3,N06A-Antidepressants,Million of national currency units,100.0
+14934,Greece,2017,3,N06A-Antidepressants,"/capita, US$ exchange rate",10.5
+14935,Greece,2017,3,G-Genito urinary system and sex hormones,"/capita, US$ exchange rate",17.5
+14936,Greece,2017,3,G-Genito urinary system and sex hormones,"/capita, US$ purchasing power parity",27.0
+14937,Greece,2017,3,N06A-Antidepressants,"/capita, US$ purchasing power parity",16.2
+14938,Greece,2017,3,J01-Antibacterials for systemic use,"Million US$, purchasing power parity",393.3
+14939,Greece,2017,3,J01-Antibacterials for systemic use,"/capita, US$ exchange rate",23.8
+14940,Greece,2017,3,J01-Antibacterials for systemic use,Million of national currency units,226.2
+14941,Greece,2017,3,J01-Antibacterials for systemic use,Million US$ at exchange rate,255.5
+14942,Greece,2017,3,A10-Drugs used in diabetes,"Million US$, purchasing power parity",710.7
+14943,Greece,2017,3,J01-Antibacterials for systemic use,"/capita, US$ purchasing power parity",36.6
+14944,Greece,2017,3,A10-Drugs used in diabetes,"/capita, US$ purchasing power parity",66.1
+14945,Greece,2017,3,A10-Drugs used in diabetes,"/capita, US$ exchange rate",42.9
+14946,Greece,2017,3,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ purchasing power parity",10.4
+14947,Greece,2017,3,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ purchasing power parity",20.9
+14948,Greece,2017,3,M01A-Antiinflammatory and antirheumatic products non-steroids,"Million US$, purchasing power parity",111.6
+14949,Greece,2017,3,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ exchange rate",6.7
+14950,Greece,2017,3,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million US$ at exchange rate,146.0
+14951,Greece,2017,3,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million of national currency units,129.2
+14952,Greece,2017,3,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ exchange rate",13.6
+14953,Greece,2017,3,"H-Systemic hormonal preparations, excluding sex hormones and insulins","Million US$, purchasing power parity",224.7
+14954,Greece,2017,3,C10-Lipid modifying agents,"/capita, US$ exchange rate",32.8
+14955,Greece,2017,3,C10-Lipid modifying agents,Million US$ at exchange rate,352.4
+14956,Greece,2017,3,C10-Lipid modifying agents,"/capita, US$ purchasing power parity",50.4
+14957,Greece,2017,3,C10-Lipid modifying agents,"Million US$, purchasing power parity",542.4
+14958,Greece,2017,3,R-Respiratory system,"/capita, US$ purchasing power parity",66.4
+14959,Greece,2017,3,R-Respiratory system,"/capita, US$ exchange rate",43.1
+14960,Greece,2017,3,M-Musculo-skeletal system,"/capita, US$ purchasing power parity",34.3
+14961,Greece,2017,3,M-Musculo-skeletal system,"/capita, US$ exchange rate",22.3
+14962,Greece,2017,3,N05C-Hypnotics and sedatives,Million of national currency units,8.4
+14963,Greece,2017,3,N05C-Hypnotics and sedatives,Million US$ at exchange rate,9.5
+14964,Greece,2017,3,A10-Drugs used in diabetes,Million US$ at exchange rate,461.7
+14965,Greece,2017,3,A10-Drugs used in diabetes,Million of national currency units,408.7
+14966,Greece,2017,3,N05C-Hypnotics and sedatives,"/capita, US$ purchasing power parity",1.4
+14967,Greece,2017,3,C10-Lipid modifying agents,Million of national currency units,311.9
+14968,Greece,2017,3,N05C-Hypnotics and sedatives,"Million US$, purchasing power parity",14.6
+14969,Greece,2017,3,N05C-Hypnotics and sedatives,"/capita, US$ exchange rate",0.9
+14970,Greece,2017,3,C-Cardiovascular system,Million US$ at exchange rate,987.0
+14971,Greece,2017,3,C-Cardiovascular system,"Million US$, purchasing power parity",1519.4
+14972,Greece,2017,3,C-Cardiovascular system,"/capita, US$ exchange rate",91.8
+14973,Greece,2017,3,C09-Agents acting on the Renin-Angiotensin system,Million of national currency units,334.4
+14974,Greece,2017,3,C-Cardiovascular system,Million of national currency units,873.7
+14975,Greece,2017,3,C01A-Cardiac glycosides,"/capita, US$ exchange rate",0.1
+14976,Greece,2017,3,C03-Diuretics,"/capita, US$ purchasing power parity",5.6
+14977,Greece,2017,3,C-Cardiovascular system,"/capita, US$ purchasing power parity",141.3
+14978,Greece,2017,3,C01A-Cardiac glycosides,"/capita, US$ purchasing power parity",0.1
+14979,Greece,2017,3,"C01B-Antiarrhythmics, Class I and III","Million US$, purchasing power parity",13.2
+14980,Greece,2017,3,"C01B-Antiarrhythmics, Class I and III","/capita, US$ exchange rate",0.8
+14981,Greece,2017,3,C03-Diuretics,"/capita, US$ exchange rate",3.6
+14982,Greece,2017,3,A-Alimentary tract and metabolism,Million of national currency units,760.9
+14983,Greece,2017,3,"C01B-Antiarrhythmics, Class I and III",Million US$ at exchange rate,8.6
+14984,Greece,2017,3,C09-Agents acting on the Renin-Angiotensin system,"Million US$, purchasing power parity",581.5
+14985,Greece,2017,3,C09-Agents acting on the Renin-Angiotensin system,Million US$ at exchange rate,377.7
+14986,Greece,2017,3,"C01B-Antiarrhythmics, Class I and III","/capita, US$ purchasing power parity",1.2
+14987,Greece,2017,3,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ purchasing power parity",54.1
+14988,Greece,2017,3,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ exchange rate",35.1
+14989,Greece,2017,3,A-Alimentary tract and metabolism,Million US$ at exchange rate,859.6
+14990,Greece,2017,3,A-Alimentary tract and metabolism,"Million US$, purchasing power parity",1323.2
+14991,Greece,2017,3,C07-Beta blocking agents,Million of national currency units,57.6
+14992,Greece,2017,3,C07-Beta blocking agents,"Million US$, purchasing power parity",100.1
+14993,Greece,2017,3,C02-Antihypertensives,Million of national currency units,24.9
+14994,Greece,2017,3,C01A-Cardiac glycosides,Million of national currency units,0.6
+14995,Greece,2017,3,C01A-Cardiac glycosides,Million US$ at exchange rate,0.7
+14996,Greece,2017,3,C07-Beta blocking agents,Million US$ at exchange rate,65.0
+14997,Greece,2017,3,C01A-Cardiac glycosides,"Million US$, purchasing power parity",1.0
+14998,Greece,2017,3,A02A-Antacids,"/capita, US$ purchasing power parity",0.7
+14999,Greece,2017,3,C02-Antihypertensives,"Million US$, purchasing power parity",43.2
+15000,Greece,2017,3,C02-Antihypertensives,Million US$ at exchange rate,28.1
+15001,Greece,2017,3,C02-Antihypertensives,"/capita, US$ purchasing power parity",4.0
+15002,Greece,2017,3,C02-Antihypertensives,"/capita, US$ exchange rate",2.6
+15003,Greece,2017,3,A02A-Antacids,Million US$ at exchange rate,5.0
+15004,Greece,2017,3,A02A-Antacids,Million of national currency units,4.4
+15005,Greece,2017,3,A02A-Antacids,"Million US$, purchasing power parity",7.6
+15006,Greece,2017,3,A02A-Antacids,"/capita, US$ exchange rate",0.5
+15007,Greece,2017,3,A-Alimentary tract and metabolism,"/capita, US$ exchange rate",79.9
+15008,Greece,2017,3,C03-Diuretics,"Million US$, purchasing power parity",60.3
+15009,Greece,2017,3,C03-Diuretics,Million US$ at exchange rate,39.2
+15010,Greece,2017,3,C08-Calcium channel blockers,"/capita, US$ purchasing power parity",7.9
+15011,Greece,2017,3,"C01B-Antiarrhythmics, Class I and III",Million of national currency units,7.6
+15012,Greece,2017,3,C07-Beta blocking agents,"/capita, US$ exchange rate",6.0
+15013,Greece,2017,3,C03-Diuretics,Million of national currency units,34.7
+15014,Greece,2017,3,A-Alimentary tract and metabolism,"/capita, US$ purchasing power parity",123.0
+15015,Greece,2017,3,C07-Beta blocking agents,"/capita, US$ purchasing power parity",9.3
+15016,Greece,2017,3,C08-Calcium channel blockers,Million of national currency units,49.1
+15017,Greece,2017,3,C08-Calcium channel blockers,Million US$ at exchange rate,55.5
+15018,Greece,2017,3,C08-Calcium channel blockers,"Million US$, purchasing power parity",85.5
+15019,Greece,2017,3,C08-Calcium channel blockers,"/capita, US$ exchange rate",5.2
+15020,Hungary,2017,12,A-Alimentary tract and metabolism,Million of national currency units,78667.7
+15021,Hungary,2017,12,C10-Lipid modifying agents,"/capita, US$ purchasing power parity",14.4
+15022,Hungary,2017,12,C10-Lipid modifying agents,% of total sales,3.9
+15023,Hungary,2017,12,A10-Drugs used in diabetes,Million US$ at exchange rate,182.3
+15024,Hungary,2017,12,A10-Drugs used in diabetes,"Million US$, purchasing power parity",367.8
+15025,Hungary,2017,12,A10-Drugs used in diabetes,Million of national currency units,50037.2
+15026,Hungary,2017,12,C03-Diuretics,"/capita, US$ exchange rate",1.7
+15027,Hungary,2017,12,C03-Diuretics,"/capita, US$ purchasing power parity",3.4
+15028,Hungary,2017,12,C03-Diuretics,% of total sales,0.9
+15029,Hungary,2017,12,C03-Diuretics,Million US$ at exchange rate,16.6
+15030,Hungary,2017,12,C03-Diuretics,"Million US$, purchasing power parity",33.4
+15031,Hungary,2017,12,C10-Lipid modifying agents,"Million US$, purchasing power parity",140.7
+15032,Hungary,2017,12,A-Alimentary tract and metabolism,"Million US$, purchasing power parity",578.3
+15033,Hungary,2017,12,A-Alimentary tract and metabolism,Million US$ at exchange rate,286.7
+15034,Hungary,2017,12,C10-Lipid modifying agents,"/capita, US$ exchange rate",7.1
+15035,Hungary,2017,12,N06A-Antidepressants,% of total sales,1.6
+15036,Hungary,2017,12,C08-Calcium channel blockers,Million of national currency units,2649.1
+15037,Hungary,2017,12,N-Nervous system,"/capita, US$ purchasing power parity",44.9
+15038,Hungary,2017,12,C08-Calcium channel blockers,"Million US$, purchasing power parity",19.5
+15039,Hungary,2017,12,C08-Calcium channel blockers,Million US$ at exchange rate,9.7
+15040,Hungary,2017,12,N06A-Antidepressants,"/capita, US$ purchasing power parity",6.0
+15041,Hungary,2017,12,N06A-Antidepressants,Million US$ at exchange rate,29.2
+15042,Hungary,2017,12,N06A-Antidepressants,Million of national currency units,8013.6
+15043,Hungary,2017,12,N06A-Antidepressants,"/capita, US$ exchange rate",3.0
+15044,Hungary,2017,12,N06A-Antidepressants,"Million US$, purchasing power parity",58.9
+15045,Hungary,2017,12,A10-Drugs used in diabetes,% of total sales,10.1
+15046,Hungary,2017,12,C01A-Cardiac glycosides,"/capita, US$ purchasing power parity",0.1
+15047,Hungary,2017,12,C01A-Cardiac glycosides,% of total sales,0.0
+15048,Hungary,2017,12,A10-Drugs used in diabetes,"/capita, US$ exchange rate",18.6
+15049,Hungary,2017,12,A10-Drugs used in diabetes,"/capita, US$ purchasing power parity",37.6
+15050,Hungary,2017,12,"C01B-Antiarrhythmics, Class I and III",% of total sales,0.3
+15051,Hungary,2017,12,N-Nervous system,% of total sales,12.1
+15052,Hungary,2017,12,C08-Calcium channel blockers,"/capita, US$ exchange rate",1.0
+15053,Hungary,2017,12,C08-Calcium channel blockers,% of total sales,0.5
+15054,Hungary,2017,12,C08-Calcium channel blockers,"/capita, US$ purchasing power parity",2.0
+15055,Hungary,2017,12,"C01B-Antiarrhythmics, Class I and III","Million US$, purchasing power parity",10.1
+15056,Hungary,2017,12,"C01B-Antiarrhythmics, Class I and III","/capita, US$ exchange rate",0.5
+15057,Hungary,2017,12,"C01B-Antiarrhythmics, Class I and III",Million of national currency units,1380.3
+15058,Hungary,2017,12,"C01B-Antiarrhythmics, Class I and III",Million US$ at exchange rate,5.0
+15059,Hungary,2017,12,A02A-Antacids,"/capita, US$ exchange rate",0.0
+15060,Hungary,2017,12,A02A-Antacids,"Million US$, purchasing power parity",0.0
+15061,Hungary,2017,12,"C01B-Antiarrhythmics, Class I and III","/capita, US$ purchasing power parity",1.0
+15062,Hungary,2017,12,A02A-Antacids,"/capita, US$ purchasing power parity",0.0
+15063,Hungary,2017,12,A02A-Antacids,% of total sales,0.0
+15064,Hungary,2017,12,A-Alimentary tract and metabolism,% of total sales,16.0
+15065,Hungary,2017,12,R-Respiratory system,"/capita, US$ exchange rate",12.8
+15066,Hungary,2017,12,R-Respiratory system,"Million US$, purchasing power parity",253.6
+15067,Hungary,2017,12,N02-Analgesics,Million of national currency units,5346.6
+15068,Hungary,2017,12,R-Respiratory system,Million of national currency units,34496.8
+15069,Hungary,2017,12,R-Respiratory system,Million US$ at exchange rate,125.7
+15070,Hungary,2017,12,A-Alimentary tract and metabolism,"/capita, US$ purchasing power parity",59.1
+15071,Hungary,2017,12,N02-Analgesics,Million US$ at exchange rate,19.5
+15072,Hungary,2017,12,R-Respiratory system,"/capita, US$ purchasing power parity",25.9
+15073,Hungary,2017,12,N02-Analgesics,"Million US$, purchasing power parity",39.3
+15074,Hungary,2017,12,R-Respiratory system,% of total sales,7.0
+15075,Hungary,2017,12,J-Antiinfectives for systemic use,"Million US$, purchasing power parity",216.0
+15076,Hungary,2017,12,C01A-Cardiac glycosides,Million US$ at exchange rate,0.6
+15077,Hungary,2017,12,N02-Analgesics,"/capita, US$ purchasing power parity",4.0
+15078,Hungary,2017,12,J-Antiinfectives for systemic use,"/capita, US$ exchange rate",10.9
+15079,Hungary,2017,12,C01A-Cardiac glycosides,Million of national currency units,162.2
+15080,Hungary,2017,12,J-Antiinfectives for systemic use,Million of national currency units,29379.9
+15081,Hungary,2017,12,A-Alimentary tract and metabolism,"/capita, US$ exchange rate",29.3
+15082,Hungary,2017,12,C03-Diuretics,Million of national currency units,4545.2
+15083,Hungary,2017,12,A02A-Antacids,Million US$ at exchange rate,0.0
+15084,Hungary,2017,12,J-Antiinfectives for systemic use,Million US$ at exchange rate,107.1
+15085,Hungary,2017,12,A02A-Antacids,Million of national currency units,0.0
+15086,Hungary,2017,12,J-Antiinfectives for systemic use,"/capita, US$ purchasing power parity",22.1
+15087,Hungary,2017,12,N02-Analgesics,"/capita, US$ exchange rate",2.0
+15088,Hungary,2017,12,J-Antiinfectives for systemic use,% of total sales,6.0
+15089,Hungary,2017,12,C01A-Cardiac glycosides,"/capita, US$ exchange rate",0.1
+15090,Hungary,2017,12,C01A-Cardiac glycosides,"Million US$, purchasing power parity",1.2
+15091,Hungary,2017,12,M-Musculo-skeletal system,% of total sales,3.6
+15092,Hungary,2017,12,M-Musculo-skeletal system,"Million US$, purchasing power parity",130.3
+15093,Hungary,2017,12,M-Musculo-skeletal system,Million of national currency units,17723.5
+15094,Hungary,2017,12,M-Musculo-skeletal system,Million US$ at exchange rate,64.6
+15095,Hungary,2017,12,M-Musculo-skeletal system,"/capita, US$ purchasing power parity",13.3
+15096,Hungary,2017,12,M-Musculo-skeletal system,"/capita, US$ exchange rate",6.6
+15097,Hungary,2017,12,N05C-Hypnotics and sedatives,% of total sales,0.0
+15098,Hungary,2017,12,C07-Beta blocking agents,% of total sales,2.0
+15099,Hungary,2017,12,C07-Beta blocking agents,"/capita, US$ purchasing power parity",7.4
+15100,Hungary,2017,12,N05C-Hypnotics and sedatives,"Million US$, purchasing power parity",0.0
+15101,Hungary,2017,12,N05C-Hypnotics and sedatives,"/capita, US$ exchange rate",0.0
+15102,Hungary,2017,12,N05C-Hypnotics and sedatives,"/capita, US$ purchasing power parity",0.0
+15103,Hungary,2017,12,C07-Beta blocking agents,Million US$ at exchange rate,35.9
+15104,Hungary,2017,12,C07-Beta blocking agents,"Million US$, purchasing power parity",72.4
+15105,Hungary,2017,12,C07-Beta blocking agents,Million of national currency units,9854.4
+15106,Hungary,2017,12,N05B-Anxiolytics,Million of national currency units,2831.3
+15107,Hungary,2017,12,C07-Beta blocking agents,"/capita, US$ exchange rate",3.7
+15108,Hungary,2017,12,N05B-Anxiolytics,Million US$ at exchange rate,10.3
+15109,Hungary,2017,12,C02-Antihypertensives,% of total sales,2.0
+15110,Hungary,2017,12,N05C-Hypnotics and sedatives,Million of national currency units,1.0
+15111,Hungary,2017,12,C09-Agents acting on the Renin-Angiotensin system,% of total sales,7.6
+15112,Hungary,2017,12,N02-Analgesics,% of total sales,1.1
+15113,Hungary,2017,12,C02-Antihypertensives,"/capita, US$ purchasing power parity",7.4
+15114,Hungary,2017,12,R03-Drugs for obstructive airway diseases,Million of national currency units,29875.7
+15115,Hungary,2017,12,R03-Drugs for obstructive airway diseases,"/capita, US$ purchasing power parity",22.4
+15116,Hungary,2017,12,R03-Drugs for obstructive airway diseases,% of total sales,6.1
+15117,Hungary,2017,12,N05C-Hypnotics and sedatives,Million US$ at exchange rate,0.0
+15118,Hungary,2017,12,R03-Drugs for obstructive airway diseases,Million US$ at exchange rate,108.9
+15119,Hungary,2017,12,R03-Drugs for obstructive airway diseases,"/capita, US$ exchange rate",11.1
+15120,Hungary,2017,12,R03-Drugs for obstructive airway diseases,"Million US$, purchasing power parity",219.6
+15121,Hungary,2017,12,G-Genito urinary system and sex hormones,"Million US$, purchasing power parity",87.7
+15122,Hungary,2017,12,G-Genito urinary system and sex hormones,"/capita, US$ purchasing power parity",9.0
+15123,Hungary,2017,12,G-Genito urinary system and sex hormones,"/capita, US$ exchange rate",4.4
+15124,Hungary,2017,12,G-Genito urinary system and sex hormones,Million US$ at exchange rate,43.5
+15125,Hungary,2017,12,G03-Sex hormones and modulators of the genital system,"/capita, US$ purchasing power parity",4.3
+15126,Hungary,2017,12,G03-Sex hormones and modulators of the genital system,% of total sales,1.2
+15127,Hungary,2017,12,G-Genito urinary system and sex hormones,Million of national currency units,11937.0
+15128,Hungary,2017,12,Total pharmaceutical sales,"Million US$, purchasing power parity",3624.2
+15129,Hungary,2017,12,Total pharmaceutical sales,Million US$ at exchange rate,1796.5
+15130,Hungary,2017,12,Total pharmaceutical sales,Million of national currency units,493022.1
+15131,Hungary,2017,12,G-Genito urinary system and sex hormones,% of total sales,2.4
+15132,Hungary,2017,12,Total pharmaceutical sales,"/capita, US$ purchasing power parity",370.3
+15133,Hungary,2017,12,Total pharmaceutical sales,"/capita, US$ exchange rate",183.5
+15134,Hungary,2017,12,M01A-Antiinflammatory and antirheumatic products non-steroids,Million US$ at exchange rate,20.5
+15135,Hungary,2017,12,N05B-Anxiolytics,"Million US$, purchasing power parity",20.8
+15136,Hungary,2017,12,M01A-Antiinflammatory and antirheumatic products non-steroids,Million of national currency units,5629.9
+15137,Hungary,2017,12,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ purchasing power parity",4.2
+15138,Hungary,2017,12,M01A-Antiinflammatory and antirheumatic products non-steroids,"Million US$, purchasing power parity",41.4
+15139,Hungary,2017,12,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ exchange rate",2.1
+15140,Hungary,2017,12,G03-Sex hormones and modulators of the genital system,Million US$ at exchange rate,20.9
+15141,Hungary,2017,12,G03-Sex hormones and modulators of the genital system,"/capita, US$ exchange rate",2.1
+15142,Hungary,2017,12,G03-Sex hormones and modulators of the genital system,"Million US$, purchasing power parity",42.2
+15143,Hungary,2017,12,G03-Sex hormones and modulators of the genital system,Million of national currency units,5743.2
+15144,Hungary,2017,12,N05B-Anxiolytics,"/capita, US$ purchasing power parity",2.1
+15145,Hungary,2017,12,N05B-Anxiolytics,"/capita, US$ exchange rate",1.1
+15146,Hungary,2017,12,M01A-Antiinflammatory and antirheumatic products non-steroids,% of total sales,1.1
+15147,Hungary,2017,12,N05B-Anxiolytics,% of total sales,0.6
+15148,Hungary,2017,12,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ purchasing power parity",28.0
+15149,Hungary,2017,12,J01-Antibacterials for systemic use,"Million US$, purchasing power parity",93.5
+15150,Hungary,2017,12,J01-Antibacterials for systemic use,Million US$ at exchange rate,46.3
+15151,Hungary,2017,12,J01-Antibacterials for systemic use,"/capita, US$ exchange rate",4.7
+15152,Hungary,2017,12,J01-Antibacterials for systemic use,% of total sales,2.6
+15153,Hungary,2017,12,J01-Antibacterials for systemic use,"/capita, US$ purchasing power parity",9.5
+15154,Hungary,2017,12,B-Blood and blood forming organs,"Million US$, purchasing power parity",370.0
+15155,Hungary,2017,12,B-Blood and blood forming organs,"/capita, US$ exchange rate",18.7
+15156,Hungary,2017,12,B-Blood and blood forming organs,"/capita, US$ purchasing power parity",37.8
+15157,Hungary,2017,12,"H-Systemic hormonal preparations, excluding sex hormones and insulins",% of total sales,2.2
+15158,Hungary,2017,12,J01-Antibacterials for systemic use,Million of national currency units,12714.9
+15159,Hungary,2017,12,B-Blood and blood forming organs,Million of national currency units,50338.2
+15160,Hungary,2017,12,B-Blood and blood forming organs,Million US$ at exchange rate,183.4
+15161,Hungary,2017,12,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million US$ at exchange rate,39.7
+15162,Hungary,2017,12,"H-Systemic hormonal preparations, excluding sex hormones and insulins","Million US$, purchasing power parity",80.2
+15163,Hungary,2017,12,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million of national currency units,10907.7
+15164,Hungary,2017,12,C10-Lipid modifying agents,Million US$ at exchange rate,69.7
+15165,Hungary,2017,12,C10-Lipid modifying agents,Million of national currency units,19139.1
+15166,Hungary,2017,12,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ exchange rate",4.1
+15167,Hungary,2017,12,N-Nervous system,Million of national currency units,59790.5
+15168,Hungary,2017,12,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ purchasing power parity",8.2
+15169,Hungary,2017,12,N-Nervous system,Million US$ at exchange rate,217.9
+15170,Hungary,2017,12,N-Nervous system,"/capita, US$ exchange rate",22.3
+15171,Hungary,2017,12,N-Nervous system,"Million US$, purchasing power parity",439.5
+15172,Hungary,2017,12,C-Cardiovascular system,"Million US$, purchasing power parity",683.4
+15173,Hungary,2017,12,C-Cardiovascular system,Million US$ at exchange rate,338.8
+15174,Hungary,2017,12,C-Cardiovascular system,% of total sales,18.9
+15175,Hungary,2017,12,C-Cardiovascular system,"/capita, US$ exchange rate",34.6
+15176,Hungary,2017,12,C-Cardiovascular system,"/capita, US$ purchasing power parity",69.8
+15177,Hungary,2017,12,C09-Agents acting on the Renin-Angiotensin system,"Million US$, purchasing power parity",274.2
+15178,Hungary,2017,12,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ exchange rate",13.9
+15179,Hungary,2017,12,C-Cardiovascular system,Million of national currency units,92973.4
+15180,Hungary,2017,12,C09-Agents acting on the Renin-Angiotensin system,Million of national currency units,37305.6
+15181,Hungary,2017,12,C09-Agents acting on the Renin-Angiotensin system,Million US$ at exchange rate,135.9
+15182,Hungary,2017,12,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ purchasing power parity",6.6
+15183,Hungary,2017,12,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ exchange rate",3.3
+15184,Hungary,2017,12,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million of national currency units,8825.9
+15185,Hungary,2017,12,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),% of total sales,1.8
+15186,Hungary,2017,12,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million US$ at exchange rate,32.2
+15187,Hungary,2017,12,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"Million US$, purchasing power parity",64.9
+15188,Hungary,2017,12,C02-Antihypertensives,Million of national currency units,9804.7
+15189,Hungary,2017,12,C02-Antihypertensives,"/capita, US$ exchange rate",3.7
+15190,Hungary,2017,12,B-Blood and blood forming organs,% of total sales,10.2
+15191,Hungary,2017,12,C02-Antihypertensives,Million US$ at exchange rate,35.7
+15192,Hungary,2017,12,C02-Antihypertensives,"Million US$, purchasing power parity",72.1
+15193,Hungary,2016,12,A-Alimentary tract and metabolism,Million of national currency units,73066.7
+15194,Hungary,2016,12,C10-Lipid modifying agents,% of total sales,3.8
+15195,Hungary,2016,12,C10-Lipid modifying agents,"/capita, US$ purchasing power parity",14.7
+15196,Hungary,2016,12,A10-Drugs used in diabetes,"Million US$, purchasing power parity",342.9
+15197,Hungary,2016,12,A10-Drugs used in diabetes,Million US$ at exchange rate,160.8
+15198,Hungary,2016,12,A10-Drugs used in diabetes,Million of national currency units,45267.9
+15199,Hungary,2016,12,C03-Diuretics,"/capita, US$ purchasing power parity",3.5
+15200,Hungary,2016,12,C03-Diuretics,% of total sales,0.9
+15201,Hungary,2016,12,C03-Diuretics,"/capita, US$ exchange rate",1.6
+15202,Hungary,2016,12,C03-Diuretics,Million US$ at exchange rate,16.1
+15203,Hungary,2016,12,C03-Diuretics,"Million US$, purchasing power parity",34.3
+15204,Hungary,2016,12,A-Alimentary tract and metabolism,"Million US$, purchasing power parity",553.4
+15205,Hungary,2016,12,A-Alimentary tract and metabolism,Million US$ at exchange rate,259.5
+15206,Hungary,2016,12,C10-Lipid modifying agents,"/capita, US$ exchange rate",6.9
+15207,Hungary,2016,12,C08-Calcium channel blockers,Million of national currency units,2787.9
+15208,Hungary,2016,12,N-Nervous system,"/capita, US$ purchasing power parity",46.1
+15209,Hungary,2016,12,N06A-Antidepressants,% of total sales,1.6
+15210,Hungary,2016,12,C08-Calcium channel blockers,"Million US$, purchasing power parity",21.1
+15211,Hungary,2016,12,C08-Calcium channel blockers,Million US$ at exchange rate,9.9
+15212,Hungary,2016,12,N06A-Antidepressants,Million US$ at exchange rate,28.6
+15213,Hungary,2016,12,N06A-Antidepressants,Million of national currency units,8047.7
+15214,Hungary,2016,12,N06A-Antidepressants,"/capita, US$ purchasing power parity",6.2
+15215,Hungary,2016,12,N06A-Antidepressants,"/capita, US$ exchange rate",2.9
+15216,Hungary,2016,12,N06A-Antidepressants,"Million US$, purchasing power parity",61.0
+15217,Hungary,2016,12,A10-Drugs used in diabetes,% of total sales,9.1
+15218,Hungary,2016,12,C01A-Cardiac glycosides,"/capita, US$ purchasing power parity",0.1
+15219,Hungary,2016,12,C01A-Cardiac glycosides,% of total sales,0.0
+15220,Hungary,2016,12,A10-Drugs used in diabetes,"/capita, US$ exchange rate",16.4
+15221,Hungary,2016,12,A10-Drugs used in diabetes,"/capita, US$ purchasing power parity",34.9
+15222,Hungary,2016,12,"C01B-Antiarrhythmics, Class I and III",% of total sales,0.3
+15223,Hungary,2016,12,N-Nervous system,% of total sales,12.0
+15224,Hungary,2016,12,C08-Calcium channel blockers,% of total sales,0.6
+15225,Hungary,2016,12,C08-Calcium channel blockers,"/capita, US$ purchasing power parity",2.2
+15226,Hungary,2016,12,C08-Calcium channel blockers,"/capita, US$ exchange rate",1.0
+15227,Hungary,2016,12,"C01B-Antiarrhythmics, Class I and III","Million US$, purchasing power parity",10.5
+15228,Hungary,2016,12,"C01B-Antiarrhythmics, Class I and III","/capita, US$ exchange rate",0.5
+15229,Hungary,2016,12,"C01B-Antiarrhythmics, Class I and III",Million US$ at exchange rate,4.9
+15230,Hungary,2016,12,"C01B-Antiarrhythmics, Class I and III",Million of national currency units,1384.4
+15231,Hungary,2016,12,"C01B-Antiarrhythmics, Class I and III","/capita, US$ purchasing power parity",1.1
+15232,Hungary,2016,12,A02A-Antacids,"/capita, US$ exchange rate",0.0
+15233,Hungary,2016,12,A02A-Antacids,"Million US$, purchasing power parity",0.0
+15234,Hungary,2016,12,A02A-Antacids,"/capita, US$ purchasing power parity",0.0
+15235,Hungary,2016,12,A02A-Antacids,% of total sales,0.0
+15236,Hungary,2016,12,N02-Analgesics,"Million US$, purchasing power parity",39.7
+15237,Hungary,2016,12,A-Alimentary tract and metabolism,% of total sales,14.6
+15238,Hungary,2016,12,R-Respiratory system,"Million US$, purchasing power parity",258.8
+15239,Hungary,2016,12,R-Respiratory system,"/capita, US$ exchange rate",12.4
+15240,Hungary,2016,12,N02-Analgesics,Million of national currency units,5247.3
+15241,Hungary,2016,12,R-Respiratory system,Million of national currency units,34173.3
+15242,Hungary,2016,12,R-Respiratory system,Million US$ at exchange rate,121.4
+15243,Hungary,2016,12,A-Alimentary tract and metabolism,"/capita, US$ purchasing power parity",56.4
+15244,Hungary,2016,12,N02-Analgesics,Million US$ at exchange rate,18.6
+15245,Hungary,2016,12,R-Respiratory system,"/capita, US$ purchasing power parity",26.4
+15246,Hungary,2016,12,R-Respiratory system,% of total sales,6.9
+15247,Hungary,2016,12,J-Antiinfectives for systemic use,"Million US$, purchasing power parity",297.0
+15248,Hungary,2016,12,C01A-Cardiac glycosides,Million US$ at exchange rate,0.6
+15249,Hungary,2016,12,J-Antiinfectives for systemic use,"/capita, US$ purchasing power parity",30.3
+15250,Hungary,2016,12,J-Antiinfectives for systemic use,"/capita, US$ exchange rate",14.2
+15251,Hungary,2016,12,J-Antiinfectives for systemic use,Million of national currency units,39211.2
+15252,Hungary,2016,12,A-Alimentary tract and metabolism,"/capita, US$ exchange rate",26.4
+15253,Hungary,2016,12,C03-Diuretics,Million of national currency units,4527.3
+15254,Hungary,2016,12,C01A-Cardiac glycosides,Million of national currency units,174.1
+15255,Hungary,2016,12,A02A-Antacids,Million US$ at exchange rate,0.0
+15256,Hungary,2016,12,J-Antiinfectives for systemic use,Million US$ at exchange rate,139.3
+15257,Hungary,2016,12,A02A-Antacids,Million of national currency units,0.0
+15258,Hungary,2016,12,N02-Analgesics,"/capita, US$ exchange rate",1.9
+15259,Hungary,2016,12,J-Antiinfectives for systemic use,% of total sales,7.9
+15260,Hungary,2016,12,C10-Lipid modifying agents,"Million US$, purchasing power parity",144.1
+15261,Hungary,2016,12,N02-Analgesics,"/capita, US$ purchasing power parity",4.0
+15262,Hungary,2016,12,C01A-Cardiac glycosides,"/capita, US$ exchange rate",0.1
+15263,Hungary,2016,12,C01A-Cardiac glycosides,"Million US$, purchasing power parity",1.3
+15264,Hungary,2016,12,M-Musculo-skeletal system,% of total sales,3.5
+15265,Hungary,2016,12,M-Musculo-skeletal system,"Million US$, purchasing power parity",133.8
+15266,Hungary,2016,12,M-Musculo-skeletal system,Million US$ at exchange rate,62.7
+15267,Hungary,2016,12,M-Musculo-skeletal system,Million of national currency units,17665.2
+15268,Hungary,2016,12,M-Musculo-skeletal system,"/capita, US$ purchasing power parity",13.6
+15269,Hungary,2016,12,M-Musculo-skeletal system,"/capita, US$ exchange rate",6.4
+15270,Hungary,2016,12,N05C-Hypnotics and sedatives,% of total sales,0.0
+15271,Hungary,2016,12,C07-Beta blocking agents,"/capita, US$ purchasing power parity",7.6
+15272,Hungary,2016,12,C07-Beta blocking agents,% of total sales,2.0
+15273,Hungary,2016,12,N05C-Hypnotics and sedatives,"Million US$, purchasing power parity",0.0
+15274,Hungary,2016,12,N05C-Hypnotics and sedatives,"/capita, US$ exchange rate",0.0
+15275,Hungary,2016,12,N05C-Hypnotics and sedatives,"/capita, US$ purchasing power parity",0.0
+15276,Hungary,2016,12,C07-Beta blocking agents,Million US$ at exchange rate,34.8
+15277,Hungary,2016,12,C07-Beta blocking agents,"Million US$, purchasing power parity",74.2
+15278,Hungary,2016,12,C07-Beta blocking agents,Million of national currency units,9800.0
+15279,Hungary,2016,12,N05B-Anxiolytics,Million of national currency units,2872.5
+15280,Hungary,2016,12,C07-Beta blocking agents,"/capita, US$ exchange rate",3.5
+15281,Hungary,2016,12,N05B-Anxiolytics,Million US$ at exchange rate,10.2
+15282,Hungary,2016,12,C02-Antihypertensives,% of total sales,1.9
+15283,Hungary,2016,12,N05C-Hypnotics and sedatives,Million of national currency units,0.9
+15284,Hungary,2016,12,C09-Agents acting on the Renin-Angiotensin system,% of total sales,7.3
+15285,Hungary,2016,12,C02-Antihypertensives,"/capita, US$ purchasing power parity",7.2
+15286,Hungary,2016,12,N02-Analgesics,% of total sales,1.1
+15287,Hungary,2016,12,R03-Drugs for obstructive airway diseases,Million of national currency units,29620.8
+15288,Hungary,2016,12,R03-Drugs for obstructive airway diseases,"/capita, US$ purchasing power parity",22.9
+15289,Hungary,2016,12,N05C-Hypnotics and sedatives,Million US$ at exchange rate,0.0
+15290,Hungary,2016,12,R03-Drugs for obstructive airway diseases,% of total sales,5.9
+15291,Hungary,2016,12,R03-Drugs for obstructive airway diseases,Million US$ at exchange rate,105.2
+15292,Hungary,2016,12,R03-Drugs for obstructive airway diseases,"/capita, US$ exchange rate",10.7
+15293,Hungary,2016,12,R03-Drugs for obstructive airway diseases,"Million US$, purchasing power parity",224.3
+15294,Hungary,2016,12,M01A-Antiinflammatory and antirheumatic products non-steroids,% of total sales,1.1
+15295,Hungary,2016,12,G-Genito urinary system and sex hormones,"Million US$, purchasing power parity",85.2
+15296,Hungary,2016,12,G-Genito urinary system and sex hormones,"/capita, US$ purchasing power parity",8.7
+15297,Hungary,2016,12,G-Genito urinary system and sex hormones,"/capita, US$ exchange rate",4.1
+15298,Hungary,2016,12,G03-Sex hormones and modulators of the genital system,"/capita, US$ purchasing power parity",4.2
+15299,Hungary,2016,12,G-Genito urinary system and sex hormones,Million US$ at exchange rate,40.0
+15300,Hungary,2016,12,G-Genito urinary system and sex hormones,Million of national currency units,11251.9
+15301,Hungary,2016,12,G03-Sex hormones and modulators of the genital system,% of total sales,1.1
+15302,Hungary,2016,12,Total pharmaceutical sales,"Million US$, purchasing power parity",3778.3
+15303,Hungary,2016,12,Total pharmaceutical sales,Million US$ at exchange rate,1772.0
+15304,Hungary,2016,12,Total pharmaceutical sales,Million of national currency units,498866.9
+15305,Hungary,2016,12,G-Genito urinary system and sex hormones,% of total sales,2.3
+15306,Hungary,2016,12,Total pharmaceutical sales,"/capita, US$ exchange rate",180.6
+15307,Hungary,2016,12,Total pharmaceutical sales,"/capita, US$ purchasing power parity",385.0
+15308,Hungary,2016,12,M01A-Antiinflammatory and antirheumatic products non-steroids,Million US$ at exchange rate,19.9
+15309,Hungary,2016,12,N05B-Anxiolytics,"Million US$, purchasing power parity",21.8
+15310,Hungary,2016,12,M01A-Antiinflammatory and antirheumatic products non-steroids,Million of national currency units,5595.1
+15311,Hungary,2016,12,M01A-Antiinflammatory and antirheumatic products non-steroids,"Million US$, purchasing power parity",42.4
+15312,Hungary,2016,12,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ purchasing power parity",4.3
+15313,Hungary,2016,12,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ exchange rate",2.0
+15314,Hungary,2016,12,G03-Sex hormones and modulators of the genital system,Million US$ at exchange rate,19.3
+15315,Hungary,2016,12,G03-Sex hormones and modulators of the genital system,"/capita, US$ exchange rate",2.0
+15316,Hungary,2016,12,G03-Sex hormones and modulators of the genital system,"Million US$, purchasing power parity",41.1
+15317,Hungary,2016,12,G03-Sex hormones and modulators of the genital system,Million of national currency units,5426.8
+15318,Hungary,2016,12,N05B-Anxiolytics,"/capita, US$ purchasing power parity",2.2
+15319,Hungary,2016,12,N05B-Anxiolytics,"/capita, US$ exchange rate",1.0
+15320,Hungary,2016,12,N05B-Anxiolytics,% of total sales,0.6
+15321,Hungary,2016,12,J01-Antibacterials for systemic use,"Million US$, purchasing power parity",97.4
+15322,Hungary,2016,12,J01-Antibacterials for systemic use,Million US$ at exchange rate,45.7
+15323,Hungary,2016,12,J01-Antibacterials for systemic use,"/capita, US$ exchange rate",4.7
+15324,Hungary,2016,12,J01-Antibacterials for systemic use,% of total sales,2.6
+15325,Hungary,2016,12,J01-Antibacterials for systemic use,"/capita, US$ purchasing power parity",9.9
+15326,Hungary,2016,12,B-Blood and blood forming organs,"Million US$, purchasing power parity",402.8
+15327,Hungary,2016,12,B-Blood and blood forming organs,"/capita, US$ exchange rate",19.3
+15328,Hungary,2016,12,B-Blood and blood forming organs,"/capita, US$ purchasing power parity",41.0
+15329,Hungary,2016,12,B-Blood and blood forming organs,Million of national currency units,53187.8
+15330,Hungary,2016,12,J01-Antibacterials for systemic use,Million of national currency units,12865.7
+15331,Hungary,2016,12,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ purchasing power parity",28.1
+15332,Hungary,2016,12,B-Blood and blood forming organs,Million US$ at exchange rate,188.9
+15333,Hungary,2016,12,"H-Systemic hormonal preparations, excluding sex hormones and insulins",% of total sales,2.1
+15334,Hungary,2016,12,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million US$ at exchange rate,37.7
+15335,Hungary,2016,12,"H-Systemic hormonal preparations, excluding sex hormones and insulins","Million US$, purchasing power parity",80.4
+15336,Hungary,2016,12,C10-Lipid modifying agents,Million US$ at exchange rate,67.6
+15337,Hungary,2016,12,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million of national currency units,10611.0
+15338,Hungary,2016,12,C10-Lipid modifying agents,Million of national currency units,19032.0
+15339,Hungary,2016,12,N-Nervous system,Million of national currency units,59756.4
+15340,Hungary,2016,12,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ purchasing power parity",8.2
+15341,Hungary,2016,12,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ exchange rate",3.8
+15342,Hungary,2016,12,N-Nervous system,"/capita, US$ exchange rate",21.6
+15343,Hungary,2016,12,N-Nervous system,Million US$ at exchange rate,212.3
+15344,Hungary,2016,12,N-Nervous system,"Million US$, purchasing power parity",452.6
+15345,Hungary,2016,12,C-Cardiovascular system,"Million US$, purchasing power parity",698.1
+15346,Hungary,2016,12,C-Cardiovascular system,Million US$ at exchange rate,327.4
+15347,Hungary,2016,12,C-Cardiovascular system,"/capita, US$ exchange rate",33.4
+15348,Hungary,2016,12,C-Cardiovascular system,% of total sales,18.5
+15349,Hungary,2016,12,C-Cardiovascular system,"/capita, US$ purchasing power parity",71.1
+15350,Hungary,2016,12,C09-Agents acting on the Renin-Angiotensin system,"Million US$, purchasing power parity",275.7
+15351,Hungary,2016,12,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ exchange rate",13.2
+15352,Hungary,2016,12,C-Cardiovascular system,Million of national currency units,92167.6
+15353,Hungary,2016,12,C09-Agents acting on the Renin-Angiotensin system,Million of national currency units,36400.5
+15354,Hungary,2016,12,C09-Agents acting on the Renin-Angiotensin system,Million US$ at exchange rate,129.3
+15355,Hungary,2016,12,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ purchasing power parity",6.6
+15356,Hungary,2016,12,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ exchange rate",3.1
+15357,Hungary,2016,12,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million of national currency units,8548.3
+15358,Hungary,2016,12,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),% of total sales,1.7
+15359,Hungary,2016,12,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million US$ at exchange rate,30.4
+15360,Hungary,2016,12,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"Million US$, purchasing power parity",64.7
+15361,Hungary,2016,12,C02-Antihypertensives,"/capita, US$ exchange rate",3.4
+15362,Hungary,2016,12,B-Blood and blood forming organs,% of total sales,10.7
+15363,Hungary,2016,12,C02-Antihypertensives,Million US$ at exchange rate,33.1
+15364,Hungary,2016,12,C02-Antihypertensives,Million of national currency units,9311.8
+15365,Hungary,2016,12,C02-Antihypertensives,"Million US$, purchasing power parity",70.5
+15366,Hungary,2015,12,C10-Lipid modifying agents,% of total sales,4.1
+15367,Hungary,2015,12,A-Alimentary tract and metabolism,Million of national currency units,67533.0
+15368,Hungary,2015,12,A10-Drugs used in diabetes,"Million US$, purchasing power parity",305.9
+15369,Hungary,2015,12,A10-Drugs used in diabetes,Million US$ at exchange rate,145.2
+15370,Hungary,2015,12,A10-Drugs used in diabetes,Million of national currency units,40546.0
+15371,Hungary,2015,12,C03-Diuretics,"/capita, US$ purchasing power parity",3.4
+15372,Hungary,2015,12,C03-Diuretics,% of total sales,1.0
+15373,Hungary,2015,12,C03-Diuretics,Million US$ at exchange rate,16.1
+15374,Hungary,2015,12,C03-Diuretics,"/capita, US$ exchange rate",1.6
+15375,Hungary,2015,12,C03-Diuretics,"Million US$, purchasing power parity",33.9
+15376,Hungary,2015,12,A-Alimentary tract and metabolism,"Million US$, purchasing power parity",509.5
+15377,Hungary,2015,12,A-Alimentary tract and metabolism,Million US$ at exchange rate,241.8
+15378,Hungary,2015,12,C10-Lipid modifying agents,"/capita, US$ exchange rate",6.9
+15379,Hungary,2015,12,C10-Lipid modifying agents,"/capita, US$ purchasing power parity",14.5
+15380,Hungary,2015,12,A10-Drugs used in diabetes,"/capita, US$ exchange rate",14.7
+15381,Hungary,2015,12,C08-Calcium channel blockers,Million of national currency units,2946.5
+15382,Hungary,2015,12,N-Nervous system,"/capita, US$ purchasing power parity",46.7
+15383,Hungary,2015,12,N06A-Antidepressants,% of total sales,2.0
+15384,Hungary,2015,12,C08-Calcium channel blockers,"Million US$, purchasing power parity",22.2
+15385,Hungary,2015,12,C08-Calcium channel blockers,Million US$ at exchange rate,10.5
+15386,Hungary,2015,12,N06A-Antidepressants,Million US$ at exchange rate,33.7
+15387,Hungary,2015,12,N06A-Antidepressants,Million of national currency units,9404.9
+15388,Hungary,2015,12,N06A-Antidepressants,"Million US$, purchasing power parity",71.0
+15389,Hungary,2015,12,N06A-Antidepressants,"/capita, US$ purchasing power parity",7.2
+15390,Hungary,2015,12,N06A-Antidepressants,"/capita, US$ exchange rate",3.4
+15391,Hungary,2015,12,A10-Drugs used in diabetes,% of total sales,8.7
+15392,Hungary,2015,12,C01A-Cardiac glycosides,"/capita, US$ purchasing power parity",0.1
+15393,Hungary,2015,12,C01A-Cardiac glycosides,% of total sales,0.0
+15394,Hungary,2015,12,A10-Drugs used in diabetes,"/capita, US$ purchasing power parity",31.1
+15395,Hungary,2015,12,N-Nervous system,% of total sales,13.1
+15396,Hungary,2015,12,C08-Calcium channel blockers,"/capita, US$ exchange rate",1.1
+15397,Hungary,2015,12,C08-Calcium channel blockers,% of total sales,0.6
+15398,Hungary,2015,12,C08-Calcium channel blockers,"/capita, US$ purchasing power parity",2.3
+15399,Hungary,2015,12,"C01B-Antiarrhythmics, Class I and III","Million US$, purchasing power parity",10.5
+15400,Hungary,2015,12,"C01B-Antiarrhythmics, Class I and III","/capita, US$ exchange rate",0.5
+15401,Hungary,2015,12,N02-Analgesics,"/capita, US$ exchange rate",1.9
+15402,Hungary,2015,12,"C01B-Antiarrhythmics, Class I and III",Million of national currency units,1391.1
+15403,Hungary,2015,12,"C01B-Antiarrhythmics, Class I and III",Million US$ at exchange rate,5.0
+15404,Hungary,2015,12,"C01B-Antiarrhythmics, Class I and III","/capita, US$ purchasing power parity",1.1
+15405,Hungary,2015,12,A02A-Antacids,"/capita, US$ exchange rate",0.0
+15406,Hungary,2015,12,A02A-Antacids,"Million US$, purchasing power parity",0.0
+15407,Hungary,2015,12,A02A-Antacids,"/capita, US$ purchasing power parity",0.0
+15408,Hungary,2015,12,"C01B-Antiarrhythmics, Class I and III",% of total sales,0.3
+15409,Hungary,2015,12,A02A-Antacids,% of total sales,0.0
+15410,Hungary,2015,12,A-Alimentary tract and metabolism,% of total sales,14.5
+15411,Hungary,2015,12,R-Respiratory system,"Million US$, purchasing power parity",252.8
+15412,Hungary,2015,12,R-Respiratory system,"/capita, US$ exchange rate",12.2
+15413,Hungary,2015,12,N02-Analgesics,Million of national currency units,5270.6
+15414,Hungary,2015,12,R-Respiratory system,Million of national currency units,33515.8
+15415,Hungary,2015,12,R-Respiratory system,Million US$ at exchange rate,120.0
+15416,Hungary,2015,12,A-Alimentary tract and metabolism,"/capita, US$ purchasing power parity",51.8
+15417,Hungary,2015,12,N02-Analgesics,Million US$ at exchange rate,18.9
+15418,Hungary,2015,12,N02-Analgesics,"Million US$, purchasing power parity",39.8
+15419,Hungary,2015,12,R-Respiratory system,"/capita, US$ purchasing power parity",25.7
+15420,Hungary,2015,12,R-Respiratory system,% of total sales,7.2
+15421,Hungary,2015,12,J-Antiinfectives for systemic use,"Million US$, purchasing power parity",236.2
+15422,Hungary,2015,12,C01A-Cardiac glycosides,Million US$ at exchange rate,0.7
+15423,Hungary,2015,12,J-Antiinfectives for systemic use,"/capita, US$ purchasing power parity",24.0
+15424,Hungary,2015,12,J-Antiinfectives for systemic use,"/capita, US$ exchange rate",11.4
+15425,Hungary,2015,12,J-Antiinfectives for systemic use,Million of national currency units,31313.2
+15426,Hungary,2015,12,C03-Diuretics,Million of national currency units,4496.7
+15427,Hungary,2015,12,A-Alimentary tract and metabolism,"/capita, US$ exchange rate",24.6
+15428,Hungary,2015,12,C01A-Cardiac glycosides,Million of national currency units,188.4
+15429,Hungary,2015,12,A02A-Antacids,Million US$ at exchange rate,0.0
+15430,Hungary,2015,12,J-Antiinfectives for systemic use,Million US$ at exchange rate,112.1
+15431,Hungary,2015,12,A02A-Antacids,Million of national currency units,0.0
+15432,Hungary,2015,12,M-Musculo-skeletal system,Million of national currency units,17492.2
+15433,Hungary,2015,12,J-Antiinfectives for systemic use,% of total sales,6.7
+15434,Hungary,2015,12,N02-Analgesics,"/capita, US$ purchasing power parity",4.0
+15435,Hungary,2015,12,C01A-Cardiac glycosides,"/capita, US$ exchange rate",0.1
+15436,Hungary,2015,12,C01A-Cardiac glycosides,"Million US$, purchasing power parity",1.4
+15437,Hungary,2015,12,M-Musculo-skeletal system,"Million US$, purchasing power parity",132.0
+15438,Hungary,2015,12,M-Musculo-skeletal system,Million US$ at exchange rate,62.6
+15439,Hungary,2015,12,M-Musculo-skeletal system,% of total sales,3.8
+15440,Hungary,2015,12,M-Musculo-skeletal system,"/capita, US$ purchasing power parity",13.4
+15441,Hungary,2015,12,M-Musculo-skeletal system,"/capita, US$ exchange rate",6.4
+15442,Hungary,2015,12,C10-Lipid modifying agents,"Million US$, purchasing power parity",142.8
+15443,Hungary,2015,12,G-Genito urinary system and sex hormones,Million of national currency units,10463.8
+15444,Hungary,2015,12,N05C-Hypnotics and sedatives,% of total sales,0.0
+15445,Hungary,2015,12,C07-Beta blocking agents,% of total sales,2.1
+15446,Hungary,2015,12,C07-Beta blocking agents,"/capita, US$ purchasing power parity",7.5
+15447,Hungary,2015,12,N05C-Hypnotics and sedatives,"/capita, US$ exchange rate",0.0
+15448,Hungary,2015,12,N05C-Hypnotics and sedatives,"Million US$, purchasing power parity",0.0
+15449,Hungary,2015,12,N05C-Hypnotics and sedatives,"/capita, US$ purchasing power parity",0.0
+15450,Hungary,2015,12,C07-Beta blocking agents,Million US$ at exchange rate,34.9
+15451,Hungary,2015,12,C07-Beta blocking agents,"Million US$, purchasing power parity",73.5
+15452,Hungary,2015,12,C07-Beta blocking agents,Million of national currency units,9746.0
+15453,Hungary,2015,12,N05B-Anxiolytics,Million of national currency units,2888.3
+15454,Hungary,2015,12,C07-Beta blocking agents,"/capita, US$ exchange rate",3.5
+15455,Hungary,2015,12,N05B-Anxiolytics,Million US$ at exchange rate,10.3
+15456,Hungary,2015,12,N05B-Anxiolytics,"Million US$, purchasing power parity",21.8
+15457,Hungary,2015,12,C02-Antihypertensives,% of total sales,1.9
+15458,Hungary,2015,12,N05C-Hypnotics and sedatives,Million of national currency units,1.1
+15459,Hungary,2015,12,R03-Drugs for obstructive airway diseases,Million of national currency units,28986.7
+15460,Hungary,2015,12,C09-Agents acting on the Renin-Angiotensin system,% of total sales,7.5
+15461,Hungary,2015,12,C02-Antihypertensives,"/capita, US$ purchasing power parity",6.6
+15462,Hungary,2015,12,N02-Analgesics,% of total sales,1.1
+15463,Hungary,2015,12,R03-Drugs for obstructive airway diseases,"/capita, US$ purchasing power parity",22.2
+15464,Hungary,2015,12,R03-Drugs for obstructive airway diseases,% of total sales,6.2
+15465,Hungary,2015,12,N05C-Hypnotics and sedatives,Million US$ at exchange rate,0.0
+15466,Hungary,2015,12,R03-Drugs for obstructive airway diseases,Million US$ at exchange rate,103.8
+15467,Hungary,2015,12,R03-Drugs for obstructive airway diseases,"/capita, US$ exchange rate",10.5
+15468,Hungary,2015,12,R03-Drugs for obstructive airway diseases,"Million US$, purchasing power parity",218.7
+15469,Hungary,2015,12,G-Genito urinary system and sex hormones,"Million US$, purchasing power parity",78.9
+15470,Hungary,2015,12,G-Genito urinary system and sex hormones,"/capita, US$ purchasing power parity",8.0
+15471,Hungary,2015,12,G-Genito urinary system and sex hormones,"/capita, US$ exchange rate",3.8
+15472,Hungary,2015,12,G-Genito urinary system and sex hormones,Million US$ at exchange rate,37.5
+15473,Hungary,2015,12,G03-Sex hormones and modulators of the genital system,"/capita, US$ purchasing power parity",3.8
+15474,Hungary,2015,12,G03-Sex hormones and modulators of the genital system,% of total sales,1.1
+15475,Hungary,2015,12,Total pharmaceutical sales,"Million US$, purchasing power parity",3518.7
+15476,Hungary,2015,12,Total pharmaceutical sales,Million of national currency units,466411.6
+15477,Hungary,2015,12,Total pharmaceutical sales,Million US$ at exchange rate,1669.7
+15478,Hungary,2015,12,G-Genito urinary system and sex hormones,% of total sales,2.2
+15479,Hungary,2015,12,Total pharmaceutical sales,"/capita, US$ exchange rate",169.6
+15480,Hungary,2015,12,Total pharmaceutical sales,"/capita, US$ purchasing power parity",357.5
+15481,Hungary,2015,12,M01A-Antiinflammatory and antirheumatic products non-steroids,Million US$ at exchange rate,19.8
+15482,Hungary,2015,12,M01A-Antiinflammatory and antirheumatic products non-steroids,Million of national currency units,5542.3
+15483,Hungary,2015,12,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ purchasing power parity",4.2
+15484,Hungary,2015,12,M01A-Antiinflammatory and antirheumatic products non-steroids,% of total sales,1.2
+15485,Hungary,2015,12,M01A-Antiinflammatory and antirheumatic products non-steroids,"Million US$, purchasing power parity",41.8
+15486,Hungary,2015,12,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ exchange rate",2.0
+15487,Hungary,2015,12,N05B-Anxiolytics,"/capita, US$ exchange rate",1.1
+15488,Hungary,2015,12,G03-Sex hormones and modulators of the genital system,Million US$ at exchange rate,17.7
+15489,Hungary,2015,12,G03-Sex hormones and modulators of the genital system,"/capita, US$ exchange rate",1.8
+15490,Hungary,2015,12,G03-Sex hormones and modulators of the genital system,"Million US$, purchasing power parity",37.4
+15491,Hungary,2015,12,N05B-Anxiolytics,"/capita, US$ purchasing power parity",2.2
+15492,Hungary,2015,12,G03-Sex hormones and modulators of the genital system,Million of national currency units,4957.9
+15493,Hungary,2015,12,N05B-Anxiolytics,% of total sales,0.6
+15494,Hungary,2015,12,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ purchasing power parity",27.0
+15495,Hungary,2015,12,J01-Antibacterials for systemic use,"Million US$, purchasing power parity",102.3
+15496,Hungary,2015,12,J01-Antibacterials for systemic use,"/capita, US$ exchange rate",4.9
+15497,Hungary,2015,12,J01-Antibacterials for systemic use,Million US$ at exchange rate,48.6
+15498,Hungary,2015,12,J01-Antibacterials for systemic use,% of total sales,2.9
+15499,Hungary,2015,12,J01-Antibacterials for systemic use,"/capita, US$ purchasing power parity",10.4
+15500,Hungary,2015,12,B-Blood and blood forming organs,"/capita, US$ exchange rate",17.6
+15501,Hungary,2015,12,B-Blood and blood forming organs,"Million US$, purchasing power parity",364.9
+15502,Hungary,2015,12,B-Blood and blood forming organs,"/capita, US$ purchasing power parity",37.1
+15503,Hungary,2015,12,B-Blood and blood forming organs,Million of national currency units,48375.2
+15504,Hungary,2015,12,J01-Antibacterials for systemic use,Million of national currency units,13565.6
+15505,Hungary,2015,12,B-Blood and blood forming organs,Million US$ at exchange rate,173.2
+15506,Hungary,2015,12,"H-Systemic hormonal preparations, excluding sex hormones and insulins",% of total sales,2.1
+15507,Hungary,2015,12,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million US$ at exchange rate,35.7
+15508,Hungary,2015,12,"H-Systemic hormonal preparations, excluding sex hormones and insulins","Million US$, purchasing power parity",75.2
+15509,Hungary,2015,12,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million of national currency units,9969.4
+15510,Hungary,2015,12,C10-Lipid modifying agents,Million US$ at exchange rate,67.8
+15511,Hungary,2015,12,C10-Lipid modifying agents,Million of national currency units,18929.3
+15512,Hungary,2015,12,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ exchange rate",3.6
+15513,Hungary,2015,12,N-Nervous system,Million of national currency units,60933.7
+15514,Hungary,2015,12,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ purchasing power parity",7.6
+15515,Hungary,2015,12,N-Nervous system,Million US$ at exchange rate,218.1
+15516,Hungary,2015,12,N-Nervous system,"Million US$, purchasing power parity",459.7
+15517,Hungary,2015,12,C-Cardiovascular system,"Million US$, purchasing power parity",683.3
+15518,Hungary,2015,12,C-Cardiovascular system,Million US$ at exchange rate,324.3
+15519,Hungary,2015,12,C-Cardiovascular system,"/capita, US$ exchange rate",32.9
+15520,Hungary,2015,12,C-Cardiovascular system,% of total sales,19.4
+15521,Hungary,2015,12,C-Cardiovascular system,"/capita, US$ purchasing power parity",69.4
+15522,Hungary,2015,12,C09-Agents acting on the Renin-Angiotensin system,"Million US$, purchasing power parity",265.3
+15523,Hungary,2015,12,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ exchange rate",12.8
+15524,Hungary,2015,12,C-Cardiovascular system,Million of national currency units,90577.6
+15525,Hungary,2015,12,C09-Agents acting on the Renin-Angiotensin system,Million of national currency units,35167.2
+15526,Hungary,2015,12,C09-Agents acting on the Renin-Angiotensin system,Million US$ at exchange rate,125.9
+15527,Hungary,2015,12,N-Nervous system,"/capita, US$ exchange rate",22.2
+15528,Hungary,2015,12,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"Million US$, purchasing power parity",67.2
+15529,Hungary,2015,12,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ purchasing power parity",6.8
+15530,Hungary,2015,12,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ exchange rate",3.2
+15531,Hungary,2015,12,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),% of total sales,1.9
+15532,Hungary,2015,12,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million US$ at exchange rate,31.9
+15533,Hungary,2015,12,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million of national currency units,8905.5
+15534,Hungary,2015,12,C02-Antihypertensives,Million of national currency units,8633.8
+15535,Hungary,2015,12,C02-Antihypertensives,Million US$ at exchange rate,30.9
+15536,Hungary,2015,12,B-Blood and blood forming organs,% of total sales,10.4
+15537,Hungary,2015,12,C02-Antihypertensives,"/capita, US$ exchange rate",3.1
+15538,Hungary,2015,12,C02-Antihypertensives,"Million US$, purchasing power parity",65.1
+15539,Hungary,2014,12,C10-Lipid modifying agents,% of total sales,4.5
+15540,Hungary,2014,12,A-Alimentary tract and metabolism,Million of national currency units,64320.4
+15541,Hungary,2014,12,A10-Drugs used in diabetes,"Million US$, purchasing power parity",297.4
+15542,Hungary,2014,12,A10-Drugs used in diabetes,Million US$ at exchange rate,165.5
+15543,Hungary,2014,12,A10-Drugs used in diabetes,Million of national currency units,38486.2
+15544,Hungary,2014,12,C03-Diuretics,"/capita, US$ purchasing power parity",3.5
+15545,Hungary,2014,12,C03-Diuretics,% of total sales,1.0
+15546,Hungary,2014,12,C03-Diuretics,"/capita, US$ exchange rate",2.0
+15547,Hungary,2014,12,C03-Diuretics,"Million US$, purchasing power parity",34.8
+15548,Hungary,2014,12,A-Alimentary tract and metabolism,"/capita, US$ exchange rate",28.0
+15549,Hungary,2014,12,A-Alimentary tract and metabolism,"Million US$, purchasing power parity",497.0
+15550,Hungary,2014,12,A-Alimentary tract and metabolism,Million US$ at exchange rate,276.5
+15551,Hungary,2014,12,C10-Lipid modifying agents,"/capita, US$ exchange rate",8.6
+15552,Hungary,2014,12,C10-Lipid modifying agents,"/capita, US$ purchasing power parity",15.5
+15553,Hungary,2014,12,A02A-Antacids,Million of national currency units,0.0
+15554,Hungary,2014,12,C08-Calcium channel blockers,Million of national currency units,3109.2
+15555,Hungary,2014,12,N-Nervous system,"/capita, US$ purchasing power parity",46.8
+15556,Hungary,2014,12,N06A-Antidepressants,% of total sales,2.4
+15557,Hungary,2014,12,C08-Calcium channel blockers,"Million US$, purchasing power parity",24.0
+15558,Hungary,2014,12,C08-Calcium channel blockers,Million US$ at exchange rate,13.4
+15559,Hungary,2014,12,N06A-Antidepressants,Million US$ at exchange rate,45.1
+15560,Hungary,2014,12,N06A-Antidepressants,Million of national currency units,10500.3
+15561,Hungary,2014,12,N06A-Antidepressants,"/capita, US$ purchasing power parity",8.2
+15562,Hungary,2014,12,N06A-Antidepressants,"/capita, US$ exchange rate",4.6
+15563,Hungary,2014,12,N06A-Antidepressants,"Million US$, purchasing power parity",81.1
+15564,Hungary,2014,12,C01A-Cardiac glycosides,"/capita, US$ purchasing power parity",0.2
+15565,Hungary,2014,12,C01A-Cardiac glycosides,% of total sales,0.0
+15566,Hungary,2014,12,C03-Diuretics,Million US$ at exchange rate,19.4
+15567,Hungary,2014,12,A10-Drugs used in diabetes,% of total sales,8.7
+15568,Hungary,2014,12,A10-Drugs used in diabetes,"/capita, US$ exchange rate",16.8
+15569,Hungary,2014,12,A10-Drugs used in diabetes,"/capita, US$ purchasing power parity",30.1
+15570,Hungary,2014,12,N-Nervous system,% of total sales,13.5
+15571,Hungary,2014,12,C08-Calcium channel blockers,"/capita, US$ exchange rate",1.4
+15572,Hungary,2014,12,C08-Calcium channel blockers,% of total sales,0.7
+15573,Hungary,2014,12,C08-Calcium channel blockers,"/capita, US$ purchasing power parity",2.4
+15574,Hungary,2014,12,J-Antiinfectives for systemic use,Million of national currency units,26838.3
+15575,Hungary,2014,12,"C01B-Antiarrhythmics, Class I and III","Million US$, purchasing power parity",10.9
+15576,Hungary,2014,12,"C01B-Antiarrhythmics, Class I and III","/capita, US$ exchange rate",0.6
+15577,Hungary,2014,12,N02-Analgesics,"/capita, US$ exchange rate",2.3
+15578,Hungary,2014,12,"C01B-Antiarrhythmics, Class I and III",Million of national currency units,1405.0
+15579,Hungary,2014,12,"C01B-Antiarrhythmics, Class I and III",Million US$ at exchange rate,6.0
+15580,Hungary,2014,12,"C01B-Antiarrhythmics, Class I and III","/capita, US$ purchasing power parity",1.1
+15581,Hungary,2014,12,A02A-Antacids,"/capita, US$ exchange rate",0.0
+15582,Hungary,2014,12,A02A-Antacids,"Million US$, purchasing power parity",0.0
+15583,Hungary,2014,12,A02A-Antacids,"/capita, US$ purchasing power parity",0.0
+15584,Hungary,2014,12,"C01B-Antiarrhythmics, Class I and III",% of total sales,0.3
+15585,Hungary,2014,12,A02A-Antacids,% of total sales,0.0
+15586,Hungary,2014,12,A-Alimentary tract and metabolism,% of total sales,14.5
+15587,Hungary,2014,12,R-Respiratory system,"Million US$, purchasing power parity",264.3
+15588,Hungary,2014,12,R-Respiratory system,"/capita, US$ exchange rate",14.9
+15589,Hungary,2014,12,R-Respiratory system,Million of national currency units,34198.5
+15590,Hungary,2014,12,R-Respiratory system,Million US$ at exchange rate,147.0
+15591,Hungary,2014,12,A-Alimentary tract and metabolism,"/capita, US$ purchasing power parity",50.4
+15592,Hungary,2014,12,N02-Analgesics,"Million US$, purchasing power parity",41.0
+15593,Hungary,2014,12,N02-Analgesics,Million US$ at exchange rate,22.8
+15594,Hungary,2014,12,R-Respiratory system,"/capita, US$ purchasing power parity",26.8
+15595,Hungary,2014,12,N02-Analgesics,Million of national currency units,5304.8
+15596,Hungary,2014,12,R-Respiratory system,% of total sales,7.7
+15597,Hungary,2014,12,J-Antiinfectives for systemic use,"Million US$, purchasing power parity",207.4
+15598,Hungary,2014,12,C01A-Cardiac glycosides,Million US$ at exchange rate,0.9
+15599,Hungary,2014,12,J-Antiinfectives for systemic use,"/capita, US$ purchasing power parity",21.0
+15600,Hungary,2014,12,J-Antiinfectives for systemic use,"/capita, US$ exchange rate",11.7
+15601,Hungary,2014,12,C03-Diuretics,Million of national currency units,4504.9
+15602,Hungary,2014,12,C01A-Cardiac glycosides,Million of national currency units,204.0
+15603,Hungary,2014,12,A02A-Antacids,Million US$ at exchange rate,0.0
+15604,Hungary,2014,12,J-Antiinfectives for systemic use,Million US$ at exchange rate,115.4
+15605,Hungary,2014,12,J-Antiinfectives for systemic use,% of total sales,6.1
+15606,Hungary,2014,12,N02-Analgesics,"/capita, US$ purchasing power parity",4.2
+15607,Hungary,2014,12,C01A-Cardiac glycosides,"/capita, US$ exchange rate",0.1
+15608,Hungary,2014,12,C01A-Cardiac glycosides,"Million US$, purchasing power parity",1.6
+15609,Hungary,2014,12,M-Musculo-skeletal system,"Million US$, purchasing power parity",137.2
+15610,Hungary,2014,12,M-Musculo-skeletal system,Million US$ at exchange rate,76.3
+15611,Hungary,2014,12,M-Musculo-skeletal system,% of total sales,4.0
+15612,Hungary,2014,12,M-Musculo-skeletal system,"/capita, US$ purchasing power parity",13.9
+15613,Hungary,2014,12,M-Musculo-skeletal system,"/capita, US$ exchange rate",7.7
+15614,Hungary,2014,12,M-Musculo-skeletal system,Million of national currency units,17751.8
+15615,Hungary,2014,12,G-Genito urinary system and sex hormones,Million of national currency units,9549.9
+15616,Hungary,2014,12,N05C-Hypnotics and sedatives,% of total sales,0.0
+15617,Hungary,2014,12,C07-Beta blocking agents,"/capita, US$ purchasing power parity",7.6
+15618,Hungary,2014,12,C07-Beta blocking agents,% of total sales,2.2
+15619,Hungary,2014,12,N05C-Hypnotics and sedatives,"/capita, US$ exchange rate",0.0
+15620,Hungary,2014,12,N05C-Hypnotics and sedatives,"Million US$, purchasing power parity",0.0
+15621,Hungary,2014,12,N05C-Hypnotics and sedatives,"/capita, US$ purchasing power parity",0.0
+15622,Hungary,2014,12,C07-Beta blocking agents,"Million US$, purchasing power parity",75.1
+15623,Hungary,2014,12,C07-Beta blocking agents,Million US$ at exchange rate,41.8
+15624,Hungary,2014,12,C07-Beta blocking agents,Million of national currency units,9722.1
+15625,Hungary,2014,12,N05B-Anxiolytics,Million of national currency units,2958.9
+15626,Hungary,2014,12,C07-Beta blocking agents,"/capita, US$ exchange rate",4.2
+15627,Hungary,2014,12,N05B-Anxiolytics,"Million US$, purchasing power parity",22.9
+15628,Hungary,2014,12,N05B-Anxiolytics,Million US$ at exchange rate,12.7
+15629,Hungary,2014,12,C02-Antihypertensives,% of total sales,1.8
+15630,Hungary,2014,12,R03-Drugs for obstructive airway diseases,Million of national currency units,29679.1
+15631,Hungary,2014,12,N05C-Hypnotics and sedatives,Million of national currency units,1.1
+15632,Hungary,2014,12,C09-Agents acting on the Renin-Angiotensin system,% of total sales,7.8
+15633,Hungary,2014,12,C02-Antihypertensives,"/capita, US$ purchasing power parity",6.3
+15634,Hungary,2014,12,N02-Analgesics,% of total sales,1.2
+15635,Hungary,2014,12,C10-Lipid modifying agents,"Million US$, purchasing power parity",153.2
+15636,Hungary,2014,12,R03-Drugs for obstructive airway diseases,"/capita, US$ purchasing power parity",23.2
+15637,Hungary,2014,12,R03-Drugs for obstructive airway diseases,% of total sales,6.7
+15638,Hungary,2014,12,N05C-Hypnotics and sedatives,Million US$ at exchange rate,0.0
+15639,Hungary,2014,12,R03-Drugs for obstructive airway diseases,Million US$ at exchange rate,127.6
+15640,Hungary,2014,12,R03-Drugs for obstructive airway diseases,"/capita, US$ exchange rate",12.9
+15641,Hungary,2014,12,R03-Drugs for obstructive airway diseases,"Million US$, purchasing power parity",229.3
+15642,Hungary,2014,12,G-Genito urinary system and sex hormones,"Million US$, purchasing power parity",73.8
+15643,Hungary,2014,12,G-Genito urinary system and sex hormones,"/capita, US$ purchasing power parity",7.5
+15644,Hungary,2014,12,G-Genito urinary system and sex hormones,"/capita, US$ exchange rate",4.2
+15645,Hungary,2014,12,G03-Sex hormones and modulators of the genital system,"/capita, US$ purchasing power parity",3.4
+15646,Hungary,2014,12,G03-Sex hormones and modulators of the genital system,% of total sales,1.0
+15647,Hungary,2014,12,G-Genito urinary system and sex hormones,Million US$ at exchange rate,41.1
+15648,Hungary,2014,12,Total pharmaceutical sales,"Million US$, purchasing power parity",3422.7
+15649,Hungary,2014,12,Total pharmaceutical sales,Million US$ at exchange rate,1904.3
+15650,Hungary,2014,12,Total pharmaceutical sales,Million of national currency units,442945.7
+15651,Hungary,2014,12,G-Genito urinary system and sex hormones,% of total sales,2.2
+15652,Hungary,2014,12,Total pharmaceutical sales,"/capita, US$ exchange rate",193.0
+15653,Hungary,2014,12,Total pharmaceutical sales,"/capita, US$ purchasing power parity",346.9
+15654,Hungary,2014,12,M01A-Antiinflammatory and antirheumatic products non-steroids,Million US$ at exchange rate,23.9
+15655,Hungary,2014,12,M01A-Antiinflammatory and antirheumatic products non-steroids,Million of national currency units,5568.3
+15656,Hungary,2014,12,M01A-Antiinflammatory and antirheumatic products non-steroids,"Million US$, purchasing power parity",43.0
+15657,Hungary,2014,12,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ purchasing power parity",4.4
+15658,Hungary,2014,12,M01A-Antiinflammatory and antirheumatic products non-steroids,% of total sales,1.3
+15659,Hungary,2014,12,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ exchange rate",2.4
+15660,Hungary,2014,12,N05B-Anxiolytics,"/capita, US$ exchange rate",1.3
+15661,Hungary,2014,12,G03-Sex hormones and modulators of the genital system,Million US$ at exchange rate,18.6
+15662,Hungary,2014,12,G03-Sex hormones and modulators of the genital system,"Million US$, purchasing power parity",33.4
+15663,Hungary,2014,12,G03-Sex hormones and modulators of the genital system,"/capita, US$ exchange rate",1.9
+15664,Hungary,2014,12,N05B-Anxiolytics,"/capita, US$ purchasing power parity",2.3
+15665,Hungary,2014,12,G03-Sex hormones and modulators of the genital system,Million of national currency units,4324.3
+15666,Hungary,2014,12,N05B-Anxiolytics,% of total sales,0.7
+15667,Hungary,2014,12,J01-Antibacterials for systemic use,"Million US$, purchasing power parity",102.3
+15668,Hungary,2014,12,J01-Antibacterials for systemic use,"/capita, US$ exchange rate",5.8
+15669,Hungary,2014,12,J01-Antibacterials for systemic use,Million US$ at exchange rate,56.9
+15670,Hungary,2014,12,J01-Antibacterials for systemic use,% of total sales,3.0
+15671,Hungary,2014,12,J01-Antibacterials for systemic use,"/capita, US$ purchasing power parity",10.4
+15672,Hungary,2014,12,B-Blood and blood forming organs,"/capita, US$ exchange rate",19.0
+15673,Hungary,2014,12,B-Blood and blood forming organs,"Million US$, purchasing power parity",337.4
+15674,Hungary,2014,12,B-Blood and blood forming organs,"/capita, US$ purchasing power parity",34.2
+15675,Hungary,2014,12,B-Blood and blood forming organs,Million of national currency units,43658.2
+15676,Hungary,2014,12,J01-Antibacterials for systemic use,Million of national currency units,13239.1
+15677,Hungary,2014,12,B-Blood and blood forming organs,Million US$ at exchange rate,187.7
+15678,Hungary,2014,12,"H-Systemic hormonal preparations, excluding sex hormones and insulins",% of total sales,2.0
+15679,Hungary,2014,12,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million US$ at exchange rate,38.9
+15680,Hungary,2014,12,"H-Systemic hormonal preparations, excluding sex hormones and insulins","Million US$, purchasing power parity",70.0
+15681,Hungary,2014,12,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ exchange rate",3.9
+15682,Hungary,2014,12,C10-Lipid modifying agents,Million US$ at exchange rate,85.3
+15683,Hungary,2014,12,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million of national currency units,9057.8
+15684,Hungary,2014,12,C10-Lipid modifying agents,Million of national currency units,19830.2
+15685,Hungary,2014,12,N-Nervous system,Million of national currency units,59797.2
+15686,Hungary,2014,12,N-Nervous system,Million US$ at exchange rate,257.1
+15687,Hungary,2014,12,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ purchasing power parity",7.1
+15688,Hungary,2014,12,N-Nervous system,"/capita, US$ exchange rate",26.1
+15689,Hungary,2014,12,N-Nervous system,"Million US$, purchasing power parity",462.1
+15690,Hungary,2014,12,C-Cardiovascular system,"/capita, US$ exchange rate",39.5
+15691,Hungary,2014,12,C-Cardiovascular system,"Million US$, purchasing power parity",700.4
+15692,Hungary,2014,12,C-Cardiovascular system,Million US$ at exchange rate,389.7
+15693,Hungary,2014,12,C-Cardiovascular system,% of total sales,20.5
+15694,Hungary,2014,12,C-Cardiovascular system,"/capita, US$ purchasing power parity",71.0
+15695,Hungary,2014,12,C09-Agents acting on the Renin-Angiotensin system,"Million US$, purchasing power parity",265.4
+15696,Hungary,2014,12,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ purchasing power parity",26.9
+15697,Hungary,2014,12,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ exchange rate",15.0
+15698,Hungary,2014,12,C-Cardiovascular system,Million of national currency units,90647.4
+15699,Hungary,2014,12,C09-Agents acting on the Renin-Angiotensin system,Million of national currency units,34341.3
+15700,Hungary,2014,12,C09-Agents acting on the Renin-Angiotensin system,Million US$ at exchange rate,147.6
+15701,Hungary,2014,12,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ purchasing power parity",6.9
+15702,Hungary,2014,12,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million of national currency units,8814.9
+15703,Hungary,2014,12,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),% of total sales,2.0
+15704,Hungary,2014,12,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ exchange rate",3.8
+15705,Hungary,2014,12,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million US$ at exchange rate,37.9
+15706,Hungary,2014,12,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"Million US$, purchasing power parity",68.1
+15707,Hungary,2014,12,C02-Antihypertensives,Million US$ at exchange rate,34.8
+15708,Hungary,2014,12,C02-Antihypertensives,Million of national currency units,8102.4
+15709,Hungary,2014,12,B-Blood and blood forming organs,% of total sales,9.9
+15710,Hungary,2014,12,C02-Antihypertensives,"/capita, US$ exchange rate",3.5
+15711,Hungary,2014,12,C02-Antihypertensives,"Million US$, purchasing power parity",62.6
+15712,Hungary,2013,12,C10-Lipid modifying agents,% of total sales,5.3
+15713,Hungary,2013,12,A-Alimentary tract and metabolism,Million of national currency units,60613.7
+15714,Hungary,2013,12,A10-Drugs used in diabetes,"Million US$, purchasing power parity",284.5
+15715,Hungary,2013,12,A10-Drugs used in diabetes,Million US$ at exchange rate,159.0
+15716,Hungary,2013,12,A10-Drugs used in diabetes,Million of national currency units,35559.7
+15717,Hungary,2013,12,A-Alimentary tract and metabolism,Million US$ at exchange rate,271.0
+15718,Hungary,2013,12,C03-Diuretics,"/capita, US$ purchasing power parity",3.8
+15719,Hungary,2013,12,C03-Diuretics,% of total sales,1.1
+15720,Hungary,2013,12,C03-Diuretics,"Million US$, purchasing power parity",37.1
+15721,Hungary,2013,12,C03-Diuretics,"/capita, US$ exchange rate",2.1
+15722,Hungary,2013,12,A-Alimentary tract and metabolism,"/capita, US$ exchange rate",27.4
+15723,Hungary,2013,12,A-Alimentary tract and metabolism,"Million US$, purchasing power parity",485.0
+15724,Hungary,2013,12,C10-Lipid modifying agents,"/capita, US$ exchange rate",10.3
+15725,Hungary,2013,12,C10-Lipid modifying agents,"/capita, US$ purchasing power parity",18.5
+15726,Hungary,2013,12,A02A-Antacids,Million of national currency units,0.0
+15727,Hungary,2013,12,A10-Drugs used in diabetes,"/capita, US$ exchange rate",16.1
+15728,Hungary,2013,12,C08-Calcium channel blockers,Million of national currency units,3769.8
+15729,Hungary,2013,12,N-Nervous system,"/capita, US$ purchasing power parity",47.6
+15730,Hungary,2013,12,N06A-Antidepressants,% of total sales,2.5
+15731,Hungary,2013,12,C08-Calcium channel blockers,"Million US$, purchasing power parity",30.2
+15732,Hungary,2013,12,C08-Calcium channel blockers,Million US$ at exchange rate,16.9
+15733,Hungary,2013,12,N06A-Antidepressants,Million US$ at exchange rate,47.9
+15734,Hungary,2013,12,N06A-Antidepressants,"Million US$, purchasing power parity",85.8
+15735,Hungary,2013,12,N06A-Antidepressants,"/capita, US$ purchasing power parity",8.7
+15736,Hungary,2013,12,N06A-Antidepressants,"/capita, US$ exchange rate",4.8
+15737,Hungary,2013,12,C01A-Cardiac glycosides,% of total sales,0.1
+15738,Hungary,2013,12,N06A-Antidepressants,Million of national currency units,10723.6
+15739,Hungary,2013,12,A10-Drugs used in diabetes,% of total sales,8.3
+15740,Hungary,2013,12,A10-Drugs used in diabetes,"/capita, US$ purchasing power parity",28.8
+15741,Hungary,2013,12,C01A-Cardiac glycosides,"/capita, US$ purchasing power parity",0.2
+15742,Hungary,2013,12,C08-Calcium channel blockers,"/capita, US$ exchange rate",1.7
+15743,Hungary,2013,12,N-Nervous system,% of total sales,13.7
+15744,Hungary,2013,12,C08-Calcium channel blockers,% of total sales,0.9
+15745,Hungary,2013,12,C08-Calcium channel blockers,"/capita, US$ purchasing power parity",3.0
+15746,Hungary,2013,12,C03-Diuretics,Million US$ at exchange rate,20.8
+15747,Hungary,2013,12,"C01B-Antiarrhythmics, Class I and III","Million US$, purchasing power parity",11.3
+15748,Hungary,2013,12,"C01B-Antiarrhythmics, Class I and III","/capita, US$ exchange rate",0.6
+15749,Hungary,2013,12,"C01B-Antiarrhythmics, Class I and III","/capita, US$ purchasing power parity",1.1
+15750,Hungary,2013,12,N02-Analgesics,"/capita, US$ exchange rate",2.4
+15751,Hungary,2013,12,"C01B-Antiarrhythmics, Class I and III",Million of national currency units,1406.9
+15752,Hungary,2013,12,"C01B-Antiarrhythmics, Class I and III",Million US$ at exchange rate,6.3
+15753,Hungary,2013,12,A02A-Antacids,"/capita, US$ exchange rate",0.0
+15754,Hungary,2013,12,A02A-Antacids,"/capita, US$ purchasing power parity",0.0
+15755,Hungary,2013,12,A02A-Antacids,"Million US$, purchasing power parity",0.0
+15756,Hungary,2013,12,"C01B-Antiarrhythmics, Class I and III",% of total sales,0.3
+15757,Hungary,2013,12,A02A-Antacids,% of total sales,0.0
+15758,Hungary,2013,12,A-Alimentary tract and metabolism,% of total sales,14.1
+15759,Hungary,2013,12,R-Respiratory system,"Million US$, purchasing power parity",274.3
+15760,Hungary,2013,12,R-Respiratory system,"/capita, US$ exchange rate",15.5
+15761,Hungary,2013,12,R-Respiratory system,Million of national currency units,34278.8
+15762,Hungary,2013,12,R-Respiratory system,Million US$ at exchange rate,153.2
+15763,Hungary,2013,12,N02-Analgesics,Million US$ at exchange rate,23.4
+15764,Hungary,2013,12,N02-Analgesics,"Million US$, purchasing power parity",41.8
+15765,Hungary,2013,12,R-Respiratory system,"/capita, US$ purchasing power parity",27.7
+15766,Hungary,2013,12,R-Respiratory system,% of total sales,8.0
+15767,Hungary,2013,12,N02-Analgesics,Million of national currency units,5228.6
+15768,Hungary,2013,12,J-Antiinfectives for systemic use,"Million US$, purchasing power parity",192.7
+15769,Hungary,2013,12,C01A-Cardiac glycosides,Million US$ at exchange rate,1.0
+15770,Hungary,2013,12,J-Antiinfectives for systemic use,"/capita, US$ exchange rate",10.9
+15771,Hungary,2013,12,J-Antiinfectives for systemic use,"/capita, US$ purchasing power parity",19.5
+15772,Hungary,2013,12,J-Antiinfectives for systemic use,Million of national currency units,24081.3
+15773,Hungary,2013,12,C03-Diuretics,Million of national currency units,4641.7
+15774,Hungary,2013,12,C01A-Cardiac glycosides,Million of national currency units,219.9
+15775,Hungary,2013,12,A02A-Antacids,Million US$ at exchange rate,0.0
+15776,Hungary,2013,12,J-Antiinfectives for systemic use,Million US$ at exchange rate,107.7
+15777,Hungary,2013,12,M-Musculo-skeletal system,Million of national currency units,18632.7
+15778,Hungary,2013,12,J-Antiinfectives for systemic use,% of total sales,5.6
+15779,Hungary,2013,12,N02-Analgesics,"/capita, US$ purchasing power parity",4.2
+15780,Hungary,2013,12,C01A-Cardiac glycosides,"/capita, US$ exchange rate",0.1
+15781,Hungary,2013,12,C01A-Cardiac glycosides,"Million US$, purchasing power parity",1.8
+15782,Hungary,2013,12,M-Musculo-skeletal system,"Million US$, purchasing power parity",149.1
+15783,Hungary,2013,12,M-Musculo-skeletal system,Million US$ at exchange rate,83.3
+15784,Hungary,2013,12,M-Musculo-skeletal system,% of total sales,4.3
+15785,Hungary,2013,12,M-Musculo-skeletal system,"/capita, US$ purchasing power parity",15.1
+15786,Hungary,2013,12,M-Musculo-skeletal system,"/capita, US$ exchange rate",8.4
+15787,Hungary,2013,12,A-Alimentary tract and metabolism,"/capita, US$ purchasing power parity",49.0
+15788,Hungary,2013,12,C10-Lipid modifying agents,"Million US$, purchasing power parity",182.7
+15789,Hungary,2013,12,G-Genito urinary system and sex hormones,Million of national currency units,9141.6
+15790,Hungary,2013,12,C07-Beta blocking agents,"/capita, US$ purchasing power parity",8.1
+15791,Hungary,2013,12,C07-Beta blocking agents,% of total sales,2.3
+15792,Hungary,2013,12,N05C-Hypnotics and sedatives,% of total sales,0.0
+15793,Hungary,2013,12,N05C-Hypnotics and sedatives,"/capita, US$ exchange rate",0.0
+15794,Hungary,2013,12,N05C-Hypnotics and sedatives,"Million US$, purchasing power parity",0.0
+15795,Hungary,2013,12,N05C-Hypnotics and sedatives,"/capita, US$ purchasing power parity",0.0
+15796,Hungary,2013,12,C07-Beta blocking agents,"Million US$, purchasing power parity",79.6
+15797,Hungary,2013,12,C07-Beta blocking agents,Million US$ at exchange rate,44.5
+15798,Hungary,2013,12,C07-Beta blocking agents,Million of national currency units,9953.6
+15799,Hungary,2013,12,N05B-Anxiolytics,Million US$ at exchange rate,13.3
+15800,Hungary,2013,12,C07-Beta blocking agents,"/capita, US$ exchange rate",4.5
+15801,Hungary,2013,12,N05B-Anxiolytics,"Million US$, purchasing power parity",23.8
+15802,Hungary,2013,12,N02-Analgesics,% of total sales,1.2
+15803,Hungary,2013,12,C02-Antihypertensives,% of total sales,1.8
+15804,Hungary,2013,12,R03-Drugs for obstructive airway diseases,Million of national currency units,29536.7
+15805,Hungary,2013,12,N05C-Hypnotics and sedatives,Million of national currency units,0.8
+15806,Hungary,2013,12,C09-Agents acting on the Renin-Angiotensin system,% of total sales,8.2
+15807,Hungary,2013,12,C02-Antihypertensives,"/capita, US$ purchasing power parity",6.1
+15808,Hungary,2013,12,R03-Drugs for obstructive airway diseases,% of total sales,6.9
+15809,Hungary,2013,12,R03-Drugs for obstructive airway diseases,"/capita, US$ purchasing power parity",23.9
+15810,Hungary,2013,12,N05C-Hypnotics and sedatives,Million US$ at exchange rate,0.0
+15811,Hungary,2013,12,R03-Drugs for obstructive airway diseases,Million US$ at exchange rate,132.0
+15812,Hungary,2013,12,R03-Drugs for obstructive airway diseases,"Million US$, purchasing power parity",236.3
+15813,Hungary,2013,12,R03-Drugs for obstructive airway diseases,"/capita, US$ exchange rate",13.3
+15814,Hungary,2013,12,G-Genito urinary system and sex hormones,"Million US$, purchasing power parity",73.1
+15815,Hungary,2013,12,G-Genito urinary system and sex hormones,"/capita, US$ exchange rate",4.1
+15816,Hungary,2013,12,G-Genito urinary system and sex hormones,"/capita, US$ purchasing power parity",7.4
+15817,Hungary,2013,12,G03-Sex hormones and modulators of the genital system,% of total sales,1.0
+15818,Hungary,2013,12,G03-Sex hormones and modulators of the genital system,"/capita, US$ purchasing power parity",3.3
+15819,Hungary,2013,12,G-Genito urinary system and sex hormones,Million US$ at exchange rate,40.9
+15820,Hungary,2013,12,Total pharmaceutical sales,"Million US$, purchasing power parity",3441.9
+15821,Hungary,2013,12,Total pharmaceutical sales,Million of national currency units,430163.5
+15822,Hungary,2013,12,Total pharmaceutical sales,Million US$ at exchange rate,1923.0
+15823,Hungary,2013,12,G-Genito urinary system and sex hormones,% of total sales,2.1
+15824,Hungary,2013,12,Total pharmaceutical sales,"/capita, US$ exchange rate",194.4
+15825,Hungary,2013,12,Total pharmaceutical sales,"/capita, US$ purchasing power parity",347.9
+15826,Hungary,2013,12,M01A-Antiinflammatory and antirheumatic products non-steroids,Million US$ at exchange rate,23.5
+15827,Hungary,2013,12,M01A-Antiinflammatory and antirheumatic products non-steroids,"Million US$, purchasing power parity",42.0
+15828,Hungary,2013,12,M01A-Antiinflammatory and antirheumatic products non-steroids,Million of national currency units,5250.0
+15829,Hungary,2013,12,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ purchasing power parity",4.2
+15830,Hungary,2013,12,M01A-Antiinflammatory and antirheumatic products non-steroids,% of total sales,1.2
+15831,Hungary,2013,12,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ exchange rate",2.4
+15832,Hungary,2013,12,N05B-Anxiolytics,"/capita, US$ exchange rate",1.3
+15833,Hungary,2013,12,G03-Sex hormones and modulators of the genital system,Million US$ at exchange rate,18.4
+15834,Hungary,2013,12,G03-Sex hormones and modulators of the genital system,"/capita, US$ exchange rate",1.9
+15835,Hungary,2013,12,G03-Sex hormones and modulators of the genital system,"Million US$, purchasing power parity",32.9
+15836,Hungary,2013,12,N05B-Anxiolytics,"/capita, US$ purchasing power parity",2.4
+15837,Hungary,2013,12,G03-Sex hormones and modulators of the genital system,Million of national currency units,4108.8
+15838,Hungary,2013,12,N05B-Anxiolytics,% of total sales,0.7
+15839,Hungary,2013,12,J01-Antibacterials for systemic use,"/capita, US$ exchange rate",5.8
+15840,Hungary,2013,12,J01-Antibacterials for systemic use,"Million US$, purchasing power parity",103.5
+15841,Hungary,2013,12,J01-Antibacterials for systemic use,Million US$ at exchange rate,57.8
+15842,Hungary,2013,12,J01-Antibacterials for systemic use,% of total sales,3.0
+15843,Hungary,2013,12,J01-Antibacterials for systemic use,"/capita, US$ purchasing power parity",10.5
+15844,Hungary,2013,12,B-Blood and blood forming organs,"/capita, US$ exchange rate",17.6
+15845,Hungary,2013,12,B-Blood and blood forming organs,"Million US$, purchasing power parity",311.8
+15846,Hungary,2013,12,B-Blood and blood forming organs,"/capita, US$ purchasing power parity",31.5
+15847,Hungary,2013,12,B-Blood and blood forming organs,Million of national currency units,38973.8
+15848,Hungary,2013,12,J01-Antibacterials for systemic use,Million of national currency units,12938.1
+15849,Hungary,2013,12,B-Blood and blood forming organs,Million US$ at exchange rate,174.2
+15850,Hungary,2013,12,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million US$ at exchange rate,37.1
+15851,Hungary,2013,12,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ exchange rate",3.8
+15852,Hungary,2013,12,"H-Systemic hormonal preparations, excluding sex hormones and insulins","Million US$, purchasing power parity",66.5
+15853,Hungary,2013,12,C10-Lipid modifying agents,Million US$ at exchange rate,102.1
+15854,Hungary,2013,12,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million of national currency units,8307.2
+15855,Hungary,2013,12,C10-Lipid modifying agents,Million of national currency units,22838.1
+15856,Hungary,2013,12,N-Nervous system,Million of national currency units,58867.3
+15857,Hungary,2013,12,N-Nervous system,Million US$ at exchange rate,263.2
+15858,Hungary,2013,12,"H-Systemic hormonal preparations, excluding sex hormones and insulins",% of total sales,1.9
+15859,Hungary,2013,12,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ purchasing power parity",6.7
+15860,Hungary,2013,12,N-Nervous system,"/capita, US$ exchange rate",26.6
+15861,Hungary,2013,12,N-Nervous system,"Million US$, purchasing power parity",471.0
+15862,Hungary,2013,12,C-Cardiovascular system,"/capita, US$ exchange rate",43.1
+15863,Hungary,2013,12,C-Cardiovascular system,"Million US$, purchasing power parity",763.3
+15864,Hungary,2013,12,C-Cardiovascular system,Million US$ at exchange rate,426.5
+15865,Hungary,2013,12,C-Cardiovascular system,% of total sales,22.2
+15866,Hungary,2013,12,C-Cardiovascular system,"/capita, US$ purchasing power parity",77.2
+15867,Hungary,2013,12,C09-Agents acting on the Renin-Angiotensin system,"Million US$, purchasing power parity",281.9
+15868,Hungary,2013,12,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ exchange rate",15.9
+15869,Hungary,2013,12,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ purchasing power parity",28.5
+15870,Hungary,2013,12,C-Cardiovascular system,Million of national currency units,95396.2
+15871,Hungary,2013,12,C09-Agents acting on the Renin-Angiotensin system,Million of national currency units,35227.6
+15872,Hungary,2013,12,C09-Agents acting on the Renin-Angiotensin system,Million US$ at exchange rate,157.5
+15873,Hungary,2013,12,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ purchasing power parity",7.3
+15874,Hungary,2013,12,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million of national currency units,9057.7
+15875,Hungary,2013,12,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),% of total sales,2.1
+15876,Hungary,2013,12,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ exchange rate",4.1
+15877,Hungary,2013,12,N05B-Anxiolytics,Million of national currency units,2974.6
+15878,Hungary,2013,12,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million US$ at exchange rate,40.5
+15879,Hungary,2013,12,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"Million US$, purchasing power parity",72.5
+15880,Hungary,2013,12,C02-Antihypertensives,Million US$ at exchange rate,33.9
+15881,Hungary,2013,12,B-Blood and blood forming organs,% of total sales,9.1
+15882,Hungary,2013,12,C02-Antihypertensives,Million of national currency units,7583.8
+15883,Hungary,2013,12,C02-Antihypertensives,"/capita, US$ exchange rate",3.4
+15884,Hungary,2013,12,C02-Antihypertensives,"Million US$, purchasing power parity",60.7
+15885,Hungary,2012,12,A-Alimentary tract and metabolism,Million of national currency units,64446.7
+15886,Hungary,2012,12,C10-Lipid modifying agents,% of total sales,6.3
+15887,Hungary,2012,12,A10-Drugs used in diabetes,"Million US$, purchasing power parity",273.7
+15888,Hungary,2012,12,A10-Drugs used in diabetes,Million of national currency units,34389.1
+15889,Hungary,2012,12,A10-Drugs used in diabetes,Million US$ at exchange rate,152.8
+15890,Hungary,2012,12,C03-Diuretics,"/capita, US$ purchasing power parity",3.9
+15891,Hungary,2012,12,C03-Diuretics,% of total sales,1.1
+15892,Hungary,2012,12,C03-Diuretics,"Million US$, purchasing power parity",38.5
+15893,Hungary,2012,12,C03-Diuretics,"/capita, US$ exchange rate",2.2
+15894,Hungary,2012,12,A-Alimentary tract and metabolism,"/capita, US$ exchange rate",28.9
+15895,Hungary,2012,12,A-Alimentary tract and metabolism,"Million US$, purchasing power parity",513.0
+15896,Hungary,2012,12,A02A-Antacids,Million of national currency units,0.0
+15897,Hungary,2012,12,C10-Lipid modifying agents,"/capita, US$ exchange rate",12.5
+15898,Hungary,2012,12,C10-Lipid modifying agents,"/capita, US$ purchasing power parity",22.4
+15899,Hungary,2012,12,A-Alimentary tract and metabolism,Million US$ at exchange rate,286.3
+15900,Hungary,2012,12,N-Nervous system,"/capita, US$ purchasing power parity",47.0
+15901,Hungary,2012,12,N06A-Antidepressants,% of total sales,2.5
+15902,Hungary,2012,12,C08-Calcium channel blockers,"Million US$, purchasing power parity",44.0
+15903,Hungary,2012,12,C08-Calcium channel blockers,Million US$ at exchange rate,24.6
+15904,Hungary,2012,12,C08-Calcium channel blockers,Million of national currency units,5530.2
+15905,Hungary,2012,12,N06A-Antidepressants,Million US$ at exchange rate,49.2
+15906,Hungary,2012,12,N06A-Antidepressants,"Million US$, purchasing power parity",88.1
+15907,Hungary,2012,12,N06A-Antidepressants,"/capita, US$ purchasing power parity",8.9
+15908,Hungary,2012,12,N06A-Antidepressants,"/capita, US$ exchange rate",5.0
+15909,Hungary,2012,12,A10-Drugs used in diabetes,"/capita, US$ exchange rate",15.4
+15910,Hungary,2012,12,C01A-Cardiac glycosides,% of total sales,0.1
+15911,Hungary,2012,12,A10-Drugs used in diabetes,"/capita, US$ purchasing power parity",27.6
+15912,Hungary,2012,12,N06A-Antidepressants,Million of national currency units,11070.4
+15913,Hungary,2012,12,C01A-Cardiac glycosides,"/capita, US$ purchasing power parity",0.2
+15914,Hungary,2012,12,A10-Drugs used in diabetes,% of total sales,7.7
+15915,Hungary,2012,12,C08-Calcium channel blockers,"/capita, US$ exchange rate",2.5
+15916,Hungary,2012,12,N-Nervous system,% of total sales,13.2
+15917,Hungary,2012,12,C08-Calcium channel blockers,% of total sales,1.2
+15918,Hungary,2012,12,C08-Calcium channel blockers,"/capita, US$ purchasing power parity",4.4
+15919,Hungary,2012,12,"C01B-Antiarrhythmics, Class I and III","Million US$, purchasing power parity",11.4
+15920,Hungary,2012,12,"C01B-Antiarrhythmics, Class I and III","/capita, US$ exchange rate",0.6
+15921,Hungary,2012,12,"C01B-Antiarrhythmics, Class I and III","/capita, US$ purchasing power parity",1.1
+15922,Hungary,2012,12,N02-Analgesics,"/capita, US$ exchange rate",2.4
+15923,Hungary,2012,12,"C01B-Antiarrhythmics, Class I and III",Million of national currency units,1427.3
+15924,Hungary,2012,12,"C01B-Antiarrhythmics, Class I and III",Million US$ at exchange rate,6.3
+15925,Hungary,2012,12,A02A-Antacids,"/capita, US$ purchasing power parity",0.0
+15926,Hungary,2012,12,A02A-Antacids,"/capita, US$ exchange rate",0.0
+15927,Hungary,2012,12,A02A-Antacids,"Million US$, purchasing power parity",0.0
+15928,Hungary,2012,12,"C01B-Antiarrhythmics, Class I and III",% of total sales,0.3
+15929,Hungary,2012,12,A02A-Antacids,% of total sales,0.0
+15930,Hungary,2012,12,A-Alimentary tract and metabolism,% of total sales,14.5
+15931,Hungary,2012,12,R-Respiratory system,"Million US$, purchasing power parity",268.8
+15932,Hungary,2012,12,R-Respiratory system,"/capita, US$ exchange rate",15.1
+15933,Hungary,2012,12,R-Respiratory system,Million of national currency units,33762.7
+15934,Hungary,2012,12,R-Respiratory system,Million US$ at exchange rate,150.0
+15935,Hungary,2012,12,A-Alimentary tract and metabolism,"/capita, US$ purchasing power parity",51.7
+15936,Hungary,2012,12,N02-Analgesics,Million US$ at exchange rate,23.4
+15937,Hungary,2012,12,N02-Analgesics,"Million US$, purchasing power parity",42.0
+15938,Hungary,2012,12,R-Respiratory system,"/capita, US$ purchasing power parity",27.1
+15939,Hungary,2012,12,R-Respiratory system,% of total sales,7.6
+15940,Hungary,2012,12,N02-Analgesics,Million of national currency units,5276.2
+15941,Hungary,2012,12,C03-Diuretics,Million US$ at exchange rate,21.5
+15942,Hungary,2012,12,J-Antiinfectives for systemic use,"Million US$, purchasing power parity",169.0
+15943,Hungary,2012,12,C01A-Cardiac glycosides,Million US$ at exchange rate,1.0
+15944,Hungary,2012,12,J-Antiinfectives for systemic use,"/capita, US$ purchasing power parity",17.0
+15945,Hungary,2012,12,J-Antiinfectives for systemic use,"/capita, US$ exchange rate",9.5
+15946,Hungary,2012,12,J-Antiinfectives for systemic use,Million of national currency units,21233.6
+15947,Hungary,2012,12,C03-Diuretics,Million of national currency units,4833.0
+15948,Hungary,2012,12,C01A-Cardiac glycosides,Million of national currency units,234.3
+15949,Hungary,2012,12,A02A-Antacids,Million US$ at exchange rate,0.0
+15950,Hungary,2012,12,J-Antiinfectives for systemic use,Million US$ at exchange rate,94.3
+15951,Hungary,2012,12,M-Musculo-skeletal system,Million of national currency units,19341.8
+15952,Hungary,2012,12,J-Antiinfectives for systemic use,% of total sales,4.8
+15953,Hungary,2012,12,N02-Analgesics,"/capita, US$ purchasing power parity",4.2
+15954,Hungary,2012,12,C01A-Cardiac glycosides,"/capita, US$ exchange rate",0.1
+15955,Hungary,2012,12,C01A-Cardiac glycosides,"Million US$, purchasing power parity",1.9
+15956,Hungary,2012,12,M-Musculo-skeletal system,"Million US$, purchasing power parity",154.0
+15957,Hungary,2012,12,M-Musculo-skeletal system,Million US$ at exchange rate,85.9
+15958,Hungary,2012,12,M-Musculo-skeletal system,% of total sales,4.4
+15959,Hungary,2012,12,M-Musculo-skeletal system,"/capita, US$ purchasing power parity",15.5
+15960,Hungary,2012,12,M-Musculo-skeletal system,"/capita, US$ exchange rate",8.7
+15961,Hungary,2012,12,G-Genito urinary system and sex hormones,Million of national currency units,8098.7
+15962,Hungary,2012,12,C07-Beta blocking agents,"/capita, US$ purchasing power parity",8.3
+15963,Hungary,2012,12,C07-Beta blocking agents,% of total sales,2.3
+15964,Hungary,2012,12,N05C-Hypnotics and sedatives,"/capita, US$ exchange rate",0.0
+15965,Hungary,2012,12,N05C-Hypnotics and sedatives,"Million US$, purchasing power parity",0.0
+15966,Hungary,2012,12,N05C-Hypnotics and sedatives,% of total sales,0.0
+15967,Hungary,2012,12,N05C-Hypnotics and sedatives,"/capita, US$ purchasing power parity",0.0
+15968,Hungary,2012,12,C07-Beta blocking agents,"Million US$, purchasing power parity",82.6
+15969,Hungary,2012,12,C07-Beta blocking agents,Million of national currency units,10376.8
+15970,Hungary,2012,12,C07-Beta blocking agents,Million US$ at exchange rate,46.1
+15971,Hungary,2012,12,N05B-Anxiolytics,Million US$ at exchange rate,13.1
+15972,Hungary,2012,12,C07-Beta blocking agents,"/capita, US$ exchange rate",4.6
+15973,Hungary,2012,12,N05B-Anxiolytics,"Million US$, purchasing power parity",23.5
+15974,Hungary,2012,12,N02-Analgesics,% of total sales,1.2
+15975,Hungary,2012,12,C02-Antihypertensives,% of total sales,1.7
+15976,Hungary,2012,12,R03-Drugs for obstructive airway diseases,Million of national currency units,28440.2
+15977,Hungary,2012,12,N05C-Hypnotics and sedatives,Million of national currency units,0.5
+15978,Hungary,2012,12,C09-Agents acting on the Renin-Angiotensin system,% of total sales,8.5
+15979,Hungary,2012,12,C02-Antihypertensives,"/capita, US$ purchasing power parity",5.9
+15980,Hungary,2012,12,R03-Drugs for obstructive airway diseases,% of total sales,6.4
+15981,Hungary,2012,12,R03-Drugs for obstructive airway diseases,"/capita, US$ purchasing power parity",22.8
+15982,Hungary,2012,12,N05C-Hypnotics and sedatives,Million US$ at exchange rate,0.0
+15983,Hungary,2012,12,R03-Drugs for obstructive airway diseases,Million US$ at exchange rate,126.3
+15984,Hungary,2012,12,R03-Drugs for obstructive airway diseases,"Million US$, purchasing power parity",226.4
+15985,Hungary,2012,12,R03-Drugs for obstructive airway diseases,"/capita, US$ exchange rate",12.7
+15986,Hungary,2012,12,G-Genito urinary system and sex hormones,"Million US$, purchasing power parity",64.5
+15987,Hungary,2012,12,G-Genito urinary system and sex hormones,"/capita, US$ purchasing power parity",6.5
+15988,Hungary,2012,12,G-Genito urinary system and sex hormones,"/capita, US$ exchange rate",3.6
+15989,Hungary,2012,12,G03-Sex hormones and modulators of the genital system,% of total sales,0.8
+15990,Hungary,2012,12,G03-Sex hormones and modulators of the genital system,"/capita, US$ purchasing power parity",2.7
+15991,Hungary,2012,12,G-Genito urinary system and sex hormones,Million US$ at exchange rate,36.0
+15992,Hungary,2012,12,Total pharmaceutical sales,"Million US$, purchasing power parity",3538.7
+15993,Hungary,2012,12,Total pharmaceutical sales,Million of national currency units,444548.6
+15994,Hungary,2012,12,Total pharmaceutical sales,Million US$ at exchange rate,1974.9
+15995,Hungary,2012,12,Total pharmaceutical sales,"/capita, US$ exchange rate",199.1
+15996,Hungary,2012,12,G-Genito urinary system and sex hormones,% of total sales,1.8
+15997,Hungary,2012,12,Total pharmaceutical sales,"/capita, US$ purchasing power parity",356.7
+15998,Hungary,2012,12,M01A-Antiinflammatory and antirheumatic products non-steroids,Million US$ at exchange rate,23.0
+15999,Hungary,2012,12,M01A-Antiinflammatory and antirheumatic products non-steroids,"Million US$, purchasing power parity",41.2
+16000,Hungary,2012,12,M01A-Antiinflammatory and antirheumatic products non-steroids,Million of national currency units,5181.6
+16001,Hungary,2012,12,N05B-Anxiolytics,"/capita, US$ exchange rate",1.3
+16002,Hungary,2012,12,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ purchasing power parity",4.2
+16003,Hungary,2012,12,M01A-Antiinflammatory and antirheumatic products non-steroids,% of total sales,1.2
+16004,Hungary,2012,12,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ exchange rate",2.3
+16005,Hungary,2012,12,G03-Sex hormones and modulators of the genital system,Million US$ at exchange rate,15.2
+16006,Hungary,2012,12,G03-Sex hormones and modulators of the genital system,"Million US$, purchasing power parity",27.3
+16007,Hungary,2012,12,G03-Sex hormones and modulators of the genital system,"/capita, US$ exchange rate",1.5
+16008,Hungary,2012,12,N05B-Anxiolytics,"/capita, US$ purchasing power parity",2.4
+16009,Hungary,2012,12,G03-Sex hormones and modulators of the genital system,Million of national currency units,3423.8
+16010,Hungary,2012,12,N05B-Anxiolytics,% of total sales,0.7
+16011,Hungary,2012,12,J01-Antibacterials for systemic use,"/capita, US$ exchange rate",5.8
+16012,Hungary,2012,12,J01-Antibacterials for systemic use,"Million US$, purchasing power parity",102.9
+16013,Hungary,2012,12,J01-Antibacterials for systemic use,Million US$ at exchange rate,57.4
+16014,Hungary,2012,12,J01-Antibacterials for systemic use,% of total sales,2.9
+16015,Hungary,2012,12,J01-Antibacterials for systemic use,"/capita, US$ purchasing power parity",10.4
+16016,Hungary,2012,12,B-Blood and blood forming organs,"/capita, US$ exchange rate",17.5
+16017,Hungary,2012,12,B-Blood and blood forming organs,"/capita, US$ purchasing power parity",31.4
+16018,Hungary,2012,12,B-Blood and blood forming organs,"Million US$, purchasing power parity",311.0
+16019,Hungary,2012,12,B-Blood and blood forming organs,Million of national currency units,39070.0
+16020,Hungary,2012,12,J01-Antibacterials for systemic use,Million of national currency units,12925.5
+16021,Hungary,2012,12,B-Blood and blood forming organs,Million US$ at exchange rate,173.6
+16022,Hungary,2012,12,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million US$ at exchange rate,36.4
+16023,Hungary,2012,12,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ exchange rate",3.7
+16024,Hungary,2012,12,"H-Systemic hormonal preparations, excluding sex hormones and insulins","Million US$, purchasing power parity",65.2
+16025,Hungary,2012,12,C10-Lipid modifying agents,Million US$ at exchange rate,124.2
+16026,Hungary,2012,12,C10-Lipid modifying agents,"Million US$, purchasing power parity",222.6
+16027,Hungary,2012,12,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million of national currency units,8192.9
+16028,Hungary,2012,12,C10-Lipid modifying agents,Million of national currency units,27959.9
+16029,Hungary,2012,12,N-Nervous system,Million of national currency units,58615.1
+16030,Hungary,2012,12,N-Nervous system,Million US$ at exchange rate,260.4
+16031,Hungary,2012,12,"H-Systemic hormonal preparations, excluding sex hormones and insulins",% of total sales,1.8
+16032,Hungary,2012,12,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ purchasing power parity",6.6
+16033,Hungary,2012,12,N-Nervous system,"/capita, US$ exchange rate",26.2
+16034,Hungary,2012,12,N-Nervous system,"Million US$, purchasing power parity",466.6
+16035,Hungary,2012,12,B-Blood and blood forming organs,% of total sales,8.8
+16036,Hungary,2012,12,C-Cardiovascular system,"/capita, US$ exchange rate",47.4
+16037,Hungary,2012,12,C-Cardiovascular system,"Million US$, purchasing power parity",843.0
+16038,Hungary,2012,12,C-Cardiovascular system,Million US$ at exchange rate,470.4
+16039,Hungary,2012,12,C-Cardiovascular system,% of total sales,23.8
+16040,Hungary,2012,12,C-Cardiovascular system,"/capita, US$ purchasing power parity",85.0
+16041,Hungary,2012,12,C09-Agents acting on the Renin-Angiotensin system,"Million US$, purchasing power parity",302.3
+16042,Hungary,2012,12,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ exchange rate",17.0
+16043,Hungary,2012,12,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ purchasing power parity",30.5
+16044,Hungary,2012,12,C-Cardiovascular system,Million of national currency units,105895.0
+16045,Hungary,2012,12,C09-Agents acting on the Renin-Angiotensin system,Million of national currency units,37976.3
+16046,Hungary,2012,12,C09-Agents acting on the Renin-Angiotensin system,Million US$ at exchange rate,168.7
+16047,Hungary,2012,12,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ purchasing power parity",10.2
+16048,Hungary,2012,12,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million of national currency units,12740.4
+16049,Hungary,2012,12,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),% of total sales,2.9
+16050,Hungary,2012,12,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ exchange rate",5.7
+16051,Hungary,2012,12,N05B-Anxiolytics,Million of national currency units,2947.0
+16052,Hungary,2012,12,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million US$ at exchange rate,56.6
+16053,Hungary,2012,12,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"Million US$, purchasing power parity",101.4
+16054,Hungary,2012,12,C02-Antihypertensives,Million US$ at exchange rate,32.8
+16055,Hungary,2012,12,C02-Antihypertensives,Million of national currency units,7380.4
+16056,Hungary,2012,12,C02-Antihypertensives,"/capita, US$ exchange rate",3.3
+16057,Hungary,2012,12,C02-Antihypertensives,"Million US$, purchasing power parity",58.8
+16058,Hungary,2010,13,A-Alimentary tract and metabolism,Million of national currency units,64095.7
+16059,Hungary,2010,13,C10-Lipid modifying agents,% of total sales,7.5
+16060,Hungary,2010,13,A10-Drugs used in diabetes,"Million US$, purchasing power parity",241.8
+16061,Hungary,2010,13,A-Alimentary tract and metabolism,Million US$ at exchange rate,308.2
+16062,Hungary,2010,13,A10-Drugs used in diabetes,Million of national currency units,30573.8
+16063,Hungary,2010,13,A10-Drugs used in diabetes,Million US$ at exchange rate,147.0
+16064,Hungary,2010,13,C03-Diuretics,"/capita, US$ purchasing power parity",3.7
+16065,Hungary,2010,13,C03-Diuretics,% of total sales,0.9
+16066,Hungary,2010,13,C03-Diuretics,"Million US$, purchasing power parity",36.7
+16067,Hungary,2010,13,C03-Diuretics,"/capita, US$ exchange rate",2.2
+16068,Hungary,2010,13,A-Alimentary tract and metabolism,"/capita, US$ exchange rate",30.8
+16069,Hungary,2010,13,A-Alimentary tract and metabolism,"Million US$, purchasing power parity",507.0
+16070,Hungary,2010,13,A10-Drugs used in diabetes,"/capita, US$ exchange rate",14.7
+16071,Hungary,2010,13,A02A-Antacids,Million of national currency units,0.0
+16072,Hungary,2010,13,C10-Lipid modifying agents,"/capita, US$ exchange rate",17.9
+16073,Hungary,2010,13,C10-Lipid modifying agents,"/capita, US$ purchasing power parity",29.4
+16074,Hungary,2010,13,N-Nervous system,"/capita, US$ purchasing power parity",49.1
+16075,Hungary,2010,13,N06A-Antidepressants,% of total sales,2.4
+16076,Hungary,2010,13,C08-Calcium channel blockers,"Million US$, purchasing power parity",55.1
+16077,Hungary,2010,13,C08-Calcium channel blockers,Million US$ at exchange rate,33.5
+16078,Hungary,2010,13,N06A-Antidepressants,"Million US$, purchasing power parity",94.5
+16079,Hungary,2010,13,N06A-Antidepressants,Million US$ at exchange rate,57.5
+16080,Hungary,2010,13,C08-Calcium channel blockers,Million of national currency units,6967.9
+16081,Hungary,2010,13,N06A-Antidepressants,"/capita, US$ purchasing power parity",9.5
+16082,Hungary,2010,13,N06A-Antidepressants,"/capita, US$ exchange rate",5.7
+16083,Hungary,2010,13,C01A-Cardiac glycosides,% of total sales,0.1
+16084,Hungary,2010,13,A10-Drugs used in diabetes,"/capita, US$ purchasing power parity",24.2
+16085,Hungary,2010,13,N06A-Antidepressants,Million of national currency units,11947.1
+16086,Hungary,2010,13,A10-Drugs used in diabetes,% of total sales,6.1
+16087,Hungary,2010,13,N-Nervous system,% of total sales,12.5
+16088,Hungary,2010,13,C08-Calcium channel blockers,"/capita, US$ exchange rate",3.4
+16089,Hungary,2010,13,C08-Calcium channel blockers,% of total sales,1.4
+16090,Hungary,2010,13,C08-Calcium channel blockers,"/capita, US$ purchasing power parity",5.5
+16091,Hungary,2010,13,"C01B-Antiarrhythmics, Class I and III","Million US$, purchasing power parity",12.0
+16092,Hungary,2010,13,"C01B-Antiarrhythmics, Class I and III","/capita, US$ exchange rate",0.7
+16093,Hungary,2010,13,"C01B-Antiarrhythmics, Class I and III","/capita, US$ purchasing power parity",1.2
+16094,Hungary,2010,13,N02-Analgesics,"/capita, US$ exchange rate",2.6
+16095,Hungary,2010,13,"C01B-Antiarrhythmics, Class I and III",Million of national currency units,1511.2
+16096,Hungary,2010,13,"C01B-Antiarrhythmics, Class I and III",Million US$ at exchange rate,7.3
+16097,Hungary,2010,13,A02A-Antacids,"/capita, US$ purchasing power parity",0.0
+16098,Hungary,2010,13,A02A-Antacids,"Million US$, purchasing power parity",0.0
+16099,Hungary,2010,13,A02A-Antacids,"/capita, US$ exchange rate",0.0
+16100,Hungary,2010,13,"C01B-Antiarrhythmics, Class I and III",% of total sales,0.3
+16101,Hungary,2010,13,A02A-Antacids,% of total sales,0.0
+16102,Hungary,2010,13,R-Respiratory system,"Million US$, purchasing power parity",269.1
+16103,Hungary,2010,13,R-Respiratory system,"/capita, US$ exchange rate",16.4
+16104,Hungary,2010,13,R-Respiratory system,Million of national currency units,34020.0
+16105,Hungary,2010,13,R-Respiratory system,Million US$ at exchange rate,163.6
+16106,Hungary,2010,13,N02-Analgesics,Million US$ at exchange rate,25.8
+16107,Hungary,2010,13,N02-Analgesics,"Million US$, purchasing power parity",42.4
+16108,Hungary,2010,13,A-Alimentary tract and metabolism,% of total sales,12.9
+16109,Hungary,2010,13,R-Respiratory system,"/capita, US$ purchasing power parity",26.9
+16110,Hungary,2010,13,R-Respiratory system,% of total sales,6.8
+16111,Hungary,2010,13,N02-Analgesics,Million of national currency units,5356.6
+16112,Hungary,2010,13,J-Antiinfectives for systemic use,"Million US$, purchasing power parity",175.0
+16113,Hungary,2010,13,C01A-Cardiac glycosides,"Million US$, purchasing power parity",2.2
+16114,Hungary,2010,13,C01A-Cardiac glycosides,Million US$ at exchange rate,1.3
+16115,Hungary,2010,13,M-Musculo-skeletal system,Million of national currency units,22271.6
+16116,Hungary,2010,13,A-Alimentary tract and metabolism,"/capita, US$ purchasing power parity",50.7
+16117,Hungary,2010,13,J-Antiinfectives for systemic use,"/capita, US$ exchange rate",10.6
+16118,Hungary,2010,13,J-Antiinfectives for systemic use,"/capita, US$ purchasing power parity",17.5
+16119,Hungary,2010,13,J-Antiinfectives for systemic use,Million of national currency units,22127.8
+16120,Hungary,2010,13,C03-Diuretics,Million of national currency units,4641.1
+16121,Hungary,2010,13,C03-Diuretics,Million US$ at exchange rate,22.3
+16122,Hungary,2010,13,J-Antiinfectives for systemic use,Million US$ at exchange rate,106.4
+16123,Hungary,2010,13,C01A-Cardiac glycosides,Million of national currency units,279.1
+16124,Hungary,2010,13,A02A-Antacids,Million US$ at exchange rate,0.0
+16125,Hungary,2010,13,J-Antiinfectives for systemic use,% of total sales,4.4
+16126,Hungary,2010,13,N02-Analgesics,"/capita, US$ purchasing power parity",4.2
+16127,Hungary,2010,13,C01A-Cardiac glycosides,"/capita, US$ purchasing power parity",0.2
+16128,Hungary,2010,13,C01A-Cardiac glycosides,"/capita, US$ exchange rate",0.1
+16129,Hungary,2010,13,M-Musculo-skeletal system,"Million US$, purchasing power parity",176.2
+16130,Hungary,2010,13,M-Musculo-skeletal system,Million US$ at exchange rate,107.1
+16131,Hungary,2010,13,M-Musculo-skeletal system,"/capita, US$ exchange rate",10.7
+16132,Hungary,2010,13,M-Musculo-skeletal system,% of total sales,4.5
+16133,Hungary,2010,13,M-Musculo-skeletal system,"/capita, US$ purchasing power parity",17.6
+16134,Hungary,2010,13,G-Genito urinary system and sex hormones,Million of national currency units,7875.0
+16135,Hungary,2010,13,C07-Beta blocking agents,% of total sales,2.4
+16136,Hungary,2010,13,C07-Beta blocking agents,"/capita, US$ purchasing power parity",9.5
+16137,Hungary,2010,13,N05C-Hypnotics and sedatives,"/capita, US$ exchange rate",0.0
+16138,Hungary,2010,13,N05C-Hypnotics and sedatives,% of total sales,0.0
+16139,Hungary,2010,13,N05C-Hypnotics and sedatives,"/capita, US$ purchasing power parity",0.0
+16140,Hungary,2010,13,C07-Beta blocking agents,"Million US$, purchasing power parity",95.5
+16141,Hungary,2010,13,C07-Beta blocking agents,Million of national currency units,12071.4
+16142,Hungary,2010,13,C07-Beta blocking agents,Million US$ at exchange rate,58.1
+16143,Hungary,2010,13,N05B-Anxiolytics,Million US$ at exchange rate,14.0
+16144,Hungary,2010,13,C07-Beta blocking agents,"/capita, US$ exchange rate",5.8
+16145,Hungary,2010,13,N05B-Anxiolytics,"Million US$, purchasing power parity",23.0
+16146,Hungary,2010,13,N05C-Hypnotics and sedatives,"Million US$, purchasing power parity",0.1
+16147,Hungary,2010,13,N02-Analgesics,% of total sales,1.1
+16148,Hungary,2010,13,C02-Antihypertensives,% of total sales,1.5
+16149,Hungary,2010,13,R03-Drugs for obstructive airway diseases,Million of national currency units,27620.8
+16150,Hungary,2010,13,N05C-Hypnotics and sedatives,Million of national currency units,9.8
+16151,Hungary,2010,13,C09-Agents acting on the Renin-Angiotensin system,% of total sales,9.7
+16152,Hungary,2010,13,C02-Antihypertensives,"/capita, US$ purchasing power parity",5.8
+16153,Hungary,2010,13,R03-Drugs for obstructive airway diseases,% of total sales,5.5
+16154,Hungary,2010,13,R03-Drugs for obstructive airway diseases,"/capita, US$ purchasing power parity",21.8
+16155,Hungary,2010,13,N05C-Hypnotics and sedatives,Million US$ at exchange rate,0.0
+16156,Hungary,2010,13,R03-Drugs for obstructive airway diseases,Million US$ at exchange rate,132.8
+16157,Hungary,2010,13,R03-Drugs for obstructive airway diseases,"Million US$, purchasing power parity",218.5
+16158,Hungary,2010,13,R03-Drugs for obstructive airway diseases,"/capita, US$ exchange rate",13.3
+16159,Hungary,2010,13,G-Genito urinary system and sex hormones,"Million US$, purchasing power parity",62.3
+16160,Hungary,2010,13,G-Genito urinary system and sex hormones,"/capita, US$ exchange rate",3.8
+16161,Hungary,2010,13,G-Genito urinary system and sex hormones,"/capita, US$ purchasing power parity",6.2
+16162,Hungary,2010,13,G03-Sex hormones and modulators of the genital system,% of total sales,0.7
+16163,Hungary,2010,13,G03-Sex hormones and modulators of the genital system,"/capita, US$ purchasing power parity",2.7
+16164,Hungary,2010,13,G-Genito urinary system and sex hormones,Million US$ at exchange rate,37.9
+16165,Hungary,2010,13,Total pharmaceutical sales,"Million US$, purchasing power parity",3940.5
+16166,Hungary,2010,13,Total pharmaceutical sales,Million of national currency units,498140.3
+16167,Hungary,2010,13,Total pharmaceutical sales,Million US$ at exchange rate,2395.5
+16168,Hungary,2010,13,Total pharmaceutical sales,"/capita, US$ exchange rate",239.6
+16169,Hungary,2010,13,G-Genito urinary system and sex hormones,% of total sales,1.6
+16170,Hungary,2010,13,Total pharmaceutical sales,"/capita, US$ purchasing power parity",394.0
+16171,Hungary,2010,13,M01A-Antiinflammatory and antirheumatic products non-steroids,Million US$ at exchange rate,31.0
+16172,Hungary,2010,13,M01A-Antiinflammatory and antirheumatic products non-steroids,"Million US$, purchasing power parity",51.0
+16173,Hungary,2010,13,N05B-Anxiolytics,"/capita, US$ exchange rate",1.4
+16174,Hungary,2010,13,M01A-Antiinflammatory and antirheumatic products non-steroids,Million of national currency units,6442.7
+16175,Hungary,2010,13,M01A-Antiinflammatory and antirheumatic products non-steroids,% of total sales,1.3
+16176,Hungary,2010,13,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ purchasing power parity",5.1
+16177,Hungary,2010,13,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ exchange rate",3.1
+16178,Hungary,2010,13,G03-Sex hormones and modulators of the genital system,"Million US$, purchasing power parity",26.5
+16179,Hungary,2010,13,G03-Sex hormones and modulators of the genital system,Million US$ at exchange rate,16.1
+16180,Hungary,2010,13,G03-Sex hormones and modulators of the genital system,"/capita, US$ exchange rate",1.6
+16181,Hungary,2010,13,N05B-Anxiolytics,"/capita, US$ purchasing power parity",2.3
+16182,Hungary,2010,13,N05B-Anxiolytics,% of total sales,0.6
+16183,Hungary,2010,13,G03-Sex hormones and modulators of the genital system,Million of national currency units,3352.5
+16184,Hungary,2010,13,J01-Antibacterials for systemic use,"/capita, US$ exchange rate",6.9
+16185,Hungary,2010,13,J01-Antibacterials for systemic use,Million US$ at exchange rate,69.0
+16186,Hungary,2010,13,J01-Antibacterials for systemic use,"Million US$, purchasing power parity",113.4
+16187,Hungary,2010,13,J01-Antibacterials for systemic use,"/capita, US$ purchasing power parity",11.3
+16188,Hungary,2010,13,J01-Antibacterials for systemic use,% of total sales,2.9
+16189,Hungary,2010,13,B-Blood and blood forming organs,"/capita, US$ exchange rate",18.9
+16190,Hungary,2010,13,B-Blood and blood forming organs,"/capita, US$ purchasing power parity",31.1
+16191,Hungary,2010,13,B-Blood and blood forming organs,"Million US$, purchasing power parity",311.2
+16192,Hungary,2010,13,B-Blood and blood forming organs,Million of national currency units,39342.1
+16193,Hungary,2010,13,J01-Antibacterials for systemic use,Million of national currency units,14338.6
+16194,Hungary,2010,13,B-Blood and blood forming organs,Million US$ at exchange rate,189.2
+16195,Hungary,2010,13,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million US$ at exchange rate,33.4
+16196,Hungary,2010,13,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ exchange rate",3.3
+16197,Hungary,2010,13,"H-Systemic hormonal preparations, excluding sex hormones and insulins","Million US$, purchasing power parity",54.9
+16198,Hungary,2010,13,C10-Lipid modifying agents,"Million US$, purchasing power parity",294.2
+16199,Hungary,2010,13,C10-Lipid modifying agents,Million US$ at exchange rate,178.8
+16200,Hungary,2010,13,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million of national currency units,6945.0
+16201,Hungary,2010,13,C10-Lipid modifying agents,Million of national currency units,37190.0
+16202,Hungary,2010,13,N-Nervous system,Million US$ at exchange rate,298.7
+16203,Hungary,2010,13,N-Nervous system,Million of national currency units,62105.9
+16204,Hungary,2010,13,"H-Systemic hormonal preparations, excluding sex hormones and insulins",% of total sales,1.4
+16205,Hungary,2010,13,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ purchasing power parity",5.5
+16206,Hungary,2010,13,N-Nervous system,"/capita, US$ exchange rate",29.9
+16207,Hungary,2010,13,N-Nervous system,"Million US$, purchasing power parity",491.3
+16208,Hungary,2010,13,B-Blood and blood forming organs,% of total sales,7.9
+16209,Hungary,2010,13,C-Cardiovascular system,"/capita, US$ exchange rate",62.5
+16210,Hungary,2010,13,C-Cardiovascular system,Million US$ at exchange rate,625.1
+16211,Hungary,2010,13,C-Cardiovascular system,"Million US$, purchasing power parity",1028.2
+16212,Hungary,2010,13,C-Cardiovascular system,% of total sales,26.1
+16213,Hungary,2010,13,C-Cardiovascular system,"/capita, US$ purchasing power parity",102.8
+16214,Hungary,2010,13,C09-Agents acting on the Renin-Angiotensin system,"Million US$, purchasing power parity",380.3
+16215,Hungary,2010,13,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ exchange rate",23.1
+16216,Hungary,2010,13,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ purchasing power parity",38.0
+16217,Hungary,2010,13,C-Cardiovascular system,Million of national currency units,129978.7
+16218,Hungary,2010,13,C09-Agents acting on the Renin-Angiotensin system,Million of national currency units,48076.5
+16219,Hungary,2010,13,C09-Agents acting on the Renin-Angiotensin system,Million US$ at exchange rate,231.2
+16220,Hungary,2010,13,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ purchasing power parity",14.8
+16221,Hungary,2010,13,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),% of total sales,3.8
+16222,Hungary,2010,13,N05B-Anxiolytics,Million of national currency units,2903.2
+16223,Hungary,2010,13,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million US$ at exchange rate,89.9
+16224,Hungary,2010,13,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ exchange rate",9.0
+16225,Hungary,2010,13,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"Million US$, purchasing power parity",147.8
+16226,Hungary,2010,13,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million of national currency units,18687.7
+16227,Hungary,2010,13,C02-Antihypertensives,Million US$ at exchange rate,35.3
+16228,Hungary,2010,13,C02-Antihypertensives,Million of national currency units,7338.5
+16229,Hungary,2010,13,C02-Antihypertensives,"/capita, US$ exchange rate",3.5
+16230,Hungary,2010,13,C02-Antihypertensives,"Million US$, purchasing power parity",58.0
+16231,Hungary,2011,13,A-Alimentary tract and metabolism,Million of national currency units,68963.5
+16232,Hungary,2011,13,C10-Lipid modifying agents,% of total sales,7.2
+16233,Hungary,2011,13,A10-Drugs used in diabetes,"Million US$, purchasing power parity",268.9
+16234,Hungary,2011,13,A10-Drugs used in diabetes,Million of national currency units,33416.2
+16235,Hungary,2011,13,A10-Drugs used in diabetes,Million US$ at exchange rate,166.2
+16236,Hungary,2011,13,A-Alimentary tract and metabolism,Million US$ at exchange rate,343.0
+16237,Hungary,2011,13,C03-Diuretics,"/capita, US$ purchasing power parity",3.9
+16238,Hungary,2011,13,C03-Diuretics,% of total sales,0.9
+16239,Hungary,2011,13,C03-Diuretics,"Million US$, purchasing power parity",39.1
+16240,Hungary,2011,13,C03-Diuretics,"/capita, US$ exchange rate",2.4
+16241,Hungary,2011,13,A-Alimentary tract and metabolism,"/capita, US$ exchange rate",34.4
+16242,Hungary,2011,13,A-Alimentary tract and metabolism,"Million US$, purchasing power parity",554.9
+16243,Hungary,2011,13,A02A-Antacids,Million of national currency units,0.0
+16244,Hungary,2011,13,C10-Lipid modifying agents,"/capita, US$ exchange rate",18.5
+16245,Hungary,2011,13,C10-Lipid modifying agents,"/capita, US$ purchasing power parity",29.9
+16246,Hungary,2011,13,A10-Drugs used in diabetes,"/capita, US$ exchange rate",16.7
+16247,Hungary,2011,13,N-Nervous system,"/capita, US$ purchasing power parity",52.0
+16248,Hungary,2011,13,N06A-Antidepressants,% of total sales,2.4
+16249,Hungary,2011,13,C08-Calcium channel blockers,"Million US$, purchasing power parity",54.7
+16250,Hungary,2011,13,C08-Calcium channel blockers,Million US$ at exchange rate,33.8
+16251,Hungary,2011,13,N06A-Antidepressants,"Million US$, purchasing power parity",101.1
+16252,Hungary,2011,13,N06A-Antidepressants,Million US$ at exchange rate,62.5
+16253,Hungary,2011,13,C08-Calcium channel blockers,Million of national currency units,6798.9
+16254,Hungary,2011,13,N06A-Antidepressants,"/capita, US$ purchasing power parity",10.1
+16255,Hungary,2011,13,N06A-Antidepressants,"/capita, US$ exchange rate",6.3
+16256,Hungary,2011,13,N-Nervous system,% of total sales,12.5
+16257,Hungary,2011,13,C01A-Cardiac glycosides,% of total sales,0.1
+16258,Hungary,2011,13,A10-Drugs used in diabetes,% of total sales,6.5
+16259,Hungary,2011,13,A10-Drugs used in diabetes,"/capita, US$ purchasing power parity",27.0
+16260,Hungary,2011,13,N06A-Antidepressants,Million of national currency units,12569.5
+16261,Hungary,2011,13,C08-Calcium channel blockers,"/capita, US$ exchange rate",3.4
+16262,Hungary,2011,13,C08-Calcium channel blockers,% of total sales,1.3
+16263,Hungary,2011,13,C08-Calcium channel blockers,"/capita, US$ purchasing power parity",5.5
+16264,Hungary,2011,13,C03-Diuretics,Million US$ at exchange rate,24.2
+16265,Hungary,2011,13,"C01B-Antiarrhythmics, Class I and III","Million US$, purchasing power parity",12.3
+16266,Hungary,2011,13,"C01B-Antiarrhythmics, Class I and III","/capita, US$ purchasing power parity",1.2
+16267,Hungary,2011,13,"C01B-Antiarrhythmics, Class I and III","/capita, US$ exchange rate",0.8
+16268,Hungary,2011,13,N02-Analgesics,"/capita, US$ exchange rate",2.7
+16269,Hungary,2011,13,"C01B-Antiarrhythmics, Class I and III",Million of national currency units,1522.8
+16270,Hungary,2011,13,"C01B-Antiarrhythmics, Class I and III",Million US$ at exchange rate,7.6
+16271,Hungary,2011,13,A02A-Antacids,"/capita, US$ purchasing power parity",0.0
+16272,Hungary,2011,13,A02A-Antacids,"/capita, US$ exchange rate",0.0
+16273,Hungary,2011,13,A02A-Antacids,"Million US$, purchasing power parity",0.0
+16274,Hungary,2011,13,"C01B-Antiarrhythmics, Class I and III",% of total sales,0.3
+16275,Hungary,2011,13,A02A-Antacids,% of total sales,0.0
+16276,Hungary,2011,13,A-Alimentary tract and metabolism,% of total sales,13.4
+16277,Hungary,2011,13,R-Respiratory system,"Million US$, purchasing power parity",287.5
+16278,Hungary,2011,13,R-Respiratory system,"/capita, US$ exchange rate",17.8
+16279,Hungary,2011,13,R-Respiratory system,Million of national currency units,35728.1
+16280,Hungary,2011,13,R-Respiratory system,Million US$ at exchange rate,177.7
+16281,Hungary,2011,13,N02-Analgesics,Million US$ at exchange rate,27.1
+16282,Hungary,2011,13,N02-Analgesics,"Million US$, purchasing power parity",43.8
+16283,Hungary,2011,13,R-Respiratory system,"/capita, US$ purchasing power parity",28.8
+16284,Hungary,2011,13,R-Respiratory system,% of total sales,6.9
+16285,Hungary,2011,13,N02-Analgesics,Million of national currency units,5439.1
+16286,Hungary,2011,13,J-Antiinfectives for systemic use,"Million US$, purchasing power parity",180.3
+16287,Hungary,2011,13,C01A-Cardiac glycosides,Million US$ at exchange rate,1.3
+16288,Hungary,2011,13,J-Antiinfectives for systemic use,"/capita, US$ exchange rate",11.2
+16289,Hungary,2011,13,M-Musculo-skeletal system,Million of national currency units,21144.6
+16290,Hungary,2011,13,A-Alimentary tract and metabolism,"/capita, US$ purchasing power parity",55.7
+16291,Hungary,2011,13,J-Antiinfectives for systemic use,"/capita, US$ purchasing power parity",18.1
+16292,Hungary,2011,13,J-Antiinfectives for systemic use,Million of national currency units,22409.7
+16293,Hungary,2011,13,C03-Diuretics,Million of national currency units,4864.6
+16294,Hungary,2011,13,J-Antiinfectives for systemic use,Million US$ at exchange rate,111.5
+16295,Hungary,2011,13,C01A-Cardiac glycosides,Million of national currency units,260.8
+16296,Hungary,2011,13,A02A-Antacids,Million US$ at exchange rate,0.0
+16297,Hungary,2011,13,J-Antiinfectives for systemic use,% of total sales,4.3
+16298,Hungary,2011,13,N02-Analgesics,"/capita, US$ purchasing power parity",4.4
+16299,Hungary,2011,13,C01A-Cardiac glycosides,"/capita, US$ purchasing power parity",0.2
+16300,Hungary,2011,13,C01A-Cardiac glycosides,"/capita, US$ exchange rate",0.1
+16301,Hungary,2011,13,C01A-Cardiac glycosides,"Million US$, purchasing power parity",2.1
+16302,Hungary,2011,13,M-Musculo-skeletal system,"Million US$, purchasing power parity",170.1
+16303,Hungary,2011,13,M-Musculo-skeletal system,Million US$ at exchange rate,105.2
+16304,Hungary,2011,13,M-Musculo-skeletal system,% of total sales,4.1
+16305,Hungary,2011,13,M-Musculo-skeletal system,"/capita, US$ exchange rate",10.5
+16306,Hungary,2011,13,M-Musculo-skeletal system,"/capita, US$ purchasing power parity",17.1
+16307,Hungary,2011,13,G-Genito urinary system and sex hormones,Million of national currency units,8316.0
+16308,Hungary,2011,13,C07-Beta blocking agents,"/capita, US$ purchasing power parity",9.8
+16309,Hungary,2011,13,C07-Beta blocking agents,% of total sales,2.4
+16310,Hungary,2011,13,N05C-Hypnotics and sedatives,% of total sales,0.0
+16311,Hungary,2011,13,N05C-Hypnotics and sedatives,"/capita, US$ exchange rate",0.0
+16312,Hungary,2011,13,N05C-Hypnotics and sedatives,"/capita, US$ purchasing power parity",0.0
+16313,Hungary,2011,13,N05C-Hypnotics and sedatives,"Million US$, purchasing power parity",0.0
+16314,Hungary,2011,13,C07-Beta blocking agents,"Million US$, purchasing power parity",98.1
+16315,Hungary,2011,13,C07-Beta blocking agents,Million US$ at exchange rate,60.6
+16316,Hungary,2011,13,C07-Beta blocking agents,Million of national currency units,12185.1
+16317,Hungary,2011,13,N05B-Anxiolytics,Million US$ at exchange rate,15.2
+16318,Hungary,2011,13,C07-Beta blocking agents,"/capita, US$ exchange rate",6.1
+16319,Hungary,2011,13,N05B-Anxiolytics,"Million US$, purchasing power parity",24.6
+16320,Hungary,2011,13,N02-Analgesics,% of total sales,1.1
+16321,Hungary,2011,13,C02-Antihypertensives,% of total sales,1.5
+16322,Hungary,2011,13,R03-Drugs for obstructive airway diseases,Million of national currency units,29340.5
+16323,Hungary,2011,13,N05C-Hypnotics and sedatives,Million of national currency units,3.3
+16324,Hungary,2011,13,C09-Agents acting on the Renin-Angiotensin system,% of total sales,8.9
+16325,Hungary,2011,13,C02-Antihypertensives,"/capita, US$ purchasing power parity",6.2
+16326,Hungary,2011,13,R03-Drugs for obstructive airway diseases,% of total sales,5.7
+16327,Hungary,2011,13,R03-Drugs for obstructive airway diseases,"/capita, US$ purchasing power parity",23.7
+16328,Hungary,2011,13,N05C-Hypnotics and sedatives,Million US$ at exchange rate,0.0
+16329,Hungary,2011,13,R03-Drugs for obstructive airway diseases,Million US$ at exchange rate,145.9
+16330,Hungary,2011,13,R03-Drugs for obstructive airway diseases,"Million US$, purchasing power parity",236.1
+16331,Hungary,2011,13,R03-Drugs for obstructive airway diseases,"/capita, US$ exchange rate",14.6
+16332,Hungary,2011,13,G-Genito urinary system and sex hormones,"Million US$, purchasing power parity",66.9
+16333,Hungary,2011,13,G-Genito urinary system and sex hormones,"/capita, US$ exchange rate",4.1
+16334,Hungary,2011,13,G-Genito urinary system and sex hormones,"/capita, US$ purchasing power parity",6.7
+16335,Hungary,2011,13,G03-Sex hormones and modulators of the genital system,% of total sales,0.7
+16336,Hungary,2011,13,G03-Sex hormones and modulators of the genital system,"/capita, US$ purchasing power parity",2.8
+16337,Hungary,2011,13,G-Genito urinary system and sex hormones,Million US$ at exchange rate,41.4
+16338,Hungary,2011,13,Total pharmaceutical sales,"Million US$, purchasing power parity",4146.5
+16339,Hungary,2011,13,Total pharmaceutical sales,Million of national currency units,515299.2
+16340,Hungary,2011,13,Total pharmaceutical sales,Million US$ at exchange rate,2563.0
+16341,Hungary,2011,13,G-Genito urinary system and sex hormones,% of total sales,1.6
+16342,Hungary,2011,13,Total pharmaceutical sales,"/capita, US$ exchange rate",257.0
+16343,Hungary,2011,13,Total pharmaceutical sales,"/capita, US$ purchasing power parity",415.8
+16344,Hungary,2011,13,M01A-Antiinflammatory and antirheumatic products non-steroids,Million US$ at exchange rate,28.2
+16345,Hungary,2011,13,M01A-Antiinflammatory and antirheumatic products non-steroids,"Million US$, purchasing power parity",45.6
+16346,Hungary,2011,13,N05B-Anxiolytics,"/capita, US$ exchange rate",1.5
+16347,Hungary,2011,13,M01A-Antiinflammatory and antirheumatic products non-steroids,Million of national currency units,5672.5
+16348,Hungary,2011,13,M01A-Antiinflammatory and antirheumatic products non-steroids,% of total sales,1.1
+16349,Hungary,2011,13,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ purchasing power parity",4.6
+16350,Hungary,2011,13,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ exchange rate",2.8
+16351,Hungary,2011,13,G03-Sex hormones and modulators of the genital system,Million US$ at exchange rate,17.3
+16352,Hungary,2011,13,G03-Sex hormones and modulators of the genital system,"Million US$, purchasing power parity",28.0
+16353,Hungary,2011,13,G03-Sex hormones and modulators of the genital system,"/capita, US$ exchange rate",1.7
+16354,Hungary,2011,13,N05B-Anxiolytics,"/capita, US$ purchasing power parity",2.5
+16355,Hungary,2011,13,G03-Sex hormones and modulators of the genital system,Million of national currency units,3483.0
+16356,Hungary,2011,13,N05B-Anxiolytics,% of total sales,0.6
+16357,Hungary,2011,13,J01-Antibacterials for systemic use,"/capita, US$ exchange rate",7.1
+16358,Hungary,2011,13,J01-Antibacterials for systemic use,"Million US$, purchasing power parity",114.9
+16359,Hungary,2011,13,J01-Antibacterials for systemic use,Million US$ at exchange rate,71.0
+16360,Hungary,2011,13,J01-Antibacterials for systemic use,% of total sales,2.8
+16361,Hungary,2011,13,J01-Antibacterials for systemic use,"/capita, US$ purchasing power parity",11.5
+16362,Hungary,2011,13,B-Blood and blood forming organs,"/capita, US$ exchange rate",20.1
+16363,Hungary,2011,13,B-Blood and blood forming organs,"/capita, US$ purchasing power parity",32.5
+16364,Hungary,2011,13,B-Blood and blood forming organs,Million of national currency units,40274.7
+16365,Hungary,2011,13,J01-Antibacterials for systemic use,Million of national currency units,14278.5
+16366,Hungary,2011,13,B-Blood and blood forming organs,"Million US$, purchasing power parity",324.1
+16367,Hungary,2011,13,B-Blood and blood forming organs,Million US$ at exchange rate,200.3
+16368,Hungary,2011,13,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million US$ at exchange rate,39.2
+16369,Hungary,2011,13,"H-Systemic hormonal preparations, excluding sex hormones and insulins","Million US$, purchasing power parity",63.4
+16370,Hungary,2011,13,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ exchange rate",3.9
+16371,Hungary,2011,13,C10-Lipid modifying agents,Million US$ at exchange rate,184.0
+16372,Hungary,2011,13,C10-Lipid modifying agents,"Million US$, purchasing power parity",297.7
+16373,Hungary,2011,13,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million of national currency units,7875.2
+16374,Hungary,2011,13,C10-Lipid modifying agents,Million of national currency units,37000.6
+16375,Hungary,2011,13,N-Nervous system,Million US$ at exchange rate,320.4
+16376,Hungary,2011,13,N-Nervous system,Million of national currency units,64409.0
+16377,Hungary,2011,13,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ purchasing power parity",6.4
+16378,Hungary,2011,13,"H-Systemic hormonal preparations, excluding sex hormones and insulins",% of total sales,1.5
+16379,Hungary,2011,13,N-Nervous system,"/capita, US$ exchange rate",32.1
+16380,Hungary,2011,13,N-Nervous system,"Million US$, purchasing power parity",518.3
+16381,Hungary,2011,13,C-Cardiovascular system,"/capita, US$ exchange rate",63.6
+16382,Hungary,2011,13,C-Cardiovascular system,"Million US$, purchasing power parity",1025.6
+16383,Hungary,2011,13,C-Cardiovascular system,Million US$ at exchange rate,633.9
+16384,Hungary,2011,13,C-Cardiovascular system,% of total sales,24.7
+16385,Hungary,2011,13,C-Cardiovascular system,"/capita, US$ purchasing power parity",102.9
+16386,Hungary,2011,13,C09-Agents acting on the Renin-Angiotensin system,"Million US$, purchasing power parity",367.8
+16387,Hungary,2011,13,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ exchange rate",22.8
+16388,Hungary,2011,13,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ purchasing power parity",36.9
+16389,Hungary,2011,13,C-Cardiovascular system,Million of national currency units,127453.0
+16390,Hungary,2011,13,C09-Agents acting on the Renin-Angiotensin system,Million of national currency units,45712.3
+16391,Hungary,2011,13,C09-Agents acting on the Renin-Angiotensin system,Million US$ at exchange rate,227.4
+16392,Hungary,2011,13,B-Blood and blood forming organs,% of total sales,7.8
+16393,Hungary,2011,13,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ purchasing power parity",14.9
+16394,Hungary,2011,13,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),% of total sales,3.6
+16395,Hungary,2011,13,N05B-Anxiolytics,Million of national currency units,3057.1
+16396,Hungary,2011,13,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million US$ at exchange rate,92.1
+16397,Hungary,2011,13,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ exchange rate",9.2
+16398,Hungary,2011,13,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"Million US$, purchasing power parity",148.9
+16399,Hungary,2011,13,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million of national currency units,18507.6
+16400,Hungary,2011,13,C02-Antihypertensives,Million US$ at exchange rate,38.3
+16401,Hungary,2011,13,C02-Antihypertensives,Million of national currency units,7703.6
+16402,Hungary,2011,13,C02-Antihypertensives,"/capita, US$ exchange rate",3.8
+16403,Hungary,2011,13,C02-Antihypertensives,"Million US$, purchasing power parity",62.0
+16404,Iceland,2010,5,N05C-Hypnotics and sedatives,Million of national currency units,461.2
+16405,Iceland,2010,5,G-Genito urinary system and sex hormones,"/capita, US$ purchasing power parity",35.4
+16406,Iceland,2010,5,G-Genito urinary system and sex hormones,% of total sales,6.0
+16407,Iceland,2010,5,N-Nervous system,"Million US$, purchasing power parity",51.0
+16408,Iceland,2010,5,N-Nervous system,Million US$ at exchange rate,55.5
+16409,Iceland,2010,5,N05C-Hypnotics and sedatives,"/capita, US$ purchasing power parity",10.9
+16410,Iceland,2010,5,N-Nervous system,"/capita, US$ exchange rate",174.5
+16411,Iceland,2010,5,N05C-Hypnotics and sedatives,"Million US$, purchasing power parity",3.5
+16412,Iceland,2010,5,N05C-Hypnotics and sedatives,Million US$ at exchange rate,3.8
+16413,Iceland,2010,5,N-Nervous system,Million of national currency units,6783.8
+16414,Iceland,2010,5,N05C-Hypnotics and sedatives,% of total sales,1.8
+16415,Iceland,2010,5,N05C-Hypnotics and sedatives,"/capita, US$ exchange rate",11.9
+16416,Iceland,2010,5,C02-Antihypertensives,"/capita, US$ purchasing power parity",0.9
+16417,Iceland,2010,5,C02-Antihypertensives,Million of national currency units,37.6
+16418,Iceland,2010,5,C02-Antihypertensives,% of total sales,0.2
+16419,Iceland,2010,5,C07-Beta blocking agents,"/capita, US$ exchange rate",8.4
+16420,Iceland,2010,5,C07-Beta blocking agents,"/capita, US$ purchasing power parity",7.7
+16421,Iceland,2010,5,C07-Beta blocking agents,% of total sales,1.3
+16422,Iceland,2010,5,J01-Antibacterials for systemic use,"Million US$, purchasing power parity",7.1
+16423,Iceland,2010,5,J01-Antibacterials for systemic use,Million US$ at exchange rate,7.7
+16424,Iceland,2010,5,J01-Antibacterials for systemic use,"/capita, US$ exchange rate",24.2
+16425,Iceland,2010,5,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million US$ at exchange rate,7.0
+16426,Iceland,2010,5,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"Million US$, purchasing power parity",6.4
+16427,Iceland,2010,5,J01-Antibacterials for systemic use,Million of national currency units,942.2
+16428,Iceland,2010,5,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million of national currency units,853.4
+16429,Iceland,2010,5,G03-Sex hormones and modulators of the genital system,% of total sales,3.4
+16430,Iceland,2010,5,G03-Sex hormones and modulators of the genital system,"/capita, US$ purchasing power parity",20.0
+16431,Iceland,2010,5,C02-Antihypertensives,"/capita, US$ exchange rate",1.0
+16432,Iceland,2010,5,C02-Antihypertensives,Million US$ at exchange rate,0.3
+16433,Iceland,2010,5,C02-Antihypertensives,"Million US$, purchasing power parity",0.3
+16434,Iceland,2010,5,C07-Beta blocking agents,Million of national currency units,327.2
+16435,Iceland,2010,5,G03-Sex hormones and modulators of the genital system,Million of national currency units,846.9
+16436,Iceland,2010,5,C07-Beta blocking agents,Million US$ at exchange rate,2.7
+16437,Iceland,2010,5,C07-Beta blocking agents,"Million US$, purchasing power parity",2.5
+16438,Iceland,2010,5,G03-Sex hormones and modulators of the genital system,"/capita, US$ exchange rate",21.8
+16439,Iceland,2010,5,G03-Sex hormones and modulators of the genital system,"Million US$, purchasing power parity",6.4
+16440,Iceland,2010,5,G03-Sex hormones and modulators of the genital system,Million US$ at exchange rate,6.9
+16441,Iceland,2010,5,A-Alimentary tract and metabolism,"/capita, US$ purchasing power parity",49.0
+16442,Iceland,2010,5,A-Alimentary tract and metabolism,% of total sales,8.3
+16443,Iceland,2010,5,A-Alimentary tract and metabolism,"/capita, US$ exchange rate",53.3
+16444,Iceland,2010,5,A02A-Antacids,"Million US$, purchasing power parity",0.4
+16445,Iceland,2010,5,A02A-Antacids,Million US$ at exchange rate,0.4
+16446,Iceland,2010,5,A02A-Antacids,"/capita, US$ exchange rate",1.4
+16447,Iceland,2010,5,N-Nervous system,% of total sales,27.1
+16448,Iceland,2010,5,N-Nervous system,"/capita, US$ purchasing power parity",160.5
+16449,Iceland,2010,5,A-Alimentary tract and metabolism,Million of national currency units,2071.3
+16450,Iceland,2010,5,A-Alimentary tract and metabolism,Million US$ at exchange rate,16.9
+16451,Iceland,2010,5,A-Alimentary tract and metabolism,"Million US$, purchasing power parity",15.6
+16452,Iceland,2010,5,A02A-Antacids,"/capita, US$ purchasing power parity",1.3
+16453,Iceland,2010,5,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ purchasing power parity",20.2
+16454,Iceland,2010,5,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),% of total sales,3.4
+16455,Iceland,2010,5,N06A-Antidepressants,Million of national currency units,1101.8
+16456,Iceland,2010,5,J01-Antibacterials for systemic use,% of total sales,3.8
+16457,Iceland,2010,5,J01-Antibacterials for systemic use,"/capita, US$ purchasing power parity",22.3
+16458,Iceland,2010,5,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ exchange rate",22.0
+16459,Iceland,2010,5,N06A-Antidepressants,% of total sales,4.4
+16460,Iceland,2010,5,N06A-Antidepressants,"/capita, US$ purchasing power parity",26.1
+16461,Iceland,2010,5,A02A-Antacids,Million of national currency units,53.9
+16462,Iceland,2010,5,N06A-Antidepressants,Million US$ at exchange rate,9.0
+16463,Iceland,2010,5,N06A-Antidepressants,"Million US$, purchasing power parity",8.3
+16464,Iceland,2010,5,N06A-Antidepressants,"/capita, US$ exchange rate",28.3
+16465,Iceland,2010,5,C08-Calcium channel blockers,"/capita, US$ exchange rate",5.7
+16466,Iceland,2010,5,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million US$ at exchange rate,4.8
+16467,Iceland,2010,5,"H-Systemic hormonal preparations, excluding sex hormones and insulins","Million US$, purchasing power parity",4.4
+16468,Iceland,2010,5,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ purchasing power parity",13.9
+16469,Iceland,2010,5,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ exchange rate",15.1
+16470,Iceland,2010,5,Products not elsewhere classified,Million of national currency units,5683.3
+16471,Iceland,2010,5,Products not elsewhere classified,"/capita, US$ exchange rate",146.2
+16472,Iceland,2010,5,Products not elsewhere classified,"Million US$, purchasing power parity",42.8
+16473,Iceland,2010,5,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million of national currency units,585.4
+16474,Iceland,2010,5,Products not elsewhere classified,Million US$ at exchange rate,46.5
+16475,Iceland,2010,5,M01A-Antiinflammatory and antirheumatic products non-steroids,% of total sales,3.6
+16476,Iceland,2010,5,B-Blood and blood forming organs,"/capita, US$ exchange rate",33.8
+16477,Iceland,2010,5,B-Blood and blood forming organs,"/capita, US$ purchasing power parity",31.1
+16478,Iceland,2010,5,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ purchasing power parity",21.4
+16479,Iceland,2010,5,B-Blood and blood forming organs,Million of national currency units,1316.0
+16480,Iceland,2010,5,"H-Systemic hormonal preparations, excluding sex hormones and insulins",% of total sales,2.3
+16481,Iceland,2010,5,Products not elsewhere classified,"/capita, US$ purchasing power parity",134.5
+16482,Iceland,2010,5,B-Blood and blood forming organs,"Million US$, purchasing power parity",9.9
+16483,Iceland,2010,5,B-Blood and blood forming organs,Million US$ at exchange rate,10.8
+16484,Iceland,2010,5,A10-Drugs used in diabetes,% of total sales,2.4
+16485,Iceland,2010,5,C03-Diuretics,"/capita, US$ exchange rate",5.3
+16486,Iceland,2010,5,C03-Diuretics,% of total sales,0.8
+16487,Iceland,2010,5,C03-Diuretics,"/capita, US$ purchasing power parity",4.8
+16488,Iceland,2010,5,A10-Drugs used in diabetes,Million US$ at exchange rate,5.0
+16489,Iceland,2010,5,A10-Drugs used in diabetes,"Million US$, purchasing power parity",4.6
+16490,Iceland,2010,5,A10-Drugs used in diabetes,"/capita, US$ purchasing power parity",14.5
+16491,Iceland,2010,5,A10-Drugs used in diabetes,"/capita, US$ exchange rate",15.8
+16492,Iceland,2010,5,C10-Lipid modifying agents,Million US$ at exchange rate,2.7
+16493,Iceland,2010,5,C10-Lipid modifying agents,"Million US$, purchasing power parity",2.5
+16494,Iceland,2010,5,Products not elsewhere classified,% of total sales,22.7
+16495,Iceland,2010,5,C10-Lipid modifying agents,Million of national currency units,335.4
+16496,Iceland,2010,5,C10-Lipid modifying agents,% of total sales,1.3
+16497,Iceland,2010,5,C10-Lipid modifying agents,"/capita, US$ exchange rate",8.6
+16498,Iceland,2010,5,C10-Lipid modifying agents,"/capita, US$ purchasing power parity",7.9
+16499,Iceland,2010,5,N05B-Anxiolytics,Million US$ at exchange rate,2.1
+16500,Iceland,2010,5,N05B-Anxiolytics,Million of national currency units,262.1
+16501,Iceland,2010,5,M01A-Antiinflammatory and antirheumatic products non-steroids,Million of national currency units,903.3
+16502,Iceland,2010,5,N05B-Anxiolytics,"/capita, US$ exchange rate",6.7
+16503,Iceland,2010,5,N05B-Anxiolytics,"Million US$, purchasing power parity",2.0
+16504,Iceland,2010,5,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ exchange rate",23.2
+16505,Iceland,2010,5,R03-Drugs for obstructive airway diseases,% of total sales,4.5
+16506,Iceland,2010,5,M01A-Antiinflammatory and antirheumatic products non-steroids,Million US$ at exchange rate,7.4
+16507,Iceland,2010,5,M01A-Antiinflammatory and antirheumatic products non-steroids,"Million US$, purchasing power parity",6.8
+16508,Iceland,2010,5,Total pharmaceutical sales,"/capita, US$ exchange rate",643.3
+16509,Iceland,2010,5,Total pharmaceutical sales,"Million US$, purchasing power parity",188.2
+16510,Iceland,2010,5,Total pharmaceutical sales,Million of national currency units,25011.6
+16511,Iceland,2010,5,Total pharmaceutical sales,Million US$ at exchange rate,204.6
+16512,Iceland,2010,5,Total pharmaceutical sales,"/capita, US$ purchasing power parity",591.8
+16513,Iceland,2010,5,N05B-Anxiolytics,"/capita, US$ purchasing power parity",6.2
+16514,Iceland,2010,5,C09-Agents acting on the Renin-Angiotensin system,% of total sales,2.2
+16515,Iceland,2010,5,N05B-Anxiolytics,% of total sales,1.0
+16516,Iceland,2010,5,C-Cardiovascular system,"Million US$, purchasing power parity",14.3
+16517,Iceland,2010,5,C-Cardiovascular system,Million US$ at exchange rate,15.6
+16518,Iceland,2010,5,C-Cardiovascular system,"/capita, US$ exchange rate",49.0
+16519,Iceland,2010,5,C09-Agents acting on the Renin-Angiotensin system,Million of national currency units,543.8
+16520,Iceland,2010,5,C-Cardiovascular system,Million of national currency units,1906.8
+16521,Iceland,2010,5,B-Blood and blood forming organs,% of total sales,5.3
+16522,Iceland,2010,5,C-Cardiovascular system,"/capita, US$ purchasing power parity",45.1
+16523,Iceland,2010,5,C-Cardiovascular system,% of total sales,7.6
+16524,Iceland,2010,5,C09-Agents acting on the Renin-Angiotensin system,Million US$ at exchange rate,4.4
+16525,Iceland,2010,5,R03-Drugs for obstructive airway diseases,"Million US$, purchasing power parity",8.4
+16526,Iceland,2010,5,R03-Drugs for obstructive airway diseases,Million US$ at exchange rate,9.1
+16527,Iceland,2010,5,R03-Drugs for obstructive airway diseases,"/capita, US$ purchasing power parity",26.4
+16528,Iceland,2010,5,R03-Drugs for obstructive airway diseases,"/capita, US$ exchange rate",28.7
+16529,Iceland,2010,5,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ exchange rate",14.0
+16530,Iceland,2010,5,C09-Agents acting on the Renin-Angiotensin system,"Million US$, purchasing power parity",4.1
+16531,Iceland,2010,5,R03-Drugs for obstructive airway diseases,Million of national currency units,1114.5
+16532,Iceland,2010,5,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ purchasing power parity",12.9
+16533,Iceland,2010,5,A10-Drugs used in diabetes,Million of national currency units,612.6
+16534,Iceland,2010,5,C01A-Cardiac glycosides,Million of national currency units,9.4
+16535,Iceland,2010,5,C08-Calcium channel blockers,% of total sales,0.9
+16536,Iceland,2010,5,M-Musculo-skeletal system,Million of national currency units,1220.1
+16537,Iceland,2010,5,M-Musculo-skeletal system,Million US$ at exchange rate,10.0
+16538,Iceland,2010,5,C08-Calcium channel blockers,"/capita, US$ purchasing power parity",5.3
+16539,Iceland,2010,5,C08-Calcium channel blockers,Million US$ at exchange rate,1.8
+16540,Iceland,2010,5,C08-Calcium channel blockers,Million of national currency units,223.5
+16541,Iceland,2010,5,"C01B-Antiarrhythmics, Class I and III",Million of national currency units,61.4
+16542,Iceland,2010,5,C08-Calcium channel blockers,"Million US$, purchasing power parity",1.7
+16543,Iceland,2010,5,M-Musculo-skeletal system,"Million US$, purchasing power parity",9.2
+16544,Iceland,2010,5,R-Respiratory system,"Million US$, purchasing power parity",13.3
+16545,Iceland,2010,5,R-Respiratory system,Million US$ at exchange rate,14.4
+16546,Iceland,2010,5,R-Respiratory system,"/capita, US$ purchasing power parity",41.7
+16547,Iceland,2010,5,R-Respiratory system,"/capita, US$ exchange rate",45.3
+16548,Iceland,2010,5,M-Musculo-skeletal system,"/capita, US$ purchasing power parity",28.9
+16549,Iceland,2010,5,M-Musculo-skeletal system,"/capita, US$ exchange rate",31.4
+16550,Iceland,2010,5,R-Respiratory system,Million of national currency units,1762.5
+16551,Iceland,2010,5,M-Musculo-skeletal system,% of total sales,4.9
+16552,Iceland,2010,5,N02-Analgesics,"Million US$, purchasing power parity",7.6
+16553,Iceland,2010,5,N02-Analgesics,Million US$ at exchange rate,8.3
+16554,Iceland,2010,5,N02-Analgesics,"/capita, US$ purchasing power parity",23.9
+16555,Iceland,2010,5,N02-Analgesics,"/capita, US$ exchange rate",26.0
+16556,Iceland,2010,5,G-Genito urinary system and sex hormones,"Million US$, purchasing power parity",11.3
+16557,Iceland,2010,5,G-Genito urinary system and sex hormones,"/capita, US$ exchange rate",38.5
+16558,Iceland,2010,5,N02-Analgesics,Million of national currency units,1011.6
+16559,Iceland,2010,5,G-Genito urinary system and sex hormones,Million of national currency units,1497.1
+16560,Iceland,2010,5,G-Genito urinary system and sex hormones,Million US$ at exchange rate,12.2
+16561,Iceland,2010,5,"C01B-Antiarrhythmics, Class I and III","/capita, US$ exchange rate",1.6
+16562,Iceland,2010,5,"C01B-Antiarrhythmics, Class I and III",Million US$ at exchange rate,0.5
+16563,Iceland,2010,5,"C01B-Antiarrhythmics, Class I and III","Million US$, purchasing power parity",0.5
+16564,Iceland,2010,5,N02-Analgesics,% of total sales,4.0
+16565,Iceland,2010,5,"C01B-Antiarrhythmics, Class I and III","/capita, US$ purchasing power parity",1.5
+16566,Iceland,2010,5,"C01B-Antiarrhythmics, Class I and III",% of total sales,0.2
+16567,Iceland,2010,5,A02A-Antacids,% of total sales,0.2
+16568,Iceland,2010,5,C01A-Cardiac glycosides,Million US$ at exchange rate,0.1
+16569,Iceland,2010,5,J-Antiinfectives for systemic use,Million of national currency units,2185.2
+16570,Iceland,2010,5,C01A-Cardiac glycosides,"Million US$, purchasing power parity",0.1
+16571,Iceland,2010,5,C01A-Cardiac glycosides,"/capita, US$ purchasing power parity",0.2
+16572,Iceland,2010,5,C01A-Cardiac glycosides,"/capita, US$ exchange rate",0.2
+16573,Iceland,2010,5,J-Antiinfectives for systemic use,Million US$ at exchange rate,17.9
+16574,Iceland,2010,5,J-Antiinfectives for systemic use,"/capita, US$ purchasing power parity",51.7
+16575,Iceland,2010,5,J-Antiinfectives for systemic use,% of total sales,8.7
+16576,Iceland,2010,5,J-Antiinfectives for systemic use,"Million US$, purchasing power parity",16.4
+16577,Iceland,2010,5,J-Antiinfectives for systemic use,"/capita, US$ exchange rate",56.2
+16578,Iceland,2010,5,C01A-Cardiac glycosides,% of total sales,0.0
+16579,Iceland,2010,5,C03-Diuretics,"Million US$, purchasing power parity",1.5
+16580,Iceland,2010,5,C03-Diuretics,Million of national currency units,204.5
+16581,Iceland,2010,5,R-Respiratory system,% of total sales,7.0
+16582,Iceland,2010,5,C03-Diuretics,Million US$ at exchange rate,1.7
+16583,Iceland,2017,4,G-Genito urinary system and sex hormones,"/capita, US$ purchasing power parity",27.5
+16584,Iceland,2017,4,G-Genito urinary system and sex hormones,% of total sales,4.9
+16585,Iceland,2017,4,N05C-Hypnotics and sedatives,Million of national currency units,509.2
+16586,Iceland,2017,4,N-Nervous system,Million US$ at exchange rate,49.3
+16587,Iceland,2017,4,N-Nervous system,Million of national currency units,5265.0
+16588,Iceland,2017,4,N05C-Hypnotics and sedatives,"/capita, US$ exchange rate",13.9
+16589,Iceland,2017,4,N-Nervous system,"Million US$, purchasing power parity",38.1
+16590,Iceland,2017,4,N05C-Hypnotics and sedatives,Million US$ at exchange rate,4.8
+16591,Iceland,2017,4,N05C-Hypnotics and sedatives,"Million US$, purchasing power parity",3.7
+16592,Iceland,2017,4,N05C-Hypnotics and sedatives,"/capita, US$ purchasing power parity",10.7
+16593,Iceland,2017,4,N05C-Hypnotics and sedatives,% of total sales,1.9
+16594,Iceland,2017,4,C02-Antihypertensives,"/capita, US$ purchasing power parity",1.1
+16595,Iceland,2017,4,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"Million US$, purchasing power parity",4.5
+16596,Iceland,2017,4,C02-Antihypertensives,% of total sales,0.2
+16597,Iceland,2017,4,C07-Beta blocking agents,% of total sales,1.3
+16598,Iceland,2017,4,C07-Beta blocking agents,"/capita, US$ exchange rate",9.5
+16599,Iceland,2017,4,C07-Beta blocking agents,"/capita, US$ purchasing power parity",7.4
+16600,Iceland,2017,4,J01-Antibacterials for systemic use,Million US$ at exchange rate,10.0
+16601,Iceland,2017,4,J01-Antibacterials for systemic use,"Million US$, purchasing power parity",7.7
+16602,Iceland,2017,4,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million US$ at exchange rate,5.9
+16603,Iceland,2017,4,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million of national currency units,626.3
+16604,Iceland,2017,4,J01-Antibacterials for systemic use,Million of national currency units,1066.3
+16605,Iceland,2017,4,C07-Beta blocking agents,"Million US$, purchasing power parity",2.5
+16606,Iceland,2017,4,G03-Sex hormones and modulators of the genital system,% of total sales,2.7
+16607,Iceland,2017,4,C02-Antihypertensives,"/capita, US$ exchange rate",1.4
+16608,Iceland,2017,4,G03-Sex hormones and modulators of the genital system,"/capita, US$ purchasing power parity",14.9
+16609,Iceland,2017,4,C02-Antihypertensives,Million of national currency units,51.0
+16610,Iceland,2017,4,C02-Antihypertensives,Million US$ at exchange rate,0.5
+16611,Iceland,2017,4,C02-Antihypertensives,"Million US$, purchasing power parity",0.4
+16612,Iceland,2017,4,J01-Antibacterials for systemic use,"/capita, US$ exchange rate",29.1
+16613,Iceland,2017,4,G03-Sex hormones and modulators of the genital system,"/capita, US$ exchange rate",19.2
+16614,Iceland,2017,4,C07-Beta blocking agents,Million of national currency units,349.6
+16615,Iceland,2017,4,C07-Beta blocking agents,Million US$ at exchange rate,3.3
+16616,Iceland,2017,4,G03-Sex hormones and modulators of the genital system,Million of national currency units,705.6
+16617,Iceland,2017,4,G03-Sex hormones and modulators of the genital system,"Million US$, purchasing power parity",5.1
+16618,Iceland,2017,4,G03-Sex hormones and modulators of the genital system,Million US$ at exchange rate,6.6
+16619,Iceland,2017,4,A-Alimentary tract and metabolism,"/capita, US$ purchasing power parity",45.5
+16620,Iceland,2017,4,A-Alimentary tract and metabolism,"Million US$, purchasing power parity",15.6
+16621,Iceland,2017,4,A-Alimentary tract and metabolism,"/capita, US$ exchange rate",58.9
+16622,Iceland,2017,4,A02A-Antacids,Million US$ at exchange rate,0.0
+16623,Iceland,2017,4,A-Alimentary tract and metabolism,% of total sales,8.1
+16624,Iceland,2017,4,A02A-Antacids,"Million US$, purchasing power parity",0.0
+16625,Iceland,2017,4,N-Nervous system,% of total sales,19.9
+16626,Iceland,2017,4,N-Nervous system,"/capita, US$ purchasing power parity",110.9
+16627,Iceland,2017,4,N-Nervous system,"/capita, US$ exchange rate",143.5
+16628,Iceland,2017,4,A-Alimentary tract and metabolism,Million US$ at exchange rate,20.2
+16629,Iceland,2017,4,A02A-Antacids,"/capita, US$ exchange rate",0.0
+16630,Iceland,2017,4,A-Alimentary tract and metabolism,Million of national currency units,2159.5
+16631,Iceland,2017,4,A02A-Antacids,Million of national currency units,0.0
+16632,Iceland,2017,4,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ purchasing power parity",13.2
+16633,Iceland,2017,4,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),% of total sales,2.4
+16634,Iceland,2017,4,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ exchange rate",17.1
+16635,Iceland,2017,4,J01-Antibacterials for systemic use,"/capita, US$ purchasing power parity",22.5
+16636,Iceland,2017,4,J01-Antibacterials for systemic use,% of total sales,4.0
+16637,Iceland,2017,4,N06A-Antidepressants,"/capita, US$ purchasing power parity",16.2
+16638,Iceland,2017,4,N06A-Antidepressants,% of total sales,2.9
+16639,Iceland,2017,4,N06A-Antidepressants,Million of national currency units,769.4
+16640,Iceland,2017,4,N06A-Antidepressants,Million US$ at exchange rate,7.2
+16641,Iceland,2017,4,N06A-Antidepressants,"Million US$, purchasing power parity",5.6
+16642,Iceland,2017,4,N06A-Antidepressants,"/capita, US$ exchange rate",21.0
+16643,Iceland,2017,4,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million US$ at exchange rate,6.5
+16644,Iceland,2017,4,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million of national currency units,690.2
+16645,Iceland,2017,4,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ exchange rate",18.8
+16646,Iceland,2017,4,"H-Systemic hormonal preparations, excluding sex hormones and insulins","Million US$, purchasing power parity",5.0
+16647,Iceland,2017,4,Products not elsewhere classified,"Million US$, purchasing power parity",58.1
+16648,Iceland,2017,4,Products not elsewhere classified,"/capita, US$ exchange rate",218.8
+16649,Iceland,2017,4,Products not elsewhere classified,Million of national currency units,8027.6
+16650,Iceland,2017,4,Products not elsewhere classified,Million US$ at exchange rate,75.1
+16651,Iceland,2017,4,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ purchasing power parity",9.1
+16652,Iceland,2017,4,M01A-Antiinflammatory and antirheumatic products non-steroids,% of total sales,1.6
+16653,Iceland,2017,4,B-Blood and blood forming organs,"/capita, US$ exchange rate",48.2
+16654,Iceland,2017,4,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ exchange rate",11.8
+16655,Iceland,2017,4,B-Blood and blood forming organs,"Million US$, purchasing power parity",12.8
+16656,Iceland,2017,4,"H-Systemic hormonal preparations, excluding sex hormones and insulins",% of total sales,2.6
+16657,Iceland,2017,4,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ purchasing power parity",14.5
+16658,Iceland,2017,4,B-Blood and blood forming organs,Million of national currency units,1768.1
+16659,Iceland,2017,4,B-Blood and blood forming organs,Million US$ at exchange rate,16.5
+16660,Iceland,2017,4,A10-Drugs used in diabetes,% of total sales,3.2
+16661,Iceland,2017,4,A10-Drugs used in diabetes,"/capita, US$ purchasing power parity",17.8
+16662,Iceland,2017,4,C03-Diuretics,"/capita, US$ purchasing power parity",4.6
+16663,Iceland,2017,4,C03-Diuretics,"/capita, US$ exchange rate",5.9
+16664,Iceland,2017,4,A10-Drugs used in diabetes,Million US$ at exchange rate,7.9
+16665,Iceland,2017,4,A10-Drugs used in diabetes,Million of national currency units,845.8
+16666,Iceland,2017,4,A10-Drugs used in diabetes,"/capita, US$ exchange rate",23.1
+16667,Iceland,2017,4,A10-Drugs used in diabetes,"Million US$, purchasing power parity",6.1
+16668,Iceland,2017,4,C10-Lipid modifying agents,Million of national currency units,344.3
+16669,Iceland,2017,4,C10-Lipid modifying agents,Million US$ at exchange rate,3.2
+16670,Iceland,2017,4,Products not elsewhere classified,"/capita, US$ purchasing power parity",169.1
+16671,Iceland,2017,4,Products not elsewhere classified,% of total sales,30.3
+16672,Iceland,2017,4,C10-Lipid modifying agents,% of total sales,1.3
+16673,Iceland,2017,4,C03-Diuretics,% of total sales,0.8
+16674,Iceland,2017,4,C10-Lipid modifying agents,"/capita, US$ purchasing power parity",7.3
+16675,Iceland,2017,4,C10-Lipid modifying agents,"/capita, US$ exchange rate",9.4
+16676,Iceland,2017,4,B-Blood and blood forming organs,"/capita, US$ purchasing power parity",37.2
+16677,Iceland,2017,4,N05B-Anxiolytics,Million of national currency units,276.7
+16678,Iceland,2017,4,N05B-Anxiolytics,Million US$ at exchange rate,2.6
+16679,Iceland,2017,4,N05B-Anxiolytics,"Million US$, purchasing power parity",2.0
+16680,Iceland,2017,4,N05B-Anxiolytics,"/capita, US$ exchange rate",7.5
+16681,Iceland,2017,4,M01A-Antiinflammatory and antirheumatic products non-steroids,Million of national currency units,431.6
+16682,Iceland,2017,4,R03-Drugs for obstructive airway diseases,% of total sales,4.3
+16683,Iceland,2017,4,M01A-Antiinflammatory and antirheumatic products non-steroids,"Million US$, purchasing power parity",3.1
+16684,Iceland,2017,4,M01A-Antiinflammatory and antirheumatic products non-steroids,Million US$ at exchange rate,4.0
+16685,Iceland,2017,4,Total pharmaceutical sales,"Million US$, purchasing power parity",191.8
+16686,Iceland,2017,4,Total pharmaceutical sales,"/capita, US$ exchange rate",722.9
+16687,Iceland,2017,4,Total pharmaceutical sales,Million of national currency units,26522.3
+16688,Iceland,2017,4,Total pharmaceutical sales,Million US$ at exchange rate,248.2
+16689,Iceland,2017,4,C09-Agents acting on the Renin-Angiotensin system,% of total sales,1.7
+16690,Iceland,2017,4,N05B-Anxiolytics,"/capita, US$ purchasing power parity",5.8
+16691,Iceland,2017,4,Total pharmaceutical sales,"/capita, US$ purchasing power parity",558.5
+16692,Iceland,2017,4,N05B-Anxiolytics,% of total sales,1.0
+16693,Iceland,2017,4,C-Cardiovascular system,Million US$ at exchange rate,17.1
+16694,Iceland,2017,4,C-Cardiovascular system,"Million US$, purchasing power parity",13.2
+16695,Iceland,2017,4,C09-Agents acting on the Renin-Angiotensin system,Million of national currency units,454.9
+16696,Iceland,2017,4,C-Cardiovascular system,Million of national currency units,1827.3
+16697,Iceland,2017,4,C-Cardiovascular system,% of total sales,6.9
+16698,Iceland,2017,4,B-Blood and blood forming organs,% of total sales,6.7
+16699,Iceland,2017,4,C-Cardiovascular system,"/capita, US$ exchange rate",49.8
+16700,Iceland,2017,4,C-Cardiovascular system,"/capita, US$ purchasing power parity",38.5
+16701,Iceland,2017,4,R03-Drugs for obstructive airway diseases,Million US$ at exchange rate,10.6
+16702,Iceland,2017,4,R03-Drugs for obstructive airway diseases,"Million US$, purchasing power parity",8.2
+16703,Iceland,2017,4,R03-Drugs for obstructive airway diseases,"/capita, US$ purchasing power parity",23.9
+16704,Iceland,2017,4,R03-Drugs for obstructive airway diseases,"/capita, US$ exchange rate",31.0
+16705,Iceland,2017,4,R03-Drugs for obstructive airway diseases,Million of national currency units,1136.8
+16706,Iceland,2017,4,C09-Agents acting on the Renin-Angiotensin system,"Million US$, purchasing power parity",3.3
+16707,Iceland,2017,4,C09-Agents acting on the Renin-Angiotensin system,Million US$ at exchange rate,4.3
+16708,Iceland,2017,4,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ purchasing power parity",9.6
+16709,Iceland,2017,4,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ exchange rate",12.4
+16710,Iceland,2017,4,C10-Lipid modifying agents,"Million US$, purchasing power parity",2.5
+16711,Iceland,2017,4,C03-Diuretics,"Million US$, purchasing power parity",1.6
+16712,Iceland,2017,4,C08-Calcium channel blockers,% of total sales,0.6
+16713,Iceland,2017,4,C08-Calcium channel blockers,"/capita, US$ purchasing power parity",3.5
+16714,Iceland,2017,4,M-Musculo-skeletal system,Million US$ at exchange rate,6.5
+16715,Iceland,2017,4,M-Musculo-skeletal system,Million of national currency units,698.3
+16716,Iceland,2017,4,C08-Calcium channel blockers,Million US$ at exchange rate,1.5
+16717,Iceland,2017,4,C08-Calcium channel blockers,Million of national currency units,164.6
+16718,Iceland,2017,4,C08-Calcium channel blockers,"/capita, US$ exchange rate",4.5
+16719,Iceland,2017,4,C08-Calcium channel blockers,"Million US$, purchasing power parity",1.2
+16720,Iceland,2017,4,R-Respiratory system,Million US$ at exchange rate,14.3
+16721,Iceland,2017,4,R-Respiratory system,Million of national currency units,1532.7
+16722,Iceland,2017,4,R-Respiratory system,"Million US$, purchasing power parity",11.1
+16723,Iceland,2017,4,R-Respiratory system,"/capita, US$ purchasing power parity",32.3
+16724,Iceland,2017,4,R-Respiratory system,"/capita, US$ exchange rate",41.8
+16725,Iceland,2017,4,M-Musculo-skeletal system,"/capita, US$ exchange rate",19.0
+16726,Iceland,2017,4,M-Musculo-skeletal system,"Million US$, purchasing power parity",5.1
+16727,Iceland,2017,4,M-Musculo-skeletal system,% of total sales,2.6
+16728,Iceland,2017,4,M-Musculo-skeletal system,"/capita, US$ purchasing power parity",14.7
+16729,Iceland,2017,4,N02-Analgesics,Million US$ at exchange rate,8.5
+16730,Iceland,2017,4,N02-Analgesics,Million of national currency units,903.0
+16731,Iceland,2017,4,N02-Analgesics,"Million US$, purchasing power parity",6.5
+16732,Iceland,2017,4,"C01B-Antiarrhythmics, Class I and III",% of total sales,0.3
+16733,Iceland,2017,4,N02-Analgesics,"/capita, US$ exchange rate",24.6
+16734,Iceland,2017,4,G-Genito urinary system and sex hormones,"Million US$, purchasing power parity",9.5
+16735,Iceland,2017,4,G-Genito urinary system and sex hormones,"/capita, US$ exchange rate",35.7
+16736,Iceland,2017,4,G-Genito urinary system and sex hormones,Million US$ at exchange rate,12.2
+16737,Iceland,2017,4,G-Genito urinary system and sex hormones,Million of national currency units,1308.1
+16738,Iceland,2017,4,"C01B-Antiarrhythmics, Class I and III","Million US$, purchasing power parity",0.6
+16739,Iceland,2017,4,N02-Analgesics,% of total sales,3.4
+16740,Iceland,2017,4,"C01B-Antiarrhythmics, Class I and III",Million of national currency units,83.5
+16741,Iceland,2017,4,"C01B-Antiarrhythmics, Class I and III",Million US$ at exchange rate,0.8
+16742,Iceland,2017,4,"C01B-Antiarrhythmics, Class I and III","/capita, US$ exchange rate",2.3
+16743,Iceland,2017,4,"C01B-Antiarrhythmics, Class I and III","/capita, US$ purchasing power parity",1.8
+16744,Iceland,2017,4,A02A-Antacids,"/capita, US$ purchasing power parity",0.0
+16745,Iceland,2017,4,N02-Analgesics,"/capita, US$ purchasing power parity",19.0
+16746,Iceland,2017,4,A02A-Antacids,% of total sales,0.0
+16747,Iceland,2017,4,C01A-Cardiac glycosides,Million US$ at exchange rate,0.1
+16748,Iceland,2017,4,C01A-Cardiac glycosides,Million of national currency units,11.3
+16749,Iceland,2017,4,J-Antiinfectives for systemic use,Million of national currency units,3067.9
+16750,Iceland,2017,4,C01A-Cardiac glycosides,"/capita, US$ purchasing power parity",0.2
+16751,Iceland,2017,4,C01A-Cardiac glycosides,"/capita, US$ exchange rate",0.3
+16752,Iceland,2017,4,C01A-Cardiac glycosides,"Million US$, purchasing power parity",0.1
+16753,Iceland,2017,4,J-Antiinfectives for systemic use,"/capita, US$ purchasing power parity",64.6
+16754,Iceland,2017,4,J-Antiinfectives for systemic use,% of total sales,11.6
+16755,Iceland,2017,4,J-Antiinfectives for systemic use,"/capita, US$ exchange rate",83.6
+16756,Iceland,2017,4,J-Antiinfectives for systemic use,Million US$ at exchange rate,28.7
+16757,Iceland,2017,4,J-Antiinfectives for systemic use,"Million US$, purchasing power parity",22.2
+16758,Iceland,2017,4,C01A-Cardiac glycosides,% of total sales,0.0
+16759,Iceland,2017,4,R-Respiratory system,% of total sales,5.8
+16760,Iceland,2017,4,C03-Diuretics,Million US$ at exchange rate,2.0
+16761,Iceland,2017,4,C03-Diuretics,Million of national currency units,216.6
+16762,Iceland,2016,4,G-Genito urinary system and sex hormones,"/capita, US$ purchasing power parity",28.4
+16763,Iceland,2016,4,G-Genito urinary system and sex hormones,% of total sales,5.3
+16764,Iceland,2016,4,N05C-Hypnotics and sedatives,Million of national currency units,471.8
+16765,Iceland,2016,4,N-Nervous system,Million US$ at exchange rate,46.0
+16766,Iceland,2016,4,N-Nervous system,Million of national currency units,5561.3
+16767,Iceland,2016,4,N05C-Hypnotics and sedatives,"/capita, US$ exchange rate",11.6
+16768,Iceland,2016,4,N-Nervous system,"Million US$, purchasing power parity",39.7
+16769,Iceland,2016,4,N05C-Hypnotics and sedatives,"Million US$, purchasing power parity",3.4
+16770,Iceland,2016,4,N05C-Hypnotics and sedatives,Million US$ at exchange rate,3.9
+16771,Iceland,2016,4,N05C-Hypnotics and sedatives,"/capita, US$ purchasing power parity",10.0
+16772,Iceland,2016,4,N05C-Hypnotics and sedatives,% of total sales,1.9
+16773,Iceland,2016,4,N06A-Antidepressants,Million US$ at exchange rate,6.2
+16774,Iceland,2016,4,C02-Antihypertensives,"/capita, US$ purchasing power parity",1.0
+16775,Iceland,2016,4,C02-Antihypertensives,% of total sales,0.2
+16776,Iceland,2016,4,C07-Beta blocking agents,% of total sales,1.3
+16777,Iceland,2016,4,C07-Beta blocking agents,"/capita, US$ exchange rate",8.4
+16778,Iceland,2016,4,C07-Beta blocking agents,"/capita, US$ purchasing power parity",7.2
+16779,Iceland,2016,4,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"Million US$, purchasing power parity",4.3
+16780,Iceland,2016,4,J01-Antibacterials for systemic use,Million US$ at exchange rate,8.8
+16781,Iceland,2016,4,J01-Antibacterials for systemic use,"/capita, US$ exchange rate",26.2
+16782,Iceland,2016,4,J01-Antibacterials for systemic use,"Million US$, purchasing power parity",7.6
+16783,Iceland,2016,4,J01-Antibacterials for systemic use,Million of national currency units,1062.7
+16784,Iceland,2016,4,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million US$ at exchange rate,4.9
+16785,Iceland,2016,4,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million of national currency units,596.9
+16786,Iceland,2016,4,C07-Beta blocking agents,"Million US$, purchasing power parity",2.4
+16787,Iceland,2016,4,G03-Sex hormones and modulators of the genital system,% of total sales,2.9
+16788,Iceland,2016,4,C02-Antihypertensives,"/capita, US$ exchange rate",1.2
+16789,Iceland,2016,4,G03-Sex hormones and modulators of the genital system,"/capita, US$ purchasing power parity",15.5
+16790,Iceland,2016,4,C02-Antihypertensives,Million of national currency units,49.0
+16791,Iceland,2016,4,C02-Antihypertensives,Million US$ at exchange rate,0.4
+16792,Iceland,2016,4,C02-Antihypertensives,"Million US$, purchasing power parity",0.3
+16793,Iceland,2016,4,C07-Beta blocking agents,Million of national currency units,340.2
+16794,Iceland,2016,4,C07-Beta blocking agents,Million US$ at exchange rate,2.8
+16795,Iceland,2016,4,G03-Sex hormones and modulators of the genital system,"/capita, US$ exchange rate",18.0
+16796,Iceland,2016,4,G03-Sex hormones and modulators of the genital system,"Million US$, purchasing power parity",5.2
+16797,Iceland,2016,4,G03-Sex hormones and modulators of the genital system,Million US$ at exchange rate,6.0
+16798,Iceland,2016,4,G03-Sex hormones and modulators of the genital system,Million of national currency units,729.9
+16799,Iceland,2016,4,A-Alimentary tract and metabolism,"/capita, US$ purchasing power parity",46.6
+16800,Iceland,2016,4,A-Alimentary tract and metabolism,"Million US$, purchasing power parity",15.6
+16801,Iceland,2016,4,A-Alimentary tract and metabolism,"/capita, US$ exchange rate",54.0
+16802,Iceland,2016,4,A-Alimentary tract and metabolism,% of total sales,8.6
+16803,Iceland,2016,4,A02A-Antacids,Million US$ at exchange rate,0.0
+16804,Iceland,2016,4,A02A-Antacids,"Million US$, purchasing power parity",0.0
+16805,Iceland,2016,4,N-Nervous system,% of total sales,21.9
+16806,Iceland,2016,4,N-Nervous system,"/capita, US$ exchange rate",137.2
+16807,Iceland,2016,4,N-Nervous system,"/capita, US$ purchasing power parity",118.4
+16808,Iceland,2016,4,A-Alimentary tract and metabolism,Million US$ at exchange rate,18.1
+16809,Iceland,2016,4,A02A-Antacids,"/capita, US$ exchange rate",0.0
+16810,Iceland,2016,4,A-Alimentary tract and metabolism,Million of national currency units,2188.8
+16811,Iceland,2016,4,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ purchasing power parity",12.7
+16812,Iceland,2016,4,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),% of total sales,2.4
+16813,Iceland,2016,4,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ exchange rate",14.7
+16814,Iceland,2016,4,J01-Antibacterials for systemic use,"/capita, US$ purchasing power parity",22.6
+16815,Iceland,2016,4,J01-Antibacterials for systemic use,% of total sales,4.2
+16816,Iceland,2016,4,N06A-Antidepressants,Million of national currency units,744.1
+16817,Iceland,2016,4,N06A-Antidepressants,"/capita, US$ purchasing power parity",15.8
+16818,Iceland,2016,4,A02A-Antacids,Million of national currency units,0.0
+16819,Iceland,2016,4,N06A-Antidepressants,% of total sales,2.9
+16820,Iceland,2016,4,N06A-Antidepressants,"/capita, US$ exchange rate",18.4
+16821,Iceland,2016,4,N06A-Antidepressants,"Million US$, purchasing power parity",5.3
+16822,Iceland,2016,4,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million US$ at exchange rate,5.5
+16823,Iceland,2016,4,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million of national currency units,670.4
+16824,Iceland,2016,4,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ exchange rate",16.5
+16825,Iceland,2016,4,"H-Systemic hormonal preparations, excluding sex hormones and insulins","Million US$, purchasing power parity",4.8
+16826,Iceland,2016,4,Products not elsewhere classified,"Million US$, purchasing power parity",52.4
+16827,Iceland,2016,4,Products not elsewhere classified,"/capita, US$ exchange rate",181.2
+16828,Iceland,2016,4,Products not elsewhere classified,Million of national currency units,7341.2
+16829,Iceland,2016,4,Products not elsewhere classified,Million US$ at exchange rate,60.8
+16830,Iceland,2016,4,M01A-Antiinflammatory and antirheumatic products non-steroids,% of total sales,1.7
+16831,Iceland,2016,4,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ purchasing power parity",9.2
+16832,Iceland,2016,4,B-Blood and blood forming organs,"/capita, US$ exchange rate",47.4
+16833,Iceland,2016,4,B-Blood and blood forming organs,"Million US$, purchasing power parity",13.7
+16834,Iceland,2016,4,"H-Systemic hormonal preparations, excluding sex hormones and insulins",% of total sales,2.6
+16835,Iceland,2016,4,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ purchasing power parity",14.3
+16836,Iceland,2016,4,B-Blood and blood forming organs,Million of national currency units,1922.6
+16837,Iceland,2016,4,B-Blood and blood forming organs,Million US$ at exchange rate,15.9
+16838,Iceland,2016,4,A10-Drugs used in diabetes,% of total sales,3.3
+16839,Iceland,2016,4,A10-Drugs used in diabetes,"/capita, US$ purchasing power parity",17.8
+16840,Iceland,2016,4,C03-Diuretics,"/capita, US$ purchasing power parity",4.4
+16841,Iceland,2016,4,C03-Diuretics,"/capita, US$ exchange rate",5.1
+16842,Iceland,2016,4,A10-Drugs used in diabetes,Million US$ at exchange rate,6.9
+16843,Iceland,2016,4,A10-Drugs used in diabetes,Million of national currency units,838.3
+16844,Iceland,2016,4,A10-Drugs used in diabetes,"/capita, US$ exchange rate",20.7
+16845,Iceland,2016,4,A10-Drugs used in diabetes,"Million US$, purchasing power parity",6.0
+16846,Iceland,2016,4,C10-Lipid modifying agents,Million of national currency units,326.4
+16847,Iceland,2016,4,C10-Lipid modifying agents,Million US$ at exchange rate,2.7
+16848,Iceland,2016,4,Products not elsewhere classified,"/capita, US$ purchasing power parity",156.3
+16849,Iceland,2016,4,Products not elsewhere classified,% of total sales,28.9
+16850,Iceland,2016,4,C10-Lipid modifying agents,"Million US$, purchasing power parity",2.3
+16851,Iceland,2016,4,C10-Lipid modifying agents,% of total sales,1.3
+16852,Iceland,2016,4,C03-Diuretics,% of total sales,0.8
+16853,Iceland,2016,4,C10-Lipid modifying agents,"/capita, US$ purchasing power parity",6.9
+16854,Iceland,2016,4,C10-Lipid modifying agents,"/capita, US$ exchange rate",8.1
+16855,Iceland,2016,4,B-Blood and blood forming organs,"/capita, US$ purchasing power parity",40.9
+16856,Iceland,2016,4,N05B-Anxiolytics,Million of national currency units,265.2
+16857,Iceland,2016,4,N05B-Anxiolytics,Million US$ at exchange rate,2.2
+16858,Iceland,2016,4,N05B-Anxiolytics,"/capita, US$ exchange rate",6.5
+16859,Iceland,2016,4,N05B-Anxiolytics,"Million US$, purchasing power parity",1.9
+16860,Iceland,2016,4,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ exchange rate",10.7
+16861,Iceland,2016,4,R03-Drugs for obstructive airway diseases,% of total sales,4.5
+16862,Iceland,2016,4,M01A-Antiinflammatory and antirheumatic products non-steroids,"Million US$, purchasing power parity",3.1
+16863,Iceland,2016,4,M01A-Antiinflammatory and antirheumatic products non-steroids,Million of national currency units,431.9
+16864,Iceland,2016,4,M01A-Antiinflammatory and antirheumatic products non-steroids,Million US$ at exchange rate,3.6
+16865,Iceland,2016,4,Total pharmaceutical sales,"Million US$, purchasing power parity",181.3
+16866,Iceland,2016,4,Total pharmaceutical sales,"/capita, US$ exchange rate",626.4
+16867,Iceland,2016,4,Total pharmaceutical sales,Million of national currency units,25384.8
+16868,Iceland,2016,4,Total pharmaceutical sales,Million US$ at exchange rate,210.1
+16869,Iceland,2016,4,C09-Agents acting on the Renin-Angiotensin system,% of total sales,1.8
+16870,Iceland,2016,4,N05B-Anxiolytics,"/capita, US$ purchasing power parity",5.6
+16871,Iceland,2016,4,Total pharmaceutical sales,"/capita, US$ purchasing power parity",540.4
+16872,Iceland,2016,4,N05B-Anxiolytics,% of total sales,1.0
+16873,Iceland,2016,4,C-Cardiovascular system,Million US$ at exchange rate,14.4
+16874,Iceland,2016,4,C-Cardiovascular system,"Million US$, purchasing power parity",12.4
+16875,Iceland,2016,4,C09-Agents acting on the Renin-Angiotensin system,Million of national currency units,448.0
+16876,Iceland,2016,4,C-Cardiovascular system,Million of national currency units,1734.6
+16877,Iceland,2016,4,C-Cardiovascular system,% of total sales,6.8
+16878,Iceland,2016,4,B-Blood and blood forming organs,% of total sales,7.6
+16879,Iceland,2016,4,C-Cardiovascular system,"/capita, US$ exchange rate",42.8
+16880,Iceland,2016,4,C-Cardiovascular system,"/capita, US$ purchasing power parity",36.9
+16881,Iceland,2016,4,R03-Drugs for obstructive airway diseases,Million US$ at exchange rate,9.4
+16882,Iceland,2016,4,R03-Drugs for obstructive airway diseases,"Million US$, purchasing power parity",8.1
+16883,Iceland,2016,4,R03-Drugs for obstructive airway diseases,"/capita, US$ purchasing power parity",24.3
+16884,Iceland,2016,4,R03-Drugs for obstructive airway diseases,"/capita, US$ exchange rate",28.2
+16885,Iceland,2016,4,R03-Drugs for obstructive airway diseases,Million of national currency units,1141.2
+16886,Iceland,2016,4,C09-Agents acting on the Renin-Angiotensin system,"Million US$, purchasing power parity",3.2
+16887,Iceland,2016,4,C09-Agents acting on the Renin-Angiotensin system,Million US$ at exchange rate,3.7
+16888,Iceland,2016,4,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ purchasing power parity",9.5
+16889,Iceland,2016,4,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ exchange rate",11.1
+16890,Iceland,2016,4,C08-Calcium channel blockers,% of total sales,0.7
+16891,Iceland,2016,4,C08-Calcium channel blockers,"/capita, US$ purchasing power parity",3.5
+16892,Iceland,2016,4,M-Musculo-skeletal system,Million US$ at exchange rate,5.8
+16893,Iceland,2016,4,M-Musculo-skeletal system,Million of national currency units,697.1
+16894,Iceland,2016,4,C08-Calcium channel blockers,Million US$ at exchange rate,1.4
+16895,Iceland,2016,4,C08-Calcium channel blockers,Million of national currency units,165.6
+16896,Iceland,2016,4,C08-Calcium channel blockers,"/capita, US$ exchange rate",4.1
+16897,Iceland,2016,4,C08-Calcium channel blockers,"Million US$, purchasing power parity",1.2
+16898,Iceland,2016,4,R-Respiratory system,"Million US$, purchasing power parity",10.8
+16899,Iceland,2016,4,R-Respiratory system,Million US$ at exchange rate,12.5
+16900,Iceland,2016,4,R-Respiratory system,"/capita, US$ purchasing power parity",32.1
+16901,Iceland,2016,4,R-Respiratory system,"/capita, US$ exchange rate",37.2
+16902,Iceland,2016,4,R-Respiratory system,Million of national currency units,1508.4
+16903,Iceland,2016,4,M-Musculo-skeletal system,"/capita, US$ exchange rate",17.2
+16904,Iceland,2016,4,M-Musculo-skeletal system,"Million US$, purchasing power parity",5.0
+16905,Iceland,2016,4,M-Musculo-skeletal system,% of total sales,2.7
+16906,Iceland,2016,4,M-Musculo-skeletal system,"/capita, US$ purchasing power parity",14.8
+16907,Iceland,2016,4,N02-Analgesics,"Million US$, purchasing power parity",6.2
+16908,Iceland,2016,4,N02-Analgesics,Million US$ at exchange rate,7.2
+16909,Iceland,2016,4,"C01B-Antiarrhythmics, Class I and III",% of total sales,0.3
+16910,Iceland,2016,4,N02-Analgesics,"/capita, US$ exchange rate",21.6
+16911,Iceland,2016,4,N02-Analgesics,Million of national currency units,873.8
+16912,Iceland,2016,4,G-Genito urinary system and sex hormones,"Million US$, purchasing power parity",9.5
+16913,Iceland,2016,4,G-Genito urinary system and sex hormones,"/capita, US$ exchange rate",32.9
+16914,Iceland,2016,4,G-Genito urinary system and sex hormones,Million US$ at exchange rate,11.1
+16915,Iceland,2016,4,G-Genito urinary system and sex hormones,Million of national currency units,1335.0
+16916,Iceland,2016,4,"C01B-Antiarrhythmics, Class I and III","Million US$, purchasing power parity",0.6
+16917,Iceland,2016,4,N02-Analgesics,% of total sales,3.4
+16918,Iceland,2016,4,"C01B-Antiarrhythmics, Class I and III","/capita, US$ exchange rate",1.9
+16919,Iceland,2016,4,"C01B-Antiarrhythmics, Class I and III",Million of national currency units,77.9
+16920,Iceland,2016,4,"C01B-Antiarrhythmics, Class I and III",Million US$ at exchange rate,0.6
+16921,Iceland,2016,4,"C01B-Antiarrhythmics, Class I and III","/capita, US$ purchasing power parity",1.7
+16922,Iceland,2016,4,A02A-Antacids,"/capita, US$ purchasing power parity",0.0
+16923,Iceland,2016,4,N02-Analgesics,"/capita, US$ purchasing power parity",18.6
+16924,Iceland,2016,4,A02A-Antacids,% of total sales,0.0
+16925,Iceland,2016,4,C01A-Cardiac glycosides,Million US$ at exchange rate,0.1
+16926,Iceland,2016,4,C01A-Cardiac glycosides,Million of national currency units,11.5
+16927,Iceland,2016,4,J-Antiinfectives for systemic use,Million of national currency units,3055.4
+16928,Iceland,2016,4,C01A-Cardiac glycosides,"/capita, US$ purchasing power parity",0.2
+16929,Iceland,2016,4,C01A-Cardiac glycosides,"/capita, US$ exchange rate",0.3
+16930,Iceland,2016,4,C01A-Cardiac glycosides,"Million US$, purchasing power parity",0.1
+16931,Iceland,2016,4,J-Antiinfectives for systemic use,"/capita, US$ purchasing power parity",65.0
+16932,Iceland,2016,4,J-Antiinfectives for systemic use,% of total sales,12.0
+16933,Iceland,2016,4,J-Antiinfectives for systemic use,Million US$ at exchange rate,25.3
+16934,Iceland,2016,4,J-Antiinfectives for systemic use,"/capita, US$ exchange rate",75.4
+16935,Iceland,2016,4,J-Antiinfectives for systemic use,"Million US$, purchasing power parity",21.8
+16936,Iceland,2016,4,C01A-Cardiac glycosides,% of total sales,0.0
+16937,Iceland,2016,4,R-Respiratory system,% of total sales,5.9
+16938,Iceland,2016,4,C03-Diuretics,"Million US$, purchasing power parity",1.5
+16939,Iceland,2016,4,C03-Diuretics,Million US$ at exchange rate,1.7
+16940,Iceland,2016,4,C03-Diuretics,Million of national currency units,205.6
+16941,Iceland,2015,4,G-Genito urinary system and sex hormones,"/capita, US$ purchasing power parity",28.0
+16942,Iceland,2015,4,N05C-Hypnotics and sedatives,Million of national currency units,460.4
+16943,Iceland,2015,4,G-Genito urinary system and sex hormones,% of total sales,5.4
+16944,Iceland,2015,4,N-Nervous system,Million US$ at exchange rate,40.5
+16945,Iceland,2015,4,N-Nervous system,Million of national currency units,5341.2
+16946,Iceland,2015,4,N-Nervous system,"Million US$, purchasing power parity",37.6
+16947,Iceland,2015,4,N05C-Hypnotics and sedatives,"/capita, US$ exchange rate",10.5
+16948,Iceland,2015,4,N05C-Hypnotics and sedatives,"Million US$, purchasing power parity",3.2
+16949,Iceland,2015,4,N05C-Hypnotics and sedatives,Million US$ at exchange rate,3.5
+16950,Iceland,2015,4,N05C-Hypnotics and sedatives,"/capita, US$ purchasing power parity",9.8
+16951,Iceland,2015,4,N05C-Hypnotics and sedatives,% of total sales,1.9
+16952,Iceland,2015,4,C02-Antihypertensives,"/capita, US$ purchasing power parity",1.1
+16953,Iceland,2015,4,C02-Antihypertensives,% of total sales,0.2
+16954,Iceland,2015,4,C07-Beta blocking agents,"/capita, US$ exchange rate",7.8
+16955,Iceland,2015,4,C07-Beta blocking agents,% of total sales,1.4
+16956,Iceland,2015,4,C07-Beta blocking agents,"/capita, US$ purchasing power parity",7.2
+16957,Iceland,2015,4,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"Million US$, purchasing power parity",4.0
+16958,Iceland,2015,4,J01-Antibacterials for systemic use,Million US$ at exchange rate,7.9
+16959,Iceland,2015,4,J01-Antibacterials for systemic use,"/capita, US$ exchange rate",23.8
+16960,Iceland,2015,4,J01-Antibacterials for systemic use,"Million US$, purchasing power parity",7.3
+16961,Iceland,2015,4,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million US$ at exchange rate,4.3
+16962,Iceland,2015,4,J01-Antibacterials for systemic use,Million of national currency units,1040.8
+16963,Iceland,2015,4,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million of national currency units,561.1
+16964,Iceland,2015,4,C07-Beta blocking agents,"Million US$, purchasing power parity",2.4
+16965,Iceland,2015,4,G03-Sex hormones and modulators of the genital system,% of total sales,3.0
+16966,Iceland,2015,4,C02-Antihypertensives,"/capita, US$ exchange rate",1.2
+16967,Iceland,2015,4,G03-Sex hormones and modulators of the genital system,"/capita, US$ purchasing power parity",15.4
+16968,Iceland,2015,4,C02-Antihypertensives,Million US$ at exchange rate,0.4
+16969,Iceland,2015,4,C02-Antihypertensives,Million of national currency units,50.5
+16970,Iceland,2015,4,C02-Antihypertensives,"Million US$, purchasing power parity",0.4
+16971,Iceland,2015,4,G03-Sex hormones and modulators of the genital system,"/capita, US$ exchange rate",16.6
+16972,Iceland,2015,4,C07-Beta blocking agents,Million of national currency units,339.2
+16973,Iceland,2015,4,C07-Beta blocking agents,Million US$ at exchange rate,2.6
+16974,Iceland,2015,4,G03-Sex hormones and modulators of the genital system,Million of national currency units,723.6
+16975,Iceland,2015,4,G03-Sex hormones and modulators of the genital system,"Million US$, purchasing power parity",5.1
+16976,Iceland,2015,4,G03-Sex hormones and modulators of the genital system,Million US$ at exchange rate,5.5
+16977,Iceland,2015,4,A-Alimentary tract and metabolism,"/capita, US$ purchasing power parity",42.7
+16978,Iceland,2015,4,A-Alimentary tract and metabolism,"/capita, US$ exchange rate",45.9
+16979,Iceland,2015,4,A-Alimentary tract and metabolism,"Million US$, purchasing power parity",14.1
+16980,Iceland,2015,4,A02A-Antacids,Million US$ at exchange rate,0.0
+16981,Iceland,2015,4,A02A-Antacids,"Million US$, purchasing power parity",0.0
+16982,Iceland,2015,4,A-Alimentary tract and metabolism,% of total sales,8.2
+16983,Iceland,2015,4,N-Nervous system,% of total sales,21.9
+16984,Iceland,2015,4,N-Nervous system,"/capita, US$ exchange rate",122.4
+16985,Iceland,2015,4,N-Nervous system,"/capita, US$ purchasing power parity",113.7
+16986,Iceland,2015,4,A-Alimentary tract and metabolism,Million US$ at exchange rate,15.2
+16987,Iceland,2015,4,A02A-Antacids,"/capita, US$ exchange rate",0.0
+16988,Iceland,2015,4,A-Alimentary tract and metabolism,Million of national currency units,2003.7
+16989,Iceland,2015,4,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ purchasing power parity",11.9
+16990,Iceland,2015,4,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),% of total sales,2.3
+16991,Iceland,2015,4,N06A-Antidepressants,Million of national currency units,759.2
+16992,Iceland,2015,4,J01-Antibacterials for systemic use,"/capita, US$ purchasing power parity",22.2
+16993,Iceland,2015,4,J01-Antibacterials for systemic use,% of total sales,4.3
+16994,Iceland,2015,4,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ exchange rate",12.9
+16995,Iceland,2015,4,N06A-Antidepressants,"/capita, US$ purchasing power parity",16.2
+16996,Iceland,2015,4,A02A-Antacids,Million of national currency units,0.0
+16997,Iceland,2015,4,N06A-Antidepressants,% of total sales,3.1
+16998,Iceland,2015,4,N06A-Antidepressants,Million US$ at exchange rate,5.8
+16999,Iceland,2015,4,N06A-Antidepressants,"/capita, US$ exchange rate",17.4
+17000,Iceland,2015,4,N06A-Antidepressants,"Million US$, purchasing power parity",5.3
+17001,Iceland,2015,4,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million US$ at exchange rate,4.8
+17002,Iceland,2015,4,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million of national currency units,636.0
+17003,Iceland,2015,4,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ exchange rate",14.6
+17004,Iceland,2015,4,"H-Systemic hormonal preparations, excluding sex hormones and insulins","Million US$, purchasing power parity",4.5
+17005,Iceland,2015,4,Products not elsewhere classified,"Million US$, purchasing power parity",48.4
+17006,Iceland,2015,4,Products not elsewhere classified,"/capita, US$ exchange rate",157.4
+17007,Iceland,2015,4,Products not elsewhere classified,Million of national currency units,6869.4
+17008,Iceland,2015,4,Products not elsewhere classified,Million US$ at exchange rate,52.1
+17009,Iceland,2015,4,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ purchasing power parity",13.5
+17010,Iceland,2015,4,M01A-Antiinflammatory and antirheumatic products non-steroids,% of total sales,1.8
+17011,Iceland,2015,4,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ purchasing power parity",9.2
+17012,Iceland,2015,4,B-Blood and blood forming organs,"/capita, US$ exchange rate",36.1
+17013,Iceland,2015,4,"H-Systemic hormonal preparations, excluding sex hormones and insulins",% of total sales,2.6
+17014,Iceland,2015,4,B-Blood and blood forming organs,Million of national currency units,1575.9
+17015,Iceland,2015,4,B-Blood and blood forming organs,"Million US$, purchasing power parity",11.1
+17016,Iceland,2015,4,B-Blood and blood forming organs,Million US$ at exchange rate,11.9
+17017,Iceland,2015,4,A10-Drugs used in diabetes,% of total sales,3.0
+17018,Iceland,2015,4,A10-Drugs used in diabetes,"/capita, US$ purchasing power parity",15.6
+17019,Iceland,2015,4,C03-Diuretics,"/capita, US$ purchasing power parity",4.0
+17020,Iceland,2015,4,C03-Diuretics,"/capita, US$ exchange rate",4.3
+17021,Iceland,2015,4,A10-Drugs used in diabetes,Million US$ at exchange rate,5.5
+17022,Iceland,2015,4,A10-Drugs used in diabetes,Million of national currency units,731.1
+17023,Iceland,2015,4,A10-Drugs used in diabetes,"/capita, US$ exchange rate",16.8
+17024,Iceland,2015,4,A10-Drugs used in diabetes,"Million US$, purchasing power parity",5.1
+17025,Iceland,2015,4,C10-Lipid modifying agents,Million US$ at exchange rate,2.3
+17026,Iceland,2015,4,C10-Lipid modifying agents,Million of national currency units,308.6
+17027,Iceland,2015,4,Products not elsewhere classified,"/capita, US$ purchasing power parity",146.3
+17028,Iceland,2015,4,Products not elsewhere classified,% of total sales,28.1
+17029,Iceland,2015,4,C10-Lipid modifying agents,"Million US$, purchasing power parity",2.2
+17030,Iceland,2015,4,C10-Lipid modifying agents,% of total sales,1.3
+17031,Iceland,2015,4,C03-Diuretics,% of total sales,0.8
+17032,Iceland,2015,4,C10-Lipid modifying agents,"/capita, US$ purchasing power parity",6.6
+17033,Iceland,2015,4,C10-Lipid modifying agents,"/capita, US$ exchange rate",7.1
+17034,Iceland,2015,4,B-Blood and blood forming organs,"/capita, US$ purchasing power parity",33.6
+17035,Iceland,2015,4,N05B-Anxiolytics,Million of national currency units,268.0
+17036,Iceland,2015,4,N05B-Anxiolytics,Million US$ at exchange rate,2.0
+17037,Iceland,2015,4,N05B-Anxiolytics,"/capita, US$ exchange rate",6.1
+17038,Iceland,2015,4,N05B-Anxiolytics,"Million US$, purchasing power parity",1.9
+17039,Iceland,2015,4,M01A-Antiinflammatory and antirheumatic products non-steroids,Million of national currency units,430.1
+17040,Iceland,2015,4,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ exchange rate",9.9
+17041,Iceland,2015,4,R03-Drugs for obstructive airway diseases,% of total sales,4.4
+17042,Iceland,2015,4,M01A-Antiinflammatory and antirheumatic products non-steroids,Million US$ at exchange rate,3.3
+17043,Iceland,2015,4,M01A-Antiinflammatory and antirheumatic products non-steroids,"Million US$, purchasing power parity",3.0
+17044,Iceland,2015,4,Total pharmaceutical sales,"Million US$, purchasing power parity",171.9
+17045,Iceland,2015,4,Total pharmaceutical sales,"/capita, US$ exchange rate",559.2
+17046,Iceland,2015,4,Total pharmaceutical sales,Million of national currency units,24403.4
+17047,Iceland,2015,4,Total pharmaceutical sales,Million US$ at exchange rate,185.0
+17048,Iceland,2015,4,C09-Agents acting on the Renin-Angiotensin system,% of total sales,1.8
+17049,Iceland,2015,4,N05B-Anxiolytics,"/capita, US$ purchasing power parity",5.7
+17050,Iceland,2015,4,Total pharmaceutical sales,"/capita, US$ purchasing power parity",519.6
+17051,Iceland,2015,4,N05B-Anxiolytics,% of total sales,1.1
+17052,Iceland,2015,4,C-Cardiovascular system,Million US$ at exchange rate,13.0
+17053,Iceland,2015,4,C-Cardiovascular system,"Million US$, purchasing power parity",12.1
+17054,Iceland,2015,4,C09-Agents acting on the Renin-Angiotensin system,Million of national currency units,438.0
+17055,Iceland,2015,4,C-Cardiovascular system,Million of national currency units,1713.3
+17056,Iceland,2015,4,C-Cardiovascular system,% of total sales,7.0
+17057,Iceland,2015,4,B-Blood and blood forming organs,% of total sales,6.5
+17058,Iceland,2015,4,C-Cardiovascular system,"/capita, US$ exchange rate",39.3
+17059,Iceland,2015,4,C-Cardiovascular system,"/capita, US$ purchasing power parity",36.5
+17060,Iceland,2015,4,R03-Drugs for obstructive airway diseases,"Million US$, purchasing power parity",7.6
+17061,Iceland,2015,4,R03-Drugs for obstructive airway diseases,Million US$ at exchange rate,8.2
+17062,Iceland,2015,4,R03-Drugs for obstructive airway diseases,"/capita, US$ purchasing power parity",23.1
+17063,Iceland,2015,4,R03-Drugs for obstructive airway diseases,"/capita, US$ exchange rate",24.9
+17064,Iceland,2015,4,R03-Drugs for obstructive airway diseases,Million of national currency units,1085.7
+17065,Iceland,2015,4,C09-Agents acting on the Renin-Angiotensin system,"Million US$, purchasing power parity",3.1
+17066,Iceland,2015,4,C09-Agents acting on the Renin-Angiotensin system,Million US$ at exchange rate,3.3
+17067,Iceland,2015,4,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ purchasing power parity",9.3
+17068,Iceland,2015,4,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ exchange rate",10.0
+17069,Iceland,2015,4,C08-Calcium channel blockers,% of total sales,0.6
+17070,Iceland,2015,4,C08-Calcium channel blockers,"/capita, US$ purchasing power parity",3.3
+17071,Iceland,2015,4,M-Musculo-skeletal system,Million US$ at exchange rate,4.9
+17072,Iceland,2015,4,M-Musculo-skeletal system,Million of national currency units,645.8
+17073,Iceland,2015,4,C08-Calcium channel blockers,Million US$ at exchange rate,1.2
+17074,Iceland,2015,4,C08-Calcium channel blockers,Million of national currency units,156.8
+17075,Iceland,2015,4,C08-Calcium channel blockers,"/capita, US$ exchange rate",3.6
+17076,Iceland,2015,4,C08-Calcium channel blockers,"Million US$, purchasing power parity",1.1
+17077,Iceland,2015,4,R-Respiratory system,"Million US$, purchasing power parity",10.2
+17078,Iceland,2015,4,R-Respiratory system,Million US$ at exchange rate,11.0
+17079,Iceland,2015,4,R-Respiratory system,"/capita, US$ purchasing power parity",30.8
+17080,Iceland,2015,4,R-Respiratory system,"/capita, US$ exchange rate",33.1
+17081,Iceland,2015,4,R-Respiratory system,Million of national currency units,1444.8
+17082,Iceland,2015,4,M-Musculo-skeletal system,"/capita, US$ exchange rate",14.8
+17083,Iceland,2015,4,M-Musculo-skeletal system,"Million US$, purchasing power parity",4.5
+17084,Iceland,2015,4,M-Musculo-skeletal system,% of total sales,2.6
+17085,Iceland,2015,4,M-Musculo-skeletal system,"/capita, US$ purchasing power parity",13.7
+17086,Iceland,2015,4,N02-Analgesics,"Million US$, purchasing power parity",5.9
+17087,Iceland,2015,4,N02-Analgesics,Million US$ at exchange rate,6.4
+17088,Iceland,2015,4,N02-Analgesics,"/capita, US$ exchange rate",19.3
+17089,Iceland,2015,4,"C01B-Antiarrhythmics, Class I and III",% of total sales,0.3
+17090,Iceland,2015,4,G-Genito urinary system and sex hormones,"Million US$, purchasing power parity",9.3
+17091,Iceland,2015,4,G-Genito urinary system and sex hormones,"/capita, US$ exchange rate",30.1
+17092,Iceland,2015,4,N02-Analgesics,Million of national currency units,841.5
+17093,Iceland,2015,4,G-Genito urinary system and sex hormones,Million of national currency units,1315.4
+17094,Iceland,2015,4,G-Genito urinary system and sex hormones,Million US$ at exchange rate,10.0
+17095,Iceland,2015,4,"C01B-Antiarrhythmics, Class I and III","/capita, US$ exchange rate",1.6
+17096,Iceland,2015,4,N02-Analgesics,% of total sales,3.4
+17097,Iceland,2015,4,"C01B-Antiarrhythmics, Class I and III","Million US$, purchasing power parity",0.5
+17098,Iceland,2015,4,"C01B-Antiarrhythmics, Class I and III",Million of national currency units,69.1
+17099,Iceland,2015,4,"C01B-Antiarrhythmics, Class I and III",Million US$ at exchange rate,0.5
+17100,Iceland,2015,4,A02A-Antacids,"/capita, US$ purchasing power parity",0.0
+17101,Iceland,2015,4,"C01B-Antiarrhythmics, Class I and III","/capita, US$ purchasing power parity",1.5
+17102,Iceland,2015,4,N02-Analgesics,"/capita, US$ purchasing power parity",17.9
+17103,Iceland,2015,4,A02A-Antacids,% of total sales,0.0
+17104,Iceland,2015,4,C01A-Cardiac glycosides,Million US$ at exchange rate,0.1
+17105,Iceland,2015,4,C01A-Cardiac glycosides,Million of national currency units,11.7
+17106,Iceland,2015,4,J-Antiinfectives for systemic use,Million of national currency units,2857.9
+17107,Iceland,2015,4,C01A-Cardiac glycosides,"/capita, US$ purchasing power parity",0.2
+17108,Iceland,2015,4,C01A-Cardiac glycosides,"Million US$, purchasing power parity",0.1
+17109,Iceland,2015,4,C01A-Cardiac glycosides,"/capita, US$ exchange rate",0.3
+17110,Iceland,2015,4,J-Antiinfectives for systemic use,"/capita, US$ purchasing power parity",60.8
+17111,Iceland,2015,4,J-Antiinfectives for systemic use,% of total sales,11.7
+17112,Iceland,2015,4,J-Antiinfectives for systemic use,"/capita, US$ exchange rate",65.5
+17113,Iceland,2015,4,J-Antiinfectives for systemic use,Million US$ at exchange rate,21.7
+17114,Iceland,2015,4,J-Antiinfectives for systemic use,"Million US$, purchasing power parity",20.1
+17115,Iceland,2015,4,C01A-Cardiac glycosides,% of total sales,0.0
+17116,Iceland,2015,4,R-Respiratory system,% of total sales,5.9
+17117,Iceland,2015,4,C03-Diuretics,"Million US$, purchasing power parity",1.3
+17118,Iceland,2015,4,C03-Diuretics,Million US$ at exchange rate,1.4
+17119,Iceland,2015,4,C03-Diuretics,Million of national currency units,186.4
+17120,Iceland,2014,5,N05C-Hypnotics and sedatives,Million of national currency units,451.9
+17121,Iceland,2014,5,G-Genito urinary system and sex hormones,"/capita, US$ purchasing power parity",29.6
+17122,Iceland,2014,5,G-Genito urinary system and sex hormones,% of total sales,5.7
+17123,Iceland,2014,5,N05C-Hypnotics and sedatives,"/capita, US$ exchange rate",11.8
+17124,Iceland,2014,5,N-Nervous system,Million US$ at exchange rate,45.5
+17125,Iceland,2014,5,N-Nervous system,Million of national currency units,5314.4
+17126,Iceland,2014,5,N-Nervous system,"Million US$, purchasing power parity",38.4
+17127,Iceland,2014,5,N05C-Hypnotics and sedatives,"Million US$, purchasing power parity",3.3
+17128,Iceland,2014,5,N05C-Hypnotics and sedatives,Million US$ at exchange rate,3.9
+17129,Iceland,2014,5,N05C-Hypnotics and sedatives,"/capita, US$ purchasing power parity",10.0
+17130,Iceland,2014,5,N05C-Hypnotics and sedatives,% of total sales,1.9
+17131,Iceland,2014,5,C02-Antihypertensives,"/capita, US$ purchasing power parity",1.0
+17132,Iceland,2014,5,C02-Antihypertensives,% of total sales,0.2
+17133,Iceland,2014,5,C07-Beta blocking agents,"/capita, US$ exchange rate",8.9
+17134,Iceland,2014,5,C07-Beta blocking agents,% of total sales,1.4
+17135,Iceland,2014,5,C07-Beta blocking agents,"/capita, US$ purchasing power parity",7.5
+17136,Iceland,2014,5,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"Million US$, purchasing power parity",4.1
+17137,Iceland,2014,5,J01-Antibacterials for systemic use,Million US$ at exchange rate,8.5
+17138,Iceland,2014,5,J01-Antibacterials for systemic use,"/capita, US$ exchange rate",26.1
+17139,Iceland,2014,5,J01-Antibacterials for systemic use,"Million US$, purchasing power parity",7.2
+17140,Iceland,2014,5,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million US$ at exchange rate,4.9
+17141,Iceland,2014,5,J01-Antibacterials for systemic use,Million of national currency units,997.1
+17142,Iceland,2014,5,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million of national currency units,569.9
+17143,Iceland,2014,5,G03-Sex hormones and modulators of the genital system,% of total sales,3.2
+17144,Iceland,2014,5,C02-Antihypertensives,"/capita, US$ exchange rate",1.2
+17145,Iceland,2014,5,G03-Sex hormones and modulators of the genital system,"/capita, US$ purchasing power parity",16.6
+17146,Iceland,2014,5,C02-Antihypertensives,Million US$ at exchange rate,0.4
+17147,Iceland,2014,5,C02-Antihypertensives,Million of national currency units,45.3
+17148,Iceland,2014,5,C02-Antihypertensives,"Million US$, purchasing power parity",0.3
+17149,Iceland,2014,5,C07-Beta blocking agents,Million of national currency units,342.1
+17150,Iceland,2014,5,C07-Beta blocking agents,"Million US$, purchasing power parity",2.5
+17151,Iceland,2014,5,C07-Beta blocking agents,Million US$ at exchange rate,2.9
+17152,Iceland,2014,5,G03-Sex hormones and modulators of the genital system,Million of national currency units,754.3
+17153,Iceland,2014,5,G03-Sex hormones and modulators of the genital system,"Million US$, purchasing power parity",5.4
+17154,Iceland,2014,5,G03-Sex hormones and modulators of the genital system,"/capita, US$ exchange rate",19.7
+17155,Iceland,2014,5,G03-Sex hormones and modulators of the genital system,Million US$ at exchange rate,6.5
+17156,Iceland,2014,5,A-Alimentary tract and metabolism,"/capita, US$ purchasing power parity",41.8
+17157,Iceland,2014,5,A-Alimentary tract and metabolism,"/capita, US$ exchange rate",49.6
+17158,Iceland,2014,5,A-Alimentary tract and metabolism,% of total sales,8.0
+17159,Iceland,2014,5,A02A-Antacids,Million US$ at exchange rate,0.0
+17160,Iceland,2014,5,A02A-Antacids,"Million US$, purchasing power parity",0.0
+17161,Iceland,2014,5,A-Alimentary tract and metabolism,"Million US$, purchasing power parity",13.7
+17162,Iceland,2014,5,N-Nervous system,% of total sales,22.4
+17163,Iceland,2014,5,N-Nervous system,"/capita, US$ exchange rate",139.0
+17164,Iceland,2014,5,N-Nervous system,"/capita, US$ purchasing power parity",117.2
+17165,Iceland,2014,5,A-Alimentary tract and metabolism,Million US$ at exchange rate,16.2
+17166,Iceland,2014,5,A02A-Antacids,"/capita, US$ exchange rate",0.0
+17167,Iceland,2014,5,A-Alimentary tract and metabolism,Million of national currency units,1897.2
+17168,Iceland,2014,5,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ purchasing power parity",12.6
+17169,Iceland,2014,5,N06A-Antidepressants,Million of national currency units,730.7
+17170,Iceland,2014,5,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),% of total sales,2.4
+17171,Iceland,2014,5,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ exchange rate",14.9
+17172,Iceland,2014,5,J01-Antibacterials for systemic use,"/capita, US$ purchasing power parity",22.0
+17173,Iceland,2014,5,J01-Antibacterials for systemic use,% of total sales,4.2
+17174,Iceland,2014,5,N06A-Antidepressants,"/capita, US$ purchasing power parity",16.1
+17175,Iceland,2014,5,A02A-Antacids,Million of national currency units,0.0
+17176,Iceland,2014,5,N06A-Antidepressants,% of total sales,3.1
+17177,Iceland,2014,5,N06A-Antidepressants,Million US$ at exchange rate,6.3
+17178,Iceland,2014,5,N06A-Antidepressants,"/capita, US$ exchange rate",19.1
+17179,Iceland,2014,5,N06A-Antidepressants,"Million US$, purchasing power parity",5.3
+17180,Iceland,2014,5,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million US$ at exchange rate,5.6
+17181,Iceland,2014,5,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million of national currency units,656.6
+17182,Iceland,2014,5,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ exchange rate",17.2
+17183,Iceland,2014,5,"H-Systemic hormonal preparations, excluding sex hormones and insulins","Million US$, purchasing power parity",4.7
+17184,Iceland,2014,5,Products not elsewhere classified,"Million US$, purchasing power parity",45.4
+17185,Iceland,2014,5,Products not elsewhere classified,"/capita, US$ exchange rate",164.5
+17186,Iceland,2014,5,Products not elsewhere classified,Million of national currency units,6288.7
+17187,Iceland,2014,5,Products not elsewhere classified,Million US$ at exchange rate,53.9
+17188,Iceland,2014,5,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ purchasing power parity",14.5
+17189,Iceland,2014,5,M01A-Antiinflammatory and antirheumatic products non-steroids,% of total sales,1.9
+17190,Iceland,2014,5,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ purchasing power parity",9.8
+17191,Iceland,2014,5,B-Blood and blood forming organs,"/capita, US$ exchange rate",39.9
+17192,Iceland,2014,5,B-Blood and blood forming organs,Million of national currency units,1526.6
+17193,Iceland,2014,5,"H-Systemic hormonal preparations, excluding sex hormones and insulins",% of total sales,2.8
+17194,Iceland,2014,5,B-Blood and blood forming organs,"Million US$, purchasing power parity",11.0
+17195,Iceland,2014,5,B-Blood and blood forming organs,Million US$ at exchange rate,13.1
+17196,Iceland,2014,5,B-Blood and blood forming organs,"/capita, US$ purchasing power parity",33.7
+17197,Iceland,2014,5,A10-Drugs used in diabetes,% of total sales,3.1
+17198,Iceland,2014,5,C03-Diuretics,"/capita, US$ purchasing power parity",4.6
+17199,Iceland,2014,5,A10-Drugs used in diabetes,"/capita, US$ purchasing power parity",16.0
+17200,Iceland,2014,5,C03-Diuretics,"/capita, US$ exchange rate",5.4
+17201,Iceland,2014,5,A10-Drugs used in diabetes,Million US$ at exchange rate,6.2
+17202,Iceland,2014,5,A10-Drugs used in diabetes,Million of national currency units,726.7
+17203,Iceland,2014,5,A10-Drugs used in diabetes,"/capita, US$ exchange rate",19.0
+17204,Iceland,2014,5,A10-Drugs used in diabetes,"Million US$, purchasing power parity",5.2
+17205,Iceland,2014,5,C03-Diuretics,% of total sales,0.9
+17206,Iceland,2014,5,C10-Lipid modifying agents,Million US$ at exchange rate,2.9
+17207,Iceland,2014,5,C10-Lipid modifying agents,Million of national currency units,333.6
+17208,Iceland,2014,5,Products not elsewhere classified,"/capita, US$ purchasing power parity",138.6
+17209,Iceland,2014,5,Products not elsewhere classified,% of total sales,26.5
+17210,Iceland,2014,5,C10-Lipid modifying agents,"Million US$, purchasing power parity",2.4
+17211,Iceland,2014,5,C10-Lipid modifying agents,% of total sales,1.4
+17212,Iceland,2014,5,C10-Lipid modifying agents,"/capita, US$ exchange rate",8.7
+17213,Iceland,2014,5,C10-Lipid modifying agents,"/capita, US$ purchasing power parity",7.4
+17214,Iceland,2014,5,N05B-Anxiolytics,Million US$ at exchange rate,2.3
+17215,Iceland,2014,5,N05B-Anxiolytics,Million of national currency units,263.5
+17216,Iceland,2014,5,N05B-Anxiolytics,"/capita, US$ exchange rate",6.9
+17217,Iceland,2014,5,M01A-Antiinflammatory and antirheumatic products non-steroids,Million of national currency units,446.0
+17218,Iceland,2014,5,N05B-Anxiolytics,"Million US$, purchasing power parity",1.9
+17219,Iceland,2014,5,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ exchange rate",11.7
+17220,Iceland,2014,5,R03-Drugs for obstructive airway diseases,% of total sales,4.9
+17221,Iceland,2014,5,M01A-Antiinflammatory and antirheumatic products non-steroids,Million US$ at exchange rate,3.8
+17222,Iceland,2014,5,M01A-Antiinflammatory and antirheumatic products non-steroids,"Million US$, purchasing power parity",3.2
+17223,Iceland,2014,5,Total pharmaceutical sales,"Million US$, purchasing power parity",171.0
+17224,Iceland,2014,5,Total pharmaceutical sales,"/capita, US$ exchange rate",619.7
+17225,Iceland,2014,5,Total pharmaceutical sales,Million of national currency units,23689.8
+17226,Iceland,2014,5,Total pharmaceutical sales,Million US$ at exchange rate,202.9
+17227,Iceland,2014,5,C09-Agents acting on the Renin-Angiotensin system,% of total sales,1.9
+17228,Iceland,2014,5,N05B-Anxiolytics,"/capita, US$ purchasing power parity",5.8
+17229,Iceland,2014,5,Total pharmaceutical sales,"/capita, US$ purchasing power parity",522.3
+17230,Iceland,2014,5,N05B-Anxiolytics,% of total sales,1.1
+17231,Iceland,2014,5,C-Cardiovascular system,Million US$ at exchange rate,15.3
+17232,Iceland,2014,5,C-Cardiovascular system,"Million US$, purchasing power parity",12.9
+17233,Iceland,2014,5,C09-Agents acting on the Renin-Angiotensin system,Million of national currency units,439.8
+17234,Iceland,2014,5,C-Cardiovascular system,Million of national currency units,1783.8
+17235,Iceland,2014,5,B-Blood and blood forming organs,% of total sales,6.4
+17236,Iceland,2014,5,C-Cardiovascular system,% of total sales,7.5
+17237,Iceland,2014,5,C-Cardiovascular system,"/capita, US$ exchange rate",46.7
+17238,Iceland,2014,5,C-Cardiovascular system,"/capita, US$ purchasing power parity",39.3
+17239,Iceland,2014,5,R03-Drugs for obstructive airway diseases,"Million US$, purchasing power parity",8.4
+17240,Iceland,2014,5,R03-Drugs for obstructive airway diseases,Million US$ at exchange rate,10.0
+17241,Iceland,2014,5,R03-Drugs for obstructive airway diseases,"/capita, US$ purchasing power parity",25.7
+17242,Iceland,2014,5,R03-Drugs for obstructive airway diseases,"/capita, US$ exchange rate",30.5
+17243,Iceland,2014,5,C09-Agents acting on the Renin-Angiotensin system,"Million US$, purchasing power parity",3.2
+17244,Iceland,2014,5,C09-Agents acting on the Renin-Angiotensin system,Million US$ at exchange rate,3.8
+17245,Iceland,2014,5,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ exchange rate",11.5
+17246,Iceland,2014,5,R03-Drugs for obstructive airway diseases,Million of national currency units,1164.2
+17247,Iceland,2014,5,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ purchasing power parity",9.7
+17248,Iceland,2014,5,C08-Calcium channel blockers,% of total sales,0.8
+17249,Iceland,2014,5,C08-Calcium channel blockers,"/capita, US$ purchasing power parity",4.1
+17250,Iceland,2014,5,M-Musculo-skeletal system,Million US$ at exchange rate,6.0
+17251,Iceland,2014,5,C01A-Cardiac glycosides,Million of national currency units,11.6
+17252,Iceland,2014,5,M-Musculo-skeletal system,Million of national currency units,699.9
+17253,Iceland,2014,5,C08-Calcium channel blockers,Million US$ at exchange rate,1.6
+17254,Iceland,2014,5,C08-Calcium channel blockers,Million of national currency units,185.1
+17255,Iceland,2014,5,C08-Calcium channel blockers,"/capita, US$ exchange rate",4.8
+17256,Iceland,2014,5,C08-Calcium channel blockers,"Million US$, purchasing power parity",1.3
+17257,Iceland,2014,5,R-Respiratory system,"Million US$, purchasing power parity",10.9
+17258,Iceland,2014,5,R-Respiratory system,Million US$ at exchange rate,13.0
+17259,Iceland,2014,5,R-Respiratory system,"/capita, US$ purchasing power parity",33.4
+17260,Iceland,2014,5,R-Respiratory system,"/capita, US$ exchange rate",39.7
+17261,Iceland,2014,5,R-Respiratory system,Million of national currency units,1516.1
+17262,Iceland,2014,5,M-Musculo-skeletal system,"/capita, US$ exchange rate",18.3
+17263,Iceland,2014,5,M-Musculo-skeletal system,"Million US$, purchasing power parity",5.1
+17264,Iceland,2014,5,M-Musculo-skeletal system,"/capita, US$ purchasing power parity",15.4
+17265,Iceland,2014,5,M-Musculo-skeletal system,% of total sales,3.0
+17266,Iceland,2014,5,"C01B-Antiarrhythmics, Class I and III",Million of national currency units,73.0
+17267,Iceland,2014,5,N02-Analgesics,"Million US$, purchasing power parity",6.1
+17268,Iceland,2014,5,N02-Analgesics,Million US$ at exchange rate,7.2
+17269,Iceland,2014,5,N02-Analgesics,"/capita, US$ exchange rate",22.1
+17270,Iceland,2014,5,N02-Analgesics,Million of national currency units,843.8
+17271,Iceland,2014,5,G-Genito urinary system and sex hormones,"Million US$, purchasing power parity",9.7
+17272,Iceland,2014,5,G-Genito urinary system and sex hormones,"/capita, US$ exchange rate",35.1
+17273,Iceland,2014,5,G-Genito urinary system and sex hormones,Million of national currency units,1343.4
+17274,Iceland,2014,5,G-Genito urinary system and sex hormones,Million US$ at exchange rate,11.5
+17275,Iceland,2014,5,"C01B-Antiarrhythmics, Class I and III",% of total sales,0.3
+17276,Iceland,2014,5,"C01B-Antiarrhythmics, Class I and III","/capita, US$ exchange rate",1.9
+17277,Iceland,2014,5,N02-Analgesics,% of total sales,3.6
+17278,Iceland,2014,5,"C01B-Antiarrhythmics, Class I and III","Million US$, purchasing power parity",0.5
+17279,Iceland,2014,5,"C01B-Antiarrhythmics, Class I and III",Million US$ at exchange rate,0.6
+17280,Iceland,2014,5,A02A-Antacids,"/capita, US$ purchasing power parity",0.0
+17281,Iceland,2014,5,"C01B-Antiarrhythmics, Class I and III","/capita, US$ purchasing power parity",1.6
+17282,Iceland,2014,5,N02-Analgesics,"/capita, US$ purchasing power parity",18.6
+17283,Iceland,2014,5,A02A-Antacids,% of total sales,0.0
+17284,Iceland,2014,5,C01A-Cardiac glycosides,Million US$ at exchange rate,0.1
+17285,Iceland,2014,5,C01A-Cardiac glycosides,"/capita, US$ purchasing power parity",0.3
+17286,Iceland,2014,5,C01A-Cardiac glycosides,"/capita, US$ exchange rate",0.3
+17287,Iceland,2014,5,C01A-Cardiac glycosides,"Million US$, purchasing power parity",0.1
+17288,Iceland,2014,5,J-Antiinfectives for systemic use,"/capita, US$ purchasing power parity",58.7
+17289,Iceland,2014,5,J-Antiinfectives for systemic use,% of total sales,11.2
+17290,Iceland,2014,5,J-Antiinfectives for systemic use,Million US$ at exchange rate,22.8
+17291,Iceland,2014,5,J-Antiinfectives for systemic use,"Million US$, purchasing power parity",19.2
+17292,Iceland,2014,5,J-Antiinfectives for systemic use,"/capita, US$ exchange rate",69.7
+17293,Iceland,2014,5,J-Antiinfectives for systemic use,Million of national currency units,2663.1
+17294,Iceland,2014,5,C01A-Cardiac glycosides,% of total sales,0.0
+17295,Iceland,2014,5,R-Respiratory system,% of total sales,6.4
+17296,Iceland,2014,5,C03-Diuretics,"Million US$, purchasing power parity",1.5
+17297,Iceland,2014,5,C03-Diuretics,Million US$ at exchange rate,1.8
+17298,Iceland,2014,5,C03-Diuretics,Million of national currency units,206.8
+17299,Iceland,2013,4,G-Genito urinary system and sex hormones,"/capita, US$ purchasing power parity",33.8
+17300,Iceland,2013,4,N05C-Hypnotics and sedatives,Million of national currency units,449.1
+17301,Iceland,2013,4,G-Genito urinary system and sex hormones,% of total sales,5.8
+17302,Iceland,2013,4,N-Nervous system,Million US$ at exchange rate,52.6
+17303,Iceland,2013,4,N-Nervous system,"Million US$, purchasing power parity",46.9
+17304,Iceland,2013,4,N05C-Hypnotics and sedatives,"/capita, US$ exchange rate",11.4
+17305,Iceland,2013,4,N05C-Hypnotics and sedatives,"/capita, US$ purchasing power parity",10.1
+17306,Iceland,2013,4,N-Nervous system,Million of national currency units,6429.3
+17307,Iceland,2013,4,N05C-Hypnotics and sedatives,"Million US$, purchasing power parity",3.3
+17308,Iceland,2013,4,N05C-Hypnotics and sedatives,Million US$ at exchange rate,3.7
+17309,Iceland,2013,4,N05C-Hypnotics and sedatives,% of total sales,1.7
+17310,Iceland,2013,4,N-Nervous system,"/capita, US$ exchange rate",162.5
+17311,Iceland,2013,4,C02-Antihypertensives,"/capita, US$ purchasing power parity",1.1
+17312,Iceland,2013,4,C02-Antihypertensives,% of total sales,0.2
+17313,Iceland,2013,4,C07-Beta blocking agents,"/capita, US$ exchange rate",8.9
+17314,Iceland,2013,4,C07-Beta blocking agents,% of total sales,1.4
+17315,Iceland,2013,4,C07-Beta blocking agents,"/capita, US$ purchasing power parity",8.0
+17316,Iceland,2013,4,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"Million US$, purchasing power parity",4.5
+17317,Iceland,2013,4,J01-Antibacterials for systemic use,Million US$ at exchange rate,8.6
+17318,Iceland,2013,4,J01-Antibacterials for systemic use,"Million US$, purchasing power parity",7.6
+17319,Iceland,2013,4,J01-Antibacterials for systemic use,"/capita, US$ exchange rate",26.5
+17320,Iceland,2013,4,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million US$ at exchange rate,5.1
+17321,Iceland,2013,4,J01-Antibacterials for systemic use,Million of national currency units,1047.8
+17322,Iceland,2013,4,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million of national currency units,621.0
+17323,Iceland,2013,4,G03-Sex hormones and modulators of the genital system,% of total sales,3.3
+17324,Iceland,2013,4,G03-Sex hormones and modulators of the genital system,"/capita, US$ purchasing power parity",19.2
+17325,Iceland,2013,4,C02-Antihypertensives,"/capita, US$ exchange rate",1.3
+17326,Iceland,2013,4,C02-Antihypertensives,Million US$ at exchange rate,0.4
+17327,Iceland,2013,4,C02-Antihypertensives,Million of national currency units,50.8
+17328,Iceland,2013,4,C02-Antihypertensives,"Million US$, purchasing power parity",0.4
+17329,Iceland,2013,4,C07-Beta blocking agents,Million of national currency units,353.3
+17330,Iceland,2013,4,G03-Sex hormones and modulators of the genital system,Million of national currency units,853.4
+17331,Iceland,2013,4,C07-Beta blocking agents,"Million US$, purchasing power parity",2.6
+17332,Iceland,2013,4,C07-Beta blocking agents,Million US$ at exchange rate,2.9
+17333,Iceland,2013,4,G03-Sex hormones and modulators of the genital system,"Million US$, purchasing power parity",6.2
+17334,Iceland,2013,4,G03-Sex hormones and modulators of the genital system,"/capita, US$ exchange rate",21.6
+17335,Iceland,2013,4,G03-Sex hormones and modulators of the genital system,Million US$ at exchange rate,7.0
+17336,Iceland,2013,4,A-Alimentary tract and metabolism,"/capita, US$ purchasing power parity",48.1
+17337,Iceland,2013,4,A-Alimentary tract and metabolism,"/capita, US$ exchange rate",53.9
+17338,Iceland,2013,4,A-Alimentary tract and metabolism,% of total sales,8.2
+17339,Iceland,2013,4,A02A-Antacids,Million US$ at exchange rate,0.0
+17340,Iceland,2013,4,A02A-Antacids,"Million US$, purchasing power parity",0.0
+17341,Iceland,2013,4,N-Nervous system,% of total sales,24.7
+17342,Iceland,2013,4,N-Nervous system,"/capita, US$ purchasing power parity",144.9
+17343,Iceland,2013,4,A-Alimentary tract and metabolism,"Million US$, purchasing power parity",15.6
+17344,Iceland,2013,4,A-Alimentary tract and metabolism,Million of national currency units,2134.0
+17345,Iceland,2013,4,A-Alimentary tract and metabolism,Million US$ at exchange rate,17.5
+17346,Iceland,2013,4,A02A-Antacids,"/capita, US$ exchange rate",0.0
+17347,Iceland,2013,4,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ purchasing power parity",14.0
+17348,Iceland,2013,4,N06A-Antidepressants,Million of national currency units,767.5
+17349,Iceland,2013,4,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),% of total sales,2.4
+17350,Iceland,2013,4,J01-Antibacterials for systemic use,"/capita, US$ purchasing power parity",23.6
+17351,Iceland,2013,4,J01-Antibacterials for systemic use,% of total sales,4.0
+17352,Iceland,2013,4,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ exchange rate",15.7
+17353,Iceland,2013,4,N06A-Antidepressants,"/capita, US$ purchasing power parity",17.3
+17354,Iceland,2013,4,N06A-Antidepressants,% of total sales,2.9
+17355,Iceland,2013,4,A02A-Antacids,Million of national currency units,0.0
+17356,Iceland,2013,4,N06A-Antidepressants,Million US$ at exchange rate,6.3
+17357,Iceland,2013,4,N06A-Antidepressants,"/capita, US$ exchange rate",19.4
+17358,Iceland,2013,4,N06A-Antidepressants,"Million US$, purchasing power parity",5.6
+17359,Iceland,2013,4,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million US$ at exchange rate,5.4
+17360,Iceland,2013,4,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million of national currency units,665.0
+17361,Iceland,2013,4,"H-Systemic hormonal preparations, excluding sex hormones and insulins","Million US$, purchasing power parity",4.9
+17362,Iceland,2013,4,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ exchange rate",16.8
+17363,Iceland,2013,4,Products not elsewhere classified,"Million US$, purchasing power parity",47.6
+17364,Iceland,2013,4,Products not elsewhere classified,"/capita, US$ exchange rate",164.9
+17365,Iceland,2013,4,Products not elsewhere classified,Million of national currency units,6524.4
+17366,Iceland,2013,4,Products not elsewhere classified,Million US$ at exchange rate,53.4
+17367,Iceland,2013,4,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ purchasing power parity",15.0
+17368,Iceland,2013,4,M01A-Antiinflammatory and antirheumatic products non-steroids,% of total sales,2.5
+17369,Iceland,2013,4,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ purchasing power parity",14.4
+17370,Iceland,2013,4,B-Blood and blood forming organs,"/capita, US$ purchasing power parity",35.1
+17371,Iceland,2013,4,B-Blood and blood forming organs,"/capita, US$ exchange rate",39.4
+17372,Iceland,2013,4,B-Blood and blood forming organs,Million of national currency units,1557.0
+17373,Iceland,2013,4,"H-Systemic hormonal preparations, excluding sex hormones and insulins",% of total sales,2.6
+17374,Iceland,2013,4,B-Blood and blood forming organs,"Million US$, purchasing power parity",11.4
+17375,Iceland,2013,4,B-Blood and blood forming organs,Million US$ at exchange rate,12.7
+17376,Iceland,2013,4,Products not elsewhere classified,"/capita, US$ purchasing power parity",147.1
+17377,Iceland,2013,4,A10-Drugs used in diabetes,% of total sales,2.8
+17378,Iceland,2013,4,C03-Diuretics,"/capita, US$ purchasing power parity",5.1
+17379,Iceland,2013,4,C03-Diuretics,"/capita, US$ exchange rate",5.7
+17380,Iceland,2013,4,A10-Drugs used in diabetes,"/capita, US$ purchasing power parity",16.6
+17381,Iceland,2013,4,A10-Drugs used in diabetes,Million US$ at exchange rate,6.0
+17382,Iceland,2013,4,A10-Drugs used in diabetes,Million of national currency units,738.0
+17383,Iceland,2013,4,A10-Drugs used in diabetes,"/capita, US$ exchange rate",18.7
+17384,Iceland,2013,4,A10-Drugs used in diabetes,"Million US$, purchasing power parity",5.4
+17385,Iceland,2013,4,C03-Diuretics,% of total sales,0.9
+17386,Iceland,2013,4,C10-Lipid modifying agents,Million US$ at exchange rate,2.5
+17387,Iceland,2013,4,C10-Lipid modifying agents,Million of national currency units,308.7
+17388,Iceland,2013,4,C10-Lipid modifying agents,"Million US$, purchasing power parity",2.3
+17389,Iceland,2013,4,Products not elsewhere classified,% of total sales,25.1
+17390,Iceland,2013,4,C10-Lipid modifying agents,% of total sales,1.2
+17391,Iceland,2013,4,C10-Lipid modifying agents,"/capita, US$ exchange rate",7.8
+17392,Iceland,2013,4,C10-Lipid modifying agents,"/capita, US$ purchasing power parity",7.0
+17393,Iceland,2013,4,N05B-Anxiolytics,Million US$ at exchange rate,2.2
+17394,Iceland,2013,4,N05B-Anxiolytics,Million of national currency units,270.4
+17395,Iceland,2013,4,M01A-Antiinflammatory and antirheumatic products non-steroids,Million of national currency units,638.8
+17396,Iceland,2013,4,N05B-Anxiolytics,"/capita, US$ exchange rate",6.8
+17397,Iceland,2013,4,N05B-Anxiolytics,"Million US$, purchasing power parity",2.0
+17398,Iceland,2013,4,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ exchange rate",16.1
+17399,Iceland,2013,4,R03-Drugs for obstructive airway diseases,% of total sales,4.7
+17400,Iceland,2013,4,M01A-Antiinflammatory and antirheumatic products non-steroids,Million US$ at exchange rate,5.2
+17401,Iceland,2013,4,M01A-Antiinflammatory and antirheumatic products non-steroids,"Million US$, purchasing power parity",4.7
+17402,Iceland,2013,4,Total pharmaceutical sales,"Million US$, purchasing power parity",189.9
+17403,Iceland,2013,4,Total pharmaceutical sales,"/capita, US$ exchange rate",657.9
+17404,Iceland,2013,4,Total pharmaceutical sales,Million of national currency units,26023.1
+17405,Iceland,2013,4,Total pharmaceutical sales,Million US$ at exchange rate,213.0
+17406,Iceland,2013,4,C09-Agents acting on the Renin-Angiotensin system,% of total sales,1.6
+17407,Iceland,2013,4,N05B-Anxiolytics,"/capita, US$ purchasing power parity",6.1
+17408,Iceland,2013,4,Total pharmaceutical sales,"/capita, US$ purchasing power parity",586.6
+17409,Iceland,2013,4,N05B-Anxiolytics,% of total sales,1.0
+17410,Iceland,2013,4,C-Cardiovascular system,Million US$ at exchange rate,14.8
+17411,Iceland,2013,4,C-Cardiovascular system,"Million US$, purchasing power parity",13.2
+17412,Iceland,2013,4,C09-Agents acting on the Renin-Angiotensin system,Million of national currency units,417.9
+17413,Iceland,2013,4,C-Cardiovascular system,Million of national currency units,1814.0
+17414,Iceland,2013,4,C-Cardiovascular system,"/capita, US$ exchange rate",45.9
+17415,Iceland,2013,4,B-Blood and blood forming organs,% of total sales,6.0
+17416,Iceland,2013,4,C-Cardiovascular system,% of total sales,7.0
+17417,Iceland,2013,4,C-Cardiovascular system,"/capita, US$ purchasing power parity",40.9
+17418,Iceland,2013,4,R03-Drugs for obstructive airway diseases,"Million US$, purchasing power parity",8.9
+17419,Iceland,2013,4,R03-Drugs for obstructive airway diseases,Million US$ at exchange rate,9.9
+17420,Iceland,2013,4,R03-Drugs for obstructive airway diseases,"/capita, US$ purchasing power parity",27.4
+17421,Iceland,2013,4,R03-Drugs for obstructive airway diseases,"/capita, US$ exchange rate",30.7
+17422,Iceland,2013,4,C09-Agents acting on the Renin-Angiotensin system,"Million US$, purchasing power parity",3.0
+17423,Iceland,2013,4,C09-Agents acting on the Renin-Angiotensin system,Million US$ at exchange rate,3.4
+17424,Iceland,2013,4,R03-Drugs for obstructive airway diseases,Million of national currency units,1215.5
+17425,Iceland,2013,4,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ exchange rate",10.6
+17426,Iceland,2013,4,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ purchasing power parity",9.4
+17427,Iceland,2013,4,C08-Calcium channel blockers,% of total sales,0.8
+17428,Iceland,2013,4,C08-Calcium channel blockers,"/capita, US$ purchasing power parity",4.5
+17429,Iceland,2013,4,C01A-Cardiac glycosides,Million of national currency units,11.3
+17430,Iceland,2013,4,M-Musculo-skeletal system,Million US$ at exchange rate,7.7
+17431,Iceland,2013,4,M-Musculo-skeletal system,Million of national currency units,945.5
+17432,Iceland,2013,4,C08-Calcium channel blockers,Million US$ at exchange rate,1.6
+17433,Iceland,2013,4,C08-Calcium channel blockers,Million of national currency units,198.8
+17434,Iceland,2013,4,C08-Calcium channel blockers,"/capita, US$ exchange rate",5.0
+17435,Iceland,2013,4,C08-Calcium channel blockers,"Million US$, purchasing power parity",1.5
+17436,Iceland,2013,4,R-Respiratory system,"Million US$, purchasing power parity",13.4
+17437,Iceland,2013,4,R-Respiratory system,Million US$ at exchange rate,15.0
+17438,Iceland,2013,4,R-Respiratory system,"/capita, US$ purchasing power parity",41.4
+17439,Iceland,2013,4,R-Respiratory system,"/capita, US$ exchange rate",46.4
+17440,Iceland,2013,4,M-Musculo-skeletal system,"/capita, US$ exchange rate",23.9
+17441,Iceland,2013,4,M-Musculo-skeletal system,"Million US$, purchasing power parity",6.9
+17442,Iceland,2013,4,M-Musculo-skeletal system,"/capita, US$ purchasing power parity",21.3
+17443,Iceland,2013,4,R-Respiratory system,Million of national currency units,1836.6
+17444,Iceland,2013,4,M-Musculo-skeletal system,% of total sales,3.6
+17445,Iceland,2013,4,N02-Analgesics,"Million US$, purchasing power parity",7.3
+17446,Iceland,2013,4,N02-Analgesics,Million US$ at exchange rate,8.2
+17447,Iceland,2013,4,N02-Analgesics,"/capita, US$ exchange rate",25.3
+17448,Iceland,2013,4,G-Genito urinary system and sex hormones,"Million US$, purchasing power parity",10.9
+17449,Iceland,2013,4,G-Genito urinary system and sex hormones,"/capita, US$ exchange rate",37.9
+17450,Iceland,2013,4,N02-Analgesics,Million of national currency units,998.9
+17451,Iceland,2013,4,G-Genito urinary system and sex hormones,Million of national currency units,1498.7
+17452,Iceland,2013,4,G-Genito urinary system and sex hormones,Million US$ at exchange rate,12.3
+17453,Iceland,2013,4,"C01B-Antiarrhythmics, Class I and III",% of total sales,0.3
+17454,Iceland,2013,4,"C01B-Antiarrhythmics, Class I and III","/capita, US$ exchange rate",2.0
+17455,Iceland,2013,4,N02-Analgesics,% of total sales,3.8
+17456,Iceland,2013,4,"C01B-Antiarrhythmics, Class I and III","Million US$, purchasing power parity",0.6
+17457,Iceland,2013,4,"C01B-Antiarrhythmics, Class I and III",Million US$ at exchange rate,0.6
+17458,Iceland,2013,4,A02A-Antacids,"/capita, US$ purchasing power parity",0.0
+17459,Iceland,2013,4,"C01B-Antiarrhythmics, Class I and III","/capita, US$ purchasing power parity",1.8
+17460,Iceland,2013,4,N02-Analgesics,"/capita, US$ purchasing power parity",22.5
+17461,Iceland,2013,4,A02A-Antacids,% of total sales,0.0
+17462,Iceland,2013,4,"C01B-Antiarrhythmics, Class I and III",Million of national currency units,79.2
+17463,Iceland,2013,4,C01A-Cardiac glycosides,Million US$ at exchange rate,0.1
+17464,Iceland,2013,4,J-Antiinfectives for systemic use,Million of national currency units,2618.6
+17465,Iceland,2013,4,C01A-Cardiac glycosides,"Million US$, purchasing power parity",0.1
+17466,Iceland,2013,4,C01A-Cardiac glycosides,"/capita, US$ purchasing power parity",0.3
+17467,Iceland,2013,4,C01A-Cardiac glycosides,"/capita, US$ exchange rate",0.3
+17468,Iceland,2013,4,J-Antiinfectives for systemic use,"/capita, US$ purchasing power parity",59.0
+17469,Iceland,2013,4,J-Antiinfectives for systemic use,% of total sales,10.1
+17470,Iceland,2013,4,J-Antiinfectives for systemic use,Million US$ at exchange rate,21.4
+17471,Iceland,2013,4,J-Antiinfectives for systemic use,"/capita, US$ exchange rate",66.2
+17472,Iceland,2013,4,J-Antiinfectives for systemic use,"Million US$, purchasing power parity",19.1
+17473,Iceland,2013,4,R-Respiratory system,% of total sales,7.1
+17474,Iceland,2013,4,C01A-Cardiac glycosides,% of total sales,0.0
+17475,Iceland,2013,4,C03-Diuretics,Million US$ at exchange rate,1.8
+17476,Iceland,2013,4,C03-Diuretics,"Million US$, purchasing power parity",1.6
+17477,Iceland,2013,4,C03-Diuretics,Million of national currency units,225.0
+17478,Iceland,2012,4,G-Genito urinary system and sex hormones,"/capita, US$ purchasing power parity",33.6
+17479,Iceland,2012,4,N05C-Hypnotics and sedatives,Million of national currency units,463.9
+17480,Iceland,2012,4,G-Genito urinary system and sex hormones,% of total sales,6.1
+17481,Iceland,2012,4,N-Nervous system,Million US$ at exchange rate,45.3
+17482,Iceland,2012,4,N-Nervous system,"Million US$, purchasing power parity",41.4
+17483,Iceland,2012,4,N05C-Hypnotics and sedatives,"/capita, US$ exchange rate",11.6
+17484,Iceland,2012,4,N05C-Hypnotics and sedatives,"/capita, US$ purchasing power parity",10.6
+17485,Iceland,2012,4,N-Nervous system,Million of national currency units,5666.6
+17486,Iceland,2012,4,N05C-Hypnotics and sedatives,"Million US$, purchasing power parity",3.4
+17487,Iceland,2012,4,N05C-Hypnotics and sedatives,Million US$ at exchange rate,3.7
+17488,Iceland,2012,4,N05C-Hypnotics and sedatives,% of total sales,1.9
+17489,Iceland,2012,4,C02-Antihypertensives,"/capita, US$ purchasing power parity",1.3
+17490,Iceland,2012,4,C02-Antihypertensives,Million of national currency units,57.7
+17491,Iceland,2012,4,C02-Antihypertensives,% of total sales,0.2
+17492,Iceland,2012,4,C07-Beta blocking agents,"/capita, US$ exchange rate",8.6
+17493,Iceland,2012,4,C07-Beta blocking agents,"/capita, US$ purchasing power parity",7.9
+17494,Iceland,2012,4,C07-Beta blocking agents,% of total sales,1.4
+17495,Iceland,2012,4,J01-Antibacterials for systemic use,Million US$ at exchange rate,8.2
+17496,Iceland,2012,4,J01-Antibacterials for systemic use,"Million US$, purchasing power parity",7.5
+17497,Iceland,2012,4,J01-Antibacterials for systemic use,"/capita, US$ exchange rate",25.7
+17498,Iceland,2012,4,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million US$ at exchange rate,4.6
+17499,Iceland,2012,4,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"Million US$, purchasing power parity",4.2
+17500,Iceland,2012,4,J01-Antibacterials for systemic use,Million of national currency units,1031.1
+17501,Iceland,2012,4,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million of national currency units,581.0
+17502,Iceland,2012,4,G03-Sex hormones and modulators of the genital system,% of total sales,3.6
+17503,Iceland,2012,4,G03-Sex hormones and modulators of the genital system,"/capita, US$ purchasing power parity",19.7
+17504,Iceland,2012,4,C02-Antihypertensives,"/capita, US$ exchange rate",1.4
+17505,Iceland,2012,4,C02-Antihypertensives,Million US$ at exchange rate,0.5
+17506,Iceland,2012,4,C02-Antihypertensives,"Million US$, purchasing power parity",0.4
+17507,Iceland,2012,4,G03-Sex hormones and modulators of the genital system,Million of national currency units,865.6
+17508,Iceland,2012,4,C07-Beta blocking agents,Million of national currency units,345.8
+17509,Iceland,2012,4,C07-Beta blocking agents,"Million US$, purchasing power parity",2.5
+17510,Iceland,2012,4,C07-Beta blocking agents,Million US$ at exchange rate,2.8
+17511,Iceland,2012,4,G03-Sex hormones and modulators of the genital system,"Million US$, purchasing power parity",6.3
+17512,Iceland,2012,4,G03-Sex hormones and modulators of the genital system,"/capita, US$ exchange rate",21.6
+17513,Iceland,2012,4,G03-Sex hormones and modulators of the genital system,Million US$ at exchange rate,6.9
+17514,Iceland,2012,4,A-Alimentary tract and metabolism,"/capita, US$ purchasing power parity",38.7
+17515,Iceland,2012,4,A-Alimentary tract and metabolism,% of total sales,7.0
+17516,Iceland,2012,4,A-Alimentary tract and metabolism,"/capita, US$ exchange rate",42.4
+17517,Iceland,2012,4,A02A-Antacids,Million US$ at exchange rate,0.0
+17518,Iceland,2012,4,A02A-Antacids,"Million US$, purchasing power parity",0.0
+17519,Iceland,2012,4,A02A-Antacids,"/capita, US$ exchange rate",0.0
+17520,Iceland,2012,4,A-Alimentary tract and metabolism,"Million US$, purchasing power parity",12.4
+17521,Iceland,2012,4,N-Nervous system,% of total sales,23.3
+17522,Iceland,2012,4,N-Nervous system,"/capita, US$ purchasing power parity",129.0
+17523,Iceland,2012,4,A-Alimentary tract and metabolism,Million US$ at exchange rate,13.6
+17524,Iceland,2012,4,A-Alimentary tract and metabolism,Million of national currency units,1700.3
+17525,Iceland,2012,4,N-Nervous system,"/capita, US$ exchange rate",141.3
+17526,Iceland,2012,4,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ purchasing power parity",13.2
+17527,Iceland,2012,4,N06A-Antidepressants,Million of national currency units,842.3
+17528,Iceland,2012,4,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),% of total sales,2.4
+17529,Iceland,2012,4,J01-Antibacterials for systemic use,"/capita, US$ purchasing power parity",23.5
+17530,Iceland,2012,4,J01-Antibacterials for systemic use,% of total sales,4.2
+17531,Iceland,2012,4,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ exchange rate",14.5
+17532,Iceland,2012,4,N06A-Antidepressants,"/capita, US$ purchasing power parity",19.2
+17533,Iceland,2012,4,N06A-Antidepressants,% of total sales,3.5
+17534,Iceland,2012,4,A02A-Antacids,Million of national currency units,0.0
+17535,Iceland,2012,4,N06A-Antidepressants,Million US$ at exchange rate,6.7
+17536,Iceland,2012,4,N06A-Antidepressants,"Million US$, purchasing power parity",6.1
+17537,Iceland,2012,4,N06A-Antidepressants,"/capita, US$ exchange rate",21.0
+17538,Iceland,2012,4,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million US$ at exchange rate,4.9
+17539,Iceland,2012,4,"H-Systemic hormonal preparations, excluding sex hormones and insulins","Million US$, purchasing power parity",4.5
+17540,Iceland,2012,4,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million of national currency units,617.7
+17541,Iceland,2012,4,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ exchange rate",15.4
+17542,Iceland,2012,4,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ purchasing power parity",14.1
+17543,Iceland,2012,4,Products not elsewhere classified,"/capita, US$ exchange rate",174.1
+17544,Iceland,2012,4,Products not elsewhere classified,"Million US$, purchasing power parity",51.0
+17545,Iceland,2012,4,Products not elsewhere classified,Million of national currency units,6983.5
+17546,Iceland,2012,4,Products not elsewhere classified,Million US$ at exchange rate,55.8
+17547,Iceland,2012,4,M01A-Antiinflammatory and antirheumatic products non-steroids,% of total sales,2.0
+17548,Iceland,2012,4,B-Blood and blood forming organs,"/capita, US$ purchasing power parity",30.2
+17549,Iceland,2012,4,B-Blood and blood forming organs,"/capita, US$ exchange rate",33.0
+17550,Iceland,2012,4,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ purchasing power parity",11.0
+17551,Iceland,2012,4,B-Blood and blood forming organs,Million of national currency units,1325.5
+17552,Iceland,2012,4,"H-Systemic hormonal preparations, excluding sex hormones and insulins",% of total sales,2.5
+17553,Iceland,2012,4,B-Blood and blood forming organs,"Million US$, purchasing power parity",9.7
+17554,Iceland,2012,4,B-Blood and blood forming organs,Million US$ at exchange rate,10.6
+17555,Iceland,2012,4,A10-Drugs used in diabetes,% of total sales,2.8
+17556,Iceland,2012,4,C03-Diuretics,"/capita, US$ exchange rate",5.5
+17557,Iceland,2012,4,C03-Diuretics,"/capita, US$ purchasing power parity",5.0
+17558,Iceland,2012,4,A10-Drugs used in diabetes,Million US$ at exchange rate,5.4
+17559,Iceland,2012,4,A10-Drugs used in diabetes,Million of national currency units,673.1
+17560,Iceland,2012,4,A10-Drugs used in diabetes,"Million US$, purchasing power parity",4.9
+17561,Iceland,2012,4,A10-Drugs used in diabetes,"/capita, US$ purchasing power parity",15.3
+17562,Iceland,2012,4,A10-Drugs used in diabetes,"/capita, US$ exchange rate",16.8
+17563,Iceland,2012,4,C03-Diuretics,% of total sales,0.9
+17564,Iceland,2012,4,C10-Lipid modifying agents,Million US$ at exchange rate,2.9
+17565,Iceland,2012,4,C10-Lipid modifying agents,"Million US$, purchasing power parity",2.7
+17566,Iceland,2012,4,C10-Lipid modifying agents,Million of national currency units,367.8
+17567,Iceland,2012,4,Products not elsewhere classified,% of total sales,28.8
+17568,Iceland,2012,4,C10-Lipid modifying agents,% of total sales,1.5
+17569,Iceland,2012,4,Products not elsewhere classified,"/capita, US$ purchasing power parity",159.0
+17570,Iceland,2012,4,C10-Lipid modifying agents,"/capita, US$ exchange rate",9.2
+17571,Iceland,2012,4,C10-Lipid modifying agents,"/capita, US$ purchasing power parity",8.4
+17572,Iceland,2012,4,N05B-Anxiolytics,Million US$ at exchange rate,2.1
+17573,Iceland,2012,4,N05B-Anxiolytics,Million of national currency units,256.8
+17574,Iceland,2012,4,M01A-Antiinflammatory and antirheumatic products non-steroids,Million of national currency units,482.3
+17575,Iceland,2012,4,N05B-Anxiolytics,"/capita, US$ exchange rate",6.4
+17576,Iceland,2012,4,N05B-Anxiolytics,"Million US$, purchasing power parity",1.9
+17577,Iceland,2012,4,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ exchange rate",12.0
+17578,Iceland,2012,4,R03-Drugs for obstructive airway diseases,% of total sales,4.9
+17579,Iceland,2012,4,M01A-Antiinflammatory and antirheumatic products non-steroids,Million US$ at exchange rate,3.9
+17580,Iceland,2012,4,M01A-Antiinflammatory and antirheumatic products non-steroids,"Million US$, purchasing power parity",3.5
+17581,Iceland,2012,4,Total pharmaceutical sales,"Million US$, purchasing power parity",177.3
+17582,Iceland,2012,4,Total pharmaceutical sales,"/capita, US$ exchange rate",605.2
+17583,Iceland,2012,4,Total pharmaceutical sales,Million of national currency units,24278.0
+17584,Iceland,2012,4,Total pharmaceutical sales,Million US$ at exchange rate,194.1
+17585,Iceland,2012,4,Total pharmaceutical sales,"/capita, US$ purchasing power parity",552.7
+17586,Iceland,2012,4,C09-Agents acting on the Renin-Angiotensin system,% of total sales,1.8
+17587,Iceland,2012,4,N05B-Anxiolytics,"/capita, US$ purchasing power parity",5.8
+17588,Iceland,2012,4,N05B-Anxiolytics,% of total sales,1.1
+17589,Iceland,2012,4,C-Cardiovascular system,"Million US$, purchasing power parity",13.6
+17590,Iceland,2012,4,C-Cardiovascular system,Million US$ at exchange rate,14.9
+17591,Iceland,2012,4,C09-Agents acting on the Renin-Angiotensin system,Million of national currency units,435.6
+17592,Iceland,2012,4,C-Cardiovascular system,Million of national currency units,1866.2
+17593,Iceland,2012,4,C-Cardiovascular system,"/capita, US$ exchange rate",46.5
+17594,Iceland,2012,4,B-Blood and blood forming organs,% of total sales,5.5
+17595,Iceland,2012,4,C-Cardiovascular system,% of total sales,7.7
+17596,Iceland,2012,4,C-Cardiovascular system,"/capita, US$ purchasing power parity",42.5
+17597,Iceland,2012,4,C09-Agents acting on the Renin-Angiotensin system,Million US$ at exchange rate,3.5
+17598,Iceland,2012,4,R03-Drugs for obstructive airway diseases,"Million US$, purchasing power parity",8.7
+17599,Iceland,2012,4,R03-Drugs for obstructive airway diseases,Million US$ at exchange rate,9.6
+17600,Iceland,2012,4,R03-Drugs for obstructive airway diseases,"/capita, US$ purchasing power parity",27.2
+17601,Iceland,2012,4,R03-Drugs for obstructive airway diseases,"/capita, US$ exchange rate",29.8
+17602,Iceland,2012,4,C09-Agents acting on the Renin-Angiotensin system,"Million US$, purchasing power parity",3.2
+17603,Iceland,2012,4,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ exchange rate",10.9
+17604,Iceland,2012,4,R03-Drugs for obstructive airway diseases,Million of national currency units,1196.5
+17605,Iceland,2012,4,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ purchasing power parity",9.9
+17606,Iceland,2012,4,C08-Calcium channel blockers,% of total sales,0.9
+17607,Iceland,2012,4,M-Musculo-skeletal system,Million US$ at exchange rate,6.1
+17608,Iceland,2012,4,M-Musculo-skeletal system,Million of national currency units,765.0
+17609,Iceland,2012,4,C08-Calcium channel blockers,"/capita, US$ purchasing power parity",4.8
+17610,Iceland,2012,4,C08-Calcium channel blockers,Million US$ at exchange rate,1.7
+17611,Iceland,2012,4,C08-Calcium channel blockers,Million of national currency units,211.5
+17612,Iceland,2012,4,C08-Calcium channel blockers,"/capita, US$ exchange rate",5.3
+17613,Iceland,2012,4,C08-Calcium channel blockers,"Million US$, purchasing power parity",1.5
+17614,Iceland,2012,4,M-Musculo-skeletal system,"Million US$, purchasing power parity",5.6
+17615,Iceland,2012,4,R-Respiratory system,"Million US$, purchasing power parity",11.6
+17616,Iceland,2012,4,R-Respiratory system,Million US$ at exchange rate,12.7
+17617,Iceland,2012,4,R-Respiratory system,"/capita, US$ purchasing power parity",36.0
+17618,Iceland,2012,4,R-Respiratory system,"/capita, US$ exchange rate",39.5
+17619,Iceland,2012,4,M-Musculo-skeletal system,"/capita, US$ exchange rate",19.1
+17620,Iceland,2012,4,M-Musculo-skeletal system,"/capita, US$ purchasing power parity",17.4
+17621,Iceland,2012,4,R-Respiratory system,Million of national currency units,1582.6
+17622,Iceland,2012,4,M-Musculo-skeletal system,% of total sales,3.2
+17623,Iceland,2012,4,"C01B-Antiarrhythmics, Class I and III",Million of national currency units,77.4
+17624,Iceland,2012,4,N02-Analgesics,"Million US$, purchasing power parity",5.7
+17625,Iceland,2012,4,N02-Analgesics,Million US$ at exchange rate,6.3
+17626,Iceland,2012,4,N02-Analgesics,"/capita, US$ exchange rate",19.6
+17627,Iceland,2012,4,G-Genito urinary system and sex hormones,"Million US$, purchasing power parity",10.8
+17628,Iceland,2012,4,G-Genito urinary system and sex hormones,"/capita, US$ exchange rate",36.8
+17629,Iceland,2012,4,N02-Analgesics,Million of national currency units,787.5
+17630,Iceland,2012,4,G-Genito urinary system and sex hormones,Million of national currency units,1476.1
+17631,Iceland,2012,4,G-Genito urinary system and sex hormones,Million US$ at exchange rate,11.8
+17632,Iceland,2012,4,"C01B-Antiarrhythmics, Class I and III",% of total sales,0.3
+17633,Iceland,2012,4,"C01B-Antiarrhythmics, Class I and III","/capita, US$ exchange rate",1.9
+17634,Iceland,2012,4,N02-Analgesics,% of total sales,3.2
+17635,Iceland,2012,4,"C01B-Antiarrhythmics, Class I and III",Million US$ at exchange rate,0.6
+17636,Iceland,2012,4,"C01B-Antiarrhythmics, Class I and III","Million US$, purchasing power parity",0.6
+17637,Iceland,2012,4,A02A-Antacids,"/capita, US$ purchasing power parity",0.0
+17638,Iceland,2012,4,"C01B-Antiarrhythmics, Class I and III","/capita, US$ purchasing power parity",1.8
+17639,Iceland,2012,4,N02-Analgesics,"/capita, US$ purchasing power parity",17.9
+17640,Iceland,2012,4,A02A-Antacids,% of total sales,0.0
+17641,Iceland,2012,4,C01A-Cardiac glycosides,Million of national currency units,10.6
+17642,Iceland,2012,4,C01A-Cardiac glycosides,Million US$ at exchange rate,0.1
+17643,Iceland,2012,4,J-Antiinfectives for systemic use,Million of national currency units,2794.5
+17644,Iceland,2012,4,C01A-Cardiac glycosides,"Million US$, purchasing power parity",0.1
+17645,Iceland,2012,4,C01A-Cardiac glycosides,"/capita, US$ purchasing power parity",0.2
+17646,Iceland,2012,4,C01A-Cardiac glycosides,"/capita, US$ exchange rate",0.3
+17647,Iceland,2012,4,J-Antiinfectives for systemic use,"/capita, US$ purchasing power parity",63.6
+17648,Iceland,2012,4,J-Antiinfectives for systemic use,% of total sales,11.5
+17649,Iceland,2012,4,J-Antiinfectives for systemic use,Million US$ at exchange rate,22.3
+17650,Iceland,2012,4,J-Antiinfectives for systemic use,"Million US$, purchasing power parity",20.4
+17651,Iceland,2012,4,J-Antiinfectives for systemic use,"/capita, US$ exchange rate",69.7
+17652,Iceland,2012,4,C03-Diuretics,Million of national currency units,221.6
+17653,Iceland,2012,4,C01A-Cardiac glycosides,% of total sales,0.0
+17654,Iceland,2012,4,C03-Diuretics,Million US$ at exchange rate,1.8
+17655,Iceland,2012,4,R-Respiratory system,% of total sales,6.5
+17656,Iceland,2012,4,C03-Diuretics,"Million US$, purchasing power parity",1.6
+17657,Iceland,2011,5,N05C-Hypnotics and sedatives,Million of national currency units,466.6
+17658,Iceland,2011,5,G-Genito urinary system and sex hormones,"/capita, US$ purchasing power parity",33.3
+17659,Iceland,2011,5,G-Genito urinary system and sex hormones,% of total sales,5.5
+17660,Iceland,2011,5,N-Nervous system,"Million US$, purchasing power parity",42.2
+17661,Iceland,2011,5,N-Nervous system,Million US$ at exchange rate,49.2
+17662,Iceland,2011,5,N05C-Hypnotics and sedatives,"/capita, US$ purchasing power parity",10.8
+17663,Iceland,2011,5,N-Nervous system,"/capita, US$ exchange rate",154.2
+17664,Iceland,2011,5,N-Nervous system,Million of national currency units,5703.4
+17665,Iceland,2011,5,N05C-Hypnotics and sedatives,"Million US$, purchasing power parity",3.5
+17666,Iceland,2011,5,N05C-Hypnotics and sedatives,Million US$ at exchange rate,4.0
+17667,Iceland,2011,5,N05C-Hypnotics and sedatives,% of total sales,1.8
+17668,Iceland,2011,5,N05C-Hypnotics and sedatives,"/capita, US$ exchange rate",12.6
+17669,Iceland,2011,5,C02-Antihypertensives,"/capita, US$ purchasing power parity",1.1
+17670,Iceland,2011,5,C02-Antihypertensives,% of total sales,0.2
+17671,Iceland,2011,5,C02-Antihypertensives,Million of national currency units,48.9
+17672,Iceland,2011,5,C07-Beta blocking agents,"/capita, US$ exchange rate",9.4
+17673,Iceland,2011,5,C07-Beta blocking agents,"/capita, US$ purchasing power parity",8.0
+17674,Iceland,2011,5,C07-Beta blocking agents,% of total sales,1.3
+17675,Iceland,2011,5,J01-Antibacterials for systemic use,Million US$ at exchange rate,8.3
+17676,Iceland,2011,5,J01-Antibacterials for systemic use,"Million US$, purchasing power parity",7.2
+17677,Iceland,2011,5,J01-Antibacterials for systemic use,"/capita, US$ exchange rate",26.1
+17678,Iceland,2011,5,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million US$ at exchange rate,7.0
+17679,Iceland,2011,5,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"Million US$, purchasing power parity",6.0
+17680,Iceland,2011,5,J01-Antibacterials for systemic use,Million of national currency units,966.8
+17681,Iceland,2011,5,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million of national currency units,808.1
+17682,Iceland,2011,5,G03-Sex hormones and modulators of the genital system,% of total sales,3.2
+17683,Iceland,2011,5,G03-Sex hormones and modulators of the genital system,"/capita, US$ purchasing power parity",19.6
+17684,Iceland,2011,5,C02-Antihypertensives,Million US$ at exchange rate,0.4
+17685,Iceland,2011,5,C02-Antihypertensives,"Million US$, purchasing power parity",0.4
+17686,Iceland,2011,5,C02-Antihypertensives,"/capita, US$ exchange rate",1.3
+17687,Iceland,2011,5,C07-Beta blocking agents,Million of national currency units,346.8
+17688,Iceland,2011,5,G03-Sex hormones and modulators of the genital system,Million of national currency units,845.0
+17689,Iceland,2011,5,C07-Beta blocking agents,Million US$ at exchange rate,3.0
+17690,Iceland,2011,5,C07-Beta blocking agents,"Million US$, purchasing power parity",2.6
+17691,Iceland,2011,5,G03-Sex hormones and modulators of the genital system,"/capita, US$ exchange rate",22.8
+17692,Iceland,2011,5,G03-Sex hormones and modulators of the genital system,"Million US$, purchasing power parity",6.3
+17693,Iceland,2011,5,G03-Sex hormones and modulators of the genital system,Million US$ at exchange rate,7.3
+17694,Iceland,2011,5,A-Alimentary tract and metabolism,"/capita, US$ purchasing power parity",43.9
+17695,Iceland,2011,5,A-Alimentary tract and metabolism,% of total sales,7.3
+17696,Iceland,2011,5,A-Alimentary tract and metabolism,"/capita, US$ exchange rate",51.2
+17697,Iceland,2011,5,A02A-Antacids,"Million US$, purchasing power parity",0.0
+17698,Iceland,2011,5,A02A-Antacids,Million US$ at exchange rate,0.0
+17699,Iceland,2011,5,A02A-Antacids,"/capita, US$ exchange rate",0.0
+17700,Iceland,2011,5,N-Nervous system,% of total sales,21.9
+17701,Iceland,2011,5,N-Nervous system,"/capita, US$ purchasing power parity",132.3
+17702,Iceland,2011,5,A-Alimentary tract and metabolism,Million of national currency units,1894.8
+17703,Iceland,2011,5,A-Alimentary tract and metabolism,Million US$ at exchange rate,16.3
+17704,Iceland,2011,5,A-Alimentary tract and metabolism,"Million US$, purchasing power parity",14.0
+17705,Iceland,2011,5,A02A-Antacids,"/capita, US$ purchasing power parity",0.0
+17706,Iceland,2011,5,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ purchasing power parity",18.7
+17707,Iceland,2011,5,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),% of total sales,3.1
+17708,Iceland,2011,5,N06A-Antidepressants,Million of national currency units,865.8
+17709,Iceland,2011,5,J01-Antibacterials for systemic use,% of total sales,3.7
+17710,Iceland,2011,5,J01-Antibacterials for systemic use,"/capita, US$ purchasing power parity",22.4
+17711,Iceland,2011,5,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ exchange rate",21.8
+17712,Iceland,2011,5,N06A-Antidepressants,"/capita, US$ purchasing power parity",20.1
+17713,Iceland,2011,5,N06A-Antidepressants,% of total sales,3.3
+17714,Iceland,2011,5,A02A-Antacids,Million of national currency units,0.0
+17715,Iceland,2011,5,N06A-Antidepressants,Million US$ at exchange rate,7.5
+17716,Iceland,2011,5,N06A-Antidepressants,"Million US$, purchasing power parity",6.4
+17717,Iceland,2011,5,N06A-Antidepressants,"/capita, US$ exchange rate",23.4
+17718,Iceland,2011,5,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million US$ at exchange rate,5.4
+17719,Iceland,2011,5,"H-Systemic hormonal preparations, excluding sex hormones and insulins","Million US$, purchasing power parity",4.6
+17720,Iceland,2011,5,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ purchasing power parity",14.5
+17721,Iceland,2011,5,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ exchange rate",16.9
+17722,Iceland,2011,5,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million of national currency units,623.4
+17723,Iceland,2011,5,Products not elsewhere classified,"/capita, US$ exchange rate",223.3
+17724,Iceland,2011,5,Products not elsewhere classified,"Million US$, purchasing power parity",61.1
+17725,Iceland,2011,5,Products not elsewhere classified,Million of national currency units,8260.8
+17726,Iceland,2011,5,Products not elsewhere classified,Million US$ at exchange rate,71.2
+17727,Iceland,2011,5,M01A-Antiinflammatory and antirheumatic products non-steroids,% of total sales,1.9
+17728,Iceland,2011,5,B-Blood and blood forming organs,"/capita, US$ exchange rate",34.7
+17729,Iceland,2011,5,B-Blood and blood forming organs,"/capita, US$ purchasing power parity",29.8
+17730,Iceland,2011,5,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ purchasing power parity",11.3
+17731,Iceland,2011,5,B-Blood and blood forming organs,Million of national currency units,1283.9
+17732,Iceland,2011,5,"H-Systemic hormonal preparations, excluding sex hormones and insulins",% of total sales,2.4
+17733,Iceland,2011,5,B-Blood and blood forming organs,"Million US$, purchasing power parity",9.5
+17734,Iceland,2011,5,B-Blood and blood forming organs,Million US$ at exchange rate,11.1
+17735,Iceland,2011,5,Products not elsewhere classified,"/capita, US$ purchasing power parity",191.6
+17736,Iceland,2011,5,A10-Drugs used in diabetes,% of total sales,2.5
+17737,Iceland,2011,5,C03-Diuretics,"/capita, US$ exchange rate",5.9
+17738,Iceland,2011,5,C03-Diuretics,"/capita, US$ purchasing power parity",5.1
+17739,Iceland,2011,5,C03-Diuretics,% of total sales,0.8
+17740,Iceland,2011,5,A10-Drugs used in diabetes,"/capita, US$ purchasing power parity",15.0
+17741,Iceland,2011,5,A10-Drugs used in diabetes,Million US$ at exchange rate,5.6
+17742,Iceland,2011,5,A10-Drugs used in diabetes,"Million US$, purchasing power parity",4.8
+17743,Iceland,2011,5,A10-Drugs used in diabetes,"/capita, US$ exchange rate",17.4
+17744,Iceland,2011,5,C10-Lipid modifying agents,Million US$ at exchange rate,3.2
+17745,Iceland,2011,5,C10-Lipid modifying agents,"Million US$, purchasing power parity",2.7
+17746,Iceland,2011,5,Products not elsewhere classified,% of total sales,31.7
+17747,Iceland,2011,5,C10-Lipid modifying agents,Million of national currency units,366.0
+17748,Iceland,2011,5,C10-Lipid modifying agents,% of total sales,1.4
+17749,Iceland,2011,5,C10-Lipid modifying agents,"/capita, US$ exchange rate",9.9
+17750,Iceland,2011,5,C10-Lipid modifying agents,"/capita, US$ purchasing power parity",8.5
+17751,Iceland,2011,5,N05B-Anxiolytics,Million US$ at exchange rate,1.9
+17752,Iceland,2011,5,N05B-Anxiolytics,Million of national currency units,214.7
+17753,Iceland,2011,5,M01A-Antiinflammatory and antirheumatic products non-steroids,Million of national currency units,485.5
+17754,Iceland,2011,5,N05B-Anxiolytics,"/capita, US$ exchange rate",5.8
+17755,Iceland,2011,5,N05B-Anxiolytics,"Million US$, purchasing power parity",1.6
+17756,Iceland,2011,5,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ exchange rate",13.1
+17757,Iceland,2011,5,R03-Drugs for obstructive airway diseases,% of total sales,4.5
+17758,Iceland,2011,5,M01A-Antiinflammatory and antirheumatic products non-steroids,Million US$ at exchange rate,4.2
+17759,Iceland,2011,5,M01A-Antiinflammatory and antirheumatic products non-steroids,"Million US$, purchasing power parity",3.6
+17760,Iceland,2011,5,Total pharmaceutical sales,"/capita, US$ exchange rate",705.1
+17761,Iceland,2011,5,Total pharmaceutical sales,"Million US$, purchasing power parity",193.0
+17762,Iceland,2011,5,Total pharmaceutical sales,Million of national currency units,26083.5
+17763,Iceland,2011,5,Total pharmaceutical sales,Million US$ at exchange rate,224.9
+17764,Iceland,2011,5,Total pharmaceutical sales,"/capita, US$ purchasing power parity",605.0
+17765,Iceland,2011,5,C09-Agents acting on the Renin-Angiotensin system,% of total sales,2.0
+17766,Iceland,2011,5,N05B-Anxiolytics,"/capita, US$ purchasing power parity",5.0
+17767,Iceland,2011,5,N05B-Anxiolytics,% of total sales,0.8
+17768,Iceland,2011,5,C-Cardiovascular system,"Million US$, purchasing power parity",14.4
+17769,Iceland,2011,5,C-Cardiovascular system,Million US$ at exchange rate,16.8
+17770,Iceland,2011,5,C09-Agents acting on the Renin-Angiotensin system,Million of national currency units,520.4
+17771,Iceland,2011,5,C-Cardiovascular system,Million of national currency units,1946.3
+17772,Iceland,2011,5,C-Cardiovascular system,"/capita, US$ exchange rate",52.6
+17773,Iceland,2011,5,B-Blood and blood forming organs,% of total sales,4.9
+17774,Iceland,2011,5,C-Cardiovascular system,"/capita, US$ purchasing power parity",45.1
+17775,Iceland,2011,5,C-Cardiovascular system,% of total sales,7.5
+17776,Iceland,2011,5,A10-Drugs used in diabetes,Million of national currency units,645.2
+17777,Iceland,2011,5,R03-Drugs for obstructive airway diseases,"Million US$, purchasing power parity",8.7
+17778,Iceland,2011,5,R03-Drugs for obstructive airway diseases,Million US$ at exchange rate,10.2
+17779,Iceland,2011,5,R03-Drugs for obstructive airway diseases,"/capita, US$ purchasing power parity",27.4
+17780,Iceland,2011,5,R03-Drugs for obstructive airway diseases,"/capita, US$ exchange rate",31.9
+17781,Iceland,2011,5,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ exchange rate",14.1
+17782,Iceland,2011,5,C09-Agents acting on the Renin-Angiotensin system,"Million US$, purchasing power parity",3.9
+17783,Iceland,2011,5,C09-Agents acting on the Renin-Angiotensin system,Million US$ at exchange rate,4.5
+17784,Iceland,2011,5,R03-Drugs for obstructive airway diseases,Million of national currency units,1180.2
+17785,Iceland,2011,5,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ purchasing power parity",12.1
+17786,Iceland,2011,5,C01A-Cardiac glycosides,Million of national currency units,10.0
+17787,Iceland,2011,5,C08-Calcium channel blockers,% of total sales,0.9
+17788,Iceland,2011,5,M-Musculo-skeletal system,Million US$ at exchange rate,6.6
+17789,Iceland,2011,5,M-Musculo-skeletal system,Million of national currency units,760.9
+17790,Iceland,2011,5,C08-Calcium channel blockers,Million US$ at exchange rate,2.0
+17791,Iceland,2011,5,C08-Calcium channel blockers,Million of national currency units,229.8
+17792,Iceland,2011,5,C08-Calcium channel blockers,"/capita, US$ purchasing power parity",5.3
+17793,Iceland,2011,5,C08-Calcium channel blockers,"/capita, US$ exchange rate",6.2
+17794,Iceland,2011,5,C08-Calcium channel blockers,"Million US$, purchasing power parity",1.7
+17795,Iceland,2011,5,M-Musculo-skeletal system,"Million US$, purchasing power parity",5.6
+17796,Iceland,2011,5,R-Respiratory system,"Million US$, purchasing power parity",11.5
+17797,Iceland,2011,5,R-Respiratory system,Million US$ at exchange rate,13.4
+17798,Iceland,2011,5,R-Respiratory system,"/capita, US$ purchasing power parity",36.1
+17799,Iceland,2011,5,R-Respiratory system,"/capita, US$ exchange rate",42.1
+17800,Iceland,2011,5,M-Musculo-skeletal system,"/capita, US$ purchasing power parity",17.6
+17801,Iceland,2011,5,M-Musculo-skeletal system,"/capita, US$ exchange rate",20.6
+17802,Iceland,2011,5,R-Respiratory system,Million of national currency units,1558.2
+17803,Iceland,2011,5,M-Musculo-skeletal system,% of total sales,2.9
+17804,Iceland,2011,5,"C01B-Antiarrhythmics, Class I and III",Million of national currency units,69.6
+17805,Iceland,2011,5,N02-Analgesics,"Million US$, purchasing power parity",5.8
+17806,Iceland,2011,5,N02-Analgesics,Million US$ at exchange rate,6.8
+17807,Iceland,2011,5,N02-Analgesics,"/capita, US$ purchasing power parity",18.3
+17808,Iceland,2011,5,N02-Analgesics,"/capita, US$ exchange rate",21.4
+17809,Iceland,2011,5,G-Genito urinary system and sex hormones,"Million US$, purchasing power parity",10.6
+17810,Iceland,2011,5,G-Genito urinary system and sex hormones,"/capita, US$ exchange rate",38.8
+17811,Iceland,2011,5,N02-Analgesics,Million of national currency units,789.8
+17812,Iceland,2011,5,G-Genito urinary system and sex hormones,Million of national currency units,1436.1
+17813,Iceland,2011,5,G-Genito urinary system and sex hormones,Million US$ at exchange rate,12.4
+17814,Iceland,2011,5,"C01B-Antiarrhythmics, Class I and III","/capita, US$ exchange rate",1.9
+17815,Iceland,2011,5,N02-Analgesics,% of total sales,3.0
+17816,Iceland,2011,5,"C01B-Antiarrhythmics, Class I and III",Million US$ at exchange rate,0.6
+17817,Iceland,2011,5,"C01B-Antiarrhythmics, Class I and III","Million US$, purchasing power parity",0.5
+17818,Iceland,2011,5,"C01B-Antiarrhythmics, Class I and III","/capita, US$ purchasing power parity",1.6
+17819,Iceland,2011,5,"C01B-Antiarrhythmics, Class I and III",% of total sales,0.3
+17820,Iceland,2011,5,A02A-Antacids,% of total sales,0.0
+17821,Iceland,2011,5,C01A-Cardiac glycosides,Million US$ at exchange rate,0.1
+17822,Iceland,2011,5,J-Antiinfectives for systemic use,Million of national currency units,2615.7
+17823,Iceland,2011,5,C01A-Cardiac glycosides,"Million US$, purchasing power parity",0.1
+17824,Iceland,2011,5,C01A-Cardiac glycosides,"/capita, US$ purchasing power parity",0.2
+17825,Iceland,2011,5,C01A-Cardiac glycosides,"/capita, US$ exchange rate",0.3
+17826,Iceland,2011,5,J-Antiinfectives for systemic use,"/capita, US$ purchasing power parity",60.7
+17827,Iceland,2011,5,J-Antiinfectives for systemic use,% of total sales,10.0
+17828,Iceland,2011,5,J-Antiinfectives for systemic use,Million US$ at exchange rate,22.6
+17829,Iceland,2011,5,J-Antiinfectives for systemic use,"Million US$, purchasing power parity",19.4
+17830,Iceland,2011,5,J-Antiinfectives for systemic use,"/capita, US$ exchange rate",70.7
+17831,Iceland,2011,5,C01A-Cardiac glycosides,% of total sales,0.0
+17832,Iceland,2011,5,C03-Diuretics,"Million US$, purchasing power parity",1.6
+17833,Iceland,2011,5,C03-Diuretics,Million of national currency units,219.2
+17834,Iceland,2011,5,R-Respiratory system,% of total sales,6.0
+17835,Iceland,2011,5,C03-Diuretics,Million US$ at exchange rate,1.9
+17836,Ireland,2017,5,N02-Analgesics,"Million US$, purchasing power parity",69.0
+17837,Ireland,2017,5,C03-Diuretics,"/capita, US$ exchange rate",3.4
+17838,Ireland,2017,5,B-Blood and blood forming organs,"/capita, US$ purchasing power parity",29.6
+17839,Ireland,2017,5,B-Blood and blood forming organs,"/capita, US$ exchange rate",26.6
+17840,Ireland,2017,5,B-Blood and blood forming organs,"Million US$, purchasing power parity",142.4
+17841,Ireland,2017,5,G03-Sex hormones and modulators of the genital system,% of total sales,1.5
+17842,Ireland,2017,5,N05B-Anxiolytics,% of total sales,0.4
+17843,Ireland,2017,5,C03-Diuretics,"/capita, US$ purchasing power parity",3.7
+17844,Ireland,2017,5,N05B-Anxiolytics,"/capita, US$ purchasing power parity",2.4
+17845,Ireland,2017,5,B-Blood and blood forming organs,% of total sales,5.3
+17846,Ireland,2017,5,N05B-Anxiolytics,"/capita, US$ exchange rate",2.1
+17847,Ireland,2017,5,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),% of total sales,2.4
+17848,Ireland,2017,5,C02-Antihypertensives,Million of national currency units,17.8
+17849,Ireland,2017,5,N05B-Anxiolytics,Million US$ at exchange rate,10.2
+17850,Ireland,2017,5,N05B-Anxiolytics,"Million US$, purchasing power parity",11.3
+17851,Ireland,2017,5,N05B-Anxiolytics,Million of national currency units,9.0
+17852,Ireland,2017,5,N02-Analgesics,Million of national currency units,54.8
+17853,Ireland,2017,5,N02-Analgesics,Million US$ at exchange rate,61.9
+17854,Ireland,2017,5,C03-Diuretics,Million of national currency units,14.3
+17855,Ireland,2017,5,C03-Diuretics,Million US$ at exchange rate,16.1
+17856,Ireland,2017,5,C03-Diuretics,"Million US$, purchasing power parity",18.0
+17857,Ireland,2017,5,"H-Systemic hormonal preparations, excluding sex hormones and insulins",% of total sales,2.6
+17858,Ireland,2017,5,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million of national currency units,51.7
+17859,Ireland,2017,5,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ exchange rate",13.0
+17860,Ireland,2017,5,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ purchasing power parity",14.5
+17861,Ireland,2017,5,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ exchange rate",12.1
+17862,Ireland,2017,5,J-Antiinfectives for systemic use,"Million US$, purchasing power parity",143.0
+17863,Ireland,2017,5,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ purchasing power parity",13.5
+17864,Ireland,2017,5,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million US$ at exchange rate,58.4
+17865,Ireland,2017,5,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"Million US$, purchasing power parity",65.1
+17866,Ireland,2017,5,J-Antiinfectives for systemic use,"/capita, US$ purchasing power parity",29.7
+17867,Ireland,2017,5,C02-Antihypertensives,"/capita, US$ purchasing power parity",4.7
+17868,Ireland,2017,5,C02-Antihypertensives,% of total sales,0.8
+17869,Ireland,2017,5,J-Antiinfectives for systemic use,% of total sales,5.3
+17870,Ireland,2017,5,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million US$ at exchange rate,62.7
+17871,Ireland,2017,5,"H-Systemic hormonal preparations, excluding sex hormones and insulins","Million US$, purchasing power parity",69.9
+17872,Ireland,2017,5,J-Antiinfectives for systemic use,"/capita, US$ exchange rate",26.7
+17873,Ireland,2017,5,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million of national currency units,55.5
+17874,Ireland,2017,5,N02-Analgesics,% of total sales,2.6
+17875,Ireland,2017,5,N05C-Hypnotics and sedatives,"Million US$, purchasing power parity",23.1
+17876,Ireland,2017,5,N05C-Hypnotics and sedatives,Million US$ at exchange rate,20.7
+17877,Ireland,2017,5,N05C-Hypnotics and sedatives,"/capita, US$ purchasing power parity",4.8
+17878,Ireland,2017,5,N05C-Hypnotics and sedatives,"/capita, US$ exchange rate",4.3
+17879,Ireland,2017,5,C02-Antihypertensives,"Million US$, purchasing power parity",22.4
+17880,Ireland,2017,5,C02-Antihypertensives,Million US$ at exchange rate,20.1
+17881,Ireland,2017,5,N05C-Hypnotics and sedatives,Million of national currency units,18.3
+17882,Ireland,2017,5,C02-Antihypertensives,"/capita, US$ exchange rate",4.2
+17883,Ireland,2017,5,N05C-Hypnotics and sedatives,% of total sales,0.9
+17884,Ireland,2017,5,B-Blood and blood forming organs,Million of national currency units,113.1
+17885,Ireland,2017,5,N02-Analgesics,"/capita, US$ exchange rate",12.9
+17886,Ireland,2017,5,N02-Analgesics,"/capita, US$ purchasing power parity",14.4
+17887,Ireland,2017,5,B-Blood and blood forming organs,Million US$ at exchange rate,127.8
+17888,Ireland,2017,5,C03-Diuretics,% of total sales,0.7
+17889,Ireland,2017,5,J-Antiinfectives for systemic use,Million of national currency units,113.6
+17890,Ireland,2017,5,J-Antiinfectives for systemic use,Million US$ at exchange rate,128.3
+17891,Ireland,2017,5,C01A-Cardiac glycosides,"/capita, US$ exchange rate",0.3
+17892,Ireland,2017,5,C01A-Cardiac glycosides,"Million US$, purchasing power parity",1.4
+17893,Ireland,2017,5,C01A-Cardiac glycosides,% of total sales,0.1
+17894,Ireland,2017,5,C01A-Cardiac glycosides,"/capita, US$ purchasing power parity",0.3
+17895,Ireland,2017,5,C01A-Cardiac glycosides,Million US$ at exchange rate,1.2
+17896,Ireland,2017,5,M-Musculo-skeletal system,"/capita, US$ purchasing power parity",17.7
+17897,Ireland,2017,5,M-Musculo-skeletal system,"/capita, US$ exchange rate",15.9
+17898,Ireland,2017,5,C01A-Cardiac glycosides,Million of national currency units,1.1
+17899,Ireland,2017,5,M-Musculo-skeletal system,% of total sales,3.2
+17900,Ireland,2017,5,C10-Lipid modifying agents,Million US$ at exchange rate,74.8
+17901,Ireland,2017,5,C10-Lipid modifying agents,"Million US$, purchasing power parity",83.3
+17902,Ireland,2017,5,Products not elsewhere classified,"/capita, US$ purchasing power parity",205.2
+17903,Ireland,2017,5,Products not elsewhere classified,% of total sales,36.9
+17904,Ireland,2017,5,C10-Lipid modifying agents,Million of national currency units,66.2
+17905,Ireland,2017,5,A10-Drugs used in diabetes,Million US$ at exchange rate,110.5
+17906,Ireland,2017,5,A10-Drugs used in diabetes,Million of national currency units,97.8
+17907,Ireland,2017,5,C10-Lipid modifying agents,% of total sales,3.1
+17908,Ireland,2017,5,C10-Lipid modifying agents,"/capita, US$ exchange rate",15.6
+17909,Ireland,2017,5,C10-Lipid modifying agents,"/capita, US$ purchasing power parity",17.3
+17910,Ireland,2017,5,M-Musculo-skeletal system,"Million US$, purchasing power parity",85.0
+17911,Ireland,2017,5,C08-Calcium channel blockers,Million US$ at exchange rate,19.9
+17912,Ireland,2017,5,C08-Calcium channel blockers,Million of national currency units,17.6
+17913,Ireland,2017,5,C08-Calcium channel blockers,"Million US$, purchasing power parity",22.2
+17914,Ireland,2017,5,C08-Calcium channel blockers,"/capita, US$ purchasing power parity",4.6
+17915,Ireland,2017,5,C08-Calcium channel blockers,"/capita, US$ exchange rate",4.1
+17916,Ireland,2017,5,A02A-Antacids,Million US$ at exchange rate,0.0
+17917,Ireland,2017,5,A02A-Antacids,Million of national currency units,0.0
+17918,Ireland,2017,5,A02A-Antacids,"Million US$, purchasing power parity",0.0
+17919,Ireland,2017,5,A02A-Antacids,"/capita, US$ purchasing power parity",0.0
+17920,Ireland,2017,5,A02A-Antacids,"/capita, US$ exchange rate",0.0
+17921,Ireland,2017,5,R-Respiratory system,"/capita, US$ exchange rate",42.7
+17922,Ireland,2017,5,R-Respiratory system,% of total sales,8.6
+17923,Ireland,2017,5,R-Respiratory system,"/capita, US$ purchasing power parity",47.6
+17924,Ireland,2017,5,M-Musculo-skeletal system,Million of national currency units,67.5
+17925,Ireland,2017,5,C08-Calcium channel blockers,% of total sales,0.8
+17926,Ireland,2017,5,R-Respiratory system,Million US$ at exchange rate,205.3
+17927,Ireland,2017,5,R-Respiratory system,Million of national currency units,181.8
+17928,Ireland,2017,5,M-Musculo-skeletal system,Million US$ at exchange rate,76.2
+17929,Ireland,2017,5,R03-Drugs for obstructive airway diseases,"/capita, US$ purchasing power parity",26.9
+17930,Ireland,2017,5,R03-Drugs for obstructive airway diseases,"/capita, US$ exchange rate",24.2
+17931,Ireland,2017,5,Total pharmaceutical sales,"/capita, US$ purchasing power parity",556.3
+17932,Ireland,2017,5,R03-Drugs for obstructive airway diseases,% of total sales,4.8
+17933,Ireland,2017,5,R03-Drugs for obstructive airway diseases,"Million US$, purchasing power parity",129.4
+17934,Ireland,2017,5,C-Cardiovascular system,Million of national currency units,211.3
+17935,Ireland,2017,5,C-Cardiovascular system,Million US$ at exchange rate,238.7
+17936,Ireland,2017,5,R03-Drugs for obstructive airway diseases,Million US$ at exchange rate,116.1
+17937,Ireland,2017,5,R03-Drugs for obstructive airway diseases,Million of national currency units,102.8
+17938,Ireland,2017,5,Total pharmaceutical sales,"/capita, US$ exchange rate",499.2
+17939,Ireland,2017,5,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ exchange rate",12.5
+17940,Ireland,2017,5,Total pharmaceutical sales,Million of national currency units,2124.4
+17941,Ireland,2017,5,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ purchasing power parity",13.9
+17942,Ireland,2017,5,C09-Agents acting on the Renin-Angiotensin system,% of total sales,2.5
+17943,Ireland,2017,5,C09-Agents acting on the Renin-Angiotensin system,"Million US$, purchasing power parity",66.9
+17944,Ireland,2017,5,Total pharmaceutical sales,Million US$ at exchange rate,2399.9
+17945,Ireland,2017,5,Total pharmaceutical sales,"Million US$, purchasing power parity",2674.3
+17946,Ireland,2017,5,C09-Agents acting on the Renin-Angiotensin system,Million US$ at exchange rate,60.0
+17947,Ireland,2017,5,C09-Agents acting on the Renin-Angiotensin system,Million of national currency units,53.1
+17948,Ireland,2017,5,A10-Drugs used in diabetes,"Million US$, purchasing power parity",123.2
+17949,Ireland,2017,5,A02A-Antacids,% of total sales,0.0
+17950,Ireland,2017,5,A10-Drugs used in diabetes,"/capita, US$ exchange rate",23.0
+17951,Ireland,2017,5,A10-Drugs used in diabetes,% of total sales,4.6
+17952,Ireland,2017,5,A10-Drugs used in diabetes,"/capita, US$ purchasing power parity",25.6
+17953,Ireland,2017,5,Products not elsewhere classified,"Million US$, purchasing power parity",986.5
+17954,Ireland,2017,5,Products not elsewhere classified,"/capita, US$ exchange rate",184.2
+17955,Ireland,2017,5,Products not elsewhere classified,Million of national currency units,783.7
+17956,Ireland,2017,5,Products not elsewhere classified,Million US$ at exchange rate,885.3
+17957,Ireland,2017,5,M01A-Antiinflammatory and antirheumatic products non-steroids,Million of national currency units,17.8
+17958,Ireland,2017,5,C-Cardiovascular system,"Million US$, purchasing power parity",266.0
+17959,Ireland,2017,5,C-Cardiovascular system,"/capita, US$ exchange rate",49.7
+17960,Ireland,2017,5,C-Cardiovascular system,"/capita, US$ purchasing power parity",55.3
+17961,Ireland,2017,5,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ purchasing power parity",4.7
+17962,Ireland,2017,5,M01A-Antiinflammatory and antirheumatic products non-steroids,% of total sales,0.8
+17963,Ireland,2017,5,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ exchange rate",4.2
+17964,Ireland,2017,5,M01A-Antiinflammatory and antirheumatic products non-steroids,Million US$ at exchange rate,20.1
+17965,Ireland,2017,5,M01A-Antiinflammatory and antirheumatic products non-steroids,"Million US$, purchasing power parity",22.4
+17966,Ireland,2017,5,C-Cardiovascular system,% of total sales,9.9
+17967,Ireland,2017,5,R-Respiratory system,"Million US$, purchasing power parity",228.8
+17968,Ireland,2017,5,N-Nervous system,"/capita, US$ purchasing power parity",81.5
+17969,Ireland,2017,5,J01-Antibacterials for systemic use,Million of national currency units,42.9
+17970,Ireland,2017,5,J01-Antibacterials for systemic use,"/capita, US$ exchange rate",10.1
+17971,Ireland,2017,5,N-Nervous system,% of total sales,14.7
+17972,Ireland,2017,5,J01-Antibacterials for systemic use,"Million US$, purchasing power parity",54.0
+17973,Ireland,2017,5,J01-Antibacterials for systemic use,"/capita, US$ purchasing power parity",11.2
+17974,Ireland,2017,5,N-Nervous system,"/capita, US$ exchange rate",73.1
+17975,Ireland,2017,5,G-Genito urinary system and sex hormones,% of total sales,3.3
+17976,Ireland,2017,5,G-Genito urinary system and sex hormones,"/capita, US$ exchange rate",16.7
+17977,Ireland,2017,5,G-Genito urinary system and sex hormones,"/capita, US$ purchasing power parity",18.6
+17978,Ireland,2017,5,N-Nervous system,"Million US$, purchasing power parity",391.8
+17979,Ireland,2017,5,N-Nervous system,Million of national currency units,311.2
+17980,Ireland,2017,5,N-Nervous system,Million US$ at exchange rate,351.6
+17981,Ireland,2017,5,N06A-Antidepressants,Million US$ at exchange rate,50.1
+17982,Ireland,2017,5,N06A-Antidepressants,"Million US$, purchasing power parity",55.8
+17983,Ireland,2017,5,A-Alimentary tract and metabolism,% of total sales,10.1
+17984,Ireland,2017,5,N06A-Antidepressants,Million of national currency units,44.4
+17985,Ireland,2017,5,N06A-Antidepressants,"/capita, US$ exchange rate",10.4
+17986,Ireland,2017,5,N06A-Antidepressants,% of total sales,2.1
+17987,Ireland,2017,5,N06A-Antidepressants,"/capita, US$ purchasing power parity",11.6
+17988,Ireland,2017,5,A-Alimentary tract and metabolism,Million of national currency units,215.6
+17989,Ireland,2017,5,J01-Antibacterials for systemic use,% of total sales,2.0
+17990,Ireland,2017,5,A-Alimentary tract and metabolism,Million US$ at exchange rate,243.5
+17991,Ireland,2017,5,A-Alimentary tract and metabolism,"/capita, US$ exchange rate",50.7
+17992,Ireland,2017,5,A-Alimentary tract and metabolism,"/capita, US$ purchasing power parity",56.4
+17993,Ireland,2017,5,A-Alimentary tract and metabolism,"Million US$, purchasing power parity",271.4
+17994,Ireland,2017,5,J01-Antibacterials for systemic use,Million US$ at exchange rate,48.5
+17995,Ireland,2017,5,G03-Sex hormones and modulators of the genital system,"Million US$, purchasing power parity",41.3
+17996,Ireland,2017,5,G03-Sex hormones and modulators of the genital system,Million US$ at exchange rate,37.0
+17997,Ireland,2017,5,G03-Sex hormones and modulators of the genital system,"/capita, US$ exchange rate",7.7
+17998,Ireland,2017,5,C07-Beta blocking agents,Million of national currency units,22.5
+17999,Ireland,2017,5,G03-Sex hormones and modulators of the genital system,Million of national currency units,32.8
+18000,Ireland,2017,5,G03-Sex hormones and modulators of the genital system,"/capita, US$ purchasing power parity",8.6
+18001,Ireland,2017,5,"C01B-Antiarrhythmics, Class I and III","/capita, US$ exchange rate",0.7
+18002,Ireland,2017,5,"C01B-Antiarrhythmics, Class I and III","/capita, US$ purchasing power parity",0.8
+18003,Ireland,2017,5,"C01B-Antiarrhythmics, Class I and III",Million of national currency units,3.1
+18004,Ireland,2017,5,"C01B-Antiarrhythmics, Class I and III",Million US$ at exchange rate,3.4
+18005,Ireland,2017,5,"C01B-Antiarrhythmics, Class I and III","Million US$, purchasing power parity",3.8
+18006,Ireland,2017,5,C07-Beta blocking agents,Million US$ at exchange rate,25.4
+18007,Ireland,2017,5,"C01B-Antiarrhythmics, Class I and III",% of total sales,0.1
+18008,Ireland,2017,5,C07-Beta blocking agents,% of total sales,1.1
+18009,Ireland,2017,5,C07-Beta blocking agents,"/capita, US$ exchange rate",5.3
+18010,Ireland,2017,5,G-Genito urinary system and sex hormones,Million US$ at exchange rate,80.4
+18011,Ireland,2017,5,G-Genito urinary system and sex hormones,"Million US$, purchasing power parity",89.6
+18012,Ireland,2017,5,G-Genito urinary system and sex hormones,Million of national currency units,71.2
+18013,Ireland,2017,5,C07-Beta blocking agents,"/capita, US$ purchasing power parity",5.9
+18014,Ireland,2017,5,C07-Beta blocking agents,"Million US$, purchasing power parity",28.3
+18015,Ireland,2016,6,N02-Analgesics,"Million US$, purchasing power parity",73.0
+18016,Ireland,2016,6,B-Blood and blood forming organs,"/capita, US$ purchasing power parity",27.8
+18017,Ireland,2016,6,B-Blood and blood forming organs,"/capita, US$ exchange rate",24.4
+18018,Ireland,2016,6,B-Blood and blood forming organs,"Million US$, purchasing power parity",132.1
+18019,Ireland,2016,6,G03-Sex hormones and modulators of the genital system,% of total sales,1.7
+18020,Ireland,2016,6,C02-Antihypertensives,Million of national currency units,18.3
+18021,Ireland,2016,6,C03-Diuretics,"/capita, US$ purchasing power parity",3.9
+18022,Ireland,2016,6,N05B-Anxiolytics,"/capita, US$ purchasing power parity",2.5
+18023,Ireland,2016,6,N05B-Anxiolytics,% of total sales,0.4
+18024,Ireland,2016,6,N05B-Anxiolytics,"/capita, US$ exchange rate",2.2
+18025,Ireland,2016,6,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),% of total sales,2.5
+18026,Ireland,2016,6,N05B-Anxiolytics,Million US$ at exchange rate,10.3
+18027,Ireland,2016,6,N05B-Anxiolytics,Million of national currency units,9.3
+18028,Ireland,2016,6,B-Blood and blood forming organs,% of total sales,5.1
+18029,Ireland,2016,6,C03-Diuretics,"/capita, US$ exchange rate",3.4
+18030,Ireland,2016,6,N02-Analgesics,Million of national currency units,58.0
+18031,Ireland,2016,6,N05B-Anxiolytics,"Million US$, purchasing power parity",11.8
+18032,Ireland,2016,6,N02-Analgesics,Million US$ at exchange rate,64.2
+18033,Ireland,2016,6,C03-Diuretics,Million of national currency units,14.7
+18034,Ireland,2016,6,C03-Diuretics,Million US$ at exchange rate,16.3
+18035,Ireland,2016,6,C03-Diuretics,"Million US$, purchasing power parity",18.6
+18036,Ireland,2016,6,"H-Systemic hormonal preparations, excluding sex hormones and insulins",% of total sales,2.7
+18037,Ireland,2016,6,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million of national currency units,52.4
+18038,Ireland,2016,6,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ exchange rate",13.0
+18039,Ireland,2016,6,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ purchasing power parity",14.8
+18040,Ireland,2016,6,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ purchasing power parity",13.9
+18041,Ireland,2016,6,J-Antiinfectives for systemic use,"Million US$, purchasing power parity",129.4
+18042,Ireland,2016,6,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ exchange rate",12.2
+18043,Ireland,2016,6,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million US$ at exchange rate,58.0
+18044,Ireland,2016,6,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"Million US$, purchasing power parity",66.0
+18045,Ireland,2016,6,J-Antiinfectives for systemic use,"/capita, US$ purchasing power parity",27.2
+18046,Ireland,2016,6,J-Antiinfectives for systemic use,% of total sales,5.0
+18047,Ireland,2016,6,C02-Antihypertensives,"/capita, US$ purchasing power parity",4.9
+18048,Ireland,2016,6,C02-Antihypertensives,% of total sales,0.9
+18049,Ireland,2016,6,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million US$ at exchange rate,61.7
+18050,Ireland,2016,6,"H-Systemic hormonal preparations, excluding sex hormones and insulins","Million US$, purchasing power parity",70.2
+18051,Ireland,2016,6,J-Antiinfectives for systemic use,"/capita, US$ exchange rate",23.9
+18052,Ireland,2016,6,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million of national currency units,55.7
+18053,Ireland,2016,6,N05C-Hypnotics and sedatives,"Million US$, purchasing power parity",23.6
+18054,Ireland,2016,6,N05C-Hypnotics and sedatives,Million US$ at exchange rate,20.8
+18055,Ireland,2016,6,N05C-Hypnotics and sedatives,"/capita, US$ exchange rate",4.4
+18056,Ireland,2016,6,N05C-Hypnotics and sedatives,"/capita, US$ purchasing power parity",5.0
+18057,Ireland,2016,6,C02-Antihypertensives,"Million US$, purchasing power parity",23.1
+18058,Ireland,2016,6,C02-Antihypertensives,Million US$ at exchange rate,20.3
+18059,Ireland,2016,6,N05C-Hypnotics and sedatives,Million of national currency units,18.8
+18060,Ireland,2016,6,C02-Antihypertensives,"/capita, US$ exchange rate",4.3
+18061,Ireland,2016,6,N05C-Hypnotics and sedatives,% of total sales,0.9
+18062,Ireland,2016,6,B-Blood and blood forming organs,Million of national currency units,104.9
+18063,Ireland,2016,6,B-Blood and blood forming organs,Million US$ at exchange rate,116.1
+18064,Ireland,2016,6,N02-Analgesics,"/capita, US$ exchange rate",13.5
+18065,Ireland,2016,6,N02-Analgesics,% of total sales,2.8
+18066,Ireland,2016,6,N02-Analgesics,"/capita, US$ purchasing power parity",15.4
+18067,Ireland,2016,6,C03-Diuretics,% of total sales,0.7
+18068,Ireland,2016,6,J-Antiinfectives for systemic use,Million of national currency units,102.8
+18069,Ireland,2016,6,J-Antiinfectives for systemic use,Million US$ at exchange rate,113.8
+18070,Ireland,2016,6,C01A-Cardiac glycosides,"/capita, US$ exchange rate",0.3
+18071,Ireland,2016,6,C01A-Cardiac glycosides,"Million US$, purchasing power parity",1.6
+18072,Ireland,2016,6,C01A-Cardiac glycosides,% of total sales,0.1
+18073,Ireland,2016,6,C01A-Cardiac glycosides,"/capita, US$ purchasing power parity",0.3
+18074,Ireland,2016,6,C01A-Cardiac glycosides,Million US$ at exchange rate,1.4
+18075,Ireland,2016,6,M-Musculo-skeletal system,"/capita, US$ purchasing power parity",17.9
+18076,Ireland,2016,6,M-Musculo-skeletal system,"/capita, US$ exchange rate",15.7
+18077,Ireland,2016,6,C01A-Cardiac glycosides,Million of national currency units,1.2
+18078,Ireland,2016,6,M-Musculo-skeletal system,% of total sales,3.2
+18079,Ireland,2016,6,C10-Lipid modifying agents,Million US$ at exchange rate,72.4
+18080,Ireland,2016,6,C10-Lipid modifying agents,"Million US$, purchasing power parity",82.3
+18081,Ireland,2016,6,Products not elsewhere classified,"/capita, US$ purchasing power parity",194.1
+18082,Ireland,2016,6,Products not elsewhere classified,% of total sales,35.3
+18083,Ireland,2016,6,C10-Lipid modifying agents,Million of national currency units,65.4
+18084,Ireland,2016,6,A10-Drugs used in diabetes,Million US$ at exchange rate,104.0
+18085,Ireland,2016,6,A10-Drugs used in diabetes,Million of national currency units,94.0
+18086,Ireland,2016,6,C10-Lipid modifying agents,"/capita, US$ exchange rate",15.2
+18087,Ireland,2016,6,C10-Lipid modifying agents,"/capita, US$ purchasing power parity",17.3
+18088,Ireland,2016,6,C10-Lipid modifying agents,% of total sales,3.1
+18089,Ireland,2016,6,M-Musculo-skeletal system,"Million US$, purchasing power parity",84.9
+18090,Ireland,2016,6,C08-Calcium channel blockers,Million US$ at exchange rate,20.0
+18091,Ireland,2016,6,C08-Calcium channel blockers,Million of national currency units,18.1
+18092,Ireland,2016,6,C08-Calcium channel blockers,"Million US$, purchasing power parity",22.7
+18093,Ireland,2016,6,C08-Calcium channel blockers,"/capita, US$ purchasing power parity",4.8
+18094,Ireland,2016,6,C08-Calcium channel blockers,"/capita, US$ exchange rate",4.2
+18095,Ireland,2016,6,A02A-Antacids,Million US$ at exchange rate,0.0
+18096,Ireland,2016,6,A02A-Antacids,Million of national currency units,0.0
+18097,Ireland,2016,6,A02A-Antacids,"/capita, US$ purchasing power parity",0.0
+18098,Ireland,2016,6,A02A-Antacids,"/capita, US$ exchange rate",0.0
+18099,Ireland,2016,6,A02A-Antacids,"Million US$, purchasing power parity",0.1
+18100,Ireland,2016,6,R-Respiratory system,"/capita, US$ exchange rate",39.1
+18101,Ireland,2016,6,R-Respiratory system,"Million US$, purchasing power parity",211.3
+18102,Ireland,2016,6,R-Respiratory system,% of total sales,8.1
+18103,Ireland,2016,6,R-Respiratory system,"/capita, US$ purchasing power parity",44.4
+18104,Ireland,2016,6,R-Respiratory system,Million US$ at exchange rate,185.7
+18105,Ireland,2016,6,M-Musculo-skeletal system,Million of national currency units,67.5
+18106,Ireland,2016,6,C08-Calcium channel blockers,% of total sales,0.9
+18107,Ireland,2016,6,M-Musculo-skeletal system,Million US$ at exchange rate,74.7
+18108,Ireland,2016,6,R-Respiratory system,Million of national currency units,167.8
+18109,Ireland,2016,6,R03-Drugs for obstructive airway diseases,"/capita, US$ purchasing power parity",29.5
+18110,Ireland,2016,6,R03-Drugs for obstructive airway diseases,"/capita, US$ exchange rate",25.9
+18111,Ireland,2016,6,Total pharmaceutical sales,"/capita, US$ purchasing power parity",549.6
+18112,Ireland,2016,6,R03-Drugs for obstructive airway diseases,% of total sales,5.4
+18113,Ireland,2016,6,R03-Drugs for obstructive airway diseases,"Million US$, purchasing power parity",140.2
+18114,Ireland,2016,6,C-Cardiovascular system,Million of national currency units,218.3
+18115,Ireland,2016,6,C-Cardiovascular system,Million US$ at exchange rate,241.6
+18116,Ireland,2016,6,R03-Drugs for obstructive airway diseases,Million US$ at exchange rate,123.2
+18117,Ireland,2016,6,R03-Drugs for obstructive airway diseases,Million of national currency units,111.3
+18118,Ireland,2016,6,Total pharmaceutical sales,"/capita, US$ exchange rate",483.2
+18119,Ireland,2016,6,Total pharmaceutical sales,Million US$ at exchange rate,2298.0
+18120,Ireland,2016,6,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ exchange rate",13.8
+18121,Ireland,2016,6,Total pharmaceutical sales,Million of national currency units,2076.0
+18122,Ireland,2016,6,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ purchasing power parity",15.7
+18123,Ireland,2016,6,C09-Agents acting on the Renin-Angiotensin system,% of total sales,2.9
+18124,Ireland,2016,6,Total pharmaceutical sales,"Million US$, purchasing power parity",2613.7
+18125,Ireland,2016,6,C09-Agents acting on the Renin-Angiotensin system,"Million US$, purchasing power parity",74.5
+18126,Ireland,2016,6,C09-Agents acting on the Renin-Angiotensin system,Million US$ at exchange rate,65.5
+18127,Ireland,2016,6,C09-Agents acting on the Renin-Angiotensin system,Million of national currency units,59.2
+18128,Ireland,2016,6,A10-Drugs used in diabetes,"/capita, US$ exchange rate",21.9
+18129,Ireland,2016,6,A10-Drugs used in diabetes,"Million US$, purchasing power parity",118.3
+18130,Ireland,2016,6,A10-Drugs used in diabetes,% of total sales,4.5
+18131,Ireland,2016,6,A10-Drugs used in diabetes,"/capita, US$ purchasing power parity",24.9
+18132,Ireland,2016,6,A02A-Antacids,% of total sales,0.0
+18133,Ireland,2016,6,Products not elsewhere classified,"Million US$, purchasing power parity",923.2
+18134,Ireland,2016,6,Products not elsewhere classified,"/capita, US$ exchange rate",170.7
+18135,Ireland,2016,6,Products not elsewhere classified,Million US$ at exchange rate,811.7
+18136,Ireland,2016,6,Products not elsewhere classified,Million of national currency units,733.3
+18137,Ireland,2016,6,M01A-Antiinflammatory and antirheumatic products non-steroids,Million of national currency units,19.2
+18138,Ireland,2016,6,C-Cardiovascular system,"/capita, US$ purchasing power parity",57.8
+18139,Ireland,2016,6,C-Cardiovascular system,"Million US$, purchasing power parity",274.8
+18140,Ireland,2016,6,C-Cardiovascular system,"/capita, US$ exchange rate",50.8
+18141,Ireland,2016,6,M01A-Antiinflammatory and antirheumatic products non-steroids,Million US$ at exchange rate,21.2
+18142,Ireland,2016,6,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ purchasing power parity",5.1
+18143,Ireland,2016,6,M01A-Antiinflammatory and antirheumatic products non-steroids,% of total sales,0.9
+18144,Ireland,2016,6,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ exchange rate",4.5
+18145,Ireland,2016,6,M01A-Antiinflammatory and antirheumatic products non-steroids,"Million US$, purchasing power parity",24.1
+18146,Ireland,2016,6,C-Cardiovascular system,% of total sales,10.5
+18147,Ireland,2016,6,J01-Antibacterials for systemic use,Million US$ at exchange rate,49.7
+18148,Ireland,2016,6,N-Nervous system,"/capita, US$ purchasing power parity",89.7
+18149,Ireland,2016,6,J01-Antibacterials for systemic use,Million of national currency units,44.9
+18150,Ireland,2016,6,J01-Antibacterials for systemic use,"/capita, US$ exchange rate",10.4
+18151,Ireland,2016,6,J01-Antibacterials for systemic use,"/capita, US$ purchasing power parity",11.9
+18152,Ireland,2016,6,N-Nervous system,% of total sales,16.3
+18153,Ireland,2016,6,J01-Antibacterials for systemic use,"Million US$, purchasing power parity",56.5
+18154,Ireland,2016,6,G-Genito urinary system and sex hormones,% of total sales,3.7
+18155,Ireland,2016,6,G-Genito urinary system and sex hormones,"/capita, US$ purchasing power parity",20.3
+18156,Ireland,2016,6,G-Genito urinary system and sex hormones,"/capita, US$ exchange rate",17.8
+18157,Ireland,2016,6,N-Nervous system,"Million US$, purchasing power parity",426.5
+18158,Ireland,2016,6,N-Nervous system,"/capita, US$ exchange rate",78.9
+18159,Ireland,2016,6,N-Nervous system,Million of national currency units,338.8
+18160,Ireland,2016,6,N-Nervous system,Million US$ at exchange rate,375.0
+18161,Ireland,2016,6,N06A-Antidepressants,Million US$ at exchange rate,55.0
+18162,Ireland,2016,6,N06A-Antidepressants,"Million US$, purchasing power parity",62.5
+18163,Ireland,2016,6,A-Alimentary tract and metabolism,% of total sales,10.1
+18164,Ireland,2016,6,N06A-Antidepressants,Million of national currency units,49.7
+18165,Ireland,2016,6,N06A-Antidepressants,"/capita, US$ exchange rate",11.6
+18166,Ireland,2016,6,N06A-Antidepressants,% of total sales,2.4
+18167,Ireland,2016,6,N06A-Antidepressants,"/capita, US$ purchasing power parity",13.2
+18168,Ireland,2016,6,A-Alimentary tract and metabolism,Million of national currency units,210.4
+18169,Ireland,2016,6,A-Alimentary tract and metabolism,Million US$ at exchange rate,232.9
+18170,Ireland,2016,6,J01-Antibacterials for systemic use,% of total sales,2.2
+18171,Ireland,2016,6,A-Alimentary tract and metabolism,"/capita, US$ exchange rate",49.0
+18172,Ireland,2016,6,A-Alimentary tract and metabolism,"/capita, US$ purchasing power parity",55.7
+18173,Ireland,2016,6,A-Alimentary tract and metabolism,"Million US$, purchasing power parity",264.9
+18174,Ireland,2016,6,G03-Sex hormones and modulators of the genital system,"Million US$, purchasing power parity",44.4
+18175,Ireland,2016,6,G03-Sex hormones and modulators of the genital system,Million US$ at exchange rate,39.0
+18176,Ireland,2016,6,G03-Sex hormones and modulators of the genital system,"/capita, US$ exchange rate",8.2
+18177,Ireland,2016,6,C07-Beta blocking agents,Million of national currency units,22.9
+18178,Ireland,2016,6,G03-Sex hormones and modulators of the genital system,Million of national currency units,35.3
+18179,Ireland,2016,6,"C01B-Antiarrhythmics, Class I and III","/capita, US$ exchange rate",0.7
+18180,Ireland,2016,6,G03-Sex hormones and modulators of the genital system,"/capita, US$ purchasing power parity",9.3
+18181,Ireland,2016,6,"C01B-Antiarrhythmics, Class I and III","/capita, US$ purchasing power parity",0.8
+18182,Ireland,2016,6,"C01B-Antiarrhythmics, Class I and III",% of total sales,0.1
+18183,Ireland,2016,6,"C01B-Antiarrhythmics, Class I and III",Million US$ at exchange rate,3.4
+18184,Ireland,2016,6,"C01B-Antiarrhythmics, Class I and III",Million of national currency units,3.1
+18185,Ireland,2016,6,C07-Beta blocking agents,Million US$ at exchange rate,25.4
+18186,Ireland,2016,6,"C01B-Antiarrhythmics, Class I and III","Million US$, purchasing power parity",3.9
+18187,Ireland,2016,6,C07-Beta blocking agents,% of total sales,1.1
+18188,Ireland,2016,6,C07-Beta blocking agents,"/capita, US$ purchasing power parity",6.1
+18189,Ireland,2016,6,C07-Beta blocking agents,"/capita, US$ exchange rate",5.3
+18190,Ireland,2016,6,G-Genito urinary system and sex hormones,"Million US$, purchasing power parity",96.5
+18191,Ireland,2016,6,G-Genito urinary system and sex hormones,Million US$ at exchange rate,84.8
+18192,Ireland,2016,6,G-Genito urinary system and sex hormones,Million of national currency units,76.6
+18193,Ireland,2016,6,C07-Beta blocking agents,"Million US$, purchasing power parity",28.9
+18194,Ireland,2015,6,N02-Analgesics,"Million US$, purchasing power parity",71.0
+18195,Ireland,2015,6,B-Blood and blood forming organs,"/capita, US$ purchasing power parity",25.0
+18196,Ireland,2015,6,B-Blood and blood forming organs,"Million US$, purchasing power parity",117.5
+18197,Ireland,2015,6,B-Blood and blood forming organs,"/capita, US$ exchange rate",22.5
+18198,Ireland,2015,6,N05B-Anxiolytics,"Million US$, purchasing power parity",11.6
+18199,Ireland,2015,6,G03-Sex hormones and modulators of the genital system,% of total sales,1.7
+18200,Ireland,2015,6,C02-Antihypertensives,Million of national currency units,17.2
+18201,Ireland,2015,6,C03-Diuretics,"/capita, US$ purchasing power parity",4.0
+18202,Ireland,2015,6,N05B-Anxiolytics,"/capita, US$ purchasing power parity",2.5
+18203,Ireland,2015,6,N05B-Anxiolytics,% of total sales,0.5
+18204,Ireland,2015,6,B-Blood and blood forming organs,% of total sales,4.8
+18205,Ireland,2015,6,N05B-Anxiolytics,"/capita, US$ exchange rate",2.2
+18206,Ireland,2015,6,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),% of total sales,2.8
+18207,Ireland,2015,6,N05B-Anxiolytics,Million US$ at exchange rate,10.4
+18208,Ireland,2015,6,N05B-Anxiolytics,Million of national currency units,9.4
+18209,Ireland,2015,6,C03-Diuretics,"/capita, US$ exchange rate",3.6
+18210,Ireland,2015,6,N02-Analgesics,Million of national currency units,57.5
+18211,Ireland,2015,6,N02-Analgesics,Million US$ at exchange rate,63.7
+18212,Ireland,2015,6,C03-Diuretics,Million of national currency units,15.4
+18213,Ireland,2015,6,C03-Diuretics,Million US$ at exchange rate,17.1
+18214,Ireland,2015,6,C03-Diuretics,"Million US$, purchasing power parity",19.0
+18215,Ireland,2015,6,"H-Systemic hormonal preparations, excluding sex hormones and insulins",% of total sales,2.7
+18216,Ireland,2015,6,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million of national currency units,55.6
+18217,Ireland,2015,6,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ exchange rate",12.6
+18218,Ireland,2015,6,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ purchasing power parity",14.0
+18219,Ireland,2015,6,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million US$ at exchange rate,61.7
+18220,Ireland,2015,6,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ purchasing power parity",14.6
+18221,Ireland,2015,6,J-Antiinfectives for systemic use,"Million US$, purchasing power parity",110.7
+18222,Ireland,2015,6,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ exchange rate",13.1
+18223,Ireland,2015,6,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"Million US$, purchasing power parity",68.6
+18224,Ireland,2015,6,J-Antiinfectives for systemic use,"/capita, US$ purchasing power parity",23.5
+18225,Ireland,2015,6,J-Antiinfectives for systemic use,% of total sales,4.5
+18226,Ireland,2015,6,C02-Antihypertensives,"/capita, US$ purchasing power parity",4.5
+18227,Ireland,2015,6,C02-Antihypertensives,% of total sales,0.9
+18228,Ireland,2015,6,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million US$ at exchange rate,59.2
+18229,Ireland,2015,6,"H-Systemic hormonal preparations, excluding sex hormones and insulins","Million US$, purchasing power parity",65.9
+18230,Ireland,2015,6,J-Antiinfectives for systemic use,"/capita, US$ exchange rate",21.2
+18231,Ireland,2015,6,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million of national currency units,53.4
+18232,Ireland,2015,6,N05C-Hypnotics and sedatives,"Million US$, purchasing power parity",22.6
+18233,Ireland,2015,6,N05C-Hypnotics and sedatives,Million US$ at exchange rate,20.3
+18234,Ireland,2015,6,N05C-Hypnotics and sedatives,"/capita, US$ exchange rate",4.3
+18235,Ireland,2015,6,N05C-Hypnotics and sedatives,"/capita, US$ purchasing power parity",4.8
+18236,Ireland,2015,6,N05C-Hypnotics and sedatives,% of total sales,0.9
+18237,Ireland,2015,6,C02-Antihypertensives,"Million US$, purchasing power parity",21.2
+18238,Ireland,2015,6,C02-Antihypertensives,Million US$ at exchange rate,19.1
+18239,Ireland,2015,6,N05C-Hypnotics and sedatives,Million of national currency units,18.3
+18240,Ireland,2015,6,C02-Antihypertensives,"/capita, US$ exchange rate",4.1
+18241,Ireland,2015,6,B-Blood and blood forming organs,Million of national currency units,95.2
+18242,Ireland,2015,6,N02-Analgesics,"/capita, US$ exchange rate",13.6
+18243,Ireland,2015,6,B-Blood and blood forming organs,Million US$ at exchange rate,105.6
+18244,Ireland,2015,6,N02-Analgesics,% of total sales,2.9
+18245,Ireland,2015,6,N02-Analgesics,"/capita, US$ purchasing power parity",15.1
+18246,Ireland,2015,6,C03-Diuretics,% of total sales,0.8
+18247,Ireland,2015,6,J-Antiinfectives for systemic use,Million of national currency units,89.6
+18248,Ireland,2015,6,J-Antiinfectives for systemic use,Million US$ at exchange rate,99.5
+18249,Ireland,2015,6,C01A-Cardiac glycosides,"/capita, US$ exchange rate",0.3
+18250,Ireland,2015,6,C01A-Cardiac glycosides,"Million US$, purchasing power parity",1.7
+18251,Ireland,2015,6,C01A-Cardiac glycosides,% of total sales,0.1
+18252,Ireland,2015,6,C01A-Cardiac glycosides,"/capita, US$ purchasing power parity",0.4
+18253,Ireland,2015,6,C01A-Cardiac glycosides,Million US$ at exchange rate,1.5
+18254,Ireland,2015,6,M-Musculo-skeletal system,"/capita, US$ purchasing power parity",17.4
+18255,Ireland,2015,6,M-Musculo-skeletal system,"/capita, US$ exchange rate",15.6
+18256,Ireland,2015,6,C01A-Cardiac glycosides,Million of national currency units,1.3
+18257,Ireland,2015,6,M-Musculo-skeletal system,% of total sales,3.3
+18258,Ireland,2015,6,C10-Lipid modifying agents,Million US$ at exchange rate,72.7
+18259,Ireland,2015,6,C10-Lipid modifying agents,"Million US$, purchasing power parity",80.9
+18260,Ireland,2015,6,Products not elsewhere classified,"/capita, US$ purchasing power parity",174.4
+18261,Ireland,2015,6,Products not elsewhere classified,% of total sales,33.4
+18262,Ireland,2015,6,C10-Lipid modifying agents,Million of national currency units,65.5
+18263,Ireland,2015,6,A10-Drugs used in diabetes,Million US$ at exchange rate,99.1
+18264,Ireland,2015,6,A10-Drugs used in diabetes,Million of national currency units,89.3
+18265,Ireland,2015,6,C10-Lipid modifying agents,% of total sales,3.3
+18266,Ireland,2015,6,C10-Lipid modifying agents,"/capita, US$ exchange rate",15.5
+18267,Ireland,2015,6,C10-Lipid modifying agents,"/capita, US$ purchasing power parity",17.2
+18268,Ireland,2015,6,C08-Calcium channel blockers,"Million US$, purchasing power parity",22.2
+18269,Ireland,2015,6,C08-Calcium channel blockers,Million US$ at exchange rate,20.0
+18270,Ireland,2015,6,C08-Calcium channel blockers,Million of national currency units,18.0
+18271,Ireland,2015,6,C08-Calcium channel blockers,"/capita, US$ purchasing power parity",4.7
+18272,Ireland,2015,6,C08-Calcium channel blockers,"/capita, US$ exchange rate",4.2
+18273,Ireland,2015,6,A02A-Antacids,Million US$ at exchange rate,0.1
+18274,Ireland,2015,6,A02A-Antacids,Million of national currency units,0.1
+18275,Ireland,2015,6,A02A-Antacids,"Million US$, purchasing power parity",0.1
+18276,Ireland,2015,6,A02A-Antacids,"/capita, US$ purchasing power parity",0.0
+18277,Ireland,2015,6,A02A-Antacids,"/capita, US$ exchange rate",0.0
+18278,Ireland,2015,6,R-Respiratory system,"/capita, US$ exchange rate",40.0
+18279,Ireland,2015,6,R-Respiratory system,"Million US$, purchasing power parity",209.4
+18280,Ireland,2015,6,M-Musculo-skeletal system,"Million US$, purchasing power parity",81.8
+18281,Ireland,2015,6,R-Respiratory system,% of total sales,8.5
+18282,Ireland,2015,6,R-Respiratory system,"/capita, US$ purchasing power parity",44.5
+18283,Ireland,2015,6,M-Musculo-skeletal system,Million of national currency units,66.2
+18284,Ireland,2015,6,C08-Calcium channel blockers,% of total sales,0.9
+18285,Ireland,2015,6,R-Respiratory system,Million US$ at exchange rate,188.1
+18286,Ireland,2015,6,R-Respiratory system,Million of national currency units,169.5
+18287,Ireland,2015,6,M-Musculo-skeletal system,Million US$ at exchange rate,73.5
+18288,Ireland,2015,6,R03-Drugs for obstructive airway diseases,"/capita, US$ purchasing power parity",30.3
+18289,Ireland,2015,6,R03-Drugs for obstructive airway diseases,"/capita, US$ exchange rate",27.2
+18290,Ireland,2015,6,Total pharmaceutical sales,"/capita, US$ purchasing power parity",521.4
+18291,Ireland,2015,6,R03-Drugs for obstructive airway diseases,% of total sales,5.8
+18292,Ireland,2015,6,R03-Drugs for obstructive airway diseases,"Million US$, purchasing power parity",142.5
+18293,Ireland,2015,6,C-Cardiovascular system,Million of national currency units,217.8
+18294,Ireland,2015,6,C-Cardiovascular system,Million US$ at exchange rate,241.7
+18295,Ireland,2015,6,R03-Drugs for obstructive airway diseases,Million US$ at exchange rate,128.0
+18296,Ireland,2015,6,R03-Drugs for obstructive airway diseases,Million of national currency units,115.4
+18297,Ireland,2015,6,Total pharmaceutical sales,Million US$ at exchange rate,2202.5
+18298,Ireland,2015,6,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ exchange rate",14.0
+18299,Ireland,2015,6,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ purchasing power parity",15.6
+18300,Ireland,2015,6,C09-Agents acting on the Renin-Angiotensin system,% of total sales,3.0
+18301,Ireland,2015,6,Total pharmaceutical sales,Million of national currency units,1985.1
+18302,Ireland,2015,6,Total pharmaceutical sales,"Million US$, purchasing power parity",2451.7
+18303,Ireland,2015,6,Total pharmaceutical sales,"/capita, US$ exchange rate",468.4
+18304,Ireland,2015,6,C09-Agents acting on the Renin-Angiotensin system,Million of national currency units,59.5
+18305,Ireland,2015,6,C09-Agents acting on the Renin-Angiotensin system,"Million US$, purchasing power parity",73.4
+18306,Ireland,2015,6,C09-Agents acting on the Renin-Angiotensin system,Million US$ at exchange rate,66.0
+18307,Ireland,2015,6,A10-Drugs used in diabetes,"/capita, US$ exchange rate",21.1
+18308,Ireland,2015,6,A10-Drugs used in diabetes,"Million US$, purchasing power parity",110.3
+18309,Ireland,2015,6,A10-Drugs used in diabetes,% of total sales,4.5
+18310,Ireland,2015,6,A10-Drugs used in diabetes,"/capita, US$ purchasing power parity",23.5
+18311,Ireland,2015,6,A02A-Antacids,% of total sales,0.0
+18312,Ireland,2015,6,Products not elsewhere classified,"Million US$, purchasing power parity",819.8
+18313,Ireland,2015,6,Products not elsewhere classified,"/capita, US$ exchange rate",156.6
+18314,Ireland,2015,6,Products not elsewhere classified,Million of national currency units,663.8
+18315,Ireland,2015,6,Products not elsewhere classified,Million US$ at exchange rate,736.5
+18316,Ireland,2015,6,C-Cardiovascular system,% of total sales,11.0
+18317,Ireland,2015,6,M01A-Antiinflammatory and antirheumatic products non-steroids,Million of national currency units,19.7
+18318,Ireland,2015,6,M01A-Antiinflammatory and antirheumatic products non-steroids,Million US$ at exchange rate,21.9
+18319,Ireland,2015,6,C-Cardiovascular system,"Million US$, purchasing power parity",269.0
+18320,Ireland,2015,6,C-Cardiovascular system,"/capita, US$ exchange rate",51.4
+18321,Ireland,2015,6,C-Cardiovascular system,"/capita, US$ purchasing power parity",57.2
+18322,Ireland,2015,6,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ purchasing power parity",5.2
+18323,Ireland,2015,6,M01A-Antiinflammatory and antirheumatic products non-steroids,% of total sales,1.0
+18324,Ireland,2015,6,M01A-Antiinflammatory and antirheumatic products non-steroids,"Million US$, purchasing power parity",24.4
+18325,Ireland,2015,6,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ exchange rate",4.7
+18326,Ireland,2015,6,J01-Antibacterials for systemic use,Million US$ at exchange rate,53.0
+18327,Ireland,2015,6,N-Nervous system,"/capita, US$ purchasing power parity",91.7
+18328,Ireland,2015,6,J01-Antibacterials for systemic use,Million of national currency units,47.7
+18329,Ireland,2015,6,J01-Antibacterials for systemic use,"/capita, US$ exchange rate",11.3
+18330,Ireland,2015,6,J01-Antibacterials for systemic use,"/capita, US$ purchasing power parity",12.5
+18331,Ireland,2015,6,N-Nervous system,% of total sales,17.6
+18332,Ireland,2015,6,J01-Antibacterials for systemic use,"Million US$, purchasing power parity",58.9
+18333,Ireland,2015,6,G-Genito urinary system and sex hormones,% of total sales,3.7
+18334,Ireland,2015,6,G-Genito urinary system and sex hormones,"/capita, US$ exchange rate",17.5
+18335,Ireland,2015,6,G-Genito urinary system and sex hormones,"/capita, US$ purchasing power parity",19.5
+18336,Ireland,2015,6,N-Nervous system,Million of national currency units,349.3
+18337,Ireland,2015,6,N-Nervous system,"Million US$, purchasing power parity",431.4
+18338,Ireland,2015,6,N-Nervous system,"/capita, US$ exchange rate",82.4
+18339,Ireland,2015,6,N-Nervous system,Million US$ at exchange rate,387.5
+18340,Ireland,2015,6,N06A-Antidepressants,Million US$ at exchange rate,62.3
+18341,Ireland,2015,6,N06A-Antidepressants,"Million US$, purchasing power parity",69.4
+18342,Ireland,2015,6,A-Alimentary tract and metabolism,% of total sales,10.4
+18343,Ireland,2015,6,N06A-Antidepressants,Million of national currency units,56.2
+18344,Ireland,2015,6,N06A-Antidepressants,"/capita, US$ exchange rate",13.3
+18345,Ireland,2015,6,N06A-Antidepressants,% of total sales,2.8
+18346,Ireland,2015,6,N06A-Antidepressants,"/capita, US$ purchasing power parity",14.8
+18347,Ireland,2015,6,A-Alimentary tract and metabolism,Million of national currency units,206.0
+18348,Ireland,2015,6,A-Alimentary tract and metabolism,Million US$ at exchange rate,228.6
+18349,Ireland,2015,6,J01-Antibacterials for systemic use,% of total sales,2.4
+18350,Ireland,2015,6,A-Alimentary tract and metabolism,"/capita, US$ purchasing power parity",54.1
+18351,Ireland,2015,6,A-Alimentary tract and metabolism,"/capita, US$ exchange rate",48.6
+18352,Ireland,2015,6,A-Alimentary tract and metabolism,"Million US$, purchasing power parity",254.4
+18353,Ireland,2015,6,G03-Sex hormones and modulators of the genital system,"Million US$, purchasing power parity",42.4
+18354,Ireland,2015,6,G03-Sex hormones and modulators of the genital system,Million US$ at exchange rate,38.1
+18355,Ireland,2015,6,G03-Sex hormones and modulators of the genital system,"/capita, US$ exchange rate",8.1
+18356,Ireland,2015,6,C07-Beta blocking agents,Million of national currency units,22.7
+18357,Ireland,2015,6,C07-Beta blocking agents,Million US$ at exchange rate,25.2
+18358,Ireland,2015,6,G03-Sex hormones and modulators of the genital system,Million of national currency units,34.3
+18359,Ireland,2015,6,"C01B-Antiarrhythmics, Class I and III","/capita, US$ exchange rate",0.7
+18360,Ireland,2015,6,G03-Sex hormones and modulators of the genital system,"/capita, US$ purchasing power parity",9.0
+18361,Ireland,2015,6,"C01B-Antiarrhythmics, Class I and III","/capita, US$ purchasing power parity",0.8
+18362,Ireland,2015,6,"C01B-Antiarrhythmics, Class I and III",% of total sales,0.1
+18363,Ireland,2015,6,"C01B-Antiarrhythmics, Class I and III",Million US$ at exchange rate,3.3
+18364,Ireland,2015,6,"C01B-Antiarrhythmics, Class I and III",Million of national currency units,3.0
+18365,Ireland,2015,6,"C01B-Antiarrhythmics, Class I and III","Million US$, purchasing power parity",3.7
+18366,Ireland,2015,6,C07-Beta blocking agents,% of total sales,1.1
+18367,Ireland,2015,6,C07-Beta blocking agents,"/capita, US$ purchasing power parity",6.0
+18368,Ireland,2015,6,C07-Beta blocking agents,"/capita, US$ exchange rate",5.4
+18369,Ireland,2015,6,G-Genito urinary system and sex hormones,"Million US$, purchasing power parity",91.7
+18370,Ireland,2015,6,G-Genito urinary system and sex hormones,Million US$ at exchange rate,82.4
+18371,Ireland,2015,6,G-Genito urinary system and sex hormones,Million of national currency units,74.3
+18372,Ireland,2015,6,C07-Beta blocking agents,"Million US$, purchasing power parity",28.0
+18373,Ireland,2014,6,B-Blood and blood forming organs,"/capita, US$ purchasing power parity",23.7
+18374,Ireland,2014,6,B-Blood and blood forming organs,"Million US$, purchasing power parity",110.5
+18375,Ireland,2014,6,B-Blood and blood forming organs,"/capita, US$ exchange rate",25.8
+18376,Ireland,2014,6,N02-Analgesics,"Million US$, purchasing power parity",67.1
+18377,Ireland,2014,6,G03-Sex hormones and modulators of the genital system,% of total sales,1.7
+18378,Ireland,2014,6,C02-Antihypertensives,Million of national currency units,16.6
+18379,Ireland,2014,6,C03-Diuretics,"/capita, US$ purchasing power parity",4.2
+18380,Ireland,2014,6,B-Blood and blood forming organs,% of total sales,4.7
+18381,Ireland,2014,6,N05B-Anxiolytics,"/capita, US$ purchasing power parity",2.4
+18382,Ireland,2014,6,N05B-Anxiolytics,% of total sales,0.5
+18383,Ireland,2014,6,N05B-Anxiolytics,"/capita, US$ exchange rate",2.6
+18384,Ireland,2014,6,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),% of total sales,3.5
+18385,Ireland,2014,6,N05B-Anxiolytics,"Million US$, purchasing power parity",11.3
+18386,Ireland,2014,6,N05B-Anxiolytics,Million US$ at exchange rate,12.3
+18387,Ireland,2014,6,N05B-Anxiolytics,Million of national currency units,9.3
+18388,Ireland,2014,6,C03-Diuretics,"/capita, US$ exchange rate",4.5
+18389,Ireland,2014,6,N02-Analgesics,Million of national currency units,54.9
+18390,Ireland,2014,6,N02-Analgesics,Million US$ at exchange rate,73.0
+18391,Ireland,2014,6,C03-Diuretics,Million of national currency units,15.9
+18392,Ireland,2014,6,C03-Diuretics,Million US$ at exchange rate,21.2
+18393,Ireland,2014,6,C03-Diuretics,"Million US$, purchasing power parity",19.5
+18394,Ireland,2014,6,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million of national currency units,66.3
+18395,Ireland,2014,6,"H-Systemic hormonal preparations, excluding sex hormones and insulins",% of total sales,2.7
+18396,Ireland,2014,6,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ exchange rate",14.7
+18397,Ireland,2014,6,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ purchasing power parity",13.5
+18398,Ireland,2014,6,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ purchasing power parity",17.4
+18399,Ireland,2014,6,J-Antiinfectives for systemic use,"Million US$, purchasing power parity",83.6
+18400,Ireland,2014,6,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million US$ at exchange rate,88.1
+18401,Ireland,2014,6,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ exchange rate",18.9
+18402,Ireland,2014,6,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"Million US$, purchasing power parity",81.0
+18403,Ireland,2014,6,J-Antiinfectives for systemic use,"/capita, US$ purchasing power parity",18.0
+18404,Ireland,2014,6,J-Antiinfectives for systemic use,% of total sales,3.6
+18405,Ireland,2014,6,C02-Antihypertensives,"/capita, US$ purchasing power parity",4.3
+18406,Ireland,2014,6,C02-Antihypertensives,% of total sales,0.9
+18407,Ireland,2014,6,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million US$ at exchange rate,68.4
+18408,Ireland,2014,6,"H-Systemic hormonal preparations, excluding sex hormones and insulins","Million US$, purchasing power parity",62.9
+18409,Ireland,2014,6,J-Antiinfectives for systemic use,"/capita, US$ exchange rate",19.5
+18410,Ireland,2014,6,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million of national currency units,51.5
+18411,Ireland,2014,6,N05C-Hypnotics and sedatives,"Million US$, purchasing power parity",22.9
+18412,Ireland,2014,6,N05C-Hypnotics and sedatives,Million US$ at exchange rate,24.9
+18413,Ireland,2014,6,N05C-Hypnotics and sedatives,"/capita, US$ exchange rate",5.4
+18414,Ireland,2014,6,N05C-Hypnotics and sedatives,% of total sales,1.0
+18415,Ireland,2014,6,N05C-Hypnotics and sedatives,"/capita, US$ purchasing power parity",4.9
+18416,Ireland,2014,6,C02-Antihypertensives,"Million US$, purchasing power parity",20.2
+18417,Ireland,2014,6,C02-Antihypertensives,Million US$ at exchange rate,22.0
+18418,Ireland,2014,6,N05C-Hypnotics and sedatives,Million of national currency units,18.8
+18419,Ireland,2014,6,C02-Antihypertensives,"/capita, US$ exchange rate",4.7
+18420,Ireland,2014,6,N02-Analgesics,"/capita, US$ exchange rate",15.7
+18421,Ireland,2014,6,B-Blood and blood forming organs,Million of national currency units,90.5
+18422,Ireland,2014,6,B-Blood and blood forming organs,Million US$ at exchange rate,120.2
+18423,Ireland,2014,6,N02-Analgesics,% of total sales,2.9
+18424,Ireland,2014,6,N02-Analgesics,"/capita, US$ purchasing power parity",14.4
+18425,Ireland,2014,6,C03-Diuretics,% of total sales,0.8
+18426,Ireland,2014,6,J-Antiinfectives for systemic use,Million of national currency units,68.5
+18427,Ireland,2014,6,J-Antiinfectives for systemic use,Million US$ at exchange rate,91.0
+18428,Ireland,2014,6,C01A-Cardiac glycosides,"/capita, US$ exchange rate",0.4
+18429,Ireland,2014,6,C01A-Cardiac glycosides,"Million US$, purchasing power parity",1.7
+18430,Ireland,2014,6,C01A-Cardiac glycosides,% of total sales,0.1
+18431,Ireland,2014,6,C01A-Cardiac glycosides,"/capita, US$ purchasing power parity",0.4
+18432,Ireland,2014,6,C01A-Cardiac glycosides,Million US$ at exchange rate,1.9
+18433,Ireland,2014,6,M-Musculo-skeletal system,"/capita, US$ purchasing power parity",17.3
+18434,Ireland,2014,6,M-Musculo-skeletal system,"/capita, US$ exchange rate",18.8
+18435,Ireland,2014,6,C01A-Cardiac glycosides,Million of national currency units,1.4
+18436,Ireland,2014,6,M-Musculo-skeletal system,% of total sales,3.4
+18437,Ireland,2014,6,C10-Lipid modifying agents,Million US$ at exchange rate,92.2
+18438,Ireland,2014,6,C10-Lipid modifying agents,"Million US$, purchasing power parity",84.7
+18439,Ireland,2014,6,Products not elsewhere classified,"/capita, US$ purchasing power parity",158.5
+18440,Ireland,2014,6,Products not elsewhere classified,% of total sales,31.6
+18441,Ireland,2014,6,C10-Lipid modifying agents,Million of national currency units,69.4
+18442,Ireland,2014,6,A10-Drugs used in diabetes,Million US$ at exchange rate,111.1
+18443,Ireland,2014,6,A10-Drugs used in diabetes,Million of national currency units,83.6
+18444,Ireland,2014,6,C10-Lipid modifying agents,"/capita, US$ exchange rate",19.8
+18445,Ireland,2014,6,C10-Lipid modifying agents,"/capita, US$ purchasing power parity",18.2
+18446,Ireland,2014,6,C10-Lipid modifying agents,% of total sales,3.6
+18447,Ireland,2014,6,C08-Calcium channel blockers,"Million US$, purchasing power parity",27.3
+18448,Ireland,2014,6,C08-Calcium channel blockers,Million US$ at exchange rate,29.7
+18449,Ireland,2014,6,C08-Calcium channel blockers,"/capita, US$ purchasing power parity",5.9
+18450,Ireland,2014,6,C08-Calcium channel blockers,"/capita, US$ exchange rate",6.4
+18451,Ireland,2014,6,C08-Calcium channel blockers,Million of national currency units,22.3
+18452,Ireland,2014,6,A02A-Antacids,Million US$ at exchange rate,0.1
+18453,Ireland,2014,6,A02A-Antacids,Million of national currency units,0.1
+18454,Ireland,2014,6,A02A-Antacids,"Million US$, purchasing power parity",0.1
+18455,Ireland,2014,6,A02A-Antacids,"/capita, US$ purchasing power parity",0.0
+18456,Ireland,2014,6,A02A-Antacids,"/capita, US$ exchange rate",0.0
+18457,Ireland,2014,6,R-Respiratory system,"/capita, US$ exchange rate",47.1
+18458,Ireland,2014,6,R-Respiratory system,"Million US$, purchasing power parity",201.5
+18459,Ireland,2014,6,M-Musculo-skeletal system,"Million US$, purchasing power parity",80.5
+18460,Ireland,2014,6,R-Respiratory system,% of total sales,8.6
+18461,Ireland,2014,6,R-Respiratory system,"/capita, US$ purchasing power parity",43.3
+18462,Ireland,2014,6,M-Musculo-skeletal system,Million of national currency units,66.0
+18463,Ireland,2014,6,C08-Calcium channel blockers,% of total sales,1.2
+18464,Ireland,2014,6,M-Musculo-skeletal system,Million US$ at exchange rate,87.6
+18465,Ireland,2014,6,R-Respiratory system,Million US$ at exchange rate,219.3
+18466,Ireland,2014,6,R-Respiratory system,Million of national currency units,165.0
+18467,Ireland,2014,6,R03-Drugs for obstructive airway diseases,"/capita, US$ purchasing power parity",29.7
+18468,Ireland,2014,6,R03-Drugs for obstructive airway diseases,"/capita, US$ exchange rate",32.4
+18469,Ireland,2014,6,Total pharmaceutical sales,"/capita, US$ purchasing power parity",501.7
+18470,Ireland,2014,6,R03-Drugs for obstructive airway diseases,% of total sales,5.9
+18471,Ireland,2014,6,C-Cardiovascular system,Million of national currency units,233.7
+18472,Ireland,2014,6,C-Cardiovascular system,Million US$ at exchange rate,310.5
+18473,Ireland,2014,6,R03-Drugs for obstructive airway diseases,"Million US$, purchasing power parity",138.5
+18474,Ireland,2014,6,R03-Drugs for obstructive airway diseases,Million US$ at exchange rate,150.7
+18475,Ireland,2014,6,R03-Drugs for obstructive airway diseases,Million of national currency units,113.5
+18476,Ireland,2014,6,Total pharmaceutical sales,Million US$ at exchange rate,2542.4
+18477,Ireland,2014,6,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ exchange rate",19.2
+18478,Ireland,2014,6,Total pharmaceutical sales,Million of national currency units,1913.8
+18479,Ireland,2014,6,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ purchasing power parity",17.6
+18480,Ireland,2014,6,C09-Agents acting on the Renin-Angiotensin system,% of total sales,3.5
+18481,Ireland,2014,6,Total pharmaceutical sales,"Million US$, purchasing power parity",2336.6
+18482,Ireland,2014,6,Total pharmaceutical sales,"/capita, US$ exchange rate",545.9
+18483,Ireland,2014,6,C09-Agents acting on the Renin-Angiotensin system,"Million US$, purchasing power parity",82.0
+18484,Ireland,2014,6,C09-Agents acting on the Renin-Angiotensin system,Million US$ at exchange rate,89.2
+18485,Ireland,2014,6,C09-Agents acting on the Renin-Angiotensin system,Million of national currency units,67.2
+18486,Ireland,2014,6,C-Cardiovascular system,"Million US$, purchasing power parity",285.4
+18487,Ireland,2014,6,A10-Drugs used in diabetes,"/capita, US$ exchange rate",23.8
+18488,Ireland,2014,6,A10-Drugs used in diabetes,"Million US$, purchasing power parity",102.1
+18489,Ireland,2014,6,A10-Drugs used in diabetes,% of total sales,4.4
+18490,Ireland,2014,6,A10-Drugs used in diabetes,"/capita, US$ purchasing power parity",21.9
+18491,Ireland,2014,6,A02A-Antacids,% of total sales,0.0
+18492,Ireland,2014,6,Products not elsewhere classified,"Million US$, purchasing power parity",738.3
+18493,Ireland,2014,6,Products not elsewhere classified,"/capita, US$ exchange rate",172.5
+18494,Ireland,2014,6,Products not elsewhere classified,Million of national currency units,604.7
+18495,Ireland,2014,6,Products not elsewhere classified,Million US$ at exchange rate,803.3
+18496,Ireland,2014,6,C-Cardiovascular system,% of total sales,12.2
+18497,Ireland,2014,6,M01A-Antiinflammatory and antirheumatic products non-steroids,Million of national currency units,19.9
+18498,Ireland,2014,6,M01A-Antiinflammatory and antirheumatic products non-steroids,Million US$ at exchange rate,26.4
+18499,Ireland,2014,6,C-Cardiovascular system,"/capita, US$ exchange rate",66.7
+18500,Ireland,2014,6,C-Cardiovascular system,"/capita, US$ purchasing power parity",61.3
+18501,Ireland,2014,6,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ purchasing power parity",5.2
+18502,Ireland,2014,6,M01A-Antiinflammatory and antirheumatic products non-steroids,% of total sales,1.0
+18503,Ireland,2014,6,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ exchange rate",5.7
+18504,Ireland,2014,6,M01A-Antiinflammatory and antirheumatic products non-steroids,"Million US$, purchasing power parity",24.3
+18505,Ireland,2014,6,J01-Antibacterials for systemic use,Million US$ at exchange rate,63.8
+18506,Ireland,2014,6,N-Nervous system,"/capita, US$ purchasing power parity",92.4
+18507,Ireland,2014,6,J01-Antibacterials for systemic use,Million of national currency units,48.0
+18508,Ireland,2014,6,J01-Antibacterials for systemic use,"/capita, US$ exchange rate",13.7
+18509,Ireland,2014,6,J01-Antibacterials for systemic use,"/capita, US$ purchasing power parity",12.6
+18510,Ireland,2014,6,N-Nervous system,% of total sales,18.4
+18511,Ireland,2014,6,J01-Antibacterials for systemic use,"Million US$, purchasing power parity",58.6
+18512,Ireland,2014,6,G-Genito urinary system and sex hormones,% of total sales,3.9
+18513,Ireland,2014,6,G-Genito urinary system and sex hormones,"/capita, US$ exchange rate",21.2
+18514,Ireland,2014,6,G-Genito urinary system and sex hormones,"/capita, US$ purchasing power parity",19.4
+18515,Ireland,2014,6,N-Nervous system,Million of national currency units,352.3
+18516,Ireland,2014,6,N-Nervous system,"Million US$, purchasing power parity",430.2
+18517,Ireland,2014,6,N-Nervous system,"/capita, US$ exchange rate",100.5
+18518,Ireland,2014,6,N-Nervous system,Million US$ at exchange rate,468.1
+18519,Ireland,2014,6,N06A-Antidepressants,Million US$ at exchange rate,93.1
+18520,Ireland,2014,6,N06A-Antidepressants,"Million US$, purchasing power parity",85.6
+18521,Ireland,2014,6,A-Alimentary tract and metabolism,% of total sales,10.8
+18522,Ireland,2014,6,N06A-Antidepressants,"/capita, US$ exchange rate",20.0
+18523,Ireland,2014,6,N06A-Antidepressants,"/capita, US$ purchasing power parity",18.4
+18524,Ireland,2014,6,N06A-Antidepressants,% of total sales,3.7
+18525,Ireland,2014,6,A-Alimentary tract and metabolism,Million of national currency units,207.4
+18526,Ireland,2014,6,A-Alimentary tract and metabolism,Million US$ at exchange rate,275.5
+18527,Ireland,2014,6,J01-Antibacterials for systemic use,% of total sales,2.5
+18528,Ireland,2014,6,N06A-Antidepressants,Million of national currency units,70.1
+18529,Ireland,2014,6,A-Alimentary tract and metabolism,"/capita, US$ purchasing power parity",54.4
+18530,Ireland,2014,6,A-Alimentary tract and metabolism,"/capita, US$ exchange rate",59.1
+18531,Ireland,2014,6,A-Alimentary tract and metabolism,"Million US$, purchasing power parity",253.2
+18532,Ireland,2014,6,G03-Sex hormones and modulators of the genital system,"Million US$, purchasing power parity",40.0
+18533,Ireland,2014,6,G03-Sex hormones and modulators of the genital system,"/capita, US$ exchange rate",9.3
+18534,Ireland,2014,6,G03-Sex hormones and modulators of the genital system,Million US$ at exchange rate,43.5
+18535,Ireland,2014,6,C07-Beta blocking agents,Million of national currency units,23.4
+18536,Ireland,2014,6,C07-Beta blocking agents,Million US$ at exchange rate,31.0
+18537,Ireland,2014,6,G03-Sex hormones and modulators of the genital system,Million of national currency units,32.8
+18538,Ireland,2014,6,"C01B-Antiarrhythmics, Class I and III","/capita, US$ exchange rate",0.7
+18539,Ireland,2014,6,"C01B-Antiarrhythmics, Class I and III","/capita, US$ purchasing power parity",0.6
+18540,Ireland,2014,6,"C01B-Antiarrhythmics, Class I and III",% of total sales,0.1
+18541,Ireland,2014,6,G03-Sex hormones and modulators of the genital system,"/capita, US$ purchasing power parity",8.6
+18542,Ireland,2014,6,"C01B-Antiarrhythmics, Class I and III",Million US$ at exchange rate,3.0
+18543,Ireland,2014,6,"C01B-Antiarrhythmics, Class I and III",Million of national currency units,2.3
+18544,Ireland,2014,6,"C01B-Antiarrhythmics, Class I and III","Million US$, purchasing power parity",2.8
+18545,Ireland,2014,6,C07-Beta blocking agents,% of total sales,1.2
+18546,Ireland,2014,6,C07-Beta blocking agents,"/capita, US$ exchange rate",6.7
+18547,Ireland,2014,6,C07-Beta blocking agents,"/capita, US$ purchasing power parity",6.1
+18548,Ireland,2014,6,G-Genito urinary system and sex hormones,"Million US$, purchasing power parity",90.6
+18549,Ireland,2014,6,G-Genito urinary system and sex hormones,Million of national currency units,74.2
+18550,Ireland,2014,6,G-Genito urinary system and sex hormones,Million US$ at exchange rate,98.6
+18551,Ireland,2014,6,C07-Beta blocking agents,"Million US$, purchasing power parity",28.5
+18552,Ireland,2013,6,N02-Analgesics,"Million US$, purchasing power parity",67.5
+18553,Ireland,2013,6,B-Blood and blood forming organs,"/capita, US$ purchasing power parity",23.9
+18554,Ireland,2013,6,B-Blood and blood forming organs,% of total sales,4.6
+18555,Ireland,2013,6,B-Blood and blood forming organs,"/capita, US$ exchange rate",25.8
+18556,Ireland,2013,6,G03-Sex hormones and modulators of the genital system,% of total sales,1.7
+18557,Ireland,2013,6,C02-Antihypertensives,Million of national currency units,16.9
+18558,Ireland,2013,6,C03-Diuretics,"/capita, US$ purchasing power parity",4.4
+18559,Ireland,2013,6,N05B-Anxiolytics,"/capita, US$ purchasing power parity",2.5
+18560,Ireland,2013,6,N05B-Anxiolytics,% of total sales,0.5
+18561,Ireland,2013,6,N05B-Anxiolytics,"/capita, US$ exchange rate",2.7
+18562,Ireland,2013,6,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),% of total sales,4.8
+18563,Ireland,2013,6,N05B-Anxiolytics,"Million US$, purchasing power parity",11.7
+18564,Ireland,2013,6,N05B-Anxiolytics,Million US$ at exchange rate,12.6
+18565,Ireland,2013,6,N05B-Anxiolytics,Million of national currency units,9.5
+18566,Ireland,2013,6,C03-Diuretics,Million of national currency units,16.4
+18567,Ireland,2013,6,C03-Diuretics,"/capita, US$ exchange rate",4.7
+18568,Ireland,2013,6,N02-Analgesics,Million of national currency units,54.7
+18569,Ireland,2013,6,N02-Analgesics,Million US$ at exchange rate,72.7
+18570,Ireland,2013,6,C03-Diuretics,Million US$ at exchange rate,21.8
+18571,Ireland,2013,6,C03-Diuretics,"Million US$, purchasing power parity",20.2
+18572,Ireland,2013,6,C02-Antihypertensives,Million US$ at exchange rate,22.4
+18573,Ireland,2013,6,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million of national currency units,95.0
+18574,Ireland,2013,6,"H-Systemic hormonal preparations, excluding sex hormones and insulins",% of total sales,2.6
+18575,Ireland,2013,6,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ purchasing power parity",13.4
+18576,Ireland,2013,6,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ exchange rate",14.4
+18577,Ireland,2013,6,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million US$ at exchange rate,126.2
+18578,Ireland,2013,6,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ purchasing power parity",25.3
+18579,Ireland,2013,6,J-Antiinfectives for systemic use,"Million US$, purchasing power parity",79.3
+18580,Ireland,2013,6,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"Million US$, purchasing power parity",117.2
+18581,Ireland,2013,6,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ exchange rate",27.3
+18582,Ireland,2013,6,J-Antiinfectives for systemic use,% of total sales,3.3
+18583,Ireland,2013,6,J-Antiinfectives for systemic use,"/capita, US$ purchasing power parity",17.2
+18584,Ireland,2013,6,C02-Antihypertensives,"/capita, US$ purchasing power parity",4.5
+18585,Ireland,2013,6,C02-Antihypertensives,% of total sales,0.9
+18586,Ireland,2013,6,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million US$ at exchange rate,66.6
+18587,Ireland,2013,6,"H-Systemic hormonal preparations, excluding sex hormones and insulins","Million US$, purchasing power parity",61.8
+18588,Ireland,2013,6,J-Antiinfectives for systemic use,"/capita, US$ exchange rate",18.5
+18589,Ireland,2013,6,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million of national currency units,50.1
+18590,Ireland,2013,6,N05C-Hypnotics and sedatives,"/capita, US$ exchange rate",5.2
+18591,Ireland,2013,6,N05C-Hypnotics and sedatives,"Million US$, purchasing power parity",22.5
+18592,Ireland,2013,6,N05C-Hypnotics and sedatives,% of total sales,0.9
+18593,Ireland,2013,6,N05C-Hypnotics and sedatives,"/capita, US$ purchasing power parity",4.9
+18594,Ireland,2013,6,N05C-Hypnotics and sedatives,Million US$ at exchange rate,24.2
+18595,Ireland,2013,6,C02-Antihypertensives,"Million US$, purchasing power parity",20.8
+18596,Ireland,2013,6,N05C-Hypnotics and sedatives,Million of national currency units,18.2
+18597,Ireland,2013,6,J-Antiinfectives for systemic use,Million of national currency units,64.3
+18598,Ireland,2013,6,C02-Antihypertensives,"/capita, US$ exchange rate",4.8
+18599,Ireland,2013,6,N02-Analgesics,"/capita, US$ exchange rate",15.7
+18600,Ireland,2013,6,B-Blood and blood forming organs,Million of national currency units,89.7
+18601,Ireland,2013,6,B-Blood and blood forming organs,Million US$ at exchange rate,119.2
+18602,Ireland,2013,6,N02-Analgesics,% of total sales,2.8
+18603,Ireland,2013,6,N02-Analgesics,"/capita, US$ purchasing power parity",14.6
+18604,Ireland,2013,6,C03-Diuretics,% of total sales,0.8
+18605,Ireland,2013,6,B-Blood and blood forming organs,"Million US$, purchasing power parity",110.6
+18606,Ireland,2013,6,J-Antiinfectives for systemic use,Million US$ at exchange rate,85.4
+18607,Ireland,2013,6,C01A-Cardiac glycosides,"/capita, US$ exchange rate",0.4
+18608,Ireland,2013,6,C01A-Cardiac glycosides,"Million US$, purchasing power parity",1.9
+18609,Ireland,2013,6,C01A-Cardiac glycosides,% of total sales,0.1
+18610,Ireland,2013,6,C01A-Cardiac glycosides,"/capita, US$ purchasing power parity",0.4
+18611,Ireland,2013,6,M-Musculo-skeletal system,"/capita, US$ purchasing power parity",17.9
+18612,Ireland,2013,6,M-Musculo-skeletal system,"/capita, US$ exchange rate",19.3
+18613,Ireland,2013,6,C01A-Cardiac glycosides,Million US$ at exchange rate,2.0
+18614,Ireland,2013,6,C01A-Cardiac glycosides,Million of national currency units,1.5
+18615,Ireland,2013,6,M-Musculo-skeletal system,% of total sales,3.4
+18616,Ireland,2013,6,C10-Lipid modifying agents,Million US$ at exchange rate,149.2
+18617,Ireland,2013,6,C10-Lipid modifying agents,"Million US$, purchasing power parity",138.5
+18618,Ireland,2013,6,Products not elsewhere classified,"/capita, US$ purchasing power parity",150.8
+18619,Ireland,2013,6,Products not elsewhere classified,% of total sales,28.9
+18620,Ireland,2013,6,C10-Lipid modifying agents,Million of national currency units,112.4
+18621,Ireland,2013,6,C10-Lipid modifying agents,"/capita, US$ exchange rate",32.3
+18622,Ireland,2013,6,A10-Drugs used in diabetes,Million US$ at exchange rate,108.9
+18623,Ireland,2013,6,A10-Drugs used in diabetes,Million of national currency units,82.0
+18624,Ireland,2013,6,C10-Lipid modifying agents,"/capita, US$ purchasing power parity",30.0
+18625,Ireland,2013,6,C10-Lipid modifying agents,% of total sales,5.7
+18626,Ireland,2013,6,C08-Calcium channel blockers,"Million US$, purchasing power parity",29.6
+18627,Ireland,2013,6,C08-Calcium channel blockers,Million US$ at exchange rate,31.8
+18628,Ireland,2013,6,C08-Calcium channel blockers,"/capita, US$ purchasing power parity",6.4
+18629,Ireland,2013,6,C08-Calcium channel blockers,"/capita, US$ exchange rate",6.9
+18630,Ireland,2013,6,C08-Calcium channel blockers,Million of national currency units,24.0
+18631,Ireland,2013,6,A02A-Antacids,"Million US$, purchasing power parity",0.1
+18632,Ireland,2013,6,A02A-Antacids,Million US$ at exchange rate,0.1
+18633,Ireland,2013,6,A02A-Antacids,Million of national currency units,0.1
+18634,Ireland,2013,6,A02A-Antacids,"/capita, US$ purchasing power parity",0.0
+18635,Ireland,2013,6,A02A-Antacids,"/capita, US$ exchange rate",0.0
+18636,Ireland,2013,6,R-Respiratory system,"/capita, US$ exchange rate",47.0
+18637,Ireland,2013,6,R-Respiratory system,"Million US$, purchasing power parity",201.5
+18638,Ireland,2013,6,M-Musculo-skeletal system,"Million US$, purchasing power parity",82.7
+18639,Ireland,2013,6,R-Respiratory system,% of total sales,8.3
+18640,Ireland,2013,6,R-Respiratory system,"/capita, US$ purchasing power parity",43.6
+18641,Ireland,2013,6,M-Musculo-skeletal system,Million of national currency units,67.1
+18642,Ireland,2013,6,C08-Calcium channel blockers,% of total sales,1.2
+18643,Ireland,2013,6,M-Musculo-skeletal system,Million US$ at exchange rate,89.1
+18644,Ireland,2013,6,R-Respiratory system,Million US$ at exchange rate,217.1
+18645,Ireland,2013,6,R-Respiratory system,Million of national currency units,163.5
+18646,Ireland,2013,6,R03-Drugs for obstructive airway diseases,"/capita, US$ purchasing power parity",31.7
+18647,Ireland,2013,6,R03-Drugs for obstructive airway diseases,"/capita, US$ exchange rate",34.2
+18648,Ireland,2013,6,Total pharmaceutical sales,"/capita, US$ purchasing power parity",522.4
+18649,Ireland,2013,6,R03-Drugs for obstructive airway diseases,% of total sales,6.1
+18650,Ireland,2013,6,C-Cardiovascular system,Million of national currency units,288.4
+18651,Ireland,2013,6,C-Cardiovascular system,Million US$ at exchange rate,383.0
+18652,Ireland,2013,6,R03-Drugs for obstructive airway diseases,Million of national currency units,119.0
+18653,Ireland,2013,6,R03-Drugs for obstructive airway diseases,"Million US$, purchasing power parity",146.7
+18654,Ireland,2013,6,R03-Drugs for obstructive airway diseases,Million US$ at exchange rate,158.1
+18655,Ireland,2013,6,Total pharmaceutical sales,Million US$ at exchange rate,2602.6
+18656,Ireland,2013,6,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ exchange rate",22.1
+18657,Ireland,2013,6,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ purchasing power parity",20.5
+18658,Ireland,2013,6,C09-Agents acting on the Renin-Angiotensin system,% of total sales,3.9
+18659,Ireland,2013,6,Total pharmaceutical sales,Million of national currency units,1959.6
+18660,Ireland,2013,6,Total pharmaceutical sales,"Million US$, purchasing power parity",2415.6
+18661,Ireland,2013,6,Total pharmaceutical sales,"/capita, US$ exchange rate",562.9
+18662,Ireland,2013,6,C09-Agents acting on the Renin-Angiotensin system,Million of national currency units,76.8
+18663,Ireland,2013,6,C09-Agents acting on the Renin-Angiotensin system,"Million US$, purchasing power parity",94.7
+18664,Ireland,2013,6,C09-Agents acting on the Renin-Angiotensin system,Million US$ at exchange rate,102.0
+18665,Ireland,2013,6,A10-Drugs used in diabetes,"/capita, US$ exchange rate",23.5
+18666,Ireland,2013,6,A10-Drugs used in diabetes,"Million US$, purchasing power parity",101.0
+18667,Ireland,2013,6,A10-Drugs used in diabetes,% of total sales,4.2
+18668,Ireland,2013,6,A10-Drugs used in diabetes,"/capita, US$ purchasing power parity",21.9
+18669,Ireland,2013,6,A02A-Antacids,% of total sales,0.0
+18670,Ireland,2013,6,Products not elsewhere classified,"Million US$, purchasing power parity",697.2
+18671,Ireland,2013,6,Products not elsewhere classified,"/capita, US$ exchange rate",162.5
+18672,Ireland,2013,6,Products not elsewhere classified,Million of national currency units,565.6
+18673,Ireland,2013,6,Products not elsewhere classified,Million US$ at exchange rate,751.2
+18674,Ireland,2013,6,C-Cardiovascular system,% of total sales,14.7
+18675,Ireland,2013,6,M01A-Antiinflammatory and antirheumatic products non-steroids,Million of national currency units,21.3
+18676,Ireland,2013,6,M01A-Antiinflammatory and antirheumatic products non-steroids,Million US$ at exchange rate,28.3
+18677,Ireland,2013,6,C-Cardiovascular system,"/capita, US$ exchange rate",82.8
+18678,Ireland,2013,6,C-Cardiovascular system,"/capita, US$ purchasing power parity",76.9
+18679,Ireland,2013,6,C-Cardiovascular system,"Million US$, purchasing power parity",355.5
+18680,Ireland,2013,6,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ purchasing power parity",5.7
+18681,Ireland,2013,6,M01A-Antiinflammatory and antirheumatic products non-steroids,% of total sales,1.1
+18682,Ireland,2013,6,M01A-Antiinflammatory and antirheumatic products non-steroids,"Million US$, purchasing power parity",26.3
+18683,Ireland,2013,6,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ exchange rate",6.1
+18684,Ireland,2013,6,J01-Antibacterials for systemic use,Million US$ at exchange rate,63.8
+18685,Ireland,2013,6,N-Nervous system,"/capita, US$ purchasing power parity",95.4
+18686,Ireland,2013,6,J01-Antibacterials for systemic use,Million of national currency units,48.1
+18687,Ireland,2013,6,J01-Antibacterials for systemic use,"/capita, US$ exchange rate",13.8
+18688,Ireland,2013,6,J01-Antibacterials for systemic use,"/capita, US$ purchasing power parity",12.8
+18689,Ireland,2013,6,N-Nervous system,% of total sales,18.3
+18690,Ireland,2013,6,J01-Antibacterials for systemic use,"Million US$, purchasing power parity",59.2
+18691,Ireland,2013,6,G-Genito urinary system and sex hormones,% of total sales,4.1
+18692,Ireland,2013,6,G-Genito urinary system and sex hormones,"/capita, US$ exchange rate",22.9
+18693,Ireland,2013,6,G-Genito urinary system and sex hormones,"/capita, US$ purchasing power parity",21.2
+18694,Ireland,2013,6,N-Nervous system,Million of national currency units,357.7
+18695,Ireland,2013,6,N-Nervous system,"Million US$, purchasing power parity",441.0
+18696,Ireland,2013,6,N-Nervous system,"/capita, US$ exchange rate",102.8
+18697,Ireland,2013,6,N-Nervous system,Million US$ at exchange rate,475.1
+18698,Ireland,2013,6,N06A-Antidepressants,Million US$ at exchange rate,96.6
+18699,Ireland,2013,6,N06A-Antidepressants,"Million US$, purchasing power parity",89.7
+18700,Ireland,2013,6,A-Alimentary tract and metabolism,% of total sales,11.9
+18701,Ireland,2013,6,N06A-Antidepressants,"/capita, US$ exchange rate",20.9
+18702,Ireland,2013,6,N06A-Antidepressants,"/capita, US$ purchasing power parity",19.4
+18703,Ireland,2013,6,N06A-Antidepressants,% of total sales,3.7
+18704,Ireland,2013,6,A-Alimentary tract and metabolism,Million of national currency units,233.4
+18705,Ireland,2013,6,A-Alimentary tract and metabolism,Million US$ at exchange rate,310.0
+18706,Ireland,2013,6,N06A-Antidepressants,Million of national currency units,72.7
+18707,Ireland,2013,6,J01-Antibacterials for systemic use,% of total sales,2.5
+18708,Ireland,2013,6,A-Alimentary tract and metabolism,"/capita, US$ purchasing power parity",62.2
+18709,Ireland,2013,6,A-Alimentary tract and metabolism,"/capita, US$ exchange rate",67.0
+18710,Ireland,2013,6,A-Alimentary tract and metabolism,"Million US$, purchasing power parity",287.7
+18711,Ireland,2013,6,G03-Sex hormones and modulators of the genital system,"Million US$, purchasing power parity",41.8
+18712,Ireland,2013,6,G03-Sex hormones and modulators of the genital system,"/capita, US$ exchange rate",9.7
+18713,Ireland,2013,6,G03-Sex hormones and modulators of the genital system,Million US$ at exchange rate,45.0
+18714,Ireland,2013,6,C07-Beta blocking agents,Million of national currency units,23.6
+18715,Ireland,2013,6,C07-Beta blocking agents,Million US$ at exchange rate,31.3
+18716,Ireland,2013,6,G03-Sex hormones and modulators of the genital system,Million of national currency units,33.9
+18717,Ireland,2013,6,G03-Sex hormones and modulators of the genital system,"/capita, US$ purchasing power parity",9.0
+18718,Ireland,2013,6,"C01B-Antiarrhythmics, Class I and III",Million of national currency units,3.0
+18719,Ireland,2013,6,"C01B-Antiarrhythmics, Class I and III","/capita, US$ purchasing power parity",0.8
+18720,Ireland,2013,6,"C01B-Antiarrhythmics, Class I and III",% of total sales,0.2
+18721,Ireland,2013,6,"C01B-Antiarrhythmics, Class I and III","/capita, US$ exchange rate",0.8
+18722,Ireland,2013,6,"C01B-Antiarrhythmics, Class I and III",Million US$ at exchange rate,3.9
+18723,Ireland,2013,6,"C01B-Antiarrhythmics, Class I and III","Million US$, purchasing power parity",3.6
+18724,Ireland,2013,6,C07-Beta blocking agents,% of total sales,1.2
+18725,Ireland,2013,6,C07-Beta blocking agents,"/capita, US$ purchasing power parity",6.3
+18726,Ireland,2013,6,C07-Beta blocking agents,"/capita, US$ exchange rate",6.8
+18727,Ireland,2013,6,G-Genito urinary system and sex hormones,"Million US$, purchasing power parity",98.2
+18728,Ireland,2013,6,G-Genito urinary system and sex hormones,Million US$ at exchange rate,105.8
+18729,Ireland,2013,6,G-Genito urinary system and sex hormones,Million of national currency units,79.7
+18730,Ireland,2013,6,C07-Beta blocking agents,"Million US$, purchasing power parity",29.0
+18731,Ireland,2012,6,B-Blood and blood forming organs,"/capita, US$ purchasing power parity",24.2
+18732,Ireland,2012,6,B-Blood and blood forming organs,% of total sales,4.5
+18733,Ireland,2012,6,N02-Analgesics,"Million US$, purchasing power parity",71.9
+18734,Ireland,2012,6,B-Blood and blood forming organs,"/capita, US$ exchange rate",25.6
+18735,Ireland,2012,6,G03-Sex hormones and modulators of the genital system,% of total sales,1.7
+18736,Ireland,2012,6,J-Antiinfectives for systemic use,Million of national currency units,69.6
+18737,Ireland,2012,6,C02-Antihypertensives,Million of national currency units,21.1
+18738,Ireland,2012,6,C03-Diuretics,"/capita, US$ purchasing power parity",4.3
+18739,Ireland,2012,6,N05B-Anxiolytics,% of total sales,0.5
+18740,Ireland,2012,6,N05B-Anxiolytics,"/capita, US$ exchange rate",2.7
+18741,Ireland,2012,6,N05B-Anxiolytics,"/capita, US$ purchasing power parity",2.6
+18742,Ireland,2012,6,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),% of total sales,5.3
+18743,Ireland,2012,6,N05B-Anxiolytics,"Million US$, purchasing power parity",11.8
+18744,Ireland,2012,6,N05B-Anxiolytics,Million US$ at exchange rate,12.5
+18745,Ireland,2012,6,N05B-Anxiolytics,Million of national currency units,9.7
+18746,Ireland,2012,6,N02-Analgesics,Million of national currency units,59.2
+18747,Ireland,2012,6,C03-Diuretics,"/capita, US$ exchange rate",4.6
+18748,Ireland,2012,6,N02-Analgesics,Million US$ at exchange rate,76.0
+18749,Ireland,2012,6,C03-Diuretics,Million US$ at exchange rate,21.1
+18750,Ireland,2012,6,C03-Diuretics,Million of national currency units,16.4
+18751,Ireland,2012,6,C03-Diuretics,"Million US$, purchasing power parity",20.0
+18752,Ireland,2012,6,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million of national currency units,108.5
+18753,Ireland,2012,6,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million US$ at exchange rate,139.4
+18754,Ireland,2012,6,"H-Systemic hormonal preparations, excluding sex hormones and insulins",% of total sales,2.4
+18755,Ireland,2012,6,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ purchasing power parity",12.8
+18756,Ireland,2012,6,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ purchasing power parity",28.7
+18757,Ireland,2012,6,J-Antiinfectives for systemic use,"Million US$, purchasing power parity",84.6
+18758,Ireland,2012,6,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"Million US$, purchasing power parity",131.8
+18759,Ireland,2012,6,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ exchange rate",30.3
+18760,Ireland,2012,6,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ exchange rate",13.6
+18761,Ireland,2012,6,J-Antiinfectives for systemic use,% of total sales,3.4
+18762,Ireland,2012,6,J-Antiinfectives for systemic use,"/capita, US$ purchasing power parity",18.4
+18763,Ireland,2012,6,C02-Antihypertensives,"/capita, US$ purchasing power parity",5.6
+18764,Ireland,2012,6,C02-Antihypertensives,% of total sales,1.0
+18765,Ireland,2012,6,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million US$ at exchange rate,62.4
+18766,Ireland,2012,6,"H-Systemic hormonal preparations, excluding sex hormones and insulins","Million US$, purchasing power parity",59.0
+18767,Ireland,2012,6,J-Antiinfectives for systemic use,"/capita, US$ exchange rate",19.5
+18768,Ireland,2012,6,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million of national currency units,48.6
+18769,Ireland,2012,6,N05C-Hypnotics and sedatives,"/capita, US$ exchange rate",4.9
+18770,Ireland,2012,6,N05C-Hypnotics and sedatives,"Million US$, purchasing power parity",21.5
+18771,Ireland,2012,6,N05C-Hypnotics and sedatives,% of total sales,0.9
+18772,Ireland,2012,6,N05C-Hypnotics and sedatives,"/capita, US$ purchasing power parity",4.7
+18773,Ireland,2012,6,C02-Antihypertensives,"Million US$, purchasing power parity",25.7
+18774,Ireland,2012,6,C02-Antihypertensives,Million US$ at exchange rate,27.1
+18775,Ireland,2012,6,N05C-Hypnotics and sedatives,Million US$ at exchange rate,22.7
+18776,Ireland,2012,6,N05C-Hypnotics and sedatives,Million of national currency units,17.7
+18777,Ireland,2012,6,C02-Antihypertensives,"/capita, US$ exchange rate",5.9
+18778,Ireland,2012,6,N02-Analgesics,"/capita, US$ exchange rate",16.5
+18779,Ireland,2012,6,B-Blood and blood forming organs,Million of national currency units,91.6
+18780,Ireland,2012,6,B-Blood and blood forming organs,Million US$ at exchange rate,117.7
+18781,Ireland,2012,6,N02-Analgesics,% of total sales,2.9
+18782,Ireland,2012,6,N02-Analgesics,"/capita, US$ purchasing power parity",15.6
+18783,Ireland,2012,6,C03-Diuretics,% of total sales,0.8
+18784,Ireland,2012,6,B-Blood and blood forming organs,"Million US$, purchasing power parity",111.3
+18785,Ireland,2012,6,J-Antiinfectives for systemic use,Million US$ at exchange rate,89.5
+18786,Ireland,2012,6,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ purchasing power parity",22.6
+18787,Ireland,2012,6,C01A-Cardiac glycosides,"/capita, US$ exchange rate",0.4
+18788,Ireland,2012,6,C01A-Cardiac glycosides,"Million US$, purchasing power parity",1.9
+18789,Ireland,2012,6,C01A-Cardiac glycosides,% of total sales,0.1
+18790,Ireland,2012,6,C01A-Cardiac glycosides,"/capita, US$ purchasing power parity",0.4
+18791,Ireland,2012,6,M-Musculo-skeletal system,"/capita, US$ purchasing power parity",19.8
+18792,Ireland,2012,6,M-Musculo-skeletal system,"/capita, US$ exchange rate",20.9
+18793,Ireland,2012,6,M-Musculo-skeletal system,% of total sales,3.7
+18794,Ireland,2012,6,C01A-Cardiac glycosides,Million US$ at exchange rate,2.0
+18795,Ireland,2012,6,C01A-Cardiac glycosides,Million of national currency units,1.5
+18796,Ireland,2012,6,C10-Lipid modifying agents,Million US$ at exchange rate,187.3
+18797,Ireland,2012,6,C10-Lipid modifying agents,"Million US$, purchasing power parity",177.2
+18798,Ireland,2012,6,Products not elsewhere classified,% of total sales,26.6
+18799,Ireland,2012,6,C10-Lipid modifying agents,Million of national currency units,145.8
+18800,Ireland,2012,6,C10-Lipid modifying agents,"/capita, US$ exchange rate",40.7
+18801,Ireland,2012,6,A10-Drugs used in diabetes,Million US$ at exchange rate,104.5
+18802,Ireland,2012,6,A10-Drugs used in diabetes,Million of national currency units,81.4
+18803,Ireland,2012,6,C10-Lipid modifying agents,"/capita, US$ purchasing power parity",38.5
+18804,Ireland,2012,6,C10-Lipid modifying agents,% of total sales,7.1
+18805,Ireland,2012,6,C08-Calcium channel blockers,"Million US$, purchasing power parity",30.6
+18806,Ireland,2012,6,C08-Calcium channel blockers,Million US$ at exchange rate,32.4
+18807,Ireland,2012,6,C08-Calcium channel blockers,"/capita, US$ purchasing power parity",6.7
+18808,Ireland,2012,6,C08-Calcium channel blockers,"/capita, US$ exchange rate",7.0
+18809,Ireland,2012,6,C08-Calcium channel blockers,Million of national currency units,25.2
+18810,Ireland,2012,6,A02A-Antacids,"Million US$, purchasing power parity",0.1
+18811,Ireland,2012,6,A02A-Antacids,Million US$ at exchange rate,0.1
+18812,Ireland,2012,6,A02A-Antacids,"/capita, US$ purchasing power parity",0.0
+18813,Ireland,2012,6,A02A-Antacids,"/capita, US$ exchange rate",0.0
+18814,Ireland,2012,6,R-Respiratory system,"/capita, US$ exchange rate",43.6
+18815,Ireland,2012,6,R-Respiratory system,"Million US$, purchasing power parity",189.5
+18816,Ireland,2012,6,R-Respiratory system,"/capita, US$ purchasing power parity",41.2
+18817,Ireland,2012,6,M-Musculo-skeletal system,"Million US$, purchasing power parity",90.9
+18818,Ireland,2012,6,R-Respiratory system,% of total sales,7.6
+18819,Ireland,2012,6,Products not elsewhere classified,"/capita, US$ purchasing power parity",143.7
+18820,Ireland,2012,6,M-Musculo-skeletal system,Million US$ at exchange rate,96.2
+18821,Ireland,2012,6,M-Musculo-skeletal system,Million of national currency units,74.9
+18822,Ireland,2012,6,C08-Calcium channel blockers,% of total sales,1.2
+18823,Ireland,2012,6,R-Respiratory system,Million US$ at exchange rate,200.4
+18824,Ireland,2012,6,R-Respiratory system,Million of national currency units,156.0
+18825,Ireland,2012,6,R03-Drugs for obstructive airway diseases,"/capita, US$ purchasing power parity",35.0
+18826,Ireland,2012,6,R03-Drugs for obstructive airway diseases,"/capita, US$ exchange rate",37.0
+18827,Ireland,2012,6,Total pharmaceutical sales,"/capita, US$ purchasing power parity",540.1
+18828,Ireland,2012,6,R03-Drugs for obstructive airway diseases,% of total sales,6.5
+18829,Ireland,2012,6,C-Cardiovascular system,Million of national currency units,337.5
+18830,Ireland,2012,6,C-Cardiovascular system,Million US$ at exchange rate,433.6
+18831,Ireland,2012,6,R03-Drugs for obstructive airway diseases,"Million US$, purchasing power parity",161.0
+18832,Ireland,2012,6,R03-Drugs for obstructive airway diseases,Million US$ at exchange rate,170.2
+18833,Ireland,2012,6,R03-Drugs for obstructive airway diseases,Million of national currency units,132.5
+18834,Ireland,2012,6,Total pharmaceutical sales,Million US$ at exchange rate,2627.1
+18835,Ireland,2012,6,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ exchange rate",23.9
+18836,Ireland,2012,6,C09-Agents acting on the Renin-Angiotensin system,% of total sales,4.2
+18837,Ireland,2012,6,Total pharmaceutical sales,Million of national currency units,2044.7
+18838,Ireland,2012,6,Total pharmaceutical sales,"Million US$, purchasing power parity",2484.3
+18839,Ireland,2012,6,Total pharmaceutical sales,"/capita, US$ exchange rate",571.2
+18840,Ireland,2012,6,C09-Agents acting on the Renin-Angiotensin system,Million of national currency units,85.7
+18841,Ireland,2012,6,C09-Agents acting on the Renin-Angiotensin system,"Million US$, purchasing power parity",104.1
+18842,Ireland,2012,6,C09-Agents acting on the Renin-Angiotensin system,Million US$ at exchange rate,110.1
+18843,Ireland,2012,6,A02A-Antacids,Million of national currency units,0.1
+18844,Ireland,2012,6,C-Cardiovascular system,"Million US$, purchasing power parity",410.0
+18845,Ireland,2012,6,A10-Drugs used in diabetes,"/capita, US$ exchange rate",22.7
+18846,Ireland,2012,6,A10-Drugs used in diabetes,"Million US$, purchasing power parity",98.8
+18847,Ireland,2012,6,A10-Drugs used in diabetes,% of total sales,4.0
+18848,Ireland,2012,6,A10-Drugs used in diabetes,"/capita, US$ purchasing power parity",21.5
+18849,Ireland,2012,6,Products not elsewhere classified,"Million US$, purchasing power parity",661.1
+18850,Ireland,2012,6,Products not elsewhere classified,"/capita, US$ exchange rate",152.0
+18851,Ireland,2012,6,A02A-Antacids,% of total sales,0.0
+18852,Ireland,2012,6,Products not elsewhere classified,Million of national currency units,544.1
+18853,Ireland,2012,6,Products not elsewhere classified,Million US$ at exchange rate,699.1
+18854,Ireland,2012,6,C-Cardiovascular system,% of total sales,16.5
+18855,Ireland,2012,6,M01A-Antiinflammatory and antirheumatic products non-steroids,Million of national currency units,27.8
+18856,Ireland,2012,6,M01A-Antiinflammatory and antirheumatic products non-steroids,Million US$ at exchange rate,35.7
+18857,Ireland,2012,6,C-Cardiovascular system,"/capita, US$ exchange rate",94.3
+18858,Ireland,2012,6,C-Cardiovascular system,"/capita, US$ purchasing power parity",89.1
+18859,Ireland,2012,6,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ purchasing power parity",7.3
+18860,Ireland,2012,6,M01A-Antiinflammatory and antirheumatic products non-steroids,% of total sales,1.4
+18861,Ireland,2012,6,M01A-Antiinflammatory and antirheumatic products non-steroids,"Million US$, purchasing power parity",33.8
+18862,Ireland,2012,6,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ exchange rate",7.8
+18863,Ireland,2012,6,J01-Antibacterials for systemic use,Million US$ at exchange rate,69.6
+18864,Ireland,2012,6,J01-Antibacterials for systemic use,"Million US$, purchasing power parity",65.8
+18865,Ireland,2012,6,N-Nervous system,"/capita, US$ purchasing power parity",102.5
+18866,Ireland,2012,6,J01-Antibacterials for systemic use,Million of national currency units,54.2
+18867,Ireland,2012,6,N-Nervous system,% of total sales,19.0
+18868,Ireland,2012,6,J01-Antibacterials for systemic use,"/capita, US$ exchange rate",15.1
+18869,Ireland,2012,6,J01-Antibacterials for systemic use,"/capita, US$ purchasing power parity",14.3
+18870,Ireland,2012,6,G-Genito urinary system and sex hormones,% of total sales,4.2
+18871,Ireland,2012,6,N-Nervous system,Million of national currency units,387.9
+18872,Ireland,2012,6,G-Genito urinary system and sex hormones,"/capita, US$ exchange rate",24.0
+18873,Ireland,2012,6,G-Genito urinary system and sex hormones,"/capita, US$ purchasing power parity",22.7
+18874,Ireland,2012,6,N-Nervous system,"Million US$, purchasing power parity",471.3
+18875,Ireland,2012,6,N-Nervous system,"/capita, US$ exchange rate",108.4
+18876,Ireland,2012,6,N-Nervous system,Million US$ at exchange rate,498.4
+18877,Ireland,2012,6,N06A-Antidepressants,"Million US$, purchasing power parity",88.5
+18878,Ireland,2012,6,N06A-Antidepressants,Million US$ at exchange rate,93.6
+18879,Ireland,2012,6,N06A-Antidepressants,"/capita, US$ exchange rate",20.3
+18880,Ireland,2012,6,N06A-Antidepressants,"/capita, US$ purchasing power parity",19.2
+18881,Ireland,2012,6,N06A-Antidepressants,% of total sales,3.6
+18882,Ireland,2012,6,A-Alimentary tract and metabolism,% of total sales,12.2
+18883,Ireland,2012,6,A-Alimentary tract and metabolism,Million of national currency units,248.8
+18884,Ireland,2012,6,A-Alimentary tract and metabolism,Million US$ at exchange rate,319.6
+18885,Ireland,2012,6,J01-Antibacterials for systemic use,% of total sales,2.6
+18886,Ireland,2012,6,N06A-Antidepressants,Million of national currency units,72.8
+18887,Ireland,2012,6,A-Alimentary tract and metabolism,"/capita, US$ purchasing power parity",65.7
+18888,Ireland,2012,6,A-Alimentary tract and metabolism,"Million US$, purchasing power parity",302.3
+18889,Ireland,2012,6,A-Alimentary tract and metabolism,"/capita, US$ exchange rate",69.5
+18890,Ireland,2012,6,G03-Sex hormones and modulators of the genital system,"Million US$, purchasing power parity",42.2
+18891,Ireland,2012,6,G03-Sex hormones and modulators of the genital system,"/capita, US$ exchange rate",9.7
+18892,Ireland,2012,6,G03-Sex hormones and modulators of the genital system,"/capita, US$ purchasing power parity",9.2
+18893,Ireland,2012,6,C07-Beta blocking agents,Million US$ at exchange rate,30.4
+18894,Ireland,2012,6,C07-Beta blocking agents,Million of national currency units,23.7
+18895,Ireland,2012,6,G03-Sex hormones and modulators of the genital system,Million of national currency units,34.7
+18896,Ireland,2012,6,G03-Sex hormones and modulators of the genital system,Million US$ at exchange rate,44.6
+18897,Ireland,2012,6,"C01B-Antiarrhythmics, Class I and III",Million of national currency units,3.1
+18898,Ireland,2012,6,"C01B-Antiarrhythmics, Class I and III","/capita, US$ purchasing power parity",0.8
+18899,Ireland,2012,6,"C01B-Antiarrhythmics, Class I and III",% of total sales,0.1
+18900,Ireland,2012,6,"C01B-Antiarrhythmics, Class I and III","/capita, US$ exchange rate",0.9
+18901,Ireland,2012,6,"C01B-Antiarrhythmics, Class I and III",Million US$ at exchange rate,3.9
+18902,Ireland,2012,6,"C01B-Antiarrhythmics, Class I and III","Million US$, purchasing power parity",3.7
+18903,Ireland,2012,6,C07-Beta blocking agents,% of total sales,1.2
+18904,Ireland,2012,6,C07-Beta blocking agents,"/capita, US$ exchange rate",6.6
+18905,Ireland,2012,6,C07-Beta blocking agents,"/capita, US$ purchasing power parity",6.2
+18906,Ireland,2012,6,G-Genito urinary system and sex hormones,"Million US$, purchasing power parity",104.2
+18907,Ireland,2012,6,G-Genito urinary system and sex hormones,Million of national currency units,85.8
+18908,Ireland,2012,6,G-Genito urinary system and sex hormones,Million US$ at exchange rate,110.2
+18909,Ireland,2012,6,C07-Beta blocking agents,"Million US$, purchasing power parity",28.7
+18910,Ireland,2010,6,N02-Analgesics,"Million US$, purchasing power parity",64.9
+18911,Ireland,2010,6,B-Blood and blood forming organs,"/capita, US$ purchasing power parity",24.2
+18912,Ireland,2010,6,B-Blood and blood forming organs,% of total sales,4.6
+18913,Ireland,2010,6,B-Blood and blood forming organs,"/capita, US$ exchange rate",27.3
+18914,Ireland,2010,6,C03-Diuretics,"/capita, US$ purchasing power parity",4.0
+18915,Ireland,2010,6,G03-Sex hormones and modulators of the genital system,% of total sales,1.7
+18916,Ireland,2010,6,J-Antiinfectives for systemic use,Million of national currency units,66.1
+18917,Ireland,2010,6,C02-Antihypertensives,Million of national currency units,21.1
+18918,Ireland,2010,6,N05B-Anxiolytics,% of total sales,0.5
+18919,Ireland,2010,6,N05B-Anxiolytics,"/capita, US$ purchasing power parity",2.5
+18920,Ireland,2010,6,N05B-Anxiolytics,"/capita, US$ exchange rate",2.8
+18921,Ireland,2010,6,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),% of total sales,6.6
+18922,Ireland,2010,6,N05B-Anxiolytics,"Million US$, purchasing power parity",11.5
+18923,Ireland,2010,6,N05B-Anxiolytics,Million US$ at exchange rate,12.9
+18924,Ireland,2010,6,N05B-Anxiolytics,Million of national currency units,9.7
+18925,Ireland,2010,6,C03-Diuretics,Million of national currency units,15.7
+18926,Ireland,2010,6,N02-Analgesics,Million of national currency units,55.1
+18927,Ireland,2010,6,N02-Analgesics,Million US$ at exchange rate,73.1
+18928,Ireland,2010,6,C03-Diuretics,"/capita, US$ exchange rate",4.6
+18929,Ireland,2010,6,C03-Diuretics,Million US$ at exchange rate,20.8
+18930,Ireland,2010,6,C03-Diuretics,"Million US$, purchasing power parity",18.4
+18931,Ireland,2010,6,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million of national currency units,135.0
+18932,Ireland,2010,6,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million US$ at exchange rate,178.9
+18933,Ireland,2010,6,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ purchasing power parity",11.4
+18934,Ireland,2010,6,"H-Systemic hormonal preparations, excluding sex hormones and insulins",% of total sales,2.2
+18935,Ireland,2010,6,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ purchasing power parity",34.8
+18936,Ireland,2010,6,J-Antiinfectives for systemic use,"Million US$, purchasing power parity",77.8
+18937,Ireland,2010,6,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"Million US$, purchasing power parity",158.9
+18938,Ireland,2010,6,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ exchange rate",39.2
+18939,Ireland,2010,6,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ exchange rate",12.9
+18940,Ireland,2010,6,J-Antiinfectives for systemic use,% of total sales,3.2
+18941,Ireland,2010,6,J-Antiinfectives for systemic use,"/capita, US$ purchasing power parity",17.1
+18942,Ireland,2010,6,C02-Antihypertensives,"/capita, US$ purchasing power parity",5.4
+18943,Ireland,2010,6,C02-Antihypertensives,% of total sales,1.0
+18944,Ireland,2010,6,"H-Systemic hormonal preparations, excluding sex hormones and insulins","Million US$, purchasing power parity",52.1
+18945,Ireland,2010,6,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million US$ at exchange rate,58.7
+18946,Ireland,2010,6,J-Antiinfectives for systemic use,"/capita, US$ exchange rate",19.2
+18947,Ireland,2010,6,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million of national currency units,44.3
+18948,Ireland,2010,6,N05C-Hypnotics and sedatives,"/capita, US$ exchange rate",4.9
+18949,Ireland,2010,6,N05C-Hypnotics and sedatives,"Million US$, purchasing power parity",19.7
+18950,Ireland,2010,6,N05C-Hypnotics and sedatives,% of total sales,0.8
+18951,Ireland,2010,6,N05C-Hypnotics and sedatives,"/capita, US$ purchasing power parity",4.3
+18952,Ireland,2010,6,C02-Antihypertensives,"Million US$, purchasing power parity",24.8
+18953,Ireland,2010,6,C02-Antihypertensives,Million US$ at exchange rate,28.0
+18954,Ireland,2010,6,N05C-Hypnotics and sedatives,Million US$ at exchange rate,22.2
+18955,Ireland,2010,6,C02-Antihypertensives,"/capita, US$ exchange rate",6.1
+18956,Ireland,2010,6,N05C-Hypnotics and sedatives,Million of national currency units,16.8
+18957,Ireland,2010,6,B-Blood and blood forming organs,Million of national currency units,93.9
+18958,Ireland,2010,6,B-Blood and blood forming organs,Million US$ at exchange rate,124.5
+18959,Ireland,2010,6,N02-Analgesics,% of total sales,2.7
+18960,Ireland,2010,6,N02-Analgesics,"/capita, US$ purchasing power parity",14.2
+18961,Ireland,2010,6,C03-Diuretics,% of total sales,0.8
+18962,Ireland,2010,6,B-Blood and blood forming organs,"Million US$, purchasing power parity",110.6
+18963,Ireland,2010,6,N02-Analgesics,"/capita, US$ exchange rate",16.0
+18964,Ireland,2010,6,J-Antiinfectives for systemic use,Million US$ at exchange rate,87.7
+18965,Ireland,2010,6,C01A-Cardiac glycosides,"/capita, US$ exchange rate",0.5
+18966,Ireland,2010,6,C01A-Cardiac glycosides,"Million US$, purchasing power parity",1.8
+18967,Ireland,2010,6,C01A-Cardiac glycosides,% of total sales,0.1
+18968,Ireland,2010,6,C01A-Cardiac glycosides,"/capita, US$ purchasing power parity",0.4
+18969,Ireland,2010,6,M-Musculo-skeletal system,"/capita, US$ purchasing power parity",22.7
+18970,Ireland,2010,6,M-Musculo-skeletal system,"/capita, US$ exchange rate",25.6
+18971,Ireland,2010,6,M-Musculo-skeletal system,% of total sales,4.3
+18972,Ireland,2010,6,C01A-Cardiac glycosides,Million US$ at exchange rate,2.1
+18973,Ireland,2010,6,C01A-Cardiac glycosides,Million of national currency units,1.6
+18974,Ireland,2010,6,A10-Drugs used in diabetes,Million of national currency units,68.0
+18975,Ireland,2010,6,C10-Lipid modifying agents,Million US$ at exchange rate,256.6
+18976,Ireland,2010,6,C10-Lipid modifying agents,"Million US$, purchasing power parity",227.8
+18977,Ireland,2010,6,Products not elsewhere classified,% of total sales,24.8
+18978,Ireland,2010,6,C10-Lipid modifying agents,Million of national currency units,193.6
+18979,Ireland,2010,6,C10-Lipid modifying agents,"/capita, US$ exchange rate",56.3
+18980,Ireland,2010,6,A10-Drugs used in diabetes,Million US$ at exchange rate,90.1
+18981,Ireland,2010,6,C10-Lipid modifying agents,"/capita, US$ purchasing power parity",50.0
+18982,Ireland,2010,6,C10-Lipid modifying agents,% of total sales,9.4
+18983,Ireland,2010,6,C08-Calcium channel blockers,"Million US$, purchasing power parity",31.5
+18984,Ireland,2010,6,C08-Calcium channel blockers,Million US$ at exchange rate,35.5
+18985,Ireland,2010,6,C08-Calcium channel blockers,"/capita, US$ purchasing power parity",6.9
+18986,Ireland,2010,6,C08-Calcium channel blockers,"/capita, US$ exchange rate",7.8
+18987,Ireland,2010,6,A02A-Antacids,"Million US$, purchasing power parity",0.2
+18988,Ireland,2010,6,A02A-Antacids,Million US$ at exchange rate,0.2
+18989,Ireland,2010,6,C08-Calcium channel blockers,Million of national currency units,26.8
+18990,Ireland,2010,6,A02A-Antacids,"/capita, US$ purchasing power parity",0.0
+18991,Ireland,2010,6,A02A-Antacids,"/capita, US$ exchange rate",0.0
+18992,Ireland,2010,6,C08-Calcium channel blockers,% of total sales,1.3
+18993,Ireland,2010,6,R-Respiratory system,"/capita, US$ exchange rate",46.1
+18994,Ireland,2010,6,R-Respiratory system,"Million US$, purchasing power parity",186.6
+18995,Ireland,2010,6,R-Respiratory system,"/capita, US$ purchasing power parity",40.9
+18996,Ireland,2010,6,R-Respiratory system,% of total sales,7.7
+18997,Ireland,2010,6,M-Musculo-skeletal system,Million US$ at exchange rate,116.8
+18998,Ireland,2010,6,M-Musculo-skeletal system,Million of national currency units,88.1
+18999,Ireland,2010,6,R-Respiratory system,Million US$ at exchange rate,210.2
+19000,Ireland,2010,6,R-Respiratory system,Million of national currency units,158.6
+19001,Ireland,2010,6,M-Musculo-skeletal system,"Million US$, purchasing power parity",103.7
+19002,Ireland,2010,6,Products not elsewhere classified,"/capita, US$ purchasing power parity",131.1
+19003,Ireland,2010,6,R03-Drugs for obstructive airway diseases,"/capita, US$ purchasing power parity",34.8
+19004,Ireland,2010,6,R03-Drugs for obstructive airway diseases,"/capita, US$ exchange rate",39.1
+19005,Ireland,2010,6,R03-Drugs for obstructive airway diseases,% of total sales,6.6
+19006,Ireland,2010,6,Total pharmaceutical sales,"/capita, US$ purchasing power parity",529.1
+19007,Ireland,2010,6,C-Cardiovascular system,Million of national currency units,398.5
+19008,Ireland,2010,6,C-Cardiovascular system,Million US$ at exchange rate,528.2
+19009,Ireland,2010,6,C-Cardiovascular system,"Million US$, purchasing power parity",469.0
+19010,Ireland,2010,6,R03-Drugs for obstructive airway diseases,Million of national currency units,134.6
+19011,Ireland,2010,6,R03-Drugs for obstructive airway diseases,"Million US$, purchasing power parity",158.5
+19012,Ireland,2010,6,R03-Drugs for obstructive airway diseases,Million US$ at exchange rate,178.5
+19013,Ireland,2010,6,Total pharmaceutical sales,Million US$ at exchange rate,2717.7
+19014,Ireland,2010,6,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ purchasing power parity",24.7
+19015,Ireland,2010,6,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ exchange rate",27.9
+19016,Ireland,2010,6,C09-Agents acting on the Renin-Angiotensin system,% of total sales,4.7
+19017,Ireland,2010,6,Total pharmaceutical sales,Million of national currency units,2050.0
+19018,Ireland,2010,6,C09-Agents acting on the Renin-Angiotensin system,Million of national currency units,95.8
+19019,Ireland,2010,6,Total pharmaceutical sales,"Million US$, purchasing power parity",2413.0
+19020,Ireland,2010,6,Total pharmaceutical sales,"/capita, US$ exchange rate",596.0
+19021,Ireland,2010,6,C09-Agents acting on the Renin-Angiotensin system,"Million US$, purchasing power parity",112.8
+19022,Ireland,2010,6,C09-Agents acting on the Renin-Angiotensin system,Million US$ at exchange rate,127.0
+19023,Ireland,2010,6,A10-Drugs used in diabetes,"/capita, US$ exchange rate",19.8
+19024,Ireland,2010,6,A10-Drugs used in diabetes,"Million US$, purchasing power parity",80.0
+19025,Ireland,2010,6,A10-Drugs used in diabetes,% of total sales,3.3
+19026,Ireland,2010,6,A10-Drugs used in diabetes,"/capita, US$ purchasing power parity",17.5
+19027,Ireland,2010,6,Products not elsewhere classified,"Million US$, purchasing power parity",597.6
+19028,Ireland,2010,6,Products not elsewhere classified,"/capita, US$ exchange rate",147.6
+19029,Ireland,2010,6,A02A-Antacids,% of total sales,0.0
+19030,Ireland,2010,6,Products not elsewhere classified,Million of national currency units,507.7
+19031,Ireland,2010,6,Products not elsewhere classified,Million US$ at exchange rate,673.1
+19032,Ireland,2010,6,C-Cardiovascular system,% of total sales,19.4
+19033,Ireland,2010,6,M01A-Antiinflammatory and antirheumatic products non-steroids,Million of national currency units,34.3
+19034,Ireland,2010,6,M01A-Antiinflammatory and antirheumatic products non-steroids,Million US$ at exchange rate,45.4
+19035,Ireland,2010,6,C-Cardiovascular system,"/capita, US$ exchange rate",115.8
+19036,Ireland,2010,6,C-Cardiovascular system,"/capita, US$ purchasing power parity",102.9
+19037,Ireland,2010,6,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ purchasing power parity",8.8
+19038,Ireland,2010,6,M01A-Antiinflammatory and antirheumatic products non-steroids,% of total sales,1.7
+19039,Ireland,2010,6,M01A-Antiinflammatory and antirheumatic products non-steroids,"Million US$, purchasing power parity",40.4
+19040,Ireland,2010,6,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ exchange rate",10.0
+19041,Ireland,2010,6,"C01B-Antiarrhythmics, Class I and III",Million of national currency units,2.6
+19042,Ireland,2010,6,J01-Antibacterials for systemic use,"Million US$, purchasing power parity",56.8
+19043,Ireland,2010,6,J01-Antibacterials for systemic use,Million US$ at exchange rate,64.0
+19044,Ireland,2010,6,N-Nervous system,"/capita, US$ purchasing power parity",89.1
+19045,Ireland,2010,6,N-Nervous system,% of total sales,16.8
+19046,Ireland,2010,6,J01-Antibacterials for systemic use,"/capita, US$ purchasing power parity",12.5
+19047,Ireland,2010,6,J01-Antibacterials for systemic use,"/capita, US$ exchange rate",14.0
+19048,Ireland,2010,6,G-Genito urinary system and sex hormones,% of total sales,4.1
+19049,Ireland,2010,6,N-Nervous system,Million of national currency units,345.2
+19050,Ireland,2010,6,G-Genito urinary system and sex hormones,"/capita, US$ purchasing power parity",21.7
+19051,Ireland,2010,6,N-Nervous system,"/capita, US$ exchange rate",100.4
+19052,Ireland,2010,6,N-Nervous system,"Million US$, purchasing power parity",406.3
+19053,Ireland,2010,6,N-Nervous system,Million US$ at exchange rate,457.6
+19054,Ireland,2010,6,N06A-Antidepressants,"Million US$, purchasing power parity",79.1
+19055,Ireland,2010,6,N06A-Antidepressants,Million US$ at exchange rate,89.1
+19056,Ireland,2010,6,A02A-Antacids,Million of national currency units,0.1
+19057,Ireland,2010,6,N06A-Antidepressants,"/capita, US$ purchasing power parity",17.4
+19058,Ireland,2010,6,N06A-Antidepressants,"/capita, US$ exchange rate",19.5
+19059,Ireland,2010,6,N06A-Antidepressants,% of total sales,3.3
+19060,Ireland,2010,6,A-Alimentary tract and metabolism,Million US$ at exchange rate,349.2
+19061,Ireland,2010,6,A-Alimentary tract and metabolism,Million of national currency units,263.4
+19062,Ireland,2010,6,J01-Antibacterials for systemic use,% of total sales,2.4
+19063,Ireland,2010,6,N06A-Antidepressants,Million of national currency units,67.2
+19064,Ireland,2010,6,A-Alimentary tract and metabolism,"/capita, US$ purchasing power parity",68.0
+19065,Ireland,2010,6,A-Alimentary tract and metabolism,"Million US$, purchasing power parity",310.0
+19066,Ireland,2010,6,A-Alimentary tract and metabolism,"/capita, US$ exchange rate",76.6
+19067,Ireland,2010,6,A-Alimentary tract and metabolism,% of total sales,12.8
+19068,Ireland,2010,6,G-Genito urinary system and sex hormones,"/capita, US$ exchange rate",24.5
+19069,Ireland,2010,6,G03-Sex hormones and modulators of the genital system,"Million US$, purchasing power parity",41.3
+19070,Ireland,2010,6,G03-Sex hormones and modulators of the genital system,"/capita, US$ purchasing power parity",9.0
+19071,Ireland,2010,6,G03-Sex hormones and modulators of the genital system,"/capita, US$ exchange rate",10.2
+19072,Ireland,2010,6,C07-Beta blocking agents,Million US$ at exchange rate,36.3
+19073,Ireland,2010,6,C07-Beta blocking agents,Million of national currency units,27.4
+19074,Ireland,2010,6,G03-Sex hormones and modulators of the genital system,Million US$ at exchange rate,46.5
+19075,Ireland,2010,6,G03-Sex hormones and modulators of the genital system,Million of national currency units,35.1
+19076,Ireland,2010,6,"C01B-Antiarrhythmics, Class I and III","/capita, US$ purchasing power parity",0.7
+19077,Ireland,2010,6,"C01B-Antiarrhythmics, Class I and III",% of total sales,0.1
+19078,Ireland,2010,6,"C01B-Antiarrhythmics, Class I and III",Million US$ at exchange rate,3.4
+19079,Ireland,2010,6,"C01B-Antiarrhythmics, Class I and III","/capita, US$ exchange rate",0.8
+19080,Ireland,2010,6,"C01B-Antiarrhythmics, Class I and III","Million US$, purchasing power parity",3.1
+19081,Ireland,2010,6,C07-Beta blocking agents,% of total sales,1.3
+19082,Ireland,2010,6,C07-Beta blocking agents,"/capita, US$ exchange rate",8.0
+19083,Ireland,2010,6,C07-Beta blocking agents,"/capita, US$ purchasing power parity",7.1
+19084,Ireland,2010,6,G-Genito urinary system and sex hormones,"Million US$, purchasing power parity",99.1
+19085,Ireland,2010,6,J01-Antibacterials for systemic use,Million of national currency units,48.2
+19086,Ireland,2010,6,G-Genito urinary system and sex hormones,Million of national currency units,84.2
+19087,Ireland,2010,6,G-Genito urinary system and sex hormones,Million US$ at exchange rate,111.6
+19088,Ireland,2010,6,C07-Beta blocking agents,"Million US$, purchasing power parity",32.2
+19089,Ireland,2011,7,B-Blood and blood forming organs,"/capita, US$ purchasing power parity",23.6
+19090,Ireland,2011,7,B-Blood and blood forming organs,% of total sales,4.6
+19091,Ireland,2011,7,N02-Analgesics,"Million US$, purchasing power parity",68.6
+19092,Ireland,2011,7,B-Blood and blood forming organs,"/capita, US$ exchange rate",27.3
+19093,Ireland,2011,7,G03-Sex hormones and modulators of the genital system,% of total sales,1.7
+19094,Ireland,2011,7,J-Antiinfectives for systemic use,Million of national currency units,60.3
+19095,Ireland,2011,7,C02-Antihypertensives,Million of national currency units,21.4
+19096,Ireland,2011,7,C03-Diuretics,"/capita, US$ purchasing power parity",4.1
+19097,Ireland,2011,7,N05B-Anxiolytics,% of total sales,0.5
+19098,Ireland,2011,7,N02-Analgesics,Million US$ at exchange rate,79.4
+19099,Ireland,2011,7,N05B-Anxiolytics,"/capita, US$ exchange rate",2.9
+19100,Ireland,2011,7,N05B-Anxiolytics,"/capita, US$ purchasing power parity",2.5
+19101,Ireland,2011,7,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),% of total sales,5.5
+19102,Ireland,2011,7,N05B-Anxiolytics,"Million US$, purchasing power parity",11.5
+19103,Ireland,2011,7,N05B-Anxiolytics,Million US$ at exchange rate,13.4
+19104,Ireland,2011,7,N05B-Anxiolytics,Million of national currency units,9.6
+19105,Ireland,2011,7,C03-Diuretics,Million of national currency units,15.8
+19106,Ireland,2011,7,N02-Analgesics,Million of national currency units,57.1
+19107,Ireland,2011,7,C03-Diuretics,"/capita, US$ exchange rate",4.8
+19108,Ireland,2011,7,C03-Diuretics,Million US$ at exchange rate,22.0
+19109,Ireland,2011,7,C03-Diuretics,"Million US$, purchasing power parity",19.0
+19110,Ireland,2011,7,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ purchasing power parity",22.4
+19111,Ireland,2011,7,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million of national currency units,107.7
+19112,Ireland,2011,7,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million US$ at exchange rate,150.0
+19113,Ireland,2011,7,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ purchasing power parity",12.0
+19114,Ireland,2011,7,"H-Systemic hormonal preparations, excluding sex hormones and insulins",% of total sales,2.3
+19115,Ireland,2011,7,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ purchasing power parity",28.3
+19116,Ireland,2011,7,J-Antiinfectives for systemic use,"Million US$, purchasing power parity",72.5
+19117,Ireland,2011,7,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"Million US$, purchasing power parity",129.6
+19118,Ireland,2011,7,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ exchange rate",32.7
+19119,Ireland,2011,7,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ exchange rate",13.9
+19120,Ireland,2011,7,J-Antiinfectives for systemic use,% of total sales,3.1
+19121,Ireland,2011,7,J-Antiinfectives for systemic use,"/capita, US$ purchasing power parity",15.8
+19122,Ireland,2011,7,C02-Antihypertensives,"/capita, US$ purchasing power parity",5.6
+19123,Ireland,2011,7,C02-Antihypertensives,% of total sales,1.1
+19124,Ireland,2011,7,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million US$ at exchange rate,63.8
+19125,Ireland,2011,7,"H-Systemic hormonal preparations, excluding sex hormones and insulins","Million US$, purchasing power parity",55.1
+19126,Ireland,2011,7,J-Antiinfectives for systemic use,"/capita, US$ exchange rate",18.3
+19127,Ireland,2011,7,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million of national currency units,45.8
+19128,Ireland,2011,7,N05C-Hypnotics and sedatives,"/capita, US$ exchange rate",5.2
+19129,Ireland,2011,7,N05C-Hypnotics and sedatives,"Million US$, purchasing power parity",20.4
+19130,Ireland,2011,7,N05C-Hypnotics and sedatives,% of total sales,0.9
+19131,Ireland,2011,7,N05C-Hypnotics and sedatives,"/capita, US$ purchasing power parity",4.5
+19132,Ireland,2011,7,N05C-Hypnotics and sedatives,Million US$ at exchange rate,23.6
+19133,Ireland,2011,7,C02-Antihypertensives,"Million US$, purchasing power parity",25.7
+19134,Ireland,2011,7,C02-Antihypertensives,Million US$ at exchange rate,29.8
+19135,Ireland,2011,7,C02-Antihypertensives,"/capita, US$ exchange rate",6.5
+19136,Ireland,2011,7,N05C-Hypnotics and sedatives,Million of national currency units,17.0
+19137,Ireland,2011,7,N02-Analgesics,"/capita, US$ exchange rate",17.3
+19138,Ireland,2011,7,B-Blood and blood forming organs,Million of national currency units,89.8
+19139,Ireland,2011,7,B-Blood and blood forming organs,Million US$ at exchange rate,124.9
+19140,Ireland,2011,7,N02-Analgesics,% of total sales,2.9
+19141,Ireland,2011,7,N02-Analgesics,"/capita, US$ purchasing power parity",15.0
+19142,Ireland,2011,7,C03-Diuretics,% of total sales,0.8
+19143,Ireland,2011,7,B-Blood and blood forming organs,"Million US$, purchasing power parity",107.9
+19144,Ireland,2011,7,J-Antiinfectives for systemic use,Million US$ at exchange rate,83.9
+19145,Ireland,2011,7,C01A-Cardiac glycosides,"/capita, US$ exchange rate",0.5
+19146,Ireland,2011,7,C01A-Cardiac glycosides,"Million US$, purchasing power parity",1.9
+19147,Ireland,2011,7,C01A-Cardiac glycosides,% of total sales,0.1
+19148,Ireland,2011,7,C01A-Cardiac glycosides,"/capita, US$ purchasing power parity",0.4
+19149,Ireland,2011,7,M-Musculo-skeletal system,"/capita, US$ purchasing power parity",19.7
+19150,Ireland,2011,7,M-Musculo-skeletal system,"/capita, US$ exchange rate",22.8
+19151,Ireland,2011,7,C01A-Cardiac glycosides,Million US$ at exchange rate,2.1
+19152,Ireland,2011,7,C01A-Cardiac glycosides,Million of national currency units,1.5
+19153,Ireland,2011,7,M-Musculo-skeletal system,% of total sales,3.8
+19154,Ireland,2011,7,C10-Lipid modifying agents,Million US$ at exchange rate,209.8
+19155,Ireland,2011,7,C10-Lipid modifying agents,"Million US$, purchasing power parity",181.3
+19156,Ireland,2011,7,Products not elsewhere classified,% of total sales,26.3
+19157,Ireland,2011,7,C10-Lipid modifying agents,Million of national currency units,150.8
+19158,Ireland,2011,7,C10-Lipid modifying agents,"/capita, US$ exchange rate",45.8
+19159,Ireland,2011,7,A10-Drugs used in diabetes,Million US$ at exchange rate,102.2
+19160,Ireland,2011,7,A10-Drugs used in diabetes,Million of national currency units,73.5
+19161,Ireland,2011,7,C10-Lipid modifying agents,"/capita, US$ purchasing power parity",39.6
+19162,Ireland,2011,7,C10-Lipid modifying agents,% of total sales,7.7
+19163,Ireland,2011,7,C08-Calcium channel blockers,"Million US$, purchasing power parity",29.8
+19164,Ireland,2011,7,C08-Calcium channel blockers,Million US$ at exchange rate,34.5
+19165,Ireland,2011,7,C08-Calcium channel blockers,"/capita, US$ purchasing power parity",6.5
+19166,Ireland,2011,7,C08-Calcium channel blockers,"/capita, US$ exchange rate",7.5
+19167,Ireland,2011,7,C08-Calcium channel blockers,Million of national currency units,24.8
+19168,Ireland,2011,7,A02A-Antacids,"Million US$, purchasing power parity",0.1
+19169,Ireland,2011,7,A02A-Antacids,Million US$ at exchange rate,0.2
+19170,Ireland,2011,7,A02A-Antacids,"/capita, US$ purchasing power parity",0.0
+19171,Ireland,2011,7,A02A-Antacids,"/capita, US$ exchange rate",0.0
+19172,Ireland,2011,7,C08-Calcium channel blockers,% of total sales,1.3
+19173,Ireland,2011,7,R-Respiratory system,"/capita, US$ exchange rate",45.9
+19174,Ireland,2011,7,R-Respiratory system,"Million US$, purchasing power parity",181.6
+19175,Ireland,2011,7,R-Respiratory system,% of total sales,7.7
+19176,Ireland,2011,7,R-Respiratory system,"/capita, US$ purchasing power parity",39.7
+19177,Ireland,2011,7,M-Musculo-skeletal system,Million US$ at exchange rate,104.3
+19178,Ireland,2011,7,M-Musculo-skeletal system,Million of national currency units,74.9
+19179,Ireland,2011,7,R-Respiratory system,Million US$ at exchange rate,210.2
+19180,Ireland,2011,7,R-Respiratory system,Million of national currency units,151.0
+19181,Ireland,2011,7,M-Musculo-skeletal system,"Million US$, purchasing power parity",90.1
+19182,Ireland,2011,7,Products not elsewhere classified,"/capita, US$ purchasing power parity",135.2
+19183,Ireland,2011,7,R03-Drugs for obstructive airway diseases,"/capita, US$ purchasing power parity",33.9
+19184,Ireland,2011,7,R03-Drugs for obstructive airway diseases,"/capita, US$ exchange rate",39.3
+19185,Ireland,2011,7,Total pharmaceutical sales,"/capita, US$ purchasing power parity",513.8
+19186,Ireland,2011,7,R03-Drugs for obstructive airway diseases,% of total sales,6.6
+19187,Ireland,2011,7,C-Cardiovascular system,Million of national currency units,339.9
+19188,Ireland,2011,7,C-Cardiovascular system,Million US$ at exchange rate,473.1
+19189,Ireland,2011,7,R03-Drugs for obstructive airway diseases,Million of national currency units,129.2
+19190,Ireland,2011,7,R03-Drugs for obstructive airway diseases,"Million US$, purchasing power parity",155.4
+19191,Ireland,2011,7,R03-Drugs for obstructive airway diseases,Million US$ at exchange rate,179.8
+19192,Ireland,2011,7,Total pharmaceutical sales,Million US$ at exchange rate,2723.5
+19193,Ireland,2011,7,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ exchange rate",25.9
+19194,Ireland,2011,7,C09-Agents acting on the Renin-Angiotensin system,% of total sales,4.4
+19195,Ireland,2011,7,Total pharmaceutical sales,Million of national currency units,1956.6
+19196,Ireland,2011,7,C-Cardiovascular system,"Million US$, purchasing power parity",408.7
+19197,Ireland,2011,7,C09-Agents acting on the Renin-Angiotensin system,Million of national currency units,85.1
+19198,Ireland,2011,7,Total pharmaceutical sales,"Million US$, purchasing power parity",2353.1
+19199,Ireland,2011,7,Total pharmaceutical sales,"/capita, US$ exchange rate",594.6
+19200,Ireland,2011,7,C09-Agents acting on the Renin-Angiotensin system,"Million US$, purchasing power parity",102.4
+19201,Ireland,2011,7,C09-Agents acting on the Renin-Angiotensin system,Million US$ at exchange rate,118.5
+19202,Ireland,2011,7,A10-Drugs used in diabetes,"/capita, US$ exchange rate",22.3
+19203,Ireland,2011,7,A10-Drugs used in diabetes,"Million US$, purchasing power parity",88.3
+19204,Ireland,2011,7,A10-Drugs used in diabetes,% of total sales,3.8
+19205,Ireland,2011,7,A10-Drugs used in diabetes,"/capita, US$ purchasing power parity",19.3
+19206,Ireland,2011,7,Products not elsewhere classified,"Million US$, purchasing power parity",619.1
+19207,Ireland,2011,7,Products not elsewhere classified,"/capita, US$ exchange rate",156.4
+19208,Ireland,2011,7,A02A-Antacids,% of total sales,0.0
+19209,Ireland,2011,7,Products not elsewhere classified,Million of national currency units,514.8
+19210,Ireland,2011,7,Products not elsewhere classified,Million US$ at exchange rate,716.6
+19211,Ireland,2011,7,C-Cardiovascular system,% of total sales,17.4
+19212,Ireland,2011,7,M01A-Antiinflammatory and antirheumatic products non-steroids,Million of national currency units,29.9
+19213,Ireland,2011,7,M01A-Antiinflammatory and antirheumatic products non-steroids,Million US$ at exchange rate,41.6
+19214,Ireland,2011,7,C-Cardiovascular system,"/capita, US$ exchange rate",103.3
+19215,Ireland,2011,7,C-Cardiovascular system,"/capita, US$ purchasing power parity",89.2
+19216,Ireland,2011,7,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ purchasing power parity",7.9
+19217,Ireland,2011,7,M01A-Antiinflammatory and antirheumatic products non-steroids,% of total sales,1.5
+19218,Ireland,2011,7,M01A-Antiinflammatory and antirheumatic products non-steroids,"Million US$, purchasing power parity",36.0
+19219,Ireland,2011,7,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ exchange rate",9.1
+19220,Ireland,2011,7,A02A-Antacids,Million of national currency units,0.1
+19221,Ireland,2011,7,J01-Antibacterials for systemic use,Million US$ at exchange rate,61.6
+19222,Ireland,2011,7,J01-Antibacterials for systemic use,"Million US$, purchasing power parity",53.2
+19223,Ireland,2011,7,N-Nervous system,"/capita, US$ purchasing power parity",94.1
+19224,Ireland,2011,7,N-Nervous system,% of total sales,18.3
+19225,Ireland,2011,7,J01-Antibacterials for systemic use,"/capita, US$ purchasing power parity",11.6
+19226,Ireland,2011,7,J01-Antibacterials for systemic use,"/capita, US$ exchange rate",13.5
+19227,Ireland,2011,7,G-Genito urinary system and sex hormones,% of total sales,4.2
+19228,Ireland,2011,7,N-Nervous system,Million of national currency units,358.3
+19229,Ireland,2011,7,G-Genito urinary system and sex hormones,"/capita, US$ purchasing power parity",21.8
+19230,Ireland,2011,7,N-Nervous system,"/capita, US$ exchange rate",108.9
+19231,Ireland,2011,7,N-Nervous system,"Million US$, purchasing power parity",430.9
+19232,Ireland,2011,7,N-Nervous system,Million US$ at exchange rate,498.7
+19233,Ireland,2011,7,G-Genito urinary system and sex hormones,"/capita, US$ exchange rate",25.2
+19234,Ireland,2011,7,N06A-Antidepressants,"Million US$, purchasing power parity",80.6
+19235,Ireland,2011,7,N06A-Antidepressants,Million US$ at exchange rate,93.3
+19236,Ireland,2011,7,N06A-Antidepressants,"/capita, US$ purchasing power parity",17.6
+19237,Ireland,2011,7,N06A-Antidepressants,"/capita, US$ exchange rate",20.4
+19238,Ireland,2011,7,N06A-Antidepressants,% of total sales,3.4
+19239,Ireland,2011,7,A-Alimentary tract and metabolism,% of total sales,12.2
+19240,Ireland,2011,7,A-Alimentary tract and metabolism,Million of national currency units,239.0
+19241,Ireland,2011,7,A-Alimentary tract and metabolism,Million US$ at exchange rate,332.6
+19242,Ireland,2011,7,J01-Antibacterials for systemic use,% of total sales,2.3
+19243,Ireland,2011,7,N06A-Antidepressants,Million of national currency units,67.1
+19244,Ireland,2011,7,A-Alimentary tract and metabolism,"/capita, US$ purchasing power parity",62.7
+19245,Ireland,2011,7,A-Alimentary tract and metabolism,"Million US$, purchasing power parity",287.4
+19246,Ireland,2011,7,A-Alimentary tract and metabolism,"/capita, US$ exchange rate",72.6
+19247,Ireland,2011,7,G03-Sex hormones and modulators of the genital system,"Million US$, purchasing power parity",41.1
+19248,Ireland,2011,7,G03-Sex hormones and modulators of the genital system,"/capita, US$ purchasing power parity",9.0
+19249,Ireland,2011,7,G03-Sex hormones and modulators of the genital system,"/capita, US$ exchange rate",10.4
+19250,Ireland,2011,7,G03-Sex hormones and modulators of the genital system,Million US$ at exchange rate,47.6
+19251,Ireland,2011,7,C07-Beta blocking agents,Million US$ at exchange rate,32.4
+19252,Ireland,2011,7,C07-Beta blocking agents,Million of national currency units,23.3
+19253,Ireland,2011,7,"C01B-Antiarrhythmics, Class I and III",Million of national currency units,3.3
+19254,Ireland,2011,7,G03-Sex hormones and modulators of the genital system,Million of national currency units,34.2
+19255,Ireland,2011,7,"C01B-Antiarrhythmics, Class I and III","/capita, US$ purchasing power parity",0.9
+19256,Ireland,2011,7,"C01B-Antiarrhythmics, Class I and III",% of total sales,0.2
+19257,Ireland,2011,7,"C01B-Antiarrhythmics, Class I and III",Million US$ at exchange rate,4.6
+19258,Ireland,2011,7,"C01B-Antiarrhythmics, Class I and III","/capita, US$ exchange rate",1.0
+19259,Ireland,2011,7,"C01B-Antiarrhythmics, Class I and III","Million US$, purchasing power parity",3.9
+19260,Ireland,2011,7,C07-Beta blocking agents,% of total sales,1.2
+19261,Ireland,2011,7,C07-Beta blocking agents,"/capita, US$ exchange rate",7.1
+19262,Ireland,2011,7,C07-Beta blocking agents,"/capita, US$ purchasing power parity",6.1
+19263,Ireland,2011,7,J01-Antibacterials for systemic use,Million of national currency units,44.3
+19264,Ireland,2011,7,G-Genito urinary system and sex hormones,"Million US$, purchasing power parity",99.7
+19265,Ireland,2011,7,G-Genito urinary system and sex hormones,Million of national currency units,82.9
+19266,Ireland,2011,7,G-Genito urinary system and sex hormones,Million US$ at exchange rate,115.4
+19267,Ireland,2011,7,C07-Beta blocking agents,"Million US$, purchasing power parity",28.0
+19268,Italy,2016,2,C03-Diuretics,"/capita, US$ exchange rate",2.0
+19269,Italy,2016,2,M01A-Antiinflammatory and antirheumatic products non-steroids,Million of national currency units,195.1
+19270,Italy,2016,2,C03-Diuretics,"/capita, US$ purchasing power parity",2.6
+19271,Italy,2016,2,C02-Antihypertensives,"Million US$, purchasing power parity",324.7
+19272,Italy,2016,2,C02-Antihypertensives,Million of national currency units,227.5
+19273,Italy,2016,2,C02-Antihypertensives,Million US$ at exchange rate,251.8
+19274,Italy,2016,2,M01A-Antiinflammatory and antirheumatic products non-steroids,"Million US$, purchasing power parity",278.5
+19275,Italy,2016,2,C03-Diuretics,Million US$ at exchange rate,121.7
+19276,Italy,2016,2,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ exchange rate",3.6
+19277,Italy,2016,2,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ purchasing power parity",4.6
+19278,Italy,2016,2,M01A-Antiinflammatory and antirheumatic products non-steroids,Million US$ at exchange rate,216.0
+19279,Italy,2016,2,C03-Diuretics,"Million US$, purchasing power parity",156.9
+19280,Italy,2016,2,C03-Diuretics,% of total sales,0.5
+19281,Italy,2016,2,B-Blood and blood forming organs,Million of national currency units,2027.0
+19282,Italy,2016,2,B-Blood and blood forming organs,Million US$ at exchange rate,2243.7
+19283,Italy,2016,2,J01-Antibacterials for systemic use,Million US$ at exchange rate,978.7
+19284,Italy,2016,2,J01-Antibacterials for systemic use,Million of national currency units,884.2
+19285,Italy,2016,2,Total pharmaceutical sales,Million US$ at exchange rate,25215.9
+19286,Italy,2016,2,Total pharmaceutical sales,Million of national currency units,22780.6
+19287,Italy,2016,2,Total pharmaceutical sales,"/capita, US$ purchasing power parity",536.4
+19288,Italy,2016,2,Total pharmaceutical sales,"/capita, US$ exchange rate",415.9
+19289,Italy,2016,2,Total pharmaceutical sales,"Million US$, purchasing power parity",32518.4
+19290,Italy,2016,2,N05B-Anxiolytics,"Million US$, purchasing power parity",4.3
+19291,Italy,2016,2,N05B-Anxiolytics,Million US$ at exchange rate,3.4
+19292,Italy,2016,2,N05B-Anxiolytics,"/capita, US$ exchange rate",0.1
+19293,Italy,2016,2,N05B-Anxiolytics,% of total sales,0.0
+19294,Italy,2016,2,N05B-Anxiolytics,"/capita, US$ purchasing power parity",0.1
+19295,Italy,2016,2,J01-Antibacterials for systemic use,"/capita, US$ exchange rate",16.1
+19296,Italy,2016,2,J01-Antibacterials for systemic use,"Million US$, purchasing power parity",1262.1
+19297,Italy,2016,2,J01-Antibacterials for systemic use,"/capita, US$ purchasing power parity",20.8
+19298,Italy,2016,2,N05B-Anxiolytics,Million of national currency units,3.0
+19299,Italy,2016,2,J01-Antibacterials for systemic use,% of total sales,3.9
+19300,Italy,2016,2,M01A-Antiinflammatory and antirheumatic products non-steroids,% of total sales,0.9
+19301,Italy,2016,2,J-Antiinfectives for systemic use,Million of national currency units,4413.6
+19302,Italy,2016,2,J-Antiinfectives for systemic use,Million US$ at exchange rate,4885.4
+19303,Italy,2016,2,M-Musculo-skeletal system,Million of national currency units,467.9
+19304,Italy,2016,2,J-Antiinfectives for systemic use,"/capita, US$ purchasing power parity",103.9
+19305,Italy,2016,2,J-Antiinfectives for systemic use,"/capita, US$ exchange rate",80.6
+19306,Italy,2016,2,J-Antiinfectives for systemic use,"Million US$, purchasing power parity",6300.2
+19307,Italy,2016,2,M-Musculo-skeletal system,% of total sales,2.1
+19308,Italy,2016,2,N-Nervous system,Million US$ at exchange rate,2000.6
+19309,Italy,2016,2,N-Nervous system,Million of national currency units,1807.4
+19310,Italy,2016,2,M-Musculo-skeletal system,Million US$ at exchange rate,517.9
+19311,Italy,2016,2,M-Musculo-skeletal system,"Million US$, purchasing power parity",667.9
+19312,Italy,2016,2,M-Musculo-skeletal system,"/capita, US$ purchasing power parity",11.0
+19313,Italy,2016,2,M-Musculo-skeletal system,"/capita, US$ exchange rate",8.5
+19314,Italy,2016,2,N02-Analgesics,"Million US$, purchasing power parity",511.2
+19315,Italy,2016,2,N02-Analgesics,Million US$ at exchange rate,396.4
+19316,Italy,2016,2,N02-Analgesics,"/capita, US$ exchange rate",6.5
+19317,Italy,2016,2,N02-Analgesics,"/capita, US$ purchasing power parity",8.4
+19318,Italy,2016,2,"C01B-Antiarrhythmics, Class I and III",Million of national currency units,77.7
+19319,Italy,2016,2,"C01B-Antiarrhythmics, Class I and III",Million US$ at exchange rate,86.0
+19320,Italy,2016,2,N02-Analgesics,Million of national currency units,358.1
+19321,Italy,2016,2,"C01B-Antiarrhythmics, Class I and III","/capita, US$ purchasing power parity",1.8
+19322,Italy,2016,2,J-Antiinfectives for systemic use,% of total sales,19.4
+19323,Italy,2016,2,"C01B-Antiarrhythmics, Class I and III",% of total sales,0.3
+19324,Italy,2016,2,N02-Analgesics,% of total sales,1.6
+19325,Italy,2016,2,"C01B-Antiarrhythmics, Class I and III","/capita, US$ exchange rate",1.4
+19326,Italy,2016,2,"C01B-Antiarrhythmics, Class I and III","Million US$, purchasing power parity",110.9
+19327,Italy,2016,2,C02-Antihypertensives,% of total sales,1.0
+19328,Italy,2016,2,A-Alimentary tract and metabolism,% of total sales,11.8
+19329,Italy,2016,2,C02-Antihypertensives,"/capita, US$ purchasing power parity",5.4
+19330,Italy,2016,2,A-Alimentary tract and metabolism,"Million US$, purchasing power parity",3847.5
+19331,Italy,2016,2,A-Alimentary tract and metabolism,"/capita, US$ exchange rate",49.2
+19332,Italy,2016,2,A-Alimentary tract and metabolism,"/capita, US$ purchasing power parity",63.5
+19333,Italy,2016,2,C02-Antihypertensives,"/capita, US$ exchange rate",4.2
+19334,Italy,2016,2,A10-Drugs used in diabetes,"/capita, US$ purchasing power parity",21.1
+19335,Italy,2016,2,A10-Drugs used in diabetes,"/capita, US$ exchange rate",16.4
+19336,Italy,2016,2,A10-Drugs used in diabetes,% of total sales,3.9
+19337,Italy,2016,2,A10-Drugs used in diabetes,Million US$ at exchange rate,994.2
+19338,Italy,2016,2,A10-Drugs used in diabetes,Million of national currency units,898.2
+19339,Italy,2016,2,A10-Drugs used in diabetes,"Million US$, purchasing power parity",1282.1
+19340,Italy,2016,2,C01A-Cardiac glycosides,Million US$ at exchange rate,7.2
+19341,Italy,2016,2,C01A-Cardiac glycosides,"/capita, US$ exchange rate",0.1
+19342,Italy,2016,2,C01A-Cardiac glycosides,"Million US$, purchasing power parity",9.3
+19343,Italy,2016,2,C01A-Cardiac glycosides,Million of national currency units,6.5
+19344,Italy,2016,2,N-Nervous system,"Million US$, purchasing power parity",2579.9
+19345,Italy,2016,2,N-Nervous system,"/capita, US$ exchange rate",33.0
+19346,Italy,2016,2,N-Nervous system,"/capita, US$ purchasing power parity",42.6
+19347,Italy,2016,2,A-Alimentary tract and metabolism,Million of national currency units,2695.4
+19348,Italy,2016,2,C03-Diuretics,Million of national currency units,109.9
+19349,Italy,2016,2,A-Alimentary tract and metabolism,Million US$ at exchange rate,2983.5
+19350,Italy,2016,2,C01A-Cardiac glycosides,"/capita, US$ purchasing power parity",0.2
+19351,Italy,2016,2,C01A-Cardiac glycosides,% of total sales,0.0
+19352,Italy,2016,2,N-Nervous system,% of total sales,7.9
+19353,Italy,2016,2,R-Respiratory system,"/capita, US$ purchasing power parity",26.1
+19354,Italy,2016,2,R-Respiratory system,% of total sales,4.9
+19355,Italy,2016,2,R-Respiratory system,"Million US$, purchasing power parity",1580.8
+19356,Italy,2016,2,R-Respiratory system,"/capita, US$ exchange rate",20.2
+19357,Italy,2016,2,B-Blood and blood forming organs,% of total sales,8.9
+19358,Italy,2016,2,B-Blood and blood forming organs,"Million US$, purchasing power parity",2893.5
+19359,Italy,2016,2,B-Blood and blood forming organs,"/capita, US$ exchange rate",37.0
+19360,Italy,2016,2,B-Blood and blood forming organs,"/capita, US$ purchasing power parity",47.7
+19361,Italy,2016,2,C10-Lipid modifying agents,% of total sales,4.6
+19362,Italy,2016,2,C08-Calcium channel blockers,"Million US$, purchasing power parity",423.1
+19363,Italy,2016,2,C08-Calcium channel blockers,"/capita, US$ exchange rate",5.4
+19364,Italy,2016,2,C08-Calcium channel blockers,Million US$ at exchange rate,328.1
+19365,Italy,2016,2,N05C-Hypnotics and sedatives,Million of national currency units,7.1
+19366,Italy,2016,2,C08-Calcium channel blockers,Million of national currency units,296.4
+19367,Italy,2016,2,R-Respiratory system,Million of national currency units,1107.4
+19368,Italy,2016,2,R-Respiratory system,Million US$ at exchange rate,1225.8
+19369,Italy,2016,2,C08-Calcium channel blockers,"/capita, US$ purchasing power parity",7.0
+19370,Italy,2016,2,C08-Calcium channel blockers,% of total sales,1.3
+19371,Italy,2016,2,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million of national currency units,489.7
+19372,Italy,2016,2,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million US$ at exchange rate,542.1
+19373,Italy,2016,2,A02A-Antacids,% of total sales,0.1
+19374,Italy,2016,2,A02A-Antacids,"/capita, US$ purchasing power parity",0.6
+19375,Italy,2016,2,A02A-Antacids,"/capita, US$ exchange rate",0.5
+19376,Italy,2016,2,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ purchasing power parity",11.5
+19377,Italy,2016,2,C-Cardiovascular system,% of total sales,15.9
+19378,Italy,2016,2,"H-Systemic hormonal preparations, excluding sex hormones and insulins","Million US$, purchasing power parity",699.0
+19379,Italy,2016,2,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ exchange rate",8.9
+19380,Italy,2016,2,C10-Lipid modifying agents,"Million US$, purchasing power parity",1483.7
+19381,Italy,2016,2,C10-Lipid modifying agents,Million US$ at exchange rate,1150.5
+19382,Italy,2016,2,C10-Lipid modifying agents,"/capita, US$ purchasing power parity",24.5
+19383,Italy,2016,2,C10-Lipid modifying agents,"/capita, US$ exchange rate",19.0
+19384,Italy,2016,2,A02A-Antacids,Million US$ at exchange rate,28.0
+19385,Italy,2016,2,A02A-Antacids,"Million US$, purchasing power parity",36.1
+19386,Italy,2016,2,C10-Lipid modifying agents,Million of national currency units,1039.4
+19387,Italy,2016,2,A02A-Antacids,Million of national currency units,25.3
+19388,Italy,2016,2,G-Genito urinary system and sex hormones,Million of national currency units,560.9
+19389,Italy,2016,2,C07-Beta blocking agents,% of total sales,1.5
+19390,Italy,2016,2,G-Genito urinary system and sex hormones,Million US$ at exchange rate,620.9
+19391,Italy,2016,2,G-Genito urinary system and sex hormones,"Million US$, purchasing power parity",800.7
+19392,Italy,2016,2,C07-Beta blocking agents,"Million US$, purchasing power parity",489.9
+19393,Italy,2016,2,C07-Beta blocking agents,Million US$ at exchange rate,379.9
+19394,Italy,2016,2,C07-Beta blocking agents,"/capita, US$ purchasing power parity",8.1
+19395,Italy,2016,2,C07-Beta blocking agents,"/capita, US$ exchange rate",6.3
+19396,Italy,2016,2,G-Genito urinary system and sex hormones,"/capita, US$ exchange rate",10.2
+19397,Italy,2016,2,N06A-Antidepressants,"/capita, US$ exchange rate",6.6
+19398,Italy,2016,2,N06A-Antidepressants,"Million US$, purchasing power parity",512.7
+19399,Italy,2016,2,N06A-Antidepressants,% of total sales,1.6
+19400,Italy,2016,2,N06A-Antidepressants,"/capita, US$ purchasing power parity",8.5
+19401,Italy,2016,2,G-Genito urinary system and sex hormones,% of total sales,2.5
+19402,Italy,2016,2,G-Genito urinary system and sex hormones,"/capita, US$ purchasing power parity",13.2
+19403,Italy,2016,2,N06A-Antidepressants,Million US$ at exchange rate,397.6
+19404,Italy,2016,2,N06A-Antidepressants,Million of national currency units,359.2
+19405,Italy,2016,2,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ purchasing power parity",21.4
+19406,Italy,2016,2,N05C-Hypnotics and sedatives,% of total sales,0.0
+19407,Italy,2016,2,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"Million US$, purchasing power parity",1294.9
+19408,Italy,2016,2,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ exchange rate",16.6
+19409,Italy,2016,2,N05C-Hypnotics and sedatives,"Million US$, purchasing power parity",10.2
+19410,Italy,2016,2,N05C-Hypnotics and sedatives,Million US$ at exchange rate,7.9
+19411,Italy,2016,2,N05C-Hypnotics and sedatives,"/capita, US$ purchasing power parity",0.2
+19412,Italy,2016,2,N05C-Hypnotics and sedatives,"/capita, US$ exchange rate",0.1
+19413,Italy,2016,2,G03-Sex hormones and modulators of the genital system,Million US$ at exchange rate,150.6
+19414,Italy,2016,2,G03-Sex hormones and modulators of the genital system,"Million US$, purchasing power parity",194.3
+19415,Italy,2016,2,C07-Beta blocking agents,Million of national currency units,343.2
+19416,Italy,2016,2,G03-Sex hormones and modulators of the genital system,Million of national currency units,136.1
+19417,Italy,2016,2,G03-Sex hormones and modulators of the genital system,"/capita, US$ exchange rate",2.5
+19418,Italy,2016,2,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million of national currency units,907.1
+19419,Italy,2016,2,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million US$ at exchange rate,1004.1
+19420,Italy,2016,2,G03-Sex hormones and modulators of the genital system,"/capita, US$ purchasing power parity",3.2
+19421,Italy,2016,2,G03-Sex hormones and modulators of the genital system,% of total sales,0.6
+19422,Italy,2016,2,"H-Systemic hormonal preparations, excluding sex hormones and insulins",% of total sales,2.1
+19423,Italy,2016,2,R03-Drugs for obstructive airway diseases,Million of national currency units,991.3
+19424,Italy,2016,2,C09-Agents acting on the Renin-Angiotensin system,% of total sales,5.9
+19425,Italy,2016,2,C-Cardiovascular system,"Million US$, purchasing power parity",5181.0
+19426,Italy,2016,2,C-Cardiovascular system,Million US$ at exchange rate,4017.5
+19427,Italy,2016,2,C09-Agents acting on the Renin-Angiotensin system,"Million US$, purchasing power parity",1916.4
+19428,Italy,2016,2,C09-Agents acting on the Renin-Angiotensin system,Million US$ at exchange rate,1486.1
+19429,Italy,2016,2,C-Cardiovascular system,Million of national currency units,3629.5
+19430,Italy,2016,2,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ purchasing power parity",31.6
+19431,Italy,2016,2,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ exchange rate",24.5
+19432,Italy,2016,2,C-Cardiovascular system,"/capita, US$ exchange rate",66.3
+19433,Italy,2016,2,R03-Drugs for obstructive airway diseases,% of total sales,4.4
+19434,Italy,2016,2,R03-Drugs for obstructive airway diseases,"/capita, US$ purchasing power parity",23.3
+19435,Italy,2016,2,C-Cardiovascular system,"/capita, US$ purchasing power parity",85.5
+19436,Italy,2016,2,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),% of total sales,4.0
+19437,Italy,2016,2,R03-Drugs for obstructive airway diseases,"/capita, US$ exchange rate",18.1
+19438,Italy,2016,2,R03-Drugs for obstructive airway diseases,"Million US$, purchasing power parity",1415.1
+19439,Italy,2016,2,R03-Drugs for obstructive airway diseases,Million US$ at exchange rate,1097.3
+19440,Italy,2016,2,C09-Agents acting on the Renin-Angiotensin system,Million of national currency units,1342.6
+19441,Italy,2015,2,C03-Diuretics,"/capita, US$ exchange rate",2.1
+19442,Italy,2015,2,C02-Antihypertensives,"/capita, US$ exchange rate",4.1
+19443,Italy,2015,2,C03-Diuretics,"/capita, US$ purchasing power parity",2.6
+19444,Italy,2015,2,M01A-Antiinflammatory and antirheumatic products non-steroids,Million of national currency units,209.1
+19445,Italy,2015,2,C02-Antihypertensives,Million of national currency units,224.1
+19446,Italy,2015,2,C02-Antihypertensives,"Million US$, purchasing power parity",303.3
+19447,Italy,2015,2,C02-Antihypertensives,Million US$ at exchange rate,248.6
+19448,Italy,2015,2,M01A-Antiinflammatory and antirheumatic products non-steroids,"Million US$, purchasing power parity",283.1
+19449,Italy,2015,2,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ exchange rate",3.8
+19450,Italy,2015,2,C03-Diuretics,Million US$ at exchange rate,127.0
+19451,Italy,2015,2,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ purchasing power parity",4.7
+19452,Italy,2015,2,M01A-Antiinflammatory and antirheumatic products non-steroids,Million US$ at exchange rate,232.0
+19453,Italy,2015,2,C03-Diuretics,"Million US$, purchasing power parity",155.0
+19454,Italy,2015,2,C03-Diuretics,% of total sales,0.5
+19455,Italy,2015,2,B-Blood and blood forming organs,Million of national currency units,1981.9
+19456,Italy,2015,2,B-Blood and blood forming organs,Million US$ at exchange rate,2198.9
+19457,Italy,2015,2,M01A-Antiinflammatory and antirheumatic products non-steroids,% of total sales,0.9
+19458,Italy,2015,2,J01-Antibacterials for systemic use,Million US$ at exchange rate,1060.9
+19459,Italy,2015,2,J01-Antibacterials for systemic use,Million of national currency units,956.2
+19460,Italy,2015,2,Total pharmaceutical sales,Million US$ at exchange rate,25092.0
+19461,Italy,2015,2,Total pharmaceutical sales,Million of national currency units,22615.3
+19462,Italy,2015,2,Total pharmaceutical sales,"Million US$, purchasing power parity",30615.3
+19463,Italy,2015,2,Total pharmaceutical sales,"/capita, US$ purchasing power parity",504.1
+19464,Italy,2015,2,Total pharmaceutical sales,"/capita, US$ exchange rate",413.2
+19465,Italy,2015,2,N05B-Anxiolytics,"Million US$, purchasing power parity",4.1
+19466,Italy,2015,2,N05B-Anxiolytics,Million US$ at exchange rate,3.4
+19467,Italy,2015,2,N05B-Anxiolytics,"/capita, US$ exchange rate",0.1
+19468,Italy,2015,2,N05B-Anxiolytics,% of total sales,0.0
+19469,Italy,2015,2,N05B-Anxiolytics,"/capita, US$ purchasing power parity",0.1
+19470,Italy,2015,2,J01-Antibacterials for systemic use,"/capita, US$ purchasing power parity",21.3
+19471,Italy,2015,2,J01-Antibacterials for systemic use,"/capita, US$ exchange rate",17.5
+19472,Italy,2015,2,J01-Antibacterials for systemic use,"Million US$, purchasing power parity",1294.4
+19473,Italy,2015,2,N05B-Anxiolytics,Million of national currency units,3.0
+19474,Italy,2015,2,J01-Antibacterials for systemic use,% of total sales,4.2
+19475,Italy,2015,2,J-Antiinfectives for systemic use,Million US$ at exchange rate,4852.6
+19476,Italy,2015,2,J-Antiinfectives for systemic use,Million of national currency units,4373.6
+19477,Italy,2015,2,M-Musculo-skeletal system,Million of national currency units,485.2
+19478,Italy,2015,2,J-Antiinfectives for systemic use,"/capita, US$ purchasing power parity",97.5
+19479,Italy,2015,2,J-Antiinfectives for systemic use,"/capita, US$ exchange rate",79.9
+19480,Italy,2015,2,J-Antiinfectives for systemic use,"Million US$, purchasing power parity",5920.7
+19481,Italy,2015,2,M-Musculo-skeletal system,Million US$ at exchange rate,538.4
+19482,Italy,2015,2,M-Musculo-skeletal system,% of total sales,2.1
+19483,Italy,2015,2,N-Nervous system,Million of national currency units,1902.0
+19484,Italy,2015,2,N-Nervous system,Million US$ at exchange rate,2110.3
+19485,Italy,2015,2,M-Musculo-skeletal system,"Million US$, purchasing power parity",656.9
+19486,Italy,2015,2,M-Musculo-skeletal system,"/capita, US$ purchasing power parity",10.8
+19487,Italy,2015,2,M-Musculo-skeletal system,"/capita, US$ exchange rate",8.9
+19488,Italy,2015,2,N02-Analgesics,"Million US$, purchasing power parity",456.4
+19489,Italy,2015,2,N02-Analgesics,"/capita, US$ purchasing power parity",7.5
+19490,Italy,2015,2,N02-Analgesics,"/capita, US$ exchange rate",6.2
+19491,Italy,2015,2,N02-Analgesics,Million US$ at exchange rate,374.0
+19492,Italy,2015,2,"C01B-Antiarrhythmics, Class I and III",Million of national currency units,77.1
+19493,Italy,2015,2,"C01B-Antiarrhythmics, Class I and III",Million US$ at exchange rate,85.5
+19494,Italy,2015,2,N02-Analgesics,Million of national currency units,337.1
+19495,Italy,2015,2,"C01B-Antiarrhythmics, Class I and III","/capita, US$ purchasing power parity",1.7
+19496,Italy,2015,2,"C01B-Antiarrhythmics, Class I and III",% of total sales,0.3
+19497,Italy,2015,2,J-Antiinfectives for systemic use,% of total sales,19.3
+19498,Italy,2015,2,N02-Analgesics,% of total sales,1.5
+19499,Italy,2015,2,"C01B-Antiarrhythmics, Class I and III","/capita, US$ exchange rate",1.4
+19500,Italy,2015,2,"C01B-Antiarrhythmics, Class I and III","Million US$, purchasing power parity",104.3
+19501,Italy,2015,2,C02-Antihypertensives,% of total sales,1.0
+19502,Italy,2015,2,A-Alimentary tract and metabolism,% of total sales,11.7
+19503,Italy,2015,2,C02-Antihypertensives,"/capita, US$ purchasing power parity",5.0
+19504,Italy,2015,2,A-Alimentary tract and metabolism,"Million US$, purchasing power parity",3594.0
+19505,Italy,2015,2,A-Alimentary tract and metabolism,"/capita, US$ exchange rate",48.5
+19506,Italy,2015,2,A-Alimentary tract and metabolism,"/capita, US$ purchasing power parity",59.2
+19507,Italy,2015,2,A10-Drugs used in diabetes,"/capita, US$ purchasing power parity",19.4
+19508,Italy,2015,2,A10-Drugs used in diabetes,"/capita, US$ exchange rate",15.9
+19509,Italy,2015,2,A10-Drugs used in diabetes,% of total sales,3.8
+19510,Italy,2015,2,A10-Drugs used in diabetes,Million US$ at exchange rate,965.1
+19511,Italy,2015,2,A10-Drugs used in diabetes,Million of national currency units,869.9
+19512,Italy,2015,2,A10-Drugs used in diabetes,"Million US$, purchasing power parity",1177.6
+19513,Italy,2015,2,C01A-Cardiac glycosides,Million US$ at exchange rate,8.0
+19514,Italy,2015,2,C01A-Cardiac glycosides,"/capita, US$ exchange rate",0.1
+19515,Italy,2015,2,C01A-Cardiac glycosides,"Million US$, purchasing power parity",9.8
+19516,Italy,2015,2,N-Nervous system,"Million US$, purchasing power parity",2574.8
+19517,Italy,2015,2,N-Nervous system,"/capita, US$ exchange rate",34.7
+19518,Italy,2015,2,C01A-Cardiac glycosides,Million of national currency units,7.2
+19519,Italy,2015,2,N-Nervous system,"/capita, US$ purchasing power parity",42.4
+19520,Italy,2015,2,A-Alimentary tract and metabolism,Million of national currency units,2654.9
+19521,Italy,2015,2,A-Alimentary tract and metabolism,Million US$ at exchange rate,2945.6
+19522,Italy,2015,2,C03-Diuretics,Million of national currency units,114.5
+19523,Italy,2015,2,C01A-Cardiac glycosides,% of total sales,0.0
+19524,Italy,2015,2,C01A-Cardiac glycosides,"/capita, US$ purchasing power parity",0.2
+19525,Italy,2015,2,N-Nervous system,% of total sales,8.4
+19526,Italy,2015,2,R-Respiratory system,"/capita, US$ purchasing power parity",25.1
+19527,Italy,2015,2,R-Respiratory system,% of total sales,5.0
+19528,Italy,2015,2,R-Respiratory system,"Million US$, purchasing power parity",1523.6
+19529,Italy,2015,2,R-Respiratory system,"/capita, US$ exchange rate",20.6
+19530,Italy,2015,2,B-Blood and blood forming organs,"Million US$, purchasing power parity",2683.0
+19531,Italy,2015,2,B-Blood and blood forming organs,"/capita, US$ exchange rate",36.2
+19532,Italy,2015,2,B-Blood and blood forming organs,% of total sales,8.8
+19533,Italy,2015,2,B-Blood and blood forming organs,"/capita, US$ purchasing power parity",44.2
+19534,Italy,2015,2,C08-Calcium channel blockers,"Million US$, purchasing power parity",408.7
+19535,Italy,2015,2,C08-Calcium channel blockers,"/capita, US$ exchange rate",5.5
+19536,Italy,2015,2,N05C-Hypnotics and sedatives,Million of national currency units,4.1
+19537,Italy,2015,2,C08-Calcium channel blockers,Million US$ at exchange rate,335.0
+19538,Italy,2015,2,C08-Calcium channel blockers,Million of national currency units,301.9
+19539,Italy,2015,2,R-Respiratory system,Million of national currency units,1125.4
+19540,Italy,2015,2,R-Respiratory system,Million US$ at exchange rate,1248.7
+19541,Italy,2015,2,C08-Calcium channel blockers,"/capita, US$ purchasing power parity",6.7
+19542,Italy,2015,2,C08-Calcium channel blockers,% of total sales,1.3
+19543,Italy,2015,2,C10-Lipid modifying agents,% of total sales,4.5
+19544,Italy,2015,2,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million of national currency units,481.1
+19545,Italy,2015,2,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million US$ at exchange rate,533.8
+19546,Italy,2015,2,A02A-Antacids,% of total sales,0.1
+19547,Italy,2015,2,A02A-Antacids,"/capita, US$ purchasing power parity",0.5
+19548,Italy,2015,2,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ purchasing power parity",10.7
+19549,Italy,2015,2,C-Cardiovascular system,% of total sales,16.0
+19550,Italy,2015,2,"H-Systemic hormonal preparations, excluding sex hormones and insulins","Million US$, purchasing power parity",651.3
+19551,Italy,2015,2,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ exchange rate",8.8
+19552,Italy,2015,2,A02A-Antacids,"/capita, US$ exchange rate",0.5
+19553,Italy,2015,2,C10-Lipid modifying agents,"Million US$, purchasing power parity",1370.3
+19554,Italy,2015,2,C10-Lipid modifying agents,Million US$ at exchange rate,1123.1
+19555,Italy,2015,2,C10-Lipid modifying agents,"/capita, US$ purchasing power parity",22.6
+19556,Italy,2015,2,C10-Lipid modifying agents,"/capita, US$ exchange rate",18.5
+19557,Italy,2015,2,A02A-Antacids,Million US$ at exchange rate,27.3
+19558,Italy,2015,2,A02A-Antacids,"Million US$, purchasing power parity",33.4
+19559,Italy,2015,2,C10-Lipid modifying agents,Million of national currency units,1012.2
+19560,Italy,2015,2,A02A-Antacids,Million of national currency units,24.6
+19561,Italy,2015,2,G-Genito urinary system and sex hormones,Million of national currency units,548.0
+19562,Italy,2015,2,C07-Beta blocking agents,% of total sales,1.5
+19563,Italy,2015,2,G-Genito urinary system and sex hormones,Million US$ at exchange rate,608.1
+19564,Italy,2015,2,G-Genito urinary system and sex hormones,"Million US$, purchasing power parity",741.9
+19565,Italy,2015,2,G-Genito urinary system and sex hormones,"/capita, US$ exchange rate",10.0
+19566,Italy,2015,2,C07-Beta blocking agents,"Million US$, purchasing power parity",451.2
+19567,Italy,2015,2,C07-Beta blocking agents,Million US$ at exchange rate,369.8
+19568,Italy,2015,2,C07-Beta blocking agents,"/capita, US$ purchasing power parity",7.4
+19569,Italy,2015,2,C07-Beta blocking agents,"/capita, US$ exchange rate",6.1
+19570,Italy,2015,2,N06A-Antidepressants,"/capita, US$ exchange rate",7.4
+19571,Italy,2015,2,N06A-Antidepressants,"Million US$, purchasing power parity",550.0
+19572,Italy,2015,2,N06A-Antidepressants,% of total sales,1.8
+19573,Italy,2015,2,N06A-Antidepressants,"/capita, US$ purchasing power parity",9.1
+19574,Italy,2015,2,G-Genito urinary system and sex hormones,% of total sales,2.4
+19575,Italy,2015,2,G-Genito urinary system and sex hormones,"/capita, US$ purchasing power parity",12.2
+19576,Italy,2015,2,N06A-Antidepressants,Million US$ at exchange rate,450.8
+19577,Italy,2015,2,N06A-Antidepressants,Million of national currency units,406.3
+19578,Italy,2015,2,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ purchasing power parity",21.9
+19579,Italy,2015,2,N05C-Hypnotics and sedatives,% of total sales,0.0
+19580,Italy,2015,2,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"Million US$, purchasing power parity",1328.9
+19581,Italy,2015,2,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ exchange rate",17.9
+19582,Italy,2015,2,N05C-Hypnotics and sedatives,"Million US$, purchasing power parity",5.5
+19583,Italy,2015,2,N05C-Hypnotics and sedatives,Million US$ at exchange rate,4.5
+19584,Italy,2015,2,N05C-Hypnotics and sedatives,"/capita, US$ purchasing power parity",0.1
+19585,Italy,2015,2,N05C-Hypnotics and sedatives,"/capita, US$ exchange rate",0.1
+19586,Italy,2015,2,G03-Sex hormones and modulators of the genital system,"Million US$, purchasing power parity",202.4
+19587,Italy,2015,2,G03-Sex hormones and modulators of the genital system,"/capita, US$ exchange rate",2.7
+19588,Italy,2015,2,G03-Sex hormones and modulators of the genital system,Million US$ at exchange rate,165.9
+19589,Italy,2015,2,C07-Beta blocking agents,Million of national currency units,333.3
+19590,Italy,2015,2,G03-Sex hormones and modulators of the genital system,Million of national currency units,149.5
+19591,Italy,2015,2,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million of national currency units,981.7
+19592,Italy,2015,2,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million US$ at exchange rate,1089.2
+19593,Italy,2015,2,G03-Sex hormones and modulators of the genital system,"/capita, US$ purchasing power parity",3.3
+19594,Italy,2015,2,G03-Sex hormones and modulators of the genital system,% of total sales,0.7
+19595,Italy,2015,2,"H-Systemic hormonal preparations, excluding sex hormones and insulins",% of total sales,2.1
+19596,Italy,2015,2,R03-Drugs for obstructive airway diseases,Million of national currency units,1020.1
+19597,Italy,2015,2,C-Cardiovascular system,"Million US$, purchasing power parity",4897.1
+19598,Italy,2015,2,C-Cardiovascular system,Million US$ at exchange rate,4013.6
+19599,Italy,2015,2,C-Cardiovascular system,"/capita, US$ exchange rate",66.1
+19600,Italy,2015,2,C09-Agents acting on the Renin-Angiotensin system,% of total sales,6.1
+19601,Italy,2015,2,C09-Agents acting on the Renin-Angiotensin system,"Million US$, purchasing power parity",1865.8
+19602,Italy,2015,2,C09-Agents acting on the Renin-Angiotensin system,Million US$ at exchange rate,1529.2
+19603,Italy,2015,2,C-Cardiovascular system,Million of national currency units,3617.5
+19604,Italy,2015,2,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ purchasing power parity",30.7
+19605,Italy,2015,2,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ exchange rate",25.2
+19606,Italy,2015,2,R03-Drugs for obstructive airway diseases,% of total sales,4.5
+19607,Italy,2015,2,R03-Drugs for obstructive airway diseases,"/capita, US$ purchasing power parity",22.7
+19608,Italy,2015,2,C-Cardiovascular system,"/capita, US$ purchasing power parity",80.6
+19609,Italy,2015,2,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),% of total sales,4.3
+19610,Italy,2015,2,R03-Drugs for obstructive airway diseases,"Million US$, purchasing power parity",1380.9
+19611,Italy,2015,2,R03-Drugs for obstructive airway diseases,"/capita, US$ exchange rate",18.6
+19612,Italy,2015,2,R03-Drugs for obstructive airway diseases,Million US$ at exchange rate,1131.8
+19613,Italy,2015,2,C09-Agents acting on the Renin-Angiotensin system,Million of national currency units,1378.2
+19614,Italy,2014,2,C03-Diuretics,"/capita, US$ exchange rate",2.5
+19615,Italy,2014,2,C02-Antihypertensives,"/capita, US$ exchange rate",4.3
+19616,Italy,2014,2,M01A-Antiinflammatory and antirheumatic products non-steroids,Million of national currency units,232.6
+19617,Italy,2014,2,M01A-Antiinflammatory and antirheumatic products non-steroids,% of total sales,1.2
+19618,Italy,2014,2,C03-Diuretics,"/capita, US$ purchasing power parity",2.6
+19619,Italy,2014,2,C02-Antihypertensives,Million of national currency units,197.8
+19620,Italy,2014,2,C02-Antihypertensives,Million US$ at exchange rate,262.8
+19621,Italy,2014,2,C02-Antihypertensives,"Million US$, purchasing power parity",267.4
+19622,Italy,2014,2,M01A-Antiinflammatory and antirheumatic products non-steroids,"Million US$, purchasing power parity",314.5
+19623,Italy,2014,2,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ exchange rate",5.1
+19624,Italy,2014,2,C03-Diuretics,Million US$ at exchange rate,153.9
+19625,Italy,2014,2,C03-Diuretics,"Million US$, purchasing power parity",156.7
+19626,Italy,2014,2,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ purchasing power parity",5.2
+19627,Italy,2014,2,M01A-Antiinflammatory and antirheumatic products non-steroids,Million US$ at exchange rate,309.0
+19628,Italy,2014,2,C03-Diuretics,% of total sales,0.6
+19629,Italy,2014,2,B-Blood and blood forming organs,Million US$ at exchange rate,2462.9
+19630,Italy,2014,2,B-Blood and blood forming organs,Million of national currency units,1853.9
+19631,Italy,2014,2,J01-Antibacterials for systemic use,Million US$ at exchange rate,1294.3
+19632,Italy,2014,2,J01-Antibacterials for systemic use,Million of national currency units,974.3
+19633,Italy,2014,2,Total pharmaceutical sales,Million of national currency units,19887.5
+19634,Italy,2014,2,Total pharmaceutical sales,Million US$ at exchange rate,26420.6
+19635,Italy,2014,2,Total pharmaceutical sales,"/capita, US$ purchasing power parity",442.3
+19636,Italy,2014,2,Total pharmaceutical sales,"/capita, US$ exchange rate",434.6
+19637,Italy,2014,2,Total pharmaceutical sales,"Million US$, purchasing power parity",26888.0
+19638,Italy,2014,2,J01-Antibacterials for systemic use,"Million US$, purchasing power parity",1317.2
+19639,Italy,2014,2,N05B-Anxiolytics,"/capita, US$ exchange rate",0.1
+19640,Italy,2014,2,N05B-Anxiolytics,"Million US$, purchasing power parity",4.7
+19641,Italy,2014,2,N05B-Anxiolytics,Million US$ at exchange rate,4.7
+19642,Italy,2014,2,N05B-Anxiolytics,% of total sales,0.0
+19643,Italy,2014,2,N05B-Anxiolytics,"/capita, US$ purchasing power parity",0.1
+19644,Italy,2014,2,J01-Antibacterials for systemic use,"/capita, US$ purchasing power parity",21.7
+19645,Italy,2014,2,J01-Antibacterials for systemic use,"/capita, US$ exchange rate",21.3
+19646,Italy,2014,2,N05B-Anxiolytics,Million of national currency units,3.5
+19647,Italy,2014,2,J01-Antibacterials for systemic use,% of total sales,4.9
+19648,Italy,2014,2,J-Antiinfectives for systemic use,Million US$ at exchange rate,3251.5
+19649,Italy,2014,2,J-Antiinfectives for systemic use,Million of national currency units,2447.5
+19650,Italy,2014,2,M-Musculo-skeletal system,Million of national currency units,505.9
+19651,Italy,2014,2,M-Musculo-skeletal system,Million US$ at exchange rate,672.1
+19652,Italy,2014,2,J-Antiinfectives for systemic use,"/capita, US$ purchasing power parity",54.4
+19653,Italy,2014,2,J-Antiinfectives for systemic use,"Million US$, purchasing power parity",3309.0
+19654,Italy,2014,2,J-Antiinfectives for systemic use,"/capita, US$ exchange rate",53.5
+19655,Italy,2014,2,M-Musculo-skeletal system,% of total sales,2.5
+19656,Italy,2014,2,N-Nervous system,Million of national currency units,1881.8
+19657,Italy,2014,2,N-Nervous system,Million US$ at exchange rate,2499.9
+19658,Italy,2014,2,M-Musculo-skeletal system,"Million US$, purchasing power parity",683.9
+19659,Italy,2014,2,M-Musculo-skeletal system,"/capita, US$ purchasing power parity",11.3
+19660,Italy,2014,2,M-Musculo-skeletal system,"/capita, US$ exchange rate",11.1
+19661,Italy,2014,2,N02-Analgesics,"Million US$, purchasing power parity",468.5
+19662,Italy,2014,2,N02-Analgesics,"/capita, US$ purchasing power parity",7.7
+19663,Italy,2014,2,N02-Analgesics,"/capita, US$ exchange rate",7.6
+19664,Italy,2014,2,"C01B-Antiarrhythmics, Class I and III",Million of national currency units,75.7
+19665,Italy,2014,2,"C01B-Antiarrhythmics, Class I and III",Million US$ at exchange rate,100.5
+19666,Italy,2014,2,N02-Analgesics,Million US$ at exchange rate,460.3
+19667,Italy,2014,2,N02-Analgesics,Million of national currency units,346.5
+19668,Italy,2014,2,"C01B-Antiarrhythmics, Class I and III","/capita, US$ purchasing power parity",1.7
+19669,Italy,2014,2,"C01B-Antiarrhythmics, Class I and III",% of total sales,0.4
+19670,Italy,2014,2,J-Antiinfectives for systemic use,% of total sales,12.3
+19671,Italy,2014,2,N02-Analgesics,% of total sales,1.7
+19672,Italy,2014,2,"C01B-Antiarrhythmics, Class I and III","/capita, US$ exchange rate",1.7
+19673,Italy,2014,2,"C01B-Antiarrhythmics, Class I and III","Million US$, purchasing power parity",102.3
+19674,Italy,2014,2,C02-Antihypertensives,% of total sales,1.0
+19675,Italy,2014,2,C02-Antihypertensives,"/capita, US$ purchasing power parity",4.4
+19676,Italy,2014,2,A-Alimentary tract and metabolism,% of total sales,13.0
+19677,Italy,2014,2,A-Alimentary tract and metabolism,"/capita, US$ exchange rate",56.5
+19678,Italy,2014,2,A-Alimentary tract and metabolism,"Million US$, purchasing power parity",3494.1
+19679,Italy,2014,2,A-Alimentary tract and metabolism,"/capita, US$ purchasing power parity",57.5
+19680,Italy,2014,2,A10-Drugs used in diabetes,"/capita, US$ purchasing power parity",18.0
+19681,Italy,2014,2,A10-Drugs used in diabetes,% of total sales,4.1
+19682,Italy,2014,2,A10-Drugs used in diabetes,"/capita, US$ exchange rate",17.7
+19683,Italy,2014,2,A10-Drugs used in diabetes,Million US$ at exchange rate,1075.6
+19684,Italy,2014,2,A10-Drugs used in diabetes,Million of national currency units,809.7
+19685,Italy,2014,2,A10-Drugs used in diabetes,"Million US$, purchasing power parity",1094.7
+19686,Italy,2014,2,C01A-Cardiac glycosides,Million US$ at exchange rate,10.7
+19687,Italy,2014,2,C01A-Cardiac glycosides,"Million US$, purchasing power parity",10.9
+19688,Italy,2014,2,C01A-Cardiac glycosides,"/capita, US$ exchange rate",0.2
+19689,Italy,2014,2,N-Nervous system,"/capita, US$ exchange rate",41.1
+19690,Italy,2014,2,N-Nervous system,"Million US$, purchasing power parity",2544.1
+19691,Italy,2014,2,C01A-Cardiac glycosides,Million of national currency units,8.1
+19692,Italy,2014,2,N-Nervous system,"/capita, US$ purchasing power parity",41.9
+19693,Italy,2014,2,A-Alimentary tract and metabolism,Million of national currency units,2584.4
+19694,Italy,2014,2,A-Alimentary tract and metabolism,Million US$ at exchange rate,3433.3
+19695,Italy,2014,2,C03-Diuretics,Million of national currency units,115.9
+19696,Italy,2014,2,C01A-Cardiac glycosides,% of total sales,0.0
+19697,Italy,2014,2,C01A-Cardiac glycosides,"/capita, US$ purchasing power parity",0.2
+19698,Italy,2014,2,N-Nervous system,% of total sales,9.5
+19699,Italy,2014,2,R-Respiratory system,% of total sales,5.5
+19700,Italy,2014,2,R-Respiratory system,"/capita, US$ purchasing power parity",24.5
+19701,Italy,2014,2,R-Respiratory system,"Million US$, purchasing power parity",1491.4
+19702,Italy,2014,2,R-Respiratory system,"/capita, US$ exchange rate",24.1
+19703,Italy,2014,2,B-Blood and blood forming organs,"/capita, US$ exchange rate",40.5
+19704,Italy,2014,2,B-Blood and blood forming organs,"Million US$, purchasing power parity",2506.4
+19705,Italy,2014,2,B-Blood and blood forming organs,% of total sales,9.3
+19706,Italy,2014,2,B-Blood and blood forming organs,"/capita, US$ purchasing power parity",41.2
+19707,Italy,2014,2,C08-Calcium channel blockers,"Million US$, purchasing power parity",430.3
+19708,Italy,2014,2,C08-Calcium channel blockers,"/capita, US$ exchange rate",7.0
+19709,Italy,2014,2,C08-Calcium channel blockers,Million US$ at exchange rate,422.8
+19710,Italy,2014,2,N05C-Hypnotics and sedatives,Million of national currency units,2.5
+19711,Italy,2014,2,C08-Calcium channel blockers,Million of national currency units,318.3
+19712,Italy,2014,2,R-Respiratory system,Million of national currency units,1103.1
+19713,Italy,2014,2,R-Respiratory system,Million US$ at exchange rate,1465.4
+19714,Italy,2014,2,C08-Calcium channel blockers,"/capita, US$ purchasing power parity",7.1
+19715,Italy,2014,2,C08-Calcium channel blockers,% of total sales,1.6
+19716,Italy,2014,2,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million of national currency units,488.9
+19717,Italy,2014,2,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million US$ at exchange rate,649.5
+19718,Italy,2014,2,A02A-Antacids,"/capita, US$ purchasing power parity",0.5
+19719,Italy,2014,2,A02A-Antacids,% of total sales,0.1
+19720,Italy,2014,2,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ purchasing power parity",10.9
+19721,Italy,2014,2,C-Cardiovascular system,% of total sales,18.2
+19722,Italy,2014,2,"H-Systemic hormonal preparations, excluding sex hormones and insulins","Million US$, purchasing power parity",661.0
+19723,Italy,2014,2,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ exchange rate",10.7
+19724,Italy,2014,2,C10-Lipid modifying agents,% of total sales,5.1
+19725,Italy,2014,2,C10-Lipid modifying agents,"Million US$, purchasing power parity",1363.1
+19726,Italy,2014,2,C10-Lipid modifying agents,Million US$ at exchange rate,1339.4
+19727,Italy,2014,2,C10-Lipid modifying agents,"/capita, US$ exchange rate",22.0
+19728,Italy,2014,2,C10-Lipid modifying agents,"/capita, US$ purchasing power parity",22.4
+19729,Italy,2014,2,A02A-Antacids,"/capita, US$ exchange rate",0.5
+19730,Italy,2014,2,A02A-Antacids,Million US$ at exchange rate,32.2
+19731,Italy,2014,2,A02A-Antacids,"Million US$, purchasing power parity",32.7
+19732,Italy,2014,2,C10-Lipid modifying agents,Million of national currency units,1008.2
+19733,Italy,2014,2,A02A-Antacids,Million of national currency units,24.2
+19734,Italy,2014,2,G-Genito urinary system and sex hormones,Million of national currency units,532.6
+19735,Italy,2014,2,C07-Beta blocking agents,% of total sales,1.6
+19736,Italy,2014,2,G-Genito urinary system and sex hormones,Million US$ at exchange rate,707.6
+19737,Italy,2014,2,G-Genito urinary system and sex hormones,"/capita, US$ exchange rate",11.6
+19738,Italy,2014,2,G-Genito urinary system and sex hormones,"Million US$, purchasing power parity",720.1
+19739,Italy,2014,2,C07-Beta blocking agents,"Million US$, purchasing power parity",437.1
+19740,Italy,2014,2,C07-Beta blocking agents,Million US$ at exchange rate,429.5
+19741,Italy,2014,2,C07-Beta blocking agents,"/capita, US$ purchasing power parity",7.2
+19742,Italy,2014,2,C07-Beta blocking agents,"/capita, US$ exchange rate",7.1
+19743,Italy,2014,2,N06A-Antidepressants,"/capita, US$ exchange rate",10.2
+19744,Italy,2014,2,N06A-Antidepressants,"Million US$, purchasing power parity",628.0
+19745,Italy,2014,2,N06A-Antidepressants,% of total sales,2.3
+19746,Italy,2014,2,N06A-Antidepressants,"/capita, US$ purchasing power parity",10.3
+19747,Italy,2014,2,G-Genito urinary system and sex hormones,% of total sales,2.7
+19748,Italy,2014,2,G-Genito urinary system and sex hormones,"/capita, US$ purchasing power parity",11.8
+19749,Italy,2014,2,N06A-Antidepressants,Million US$ at exchange rate,617.1
+19750,Italy,2014,2,N06A-Antidepressants,Million of national currency units,464.5
+19751,Italy,2014,2,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ purchasing power parity",23.1
+19752,Italy,2014,2,N05C-Hypnotics and sedatives,% of total sales,0.0
+19753,Italy,2014,2,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"Million US$, purchasing power parity",1402.0
+19754,Italy,2014,2,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ exchange rate",22.7
+19755,Italy,2014,2,N05C-Hypnotics and sedatives,"Million US$, purchasing power parity",3.4
+19756,Italy,2014,2,N05C-Hypnotics and sedatives,Million US$ at exchange rate,3.3
+19757,Italy,2014,2,N05C-Hypnotics and sedatives,"/capita, US$ purchasing power parity",0.1
+19758,Italy,2014,2,N05C-Hypnotics and sedatives,"/capita, US$ exchange rate",0.1
+19759,Italy,2014,2,G03-Sex hormones and modulators of the genital system,"Million US$, purchasing power parity",209.1
+19760,Italy,2014,2,G03-Sex hormones and modulators of the genital system,"/capita, US$ exchange rate",3.4
+19761,Italy,2014,2,C07-Beta blocking agents,Million of national currency units,323.3
+19762,Italy,2014,2,G03-Sex hormones and modulators of the genital system,Million US$ at exchange rate,205.5
+19763,Italy,2014,2,G03-Sex hormones and modulators of the genital system,Million of national currency units,154.7
+19764,Italy,2014,2,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million of national currency units,1037.0
+19765,Italy,2014,2,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million US$ at exchange rate,1377.7
+19766,Italy,2014,2,G03-Sex hormones and modulators of the genital system,"/capita, US$ purchasing power parity",3.4
+19767,Italy,2014,2,G03-Sex hormones and modulators of the genital system,% of total sales,0.8
+19768,Italy,2014,2,"H-Systemic hormonal preparations, excluding sex hormones and insulins",% of total sales,2.5
+19769,Italy,2014,2,R03-Drugs for obstructive airway diseases,Million of national currency units,1009.2
+19770,Italy,2014,2,C-Cardiovascular system,"/capita, US$ exchange rate",79.2
+19771,Italy,2014,2,C-Cardiovascular system,"Million US$, purchasing power parity",4899.6
+19772,Italy,2014,2,C-Cardiovascular system,Million US$ at exchange rate,4814.5
+19773,Italy,2014,2,C09-Agents acting on the Renin-Angiotensin system,"Million US$, purchasing power parity",1890.3
+19774,Italy,2014,2,C09-Agents acting on the Renin-Angiotensin system,Million US$ at exchange rate,1857.5
+19775,Italy,2014,2,C-Cardiovascular system,Million of national currency units,3624.0
+19776,Italy,2014,2,C09-Agents acting on the Renin-Angiotensin system,% of total sales,7.0
+19777,Italy,2014,2,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ purchasing power parity",31.1
+19778,Italy,2014,2,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ exchange rate",30.6
+19779,Italy,2014,2,R03-Drugs for obstructive airway diseases,% of total sales,5.1
+19780,Italy,2014,2,R03-Drugs for obstructive airway diseases,"/capita, US$ purchasing power parity",22.4
+19781,Italy,2014,2,C-Cardiovascular system,"/capita, US$ purchasing power parity",80.6
+19782,Italy,2014,2,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),% of total sales,5.2
+19783,Italy,2014,2,R03-Drugs for obstructive airway diseases,"Million US$, purchasing power parity",1364.4
+19784,Italy,2014,2,R03-Drugs for obstructive airway diseases,Million US$ at exchange rate,1340.7
+19785,Italy,2014,2,R03-Drugs for obstructive airway diseases,"/capita, US$ exchange rate",22.1
+19786,Italy,2014,2,C09-Agents acting on the Renin-Angiotensin system,Million of national currency units,1398.2
+19787,Italy,2013,2,C03-Diuretics,"/capita, US$ exchange rate",2.4
+19788,Italy,2013,2,C02-Antihypertensives,"/capita, US$ exchange rate",4.2
+19789,Italy,2013,2,M01A-Antiinflammatory and antirheumatic products non-steroids,Million of national currency units,235.2
+19790,Italy,2013,2,C03-Diuretics,"/capita, US$ purchasing power parity",2.5
+19791,Italy,2013,2,C02-Antihypertensives,Million US$ at exchange rate,251.4
+19792,Italy,2013,2,C02-Antihypertensives,"Million US$, purchasing power parity",256.7
+19793,Italy,2013,2,C03-Diuretics,"Million US$, purchasing power parity",149.4
+19794,Italy,2013,2,M01A-Antiinflammatory and antirheumatic products non-steroids,"Million US$, purchasing power parity",319.0
+19795,Italy,2013,2,C03-Diuretics,Million US$ at exchange rate,146.3
+19796,Italy,2013,2,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ purchasing power parity",5.3
+19797,Italy,2013,2,M01A-Antiinflammatory and antirheumatic products non-steroids,% of total sales,1.2
+19798,Italy,2013,2,M01A-Antiinflammatory and antirheumatic products non-steroids,Million US$ at exchange rate,312.4
+19799,Italy,2013,2,C03-Diuretics,% of total sales,0.6
+19800,Italy,2013,2,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ exchange rate",5.2
+19801,Italy,2013,2,B-Blood and blood forming organs,Million US$ at exchange rate,2280.7
+19802,Italy,2013,2,C02-Antihypertensives,Million of national currency units,189.3
+19803,Italy,2013,2,B-Blood and blood forming organs,Million of national currency units,1717.3
+19804,Italy,2013,2,J01-Antibacterials for systemic use,Million US$ at exchange rate,1300.7
+19805,Italy,2013,2,J01-Antibacterials for systemic use,Million of national currency units,979.4
+19806,Italy,2013,2,Total pharmaceutical sales,Million of national currency units,19445.0
+19807,Italy,2013,2,Total pharmaceutical sales,Million US$ at exchange rate,25825.3
+19808,Italy,2013,2,Total pharmaceutical sales,"Million US$, purchasing power parity",26373.3
+19809,Italy,2013,2,Total pharmaceutical sales,"/capita, US$ purchasing power parity",437.8
+19810,Italy,2013,2,Total pharmaceutical sales,"/capita, US$ exchange rate",428.7
+19811,Italy,2013,2,N05B-Anxiolytics,"/capita, US$ exchange rate",0.1
+19812,Italy,2013,2,N05B-Anxiolytics,"Million US$, purchasing power parity",5.4
+19813,Italy,2013,2,N05B-Anxiolytics,% of total sales,0.0
+19814,Italy,2013,2,N05B-Anxiolytics,"/capita, US$ purchasing power parity",0.1
+19815,Italy,2013,2,N05B-Anxiolytics,Million US$ at exchange rate,5.3
+19816,Italy,2013,2,J01-Antibacterials for systemic use,"/capita, US$ purchasing power parity",22.1
+19817,Italy,2013,2,J01-Antibacterials for systemic use,"/capita, US$ exchange rate",21.6
+19818,Italy,2013,2,J01-Antibacterials for systemic use,"Million US$, purchasing power parity",1328.3
+19819,Italy,2013,2,N05B-Anxiolytics,Million of national currency units,4.0
+19820,Italy,2013,2,J01-Antibacterials for systemic use,% of total sales,5.0
+19821,Italy,2013,2,J-Antiinfectives for systemic use,Million US$ at exchange rate,3234.2
+19822,Italy,2013,2,J-Antiinfectives for systemic use,Million of national currency units,2435.2
+19823,Italy,2013,2,M-Musculo-skeletal system,Million US$ at exchange rate,732.0
+19824,Italy,2013,2,M-Musculo-skeletal system,Million of national currency units,551.2
+19825,Italy,2013,2,J-Antiinfectives for systemic use,"/capita, US$ purchasing power parity",54.8
+19826,Italy,2013,2,J-Antiinfectives for systemic use,"Million US$, purchasing power parity",3302.9
+19827,Italy,2013,2,J-Antiinfectives for systemic use,"/capita, US$ exchange rate",53.7
+19828,Italy,2013,2,M-Musculo-skeletal system,% of total sales,2.8
+19829,Italy,2013,2,N-Nervous system,Million of national currency units,1897.9
+19830,Italy,2013,2,N-Nervous system,Million US$ at exchange rate,2520.6
+19831,Italy,2013,2,M-Musculo-skeletal system,"Million US$, purchasing power parity",747.6
+19832,Italy,2013,2,M-Musculo-skeletal system,"/capita, US$ purchasing power parity",12.4
+19833,Italy,2013,2,M-Musculo-skeletal system,"/capita, US$ exchange rate",12.2
+19834,Italy,2013,2,J-Antiinfectives for systemic use,% of total sales,12.5
+19835,Italy,2013,2,N02-Analgesics,"Million US$, purchasing power parity",442.8
+19836,Italy,2013,2,N02-Analgesics,"/capita, US$ purchasing power parity",7.4
+19837,Italy,2013,2,N02-Analgesics,"/capita, US$ exchange rate",7.2
+19838,Italy,2013,2,N02-Analgesics,Million US$ at exchange rate,433.6
+19839,Italy,2013,2,"C01B-Antiarrhythmics, Class I and III",Million US$ at exchange rate,99.3
+19840,Italy,2013,2,"C01B-Antiarrhythmics, Class I and III",Million of national currency units,74.8
+19841,Italy,2013,2,N02-Analgesics,Million of national currency units,326.5
+19842,Italy,2013,2,"C01B-Antiarrhythmics, Class I and III","/capita, US$ purchasing power parity",1.7
+19843,Italy,2013,2,"C01B-Antiarrhythmics, Class I and III",% of total sales,0.4
+19844,Italy,2013,2,N02-Analgesics,% of total sales,1.7
+19845,Italy,2013,2,"C01B-Antiarrhythmics, Class I and III","/capita, US$ exchange rate",1.6
+19846,Italy,2013,2,"C01B-Antiarrhythmics, Class I and III","Million US$, purchasing power parity",101.4
+19847,Italy,2013,2,C02-Antihypertensives,% of total sales,1.0
+19848,Italy,2013,2,C02-Antihypertensives,"/capita, US$ purchasing power parity",4.3
+19849,Italy,2013,2,A-Alimentary tract and metabolism,"/capita, US$ exchange rate",54.7
+19850,Italy,2013,2,A-Alimentary tract and metabolism,"Million US$, purchasing power parity",3361.9
+19851,Italy,2013,2,A-Alimentary tract and metabolism,% of total sales,12.7
+19852,Italy,2013,2,A-Alimentary tract and metabolism,"/capita, US$ purchasing power parity",55.8
+19853,Italy,2013,2,A10-Drugs used in diabetes,"/capita, US$ purchasing power parity",18.3
+19854,Italy,2013,2,A10-Drugs used in diabetes,% of total sales,4.2
+19855,Italy,2013,2,A10-Drugs used in diabetes,"/capita, US$ exchange rate",17.9
+19856,Italy,2013,2,A10-Drugs used in diabetes,Million US$ at exchange rate,1078.4
+19857,Italy,2013,2,A10-Drugs used in diabetes,Million of national currency units,812.0
+19858,Italy,2013,2,A10-Drugs used in diabetes,"Million US$, purchasing power parity",1101.3
+19859,Italy,2013,2,C01A-Cardiac glycosides,Million US$ at exchange rate,11.7
+19860,Italy,2013,2,C01A-Cardiac glycosides,"Million US$, purchasing power parity",11.9
+19861,Italy,2013,2,C01A-Cardiac glycosides,"/capita, US$ exchange rate",0.2
+19862,Italy,2013,2,N-Nervous system,"/capita, US$ exchange rate",41.8
+19863,Italy,2013,2,N-Nervous system,"Million US$, purchasing power parity",2574.1
+19864,Italy,2013,2,C01A-Cardiac glycosides,Million of national currency units,8.8
+19865,Italy,2013,2,N-Nervous system,"/capita, US$ purchasing power parity",42.7
+19866,Italy,2013,2,A-Alimentary tract and metabolism,Million of national currency units,2478.7
+19867,Italy,2013,2,A-Alimentary tract and metabolism,Million US$ at exchange rate,3292.0
+19868,Italy,2013,2,C03-Diuretics,Million of national currency units,110.2
+19869,Italy,2013,2,C01A-Cardiac glycosides,% of total sales,0.0
+19870,Italy,2013,2,C01A-Cardiac glycosides,"/capita, US$ purchasing power parity",0.2
+19871,Italy,2013,2,N-Nervous system,% of total sales,9.8
+19872,Italy,2013,2,R-Respiratory system,% of total sales,5.5
+19873,Italy,2013,2,R-Respiratory system,"Million US$, purchasing power parity",1459.8
+19874,Italy,2013,2,R-Respiratory system,"/capita, US$ purchasing power parity",24.2
+19875,Italy,2013,2,R-Respiratory system,"/capita, US$ exchange rate",23.7
+19876,Italy,2013,2,B-Blood and blood forming organs,"/capita, US$ exchange rate",37.9
+19877,Italy,2013,2,B-Blood and blood forming organs,"Million US$, purchasing power parity",2329.1
+19878,Italy,2013,2,B-Blood and blood forming organs,% of total sales,8.8
+19879,Italy,2013,2,B-Blood and blood forming organs,"/capita, US$ purchasing power parity",38.7
+19880,Italy,2013,2,C08-Calcium channel blockers,"Million US$, purchasing power parity",438.5
+19881,Italy,2013,2,C08-Calcium channel blockers,"/capita, US$ exchange rate",7.1
+19882,Italy,2013,2,N05C-Hypnotics and sedatives,Million of national currency units,3.1
+19883,Italy,2013,2,C08-Calcium channel blockers,Million of national currency units,323.3
+19884,Italy,2013,2,C08-Calcium channel blockers,Million US$ at exchange rate,429.4
+19885,Italy,2013,2,R-Respiratory system,Million of national currency units,1076.3
+19886,Italy,2013,2,R-Respiratory system,Million US$ at exchange rate,1429.5
+19887,Italy,2013,2,C08-Calcium channel blockers,"/capita, US$ purchasing power parity",7.3
+19888,Italy,2013,2,C08-Calcium channel blockers,% of total sales,1.7
+19889,Italy,2013,2,C10-Lipid modifying agents,% of total sales,5.3
+19890,Italy,2013,2,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million of national currency units,484.7
+19891,Italy,2013,2,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million US$ at exchange rate,643.7
+19892,Italy,2013,2,A02A-Antacids,"/capita, US$ purchasing power parity",0.5
+19893,Italy,2013,2,A02A-Antacids,% of total sales,0.1
+19894,Italy,2013,2,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ purchasing power parity",10.9
+19895,Italy,2013,2,C-Cardiovascular system,% of total sales,19.4
+19896,Italy,2013,2,"H-Systemic hormonal preparations, excluding sex hormones and insulins","Million US$, purchasing power parity",657.4
+19897,Italy,2013,2,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ exchange rate",10.7
+19898,Italy,2013,2,A02A-Antacids,"/capita, US$ exchange rate",0.5
+19899,Italy,2013,2,C10-Lipid modifying agents,"Million US$, purchasing power parity",1401.2
+19900,Italy,2013,2,C10-Lipid modifying agents,Million US$ at exchange rate,1372.1
+19901,Italy,2013,2,C10-Lipid modifying agents,"/capita, US$ exchange rate",22.8
+19902,Italy,2013,2,C10-Lipid modifying agents,"/capita, US$ purchasing power parity",23.3
+19903,Italy,2013,2,A02A-Antacids,"Million US$, purchasing power parity",30.0
+19904,Italy,2013,2,A02A-Antacids,Million US$ at exchange rate,29.4
+19905,Italy,2013,2,C10-Lipid modifying agents,Million of national currency units,1033.1
+19906,Italy,2013,2,A02A-Antacids,Million of national currency units,22.1
+19907,Italy,2013,2,G-Genito urinary system and sex hormones,Million US$ at exchange rate,686.0
+19908,Italy,2013,2,G-Genito urinary system and sex hormones,Million of national currency units,516.5
+19909,Italy,2013,2,G-Genito urinary system and sex hormones,"/capita, US$ exchange rate",11.4
+19910,Italy,2013,2,G-Genito urinary system and sex hormones,"Million US$, purchasing power parity",700.6
+19911,Italy,2013,2,C07-Beta blocking agents,% of total sales,1.6
+19912,Italy,2013,2,C07-Beta blocking agents,"Million US$, purchasing power parity",410.7
+19913,Italy,2013,2,C07-Beta blocking agents,Million US$ at exchange rate,402.1
+19914,Italy,2013,2,C07-Beta blocking agents,"/capita, US$ purchasing power parity",6.8
+19915,Italy,2013,2,C07-Beta blocking agents,"/capita, US$ exchange rate",6.7
+19916,Italy,2013,2,N06A-Antidepressants,"/capita, US$ exchange rate",10.9
+19917,Italy,2013,2,N06A-Antidepressants,"Million US$, purchasing power parity",668.9
+19918,Italy,2013,2,N06A-Antidepressants,% of total sales,2.5
+19919,Italy,2013,2,N06A-Antidepressants,"/capita, US$ purchasing power parity",11.1
+19920,Italy,2013,2,G-Genito urinary system and sex hormones,% of total sales,2.7
+19921,Italy,2013,2,G-Genito urinary system and sex hormones,"/capita, US$ purchasing power parity",11.6
+19922,Italy,2013,2,N06A-Antidepressants,Million US$ at exchange rate,655.0
+19923,Italy,2013,2,N06A-Antidepressants,Million of national currency units,493.2
+19924,Italy,2013,2,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ purchasing power parity",22.5
+19925,Italy,2013,2,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),% of total sales,5.1
+19926,Italy,2013,2,N05C-Hypnotics and sedatives,% of total sales,0.0
+19927,Italy,2013,2,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"Million US$, purchasing power parity",1352.6
+19928,Italy,2013,2,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ exchange rate",22.0
+19929,Italy,2013,2,N05C-Hypnotics and sedatives,"Million US$, purchasing power parity",4.2
+19930,Italy,2013,2,N05C-Hypnotics and sedatives,Million US$ at exchange rate,4.1
+19931,Italy,2013,2,N05C-Hypnotics and sedatives,"/capita, US$ purchasing power parity",0.1
+19932,Italy,2013,2,N05C-Hypnotics and sedatives,"/capita, US$ exchange rate",0.1
+19933,Italy,2013,2,G03-Sex hormones and modulators of the genital system,"Million US$, purchasing power parity",222.1
+19934,Italy,2013,2,G03-Sex hormones and modulators of the genital system,"/capita, US$ exchange rate",3.6
+19935,Italy,2013,2,G03-Sex hormones and modulators of the genital system,Million US$ at exchange rate,217.5
+19936,Italy,2013,2,C07-Beta blocking agents,Million of national currency units,302.8
+19937,Italy,2013,2,G03-Sex hormones and modulators of the genital system,Million of national currency units,163.8
+19938,Italy,2013,2,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million of national currency units,997.3
+19939,Italy,2013,2,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million US$ at exchange rate,1324.5
+19940,Italy,2013,2,G03-Sex hormones and modulators of the genital system,"/capita, US$ purchasing power parity",3.7
+19941,Italy,2013,2,G03-Sex hormones and modulators of the genital system,% of total sales,0.8
+19942,Italy,2013,2,"H-Systemic hormonal preparations, excluding sex hormones and insulins",% of total sales,2.5
+19943,Italy,2013,2,R03-Drugs for obstructive airway diseases,Million of national currency units,986.1
+19944,Italy,2013,2,C-Cardiovascular system,Million of national currency units,3769.3
+19945,Italy,2013,2,C-Cardiovascular system,"Million US$, purchasing power parity",5112.3
+19946,Italy,2013,2,C-Cardiovascular system,Million US$ at exchange rate,5006.1
+19947,Italy,2013,2,C09-Agents acting on the Renin-Angiotensin system,% of total sales,8.0
+19948,Italy,2013,2,C09-Agents acting on the Renin-Angiotensin system,"Million US$, purchasing power parity",2104.9
+19949,Italy,2013,2,C09-Agents acting on the Renin-Angiotensin system,Million US$ at exchange rate,2061.2
+19950,Italy,2013,2,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ purchasing power parity",34.9
+19951,Italy,2013,2,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ exchange rate",34.2
+19952,Italy,2013,2,C-Cardiovascular system,"/capita, US$ exchange rate",83.1
+19953,Italy,2013,2,R03-Drugs for obstructive airway diseases,% of total sales,5.1
+19954,Italy,2013,2,R03-Drugs for obstructive airway diseases,"/capita, US$ purchasing power parity",22.2
+19955,Italy,2013,2,C-Cardiovascular system,"/capita, US$ purchasing power parity",84.9
+19956,Italy,2013,2,R03-Drugs for obstructive airway diseases,"Million US$, purchasing power parity",1337.4
+19957,Italy,2013,2,R03-Drugs for obstructive airway diseases,Million US$ at exchange rate,1309.6
+19958,Italy,2013,2,R03-Drugs for obstructive airway diseases,"/capita, US$ exchange rate",21.7
+19959,Italy,2013,2,C09-Agents acting on the Renin-Angiotensin system,Million of national currency units,1551.9
+19960,Italy,2012,2,C03-Diuretics,"/capita, US$ exchange rate",2.3
+19961,Italy,2012,2,C02-Antihypertensives,"/capita, US$ exchange rate",4.2
+19962,Italy,2012,2,M01A-Antiinflammatory and antirheumatic products non-steroids,Million of national currency units,234.5
+19963,Italy,2012,2,C02-Antihypertensives,Million US$ at exchange rate,249.9
+19964,Italy,2012,2,C03-Diuretics,"/capita, US$ purchasing power parity",2.4
+19965,Italy,2012,2,C02-Antihypertensives,"Million US$, purchasing power parity",260.2
+19966,Italy,2012,2,M01A-Antiinflammatory and antirheumatic products non-steroids,Million US$ at exchange rate,301.3
+19967,Italy,2012,2,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ exchange rate",5.1
+19968,Italy,2012,2,M01A-Antiinflammatory and antirheumatic products non-steroids,"Million US$, purchasing power parity",313.6
+19969,Italy,2012,2,C03-Diuretics,"Million US$, purchasing power parity",145.0
+19970,Italy,2012,2,C03-Diuretics,Million US$ at exchange rate,139.3
+19971,Italy,2012,2,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ purchasing power parity",5.3
+19972,Italy,2012,2,M01A-Antiinflammatory and antirheumatic products non-steroids,% of total sales,1.2
+19973,Italy,2012,2,C03-Diuretics,% of total sales,0.6
+19974,Italy,2012,2,B-Blood and blood forming organs,Million US$ at exchange rate,2267.4
+19975,Italy,2012,2,C02-Antihypertensives,Million of national currency units,194.5
+19976,Italy,2012,2,B-Blood and blood forming organs,Million of national currency units,1764.8
+19977,Italy,2012,2,J01-Antibacterials for systemic use,Million US$ at exchange rate,1282.4
+19978,Italy,2012,2,J01-Antibacterials for systemic use,Million of national currency units,998.1
+19979,Italy,2012,2,Total pharmaceutical sales,Million of national currency units,19077.9
+19980,Italy,2012,2,Total pharmaceutical sales,Million US$ at exchange rate,24511.0
+19981,Italy,2012,2,Total pharmaceutical sales,"Million US$, purchasing power parity",25514.3
+19982,Italy,2012,2,Total pharmaceutical sales,"/capita, US$ purchasing power parity",428.5
+19983,Italy,2012,2,Total pharmaceutical sales,"/capita, US$ exchange rate",411.7
+19984,Italy,2012,2,J01-Antibacterials for systemic use,"Million US$, purchasing power parity",1334.9
+19985,Italy,2012,2,N05B-Anxiolytics,"/capita, US$ exchange rate",0.1
+19986,Italy,2012,2,N05B-Anxiolytics,"Million US$, purchasing power parity",5.2
+19987,Italy,2012,2,N05B-Anxiolytics,% of total sales,0.0
+19988,Italy,2012,2,N05B-Anxiolytics,"/capita, US$ purchasing power parity",0.1
+19989,Italy,2012,2,N05B-Anxiolytics,Million US$ at exchange rate,5.0
+19990,Italy,2012,2,J01-Antibacterials for systemic use,"/capita, US$ purchasing power parity",22.4
+19991,Italy,2012,2,J01-Antibacterials for systemic use,"/capita, US$ exchange rate",21.5
+19992,Italy,2012,2,N05B-Anxiolytics,Million of national currency units,3.9
+19993,Italy,2012,2,J01-Antibacterials for systemic use,% of total sales,5.2
+19994,Italy,2012,2,J-Antiinfectives for systemic use,Million US$ at exchange rate,3027.7
+19995,Italy,2012,2,J-Antiinfectives for systemic use,Million of national currency units,2356.5
+19996,Italy,2012,2,M-Musculo-skeletal system,Million US$ at exchange rate,757.3
+19997,Italy,2012,2,M-Musculo-skeletal system,Million of national currency units,589.4
+19998,Italy,2012,2,J-Antiinfectives for systemic use,"/capita, US$ purchasing power parity",52.9
+19999,Italy,2012,2,J-Antiinfectives for systemic use,"Million US$, purchasing power parity",3151.6
+20000,Italy,2012,2,J-Antiinfectives for systemic use,"/capita, US$ exchange rate",50.9
+20001,Italy,2012,2,M-Musculo-skeletal system,% of total sales,3.1
+20002,Italy,2012,2,N-Nervous system,Million of national currency units,1936.9
+20003,Italy,2012,2,N-Nervous system,Million US$ at exchange rate,2488.5
+20004,Italy,2012,2,M-Musculo-skeletal system,"Million US$, purchasing power parity",788.3
+20005,Italy,2012,2,M-Musculo-skeletal system,"/capita, US$ exchange rate",12.7
+20006,Italy,2012,2,M-Musculo-skeletal system,"/capita, US$ purchasing power parity",13.2
+20007,Italy,2012,2,J-Antiinfectives for systemic use,% of total sales,12.4
+20008,Italy,2012,2,N02-Analgesics,"Million US$, purchasing power parity",409.5
+20009,Italy,2012,2,N02-Analgesics,"/capita, US$ purchasing power parity",6.9
+20010,Italy,2012,2,N02-Analgesics,"/capita, US$ exchange rate",6.6
+20011,Italy,2012,2,"C01B-Antiarrhythmics, Class I and III",Million US$ at exchange rate,94.3
+20012,Italy,2012,2,"C01B-Antiarrhythmics, Class I and III",Million of national currency units,73.4
+20013,Italy,2012,2,N02-Analgesics,Million US$ at exchange rate,393.4
+20014,Italy,2012,2,N02-Analgesics,Million of national currency units,306.2
+20015,Italy,2012,2,"C01B-Antiarrhythmics, Class I and III","/capita, US$ purchasing power parity",1.6
+20016,Italy,2012,2,"C01B-Antiarrhythmics, Class I and III",% of total sales,0.4
+20017,Italy,2012,2,N02-Analgesics,% of total sales,1.6
+20018,Italy,2012,2,"C01B-Antiarrhythmics, Class I and III","Million US$, purchasing power parity",98.1
+20019,Italy,2012,2,"C01B-Antiarrhythmics, Class I and III","/capita, US$ exchange rate",1.6
+20020,Italy,2012,2,C02-Antihypertensives,% of total sales,1.0
+20021,Italy,2012,2,C02-Antihypertensives,"/capita, US$ purchasing power parity",4.4
+20022,Italy,2012,2,A-Alimentary tract and metabolism,% of total sales,12.4
+20023,Italy,2012,2,A-Alimentary tract and metabolism,"/capita, US$ exchange rate",51.0
+20024,Italy,2012,2,A-Alimentary tract and metabolism,"Million US$, purchasing power parity",3160.4
+20025,Italy,2012,2,A-Alimentary tract and metabolism,"/capita, US$ purchasing power parity",53.1
+20026,Italy,2012,2,A10-Drugs used in diabetes,"/capita, US$ purchasing power parity",17.5
+20027,Italy,2012,2,A10-Drugs used in diabetes,% of total sales,4.1
+20028,Italy,2012,2,A10-Drugs used in diabetes,"/capita, US$ exchange rate",16.8
+20029,Italy,2012,2,A10-Drugs used in diabetes,Million US$ at exchange rate,1001.8
+20030,Italy,2012,2,A10-Drugs used in diabetes,Million of national currency units,779.7
+20031,Italy,2012,2,A10-Drugs used in diabetes,"Million US$, purchasing power parity",1042.8
+20032,Italy,2012,2,C01A-Cardiac glycosides,Million US$ at exchange rate,12.5
+20033,Italy,2012,2,C01A-Cardiac glycosides,"Million US$, purchasing power parity",13.0
+20034,Italy,2012,2,C01A-Cardiac glycosides,"/capita, US$ exchange rate",0.2
+20035,Italy,2012,2,N-Nervous system,"/capita, US$ exchange rate",41.8
+20036,Italy,2012,2,N-Nervous system,"Million US$, purchasing power parity",2590.3
+20037,Italy,2012,2,C01A-Cardiac glycosides,Million of national currency units,9.7
+20038,Italy,2012,2,N-Nervous system,"/capita, US$ purchasing power parity",43.5
+20039,Italy,2012,2,A-Alimentary tract and metabolism,Million of national currency units,2363.1
+20040,Italy,2012,2,A-Alimentary tract and metabolism,Million US$ at exchange rate,3036.1
+20041,Italy,2012,2,C03-Diuretics,Million of national currency units,108.5
+20042,Italy,2012,2,C01A-Cardiac glycosides,% of total sales,0.1
+20043,Italy,2012,2,C01A-Cardiac glycosides,"/capita, US$ purchasing power parity",0.2
+20044,Italy,2012,2,N-Nervous system,% of total sales,10.2
+20045,Italy,2012,2,R-Respiratory system,% of total sales,5.8
+20046,Italy,2012,2,R-Respiratory system,"/capita, US$ purchasing power parity",24.9
+20047,Italy,2012,2,R-Respiratory system,"/capita, US$ exchange rate",23.9
+20048,Italy,2012,2,R-Respiratory system,"Million US$, purchasing power parity",1484.1
+20049,Italy,2012,2,B-Blood and blood forming organs,"/capita, US$ exchange rate",38.1
+20050,Italy,2012,2,B-Blood and blood forming organs,"Million US$, purchasing power parity",2360.2
+20051,Italy,2012,2,B-Blood and blood forming organs,% of total sales,9.3
+20052,Italy,2012,2,B-Blood and blood forming organs,"/capita, US$ purchasing power parity",39.6
+20053,Italy,2012,2,C08-Calcium channel blockers,"Million US$, purchasing power parity",444.8
+20054,Italy,2012,2,C08-Calcium channel blockers,"/capita, US$ exchange rate",7.2
+20055,Italy,2012,2,N05C-Hypnotics and sedatives,Million of national currency units,3.8
+20056,Italy,2012,2,C08-Calcium channel blockers,Million of national currency units,332.6
+20057,Italy,2012,2,C08-Calcium channel blockers,Million US$ at exchange rate,427.3
+20058,Italy,2012,2,R-Respiratory system,Million of national currency units,1109.7
+20059,Italy,2012,2,R-Respiratory system,Million US$ at exchange rate,1425.7
+20060,Italy,2012,2,C08-Calcium channel blockers,"/capita, US$ purchasing power parity",7.5
+20061,Italy,2012,2,C08-Calcium channel blockers,% of total sales,1.7
+20062,Italy,2012,2,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million of national currency units,478.2
+20063,Italy,2012,2,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million US$ at exchange rate,614.3
+20064,Italy,2012,2,A02A-Antacids,"/capita, US$ purchasing power parity",0.5
+20065,Italy,2012,2,A02A-Antacids,% of total sales,0.1
+20066,Italy,2012,2,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ purchasing power parity",10.7
+20067,Italy,2012,2,"H-Systemic hormonal preparations, excluding sex hormones and insulins","Million US$, purchasing power parity",639.5
+20068,Italy,2012,2,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ exchange rate",10.3
+20069,Italy,2012,2,C10-Lipid modifying agents,"Million US$, purchasing power parity",1531.3
+20070,Italy,2012,2,C10-Lipid modifying agents,Million US$ at exchange rate,1471.1
+20071,Italy,2012,2,C10-Lipid modifying agents,"/capita, US$ exchange rate",24.7
+20072,Italy,2012,2,C10-Lipid modifying agents,% of total sales,6.0
+20073,Italy,2012,2,C10-Lipid modifying agents,"/capita, US$ purchasing power parity",25.7
+20074,Italy,2012,2,A02A-Antacids,"Million US$, purchasing power parity",29.1
+20075,Italy,2012,2,A02A-Antacids,"/capita, US$ exchange rate",0.5
+20076,Italy,2012,2,C10-Lipid modifying agents,Million of national currency units,1145.0
+20077,Italy,2012,2,A02A-Antacids,Million US$ at exchange rate,27.9
+20078,Italy,2012,2,A02A-Antacids,Million of national currency units,21.7
+20079,Italy,2012,2,C-Cardiovascular system,% of total sales,20.8
+20080,Italy,2012,2,G-Genito urinary system and sex hormones,Million US$ at exchange rate,643.1
+20081,Italy,2012,2,G-Genito urinary system and sex hormones,Million of national currency units,500.5
+20082,Italy,2012,2,G-Genito urinary system and sex hormones,"/capita, US$ exchange rate",10.8
+20083,Italy,2012,2,G-Genito urinary system and sex hormones,"Million US$, purchasing power parity",669.4
+20084,Italy,2012,2,C07-Beta blocking agents,"Million US$, purchasing power parity",387.4
+20085,Italy,2012,2,C07-Beta blocking agents,Million US$ at exchange rate,372.2
+20086,Italy,2012,2,C07-Beta blocking agents,% of total sales,1.5
+20087,Italy,2012,2,C07-Beta blocking agents,"/capita, US$ exchange rate",6.3
+20088,Italy,2012,2,C07-Beta blocking agents,"/capita, US$ purchasing power parity",6.5
+20089,Italy,2012,2,N06A-Antidepressants,"/capita, US$ exchange rate",10.6
+20090,Italy,2012,2,N06A-Antidepressants,"Million US$, purchasing power parity",659.4
+20091,Italy,2012,2,N06A-Antidepressants,"/capita, US$ purchasing power parity",11.1
+20092,Italy,2012,2,N06A-Antidepressants,% of total sales,2.6
+20093,Italy,2012,2,G-Genito urinary system and sex hormones,% of total sales,2.6
+20094,Italy,2012,2,G-Genito urinary system and sex hormones,"/capita, US$ purchasing power parity",11.2
+20095,Italy,2012,2,N06A-Antidepressants,Million US$ at exchange rate,633.4
+20096,Italy,2012,2,N06A-Antidepressants,Million of national currency units,493.0
+20097,Italy,2012,2,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ purchasing power parity",22.0
+20098,Italy,2012,2,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),% of total sales,5.1
+20099,Italy,2012,2,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"Million US$, purchasing power parity",1310.5
+20100,Italy,2012,2,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ exchange rate",21.1
+20101,Italy,2012,2,N05C-Hypnotics and sedatives,% of total sales,0.0
+20102,Italy,2012,2,N05C-Hypnotics and sedatives,"Million US$, purchasing power parity",5.1
+20103,Italy,2012,2,N05C-Hypnotics and sedatives,Million US$ at exchange rate,4.9
+20104,Italy,2012,2,N05C-Hypnotics and sedatives,"/capita, US$ purchasing power parity",0.1
+20105,Italy,2012,2,N05C-Hypnotics and sedatives,"/capita, US$ exchange rate",0.1
+20106,Italy,2012,2,G03-Sex hormones and modulators of the genital system,"Million US$, purchasing power parity",227.0
+20107,Italy,2012,2,G03-Sex hormones and modulators of the genital system,"/capita, US$ exchange rate",3.7
+20108,Italy,2012,2,C07-Beta blocking agents,Million of national currency units,289.7
+20109,Italy,2012,2,G03-Sex hormones and modulators of the genital system,Million of national currency units,169.7
+20110,Italy,2012,2,G03-Sex hormones and modulators of the genital system,Million US$ at exchange rate,218.0
+20111,Italy,2012,2,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million of national currency units,979.9
+20112,Italy,2012,2,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million US$ at exchange rate,1259.0
+20113,Italy,2012,2,G03-Sex hormones and modulators of the genital system,"/capita, US$ purchasing power parity",3.8
+20114,Italy,2012,2,G03-Sex hormones and modulators of the genital system,% of total sales,0.9
+20115,Italy,2012,2,"H-Systemic hormonal preparations, excluding sex hormones and insulins",% of total sales,2.5
+20116,Italy,2012,2,R03-Drugs for obstructive airway diseases,Million of national currency units,1008.3
+20117,Italy,2012,2,C-Cardiovascular system,Million of national currency units,3968.6
+20118,Italy,2012,2,C-Cardiovascular system,"/capita, US$ exchange rate",85.6
+20119,Italy,2012,2,C-Cardiovascular system,"Million US$, purchasing power parity",5307.5
+20120,Italy,2012,2,C-Cardiovascular system,Million US$ at exchange rate,5098.8
+20121,Italy,2012,2,C09-Agents acting on the Renin-Angiotensin system,"Million US$, purchasing power parity",2201.1
+20122,Italy,2012,2,C09-Agents acting on the Renin-Angiotensin system,% of total sales,8.6
+20123,Italy,2012,2,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ purchasing power parity",37.0
+20124,Italy,2012,2,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ exchange rate",35.5
+20125,Italy,2012,2,R03-Drugs for obstructive airway diseases,% of total sales,5.3
+20126,Italy,2012,2,R03-Drugs for obstructive airway diseases,"/capita, US$ purchasing power parity",22.6
+20127,Italy,2012,2,C-Cardiovascular system,"/capita, US$ purchasing power parity",89.1
+20128,Italy,2012,2,R03-Drugs for obstructive airway diseases,"Million US$, purchasing power parity",1348.5
+20129,Italy,2012,2,R03-Drugs for obstructive airway diseases,Million US$ at exchange rate,1295.5
+20130,Italy,2012,2,C09-Agents acting on the Renin-Angiotensin system,Million US$ at exchange rate,2114.6
+20131,Italy,2012,2,R03-Drugs for obstructive airway diseases,"/capita, US$ exchange rate",21.8
+20132,Italy,2012,2,C09-Agents acting on the Renin-Angiotensin system,Million of national currency units,1645.8
+20133,Italy,2017,2,C03-Diuretics,"/capita, US$ exchange rate",2.1
+20134,Italy,2017,2,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ exchange rate",3.3
+20135,Italy,2017,2,M01A-Antiinflammatory and antirheumatic products non-steroids,Million of national currency units,174.7
+20136,Italy,2017,2,C03-Diuretics,"/capita, US$ purchasing power parity",2.7
+20137,Italy,2017,2,C02-Antihypertensives,Million of national currency units,221.7
+20138,Italy,2017,2,C02-Antihypertensives,"Million US$, purchasing power parity",321.3
+20139,Italy,2017,2,C02-Antihypertensives,Million US$ at exchange rate,250.4
+20140,Italy,2017,2,M01A-Antiinflammatory and antirheumatic products non-steroids,"Million US$, purchasing power parity",253.2
+20141,Italy,2017,2,C03-Diuretics,Million US$ at exchange rate,127.7
+20142,Italy,2017,2,M01A-Antiinflammatory and antirheumatic products non-steroids,Million US$ at exchange rate,197.3
+20143,Italy,2017,2,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ purchasing power parity",4.2
+20144,Italy,2017,2,C03-Diuretics,"Million US$, purchasing power parity",163.8
+20145,Italy,2017,2,C03-Diuretics,% of total sales,0.5
+20146,Italy,2017,2,J01-Antibacterials for systemic use,% of total sales,3.9
+20147,Italy,2017,2,B-Blood and blood forming organs,Million of national currency units,2088.3
+20148,Italy,2017,2,B-Blood and blood forming organs,Million US$ at exchange rate,2359.1
+20149,Italy,2017,2,J01-Antibacterials for systemic use,Million US$ at exchange rate,983.9
+20150,Italy,2017,2,J01-Antibacterials for systemic use,Million of national currency units,871.0
+20151,Italy,2017,2,Total pharmaceutical sales,"/capita, US$ purchasing power parity",541.6
+20152,Italy,2017,2,Total pharmaceutical sales,Million US$ at exchange rate,25552.0
+20153,Italy,2017,2,Total pharmaceutical sales,Million of national currency units,22618.8
+20154,Italy,2017,2,Total pharmaceutical sales,"/capita, US$ exchange rate",422.1
+20155,Italy,2017,2,Total pharmaceutical sales,"Million US$, purchasing power parity",32785.9
+20156,Italy,2017,2,N05B-Anxiolytics,"Million US$, purchasing power parity",4.8
+20157,Italy,2017,2,N05B-Anxiolytics,Million US$ at exchange rate,3.7
+20158,Italy,2017,2,N05B-Anxiolytics,"/capita, US$ exchange rate",0.1
+20159,Italy,2017,2,N05B-Anxiolytics,% of total sales,0.0
+20160,Italy,2017,2,N05B-Anxiolytics,"/capita, US$ purchasing power parity",0.1
+20161,Italy,2017,2,J01-Antibacterials for systemic use,"/capita, US$ exchange rate",16.3
+20162,Italy,2017,2,J01-Antibacterials for systemic use,"Million US$, purchasing power parity",1262.5
+20163,Italy,2017,2,J01-Antibacterials for systemic use,"/capita, US$ purchasing power parity",20.9
+20164,Italy,2017,2,N05B-Anxiolytics,Million of national currency units,3.3
+20165,Italy,2017,2,J-Antiinfectives for systemic use,Million of national currency units,3501.5
+20166,Italy,2017,2,J-Antiinfectives for systemic use,Million US$ at exchange rate,3955.6
+20167,Italy,2017,2,M-Musculo-skeletal system,Million of national currency units,462.0
+20168,Italy,2017,2,J-Antiinfectives for systemic use,"/capita, US$ purchasing power parity",83.8
+20169,Italy,2017,2,J-Antiinfectives for systemic use,"/capita, US$ exchange rate",65.3
+20170,Italy,2017,2,J-Antiinfectives for systemic use,"Million US$, purchasing power parity",5075.4
+20171,Italy,2017,2,M-Musculo-skeletal system,Million US$ at exchange rate,521.9
+20172,Italy,2017,2,M-Musculo-skeletal system,% of total sales,2.0
+20173,Italy,2017,2,N-Nervous system,Million US$ at exchange rate,2019.4
+20174,Italy,2017,2,N-Nervous system,Million of national currency units,1787.6
+20175,Italy,2017,2,M-Musculo-skeletal system,"/capita, US$ purchasing power parity",11.1
+20176,Italy,2017,2,M-Musculo-skeletal system,"Million US$, purchasing power parity",669.7
+20177,Italy,2017,2,M-Musculo-skeletal system,"/capita, US$ exchange rate",8.6
+20178,Italy,2017,2,N02-Analgesics,"Million US$, purchasing power parity",540.3
+20179,Italy,2017,2,N02-Analgesics,Million US$ at exchange rate,421.1
+20180,Italy,2017,2,N02-Analgesics,"/capita, US$ exchange rate",7.0
+20181,Italy,2017,2,"C01B-Antiarrhythmics, Class I and III",Million of national currency units,79.0
+20182,Italy,2017,2,"C01B-Antiarrhythmics, Class I and III",Million US$ at exchange rate,89.2
+20183,Italy,2017,2,N02-Analgesics,Million of national currency units,372.7
+20184,Italy,2017,2,N02-Analgesics,"/capita, US$ purchasing power parity",8.9
+20185,Italy,2017,2,"C01B-Antiarrhythmics, Class I and III","/capita, US$ purchasing power parity",1.9
+20186,Italy,2017,2,J-Antiinfectives for systemic use,% of total sales,15.5
+20187,Italy,2017,2,"C01B-Antiarrhythmics, Class I and III",% of total sales,0.3
+20188,Italy,2017,2,"C01B-Antiarrhythmics, Class I and III","/capita, US$ exchange rate",1.5
+20189,Italy,2017,2,N02-Analgesics,% of total sales,1.6
+20190,Italy,2017,2,"C01B-Antiarrhythmics, Class I and III","Million US$, purchasing power parity",114.5
+20191,Italy,2017,2,C02-Antihypertensives,% of total sales,1.0
+20192,Italy,2017,2,A-Alimentary tract and metabolism,% of total sales,12.2
+20193,Italy,2017,2,C02-Antihypertensives,"/capita, US$ purchasing power parity",5.3
+20194,Italy,2017,2,A-Alimentary tract and metabolism,"Million US$, purchasing power parity",3992.0
+20195,Italy,2017,2,A-Alimentary tract and metabolism,"/capita, US$ exchange rate",51.4
+20196,Italy,2017,2,A-Alimentary tract and metabolism,"/capita, US$ purchasing power parity",65.9
+20197,Italy,2017,2,C02-Antihypertensives,"/capita, US$ exchange rate",4.1
+20198,Italy,2017,2,A10-Drugs used in diabetes,"/capita, US$ purchasing power parity",21.6
+20199,Italy,2017,2,A10-Drugs used in diabetes,"/capita, US$ exchange rate",16.9
+20200,Italy,2017,2,A10-Drugs used in diabetes,% of total sales,4.0
+20201,Italy,2017,2,A10-Drugs used in diabetes,Million of national currency units,904.1
+20202,Italy,2017,2,A10-Drugs used in diabetes,Million US$ at exchange rate,1021.3
+20203,Italy,2017,2,A10-Drugs used in diabetes,"Million US$, purchasing power parity",1310.5
+20204,Italy,2017,2,M01A-Antiinflammatory and antirheumatic products non-steroids,% of total sales,0.8
+20205,Italy,2017,2,C01A-Cardiac glycosides,Million US$ at exchange rate,6.7
+20206,Italy,2017,2,C01A-Cardiac glycosides,"/capita, US$ exchange rate",0.1
+20207,Italy,2017,2,C01A-Cardiac glycosides,"Million US$, purchasing power parity",8.6
+20208,Italy,2017,2,N-Nervous system,"Million US$, purchasing power parity",2591.1
+20209,Italy,2017,2,N-Nervous system,"/capita, US$ exchange rate",33.4
+20210,Italy,2017,2,C01A-Cardiac glycosides,Million of national currency units,5.9
+20211,Italy,2017,2,A-Alimentary tract and metabolism,Million of national currency units,2754.0
+20212,Italy,2017,2,C03-Diuretics,Million of national currency units,113.0
+20213,Italy,2017,2,A-Alimentary tract and metabolism,Million US$ at exchange rate,3111.2
+20214,Italy,2017,2,N-Nervous system,% of total sales,7.9
+20215,Italy,2017,2,C01A-Cardiac glycosides,"/capita, US$ purchasing power parity",0.1
+20216,Italy,2017,2,C01A-Cardiac glycosides,% of total sales,0.0
+20217,Italy,2017,2,N-Nervous system,"/capita, US$ purchasing power parity",42.8
+20218,Italy,2017,2,R-Respiratory system,"/capita, US$ purchasing power parity",26.8
+20219,Italy,2017,2,R-Respiratory system,% of total sales,5.0
+20220,Italy,2017,2,R-Respiratory system,"Million US$, purchasing power parity",1623.1
+20221,Italy,2017,2,R-Respiratory system,"/capita, US$ exchange rate",20.9
+20222,Italy,2017,2,B-Blood and blood forming organs,"Million US$, purchasing power parity",3027.0
+20223,Italy,2017,2,C10-Lipid modifying agents,% of total sales,4.8
+20224,Italy,2017,2,B-Blood and blood forming organs,% of total sales,9.2
+20225,Italy,2017,2,B-Blood and blood forming organs,"/capita, US$ exchange rate",39.0
+20226,Italy,2017,2,B-Blood and blood forming organs,"/capita, US$ purchasing power parity",50.0
+20227,Italy,2017,2,C08-Calcium channel blockers,Million US$ at exchange rate,323.9
+20228,Italy,2017,2,C08-Calcium channel blockers,"Million US$, purchasing power parity",415.5
+20229,Italy,2017,2,N05C-Hypnotics and sedatives,Million of national currency units,10.1
+20230,Italy,2017,2,C08-Calcium channel blockers,Million of national currency units,286.7
+20231,Italy,2017,2,C08-Calcium channel blockers,"/capita, US$ exchange rate",5.3
+20232,Italy,2017,2,R-Respiratory system,Million of national currency units,1119.8
+20233,Italy,2017,2,R-Respiratory system,Million US$ at exchange rate,1265.0
+20234,Italy,2017,2,C08-Calcium channel blockers,"/capita, US$ purchasing power parity",6.9
+20235,Italy,2017,2,C08-Calcium channel blockers,% of total sales,1.3
+20236,Italy,2017,2,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million of national currency units,509.2
+20237,Italy,2017,2,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million US$ at exchange rate,575.2
+20238,Italy,2017,2,A02A-Antacids,% of total sales,0.1
+20239,Italy,2017,2,A02A-Antacids,"/capita, US$ exchange rate",0.5
+20240,Italy,2017,2,A02A-Antacids,"/capita, US$ purchasing power parity",0.6
+20241,Italy,2017,2,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ purchasing power parity",12.2
+20242,Italy,2017,2,C-Cardiovascular system,% of total sales,15.7
+20243,Italy,2017,2,"H-Systemic hormonal preparations, excluding sex hormones and insulins","Million US$, purchasing power parity",738.0
+20244,Italy,2017,2,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ exchange rate",9.5
+20245,Italy,2017,2,C10-Lipid modifying agents,"Million US$, purchasing power parity",1583.1
+20246,Italy,2017,2,C10-Lipid modifying agents,Million US$ at exchange rate,1233.8
+20247,Italy,2017,2,C10-Lipid modifying agents,"/capita, US$ purchasing power parity",26.2
+20248,Italy,2017,2,C10-Lipid modifying agents,"/capita, US$ exchange rate",20.4
+20249,Italy,2017,2,A02A-Antacids,Million US$ at exchange rate,28.7
+20250,Italy,2017,2,A02A-Antacids,"Million US$, purchasing power parity",36.9
+20251,Italy,2017,2,C10-Lipid modifying agents,Million of national currency units,1092.2
+20252,Italy,2017,2,A02A-Antacids,Million of national currency units,25.4
+20253,Italy,2017,2,G-Genito urinary system and sex hormones,Million of national currency units,514.6
+20254,Italy,2017,2,C07-Beta blocking agents,% of total sales,1.5
+20255,Italy,2017,2,G-Genito urinary system and sex hormones,"Million US$, purchasing power parity",746.0
+20256,Italy,2017,2,G-Genito urinary system and sex hormones,Million US$ at exchange rate,581.4
+20257,Italy,2017,2,C07-Beta blocking agents,"Million US$, purchasing power parity",504.0
+20258,Italy,2017,2,C07-Beta blocking agents,Million US$ at exchange rate,392.8
+20259,Italy,2017,2,C07-Beta blocking agents,"/capita, US$ purchasing power parity",8.3
+20260,Italy,2017,2,C07-Beta blocking agents,"/capita, US$ exchange rate",6.5
+20261,Italy,2017,2,N06A-Antidepressants,"/capita, US$ exchange rate",6.9
+20262,Italy,2017,2,N06A-Antidepressants,"Million US$, purchasing power parity",534.9
+20263,Italy,2017,2,N06A-Antidepressants,% of total sales,1.6
+20264,Italy,2017,2,N06A-Antidepressants,"/capita, US$ purchasing power parity",8.8
+20265,Italy,2017,2,G-Genito urinary system and sex hormones,"/capita, US$ exchange rate",9.6
+20266,Italy,2017,2,G-Genito urinary system and sex hormones,% of total sales,2.3
+20267,Italy,2017,2,G-Genito urinary system and sex hormones,"/capita, US$ purchasing power parity",12.3
+20268,Italy,2017,2,N06A-Antidepressants,Million US$ at exchange rate,416.9
+20269,Italy,2017,2,N06A-Antidepressants,Million of national currency units,369.0
+20270,Italy,2017,2,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ purchasing power parity",21.3
+20271,Italy,2017,2,N05C-Hypnotics and sedatives,% of total sales,0.0
+20272,Italy,2017,2,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"Million US$, purchasing power parity",1289.8
+20273,Italy,2017,2,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ exchange rate",16.6
+20274,Italy,2017,2,N05C-Hypnotics and sedatives,"Million US$, purchasing power parity",14.6
+20275,Italy,2017,2,N05C-Hypnotics and sedatives,Million US$ at exchange rate,11.4
+20276,Italy,2017,2,N05C-Hypnotics and sedatives,"/capita, US$ purchasing power parity",0.2
+20277,Italy,2017,2,N05C-Hypnotics and sedatives,"/capita, US$ exchange rate",0.2
+20278,Italy,2017,2,G03-Sex hormones and modulators of the genital system,Million US$ at exchange rate,139.8
+20279,Italy,2017,2,G03-Sex hormones and modulators of the genital system,"Million US$, purchasing power parity",179.3
+20280,Italy,2017,2,C07-Beta blocking agents,Million of national currency units,347.7
+20281,Italy,2017,2,G03-Sex hormones and modulators of the genital system,Million of national currency units,123.7
+20282,Italy,2017,2,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million of national currency units,889.8
+20283,Italy,2017,2,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million US$ at exchange rate,1005.2
+20284,Italy,2017,2,G03-Sex hormones and modulators of the genital system,"/capita, US$ exchange rate",2.3
+20285,Italy,2017,2,G03-Sex hormones and modulators of the genital system,% of total sales,0.5
+20286,Italy,2017,2,G03-Sex hormones and modulators of the genital system,"/capita, US$ purchasing power parity",3.0
+20287,Italy,2017,2,R03-Drugs for obstructive airway diseases,Million of national currency units,988.2
+20288,Italy,2017,2,"H-Systemic hormonal preparations, excluding sex hormones and insulins",% of total sales,2.3
+20289,Italy,2017,2,C09-Agents acting on the Renin-Angiotensin system,% of total sales,5.4
+20290,Italy,2017,2,C-Cardiovascular system,"Million US$, purchasing power parity",5145.2
+20291,Italy,2017,2,C-Cardiovascular system,Million US$ at exchange rate,4010.0
+20292,Italy,2017,2,C09-Agents acting on the Renin-Angiotensin system,"Million US$, purchasing power parity",1757.8
+20293,Italy,2017,2,C09-Agents acting on the Renin-Angiotensin system,Million US$ at exchange rate,1370.0
+20294,Italy,2017,2,C-Cardiovascular system,Million of national currency units,3549.6
+20295,Italy,2017,2,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ purchasing power parity",29.0
+20296,Italy,2017,2,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ exchange rate",22.6
+20297,Italy,2017,2,R03-Drugs for obstructive airway diseases,"/capita, US$ purchasing power parity",23.7
+20298,Italy,2017,2,C-Cardiovascular system,"/capita, US$ exchange rate",66.2
+20299,Italy,2017,2,R03-Drugs for obstructive airway diseases,"/capita, US$ exchange rate",18.4
+20300,Italy,2017,2,R03-Drugs for obstructive airway diseases,% of total sales,4.4
+20301,Italy,2017,2,C-Cardiovascular system,"/capita, US$ purchasing power parity",85.0
+20302,Italy,2017,2,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),% of total sales,3.9
+20303,Italy,2017,2,R03-Drugs for obstructive airway diseases,"Million US$, purchasing power parity",1432.4
+20304,Italy,2017,2,R03-Drugs for obstructive airway diseases,Million US$ at exchange rate,1116.4
+20305,Italy,2017,2,C09-Agents acting on the Renin-Angiotensin system,Million of national currency units,1212.7
+20306,Italy,2011,2,C03-Diuretics,"/capita, US$ exchange rate",2.5
+20307,Italy,2011,2,M01A-Antiinflammatory and antirheumatic products non-steroids,Million of national currency units,250.0
+20308,Italy,2011,2,C02-Antihypertensives,"/capita, US$ exchange rate",4.6
+20309,Italy,2011,2,C02-Antihypertensives,Million US$ at exchange rate,274.6
+20310,Italy,2011,2,C03-Diuretics,"/capita, US$ purchasing power parity",2.4
+20311,Italy,2011,2,C02-Antihypertensives,"Million US$, purchasing power parity",260.1
+20312,Italy,2011,2,M01A-Antiinflammatory and antirheumatic products non-steroids,Million US$ at exchange rate,347.9
+20313,Italy,2011,2,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ exchange rate",5.9
+20314,Italy,2011,2,M01A-Antiinflammatory and antirheumatic products non-steroids,"Million US$, purchasing power parity",329.5
+20315,Italy,2011,2,C03-Diuretics,Million US$ at exchange rate,151.3
+20316,Italy,2011,2,C03-Diuretics,"Million US$, purchasing power parity",143.3
+20317,Italy,2011,2,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ purchasing power parity",5.5
+20318,Italy,2011,2,M01A-Antiinflammatory and antirheumatic products non-steroids,% of total sales,1.3
+20319,Italy,2011,2,C03-Diuretics,% of total sales,0.6
+20320,Italy,2011,2,B-Blood and blood forming organs,Million US$ at exchange rate,2471.4
+20321,Italy,2011,2,C02-Antihypertensives,Million of national currency units,197.3
+20322,Italy,2011,2,J01-Antibacterials for systemic use,Million US$ at exchange rate,1565.3
+20323,Italy,2011,2,J01-Antibacterials for systemic use,Million of national currency units,1124.5
+20324,Italy,2011,2,B-Blood and blood forming organs,Million of national currency units,1775.5
+20325,Italy,2011,2,Total pharmaceutical sales,"Million US$, purchasing power parity",25720.8
+20326,Italy,2011,2,Total pharmaceutical sales,Million of national currency units,19514.0
+20327,Italy,2011,2,Total pharmaceutical sales,Million US$ at exchange rate,27162.7
+20328,Italy,2011,2,J01-Antibacterials for systemic use,"Million US$, purchasing power parity",1482.2
+20329,Italy,2011,2,Total pharmaceutical sales,"/capita, US$ purchasing power parity",433.2
+20330,Italy,2011,2,Total pharmaceutical sales,"/capita, US$ exchange rate",457.4
+20331,Italy,2011,2,N05B-Anxiolytics,"/capita, US$ exchange rate",0.1
+20332,Italy,2011,2,N05B-Anxiolytics,"Million US$, purchasing power parity",4.8
+20333,Italy,2011,2,N05B-Anxiolytics,% of total sales,0.0
+20334,Italy,2011,2,N05B-Anxiolytics,"/capita, US$ purchasing power parity",0.1
+20335,Italy,2011,2,N05B-Anxiolytics,Million US$ at exchange rate,5.1
+20336,Italy,2011,2,J01-Antibacterials for systemic use,"/capita, US$ purchasing power parity",25.0
+20337,Italy,2011,2,J01-Antibacterials for systemic use,"/capita, US$ exchange rate",26.4
+20338,Italy,2011,2,N05B-Anxiolytics,Million of national currency units,3.7
+20339,Italy,2011,2,J01-Antibacterials for systemic use,% of total sales,5.8
+20340,Italy,2011,2,J-Antiinfectives for systemic use,Million US$ at exchange rate,3335.7
+20341,Italy,2011,2,M-Musculo-skeletal system,Million US$ at exchange rate,891.0
+20342,Italy,2011,2,M-Musculo-skeletal system,Million of national currency units,640.1
+20343,Italy,2011,2,J-Antiinfectives for systemic use,Million of national currency units,2396.4
+20344,Italy,2011,2,J-Antiinfectives for systemic use,"/capita, US$ purchasing power parity",53.2
+20345,Italy,2011,2,J-Antiinfectives for systemic use,"Million US$, purchasing power parity",3158.6
+20346,Italy,2011,2,J-Antiinfectives for systemic use,"/capita, US$ exchange rate",56.2
+20347,Italy,2011,2,N-Nervous system,Million of national currency units,1995.7
+20348,Italy,2011,2,M-Musculo-skeletal system,% of total sales,3.3
+20349,Italy,2011,2,N-Nervous system,Million US$ at exchange rate,2778.0
+20350,Italy,2011,2,M-Musculo-skeletal system,"Million US$, purchasing power parity",843.7
+20351,Italy,2011,2,M-Musculo-skeletal system,"/capita, US$ exchange rate",15.0
+20352,Italy,2011,2,M-Musculo-skeletal system,"/capita, US$ purchasing power parity",14.2
+20353,Italy,2011,2,J-Antiinfectives for systemic use,% of total sales,12.3
+20354,Italy,2011,2,N02-Analgesics,"Million US$, purchasing power parity",375.6
+20355,Italy,2011,2,N02-Analgesics,"/capita, US$ exchange rate",6.7
+20356,Italy,2011,2,N02-Analgesics,"/capita, US$ purchasing power parity",6.3
+20357,Italy,2011,2,"C01B-Antiarrhythmics, Class I and III",Million US$ at exchange rate,104.8
+20358,Italy,2011,2,"C01B-Antiarrhythmics, Class I and III",Million of national currency units,75.3
+20359,Italy,2011,2,N02-Analgesics,Million US$ at exchange rate,396.7
+20360,Italy,2011,2,N02-Analgesics,Million of national currency units,285.0
+20361,Italy,2011,2,"C01B-Antiarrhythmics, Class I and III",% of total sales,0.4
+20362,Italy,2011,2,"C01B-Antiarrhythmics, Class I and III","/capita, US$ purchasing power parity",1.7
+20363,Italy,2011,2,N02-Analgesics,% of total sales,1.5
+20364,Italy,2011,2,"C01B-Antiarrhythmics, Class I and III","/capita, US$ exchange rate",1.8
+20365,Italy,2011,2,"C01B-Antiarrhythmics, Class I and III","Million US$, purchasing power parity",99.2
+20366,Italy,2011,2,N-Nervous system,"Million US$, purchasing power parity",2630.5
+20367,Italy,2011,2,C02-Antihypertensives,% of total sales,1.0
+20368,Italy,2011,2,C02-Antihypertensives,"/capita, US$ purchasing power parity",4.4
+20369,Italy,2011,2,A-Alimentary tract and metabolism,"/capita, US$ exchange rate",53.5
+20370,Italy,2011,2,A-Alimentary tract and metabolism,% of total sales,11.7
+20371,Italy,2011,2,A-Alimentary tract and metabolism,"/capita, US$ purchasing power parity",50.7
+20372,Italy,2011,2,A10-Drugs used in diabetes,Million of national currency units,742.4
+20373,Italy,2011,2,A10-Drugs used in diabetes,"/capita, US$ purchasing power parity",16.5
+20374,Italy,2011,2,A10-Drugs used in diabetes,% of total sales,3.8
+20375,Italy,2011,2,A10-Drugs used in diabetes,Million US$ at exchange rate,1033.4
+20376,Italy,2011,2,A10-Drugs used in diabetes,"/capita, US$ exchange rate",17.4
+20377,Italy,2011,2,A10-Drugs used in diabetes,"Million US$, purchasing power parity",978.5
+20378,Italy,2011,2,C01A-Cardiac glycosides,Million US$ at exchange rate,14.7
+20379,Italy,2011,2,C01A-Cardiac glycosides,"Million US$, purchasing power parity",14.0
+20380,Italy,2011,2,C01A-Cardiac glycosides,"/capita, US$ exchange rate",0.2
+20381,Italy,2011,2,N-Nervous system,"/capita, US$ exchange rate",46.8
+20382,Italy,2011,2,C01A-Cardiac glycosides,Million of national currency units,10.6
+20383,Italy,2011,2,N-Nervous system,"/capita, US$ purchasing power parity",44.3
+20384,Italy,2011,2,A-Alimentary tract and metabolism,Million US$ at exchange rate,3176.3
+20385,Italy,2011,2,A-Alimentary tract and metabolism,Million of national currency units,2281.9
+20386,Italy,2011,2,C03-Diuretics,Million of national currency units,108.7
+20387,Italy,2011,2,A-Alimentary tract and metabolism,"Million US$, purchasing power parity",3007.7
+20388,Italy,2011,2,C01A-Cardiac glycosides,% of total sales,0.1
+20389,Italy,2011,2,C01A-Cardiac glycosides,"/capita, US$ purchasing power parity",0.2
+20390,Italy,2011,2,N-Nervous system,% of total sales,10.2
+20391,Italy,2011,2,R-Respiratory system,Million of national currency units,1136.7
+20392,Italy,2011,2,R-Respiratory system,% of total sales,5.8
+20393,Italy,2011,2,R-Respiratory system,"/capita, US$ exchange rate",26.6
+20394,Italy,2011,2,R-Respiratory system,"/capita, US$ purchasing power parity",25.2
+20395,Italy,2011,2,B-Blood and blood forming organs,"/capita, US$ exchange rate",41.6
+20396,Italy,2011,2,B-Blood and blood forming organs,"Million US$, purchasing power parity",2340.2
+20397,Italy,2011,2,B-Blood and blood forming organs,% of total sales,9.1
+20398,Italy,2011,2,B-Blood and blood forming organs,"/capita, US$ purchasing power parity",39.4
+20399,Italy,2011,2,R-Respiratory system,"Million US$, purchasing power parity",1498.3
+20400,Italy,2011,2,C08-Calcium channel blockers,"Million US$, purchasing power parity",512.7
+20401,Italy,2011,2,C08-Calcium channel blockers,"/capita, US$ exchange rate",9.1
+20402,Italy,2011,2,N05C-Hypnotics and sedatives,Million of national currency units,3.1
+20403,Italy,2011,2,C08-Calcium channel blockers,Million of national currency units,389.0
+20404,Italy,2011,2,C08-Calcium channel blockers,Million US$ at exchange rate,541.5
+20405,Italy,2011,2,R-Respiratory system,Million US$ at exchange rate,1582.3
+20406,Italy,2011,2,C08-Calcium channel blockers,"/capita, US$ purchasing power parity",8.6
+20407,Italy,2011,2,C08-Calcium channel blockers,% of total sales,2.0
+20408,Italy,2011,2,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million of national currency units,462.9
+20409,Italy,2011,2,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million US$ at exchange rate,644.4
+20410,Italy,2011,2,A02A-Antacids,"/capita, US$ purchasing power parity",0.5
+20411,Italy,2011,2,A02A-Antacids,% of total sales,0.1
+20412,Italy,2011,2,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ purchasing power parity",10.3
+20413,Italy,2011,2,"H-Systemic hormonal preparations, excluding sex hormones and insulins",% of total sales,2.4
+20414,Italy,2011,2,"H-Systemic hormonal preparations, excluding sex hormones and insulins","Million US$, purchasing power parity",610.2
+20415,Italy,2011,2,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ exchange rate",10.9
+20416,Italy,2011,2,C10-Lipid modifying agents,"/capita, US$ exchange rate",32.3
+20417,Italy,2011,2,C10-Lipid modifying agents,"Million US$, purchasing power parity",1815.3
+20418,Italy,2011,2,C10-Lipid modifying agents,% of total sales,7.1
+20419,Italy,2011,2,C10-Lipid modifying agents,"/capita, US$ purchasing power parity",30.6
+20420,Italy,2011,2,C10-Lipid modifying agents,Million US$ at exchange rate,1917.0
+20421,Italy,2011,2,A02A-Antacids,"Million US$, purchasing power parity",28.9
+20422,Italy,2011,2,A02A-Antacids,"/capita, US$ exchange rate",0.5
+20423,Italy,2011,2,A02A-Antacids,Million US$ at exchange rate,30.5
+20424,Italy,2011,2,C10-Lipid modifying agents,Million of national currency units,1377.2
+20425,Italy,2011,2,A02A-Antacids,Million of national currency units,21.9
+20426,Italy,2011,2,G-Genito urinary system and sex hormones,Million US$ at exchange rate,700.8
+20427,Italy,2011,2,G-Genito urinary system and sex hormones,Million of national currency units,503.5
+20428,Italy,2011,2,G-Genito urinary system and sex hormones,"/capita, US$ exchange rate",11.8
+20429,Italy,2011,2,G-Genito urinary system and sex hormones,"Million US$, purchasing power parity",663.6
+20430,Italy,2011,2,C07-Beta blocking agents,% of total sales,1.5
+20431,Italy,2011,2,C07-Beta blocking agents,"Million US$, purchasing power parity",375.0
+20432,Italy,2011,2,C07-Beta blocking agents,Million US$ at exchange rate,396.0
+20433,Italy,2011,2,C07-Beta blocking agents,"/capita, US$ exchange rate",6.7
+20434,Italy,2011,2,C07-Beta blocking agents,"/capita, US$ purchasing power parity",6.3
+20435,Italy,2011,2,N06A-Antidepressants,"/capita, US$ exchange rate",11.7
+20436,Italy,2011,2,N06A-Antidepressants,"Million US$, purchasing power parity",655.6
+20437,Italy,2011,2,N06A-Antidepressants,"/capita, US$ purchasing power parity",11.0
+20438,Italy,2011,2,N06A-Antidepressants,% of total sales,2.5
+20439,Italy,2011,2,G-Genito urinary system and sex hormones,% of total sales,2.6
+20440,Italy,2011,2,G-Genito urinary system and sex hormones,"/capita, US$ purchasing power parity",11.2
+20441,Italy,2011,2,N06A-Antidepressants,Million US$ at exchange rate,692.4
+20442,Italy,2011,2,N06A-Antidepressants,Million of national currency units,497.4
+20443,Italy,2011,2,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),% of total sales,5.1
+20444,Italy,2011,2,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ purchasing power parity",21.9
+20445,Italy,2011,2,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"Million US$, purchasing power parity",1301.5
+20446,Italy,2011,2,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ exchange rate",23.1
+20447,Italy,2011,2,N05C-Hypnotics and sedatives,"Million US$, purchasing power parity",4.1
+20448,Italy,2011,2,N05C-Hypnotics and sedatives,Million US$ at exchange rate,4.3
+20449,Italy,2011,2,N05C-Hypnotics and sedatives,% of total sales,0.0
+20450,Italy,2011,2,N05C-Hypnotics and sedatives,"/capita, US$ exchange rate",0.1
+20451,Italy,2011,2,N05C-Hypnotics and sedatives,"/capita, US$ purchasing power parity",0.1
+20452,Italy,2011,2,G03-Sex hormones and modulators of the genital system,"Million US$, purchasing power parity",232.5
+20453,Italy,2011,2,G03-Sex hormones and modulators of the genital system,"/capita, US$ exchange rate",4.1
+20454,Italy,2011,2,C07-Beta blocking agents,Million of national currency units,284.5
+20455,Italy,2011,2,G03-Sex hormones and modulators of the genital system,Million of national currency units,176.4
+20456,Italy,2011,2,G03-Sex hormones and modulators of the genital system,Million US$ at exchange rate,245.5
+20457,Italy,2011,2,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million of national currency units,987.4
+20458,Italy,2011,2,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million US$ at exchange rate,1374.5
+20459,Italy,2011,2,G03-Sex hormones and modulators of the genital system,"/capita, US$ purchasing power parity",3.9
+20460,Italy,2011,2,G03-Sex hormones and modulators of the genital system,% of total sales,0.9
+20461,Italy,2011,2,C-Cardiovascular system,% of total sales,23.3
+20462,Italy,2011,2,R03-Drugs for obstructive airway diseases,Million of national currency units,1030.5
+20463,Italy,2011,2,C-Cardiovascular system,Million of national currency units,4542.7
+20464,Italy,2011,2,C-Cardiovascular system,"/capita, US$ exchange rate",106.5
+20465,Italy,2011,2,C-Cardiovascular system,"Million US$, purchasing power parity",5987.5
+20466,Italy,2011,2,C09-Agents acting on the Renin-Angiotensin system,"Million US$, purchasing power parity",2546.9
+20467,Italy,2011,2,C-Cardiovascular system,Million US$ at exchange rate,6323.2
+20468,Italy,2011,2,C09-Agents acting on the Renin-Angiotensin system,% of total sales,9.9
+20469,Italy,2011,2,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ purchasing power parity",42.9
+20470,Italy,2011,2,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ exchange rate",45.3
+20471,Italy,2011,2,R03-Drugs for obstructive airway diseases,% of total sales,5.3
+20472,Italy,2011,2,R03-Drugs for obstructive airway diseases,"/capita, US$ purchasing power parity",22.9
+20473,Italy,2011,2,C-Cardiovascular system,"/capita, US$ purchasing power parity",100.8
+20474,Italy,2011,2,R03-Drugs for obstructive airway diseases,"Million US$, purchasing power parity",1358.2
+20475,Italy,2011,2,R03-Drugs for obstructive airway diseases,Million US$ at exchange rate,1434.4
+20476,Italy,2011,2,C09-Agents acting on the Renin-Angiotensin system,Million US$ at exchange rate,2689.7
+20477,Italy,2011,2,R03-Drugs for obstructive airway diseases,"/capita, US$ exchange rate",24.2
+20478,Italy,2011,2,C09-Agents acting on the Renin-Angiotensin system,Million of national currency units,1932.3
+20479,Japan,2016,5,Products not elsewhere classified,% of total sales,50.4
+20480,Japan,2016,5,Total pharmaceutical sales,"Million US$, purchasing power parity",62773.8
+20481,Japan,2016,5,Products not elsewhere classified,Million US$ at exchange rate,30673.2
+20482,Japan,2016,5,Products not elsewhere classified,Million of national currency units,3337024.0
+20483,Japan,2016,5,Products not elsewhere classified,"/capita, US$ exchange rate",241.6
+20484,Japan,2016,5,Products not elsewhere classified,"Million US$, purchasing power parity",31624.7
+20485,Japan,2016,5,J-Antiinfectives for systemic use,"/capita, US$ exchange rate",15.2
+20486,Japan,2016,5,J-Antiinfectives for systemic use,"Million US$, purchasing power parity",1989.1
+20487,Japan,2016,5,J-Antiinfectives for systemic use,% of total sales,3.2
+20488,Japan,2016,5,J-Antiinfectives for systemic use,"/capita, US$ purchasing power parity",15.7
+20489,Japan,2016,5,R-Respiratory system,"Million US$, purchasing power parity",1133.6
+20490,Japan,2016,5,R-Respiratory system,Million US$ at exchange rate,1099.5
+20491,Japan,2016,5,R-Respiratory system,Million of national currency units,119619.0
+20492,Japan,2016,5,Total pharmaceutical sales,"/capita, US$ exchange rate",479.7
+20493,Japan,2016,5,R-Respiratory system,% of total sales,1.8
+20494,Japan,2016,5,Products not elsewhere classified,"/capita, US$ purchasing power parity",249.1
+20495,Japan,2016,5,R-Respiratory system,"/capita, US$ exchange rate",8.7
+20496,Japan,2016,5,R-Respiratory system,"/capita, US$ purchasing power parity",8.9
+20497,Japan,2016,5,A-Alimentary tract and metabolism,"Million US$, purchasing power parity",3793.9
+20498,Japan,2016,5,A-Alimentary tract and metabolism,Million US$ at exchange rate,3679.7
+20499,Japan,2016,5,A-Alimentary tract and metabolism,Million of national currency units,400328.0
+20500,Japan,2016,5,A-Alimentary tract and metabolism,"/capita, US$ exchange rate",29.0
+20501,Japan,2016,5,G-Genito urinary system and sex hormones,% of total sales,2.0
+20502,Japan,2016,5,G-Genito urinary system and sex hormones,"/capita, US$ purchasing power parity",10.0
+20503,Japan,2016,5,A-Alimentary tract and metabolism,"/capita, US$ purchasing power parity",29.9
+20504,Japan,2016,5,N-Nervous system,"Million US$, purchasing power parity",7865.8
+20505,Japan,2016,5,N-Nervous system,"/capita, US$ exchange rate",60.1
+20506,Japan,2016,5,N-Nervous system,Million US$ at exchange rate,7629.2
+20507,Japan,2016,5,N-Nervous system,% of total sales,12.5
+20508,Japan,2016,5,N-Nervous system,"/capita, US$ purchasing power parity",62.0
+20509,Japan,2016,5,Total pharmaceutical sales,Million US$ at exchange rate,60885.0
+20510,Japan,2016,5,C-Cardiovascular system,"Million US$, purchasing power parity",9550.3
+20511,Japan,2016,5,C-Cardiovascular system,"/capita, US$ purchasing power parity",75.2
+20512,Japan,2016,5,C-Cardiovascular system,"/capita, US$ exchange rate",73.0
+20513,Japan,2016,5,Total pharmaceutical sales,Million of national currency units,6623860.0
+20514,Japan,2016,5,C-Cardiovascular system,Million US$ at exchange rate,9263.0
+20515,Japan,2016,5,C-Cardiovascular system,Million of national currency units,1007745.0
+20516,Japan,2016,5,G-Genito urinary system and sex hormones,"Million US$, purchasing power parity",1274.6
+20517,Japan,2016,5,G-Genito urinary system and sex hormones,Million US$ at exchange rate,1236.2
+20518,Japan,2016,5,G-Genito urinary system and sex hormones,"/capita, US$ exchange rate",9.7
+20519,Japan,2016,5,A-Alimentary tract and metabolism,% of total sales,6.0
+20520,Japan,2016,5,C-Cardiovascular system,% of total sales,15.2
+20521,Japan,2016,5,G-Genito urinary system and sex hormones,Million of national currency units,134491.0
+20522,Japan,2016,5,N-Nervous system,Million of national currency units,830000.0
+20523,Japan,2016,5,Total pharmaceutical sales,"/capita, US$ purchasing power parity",494.5
+20524,Japan,2016,5,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million of national currency units,159150.0
+20525,Japan,2016,5,"H-Systemic hormonal preparations, excluding sex hormones and insulins","Million US$, purchasing power parity",1508.3
+20526,Japan,2016,5,B-Blood and blood forming organs,Million of national currency units,425618.0
+20527,Japan,2016,5,"H-Systemic hormonal preparations, excluding sex hormones and insulins",% of total sales,2.4
+20528,Japan,2016,5,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ purchasing power parity",11.9
+20529,Japan,2016,5,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ exchange rate",11.5
+20530,Japan,2016,5,B-Blood and blood forming organs,"/capita, US$ purchasing power parity",31.8
+20531,Japan,2016,5,B-Blood and blood forming organs,% of total sales,6.4
+20532,Japan,2016,5,B-Blood and blood forming organs,"/capita, US$ exchange rate",30.8
+20533,Japan,2016,5,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million US$ at exchange rate,1462.9
+20534,Japan,2016,5,J-Antiinfectives for systemic use,Million US$ at exchange rate,1929.2
+20535,Japan,2016,5,J-Antiinfectives for systemic use,Million of national currency units,209885.0
+20536,Japan,2016,5,B-Blood and blood forming organs,Million US$ at exchange rate,3912.2
+20537,Japan,2016,5,B-Blood and blood forming organs,"Million US$, purchasing power parity",4033.5
+20538,Japan,2015,5,Products not elsewhere classified,% of total sales,48.2
+20539,Japan,2015,5,Total pharmaceutical sales,"Million US$, purchasing power parity",65218.5
+20540,Japan,2015,5,Total pharmaceutical sales,"/capita, US$ exchange rate",438.6
+20541,Japan,2015,5,Products not elsewhere classified,Million US$ at exchange rate,26853.0
+20542,Japan,2015,5,Products not elsewhere classified,Million of national currency units,3250399.0
+20543,Japan,2015,5,Products not elsewhere classified,"/capita, US$ exchange rate",211.3
+20544,Japan,2015,5,Products not elsewhere classified,"Million US$, purchasing power parity",31414.1
+20545,Japan,2015,5,J-Antiinfectives for systemic use,"/capita, US$ exchange rate",14.3
+20546,Japan,2015,5,J-Antiinfectives for systemic use,% of total sales,3.3
+20547,Japan,2015,5,J-Antiinfectives for systemic use,"/capita, US$ purchasing power parity",16.7
+20548,Japan,2015,5,R-Respiratory system,"Million US$, purchasing power parity",1150.3
+20549,Japan,2015,5,R-Respiratory system,Million US$ at exchange rate,983.3
+20550,Japan,2015,5,R-Respiratory system,Million of national currency units,119017.0
+20551,Japan,2015,5,R-Respiratory system,"/capita, US$ exchange rate",7.7
+20552,Japan,2015,5,Products not elsewhere classified,"/capita, US$ purchasing power parity",247.2
+20553,Japan,2015,5,R-Respiratory system,% of total sales,1.8
+20554,Japan,2015,5,R-Respiratory system,"/capita, US$ purchasing power parity",9.1
+20555,Japan,2015,5,Total pharmaceutical sales,Million US$ at exchange rate,55749.3
+20556,Japan,2015,5,A-Alimentary tract and metabolism,"Million US$, purchasing power parity",4485.1
+20557,Japan,2015,5,A-Alimentary tract and metabolism,"/capita, US$ exchange rate",30.2
+20558,Japan,2015,5,A-Alimentary tract and metabolism,Million US$ at exchange rate,3833.9
+20559,Japan,2015,5,G-Genito urinary system and sex hormones,% of total sales,2.2
+20560,Japan,2015,5,A-Alimentary tract and metabolism,"/capita, US$ purchasing power parity",35.3
+20561,Japan,2015,5,A-Alimentary tract and metabolism,Million of national currency units,464073.0
+20562,Japan,2015,5,N-Nervous system,"Million US$, purchasing power parity",7869.6
+20563,Japan,2015,5,N-Nervous system,"/capita, US$ exchange rate",52.9
+20564,Japan,2015,5,N-Nervous system,Million US$ at exchange rate,6727.0
+20565,Japan,2015,5,N-Nervous system,Million of national currency units,814267.0
+20566,Japan,2015,5,N-Nervous system,% of total sales,12.1
+20567,Japan,2015,5,G-Genito urinary system and sex hormones,"/capita, US$ purchasing power parity",11.2
+20568,Japan,2015,5,N-Nervous system,"/capita, US$ purchasing power parity",61.9
+20569,Japan,2015,5,C-Cardiovascular system,"Million US$, purchasing power parity",10519.8
+20570,Japan,2015,5,C-Cardiovascular system,"/capita, US$ exchange rate",70.8
+20571,Japan,2015,5,C-Cardiovascular system,"/capita, US$ purchasing power parity",82.8
+20572,Japan,2015,5,J-Antiinfectives for systemic use,"Million US$, purchasing power parity",2121.2
+20573,Japan,2015,5,Total pharmaceutical sales,Million of national currency units,6748121.0
+20574,Japan,2015,5,C-Cardiovascular system,Million of national currency units,1088475.0
+20575,Japan,2015,5,C-Cardiovascular system,Million US$ at exchange rate,8992.4
+20576,Japan,2015,5,G-Genito urinary system and sex hormones,"Million US$, purchasing power parity",1427.3
+20577,Japan,2015,5,G-Genito urinary system and sex hormones,Million US$ at exchange rate,1220.1
+20578,Japan,2015,5,G-Genito urinary system and sex hormones,"/capita, US$ exchange rate",9.6
+20579,Japan,2015,5,C-Cardiovascular system,% of total sales,16.1
+20580,Japan,2015,5,A-Alimentary tract and metabolism,% of total sales,6.9
+20581,Japan,2015,5,G-Genito urinary system and sex hormones,Million of national currency units,147680.0
+20582,Japan,2015,5,Total pharmaceutical sales,"/capita, US$ purchasing power parity",513.1
+20583,Japan,2015,5,"H-Systemic hormonal preparations, excluding sex hormones and insulins","Million US$, purchasing power parity",1767.7
+20584,Japan,2015,5,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million of national currency units,182902.0
+20585,Japan,2015,5,B-Blood and blood forming organs,"/capita, US$ purchasing power parity",35.1
+20586,Japan,2015,5,B-Blood and blood forming organs,Million of national currency units,461825.0
+20587,Japan,2015,5,"H-Systemic hormonal preparations, excluding sex hormones and insulins",% of total sales,2.7
+20588,Japan,2015,5,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ purchasing power parity",13.9
+20589,Japan,2015,5,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ exchange rate",11.9
+20590,Japan,2015,5,B-Blood and blood forming organs,% of total sales,6.8
+20591,Japan,2015,5,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million US$ at exchange rate,1511.0
+20592,Japan,2015,5,J-Antiinfectives for systemic use,Million US$ at exchange rate,1813.2
+20593,Japan,2015,5,J-Antiinfectives for systemic use,Million of national currency units,219483.0
+20594,Japan,2015,5,B-Blood and blood forming organs,Million US$ at exchange rate,3815.3
+20595,Japan,2015,5,B-Blood and blood forming organs,"/capita, US$ exchange rate",30.0
+20596,Japan,2015,5,B-Blood and blood forming organs,"Million US$, purchasing power parity",4463.4
+20597,Japan,2014,5,Total pharmaceutical sales,"/capita, US$ exchange rate",488.9
+20598,Japan,2014,5,Products not elsewhere classified,% of total sales,46.0
+20599,Japan,2014,5,Total pharmaceutical sales,"Million US$, purchasing power parity",63945.9
+20600,Japan,2014,5,R-Respiratory system,"Million US$, purchasing power parity",951.6
+20601,Japan,2014,5,Products not elsewhere classified,Million US$ at exchange rate,28623.7
+20602,Japan,2014,5,Products not elsewhere classified,Million of national currency units,3032529.0
+20603,Japan,2014,5,Products not elsewhere classified,"/capita, US$ exchange rate",225.0
+20604,Japan,2014,5,Products not elsewhere classified,"Million US$, purchasing power parity",29427.2
+20605,Japan,2014,5,J-Antiinfectives for systemic use,"/capita, US$ exchange rate",17.5
+20606,Japan,2014,5,J-Antiinfectives for systemic use,"/capita, US$ purchasing power parity",18.0
+20607,Japan,2014,5,J-Antiinfectives for systemic use,% of total sales,3.6
+20608,Japan,2014,5,R-Respiratory system,Million US$ at exchange rate,925.6
+20609,Japan,2014,5,R-Respiratory system,Million of national currency units,98066.0
+20610,Japan,2014,5,Products not elsewhere classified,"/capita, US$ purchasing power parity",231.3
+20611,Japan,2014,5,R-Respiratory system,% of total sales,1.5
+20612,Japan,2014,5,R-Respiratory system,"/capita, US$ exchange rate",7.3
+20613,Japan,2014,5,R-Respiratory system,"/capita, US$ purchasing power parity",7.5
+20614,Japan,2014,5,A-Alimentary tract and metabolism,"Million US$, purchasing power parity",4699.9
+20615,Japan,2014,5,A-Alimentary tract and metabolism,"/capita, US$ exchange rate",35.9
+20616,Japan,2014,5,A-Alimentary tract and metabolism,Million US$ at exchange rate,4571.5
+20617,Japan,2014,5,G-Genito urinary system and sex hormones,% of total sales,2.3
+20618,Japan,2014,5,A-Alimentary tract and metabolism,"/capita, US$ purchasing power parity",36.9
+20619,Japan,2014,5,A-Alimentary tract and metabolism,Million of national currency units,484331.0
+20620,Japan,2014,5,N-Nervous system,"Million US$, purchasing power parity",7970.7
+20621,Japan,2014,5,N-Nervous system,"/capita, US$ exchange rate",60.9
+20622,Japan,2014,5,N-Nervous system,Million US$ at exchange rate,7753.0
+20623,Japan,2014,5,N-Nervous system,Million of national currency units,821393.0
+20624,Japan,2014,5,N-Nervous system,% of total sales,12.5
+20625,Japan,2014,5,N-Nervous system,"/capita, US$ purchasing power parity",62.6
+20626,Japan,2014,5,G-Genito urinary system and sex hormones,"/capita, US$ purchasing power parity",11.6
+20627,Japan,2014,5,C-Cardiovascular system,"Million US$, purchasing power parity",11229.5
+20628,Japan,2014,5,C-Cardiovascular system,"/capita, US$ exchange rate",85.8
+20629,Japan,2014,5,C-Cardiovascular system,"/capita, US$ purchasing power parity",88.3
+20630,Japan,2014,5,Total pharmaceutical sales,Million of national currency units,6589762.0
+20631,Japan,2014,5,Total pharmaceutical sales,Million US$ at exchange rate,62200.0
+20632,Japan,2014,5,C-Cardiovascular system,Million US$ at exchange rate,10922.9
+20633,Japan,2014,5,C-Cardiovascular system,Million of national currency units,1157221.0
+20634,Japan,2014,5,G-Genito urinary system and sex hormones,"Million US$, purchasing power parity",1477.3
+20635,Japan,2014,5,G-Genito urinary system and sex hormones,Million US$ at exchange rate,1437.0
+20636,Japan,2014,5,G-Genito urinary system and sex hormones,"/capita, US$ exchange rate",11.3
+20637,Japan,2014,5,C-Cardiovascular system,% of total sales,17.6
+20638,Japan,2014,5,A-Alimentary tract and metabolism,% of total sales,7.3
+20639,Japan,2014,5,G-Genito urinary system and sex hormones,Million of national currency units,152239.0
+20640,Japan,2014,5,J-Antiinfectives for systemic use,"Million US$, purchasing power parity",2293.1
+20641,Japan,2014,5,Total pharmaceutical sales,"/capita, US$ purchasing power parity",502.6
+20642,Japan,2014,5,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million of national currency units,158691.0
+20643,Japan,2014,5,"H-Systemic hormonal preparations, excluding sex hormones and insulins","Million US$, purchasing power parity",1539.9
+20644,Japan,2014,5,B-Blood and blood forming organs,"/capita, US$ purchasing power parity",34.2
+20645,Japan,2014,5,B-Blood and blood forming organs,Million of national currency units,448987.0
+20646,Japan,2014,5,"H-Systemic hormonal preparations, excluding sex hormones and insulins",% of total sales,2.4
+20647,Japan,2014,5,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ purchasing power parity",12.1
+20648,Japan,2014,5,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ exchange rate",11.8
+20649,Japan,2014,5,B-Blood and blood forming organs,% of total sales,6.8
+20650,Japan,2014,5,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million US$ at exchange rate,1497.9
+20651,Japan,2014,5,J-Antiinfectives for systemic use,Million of national currency units,236305.0
+20652,Japan,2014,5,J-Antiinfectives for systemic use,Million US$ at exchange rate,2230.5
+20653,Japan,2014,5,B-Blood and blood forming organs,Million US$ at exchange rate,4237.9
+20654,Japan,2014,5,B-Blood and blood forming organs,"Million US$, purchasing power parity",4356.9
+20655,Japan,2014,5,B-Blood and blood forming organs,"/capita, US$ exchange rate",33.3
+20656,Japan,2013,5,Total pharmaceutical sales,"/capita, US$ exchange rate",554.4
+20657,Japan,2013,5,Total pharmaceutical sales,"Million US$, purchasing power parity",68053.6
+20658,Japan,2013,5,Products not elsewhere classified,Million US$ at exchange rate,31664.9
+20659,Japan,2013,5,Products not elsewhere classified,"Million US$, purchasing power parity",30506.2
+20660,Japan,2013,5,Products not elsewhere classified,"/capita, US$ exchange rate",248.5
+20661,Japan,2013,5,Products not elsewhere classified,Million of national currency units,3090356.0
+20662,Japan,2013,5,J-Antiinfectives for systemic use,"/capita, US$ exchange rate",18.9
+20663,Japan,2013,5,J-Antiinfectives for systemic use,"/capita, US$ purchasing power parity",18.2
+20664,Japan,2013,5,J-Antiinfectives for systemic use,% of total sales,3.4
+20665,Japan,2013,5,R-Respiratory system,"Million US$, purchasing power parity",1168.8
+20666,Japan,2013,5,R-Respiratory system,Million US$ at exchange rate,1213.2
+20667,Japan,2013,5,R-Respiratory system,Million of national currency units,118406.0
+20668,Japan,2013,5,R-Respiratory system,"/capita, US$ exchange rate",9.5
+20669,Japan,2013,5,Products not elsewhere classified,% of total sales,44.8
+20670,Japan,2013,5,Products not elsewhere classified,"/capita, US$ purchasing power parity",239.4
+20671,Japan,2013,5,R-Respiratory system,% of total sales,1.7
+20672,Japan,2013,5,R-Respiratory system,"/capita, US$ purchasing power parity",9.2
+20673,Japan,2013,5,A-Alimentary tract and metabolism,"Million US$, purchasing power parity",5257.4
+20674,Japan,2013,5,A-Alimentary tract and metabolism,"/capita, US$ exchange rate",42.8
+20675,Japan,2013,5,A-Alimentary tract and metabolism,Million US$ at exchange rate,5457.1
+20676,Japan,2013,5,G-Genito urinary system and sex hormones,% of total sales,2.4
+20677,Japan,2013,5,A-Alimentary tract and metabolism,"/capita, US$ purchasing power parity",41.3
+20678,Japan,2013,5,A-Alimentary tract and metabolism,Million of national currency units,532593.0
+20679,Japan,2013,5,N-Nervous system,"Million US$, purchasing power parity",8200.2
+20680,Japan,2013,5,N-Nervous system,"/capita, US$ exchange rate",66.8
+20681,Japan,2013,5,N-Nervous system,Million US$ at exchange rate,8511.7
+20682,Japan,2013,5,N-Nervous system,Million of national currency units,830706.0
+20683,Japan,2013,5,N-Nervous system,% of total sales,12.0
+20684,Japan,2013,5,N-Nervous system,"/capita, US$ purchasing power parity",64.4
+20685,Japan,2013,5,C-Cardiovascular system,"/capita, US$ exchange rate",100.9
+20686,Japan,2013,5,C-Cardiovascular system,"Million US$, purchasing power parity",12388.8
+20687,Japan,2013,5,C-Cardiovascular system,"/capita, US$ purchasing power parity",97.2
+20688,Japan,2013,5,Total pharmaceutical sales,Million of national currency units,6894014.0
+20689,Japan,2013,5,Total pharmaceutical sales,Million US$ at exchange rate,70638.5
+20690,Japan,2013,5,C-Cardiovascular system,Million of national currency units,1255017.0
+20691,Japan,2013,5,C-Cardiovascular system,Million US$ at exchange rate,12859.4
+20692,Japan,2013,5,G-Genito urinary system and sex hormones,"Million US$, purchasing power parity",1658.5
+20693,Japan,2013,5,G-Genito urinary system and sex hormones,Million US$ at exchange rate,1721.5
+20694,Japan,2013,5,G-Genito urinary system and sex hormones,"/capita, US$ exchange rate",13.5
+20695,Japan,2013,5,C-Cardiovascular system,% of total sales,18.2
+20696,Japan,2013,5,A-Alimentary tract and metabolism,% of total sales,7.7
+20697,Japan,2013,5,G-Genito urinary system and sex hormones,"/capita, US$ purchasing power parity",13.0
+20698,Japan,2013,5,G-Genito urinary system and sex hormones,Million of national currency units,168011.0
+20699,Japan,2013,5,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million of national currency units,166912.0
+20700,Japan,2013,5,"H-Systemic hormonal preparations, excluding sex hormones and insulins","Million US$, purchasing power parity",1647.7
+20701,Japan,2013,5,Total pharmaceutical sales,"/capita, US$ purchasing power parity",534.1
+20702,Japan,2013,5,B-Blood and blood forming organs,"/capita, US$ purchasing power parity",38.5
+20703,Japan,2013,5,B-Blood and blood forming organs,Million of national currency units,497196.0
+20704,Japan,2013,5,"H-Systemic hormonal preparations, excluding sex hormones and insulins",% of total sales,2.4
+20705,Japan,2013,5,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ purchasing power parity",12.9
+20706,Japan,2013,5,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ exchange rate",13.4
+20707,Japan,2013,5,B-Blood and blood forming organs,% of total sales,7.2
+20708,Japan,2013,5,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million US$ at exchange rate,1710.2
+20709,Japan,2013,5,J-Antiinfectives for systemic use,Million of national currency units,234817.0
+20710,Japan,2013,5,J-Antiinfectives for systemic use,Million US$ at exchange rate,2406.0
+20711,Japan,2013,5,B-Blood and blood forming organs,"Million US$, purchasing power parity",4908.0
+20712,Japan,2013,5,B-Blood and blood forming organs,Million US$ at exchange rate,5094.4
+20713,Japan,2013,5,B-Blood and blood forming organs,"/capita, US$ exchange rate",40.0
+20714,Japan,2013,5,J-Antiinfectives for systemic use,"Million US$, purchasing power parity",2318.0
+20715,Japan,2012,5,Total pharmaceutical sales,"/capita, US$ exchange rate",685.3
+20716,Japan,2012,5,Total pharmaceutical sales,"Million US$, purchasing power parity",66907.5
+20717,Japan,2012,5,Products not elsewhere classified,Million US$ at exchange rate,37641.3
+20718,Japan,2012,5,Products not elsewhere classified,"/capita, US$ exchange rate",295.0
+20719,Japan,2012,5,Products not elsewhere classified,"Million US$, purchasing power parity",28803.1
+20720,Japan,2012,5,Products not elsewhere classified,Million of national currency units,3003413.0
+20721,Japan,2012,5,J-Antiinfectives for systemic use,"/capita, US$ exchange rate",24.7
+20722,Japan,2012,5,J-Antiinfectives for systemic use,"/capita, US$ purchasing power parity",18.9
+20723,Japan,2012,5,J-Antiinfectives for systemic use,% of total sales,3.6
+20724,Japan,2012,5,Products not elsewhere classified,"/capita, US$ purchasing power parity",225.7
+20725,Japan,2012,5,R-Respiratory system,"Million US$, purchasing power parity",1221.6
+20726,Japan,2012,5,R-Respiratory system,Million of national currency units,127386.0
+20727,Japan,2012,5,R-Respiratory system,"/capita, US$ exchange rate",12.5
+20728,Japan,2012,5,R-Respiratory system,Million US$ at exchange rate,1596.5
+20729,Japan,2012,5,Products not elsewhere classified,% of total sales,43.0
+20730,Japan,2012,5,R-Respiratory system,% of total sales,1.8
+20731,Japan,2012,5,R-Respiratory system,"/capita, US$ purchasing power parity",9.6
+20732,Japan,2012,5,A-Alimentary tract and metabolism,"Million US$, purchasing power parity",5488.9
+20733,Japan,2012,5,A-Alimentary tract and metabolism,"/capita, US$ exchange rate",56.2
+20734,Japan,2012,5,A-Alimentary tract and metabolism,Million US$ at exchange rate,7173.2
+20735,Japan,2012,5,G-Genito urinary system and sex hormones,% of total sales,2.5
+20736,Japan,2012,5,A-Alimentary tract and metabolism,"/capita, US$ purchasing power parity",43.0
+20737,Japan,2012,5,N-Nervous system,"/capita, US$ exchange rate",86.9
+20738,Japan,2012,5,N-Nervous system,"Million US$, purchasing power parity",8481.0
+20739,Japan,2012,5,N-Nervous system,Million US$ at exchange rate,11083.3
+20740,Japan,2012,5,N-Nervous system,Million of national currency units,884343.0
+20741,Japan,2012,5,A-Alimentary tract and metabolism,Million of national currency units,572354.0
+20742,Japan,2012,5,N-Nervous system,% of total sales,12.7
+20743,Japan,2012,5,N-Nervous system,"/capita, US$ purchasing power parity",66.5
+20744,Japan,2012,5,G-Genito urinary system and sex hormones,"/capita, US$ purchasing power parity",13.3
+20745,Japan,2012,5,C-Cardiovascular system,"/capita, US$ exchange rate",127.4
+20746,Japan,2012,5,C-Cardiovascular system,"Million US$, purchasing power parity",12438.7
+20747,Japan,2012,5,C-Cardiovascular system,"/capita, US$ purchasing power parity",97.5
+20748,Japan,2012,5,Total pharmaceutical sales,Million US$ at exchange rate,87437.9
+20749,Japan,2012,5,C-Cardiovascular system,Million of national currency units,1297037.0
+20750,Japan,2012,5,C-Cardiovascular system,Million US$ at exchange rate,16255.5
+20751,Japan,2012,5,C-Cardiovascular system,% of total sales,18.6
+20752,Japan,2012,5,G-Genito urinary system and sex hormones,"Million US$, purchasing power parity",1695.6
+20753,Japan,2012,5,G-Genito urinary system and sex hormones,"/capita, US$ exchange rate",17.4
+20754,Japan,2012,5,G-Genito urinary system and sex hormones,Million US$ at exchange rate,2215.9
+20755,Japan,2012,5,A-Alimentary tract and metabolism,% of total sales,8.2
+20756,Japan,2012,5,G-Genito urinary system and sex hormones,Million of national currency units,176807.0
+20757,Japan,2012,5,Total pharmaceutical sales,Million of national currency units,6976712.0
+20758,Japan,2012,5,J-Antiinfectives for systemic use,"Million US$, purchasing power parity",2412.6
+20759,Japan,2012,5,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million of national currency units,152914.0
+20760,Japan,2012,5,B-Blood and blood forming organs,"/capita, US$ purchasing power parity",38.4
+20761,Japan,2012,5,Total pharmaceutical sales,"/capita, US$ purchasing power parity",524.4
+20762,Japan,2012,5,B-Blood and blood forming organs,Million of national currency units,510891.0
+20763,Japan,2012,5,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ exchange rate",15.0
+20764,Japan,2012,5,"H-Systemic hormonal preparations, excluding sex hormones and insulins",% of total sales,2.2
+20765,Japan,2012,5,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ purchasing power parity",11.5
+20766,Japan,2012,5,B-Blood and blood forming organs,% of total sales,7.3
+20767,Japan,2012,5,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million US$ at exchange rate,1916.4
+20768,Japan,2012,5,J-Antiinfectives for systemic use,Million of national currency units,251567.0
+20769,Japan,2012,5,J-Antiinfectives for systemic use,Million US$ at exchange rate,3152.8
+20770,Japan,2012,5,"H-Systemic hormonal preparations, excluding sex hormones and insulins","Million US$, purchasing power parity",1466.5
+20771,Japan,2012,5,B-Blood and blood forming organs,"Million US$, purchasing power parity",4899.5
+20772,Japan,2012,5,B-Blood and blood forming organs,Million US$ at exchange rate,6402.9
+20773,Japan,2012,5,B-Blood and blood forming organs,"/capita, US$ exchange rate",50.2
+20774,Japan,2011,6,Total pharmaceutical sales,"/capita, US$ exchange rate",684.9
+20775,Japan,2011,6,Total pharmaceutical sales,"Million US$, purchasing power parity",65026.4
+20776,Japan,2011,6,Products not elsewhere classified,Million US$ at exchange rate,37960.1
+20777,Japan,2011,6,Products not elsewhere classified,"Million US$, purchasing power parity",28193.3
+20778,Japan,2011,6,Products not elsewhere classified,"/capita, US$ exchange rate",296.9
+20779,Japan,2011,6,Products not elsewhere classified,Million of national currency units,3029486.0
+20780,Japan,2011,6,J-Antiinfectives for systemic use,"/capita, US$ exchange rate",26.1
+20781,Japan,2011,6,J-Antiinfectives for systemic use,"/capita, US$ purchasing power parity",19.4
+20782,Japan,2011,6,J-Antiinfectives for systemic use,% of total sales,3.8
+20783,Japan,2011,6,Products not elsewhere classified,"/capita, US$ purchasing power parity",220.5
+20784,Japan,2011,6,R-Respiratory system,"Million US$, purchasing power parity",1152.4
+20785,Japan,2011,6,R-Respiratory system,"/capita, US$ exchange rate",12.1
+20786,Japan,2011,6,R-Respiratory system,Million of national currency units,123835.0
+20787,Japan,2011,6,R-Respiratory system,Million US$ at exchange rate,1551.7
+20788,Japan,2011,6,Products not elsewhere classified,% of total sales,43.4
+20789,Japan,2011,6,R-Respiratory system,"/capita, US$ purchasing power parity",9.0
+20790,Japan,2011,6,R-Respiratory system,% of total sales,1.8
+20791,Japan,2011,6,A-Alimentary tract and metabolism,"/capita, US$ exchange rate",55.9
+20792,Japan,2011,6,A-Alimentary tract and metabolism,"Million US$, purchasing power parity",5305.8
+20793,Japan,2011,6,A-Alimentary tract and metabolism,Million US$ at exchange rate,7143.9
+20794,Japan,2011,6,G-Genito urinary system and sex hormones,% of total sales,2.2
+20795,Japan,2011,6,A-Alimentary tract and metabolism,"/capita, US$ purchasing power parity",41.5
+20796,Japan,2011,6,N-Nervous system,"/capita, US$ exchange rate",87.2
+20797,Japan,2011,6,N-Nervous system,"Million US$, purchasing power parity",8282.7
+20798,Japan,2011,6,N-Nervous system,Million US$ at exchange rate,11152.0
+20799,Japan,2011,6,N-Nervous system,Million of national currency units,890011.0
+20800,Japan,2011,6,A-Alimentary tract and metabolism,Million of national currency units,570135.0
+20801,Japan,2011,6,N-Nervous system,"/capita, US$ purchasing power parity",64.8
+20802,Japan,2011,6,N-Nervous system,% of total sales,12.7
+20803,Japan,2011,6,C-Cardiovascular system,"/capita, US$ exchange rate",132.1
+20804,Japan,2011,6,C-Cardiovascular system,"Million US$, purchasing power parity",12544.8
+20805,Japan,2011,6,C-Cardiovascular system,"/capita, US$ purchasing power parity",98.1
+20806,Japan,2011,6,C-Cardiovascular system,Million of national currency units,1347996.0
+20807,Japan,2011,6,Total pharmaceutical sales,Million US$ at exchange rate,87553.3
+20808,Japan,2011,6,C-Cardiovascular system,Million US$ at exchange rate,16890.7
+20809,Japan,2011,6,C-Cardiovascular system,% of total sales,19.3
+20810,Japan,2011,6,G-Genito urinary system and sex hormones,"Million US$, purchasing power parity",1452.9
+20811,Japan,2011,6,G-Genito urinary system and sex hormones,"/capita, US$ purchasing power parity",11.4
+20812,Japan,2011,6,G-Genito urinary system and sex hormones,"/capita, US$ exchange rate",15.3
+20813,Japan,2011,6,G-Genito urinary system and sex hormones,Million US$ at exchange rate,1956.2
+20814,Japan,2011,6,G-Genito urinary system and sex hormones,Million of national currency units,156118.0
+20815,Japan,2011,6,Total pharmaceutical sales,Million of national currency units,6987367.0
+20816,Japan,2011,6,A-Alimentary tract and metabolism,% of total sales,8.2
+20817,Japan,2011,6,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million of national currency units,139935.0
+20818,Japan,2011,6,Total pharmaceutical sales,"/capita, US$ purchasing power parity",508.7
+20819,Japan,2011,6,B-Blood and blood forming organs,"/capita, US$ purchasing power parity",33.8
+20820,Japan,2011,6,B-Blood and blood forming organs,Million of national currency units,463919.0
+20821,Japan,2011,6,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ exchange rate",13.7
+20822,Japan,2011,6,"H-Systemic hormonal preparations, excluding sex hormones and insulins",% of total sales,2.0
+20823,Japan,2011,6,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ purchasing power parity",10.2
+20824,Japan,2011,6,B-Blood and blood forming organs,% of total sales,6.6
+20825,Japan,2011,6,B-Blood and blood forming organs,Million US$ at exchange rate,5813.0
+20826,Japan,2011,6,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million US$ at exchange rate,1753.4
+20827,Japan,2011,6,J-Antiinfectives for systemic use,Million of national currency units,265932.0
+20828,Japan,2011,6,"H-Systemic hormonal preparations, excluding sex hormones and insulins","Million US$, purchasing power parity",1302.3
+20829,Japan,2011,6,J-Antiinfectives for systemic use,"Million US$, purchasing power parity",2474.8
+20830,Japan,2011,6,J-Antiinfectives for systemic use,Million US$ at exchange rate,3332.2
+20831,Japan,2011,6,B-Blood and blood forming organs,"Million US$, purchasing power parity",4317.4
+20832,Japan,2011,6,B-Blood and blood forming organs,"/capita, US$ exchange rate",45.5
+20833,Japan,2010,6,Total pharmaceutical sales,"/capita, US$ exchange rate",603.1
+20834,Japan,2010,6,Total pharmaceutical sales,"Million US$, purchasing power parity",60685.0
+20835,Japan,2010,6,C-Cardiovascular system,Million of national currency units,1401736.0
+20836,Japan,2010,6,Products not elsewhere classified,Million US$ at exchange rate,33031.6
+20837,Japan,2010,6,Products not elsewhere classified,"Million US$, purchasing power parity",25955.8
+20838,Japan,2010,6,Products not elsewhere classified,"/capita, US$ exchange rate",257.9
+20839,Japan,2010,6,J-Antiinfectives for systemic use,"/capita, US$ purchasing power parity",16.8
+20840,Japan,2010,6,J-Antiinfectives for systemic use,"/capita, US$ exchange rate",21.4
+20841,Japan,2010,6,Products not elsewhere classified,Million of national currency units,2899512.0
+20842,Japan,2010,6,J-Antiinfectives for systemic use,% of total sales,3.5
+20843,Japan,2010,6,Products not elsewhere classified,"/capita, US$ purchasing power parity",202.7
+20844,Japan,2010,6,R-Respiratory system,"Million US$, purchasing power parity",1102.5
+20845,Japan,2010,6,R-Respiratory system,"/capita, US$ exchange rate",11.0
+20846,Japan,2010,6,Total pharmaceutical sales,"/capita, US$ purchasing power parity",473.9
+20847,Japan,2010,6,R-Respiratory system,Million of national currency units,123160.0
+20848,Japan,2010,6,R-Respiratory system,Million US$ at exchange rate,1403.1
+20849,Japan,2010,6,Products not elsewhere classified,% of total sales,42.8
+20850,Japan,2010,6,R-Respiratory system,"/capita, US$ purchasing power parity",8.6
+20851,Japan,2010,6,R-Respiratory system,% of total sales,1.8
+20852,Japan,2010,6,A-Alimentary tract and metabolism,"/capita, US$ exchange rate",51.8
+20853,Japan,2010,6,A-Alimentary tract and metabolism,"Million US$, purchasing power parity",5209.6
+20854,Japan,2010,6,A-Alimentary tract and metabolism,Million US$ at exchange rate,6629.8
+20855,Japan,2010,6,G-Genito urinary system and sex hormones,% of total sales,2.3
+20856,Japan,2010,6,A-Alimentary tract and metabolism,% of total sales,8.6
+20857,Japan,2010,6,A-Alimentary tract and metabolism,"/capita, US$ purchasing power parity",40.7
+20858,Japan,2010,6,N-Nervous system,"/capita, US$ exchange rate",72.3
+20859,Japan,2010,6,N-Nervous system,Million US$ at exchange rate,9253.3
+20860,Japan,2010,6,N-Nervous system,"Million US$, purchasing power parity",7271.1
+20861,Japan,2010,6,N-Nervous system,Million of national currency units,812255.0
+20862,Japan,2010,6,A-Alimentary tract and metabolism,Million of national currency units,581966.0
+20863,Japan,2010,6,N-Nervous system,"/capita, US$ purchasing power parity",56.8
+20864,Japan,2010,6,N-Nervous system,% of total sales,12.0
+20865,Japan,2010,6,C-Cardiovascular system,"/capita, US$ exchange rate",124.7
+20866,Japan,2010,6,C-Cardiovascular system,"Million US$, purchasing power parity",12548.0
+20867,Japan,2010,6,C-Cardiovascular system,"/capita, US$ purchasing power parity",98.0
+20868,Japan,2010,6,Total pharmaceutical sales,Million US$ at exchange rate,77228.4
+20869,Japan,2010,6,C-Cardiovascular system,Million US$ at exchange rate,15968.8
+20870,Japan,2010,6,C-Cardiovascular system,% of total sales,20.7
+20871,Japan,2010,6,G-Genito urinary system and sex hormones,"Million US$, purchasing power parity",1419.4
+20872,Japan,2010,6,G-Genito urinary system and sex hormones,"/capita, US$ purchasing power parity",11.1
+20873,Japan,2010,6,G-Genito urinary system and sex hormones,"/capita, US$ exchange rate",14.1
+20874,Japan,2010,6,G-Genito urinary system and sex hormones,Million US$ at exchange rate,1806.3
+20875,Japan,2010,6,G-Genito urinary system and sex hormones,Million of national currency units,158560.0
+20876,Japan,2010,6,Total pharmaceutical sales,Million of national currency units,6779099.0
+20877,Japan,2010,6,B-Blood and blood forming organs,"/capita, US$ purchasing power parity",31.2
+20878,Japan,2010,6,B-Blood and blood forming organs,Million US$ at exchange rate,5088.9
+20879,Japan,2010,6,B-Blood and blood forming organs,Million of national currency units,446699.0
+20880,Japan,2010,6,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ exchange rate",10.2
+20881,Japan,2010,6,"H-Systemic hormonal preparations, excluding sex hormones and insulins",% of total sales,1.7
+20882,Japan,2010,6,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ purchasing power parity",8.0
+20883,Japan,2010,6,B-Blood and blood forming organs,% of total sales,6.6
+20884,Japan,2010,6,J-Antiinfectives for systemic use,Million of national currency units,240226.0
+20885,Japan,2010,6,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million of national currency units,114985.0
+20886,Japan,2010,6,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million US$ at exchange rate,1309.9
+20887,Japan,2010,6,"H-Systemic hormonal preparations, excluding sex hormones and insulins","Million US$, purchasing power parity",1029.3
+20888,Japan,2010,6,J-Antiinfectives for systemic use,"Million US$, purchasing power parity",2150.5
+20889,Japan,2010,6,J-Antiinfectives for systemic use,Million US$ at exchange rate,2736.7
+20890,Japan,2010,6,B-Blood and blood forming organs,"Million US$, purchasing power parity",3998.8
+20891,Japan,2010,6,B-Blood and blood forming organs,"/capita, US$ exchange rate",39.7
+20892,Japan,2017,5,N-Nervous system,Million of national currency units,779318.0
+20893,Japan,2017,5,Products not elsewhere classified,% of total sales,52.7
+20894,Japan,2017,5,Total pharmaceutical sales,"Million US$, purchasing power parity",63950.5
+20895,Japan,2017,5,Total pharmaceutical sales,"/capita, US$ exchange rate",472.9
+20896,Japan,2017,5,Products not elsewhere classified,Million US$ at exchange rate,31572.7
+20897,Japan,2017,5,Products not elsewhere classified,Million of national currency units,3541392.0
+20898,Japan,2017,5,Products not elsewhere classified,"/capita, US$ exchange rate",249.2
+20899,Japan,2017,5,Products not elsewhere classified,"Million US$, purchasing power parity",33694.8
+20900,Japan,2017,5,J-Antiinfectives for systemic use,"/capita, US$ exchange rate",11.9
+20901,Japan,2017,5,J-Antiinfectives for systemic use,"Million US$, purchasing power parity",1609.2
+20902,Japan,2017,5,J-Antiinfectives for systemic use,% of total sales,2.5
+20903,Japan,2017,5,J-Antiinfectives for systemic use,"/capita, US$ purchasing power parity",12.7
+20904,Japan,2017,5,R-Respiratory system,Million US$ at exchange rate,1204.0
+20905,Japan,2017,5,R-Respiratory system,"Million US$, purchasing power parity",1285.0
+20906,Japan,2017,5,R-Respiratory system,Million of national currency units,135053.0
+20907,Japan,2017,5,R-Respiratory system,% of total sales,2.0
+20908,Japan,2017,5,Products not elsewhere classified,"/capita, US$ purchasing power parity",265.9
+20909,Japan,2017,5,R-Respiratory system,"/capita, US$ exchange rate",9.5
+20910,Japan,2017,5,R-Respiratory system,"/capita, US$ purchasing power parity",10.1
+20911,Japan,2017,5,Total pharmaceutical sales,Million US$ at exchange rate,59922.9
+20912,Japan,2017,5,A-Alimentary tract and metabolism,"Million US$, purchasing power parity",3839.1
+20913,Japan,2017,5,A-Alimentary tract and metabolism,Million of national currency units,403493.0
+20914,Japan,2017,5,A-Alimentary tract and metabolism,Million US$ at exchange rate,3597.3
+20915,Japan,2017,5,G-Genito urinary system and sex hormones,% of total sales,2.4
+20916,Japan,2017,5,G-Genito urinary system and sex hormones,"/capita, US$ purchasing power parity",12.2
+20917,Japan,2017,5,A-Alimentary tract and metabolism,"/capita, US$ exchange rate",28.4
+20918,Japan,2017,5,A-Alimentary tract and metabolism,"/capita, US$ purchasing power parity",30.3
+20919,Japan,2017,5,N-Nervous system,"Million US$, purchasing power parity",7414.9
+20920,Japan,2017,5,N-Nervous system,Million US$ at exchange rate,6947.9
+20921,Japan,2017,5,N-Nervous system,"/capita, US$ exchange rate",54.8
+20922,Japan,2017,5,N-Nervous system,% of total sales,11.6
+20923,Japan,2017,5,N-Nervous system,"/capita, US$ purchasing power parity",58.5
+20924,Japan,2017,5,C-Cardiovascular system,"Million US$, purchasing power parity",8890.8
+20925,Japan,2017,5,C-Cardiovascular system,"/capita, US$ exchange rate",65.7
+20926,Japan,2017,5,C-Cardiovascular system,"/capita, US$ purchasing power parity",70.2
+20927,Japan,2017,5,Total pharmaceutical sales,Million of national currency units,6721317.0
+20928,Japan,2017,5,C-Cardiovascular system,Million US$ at exchange rate,8330.8
+20929,Japan,2017,5,C-Cardiovascular system,Million of national currency units,934437.0
+20930,Japan,2017,5,G-Genito urinary system and sex hormones,Million US$ at exchange rate,1448.0
+20931,Japan,2017,5,G-Genito urinary system and sex hormones,"Million US$, purchasing power parity",1545.3
+20932,Japan,2017,5,G-Genito urinary system and sex hormones,"/capita, US$ exchange rate",11.4
+20933,Japan,2017,5,A-Alimentary tract and metabolism,% of total sales,6.0
+20934,Japan,2017,5,C-Cardiovascular system,% of total sales,13.9
+20935,Japan,2017,5,G-Genito urinary system and sex hormones,Million of national currency units,162419.0
+20936,Japan,2017,5,Total pharmaceutical sales,"/capita, US$ purchasing power parity",504.7
+20937,Japan,2017,5,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million of national currency units,175173.0
+20938,Japan,2017,5,"H-Systemic hormonal preparations, excluding sex hormones and insulins","Million US$, purchasing power parity",1666.7
+20939,Japan,2017,5,B-Blood and blood forming organs,Million of national currency units,420896.0
+20940,Japan,2017,5,"H-Systemic hormonal preparations, excluding sex hormones and insulins",% of total sales,2.6
+20941,Japan,2017,5,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ purchasing power parity",13.2
+20942,Japan,2017,5,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ exchange rate",12.3
+20943,Japan,2017,5,B-Blood and blood forming organs,"/capita, US$ purchasing power parity",31.6
+20944,Japan,2017,5,B-Blood and blood forming organs,% of total sales,6.3
+20945,Japan,2017,5,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million US$ at exchange rate,1561.7
+20946,Japan,2017,5,J-Antiinfectives for systemic use,Million US$ at exchange rate,1507.9
+20947,Japan,2017,5,J-Antiinfectives for systemic use,Million of national currency units,169135.0
+20948,Japan,2017,5,B-Blood and blood forming organs,"/capita, US$ exchange rate",29.6
+20949,Japan,2017,5,B-Blood and blood forming organs,Million US$ at exchange rate,3752.4
+20950,Japan,2017,5,B-Blood and blood forming organs,"Million US$, purchasing power parity",4004.6
+20951,Latvia,2010,26,A-Alimentary tract and metabolism,Million of national currency units,35.8
+20952,Latvia,2010,26,A02A-Antacids,Million of national currency units,0.4
+20953,Latvia,2010,26,C09-Agents acting on the Renin-Angiotensin system,% of total sales,6.5
+20954,Latvia,2010,26,C01A-Cardiac glycosides,% of total sales,0.0
+20955,Latvia,2010,26,Total pharmaceutical sales,Million of national currency units,276.2
+20956,Latvia,2010,26,N05B-Anxiolytics,% of total sales,0.8
+20957,Latvia,2010,26,G03-Sex hormones and modulators of the genital system,% of total sales,2.1
+20958,Latvia,2010,26,N-Nervous system,% of total sales,12.0
+20959,Latvia,2010,26,M-Musculo-skeletal system,% of total sales,6.6
+20960,Latvia,2010,26,A02A-Antacids,% of total sales,0.1
+20961,Latvia,2010,26,J01-Antibacterials for systemic use,% of total sales,3.4
+20962,Latvia,2010,26,R03-Drugs for obstructive airway diseases,% of total sales,3.1
+20963,Latvia,2010,26,B-Blood and blood forming organs,% of total sales,6.8
+20964,Latvia,2010,26,N02-Analgesics,% of total sales,2.6
+20965,Latvia,2010,26,"H-Systemic hormonal preparations, excluding sex hormones and insulins",% of total sales,1.7
+20966,Latvia,2010,26,C-Cardiovascular system,% of total sales,18.9
+20967,Latvia,2010,26,C10-Lipid modifying agents,% of total sales,2.6
+20968,Latvia,2010,26,N05C-Hypnotics and sedatives,% of total sales,0.9
+20969,Latvia,2010,26,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),% of total sales,1.5
+20970,Latvia,2010,26,C07-Beta blocking agents,% of total sales,2.4
+20971,Latvia,2010,26,"C01B-Antiarrhythmics, Class I and III",% of total sales,0.1
+20972,Latvia,2010,26,N06A-Antidepressants,% of total sales,0.8
+20973,Latvia,2010,26,R-Respiratory system,% of total sales,7.4
+20974,Latvia,2010,26,C03-Diuretics,% of total sales,0.8
+20975,Latvia,2010,26,A-Alimentary tract and metabolism,% of total sales,13.0
+20976,Latvia,2010,26,M01A-Antiinflammatory and antirheumatic products non-steroids,% of total sales,3.7
+20977,Latvia,2010,26,A10-Drugs used in diabetes,% of total sales,5.5
+20978,Latvia,2010,26,C02-Antihypertensives,% of total sales,0.9
+20979,Latvia,2010,26,C08-Calcium channel blockers,% of total sales,1.5
+20980,Latvia,2010,26,J-Antiinfectives for systemic use,% of total sales,9.3
+20981,Latvia,2010,26,G-Genito urinary system and sex hormones,% of total sales,4.5
+20982,Latvia,2010,26,G-Genito urinary system and sex hormones,"/capita, US$ exchange rate",7.8
+20983,Latvia,2010,26,C10-Lipid modifying agents,"/capita, US$ exchange rate",4.6
+20984,Latvia,2010,26,C01A-Cardiac glycosides,"/capita, US$ purchasing power parity",0.1
+20985,Latvia,2010,26,G03-Sex hormones and modulators of the genital system,"/capita, US$ exchange rate",3.6
+20986,Latvia,2010,26,C07-Beta blocking agents,"/capita, US$ purchasing power parity",6.4
+20987,Latvia,2010,26,C08-Calcium channel blockers,"/capita, US$ purchasing power parity",4.0
+20988,Latvia,2010,26,C03-Diuretics,"/capita, US$ purchasing power parity",2.1
+20989,Latvia,2010,26,"C01B-Antiarrhythmics, Class I and III","/capita, US$ purchasing power parity",0.4
+20990,Latvia,2010,26,C02-Antihypertensives,"/capita, US$ purchasing power parity",2.5
+20991,Latvia,2010,26,R-Respiratory system,Million US$ at exchange rate,27.3
+20992,Latvia,2010,26,N06A-Antidepressants,Million US$ at exchange rate,3.0
+20993,Latvia,2010,26,R03-Drugs for obstructive airway diseases,Million US$ at exchange rate,11.2
+20994,Latvia,2010,26,A-Alimentary tract and metabolism,"Million US$, purchasing power parity",73.5
+20995,Latvia,2010,26,Total pharmaceutical sales,"Million US$, purchasing power parity",567.2
+20996,Latvia,2010,26,B-Blood and blood forming organs,"/capita, US$ purchasing power parity",18.3
+20997,Latvia,2010,26,A10-Drugs used in diabetes,"/capita, US$ purchasing power parity",14.9
+20998,Latvia,2010,26,C-Cardiovascular system,"/capita, US$ purchasing power parity",51.2
+20999,Latvia,2010,26,A02A-Antacids,"/capita, US$ purchasing power parity",0.4
+21000,Latvia,2010,26,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ purchasing power parity",4.1
+21001,Latvia,2010,26,N05C-Hypnotics and sedatives,Million US$ at exchange rate,3.2
+21002,Latvia,2010,26,Total pharmaceutical sales,"/capita, US$ exchange rate",174.5
+21003,Latvia,2010,26,A-Alimentary tract and metabolism,"/capita, US$ exchange rate",22.6
+21004,Latvia,2010,26,A02A-Antacids,"/capita, US$ exchange rate",0.2
+21005,Latvia,2010,26,N05B-Anxiolytics,Million US$ at exchange rate,2.8
+21006,Latvia,2010,26,M01A-Antiinflammatory and antirheumatic products non-steroids,Million US$ at exchange rate,13.7
+21007,Latvia,2010,26,M-Musculo-skeletal system,Million US$ at exchange rate,24.1
+21008,Latvia,2010,26,N02-Analgesics,Million US$ at exchange rate,9.5
+21009,Latvia,2010,26,N-Nervous system,Million US$ at exchange rate,43.8
+21010,Latvia,2010,26,G03-Sex hormones and modulators of the genital system,"/capita, US$ purchasing power parity",5.6
+21011,Latvia,2010,26,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ purchasing power parity",4.5
+21012,Latvia,2010,26,G-Genito urinary system and sex hormones,"/capita, US$ purchasing power parity",12.2
+21013,Latvia,2010,26,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ purchasing power parity",17.6
+21014,Latvia,2010,26,C10-Lipid modifying agents,"/capita, US$ purchasing power parity",7.1
+21015,Latvia,2010,26,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ exchange rate",11.4
+21016,Latvia,2010,26,C08-Calcium channel blockers,"/capita, US$ exchange rate",2.6
+21017,Latvia,2010,26,C07-Beta blocking agents,"/capita, US$ exchange rate",4.1
+21018,Latvia,2010,26,J-Antiinfectives for systemic use,"/capita, US$ purchasing power parity",25.0
+21019,Latvia,2010,26,J01-Antibacterials for systemic use,"/capita, US$ purchasing power parity",9.2
+21020,Latvia,2010,26,J01-Antibacterials for systemic use,Million US$ at exchange rate,12.4
+21021,Latvia,2010,26,R03-Drugs for obstructive airway diseases,"Million US$, purchasing power parity",17.3
+21022,Latvia,2010,26,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ exchange rate",6.5
+21023,Latvia,2010,26,N-Nervous system,"/capita, US$ exchange rate",20.9
+21024,Latvia,2010,26,N02-Analgesics,"Million US$, purchasing power parity",14.7
+21025,Latvia,2010,26,N05B-Anxiolytics,"/capita, US$ exchange rate",1.3
+21026,Latvia,2010,26,N02-Analgesics,"/capita, US$ exchange rate",4.5
+21027,Latvia,2010,26,M01A-Antiinflammatory and antirheumatic products non-steroids,"Million US$, purchasing power parity",21.2
+21028,Latvia,2010,26,M-Musculo-skeletal system,"Million US$, purchasing power parity",37.4
+21029,Latvia,2010,26,M-Musculo-skeletal system,"/capita, US$ exchange rate",11.5
+21030,Latvia,2010,26,N-Nervous system,"Million US$, purchasing power parity",67.9
+21031,Latvia,2010,26,R03-Drugs for obstructive airway diseases,"/capita, US$ exchange rate",5.3
+21032,Latvia,2010,26,Total pharmaceutical sales,"/capita, US$ purchasing power parity",270.4
+21033,Latvia,2010,26,N05C-Hypnotics and sedatives,"/capita, US$ exchange rate",1.5
+21034,Latvia,2010,26,N06A-Antidepressants,"/capita, US$ exchange rate",1.4
+21035,Latvia,2010,26,R-Respiratory system,"/capita, US$ exchange rate",13.0
+21036,Latvia,2010,26,N05C-Hypnotics and sedatives,"Million US$, purchasing power parity",5.0
+21037,Latvia,2010,26,N05B-Anxiolytics,"Million US$, purchasing power parity",4.3
+21038,Latvia,2010,26,A-Alimentary tract and metabolism,"/capita, US$ purchasing power parity",35.0
+21039,Latvia,2010,26,R-Respiratory system,"Million US$, purchasing power parity",42.3
+21040,Latvia,2010,26,N06A-Antidepressants,"Million US$, purchasing power parity",4.7
+21041,Latvia,2010,26,"C01B-Antiarrhythmics, Class I and III","Million US$, purchasing power parity",0.8
+21042,Latvia,2010,26,C01A-Cardiac glycosides,"Million US$, purchasing power parity",0.2
+21043,Latvia,2010,26,C02-Antihypertensives,"Million US$, purchasing power parity",5.3
+21044,Latvia,2010,26,C07-Beta blocking agents,"Million US$, purchasing power parity",13.4
+21045,Latvia,2010,26,C03-Diuretics,"Million US$, purchasing power parity",4.4
+21046,Latvia,2010,26,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"Million US$, purchasing power parity",8.7
+21047,Latvia,2010,26,A02A-Antacids,"Million US$, purchasing power parity",0.8
+21048,Latvia,2010,26,A10-Drugs used in diabetes,"Million US$, purchasing power parity",31.2
+21049,Latvia,2010,26,C-Cardiovascular system,"Million US$, purchasing power parity",107.3
+21050,Latvia,2010,26,B-Blood and blood forming organs,"Million US$, purchasing power parity",38.5
+21051,Latvia,2010,26,J01-Antibacterials for systemic use,"/capita, US$ exchange rate",5.9
+21052,Latvia,2010,26,G03-Sex hormones and modulators of the genital system,"Million US$, purchasing power parity",11.7
+21053,Latvia,2010,26,J01-Antibacterials for systemic use,"Million US$, purchasing power parity",19.2
+21054,Latvia,2010,26,J-Antiinfectives for systemic use,"Million US$, purchasing power parity",52.5
+21055,Latvia,2010,26,"H-Systemic hormonal preparations, excluding sex hormones and insulins","Million US$, purchasing power parity",9.4
+21056,Latvia,2010,26,C09-Agents acting on the Renin-Angiotensin system,"Million US$, purchasing power parity",36.9
+21057,Latvia,2010,26,C08-Calcium channel blockers,"Million US$, purchasing power parity",8.3
+21058,Latvia,2010,26,C10-Lipid modifying agents,"Million US$, purchasing power parity",14.9
+21059,Latvia,2010,26,G-Genito urinary system and sex hormones,"Million US$, purchasing power parity",25.5
+21060,Latvia,2010,26,J-Antiinfectives for systemic use,"/capita, US$ exchange rate",16.2
+21061,Latvia,2010,26,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ exchange rate",2.9
+21062,Latvia,2010,26,N02-Analgesics,Million of national currency units,7.2
+21063,Latvia,2010,26,N-Nervous system,Million of national currency units,33.1
+21064,Latvia,2010,26,N05C-Hypnotics and sedatives,Million of national currency units,2.4
+21065,Latvia,2010,26,N05B-Anxiolytics,Million of national currency units,2.1
+21066,Latvia,2010,26,M01A-Antiinflammatory and antirheumatic products non-steroids,Million of national currency units,10.3
+21067,Latvia,2010,26,J-Antiinfectives for systemic use,Million of national currency units,25.6
+21068,Latvia,2010,26,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million of national currency units,4.6
+21069,Latvia,2010,26,M-Musculo-skeletal system,Million of national currency units,18.2
+21070,Latvia,2010,26,J01-Antibacterials for systemic use,Million of national currency units,9.4
+21071,Latvia,2010,26,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million US$ at exchange rate,5.6
+21072,Latvia,2010,26,A02A-Antacids,Million US$ at exchange rate,0.5
+21073,Latvia,2010,26,A10-Drugs used in diabetes,Million US$ at exchange rate,20.1
+21074,Latvia,2010,26,C-Cardiovascular system,Million US$ at exchange rate,69.2
+21075,Latvia,2010,26,B-Blood and blood forming organs,Million US$ at exchange rate,24.8
+21076,Latvia,2010,26,R-Respiratory system,Million of national currency units,20.6
+21077,Latvia,2010,26,N06A-Antidepressants,Million of national currency units,2.3
+21078,Latvia,2010,26,R03-Drugs for obstructive airway diseases,Million of national currency units,8.4
+21079,Latvia,2010,26,A-Alimentary tract and metabolism,Million US$ at exchange rate,47.4
+21080,Latvia,2010,26,Total pharmaceutical sales,Million US$ at exchange rate,365.9
+21081,Latvia,2010,26,C03-Diuretics,"/capita, US$ exchange rate",1.3
+21082,Latvia,2010,26,"C01B-Antiarrhythmics, Class I and III",Million of national currency units,0.4
+21083,Latvia,2010,26,"C01B-Antiarrhythmics, Class I and III","/capita, US$ exchange rate",0.3
+21084,Latvia,2010,26,C02-Antihypertensives,"/capita, US$ exchange rate",1.6
+21085,Latvia,2010,26,A10-Drugs used in diabetes,Million of national currency units,15.2
+21086,Latvia,2010,26,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million of national currency units,4.2
+21087,Latvia,2010,26,C01A-Cardiac glycosides,Million of national currency units,0.1
+21088,Latvia,2010,26,C-Cardiovascular system,Million of national currency units,52.3
+21089,Latvia,2010,26,B-Blood and blood forming organs,Million of national currency units,18.7
+21090,Latvia,2010,26,C09-Agents acting on the Renin-Angiotensin system,Million of national currency units,18.0
+21091,Latvia,2010,26,C08-Calcium channel blockers,Million of national currency units,4.0
+21092,Latvia,2010,26,G03-Sex hormones and modulators of the genital system,Million of national currency units,5.7
+21093,Latvia,2010,26,G-Genito urinary system and sex hormones,Million of national currency units,12.4
+21094,Latvia,2010,26,C10-Lipid modifying agents,Million of national currency units,7.3
+21095,Latvia,2010,26,C-Cardiovascular system,"/capita, US$ exchange rate",33.0
+21096,Latvia,2010,26,C01A-Cardiac glycosides,"/capita, US$ exchange rate",0.1
+21097,Latvia,2010,26,C02-Antihypertensives,Million of national currency units,2.6
+21098,Latvia,2010,26,C07-Beta blocking agents,Million of national currency units,6.5
+21099,Latvia,2010,26,C03-Diuretics,Million of national currency units,2.1
+21100,Latvia,2010,26,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ exchange rate",2.7
+21101,Latvia,2010,26,C02-Antihypertensives,Million US$ at exchange rate,3.4
+21102,Latvia,2010,26,R-Respiratory system,"/capita, US$ purchasing power parity",20.1
+21103,Latvia,2010,26,R03-Drugs for obstructive airway diseases,"/capita, US$ purchasing power parity",8.3
+21104,Latvia,2010,26,C07-Beta blocking agents,Million US$ at exchange rate,8.7
+21105,Latvia,2010,26,C03-Diuretics,Million US$ at exchange rate,2.8
+21106,Latvia,2010,26,A10-Drugs used in diabetes,"/capita, US$ exchange rate",9.6
+21107,Latvia,2010,26,N-Nervous system,"/capita, US$ purchasing power parity",32.4
+21108,Latvia,2010,26,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ purchasing power parity",10.1
+21109,Latvia,2010,26,"C01B-Antiarrhythmics, Class I and III",Million US$ at exchange rate,0.5
+21110,Latvia,2010,26,M-Musculo-skeletal system,"/capita, US$ purchasing power parity",17.8
+21111,Latvia,2010,26,N05C-Hypnotics and sedatives,"/capita, US$ purchasing power parity",2.4
+21112,Latvia,2010,26,N06A-Antidepressants,"/capita, US$ purchasing power parity",2.2
+21113,Latvia,2010,26,N02-Analgesics,"/capita, US$ purchasing power parity",7.0
+21114,Latvia,2010,26,N05B-Anxiolytics,"/capita, US$ purchasing power parity",2.0
+21115,Latvia,2010,26,J-Antiinfectives for systemic use,Million US$ at exchange rate,33.9
+21116,Latvia,2010,26,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million US$ at exchange rate,6.0
+21117,Latvia,2010,26,B-Blood and blood forming organs,"/capita, US$ exchange rate",11.8
+21118,Latvia,2010,26,C01A-Cardiac glycosides,Million US$ at exchange rate,0.1
+21119,Latvia,2010,26,C10-Lipid modifying agents,Million US$ at exchange rate,9.6
+21120,Latvia,2010,26,C08-Calcium channel blockers,Million US$ at exchange rate,5.4
+21121,Latvia,2010,26,C09-Agents acting on the Renin-Angiotensin system,Million US$ at exchange rate,23.8
+21122,Latvia,2010,26,G03-Sex hormones and modulators of the genital system,Million US$ at exchange rate,7.6
+21123,Latvia,2010,26,G-Genito urinary system and sex hormones,Million US$ at exchange rate,16.5
+21124,Latvia,2016,26,A-Alimentary tract and metabolism,Million of national currency units,49.1
+21125,Latvia,2016,26,A02A-Antacids,% of total sales,0.1
+21126,Latvia,2016,26,A02A-Antacids,Million of national currency units,0.4
+21127,Latvia,2016,26,Total pharmaceutical sales,Million of national currency units,369.2
+21128,Latvia,2016,26,C01A-Cardiac glycosides,% of total sales,0.0
+21129,Latvia,2016,26,C09-Agents acting on the Renin-Angiotensin system,% of total sales,5.1
+21130,Latvia,2016,26,N05B-Anxiolytics,% of total sales,0.8
+21131,Latvia,2016,26,N-Nervous system,% of total sales,9.6
+21132,Latvia,2016,26,N06A-Antidepressants,% of total sales,0.7
+21133,Latvia,2016,26,G03-Sex hormones and modulators of the genital system,% of total sales,1.7
+21134,Latvia,2016,26,J01-Antibacterials for systemic use,% of total sales,2.7
+21135,Latvia,2016,26,N05C-Hypnotics and sedatives,% of total sales,0.8
+21136,Latvia,2016,26,R03-Drugs for obstructive airway diseases,% of total sales,2.5
+21137,Latvia,2016,26,B-Blood and blood forming organs,% of total sales,6.7
+21138,Latvia,2016,26,A-Alimentary tract and metabolism,% of total sales,13.3
+21139,Latvia,2016,26,C10-Lipid modifying agents,% of total sales,1.5
+21140,Latvia,2016,26,N02-Analgesics,% of total sales,2.1
+21141,Latvia,2016,26,C-Cardiovascular system,% of total sales,14.9
+21142,Latvia,2016,26,M-Musculo-skeletal system,% of total sales,6.2
+21143,Latvia,2016,26,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),% of total sales,1.4
+21144,Latvia,2016,26,"H-Systemic hormonal preparations, excluding sex hormones and insulins",% of total sales,1.6
+21145,Latvia,2016,26,"C01B-Antiarrhythmics, Class I and III",% of total sales,0.2
+21146,Latvia,2016,26,C07-Beta blocking agents,% of total sales,2.1
+21147,Latvia,2016,26,C03-Diuretics,% of total sales,0.6
+21148,Latvia,2016,26,A10-Drugs used in diabetes,% of total sales,5.7
+21149,Latvia,2016,26,M01A-Antiinflammatory and antirheumatic products non-steroids,% of total sales,4.0
+21150,Latvia,2016,26,R-Respiratory system,% of total sales,7.0
+21151,Latvia,2016,26,C02-Antihypertensives,% of total sales,1.0
+21152,Latvia,2016,26,C08-Calcium channel blockers,% of total sales,0.7
+21153,Latvia,2016,26,J-Antiinfectives for systemic use,% of total sales,15.0
+21154,Latvia,2016,26,G-Genito urinary system and sex hormones,% of total sales,3.8
+21155,Latvia,2016,26,G-Genito urinary system and sex hormones,"/capita, US$ exchange rate",8.0
+21156,Latvia,2016,26,C10-Lipid modifying agents,"/capita, US$ exchange rate",3.1
+21157,Latvia,2016,26,R03-Drugs for obstructive airway diseases,"Million US$, purchasing power parity",19.1
+21158,Latvia,2016,26,G03-Sex hormones and modulators of the genital system,"/capita, US$ exchange rate",3.5
+21159,Latvia,2016,26,C01A-Cardiac glycosides,"/capita, US$ purchasing power parity",0.1
+21160,Latvia,2016,26,C-Cardiovascular system,"/capita, US$ purchasing power parity",57.9
+21161,Latvia,2016,26,C03-Diuretics,"/capita, US$ purchasing power parity",2.4
+21162,Latvia,2016,26,C07-Beta blocking agents,"/capita, US$ purchasing power parity",8.3
+21163,Latvia,2016,26,"C01B-Antiarrhythmics, Class I and III","/capita, US$ purchasing power parity",0.8
+21164,Latvia,2016,26,C02-Antihypertensives,"/capita, US$ purchasing power parity",3.7
+21165,Latvia,2016,26,C08-Calcium channel blockers,"/capita, US$ purchasing power parity",2.7
+21166,Latvia,2016,26,R-Respiratory system,Million US$ at exchange rate,28.4
+21167,Latvia,2016,26,N06A-Antidepressants,Million US$ at exchange rate,2.9
+21168,Latvia,2016,26,Total pharmaceutical sales,"Million US$, purchasing power parity",762.0
+21169,Latvia,2016,26,R03-Drugs for obstructive airway diseases,Million US$ at exchange rate,10.3
+21170,Latvia,2016,26,A-Alimentary tract and metabolism,"/capita, US$ purchasing power parity",51.7
+21171,Latvia,2016,26,A10-Drugs used in diabetes,"/capita, US$ purchasing power parity",22.2
+21172,Latvia,2016,26,B-Blood and blood forming organs,"/capita, US$ purchasing power parity",26.0
+21173,Latvia,2016,26,A02A-Antacids,"/capita, US$ purchasing power parity",0.4
+21174,Latvia,2016,26,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ purchasing power parity",5.4
+21175,Latvia,2016,26,A02A-Antacids,"/capita, US$ exchange rate",0.2
+21176,Latvia,2016,26,N05C-Hypnotics and sedatives,Million US$ at exchange rate,3.3
+21177,Latvia,2016,26,N05B-Anxiolytics,Million US$ at exchange rate,3.1
+21178,Latvia,2016,26,Total pharmaceutical sales,"/capita, US$ exchange rate",208.6
+21179,Latvia,2016,26,A-Alimentary tract and metabolism,"/capita, US$ exchange rate",27.7
+21180,Latvia,2016,26,M-Musculo-skeletal system,Million US$ at exchange rate,25.3
+21181,Latvia,2016,26,J01-Antibacterials for systemic use,Million US$ at exchange rate,11.1
+21182,Latvia,2016,26,M01A-Antiinflammatory and antirheumatic products non-steroids,Million US$ at exchange rate,16.4
+21183,Latvia,2016,26,N02-Analgesics,Million US$ at exchange rate,8.8
+21184,Latvia,2016,26,N-Nervous system,Million US$ at exchange rate,39.1
+21185,Latvia,2016,26,G-Genito urinary system and sex hormones,"/capita, US$ purchasing power parity",14.9
+21186,Latvia,2016,26,G03-Sex hormones and modulators of the genital system,"/capita, US$ purchasing power parity",6.6
+21187,Latvia,2016,26,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ purchasing power parity",19.8
+21188,Latvia,2016,26,C10-Lipid modifying agents,"/capita, US$ purchasing power parity",5.9
+21189,Latvia,2016,26,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ purchasing power parity",6.4
+21190,Latvia,2016,26,C08-Calcium channel blockers,"/capita, US$ exchange rate",1.5
+21191,Latvia,2016,26,C07-Beta blocking agents,"/capita, US$ exchange rate",4.5
+21192,Latvia,2016,26,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ exchange rate",10.6
+21193,Latvia,2016,26,J-Antiinfectives for systemic use,"/capita, US$ purchasing power parity",58.5
+21194,Latvia,2016,26,J01-Antibacterials for systemic use,"/capita, US$ purchasing power parity",10.6
+21195,Latvia,2016,26,A-Alimentary tract and metabolism,"Million US$, purchasing power parity",101.3
+21196,Latvia,2016,26,N-Nervous system,"/capita, US$ exchange rate",19.9
+21197,Latvia,2016,26,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ exchange rate",8.4
+21198,Latvia,2016,26,R-Respiratory system,"Million US$, purchasing power parity",53.0
+21199,Latvia,2016,26,N02-Analgesics,"/capita, US$ exchange rate",4.5
+21200,Latvia,2016,26,M01A-Antiinflammatory and antirheumatic products non-steroids,"Million US$, purchasing power parity",30.7
+21201,Latvia,2016,26,M-Musculo-skeletal system,"Million US$, purchasing power parity",47.1
+21202,Latvia,2016,26,J01-Antibacterials for systemic use,"Million US$, purchasing power parity",20.8
+21203,Latvia,2016,26,M-Musculo-skeletal system,"/capita, US$ exchange rate",12.9
+21204,Latvia,2016,26,J01-Antibacterials for systemic use,"/capita, US$ exchange rate",5.7
+21205,Latvia,2016,26,N-Nervous system,"Million US$, purchasing power parity",72.8
+21206,Latvia,2016,26,N05B-Anxiolytics,"/capita, US$ exchange rate",1.6
+21207,Latvia,2016,26,R03-Drugs for obstructive airway diseases,"/capita, US$ exchange rate",5.2
+21208,Latvia,2016,26,N06A-Antidepressants,"/capita, US$ exchange rate",1.5
+21209,Latvia,2016,26,R-Respiratory system,"/capita, US$ exchange rate",14.5
+21210,Latvia,2016,26,N05C-Hypnotics and sedatives,"/capita, US$ exchange rate",1.7
+21211,Latvia,2016,26,N05C-Hypnotics and sedatives,"Million US$, purchasing power parity",6.2
+21212,Latvia,2016,26,N05B-Anxiolytics,"Million US$, purchasing power parity",5.8
+21213,Latvia,2016,26,N02-Analgesics,"Million US$, purchasing power parity",16.4
+21214,Latvia,2016,26,N06A-Antidepressants,"Million US$, purchasing power parity",5.4
+21215,Latvia,2016,26,Total pharmaceutical sales,"/capita, US$ purchasing power parity",388.9
+21216,Latvia,2016,26,"C01B-Antiarrhythmics, Class I and III","Million US$, purchasing power parity",1.6
+21217,Latvia,2016,26,C01A-Cardiac glycosides,"Million US$, purchasing power parity",0.2
+21218,Latvia,2016,26,C03-Diuretics,"Million US$, purchasing power parity",4.8
+21219,Latvia,2016,26,C02-Antihypertensives,"Million US$, purchasing power parity",7.3
+21220,Latvia,2016,26,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"Million US$, purchasing power parity",10.5
+21221,Latvia,2016,26,A02A-Antacids,"Million US$, purchasing power parity",0.8
+21222,Latvia,2016,26,B-Blood and blood forming organs,"Million US$, purchasing power parity",50.9
+21223,Latvia,2016,26,A10-Drugs used in diabetes,"Million US$, purchasing power parity",43.6
+21224,Latvia,2016,26,C-Cardiovascular system,"Million US$, purchasing power parity",113.4
+21225,Latvia,2016,26,C07-Beta blocking agents,"Million US$, purchasing power parity",16.3
+21226,Latvia,2016,26,G03-Sex hormones and modulators of the genital system,"Million US$, purchasing power parity",12.9
+21227,Latvia,2016,26,J-Antiinfectives for systemic use,"/capita, US$ exchange rate",31.4
+21228,Latvia,2016,26,J-Antiinfectives for systemic use,"Million US$, purchasing power parity",114.6
+21229,Latvia,2016,26,"H-Systemic hormonal preparations, excluding sex hormones and insulins","Million US$, purchasing power parity",12.5
+21230,Latvia,2016,26,G-Genito urinary system and sex hormones,"Million US$, purchasing power parity",29.2
+21231,Latvia,2016,26,C09-Agents acting on the Renin-Angiotensin system,"Million US$, purchasing power parity",38.9
+21232,Latvia,2016,26,C08-Calcium channel blockers,"Million US$, purchasing power parity",5.3
+21233,Latvia,2016,26,C10-Lipid modifying agents,"Million US$, purchasing power parity",11.5
+21234,Latvia,2016,26,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ exchange rate",3.4
+21235,Latvia,2016,26,N-Nervous system,Million of national currency units,35.3
+21236,Latvia,2016,26,M01A-Antiinflammatory and antirheumatic products non-steroids,Million of national currency units,14.9
+21237,Latvia,2016,26,N02-Analgesics,Million of national currency units,7.9
+21238,Latvia,2016,26,N05C-Hypnotics and sedatives,Million of national currency units,3.0
+21239,Latvia,2016,26,N05B-Anxiolytics,Million of national currency units,2.8
+21240,Latvia,2016,26,J-Antiinfectives for systemic use,Million of national currency units,55.5
+21241,Latvia,2016,26,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million of national currency units,6.0
+21242,Latvia,2016,26,G03-Sex hormones and modulators of the genital system,Million of national currency units,6.3
+21243,Latvia,2016,26,M-Musculo-skeletal system,Million of national currency units,22.8
+21244,Latvia,2016,26,J01-Antibacterials for systemic use,Million of national currency units,10.1
+21245,Latvia,2016,26,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million US$ at exchange rate,5.6
+21246,Latvia,2016,26,A02A-Antacids,Million US$ at exchange rate,0.5
+21247,Latvia,2016,26,B-Blood and blood forming organs,Million US$ at exchange rate,27.3
+21248,Latvia,2016,26,A10-Drugs used in diabetes,Million US$ at exchange rate,23.4
+21249,Latvia,2016,26,R-Respiratory system,Million of national currency units,25.7
+21250,Latvia,2016,26,N06A-Antidepressants,Million of national currency units,2.6
+21251,Latvia,2016,26,A-Alimentary tract and metabolism,Million US$ at exchange rate,54.4
+21252,Latvia,2016,26,Total pharmaceutical sales,Million US$ at exchange rate,408.7
+21253,Latvia,2016,26,R03-Drugs for obstructive airway diseases,Million of national currency units,9.3
+21254,Latvia,2016,26,C03-Diuretics,"/capita, US$ exchange rate",1.3
+21255,Latvia,2016,26,C01A-Cardiac glycosides,Million of national currency units,0.1
+21256,Latvia,2016,26,"C01B-Antiarrhythmics, Class I and III","/capita, US$ exchange rate",0.4
+21257,Latvia,2016,26,C02-Antihypertensives,"/capita, US$ exchange rate",2.0
+21258,Latvia,2016,26,A10-Drugs used in diabetes,Million of national currency units,21.1
+21259,Latvia,2016,26,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million of national currency units,5.1
+21260,Latvia,2016,26,C01A-Cardiac glycosides,"/capita, US$ exchange rate",0.1
+21261,Latvia,2016,26,C-Cardiovascular system,Million of national currency units,54.9
+21262,Latvia,2016,26,B-Blood and blood forming organs,Million of national currency units,24.6
+21263,Latvia,2016,26,C09-Agents acting on the Renin-Angiotensin system,Million of national currency units,18.8
+21264,Latvia,2016,26,C08-Calcium channel blockers,Million of national currency units,2.6
+21265,Latvia,2016,26,G-Genito urinary system and sex hormones,Million of national currency units,14.2
+21266,Latvia,2016,26,C10-Lipid modifying agents,Million of national currency units,5.6
+21267,Latvia,2016,26,C07-Beta blocking agents,Million of national currency units,7.9
+21268,Latvia,2016,26,"C01B-Antiarrhythmics, Class I and III",Million of national currency units,0.8
+21269,Latvia,2016,26,C-Cardiovascular system,"/capita, US$ exchange rate",31.0
+21270,Latvia,2016,26,C03-Diuretics,Million of national currency units,2.3
+21271,Latvia,2016,26,C02-Antihypertensives,Million of national currency units,3.6
+21272,Latvia,2016,26,R03-Drugs for obstructive airway diseases,"/capita, US$ purchasing power parity",9.8
+21273,Latvia,2016,26,C02-Antihypertensives,Million US$ at exchange rate,3.9
+21274,Latvia,2016,26,R-Respiratory system,"/capita, US$ purchasing power parity",27.0
+21275,Latvia,2016,26,C03-Diuretics,Million US$ at exchange rate,2.6
+21276,Latvia,2016,26,C07-Beta blocking agents,Million US$ at exchange rate,8.7
+21277,Latvia,2016,26,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ exchange rate",2.9
+21278,Latvia,2016,26,A10-Drugs used in diabetes,"/capita, US$ exchange rate",11.9
+21279,Latvia,2016,26,N06A-Antidepressants,"/capita, US$ purchasing power parity",2.7
+21280,Latvia,2016,26,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ purchasing power parity",15.7
+21281,Latvia,2016,26,N-Nervous system,"/capita, US$ purchasing power parity",37.2
+21282,Latvia,2016,26,"C01B-Antiarrhythmics, Class I and III",Million US$ at exchange rate,0.8
+21283,Latvia,2016,26,M-Musculo-skeletal system,"/capita, US$ purchasing power parity",24.0
+21284,Latvia,2016,26,N05C-Hypnotics and sedatives,"/capita, US$ purchasing power parity",3.2
+21285,Latvia,2016,26,N02-Analgesics,"/capita, US$ purchasing power parity",8.4
+21286,Latvia,2016,26,N05B-Anxiolytics,"/capita, US$ purchasing power parity",2.9
+21287,Latvia,2016,26,J-Antiinfectives for systemic use,Million US$ at exchange rate,61.5
+21288,Latvia,2016,26,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million US$ at exchange rate,6.7
+21289,Latvia,2016,26,C-Cardiovascular system,Million US$ at exchange rate,60.8
+21290,Latvia,2016,26,C01A-Cardiac glycosides,Million US$ at exchange rate,0.1
+21291,Latvia,2016,26,B-Blood and blood forming organs,"/capita, US$ exchange rate",13.9
+21292,Latvia,2016,26,C09-Agents acting on the Renin-Angiotensin system,Million US$ at exchange rate,20.8
+21293,Latvia,2016,26,C08-Calcium channel blockers,Million US$ at exchange rate,2.9
+21294,Latvia,2016,26,G03-Sex hormones and modulators of the genital system,Million US$ at exchange rate,6.9
+21295,Latvia,2016,26,G-Genito urinary system and sex hormones,Million US$ at exchange rate,15.7
+21296,Latvia,2016,26,C10-Lipid modifying agents,Million US$ at exchange rate,6.2
+21297,Latvia,2015,23,A-Alimentary tract and metabolism,Million of national currency units,45.6
+21298,Latvia,2015,23,A02A-Antacids,% of total sales,0.1
+21299,Latvia,2015,23,A02A-Antacids,Million of national currency units,0.4
+21300,Latvia,2015,23,C01A-Cardiac glycosides,% of total sales,0.0
+21301,Latvia,2015,23,C09-Agents acting on the Renin-Angiotensin system,% of total sales,5.6
+21302,Latvia,2015,23,N05B-Anxiolytics,% of total sales,0.8
+21303,Latvia,2015,23,Total pharmaceutical sales,Million of national currency units,331.6
+21304,Latvia,2015,23,N-Nervous system,% of total sales,10.5
+21305,Latvia,2015,23,G03-Sex hormones and modulators of the genital system,% of total sales,1.9
+21306,Latvia,2015,23,N06A-Antidepressants,% of total sales,0.8
+21307,Latvia,2015,23,J01-Antibacterials for systemic use,% of total sales,3.0
+21308,Latvia,2015,23,N05C-Hypnotics and sedatives,% of total sales,0.9
+21309,Latvia,2015,23,R03-Drugs for obstructive airway diseases,% of total sales,2.8
+21310,Latvia,2015,23,B-Blood and blood forming organs,% of total sales,7.0
+21311,Latvia,2015,23,C10-Lipid modifying agents,% of total sales,1.6
+21312,Latvia,2015,23,N02-Analgesics,% of total sales,2.3
+21313,Latvia,2015,23,C-Cardiovascular system,% of total sales,16.2
+21314,Latvia,2015,23,M-Musculo-skeletal system,% of total sales,6.6
+21315,Latvia,2015,23,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),% of total sales,1.5
+21316,Latvia,2015,23,"H-Systemic hormonal preparations, excluding sex hormones and insulins",% of total sales,1.8
+21317,Latvia,2015,23,"C01B-Antiarrhythmics, Class I and III",% of total sales,0.2
+21318,Latvia,2015,23,C07-Beta blocking agents,% of total sales,2.3
+21319,Latvia,2015,23,C03-Diuretics,% of total sales,0.7
+21320,Latvia,2015,23,A10-Drugs used in diabetes,% of total sales,6.0
+21321,Latvia,2015,23,R-Respiratory system,% of total sales,7.3
+21322,Latvia,2015,23,M01A-Antiinflammatory and antirheumatic products non-steroids,% of total sales,4.2
+21323,Latvia,2015,23,C02-Antihypertensives,% of total sales,1.0
+21324,Latvia,2015,23,C08-Calcium channel blockers,% of total sales,0.9
+21325,Latvia,2015,23,J-Antiinfectives for systemic use,% of total sales,10.6
+21326,Latvia,2015,23,G-Genito urinary system and sex hormones,% of total sales,4.3
+21327,Latvia,2015,23,A-Alimentary tract and metabolism,% of total sales,13.7
+21328,Latvia,2015,23,G-Genito urinary system and sex hormones,"/capita, US$ exchange rate",7.9
+21329,Latvia,2015,23,C10-Lipid modifying agents,"/capita, US$ exchange rate",3.0
+21330,Latvia,2015,23,C01A-Cardiac glycosides,"/capita, US$ purchasing power parity",0.1
+21331,Latvia,2015,23,R03-Drugs for obstructive airway diseases,"Million US$, purchasing power parity",18.4
+21332,Latvia,2015,23,G03-Sex hormones and modulators of the genital system,"/capita, US$ exchange rate",3.5
+21333,Latvia,2015,23,C03-Diuretics,"/capita, US$ purchasing power parity",2.2
+21334,Latvia,2015,23,C08-Calcium channel blockers,"/capita, US$ purchasing power parity",2.9
+21335,Latvia,2015,23,C07-Beta blocking agents,"/capita, US$ purchasing power parity",7.7
+21336,Latvia,2015,23,"C01B-Antiarrhythmics, Class I and III","/capita, US$ purchasing power parity",0.7
+21337,Latvia,2015,23,C02-Antihypertensives,"/capita, US$ purchasing power parity",3.3
+21338,Latvia,2015,23,C-Cardiovascular system,"/capita, US$ purchasing power parity",54.5
+21339,Latvia,2015,23,R-Respiratory system,Million US$ at exchange rate,26.9
+21340,Latvia,2015,23,N06A-Antidepressants,Million US$ at exchange rate,2.8
+21341,Latvia,2015,23,Total pharmaceutical sales,"Million US$, purchasing power parity",666.4
+21342,Latvia,2015,23,R03-Drugs for obstructive airway diseases,Million US$ at exchange rate,10.2
+21343,Latvia,2015,23,A10-Drugs used in diabetes,"/capita, US$ purchasing power parity",20.1
+21344,Latvia,2015,23,B-Blood and blood forming organs,"/capita, US$ purchasing power parity",23.5
+21345,Latvia,2015,23,A02A-Antacids,"/capita, US$ purchasing power parity",0.4
+21346,Latvia,2015,23,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ purchasing power parity",5.0
+21347,Latvia,2015,23,A-Alimentary tract and metabolism,"/capita, US$ purchasing power parity",46.3
+21348,Latvia,2015,23,A02A-Antacids,"/capita, US$ exchange rate",0.2
+21349,Latvia,2015,23,N05C-Hypnotics and sedatives,Million US$ at exchange rate,3.2
+21350,Latvia,2015,23,N05B-Anxiolytics,Million US$ at exchange rate,3.0
+21351,Latvia,2015,23,Total pharmaceutical sales,"/capita, US$ exchange rate",186.0
+21352,Latvia,2015,23,A-Alimentary tract and metabolism,"/capita, US$ exchange rate",25.6
+21353,Latvia,2015,23,M-Musculo-skeletal system,Million US$ at exchange rate,24.1
+21354,Latvia,2015,23,J01-Antibacterials for systemic use,Million US$ at exchange rate,11.0
+21355,Latvia,2015,23,M01A-Antiinflammatory and antirheumatic products non-steroids,Million US$ at exchange rate,15.5
+21356,Latvia,2015,23,N02-Analgesics,Million US$ at exchange rate,8.5
+21357,Latvia,2015,23,N-Nervous system,Million US$ at exchange rate,38.5
+21358,Latvia,2015,23,G-Genito urinary system and sex hormones,"/capita, US$ purchasing power parity",14.4
+21359,Latvia,2015,23,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ purchasing power parity",6.0
+21360,Latvia,2015,23,G03-Sex hormones and modulators of the genital system,"/capita, US$ purchasing power parity",6.3
+21361,Latvia,2015,23,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ purchasing power parity",19.0
+21362,Latvia,2015,23,C10-Lipid modifying agents,"/capita, US$ purchasing power parity",5.4
+21363,Latvia,2015,23,C08-Calcium channel blockers,"/capita, US$ exchange rate",1.6
+21364,Latvia,2015,23,C07-Beta blocking agents,"/capita, US$ exchange rate",4.3
+21365,Latvia,2015,23,A-Alimentary tract and metabolism,"Million US$, purchasing power parity",91.6
+21366,Latvia,2015,23,J-Antiinfectives for systemic use,"/capita, US$ purchasing power parity",35.9
+21367,Latvia,2015,23,J01-Antibacterials for systemic use,"/capita, US$ purchasing power parity",10.1
+21368,Latvia,2015,23,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ exchange rate",10.5
+21369,Latvia,2015,23,N-Nervous system,"/capita, US$ exchange rate",19.5
+21370,Latvia,2015,23,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ exchange rate",7.8
+21371,Latvia,2015,23,N05B-Anxiolytics,"/capita, US$ exchange rate",1.5
+21372,Latvia,2015,23,N02-Analgesics,"/capita, US$ exchange rate",4.3
+21373,Latvia,2015,23,R-Respiratory system,"Million US$, purchasing power parity",48.8
+21374,Latvia,2015,23,M01A-Antiinflammatory and antirheumatic products non-steroids,"Million US$, purchasing power parity",28.0
+21375,Latvia,2015,23,J01-Antibacterials for systemic use,"Million US$, purchasing power parity",19.9
+21376,Latvia,2015,23,M-Musculo-skeletal system,"Million US$, purchasing power parity",43.7
+21377,Latvia,2015,23,M-Musculo-skeletal system,"/capita, US$ exchange rate",12.2
+21378,Latvia,2015,23,J01-Antibacterials for systemic use,"/capita, US$ exchange rate",5.6
+21379,Latvia,2015,23,N-Nervous system,"Million US$, purchasing power parity",69.8
+21380,Latvia,2015,23,R03-Drugs for obstructive airway diseases,"/capita, US$ exchange rate",5.1
+21381,Latvia,2015,23,N06A-Antidepressants,"/capita, US$ exchange rate",1.4
+21382,Latvia,2015,23,R-Respiratory system,"/capita, US$ exchange rate",13.6
+21383,Latvia,2015,23,N05C-Hypnotics and sedatives,"/capita, US$ exchange rate",1.6
+21384,Latvia,2015,23,Total pharmaceutical sales,"/capita, US$ purchasing power parity",337.0
+21385,Latvia,2015,23,N05C-Hypnotics and sedatives,"Million US$, purchasing power parity",5.7
+21386,Latvia,2015,23,N02-Analgesics,"Million US$, purchasing power parity",15.4
+21387,Latvia,2015,23,N05B-Anxiolytics,"Million US$, purchasing power parity",5.5
+21388,Latvia,2015,23,N06A-Antidepressants,"Million US$, purchasing power parity",5.0
+21389,Latvia,2015,23,"C01B-Antiarrhythmics, Class I and III","Million US$, purchasing power parity",1.4
+21390,Latvia,2015,23,C01A-Cardiac glycosides,"Million US$, purchasing power parity",0.2
+21391,Latvia,2015,23,C03-Diuretics,"Million US$, purchasing power parity",4.4
+21392,Latvia,2015,23,C02-Antihypertensives,"Million US$, purchasing power parity",6.6
+21393,Latvia,2015,23,C07-Beta blocking agents,"Million US$, purchasing power parity",15.3
+21394,Latvia,2015,23,C-Cardiovascular system,"Million US$, purchasing power parity",107.7
+21395,Latvia,2015,23,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"Million US$, purchasing power parity",9.9
+21396,Latvia,2015,23,A02A-Antacids,"Million US$, purchasing power parity",0.8
+21397,Latvia,2015,23,B-Blood and blood forming organs,"Million US$, purchasing power parity",46.5
+21398,Latvia,2015,23,A10-Drugs used in diabetes,"Million US$, purchasing power parity",39.8
+21399,Latvia,2015,23,G03-Sex hormones and modulators of the genital system,"Million US$, purchasing power parity",12.5
+21400,Latvia,2015,23,J-Antiinfectives for systemic use,"/capita, US$ exchange rate",19.8
+21401,Latvia,2015,23,J-Antiinfectives for systemic use,"Million US$, purchasing power parity",70.9
+21402,Latvia,2015,23,"H-Systemic hormonal preparations, excluding sex hormones and insulins","Million US$, purchasing power parity",11.8
+21403,Latvia,2015,23,G-Genito urinary system and sex hormones,"Million US$, purchasing power parity",28.4
+21404,Latvia,2015,23,C09-Agents acting on the Renin-Angiotensin system,"Million US$, purchasing power parity",37.6
+21405,Latvia,2015,23,C08-Calcium channel blockers,"Million US$, purchasing power parity",5.8
+21406,Latvia,2015,23,C10-Lipid modifying agents,"Million US$, purchasing power parity",10.7
+21407,Latvia,2015,23,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ exchange rate",3.3
+21408,Latvia,2015,23,N-Nervous system,Million of national currency units,34.7
+21409,Latvia,2015,23,M01A-Antiinflammatory and antirheumatic products non-steroids,Million of national currency units,13.9
+21410,Latvia,2015,23,N02-Analgesics,Million of national currency units,7.7
+21411,Latvia,2015,23,N05C-Hypnotics and sedatives,Million of national currency units,2.8
+21412,Latvia,2015,23,N05B-Anxiolytics,Million of national currency units,2.7
+21413,Latvia,2015,23,J-Antiinfectives for systemic use,Million of national currency units,35.3
+21414,Latvia,2015,23,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million of national currency units,5.9
+21415,Latvia,2015,23,G03-Sex hormones and modulators of the genital system,Million of national currency units,6.2
+21416,Latvia,2015,23,M-Musculo-skeletal system,Million of national currency units,21.7
+21417,Latvia,2015,23,J01-Antibacterials for systemic use,Million of national currency units,9.9
+21418,Latvia,2015,23,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million US$ at exchange rate,5.5
+21419,Latvia,2015,23,A02A-Antacids,Million US$ at exchange rate,0.5
+21420,Latvia,2015,23,B-Blood and blood forming organs,Million US$ at exchange rate,25.7
+21421,Latvia,2015,23,A10-Drugs used in diabetes,Million US$ at exchange rate,22.0
+21422,Latvia,2015,23,A-Alimentary tract and metabolism,Million US$ at exchange rate,50.6
+21423,Latvia,2015,23,R-Respiratory system,Million of national currency units,24.3
+21424,Latvia,2015,23,N06A-Antidepressants,Million of national currency units,2.5
+21425,Latvia,2015,23,Total pharmaceutical sales,Million US$ at exchange rate,367.9
+21426,Latvia,2015,23,R03-Drugs for obstructive airway diseases,Million of national currency units,9.2
+21427,Latvia,2015,23,C03-Diuretics,"/capita, US$ exchange rate",1.2
+21428,Latvia,2015,23,C01A-Cardiac glycosides,Million of national currency units,0.1
+21429,Latvia,2015,23,"C01B-Antiarrhythmics, Class I and III","/capita, US$ exchange rate",0.4
+21430,Latvia,2015,23,C02-Antihypertensives,"/capita, US$ exchange rate",1.8
+21431,Latvia,2015,23,A10-Drugs used in diabetes,Million of national currency units,19.8
+21432,Latvia,2015,23,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million of national currency units,4.9
+21433,Latvia,2015,23,C-Cardiovascular system,Million of national currency units,53.6
+21434,Latvia,2015,23,B-Blood and blood forming organs,Million of national currency units,23.1
+21435,Latvia,2015,23,C01A-Cardiac glycosides,"/capita, US$ exchange rate",0.1
+21436,Latvia,2015,23,C09-Agents acting on the Renin-Angiotensin system,Million of national currency units,18.7
+21437,Latvia,2015,23,C08-Calcium channel blockers,Million of national currency units,2.9
+21438,Latvia,2015,23,G-Genito urinary system and sex hormones,Million of national currency units,14.2
+21439,Latvia,2015,23,C10-Lipid modifying agents,Million of national currency units,5.3
+21440,Latvia,2015,23,"C01B-Antiarrhythmics, Class I and III",Million of national currency units,0.7
+21441,Latvia,2015,23,C-Cardiovascular system,"/capita, US$ exchange rate",30.1
+21442,Latvia,2015,23,C07-Beta blocking agents,Million of national currency units,7.6
+21443,Latvia,2015,23,C03-Diuretics,Million of national currency units,2.2
+21444,Latvia,2015,23,C02-Antihypertensives,Million of national currency units,3.3
+21445,Latvia,2015,23,C02-Antihypertensives,Million US$ at exchange rate,3.6
+21446,Latvia,2015,23,R03-Drugs for obstructive airway diseases,"/capita, US$ purchasing power parity",9.3
+21447,Latvia,2015,23,R-Respiratory system,"/capita, US$ purchasing power parity",24.7
+21448,Latvia,2015,23,C03-Diuretics,Million US$ at exchange rate,2.4
+21449,Latvia,2015,23,C07-Beta blocking agents,Million US$ at exchange rate,8.4
+21450,Latvia,2015,23,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ exchange rate",2.8
+21451,Latvia,2015,23,A10-Drugs used in diabetes,"/capita, US$ exchange rate",11.1
+21452,Latvia,2015,23,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ purchasing power parity",14.2
+21453,Latvia,2015,23,N-Nervous system,"/capita, US$ purchasing power parity",35.3
+21454,Latvia,2015,23,"C01B-Antiarrhythmics, Class I and III",Million US$ at exchange rate,0.8
+21455,Latvia,2015,23,M-Musculo-skeletal system,"/capita, US$ purchasing power parity",22.1
+21456,Latvia,2015,23,N05C-Hypnotics and sedatives,"/capita, US$ purchasing power parity",2.9
+21457,Latvia,2015,23,N06A-Antidepressants,"/capita, US$ purchasing power parity",2.5
+21458,Latvia,2015,23,N02-Analgesics,"/capita, US$ purchasing power parity",7.8
+21459,Latvia,2015,23,N05B-Anxiolytics,"/capita, US$ purchasing power parity",2.8
+21460,Latvia,2015,23,J-Antiinfectives for systemic use,Million US$ at exchange rate,39.1
+21461,Latvia,2015,23,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million US$ at exchange rate,6.5
+21462,Latvia,2015,23,C-Cardiovascular system,Million US$ at exchange rate,59.5
+21463,Latvia,2015,23,C01A-Cardiac glycosides,Million US$ at exchange rate,0.1
+21464,Latvia,2015,23,B-Blood and blood forming organs,"/capita, US$ exchange rate",13.0
+21465,Latvia,2015,23,G03-Sex hormones and modulators of the genital system,Million US$ at exchange rate,6.9
+21466,Latvia,2015,23,C08-Calcium channel blockers,Million US$ at exchange rate,3.2
+21467,Latvia,2015,23,C09-Agents acting on the Renin-Angiotensin system,Million US$ at exchange rate,20.7
+21468,Latvia,2015,23,G-Genito urinary system and sex hormones,Million US$ at exchange rate,15.7
+21469,Latvia,2015,23,C10-Lipid modifying agents,Million US$ at exchange rate,5.9
+21470,Latvia,2014,24,A-Alimentary tract and metabolism,Million of national currency units,42.6
+21471,Latvia,2014,24,A02A-Antacids,% of total sales,0.1
+21472,Latvia,2014,24,A02A-Antacids,Million of national currency units,0.4
+21473,Latvia,2014,24,Total pharmaceutical sales,Million of national currency units,315.9
+21474,Latvia,2014,24,C09-Agents acting on the Renin-Angiotensin system,% of total sales,6.1
+21475,Latvia,2014,24,C01A-Cardiac glycosides,% of total sales,0.0
+21476,Latvia,2014,24,N05B-Anxiolytics,% of total sales,0.8
+21477,Latvia,2014,24,N-Nervous system,% of total sales,10.7
+21478,Latvia,2014,24,G03-Sex hormones and modulators of the genital system,% of total sales,2.0
+21479,Latvia,2014,24,N06A-Antidepressants,% of total sales,0.7
+21480,Latvia,2014,24,J01-Antibacterials for systemic use,% of total sales,3.1
+21481,Latvia,2014,24,N05C-Hypnotics and sedatives,% of total sales,0.9
+21482,Latvia,2014,24,R03-Drugs for obstructive airway diseases,% of total sales,3.0
+21483,Latvia,2014,24,B-Blood and blood forming organs,% of total sales,7.0
+21484,Latvia,2014,24,A-Alimentary tract and metabolism,% of total sales,13.5
+21485,Latvia,2014,24,C10-Lipid modifying agents,% of total sales,1.8
+21486,Latvia,2014,24,N02-Analgesics,% of total sales,2.3
+21487,Latvia,2014,24,C-Cardiovascular system,% of total sales,17.2
+21488,Latvia,2014,24,M-Musculo-skeletal system,% of total sales,6.6
+21489,Latvia,2014,24,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),% of total sales,1.5
+21490,Latvia,2014,24,"H-Systemic hormonal preparations, excluding sex hormones and insulins",% of total sales,1.8
+21491,Latvia,2014,24,"C01B-Antiarrhythmics, Class I and III",% of total sales,0.2
+21492,Latvia,2014,24,C07-Beta blocking agents,% of total sales,2.4
+21493,Latvia,2014,24,C03-Diuretics,% of total sales,0.7
+21494,Latvia,2014,24,A10-Drugs used in diabetes,% of total sales,5.7
+21495,Latvia,2014,24,R-Respiratory system,% of total sales,7.6
+21496,Latvia,2014,24,M01A-Antiinflammatory and antirheumatic products non-steroids,% of total sales,4.1
+21497,Latvia,2014,24,C02-Antihypertensives,% of total sales,1.0
+21498,Latvia,2014,24,C08-Calcium channel blockers,% of total sales,1.0
+21499,Latvia,2014,24,J-Antiinfectives for systemic use,% of total sales,9.9
+21500,Latvia,2014,24,G-Genito urinary system and sex hormones,% of total sales,4.5
+21501,Latvia,2014,24,M01A-Antiinflammatory and antirheumatic products non-steroids,Million US$ at exchange rate,17.3
+21502,Latvia,2014,24,G-Genito urinary system and sex hormones,"/capita, US$ exchange rate",9.5
+21503,Latvia,2014,24,C10-Lipid modifying agents,"/capita, US$ exchange rate",3.7
+21504,Latvia,2014,24,C01A-Cardiac glycosides,"/capita, US$ purchasing power parity",0.1
+21505,Latvia,2014,24,R03-Drugs for obstructive airway diseases,"Million US$, purchasing power parity",19.2
+21506,Latvia,2014,24,G03-Sex hormones and modulators of the genital system,"/capita, US$ exchange rate",4.1
+21507,Latvia,2014,24,C03-Diuretics,"/capita, US$ purchasing power parity",2.2
+21508,Latvia,2014,24,C07-Beta blocking agents,"/capita, US$ purchasing power parity",7.6
+21509,Latvia,2014,24,C08-Calcium channel blockers,"/capita, US$ purchasing power parity",3.2
+21510,Latvia,2014,24,"C01B-Antiarrhythmics, Class I and III","/capita, US$ purchasing power parity",0.6
+21511,Latvia,2014,24,C02-Antihypertensives,"/capita, US$ purchasing power parity",3.2
+21512,Latvia,2014,24,R-Respiratory system,Million US$ at exchange rate,31.8
+21513,Latvia,2014,24,N06A-Antidepressants,Million US$ at exchange rate,3.0
+21514,Latvia,2014,24,A-Alimentary tract and metabolism,"Million US$, purchasing power parity",85.7
+21515,Latvia,2014,24,Total pharmaceutical sales,"Million US$, purchasing power parity",634.9
+21516,Latvia,2014,24,R03-Drugs for obstructive airway diseases,Million US$ at exchange rate,12.7
+21517,Latvia,2014,24,C-Cardiovascular system,"/capita, US$ purchasing power parity",54.6
+21518,Latvia,2014,24,A-Alimentary tract and metabolism,"/capita, US$ purchasing power parity",43.0
+21519,Latvia,2014,24,A10-Drugs used in diabetes,"/capita, US$ purchasing power parity",18.2
+21520,Latvia,2014,24,B-Blood and blood forming organs,"/capita, US$ purchasing power parity",22.3
+21521,Latvia,2014,24,A02A-Antacids,"/capita, US$ purchasing power parity",0.4
+21522,Latvia,2014,24,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ purchasing power parity",4.9
+21523,Latvia,2014,24,N05C-Hypnotics and sedatives,Million US$ at exchange rate,3.6
+21524,Latvia,2014,24,A02A-Antacids,"/capita, US$ exchange rate",0.3
+21525,Latvia,2014,24,N05B-Anxiolytics,Million US$ at exchange rate,3.4
+21526,Latvia,2014,24,Total pharmaceutical sales,"/capita, US$ exchange rate",210.5
+21527,Latvia,2014,24,A-Alimentary tract and metabolism,"/capita, US$ exchange rate",28.4
+21528,Latvia,2014,24,M-Musculo-skeletal system,Million US$ at exchange rate,27.6
+21529,Latvia,2014,24,J01-Antibacterials for systemic use,Million US$ at exchange rate,13.0
+21530,Latvia,2014,24,N02-Analgesics,Million US$ at exchange rate,9.8
+21531,Latvia,2014,24,N-Nervous system,Million US$ at exchange rate,44.8
+21532,Latvia,2014,24,G-Genito urinary system and sex hormones,"/capita, US$ purchasing power parity",14.4
+21533,Latvia,2014,24,G03-Sex hormones and modulators of the genital system,"/capita, US$ purchasing power parity",6.3
+21534,Latvia,2014,24,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ purchasing power parity",5.8
+21535,Latvia,2014,24,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ purchasing power parity",19.3
+21536,Latvia,2014,24,C10-Lipid modifying agents,"/capita, US$ purchasing power parity",5.7
+21537,Latvia,2014,24,C08-Calcium channel blockers,"/capita, US$ exchange rate",2.1
+21538,Latvia,2014,24,C07-Beta blocking agents,"/capita, US$ exchange rate",5.0
+21539,Latvia,2014,24,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ exchange rate",12.7
+21540,Latvia,2014,24,J-Antiinfectives for systemic use,"/capita, US$ purchasing power parity",31.4
+21541,Latvia,2014,24,J01-Antibacterials for systemic use,"/capita, US$ purchasing power parity",9.9
+21542,Latvia,2014,24,N-Nervous system,"/capita, US$ exchange rate",22.5
+21543,Latvia,2014,24,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ exchange rate",8.7
+21544,Latvia,2014,24,N05B-Anxiolytics,"/capita, US$ exchange rate",1.7
+21545,Latvia,2014,24,N02-Analgesics,"/capita, US$ exchange rate",4.9
+21546,Latvia,2014,24,M01A-Antiinflammatory and antirheumatic products non-steroids,"Million US$, purchasing power parity",26.1
+21547,Latvia,2014,24,M-Musculo-skeletal system,"Million US$, purchasing power parity",41.8
+21548,Latvia,2014,24,M-Musculo-skeletal system,"/capita, US$ exchange rate",13.9
+21549,Latvia,2014,24,N-Nervous system,"Million US$, purchasing power parity",67.7
+21550,Latvia,2014,24,J01-Antibacterials for systemic use,"Million US$, purchasing power parity",19.7
+21551,Latvia,2014,24,N02-Analgesics,"Million US$, purchasing power parity",14.9
+21552,Latvia,2014,24,R03-Drugs for obstructive airway diseases,"/capita, US$ exchange rate",6.4
+21553,Latvia,2014,24,N06A-Antidepressants,"/capita, US$ exchange rate",1.5
+21554,Latvia,2014,24,R-Respiratory system,"/capita, US$ exchange rate",16.0
+21555,Latvia,2014,24,N05C-Hypnotics and sedatives,"/capita, US$ exchange rate",1.8
+21556,Latvia,2014,24,Total pharmaceutical sales,"/capita, US$ purchasing power parity",318.5
+21557,Latvia,2014,24,N05C-Hypnotics and sedatives,"Million US$, purchasing power parity",5.5
+21558,Latvia,2014,24,N05B-Anxiolytics,"Million US$, purchasing power parity",5.2
+21559,Latvia,2014,24,R-Respiratory system,"Million US$, purchasing power parity",48.2
+21560,Latvia,2014,24,N06A-Antidepressants,"Million US$, purchasing power parity",4.6
+21561,Latvia,2014,24,"C01B-Antiarrhythmics, Class I and III","Million US$, purchasing power parity",1.3
+21562,Latvia,2014,24,C01A-Cardiac glycosides,"Million US$, purchasing power parity",0.2
+21563,Latvia,2014,24,C07-Beta blocking agents,"Million US$, purchasing power parity",15.1
+21564,Latvia,2014,24,C03-Diuretics,"Million US$, purchasing power parity",4.4
+21565,Latvia,2014,24,C02-Antihypertensives,"Million US$, purchasing power parity",6.3
+21566,Latvia,2014,24,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"Million US$, purchasing power parity",9.8
+21567,Latvia,2014,24,A02A-Antacids,"Million US$, purchasing power parity",0.8
+21568,Latvia,2014,24,C-Cardiovascular system,"Million US$, purchasing power parity",108.9
+21569,Latvia,2014,24,B-Blood and blood forming organs,"Million US$, purchasing power parity",44.4
+21570,Latvia,2014,24,A10-Drugs used in diabetes,"Million US$, purchasing power parity",36.3
+21571,Latvia,2014,24,G03-Sex hormones and modulators of the genital system,"Million US$, purchasing power parity",12.5
+21572,Latvia,2014,24,J01-Antibacterials for systemic use,"/capita, US$ exchange rate",6.5
+21573,Latvia,2014,24,J-Antiinfectives for systemic use,"/capita, US$ exchange rate",20.7
+21574,Latvia,2014,24,J-Antiinfectives for systemic use,"Million US$, purchasing power parity",62.6
+21575,Latvia,2014,24,"H-Systemic hormonal preparations, excluding sex hormones and insulins","Million US$, purchasing power parity",11.5
+21576,Latvia,2014,24,G-Genito urinary system and sex hormones,"Million US$, purchasing power parity",28.7
+21577,Latvia,2014,24,C09-Agents acting on the Renin-Angiotensin system,"Million US$, purchasing power parity",38.4
+21578,Latvia,2014,24,C08-Calcium channel blockers,"Million US$, purchasing power parity",6.4
+21579,Latvia,2014,24,C10-Lipid modifying agents,"Million US$, purchasing power parity",11.3
+21580,Latvia,2014,24,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ exchange rate",3.8
+21581,Latvia,2014,24,N-Nervous system,Million of national currency units,33.7
+21582,Latvia,2014,24,M01A-Antiinflammatory and antirheumatic products non-steroids,Million of national currency units,13.0
+21583,Latvia,2014,24,N02-Analgesics,Million of national currency units,7.4
+21584,Latvia,2014,24,N05C-Hypnotics and sedatives,Million of national currency units,2.7
+21585,Latvia,2014,24,N05B-Anxiolytics,Million of national currency units,2.6
+21586,Latvia,2014,24,J-Antiinfectives for systemic use,Million of national currency units,31.1
+21587,Latvia,2014,24,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million of national currency units,5.7
+21588,Latvia,2014,24,M-Musculo-skeletal system,Million of national currency units,20.8
+21589,Latvia,2014,24,J01-Antibacterials for systemic use,Million of national currency units,9.8
+21590,Latvia,2014,24,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million US$ at exchange rate,6.4
+21591,Latvia,2014,24,A02A-Antacids,Million US$ at exchange rate,0.5
+21592,Latvia,2014,24,B-Blood and blood forming organs,Million US$ at exchange rate,29.3
+21593,Latvia,2014,24,A10-Drugs used in diabetes,Million US$ at exchange rate,24.0
+21594,Latvia,2014,24,G03-Sex hormones and modulators of the genital system,Million of national currency units,6.2
+21595,Latvia,2014,24,R-Respiratory system,Million of national currency units,24.0
+21596,Latvia,2014,24,N06A-Antidepressants,Million of national currency units,2.3
+21597,Latvia,2014,24,A-Alimentary tract and metabolism,Million US$ at exchange rate,56.6
+21598,Latvia,2014,24,Total pharmaceutical sales,Million US$ at exchange rate,419.7
+21599,Latvia,2014,24,R03-Drugs for obstructive airway diseases,Million of national currency units,9.6
+21600,Latvia,2014,24,C03-Diuretics,"/capita, US$ exchange rate",1.5
+21601,Latvia,2014,24,"C01B-Antiarrhythmics, Class I and III",Million of national currency units,0.6
+21602,Latvia,2014,24,"C01B-Antiarrhythmics, Class I and III","/capita, US$ exchange rate",0.4
+21603,Latvia,2014,24,C02-Antihypertensives,"/capita, US$ exchange rate",2.1
+21604,Latvia,2014,24,C01A-Cardiac glycosides,Million of national currency units,0.1
+21605,Latvia,2014,24,A10-Drugs used in diabetes,Million of national currency units,18.1
+21606,Latvia,2014,24,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million of national currency units,4.9
+21607,Latvia,2014,24,C-Cardiovascular system,Million of national currency units,54.2
+21608,Latvia,2014,24,B-Blood and blood forming organs,Million of national currency units,22.1
+21609,Latvia,2014,24,C01A-Cardiac glycosides,"/capita, US$ exchange rate",0.1
+21610,Latvia,2014,24,C09-Agents acting on the Renin-Angiotensin system,Million of national currency units,19.1
+21611,Latvia,2014,24,C08-Calcium channel blockers,Million of national currency units,3.2
+21612,Latvia,2014,24,G-Genito urinary system and sex hormones,Million of national currency units,14.3
+21613,Latvia,2014,24,C10-Lipid modifying agents,Million of national currency units,5.6
+21614,Latvia,2014,24,C07-Beta blocking agents,Million of national currency units,7.5
+21615,Latvia,2014,24,C-Cardiovascular system,"/capita, US$ exchange rate",36.1
+21616,Latvia,2014,24,C03-Diuretics,Million of national currency units,2.2
+21617,Latvia,2014,24,C02-Antihypertensives,Million of national currency units,3.1
+21618,Latvia,2014,24,C02-Antihypertensives,Million US$ at exchange rate,4.2
+21619,Latvia,2014,24,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ exchange rate",3.2
+21620,Latvia,2014,24,R03-Drugs for obstructive airway diseases,"/capita, US$ purchasing power parity",9.6
+21621,Latvia,2014,24,R-Respiratory system,"/capita, US$ purchasing power parity",24.2
+21622,Latvia,2014,24,C03-Diuretics,Million US$ at exchange rate,2.9
+21623,Latvia,2014,24,C07-Beta blocking agents,Million US$ at exchange rate,10.0
+21624,Latvia,2014,24,A10-Drugs used in diabetes,"/capita, US$ exchange rate",12.0
+21625,Latvia,2014,24,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ purchasing power parity",13.1
+21626,Latvia,2014,24,N-Nervous system,"/capita, US$ purchasing power parity",34.0
+21627,Latvia,2014,24,"C01B-Antiarrhythmics, Class I and III",Million US$ at exchange rate,0.9
+21628,Latvia,2014,24,M-Musculo-skeletal system,"/capita, US$ purchasing power parity",21.0
+21629,Latvia,2014,24,N05C-Hypnotics and sedatives,"/capita, US$ purchasing power parity",2.8
+21630,Latvia,2014,24,N06A-Antidepressants,"/capita, US$ purchasing power parity",2.3
+21631,Latvia,2014,24,N02-Analgesics,"/capita, US$ purchasing power parity",7.4
+21632,Latvia,2014,24,N05B-Anxiolytics,"/capita, US$ purchasing power parity",2.6
+21633,Latvia,2014,24,J-Antiinfectives for systemic use,Million US$ at exchange rate,41.4
+21634,Latvia,2014,24,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million US$ at exchange rate,7.6
+21635,Latvia,2014,24,C-Cardiovascular system,Million US$ at exchange rate,72.0
+21636,Latvia,2014,24,B-Blood and blood forming organs,"/capita, US$ exchange rate",14.7
+21637,Latvia,2014,24,C01A-Cardiac glycosides,Million US$ at exchange rate,0.1
+21638,Latvia,2014,24,C08-Calcium channel blockers,Million US$ at exchange rate,4.2
+21639,Latvia,2014,24,C09-Agents acting on the Renin-Angiotensin system,Million US$ at exchange rate,25.4
+21640,Latvia,2014,24,G-Genito urinary system and sex hormones,Million US$ at exchange rate,19.0
+21641,Latvia,2014,24,C10-Lipid modifying agents,Million US$ at exchange rate,7.5
+21642,Latvia,2014,24,G03-Sex hormones and modulators of the genital system,Million US$ at exchange rate,8.3
+21643,Latvia,2013,27,A-Alimentary tract and metabolism,Million of national currency units,40.5
+21644,Latvia,2013,27,A02A-Antacids,% of total sales,0.1
+21645,Latvia,2013,27,A02A-Antacids,Million of national currency units,0.4
+21646,Latvia,2013,27,C09-Agents acting on the Renin-Angiotensin system,% of total sales,6.3
+21647,Latvia,2013,27,C01A-Cardiac glycosides,% of total sales,0.0
+21648,Latvia,2013,27,Total pharmaceutical sales,Million of national currency units,307.6
+21649,Latvia,2013,27,N05B-Anxiolytics,% of total sales,0.8
+21650,Latvia,2013,27,N05C-Hypnotics and sedatives,% of total sales,0.8
+21651,Latvia,2013,27,G03-Sex hormones and modulators of the genital system,% of total sales,2.0
+21652,Latvia,2013,27,N-Nervous system,% of total sales,10.8
+21653,Latvia,2013,27,J01-Antibacterials for systemic use,% of total sales,3.1
+21654,Latvia,2013,27,R03-Drugs for obstructive airway diseases,% of total sales,3.0
+21655,Latvia,2013,27,B-Blood and blood forming organs,% of total sales,6.7
+21656,Latvia,2013,27,C10-Lipid modifying agents,% of total sales,2.2
+21657,Latvia,2013,27,N02-Analgesics,% of total sales,2.4
+21658,Latvia,2013,27,C-Cardiovascular system,% of total sales,18.0
+21659,Latvia,2013,27,M-Musculo-skeletal system,% of total sales,6.5
+21660,Latvia,2013,27,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),% of total sales,1.5
+21661,Latvia,2013,27,"H-Systemic hormonal preparations, excluding sex hormones and insulins",% of total sales,2.0
+21662,Latvia,2013,27,"C01B-Antiarrhythmics, Class I and III",% of total sales,0.2
+21663,Latvia,2013,27,N06A-Antidepressants,% of total sales,0.7
+21664,Latvia,2013,27,C07-Beta blocking agents,% of total sales,2.4
+21665,Latvia,2013,27,C03-Diuretics,% of total sales,0.7
+21666,Latvia,2013,27,A10-Drugs used in diabetes,% of total sales,5.6
+21667,Latvia,2013,27,R-Respiratory system,% of total sales,7.6
+21668,Latvia,2013,27,A-Alimentary tract and metabolism,% of total sales,13.2
+21669,Latvia,2013,27,M01A-Antiinflammatory and antirheumatic products non-steroids,% of total sales,4.0
+21670,Latvia,2013,27,C02-Antihypertensives,% of total sales,1.0
+21671,Latvia,2013,27,C08-Calcium channel blockers,% of total sales,1.1
+21672,Latvia,2013,27,J-Antiinfectives for systemic use,% of total sales,10.4
+21673,Latvia,2013,27,G-Genito urinary system and sex hormones,% of total sales,4.5
+21674,Latvia,2013,27,G-Genito urinary system and sex hormones,"/capita, US$ exchange rate",9.1
+21675,Latvia,2013,27,C10-Lipid modifying agents,"/capita, US$ exchange rate",4.5
+21676,Latvia,2013,27,C01A-Cardiac glycosides,"/capita, US$ purchasing power parity",0.1
+21677,Latvia,2013,27,G03-Sex hormones and modulators of the genital system,"/capita, US$ exchange rate",4.0
+21678,Latvia,2013,27,C07-Beta blocking agents,"/capita, US$ purchasing power parity",7.2
+21679,Latvia,2013,27,C03-Diuretics,"/capita, US$ purchasing power parity",2.2
+21680,Latvia,2013,27,C08-Calcium channel blockers,"/capita, US$ purchasing power parity",3.4
+21681,Latvia,2013,27,"C01B-Antiarrhythmics, Class I and III","/capita, US$ purchasing power parity",0.6
+21682,Latvia,2013,27,C02-Antihypertensives,"/capita, US$ purchasing power parity",3.0
+21683,Latvia,2013,27,C-Cardiovascular system,"/capita, US$ purchasing power parity",55.0
+21684,Latvia,2013,27,R-Respiratory system,Million US$ at exchange rate,30.9
+21685,Latvia,2013,27,N06A-Antidepressants,Million US$ at exchange rate,3.0
+21686,Latvia,2013,27,A-Alimentary tract and metabolism,"Million US$, purchasing power parity",81.2
+21687,Latvia,2013,27,Total pharmaceutical sales,"Million US$, purchasing power parity",616.0
+21688,Latvia,2013,27,R03-Drugs for obstructive airway diseases,Million US$ at exchange rate,12.4
+21689,Latvia,2013,27,A10-Drugs used in diabetes,"/capita, US$ purchasing power parity",17.2
+21690,Latvia,2013,27,B-Blood and blood forming organs,"/capita, US$ purchasing power parity",20.4
+21691,Latvia,2013,27,A02A-Antacids,"/capita, US$ purchasing power parity",0.4
+21692,Latvia,2013,27,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ purchasing power parity",4.6
+21693,Latvia,2013,27,N05C-Hypnotics and sedatives,Million US$ at exchange rate,3.5
+21694,Latvia,2013,27,N05B-Anxiolytics,Million US$ at exchange rate,3.2
+21695,Latvia,2013,27,A02A-Antacids,"/capita, US$ exchange rate",0.3
+21696,Latvia,2013,27,Total pharmaceutical sales,"/capita, US$ exchange rate",202.9
+21697,Latvia,2013,27,A-Alimentary tract and metabolism,"/capita, US$ exchange rate",26.7
+21698,Latvia,2013,27,M-Musculo-skeletal system,Million US$ at exchange rate,26.7
+21699,Latvia,2013,27,M01A-Antiinflammatory and antirheumatic products non-steroids,Million US$ at exchange rate,16.4
+21700,Latvia,2013,27,J01-Antibacterials for systemic use,Million US$ at exchange rate,12.7
+21701,Latvia,2013,27,N02-Analgesics,Million US$ at exchange rate,9.9
+21702,Latvia,2013,27,N-Nervous system,Million US$ at exchange rate,44.2
+21703,Latvia,2013,27,G03-Sex hormones and modulators of the genital system,"/capita, US$ purchasing power parity",6.1
+21704,Latvia,2013,27,G-Genito urinary system and sex hormones,"/capita, US$ purchasing power parity",13.8
+21705,Latvia,2013,27,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ purchasing power parity",6.1
+21706,Latvia,2013,27,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ purchasing power parity",19.4
+21707,Latvia,2013,27,C10-Lipid modifying agents,"/capita, US$ purchasing power parity",6.8
+21708,Latvia,2013,27,C08-Calcium channel blockers,"/capita, US$ exchange rate",2.3
+21709,Latvia,2013,27,C07-Beta blocking agents,"/capita, US$ exchange rate",4.8
+21710,Latvia,2013,27,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ exchange rate",12.8
+21711,Latvia,2013,27,J-Antiinfectives for systemic use,"/capita, US$ purchasing power parity",31.8
+21712,Latvia,2013,27,J01-Antibacterials for systemic use,"/capita, US$ purchasing power parity",9.5
+21713,Latvia,2013,27,R03-Drugs for obstructive airway diseases,"Million US$, purchasing power parity",18.7
+21714,Latvia,2013,27,N-Nervous system,"/capita, US$ exchange rate",22.0
+21715,Latvia,2013,27,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ exchange rate",8.1
+21716,Latvia,2013,27,N05B-Anxiolytics,"/capita, US$ exchange rate",1.6
+21717,Latvia,2013,27,N02-Analgesics,"/capita, US$ exchange rate",4.9
+21718,Latvia,2013,27,M01A-Antiinflammatory and antirheumatic products non-steroids,"Million US$, purchasing power parity",24.7
+21719,Latvia,2013,27,M-Musculo-skeletal system,"Million US$, purchasing power parity",40.2
+21720,Latvia,2013,27,M-Musculo-skeletal system,"/capita, US$ exchange rate",13.2
+21721,Latvia,2013,27,N-Nervous system,"Million US$, purchasing power parity",66.7
+21722,Latvia,2013,27,Total pharmaceutical sales,"/capita, US$ purchasing power parity",306.1
+21723,Latvia,2013,27,R03-Drugs for obstructive airway diseases,"/capita, US$ exchange rate",6.2
+21724,Latvia,2013,27,N06A-Antidepressants,"/capita, US$ exchange rate",1.5
+21725,Latvia,2013,27,R-Respiratory system,"/capita, US$ exchange rate",15.3
+21726,Latvia,2013,27,N05C-Hypnotics and sedatives,"/capita, US$ exchange rate",1.7
+21727,Latvia,2013,27,N02-Analgesics,"Million US$, purchasing power parity",14.9
+21728,Latvia,2013,27,N05C-Hypnotics and sedatives,"Million US$, purchasing power parity",5.2
+21729,Latvia,2013,27,N05B-Anxiolytics,"Million US$, purchasing power parity",4.9
+21730,Latvia,2013,27,A-Alimentary tract and metabolism,"/capita, US$ purchasing power parity",40.3
+21731,Latvia,2013,27,R-Respiratory system,"Million US$, purchasing power parity",46.6
+21732,Latvia,2013,27,N06A-Antidepressants,"Million US$, purchasing power parity",4.5
+21733,Latvia,2013,27,J01-Antibacterials for systemic use,"Million US$, purchasing power parity",19.1
+21734,Latvia,2013,27,"C01B-Antiarrhythmics, Class I and III","Million US$, purchasing power parity",1.2
+21735,Latvia,2013,27,C01A-Cardiac glycosides,"Million US$, purchasing power parity",0.2
+21736,Latvia,2013,27,C07-Beta blocking agents,"Million US$, purchasing power parity",14.5
+21737,Latvia,2013,27,C03-Diuretics,"Million US$, purchasing power parity",4.4
+21738,Latvia,2013,27,C02-Antihypertensives,"Million US$, purchasing power parity",6.1
+21739,Latvia,2013,27,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"Million US$, purchasing power parity",9.3
+21740,Latvia,2013,27,A02A-Antacids,"Million US$, purchasing power parity",0.8
+21741,Latvia,2013,27,C-Cardiovascular system,"Million US$, purchasing power parity",110.6
+21742,Latvia,2013,27,B-Blood and blood forming organs,"Million US$, purchasing power parity",41.1
+21743,Latvia,2013,27,A10-Drugs used in diabetes,"Million US$, purchasing power parity",34.5
+21744,Latvia,2013,27,G03-Sex hormones and modulators of the genital system,"Million US$, purchasing power parity",12.2
+21745,Latvia,2013,27,J01-Antibacterials for systemic use,"/capita, US$ exchange rate",6.3
+21746,Latvia,2013,27,J-Antiinfectives for systemic use,"/capita, US$ exchange rate",21.1
+21747,Latvia,2013,27,J-Antiinfectives for systemic use,"Million US$, purchasing power parity",64.0
+21748,Latvia,2013,27,"H-Systemic hormonal preparations, excluding sex hormones and insulins","Million US$, purchasing power parity",12.3
+21749,Latvia,2013,27,G-Genito urinary system and sex hormones,"Million US$, purchasing power parity",27.7
+21750,Latvia,2013,27,C09-Agents acting on the Renin-Angiotensin system,"Million US$, purchasing power parity",39.0
+21751,Latvia,2013,27,C08-Calcium channel blockers,"Million US$, purchasing power parity",6.9
+21752,Latvia,2013,27,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ exchange rate",4.0
+21753,Latvia,2013,27,C10-Lipid modifying agents,"Million US$, purchasing power parity",13.7
+21754,Latvia,2013,27,N02-Analgesics,Million of national currency units,7.4
+21755,Latvia,2013,27,N-Nervous system,Million of national currency units,33.3
+21756,Latvia,2013,27,M01A-Antiinflammatory and antirheumatic products non-steroids,Million of national currency units,12.3
+21757,Latvia,2013,27,N05C-Hypnotics and sedatives,Million of national currency units,2.6
+21758,Latvia,2013,27,N05B-Anxiolytics,Million of national currency units,2.4
+21759,Latvia,2013,27,J-Antiinfectives for systemic use,Million of national currency units,32.0
+21760,Latvia,2013,27,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million of national currency units,6.1
+21761,Latvia,2013,27,M-Musculo-skeletal system,Million of national currency units,20.1
+21762,Latvia,2013,27,J01-Antibacterials for systemic use,Million of national currency units,9.5
+21763,Latvia,2013,27,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million US$ at exchange rate,6.2
+21764,Latvia,2013,27,A02A-Antacids,Million US$ at exchange rate,0.5
+21765,Latvia,2013,27,B-Blood and blood forming organs,Million US$ at exchange rate,27.2
+21766,Latvia,2013,27,A10-Drugs used in diabetes,Million US$ at exchange rate,22.9
+21767,Latvia,2013,27,R-Respiratory system,Million of national currency units,23.3
+21768,Latvia,2013,27,N06A-Antidepressants,Million of national currency units,2.2
+21769,Latvia,2013,27,R03-Drugs for obstructive airway diseases,Million of national currency units,9.3
+21770,Latvia,2013,27,A-Alimentary tract and metabolism,Million US$ at exchange rate,53.8
+21771,Latvia,2013,27,Total pharmaceutical sales,Million US$ at exchange rate,408.3
+21772,Latvia,2013,27,G03-Sex hormones and modulators of the genital system,Million of national currency units,6.1
+21773,Latvia,2013,27,C03-Diuretics,"/capita, US$ exchange rate",1.4
+21774,Latvia,2013,27,"C01B-Antiarrhythmics, Class I and III",Million of national currency units,0.6
+21775,Latvia,2013,27,"C01B-Antiarrhythmics, Class I and III","/capita, US$ exchange rate",0.4
+21776,Latvia,2013,27,C02-Antihypertensives,"/capita, US$ exchange rate",2.0
+21777,Latvia,2013,27,C01A-Cardiac glycosides,Million of national currency units,0.1
+21778,Latvia,2013,27,A10-Drugs used in diabetes,Million of national currency units,17.2
+21779,Latvia,2013,27,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million of national currency units,4.7
+21780,Latvia,2013,27,C-Cardiovascular system,Million of national currency units,55.2
+21781,Latvia,2013,27,B-Blood and blood forming organs,Million of national currency units,20.5
+21782,Latvia,2013,27,C01A-Cardiac glycosides,"/capita, US$ exchange rate",0.1
+21783,Latvia,2013,27,C09-Agents acting on the Renin-Angiotensin system,Million of national currency units,19.5
+21784,Latvia,2013,27,C08-Calcium channel blockers,Million of national currency units,3.4
+21785,Latvia,2013,27,G-Genito urinary system and sex hormones,Million of national currency units,13.8
+21786,Latvia,2013,27,C10-Lipid modifying agents,Million of national currency units,6.9
+21787,Latvia,2013,27,C-Cardiovascular system,"/capita, US$ exchange rate",36.4
+21788,Latvia,2013,27,C07-Beta blocking agents,Million of national currency units,7.2
+21789,Latvia,2013,27,C03-Diuretics,Million of national currency units,2.2
+21790,Latvia,2013,27,C02-Antihypertensives,Million of national currency units,3.0
+21791,Latvia,2013,27,C-Cardiovascular system,Million US$ at exchange rate,73.3
+21792,Latvia,2013,27,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ exchange rate",3.1
+21793,Latvia,2013,27,C02-Antihypertensives,Million US$ at exchange rate,4.0
+21794,Latvia,2013,27,R-Respiratory system,"/capita, US$ purchasing power parity",23.2
+21795,Latvia,2013,27,R03-Drugs for obstructive airway diseases,"/capita, US$ purchasing power parity",9.3
+21796,Latvia,2013,27,C03-Diuretics,Million US$ at exchange rate,2.9
+21797,Latvia,2013,27,C07-Beta blocking agents,Million US$ at exchange rate,9.6
+21798,Latvia,2013,27,A10-Drugs used in diabetes,"/capita, US$ exchange rate",11.4
+21799,Latvia,2013,27,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ purchasing power parity",12.3
+21800,Latvia,2013,27,N-Nervous system,"/capita, US$ purchasing power parity",33.1
+21801,Latvia,2013,27,"C01B-Antiarrhythmics, Class I and III",Million US$ at exchange rate,0.8
+21802,Latvia,2013,27,M-Musculo-skeletal system,"/capita, US$ purchasing power parity",20.0
+21803,Latvia,2013,27,N05C-Hypnotics and sedatives,"/capita, US$ purchasing power parity",2.6
+21804,Latvia,2013,27,N06A-Antidepressants,"/capita, US$ purchasing power parity",2.2
+21805,Latvia,2013,27,N02-Analgesics,"/capita, US$ purchasing power parity",7.4
+21806,Latvia,2013,27,N05B-Anxiolytics,"/capita, US$ purchasing power parity",2.4
+21807,Latvia,2013,27,J-Antiinfectives for systemic use,Million US$ at exchange rate,42.4
+21808,Latvia,2013,27,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million US$ at exchange rate,8.1
+21809,Latvia,2013,27,C01A-Cardiac glycosides,Million US$ at exchange rate,0.1
+21810,Latvia,2013,27,B-Blood and blood forming organs,"/capita, US$ exchange rate",13.5
+21811,Latvia,2013,27,C08-Calcium channel blockers,Million US$ at exchange rate,4.6
+21812,Latvia,2013,27,C09-Agents acting on the Renin-Angiotensin system,Million US$ at exchange rate,25.8
+21813,Latvia,2013,27,G-Genito urinary system and sex hormones,Million US$ at exchange rate,18.4
+21814,Latvia,2013,27,G03-Sex hormones and modulators of the genital system,Million US$ at exchange rate,8.1
+21815,Latvia,2013,27,C10-Lipid modifying agents,Million US$ at exchange rate,9.1
+21816,Latvia,2012,23,A-Alimentary tract and metabolism,Million of national currency units,38.9
+21817,Latvia,2012,23,A02A-Antacids,Million of national currency units,0.4
+21818,Latvia,2012,23,A02A-Antacids,% of total sales,0.1
+21819,Latvia,2012,23,C09-Agents acting on the Renin-Angiotensin system,% of total sales,6.4
+21820,Latvia,2012,23,C01A-Cardiac glycosides,% of total sales,0.0
+21821,Latvia,2012,23,Total pharmaceutical sales,Million of national currency units,295.4
+21822,Latvia,2012,23,N05B-Anxiolytics,% of total sales,0.8
+21823,Latvia,2012,23,G03-Sex hormones and modulators of the genital system,% of total sales,2.0
+21824,Latvia,2012,23,N-Nervous system,% of total sales,11.3
+21825,Latvia,2012,23,N05C-Hypnotics and sedatives,% of total sales,0.8
+21826,Latvia,2012,23,J01-Antibacterials for systemic use,% of total sales,3.2
+21827,Latvia,2012,23,R03-Drugs for obstructive airway diseases,% of total sales,3.1
+21828,Latvia,2012,23,B-Blood and blood forming organs,% of total sales,6.6
+21829,Latvia,2012,23,C10-Lipid modifying agents,% of total sales,2.6
+21830,Latvia,2012,23,N02-Analgesics,% of total sales,2.5
+21831,Latvia,2012,23,C-Cardiovascular system,% of total sales,18.6
+21832,Latvia,2012,23,M-Musculo-skeletal system,% of total sales,6.6
+21833,Latvia,2012,23,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),% of total sales,1.6
+21834,Latvia,2012,23,"H-Systemic hormonal preparations, excluding sex hormones and insulins",% of total sales,1.9
+21835,Latvia,2012,23,C07-Beta blocking agents,% of total sales,2.4
+21836,Latvia,2012,23,"C01B-Antiarrhythmics, Class I and III",% of total sales,0.2
+21837,Latvia,2012,23,N06A-Antidepressants,% of total sales,0.8
+21838,Latvia,2012,23,R-Respiratory system,% of total sales,7.6
+21839,Latvia,2012,23,C03-Diuretics,% of total sales,0.7
+21840,Latvia,2012,23,A-Alimentary tract and metabolism,% of total sales,13.2
+21841,Latvia,2012,23,M01A-Antiinflammatory and antirheumatic products non-steroids,% of total sales,3.9
+21842,Latvia,2012,23,A10-Drugs used in diabetes,% of total sales,5.7
+21843,Latvia,2012,23,C02-Antihypertensives,% of total sales,1.0
+21844,Latvia,2012,23,C08-Calcium channel blockers,% of total sales,1.2
+21845,Latvia,2012,23,J-Antiinfectives for systemic use,% of total sales,9.9
+21846,Latvia,2012,23,G-Genito urinary system and sex hormones,% of total sales,4.4
+21847,Latvia,2012,23,G-Genito urinary system and sex hormones,"/capita, US$ exchange rate",8.3
+21848,Latvia,2012,23,C10-Lipid modifying agents,"/capita, US$ exchange rate",4.8
+21849,Latvia,2012,23,C01A-Cardiac glycosides,"/capita, US$ purchasing power parity",0.1
+21850,Latvia,2012,23,G03-Sex hormones and modulators of the genital system,"/capita, US$ exchange rate",3.7
+21851,Latvia,2012,23,C07-Beta blocking agents,"/capita, US$ purchasing power parity",6.8
+21852,Latvia,2012,23,C08-Calcium channel blockers,"/capita, US$ purchasing power parity",3.6
+21853,Latvia,2012,23,C03-Diuretics,"/capita, US$ purchasing power parity",2.1
+21854,Latvia,2012,23,"C01B-Antiarrhythmics, Class I and III","/capita, US$ purchasing power parity",0.5
+21855,Latvia,2012,23,C02-Antihypertensives,"/capita, US$ purchasing power parity",2.9
+21856,Latvia,2012,23,R-Respiratory system,Million US$ at exchange rate,28.7
+21857,Latvia,2012,23,N06A-Antidepressants,Million US$ at exchange rate,2.9
+21858,Latvia,2012,23,A-Alimentary tract and metabolism,"Million US$, purchasing power parity",76.8
+21859,Latvia,2012,23,Total pharmaceutical sales,"Million US$, purchasing power parity",583.5
+21860,Latvia,2012,23,R03-Drugs for obstructive airway diseases,Million US$ at exchange rate,11.7
+21861,Latvia,2012,23,A10-Drugs used in diabetes,"/capita, US$ purchasing power parity",16.2
+21862,Latvia,2012,23,C-Cardiovascular system,"/capita, US$ purchasing power parity",53.5
+21863,Latvia,2012,23,B-Blood and blood forming organs,"/capita, US$ purchasing power parity",19.0
+21864,Latvia,2012,23,A02A-Antacids,"/capita, US$ purchasing power parity",0.4
+21865,Latvia,2012,23,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ purchasing power parity",4.5
+21866,Latvia,2012,23,N05C-Hypnotics and sedatives,Million US$ at exchange rate,3.2
+21867,Latvia,2012,23,N05B-Anxiolytics,Million US$ at exchange rate,3.0
+21868,Latvia,2012,23,A02A-Antacids,"/capita, US$ exchange rate",0.3
+21869,Latvia,2012,23,Total pharmaceutical sales,"/capita, US$ exchange rate",186.6
+21870,Latvia,2012,23,A-Alimentary tract and metabolism,"/capita, US$ exchange rate",24.6
+21871,Latvia,2012,23,M01A-Antiinflammatory and antirheumatic products non-steroids,Million US$ at exchange rate,14.8
+21872,Latvia,2012,23,M-Musculo-skeletal system,Million US$ at exchange rate,24.9
+21873,Latvia,2012,23,J01-Antibacterials for systemic use,Million US$ at exchange rate,12.2
+21874,Latvia,2012,23,N02-Analgesics,Million US$ at exchange rate,9.4
+21875,Latvia,2012,23,N-Nervous system,Million US$ at exchange rate,43.0
+21876,Latvia,2012,23,G03-Sex hormones and modulators of the genital system,"/capita, US$ purchasing power parity",5.7
+21877,Latvia,2012,23,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ purchasing power parity",5.3
+21878,Latvia,2012,23,G-Genito urinary system and sex hormones,"/capita, US$ purchasing power parity",12.8
+21879,Latvia,2012,23,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ purchasing power parity",18.5
+21880,Latvia,2012,23,C10-Lipid modifying agents,"/capita, US$ purchasing power parity",7.4
+21881,Latvia,2012,23,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ exchange rate",12.0
+21882,Latvia,2012,23,C08-Calcium channel blockers,"/capita, US$ exchange rate",2.3
+21883,Latvia,2012,23,C07-Beta blocking agents,"/capita, US$ exchange rate",4.4
+21884,Latvia,2012,23,J-Antiinfectives for systemic use,"/capita, US$ purchasing power parity",28.4
+21885,Latvia,2012,23,J01-Antibacterials for systemic use,"/capita, US$ purchasing power parity",9.2
+21886,Latvia,2012,23,R03-Drugs for obstructive airway diseases,"Million US$, purchasing power parity",18.0
+21887,Latvia,2012,23,N-Nervous system,"/capita, US$ exchange rate",21.2
+21888,Latvia,2012,23,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ exchange rate",7.3
+21889,Latvia,2012,23,N05B-Anxiolytics,"/capita, US$ exchange rate",1.5
+21890,Latvia,2012,23,N02-Analgesics,"/capita, US$ exchange rate",4.6
+21891,Latvia,2012,23,M01A-Antiinflammatory and antirheumatic products non-steroids,"Million US$, purchasing power parity",22.8
+21892,Latvia,2012,23,M-Musculo-skeletal system,"Million US$, purchasing power parity",38.3
+21893,Latvia,2012,23,M-Musculo-skeletal system,"/capita, US$ exchange rate",12.2
+21894,Latvia,2012,23,N-Nervous system,"Million US$, purchasing power parity",66.2
+21895,Latvia,2012,23,N02-Analgesics,"Million US$, purchasing power parity",14.5
+21896,Latvia,2012,23,R03-Drugs for obstructive airway diseases,"/capita, US$ exchange rate",5.7
+21897,Latvia,2012,23,Total pharmaceutical sales,"/capita, US$ purchasing power parity",286.8
+21898,Latvia,2012,23,N05C-Hypnotics and sedatives,"/capita, US$ exchange rate",1.6
+21899,Latvia,2012,23,N06A-Antidepressants,"/capita, US$ exchange rate",1.4
+21900,Latvia,2012,23,R-Respiratory system,"/capita, US$ exchange rate",14.1
+21901,Latvia,2012,23,N05C-Hypnotics and sedatives,"Million US$, purchasing power parity",4.9
+21902,Latvia,2012,23,N05B-Anxiolytics,"Million US$, purchasing power parity",4.7
+21903,Latvia,2012,23,A-Alimentary tract and metabolism,"/capita, US$ purchasing power parity",37.7
+21904,Latvia,2012,23,R-Respiratory system,"Million US$, purchasing power parity",44.1
+21905,Latvia,2012,23,N06A-Antidepressants,"Million US$, purchasing power parity",4.5
+21906,Latvia,2012,23,J01-Antibacterials for systemic use,"Million US$, purchasing power parity",18.8
+21907,Latvia,2012,23,"C01B-Antiarrhythmics, Class I and III","Million US$, purchasing power parity",1.0
+21908,Latvia,2012,23,C01A-Cardiac glycosides,"Million US$, purchasing power parity",0.2
+21909,Latvia,2012,23,C07-Beta blocking agents,"Million US$, purchasing power parity",13.9
+21910,Latvia,2012,23,C03-Diuretics,"Million US$, purchasing power parity",4.3
+21911,Latvia,2012,23,C02-Antihypertensives,"Million US$, purchasing power parity",5.8
+21912,Latvia,2012,23,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"Million US$, purchasing power parity",9.1
+21913,Latvia,2012,23,A02A-Antacids,"Million US$, purchasing power parity",0.8
+21914,Latvia,2012,23,C-Cardiovascular system,"Million US$, purchasing power parity",108.8
+21915,Latvia,2012,23,B-Blood and blood forming organs,"Million US$, purchasing power parity",38.6
+21916,Latvia,2012,23,A10-Drugs used in diabetes,"Million US$, purchasing power parity",33.0
+21917,Latvia,2012,23,G03-Sex hormones and modulators of the genital system,"Million US$, purchasing power parity",11.6
+21918,Latvia,2012,23,J01-Antibacterials for systemic use,"/capita, US$ exchange rate",6.0
+21919,Latvia,2012,23,J-Antiinfectives for systemic use,"Million US$, purchasing power parity",57.8
+21920,Latvia,2012,23,"H-Systemic hormonal preparations, excluding sex hormones and insulins","Million US$, purchasing power parity",10.8
+21921,Latvia,2012,23,C09-Agents acting on the Renin-Angiotensin system,"Million US$, purchasing power parity",37.6
+21922,Latvia,2012,23,C08-Calcium channel blockers,"Million US$, purchasing power parity",7.3
+21923,Latvia,2012,23,C10-Lipid modifying agents,"Million US$, purchasing power parity",15.0
+21924,Latvia,2012,23,G-Genito urinary system and sex hormones,"Million US$, purchasing power parity",25.9
+21925,Latvia,2012,23,J-Antiinfectives for systemic use,"/capita, US$ exchange rate",18.5
+21926,Latvia,2012,23,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ exchange rate",3.5
+21927,Latvia,2012,23,N02-Analgesics,Million of national currency units,7.3
+21928,Latvia,2012,23,N-Nervous system,Million of national currency units,33.5
+21929,Latvia,2012,23,N05C-Hypnotics and sedatives,Million of national currency units,2.5
+21930,Latvia,2012,23,N05B-Anxiolytics,Million of national currency units,2.4
+21931,Latvia,2012,23,M01A-Antiinflammatory and antirheumatic products non-steroids,Million of national currency units,11.6
+21932,Latvia,2012,23,J-Antiinfectives for systemic use,Million of national currency units,29.3
+21933,Latvia,2012,23,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million of national currency units,5.5
+21934,Latvia,2012,23,M-Musculo-skeletal system,Million of national currency units,19.4
+21935,Latvia,2012,23,J01-Antibacterials for systemic use,Million of national currency units,9.5
+21936,Latvia,2012,23,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million US$ at exchange rate,5.9
+21937,Latvia,2012,23,A02A-Antacids,Million US$ at exchange rate,0.5
+21938,Latvia,2012,23,B-Blood and blood forming organs,Million US$ at exchange rate,25.1
+21939,Latvia,2012,23,A10-Drugs used in diabetes,Million US$ at exchange rate,21.5
+21940,Latvia,2012,23,R-Respiratory system,Million of national currency units,22.3
+21941,Latvia,2012,23,N06A-Antidepressants,Million of national currency units,2.3
+21942,Latvia,2012,23,A-Alimentary tract and metabolism,Million US$ at exchange rate,49.9
+21943,Latvia,2012,23,Total pharmaceutical sales,Million US$ at exchange rate,379.6
+21944,Latvia,2012,23,R03-Drugs for obstructive airway diseases,Million of national currency units,9.1
+21945,Latvia,2012,23,C-Cardiovascular system,Million US$ at exchange rate,70.8
+21946,Latvia,2012,23,C03-Diuretics,"/capita, US$ exchange rate",1.4
+21947,Latvia,2012,23,"C01B-Antiarrhythmics, Class I and III",Million of national currency units,0.5
+21948,Latvia,2012,23,"C01B-Antiarrhythmics, Class I and III","/capita, US$ exchange rate",0.3
+21949,Latvia,2012,23,C02-Antihypertensives,"/capita, US$ exchange rate",1.9
+21950,Latvia,2012,23,C01A-Cardiac glycosides,Million of national currency units,0.1
+21951,Latvia,2012,23,A10-Drugs used in diabetes,Million of national currency units,16.7
+21952,Latvia,2012,23,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million of national currency units,4.6
+21953,Latvia,2012,23,C-Cardiovascular system,Million of national currency units,55.1
+21954,Latvia,2012,23,B-Blood and blood forming organs,Million of national currency units,19.5
+21955,Latvia,2012,23,C09-Agents acting on the Renin-Angiotensin system,Million of national currency units,19.0
+21956,Latvia,2012,23,C08-Calcium channel blockers,Million of national currency units,3.7
+21957,Latvia,2012,23,G-Genito urinary system and sex hormones,Million of national currency units,13.1
+21958,Latvia,2012,23,C10-Lipid modifying agents,Million of national currency units,7.6
+21959,Latvia,2012,23,G03-Sex hormones and modulators of the genital system,Million of national currency units,5.9
+21960,Latvia,2012,23,C-Cardiovascular system,"/capita, US$ exchange rate",34.8
+21961,Latvia,2012,23,C01A-Cardiac glycosides,"/capita, US$ exchange rate",0.1
+21962,Latvia,2012,23,C02-Antihypertensives,Million of national currency units,3.0
+21963,Latvia,2012,23,C07-Beta blocking agents,Million of national currency units,7.0
+21964,Latvia,2012,23,C03-Diuretics,Million of national currency units,2.2
+21965,Latvia,2012,23,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ exchange rate",2.9
+21966,Latvia,2012,23,C02-Antihypertensives,Million US$ at exchange rate,3.8
+21967,Latvia,2012,23,R-Respiratory system,"/capita, US$ purchasing power parity",21.7
+21968,Latvia,2012,23,R03-Drugs for obstructive airway diseases,"/capita, US$ purchasing power parity",8.8
+21969,Latvia,2012,23,C03-Diuretics,Million US$ at exchange rate,2.8
+21970,Latvia,2012,23,C07-Beta blocking agents,Million US$ at exchange rate,9.0
+21971,Latvia,2012,23,A10-Drugs used in diabetes,"/capita, US$ exchange rate",10.6
+21972,Latvia,2012,23,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ purchasing power parity",11.2
+21973,Latvia,2012,23,N-Nervous system,"/capita, US$ purchasing power parity",32.5
+21974,Latvia,2012,23,"C01B-Antiarrhythmics, Class I and III",Million US$ at exchange rate,0.7
+21975,Latvia,2012,23,M-Musculo-skeletal system,"/capita, US$ purchasing power parity",18.8
+21976,Latvia,2012,23,N05C-Hypnotics and sedatives,"/capita, US$ purchasing power parity",2.4
+21977,Latvia,2012,23,N06A-Antidepressants,"/capita, US$ purchasing power parity",2.2
+21978,Latvia,2012,23,N02-Analgesics,"/capita, US$ purchasing power parity",7.1
+21979,Latvia,2012,23,N05B-Anxiolytics,"/capita, US$ purchasing power parity",2.3
+21980,Latvia,2012,23,J-Antiinfectives for systemic use,Million US$ at exchange rate,37.6
+21981,Latvia,2012,23,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million US$ at exchange rate,7.0
+21982,Latvia,2012,23,C01A-Cardiac glycosides,Million US$ at exchange rate,0.1
+21983,Latvia,2012,23,B-Blood and blood forming organs,"/capita, US$ exchange rate",12.3
+21984,Latvia,2012,23,C10-Lipid modifying agents,Million US$ at exchange rate,9.8
+21985,Latvia,2012,23,C08-Calcium channel blockers,Million US$ at exchange rate,4.7
+21986,Latvia,2012,23,C09-Agents acting on the Renin-Angiotensin system,Million US$ at exchange rate,24.5
+21987,Latvia,2012,23,G-Genito urinary system and sex hormones,Million US$ at exchange rate,16.9
+21988,Latvia,2012,23,G03-Sex hormones and modulators of the genital system,Million US$ at exchange rate,7.5
+21989,Latvia,2011,26,A-Alimentary tract and metabolism,Million of national currency units,38.1
+21990,Latvia,2011,26,A02A-Antacids,Million of national currency units,0.4
+21991,Latvia,2011,26,C01A-Cardiac glycosides,% of total sales,0.0
+21992,Latvia,2011,26,C09-Agents acting on the Renin-Angiotensin system,% of total sales,6.3
+21993,Latvia,2011,26,Total pharmaceutical sales,Million of national currency units,289.9
+21994,Latvia,2011,26,N05B-Anxiolytics,% of total sales,0.8
+21995,Latvia,2011,26,G03-Sex hormones and modulators of the genital system,% of total sales,2.0
+21996,Latvia,2011,26,N-Nervous system,% of total sales,11.6
+21997,Latvia,2011,26,A02A-Antacids,% of total sales,0.1
+21998,Latvia,2011,26,J01-Antibacterials for systemic use,% of total sales,3.3
+21999,Latvia,2011,26,R03-Drugs for obstructive airway diseases,% of total sales,3.1
+22000,Latvia,2011,26,B-Blood and blood forming organs,% of total sales,6.5
+22001,Latvia,2011,26,J-Antiinfectives for systemic use,% of total sales,9.2
+22002,Latvia,2011,26,N02-Analgesics,% of total sales,2.6
+22003,Latvia,2011,26,N05C-Hypnotics and sedatives,% of total sales,0.9
+22004,Latvia,2011,26,C10-Lipid modifying agents,% of total sales,2.7
+22005,Latvia,2011,26,C-Cardiovascular system,% of total sales,18.6
+22006,Latvia,2011,26,M-Musculo-skeletal system,% of total sales,6.6
+22007,Latvia,2011,26,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),% of total sales,1.5
+22008,Latvia,2011,26,"H-Systemic hormonal preparations, excluding sex hormones and insulins",% of total sales,1.7
+22009,Latvia,2011,26,"C01B-Antiarrhythmics, Class I and III",% of total sales,0.2
+22010,Latvia,2011,26,C07-Beta blocking agents,% of total sales,2.4
+22011,Latvia,2011,26,N06A-Antidepressants,% of total sales,0.8
+22012,Latvia,2011,26,R-Respiratory system,% of total sales,7.4
+22013,Latvia,2011,26,C03-Diuretics,% of total sales,0.7
+22014,Latvia,2011,26,A-Alimentary tract and metabolism,% of total sales,13.1
+22015,Latvia,2011,26,M01A-Antiinflammatory and antirheumatic products non-steroids,% of total sales,3.9
+22016,Latvia,2011,26,A10-Drugs used in diabetes,% of total sales,5.8
+22017,Latvia,2011,26,C02-Antihypertensives,% of total sales,1.0
+22018,Latvia,2011,26,C08-Calcium channel blockers,% of total sales,1.3
+22019,Latvia,2011,26,G-Genito urinary system and sex hormones,% of total sales,4.5
+22020,Latvia,2011,26,G-Genito urinary system and sex hormones,"/capita, US$ exchange rate",8.8
+22021,Latvia,2011,26,C10-Lipid modifying agents,"/capita, US$ exchange rate",5.2
+22022,Latvia,2011,26,C01A-Cardiac glycosides,"/capita, US$ purchasing power parity",0.1
+22023,Latvia,2011,26,G03-Sex hormones and modulators of the genital system,"/capita, US$ exchange rate",4.0
+22024,Latvia,2011,26,C07-Beta blocking agents,"/capita, US$ purchasing power parity",6.7
+22025,Latvia,2011,26,C08-Calcium channel blockers,"/capita, US$ purchasing power parity",3.8
+22026,Latvia,2011,26,C03-Diuretics,"/capita, US$ purchasing power parity",2.1
+22027,Latvia,2011,26,"C01B-Antiarrhythmics, Class I and III","/capita, US$ purchasing power parity",0.4
+22028,Latvia,2011,26,C02-Antihypertensives,"/capita, US$ purchasing power parity",2.8
+22029,Latvia,2011,26,R-Respiratory system,Million US$ at exchange rate,30.0
+22030,Latvia,2011,26,N06A-Antidepressants,Million US$ at exchange rate,3.2
+22031,Latvia,2011,26,R03-Drugs for obstructive airway diseases,Million US$ at exchange rate,12.5
+22032,Latvia,2011,26,A-Alimentary tract and metabolism,"Million US$, purchasing power parity",76.4
+22033,Latvia,2011,26,Total pharmaceutical sales,"Million US$, purchasing power parity",581.5
+22034,Latvia,2011,26,A10-Drugs used in diabetes,"/capita, US$ purchasing power parity",16.4
+22035,Latvia,2011,26,B-Blood and blood forming organs,"/capita, US$ purchasing power parity",18.5
+22036,Latvia,2011,26,C-Cardiovascular system,"/capita, US$ purchasing power parity",52.5
+22037,Latvia,2011,26,A02A-Antacids,"/capita, US$ purchasing power parity",0.4
+22038,Latvia,2011,26,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ purchasing power parity",4.3
+22039,Latvia,2011,26,N05B-Anxiolytics,Million US$ at exchange rate,3.1
+22040,Latvia,2011,26,N05C-Hypnotics and sedatives,Million US$ at exchange rate,3.5
+22041,Latvia,2011,26,A02A-Antacids,"/capita, US$ exchange rate",0.3
+22042,Latvia,2011,26,Total pharmaceutical sales,"/capita, US$ exchange rate",197.3
+22043,Latvia,2011,26,A-Alimentary tract and metabolism,"/capita, US$ exchange rate",25.9
+22044,Latvia,2011,26,M01A-Antiinflammatory and antirheumatic products non-steroids,Million US$ at exchange rate,15.8
+22045,Latvia,2011,26,J01-Antibacterials for systemic use,Million US$ at exchange rate,13.4
+22046,Latvia,2011,26,M-Musculo-skeletal system,Million US$ at exchange rate,26.8
+22047,Latvia,2011,26,N02-Analgesics,Million US$ at exchange rate,10.4
+22048,Latvia,2011,26,N-Nervous system,Million US$ at exchange rate,47.0
+22049,Latvia,2011,26,G03-Sex hormones and modulators of the genital system,"/capita, US$ purchasing power parity",5.7
+22050,Latvia,2011,26,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ purchasing power parity",4.9
+22051,Latvia,2011,26,G-Genito urinary system and sex hormones,"/capita, US$ purchasing power parity",12.7
+22052,Latvia,2011,26,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ purchasing power parity",17.9
+22053,Latvia,2011,26,C10-Lipid modifying agents,"/capita, US$ purchasing power parity",7.5
+22054,Latvia,2011,26,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ exchange rate",12.5
+22055,Latvia,2011,26,C08-Calcium channel blockers,"/capita, US$ exchange rate",2.6
+22056,Latvia,2011,26,C07-Beta blocking agents,"/capita, US$ exchange rate",4.7
+22057,Latvia,2011,26,J-Antiinfectives for systemic use,"/capita, US$ purchasing power parity",26.1
+22058,Latvia,2011,26,J01-Antibacterials for systemic use,"/capita, US$ purchasing power parity",9.3
+22059,Latvia,2011,26,R03-Drugs for obstructive airway diseases,"Million US$, purchasing power parity",17.9
+22060,Latvia,2011,26,N-Nervous system,"/capita, US$ exchange rate",22.8
+22061,Latvia,2011,26,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ exchange rate",7.7
+22062,Latvia,2011,26,N05B-Anxiolytics,"/capita, US$ exchange rate",1.5
+22063,Latvia,2011,26,N02-Analgesics,"/capita, US$ exchange rate",5.0
+22064,Latvia,2011,26,N02-Analgesics,"Million US$, purchasing power parity",14.8
+22065,Latvia,2011,26,M01A-Antiinflammatory and antirheumatic products non-steroids,"Million US$, purchasing power parity",22.5
+22066,Latvia,2011,26,M-Musculo-skeletal system,"Million US$, purchasing power parity",38.3
+22067,Latvia,2011,26,M-Musculo-skeletal system,"/capita, US$ exchange rate",13.0
+22068,Latvia,2011,26,N-Nervous system,"Million US$, purchasing power parity",67.3
+22069,Latvia,2011,26,R03-Drugs for obstructive airway diseases,"/capita, US$ exchange rate",6.1
+22070,Latvia,2011,26,Total pharmaceutical sales,"/capita, US$ purchasing power parity",282.3
+22071,Latvia,2011,26,N05C-Hypnotics and sedatives,"/capita, US$ exchange rate",1.7
+22072,Latvia,2011,26,N06A-Antidepressants,"/capita, US$ exchange rate",1.6
+22073,Latvia,2011,26,R-Respiratory system,"/capita, US$ exchange rate",14.6
+22074,Latvia,2011,26,N05C-Hypnotics and sedatives,"Million US$, purchasing power parity",5.0
+22075,Latvia,2011,26,N05B-Anxiolytics,"Million US$, purchasing power parity",4.5
+22076,Latvia,2011,26,A-Alimentary tract and metabolism,"/capita, US$ purchasing power parity",37.1
+22077,Latvia,2011,26,R-Respiratory system,"Million US$, purchasing power parity",43.0
+22078,Latvia,2011,26,N06A-Antidepressants,"Million US$, purchasing power parity",4.6
+22079,Latvia,2011,26,J01-Antibacterials for systemic use,"Million US$, purchasing power parity",19.2
+22080,Latvia,2011,26,"C01B-Antiarrhythmics, Class I and III","Million US$, purchasing power parity",0.9
+22081,Latvia,2011,26,C01A-Cardiac glycosides,"Million US$, purchasing power parity",0.2
+22082,Latvia,2011,26,C02-Antihypertensives,"Million US$, purchasing power parity",5.7
+22083,Latvia,2011,26,C07-Beta blocking agents,"Million US$, purchasing power parity",13.9
+22084,Latvia,2011,26,C03-Diuretics,"Million US$, purchasing power parity",4.2
+22085,Latvia,2011,26,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"Million US$, purchasing power parity",8.8
+22086,Latvia,2011,26,A02A-Antacids,"Million US$, purchasing power parity",0.8
+22087,Latvia,2011,26,A10-Drugs used in diabetes,"Million US$, purchasing power parity",33.7
+22088,Latvia,2011,26,C-Cardiovascular system,"Million US$, purchasing power parity",108.2
+22089,Latvia,2011,26,B-Blood and blood forming organs,"Million US$, purchasing power parity",38.0
+22090,Latvia,2011,26,J01-Antibacterials for systemic use,"/capita, US$ exchange rate",6.5
+22091,Latvia,2011,26,G03-Sex hormones and modulators of the genital system,"Million US$, purchasing power parity",11.8
+22092,Latvia,2011,26,J-Antiinfectives for systemic use,"Million US$, purchasing power parity",53.7
+22093,Latvia,2011,26,"H-Systemic hormonal preparations, excluding sex hormones and insulins","Million US$, purchasing power parity",10.0
+22094,Latvia,2011,26,C09-Agents acting on the Renin-Angiotensin system,"Million US$, purchasing power parity",36.8
+22095,Latvia,2011,26,C08-Calcium channel blockers,"Million US$, purchasing power parity",7.7
+22096,Latvia,2011,26,G-Genito urinary system and sex hormones,"Million US$, purchasing power parity",26.1
+22097,Latvia,2011,26,J-Antiinfectives for systemic use,"/capita, US$ exchange rate",18.2
+22098,Latvia,2011,26,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ exchange rate",3.4
+22099,Latvia,2011,26,C10-Lipid modifying agents,"Million US$, purchasing power parity",15.4
+22100,Latvia,2011,26,N02-Analgesics,Million of national currency units,7.4
+22101,Latvia,2011,26,N-Nervous system,Million of national currency units,33.5
+22102,Latvia,2011,26,N05C-Hypnotics and sedatives,Million of national currency units,2.5
+22103,Latvia,2011,26,N05B-Anxiolytics,Million of national currency units,2.2
+22104,Latvia,2011,26,M01A-Antiinflammatory and antirheumatic products non-steroids,Million of national currency units,11.2
+22105,Latvia,2011,26,J-Antiinfectives for systemic use,Million of national currency units,26.8
+22106,Latvia,2011,26,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million of national currency units,5.0
+22107,Latvia,2011,26,M-Musculo-skeletal system,Million of national currency units,19.1
+22108,Latvia,2011,26,J01-Antibacterials for systemic use,Million of national currency units,9.6
+22109,Latvia,2011,26,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million US$ at exchange rate,6.2
+22110,Latvia,2011,26,A02A-Antacids,Million US$ at exchange rate,0.5
+22111,Latvia,2011,26,C-Cardiovascular system,Million US$ at exchange rate,75.6
+22112,Latvia,2011,26,B-Blood and blood forming organs,Million US$ at exchange rate,26.6
+22113,Latvia,2011,26,A10-Drugs used in diabetes,Million US$ at exchange rate,23.5
+22114,Latvia,2011,26,R-Respiratory system,Million of national currency units,21.4
+22115,Latvia,2011,26,N06A-Antidepressants,Million of national currency units,2.3
+22116,Latvia,2011,26,R03-Drugs for obstructive airway diseases,Million of national currency units,8.9
+22117,Latvia,2011,26,A-Alimentary tract and metabolism,Million US$ at exchange rate,53.4
+22118,Latvia,2011,26,Total pharmaceutical sales,Million US$ at exchange rate,406.4
+22119,Latvia,2011,26,G03-Sex hormones and modulators of the genital system,Million of national currency units,5.9
+22120,Latvia,2011,26,C03-Diuretics,"/capita, US$ exchange rate",1.4
+22121,Latvia,2011,26,"C01B-Antiarrhythmics, Class I and III",Million of national currency units,0.5
+22122,Latvia,2011,26,"C01B-Antiarrhythmics, Class I and III","/capita, US$ exchange rate",0.3
+22123,Latvia,2011,26,C02-Antihypertensives,"/capita, US$ exchange rate",1.9
+22124,Latvia,2011,26,C01A-Cardiac glycosides,Million of national currency units,0.1
+22125,Latvia,2011,26,A10-Drugs used in diabetes,Million of national currency units,16.8
+22126,Latvia,2011,26,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million of national currency units,4.4
+22127,Latvia,2011,26,C-Cardiovascular system,Million of national currency units,53.9
+22128,Latvia,2011,26,B-Blood and blood forming organs,Million of national currency units,18.9
+22129,Latvia,2011,26,C09-Agents acting on the Renin-Angiotensin system,Million of national currency units,18.4
+22130,Latvia,2011,26,C08-Calcium channel blockers,Million of national currency units,3.9
+22131,Latvia,2011,26,G-Genito urinary system and sex hormones,Million of national currency units,13.0
+22132,Latvia,2011,26,C10-Lipid modifying agents,Million of national currency units,7.7
+22133,Latvia,2011,26,C-Cardiovascular system,"/capita, US$ exchange rate",36.7
+22134,Latvia,2011,26,C01A-Cardiac glycosides,"/capita, US$ exchange rate",0.1
+22135,Latvia,2011,26,C07-Beta blocking agents,Million of national currency units,6.9
+22136,Latvia,2011,26,C03-Diuretics,Million of national currency units,2.1
+22137,Latvia,2011,26,C02-Antihypertensives,Million of national currency units,2.9
+22138,Latvia,2011,26,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ exchange rate",3.0
+22139,Latvia,2011,26,C02-Antihypertensives,Million US$ at exchange rate,4.0
+22140,Latvia,2011,26,R-Respiratory system,"/capita, US$ purchasing power parity",20.9
+22141,Latvia,2011,26,R03-Drugs for obstructive airway diseases,"/capita, US$ purchasing power parity",8.7
+22142,Latvia,2011,26,C03-Diuretics,Million US$ at exchange rate,3.0
+22143,Latvia,2011,26,C07-Beta blocking agents,Million US$ at exchange rate,9.7
+22144,Latvia,2011,26,A10-Drugs used in diabetes,"/capita, US$ exchange rate",11.4
+22145,Latvia,2011,26,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ purchasing power parity",10.9
+22146,Latvia,2011,26,N-Nervous system,"/capita, US$ purchasing power parity",32.7
+22147,Latvia,2011,26,"C01B-Antiarrhythmics, Class I and III",Million US$ at exchange rate,0.6
+22148,Latvia,2011,26,M-Musculo-skeletal system,"/capita, US$ purchasing power parity",18.6
+22149,Latvia,2011,26,N05C-Hypnotics and sedatives,"/capita, US$ purchasing power parity",2.4
+22150,Latvia,2011,26,N06A-Antidepressants,"/capita, US$ purchasing power parity",2.2
+22151,Latvia,2011,26,N02-Analgesics,"/capita, US$ purchasing power parity",7.2
+22152,Latvia,2011,26,N05B-Anxiolytics,"/capita, US$ purchasing power parity",2.2
+22153,Latvia,2011,26,J-Antiinfectives for systemic use,Million US$ at exchange rate,37.5
+22154,Latvia,2011,26,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million US$ at exchange rate,7.0
+22155,Latvia,2011,26,C01A-Cardiac glycosides,Million US$ at exchange rate,0.1
+22156,Latvia,2011,26,B-Blood and blood forming organs,"/capita, US$ exchange rate",12.9
+22157,Latvia,2011,26,C10-Lipid modifying agents,Million US$ at exchange rate,10.8
+22158,Latvia,2011,26,C08-Calcium channel blockers,Million US$ at exchange rate,5.4
+22159,Latvia,2011,26,C09-Agents acting on the Renin-Angiotensin system,Million US$ at exchange rate,25.7
+22160,Latvia,2011,26,G-Genito urinary system and sex hormones,Million US$ at exchange rate,18.2
+22161,Latvia,2011,26,G03-Sex hormones and modulators of the genital system,Million US$ at exchange rate,8.2
+22162,Latvia,2017,19,A-Alimentary tract and metabolism,Million of national currency units,50.4
+22163,Latvia,2017,19,A02A-Antacids,Million of national currency units,0.4
+22164,Latvia,2017,19,Total pharmaceutical sales,Million of national currency units,392.8
+22165,Latvia,2017,19,C01A-Cardiac glycosides,% of total sales,0.0
+22166,Latvia,2017,19,C09-Agents acting on the Renin-Angiotensin system,% of total sales,5.0
+22167,Latvia,2017,19,N05B-Anxiolytics,% of total sales,0.7
+22168,Latvia,2017,19,N-Nervous system,% of total sales,9.5
+22169,Latvia,2017,19,A-Alimentary tract and metabolism,% of total sales,12.8
+22170,Latvia,2017,19,N06A-Antidepressants,% of total sales,0.7
+22171,Latvia,2017,19,G03-Sex hormones and modulators of the genital system,% of total sales,1.7
+22172,Latvia,2017,19,R03-Drugs for obstructive airway diseases,% of total sales,2.5
+22173,Latvia,2017,19,J01-Antibacterials for systemic use,% of total sales,2.7
+22174,Latvia,2017,19,N05C-Hypnotics and sedatives,% of total sales,0.8
+22175,Latvia,2017,19,B-Blood and blood forming organs,% of total sales,7.2
+22176,Latvia,2017,19,C10-Lipid modifying agents,% of total sales,1.6
+22177,Latvia,2017,19,N02-Analgesics,% of total sales,2.1
+22178,Latvia,2017,19,A02A-Antacids,% of total sales,0.1
+22179,Latvia,2017,19,M-Musculo-skeletal system,% of total sales,6.3
+22180,Latvia,2017,19,C-Cardiovascular system,% of total sales,14.5
+22181,Latvia,2017,19,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),% of total sales,1.3
+22182,Latvia,2017,19,"H-Systemic hormonal preparations, excluding sex hormones and insulins",% of total sales,1.6
+22183,Latvia,2017,19,"C01B-Antiarrhythmics, Class I and III",% of total sales,0.2
+22184,Latvia,2017,19,C07-Beta blocking agents,% of total sales,2.0
+22185,Latvia,2017,19,C03-Diuretics,% of total sales,0.6
+22186,Latvia,2017,19,A10-Drugs used in diabetes,% of total sales,5.7
+22187,Latvia,2017,19,M01A-Antiinflammatory and antirheumatic products non-steroids,% of total sales,3.9
+22188,Latvia,2017,19,R-Respiratory system,% of total sales,7.1
+22189,Latvia,2017,19,C02-Antihypertensives,% of total sales,1.0
+22190,Latvia,2017,19,C08-Calcium channel blockers,% of total sales,0.6
+22191,Latvia,2017,19,J-Antiinfectives for systemic use,% of total sales,15.4
+22192,Latvia,2017,19,G-Genito urinary system and sex hormones,% of total sales,3.8
+22193,Latvia,2017,19,G-Genito urinary system and sex hormones,"/capita, US$ exchange rate",8.7
+22194,Latvia,2017,19,C10-Lipid modifying agents,"/capita, US$ exchange rate",3.6
+22195,Latvia,2017,19,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ exchange rate",11.5
+22196,Latvia,2017,19,C-Cardiovascular system,"/capita, US$ purchasing power parity",60.3
+22197,Latvia,2017,19,R03-Drugs for obstructive airway diseases,"Million US$, purchasing power parity",20.1
+22198,Latvia,2017,19,G03-Sex hormones and modulators of the genital system,"/capita, US$ exchange rate",3.8
+22199,Latvia,2017,19,C01A-Cardiac glycosides,"/capita, US$ purchasing power parity",0.1
+22200,Latvia,2017,19,C03-Diuretics,"/capita, US$ purchasing power parity",2.6
+22201,Latvia,2017,19,C07-Beta blocking agents,"/capita, US$ purchasing power parity",8.3
+22202,Latvia,2017,19,"C01B-Antiarrhythmics, Class I and III","/capita, US$ purchasing power parity",0.9
+22203,Latvia,2017,19,C02-Antihypertensives,"/capita, US$ purchasing power parity",4.0
+22204,Latvia,2017,19,R-Respiratory system,Million US$ at exchange rate,31.3
+22205,Latvia,2017,19,N06A-Antidepressants,Million US$ at exchange rate,3.2
+22206,Latvia,2017,19,Total pharmaceutical sales,"Million US$, purchasing power parity",810.6
+22207,Latvia,2017,19,R03-Drugs for obstructive airway diseases,Million US$ at exchange rate,11.0
+22208,Latvia,2017,19,A10-Drugs used in diabetes,"/capita, US$ purchasing power parity",23.8
+22209,Latvia,2017,19,B-Blood and blood forming organs,"/capita, US$ purchasing power parity",30.1
+22210,Latvia,2017,19,A-Alimentary tract and metabolism,"/capita, US$ purchasing power parity",53.6
+22211,Latvia,2017,19,A02A-Antacids,"/capita, US$ purchasing power parity",0.5
+22212,Latvia,2017,19,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ purchasing power parity",5.5
+22213,Latvia,2017,19,C08-Calcium channel blockers,"/capita, US$ purchasing power parity",2.5
+22214,Latvia,2017,19,A02A-Antacids,"/capita, US$ exchange rate",0.3
+22215,Latvia,2017,19,N05C-Hypnotics and sedatives,Million US$ at exchange rate,3.5
+22216,Latvia,2017,19,N05B-Anxiolytics,Million US$ at exchange rate,3.3
+22217,Latvia,2017,19,Total pharmaceutical sales,"/capita, US$ exchange rate",228.5
+22218,Latvia,2017,19,A-Alimentary tract and metabolism,"/capita, US$ exchange rate",29.3
+22219,Latvia,2017,19,M-Musculo-skeletal system,Million US$ at exchange rate,27.7
+22220,Latvia,2017,19,J01-Antibacterials for systemic use,Million US$ at exchange rate,12.0
+22221,Latvia,2017,19,N02-Analgesics,Million US$ at exchange rate,9.4
+22222,Latvia,2017,19,N-Nervous system,Million US$ at exchange rate,42.2
+22223,Latvia,2017,19,M01A-Antiinflammatory and antirheumatic products non-steroids,Million US$ at exchange rate,17.4
+22224,Latvia,2017,19,G-Genito urinary system and sex hormones,"/capita, US$ purchasing power parity",15.9
+22225,Latvia,2017,19,G03-Sex hormones and modulators of the genital system,"/capita, US$ purchasing power parity",6.9
+22226,Latvia,2017,19,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ purchasing power parity",21.1
+22227,Latvia,2017,19,C10-Lipid modifying agents,"/capita, US$ purchasing power parity",6.6
+22228,Latvia,2017,19,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ purchasing power parity",6.5
+22229,Latvia,2017,19,C08-Calcium channel blockers,"/capita, US$ exchange rate",1.4
+22230,Latvia,2017,19,C07-Beta blocking agents,"/capita, US$ exchange rate",4.6
+22231,Latvia,2017,19,J-Antiinfectives for systemic use,"/capita, US$ purchasing power parity",64.3
+22232,Latvia,2017,19,J01-Antibacterials for systemic use,"/capita, US$ purchasing power parity",11.3
+22233,Latvia,2017,19,N-Nervous system,"/capita, US$ exchange rate",21.7
+22234,Latvia,2017,19,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ exchange rate",9.0
+22235,Latvia,2017,19,R-Respiratory system,"Million US$, purchasing power parity",57.2
+22236,Latvia,2017,19,N02-Analgesics,"/capita, US$ exchange rate",4.9
+22237,Latvia,2017,19,M-Musculo-skeletal system,"Million US$, purchasing power parity",50.7
+22238,Latvia,2017,19,M01A-Antiinflammatory and antirheumatic products non-steroids,"Million US$, purchasing power parity",31.8
+22239,Latvia,2017,19,J01-Antibacterials for systemic use,"Million US$, purchasing power parity",21.9
+22240,Latvia,2017,19,M-Musculo-skeletal system,"/capita, US$ exchange rate",14.3
+22241,Latvia,2017,19,J01-Antibacterials for systemic use,"/capita, US$ exchange rate",6.2
+22242,Latvia,2017,19,N-Nervous system,"Million US$, purchasing power parity",77.1
+22243,Latvia,2017,19,N05B-Anxiolytics,"/capita, US$ exchange rate",1.7
+22244,Latvia,2017,19,R03-Drugs for obstructive airway diseases,"/capita, US$ exchange rate",5.7
+22245,Latvia,2017,19,N06A-Antidepressants,"/capita, US$ exchange rate",1.7
+22246,Latvia,2017,19,R-Respiratory system,"/capita, US$ exchange rate",16.1
+22247,Latvia,2017,19,N05C-Hypnotics and sedatives,"/capita, US$ exchange rate",1.8
+22248,Latvia,2017,19,Total pharmaceutical sales,"/capita, US$ purchasing power parity",417.4
+22249,Latvia,2017,19,N05B-Anxiolytics,"Million US$, purchasing power parity",6.0
+22250,Latvia,2017,19,N05C-Hypnotics and sedatives,"Million US$, purchasing power parity",6.4
+22251,Latvia,2017,19,N02-Analgesics,"Million US$, purchasing power parity",17.2
+22252,Latvia,2017,19,N06A-Antidepressants,"Million US$, purchasing power parity",5.9
+22253,Latvia,2017,19,"C01B-Antiarrhythmics, Class I and III","Million US$, purchasing power parity",1.7
+22254,Latvia,2017,19,C01A-Cardiac glycosides,"Million US$, purchasing power parity",0.2
+22255,Latvia,2017,19,C03-Diuretics,"Million US$, purchasing power parity",5.1
+22256,Latvia,2017,19,C02-Antihypertensives,"Million US$, purchasing power parity",7.7
+22257,Latvia,2017,19,C-Cardiovascular system,"Million US$, purchasing power parity",117.2
+22258,Latvia,2017,19,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"Million US$, purchasing power parity",10.7
+22259,Latvia,2017,19,A02A-Antacids,"Million US$, purchasing power parity",0.9
+22260,Latvia,2017,19,B-Blood and blood forming organs,"Million US$, purchasing power parity",58.4
+22261,Latvia,2017,19,A10-Drugs used in diabetes,"Million US$, purchasing power parity",46.1
+22262,Latvia,2017,19,C07-Beta blocking agents,"Million US$, purchasing power parity",16.2
+22263,Latvia,2017,19,G03-Sex hormones and modulators of the genital system,"Million US$, purchasing power parity",13.5
+22264,Latvia,2017,19,J-Antiinfectives for systemic use,"/capita, US$ exchange rate",35.2
+22265,Latvia,2017,19,G-Genito urinary system and sex hormones,"Million US$, purchasing power parity",30.8
+22266,Latvia,2017,19,J-Antiinfectives for systemic use,"Million US$, purchasing power parity",124.9
+22267,Latvia,2017,19,"H-Systemic hormonal preparations, excluding sex hormones and insulins","Million US$, purchasing power parity",12.6
+22268,Latvia,2017,19,C09-Agents acting on the Renin-Angiotensin system,"Million US$, purchasing power parity",40.9
+22269,Latvia,2017,19,C08-Calcium channel blockers,"Million US$, purchasing power parity",5.0
+22270,Latvia,2017,19,A-Alimentary tract and metabolism,"Million US$, purchasing power parity",104.0
+22271,Latvia,2017,19,C10-Lipid modifying agents,"Million US$, purchasing power parity",12.9
+22272,Latvia,2017,19,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ exchange rate",3.5
+22273,Latvia,2017,19,N-Nervous system,Million of national currency units,37.4
+22274,Latvia,2017,19,M01A-Antiinflammatory and antirheumatic products non-steroids,Million of national currency units,15.4
+22275,Latvia,2017,19,N05C-Hypnotics and sedatives,Million of national currency units,3.1
+22276,Latvia,2017,19,N05B-Anxiolytics,Million of national currency units,2.9
+22277,Latvia,2017,19,N02-Analgesics,Million of national currency units,8.3
+22278,Latvia,2017,19,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million of national currency units,6.1
+22279,Latvia,2017,19,G03-Sex hormones and modulators of the genital system,Million of national currency units,6.5
+22280,Latvia,2017,19,J-Antiinfectives for systemic use,Million of national currency units,60.5
+22281,Latvia,2017,19,M-Musculo-skeletal system,Million of national currency units,24.6
+22282,Latvia,2017,19,J01-Antibacterials for systemic use,Million of national currency units,10.6
+22283,Latvia,2017,19,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million US$ at exchange rate,5.9
+22284,Latvia,2017,19,A02A-Antacids,Million US$ at exchange rate,0.5
+22285,Latvia,2017,19,B-Blood and blood forming organs,Million US$ at exchange rate,32.0
+22286,Latvia,2017,19,A10-Drugs used in diabetes,Million US$ at exchange rate,25.3
+22287,Latvia,2017,19,A-Alimentary tract and metabolism,Million US$ at exchange rate,57.0
+22288,Latvia,2017,19,R-Respiratory system,Million of national currency units,27.7
+22289,Latvia,2017,19,N06A-Antidepressants,Million of national currency units,2.8
+22290,Latvia,2017,19,Total pharmaceutical sales,Million US$ at exchange rate,443.7
+22291,Latvia,2017,19,R03-Drugs for obstructive airway diseases,Million of national currency units,9.8
+22292,Latvia,2017,19,C03-Diuretics,"/capita, US$ exchange rate",1.4
+22293,Latvia,2017,19,C01A-Cardiac glycosides,Million of national currency units,0.1
+22294,Latvia,2017,19,C01A-Cardiac glycosides,"/capita, US$ exchange rate",0.1
+22295,Latvia,2017,19,"C01B-Antiarrhythmics, Class I and III","/capita, US$ exchange rate",0.5
+22296,Latvia,2017,19,C02-Antihypertensives,"/capita, US$ exchange rate",2.2
+22297,Latvia,2017,19,A10-Drugs used in diabetes,Million of national currency units,22.4
+22298,Latvia,2017,19,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million of national currency units,5.2
+22299,Latvia,2017,19,C-Cardiovascular system,Million of national currency units,56.8
+22300,Latvia,2017,19,B-Blood and blood forming organs,Million of national currency units,28.3
+22301,Latvia,2017,19,C09-Agents acting on the Renin-Angiotensin system,Million of national currency units,19.8
+22302,Latvia,2017,19,C08-Calcium channel blockers,Million of national currency units,2.4
+22303,Latvia,2017,19,C07-Beta blocking agents,Million of national currency units,7.9
+22304,Latvia,2017,19,G-Genito urinary system and sex hormones,Million of national currency units,14.9
+22305,Latvia,2017,19,C10-Lipid modifying agents,Million of national currency units,6.2
+22306,Latvia,2017,19,"C01B-Antiarrhythmics, Class I and III",Million of national currency units,0.8
+22307,Latvia,2017,19,C-Cardiovascular system,"/capita, US$ exchange rate",33.0
+22308,Latvia,2017,19,C03-Diuretics,Million of national currency units,2.5
+22309,Latvia,2017,19,C02-Antihypertensives,Million of national currency units,3.8
+22310,Latvia,2017,19,R03-Drugs for obstructive airway diseases,"/capita, US$ purchasing power parity",10.4
+22311,Latvia,2017,19,R-Respiratory system,"/capita, US$ purchasing power parity",29.4
+22312,Latvia,2017,19,C02-Antihypertensives,Million US$ at exchange rate,4.2
+22313,Latvia,2017,19,C03-Diuretics,Million US$ at exchange rate,2.8
+22314,Latvia,2017,19,C07-Beta blocking agents,Million US$ at exchange rate,8.9
+22315,Latvia,2017,19,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ exchange rate",3.0
+22316,Latvia,2017,19,A10-Drugs used in diabetes,"/capita, US$ exchange rate",13.0
+22317,Latvia,2017,19,N06A-Antidepressants,"/capita, US$ purchasing power parity",3.0
+22318,Latvia,2017,19,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ purchasing power parity",16.4
+22319,Latvia,2017,19,N-Nervous system,"/capita, US$ purchasing power parity",39.7
+22320,Latvia,2017,19,"C01B-Antiarrhythmics, Class I and III",Million US$ at exchange rate,0.9
+22321,Latvia,2017,19,M-Musculo-skeletal system,"/capita, US$ purchasing power parity",26.1
+22322,Latvia,2017,19,N05C-Hypnotics and sedatives,"/capita, US$ purchasing power parity",3.3
+22323,Latvia,2017,19,N02-Analgesics,"/capita, US$ purchasing power parity",8.9
+22324,Latvia,2017,19,N05B-Anxiolytics,"/capita, US$ purchasing power parity",3.1
+22325,Latvia,2017,19,J-Antiinfectives for systemic use,Million US$ at exchange rate,68.4
+22326,Latvia,2017,19,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million US$ at exchange rate,6.9
+22327,Latvia,2017,19,C-Cardiovascular system,Million US$ at exchange rate,64.2
+22328,Latvia,2017,19,C01A-Cardiac glycosides,Million US$ at exchange rate,0.1
+22329,Latvia,2017,19,B-Blood and blood forming organs,"/capita, US$ exchange rate",16.5
+22330,Latvia,2017,19,G03-Sex hormones and modulators of the genital system,Million US$ at exchange rate,7.4
+22331,Latvia,2017,19,C09-Agents acting on the Renin-Angiotensin system,Million US$ at exchange rate,22.4
+22332,Latvia,2017,19,C08-Calcium channel blockers,Million US$ at exchange rate,2.7
+22333,Latvia,2017,19,G-Genito urinary system and sex hormones,Million US$ at exchange rate,16.9
+22334,Latvia,2017,19,C10-Lipid modifying agents,Million US$ at exchange rate,7.0
+22335,Luxembourg,2016,5,N05B-Anxiolytics,Million US$ at exchange rate,2.8
+22336,Luxembourg,2016,5,N05B-Anxiolytics,Million of national currency units,2.5
+22337,Luxembourg,2016,5,N05B-Anxiolytics,"/capita, US$ purchasing power parity",5.5
+22338,Luxembourg,2016,5,N05B-Anxiolytics,% of total sales,1.3
+22339,Luxembourg,2016,5,N05B-Anxiolytics,"Million US$, purchasing power parity",2.9
+22340,Luxembourg,2016,5,N05B-Anxiolytics,"/capita, US$ exchange rate",5.2
+22341,Luxembourg,2016,5,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ exchange rate",15.3
+22342,Luxembourg,2016,5,A02A-Antacids,"/capita, US$ purchasing power parity",0.8
+22343,Luxembourg,2016,5,A02A-Antacids,% of total sales,0.2
+22344,Luxembourg,2016,5,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ purchasing power parity",16.2
+22345,Luxembourg,2016,5,A02A-Antacids,"/capita, US$ exchange rate",0.8
+22346,Luxembourg,2016,5,A02A-Antacids,"Million US$, purchasing power parity",0.4
+22347,Luxembourg,2016,5,R03-Drugs for obstructive airway diseases,"/capita, US$ purchasing power parity",22.2
+22348,Luxembourg,2016,5,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),% of total sales,3.7
+22349,Luxembourg,2016,5,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million of national currency units,7.3
+22350,Luxembourg,2016,5,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million US$ at exchange rate,8.1
+22351,Luxembourg,2016,5,R03-Drugs for obstructive airway diseases,% of total sales,5.1
+22352,Luxembourg,2016,5,A02A-Antacids,Million US$ at exchange rate,0.4
+22353,Luxembourg,2016,5,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"Million US$, purchasing power parity",8.5
+22354,Luxembourg,2016,5,R03-Drugs for obstructive airway diseases,"Million US$, purchasing power parity",11.7
+22355,Luxembourg,2016,5,R03-Drugs for obstructive airway diseases,"/capita, US$ exchange rate",20.9
+22356,Luxembourg,2016,5,R03-Drugs for obstructive airway diseases,Million of national currency units,10.0
+22357,Luxembourg,2016,5,R03-Drugs for obstructive airway diseases,Million US$ at exchange rate,11.0
+22358,Luxembourg,2016,5,A-Alimentary tract and metabolism,"/capita, US$ purchasing power parity",76.6
+22359,Luxembourg,2016,5,N05C-Hypnotics and sedatives,% of total sales,1.8
+22360,Luxembourg,2016,5,A-Alimentary tract and metabolism,% of total sales,17.6
+22361,Luxembourg,2016,5,A-Alimentary tract and metabolism,"/capita, US$ exchange rate",72.2
+22362,Luxembourg,2016,5,A-Alimentary tract and metabolism,Million US$ at exchange rate,38.0
+22363,Luxembourg,2016,5,A-Alimentary tract and metabolism,"Million US$, purchasing power parity",40.3
+22364,Luxembourg,2016,5,N05C-Hypnotics and sedatives,"/capita, US$ exchange rate",7.2
+22365,Luxembourg,2016,5,N05C-Hypnotics and sedatives,"Million US$, purchasing power parity",4.0
+22366,Luxembourg,2016,5,N05C-Hypnotics and sedatives,Million US$ at exchange rate,3.8
+22367,Luxembourg,2016,5,N05C-Hypnotics and sedatives,"/capita, US$ purchasing power parity",7.7
+22368,Luxembourg,2016,5,A-Alimentary tract and metabolism,Million of national currency units,34.4
+22369,Luxembourg,2016,5,N-Nervous system,"/capita, US$ purchasing power parity",70.9
+22370,Luxembourg,2016,5,N-Nervous system,"/capita, US$ exchange rate",66.8
+22371,Luxembourg,2016,5,N-Nervous system,% of total sales,16.3
+22372,Luxembourg,2016,5,N-Nervous system,Million of national currency units,31.8
+22373,Luxembourg,2016,5,N-Nervous system,Million US$ at exchange rate,35.2
+22374,Luxembourg,2016,5,N-Nervous system,"Million US$, purchasing power parity",37.3
+22375,Luxembourg,2016,5,N06A-Antidepressants,Million US$ at exchange rate,5.9
+22376,Luxembourg,2016,5,N06A-Antidepressants,Million of national currency units,5.4
+22377,Luxembourg,2016,5,N06A-Antidepressants,"Million US$, purchasing power parity",6.3
+22378,Luxembourg,2016,5,N06A-Antidepressants,"/capita, US$ purchasing power parity",11.9
+22379,Luxembourg,2016,5,N06A-Antidepressants,% of total sales,2.7
+22380,Luxembourg,2016,5,N06A-Antidepressants,"/capita, US$ exchange rate",11.2
+22381,Luxembourg,2016,5,Total pharmaceutical sales,Million US$ at exchange rate,215.7
+22382,Luxembourg,2016,5,M01A-Antiinflammatory and antirheumatic products non-steroids,% of total sales,3.0
+22383,Luxembourg,2016,5,Total pharmaceutical sales,Million of national currency units,194.9
+22384,Luxembourg,2016,5,Total pharmaceutical sales,"/capita, US$ purchasing power parity",434.3
+22385,Luxembourg,2016,5,Total pharmaceutical sales,"Million US$, purchasing power parity",228.8
+22386,Luxembourg,2016,5,Total pharmaceutical sales,"/capita, US$ exchange rate",409.6
+22387,Luxembourg,2016,5,M01A-Antiinflammatory and antirheumatic products non-steroids,Million US$ at exchange rate,6.6
+22388,Luxembourg,2016,5,M01A-Antiinflammatory and antirheumatic products non-steroids,Million of national currency units,5.9
+22389,Luxembourg,2016,5,A02A-Antacids,Million of national currency units,0.4
+22390,Luxembourg,2016,5,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ purchasing power parity",13.2
+22391,Luxembourg,2016,5,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ exchange rate",12.5
+22392,Luxembourg,2016,5,M01A-Antiinflammatory and antirheumatic products non-steroids,"Million US$, purchasing power parity",7.0
+22393,Luxembourg,2016,5,R-Respiratory system,% of total sales,7.2
+22394,Luxembourg,2016,5,N02-Analgesics,"/capita, US$ exchange rate",16.3
+22395,Luxembourg,2016,5,N02-Analgesics,"Million US$, purchasing power parity",9.1
+22396,Luxembourg,2016,5,N02-Analgesics,"/capita, US$ purchasing power parity",17.3
+22397,Luxembourg,2016,5,N02-Analgesics,Million of national currency units,7.8
+22398,Luxembourg,2016,5,N05C-Hypnotics and sedatives,Million of national currency units,3.4
+22399,Luxembourg,2016,5,N02-Analgesics,Million US$ at exchange rate,8.6
+22400,Luxembourg,2016,5,R-Respiratory system,"/capita, US$ exchange rate",29.6
+22401,Luxembourg,2016,5,R-Respiratory system,"/capita, US$ purchasing power parity",31.4
+22402,Luxembourg,2016,5,R-Respiratory system,"Million US$, purchasing power parity",16.5
+22403,Luxembourg,2016,5,R-Respiratory system,Million of national currency units,14.1
+22404,Luxembourg,2016,5,N02-Analgesics,% of total sales,4.0
+22405,Luxembourg,2016,5,R-Respiratory system,Million US$ at exchange rate,15.6
+22406,Luxembourg,2016,5,B-Blood and blood forming organs,"Million US$, purchasing power parity",16.9
+22407,Luxembourg,2016,5,B-Blood and blood forming organs,Million of national currency units,14.4
+22408,Luxembourg,2016,5,B-Blood and blood forming organs,Million US$ at exchange rate,15.9
+22409,Luxembourg,2016,5,B-Blood and blood forming organs,% of total sales,7.4
+22410,Luxembourg,2016,5,C02-Antihypertensives,% of total sales,0.2
+22411,Luxembourg,2016,5,B-Blood and blood forming organs,"/capita, US$ exchange rate",30.3
+22412,Luxembourg,2016,5,B-Blood and blood forming organs,"/capita, US$ purchasing power parity",32.1
+22413,Luxembourg,2016,5,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ purchasing power parity",11.7
+22414,Luxembourg,2016,5,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ exchange rate",11.1
+22415,Luxembourg,2016,5,"H-Systemic hormonal preparations, excluding sex hormones and insulins",% of total sales,2.7
+22416,Luxembourg,2016,5,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million of national currency units,5.3
+22417,Luxembourg,2016,5,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million US$ at exchange rate,5.8
+22418,Luxembourg,2016,5,"H-Systemic hormonal preparations, excluding sex hormones and insulins","Million US$, purchasing power parity",6.2
+22419,Luxembourg,2016,5,C01A-Cardiac glycosides,"/capita, US$ exchange rate",0.1
+22420,Luxembourg,2016,5,C01A-Cardiac glycosides,Million US$ at exchange rate,0.0
+22421,Luxembourg,2016,5,M-Musculo-skeletal system,"/capita, US$ exchange rate",23.5
+22422,Luxembourg,2016,5,C01A-Cardiac glycosides,"Million US$, purchasing power parity",0.0
+22423,Luxembourg,2016,5,M-Musculo-skeletal system,% of total sales,5.7
+22424,Luxembourg,2016,5,C09-Agents acting on the Renin-Angiotensin system,% of total sales,5.5
+22425,Luxembourg,2016,5,M-Musculo-skeletal system,"/capita, US$ purchasing power parity",25.0
+22426,Luxembourg,2016,5,J-Antiinfectives for systemic use,% of total sales,4.6
+22427,Luxembourg,2016,5,M-Musculo-skeletal system,Million of national currency units,11.2
+22428,Luxembourg,2016,5,C10-Lipid modifying agents,% of total sales,6.5
+22429,Luxembourg,2016,5,C01A-Cardiac glycosides,Million of national currency units,0.0
+22430,Luxembourg,2016,5,M-Musculo-skeletal system,Million US$ at exchange rate,12.4
+22431,Luxembourg,2016,5,M-Musculo-skeletal system,"Million US$, purchasing power parity",13.1
+22432,Luxembourg,2016,5,C02-Antihypertensives,"/capita, US$ purchasing power parity",1.0
+22433,Luxembourg,2016,5,C10-Lipid modifying agents,Million of national currency units,12.6
+22434,Luxembourg,2016,5,C03-Diuretics,Million of national currency units,1.6
+22435,Luxembourg,2016,5,C10-Lipid modifying agents,Million US$ at exchange rate,13.9
+22436,Luxembourg,2016,5,C03-Diuretics,"/capita, US$ exchange rate",3.3
+22437,Luxembourg,2016,5,C03-Diuretics,Million US$ at exchange rate,1.7
+22438,Luxembourg,2016,5,C03-Diuretics,"Million US$, purchasing power parity",1.8
+22439,Luxembourg,2016,5,C03-Diuretics,"/capita, US$ purchasing power parity",3.5
+22440,Luxembourg,2016,5,C02-Antihypertensives,"Million US$, purchasing power parity",0.5
+22441,Luxembourg,2016,5,C02-Antihypertensives,Million of national currency units,0.5
+22442,Luxembourg,2016,5,C02-Antihypertensives,Million US$ at exchange rate,0.5
+22443,Luxembourg,2016,5,C10-Lipid modifying agents,"Million US$, purchasing power parity",14.8
+22444,Luxembourg,2016,5,C10-Lipid modifying agents,"/capita, US$ exchange rate",26.5
+22445,Luxembourg,2016,5,C02-Antihypertensives,"/capita, US$ exchange rate",0.9
+22446,Luxembourg,2016,5,C10-Lipid modifying agents,"/capita, US$ purchasing power parity",28.1
+22447,Luxembourg,2016,5,"C01B-Antiarrhythmics, Class I and III","/capita, US$ purchasing power parity",1.2
+22448,Luxembourg,2016,5,"C01B-Antiarrhythmics, Class I and III","/capita, US$ exchange rate",1.1
+22449,Luxembourg,2016,5,"C01B-Antiarrhythmics, Class I and III",% of total sales,0.3
+22450,Luxembourg,2016,5,"C01B-Antiarrhythmics, Class I and III",Million of national currency units,0.5
+22451,Luxembourg,2016,5,"C01B-Antiarrhythmics, Class I and III",Million US$ at exchange rate,0.6
+22452,Luxembourg,2016,5,"C01B-Antiarrhythmics, Class I and III","Million US$, purchasing power parity",0.6
+22453,Luxembourg,2016,5,J-Antiinfectives for systemic use,Million of national currency units,9.0
+22454,Luxembourg,2016,5,C03-Diuretics,% of total sales,0.8
+22455,Luxembourg,2016,5,J-Antiinfectives for systemic use,Million US$ at exchange rate,10.0
+22456,Luxembourg,2016,5,J-Antiinfectives for systemic use,"/capita, US$ exchange rate",19.0
+22457,Luxembourg,2016,5,J-Antiinfectives for systemic use,"/capita, US$ purchasing power parity",20.1
+22458,Luxembourg,2016,5,J-Antiinfectives for systemic use,"Million US$, purchasing power parity",10.6
+22459,Luxembourg,2016,5,J01-Antibacterials for systemic use,Million US$ at exchange rate,6.4
+22460,Luxembourg,2016,5,J01-Antibacterials for systemic use,"Million US$, purchasing power parity",6.7
+22461,Luxembourg,2016,5,G03-Sex hormones and modulators of the genital system,"/capita, US$ purchasing power parity",7.8
+22462,Luxembourg,2016,5,C01A-Cardiac glycosides,"/capita, US$ purchasing power parity",0.1
+22463,Luxembourg,2016,5,G03-Sex hormones and modulators of the genital system,% of total sales,1.8
+22464,Luxembourg,2016,5,J01-Antibacterials for systemic use,Million of national currency units,5.8
+22465,Luxembourg,2016,5,C01A-Cardiac glycosides,% of total sales,0.0
+22466,Luxembourg,2016,5,G03-Sex hormones and modulators of the genital system,Million of national currency units,3.5
+22467,Luxembourg,2016,5,J01-Antibacterials for systemic use,"/capita, US$ exchange rate",12.1
+22468,Luxembourg,2016,5,J01-Antibacterials for systemic use,"/capita, US$ purchasing power parity",12.8
+22469,Luxembourg,2016,5,G03-Sex hormones and modulators of the genital system,"Million US$, purchasing power parity",4.1
+22470,Luxembourg,2016,5,G03-Sex hormones and modulators of the genital system,"/capita, US$ exchange rate",7.4
+22471,Luxembourg,2016,5,G03-Sex hormones and modulators of the genital system,Million US$ at exchange rate,3.9
+22472,Luxembourg,2016,5,A10-Drugs used in diabetes,"/capita, US$ purchasing power parity",35.3
+22473,Luxembourg,2016,5,A10-Drugs used in diabetes,"/capita, US$ exchange rate",33.3
+22474,Luxembourg,2016,5,A10-Drugs used in diabetes,% of total sales,8.1
+22475,Luxembourg,2016,5,A10-Drugs used in diabetes,Million of national currency units,15.8
+22476,Luxembourg,2016,5,A10-Drugs used in diabetes,Million US$ at exchange rate,17.5
+22477,Luxembourg,2016,5,A10-Drugs used in diabetes,"Million US$, purchasing power parity",18.6
+22478,Luxembourg,2016,5,G-Genito urinary system and sex hormones,"/capita, US$ exchange rate",18.2
+22479,Luxembourg,2016,5,G-Genito urinary system and sex hormones,"Million US$, purchasing power parity",10.2
+22480,Luxembourg,2016,5,G-Genito urinary system and sex hormones,"/capita, US$ purchasing power parity",19.3
+22481,Luxembourg,2016,5,G-Genito urinary system and sex hormones,Million of national currency units,8.7
+22482,Luxembourg,2016,5,G-Genito urinary system and sex hormones,Million US$ at exchange rate,9.6
+22483,Luxembourg,2016,5,C-Cardiovascular system,% of total sales,16.7
+22484,Luxembourg,2016,5,C09-Agents acting on the Renin-Angiotensin system,"Million US$, purchasing power parity",12.5
+22485,Luxembourg,2016,5,C07-Beta blocking agents,% of total sales,1.9
+22486,Luxembourg,2016,5,C07-Beta blocking agents,"/capita, US$ purchasing power parity",8.2
+22487,Luxembourg,2016,5,C08-Calcium channel blockers,% of total sales,0.9
+22488,Luxembourg,2016,5,C09-Agents acting on the Renin-Angiotensin system,Million of national currency units,10.7
+22489,Luxembourg,2016,5,C09-Agents acting on the Renin-Angiotensin system,Million US$ at exchange rate,11.8
+22490,Luxembourg,2016,5,C07-Beta blocking agents,Million of national currency units,3.7
+22491,Luxembourg,2016,5,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ exchange rate",22.4
+22492,Luxembourg,2016,5,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ purchasing power parity",23.7
+22493,Luxembourg,2016,5,C07-Beta blocking agents,"Million US$, purchasing power parity",4.3
+22494,Luxembourg,2016,5,C07-Beta blocking agents,"/capita, US$ exchange rate",7.7
+22495,Luxembourg,2016,5,C07-Beta blocking agents,Million US$ at exchange rate,4.1
+22496,Luxembourg,2016,5,C08-Calcium channel blockers,"/capita, US$ purchasing power parity",4.1
+22497,Luxembourg,2016,5,C-Cardiovascular system,"Million US$, purchasing power parity",38.1
+22498,Luxembourg,2016,5,C-Cardiovascular system,Million US$ at exchange rate,36.0
+22499,Luxembourg,2016,5,C-Cardiovascular system,Million of national currency units,32.5
+22500,Luxembourg,2016,5,C-Cardiovascular system,"/capita, US$ exchange rate",68.3
+22501,Luxembourg,2016,5,G-Genito urinary system and sex hormones,% of total sales,4.4
+22502,Luxembourg,2016,5,J01-Antibacterials for systemic use,% of total sales,3.0
+22503,Luxembourg,2016,5,C-Cardiovascular system,"/capita, US$ purchasing power parity",72.4
+22504,Luxembourg,2016,5,C08-Calcium channel blockers,Million US$ at exchange rate,2.0
+22505,Luxembourg,2016,5,C08-Calcium channel blockers,Million of national currency units,1.8
+22506,Luxembourg,2016,5,C08-Calcium channel blockers,"/capita, US$ exchange rate",3.8
+22507,Luxembourg,2016,5,C08-Calcium channel blockers,"Million US$, purchasing power parity",2.1
+22508,Luxembourg,2015,5,N05B-Anxiolytics,Million of national currency units,2.4
+22509,Luxembourg,2015,5,N05B-Anxiolytics,Million US$ at exchange rate,2.7
+22510,Luxembourg,2015,5,N05B-Anxiolytics,"Million US$, purchasing power parity",2.7
+22511,Luxembourg,2015,5,N05B-Anxiolytics,"/capita, US$ purchasing power parity",5.2
+22512,Luxembourg,2015,5,N05B-Anxiolytics,% of total sales,1.2
+22513,Luxembourg,2015,5,N05B-Anxiolytics,"/capita, US$ exchange rate",5.1
+22514,Luxembourg,2015,5,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ exchange rate",15.5
+22515,Luxembourg,2015,5,A02A-Antacids,"/capita, US$ purchasing power parity",0.8
+22516,Luxembourg,2015,5,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ purchasing power parity",15.9
+22517,Luxembourg,2015,5,A02A-Antacids,% of total sales,0.2
+22518,Luxembourg,2015,5,A02A-Antacids,"Million US$, purchasing power parity",0.4
+22519,Luxembourg,2015,5,R03-Drugs for obstructive airway diseases,"/capita, US$ purchasing power parity",22.9
+22520,Luxembourg,2015,5,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),% of total sales,3.8
+22521,Luxembourg,2015,5,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"Million US$, purchasing power parity",8.2
+22522,Luxembourg,2015,5,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million of national currency units,7.2
+22523,Luxembourg,2015,5,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million US$ at exchange rate,8.0
+22524,Luxembourg,2015,5,R03-Drugs for obstructive airway diseases,% of total sales,5.4
+22525,Luxembourg,2015,5,A02A-Antacids,"/capita, US$ exchange rate",0.8
+22526,Luxembourg,2015,5,A02A-Antacids,Million US$ at exchange rate,0.4
+22527,Luxembourg,2015,5,R03-Drugs for obstructive airway diseases,"/capita, US$ exchange rate",22.4
+22528,Luxembourg,2015,5,R03-Drugs for obstructive airway diseases,"Million US$, purchasing power parity",11.9
+22529,Luxembourg,2015,5,R03-Drugs for obstructive airway diseases,Million of national currency units,10.5
+22530,Luxembourg,2015,5,R03-Drugs for obstructive airway diseases,Million US$ at exchange rate,11.6
+22531,Luxembourg,2015,5,A-Alimentary tract and metabolism,"/capita, US$ purchasing power parity",72.9
+22532,Luxembourg,2015,5,A-Alimentary tract and metabolism,% of total sales,17.3
+22533,Luxembourg,2015,5,A-Alimentary tract and metabolism,Million US$ at exchange rate,36.9
+22534,Luxembourg,2015,5,A-Alimentary tract and metabolism,"/capita, US$ exchange rate",71.2
+22535,Luxembourg,2015,5,A-Alimentary tract and metabolism,"Million US$, purchasing power parity",37.8
+22536,Luxembourg,2015,5,N05C-Hypnotics and sedatives,% of total sales,1.8
+22537,Luxembourg,2015,5,N05C-Hypnotics and sedatives,"/capita, US$ exchange rate",7.3
+22538,Luxembourg,2015,5,N05C-Hypnotics and sedatives,Million US$ at exchange rate,3.8
+22539,Luxembourg,2015,5,N05C-Hypnotics and sedatives,"Million US$, purchasing power parity",3.9
+22540,Luxembourg,2015,5,N05C-Hypnotics and sedatives,"/capita, US$ purchasing power parity",7.5
+22541,Luxembourg,2015,5,A-Alimentary tract and metabolism,Million of national currency units,33.3
+22542,Luxembourg,2015,5,N-Nervous system,"/capita, US$ purchasing power parity",72.7
+22543,Luxembourg,2015,5,N-Nervous system,"/capita, US$ exchange rate",71.1
+22544,Luxembourg,2015,5,N-Nervous system,% of total sales,17.2
+22545,Luxembourg,2015,5,N-Nervous system,Million US$ at exchange rate,36.8
+22546,Luxembourg,2015,5,N-Nervous system,Million of national currency units,33.2
+22547,Luxembourg,2015,5,N-Nervous system,"Million US$, purchasing power parity",37.7
+22548,Luxembourg,2015,5,N06A-Antidepressants,Million US$ at exchange rate,6.3
+22549,Luxembourg,2015,5,N06A-Antidepressants,"Million US$, purchasing power parity",6.5
+22550,Luxembourg,2015,5,N06A-Antidepressants,Million of national currency units,5.7
+22551,Luxembourg,2015,5,N06A-Antidepressants,"/capita, US$ purchasing power parity",12.5
+22552,Luxembourg,2015,5,N06A-Antidepressants,% of total sales,3.0
+22553,Luxembourg,2015,5,N06A-Antidepressants,"/capita, US$ exchange rate",12.2
+22554,Luxembourg,2015,5,Total pharmaceutical sales,Million US$ at exchange rate,213.7
+22555,Luxembourg,2015,5,M01A-Antiinflammatory and antirheumatic products non-steroids,% of total sales,3.1
+22556,Luxembourg,2015,5,Total pharmaceutical sales,Million of national currency units,192.6
+22557,Luxembourg,2015,5,Total pharmaceutical sales,"/capita, US$ purchasing power parity",421.8
+22558,Luxembourg,2015,5,Total pharmaceutical sales,"Million US$, purchasing power parity",218.6
+22559,Luxembourg,2015,5,Total pharmaceutical sales,"/capita, US$ exchange rate",412.5
+22560,Luxembourg,2015,5,M01A-Antiinflammatory and antirheumatic products non-steroids,Million US$ at exchange rate,6.5
+22561,Luxembourg,2015,5,M01A-Antiinflammatory and antirheumatic products non-steroids,Million of national currency units,5.9
+22562,Luxembourg,2015,5,A02A-Antacids,Million of national currency units,0.4
+22563,Luxembourg,2015,5,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ purchasing power parity",12.9
+22564,Luxembourg,2015,5,M01A-Antiinflammatory and antirheumatic products non-steroids,"Million US$, purchasing power parity",6.7
+22565,Luxembourg,2015,5,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ exchange rate",12.6
+22566,Luxembourg,2015,5,N02-Analgesics,"/capita, US$ exchange rate",16.6
+22567,Luxembourg,2015,5,N02-Analgesics,"Million US$, purchasing power parity",8.8
+22568,Luxembourg,2015,5,N02-Analgesics,"/capita, US$ purchasing power parity",16.9
+22569,Luxembourg,2015,5,N02-Analgesics,Million of national currency units,7.7
+22570,Luxembourg,2015,5,N05C-Hypnotics and sedatives,Million of national currency units,3.4
+22571,Luxembourg,2015,5,N02-Analgesics,Million US$ at exchange rate,8.6
+22572,Luxembourg,2015,5,N02-Analgesics,% of total sales,4.0
+22573,Luxembourg,2015,5,R-Respiratory system,"/capita, US$ exchange rate",31.1
+22574,Luxembourg,2015,5,R-Respiratory system,% of total sales,7.5
+22575,Luxembourg,2015,5,R-Respiratory system,"/capita, US$ purchasing power parity",31.8
+22576,Luxembourg,2015,5,R-Respiratory system,Million of national currency units,14.5
+22577,Luxembourg,2015,5,R-Respiratory system,Million US$ at exchange rate,16.1
+22578,Luxembourg,2015,5,R-Respiratory system,"Million US$, purchasing power parity",16.5
+22579,Luxembourg,2015,5,B-Blood and blood forming organs,"Million US$, purchasing power parity",14.8
+22580,Luxembourg,2015,5,B-Blood and blood forming organs,Million of national currency units,13.0
+22581,Luxembourg,2015,5,B-Blood and blood forming organs,Million US$ at exchange rate,14.5
+22582,Luxembourg,2015,5,B-Blood and blood forming organs,"/capita, US$ exchange rate",27.9
+22583,Luxembourg,2015,5,B-Blood and blood forming organs,% of total sales,6.8
+22584,Luxembourg,2015,5,C02-Antihypertensives,% of total sales,0.2
+22585,Luxembourg,2015,5,B-Blood and blood forming organs,"/capita, US$ purchasing power parity",28.6
+22586,Luxembourg,2015,5,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ purchasing power parity",11.2
+22587,Luxembourg,2015,5,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ exchange rate",11.0
+22588,Luxembourg,2015,5,"H-Systemic hormonal preparations, excluding sex hormones and insulins",% of total sales,2.7
+22589,Luxembourg,2015,5,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million of national currency units,5.1
+22590,Luxembourg,2015,5,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million US$ at exchange rate,5.7
+22591,Luxembourg,2015,5,"H-Systemic hormonal preparations, excluding sex hormones and insulins","Million US$, purchasing power parity",5.8
+22592,Luxembourg,2015,5,C01A-Cardiac glycosides,"/capita, US$ exchange rate",0.1
+22593,Luxembourg,2015,5,M-Musculo-skeletal system,"/capita, US$ exchange rate",23.0
+22594,Luxembourg,2015,5,C01A-Cardiac glycosides,Million US$ at exchange rate,0.0
+22595,Luxembourg,2015,5,C01A-Cardiac glycosides,"Million US$, purchasing power parity",0.0
+22596,Luxembourg,2015,5,C09-Agents acting on the Renin-Angiotensin system,% of total sales,5.7
+22597,Luxembourg,2015,5,M-Musculo-skeletal system,% of total sales,5.6
+22598,Luxembourg,2015,5,M-Musculo-skeletal system,"/capita, US$ purchasing power parity",23.5
+22599,Luxembourg,2015,5,J-Antiinfectives for systemic use,% of total sales,4.9
+22600,Luxembourg,2015,5,M-Musculo-skeletal system,Million of national currency units,10.8
+22601,Luxembourg,2015,5,C10-Lipid modifying agents,% of total sales,6.6
+22602,Luxembourg,2015,5,C01A-Cardiac glycosides,Million of national currency units,0.0
+22603,Luxembourg,2015,5,M-Musculo-skeletal system,Million US$ at exchange rate,11.9
+22604,Luxembourg,2015,5,M-Musculo-skeletal system,"Million US$, purchasing power parity",12.2
+22605,Luxembourg,2015,5,C03-Diuretics,Million of national currency units,1.6
+22606,Luxembourg,2015,5,C10-Lipid modifying agents,Million US$ at exchange rate,14.1
+22607,Luxembourg,2015,5,C03-Diuretics,Million US$ at exchange rate,1.8
+22608,Luxembourg,2015,5,C03-Diuretics,"/capita, US$ exchange rate",3.4
+22609,Luxembourg,2015,5,C03-Diuretics,"/capita, US$ purchasing power parity",3.5
+22610,Luxembourg,2015,5,C03-Diuretics,"Million US$, purchasing power parity",1.8
+22611,Luxembourg,2015,5,C10-Lipid modifying agents,"Million US$, purchasing power parity",14.4
+22612,Luxembourg,2015,5,C02-Antihypertensives,"Million US$, purchasing power parity",0.5
+22613,Luxembourg,2015,5,C02-Antihypertensives,Million of national currency units,0.4
+22614,Luxembourg,2015,5,C02-Antihypertensives,Million US$ at exchange rate,0.5
+22615,Luxembourg,2015,5,C02-Antihypertensives,"/capita, US$ exchange rate",0.9
+22616,Luxembourg,2015,5,C10-Lipid modifying agents,"/capita, US$ exchange rate",27.1
+22617,Luxembourg,2015,5,C10-Lipid modifying agents,"/capita, US$ purchasing power parity",27.7
+22618,Luxembourg,2015,5,"C01B-Antiarrhythmics, Class I and III","/capita, US$ purchasing power parity",1.2
+22619,Luxembourg,2015,5,"C01B-Antiarrhythmics, Class I and III","/capita, US$ exchange rate",1.2
+22620,Luxembourg,2015,5,"C01B-Antiarrhythmics, Class I and III",% of total sales,0.3
+22621,Luxembourg,2015,5,"C01B-Antiarrhythmics, Class I and III",Million of national currency units,0.6
+22622,Luxembourg,2015,5,"C01B-Antiarrhythmics, Class I and III",Million US$ at exchange rate,0.6
+22623,Luxembourg,2015,5,"C01B-Antiarrhythmics, Class I and III","Million US$, purchasing power parity",0.6
+22624,Luxembourg,2015,5,J-Antiinfectives for systemic use,Million of national currency units,9.4
+22625,Luxembourg,2015,5,C03-Diuretics,% of total sales,0.8
+22626,Luxembourg,2015,5,C10-Lipid modifying agents,Million of national currency units,12.7
+22627,Luxembourg,2015,5,J-Antiinfectives for systemic use,Million US$ at exchange rate,10.4
+22628,Luxembourg,2015,5,J-Antiinfectives for systemic use,"/capita, US$ exchange rate",20.0
+22629,Luxembourg,2015,5,J-Antiinfectives for systemic use,"/capita, US$ purchasing power parity",20.5
+22630,Luxembourg,2015,5,C02-Antihypertensives,"/capita, US$ purchasing power parity",0.9
+22631,Luxembourg,2015,5,J-Antiinfectives for systemic use,"Million US$, purchasing power parity",10.6
+22632,Luxembourg,2015,5,J01-Antibacterials for systemic use,Million US$ at exchange rate,6.4
+22633,Luxembourg,2015,5,J01-Antibacterials for systemic use,"Million US$, purchasing power parity",6.6
+22634,Luxembourg,2015,5,G03-Sex hormones and modulators of the genital system,"/capita, US$ purchasing power parity",7.5
+22635,Luxembourg,2015,5,C01A-Cardiac glycosides,"/capita, US$ purchasing power parity",0.1
+22636,Luxembourg,2015,5,G03-Sex hormones and modulators of the genital system,% of total sales,1.8
+22637,Luxembourg,2015,5,J01-Antibacterials for systemic use,Million of national currency units,5.8
+22638,Luxembourg,2015,5,C01A-Cardiac glycosides,% of total sales,0.0
+22639,Luxembourg,2015,5,J01-Antibacterials for systemic use,"/capita, US$ exchange rate",12.4
+22640,Luxembourg,2015,5,G03-Sex hormones and modulators of the genital system,Million of national currency units,3.4
+22641,Luxembourg,2015,5,J01-Antibacterials for systemic use,"/capita, US$ purchasing power parity",12.7
+22642,Luxembourg,2015,5,G03-Sex hormones and modulators of the genital system,"Million US$, purchasing power parity",3.9
+22643,Luxembourg,2015,5,G03-Sex hormones and modulators of the genital system,"/capita, US$ exchange rate",7.3
+22644,Luxembourg,2015,5,G03-Sex hormones and modulators of the genital system,Million US$ at exchange rate,3.8
+22645,Luxembourg,2015,5,A10-Drugs used in diabetes,"/capita, US$ purchasing power parity",33.1
+22646,Luxembourg,2015,5,A10-Drugs used in diabetes,"/capita, US$ exchange rate",32.4
+22647,Luxembourg,2015,5,A10-Drugs used in diabetes,% of total sales,7.8
+22648,Luxembourg,2015,5,A10-Drugs used in diabetes,Million US$ at exchange rate,16.8
+22649,Luxembourg,2015,5,A10-Drugs used in diabetes,Million of national currency units,15.1
+22650,Luxembourg,2015,5,A10-Drugs used in diabetes,"Million US$, purchasing power parity",17.2
+22651,Luxembourg,2015,5,G-Genito urinary system and sex hormones,"/capita, US$ exchange rate",17.8
+22652,Luxembourg,2015,5,G-Genito urinary system and sex hormones,"Million US$, purchasing power parity",9.4
+22653,Luxembourg,2015,5,G-Genito urinary system and sex hormones,"/capita, US$ purchasing power parity",18.2
+22654,Luxembourg,2015,5,G-Genito urinary system and sex hormones,Million of national currency units,8.3
+22655,Luxembourg,2015,5,G-Genito urinary system and sex hormones,Million US$ at exchange rate,9.2
+22656,Luxembourg,2015,5,C-Cardiovascular system,% of total sales,17.1
+22657,Luxembourg,2015,5,C09-Agents acting on the Renin-Angiotensin system,"Million US$, purchasing power parity",12.5
+22658,Luxembourg,2015,5,C07-Beta blocking agents,% of total sales,1.9
+22659,Luxembourg,2015,5,C07-Beta blocking agents,"/capita, US$ purchasing power parity",7.9
+22660,Luxembourg,2015,5,C09-Agents acting on the Renin-Angiotensin system,Million US$ at exchange rate,12.2
+22661,Luxembourg,2015,5,C08-Calcium channel blockers,% of total sales,1.0
+22662,Luxembourg,2015,5,C09-Agents acting on the Renin-Angiotensin system,Million of national currency units,11.0
+22663,Luxembourg,2015,5,C07-Beta blocking agents,Million of national currency units,3.6
+22664,Luxembourg,2015,5,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ exchange rate",23.6
+22665,Luxembourg,2015,5,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ purchasing power parity",24.1
+22666,Luxembourg,2015,5,C07-Beta blocking agents,"/capita, US$ exchange rate",7.7
+22667,Luxembourg,2015,5,C07-Beta blocking agents,"Million US$, purchasing power parity",4.1
+22668,Luxembourg,2015,5,C07-Beta blocking agents,Million US$ at exchange rate,4.0
+22669,Luxembourg,2015,5,C-Cardiovascular system,"Million US$, purchasing power parity",37.4
+22670,Luxembourg,2015,5,C08-Calcium channel blockers,"/capita, US$ purchasing power parity",4.2
+22671,Luxembourg,2015,5,C-Cardiovascular system,Million US$ at exchange rate,36.6
+22672,Luxembourg,2015,5,G-Genito urinary system and sex hormones,% of total sales,4.3
+22673,Luxembourg,2015,5,J01-Antibacterials for systemic use,% of total sales,3.0
+22674,Luxembourg,2015,5,C-Cardiovascular system,"/capita, US$ exchange rate",70.6
+22675,Luxembourg,2015,5,C-Cardiovascular system,"/capita, US$ purchasing power parity",72.2
+22676,Luxembourg,2015,5,C-Cardiovascular system,Million of national currency units,33.0
+22677,Luxembourg,2015,5,C08-Calcium channel blockers,Million US$ at exchange rate,2.1
+22678,Luxembourg,2015,5,C08-Calcium channel blockers,Million of national currency units,1.9
+22679,Luxembourg,2015,5,C08-Calcium channel blockers,"Million US$, purchasing power parity",2.2
+22680,Luxembourg,2015,5,C08-Calcium channel blockers,"/capita, US$ exchange rate",4.1
+22681,Luxembourg,2014,6,N05B-Anxiolytics,Million of national currency units,2.4
+22682,Luxembourg,2014,6,N05B-Anxiolytics,Million US$ at exchange rate,3.2
+22683,Luxembourg,2014,6,N05B-Anxiolytics,"/capita, US$ purchasing power parity",5.3
+22684,Luxembourg,2014,6,N05B-Anxiolytics,"Million US$, purchasing power parity",2.7
+22685,Luxembourg,2014,6,N05B-Anxiolytics,"/capita, US$ exchange rate",6.2
+22686,Luxembourg,2014,6,N05B-Anxiolytics,% of total sales,1.2
+22687,Luxembourg,2014,6,A02A-Antacids,"/capita, US$ exchange rate",0.9
+22688,Luxembourg,2014,6,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ exchange rate",21.6
+22689,Luxembourg,2014,6,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ purchasing power parity",18.4
+22690,Luxembourg,2014,6,A02A-Antacids,"/capita, US$ purchasing power parity",0.8
+22691,Luxembourg,2014,6,A02A-Antacids,% of total sales,0.2
+22692,Luxembourg,2014,6,A02A-Antacids,"Million US$, purchasing power parity",0.4
+22693,Luxembourg,2014,6,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),% of total sales,4.4
+22694,Luxembourg,2014,6,R03-Drugs for obstructive airway diseases,"/capita, US$ purchasing power parity",23.5
+22695,Luxembourg,2014,6,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million of national currency units,8.3
+22696,Luxembourg,2014,6,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million US$ at exchange rate,11.1
+22697,Luxembourg,2014,6,R03-Drugs for obstructive airway diseases,% of total sales,5.5
+22698,Luxembourg,2014,6,A02A-Antacids,Million US$ at exchange rate,0.5
+22699,Luxembourg,2014,6,R03-Drugs for obstructive airway diseases,"/capita, US$ exchange rate",27.5
+22700,Luxembourg,2014,6,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"Million US$, purchasing power parity",9.4
+22701,Luxembourg,2014,6,R03-Drugs for obstructive airway diseases,"Million US$, purchasing power parity",12.0
+22702,Luxembourg,2014,6,R03-Drugs for obstructive airway diseases,Million of national currency units,10.6
+22703,Luxembourg,2014,6,R03-Drugs for obstructive airway diseases,Million US$ at exchange rate,14.1
+22704,Luxembourg,2014,6,A-Alimentary tract and metabolism,"/capita, US$ purchasing power parity",72.8
+22705,Luxembourg,2014,6,A-Alimentary tract and metabolism,% of total sales,17.2
+22706,Luxembourg,2014,6,A-Alimentary tract and metabolism,Million US$ at exchange rate,43.7
+22707,Luxembourg,2014,6,A-Alimentary tract and metabolism,"/capita, US$ exchange rate",85.5
+22708,Luxembourg,2014,6,A-Alimentary tract and metabolism,"Million US$, purchasing power parity",37.2
+22709,Luxembourg,2014,6,N05C-Hypnotics and sedatives,% of total sales,1.6
+22710,Luxembourg,2014,6,N05C-Hypnotics and sedatives,"/capita, US$ exchange rate",8.2
+22711,Luxembourg,2014,6,N05C-Hypnotics and sedatives,"Million US$, purchasing power parity",3.6
+22712,Luxembourg,2014,6,N05C-Hypnotics and sedatives,Million US$ at exchange rate,4.2
+22713,Luxembourg,2014,6,N05C-Hypnotics and sedatives,"/capita, US$ purchasing power parity",7.0
+22714,Luxembourg,2014,6,A-Alimentary tract and metabolism,Million of national currency units,32.9
+22715,Luxembourg,2014,6,N-Nervous system,"/capita, US$ purchasing power parity",70.5
+22716,Luxembourg,2014,6,N-Nervous system,"/capita, US$ exchange rate",82.8
+22717,Luxembourg,2014,6,N-Nervous system,% of total sales,16.6
+22718,Luxembourg,2014,6,N-Nervous system,Million US$ at exchange rate,42.3
+22719,Luxembourg,2014,6,N-Nervous system,Million of national currency units,31.8
+22720,Luxembourg,2014,6,N-Nervous system,"Million US$, purchasing power parity",36.0
+22721,Luxembourg,2014,6,N06A-Antidepressants,Million US$ at exchange rate,8.3
+22722,Luxembourg,2014,6,N06A-Antidepressants,"Million US$, purchasing power parity",7.1
+22723,Luxembourg,2014,6,N06A-Antidepressants,Million of national currency units,6.3
+22724,Luxembourg,2014,6,N06A-Antidepressants,"/capita, US$ purchasing power parity",13.8
+22725,Luxembourg,2014,6,N06A-Antidepressants,% of total sales,3.3
+22726,Luxembourg,2014,6,N06A-Antidepressants,"/capita, US$ exchange rate",16.3
+22727,Luxembourg,2014,6,Total pharmaceutical sales,Million US$ at exchange rate,254.1
+22728,Luxembourg,2014,6,M01A-Antiinflammatory and antirheumatic products non-steroids,% of total sales,3.2
+22729,Luxembourg,2014,6,Total pharmaceutical sales,Million of national currency units,191.3
+22730,Luxembourg,2014,6,Total pharmaceutical sales,"Million US$, purchasing power parity",216.3
+22731,Luxembourg,2014,6,Total pharmaceutical sales,"/capita, US$ purchasing power parity",423.6
+22732,Luxembourg,2014,6,Total pharmaceutical sales,"/capita, US$ exchange rate",497.5
+22733,Luxembourg,2014,6,M01A-Antiinflammatory and antirheumatic products non-steroids,Million US$ at exchange rate,8.1
+22734,Luxembourg,2014,6,M01A-Antiinflammatory and antirheumatic products non-steroids,Million of national currency units,6.1
+22735,Luxembourg,2014,6,A02A-Antacids,Million of national currency units,0.4
+22736,Luxembourg,2014,6,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ purchasing power parity",13.6
+22737,Luxembourg,2014,6,M01A-Antiinflammatory and antirheumatic products non-steroids,"Million US$, purchasing power parity",6.9
+22738,Luxembourg,2014,6,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ exchange rate",15.9
+22739,Luxembourg,2014,6,N02-Analgesics,"/capita, US$ exchange rate",19.8
+22740,Luxembourg,2014,6,N02-Analgesics,"Million US$, purchasing power parity",8.6
+22741,Luxembourg,2014,6,N02-Analgesics,"/capita, US$ purchasing power parity",16.8
+22742,Luxembourg,2014,6,N02-Analgesics,Million of national currency units,7.6
+22743,Luxembourg,2014,6,N05C-Hypnotics and sedatives,Million of national currency units,3.1
+22744,Luxembourg,2014,6,N02-Analgesics,Million US$ at exchange rate,10.1
+22745,Luxembourg,2014,6,N02-Analgesics,% of total sales,4.0
+22746,Luxembourg,2014,6,R-Respiratory system,"/capita, US$ exchange rate",38.4
+22747,Luxembourg,2014,6,R-Respiratory system,% of total sales,7.7
+22748,Luxembourg,2014,6,R-Respiratory system,"/capita, US$ purchasing power parity",32.7
+22749,Luxembourg,2014,6,R-Respiratory system,"Million US$, purchasing power parity",16.7
+22750,Luxembourg,2014,6,R-Respiratory system,Million of national currency units,14.8
+22751,Luxembourg,2014,6,R-Respiratory system,Million US$ at exchange rate,19.6
+22752,Luxembourg,2014,6,B-Blood and blood forming organs,"Million US$, purchasing power parity",13.4
+22753,Luxembourg,2014,6,B-Blood and blood forming organs,Million of national currency units,11.9
+22754,Luxembourg,2014,6,B-Blood and blood forming organs,"/capita, US$ exchange rate",30.8
+22755,Luxembourg,2014,6,B-Blood and blood forming organs,Million US$ at exchange rate,15.7
+22756,Luxembourg,2014,6,B-Blood and blood forming organs,% of total sales,6.2
+22757,Luxembourg,2014,6,C02-Antihypertensives,% of total sales,0.2
+22758,Luxembourg,2014,6,B-Blood and blood forming organs,"/capita, US$ purchasing power parity",26.2
+22759,Luxembourg,2014,6,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ purchasing power parity",11.8
+22760,Luxembourg,2014,6,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ exchange rate",13.8
+22761,Luxembourg,2014,6,"H-Systemic hormonal preparations, excluding sex hormones and insulins",% of total sales,2.8
+22762,Luxembourg,2014,6,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million of national currency units,5.3
+22763,Luxembourg,2014,6,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million US$ at exchange rate,7.1
+22764,Luxembourg,2014,6,"H-Systemic hormonal preparations, excluding sex hormones and insulins","Million US$, purchasing power parity",6.0
+22765,Luxembourg,2014,6,C01A-Cardiac glycosides,"/capita, US$ exchange rate",0.1
+22766,Luxembourg,2014,6,C01A-Cardiac glycosides,Million US$ at exchange rate,0.1
+22767,Luxembourg,2014,6,C01A-Cardiac glycosides,"Million US$, purchasing power parity",0.0
+22768,Luxembourg,2014,6,C09-Agents acting on the Renin-Angiotensin system,% of total sales,6.0
+22769,Luxembourg,2014,6,M-Musculo-skeletal system,% of total sales,5.6
+22770,Luxembourg,2014,6,M-Musculo-skeletal system,"/capita, US$ purchasing power parity",23.7
+22771,Luxembourg,2014,6,J-Antiinfectives for systemic use,% of total sales,4.9
+22772,Luxembourg,2014,6,C10-Lipid modifying agents,% of total sales,6.9
+22773,Luxembourg,2014,6,M-Musculo-skeletal system,Million of national currency units,10.7
+22774,Luxembourg,2014,6,M-Musculo-skeletal system,"/capita, US$ exchange rate",27.9
+22775,Luxembourg,2014,6,C01A-Cardiac glycosides,Million of national currency units,0.0
+22776,Luxembourg,2014,6,M-Musculo-skeletal system,Million US$ at exchange rate,14.2
+22777,Luxembourg,2014,6,M-Musculo-skeletal system,"Million US$, purchasing power parity",12.1
+22778,Luxembourg,2014,6,C02-Antihypertensives,"/capita, US$ purchasing power parity",1.0
+22779,Luxembourg,2014,6,C03-Diuretics,Million of national currency units,1.7
+22780,Luxembourg,2014,6,C10-Lipid modifying agents,Million US$ at exchange rate,17.4
+22781,Luxembourg,2014,6,C10-Lipid modifying agents,"Million US$, purchasing power parity",14.8
+22782,Luxembourg,2014,6,C03-Diuretics,"/capita, US$ exchange rate",4.3
+22783,Luxembourg,2014,6,C03-Diuretics,"/capita, US$ purchasing power parity",3.7
+22784,Luxembourg,2014,6,C03-Diuretics,Million US$ at exchange rate,2.2
+22785,Luxembourg,2014,6,C03-Diuretics,"Million US$, purchasing power parity",1.9
+22786,Luxembourg,2014,6,C02-Antihypertensives,"Million US$, purchasing power parity",0.5
+22787,Luxembourg,2014,6,C02-Antihypertensives,Million of national currency units,0.4
+22788,Luxembourg,2014,6,C02-Antihypertensives,Million US$ at exchange rate,0.6
+22789,Luxembourg,2014,6,C10-Lipid modifying agents,"/capita, US$ exchange rate",34.1
+22790,Luxembourg,2014,6,C02-Antihypertensives,"/capita, US$ exchange rate",1.1
+22791,Luxembourg,2014,6,C10-Lipid modifying agents,"/capita, US$ purchasing power parity",29.1
+22792,Luxembourg,2014,6,"C01B-Antiarrhythmics, Class I and III","/capita, US$ purchasing power parity",1.3
+22793,Luxembourg,2014,6,"C01B-Antiarrhythmics, Class I and III","/capita, US$ exchange rate",1.5
+22794,Luxembourg,2014,6,"C01B-Antiarrhythmics, Class I and III",% of total sales,0.3
+22795,Luxembourg,2014,6,"C01B-Antiarrhythmics, Class I and III",Million of national currency units,0.6
+22796,Luxembourg,2014,6,"C01B-Antiarrhythmics, Class I and III",Million US$ at exchange rate,0.8
+22797,Luxembourg,2014,6,"C01B-Antiarrhythmics, Class I and III","Million US$, purchasing power parity",0.6
+22798,Luxembourg,2014,6,J-Antiinfectives for systemic use,Million of national currency units,9.4
+22799,Luxembourg,2014,6,C03-Diuretics,% of total sales,0.9
+22800,Luxembourg,2014,6,J-Antiinfectives for systemic use,Million US$ at exchange rate,12.5
+22801,Luxembourg,2014,6,C10-Lipid modifying agents,Million of national currency units,13.1
+22802,Luxembourg,2014,6,J-Antiinfectives for systemic use,"/capita, US$ exchange rate",24.6
+22803,Luxembourg,2014,6,J-Antiinfectives for systemic use,"/capita, US$ purchasing power parity",20.9
+22804,Luxembourg,2014,6,J-Antiinfectives for systemic use,"Million US$, purchasing power parity",10.7
+22805,Luxembourg,2014,6,J01-Antibacterials for systemic use,"Million US$, purchasing power parity",6.7
+22806,Luxembourg,2014,6,J01-Antibacterials for systemic use,Million US$ at exchange rate,7.9
+22807,Luxembourg,2014,6,G03-Sex hormones and modulators of the genital system,"/capita, US$ purchasing power parity",7.6
+22808,Luxembourg,2014,6,C01A-Cardiac glycosides,"/capita, US$ purchasing power parity",0.1
+22809,Luxembourg,2014,6,G03-Sex hormones and modulators of the genital system,% of total sales,1.8
+22810,Luxembourg,2014,6,C01A-Cardiac glycosides,% of total sales,0.0
+22811,Luxembourg,2014,6,J01-Antibacterials for systemic use,Million of national currency units,6.0
+22812,Luxembourg,2014,6,J01-Antibacterials for systemic use,"/capita, US$ exchange rate",15.5
+22813,Luxembourg,2014,6,G03-Sex hormones and modulators of the genital system,Million of national currency units,3.4
+22814,Luxembourg,2014,6,J01-Antibacterials for systemic use,"/capita, US$ purchasing power parity",13.2
+22815,Luxembourg,2014,6,G03-Sex hormones and modulators of the genital system,"/capita, US$ exchange rate",8.9
+22816,Luxembourg,2014,6,G03-Sex hormones and modulators of the genital system,"Million US$, purchasing power parity",3.9
+22817,Luxembourg,2014,6,G03-Sex hormones and modulators of the genital system,Million US$ at exchange rate,4.5
+22818,Luxembourg,2014,6,A10-Drugs used in diabetes,"/capita, US$ purchasing power parity",30.7
+22819,Luxembourg,2014,6,A10-Drugs used in diabetes,"/capita, US$ exchange rate",36.0
+22820,Luxembourg,2014,6,A10-Drugs used in diabetes,% of total sales,7.2
+22821,Luxembourg,2014,6,A10-Drugs used in diabetes,Million US$ at exchange rate,18.4
+22822,Luxembourg,2014,6,A10-Drugs used in diabetes,Million of national currency units,13.8
+22823,Luxembourg,2014,6,A10-Drugs used in diabetes,"Million US$, purchasing power parity",15.7
+22824,Luxembourg,2014,6,G-Genito urinary system and sex hormones,Million of national currency units,8.2
+22825,Luxembourg,2014,6,G-Genito urinary system and sex hormones,"/capita, US$ exchange rate",21.4
+22826,Luxembourg,2014,6,G-Genito urinary system and sex hormones,"Million US$, purchasing power parity",9.3
+22827,Luxembourg,2014,6,G-Genito urinary system and sex hormones,"/capita, US$ purchasing power parity",18.2
+22828,Luxembourg,2014,6,G-Genito urinary system and sex hormones,Million US$ at exchange rate,10.9
+22829,Luxembourg,2014,6,C-Cardiovascular system,% of total sales,17.9
+22830,Luxembourg,2014,6,C09-Agents acting on the Renin-Angiotensin system,"Million US$, purchasing power parity",12.9
+22831,Luxembourg,2014,6,C07-Beta blocking agents,"/capita, US$ purchasing power parity",8.0
+22832,Luxembourg,2014,6,C07-Beta blocking agents,% of total sales,1.9
+22833,Luxembourg,2014,6,C08-Calcium channel blockers,% of total sales,1.1
+22834,Luxembourg,2014,6,C09-Agents acting on the Renin-Angiotensin system,Million US$ at exchange rate,15.1
+22835,Luxembourg,2014,6,C09-Agents acting on the Renin-Angiotensin system,Million of national currency units,11.4
+22836,Luxembourg,2014,6,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ exchange rate",29.6
+22837,Luxembourg,2014,6,C07-Beta blocking agents,Million of national currency units,3.6
+22838,Luxembourg,2014,6,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ purchasing power parity",25.2
+22839,Luxembourg,2014,6,C07-Beta blocking agents,"/capita, US$ exchange rate",9.4
+22840,Luxembourg,2014,6,C07-Beta blocking agents,"Million US$, purchasing power parity",4.1
+22841,Luxembourg,2014,6,C07-Beta blocking agents,Million US$ at exchange rate,4.8
+22842,Luxembourg,2014,6,C08-Calcium channel blockers,"/capita, US$ purchasing power parity",4.7
+22843,Luxembourg,2014,6,C-Cardiovascular system,"Million US$, purchasing power parity",38.7
+22844,Luxembourg,2014,6,C-Cardiovascular system,Million US$ at exchange rate,45.4
+22845,Luxembourg,2014,6,C-Cardiovascular system,"/capita, US$ exchange rate",88.9
+22846,Luxembourg,2014,6,G-Genito urinary system and sex hormones,% of total sales,4.3
+22847,Luxembourg,2014,6,J01-Antibacterials for systemic use,% of total sales,3.1
+22848,Luxembourg,2014,6,C-Cardiovascular system,"/capita, US$ purchasing power parity",75.7
+22849,Luxembourg,2014,6,C08-Calcium channel blockers,Million US$ at exchange rate,2.8
+22850,Luxembourg,2014,6,C-Cardiovascular system,Million of national currency units,34.2
+22851,Luxembourg,2014,6,C08-Calcium channel blockers,"Million US$, purchasing power parity",2.4
+22852,Luxembourg,2014,6,C08-Calcium channel blockers,Million of national currency units,2.1
+22853,Luxembourg,2014,6,C08-Calcium channel blockers,"/capita, US$ exchange rate",5.5
+22854,Luxembourg,2013,6,N05B-Anxiolytics,Million of national currency units,2.3
+22855,Luxembourg,2013,6,N05B-Anxiolytics,Million US$ at exchange rate,3.1
+22856,Luxembourg,2013,6,N05B-Anxiolytics,"Million US$, purchasing power parity",2.6
+22857,Luxembourg,2013,6,N05B-Anxiolytics,% of total sales,1.2
+22858,Luxembourg,2013,6,N05B-Anxiolytics,"/capita, US$ purchasing power parity",5.2
+22859,Luxembourg,2013,6,N05B-Anxiolytics,"/capita, US$ exchange rate",6.2
+22860,Luxembourg,2013,6,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ exchange rate",23.6
+22861,Luxembourg,2013,6,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ purchasing power parity",19.9
+22862,Luxembourg,2013,6,A02A-Antacids,"/capita, US$ purchasing power parity",0.7
+22863,Luxembourg,2013,6,A02A-Antacids,% of total sales,0.2
+22864,Luxembourg,2013,6,A02A-Antacids,"/capita, US$ exchange rate",0.8
+22865,Luxembourg,2013,6,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),% of total sales,4.6
+22866,Luxembourg,2013,6,R03-Drugs for obstructive airway diseases,"/capita, US$ purchasing power parity",25.4
+22867,Luxembourg,2013,6,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million of national currency units,8.9
+22868,Luxembourg,2013,6,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million US$ at exchange rate,11.8
+22869,Luxembourg,2013,6,A02A-Antacids,"Million US$, purchasing power parity",0.4
+22870,Luxembourg,2013,6,R03-Drugs for obstructive airway diseases,% of total sales,5.9
+22871,Luxembourg,2013,6,A02A-Antacids,Million US$ at exchange rate,0.4
+22872,Luxembourg,2013,6,R03-Drugs for obstructive airway diseases,Million of national currency units,11.4
+22873,Luxembourg,2013,6,R03-Drugs for obstructive airway diseases,"/capita, US$ exchange rate",30.2
+22874,Luxembourg,2013,6,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"Million US$, purchasing power parity",10.0
+22875,Luxembourg,2013,6,R03-Drugs for obstructive airway diseases,"Million US$, purchasing power parity",12.7
+22876,Luxembourg,2013,6,R03-Drugs for obstructive airway diseases,Million US$ at exchange rate,15.2
+22877,Luxembourg,2013,6,A-Alimentary tract and metabolism,"/capita, US$ purchasing power parity",70.3
+22878,Luxembourg,2013,6,A-Alimentary tract and metabolism,% of total sales,16.2
+22879,Luxembourg,2013,6,A-Alimentary tract and metabolism,Million US$ at exchange rate,42.0
+22880,Luxembourg,2013,6,A-Alimentary tract and metabolism,"/capita, US$ exchange rate",83.6
+22881,Luxembourg,2013,6,A-Alimentary tract and metabolism,"Million US$, purchasing power parity",35.3
+22882,Luxembourg,2013,6,N05C-Hypnotics and sedatives,"/capita, US$ exchange rate",8.0
+22883,Luxembourg,2013,6,N05C-Hypnotics and sedatives,Million US$ at exchange rate,4.0
+22884,Luxembourg,2013,6,N05C-Hypnotics and sedatives,"Million US$, purchasing power parity",3.4
+22885,Luxembourg,2013,6,N05C-Hypnotics and sedatives,"/capita, US$ purchasing power parity",6.7
+22886,Luxembourg,2013,6,N05C-Hypnotics and sedatives,% of total sales,1.6
+22887,Luxembourg,2013,6,N-Nervous system,"/capita, US$ purchasing power parity",70.4
+22888,Luxembourg,2013,6,N-Nervous system,"/capita, US$ exchange rate",83.7
+22889,Luxembourg,2013,6,N-Nervous system,% of total sales,16.2
+22890,Luxembourg,2013,6,N-Nervous system,Million US$ at exchange rate,42.0
+22891,Luxembourg,2013,6,N-Nervous system,Million of national currency units,31.7
+22892,Luxembourg,2013,6,N-Nervous system,"Million US$, purchasing power parity",35.4
+22893,Luxembourg,2013,6,N06A-Antidepressants,Million US$ at exchange rate,8.7
+22894,Luxembourg,2013,6,N06A-Antidepressants,"Million US$, purchasing power parity",7.3
+22895,Luxembourg,2013,6,A-Alimentary tract and metabolism,Million of national currency units,31.6
+22896,Luxembourg,2013,6,N06A-Antidepressants,Million of national currency units,6.5
+22897,Luxembourg,2013,6,N06A-Antidepressants,% of total sales,3.3
+22898,Luxembourg,2013,6,N06A-Antidepressants,"/capita, US$ purchasing power parity",14.5
+22899,Luxembourg,2013,6,N06A-Antidepressants,"/capita, US$ exchange rate",17.3
+22900,Luxembourg,2013,6,Total pharmaceutical sales,Million US$ at exchange rate,258.9
+22901,Luxembourg,2013,6,Total pharmaceutical sales,Million of national currency units,194.9
+22902,Luxembourg,2013,6,Total pharmaceutical sales,"Million US$, purchasing power parity",217.7
+22903,Luxembourg,2013,6,Total pharmaceutical sales,"/capita, US$ purchasing power parity",433.8
+22904,Luxembourg,2013,6,Total pharmaceutical sales,"/capita, US$ exchange rate",515.8
+22905,Luxembourg,2013,6,M01A-Antiinflammatory and antirheumatic products non-steroids,% of total sales,3.2
+22906,Luxembourg,2013,6,M01A-Antiinflammatory and antirheumatic products non-steroids,Million US$ at exchange rate,8.2
+22907,Luxembourg,2013,6,A02A-Antacids,Million of national currency units,0.3
+22908,Luxembourg,2013,6,M01A-Antiinflammatory and antirheumatic products non-steroids,Million of national currency units,6.2
+22909,Luxembourg,2013,6,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ purchasing power parity",13.7
+22910,Luxembourg,2013,6,M01A-Antiinflammatory and antirheumatic products non-steroids,"Million US$, purchasing power parity",6.9
+22911,Luxembourg,2013,6,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ exchange rate",16.3
+22912,Luxembourg,2013,6,N02-Analgesics,"/capita, US$ exchange rate",20.2
+22913,Luxembourg,2013,6,N02-Analgesics,"/capita, US$ purchasing power parity",17.0
+22914,Luxembourg,2013,6,N02-Analgesics,"Million US$, purchasing power parity",8.5
+22915,Luxembourg,2013,6,N02-Analgesics,Million of national currency units,7.6
+22916,Luxembourg,2013,6,N05C-Hypnotics and sedatives,Million of national currency units,3.0
+22917,Luxembourg,2013,6,N02-Analgesics,Million US$ at exchange rate,10.1
+22918,Luxembourg,2013,6,N02-Analgesics,% of total sales,3.9
+22919,Luxembourg,2013,6,R-Respiratory system,"/capita, US$ exchange rate",41.4
+22920,Luxembourg,2013,6,R-Respiratory system,% of total sales,8.0
+22921,Luxembourg,2013,6,R-Respiratory system,"/capita, US$ purchasing power parity",34.8
+22922,Luxembourg,2013,6,R-Respiratory system,Million of national currency units,15.6
+22923,Luxembourg,2013,6,R-Respiratory system,"Million US$, purchasing power parity",17.5
+22924,Luxembourg,2013,6,R-Respiratory system,Million US$ at exchange rate,20.8
+22925,Luxembourg,2013,6,C01A-Cardiac glycosides,"/capita, US$ purchasing power parity",0.1
+22926,Luxembourg,2013,6,B-Blood and blood forming organs,"Million US$, purchasing power parity",12.1
+22927,Luxembourg,2013,6,B-Blood and blood forming organs,"/capita, US$ exchange rate",28.6
+22928,Luxembourg,2013,6,B-Blood and blood forming organs,Million US$ at exchange rate,14.4
+22929,Luxembourg,2013,6,B-Blood and blood forming organs,Million of national currency units,10.8
+22930,Luxembourg,2013,6,C02-Antihypertensives,% of total sales,0.2
+22931,Luxembourg,2013,6,B-Blood and blood forming organs,% of total sales,5.6
+22932,Luxembourg,2013,6,B-Blood and blood forming organs,"/capita, US$ purchasing power parity",24.1
+22933,Luxembourg,2013,6,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ purchasing power parity",11.5
+22934,Luxembourg,2013,6,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ exchange rate",13.6
+22935,Luxembourg,2013,6,"H-Systemic hormonal preparations, excluding sex hormones and insulins",% of total sales,2.6
+22936,Luxembourg,2013,6,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million US$ at exchange rate,6.8
+22937,Luxembourg,2013,6,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million of national currency units,5.2
+22938,Luxembourg,2013,6,"H-Systemic hormonal preparations, excluding sex hormones and insulins","Million US$, purchasing power parity",5.8
+22939,Luxembourg,2013,6,C01A-Cardiac glycosides,"/capita, US$ exchange rate",0.1
+22940,Luxembourg,2013,6,C01A-Cardiac glycosides,Million US$ at exchange rate,0.1
+22941,Luxembourg,2013,6,C01A-Cardiac glycosides,"Million US$, purchasing power parity",0.1
+22942,Luxembourg,2013,6,C09-Agents acting on the Renin-Angiotensin system,% of total sales,6.8
+22943,Luxembourg,2013,6,M-Musculo-skeletal system,% of total sales,5.4
+22944,Luxembourg,2013,6,M-Musculo-skeletal system,"/capita, US$ purchasing power parity",23.4
+22945,Luxembourg,2013,6,J-Antiinfectives for systemic use,% of total sales,5.4
+22946,Luxembourg,2013,6,C10-Lipid modifying agents,% of total sales,8.0
+22947,Luxembourg,2013,6,M-Musculo-skeletal system,Million of national currency units,10.5
+22948,Luxembourg,2013,6,M-Musculo-skeletal system,"/capita, US$ exchange rate",27.8
+22949,Luxembourg,2013,6,C01A-Cardiac glycosides,Million of national currency units,0.1
+22950,Luxembourg,2013,6,M-Musculo-skeletal system,Million US$ at exchange rate,13.9
+22951,Luxembourg,2013,6,M-Musculo-skeletal system,"Million US$, purchasing power parity",11.7
+22952,Luxembourg,2013,6,C03-Diuretics,Million of national currency units,1.6
+22953,Luxembourg,2013,6,C10-Lipid modifying agents,"Million US$, purchasing power parity",17.4
+22954,Luxembourg,2013,6,C10-Lipid modifying agents,Million US$ at exchange rate,20.7
+22955,Luxembourg,2013,6,C03-Diuretics,Million US$ at exchange rate,2.2
+22956,Luxembourg,2013,6,C03-Diuretics,"/capita, US$ exchange rate",4.3
+22957,Luxembourg,2013,6,C03-Diuretics,"/capita, US$ purchasing power parity",3.6
+22958,Luxembourg,2013,6,C03-Diuretics,"Million US$, purchasing power parity",1.8
+22959,Luxembourg,2013,6,C02-Antihypertensives,"Million US$, purchasing power parity",0.5
+22960,Luxembourg,2013,6,C02-Antihypertensives,Million of national currency units,0.4
+22961,Luxembourg,2013,6,C02-Antihypertensives,Million US$ at exchange rate,0.5
+22962,Luxembourg,2013,6,C02-Antihypertensives,"/capita, US$ exchange rate",1.1
+22963,Luxembourg,2013,6,C10-Lipid modifying agents,"/capita, US$ exchange rate",41.3
+22964,Luxembourg,2013,6,C10-Lipid modifying agents,"/capita, US$ purchasing power parity",34.7
+22965,Luxembourg,2013,6,"C01B-Antiarrhythmics, Class I and III","/capita, US$ purchasing power parity",1.3
+22966,Luxembourg,2013,6,C02-Antihypertensives,"/capita, US$ purchasing power parity",0.9
+22967,Luxembourg,2013,6,"C01B-Antiarrhythmics, Class I and III","/capita, US$ exchange rate",1.5
+22968,Luxembourg,2013,6,"C01B-Antiarrhythmics, Class I and III",% of total sales,0.3
+22969,Luxembourg,2013,6,"C01B-Antiarrhythmics, Class I and III",Million US$ at exchange rate,0.8
+22970,Luxembourg,2013,6,"C01B-Antiarrhythmics, Class I and III",Million of national currency units,0.6
+22971,Luxembourg,2013,6,"C01B-Antiarrhythmics, Class I and III","Million US$, purchasing power parity",0.6
+22972,Luxembourg,2013,6,J-Antiinfectives for systemic use,Million of national currency units,10.4
+22973,Luxembourg,2013,6,J-Antiinfectives for systemic use,Million US$ at exchange rate,13.9
+22974,Luxembourg,2013,6,C10-Lipid modifying agents,Million of national currency units,15.6
+22975,Luxembourg,2013,6,C03-Diuretics,% of total sales,0.8
+22976,Luxembourg,2013,6,J-Antiinfectives for systemic use,"/capita, US$ exchange rate",27.6
+22977,Luxembourg,2013,6,J-Antiinfectives for systemic use,"/capita, US$ purchasing power parity",23.2
+22978,Luxembourg,2013,6,J-Antiinfectives for systemic use,"Million US$, purchasing power parity",11.7
+22979,Luxembourg,2013,6,J01-Antibacterials for systemic use,"Million US$, purchasing power parity",7.0
+22980,Luxembourg,2013,6,J01-Antibacterials for systemic use,Million US$ at exchange rate,8.4
+22981,Luxembourg,2013,6,G03-Sex hormones and modulators of the genital system,"/capita, US$ purchasing power parity",7.4
+22982,Luxembourg,2013,6,G03-Sex hormones and modulators of the genital system,% of total sales,1.7
+22983,Luxembourg,2013,6,C01A-Cardiac glycosides,% of total sales,0.0
+22984,Luxembourg,2013,6,G03-Sex hormones and modulators of the genital system,Million of national currency units,3.3
+22985,Luxembourg,2013,6,J01-Antibacterials for systemic use,"/capita, US$ purchasing power parity",14.0
+22986,Luxembourg,2013,6,G03-Sex hormones and modulators of the genital system,"/capita, US$ exchange rate",8.8
+22987,Luxembourg,2013,6,G03-Sex hormones and modulators of the genital system,"Million US$, purchasing power parity",3.7
+22988,Luxembourg,2013,6,G03-Sex hormones and modulators of the genital system,Million US$ at exchange rate,4.4
+22989,Luxembourg,2013,6,J01-Antibacterials for systemic use,Million of national currency units,6.3
+22990,Luxembourg,2013,6,A10-Drugs used in diabetes,"/capita, US$ purchasing power parity",26.9
+22991,Luxembourg,2013,6,A10-Drugs used in diabetes,% of total sales,6.2
+22992,Luxembourg,2013,6,A10-Drugs used in diabetes,"/capita, US$ exchange rate",32.0
+22993,Luxembourg,2013,6,A10-Drugs used in diabetes,Million US$ at exchange rate,16.1
+22994,Luxembourg,2013,6,A10-Drugs used in diabetes,Million of national currency units,12.1
+22995,Luxembourg,2013,6,A10-Drugs used in diabetes,"Million US$, purchasing power parity",13.5
+22996,Luxembourg,2013,6,G-Genito urinary system and sex hormones,Million of national currency units,8.0
+22997,Luxembourg,2013,6,G-Genito urinary system and sex hormones,"/capita, US$ exchange rate",21.2
+22998,Luxembourg,2013,6,G-Genito urinary system and sex hormones,"Million US$, purchasing power parity",9.0
+22999,Luxembourg,2013,6,G-Genito urinary system and sex hormones,"/capita, US$ purchasing power parity",17.9
+23000,Luxembourg,2013,6,G-Genito urinary system and sex hormones,Million US$ at exchange rate,10.7
+23001,Luxembourg,2013,6,C-Cardiovascular system,% of total sales,19.8
+23002,Luxembourg,2013,6,J01-Antibacterials for systemic use,"/capita, US$ exchange rate",16.6
+23003,Luxembourg,2013,6,J01-Antibacterials for systemic use,% of total sales,3.2
+23004,Luxembourg,2013,6,C09-Agents acting on the Renin-Angiotensin system,"Million US$, purchasing power parity",14.8
+23005,Luxembourg,2013,6,C07-Beta blocking agents,"/capita, US$ purchasing power parity",8.1
+23006,Luxembourg,2013,6,C07-Beta blocking agents,% of total sales,1.9
+23007,Luxembourg,2013,6,C08-Calcium channel blockers,% of total sales,1.2
+23008,Luxembourg,2013,6,C09-Agents acting on the Renin-Angiotensin system,Million US$ at exchange rate,17.6
+23009,Luxembourg,2013,6,C09-Agents acting on the Renin-Angiotensin system,Million of national currency units,13.3
+23010,Luxembourg,2013,6,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ exchange rate",35.1
+23011,Luxembourg,2013,6,C07-Beta blocking agents,Million of national currency units,3.7
+23012,Luxembourg,2013,6,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ purchasing power parity",29.5
+23013,Luxembourg,2013,6,C07-Beta blocking agents,"/capita, US$ exchange rate",9.7
+23014,Luxembourg,2013,6,C07-Beta blocking agents,Million US$ at exchange rate,4.9
+23015,Luxembourg,2013,6,C07-Beta blocking agents,"Million US$, purchasing power parity",4.1
+23016,Luxembourg,2013,6,C-Cardiovascular system,"Million US$, purchasing power parity",43.2
+23017,Luxembourg,2013,6,C-Cardiovascular system,"/capita, US$ exchange rate",102.4
+23018,Luxembourg,2013,6,C-Cardiovascular system,Million US$ at exchange rate,51.4
+23019,Luxembourg,2013,6,G-Genito urinary system and sex hormones,% of total sales,4.1
+23020,Luxembourg,2013,6,C-Cardiovascular system,"/capita, US$ purchasing power parity",86.1
+23021,Luxembourg,2013,6,C-Cardiovascular system,Million of national currency units,38.7
+23022,Luxembourg,2013,6,C08-Calcium channel blockers,Million US$ at exchange rate,3.0
+23023,Luxembourg,2013,6,C08-Calcium channel blockers,"Million US$, purchasing power parity",2.5
+23024,Luxembourg,2013,6,C08-Calcium channel blockers,"/capita, US$ purchasing power parity",5.0
+23025,Luxembourg,2013,6,C08-Calcium channel blockers,"/capita, US$ exchange rate",6.0
+23026,Luxembourg,2013,6,C08-Calcium channel blockers,Million of national currency units,2.3
+23027,Luxembourg,2012,7,N05B-Anxiolytics,Million of national currency units,2.3
+23028,Luxembourg,2012,7,N05B-Anxiolytics,"Million US$, purchasing power parity",2.6
+23029,Luxembourg,2012,7,N05B-Anxiolytics,% of total sales,1.2
+23030,Luxembourg,2012,7,N05B-Anxiolytics,"/capita, US$ exchange rate",6.1
+23031,Luxembourg,2012,7,N05B-Anxiolytics,"/capita, US$ purchasing power parity",5.2
+23032,Luxembourg,2012,7,A02A-Antacids,"/capita, US$ purchasing power parity",0.8
+23033,Luxembourg,2012,7,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ exchange rate",22.8
+23034,Luxembourg,2012,7,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ purchasing power parity",19.6
+23035,Luxembourg,2012,7,A02A-Antacids,% of total sales,0.2
+23036,Luxembourg,2012,7,A02A-Antacids,"/capita, US$ exchange rate",0.9
+23037,Luxembourg,2012,7,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),% of total sales,4.5
+23038,Luxembourg,2012,7,R03-Drugs for obstructive airway diseases,"/capita, US$ purchasing power parity",25.0
+23039,Luxembourg,2012,7,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million US$ at exchange rate,11.2
+23040,Luxembourg,2012,7,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million of national currency units,8.8
+23041,Luxembourg,2012,7,R03-Drugs for obstructive airway diseases,% of total sales,5.7
+23042,Luxembourg,2012,7,A02A-Antacids,Million US$ at exchange rate,0.4
+23043,Luxembourg,2012,7,A02A-Antacids,"Million US$, purchasing power parity",0.4
+23044,Luxembourg,2012,7,R03-Drugs for obstructive airway diseases,"/capita, US$ exchange rate",29.2
+23045,Luxembourg,2012,7,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"Million US$, purchasing power parity",9.6
+23046,Luxembourg,2012,7,R03-Drugs for obstructive airway diseases,"Million US$, purchasing power parity",12.3
+23047,Luxembourg,2012,7,R03-Drugs for obstructive airway diseases,Million of national currency units,11.2
+23048,Luxembourg,2012,7,R03-Drugs for obstructive airway diseases,Million US$ at exchange rate,14.4
+23049,Luxembourg,2012,7,R-Respiratory system,"Million US$, purchasing power parity",16.7
+23050,Luxembourg,2012,7,A-Alimentary tract and metabolism,"/capita, US$ purchasing power parity",66.9
+23051,Luxembourg,2012,7,A-Alimentary tract and metabolism,% of total sales,15.3
+23052,Luxembourg,2012,7,A-Alimentary tract and metabolism,Million US$ at exchange rate,38.4
+23053,Luxembourg,2012,7,A-Alimentary tract and metabolism,"/capita, US$ exchange rate",78.0
+23054,Luxembourg,2012,7,A-Alimentary tract and metabolism,"Million US$, purchasing power parity",33.0
+23055,Luxembourg,2012,7,N05C-Hypnotics and sedatives,% of total sales,1.5
+23056,Luxembourg,2012,7,N05C-Hypnotics and sedatives,"/capita, US$ exchange rate",7.8
+23057,Luxembourg,2012,7,N05C-Hypnotics and sedatives,Million US$ at exchange rate,3.9
+23058,Luxembourg,2012,7,N05C-Hypnotics and sedatives,"Million US$, purchasing power parity",3.3
+23059,Luxembourg,2012,7,N05C-Hypnotics and sedatives,"/capita, US$ purchasing power parity",6.7
+23060,Luxembourg,2012,7,N-Nervous system,"/capita, US$ purchasing power parity",73.6
+23061,Luxembourg,2012,7,N-Nervous system,% of total sales,16.8
+23062,Luxembourg,2012,7,N-Nervous system,"/capita, US$ exchange rate",85.7
+23063,Luxembourg,2012,7,N-Nervous system,Million US$ at exchange rate,42.2
+23064,Luxembourg,2012,7,N-Nervous system,Million of national currency units,32.9
+23065,Luxembourg,2012,7,N-Nervous system,"Million US$, purchasing power parity",36.2
+23066,Luxembourg,2012,7,N06A-Antidepressants,Million US$ at exchange rate,8.6
+23067,Luxembourg,2012,7,N06A-Antidepressants,"Million US$, purchasing power parity",7.4
+23068,Luxembourg,2012,7,A-Alimentary tract and metabolism,Million of national currency units,29.9
+23069,Luxembourg,2012,7,N05B-Anxiolytics,Million US$ at exchange rate,3.0
+23070,Luxembourg,2012,7,N06A-Antidepressants,Million of national currency units,6.7
+23071,Luxembourg,2012,7,N06A-Antidepressants,% of total sales,3.4
+23072,Luxembourg,2012,7,N06A-Antidepressants,"/capita, US$ purchasing power parity",15.1
+23073,Luxembourg,2012,7,N06A-Antidepressants,"/capita, US$ exchange rate",17.6
+23074,Luxembourg,2012,7,Total pharmaceutical sales,Million US$ at exchange rate,251.5
+23075,Luxembourg,2012,7,Total pharmaceutical sales,Million of national currency units,195.8
+23076,Luxembourg,2012,7,Total pharmaceutical sales,"Million US$, purchasing power parity",215.9
+23077,Luxembourg,2012,7,Total pharmaceutical sales,"/capita, US$ purchasing power parity",438.3
+23078,Luxembourg,2012,7,Total pharmaceutical sales,"/capita, US$ exchange rate",510.7
+23079,Luxembourg,2012,7,M01A-Antiinflammatory and antirheumatic products non-steroids,% of total sales,3.1
+23080,Luxembourg,2012,7,M01A-Antiinflammatory and antirheumatic products non-steroids,Million US$ at exchange rate,7.7
+23081,Luxembourg,2012,7,A02A-Antacids,Million of national currency units,0.3
+23082,Luxembourg,2012,7,M01A-Antiinflammatory and antirheumatic products non-steroids,Million of national currency units,6.0
+23083,Luxembourg,2012,7,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ purchasing power parity",13.4
+23084,Luxembourg,2012,7,M01A-Antiinflammatory and antirheumatic products non-steroids,"Million US$, purchasing power parity",6.6
+23085,Luxembourg,2012,7,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ exchange rate",15.7
+23086,Luxembourg,2012,7,N02-Analgesics,"/capita, US$ exchange rate",19.5
+23087,Luxembourg,2012,7,N02-Analgesics,"/capita, US$ purchasing power parity",16.7
+23088,Luxembourg,2012,7,N02-Analgesics,"Million US$, purchasing power parity",8.2
+23089,Luxembourg,2012,7,N02-Analgesics,Million of national currency units,7.5
+23090,Luxembourg,2012,7,N05C-Hypnotics and sedatives,Million of national currency units,3.0
+23091,Luxembourg,2012,7,N02-Analgesics,Million US$ at exchange rate,9.6
+23092,Luxembourg,2012,7,N02-Analgesics,% of total sales,3.8
+23093,Luxembourg,2012,7,R-Respiratory system,"/capita, US$ exchange rate",39.4
+23094,Luxembourg,2012,7,R-Respiratory system,% of total sales,7.7
+23095,Luxembourg,2012,7,R-Respiratory system,"/capita, US$ purchasing power parity",33.9
+23096,Luxembourg,2012,7,R-Respiratory system,Million of national currency units,15.1
+23097,Luxembourg,2012,7,R-Respiratory system,Million US$ at exchange rate,19.4
+23098,Luxembourg,2012,7,B-Blood and blood forming organs,"Million US$, purchasing power parity",11.1
+23099,Luxembourg,2012,7,B-Blood and blood forming organs,"/capita, US$ exchange rate",26.2
+23100,Luxembourg,2012,7,B-Blood and blood forming organs,Million US$ at exchange rate,12.9
+23101,Luxembourg,2012,7,C02-Antihypertensives,% of total sales,0.2
+23102,Luxembourg,2012,7,B-Blood and blood forming organs,% of total sales,5.1
+23103,Luxembourg,2012,7,B-Blood and blood forming organs,"/capita, US$ purchasing power parity",22.5
+23104,Luxembourg,2012,7,B-Blood and blood forming organs,Million of national currency units,10.1
+23105,Luxembourg,2012,7,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ purchasing power parity",10.9
+23106,Luxembourg,2012,7,"H-Systemic hormonal preparations, excluding sex hormones and insulins",% of total sales,2.5
+23107,Luxembourg,2012,7,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ exchange rate",12.7
+23108,Luxembourg,2012,7,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million US$ at exchange rate,6.2
+23109,Luxembourg,2012,7,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million of national currency units,4.9
+23110,Luxembourg,2012,7,"H-Systemic hormonal preparations, excluding sex hormones and insulins","Million US$, purchasing power parity",5.3
+23111,Luxembourg,2012,7,C01A-Cardiac glycosides,"/capita, US$ exchange rate",0.1
+23112,Luxembourg,2012,7,C01A-Cardiac glycosides,Million US$ at exchange rate,0.1
+23113,Luxembourg,2012,7,C01A-Cardiac glycosides,"Million US$, purchasing power parity",0.1
+23114,Luxembourg,2012,7,M-Musculo-skeletal system,% of total sales,5.0
+23115,Luxembourg,2012,7,M-Musculo-skeletal system,"/capita, US$ purchasing power parity",21.9
+23116,Luxembourg,2012,7,J-Antiinfectives for systemic use,% of total sales,5.6
+23117,Luxembourg,2012,7,C01A-Cardiac glycosides,"/capita, US$ purchasing power parity",0.1
+23118,Luxembourg,2012,7,M-Musculo-skeletal system,Million of national currency units,9.8
+23119,Luxembourg,2012,7,M-Musculo-skeletal system,"/capita, US$ exchange rate",25.6
+23120,Luxembourg,2012,7,C01A-Cardiac glycosides,Million of national currency units,0.1
+23121,Luxembourg,2012,7,M-Musculo-skeletal system,Million US$ at exchange rate,12.6
+23122,Luxembourg,2012,7,M-Musculo-skeletal system,"Million US$, purchasing power parity",10.8
+23123,Luxembourg,2012,7,C09-Agents acting on the Renin-Angiotensin system,% of total sales,7.4
+23124,Luxembourg,2012,7,C03-Diuretics,Million of national currency units,1.6
+23125,Luxembourg,2012,7,C10-Lipid modifying agents,"Million US$, purchasing power parity",19.3
+23126,Luxembourg,2012,7,C03-Diuretics,Million US$ at exchange rate,2.0
+23127,Luxembourg,2012,7,C10-Lipid modifying agents,Million US$ at exchange rate,22.4
+23128,Luxembourg,2012,7,C03-Diuretics,"/capita, US$ exchange rate",4.1
+23129,Luxembourg,2012,7,C03-Diuretics,"/capita, US$ purchasing power parity",3.5
+23130,Luxembourg,2012,7,C03-Diuretics,"Million US$, purchasing power parity",1.7
+23131,Luxembourg,2012,7,C02-Antihypertensives,"Million US$, purchasing power parity",0.4
+23132,Luxembourg,2012,7,C02-Antihypertensives,Million of national currency units,0.4
+23133,Luxembourg,2012,7,C02-Antihypertensives,"/capita, US$ exchange rate",1.0
+23134,Luxembourg,2012,7,C02-Antihypertensives,Million US$ at exchange rate,0.5
+23135,Luxembourg,2012,7,C10-Lipid modifying agents,"/capita, US$ exchange rate",45.5
+23136,Luxembourg,2012,7,C10-Lipid modifying agents,"/capita, US$ purchasing power parity",39.1
+23137,Luxembourg,2012,7,C10-Lipid modifying agents,% of total sales,8.9
+23138,Luxembourg,2012,7,"C01B-Antiarrhythmics, Class I and III","/capita, US$ purchasing power parity",1.3
+23139,Luxembourg,2012,7,C02-Antihypertensives,"/capita, US$ purchasing power parity",0.9
+23140,Luxembourg,2012,7,"C01B-Antiarrhythmics, Class I and III",% of total sales,0.3
+23141,Luxembourg,2012,7,"C01B-Antiarrhythmics, Class I and III","/capita, US$ exchange rate",1.5
+23142,Luxembourg,2012,7,"C01B-Antiarrhythmics, Class I and III",Million US$ at exchange rate,0.7
+23143,Luxembourg,2012,7,"C01B-Antiarrhythmics, Class I and III",Million of national currency units,0.6
+23144,Luxembourg,2012,7,"C01B-Antiarrhythmics, Class I and III","Million US$, purchasing power parity",0.6
+23145,Luxembourg,2012,7,J-Antiinfectives for systemic use,Million of national currency units,11.1
+23146,Luxembourg,2012,7,J-Antiinfectives for systemic use,Million US$ at exchange rate,14.2
+23147,Luxembourg,2012,7,C10-Lipid modifying agents,Million of national currency units,17.5
+23148,Luxembourg,2012,7,C03-Diuretics,% of total sales,0.8
+23149,Luxembourg,2012,7,J-Antiinfectives for systemic use,"/capita, US$ purchasing power parity",24.8
+23150,Luxembourg,2012,7,J-Antiinfectives for systemic use,"/capita, US$ exchange rate",28.8
+23151,Luxembourg,2012,7,J-Antiinfectives for systemic use,"Million US$, purchasing power parity",12.2
+23152,Luxembourg,2012,7,J01-Antibacterials for systemic use,"Million US$, purchasing power parity",7.1
+23153,Luxembourg,2012,7,J01-Antibacterials for systemic use,Million US$ at exchange rate,8.3
+23154,Luxembourg,2012,7,G03-Sex hormones and modulators of the genital system,"/capita, US$ purchasing power parity",7.9
+23155,Luxembourg,2012,7,G03-Sex hormones and modulators of the genital system,% of total sales,1.8
+23156,Luxembourg,2012,7,C01A-Cardiac glycosides,% of total sales,0.0
+23157,Luxembourg,2012,7,J01-Antibacterials for systemic use,"/capita, US$ exchange rate",16.9
+23158,Luxembourg,2012,7,G03-Sex hormones and modulators of the genital system,Million of national currency units,3.5
+23159,Luxembourg,2012,7,J01-Antibacterials for systemic use,"/capita, US$ purchasing power parity",14.5
+23160,Luxembourg,2012,7,G03-Sex hormones and modulators of the genital system,"/capita, US$ exchange rate",9.2
+23161,Luxembourg,2012,7,G03-Sex hormones and modulators of the genital system,"Million US$, purchasing power parity",3.9
+23162,Luxembourg,2012,7,G03-Sex hormones and modulators of the genital system,Million US$ at exchange rate,4.5
+23163,Luxembourg,2012,7,J01-Antibacterials for systemic use,Million of national currency units,6.5
+23164,Luxembourg,2012,7,A10-Drugs used in diabetes,"/capita, US$ purchasing power parity",24.7
+23165,Luxembourg,2012,7,A10-Drugs used in diabetes,% of total sales,5.6
+23166,Luxembourg,2012,7,A10-Drugs used in diabetes,"/capita, US$ exchange rate",28.8
+23167,Luxembourg,2012,7,A10-Drugs used in diabetes,Million US$ at exchange rate,14.2
+23168,Luxembourg,2012,7,A10-Drugs used in diabetes,Million of national currency units,11.0
+23169,Luxembourg,2012,7,A10-Drugs used in diabetes,"Million US$, purchasing power parity",12.2
+23170,Luxembourg,2012,7,G-Genito urinary system and sex hormones,Million of national currency units,8.1
+23171,Luxembourg,2012,7,G-Genito urinary system and sex hormones,"/capita, US$ exchange rate",21.0
+23172,Luxembourg,2012,7,G-Genito urinary system and sex hormones,"/capita, US$ purchasing power parity",18.0
+23173,Luxembourg,2012,7,G-Genito urinary system and sex hormones,"Million US$, purchasing power parity",8.9
+23174,Luxembourg,2012,7,G-Genito urinary system and sex hormones,Million US$ at exchange rate,10.3
+23175,Luxembourg,2012,7,C-Cardiovascular system,% of total sales,21.3
+23176,Luxembourg,2012,7,C09-Agents acting on the Renin-Angiotensin system,"Million US$, purchasing power parity",15.9
+23177,Luxembourg,2012,7,C07-Beta blocking agents,"/capita, US$ purchasing power parity",7.9
+23178,Luxembourg,2012,7,C07-Beta blocking agents,% of total sales,1.8
+23179,Luxembourg,2012,7,C08-Calcium channel blockers,% of total sales,1.2
+23180,Luxembourg,2012,7,C09-Agents acting on the Renin-Angiotensin system,Million US$ at exchange rate,18.6
+23181,Luxembourg,2012,7,J01-Antibacterials for systemic use,% of total sales,3.3
+23182,Luxembourg,2012,7,C09-Agents acting on the Renin-Angiotensin system,Million of national currency units,14.4
+23183,Luxembourg,2012,7,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ exchange rate",37.7
+23184,Luxembourg,2012,7,C07-Beta blocking agents,Million of national currency units,3.5
+23185,Luxembourg,2012,7,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ purchasing power parity",32.3
+23186,Luxembourg,2012,7,C07-Beta blocking agents,"/capita, US$ exchange rate",9.2
+23187,Luxembourg,2012,7,C07-Beta blocking agents,"Million US$, purchasing power parity",3.9
+23188,Luxembourg,2012,7,C07-Beta blocking agents,Million US$ at exchange rate,4.5
+23189,Luxembourg,2012,7,C-Cardiovascular system,"Million US$, purchasing power parity",46.0
+23190,Luxembourg,2012,7,C-Cardiovascular system,"/capita, US$ exchange rate",108.8
+23191,Luxembourg,2012,7,C-Cardiovascular system,Million US$ at exchange rate,53.6
+23192,Luxembourg,2012,7,G-Genito urinary system and sex hormones,% of total sales,4.1
+23193,Luxembourg,2012,7,C-Cardiovascular system,"/capita, US$ purchasing power parity",93.4
+23194,Luxembourg,2012,7,C08-Calcium channel blockers,Million US$ at exchange rate,3.1
+23195,Luxembourg,2012,7,C08-Calcium channel blockers,"Million US$, purchasing power parity",2.6
+23196,Luxembourg,2012,7,C08-Calcium channel blockers,"/capita, US$ purchasing power parity",5.4
+23197,Luxembourg,2012,7,C08-Calcium channel blockers,"/capita, US$ exchange rate",6.2
+23198,Luxembourg,2012,7,C-Cardiovascular system,Million of national currency units,41.7
+23199,Luxembourg,2012,7,C08-Calcium channel blockers,Million of national currency units,2.4
+23200,Luxembourg,2011,8,N05B-Anxiolytics,"Million US$, purchasing power parity",2.6
+23201,Luxembourg,2011,8,N05B-Anxiolytics,Million of national currency units,2.4
+23202,Luxembourg,2011,8,N05B-Anxiolytics,% of total sales,1.3
+23203,Luxembourg,2011,8,N05B-Anxiolytics,"/capita, US$ purchasing power parity",5.5
+23204,Luxembourg,2011,8,N05B-Anxiolytics,"/capita, US$ exchange rate",6.9
+23205,Luxembourg,2011,8,A02A-Antacids,"/capita, US$ purchasing power parity",0.7
+23206,Luxembourg,2011,8,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ exchange rate",25.0
+23207,Luxembourg,2011,8,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ purchasing power parity",19.8
+23208,Luxembourg,2011,8,A02A-Antacids,% of total sales,0.2
+23209,Luxembourg,2011,8,R03-Drugs for obstructive airway diseases,% of total sales,5.8
+23210,Luxembourg,2011,8,A02A-Antacids,"/capita, US$ exchange rate",0.9
+23211,Luxembourg,2011,8,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),% of total sales,4.5
+23212,Luxembourg,2011,8,R03-Drugs for obstructive airway diseases,"/capita, US$ purchasing power parity",25.1
+23213,Luxembourg,2011,8,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million US$ at exchange rate,12.0
+23214,Luxembourg,2011,8,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million of national currency units,8.6
+23215,Luxembourg,2011,8,A02A-Antacids,"Million US$, purchasing power parity",0.3
+23216,Luxembourg,2011,8,R03-Drugs for obstructive airway diseases,Million of national currency units,11.0
+23217,Luxembourg,2011,8,R03-Drugs for obstructive airway diseases,"/capita, US$ exchange rate",31.6
+23218,Luxembourg,2011,8,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"Million US$, purchasing power parity",9.5
+23219,Luxembourg,2011,8,R03-Drugs for obstructive airway diseases,Million US$ at exchange rate,15.2
+23220,Luxembourg,2011,8,R03-Drugs for obstructive airway diseases,"Million US$, purchasing power parity",12.1
+23221,Luxembourg,2011,8,N-Nervous system,Million of national currency units,33.5
+23222,Luxembourg,2011,8,A-Alimentary tract and metabolism,"/capita, US$ purchasing power parity",65.1
+23223,Luxembourg,2011,8,A-Alimentary tract and metabolism,% of total sales,14.9
+23224,Luxembourg,2011,8,A-Alimentary tract and metabolism,Million US$ at exchange rate,39.5
+23225,Luxembourg,2011,8,A-Alimentary tract and metabolism,"Million US$, purchasing power parity",31.4
+23226,Luxembourg,2011,8,A-Alimentary tract and metabolism,"/capita, US$ exchange rate",82.0
+23227,Luxembourg,2011,8,N05C-Hypnotics and sedatives,"/capita, US$ exchange rate",8.7
+23228,Luxembourg,2011,8,N05C-Hypnotics and sedatives,Million US$ at exchange rate,4.2
+23229,Luxembourg,2011,8,N05C-Hypnotics and sedatives,"Million US$, purchasing power parity",3.3
+23230,Luxembourg,2011,8,N05C-Hypnotics and sedatives,"/capita, US$ purchasing power parity",6.9
+23231,Luxembourg,2011,8,N05C-Hypnotics and sedatives,% of total sales,1.6
+23232,Luxembourg,2011,8,N-Nervous system,"/capita, US$ purchasing power parity",76.8
+23233,Luxembourg,2011,8,N-Nervous system,% of total sales,17.6
+23234,Luxembourg,2011,8,N-Nervous system,"/capita, US$ exchange rate",96.8
+23235,Luxembourg,2011,8,N-Nervous system,Million US$ at exchange rate,46.6
+23236,Luxembourg,2011,8,N-Nervous system,"Million US$, purchasing power parity",37.0
+23237,Luxembourg,2011,8,N06A-Antidepressants,"Million US$, purchasing power parity",7.5
+23238,Luxembourg,2011,8,N06A-Antidepressants,Million US$ at exchange rate,9.5
+23239,Luxembourg,2011,8,A-Alimentary tract and metabolism,Million of national currency units,28.4
+23240,Luxembourg,2011,8,N06A-Antidepressants,Million of national currency units,6.8
+23241,Luxembourg,2011,8,N06A-Antidepressants,% of total sales,3.6
+23242,Luxembourg,2011,8,N06A-Antidepressants,"/capita, US$ purchasing power parity",15.6
+23243,Luxembourg,2011,8,N06A-Antidepressants,"/capita, US$ exchange rate",19.6
+23244,Luxembourg,2011,8,Total pharmaceutical sales,Million US$ at exchange rate,265.0
+23245,Luxembourg,2011,8,Total pharmaceutical sales,"Million US$, purchasing power parity",210.4
+23246,Luxembourg,2011,8,Total pharmaceutical sales,Million of national currency units,190.4
+23247,Luxembourg,2011,8,Total pharmaceutical sales,"/capita, US$ purchasing power parity",436.5
+23248,Luxembourg,2011,8,Total pharmaceutical sales,"/capita, US$ exchange rate",549.9
+23249,Luxembourg,2011,8,M01A-Antiinflammatory and antirheumatic products non-steroids,% of total sales,2.9
+23250,Luxembourg,2011,8,M01A-Antiinflammatory and antirheumatic products non-steroids,Million US$ at exchange rate,7.7
+23251,Luxembourg,2011,8,A02A-Antacids,Million of national currency units,0.3
+23252,Luxembourg,2011,8,M01A-Antiinflammatory and antirheumatic products non-steroids,Million of national currency units,5.5
+23253,Luxembourg,2011,8,M01A-Antiinflammatory and antirheumatic products non-steroids,"Million US$, purchasing power parity",6.1
+23254,Luxembourg,2011,8,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ purchasing power parity",12.6
+23255,Luxembourg,2011,8,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ exchange rate",15.9
+23256,Luxembourg,2011,8,A02A-Antacids,Million US$ at exchange rate,0.4
+23257,Luxembourg,2011,8,N02-Analgesics,"/capita, US$ exchange rate",21.0
+23258,Luxembourg,2011,8,N02-Analgesics,% of total sales,3.8
+23259,Luxembourg,2011,8,N02-Analgesics,"/capita, US$ purchasing power parity",16.7
+23260,Luxembourg,2011,8,N02-Analgesics,"Million US$, purchasing power parity",8.0
+23261,Luxembourg,2011,8,N02-Analgesics,Million of national currency units,7.3
+23262,Luxembourg,2011,8,N05C-Hypnotics and sedatives,Million of national currency units,3.0
+23263,Luxembourg,2011,8,N02-Analgesics,Million US$ at exchange rate,10.1
+23264,Luxembourg,2011,8,R-Respiratory system,"/capita, US$ exchange rate",43.2
+23265,Luxembourg,2011,8,R-Respiratory system,"/capita, US$ purchasing power parity",34.3
+23266,Luxembourg,2011,8,R-Respiratory system,% of total sales,7.9
+23267,Luxembourg,2011,8,R-Respiratory system,Million of national currency units,15.0
+23268,Luxembourg,2011,8,R-Respiratory system,"Million US$, purchasing power parity",16.5
+23269,Luxembourg,2011,8,R-Respiratory system,Million US$ at exchange rate,20.8
+23270,Luxembourg,2011,8,N05B-Anxiolytics,Million US$ at exchange rate,3.3
+23271,Luxembourg,2011,8,A10-Drugs used in diabetes,Million of national currency units,10.3
+23272,Luxembourg,2011,8,B-Blood and blood forming organs,"Million US$, purchasing power parity",10.1
+23273,Luxembourg,2011,8,B-Blood and blood forming organs,"/capita, US$ exchange rate",26.4
+23274,Luxembourg,2011,8,B-Blood and blood forming organs,Million US$ at exchange rate,12.7
+23275,Luxembourg,2011,8,C02-Antihypertensives,% of total sales,0.2
+23276,Luxembourg,2011,8,B-Blood and blood forming organs,% of total sales,4.8
+23277,Luxembourg,2011,8,B-Blood and blood forming organs,"/capita, US$ purchasing power parity",21.0
+23278,Luxembourg,2011,8,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ purchasing power parity",9.9
+23279,Luxembourg,2011,8,"H-Systemic hormonal preparations, excluding sex hormones and insulins",% of total sales,2.3
+23280,Luxembourg,2011,8,B-Blood and blood forming organs,Million of national currency units,9.2
+23281,Luxembourg,2011,8,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million US$ at exchange rate,6.0
+23282,Luxembourg,2011,8,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million of national currency units,4.3
+23283,Luxembourg,2011,8,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ exchange rate",12.4
+23284,Luxembourg,2011,8,"H-Systemic hormonal preparations, excluding sex hormones and insulins","Million US$, purchasing power parity",4.8
+23285,Luxembourg,2011,8,C01A-Cardiac glycosides,"/capita, US$ exchange rate",0.1
+23286,Luxembourg,2011,8,C01A-Cardiac glycosides,"Million US$, purchasing power parity",0.1
+23287,Luxembourg,2011,8,C01A-Cardiac glycosides,Million US$ at exchange rate,0.1
+23288,Luxembourg,2011,8,C02-Antihypertensives,Million of national currency units,0.4
+23289,Luxembourg,2011,8,M-Musculo-skeletal system,"/capita, US$ purchasing power parity",21.2
+23290,Luxembourg,2011,8,M-Musculo-skeletal system,% of total sales,4.8
+23291,Luxembourg,2011,8,J-Antiinfectives for systemic use,% of total sales,5.6
+23292,Luxembourg,2011,8,M-Musculo-skeletal system,Million of national currency units,9.2
+23293,Luxembourg,2011,8,M-Musculo-skeletal system,Million US$ at exchange rate,12.8
+23294,Luxembourg,2011,8,M-Musculo-skeletal system,"/capita, US$ exchange rate",26.7
+23295,Luxembourg,2011,8,C01A-Cardiac glycosides,Million of national currency units,0.1
+23296,Luxembourg,2011,8,M-Musculo-skeletal system,"Million US$, purchasing power parity",10.2
+23297,Luxembourg,2011,8,C03-Diuretics,Million of national currency units,1.6
+23298,Luxembourg,2011,8,C03-Diuretics,Million US$ at exchange rate,2.3
+23299,Luxembourg,2011,8,C10-Lipid modifying agents,"Million US$, purchasing power parity",19.3
+23300,Luxembourg,2011,8,C10-Lipid modifying agents,Million US$ at exchange rate,24.3
+23301,Luxembourg,2011,8,C03-Diuretics,"/capita, US$ purchasing power parity",3.7
+23302,Luxembourg,2011,8,C03-Diuretics,"/capita, US$ exchange rate",4.7
+23303,Luxembourg,2011,8,C03-Diuretics,"Million US$, purchasing power parity",1.8
+23304,Luxembourg,2011,8,C02-Antihypertensives,"Million US$, purchasing power parity",0.5
+23305,Luxembourg,2011,8,C02-Antihypertensives,"/capita, US$ exchange rate",1.2
+23306,Luxembourg,2011,8,C02-Antihypertensives,Million US$ at exchange rate,0.6
+23307,Luxembourg,2011,8,C10-Lipid modifying agents,"/capita, US$ exchange rate",50.3
+23308,Luxembourg,2011,8,C10-Lipid modifying agents,"/capita, US$ purchasing power parity",40.0
+23309,Luxembourg,2011,8,C10-Lipid modifying agents,% of total sales,9.2
+23310,Luxembourg,2011,8,"C01B-Antiarrhythmics, Class I and III","/capita, US$ purchasing power parity",1.3
+23311,Luxembourg,2011,8,C02-Antihypertensives,"/capita, US$ purchasing power parity",1.0
+23312,Luxembourg,2011,8,"C01B-Antiarrhythmics, Class I and III",% of total sales,0.3
+23313,Luxembourg,2011,8,"C01B-Antiarrhythmics, Class I and III",Million US$ at exchange rate,0.8
+23314,Luxembourg,2011,8,"C01B-Antiarrhythmics, Class I and III",Million of national currency units,0.6
+23315,Luxembourg,2011,8,"C01B-Antiarrhythmics, Class I and III","/capita, US$ exchange rate",1.6
+23316,Luxembourg,2011,8,"C01B-Antiarrhythmics, Class I and III","Million US$, purchasing power parity",0.6
+23317,Luxembourg,2011,8,J-Antiinfectives for systemic use,Million of national currency units,10.6
+23318,Luxembourg,2011,8,J-Antiinfectives for systemic use,Million US$ at exchange rate,14.8
+23319,Luxembourg,2011,8,C10-Lipid modifying agents,Million of national currency units,17.4
+23320,Luxembourg,2011,8,C03-Diuretics,% of total sales,0.9
+23321,Luxembourg,2011,8,J-Antiinfectives for systemic use,"/capita, US$ purchasing power parity",24.3
+23322,Luxembourg,2011,8,J-Antiinfectives for systemic use,"Million US$, purchasing power parity",11.7
+23323,Luxembourg,2011,8,J-Antiinfectives for systemic use,"/capita, US$ exchange rate",30.6
+23324,Luxembourg,2011,8,C09-Agents acting on the Renin-Angiotensin system,% of total sales,7.7
+23325,Luxembourg,2011,8,J01-Antibacterials for systemic use,"Million US$, purchasing power parity",7.5
+23326,Luxembourg,2011,8,J01-Antibacterials for systemic use,Million US$ at exchange rate,9.5
+23327,Luxembourg,2011,8,G03-Sex hormones and modulators of the genital system,"/capita, US$ purchasing power parity",5.7
+23328,Luxembourg,2011,8,G03-Sex hormones and modulators of the genital system,% of total sales,1.3
+23329,Luxembourg,2011,8,C01A-Cardiac glycosides,% of total sales,0.0
+23330,Luxembourg,2011,8,J01-Antibacterials for systemic use,"/capita, US$ exchange rate",19.7
+23331,Luxembourg,2011,8,G03-Sex hormones and modulators of the genital system,Million of national currency units,2.5
+23332,Luxembourg,2011,8,J01-Antibacterials for systemic use,"/capita, US$ purchasing power parity",15.6
+23333,Luxembourg,2011,8,G03-Sex hormones and modulators of the genital system,"/capita, US$ exchange rate",7.1
+23334,Luxembourg,2011,8,G03-Sex hormones and modulators of the genital system,Million US$ at exchange rate,3.4
+23335,Luxembourg,2011,8,G03-Sex hormones and modulators of the genital system,"Million US$, purchasing power parity",2.7
+23336,Luxembourg,2011,8,J01-Antibacterials for systemic use,Million of national currency units,6.8
+23337,Luxembourg,2011,8,A10-Drugs used in diabetes,"/capita, US$ purchasing power parity",23.6
+23338,Luxembourg,2011,8,A10-Drugs used in diabetes,% of total sales,5.4
+23339,Luxembourg,2011,8,G-Genito urinary system and sex hormones,Million of national currency units,6.8
+23340,Luxembourg,2011,8,A10-Drugs used in diabetes,Million US$ at exchange rate,14.4
+23341,Luxembourg,2011,8,A10-Drugs used in diabetes,"Million US$, purchasing power parity",11.4
+23342,Luxembourg,2011,8,A10-Drugs used in diabetes,"/capita, US$ exchange rate",29.8
+23343,Luxembourg,2011,8,G-Genito urinary system and sex hormones,"/capita, US$ exchange rate",19.7
+23344,Luxembourg,2011,8,G-Genito urinary system and sex hormones,"/capita, US$ purchasing power parity",15.6
+23345,Luxembourg,2011,8,G-Genito urinary system and sex hormones,"Million US$, purchasing power parity",7.5
+23346,Luxembourg,2011,8,G-Genito urinary system and sex hormones,Million US$ at exchange rate,9.5
+23347,Luxembourg,2011,8,C-Cardiovascular system,% of total sales,22.0
+23348,Luxembourg,2011,8,J01-Antibacterials for systemic use,% of total sales,3.6
+23349,Luxembourg,2011,8,C09-Agents acting on the Renin-Angiotensin system,"Million US$, purchasing power parity",16.1
+23350,Luxembourg,2011,8,C07-Beta blocking agents,"/capita, US$ purchasing power parity",7.6
+23351,Luxembourg,2011,8,C07-Beta blocking agents,% of total sales,1.7
+23352,Luxembourg,2011,8,C08-Calcium channel blockers,% of total sales,1.4
+23353,Luxembourg,2011,8,C09-Agents acting on the Renin-Angiotensin system,Million of national currency units,14.6
+23354,Luxembourg,2011,8,C09-Agents acting on the Renin-Angiotensin system,Million US$ at exchange rate,20.3
+23355,Luxembourg,2011,8,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ exchange rate",42.2
+23356,Luxembourg,2011,8,C07-Beta blocking agents,Million of national currency units,3.3
+23357,Luxembourg,2011,8,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ purchasing power parity",33.5
+23358,Luxembourg,2011,8,C07-Beta blocking agents,"/capita, US$ exchange rate",9.6
+23359,Luxembourg,2011,8,C07-Beta blocking agents,Million US$ at exchange rate,4.6
+23360,Luxembourg,2011,8,C07-Beta blocking agents,"Million US$, purchasing power parity",3.7
+23361,Luxembourg,2011,8,C01A-Cardiac glycosides,"/capita, US$ purchasing power parity",0.1
+23362,Luxembourg,2011,8,C-Cardiovascular system,"Million US$, purchasing power parity",46.3
+23363,Luxembourg,2011,8,C-Cardiovascular system,"/capita, US$ exchange rate",121.2
+23364,Luxembourg,2011,8,C-Cardiovascular system,Million US$ at exchange rate,58.4
+23365,Luxembourg,2011,8,G-Genito urinary system and sex hormones,% of total sales,3.6
+23366,Luxembourg,2011,8,C-Cardiovascular system,"/capita, US$ purchasing power parity",96.2
+23367,Luxembourg,2011,8,C08-Calcium channel blockers,"Million US$, purchasing power parity",2.9
+23368,Luxembourg,2011,8,C08-Calcium channel blockers,"/capita, US$ purchasing power parity",5.9
+23369,Luxembourg,2011,8,C08-Calcium channel blockers,"/capita, US$ exchange rate",7.5
+23370,Luxembourg,2011,8,C08-Calcium channel blockers,Million US$ at exchange rate,3.6
+23371,Luxembourg,2011,8,C-Cardiovascular system,Million of national currency units,42.0
+23372,Luxembourg,2011,8,C08-Calcium channel blockers,Million of national currency units,2.6
+23373,Luxembourg,2010,8,N05B-Anxiolytics,"Million US$, purchasing power parity",2.6
+23374,Luxembourg,2010,8,N05B-Anxiolytics,Million of national currency units,2.4
+23375,Luxembourg,2010,8,N05B-Anxiolytics,Million US$ at exchange rate,3.2
+23376,Luxembourg,2010,8,N05B-Anxiolytics,"/capita, US$ exchange rate",6.7
+23377,Luxembourg,2010,8,N05B-Anxiolytics,% of total sales,1.3
+23378,Luxembourg,2010,8,N05B-Anxiolytics,"/capita, US$ purchasing power parity",5.5
+23379,Luxembourg,2010,8,A02A-Antacids,"/capita, US$ purchasing power parity",0.6
+23380,Luxembourg,2010,8,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ purchasing power parity",24.1
+23381,Luxembourg,2010,8,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ exchange rate",29.6
+23382,Luxembourg,2010,8,A02A-Antacids,% of total sales,0.1
+23383,Luxembourg,2010,8,R03-Drugs for obstructive airway diseases,% of total sales,5.6
+23384,Luxembourg,2010,8,A02A-Antacids,"/capita, US$ exchange rate",0.8
+23385,Luxembourg,2010,8,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),% of total sales,5.6
+23386,Luxembourg,2010,8,R03-Drugs for obstructive airway diseases,"/capita, US$ purchasing power parity",24.3
+23387,Luxembourg,2010,8,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million US$ at exchange rate,14.0
+23388,Luxembourg,2010,8,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million of national currency units,10.6
+23389,Luxembourg,2010,8,R03-Drugs for obstructive airway diseases,Million of national currency units,10.7
+23390,Luxembourg,2010,8,A02A-Antacids,"Million US$, purchasing power parity",0.3
+23391,Luxembourg,2010,8,R03-Drugs for obstructive airway diseases,"/capita, US$ exchange rate",29.8
+23392,Luxembourg,2010,8,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"Million US$, purchasing power parity",11.4
+23393,Luxembourg,2010,8,R03-Drugs for obstructive airway diseases,Million US$ at exchange rate,14.1
+23394,Luxembourg,2010,8,R03-Drugs for obstructive airway diseases,"Million US$, purchasing power parity",11.5
+23395,Luxembourg,2010,8,A02A-Antacids,Million US$ at exchange rate,0.4
+23396,Luxembourg,2010,8,A-Alimentary tract and metabolism,% of total sales,15.1
+23397,Luxembourg,2010,8,A-Alimentary tract and metabolism,"/capita, US$ purchasing power parity",65.1
+23398,Luxembourg,2010,8,A-Alimentary tract and metabolism,Million US$ at exchange rate,37.8
+23399,Luxembourg,2010,8,A-Alimentary tract and metabolism,"Million US$, purchasing power parity",30.8
+23400,Luxembourg,2010,8,A-Alimentary tract and metabolism,"/capita, US$ exchange rate",79.9
+23401,Luxembourg,2010,8,N05C-Hypnotics and sedatives,"/capita, US$ exchange rate",8.4
+23402,Luxembourg,2010,8,N05C-Hypnotics and sedatives,"Million US$, purchasing power parity",3.2
+23403,Luxembourg,2010,8,N05C-Hypnotics and sedatives,"/capita, US$ purchasing power parity",6.8
+23404,Luxembourg,2010,8,N05C-Hypnotics and sedatives,% of total sales,1.6
+23405,Luxembourg,2010,8,N-Nervous system,"/capita, US$ purchasing power parity",74.7
+23406,Luxembourg,2010,8,N-Nervous system,% of total sales,17.3
+23407,Luxembourg,2010,8,N-Nervous system,"/capita, US$ exchange rate",91.7
+23408,Luxembourg,2010,8,N-Nervous system,Million US$ at exchange rate,43.4
+23409,Luxembourg,2010,8,N-Nervous system,"Million US$, purchasing power parity",35.3
+23410,Luxembourg,2010,8,N06A-Antidepressants,"Million US$, purchasing power parity",7.6
+23411,Luxembourg,2010,8,N06A-Antidepressants,Million US$ at exchange rate,9.4
+23412,Luxembourg,2010,8,A-Alimentary tract and metabolism,Million of national currency units,28.5
+23413,Luxembourg,2010,8,N06A-Antidepressants,Million of national currency units,7.1
+23414,Luxembourg,2010,8,N05C-Hypnotics and sedatives,Million US$ at exchange rate,4.0
+23415,Luxembourg,2010,8,N06A-Antidepressants,% of total sales,3.7
+23416,Luxembourg,2010,8,N06A-Antidepressants,"/capita, US$ exchange rate",19.8
+23417,Luxembourg,2010,8,N06A-Antidepressants,"/capita, US$ purchasing power parity",16.2
+23418,Luxembourg,2010,8,Total pharmaceutical sales,Million US$ at exchange rate,251.1
+23419,Luxembourg,2010,8,Total pharmaceutical sales,"Million US$, purchasing power parity",204.6
+23420,Luxembourg,2010,8,Total pharmaceutical sales,Million of national currency units,189.4
+23421,Luxembourg,2010,8,Total pharmaceutical sales,"/capita, US$ purchasing power parity",432.5
+23422,Luxembourg,2010,8,Total pharmaceutical sales,"/capita, US$ exchange rate",530.7
+23423,Luxembourg,2010,8,M01A-Antiinflammatory and antirheumatic products non-steroids,% of total sales,2.9
+23424,Luxembourg,2010,8,M01A-Antiinflammatory and antirheumatic products non-steroids,Million US$ at exchange rate,7.3
+23425,Luxembourg,2010,8,A02A-Antacids,Million of national currency units,0.3
+23426,Luxembourg,2010,8,M01A-Antiinflammatory and antirheumatic products non-steroids,Million of national currency units,5.5
+23427,Luxembourg,2010,8,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ purchasing power parity",12.6
+23428,Luxembourg,2010,8,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ exchange rate",15.5
+23429,Luxembourg,2010,8,M01A-Antiinflammatory and antirheumatic products non-steroids,"Million US$, purchasing power parity",6.0
+23430,Luxembourg,2010,8,N02-Analgesics,"/capita, US$ exchange rate",19.1
+23431,Luxembourg,2010,8,N02-Analgesics,% of total sales,3.6
+23432,Luxembourg,2010,8,N02-Analgesics,"/capita, US$ purchasing power parity",15.6
+23433,Luxembourg,2010,8,N02-Analgesics,Million of national currency units,6.8
+23434,Luxembourg,2010,8,N05C-Hypnotics and sedatives,Million of national currency units,3.0
+23435,Luxembourg,2010,8,N02-Analgesics,"Million US$, purchasing power parity",7.4
+23436,Luxembourg,2010,8,N02-Analgesics,Million US$ at exchange rate,9.0
+23437,Luxembourg,2010,8,R-Respiratory system,"/capita, US$ exchange rate",42.9
+23438,Luxembourg,2010,8,R-Respiratory system,"/capita, US$ purchasing power parity",34.9
+23439,Luxembourg,2010,8,R-Respiratory system,% of total sales,8.1
+23440,Luxembourg,2010,8,R-Respiratory system,Million of national currency units,15.3
+23441,Luxembourg,2010,8,N-Nervous system,Million of national currency units,32.7
+23442,Luxembourg,2010,8,R-Respiratory system,"Million US$, purchasing power parity",16.5
+23443,Luxembourg,2010,8,R-Respiratory system,Million US$ at exchange rate,20.3
+23444,Luxembourg,2010,8,B-Blood and blood forming organs,"Million US$, purchasing power parity",10.4
+23445,Luxembourg,2010,8,B-Blood and blood forming organs,"/capita, US$ exchange rate",26.9
+23446,Luxembourg,2010,8,B-Blood and blood forming organs,Million US$ at exchange rate,12.7
+23447,Luxembourg,2010,8,C02-Antihypertensives,% of total sales,0.2
+23448,Luxembourg,2010,8,B-Blood and blood forming organs,% of total sales,5.1
+23449,Luxembourg,2010,8,B-Blood and blood forming organs,"/capita, US$ purchasing power parity",21.9
+23450,Luxembourg,2010,8,B-Blood and blood forming organs,Million of national currency units,9.6
+23451,Luxembourg,2010,8,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ purchasing power parity",9.4
+23452,Luxembourg,2010,8,"H-Systemic hormonal preparations, excluding sex hormones and insulins",% of total sales,2.2
+23453,Luxembourg,2010,8,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ exchange rate",11.5
+23454,Luxembourg,2010,8,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million US$ at exchange rate,5.4
+23455,Luxembourg,2010,8,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million of national currency units,4.1
+23456,Luxembourg,2010,8,"H-Systemic hormonal preparations, excluding sex hormones and insulins","Million US$, purchasing power parity",4.4
+23457,Luxembourg,2010,8,C01A-Cardiac glycosides,"/capita, US$ exchange rate",0.1
+23458,Luxembourg,2010,8,C01A-Cardiac glycosides,"/capita, US$ purchasing power parity",0.1
+23459,Luxembourg,2010,8,C01A-Cardiac glycosides,"Million US$, purchasing power parity",0.0
+23460,Luxembourg,2010,8,M-Musculo-skeletal system,"/capita, US$ purchasing power parity",22.0
+23461,Luxembourg,2010,8,M-Musculo-skeletal system,% of total sales,5.1
+23462,Luxembourg,2010,8,C01A-Cardiac glycosides,Million US$ at exchange rate,0.0
+23463,Luxembourg,2010,8,J-Antiinfectives for systemic use,% of total sales,5.6
+23464,Luxembourg,2010,8,M-Musculo-skeletal system,Million of national currency units,9.7
+23465,Luxembourg,2010,8,M-Musculo-skeletal system,Million US$ at exchange rate,12.8
+23466,Luxembourg,2010,8,M-Musculo-skeletal system,"/capita, US$ exchange rate",27.0
+23467,Luxembourg,2010,8,C01A-Cardiac glycosides,Million of national currency units,0.0
+23468,Luxembourg,2010,8,M-Musculo-skeletal system,"Million US$, purchasing power parity",10.4
+23469,Luxembourg,2010,8,C03-Diuretics,Million of national currency units,1.7
+23470,Luxembourg,2010,8,C03-Diuretics,Million US$ at exchange rate,2.3
+23471,Luxembourg,2010,8,C10-Lipid modifying agents,"Million US$, purchasing power parity",17.1
+23472,Luxembourg,2010,8,C10-Lipid modifying agents,Million US$ at exchange rate,21.0
+23473,Luxembourg,2010,8,C03-Diuretics,"/capita, US$ purchasing power parity",3.9
+23474,Luxembourg,2010,8,C03-Diuretics,"/capita, US$ exchange rate",4.8
+23475,Luxembourg,2010,8,C03-Diuretics,"Million US$, purchasing power parity",1.8
+23476,Luxembourg,2010,8,C02-Antihypertensives,"Million US$, purchasing power parity",0.5
+23477,Luxembourg,2010,8,C02-Antihypertensives,"/capita, US$ exchange rate",1.3
+23478,Luxembourg,2010,8,C02-Antihypertensives,Million US$ at exchange rate,0.6
+23479,Luxembourg,2010,8,C10-Lipid modifying agents,"/capita, US$ exchange rate",44.4
+23480,Luxembourg,2010,8,C10-Lipid modifying agents,"/capita, US$ purchasing power parity",36.1
+23481,Luxembourg,2010,8,C10-Lipid modifying agents,% of total sales,8.4
+23482,Luxembourg,2010,8,"C01B-Antiarrhythmics, Class I and III","/capita, US$ purchasing power parity",1.3
+23483,Luxembourg,2010,8,C02-Antihypertensives,"/capita, US$ purchasing power parity",1.0
+23484,Luxembourg,2010,8,"C01B-Antiarrhythmics, Class I and III",% of total sales,0.3
+23485,Luxembourg,2010,8,"C01B-Antiarrhythmics, Class I and III","/capita, US$ exchange rate",1.6
+23486,Luxembourg,2010,8,"C01B-Antiarrhythmics, Class I and III",Million US$ at exchange rate,0.7
+23487,Luxembourg,2010,8,"C01B-Antiarrhythmics, Class I and III",Million of national currency units,0.6
+23488,Luxembourg,2010,8,"C01B-Antiarrhythmics, Class I and III","Million US$, purchasing power parity",0.6
+23489,Luxembourg,2010,8,J-Antiinfectives for systemic use,Million of national currency units,10.7
+23490,Luxembourg,2010,8,J-Antiinfectives for systemic use,Million US$ at exchange rate,14.1
+23491,Luxembourg,2010,8,C10-Lipid modifying agents,Million of national currency units,15.8
+23492,Luxembourg,2010,8,C03-Diuretics,% of total sales,0.9
+23493,Luxembourg,2010,8,J-Antiinfectives for systemic use,"/capita, US$ purchasing power parity",24.3
+23494,Luxembourg,2010,8,J-Antiinfectives for systemic use,"/capita, US$ exchange rate",29.8
+23495,Luxembourg,2010,8,J-Antiinfectives for systemic use,"Million US$, purchasing power parity",11.5
+23496,Luxembourg,2010,8,J01-Antibacterials for systemic use,"Million US$, purchasing power parity",7.7
+23497,Luxembourg,2010,8,G03-Sex hormones and modulators of the genital system,"/capita, US$ purchasing power parity",5.5
+23498,Luxembourg,2010,8,G03-Sex hormones and modulators of the genital system,% of total sales,1.3
+23499,Luxembourg,2010,8,J01-Antibacterials for systemic use,Million US$ at exchange rate,9.4
+23500,Luxembourg,2010,8,C01A-Cardiac glycosides,% of total sales,0.0
+23501,Luxembourg,2010,8,C09-Agents acting on the Renin-Angiotensin system,% of total sales,7.9
+23502,Luxembourg,2010,8,J01-Antibacterials for systemic use,"/capita, US$ exchange rate",19.9
+23503,Luxembourg,2010,8,G03-Sex hormones and modulators of the genital system,Million of national currency units,2.4
+23504,Luxembourg,2010,8,J01-Antibacterials for systemic use,"/capita, US$ purchasing power parity",16.2
+23505,Luxembourg,2010,8,G03-Sex hormones and modulators of the genital system,"/capita, US$ exchange rate",6.8
+23506,Luxembourg,2010,8,G03-Sex hormones and modulators of the genital system,Million US$ at exchange rate,3.2
+23507,Luxembourg,2010,8,G03-Sex hormones and modulators of the genital system,"Million US$, purchasing power parity",2.6
+23508,Luxembourg,2010,8,A10-Drugs used in diabetes,"/capita, US$ purchasing power parity",20.9
+23509,Luxembourg,2010,8,G-Genito urinary system and sex hormones,Million of national currency units,6.8
+23510,Luxembourg,2010,8,A10-Drugs used in diabetes,Million of national currency units,9.1
+23511,Luxembourg,2010,8,A10-Drugs used in diabetes,% of total sales,4.8
+23512,Luxembourg,2010,8,A10-Drugs used in diabetes,"/capita, US$ exchange rate",25.6
+23513,Luxembourg,2010,8,A10-Drugs used in diabetes,Million US$ at exchange rate,12.1
+23514,Luxembourg,2010,8,A10-Drugs used in diabetes,"Million US$, purchasing power parity",9.9
+23515,Luxembourg,2010,8,G-Genito urinary system and sex hormones,"/capita, US$ exchange rate",19.1
+23516,Luxembourg,2010,8,J01-Antibacterials for systemic use,Million of national currency units,7.1
+23517,Luxembourg,2010,8,G-Genito urinary system and sex hormones,"/capita, US$ purchasing power parity",15.5
+23518,Luxembourg,2010,8,G-Genito urinary system and sex hormones,"Million US$, purchasing power parity",7.3
+23519,Luxembourg,2010,8,G-Genito urinary system and sex hormones,Million US$ at exchange rate,9.0
+23520,Luxembourg,2010,8,C-Cardiovascular system,% of total sales,21.7
+23521,Luxembourg,2010,8,J01-Antibacterials for systemic use,% of total sales,3.7
+23522,Luxembourg,2010,8,C09-Agents acting on the Renin-Angiotensin system,"Million US$, purchasing power parity",16.1
+23523,Luxembourg,2010,8,C07-Beta blocking agents,% of total sales,1.8
+23524,Luxembourg,2010,8,C07-Beta blocking agents,"/capita, US$ purchasing power parity",7.8
+23525,Luxembourg,2010,8,C08-Calcium channel blockers,% of total sales,1.5
+23526,Luxembourg,2010,8,C09-Agents acting on the Renin-Angiotensin system,Million of national currency units,14.9
+23527,Luxembourg,2010,8,C09-Agents acting on the Renin-Angiotensin system,Million US$ at exchange rate,19.8
+23528,Luxembourg,2010,8,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ exchange rate",41.8
+23529,Luxembourg,2010,8,C07-Beta blocking agents,Million of national currency units,3.4
+23530,Luxembourg,2010,8,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ purchasing power parity",34.0
+23531,Luxembourg,2010,8,C07-Beta blocking agents,"/capita, US$ exchange rate",9.6
+23532,Luxembourg,2010,8,C07-Beta blocking agents,Million US$ at exchange rate,4.5
+23533,Luxembourg,2010,8,C07-Beta blocking agents,"Million US$, purchasing power parity",3.7
+23534,Luxembourg,2010,8,C-Cardiovascular system,"Million US$, purchasing power parity",44.4
+23535,Luxembourg,2010,8,C-Cardiovascular system,"/capita, US$ exchange rate",115.1
+23536,Luxembourg,2010,8,C-Cardiovascular system,Million US$ at exchange rate,54.4
+23537,Luxembourg,2010,8,G-Genito urinary system and sex hormones,% of total sales,3.6
+23538,Luxembourg,2010,8,C-Cardiovascular system,"/capita, US$ purchasing power parity",93.8
+23539,Luxembourg,2010,8,C02-Antihypertensives,Million of national currency units,0.5
+23540,Luxembourg,2010,8,C08-Calcium channel blockers,"Million US$, purchasing power parity",3.0
+23541,Luxembourg,2010,8,C08-Calcium channel blockers,Million US$ at exchange rate,3.6
+23542,Luxembourg,2010,8,C08-Calcium channel blockers,"/capita, US$ purchasing power parity",6.3
+23543,Luxembourg,2010,8,C08-Calcium channel blockers,"/capita, US$ exchange rate",7.7
+23544,Luxembourg,2010,8,C08-Calcium channel blockers,Million of national currency units,2.8
+23545,Luxembourg,2010,8,C-Cardiovascular system,Million of national currency units,41.1
+23546,Luxembourg,2017,5,N05B-Anxiolytics,Million of national currency units,2.6
+23547,Luxembourg,2017,5,N05B-Anxiolytics,Million US$ at exchange rate,2.9
+23548,Luxembourg,2017,5,N05B-Anxiolytics,"/capita, US$ purchasing power parity",5.6
+23549,Luxembourg,2017,5,N05B-Anxiolytics,% of total sales,1.3
+23550,Luxembourg,2017,5,N05B-Anxiolytics,"Million US$, purchasing power parity",3.0
+23551,Luxembourg,2017,5,N05B-Anxiolytics,"/capita, US$ exchange rate",5.4
+23552,Luxembourg,2017,5,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ exchange rate",14.8
+23553,Luxembourg,2017,5,A02A-Antacids,% of total sales,0.2
+23554,Luxembourg,2017,5,A02A-Antacids,"/capita, US$ purchasing power parity",0.8
+23555,Luxembourg,2017,5,A02A-Antacids,"/capita, US$ exchange rate",0.8
+23556,Luxembourg,2017,5,A02A-Antacids,"Million US$, purchasing power parity",0.4
+23557,Luxembourg,2017,5,R03-Drugs for obstructive airway diseases,"/capita, US$ purchasing power parity",20.7
+23558,Luxembourg,2017,5,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ purchasing power parity",15.4
+23559,Luxembourg,2017,5,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),% of total sales,3.6
+23560,Luxembourg,2017,5,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"Million US$, purchasing power parity",8.3
+23561,Luxembourg,2017,5,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million of national currency units,7.0
+23562,Luxembourg,2017,5,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million US$ at exchange rate,7.9
+23563,Luxembourg,2017,5,R03-Drugs for obstructive airway diseases,% of total sales,4.9
+23564,Luxembourg,2017,5,A02A-Antacids,Million US$ at exchange rate,0.4
+23565,Luxembourg,2017,5,R03-Drugs for obstructive airway diseases,"Million US$, purchasing power parity",11.1
+23566,Luxembourg,2017,5,R03-Drugs for obstructive airway diseases,"/capita, US$ exchange rate",19.9
+23567,Luxembourg,2017,5,R03-Drugs for obstructive airway diseases,Million of national currency units,9.4
+23568,Luxembourg,2017,5,R03-Drugs for obstructive airway diseases,Million US$ at exchange rate,10.6
+23569,Luxembourg,2017,5,A-Alimentary tract and metabolism,"/capita, US$ purchasing power parity",77.5
+23570,Luxembourg,2017,5,N05C-Hypnotics and sedatives,% of total sales,1.8
+23571,Luxembourg,2017,5,A-Alimentary tract and metabolism,% of total sales,18.2
+23572,Luxembourg,2017,5,A-Alimentary tract and metabolism,"/capita, US$ exchange rate",74.3
+23573,Luxembourg,2017,5,A-Alimentary tract and metabolism,Million US$ at exchange rate,39.8
+23574,Luxembourg,2017,5,A-Alimentary tract and metabolism,"Million US$, purchasing power parity",41.5
+23575,Luxembourg,2017,5,A-Alimentary tract and metabolism,Million of national currency units,35.2
+23576,Luxembourg,2017,5,N05C-Hypnotics and sedatives,"Million US$, purchasing power parity",4.0
+23577,Luxembourg,2017,5,N05C-Hypnotics and sedatives,"/capita, US$ exchange rate",7.2
+23578,Luxembourg,2017,5,N05C-Hypnotics and sedatives,Million US$ at exchange rate,3.9
+23579,Luxembourg,2017,5,N05C-Hypnotics and sedatives,"/capita, US$ purchasing power parity",7.5
+23580,Luxembourg,2017,5,N-Nervous system,"/capita, US$ purchasing power parity",69.3
+23581,Luxembourg,2017,5,N-Nervous system,"/capita, US$ exchange rate",66.4
+23582,Luxembourg,2017,5,N-Nervous system,% of total sales,16.2
+23583,Luxembourg,2017,5,N-Nervous system,Million of national currency units,31.5
+23584,Luxembourg,2017,5,N-Nervous system,Million US$ at exchange rate,35.6
+23585,Luxembourg,2017,5,N-Nervous system,"Million US$, purchasing power parity",37.2
+23586,Luxembourg,2017,5,N06A-Antidepressants,Million US$ at exchange rate,5.8
+23587,Luxembourg,2017,5,N06A-Antidepressants,Million of national currency units,5.1
+23588,Luxembourg,2017,5,N06A-Antidepressants,"Million US$, purchasing power parity",6.0
+23589,Luxembourg,2017,5,N06A-Antidepressants,"/capita, US$ purchasing power parity",11.3
+23590,Luxembourg,2017,5,N06A-Antidepressants,% of total sales,2.6
+23591,Luxembourg,2017,5,N06A-Antidepressants,"/capita, US$ exchange rate",10.8
+23592,Luxembourg,2017,5,Total pharmaceutical sales,Million US$ at exchange rate,219.2
+23593,Luxembourg,2017,5,Total pharmaceutical sales,Million of national currency units,194.1
+23594,Luxembourg,2017,5,M01A-Antiinflammatory and antirheumatic products non-steroids,% of total sales,2.8
+23595,Luxembourg,2017,5,Total pharmaceutical sales,"/capita, US$ purchasing power parity",426.8
+23596,Luxembourg,2017,5,Total pharmaceutical sales,"Million US$, purchasing power parity",228.8
+23597,Luxembourg,2017,5,Total pharmaceutical sales,"/capita, US$ exchange rate",409.0
+23598,Luxembourg,2017,5,M01A-Antiinflammatory and antirheumatic products non-steroids,Million of national currency units,5.5
+23599,Luxembourg,2017,5,M01A-Antiinflammatory and antirheumatic products non-steroids,Million US$ at exchange rate,6.2
+23600,Luxembourg,2017,5,A02A-Antacids,Million of national currency units,0.4
+23601,Luxembourg,2017,5,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ purchasing power parity",12.0
+23602,Luxembourg,2017,5,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ exchange rate",11.5
+23603,Luxembourg,2017,5,M01A-Antiinflammatory and antirheumatic products non-steroids,"Million US$, purchasing power parity",6.4
+23604,Luxembourg,2017,5,N02-Analgesics,"/capita, US$ exchange rate",16.3
+23605,Luxembourg,2017,5,N02-Analgesics,"Million US$, purchasing power parity",9.1
+23606,Luxembourg,2017,5,N02-Analgesics,"/capita, US$ purchasing power parity",17.0
+23607,Luxembourg,2017,5,N05C-Hypnotics and sedatives,Million of national currency units,3.4
+23608,Luxembourg,2017,5,N02-Analgesics,Million of national currency units,7.7
+23609,Luxembourg,2017,5,N02-Analgesics,Million US$ at exchange rate,8.7
+23610,Luxembourg,2017,5,R-Respiratory system,"/capita, US$ exchange rate",27.7
+23611,Luxembourg,2017,5,R-Respiratory system,"/capita, US$ purchasing power parity",28.9
+23612,Luxembourg,2017,5,R-Respiratory system,"Million US$, purchasing power parity",15.5
+23613,Luxembourg,2017,5,R-Respiratory system,% of total sales,6.8
+23614,Luxembourg,2017,5,R-Respiratory system,Million of national currency units,13.2
+23615,Luxembourg,2017,5,N02-Analgesics,% of total sales,4.0
+23616,Luxembourg,2017,5,R-Respiratory system,Million US$ at exchange rate,14.9
+23617,Luxembourg,2017,5,B-Blood and blood forming organs,"Million US$, purchasing power parity",18.4
+23618,Luxembourg,2017,5,B-Blood and blood forming organs,Million of national currency units,15.6
+23619,Luxembourg,2017,5,B-Blood and blood forming organs,Million US$ at exchange rate,17.6
+23620,Luxembourg,2017,5,B-Blood and blood forming organs,"/capita, US$ exchange rate",32.9
+23621,Luxembourg,2017,5,B-Blood and blood forming organs,% of total sales,8.0
+23622,Luxembourg,2017,5,B-Blood and blood forming organs,"/capita, US$ purchasing power parity",34.4
+23623,Luxembourg,2017,5,C02-Antihypertensives,% of total sales,0.2
+23624,Luxembourg,2017,5,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ purchasing power parity",11.7
+23625,Luxembourg,2017,5,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ exchange rate",11.3
+23626,Luxembourg,2017,5,"H-Systemic hormonal preparations, excluding sex hormones and insulins",% of total sales,2.8
+23627,Luxembourg,2017,5,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million of national currency units,5.3
+23628,Luxembourg,2017,5,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million US$ at exchange rate,6.0
+23629,Luxembourg,2017,5,"H-Systemic hormonal preparations, excluding sex hormones and insulins","Million US$, purchasing power parity",6.3
+23630,Luxembourg,2017,5,C01A-Cardiac glycosides,"/capita, US$ exchange rate",0.1
+23631,Luxembourg,2017,5,C01A-Cardiac glycosides,"Million US$, purchasing power parity",0.0
+23632,Luxembourg,2017,5,C01A-Cardiac glycosides,Million US$ at exchange rate,0.0
+23633,Luxembourg,2017,5,M-Musculo-skeletal system,"/capita, US$ exchange rate",22.5
+23634,Luxembourg,2017,5,M-Musculo-skeletal system,% of total sales,5.5
+23635,Luxembourg,2017,5,C09-Agents acting on the Renin-Angiotensin system,% of total sales,5.0
+23636,Luxembourg,2017,5,M-Musculo-skeletal system,"/capita, US$ purchasing power parity",23.5
+23637,Luxembourg,2017,5,J-Antiinfectives for systemic use,% of total sales,4.6
+23638,Luxembourg,2017,5,M-Musculo-skeletal system,Million of national currency units,10.7
+23639,Luxembourg,2017,5,C10-Lipid modifying agents,% of total sales,6.0
+23640,Luxembourg,2017,5,C01A-Cardiac glycosides,Million of national currency units,0.0
+23641,Luxembourg,2017,5,C02-Antihypertensives,"/capita, US$ purchasing power parity",1.0
+23642,Luxembourg,2017,5,M-Musculo-skeletal system,"Million US$, purchasing power parity",12.6
+23643,Luxembourg,2017,5,M-Musculo-skeletal system,Million US$ at exchange rate,12.1
+23644,Luxembourg,2017,5,C10-Lipid modifying agents,Million of national currency units,11.6
+23645,Luxembourg,2017,5,C03-Diuretics,Million of national currency units,1.4
+23646,Luxembourg,2017,5,C10-Lipid modifying agents,Million US$ at exchange rate,13.1
+23647,Luxembourg,2017,5,C03-Diuretics,"/capita, US$ exchange rate",3.0
+23648,Luxembourg,2017,5,C03-Diuretics,Million US$ at exchange rate,1.6
+23649,Luxembourg,2017,5,C03-Diuretics,"Million US$, purchasing power parity",1.7
+23650,Luxembourg,2017,5,C10-Lipid modifying agents,"Million US$, purchasing power parity",13.7
+23651,Luxembourg,2017,5,C02-Antihypertensives,"Million US$, purchasing power parity",0.5
+23652,Luxembourg,2017,5,C02-Antihypertensives,Million US$ at exchange rate,0.5
+23653,Luxembourg,2017,5,C02-Antihypertensives,Million of national currency units,0.4
+23654,Luxembourg,2017,5,C10-Lipid modifying agents,"/capita, US$ exchange rate",24.5
+23655,Luxembourg,2017,5,C02-Antihypertensives,"/capita, US$ exchange rate",0.9
+23656,Luxembourg,2017,5,C10-Lipid modifying agents,"/capita, US$ purchasing power parity",25.5
+23657,Luxembourg,2017,5,C03-Diuretics,"/capita, US$ purchasing power parity",3.1
+23658,Luxembourg,2017,5,"C01B-Antiarrhythmics, Class I and III","/capita, US$ purchasing power parity",1.2
+23659,Luxembourg,2017,5,"C01B-Antiarrhythmics, Class I and III","/capita, US$ exchange rate",1.1
+23660,Luxembourg,2017,5,"C01B-Antiarrhythmics, Class I and III",% of total sales,0.3
+23661,Luxembourg,2017,5,"C01B-Antiarrhythmics, Class I and III",Million of national currency units,0.5
+23662,Luxembourg,2017,5,"C01B-Antiarrhythmics, Class I and III",Million US$ at exchange rate,0.6
+23663,Luxembourg,2017,5,"C01B-Antiarrhythmics, Class I and III","Million US$, purchasing power parity",0.6
+23664,Luxembourg,2017,5,J-Antiinfectives for systemic use,Million of national currency units,8.9
+23665,Luxembourg,2017,5,C03-Diuretics,% of total sales,0.7
+23666,Luxembourg,2017,5,J-Antiinfectives for systemic use,Million US$ at exchange rate,10.0
+23667,Luxembourg,2017,5,J-Antiinfectives for systemic use,"/capita, US$ exchange rate",18.7
+23668,Luxembourg,2017,5,J-Antiinfectives for systemic use,"/capita, US$ purchasing power parity",19.5
+23669,Luxembourg,2017,5,J-Antiinfectives for systemic use,"Million US$, purchasing power parity",10.4
+23670,Luxembourg,2017,5,J01-Antibacterials for systemic use,Million US$ at exchange rate,6.2
+23671,Luxembourg,2017,5,J01-Antibacterials for systemic use,"Million US$, purchasing power parity",6.4
+23672,Luxembourg,2017,5,G03-Sex hormones and modulators of the genital system,"/capita, US$ purchasing power parity",8.0
+23673,Luxembourg,2017,5,C01A-Cardiac glycosides,"/capita, US$ purchasing power parity",0.1
+23674,Luxembourg,2017,5,G03-Sex hormones and modulators of the genital system,% of total sales,1.9
+23675,Luxembourg,2017,5,J01-Antibacterials for systemic use,Million of national currency units,5.5
+23676,Luxembourg,2017,5,C01A-Cardiac glycosides,% of total sales,0.0
+23677,Luxembourg,2017,5,J01-Antibacterials for systemic use,"/capita, US$ exchange rate",11.5
+23678,Luxembourg,2017,5,J01-Antibacterials for systemic use,"/capita, US$ purchasing power parity",12.0
+23679,Luxembourg,2017,5,G03-Sex hormones and modulators of the genital system,Million of national currency units,3.6
+23680,Luxembourg,2017,5,G03-Sex hormones and modulators of the genital system,"Million US$, purchasing power parity",4.3
+23681,Luxembourg,2017,5,G03-Sex hormones and modulators of the genital system,"/capita, US$ exchange rate",7.7
+23682,Luxembourg,2017,5,G03-Sex hormones and modulators of the genital system,Million US$ at exchange rate,4.1
+23683,Luxembourg,2017,5,A10-Drugs used in diabetes,"/capita, US$ purchasing power parity",37.6
+23684,Luxembourg,2017,5,A10-Drugs used in diabetes,"/capita, US$ exchange rate",36.0
+23685,Luxembourg,2017,5,A10-Drugs used in diabetes,% of total sales,8.8
+23686,Luxembourg,2017,5,A10-Drugs used in diabetes,Million of national currency units,17.1
+23687,Luxembourg,2017,5,A10-Drugs used in diabetes,Million US$ at exchange rate,19.3
+23688,Luxembourg,2017,5,A10-Drugs used in diabetes,"Million US$, purchasing power parity",20.1
+23689,Luxembourg,2017,5,G-Genito urinary system and sex hormones,"Million US$, purchasing power parity",10.4
+23690,Luxembourg,2017,5,G-Genito urinary system and sex hormones,"/capita, US$ exchange rate",18.7
+23691,Luxembourg,2017,5,G-Genito urinary system and sex hormones,"/capita, US$ purchasing power parity",19.5
+23692,Luxembourg,2017,5,G-Genito urinary system and sex hormones,Million of national currency units,8.9
+23693,Luxembourg,2017,5,G-Genito urinary system and sex hormones,Million US$ at exchange rate,10.0
+23694,Luxembourg,2017,5,C-Cardiovascular system,% of total sales,15.6
+23695,Luxembourg,2017,5,C09-Agents acting on the Renin-Angiotensin system,"Million US$, purchasing power parity",11.5
+23696,Luxembourg,2017,5,C07-Beta blocking agents,% of total sales,1.8
+23697,Luxembourg,2017,5,C07-Beta blocking agents,"/capita, US$ purchasing power parity",7.9
+23698,Luxembourg,2017,5,C09-Agents acting on the Renin-Angiotensin system,Million US$ at exchange rate,11.0
+23699,Luxembourg,2017,5,C08-Calcium channel blockers,% of total sales,0.9
+23700,Luxembourg,2017,5,C09-Agents acting on the Renin-Angiotensin system,Million of national currency units,9.8
+23701,Luxembourg,2017,5,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ exchange rate",20.6
+23702,Luxembourg,2017,5,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ purchasing power parity",21.5
+23703,Luxembourg,2017,5,C07-Beta blocking agents,Million of national currency units,3.6
+23704,Luxembourg,2017,5,C07-Beta blocking agents,"Million US$, purchasing power parity",4.2
+23705,Luxembourg,2017,5,C07-Beta blocking agents,"/capita, US$ exchange rate",7.6
+23706,Luxembourg,2017,5,C08-Calcium channel blockers,"/capita, US$ purchasing power parity",3.8
+23707,Luxembourg,2017,5,C07-Beta blocking agents,Million US$ at exchange rate,4.1
+23708,Luxembourg,2017,5,C-Cardiovascular system,"Million US$, purchasing power parity",35.6
+23709,Luxembourg,2017,5,C-Cardiovascular system,Million of national currency units,30.2
+23710,Luxembourg,2017,5,C-Cardiovascular system,Million US$ at exchange rate,34.2
+23711,Luxembourg,2017,5,G-Genito urinary system and sex hormones,% of total sales,4.6
+23712,Luxembourg,2017,5,J01-Antibacterials for systemic use,% of total sales,2.8
+23713,Luxembourg,2017,5,C-Cardiovascular system,"/capita, US$ exchange rate",63.7
+23714,Luxembourg,2017,5,C-Cardiovascular system,"/capita, US$ purchasing power parity",66.5
+23715,Luxembourg,2017,5,C08-Calcium channel blockers,Million US$ at exchange rate,2.0
+23716,Luxembourg,2017,5,C08-Calcium channel blockers,Million of national currency units,1.7
+23717,Luxembourg,2017,5,C08-Calcium channel blockers,"/capita, US$ exchange rate",3.6
+23718,Luxembourg,2017,5,C08-Calcium channel blockers,"Million US$, purchasing power parity",2.0
+23719,Mexico,2016,34,M-Musculo-skeletal system,Million of national currency units,2604.0
+23720,Mexico,2016,34,R-Respiratory system,Million of national currency units,6149.0
+23721,Mexico,2016,34,M-Musculo-skeletal system,"/capita, US$ exchange rate",1.1
+23722,Mexico,2016,34,M-Musculo-skeletal system,Million US$ at exchange rate,139.5
+23723,Mexico,2016,34,M-Musculo-skeletal system,"Million US$, purchasing power parity",308.3
+23724,Mexico,2016,34,C-Cardiovascular system,"/capita, US$ exchange rate",5.2
+23725,Mexico,2016,34,C-Cardiovascular system,"Million US$, purchasing power parity",1402.6
+23726,Mexico,2016,34,C-Cardiovascular system,Million US$ at exchange rate,634.7
+23727,Mexico,2016,34,J-Antiinfectives for systemic use,"/capita, US$ purchasing power parity",20.2
+23728,Mexico,2016,34,C-Cardiovascular system,"/capita, US$ purchasing power parity",11.4
+23729,Mexico,2016,34,Products not elsewhere classified,"/capita, US$ exchange rate",8.4
+23730,Mexico,2016,34,Products not elsewhere classified,"Million US$, purchasing power parity",2270.2
+23731,Mexico,2016,34,Products not elsewhere classified,"/capita, US$ purchasing power parity",18.5
+23732,Mexico,2016,34,J-Antiinfectives for systemic use,"/capita, US$ exchange rate",9.1
+23733,Mexico,2016,34,Products not elsewhere classified,Million of national currency units,19174.5
+23734,Mexico,2016,34,C-Cardiovascular system,Million of national currency units,11846.0
+23735,Mexico,2016,34,Products not elsewhere classified,Million US$ at exchange rate,1027.3
+23736,Mexico,2016,34,N-Nervous system,Million of national currency units,15668.0
+23737,Mexico,2016,34,N-Nervous system,Million US$ at exchange rate,839.5
+23738,Mexico,2016,34,R-Respiratory system,"/capita, US$ purchasing power parity",5.9
+23739,Mexico,2016,34,R-Respiratory system,"Million US$, purchasing power parity",728.0
+23740,Mexico,2016,34,R-Respiratory system,Million US$ at exchange rate,329.5
+23741,Mexico,2016,34,R-Respiratory system,"/capita, US$ exchange rate",2.7
+23742,Mexico,2016,34,N-Nervous system,"Million US$, purchasing power parity",1855.1
+23743,Mexico,2016,34,J-Antiinfectives for systemic use,Million US$ at exchange rate,1122.0
+23744,Mexico,2016,34,J-Antiinfectives for systemic use,Million of national currency units,20942.0
+23745,Mexico,2016,34,J-Antiinfectives for systemic use,"Million US$, purchasing power parity",2479.5
+23746,Mexico,2016,34,N-Nervous system,"/capita, US$ exchange rate",6.8
+23747,Mexico,2016,34,N-Nervous system,"/capita, US$ purchasing power parity",15.1
+23748,Mexico,2016,34,M-Musculo-skeletal system,"/capita, US$ purchasing power parity",2.5
+23749,Mexico,2016,34,B-Blood and blood forming organs,Million of national currency units,1766.0
+23750,Mexico,2016,34,B-Blood and blood forming organs,Million US$ at exchange rate,94.6
+23751,Mexico,2016,34,B-Blood and blood forming organs,"/capita, US$ purchasing power parity",1.7
+23752,Mexico,2016,34,B-Blood and blood forming organs,"Million US$, purchasing power parity",209.1
+23753,Mexico,2016,34,B-Blood and blood forming organs,"/capita, US$ exchange rate",0.8
+23754,Mexico,2015,36,M-Musculo-skeletal system,Million of national currency units,3283.0
+23755,Mexico,2015,36,R-Respiratory system,Million of national currency units,5656.0
+23756,Mexico,2015,36,M-Musculo-skeletal system,"/capita, US$ exchange rate",1.7
+23757,Mexico,2015,36,M-Musculo-skeletal system,Million US$ at exchange rate,207.2
+23758,Mexico,2015,36,M-Musculo-skeletal system,"Million US$, purchasing power parity",394.2
+23759,Mexico,2015,36,R-Respiratory system,Million US$ at exchange rate,356.9
+23760,Mexico,2015,36,C-Cardiovascular system,"/capita, US$ exchange rate",5.0
+23761,Mexico,2015,36,C-Cardiovascular system,"Million US$, purchasing power parity",1150.8
+23762,Mexico,2015,36,C-Cardiovascular system,Million US$ at exchange rate,604.7
+23763,Mexico,2015,36,J-Antiinfectives for systemic use,"/capita, US$ purchasing power parity",18.8
+23764,Mexico,2015,36,C-Cardiovascular system,"/capita, US$ purchasing power parity",9.5
+23765,Mexico,2015,36,Products not elsewhere classified,"/capita, US$ exchange rate",9.1
+23766,Mexico,2015,36,Products not elsewhere classified,"Million US$, purchasing power parity",2108.6
+23767,Mexico,2015,36,Products not elsewhere classified,"/capita, US$ purchasing power parity",17.4
+23768,Mexico,2015,36,Products not elsewhere classified,Million of national currency units,17559.7
+23769,Mexico,2015,36,C-Cardiovascular system,Million of national currency units,9583.0
+23770,Mexico,2015,36,Products not elsewhere classified,Million US$ at exchange rate,1108.0
+23771,Mexico,2015,36,J-Antiinfectives for systemic use,"/capita, US$ exchange rate",9.9
+23772,Mexico,2015,36,N-Nervous system,Million of national currency units,14984.0
+23773,Mexico,2015,36,N-Nervous system,Million US$ at exchange rate,945.5
+23774,Mexico,2015,36,R-Respiratory system,"Million US$, purchasing power parity",679.2
+23775,Mexico,2015,36,R-Respiratory system,"/capita, US$ purchasing power parity",5.6
+23776,Mexico,2015,36,R-Respiratory system,"/capita, US$ exchange rate",2.9
+23777,Mexico,2015,36,J-Antiinfectives for systemic use,Million US$ at exchange rate,1200.3
+23778,Mexico,2015,36,J-Antiinfectives for systemic use,Million of national currency units,19023.0
+23779,Mexico,2015,36,J-Antiinfectives for systemic use,"Million US$, purchasing power parity",2284.3
+23780,Mexico,2015,36,N-Nervous system,"Million US$, purchasing power parity",1799.3
+23781,Mexico,2015,36,N-Nervous system,"/capita, US$ exchange rate",7.8
+23782,Mexico,2015,36,N-Nervous system,"/capita, US$ purchasing power parity",14.8
+23783,Mexico,2015,36,B-Blood and blood forming organs,Million of national currency units,2320.0
+23784,Mexico,2015,36,B-Blood and blood forming organs,Million US$ at exchange rate,146.4
+23785,Mexico,2015,36,B-Blood and blood forming organs,"Million US$, purchasing power parity",278.6
+23786,Mexico,2015,36,B-Blood and blood forming organs,"/capita, US$ exchange rate",1.2
+23787,Mexico,2015,36,B-Blood and blood forming organs,"/capita, US$ purchasing power parity",2.3
+23788,Mexico,2015,36,M-Musculo-skeletal system,"/capita, US$ purchasing power parity",3.2
+23789,Mexico,2014,38,M-Musculo-skeletal system,Million of national currency units,3091.0
+23790,Mexico,2014,38,R-Respiratory system,Million of national currency units,6950.0
+23791,Mexico,2014,38,M-Musculo-skeletal system,"/capita, US$ exchange rate",1.9
+23792,Mexico,2014,38,M-Musculo-skeletal system,Million US$ at exchange rate,232.5
+23793,Mexico,2014,38,M-Musculo-skeletal system,"Million US$, purchasing power parity",384.2
+23794,Mexico,2014,38,C-Cardiovascular system,"/capita, US$ exchange rate",5.3
+23795,Mexico,2014,38,C-Cardiovascular system,"Million US$, purchasing power parity",1042.6
+23796,Mexico,2014,38,C-Cardiovascular system,Million US$ at exchange rate,631.0
+23797,Mexico,2014,38,J-Antiinfectives for systemic use,"/capita, US$ purchasing power parity",18.4
+23798,Mexico,2014,38,C-Cardiovascular system,"/capita, US$ purchasing power parity",8.7
+23799,Mexico,2014,38,Products not elsewhere classified,"/capita, US$ exchange rate",10.7
+23800,Mexico,2014,38,Products not elsewhere classified,"Million US$, purchasing power parity",2126.5
+23801,Mexico,2014,38,Products not elsewhere classified,"/capita, US$ purchasing power parity",17.7
+23802,Mexico,2014,38,Products not elsewhere classified,Million of national currency units,17108.4
+23803,Mexico,2014,38,C-Cardiovascular system,Million of national currency units,8388.0
+23804,Mexico,2014,38,Products not elsewhere classified,Million US$ at exchange rate,1287.1
+23805,Mexico,2014,38,J-Antiinfectives for systemic use,"/capita, US$ exchange rate",11.1
+23806,Mexico,2014,38,N-Nervous system,Million of national currency units,14128.0
+23807,Mexico,2014,38,N-Nervous system,Million US$ at exchange rate,1062.9
+23808,Mexico,2014,38,R-Respiratory system,"/capita, US$ purchasing power parity",7.2
+23809,Mexico,2014,38,R-Respiratory system,"Million US$, purchasing power parity",863.9
+23810,Mexico,2014,38,R-Respiratory system,"/capita, US$ exchange rate",4.4
+23811,Mexico,2014,38,R-Respiratory system,Million US$ at exchange rate,522.9
+23812,Mexico,2014,38,N-Nervous system,"Million US$, purchasing power parity",1756.1
+23813,Mexico,2014,38,J-Antiinfectives for systemic use,Million US$ at exchange rate,1333.1
+23814,Mexico,2014,38,J-Antiinfectives for systemic use,"Million US$, purchasing power parity",2202.5
+23815,Mexico,2014,38,J-Antiinfectives for systemic use,Million of national currency units,17720.0
+23816,Mexico,2014,38,N-Nervous system,"/capita, US$ exchange rate",8.9
+23817,Mexico,2014,38,N-Nervous system,"/capita, US$ purchasing power parity",14.6
+23818,Mexico,2014,38,M-Musculo-skeletal system,"/capita, US$ purchasing power parity",3.2
+23819,Mexico,2014,38,B-Blood and blood forming organs,"Million US$, purchasing power parity",270.5
+23820,Mexico,2014,38,B-Blood and blood forming organs,Million US$ at exchange rate,163.7
+23821,Mexico,2014,38,B-Blood and blood forming organs,Million of national currency units,2176.0
+23822,Mexico,2014,38,B-Blood and blood forming organs,"/capita, US$ purchasing power parity",2.3
+23823,Mexico,2014,38,B-Blood and blood forming organs,"/capita, US$ exchange rate",1.4
+23824,Mexico,2013,39,M-Musculo-skeletal system,Million of national currency units,3553.0
+23825,Mexico,2013,39,R-Respiratory system,Million of national currency units,7254.0
+23826,Mexico,2013,39,R-Respiratory system,Million US$ at exchange rate,568.0
+23827,Mexico,2013,39,M-Musculo-skeletal system,Million US$ at exchange rate,278.2
+23828,Mexico,2013,39,M-Musculo-skeletal system,"/capita, US$ exchange rate",2.3
+23829,Mexico,2013,39,M-Musculo-skeletal system,"Million US$, purchasing power parity",450.6
+23830,Mexico,2013,39,C-Cardiovascular system,"/capita, US$ exchange rate",6.6
+23831,Mexico,2013,39,C-Cardiovascular system,"Million US$, purchasing power parity",1258.9
+23832,Mexico,2013,39,C-Cardiovascular system,Million US$ at exchange rate,777.2
+23833,Mexico,2013,39,J-Antiinfectives for systemic use,"/capita, US$ purchasing power parity",19.5
+23834,Mexico,2013,39,J-Antiinfectives for systemic use,% of total sales,12.8
+23835,Mexico,2013,39,C-Cardiovascular system,"/capita, US$ purchasing power parity",10.6
+23836,Mexico,2013,39,C-Cardiovascular system,% of total sales,7.0
+23837,Mexico,2013,39,Products not elsewhere classified,"/capita, US$ exchange rate",11.8
+23838,Mexico,2013,39,Products not elsewhere classified,% of total sales,12.6
+23839,Mexico,2013,39,Products not elsewhere classified,"/capita, US$ purchasing power parity",19.1
+23840,Mexico,2013,39,Products not elsewhere classified,"Million US$, purchasing power parity",2258.6
+23841,Mexico,2013,39,Products not elsewhere classified,Million of national currency units,17807.7
+23842,Mexico,2013,39,C-Cardiovascular system,Million of national currency units,9926.0
+23843,Mexico,2013,39,Products not elsewhere classified,Million US$ at exchange rate,1394.3
+23844,Mexico,2013,39,J-Antiinfectives for systemic use,"/capita, US$ exchange rate",12.0
+23845,Mexico,2013,39,N-Nervous system,Million of national currency units,13836.0
+23846,Mexico,2013,39,R-Respiratory system,% of total sales,5.1
+23847,Mexico,2013,39,N-Nervous system,Million US$ at exchange rate,1083.3
+23848,Mexico,2013,39,N-Nervous system,"Million US$, purchasing power parity",1754.9
+23849,Mexico,2013,39,R-Respiratory system,"Million US$, purchasing power parity",920.0
+23850,Mexico,2013,39,R-Respiratory system,"/capita, US$ purchasing power parity",7.8
+23851,Mexico,2013,39,R-Respiratory system,"/capita, US$ exchange rate",4.8
+23852,Mexico,2013,39,J-Antiinfectives for systemic use,Million US$ at exchange rate,1426.0
+23853,Mexico,2013,39,J-Antiinfectives for systemic use,"Million US$, purchasing power parity",2310.0
+23854,Mexico,2013,39,M-Musculo-skeletal system,"/capita, US$ purchasing power parity",3.8
+23855,Mexico,2013,39,N-Nervous system,"/capita, US$ exchange rate",9.1
+23856,Mexico,2013,39,J-Antiinfectives for systemic use,Million of national currency units,18213.0
+23857,Mexico,2013,39,N-Nervous system,% of total sales,9.8
+23858,Mexico,2013,39,N-Nervous system,"/capita, US$ purchasing power parity",14.8
+23859,Mexico,2013,39,B-Blood and blood forming organs,"Million US$, purchasing power parity",281.3
+23860,Mexico,2013,39,B-Blood and blood forming organs,Million US$ at exchange rate,173.7
+23861,Mexico,2013,39,Total pharmaceutical sales,"/capita, US$ purchasing power parity",151.8
+23862,Mexico,2013,39,Total pharmaceutical sales,"/capita, US$ exchange rate",93.7
+23863,Mexico,2013,39,Total pharmaceutical sales,"Million US$, purchasing power parity",17978.4
+23864,Mexico,2013,39,Total pharmaceutical sales,Million US$ at exchange rate,11098.4
+23865,Mexico,2013,39,Total pharmaceutical sales,Million of national currency units,141748.4
+23866,Mexico,2013,39,B-Blood and blood forming organs,"/capita, US$ purchasing power parity",2.4
+23867,Mexico,2013,39,B-Blood and blood forming organs,"/capita, US$ exchange rate",1.5
+23868,Mexico,2013,39,B-Blood and blood forming organs,Million of national currency units,2218.0
+23869,Mexico,2013,39,B-Blood and blood forming organs,% of total sales,1.6
+23870,Mexico,2013,39,M-Musculo-skeletal system,% of total sales,2.5
+23871,Mexico,2012,41,M-Musculo-skeletal system,Million of national currency units,4445.0
+23872,Mexico,2012,41,R-Respiratory system,Million US$ at exchange rate,607.4
+23873,Mexico,2012,41,R-Respiratory system,Million of national currency units,7999.0
+23874,Mexico,2012,41,M-Musculo-skeletal system,Million US$ at exchange rate,337.5
+23875,Mexico,2012,41,M-Musculo-skeletal system,"/capita, US$ exchange rate",2.9
+23876,Mexico,2012,41,M-Musculo-skeletal system,"/capita, US$ purchasing power parity",4.8
+23877,Mexico,2012,41,M-Musculo-skeletal system,"Million US$, purchasing power parity",565.6
+23878,Mexico,2012,41,C-Cardiovascular system,"/capita, US$ exchange rate",6.3
+23879,Mexico,2012,41,C-Cardiovascular system,Million US$ at exchange rate,740.1
+23880,Mexico,2012,41,C-Cardiovascular system,"Million US$, purchasing power parity",1240.3
+23881,Mexico,2012,41,J-Antiinfectives for systemic use,"/capita, US$ purchasing power parity",13.2
+23882,Mexico,2012,41,C-Cardiovascular system,"/capita, US$ purchasing power parity",10.6
+23883,Mexico,2012,41,Products not elsewhere classified,"/capita, US$ exchange rate",10.4
+23884,Mexico,2012,41,Products not elsewhere classified,"/capita, US$ purchasing power parity",17.4
+23885,Mexico,2012,41,Products not elsewhere classified,Million of national currency units,15972.0
+23886,Mexico,2012,41,C-Cardiovascular system,Million of national currency units,9747.0
+23887,Mexico,2012,41,Products not elsewhere classified,"Million US$, purchasing power parity",2032.4
+23888,Mexico,2012,41,Products not elsewhere classified,Million US$ at exchange rate,1212.8
+23889,Mexico,2012,41,N-Nervous system,Million of national currency units,12804.0
+23890,Mexico,2012,41,N-Nervous system,"Million US$, purchasing power parity",1629.3
+23891,Mexico,2012,41,N-Nervous system,Million US$ at exchange rate,972.2
+23892,Mexico,2012,41,R-Respiratory system,"Million US$, purchasing power parity",1017.9
+23893,Mexico,2012,41,R-Respiratory system,"/capita, US$ purchasing power parity",8.7
+23894,Mexico,2012,41,R-Respiratory system,"/capita, US$ exchange rate",5.2
+23895,Mexico,2012,41,J-Antiinfectives for systemic use,Million US$ at exchange rate,924.3
+23896,Mexico,2012,41,J-Antiinfectives for systemic use,"/capita, US$ exchange rate",7.9
+23897,Mexico,2012,41,J-Antiinfectives for systemic use,"Million US$, purchasing power parity",1549.0
+23898,Mexico,2012,41,J-Antiinfectives for systemic use,Million of national currency units,12173.0
+23899,Mexico,2012,41,N-Nervous system,"/capita, US$ exchange rate",8.3
+23900,Mexico,2012,41,N-Nervous system,"/capita, US$ purchasing power parity",13.9
+23901,Mexico,2012,41,B-Blood and blood forming organs,"Million US$, purchasing power parity",530.9
+23902,Mexico,2012,41,B-Blood and blood forming organs,Million US$ at exchange rate,316.8
+23903,Mexico,2012,41,B-Blood and blood forming organs,"/capita, US$ purchasing power parity",4.5
+23904,Mexico,2012,41,B-Blood and blood forming organs,"/capita, US$ exchange rate",2.7
+23905,Mexico,2012,41,B-Blood and blood forming organs,Million of national currency units,4172.0
+23906,Mexico,2011,43,M-Musculo-skeletal system,Million of national currency units,4208.0
+23907,Mexico,2011,43,M-Musculo-skeletal system,"/capita, US$ purchasing power parity",4.8
+23908,Mexico,2011,43,R-Respiratory system,Million of national currency units,7354.0
+23909,Mexico,2011,43,R-Respiratory system,Million US$ at exchange rate,592.0
+23910,Mexico,2011,43,M-Musculo-skeletal system,Million US$ at exchange rate,338.7
+23911,Mexico,2011,43,M-Musculo-skeletal system,"/capita, US$ exchange rate",2.9
+23912,Mexico,2011,43,M-Musculo-skeletal system,"Million US$, purchasing power parity",548.4
+23913,Mexico,2011,43,C-Cardiovascular system,"/capita, US$ exchange rate",7.2
+23914,Mexico,2011,43,C-Cardiovascular system,Million US$ at exchange rate,827.2
+23915,Mexico,2011,43,C-Cardiovascular system,"Million US$, purchasing power parity",1339.4
+23916,Mexico,2011,43,J-Antiinfectives for systemic use,"/capita, US$ purchasing power parity",9.0
+23917,Mexico,2011,43,C-Cardiovascular system,"/capita, US$ purchasing power parity",11.6
+23918,Mexico,2011,43,Products not elsewhere classified,"/capita, US$ exchange rate",11.9
+23919,Mexico,2011,43,Products not elsewhere classified,"/capita, US$ purchasing power parity",19.2
+23920,Mexico,2011,43,Products not elsewhere classified,"Million US$, purchasing power parity",2217.4
+23921,Mexico,2011,43,Products not elsewhere classified,Million of national currency units,17014.0
+23922,Mexico,2011,43,C-Cardiovascular system,Million of national currency units,10277.0
+23923,Mexico,2011,43,Products not elsewhere classified,Million US$ at exchange rate,1369.5
+23924,Mexico,2011,43,N-Nervous system,Million of national currency units,12584.0
+23925,Mexico,2011,43,N-Nervous system,"Million US$, purchasing power parity",1640.0
+23926,Mexico,2011,43,N-Nervous system,Million US$ at exchange rate,1012.9
+23927,Mexico,2011,43,R-Respiratory system,"Million US$, purchasing power parity",958.4
+23928,Mexico,2011,43,R-Respiratory system,"/capita, US$ purchasing power parity",8.3
+23929,Mexico,2011,43,R-Respiratory system,"/capita, US$ exchange rate",5.1
+23930,Mexico,2011,43,J-Antiinfectives for systemic use,Million US$ at exchange rate,638.8
+23931,Mexico,2011,43,J-Antiinfectives for systemic use,"/capita, US$ exchange rate",5.5
+23932,Mexico,2011,43,J-Antiinfectives for systemic use,"Million US$, purchasing power parity",1034.3
+23933,Mexico,2011,43,N-Nervous system,"/capita, US$ exchange rate",8.8
+23934,Mexico,2011,43,J-Antiinfectives for systemic use,Million of national currency units,7936.0
+23935,Mexico,2011,43,N-Nervous system,"/capita, US$ purchasing power parity",14.2
+23936,Mexico,2011,43,B-Blood and blood forming organs,"Million US$, purchasing power parity",290.8
+23937,Mexico,2011,43,B-Blood and blood forming organs,Million US$ at exchange rate,179.6
+23938,Mexico,2011,43,B-Blood and blood forming organs,"/capita, US$ exchange rate",1.6
+23939,Mexico,2011,43,B-Blood and blood forming organs,"/capita, US$ purchasing power parity",2.5
+23940,Mexico,2011,43,B-Blood and blood forming organs,Million of national currency units,2231.0
+23941,Mexico,2010,46,M-Musculo-skeletal system,Million of national currency units,5495.0
+23942,Mexico,2010,46,M-Musculo-skeletal system,Million US$ at exchange rate,434.9
+23943,Mexico,2010,46,R-Respiratory system,Million of national currency units,8936.0
+23944,Mexico,2010,46,R-Respiratory system,Million US$ at exchange rate,707.2
+23945,Mexico,2010,46,M-Musculo-skeletal system,"/capita, US$ exchange rate",3.8
+23946,Mexico,2010,46,M-Musculo-skeletal system,"/capita, US$ purchasing power parity",6.3
+23947,Mexico,2010,46,M-Musculo-skeletal system,"Million US$, purchasing power parity",715.5
+23948,Mexico,2010,46,C-Cardiovascular system,"/capita, US$ exchange rate",7.0
+23949,Mexico,2010,46,C-Cardiovascular system,Million US$ at exchange rate,801.1
+23950,Mexico,2010,46,C-Cardiovascular system,"Million US$, purchasing power parity",1318.2
+23951,Mexico,2010,46,J-Antiinfectives for systemic use,"/capita, US$ purchasing power parity",8.6
+23952,Mexico,2010,46,C-Cardiovascular system,"/capita, US$ purchasing power parity",11.6
+23953,Mexico,2010,46,Products not elsewhere classified,"/capita, US$ exchange rate",12.0
+23954,Mexico,2010,46,Products not elsewhere classified,"/capita, US$ purchasing power parity",19.7
+23955,Mexico,2010,46,Products not elsewhere classified,Million of national currency units,17216.0
+23956,Mexico,2010,46,C-Cardiovascular system,Million of national currency units,10123.0
+23957,Mexico,2010,46,Products not elsewhere classified,"Million US$, purchasing power parity",2241.8
+23958,Mexico,2010,46,Products not elsewhere classified,Million US$ at exchange rate,1362.5
+23959,Mexico,2010,46,N-Nervous system,Million of national currency units,14077.0
+23960,Mexico,2010,46,N-Nervous system,"Million US$, purchasing power parity",1833.0
+23961,Mexico,2010,46,N-Nervous system,Million US$ at exchange rate,1114.0
+23962,Mexico,2010,46,R-Respiratory system,"Million US$, purchasing power parity",1163.6
+23963,Mexico,2010,46,R-Respiratory system,"/capita, US$ exchange rate",6.2
+23964,Mexico,2010,46,R-Respiratory system,"/capita, US$ purchasing power parity",10.2
+23965,Mexico,2010,46,J-Antiinfectives for systemic use,Million US$ at exchange rate,591.8
+23966,Mexico,2010,46,J-Antiinfectives for systemic use,"/capita, US$ exchange rate",5.2
+23967,Mexico,2010,46,J-Antiinfectives for systemic use,"Million US$, purchasing power parity",973.7
+23968,Mexico,2010,46,N-Nervous system,"/capita, US$ exchange rate",9.8
+23969,Mexico,2010,46,N-Nervous system,"/capita, US$ purchasing power parity",16.1
+23970,Mexico,2010,46,J-Antiinfectives for systemic use,Million of national currency units,7478.0
+23971,Mexico,2010,46,B-Blood and blood forming organs,"Million US$, purchasing power parity",511.7
+23972,Mexico,2010,46,B-Blood and blood forming organs,Million US$ at exchange rate,311.0
+23973,Mexico,2010,46,B-Blood and blood forming organs,"/capita, US$ exchange rate",2.7
+23974,Mexico,2010,46,B-Blood and blood forming organs,"/capita, US$ purchasing power parity",4.5
+23975,Mexico,2010,46,B-Blood and blood forming organs,Million of national currency units,3930.0
+23976,Mexico,2017,33,M-Musculo-skeletal system,Million of national currency units,2708.0
+23977,Mexico,2017,33,R-Respiratory system,Million of national currency units,5570.0
+23978,Mexico,2017,33,M-Musculo-skeletal system,"/capita, US$ exchange rate",1.2
+23979,Mexico,2017,33,M-Musculo-skeletal system,Million US$ at exchange rate,143.1
+23980,Mexico,2017,33,M-Musculo-skeletal system,"Million US$, purchasing power parity",303.8
+23981,Mexico,2017,33,N-Nervous system,"/capita, US$ exchange rate",7.1
+23982,Mexico,2017,33,C-Cardiovascular system,"Million US$, purchasing power parity",1176.9
+23983,Mexico,2017,33,C-Cardiovascular system,"/capita, US$ exchange rate",4.5
+23984,Mexico,2017,33,C-Cardiovascular system,Million US$ at exchange rate,554.2
+23985,Mexico,2017,33,J-Antiinfectives for systemic use,"/capita, US$ purchasing power parity",20.4
+23986,Mexico,2017,33,J-Antiinfectives for systemic use,"/capita, US$ exchange rate",9.6
+23987,Mexico,2017,33,C-Cardiovascular system,"/capita, US$ purchasing power parity",9.5
+23988,Mexico,2017,33,Products not elsewhere classified,"/capita, US$ exchange rate",8.4
+23989,Mexico,2017,33,Products not elsewhere classified,"Million US$, purchasing power parity",2221.4
+23990,Mexico,2017,33,Products not elsewhere classified,"/capita, US$ purchasing power parity",17.9
+23991,Mexico,2017,33,Products not elsewhere classified,Million of national currency units,19800.8
+23992,Mexico,2017,33,C-Cardiovascular system,Million of national currency units,10490.0
+23993,Mexico,2017,33,Products not elsewhere classified,Million US$ at exchange rate,1046.2
+23994,Mexico,2017,33,N-Nervous system,Million of national currency units,16565.0
+23995,Mexico,2017,33,R-Respiratory system,"/capita, US$ purchasing power parity",5.0
+23996,Mexico,2017,33,N-Nervous system,Million US$ at exchange rate,875.2
+23997,Mexico,2017,33,R-Respiratory system,"Million US$, purchasing power parity",624.9
+23998,Mexico,2017,33,R-Respiratory system,Million US$ at exchange rate,294.3
+23999,Mexico,2017,33,R-Respiratory system,"/capita, US$ exchange rate",2.4
+24000,Mexico,2017,33,J-Antiinfectives for systemic use,Million US$ at exchange rate,1192.2
+24001,Mexico,2017,33,J-Antiinfectives for systemic use,Million of national currency units,22564.0
+24002,Mexico,2017,33,J-Antiinfectives for systemic use,"Million US$, purchasing power parity",2531.4
+24003,Mexico,2017,33,N-Nervous system,"Million US$, purchasing power parity",1858.4
+24004,Mexico,2017,33,N-Nervous system,"/capita, US$ purchasing power parity",15.0
+24005,Mexico,2017,33,B-Blood and blood forming organs,Million US$ at exchange rate,86.7
+24006,Mexico,2017,33,B-Blood and blood forming organs,Million of national currency units,1640.0
+24007,Mexico,2017,33,B-Blood and blood forming organs,"/capita, US$ purchasing power parity",1.5
+24008,Mexico,2017,33,B-Blood and blood forming organs,"Million US$, purchasing power parity",184.0
+24009,Mexico,2017,33,B-Blood and blood forming organs,"/capita, US$ exchange rate",0.7
+24010,Mexico,2017,33,M-Musculo-skeletal system,"/capita, US$ purchasing power parity",2.4
+24011,Netherlands,2016,6,Total pharmaceutical sales,"/capita, US$ purchasing power parity",334.6
+24012,Netherlands,2016,6,Total pharmaceutical sales,"Million US$, purchasing power parity",5697.7
+24013,Netherlands,2016,6,Total pharmaceutical sales,Million of national currency units,4532.2
+24014,Netherlands,2016,6,Total pharmaceutical sales,Million US$ at exchange rate,5016.8
+24015,Netherlands,2016,6,Total pharmaceutical sales,"/capita, US$ exchange rate",294.6
+24016,Netherlands,2015,6,Total pharmaceutical sales,"/capita, US$ purchasing power parity",325.3
+24017,Netherlands,2015,6,Total pharmaceutical sales,"Million US$, purchasing power parity",5510.4
+24018,Netherlands,2015,6,Total pharmaceutical sales,Million US$ at exchange rate,4952.1
+24019,Netherlands,2015,6,Total pharmaceutical sales,Million of national currency units,4463.3
+24020,Netherlands,2015,6,Total pharmaceutical sales,"/capita, US$ exchange rate",292.3
+24021,Netherlands,2014,6,R03-Drugs for obstructive airway diseases,"/capita, US$ purchasing power parity",30.4
+24022,Netherlands,2014,6,R03-Drugs for obstructive airway diseases,"/capita, US$ exchange rate",32.6
+24023,Netherlands,2014,6,J-Antiinfectives for systemic use,Million of national currency units,387.7
+24024,Netherlands,2014,6,J-Antiinfectives for systemic use,Million US$ at exchange rate,515.0
+24025,Netherlands,2014,6,J-Antiinfectives for systemic use,"Million US$, purchasing power parity",479.3
+24026,Netherlands,2014,6,R03-Drugs for obstructive airway diseases,% of total sales,9.6
+24027,Netherlands,2014,6,B-Blood and blood forming organs,Million of national currency units,267.6
+24028,Netherlands,2014,6,N06A-Antidepressants,% of total sales,2.3
+24029,Netherlands,2014,6,B-Blood and blood forming organs,"/capita, US$ purchasing power parity",19.6
+24030,Netherlands,2014,6,B-Blood and blood forming organs,"/capita, US$ exchange rate",21.1
+24031,Netherlands,2014,6,B-Blood and blood forming organs,"Million US$, purchasing power parity",330.9
+24032,Netherlands,2014,6,B-Blood and blood forming organs,Million US$ at exchange rate,355.5
+24033,Netherlands,2014,6,J-Antiinfectives for systemic use,"/capita, US$ exchange rate",30.5
+24034,Netherlands,2014,6,C09-Agents acting on the Renin-Angiotensin system,Million of national currency units,141.1
+24035,Netherlands,2014,6,R03-Drugs for obstructive airway diseases,"Million US$, purchasing power parity",512.0
+24036,Netherlands,2014,6,R03-Drugs for obstructive airway diseases,Million US$ at exchange rate,550.2
+24037,Netherlands,2014,6,R03-Drugs for obstructive airway diseases,Million of national currency units,414.1
+24038,Netherlands,2014,6,C09-Agents acting on the Renin-Angiotensin system,Million US$ at exchange rate,187.5
+24039,Netherlands,2014,6,J-Antiinfectives for systemic use,"/capita, US$ purchasing power parity",28.4
+24040,Netherlands,2014,6,J-Antiinfectives for systemic use,% of total sales,9.0
+24041,Netherlands,2014,6,C09-Agents acting on the Renin-Angiotensin system,% of total sales,3.3
+24042,Netherlands,2014,6,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ purchasing power parity",10.3
+24043,Netherlands,2014,6,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ exchange rate",11.1
+24044,Netherlands,2014,6,C09-Agents acting on the Renin-Angiotensin system,"Million US$, purchasing power parity",174.5
+24045,Netherlands,2014,6,"C01B-Antiarrhythmics, Class I and III",Million of national currency units,9.6
+24046,Netherlands,2014,6,"C01B-Antiarrhythmics, Class I and III",Million US$ at exchange rate,12.8
+24047,Netherlands,2014,6,"C01B-Antiarrhythmics, Class I and III","Million US$, purchasing power parity",11.9
+24048,Netherlands,2014,6,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million of national currency units,129.9
+24049,Netherlands,2014,6,Total pharmaceutical sales,"/capita, US$ purchasing power parity",317.3
+24050,Netherlands,2014,6,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ exchange rate",10.2
+24051,Netherlands,2014,6,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ purchasing power parity",9.5
+24052,Netherlands,2014,6,"H-Systemic hormonal preparations, excluding sex hormones and insulins",% of total sales,3.0
+24053,Netherlands,2014,6,C03-Diuretics,% of total sales,1.9
+24054,Netherlands,2014,6,"H-Systemic hormonal preparations, excluding sex hormones and insulins","Million US$, purchasing power parity",160.6
+24055,Netherlands,2014,6,"C01B-Antiarrhythmics, Class I and III","/capita, US$ exchange rate",0.8
+24056,Netherlands,2014,6,"C01B-Antiarrhythmics, Class I and III","/capita, US$ purchasing power parity",0.7
+24057,Netherlands,2014,6,"C01B-Antiarrhythmics, Class I and III",% of total sales,0.2
+24058,Netherlands,2014,6,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million US$ at exchange rate,172.6
+24059,Netherlands,2014,6,Total pharmaceutical sales,"Million US$, purchasing power parity",5351.6
+24060,Netherlands,2014,6,Total pharmaceutical sales,Million of national currency units,4328.4
+24061,Netherlands,2014,6,N06A-Antidepressants,"/capita, US$ purchasing power parity",7.3
+24062,Netherlands,2014,6,Total pharmaceutical sales,Million US$ at exchange rate,5750.2
+24063,Netherlands,2014,6,N-Nervous system,% of total sales,13.2
+24064,Netherlands,2014,6,N-Nervous system,Million of national currency units,571.7
+24065,Netherlands,2014,6,Total pharmaceutical sales,"/capita, US$ exchange rate",341.0
+24066,Netherlands,2014,6,N-Nervous system,Million US$ at exchange rate,759.6
+24067,Netherlands,2014,6,N-Nervous system,"/capita, US$ purchasing power parity",41.9
+24068,Netherlands,2014,6,N-Nervous system,"Million US$, purchasing power parity",706.9
+24069,Netherlands,2014,6,N-Nervous system,"/capita, US$ exchange rate",45.0
+24070,Netherlands,2014,6,J01-Antibacterials for systemic use,"/capita, US$ purchasing power parity",7.5
+24071,Netherlands,2014,6,J01-Antibacterials for systemic use,"/capita, US$ exchange rate",8.1
+24072,Netherlands,2014,6,C-Cardiovascular system,Million US$ at exchange rate,906.2
+24073,Netherlands,2014,6,C-Cardiovascular system,Million of national currency units,682.1
+24074,Netherlands,2014,6,C01A-Cardiac glycosides,% of total sales,0.1
+24075,Netherlands,2014,6,B-Blood and blood forming organs,% of total sales,6.2
+24076,Netherlands,2014,6,J01-Antibacterials for systemic use,Million of national currency units,102.9
+24077,Netherlands,2014,6,J01-Antibacterials for systemic use,Million US$ at exchange rate,136.7
+24078,Netherlands,2014,6,J01-Antibacterials for systemic use,"Million US$, purchasing power parity",127.2
+24079,Netherlands,2014,6,C-Cardiovascular system,"Million US$, purchasing power parity",843.4
+24080,Netherlands,2014,6,N05C-Hypnotics and sedatives,"/capita, US$ purchasing power parity",1.0
+24081,Netherlands,2014,6,N05C-Hypnotics and sedatives,"/capita, US$ exchange rate",1.1
+24082,Netherlands,2014,6,N05C-Hypnotics and sedatives,"Million US$, purchasing power parity",17.2
+24083,Netherlands,2014,6,N05C-Hypnotics and sedatives,Million US$ at exchange rate,18.5
+24084,Netherlands,2014,6,C-Cardiovascular system,"/capita, US$ exchange rate",53.7
+24085,Netherlands,2014,6,C-Cardiovascular system,"/capita, US$ purchasing power parity",50.0
+24086,Netherlands,2014,6,C-Cardiovascular system,% of total sales,15.8
+24087,Netherlands,2014,6,J01-Antibacterials for systemic use,% of total sales,2.4
+24088,Netherlands,2014,6,N05C-Hypnotics and sedatives,% of total sales,0.3
+24089,Netherlands,2014,6,A10-Drugs used in diabetes,"/capita, US$ purchasing power parity",19.7
+24090,Netherlands,2014,6,A10-Drugs used in diabetes,% of total sales,6.2
+24091,Netherlands,2014,6,G03-Sex hormones and modulators of the genital system,% of total sales,0.6
+24092,Netherlands,2014,6,G03-Sex hormones and modulators of the genital system,"/capita, US$ purchasing power parity",2.1
+24093,Netherlands,2014,6,G03-Sex hormones and modulators of the genital system,"/capita, US$ exchange rate",2.2
+24094,Netherlands,2014,6,A10-Drugs used in diabetes,Million of national currency units,268.1
+24095,Netherlands,2014,6,A10-Drugs used in diabetes,"/capita, US$ exchange rate",21.1
+24096,Netherlands,2014,6,A10-Drugs used in diabetes,"Million US$, purchasing power parity",331.5
+24097,Netherlands,2014,6,A10-Drugs used in diabetes,Million US$ at exchange rate,356.2
+24098,Netherlands,2014,6,C01A-Cardiac glycosides,Million US$ at exchange rate,7.9
+24099,Netherlands,2014,6,C01A-Cardiac glycosides,"Million US$, purchasing power parity",7.4
+24100,Netherlands,2014,6,C01A-Cardiac glycosides,"/capita, US$ exchange rate",0.5
+24101,Netherlands,2014,6,C01A-Cardiac glycosides,"/capita, US$ purchasing power parity",0.4
+24102,Netherlands,2014,6,C01A-Cardiac glycosides,Million of national currency units,6.0
+24103,Netherlands,2014,6,G03-Sex hormones and modulators of the genital system,"Million US$, purchasing power parity",34.7
+24104,Netherlands,2014,6,G03-Sex hormones and modulators of the genital system,Million US$ at exchange rate,37.3
+24105,Netherlands,2014,6,G03-Sex hormones and modulators of the genital system,Million of national currency units,28.1
+24106,Netherlands,2014,6,N05C-Hypnotics and sedatives,Million of national currency units,13.9
+24107,Netherlands,2014,6,M01A-Antiinflammatory and antirheumatic products non-steroids,Million of national currency units,69.0
+24108,Netherlands,2014,6,M01A-Antiinflammatory and antirheumatic products non-steroids,Million US$ at exchange rate,91.6
+24109,Netherlands,2014,6,M01A-Antiinflammatory and antirheumatic products non-steroids,"Million US$, purchasing power parity",85.3
+24110,Netherlands,2014,6,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ exchange rate",5.4
+24111,Netherlands,2014,6,N06A-Antidepressants,"Million US$, purchasing power parity",123.3
+24112,Netherlands,2014,6,A02A-Antacids,"Million US$, purchasing power parity",0.0
+24113,Netherlands,2014,6,A02A-Antacids,"/capita, US$ exchange rate",0.0
+24114,Netherlands,2014,6,A02A-Antacids,"/capita, US$ purchasing power parity",0.0
+24115,Netherlands,2014,6,A02A-Antacids,% of total sales,0.0
+24116,Netherlands,2014,6,C07-Beta blocking agents,Million US$ at exchange rate,123.9
+24117,Netherlands,2014,6,C07-Beta blocking agents,Million of national currency units,93.3
+24118,Netherlands,2014,6,N06A-Antidepressants,"/capita, US$ exchange rate",7.9
+24119,Netherlands,2014,6,C07-Beta blocking agents,"Million US$, purchasing power parity",115.3
+24120,Netherlands,2014,6,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ purchasing power parity",5.1
+24121,Netherlands,2014,6,M01A-Antiinflammatory and antirheumatic products non-steroids,% of total sales,1.6
+24122,Netherlands,2014,6,C07-Beta blocking agents,% of total sales,2.2
+24123,Netherlands,2014,6,C07-Beta blocking agents,"/capita, US$ purchasing power parity",6.8
+24124,Netherlands,2014,6,C07-Beta blocking agents,"/capita, US$ exchange rate",7.3
+24125,Netherlands,2014,6,C08-Calcium channel blockers,Million US$ at exchange rate,87.5
+24126,Netherlands,2014,6,C08-Calcium channel blockers,"Million US$, purchasing power parity",81.4
+24127,Netherlands,2014,6,C08-Calcium channel blockers,"/capita, US$ exchange rate",5.2
+24128,Netherlands,2014,6,C08-Calcium channel blockers,"/capita, US$ purchasing power parity",4.8
+24129,Netherlands,2014,6,C08-Calcium channel blockers,Million of national currency units,65.8
+24130,Netherlands,2014,6,N06A-Antidepressants,Million of national currency units,99.7
+24131,Netherlands,2014,6,N06A-Antidepressants,Million US$ at exchange rate,132.4
+24132,Netherlands,2014,6,N02-Analgesics,"/capita, US$ purchasing power parity",10.5
+24133,Netherlands,2014,6,N02-Analgesics,% of total sales,3.3
+24134,Netherlands,2014,6,A02A-Antacids,Million of national currency units,0.0
+24135,Netherlands,2014,6,A02A-Antacids,Million US$ at exchange rate,0.0
+24136,Netherlands,2014,6,N02-Analgesics,"/capita, US$ exchange rate",11.3
+24137,Netherlands,2014,6,C08-Calcium channel blockers,% of total sales,1.5
+24138,Netherlands,2014,6,N02-Analgesics,Million of national currency units,143.6
+24139,Netherlands,2014,6,N02-Analgesics,Million US$ at exchange rate,190.8
+24140,Netherlands,2014,6,N02-Analgesics,"Million US$, purchasing power parity",177.6
+24141,Netherlands,2014,6,C03-Diuretics,"/capita, US$ purchasing power parity",5.9
+24142,Netherlands,2014,6,N05B-Anxiolytics,Million of national currency units,20.4
+24143,Netherlands,2014,6,R-Respiratory system,Million US$ at exchange rate,686.1
+24144,Netherlands,2014,6,R-Respiratory system,Million of national currency units,516.5
+24145,Netherlands,2014,6,N05B-Anxiolytics,"/capita, US$ purchasing power parity",1.5
+24146,Netherlands,2014,6,N05B-Anxiolytics,"/capita, US$ exchange rate",1.6
+24147,Netherlands,2014,6,N05B-Anxiolytics,"Million US$, purchasing power parity",25.2
+24148,Netherlands,2014,6,N05B-Anxiolytics,Million US$ at exchange rate,27.1
+24149,Netherlands,2014,6,G-Genito urinary system and sex hormones,% of total sales,2.4
+24150,Netherlands,2014,6,R-Respiratory system,% of total sales,11.9
+24151,Netherlands,2014,6,G-Genito urinary system and sex hormones,"Million US$, purchasing power parity",129.8
+24152,Netherlands,2014,6,R-Respiratory system,"/capita, US$ purchasing power parity",37.9
+24153,Netherlands,2014,6,G-Genito urinary system and sex hormones,Million US$ at exchange rate,139.5
+24154,Netherlands,2014,6,G-Genito urinary system and sex hormones,Million of national currency units,105.0
+24155,Netherlands,2014,6,G-Genito urinary system and sex hormones,"/capita, US$ purchasing power parity",7.7
+24156,Netherlands,2014,6,G-Genito urinary system and sex hormones,"/capita, US$ exchange rate",8.3
+24157,Netherlands,2014,6,R-Respiratory system,"Million US$, purchasing power parity",638.6
+24158,Netherlands,2014,6,R-Respiratory system,"/capita, US$ exchange rate",40.7
+24159,Netherlands,2014,6,N05B-Anxiolytics,% of total sales,0.5
+24160,Netherlands,2014,6,C02-Antihypertensives,% of total sales,0.8
+24161,Netherlands,2014,6,C10-Lipid modifying agents,Million of national currency units,213.7
+24162,Netherlands,2014,6,C02-Antihypertensives,"/capita, US$ purchasing power parity",2.6
+24163,Netherlands,2014,6,C10-Lipid modifying agents,Million US$ at exchange rate,283.9
+24164,Netherlands,2014,6,C10-Lipid modifying agents,"Million US$, purchasing power parity",264.2
+24165,Netherlands,2014,6,C02-Antihypertensives,"Million US$, purchasing power parity",43.3
+24166,Netherlands,2014,6,C02-Antihypertensives,Million US$ at exchange rate,46.6
+24167,Netherlands,2014,6,C02-Antihypertensives,Million of national currency units,35.0
+24168,Netherlands,2014,6,C02-Antihypertensives,"/capita, US$ exchange rate",2.8
+24169,Netherlands,2014,6,A-Alimentary tract and metabolism,"Million US$, purchasing power parity",805.6
+24170,Netherlands,2014,6,A-Alimentary tract and metabolism,Million US$ at exchange rate,865.6
+24171,Netherlands,2014,6,A-Alimentary tract and metabolism,Million of national currency units,651.6
+24172,Netherlands,2014,6,A-Alimentary tract and metabolism,"/capita, US$ exchange rate",51.3
+24173,Netherlands,2014,6,C10-Lipid modifying agents,"/capita, US$ exchange rate",16.8
+24174,Netherlands,2014,6,C10-Lipid modifying agents,"/capita, US$ purchasing power parity",15.7
+24175,Netherlands,2014,6,C10-Lipid modifying agents,% of total sales,4.9
+24176,Netherlands,2014,6,A-Alimentary tract and metabolism,% of total sales,15.1
+24177,Netherlands,2014,6,A-Alimentary tract and metabolism,"/capita, US$ purchasing power parity",47.8
+24178,Netherlands,2014,6,M-Musculo-skeletal system,Million of national currency units,121.1
+24179,Netherlands,2014,6,C03-Diuretics,"/capita, US$ exchange rate",6.3
+24180,Netherlands,2014,6,C03-Diuretics,"Million US$, purchasing power parity",99.5
+24181,Netherlands,2014,6,C03-Diuretics,Million US$ at exchange rate,106.9
+24182,Netherlands,2014,6,M-Musculo-skeletal system,Million US$ at exchange rate,160.9
+24183,Netherlands,2014,6,M-Musculo-skeletal system,"/capita, US$ purchasing power parity",8.9
+24184,Netherlands,2014,6,M-Musculo-skeletal system,"/capita, US$ exchange rate",9.5
+24185,Netherlands,2014,6,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"Million US$, purchasing power parity",144.8
+24186,Netherlands,2014,6,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ exchange rate",9.2
+24187,Netherlands,2014,6,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ purchasing power parity",8.6
+24188,Netherlands,2014,6,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),% of total sales,2.7
+24189,Netherlands,2014,6,C03-Diuretics,Million of national currency units,80.5
+24190,Netherlands,2014,6,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million of national currency units,117.1
+24191,Netherlands,2014,6,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million US$ at exchange rate,155.6
+24192,Netherlands,2014,6,M-Musculo-skeletal system,% of total sales,2.8
+24193,Netherlands,2014,6,M-Musculo-skeletal system,"Million US$, purchasing power parity",149.7
+24194,Netherlands,2013,6,R03-Drugs for obstructive airway diseases,"/capita, US$ purchasing power parity",32.1
+24195,Netherlands,2013,6,R03-Drugs for obstructive airway diseases,"/capita, US$ exchange rate",34.0
+24196,Netherlands,2013,6,J-Antiinfectives for systemic use,Million of national currency units,393.7
+24197,Netherlands,2013,6,J-Antiinfectives for systemic use,Million US$ at exchange rate,522.8
+24198,Netherlands,2013,6,J-Antiinfectives for systemic use,"Million US$, purchasing power parity",493.2
+24199,Netherlands,2013,6,R03-Drugs for obstructive airway diseases,% of total sales,10.0
+24200,Netherlands,2013,6,B-Blood and blood forming organs,Million of national currency units,258.1
+24201,Netherlands,2013,6,N06A-Antidepressants,% of total sales,2.3
+24202,Netherlands,2013,6,B-Blood and blood forming organs,"/capita, US$ purchasing power parity",19.2
+24203,Netherlands,2013,6,B-Blood and blood forming organs,"/capita, US$ exchange rate",20.4
+24204,Netherlands,2013,6,B-Blood and blood forming organs,"Million US$, purchasing power parity",323.4
+24205,Netherlands,2013,6,C09-Agents acting on the Renin-Angiotensin system,Million US$ at exchange rate,222.7
+24206,Netherlands,2013,6,C09-Agents acting on the Renin-Angiotensin system,Million of national currency units,167.6
+24207,Netherlands,2013,6,R03-Drugs for obstructive airway diseases,"Million US$, purchasing power parity",538.9
+24208,Netherlands,2013,6,R03-Drugs for obstructive airway diseases,Million US$ at exchange rate,571.3
+24209,Netherlands,2013,6,R03-Drugs for obstructive airway diseases,Million of national currency units,430.1
+24210,Netherlands,2013,6,J-Antiinfectives for systemic use,"/capita, US$ exchange rate",31.1
+24211,Netherlands,2013,6,B-Blood and blood forming organs,Million US$ at exchange rate,342.8
+24212,Netherlands,2013,6,J-Antiinfectives for systemic use,% of total sales,9.2
+24213,Netherlands,2013,6,C09-Agents acting on the Renin-Angiotensin system,% of total sales,3.9
+24214,Netherlands,2013,6,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ purchasing power parity",12.5
+24215,Netherlands,2013,6,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ exchange rate",13.2
+24216,Netherlands,2013,6,C09-Agents acting on the Renin-Angiotensin system,"Million US$, purchasing power parity",210.0
+24217,Netherlands,2013,6,J-Antiinfectives for systemic use,"/capita, US$ purchasing power parity",29.3
+24218,Netherlands,2013,6,"C01B-Antiarrhythmics, Class I and III",Million of national currency units,9.7
+24219,Netherlands,2013,6,"C01B-Antiarrhythmics, Class I and III",Million US$ at exchange rate,12.9
+24220,Netherlands,2013,6,"C01B-Antiarrhythmics, Class I and III","Million US$, purchasing power parity",12.2
+24221,Netherlands,2013,6,Total pharmaceutical sales,"/capita, US$ purchasing power parity",320.7
+24222,Netherlands,2013,6,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million of national currency units,127.9
+24223,Netherlands,2013,6,"C01B-Antiarrhythmics, Class I and III","/capita, US$ exchange rate",0.8
+24224,Netherlands,2013,6,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ exchange rate",10.1
+24225,Netherlands,2013,6,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ purchasing power parity",9.5
+24226,Netherlands,2013,6,"H-Systemic hormonal preparations, excluding sex hormones and insulins",% of total sales,3.0
+24227,Netherlands,2013,6,C03-Diuretics,% of total sales,1.9
+24228,Netherlands,2013,6,"H-Systemic hormonal preparations, excluding sex hormones and insulins","Million US$, purchasing power parity",160.2
+24229,Netherlands,2013,6,"C01B-Antiarrhythmics, Class I and III","/capita, US$ purchasing power parity",0.7
+24230,Netherlands,2013,6,"C01B-Antiarrhythmics, Class I and III",% of total sales,0.2
+24231,Netherlands,2013,6,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million US$ at exchange rate,169.8
+24232,Netherlands,2013,6,Total pharmaceutical sales,"Million US$, purchasing power parity",5388.7
+24233,Netherlands,2013,6,Total pharmaceutical sales,Million of national currency units,4301.1
+24234,Netherlands,2013,6,Total pharmaceutical sales,Million US$ at exchange rate,5712.3
+24235,Netherlands,2013,6,N-Nervous system,% of total sales,13.2
+24236,Netherlands,2013,6,N-Nervous system,Million of national currency units,568.2
+24237,Netherlands,2013,6,Total pharmaceutical sales,"/capita, US$ exchange rate",339.9
+24238,Netherlands,2013,6,N-Nervous system,Million US$ at exchange rate,754.7
+24239,Netherlands,2013,6,N-Nervous system,"/capita, US$ purchasing power parity",42.4
+24240,Netherlands,2013,6,N-Nervous system,"/capita, US$ exchange rate",44.9
+24241,Netherlands,2013,6,N-Nervous system,"Million US$, purchasing power parity",711.9
+24242,Netherlands,2013,6,N06A-Antidepressants,"/capita, US$ purchasing power parity",7.3
+24243,Netherlands,2013,6,N06A-Antidepressants,"/capita, US$ exchange rate",7.8
+24244,Netherlands,2013,6,J01-Antibacterials for systemic use,"/capita, US$ purchasing power parity",9.0
+24245,Netherlands,2013,6,C-Cardiovascular system,Million of national currency units,714.1
+24246,Netherlands,2013,6,C-Cardiovascular system,Million US$ at exchange rate,948.4
+24247,Netherlands,2013,6,C-Cardiovascular system,"Million US$, purchasing power parity",894.7
+24248,Netherlands,2013,6,J01-Antibacterials for systemic use,"/capita, US$ exchange rate",9.5
+24249,Netherlands,2013,6,J01-Antibacterials for systemic use,Million of national currency units,120.2
+24250,Netherlands,2013,6,J01-Antibacterials for systemic use,Million US$ at exchange rate,159.6
+24251,Netherlands,2013,6,J01-Antibacterials for systemic use,"Million US$, purchasing power parity",150.6
+24252,Netherlands,2013,6,N05C-Hypnotics and sedatives,"/capita, US$ purchasing power parity",0.9
+24253,Netherlands,2013,6,N05C-Hypnotics and sedatives,"/capita, US$ exchange rate",1.0
+24254,Netherlands,2013,6,N05C-Hypnotics and sedatives,"Million US$, purchasing power parity",16.0
+24255,Netherlands,2013,6,N05C-Hypnotics and sedatives,Million US$ at exchange rate,16.9
+24256,Netherlands,2013,6,N05C-Hypnotics and sedatives,% of total sales,0.3
+24257,Netherlands,2013,6,C-Cardiovascular system,"/capita, US$ exchange rate",56.4
+24258,Netherlands,2013,6,C-Cardiovascular system,"/capita, US$ purchasing power parity",53.2
+24259,Netherlands,2013,6,C-Cardiovascular system,% of total sales,16.6
+24260,Netherlands,2013,6,J01-Antibacterials for systemic use,% of total sales,2.8
+24261,Netherlands,2013,6,C01A-Cardiac glycosides,% of total sales,0.1
+24262,Netherlands,2013,6,A10-Drugs used in diabetes,"/capita, US$ purchasing power parity",20.1
+24263,Netherlands,2013,6,A10-Drugs used in diabetes,% of total sales,6.3
+24264,Netherlands,2013,6,G03-Sex hormones and modulators of the genital system,"/capita, US$ purchasing power parity",4.5
+24265,Netherlands,2013,6,G03-Sex hormones and modulators of the genital system,% of total sales,1.4
+24266,Netherlands,2013,6,A10-Drugs used in diabetes,"/capita, US$ exchange rate",21.3
+24267,Netherlands,2013,6,A10-Drugs used in diabetes,Million of national currency units,269.8
+24268,Netherlands,2013,6,A10-Drugs used in diabetes,Million US$ at exchange rate,358.3
+24269,Netherlands,2013,6,A10-Drugs used in diabetes,"Million US$, purchasing power parity",338.0
+24270,Netherlands,2013,6,G03-Sex hormones and modulators of the genital system,"/capita, US$ exchange rate",4.7
+24271,Netherlands,2013,6,C01A-Cardiac glycosides,Million US$ at exchange rate,8.6
+24272,Netherlands,2013,6,C01A-Cardiac glycosides,"Million US$, purchasing power parity",8.1
+24273,Netherlands,2013,6,C01A-Cardiac glycosides,"/capita, US$ exchange rate",0.5
+24274,Netherlands,2013,6,C01A-Cardiac glycosides,"/capita, US$ purchasing power parity",0.5
+24275,Netherlands,2013,6,C01A-Cardiac glycosides,Million of national currency units,6.4
+24276,Netherlands,2013,6,G03-Sex hormones and modulators of the genital system,"Million US$, purchasing power parity",75.1
+24277,Netherlands,2013,6,G03-Sex hormones and modulators of the genital system,Million US$ at exchange rate,79.6
+24278,Netherlands,2013,6,G03-Sex hormones and modulators of the genital system,Million of national currency units,59.9
+24279,Netherlands,2013,6,N05C-Hypnotics and sedatives,Million of national currency units,12.7
+24280,Netherlands,2013,6,M01A-Antiinflammatory and antirheumatic products non-steroids,Million of national currency units,80.9
+24281,Netherlands,2013,6,M01A-Antiinflammatory and antirheumatic products non-steroids,Million US$ at exchange rate,107.5
+24282,Netherlands,2013,6,M01A-Antiinflammatory and antirheumatic products non-steroids,"Million US$, purchasing power parity",101.4
+24283,Netherlands,2013,6,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ exchange rate",6.4
+24284,Netherlands,2013,6,A02A-Antacids,"/capita, US$ exchange rate",0.0
+24285,Netherlands,2013,6,A02A-Antacids,% of total sales,0.0
+24286,Netherlands,2013,6,N06A-Antidepressants,"Million US$, purchasing power parity",123.2
+24287,Netherlands,2013,6,A02A-Antacids,"/capita, US$ purchasing power parity",0.0
+24288,Netherlands,2013,6,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ purchasing power parity",6.0
+24289,Netherlands,2013,6,C07-Beta blocking agents,Million US$ at exchange rate,124.7
+24290,Netherlands,2013,6,C07-Beta blocking agents,"Million US$, purchasing power parity",117.7
+24291,Netherlands,2013,6,C07-Beta blocking agents,Million of national currency units,93.9
+24292,Netherlands,2013,6,M01A-Antiinflammatory and antirheumatic products non-steroids,% of total sales,1.9
+24293,Netherlands,2013,6,C07-Beta blocking agents,% of total sales,2.2
+24294,Netherlands,2013,6,C07-Beta blocking agents,"/capita, US$ purchasing power parity",7.0
+24295,Netherlands,2013,6,C07-Beta blocking agents,"/capita, US$ exchange rate",7.4
+24296,Netherlands,2013,6,A02A-Antacids,"Million US$, purchasing power parity",0.0
+24297,Netherlands,2013,6,C08-Calcium channel blockers,Million US$ at exchange rate,86.2
+24298,Netherlands,2013,6,C08-Calcium channel blockers,"Million US$, purchasing power parity",81.3
+24299,Netherlands,2013,6,C08-Calcium channel blockers,"/capita, US$ exchange rate",5.1
+24300,Netherlands,2013,6,C08-Calcium channel blockers,"/capita, US$ purchasing power parity",4.8
+24301,Netherlands,2013,6,C08-Calcium channel blockers,Million of national currency units,64.9
+24302,Netherlands,2013,6,B-Blood and blood forming organs,% of total sales,6.0
+24303,Netherlands,2013,6,N06A-Antidepressants,Million of national currency units,98.3
+24304,Netherlands,2013,6,N06A-Antidepressants,Million US$ at exchange rate,130.6
+24305,Netherlands,2013,6,C08-Calcium channel blockers,% of total sales,1.5
+24306,Netherlands,2013,6,N02-Analgesics,"/capita, US$ purchasing power parity",11.1
+24307,Netherlands,2013,6,N02-Analgesics,% of total sales,3.5
+24308,Netherlands,2013,6,A02A-Antacids,Million of national currency units,0.0
+24309,Netherlands,2013,6,A02A-Antacids,Million US$ at exchange rate,0.0
+24310,Netherlands,2013,6,N02-Analgesics,"/capita, US$ exchange rate",11.8
+24311,Netherlands,2013,6,N02-Analgesics,Million of national currency units,148.9
+24312,Netherlands,2013,6,N02-Analgesics,Million US$ at exchange rate,197.7
+24313,Netherlands,2013,6,N02-Analgesics,"Million US$, purchasing power parity",186.5
+24314,Netherlands,2013,6,N05B-Anxiolytics,Million of national currency units,20.1
+24315,Netherlands,2013,6,R-Respiratory system,Million of national currency units,540.6
+24316,Netherlands,2013,6,R-Respiratory system,Million US$ at exchange rate,718.0
+24317,Netherlands,2013,6,N05B-Anxiolytics,Million US$ at exchange rate,26.7
+24318,Netherlands,2013,6,N05B-Anxiolytics,"/capita, US$ purchasing power parity",1.5
+24319,Netherlands,2013,6,N05B-Anxiolytics,"/capita, US$ exchange rate",1.6
+24320,Netherlands,2013,6,N05B-Anxiolytics,"Million US$, purchasing power parity",25.2
+24321,Netherlands,2013,6,R-Respiratory system,"Million US$, purchasing power parity",677.3
+24322,Netherlands,2013,6,N05B-Anxiolytics,% of total sales,0.5
+24323,Netherlands,2013,6,R-Respiratory system,% of total sales,12.6
+24324,Netherlands,2013,6,G-Genito urinary system and sex hormones,"Million US$, purchasing power parity",171.4
+24325,Netherlands,2013,6,G-Genito urinary system and sex hormones,Million US$ at exchange rate,181.7
+24326,Netherlands,2013,6,G-Genito urinary system and sex hormones,Million of national currency units,136.8
+24327,Netherlands,2013,6,R-Respiratory system,"/capita, US$ purchasing power parity",40.3
+24328,Netherlands,2013,6,G-Genito urinary system and sex hormones,"/capita, US$ purchasing power parity",10.2
+24329,Netherlands,2013,6,G-Genito urinary system and sex hormones,"/capita, US$ exchange rate",10.8
+24330,Netherlands,2013,6,R-Respiratory system,"/capita, US$ exchange rate",42.7
+24331,Netherlands,2013,6,G-Genito urinary system and sex hormones,% of total sales,3.2
+24332,Netherlands,2013,6,C02-Antihypertensives,% of total sales,0.8
+24333,Netherlands,2013,6,C10-Lipid modifying agents,Million of national currency units,213.2
+24334,Netherlands,2013,6,C10-Lipid modifying agents,Million US$ at exchange rate,283.2
+24335,Netherlands,2013,6,C10-Lipid modifying agents,"Million US$, purchasing power parity",267.1
+24336,Netherlands,2013,6,C02-Antihypertensives,"/capita, US$ purchasing power parity",2.6
+24337,Netherlands,2013,6,C02-Antihypertensives,"Million US$, purchasing power parity",42.9
+24338,Netherlands,2013,6,C02-Antihypertensives,Million US$ at exchange rate,45.5
+24339,Netherlands,2013,6,C02-Antihypertensives,Million of national currency units,34.2
+24340,Netherlands,2013,6,C02-Antihypertensives,"/capita, US$ exchange rate",2.7
+24341,Netherlands,2013,6,C10-Lipid modifying agents,"/capita, US$ exchange rate",16.9
+24342,Netherlands,2013,6,A-Alimentary tract and metabolism,"Million US$, purchasing power parity",816.6
+24343,Netherlands,2013,6,A-Alimentary tract and metabolism,Million US$ at exchange rate,865.6
+24344,Netherlands,2013,6,A-Alimentary tract and metabolism,Million of national currency units,651.8
+24345,Netherlands,2013,6,A-Alimentary tract and metabolism,"/capita, US$ exchange rate",51.5
+24346,Netherlands,2013,6,C10-Lipid modifying agents,"/capita, US$ purchasing power parity",15.9
+24347,Netherlands,2013,6,C10-Lipid modifying agents,% of total sales,5.0
+24348,Netherlands,2013,6,A-Alimentary tract and metabolism,% of total sales,15.2
+24349,Netherlands,2013,6,A-Alimentary tract and metabolism,"/capita, US$ purchasing power parity",48.6
+24350,Netherlands,2013,6,M-Musculo-skeletal system,Million of national currency units,133.3
+24351,Netherlands,2013,6,C03-Diuretics,"/capita, US$ exchange rate",6.4
+24352,Netherlands,2013,6,C03-Diuretics,"Million US$, purchasing power parity",102.2
+24353,Netherlands,2013,6,M-Musculo-skeletal system,Million US$ at exchange rate,177.1
+24354,Netherlands,2013,6,M-Musculo-skeletal system,"/capita, US$ purchasing power parity",9.9
+24355,Netherlands,2013,6,M-Musculo-skeletal system,"/capita, US$ exchange rate",10.5
+24356,Netherlands,2013,6,M-Musculo-skeletal system,"Million US$, purchasing power parity",167.1
+24357,Netherlands,2013,6,C03-Diuretics,Million US$ at exchange rate,108.3
+24358,Netherlands,2013,6,M-Musculo-skeletal system,% of total sales,3.1
+24359,Netherlands,2013,6,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ exchange rate",9.4
+24360,Netherlands,2013,6,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"Million US$, purchasing power parity",148.3
+24361,Netherlands,2013,6,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ purchasing power parity",8.8
+24362,Netherlands,2013,6,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),% of total sales,2.8
+24363,Netherlands,2013,6,C03-Diuretics,Million of national currency units,81.5
+24364,Netherlands,2013,6,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million of national currency units,118.4
+24365,Netherlands,2013,6,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million US$ at exchange rate,157.3
+24366,Netherlands,2013,6,C03-Diuretics,"/capita, US$ purchasing power parity",6.1
+24367,Netherlands,2012,7,R03-Drugs for obstructive airway diseases,"/capita, US$ purchasing power parity",32.2
+24368,Netherlands,2012,7,R03-Drugs for obstructive airway diseases,"/capita, US$ exchange rate",34.2
+24369,Netherlands,2012,7,J-Antiinfectives for systemic use,Million of national currency units,375.5
+24370,Netherlands,2012,7,J-Antiinfectives for systemic use,Million US$ at exchange rate,482.5
+24371,Netherlands,2012,7,J-Antiinfectives for systemic use,"Million US$, purchasing power parity",455.5
+24372,Netherlands,2012,7,R03-Drugs for obstructive airway diseases,% of total sales,9.7
+24373,Netherlands,2012,7,B-Blood and blood forming organs,Million of national currency units,244.3
+24374,Netherlands,2012,7,B-Blood and blood forming organs,Million US$ at exchange rate,313.9
+24375,Netherlands,2012,7,N06A-Antidepressants,% of total sales,2.1
+24376,Netherlands,2012,7,B-Blood and blood forming organs,% of total sales,5.3
+24377,Netherlands,2012,7,B-Blood and blood forming organs,"/capita, US$ purchasing power parity",17.7
+24378,Netherlands,2012,7,B-Blood and blood forming organs,"/capita, US$ exchange rate",18.7
+24379,Netherlands,2012,7,J-Antiinfectives for systemic use,"/capita, US$ exchange rate",28.8
+24380,Netherlands,2012,7,C09-Agents acting on the Renin-Angiotensin system,Million US$ at exchange rate,265.6
+24381,Netherlands,2012,7,C09-Agents acting on the Renin-Angiotensin system,Million of national currency units,206.8
+24382,Netherlands,2012,7,R03-Drugs for obstructive airway diseases,"Million US$, purchasing power parity",540.2
+24383,Netherlands,2012,7,R03-Drugs for obstructive airway diseases,Million US$ at exchange rate,572.2
+24384,Netherlands,2012,7,R03-Drugs for obstructive airway diseases,Million of national currency units,445.4
+24385,Netherlands,2012,7,B-Blood and blood forming organs,"Million US$, purchasing power parity",296.4
+24386,Netherlands,2012,7,C09-Agents acting on the Renin-Angiotensin system,"Million US$, purchasing power parity",250.8
+24387,Netherlands,2012,7,J-Antiinfectives for systemic use,"/capita, US$ purchasing power parity",27.2
+24388,Netherlands,2012,7,J-Antiinfectives for systemic use,% of total sales,8.1
+24389,Netherlands,2012,7,C09-Agents acting on the Renin-Angiotensin system,% of total sales,4.5
+24390,Netherlands,2012,7,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ purchasing power parity",15.0
+24391,Netherlands,2012,7,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ exchange rate",15.9
+24392,Netherlands,2012,7,"C01B-Antiarrhythmics, Class I and III",Million of national currency units,9.7
+24393,Netherlands,2012,7,"C01B-Antiarrhythmics, Class I and III",Million US$ at exchange rate,12.5
+24394,Netherlands,2012,7,"C01B-Antiarrhythmics, Class I and III","Million US$, purchasing power parity",11.8
+24395,Netherlands,2012,7,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million US$ at exchange rate,223.8
+24396,Netherlands,2012,7,Total pharmaceutical sales,"/capita, US$ purchasing power parity",333.6
+24397,Netherlands,2012,7,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million of national currency units,174.2
+24398,Netherlands,2012,7,"C01B-Antiarrhythmics, Class I and III","/capita, US$ exchange rate",0.7
+24399,Netherlands,2012,7,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ exchange rate",13.4
+24400,Netherlands,2012,7,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ purchasing power parity",12.6
+24401,Netherlands,2012,7,"H-Systemic hormonal preparations, excluding sex hormones and insulins",% of total sales,3.8
+24402,Netherlands,2012,7,"C01B-Antiarrhythmics, Class I and III","/capita, US$ purchasing power parity",0.7
+24403,Netherlands,2012,7,"H-Systemic hormonal preparations, excluding sex hormones and insulins","Million US$, purchasing power parity",211.3
+24404,Netherlands,2012,7,"C01B-Antiarrhythmics, Class I and III",% of total sales,0.2
+24405,Netherlands,2012,7,Total pharmaceutical sales,"Million US$, purchasing power parity",5589.9
+24406,Netherlands,2012,7,Total pharmaceutical sales,Million of national currency units,4608.3
+24407,Netherlands,2012,7,Total pharmaceutical sales,Million US$ at exchange rate,5920.7
+24408,Netherlands,2012,7,N-Nervous system,Million US$ at exchange rate,761.8
+24409,Netherlands,2012,7,N-Nervous system,Million of national currency units,592.9
+24410,Netherlands,2012,7,Total pharmaceutical sales,"/capita, US$ exchange rate",353.4
+24411,Netherlands,2012,7,N-Nervous system,% of total sales,12.9
+24412,Netherlands,2012,7,N-Nervous system,"/capita, US$ purchasing power parity",42.9
+24413,Netherlands,2012,7,N-Nervous system,"/capita, US$ exchange rate",45.5
+24414,Netherlands,2012,7,N-Nervous system,"Million US$, purchasing power parity",719.2
+24415,Netherlands,2012,7,J01-Antibacterials for systemic use,"/capita, US$ purchasing power parity",8.7
+24416,Netherlands,2012,7,C-Cardiovascular system,Million of national currency units,776.6
+24417,Netherlands,2012,7,C-Cardiovascular system,Million US$ at exchange rate,997.8
+24418,Netherlands,2012,7,C-Cardiovascular system,"Million US$, purchasing power parity",942.0
+24419,Netherlands,2012,7,J01-Antibacterials for systemic use,Million of national currency units,120.6
+24420,Netherlands,2012,7,J01-Antibacterials for systemic use,"/capita, US$ exchange rate",9.3
+24421,Netherlands,2012,7,J01-Antibacterials for systemic use,"Million US$, purchasing power parity",146.3
+24422,Netherlands,2012,7,J01-Antibacterials for systemic use,Million US$ at exchange rate,155.0
+24423,Netherlands,2012,7,N05C-Hypnotics and sedatives,"/capita, US$ purchasing power parity",0.9
+24424,Netherlands,2012,7,N05C-Hypnotics and sedatives,"/capita, US$ exchange rate",1.0
+24425,Netherlands,2012,7,N05C-Hypnotics and sedatives,"Million US$, purchasing power parity",15.1
+24426,Netherlands,2012,7,N05C-Hypnotics and sedatives,Million US$ at exchange rate,16.0
+24427,Netherlands,2012,7,N05C-Hypnotics and sedatives,% of total sales,0.3
+24428,Netherlands,2012,7,C-Cardiovascular system,"/capita, US$ exchange rate",59.6
+24429,Netherlands,2012,7,C-Cardiovascular system,"/capita, US$ purchasing power parity",56.2
+24430,Netherlands,2012,7,C-Cardiovascular system,% of total sales,16.9
+24431,Netherlands,2012,7,J01-Antibacterials for systemic use,% of total sales,2.6
+24432,Netherlands,2012,7,C01A-Cardiac glycosides,% of total sales,0.1
+24433,Netherlands,2012,7,A10-Drugs used in diabetes,"/capita, US$ purchasing power parity",18.8
+24434,Netherlands,2012,7,A10-Drugs used in diabetes,% of total sales,5.6
+24435,Netherlands,2012,7,G03-Sex hormones and modulators of the genital system,% of total sales,1.5
+24436,Netherlands,2012,7,G03-Sex hormones and modulators of the genital system,"/capita, US$ purchasing power parity",4.9
+24437,Netherlands,2012,7,A10-Drugs used in diabetes,Million of national currency units,260.2
+24438,Netherlands,2012,7,A10-Drugs used in diabetes,Million US$ at exchange rate,334.2
+24439,Netherlands,2012,7,A10-Drugs used in diabetes,"Million US$, purchasing power parity",315.6
+24440,Netherlands,2012,7,A10-Drugs used in diabetes,"/capita, US$ exchange rate",19.9
+24441,Netherlands,2012,7,G03-Sex hormones and modulators of the genital system,"/capita, US$ exchange rate",5.2
+24442,Netherlands,2012,7,C01A-Cardiac glycosides,Million US$ at exchange rate,8.3
+24443,Netherlands,2012,7,C01A-Cardiac glycosides,"Million US$, purchasing power parity",7.8
+24444,Netherlands,2012,7,C01A-Cardiac glycosides,"/capita, US$ exchange rate",0.5
+24445,Netherlands,2012,7,C01A-Cardiac glycosides,"/capita, US$ purchasing power parity",0.5
+24446,Netherlands,2012,7,G03-Sex hormones and modulators of the genital system,"Million US$, purchasing power parity",82.7
+24447,Netherlands,2012,7,G03-Sex hormones and modulators of the genital system,Million US$ at exchange rate,87.6
+24448,Netherlands,2012,7,G03-Sex hormones and modulators of the genital system,Million of national currency units,68.2
+24449,Netherlands,2012,7,C01A-Cardiac glycosides,Million of national currency units,6.5
+24450,Netherlands,2012,7,M01A-Antiinflammatory and antirheumatic products non-steroids,Million of national currency units,83.9
+24451,Netherlands,2012,7,M01A-Antiinflammatory and antirheumatic products non-steroids,Million US$ at exchange rate,107.8
+24452,Netherlands,2012,7,M01A-Antiinflammatory and antirheumatic products non-steroids,"Million US$, purchasing power parity",101.8
+24453,Netherlands,2012,7,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ exchange rate",6.4
+24454,Netherlands,2012,7,A02A-Antacids,"/capita, US$ exchange rate",0.0
+24455,Netherlands,2012,7,A02A-Antacids,"/capita, US$ purchasing power parity",0.0
+24456,Netherlands,2012,7,A02A-Antacids,% of total sales,0.0
+24457,Netherlands,2012,7,N06A-Antidepressants,"Million US$, purchasing power parity",115.1
+24458,Netherlands,2012,7,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ purchasing power parity",6.1
+24459,Netherlands,2012,7,C07-Beta blocking agents,"Million US$, purchasing power parity",113.9
+24460,Netherlands,2012,7,C07-Beta blocking agents,Million US$ at exchange rate,120.7
+24461,Netherlands,2012,7,C07-Beta blocking agents,Million of national currency units,93.9
+24462,Netherlands,2012,7,N06A-Antidepressants,"/capita, US$ exchange rate",7.3
+24463,Netherlands,2012,7,C03-Diuretics,% of total sales,1.7
+24464,Netherlands,2012,7,M01A-Antiinflammatory and antirheumatic products non-steroids,% of total sales,1.8
+24465,Netherlands,2012,7,C07-Beta blocking agents,% of total sales,2.0
+24466,Netherlands,2012,7,C07-Beta blocking agents,"/capita, US$ purchasing power parity",6.8
+24467,Netherlands,2012,7,C07-Beta blocking agents,"/capita, US$ exchange rate",7.2
+24468,Netherlands,2012,7,A02A-Antacids,"Million US$, purchasing power parity",0.0
+24469,Netherlands,2012,7,C08-Calcium channel blockers,Million US$ at exchange rate,78.2
+24470,Netherlands,2012,7,C08-Calcium channel blockers,"Million US$, purchasing power parity",73.9
+24471,Netherlands,2012,7,C08-Calcium channel blockers,"/capita, US$ exchange rate",4.7
+24472,Netherlands,2012,7,C08-Calcium channel blockers,"/capita, US$ purchasing power parity",4.4
+24473,Netherlands,2012,7,N05C-Hypnotics and sedatives,Million of national currency units,12.4
+24474,Netherlands,2012,7,N06A-Antidepressants,Million of national currency units,94.9
+24475,Netherlands,2012,7,N06A-Antidepressants,Million US$ at exchange rate,121.9
+24476,Netherlands,2012,7,C08-Calcium channel blockers,Million of national currency units,60.9
+24477,Netherlands,2012,7,N06A-Antidepressants,"/capita, US$ purchasing power parity",6.9
+24478,Netherlands,2012,7,N02-Analgesics,"/capita, US$ purchasing power parity",11.8
+24479,Netherlands,2012,7,N02-Analgesics,% of total sales,3.5
+24480,Netherlands,2012,7,A02A-Antacids,Million of national currency units,0.0
+24481,Netherlands,2012,7,A02A-Antacids,Million US$ at exchange rate,0.0
+24482,Netherlands,2012,7,N02-Analgesics,Million of national currency units,162.5
+24483,Netherlands,2012,7,N02-Analgesics,Million US$ at exchange rate,208.8
+24484,Netherlands,2012,7,N02-Analgesics,"Million US$, purchasing power parity",197.1
+24485,Netherlands,2012,7,N02-Analgesics,"/capita, US$ exchange rate",12.5
+24486,Netherlands,2012,7,C08-Calcium channel blockers,% of total sales,1.3
+24487,Netherlands,2012,7,N05B-Anxiolytics,Million of national currency units,19.6
+24488,Netherlands,2012,7,R-Respiratory system,Million of national currency units,559.6
+24489,Netherlands,2012,7,R-Respiratory system,Million US$ at exchange rate,719.0
+24490,Netherlands,2012,7,R-Respiratory system,"Million US$, purchasing power parity",678.8
+24491,Netherlands,2012,7,N05B-Anxiolytics,Million US$ at exchange rate,25.1
+24492,Netherlands,2012,7,N05B-Anxiolytics,% of total sales,0.4
+24493,Netherlands,2012,7,N05B-Anxiolytics,"/capita, US$ purchasing power parity",1.4
+24494,Netherlands,2012,7,N05B-Anxiolytics,"/capita, US$ exchange rate",1.5
+24495,Netherlands,2012,7,N05B-Anxiolytics,"Million US$, purchasing power parity",23.7
+24496,Netherlands,2012,7,G-Genito urinary system and sex hormones,% of total sales,3.2
+24497,Netherlands,2012,7,R-Respiratory system,% of total sales,12.1
+24498,Netherlands,2012,7,G-Genito urinary system and sex hormones,"Million US$, purchasing power parity",179.2
+24499,Netherlands,2012,7,G-Genito urinary system and sex hormones,Million US$ at exchange rate,189.8
+24500,Netherlands,2012,7,G-Genito urinary system and sex hormones,Million of national currency units,147.7
+24501,Netherlands,2012,7,R-Respiratory system,"/capita, US$ purchasing power parity",40.5
+24502,Netherlands,2012,7,G-Genito urinary system and sex hormones,"/capita, US$ purchasing power parity",10.7
+24503,Netherlands,2012,7,G-Genito urinary system and sex hormones,"/capita, US$ exchange rate",11.3
+24504,Netherlands,2012,7,R-Respiratory system,"/capita, US$ exchange rate",42.9
+24505,Netherlands,2012,7,C10-Lipid modifying agents,Million of national currency units,242.3
+24506,Netherlands,2012,7,C10-Lipid modifying agents,Million US$ at exchange rate,311.4
+24507,Netherlands,2012,7,C10-Lipid modifying agents,"Million US$, purchasing power parity",294.0
+24508,Netherlands,2012,7,C02-Antihypertensives,"/capita, US$ purchasing power parity",2.5
+24509,Netherlands,2012,7,C02-Antihypertensives,"Million US$, purchasing power parity",42.1
+24510,Netherlands,2012,7,C02-Antihypertensives,Million US$ at exchange rate,44.6
+24511,Netherlands,2012,7,C02-Antihypertensives,Million of national currency units,34.7
+24512,Netherlands,2012,7,C02-Antihypertensives,"/capita, US$ exchange rate",2.7
+24513,Netherlands,2012,7,C10-Lipid modifying agents,"/capita, US$ exchange rate",18.6
+24514,Netherlands,2012,7,A-Alimentary tract and metabolism,"/capita, US$ exchange rate",49.6
+24515,Netherlands,2012,7,A-Alimentary tract and metabolism,"Million US$, purchasing power parity",784.3
+24516,Netherlands,2012,7,A-Alimentary tract and metabolism,Million US$ at exchange rate,830.8
+24517,Netherlands,2012,7,A-Alimentary tract and metabolism,Million of national currency units,646.6
+24518,Netherlands,2012,7,C02-Antihypertensives,% of total sales,0.8
+24519,Netherlands,2012,7,C10-Lipid modifying agents,"/capita, US$ purchasing power parity",17.5
+24520,Netherlands,2012,7,C10-Lipid modifying agents,% of total sales,5.3
+24521,Netherlands,2012,7,A-Alimentary tract and metabolism,% of total sales,14.0
+24522,Netherlands,2012,7,A-Alimentary tract and metabolism,"/capita, US$ purchasing power parity",46.8
+24523,Netherlands,2012,7,M-Musculo-skeletal system,Million US$ at exchange rate,175.4
+24524,Netherlands,2012,7,C03-Diuretics,"/capita, US$ exchange rate",6.1
+24525,Netherlands,2012,7,C03-Diuretics,"Million US$, purchasing power parity",95.9
+24526,Netherlands,2012,7,M-Musculo-skeletal system,% of total sales,3.0
+24527,Netherlands,2012,7,M-Musculo-skeletal system,"/capita, US$ purchasing power parity",9.9
+24528,Netherlands,2012,7,M-Musculo-skeletal system,"/capita, US$ exchange rate",10.5
+24529,Netherlands,2012,7,M-Musculo-skeletal system,Million of national currency units,136.5
+24530,Netherlands,2012,7,M-Musculo-skeletal system,"Million US$, purchasing power parity",165.6
+24531,Netherlands,2012,7,C03-Diuretics,Million US$ at exchange rate,101.5
+24532,Netherlands,2012,7,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ exchange rate",9.6
+24533,Netherlands,2012,7,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),% of total sales,2.7
+24534,Netherlands,2012,7,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ purchasing power parity",9.1
+24535,Netherlands,2012,7,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"Million US$, purchasing power parity",152.6
+24536,Netherlands,2012,7,C03-Diuretics,Million of national currency units,79.0
+24537,Netherlands,2012,7,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million of national currency units,125.8
+24538,Netherlands,2012,7,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million US$ at exchange rate,161.7
+24539,Netherlands,2012,7,C03-Diuretics,"/capita, US$ purchasing power parity",5.7
+24540,Netherlands,2011,7,B-Blood and blood forming organs,"Million US$, purchasing power parity",290.3
+24541,Netherlands,2011,7,R03-Drugs for obstructive airway diseases,"/capita, US$ purchasing power parity",32.8
+24542,Netherlands,2011,7,R03-Drugs for obstructive airway diseases,"/capita, US$ exchange rate",38.1
+24543,Netherlands,2011,7,J-Antiinfectives for systemic use,Million of national currency units,358.2
+24544,Netherlands,2011,7,J-Antiinfectives for systemic use,Million US$ at exchange rate,498.6
+24545,Netherlands,2011,7,J-Antiinfectives for systemic use,"Million US$, purchasing power parity",428.5
+24546,Netherlands,2011,7,R03-Drugs for obstructive airway diseases,% of total sales,8.8
+24547,Netherlands,2011,7,B-Blood and blood forming organs,Million of national currency units,242.7
+24548,Netherlands,2011,7,B-Blood and blood forming organs,Million US$ at exchange rate,337.8
+24549,Netherlands,2011,7,N06A-Antidepressants,% of total sales,1.8
+24550,Netherlands,2011,7,B-Blood and blood forming organs,% of total sales,4.7
+24551,Netherlands,2011,7,B-Blood and blood forming organs,"/capita, US$ purchasing power parity",17.4
+24552,Netherlands,2011,7,B-Blood and blood forming organs,"/capita, US$ exchange rate",20.2
+24553,Netherlands,2011,7,J-Antiinfectives for systemic use,"/capita, US$ exchange rate",29.9
+24554,Netherlands,2011,7,C09-Agents acting on the Renin-Angiotensin system,Million US$ at exchange rate,356.5
+24555,Netherlands,2011,7,C09-Agents acting on the Renin-Angiotensin system,Million of national currency units,256.1
+24556,Netherlands,2011,7,R03-Drugs for obstructive airway diseases,"Million US$, purchasing power parity",546.7
+24557,Netherlands,2011,7,R03-Drugs for obstructive airway diseases,Million US$ at exchange rate,636.3
+24558,Netherlands,2011,7,R03-Drugs for obstructive airway diseases,Million of national currency units,457.1
+24559,Netherlands,2011,7,J-Antiinfectives for systemic use,"/capita, US$ purchasing power parity",25.7
+24560,Netherlands,2011,7,J-Antiinfectives for systemic use,% of total sales,6.9
+24561,Netherlands,2011,7,C09-Agents acting on the Renin-Angiotensin system,% of total sales,4.9
+24562,Netherlands,2011,7,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ purchasing power parity",18.4
+24563,Netherlands,2011,7,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ exchange rate",21.4
+24564,Netherlands,2011,7,C09-Agents acting on the Renin-Angiotensin system,"Million US$, purchasing power parity",306.4
+24565,Netherlands,2011,7,Total pharmaceutical sales,Million of national currency units,5210.0
+24566,Netherlands,2011,7,"C01B-Antiarrhythmics, Class I and III",Million of national currency units,10.2
+24567,Netherlands,2011,7,"C01B-Antiarrhythmics, Class I and III",Million US$ at exchange rate,14.3
+24568,Netherlands,2011,7,"C01B-Antiarrhythmics, Class I and III","Million US$, purchasing power parity",12.3
+24569,Netherlands,2011,7,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million US$ at exchange rate,242.8
+24570,Netherlands,2011,7,Total pharmaceutical sales,"/capita, US$ purchasing power parity",373.3
+24571,Netherlands,2011,7,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million of national currency units,174.4
+24572,Netherlands,2011,7,"C01B-Antiarrhythmics, Class I and III","/capita, US$ exchange rate",0.9
+24573,Netherlands,2011,7,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ purchasing power parity",12.5
+24574,Netherlands,2011,7,"H-Systemic hormonal preparations, excluding sex hormones and insulins",% of total sales,3.3
+24575,Netherlands,2011,7,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ exchange rate",14.5
+24576,Netherlands,2011,7,"C01B-Antiarrhythmics, Class I and III","/capita, US$ purchasing power parity",0.7
+24577,Netherlands,2011,7,"C01B-Antiarrhythmics, Class I and III",% of total sales,0.2
+24578,Netherlands,2011,7,"H-Systemic hormonal preparations, excluding sex hormones and insulins","Million US$, purchasing power parity",208.6
+24579,Netherlands,2011,7,Total pharmaceutical sales,"Million US$, purchasing power parity",6231.5
+24580,Netherlands,2011,7,Total pharmaceutical sales,Million US$ at exchange rate,7252.1
+24581,Netherlands,2011,7,Total pharmaceutical sales,"/capita, US$ exchange rate",434.4
+24582,Netherlands,2011,7,N-Nervous system,Million US$ at exchange rate,877.2
+24583,Netherlands,2011,7,N-Nervous system,Million of national currency units,630.2
+24584,Netherlands,2011,7,N-Nervous system,"Million US$, purchasing power parity",753.8
+24585,Netherlands,2011,7,N-Nervous system,% of total sales,12.1
+24586,Netherlands,2011,7,N-Nervous system,"/capita, US$ purchasing power parity",45.2
+24587,Netherlands,2011,7,N-Nervous system,"/capita, US$ exchange rate",52.6
+24588,Netherlands,2011,7,N06A-Antidepressants,"/capita, US$ purchasing power parity",6.9
+24589,Netherlands,2011,7,J01-Antibacterials for systemic use,"/capita, US$ purchasing power parity",9.1
+24590,Netherlands,2011,7,C-Cardiovascular system,Million of national currency units,896.2
+24591,Netherlands,2011,7,C-Cardiovascular system,Million US$ at exchange rate,1247.4
+24592,Netherlands,2011,7,C-Cardiovascular system,"Million US$, purchasing power parity",1071.9
+24593,Netherlands,2011,7,J01-Antibacterials for systemic use,"/capita, US$ exchange rate",10.6
+24594,Netherlands,2011,7,J01-Antibacterials for systemic use,Million of national currency units,126.9
+24595,Netherlands,2011,7,J01-Antibacterials for systemic use,Million US$ at exchange rate,176.7
+24596,Netherlands,2011,7,J01-Antibacterials for systemic use,"Million US$, purchasing power parity",151.8
+24597,Netherlands,2011,7,C-Cardiovascular system,"/capita, US$ exchange rate",74.7
+24598,Netherlands,2011,7,N05C-Hypnotics and sedatives,"/capita, US$ purchasing power parity",0.9
+24599,Netherlands,2011,7,N05C-Hypnotics and sedatives,"/capita, US$ exchange rate",1.0
+24600,Netherlands,2011,7,N05C-Hypnotics and sedatives,"Million US$, purchasing power parity",14.8
+24601,Netherlands,2011,7,N05C-Hypnotics and sedatives,% of total sales,0.2
+24602,Netherlands,2011,7,C-Cardiovascular system,"/capita, US$ purchasing power parity",64.2
+24603,Netherlands,2011,7,C-Cardiovascular system,% of total sales,17.2
+24604,Netherlands,2011,7,J01-Antibacterials for systemic use,% of total sales,2.4
+24605,Netherlands,2011,7,N05C-Hypnotics and sedatives,Million US$ at exchange rate,17.3
+24606,Netherlands,2011,7,A10-Drugs used in diabetes,% of total sales,4.8
+24607,Netherlands,2011,7,A10-Drugs used in diabetes,"/capita, US$ purchasing power parity",18.1
+24608,Netherlands,2011,7,G03-Sex hormones and modulators of the genital system,% of total sales,1.4
+24609,Netherlands,2011,7,G03-Sex hormones and modulators of the genital system,"/capita, US$ purchasing power parity",5.2
+24610,Netherlands,2011,7,A10-Drugs used in diabetes,Million of national currency units,252.0
+24611,Netherlands,2011,7,A10-Drugs used in diabetes,Million US$ at exchange rate,350.8
+24612,Netherlands,2011,7,A10-Drugs used in diabetes,"Million US$, purchasing power parity",301.5
+24613,Netherlands,2011,7,A10-Drugs used in diabetes,"/capita, US$ exchange rate",21.0
+24614,Netherlands,2011,7,G03-Sex hormones and modulators of the genital system,"/capita, US$ exchange rate",6.0
+24615,Netherlands,2011,7,C01A-Cardiac glycosides,"Million US$, purchasing power parity",7.7
+24616,Netherlands,2011,7,C01A-Cardiac glycosides,Million US$ at exchange rate,9.0
+24617,Netherlands,2011,7,C01A-Cardiac glycosides,"/capita, US$ purchasing power parity",0.5
+24618,Netherlands,2011,7,C01A-Cardiac glycosides,"/capita, US$ exchange rate",0.5
+24619,Netherlands,2011,7,G03-Sex hormones and modulators of the genital system,"Million US$, purchasing power parity",86.3
+24620,Netherlands,2011,7,G03-Sex hormones and modulators of the genital system,Million US$ at exchange rate,100.4
+24621,Netherlands,2011,7,G03-Sex hormones and modulators of the genital system,Million of national currency units,72.2
+24622,Netherlands,2011,7,C01A-Cardiac glycosides,Million of national currency units,6.5
+24623,Netherlands,2011,7,C01A-Cardiac glycosides,% of total sales,0.1
+24624,Netherlands,2011,7,M01A-Antiinflammatory and antirheumatic products non-steroids,Million US$ at exchange rate,127.6
+24625,Netherlands,2011,7,M01A-Antiinflammatory and antirheumatic products non-steroids,Million of national currency units,91.7
+24626,Netherlands,2011,7,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ exchange rate",7.6
+24627,Netherlands,2011,7,M01A-Antiinflammatory and antirheumatic products non-steroids,"Million US$, purchasing power parity",109.6
+24628,Netherlands,2011,7,A02A-Antacids,"/capita, US$ exchange rate",0.0
+24629,Netherlands,2011,7,A02A-Antacids,"/capita, US$ purchasing power parity",0.0
+24630,Netherlands,2011,7,A02A-Antacids,% of total sales,0.0
+24631,Netherlands,2011,7,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ purchasing power parity",6.6
+24632,Netherlands,2011,7,C07-Beta blocking agents,"Million US$, purchasing power parity",115.5
+24633,Netherlands,2011,7,C07-Beta blocking agents,Million US$ at exchange rate,134.4
+24634,Netherlands,2011,7,C07-Beta blocking agents,Million of national currency units,96.6
+24635,Netherlands,2011,7,N06A-Antidepressants,"/capita, US$ exchange rate",8.0
+24636,Netherlands,2011,7,C07-Beta blocking agents,"/capita, US$ exchange rate",8.1
+24637,Netherlands,2011,7,M01A-Antiinflammatory and antirheumatic products non-steroids,% of total sales,1.8
+24638,Netherlands,2011,7,C07-Beta blocking agents,% of total sales,1.9
+24639,Netherlands,2011,7,C07-Beta blocking agents,"/capita, US$ purchasing power parity",6.9
+24640,Netherlands,2011,7,A02A-Antacids,"Million US$, purchasing power parity",0.0
+24641,Netherlands,2011,7,C08-Calcium channel blockers,"Million US$, purchasing power parity",72.8
+24642,Netherlands,2011,7,C08-Calcium channel blockers,Million US$ at exchange rate,84.7
+24643,Netherlands,2011,7,C08-Calcium channel blockers,"/capita, US$ purchasing power parity",4.4
+24644,Netherlands,2011,7,C08-Calcium channel blockers,"/capita, US$ exchange rate",5.1
+24645,Netherlands,2011,7,N05C-Hypnotics and sedatives,Million of national currency units,12.4
+24646,Netherlands,2011,7,N06A-Antidepressants,Million of national currency units,95.7
+24647,Netherlands,2011,7,N06A-Antidepressants,Million US$ at exchange rate,133.3
+24648,Netherlands,2011,7,N06A-Antidepressants,"Million US$, purchasing power parity",114.5
+24649,Netherlands,2011,7,C08-Calcium channel blockers,Million of national currency units,60.9
+24650,Netherlands,2011,7,C08-Calcium channel blockers,% of total sales,1.2
+24651,Netherlands,2011,7,N02-Analgesics,% of total sales,3.1
+24652,Netherlands,2011,7,N02-Analgesics,"/capita, US$ purchasing power parity",11.4
+24653,Netherlands,2011,7,A02A-Antacids,Million US$ at exchange rate,0.0
+24654,Netherlands,2011,7,A02A-Antacids,Million of national currency units,0.0
+24655,Netherlands,2011,7,N02-Analgesics,Million of national currency units,159.7
+24656,Netherlands,2011,7,N02-Analgesics,Million US$ at exchange rate,222.3
+24657,Netherlands,2011,7,N02-Analgesics,"Million US$, purchasing power parity",191.1
+24658,Netherlands,2011,7,N02-Analgesics,"/capita, US$ exchange rate",13.3
+24659,Netherlands,2011,7,C03-Diuretics,% of total sales,1.5
+24660,Netherlands,2011,7,N05B-Anxiolytics,Million of national currency units,20.3
+24661,Netherlands,2011,7,R-Respiratory system,Million of national currency units,586.7
+24662,Netherlands,2011,7,R-Respiratory system,Million US$ at exchange rate,816.7
+24663,Netherlands,2011,7,R-Respiratory system,"Million US$, purchasing power parity",701.8
+24664,Netherlands,2011,7,N05B-Anxiolytics,Million US$ at exchange rate,28.3
+24665,Netherlands,2011,7,N05B-Anxiolytics,% of total sales,0.4
+24666,Netherlands,2011,7,N05B-Anxiolytics,"/capita, US$ purchasing power parity",1.5
+24667,Netherlands,2011,7,N05B-Anxiolytics,"/capita, US$ exchange rate",1.7
+24668,Netherlands,2011,7,N05B-Anxiolytics,"Million US$, purchasing power parity",24.3
+24669,Netherlands,2011,7,R-Respiratory system,% of total sales,11.3
+24670,Netherlands,2011,7,G-Genito urinary system and sex hormones,"Million US$, purchasing power parity",179.2
+24671,Netherlands,2011,7,G-Genito urinary system and sex hormones,Million US$ at exchange rate,208.5
+24672,Netherlands,2011,7,R-Respiratory system,"/capita, US$ purchasing power parity",42.0
+24673,Netherlands,2011,7,G-Genito urinary system and sex hormones,% of total sales,2.9
+24674,Netherlands,2011,7,G-Genito urinary system and sex hormones,"/capita, US$ purchasing power parity",10.7
+24675,Netherlands,2011,7,G-Genito urinary system and sex hormones,"/capita, US$ exchange rate",12.5
+24676,Netherlands,2011,7,R-Respiratory system,"/capita, US$ exchange rate",48.9
+24677,Netherlands,2011,7,C02-Antihypertensives,% of total sales,0.7
+24678,Netherlands,2011,7,C10-Lipid modifying agents,Million of national currency units,309.8
+24679,Netherlands,2011,7,C10-Lipid modifying agents,"Million US$, purchasing power parity",370.5
+24680,Netherlands,2011,7,C10-Lipid modifying agents,Million US$ at exchange rate,431.2
+24681,Netherlands,2011,7,C02-Antihypertensives,"/capita, US$ purchasing power parity",2.5
+24682,Netherlands,2011,7,C02-Antihypertensives,"Million US$, purchasing power parity",41.4
+24683,Netherlands,2011,7,C02-Antihypertensives,Million US$ at exchange rate,48.2
+24684,Netherlands,2011,7,C02-Antihypertensives,Million of national currency units,34.6
+24685,Netherlands,2011,7,C10-Lipid modifying agents,"/capita, US$ exchange rate",25.8
+24686,Netherlands,2011,7,A-Alimentary tract and metabolism,"/capita, US$ exchange rate",57.1
+24687,Netherlands,2011,7,A-Alimentary tract and metabolism,"Million US$, purchasing power parity",818.5
+24688,Netherlands,2011,7,A-Alimentary tract and metabolism,Million US$ at exchange rate,952.6
+24689,Netherlands,2011,7,A-Alimentary tract and metabolism,Million of national currency units,684.3
+24690,Netherlands,2011,7,G-Genito urinary system and sex hormones,Million of national currency units,149.8
+24691,Netherlands,2011,7,A-Alimentary tract and metabolism,"/capita, US$ purchasing power parity",49.0
+24692,Netherlands,2011,7,C10-Lipid modifying agents,"/capita, US$ purchasing power parity",22.2
+24693,Netherlands,2011,7,C10-Lipid modifying agents,% of total sales,5.9
+24694,Netherlands,2011,7,A-Alimentary tract and metabolism,% of total sales,13.1
+24695,Netherlands,2011,7,C02-Antihypertensives,"/capita, US$ exchange rate",2.9
+24696,Netherlands,2011,7,M-Musculo-skeletal system,Million US$ at exchange rate,206.6
+24697,Netherlands,2011,7,C03-Diuretics,"Million US$, purchasing power parity",93.2
+24698,Netherlands,2011,7,C03-Diuretics,"/capita, US$ exchange rate",6.5
+24699,Netherlands,2011,7,M-Musculo-skeletal system,% of total sales,2.8
+24700,Netherlands,2011,7,M-Musculo-skeletal system,"/capita, US$ purchasing power parity",10.6
+24701,Netherlands,2011,7,M-Musculo-skeletal system,"/capita, US$ exchange rate",12.4
+24702,Netherlands,2011,7,M-Musculo-skeletal system,"Million US$, purchasing power parity",177.5
+24703,Netherlands,2011,7,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ exchange rate",15.4
+24704,Netherlands,2011,7,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ purchasing power parity",13.3
+24705,Netherlands,2011,7,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),% of total sales,3.6
+24706,Netherlands,2011,7,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"Million US$, purchasing power parity",221.5
+24707,Netherlands,2011,7,C03-Diuretics,Million of national currency units,78.0
+24708,Netherlands,2011,7,M-Musculo-skeletal system,Million of national currency units,148.4
+24709,Netherlands,2011,7,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million of national currency units,185.2
+24710,Netherlands,2011,7,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million US$ at exchange rate,257.8
+24711,Netherlands,2011,7,C03-Diuretics,Million US$ at exchange rate,108.5
+24712,Netherlands,2011,7,C03-Diuretics,"/capita, US$ purchasing power parity",5.6
+24713,Netherlands,2010,7,R03-Drugs for obstructive airway diseases,% of total sales,8.4
+24714,Netherlands,2010,7,R03-Drugs for obstructive airway diseases,"/capita, US$ purchasing power parity",30.7
+24715,Netherlands,2010,7,J-Antiinfectives for systemic use,Million of national currency units,350.8
+24716,Netherlands,2010,7,J-Antiinfectives for systemic use,Million US$ at exchange rate,465.1
+24717,Netherlands,2010,7,J-Antiinfectives for systemic use,"Million US$, purchasing power parity",410.8
+24718,Netherlands,2010,7,J-Antiinfectives for systemic use,"/capita, US$ exchange rate",28.0
+24719,Netherlands,2010,7,B-Blood and blood forming organs,Million US$ at exchange rate,325.8
+24720,Netherlands,2010,7,N06A-Antidepressants,% of total sales,1.8
+24721,Netherlands,2010,7,B-Blood and blood forming organs,% of total sales,4.7
+24722,Netherlands,2010,7,B-Blood and blood forming organs,"/capita, US$ purchasing power parity",17.3
+24723,Netherlands,2010,7,B-Blood and blood forming organs,"/capita, US$ exchange rate",19.6
+24724,Netherlands,2010,7,C09-Agents acting on the Renin-Angiotensin system,Million US$ at exchange rate,352.0
+24725,Netherlands,2010,7,C09-Agents acting on the Renin-Angiotensin system,Million of national currency units,265.5
+24726,Netherlands,2010,7,R03-Drugs for obstructive airway diseases,"/capita, US$ exchange rate",34.8
+24727,Netherlands,2010,7,B-Blood and blood forming organs,Million of national currency units,245.7
+24728,Netherlands,2010,7,R03-Drugs for obstructive airway diseases,"Million US$, purchasing power parity",510.5
+24729,Netherlands,2010,7,R03-Drugs for obstructive airway diseases,Million US$ at exchange rate,578.0
+24730,Netherlands,2010,7,R03-Drugs for obstructive airway diseases,Million of national currency units,436.0
+24731,Netherlands,2010,7,C09-Agents acting on the Renin-Angiotensin system,"Million US$, purchasing power parity",310.9
+24732,Netherlands,2010,7,J-Antiinfectives for systemic use,"/capita, US$ purchasing power parity",24.7
+24733,Netherlands,2010,7,J-Antiinfectives for systemic use,% of total sales,6.7
+24734,Netherlands,2010,7,C09-Agents acting on the Renin-Angiotensin system,% of total sales,5.1
+24735,Netherlands,2010,7,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ purchasing power parity",18.7
+24736,Netherlands,2010,7,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ exchange rate",21.2
+24737,Netherlands,2010,7,"C01B-Antiarrhythmics, Class I and III",Million of national currency units,10.7
+24738,Netherlands,2010,7,"C01B-Antiarrhythmics, Class I and III",Million US$ at exchange rate,14.1
+24739,Netherlands,2010,7,"C01B-Antiarrhythmics, Class I and III","Million US$, purchasing power parity",12.5
+24740,Netherlands,2010,7,"C01B-Antiarrhythmics, Class I and III","/capita, US$ exchange rate",0.9
+24741,Netherlands,2010,7,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million of national currency units,169.1
+24742,Netherlands,2010,7,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million US$ at exchange rate,224.1
+24743,Netherlands,2010,7,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ purchasing power parity",11.9
+24744,Netherlands,2010,7,"H-Systemic hormonal preparations, excluding sex hormones and insulins",% of total sales,3.2
+24745,Netherlands,2010,7,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ exchange rate",13.5
+24746,Netherlands,2010,7,"C01B-Antiarrhythmics, Class I and III","/capita, US$ purchasing power parity",0.8
+24747,Netherlands,2010,7,"C01B-Antiarrhythmics, Class I and III",% of total sales,0.2
+24748,Netherlands,2010,7,Total pharmaceutical sales,"/capita, US$ purchasing power parity",367.4
+24749,Netherlands,2010,7,"H-Systemic hormonal preparations, excluding sex hormones and insulins","Million US$, purchasing power parity",197.9
+24750,Netherlands,2010,7,Total pharmaceutical sales,Million of national currency units,5213.1
+24751,Netherlands,2010,7,Total pharmaceutical sales,"Million US$, purchasing power parity",6103.7
+24752,Netherlands,2010,7,Total pharmaceutical sales,"/capita, US$ exchange rate",415.9
+24753,Netherlands,2010,7,Total pharmaceutical sales,Million US$ at exchange rate,6911.1
+24754,Netherlands,2010,7,N-Nervous system,Million US$ at exchange rate,793.6
+24755,Netherlands,2010,7,N-Nervous system,Million of national currency units,598.6
+24756,Netherlands,2010,7,N-Nervous system,"Million US$, purchasing power parity",700.9
+24757,Netherlands,2010,7,N-Nervous system,% of total sales,11.5
+24758,Netherlands,2010,7,N-Nervous system,"/capita, US$ purchasing power parity",42.2
+24759,Netherlands,2010,7,N-Nervous system,"/capita, US$ exchange rate",47.8
+24760,Netherlands,2010,7,J01-Antibacterials for systemic use,"/capita, US$ purchasing power parity",9.3
+24761,Netherlands,2010,7,C-Cardiovascular system,Million of national currency units,906.4
+24762,Netherlands,2010,7,C-Cardiovascular system,Million US$ at exchange rate,1201.6
+24763,Netherlands,2010,7,C-Cardiovascular system,"Million US$, purchasing power parity",1061.2
+24764,Netherlands,2010,7,J01-Antibacterials for systemic use,Million of national currency units,131.9
+24765,Netherlands,2010,7,J01-Antibacterials for systemic use,Million US$ at exchange rate,174.8
+24766,Netherlands,2010,7,J01-Antibacterials for systemic use,"Million US$, purchasing power parity",154.4
+24767,Netherlands,2010,7,J01-Antibacterials for systemic use,"/capita, US$ exchange rate",10.5
+24768,Netherlands,2010,7,C-Cardiovascular system,"/capita, US$ exchange rate",72.3
+24769,Netherlands,2010,7,N05C-Hypnotics and sedatives,"/capita, US$ purchasing power parity",0.8
+24770,Netherlands,2010,7,N05C-Hypnotics and sedatives,% of total sales,0.2
+24771,Netherlands,2010,7,N05C-Hypnotics and sedatives,"Million US$, purchasing power parity",13.7
+24772,Netherlands,2010,7,N05C-Hypnotics and sedatives,"/capita, US$ exchange rate",0.9
+24773,Netherlands,2010,7,C-Cardiovascular system,"/capita, US$ purchasing power parity",63.9
+24774,Netherlands,2010,7,C-Cardiovascular system,% of total sales,17.4
+24775,Netherlands,2010,7,J01-Antibacterials for systemic use,% of total sales,2.5
+24776,Netherlands,2010,7,C01A-Cardiac glycosides,% of total sales,0.1
+24777,Netherlands,2010,7,A10-Drugs used in diabetes,% of total sales,4.6
+24778,Netherlands,2010,7,G03-Sex hormones and modulators of the genital system,% of total sales,2.4
+24779,Netherlands,2010,7,G03-Sex hormones and modulators of the genital system,"/capita, US$ purchasing power parity",8.6
+24780,Netherlands,2010,7,A10-Drugs used in diabetes,"/capita, US$ purchasing power parity",17.1
+24781,Netherlands,2010,7,A10-Drugs used in diabetes,Million of national currency units,242.2
+24782,Netherlands,2010,7,A10-Drugs used in diabetes,Million US$ at exchange rate,321.1
+24783,Netherlands,2010,7,A10-Drugs used in diabetes,"Million US$, purchasing power parity",283.6
+24784,Netherlands,2010,7,A10-Drugs used in diabetes,"/capita, US$ exchange rate",19.3
+24785,Netherlands,2010,7,C01A-Cardiac glycosides,"Million US$, purchasing power parity",7.4
+24786,Netherlands,2010,7,C01A-Cardiac glycosides,"/capita, US$ exchange rate",0.5
+24787,Netherlands,2010,7,C01A-Cardiac glycosides,"/capita, US$ purchasing power parity",0.4
+24788,Netherlands,2010,7,C01A-Cardiac glycosides,Million US$ at exchange rate,8.4
+24789,Netherlands,2010,7,G03-Sex hormones and modulators of the genital system,"/capita, US$ exchange rate",9.8
+24790,Netherlands,2010,7,G03-Sex hormones and modulators of the genital system,"Million US$, purchasing power parity",143.7
+24791,Netherlands,2010,7,G03-Sex hormones and modulators of the genital system,Million US$ at exchange rate,162.7
+24792,Netherlands,2010,7,G03-Sex hormones and modulators of the genital system,Million of national currency units,122.7
+24793,Netherlands,2010,7,C01A-Cardiac glycosides,Million of national currency units,6.4
+24794,Netherlands,2010,7,N05C-Hypnotics and sedatives,Million US$ at exchange rate,15.5
+24795,Netherlands,2010,7,M01A-Antiinflammatory and antirheumatic products non-steroids,Million US$ at exchange rate,125.0
+24796,Netherlands,2010,7,M01A-Antiinflammatory and antirheumatic products non-steroids,"Million US$, purchasing power parity",110.4
+24797,Netherlands,2010,7,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ exchange rate",7.5
+24798,Netherlands,2010,7,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ purchasing power parity",6.6
+24799,Netherlands,2010,7,M01A-Antiinflammatory and antirheumatic products non-steroids,Million of national currency units,94.3
+24800,Netherlands,2010,7,A02A-Antacids,"/capita, US$ exchange rate",0.0
+24801,Netherlands,2010,7,A02A-Antacids,"/capita, US$ purchasing power parity",0.0
+24802,Netherlands,2010,7,N06A-Antidepressants,"/capita, US$ exchange rate",7.3
+24803,Netherlands,2010,7,A02A-Antacids,% of total sales,0.0
+24804,Netherlands,2010,7,C07-Beta blocking agents,"Million US$, purchasing power parity",129.3
+24805,Netherlands,2010,7,C07-Beta blocking agents,Million US$ at exchange rate,146.4
+24806,Netherlands,2010,7,C07-Beta blocking agents,Million of national currency units,110.5
+24807,Netherlands,2010,7,N06A-Antidepressants,"/capita, US$ purchasing power parity",6.5
+24808,Netherlands,2010,7,C07-Beta blocking agents,"/capita, US$ exchange rate",8.8
+24809,Netherlands,2010,7,M01A-Antiinflammatory and antirheumatic products non-steroids,% of total sales,1.8
+24810,Netherlands,2010,7,C07-Beta blocking agents,% of total sales,2.1
+24811,Netherlands,2010,7,C07-Beta blocking agents,"/capita, US$ purchasing power parity",7.8
+24812,Netherlands,2010,7,A02A-Antacids,"Million US$, purchasing power parity",0.0
+24813,Netherlands,2010,7,C08-Calcium channel blockers,"Million US$, purchasing power parity",72.9
+24814,Netherlands,2010,7,C08-Calcium channel blockers,"/capita, US$ exchange rate",5.0
+24815,Netherlands,2010,7,C08-Calcium channel blockers,"/capita, US$ purchasing power parity",4.4
+24816,Netherlands,2010,7,C08-Calcium channel blockers,Million US$ at exchange rate,82.5
+24817,Netherlands,2010,7,N05C-Hypnotics and sedatives,Million of national currency units,11.7
+24818,Netherlands,2010,7,N06A-Antidepressants,Million of national currency units,91.7
+24819,Netherlands,2010,7,N06A-Antidepressants,Million US$ at exchange rate,121.6
+24820,Netherlands,2010,7,N06A-Antidepressants,"Million US$, purchasing power parity",107.4
+24821,Netherlands,2010,7,C08-Calcium channel blockers,Million of national currency units,62.2
+24822,Netherlands,2010,7,C08-Calcium channel blockers,% of total sales,1.2
+24823,Netherlands,2010,7,N02-Analgesics,% of total sales,2.8
+24824,Netherlands,2010,7,A02A-Antacids,Million of national currency units,0.0
+24825,Netherlands,2010,7,A02A-Antacids,Million US$ at exchange rate,0.0
+24826,Netherlands,2010,7,N02-Analgesics,"/capita, US$ purchasing power parity",10.3
+24827,Netherlands,2010,7,N02-Analgesics,Million of national currency units,146.5
+24828,Netherlands,2010,7,N02-Analgesics,Million US$ at exchange rate,194.2
+24829,Netherlands,2010,7,N02-Analgesics,"Million US$, purchasing power parity",171.5
+24830,Netherlands,2010,7,N02-Analgesics,"/capita, US$ exchange rate",11.7
+24831,Netherlands,2010,7,B-Blood and blood forming organs,"Million US$, purchasing power parity",287.7
+24832,Netherlands,2010,7,N05B-Anxiolytics,Million of national currency units,21.3
+24833,Netherlands,2010,7,R-Respiratory system,Million of national currency units,566.5
+24834,Netherlands,2010,7,N05B-Anxiolytics,Million US$ at exchange rate,28.3
+24835,Netherlands,2010,7,R-Respiratory system,Million US$ at exchange rate,751.0
+24836,Netherlands,2010,7,R-Respiratory system,"Million US$, purchasing power parity",663.2
+24837,Netherlands,2010,7,N05B-Anxiolytics,% of total sales,0.4
+24838,Netherlands,2010,7,N05B-Anxiolytics,"/capita, US$ purchasing power parity",1.5
+24839,Netherlands,2010,7,N05B-Anxiolytics,"/capita, US$ exchange rate",1.7
+24840,Netherlands,2010,7,C02-Antihypertensives,"/capita, US$ exchange rate",2.8
+24841,Netherlands,2010,7,R-Respiratory system,% of total sales,10.9
+24842,Netherlands,2010,7,G-Genito urinary system and sex hormones,Million US$ at exchange rate,273.1
+24843,Netherlands,2010,7,G-Genito urinary system and sex hormones,"Million US$, purchasing power parity",241.2
+24844,Netherlands,2010,7,G-Genito urinary system and sex hormones,% of total sales,4.0
+24845,Netherlands,2010,7,G-Genito urinary system and sex hormones,"/capita, US$ purchasing power parity",14.5
+24846,Netherlands,2010,7,G-Genito urinary system and sex hormones,"/capita, US$ exchange rate",16.4
+24847,Netherlands,2010,7,R-Respiratory system,"/capita, US$ exchange rate",45.2
+24848,Netherlands,2010,7,R-Respiratory system,"/capita, US$ purchasing power parity",39.9
+24849,Netherlands,2010,7,C02-Antihypertensives,% of total sales,0.7
+24850,Netherlands,2010,7,C03-Diuretics,% of total sales,1.4
+24851,Netherlands,2010,7,C10-Lipid modifying agents,Million of national currency units,298.9
+24852,Netherlands,2010,7,C10-Lipid modifying agents,Million US$ at exchange rate,396.2
+24853,Netherlands,2010,7,C10-Lipid modifying agents,"Million US$, purchasing power parity",349.9
+24854,Netherlands,2010,7,C02-Antihypertensives,"Million US$, purchasing power parity",41.6
+24855,Netherlands,2010,7,C02-Antihypertensives,Million US$ at exchange rate,47.1
+24856,Netherlands,2010,7,C02-Antihypertensives,Million of national currency units,35.6
+24857,Netherlands,2010,7,C02-Antihypertensives,"/capita, US$ purchasing power parity",2.5
+24858,Netherlands,2010,7,C10-Lipid modifying agents,"/capita, US$ exchange rate",23.8
+24859,Netherlands,2010,7,A-Alimentary tract and metabolism,"/capita, US$ exchange rate",53.3
+24860,Netherlands,2010,7,A-Alimentary tract and metabolism,"Million US$, purchasing power parity",782.1
+24861,Netherlands,2010,7,A-Alimentary tract and metabolism,Million US$ at exchange rate,885.6
+24862,Netherlands,2010,7,A-Alimentary tract and metabolism,Million of national currency units,668.0
+24863,Netherlands,2010,7,C10-Lipid modifying agents,"/capita, US$ purchasing power parity",21.1
+24864,Netherlands,2010,7,C10-Lipid modifying agents,% of total sales,5.7
+24865,Netherlands,2010,7,A-Alimentary tract and metabolism,% of total sales,12.8
+24866,Netherlands,2010,7,A-Alimentary tract and metabolism,"/capita, US$ purchasing power parity",47.1
+24867,Netherlands,2010,7,G-Genito urinary system and sex hormones,Million of national currency units,206.0
+24868,Netherlands,2010,7,N05B-Anxiolytics,"Million US$, purchasing power parity",25.0
+24869,Netherlands,2010,7,M-Musculo-skeletal system,Million US$ at exchange rate,212.2
+24870,Netherlands,2010,7,C03-Diuretics,"/capita, US$ purchasing power parity",5.3
+24871,Netherlands,2010,7,C03-Diuretics,"/capita, US$ exchange rate",5.9
+24872,Netherlands,2010,7,C03-Diuretics,"Million US$, purchasing power parity",87.3
+24873,Netherlands,2010,7,M-Musculo-skeletal system,"Million US$, purchasing power parity",187.4
+24874,Netherlands,2010,7,M-Musculo-skeletal system,% of total sales,3.1
+24875,Netherlands,2010,7,M-Musculo-skeletal system,"/capita, US$ purchasing power parity",11.3
+24876,Netherlands,2010,7,M-Musculo-skeletal system,"/capita, US$ exchange rate",12.8
+24877,Netherlands,2010,7,C03-Diuretics,Million US$ at exchange rate,98.8
+24878,Netherlands,2010,7,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ exchange rate",16.1
+24879,Netherlands,2010,7,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ purchasing power parity",14.2
+24880,Netherlands,2010,7,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),% of total sales,3.9
+24881,Netherlands,2010,7,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"Million US$, purchasing power parity",236.7
+24882,Netherlands,2010,7,C03-Diuretics,Million of national currency units,74.5
+24883,Netherlands,2010,7,M-Musculo-skeletal system,Million of national currency units,160.1
+24884,Netherlands,2010,7,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million of national currency units,202.1
+24885,Netherlands,2010,7,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million US$ at exchange rate,268.0
+24886,Netherlands,2017,5,Total pharmaceutical sales,"/capita, US$ purchasing power parity",340.4
+24887,Netherlands,2017,5,Total pharmaceutical sales,"Million US$, purchasing power parity",5831.7
+24888,Netherlands,2017,5,Total pharmaceutical sales,Million US$ at exchange rate,5152.7
+24889,Netherlands,2017,5,Total pharmaceutical sales,Million of national currency units,4561.2
+24890,Netherlands,2017,5,Total pharmaceutical sales,"/capita, US$ exchange rate",300.8
+24891,New Zealand,2011,10,C10-Lipid modifying agents,"/capita, US$ exchange rate",9.6
+24892,New Zealand,2011,10,N05C-Hypnotics and sedatives,Million of national currency units,1.7
+24893,New Zealand,2011,10,Products not elsewhere classified,Million US$ at exchange rate,160.0
+24894,New Zealand,2011,10,N05C-Hypnotics and sedatives,Million US$ at exchange rate,1.3
+24895,New Zealand,2011,10,C08-Calcium channel blockers,"Million US$, purchasing power parity",10.0
+24896,New Zealand,2011,10,C08-Calcium channel blockers,Million US$ at exchange rate,11.7
+24897,New Zealand,2011,10,Products not elsewhere classified,"/capita, US$ exchange rate",36.5
+24898,New Zealand,2011,10,C10-Lipid modifying agents,"Million US$, purchasing power parity",36.0
+24899,New Zealand,2011,10,C10-Lipid modifying agents,Million US$ at exchange rate,42.3
+24900,New Zealand,2011,10,Products not elsewhere classified,"Million US$, purchasing power parity",136.3
+24901,New Zealand,2011,10,C10-Lipid modifying agents,Million of national currency units,53.5
+24902,New Zealand,2011,10,C08-Calcium channel blockers,Million of national currency units,14.8
+24903,New Zealand,2011,10,N02-Analgesics,"/capita, US$ purchasing power parity",4.6
+24904,New Zealand,2011,10,N02-Analgesics,"Million US$, purchasing power parity",20.1
+24905,New Zealand,2011,10,N02-Analgesics,"/capita, US$ exchange rate",5.4
+24906,New Zealand,2011,10,Products not elsewhere classified,% of total sales,24.8
+24907,New Zealand,2011,10,N02-Analgesics,% of total sales,3.7
+24908,New Zealand,2011,10,C08-Calcium channel blockers,"/capita, US$ purchasing power parity",2.3
+24909,New Zealand,2011,10,C08-Calcium channel blockers,% of total sales,1.8
+24910,New Zealand,2011,10,C08-Calcium channel blockers,"/capita, US$ exchange rate",2.7
+24911,New Zealand,2011,10,N02-Analgesics,Million US$ at exchange rate,23.6
+24912,New Zealand,2011,10,N02-Analgesics,Million of national currency units,29.8
+24913,New Zealand,2011,10,Products not elsewhere classified,"/capita, US$ purchasing power parity",31.1
+24914,New Zealand,2011,10,G-Genito urinary system and sex hormones,Million US$ at exchange rate,16.8
+24915,New Zealand,2011,10,B-Blood and blood forming organs,Million of national currency units,26.3
+24916,New Zealand,2011,10,G-Genito urinary system and sex hormones,Million of national currency units,21.3
+24917,New Zealand,2011,10,B-Blood and blood forming organs,"/capita, US$ exchange rate",4.7
+24918,New Zealand,2011,10,B-Blood and blood forming organs,"Million US$, purchasing power parity",17.7
+24919,New Zealand,2011,10,B-Blood and blood forming organs,Million US$ at exchange rate,20.7
+24920,New Zealand,2011,10,G03-Sex hormones and modulators of the genital system,% of total sales,1.6
+24921,New Zealand,2011,10,G03-Sex hormones and modulators of the genital system,"Million US$, purchasing power parity",8.9
+24922,New Zealand,2011,10,G03-Sex hormones and modulators of the genital system,"/capita, US$ exchange rate",2.4
+24923,New Zealand,2011,10,G03-Sex hormones and modulators of the genital system,"/capita, US$ purchasing power parity",2.0
+24924,New Zealand,2011,10,C10-Lipid modifying agents,% of total sales,6.6
+24925,New Zealand,2011,10,G03-Sex hormones and modulators of the genital system,Million of national currency units,13.2
+24926,New Zealand,2011,10,G03-Sex hormones and modulators of the genital system,Million US$ at exchange rate,10.5
+24927,New Zealand,2011,10,N05C-Hypnotics and sedatives,% of total sales,0.2
+24928,New Zealand,2011,10,B-Blood and blood forming organs,% of total sales,3.2
+24929,New Zealand,2011,10,N05C-Hypnotics and sedatives,"/capita, US$ exchange rate",0.3
+24930,New Zealand,2011,10,N05C-Hypnotics and sedatives,"Million US$, purchasing power parity",1.1
+24931,New Zealand,2011,10,N05C-Hypnotics and sedatives,"/capita, US$ purchasing power parity",0.3
+24932,New Zealand,2011,10,B-Blood and blood forming organs,"/capita, US$ purchasing power parity",4.0
+24933,New Zealand,2011,10,G-Genito urinary system and sex hormones,"Million US$, purchasing power parity",14.3
+24934,New Zealand,2011,10,G-Genito urinary system and sex hormones,"/capita, US$ exchange rate",3.8
+24935,New Zealand,2011,10,C10-Lipid modifying agents,"/capita, US$ purchasing power parity",8.2
+24936,New Zealand,2011,10,Products not elsewhere classified,Million of national currency units,202.6
+24937,New Zealand,2011,10,G-Genito urinary system and sex hormones,"/capita, US$ purchasing power parity",3.3
+24938,New Zealand,2011,10,J-Antiinfectives for systemic use,"Million US$, purchasing power parity",33.6
+24939,New Zealand,2011,10,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ purchasing power parity",5.3
+24940,New Zealand,2011,10,C09-Agents acting on the Renin-Angiotensin system,% of total sales,4.2
+24941,New Zealand,2011,10,J-Antiinfectives for systemic use,Million US$ at exchange rate,39.5
+24942,New Zealand,2011,10,R-Respiratory system,Million US$ at exchange rate,65.7
+24943,New Zealand,2011,10,R-Respiratory system,"Million US$, purchasing power parity",56.0
+24944,New Zealand,2011,10,J-Antiinfectives for systemic use,Million of national currency units,50.0
+24945,New Zealand,2011,10,R-Respiratory system,Million of national currency units,83.2
+24946,New Zealand,2011,10,N05B-Anxiolytics,Million of national currency units,1.2
+24947,New Zealand,2011,10,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),% of total sales,1.5
+24948,New Zealand,2011,10,R03-Drugs for obstructive airway diseases,Million of national currency units,73.3
+24949,New Zealand,2011,10,N05B-Anxiolytics,Million US$ at exchange rate,0.9
+24950,New Zealand,2011,10,C09-Agents acting on the Renin-Angiotensin system,Million of national currency units,34.6
+24951,New Zealand,2011,10,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ exchange rate",6.2
+24952,New Zealand,2011,10,C09-Agents acting on the Renin-Angiotensin system,"Million US$, purchasing power parity",23.3
+24953,New Zealand,2011,10,C09-Agents acting on the Renin-Angiotensin system,Million US$ at exchange rate,27.3
+24954,New Zealand,2011,10,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ purchasing power parity",2.9
+24955,New Zealand,2011,10,"H-Systemic hormonal preparations, excluding sex hormones and insulins",% of total sales,2.3
+24956,New Zealand,2011,10,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million of national currency units,11.9
+24957,New Zealand,2011,10,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million US$ at exchange rate,14.7
+24958,New Zealand,2011,10,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ exchange rate",3.4
+24959,New Zealand,2011,10,"H-Systemic hormonal preparations, excluding sex hormones and insulins","Million US$, purchasing power parity",12.6
+24960,New Zealand,2011,10,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million of national currency units,18.7
+24961,New Zealand,2011,10,R-Respiratory system,% of total sales,10.2
+24962,New Zealand,2011,10,R-Respiratory system,"/capita, US$ purchasing power parity",12.8
+24963,New Zealand,2011,10,R-Respiratory system,"/capita, US$ exchange rate",15.0
+24964,New Zealand,2011,10,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"Million US$, purchasing power parity",8.0
+24965,New Zealand,2011,10,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million US$ at exchange rate,9.4
+24966,New Zealand,2011,10,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ purchasing power parity",1.8
+24967,New Zealand,2011,10,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ exchange rate",2.1
+24968,New Zealand,2011,10,N06A-Antidepressants,Million US$ at exchange rate,25.4
+24969,New Zealand,2011,10,N06A-Antidepressants,"Million US$, purchasing power parity",21.7
+24970,New Zealand,2011,10,N06A-Antidepressants,Million of national currency units,32.2
+24971,New Zealand,2011,10,N06A-Antidepressants,% of total sales,3.9
+24972,New Zealand,2011,10,N05B-Anxiolytics,"/capita, US$ exchange rate",0.2
+24973,New Zealand,2011,10,N06A-Antidepressants,"/capita, US$ exchange rate",5.8
+24974,New Zealand,2011,10,N06A-Antidepressants,"/capita, US$ purchasing power parity",4.9
+24975,New Zealand,2011,10,G-Genito urinary system and sex hormones,% of total sales,2.6
+24976,New Zealand,2011,10,A02A-Antacids,Million of national currency units,0.3
+24977,New Zealand,2011,10,A02A-Antacids,Million US$ at exchange rate,0.2
+24978,New Zealand,2011,10,N05B-Anxiolytics,"/capita, US$ purchasing power parity",0.2
+24979,New Zealand,2011,10,N05B-Anxiolytics,% of total sales,0.1
+24980,New Zealand,2011,10,N05B-Anxiolytics,"Million US$, purchasing power parity",0.8
+24981,New Zealand,2011,10,R03-Drugs for obstructive airway diseases,% of total sales,9.0
+24982,New Zealand,2011,10,J-Antiinfectives for systemic use,"/capita, US$ purchasing power parity",7.7
+24983,New Zealand,2011,10,J-Antiinfectives for systemic use,"/capita, US$ exchange rate",9.0
+24984,New Zealand,2011,10,R03-Drugs for obstructive airway diseases,"Million US$, purchasing power parity",49.4
+24985,New Zealand,2011,10,R03-Drugs for obstructive airway diseases,Million US$ at exchange rate,57.9
+24986,New Zealand,2011,10,R03-Drugs for obstructive airway diseases,"/capita, US$ purchasing power parity",11.3
+24987,New Zealand,2011,10,R03-Drugs for obstructive airway diseases,"/capita, US$ exchange rate",13.2
+24988,New Zealand,2011,10,A02A-Antacids,"/capita, US$ exchange rate",0.0
+24989,New Zealand,2011,10,A02A-Antacids,"Million US$, purchasing power parity",0.2
+24990,New Zealand,2011,10,A02A-Antacids,"/capita, US$ purchasing power parity",0.0
+24991,New Zealand,2011,10,J-Antiinfectives for systemic use,% of total sales,6.1
+24992,New Zealand,2011,10,A02A-Antacids,% of total sales,0.0
+24993,New Zealand,2011,10,C07-Beta blocking agents,Million US$ at exchange rate,14.4
+24994,New Zealand,2011,10,C07-Beta blocking agents,Million of national currency units,18.2
+24995,New Zealand,2011,10,C-Cardiovascular system,"/capita, US$ purchasing power parity",20.7
+24996,New Zealand,2011,10,C07-Beta blocking agents,"/capita, US$ exchange rate",3.3
+24997,New Zealand,2011,10,C07-Beta blocking agents,"/capita, US$ purchasing power parity",2.8
+24998,New Zealand,2011,10,C07-Beta blocking agents,"Million US$, purchasing power parity",12.3
+24999,New Zealand,2011,10,M-Musculo-skeletal system,% of total sales,3.2
+25000,New Zealand,2011,10,C03-Diuretics,Million US$ at exchange rate,1.8
+25001,New Zealand,2011,10,C-Cardiovascular system,% of total sales,16.5
+25002,New Zealand,2011,10,M-Musculo-skeletal system,"/capita, US$ exchange rate",4.7
+25003,New Zealand,2011,10,M-Musculo-skeletal system,"/capita, US$ purchasing power parity",4.0
+25004,New Zealand,2011,10,M01A-Antiinflammatory and antirheumatic products non-steroids,"Million US$, purchasing power parity",4.4
+25005,New Zealand,2011,10,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ exchange rate",1.2
+25006,New Zealand,2011,10,M01A-Antiinflammatory and antirheumatic products non-steroids,Million US$ at exchange rate,5.2
+25007,New Zealand,2011,10,M-Musculo-skeletal system,Million of national currency units,26.2
+25008,New Zealand,2011,10,M01A-Antiinflammatory and antirheumatic products non-steroids,Million of national currency units,6.5
+25009,New Zealand,2011,10,M-Musculo-skeletal system,"Million US$, purchasing power parity",17.6
+25010,New Zealand,2011,10,C07-Beta blocking agents,% of total sales,2.2
+25011,New Zealand,2011,10,M01A-Antiinflammatory and antirheumatic products non-steroids,% of total sales,0.8
+25012,New Zealand,2011,10,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ purchasing power parity",1.0
+25013,New Zealand,2011,10,M-Musculo-skeletal system,Million US$ at exchange rate,20.7
+25014,New Zealand,2011,10,"C01B-Antiarrhythmics, Class I and III",Million of national currency units,4.8
+25015,New Zealand,2011,10,"C01B-Antiarrhythmics, Class I and III",Million US$ at exchange rate,3.8
+25016,New Zealand,2011,10,"C01B-Antiarrhythmics, Class I and III","Million US$, purchasing power parity",3.2
+25017,New Zealand,2011,10,Total pharmaceutical sales,"/capita, US$ purchasing power parity",125.4
+25018,New Zealand,2011,10,Total pharmaceutical sales,"/capita, US$ exchange rate",147.2
+25019,New Zealand,2011,10,N-Nervous system,% of total sales,22.3
+25020,New Zealand,2011,10,C02-Antihypertensives,Million US$ at exchange rate,2.4
+25021,New Zealand,2011,10,C02-Antihypertensives,Million of national currency units,3.0
+25022,New Zealand,2011,10,"C01B-Antiarrhythmics, Class I and III",% of total sales,0.6
+25023,New Zealand,2011,10,"C01B-Antiarrhythmics, Class I and III","/capita, US$ exchange rate",0.9
+25024,New Zealand,2011,10,"C01B-Antiarrhythmics, Class I and III","/capita, US$ purchasing power parity",0.7
+25025,New Zealand,2011,10,N-Nervous system,Million of national currency units,182.6
+25026,New Zealand,2011,10,C03-Diuretics,% of total sales,0.3
+25027,New Zealand,2011,10,Total pharmaceutical sales,Million of national currency units,817.0
+25028,New Zealand,2011,10,C03-Diuretics,"Million US$, purchasing power parity",1.5
+25029,New Zealand,2011,10,C03-Diuretics,"/capita, US$ exchange rate",0.4
+25030,New Zealand,2011,10,C03-Diuretics,"/capita, US$ purchasing power parity",0.4
+25031,New Zealand,2011,10,Total pharmaceutical sales,Million US$ at exchange rate,645.4
+25032,New Zealand,2011,10,N-Nervous system,"/capita, US$ purchasing power parity",28.0
+25033,New Zealand,2011,10,Total pharmaceutical sales,"Million US$, purchasing power parity",549.8
+25034,New Zealand,2011,10,N-Nervous system,"Million US$, purchasing power parity",122.9
+25035,New Zealand,2011,10,N-Nervous system,Million US$ at exchange rate,144.2
+25036,New Zealand,2011,10,N-Nervous system,"/capita, US$ exchange rate",32.9
+25037,New Zealand,2011,10,J01-Antibacterials for systemic use,"/capita, US$ exchange rate",3.4
+25038,New Zealand,2011,10,J01-Antibacterials for systemic use,% of total sales,2.3
+25039,New Zealand,2011,10,J01-Antibacterials for systemic use,"/capita, US$ purchasing power parity",2.9
+25040,New Zealand,2011,10,J01-Antibacterials for systemic use,Million US$ at exchange rate,14.9
+25041,New Zealand,2011,10,J01-Antibacterials for systemic use,"Million US$, purchasing power parity",12.7
+25042,New Zealand,2011,10,C-Cardiovascular system,"/capita, US$ exchange rate",24.2
+25043,New Zealand,2011,10,C01A-Cardiac glycosides,"Million US$, purchasing power parity",0.3
+25044,New Zealand,2011,10,C01A-Cardiac glycosides,Million of national currency units,0.4
+25045,New Zealand,2011,10,C01A-Cardiac glycosides,Million US$ at exchange rate,0.3
+25046,New Zealand,2011,10,C01A-Cardiac glycosides,"/capita, US$ exchange rate",0.1
+25047,New Zealand,2011,10,A10-Drugs used in diabetes,Million US$ at exchange rate,25.6
+25048,New Zealand,2011,10,A10-Drugs used in diabetes,"Million US$, purchasing power parity",21.8
+25049,New Zealand,2011,10,C02-Antihypertensives,% of total sales,0.4
+25050,New Zealand,2011,10,C02-Antihypertensives,"/capita, US$ purchasing power parity",0.5
+25051,New Zealand,2011,10,A10-Drugs used in diabetes,Million of national currency units,32.4
+25052,New Zealand,2011,10,J01-Antibacterials for systemic use,Million of national currency units,18.9
+25053,New Zealand,2011,10,A10-Drugs used in diabetes,"/capita, US$ exchange rate",5.8
+25054,New Zealand,2011,10,C-Cardiovascular system,Million of national currency units,134.6
+25055,New Zealand,2011,10,C-Cardiovascular system,"Million US$, purchasing power parity",90.6
+25056,New Zealand,2011,10,C-Cardiovascular system,Million US$ at exchange rate,106.3
+25057,New Zealand,2011,10,A10-Drugs used in diabetes,"/capita, US$ purchasing power parity",5.0
+25058,New Zealand,2011,10,A10-Drugs used in diabetes,% of total sales,4.0
+25059,New Zealand,2011,10,A-Alimentary tract and metabolism,"/capita, US$ exchange rate",12.9
+25060,New Zealand,2011,10,A-Alimentary tract and metabolism,"Million US$, purchasing power parity",48.2
+25061,New Zealand,2011,10,A-Alimentary tract and metabolism,% of total sales,8.8
+25062,New Zealand,2011,10,A-Alimentary tract and metabolism,"/capita, US$ purchasing power parity",11.0
+25063,New Zealand,2011,10,C02-Antihypertensives,"/capita, US$ exchange rate",0.5
+25064,New Zealand,2011,10,C02-Antihypertensives,"Million US$, purchasing power parity",2.0
+25065,New Zealand,2011,10,C03-Diuretics,Million of national currency units,2.3
+25066,New Zealand,2011,10,A-Alimentary tract and metabolism,Million US$ at exchange rate,56.6
+25067,New Zealand,2011,10,A-Alimentary tract and metabolism,Million of national currency units,71.7
+25068,New Zealand,2011,10,C01A-Cardiac glycosides,"/capita, US$ purchasing power parity",0.1
+25069,New Zealand,2011,10,C01A-Cardiac glycosides,% of total sales,0.0
+25070,New Zealand,2017,9,C08-Calcium channel blockers,Million of national currency units,5.8
+25071,New Zealand,2017,9,C10-Lipid modifying agents,"Million US$, purchasing power parity",6.4
+25072,New Zealand,2017,9,N05C-Hypnotics and sedatives,Million of national currency units,1.1
+25073,New Zealand,2017,9,N05C-Hypnotics and sedatives,Million US$ at exchange rate,0.8
+25074,New Zealand,2017,9,C08-Calcium channel blockers,Million US$ at exchange rate,4.1
+25075,New Zealand,2017,9,Products not elsewhere classified,"Million US$, purchasing power parity",456.5
+25076,New Zealand,2017,9,C10-Lipid modifying agents,Million US$ at exchange rate,6.5
+25077,New Zealand,2017,9,Products not elsewhere classified,Million US$ at exchange rate,464.1
+25078,New Zealand,2017,9,C10-Lipid modifying agents,Million of national currency units,9.1
+25079,New Zealand,2017,9,N02-Analgesics,"/capita, US$ exchange rate",2.5
+25080,New Zealand,2017,9,N02-Analgesics,"/capita, US$ purchasing power parity",2.5
+25081,New Zealand,2017,9,N02-Analgesics,"Million US$, purchasing power parity",11.8
+25082,New Zealand,2017,9,Products not elsewhere classified,"/capita, US$ purchasing power parity",94.8
+25083,New Zealand,2017,9,Products not elsewhere classified,% of total sales,51.7
+25084,New Zealand,2017,9,N02-Analgesics,% of total sales,1.3
+25085,New Zealand,2017,9,N02-Analgesics,Million US$ at exchange rate,12.0
+25086,New Zealand,2017,9,C08-Calcium channel blockers,"/capita, US$ purchasing power parity",0.8
+25087,New Zealand,2017,9,C08-Calcium channel blockers,"Million US$, purchasing power parity",4.0
+25088,New Zealand,2017,9,C08-Calcium channel blockers,"/capita, US$ exchange rate",0.8
+25089,New Zealand,2017,9,N02-Analgesics,Million of national currency units,16.9
+25090,New Zealand,2017,9,C08-Calcium channel blockers,% of total sales,0.5
+25091,New Zealand,2017,9,Products not elsewhere classified,"/capita, US$ exchange rate",96.4
+25092,New Zealand,2017,9,G-Genito urinary system and sex hormones,Million of national currency units,20.2
+25093,New Zealand,2017,9,G03-Sex hormones and modulators of the genital system,% of total sales,0.9
+25094,New Zealand,2017,9,B-Blood and blood forming organs,Million of national currency units,68.3
+25095,New Zealand,2017,9,B-Blood and blood forming organs,"Million US$, purchasing power parity",47.7
+25096,New Zealand,2017,9,G-Genito urinary system and sex hormones,Million US$ at exchange rate,14.3
+25097,New Zealand,2017,9,B-Blood and blood forming organs,Million US$ at exchange rate,48.5
+25098,New Zealand,2017,9,G03-Sex hormones and modulators of the genital system,"Million US$, purchasing power parity",7.9
+25099,New Zealand,2017,9,G03-Sex hormones and modulators of the genital system,"/capita, US$ exchange rate",1.7
+25100,New Zealand,2017,9,G03-Sex hormones and modulators of the genital system,Million US$ at exchange rate,8.1
+25101,New Zealand,2017,9,C10-Lipid modifying agents,% of total sales,0.7
+25102,New Zealand,2017,9,G03-Sex hormones and modulators of the genital system,"/capita, US$ purchasing power parity",1.6
+25103,New Zealand,2017,9,G03-Sex hormones and modulators of the genital system,Million of national currency units,11.4
+25104,New Zealand,2017,9,N05C-Hypnotics and sedatives,% of total sales,0.1
+25105,New Zealand,2017,9,C10-Lipid modifying agents,"/capita, US$ exchange rate",1.3
+25106,New Zealand,2017,9,B-Blood and blood forming organs,% of total sales,5.4
+25107,New Zealand,2017,9,N05C-Hypnotics and sedatives,"Million US$, purchasing power parity",0.8
+25108,New Zealand,2017,9,N05C-Hypnotics and sedatives,"/capita, US$ purchasing power parity",0.2
+25109,New Zealand,2017,9,N05C-Hypnotics and sedatives,"/capita, US$ exchange rate",0.2
+25110,New Zealand,2017,9,B-Blood and blood forming organs,"/capita, US$ exchange rate",10.1
+25111,New Zealand,2017,9,G-Genito urinary system and sex hormones,"Million US$, purchasing power parity",14.1
+25112,New Zealand,2017,9,B-Blood and blood forming organs,"/capita, US$ purchasing power parity",9.9
+25113,New Zealand,2017,9,C10-Lipid modifying agents,"/capita, US$ purchasing power parity",1.3
+25114,New Zealand,2017,9,G-Genito urinary system and sex hormones,"/capita, US$ exchange rate",3.0
+25115,New Zealand,2017,9,Products not elsewhere classified,Million of national currency units,653.2
+25116,New Zealand,2017,9,J-Antiinfectives for systemic use,Million US$ at exchange rate,121.0
+25117,New Zealand,2017,9,C09-Agents acting on the Renin-Angiotensin system,% of total sales,0.9
+25118,New Zealand,2017,9,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ purchasing power parity",1.7
+25119,New Zealand,2017,9,R-Respiratory system,Million US$ at exchange rate,69.3
+25120,New Zealand,2017,9,R-Respiratory system,Million of national currency units,97.6
+25121,New Zealand,2017,9,J-Antiinfectives for systemic use,Million of national currency units,170.3
+25122,New Zealand,2017,9,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ purchasing power parity",0.9
+25123,New Zealand,2017,9,R03-Drugs for obstructive airway diseases,Million of national currency units,89.1
+25124,New Zealand,2017,9,N05B-Anxiolytics,Million of national currency units,1.2
+25125,New Zealand,2017,9,C09-Agents acting on the Renin-Angiotensin system,"Million US$, purchasing power parity",8.2
+25126,New Zealand,2017,9,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ exchange rate",1.7
+25127,New Zealand,2017,9,C09-Agents acting on the Renin-Angiotensin system,Million of national currency units,11.8
+25128,New Zealand,2017,9,C09-Agents acting on the Renin-Angiotensin system,Million US$ at exchange rate,8.4
+25129,New Zealand,2017,9,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ purchasing power parity",3.6
+25130,New Zealand,2017,9,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ exchange rate",3.7
+25131,New Zealand,2017,9,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million of national currency units,5.9
+25132,New Zealand,2017,9,"H-Systemic hormonal preparations, excluding sex hormones and insulins",% of total sales,2.0
+25133,New Zealand,2017,9,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million of national currency units,25.0
+25134,New Zealand,2017,9,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million US$ at exchange rate,17.8
+25135,New Zealand,2017,9,"H-Systemic hormonal preparations, excluding sex hormones and insulins","Million US$, purchasing power parity",17.5
+25136,New Zealand,2017,9,R-Respiratory system,"/capita, US$ purchasing power parity",14.2
+25137,New Zealand,2017,9,R-Respiratory system,% of total sales,7.7
+25138,New Zealand,2017,9,R-Respiratory system,"Million US$, purchasing power parity",68.2
+25139,New Zealand,2017,9,R-Respiratory system,"/capita, US$ exchange rate",14.4
+25140,New Zealand,2017,9,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million US$ at exchange rate,4.2
+25141,New Zealand,2017,9,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"Million US$, purchasing power parity",4.1
+25142,New Zealand,2017,9,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ exchange rate",0.9
+25143,New Zealand,2017,9,N06A-Antidepressants,Million US$ at exchange rate,9.6
+25144,New Zealand,2017,9,N05B-Anxiolytics,"Million US$, purchasing power parity",0.9
+25145,New Zealand,2017,9,N06A-Antidepressants,Million of national currency units,13.5
+25146,New Zealand,2017,9,N06A-Antidepressants,"Million US$, purchasing power parity",9.4
+25147,New Zealand,2017,9,N06A-Antidepressants,% of total sales,1.1
+25148,New Zealand,2017,9,N06A-Antidepressants,"/capita, US$ purchasing power parity",2.0
+25149,New Zealand,2017,9,N06A-Antidepressants,"/capita, US$ exchange rate",2.0
+25150,New Zealand,2017,9,G-Genito urinary system and sex hormones,"/capita, US$ purchasing power parity",2.9
+25151,New Zealand,2017,9,G-Genito urinary system and sex hormones,% of total sales,1.6
+25152,New Zealand,2017,9,A02A-Antacids,Million of national currency units,0.3
+25153,New Zealand,2017,9,N05B-Anxiolytics,"/capita, US$ purchasing power parity",0.2
+25154,New Zealand,2017,9,N05B-Anxiolytics,"/capita, US$ exchange rate",0.2
+25155,New Zealand,2017,9,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),% of total sales,0.5
+25156,New Zealand,2017,9,N05B-Anxiolytics,% of total sales,0.1
+25157,New Zealand,2017,9,R03-Drugs for obstructive airway diseases,% of total sales,7.1
+25158,New Zealand,2017,9,R03-Drugs for obstructive airway diseases,"/capita, US$ purchasing power parity",12.9
+25159,New Zealand,2017,9,J-Antiinfectives for systemic use,"Million US$, purchasing power parity",119.0
+25160,New Zealand,2017,9,J-Antiinfectives for systemic use,"/capita, US$ exchange rate",25.1
+25161,New Zealand,2017,9,R03-Drugs for obstructive airway diseases,Million US$ at exchange rate,63.3
+25162,New Zealand,2017,9,R03-Drugs for obstructive airway diseases,"Million US$, purchasing power parity",62.2
+25163,New Zealand,2017,9,R03-Drugs for obstructive airway diseases,"/capita, US$ exchange rate",13.1
+25164,New Zealand,2017,9,A02A-Antacids,"Million US$, purchasing power parity",0.2
+25165,New Zealand,2017,9,A02A-Antacids,"/capita, US$ exchange rate",0.0
+25166,New Zealand,2017,9,N05B-Anxiolytics,Million US$ at exchange rate,0.9
+25167,New Zealand,2017,9,A02A-Antacids,Million US$ at exchange rate,0.2
+25168,New Zealand,2017,9,J-Antiinfectives for systemic use,% of total sales,13.5
+25169,New Zealand,2017,9,J-Antiinfectives for systemic use,"/capita, US$ purchasing power parity",24.7
+25170,New Zealand,2017,9,A02A-Antacids,"/capita, US$ purchasing power parity",0.0
+25171,New Zealand,2017,9,A02A-Antacids,% of total sales,0.0
+25172,New Zealand,2017,9,C07-Beta blocking agents,Million of national currency units,12.1
+25173,New Zealand,2017,9,C-Cardiovascular system,"/capita, US$ purchasing power parity",7.5
+25174,New Zealand,2017,9,C07-Beta blocking agents,Million US$ at exchange rate,8.6
+25175,New Zealand,2017,9,C07-Beta blocking agents,"/capita, US$ exchange rate",1.8
+25176,New Zealand,2017,9,C07-Beta blocking agents,"Million US$, purchasing power parity",8.5
+25177,New Zealand,2017,9,M-Musculo-skeletal system,% of total sales,1.7
+25178,New Zealand,2017,9,M-Musculo-skeletal system,"/capita, US$ purchasing power parity",3.1
+25179,New Zealand,2017,9,C03-Diuretics,Million of national currency units,2.3
+25180,New Zealand,2017,9,C-Cardiovascular system,% of total sales,4.1
+25181,New Zealand,2017,9,M-Musculo-skeletal system,"/capita, US$ exchange rate",3.2
+25182,New Zealand,2017,9,C03-Diuretics,Million US$ at exchange rate,1.7
+25183,New Zealand,2017,9,M01A-Antiinflammatory and antirheumatic products non-steroids,Million US$ at exchange rate,5.0
+25184,New Zealand,2017,9,M01A-Antiinflammatory and antirheumatic products non-steroids,"Million US$, purchasing power parity",4.9
+25185,New Zealand,2017,9,C02-Antihypertensives,Million US$ at exchange rate,1.6
+25186,New Zealand,2017,9,M-Musculo-skeletal system,Million of national currency units,21.7
+25187,New Zealand,2017,9,M01A-Antiinflammatory and antirheumatic products non-steroids,Million of national currency units,7.0
+25188,New Zealand,2017,9,M-Musculo-skeletal system,"Million US$, purchasing power parity",15.2
+25189,New Zealand,2017,9,C07-Beta blocking agents,% of total sales,1.0
+25190,New Zealand,2017,9,C07-Beta blocking agents,"/capita, US$ purchasing power parity",1.8
+25191,New Zealand,2017,9,M-Musculo-skeletal system,Million US$ at exchange rate,15.4
+25192,New Zealand,2017,9,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ purchasing power parity",1.0
+25193,New Zealand,2017,9,M01A-Antiinflammatory and antirheumatic products non-steroids,% of total sales,0.6
+25194,New Zealand,2017,9,"C01B-Antiarrhythmics, Class I and III",Million of national currency units,4.1
+25195,New Zealand,2017,9,"C01B-Antiarrhythmics, Class I and III",Million US$ at exchange rate,2.9
+25196,New Zealand,2017,9,N-Nervous system,% of total sales,13.3
+25197,New Zealand,2017,9,Total pharmaceutical sales,"/capita, US$ exchange rate",186.3
+25198,New Zealand,2017,9,Total pharmaceutical sales,"/capita, US$ purchasing power parity",183.2
+25199,New Zealand,2017,9,"C01B-Antiarrhythmics, Class I and III",% of total sales,0.3
+25200,New Zealand,2017,9,C02-Antihypertensives,Million of national currency units,2.2
+25201,New Zealand,2017,9,C03-Diuretics,% of total sales,0.2
+25202,New Zealand,2017,9,"C01B-Antiarrhythmics, Class I and III","/capita, US$ exchange rate",0.6
+25203,New Zealand,2017,9,"C01B-Antiarrhythmics, Class I and III","Million US$, purchasing power parity",2.9
+25204,New Zealand,2017,9,"C01B-Antiarrhythmics, Class I and III","/capita, US$ purchasing power parity",0.6
+25205,New Zealand,2017,9,N-Nervous system,Million of national currency units,167.6
+25206,New Zealand,2017,9,Total pharmaceutical sales,Million of national currency units,1262.2
+25207,New Zealand,2017,9,C03-Diuretics,"/capita, US$ purchasing power parity",0.3
+25208,New Zealand,2017,9,C03-Diuretics,"Million US$, purchasing power parity",1.6
+25209,New Zealand,2017,9,C03-Diuretics,"/capita, US$ exchange rate",0.3
+25210,New Zealand,2017,9,N-Nervous system,"/capita, US$ purchasing power parity",24.3
+25211,New Zealand,2017,9,Total pharmaceutical sales,"Million US$, purchasing power parity",882.1
+25212,New Zealand,2017,9,Total pharmaceutical sales,Million US$ at exchange rate,896.8
+25213,New Zealand,2017,9,N-Nervous system,Million US$ at exchange rate,119.1
+25214,New Zealand,2017,9,N-Nervous system,"/capita, US$ exchange rate",24.7
+25215,New Zealand,2017,9,N-Nervous system,"Million US$, purchasing power parity",117.1
+25216,New Zealand,2017,9,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ exchange rate",1.0
+25217,New Zealand,2017,9,J01-Antibacterials for systemic use,"/capita, US$ exchange rate",2.3
+25218,New Zealand,2017,9,J01-Antibacterials for systemic use,Million of national currency units,15.3
+25219,New Zealand,2017,9,J01-Antibacterials for systemic use,Million US$ at exchange rate,10.9
+25220,New Zealand,2017,9,J01-Antibacterials for systemic use,"Million US$, purchasing power parity",10.7
+25221,New Zealand,2017,9,C-Cardiovascular system,"Million US$, purchasing power parity",36.1
+25222,New Zealand,2017,9,C01A-Cardiac glycosides,"Million US$, purchasing power parity",0.2
+25223,New Zealand,2017,9,C-Cardiovascular system,"/capita, US$ exchange rate",7.6
+25224,New Zealand,2017,9,J01-Antibacterials for systemic use,% of total sales,1.2
+25225,New Zealand,2017,9,C01A-Cardiac glycosides,Million of national currency units,0.4
+25226,New Zealand,2017,9,C01A-Cardiac glycosides,Million US$ at exchange rate,0.2
+25227,New Zealand,2017,9,A10-Drugs used in diabetes,Million US$ at exchange rate,37.8
+25228,New Zealand,2017,9,A10-Drugs used in diabetes,"Million US$, purchasing power parity",37.2
+25229,New Zealand,2017,9,A10-Drugs used in diabetes,Million of national currency units,53.2
+25230,New Zealand,2017,9,C02-Antihypertensives,% of total sales,0.2
+25231,New Zealand,2017,9,C02-Antihypertensives,"/capita, US$ purchasing power parity",0.3
+25232,New Zealand,2017,9,C-Cardiovascular system,Million of national currency units,51.6
+25233,New Zealand,2017,9,C-Cardiovascular system,Million US$ at exchange rate,36.7
+25234,New Zealand,2017,9,A10-Drugs used in diabetes,"/capita, US$ exchange rate",7.9
+25235,New Zealand,2017,9,A10-Drugs used in diabetes,"/capita, US$ purchasing power parity",7.7
+25236,New Zealand,2017,9,A10-Drugs used in diabetes,% of total sales,4.2
+25237,New Zealand,2017,9,J01-Antibacterials for systemic use,"/capita, US$ purchasing power parity",2.2
+25238,New Zealand,2017,9,A-Alimentary tract and metabolism,"/capita, US$ exchange rate",13.1
+25239,New Zealand,2017,9,A-Alimentary tract and metabolism,"Million US$, purchasing power parity",62.0
+25240,New Zealand,2017,9,A-Alimentary tract and metabolism,% of total sales,7.0
+25241,New Zealand,2017,9,A-Alimentary tract and metabolism,"/capita, US$ purchasing power parity",12.9
+25242,New Zealand,2017,9,C02-Antihypertensives,"Million US$, purchasing power parity",1.6
+25243,New Zealand,2017,9,C02-Antihypertensives,"/capita, US$ exchange rate",0.3
+25244,New Zealand,2017,9,A-Alimentary tract and metabolism,Million US$ at exchange rate,63.0
+25245,New Zealand,2017,9,A-Alimentary tract and metabolism,Million of national currency units,88.7
+25246,New Zealand,2017,9,C01A-Cardiac glycosides,"/capita, US$ purchasing power parity",0.1
+25247,New Zealand,2017,9,C01A-Cardiac glycosides,% of total sales,0.0
+25248,New Zealand,2017,9,C01A-Cardiac glycosides,"/capita, US$ exchange rate",0.1
+25249,New Zealand,2016,10,N05C-Hypnotics and sedatives,Million of national currency units,1.8
+25250,New Zealand,2016,10,C08-Calcium channel blockers,Million of national currency units,5.7
+25251,New Zealand,2016,10,C10-Lipid modifying agents,"Million US$, purchasing power parity",8.1
+25252,New Zealand,2016,10,N05C-Hypnotics and sedatives,Million US$ at exchange rate,1.2
+25253,New Zealand,2016,10,C08-Calcium channel blockers,Million US$ at exchange rate,4.0
+25254,New Zealand,2016,10,C10-Lipid modifying agents,Million US$ at exchange rate,8.1
+25255,New Zealand,2016,10,Products not elsewhere classified,"Million US$, purchasing power parity",266.2
+25256,New Zealand,2016,10,Products not elsewhere classified,Million US$ at exchange rate,267.0
+25257,New Zealand,2016,10,C10-Lipid modifying agents,Million of national currency units,11.7
+25258,New Zealand,2016,10,N02-Analgesics,"/capita, US$ exchange rate",2.9
+25259,New Zealand,2016,10,N02-Analgesics,"/capita, US$ purchasing power parity",2.9
+25260,New Zealand,2016,10,N02-Analgesics,"Million US$, purchasing power parity",13.6
+25261,New Zealand,2016,10,Products not elsewhere classified,% of total sales,35.8
+25262,New Zealand,2016,10,Products not elsewhere classified,"/capita, US$ purchasing power parity",56.5
+25263,New Zealand,2016,10,N02-Analgesics,% of total sales,1.8
+25264,New Zealand,2016,10,C08-Calcium channel blockers,"/capita, US$ purchasing power parity",0.8
+25265,New Zealand,2016,10,C08-Calcium channel blockers,"Million US$, purchasing power parity",4.0
+25266,New Zealand,2016,10,C08-Calcium channel blockers,"/capita, US$ exchange rate",0.8
+25267,New Zealand,2016,10,N02-Analgesics,Million of national currency units,19.6
+25268,New Zealand,2016,10,N02-Analgesics,Million US$ at exchange rate,13.7
+25269,New Zealand,2016,10,C08-Calcium channel blockers,% of total sales,0.5
+25270,New Zealand,2016,10,Products not elsewhere classified,"/capita, US$ exchange rate",56.6
+25271,New Zealand,2016,10,G03-Sex hormones and modulators of the genital system,% of total sales,1.2
+25272,New Zealand,2016,10,G-Genito urinary system and sex hormones,Million of national currency units,21.6
+25273,New Zealand,2016,10,B-Blood and blood forming organs,Million of national currency units,84.8
+25274,New Zealand,2016,10,B-Blood and blood forming organs,"Million US$, purchasing power parity",58.8
+25275,New Zealand,2016,10,G-Genito urinary system and sex hormones,Million US$ at exchange rate,15.0
+25276,New Zealand,2016,10,B-Blood and blood forming organs,Million US$ at exchange rate,59.0
+25277,New Zealand,2016,10,G03-Sex hormones and modulators of the genital system,"Million US$, purchasing power parity",8.8
+25278,New Zealand,2016,10,G03-Sex hormones and modulators of the genital system,"/capita, US$ exchange rate",1.9
+25279,New Zealand,2016,10,C10-Lipid modifying agents,% of total sales,1.1
+25280,New Zealand,2016,10,G03-Sex hormones and modulators of the genital system,Million US$ at exchange rate,8.8
+25281,New Zealand,2016,10,G03-Sex hormones and modulators of the genital system,Million of national currency units,12.6
+25282,New Zealand,2016,10,N05C-Hypnotics and sedatives,% of total sales,0.2
+25283,New Zealand,2016,10,C10-Lipid modifying agents,"/capita, US$ exchange rate",1.7
+25284,New Zealand,2016,10,B-Blood and blood forming organs,% of total sales,7.9
+25285,New Zealand,2016,10,N05C-Hypnotics and sedatives,"Million US$, purchasing power parity",1.2
+25286,New Zealand,2016,10,N05C-Hypnotics and sedatives,"/capita, US$ exchange rate",0.3
+25287,New Zealand,2016,10,N05C-Hypnotics and sedatives,"/capita, US$ purchasing power parity",0.3
+25288,New Zealand,2016,10,G03-Sex hormones and modulators of the genital system,"/capita, US$ purchasing power parity",1.9
+25289,New Zealand,2016,10,B-Blood and blood forming organs,"/capita, US$ exchange rate",12.5
+25290,New Zealand,2016,10,B-Blood and blood forming organs,"/capita, US$ purchasing power parity",12.5
+25291,New Zealand,2016,10,G-Genito urinary system and sex hormones,"Million US$, purchasing power parity",15.0
+25292,New Zealand,2016,10,C10-Lipid modifying agents,"/capita, US$ purchasing power parity",1.7
+25293,New Zealand,2016,10,G-Genito urinary system and sex hormones,"/capita, US$ exchange rate",3.2
+25294,New Zealand,2016,10,Products not elsewhere classified,Million of national currency units,383.6
+25295,New Zealand,2016,10,J-Antiinfectives for systemic use,Million US$ at exchange rate,80.0
+25296,New Zealand,2016,10,C09-Agents acting on the Renin-Angiotensin system,% of total sales,1.1
+25297,New Zealand,2016,10,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ purchasing power parity",1.8
+25298,New Zealand,2016,10,R-Respiratory system,Million US$ at exchange rate,71.9
+25299,New Zealand,2016,10,J-Antiinfectives for systemic use,Million of national currency units,114.9
+25300,New Zealand,2016,10,R-Respiratory system,Million of national currency units,103.2
+25301,New Zealand,2016,10,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ purchasing power parity",0.9
+25302,New Zealand,2016,10,N05B-Anxiolytics,Million of national currency units,2.7
+25303,New Zealand,2016,10,R03-Drugs for obstructive airway diseases,Million of national currency units,92.7
+25304,New Zealand,2016,10,C09-Agents acting on the Renin-Angiotensin system,"Million US$, purchasing power parity",8.5
+25305,New Zealand,2016,10,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ exchange rate",1.8
+25306,New Zealand,2016,10,C09-Agents acting on the Renin-Angiotensin system,Million of national currency units,12.3
+25307,New Zealand,2016,10,C09-Agents acting on the Renin-Angiotensin system,Million US$ at exchange rate,8.6
+25308,New Zealand,2016,10,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ purchasing power parity",4.1
+25309,New Zealand,2016,10,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million of national currency units,6.0
+25310,New Zealand,2016,10,"H-Systemic hormonal preparations, excluding sex hormones and insulins",% of total sales,2.6
+25311,New Zealand,2016,10,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ exchange rate",4.2
+25312,New Zealand,2016,10,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million of national currency units,28.2
+25313,New Zealand,2016,10,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million US$ at exchange rate,19.6
+25314,New Zealand,2016,10,"H-Systemic hormonal preparations, excluding sex hormones and insulins","Million US$, purchasing power parity",19.6
+25315,New Zealand,2016,10,R-Respiratory system,"/capita, US$ purchasing power parity",15.2
+25316,New Zealand,2016,10,R-Respiratory system,% of total sales,9.6
+25317,New Zealand,2016,10,R-Respiratory system,"Million US$, purchasing power parity",71.6
+25318,New Zealand,2016,10,R-Respiratory system,"/capita, US$ exchange rate",15.2
+25319,New Zealand,2016,10,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million US$ at exchange rate,4.2
+25320,New Zealand,2016,10,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"Million US$, purchasing power parity",4.2
+25321,New Zealand,2016,10,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ exchange rate",0.9
+25322,New Zealand,2016,10,N06A-Antidepressants,Million US$ at exchange rate,9.5
+25323,New Zealand,2016,10,N06A-Antidepressants,"Million US$, purchasing power parity",9.5
+25324,New Zealand,2016,10,N05B-Anxiolytics,"Million US$, purchasing power parity",1.9
+25325,New Zealand,2016,10,N06A-Antidepressants,Million of national currency units,13.7
+25326,New Zealand,2016,10,N06A-Antidepressants,% of total sales,1.3
+25327,New Zealand,2016,10,N06A-Antidepressants,"/capita, US$ purchasing power parity",2.0
+25328,New Zealand,2016,10,N06A-Antidepressants,"/capita, US$ exchange rate",2.0
+25329,New Zealand,2016,10,G-Genito urinary system and sex hormones,"/capita, US$ purchasing power parity",3.2
+25330,New Zealand,2016,10,G-Genito urinary system and sex hormones,% of total sales,2.0
+25331,New Zealand,2016,10,A02A-Antacids,Million US$ at exchange rate,0.3
+25332,New Zealand,2016,10,A02A-Antacids,Million of national currency units,0.4
+25333,New Zealand,2016,10,N05B-Anxiolytics,"/capita, US$ purchasing power parity",0.4
+25334,New Zealand,2016,10,N05B-Anxiolytics,"/capita, US$ exchange rate",0.4
+25335,New Zealand,2016,10,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),% of total sales,0.6
+25336,New Zealand,2016,10,N05B-Anxiolytics,% of total sales,0.3
+25337,New Zealand,2016,10,R03-Drugs for obstructive airway diseases,% of total sales,8.7
+25338,New Zealand,2016,10,J-Antiinfectives for systemic use,"Million US$, purchasing power parity",79.8
+25339,New Zealand,2016,10,J-Antiinfectives for systemic use,"/capita, US$ exchange rate",17.0
+25340,New Zealand,2016,10,R03-Drugs for obstructive airway diseases,"/capita, US$ purchasing power parity",13.7
+25341,New Zealand,2016,10,R03-Drugs for obstructive airway diseases,Million US$ at exchange rate,64.6
+25342,New Zealand,2016,10,R03-Drugs for obstructive airway diseases,"Million US$, purchasing power parity",64.4
+25343,New Zealand,2016,10,R03-Drugs for obstructive airway diseases,"/capita, US$ exchange rate",13.7
+25344,New Zealand,2016,10,A02A-Antacids,"/capita, US$ exchange rate",0.1
+25345,New Zealand,2016,10,A02A-Antacids,"Million US$, purchasing power parity",0.3
+25346,New Zealand,2016,10,N05B-Anxiolytics,Million US$ at exchange rate,1.9
+25347,New Zealand,2016,10,J-Antiinfectives for systemic use,% of total sales,10.7
+25348,New Zealand,2016,10,J-Antiinfectives for systemic use,"/capita, US$ purchasing power parity",16.9
+25349,New Zealand,2016,10,A02A-Antacids,"/capita, US$ purchasing power parity",0.1
+25350,New Zealand,2016,10,A02A-Antacids,% of total sales,0.0
+25351,New Zealand,2016,10,C07-Beta blocking agents,Million of national currency units,7.9
+25352,New Zealand,2016,10,C-Cardiovascular system,"/capita, US$ purchasing power parity",7.5
+25353,New Zealand,2016,10,C07-Beta blocking agents,Million US$ at exchange rate,5.5
+25354,New Zealand,2016,10,C07-Beta blocking agents,"/capita, US$ exchange rate",1.2
+25355,New Zealand,2016,10,C07-Beta blocking agents,"Million US$, purchasing power parity",5.5
+25356,New Zealand,2016,10,M-Musculo-skeletal system,% of total sales,2.0
+25357,New Zealand,2016,10,C03-Diuretics,Million US$ at exchange rate,1.6
+25358,New Zealand,2016,10,C03-Diuretics,Million of national currency units,2.2
+25359,New Zealand,2016,10,M-Musculo-skeletal system,"/capita, US$ purchasing power parity",3.2
+25360,New Zealand,2016,10,C-Cardiovascular system,% of total sales,4.8
+25361,New Zealand,2016,10,M-Musculo-skeletal system,"/capita, US$ exchange rate",3.2
+25362,New Zealand,2016,10,M01A-Antiinflammatory and antirheumatic products non-steroids,Million US$ at exchange rate,5.5
+25363,New Zealand,2016,10,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ exchange rate",1.2
+25364,New Zealand,2016,10,M01A-Antiinflammatory and antirheumatic products non-steroids,"Million US$, purchasing power parity",5.5
+25365,New Zealand,2016,10,C02-Antihypertensives,Million US$ at exchange rate,1.8
+25366,New Zealand,2016,10,M-Musculo-skeletal system,Million of national currency units,21.7
+25367,New Zealand,2016,10,M01A-Antiinflammatory and antirheumatic products non-steroids,Million of national currency units,7.9
+25368,New Zealand,2016,10,M-Musculo-skeletal system,"Million US$, purchasing power parity",15.1
+25369,New Zealand,2016,10,C07-Beta blocking agents,"/capita, US$ purchasing power parity",1.2
+25370,New Zealand,2016,10,C07-Beta blocking agents,% of total sales,0.7
+25371,New Zealand,2016,10,M-Musculo-skeletal system,Million US$ at exchange rate,15.1
+25372,New Zealand,2016,10,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ purchasing power parity",1.2
+25373,New Zealand,2016,10,M01A-Antiinflammatory and antirheumatic products non-steroids,% of total sales,0.7
+25374,New Zealand,2016,10,"C01B-Antiarrhythmics, Class I and III",Million of national currency units,4.7
+25375,New Zealand,2016,10,"C01B-Antiarrhythmics, Class I and III",Million US$ at exchange rate,3.3
+25376,New Zealand,2016,10,N-Nervous system,% of total sales,16.0
+25377,New Zealand,2016,10,Total pharmaceutical sales,"/capita, US$ exchange rate",158.3
+25378,New Zealand,2016,10,Total pharmaceutical sales,"/capita, US$ purchasing power parity",157.8
+25379,New Zealand,2016,10,"C01B-Antiarrhythmics, Class I and III","Million US$, purchasing power parity",3.3
+25380,New Zealand,2016,10,"C01B-Antiarrhythmics, Class I and III",% of total sales,0.4
+25381,New Zealand,2016,10,C03-Diuretics,% of total sales,0.2
+25382,New Zealand,2016,10,C02-Antihypertensives,Million of national currency units,2.6
+25383,New Zealand,2016,10,"C01B-Antiarrhythmics, Class I and III","/capita, US$ exchange rate",0.7
+25384,New Zealand,2016,10,"C01B-Antiarrhythmics, Class I and III","/capita, US$ purchasing power parity",0.7
+25385,New Zealand,2016,10,N-Nervous system,Million of national currency units,171.8
+25386,New Zealand,2016,10,Total pharmaceutical sales,Million of national currency units,1072.1
+25387,New Zealand,2016,10,C03-Diuretics,"/capita, US$ purchasing power parity",0.3
+25388,New Zealand,2016,10,C03-Diuretics,"Million US$, purchasing power parity",1.6
+25389,New Zealand,2016,10,C03-Diuretics,"/capita, US$ exchange rate",0.3
+25390,New Zealand,2016,10,N-Nervous system,"/capita, US$ purchasing power parity",25.3
+25391,New Zealand,2016,10,Total pharmaceutical sales,Million US$ at exchange rate,746.3
+25392,New Zealand,2016,10,Total pharmaceutical sales,"Million US$, purchasing power parity",744.0
+25393,New Zealand,2016,10,N-Nervous system,Million US$ at exchange rate,119.6
+25394,New Zealand,2016,10,N-Nervous system,"/capita, US$ exchange rate",25.4
+25395,New Zealand,2016,10,N-Nervous system,"Million US$, purchasing power parity",119.2
+25396,New Zealand,2016,10,J01-Antibacterials for systemic use,"/capita, US$ exchange rate",2.7
+25397,New Zealand,2016,10,J01-Antibacterials for systemic use,"/capita, US$ purchasing power parity",2.7
+25398,New Zealand,2016,10,J01-Antibacterials for systemic use,Million of national currency units,18.5
+25399,New Zealand,2016,10,J01-Antibacterials for systemic use,"Million US$, purchasing power parity",12.8
+25400,New Zealand,2016,10,J01-Antibacterials for systemic use,Million US$ at exchange rate,12.9
+25401,New Zealand,2016,10,J01-Antibacterials for systemic use,% of total sales,1.7
+25402,New Zealand,2016,10,C-Cardiovascular system,"Million US$, purchasing power parity",35.4
+25403,New Zealand,2016,10,C-Cardiovascular system,"/capita, US$ exchange rate",7.5
+25404,New Zealand,2016,10,C01A-Cardiac glycosides,"Million US$, purchasing power parity",0.2
+25405,New Zealand,2016,10,C01A-Cardiac glycosides,Million of national currency units,0.3
+25406,New Zealand,2016,10,C01A-Cardiac glycosides,Million US$ at exchange rate,0.2
+25407,New Zealand,2016,10,A10-Drugs used in diabetes,Million US$ at exchange rate,34.8
+25408,New Zealand,2016,10,A10-Drugs used in diabetes,"Million US$, purchasing power parity",34.7
+25409,New Zealand,2016,10,C02-Antihypertensives,% of total sales,0.2
+25410,New Zealand,2016,10,A10-Drugs used in diabetes,Million of national currency units,50.0
+25411,New Zealand,2016,10,C02-Antihypertensives,"/capita, US$ purchasing power parity",0.4
+25412,New Zealand,2016,10,C-Cardiovascular system,Million of national currency units,51.0
+25413,New Zealand,2016,10,C-Cardiovascular system,Million US$ at exchange rate,35.5
+25414,New Zealand,2016,10,A10-Drugs used in diabetes,"/capita, US$ exchange rate",7.4
+25415,New Zealand,2016,10,A10-Drugs used in diabetes,% of total sales,4.7
+25416,New Zealand,2016,10,A10-Drugs used in diabetes,"/capita, US$ purchasing power parity",7.4
+25417,New Zealand,2016,10,A-Alimentary tract and metabolism,"/capita, US$ exchange rate",13.5
+25418,New Zealand,2016,10,A-Alimentary tract and metabolism,"Million US$, purchasing power parity",63.2
+25419,New Zealand,2016,10,A-Alimentary tract and metabolism,% of total sales,8.5
+25420,New Zealand,2016,10,A-Alimentary tract and metabolism,"/capita, US$ purchasing power parity",13.4
+25421,New Zealand,2016,10,C02-Antihypertensives,"/capita, US$ exchange rate",0.4
+25422,New Zealand,2016,10,C02-Antihypertensives,"Million US$, purchasing power parity",1.8
+25423,New Zealand,2016,10,A-Alimentary tract and metabolism,Million US$ at exchange rate,63.4
+25424,New Zealand,2016,10,A-Alimentary tract and metabolism,Million of national currency units,91.1
+25425,New Zealand,2016,10,C01A-Cardiac glycosides,% of total sales,0.0
+25426,New Zealand,2016,10,C01A-Cardiac glycosides,"/capita, US$ exchange rate",0.0
+25427,New Zealand,2016,10,C01A-Cardiac glycosides,"/capita, US$ purchasing power parity",0.0
+25428,New Zealand,2015,10,N05C-Hypnotics and sedatives,Million of national currency units,1.7
+25429,New Zealand,2015,10,C08-Calcium channel blockers,Million of national currency units,8.2
+25430,New Zealand,2015,10,C10-Lipid modifying agents,"Million US$, purchasing power parity",11.8
+25431,New Zealand,2015,10,N05C-Hypnotics and sedatives,Million US$ at exchange rate,1.2
+25432,New Zealand,2015,10,C08-Calcium channel blockers,Million US$ at exchange rate,5.7
+25433,New Zealand,2015,10,C10-Lipid modifying agents,Million US$ at exchange rate,12.2
+25434,New Zealand,2015,10,Products not elsewhere classified,Million US$ at exchange rate,239.3
+25435,New Zealand,2015,10,Products not elsewhere classified,"Million US$, purchasing power parity",232.1
+25436,New Zealand,2015,10,Products not elsewhere classified,"/capita, US$ exchange rate",51.9
+25437,New Zealand,2015,10,C10-Lipid modifying agents,Million of national currency units,17.4
+25438,New Zealand,2015,10,N02-Analgesics,"/capita, US$ exchange rate",3.1
+25439,New Zealand,2015,10,N02-Analgesics,"/capita, US$ purchasing power parity",3.0
+25440,New Zealand,2015,10,N02-Analgesics,"Million US$, purchasing power parity",13.8
+25441,New Zealand,2015,10,Products not elsewhere classified,% of total sales,34.7
+25442,New Zealand,2015,10,Products not elsewhere classified,"/capita, US$ purchasing power parity",50.4
+25443,New Zealand,2015,10,N02-Analgesics,% of total sales,2.1
+25444,New Zealand,2015,10,C08-Calcium channel blockers,"/capita, US$ purchasing power parity",1.2
+25445,New Zealand,2015,10,C08-Calcium channel blockers,"Million US$, purchasing power parity",5.5
+25446,New Zealand,2015,10,C08-Calcium channel blockers,"/capita, US$ exchange rate",1.2
+25447,New Zealand,2015,10,C08-Calcium channel blockers,% of total sales,0.8
+25448,New Zealand,2015,10,N02-Analgesics,Million of national currency units,20.4
+25449,New Zealand,2015,10,N02-Analgesics,Million US$ at exchange rate,14.2
+25450,New Zealand,2015,10,G03-Sex hormones and modulators of the genital system,"/capita, US$ purchasing power parity",1.9
+25451,New Zealand,2015,10,G-Genito urinary system and sex hormones,Million US$ at exchange rate,15.6
+25452,New Zealand,2015,10,B-Blood and blood forming organs,Million of national currency units,99.0
+25453,New Zealand,2015,10,G-Genito urinary system and sex hormones,Million of national currency units,22.4
+25454,New Zealand,2015,10,G03-Sex hormones and modulators of the genital system,% of total sales,1.3
+25455,New Zealand,2015,10,B-Blood and blood forming organs,"Million US$, purchasing power parity",67.0
+25456,New Zealand,2015,10,B-Blood and blood forming organs,Million US$ at exchange rate,69.1
+25457,New Zealand,2015,10,G03-Sex hormones and modulators of the genital system,"Million US$, purchasing power parity",8.7
+25458,New Zealand,2015,10,G03-Sex hormones and modulators of the genital system,"/capita, US$ exchange rate",1.9
+25459,New Zealand,2015,10,G03-Sex hormones and modulators of the genital system,Million US$ at exchange rate,9.0
+25460,New Zealand,2015,10,C10-Lipid modifying agents,% of total sales,1.8
+25461,New Zealand,2015,10,G03-Sex hormones and modulators of the genital system,Million of national currency units,12.9
+25462,New Zealand,2015,10,N05C-Hypnotics and sedatives,% of total sales,0.2
+25463,New Zealand,2015,10,C10-Lipid modifying agents,"/capita, US$ exchange rate",2.6
+25464,New Zealand,2015,10,B-Blood and blood forming organs,% of total sales,10.0
+25465,New Zealand,2015,10,N05C-Hypnotics and sedatives,"Million US$, purchasing power parity",1.1
+25466,New Zealand,2015,10,N05C-Hypnotics and sedatives,"/capita, US$ exchange rate",0.3
+25467,New Zealand,2015,10,N05C-Hypnotics and sedatives,"/capita, US$ purchasing power parity",0.2
+25468,New Zealand,2015,10,B-Blood and blood forming organs,"/capita, US$ exchange rate",15.0
+25469,New Zealand,2015,10,B-Blood and blood forming organs,"/capita, US$ purchasing power parity",14.5
+25470,New Zealand,2015,10,G-Genito urinary system and sex hormones,"Million US$, purchasing power parity",15.2
+25471,New Zealand,2015,10,G-Genito urinary system and sex hormones,"/capita, US$ exchange rate",3.4
+25472,New Zealand,2015,10,C10-Lipid modifying agents,"/capita, US$ purchasing power parity",2.6
+25473,New Zealand,2015,10,Products not elsewhere classified,Million of national currency units,343.1
+25474,New Zealand,2015,10,J-Antiinfectives for systemic use,"Million US$, purchasing power parity",74.4
+25475,New Zealand,2015,10,J-Antiinfectives for systemic use,Million US$ at exchange rate,76.7
+25476,New Zealand,2015,10,C09-Agents acting on the Renin-Angiotensin system,% of total sales,1.4
+25477,New Zealand,2015,10,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ purchasing power parity",2.0
+25478,New Zealand,2015,10,R-Respiratory system,Million US$ at exchange rate,70.2
+25479,New Zealand,2015,10,R-Respiratory system,Million of national currency units,100.6
+25480,New Zealand,2015,10,J-Antiinfectives for systemic use,Million of national currency units,109.9
+25481,New Zealand,2015,10,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ purchasing power parity",0.9
+25482,New Zealand,2015,10,N05B-Anxiolytics,Million of national currency units,2.5
+25483,New Zealand,2015,10,R03-Drugs for obstructive airway diseases,Million of national currency units,90.5
+25484,New Zealand,2015,10,C09-Agents acting on the Renin-Angiotensin system,"Million US$, purchasing power parity",9.1
+25485,New Zealand,2015,10,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ exchange rate",2.0
+25486,New Zealand,2015,10,C09-Agents acting on the Renin-Angiotensin system,Million of national currency units,13.4
+25487,New Zealand,2015,10,C09-Agents acting on the Renin-Angiotensin system,Million US$ at exchange rate,9.4
+25488,New Zealand,2015,10,R-Respiratory system,"Million US$, purchasing power parity",68.1
+25489,New Zealand,2015,10,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ purchasing power parity",4.2
+25490,New Zealand,2015,10,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million of national currency units,6.3
+25491,New Zealand,2015,10,"H-Systemic hormonal preparations, excluding sex hormones and insulins",% of total sales,2.9
+25492,New Zealand,2015,10,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ exchange rate",4.3
+25493,New Zealand,2015,10,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million of national currency units,28.5
+25494,New Zealand,2015,10,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million US$ at exchange rate,19.9
+25495,New Zealand,2015,10,"H-Systemic hormonal preparations, excluding sex hormones and insulins","Million US$, purchasing power parity",19.3
+25496,New Zealand,2015,10,R-Respiratory system,"/capita, US$ purchasing power parity",14.8
+25497,New Zealand,2015,10,R-Respiratory system,% of total sales,10.2
+25498,New Zealand,2015,10,R-Respiratory system,"/capita, US$ exchange rate",15.2
+25499,New Zealand,2015,10,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"Million US$, purchasing power parity",4.3
+25500,New Zealand,2015,10,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million US$ at exchange rate,4.4
+25501,New Zealand,2015,10,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ exchange rate",1.0
+25502,New Zealand,2015,10,N06A-Antidepressants,Million US$ at exchange rate,10.8
+25503,New Zealand,2015,10,N06A-Antidepressants,"Million US$, purchasing power parity",10.5
+25504,New Zealand,2015,10,N06A-Antidepressants,Million of national currency units,15.6
+25505,New Zealand,2015,10,N06A-Antidepressants,% of total sales,1.6
+25506,New Zealand,2015,10,N05B-Anxiolytics,"Million US$, purchasing power parity",1.7
+25507,New Zealand,2015,10,N06A-Antidepressants,"/capita, US$ exchange rate",2.4
+25508,New Zealand,2015,10,N06A-Antidepressants,"/capita, US$ purchasing power parity",2.3
+25509,New Zealand,2015,10,G-Genito urinary system and sex hormones,"/capita, US$ purchasing power parity",3.3
+25510,New Zealand,2015,10,G-Genito urinary system and sex hormones,% of total sales,2.3
+25511,New Zealand,2015,10,A02A-Antacids,Million US$ at exchange rate,0.3
+25512,New Zealand,2015,10,A02A-Antacids,Million of national currency units,0.4
+25513,New Zealand,2015,10,N05B-Anxiolytics,"/capita, US$ purchasing power parity",0.4
+25514,New Zealand,2015,10,N05B-Anxiolytics,"/capita, US$ exchange rate",0.4
+25515,New Zealand,2015,10,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),% of total sales,0.6
+25516,New Zealand,2015,10,N05B-Anxiolytics,% of total sales,0.3
+25517,New Zealand,2015,10,R03-Drugs for obstructive airway diseases,% of total sales,9.2
+25518,New Zealand,2015,10,J-Antiinfectives for systemic use,"/capita, US$ exchange rate",16.6
+25519,New Zealand,2015,10,R03-Drugs for obstructive airway diseases,"/capita, US$ purchasing power parity",13.3
+25520,New Zealand,2015,10,R03-Drugs for obstructive airway diseases,"Million US$, purchasing power parity",61.2
+25521,New Zealand,2015,10,R03-Drugs for obstructive airway diseases,Million US$ at exchange rate,63.1
+25522,New Zealand,2015,10,R03-Drugs for obstructive airway diseases,"/capita, US$ exchange rate",13.7
+25523,New Zealand,2015,10,J-Antiinfectives for systemic use,"/capita, US$ purchasing power parity",16.1
+25524,New Zealand,2015,10,A02A-Antacids,"/capita, US$ exchange rate",0.1
+25525,New Zealand,2015,10,A02A-Antacids,"Million US$, purchasing power parity",0.3
+25526,New Zealand,2015,10,N05B-Anxiolytics,Million US$ at exchange rate,1.8
+25527,New Zealand,2015,10,J-Antiinfectives for systemic use,% of total sales,11.1
+25528,New Zealand,2015,10,A02A-Antacids,"/capita, US$ purchasing power parity",0.1
+25529,New Zealand,2015,10,A02A-Antacids,% of total sales,0.0
+25530,New Zealand,2015,10,C07-Beta blocking agents,Million of national currency units,14.1
+25531,New Zealand,2015,10,C-Cardiovascular system,"/capita, US$ purchasing power parity",9.8
+25532,New Zealand,2015,10,C07-Beta blocking agents,Million US$ at exchange rate,9.9
+25533,New Zealand,2015,10,C07-Beta blocking agents,"/capita, US$ exchange rate",2.1
+25534,New Zealand,2015,10,C07-Beta blocking agents,"Million US$, purchasing power parity",9.6
+25535,New Zealand,2015,10,M-Musculo-skeletal system,% of total sales,2.2
+25536,New Zealand,2015,10,C03-Diuretics,Million US$ at exchange rate,1.5
+25537,New Zealand,2015,10,M-Musculo-skeletal system,"/capita, US$ purchasing power parity",3.2
+25538,New Zealand,2015,10,C-Cardiovascular system,% of total sales,6.7
+25539,New Zealand,2015,10,M-Musculo-skeletal system,"/capita, US$ exchange rate",3.3
+25540,New Zealand,2015,10,C07-Beta blocking agents,"/capita, US$ purchasing power parity",2.1
+25541,New Zealand,2015,10,M01A-Antiinflammatory and antirheumatic products non-steroids,Million US$ at exchange rate,5.4
+25542,New Zealand,2015,10,M01A-Antiinflammatory and antirheumatic products non-steroids,"Million US$, purchasing power parity",5.2
+25543,New Zealand,2015,10,C03-Diuretics,% of total sales,0.2
+25544,New Zealand,2015,10,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ exchange rate",1.2
+25545,New Zealand,2015,10,M-Musculo-skeletal system,Million of national currency units,21.9
+25546,New Zealand,2015,10,C02-Antihypertensives,Million US$ at exchange rate,2.5
+25547,New Zealand,2015,10,M01A-Antiinflammatory and antirheumatic products non-steroids,Million of national currency units,7.7
+25548,New Zealand,2015,10,M-Musculo-skeletal system,"Million US$, purchasing power parity",14.8
+25549,New Zealand,2015,10,C07-Beta blocking agents,% of total sales,1.4
+25550,New Zealand,2015,10,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ purchasing power parity",1.1
+25551,New Zealand,2015,10,M-Musculo-skeletal system,Million US$ at exchange rate,15.3
+25552,New Zealand,2015,10,M01A-Antiinflammatory and antirheumatic products non-steroids,% of total sales,0.8
+25553,New Zealand,2015,10,"C01B-Antiarrhythmics, Class I and III",Million of national currency units,4.6
+25554,New Zealand,2015,10,"C01B-Antiarrhythmics, Class I and III",Million US$ at exchange rate,3.2
+25555,New Zealand,2015,10,Total pharmaceutical sales,"/capita, US$ exchange rate",149.4
+25556,New Zealand,2015,10,N-Nervous system,% of total sales,17.0
+25557,New Zealand,2015,10,Total pharmaceutical sales,"/capita, US$ purchasing power parity",145.0
+25558,New Zealand,2015,10,"C01B-Antiarrhythmics, Class I and III",% of total sales,0.5
+25559,New Zealand,2015,10,C02-Antihypertensives,Million of national currency units,3.5
+25560,New Zealand,2015,10,"C01B-Antiarrhythmics, Class I and III","/capita, US$ exchange rate",0.7
+25561,New Zealand,2015,10,"C01B-Antiarrhythmics, Class I and III","/capita, US$ purchasing power parity",0.7
+25562,New Zealand,2015,10,"C01B-Antiarrhythmics, Class I and III","Million US$, purchasing power parity",3.1
+25563,New Zealand,2015,10,N-Nervous system,Million of national currency units,167.5
+25564,New Zealand,2015,10,Total pharmaceutical sales,Million of national currency units,987.6
+25565,New Zealand,2015,10,C03-Diuretics,"/capita, US$ purchasing power parity",0.3
+25566,New Zealand,2015,10,C03-Diuretics,"Million US$, purchasing power parity",1.5
+25567,New Zealand,2015,10,C03-Diuretics,"/capita, US$ exchange rate",0.3
+25568,New Zealand,2015,10,N-Nervous system,"/capita, US$ purchasing power parity",24.6
+25569,New Zealand,2015,10,Total pharmaceutical sales,Million US$ at exchange rate,688.7
+25570,New Zealand,2015,10,Total pharmaceutical sales,"Million US$, purchasing power parity",668.2
+25571,New Zealand,2015,10,N-Nervous system,Million US$ at exchange rate,116.8
+25572,New Zealand,2015,10,N-Nervous system,"Million US$, purchasing power parity",113.4
+25573,New Zealand,2015,10,N-Nervous system,"/capita, US$ exchange rate",25.3
+25574,New Zealand,2015,10,C03-Diuretics,Million of national currency units,2.2
+25575,New Zealand,2015,10,J01-Antibacterials for systemic use,"/capita, US$ exchange rate",2.6
+25576,New Zealand,2015,10,J01-Antibacterials for systemic use,"/capita, US$ purchasing power parity",2.5
+25577,New Zealand,2015,10,J01-Antibacterials for systemic use,Million of national currency units,17.0
+25578,New Zealand,2015,10,J01-Antibacterials for systemic use,Million US$ at exchange rate,11.9
+25579,New Zealand,2015,10,J01-Antibacterials for systemic use,"Million US$, purchasing power parity",11.5
+25580,New Zealand,2015,10,C-Cardiovascular system,"Million US$, purchasing power parity",45.1
+25581,New Zealand,2015,10,C-Cardiovascular system,"/capita, US$ exchange rate",10.1
+25582,New Zealand,2015,10,C01A-Cardiac glycosides,"Million US$, purchasing power parity",0.2
+25583,New Zealand,2015,10,J01-Antibacterials for systemic use,% of total sales,1.7
+25584,New Zealand,2015,10,C01A-Cardiac glycosides,Million of national currency units,0.4
+25585,New Zealand,2015,10,C01A-Cardiac glycosides,Million US$ at exchange rate,0.2
+25586,New Zealand,2015,10,A10-Drugs used in diabetes,Million US$ at exchange rate,32.3
+25587,New Zealand,2015,10,A10-Drugs used in diabetes,"Million US$, purchasing power parity",31.4
+25588,New Zealand,2015,10,A10-Drugs used in diabetes,Million of national currency units,46.4
+25589,New Zealand,2015,10,C02-Antihypertensives,% of total sales,0.4
+25590,New Zealand,2015,10,C02-Antihypertensives,"/capita, US$ purchasing power parity",0.5
+25591,New Zealand,2015,10,C-Cardiovascular system,Million of national currency units,66.6
+25592,New Zealand,2015,10,C-Cardiovascular system,Million US$ at exchange rate,46.5
+25593,New Zealand,2015,10,A10-Drugs used in diabetes,"/capita, US$ exchange rate",7.0
+25594,New Zealand,2015,10,A10-Drugs used in diabetes,"/capita, US$ purchasing power parity",6.8
+25595,New Zealand,2015,10,A10-Drugs used in diabetes,% of total sales,4.7
+25596,New Zealand,2015,10,A-Alimentary tract and metabolism,"/capita, US$ exchange rate",13.6
+25597,New Zealand,2015,10,A-Alimentary tract and metabolism,"Million US$, purchasing power parity",61.0
+25598,New Zealand,2015,10,A-Alimentary tract and metabolism,% of total sales,9.1
+25599,New Zealand,2015,10,A-Alimentary tract and metabolism,"/capita, US$ purchasing power parity",13.2
+25600,New Zealand,2015,10,C02-Antihypertensives,"/capita, US$ exchange rate",0.5
+25601,New Zealand,2015,10,C02-Antihypertensives,"Million US$, purchasing power parity",2.4
+25602,New Zealand,2015,10,A-Alimentary tract and metabolism,Million US$ at exchange rate,62.9
+25603,New Zealand,2015,10,A-Alimentary tract and metabolism,Million of national currency units,90.2
+25604,New Zealand,2015,10,C01A-Cardiac glycosides,% of total sales,0.0
+25605,New Zealand,2015,10,C01A-Cardiac glycosides,"/capita, US$ exchange rate",0.1
+25606,New Zealand,2015,10,C01A-Cardiac glycosides,"/capita, US$ purchasing power parity",0.1
+25607,New Zealand,2014,10,N05C-Hypnotics and sedatives,Million of national currency units,1.6
+25608,New Zealand,2014,10,C10-Lipid modifying agents,"Million US$, purchasing power parity",12.1
+25609,New Zealand,2014,10,N05C-Hypnotics and sedatives,Million US$ at exchange rate,1.3
+25610,New Zealand,2014,10,C08-Calcium channel blockers,Million US$ at exchange rate,6.8
+25611,New Zealand,2014,10,C10-Lipid modifying agents,Million US$ at exchange rate,14.5
+25612,New Zealand,2014,10,Products not elsewhere classified,Million US$ at exchange rate,268.0
+25613,New Zealand,2014,10,Products not elsewhere classified,"/capita, US$ exchange rate",59.3
+25614,New Zealand,2014,10,Products not elsewhere classified,"Million US$, purchasing power parity",224.3
+25615,New Zealand,2014,10,C08-Calcium channel blockers,Million of national currency units,8.3
+25616,New Zealand,2014,10,C10-Lipid modifying agents,Million of national currency units,17.5
+25617,New Zealand,2014,10,C08-Calcium channel blockers,"Million US$, purchasing power parity",5.7
+25618,New Zealand,2014,10,N02-Analgesics,"/capita, US$ exchange rate",3.9
+25619,New Zealand,2014,10,N02-Analgesics,"/capita, US$ purchasing power parity",3.3
+25620,New Zealand,2014,10,N02-Analgesics,"Million US$, purchasing power parity",14.7
+25621,New Zealand,2014,10,Products not elsewhere classified,% of total sales,33.7
+25622,New Zealand,2014,10,Products not elsewhere classified,"/capita, US$ purchasing power parity",49.7
+25623,New Zealand,2014,10,N02-Analgesics,% of total sales,2.2
+25624,New Zealand,2014,10,C08-Calcium channel blockers,"/capita, US$ purchasing power parity",1.3
+25625,New Zealand,2014,10,C08-Calcium channel blockers,"/capita, US$ exchange rate",1.5
+25626,New Zealand,2014,10,N02-Analgesics,Million of national currency units,21.2
+25627,New Zealand,2014,10,N02-Analgesics,Million US$ at exchange rate,17.6
+25628,New Zealand,2014,10,C08-Calcium channel blockers,% of total sales,0.9
+25629,New Zealand,2014,10,G-Genito urinary system and sex hormones,Million US$ at exchange rate,17.5
+25630,New Zealand,2014,10,B-Blood and blood forming organs,Million of national currency units,87.1
+25631,New Zealand,2014,10,G03-Sex hormones and modulators of the genital system,% of total sales,1.2
+25632,New Zealand,2014,10,G-Genito urinary system and sex hormones,Million of national currency units,21.1
+25633,New Zealand,2014,10,B-Blood and blood forming organs,"Million US$, purchasing power parity",60.5
+25634,New Zealand,2014,10,B-Blood and blood forming organs,Million US$ at exchange rate,72.3
+25635,New Zealand,2014,10,G03-Sex hormones and modulators of the genital system,"Million US$, purchasing power parity",7.7
+25636,New Zealand,2014,10,G03-Sex hormones and modulators of the genital system,"/capita, US$ purchasing power parity",1.7
+25637,New Zealand,2014,10,G03-Sex hormones and modulators of the genital system,"/capita, US$ exchange rate",2.0
+25638,New Zealand,2014,10,C10-Lipid modifying agents,% of total sales,1.8
+25639,New Zealand,2014,10,G03-Sex hormones and modulators of the genital system,Million US$ at exchange rate,9.2
+25640,New Zealand,2014,10,G03-Sex hormones and modulators of the genital system,Million of national currency units,11.1
+25641,New Zealand,2014,10,N05C-Hypnotics and sedatives,% of total sales,0.2
+25642,New Zealand,2014,10,C10-Lipid modifying agents,"/capita, US$ exchange rate",3.2
+25643,New Zealand,2014,10,B-Blood and blood forming organs,% of total sales,9.1
+25644,New Zealand,2014,10,N05C-Hypnotics and sedatives,"Million US$, purchasing power parity",1.1
+25645,New Zealand,2014,10,N05C-Hypnotics and sedatives,"/capita, US$ exchange rate",0.3
+25646,New Zealand,2014,10,N05C-Hypnotics and sedatives,"/capita, US$ purchasing power parity",0.2
+25647,New Zealand,2014,10,B-Blood and blood forming organs,"/capita, US$ exchange rate",16.0
+25648,New Zealand,2014,10,B-Blood and blood forming organs,"/capita, US$ purchasing power parity",13.4
+25649,New Zealand,2014,10,G-Genito urinary system and sex hormones,"/capita, US$ exchange rate",3.9
+25650,New Zealand,2014,10,G-Genito urinary system and sex hormones,"Million US$, purchasing power parity",14.6
+25651,New Zealand,2014,10,C10-Lipid modifying agents,"/capita, US$ purchasing power parity",2.7
+25652,New Zealand,2014,10,Products not elsewhere classified,Million of national currency units,323.1
+25653,New Zealand,2014,10,J-Antiinfectives for systemic use,"Million US$, purchasing power parity",70.6
+25654,New Zealand,2014,10,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ purchasing power parity",2.3
+25655,New Zealand,2014,10,C09-Agents acting on the Renin-Angiotensin system,% of total sales,1.5
+25656,New Zealand,2014,10,J-Antiinfectives for systemic use,Million US$ at exchange rate,84.4
+25657,New Zealand,2014,10,R-Respiratory system,Million US$ at exchange rate,76.4
+25658,New Zealand,2014,10,J-Antiinfectives for systemic use,Million of national currency units,101.7
+25659,New Zealand,2014,10,R-Respiratory system,Million of national currency units,92.1
+25660,New Zealand,2014,10,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ purchasing power parity",1.1
+25661,New Zealand,2014,10,N05B-Anxiolytics,Million of national currency units,1.3
+25662,New Zealand,2014,10,R03-Drugs for obstructive airway diseases,Million of national currency units,84.7
+25663,New Zealand,2014,10,C09-Agents acting on the Renin-Angiotensin system,Million of national currency units,14.7
+25664,New Zealand,2014,10,C09-Agents acting on the Renin-Angiotensin system,"Million US$, purchasing power parity",10.2
+25665,New Zealand,2014,10,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ exchange rate",2.7
+25666,New Zealand,2014,10,C09-Agents acting on the Renin-Angiotensin system,Million US$ at exchange rate,12.2
+25667,New Zealand,2014,10,R-Respiratory system,"Million US$, purchasing power parity",63.9
+25668,New Zealand,2014,10,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ purchasing power parity",3.8
+25669,New Zealand,2014,10,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million of national currency units,7.0
+25670,New Zealand,2014,10,"H-Systemic hormonal preparations, excluding sex hormones and insulins",% of total sales,2.5
+25671,New Zealand,2014,10,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ exchange rate",4.5
+25672,New Zealand,2014,10,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million of national currency units,24.5
+25673,New Zealand,2014,10,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million US$ at exchange rate,20.3
+25674,New Zealand,2014,10,"H-Systemic hormonal preparations, excluding sex hormones and insulins","Million US$, purchasing power parity",17.0
+25675,New Zealand,2014,10,R-Respiratory system,"/capita, US$ purchasing power parity",14.2
+25676,New Zealand,2014,10,R-Respiratory system,% of total sales,9.6
+25677,New Zealand,2014,10,R-Respiratory system,"/capita, US$ exchange rate",16.9
+25678,New Zealand,2014,10,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"Million US$, purchasing power parity",4.8
+25679,New Zealand,2014,10,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million US$ at exchange rate,5.8
+25680,New Zealand,2014,10,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ exchange rate",1.3
+25681,New Zealand,2014,10,N06A-Antidepressants,Million US$ at exchange rate,14.5
+25682,New Zealand,2014,10,N06A-Antidepressants,"Million US$, purchasing power parity",12.1
+25683,New Zealand,2014,10,N06A-Antidepressants,Million of national currency units,17.5
+25684,New Zealand,2014,10,N06A-Antidepressants,% of total sales,1.8
+25685,New Zealand,2014,10,N06A-Antidepressants,"/capita, US$ purchasing power parity",2.7
+25686,New Zealand,2014,10,N06A-Antidepressants,"/capita, US$ exchange rate",3.2
+25687,New Zealand,2014,10,N05B-Anxiolytics,"Million US$, purchasing power parity",0.9
+25688,New Zealand,2014,10,N05B-Anxiolytics,"/capita, US$ exchange rate",0.2
+25689,New Zealand,2014,10,G-Genito urinary system and sex hormones,"/capita, US$ purchasing power parity",3.2
+25690,New Zealand,2014,10,G-Genito urinary system and sex hormones,% of total sales,2.2
+25691,New Zealand,2014,10,A02A-Antacids,Million US$ at exchange rate,0.2
+25692,New Zealand,2014,10,A02A-Antacids,Million of national currency units,0.3
+25693,New Zealand,2014,10,N05B-Anxiolytics,"/capita, US$ purchasing power parity",0.2
+25694,New Zealand,2014,10,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),% of total sales,0.7
+25695,New Zealand,2014,10,N05B-Anxiolytics,% of total sales,0.1
+25696,New Zealand,2014,10,R03-Drugs for obstructive airway diseases,% of total sales,8.8
+25697,New Zealand,2014,10,J-Antiinfectives for systemic use,"/capita, US$ exchange rate",18.7
+25698,New Zealand,2014,10,R03-Drugs for obstructive airway diseases,"/capita, US$ purchasing power parity",13.0
+25699,New Zealand,2014,10,R03-Drugs for obstructive airway diseases,"Million US$, purchasing power parity",58.8
+25700,New Zealand,2014,10,R03-Drugs for obstructive airway diseases,Million US$ at exchange rate,70.3
+25701,New Zealand,2014,10,R03-Drugs for obstructive airway diseases,"/capita, US$ exchange rate",15.6
+25702,New Zealand,2014,10,J-Antiinfectives for systemic use,"/capita, US$ purchasing power parity",15.6
+25703,New Zealand,2014,10,A02A-Antacids,"/capita, US$ exchange rate",0.1
+25704,New Zealand,2014,10,N05B-Anxiolytics,Million US$ at exchange rate,1.1
+25705,New Zealand,2014,10,A02A-Antacids,"Million US$, purchasing power parity",0.2
+25706,New Zealand,2014,10,J-Antiinfectives for systemic use,% of total sales,10.6
+25707,New Zealand,2014,10,A02A-Antacids,"/capita, US$ purchasing power parity",0.0
+25708,New Zealand,2014,10,A02A-Antacids,% of total sales,0.0
+25709,New Zealand,2014,10,C07-Beta blocking agents,Million of national currency units,14.7
+25710,New Zealand,2014,10,C07-Beta blocking agents,Million US$ at exchange rate,12.2
+25711,New Zealand,2014,10,C-Cardiovascular system,"/capita, US$ purchasing power parity",10.7
+25712,New Zealand,2014,10,C07-Beta blocking agents,"/capita, US$ exchange rate",2.7
+25713,New Zealand,2014,10,C07-Beta blocking agents,"Million US$, purchasing power parity",10.2
+25714,New Zealand,2014,10,M-Musculo-skeletal system,% of total sales,2.6
+25715,New Zealand,2014,10,C03-Diuretics,Million US$ at exchange rate,1.8
+25716,New Zealand,2014,10,M-Musculo-skeletal system,"/capita, US$ purchasing power parity",3.8
+25717,New Zealand,2014,10,C-Cardiovascular system,% of total sales,7.3
+25718,New Zealand,2014,10,M-Musculo-skeletal system,"/capita, US$ exchange rate",4.6
+25719,New Zealand,2014,10,M01A-Antiinflammatory and antirheumatic products non-steroids,"Million US$, purchasing power parity",5.2
+25720,New Zealand,2014,10,M01A-Antiinflammatory and antirheumatic products non-steroids,Million US$ at exchange rate,6.2
+25721,New Zealand,2014,10,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ exchange rate",1.4
+25722,New Zealand,2014,10,M-Musculo-skeletal system,Million of national currency units,24.8
+25723,New Zealand,2014,10,C02-Antihypertensives,Million US$ at exchange rate,3.2
+25724,New Zealand,2014,10,M01A-Antiinflammatory and antirheumatic products non-steroids,Million of national currency units,7.5
+25725,New Zealand,2014,10,C07-Beta blocking agents,"/capita, US$ purchasing power parity",2.3
+25726,New Zealand,2014,10,M-Musculo-skeletal system,"Million US$, purchasing power parity",17.2
+25727,New Zealand,2014,10,C07-Beta blocking agents,% of total sales,1.5
+25728,New Zealand,2014,10,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ purchasing power parity",1.1
+25729,New Zealand,2014,10,M01A-Antiinflammatory and antirheumatic products non-steroids,% of total sales,0.8
+25730,New Zealand,2014,10,M-Musculo-skeletal system,Million US$ at exchange rate,20.6
+25731,New Zealand,2014,10,"C01B-Antiarrhythmics, Class I and III",Million of national currency units,5.1
+25732,New Zealand,2014,10,"C01B-Antiarrhythmics, Class I and III",Million US$ at exchange rate,4.2
+25733,New Zealand,2014,10,Total pharmaceutical sales,"/capita, US$ exchange rate",176.2
+25734,New Zealand,2014,10,Total pharmaceutical sales,"/capita, US$ purchasing power parity",147.5
+25735,New Zealand,2014,10,N-Nervous system,% of total sales,14.2
+25736,New Zealand,2014,10,"C01B-Antiarrhythmics, Class I and III","Million US$, purchasing power parity",3.5
+25737,New Zealand,2014,10,"C01B-Antiarrhythmics, Class I and III",% of total sales,0.5
+25738,New Zealand,2014,10,C02-Antihypertensives,Million of national currency units,3.9
+25739,New Zealand,2014,10,"C01B-Antiarrhythmics, Class I and III","/capita, US$ exchange rate",0.9
+25740,New Zealand,2014,10,"C01B-Antiarrhythmics, Class I and III","/capita, US$ purchasing power parity",0.8
+25741,New Zealand,2014,10,N-Nervous system,Million of national currency units,136.0
+25742,New Zealand,2014,10,Total pharmaceutical sales,Million of national currency units,959.5
+25743,New Zealand,2014,10,C03-Diuretics,"Million US$, purchasing power parity",1.5
+25744,New Zealand,2014,10,C03-Diuretics,"/capita, US$ purchasing power parity",0.3
+25745,New Zealand,2014,10,C03-Diuretics,"/capita, US$ exchange rate",0.4
+25746,New Zealand,2014,10,N-Nervous system,"/capita, US$ purchasing power parity",20.9
+25747,New Zealand,2014,10,Total pharmaceutical sales,Million US$ at exchange rate,796.0
+25748,New Zealand,2014,10,Total pharmaceutical sales,"Million US$, purchasing power parity",666.0
+25749,New Zealand,2014,10,N-Nervous system,Million US$ at exchange rate,112.9
+25750,New Zealand,2014,10,N-Nervous system,"Million US$, purchasing power parity",94.4
+25751,New Zealand,2014,10,N-Nervous system,"/capita, US$ exchange rate",25.0
+25752,New Zealand,2014,10,J01-Antibacterials for systemic use,"/capita, US$ exchange rate",2.8
+25753,New Zealand,2014,10,J01-Antibacterials for systemic use,"/capita, US$ purchasing power parity",2.3
+25754,New Zealand,2014,10,C03-Diuretics,Million of national currency units,2.2
+25755,New Zealand,2014,10,J01-Antibacterials for systemic use,Million of national currency units,15.0
+25756,New Zealand,2014,10,J01-Antibacterials for systemic use,Million US$ at exchange rate,12.4
+25757,New Zealand,2014,10,J01-Antibacterials for systemic use,"Million US$, purchasing power parity",10.4
+25758,New Zealand,2014,10,J01-Antibacterials for systemic use,% of total sales,1.6
+25759,New Zealand,2014,10,C-Cardiovascular system,"/capita, US$ exchange rate",12.8
+25760,New Zealand,2014,10,C-Cardiovascular system,"Million US$, purchasing power parity",48.5
+25761,New Zealand,2014,10,C01A-Cardiac glycosides,"Million US$, purchasing power parity",0.3
+25762,New Zealand,2014,10,C01A-Cardiac glycosides,Million of national currency units,0.4
+25763,New Zealand,2014,10,C01A-Cardiac glycosides,Million US$ at exchange rate,0.3
+25764,New Zealand,2014,10,A10-Drugs used in diabetes,Million US$ at exchange rate,35.3
+25765,New Zealand,2014,10,A10-Drugs used in diabetes,"Million US$, purchasing power parity",29.5
+25766,New Zealand,2014,10,C02-Antihypertensives,% of total sales,0.4
+25767,New Zealand,2014,10,C02-Antihypertensives,"/capita, US$ purchasing power parity",0.6
+25768,New Zealand,2014,10,A10-Drugs used in diabetes,Million of national currency units,42.5
+25769,New Zealand,2014,10,C-Cardiovascular system,Million of national currency units,69.9
+25770,New Zealand,2014,10,C-Cardiovascular system,Million US$ at exchange rate,58.0
+25771,New Zealand,2014,10,A10-Drugs used in diabetes,"/capita, US$ exchange rate",7.8
+25772,New Zealand,2014,10,A10-Drugs used in diabetes,"/capita, US$ purchasing power parity",6.5
+25773,New Zealand,2014,10,A10-Drugs used in diabetes,% of total sales,4.4
+25774,New Zealand,2014,10,C01A-Cardiac glycosides,"/capita, US$ exchange rate",0.1
+25775,New Zealand,2014,10,A-Alimentary tract and metabolism,"/capita, US$ exchange rate",14.5
+25776,New Zealand,2014,10,A-Alimentary tract and metabolism,"Million US$, purchasing power parity",55.0
+25777,New Zealand,2014,10,A-Alimentary tract and metabolism,% of total sales,8.3
+25778,New Zealand,2014,10,A-Alimentary tract and metabolism,"/capita, US$ purchasing power parity",12.2
+25779,New Zealand,2014,10,C02-Antihypertensives,"/capita, US$ exchange rate",0.7
+25780,New Zealand,2014,10,C02-Antihypertensives,"Million US$, purchasing power parity",2.7
+25781,New Zealand,2014,10,A-Alimentary tract and metabolism,Million US$ at exchange rate,65.7
+25782,New Zealand,2014,10,A-Alimentary tract and metabolism,Million of national currency units,79.2
+25783,New Zealand,2014,10,C03-Diuretics,% of total sales,0.2
+25784,New Zealand,2014,10,C01A-Cardiac glycosides,"/capita, US$ purchasing power parity",0.1
+25785,New Zealand,2014,10,C01A-Cardiac glycosides,% of total sales,0.0
+25786,New Zealand,2013,9,C10-Lipid modifying agents,Million US$ at exchange rate,24.7
+25787,New Zealand,2013,9,N05C-Hypnotics and sedatives,Million of national currency units,1.5
+25788,New Zealand,2013,9,N05C-Hypnotics and sedatives,Million US$ at exchange rate,1.3
+25789,New Zealand,2013,9,C08-Calcium channel blockers,Million US$ at exchange rate,7.8
+25790,New Zealand,2013,9,Products not elsewhere classified,"/capita, US$ exchange rate",57.5
+25791,New Zealand,2013,9,C10-Lipid modifying agents,"Million US$, purchasing power parity",20.8
+25792,New Zealand,2013,9,Products not elsewhere classified,Million US$ at exchange rate,255.2
+25793,New Zealand,2013,9,C08-Calcium channel blockers,Million of national currency units,9.6
+25794,New Zealand,2013,9,C10-Lipid modifying agents,Million of national currency units,30.1
+25795,New Zealand,2013,9,Products not elsewhere classified,"Million US$, purchasing power parity",215.2
+25796,New Zealand,2013,9,N02-Analgesics,"/capita, US$ exchange rate",4.4
+25797,New Zealand,2013,9,N02-Analgesics,"/capita, US$ purchasing power parity",3.7
+25798,New Zealand,2013,9,N02-Analgesics,"Million US$, purchasing power parity",16.5
+25799,New Zealand,2013,9,Products not elsewhere classified,% of total sales,33.7
+25800,New Zealand,2013,9,N02-Analgesics,% of total sales,2.6
+25801,New Zealand,2013,9,Products not elsewhere classified,"/capita, US$ purchasing power parity",48.5
+25802,New Zealand,2013,9,C08-Calcium channel blockers,"Million US$, purchasing power parity",6.6
+25803,New Zealand,2013,9,C08-Calcium channel blockers,"/capita, US$ purchasing power parity",1.5
+25804,New Zealand,2013,9,C08-Calcium channel blockers,"/capita, US$ exchange rate",1.8
+25805,New Zealand,2013,9,C08-Calcium channel blockers,% of total sales,1.0
+25806,New Zealand,2013,9,N02-Analgesics,Million of national currency units,23.9
+25807,New Zealand,2013,9,N02-Analgesics,Million US$ at exchange rate,19.6
+25808,New Zealand,2013,9,G-Genito urinary system and sex hormones,Million US$ at exchange rate,17.2
+25809,New Zealand,2013,9,B-Blood and blood forming organs,Million of national currency units,48.2
+25810,New Zealand,2013,9,G03-Sex hormones and modulators of the genital system,% of total sales,1.2
+25811,New Zealand,2013,9,G-Genito urinary system and sex hormones,Million of national currency units,21.0
+25812,New Zealand,2013,9,B-Blood and blood forming organs,"Million US$, purchasing power parity",33.3
+25813,New Zealand,2013,9,B-Blood and blood forming organs,Million US$ at exchange rate,39.5
+25814,New Zealand,2013,9,G03-Sex hormones and modulators of the genital system,"Million US$, purchasing power parity",7.9
+25815,New Zealand,2013,9,G03-Sex hormones and modulators of the genital system,"/capita, US$ purchasing power parity",1.8
+25816,New Zealand,2013,9,G03-Sex hormones and modulators of the genital system,"/capita, US$ exchange rate",2.1
+25817,New Zealand,2013,9,C10-Lipid modifying agents,% of total sales,3.3
+25818,New Zealand,2013,9,G03-Sex hormones and modulators of the genital system,Million US$ at exchange rate,9.4
+25819,New Zealand,2013,9,G03-Sex hormones and modulators of the genital system,Million of national currency units,11.4
+25820,New Zealand,2013,9,N05C-Hypnotics and sedatives,% of total sales,0.2
+25821,New Zealand,2013,9,C10-Lipid modifying agents,"/capita, US$ exchange rate",5.6
+25822,New Zealand,2013,9,B-Blood and blood forming organs,% of total sales,5.2
+25823,New Zealand,2013,9,N05C-Hypnotics and sedatives,"Million US$, purchasing power parity",1.1
+25824,New Zealand,2013,9,N05C-Hypnotics and sedatives,"/capita, US$ exchange rate",0.3
+25825,New Zealand,2013,9,B-Blood and blood forming organs,"/capita, US$ purchasing power parity",7.5
+25826,New Zealand,2013,9,B-Blood and blood forming organs,"/capita, US$ exchange rate",8.9
+25827,New Zealand,2013,9,G-Genito urinary system and sex hormones,"/capita, US$ exchange rate",3.9
+25828,New Zealand,2013,9,G-Genito urinary system and sex hormones,"Million US$, purchasing power parity",14.5
+25829,New Zealand,2013,9,C10-Lipid modifying agents,"/capita, US$ purchasing power parity",4.7
+25830,New Zealand,2013,9,Products not elsewhere classified,Million of national currency units,311.2
+25831,New Zealand,2013,9,N05C-Hypnotics and sedatives,"/capita, US$ purchasing power parity",0.2
+25832,New Zealand,2013,9,J-Antiinfectives for systemic use,"Million US$, purchasing power parity",67.9
+25833,New Zealand,2013,9,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ purchasing power parity",2.8
+25834,New Zealand,2013,9,C09-Agents acting on the Renin-Angiotensin system,% of total sales,1.9
+25835,New Zealand,2013,9,J-Antiinfectives for systemic use,Million US$ at exchange rate,80.5
+25836,New Zealand,2013,9,R-Respiratory system,Million US$ at exchange rate,73.8
+25837,New Zealand,2013,9,J-Antiinfectives for systemic use,Million of national currency units,98.1
+25838,New Zealand,2013,9,R-Respiratory system,Million of national currency units,90.0
+25839,New Zealand,2013,9,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),% of total sales,0.7
+25840,New Zealand,2013,9,N05B-Anxiolytics,Million of national currency units,1.2
+25841,New Zealand,2013,9,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ purchasing power parity",1.1
+25842,New Zealand,2013,9,R03-Drugs for obstructive airway diseases,Million of national currency units,79.6
+25843,New Zealand,2013,9,N05B-Anxiolytics,Million US$ at exchange rate,1.0
+25844,New Zealand,2013,9,C09-Agents acting on the Renin-Angiotensin system,Million of national currency units,17.8
+25845,New Zealand,2013,9,C09-Agents acting on the Renin-Angiotensin system,"Million US$, purchasing power parity",12.3
+25846,New Zealand,2013,9,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ exchange rate",3.3
+25847,New Zealand,2013,9,C09-Agents acting on the Renin-Angiotensin system,Million US$ at exchange rate,14.6
+25848,New Zealand,2013,9,R-Respiratory system,"Million US$, purchasing power parity",62.3
+25849,New Zealand,2013,9,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ purchasing power parity",3.5
+25850,New Zealand,2013,9,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million of national currency units,6.9
+25851,New Zealand,2013,9,"H-Systemic hormonal preparations, excluding sex hormones and insulins",% of total sales,2.5
+25852,New Zealand,2013,9,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ exchange rate",4.2
+25853,New Zealand,2013,9,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million US$ at exchange rate,18.6
+25854,New Zealand,2013,9,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million of national currency units,22.7
+25855,New Zealand,2013,9,"H-Systemic hormonal preparations, excluding sex hormones and insulins","Million US$, purchasing power parity",15.7
+25856,New Zealand,2013,9,R-Respiratory system,"/capita, US$ purchasing power parity",14.0
+25857,New Zealand,2013,9,R-Respiratory system,% of total sales,9.8
+25858,New Zealand,2013,9,R-Respiratory system,"/capita, US$ exchange rate",16.6
+25859,New Zealand,2013,9,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"Million US$, purchasing power parity",4.8
+25860,New Zealand,2013,9,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million US$ at exchange rate,5.7
+25861,New Zealand,2013,9,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ exchange rate",1.3
+25862,New Zealand,2013,9,N06A-Antidepressants,Million US$ at exchange rate,24.0
+25863,New Zealand,2013,9,N06A-Antidepressants,"Million US$, purchasing power parity",20.2
+25864,New Zealand,2013,9,N06A-Antidepressants,Million of national currency units,29.2
+25865,New Zealand,2013,9,N06A-Antidepressants,% of total sales,3.2
+25866,New Zealand,2013,9,N06A-Antidepressants,"/capita, US$ exchange rate",5.4
+25867,New Zealand,2013,9,N06A-Antidepressants,"/capita, US$ purchasing power parity",4.5
+25868,New Zealand,2013,9,G-Genito urinary system and sex hormones,% of total sales,2.3
+25869,New Zealand,2013,9,G-Genito urinary system and sex hormones,"/capita, US$ purchasing power parity",3.3
+25870,New Zealand,2013,9,A02A-Antacids,Million of national currency units,0.3
+25871,New Zealand,2013,9,A02A-Antacids,Million US$ at exchange rate,0.2
+25872,New Zealand,2013,9,N05B-Anxiolytics,"/capita, US$ purchasing power parity",0.2
+25873,New Zealand,2013,9,N05B-Anxiolytics,"/capita, US$ exchange rate",0.2
+25874,New Zealand,2013,9,N05B-Anxiolytics,% of total sales,0.1
+25875,New Zealand,2013,9,N05B-Anxiolytics,"Million US$, purchasing power parity",0.9
+25876,New Zealand,2013,9,R03-Drugs for obstructive airway diseases,% of total sales,8.6
+25877,New Zealand,2013,9,J-Antiinfectives for systemic use,"/capita, US$ exchange rate",18.1
+25878,New Zealand,2013,9,R03-Drugs for obstructive airway diseases,"/capita, US$ purchasing power parity",12.4
+25879,New Zealand,2013,9,R03-Drugs for obstructive airway diseases,"Million US$, purchasing power parity",55.0
+25880,New Zealand,2013,9,R03-Drugs for obstructive airway diseases,Million US$ at exchange rate,65.2
+25881,New Zealand,2013,9,R03-Drugs for obstructive airway diseases,"/capita, US$ exchange rate",14.7
+25882,New Zealand,2013,9,J-Antiinfectives for systemic use,"/capita, US$ purchasing power parity",15.3
+25883,New Zealand,2013,9,A02A-Antacids,"/capita, US$ exchange rate",0.1
+25884,New Zealand,2013,9,A02A-Antacids,"Million US$, purchasing power parity",0.2
+25885,New Zealand,2013,9,A02A-Antacids,"/capita, US$ purchasing power parity",0.0
+25886,New Zealand,2013,9,J-Antiinfectives for systemic use,% of total sales,10.6
+25887,New Zealand,2013,9,A02A-Antacids,% of total sales,0.0
+25888,New Zealand,2013,9,C07-Beta blocking agents,Million of national currency units,14.4
+25889,New Zealand,2013,9,C07-Beta blocking agents,Million US$ at exchange rate,11.8
+25890,New Zealand,2013,9,C-Cardiovascular system,"/capita, US$ purchasing power parity",13.5
+25891,New Zealand,2013,9,C07-Beta blocking agents,"/capita, US$ exchange rate",2.7
+25892,New Zealand,2013,9,C07-Beta blocking agents,"Million US$, purchasing power parity",10.0
+25893,New Zealand,2013,9,M-Musculo-skeletal system,% of total sales,2.6
+25894,New Zealand,2013,9,C03-Diuretics,Million US$ at exchange rate,1.8
+25895,New Zealand,2013,9,C-Cardiovascular system,% of total sales,9.4
+25896,New Zealand,2013,9,M-Musculo-skeletal system,"/capita, US$ purchasing power parity",3.8
+25897,New Zealand,2013,9,M-Musculo-skeletal system,"/capita, US$ exchange rate",4.5
+25898,New Zealand,2013,9,C07-Beta blocking agents,"/capita, US$ purchasing power parity",2.2
+25899,New Zealand,2013,9,M01A-Antiinflammatory and antirheumatic products non-steroids,"Million US$, purchasing power parity",5.1
+25900,New Zealand,2013,9,M01A-Antiinflammatory and antirheumatic products non-steroids,Million US$ at exchange rate,6.0
+25901,New Zealand,2013,9,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ exchange rate",1.4
+25902,New Zealand,2013,9,M-Musculo-skeletal system,Million of national currency units,24.3
+25903,New Zealand,2013,9,M01A-Antiinflammatory and antirheumatic products non-steroids,Million of national currency units,7.3
+25904,New Zealand,2013,9,M-Musculo-skeletal system,"Million US$, purchasing power parity",16.8
+25905,New Zealand,2013,9,C07-Beta blocking agents,% of total sales,1.6
+25906,New Zealand,2013,9,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ purchasing power parity",1.1
+25907,New Zealand,2013,9,M01A-Antiinflammatory and antirheumatic products non-steroids,% of total sales,0.8
+25908,New Zealand,2013,9,M-Musculo-skeletal system,Million US$ at exchange rate,19.9
+25909,New Zealand,2013,9,"C01B-Antiarrhythmics, Class I and III",Million of national currency units,5.0
+25910,New Zealand,2013,9,"C01B-Antiarrhythmics, Class I and III",Million US$ at exchange rate,4.1
+25911,New Zealand,2013,9,Total pharmaceutical sales,"/capita, US$ exchange rate",170.4
+25912,New Zealand,2013,9,Total pharmaceutical sales,"/capita, US$ purchasing power parity",143.7
+25913,New Zealand,2013,9,N-Nervous system,% of total sales,16.0
+25914,New Zealand,2013,9,"C01B-Antiarrhythmics, Class I and III","Million US$, purchasing power parity",3.5
+25915,New Zealand,2013,9,C02-Antihypertensives,Million US$ at exchange rate,3.1
+25916,New Zealand,2013,9,C02-Antihypertensives,Million of national currency units,3.8
+25917,New Zealand,2013,9,"C01B-Antiarrhythmics, Class I and III",% of total sales,0.5
+25918,New Zealand,2013,9,"C01B-Antiarrhythmics, Class I and III","/capita, US$ exchange rate",0.9
+25919,New Zealand,2013,9,"C01B-Antiarrhythmics, Class I and III","/capita, US$ purchasing power parity",0.8
+25920,New Zealand,2013,9,N-Nervous system,Million of national currency units,147.4
+25921,New Zealand,2013,9,C03-Diuretics,% of total sales,0.2
+25922,New Zealand,2013,9,Total pharmaceutical sales,Million of national currency units,922.9
+25923,New Zealand,2013,9,C03-Diuretics,"Million US$, purchasing power parity",1.5
+25924,New Zealand,2013,9,C03-Diuretics,"/capita, US$ purchasing power parity",0.3
+25925,New Zealand,2013,9,C03-Diuretics,"/capita, US$ exchange rate",0.4
+25926,New Zealand,2013,9,Total pharmaceutical sales,Million US$ at exchange rate,756.8
+25927,New Zealand,2013,9,N-Nervous system,"/capita, US$ purchasing power parity",22.9
+25928,New Zealand,2013,9,Total pharmaceutical sales,"Million US$, purchasing power parity",638.2
+25929,New Zealand,2013,9,N-Nervous system,Million US$ at exchange rate,120.9
+25930,New Zealand,2013,9,N-Nervous system,"Million US$, purchasing power parity",101.9
+25931,New Zealand,2013,9,N-Nervous system,"/capita, US$ exchange rate",27.2
+25932,New Zealand,2013,9,C03-Diuretics,Million of national currency units,2.2
+25933,New Zealand,2013,9,J01-Antibacterials for systemic use,"/capita, US$ exchange rate",2.9
+25934,New Zealand,2013,9,J01-Antibacterials for systemic use,"/capita, US$ purchasing power parity",2.5
+25935,New Zealand,2013,9,J01-Antibacterials for systemic use,% of total sales,1.7
+25936,New Zealand,2013,9,J01-Antibacterials for systemic use,Million US$ at exchange rate,13.0
+25937,New Zealand,2013,9,J01-Antibacterials for systemic use,"Million US$, purchasing power parity",11.0
+25938,New Zealand,2013,9,J01-Antibacterials for systemic use,Million of national currency units,15.9
+25939,New Zealand,2013,9,C-Cardiovascular system,"/capita, US$ exchange rate",16.0
+25940,New Zealand,2013,9,C01A-Cardiac glycosides,"Million US$, purchasing power parity",0.3
+25941,New Zealand,2013,9,C-Cardiovascular system,"Million US$, purchasing power parity",59.8
+25942,New Zealand,2013,9,C01A-Cardiac glycosides,Million of national currency units,0.4
+25943,New Zealand,2013,9,C01A-Cardiac glycosides,Million US$ at exchange rate,0.3
+25944,New Zealand,2013,9,A10-Drugs used in diabetes,Million US$ at exchange rate,32.1
+25945,New Zealand,2013,9,A10-Drugs used in diabetes,"Million US$, purchasing power parity",27.0
+25946,New Zealand,2013,9,C02-Antihypertensives,% of total sales,0.4
+25947,New Zealand,2013,9,C02-Antihypertensives,"/capita, US$ purchasing power parity",0.6
+25948,New Zealand,2013,9,A10-Drugs used in diabetes,Million of national currency units,39.1
+25949,New Zealand,2013,9,A10-Drugs used in diabetes,"/capita, US$ exchange rate",7.2
+25950,New Zealand,2013,9,C-Cardiovascular system,Million of national currency units,86.4
+25951,New Zealand,2013,9,C-Cardiovascular system,Million US$ at exchange rate,70.9
+25952,New Zealand,2013,9,A10-Drugs used in diabetes,"/capita, US$ purchasing power parity",6.1
+25953,New Zealand,2013,9,A10-Drugs used in diabetes,% of total sales,4.2
+25954,New Zealand,2013,9,A-Alimentary tract and metabolism,"/capita, US$ exchange rate",13.9
+25955,New Zealand,2013,9,A-Alimentary tract and metabolism,"Million US$, purchasing power parity",52.0
+25956,New Zealand,2013,9,A-Alimentary tract and metabolism,% of total sales,8.1
+25957,New Zealand,2013,9,A-Alimentary tract and metabolism,"/capita, US$ purchasing power parity",11.7
+25958,New Zealand,2013,9,C01A-Cardiac glycosides,"/capita, US$ exchange rate",0.1
+25959,New Zealand,2013,9,C02-Antihypertensives,"/capita, US$ exchange rate",0.7
+25960,New Zealand,2013,9,C02-Antihypertensives,"Million US$, purchasing power parity",2.6
+25961,New Zealand,2013,9,A-Alimentary tract and metabolism,Million US$ at exchange rate,61.7
+25962,New Zealand,2013,9,A-Alimentary tract and metabolism,Million of national currency units,75.2
+25963,New Zealand,2013,9,C01A-Cardiac glycosides,"/capita, US$ purchasing power parity",0.1
+25964,New Zealand,2013,9,C01A-Cardiac glycosides,% of total sales,0.0
+25965,New Zealand,2012,10,C10-Lipid modifying agents,"/capita, US$ exchange rate",14.1
+25966,New Zealand,2012,10,N05C-Hypnotics and sedatives,Million of national currency units,1.4
+25967,New Zealand,2012,10,N05C-Hypnotics and sedatives,Million US$ at exchange rate,1.2
+25968,New Zealand,2012,10,C08-Calcium channel blockers,Million US$ at exchange rate,10.9
+25969,New Zealand,2012,10,Products not elsewhere classified,Million US$ at exchange rate,234.9
+25970,New Zealand,2012,10,Products not elsewhere classified,"/capita, US$ exchange rate",53.3
+25971,New Zealand,2012,10,C10-Lipid modifying agents,"Million US$, purchasing power parity",51.2
+25972,New Zealand,2012,10,C10-Lipid modifying agents,Million US$ at exchange rate,62.0
+25973,New Zealand,2012,10,Products not elsewhere classified,"Million US$, purchasing power parity",193.9
+25974,New Zealand,2012,10,C08-Calcium channel blockers,Million of national currency units,13.5
+25975,New Zealand,2012,10,C10-Lipid modifying agents,Million of national currency units,76.5
+25976,New Zealand,2012,10,C08-Calcium channel blockers,"Million US$, purchasing power parity",9.0
+25977,New Zealand,2012,10,C08-Calcium channel blockers,"/capita, US$ purchasing power parity",2.0
+25978,New Zealand,2012,10,N02-Analgesics,"/capita, US$ purchasing power parity",4.4
+25979,New Zealand,2012,10,N02-Analgesics,"/capita, US$ exchange rate",5.3
+25980,New Zealand,2012,10,N02-Analgesics,"Million US$, purchasing power parity",19.2
+25981,New Zealand,2012,10,Products not elsewhere classified,"/capita, US$ purchasing power parity",44.0
+25982,New Zealand,2012,10,Products not elsewhere classified,% of total sales,31.4
+25983,New Zealand,2012,10,N02-Analgesics,% of total sales,3.1
+25984,New Zealand,2012,10,C08-Calcium channel blockers,% of total sales,1.5
+25985,New Zealand,2012,10,C08-Calcium channel blockers,"/capita, US$ exchange rate",2.5
+25986,New Zealand,2012,10,N02-Analgesics,Million US$ at exchange rate,23.2
+25987,New Zealand,2012,10,N02-Analgesics,Million of national currency units,28.7
+25988,New Zealand,2012,10,G-Genito urinary system and sex hormones,Million US$ at exchange rate,18.5
+25989,New Zealand,2012,10,B-Blood and blood forming organs,Million of national currency units,42.8
+25990,New Zealand,2012,10,G-Genito urinary system and sex hormones,Million of national currency units,22.8
+25991,New Zealand,2012,10,B-Blood and blood forming organs,"/capita, US$ exchange rate",7.9
+25992,New Zealand,2012,10,B-Blood and blood forming organs,"Million US$, purchasing power parity",28.6
+25993,New Zealand,2012,10,B-Blood and blood forming organs,Million US$ at exchange rate,34.7
+25994,New Zealand,2012,10,G03-Sex hormones and modulators of the genital system,% of total sales,1.5
+25995,New Zealand,2012,10,G03-Sex hormones and modulators of the genital system,"Million US$, purchasing power parity",9.1
+25996,New Zealand,2012,10,G03-Sex hormones and modulators of the genital system,"/capita, US$ purchasing power parity",2.1
+25997,New Zealand,2012,10,G03-Sex hormones and modulators of the genital system,"/capita, US$ exchange rate",2.5
+25998,New Zealand,2012,10,C10-Lipid modifying agents,% of total sales,8.3
+25999,New Zealand,2012,10,G03-Sex hormones and modulators of the genital system,Million US$ at exchange rate,11.0
+26000,New Zealand,2012,10,G03-Sex hormones and modulators of the genital system,Million of national currency units,13.6
+26001,New Zealand,2012,10,N05C-Hypnotics and sedatives,% of total sales,0.2
+26002,New Zealand,2012,10,B-Blood and blood forming organs,% of total sales,4.6
+26003,New Zealand,2012,10,N05C-Hypnotics and sedatives,"/capita, US$ exchange rate",0.3
+26004,New Zealand,2012,10,N05C-Hypnotics and sedatives,"Million US$, purchasing power parity",1.0
+26005,New Zealand,2012,10,N05C-Hypnotics and sedatives,"/capita, US$ purchasing power parity",0.2
+26006,New Zealand,2012,10,B-Blood and blood forming organs,"/capita, US$ purchasing power parity",6.5
+26007,New Zealand,2012,10,G-Genito urinary system and sex hormones,"/capita, US$ exchange rate",4.2
+26008,New Zealand,2012,10,G-Genito urinary system and sex hormones,"Million US$, purchasing power parity",15.2
+26009,New Zealand,2012,10,C10-Lipid modifying agents,"/capita, US$ purchasing power parity",11.6
+26010,New Zealand,2012,10,Products not elsewhere classified,Million of national currency units,290.0
+26011,New Zealand,2012,10,J-Antiinfectives for systemic use,"Million US$, purchasing power parity",35.5
+26012,New Zealand,2012,10,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ purchasing power parity",4.8
+26013,New Zealand,2012,10,C09-Agents acting on the Renin-Angiotensin system,% of total sales,3.4
+26014,New Zealand,2012,10,J-Antiinfectives for systemic use,Million US$ at exchange rate,43.1
+26015,New Zealand,2012,10,R-Respiratory system,Million US$ at exchange rate,71.9
+26016,New Zealand,2012,10,J-Antiinfectives for systemic use,Million of national currency units,53.1
+26017,New Zealand,2012,10,R-Respiratory system,Million of national currency units,88.7
+26018,New Zealand,2012,10,R-Respiratory system,"Million US$, purchasing power parity",59.3
+26019,New Zealand,2012,10,N05B-Anxiolytics,Million of national currency units,1.3
+26020,New Zealand,2012,10,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),% of total sales,0.8
+26021,New Zealand,2012,10,R03-Drugs for obstructive airway diseases,Million of national currency units,77.2
+26022,New Zealand,2012,10,N05B-Anxiolytics,Million US$ at exchange rate,1.0
+26023,New Zealand,2012,10,C09-Agents acting on the Renin-Angiotensin system,Million of national currency units,31.7
+26024,New Zealand,2012,10,C09-Agents acting on the Renin-Angiotensin system,"Million US$, purchasing power parity",21.2
+26025,New Zealand,2012,10,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ exchange rate",5.8
+26026,New Zealand,2012,10,C09-Agents acting on the Renin-Angiotensin system,Million US$ at exchange rate,25.7
+26027,New Zealand,2012,10,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ purchasing power parity",3.2
+26028,New Zealand,2012,10,"H-Systemic hormonal preparations, excluding sex hormones and insulins",% of total sales,2.3
+26029,New Zealand,2012,10,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million of national currency units,7.8
+26030,New Zealand,2012,10,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million US$ at exchange rate,17.2
+26031,New Zealand,2012,10,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million of national currency units,21.2
+26032,New Zealand,2012,10,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ exchange rate",3.9
+26033,New Zealand,2012,10,"H-Systemic hormonal preparations, excluding sex hormones and insulins","Million US$, purchasing power parity",14.2
+26034,New Zealand,2012,10,R-Respiratory system,% of total sales,9.6
+26035,New Zealand,2012,10,R-Respiratory system,"/capita, US$ purchasing power parity",13.5
+26036,New Zealand,2012,10,R-Respiratory system,"/capita, US$ exchange rate",16.3
+26037,New Zealand,2012,10,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"Million US$, purchasing power parity",5.2
+26038,New Zealand,2012,10,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million US$ at exchange rate,6.3
+26039,New Zealand,2012,10,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ purchasing power parity",1.2
+26040,New Zealand,2012,10,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ exchange rate",1.4
+26041,New Zealand,2012,10,N06A-Antidepressants,Million US$ at exchange rate,26.6
+26042,New Zealand,2012,10,N06A-Antidepressants,"Million US$, purchasing power parity",22.0
+26043,New Zealand,2012,10,N06A-Antidepressants,Million of national currency units,32.9
+26044,New Zealand,2012,10,N06A-Antidepressants,% of total sales,3.6
+26045,New Zealand,2012,10,N06A-Antidepressants,"/capita, US$ exchange rate",6.0
+26046,New Zealand,2012,10,N06A-Antidepressants,"/capita, US$ purchasing power parity",5.0
+26047,New Zealand,2012,10,N05B-Anxiolytics,"/capita, US$ exchange rate",0.2
+26048,New Zealand,2012,10,G-Genito urinary system and sex hormones,% of total sales,2.5
+26049,New Zealand,2012,10,G-Genito urinary system and sex hormones,"/capita, US$ purchasing power parity",3.5
+26050,New Zealand,2012,10,A02A-Antacids,Million of national currency units,0.3
+26051,New Zealand,2012,10,A02A-Antacids,Million US$ at exchange rate,0.2
+26052,New Zealand,2012,10,N05B-Anxiolytics,"/capita, US$ purchasing power parity",0.2
+26053,New Zealand,2012,10,N05B-Anxiolytics,% of total sales,0.1
+26054,New Zealand,2012,10,N05B-Anxiolytics,"Million US$, purchasing power parity",0.9
+26055,New Zealand,2012,10,R03-Drugs for obstructive airway diseases,% of total sales,8.3
+26056,New Zealand,2012,10,J-Antiinfectives for systemic use,"/capita, US$ exchange rate",9.8
+26057,New Zealand,2012,10,R03-Drugs for obstructive airway diseases,"Million US$, purchasing power parity",51.6
+26058,New Zealand,2012,10,R03-Drugs for obstructive airway diseases,Million US$ at exchange rate,62.5
+26059,New Zealand,2012,10,J-Antiinfectives for systemic use,"/capita, US$ purchasing power parity",8.1
+26060,New Zealand,2012,10,R03-Drugs for obstructive airway diseases,"/capita, US$ purchasing power parity",11.7
+26061,New Zealand,2012,10,R03-Drugs for obstructive airway diseases,"/capita, US$ exchange rate",14.2
+26062,New Zealand,2012,10,A02A-Antacids,"/capita, US$ exchange rate",0.1
+26063,New Zealand,2012,10,A02A-Antacids,"Million US$, purchasing power parity",0.2
+26064,New Zealand,2012,10,J-Antiinfectives for systemic use,% of total sales,5.8
+26065,New Zealand,2012,10,A02A-Antacids,"/capita, US$ purchasing power parity",0.0
+26066,New Zealand,2012,10,A02A-Antacids,% of total sales,0.0
+26067,New Zealand,2012,10,Total pharmaceutical sales,"/capita, US$ purchasing power parity",140.2
+26068,New Zealand,2012,10,C07-Beta blocking agents,Million of national currency units,18.5
+26069,New Zealand,2012,10,C07-Beta blocking agents,Million US$ at exchange rate,15.0
+26070,New Zealand,2012,10,C-Cardiovascular system,"/capita, US$ purchasing power parity",23.3
+26071,New Zealand,2012,10,C07-Beta blocking agents,"/capita, US$ exchange rate",3.4
+26072,New Zealand,2012,10,C07-Beta blocking agents,"Million US$, purchasing power parity",12.4
+26073,New Zealand,2012,10,C07-Beta blocking agents,"/capita, US$ purchasing power parity",2.8
+26074,New Zealand,2012,10,M-Musculo-skeletal system,% of total sales,2.5
+26075,New Zealand,2012,10,C03-Diuretics,Million US$ at exchange rate,1.9
+26076,New Zealand,2012,10,C-Cardiovascular system,% of total sales,16.6
+26077,New Zealand,2012,10,M-Musculo-skeletal system,"/capita, US$ purchasing power parity",3.5
+26078,New Zealand,2012,10,M-Musculo-skeletal system,"/capita, US$ exchange rate",4.3
+26079,New Zealand,2012,10,M01A-Antiinflammatory and antirheumatic products non-steroids,"Million US$, purchasing power parity",4.8
+26080,New Zealand,2012,10,M01A-Antiinflammatory and antirheumatic products non-steroids,Million US$ at exchange rate,5.8
+26081,New Zealand,2012,10,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ exchange rate",1.3
+26082,New Zealand,2012,10,M-Musculo-skeletal system,Million of national currency units,23.3
+26083,New Zealand,2012,10,M01A-Antiinflammatory and antirheumatic products non-steroids,Million of national currency units,7.2
+26084,New Zealand,2012,10,M-Musculo-skeletal system,"Million US$, purchasing power parity",15.6
+26085,New Zealand,2012,10,C07-Beta blocking agents,% of total sales,2.0
+26086,New Zealand,2012,10,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ purchasing power parity",1.1
+26087,New Zealand,2012,10,M01A-Antiinflammatory and antirheumatic products non-steroids,% of total sales,0.8
+26088,New Zealand,2012,10,M-Musculo-skeletal system,Million US$ at exchange rate,18.9
+26089,New Zealand,2012,10,"C01B-Antiarrhythmics, Class I and III",Million of national currency units,4.9
+26090,New Zealand,2012,10,"C01B-Antiarrhythmics, Class I and III","Million US$, purchasing power parity",3.3
+26091,New Zealand,2012,10,"C01B-Antiarrhythmics, Class I and III",Million US$ at exchange rate,3.9
+26092,New Zealand,2012,10,Total pharmaceutical sales,"/capita, US$ exchange rate",169.8
+26093,New Zealand,2012,10,N-Nervous system,% of total sales,17.0
+26094,New Zealand,2012,10,C02-Antihypertensives,Million US$ at exchange rate,2.3
+26095,New Zealand,2012,10,C02-Antihypertensives,Million of national currency units,2.9
+26096,New Zealand,2012,10,"C01B-Antiarrhythmics, Class I and III",% of total sales,0.5
+26097,New Zealand,2012,10,"C01B-Antiarrhythmics, Class I and III","/capita, US$ exchange rate",0.9
+26098,New Zealand,2012,10,"C01B-Antiarrhythmics, Class I and III","/capita, US$ purchasing power parity",0.7
+26099,New Zealand,2012,10,N-Nervous system,Million of national currency units,156.7
+26100,New Zealand,2012,10,C03-Diuretics,% of total sales,0.2
+26101,New Zealand,2012,10,Total pharmaceutical sales,Million of national currency units,924.1
+26102,New Zealand,2012,10,C03-Diuretics,"Million US$, purchasing power parity",1.5
+26103,New Zealand,2012,10,C03-Diuretics,"/capita, US$ exchange rate",0.4
+26104,New Zealand,2012,10,C03-Diuretics,"/capita, US$ purchasing power parity",0.3
+26105,New Zealand,2012,10,Total pharmaceutical sales,Million US$ at exchange rate,748.7
+26106,New Zealand,2012,10,N-Nervous system,"/capita, US$ purchasing power parity",23.8
+26107,New Zealand,2012,10,Total pharmaceutical sales,"Million US$, purchasing power parity",617.9
+26108,New Zealand,2012,10,N-Nervous system,"Million US$, purchasing power parity",104.8
+26109,New Zealand,2012,10,N-Nervous system,Million US$ at exchange rate,126.9
+26110,New Zealand,2012,10,N-Nervous system,"/capita, US$ exchange rate",28.8
+26111,New Zealand,2012,10,J01-Antibacterials for systemic use,"/capita, US$ exchange rate",3.5
+26112,New Zealand,2012,10,J01-Antibacterials for systemic use,"/capita, US$ purchasing power parity",2.9
+26113,New Zealand,2012,10,J01-Antibacterials for systemic use,% of total sales,2.0
+26114,New Zealand,2012,10,J01-Antibacterials for systemic use,Million US$ at exchange rate,15.3
+26115,New Zealand,2012,10,J01-Antibacterials for systemic use,"Million US$, purchasing power parity",12.6
+26116,New Zealand,2012,10,C-Cardiovascular system,"/capita, US$ exchange rate",28.2
+26117,New Zealand,2012,10,C01A-Cardiac glycosides,"Million US$, purchasing power parity",0.3
+26118,New Zealand,2012,10,C01A-Cardiac glycosides,Million of national currency units,0.4
+26119,New Zealand,2012,10,C01A-Cardiac glycosides,Million US$ at exchange rate,0.3
+26120,New Zealand,2012,10,J01-Antibacterials for systemic use,Million of national currency units,18.8
+26121,New Zealand,2012,10,A10-Drugs used in diabetes,Million US$ at exchange rate,28.7
+26122,New Zealand,2012,10,A10-Drugs used in diabetes,"Million US$, purchasing power parity",23.7
+26123,New Zealand,2012,10,C02-Antihypertensives,% of total sales,0.3
+26124,New Zealand,2012,10,C02-Antihypertensives,"/capita, US$ purchasing power parity",0.4
+26125,New Zealand,2012,10,A10-Drugs used in diabetes,Million of national currency units,35.5
+26126,New Zealand,2012,10,C-Cardiovascular system,Million of national currency units,153.7
+26127,New Zealand,2012,10,C-Cardiovascular system,Million US$ at exchange rate,124.5
+26128,New Zealand,2012,10,C-Cardiovascular system,"Million US$, purchasing power parity",102.8
+26129,New Zealand,2012,10,A10-Drugs used in diabetes,"/capita, US$ exchange rate",6.5
+26130,New Zealand,2012,10,A10-Drugs used in diabetes,"/capita, US$ purchasing power parity",5.4
+26131,New Zealand,2012,10,A10-Drugs used in diabetes,% of total sales,3.8
+26132,New Zealand,2012,10,C01A-Cardiac glycosides,"/capita, US$ exchange rate",0.1
+26133,New Zealand,2012,10,A-Alimentary tract and metabolism,"/capita, US$ exchange rate",13.2
+26134,New Zealand,2012,10,A-Alimentary tract and metabolism,"Million US$, purchasing power parity",48.0
+26135,New Zealand,2012,10,A-Alimentary tract and metabolism,% of total sales,7.8
+26136,New Zealand,2012,10,A-Alimentary tract and metabolism,"/capita, US$ purchasing power parity",10.9
+26137,New Zealand,2012,10,C02-Antihypertensives,"/capita, US$ exchange rate",0.5
+26138,New Zealand,2012,10,C02-Antihypertensives,"Million US$, purchasing power parity",1.9
+26139,New Zealand,2012,10,C03-Diuretics,Million of national currency units,2.3
+26140,New Zealand,2012,10,A-Alimentary tract and metabolism,Million US$ at exchange rate,58.1
+26141,New Zealand,2012,10,A-Alimentary tract and metabolism,Million of national currency units,71.7
+26142,New Zealand,2012,10,C01A-Cardiac glycosides,"/capita, US$ purchasing power parity",0.1
+26143,New Zealand,2012,10,C01A-Cardiac glycosides,% of total sales,0.0
+26144,New Zealand,2010,11,C10-Lipid modifying agents,"/capita, US$ exchange rate",6.3
+26145,New Zealand,2010,11,N05C-Hypnotics and sedatives,Million of national currency units,1.5
+26146,New Zealand,2010,11,N05C-Hypnotics and sedatives,Million US$ at exchange rate,1.0
+26147,New Zealand,2010,11,C08-Calcium channel blockers,"Million US$, purchasing power parity",8.9
+26148,New Zealand,2010,11,C08-Calcium channel blockers,Million US$ at exchange rate,9.6
+26149,New Zealand,2010,11,Products not elsewhere classified,"/capita, US$ exchange rate",30.9
+26150,New Zealand,2010,11,C10-Lipid modifying agents,"Million US$, purchasing power parity",25.3
+26151,New Zealand,2010,11,C10-Lipid modifying agents,Million US$ at exchange rate,27.3
+26152,New Zealand,2010,11,Products not elsewhere classified,"Million US$, purchasing power parity",124.5
+26153,New Zealand,2010,11,C08-Calcium channel blockers,Million of national currency units,13.3
+26154,New Zealand,2010,11,C10-Lipid modifying agents,Million of national currency units,37.9
+26155,New Zealand,2010,11,N02-Analgesics,"/capita, US$ purchasing power parity",4.6
+26156,New Zealand,2010,11,N02-Analgesics,"/capita, US$ exchange rate",4.9
+26157,New Zealand,2010,11,N02-Analgesics,"Million US$, purchasing power parity",19.9
+26158,New Zealand,2010,11,Products not elsewhere classified,% of total sales,24.9
+26159,New Zealand,2010,11,N02-Analgesics,% of total sales,4.0
+26160,New Zealand,2010,11,C08-Calcium channel blockers,"/capita, US$ purchasing power parity",2.0
+26161,New Zealand,2010,11,C08-Calcium channel blockers,% of total sales,1.8
+26162,New Zealand,2010,11,C08-Calcium channel blockers,"/capita, US$ exchange rate",2.2
+26163,New Zealand,2010,11,N02-Analgesics,Million US$ at exchange rate,21.4
+26164,New Zealand,2010,11,N02-Analgesics,Million of national currency units,29.7
+26165,New Zealand,2010,11,Products not elsewhere classified,"/capita, US$ purchasing power parity",28.6
+26166,New Zealand,2010,11,N05C-Hypnotics and sedatives,"Million US$, purchasing power parity",1.0
+26167,New Zealand,2010,11,G-Genito urinary system and sex hormones,Million US$ at exchange rate,13.0
+26168,New Zealand,2010,11,B-Blood and blood forming organs,Million of national currency units,26.2
+26169,New Zealand,2010,11,G-Genito urinary system and sex hormones,Million of national currency units,18.0
+26170,New Zealand,2010,11,B-Blood and blood forming organs,"/capita, US$ exchange rate",4.3
+26171,New Zealand,2010,11,B-Blood and blood forming organs,"Million US$, purchasing power parity",17.5
+26172,New Zealand,2010,11,B-Blood and blood forming organs,Million US$ at exchange rate,18.9
+26173,New Zealand,2010,11,G03-Sex hormones and modulators of the genital system,% of total sales,1.6
+26174,New Zealand,2010,11,G03-Sex hormones and modulators of the genital system,"Million US$, purchasing power parity",8.1
+26175,New Zealand,2010,11,G03-Sex hormones and modulators of the genital system,"/capita, US$ exchange rate",2.0
+26176,New Zealand,2010,11,G03-Sex hormones and modulators of the genital system,"/capita, US$ purchasing power parity",1.9
+26177,New Zealand,2010,11,G03-Sex hormones and modulators of the genital system,Million of national currency units,12.1
+26178,New Zealand,2010,11,G03-Sex hormones and modulators of the genital system,Million US$ at exchange rate,8.7
+26179,New Zealand,2010,11,B-Blood and blood forming organs,% of total sales,3.5
+26180,New Zealand,2010,11,N05C-Hypnotics and sedatives,% of total sales,0.2
+26181,New Zealand,2010,11,N05C-Hypnotics and sedatives,"/capita, US$ exchange rate",0.2
+26182,New Zealand,2010,11,N05C-Hypnotics and sedatives,"/capita, US$ purchasing power parity",0.2
+26183,New Zealand,2010,11,B-Blood and blood forming organs,"/capita, US$ purchasing power parity",4.0
+26184,New Zealand,2010,11,G-Genito urinary system and sex hormones,"Million US$, purchasing power parity",12.0
+26185,New Zealand,2010,11,G-Genito urinary system and sex hormones,"/capita, US$ exchange rate",3.0
+26186,New Zealand,2010,11,Products not elsewhere classified,Million US$ at exchange rate,134.3
+26187,New Zealand,2010,11,C10-Lipid modifying agents,% of total sales,5.1
+26188,New Zealand,2010,11,C10-Lipid modifying agents,"/capita, US$ purchasing power parity",5.8
+26189,New Zealand,2010,11,Products not elsewhere classified,Million of national currency units,186.3
+26190,New Zealand,2010,11,J-Antiinfectives for systemic use,"Million US$, purchasing power parity",28.8
+26191,New Zealand,2010,11,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ purchasing power parity",5.3
+26192,New Zealand,2010,11,C09-Agents acting on the Renin-Angiotensin system,% of total sales,4.6
+26193,New Zealand,2010,11,R-Respiratory system,Million US$ at exchange rate,54.4
+26194,New Zealand,2010,11,R-Respiratory system,"Million US$, purchasing power parity",50.4
+26195,New Zealand,2010,11,J-Antiinfectives for systemic use,Million US$ at exchange rate,31.1
+26196,New Zealand,2010,11,J-Antiinfectives for systemic use,Million of national currency units,43.2
+26197,New Zealand,2010,11,R-Respiratory system,Million of national currency units,75.5
+26198,New Zealand,2010,11,N05B-Anxiolytics,Million of national currency units,0.9
+26199,New Zealand,2010,11,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),% of total sales,1.7
+26200,New Zealand,2010,11,C09-Agents acting on the Renin-Angiotensin system,Million of national currency units,34.5
+26201,New Zealand,2010,11,R03-Drugs for obstructive airway diseases,Million of national currency units,68.3
+26202,New Zealand,2010,11,N05B-Anxiolytics,Million US$ at exchange rate,0.6
+26203,New Zealand,2010,11,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ exchange rate",5.7
+26204,New Zealand,2010,11,C09-Agents acting on the Renin-Angiotensin system,"Million US$, purchasing power parity",23.0
+26205,New Zealand,2010,11,C09-Agents acting on the Renin-Angiotensin system,Million US$ at exchange rate,24.8
+26206,New Zealand,2010,11,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ purchasing power parity",2.9
+26207,New Zealand,2010,11,"H-Systemic hormonal preparations, excluding sex hormones and insulins",% of total sales,2.5
+26208,New Zealand,2010,11,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million of national currency units,12.5
+26209,New Zealand,2010,11,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million US$ at exchange rate,13.4
+26210,New Zealand,2010,11,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million of national currency units,18.7
+26211,New Zealand,2010,11,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ exchange rate",3.1
+26212,New Zealand,2010,11,"H-Systemic hormonal preparations, excluding sex hormones and insulins","Million US$, purchasing power parity",12.5
+26213,New Zealand,2010,11,R-Respiratory system,% of total sales,10.1
+26214,New Zealand,2010,11,R-Respiratory system,"/capita, US$ exchange rate",12.5
+26215,New Zealand,2010,11,R-Respiratory system,"/capita, US$ purchasing power parity",11.6
+26216,New Zealand,2010,11,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"Million US$, purchasing power parity",8.4
+26217,New Zealand,2010,11,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million US$ at exchange rate,9.0
+26218,New Zealand,2010,11,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ purchasing power parity",1.9
+26219,New Zealand,2010,11,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ exchange rate",2.1
+26220,New Zealand,2010,11,G-Genito urinary system and sex hormones,"/capita, US$ purchasing power parity",2.8
+26221,New Zealand,2010,11,N06A-Antidepressants,"Million US$, purchasing power parity",19.7
+26222,New Zealand,2010,11,N06A-Antidepressants,Million US$ at exchange rate,21.2
+26223,New Zealand,2010,11,N05B-Anxiolytics,"/capita, US$ exchange rate",0.1
+26224,New Zealand,2010,11,N06A-Antidepressants,Million of national currency units,29.5
+26225,New Zealand,2010,11,N06A-Antidepressants,% of total sales,3.9
+26226,New Zealand,2010,11,N06A-Antidepressants,"/capita, US$ exchange rate",4.9
+26227,New Zealand,2010,11,N06A-Antidepressants,"/capita, US$ purchasing power parity",4.5
+26228,New Zealand,2010,11,G-Genito urinary system and sex hormones,% of total sales,2.4
+26229,New Zealand,2010,11,A02A-Antacids,Million of national currency units,0.2
+26230,New Zealand,2010,11,A02A-Antacids,Million US$ at exchange rate,0.2
+26231,New Zealand,2010,11,N05B-Anxiolytics,"/capita, US$ purchasing power parity",0.1
+26232,New Zealand,2010,11,N05B-Anxiolytics,% of total sales,0.1
+26233,New Zealand,2010,11,R03-Drugs for obstructive airway diseases,% of total sales,9.1
+26234,New Zealand,2010,11,J-Antiinfectives for systemic use,"/capita, US$ purchasing power parity",6.6
+26235,New Zealand,2010,11,J-Antiinfectives for systemic use,"/capita, US$ exchange rate",7.1
+26236,New Zealand,2010,11,R03-Drugs for obstructive airway diseases,"Million US$, purchasing power parity",45.6
+26237,New Zealand,2010,11,R03-Drugs for obstructive airway diseases,Million US$ at exchange rate,49.2
+26238,New Zealand,2010,11,R03-Drugs for obstructive airway diseases,"/capita, US$ purchasing power parity",10.5
+26239,New Zealand,2010,11,R03-Drugs for obstructive airway diseases,"/capita, US$ exchange rate",11.3
+26240,New Zealand,2010,11,A02A-Antacids,"/capita, US$ exchange rate",0.0
+26241,New Zealand,2010,11,A02A-Antacids,"/capita, US$ purchasing power parity",0.0
+26242,New Zealand,2010,11,N05B-Anxiolytics,"Million US$, purchasing power parity",0.6
+26243,New Zealand,2010,11,A02A-Antacids,"Million US$, purchasing power parity",0.2
+26244,New Zealand,2010,11,J-Antiinfectives for systemic use,% of total sales,5.8
+26245,New Zealand,2010,11,A02A-Antacids,% of total sales,0.0
+26246,New Zealand,2010,11,C07-Beta blocking agents,Million US$ at exchange rate,16.8
+26247,New Zealand,2010,11,C07-Beta blocking agents,Million of national currency units,23.3
+26248,New Zealand,2010,11,C-Cardiovascular system,"/capita, US$ purchasing power parity",18.8
+26249,New Zealand,2010,11,C07-Beta blocking agents,"/capita, US$ exchange rate",3.9
+26250,New Zealand,2010,11,C07-Beta blocking agents,"/capita, US$ purchasing power parity",3.6
+26251,New Zealand,2010,11,C07-Beta blocking agents,"Million US$, purchasing power parity",15.6
+26252,New Zealand,2010,11,C-Cardiovascular system,% of total sales,16.3
+26253,New Zealand,2010,11,M-Musculo-skeletal system,% of total sales,3.4
+26254,New Zealand,2010,11,C03-Diuretics,Million US$ at exchange rate,2.0
+26255,New Zealand,2010,11,M-Musculo-skeletal system,"/capita, US$ exchange rate",4.3
+26256,New Zealand,2010,11,M-Musculo-skeletal system,"/capita, US$ purchasing power parity",4.0
+26257,New Zealand,2010,11,M01A-Antiinflammatory and antirheumatic products non-steroids,"Million US$, purchasing power parity",4.4
+26258,New Zealand,2010,11,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ exchange rate",1.1
+26259,New Zealand,2010,11,M01A-Antiinflammatory and antirheumatic products non-steroids,Million US$ at exchange rate,4.7
+26260,New Zealand,2010,11,M-Musculo-skeletal system,Million of national currency units,25.8
+26261,New Zealand,2010,11,M01A-Antiinflammatory and antirheumatic products non-steroids,Million of national currency units,6.5
+26262,New Zealand,2010,11,M-Musculo-skeletal system,"Million US$, purchasing power parity",17.2
+26263,New Zealand,2010,11,C07-Beta blocking agents,% of total sales,3.1
+26264,New Zealand,2010,11,M01A-Antiinflammatory and antirheumatic products non-steroids,% of total sales,0.9
+26265,New Zealand,2010,11,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ purchasing power parity",1.0
+26266,New Zealand,2010,11,M-Musculo-skeletal system,Million US$ at exchange rate,18.6
+26267,New Zealand,2010,11,"C01B-Antiarrhythmics, Class I and III",Million of national currency units,4.6
+26268,New Zealand,2010,11,"C01B-Antiarrhythmics, Class I and III","Million US$, purchasing power parity",3.1
+26269,New Zealand,2010,11,"C01B-Antiarrhythmics, Class I and III",Million US$ at exchange rate,3.3
+26270,New Zealand,2010,11,Total pharmaceutical sales,"/capita, US$ purchasing power parity",115.0
+26271,New Zealand,2010,11,Total pharmaceutical sales,"/capita, US$ exchange rate",124.0
+26272,New Zealand,2010,11,N-Nervous system,% of total sales,22.0
+26273,New Zealand,2010,11,C02-Antihypertensives,Million US$ at exchange rate,2.0
+26274,New Zealand,2010,11,C02-Antihypertensives,Million of national currency units,2.8
+26275,New Zealand,2010,11,"C01B-Antiarrhythmics, Class I and III","/capita, US$ exchange rate",0.8
+26276,New Zealand,2010,11,"C01B-Antiarrhythmics, Class I and III",% of total sales,0.6
+26277,New Zealand,2010,11,"C01B-Antiarrhythmics, Class I and III","/capita, US$ purchasing power parity",0.7
+26278,New Zealand,2010,11,N-Nervous system,Million of national currency units,164.5
+26279,New Zealand,2010,11,Total pharmaceutical sales,Million of national currency units,748.7
+26280,New Zealand,2010,11,C03-Diuretics,% of total sales,0.4
+26281,New Zealand,2010,11,Total pharmaceutical sales,Million US$ at exchange rate,539.5
+26282,New Zealand,2010,11,C03-Diuretics,"Million US$, purchasing power parity",1.8
+26283,New Zealand,2010,11,C03-Diuretics,"/capita, US$ exchange rate",0.5
+26284,New Zealand,2010,11,C03-Diuretics,"/capita, US$ purchasing power parity",0.4
+26285,New Zealand,2010,11,N-Nervous system,Million US$ at exchange rate,118.5
+26286,New Zealand,2010,11,N-Nervous system,"/capita, US$ purchasing power parity",25.3
+26287,New Zealand,2010,11,Total pharmaceutical sales,"Million US$, purchasing power parity",500.2
+26288,New Zealand,2010,11,C02-Antihypertensives,"Million US$, purchasing power parity",1.9
+26289,New Zealand,2010,11,N-Nervous system,"Million US$, purchasing power parity",109.9
+26290,New Zealand,2010,11,N-Nervous system,"/capita, US$ exchange rate",27.2
+26291,New Zealand,2010,11,J01-Antibacterials for systemic use,"/capita, US$ exchange rate",2.8
+26292,New Zealand,2010,11,J01-Antibacterials for systemic use,"/capita, US$ purchasing power parity",2.6
+26293,New Zealand,2010,11,J01-Antibacterials for systemic use,% of total sales,2.2
+26294,New Zealand,2010,11,J01-Antibacterials for systemic use,Million US$ at exchange rate,12.0
+26295,New Zealand,2010,11,J01-Antibacterials for systemic use,"Million US$, purchasing power parity",11.1
+26296,New Zealand,2010,11,C-Cardiovascular system,"/capita, US$ exchange rate",20.3
+26297,New Zealand,2010,11,C01A-Cardiac glycosides,"Million US$, purchasing power parity",0.3
+26298,New Zealand,2010,11,C01A-Cardiac glycosides,"/capita, US$ exchange rate",0.1
+26299,New Zealand,2010,11,C01A-Cardiac glycosides,Million of national currency units,0.4
+26300,New Zealand,2010,11,C01A-Cardiac glycosides,Million US$ at exchange rate,0.3
+26301,New Zealand,2010,11,J01-Antibacterials for systemic use,Million of national currency units,16.7
+26302,New Zealand,2010,11,A10-Drugs used in diabetes,Million US$ at exchange rate,21.4
+26303,New Zealand,2010,11,A10-Drugs used in diabetes,"Million US$, purchasing power parity",19.8
+26304,New Zealand,2010,11,A10-Drugs used in diabetes,"/capita, US$ exchange rate",4.9
+26305,New Zealand,2010,11,C02-Antihypertensives,% of total sales,0.4
+26306,New Zealand,2010,11,A10-Drugs used in diabetes,Million of national currency units,29.7
+26307,New Zealand,2010,11,C-Cardiovascular system,Million of national currency units,122.4
+26308,New Zealand,2010,11,C-Cardiovascular system,Million US$ at exchange rate,88.2
+26309,New Zealand,2010,11,C-Cardiovascular system,"Million US$, purchasing power parity",81.8
+26310,New Zealand,2010,11,A10-Drugs used in diabetes,"/capita, US$ purchasing power parity",4.6
+26311,New Zealand,2010,11,A10-Drugs used in diabetes,% of total sales,4.0
+26312,New Zealand,2010,11,A-Alimentary tract and metabolism,"/capita, US$ exchange rate",11.3
+26313,New Zealand,2010,11,A-Alimentary tract and metabolism,"Million US$, purchasing power parity",45.6
+26314,New Zealand,2010,11,A-Alimentary tract and metabolism,% of total sales,9.1
+26315,New Zealand,2010,11,A-Alimentary tract and metabolism,"/capita, US$ purchasing power parity",10.5
+26316,New Zealand,2010,11,C02-Antihypertensives,"/capita, US$ exchange rate",0.5
+26317,New Zealand,2010,11,C03-Diuretics,Million of national currency units,2.7
+26318,New Zealand,2010,11,A-Alimentary tract and metabolism,Million US$ at exchange rate,49.2
+26319,New Zealand,2010,11,A-Alimentary tract and metabolism,Million of national currency units,68.2
+26320,New Zealand,2010,11,C02-Antihypertensives,"/capita, US$ purchasing power parity",0.4
+26321,New Zealand,2010,11,C01A-Cardiac glycosides,"/capita, US$ purchasing power parity",0.1
+26322,New Zealand,2010,11,C01A-Cardiac glycosides,% of total sales,0.1
+26323,Norway,2011,4,M-Musculo-skeletal system,"Million US$, purchasing power parity",69.4
+26324,Norway,2011,4,M-Musculo-skeletal system,Million US$ at exchange rate,112.4
+26325,Norway,2011,4,C10-Lipid modifying agents,Million US$ at exchange rate,72.3
+26326,Norway,2011,4,C10-Lipid modifying agents,"Million US$, purchasing power parity",44.6
+26327,Norway,2011,4,C10-Lipid modifying agents,Million of national currency units,405.0
+26328,Norway,2011,4,A-Alimentary tract and metabolism,% of total sales,10.4
+26329,Norway,2011,4,A-Alimentary tract and metabolism,"/capita, US$ purchasing power parity",41.9
+26330,Norway,2011,4,G-Genito urinary system and sex hormones,Million of national currency units,925.0
+26331,Norway,2011,4,C02-Antihypertensives,Million of national currency units,56.0
+26332,Norway,2011,4,G-Genito urinary system and sex hormones,Million US$ at exchange rate,165.0
+26333,Norway,2011,4,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million US$ at exchange rate,79.8
+26334,Norway,2011,4,M-Musculo-skeletal system,"/capita, US$ purchasing power parity",14.0
+26335,Norway,2011,4,M-Musculo-skeletal system,"/capita, US$ exchange rate",22.7
+26336,Norway,2011,4,M-Musculo-skeletal system,% of total sales,3.5
+26337,Norway,2011,4,"H-Systemic hormonal preparations, excluding sex hormones and insulins",% of total sales,2.4
+26338,Norway,2011,4,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"Million US$, purchasing power parity",49.2
+26339,Norway,2011,4,C10-Lipid modifying agents,% of total sales,2.2
+26340,Norway,2011,4,N05B-Anxiolytics,"/capita, US$ exchange rate",4.3
+26341,Norway,2011,4,A-Alimentary tract and metabolism,"/capita, US$ exchange rate",67.9
+26342,Norway,2011,4,M-Musculo-skeletal system,Million of national currency units,630.0
+26343,Norway,2011,4,A-Alimentary tract and metabolism,"Million US$, purchasing power parity",207.6
+26344,Norway,2011,4,N05B-Anxiolytics,Million US$ at exchange rate,21.1
+26345,Norway,2011,4,N05B-Anxiolytics,"Million US$, purchasing power parity",13.0
+26346,Norway,2011,4,A-Alimentary tract and metabolism,Million of national currency units,1886.0
+26347,Norway,2011,4,A-Alimentary tract and metabolism,Million US$ at exchange rate,336.5
+26348,Norway,2011,4,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ purchasing power parity",9.9
+26349,Norway,2011,4,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),% of total sales,2.5
+26350,Norway,2011,4,C10-Lipid modifying agents,"/capita, US$ exchange rate",14.6
+26351,Norway,2011,4,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ exchange rate",16.1
+26352,Norway,2011,4,N05B-Anxiolytics,"/capita, US$ purchasing power parity",2.6
+26353,Norway,2011,4,N05B-Anxiolytics,Million of national currency units,118.0
+26354,Norway,2011,4,N05B-Anxiolytics,% of total sales,0.6
+26355,Norway,2011,4,C10-Lipid modifying agents,"/capita, US$ purchasing power parity",9.0
+26356,Norway,2011,4,N05C-Hypnotics and sedatives,% of total sales,0.9
+26357,Norway,2011,4,N05C-Hypnotics and sedatives,"/capita, US$ purchasing power parity",3.8
+26358,Norway,2011,4,N05C-Hypnotics and sedatives,"/capita, US$ exchange rate",6.2
+26359,Norway,2011,4,N05C-Hypnotics and sedatives,"Million US$, purchasing power parity",18.9
+26360,Norway,2011,4,B-Blood and blood forming organs,"/capita, US$ exchange rate",43.3
+26361,Norway,2011,4,B-Blood and blood forming organs,"/capita, US$ purchasing power parity",26.7
+26362,Norway,2011,4,B-Blood and blood forming organs,% of total sales,6.6
+26363,Norway,2011,4,C01A-Cardiac glycosides,% of total sales,0.0
+26364,Norway,2011,4,N06A-Antidepressants,Million of national currency units,266.0
+26365,Norway,2011,4,M01A-Antiinflammatory and antirheumatic products non-steroids,Million of national currency units,437.0
+26366,Norway,2011,4,N05C-Hypnotics and sedatives,Million US$ at exchange rate,30.7
+26367,Norway,2011,4,N05C-Hypnotics and sedatives,Million of national currency units,172.0
+26368,Norway,2011,4,C01A-Cardiac glycosides,"/capita, US$ purchasing power parity",0.1
+26369,Norway,2011,4,C01A-Cardiac glycosides,"/capita, US$ exchange rate",0.1
+26370,Norway,2011,4,A10-Drugs used in diabetes,Million of national currency units,556.0
+26371,Norway,2011,4,G03-Sex hormones and modulators of the genital system,Million of national currency units,436.0
+26372,Norway,2011,4,G03-Sex hormones and modulators of the genital system,% of total sales,2.4
+26373,Norway,2011,4,A10-Drugs used in diabetes,"Million US$, purchasing power parity",61.2
+26374,Norway,2011,4,A10-Drugs used in diabetes,Million US$ at exchange rate,99.2
+26375,Norway,2011,4,G03-Sex hormones and modulators of the genital system,"Million US$, purchasing power parity",48.0
+26376,Norway,2011,4,G03-Sex hormones and modulators of the genital system,"/capita, US$ purchasing power parity",9.7
+26377,Norway,2011,4,G03-Sex hormones and modulators of the genital system,"/capita, US$ exchange rate",15.7
+26378,Norway,2011,4,B-Blood and blood forming organs,"Million US$, purchasing power parity",132.4
+26379,Norway,2011,4,C01A-Cardiac glycosides,"Million US$, purchasing power parity",0.3
+26380,Norway,2011,4,C01A-Cardiac glycosides,Million US$ at exchange rate,0.5
+26381,Norway,2011,4,B-Blood and blood forming organs,Million of national currency units,1203.0
+26382,Norway,2011,4,B-Blood and blood forming organs,Million US$ at exchange rate,214.6
+26383,Norway,2011,4,A10-Drugs used in diabetes,"/capita, US$ purchasing power parity",12.4
+26384,Norway,2011,4,A10-Drugs used in diabetes,"/capita, US$ exchange rate",20.0
+26385,Norway,2011,4,C01A-Cardiac glycosides,Million of national currency units,3.0
+26386,Norway,2011,4,A10-Drugs used in diabetes,% of total sales,3.1
+26387,Norway,2011,4,"C01B-Antiarrhythmics, Class I and III",Million US$ at exchange rate,5.2
+26388,Norway,2011,4,"C01B-Antiarrhythmics, Class I and III",Million of national currency units,29.0
+26389,Norway,2011,4,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million US$ at exchange rate,79.4
+26390,Norway,2011,4,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million of national currency units,445.0
+26391,Norway,2011,4,Total pharmaceutical sales,"Million US$, purchasing power parity",2003.8
+26392,Norway,2011,4,Total pharmaceutical sales,Million US$ at exchange rate,3247.3
+26393,Norway,2011,4,Total pharmaceutical sales,"/capita, US$ purchasing power parity",404.6
+26394,Norway,2011,4,Total pharmaceutical sales,"/capita, US$ exchange rate",655.6
+26395,Norway,2011,4,"C01B-Antiarrhythmics, Class I and III","/capita, US$ purchasing power parity",0.6
+26396,Norway,2011,4,"C01B-Antiarrhythmics, Class I and III","/capita, US$ exchange rate",1.0
+26397,Norway,2011,4,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million of national currency units,447.0
+26398,Norway,2011,4,"C01B-Antiarrhythmics, Class I and III",% of total sales,0.2
+26399,Norway,2011,4,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ exchange rate",16.0
+26400,Norway,2011,4,"H-Systemic hormonal preparations, excluding sex hormones and insulins","Million US$, purchasing power parity",49.0
+26401,Norway,2011,4,"C01B-Antiarrhythmics, Class I and III","Million US$, purchasing power parity",3.2
+26402,Norway,2011,4,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ purchasing power parity",9.9
+26403,Norway,2011,4,N06A-Antidepressants,% of total sales,1.5
+26404,Norway,2011,4,M01A-Antiinflammatory and antirheumatic products non-steroids,Million US$ at exchange rate,78.0
+26405,Norway,2011,4,M01A-Antiinflammatory and antirheumatic products non-steroids,"Million US$, purchasing power parity",48.1
+26406,Norway,2011,4,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ exchange rate",15.7
+26407,Norway,2011,4,N06A-Antidepressants,"/capita, US$ purchasing power parity",5.9
+26408,Norway,2011,4,N06A-Antidepressants,Million US$ at exchange rate,47.5
+26409,Norway,2011,4,N06A-Antidepressants,"Million US$, purchasing power parity",29.3
+26410,Norway,2011,4,N06A-Antidepressants,"/capita, US$ exchange rate",9.6
+26411,Norway,2011,4,G-Genito urinary system and sex hormones,"/capita, US$ exchange rate",33.3
+26412,Norway,2011,4,G-Genito urinary system and sex hormones,"/capita, US$ purchasing power parity",20.6
+26413,Norway,2011,4,Total pharmaceutical sales,Million of national currency units,18200.0
+26414,Norway,2011,4,G-Genito urinary system and sex hormones,"Million US$, purchasing power parity",101.8
+26415,Norway,2011,4,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ purchasing power parity",9.7
+26416,Norway,2011,4,M01A-Antiinflammatory and antirheumatic products non-steroids,% of total sales,2.4
+26417,Norway,2011,4,G-Genito urinary system and sex hormones,% of total sales,5.1
+26418,Norway,2011,4,C02-Antihypertensives,Million US$ at exchange rate,10.0
+26419,Norway,2011,4,R03-Drugs for obstructive airway diseases,% of total sales,6.2
+26420,Norway,2011,4,A02A-Antacids,Million US$ at exchange rate,5.0
+26421,Norway,2011,4,J-Antiinfectives for systemic use,"/capita, US$ exchange rate",51.4
+26422,Norway,2011,4,A02A-Antacids,Million of national currency units,28.0
+26423,Norway,2011,4,R03-Drugs for obstructive airway diseases,"Million US$, purchasing power parity",125.1
+26424,Norway,2011,4,R03-Drugs for obstructive airway diseases,"/capita, US$ purchasing power parity",25.3
+26425,Norway,2011,4,R03-Drugs for obstructive airway diseases,"/capita, US$ exchange rate",40.9
+26426,Norway,2011,4,C07-Beta blocking agents,Million of national currency units,166.0
+26427,Norway,2011,4,C-Cardiovascular system,Million of national currency units,1797.0
+26428,Norway,2011,4,C08-Calcium channel blockers,"/capita, US$ purchasing power parity",3.1
+26429,Norway,2011,4,C08-Calcium channel blockers,% of total sales,0.8
+26430,Norway,2011,4,C-Cardiovascular system,"/capita, US$ exchange rate",64.7
+26431,Norway,2011,4,C-Cardiovascular system,"/capita, US$ purchasing power parity",39.9
+26432,Norway,2011,4,C-Cardiovascular system,Million US$ at exchange rate,320.6
+26433,Norway,2011,4,C-Cardiovascular system,"Million US$, purchasing power parity",197.8
+26434,Norway,2011,4,C03-Diuretics,Million US$ at exchange rate,18.2
+26435,Norway,2011,4,C03-Diuretics,Million of national currency units,102.0
+26436,Norway,2011,4,C03-Diuretics,"/capita, US$ exchange rate",3.7
+26437,Norway,2011,4,C03-Diuretics,"Million US$, purchasing power parity",11.2
+26438,Norway,2011,4,C09-Agents acting on the Renin-Angiotensin system,"Million US$, purchasing power parity",86.1
+26439,Norway,2011,4,C09-Agents acting on the Renin-Angiotensin system,Million US$ at exchange rate,139.5
+26440,Norway,2011,4,N-Nervous system,% of total sales,19.0
+26441,Norway,2011,4,C09-Agents acting on the Renin-Angiotensin system,Million of national currency units,782.0
+26442,Norway,2011,4,J-Antiinfectives for systemic use,Million of national currency units,1426.0
+26443,Norway,2011,4,C-Cardiovascular system,% of total sales,9.9
+26444,Norway,2011,4,J-Antiinfectives for systemic use,Million US$ at exchange rate,254.4
+26445,Norway,2011,4,C03-Diuretics,% of total sales,0.6
+26446,Norway,2011,4,C03-Diuretics,"/capita, US$ purchasing power parity",2.3
+26447,Norway,2011,4,R03-Drugs for obstructive airway diseases,Million US$ at exchange rate,202.7
+26448,Norway,2011,4,R03-Drugs for obstructive airway diseases,Million of national currency units,1136.0
+26449,Norway,2011,4,J-Antiinfectives for systemic use,"Million US$, purchasing power parity",157.0
+26450,Norway,2011,4,J01-Antibacterials for systemic use,"/capita, US$ purchasing power parity",10.0
+26451,Norway,2011,4,G03-Sex hormones and modulators of the genital system,Million US$ at exchange rate,77.8
+26452,Norway,2011,4,C08-Calcium channel blockers,Million of national currency units,141.0
+26453,Norway,2011,4,J01-Antibacterials for systemic use,"Million US$, purchasing power parity",49.3
+26454,Norway,2011,4,J01-Antibacterials for systemic use,"/capita, US$ exchange rate",16.1
+26455,Norway,2011,4,C08-Calcium channel blockers,"/capita, US$ exchange rate",5.1
+26456,Norway,2011,4,C08-Calcium channel blockers,Million US$ at exchange rate,25.2
+26457,Norway,2011,4,C08-Calcium channel blockers,"Million US$, purchasing power parity",15.5
+26458,Norway,2011,4,Products not elsewhere classified,"Million US$, purchasing power parity",495.2
+26459,Norway,2011,4,Products not elsewhere classified,"/capita, US$ exchange rate",162.0
+26460,Norway,2011,4,Products not elsewhere classified,Million of national currency units,4498.0
+26461,Norway,2011,4,Products not elsewhere classified,Million US$ at exchange rate,802.6
+26462,Norway,2011,4,J01-Antibacterials for systemic use,Million of national currency units,448.0
+26463,Norway,2011,4,J01-Antibacterials for systemic use,Million US$ at exchange rate,79.9
+26464,Norway,2011,4,Products not elsewhere classified,"/capita, US$ purchasing power parity",100.0
+26465,Norway,2011,4,Products not elsewhere classified,% of total sales,24.7
+26466,Norway,2011,4,J-Antiinfectives for systemic use,% of total sales,7.8
+26467,Norway,2011,4,N02-Analgesics,Million US$ at exchange rate,217.5
+26468,Norway,2011,4,N02-Analgesics,"Million US$, purchasing power parity",134.2
+26469,Norway,2011,4,C07-Beta blocking agents,Million US$ at exchange rate,29.6
+26470,Norway,2011,4,N02-Analgesics,Million of national currency units,1219.0
+26471,Norway,2011,4,N02-Analgesics,% of total sales,6.7
+26472,Norway,2011,4,N02-Analgesics,"/capita, US$ exchange rate",43.9
+26473,Norway,2011,4,N02-Analgesics,"/capita, US$ purchasing power parity",27.1
+26474,Norway,2011,4,J01-Antibacterials for systemic use,% of total sales,2.5
+26475,Norway,2011,4,J-Antiinfectives for systemic use,"/capita, US$ purchasing power parity",31.7
+26476,Norway,2011,4,C07-Beta blocking agents,"/capita, US$ exchange rate",6.0
+26477,Norway,2011,4,C07-Beta blocking agents,"Million US$, purchasing power parity",18.3
+26478,Norway,2011,4,C07-Beta blocking agents,% of total sales,0.9
+26479,Norway,2011,4,C07-Beta blocking agents,"/capita, US$ purchasing power parity",3.7
+26480,Norway,2011,4,R-Respiratory system,Million US$ at exchange rate,339.4
+26481,Norway,2011,4,R-Respiratory system,Million of national currency units,1902.0
+26482,Norway,2011,4,R-Respiratory system,"/capita, US$ exchange rate",68.5
+26483,Norway,2011,4,R-Respiratory system,"Million US$, purchasing power parity",209.4
+26484,Norway,2011,4,C02-Antihypertensives,"/capita, US$ purchasing power parity",1.2
+26485,Norway,2011,4,N-Nervous system,"Million US$, purchasing power parity",380.7
+26486,Norway,2011,4,N-Nervous system,Million US$ at exchange rate,617.0
+26487,Norway,2011,4,C02-Antihypertensives,% of total sales,0.3
+26488,Norway,2011,4,A02A-Antacids,"/capita, US$ purchasing power parity",0.6
+26489,Norway,2011,4,A02A-Antacids,"/capita, US$ exchange rate",1.0
+26490,Norway,2011,4,A02A-Antacids,% of total sales,0.2
+26491,Norway,2011,4,R-Respiratory system,"/capita, US$ purchasing power parity",42.3
+26492,Norway,2011,4,N-Nervous system,Million of national currency units,3458.0
+26493,Norway,2011,4,R-Respiratory system,% of total sales,10.5
+26494,Norway,2011,4,A02A-Antacids,"Million US$, purchasing power parity",3.1
+26495,Norway,2011,4,N-Nervous system,"/capita, US$ purchasing power parity",76.9
+26496,Norway,2011,4,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ exchange rate",28.2
+26497,Norway,2011,4,C02-Antihypertensives,"/capita, US$ exchange rate",2.0
+26498,Norway,2011,4,C09-Agents acting on the Renin-Angiotensin system,% of total sales,4.3
+26499,Norway,2011,4,C02-Antihypertensives,"Million US$, purchasing power parity",6.2
+26500,Norway,2011,4,N-Nervous system,"/capita, US$ exchange rate",124.6
+26501,Norway,2011,4,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ purchasing power parity",17.4
+26502,Norway,2012,3,M-Musculo-skeletal system,"Million US$, purchasing power parity",73.1
+26503,Norway,2012,3,M-Musculo-skeletal system,Million US$ at exchange rate,113.6
+26504,Norway,2012,3,C10-Lipid modifying agents,Million US$ at exchange rate,64.5
+26505,Norway,2012,3,C10-Lipid modifying agents,"Million US$, purchasing power parity",41.5
+26506,Norway,2012,3,N05B-Anxiolytics,% of total sales,0.6
+26507,Norway,2012,3,A-Alimentary tract and metabolism,"/capita, US$ purchasing power parity",42.1
+26508,Norway,2012,3,C10-Lipid modifying agents,Million of national currency units,375.0
+26509,Norway,2012,3,A-Alimentary tract and metabolism,% of total sales,10.2
+26510,Norway,2012,3,N05B-Anxiolytics,"Million US$, purchasing power parity",12.8
+26511,Norway,2012,3,G-Genito urinary system and sex hormones,Million of national currency units,948.0
+26512,Norway,2012,3,C02-Antihypertensives,Million of national currency units,61.0
+26513,Norway,2012,3,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million US$ at exchange rate,71.2
+26514,Norway,2012,3,G-Genito urinary system and sex hormones,Million US$ at exchange rate,163.0
+26515,Norway,2012,3,M-Musculo-skeletal system,% of total sales,3.5
+26516,Norway,2012,3,M-Musculo-skeletal system,"/capita, US$ purchasing power parity",14.6
+26517,Norway,2012,3,M-Musculo-skeletal system,"/capita, US$ exchange rate",22.6
+26518,Norway,2012,3,"H-Systemic hormonal preparations, excluding sex hormones and insulins",% of total sales,2.5
+26519,Norway,2012,3,A-Alimentary tract and metabolism,"Million US$, purchasing power parity",211.4
+26520,Norway,2012,3,C10-Lipid modifying agents,% of total sales,2.0
+26521,Norway,2012,3,A-Alimentary tract and metabolism,"/capita, US$ exchange rate",65.4
+26522,Norway,2012,3,N05B-Anxiolytics,"/capita, US$ exchange rate",4.0
+26523,Norway,2012,3,M-Musculo-skeletal system,Million of national currency units,661.0
+26524,Norway,2012,3,N05B-Anxiolytics,Million US$ at exchange rate,19.9
+26525,Norway,2012,3,A-Alimentary tract and metabolism,Million of national currency units,1910.0
+26526,Norway,2012,3,A-Alimentary tract and metabolism,Million US$ at exchange rate,328.3
+26527,Norway,2012,3,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ purchasing power parity",9.1
+26528,Norway,2012,3,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),% of total sales,2.2
+26529,Norway,2012,3,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"Million US$, purchasing power parity",45.8
+26530,Norway,2012,3,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ exchange rate",14.2
+26531,Norway,2012,3,N05B-Anxiolytics,"/capita, US$ purchasing power parity",2.6
+26532,Norway,2012,3,N05B-Anxiolytics,Million of national currency units,116.0
+26533,Norway,2012,3,C10-Lipid modifying agents,"/capita, US$ exchange rate",12.8
+26534,Norway,2012,3,C10-Lipid modifying agents,"/capita, US$ purchasing power parity",8.3
+26535,Norway,2012,3,N05C-Hypnotics and sedatives,"/capita, US$ purchasing power parity",4.3
+26536,Norway,2012,3,N05C-Hypnotics and sedatives,% of total sales,1.0
+26537,Norway,2012,3,N05C-Hypnotics and sedatives,"Million US$, purchasing power parity",21.5
+26538,Norway,2012,3,N05C-Hypnotics and sedatives,"/capita, US$ exchange rate",6.6
+26539,Norway,2012,3,B-Blood and blood forming organs,"/capita, US$ exchange rate",43.6
+26540,Norway,2012,3,B-Blood and blood forming organs,"/capita, US$ purchasing power parity",28.1
+26541,Norway,2012,3,B-Blood and blood forming organs,% of total sales,6.8
+26542,Norway,2012,3,G03-Sex hormones and modulators of the genital system,% of total sales,2.3
+26543,Norway,2012,3,C01A-Cardiac glycosides,% of total sales,0.0
+26544,Norway,2012,3,M01A-Antiinflammatory and antirheumatic products non-steroids,Million of national currency units,446.0
+26545,Norway,2012,3,C01A-Cardiac glycosides,"/capita, US$ purchasing power parity",0.1
+26546,Norway,2012,3,N05C-Hypnotics and sedatives,Million US$ at exchange rate,33.3
+26547,Norway,2012,3,N05C-Hypnotics and sedatives,Million of national currency units,194.0
+26548,Norway,2012,3,C01A-Cardiac glycosides,"/capita, US$ exchange rate",0.1
+26549,Norway,2012,3,N06A-Antidepressants,Million of national currency units,266.0
+26550,Norway,2012,3,B-Blood and blood forming organs,"Million US$, purchasing power parity",141.0
+26551,Norway,2012,3,A10-Drugs used in diabetes,Million of national currency units,596.0
+26552,Norway,2012,3,G03-Sex hormones and modulators of the genital system,Million of national currency units,441.0
+26553,Norway,2012,3,A10-Drugs used in diabetes,"Million US$, purchasing power parity",66.0
+26554,Norway,2012,3,A10-Drugs used in diabetes,Million US$ at exchange rate,102.4
+26555,Norway,2012,3,G03-Sex hormones and modulators of the genital system,"Million US$, purchasing power parity",48.8
+26556,Norway,2012,3,G03-Sex hormones and modulators of the genital system,Million US$ at exchange rate,75.8
+26557,Norway,2012,3,G03-Sex hormones and modulators of the genital system,"/capita, US$ purchasing power parity",9.7
+26558,Norway,2012,3,G03-Sex hormones and modulators of the genital system,"/capita, US$ exchange rate",15.1
+26559,Norway,2012,3,C01A-Cardiac glycosides,"Million US$, purchasing power parity",0.3
+26560,Norway,2012,3,C01A-Cardiac glycosides,Million US$ at exchange rate,0.5
+26561,Norway,2012,3,B-Blood and blood forming organs,Million of national currency units,1274.0
+26562,Norway,2012,3,B-Blood and blood forming organs,Million US$ at exchange rate,219.0
+26563,Norway,2012,3,A10-Drugs used in diabetes,"/capita, US$ purchasing power parity",13.1
+26564,Norway,2012,3,A10-Drugs used in diabetes,"/capita, US$ exchange rate",20.4
+26565,Norway,2012,3,C01A-Cardiac glycosides,Million of national currency units,3.0
+26566,Norway,2012,3,A10-Drugs used in diabetes,% of total sales,3.2
+26567,Norway,2012,3,"C01B-Antiarrhythmics, Class I and III",Million US$ at exchange rate,5.0
+26568,Norway,2012,3,"C01B-Antiarrhythmics, Class I and III",Million of national currency units,29.0
+26569,Norway,2012,3,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million US$ at exchange rate,80.4
+26570,Norway,2012,3,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million of national currency units,468.0
+26571,Norway,2012,3,Total pharmaceutical sales,"Million US$, purchasing power parity",2080.3
+26572,Norway,2012,3,Total pharmaceutical sales,Million US$ at exchange rate,3231.6
+26573,Norway,2012,3,Total pharmaceutical sales,"/capita, US$ purchasing power parity",414.5
+26574,Norway,2012,3,Total pharmaceutical sales,"/capita, US$ exchange rate",643.9
+26575,Norway,2012,3,"C01B-Antiarrhythmics, Class I and III","/capita, US$ purchasing power parity",0.6
+26576,Norway,2012,3,"C01B-Antiarrhythmics, Class I and III","/capita, US$ exchange rate",1.0
+26577,Norway,2012,3,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million of national currency units,414.0
+26578,Norway,2012,3,"C01B-Antiarrhythmics, Class I and III",% of total sales,0.2
+26579,Norway,2012,3,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ exchange rate",16.0
+26580,Norway,2012,3,"H-Systemic hormonal preparations, excluding sex hormones and insulins","Million US$, purchasing power parity",51.8
+26581,Norway,2012,3,"C01B-Antiarrhythmics, Class I and III","Million US$, purchasing power parity",3.2
+26582,Norway,2012,3,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ purchasing power parity",10.3
+26583,Norway,2012,3,N06A-Antidepressants,% of total sales,1.4
+26584,Norway,2012,3,M01A-Antiinflammatory and antirheumatic products non-steroids,Million US$ at exchange rate,76.7
+26585,Norway,2012,3,M01A-Antiinflammatory and antirheumatic products non-steroids,"Million US$, purchasing power parity",49.4
+26586,Norway,2012,3,N06A-Antidepressants,Million US$ at exchange rate,45.7
+26587,Norway,2012,3,N06A-Antidepressants,"Million US$, purchasing power parity",29.4
+26588,Norway,2012,3,N06A-Antidepressants,"/capita, US$ purchasing power parity",5.9
+26589,Norway,2012,3,N06A-Antidepressants,"/capita, US$ exchange rate",9.1
+26590,Norway,2012,3,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ exchange rate",15.3
+26591,Norway,2012,3,G-Genito urinary system and sex hormones,"/capita, US$ exchange rate",32.5
+26592,Norway,2012,3,G-Genito urinary system and sex hormones,"/capita, US$ purchasing power parity",20.9
+26593,Norway,2012,3,Total pharmaceutical sales,Million of national currency units,18800.0
+26594,Norway,2012,3,G-Genito urinary system and sex hormones,"Million US$, purchasing power parity",104.9
+26595,Norway,2012,3,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ purchasing power parity",9.8
+26596,Norway,2012,3,M01A-Antiinflammatory and antirheumatic products non-steroids,% of total sales,2.4
+26597,Norway,2012,3,G-Genito urinary system and sex hormones,% of total sales,5.0
+26598,Norway,2012,3,R03-Drugs for obstructive airway diseases,% of total sales,6.0
+26599,Norway,2012,3,A02A-Antacids,Million of national currency units,28.0
+26600,Norway,2012,3,A02A-Antacids,Million US$ at exchange rate,4.8
+26601,Norway,2012,3,R03-Drugs for obstructive airway diseases,"Million US$, purchasing power parity",123.8
+26602,Norway,2012,3,R03-Drugs for obstructive airway diseases,Million US$ at exchange rate,192.4
+26603,Norway,2012,3,R03-Drugs for obstructive airway diseases,"/capita, US$ purchasing power parity",24.7
+26604,Norway,2012,3,R03-Drugs for obstructive airway diseases,"/capita, US$ exchange rate",38.3
+26605,Norway,2012,3,C-Cardiovascular system,"/capita, US$ purchasing power parity",36.0
+26606,Norway,2012,3,C07-Beta blocking agents,Million of national currency units,165.0
+26607,Norway,2012,3,C-Cardiovascular system,Million of national currency units,1631.0
+26608,Norway,2012,3,C08-Calcium channel blockers,% of total sales,0.7
+26609,Norway,2012,3,C08-Calcium channel blockers,"/capita, US$ purchasing power parity",2.9
+26610,Norway,2012,3,C-Cardiovascular system,"/capita, US$ exchange rate",55.9
+26611,Norway,2012,3,C-Cardiovascular system,Million US$ at exchange rate,280.4
+26612,Norway,2012,3,C-Cardiovascular system,"Million US$, purchasing power parity",180.5
+26613,Norway,2012,3,J-Antiinfectives for systemic use,"Million US$, purchasing power parity",169.7
+26614,Norway,2012,3,C03-Diuretics,Million US$ at exchange rate,17.0
+26615,Norway,2012,3,C03-Diuretics,Million of national currency units,99.0
+26616,Norway,2012,3,C03-Diuretics,"/capita, US$ exchange rate",3.4
+26617,Norway,2012,3,C03-Diuretics,"Million US$, purchasing power parity",11.0
+26618,Norway,2012,3,C09-Agents acting on the Renin-Angiotensin system,Million US$ at exchange rate,111.2
+26619,Norway,2012,3,C09-Agents acting on the Renin-Angiotensin system,"Million US$, purchasing power parity",71.6
+26620,Norway,2012,3,N-Nervous system,% of total sales,19.1
+26621,Norway,2012,3,C09-Agents acting on the Renin-Angiotensin system,Million of national currency units,647.0
+26622,Norway,2012,3,J-Antiinfectives for systemic use,Million of national currency units,1534.0
+26623,Norway,2012,3,C-Cardiovascular system,% of total sales,8.7
+26624,Norway,2012,3,J-Antiinfectives for systemic use,Million US$ at exchange rate,263.7
+26625,Norway,2012,3,C03-Diuretics,% of total sales,0.5
+26626,Norway,2012,3,C03-Diuretics,"/capita, US$ purchasing power parity",2.2
+26627,Norway,2012,3,R03-Drugs for obstructive airway diseases,Million of national currency units,1119.0
+26628,Norway,2012,3,C08-Calcium channel blockers,"/capita, US$ exchange rate",4.5
+26629,Norway,2012,3,J01-Antibacterials for systemic use,"/capita, US$ purchasing power parity",10.1
+26630,Norway,2012,3,C08-Calcium channel blockers,Million of national currency units,132.0
+26631,Norway,2012,3,J01-Antibacterials for systemic use,"/capita, US$ exchange rate",15.7
+26632,Norway,2012,3,J01-Antibacterials for systemic use,"Million US$, purchasing power parity",50.7
+26633,Norway,2012,3,J-Antiinfectives for systemic use,% of total sales,8.2
+26634,Norway,2012,3,C08-Calcium channel blockers,"Million US$, purchasing power parity",14.6
+26635,Norway,2012,3,C08-Calcium channel blockers,Million US$ at exchange rate,22.7
+26636,Norway,2012,3,Products not elsewhere classified,"Million US$, purchasing power parity",535.8
+26637,Norway,2012,3,Products not elsewhere classified,"/capita, US$ exchange rate",165.8
+26638,Norway,2012,3,Products not elsewhere classified,Million of national currency units,4842.0
+26639,Norway,2012,3,Products not elsewhere classified,Million US$ at exchange rate,832.3
+26640,Norway,2012,3,J01-Antibacterials for systemic use,Million of national currency units,458.0
+26641,Norway,2012,3,J01-Antibacterials for systemic use,Million US$ at exchange rate,78.7
+26642,Norway,2012,3,Products not elsewhere classified,"/capita, US$ purchasing power parity",106.8
+26643,Norway,2012,3,Products not elsewhere classified,% of total sales,25.8
+26644,Norway,2012,3,N02-Analgesics,Million US$ at exchange rate,215.9
+26645,Norway,2012,3,N02-Analgesics,"Million US$, purchasing power parity",139.0
+26646,Norway,2012,3,C07-Beta blocking agents,Million US$ at exchange rate,28.4
+26647,Norway,2012,3,N02-Analgesics,Million of national currency units,1256.0
+26648,Norway,2012,3,N02-Analgesics,% of total sales,6.7
+26649,Norway,2012,3,N02-Analgesics,"/capita, US$ purchasing power parity",27.7
+26650,Norway,2012,3,N02-Analgesics,"/capita, US$ exchange rate",43.0
+26651,Norway,2012,3,J01-Antibacterials for systemic use,% of total sales,2.4
+26652,Norway,2012,3,J-Antiinfectives for systemic use,"/capita, US$ purchasing power parity",33.8
+26653,Norway,2012,3,J-Antiinfectives for systemic use,"/capita, US$ exchange rate",52.5
+26654,Norway,2012,3,C07-Beta blocking agents,"/capita, US$ exchange rate",5.7
+26655,Norway,2012,3,C07-Beta blocking agents,"Million US$, purchasing power parity",18.3
+26656,Norway,2012,3,C07-Beta blocking agents,% of total sales,0.9
+26657,Norway,2012,3,C07-Beta blocking agents,"/capita, US$ purchasing power parity",3.6
+26658,Norway,2012,3,R-Respiratory system,Million US$ at exchange rate,331.4
+26659,Norway,2012,3,R-Respiratory system,Million of national currency units,1928.0
+26660,Norway,2012,3,R-Respiratory system,"/capita, US$ exchange rate",66.0
+26661,Norway,2012,3,R-Respiratory system,"Million US$, purchasing power parity",213.3
+26662,Norway,2012,3,C02-Antihypertensives,"/capita, US$ purchasing power parity",1.3
+26663,Norway,2012,3,N-Nervous system,Million US$ at exchange rate,618.7
+26664,Norway,2012,3,C02-Antihypertensives,% of total sales,0.3
+26665,Norway,2012,3,A02A-Antacids,"/capita, US$ purchasing power parity",0.6
+26666,Norway,2012,3,A02A-Antacids,"/capita, US$ exchange rate",1.0
+26667,Norway,2012,3,A02A-Antacids,% of total sales,0.1
+26668,Norway,2012,3,N-Nervous system,"Million US$, purchasing power parity",398.2
+26669,Norway,2012,3,R-Respiratory system,"/capita, US$ purchasing power parity",42.5
+26670,Norway,2012,3,N-Nervous system,Million of national currency units,3599.0
+26671,Norway,2012,3,A02A-Antacids,"Million US$, purchasing power parity",3.1
+26672,Norway,2012,3,R-Respiratory system,% of total sales,10.3
+26673,Norway,2012,3,N-Nervous system,"/capita, US$ purchasing power parity",79.4
+26674,Norway,2012,3,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ exchange rate",22.2
+26675,Norway,2012,3,C09-Agents acting on the Renin-Angiotensin system,% of total sales,3.4
+26676,Norway,2012,3,C02-Antihypertensives,"Million US$, purchasing power parity",6.7
+26677,Norway,2012,3,N-Nervous system,"/capita, US$ exchange rate",123.3
+26678,Norway,2012,3,C02-Antihypertensives,Million US$ at exchange rate,10.5
+26679,Norway,2012,3,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ purchasing power parity",14.3
+26680,Norway,2012,3,C02-Antihypertensives,"/capita, US$ exchange rate",2.1
+26681,Norway,2013,3,M-Musculo-skeletal system,"Million US$, purchasing power parity",79.1
+26682,Norway,2013,3,M-Musculo-skeletal system,Million US$ at exchange rate,121.5
+26683,Norway,2013,3,N05B-Anxiolytics,% of total sales,0.6
+26684,Norway,2013,3,C10-Lipid modifying agents,Million US$ at exchange rate,66.6
+26685,Norway,2013,3,C10-Lipid modifying agents,"Million US$, purchasing power parity",43.3
+26686,Norway,2013,3,C10-Lipid modifying agents,Million of national currency units,391.0
+26687,Norway,2013,3,A-Alimentary tract and metabolism,% of total sales,9.9
+26688,Norway,2013,3,A-Alimentary tract and metabolism,"/capita, US$ purchasing power parity",41.8
+26689,Norway,2013,3,G-Genito urinary system and sex hormones,Million of national currency units,983.0
+26690,Norway,2013,3,C02-Antihypertensives,Million of national currency units,69.0
+26691,Norway,2013,3,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million US$ at exchange rate,65.9
+26692,Norway,2013,3,G-Genito urinary system and sex hormones,Million US$ at exchange rate,167.3
+26693,Norway,2013,3,M-Musculo-skeletal system,"/capita, US$ purchasing power parity",15.6
+26694,Norway,2013,3,M-Musculo-skeletal system,"/capita, US$ exchange rate",23.9
+26695,Norway,2013,3,"H-Systemic hormonal preparations, excluding sex hormones and insulins",% of total sales,2.5
+26696,Norway,2013,3,M-Musculo-skeletal system,% of total sales,3.7
+26697,Norway,2013,3,A-Alimentary tract and metabolism,"Million US$, purchasing power parity",212.1
+26698,Norway,2013,3,C10-Lipid modifying agents,% of total sales,2.0
+26699,Norway,2013,3,N05B-Anxiolytics,"/capita, US$ exchange rate",3.8
+26700,Norway,2013,3,A-Alimentary tract and metabolism,"/capita, US$ exchange rate",64.2
+26701,Norway,2013,3,M-Musculo-skeletal system,Million of national currency units,714.0
+26702,Norway,2013,3,N05B-Anxiolytics,Million US$ at exchange rate,19.4
+26703,Norway,2013,3,A-Alimentary tract and metabolism,Million of national currency units,1915.0
+26704,Norway,2013,3,A-Alimentary tract and metabolism,Million US$ at exchange rate,326.0
+26705,Norway,2013,3,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ purchasing power parity",8.4
+26706,Norway,2013,3,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),% of total sales,2.0
+26707,Norway,2013,3,N05B-Anxiolytics,"Million US$, purchasing power parity",12.6
+26708,Norway,2013,3,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"Million US$, purchasing power parity",42.9
+26709,Norway,2013,3,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ exchange rate",13.0
+26710,Norway,2013,3,N05B-Anxiolytics,"/capita, US$ purchasing power parity",2.5
+26711,Norway,2013,3,N05B-Anxiolytics,Million of national currency units,114.0
+26712,Norway,2013,3,C10-Lipid modifying agents,"/capita, US$ exchange rate",13.1
+26713,Norway,2013,3,C10-Lipid modifying agents,"/capita, US$ purchasing power parity",8.5
+26714,Norway,2013,3,N05C-Hypnotics and sedatives,"/capita, US$ purchasing power parity",4.2
+26715,Norway,2013,3,N05C-Hypnotics and sedatives,% of total sales,1.0
+26716,Norway,2013,3,N05C-Hypnotics and sedatives,"Million US$, purchasing power parity",21.2
+26717,Norway,2013,3,N05C-Hypnotics and sedatives,"/capita, US$ exchange rate",6.4
+26718,Norway,2013,3,B-Blood and blood forming organs,"/capita, US$ exchange rate",50.2
+26719,Norway,2013,3,B-Blood and blood forming organs,% of total sales,7.8
+26720,Norway,2013,3,B-Blood and blood forming organs,"/capita, US$ purchasing power parity",32.7
+26721,Norway,2013,3,B-Blood and blood forming organs,"Million US$, purchasing power parity",165.9
+26722,Norway,2013,3,C01A-Cardiac glycosides,% of total sales,0.0
+26723,Norway,2013,3,G03-Sex hormones and modulators of the genital system,% of total sales,2.4
+26724,Norway,2013,3,M01A-Antiinflammatory and antirheumatic products non-steroids,Million of national currency units,464.0
+26725,Norway,2013,3,N05C-Hypnotics and sedatives,Million of national currency units,191.0
+26726,Norway,2013,3,N05C-Hypnotics and sedatives,Million US$ at exchange rate,32.5
+26727,Norway,2013,3,C01A-Cardiac glycosides,"/capita, US$ purchasing power parity",0.1
+26728,Norway,2013,3,C01A-Cardiac glycosides,"/capita, US$ exchange rate",0.2
+26729,Norway,2013,3,A10-Drugs used in diabetes,Million of national currency units,601.0
+26730,Norway,2013,3,G03-Sex hormones and modulators of the genital system,Million of national currency units,454.0
+26731,Norway,2013,3,A10-Drugs used in diabetes,"Million US$, purchasing power parity",66.6
+26732,Norway,2013,3,A10-Drugs used in diabetes,Million US$ at exchange rate,102.3
+26733,Norway,2013,3,G03-Sex hormones and modulators of the genital system,"Million US$, purchasing power parity",50.3
+26734,Norway,2013,3,G03-Sex hormones and modulators of the genital system,Million US$ at exchange rate,77.3
+26735,Norway,2013,3,G03-Sex hormones and modulators of the genital system,"/capita, US$ purchasing power parity",9.9
+26736,Norway,2013,3,G03-Sex hormones and modulators of the genital system,"/capita, US$ exchange rate",15.2
+26737,Norway,2013,3,C01A-Cardiac glycosides,"Million US$, purchasing power parity",0.6
+26738,Norway,2013,3,C01A-Cardiac glycosides,Million US$ at exchange rate,0.9
+26739,Norway,2013,3,B-Blood and blood forming organs,Million of national currency units,1498.0
+26740,Norway,2013,3,B-Blood and blood forming organs,Million US$ at exchange rate,255.0
+26741,Norway,2013,3,A10-Drugs used in diabetes,"/capita, US$ purchasing power parity",13.1
+26742,Norway,2013,3,A10-Drugs used in diabetes,"/capita, US$ exchange rate",20.1
+26743,Norway,2013,3,C01A-Cardiac glycosides,Million of national currency units,5.0
+26744,Norway,2013,3,A10-Drugs used in diabetes,% of total sales,3.1
+26745,Norway,2013,3,N06A-Antidepressants,Million of national currency units,261.0
+26746,Norway,2013,3,"C01B-Antiarrhythmics, Class I and III",Million US$ at exchange rate,5.3
+26747,Norway,2013,3,"C01B-Antiarrhythmics, Class I and III",Million of national currency units,31.0
+26748,Norway,2013,3,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million US$ at exchange rate,82.6
+26749,Norway,2013,3,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million of national currency units,485.0
+26750,Norway,2013,3,Total pharmaceutical sales,"Million US$, purchasing power parity",2137.5
+26751,Norway,2013,3,Total pharmaceutical sales,Million US$ at exchange rate,3285.1
+26752,Norway,2013,3,Total pharmaceutical sales,"/capita, US$ purchasing power parity",420.8
+26753,Norway,2013,3,Total pharmaceutical sales,"/capita, US$ exchange rate",646.7
+26754,Norway,2013,3,"C01B-Antiarrhythmics, Class I and III","/capita, US$ purchasing power parity",0.7
+26755,Norway,2013,3,"C01B-Antiarrhythmics, Class I and III","/capita, US$ exchange rate",1.0
+26756,Norway,2013,3,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million of national currency units,387.0
+26757,Norway,2013,3,"C01B-Antiarrhythmics, Class I and III",% of total sales,0.2
+26758,Norway,2013,3,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ exchange rate",16.3
+26759,Norway,2013,3,"H-Systemic hormonal preparations, excluding sex hormones and insulins","Million US$, purchasing power parity",53.7
+26760,Norway,2013,3,"C01B-Antiarrhythmics, Class I and III","Million US$, purchasing power parity",3.4
+26761,Norway,2013,3,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ purchasing power parity",10.6
+26762,Norway,2013,3,N06A-Antidepressants,% of total sales,1.4
+26763,Norway,2013,3,M01A-Antiinflammatory and antirheumatic products non-steroids,Million US$ at exchange rate,79.0
+26764,Norway,2013,3,M01A-Antiinflammatory and antirheumatic products non-steroids,"Million US$, purchasing power parity",51.4
+26765,Norway,2013,3,N06A-Antidepressants,"/capita, US$ purchasing power parity",5.7
+26766,Norway,2013,3,N06A-Antidepressants,Million US$ at exchange rate,44.4
+26767,Norway,2013,3,N06A-Antidepressants,"Million US$, purchasing power parity",28.9
+26768,Norway,2013,3,N06A-Antidepressants,"/capita, US$ exchange rate",8.7
+26769,Norway,2013,3,G-Genito urinary system and sex hormones,"/capita, US$ exchange rate",32.9
+26770,Norway,2013,3,G-Genito urinary system and sex hormones,"/capita, US$ purchasing power parity",21.4
+26771,Norway,2013,3,Total pharmaceutical sales,Million of national currency units,19300.0
+26772,Norway,2013,3,G-Genito urinary system and sex hormones,"Million US$, purchasing power parity",108.9
+26773,Norway,2013,3,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ exchange rate",15.5
+26774,Norway,2013,3,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ purchasing power parity",10.1
+26775,Norway,2013,3,M01A-Antiinflammatory and antirheumatic products non-steroids,% of total sales,2.4
+26776,Norway,2013,3,G-Genito urinary system and sex hormones,% of total sales,5.1
+26777,Norway,2013,3,R03-Drugs for obstructive airway diseases,% of total sales,5.4
+26778,Norway,2013,3,A02A-Antacids,Million of national currency units,29.0
+26779,Norway,2013,3,A02A-Antacids,Million US$ at exchange rate,4.9
+26780,Norway,2013,3,R03-Drugs for obstructive airway diseases,"Million US$, purchasing power parity",115.7
+26781,Norway,2013,3,R03-Drugs for obstructive airway diseases,Million US$ at exchange rate,177.9
+26782,Norway,2013,3,R03-Drugs for obstructive airway diseases,"/capita, US$ purchasing power parity",22.8
+26783,Norway,2013,3,R03-Drugs for obstructive airway diseases,"/capita, US$ exchange rate",35.0
+26784,Norway,2013,3,C-Cardiovascular system,"/capita, US$ purchasing power parity",32.3
+26785,Norway,2013,3,C08-Calcium channel blockers,% of total sales,0.7
+26786,Norway,2013,3,C07-Beta blocking agents,Million of national currency units,167.0
+26787,Norway,2013,3,C-Cardiovascular system,Million of national currency units,1481.0
+26788,Norway,2013,3,C08-Calcium channel blockers,"/capita, US$ purchasing power parity",2.8
+26789,Norway,2013,3,C-Cardiovascular system,"/capita, US$ exchange rate",49.6
+26790,Norway,2013,3,C-Cardiovascular system,Million US$ at exchange rate,252.1
+26791,Norway,2013,3,C-Cardiovascular system,"Million US$, purchasing power parity",164.0
+26792,Norway,2013,3,J-Antiinfectives for systemic use,"Million US$, purchasing power parity",167.7
+26793,Norway,2013,3,C03-Diuretics,Million US$ at exchange rate,16.7
+26794,Norway,2013,3,C03-Diuretics,Million of national currency units,98.0
+26795,Norway,2013,3,C03-Diuretics,"/capita, US$ exchange rate",3.3
+26796,Norway,2013,3,C03-Diuretics,"Million US$, purchasing power parity",10.9
+26797,Norway,2013,3,C09-Agents acting on the Renin-Angiotensin system,Million US$ at exchange rate,80.2
+26798,Norway,2013,3,C09-Agents acting on the Renin-Angiotensin system,"Million US$, purchasing power parity",52.2
+26799,Norway,2013,3,N-Nervous system,% of total sales,18.5
+26800,Norway,2013,3,C09-Agents acting on the Renin-Angiotensin system,Million of national currency units,471.0
+26801,Norway,2013,3,C-Cardiovascular system,% of total sales,7.7
+26802,Norway,2013,3,J-Antiinfectives for systemic use,Million of national currency units,1514.0
+26803,Norway,2013,3,J-Antiinfectives for systemic use,Million US$ at exchange rate,257.7
+26804,Norway,2013,3,C03-Diuretics,% of total sales,0.5
+26805,Norway,2013,3,C03-Diuretics,"/capita, US$ purchasing power parity",2.1
+26806,Norway,2013,3,R03-Drugs for obstructive airway diseases,Million of national currency units,1045.0
+26807,Norway,2013,3,C08-Calcium channel blockers,"/capita, US$ exchange rate",4.3
+26808,Norway,2013,3,C08-Calcium channel blockers,Million of national currency units,128.0
+26809,Norway,2013,3,J01-Antibacterials for systemic use,"/capita, US$ purchasing power parity",9.2
+26810,Norway,2013,3,J01-Antibacterials for systemic use,"Million US$, purchasing power parity",46.8
+26811,Norway,2013,3,J01-Antibacterials for systemic use,"/capita, US$ exchange rate",14.2
+26812,Norway,2013,3,J-Antiinfectives for systemic use,% of total sales,7.8
+26813,Norway,2013,3,C08-Calcium channel blockers,Million US$ at exchange rate,21.8
+26814,Norway,2013,3,C08-Calcium channel blockers,"Million US$, purchasing power parity",14.2
+26815,Norway,2013,3,Products not elsewhere classified,"Million US$, purchasing power parity",580.7
+26816,Norway,2013,3,Products not elsewhere classified,"/capita, US$ exchange rate",175.7
+26817,Norway,2013,3,Products not elsewhere classified,Million of national currency units,5243.0
+26818,Norway,2013,3,Products not elsewhere classified,Million US$ at exchange rate,892.4
+26819,Norway,2013,3,J01-Antibacterials for systemic use,Million of national currency units,423.0
+26820,Norway,2013,3,J01-Antibacterials for systemic use,Million US$ at exchange rate,72.0
+26821,Norway,2013,3,Products not elsewhere classified,"/capita, US$ purchasing power parity",114.3
+26822,Norway,2013,3,Products not elsewhere classified,% of total sales,27.2
+26823,Norway,2013,3,N02-Analgesics,Million US$ at exchange rate,213.6
+26824,Norway,2013,3,N02-Analgesics,"Million US$, purchasing power parity",139.0
+26825,Norway,2013,3,C07-Beta blocking agents,Million US$ at exchange rate,28.4
+26826,Norway,2013,3,N02-Analgesics,Million of national currency units,1255.0
+26827,Norway,2013,3,N02-Analgesics,% of total sales,6.5
+26828,Norway,2013,3,N02-Analgesics,"/capita, US$ purchasing power parity",27.4
+26829,Norway,2013,3,N02-Analgesics,"/capita, US$ exchange rate",42.1
+26830,Norway,2013,3,J01-Antibacterials for systemic use,% of total sales,2.2
+26831,Norway,2013,3,J-Antiinfectives for systemic use,"/capita, US$ exchange rate",50.7
+26832,Norway,2013,3,J-Antiinfectives for systemic use,"/capita, US$ purchasing power parity",33.0
+26833,Norway,2013,3,C07-Beta blocking agents,"/capita, US$ exchange rate",5.6
+26834,Norway,2013,3,C07-Beta blocking agents,"Million US$, purchasing power parity",18.5
+26835,Norway,2013,3,C07-Beta blocking agents,% of total sales,0.9
+26836,Norway,2013,3,C07-Beta blocking agents,"/capita, US$ purchasing power parity",3.6
+26837,Norway,2013,3,R-Respiratory system,Million US$ at exchange rate,316.4
+26838,Norway,2013,3,R-Respiratory system,Million of national currency units,1859.0
+26839,Norway,2013,3,R-Respiratory system,"Million US$, purchasing power parity",205.9
+26840,Norway,2013,3,C02-Antihypertensives,"/capita, US$ purchasing power parity",1.5
+26841,Norway,2013,3,N-Nervous system,Million US$ at exchange rate,607.7
+26842,Norway,2013,3,C02-Antihypertensives,% of total sales,0.4
+26843,Norway,2013,3,R-Respiratory system,"/capita, US$ exchange rate",62.3
+26844,Norway,2013,3,A02A-Antacids,"/capita, US$ purchasing power parity",0.6
+26845,Norway,2013,3,A02A-Antacids,"/capita, US$ exchange rate",1.0
+26846,Norway,2013,3,A02A-Antacids,% of total sales,0.2
+26847,Norway,2013,3,R-Respiratory system,"/capita, US$ purchasing power parity",40.5
+26848,Norway,2013,3,N-Nervous system,Million of national currency units,3570.0
+26849,Norway,2013,3,A02A-Antacids,"Million US$, purchasing power parity",3.2
+26850,Norway,2013,3,R-Respiratory system,% of total sales,9.6
+26851,Norway,2013,3,N-Nervous system,"Million US$, purchasing power parity",395.4
+26852,Norway,2013,3,N-Nervous system,"/capita, US$ purchasing power parity",77.8
+26853,Norway,2013,3,N-Nervous system,"/capita, US$ exchange rate",119.6
+26854,Norway,2013,3,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ exchange rate",15.8
+26855,Norway,2013,3,C09-Agents acting on the Renin-Angiotensin system,% of total sales,2.4
+26856,Norway,2013,3,C02-Antihypertensives,"Million US$, purchasing power parity",7.6
+26857,Norway,2013,3,C02-Antihypertensives,"/capita, US$ exchange rate",2.3
+26858,Norway,2013,3,C02-Antihypertensives,Million US$ at exchange rate,11.7
+26859,Norway,2013,3,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ purchasing power parity",10.3
+26860,Norway,2017,2,N05B-Anxiolytics,% of total sales,0.4
+26861,Norway,2017,2,M-Musculo-skeletal system,Million of national currency units,998.0
+26862,Norway,2017,2,M-Musculo-skeletal system,"Million US$, purchasing power parity",102.4
+26863,Norway,2017,2,M-Musculo-skeletal system,Million US$ at exchange rate,120.7
+26864,Norway,2017,2,C10-Lipid modifying agents,Million of national currency units,504.0
+26865,Norway,2017,2,C10-Lipid modifying agents,Million US$ at exchange rate,60.9
+26866,Norway,2017,2,A-Alimentary tract and metabolism,% of total sales,10.4
+26867,Norway,2017,2,A-Alimentary tract and metabolism,"/capita, US$ purchasing power parity",53.9
+26868,Norway,2017,2,G-Genito urinary system and sex hormones,Million of national currency units,1228.0
+26869,Norway,2017,2,M-Musculo-skeletal system,% of total sales,3.7
+26870,Norway,2017,2,C02-Antihypertensives,Million of national currency units,110.0
+26871,Norway,2017,2,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million US$ at exchange rate,39.9
+26872,Norway,2017,2,G-Genito urinary system and sex hormones,Million US$ at exchange rate,148.5
+26873,Norway,2017,2,M-Musculo-skeletal system,"/capita, US$ purchasing power parity",19.4
+26874,Norway,2017,2,M-Musculo-skeletal system,"/capita, US$ exchange rate",22.9
+26875,Norway,2017,2,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ purchasing power parity",10.6
+26876,Norway,2017,2,"H-Systemic hormonal preparations, excluding sex hormones and insulins",% of total sales,2.0
+26877,Norway,2017,2,C10-Lipid modifying agents,"Million US$, purchasing power parity",51.7
+26878,Norway,2017,2,A-Alimentary tract and metabolism,"Million US$, purchasing power parity",284.6
+26879,Norway,2017,2,C10-Lipid modifying agents,% of total sales,1.9
+26880,Norway,2017,2,N05B-Anxiolytics,Million of national currency units,116.0
+26881,Norway,2017,2,N05B-Anxiolytics,Million US$ at exchange rate,14.0
+26882,Norway,2017,2,N05B-Anxiolytics,"Million US$, purchasing power parity",11.9
+26883,Norway,2017,2,A-Alimentary tract and metabolism,Million US$ at exchange rate,335.5
+26884,Norway,2017,2,A-Alimentary tract and metabolism,Million of national currency units,2775.0
+26885,Norway,2017,2,N05B-Anxiolytics,"/capita, US$ exchange rate",2.7
+26886,Norway,2017,2,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ purchasing power parity",6.4
+26887,Norway,2017,2,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),% of total sales,1.2
+26888,Norway,2017,2,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ exchange rate",7.6
+26889,Norway,2017,2,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"Million US$, purchasing power parity",33.8
+26890,Norway,2017,2,N05B-Anxiolytics,"/capita, US$ purchasing power parity",2.3
+26891,Norway,2017,2,A-Alimentary tract and metabolism,"/capita, US$ exchange rate",63.6
+26892,Norway,2017,2,C10-Lipid modifying agents,"/capita, US$ exchange rate",11.5
+26893,Norway,2017,2,C10-Lipid modifying agents,"/capita, US$ purchasing power parity",9.8
+26894,Norway,2017,2,N05C-Hypnotics and sedatives,"/capita, US$ purchasing power parity",5.0
+26895,Norway,2017,2,N05C-Hypnotics and sedatives,% of total sales,1.0
+26896,Norway,2017,2,N05C-Hypnotics and sedatives,"Million US$, purchasing power parity",26.4
+26897,Norway,2017,2,N05C-Hypnotics and sedatives,"/capita, US$ exchange rate",5.9
+26898,Norway,2017,2,B-Blood and blood forming organs,"/capita, US$ exchange rate",53.4
+26899,Norway,2017,2,B-Blood and blood forming organs,"Million US$, purchasing power parity",239.0
+26900,Norway,2017,2,B-Blood and blood forming organs,% of total sales,8.7
+26901,Norway,2017,2,B-Blood and blood forming organs,"/capita, US$ purchasing power parity",45.3
+26902,Norway,2017,2,C01A-Cardiac glycosides,% of total sales,0.0
+26903,Norway,2017,2,C01A-Cardiac glycosides,"/capita, US$ purchasing power parity",0.1
+26904,Norway,2017,2,M01A-Antiinflammatory and antirheumatic products non-steroids,Million of national currency units,550.0
+26905,Norway,2017,2,G03-Sex hormones and modulators of the genital system,% of total sales,2.1
+26906,Norway,2017,2,N05C-Hypnotics and sedatives,Million of national currency units,257.0
+26907,Norway,2017,2,N05C-Hypnotics and sedatives,Million US$ at exchange rate,31.1
+26908,Norway,2017,2,C01A-Cardiac glycosides,"/capita, US$ exchange rate",0.1
+26909,Norway,2017,2,C01A-Cardiac glycosides,"Million US$, purchasing power parity",0.5
+26910,Norway,2017,2,G03-Sex hormones and modulators of the genital system,Million of national currency units,562.0
+26911,Norway,2017,2,A10-Drugs used in diabetes,Million of national currency units,1001.0
+26912,Norway,2017,2,A10-Drugs used in diabetes,Million US$ at exchange rate,121.0
+26913,Norway,2017,2,A10-Drugs used in diabetes,"Million US$, purchasing power parity",102.7
+26914,Norway,2017,2,G03-Sex hormones and modulators of the genital system,"Million US$, purchasing power parity",57.6
+26915,Norway,2017,2,G03-Sex hormones and modulators of the genital system,Million US$ at exchange rate,67.9
+26916,Norway,2017,2,G03-Sex hormones and modulators of the genital system,"/capita, US$ purchasing power parity",10.9
+26917,Norway,2017,2,G03-Sex hormones and modulators of the genital system,"/capita, US$ exchange rate",12.9
+26918,Norway,2017,2,C01A-Cardiac glycosides,Million US$ at exchange rate,0.6
+26919,Norway,2017,2,B-Blood and blood forming organs,Million US$ at exchange rate,281.7
+26920,Norway,2017,2,B-Blood and blood forming organs,Million of national currency units,2330.0
+26921,Norway,2017,2,A10-Drugs used in diabetes,"/capita, US$ exchange rate",22.9
+26922,Norway,2017,2,A10-Drugs used in diabetes,"/capita, US$ purchasing power parity",19.5
+26923,Norway,2017,2,C01A-Cardiac glycosides,Million of national currency units,5.0
+26924,Norway,2017,2,A10-Drugs used in diabetes,% of total sales,3.8
+26925,Norway,2017,2,"C01B-Antiarrhythmics, Class I and III",Million of national currency units,41.0
+26926,Norway,2017,2,"C01B-Antiarrhythmics, Class I and III",Million US$ at exchange rate,5.0
+26927,Norway,2017,2,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million US$ at exchange rate,65.6
+26928,Norway,2017,2,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million of national currency units,543.0
+26929,Norway,2017,2,Total pharmaceutical sales,"/capita, US$ purchasing power parity",518.0
+26930,Norway,2017,2,Total pharmaceutical sales,Million US$ at exchange rate,3221.8
+26931,Norway,2017,2,Total pharmaceutical sales,"Million US$, purchasing power parity",2733.4
+26932,Norway,2017,2,Total pharmaceutical sales,"/capita, US$ exchange rate",610.5
+26933,Norway,2017,2,"C01B-Antiarrhythmics, Class I and III","/capita, US$ purchasing power parity",0.8
+26934,Norway,2017,2,"C01B-Antiarrhythmics, Class I and III","/capita, US$ exchange rate",0.9
+26935,Norway,2017,2,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million of national currency units,330.0
+26936,Norway,2017,2,"C01B-Antiarrhythmics, Class I and III",% of total sales,0.2
+26937,Norway,2017,2,"H-Systemic hormonal preparations, excluding sex hormones and insulins","Million US$, purchasing power parity",55.7
+26938,Norway,2017,2,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ exchange rate",12.4
+26939,Norway,2017,2,"C01B-Antiarrhythmics, Class I and III","Million US$, purchasing power parity",4.2
+26940,Norway,2017,2,N06A-Antidepressants,% of total sales,1.0
+26941,Norway,2017,2,N06A-Antidepressants,"/capita, US$ purchasing power parity",5.4
+26942,Norway,2017,2,M01A-Antiinflammatory and antirheumatic products non-steroids,"Million US$, purchasing power parity",56.4
+26943,Norway,2017,2,M01A-Antiinflammatory and antirheumatic products non-steroids,Million US$ at exchange rate,66.5
+26944,Norway,2017,2,N06A-Antidepressants,Million US$ at exchange rate,33.5
+26945,Norway,2017,2,N06A-Antidepressants,Million of national currency units,277.0
+26946,Norway,2017,2,N06A-Antidepressants,"/capita, US$ exchange rate",6.3
+26947,Norway,2017,2,N06A-Antidepressants,"Million US$, purchasing power parity",28.4
+26948,Norway,2017,2,Total pharmaceutical sales,Million of national currency units,26650.0
+26949,Norway,2017,2,G-Genito urinary system and sex hormones,"/capita, US$ exchange rate",28.1
+26950,Norway,2017,2,G-Genito urinary system and sex hormones,"/capita, US$ purchasing power parity",23.9
+26951,Norway,2017,2,G-Genito urinary system and sex hormones,"Million US$, purchasing power parity",126.0
+26952,Norway,2017,2,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ purchasing power parity",10.7
+26953,Norway,2017,2,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ exchange rate",12.6
+26954,Norway,2017,2,G-Genito urinary system and sex hormones,% of total sales,4.6
+26955,Norway,2017,2,M01A-Antiinflammatory and antirheumatic products non-steroids,% of total sales,2.1
+26956,Norway,2017,2,J-Antiinfectives for systemic use,"Million US$, purchasing power parity",241.2
+26957,Norway,2017,2,R03-Drugs for obstructive airway diseases,% of total sales,4.6
+26958,Norway,2017,2,A02A-Antacids,Million of national currency units,29.0
+26959,Norway,2017,2,R03-Drugs for obstructive airway diseases,"/capita, US$ purchasing power parity",23.6
+26960,Norway,2017,2,R03-Drugs for obstructive airway diseases,"Million US$, purchasing power parity",124.5
+26961,Norway,2017,2,R03-Drugs for obstructive airway diseases,Million US$ at exchange rate,146.8
+26962,Norway,2017,2,R03-Drugs for obstructive airway diseases,"/capita, US$ exchange rate",27.8
+26963,Norway,2017,2,C08-Calcium channel blockers,% of total sales,0.5
+26964,Norway,2017,2,C08-Calcium channel blockers,"/capita, US$ exchange rate",2.9
+26965,Norway,2017,2,C08-Calcium channel blockers,"/capita, US$ purchasing power parity",2.5
+26966,Norway,2017,2,C-Cardiovascular system,Million of national currency units,1708.0
+26967,Norway,2017,2,C-Cardiovascular system,"Million US$, purchasing power parity",175.2
+26968,Norway,2017,2,C-Cardiovascular system,"/capita, US$ exchange rate",39.1
+26969,Norway,2017,2,C-Cardiovascular system,Million US$ at exchange rate,206.5
+26970,Norway,2017,2,C03-Diuretics,Million US$ at exchange rate,14.7
+26971,Norway,2017,2,C03-Diuretics,Million of national currency units,122.0
+26972,Norway,2017,2,C03-Diuretics,"Million US$, purchasing power parity",12.5
+26973,Norway,2017,2,C09-Agents acting on the Renin-Angiotensin system,Million US$ at exchange rate,54.5
+26974,Norway,2017,2,C09-Agents acting on the Renin-Angiotensin system,"Million US$, purchasing power parity",46.3
+26975,Norway,2017,2,N-Nervous system,% of total sales,16.0
+26976,Norway,2017,2,C09-Agents acting on the Renin-Angiotensin system,Million of national currency units,451.0
+26977,Norway,2017,2,C03-Diuretics,"/capita, US$ exchange rate",2.8
+26978,Norway,2017,2,C-Cardiovascular system,"/capita, US$ purchasing power parity",33.2
+26979,Norway,2017,2,C-Cardiovascular system,% of total sales,6.4
+26980,Norway,2017,2,J-Antiinfectives for systemic use,Million US$ at exchange rate,284.3
+26981,Norway,2017,2,J-Antiinfectives for systemic use,Million of national currency units,2352.0
+26982,Norway,2017,2,C03-Diuretics,"/capita, US$ purchasing power parity",2.4
+26983,Norway,2017,2,R03-Drugs for obstructive airway diseases,Million of national currency units,1214.0
+26984,Norway,2017,2,C03-Diuretics,% of total sales,0.5
+26985,Norway,2017,2,J01-Antibacterials for systemic use,"/capita, US$ exchange rate",9.9
+26986,Norway,2017,2,J01-Antibacterials for systemic use,"/capita, US$ purchasing power parity",8.4
+26987,Norway,2017,2,J01-Antibacterials for systemic use,"Million US$, purchasing power parity",44.5
+26988,Norway,2017,2,J01-Antibacterials for systemic use,Million US$ at exchange rate,52.5
+26989,Norway,2017,2,C08-Calcium channel blockers,Million of national currency units,128.0
+26990,Norway,2017,2,C08-Calcium channel blockers,"Million US$, purchasing power parity",13.1
+26991,Norway,2017,2,J-Antiinfectives for systemic use,% of total sales,8.8
+26992,Norway,2017,2,C08-Calcium channel blockers,Million US$ at exchange rate,15.5
+26993,Norway,2017,2,Products not elsewhere classified,"Million US$, purchasing power parity",822.4
+26994,Norway,2017,2,Products not elsewhere classified,"/capita, US$ exchange rate",183.7
+26995,Norway,2017,2,Products not elsewhere classified,Million of national currency units,8018.0
+26996,Norway,2017,2,Products not elsewhere classified,Million US$ at exchange rate,969.3
+26997,Norway,2017,2,J01-Antibacterials for systemic use,Million of national currency units,434.0
+26998,Norway,2017,2,Products not elsewhere classified,% of total sales,30.1
+26999,Norway,2017,2,Products not elsewhere classified,"/capita, US$ purchasing power parity",155.8
+27000,Norway,2017,2,N02-Analgesics,Million US$ at exchange rate,179.2
+27001,Norway,2017,2,N02-Analgesics,Million of national currency units,1482.0
+27002,Norway,2017,2,C07-Beta blocking agents,Million US$ at exchange rate,22.1
+27003,Norway,2017,2,C07-Beta blocking agents,Million of national currency units,183.0
+27004,Norway,2017,2,N02-Analgesics,"/capita, US$ purchasing power parity",28.8
+27005,Norway,2017,2,N02-Analgesics,% of total sales,5.6
+27006,Norway,2017,2,N02-Analgesics,"Million US$, purchasing power parity",152.0
+27007,Norway,2017,2,N02-Analgesics,"/capita, US$ exchange rate",34.0
+27008,Norway,2017,2,J01-Antibacterials for systemic use,% of total sales,1.6
+27009,Norway,2017,2,J-Antiinfectives for systemic use,"/capita, US$ purchasing power parity",45.7
+27010,Norway,2017,2,J-Antiinfectives for systemic use,"/capita, US$ exchange rate",53.9
+27011,Norway,2017,2,C07-Beta blocking agents,% of total sales,0.7
+27012,Norway,2017,2,C07-Beta blocking agents,"Million US$, purchasing power parity",18.8
+27013,Norway,2017,2,C07-Beta blocking agents,"/capita, US$ exchange rate",4.2
+27014,Norway,2017,2,C07-Beta blocking agents,"/capita, US$ purchasing power parity",3.6
+27015,Norway,2017,2,R-Respiratory system,Million of national currency units,2421.0
+27016,Norway,2017,2,R-Respiratory system,Million US$ at exchange rate,292.7
+27017,Norway,2017,2,R-Respiratory system,"Million US$, purchasing power parity",248.3
+27018,Norway,2017,2,C02-Antihypertensives,"/capita, US$ purchasing power parity",2.1
+27019,Norway,2017,2,N-Nervous system,Million US$ at exchange rate,517.1
+27020,Norway,2017,2,N-Nervous system,Million of national currency units,4277.0
+27021,Norway,2017,2,C02-Antihypertensives,% of total sales,0.4
+27022,Norway,2017,2,A02A-Antacids,"/capita, US$ exchange rate",0.7
+27023,Norway,2017,2,A02A-Antacids,% of total sales,0.1
+27024,Norway,2017,2,A02A-Antacids,"/capita, US$ purchasing power parity",0.6
+27025,Norway,2017,2,A02A-Antacids,"Million US$, purchasing power parity",3.0
+27026,Norway,2017,2,R-Respiratory system,"/capita, US$ purchasing power parity",47.1
+27027,Norway,2017,2,R-Respiratory system,"/capita, US$ exchange rate",55.5
+27028,Norway,2017,2,A02A-Antacids,Million US$ at exchange rate,3.5
+27029,Norway,2017,2,R-Respiratory system,% of total sales,9.1
+27030,Norway,2017,2,N-Nervous system,"/capita, US$ purchasing power parity",83.1
+27031,Norway,2017,2,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ exchange rate",10.3
+27032,Norway,2017,2,C09-Agents acting on the Renin-Angiotensin system,% of total sales,1.7
+27033,Norway,2017,2,N-Nervous system,"/capita, US$ exchange rate",98.0
+27034,Norway,2017,2,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ purchasing power parity",8.8
+27035,Norway,2017,2,C02-Antihypertensives,"Million US$, purchasing power parity",11.3
+27036,Norway,2017,2,C02-Antihypertensives,"/capita, US$ exchange rate",2.5
+27037,Norway,2017,2,N-Nervous system,"Million US$, purchasing power parity",438.7
+27038,Norway,2017,2,C02-Antihypertensives,Million US$ at exchange rate,13.3
+27039,Norway,2015,3,N05B-Anxiolytics,% of total sales,0.5
+27040,Norway,2015,3,M-Musculo-skeletal system,"Million US$, purchasing power parity",83.9
+27041,Norway,2015,3,M-Musculo-skeletal system,Million US$ at exchange rate,103.3
+27042,Norway,2015,3,C10-Lipid modifying agents,Million of national currency units,406.0
+27043,Norway,2015,3,C10-Lipid modifying agents,Million US$ at exchange rate,50.3
+27044,Norway,2015,3,A-Alimentary tract and metabolism,% of total sales,9.8
+27045,Norway,2015,3,A-Alimentary tract and metabolism,"/capita, US$ purchasing power parity",43.2
+27046,Norway,2015,3,G-Genito urinary system and sex hormones,Million of national currency units,1082.0
+27047,Norway,2015,3,C02-Antihypertensives,Million of national currency units,91.0
+27048,Norway,2015,3,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million US$ at exchange rate,39.7
+27049,Norway,2015,3,G-Genito urinary system and sex hormones,Million US$ at exchange rate,134.2
+27050,Norway,2015,3,M-Musculo-skeletal system,% of total sales,3.7
+27051,Norway,2015,3,M-Musculo-skeletal system,"/capita, US$ purchasing power parity",16.2
+27052,Norway,2015,3,M-Musculo-skeletal system,"/capita, US$ exchange rate",19.9
+27053,Norway,2015,3,"H-Systemic hormonal preparations, excluding sex hormones and insulins",% of total sales,2.4
+27054,Norway,2015,3,C10-Lipid modifying agents,"Million US$, purchasing power parity",40.9
+27055,Norway,2015,3,A-Alimentary tract and metabolism,"Million US$, purchasing power parity",223.9
+27056,Norway,2015,3,C10-Lipid modifying agents,% of total sales,1.8
+27057,Norway,2015,3,N05B-Anxiolytics,"/capita, US$ exchange rate",2.7
+27058,Norway,2015,3,A-Alimentary tract and metabolism,"/capita, US$ exchange rate",53.2
+27059,Norway,2015,3,M-Musculo-skeletal system,Million of national currency units,833.0
+27060,Norway,2015,3,N05B-Anxiolytics,Million US$ at exchange rate,14.3
+27061,Norway,2015,3,N05B-Anxiolytics,"Million US$, purchasing power parity",11.6
+27062,Norway,2015,3,A-Alimentary tract and metabolism,Million of national currency units,2224.0
+27063,Norway,2015,3,A-Alimentary tract and metabolism,Million US$ at exchange rate,275.8
+27064,Norway,2015,3,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ purchasing power parity",6.2
+27065,Norway,2015,3,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),% of total sales,1.4
+27066,Norway,2015,3,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ exchange rate",7.6
+27067,Norway,2015,3,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"Million US$, purchasing power parity",32.2
+27068,Norway,2015,3,N05B-Anxiolytics,Million of national currency units,115.0
+27069,Norway,2015,3,N05B-Anxiolytics,"/capita, US$ purchasing power parity",2.2
+27070,Norway,2015,3,C10-Lipid modifying agents,"/capita, US$ exchange rate",9.7
+27071,Norway,2015,3,C10-Lipid modifying agents,"/capita, US$ purchasing power parity",7.9
+27072,Norway,2015,3,N05C-Hypnotics and sedatives,"/capita, US$ purchasing power parity",4.3
+27073,Norway,2015,3,N05C-Hypnotics and sedatives,% of total sales,1.0
+27074,Norway,2015,3,N05C-Hypnotics and sedatives,"Million US$, purchasing power parity",22.4
+27075,Norway,2015,3,N05C-Hypnotics and sedatives,"/capita, US$ exchange rate",5.3
+27076,Norway,2015,3,B-Blood and blood forming organs,"/capita, US$ exchange rate",44.1
+27077,Norway,2015,3,B-Blood and blood forming organs,"Million US$, purchasing power parity",185.9
+27078,Norway,2015,3,B-Blood and blood forming organs,% of total sales,8.1
+27079,Norway,2015,3,B-Blood and blood forming organs,"/capita, US$ purchasing power parity",35.8
+27080,Norway,2015,3,C01A-Cardiac glycosides,% of total sales,0.0
+27081,Norway,2015,3,G03-Sex hormones and modulators of the genital system,% of total sales,2.2
+27082,Norway,2015,3,C01A-Cardiac glycosides,"/capita, US$ purchasing power parity",0.1
+27083,Norway,2015,3,M01A-Antiinflammatory and antirheumatic products non-steroids,Million of national currency units,515.0
+27084,Norway,2015,3,N05C-Hypnotics and sedatives,Million of national currency units,222.0
+27085,Norway,2015,3,N05C-Hypnotics and sedatives,Million US$ at exchange rate,27.5
+27086,Norway,2015,3,C01A-Cardiac glycosides,"Million US$, purchasing power parity",0.5
+27087,Norway,2015,3,C01A-Cardiac glycosides,"/capita, US$ exchange rate",0.1
+27088,Norway,2015,3,A10-Drugs used in diabetes,Million of national currency units,786.0
+27089,Norway,2015,3,G03-Sex hormones and modulators of the genital system,Million of national currency units,512.0
+27090,Norway,2015,3,A10-Drugs used in diabetes,"Million US$, purchasing power parity",79.1
+27091,Norway,2015,3,A10-Drugs used in diabetes,Million US$ at exchange rate,97.5
+27092,Norway,2015,3,G03-Sex hormones and modulators of the genital system,"Million US$, purchasing power parity",51.5
+27093,Norway,2015,3,G03-Sex hormones and modulators of the genital system,Million US$ at exchange rate,63.5
+27094,Norway,2015,3,G03-Sex hormones and modulators of the genital system,"/capita, US$ purchasing power parity",9.9
+27095,Norway,2015,3,G03-Sex hormones and modulators of the genital system,"/capita, US$ exchange rate",12.2
+27096,Norway,2015,3,C01A-Cardiac glycosides,Million US$ at exchange rate,0.6
+27097,Norway,2015,3,B-Blood and blood forming organs,Million US$ at exchange rate,228.9
+27098,Norway,2015,3,B-Blood and blood forming organs,Million of national currency units,1846.0
+27099,Norway,2015,3,A10-Drugs used in diabetes,"/capita, US$ purchasing power parity",15.3
+27100,Norway,2015,3,A10-Drugs used in diabetes,"/capita, US$ exchange rate",18.8
+27101,Norway,2015,3,C01A-Cardiac glycosides,Million of national currency units,5.0
+27102,Norway,2015,3,A10-Drugs used in diabetes,% of total sales,3.5
+27103,Norway,2015,3,N06A-Antidepressants,Million of national currency units,264.0
+27104,Norway,2015,3,"C01B-Antiarrhythmics, Class I and III",Million of national currency units,36.0
+27105,Norway,2015,3,"C01B-Antiarrhythmics, Class I and III",Million US$ at exchange rate,4.5
+27106,Norway,2015,3,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million US$ at exchange rate,68.1
+27107,Norway,2015,3,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million of national currency units,549.0
+27108,Norway,2015,3,Total pharmaceutical sales,"/capita, US$ purchasing power parity",441.8
+27109,Norway,2015,3,Total pharmaceutical sales,Million US$ at exchange rate,2823.5
+27110,Norway,2015,3,Total pharmaceutical sales,"Million US$, purchasing power parity",2292.4
+27111,Norway,2015,3,Total pharmaceutical sales,"/capita, US$ exchange rate",544.2
+27112,Norway,2015,3,"C01B-Antiarrhythmics, Class I and III","/capita, US$ purchasing power parity",0.7
+27113,Norway,2015,3,"C01B-Antiarrhythmics, Class I and III","/capita, US$ exchange rate",0.9
+27114,Norway,2015,3,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million of national currency units,320.0
+27115,Norway,2015,3,"C01B-Antiarrhythmics, Class I and III",% of total sales,0.2
+27116,Norway,2015,3,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ exchange rate",13.1
+27117,Norway,2015,3,"H-Systemic hormonal preparations, excluding sex hormones and insulins","Million US$, purchasing power parity",55.3
+27118,Norway,2015,3,"C01B-Antiarrhythmics, Class I and III","Million US$, purchasing power parity",3.6
+27119,Norway,2015,3,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ purchasing power parity",10.7
+27120,Norway,2015,3,N06A-Antidepressants,% of total sales,1.2
+27121,Norway,2015,3,N06A-Antidepressants,"/capita, US$ purchasing power parity",5.1
+27122,Norway,2015,3,M01A-Antiinflammatory and antirheumatic products non-steroids,"Million US$, purchasing power parity",51.8
+27123,Norway,2015,3,M01A-Antiinflammatory and antirheumatic products non-steroids,Million US$ at exchange rate,63.9
+27124,Norway,2015,3,N06A-Antidepressants,Million US$ at exchange rate,32.7
+27125,Norway,2015,3,N06A-Antidepressants,"/capita, US$ exchange rate",6.3
+27126,Norway,2015,3,N06A-Antidepressants,"Million US$, purchasing power parity",26.6
+27127,Norway,2015,3,G-Genito urinary system and sex hormones,"/capita, US$ exchange rate",25.9
+27128,Norway,2015,3,G-Genito urinary system and sex hormones,"/capita, US$ purchasing power parity",21.0
+27129,Norway,2015,3,Total pharmaceutical sales,Million of national currency units,22769.0
+27130,Norway,2015,3,G-Genito urinary system and sex hormones,"Million US$, purchasing power parity",108.9
+27131,Norway,2015,3,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ purchasing power parity",10.0
+27132,Norway,2015,3,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ exchange rate",12.3
+27133,Norway,2015,3,G-Genito urinary system and sex hormones,% of total sales,4.8
+27134,Norway,2015,3,M01A-Antiinflammatory and antirheumatic products non-steroids,% of total sales,2.3
+27135,Norway,2015,3,R03-Drugs for obstructive airway diseases,% of total sales,4.9
+27136,Norway,2015,3,A02A-Antacids,Million of national currency units,28.0
+27137,Norway,2015,3,A02A-Antacids,Million US$ at exchange rate,3.5
+27138,Norway,2015,3,R03-Drugs for obstructive airway diseases,"/capita, US$ purchasing power parity",21.5
+27139,Norway,2015,3,R03-Drugs for obstructive airway diseases,"Million US$, purchasing power parity",111.6
+27140,Norway,2015,3,R03-Drugs for obstructive airway diseases,Million US$ at exchange rate,137.4
+27141,Norway,2015,3,J-Antiinfectives for systemic use,"Million US$, purchasing power parity",222.9
+27142,Norway,2015,3,R03-Drugs for obstructive airway diseases,"/capita, US$ exchange rate",26.5
+27143,Norway,2015,3,C08-Calcium channel blockers,% of total sales,0.5
+27144,Norway,2015,3,C07-Beta blocking agents,Million of national currency units,174.0
+27145,Norway,2015,3,C-Cardiovascular system,Million of national currency units,1508.0
+27146,Norway,2015,3,C08-Calcium channel blockers,"/capita, US$ purchasing power parity",2.3
+27147,Norway,2015,3,C-Cardiovascular system,"/capita, US$ exchange rate",36.0
+27148,Norway,2015,3,C-Cardiovascular system,"Million US$, purchasing power parity",151.8
+27149,Norway,2015,3,C-Cardiovascular system,Million US$ at exchange rate,187.0
+27150,Norway,2015,3,C08-Calcium channel blockers,"/capita, US$ exchange rate",2.9
+27151,Norway,2015,3,C03-Diuretics,Million US$ at exchange rate,13.6
+27152,Norway,2015,3,C03-Diuretics,Million of national currency units,110.0
+27153,Norway,2015,3,C03-Diuretics,"Million US$, purchasing power parity",11.1
+27154,Norway,2015,3,C03-Diuretics,"/capita, US$ exchange rate",2.6
+27155,Norway,2015,3,C09-Agents acting on the Renin-Angiotensin system,Million US$ at exchange rate,52.1
+27156,Norway,2015,3,C09-Agents acting on the Renin-Angiotensin system,"Million US$, purchasing power parity",42.3
+27157,Norway,2015,3,N-Nervous system,% of total sales,17.3
+27158,Norway,2015,3,C09-Agents acting on the Renin-Angiotensin system,Million of national currency units,420.0
+27159,Norway,2015,3,C-Cardiovascular system,"/capita, US$ purchasing power parity",29.3
+27160,Norway,2015,3,C-Cardiovascular system,% of total sales,6.6
+27161,Norway,2015,3,J-Antiinfectives for systemic use,Million of national currency units,2214.0
+27162,Norway,2015,3,J-Antiinfectives for systemic use,Million US$ at exchange rate,274.5
+27163,Norway,2015,3,C03-Diuretics,"/capita, US$ purchasing power parity",2.1
+27164,Norway,2015,3,C03-Diuretics,% of total sales,0.5
+27165,Norway,2015,3,R03-Drugs for obstructive airway diseases,Million of national currency units,1108.0
+27166,Norway,2015,3,J01-Antibacterials for systemic use,"/capita, US$ exchange rate",11.0
+27167,Norway,2015,3,J01-Antibacterials for systemic use,"/capita, US$ purchasing power parity",8.9
+27168,Norway,2015,3,J01-Antibacterials for systemic use,"Million US$, purchasing power parity",46.3
+27169,Norway,2015,3,C08-Calcium channel blockers,Million of national currency units,121.0
+27170,Norway,2015,3,C08-Calcium channel blockers,"Million US$, purchasing power parity",12.2
+27171,Norway,2015,3,J-Antiinfectives for systemic use,% of total sales,9.7
+27172,Norway,2015,3,C08-Calcium channel blockers,Million US$ at exchange rate,15.0
+27173,Norway,2015,3,J01-Antibacterials for systemic use,Million US$ at exchange rate,57.0
+27174,Norway,2015,3,Products not elsewhere classified,"Million US$, purchasing power parity",653.5
+27175,Norway,2015,3,Products not elsewhere classified,"/capita, US$ exchange rate",155.1
+27176,Norway,2015,3,Products not elsewhere classified,Million of national currency units,6491.0
+27177,Norway,2015,3,Products not elsewhere classified,Million US$ at exchange rate,804.9
+27178,Norway,2015,3,J01-Antibacterials for systemic use,Million of national currency units,460.0
+27179,Norway,2015,3,Products not elsewhere classified,"/capita, US$ purchasing power parity",126.0
+27180,Norway,2015,3,Products not elsewhere classified,% of total sales,28.5
+27181,Norway,2015,3,N02-Analgesics,Million US$ at exchange rate,172.5
+27182,Norway,2015,3,N02-Analgesics,Million of national currency units,1391.0
+27183,Norway,2015,3,C07-Beta blocking agents,Million US$ at exchange rate,21.6
+27184,Norway,2015,3,N02-Analgesics,"Million US$, purchasing power parity",140.0
+27185,Norway,2015,3,N02-Analgesics,"/capita, US$ purchasing power parity",27.0
+27186,Norway,2015,3,N02-Analgesics,% of total sales,6.1
+27187,Norway,2015,3,N02-Analgesics,"/capita, US$ exchange rate",33.2
+27188,Norway,2015,3,J01-Antibacterials for systemic use,% of total sales,2.0
+27189,Norway,2015,3,J-Antiinfectives for systemic use,"/capita, US$ purchasing power parity",43.0
+27190,Norway,2015,3,J-Antiinfectives for systemic use,"/capita, US$ exchange rate",52.9
+27191,Norway,2015,3,C07-Beta blocking agents,% of total sales,0.8
+27192,Norway,2015,3,C07-Beta blocking agents,"/capita, US$ exchange rate",4.2
+27193,Norway,2015,3,C07-Beta blocking agents,"Million US$, purchasing power parity",17.5
+27194,Norway,2015,3,C07-Beta blocking agents,"/capita, US$ purchasing power parity",3.4
+27195,Norway,2015,3,R-Respiratory system,Million US$ at exchange rate,259.5
+27196,Norway,2015,3,R-Respiratory system,Million of national currency units,2093.0
+27197,Norway,2015,3,R-Respiratory system,"Million US$, purchasing power parity",210.7
+27198,Norway,2015,3,C02-Antihypertensives,"/capita, US$ purchasing power parity",1.8
+27199,Norway,2015,3,N-Nervous system,Million of national currency units,3929.0
+27200,Norway,2015,3,N-Nervous system,Million US$ at exchange rate,487.2
+27201,Norway,2015,3,C02-Antihypertensives,% of total sales,0.4
+27202,Norway,2015,3,R-Respiratory system,"/capita, US$ exchange rate",50.0
+27203,Norway,2015,3,A02A-Antacids,"/capita, US$ exchange rate",0.7
+27204,Norway,2015,3,A02A-Antacids,"/capita, US$ purchasing power parity",0.5
+27205,Norway,2015,3,A02A-Antacids,% of total sales,0.1
+27206,Norway,2015,3,A02A-Antacids,"Million US$, purchasing power parity",2.8
+27207,Norway,2015,3,R-Respiratory system,"/capita, US$ purchasing power parity",40.6
+27208,Norway,2015,3,R-Respiratory system,% of total sales,9.2
+27209,Norway,2015,3,N-Nervous system,"Million US$, purchasing power parity",395.6
+27210,Norway,2015,3,N-Nervous system,"/capita, US$ purchasing power parity",76.2
+27211,Norway,2015,3,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ exchange rate",10.0
+27212,Norway,2015,3,N-Nervous system,"/capita, US$ exchange rate",93.9
+27213,Norway,2015,3,C09-Agents acting on the Renin-Angiotensin system,% of total sales,1.8
+27214,Norway,2015,3,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ purchasing power parity",8.1
+27215,Norway,2015,3,C02-Antihypertensives,"Million US$, purchasing power parity",9.2
+27216,Norway,2015,3,C02-Antihypertensives,"/capita, US$ exchange rate",2.2
+27217,Norway,2015,3,C02-Antihypertensives,Million US$ at exchange rate,11.3
+27218,Norway,2016,3,N05B-Anxiolytics,% of total sales,0.5
+27219,Norway,2016,3,M-Musculo-skeletal system,Million of national currency units,922.0
+27220,Norway,2016,3,M-Musculo-skeletal system,"Million US$, purchasing power parity",91.8
+27221,Norway,2016,3,M-Musculo-skeletal system,Million US$ at exchange rate,109.8
+27222,Norway,2016,3,C10-Lipid modifying agents,Million of national currency units,473.0
+27223,Norway,2016,3,C10-Lipid modifying agents,Million US$ at exchange rate,56.3
+27224,Norway,2016,3,A-Alimentary tract and metabolism,% of total sales,10.3
+27225,Norway,2016,3,A-Alimentary tract and metabolism,"/capita, US$ purchasing power parity",48.7
+27226,Norway,2016,3,G-Genito urinary system and sex hormones,Million of national currency units,1162.0
+27227,Norway,2016,3,M-Musculo-skeletal system,% of total sales,3.7
+27228,Norway,2016,3,C02-Antihypertensives,Million of national currency units,103.0
+27229,Norway,2016,3,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million US$ at exchange rate,39.2
+27230,Norway,2016,3,G-Genito urinary system and sex hormones,Million US$ at exchange rate,138.3
+27231,Norway,2016,3,M-Musculo-skeletal system,"/capita, US$ purchasing power parity",17.5
+27232,Norway,2016,3,M-Musculo-skeletal system,"/capita, US$ exchange rate",21.0
+27233,Norway,2016,3,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ purchasing power parity",10.8
+27234,Norway,2016,3,"H-Systemic hormonal preparations, excluding sex hormones and insulins",% of total sales,2.3
+27235,Norway,2016,3,A-Alimentary tract and metabolism,"Million US$, purchasing power parity",254.8
+27236,Norway,2016,3,C10-Lipid modifying agents,% of total sales,1.9
+27237,Norway,2016,3,N05B-Anxiolytics,"/capita, US$ exchange rate",2.7
+27238,Norway,2016,3,N05B-Anxiolytics,Million of national currency units,119.0
+27239,Norway,2016,3,N05B-Anxiolytics,Million US$ at exchange rate,14.2
+27240,Norway,2016,3,A-Alimentary tract and metabolism,Million US$ at exchange rate,304.6
+27241,Norway,2016,3,N05B-Anxiolytics,"Million US$, purchasing power parity",11.9
+27242,Norway,2016,3,A-Alimentary tract and metabolism,Million of national currency units,2559.0
+27243,Norway,2016,3,C10-Lipid modifying agents,"Million US$, purchasing power parity",47.1
+27244,Norway,2016,3,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ purchasing power parity",6.3
+27245,Norway,2016,3,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),% of total sales,1.3
+27246,Norway,2016,3,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ exchange rate",7.5
+27247,Norway,2016,3,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"Million US$, purchasing power parity",32.8
+27248,Norway,2016,3,N05B-Anxiolytics,"/capita, US$ purchasing power parity",2.3
+27249,Norway,2016,3,A-Alimentary tract and metabolism,"/capita, US$ exchange rate",58.2
+27250,Norway,2016,3,C10-Lipid modifying agents,"/capita, US$ purchasing power parity",9.0
+27251,Norway,2016,3,C10-Lipid modifying agents,"/capita, US$ exchange rate",10.8
+27252,Norway,2016,3,N05C-Hypnotics and sedatives,"/capita, US$ purchasing power parity",4.8
+27253,Norway,2016,3,N05C-Hypnotics and sedatives,% of total sales,1.0
+27254,Norway,2016,3,N05C-Hypnotics and sedatives,"Million US$, purchasing power parity",25.3
+27255,Norway,2016,3,N05C-Hypnotics and sedatives,"/capita, US$ exchange rate",5.8
+27256,Norway,2016,3,B-Blood and blood forming organs,"/capita, US$ exchange rate",48.4
+27257,Norway,2016,3,B-Blood and blood forming organs,"Million US$, purchasing power parity",211.8
+27258,Norway,2016,3,B-Blood and blood forming organs,% of total sales,8.6
+27259,Norway,2016,3,B-Blood and blood forming organs,"/capita, US$ purchasing power parity",40.5
+27260,Norway,2016,3,C01A-Cardiac glycosides,% of total sales,0.0
+27261,Norway,2016,3,C01A-Cardiac glycosides,"/capita, US$ purchasing power parity",0.1
+27262,Norway,2016,3,G03-Sex hormones and modulators of the genital system,% of total sales,2.2
+27263,Norway,2016,3,M01A-Antiinflammatory and antirheumatic products non-steroids,Million of national currency units,537.0
+27264,Norway,2016,3,N05C-Hypnotics and sedatives,Million of national currency units,254.0
+27265,Norway,2016,3,N05C-Hypnotics and sedatives,Million US$ at exchange rate,30.2
+27266,Norway,2016,3,C01A-Cardiac glycosides,"/capita, US$ exchange rate",0.1
+27267,Norway,2016,3,C01A-Cardiac glycosides,"Million US$, purchasing power parity",0.5
+27268,Norway,2016,3,A10-Drugs used in diabetes,Million of national currency units,913.0
+27269,Norway,2016,3,G03-Sex hormones and modulators of the genital system,Million of national currency units,545.0
+27270,Norway,2016,3,A10-Drugs used in diabetes,"Million US$, purchasing power parity",90.9
+27271,Norway,2016,3,A10-Drugs used in diabetes,Million US$ at exchange rate,108.7
+27272,Norway,2016,3,G03-Sex hormones and modulators of the genital system,"Million US$, purchasing power parity",54.3
+27273,Norway,2016,3,G03-Sex hormones and modulators of the genital system,Million US$ at exchange rate,64.9
+27274,Norway,2016,3,G03-Sex hormones and modulators of the genital system,"/capita, US$ purchasing power parity",10.4
+27275,Norway,2016,3,G03-Sex hormones and modulators of the genital system,"/capita, US$ exchange rate",12.4
+27276,Norway,2016,3,C01A-Cardiac glycosides,Million US$ at exchange rate,0.6
+27277,Norway,2016,3,B-Blood and blood forming organs,Million US$ at exchange rate,253.2
+27278,Norway,2016,3,B-Blood and blood forming organs,Million of national currency units,2127.0
+27279,Norway,2016,3,C01A-Cardiac glycosides,Million of national currency units,5.0
+27280,Norway,2016,3,A10-Drugs used in diabetes,"/capita, US$ exchange rate",20.8
+27281,Norway,2016,3,A10-Drugs used in diabetes,"/capita, US$ purchasing power parity",17.4
+27282,Norway,2016,3,A10-Drugs used in diabetes,% of total sales,3.7
+27283,Norway,2016,3,"C01B-Antiarrhythmics, Class I and III",Million of national currency units,38.0
+27284,Norway,2016,3,"C01B-Antiarrhythmics, Class I and III",Million US$ at exchange rate,4.5
+27285,Norway,2016,3,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million US$ at exchange rate,67.9
+27286,Norway,2016,3,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million of national currency units,570.0
+27287,Norway,2016,3,Total pharmaceutical sales,Million US$ at exchange rate,2948.7
+27288,Norway,2016,3,Total pharmaceutical sales,"Million US$, purchasing power parity",2466.6
+27289,Norway,2016,3,Total pharmaceutical sales,"/capita, US$ purchasing power parity",471.2
+27290,Norway,2016,3,Total pharmaceutical sales,"/capita, US$ exchange rate",563.3
+27291,Norway,2016,3,"C01B-Antiarrhythmics, Class I and III","/capita, US$ purchasing power parity",0.7
+27292,Norway,2016,3,"C01B-Antiarrhythmics, Class I and III","/capita, US$ exchange rate",0.9
+27293,Norway,2016,3,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million of national currency units,329.0
+27294,Norway,2016,3,"C01B-Antiarrhythmics, Class I and III",% of total sales,0.2
+27295,Norway,2016,3,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ exchange rate",13.0
+27296,Norway,2016,3,"H-Systemic hormonal preparations, excluding sex hormones and insulins","Million US$, purchasing power parity",56.8
+27297,Norway,2016,3,"C01B-Antiarrhythmics, Class I and III","Million US$, purchasing power parity",3.8
+27298,Norway,2016,3,Total pharmaceutical sales,Million of national currency units,24769.0
+27299,Norway,2016,3,N06A-Antidepressants,% of total sales,1.1
+27300,Norway,2016,3,N06A-Antidepressants,"/capita, US$ purchasing power parity",5.1
+27301,Norway,2016,3,M01A-Antiinflammatory and antirheumatic products non-steroids,"Million US$, purchasing power parity",53.5
+27302,Norway,2016,3,M01A-Antiinflammatory and antirheumatic products non-steroids,Million US$ at exchange rate,63.9
+27303,Norway,2016,3,N06A-Antidepressants,Million US$ at exchange rate,31.8
+27304,Norway,2016,3,N06A-Antidepressants,Million of national currency units,267.0
+27305,Norway,2016,3,N06A-Antidepressants,"/capita, US$ exchange rate",6.1
+27306,Norway,2016,3,N06A-Antidepressants,"Million US$, purchasing power parity",26.6
+27307,Norway,2016,3,G-Genito urinary system and sex hormones,"/capita, US$ exchange rate",26.4
+27308,Norway,2016,3,G-Genito urinary system and sex hormones,"/capita, US$ purchasing power parity",22.1
+27309,Norway,2016,3,G-Genito urinary system and sex hormones,"Million US$, purchasing power parity",115.7
+27310,Norway,2016,3,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ purchasing power parity",10.2
+27311,Norway,2016,3,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ exchange rate",12.2
+27312,Norway,2016,3,G-Genito urinary system and sex hormones,% of total sales,4.7
+27313,Norway,2016,3,M01A-Antiinflammatory and antirheumatic products non-steroids,% of total sales,2.2
+27314,Norway,2016,3,J-Antiinfectives for systemic use,"Million US$, purchasing power parity",226.9
+27315,Norway,2016,3,R03-Drugs for obstructive airway diseases,% of total sales,4.8
+27316,Norway,2016,3,A02A-Antacids,Million of national currency units,30.0
+27317,Norway,2016,3,A02A-Antacids,Million US$ at exchange rate,3.6
+27318,Norway,2016,3,R03-Drugs for obstructive airway diseases,"Million US$, purchasing power parity",118.1
+27319,Norway,2016,3,R03-Drugs for obstructive airway diseases,Million US$ at exchange rate,141.2
+27320,Norway,2016,3,R03-Drugs for obstructive airway diseases,"/capita, US$ purchasing power parity",22.6
+27321,Norway,2016,3,R03-Drugs for obstructive airway diseases,"/capita, US$ exchange rate",27.0
+27322,Norway,2016,3,C08-Calcium channel blockers,% of total sales,0.5
+27323,Norway,2016,3,C08-Calcium channel blockers,"/capita, US$ exchange rate",2.9
+27324,Norway,2016,3,C08-Calcium channel blockers,"/capita, US$ purchasing power parity",2.4
+27325,Norway,2016,3,C-Cardiovascular system,Million of national currency units,1632.0
+27326,Norway,2016,3,C-Cardiovascular system,"/capita, US$ exchange rate",37.1
+27327,Norway,2016,3,C-Cardiovascular system,"Million US$, purchasing power parity",162.5
+27328,Norway,2016,3,C-Cardiovascular system,Million US$ at exchange rate,194.3
+27329,Norway,2016,3,C03-Diuretics,Million US$ at exchange rate,13.3
+27330,Norway,2016,3,C03-Diuretics,Million of national currency units,112.0
+27331,Norway,2016,3,C03-Diuretics,"Million US$, purchasing power parity",11.2
+27332,Norway,2016,3,C09-Agents acting on the Renin-Angiotensin system,Million US$ at exchange rate,52.4
+27333,Norway,2016,3,C09-Agents acting on the Renin-Angiotensin system,"Million US$, purchasing power parity",43.8
+27334,Norway,2016,3,N-Nervous system,% of total sales,16.7
+27335,Norway,2016,3,C09-Agents acting on the Renin-Angiotensin system,Million of national currency units,440.0
+27336,Norway,2016,3,C03-Diuretics,"/capita, US$ exchange rate",2.5
+27337,Norway,2016,3,C-Cardiovascular system,% of total sales,6.6
+27338,Norway,2016,3,J-Antiinfectives for systemic use,Million US$ at exchange rate,271.3
+27339,Norway,2016,3,J-Antiinfectives for systemic use,Million of national currency units,2279.0
+27340,Norway,2016,3,C03-Diuretics,"/capita, US$ purchasing power parity",2.1
+27341,Norway,2016,3,C03-Diuretics,% of total sales,0.5
+27342,Norway,2016,3,R03-Drugs for obstructive airway diseases,Million of national currency units,1186.0
+27343,Norway,2016,3,J01-Antibacterials for systemic use,"/capita, US$ exchange rate",10.7
+27344,Norway,2016,3,J01-Antibacterials for systemic use,"/capita, US$ purchasing power parity",8.9
+27345,Norway,2016,3,J01-Antibacterials for systemic use,"Million US$, purchasing power parity",46.7
+27346,Norway,2016,3,C08-Calcium channel blockers,"Million US$, purchasing power parity",12.5
+27347,Norway,2016,3,J-Antiinfectives for systemic use,% of total sales,9.2
+27348,Norway,2016,3,C08-Calcium channel blockers,Million of national currency units,126.0
+27349,Norway,2016,3,C08-Calcium channel blockers,Million US$ at exchange rate,15.0
+27350,Norway,2016,3,J01-Antibacterials for systemic use,Million US$ at exchange rate,55.8
+27351,Norway,2016,3,Products not elsewhere classified,"Million US$, purchasing power parity",708.2
+27352,Norway,2016,3,Products not elsewhere classified,"/capita, US$ exchange rate",161.7
+27353,Norway,2016,3,Products not elsewhere classified,Million of national currency units,7112.0
+27354,Norway,2016,3,Products not elsewhere classified,Million US$ at exchange rate,846.7
+27355,Norway,2016,3,J01-Antibacterials for systemic use,Million of national currency units,469.0
+27356,Norway,2016,3,Products not elsewhere classified,% of total sales,28.7
+27357,Norway,2016,3,Products not elsewhere classified,"/capita, US$ purchasing power parity",135.3
+27358,Norway,2016,3,N02-Analgesics,Million US$ at exchange rate,174.4
+27359,Norway,2016,3,C07-Beta blocking agents,Million US$ at exchange rate,21.4
+27360,Norway,2016,3,N02-Analgesics,Million of national currency units,1465.0
+27361,Norway,2016,3,C07-Beta blocking agents,Million of national currency units,180.0
+27362,Norway,2016,3,N02-Analgesics,"Million US$, purchasing power parity",145.9
+27363,Norway,2016,3,N02-Analgesics,"/capita, US$ purchasing power parity",27.9
+27364,Norway,2016,3,N02-Analgesics,% of total sales,5.9
+27365,Norway,2016,3,N02-Analgesics,"/capita, US$ exchange rate",33.3
+27366,Norway,2016,3,J01-Antibacterials for systemic use,% of total sales,1.9
+27367,Norway,2016,3,J-Antiinfectives for systemic use,"/capita, US$ purchasing power parity",43.4
+27368,Norway,2016,3,J-Antiinfectives for systemic use,"/capita, US$ exchange rate",51.8
+27369,Norway,2016,3,C07-Beta blocking agents,% of total sales,0.7
+27370,Norway,2016,3,C07-Beta blocking agents,"/capita, US$ exchange rate",4.1
+27371,Norway,2016,3,C07-Beta blocking agents,"Million US$, purchasing power parity",17.9
+27372,Norway,2016,3,C07-Beta blocking agents,"/capita, US$ purchasing power parity",3.4
+27373,Norway,2016,3,C-Cardiovascular system,"/capita, US$ purchasing power parity",31.0
+27374,Norway,2016,3,R-Respiratory system,Million US$ at exchange rate,270.6
+27375,Norway,2016,3,R-Respiratory system,Million of national currency units,2273.0
+27376,Norway,2016,3,R-Respiratory system,"Million US$, purchasing power parity",226.4
+27377,Norway,2016,3,C02-Antihypertensives,"/capita, US$ purchasing power parity",2.0
+27378,Norway,2016,3,N-Nervous system,Million US$ at exchange rate,492.0
+27379,Norway,2016,3,N-Nervous system,Million of national currency units,4133.0
+27380,Norway,2016,3,C02-Antihypertensives,% of total sales,0.4
+27381,Norway,2016,3,R-Respiratory system,"/capita, US$ exchange rate",51.7
+27382,Norway,2016,3,A02A-Antacids,"/capita, US$ exchange rate",0.7
+27383,Norway,2016,3,A02A-Antacids,% of total sales,0.1
+27384,Norway,2016,3,A02A-Antacids,"/capita, US$ purchasing power parity",0.6
+27385,Norway,2016,3,R-Respiratory system,"/capita, US$ purchasing power parity",43.2
+27386,Norway,2016,3,R-Respiratory system,% of total sales,9.2
+27387,Norway,2016,3,A02A-Antacids,"Million US$, purchasing power parity",3.0
+27388,Norway,2016,3,N-Nervous system,"/capita, US$ purchasing power parity",78.6
+27389,Norway,2016,3,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ exchange rate",10.0
+27390,Norway,2016,3,N-Nervous system,"/capita, US$ exchange rate",94.0
+27391,Norway,2016,3,C09-Agents acting on the Renin-Angiotensin system,% of total sales,1.8
+27392,Norway,2016,3,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ purchasing power parity",8.4
+27393,Norway,2016,3,C02-Antihypertensives,"Million US$, purchasing power parity",10.3
+27394,Norway,2016,3,C02-Antihypertensives,"/capita, US$ exchange rate",2.3
+27395,Norway,2016,3,N-Nervous system,"Million US$, purchasing power parity",411.6
+27396,Norway,2016,3,C02-Antihypertensives,Million US$ at exchange rate,12.3
+27397,Norway,2010,4,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"Million US$, purchasing power parity",50.2
+27398,Norway,2010,4,M-Musculo-skeletal system,"Million US$, purchasing power parity",66.5
+27399,Norway,2010,4,M-Musculo-skeletal system,Million US$ at exchange rate,100.8
+27400,Norway,2010,4,C10-Lipid modifying agents,Million of national currency units,440.0
+27401,Norway,2010,4,C10-Lipid modifying agents,Million US$ at exchange rate,72.8
+27402,Norway,2010,4,C10-Lipid modifying agents,"Million US$, purchasing power parity",48.1
+27403,Norway,2010,4,A-Alimentary tract and metabolism,"/capita, US$ purchasing power parity",40.9
+27404,Norway,2010,4,A-Alimentary tract and metabolism,% of total sales,10.2
+27405,Norway,2010,4,G-Genito urinary system and sex hormones,Million of national currency units,914.0
+27406,Norway,2010,4,C02-Antihypertensives,Million of national currency units,54.0
+27407,Norway,2010,4,G-Genito urinary system and sex hormones,Million US$ at exchange rate,151.2
+27408,Norway,2010,4,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million US$ at exchange rate,75.9
+27409,Norway,2010,4,M-Musculo-skeletal system,"/capita, US$ purchasing power parity",13.6
+27410,Norway,2010,4,M-Musculo-skeletal system,"/capita, US$ exchange rate",20.6
+27411,Norway,2010,4,M-Musculo-skeletal system,% of total sales,3.4
+27412,Norway,2010,4,"H-Systemic hormonal preparations, excluding sex hormones and insulins",% of total sales,2.5
+27413,Norway,2010,4,C10-Lipid modifying agents,% of total sales,2.5
+27414,Norway,2010,4,A-Alimentary tract and metabolism,"/capita, US$ exchange rate",61.9
+27415,Norway,2010,4,N05B-Anxiolytics,"/capita, US$ exchange rate",4.1
+27416,Norway,2010,4,M-Musculo-skeletal system,Million of national currency units,609.0
+27417,Norway,2010,4,N05B-Anxiolytics,Million US$ at exchange rate,20.2
+27418,Norway,2010,4,N05B-Anxiolytics,"Million US$, purchasing power parity",13.3
+27419,Norway,2010,4,A-Alimentary tract and metabolism,"Million US$, purchasing power parity",199.9
+27420,Norway,2010,4,A-Alimentary tract and metabolism,Million of national currency units,1829.0
+27421,Norway,2010,4,A-Alimentary tract and metabolism,Million US$ at exchange rate,302.6
+27422,Norway,2010,4,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ purchasing power parity",10.3
+27423,Norway,2010,4,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),% of total sales,2.6
+27424,Norway,2010,4,C10-Lipid modifying agents,"/capita, US$ exchange rate",14.9
+27425,Norway,2010,4,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ exchange rate",15.5
+27426,Norway,2010,4,N05B-Anxiolytics,"/capita, US$ purchasing power parity",2.7
+27427,Norway,2010,4,N05B-Anxiolytics,Million of national currency units,122.0
+27428,Norway,2010,4,N05B-Anxiolytics,% of total sales,0.7
+27429,Norway,2010,4,C10-Lipid modifying agents,"/capita, US$ purchasing power parity",9.8
+27430,Norway,2010,4,N05C-Hypnotics and sedatives,% of total sales,1.0
+27431,Norway,2010,4,N05C-Hypnotics and sedatives,"/capita, US$ purchasing power parity",3.8
+27432,Norway,2010,4,N05C-Hypnotics and sedatives,"/capita, US$ exchange rate",5.8
+27433,Norway,2010,4,B-Blood and blood forming organs,"/capita, US$ exchange rate",40.2
+27434,Norway,2010,4,B-Blood and blood forming organs,"/capita, US$ purchasing power parity",26.6
+27435,Norway,2010,4,B-Blood and blood forming organs,% of total sales,6.6
+27436,Norway,2010,4,N05C-Hypnotics and sedatives,"Million US$, purchasing power parity",18.8
+27437,Norway,2010,4,C01A-Cardiac glycosides,% of total sales,0.0
+27438,Norway,2010,4,N06A-Antidepressants,Million of national currency units,324.0
+27439,Norway,2010,4,M01A-Antiinflammatory and antirheumatic products non-steroids,Million US$ at exchange rate,70.3
+27440,Norway,2010,4,M01A-Antiinflammatory and antirheumatic products non-steroids,Million of national currency units,425.0
+27441,Norway,2010,4,N05C-Hypnotics and sedatives,Million US$ at exchange rate,28.5
+27442,Norway,2010,4,N05C-Hypnotics and sedatives,Million of national currency units,172.0
+27443,Norway,2010,4,C01A-Cardiac glycosides,"/capita, US$ purchasing power parity",0.1
+27444,Norway,2010,4,C01A-Cardiac glycosides,"/capita, US$ exchange rate",0.2
+27445,Norway,2010,4,B-Blood and blood forming organs,"Million US$, purchasing power parity",129.8
+27446,Norway,2010,4,A10-Drugs used in diabetes,Million of national currency units,517.0
+27447,Norway,2010,4,G03-Sex hormones and modulators of the genital system,Million of national currency units,433.0
+27448,Norway,2010,4,A10-Drugs used in diabetes,"Million US$, purchasing power parity",56.5
+27449,Norway,2010,4,G03-Sex hormones and modulators of the genital system,% of total sales,2.4
+27450,Norway,2010,4,A10-Drugs used in diabetes,Million US$ at exchange rate,85.5
+27451,Norway,2010,4,G03-Sex hormones and modulators of the genital system,"Million US$, purchasing power parity",47.3
+27452,Norway,2010,4,G03-Sex hormones and modulators of the genital system,"/capita, US$ exchange rate",14.7
+27453,Norway,2010,4,G03-Sex hormones and modulators of the genital system,"/capita, US$ purchasing power parity",9.7
+27454,Norway,2010,4,C01A-Cardiac glycosides,"Million US$, purchasing power parity",0.5
+27455,Norway,2010,4,C01A-Cardiac glycosides,Million US$ at exchange rate,0.8
+27456,Norway,2010,4,B-Blood and blood forming organs,Million of national currency units,1188.0
+27457,Norway,2010,4,B-Blood and blood forming organs,Million US$ at exchange rate,196.6
+27458,Norway,2010,4,A10-Drugs used in diabetes,"/capita, US$ purchasing power parity",11.6
+27459,Norway,2010,4,A10-Drugs used in diabetes,"/capita, US$ exchange rate",17.5
+27460,Norway,2010,4,C01A-Cardiac glycosides,Million of national currency units,5.0
+27461,Norway,2010,4,A10-Drugs used in diabetes,% of total sales,2.9
+27462,Norway,2010,4,"C01B-Antiarrhythmics, Class I and III",Million US$ at exchange rate,4.1
+27463,Norway,2010,4,"C01B-Antiarrhythmics, Class I and III",Million of national currency units,25.0
+27464,Norway,2010,4,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million US$ at exchange rate,72.8
+27465,Norway,2010,4,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million of national currency units,440.0
+27466,Norway,2010,4,Total pharmaceutical sales,"Million US$, purchasing power parity",1954.8
+27467,Norway,2010,4,Total pharmaceutical sales,Million US$ at exchange rate,2959.9
+27468,Norway,2010,4,Total pharmaceutical sales,"/capita, US$ purchasing power parity",399.8
+27469,Norway,2010,4,Total pharmaceutical sales,"/capita, US$ exchange rate",605.4
+27470,Norway,2010,4,"C01B-Antiarrhythmics, Class I and III","/capita, US$ purchasing power parity",0.6
+27471,Norway,2010,4,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million of national currency units,459.0
+27472,Norway,2010,4,"C01B-Antiarrhythmics, Class I and III","/capita, US$ exchange rate",0.8
+27473,Norway,2010,4,"C01B-Antiarrhythmics, Class I and III",% of total sales,0.1
+27474,Norway,2010,4,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ exchange rate",14.9
+27475,Norway,2010,4,"H-Systemic hormonal preparations, excluding sex hormones and insulins","Million US$, purchasing power parity",48.1
+27476,Norway,2010,4,"C01B-Antiarrhythmics, Class I and III","Million US$, purchasing power parity",2.7
+27477,Norway,2010,4,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ purchasing power parity",9.8
+27478,Norway,2010,4,N06A-Antidepressants,% of total sales,1.8
+27479,Norway,2010,4,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ exchange rate",14.4
+27480,Norway,2010,4,M01A-Antiinflammatory and antirheumatic products non-steroids,"Million US$, purchasing power parity",46.4
+27481,Norway,2010,4,N06A-Antidepressants,"Million US$, purchasing power parity",35.4
+27482,Norway,2010,4,N06A-Antidepressants,Million US$ at exchange rate,53.6
+27483,Norway,2010,4,N06A-Antidepressants,"/capita, US$ purchasing power parity",7.2
+27484,Norway,2010,4,N06A-Antidepressants,"/capita, US$ exchange rate",11.0
+27485,Norway,2010,4,G-Genito urinary system and sex hormones,"/capita, US$ purchasing power parity",20.4
+27486,Norway,2010,4,G-Genito urinary system and sex hormones,"/capita, US$ exchange rate",30.9
+27487,Norway,2010,4,Total pharmaceutical sales,Million of national currency units,17890.0
+27488,Norway,2010,4,G-Genito urinary system and sex hormones,"Million US$, purchasing power parity",99.9
+27489,Norway,2010,4,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ purchasing power parity",9.5
+27490,Norway,2010,4,M01A-Antiinflammatory and antirheumatic products non-steroids,% of total sales,2.4
+27491,Norway,2010,4,G-Genito urinary system and sex hormones,% of total sales,5.1
+27492,Norway,2010,4,G03-Sex hormones and modulators of the genital system,Million US$ at exchange rate,71.6
+27493,Norway,2010,4,R03-Drugs for obstructive airway diseases,% of total sales,6.5
+27494,Norway,2010,4,A02A-Antacids,Million US$ at exchange rate,4.6
+27495,Norway,2010,4,J-Antiinfectives for systemic use,"/capita, US$ exchange rate",42.5
+27496,Norway,2010,4,R03-Drugs for obstructive airway diseases,"Million US$, purchasing power parity",126.3
+27497,Norway,2010,4,R03-Drugs for obstructive airway diseases,"/capita, US$ purchasing power parity",25.8
+27498,Norway,2010,4,R03-Drugs for obstructive airway diseases,"/capita, US$ exchange rate",39.1
+27499,Norway,2010,4,A02A-Antacids,Million of national currency units,28.0
+27500,Norway,2010,4,C07-Beta blocking agents,Million of national currency units,168.0
+27501,Norway,2010,4,C-Cardiovascular system,Million of national currency units,1869.0
+27502,Norway,2010,4,C08-Calcium channel blockers,% of total sales,0.9
+27503,Norway,2010,4,C08-Calcium channel blockers,"/capita, US$ purchasing power parity",3.6
+27504,Norway,2010,4,C-Cardiovascular system,"/capita, US$ exchange rate",63.2
+27505,Norway,2010,4,C-Cardiovascular system,"/capita, US$ purchasing power parity",41.8
+27506,Norway,2010,4,C-Cardiovascular system,Million US$ at exchange rate,309.2
+27507,Norway,2010,4,C-Cardiovascular system,"Million US$, purchasing power parity",204.2
+27508,Norway,2010,4,J-Antiinfectives for systemic use,"Million US$, purchasing power parity",137.2
+27509,Norway,2010,4,C03-Diuretics,Million US$ at exchange rate,16.4
+27510,Norway,2010,4,C03-Diuretics,Million of national currency units,99.0
+27511,Norway,2010,4,C03-Diuretics,"/capita, US$ exchange rate",3.4
+27512,Norway,2010,4,C03-Diuretics,"Million US$, purchasing power parity",10.8
+27513,Norway,2010,4,C09-Agents acting on the Renin-Angiotensin system,"Million US$, purchasing power parity",88.3
+27514,Norway,2010,4,C09-Agents acting on the Renin-Angiotensin system,Million of national currency units,808.0
+27515,Norway,2010,4,C09-Agents acting on the Renin-Angiotensin system,Million US$ at exchange rate,133.7
+27516,Norway,2010,4,J-Antiinfectives for systemic use,Million of national currency units,1256.0
+27517,Norway,2010,4,C02-Antihypertensives,Million US$ at exchange rate,8.9
+27518,Norway,2010,4,C-Cardiovascular system,% of total sales,10.4
+27519,Norway,2010,4,J-Antiinfectives for systemic use,Million US$ at exchange rate,207.8
+27520,Norway,2010,4,C03-Diuretics,% of total sales,0.6
+27521,Norway,2010,4,C03-Diuretics,"/capita, US$ purchasing power parity",2.2
+27522,Norway,2010,4,R03-Drugs for obstructive airway diseases,Million US$ at exchange rate,191.3
+27523,Norway,2010,4,R03-Drugs for obstructive airway diseases,Million of national currency units,1156.0
+27524,Norway,2010,4,J01-Antibacterials for systemic use,"/capita, US$ purchasing power parity",10.1
+27525,Norway,2010,4,C08-Calcium channel blockers,Million of national currency units,159.0
+27526,Norway,2010,4,J01-Antibacterials for systemic use,"Million US$, purchasing power parity",49.6
+27527,Norway,2010,4,J01-Antibacterials for systemic use,"/capita, US$ exchange rate",15.4
+27528,Norway,2010,4,C08-Calcium channel blockers,"/capita, US$ exchange rate",5.4
+27529,Norway,2010,4,C08-Calcium channel blockers,Million US$ at exchange rate,26.3
+27530,Norway,2010,4,C08-Calcium channel blockers,"Million US$, purchasing power parity",17.4
+27531,Norway,2010,4,Products not elsewhere classified,"Million US$, purchasing power parity",481.1
+27532,Norway,2010,4,Products not elsewhere classified,"/capita, US$ exchange rate",149.0
+27533,Norway,2010,4,Products not elsewhere classified,Million of national currency units,4403.0
+27534,Norway,2010,4,Products not elsewhere classified,Million US$ at exchange rate,728.5
+27535,Norway,2010,4,J01-Antibacterials for systemic use,Million of national currency units,454.0
+27536,Norway,2010,4,J01-Antibacterials for systemic use,Million US$ at exchange rate,75.1
+27537,Norway,2010,4,Products not elsewhere classified,"/capita, US$ purchasing power parity",98.4
+27538,Norway,2010,4,Products not elsewhere classified,% of total sales,24.6
+27539,Norway,2010,4,J-Antiinfectives for systemic use,% of total sales,7.0
+27540,Norway,2010,4,N02-Analgesics,Million US$ at exchange rate,197.5
+27541,Norway,2010,4,N02-Analgesics,"Million US$, purchasing power parity",130.5
+27542,Norway,2010,4,C07-Beta blocking agents,Million US$ at exchange rate,27.8
+27543,Norway,2010,4,N02-Analgesics,Million of national currency units,1194.0
+27544,Norway,2010,4,N02-Analgesics,% of total sales,6.7
+27545,Norway,2010,4,N02-Analgesics,"/capita, US$ exchange rate",40.4
+27546,Norway,2010,4,N02-Analgesics,"/capita, US$ purchasing power parity",26.7
+27547,Norway,2010,4,J01-Antibacterials for systemic use,% of total sales,2.5
+27548,Norway,2010,4,J-Antiinfectives for systemic use,"/capita, US$ purchasing power parity",28.1
+27549,Norway,2010,4,C07-Beta blocking agents,"/capita, US$ exchange rate",5.7
+27550,Norway,2010,4,C07-Beta blocking agents,"Million US$, purchasing power parity",18.4
+27551,Norway,2010,4,C07-Beta blocking agents,% of total sales,0.9
+27552,Norway,2010,4,C07-Beta blocking agents,"/capita, US$ purchasing power parity",3.8
+27553,Norway,2010,4,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ exchange rate",27.3
+27554,Norway,2010,4,R-Respiratory system,Million US$ at exchange rate,317.2
+27555,Norway,2010,4,R-Respiratory system,Million of national currency units,1917.0
+27556,Norway,2010,4,R-Respiratory system,"/capita, US$ exchange rate",64.9
+27557,Norway,2010,4,R-Respiratory system,"Million US$, purchasing power parity",209.5
+27558,Norway,2010,4,C02-Antihypertensives,"/capita, US$ purchasing power parity",1.2
+27559,Norway,2010,4,N-Nervous system,"Million US$, purchasing power parity",378.4
+27560,Norway,2010,4,C02-Antihypertensives,% of total sales,0.3
+27561,Norway,2010,4,N-Nervous system,Million US$ at exchange rate,572.9
+27562,Norway,2010,4,A02A-Antacids,"/capita, US$ purchasing power parity",0.6
+27563,Norway,2010,4,A02A-Antacids,"/capita, US$ exchange rate",0.9
+27564,Norway,2010,4,A02A-Antacids,% of total sales,0.2
+27565,Norway,2010,4,R-Respiratory system,"/capita, US$ purchasing power parity",42.8
+27566,Norway,2010,4,N-Nervous system,Million of national currency units,3463.0
+27567,Norway,2010,4,A02A-Antacids,"Million US$, purchasing power parity",3.1
+27568,Norway,2010,4,R-Respiratory system,% of total sales,10.7
+27569,Norway,2010,4,N-Nervous system,"/capita, US$ purchasing power parity",77.4
+27570,Norway,2010,4,C02-Antihypertensives,"/capita, US$ exchange rate",1.8
+27571,Norway,2010,4,N-Nervous system,% of total sales,19.4
+27572,Norway,2010,4,C02-Antihypertensives,"Million US$, purchasing power parity",5.9
+27573,Norway,2010,4,N-Nervous system,"/capita, US$ exchange rate",117.2
+27574,Norway,2010,4,C09-Agents acting on the Renin-Angiotensin system,% of total sales,4.5
+27575,Norway,2010,4,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ purchasing power parity",18.1
+27576,Norway,2014,3,M-Musculo-skeletal system,Million US$ at exchange rate,119.7
+27577,Norway,2014,3,M-Musculo-skeletal system,"Million US$, purchasing power parity",81.3
+27578,Norway,2014,3,N05B-Anxiolytics,% of total sales,0.6
+27579,Norway,2014,3,C10-Lipid modifying agents,Million of national currency units,377.0
+27580,Norway,2014,3,C10-Lipid modifying agents,Million US$ at exchange rate,59.8
+27581,Norway,2014,3,A-Alimentary tract and metabolism,% of total sales,9.8
+27582,Norway,2014,3,A-Alimentary tract and metabolism,"/capita, US$ purchasing power parity",43.2
+27583,Norway,2014,3,G-Genito urinary system and sex hormones,Million of national currency units,1015.0
+27584,Norway,2014,3,C02-Antihypertensives,Million of national currency units,74.0
+27585,Norway,2014,3,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million US$ at exchange rate,59.2
+27586,Norway,2014,3,G-Genito urinary system and sex hormones,Million US$ at exchange rate,161.1
+27587,Norway,2014,3,M-Musculo-skeletal system,% of total sales,3.6
+27588,Norway,2014,3,M-Musculo-skeletal system,"/capita, US$ purchasing power parity",15.8
+27589,Norway,2014,3,C10-Lipid modifying agents,"Million US$, purchasing power parity",40.6
+27590,Norway,2014,3,M-Musculo-skeletal system,"/capita, US$ exchange rate",23.3
+27591,Norway,2014,3,"H-Systemic hormonal preparations, excluding sex hormones and insulins",% of total sales,2.4
+27592,Norway,2014,3,A-Alimentary tract and metabolism,"Million US$, purchasing power parity",222.1
+27593,Norway,2014,3,C10-Lipid modifying agents,% of total sales,1.8
+27594,Norway,2014,3,N05B-Anxiolytics,"/capita, US$ exchange rate",3.7
+27595,Norway,2014,3,A-Alimentary tract and metabolism,"/capita, US$ exchange rate",63.7
+27596,Norway,2014,3,M-Musculo-skeletal system,Million of national currency units,754.0
+27597,Norway,2014,3,N05B-Anxiolytics,Million US$ at exchange rate,19.2
+27598,Norway,2014,3,N05B-Anxiolytics,"Million US$, purchasing power parity",13.0
+27599,Norway,2014,3,A-Alimentary tract and metabolism,Million of national currency units,2061.0
+27600,Norway,2014,3,A-Alimentary tract and metabolism,Million US$ at exchange rate,327.1
+27601,Norway,2014,3,N05B-Anxiolytics,Million of national currency units,121.0
+27602,Norway,2014,3,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ purchasing power parity",7.8
+27603,Norway,2014,3,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),% of total sales,1.8
+27604,Norway,2014,3,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"Million US$, purchasing power parity",40.2
+27605,Norway,2014,3,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ exchange rate",11.5
+27606,Norway,2014,3,N05B-Anxiolytics,"/capita, US$ purchasing power parity",2.5
+27607,Norway,2014,3,C10-Lipid modifying agents,"/capita, US$ exchange rate",11.6
+27608,Norway,2014,3,C10-Lipid modifying agents,"/capita, US$ purchasing power parity",7.9
+27609,Norway,2014,3,N05C-Hypnotics and sedatives,"/capita, US$ purchasing power parity",4.4
+27610,Norway,2014,3,N05C-Hypnotics and sedatives,% of total sales,1.0
+27611,Norway,2014,3,N05C-Hypnotics and sedatives,"Million US$, purchasing power parity",22.7
+27612,Norway,2014,3,N05C-Hypnotics and sedatives,"/capita, US$ exchange rate",6.5
+27613,Norway,2014,3,B-Blood and blood forming organs,"/capita, US$ exchange rate",51.1
+27614,Norway,2014,3,B-Blood and blood forming organs,"Million US$, purchasing power parity",178.3
+27615,Norway,2014,3,B-Blood and blood forming organs,% of total sales,7.8
+27616,Norway,2014,3,B-Blood and blood forming organs,"/capita, US$ purchasing power parity",34.7
+27617,Norway,2014,3,C01A-Cardiac glycosides,% of total sales,0.0
+27618,Norway,2014,3,G03-Sex hormones and modulators of the genital system,% of total sales,2.2
+27619,Norway,2014,3,M01A-Antiinflammatory and antirheumatic products non-steroids,Million of national currency units,474.0
+27620,Norway,2014,3,C01A-Cardiac glycosides,"/capita, US$ purchasing power parity",0.1
+27621,Norway,2014,3,N05C-Hypnotics and sedatives,Million of national currency units,211.0
+27622,Norway,2014,3,N05C-Hypnotics and sedatives,Million US$ at exchange rate,33.5
+27623,Norway,2014,3,C01A-Cardiac glycosides,"/capita, US$ exchange rate",0.2
+27624,Norway,2014,3,A10-Drugs used in diabetes,Million of national currency units,683.0
+27625,Norway,2014,3,G03-Sex hormones and modulators of the genital system,Million of national currency units,471.0
+27626,Norway,2014,3,A10-Drugs used in diabetes,"Million US$, purchasing power parity",73.6
+27627,Norway,2014,3,A10-Drugs used in diabetes,Million US$ at exchange rate,108.4
+27628,Norway,2014,3,G03-Sex hormones and modulators of the genital system,"Million US$, purchasing power parity",50.8
+27629,Norway,2014,3,G03-Sex hormones and modulators of the genital system,Million US$ at exchange rate,74.7
+27630,Norway,2014,3,G03-Sex hormones and modulators of the genital system,"/capita, US$ purchasing power parity",9.9
+27631,Norway,2014,3,G03-Sex hormones and modulators of the genital system,"/capita, US$ exchange rate",14.5
+27632,Norway,2014,3,C01A-Cardiac glycosides,"Million US$, purchasing power parity",0.5
+27633,Norway,2014,3,C01A-Cardiac glycosides,Million US$ at exchange rate,0.8
+27634,Norway,2014,3,B-Blood and blood forming organs,Million US$ at exchange rate,262.5
+27635,Norway,2014,3,B-Blood and blood forming organs,Million of national currency units,1654.0
+27636,Norway,2014,3,A10-Drugs used in diabetes,"/capita, US$ purchasing power parity",14.3
+27637,Norway,2014,3,A10-Drugs used in diabetes,"/capita, US$ exchange rate",21.1
+27638,Norway,2014,3,C01A-Cardiac glycosides,Million of national currency units,5.0
+27639,Norway,2014,3,A10-Drugs used in diabetes,% of total sales,3.2
+27640,Norway,2014,3,"C01B-Antiarrhythmics, Class I and III",Million of national currency units,33.0
+27641,Norway,2014,3,"C01B-Antiarrhythmics, Class I and III",Million US$ at exchange rate,5.2
+27642,Norway,2014,3,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million US$ at exchange rate,81.9
+27643,Norway,2014,3,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million of national currency units,516.0
+27644,Norway,2014,3,Total pharmaceutical sales,"Million US$, purchasing power parity",2271.6
+27645,Norway,2014,3,Total pharmaceutical sales,Million US$ at exchange rate,3344.7
+27646,Norway,2014,3,Total pharmaceutical sales,"/capita, US$ purchasing power parity",442.2
+27647,Norway,2014,3,Total pharmaceutical sales,"/capita, US$ exchange rate",651.1
+27648,Norway,2014,3,"C01B-Antiarrhythmics, Class I and III","/capita, US$ purchasing power parity",0.7
+27649,Norway,2014,3,"C01B-Antiarrhythmics, Class I and III","/capita, US$ exchange rate",1.0
+27650,Norway,2014,3,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million of national currency units,373.0
+27651,Norway,2014,3,"C01B-Antiarrhythmics, Class I and III",% of total sales,0.2
+27652,Norway,2014,3,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ exchange rate",15.9
+27653,Norway,2014,3,"H-Systemic hormonal preparations, excluding sex hormones and insulins","Million US$, purchasing power parity",55.6
+27654,Norway,2014,3,"C01B-Antiarrhythmics, Class I and III","Million US$, purchasing power parity",3.6
+27655,Norway,2014,3,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ purchasing power parity",10.8
+27656,Norway,2014,3,N06A-Antidepressants,Million of national currency units,263.0
+27657,Norway,2014,3,N06A-Antidepressants,% of total sales,1.2
+27658,Norway,2014,3,M01A-Antiinflammatory and antirheumatic products non-steroids,Million US$ at exchange rate,75.2
+27659,Norway,2014,3,M01A-Antiinflammatory and antirheumatic products non-steroids,"Million US$, purchasing power parity",51.1
+27660,Norway,2014,3,N06A-Antidepressants,"/capita, US$ purchasing power parity",5.5
+27661,Norway,2014,3,N06A-Antidepressants,Million US$ at exchange rate,41.7
+27662,Norway,2014,3,N06A-Antidepressants,"Million US$, purchasing power parity",28.3
+27663,Norway,2014,3,N06A-Antidepressants,"/capita, US$ exchange rate",8.1
+27664,Norway,2014,3,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ exchange rate",14.6
+27665,Norway,2014,3,G-Genito urinary system and sex hormones,"/capita, US$ exchange rate",31.4
+27666,Norway,2014,3,G-Genito urinary system and sex hormones,"/capita, US$ purchasing power parity",21.3
+27667,Norway,2014,3,Total pharmaceutical sales,Million of national currency units,21077.0
+27668,Norway,2014,3,G-Genito urinary system and sex hormones,"Million US$, purchasing power parity",109.4
+27669,Norway,2014,3,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ purchasing power parity",9.9
+27670,Norway,2014,3,G-Genito urinary system and sex hormones,% of total sales,4.8
+27671,Norway,2014,3,M01A-Antiinflammatory and antirheumatic products non-steroids,% of total sales,2.2
+27672,Norway,2014,3,R03-Drugs for obstructive airway diseases,% of total sales,5.2
+27673,Norway,2014,3,A02A-Antacids,Million of national currency units,28.0
+27674,Norway,2014,3,A02A-Antacids,Million US$ at exchange rate,4.4
+27675,Norway,2014,3,R03-Drugs for obstructive airway diseases,"Million US$, purchasing power parity",118.3
+27676,Norway,2014,3,R03-Drugs for obstructive airway diseases,Million US$ at exchange rate,174.2
+27677,Norway,2014,3,J-Antiinfectives for systemic use,"Million US$, purchasing power parity",197.2
+27678,Norway,2014,3,R03-Drugs for obstructive airway diseases,"/capita, US$ purchasing power parity",23.0
+27679,Norway,2014,3,R03-Drugs for obstructive airway diseases,"/capita, US$ exchange rate",33.9
+27680,Norway,2014,3,C08-Calcium channel blockers,% of total sales,0.6
+27681,Norway,2014,3,C-Cardiovascular system,Million of national currency units,1477.0
+27682,Norway,2014,3,C07-Beta blocking agents,Million of national currency units,172.0
+27683,Norway,2014,3,C08-Calcium channel blockers,"/capita, US$ purchasing power parity",2.7
+27684,Norway,2014,3,C-Cardiovascular system,"/capita, US$ exchange rate",45.6
+27685,Norway,2014,3,C-Cardiovascular system,"Million US$, purchasing power parity",159.2
+27686,Norway,2014,3,C-Cardiovascular system,Million US$ at exchange rate,234.4
+27687,Norway,2014,3,C03-Diuretics,Million US$ at exchange rate,16.7
+27688,Norway,2014,3,C03-Diuretics,Million of national currency units,105.0
+27689,Norway,2014,3,C03-Diuretics,"/capita, US$ exchange rate",3.2
+27690,Norway,2014,3,C03-Diuretics,"Million US$, purchasing power parity",11.3
+27691,Norway,2014,3,C09-Agents acting on the Renin-Angiotensin system,Million US$ at exchange rate,70.3
+27692,Norway,2014,3,C09-Agents acting on the Renin-Angiotensin system,"Million US$, purchasing power parity",47.7
+27693,Norway,2014,3,N-Nervous system,% of total sales,17.8
+27694,Norway,2014,3,C09-Agents acting on the Renin-Angiotensin system,Million of national currency units,443.0
+27695,Norway,2014,3,C-Cardiovascular system,"/capita, US$ purchasing power parity",31.0
+27696,Norway,2014,3,C-Cardiovascular system,% of total sales,7.0
+27697,Norway,2014,3,J-Antiinfectives for systemic use,Million US$ at exchange rate,290.4
+27698,Norway,2014,3,J-Antiinfectives for systemic use,Million of national currency units,1830.0
+27699,Norway,2014,3,C03-Diuretics,"/capita, US$ purchasing power parity",2.2
+27700,Norway,2014,3,C03-Diuretics,% of total sales,0.5
+27701,Norway,2014,3,R03-Drugs for obstructive airway diseases,Million of national currency units,1098.0
+27702,Norway,2014,3,C08-Calcium channel blockers,"/capita, US$ exchange rate",4.0
+27703,Norway,2014,3,J01-Antibacterials for systemic use,"/capita, US$ purchasing power parity",9.5
+27704,Norway,2014,3,C08-Calcium channel blockers,Million of national currency units,130.0
+27705,Norway,2014,3,J01-Antibacterials for systemic use,"/capita, US$ exchange rate",14.0
+27706,Norway,2014,3,J01-Antibacterials for systemic use,"Million US$, purchasing power parity",48.9
+27707,Norway,2014,3,J-Antiinfectives for systemic use,% of total sales,8.7
+27708,Norway,2014,3,C08-Calcium channel blockers,"Million US$, purchasing power parity",14.0
+27709,Norway,2014,3,C08-Calcium channel blockers,Million US$ at exchange rate,20.6
+27710,Norway,2014,3,J01-Antibacterials for systemic use,Million US$ at exchange rate,72.0
+27711,Norway,2014,3,Products not elsewhere classified,"Million US$, purchasing power parity",648.2
+27712,Norway,2014,3,Products not elsewhere classified,"/capita, US$ exchange rate",185.8
+27713,Norway,2014,3,Products not elsewhere classified,Million of national currency units,6014.0
+27714,Norway,2014,3,Products not elsewhere classified,Million US$ at exchange rate,954.4
+27715,Norway,2014,3,J01-Antibacterials for systemic use,Million of national currency units,454.0
+27716,Norway,2014,3,Products not elsewhere classified,"/capita, US$ purchasing power parity",126.2
+27717,Norway,2014,3,Products not elsewhere classified,% of total sales,28.5
+27718,Norway,2014,3,N02-Analgesics,Million US$ at exchange rate,209.0
+27719,Norway,2014,3,C07-Beta blocking agents,Million US$ at exchange rate,27.3
+27720,Norway,2014,3,N02-Analgesics,Million of national currency units,1317.0
+27721,Norway,2014,3,N02-Analgesics,"Million US$, purchasing power parity",141.9
+27722,Norway,2014,3,N02-Analgesics,% of total sales,6.2
+27723,Norway,2014,3,N02-Analgesics,"/capita, US$ purchasing power parity",27.6
+27724,Norway,2014,3,N02-Analgesics,"/capita, US$ exchange rate",40.7
+27725,Norway,2014,3,J01-Antibacterials for systemic use,% of total sales,2.2
+27726,Norway,2014,3,J-Antiinfectives for systemic use,"/capita, US$ purchasing power parity",38.4
+27727,Norway,2014,3,J-Antiinfectives for systemic use,"/capita, US$ exchange rate",56.5
+27728,Norway,2014,3,C07-Beta blocking agents,"/capita, US$ exchange rate",5.3
+27729,Norway,2014,3,C07-Beta blocking agents,"Million US$, purchasing power parity",18.5
+27730,Norway,2014,3,C07-Beta blocking agents,% of total sales,0.8
+27731,Norway,2014,3,C07-Beta blocking agents,"/capita, US$ purchasing power parity",3.6
+27732,Norway,2014,3,R-Respiratory system,Million US$ at exchange rate,317.5
+27733,Norway,2014,3,R-Respiratory system,Million of national currency units,2001.0
+27734,Norway,2014,3,R-Respiratory system,"Million US$, purchasing power parity",215.7
+27735,Norway,2014,3,N-Nervous system,Million of national currency units,3753.0
+27736,Norway,2014,3,C02-Antihypertensives,"/capita, US$ purchasing power parity",1.6
+27737,Norway,2014,3,N-Nervous system,Million US$ at exchange rate,595.6
+27738,Norway,2014,3,C02-Antihypertensives,% of total sales,0.4
+27739,Norway,2014,3,R-Respiratory system,"/capita, US$ exchange rate",61.8
+27740,Norway,2014,3,A02A-Antacids,"/capita, US$ exchange rate",0.9
+27741,Norway,2014,3,A02A-Antacids,"/capita, US$ purchasing power parity",0.6
+27742,Norway,2014,3,A02A-Antacids,% of total sales,0.1
+27743,Norway,2014,3,R-Respiratory system,"/capita, US$ purchasing power parity",42.0
+27744,Norway,2014,3,A02A-Antacids,"Million US$, purchasing power parity",3.0
+27745,Norway,2014,3,R-Respiratory system,% of total sales,9.5
+27746,Norway,2014,3,N-Nervous system,"/capita, US$ purchasing power parity",78.7
+27747,Norway,2014,3,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ exchange rate",13.7
+27748,Norway,2014,3,N-Nervous system,"/capita, US$ exchange rate",115.9
+27749,Norway,2014,3,C09-Agents acting on the Renin-Angiotensin system,% of total sales,2.1
+27750,Norway,2014,3,C02-Antihypertensives,"Million US$, purchasing power parity",8.0
+27751,Norway,2014,3,C02-Antihypertensives,"/capita, US$ exchange rate",2.3
+27752,Norway,2014,3,N-Nervous system,"Million US$, purchasing power parity",404.5
+27753,Norway,2014,3,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ purchasing power parity",9.3
+27754,Norway,2014,3,C02-Antihypertensives,Million US$ at exchange rate,11.7
+27755,Portugal,2011,9,C01A-Cardiac glycosides,"Million US$, purchasing power parity",1.4
+27756,Portugal,2011,9,C01A-Cardiac glycosides,Million US$ at exchange rate,1.3
+27757,Portugal,2011,9,C01A-Cardiac glycosides,Million of national currency units,0.9
+27758,Portugal,2011,9,C02-Antihypertensives,"Million US$, purchasing power parity",6.6
+27759,Portugal,2011,9,R-Respiratory system,% of total sales,7.3
+27760,Portugal,2011,9,C02-Antihypertensives,% of total sales,0.1
+27761,Portugal,2011,9,C02-Antihypertensives,"/capita, US$ purchasing power parity",0.6
+27762,Portugal,2011,9,C02-Antihypertensives,"/capita, US$ exchange rate",0.5
+27763,Portugal,2011,9,G-Genito urinary system and sex hormones,"/capita, US$ purchasing power parity",26.2
+27764,Portugal,2011,9,G-Genito urinary system and sex hormones,% of total sales,5.9
+27765,Portugal,2011,9,A02A-Antacids,"/capita, US$ purchasing power parity",0.9
+27766,Portugal,2011,9,G-Genito urinary system and sex hormones,"/capita, US$ exchange rate",22.7
+27767,Portugal,2011,9,G-Genito urinary system and sex hormones,"Million US$, purchasing power parity",276.6
+27768,Portugal,2011,9,C01A-Cardiac glycosides,% of total sales,0.0
+27769,Portugal,2011,9,R-Respiratory system,"/capita, US$ purchasing power parity",32.4
+27770,Portugal,2011,9,A02A-Antacids,% of total sales,0.2
+27771,Portugal,2011,9,C01A-Cardiac glycosides,"/capita, US$ purchasing power parity",0.1
+27772,Portugal,2011,9,C01A-Cardiac glycosides,"/capita, US$ exchange rate",0.1
+27773,Portugal,2011,9,B-Blood and blood forming organs,"Million US$, purchasing power parity",169.6
+27774,Portugal,2011,9,B-Blood and blood forming organs,"/capita, US$ purchasing power parity",16.1
+27775,Portugal,2011,9,B-Blood and blood forming organs,% of total sales,3.6
+27776,Portugal,2011,9,B-Blood and blood forming organs,"/capita, US$ exchange rate",13.9
+27777,Portugal,2011,9,C07-Beta blocking agents,"/capita, US$ exchange rate",4.1
+27778,Portugal,2011,9,Products not elsewhere classified,"/capita, US$ exchange rate",0.0
+27779,Portugal,2011,9,C07-Beta blocking agents,% of total sales,1.1
+27780,Portugal,2011,9,C07-Beta blocking agents,"/capita, US$ purchasing power parity",4.8
+27781,Portugal,2011,9,Products not elsewhere classified,"Million US$, purchasing power parity",0.0
+27782,Portugal,2011,9,C02-Antihypertensives,Million of national currency units,4.1
+27783,Portugal,2011,9,C07-Beta blocking agents,"Million US$, purchasing power parity",50.3
+27784,Portugal,2011,9,Products not elsewhere classified,% of total sales,0.0
+27785,Portugal,2011,9,Products not elsewhere classified,"/capita, US$ purchasing power parity",0.0
+27786,Portugal,2011,9,A-Alimentary tract and metabolism,Million of national currency units,455.8
+27787,Portugal,2011,9,A-Alimentary tract and metabolism,Million US$ at exchange rate,634.4
+27788,Portugal,2011,9,A-Alimentary tract and metabolism,"Million US$, purchasing power parity",731.5
+27789,Portugal,2011,9,R-Respiratory system,Million US$ at exchange rate,297.0
+27790,Portugal,2011,9,B-Blood and blood forming organs,Million of national currency units,105.7
+27791,Portugal,2011,9,C07-Beta blocking agents,Million of national currency units,31.4
+27792,Portugal,2011,9,R-Respiratory system,Million of national currency units,213.4
+27793,Portugal,2011,9,B-Blood and blood forming organs,Million US$ at exchange rate,147.1
+27794,Portugal,2011,9,R-Respiratory system,"/capita, US$ exchange rate",28.1
+27795,Portugal,2011,9,R-Respiratory system,"Million US$, purchasing power parity",342.5
+27796,Portugal,2011,9,Products not elsewhere classified,Million of national currency units,0.0
+27797,Portugal,2011,9,A-Alimentary tract and metabolism,"/capita, US$ exchange rate",60.1
+27798,Portugal,2011,9,C02-Antihypertensives,Million US$ at exchange rate,5.8
+27799,Portugal,2011,9,Products not elsewhere classified,Million US$ at exchange rate,0.0
+27800,Portugal,2011,9,C07-Beta blocking agents,Million US$ at exchange rate,43.6
+27801,Portugal,2011,9,A-Alimentary tract and metabolism,"/capita, US$ purchasing power parity",69.3
+27802,Portugal,2011,9,A-Alimentary tract and metabolism,% of total sales,15.5
+27803,Portugal,2011,9,C-Cardiovascular system,"Million US$, purchasing power parity",1254.5
+27804,Portugal,2011,9,Total pharmaceutical sales,"/capita, US$ exchange rate",388.0
+27805,Portugal,2011,9,Total pharmaceutical sales,"/capita, US$ purchasing power parity",447.3
+27806,Portugal,2011,9,C-Cardiovascular system,% of total sales,26.6
+27807,Portugal,2011,9,C-Cardiovascular system,"/capita, US$ exchange rate",103.1
+27808,Portugal,2011,9,C-Cardiovascular system,"/capita, US$ purchasing power parity",118.8
+27809,Portugal,2011,9,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ purchasing power parity",56.9
+27810,Portugal,2011,9,C-Cardiovascular system,Million of national currency units,781.6
+27811,Portugal,2011,9,C09-Agents acting on the Renin-Angiotensin system,% of total sales,12.7
+27812,Portugal,2011,9,Total pharmaceutical sales,Million US$ at exchange rate,4096.0
+27813,Portugal,2011,9,Total pharmaceutical sales,"Million US$, purchasing power parity",4722.6
+27814,Portugal,2011,9,C-Cardiovascular system,Million US$ at exchange rate,1088.0
+27815,Portugal,2011,9,Total pharmaceutical sales,Million of national currency units,2942.6
+27816,Portugal,2011,9,"C01B-Antiarrhythmics, Class I and III","/capita, US$ exchange rate",0.6
+27817,Portugal,2011,9,"C01B-Antiarrhythmics, Class I and III","Million US$, purchasing power parity",6.9
+27818,Portugal,2011,9,"C01B-Antiarrhythmics, Class I and III",Million US$ at exchange rate,5.9
+27819,Portugal,2011,9,"C01B-Antiarrhythmics, Class I and III",% of total sales,0.1
+27820,Portugal,2011,9,C09-Agents acting on the Renin-Angiotensin system,Million US$ at exchange rate,521.2
+27821,Portugal,2011,9,C09-Agents acting on the Renin-Angiotensin system,Million of national currency units,374.4
+27822,Portugal,2011,9,"C01B-Antiarrhythmics, Class I and III","/capita, US$ purchasing power parity",0.6
+27823,Portugal,2011,9,C03-Diuretics,"/capita, US$ exchange rate",3.3
+27824,Portugal,2011,9,C03-Diuretics,"Million US$, purchasing power parity",39.9
+27825,Portugal,2011,9,C03-Diuretics,% of total sales,0.8
+27826,Portugal,2011,9,C03-Diuretics,"/capita, US$ purchasing power parity",3.8
+27827,Portugal,2011,9,"C01B-Antiarrhythmics, Class I and III",Million of national currency units,4.3
+27828,Portugal,2011,9,C09-Agents acting on the Renin-Angiotensin system,"Million US$, purchasing power parity",600.9
+27829,Portugal,2011,9,C03-Diuretics,Million US$ at exchange rate,34.6
+27830,Portugal,2011,9,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ exchange rate",49.4
+27831,Portugal,2011,9,C03-Diuretics,Million of national currency units,24.9
+27832,Portugal,2011,9,A02A-Antacids,Million of national currency units,6.0
+27833,Portugal,2011,9,C10-Lipid modifying agents,Million of national currency units,202.3
+27834,Portugal,2011,9,N06A-Antidepressants,Million of national currency units,140.4
+27835,Portugal,2011,9,A02A-Antacids,"Million US$, purchasing power parity",9.7
+27836,Portugal,2011,9,A02A-Antacids,Million US$ at exchange rate,8.4
+27837,Portugal,2011,9,N06A-Antidepressants,"/capita, US$ exchange rate",18.5
+27838,Portugal,2011,9,N06A-Antidepressants,"/capita, US$ purchasing power parity",21.3
+27839,Portugal,2011,9,N06A-Antidepressants,Million US$ at exchange rate,195.4
+27840,Portugal,2011,9,N06A-Antidepressants,"Million US$, purchasing power parity",225.3
+27841,Portugal,2011,9,C08-Calcium channel blockers,Million US$ at exchange rate,61.8
+27842,Portugal,2011,9,C08-Calcium channel blockers,"Million US$, purchasing power parity",71.2
+27843,Portugal,2011,9,A02A-Antacids,"/capita, US$ exchange rate",0.8
+27844,Portugal,2011,9,C08-Calcium channel blockers,Million of national currency units,44.4
+27845,Portugal,2011,9,C08-Calcium channel blockers,% of total sales,1.5
+27846,Portugal,2011,9,C08-Calcium channel blockers,"/capita, US$ purchasing power parity",6.7
+27847,Portugal,2011,9,C08-Calcium channel blockers,"/capita, US$ exchange rate",5.9
+27848,Portugal,2011,9,G-Genito urinary system and sex hormones,Million of national currency units,172.4
+27849,Portugal,2011,9,R03-Drugs for obstructive airway diseases,Million US$ at exchange rate,183.9
+27850,Portugal,2011,9,G-Genito urinary system and sex hormones,Million US$ at exchange rate,239.9
+27851,Portugal,2011,9,R03-Drugs for obstructive airway diseases,"Million US$, purchasing power parity",212.0
+27852,Portugal,2011,9,C10-Lipid modifying agents,"/capita, US$ purchasing power parity",30.8
+27853,Portugal,2011,9,C10-Lipid modifying agents,% of total sales,6.9
+27854,Portugal,2011,9,R03-Drugs for obstructive airway diseases,Million of national currency units,132.1
+27855,Portugal,2011,9,C10-Lipid modifying agents,"/capita, US$ exchange rate",26.7
+27856,Portugal,2011,9,C10-Lipid modifying agents,Million US$ at exchange rate,281.6
+27857,Portugal,2011,9,C10-Lipid modifying agents,"Million US$, purchasing power parity",324.7
+27858,Portugal,2011,9,N06A-Antidepressants,% of total sales,4.8
+27859,Portugal,2011,9,R03-Drugs for obstructive airway diseases,"/capita, US$ exchange rate",17.4
+27860,Portugal,2011,9,R03-Drugs for obstructive airway diseases,% of total sales,4.5
+27861,Portugal,2011,9,R03-Drugs for obstructive airway diseases,"/capita, US$ purchasing power parity",20.1
+27862,Portugal,2011,9,N02-Analgesics,% of total sales,3.7
+27863,Portugal,2011,9,J01-Antibacterials for systemic use,Million of national currency units,91.4
+27864,Portugal,2011,9,N-Nervous system,"/capita, US$ exchange rate",85.1
+27865,Portugal,2011,9,N02-Analgesics,"/capita, US$ exchange rate",14.3
+27866,Portugal,2011,9,N02-Analgesics,"/capita, US$ purchasing power parity",16.4
+27867,Portugal,2011,9,J01-Antibacterials for systemic use,Million US$ at exchange rate,127.2
+27868,Portugal,2011,9,N05B-Anxiolytics,Million US$ at exchange rate,80.1
+27869,Portugal,2011,9,N05B-Anxiolytics,"Million US$, purchasing power parity",92.4
+27870,Portugal,2011,9,M01A-Antiinflammatory and antirheumatic products non-steroids,Million of national currency units,112.3
+27871,Portugal,2011,9,N05B-Anxiolytics,Million of national currency units,57.6
+27872,Portugal,2011,9,"H-Systemic hormonal preparations, excluding sex hormones and insulins",% of total sales,0.8
+27873,Portugal,2011,9,N-Nervous system,"Million US$, purchasing power parity",1035.5
+27874,Portugal,2011,9,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),% of total sales,4.2
+27875,Portugal,2011,9,M01A-Antiinflammatory and antirheumatic products non-steroids,% of total sales,3.8
+27876,Portugal,2011,9,A10-Drugs used in diabetes,"/capita, US$ exchange rate",29.3
+27877,Portugal,2011,9,A10-Drugs used in diabetes,"/capita, US$ purchasing power parity",33.8
+27878,Portugal,2011,9,A10-Drugs used in diabetes,% of total sales,7.6
+27879,Portugal,2011,9,J-Antiinfectives for systemic use,Million of national currency units,163.6
+27880,Portugal,2011,9,N-Nervous system,Million of national currency units,645.2
+27881,Portugal,2011,9,N-Nervous system,Million US$ at exchange rate,898.1
+27882,Portugal,2011,9,N02-Analgesics,Million of national currency units,108.1
+27883,Portugal,2011,9,N02-Analgesics,Million US$ at exchange rate,150.5
+27884,Portugal,2011,9,N02-Analgesics,"Million US$, purchasing power parity",173.5
+27885,Portugal,2011,9,M01A-Antiinflammatory and antirheumatic products non-steroids,Million US$ at exchange rate,156.3
+27886,Portugal,2011,9,N-Nervous system,"/capita, US$ purchasing power parity",98.1
+27887,Portugal,2011,9,N-Nervous system,% of total sales,21.9
+27888,Portugal,2011,9,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ exchange rate",16.4
+27889,Portugal,2011,9,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"Million US$, purchasing power parity",199.9
+27890,Portugal,2011,9,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ purchasing power parity",17.1
+27891,Portugal,2011,9,M01A-Antiinflammatory and antirheumatic products non-steroids,"Million US$, purchasing power parity",180.2
+27892,Portugal,2011,9,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ exchange rate",14.8
+27893,Portugal,2011,9,J01-Antibacterials for systemic use,% of total sales,3.1
+27894,Portugal,2011,9,N05B-Anxiolytics,% of total sales,2.0
+27895,Portugal,2011,9,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ purchasing power parity",18.9
+27896,Portugal,2011,9,N05B-Anxiolytics,"/capita, US$ exchange rate",7.6
+27897,Portugal,2011,9,N05B-Anxiolytics,"/capita, US$ purchasing power parity",8.8
+27898,Portugal,2011,9,G03-Sex hormones and modulators of the genital system,% of total sales,2.7
+27899,Portugal,2011,9,J01-Antibacterials for systemic use,"/capita, US$ purchasing power parity",13.9
+27900,Portugal,2011,9,J01-Antibacterials for systemic use,"Million US$, purchasing power parity",146.6
+27901,Portugal,2011,9,J01-Antibacterials for systemic use,"/capita, US$ exchange rate",12.0
+27902,Portugal,2011,9,M-Musculo-skeletal system,Million of national currency units,226.7
+27903,Portugal,2011,9,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ exchange rate",3.0
+27904,Portugal,2011,9,M-Musculo-skeletal system,Million US$ at exchange rate,315.5
+27905,Portugal,2011,9,N05C-Hypnotics and sedatives,% of total sales,0.6
+27906,Portugal,2011,9,J-Antiinfectives for systemic use,"Million US$, purchasing power parity",262.5
+27907,Portugal,2011,9,J-Antiinfectives for systemic use,Million US$ at exchange rate,227.7
+27908,Portugal,2011,9,N05C-Hypnotics and sedatives,"Million US$, purchasing power parity",28.5
+27909,Portugal,2011,9,N05C-Hypnotics and sedatives,Million US$ at exchange rate,24.7
+27910,Portugal,2011,9,N05C-Hypnotics and sedatives,"/capita, US$ purchasing power parity",2.7
+27911,Portugal,2011,9,N05C-Hypnotics and sedatives,"/capita, US$ exchange rate",2.3
+27912,Portugal,2011,9,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ purchasing power parity",3.5
+27913,Portugal,2011,9,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million US$ at exchange rate,173.4
+27914,Portugal,2011,9,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million of national currency units,124.6
+27915,Portugal,2011,9,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million of national currency units,22.7
+27916,Portugal,2011,9,J-Antiinfectives for systemic use,"/capita, US$ exchange rate",21.6
+27917,Portugal,2011,9,"H-Systemic hormonal preparations, excluding sex hormones and insulins","Million US$, purchasing power parity",36.5
+27918,Portugal,2011,9,A10-Drugs used in diabetes,"Million US$, purchasing power parity",356.8
+27919,Portugal,2011,9,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million US$ at exchange rate,31.7
+27920,Portugal,2011,9,M-Musculo-skeletal system,"Million US$, purchasing power parity",363.8
+27921,Portugal,2011,9,M-Musculo-skeletal system,"/capita, US$ purchasing power parity",34.5
+27922,Portugal,2011,9,J-Antiinfectives for systemic use,"/capita, US$ purchasing power parity",24.9
+27923,Portugal,2011,9,A10-Drugs used in diabetes,Million US$ at exchange rate,309.5
+27924,Portugal,2011,9,A10-Drugs used in diabetes,Million of national currency units,222.3
+27925,Portugal,2011,9,M-Musculo-skeletal system,% of total sales,7.7
+27926,Portugal,2011,9,J-Antiinfectives for systemic use,% of total sales,5.6
+27927,Portugal,2011,9,G03-Sex hormones and modulators of the genital system,"/capita, US$ purchasing power parity",11.9
+27928,Portugal,2011,9,M-Musculo-skeletal system,"/capita, US$ exchange rate",29.9
+27929,Portugal,2011,9,G03-Sex hormones and modulators of the genital system,Million US$ at exchange rate,108.9
+27930,Portugal,2011,9,N05C-Hypnotics and sedatives,Million of national currency units,17.8
+27931,Portugal,2011,9,G03-Sex hormones and modulators of the genital system,Million of national currency units,78.3
+27932,Portugal,2011,9,G03-Sex hormones and modulators of the genital system,"/capita, US$ exchange rate",10.3
+27933,Portugal,2011,9,G03-Sex hormones and modulators of the genital system,"Million US$, purchasing power parity",125.6
+27934,Portugal,2012,9,C01A-Cardiac glycosides,"Million US$, purchasing power parity",1.5
+27935,Portugal,2012,9,C01A-Cardiac glycosides,Million of national currency units,0.9
+27936,Portugal,2012,9,C01A-Cardiac glycosides,Million US$ at exchange rate,1.1
+27937,Portugal,2012,9,C02-Antihypertensives,"Million US$, purchasing power parity",6.4
+27938,Portugal,2012,9,R-Respiratory system,"/capita, US$ purchasing power parity",33.7
+27939,Portugal,2012,9,R-Respiratory system,% of total sales,8.2
+27940,Portugal,2012,9,C02-Antihypertensives,% of total sales,0.1
+27941,Portugal,2012,9,C02-Antihypertensives,"/capita, US$ purchasing power parity",0.6
+27942,Portugal,2012,9,C02-Antihypertensives,"/capita, US$ exchange rate",0.5
+27943,Portugal,2012,9,G-Genito urinary system and sex hormones,"/capita, US$ purchasing power parity",25.0
+27944,Portugal,2012,9,G-Genito urinary system and sex hormones,% of total sales,6.1
+27945,Portugal,2012,9,G-Genito urinary system and sex hormones,"/capita, US$ exchange rate",19.4
+27946,Portugal,2012,9,A02A-Antacids,"/capita, US$ purchasing power parity",1.0
+27947,Portugal,2012,9,C01A-Cardiac glycosides,% of total sales,0.0
+27948,Portugal,2012,9,G-Genito urinary system and sex hormones,"Million US$, purchasing power parity",262.9
+27949,Portugal,2012,9,A02A-Antacids,% of total sales,0.2
+27950,Portugal,2012,9,C01A-Cardiac glycosides,"/capita, US$ exchange rate",0.1
+27951,Portugal,2012,9,C01A-Cardiac glycosides,"/capita, US$ purchasing power parity",0.1
+27952,Portugal,2012,9,B-Blood and blood forming organs,"Million US$, purchasing power parity",144.4
+27953,Portugal,2012,9,B-Blood and blood forming organs,"/capita, US$ purchasing power parity",13.7
+27954,Portugal,2012,9,B-Blood and blood forming organs,% of total sales,3.3
+27955,Portugal,2012,9,B-Blood and blood forming organs,"/capita, US$ exchange rate",10.7
+27956,Portugal,2012,9,C07-Beta blocking agents,"/capita, US$ exchange rate",3.6
+27957,Portugal,2012,9,Products not elsewhere classified,"/capita, US$ exchange rate",0.0
+27958,Portugal,2012,9,C07-Beta blocking agents,% of total sales,1.1
+27959,Portugal,2012,9,C07-Beta blocking agents,"/capita, US$ purchasing power parity",4.6
+27960,Portugal,2012,9,Products not elsewhere classified,"Million US$, purchasing power parity",0.0
+27961,Portugal,2012,9,C02-Antihypertensives,Million of national currency units,3.9
+27962,Portugal,2012,9,C07-Beta blocking agents,"Million US$, purchasing power parity",48.6
+27963,Portugal,2012,9,Products not elsewhere classified,% of total sales,0.0
+27964,Portugal,2012,9,Products not elsewhere classified,"/capita, US$ purchasing power parity",0.0
+27965,Portugal,2012,9,A-Alimentary tract and metabolism,Million of national currency units,400.8
+27966,Portugal,2012,9,A-Alimentary tract and metabolism,"Million US$, purchasing power parity",662.1
+27967,Portugal,2012,9,A-Alimentary tract and metabolism,Million US$ at exchange rate,515.0
+27968,Portugal,2012,9,R-Respiratory system,Million US$ at exchange rate,275.9
+27969,Portugal,2012,9,B-Blood and blood forming organs,Million of national currency units,87.4
+27970,Portugal,2012,9,C07-Beta blocking agents,Million of national currency units,29.4
+27971,Portugal,2012,9,R-Respiratory system,Million of national currency units,214.8
+27972,Portugal,2012,9,B-Blood and blood forming organs,Million US$ at exchange rate,112.3
+27973,Portugal,2012,9,R-Respiratory system,"/capita, US$ exchange rate",26.2
+27974,Portugal,2012,9,R-Respiratory system,"Million US$, purchasing power parity",354.8
+27975,Portugal,2012,9,Products not elsewhere classified,Million of national currency units,0.0
+27976,Portugal,2012,9,A-Alimentary tract and metabolism,"/capita, US$ exchange rate",49.0
+27977,Portugal,2012,9,C02-Antihypertensives,Million US$ at exchange rate,5.0
+27978,Portugal,2012,9,Products not elsewhere classified,Million US$ at exchange rate,0.0
+27979,Portugal,2012,9,C07-Beta blocking agents,Million US$ at exchange rate,37.8
+27980,Portugal,2012,9,A-Alimentary tract and metabolism,% of total sales,15.3
+27981,Portugal,2012,9,A-Alimentary tract and metabolism,"/capita, US$ purchasing power parity",63.0
+27982,Portugal,2012,9,C-Cardiovascular system,"Million US$, purchasing power parity",1104.8
+27983,Portugal,2012,9,Total pharmaceutical sales,"/capita, US$ purchasing power parity",410.6
+27984,Portugal,2012,9,Total pharmaceutical sales,"/capita, US$ exchange rate",319.4
+27985,Portugal,2012,9,C-Cardiovascular system,% of total sales,25.6
+27986,Portugal,2012,9,C-Cardiovascular system,"/capita, US$ exchange rate",81.7
+27987,Portugal,2012,9,C-Cardiovascular system,"/capita, US$ purchasing power parity",105.1
+27988,Portugal,2012,9,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ purchasing power parity",50.3
+27989,Portugal,2012,9,C-Cardiovascular system,Million of national currency units,668.8
+27990,Portugal,2012,9,C09-Agents acting on the Renin-Angiotensin system,% of total sales,12.3
+27991,Portugal,2012,9,Total pharmaceutical sales,Million US$ at exchange rate,3358.4
+27992,Portugal,2012,9,Total pharmaceutical sales,"Million US$, purchasing power parity",4317.7
+27993,Portugal,2012,9,C-Cardiovascular system,Million US$ at exchange rate,859.3
+27994,Portugal,2012,9,Total pharmaceutical sales,Million of national currency units,2614.0
+27995,Portugal,2012,9,"C01B-Antiarrhythmics, Class I and III","/capita, US$ exchange rate",0.5
+27996,Portugal,2012,9,"C01B-Antiarrhythmics, Class I and III",Million US$ at exchange rate,5.3
+27997,Portugal,2012,9,"C01B-Antiarrhythmics, Class I and III","Million US$, purchasing power parity",6.9
+27998,Portugal,2012,9,"C01B-Antiarrhythmics, Class I and III",% of total sales,0.2
+27999,Portugal,2012,9,"C01B-Antiarrhythmics, Class I and III","/capita, US$ purchasing power parity",0.7
+28000,Portugal,2012,9,C09-Agents acting on the Renin-Angiotensin system,Million US$ at exchange rate,411.4
+28001,Portugal,2012,9,C09-Agents acting on the Renin-Angiotensin system,Million of national currency units,320.2
+28002,Portugal,2012,9,C03-Diuretics,"/capita, US$ exchange rate",2.9
+28003,Portugal,2012,9,C03-Diuretics,"Million US$, purchasing power parity",39.3
+28004,Portugal,2012,9,C03-Diuretics,% of total sales,0.9
+28005,Portugal,2012,9,C03-Diuretics,"/capita, US$ purchasing power parity",3.7
+28006,Portugal,2012,9,C09-Agents acting on the Renin-Angiotensin system,"Million US$, purchasing power parity",529.0
+28007,Portugal,2012,9,"C01B-Antiarrhythmics, Class I and III",Million of national currency units,4.2
+28008,Portugal,2012,9,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ exchange rate",39.1
+28009,Portugal,2012,9,C03-Diuretics,Million US$ at exchange rate,30.6
+28010,Portugal,2012,9,C03-Diuretics,Million of national currency units,23.8
+28011,Portugal,2012,9,A02A-Antacids,Million of national currency units,6.1
+28012,Portugal,2012,9,C10-Lipid modifying agents,Million of national currency units,163.9
+28013,Portugal,2012,9,N06A-Antidepressants,Million of national currency units,116.6
+28014,Portugal,2012,9,A02A-Antacids,"Million US$, purchasing power parity",10.0
+28015,Portugal,2012,9,A02A-Antacids,Million US$ at exchange rate,7.8
+28016,Portugal,2012,9,N06A-Antidepressants,"/capita, US$ exchange rate",14.3
+28017,Portugal,2012,9,N06A-Antidepressants,"/capita, US$ purchasing power parity",18.3
+28018,Portugal,2012,9,N06A-Antidepressants,Million US$ at exchange rate,149.9
+28019,Portugal,2012,9,N06A-Antidepressants,"Million US$, purchasing power parity",192.7
+28020,Portugal,2012,9,C08-Calcium channel blockers,Million US$ at exchange rate,45.1
+28021,Portugal,2012,9,A02A-Antacids,"/capita, US$ exchange rate",0.7
+28022,Portugal,2012,9,C08-Calcium channel blockers,Million of national currency units,35.1
+28023,Portugal,2012,9,C08-Calcium channel blockers,"Million US$, purchasing power parity",58.0
+28024,Portugal,2012,9,C08-Calcium channel blockers,"/capita, US$ purchasing power parity",5.5
+28025,Portugal,2012,9,C08-Calcium channel blockers,% of total sales,1.3
+28026,Portugal,2012,9,C08-Calcium channel blockers,"/capita, US$ exchange rate",4.3
+28027,Portugal,2012,9,R03-Drugs for obstructive airway diseases,Million US$ at exchange rate,167.9
+28028,Portugal,2012,9,G-Genito urinary system and sex hormones,Million of national currency units,159.2
+28029,Portugal,2012,9,C10-Lipid modifying agents,"Million US$, purchasing power parity",270.7
+28030,Portugal,2012,9,G-Genito urinary system and sex hormones,Million US$ at exchange rate,204.5
+28031,Portugal,2012,9,C10-Lipid modifying agents,"/capita, US$ purchasing power parity",25.7
+28032,Portugal,2012,9,C10-Lipid modifying agents,% of total sales,6.3
+28033,Portugal,2012,9,R03-Drugs for obstructive airway diseases,Million of national currency units,130.7
+28034,Portugal,2012,9,C10-Lipid modifying agents,"/capita, US$ exchange rate",20.0
+28035,Portugal,2012,9,R03-Drugs for obstructive airway diseases,"Million US$, purchasing power parity",215.9
+28036,Portugal,2012,9,C10-Lipid modifying agents,Million US$ at exchange rate,210.6
+28037,Portugal,2012,9,N06A-Antidepressants,% of total sales,4.5
+28038,Portugal,2012,9,R03-Drugs for obstructive airway diseases,"/capita, US$ exchange rate",16.0
+28039,Portugal,2012,9,R03-Drugs for obstructive airway diseases,"/capita, US$ purchasing power parity",20.5
+28040,Portugal,2012,9,R03-Drugs for obstructive airway diseases,% of total sales,5.0
+28041,Portugal,2012,9,N02-Analgesics,% of total sales,4.3
+28042,Portugal,2012,9,J01-Antibacterials for systemic use,Million of national currency units,75.9
+28043,Portugal,2012,9,N02-Analgesics,"/capita, US$ exchange rate",13.7
+28044,Portugal,2012,9,N02-Analgesics,"/capita, US$ purchasing power parity",17.6
+28045,Portugal,2012,9,N05B-Anxiolytics,Million US$ at exchange rate,72.1
+28046,Portugal,2012,9,M01A-Antiinflammatory and antirheumatic products non-steroids,Million of national currency units,105.0
+28047,Portugal,2012,9,J01-Antibacterials for systemic use,Million US$ at exchange rate,97.5
+28048,Portugal,2012,9,"H-Systemic hormonal preparations, excluding sex hormones and insulins",% of total sales,0.8
+28049,Portugal,2012,9,N05B-Anxiolytics,Million of national currency units,56.1
+28050,Portugal,2012,9,N-Nervous system,"Million US$, purchasing power parity",944.4
+28051,Portugal,2012,9,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),% of total sales,2.6
+28052,Portugal,2012,9,A10-Drugs used in diabetes,"/capita, US$ exchange rate",27.4
+28053,Portugal,2012,9,J-Antiinfectives for systemic use,Million of national currency units,130.0
+28054,Portugal,2012,9,A10-Drugs used in diabetes,"/capita, US$ purchasing power parity",35.2
+28055,Portugal,2012,9,A10-Drugs used in diabetes,% of total sales,8.6
+28056,Portugal,2012,9,N-Nervous system,Million of national currency units,571.7
+28057,Portugal,2012,9,N-Nervous system,Million US$ at exchange rate,734.5
+28058,Portugal,2012,9,N02-Analgesics,Million of national currency units,111.8
+28059,Portugal,2012,9,N02-Analgesics,Million US$ at exchange rate,143.7
+28060,Portugal,2012,9,N02-Analgesics,"Million US$, purchasing power parity",184.7
+28061,Portugal,2012,9,N-Nervous system,"/capita, US$ exchange rate",69.9
+28062,Portugal,2012,9,N-Nervous system,"/capita, US$ purchasing power parity",89.8
+28063,Portugal,2012,9,N-Nervous system,% of total sales,21.9
+28064,Portugal,2012,9,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ exchange rate",8.2
+28065,Portugal,2012,9,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"Million US$, purchasing power parity",110.5
+28066,Portugal,2012,9,J01-Antibacterials for systemic use,% of total sales,2.9
+28067,Portugal,2012,9,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ purchasing power parity",16.5
+28068,Portugal,2012,9,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ exchange rate",12.8
+28069,Portugal,2012,9,M01A-Antiinflammatory and antirheumatic products non-steroids,"Million US$, purchasing power parity",173.5
+28070,Portugal,2012,9,N05B-Anxiolytics,% of total sales,2.1
+28071,Portugal,2012,9,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ purchasing power parity",10.5
+28072,Portugal,2012,9,M01A-Antiinflammatory and antirheumatic products non-steroids,Million US$ at exchange rate,135.0
+28073,Portugal,2012,9,N05B-Anxiolytics,"Million US$, purchasing power parity",92.7
+28074,Portugal,2012,9,N05B-Anxiolytics,"/capita, US$ purchasing power parity",8.8
+28075,Portugal,2012,9,N05B-Anxiolytics,"/capita, US$ exchange rate",6.9
+28076,Portugal,2012,9,J01-Antibacterials for systemic use,"/capita, US$ purchasing power parity",11.9
+28077,Portugal,2012,9,G03-Sex hormones and modulators of the genital system,% of total sales,2.9
+28078,Portugal,2012,9,J01-Antibacterials for systemic use,"Million US$, purchasing power parity",125.3
+28079,Portugal,2012,9,J01-Antibacterials for systemic use,"/capita, US$ exchange rate",9.3
+28080,Portugal,2012,9,M01A-Antiinflammatory and antirheumatic products non-steroids,% of total sales,4.0
+28081,Portugal,2012,9,M-Musculo-skeletal system,Million US$ at exchange rate,262.5
+28082,Portugal,2012,9,N05C-Hypnotics and sedatives,% of total sales,0.7
+28083,Portugal,2012,9,M-Musculo-skeletal system,Million of national currency units,204.3
+28084,Portugal,2012,9,J-Antiinfectives for systemic use,Million US$ at exchange rate,167.0
+28085,Portugal,2012,9,N05C-Hypnotics and sedatives,"Million US$, purchasing power parity",30.9
+28086,Portugal,2012,9,N05C-Hypnotics and sedatives,Million US$ at exchange rate,24.0
+28087,Portugal,2012,9,N05C-Hypnotics and sedatives,"/capita, US$ purchasing power parity",2.9
+28088,Portugal,2012,9,N05C-Hypnotics and sedatives,"/capita, US$ exchange rate",2.3
+28089,Portugal,2012,9,J-Antiinfectives for systemic use,"Million US$, purchasing power parity",214.7
+28090,Portugal,2012,9,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ exchange rate",2.5
+28091,Portugal,2012,9,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million US$ at exchange rate,86.0
+28092,Portugal,2012,9,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million of national currency units,66.9
+28093,Portugal,2012,9,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ purchasing power parity",3.2
+28094,Portugal,2012,9,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million of national currency units,20.6
+28095,Portugal,2012,9,J-Antiinfectives for systemic use,"/capita, US$ exchange rate",15.9
+28096,Portugal,2012,9,"H-Systemic hormonal preparations, excluding sex hormones and insulins","Million US$, purchasing power parity",34.1
+28097,Portugal,2012,9,A10-Drugs used in diabetes,"Million US$, purchasing power parity",370.4
+28098,Portugal,2012,9,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million US$ at exchange rate,26.5
+28099,Portugal,2012,9,M-Musculo-skeletal system,"/capita, US$ purchasing power parity",32.1
+28100,Portugal,2012,9,A10-Drugs used in diabetes,Million US$ at exchange rate,288.1
+28101,Portugal,2012,9,J-Antiinfectives for systemic use,"/capita, US$ purchasing power parity",20.4
+28102,Portugal,2012,9,A10-Drugs used in diabetes,Million of national currency units,224.2
+28103,Portugal,2012,9,M-Musculo-skeletal system,% of total sales,7.8
+28104,Portugal,2012,9,M-Musculo-skeletal system,"/capita, US$ exchange rate",25.0
+28105,Portugal,2012,9,J-Antiinfectives for systemic use,% of total sales,5.0
+28106,Portugal,2012,9,G03-Sex hormones and modulators of the genital system,"/capita, US$ purchasing power parity",11.7
+28107,Portugal,2012,9,G03-Sex hormones and modulators of the genital system,Million US$ at exchange rate,95.9
+28108,Portugal,2012,9,M-Musculo-skeletal system,"Million US$, purchasing power parity",337.5
+28109,Portugal,2012,9,G03-Sex hormones and modulators of the genital system,Million of national currency units,74.7
+28110,Portugal,2012,9,N05C-Hypnotics and sedatives,Million of national currency units,18.7
+28111,Portugal,2012,9,G03-Sex hormones and modulators of the genital system,"/capita, US$ exchange rate",9.1
+28112,Portugal,2012,9,G03-Sex hormones and modulators of the genital system,"Million US$, purchasing power parity",123.3
+28113,Portugal,2013,8,C01A-Cardiac glycosides,"Million US$, purchasing power parity",1.4
+28114,Portugal,2013,8,C01A-Cardiac glycosides,Million of national currency units,0.8
+28115,Portugal,2013,8,C01A-Cardiac glycosides,Million US$ at exchange rate,1.1
+28116,Portugal,2013,8,C02-Antihypertensives,Million US$ at exchange rate,4.8
+28117,Portugal,2013,8,C02-Antihypertensives,"Million US$, purchasing power parity",6.1
+28118,Portugal,2013,8,R-Respiratory system,"/capita, US$ purchasing power parity",33.1
+28119,Portugal,2013,8,R-Respiratory system,% of total sales,8.4
+28120,Portugal,2013,8,C02-Antihypertensives,"/capita, US$ purchasing power parity",0.6
+28121,Portugal,2013,8,C02-Antihypertensives,% of total sales,0.1
+28122,Portugal,2013,8,C02-Antihypertensives,"/capita, US$ exchange rate",0.5
+28123,Portugal,2013,8,G-Genito urinary system and sex hormones,"/capita, US$ purchasing power parity",24.5
+28124,Portugal,2013,8,G-Genito urinary system and sex hormones,"/capita, US$ exchange rate",19.0
+28125,Portugal,2013,8,G-Genito urinary system and sex hormones,% of total sales,6.2
+28126,Portugal,2013,8,A02A-Antacids,"/capita, US$ purchasing power parity",0.8
+28127,Portugal,2013,8,C01A-Cardiac glycosides,% of total sales,0.0
+28128,Portugal,2013,8,G-Genito urinary system and sex hormones,"Million US$, purchasing power parity",255.8
+28129,Portugal,2013,8,A02A-Antacids,% of total sales,0.2
+28130,Portugal,2013,8,C01A-Cardiac glycosides,"/capita, US$ purchasing power parity",0.1
+28131,Portugal,2013,8,C01A-Cardiac glycosides,"/capita, US$ exchange rate",0.1
+28132,Portugal,2013,8,B-Blood and blood forming organs,"/capita, US$ purchasing power parity",15.0
+28133,Portugal,2013,8,B-Blood and blood forming organs,% of total sales,3.8
+28134,Portugal,2013,8,B-Blood and blood forming organs,"Million US$, purchasing power parity",157.3
+28135,Portugal,2013,8,B-Blood and blood forming organs,"/capita, US$ exchange rate",11.7
+28136,Portugal,2013,8,C07-Beta blocking agents,"/capita, US$ exchange rate",3.8
+28137,Portugal,2013,8,Products not elsewhere classified,"/capita, US$ exchange rate",0.0
+28138,Portugal,2013,8,C07-Beta blocking agents,"/capita, US$ purchasing power parity",4.9
+28139,Portugal,2013,8,Products not elsewhere classified,"Million US$, purchasing power parity",0.0
+28140,Portugal,2013,8,C02-Antihypertensives,Million of national currency units,3.6
+28141,Portugal,2013,8,C07-Beta blocking agents,"Million US$, purchasing power parity",51.6
+28142,Portugal,2013,8,C07-Beta blocking agents,% of total sales,1.2
+28143,Portugal,2013,8,Products not elsewhere classified,% of total sales,0.0
+28144,Portugal,2013,8,Products not elsewhere classified,"/capita, US$ purchasing power parity",0.0
+28145,Portugal,2013,8,A-Alimentary tract and metabolism,Million of national currency units,396.1
+28146,Portugal,2013,8,A-Alimentary tract and metabolism,"Million US$, purchasing power parity",678.6
+28147,Portugal,2013,8,A-Alimentary tract and metabolism,Million US$ at exchange rate,526.0
+28148,Portugal,2013,8,R-Respiratory system,Million US$ at exchange rate,268.2
+28149,Portugal,2013,8,B-Blood and blood forming organs,Million of national currency units,91.8
+28150,Portugal,2013,8,C07-Beta blocking agents,Million of national currency units,30.1
+28151,Portugal,2013,8,R-Respiratory system,Million of national currency units,201.9
+28152,Portugal,2013,8,B-Blood and blood forming organs,Million US$ at exchange rate,121.9
+28153,Portugal,2013,8,R-Respiratory system,"/capita, US$ exchange rate",25.6
+28154,Portugal,2013,8,R-Respiratory system,"Million US$, purchasing power parity",346.0
+28155,Portugal,2013,8,Products not elsewhere classified,Million of national currency units,0.0
+28156,Portugal,2013,8,A-Alimentary tract and metabolism,"/capita, US$ exchange rate",50.3
+28157,Portugal,2013,8,Products not elsewhere classified,Million US$ at exchange rate,0.0
+28158,Portugal,2013,8,C07-Beta blocking agents,Million US$ at exchange rate,40.0
+28159,Portugal,2013,8,A-Alimentary tract and metabolism,% of total sales,16.4
+28160,Portugal,2013,8,A-Alimentary tract and metabolism,"/capita, US$ purchasing power parity",64.9
+28161,Portugal,2013,8,C-Cardiovascular system,"Million US$, purchasing power parity",1013.0
+28162,Portugal,2013,8,Total pharmaceutical sales,"/capita, US$ purchasing power parity",394.8
+28163,Portugal,2013,8,Total pharmaceutical sales,"/capita, US$ exchange rate",306.0
+28164,Portugal,2013,8,C-Cardiovascular system,% of total sales,24.5
+28165,Portugal,2013,8,C-Cardiovascular system,"/capita, US$ exchange rate",75.1
+28166,Portugal,2013,8,C-Cardiovascular system,"/capita, US$ purchasing power parity",96.9
+28167,Portugal,2013,8,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ purchasing power parity",44.0
+28168,Portugal,2013,8,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ exchange rate",34.1
+28169,Portugal,2013,8,C-Cardiovascular system,Million of national currency units,591.2
+28170,Portugal,2013,8,C09-Agents acting on the Renin-Angiotensin system,% of total sales,11.1
+28171,Portugal,2013,8,Total pharmaceutical sales,Million US$ at exchange rate,3200.1
+28172,Portugal,2013,8,Total pharmaceutical sales,"Million US$, purchasing power parity",4128.6
+28173,Portugal,2013,8,C-Cardiovascular system,Million US$ at exchange rate,785.2
+28174,Portugal,2013,8,Total pharmaceutical sales,Million of national currency units,2409.5
+28175,Portugal,2013,8,C03-Diuretics,% of total sales,0.9
+28176,Portugal,2013,8,"C01B-Antiarrhythmics, Class I and III","/capita, US$ exchange rate",0.5
+28177,Portugal,2013,8,"C01B-Antiarrhythmics, Class I and III","Million US$, purchasing power parity",6.6
+28178,Portugal,2013,8,"C01B-Antiarrhythmics, Class I and III",Million US$ at exchange rate,5.1
+28179,Portugal,2013,8,"C01B-Antiarrhythmics, Class I and III",% of total sales,0.2
+28180,Portugal,2013,8,C09-Agents acting on the Renin-Angiotensin system,Million US$ at exchange rate,356.4
+28181,Portugal,2013,8,"C01B-Antiarrhythmics, Class I and III","/capita, US$ purchasing power parity",0.6
+28182,Portugal,2013,8,C09-Agents acting on the Renin-Angiotensin system,Million of national currency units,268.4
+28183,Portugal,2013,8,"C01B-Antiarrhythmics, Class I and III",Million of national currency units,3.8
+28184,Portugal,2013,8,C03-Diuretics,"/capita, US$ exchange rate",2.9
+28185,Portugal,2013,8,C03-Diuretics,"Million US$, purchasing power parity",38.8
+28186,Portugal,2013,8,C03-Diuretics,"/capita, US$ purchasing power parity",3.7
+28187,Portugal,2013,8,C09-Agents acting on the Renin-Angiotensin system,"Million US$, purchasing power parity",459.8
+28188,Portugal,2013,8,C03-Diuretics,Million US$ at exchange rate,30.0
+28189,Portugal,2013,8,C03-Diuretics,Million of national currency units,22.6
+28190,Portugal,2013,8,A02A-Antacids,Million of national currency units,5.1
+28191,Portugal,2013,8,C10-Lipid modifying agents,Million of national currency units,153.4
+28192,Portugal,2013,8,N06A-Antidepressants,Million of national currency units,97.7
+28193,Portugal,2013,8,A02A-Antacids,"Million US$, purchasing power parity",8.8
+28194,Portugal,2013,8,A02A-Antacids,Million US$ at exchange rate,6.8
+28195,Portugal,2013,8,N06A-Antidepressants,"/capita, US$ exchange rate",12.4
+28196,Portugal,2013,8,N06A-Antidepressants,"/capita, US$ purchasing power parity",16.0
+28197,Portugal,2013,8,N06A-Antidepressants,Million US$ at exchange rate,129.8
+28198,Portugal,2013,8,N06A-Antidepressants,"Million US$, purchasing power parity",167.4
+28199,Portugal,2013,8,C08-Calcium channel blockers,Million US$ at exchange rate,38.9
+28200,Portugal,2013,8,C08-Calcium channel blockers,Million of national currency units,29.3
+28201,Portugal,2013,8,A02A-Antacids,"/capita, US$ exchange rate",0.7
+28202,Portugal,2013,8,C08-Calcium channel blockers,"/capita, US$ purchasing power parity",4.8
+28203,Portugal,2013,8,C08-Calcium channel blockers,% of total sales,1.2
+28204,Portugal,2013,8,C08-Calcium channel blockers,"Million US$, purchasing power parity",50.2
+28205,Portugal,2013,8,C08-Calcium channel blockers,"/capita, US$ exchange rate",3.7
+28206,Portugal,2013,8,R03-Drugs for obstructive airway diseases,Million US$ at exchange rate,165.1
+28207,Portugal,2013,8,C10-Lipid modifying agents,"Million US$, purchasing power parity",262.8
+28208,Portugal,2013,8,G-Genito urinary system and sex hormones,Million of national currency units,149.3
+28209,Portugal,2013,8,G-Genito urinary system and sex hormones,Million US$ at exchange rate,198.3
+28210,Portugal,2013,8,C10-Lipid modifying agents,"/capita, US$ purchasing power parity",25.1
+28211,Portugal,2013,8,C10-Lipid modifying agents,% of total sales,6.4
+28212,Portugal,2013,8,R03-Drugs for obstructive airway diseases,Million of national currency units,124.3
+28213,Portugal,2013,8,C10-Lipid modifying agents,"/capita, US$ exchange rate",19.5
+28214,Portugal,2013,8,C10-Lipid modifying agents,Million US$ at exchange rate,203.7
+28215,Portugal,2013,8,N06A-Antidepressants,% of total sales,4.1
+28216,Portugal,2013,8,R03-Drugs for obstructive airway diseases,"Million US$, purchasing power parity",212.9
+28217,Portugal,2013,8,R03-Drugs for obstructive airway diseases,"/capita, US$ exchange rate",15.8
+28218,Portugal,2013,8,R03-Drugs for obstructive airway diseases,% of total sales,5.2
+28219,Portugal,2013,8,R03-Drugs for obstructive airway diseases,"/capita, US$ purchasing power parity",20.4
+28220,Portugal,2013,8,N02-Analgesics,% of total sales,4.5
+28221,Portugal,2013,8,J01-Antibacterials for systemic use,Million of national currency units,68.6
+28222,Portugal,2013,8,N02-Analgesics,"/capita, US$ exchange rate",13.8
+28223,Portugal,2013,8,N02-Analgesics,"/capita, US$ purchasing power parity",17.8
+28224,Portugal,2013,8,N-Nervous system,"Million US$, purchasing power parity",877.7
+28225,Portugal,2013,8,N05B-Anxiolytics,Million US$ at exchange rate,71.8
+28226,Portugal,2013,8,M01A-Antiinflammatory and antirheumatic products non-steroids,Million of national currency units,99.8
+28227,Portugal,2013,8,J01-Antibacterials for systemic use,Million US$ at exchange rate,91.1
+28228,Portugal,2013,8,"H-Systemic hormonal preparations, excluding sex hormones and insulins",% of total sales,0.8
+28229,Portugal,2013,8,N05B-Anxiolytics,Million of national currency units,54.1
+28230,Portugal,2013,8,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),% of total sales,2.6
+28231,Portugal,2013,8,J-Antiinfectives for systemic use,Million of national currency units,116.1
+28232,Portugal,2013,8,A10-Drugs used in diabetes,"/capita, US$ exchange rate",29.0
+28233,Portugal,2013,8,A10-Drugs used in diabetes,% of total sales,9.5
+28234,Portugal,2013,8,A10-Drugs used in diabetes,"/capita, US$ purchasing power parity",37.4
+28235,Portugal,2013,8,N-Nervous system,Million of national currency units,512.2
+28236,Portugal,2013,8,N-Nervous system,Million US$ at exchange rate,680.3
+28237,Portugal,2013,8,N02-Analgesics,Million of national currency units,108.8
+28238,Portugal,2013,8,N02-Analgesics,"Million US$, purchasing power parity",186.5
+28239,Portugal,2013,8,N02-Analgesics,Million US$ at exchange rate,144.5
+28240,Portugal,2013,8,N-Nervous system,"/capita, US$ exchange rate",65.1
+28241,Portugal,2013,8,N-Nervous system,"/capita, US$ purchasing power parity",83.9
+28242,Portugal,2013,8,N-Nervous system,% of total sales,21.3
+28243,Portugal,2013,8,J01-Antibacterials for systemic use,% of total sales,2.8
+28244,Portugal,2013,8,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ exchange rate",7.9
+28245,Portugal,2013,8,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"Million US$, purchasing power parity",107.2
+28246,Portugal,2013,8,M01A-Antiinflammatory and antirheumatic products non-steroids,% of total sales,4.1
+28247,Portugal,2013,8,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ purchasing power parity",16.4
+28248,Portugal,2013,8,M01A-Antiinflammatory and antirheumatic products non-steroids,"Million US$, purchasing power parity",171.0
+28249,Portugal,2013,8,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ exchange rate",12.7
+28250,Portugal,2013,8,N05B-Anxiolytics,% of total sales,2.2
+28251,Portugal,2013,8,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ purchasing power parity",10.3
+28252,Portugal,2013,8,M01A-Antiinflammatory and antirheumatic products non-steroids,Million US$ at exchange rate,132.6
+28253,Portugal,2013,8,N05B-Anxiolytics,"Million US$, purchasing power parity",92.6
+28254,Portugal,2013,8,N05B-Anxiolytics,"/capita, US$ exchange rate",6.9
+28255,Portugal,2013,8,N05B-Anxiolytics,"/capita, US$ purchasing power parity",8.9
+28256,Portugal,2013,8,J01-Antibacterials for systemic use,"/capita, US$ purchasing power parity",11.2
+28257,Portugal,2013,8,G03-Sex hormones and modulators of the genital system,% of total sales,2.8
+28258,Portugal,2013,8,J01-Antibacterials for systemic use,"Million US$, purchasing power parity",117.5
+28259,Portugal,2013,8,J01-Antibacterials for systemic use,"/capita, US$ exchange rate",8.7
+28260,Portugal,2013,8,N05C-Hypnotics and sedatives,% of total sales,0.8
+28261,Portugal,2013,8,M-Musculo-skeletal system,Million US$ at exchange rate,245.5
+28262,Portugal,2013,8,J-Antiinfectives for systemic use,Million US$ at exchange rate,154.2
+28263,Portugal,2013,8,M-Musculo-skeletal system,Million of national currency units,184.9
+28264,Portugal,2013,8,A10-Drugs used in diabetes,Million US$ at exchange rate,303.4
+28265,Portugal,2013,8,N05C-Hypnotics and sedatives,"Million US$, purchasing power parity",34.5
+28266,Portugal,2013,8,N05C-Hypnotics and sedatives,Million US$ at exchange rate,26.7
+28267,Portugal,2013,8,N05C-Hypnotics and sedatives,"/capita, US$ purchasing power parity",3.3
+28268,Portugal,2013,8,N05C-Hypnotics and sedatives,"/capita, US$ exchange rate",2.6
+28269,Portugal,2013,8,J-Antiinfectives for systemic use,"Million US$, purchasing power parity",198.9
+28270,Portugal,2013,8,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ exchange rate",2.5
+28271,Portugal,2013,8,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million US$ at exchange rate,83.1
+28272,Portugal,2013,8,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million of national currency units,62.6
+28273,Portugal,2013,8,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ purchasing power parity",3.3
+28274,Portugal,2013,8,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million of national currency units,20.0
+28275,Portugal,2013,8,J-Antiinfectives for systemic use,"/capita, US$ exchange rate",14.7
+28276,Portugal,2013,8,"H-Systemic hormonal preparations, excluding sex hormones and insulins","Million US$, purchasing power parity",34.3
+28277,Portugal,2013,8,A10-Drugs used in diabetes,"Million US$, purchasing power parity",391.4
+28278,Portugal,2013,8,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million US$ at exchange rate,26.6
+28279,Portugal,2013,8,M-Musculo-skeletal system,"/capita, US$ purchasing power parity",30.3
+28280,Portugal,2013,8,M-Musculo-skeletal system,"/capita, US$ exchange rate",23.5
+28281,Portugal,2013,8,A10-Drugs used in diabetes,Million of national currency units,228.4
+28282,Portugal,2013,8,J-Antiinfectives for systemic use,"/capita, US$ purchasing power parity",19.0
+28283,Portugal,2013,8,M-Musculo-skeletal system,% of total sales,7.7
+28284,Portugal,2013,8,J-Antiinfectives for systemic use,% of total sales,4.8
+28285,Portugal,2013,8,G03-Sex hormones and modulators of the genital system,"/capita, US$ purchasing power parity",11.0
+28286,Portugal,2013,8,G03-Sex hormones and modulators of the genital system,Million US$ at exchange rate,88.9
+28287,Portugal,2013,8,M-Musculo-skeletal system,"Million US$, purchasing power parity",316.7
+28288,Portugal,2013,8,N05C-Hypnotics and sedatives,Million of national currency units,20.1
+28289,Portugal,2013,8,G03-Sex hormones and modulators of the genital system,Million of national currency units,66.9
+28290,Portugal,2013,8,G03-Sex hormones and modulators of the genital system,"/capita, US$ exchange rate",8.5
+28291,Portugal,2013,8,G03-Sex hormones and modulators of the genital system,"Million US$, purchasing power parity",114.6
+28292,Portugal,2017,8,C01A-Cardiac glycosides,Million US$ at exchange rate,0.8
+28293,Portugal,2017,8,C01A-Cardiac glycosides,Million of national currency units,0.7
+28294,Portugal,2017,8,C02-Antihypertensives,% of total sales,0.1
+28295,Portugal,2017,8,C02-Antihypertensives,Million US$ at exchange rate,3.5
+28296,Portugal,2017,8,R-Respiratory system,"/capita, US$ purchasing power parity",37.5
+28297,Portugal,2017,8,R-Respiratory system,% of total sales,8.7
+28298,Portugal,2017,8,C02-Antihypertensives,"Million US$, purchasing power parity",5.4
+28299,Portugal,2017,8,C02-Antihypertensives,"/capita, US$ purchasing power parity",0.5
+28300,Portugal,2017,8,C02-Antihypertensives,"/capita, US$ exchange rate",0.3
+28301,Portugal,2017,8,G-Genito urinary system and sex hormones,"/capita, US$ purchasing power parity",26.8
+28302,Portugal,2017,8,G-Genito urinary system and sex hormones,"/capita, US$ exchange rate",17.4
+28303,Portugal,2017,8,G-Genito urinary system and sex hormones,% of total sales,6.2
+28304,Portugal,2017,8,B-Blood and blood forming organs,% of total sales,7.5
+28305,Portugal,2017,8,C01A-Cardiac glycosides,% of total sales,0.0
+28306,Portugal,2017,8,A02A-Antacids,"/capita, US$ purchasing power parity",1.0
+28307,Portugal,2017,8,G-Genito urinary system and sex hormones,"Million US$, purchasing power parity",276.2
+28308,Portugal,2017,8,C01A-Cardiac glycosides,"/capita, US$ purchasing power parity",0.1
+28309,Portugal,2017,8,A02A-Antacids,% of total sales,0.2
+28310,Portugal,2017,8,C01A-Cardiac glycosides,"/capita, US$ exchange rate",0.1
+28311,Portugal,2017,8,B-Blood and blood forming organs,"/capita, US$ purchasing power parity",32.4
+28312,Portugal,2017,8,B-Blood and blood forming organs,"Million US$, purchasing power parity",333.6
+28313,Portugal,2017,8,B-Blood and blood forming organs,"/capita, US$ exchange rate",21.1
+28314,Portugal,2017,8,C01A-Cardiac glycosides,"Million US$, purchasing power parity",1.3
+28315,Portugal,2017,8,C07-Beta blocking agents,"/capita, US$ exchange rate",3.6
+28316,Portugal,2017,8,C07-Beta blocking agents,"/capita, US$ purchasing power parity",5.5
+28317,Portugal,2017,8,Products not elsewhere classified,"Million US$, purchasing power parity",0.0
+28318,Portugal,2017,8,C02-Antihypertensives,Million of national currency units,3.1
+28319,Portugal,2017,8,C07-Beta blocking agents,Million US$ at exchange rate,37.0
+28320,Portugal,2017,8,C07-Beta blocking agents,"Million US$, purchasing power parity",56.9
+28321,Portugal,2017,8,Products not elsewhere classified,% of total sales,0.0
+28322,Portugal,2017,8,Products not elsewhere classified,"/capita, US$ exchange rate",0.0
+28323,Portugal,2017,8,Products not elsewhere classified,"/capita, US$ purchasing power parity",0.0
+28324,Portugal,2017,8,A-Alimentary tract and metabolism,"Million US$, purchasing power parity",830.4
+28325,Portugal,2017,8,A-Alimentary tract and metabolism,Million of national currency units,478.0
+28326,Portugal,2017,8,C07-Beta blocking agents,% of total sales,1.3
+28327,Portugal,2017,8,A-Alimentary tract and metabolism,Million US$ at exchange rate,540.0
+28328,Portugal,2017,8,B-Blood and blood forming organs,Million of national currency units,192.1
+28329,Portugal,2017,8,R-Respiratory system,Million of national currency units,222.4
+28330,Portugal,2017,8,R-Respiratory system,"Million US$, purchasing power parity",386.3
+28331,Portugal,2017,8,R-Respiratory system,"/capita, US$ exchange rate",24.4
+28332,Portugal,2017,8,B-Blood and blood forming organs,Million US$ at exchange rate,217.0
+28333,Portugal,2017,8,R-Respiratory system,Million US$ at exchange rate,251.2
+28334,Portugal,2017,8,C07-Beta blocking agents,Million of national currency units,32.8
+28335,Portugal,2017,8,Products not elsewhere classified,Million of national currency units,0.0
+28336,Portugal,2017,8,Products not elsewhere classified,Million US$ at exchange rate,0.0
+28337,Portugal,2017,8,A-Alimentary tract and metabolism,"/capita, US$ exchange rate",52.4
+28338,Portugal,2017,8,A-Alimentary tract and metabolism,% of total sales,18.7
+28339,Portugal,2017,8,A-Alimentary tract and metabolism,"/capita, US$ purchasing power parity",80.6
+28340,Portugal,2017,8,Total pharmaceutical sales,"/capita, US$ purchasing power parity",430.9
+28341,Portugal,2017,8,C-Cardiovascular system,"Million US$, purchasing power parity",902.5
+28342,Portugal,2017,8,Total pharmaceutical sales,"/capita, US$ exchange rate",280.2
+28343,Portugal,2017,8,C-Cardiovascular system,% of total sales,20.3
+28344,Portugal,2017,8,C03-Diuretics,% of total sales,0.9
+28345,Portugal,2017,8,Total pharmaceutical sales,"Million US$, purchasing power parity",4438.6
+28346,Portugal,2017,8,C-Cardiovascular system,"/capita, US$ exchange rate",57.0
+28347,Portugal,2017,8,C-Cardiovascular system,"/capita, US$ purchasing power parity",87.6
+28348,Portugal,2017,8,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ exchange rate",22.2
+28349,Portugal,2017,8,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ purchasing power parity",34.2
+28350,Portugal,2017,8,C09-Agents acting on the Renin-Angiotensin system,% of total sales,7.9
+28351,Portugal,2017,8,C-Cardiovascular system,Million of national currency units,519.6
+28352,Portugal,2017,8,Total pharmaceutical sales,Million US$ at exchange rate,2886.6
+28353,Portugal,2017,8,Total pharmaceutical sales,Million of national currency units,2555.3
+28354,Portugal,2017,8,C-Cardiovascular system,Million US$ at exchange rate,587.0
+28355,Portugal,2017,8,"C01B-Antiarrhythmics, Class I and III","Million US$, purchasing power parity",6.4
+28356,Portugal,2017,8,"C01B-Antiarrhythmics, Class I and III","/capita, US$ exchange rate",0.4
+28357,Portugal,2017,8,"C01B-Antiarrhythmics, Class I and III",Million of national currency units,3.7
+28358,Portugal,2017,8,"C01B-Antiarrhythmics, Class I and III",Million US$ at exchange rate,4.2
+28359,Portugal,2017,8,C09-Agents acting on the Renin-Angiotensin system,Million US$ at exchange rate,228.9
+28360,Portugal,2017,8,"C01B-Antiarrhythmics, Class I and III","/capita, US$ purchasing power parity",0.6
+28361,Portugal,2017,8,"C01B-Antiarrhythmics, Class I and III",% of total sales,0.1
+28362,Portugal,2017,8,C09-Agents acting on the Renin-Angiotensin system,Million of national currency units,202.7
+28363,Portugal,2017,8,C03-Diuretics,"Million US$, purchasing power parity",37.8
+28364,Portugal,2017,8,C03-Diuretics,"/capita, US$ purchasing power parity",3.7
+28365,Portugal,2017,8,C03-Diuretics,"/capita, US$ exchange rate",2.4
+28366,Portugal,2017,8,C03-Diuretics,Million US$ at exchange rate,24.6
+28367,Portugal,2017,8,C09-Agents acting on the Renin-Angiotensin system,"Million US$, purchasing power parity",352.0
+28368,Portugal,2017,8,C03-Diuretics,Million of national currency units,21.8
+28369,Portugal,2017,8,C10-Lipid modifying agents,% of total sales,6.3
+28370,Portugal,2017,8,N06A-Antidepressants,Million of national currency units,96.0
+28371,Portugal,2017,8,A02A-Antacids,Million of national currency units,6.0
+28372,Portugal,2017,8,A02A-Antacids,Million US$ at exchange rate,6.8
+28373,Portugal,2017,8,N06A-Antidepressants,"/capita, US$ exchange rate",10.5
+28374,Portugal,2017,8,N06A-Antidepressants,Million US$ at exchange rate,108.4
+28375,Portugal,2017,8,N06A-Antidepressants,"Million US$, purchasing power parity",166.8
+28376,Portugal,2017,8,C08-Calcium channel blockers,Million of national currency units,24.3
+28377,Portugal,2017,8,C08-Calcium channel blockers,Million US$ at exchange rate,27.5
+28378,Portugal,2017,8,A02A-Antacids,"/capita, US$ exchange rate",0.7
+28379,Portugal,2017,8,A02A-Antacids,"Million US$, purchasing power parity",10.5
+28380,Portugal,2017,8,C08-Calcium channel blockers,"/capita, US$ purchasing power parity",4.1
+28381,Portugal,2017,8,C08-Calcium channel blockers,% of total sales,1.0
+28382,Portugal,2017,8,C08-Calcium channel blockers,"Million US$, purchasing power parity",42.2
+28383,Portugal,2017,8,C08-Calcium channel blockers,"/capita, US$ exchange rate",2.7
+28384,Portugal,2017,8,N06A-Antidepressants,"/capita, US$ purchasing power parity",16.2
+28385,Portugal,2017,8,R03-Drugs for obstructive airway diseases,Million US$ at exchange rate,148.9
+28386,Portugal,2017,8,R03-Drugs for obstructive airway diseases,Million of national currency units,131.8
+28387,Portugal,2017,8,G-Genito urinary system and sex hormones,Million US$ at exchange rate,179.6
+28388,Portugal,2017,8,G-Genito urinary system and sex hormones,Million of national currency units,159.0
+28389,Portugal,2017,8,C10-Lipid modifying agents,"Million US$, purchasing power parity",278.4
+28390,Portugal,2017,8,C10-Lipid modifying agents,"/capita, US$ purchasing power parity",27.0
+28391,Portugal,2017,8,C10-Lipid modifying agents,"/capita, US$ exchange rate",17.6
+28392,Portugal,2017,8,C10-Lipid modifying agents,Million of national currency units,160.3
+28393,Portugal,2017,8,C10-Lipid modifying agents,Million US$ at exchange rate,181.0
+28394,Portugal,2017,8,N06A-Antidepressants,% of total sales,3.8
+28395,Portugal,2017,8,R03-Drugs for obstructive airway diseases,"/capita, US$ exchange rate",14.5
+28396,Portugal,2017,8,R03-Drugs for obstructive airway diseases,"Million US$, purchasing power parity",228.9
+28397,Portugal,2017,8,R03-Drugs for obstructive airway diseases,% of total sales,5.2
+28398,Portugal,2017,8,R03-Drugs for obstructive airway diseases,"/capita, US$ purchasing power parity",22.2
+28399,Portugal,2017,8,G03-Sex hormones and modulators of the genital system,"Million US$, purchasing power parity",107.0
+28400,Portugal,2017,8,N02-Analgesics,% of total sales,4.9
+28401,Portugal,2017,8,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ purchasing power parity",10.4
+28402,Portugal,2017,8,J01-Antibacterials for systemic use,Million of national currency units,59.9
+28403,Portugal,2017,8,N02-Analgesics,"/capita, US$ purchasing power parity",21.1
+28404,Portugal,2017,8,N-Nervous system,"Million US$, purchasing power parity",898.4
+28405,Portugal,2017,8,N02-Analgesics,"/capita, US$ exchange rate",13.7
+28406,Portugal,2017,8,N05B-Anxiolytics,Million US$ at exchange rate,58.0
+28407,Portugal,2017,8,M01A-Antiinflammatory and antirheumatic products non-steroids,Million of national currency units,93.0
+28408,Portugal,2017,8,N05B-Anxiolytics,Million of national currency units,51.4
+28409,Portugal,2017,8,"H-Systemic hormonal preparations, excluding sex hormones and insulins",% of total sales,1.0
+28410,Portugal,2017,8,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ purchasing power parity",4.3
+28411,Portugal,2017,8,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),% of total sales,2.4
+28412,Portugal,2017,8,J-Antiinfectives for systemic use,Million of national currency units,116.6
+28413,Portugal,2017,8,A10-Drugs used in diabetes,% of total sales,11.4
+28414,Portugal,2017,8,A10-Drugs used in diabetes,"/capita, US$ exchange rate",32.0
+28415,Portugal,2017,8,A10-Drugs used in diabetes,"/capita, US$ purchasing power parity",49.2
+28416,Portugal,2017,8,N-Nervous system,Million of national currency units,517.2
+28417,Portugal,2017,8,N-Nervous system,Million US$ at exchange rate,584.3
+28418,Portugal,2017,8,N02-Analgesics,"Million US$, purchasing power parity",217.1
+28419,Portugal,2017,8,N02-Analgesics,Million of national currency units,125.0
+28420,Portugal,2017,8,N02-Analgesics,Million US$ at exchange rate,141.2
+28421,Portugal,2017,8,N-Nervous system,"/capita, US$ exchange rate",56.7
+28422,Portugal,2017,8,N-Nervous system,"/capita, US$ purchasing power parity",87.2
+28423,Portugal,2017,8,J01-Antibacterials for systemic use,% of total sales,2.3
+28424,Portugal,2017,8,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"Million US$, purchasing power parity",107.0
+28425,Portugal,2017,8,M01A-Antiinflammatory and antirheumatic products non-steroids,% of total sales,3.6
+28426,Portugal,2017,8,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ purchasing power parity",15.7
+28427,Portugal,2017,8,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ exchange rate",10.2
+28428,Portugal,2017,8,M01A-Antiinflammatory and antirheumatic products non-steroids,Million US$ at exchange rate,105.1
+28429,Portugal,2017,8,N-Nervous system,% of total sales,20.2
+28430,Portugal,2017,8,M01A-Antiinflammatory and antirheumatic products non-steroids,"Million US$, purchasing power parity",161.6
+28431,Portugal,2017,8,N05B-Anxiolytics,% of total sales,2.0
+28432,Portugal,2017,8,J01-Antibacterials for systemic use,Million US$ at exchange rate,67.7
+28433,Portugal,2017,8,N05B-Anxiolytics,"/capita, US$ purchasing power parity",8.7
+28434,Portugal,2017,8,N05B-Anxiolytics,"Million US$, purchasing power parity",89.2
+28435,Portugal,2017,8,N05B-Anxiolytics,"/capita, US$ exchange rate",5.6
+28436,Portugal,2017,8,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ exchange rate",6.8
+28437,Portugal,2017,8,J01-Antibacterials for systemic use,"/capita, US$ purchasing power parity",10.1
+28438,Portugal,2017,8,G03-Sex hormones and modulators of the genital system,"/capita, US$ purchasing power parity",10.4
+28439,Portugal,2017,8,G03-Sex hormones and modulators of the genital system,% of total sales,2.4
+28440,Portugal,2017,8,J01-Antibacterials for systemic use,"Million US$, purchasing power parity",104.1
+28441,Portugal,2017,8,J01-Antibacterials for systemic use,"/capita, US$ exchange rate",6.6
+28442,Portugal,2017,8,M-Musculo-skeletal system,Million of national currency units,161.1
+28443,Portugal,2017,8,N05C-Hypnotics and sedatives,% of total sales,0.7
+28444,Portugal,2017,8,J-Antiinfectives for systemic use,Million US$ at exchange rate,131.8
+28445,Portugal,2017,8,N05C-Hypnotics and sedatives,Million US$ at exchange rate,21.4
+28446,Portugal,2017,8,M-Musculo-skeletal system,Million US$ at exchange rate,182.0
+28447,Portugal,2017,8,N05C-Hypnotics and sedatives,"Million US$, purchasing power parity",32.9
+28448,Portugal,2017,8,N05C-Hypnotics and sedatives,"/capita, US$ purchasing power parity",3.2
+28449,Portugal,2017,8,N05C-Hypnotics and sedatives,"/capita, US$ exchange rate",2.1
+28450,Portugal,2017,8,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ exchange rate",2.8
+28451,Portugal,2017,8,A10-Drugs used in diabetes,"Million US$, purchasing power parity",506.9
+28452,Portugal,2017,8,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million US$ at exchange rate,69.6
+28453,Portugal,2017,8,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million of national currency units,61.6
+28454,Portugal,2017,8,"H-Systemic hormonal preparations, excluding sex hormones and insulins","Million US$, purchasing power parity",44.6
+28455,Portugal,2017,8,A10-Drugs used in diabetes,Million US$ at exchange rate,329.7
+28456,Portugal,2017,8,J-Antiinfectives for systemic use,"Million US$, purchasing power parity",202.6
+28457,Portugal,2017,8,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million of national currency units,25.7
+28458,Portugal,2017,8,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million US$ at exchange rate,29.0
+28459,Portugal,2017,8,M-Musculo-skeletal system,"/capita, US$ purchasing power parity",27.2
+28460,Portugal,2017,8,J-Antiinfectives for systemic use,"/capita, US$ exchange rate",12.8
+28461,Portugal,2017,8,M-Musculo-skeletal system,"/capita, US$ exchange rate",17.7
+28462,Portugal,2017,8,A10-Drugs used in diabetes,Million of national currency units,291.8
+28463,Portugal,2017,8,J-Antiinfectives for systemic use,% of total sales,4.6
+28464,Portugal,2017,8,M-Musculo-skeletal system,% of total sales,6.3
+28465,Portugal,2017,8,J-Antiinfectives for systemic use,"/capita, US$ purchasing power parity",19.7
+28466,Portugal,2017,8,G03-Sex hormones and modulators of the genital system,"/capita, US$ exchange rate",6.8
+28467,Portugal,2017,8,G03-Sex hormones and modulators of the genital system,Million US$ at exchange rate,69.6
+28468,Portugal,2017,8,M-Musculo-skeletal system,"Million US$, purchasing power parity",279.8
+28469,Portugal,2017,8,G03-Sex hormones and modulators of the genital system,Million of national currency units,61.6
+28470,Portugal,2017,8,N05C-Hypnotics and sedatives,Million of national currency units,19.0
+28471,Portugal,2015,9,C01A-Cardiac glycosides,Million of national currency units,0.9
+28472,Portugal,2015,9,C01A-Cardiac glycosides,Million US$ at exchange rate,1.0
+28473,Portugal,2015,9,C02-Antihypertensives,Million US$ at exchange rate,4.0
+28474,Portugal,2015,9,R-Respiratory system,"/capita, US$ purchasing power parity",35.4
+28475,Portugal,2015,9,R-Respiratory system,% of total sales,8.6
+28476,Portugal,2015,9,C02-Antihypertensives,"Million US$, purchasing power parity",6.1
+28477,Portugal,2015,9,C02-Antihypertensives,"/capita, US$ purchasing power parity",0.6
+28478,Portugal,2015,9,C02-Antihypertensives,% of total sales,0.1
+28479,Portugal,2015,9,C01A-Cardiac glycosides,"Million US$, purchasing power parity",1.5
+28480,Portugal,2015,9,C02-Antihypertensives,"/capita, US$ exchange rate",0.4
+28481,Portugal,2015,9,G-Genito urinary system and sex hormones,"/capita, US$ purchasing power parity",25.0
+28482,Portugal,2015,9,G-Genito urinary system and sex hormones,"/capita, US$ exchange rate",16.2
+28483,Portugal,2015,9,G-Genito urinary system and sex hormones,% of total sales,6.1
+28484,Portugal,2015,9,C01A-Cardiac glycosides,% of total sales,0.0
+28485,Portugal,2015,9,A02A-Antacids,"/capita, US$ purchasing power parity",0.9
+28486,Portugal,2015,9,G-Genito urinary system and sex hormones,"Million US$, purchasing power parity",259.0
+28487,Portugal,2015,9,B-Blood and blood forming organs,% of total sales,5.6
+28488,Portugal,2015,9,C01A-Cardiac glycosides,"/capita, US$ purchasing power parity",0.1
+28489,Portugal,2015,9,A02A-Antacids,% of total sales,0.2
+28490,Portugal,2015,9,C01A-Cardiac glycosides,"/capita, US$ exchange rate",0.1
+28491,Portugal,2015,9,B-Blood and blood forming organs,"/capita, US$ purchasing power parity",23.2
+28492,Portugal,2015,9,B-Blood and blood forming organs,"Million US$, purchasing power parity",240.3
+28493,Portugal,2015,9,B-Blood and blood forming organs,"/capita, US$ exchange rate",15.1
+28494,Portugal,2015,9,C07-Beta blocking agents,"/capita, US$ exchange rate",3.4
+28495,Portugal,2015,9,C07-Beta blocking agents,"/capita, US$ purchasing power parity",5.2
+28496,Portugal,2015,9,C07-Beta blocking agents,Million US$ at exchange rate,35.0
+28497,Portugal,2015,9,Products not elsewhere classified,"Million US$, purchasing power parity",0.0
+28498,Portugal,2015,9,C02-Antihypertensives,Million of national currency units,3.6
+28499,Portugal,2015,9,C07-Beta blocking agents,"Million US$, purchasing power parity",53.9
+28500,Portugal,2015,9,Products not elsewhere classified,% of total sales,0.0
+28501,Portugal,2015,9,Products not elsewhere classified,"/capita, US$ exchange rate",0.0
+28502,Portugal,2015,9,Products not elsewhere classified,"/capita, US$ purchasing power parity",0.0
+28503,Portugal,2015,9,A-Alimentary tract and metabolism,"Million US$, purchasing power parity",752.2
+28504,Portugal,2015,9,A-Alimentary tract and metabolism,Million US$ at exchange rate,488.2
+28505,Portugal,2015,9,C07-Beta blocking agents,% of total sales,1.3
+28506,Portugal,2015,9,B-Blood and blood forming organs,Million of national currency units,140.5
+28507,Portugal,2015,9,C07-Beta blocking agents,Million of national currency units,31.5
+28508,Portugal,2015,9,R-Respiratory system,Million of national currency units,214.3
+28509,Portugal,2015,9,R-Respiratory system,"/capita, US$ exchange rate",23.0
+28510,Portugal,2015,9,R-Respiratory system,"Million US$, purchasing power parity",366.4
+28511,Portugal,2015,9,B-Blood and blood forming organs,Million US$ at exchange rate,155.9
+28512,Portugal,2015,9,R-Respiratory system,Million US$ at exchange rate,237.8
+28513,Portugal,2015,9,Products not elsewhere classified,Million of national currency units,0.0
+28514,Portugal,2015,9,A-Alimentary tract and metabolism,"/capita, US$ exchange rate",47.1
+28515,Portugal,2015,9,Products not elsewhere classified,Million US$ at exchange rate,0.0
+28516,Portugal,2015,9,A-Alimentary tract and metabolism,% of total sales,17.7
+28517,Portugal,2015,9,A-Alimentary tract and metabolism,"/capita, US$ purchasing power parity",72.6
+28518,Portugal,2015,9,C-Cardiovascular system,"Million US$, purchasing power parity",947.9
+28519,Portugal,2015,9,Total pharmaceutical sales,"/capita, US$ purchasing power parity",411.2
+28520,Portugal,2015,9,Total pharmaceutical sales,"/capita, US$ exchange rate",266.9
+28521,Portugal,2015,9,C-Cardiovascular system,% of total sales,22.3
+28522,Portugal,2015,9,C-Cardiovascular system,"/capita, US$ exchange rate",59.4
+28523,Portugal,2015,9,C-Cardiovascular system,"/capita, US$ purchasing power parity",91.5
+28524,Portugal,2015,9,Total pharmaceutical sales,"Million US$, purchasing power parity",4259.0
+28525,Portugal,2015,9,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ exchange rate",25.0
+28526,Portugal,2015,9,C-Cardiovascular system,Million of national currency units,554.5
+28527,Portugal,2015,9,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ purchasing power parity",38.5
+28528,Portugal,2015,9,C09-Agents acting on the Renin-Angiotensin system,% of total sales,9.4
+28529,Portugal,2015,9,Total pharmaceutical sales,Million US$ at exchange rate,2764.1
+28530,Portugal,2015,9,C-Cardiovascular system,Million US$ at exchange rate,615.2
+28531,Portugal,2015,9,Total pharmaceutical sales,Million of national currency units,2491.3
+28532,Portugal,2015,9,C03-Diuretics,% of total sales,0.9
+28533,Portugal,2015,9,"C01B-Antiarrhythmics, Class I and III","Million US$, purchasing power parity",6.3
+28534,Portugal,2015,9,"C01B-Antiarrhythmics, Class I and III","/capita, US$ exchange rate",0.4
+28535,Portugal,2015,9,"C01B-Antiarrhythmics, Class I and III",Million US$ at exchange rate,4.1
+28536,Portugal,2015,9,C09-Agents acting on the Renin-Angiotensin system,Million US$ at exchange rate,258.7
+28537,Portugal,2015,9,"C01B-Antiarrhythmics, Class I and III","/capita, US$ purchasing power parity",0.6
+28538,Portugal,2015,9,"C01B-Antiarrhythmics, Class I and III",% of total sales,0.1
+28539,Portugal,2015,9,C09-Agents acting on the Renin-Angiotensin system,Million of national currency units,233.2
+28540,Portugal,2015,9,"C01B-Antiarrhythmics, Class I and III",Million of national currency units,3.7
+28541,Portugal,2015,9,C03-Diuretics,"/capita, US$ exchange rate",2.4
+28542,Portugal,2015,9,C03-Diuretics,"Million US$, purchasing power parity",38.0
+28543,Portugal,2015,9,C03-Diuretics,"/capita, US$ purchasing power parity",3.7
+28544,Portugal,2015,9,C09-Agents acting on the Renin-Angiotensin system,"Million US$, purchasing power parity",398.6
+28545,Portugal,2015,9,C03-Diuretics,Million US$ at exchange rate,24.7
+28546,Portugal,2015,9,C03-Diuretics,Million of national currency units,22.3
+28547,Portugal,2015,9,A02A-Antacids,Million of national currency units,5.6
+28548,Portugal,2015,9,C10-Lipid modifying agents,Million of national currency units,161.0
+28549,Portugal,2015,9,N06A-Antidepressants,Million of national currency units,92.9
+28550,Portugal,2015,9,A02A-Antacids,Million US$ at exchange rate,6.2
+28551,Portugal,2015,9,N06A-Antidepressants,"/capita, US$ exchange rate",10.0
+28552,Portugal,2015,9,N06A-Antidepressants,Million US$ at exchange rate,103.1
+28553,Portugal,2015,9,N06A-Antidepressants,"Million US$, purchasing power parity",158.8
+28554,Portugal,2015,9,A02A-Antacids,"Million US$, purchasing power parity",9.6
+28555,Portugal,2015,9,C08-Calcium channel blockers,Million US$ at exchange rate,28.8
+28556,Portugal,2015,9,C08-Calcium channel blockers,Million of national currency units,26.0
+28557,Portugal,2015,9,A02A-Antacids,"/capita, US$ exchange rate",0.6
+28558,Portugal,2015,9,C08-Calcium channel blockers,"/capita, US$ purchasing power parity",4.3
+28559,Portugal,2015,9,C08-Calcium channel blockers,% of total sales,1.0
+28560,Portugal,2015,9,C08-Calcium channel blockers,"Million US$, purchasing power parity",44.4
+28561,Portugal,2015,9,C08-Calcium channel blockers,"/capita, US$ exchange rate",2.8
+28562,Portugal,2015,9,N06A-Antidepressants,"/capita, US$ purchasing power parity",15.3
+28563,Portugal,2015,9,R03-Drugs for obstructive airway diseases,Million US$ at exchange rate,138.0
+28564,Portugal,2015,9,G-Genito urinary system and sex hormones,Million of national currency units,151.5
+28565,Portugal,2015,9,G-Genito urinary system and sex hormones,Million US$ at exchange rate,168.1
+28566,Portugal,2015,9,C10-Lipid modifying agents,"Million US$, purchasing power parity",275.3
+28567,Portugal,2015,9,C10-Lipid modifying agents,"/capita, US$ purchasing power parity",26.6
+28568,Portugal,2015,9,C10-Lipid modifying agents,% of total sales,6.5
+28569,Portugal,2015,9,R03-Drugs for obstructive airway diseases,Million of national currency units,124.4
+28570,Portugal,2015,9,C10-Lipid modifying agents,"/capita, US$ exchange rate",17.3
+28571,Portugal,2015,9,C10-Lipid modifying agents,Million US$ at exchange rate,178.7
+28572,Portugal,2015,9,N06A-Antidepressants,% of total sales,3.7
+28573,Portugal,2015,9,R03-Drugs for obstructive airway diseases,"/capita, US$ exchange rate",13.3
+28574,Portugal,2015,9,R03-Drugs for obstructive airway diseases,"Million US$, purchasing power parity",212.7
+28575,Portugal,2015,9,R03-Drugs for obstructive airway diseases,% of total sales,5.0
+28576,Portugal,2015,9,R03-Drugs for obstructive airway diseases,"/capita, US$ purchasing power parity",20.5
+28577,Portugal,2015,9,A-Alimentary tract and metabolism,Million of national currency units,440.0
+28578,Portugal,2015,9,N02-Analgesics,% of total sales,4.9
+28579,Portugal,2015,9,J01-Antibacterials for systemic use,Million of national currency units,66.8
+28580,Portugal,2015,9,N-Nervous system,"Million US$, purchasing power parity",870.6
+28581,Portugal,2015,9,N02-Analgesics,"/capita, US$ exchange rate",13.1
+28582,Portugal,2015,9,N02-Analgesics,"/capita, US$ purchasing power parity",20.2
+28583,Portugal,2015,9,N05B-Anxiolytics,Million US$ at exchange rate,60.3
+28584,Portugal,2015,9,M01A-Antiinflammatory and antirheumatic products non-steroids,Million of national currency units,97.4
+28585,Portugal,2015,9,J01-Antibacterials for systemic use,Million US$ at exchange rate,74.1
+28586,Portugal,2015,9,"H-Systemic hormonal preparations, excluding sex hormones and insulins",% of total sales,0.9
+28587,Portugal,2015,9,N05B-Anxiolytics,Million of national currency units,54.4
+28588,Portugal,2015,9,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),% of total sales,2.5
+28589,Portugal,2015,9,J-Antiinfectives for systemic use,Million of national currency units,133.5
+28590,Portugal,2015,9,A10-Drugs used in diabetes,% of total sales,10.6
+28591,Portugal,2015,9,A10-Drugs used in diabetes,"/capita, US$ exchange rate",28.4
+28592,Portugal,2015,9,A10-Drugs used in diabetes,"/capita, US$ purchasing power parity",43.7
+28593,Portugal,2015,9,N-Nervous system,Million of national currency units,509.2
+28594,Portugal,2015,9,N-Nervous system,Million US$ at exchange rate,565.0
+28595,Portugal,2015,9,N02-Analgesics,"Million US$, purchasing power parity",209.1
+28596,Portugal,2015,9,N02-Analgesics,Million of national currency units,122.3
+28597,Portugal,2015,9,N02-Analgesics,Million US$ at exchange rate,135.7
+28598,Portugal,2015,9,N-Nervous system,"/capita, US$ exchange rate",54.5
+28599,Portugal,2015,9,N-Nervous system,"/capita, US$ purchasing power parity",84.0
+28600,Portugal,2015,9,J01-Antibacterials for systemic use,% of total sales,2.7
+28601,Portugal,2015,9,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ exchange rate",6.7
+28602,Portugal,2015,9,N-Nervous system,% of total sales,20.4
+28603,Portugal,2015,9,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"Million US$, purchasing power parity",107.3
+28604,Portugal,2015,9,M01A-Antiinflammatory and antirheumatic products non-steroids,% of total sales,3.9
+28605,Portugal,2015,9,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ purchasing power parity",16.1
+28606,Portugal,2015,9,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ exchange rate",10.4
+28607,Portugal,2015,9,M01A-Antiinflammatory and antirheumatic products non-steroids,Million US$ at exchange rate,108.1
+28608,Portugal,2015,9,M01A-Antiinflammatory and antirheumatic products non-steroids,"Million US$, purchasing power parity",166.5
+28609,Portugal,2015,9,N05B-Anxiolytics,% of total sales,2.2
+28610,Portugal,2015,9,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ purchasing power parity",10.4
+28611,Portugal,2015,9,N05B-Anxiolytics,"/capita, US$ purchasing power parity",9.0
+28612,Portugal,2015,9,N05B-Anxiolytics,"Million US$, purchasing power parity",92.9
+28613,Portugal,2015,9,N05B-Anxiolytics,"/capita, US$ exchange rate",5.8
+28614,Portugal,2015,9,J01-Antibacterials for systemic use,"/capita, US$ purchasing power parity",11.0
+28615,Portugal,2015,9,G03-Sex hormones and modulators of the genital system,"/capita, US$ purchasing power parity",10.1
+28616,Portugal,2015,9,G03-Sex hormones and modulators of the genital system,% of total sales,2.4
+28617,Portugal,2015,9,J01-Antibacterials for systemic use,"Million US$, purchasing power parity",114.1
+28618,Portugal,2015,9,J01-Antibacterials for systemic use,"/capita, US$ exchange rate",7.2
+28619,Portugal,2015,9,N05C-Hypnotics and sedatives,% of total sales,0.8
+28620,Portugal,2015,9,M-Musculo-skeletal system,Million of national currency units,169.1
+28621,Portugal,2015,9,A10-Drugs used in diabetes,Million US$ at exchange rate,294.0
+28622,Portugal,2015,9,J-Antiinfectives for systemic use,Million US$ at exchange rate,148.1
+28623,Portugal,2015,9,M-Musculo-skeletal system,Million US$ at exchange rate,187.6
+28624,Portugal,2015,9,N05C-Hypnotics and sedatives,"Million US$, purchasing power parity",35.5
+28625,Portugal,2015,9,N05C-Hypnotics and sedatives,Million US$ at exchange rate,23.1
+28626,Portugal,2015,9,N05C-Hypnotics and sedatives,"/capita, US$ purchasing power parity",3.4
+28627,Portugal,2015,9,N05C-Hypnotics and sedatives,"/capita, US$ exchange rate",2.2
+28628,Portugal,2015,9,J-Antiinfectives for systemic use,"Million US$, purchasing power parity",228.3
+28629,Portugal,2015,9,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ exchange rate",2.5
+28630,Portugal,2015,9,A10-Drugs used in diabetes,"Million US$, purchasing power parity",453.0
+28631,Portugal,2015,9,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million US$ at exchange rate,69.6
+28632,Portugal,2015,9,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million of national currency units,62.8
+28633,Portugal,2015,9,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ purchasing power parity",3.9
+28634,Portugal,2015,9,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million of national currency units,23.4
+28635,Portugal,2015,9,J-Antiinfectives for systemic use,"/capita, US$ exchange rate",14.3
+28636,Portugal,2015,9,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million US$ at exchange rate,25.9
+28637,Portugal,2015,9,"H-Systemic hormonal preparations, excluding sex hormones and insulins","Million US$, purchasing power parity",39.9
+28638,Portugal,2015,9,M-Musculo-skeletal system,"/capita, US$ purchasing power parity",27.9
+28639,Portugal,2015,9,M-Musculo-skeletal system,"/capita, US$ exchange rate",18.1
+28640,Portugal,2015,9,A10-Drugs used in diabetes,Million of national currency units,265.0
+28641,Portugal,2015,9,J-Antiinfectives for systemic use,"/capita, US$ purchasing power parity",22.0
+28642,Portugal,2015,9,J-Antiinfectives for systemic use,% of total sales,5.4
+28643,Portugal,2015,9,M-Musculo-skeletal system,% of total sales,6.8
+28644,Portugal,2015,9,G03-Sex hormones and modulators of the genital system,"/capita, US$ exchange rate",6.5
+28645,Portugal,2015,9,G03-Sex hormones and modulators of the genital system,Million US$ at exchange rate,67.6
+28646,Portugal,2015,9,M-Musculo-skeletal system,"Million US$, purchasing power parity",289.1
+28647,Portugal,2015,9,N05C-Hypnotics and sedatives,Million of national currency units,20.8
+28648,Portugal,2015,9,G03-Sex hormones and modulators of the genital system,Million of national currency units,60.9
+28649,Portugal,2015,9,G03-Sex hormones and modulators of the genital system,"Million US$, purchasing power parity",104.1
+28650,Portugal,2016,9,C01A-Cardiac glycosides,Million US$ at exchange rate,0.9
+28651,Portugal,2016,9,C01A-Cardiac glycosides,Million of national currency units,0.8
+28652,Portugal,2016,9,C02-Antihypertensives,% of total sales,0.1
+28653,Portugal,2016,9,C02-Antihypertensives,Million US$ at exchange rate,3.5
+28654,Portugal,2016,9,R-Respiratory system,% of total sales,8.8
+28655,Portugal,2016,9,R-Respiratory system,"/capita, US$ purchasing power parity",37.8
+28656,Portugal,2016,9,C02-Antihypertensives,"/capita, US$ purchasing power parity",0.5
+28657,Portugal,2016,9,C02-Antihypertensives,"Million US$, purchasing power parity",5.5
+28658,Portugal,2016,9,C02-Antihypertensives,"/capita, US$ exchange rate",0.3
+28659,Portugal,2016,9,C01A-Cardiac glycosides,"Million US$, purchasing power parity",1.4
+28660,Portugal,2016,9,G-Genito urinary system and sex hormones,"/capita, US$ purchasing power parity",26.7
+28661,Portugal,2016,9,G-Genito urinary system and sex hormones,"/capita, US$ exchange rate",16.9
+28662,Portugal,2016,9,G-Genito urinary system and sex hormones,% of total sales,6.2
+28663,Portugal,2016,9,C01A-Cardiac glycosides,% of total sales,0.0
+28664,Portugal,2016,9,A02A-Antacids,"/capita, US$ purchasing power parity",0.9
+28665,Portugal,2016,9,G-Genito urinary system and sex hormones,"Million US$, purchasing power parity",275.6
+28666,Portugal,2016,9,B-Blood and blood forming organs,% of total sales,6.9
+28667,Portugal,2016,9,C01A-Cardiac glycosides,"/capita, US$ purchasing power parity",0.1
+28668,Portugal,2016,9,A02A-Antacids,% of total sales,0.2
+28669,Portugal,2016,9,C01A-Cardiac glycosides,"/capita, US$ exchange rate",0.1
+28670,Portugal,2016,9,B-Blood and blood forming organs,"/capita, US$ purchasing power parity",29.7
+28671,Portugal,2016,9,B-Blood and blood forming organs,"Million US$, purchasing power parity",307.2
+28672,Portugal,2016,9,B-Blood and blood forming organs,"/capita, US$ exchange rate",18.8
+28673,Portugal,2016,9,C07-Beta blocking agents,"/capita, US$ exchange rate",3.5
+28674,Portugal,2016,9,C07-Beta blocking agents,"/capita, US$ purchasing power parity",5.5
+28675,Portugal,2016,9,C07-Beta blocking agents,Million US$ at exchange rate,36.0
+28676,Portugal,2016,9,C02-Antihypertensives,Million of national currency units,3.1
+28677,Portugal,2016,9,Products not elsewhere classified,"Million US$, purchasing power parity",0.0
+28678,Portugal,2016,9,C07-Beta blocking agents,"Million US$, purchasing power parity",57.0
+28679,Portugal,2016,9,C07-Beta blocking agents,% of total sales,1.3
+28680,Portugal,2016,9,Products not elsewhere classified,% of total sales,0.0
+28681,Portugal,2016,9,Products not elsewhere classified,"/capita, US$ exchange rate",0.0
+28682,Portugal,2016,9,Products not elsewhere classified,"/capita, US$ purchasing power parity",0.0
+28683,Portugal,2016,9,A-Alimentary tract and metabolism,"Million US$, purchasing power parity",806.0
+28684,Portugal,2016,9,A-Alimentary tract and metabolism,Million of national currency units,460.6
+28685,Portugal,2016,9,A-Alimentary tract and metabolism,Million US$ at exchange rate,509.8
+28686,Portugal,2016,9,B-Blood and blood forming organs,Million of national currency units,175.5
+28687,Portugal,2016,9,R-Respiratory system,Million of national currency units,222.8
+28688,Portugal,2016,9,R-Respiratory system,"/capita, US$ exchange rate",23.9
+28689,Portugal,2016,9,R-Respiratory system,"Million US$, purchasing power parity",389.8
+28690,Portugal,2016,9,B-Blood and blood forming organs,Million US$ at exchange rate,194.3
+28691,Portugal,2016,9,R-Respiratory system,Million US$ at exchange rate,246.6
+28692,Portugal,2016,9,C07-Beta blocking agents,Million of national currency units,32.5
+28693,Portugal,2016,9,Products not elsewhere classified,Million of national currency units,0.0
+28694,Portugal,2016,9,A-Alimentary tract and metabolism,"/capita, US$ exchange rate",49.4
+28695,Portugal,2016,9,Products not elsewhere classified,Million US$ at exchange rate,0.0
+28696,Portugal,2016,9,A-Alimentary tract and metabolism,% of total sales,18.2
+28697,Portugal,2016,9,A-Alimentary tract and metabolism,"/capita, US$ purchasing power parity",78.1
+28698,Portugal,2016,9,Total pharmaceutical sales,"/capita, US$ purchasing power parity",428.9
+28699,Portugal,2016,9,C-Cardiovascular system,"Million US$, purchasing power parity",944.9
+28700,Portugal,2016,9,Total pharmaceutical sales,"/capita, US$ exchange rate",271.3
+28701,Portugal,2016,9,C-Cardiovascular system,% of total sales,21.3
+28702,Portugal,2016,9,C-Cardiovascular system,"/capita, US$ exchange rate",57.9
+28703,Portugal,2016,9,C-Cardiovascular system,"/capita, US$ purchasing power parity",91.5
+28704,Portugal,2016,9,Total pharmaceutical sales,"Million US$, purchasing power parity",4428.3
+28705,Portugal,2016,9,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ exchange rate",23.3
+28706,Portugal,2016,9,C-Cardiovascular system,Million of national currency units,539.9
+28707,Portugal,2016,9,C09-Agents acting on the Renin-Angiotensin system,% of total sales,8.6
+28708,Portugal,2016,9,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ purchasing power parity",36.8
+28709,Portugal,2016,9,C03-Diuretics,% of total sales,0.9
+28710,Portugal,2016,9,Total pharmaceutical sales,Million US$ at exchange rate,2800.9
+28711,Portugal,2016,9,Total pharmaceutical sales,Million of national currency units,2530.4
+28712,Portugal,2016,9,C-Cardiovascular system,Million US$ at exchange rate,597.6
+28713,Portugal,2016,9,"C01B-Antiarrhythmics, Class I and III","Million US$, purchasing power parity",6.5
+28714,Portugal,2016,9,"C01B-Antiarrhythmics, Class I and III","/capita, US$ exchange rate",0.4
+28715,Portugal,2016,9,"C01B-Antiarrhythmics, Class I and III",Million US$ at exchange rate,4.1
+28716,Portugal,2016,9,"C01B-Antiarrhythmics, Class I and III",Million of national currency units,3.7
+28717,Portugal,2016,9,"C01B-Antiarrhythmics, Class I and III","/capita, US$ purchasing power parity",0.6
+28718,Portugal,2016,9,"C01B-Antiarrhythmics, Class I and III",% of total sales,0.1
+28719,Portugal,2016,9,C09-Agents acting on the Renin-Angiotensin system,Million US$ at exchange rate,240.2
+28720,Portugal,2016,9,C09-Agents acting on the Renin-Angiotensin system,Million of national currency units,217.0
+28721,Portugal,2016,9,C03-Diuretics,"Million US$, purchasing power parity",38.4
+28722,Portugal,2016,9,C03-Diuretics,"/capita, US$ exchange rate",2.4
+28723,Portugal,2016,9,C03-Diuretics,"/capita, US$ purchasing power parity",3.7
+28724,Portugal,2016,9,C09-Agents acting on the Renin-Angiotensin system,"Million US$, purchasing power parity",379.7
+28725,Portugal,2016,9,C03-Diuretics,Million US$ at exchange rate,24.3
+28726,Portugal,2016,9,C03-Diuretics,Million of national currency units,21.9
+28727,Portugal,2016,9,A02A-Antacids,Million of national currency units,5.3
+28728,Portugal,2016,9,N06A-Antidepressants,Million of national currency units,93.6
+28729,Portugal,2016,9,A02A-Antacids,Million US$ at exchange rate,5.9
+28730,Portugal,2016,9,N06A-Antidepressants,"/capita, US$ exchange rate",10.0
+28731,Portugal,2016,9,N06A-Antidepressants,"Million US$, purchasing power parity",163.7
+28732,Portugal,2016,9,N06A-Antidepressants,Million US$ at exchange rate,103.6
+28733,Portugal,2016,9,C08-Calcium channel blockers,Million of national currency units,25.1
+28734,Portugal,2016,9,C08-Calcium channel blockers,Million US$ at exchange rate,27.8
+28735,Portugal,2016,9,A02A-Antacids,"/capita, US$ exchange rate",0.6
+28736,Portugal,2016,9,A02A-Antacids,"Million US$, purchasing power parity",9.3
+28737,Portugal,2016,9,C08-Calcium channel blockers,"/capita, US$ purchasing power parity",4.3
+28738,Portugal,2016,9,C08-Calcium channel blockers,% of total sales,1.0
+28739,Portugal,2016,9,C08-Calcium channel blockers,"Million US$, purchasing power parity",43.9
+28740,Portugal,2016,9,C08-Calcium channel blockers,"/capita, US$ exchange rate",2.7
+28741,Portugal,2016,9,R03-Drugs for obstructive airway diseases,Million US$ at exchange rate,144.6
+28742,Portugal,2016,9,R03-Drugs for obstructive airway diseases,Million of national currency units,130.7
+28743,Portugal,2016,9,G-Genito urinary system and sex hormones,Million US$ at exchange rate,174.3
+28744,Portugal,2016,9,G-Genito urinary system and sex hormones,Million of national currency units,157.5
+28745,Portugal,2016,9,C10-Lipid modifying agents,"/capita, US$ purchasing power parity",28.2
+28746,Portugal,2016,9,C10-Lipid modifying agents,% of total sales,6.6
+28747,Portugal,2016,9,C10-Lipid modifying agents,"Million US$, purchasing power parity",291.0
+28748,Portugal,2016,9,C10-Lipid modifying agents,"/capita, US$ exchange rate",17.8
+28749,Portugal,2016,9,N06A-Antidepressants,"/capita, US$ purchasing power parity",15.9
+28750,Portugal,2016,9,C10-Lipid modifying agents,Million of national currency units,166.3
+28751,Portugal,2016,9,C10-Lipid modifying agents,Million US$ at exchange rate,184.0
+28752,Portugal,2016,9,N06A-Antidepressants,% of total sales,3.7
+28753,Portugal,2016,9,R03-Drugs for obstructive airway diseases,"/capita, US$ exchange rate",14.0
+28754,Portugal,2016,9,R03-Drugs for obstructive airway diseases,"Million US$, purchasing power parity",228.7
+28755,Portugal,2016,9,R03-Drugs for obstructive airway diseases,% of total sales,5.2
+28756,Portugal,2016,9,R03-Drugs for obstructive airway diseases,"/capita, US$ purchasing power parity",22.1
+28757,Portugal,2016,9,N02-Analgesics,% of total sales,4.7
+28758,Portugal,2016,9,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ purchasing power parity",11.0
+28759,Portugal,2016,9,J01-Antibacterials for systemic use,Million of national currency units,63.4
+28760,Portugal,2016,9,N02-Analgesics,"/capita, US$ purchasing power parity",20.2
+28761,Portugal,2016,9,N-Nervous system,"Million US$, purchasing power parity",887.0
+28762,Portugal,2016,9,N02-Analgesics,"/capita, US$ exchange rate",12.8
+28763,Portugal,2016,9,N05B-Anxiolytics,Million US$ at exchange rate,58.2
+28764,Portugal,2016,9,M01A-Antiinflammatory and antirheumatic products non-steroids,Million of national currency units,96.9
+28765,Portugal,2016,9,N05B-Anxiolytics,Million of national currency units,52.6
+28766,Portugal,2016,9,"H-Systemic hormonal preparations, excluding sex hormones and insulins",% of total sales,1.0
+28767,Portugal,2016,9,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ purchasing power parity",4.1
+28768,Portugal,2016,9,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),% of total sales,2.6
+28769,Portugal,2016,9,J-Antiinfectives for systemic use,Million of national currency units,118.1
+28770,Portugal,2016,9,A10-Drugs used in diabetes,% of total sales,11.0
+28771,Portugal,2016,9,A10-Drugs used in diabetes,"/capita, US$ exchange rate",29.9
+28772,Portugal,2016,9,A10-Drugs used in diabetes,"/capita, US$ purchasing power parity",47.3
+28773,Portugal,2016,9,N-Nervous system,Million of national currency units,506.8
+28774,Portugal,2016,9,N-Nervous system,Million US$ at exchange rate,561.0
+28775,Portugal,2016,9,N02-Analgesics,Million of national currency units,119.1
+28776,Portugal,2016,9,N02-Analgesics,"Million US$, purchasing power parity",208.5
+28777,Portugal,2016,9,N02-Analgesics,Million US$ at exchange rate,131.9
+28778,Portugal,2016,9,N-Nervous system,"/capita, US$ exchange rate",54.3
+28779,Portugal,2016,9,N-Nervous system,"/capita, US$ purchasing power parity",85.9
+28780,Portugal,2016,9,J01-Antibacterials for systemic use,% of total sales,2.5
+28781,Portugal,2016,9,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"Million US$, purchasing power parity",113.4
+28782,Portugal,2016,9,N-Nervous system,% of total sales,20.0
+28783,Portugal,2016,9,M01A-Antiinflammatory and antirheumatic products non-steroids,% of total sales,3.8
+28784,Portugal,2016,9,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ purchasing power parity",16.4
+28785,Portugal,2016,9,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ exchange rate",10.4
+28786,Portugal,2016,9,M01A-Antiinflammatory and antirheumatic products non-steroids,Million US$ at exchange rate,107.2
+28787,Portugal,2016,9,M01A-Antiinflammatory and antirheumatic products non-steroids,"Million US$, purchasing power parity",169.5
+28788,Portugal,2016,9,N05B-Anxiolytics,% of total sales,2.1
+28789,Portugal,2016,9,J01-Antibacterials for systemic use,Million US$ at exchange rate,70.2
+28790,Portugal,2016,9,N05B-Anxiolytics,"/capita, US$ purchasing power parity",8.9
+28791,Portugal,2016,9,N05B-Anxiolytics,"Million US$, purchasing power parity",92.0
+28792,Portugal,2016,9,N05B-Anxiolytics,"/capita, US$ exchange rate",5.6
+28793,Portugal,2016,9,J01-Antibacterials for systemic use,"/capita, US$ purchasing power parity",10.7
+28794,Portugal,2016,9,G03-Sex hormones and modulators of the genital system,"/capita, US$ purchasing power parity",10.3
+28795,Portugal,2016,9,G03-Sex hormones and modulators of the genital system,% of total sales,2.4
+28796,Portugal,2016,9,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ exchange rate",6.9
+28797,Portugal,2016,9,J01-Antibacterials for systemic use,"Million US$, purchasing power parity",110.9
+28798,Portugal,2016,9,J01-Antibacterials for systemic use,"/capita, US$ exchange rate",6.8
+28799,Portugal,2016,9,M-Musculo-skeletal system,Million of national currency units,167.0
+28800,Portugal,2016,9,N05C-Hypnotics and sedatives,% of total sales,0.8
+28801,Portugal,2016,9,A10-Drugs used in diabetes,Million US$ at exchange rate,309.1
+28802,Portugal,2016,9,J-Antiinfectives for systemic use,Million US$ at exchange rate,130.7
+28803,Portugal,2016,9,N05C-Hypnotics and sedatives,Million US$ at exchange rate,22.0
+28804,Portugal,2016,9,M-Musculo-skeletal system,Million US$ at exchange rate,184.8
+28805,Portugal,2016,9,N05C-Hypnotics and sedatives,"Million US$, purchasing power parity",34.7
+28806,Portugal,2016,9,N05C-Hypnotics and sedatives,"/capita, US$ purchasing power parity",3.4
+28807,Portugal,2016,9,N05C-Hypnotics and sedatives,"/capita, US$ exchange rate",2.1
+28808,Portugal,2016,9,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ exchange rate",2.6
+28809,Portugal,2016,9,A10-Drugs used in diabetes,"Million US$, purchasing power parity",488.7
+28810,Portugal,2016,9,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million US$ at exchange rate,71.7
+28811,Portugal,2016,9,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million of national currency units,64.8
+28812,Portugal,2016,9,"H-Systemic hormonal preparations, excluding sex hormones and insulins","Million US$, purchasing power parity",42.8
+28813,Portugal,2016,9,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million of national currency units,24.5
+28814,Portugal,2016,9,J-Antiinfectives for systemic use,"Million US$, purchasing power parity",206.6
+28815,Portugal,2016,9,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million US$ at exchange rate,27.1
+28816,Portugal,2016,9,M-Musculo-skeletal system,"/capita, US$ purchasing power parity",28.3
+28817,Portugal,2016,9,J-Antiinfectives for systemic use,"/capita, US$ exchange rate",12.7
+28818,Portugal,2016,9,M-Musculo-skeletal system,"/capita, US$ exchange rate",17.9
+28819,Portugal,2016,9,A10-Drugs used in diabetes,Million of national currency units,279.2
+28820,Portugal,2016,9,J-Antiinfectives for systemic use,% of total sales,4.7
+28821,Portugal,2016,9,M-Musculo-skeletal system,% of total sales,6.6
+28822,Portugal,2016,9,J-Antiinfectives for systemic use,"/capita, US$ purchasing power parity",20.0
+28823,Portugal,2016,9,G03-Sex hormones and modulators of the genital system,"/capita, US$ exchange rate",6.5
+28824,Portugal,2016,9,G03-Sex hormones and modulators of the genital system,Million US$ at exchange rate,67.5
+28825,Portugal,2016,9,M-Musculo-skeletal system,"Million US$, purchasing power parity",292.2
+28826,Portugal,2016,9,N05C-Hypnotics and sedatives,Million of national currency units,19.8
+28827,Portugal,2016,9,G03-Sex hormones and modulators of the genital system,Million of national currency units,61.0
+28828,Portugal,2016,9,G03-Sex hormones and modulators of the genital system,"Million US$, purchasing power parity",106.8
+28829,Portugal,2010,9,C01A-Cardiac glycosides,"Million US$, purchasing power parity",1.6
+28830,Portugal,2010,9,C01A-Cardiac glycosides,Million of national currency units,1.0
+28831,Portugal,2010,9,C01A-Cardiac glycosides,Million US$ at exchange rate,1.3
+28832,Portugal,2010,9,C02-Antihypertensives,"Million US$, purchasing power parity",7.2
+28833,Portugal,2010,9,R-Respiratory system,% of total sales,6.6
+28834,Portugal,2010,9,C02-Antihypertensives,% of total sales,0.1
+28835,Portugal,2010,9,C02-Antihypertensives,"/capita, US$ exchange rate",0.6
+28836,Portugal,2010,9,C02-Antihypertensives,"/capita, US$ purchasing power parity",0.7
+28837,Portugal,2010,9,G-Genito urinary system and sex hormones,"/capita, US$ purchasing power parity",27.3
+28838,Portugal,2010,9,G-Genito urinary system and sex hormones,% of total sales,5.6
+28839,Portugal,2010,9,G-Genito urinary system and sex hormones,"/capita, US$ exchange rate",22.6
+28840,Portugal,2010,9,G-Genito urinary system and sex hormones,"Million US$, purchasing power parity",289.1
+28841,Portugal,2010,9,C01A-Cardiac glycosides,% of total sales,0.0
+28842,Portugal,2010,9,A02A-Antacids,% of total sales,0.2
+28843,Portugal,2010,9,C01A-Cardiac glycosides,"/capita, US$ exchange rate",0.1
+28844,Portugal,2010,9,C01A-Cardiac glycosides,"/capita, US$ purchasing power parity",0.2
+28845,Portugal,2010,9,B-Blood and blood forming organs,"Million US$, purchasing power parity",193.4
+28846,Portugal,2010,9,B-Blood and blood forming organs,"/capita, US$ purchasing power parity",18.3
+28847,Portugal,2010,9,B-Blood and blood forming organs,% of total sales,3.7
+28848,Portugal,2010,9,B-Blood and blood forming organs,"/capita, US$ exchange rate",15.1
+28849,Portugal,2010,9,R-Respiratory system,"/capita, US$ purchasing power parity",32.6
+28850,Portugal,2010,9,Products not elsewhere classified,"/capita, US$ exchange rate",0.0
+28851,Portugal,2010,9,C07-Beta blocking agents,"/capita, US$ exchange rate",4.3
+28852,Portugal,2010,9,C07-Beta blocking agents,% of total sales,1.1
+28853,Portugal,2010,9,C07-Beta blocking agents,"/capita, US$ purchasing power parity",5.2
+28854,Portugal,2010,9,C02-Antihypertensives,Million of national currency units,4.5
+28855,Portugal,2010,9,C07-Beta blocking agents,"Million US$, purchasing power parity",55.2
+28856,Portugal,2010,9,Products not elsewhere classified,% of total sales,0.0
+28857,Portugal,2010,9,Products not elsewhere classified,"/capita, US$ purchasing power parity",0.0
+28858,Portugal,2010,9,A-Alimentary tract and metabolism,Million of national currency units,511.4
+28859,Portugal,2010,9,A-Alimentary tract and metabolism,Million US$ at exchange rate,677.9
+28860,Portugal,2010,9,A-Alimentary tract and metabolism,"Million US$, purchasing power parity",820.6
+28861,Portugal,2010,9,C02-Antihypertensives,Million US$ at exchange rate,6.0
+28862,Portugal,2010,9,B-Blood and blood forming organs,Million of national currency units,120.5
+28863,Portugal,2010,9,R-Respiratory system,Million US$ at exchange rate,284.6
+28864,Portugal,2010,9,B-Blood and blood forming organs,Million US$ at exchange rate,159.8
+28865,Portugal,2010,9,C07-Beta blocking agents,Million of national currency units,34.4
+28866,Portugal,2010,9,R-Respiratory system,Million of national currency units,214.6
+28867,Portugal,2010,9,R-Respiratory system,"/capita, US$ exchange rate",26.9
+28868,Portugal,2010,9,R-Respiratory system,"Million US$, purchasing power parity",344.5
+28869,Portugal,2010,9,Products not elsewhere classified,Million of national currency units,0.0
+28870,Portugal,2010,9,A-Alimentary tract and metabolism,"/capita, US$ exchange rate",64.1
+28871,Portugal,2010,9,Products not elsewhere classified,"Million US$, purchasing power parity",0.0
+28872,Portugal,2010,9,Products not elsewhere classified,Million US$ at exchange rate,0.0
+28873,Portugal,2010,9,A02A-Antacids,"/capita, US$ purchasing power parity",1.0
+28874,Portugal,2010,9,C07-Beta blocking agents,Million US$ at exchange rate,45.6
+28875,Portugal,2010,9,A-Alimentary tract and metabolism,"/capita, US$ purchasing power parity",77.6
+28876,Portugal,2010,9,A-Alimentary tract and metabolism,% of total sales,15.8
+28877,Portugal,2010,9,C-Cardiovascular system,"Million US$, purchasing power parity",1431.7
+28878,Portugal,2010,9,Total pharmaceutical sales,"/capita, US$ exchange rate",406.0
+28879,Portugal,2010,9,Total pharmaceutical sales,"/capita, US$ purchasing power parity",491.4
+28880,Portugal,2010,9,C-Cardiovascular system,"/capita, US$ exchange rate",111.9
+28881,Portugal,2010,9,C-Cardiovascular system,% of total sales,27.6
+28882,Portugal,2010,9,C-Cardiovascular system,"/capita, US$ purchasing power parity",135.4
+28883,Portugal,2010,9,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ purchasing power parity",60.4
+28884,Portugal,2010,9,C-Cardiovascular system,Million of national currency units,892.1
+28885,Portugal,2010,9,C09-Agents acting on the Renin-Angiotensin system,% of total sales,12.3
+28886,Portugal,2010,9,Total pharmaceutical sales,Million US$ at exchange rate,4292.5
+28887,Portugal,2010,9,Total pharmaceutical sales,"Million US$, purchasing power parity",5195.9
+28888,Portugal,2010,9,C-Cardiovascular system,Million US$ at exchange rate,1182.7
+28889,Portugal,2010,9,Total pharmaceutical sales,Million of national currency units,3237.9
+28890,Portugal,2010,9,"C01B-Antiarrhythmics, Class I and III","/capita, US$ exchange rate",0.6
+28891,Portugal,2010,9,"C01B-Antiarrhythmics, Class I and III",Million US$ at exchange rate,6.4
+28892,Portugal,2010,9,"C01B-Antiarrhythmics, Class I and III","Million US$, purchasing power parity",7.7
+28893,Portugal,2010,9,"C01B-Antiarrhythmics, Class I and III",% of total sales,0.1
+28894,Portugal,2010,9,C09-Agents acting on the Renin-Angiotensin system,Million US$ at exchange rate,527.3
+28895,Portugal,2010,9,C09-Agents acting on the Renin-Angiotensin system,Million of national currency units,397.7
+28896,Portugal,2010,9,"C01B-Antiarrhythmics, Class I and III","/capita, US$ purchasing power parity",0.7
+28897,Portugal,2010,9,C03-Diuretics,"/capita, US$ exchange rate",3.6
+28898,Portugal,2010,9,C03-Diuretics,"Million US$, purchasing power parity",46.3
+28899,Portugal,2010,9,C03-Diuretics,% of total sales,0.9
+28900,Portugal,2010,9,C03-Diuretics,"/capita, US$ purchasing power parity",4.4
+28901,Portugal,2010,9,C09-Agents acting on the Renin-Angiotensin system,"Million US$, purchasing power parity",638.2
+28902,Portugal,2010,9,"C01B-Antiarrhythmics, Class I and III",Million of national currency units,4.8
+28903,Portugal,2010,9,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ exchange rate",49.9
+28904,Portugal,2010,9,C03-Diuretics,Million US$ at exchange rate,38.3
+28905,Portugal,2010,9,C03-Diuretics,Million of national currency units,28.9
+28906,Portugal,2010,9,A02A-Antacids,Million of national currency units,6.4
+28907,Portugal,2010,9,C10-Lipid modifying agents,Million of national currency units,256.5
+28908,Portugal,2010,9,N06A-Antidepressants,Million of national currency units,158.3
+28909,Portugal,2010,9,A02A-Antacids,"Million US$, purchasing power parity",10.2
+28910,Portugal,2010,9,A02A-Antacids,Million US$ at exchange rate,8.5
+28911,Portugal,2010,9,N06A-Antidepressants,"/capita, US$ exchange rate",19.9
+28912,Portugal,2010,9,N06A-Antidepressants,"/capita, US$ purchasing power parity",24.0
+28913,Portugal,2010,9,N06A-Antidepressants,Million US$ at exchange rate,209.9
+28914,Portugal,2010,9,N06A-Antidepressants,"Million US$, purchasing power parity",254.1
+28915,Portugal,2010,9,C08-Calcium channel blockers,Million US$ at exchange rate,72.1
+28916,Portugal,2010,9,C08-Calcium channel blockers,"Million US$, purchasing power parity",87.2
+28917,Portugal,2010,9,A02A-Antacids,"/capita, US$ exchange rate",0.8
+28918,Portugal,2010,9,C08-Calcium channel blockers,Million of national currency units,54.4
+28919,Portugal,2010,9,C08-Calcium channel blockers,% of total sales,1.7
+28920,Portugal,2010,9,C08-Calcium channel blockers,"/capita, US$ exchange rate",6.8
+28921,Portugal,2010,9,C08-Calcium channel blockers,"/capita, US$ purchasing power parity",8.3
+28922,Portugal,2010,9,G-Genito urinary system and sex hormones,Million of national currency units,180.2
+28923,Portugal,2010,9,R03-Drugs for obstructive airway diseases,Million US$ at exchange rate,174.3
+28924,Portugal,2010,9,R03-Drugs for obstructive airway diseases,"Million US$, purchasing power parity",211.0
+28925,Portugal,2010,9,G-Genito urinary system and sex hormones,Million US$ at exchange rate,238.8
+28926,Portugal,2010,9,C10-Lipid modifying agents,"/capita, US$ purchasing power parity",38.9
+28927,Portugal,2010,9,C10-Lipid modifying agents,% of total sales,7.9
+28928,Portugal,2010,9,R03-Drugs for obstructive airway diseases,Million of national currency units,131.5
+28929,Portugal,2010,9,C10-Lipid modifying agents,"/capita, US$ exchange rate",32.2
+28930,Portugal,2010,9,C10-Lipid modifying agents,Million US$ at exchange rate,340.1
+28931,Portugal,2010,9,C10-Lipid modifying agents,"Million US$, purchasing power parity",411.6
+28932,Portugal,2010,9,N06A-Antidepressants,% of total sales,4.9
+28933,Portugal,2010,9,R03-Drugs for obstructive airway diseases,"/capita, US$ exchange rate",16.5
+28934,Portugal,2010,9,R03-Drugs for obstructive airway diseases,"/capita, US$ purchasing power parity",20.0
+28935,Portugal,2010,9,R03-Drugs for obstructive airway diseases,% of total sales,4.1
+28936,Portugal,2010,9,N02-Analgesics,% of total sales,3.4
+28937,Portugal,2010,9,J01-Antibacterials for systemic use,Million of national currency units,102.5
+28938,Portugal,2010,9,N-Nervous system,"/capita, US$ exchange rate",87.8
+28939,Portugal,2010,9,N02-Analgesics,"/capita, US$ exchange rate",13.8
+28940,Portugal,2010,9,N02-Analgesics,"/capita, US$ purchasing power parity",16.7
+28941,Portugal,2010,9,N05B-Anxiolytics,Million US$ at exchange rate,81.2
+28942,Portugal,2010,9,N05B-Anxiolytics,"Million US$, purchasing power parity",98.3
+28943,Portugal,2010,9,M01A-Antiinflammatory and antirheumatic products non-steroids,Million of national currency units,127.9
+28944,Portugal,2010,9,J01-Antibacterials for systemic use,Million US$ at exchange rate,135.8
+28945,Portugal,2010,9,"H-Systemic hormonal preparations, excluding sex hormones and insulins",% of total sales,0.7
+28946,Portugal,2010,9,N05B-Anxiolytics,Million of national currency units,61.2
+28947,Portugal,2010,9,N-Nervous system,"Million US$, purchasing power parity",1124.0
+28948,Portugal,2010,9,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),% of total sales,5.8
+28949,Portugal,2010,9,A10-Drugs used in diabetes,"/capita, US$ purchasing power parity",31.7
+28950,Portugal,2010,9,A10-Drugs used in diabetes,% of total sales,6.4
+28951,Portugal,2010,9,J-Antiinfectives for systemic use,Million of national currency units,182.1
+28952,Portugal,2010,9,N02-Analgesics,Million of national currency units,110.3
+28953,Portugal,2010,9,N-Nervous system,Million of national currency units,700.4
+28954,Portugal,2010,9,N-Nervous system,Million US$ at exchange rate,928.6
+28955,Portugal,2010,9,N02-Analgesics,Million US$ at exchange rate,146.2
+28956,Portugal,2010,9,N02-Analgesics,"Million US$, purchasing power parity",176.9
+28957,Portugal,2010,9,M-Musculo-skeletal system,Million of national currency units,252.5
+28958,Portugal,2010,9,N-Nervous system,"/capita, US$ purchasing power parity",106.3
+28959,Portugal,2010,9,N-Nervous system,% of total sales,21.6
+28960,Portugal,2010,9,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"Million US$, purchasing power parity",299.3
+28961,Portugal,2010,9,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ exchange rate",23.4
+28962,Portugal,2010,9,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ purchasing power parity",19.4
+28963,Portugal,2010,9,M01A-Antiinflammatory and antirheumatic products non-steroids,% of total sales,3.9
+28964,Portugal,2010,9,M01A-Antiinflammatory and antirheumatic products non-steroids,"Million US$, purchasing power parity",205.2
+28965,Portugal,2010,9,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ exchange rate",16.0
+28966,Portugal,2010,9,N05B-Anxiolytics,% of total sales,1.9
+28967,Portugal,2010,9,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ purchasing power parity",28.3
+28968,Portugal,2010,9,N05B-Anxiolytics,"/capita, US$ exchange rate",7.7
+28969,Portugal,2010,9,N05B-Anxiolytics,"/capita, US$ purchasing power parity",9.3
+28970,Portugal,2010,9,J01-Antibacterials for systemic use,% of total sales,3.2
+28971,Portugal,2010,9,G03-Sex hormones and modulators of the genital system,% of total sales,2.5
+28972,Portugal,2010,9,M01A-Antiinflammatory and antirheumatic products non-steroids,Million US$ at exchange rate,169.5
+28973,Portugal,2010,9,J01-Antibacterials for systemic use,"Million US$, purchasing power parity",164.4
+28974,Portugal,2010,9,J01-Antibacterials for systemic use,"/capita, US$ purchasing power parity",15.6
+28975,Portugal,2010,9,J01-Antibacterials for systemic use,"/capita, US$ exchange rate",12.8
+28976,Portugal,2010,9,M-Musculo-skeletal system,Million US$ at exchange rate,334.8
+28977,Portugal,2010,9,N05C-Hypnotics and sedatives,% of total sales,0.6
+28978,Portugal,2010,9,J-Antiinfectives for systemic use,"Million US$, purchasing power parity",292.3
+28979,Portugal,2010,9,J-Antiinfectives for systemic use,Million US$ at exchange rate,241.5
+28980,Portugal,2010,9,N05C-Hypnotics and sedatives,"Million US$, purchasing power parity",29.6
+28981,Portugal,2010,9,N05C-Hypnotics and sedatives,Million US$ at exchange rate,24.4
+28982,Portugal,2010,9,N05C-Hypnotics and sedatives,"/capita, US$ purchasing power parity",2.8
+28983,Portugal,2010,9,N05C-Hypnotics and sedatives,"/capita, US$ exchange rate",2.3
+28984,Portugal,2010,9,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ exchange rate",3.0
+28985,Portugal,2010,9,A10-Drugs used in diabetes,"/capita, US$ exchange rate",26.2
+28986,Portugal,2010,9,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ purchasing power parity",3.6
+28987,Portugal,2010,9,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million US$ at exchange rate,247.2
+28988,Portugal,2010,9,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million of national currency units,186.5
+28989,Portugal,2010,9,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million of national currency units,24.0
+28990,Portugal,2010,9,J-Antiinfectives for systemic use,"/capita, US$ exchange rate",22.8
+28991,Portugal,2010,9,"H-Systemic hormonal preparations, excluding sex hormones and insulins","Million US$, purchasing power parity",38.5
+28992,Portugal,2010,9,A10-Drugs used in diabetes,"Million US$, purchasing power parity",334.7
+28993,Portugal,2010,9,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million US$ at exchange rate,31.8
+28994,Portugal,2010,9,M-Musculo-skeletal system,"/capita, US$ purchasing power parity",38.3
+28995,Portugal,2010,9,J-Antiinfectives for systemic use,"/capita, US$ purchasing power parity",27.6
+28996,Portugal,2010,9,A10-Drugs used in diabetes,Million US$ at exchange rate,276.5
+28997,Portugal,2010,9,M-Musculo-skeletal system,"Million US$, purchasing power parity",405.2
+28998,Portugal,2010,9,A10-Drugs used in diabetes,Million of national currency units,208.6
+28999,Portugal,2010,9,M-Musculo-skeletal system,% of total sales,7.8
+29000,Portugal,2010,9,J-Antiinfectives for systemic use,% of total sales,5.6
+29001,Portugal,2010,9,G03-Sex hormones and modulators of the genital system,"/capita, US$ purchasing power parity",12.4
+29002,Portugal,2010,9,G03-Sex hormones and modulators of the genital system,Million US$ at exchange rate,108.0
+29003,Portugal,2010,9,M-Musculo-skeletal system,"/capita, US$ exchange rate",31.7
+29004,Portugal,2010,9,N05C-Hypnotics and sedatives,Million of national currency units,18.4
+29005,Portugal,2010,9,G03-Sex hormones and modulators of the genital system,Million of national currency units,81.5
+29006,Portugal,2010,9,G03-Sex hormones and modulators of the genital system,"/capita, US$ exchange rate",10.2
+29007,Portugal,2010,9,G03-Sex hormones and modulators of the genital system,"Million US$, purchasing power parity",130.7
+29008,Portugal,2014,8,C01A-Cardiac glycosides,"Million US$, purchasing power parity",1.6
+29009,Portugal,2014,8,C01A-Cardiac glycosides,Million US$ at exchange rate,1.2
+29010,Portugal,2014,8,C01A-Cardiac glycosides,Million of national currency units,0.9
+29011,Portugal,2014,8,C02-Antihypertensives,Million US$ at exchange rate,4.8
+29012,Portugal,2014,8,C02-Antihypertensives,"Million US$, purchasing power parity",6.3
+29013,Portugal,2014,8,R-Respiratory system,"/capita, US$ purchasing power parity",31.9
+29014,Portugal,2014,8,R-Respiratory system,% of total sales,8.0
+29015,Portugal,2014,8,C02-Antihypertensives,"/capita, US$ purchasing power parity",0.6
+29016,Portugal,2014,8,C02-Antihypertensives,% of total sales,0.2
+29017,Portugal,2014,8,C02-Antihypertensives,"/capita, US$ exchange rate",0.5
+29018,Portugal,2014,8,G-Genito urinary system and sex hormones,"/capita, US$ purchasing power parity",25.1
+29019,Portugal,2014,8,G-Genito urinary system and sex hormones,"/capita, US$ exchange rate",19.3
+29020,Portugal,2014,8,G-Genito urinary system and sex hormones,% of total sales,6.3
+29021,Portugal,2014,8,A02A-Antacids,"/capita, US$ purchasing power parity",0.8
+29022,Portugal,2014,8,C01A-Cardiac glycosides,% of total sales,0.0
+29023,Portugal,2014,8,G-Genito urinary system and sex hormones,"Million US$, purchasing power parity",261.1
+29024,Portugal,2014,8,B-Blood and blood forming organs,% of total sales,4.6
+29025,Portugal,2014,8,C01A-Cardiac glycosides,"/capita, US$ purchasing power parity",0.2
+29026,Portugal,2014,8,A02A-Antacids,% of total sales,0.2
+29027,Portugal,2014,8,C01A-Cardiac glycosides,"/capita, US$ exchange rate",0.1
+29028,Portugal,2014,8,B-Blood and blood forming organs,"/capita, US$ purchasing power parity",18.4
+29029,Portugal,2014,8,B-Blood and blood forming organs,"Million US$, purchasing power parity",191.7
+29030,Portugal,2014,8,B-Blood and blood forming organs,"/capita, US$ exchange rate",14.2
+29031,Portugal,2014,8,C07-Beta blocking agents,"/capita, US$ exchange rate",3.9
+29032,Portugal,2014,8,Products not elsewhere classified,"/capita, US$ exchange rate",0.0
+29033,Portugal,2014,8,C07-Beta blocking agents,"/capita, US$ purchasing power parity",5.1
+29034,Portugal,2014,8,Products not elsewhere classified,"Million US$, purchasing power parity",0.0
+29035,Portugal,2014,8,C02-Antihypertensives,Million of national currency units,3.6
+29036,Portugal,2014,8,C07-Beta blocking agents,"Million US$, purchasing power parity",52.5
+29037,Portugal,2014,8,C07-Beta blocking agents,% of total sales,1.3
+29038,Portugal,2014,8,Products not elsewhere classified,% of total sales,0.0
+29039,Portugal,2014,8,Products not elsewhere classified,"/capita, US$ purchasing power parity",0.0
+29040,Portugal,2014,8,A-Alimentary tract and metabolism,Million of national currency units,404.8
+29041,Portugal,2014,8,A-Alimentary tract and metabolism,"Million US$, purchasing power parity",699.3
+29042,Portugal,2014,8,A-Alimentary tract and metabolism,Million US$ at exchange rate,537.8
+29043,Portugal,2014,8,R-Respiratory system,Million US$ at exchange rate,255.4
+29044,Portugal,2014,8,B-Blood and blood forming organs,Million of national currency units,110.9
+29045,Portugal,2014,8,C07-Beta blocking agents,Million of national currency units,30.4
+29046,Portugal,2014,8,R-Respiratory system,Million of national currency units,192.3
+29047,Portugal,2014,8,R-Respiratory system,"/capita, US$ exchange rate",24.6
+29048,Portugal,2014,8,R-Respiratory system,"Million US$, purchasing power parity",332.1
+29049,Portugal,2014,8,B-Blood and blood forming organs,Million US$ at exchange rate,147.4
+29050,Portugal,2014,8,Products not elsewhere classified,Million of national currency units,0.0
+29051,Portugal,2014,8,A-Alimentary tract and metabolism,"/capita, US$ exchange rate",51.7
+29052,Portugal,2014,8,Products not elsewhere classified,Million US$ at exchange rate,0.0
+29053,Portugal,2014,8,C07-Beta blocking agents,Million US$ at exchange rate,40.4
+29054,Portugal,2014,8,A-Alimentary tract and metabolism,% of total sales,16.9
+29055,Portugal,2014,8,A-Alimentary tract and metabolism,"/capita, US$ purchasing power parity",67.2
+29056,Portugal,2014,8,C-Cardiovascular system,"Million US$, purchasing power parity",981.9
+29057,Portugal,2014,8,Total pharmaceutical sales,"/capita, US$ purchasing power parity",398.2
+29058,Portugal,2014,8,Total pharmaceutical sales,"/capita, US$ exchange rate",306.2
+29059,Portugal,2014,8,C-Cardiovascular system,% of total sales,23.7
+29060,Portugal,2014,8,C-Cardiovascular system,"/capita, US$ exchange rate",72.6
+29061,Portugal,2014,8,C-Cardiovascular system,"/capita, US$ purchasing power parity",94.4
+29062,Portugal,2014,8,Total pharmaceutical sales,"Million US$, purchasing power parity",4141.9
+29063,Portugal,2014,8,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ purchasing power parity",41.5
+29064,Portugal,2014,8,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ exchange rate",31.9
+29065,Portugal,2014,8,C-Cardiovascular system,Million of national currency units,568.4
+29066,Portugal,2014,8,C09-Agents acting on the Renin-Angiotensin system,% of total sales,10.4
+29067,Portugal,2014,8,Total pharmaceutical sales,Million US$ at exchange rate,3185.2
+29068,Portugal,2014,8,C-Cardiovascular system,Million US$ at exchange rate,755.1
+29069,Portugal,2014,8,Total pharmaceutical sales,Million of national currency units,2397.6
+29070,Portugal,2014,8,C03-Diuretics,% of total sales,0.9
+29071,Portugal,2014,8,"C01B-Antiarrhythmics, Class I and III","Million US$, purchasing power parity",6.5
+29072,Portugal,2014,8,"C01B-Antiarrhythmics, Class I and III","/capita, US$ exchange rate",0.5
+29073,Portugal,2014,8,"C01B-Antiarrhythmics, Class I and III",Million US$ at exchange rate,5.0
+29074,Portugal,2014,8,"C01B-Antiarrhythmics, Class I and III",% of total sales,0.2
+29075,Portugal,2014,8,"C01B-Antiarrhythmics, Class I and III","/capita, US$ purchasing power parity",0.6
+29076,Portugal,2014,8,C09-Agents acting on the Renin-Angiotensin system,Million US$ at exchange rate,332.1
+29077,Portugal,2014,8,C09-Agents acting on the Renin-Angiotensin system,Million of national currency units,250.0
+29078,Portugal,2014,8,C03-Diuretics,"/capita, US$ exchange rate",2.9
+29079,Portugal,2014,8,C03-Diuretics,"Million US$, purchasing power parity",38.8
+29080,Portugal,2014,8,C03-Diuretics,"/capita, US$ purchasing power parity",3.7
+29081,Portugal,2014,8,"C01B-Antiarrhythmics, Class I and III",Million of national currency units,3.7
+29082,Portugal,2014,8,C09-Agents acting on the Renin-Angiotensin system,"Million US$, purchasing power parity",431.9
+29083,Portugal,2014,8,C03-Diuretics,Million US$ at exchange rate,29.8
+29084,Portugal,2014,8,C03-Diuretics,Million of national currency units,22.5
+29085,Portugal,2014,8,A02A-Antacids,Million of national currency units,4.7
+29086,Portugal,2014,8,N06A-Antidepressants,Million of national currency units,95.4
+29087,Portugal,2014,8,C10-Lipid modifying agents,Million of national currency units,157.8
+29088,Portugal,2014,8,A02A-Antacids,Million US$ at exchange rate,6.2
+29089,Portugal,2014,8,A02A-Antacids,"Million US$, purchasing power parity",8.1
+29090,Portugal,2014,8,N06A-Antidepressants,"/capita, US$ exchange rate",12.2
+29091,Portugal,2014,8,N06A-Antidepressants,Million US$ at exchange rate,126.7
+29092,Portugal,2014,8,N06A-Antidepressants,"Million US$, purchasing power parity",164.8
+29093,Portugal,2014,8,N06A-Antidepressants,"/capita, US$ purchasing power parity",15.8
+29094,Portugal,2014,8,C08-Calcium channel blockers,Million US$ at exchange rate,35.8
+29095,Portugal,2014,8,A02A-Antacids,"/capita, US$ exchange rate",0.6
+29096,Portugal,2014,8,C08-Calcium channel blockers,Million of national currency units,27.0
+29097,Portugal,2014,8,C08-Calcium channel blockers,"Million US$, purchasing power parity",46.6
+29098,Portugal,2014,8,C08-Calcium channel blockers,"/capita, US$ purchasing power parity",4.5
+29099,Portugal,2014,8,C08-Calcium channel blockers,% of total sales,1.1
+29100,Portugal,2014,8,C08-Calcium channel blockers,"/capita, US$ exchange rate",3.4
+29101,Portugal,2014,8,R03-Drugs for obstructive airway diseases,Million US$ at exchange rate,155.6
+29102,Portugal,2014,8,C10-Lipid modifying agents,"Million US$, purchasing power parity",272.7
+29103,Portugal,2014,8,G-Genito urinary system and sex hormones,Million US$ at exchange rate,200.8
+29104,Portugal,2014,8,G-Genito urinary system and sex hormones,Million of national currency units,151.1
+29105,Portugal,2014,8,C10-Lipid modifying agents,"/capita, US$ purchasing power parity",26.2
+29106,Portugal,2014,8,C10-Lipid modifying agents,% of total sales,6.6
+29107,Portugal,2014,8,R03-Drugs for obstructive airway diseases,Million of national currency units,117.1
+29108,Portugal,2014,8,C10-Lipid modifying agents,"/capita, US$ exchange rate",20.2
+29109,Portugal,2014,8,R03-Drugs for obstructive airway diseases,"Million US$, purchasing power parity",202.3
+29110,Portugal,2014,8,C10-Lipid modifying agents,Million US$ at exchange rate,209.7
+29111,Portugal,2014,8,N06A-Antidepressants,% of total sales,4.0
+29112,Portugal,2014,8,R03-Drugs for obstructive airway diseases,"/capita, US$ exchange rate",15.0
+29113,Portugal,2014,8,R03-Drugs for obstructive airway diseases,% of total sales,4.9
+29114,Portugal,2014,8,R03-Drugs for obstructive airway diseases,"/capita, US$ purchasing power parity",19.4
+29115,Portugal,2014,8,N02-Analgesics,% of total sales,5.1
+29116,Portugal,2014,8,J01-Antibacterials for systemic use,Million of national currency units,64.8
+29117,Portugal,2014,8,N-Nervous system,"Million US$, purchasing power parity",882.9
+29118,Portugal,2014,8,N02-Analgesics,"/capita, US$ purchasing power parity",20.2
+29119,Portugal,2014,8,N02-Analgesics,"/capita, US$ exchange rate",15.5
+29120,Portugal,2014,8,N05B-Anxiolytics,Million US$ at exchange rate,72.8
+29121,Portugal,2014,8,M01A-Antiinflammatory and antirheumatic products non-steroids,Million of national currency units,98.3
+29122,Portugal,2014,8,J01-Antibacterials for systemic use,Million US$ at exchange rate,86.1
+29123,Portugal,2014,8,"H-Systemic hormonal preparations, excluding sex hormones and insulins",% of total sales,0.9
+29124,Portugal,2014,8,N05B-Anxiolytics,Million of national currency units,54.8
+29125,Portugal,2014,8,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),% of total sales,2.6
+29126,Portugal,2014,8,J-Antiinfectives for systemic use,Million of national currency units,119.0
+29127,Portugal,2014,8,A10-Drugs used in diabetes,"/capita, US$ exchange rate",30.5
+29128,Portugal,2014,8,A10-Drugs used in diabetes,"/capita, US$ purchasing power parity",39.7
+29129,Portugal,2014,8,A10-Drugs used in diabetes,% of total sales,10.0
+29130,Portugal,2014,8,N-Nervous system,Million of national currency units,511.1
+29131,Portugal,2014,8,N-Nervous system,Million US$ at exchange rate,678.9
+29132,Portugal,2014,8,N02-Analgesics,Million of national currency units,121.6
+29133,Portugal,2014,8,N02-Analgesics,Million US$ at exchange rate,161.5
+29134,Portugal,2014,8,N02-Analgesics,"Million US$, purchasing power parity",210.0
+29135,Portugal,2014,8,N-Nervous system,"/capita, US$ exchange rate",65.3
+29136,Portugal,2014,8,N-Nervous system,"/capita, US$ purchasing power parity",84.9
+29137,Portugal,2014,8,N-Nervous system,% of total sales,21.3
+29138,Portugal,2014,8,J01-Antibacterials for systemic use,% of total sales,2.7
+29139,Portugal,2014,8,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ exchange rate",8.0
+29140,Portugal,2014,8,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"Million US$, purchasing power parity",108.4
+29141,Portugal,2014,8,M01A-Antiinflammatory and antirheumatic products non-steroids,% of total sales,4.1
+29142,Portugal,2014,8,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ purchasing power parity",16.3
+29143,Portugal,2014,8,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ exchange rate",12.6
+29144,Portugal,2014,8,M01A-Antiinflammatory and antirheumatic products non-steroids,Million US$ at exchange rate,130.6
+29145,Portugal,2014,8,M01A-Antiinflammatory and antirheumatic products non-steroids,"Million US$, purchasing power parity",169.9
+29146,Portugal,2014,8,N05B-Anxiolytics,% of total sales,2.3
+29147,Portugal,2014,8,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ purchasing power parity",10.4
+29148,Portugal,2014,8,N05B-Anxiolytics,"/capita, US$ purchasing power parity",9.1
+29149,Portugal,2014,8,N05B-Anxiolytics,"Million US$, purchasing power parity",94.6
+29150,Portugal,2014,8,N05B-Anxiolytics,"/capita, US$ exchange rate",7.0
+29151,Portugal,2014,8,J01-Antibacterials for systemic use,"/capita, US$ purchasing power parity",10.8
+29152,Portugal,2014,8,G03-Sex hormones and modulators of the genital system,% of total sales,2.6
+29153,Portugal,2014,8,J01-Antibacterials for systemic use,"Million US$, purchasing power parity",112.0
+29154,Portugal,2014,8,J01-Antibacterials for systemic use,"/capita, US$ exchange rate",8.3
+29155,Portugal,2014,8,N05C-Hypnotics and sedatives,% of total sales,0.9
+29156,Portugal,2014,8,M-Musculo-skeletal system,Million of national currency units,172.5
+29157,Portugal,2014,8,A10-Drugs used in diabetes,Million US$ at exchange rate,317.3
+29158,Portugal,2014,8,J-Antiinfectives for systemic use,Million US$ at exchange rate,158.1
+29159,Portugal,2014,8,N05C-Hypnotics and sedatives,"Million US$, purchasing power parity",36.7
+29160,Portugal,2014,8,M-Musculo-skeletal system,Million US$ at exchange rate,229.1
+29161,Portugal,2014,8,N05C-Hypnotics and sedatives,Million US$ at exchange rate,28.3
+29162,Portugal,2014,8,N05C-Hypnotics and sedatives,"/capita, US$ purchasing power parity",3.5
+29163,Portugal,2014,8,N05C-Hypnotics and sedatives,"/capita, US$ exchange rate",2.7
+29164,Portugal,2014,8,J-Antiinfectives for systemic use,"Million US$, purchasing power parity",205.6
+29165,Portugal,2014,8,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ exchange rate",2.7
+29166,Portugal,2014,8,A10-Drugs used in diabetes,"Million US$, purchasing power parity",412.6
+29167,Portugal,2014,8,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million US$ at exchange rate,83.3
+29168,Portugal,2014,8,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million of national currency units,62.7
+29169,Portugal,2014,8,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ purchasing power parity",3.6
+29170,Portugal,2014,8,"H-Systemic hormonal preparations, excluding sex hormones and insulins","Million US$, purchasing power parity",37.1
+29171,Portugal,2014,8,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million of national currency units,21.5
+29172,Portugal,2014,8,J-Antiinfectives for systemic use,"/capita, US$ exchange rate",15.2
+29173,Portugal,2014,8,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million US$ at exchange rate,28.6
+29174,Portugal,2014,8,M-Musculo-skeletal system,"/capita, US$ purchasing power parity",28.6
+29175,Portugal,2014,8,M-Musculo-skeletal system,"/capita, US$ exchange rate",22.0
+29176,Portugal,2014,8,J-Antiinfectives for systemic use,"/capita, US$ purchasing power parity",19.8
+29177,Portugal,2014,8,J-Antiinfectives for systemic use,% of total sales,5.0
+29178,Portugal,2014,8,M-Musculo-skeletal system,% of total sales,7.2
+29179,Portugal,2014,8,G03-Sex hormones and modulators of the genital system,"/capita, US$ purchasing power parity",10.5
+29180,Portugal,2014,8,G03-Sex hormones and modulators of the genital system,"/capita, US$ exchange rate",8.1
+29181,Portugal,2014,8,A10-Drugs used in diabetes,Million of national currency units,238.9
+29182,Portugal,2014,8,G03-Sex hormones and modulators of the genital system,Million US$ at exchange rate,84.1
+29183,Portugal,2014,8,M-Musculo-skeletal system,"Million US$, purchasing power parity",298.0
+29184,Portugal,2014,8,N05C-Hypnotics and sedatives,Million of national currency units,21.3
+29185,Portugal,2014,8,G03-Sex hormones and modulators of the genital system,Million of national currency units,63.3
+29186,Portugal,2014,8,G03-Sex hormones and modulators of the genital system,"Million US$, purchasing power parity",109.3
+29187,Slovenia,2016,7,R03-Drugs for obstructive airway diseases,"Million US$, purchasing power parity",38.5
+29188,Slovenia,2016,7,R03-Drugs for obstructive airway diseases,Million of national currency units,22.2
+29189,Slovenia,2016,7,R03-Drugs for obstructive airway diseases,Million US$ at exchange rate,24.6
+29190,Slovenia,2016,7,C02-Antihypertensives,"/capita, US$ purchasing power parity",2.7
+29191,Slovenia,2016,7,R03-Drugs for obstructive airway diseases,"/capita, US$ exchange rate",11.9
+29192,Slovenia,2016,7,C-Cardiovascular system,Million US$ at exchange rate,83.7
+29193,Slovenia,2016,7,R03-Drugs for obstructive airway diseases,"/capita, US$ purchasing power parity",18.6
+29194,Slovenia,2016,7,N02-Analgesics,"/capita, US$ purchasing power parity",15.6
+29195,Slovenia,2016,7,N02-Analgesics,% of total sales,4.0
+29196,Slovenia,2016,7,N02-Analgesics,"Million US$, purchasing power parity",32.2
+29197,Slovenia,2016,7,N02-Analgesics,"/capita, US$ exchange rate",10.0
+29198,Slovenia,2016,7,C02-Antihypertensives,"Million US$, purchasing power parity",5.5
+29199,Slovenia,2016,7,C08-Calcium channel blockers,% of total sales,1.3
+29200,Slovenia,2016,7,C-Cardiovascular system,"Million US$, purchasing power parity",130.9
+29201,Slovenia,2016,7,R03-Drugs for obstructive airway diseases,% of total sales,4.8
+29202,Slovenia,2016,7,C02-Antihypertensives,"/capita, US$ exchange rate",1.7
+29203,Slovenia,2016,7,R-Respiratory system,Million US$ at exchange rate,30.1
+29204,Slovenia,2016,7,C08-Calcium channel blockers,Million US$ at exchange rate,6.6
+29205,Slovenia,2016,7,R-Respiratory system,"/capita, US$ exchange rate",14.6
+29206,Slovenia,2016,7,R-Respiratory system,"Million US$, purchasing power parity",47.1
+29207,Slovenia,2016,7,R-Respiratory system,Million of national currency units,27.2
+29208,Slovenia,2016,7,C02-Antihypertensives,Million US$ at exchange rate,3.5
+29209,Slovenia,2016,7,C08-Calcium channel blockers,Million of national currency units,6.0
+29210,Slovenia,2016,7,C02-Antihypertensives,Million of national currency units,3.2
+29211,Slovenia,2016,7,C08-Calcium channel blockers,"/capita, US$ purchasing power parity",5.0
+29212,Slovenia,2016,7,C-Cardiovascular system,Million of national currency units,75.6
+29213,Slovenia,2016,7,J01-Antibacterials for systemic use,% of total sales,2.4
+29214,Slovenia,2016,7,R-Respiratory system,% of total sales,5.8
+29215,Slovenia,2016,7,R-Respiratory system,"/capita, US$ purchasing power parity",22.8
+29216,Slovenia,2016,7,C08-Calcium channel blockers,"/capita, US$ exchange rate",3.2
+29217,Slovenia,2016,7,C08-Calcium channel blockers,"Million US$, purchasing power parity",10.3
+29218,Slovenia,2016,7,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million of national currency units,10.8
+29219,Slovenia,2016,7,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million US$ at exchange rate,11.9
+29220,Slovenia,2016,7,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ purchasing power parity",9.0
+29221,Slovenia,2016,7,"H-Systemic hormonal preparations, excluding sex hormones and insulins",% of total sales,2.3
+29222,Slovenia,2016,7,B-Blood and blood forming organs,"/capita, US$ purchasing power parity",33.6
+29223,Slovenia,2016,7,B-Blood and blood forming organs,% of total sales,8.6
+29224,Slovenia,2016,7,B-Blood and blood forming organs,"Million US$, purchasing power parity",69.3
+29225,Slovenia,2016,7,B-Blood and blood forming organs,"/capita, US$ exchange rate",21.4
+29226,Slovenia,2016,7,J01-Antibacterials for systemic use,"Million US$, purchasing power parity",19.5
+29227,Slovenia,2016,7,J01-Antibacterials for systemic use,Million US$ at exchange rate,12.4
+29228,Slovenia,2016,7,J01-Antibacterials for systemic use,"/capita, US$ purchasing power parity",9.4
+29229,Slovenia,2016,7,J01-Antibacterials for systemic use,"/capita, US$ exchange rate",6.0
+29230,Slovenia,2016,7,B-Blood and blood forming organs,Million US$ at exchange rate,44.3
+29231,Slovenia,2016,7,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ exchange rate",5.8
+29232,Slovenia,2016,7,"H-Systemic hormonal preparations, excluding sex hormones and insulins","Million US$, purchasing power parity",18.7
+29233,Slovenia,2016,7,C09-Agents acting on the Renin-Angiotensin system,"Million US$, purchasing power parity",48.8
+29234,Slovenia,2016,7,C09-Agents acting on the Renin-Angiotensin system,Million US$ at exchange rate,31.2
+29235,Slovenia,2016,7,A-Alimentary tract and metabolism,% of total sales,12.0
+29236,Slovenia,2016,7,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ exchange rate",15.1
+29237,Slovenia,2016,7,N02-Analgesics,Million of national currency units,18.6
+29238,Slovenia,2016,7,N02-Analgesics,Million US$ at exchange rate,20.6
+29239,Slovenia,2016,7,C09-Agents acting on the Renin-Angiotensin system,Million of national currency units,28.2
+29240,Slovenia,2016,7,A-Alimentary tract and metabolism,"/capita, US$ purchasing power parity",47.1
+29241,Slovenia,2016,7,C-Cardiovascular system,"/capita, US$ exchange rate",40.5
+29242,Slovenia,2016,7,A-Alimentary tract and metabolism,Million of national currency units,56.1
+29243,Slovenia,2016,7,A-Alimentary tract and metabolism,Million US$ at exchange rate,62.1
+29244,Slovenia,2016,7,C09-Agents acting on the Renin-Angiotensin system,% of total sales,6.0
+29245,Slovenia,2016,7,J01-Antibacterials for systemic use,Million of national currency units,11.2
+29246,Slovenia,2016,7,A-Alimentary tract and metabolism,"/capita, US$ exchange rate",30.1
+29247,Slovenia,2016,7,A-Alimentary tract and metabolism,"Million US$, purchasing power parity",97.3
+29248,Slovenia,2016,7,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ purchasing power parity",23.6
+29249,Slovenia,2016,7,N05B-Anxiolytics,"/capita, US$ exchange rate",1.4
+29250,Slovenia,2016,7,N05B-Anxiolytics,"Million US$, purchasing power parity",4.7
+29251,Slovenia,2016,7,N05B-Anxiolytics,% of total sales,0.6
+29252,Slovenia,2016,7,N05B-Anxiolytics,"/capita, US$ purchasing power parity",2.3
+29253,Slovenia,2016,7,N06A-Antidepressants,Million of national currency units,11.2
+29254,Slovenia,2016,7,N06A-Antidepressants,Million US$ at exchange rate,12.4
+29255,Slovenia,2016,7,N05B-Anxiolytics,Million US$ at exchange rate,3.0
+29256,Slovenia,2016,7,N05B-Anxiolytics,Million of national currency units,2.7
+29257,Slovenia,2016,7,G03-Sex hormones and modulators of the genital system,Million of national currency units,7.5
+29258,Slovenia,2016,7,G03-Sex hormones and modulators of the genital system,Million US$ at exchange rate,8.3
+29259,Slovenia,2016,7,N-Nervous system,"/capita, US$ exchange rate",34.9
+29260,Slovenia,2016,7,N-Nervous system,"/capita, US$ purchasing power parity",54.7
+29261,Slovenia,2016,7,G03-Sex hormones and modulators of the genital system,"/capita, US$ purchasing power parity",6.3
+29262,Slovenia,2016,7,G03-Sex hormones and modulators of the genital system,% of total sales,1.6
+29263,Slovenia,2016,7,G03-Sex hormones and modulators of the genital system,"Million US$, purchasing power parity",13.0
+29264,Slovenia,2016,7,G03-Sex hormones and modulators of the genital system,"/capita, US$ exchange rate",4.0
+29265,Slovenia,2016,7,A02A-Antacids,Million of national currency units,0.7
+29266,Slovenia,2016,7,C01A-Cardiac glycosides,"/capita, US$ purchasing power parity",0.2
+29267,Slovenia,2016,7,A02A-Antacids,Million US$ at exchange rate,0.8
+29268,Slovenia,2016,7,A02A-Antacids,"Million US$, purchasing power parity",1.3
+29269,Slovenia,2016,7,C10-Lipid modifying agents,% of total sales,3.0
+29270,Slovenia,2016,7,C10-Lipid modifying agents,"/capita, US$ purchasing power parity",11.8
+29271,Slovenia,2016,7,C01A-Cardiac glycosides,% of total sales,0.1
+29272,Slovenia,2016,7,Total pharmaceutical sales,Million of national currency units,466.7
+29273,Slovenia,2016,7,N06A-Antidepressants,"/capita, US$ purchasing power parity",9.4
+29274,Slovenia,2016,7,N06A-Antidepressants,% of total sales,2.4
+29275,Slovenia,2016,7,N06A-Antidepressants,"Million US$, purchasing power parity",19.4
+29276,Slovenia,2016,7,N06A-Antidepressants,"/capita, US$ exchange rate",6.0
+29277,Slovenia,2016,7,A02A-Antacids,"/capita, US$ exchange rate",0.4
+29278,Slovenia,2016,7,A02A-Antacids,"/capita, US$ purchasing power parity",0.6
+29279,Slovenia,2016,7,A02A-Antacids,% of total sales,0.2
+29280,Slovenia,2016,7,N05C-Hypnotics and sedatives,"/capita, US$ purchasing power parity",2.0
+29281,Slovenia,2016,7,N05C-Hypnotics and sedatives,"/capita, US$ exchange rate",1.3
+29282,Slovenia,2016,7,N05C-Hypnotics and sedatives,"Million US$, purchasing power parity",4.1
+29283,Slovenia,2016,7,N05C-Hypnotics and sedatives,% of total sales,0.5
+29284,Slovenia,2016,7,C03-Diuretics,Million US$ at exchange rate,7.0
+29285,Slovenia,2016,7,C03-Diuretics,"Million US$, purchasing power parity",11.0
+29286,Slovenia,2016,7,C03-Diuretics,Million of national currency units,6.4
+29287,Slovenia,2016,7,M-Musculo-skeletal system,"/capita, US$ exchange rate",8.4
+29288,Slovenia,2016,7,M-Musculo-skeletal system,"Million US$, purchasing power parity",27.0
+29289,Slovenia,2016,7,M-Musculo-skeletal system,% of total sales,3.3
+29290,Slovenia,2016,7,M-Musculo-skeletal system,"/capita, US$ purchasing power parity",13.1
+29291,Slovenia,2016,7,N05C-Hypnotics and sedatives,Million US$ at exchange rate,2.6
+29292,Slovenia,2016,7,N05C-Hypnotics and sedatives,Million of national currency units,2.4
+29293,Slovenia,2016,7,M-Musculo-skeletal system,Million of national currency units,15.6
+29294,Slovenia,2016,7,M-Musculo-skeletal system,Million US$ at exchange rate,17.3
+29295,Slovenia,2016,7,C01A-Cardiac glycosides,Million US$ at exchange rate,0.3
+29296,Slovenia,2016,7,C01A-Cardiac glycosides,"Million US$, purchasing power parity",0.5
+29297,Slovenia,2016,7,C03-Diuretics,% of total sales,1.4
+29298,Slovenia,2016,7,C01A-Cardiac glycosides,Million of national currency units,0.3
+29299,Slovenia,2016,7,N-Nervous system,Million US$ at exchange rate,72.1
+29300,Slovenia,2016,7,N-Nervous system,"Million US$, purchasing power parity",112.9
+29301,Slovenia,2016,7,C01A-Cardiac glycosides,"/capita, US$ exchange rate",0.2
+29302,Slovenia,2016,7,N-Nervous system,Million of national currency units,65.1
+29303,Slovenia,2016,7,G-Genito urinary system and sex hormones,Million of national currency units,23.5
+29304,Slovenia,2016,7,G-Genito urinary system and sex hormones,% of total sales,5.0
+29305,Slovenia,2016,7,G-Genito urinary system and sex hormones,"/capita, US$ purchasing power parity",19.7
+29306,Slovenia,2016,7,C03-Diuretics,"/capita, US$ exchange rate",3.4
+29307,Slovenia,2016,7,C03-Diuretics,"/capita, US$ purchasing power parity",5.3
+29308,Slovenia,2016,7,G-Genito urinary system and sex hormones,Million US$ at exchange rate,26.0
+29309,Slovenia,2016,7,G-Genito urinary system and sex hormones,"/capita, US$ exchange rate",12.6
+29310,Slovenia,2016,7,G-Genito urinary system and sex hormones,"Million US$, purchasing power parity",40.7
+29311,Slovenia,2016,7,C07-Beta blocking agents,"/capita, US$ purchasing power parity",8.4
+29312,Slovenia,2016,7,C07-Beta blocking agents,% of total sales,2.2
+29313,Slovenia,2016,7,M01A-Antiinflammatory and antirheumatic products non-steroids,Million US$ at exchange rate,9.5
+29314,Slovenia,2016,7,M01A-Antiinflammatory and antirheumatic products non-steroids,"Million US$, purchasing power parity",14.9
+29315,Slovenia,2016,7,A10-Drugs used in diabetes,Million of national currency units,30.4
+29316,Slovenia,2016,7,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million of national currency units,10.6
+29317,Slovenia,2016,7,C07-Beta blocking agents,Million US$ at exchange rate,11.1
+29318,Slovenia,2016,7,C07-Beta blocking agents,Million of national currency units,10.1
+29319,Slovenia,2016,7,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million US$ at exchange rate,11.7
+29320,Slovenia,2016,7,M01A-Antiinflammatory and antirheumatic products non-steroids,Million of national currency units,8.6
+29321,Slovenia,2016,7,C07-Beta blocking agents,"Million US$, purchasing power parity",17.4
+29322,Slovenia,2016,7,A10-Drugs used in diabetes,Million US$ at exchange rate,33.6
+29323,Slovenia,2016,7,C07-Beta blocking agents,"/capita, US$ exchange rate",5.4
+29324,Slovenia,2016,7,J-Antiinfectives for systemic use,"/capita, US$ exchange rate",15.8
+29325,Slovenia,2016,7,J-Antiinfectives for systemic use,Million US$ at exchange rate,32.7
+29326,Slovenia,2016,7,J-Antiinfectives for systemic use,"Million US$, purchasing power parity",51.1
+29327,Slovenia,2016,7,J-Antiinfectives for systemic use,"/capita, US$ purchasing power parity",24.8
+29328,Slovenia,2016,7,A10-Drugs used in diabetes,% of total sales,6.5
+29329,Slovenia,2016,7,M01A-Antiinflammatory and antirheumatic products non-steroids,% of total sales,1.8
+29330,Slovenia,2016,7,J-Antiinfectives for systemic use,% of total sales,6.3
+29331,Slovenia,2016,7,A10-Drugs used in diabetes,"/capita, US$ exchange rate",16.3
+29332,Slovenia,2016,7,A10-Drugs used in diabetes,"/capita, US$ purchasing power parity",25.5
+29333,Slovenia,2016,7,A10-Drugs used in diabetes,"Million US$, purchasing power parity",52.6
+29334,Slovenia,2016,7,J-Antiinfectives for systemic use,Million of national currency units,29.5
+29335,Slovenia,2016,7,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ purchasing power parity",7.2
+29336,Slovenia,2016,7,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ exchange rate",4.6
+29337,Slovenia,2016,7,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"Million US$, purchasing power parity",18.3
+29338,Slovenia,2016,7,C-Cardiovascular system,% of total sales,16.2
+29339,Slovenia,2016,7,"C01B-Antiarrhythmics, Class I and III",% of total sales,0.2
+29340,Slovenia,2016,7,C-Cardiovascular system,"/capita, US$ purchasing power parity",63.4
+29341,Slovenia,2016,7,Total pharmaceutical sales,"Million US$, purchasing power parity",808.7
+29342,Slovenia,2016,7,"C01B-Antiarrhythmics, Class I and III","/capita, US$ purchasing power parity",0.8
+29343,Slovenia,2016,7,C10-Lipid modifying agents,Million US$ at exchange rate,15.6
+29344,Slovenia,2016,7,C10-Lipid modifying agents,"/capita, US$ exchange rate",7.5
+29345,Slovenia,2016,7,C10-Lipid modifying agents,"Million US$, purchasing power parity",24.4
+29346,Slovenia,2016,7,B-Blood and blood forming organs,Million of national currency units,40.0
+29347,Slovenia,2016,7,Total pharmaceutical sales,Million US$ at exchange rate,516.6
+29348,Slovenia,2016,7,C10-Lipid modifying agents,Million of national currency units,14.1
+29349,Slovenia,2016,7,Total pharmaceutical sales,"/capita, US$ exchange rate",250.2
+29350,Slovenia,2016,7,N-Nervous system,% of total sales,14.0
+29351,Slovenia,2016,7,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),% of total sales,2.3
+29352,Slovenia,2016,7,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ exchange rate",5.7
+29353,Slovenia,2016,7,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ purchasing power parity",8.9
+29354,Slovenia,2016,7,"C01B-Antiarrhythmics, Class I and III",Million US$ at exchange rate,1.1
+29355,Slovenia,2016,7,"C01B-Antiarrhythmics, Class I and III",Million of national currency units,1.0
+29356,Slovenia,2016,7,"C01B-Antiarrhythmics, Class I and III","Million US$, purchasing power parity",1.7
+29357,Slovenia,2016,7,"C01B-Antiarrhythmics, Class I and III","/capita, US$ exchange rate",0.5
+29358,Slovenia,2016,7,Total pharmaceutical sales,"/capita, US$ purchasing power parity",391.6
+29359,Slovenia,2016,7,C02-Antihypertensives,% of total sales,0.7
+29360,Slovenia,2015,7,R03-Drugs for obstructive airway diseases,"Million US$, purchasing power parity",35.8
+29361,Slovenia,2015,7,R03-Drugs for obstructive airway diseases,Million of national currency units,21.3
+29362,Slovenia,2015,7,R03-Drugs for obstructive airway diseases,Million US$ at exchange rate,23.6
+29363,Slovenia,2015,7,R03-Drugs for obstructive airway diseases,% of total sales,4.8
+29364,Slovenia,2015,7,C02-Antihypertensives,"/capita, US$ purchasing power parity",2.8
+29365,Slovenia,2015,7,R03-Drugs for obstructive airway diseases,"/capita, US$ exchange rate",11.5
+29366,Slovenia,2015,7,C-Cardiovascular system,Million US$ at exchange rate,85.5
+29367,Slovenia,2015,7,R03-Drugs for obstructive airway diseases,"/capita, US$ purchasing power parity",17.3
+29368,Slovenia,2015,7,C-Cardiovascular system,"Million US$, purchasing power parity",129.4
+29369,Slovenia,2015,7,N02-Analgesics,"/capita, US$ purchasing power parity",15.0
+29370,Slovenia,2015,7,N02-Analgesics,% of total sales,4.1
+29371,Slovenia,2015,7,N02-Analgesics,"Million US$, purchasing power parity",30.9
+29372,Slovenia,2015,7,N02-Analgesics,"/capita, US$ exchange rate",9.9
+29373,Slovenia,2015,7,C08-Calcium channel blockers,% of total sales,1.4
+29374,Slovenia,2015,7,C02-Antihypertensives,"/capita, US$ exchange rate",1.8
+29375,Slovenia,2015,7,R-Respiratory system,Million US$ at exchange rate,29.3
+29376,Slovenia,2015,7,C08-Calcium channel blockers,Million US$ at exchange rate,6.8
+29377,Slovenia,2015,7,R-Respiratory system,"/capita, US$ exchange rate",14.2
+29378,Slovenia,2015,7,R-Respiratory system,"Million US$, purchasing power parity",44.4
+29379,Slovenia,2015,7,C02-Antihypertensives,"Million US$, purchasing power parity",5.7
+29380,Slovenia,2015,7,C02-Antihypertensives,Million US$ at exchange rate,3.8
+29381,Slovenia,2015,7,C08-Calcium channel blockers,Million of national currency units,6.2
+29382,Slovenia,2015,7,C-Cardiovascular system,Million of national currency units,77.0
+29383,Slovenia,2015,7,C02-Antihypertensives,Million of national currency units,3.4
+29384,Slovenia,2015,7,C08-Calcium channel blockers,"/capita, US$ purchasing power parity",5.0
+29385,Slovenia,2015,7,R-Respiratory system,Million of national currency units,26.4
+29386,Slovenia,2015,7,J01-Antibacterials for systemic use,% of total sales,2.6
+29387,Slovenia,2015,7,R-Respiratory system,% of total sales,5.9
+29388,Slovenia,2015,7,R-Respiratory system,"/capita, US$ purchasing power parity",21.5
+29389,Slovenia,2015,7,C08-Calcium channel blockers,"/capita, US$ exchange rate",3.3
+29390,Slovenia,2015,7,C08-Calcium channel blockers,"Million US$, purchasing power parity",10.3
+29391,Slovenia,2015,7,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million US$ at exchange rate,11.0
+29392,Slovenia,2015,7,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million of national currency units,9.9
+29393,Slovenia,2015,7,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ purchasing power parity",8.1
+29394,Slovenia,2015,7,"H-Systemic hormonal preparations, excluding sex hormones and insulins",% of total sales,2.2
+29395,Slovenia,2015,7,B-Blood and blood forming organs,"/capita, US$ purchasing power parity",28.5
+29396,Slovenia,2015,7,B-Blood and blood forming organs,% of total sales,7.8
+29397,Slovenia,2015,7,B-Blood and blood forming organs,"Million US$, purchasing power parity",58.8
+29398,Slovenia,2015,7,B-Blood and blood forming organs,"/capita, US$ exchange rate",18.8
+29399,Slovenia,2015,7,J01-Antibacterials for systemic use,"Million US$, purchasing power parity",19.2
+29400,Slovenia,2015,7,J01-Antibacterials for systemic use,"/capita, US$ exchange rate",6.1
+29401,Slovenia,2015,7,J01-Antibacterials for systemic use,"/capita, US$ purchasing power parity",9.3
+29402,Slovenia,2015,7,J01-Antibacterials for systemic use,Million US$ at exchange rate,12.6
+29403,Slovenia,2015,7,B-Blood and blood forming organs,Million US$ at exchange rate,38.8
+29404,Slovenia,2015,7,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ exchange rate",5.3
+29405,Slovenia,2015,7,"H-Systemic hormonal preparations, excluding sex hormones and insulins","Million US$, purchasing power parity",16.7
+29406,Slovenia,2015,7,C09-Agents acting on the Renin-Angiotensin system,"Million US$, purchasing power parity",50.4
+29407,Slovenia,2015,7,C09-Agents acting on the Renin-Angiotensin system,Million US$ at exchange rate,33.3
+29408,Slovenia,2015,7,A-Alimentary tract and metabolism,% of total sales,11.8
+29409,Slovenia,2015,7,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ exchange rate",16.1
+29410,Slovenia,2015,7,N02-Analgesics,Million of national currency units,18.4
+29411,Slovenia,2015,7,N02-Analgesics,Million US$ at exchange rate,20.4
+29412,Slovenia,2015,7,C09-Agents acting on the Renin-Angiotensin system,Million of national currency units,30.0
+29413,Slovenia,2015,7,C-Cardiovascular system,"/capita, US$ exchange rate",41.4
+29414,Slovenia,2015,7,A-Alimentary tract and metabolism,"/capita, US$ purchasing power parity",43.0
+29415,Slovenia,2015,7,A-Alimentary tract and metabolism,Million of national currency units,52.8
+29416,Slovenia,2015,7,A-Alimentary tract and metabolism,Million US$ at exchange rate,58.5
+29417,Slovenia,2015,7,C09-Agents acting on the Renin-Angiotensin system,% of total sales,6.7
+29418,Slovenia,2015,7,J01-Antibacterials for systemic use,Million of national currency units,11.4
+29419,Slovenia,2015,7,A-Alimentary tract and metabolism,"/capita, US$ exchange rate",28.4
+29420,Slovenia,2015,7,A-Alimentary tract and metabolism,"Million US$, purchasing power parity",88.6
+29421,Slovenia,2015,7,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ purchasing power parity",24.4
+29422,Slovenia,2015,7,N05B-Anxiolytics,"/capita, US$ exchange rate",1.5
+29423,Slovenia,2015,7,N05B-Anxiolytics,"Million US$, purchasing power parity",4.6
+29424,Slovenia,2015,7,N05B-Anxiolytics,% of total sales,0.6
+29425,Slovenia,2015,7,N05B-Anxiolytics,"/capita, US$ purchasing power parity",2.2
+29426,Slovenia,2015,7,N06A-Antidepressants,Million of national currency units,11.7
+29427,Slovenia,2015,7,N06A-Antidepressants,Million US$ at exchange rate,13.0
+29428,Slovenia,2015,7,N05B-Anxiolytics,Million of national currency units,2.7
+29429,Slovenia,2015,7,N05B-Anxiolytics,Million US$ at exchange rate,3.1
+29430,Slovenia,2015,7,G03-Sex hormones and modulators of the genital system,Million of national currency units,7.7
+29431,Slovenia,2015,7,G03-Sex hormones and modulators of the genital system,Million US$ at exchange rate,8.5
+29432,Slovenia,2015,7,N-Nervous system,"/capita, US$ exchange rate",35.4
+29433,Slovenia,2015,7,N-Nervous system,"/capita, US$ purchasing power parity",53.7
+29434,Slovenia,2015,7,G03-Sex hormones and modulators of the genital system,"/capita, US$ purchasing power parity",6.3
+29435,Slovenia,2015,7,G03-Sex hormones and modulators of the genital system,% of total sales,1.7
+29436,Slovenia,2015,7,G03-Sex hormones and modulators of the genital system,"Million US$, purchasing power parity",12.9
+29437,Slovenia,2015,7,G03-Sex hormones and modulators of the genital system,"/capita, US$ exchange rate",4.1
+29438,Slovenia,2015,7,A02A-Antacids,Million of national currency units,0.7
+29439,Slovenia,2015,7,C01A-Cardiac glycosides,"/capita, US$ purchasing power parity",0.2
+29440,Slovenia,2015,7,A02A-Antacids,"Million US$, purchasing power parity",1.1
+29441,Slovenia,2015,7,A02A-Antacids,Million US$ at exchange rate,0.7
+29442,Slovenia,2015,7,C10-Lipid modifying agents,% of total sales,3.1
+29443,Slovenia,2015,7,C10-Lipid modifying agents,"/capita, US$ purchasing power parity",11.4
+29444,Slovenia,2015,7,C01A-Cardiac glycosides,% of total sales,0.1
+29445,Slovenia,2015,7,Total pharmaceutical sales,Million of national currency units,446.0
+29446,Slovenia,2015,7,N06A-Antidepressants,"/capita, US$ purchasing power parity",9.5
+29447,Slovenia,2015,7,N06A-Antidepressants,% of total sales,2.6
+29448,Slovenia,2015,7,N06A-Antidepressants,"Million US$, purchasing power parity",19.6
+29449,Slovenia,2015,7,N06A-Antidepressants,"/capita, US$ exchange rate",6.3
+29450,Slovenia,2015,7,A02A-Antacids,"/capita, US$ exchange rate",0.4
+29451,Slovenia,2015,7,A02A-Antacids,"/capita, US$ purchasing power parity",0.5
+29452,Slovenia,2015,7,A02A-Antacids,% of total sales,0.1
+29453,Slovenia,2015,7,N05C-Hypnotics and sedatives,"/capita, US$ purchasing power parity",2.0
+29454,Slovenia,2015,7,N05C-Hypnotics and sedatives,"Million US$, purchasing power parity",4.1
+29455,Slovenia,2015,7,N05C-Hypnotics and sedatives,"/capita, US$ exchange rate",1.3
+29456,Slovenia,2015,7,C03-Diuretics,"Million US$, purchasing power parity",10.5
+29457,Slovenia,2015,7,C03-Diuretics,Million US$ at exchange rate,7.0
+29458,Slovenia,2015,7,N05C-Hypnotics and sedatives,% of total sales,0.6
+29459,Slovenia,2015,7,C03-Diuretics,Million of national currency units,6.3
+29460,Slovenia,2015,7,N05C-Hypnotics and sedatives,Million US$ at exchange rate,2.7
+29461,Slovenia,2015,7,M-Musculo-skeletal system,"/capita, US$ exchange rate",8.4
+29462,Slovenia,2015,7,M-Musculo-skeletal system,"Million US$, purchasing power parity",26.3
+29463,Slovenia,2015,7,M-Musculo-skeletal system,% of total sales,3.5
+29464,Slovenia,2015,7,M-Musculo-skeletal system,"/capita, US$ purchasing power parity",12.8
+29465,Slovenia,2015,7,N05C-Hypnotics and sedatives,Million of national currency units,2.5
+29466,Slovenia,2015,7,M-Musculo-skeletal system,Million US$ at exchange rate,17.4
+29467,Slovenia,2015,7,M-Musculo-skeletal system,Million of national currency units,15.7
+29468,Slovenia,2015,7,C01A-Cardiac glycosides,Million US$ at exchange rate,0.3
+29469,Slovenia,2015,7,C01A-Cardiac glycosides,"Million US$, purchasing power parity",0.5
+29470,Slovenia,2015,7,C03-Diuretics,% of total sales,1.4
+29471,Slovenia,2015,7,C01A-Cardiac glycosides,Million of national currency units,0.3
+29472,Slovenia,2015,7,N-Nervous system,Million US$ at exchange rate,73.2
+29473,Slovenia,2015,7,N-Nervous system,"Million US$, purchasing power parity",110.8
+29474,Slovenia,2015,7,C01A-Cardiac glycosides,"/capita, US$ exchange rate",0.2
+29475,Slovenia,2015,7,N-Nervous system,Million of national currency units,65.9
+29476,Slovenia,2015,7,G-Genito urinary system and sex hormones,Million of national currency units,22.6
+29477,Slovenia,2015,7,G-Genito urinary system and sex hormones,% of total sales,5.1
+29478,Slovenia,2015,7,G-Genito urinary system and sex hormones,"/capita, US$ purchasing power parity",18.4
+29479,Slovenia,2015,7,C03-Diuretics,"/capita, US$ exchange rate",3.4
+29480,Slovenia,2015,7,C03-Diuretics,"/capita, US$ purchasing power parity",5.1
+29481,Slovenia,2015,7,G-Genito urinary system and sex hormones,Million US$ at exchange rate,25.1
+29482,Slovenia,2015,7,G-Genito urinary system and sex hormones,"Million US$, purchasing power parity",38.0
+29483,Slovenia,2015,7,G-Genito urinary system and sex hormones,"/capita, US$ exchange rate",12.2
+29484,Slovenia,2015,7,C07-Beta blocking agents,"/capita, US$ purchasing power parity",7.7
+29485,Slovenia,2015,7,C07-Beta blocking agents,% of total sales,2.1
+29486,Slovenia,2015,7,M01A-Antiinflammatory and antirheumatic products non-steroids,Million US$ at exchange rate,9.9
+29487,Slovenia,2015,7,M01A-Antiinflammatory and antirheumatic products non-steroids,"Million US$, purchasing power parity",15.0
+29488,Slovenia,2015,7,A10-Drugs used in diabetes,Million of national currency units,28.8
+29489,Slovenia,2015,7,A10-Drugs used in diabetes,Million US$ at exchange rate,32.0
+29490,Slovenia,2015,7,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million of national currency units,10.7
+29491,Slovenia,2015,7,C07-Beta blocking agents,Million US$ at exchange rate,10.5
+29492,Slovenia,2015,7,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million US$ at exchange rate,11.9
+29493,Slovenia,2015,7,C07-Beta blocking agents,Million of national currency units,9.5
+29494,Slovenia,2015,7,C07-Beta blocking agents,"Million US$, purchasing power parity",15.9
+29495,Slovenia,2015,7,C07-Beta blocking agents,"/capita, US$ exchange rate",5.1
+29496,Slovenia,2015,7,J-Antiinfectives for systemic use,"/capita, US$ exchange rate",14.3
+29497,Slovenia,2015,7,J-Antiinfectives for systemic use,"Million US$, purchasing power parity",44.7
+29498,Slovenia,2015,7,J-Antiinfectives for systemic use,"/capita, US$ purchasing power parity",21.6
+29499,Slovenia,2015,7,A10-Drugs used in diabetes,% of total sales,6.5
+29500,Slovenia,2015,7,M01A-Antiinflammatory and antirheumatic products non-steroids,% of total sales,2.0
+29501,Slovenia,2015,7,J-Antiinfectives for systemic use,Million US$ at exchange rate,29.5
+29502,Slovenia,2015,7,J-Antiinfectives for systemic use,% of total sales,6.0
+29503,Slovenia,2015,7,A10-Drugs used in diabetes,"/capita, US$ exchange rate",15.5
+29504,Slovenia,2015,7,A10-Drugs used in diabetes,"/capita, US$ purchasing power parity",23.5
+29505,Slovenia,2015,7,A10-Drugs used in diabetes,"Million US$, purchasing power parity",48.4
+29506,Slovenia,2015,7,J-Antiinfectives for systemic use,Million of national currency units,26.6
+29507,Slovenia,2015,7,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ purchasing power parity",7.3
+29508,Slovenia,2015,7,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ exchange rate",4.8
+29509,Slovenia,2015,7,M01A-Antiinflammatory and antirheumatic products non-steroids,Million of national currency units,8.9
+29510,Slovenia,2015,7,C-Cardiovascular system,% of total sales,17.3
+29511,Slovenia,2015,7,"C01B-Antiarrhythmics, Class I and III",% of total sales,0.2
+29512,Slovenia,2015,7,C-Cardiovascular system,"/capita, US$ purchasing power parity",62.7
+29513,Slovenia,2015,7,Total pharmaceutical sales,"Million US$, purchasing power parity",749.3
+29514,Slovenia,2015,7,"C01B-Antiarrhythmics, Class I and III","/capita, US$ purchasing power parity",0.8
+29515,Slovenia,2015,7,C10-Lipid modifying agents,Million US$ at exchange rate,15.5
+29516,Slovenia,2015,7,C10-Lipid modifying agents,"Million US$, purchasing power parity",23.5
+29517,Slovenia,2015,7,C10-Lipid modifying agents,"/capita, US$ exchange rate",7.5
+29518,Slovenia,2015,7,B-Blood and blood forming organs,Million of national currency units,35.0
+29519,Slovenia,2015,7,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"Million US$, purchasing power parity",18.0
+29520,Slovenia,2015,7,C10-Lipid modifying agents,Million of national currency units,14.0
+29521,Slovenia,2015,7,Total pharmaceutical sales,Million US$ at exchange rate,494.9
+29522,Slovenia,2015,7,Total pharmaceutical sales,"/capita, US$ exchange rate",239.8
+29523,Slovenia,2015,7,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),% of total sales,2.4
+29524,Slovenia,2015,7,N-Nervous system,% of total sales,14.8
+29525,Slovenia,2015,7,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ exchange rate",5.7
+29526,Slovenia,2015,7,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ purchasing power parity",8.7
+29527,Slovenia,2015,7,"C01B-Antiarrhythmics, Class I and III",Million US$ at exchange rate,1.2
+29528,Slovenia,2015,7,"C01B-Antiarrhythmics, Class I and III",Million of national currency units,1.0
+29529,Slovenia,2015,7,"C01B-Antiarrhythmics, Class I and III","/capita, US$ exchange rate",0.6
+29530,Slovenia,2015,7,Total pharmaceutical sales,"/capita, US$ purchasing power parity",363.1
+29531,Slovenia,2015,7,"C01B-Antiarrhythmics, Class I and III","Million US$, purchasing power parity",1.7
+29532,Slovenia,2015,7,C02-Antihypertensives,% of total sales,0.8
+29533,Slovenia,2014,7,R03-Drugs for obstructive airway diseases,"Million US$, purchasing power parity",36.1
+29534,Slovenia,2014,7,R03-Drugs for obstructive airway diseases,Million of national currency units,21.3
+29535,Slovenia,2014,7,R03-Drugs for obstructive airway diseases,Million US$ at exchange rate,28.3
+29536,Slovenia,2014,7,R03-Drugs for obstructive airway diseases,"/capita, US$ exchange rate",13.7
+29537,Slovenia,2014,7,R03-Drugs for obstructive airway diseases,% of total sales,4.9
+29538,Slovenia,2014,7,C02-Antihypertensives,"/capita, US$ purchasing power parity",3.3
+29539,Slovenia,2014,7,C-Cardiovascular system,Million US$ at exchange rate,107.8
+29540,Slovenia,2014,7,R03-Drugs for obstructive airway diseases,"/capita, US$ purchasing power parity",17.5
+29541,Slovenia,2014,7,N02-Analgesics,"/capita, US$ purchasing power parity",14.6
+29542,Slovenia,2014,7,N02-Analgesics,% of total sales,4.1
+29543,Slovenia,2014,7,N02-Analgesics,"Million US$, purchasing power parity",30.1
+29544,Slovenia,2014,7,N02-Analgesics,"/capita, US$ exchange rate",11.5
+29545,Slovenia,2014,7,C08-Calcium channel blockers,% of total sales,1.5
+29546,Slovenia,2014,7,C-Cardiovascular system,"Million US$, purchasing power parity",137.3
+29547,Slovenia,2014,7,C02-Antihypertensives,"/capita, US$ exchange rate",2.6
+29548,Slovenia,2014,7,R-Respiratory system,Million US$ at exchange rate,35.4
+29549,Slovenia,2014,7,C08-Calcium channel blockers,"Million US$, purchasing power parity",10.8
+29550,Slovenia,2014,7,C08-Calcium channel blockers,Million US$ at exchange rate,8.5
+29551,Slovenia,2014,7,R-Respiratory system,"/capita, US$ exchange rate",17.2
+29552,Slovenia,2014,7,R-Respiratory system,"Million US$, purchasing power parity",45.1
+29553,Slovenia,2014,7,C02-Antihypertensives,"Million US$, purchasing power parity",6.8
+29554,Slovenia,2014,7,C08-Calcium channel blockers,Million of national currency units,6.4
+29555,Slovenia,2014,7,C02-Antihypertensives,Million US$ at exchange rate,5.3
+29556,Slovenia,2014,7,C-Cardiovascular system,Million of national currency units,81.2
+29557,Slovenia,2014,7,C02-Antihypertensives,Million of national currency units,4.0
+29558,Slovenia,2014,7,C08-Calcium channel blockers,"/capita, US$ purchasing power parity",5.2
+29559,Slovenia,2014,7,J01-Antibacterials for systemic use,% of total sales,2.6
+29560,Slovenia,2014,7,R-Respiratory system,% of total sales,6.2
+29561,Slovenia,2014,7,R-Respiratory system,"/capita, US$ purchasing power parity",21.9
+29562,Slovenia,2014,7,C08-Calcium channel blockers,"/capita, US$ exchange rate",4.1
+29563,Slovenia,2014,7,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million US$ at exchange rate,12.3
+29564,Slovenia,2014,7,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million of national currency units,9.3
+29565,Slovenia,2014,7,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ purchasing power parity",7.6
+29566,Slovenia,2014,7,"H-Systemic hormonal preparations, excluding sex hormones and insulins",% of total sales,2.1
+29567,Slovenia,2014,7,B-Blood and blood forming organs,"/capita, US$ purchasing power parity",25.6
+29568,Slovenia,2014,7,B-Blood and blood forming organs,% of total sales,7.2
+29569,Slovenia,2014,7,B-Blood and blood forming organs,"Million US$, purchasing power parity",52.9
+29570,Slovenia,2014,7,B-Blood and blood forming organs,"/capita, US$ exchange rate",20.1
+29571,Slovenia,2014,7,J01-Antibacterials for systemic use,"Million US$, purchasing power parity",18.9
+29572,Slovenia,2014,7,J01-Antibacterials for systemic use,"/capita, US$ purchasing power parity",9.2
+29573,Slovenia,2014,7,J01-Antibacterials for systemic use,"/capita, US$ exchange rate",7.2
+29574,Slovenia,2014,7,J01-Antibacterials for systemic use,Million US$ at exchange rate,14.8
+29575,Slovenia,2014,7,"H-Systemic hormonal preparations, excluding sex hormones and insulins","Million US$, purchasing power parity",15.7
+29576,Slovenia,2014,7,B-Blood and blood forming organs,Million US$ at exchange rate,41.5
+29577,Slovenia,2014,7,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ exchange rate",6.0
+29578,Slovenia,2014,7,C09-Agents acting on the Renin-Angiotensin system,"Million US$, purchasing power parity",57.1
+29579,Slovenia,2014,7,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ exchange rate",21.8
+29580,Slovenia,2014,7,A-Alimentary tract and metabolism,% of total sales,11.6
+29581,Slovenia,2014,7,C09-Agents acting on the Renin-Angiotensin system,Million US$ at exchange rate,44.9
+29582,Slovenia,2014,7,N02-Analgesics,Million of national currency units,17.8
+29583,Slovenia,2014,7,N02-Analgesics,Million US$ at exchange rate,23.6
+29584,Slovenia,2014,7,C09-Agents acting on the Renin-Angiotensin system,Million of national currency units,33.8
+29585,Slovenia,2014,7,C-Cardiovascular system,"/capita, US$ exchange rate",52.3
+29586,Slovenia,2014,7,A-Alimentary tract and metabolism,Million of national currency units,50.1
+29587,Slovenia,2014,7,A-Alimentary tract and metabolism,Million US$ at exchange rate,66.6
+29588,Slovenia,2014,7,C09-Agents acting on the Renin-Angiotensin system,% of total sales,7.8
+29589,Slovenia,2014,7,J01-Antibacterials for systemic use,Million of national currency units,11.2
+29590,Slovenia,2014,7,A-Alimentary tract and metabolism,"/capita, US$ exchange rate",32.3
+29591,Slovenia,2014,7,A-Alimentary tract and metabolism,"Million US$, purchasing power parity",84.8
+29592,Slovenia,2014,7,A-Alimentary tract and metabolism,"/capita, US$ purchasing power parity",41.1
+29593,Slovenia,2014,7,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ purchasing power parity",27.7
+29594,Slovenia,2014,7,R-Respiratory system,Million of national currency units,26.6
+29595,Slovenia,2014,7,N05B-Anxiolytics,"/capita, US$ exchange rate",1.8
+29596,Slovenia,2014,7,N05B-Anxiolytics,"Million US$, purchasing power parity",4.8
+29597,Slovenia,2014,7,N05B-Anxiolytics,% of total sales,0.7
+29598,Slovenia,2014,7,N05B-Anxiolytics,"/capita, US$ purchasing power parity",2.3
+29599,Slovenia,2014,7,N06A-Antidepressants,Million of national currency units,13.5
+29600,Slovenia,2014,7,N06A-Antidepressants,Million US$ at exchange rate,17.9
+29601,Slovenia,2014,7,N05B-Anxiolytics,Million US$ at exchange rate,3.7
+29602,Slovenia,2014,7,G03-Sex hormones and modulators of the genital system,Million of national currency units,8.1
+29603,Slovenia,2014,7,G03-Sex hormones and modulators of the genital system,Million US$ at exchange rate,10.8
+29604,Slovenia,2014,7,N-Nervous system,"/capita, US$ exchange rate",44.9
+29605,Slovenia,2014,7,N-Nervous system,"/capita, US$ purchasing power parity",57.1
+29606,Slovenia,2014,7,G03-Sex hormones and modulators of the genital system,"/capita, US$ purchasing power parity",6.7
+29607,Slovenia,2014,7,G03-Sex hormones and modulators of the genital system,% of total sales,1.9
+29608,Slovenia,2014,7,G03-Sex hormones and modulators of the genital system,"Million US$, purchasing power parity",13.7
+29609,Slovenia,2014,7,G03-Sex hormones and modulators of the genital system,"/capita, US$ exchange rate",5.2
+29610,Slovenia,2014,7,A02A-Antacids,Million of national currency units,0.6
+29611,Slovenia,2014,7,C01A-Cardiac glycosides,"/capita, US$ purchasing power parity",0.2
+29612,Slovenia,2014,7,A02A-Antacids,"Million US$, purchasing power parity",1.0
+29613,Slovenia,2014,7,A02A-Antacids,Million US$ at exchange rate,0.8
+29614,Slovenia,2014,7,C10-Lipid modifying agents,% of total sales,3.3
+29615,Slovenia,2014,7,C10-Lipid modifying agents,"/capita, US$ purchasing power parity",11.8
+29616,Slovenia,2014,7,C01A-Cardiac glycosides,% of total sales,0.1
+29617,Slovenia,2014,7,Total pharmaceutical sales,Million of national currency units,432.3
+29618,Slovenia,2014,7,N06A-Antidepressants,"/capita, US$ purchasing power parity",11.1
+29619,Slovenia,2014,7,N06A-Antidepressants,% of total sales,3.1
+29620,Slovenia,2014,7,N06A-Antidepressants,"Million US$, purchasing power parity",22.8
+29621,Slovenia,2014,7,N06A-Antidepressants,"/capita, US$ exchange rate",8.7
+29622,Slovenia,2014,7,A02A-Antacids,"/capita, US$ purchasing power parity",0.5
+29623,Slovenia,2014,7,A02A-Antacids,"/capita, US$ exchange rate",0.4
+29624,Slovenia,2014,7,N05B-Anxiolytics,Million of national currency units,2.8
+29625,Slovenia,2014,7,A02A-Antacids,% of total sales,0.1
+29626,Slovenia,2014,7,N05C-Hypnotics and sedatives,"/capita, US$ purchasing power parity",2.0
+29627,Slovenia,2014,7,N05C-Hypnotics and sedatives,"/capita, US$ exchange rate",1.6
+29628,Slovenia,2014,7,N05C-Hypnotics and sedatives,"Million US$, purchasing power parity",4.1
+29629,Slovenia,2014,7,N05C-Hypnotics and sedatives,% of total sales,0.6
+29630,Slovenia,2014,7,C03-Diuretics,"Million US$, purchasing power parity",10.3
+29631,Slovenia,2014,7,C03-Diuretics,Million US$ at exchange rate,8.1
+29632,Slovenia,2014,7,C03-Diuretics,Million of national currency units,6.1
+29633,Slovenia,2014,7,M-Musculo-skeletal system,"/capita, US$ exchange rate",10.1
+29634,Slovenia,2014,7,M-Musculo-skeletal system,"/capita, US$ purchasing power parity",12.9
+29635,Slovenia,2014,7,M-Musculo-skeletal system,% of total sales,3.6
+29636,Slovenia,2014,7,M-Musculo-skeletal system,"Million US$, purchasing power parity",26.6
+29637,Slovenia,2014,7,N05C-Hypnotics and sedatives,Million of national currency units,2.4
+29638,Slovenia,2014,7,N05C-Hypnotics and sedatives,Million US$ at exchange rate,3.2
+29639,Slovenia,2014,7,M-Musculo-skeletal system,Million of national currency units,15.7
+29640,Slovenia,2014,7,M-Musculo-skeletal system,Million US$ at exchange rate,20.9
+29641,Slovenia,2014,7,C03-Diuretics,"/capita, US$ exchange rate",3.9
+29642,Slovenia,2014,7,C01A-Cardiac glycosides,Million US$ at exchange rate,0.4
+29643,Slovenia,2014,7,C01A-Cardiac glycosides,"Million US$, purchasing power parity",0.5
+29644,Slovenia,2014,7,C01A-Cardiac glycosides,Million of national currency units,0.3
+29645,Slovenia,2014,7,N-Nervous system,Million US$ at exchange rate,92.5
+29646,Slovenia,2014,7,N-Nervous system,"Million US$, purchasing power parity",117.8
+29647,Slovenia,2014,7,C01A-Cardiac glycosides,"/capita, US$ exchange rate",0.2
+29648,Slovenia,2014,7,N-Nervous system,Million of national currency units,69.6
+29649,Slovenia,2014,7,G-Genito urinary system and sex hormones,Million of national currency units,23.8
+29650,Slovenia,2014,7,C03-Diuretics,% of total sales,1.4
+29651,Slovenia,2014,7,G-Genito urinary system and sex hormones,% of total sales,5.5
+29652,Slovenia,2014,7,C03-Diuretics,"/capita, US$ purchasing power parity",5.0
+29653,Slovenia,2014,7,G-Genito urinary system and sex hormones,"/capita, US$ purchasing power parity",19.5
+29654,Slovenia,2014,7,G-Genito urinary system and sex hormones,Million US$ at exchange rate,31.6
+29655,Slovenia,2014,7,G-Genito urinary system and sex hormones,"Million US$, purchasing power parity",40.2
+29656,Slovenia,2014,7,G-Genito urinary system and sex hormones,"/capita, US$ exchange rate",15.3
+29657,Slovenia,2014,7,C07-Beta blocking agents,"/capita, US$ purchasing power parity",7.3
+29658,Slovenia,2014,7,C07-Beta blocking agents,% of total sales,2.1
+29659,Slovenia,2014,7,M01A-Antiinflammatory and antirheumatic products non-steroids,"Million US$, purchasing power parity",14.5
+29660,Slovenia,2014,7,M01A-Antiinflammatory and antirheumatic products non-steroids,Million US$ at exchange rate,11.4
+29661,Slovenia,2014,7,A10-Drugs used in diabetes,Million of national currency units,28.3
+29662,Slovenia,2014,7,A10-Drugs used in diabetes,Million US$ at exchange rate,37.6
+29663,Slovenia,2014,7,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million US$ at exchange rate,14.5
+29664,Slovenia,2014,7,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million of national currency units,10.9
+29665,Slovenia,2014,7,C07-Beta blocking agents,Million US$ at exchange rate,11.9
+29666,Slovenia,2014,7,C07-Beta blocking agents,Million of national currency units,8.9
+29667,Slovenia,2014,7,C07-Beta blocking agents,"Million US$, purchasing power parity",15.1
+29668,Slovenia,2014,7,M01A-Antiinflammatory and antirheumatic products non-steroids,Million of national currency units,8.5
+29669,Slovenia,2014,7,M01A-Antiinflammatory and antirheumatic products non-steroids,% of total sales,2.0
+29670,Slovenia,2014,7,C07-Beta blocking agents,"/capita, US$ exchange rate",5.8
+29671,Slovenia,2014,7,J-Antiinfectives for systemic use,"/capita, US$ exchange rate",12.8
+29672,Slovenia,2014,7,J-Antiinfectives for systemic use,"/capita, US$ purchasing power parity",16.3
+29673,Slovenia,2014,7,J-Antiinfectives for systemic use,"Million US$, purchasing power parity",33.6
+29674,Slovenia,2014,7,A10-Drugs used in diabetes,% of total sales,6.5
+29675,Slovenia,2014,7,J-Antiinfectives for systemic use,% of total sales,4.6
+29676,Slovenia,2014,7,J-Antiinfectives for systemic use,Million US$ at exchange rate,26.4
+29677,Slovenia,2014,7,A10-Drugs used in diabetes,"/capita, US$ purchasing power parity",23.2
+29678,Slovenia,2014,7,A10-Drugs used in diabetes,"/capita, US$ exchange rate",18.2
+29679,Slovenia,2014,7,A10-Drugs used in diabetes,"Million US$, purchasing power parity",47.9
+29680,Slovenia,2014,7,J-Antiinfectives for systemic use,Million of national currency units,19.9
+29681,Slovenia,2014,7,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ exchange rate",5.5
+29682,Slovenia,2014,7,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ purchasing power parity",7.0
+29683,Slovenia,2014,7,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"Million US$, purchasing power parity",18.5
+29684,Slovenia,2014,7,"C01B-Antiarrhythmics, Class I and III",% of total sales,0.2
+29685,Slovenia,2014,7,C-Cardiovascular system,% of total sales,18.8
+29686,Slovenia,2014,7,C-Cardiovascular system,"/capita, US$ purchasing power parity",66.6
+29687,Slovenia,2014,7,Total pharmaceutical sales,"Million US$, purchasing power parity",731.2
+29688,Slovenia,2014,7,Total pharmaceutical sales,"/capita, US$ exchange rate",278.5
+29689,Slovenia,2014,7,"C01B-Antiarrhythmics, Class I and III","/capita, US$ purchasing power parity",0.9
+29690,Slovenia,2014,7,C10-Lipid modifying agents,Million US$ at exchange rate,19.1
+29691,Slovenia,2014,7,C10-Lipid modifying agents,"/capita, US$ exchange rate",9.3
+29692,Slovenia,2014,7,C10-Lipid modifying agents,"Million US$, purchasing power parity",24.3
+29693,Slovenia,2014,7,B-Blood and blood forming organs,Million of national currency units,31.3
+29694,Slovenia,2014,7,C10-Lipid modifying agents,Million of national currency units,14.4
+29695,Slovenia,2014,7,Total pharmaceutical sales,Million US$ at exchange rate,574.3
+29696,Slovenia,2014,7,N-Nervous system,% of total sales,16.1
+29697,Slovenia,2014,7,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),% of total sales,2.5
+29698,Slovenia,2014,7,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ exchange rate",7.0
+29699,Slovenia,2014,7,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ purchasing power parity",8.9
+29700,Slovenia,2014,7,"C01B-Antiarrhythmics, Class I and III",Million US$ at exchange rate,1.4
+29701,Slovenia,2014,7,"C01B-Antiarrhythmics, Class I and III","Million US$, purchasing power parity",1.8
+29702,Slovenia,2014,7,Total pharmaceutical sales,"/capita, US$ purchasing power parity",354.6
+29703,Slovenia,2014,7,"C01B-Antiarrhythmics, Class I and III","/capita, US$ exchange rate",0.7
+29704,Slovenia,2014,7,"C01B-Antiarrhythmics, Class I and III",Million of national currency units,1.0
+29705,Slovenia,2014,7,C02-Antihypertensives,% of total sales,0.9
+29706,Slovenia,2013,7,R03-Drugs for obstructive airway diseases,"Million US$, purchasing power parity",37.4
+29707,Slovenia,2013,7,R03-Drugs for obstructive airway diseases,Million of national currency units,22.1
+29708,Slovenia,2013,7,R03-Drugs for obstructive airway diseases,Million US$ at exchange rate,29.3
+29709,Slovenia,2013,7,R03-Drugs for obstructive airway diseases,% of total sales,4.9
+29710,Slovenia,2013,7,C02-Antihypertensives,"/capita, US$ purchasing power parity",3.6
+29711,Slovenia,2013,7,R03-Drugs for obstructive airway diseases,"/capita, US$ exchange rate",14.2
+29712,Slovenia,2013,7,C-Cardiovascular system,Million US$ at exchange rate,133.7
+29713,Slovenia,2013,7,R03-Drugs for obstructive airway diseases,"/capita, US$ purchasing power parity",18.2
+29714,Slovenia,2013,7,N02-Analgesics,"/capita, US$ purchasing power parity",14.2
+29715,Slovenia,2013,7,N02-Analgesics,% of total sales,3.8
+29716,Slovenia,2013,7,N02-Analgesics,"Million US$, purchasing power parity",29.2
+29717,Slovenia,2013,7,N02-Analgesics,"/capita, US$ exchange rate",11.1
+29718,Slovenia,2013,7,C08-Calcium channel blockers,% of total sales,1.5
+29719,Slovenia,2013,7,C-Cardiovascular system,"Million US$, purchasing power parity",170.5
+29720,Slovenia,2013,7,C02-Antihypertensives,"/capita, US$ exchange rate",2.8
+29721,Slovenia,2013,7,C08-Calcium channel blockers,"Million US$, purchasing power parity",11.2
+29722,Slovenia,2013,7,C08-Calcium channel blockers,Million US$ at exchange rate,8.8
+29723,Slovenia,2013,7,R-Respiratory system,"/capita, US$ exchange rate",17.6
+29724,Slovenia,2013,7,R-Respiratory system,"Million US$, purchasing power parity",46.1
+29725,Slovenia,2013,7,C02-Antihypertensives,"Million US$, purchasing power parity",7.4
+29726,Slovenia,2013,7,R-Respiratory system,Million US$ at exchange rate,36.2
+29727,Slovenia,2013,7,C08-Calcium channel blockers,Million of national currency units,6.6
+29728,Slovenia,2013,7,C02-Antihypertensives,Million US$ at exchange rate,5.8
+29729,Slovenia,2013,7,C-Cardiovascular system,Million of national currency units,100.7
+29730,Slovenia,2013,7,C02-Antihypertensives,Million of national currency units,4.4
+29731,Slovenia,2013,7,C08-Calcium channel blockers,"/capita, US$ purchasing power parity",5.5
+29732,Slovenia,2013,7,J01-Antibacterials for systemic use,% of total sales,2.6
+29733,Slovenia,2013,7,R-Respiratory system,% of total sales,6.0
+29734,Slovenia,2013,7,R-Respiratory system,"/capita, US$ purchasing power parity",22.4
+29735,Slovenia,2013,7,C08-Calcium channel blockers,"/capita, US$ exchange rate",4.3
+29736,Slovenia,2013,7,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million US$ at exchange rate,11.7
+29737,Slovenia,2013,7,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million of national currency units,8.8
+29738,Slovenia,2013,7,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ purchasing power parity",7.3
+29739,Slovenia,2013,7,"H-Systemic hormonal preparations, excluding sex hormones and insulins",% of total sales,2.0
+29740,Slovenia,2013,7,B-Blood and blood forming organs,"/capita, US$ purchasing power parity",23.6
+29741,Slovenia,2013,7,B-Blood and blood forming organs,% of total sales,6.4
+29742,Slovenia,2013,7,B-Blood and blood forming organs,"Million US$, purchasing power parity",48.5
+29743,Slovenia,2013,7,B-Blood and blood forming organs,"/capita, US$ exchange rate",18.5
+29744,Slovenia,2013,7,J01-Antibacterials for systemic use,"Million US$, purchasing power parity",19.6
+29745,Slovenia,2013,7,J01-Antibacterials for systemic use,"/capita, US$ exchange rate",7.5
+29746,Slovenia,2013,7,J01-Antibacterials for systemic use,"/capita, US$ purchasing power parity",9.5
+29747,Slovenia,2013,7,J01-Antibacterials for systemic use,Million US$ at exchange rate,15.4
+29748,Slovenia,2013,7,"H-Systemic hormonal preparations, excluding sex hormones and insulins","Million US$, purchasing power parity",15.0
+29749,Slovenia,2013,7,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ exchange rate",5.7
+29750,Slovenia,2013,7,B-Blood and blood forming organs,Million US$ at exchange rate,38.1
+29751,Slovenia,2013,7,C09-Agents acting on the Renin-Angiotensin system,"Million US$, purchasing power parity",72.0
+29752,Slovenia,2013,7,A-Alimentary tract and metabolism,% of total sales,11.1
+29753,Slovenia,2013,7,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ exchange rate",27.4
+29754,Slovenia,2013,7,C09-Agents acting on the Renin-Angiotensin system,Million US$ at exchange rate,56.5
+29755,Slovenia,2013,7,N02-Analgesics,Million US$ at exchange rate,22.9
+29756,Slovenia,2013,7,N02-Analgesics,Million of national currency units,17.2
+29757,Slovenia,2013,7,C-Cardiovascular system,"/capita, US$ exchange rate",64.9
+29758,Slovenia,2013,7,C09-Agents acting on the Renin-Angiotensin system,Million of national currency units,42.5
+29759,Slovenia,2013,7,A-Alimentary tract and metabolism,"/capita, US$ purchasing power parity",41.0
+29760,Slovenia,2013,7,A-Alimentary tract and metabolism,Million of national currency units,49.9
+29761,Slovenia,2013,7,A-Alimentary tract and metabolism,Million US$ at exchange rate,66.3
+29762,Slovenia,2013,7,C09-Agents acting on the Renin-Angiotensin system,% of total sales,9.4
+29763,Slovenia,2013,7,J01-Antibacterials for systemic use,Million of national currency units,11.6
+29764,Slovenia,2013,7,A-Alimentary tract and metabolism,"/capita, US$ exchange rate",32.2
+29765,Slovenia,2013,7,A-Alimentary tract and metabolism,"Million US$, purchasing power parity",84.5
+29766,Slovenia,2013,7,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ purchasing power parity",35.0
+29767,Slovenia,2013,7,N05B-Anxiolytics,"/capita, US$ exchange rate",1.9
+29768,Slovenia,2013,7,N05B-Anxiolytics,"/capita, US$ purchasing power parity",2.4
+29769,Slovenia,2013,7,N05B-Anxiolytics,% of total sales,0.7
+29770,Slovenia,2013,7,N05B-Anxiolytics,"Million US$, purchasing power parity",5.0
+29771,Slovenia,2013,7,N06A-Antidepressants,Million of national currency units,14.5
+29772,Slovenia,2013,7,N06A-Antidepressants,Million US$ at exchange rate,19.3
+29773,Slovenia,2013,7,N05B-Anxiolytics,Million US$ at exchange rate,3.9
+29774,Slovenia,2013,7,G03-Sex hormones and modulators of the genital system,Million US$ at exchange rate,10.9
+29775,Slovenia,2013,7,G03-Sex hormones and modulators of the genital system,Million of national currency units,8.2
+29776,Slovenia,2013,7,N-Nervous system,"/capita, US$ exchange rate",46.3
+29777,Slovenia,2013,7,N-Nervous system,"/capita, US$ purchasing power parity",59.1
+29778,Slovenia,2013,7,G03-Sex hormones and modulators of the genital system,"/capita, US$ purchasing power parity",6.8
+29779,Slovenia,2013,7,G03-Sex hormones and modulators of the genital system,% of total sales,1.8
+29780,Slovenia,2013,7,G03-Sex hormones and modulators of the genital system,"Million US$, purchasing power parity",14.0
+29781,Slovenia,2013,7,G03-Sex hormones and modulators of the genital system,"/capita, US$ exchange rate",5.3
+29782,Slovenia,2013,7,A02A-Antacids,Million of national currency units,0.5
+29783,Slovenia,2013,7,C01A-Cardiac glycosides,"/capita, US$ purchasing power parity",0.3
+29784,Slovenia,2013,7,A02A-Antacids,"Million US$, purchasing power parity",0.9
+29785,Slovenia,2013,7,A02A-Antacids,Million US$ at exchange rate,0.7
+29786,Slovenia,2013,7,C10-Lipid modifying agents,% of total sales,5.5
+29787,Slovenia,2013,7,C10-Lipid modifying agents,"/capita, US$ purchasing power parity",20.3
+29788,Slovenia,2013,7,C01A-Cardiac glycosides,% of total sales,0.1
+29789,Slovenia,2013,7,Total pharmaceutical sales,Million of national currency units,451.1
+29790,Slovenia,2013,7,N06A-Antidepressants,"/capita, US$ purchasing power parity",11.9
+29791,Slovenia,2013,7,N06A-Antidepressants,% of total sales,3.2
+29792,Slovenia,2013,7,N06A-Antidepressants,"Million US$, purchasing power parity",24.6
+29793,Slovenia,2013,7,N06A-Antidepressants,"/capita, US$ exchange rate",9.3
+29794,Slovenia,2013,7,A02A-Antacids,"/capita, US$ purchasing power parity",0.4
+29795,Slovenia,2013,7,A02A-Antacids,"/capita, US$ exchange rate",0.4
+29796,Slovenia,2013,7,N05B-Anxiolytics,Million of national currency units,3.0
+29797,Slovenia,2013,7,A02A-Antacids,% of total sales,0.1
+29798,Slovenia,2013,7,R-Respiratory system,Million of national currency units,27.2
+29799,Slovenia,2013,7,N05C-Hypnotics and sedatives,"/capita, US$ purchasing power parity",2.1
+29800,Slovenia,2013,7,N05C-Hypnotics and sedatives,% of total sales,0.6
+29801,Slovenia,2013,7,N05C-Hypnotics and sedatives,"Million US$, purchasing power parity",4.3
+29802,Slovenia,2013,7,N05C-Hypnotics and sedatives,"/capita, US$ exchange rate",1.6
+29803,Slovenia,2013,7,C03-Diuretics,"Million US$, purchasing power parity",10.5
+29804,Slovenia,2013,7,C03-Diuretics,Million of national currency units,6.2
+29805,Slovenia,2013,7,C03-Diuretics,Million US$ at exchange rate,8.2
+29806,Slovenia,2013,7,M-Musculo-skeletal system,"/capita, US$ exchange rate",11.2
+29807,Slovenia,2013,7,M-Musculo-skeletal system,% of total sales,3.9
+29808,Slovenia,2013,7,M-Musculo-skeletal system,"/capita, US$ purchasing power parity",14.3
+29809,Slovenia,2013,7,N05C-Hypnotics and sedatives,Million of national currency units,2.5
+29810,Slovenia,2013,7,N05C-Hypnotics and sedatives,Million US$ at exchange rate,3.3
+29811,Slovenia,2013,7,M-Musculo-skeletal system,Million of national currency units,17.4
+29812,Slovenia,2013,7,M-Musculo-skeletal system,"Million US$, purchasing power parity",29.4
+29813,Slovenia,2013,7,M-Musculo-skeletal system,Million US$ at exchange rate,23.1
+29814,Slovenia,2013,7,C03-Diuretics,"/capita, US$ exchange rate",4.0
+29815,Slovenia,2013,7,C01A-Cardiac glycosides,Million US$ at exchange rate,0.4
+29816,Slovenia,2013,7,C01A-Cardiac glycosides,"Million US$, purchasing power parity",0.5
+29817,Slovenia,2013,7,C01A-Cardiac glycosides,Million of national currency units,0.3
+29818,Slovenia,2013,7,G-Genito urinary system and sex hormones,Million of national currency units,23.5
+29819,Slovenia,2013,7,N-Nervous system,Million US$ at exchange rate,95.5
+29820,Slovenia,2013,7,N-Nervous system,"Million US$, purchasing power parity",121.8
+29821,Slovenia,2013,7,C01A-Cardiac glycosides,"/capita, US$ exchange rate",0.2
+29822,Slovenia,2013,7,N-Nervous system,Million of national currency units,71.9
+29823,Slovenia,2013,7,G-Genito urinary system and sex hormones,% of total sales,5.2
+29824,Slovenia,2013,7,C03-Diuretics,% of total sales,1.4
+29825,Slovenia,2013,7,C03-Diuretics,"/capita, US$ purchasing power parity",5.1
+29826,Slovenia,2013,7,G-Genito urinary system and sex hormones,"/capita, US$ purchasing power parity",19.3
+29827,Slovenia,2013,7,G-Genito urinary system and sex hormones,Million US$ at exchange rate,31.1
+29828,Slovenia,2013,7,G-Genito urinary system and sex hormones,"Million US$, purchasing power parity",39.7
+29829,Slovenia,2013,7,G-Genito urinary system and sex hormones,"/capita, US$ exchange rate",15.1
+29830,Slovenia,2013,7,C07-Beta blocking agents,% of total sales,1.9
+29831,Slovenia,2013,7,M01A-Antiinflammatory and antirheumatic products non-steroids,"Million US$, purchasing power parity",13.9
+29832,Slovenia,2013,7,A10-Drugs used in diabetes,Million of national currency units,28.0
+29833,Slovenia,2013,7,A10-Drugs used in diabetes,Million US$ at exchange rate,37.1
+29834,Slovenia,2013,7,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million US$ at exchange rate,15.5
+29835,Slovenia,2013,7,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million of national currency units,11.7
+29836,Slovenia,2013,7,M01A-Antiinflammatory and antirheumatic products non-steroids,Million US$ at exchange rate,10.9
+29837,Slovenia,2013,7,C07-Beta blocking agents,Million US$ at exchange rate,11.6
+29838,Slovenia,2013,7,C07-Beta blocking agents,Million of national currency units,8.7
+29839,Slovenia,2013,7,C07-Beta blocking agents,"Million US$, purchasing power parity",14.7
+29840,Slovenia,2013,7,C07-Beta blocking agents,"/capita, US$ purchasing power parity",7.2
+29841,Slovenia,2013,7,M01A-Antiinflammatory and antirheumatic products non-steroids,Million of national currency units,8.2
+29842,Slovenia,2013,7,C07-Beta blocking agents,"/capita, US$ exchange rate",5.6
+29843,Slovenia,2013,7,J-Antiinfectives for systemic use,"/capita, US$ exchange rate",13.7
+29844,Slovenia,2013,7,J-Antiinfectives for systemic use,"/capita, US$ purchasing power parity",17.5
+29845,Slovenia,2013,7,J-Antiinfectives for systemic use,"Million US$, purchasing power parity",36.0
+29846,Slovenia,2013,7,A10-Drugs used in diabetes,% of total sales,6.2
+29847,Slovenia,2013,7,J-Antiinfectives for systemic use,% of total sales,4.7
+29848,Slovenia,2013,7,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"Million US$, purchasing power parity",19.8
+29849,Slovenia,2013,7,A10-Drugs used in diabetes,"/capita, US$ purchasing power parity",23.0
+29850,Slovenia,2013,7,A10-Drugs used in diabetes,"/capita, US$ exchange rate",18.0
+29851,Slovenia,2013,7,A10-Drugs used in diabetes,"Million US$, purchasing power parity",47.4
+29852,Slovenia,2013,7,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ exchange rate",5.3
+29853,Slovenia,2013,7,J-Antiinfectives for systemic use,Million US$ at exchange rate,28.2
+29854,Slovenia,2013,7,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ purchasing power parity",6.8
+29855,Slovenia,2013,7,"C01B-Antiarrhythmics, Class I and III",% of total sales,0.2
+29856,Slovenia,2013,7,C-Cardiovascular system,"/capita, US$ purchasing power parity",82.8
+29857,Slovenia,2013,7,C-Cardiovascular system,% of total sales,22.3
+29858,Slovenia,2013,7,Total pharmaceutical sales,"Million US$, purchasing power parity",764.0
+29859,Slovenia,2013,7,Total pharmaceutical sales,"/capita, US$ exchange rate",290.8
+29860,Slovenia,2013,7,"C01B-Antiarrhythmics, Class I and III","/capita, US$ purchasing power parity",0.9
+29861,Slovenia,2013,7,C10-Lipid modifying agents,Million US$ at exchange rate,32.8
+29862,Slovenia,2013,7,C10-Lipid modifying agents,"Million US$, purchasing power parity",41.8
+29863,Slovenia,2013,7,C10-Lipid modifying agents,"/capita, US$ exchange rate",15.9
+29864,Slovenia,2013,7,B-Blood and blood forming organs,Million of national currency units,28.7
+29865,Slovenia,2013,7,C10-Lipid modifying agents,Million of national currency units,24.7
+29866,Slovenia,2013,7,Total pharmaceutical sales,Million US$ at exchange rate,599.1
+29867,Slovenia,2013,7,N-Nervous system,% of total sales,15.9
+29868,Slovenia,2013,7,J-Antiinfectives for systemic use,Million of national currency units,21.2
+29869,Slovenia,2013,7,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),% of total sales,2.6
+29870,Slovenia,2013,7,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ exchange rate",7.5
+29871,Slovenia,2013,7,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ purchasing power parity",9.6
+29872,Slovenia,2013,7,M01A-Antiinflammatory and antirheumatic products non-steroids,% of total sales,1.8
+29873,Slovenia,2013,7,"C01B-Antiarrhythmics, Class I and III","Million US$, purchasing power parity",1.8
+29874,Slovenia,2013,7,"C01B-Antiarrhythmics, Class I and III",Million US$ at exchange rate,1.5
+29875,Slovenia,2013,7,"C01B-Antiarrhythmics, Class I and III","/capita, US$ exchange rate",0.7
+29876,Slovenia,2013,7,"C01B-Antiarrhythmics, Class I and III",Million of national currency units,1.1
+29877,Slovenia,2013,7,Total pharmaceutical sales,"/capita, US$ purchasing power parity",370.9
+29878,Slovenia,2013,7,C02-Antihypertensives,% of total sales,1.0
+29879,Slovenia,2012,7,R03-Drugs for obstructive airway diseases,Million US$ at exchange rate,29.3
+29880,Slovenia,2012,7,R03-Drugs for obstructive airway diseases,"Million US$, purchasing power parity",37.6
+29881,Slovenia,2012,7,R03-Drugs for obstructive airway diseases,"/capita, US$ exchange rate",14.3
+29882,Slovenia,2012,7,R03-Drugs for obstructive airway diseases,% of total sales,5.0
+29883,Slovenia,2012,7,C02-Antihypertensives,"/capita, US$ purchasing power parity",3.5
+29884,Slovenia,2012,7,R03-Drugs for obstructive airway diseases,Million of national currency units,22.8
+29885,Slovenia,2012,7,R03-Drugs for obstructive airway diseases,"/capita, US$ purchasing power parity",18.3
+29886,Slovenia,2012,7,C-Cardiovascular system,Million US$ at exchange rate,135.4
+29887,Slovenia,2012,7,N02-Analgesics,"/capita, US$ purchasing power parity",12.8
+29888,Slovenia,2012,7,N02-Analgesics,% of total sales,3.5
+29889,Slovenia,2012,7,N02-Analgesics,"/capita, US$ exchange rate",10.0
+29890,Slovenia,2012,7,C08-Calcium channel blockers,% of total sales,1.5
+29891,Slovenia,2012,7,C-Cardiovascular system,"Million US$, purchasing power parity",173.6
+29892,Slovenia,2012,7,C02-Antihypertensives,"/capita, US$ exchange rate",2.7
+29893,Slovenia,2012,7,C08-Calcium channel blockers,"Million US$, purchasing power parity",11.0
+29894,Slovenia,2012,7,C08-Calcium channel blockers,Million US$ at exchange rate,8.6
+29895,Slovenia,2012,7,R-Respiratory system,"/capita, US$ exchange rate",17.6
+29896,Slovenia,2012,7,R-Respiratory system,"Million US$, purchasing power parity",46.5
+29897,Slovenia,2012,7,C02-Antihypertensives,"Million US$, purchasing power parity",7.1
+29898,Slovenia,2012,7,R-Respiratory system,Million US$ at exchange rate,36.2
+29899,Slovenia,2012,7,C08-Calcium channel blockers,Million of national currency units,6.7
+29900,Slovenia,2012,7,C02-Antihypertensives,Million US$ at exchange rate,5.5
+29901,Slovenia,2012,7,C-Cardiovascular system,Million of national currency units,105.4
+29902,Slovenia,2012,7,C02-Antihypertensives,Million of national currency units,4.3
+29903,Slovenia,2012,7,C08-Calcium channel blockers,"/capita, US$ purchasing power parity",5.3
+29904,Slovenia,2012,7,J01-Antibacterials for systemic use,% of total sales,2.5
+29905,Slovenia,2012,7,N02-Analgesics,"Million US$, purchasing power parity",26.4
+29906,Slovenia,2012,7,R-Respiratory system,% of total sales,6.2
+29907,Slovenia,2012,7,R-Respiratory system,"/capita, US$ purchasing power parity",22.6
+29908,Slovenia,2012,7,C08-Calcium channel blockers,"/capita, US$ exchange rate",4.2
+29909,Slovenia,2012,7,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million US$ at exchange rate,11.5
+29910,Slovenia,2012,7,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million of national currency units,8.9
+29911,Slovenia,2012,7,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ purchasing power parity",7.2
+29912,Slovenia,2012,7,"H-Systemic hormonal preparations, excluding sex hormones and insulins",% of total sales,2.0
+29913,Slovenia,2012,7,B-Blood and blood forming organs,"/capita, US$ purchasing power parity",20.3
+29914,Slovenia,2012,7,B-Blood and blood forming organs,% of total sales,5.6
+29915,Slovenia,2012,7,B-Blood and blood forming organs,"Million US$, purchasing power parity",41.9
+29916,Slovenia,2012,7,B-Blood and blood forming organs,"/capita, US$ exchange rate",15.9
+29917,Slovenia,2012,7,J01-Antibacterials for systemic use,"Million US$, purchasing power parity",18.8
+29918,Slovenia,2012,7,J01-Antibacterials for systemic use,"/capita, US$ exchange rate",7.1
+29919,Slovenia,2012,7,J01-Antibacterials for systemic use,"/capita, US$ purchasing power parity",9.2
+29920,Slovenia,2012,7,"H-Systemic hormonal preparations, excluding sex hormones and insulins","Million US$, purchasing power parity",14.7
+29921,Slovenia,2012,7,J01-Antibacterials for systemic use,Million US$ at exchange rate,14.7
+29922,Slovenia,2012,7,B-Blood and blood forming organs,Million US$ at exchange rate,32.6
+29923,Slovenia,2012,7,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ exchange rate",5.6
+29924,Slovenia,2012,7,C09-Agents acting on the Renin-Angiotensin system,"Million US$, purchasing power parity",77.4
+29925,Slovenia,2012,7,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ exchange rate",29.3
+29926,Slovenia,2012,7,A-Alimentary tract and metabolism,% of total sales,11.4
+29927,Slovenia,2012,7,C09-Agents acting on the Renin-Angiotensin system,Million US$ at exchange rate,60.3
+29928,Slovenia,2012,7,N02-Analgesics,Million US$ at exchange rate,20.6
+29929,Slovenia,2012,7,N02-Analgesics,Million of national currency units,16.0
+29930,Slovenia,2012,7,C09-Agents acting on the Renin-Angiotensin system,Million of national currency units,47.0
+29931,Slovenia,2012,7,C-Cardiovascular system,"/capita, US$ exchange rate",65.8
+29932,Slovenia,2012,7,A-Alimentary tract and metabolism,Million of national currency units,51.8
+29933,Slovenia,2012,7,A-Alimentary tract and metabolism,Million US$ at exchange rate,66.6
+29934,Slovenia,2012,7,C09-Agents acting on the Renin-Angiotensin system,% of total sales,10.3
+29935,Slovenia,2012,7,J01-Antibacterials for systemic use,Million of national currency units,11.4
+29936,Slovenia,2012,7,A-Alimentary tract and metabolism,"/capita, US$ exchange rate",32.4
+29937,Slovenia,2012,7,A-Alimentary tract and metabolism,"/capita, US$ purchasing power parity",41.5
+29938,Slovenia,2012,7,A-Alimentary tract and metabolism,"Million US$, purchasing power parity",85.4
+29939,Slovenia,2012,7,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ purchasing power parity",37.6
+29940,Slovenia,2012,7,R-Respiratory system,Million of national currency units,28.2
+29941,Slovenia,2012,7,N05B-Anxiolytics,"/capita, US$ exchange rate",1.8
+29942,Slovenia,2012,7,N05B-Anxiolytics,% of total sales,0.6
+29943,Slovenia,2012,7,N05B-Anxiolytics,"/capita, US$ purchasing power parity",2.3
+29944,Slovenia,2012,7,N06A-Antidepressants,Million US$ at exchange rate,18.8
+29945,Slovenia,2012,7,N06A-Antidepressants,Million of national currency units,14.6
+29946,Slovenia,2012,7,N05B-Anxiolytics,"Million US$, purchasing power parity",4.7
+29947,Slovenia,2012,7,N05B-Anxiolytics,Million US$ at exchange rate,3.7
+29948,Slovenia,2012,7,G03-Sex hormones and modulators of the genital system,Million US$ at exchange rate,11.6
+29949,Slovenia,2012,7,G03-Sex hormones and modulators of the genital system,Million of national currency units,9.1
+29950,Slovenia,2012,7,N-Nervous system,"/capita, US$ exchange rate",46.3
+29951,Slovenia,2012,7,N-Nervous system,"/capita, US$ purchasing power parity",59.4
+29952,Slovenia,2012,7,G03-Sex hormones and modulators of the genital system,"Million US$, purchasing power parity",14.9
+29953,Slovenia,2012,7,G03-Sex hormones and modulators of the genital system,"/capita, US$ purchasing power parity",7.3
+29954,Slovenia,2012,7,G03-Sex hormones and modulators of the genital system,% of total sales,2.0
+29955,Slovenia,2012,7,G03-Sex hormones and modulators of the genital system,"/capita, US$ exchange rate",5.7
+29956,Slovenia,2012,7,A02A-Antacids,Million of national currency units,0.5
+29957,Slovenia,2012,7,C01A-Cardiac glycosides,"/capita, US$ purchasing power parity",0.3
+29958,Slovenia,2012,7,A02A-Antacids,"Million US$, purchasing power parity",0.8
+29959,Slovenia,2012,7,A02A-Antacids,Million US$ at exchange rate,0.6
+29960,Slovenia,2012,7,C01A-Cardiac glycosides,% of total sales,0.1
+29961,Slovenia,2012,7,C10-Lipid modifying agents,% of total sales,5.6
+29962,Slovenia,2012,7,C10-Lipid modifying agents,"/capita, US$ purchasing power parity",20.3
+29963,Slovenia,2012,7,Total pharmaceutical sales,Million of national currency units,454.4
+29964,Slovenia,2012,7,N06A-Antidepressants,"/capita, US$ purchasing power parity",11.7
+29965,Slovenia,2012,7,N06A-Antidepressants,% of total sales,3.2
+29966,Slovenia,2012,7,N06A-Antidepressants,"Million US$, purchasing power parity",24.1
+29967,Slovenia,2012,7,N06A-Antidepressants,"/capita, US$ exchange rate",9.1
+29968,Slovenia,2012,7,A02A-Antacids,"/capita, US$ purchasing power parity",0.4
+29969,Slovenia,2012,7,A02A-Antacids,"/capita, US$ exchange rate",0.3
+29970,Slovenia,2012,7,N05B-Anxiolytics,Million of national currency units,2.9
+29971,Slovenia,2012,7,A02A-Antacids,% of total sales,0.1
+29972,Slovenia,2012,7,N05C-Hypnotics and sedatives,"/capita, US$ purchasing power parity",2.1
+29973,Slovenia,2012,7,N05C-Hypnotics and sedatives,% of total sales,0.6
+29974,Slovenia,2012,7,N05C-Hypnotics and sedatives,"Million US$, purchasing power parity",4.2
+29975,Slovenia,2012,7,N05C-Hypnotics and sedatives,"/capita, US$ exchange rate",1.6
+29976,Slovenia,2012,7,C03-Diuretics,"Million US$, purchasing power parity",10.0
+29977,Slovenia,2012,7,C03-Diuretics,Million US$ at exchange rate,7.8
+29978,Slovenia,2012,7,C03-Diuretics,Million of national currency units,6.0
+29979,Slovenia,2012,7,M-Musculo-skeletal system,"/capita, US$ exchange rate",11.6
+29980,Slovenia,2012,7,M-Musculo-skeletal system,"/capita, US$ purchasing power parity",14.9
+29981,Slovenia,2012,7,M-Musculo-skeletal system,% of total sales,4.1
+29982,Slovenia,2012,7,M-Musculo-skeletal system,"Million US$, purchasing power parity",30.6
+29983,Slovenia,2012,7,M-Musculo-skeletal system,Million of national currency units,18.6
+29984,Slovenia,2012,7,N05C-Hypnotics and sedatives,Million of national currency units,2.6
+29985,Slovenia,2012,7,N05C-Hypnotics and sedatives,Million US$ at exchange rate,3.3
+29986,Slovenia,2012,7,M-Musculo-skeletal system,Million US$ at exchange rate,23.9
+29987,Slovenia,2012,7,C03-Diuretics,"/capita, US$ exchange rate",3.8
+29988,Slovenia,2012,7,C01A-Cardiac glycosides,Million US$ at exchange rate,0.4
+29989,Slovenia,2012,7,C01A-Cardiac glycosides,"Million US$, purchasing power parity",0.5
+29990,Slovenia,2012,7,G-Genito urinary system and sex hormones,Million of national currency units,24.7
+29991,Slovenia,2012,7,C01A-Cardiac glycosides,Million of national currency units,0.3
+29992,Slovenia,2012,7,N-Nervous system,Million US$ at exchange rate,95.2
+29993,Slovenia,2012,7,N-Nervous system,"Million US$, purchasing power parity",122.2
+29994,Slovenia,2012,7,C01A-Cardiac glycosides,"/capita, US$ exchange rate",0.2
+29995,Slovenia,2012,7,N-Nervous system,Million of national currency units,74.1
+29996,Slovenia,2012,7,G-Genito urinary system and sex hormones,% of total sales,5.4
+29997,Slovenia,2012,7,C03-Diuretics,% of total sales,1.3
+29998,Slovenia,2012,7,C03-Diuretics,"/capita, US$ purchasing power parity",4.8
+29999,Slovenia,2012,7,G-Genito urinary system and sex hormones,"/capita, US$ purchasing power parity",19.8
+30000,Slovenia,2012,7,G-Genito urinary system and sex hormones,Million US$ at exchange rate,31.7
+30001,Slovenia,2012,7,G-Genito urinary system and sex hormones,"Million US$, purchasing power parity",40.7
+30002,Slovenia,2012,7,G-Genito urinary system and sex hormones,"/capita, US$ exchange rate",15.4
+30003,Slovenia,2012,7,C07-Beta blocking agents,% of total sales,1.8
+30004,Slovenia,2012,7,M01A-Antiinflammatory and antirheumatic products non-steroids,"Million US$, purchasing power parity",12.9
+30005,Slovenia,2012,7,A10-Drugs used in diabetes,Million of national currency units,28.2
+30006,Slovenia,2012,7,A10-Drugs used in diabetes,Million US$ at exchange rate,36.2
+30007,Slovenia,2012,7,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million US$ at exchange rate,17.3
+30008,Slovenia,2012,7,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million of national currency units,13.4
+30009,Slovenia,2012,7,M01A-Antiinflammatory and antirheumatic products non-steroids,Million US$ at exchange rate,10.1
+30010,Slovenia,2012,7,C07-Beta blocking agents,Million US$ at exchange rate,10.7
+30011,Slovenia,2012,7,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"Million US$, purchasing power parity",22.1
+30012,Slovenia,2012,7,C07-Beta blocking agents,Million of national currency units,8.3
+30013,Slovenia,2012,7,C07-Beta blocking agents,"Million US$, purchasing power parity",13.8
+30014,Slovenia,2012,7,C07-Beta blocking agents,"/capita, US$ purchasing power parity",6.7
+30015,Slovenia,2012,7,M01A-Antiinflammatory and antirheumatic products non-steroids,Million of national currency units,7.8
+30016,Slovenia,2012,7,C07-Beta blocking agents,"/capita, US$ exchange rate",5.2
+30017,Slovenia,2012,7,J-Antiinfectives for systemic use,"/capita, US$ exchange rate",12.4
+30018,Slovenia,2012,7,J-Antiinfectives for systemic use,"/capita, US$ purchasing power parity",15.9
+30019,Slovenia,2012,7,J-Antiinfectives for systemic use,"Million US$, purchasing power parity",32.7
+30020,Slovenia,2012,7,A10-Drugs used in diabetes,% of total sales,6.2
+30021,Slovenia,2012,7,J-Antiinfectives for systemic use,% of total sales,4.4
+30022,Slovenia,2012,7,J-Antiinfectives for systemic use,Million US$ at exchange rate,25.5
+30023,Slovenia,2012,7,A10-Drugs used in diabetes,"/capita, US$ purchasing power parity",22.6
+30024,Slovenia,2012,7,A10-Drugs used in diabetes,"Million US$, purchasing power parity",46.4
+30025,Slovenia,2012,7,A10-Drugs used in diabetes,"/capita, US$ exchange rate",17.6
+30026,Slovenia,2012,7,M01A-Antiinflammatory and antirheumatic products non-steroids,% of total sales,1.7
+30027,Slovenia,2012,7,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ exchange rate",4.9
+30028,Slovenia,2012,7,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ purchasing power parity",6.3
+30029,Slovenia,2012,7,C-Cardiovascular system,% of total sales,23.2
+30030,Slovenia,2012,7,C-Cardiovascular system,"/capita, US$ purchasing power parity",84.4
+30031,Slovenia,2012,7,"C01B-Antiarrhythmics, Class I and III",% of total sales,0.2
+30032,Slovenia,2012,7,Total pharmaceutical sales,"Million US$, purchasing power parity",748.8
+30033,Slovenia,2012,7,Total pharmaceutical sales,"/capita, US$ exchange rate",283.8
+30034,Slovenia,2012,7,"C01B-Antiarrhythmics, Class I and III","/capita, US$ purchasing power parity",0.9
+30035,Slovenia,2012,7,C10-Lipid modifying agents,"Million US$, purchasing power parity",41.8
+30036,Slovenia,2012,7,C10-Lipid modifying agents,Million US$ at exchange rate,32.6
+30037,Slovenia,2012,7,C10-Lipid modifying agents,"/capita, US$ exchange rate",15.8
+30038,Slovenia,2012,7,B-Blood and blood forming organs,Million of national currency units,25.4
+30039,Slovenia,2012,7,C10-Lipid modifying agents,Million of national currency units,25.3
+30040,Slovenia,2012,7,Total pharmaceutical sales,Million US$ at exchange rate,583.8
+30041,Slovenia,2012,7,J-Antiinfectives for systemic use,Million of national currency units,19.9
+30042,Slovenia,2012,7,N-Nervous system,% of total sales,16.3
+30043,Slovenia,2012,7,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ exchange rate",8.4
+30044,Slovenia,2012,7,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ purchasing power parity",10.8
+30045,Slovenia,2012,7,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),% of total sales,3.0
+30046,Slovenia,2012,7,"C01B-Antiarrhythmics, Class I and III",Million US$ at exchange rate,1.4
+30047,Slovenia,2012,7,"C01B-Antiarrhythmics, Class I and III","/capita, US$ exchange rate",0.7
+30048,Slovenia,2012,7,"C01B-Antiarrhythmics, Class I and III","Million US$, purchasing power parity",1.9
+30049,Slovenia,2012,7,"C01B-Antiarrhythmics, Class I and III",Million of national currency units,1.1
+30050,Slovenia,2012,7,Total pharmaceutical sales,"/capita, US$ purchasing power parity",364.0
+30051,Slovenia,2012,7,C02-Antihypertensives,% of total sales,0.9
+30052,Slovenia,2011,8,R03-Drugs for obstructive airway diseases,"Million US$, purchasing power parity",36.9
+30053,Slovenia,2011,8,R03-Drugs for obstructive airway diseases,"/capita, US$ exchange rate",15.6
+30054,Slovenia,2011,8,R03-Drugs for obstructive airway diseases,Million US$ at exchange rate,32.0
+30055,Slovenia,2011,8,R03-Drugs for obstructive airway diseases,% of total sales,4.9
+30056,Slovenia,2011,8,C02-Antihypertensives,"/capita, US$ purchasing power parity",3.5
+30057,Slovenia,2011,8,R03-Drugs for obstructive airway diseases,"/capita, US$ purchasing power parity",18.0
+30058,Slovenia,2011,8,R03-Drugs for obstructive airway diseases,Million of national currency units,23.0
+30059,Slovenia,2011,8,N02-Analgesics,"/capita, US$ purchasing power parity",13.0
+30060,Slovenia,2011,8,N02-Analgesics,% of total sales,3.5
+30061,Slovenia,2011,8,N02-Analgesics,"/capita, US$ exchange rate",11.3
+30062,Slovenia,2011,8,C-Cardiovascular system,"Million US$, purchasing power parity",182.1
+30063,Slovenia,2011,8,C08-Calcium channel blockers,% of total sales,1.7
+30064,Slovenia,2011,8,C02-Antihypertensives,"/capita, US$ exchange rate",3.0
+30065,Slovenia,2011,8,C08-Calcium channel blockers,"Million US$, purchasing power parity",13.1
+30066,Slovenia,2011,8,C08-Calcium channel blockers,Million US$ at exchange rate,11.4
+30067,Slovenia,2011,8,R-Respiratory system,"/capita, US$ exchange rate",19.8
+30068,Slovenia,2011,8,R-Respiratory system,"Million US$, purchasing power parity",46.8
+30069,Slovenia,2011,8,C02-Antihypertensives,"Million US$, purchasing power parity",7.2
+30070,Slovenia,2011,8,R-Respiratory system,Million US$ at exchange rate,40.6
+30071,Slovenia,2011,8,C08-Calcium channel blockers,Million of national currency units,8.2
+30072,Slovenia,2011,8,C02-Antihypertensives,Million US$ at exchange rate,6.2
+30073,Slovenia,2011,8,C-Cardiovascular system,Million of national currency units,113.7
+30074,Slovenia,2011,8,C02-Antihypertensives,Million of national currency units,4.5
+30075,Slovenia,2011,8,C-Cardiovascular system,Million US$ at exchange rate,158.2
+30076,Slovenia,2011,8,J01-Antibacterials for systemic use,% of total sales,2.5
+30077,Slovenia,2011,8,C08-Calcium channel blockers,"/capita, US$ purchasing power parity",6.4
+30078,Slovenia,2011,8,R-Respiratory system,% of total sales,6.2
+30079,Slovenia,2011,8,R-Respiratory system,"/capita, US$ purchasing power parity",22.8
+30080,Slovenia,2011,8,C08-Calcium channel blockers,"/capita, US$ exchange rate",5.5
+30081,Slovenia,2011,8,N02-Analgesics,"Million US$, purchasing power parity",26.7
+30082,Slovenia,2011,8,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million US$ at exchange rate,12.8
+30083,Slovenia,2011,8,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million of national currency units,9.2
+30084,Slovenia,2011,8,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ purchasing power parity",7.2
+30085,Slovenia,2011,8,"H-Systemic hormonal preparations, excluding sex hormones and insulins",% of total sales,2.0
+30086,Slovenia,2011,8,B-Blood and blood forming organs,"/capita, US$ purchasing power parity",19.6
+30087,Slovenia,2011,8,B-Blood and blood forming organs,% of total sales,5.4
+30088,Slovenia,2011,8,B-Blood and blood forming organs,"Million US$, purchasing power parity",40.3
+30089,Slovenia,2011,8,B-Blood and blood forming organs,"/capita, US$ exchange rate",17.1
+30090,Slovenia,2011,8,J01-Antibacterials for systemic use,"/capita, US$ exchange rate",8.0
+30091,Slovenia,2011,8,J01-Antibacterials for systemic use,"Million US$, purchasing power parity",18.8
+30092,Slovenia,2011,8,J01-Antibacterials for systemic use,"/capita, US$ purchasing power parity",9.2
+30093,Slovenia,2011,8,"H-Systemic hormonal preparations, excluding sex hormones and insulins","Million US$, purchasing power parity",14.7
+30094,Slovenia,2011,8,J01-Antibacterials for systemic use,Million US$ at exchange rate,16.4
+30095,Slovenia,2011,8,B-Blood and blood forming organs,Million US$ at exchange rate,35.0
+30096,Slovenia,2011,8,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ exchange rate",6.2
+30097,Slovenia,2011,8,C09-Agents acting on the Renin-Angiotensin system,"Million US$, purchasing power parity",82.6
+30098,Slovenia,2011,8,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ exchange rate",35.0
+30099,Slovenia,2011,8,A-Alimentary tract and metabolism,% of total sales,11.7
+30100,Slovenia,2011,8,N02-Analgesics,Million US$ at exchange rate,23.1
+30101,Slovenia,2011,8,N02-Analgesics,Million of national currency units,16.6
+30102,Slovenia,2011,8,C09-Agents acting on the Renin-Angiotensin system,Million US$ at exchange rate,71.8
+30103,Slovenia,2011,8,C09-Agents acting on the Renin-Angiotensin system,Million of national currency units,51.6
+30104,Slovenia,2011,8,C-Cardiovascular system,"/capita, US$ exchange rate",77.1
+30105,Slovenia,2011,8,A-Alimentary tract and metabolism,Million US$ at exchange rate,76.8
+30106,Slovenia,2011,8,A-Alimentary tract and metabolism,Million of national currency units,55.2
+30107,Slovenia,2011,8,J01-Antibacterials for systemic use,Million of national currency units,11.7
+30108,Slovenia,2011,8,C09-Agents acting on the Renin-Angiotensin system,% of total sales,11.0
+30109,Slovenia,2011,8,A-Alimentary tract and metabolism,"/capita, US$ exchange rate",37.4
+30110,Slovenia,2011,8,A-Alimentary tract and metabolism,"/capita, US$ purchasing power parity",43.1
+30111,Slovenia,2011,8,A-Alimentary tract and metabolism,"Million US$, purchasing power parity",88.4
+30112,Slovenia,2011,8,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ purchasing power parity",40.2
+30113,Slovenia,2011,8,N05B-Anxiolytics,"/capita, US$ exchange rate",2.0
+30114,Slovenia,2011,8,N05B-Anxiolytics,"/capita, US$ purchasing power parity",2.3
+30115,Slovenia,2011,8,N05B-Anxiolytics,% of total sales,0.6
+30116,Slovenia,2011,8,N05B-Anxiolytics,"Million US$, purchasing power parity",4.7
+30117,Slovenia,2011,8,N06A-Antidepressants,Million US$ at exchange rate,22.1
+30118,Slovenia,2011,8,N06A-Antidepressants,Million of national currency units,15.9
+30119,Slovenia,2011,8,N05B-Anxiolytics,Million US$ at exchange rate,4.1
+30120,Slovenia,2011,8,G03-Sex hormones and modulators of the genital system,Million US$ at exchange rate,13.7
+30121,Slovenia,2011,8,N-Nervous system,"/capita, US$ exchange rate",54.2
+30122,Slovenia,2011,8,N-Nervous system,"/capita, US$ purchasing power parity",62.4
+30123,Slovenia,2011,8,G03-Sex hormones and modulators of the genital system,Million of national currency units,9.8
+30124,Slovenia,2011,8,G03-Sex hormones and modulators of the genital system,% of total sales,2.1
+30125,Slovenia,2011,8,G03-Sex hormones and modulators of the genital system,"/capita, US$ purchasing power parity",7.7
+30126,Slovenia,2011,8,G03-Sex hormones and modulators of the genital system,"Million US$, purchasing power parity",15.7
+30127,Slovenia,2011,8,G03-Sex hormones and modulators of the genital system,"/capita, US$ exchange rate",6.7
+30128,Slovenia,2011,8,N06A-Antidepressants,"Million US$, purchasing power parity",25.5
+30129,Slovenia,2011,8,A02A-Antacids,Million of national currency units,0.4
+30130,Slovenia,2011,8,C01A-Cardiac glycosides,"/capita, US$ purchasing power parity",0.2
+30131,Slovenia,2011,8,A02A-Antacids,"Million US$, purchasing power parity",0.7
+30132,Slovenia,2011,8,A02A-Antacids,Million US$ at exchange rate,0.6
+30133,Slovenia,2011,8,C10-Lipid modifying agents,% of total sales,5.9
+30134,Slovenia,2011,8,C10-Lipid modifying agents,"/capita, US$ purchasing power parity",21.7
+30135,Slovenia,2011,8,C01A-Cardiac glycosides,% of total sales,0.1
+30136,Slovenia,2011,8,Total pharmaceutical sales,Million of national currency units,470.0
+30137,Slovenia,2011,8,N06A-Antidepressants,"/capita, US$ purchasing power parity",12.4
+30138,Slovenia,2011,8,N06A-Antidepressants,% of total sales,3.4
+30139,Slovenia,2011,8,N06A-Antidepressants,"/capita, US$ exchange rate",10.8
+30140,Slovenia,2011,8,A02A-Antacids,"/capita, US$ purchasing power parity",0.3
+30141,Slovenia,2011,8,A02A-Antacids,"/capita, US$ exchange rate",0.3
+30142,Slovenia,2011,8,N05B-Anxiolytics,Million of national currency units,2.9
+30143,Slovenia,2011,8,A02A-Antacids,% of total sales,0.1
+30144,Slovenia,2011,8,N05C-Hypnotics and sedatives,"/capita, US$ purchasing power parity",2.1
+30145,Slovenia,2011,8,N05C-Hypnotics and sedatives,% of total sales,0.6
+30146,Slovenia,2011,8,N05C-Hypnotics and sedatives,"Million US$, purchasing power parity",4.3
+30147,Slovenia,2011,8,N05C-Hypnotics and sedatives,"/capita, US$ exchange rate",1.8
+30148,Slovenia,2011,8,C03-Diuretics,"Million US$, purchasing power parity",9.8
+30149,Slovenia,2011,8,C03-Diuretics,Million of national currency units,6.1
+30150,Slovenia,2011,8,C03-Diuretics,Million US$ at exchange rate,8.5
+30151,Slovenia,2011,8,C03-Diuretics,"/capita, US$ exchange rate",4.1
+30152,Slovenia,2011,8,M-Musculo-skeletal system,"/capita, US$ exchange rate",13.1
+30153,Slovenia,2011,8,M-Musculo-skeletal system,"/capita, US$ purchasing power parity",15.1
+30154,Slovenia,2011,8,M-Musculo-skeletal system,% of total sales,4.1
+30155,Slovenia,2011,8,M-Musculo-skeletal system,Million of national currency units,19.3
+30156,Slovenia,2011,8,N05C-Hypnotics and sedatives,Million of national currency units,2.7
+30157,Slovenia,2011,8,N05C-Hypnotics and sedatives,Million US$ at exchange rate,3.8
+30158,Slovenia,2011,8,M-Musculo-skeletal system,"Million US$, purchasing power parity",31.0
+30159,Slovenia,2011,8,M-Musculo-skeletal system,Million US$ at exchange rate,26.9
+30160,Slovenia,2011,8,C01A-Cardiac glycosides,Million US$ at exchange rate,0.4
+30161,Slovenia,2011,8,C01A-Cardiac glycosides,"Million US$, purchasing power parity",0.5
+30162,Slovenia,2011,8,G-Genito urinary system and sex hormones,Million of national currency units,26.3
+30163,Slovenia,2011,8,C01A-Cardiac glycosides,Million of national currency units,0.3
+30164,Slovenia,2011,8,N-Nervous system,Million US$ at exchange rate,111.2
+30165,Slovenia,2011,8,N-Nervous system,"Million US$, purchasing power parity",128.1
+30166,Slovenia,2011,8,C01A-Cardiac glycosides,"/capita, US$ exchange rate",0.2
+30167,Slovenia,2011,8,N-Nervous system,Million of national currency units,79.9
+30168,Slovenia,2011,8,G-Genito urinary system and sex hormones,% of total sales,5.6
+30169,Slovenia,2011,8,C03-Diuretics,"/capita, US$ purchasing power parity",4.8
+30170,Slovenia,2011,8,C03-Diuretics,% of total sales,1.3
+30171,Slovenia,2011,8,G-Genito urinary system and sex hormones,"Million US$, purchasing power parity",42.2
+30172,Slovenia,2011,8,G-Genito urinary system and sex hormones,Million US$ at exchange rate,36.7
+30173,Slovenia,2011,8,G-Genito urinary system and sex hormones,"/capita, US$ purchasing power parity",20.6
+30174,Slovenia,2011,8,G-Genito urinary system and sex hormones,"/capita, US$ exchange rate",17.9
+30175,Slovenia,2011,8,C07-Beta blocking agents,% of total sales,1.7
+30176,Slovenia,2011,8,M01A-Antiinflammatory and antirheumatic products non-steroids,"Million US$, purchasing power parity",13.3
+30177,Slovenia,2011,8,A10-Drugs used in diabetes,Million US$ at exchange rate,37.5
+30178,Slovenia,2011,8,A10-Drugs used in diabetes,Million of national currency units,26.9
+30179,Slovenia,2011,8,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million of national currency units,17.9
+30180,Slovenia,2011,8,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million US$ at exchange rate,24.9
+30181,Slovenia,2011,8,M01A-Antiinflammatory and antirheumatic products non-steroids,Million US$ at exchange rate,11.6
+30182,Slovenia,2011,8,C07-Beta blocking agents,Million US$ at exchange rate,10.9
+30183,Slovenia,2011,8,C07-Beta blocking agents,"Million US$, purchasing power parity",12.6
+30184,Slovenia,2011,8,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"Million US$, purchasing power parity",28.7
+30185,Slovenia,2011,8,C07-Beta blocking agents,Million of national currency units,7.8
+30186,Slovenia,2011,8,C07-Beta blocking agents,"/capita, US$ purchasing power parity",6.1
+30187,Slovenia,2011,8,M01A-Antiinflammatory and antirheumatic products non-steroids,Million of national currency units,8.3
+30188,Slovenia,2011,8,C07-Beta blocking agents,"/capita, US$ exchange rate",5.3
+30189,Slovenia,2011,8,J-Antiinfectives for systemic use,"/capita, US$ exchange rate",13.3
+30190,Slovenia,2011,8,J-Antiinfectives for systemic use,"/capita, US$ purchasing power parity",15.3
+30191,Slovenia,2011,8,J-Antiinfectives for systemic use,"Million US$, purchasing power parity",31.5
+30192,Slovenia,2011,8,A10-Drugs used in diabetes,% of total sales,5.7
+30193,Slovenia,2011,8,J-Antiinfectives for systemic use,% of total sales,4.2
+30194,Slovenia,2011,8,A10-Drugs used in diabetes,"/capita, US$ purchasing power parity",21.0
+30195,Slovenia,2011,8,A10-Drugs used in diabetes,"/capita, US$ exchange rate",18.3
+30196,Slovenia,2011,8,A10-Drugs used in diabetes,"Million US$, purchasing power parity",43.2
+30197,Slovenia,2011,8,M01A-Antiinflammatory and antirheumatic products non-steroids,% of total sales,1.8
+30198,Slovenia,2011,8,J-Antiinfectives for systemic use,Million US$ at exchange rate,27.3
+30199,Slovenia,2011,8,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ exchange rate",5.6
+30200,Slovenia,2011,8,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ purchasing power parity",6.5
+30201,Slovenia,2011,8,C-Cardiovascular system,"/capita, US$ purchasing power parity",88.7
+30202,Slovenia,2011,8,C-Cardiovascular system,% of total sales,24.2
+30203,Slovenia,2011,8,Total pharmaceutical sales,"Million US$, purchasing power parity",753.3
+30204,Slovenia,2011,8,Total pharmaceutical sales,"/capita, US$ exchange rate",318.7
+30205,Slovenia,2011,8,"C01B-Antiarrhythmics, Class I and III",% of total sales,0.3
+30206,Slovenia,2011,8,"C01B-Antiarrhythmics, Class I and III","/capita, US$ purchasing power parity",1.0
+30207,Slovenia,2011,8,C10-Lipid modifying agents,"Million US$, purchasing power parity",44.5
+30208,Slovenia,2011,8,C10-Lipid modifying agents,Million US$ at exchange rate,38.7
+30209,Slovenia,2011,8,C10-Lipid modifying agents,"/capita, US$ exchange rate",18.8
+30210,Slovenia,2011,8,R-Respiratory system,Million of national currency units,29.2
+30211,Slovenia,2011,8,C10-Lipid modifying agents,Million of national currency units,27.8
+30212,Slovenia,2011,8,Total pharmaceutical sales,Million US$ at exchange rate,654.3
+30213,Slovenia,2011,8,B-Blood and blood forming organs,Million of national currency units,25.2
+30214,Slovenia,2011,8,J-Antiinfectives for systemic use,Million of national currency units,19.6
+30215,Slovenia,2011,8,N-Nervous system,% of total sales,17.0
+30216,Slovenia,2011,8,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),% of total sales,3.8
+30217,Slovenia,2011,8,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ exchange rate",12.1
+30218,Slovenia,2011,8,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ purchasing power parity",14.0
+30219,Slovenia,2011,8,"C01B-Antiarrhythmics, Class I and III","Million US$, purchasing power parity",2.0
+30220,Slovenia,2011,8,"C01B-Antiarrhythmics, Class I and III",Million US$ at exchange rate,1.7
+30221,Slovenia,2011,8,"C01B-Antiarrhythmics, Class I and III","/capita, US$ exchange rate",0.8
+30222,Slovenia,2011,8,Total pharmaceutical sales,"/capita, US$ purchasing power parity",367.0
+30223,Slovenia,2011,8,"C01B-Antiarrhythmics, Class I and III",Million of national currency units,1.2
+30224,Slovenia,2011,8,C02-Antihypertensives,% of total sales,1.0
+30225,Slovenia,2010,8,R03-Drugs for obstructive airway diseases,"/capita, US$ exchange rate",14.9
+30226,Slovenia,2010,8,R03-Drugs for obstructive airway diseases,Million US$ at exchange rate,30.5
+30227,Slovenia,2010,8,R03-Drugs for obstructive airway diseases,"Million US$, purchasing power parity",36.0
+30228,Slovenia,2010,8,R03-Drugs for obstructive airway diseases,% of total sales,4.8
+30229,Slovenia,2010,8,C02-Antihypertensives,"/capita, US$ purchasing power parity",3.2
+30230,Slovenia,2010,8,C02-Antihypertensives,% of total sales,0.9
+30231,Slovenia,2010,8,R03-Drugs for obstructive airway diseases,"/capita, US$ purchasing power parity",17.6
+30232,Slovenia,2010,8,N02-Analgesics,% of total sales,3.6
+30233,Slovenia,2010,8,N02-Analgesics,"/capita, US$ purchasing power parity",13.1
+30234,Slovenia,2010,8,N02-Analgesics,"/capita, US$ exchange rate",11.1
+30235,Slovenia,2010,8,C-Cardiovascular system,"Million US$, purchasing power parity",192.0
+30236,Slovenia,2010,8,C08-Calcium channel blockers,% of total sales,2.1
+30237,Slovenia,2010,8,R03-Drugs for obstructive airway diseases,Million of national currency units,23.0
+30238,Slovenia,2010,8,C02-Antihypertensives,"/capita, US$ exchange rate",2.7
+30239,Slovenia,2010,8,C08-Calcium channel blockers,"Million US$, purchasing power parity",15.8
+30240,Slovenia,2010,8,R-Respiratory system,"/capita, US$ exchange rate",18.9
+30241,Slovenia,2010,8,R-Respiratory system,"Million US$, purchasing power parity",45.9
+30242,Slovenia,2010,8,C08-Calcium channel blockers,Million US$ at exchange rate,13.3
+30243,Slovenia,2010,8,C02-Antihypertensives,"Million US$, purchasing power parity",6.5
+30244,Slovenia,2010,8,R-Respiratory system,Million US$ at exchange rate,38.8
+30245,Slovenia,2010,8,C08-Calcium channel blockers,Million of national currency units,10.0
+30246,Slovenia,2010,8,C02-Antihypertensives,Million US$ at exchange rate,5.5
+30247,Slovenia,2010,8,C-Cardiovascular system,Million of national currency units,122.5
+30248,Slovenia,2010,8,C02-Antihypertensives,Million of national currency units,4.1
+30249,Slovenia,2010,8,C-Cardiovascular system,Million US$ at exchange rate,162.4
+30250,Slovenia,2010,8,C08-Calcium channel blockers,"/capita, US$ purchasing power parity",7.7
+30251,Slovenia,2010,8,R-Respiratory system,% of total sales,6.2
+30252,Slovenia,2010,8,R-Respiratory system,"/capita, US$ purchasing power parity",22.4
+30253,Slovenia,2010,8,C08-Calcium channel blockers,"/capita, US$ exchange rate",6.5
+30254,Slovenia,2010,8,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million US$ at exchange rate,11.9
+30255,Slovenia,2010,8,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million of national currency units,9.0
+30256,Slovenia,2010,8,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ purchasing power parity",6.9
+30257,Slovenia,2010,8,"H-Systemic hormonal preparations, excluding sex hormones and insulins",% of total sales,1.9
+30258,Slovenia,2010,8,B-Blood and blood forming organs,"/capita, US$ purchasing power parity",19.5
+30259,Slovenia,2010,8,B-Blood and blood forming organs,% of total sales,5.4
+30260,Slovenia,2010,8,B-Blood and blood forming organs,"Million US$, purchasing power parity",39.9
+30261,Slovenia,2010,8,B-Blood and blood forming organs,"/capita, US$ exchange rate",16.5
+30262,Slovenia,2010,8,J01-Antibacterials for systemic use,"/capita, US$ exchange rate",7.6
+30263,Slovenia,2010,8,J01-Antibacterials for systemic use,"Million US$, purchasing power parity",18.5
+30264,Slovenia,2010,8,J01-Antibacterials for systemic use,% of total sales,2.5
+30265,Slovenia,2010,8,J01-Antibacterials for systemic use,"/capita, US$ purchasing power parity",9.0
+30266,Slovenia,2010,8,"H-Systemic hormonal preparations, excluding sex hormones and insulins","Million US$, purchasing power parity",14.1
+30267,Slovenia,2010,8,J01-Antibacterials for systemic use,Million US$ at exchange rate,15.6
+30268,Slovenia,2010,8,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ exchange rate",5.8
+30269,Slovenia,2010,8,B-Blood and blood forming organs,Million US$ at exchange rate,33.8
+30270,Slovenia,2010,8,N02-Analgesics,"Million US$, purchasing power parity",26.9
+30271,Slovenia,2010,8,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ exchange rate",35.5
+30272,Slovenia,2010,8,C09-Agents acting on the Renin-Angiotensin system,"Million US$, purchasing power parity",86.1
+30273,Slovenia,2010,8,A-Alimentary tract and metabolism,% of total sales,11.7
+30274,Slovenia,2010,8,N02-Analgesics,Million US$ at exchange rate,22.7
+30275,Slovenia,2010,8,N02-Analgesics,Million of national currency units,17.2
+30276,Slovenia,2010,8,C09-Agents acting on the Renin-Angiotensin system,Million US$ at exchange rate,72.8
+30277,Slovenia,2010,8,C09-Agents acting on the Renin-Angiotensin system,Million of national currency units,54.9
+30278,Slovenia,2010,8,C-Cardiovascular system,"/capita, US$ exchange rate",79.3
+30279,Slovenia,2010,8,A-Alimentary tract and metabolism,Million US$ at exchange rate,73.5
+30280,Slovenia,2010,8,A-Alimentary tract and metabolism,Million of national currency units,55.5
+30281,Slovenia,2010,8,C09-Agents acting on the Renin-Angiotensin system,% of total sales,11.6
+30282,Slovenia,2010,8,J01-Antibacterials for systemic use,Million of national currency units,11.8
+30283,Slovenia,2010,8,A-Alimentary tract and metabolism,"Million US$, purchasing power parity",86.9
+30284,Slovenia,2010,8,A-Alimentary tract and metabolism,"/capita, US$ exchange rate",35.9
+30285,Slovenia,2010,8,A-Alimentary tract and metabolism,"/capita, US$ purchasing power parity",42.4
+30286,Slovenia,2010,8,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ purchasing power parity",42.0
+30287,Slovenia,2010,8,N05B-Anxiolytics,"/capita, US$ exchange rate",1.9
+30288,Slovenia,2010,8,N05B-Anxiolytics,"/capita, US$ purchasing power parity",2.3
+30289,Slovenia,2010,8,N05B-Anxiolytics,% of total sales,0.6
+30290,Slovenia,2010,8,N06A-Antidepressants,Million US$ at exchange rate,20.6
+30291,Slovenia,2010,8,N05B-Anxiolytics,"Million US$, purchasing power parity",4.7
+30292,Slovenia,2010,8,N05B-Anxiolytics,Million US$ at exchange rate,4.0
+30293,Slovenia,2010,8,N06A-Antidepressants,Million of national currency units,15.6
+30294,Slovenia,2010,8,G03-Sex hormones and modulators of the genital system,Million US$ at exchange rate,13.4
+30295,Slovenia,2010,8,G03-Sex hormones and modulators of the genital system,Million of national currency units,10.1
+30296,Slovenia,2010,8,N-Nervous system,"/capita, US$ exchange rate",52.0
+30297,Slovenia,2010,8,N-Nervous system,"/capita, US$ purchasing power parity",61.5
+30298,Slovenia,2010,8,G03-Sex hormones and modulators of the genital system,"Million US$, purchasing power parity",15.9
+30299,Slovenia,2010,8,G03-Sex hormones and modulators of the genital system,% of total sales,2.1
+30300,Slovenia,2010,8,G03-Sex hormones and modulators of the genital system,"/capita, US$ purchasing power parity",7.8
+30301,Slovenia,2010,8,G03-Sex hormones and modulators of the genital system,"/capita, US$ exchange rate",6.6
+30302,Slovenia,2010,8,N06A-Antidepressants,"Million US$, purchasing power parity",24.4
+30303,Slovenia,2010,8,A02A-Antacids,Million of national currency units,0.3
+30304,Slovenia,2010,8,C01A-Cardiac glycosides,"/capita, US$ purchasing power parity",0.3
+30305,Slovenia,2010,8,A02A-Antacids,"Million US$, purchasing power parity",0.5
+30306,Slovenia,2010,8,A02A-Antacids,Million US$ at exchange rate,0.5
+30307,Slovenia,2010,8,C01A-Cardiac glycosides,% of total sales,0.1
+30308,Slovenia,2010,8,C10-Lipid modifying agents,% of total sales,6.5
+30309,Slovenia,2010,8,C10-Lipid modifying agents,"/capita, US$ purchasing power parity",23.7
+30310,Slovenia,2010,8,Total pharmaceutical sales,Million of national currency units,474.4
+30311,Slovenia,2010,8,N06A-Antidepressants,% of total sales,3.3
+30312,Slovenia,2010,8,N06A-Antidepressants,"/capita, US$ purchasing power parity",11.9
+30313,Slovenia,2010,8,N06A-Antidepressants,"/capita, US$ exchange rate",10.1
+30314,Slovenia,2010,8,A02A-Antacids,"/capita, US$ purchasing power parity",0.3
+30315,Slovenia,2010,8,A02A-Antacids,"/capita, US$ exchange rate",0.2
+30316,Slovenia,2010,8,N05B-Anxiolytics,Million of national currency units,3.0
+30317,Slovenia,2010,8,A02A-Antacids,% of total sales,0.1
+30318,Slovenia,2010,8,N05C-Hypnotics and sedatives,"/capita, US$ purchasing power parity",2.2
+30319,Slovenia,2010,8,N05C-Hypnotics and sedatives,% of total sales,0.6
+30320,Slovenia,2010,8,N05C-Hypnotics and sedatives,"Million US$, purchasing power parity",4.5
+30321,Slovenia,2010,8,N05C-Hypnotics and sedatives,"/capita, US$ exchange rate",1.9
+30322,Slovenia,2010,8,C03-Diuretics,"Million US$, purchasing power parity",9.9
+30323,Slovenia,2010,8,C03-Diuretics,"/capita, US$ exchange rate",4.1
+30324,Slovenia,2010,8,C03-Diuretics,Million of national currency units,6.3
+30325,Slovenia,2010,8,C03-Diuretics,Million US$ at exchange rate,8.4
+30326,Slovenia,2010,8,M-Musculo-skeletal system,"/capita, US$ purchasing power parity",16.1
+30327,Slovenia,2010,8,M-Musculo-skeletal system,"/capita, US$ exchange rate",13.6
+30328,Slovenia,2010,8,M-Musculo-skeletal system,% of total sales,4.4
+30329,Slovenia,2010,8,M-Musculo-skeletal system,Million of national currency units,21.0
+30330,Slovenia,2010,8,N05C-Hypnotics and sedatives,Million of national currency units,2.9
+30331,Slovenia,2010,8,N05C-Hypnotics and sedatives,Million US$ at exchange rate,3.8
+30332,Slovenia,2010,8,M-Musculo-skeletal system,"Million US$, purchasing power parity",32.9
+30333,Slovenia,2010,8,M-Musculo-skeletal system,Million US$ at exchange rate,27.8
+30334,Slovenia,2010,8,C01A-Cardiac glycosides,"Million US$, purchasing power parity",0.5
+30335,Slovenia,2010,8,C01A-Cardiac glycosides,Million US$ at exchange rate,0.4
+30336,Slovenia,2010,8,G-Genito urinary system and sex hormones,Million of national currency units,26.3
+30337,Slovenia,2010,8,C01A-Cardiac glycosides,Million of national currency units,0.3
+30338,Slovenia,2010,8,N-Nervous system,"Million US$, purchasing power parity",126.0
+30339,Slovenia,2010,8,N-Nervous system,Million US$ at exchange rate,106.5
+30340,Slovenia,2010,8,C01A-Cardiac glycosides,"/capita, US$ exchange rate",0.2
+30341,Slovenia,2010,8,N-Nervous system,Million of national currency units,80.4
+30342,Slovenia,2010,8,G-Genito urinary system and sex hormones,% of total sales,5.5
+30343,Slovenia,2010,8,C03-Diuretics,% of total sales,1.3
+30344,Slovenia,2010,8,C03-Diuretics,"/capita, US$ purchasing power parity",4.8
+30345,Slovenia,2010,8,G-Genito urinary system and sex hormones,"Million US$, purchasing power parity",41.2
+30346,Slovenia,2010,8,G-Genito urinary system and sex hormones,Million US$ at exchange rate,34.9
+30347,Slovenia,2010,8,G-Genito urinary system and sex hormones,"/capita, US$ purchasing power parity",20.1
+30348,Slovenia,2010,8,G-Genito urinary system and sex hormones,"/capita, US$ exchange rate",17.0
+30349,Slovenia,2010,8,C07-Beta blocking agents,% of total sales,1.8
+30350,Slovenia,2010,8,M01A-Antiinflammatory and antirheumatic products non-steroids,"Million US$, purchasing power parity",14.5
+30351,Slovenia,2010,8,A10-Drugs used in diabetes,Million US$ at exchange rate,34.0
+30352,Slovenia,2010,8,A10-Drugs used in diabetes,Million of national currency units,25.6
+30353,Slovenia,2010,8,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million US$ at exchange rate,26.4
+30354,Slovenia,2010,8,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million of national currency units,19.9
+30355,Slovenia,2010,8,C07-Beta blocking agents,Million US$ at exchange rate,11.1
+30356,Slovenia,2010,8,C07-Beta blocking agents,"Million US$, purchasing power parity",13.1
+30357,Slovenia,2010,8,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"Million US$, purchasing power parity",31.2
+30358,Slovenia,2010,8,C07-Beta blocking agents,Million of national currency units,8.4
+30359,Slovenia,2010,8,M01A-Antiinflammatory and antirheumatic products non-steroids,Million of national currency units,9.2
+30360,Slovenia,2010,8,M01A-Antiinflammatory and antirheumatic products non-steroids,Million US$ at exchange rate,12.2
+30361,Slovenia,2010,8,C07-Beta blocking agents,"/capita, US$ purchasing power parity",6.4
+30362,Slovenia,2010,8,C07-Beta blocking agents,"/capita, US$ exchange rate",5.4
+30363,Slovenia,2010,8,J-Antiinfectives for systemic use,"/capita, US$ exchange rate",12.3
+30364,Slovenia,2010,8,J-Antiinfectives for systemic use,"/capita, US$ purchasing power parity",14.6
+30365,Slovenia,2010,8,J-Antiinfectives for systemic use,"Million US$, purchasing power parity",29.8
+30366,Slovenia,2010,8,A10-Drugs used in diabetes,% of total sales,5.4
+30367,Slovenia,2010,8,J-Antiinfectives for systemic use,% of total sales,4.0
+30368,Slovenia,2010,8,A10-Drugs used in diabetes,"/capita, US$ purchasing power parity",19.6
+30369,Slovenia,2010,8,A10-Drugs used in diabetes,"Million US$, purchasing power parity",40.2
+30370,Slovenia,2010,8,A10-Drugs used in diabetes,"/capita, US$ exchange rate",16.6
+30371,Slovenia,2010,8,M01A-Antiinflammatory and antirheumatic products non-steroids,% of total sales,1.9
+30372,Slovenia,2010,8,J-Antiinfectives for systemic use,Million US$ at exchange rate,25.2
+30373,Slovenia,2010,8,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ exchange rate",6.0
+30374,Slovenia,2010,8,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ purchasing power parity",7.1
+30375,Slovenia,2010,8,C-Cardiovascular system,"/capita, US$ purchasing power parity",93.7
+30376,Slovenia,2010,8,C-Cardiovascular system,% of total sales,25.8
+30377,Slovenia,2010,8,"C01B-Antiarrhythmics, Class I and III",% of total sales,0.2
+30378,Slovenia,2010,8,Total pharmaceutical sales,"/capita, US$ exchange rate",307.0
+30379,Slovenia,2010,8,"C01B-Antiarrhythmics, Class I and III","/capita, US$ purchasing power parity",0.8
+30380,Slovenia,2010,8,C10-Lipid modifying agents,"Million US$, purchasing power parity",48.6
+30381,Slovenia,2010,8,C10-Lipid modifying agents,Million US$ at exchange rate,41.1
+30382,Slovenia,2010,8,C10-Lipid modifying agents,"/capita, US$ exchange rate",20.1
+30383,Slovenia,2010,8,Total pharmaceutical sales,"Million US$, purchasing power parity",743.6
+30384,Slovenia,2010,8,R-Respiratory system,Million of national currency units,29.3
+30385,Slovenia,2010,8,B-Blood and blood forming organs,Million of national currency units,25.5
+30386,Slovenia,2010,8,C10-Lipid modifying agents,Million of national currency units,31.0
+30387,Slovenia,2010,8,Total pharmaceutical sales,Million US$ at exchange rate,628.9
+30388,Slovenia,2010,8,J-Antiinfectives for systemic use,Million of national currency units,19.0
+30389,Slovenia,2010,8,N-Nervous system,% of total sales,16.9
+30390,Slovenia,2010,8,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ exchange rate",12.9
+30391,Slovenia,2010,8,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),% of total sales,4.2
+30392,Slovenia,2010,8,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ purchasing power parity",15.2
+30393,Slovenia,2010,8,"C01B-Antiarrhythmics, Class I and III","Million US$, purchasing power parity",1.7
+30394,Slovenia,2010,8,"C01B-Antiarrhythmics, Class I and III",Million US$ at exchange rate,1.4
+30395,Slovenia,2010,8,"C01B-Antiarrhythmics, Class I and III","/capita, US$ exchange rate",0.7
+30396,Slovenia,2010,8,"C01B-Antiarrhythmics, Class I and III",Million of national currency units,1.1
+30397,Slovenia,2010,8,Total pharmaceutical sales,"/capita, US$ purchasing power parity",363.0
+30398,Slovenia,2017,7,R03-Drugs for obstructive airway diseases,"Million US$, purchasing power parity",36.2
+30399,Slovenia,2017,7,R03-Drugs for obstructive airway diseases,Million of national currency units,20.6
+30400,Slovenia,2017,7,R03-Drugs for obstructive airway diseases,Million US$ at exchange rate,23.3
+30401,Slovenia,2017,7,C02-Antihypertensives,"/capita, US$ purchasing power parity",2.7
+30402,Slovenia,2017,7,R03-Drugs for obstructive airway diseases,"/capita, US$ exchange rate",11.3
+30403,Slovenia,2017,7,C-Cardiovascular system,Million US$ at exchange rate,85.7
+30404,Slovenia,2017,7,R03-Drugs for obstructive airway diseases,"/capita, US$ purchasing power parity",17.5
+30405,Slovenia,2017,7,N02-Analgesics,"/capita, US$ purchasing power parity",15.5
+30406,Slovenia,2017,7,N02-Analgesics,% of total sales,3.8
+30407,Slovenia,2017,7,N02-Analgesics,"Million US$, purchasing power parity",32.1
+30408,Slovenia,2017,7,N02-Analgesics,"/capita, US$ exchange rate",10.0
+30409,Slovenia,2017,7,C08-Calcium channel blockers,% of total sales,1.2
+30410,Slovenia,2017,7,C02-Antihypertensives,"Million US$, purchasing power parity",5.6
+30411,Slovenia,2017,7,C-Cardiovascular system,"Million US$, purchasing power parity",133.1
+30412,Slovenia,2017,7,C02-Antihypertensives,"/capita, US$ exchange rate",1.7
+30413,Slovenia,2017,7,R03-Drugs for obstructive airway diseases,% of total sales,4.3
+30414,Slovenia,2017,7,R-Respiratory system,Million US$ at exchange rate,28.9
+30415,Slovenia,2017,7,C08-Calcium channel blockers,Million US$ at exchange rate,6.6
+30416,Slovenia,2017,7,R-Respiratory system,"/capita, US$ exchange rate",14.0
+30417,Slovenia,2017,7,R-Respiratory system,"Million US$, purchasing power parity",44.8
+30418,Slovenia,2017,7,R-Respiratory system,Million of national currency units,25.6
+30419,Slovenia,2017,7,C02-Antihypertensives,Million US$ at exchange rate,3.6
+30420,Slovenia,2017,7,C08-Calcium channel blockers,Million of national currency units,5.8
+30421,Slovenia,2017,7,C02-Antihypertensives,Million of national currency units,3.2
+30422,Slovenia,2017,7,C08-Calcium channel blockers,"/capita, US$ purchasing power parity",4.9
+30423,Slovenia,2017,7,C-Cardiovascular system,Million of national currency units,75.9
+30424,Slovenia,2017,7,J01-Antibacterials for systemic use,% of total sales,2.3
+30425,Slovenia,2017,7,R-Respiratory system,"/capita, US$ purchasing power parity",21.7
+30426,Slovenia,2017,7,R-Respiratory system,% of total sales,5.3
+30427,Slovenia,2017,7,C08-Calcium channel blockers,"/capita, US$ exchange rate",3.2
+30428,Slovenia,2017,7,C08-Calcium channel blockers,"Million US$, purchasing power parity",10.2
+30429,Slovenia,2017,7,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million of national currency units,10.8
+30430,Slovenia,2017,7,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million US$ at exchange rate,12.2
+30431,Slovenia,2017,7,"H-Systemic hormonal preparations, excluding sex hormones and insulins",% of total sales,2.2
+30432,Slovenia,2017,7,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ purchasing power parity",9.2
+30433,Slovenia,2017,7,B-Blood and blood forming organs,"/capita, US$ purchasing power parity",39.6
+30434,Slovenia,2017,7,B-Blood and blood forming organs,"Million US$, purchasing power parity",81.8
+30435,Slovenia,2017,7,B-Blood and blood forming organs,"/capita, US$ exchange rate",25.5
+30436,Slovenia,2017,7,B-Blood and blood forming organs,% of total sales,9.6
+30437,Slovenia,2017,7,J01-Antibacterials for systemic use,"Million US$, purchasing power parity",19.8
+30438,Slovenia,2017,7,J01-Antibacterials for systemic use,Million US$ at exchange rate,12.7
+30439,Slovenia,2017,7,J01-Antibacterials for systemic use,"/capita, US$ purchasing power parity",9.6
+30440,Slovenia,2017,7,J01-Antibacterials for systemic use,"/capita, US$ exchange rate",6.2
+30441,Slovenia,2017,7,B-Blood and blood forming organs,Million US$ at exchange rate,52.7
+30442,Slovenia,2017,7,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ exchange rate",5.9
+30443,Slovenia,2017,7,"H-Systemic hormonal preparations, excluding sex hormones and insulins","Million US$, purchasing power parity",19.0
+30444,Slovenia,2017,7,C09-Agents acting on the Renin-Angiotensin system,"Million US$, purchasing power parity",49.8
+30445,Slovenia,2017,7,C09-Agents acting on the Renin-Angiotensin system,Million US$ at exchange rate,32.1
+30446,Slovenia,2017,7,A-Alimentary tract and metabolism,"/capita, US$ purchasing power parity",49.0
+30447,Slovenia,2017,7,A-Alimentary tract and metabolism,% of total sales,11.9
+30448,Slovenia,2017,7,N02-Analgesics,Million of national currency units,18.3
+30449,Slovenia,2017,7,N02-Analgesics,Million US$ at exchange rate,20.7
+30450,Slovenia,2017,7,C09-Agents acting on the Renin-Angiotensin system,Million of national currency units,28.4
+30451,Slovenia,2017,7,C-Cardiovascular system,"/capita, US$ exchange rate",41.5
+30452,Slovenia,2017,7,A-Alimentary tract and metabolism,Million of national currency units,57.8
+30453,Slovenia,2017,7,A-Alimentary tract and metabolism,Million US$ at exchange rate,65.3
+30454,Slovenia,2017,7,C09-Agents acting on the Renin-Angiotensin system,% of total sales,5.9
+30455,Slovenia,2017,7,J01-Antibacterials for systemic use,Million of national currency units,11.3
+30456,Slovenia,2017,7,A-Alimentary tract and metabolism,"/capita, US$ exchange rate",31.6
+30457,Slovenia,2017,7,A-Alimentary tract and metabolism,"Million US$, purchasing power parity",101.3
+30458,Slovenia,2017,7,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ purchasing power parity",24.1
+30459,Slovenia,2017,7,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ exchange rate",15.5
+30460,Slovenia,2017,7,N05B-Anxiolytics,"/capita, US$ exchange rate",1.4
+30461,Slovenia,2017,7,N05B-Anxiolytics,"Million US$, purchasing power parity",4.6
+30462,Slovenia,2017,7,N05B-Anxiolytics,% of total sales,0.5
+30463,Slovenia,2017,7,N05B-Anxiolytics,"/capita, US$ purchasing power parity",2.2
+30464,Slovenia,2017,7,N06A-Antidepressants,Million of national currency units,10.6
+30465,Slovenia,2017,7,N06A-Antidepressants,Million US$ at exchange rate,11.9
+30466,Slovenia,2017,7,N05B-Anxiolytics,Million US$ at exchange rate,3.0
+30467,Slovenia,2017,7,N05B-Anxiolytics,Million of national currency units,2.6
+30468,Slovenia,2017,7,G03-Sex hormones and modulators of the genital system,Million of national currency units,7.5
+30469,Slovenia,2017,7,G03-Sex hormones and modulators of the genital system,Million US$ at exchange rate,8.4
+30470,Slovenia,2017,7,N-Nervous system,"/capita, US$ exchange rate",34.6
+30471,Slovenia,2017,7,N-Nervous system,"/capita, US$ purchasing power parity",53.7
+30472,Slovenia,2017,7,G03-Sex hormones and modulators of the genital system,"/capita, US$ purchasing power parity",6.3
+30473,Slovenia,2017,7,G03-Sex hormones and modulators of the genital system,% of total sales,1.5
+30474,Slovenia,2017,7,G03-Sex hormones and modulators of the genital system,"Million US$, purchasing power parity",13.1
+30475,Slovenia,2017,7,G03-Sex hormones and modulators of the genital system,"/capita, US$ exchange rate",4.1
+30476,Slovenia,2017,7,C01A-Cardiac glycosides,"/capita, US$ purchasing power parity",0.3
+30477,Slovenia,2017,7,A02A-Antacids,Million of national currency units,0.8
+30478,Slovenia,2017,7,A02A-Antacids,Million US$ at exchange rate,0.9
+30479,Slovenia,2017,7,C10-Lipid modifying agents,% of total sales,3.0
+30480,Slovenia,2017,7,C10-Lipid modifying agents,"/capita, US$ purchasing power parity",12.1
+30481,Slovenia,2017,7,C01A-Cardiac glycosides,% of total sales,0.1
+30482,Slovenia,2017,7,Total pharmaceutical sales,Million of national currency units,484.2
+30483,Slovenia,2017,7,A02A-Antacids,"Million US$, purchasing power parity",1.3
+30484,Slovenia,2017,7,N06A-Antidepressants,"/capita, US$ purchasing power parity",9.0
+30485,Slovenia,2017,7,N06A-Antidepressants,% of total sales,2.2
+30486,Slovenia,2017,7,N06A-Antidepressants,"Million US$, purchasing power parity",18.5
+30487,Slovenia,2017,7,N06A-Antidepressants,"/capita, US$ exchange rate",5.8
+30488,Slovenia,2017,7,A02A-Antacids,"/capita, US$ exchange rate",0.4
+30489,Slovenia,2017,7,A02A-Antacids,"/capita, US$ purchasing power parity",0.6
+30490,Slovenia,2017,7,A02A-Antacids,% of total sales,0.2
+30491,Slovenia,2017,7,N05C-Hypnotics and sedatives,"/capita, US$ purchasing power parity",2.0
+30492,Slovenia,2017,7,N05C-Hypnotics and sedatives,"/capita, US$ exchange rate",1.3
+30493,Slovenia,2017,7,N05C-Hypnotics and sedatives,"Million US$, purchasing power parity",4.1
+30494,Slovenia,2017,7,C03-Diuretics,Million US$ at exchange rate,7.1
+30495,Slovenia,2017,7,C03-Diuretics,"Million US$, purchasing power parity",11.0
+30496,Slovenia,2017,7,N05C-Hypnotics and sedatives,% of total sales,0.5
+30497,Slovenia,2017,7,C03-Diuretics,Million of national currency units,6.3
+30498,Slovenia,2017,7,N05C-Hypnotics and sedatives,Million US$ at exchange rate,2.6
+30499,Slovenia,2017,7,M-Musculo-skeletal system,"/capita, US$ exchange rate",9.0
+30500,Slovenia,2017,7,M-Musculo-skeletal system,"Million US$, purchasing power parity",28.7
+30501,Slovenia,2017,7,M-Musculo-skeletal system,% of total sales,3.4
+30502,Slovenia,2017,7,M-Musculo-skeletal system,"/capita, US$ purchasing power parity",13.9
+30503,Slovenia,2017,7,N05C-Hypnotics and sedatives,Million of national currency units,2.3
+30504,Slovenia,2017,7,M-Musculo-skeletal system,Million US$ at exchange rate,18.5
+30505,Slovenia,2017,7,M-Musculo-skeletal system,Million of national currency units,16.4
+30506,Slovenia,2017,7,C01A-Cardiac glycosides,Million US$ at exchange rate,0.4
+30507,Slovenia,2017,7,C01A-Cardiac glycosides,"Million US$, purchasing power parity",0.6
+30508,Slovenia,2017,7,C03-Diuretics,% of total sales,1.3
+30509,Slovenia,2017,7,C01A-Cardiac glycosides,Million of national currency units,0.3
+30510,Slovenia,2017,7,N-Nervous system,Million US$ at exchange rate,71.4
+30511,Slovenia,2017,7,N-Nervous system,"Million US$, purchasing power parity",110.9
+30512,Slovenia,2017,7,C01A-Cardiac glycosides,"/capita, US$ exchange rate",0.2
+30513,Slovenia,2017,7,N-Nervous system,Million of national currency units,63.2
+30514,Slovenia,2017,7,G-Genito urinary system and sex hormones,% of total sales,4.9
+30515,Slovenia,2017,7,G-Genito urinary system and sex hormones,"/capita, US$ purchasing power parity",20.2
+30516,Slovenia,2017,7,C03-Diuretics,"/capita, US$ exchange rate",3.4
+30517,Slovenia,2017,7,C03-Diuretics,"/capita, US$ purchasing power parity",5.3
+30518,Slovenia,2017,7,G-Genito urinary system and sex hormones,Million US$ at exchange rate,26.9
+30519,Slovenia,2017,7,G-Genito urinary system and sex hormones,Million of national currency units,23.8
+30520,Slovenia,2017,7,G-Genito urinary system and sex hormones,"/capita, US$ exchange rate",13.0
+30521,Slovenia,2017,7,G-Genito urinary system and sex hormones,"Million US$, purchasing power parity",41.7
+30522,Slovenia,2017,7,C07-Beta blocking agents,"/capita, US$ purchasing power parity",8.7
+30523,Slovenia,2017,7,C07-Beta blocking agents,% of total sales,2.1
+30524,Slovenia,2017,7,M01A-Antiinflammatory and antirheumatic products non-steroids,Million US$ at exchange rate,9.5
+30525,Slovenia,2017,7,M01A-Antiinflammatory and antirheumatic products non-steroids,"Million US$, purchasing power parity",14.7
+30526,Slovenia,2017,7,A10-Drugs used in diabetes,Million of national currency units,31.5
+30527,Slovenia,2017,7,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million of national currency units,9.5
+30528,Slovenia,2017,7,C07-Beta blocking agents,Million US$ at exchange rate,11.5
+30529,Slovenia,2017,7,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million US$ at exchange rate,10.8
+30530,Slovenia,2017,7,C07-Beta blocking agents,Million of national currency units,10.2
+30531,Slovenia,2017,7,M01A-Antiinflammatory and antirheumatic products non-steroids,Million of national currency units,8.4
+30532,Slovenia,2017,7,C07-Beta blocking agents,"Million US$, purchasing power parity",17.9
+30533,Slovenia,2017,7,C07-Beta blocking agents,"/capita, US$ exchange rate",5.6
+30534,Slovenia,2017,7,A10-Drugs used in diabetes,Million US$ at exchange rate,35.6
+30535,Slovenia,2017,7,J-Antiinfectives for systemic use,"/capita, US$ exchange rate",14.9
+30536,Slovenia,2017,7,J-Antiinfectives for systemic use,Million US$ at exchange rate,30.8
+30537,Slovenia,2017,7,J-Antiinfectives for systemic use,"Million US$, purchasing power parity",47.8
+30538,Slovenia,2017,7,J-Antiinfectives for systemic use,"/capita, US$ purchasing power parity",23.1
+30539,Slovenia,2017,7,A10-Drugs used in diabetes,% of total sales,6.5
+30540,Slovenia,2017,7,M01A-Antiinflammatory and antirheumatic products non-steroids,% of total sales,1.7
+30541,Slovenia,2017,7,J-Antiinfectives for systemic use,% of total sales,5.6
+30542,Slovenia,2017,7,A10-Drugs used in diabetes,"/capita, US$ exchange rate",17.2
+30543,Slovenia,2017,7,A10-Drugs used in diabetes,"/capita, US$ purchasing power parity",26.7
+30544,Slovenia,2017,7,A10-Drugs used in diabetes,"Million US$, purchasing power parity",55.2
+30545,Slovenia,2017,7,J-Antiinfectives for systemic use,Million of national currency units,27.2
+30546,Slovenia,2017,7,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ purchasing power parity",7.1
+30547,Slovenia,2017,7,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ exchange rate",4.6
+30548,Slovenia,2017,7,C-Cardiovascular system,% of total sales,15.7
+30549,Slovenia,2017,7,"C01B-Antiarrhythmics, Class I and III",% of total sales,0.2
+30550,Slovenia,2017,7,C-Cardiovascular system,"/capita, US$ purchasing power parity",64.4
+30551,Slovenia,2017,7,Total pharmaceutical sales,"Million US$, purchasing power parity",849.3
+30552,Slovenia,2017,7,"C01B-Antiarrhythmics, Class I and III","/capita, US$ exchange rate",0.5
+30553,Slovenia,2017,7,"C01B-Antiarrhythmics, Class I and III","/capita, US$ purchasing power parity",0.8
+30554,Slovenia,2017,7,C10-Lipid modifying agents,Million US$ at exchange rate,16.1
+30555,Slovenia,2017,7,C10-Lipid modifying agents,"/capita, US$ exchange rate",7.8
+30556,Slovenia,2017,7,C10-Lipid modifying agents,"Million US$, purchasing power parity",25.1
+30557,Slovenia,2017,7,B-Blood and blood forming organs,Million of national currency units,46.7
+30558,Slovenia,2017,7,Total pharmaceutical sales,Million US$ at exchange rate,547.0
+30559,Slovenia,2017,7,C10-Lipid modifying agents,Million of national currency units,14.3
+30560,Slovenia,2017,7,N-Nervous system,% of total sales,13.1
+30561,Slovenia,2017,7,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),% of total sales,2.0
+30562,Slovenia,2017,7,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ exchange rate",5.2
+30563,Slovenia,2017,7,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"Million US$, purchasing power parity",16.7
+30564,Slovenia,2017,7,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ purchasing power parity",8.1
+30565,Slovenia,2017,7,Total pharmaceutical sales,"/capita, US$ exchange rate",264.7
+30566,Slovenia,2017,7,"C01B-Antiarrhythmics, Class I and III",Million US$ at exchange rate,1.1
+30567,Slovenia,2017,7,"C01B-Antiarrhythmics, Class I and III",Million of national currency units,1.0
+30568,Slovenia,2017,7,Total pharmaceutical sales,"/capita, US$ purchasing power parity",411.0
+30569,Slovenia,2017,7,"C01B-Antiarrhythmics, Class I and III","Million US$, purchasing power parity",1.7
+30570,Slovenia,2017,7,C02-Antihypertensives,% of total sales,0.7
+30571,Spain,2011,4,J01-Antibacterials for systemic use,"/capita, US$ purchasing power parity",7.8
+30572,Spain,2011,4,J01-Antibacterials for systemic use,Million of national currency units,260.9
+30573,Spain,2011,4,J01-Antibacterials for systemic use,% of total sales,2.1
+30574,Spain,2011,4,J01-Antibacterials for systemic use,Million US$ at exchange rate,363.1
+30575,Spain,2011,4,J01-Antibacterials for systemic use,"Million US$, purchasing power parity",365.3
+30576,Spain,2011,4,J01-Antibacterials for systemic use,"/capita, US$ exchange rate",7.8
+30577,Spain,2011,4,C02-Antihypertensives,"Million US$, purchasing power parity",63.1
+30578,Spain,2011,4,C02-Antihypertensives,"/capita, US$ purchasing power parity",1.3
+30579,Spain,2011,4,C02-Antihypertensives,"/capita, US$ exchange rate",1.3
+30580,Spain,2011,4,C08-Calcium channel blockers,"/capita, US$ exchange rate",5.6
+30581,Spain,2011,4,C02-Antihypertensives,% of total sales,0.4
+30582,Spain,2011,4,C08-Calcium channel blockers,"/capita, US$ purchasing power parity",5.6
+30583,Spain,2011,4,C08-Calcium channel blockers,% of total sales,1.5
+30584,Spain,2011,4,C-Cardiovascular system,"Million US$, purchasing power parity",3628.2
+30585,Spain,2011,4,J-Antiinfectives for systemic use,"/capita, US$ exchange rate",9.3
+30586,Spain,2011,4,J-Antiinfectives for systemic use,"/capita, US$ purchasing power parity",9.3
+30587,Spain,2011,4,J-Antiinfectives for systemic use,Million US$ at exchange rate,433.6
+30588,Spain,2011,4,J-Antiinfectives for systemic use,"Million US$, purchasing power parity",436.2
+30589,Spain,2011,4,C03-Diuretics,Million US$ at exchange rate,167.4
+30590,Spain,2011,4,C03-Diuretics,"Million US$, purchasing power parity",168.4
+30591,Spain,2011,4,J-Antiinfectives for systemic use,% of total sales,2.5
+30592,Spain,2011,4,C03-Diuretics,Million of national currency units,120.2
+30593,Spain,2011,4,C07-Beta blocking agents,% of total sales,0.7
+30594,Spain,2011,4,C07-Beta blocking agents,"/capita, US$ purchasing power parity",2.5
+30595,Spain,2011,4,N-Nervous system,Million of national currency units,3080.3
+30596,Spain,2011,4,N-Nervous system,Million US$ at exchange rate,4287.7
+30597,Spain,2011,4,C07-Beta blocking agents,Million US$ at exchange rate,118.1
+30598,Spain,2011,4,C07-Beta blocking agents,Million of national currency units,84.9
+30599,Spain,2011,4,J-Antiinfectives for systemic use,Million of national currency units,311.5
+30600,Spain,2011,4,C07-Beta blocking agents,"/capita, US$ exchange rate",2.5
+30601,Spain,2011,4,C07-Beta blocking agents,"Million US$, purchasing power parity",118.8
+30602,Spain,2011,4,N-Nervous system,"/capita, US$ purchasing power parity",92.3
+30603,Spain,2011,4,N-Nervous system,"/capita, US$ exchange rate",91.7
+30604,Spain,2011,4,N-Nervous system,% of total sales,24.9
+30605,Spain,2011,4,C08-Calcium channel blockers,"Million US$, purchasing power parity",261.8
+30606,Spain,2011,4,C-Cardiovascular system,Million US$ at exchange rate,3606.5
+30607,Spain,2011,4,C-Cardiovascular system,Million of national currency units,2591.0
+30608,Spain,2011,4,N-Nervous system,"Million US$, purchasing power parity",4313.4
+30609,Spain,2011,4,C03-Diuretics,% of total sales,1.0
+30610,Spain,2011,4,C03-Diuretics,"/capita, US$ exchange rate",3.6
+30611,Spain,2011,4,C03-Diuretics,"/capita, US$ purchasing power parity",3.6
+30612,Spain,2011,4,C-Cardiovascular system,% of total sales,21.0
+30613,Spain,2011,4,C08-Calcium channel blockers,Million of national currency units,187.0
+30614,Spain,2011,4,C08-Calcium channel blockers,Million US$ at exchange rate,260.2
+30615,Spain,2011,4,C-Cardiovascular system,"/capita, US$ exchange rate",77.2
+30616,Spain,2011,4,C-Cardiovascular system,"/capita, US$ purchasing power parity",77.6
+30617,Spain,2011,4,C10-Lipid modifying agents,"Million US$, purchasing power parity",1051.7
+30618,Spain,2011,4,C10-Lipid modifying agents,Million US$ at exchange rate,1045.5
+30619,Spain,2011,4,C10-Lipid modifying agents,Million of national currency units,751.1
+30620,Spain,2011,4,C10-Lipid modifying agents,"/capita, US$ purchasing power parity",22.5
+30621,Spain,2011,4,C10-Lipid modifying agents,"/capita, US$ exchange rate",22.4
+30622,Spain,2011,4,M-Musculo-skeletal system,"/capita, US$ exchange rate",22.6
+30623,Spain,2011,4,M-Musculo-skeletal system,"Million US$, purchasing power parity",1063.0
+30624,Spain,2011,4,M-Musculo-skeletal system,% of total sales,6.1
+30625,Spain,2011,4,M-Musculo-skeletal system,"/capita, US$ purchasing power parity",22.7
+30626,Spain,2011,4,Total pharmaceutical sales,Million of national currency units,12356.1
+30627,Spain,2011,4,Total pharmaceutical sales,Million US$ at exchange rate,17199.1
+30628,Spain,2011,4,B-Blood and blood forming organs,% of total sales,4.3
+30629,Spain,2011,4,M01A-Antiinflammatory and antirheumatic products non-steroids,% of total sales,3.1
+30630,Spain,2011,4,Total pharmaceutical sales,"/capita, US$ purchasing power parity",370.2
+30631,Spain,2011,4,C10-Lipid modifying agents,% of total sales,6.1
+30632,Spain,2011,4,Total pharmaceutical sales,"Million US$, purchasing power parity",17302.4
+30633,Spain,2011,4,Total pharmaceutical sales,"/capita, US$ exchange rate",368.0
+30634,Spain,2011,4,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ purchasing power parity",11.5
+30635,Spain,2011,4,M-Musculo-skeletal system,Million of national currency units,759.1
+30636,Spain,2011,4,R-Respiratory system,Million of national currency units,1311.5
+30637,Spain,2011,4,R-Respiratory system,Million US$ at exchange rate,1825.5
+30638,Spain,2011,4,"H-Systemic hormonal preparations, excluding sex hormones and insulins",% of total sales,2.1
+30639,Spain,2011,4,M-Musculo-skeletal system,Million US$ at exchange rate,1056.6
+30640,Spain,2011,4,R-Respiratory system,"/capita, US$ purchasing power parity",39.3
+30641,Spain,2011,4,R-Respiratory system,% of total sales,10.6
+30642,Spain,2011,4,R-Respiratory system,"Million US$, purchasing power parity",1836.5
+30643,Spain,2011,4,R-Respiratory system,"/capita, US$ exchange rate",39.1
+30644,Spain,2011,4,N05B-Anxiolytics,"Million US$, purchasing power parity",158.8
+30645,Spain,2011,4,N05B-Anxiolytics,Million US$ at exchange rate,157.9
+30646,Spain,2011,4,N05B-Anxiolytics,% of total sales,0.9
+30647,Spain,2011,4,N05B-Anxiolytics,"/capita, US$ exchange rate",3.4
+30648,Spain,2011,4,N05B-Anxiolytics,"/capita, US$ purchasing power parity",3.4
+30649,Spain,2011,4,"H-Systemic hormonal preparations, excluding sex hormones and insulins","Million US$, purchasing power parity",362.5
+30650,Spain,2011,4,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ exchange rate",7.7
+30651,Spain,2011,4,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ purchasing power parity",7.8
+30652,Spain,2011,4,N05B-Anxiolytics,Million of national currency units,113.4
+30653,Spain,2011,4,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million of national currency units,258.9
+30654,Spain,2011,4,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million US$ at exchange rate,360.3
+30655,Spain,2011,4,C01A-Cardiac glycosides,"Million US$, purchasing power parity",5.2
+30656,Spain,2011,4,C01A-Cardiac glycosides,"/capita, US$ exchange rate",0.1
+30657,Spain,2011,4,B-Blood and blood forming organs,"/capita, US$ purchasing power parity",15.9
+30658,Spain,2011,4,C01A-Cardiac glycosides,Million of national currency units,3.7
+30659,Spain,2011,4,C01A-Cardiac glycosides,Million US$ at exchange rate,5.2
+30660,Spain,2011,4,G-Genito urinary system and sex hormones,% of total sales,4.1
+30661,Spain,2011,4,G-Genito urinary system and sex hormones,"/capita, US$ purchasing power parity",15.1
+30662,Spain,2011,4,C01A-Cardiac glycosides,"/capita, US$ purchasing power parity",0.1
+30663,Spain,2011,4,C01A-Cardiac glycosides,% of total sales,0.0
+30664,Spain,2011,4,N05C-Hypnotics and sedatives,"/capita, US$ exchange rate",1.2
+30665,Spain,2011,4,N05C-Hypnotics and sedatives,"Million US$, purchasing power parity",57.6
+30666,Spain,2011,4,N05C-Hypnotics and sedatives,% of total sales,0.3
+30667,Spain,2011,4,N05C-Hypnotics and sedatives,"/capita, US$ purchasing power parity",1.2
+30668,Spain,2011,4,B-Blood and blood forming organs,"Million US$, purchasing power parity",741.7
+30669,Spain,2011,4,B-Blood and blood forming organs,"/capita, US$ exchange rate",15.8
+30670,Spain,2011,4,B-Blood and blood forming organs,Million US$ at exchange rate,737.2
+30671,Spain,2011,4,N05C-Hypnotics and sedatives,Million US$ at exchange rate,57.3
+30672,Spain,2011,4,N05C-Hypnotics and sedatives,Million of national currency units,41.2
+30673,Spain,2011,4,B-Blood and blood forming organs,Million of national currency units,529.6
+30674,Spain,2011,4,N06A-Antidepressants,"/capita, US$ exchange rate",17.6
+30675,Spain,2011,4,N06A-Antidepressants,"/capita, US$ purchasing power parity",17.7
+30676,Spain,2011,4,N06A-Antidepressants,Million US$ at exchange rate,821.9
+30677,Spain,2011,4,N06A-Antidepressants,"Million US$, purchasing power parity",826.8
+30678,Spain,2011,4,N06A-Antidepressants,% of total sales,4.8
+30679,Spain,2011,4,M01A-Antiinflammatory and antirheumatic products non-steroids,"Million US$, purchasing power parity",539.0
+30680,Spain,2011,4,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ exchange rate",11.5
+30681,Spain,2011,4,M01A-Antiinflammatory and antirheumatic products non-steroids,Million of national currency units,385.0
+30682,Spain,2011,4,M01A-Antiinflammatory and antirheumatic products non-steroids,Million US$ at exchange rate,535.8
+30683,Spain,2011,4,G-Genito urinary system and sex hormones,Million of national currency units,502.5
+30684,Spain,2011,4,G03-Sex hormones and modulators of the genital system,Million of national currency units,114.8
+30685,Spain,2011,4,G03-Sex hormones and modulators of the genital system,Million US$ at exchange rate,159.7
+30686,Spain,2011,4,G-Genito urinary system and sex hormones,"/capita, US$ exchange rate",15.0
+30687,Spain,2011,4,G-Genito urinary system and sex hormones,Million US$ at exchange rate,699.4
+30688,Spain,2011,4,G-Genito urinary system and sex hormones,"Million US$, purchasing power parity",703.6
+30689,Spain,2011,4,G03-Sex hormones and modulators of the genital system,"/capita, US$ purchasing power parity",3.4
+30690,Spain,2011,4,G03-Sex hormones and modulators of the genital system,% of total sales,0.9
+30691,Spain,2011,4,N06A-Antidepressants,Million of national currency units,590.4
+30692,Spain,2011,4,G03-Sex hormones and modulators of the genital system,"Million US$, purchasing power parity",160.7
+30693,Spain,2011,4,G03-Sex hormones and modulators of the genital system,"/capita, US$ exchange rate",3.4
+30694,Spain,2011,4,"C01B-Antiarrhythmics, Class I and III",Million of national currency units,33.6
+30695,Spain,2011,4,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ purchasing power parity",16.9
+30696,Spain,2011,4,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),% of total sales,4.6
+30697,Spain,2011,4,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"Million US$, purchasing power parity",788.1
+30698,Spain,2011,4,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ exchange rate",16.8
+30699,Spain,2011,4,A-Alimentary tract and metabolism,"Million US$, purchasing power parity",2489.0
+30700,Spain,2011,4,A-Alimentary tract and metabolism,"/capita, US$ exchange rate",52.9
+30701,Spain,2011,4,A-Alimentary tract and metabolism,Million of national currency units,1777.5
+30702,Spain,2011,4,A-Alimentary tract and metabolism,Million US$ at exchange rate,2474.2
+30703,Spain,2011,4,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ exchange rate",33.9
+30704,Spain,2011,4,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ purchasing power parity",34.1
+30705,Spain,2011,4,C09-Agents acting on the Renin-Angiotensin system,% of total sales,9.2
+30706,Spain,2011,4,C09-Agents acting on the Renin-Angiotensin system,"Million US$, purchasing power parity",1592.6
+30707,Spain,2011,4,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million of national currency units,562.8
+30708,Spain,2011,4,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million US$ at exchange rate,783.4
+30709,Spain,2011,4,C09-Agents acting on the Renin-Angiotensin system,Million of national currency units,1137.3
+30710,Spain,2011,4,C09-Agents acting on the Renin-Angiotensin system,Million US$ at exchange rate,1583.1
+30711,Spain,2011,4,N02-Analgesics,"/capita, US$ purchasing power parity",14.4
+30712,Spain,2011,4,N02-Analgesics,"/capita, US$ exchange rate",14.4
+30713,Spain,2011,4,N02-Analgesics,% of total sales,3.9
+30714,Spain,2011,4,N02-Analgesics,Million of national currency units,482.3
+30715,Spain,2011,4,C02-Antihypertensives,Million of national currency units,45.0
+30716,Spain,2011,4,C02-Antihypertensives,Million US$ at exchange rate,62.7
+30717,Spain,2011,4,N02-Analgesics,"Million US$, purchasing power parity",675.4
+30718,Spain,2011,4,N02-Analgesics,Million US$ at exchange rate,671.3
+30719,Spain,2011,4,R03-Drugs for obstructive airway diseases,Million of national currency units,1063.0
+30720,Spain,2011,4,R03-Drugs for obstructive airway diseases,Million US$ at exchange rate,1479.7
+30721,Spain,2011,4,A-Alimentary tract and metabolism,"/capita, US$ purchasing power parity",53.2
+30722,Spain,2011,4,A-Alimentary tract and metabolism,% of total sales,14.4
+30723,Spain,2011,4,R03-Drugs for obstructive airway diseases,"/capita, US$ purchasing power parity",31.8
+30724,Spain,2011,4,R03-Drugs for obstructive airway diseases,% of total sales,8.6
+30725,Spain,2011,4,R03-Drugs for obstructive airway diseases,"Million US$, purchasing power parity",1488.5
+30726,Spain,2011,4,R03-Drugs for obstructive airway diseases,"/capita, US$ exchange rate",31.7
+30727,Spain,2011,4,A02A-Antacids,Million US$ at exchange rate,24.9
+30728,Spain,2011,4,A02A-Antacids,Million of national currency units,17.9
+30729,Spain,2011,4,A10-Drugs used in diabetes,Million of national currency units,890.8
+30730,Spain,2011,4,A10-Drugs used in diabetes,Million US$ at exchange rate,1239.9
+30731,Spain,2011,4,A02A-Antacids,"Million US$, purchasing power parity",25.0
+30732,Spain,2011,4,"C01B-Antiarrhythmics, Class I and III",% of total sales,0.3
+30733,Spain,2011,4,A02A-Antacids,% of total sales,0.1
+30734,Spain,2011,4,A02A-Antacids,"/capita, US$ purchasing power parity",0.5
+30735,Spain,2011,4,A02A-Antacids,"/capita, US$ exchange rate",0.5
+30736,Spain,2011,4,A10-Drugs used in diabetes,"/capita, US$ purchasing power parity",26.7
+30737,Spain,2011,4,A10-Drugs used in diabetes,% of total sales,7.2
+30738,Spain,2011,4,A10-Drugs used in diabetes,"Million US$, purchasing power parity",1247.4
+30739,Spain,2011,4,A10-Drugs used in diabetes,"/capita, US$ exchange rate",26.5
+30740,Spain,2011,4,"C01B-Antiarrhythmics, Class I and III","Million US$, purchasing power parity",47.1
+30741,Spain,2011,4,"C01B-Antiarrhythmics, Class I and III","/capita, US$ exchange rate",1.0
+30742,Spain,2011,4,"C01B-Antiarrhythmics, Class I and III",Million US$ at exchange rate,46.8
+30743,Spain,2011,4,"C01B-Antiarrhythmics, Class I and III","/capita, US$ purchasing power parity",1.0
+30744,Spain,2012,4,J01-Antibacterials for systemic use,"/capita, US$ purchasing power parity",7.0
+30745,Spain,2012,4,J01-Antibacterials for systemic use,% of total sales,2.1
+30746,Spain,2012,4,J01-Antibacterials for systemic use,Million of national currency units,227.4
+30747,Spain,2012,4,J01-Antibacterials for systemic use,"/capita, US$ exchange rate",6.2
+30748,Spain,2012,4,J01-Antibacterials for systemic use,Million US$ at exchange rate,292.1
+30749,Spain,2012,4,J01-Antibacterials for systemic use,"Million US$, purchasing power parity",327.1
+30750,Spain,2012,4,C08-Calcium channel blockers,"/capita, US$ exchange rate",3.5
+30751,Spain,2012,4,C02-Antihypertensives,"Million US$, purchasing power parity",58.4
+30752,Spain,2012,4,C02-Antihypertensives,"/capita, US$ purchasing power parity",1.2
+30753,Spain,2012,4,C02-Antihypertensives,"/capita, US$ exchange rate",1.1
+30754,Spain,2012,4,C08-Calcium channel blockers,"/capita, US$ purchasing power parity",3.9
+30755,Spain,2012,4,C02-Antihypertensives,% of total sales,0.4
+30756,Spain,2012,4,C08-Calcium channel blockers,% of total sales,1.1
+30757,Spain,2012,4,C03-Diuretics,"/capita, US$ exchange rate",3.1
+30758,Spain,2012,4,J-Antiinfectives for systemic use,"/capita, US$ exchange rate",7.5
+30759,Spain,2012,4,J-Antiinfectives for systemic use,"/capita, US$ purchasing power parity",8.5
+30760,Spain,2012,4,J-Antiinfectives for systemic use,Million US$ at exchange rate,353.1
+30761,Spain,2012,4,J-Antiinfectives for systemic use,"Million US$, purchasing power parity",395.5
+30762,Spain,2012,4,C03-Diuretics,Million US$ at exchange rate,143.3
+30763,Spain,2012,4,C03-Diuretics,"Million US$, purchasing power parity",160.5
+30764,Spain,2012,4,J-Antiinfectives for systemic use,% of total sales,2.5
+30765,Spain,2012,4,C03-Diuretics,Million of national currency units,111.6
+30766,Spain,2012,4,C07-Beta blocking agents,% of total sales,0.7
+30767,Spain,2012,4,C07-Beta blocking agents,"/capita, US$ purchasing power parity",2.4
+30768,Spain,2012,4,N-Nervous system,Million of national currency units,2838.9
+30769,Spain,2012,4,C07-Beta blocking agents,"/capita, US$ exchange rate",2.2
+30770,Spain,2012,4,J-Antiinfectives for systemic use,Million of national currency units,274.8
+30771,Spain,2012,4,C07-Beta blocking agents,Million of national currency units,79.1
+30772,Spain,2012,4,C07-Beta blocking agents,Million US$ at exchange rate,101.6
+30773,Spain,2012,4,C07-Beta blocking agents,"Million US$, purchasing power parity",113.8
+30774,Spain,2012,4,N-Nervous system,"/capita, US$ purchasing power parity",87.3
+30775,Spain,2012,4,N-Nervous system,"/capita, US$ exchange rate",78.0
+30776,Spain,2012,4,C08-Calcium channel blockers,"Million US$, purchasing power parity",182.3
+30777,Spain,2012,4,N-Nervous system,% of total sales,25.6
+30778,Spain,2012,4,C-Cardiovascular system,Million US$ at exchange rate,2838.9
+30779,Spain,2012,4,C-Cardiovascular system,Million of national currency units,2209.6
+30780,Spain,2012,4,N-Nervous system,"Million US$, purchasing power parity",4084.9
+30781,Spain,2012,4,N-Nervous system,Million US$ at exchange rate,3647.4
+30782,Spain,2012,4,C-Cardiovascular system,"Million US$, purchasing power parity",3179.4
+30783,Spain,2012,4,C03-Diuretics,% of total sales,1.0
+30784,Spain,2012,4,C03-Diuretics,"/capita, US$ purchasing power parity",3.4
+30785,Spain,2012,4,C-Cardiovascular system,% of total sales,20.0
+30786,Spain,2012,4,C08-Calcium channel blockers,Million of national currency units,126.7
+30787,Spain,2012,4,C08-Calcium channel blockers,Million US$ at exchange rate,162.8
+30788,Spain,2012,4,C-Cardiovascular system,"/capita, US$ exchange rate",60.7
+30789,Spain,2012,4,C-Cardiovascular system,"/capita, US$ purchasing power parity",68.0
+30790,Spain,2012,4,C10-Lipid modifying agents,"Million US$, purchasing power parity",952.6
+30791,Spain,2012,4,C10-Lipid modifying agents,Million US$ at exchange rate,850.6
+30792,Spain,2012,4,C10-Lipid modifying agents,Million of national currency units,662.0
+30793,Spain,2012,4,C10-Lipid modifying agents,"/capita, US$ purchasing power parity",20.4
+30794,Spain,2012,4,C10-Lipid modifying agents,"/capita, US$ exchange rate",18.2
+30795,Spain,2012,4,M-Musculo-skeletal system,"/capita, US$ exchange rate",17.5
+30796,Spain,2012,4,M-Musculo-skeletal system,"Million US$, purchasing power parity",914.2
+30797,Spain,2012,4,M-Musculo-skeletal system,% of total sales,5.7
+30798,Spain,2012,4,M-Musculo-skeletal system,"/capita, US$ purchasing power parity",19.5
+30799,Spain,2012,4,B-Blood and blood forming organs,% of total sales,4.5
+30800,Spain,2012,4,Total pharmaceutical sales,Million of national currency units,11072.0
+30801,Spain,2012,4,Total pharmaceutical sales,Million US$ at exchange rate,14225.2
+30802,Spain,2012,4,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ purchasing power parity",10.8
+30803,Spain,2012,4,M01A-Antiinflammatory and antirheumatic products non-steroids,% of total sales,3.2
+30804,Spain,2012,4,Total pharmaceutical sales,"/capita, US$ purchasing power parity",340.6
+30805,Spain,2012,4,C10-Lipid modifying agents,% of total sales,6.0
+30806,Spain,2012,4,Total pharmaceutical sales,"Million US$, purchasing power parity",15931.5
+30807,Spain,2012,4,Total pharmaceutical sales,"/capita, US$ exchange rate",304.1
+30808,Spain,2012,4,M-Musculo-skeletal system,Million of national currency units,635.4
+30809,Spain,2012,4,R-Respiratory system,Million of national currency units,1201.6
+30810,Spain,2012,4,R-Respiratory system,Million US$ at exchange rate,1543.8
+30811,Spain,2012,4,M-Musculo-skeletal system,Million US$ at exchange rate,816.3
+30812,Spain,2012,4,"H-Systemic hormonal preparations, excluding sex hormones and insulins",% of total sales,2.1
+30813,Spain,2012,4,R-Respiratory system,"/capita, US$ purchasing power parity",37.0
+30814,Spain,2012,4,R-Respiratory system,% of total sales,10.9
+30815,Spain,2012,4,R-Respiratory system,"Million US$, purchasing power parity",1729.0
+30816,Spain,2012,4,R-Respiratory system,"/capita, US$ exchange rate",33.0
+30817,Spain,2012,4,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ purchasing power parity",7.3
+30818,Spain,2012,4,N05B-Anxiolytics,"Million US$, purchasing power parity",141.3
+30819,Spain,2012,4,N05B-Anxiolytics,Million US$ at exchange rate,126.2
+30820,Spain,2012,4,N05B-Anxiolytics,% of total sales,0.9
+30821,Spain,2012,4,N05B-Anxiolytics,"/capita, US$ purchasing power parity",3.0
+30822,Spain,2012,4,N05B-Anxiolytics,"/capita, US$ exchange rate",2.7
+30823,Spain,2012,4,"H-Systemic hormonal preparations, excluding sex hormones and insulins","Million US$, purchasing power parity",339.1
+30824,Spain,2012,4,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ exchange rate",6.5
+30825,Spain,2012,4,N05B-Anxiolytics,Million of national currency units,98.2
+30826,Spain,2012,4,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million of national currency units,235.7
+30827,Spain,2012,4,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million US$ at exchange rate,302.8
+30828,Spain,2012,4,C01A-Cardiac glycosides,"Million US$, purchasing power parity",4.8
+30829,Spain,2012,4,C01A-Cardiac glycosides,"/capita, US$ exchange rate",0.1
+30830,Spain,2012,4,B-Blood and blood forming organs,"/capita, US$ purchasing power parity",15.4
+30831,Spain,2012,4,C01A-Cardiac glycosides,Million of national currency units,3.4
+30832,Spain,2012,4,C01A-Cardiac glycosides,Million US$ at exchange rate,4.3
+30833,Spain,2012,4,G-Genito urinary system and sex hormones,% of total sales,4.3
+30834,Spain,2012,4,G-Genito urinary system and sex hormones,"/capita, US$ purchasing power parity",14.7
+30835,Spain,2012,4,C01A-Cardiac glycosides,"/capita, US$ purchasing power parity",0.1
+30836,Spain,2012,4,C01A-Cardiac glycosides,% of total sales,0.0
+30837,Spain,2012,4,N05C-Hypnotics and sedatives,"/capita, US$ exchange rate",1.1
+30838,Spain,2012,4,N05C-Hypnotics and sedatives,"Million US$, purchasing power parity",57.7
+30839,Spain,2012,4,N05C-Hypnotics and sedatives,% of total sales,0.4
+30840,Spain,2012,4,N05C-Hypnotics and sedatives,"/capita, US$ purchasing power parity",1.2
+30841,Spain,2012,4,N05C-Hypnotics and sedatives,Million US$ at exchange rate,51.5
+30842,Spain,2012,4,B-Blood and blood forming organs,"Million US$, purchasing power parity",722.0
+30843,Spain,2012,4,B-Blood and blood forming organs,"/capita, US$ exchange rate",13.8
+30844,Spain,2012,4,B-Blood and blood forming organs,Million US$ at exchange rate,644.7
+30845,Spain,2012,4,N05C-Hypnotics and sedatives,Million of national currency units,40.1
+30846,Spain,2012,4,B-Blood and blood forming organs,Million of national currency units,501.8
+30847,Spain,2012,4,N06A-Antidepressants,"/capita, US$ exchange rate",13.4
+30848,Spain,2012,4,N06A-Antidepressants,"/capita, US$ purchasing power parity",15.0
+30849,Spain,2012,4,N06A-Antidepressants,Million US$ at exchange rate,627.9
+30850,Spain,2012,4,N06A-Antidepressants,"Million US$, purchasing power parity",703.2
+30851,Spain,2012,4,M01A-Antiinflammatory and antirheumatic products non-steroids,"Million US$, purchasing power parity",507.1
+30852,Spain,2012,4,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ exchange rate",9.7
+30853,Spain,2012,4,M01A-Antiinflammatory and antirheumatic products non-steroids,Million of national currency units,352.4
+30854,Spain,2012,4,N06A-Antidepressants,% of total sales,4.4
+30855,Spain,2012,4,M01A-Antiinflammatory and antirheumatic products non-steroids,Million US$ at exchange rate,452.8
+30856,Spain,2012,4,N06A-Antidepressants,Million of national currency units,488.7
+30857,Spain,2012,4,G-Genito urinary system and sex hormones,Million of national currency units,478.2
+30858,Spain,2012,4,G03-Sex hormones and modulators of the genital system,Million of national currency units,125.1
+30859,Spain,2012,4,G03-Sex hormones and modulators of the genital system,Million US$ at exchange rate,160.7
+30860,Spain,2012,4,G-Genito urinary system and sex hormones,"/capita, US$ exchange rate",13.1
+30861,Spain,2012,4,G-Genito urinary system and sex hormones,"Million US$, purchasing power parity",688.0
+30862,Spain,2012,4,G-Genito urinary system and sex hormones,Million US$ at exchange rate,614.3
+30863,Spain,2012,4,G03-Sex hormones and modulators of the genital system,"/capita, US$ purchasing power parity",3.8
+30864,Spain,2012,4,G03-Sex hormones and modulators of the genital system,% of total sales,1.1
+30865,Spain,2012,4,G03-Sex hormones and modulators of the genital system,"Million US$, purchasing power parity",179.9
+30866,Spain,2012,4,G03-Sex hormones and modulators of the genital system,"/capita, US$ exchange rate",3.4
+30867,Spain,2012,4,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ purchasing power parity",13.8
+30868,Spain,2012,4,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),% of total sales,4.1
+30869,Spain,2012,4,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"Million US$, purchasing power parity",646.3
+30870,Spain,2012,4,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ exchange rate",12.3
+30871,Spain,2012,4,A-Alimentary tract and metabolism,"Million US$, purchasing power parity",2415.6
+30872,Spain,2012,4,A-Alimentary tract and metabolism,"/capita, US$ exchange rate",46.1
+30873,Spain,2012,4,A-Alimentary tract and metabolism,Million of national currency units,1678.8
+30874,Spain,2012,4,A-Alimentary tract and metabolism,Million US$ at exchange rate,2156.9
+30875,Spain,2012,4,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ exchange rate",26.5
+30876,Spain,2012,4,"C01B-Antiarrhythmics, Class I and III",Million of national currency units,31.2
+30877,Spain,2012,4,C09-Agents acting on the Renin-Angiotensin system,% of total sales,8.7
+30878,Spain,2012,4,C09-Agents acting on the Renin-Angiotensin system,"Million US$, purchasing power parity",1385.6
+30879,Spain,2012,4,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ purchasing power parity",29.6
+30880,Spain,2012,4,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million of national currency units,449.2
+30881,Spain,2012,4,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million US$ at exchange rate,577.1
+30882,Spain,2012,4,C09-Agents acting on the Renin-Angiotensin system,Million of national currency units,963.0
+30883,Spain,2012,4,C09-Agents acting on the Renin-Angiotensin system,Million US$ at exchange rate,1237.2
+30884,Spain,2012,4,N02-Analgesics,"/capita, US$ exchange rate",12.9
+30885,Spain,2012,4,N02-Analgesics,"/capita, US$ purchasing power parity",14.4
+30886,Spain,2012,4,N02-Analgesics,% of total sales,4.2
+30887,Spain,2012,4,N02-Analgesics,Million of national currency units,468.8
+30888,Spain,2012,4,C02-Antihypertensives,Million of national currency units,40.6
+30889,Spain,2012,4,C02-Antihypertensives,Million US$ at exchange rate,52.2
+30890,Spain,2012,4,N02-Analgesics,"Million US$, purchasing power parity",674.6
+30891,Spain,2012,4,N02-Analgesics,Million US$ at exchange rate,602.3
+30892,Spain,2012,4,R03-Drugs for obstructive airway diseases,Million of national currency units,1009.0
+30893,Spain,2012,4,R03-Drugs for obstructive airway diseases,Million US$ at exchange rate,1296.3
+30894,Spain,2012,4,A-Alimentary tract and metabolism,"/capita, US$ purchasing power parity",51.6
+30895,Spain,2012,4,A-Alimentary tract and metabolism,% of total sales,15.2
+30896,Spain,2012,4,R03-Drugs for obstructive airway diseases,"/capita, US$ purchasing power parity",31.0
+30897,Spain,2012,4,R03-Drugs for obstructive airway diseases,% of total sales,9.1
+30898,Spain,2012,4,R03-Drugs for obstructive airway diseases,"Million US$, purchasing power parity",1451.8
+30899,Spain,2012,4,R03-Drugs for obstructive airway diseases,"/capita, US$ exchange rate",27.7
+30900,Spain,2012,4,A02A-Antacids,Million US$ at exchange rate,15.0
+30901,Spain,2012,4,A02A-Antacids,Million of national currency units,11.7
+30902,Spain,2012,4,A10-Drugs used in diabetes,Million of national currency units,941.9
+30903,Spain,2012,4,A10-Drugs used in diabetes,Million US$ at exchange rate,1210.1
+30904,Spain,2012,4,"C01B-Antiarrhythmics, Class I and III",% of total sales,0.3
+30905,Spain,2012,4,A02A-Antacids,% of total sales,0.1
+30906,Spain,2012,4,A02A-Antacids,"/capita, US$ purchasing power parity",0.4
+30907,Spain,2012,4,A02A-Antacids,"/capita, US$ exchange rate",0.3
+30908,Spain,2012,4,A02A-Antacids,"Million US$, purchasing power parity",16.8
+30909,Spain,2012,4,A10-Drugs used in diabetes,"/capita, US$ purchasing power parity",29.0
+30910,Spain,2012,4,A10-Drugs used in diabetes,% of total sales,8.5
+30911,Spain,2012,4,A10-Drugs used in diabetes,"Million US$, purchasing power parity",1355.3
+30912,Spain,2012,4,A10-Drugs used in diabetes,"/capita, US$ exchange rate",25.9
+30913,Spain,2012,4,"C01B-Antiarrhythmics, Class I and III","Million US$, purchasing power parity",44.9
+30914,Spain,2012,4,"C01B-Antiarrhythmics, Class I and III","/capita, US$ exchange rate",0.9
+30915,Spain,2012,4,"C01B-Antiarrhythmics, Class I and III",Million US$ at exchange rate,40.1
+30916,Spain,2012,4,"C01B-Antiarrhythmics, Class I and III","/capita, US$ purchasing power parity",1.0
+30917,Spain,2013,4,J01-Antibacterials for systemic use,"/capita, US$ purchasing power parity",7.2
+30918,Spain,2013,4,J01-Antibacterials for systemic use,% of total sales,2.1
+30919,Spain,2013,4,J01-Antibacterials for systemic use,Million US$ at exchange rate,302.5
+30920,Spain,2013,4,J01-Antibacterials for systemic use,"Million US$, purchasing power parity",337.5
+30921,Spain,2013,4,J01-Antibacterials for systemic use,"/capita, US$ exchange rate",6.5
+30922,Spain,2013,4,J01-Antibacterials for systemic use,Million of national currency units,227.8
+30923,Spain,2013,4,C-Cardiovascular system,"Million US$, purchasing power parity",3080.4
+30924,Spain,2013,4,C02-Antihypertensives,"Million US$, purchasing power parity",59.4
+30925,Spain,2013,4,C02-Antihypertensives,"/capita, US$ purchasing power parity",1.3
+30926,Spain,2013,4,C08-Calcium channel blockers,"/capita, US$ purchasing power parity",3.5
+30927,Spain,2013,4,C08-Calcium channel blockers,"/capita, US$ exchange rate",3.2
+30928,Spain,2013,4,C02-Antihypertensives,"/capita, US$ exchange rate",1.1
+30929,Spain,2013,4,C02-Antihypertensives,% of total sales,0.4
+30930,Spain,2013,4,C08-Calcium channel blockers,% of total sales,1.0
+30931,Spain,2013,4,J-Antiinfectives for systemic use,"/capita, US$ exchange rate",7.8
+30932,Spain,2013,4,J-Antiinfectives for systemic use,Million US$ at exchange rate,364.5
+30933,Spain,2013,4,J-Antiinfectives for systemic use,"Million US$, purchasing power parity",406.7
+30934,Spain,2013,4,C03-Diuretics,Million US$ at exchange rate,135.0
+30935,Spain,2013,4,C03-Diuretics,"Million US$, purchasing power parity",150.6
+30936,Spain,2013,4,J-Antiinfectives for systemic use,% of total sales,2.6
+30937,Spain,2013,4,C03-Diuretics,Million of national currency units,101.6
+30938,Spain,2013,4,C07-Beta blocking agents,"/capita, US$ purchasing power parity",2.6
+30939,Spain,2013,4,C07-Beta blocking agents,% of total sales,0.8
+30940,Spain,2013,4,N-Nervous system,Million of national currency units,2862.9
+30941,Spain,2013,4,C07-Beta blocking agents,"/capita, US$ exchange rate",2.3
+30942,Spain,2013,4,C07-Beta blocking agents,Million of national currency units,80.7
+30943,Spain,2013,4,J-Antiinfectives for systemic use,Million of national currency units,274.4
+30944,Spain,2013,4,C07-Beta blocking agents,Million US$ at exchange rate,107.2
+30945,Spain,2013,4,C07-Beta blocking agents,"Million US$, purchasing power parity",119.6
+30946,Spain,2013,4,N-Nervous system,"/capita, US$ purchasing power parity",91.0
+30947,Spain,2013,4,N-Nervous system,"/capita, US$ exchange rate",81.6
+30948,Spain,2013,4,C08-Calcium channel blockers,"Million US$, purchasing power parity",164.3
+30949,Spain,2013,4,N-Nervous system,% of total sales,26.8
+30950,Spain,2013,4,C-Cardiovascular system,Million US$ at exchange rate,2760.7
+30951,Spain,2013,4,C-Cardiovascular system,Million of national currency units,2078.7
+30952,Spain,2013,4,N-Nervous system,"Million US$, purchasing power parity",4242.6
+30953,Spain,2013,4,N-Nervous system,Million US$ at exchange rate,3802.2
+30954,Spain,2013,4,C03-Diuretics,% of total sales,1.0
+30955,Spain,2013,4,C-Cardiovascular system,% of total sales,19.5
+30956,Spain,2013,4,C03-Diuretics,"/capita, US$ exchange rate",2.9
+30957,Spain,2013,4,C03-Diuretics,"/capita, US$ purchasing power parity",3.2
+30958,Spain,2013,4,C08-Calcium channel blockers,Million of national currency units,110.8
+30959,Spain,2013,4,C08-Calcium channel blockers,Million US$ at exchange rate,147.2
+30960,Spain,2013,4,C-Cardiovascular system,"/capita, US$ purchasing power parity",66.1
+30961,Spain,2013,4,C-Cardiovascular system,"/capita, US$ exchange rate",59.2
+30962,Spain,2013,4,J-Antiinfectives for systemic use,"/capita, US$ purchasing power parity",8.7
+30963,Spain,2013,4,C10-Lipid modifying agents,Million US$ at exchange rate,864.0
+30964,Spain,2013,4,C10-Lipid modifying agents,Million of national currency units,650.6
+30965,Spain,2013,4,C10-Lipid modifying agents,"Million US$, purchasing power parity",964.1
+30966,Spain,2013,4,C10-Lipid modifying agents,"/capita, US$ purchasing power parity",20.7
+30967,Spain,2013,4,C10-Lipid modifying agents,"/capita, US$ exchange rate",18.5
+30968,Spain,2013,4,M-Musculo-skeletal system,"/capita, US$ exchange rate",15.6
+30969,Spain,2013,4,M-Musculo-skeletal system,"Million US$, purchasing power parity",812.4
+30970,Spain,2013,4,M-Musculo-skeletal system,% of total sales,5.1
+30971,Spain,2013,4,M-Musculo-skeletal system,"/capita, US$ purchasing power parity",17.4
+30972,Spain,2013,4,B-Blood and blood forming organs,% of total sales,4.9
+30973,Spain,2013,4,Total pharmaceutical sales,Million of national currency units,10669.9
+30974,Spain,2013,4,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ purchasing power parity",10.6
+30975,Spain,2013,4,Total pharmaceutical sales,Million US$ at exchange rate,14170.8
+30976,Spain,2013,4,M01A-Antiinflammatory and antirheumatic products non-steroids,% of total sales,3.1
+30977,Spain,2013,4,Total pharmaceutical sales,"/capita, US$ purchasing power parity",339.2
+30978,Spain,2013,4,C10-Lipid modifying agents,% of total sales,6.1
+30979,Spain,2013,4,Total pharmaceutical sales,"Million US$, purchasing power parity",15811.9
+30980,Spain,2013,4,Total pharmaceutical sales,"/capita, US$ exchange rate",304.0
+30981,Spain,2013,4,N05B-Anxiolytics,% of total sales,0.9
+30982,Spain,2013,4,M-Musculo-skeletal system,Million of national currency units,548.2
+30983,Spain,2013,4,R-Respiratory system,Million of national currency units,1092.6
+30984,Spain,2013,4,"H-Systemic hormonal preparations, excluding sex hormones and insulins",% of total sales,1.9
+30985,Spain,2013,4,M-Musculo-skeletal system,Million US$ at exchange rate,728.1
+30986,Spain,2013,4,R-Respiratory system,Million US$ at exchange rate,1451.1
+30987,Spain,2013,4,R-Respiratory system,"/capita, US$ purchasing power parity",34.7
+30988,Spain,2013,4,R-Respiratory system,% of total sales,10.2
+30989,Spain,2013,4,R-Respiratory system,"Million US$, purchasing power parity",1619.2
+30990,Spain,2013,4,R-Respiratory system,"/capita, US$ exchange rate",31.1
+30991,Spain,2013,4,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ purchasing power parity",6.6
+30992,Spain,2013,4,N05B-Anxiolytics,"Million US$, purchasing power parity",145.6
+30993,Spain,2013,4,N05B-Anxiolytics,Million US$ at exchange rate,130.5
+30994,Spain,2013,4,N05B-Anxiolytics,"/capita, US$ purchasing power parity",3.1
+30995,Spain,2013,4,N05B-Anxiolytics,"/capita, US$ exchange rate",2.8
+30996,Spain,2013,4,"H-Systemic hormonal preparations, excluding sex hormones and insulins","Million US$, purchasing power parity",305.5
+30997,Spain,2013,4,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ exchange rate",5.9
+30998,Spain,2013,4,N05B-Anxiolytics,Million of national currency units,98.3
+30999,Spain,2013,4,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million of national currency units,206.1
+31000,Spain,2013,4,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million US$ at exchange rate,273.8
+31001,Spain,2013,4,C01A-Cardiac glycosides,"Million US$, purchasing power parity",4.6
+31002,Spain,2013,4,C01A-Cardiac glycosides,"/capita, US$ exchange rate",0.1
+31003,Spain,2013,4,C01A-Cardiac glycosides,Million US$ at exchange rate,4.1
+31004,Spain,2013,4,B-Blood and blood forming organs,"/capita, US$ purchasing power parity",16.7
+31005,Spain,2013,4,C01A-Cardiac glycosides,Million of national currency units,3.1
+31006,Spain,2013,4,G-Genito urinary system and sex hormones,% of total sales,4.6
+31007,Spain,2013,4,G-Genito urinary system and sex hormones,"/capita, US$ purchasing power parity",15.5
+31008,Spain,2013,4,C01A-Cardiac glycosides,"/capita, US$ purchasing power parity",0.1
+31009,Spain,2013,4,C01A-Cardiac glycosides,% of total sales,0.0
+31010,Spain,2013,4,N05C-Hypnotics and sedatives,"/capita, US$ exchange rate",1.2
+31011,Spain,2013,4,N05C-Hypnotics and sedatives,"Million US$, purchasing power parity",62.1
+31012,Spain,2013,4,N05C-Hypnotics and sedatives,% of total sales,0.4
+31013,Spain,2013,4,N05C-Hypnotics and sedatives,"/capita, US$ purchasing power parity",1.3
+31014,Spain,2013,4,B-Blood and blood forming organs,"Million US$, purchasing power parity",780.7
+31015,Spain,2013,4,B-Blood and blood forming organs,"/capita, US$ exchange rate",15.0
+31016,Spain,2013,4,B-Blood and blood forming organs,Million US$ at exchange rate,699.7
+31017,Spain,2013,4,N05C-Hypnotics and sedatives,Million of national currency units,41.9
+31018,Spain,2013,4,N05C-Hypnotics and sedatives,Million US$ at exchange rate,55.7
+31019,Spain,2013,4,B-Blood and blood forming organs,Million of national currency units,526.8
+31020,Spain,2013,4,G-Genito urinary system and sex hormones,"/capita, US$ exchange rate",13.9
+31021,Spain,2013,4,N06A-Antidepressants,"/capita, US$ exchange rate",14.3
+31022,Spain,2013,4,N06A-Antidepressants,"/capita, US$ purchasing power parity",15.9
+31023,Spain,2013,4,N06A-Antidepressants,Million US$ at exchange rate,664.9
+31024,Spain,2013,4,N06A-Antidepressants,"Million US$, purchasing power parity",741.9
+31025,Spain,2013,4,N06A-Antidepressants,% of total sales,4.7
+31026,Spain,2013,4,M01A-Antiinflammatory and antirheumatic products non-steroids,"Million US$, purchasing power parity",493.0
+31027,Spain,2013,4,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ exchange rate",9.5
+31028,Spain,2013,4,M01A-Antiinflammatory and antirheumatic products non-steroids,Million of national currency units,332.7
+31029,Spain,2013,4,M01A-Antiinflammatory and antirheumatic products non-steroids,Million US$ at exchange rate,441.9
+31030,Spain,2013,4,G-Genito urinary system and sex hormones,Million of national currency units,487.0
+31031,Spain,2013,4,G03-Sex hormones and modulators of the genital system,Million of national currency units,121.7
+31032,Spain,2013,4,G03-Sex hormones and modulators of the genital system,Million US$ at exchange rate,161.7
+31033,Spain,2013,4,G-Genito urinary system and sex hormones,"Million US$, purchasing power parity",721.6
+31034,Spain,2013,4,G-Genito urinary system and sex hormones,Million US$ at exchange rate,646.7
+31035,Spain,2013,4,N06A-Antidepressants,Million of national currency units,500.6
+31036,Spain,2013,4,G03-Sex hormones and modulators of the genital system,"/capita, US$ purchasing power parity",3.9
+31037,Spain,2013,4,G03-Sex hormones and modulators of the genital system,% of total sales,1.1
+31038,Spain,2013,4,G03-Sex hormones and modulators of the genital system,"Million US$, purchasing power parity",180.4
+31039,Spain,2013,4,G03-Sex hormones and modulators of the genital system,"/capita, US$ exchange rate",3.5
+31040,Spain,2013,4,"C01B-Antiarrhythmics, Class I and III",Million of national currency units,31.7
+31041,Spain,2013,4,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ purchasing power parity",13.3
+31042,Spain,2013,4,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),% of total sales,3.9
+31043,Spain,2013,4,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"Million US$, purchasing power parity",621.4
+31044,Spain,2013,4,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ exchange rate",11.9
+31045,Spain,2013,4,A-Alimentary tract and metabolism,"Million US$, purchasing power parity",2497.4
+31046,Spain,2013,4,A-Alimentary tract and metabolism,"/capita, US$ exchange rate",48.0
+31047,Spain,2013,4,A-Alimentary tract and metabolism,Million of national currency units,1685.3
+31048,Spain,2013,4,A-Alimentary tract and metabolism,Million US$ at exchange rate,2238.2
+31049,Spain,2013,4,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ exchange rate",26.3
+31050,Spain,2013,4,C09-Agents acting on the Renin-Angiotensin system,"Million US$, purchasing power parity",1367.8
+31051,Spain,2013,4,C09-Agents acting on the Renin-Angiotensin system,% of total sales,8.7
+31052,Spain,2013,4,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ purchasing power parity",29.3
+31053,Spain,2013,4,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million of national currency units,419.3
+31054,Spain,2013,4,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million US$ at exchange rate,556.9
+31055,Spain,2013,4,C09-Agents acting on the Renin-Angiotensin system,Million US$ at exchange rate,1225.8
+31056,Spain,2013,4,C09-Agents acting on the Renin-Angiotensin system,Million of national currency units,923.0
+31057,Spain,2013,4,N02-Analgesics,"/capita, US$ exchange rate",13.9
+31058,Spain,2013,4,N02-Analgesics,"/capita, US$ purchasing power parity",15.6
+31059,Spain,2013,4,N02-Analgesics,% of total sales,4.6
+31060,Spain,2013,4,N02-Analgesics,"Million US$, purchasing power parity",725.0
+31061,Spain,2013,4,C02-Antihypertensives,Million of national currency units,40.1
+31062,Spain,2013,4,C02-Antihypertensives,Million US$ at exchange rate,53.2
+31063,Spain,2013,4,N02-Analgesics,Million of national currency units,489.2
+31064,Spain,2013,4,N02-Analgesics,Million US$ at exchange rate,649.7
+31065,Spain,2013,4,R03-Drugs for obstructive airway diseases,Million of national currency units,945.0
+31066,Spain,2013,4,R03-Drugs for obstructive airway diseases,Million US$ at exchange rate,1255.1
+31067,Spain,2013,4,A-Alimentary tract and metabolism,"/capita, US$ purchasing power parity",53.6
+31068,Spain,2013,4,A-Alimentary tract and metabolism,% of total sales,15.8
+31069,Spain,2013,4,R03-Drugs for obstructive airway diseases,"/capita, US$ purchasing power parity",30.0
+31070,Spain,2013,4,R03-Drugs for obstructive airway diseases,% of total sales,8.9
+31071,Spain,2013,4,R03-Drugs for obstructive airway diseases,"Million US$, purchasing power parity",1400.5
+31072,Spain,2013,4,R03-Drugs for obstructive airway diseases,"/capita, US$ exchange rate",26.9
+31073,Spain,2013,4,A10-Drugs used in diabetes,Million of national currency units,1024.7
+31074,Spain,2013,4,A10-Drugs used in diabetes,Million US$ at exchange rate,1361.0
+31075,Spain,2013,4,"C01B-Antiarrhythmics, Class I and III",% of total sales,0.3
+31076,Spain,2013,4,A10-Drugs used in diabetes,"/capita, US$ purchasing power parity",32.6
+31077,Spain,2013,4,A10-Drugs used in diabetes,% of total sales,9.6
+31078,Spain,2013,4,A10-Drugs used in diabetes,"Million US$, purchasing power parity",1518.6
+31079,Spain,2013,4,A10-Drugs used in diabetes,"/capita, US$ exchange rate",29.2
+31080,Spain,2013,4,"C01B-Antiarrhythmics, Class I and III","Million US$, purchasing power parity",47.0
+31081,Spain,2013,4,"C01B-Antiarrhythmics, Class I and III","/capita, US$ exchange rate",0.9
+31082,Spain,2013,4,"C01B-Antiarrhythmics, Class I and III",Million US$ at exchange rate,42.1
+31083,Spain,2013,4,"C01B-Antiarrhythmics, Class I and III","/capita, US$ purchasing power parity",1.0
+31084,Spain,2010,4,J01-Antibacterials for systemic use,"/capita, US$ purchasing power parity",9.0
+31085,Spain,2010,4,J01-Antibacterials for systemic use,Million of national currency units,305.1
+31086,Spain,2010,4,J01-Antibacterials for systemic use,% of total sales,2.3
+31087,Spain,2010,4,J01-Antibacterials for systemic use,Million US$ at exchange rate,404.5
+31088,Spain,2010,4,J01-Antibacterials for systemic use,"Million US$, purchasing power parity",419.7
+31089,Spain,2010,4,J01-Antibacterials for systemic use,"/capita, US$ exchange rate",8.7
+31090,Spain,2010,4,C08-Calcium channel blockers,"/capita, US$ exchange rate",6.8
+31091,Spain,2010,4,C02-Antihypertensives,"Million US$, purchasing power parity",81.5
+31092,Spain,2010,4,C02-Antihypertensives,"/capita, US$ purchasing power parity",1.7
+31093,Spain,2010,4,C02-Antihypertensives,"/capita, US$ exchange rate",1.7
+31094,Spain,2010,4,C08-Calcium channel blockers,"/capita, US$ purchasing power parity",7.0
+31095,Spain,2010,4,C02-Antihypertensives,% of total sales,0.4
+31096,Spain,2010,4,C08-Calcium channel blockers,% of total sales,1.8
+31097,Spain,2010,4,J-Antiinfectives for systemic use,"/capita, US$ exchange rate",10.4
+31098,Spain,2010,4,J-Antiinfectives for systemic use,"/capita, US$ purchasing power parity",10.8
+31099,Spain,2010,4,J-Antiinfectives for systemic use,Million US$ at exchange rate,485.0
+31100,Spain,2010,4,J-Antiinfectives for systemic use,"Million US$, purchasing power parity",503.3
+31101,Spain,2010,4,C03-Diuretics,Million US$ at exchange rate,165.2
+31102,Spain,2010,4,C03-Diuretics,"Million US$, purchasing power parity",171.4
+31103,Spain,2010,4,J-Antiinfectives for systemic use,% of total sales,2.8
+31104,Spain,2010,4,C03-Diuretics,Million of national currency units,124.6
+31105,Spain,2010,4,C07-Beta blocking agents,% of total sales,0.7
+31106,Spain,2010,4,C07-Beta blocking agents,"/capita, US$ purchasing power parity",2.9
+31107,Spain,2010,4,N-Nervous system,Million of national currency units,3140.7
+31108,Spain,2010,4,N-Nervous system,Million US$ at exchange rate,4163.7
+31109,Spain,2010,4,C07-Beta blocking agents,Million US$ at exchange rate,131.3
+31110,Spain,2010,4,C07-Beta blocking agents,Million of national currency units,99.0
+31111,Spain,2010,4,J-Antiinfectives for systemic use,Million of national currency units,365.9
+31112,Spain,2010,4,C07-Beta blocking agents,"/capita, US$ exchange rate",2.8
+31113,Spain,2010,4,C07-Beta blocking agents,"Million US$, purchasing power parity",136.2
+31114,Spain,2010,4,N-Nervous system,"/capita, US$ purchasing power parity",92.8
+31115,Spain,2010,4,C08-Calcium channel blockers,"Million US$, purchasing power parity",327.9
+31116,Spain,2010,4,N-Nervous system,% of total sales,23.7
+31117,Spain,2010,4,N-Nervous system,"/capita, US$ exchange rate",89.4
+31118,Spain,2010,4,C-Cardiovascular system,Million US$ at exchange rate,4080.1
+31119,Spain,2010,4,C-Cardiovascular system,"Million US$, purchasing power parity",4233.6
+31120,Spain,2010,4,N-Nervous system,"Million US$, purchasing power parity",4320.3
+31121,Spain,2010,4,C-Cardiovascular system,Million of national currency units,3077.7
+31122,Spain,2010,4,C03-Diuretics,% of total sales,0.9
+31123,Spain,2010,4,C03-Diuretics,"/capita, US$ exchange rate",3.5
+31124,Spain,2010,4,C03-Diuretics,"/capita, US$ purchasing power parity",3.7
+31125,Spain,2010,4,C-Cardiovascular system,% of total sales,23.2
+31126,Spain,2010,4,C08-Calcium channel blockers,Million of national currency units,238.3
+31127,Spain,2010,4,C08-Calcium channel blockers,Million US$ at exchange rate,316.0
+31128,Spain,2010,4,C-Cardiovascular system,"/capita, US$ exchange rate",87.6
+31129,Spain,2010,4,C-Cardiovascular system,"/capita, US$ purchasing power parity",90.9
+31130,Spain,2010,4,C10-Lipid modifying agents,"Million US$, purchasing power parity",1408.7
+31131,Spain,2010,4,C10-Lipid modifying agents,Million US$ at exchange rate,1357.6
+31132,Spain,2010,4,C10-Lipid modifying agents,"/capita, US$ purchasing power parity",30.2
+31133,Spain,2010,4,C10-Lipid modifying agents,"/capita, US$ exchange rate",29.1
+31134,Spain,2010,4,C10-Lipid modifying agents,Million of national currency units,1024.0
+31135,Spain,2010,4,M-Musculo-skeletal system,"/capita, US$ exchange rate",24.1
+31136,Spain,2010,4,M-Musculo-skeletal system,"Million US$, purchasing power parity",1163.2
+31137,Spain,2010,4,M-Musculo-skeletal system,% of total sales,6.4
+31138,Spain,2010,4,M-Musculo-skeletal system,"/capita, US$ purchasing power parity",25.0
+31139,Spain,2010,4,Total pharmaceutical sales,Million of national currency units,13238.8
+31140,Spain,2010,4,Total pharmaceutical sales,Million US$ at exchange rate,17550.9
+31141,Spain,2010,4,B-Blood and blood forming organs,% of total sales,4.6
+31142,Spain,2010,4,M01A-Antiinflammatory and antirheumatic products non-steroids,% of total sales,3.0
+31143,Spain,2010,4,Total pharmaceutical sales,"/capita, US$ purchasing power parity",391.0
+31144,Spain,2010,4,C10-Lipid modifying agents,% of total sales,7.7
+31145,Spain,2010,4,Total pharmaceutical sales,"Million US$, purchasing power parity",18211.2
+31146,Spain,2010,4,Total pharmaceutical sales,"/capita, US$ exchange rate",376.8
+31147,Spain,2010,4,M-Musculo-skeletal system,Million of national currency units,845.6
+31148,Spain,2010,4,R-Respiratory system,Million of national currency units,1304.6
+31149,Spain,2010,4,R-Respiratory system,Million US$ at exchange rate,1729.5
+31150,Spain,2010,4,M-Musculo-skeletal system,Million US$ at exchange rate,1121.0
+31151,Spain,2010,4,"H-Systemic hormonal preparations, excluding sex hormones and insulins",% of total sales,1.9
+31152,Spain,2010,4,R-Respiratory system,"/capita, US$ purchasing power parity",38.5
+31153,Spain,2010,4,R-Respiratory system,% of total sales,9.9
+31154,Spain,2010,4,R-Respiratory system,"Million US$, purchasing power parity",1794.5
+31155,Spain,2010,4,R-Respiratory system,"/capita, US$ exchange rate",37.1
+31156,Spain,2010,4,N05B-Anxiolytics,"Million US$, purchasing power parity",167.9
+31157,Spain,2010,4,N05B-Anxiolytics,"/capita, US$ exchange rate",3.5
+31158,Spain,2010,4,N05B-Anxiolytics,% of total sales,0.9
+31159,Spain,2010,4,N05B-Anxiolytics,"/capita, US$ purchasing power parity",3.6
+31160,Spain,2010,4,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ exchange rate",7.3
+31161,Spain,2010,4,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ purchasing power parity",7.6
+31162,Spain,2010,4,"H-Systemic hormonal preparations, excluding sex hormones and insulins","Million US$, purchasing power parity",353.3
+31163,Spain,2010,4,N05B-Anxiolytics,Million of national currency units,122.0
+31164,Spain,2010,4,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million of national currency units,256.8
+31165,Spain,2010,4,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million US$ at exchange rate,340.5
+31166,Spain,2010,4,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ purchasing power parity",11.9
+31167,Spain,2010,4,C01A-Cardiac glycosides,"Million US$, purchasing power parity",5.4
+31168,Spain,2010,4,C01A-Cardiac glycosides,"/capita, US$ exchange rate",0.1
+31169,Spain,2010,4,B-Blood and blood forming organs,"/capita, US$ purchasing power parity",18.1
+31170,Spain,2010,4,C01A-Cardiac glycosides,Million of national currency units,4.0
+31171,Spain,2010,4,C01A-Cardiac glycosides,Million US$ at exchange rate,5.2
+31172,Spain,2010,4,G-Genito urinary system and sex hormones,% of total sales,3.9
+31173,Spain,2010,4,G-Genito urinary system and sex hormones,"/capita, US$ purchasing power parity",15.1
+31174,Spain,2010,4,C01A-Cardiac glycosides,"/capita, US$ purchasing power parity",0.1
+31175,Spain,2010,4,C01A-Cardiac glycosides,% of total sales,0.0
+31176,Spain,2010,4,N05C-Hypnotics and sedatives,"/capita, US$ exchange rate",1.2
+31177,Spain,2010,4,N05C-Hypnotics and sedatives,"Million US$, purchasing power parity",57.9
+31178,Spain,2010,4,N05C-Hypnotics and sedatives,% of total sales,0.3
+31179,Spain,2010,4,N05C-Hypnotics and sedatives,"/capita, US$ purchasing power parity",1.2
+31180,Spain,2010,4,B-Blood and blood forming organs,"Million US$, purchasing power parity",842.7
+31181,Spain,2010,4,B-Blood and blood forming organs,"/capita, US$ exchange rate",17.4
+31182,Spain,2010,4,B-Blood and blood forming organs,Million US$ at exchange rate,812.1
+31183,Spain,2010,4,N05C-Hypnotics and sedatives,Million US$ at exchange rate,55.8
+31184,Spain,2010,4,B-Blood and blood forming organs,Million of national currency units,612.6
+31185,Spain,2010,4,N05C-Hypnotics and sedatives,Million of national currency units,42.1
+31186,Spain,2010,4,N06A-Antidepressants,"/capita, US$ exchange rate",19.6
+31187,Spain,2010,4,N06A-Antidepressants,"/capita, US$ purchasing power parity",20.3
+31188,Spain,2010,4,N06A-Antidepressants,Million US$ at exchange rate,911.0
+31189,Spain,2010,4,N06A-Antidepressants,% of total sales,5.2
+31190,Spain,2010,4,N06A-Antidepressants,"Million US$, purchasing power parity",945.2
+31191,Spain,2010,4,M01A-Antiinflammatory and antirheumatic products non-steroids,"Million US$, purchasing power parity",554.4
+31192,Spain,2010,4,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ exchange rate",11.5
+31193,Spain,2010,4,M01A-Antiinflammatory and antirheumatic products non-steroids,Million of national currency units,403.0
+31194,Spain,2010,4,M01A-Antiinflammatory and antirheumatic products non-steroids,Million US$ at exchange rate,534.3
+31195,Spain,2010,4,"C01B-Antiarrhythmics, Class I and III",Million of national currency units,22.8
+31196,Spain,2010,4,G-Genito urinary system and sex hormones,Million of national currency units,512.2
+31197,Spain,2010,4,G03-Sex hormones and modulators of the genital system,Million of national currency units,124.8
+31198,Spain,2010,4,G03-Sex hormones and modulators of the genital system,Million US$ at exchange rate,165.5
+31199,Spain,2010,4,G-Genito urinary system and sex hormones,Million US$ at exchange rate,679.0
+31200,Spain,2010,4,G-Genito urinary system and sex hormones,"/capita, US$ exchange rate",14.6
+31201,Spain,2010,4,G-Genito urinary system and sex hormones,"Million US$, purchasing power parity",704.5
+31202,Spain,2010,4,G03-Sex hormones and modulators of the genital system,% of total sales,0.9
+31203,Spain,2010,4,N06A-Antidepressants,Million of national currency units,687.2
+31204,Spain,2010,4,G03-Sex hormones and modulators of the genital system,"/capita, US$ purchasing power parity",3.7
+31205,Spain,2010,4,G03-Sex hormones and modulators of the genital system,"Million US$, purchasing power parity",171.7
+31206,Spain,2010,4,G03-Sex hormones and modulators of the genital system,"/capita, US$ exchange rate",3.6
+31207,Spain,2010,4,N05B-Anxiolytics,Million US$ at exchange rate,161.8
+31208,Spain,2010,4,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),% of total sales,5.0
+31209,Spain,2010,4,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ purchasing power parity",19.4
+31210,Spain,2010,4,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ exchange rate",18.7
+31211,Spain,2010,4,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"Million US$, purchasing power parity",901.5
+31212,Spain,2010,4,A-Alimentary tract and metabolism,"Million US$, purchasing power parity",2446.7
+31213,Spain,2010,4,A-Alimentary tract and metabolism,"/capita, US$ exchange rate",50.6
+31214,Spain,2010,4,A-Alimentary tract and metabolism,Million of national currency units,1778.6
+31215,Spain,2010,4,A-Alimentary tract and metabolism,Million US$ at exchange rate,2358.0
+31216,Spain,2010,4,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ exchange rate",35.5
+31217,Spain,2010,4,C09-Agents acting on the Renin-Angiotensin system,% of total sales,9.4
+31218,Spain,2010,4,C09-Agents acting on the Renin-Angiotensin system,"Million US$, purchasing power parity",1714.3
+31219,Spain,2010,4,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million of national currency units,655.4
+31220,Spain,2010,4,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million US$ at exchange rate,868.9
+31221,Spain,2010,4,C09-Agents acting on the Renin-Angiotensin system,Million of national currency units,1246.3
+31222,Spain,2010,4,C09-Agents acting on the Renin-Angiotensin system,Million US$ at exchange rate,1652.2
+31223,Spain,2010,4,N02-Analgesics,"/capita, US$ purchasing power parity",14.3
+31224,Spain,2010,4,N02-Analgesics,"/capita, US$ exchange rate",13.8
+31225,Spain,2010,4,N02-Analgesics,% of total sales,3.7
+31226,Spain,2010,4,N02-Analgesics,Million of national currency units,485.0
+31227,Spain,2010,4,C02-Antihypertensives,Million of national currency units,59.2
+31228,Spain,2010,4,C02-Antihypertensives,Million US$ at exchange rate,78.5
+31229,Spain,2010,4,N02-Analgesics,"Million US$, purchasing power parity",667.2
+31230,Spain,2010,4,N02-Analgesics,Million US$ at exchange rate,643.0
+31231,Spain,2010,4,R03-Drugs for obstructive airway diseases,Million of national currency units,1043.8
+31232,Spain,2010,4,R03-Drugs for obstructive airway diseases,Million US$ at exchange rate,1383.8
+31233,Spain,2010,4,A-Alimentary tract and metabolism,"/capita, US$ purchasing power parity",52.5
+31234,Spain,2010,4,A-Alimentary tract and metabolism,% of total sales,13.4
+31235,Spain,2010,4,R03-Drugs for obstructive airway diseases,"/capita, US$ purchasing power parity",30.8
+31236,Spain,2010,4,R03-Drugs for obstructive airway diseases,% of total sales,7.9
+31237,Spain,2010,4,R03-Drugs for obstructive airway diseases,"Million US$, purchasing power parity",1435.9
+31238,Spain,2010,4,R03-Drugs for obstructive airway diseases,"/capita, US$ exchange rate",29.7
+31239,Spain,2010,4,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ purchasing power parity",36.8
+31240,Spain,2010,4,A02A-Antacids,Million US$ at exchange rate,25.6
+31241,Spain,2010,4,A02A-Antacids,Million of national currency units,19.3
+31242,Spain,2010,4,A10-Drugs used in diabetes,Million of national currency units,802.4
+31243,Spain,2010,4,A10-Drugs used in diabetes,Million US$ at exchange rate,1063.8
+31244,Spain,2010,4,A02A-Antacids,"Million US$, purchasing power parity",26.6
+31245,Spain,2010,4,A02A-Antacids,"/capita, US$ exchange rate",0.6
+31246,Spain,2010,4,"C01B-Antiarrhythmics, Class I and III",% of total sales,0.2
+31247,Spain,2010,4,A02A-Antacids,% of total sales,0.1
+31248,Spain,2010,4,A02A-Antacids,"/capita, US$ purchasing power parity",0.6
+31249,Spain,2010,4,A10-Drugs used in diabetes,"/capita, US$ purchasing power parity",23.7
+31250,Spain,2010,4,A10-Drugs used in diabetes,% of total sales,6.1
+31251,Spain,2010,4,A10-Drugs used in diabetes,"Million US$, purchasing power parity",1103.8
+31252,Spain,2010,4,A10-Drugs used in diabetes,"/capita, US$ exchange rate",22.8
+31253,Spain,2010,4,"C01B-Antiarrhythmics, Class I and III","Million US$, purchasing power parity",31.4
+31254,Spain,2010,4,"C01B-Antiarrhythmics, Class I and III","/capita, US$ exchange rate",0.6
+31255,Spain,2010,4,"C01B-Antiarrhythmics, Class I and III","/capita, US$ purchasing power parity",0.7
+31256,Spain,2010,4,"C01B-Antiarrhythmics, Class I and III",Million US$ at exchange rate,30.2
+31257,Spain,2015,4,J01-Antibacterials for systemic use,"/capita, US$ purchasing power parity",8.1
+31258,Spain,2015,4,J01-Antibacterials for systemic use,% of total sales,2.2
+31259,Spain,2015,4,J01-Antibacterials for systemic use,"/capita, US$ exchange rate",6.0
+31260,Spain,2015,4,J01-Antibacterials for systemic use,Million US$ at exchange rate,277.1
+31261,Spain,2015,4,J01-Antibacterials for systemic use,"Million US$, purchasing power parity",375.7
+31262,Spain,2015,4,J01-Antibacterials for systemic use,Million of national currency units,249.7
+31263,Spain,2015,4,C02-Antihypertensives,"Million US$, purchasing power parity",61.6
+31264,Spain,2015,4,C02-Antihypertensives,"/capita, US$ purchasing power parity",1.3
+31265,Spain,2015,4,C-Cardiovascular system,"Million US$, purchasing power parity",3237.1
+31266,Spain,2015,4,C02-Antihypertensives,"/capita, US$ exchange rate",1.0
+31267,Spain,2015,4,C08-Calcium channel blockers,"/capita, US$ purchasing power parity",3.5
+31268,Spain,2015,4,C08-Calcium channel blockers,"/capita, US$ exchange rate",2.6
+31269,Spain,2015,4,C02-Antihypertensives,% of total sales,0.4
+31270,Spain,2015,4,C08-Calcium channel blockers,% of total sales,0.9
+31271,Spain,2015,4,J-Antiinfectives for systemic use,"/capita, US$ exchange rate",7.2
+31272,Spain,2015,4,J-Antiinfectives for systemic use,"/capita, US$ purchasing power parity",9.8
+31273,Spain,2015,4,J-Antiinfectives for systemic use,Million US$ at exchange rate,335.6
+31274,Spain,2015,4,J-Antiinfectives for systemic use,"Million US$, purchasing power parity",455.0
+31275,Spain,2015,4,C03-Diuretics,Million US$ at exchange rate,102.8
+31276,Spain,2015,4,C03-Diuretics,"Million US$, purchasing power parity",139.4
+31277,Spain,2015,4,J-Antiinfectives for systemic use,% of total sales,2.7
+31278,Spain,2015,4,C03-Diuretics,Million of national currency units,92.6
+31279,Spain,2015,4,C07-Beta blocking agents,"/capita, US$ purchasing power parity",2.7
+31280,Spain,2015,4,C07-Beta blocking agents,"/capita, US$ exchange rate",2.0
+31281,Spain,2015,4,C07-Beta blocking agents,% of total sales,0.7
+31282,Spain,2015,4,N-Nervous system,Million of national currency units,2946.2
+31283,Spain,2015,4,C07-Beta blocking agents,Million of national currency units,82.9
+31284,Spain,2015,4,J-Antiinfectives for systemic use,Million of national currency units,302.5
+31285,Spain,2015,4,C07-Beta blocking agents,"Million US$, purchasing power parity",124.6
+31286,Spain,2015,4,C07-Beta blocking agents,Million US$ at exchange rate,91.9
+31287,Spain,2015,4,N-Nervous system,"/capita, US$ purchasing power parity",95.4
+31288,Spain,2015,4,N-Nervous system,"/capita, US$ exchange rate",70.4
+31289,Spain,2015,4,C08-Calcium channel blockers,"Million US$, purchasing power parity",162.8
+31290,Spain,2015,4,N-Nervous system,% of total sales,25.8
+31291,Spain,2015,4,C-Cardiovascular system,Million of national currency units,2151.8
+31292,Spain,2015,4,C-Cardiovascular system,Million US$ at exchange rate,2387.5
+31293,Spain,2015,4,N-Nervous system,"Million US$, purchasing power parity",4432.1
+31294,Spain,2015,4,N-Nervous system,Million US$ at exchange rate,3268.8
+31295,Spain,2015,4,C08-Calcium channel blockers,Million US$ at exchange rate,120.1
+31296,Spain,2015,4,C03-Diuretics,% of total sales,0.8
+31297,Spain,2015,4,C-Cardiovascular system,% of total sales,18.9
+31298,Spain,2015,4,C03-Diuretics,"/capita, US$ exchange rate",2.2
+31299,Spain,2015,4,C03-Diuretics,"/capita, US$ purchasing power parity",3.0
+31300,Spain,2015,4,C08-Calcium channel blockers,Million of national currency units,108.2
+31301,Spain,2015,4,C-Cardiovascular system,"/capita, US$ purchasing power parity",69.7
+31302,Spain,2015,4,C-Cardiovascular system,"/capita, US$ exchange rate",51.4
+31303,Spain,2015,4,C02-Antihypertensives,Million US$ at exchange rate,45.4
+31304,Spain,2015,4,C10-Lipid modifying agents,Million US$ at exchange rate,849.1
+31305,Spain,2015,4,C10-Lipid modifying agents,Million of national currency units,765.3
+31306,Spain,2015,4,C10-Lipid modifying agents,"/capita, US$ purchasing power parity",24.8
+31307,Spain,2015,4,C10-Lipid modifying agents,"/capita, US$ exchange rate",18.3
+31308,Spain,2015,4,C10-Lipid modifying agents,"Million US$, purchasing power parity",1151.3
+31309,Spain,2015,4,M-Musculo-skeletal system,"Million US$, purchasing power parity",694.3
+31310,Spain,2015,4,M-Musculo-skeletal system,"/capita, US$ exchange rate",11.0
+31311,Spain,2015,4,M-Musculo-skeletal system,% of total sales,4.0
+31312,Spain,2015,4,M-Musculo-skeletal system,"/capita, US$ purchasing power parity",14.9
+31313,Spain,2015,4,B-Blood and blood forming organs,% of total sales,5.7
+31314,Spain,2015,4,Total pharmaceutical sales,Million of national currency units,11403.6
+31315,Spain,2015,4,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ purchasing power parity",8.8
+31316,Spain,2015,4,M01A-Antiinflammatory and antirheumatic products non-steroids,% of total sales,2.4
+31317,Spain,2015,4,Total pharmaceutical sales,"/capita, US$ purchasing power parity",369.4
+31318,Spain,2015,4,C10-Lipid modifying agents,% of total sales,6.7
+31319,Spain,2015,4,Total pharmaceutical sales,"Million US$, purchasing power parity",17155.0
+31320,Spain,2015,4,Total pharmaceutical sales,Million US$ at exchange rate,12652.5
+31321,Spain,2015,4,Total pharmaceutical sales,"/capita, US$ exchange rate",272.4
+31322,Spain,2015,4,N05B-Anxiolytics,% of total sales,0.9
+31323,Spain,2015,4,M-Musculo-skeletal system,Million of national currency units,461.5
+31324,Spain,2015,4,R-Respiratory system,Million of national currency units,1182.8
+31325,Spain,2015,4,"H-Systemic hormonal preparations, excluding sex hormones and insulins",% of total sales,2.0
+31326,Spain,2015,4,M-Musculo-skeletal system,Million US$ at exchange rate,512.1
+31327,Spain,2015,4,R-Respiratory system,Million US$ at exchange rate,1312.3
+31328,Spain,2015,4,R-Respiratory system,"/capita, US$ purchasing power parity",38.3
+31329,Spain,2015,4,R-Respiratory system,% of total sales,10.4
+31330,Spain,2015,4,R-Respiratory system,"Million US$, purchasing power parity",1779.3
+31331,Spain,2015,4,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ purchasing power parity",7.4
+31332,Spain,2015,4,R-Respiratory system,"/capita, US$ exchange rate",28.3
+31333,Spain,2015,4,N05B-Anxiolytics,"Million US$, purchasing power parity",151.4
+31334,Spain,2015,4,N05B-Anxiolytics,Million US$ at exchange rate,111.7
+31335,Spain,2015,4,N05B-Anxiolytics,"/capita, US$ purchasing power parity",3.3
+31336,Spain,2015,4,N05B-Anxiolytics,"/capita, US$ exchange rate",2.4
+31337,Spain,2015,4,N05B-Anxiolytics,Million of national currency units,100.7
+31338,Spain,2015,4,"H-Systemic hormonal preparations, excluding sex hormones and insulins","Million US$, purchasing power parity",343.8
+31339,Spain,2015,4,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ exchange rate",5.5
+31340,Spain,2015,4,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million of national currency units,228.5
+31341,Spain,2015,4,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million US$ at exchange rate,253.5
+31342,Spain,2015,4,C01A-Cardiac glycosides,"Million US$, purchasing power parity",4.5
+31343,Spain,2015,4,C01A-Cardiac glycosides,"/capita, US$ exchange rate",0.1
+31344,Spain,2015,4,C01A-Cardiac glycosides,Million US$ at exchange rate,3.3
+31345,Spain,2015,4,B-Blood and blood forming organs,"/capita, US$ purchasing power parity",21.1
+31346,Spain,2015,4,C01A-Cardiac glycosides,Million of national currency units,3.0
+31347,Spain,2015,4,G-Genito urinary system and sex hormones,% of total sales,4.7
+31348,Spain,2015,4,G-Genito urinary system and sex hormones,"/capita, US$ purchasing power parity",17.3
+31349,Spain,2015,4,C01A-Cardiac glycosides,"/capita, US$ purchasing power parity",0.1
+31350,Spain,2015,4,C01A-Cardiac glycosides,% of total sales,0.0
+31351,Spain,2015,4,B-Blood and blood forming organs,"/capita, US$ exchange rate",15.6
+31352,Spain,2015,4,N05C-Hypnotics and sedatives,"/capita, US$ exchange rate",1.1
+31353,Spain,2015,4,N05C-Hypnotics and sedatives,"Million US$, purchasing power parity",68.6
+31354,Spain,2015,4,N05C-Hypnotics and sedatives,% of total sales,0.4
+31355,Spain,2015,4,N05C-Hypnotics and sedatives,Million US$ at exchange rate,50.6
+31356,Spain,2015,4,N05C-Hypnotics and sedatives,"/capita, US$ purchasing power parity",1.5
+31357,Spain,2015,4,B-Blood and blood forming organs,Million US$ at exchange rate,724.3
+31358,Spain,2015,4,B-Blood and blood forming organs,"Million US$, purchasing power parity",982.0
+31359,Spain,2015,4,N05C-Hypnotics and sedatives,Million of national currency units,45.6
+31360,Spain,2015,4,B-Blood and blood forming organs,Million of national currency units,652.8
+31361,Spain,2015,4,G-Genito urinary system and sex hormones,"/capita, US$ exchange rate",12.8
+31362,Spain,2015,4,N06A-Antidepressants,"/capita, US$ exchange rate",11.6
+31363,Spain,2015,4,N06A-Antidepressants,"/capita, US$ purchasing power parity",15.7
+31364,Spain,2015,4,N06A-Antidepressants,Million US$ at exchange rate,537.7
+31365,Spain,2015,4,N06A-Antidepressants,"Million US$, purchasing power parity",729.0
+31366,Spain,2015,4,N06A-Antidepressants,Million of national currency units,484.6
+31367,Spain,2015,4,M01A-Antiinflammatory and antirheumatic products non-steroids,"Million US$, purchasing power parity",409.4
+31368,Spain,2015,4,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ exchange rate",6.5
+31369,Spain,2015,4,N06A-Antidepressants,% of total sales,4.2
+31370,Spain,2015,4,M01A-Antiinflammatory and antirheumatic products non-steroids,Million US$ at exchange rate,302.0
+31371,Spain,2015,4,M01A-Antiinflammatory and antirheumatic products non-steroids,Million of national currency units,272.2
+31372,Spain,2015,4,G-Genito urinary system and sex hormones,Million of national currency units,534.8
+31373,Spain,2015,4,G03-Sex hormones and modulators of the genital system,Million of national currency units,96.6
+31374,Spain,2015,4,G-Genito urinary system and sex hormones,"Million US$, purchasing power parity",804.6
+31375,Spain,2015,4,G-Genito urinary system and sex hormones,Million US$ at exchange rate,593.4
+31376,Spain,2015,4,G03-Sex hormones and modulators of the genital system,Million US$ at exchange rate,107.1
+31377,Spain,2015,4,G03-Sex hormones and modulators of the genital system,"/capita, US$ purchasing power parity",3.1
+31378,Spain,2015,4,G03-Sex hormones and modulators of the genital system,% of total sales,0.8
+31379,Spain,2015,4,G03-Sex hormones and modulators of the genital system,"Million US$, purchasing power parity",145.3
+31380,Spain,2015,4,G03-Sex hormones and modulators of the genital system,"/capita, US$ exchange rate",2.3
+31381,Spain,2015,4,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ purchasing power parity",13.4
+31382,Spain,2015,4,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),% of total sales,3.6
+31383,Spain,2015,4,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"Million US$, purchasing power parity",623.5
+31384,Spain,2015,4,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ exchange rate",9.9
+31385,Spain,2015,4,A-Alimentary tract and metabolism,"Million US$, purchasing power parity",2945.5
+31386,Spain,2015,4,A-Alimentary tract and metabolism,"/capita, US$ exchange rate",46.8
+31387,Spain,2015,4,A-Alimentary tract and metabolism,Million of national currency units,1958.0
+31388,Spain,2015,4,A-Alimentary tract and metabolism,Million US$ at exchange rate,2172.4
+31389,Spain,2015,4,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ exchange rate",20.8
+31390,Spain,2015,4,C09-Agents acting on the Renin-Angiotensin system,"Million US$, purchasing power parity",1308.9
+31391,Spain,2015,4,C09-Agents acting on the Renin-Angiotensin system,% of total sales,7.6
+31392,Spain,2015,4,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ purchasing power parity",28.2
+31393,Spain,2015,4,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million of national currency units,414.5
+31394,Spain,2015,4,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million US$ at exchange rate,459.8
+31395,Spain,2015,4,C09-Agents acting on the Renin-Angiotensin system,Million US$ at exchange rate,965.3
+31396,Spain,2015,4,C09-Agents acting on the Renin-Angiotensin system,Million of national currency units,870.1
+31397,Spain,2015,4,N02-Analgesics,"/capita, US$ exchange rate",14.8
+31398,Spain,2015,4,N02-Analgesics,"/capita, US$ purchasing power parity",20.1
+31399,Spain,2015,4,N02-Analgesics,% of total sales,5.4
+31400,Spain,2015,4,N02-Analgesics,"Million US$, purchasing power parity",932.7
+31401,Spain,2015,4,C02-Antihypertensives,Million of national currency units,40.9
+31402,Spain,2015,4,N02-Analgesics,Million of national currency units,620.0
+31403,Spain,2015,4,N02-Analgesics,Million US$ at exchange rate,687.9
+31404,Spain,2015,4,R03-Drugs for obstructive airway diseases,Million of national currency units,1007.5
+31405,Spain,2015,4,R03-Drugs for obstructive airway diseases,Million US$ at exchange rate,1117.9
+31406,Spain,2015,4,A-Alimentary tract and metabolism,"/capita, US$ purchasing power parity",63.4
+31407,Spain,2015,4,A-Alimentary tract and metabolism,% of total sales,17.2
+31408,Spain,2015,4,R03-Drugs for obstructive airway diseases,"/capita, US$ purchasing power parity",32.6
+31409,Spain,2015,4,R03-Drugs for obstructive airway diseases,% of total sales,8.8
+31410,Spain,2015,4,R03-Drugs for obstructive airway diseases,"Million US$, purchasing power parity",1515.7
+31411,Spain,2015,4,R03-Drugs for obstructive airway diseases,"/capita, US$ exchange rate",24.1
+31412,Spain,2015,4,A10-Drugs used in diabetes,Million of national currency units,1269.7
+31413,Spain,2015,4,A10-Drugs used in diabetes,Million US$ at exchange rate,1408.7
+31414,Spain,2015,4,"C01B-Antiarrhythmics, Class I and III",% of total sales,0.3
+31415,Spain,2015,4,A10-Drugs used in diabetes,% of total sales,11.1
+31416,Spain,2015,4,A10-Drugs used in diabetes,"/capita, US$ purchasing power parity",41.1
+31417,Spain,2015,4,A10-Drugs used in diabetes,"Million US$, purchasing power parity",1910.0
+31418,Spain,2015,4,A10-Drugs used in diabetes,"/capita, US$ exchange rate",30.3
+31419,Spain,2015,4,"C01B-Antiarrhythmics, Class I and III",Million US$ at exchange rate,40.7
+31420,Spain,2015,4,"C01B-Antiarrhythmics, Class I and III","Million US$, purchasing power parity",55.2
+31421,Spain,2015,4,"C01B-Antiarrhythmics, Class I and III",Million of national currency units,36.7
+31422,Spain,2015,4,"C01B-Antiarrhythmics, Class I and III","/capita, US$ exchange rate",0.9
+31423,Spain,2015,4,"C01B-Antiarrhythmics, Class I and III","/capita, US$ purchasing power parity",1.2
+31424,Spain,2016,4,J01-Antibacterials for systemic use,"/capita, US$ purchasing power parity",8.1
+31425,Spain,2016,4,J01-Antibacterials for systemic use,% of total sales,2.1
+31426,Spain,2016,4,J01-Antibacterials for systemic use,Million US$ at exchange rate,268.9
+31427,Spain,2016,4,J01-Antibacterials for systemic use,"Million US$, purchasing power parity",378.1
+31428,Spain,2016,4,J01-Antibacterials for systemic use,Million of national currency units,243.0
+31429,Spain,2016,4,J01-Antibacterials for systemic use,"/capita, US$ exchange rate",5.8
+31430,Spain,2016,4,C02-Antihypertensives,"Million US$, purchasing power parity",64.0
+31431,Spain,2016,4,C02-Antihypertensives,"/capita, US$ purchasing power parity",1.4
+31432,Spain,2016,4,C-Cardiovascular system,"Million US$, purchasing power parity",3478.8
+31433,Spain,2016,4,C02-Antihypertensives,"/capita, US$ exchange rate",1.0
+31434,Spain,2016,4,C08-Calcium channel blockers,"/capita, US$ purchasing power parity",3.6
+31435,Spain,2016,4,C08-Calcium channel blockers,"/capita, US$ exchange rate",2.6
+31436,Spain,2016,4,C02-Antihypertensives,% of total sales,0.3
+31437,Spain,2016,4,C08-Calcium channel blockers,% of total sales,0.9
+31438,Spain,2016,4,J-Antiinfectives for systemic use,"/capita, US$ exchange rate",7.1
+31439,Spain,2016,4,J-Antiinfectives for systemic use,"/capita, US$ purchasing power parity",10.0
+31440,Spain,2016,4,J-Antiinfectives for systemic use,Million US$ at exchange rate,329.7
+31441,Spain,2016,4,J-Antiinfectives for systemic use,"Million US$, purchasing power parity",463.5
+31442,Spain,2016,4,C03-Diuretics,Million US$ at exchange rate,104.6
+31443,Spain,2016,4,C03-Diuretics,"Million US$, purchasing power parity",147.1
+31444,Spain,2016,4,J-Antiinfectives for systemic use,% of total sales,2.5
+31445,Spain,2016,4,C03-Diuretics,Million of national currency units,94.5
+31446,Spain,2016,4,C07-Beta blocking agents,"/capita, US$ purchasing power parity",2.9
+31447,Spain,2016,4,C07-Beta blocking agents,"/capita, US$ exchange rate",2.0
+31448,Spain,2016,4,N-Nervous system,Million of national currency units,3022.3
+31449,Spain,2016,4,C07-Beta blocking agents,% of total sales,0.7
+31450,Spain,2016,4,C07-Beta blocking agents,Million of national currency units,85.9
+31451,Spain,2016,4,J-Antiinfectives for systemic use,Million of national currency units,297.9
+31452,Spain,2016,4,C07-Beta blocking agents,"Million US$, purchasing power parity",133.7
+31453,Spain,2016,4,C07-Beta blocking agents,Million US$ at exchange rate,95.1
+31454,Spain,2016,4,N-Nervous system,"/capita, US$ purchasing power parity",101.2
+31455,Spain,2016,4,N-Nervous system,"/capita, US$ exchange rate",72.0
+31456,Spain,2016,4,C08-Calcium channel blockers,"Million US$, purchasing power parity",168.9
+31457,Spain,2016,4,N-Nervous system,% of total sales,25.5
+31458,Spain,2016,4,C-Cardiovascular system,Million of national currency units,2235.6
+31459,Spain,2016,4,C-Cardiovascular system,Million US$ at exchange rate,2474.6
+31460,Spain,2016,4,N-Nervous system,"Million US$, purchasing power parity",4702.9
+31461,Spain,2016,4,N-Nervous system,Million US$ at exchange rate,3345.4
+31462,Spain,2016,4,C03-Diuretics,% of total sales,0.8
+31463,Spain,2016,4,C-Cardiovascular system,% of total sales,18.9
+31464,Spain,2016,4,C03-Diuretics,"/capita, US$ exchange rate",2.3
+31465,Spain,2016,4,C03-Diuretics,"/capita, US$ purchasing power parity",3.2
+31466,Spain,2016,4,C08-Calcium channel blockers,Million of national currency units,108.6
+31467,Spain,2016,4,C-Cardiovascular system,"/capita, US$ purchasing power parity",74.8
+31468,Spain,2016,4,C-Cardiovascular system,"/capita, US$ exchange rate",53.2
+31469,Spain,2016,4,C08-Calcium channel blockers,Million US$ at exchange rate,120.2
+31470,Spain,2016,4,C10-Lipid modifying agents,Million US$ at exchange rate,915.8
+31471,Spain,2016,4,C10-Lipid modifying agents,Million of national currency units,827.3
+31472,Spain,2016,4,C10-Lipid modifying agents,"Million US$, purchasing power parity",1287.4
+31473,Spain,2016,4,C10-Lipid modifying agents,"/capita, US$ purchasing power parity",27.7
+31474,Spain,2016,4,C10-Lipid modifying agents,"/capita, US$ exchange rate",19.7
+31475,Spain,2016,4,M-Musculo-skeletal system,"Million US$, purchasing power parity",724.2
+31476,Spain,2016,4,M-Musculo-skeletal system,"/capita, US$ exchange rate",11.1
+31477,Spain,2016,4,M-Musculo-skeletal system,% of total sales,3.9
+31478,Spain,2016,4,M-Musculo-skeletal system,"/capita, US$ purchasing power parity",15.6
+31479,Spain,2016,4,B-Blood and blood forming organs,% of total sales,6.2
+31480,Spain,2016,4,Total pharmaceutical sales,Million of national currency units,11833.0
+31481,Spain,2016,4,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ purchasing power parity",9.0
+31482,Spain,2016,4,M01A-Antiinflammatory and antirheumatic products non-steroids,% of total sales,2.3
+31483,Spain,2016,4,N05B-Anxiolytics,% of total sales,0.9
+31484,Spain,2016,4,Total pharmaceutical sales,Million US$ at exchange rate,13098.0
+31485,Spain,2016,4,Total pharmaceutical sales,"/capita, US$ purchasing power parity",396.1
+31486,Spain,2016,4,C10-Lipid modifying agents,% of total sales,7.0
+31487,Spain,2016,4,Total pharmaceutical sales,"Million US$, purchasing power parity",18412.9
+31488,Spain,2016,4,Total pharmaceutical sales,"/capita, US$ exchange rate",281.8
+31489,Spain,2016,4,M-Musculo-skeletal system,Million of national currency units,465.4
+31490,Spain,2016,4,R-Respiratory system,Million of national currency units,1161.6
+31491,Spain,2016,4,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ purchasing power parity",7.9
+31492,Spain,2016,4,"H-Systemic hormonal preparations, excluding sex hormones and insulins",% of total sales,2.0
+31493,Spain,2016,4,M-Musculo-skeletal system,Million US$ at exchange rate,515.2
+31494,Spain,2016,4,R-Respiratory system,"/capita, US$ purchasing power parity",38.9
+31495,Spain,2016,4,R-Respiratory system,% of total sales,9.8
+31496,Spain,2016,4,R-Respiratory system,Million US$ at exchange rate,1285.8
+31497,Spain,2016,4,R-Respiratory system,"Million US$, purchasing power parity",1807.6
+31498,Spain,2016,4,R-Respiratory system,"/capita, US$ exchange rate",27.7
+31499,Spain,2016,4,N05B-Anxiolytics,"Million US$, purchasing power parity",157.0
+31500,Spain,2016,4,N05B-Anxiolytics,Million US$ at exchange rate,111.7
+31501,Spain,2016,4,C02-Antihypertensives,Million US$ at exchange rate,45.5
+31502,Spain,2016,4,N05B-Anxiolytics,"/capita, US$ purchasing power parity",3.4
+31503,Spain,2016,4,N05B-Anxiolytics,"/capita, US$ exchange rate",2.4
+31504,Spain,2016,4,"H-Systemic hormonal preparations, excluding sex hormones and insulins","Million US$, purchasing power parity",368.2
+31505,Spain,2016,4,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ exchange rate",5.6
+31506,Spain,2016,4,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million of national currency units,236.6
+31507,Spain,2016,4,N05B-Anxiolytics,Million of national currency units,100.9
+31508,Spain,2016,4,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million US$ at exchange rate,261.9
+31509,Spain,2016,4,C01A-Cardiac glycosides,"Million US$, purchasing power parity",4.3
+31510,Spain,2016,4,C01A-Cardiac glycosides,"/capita, US$ exchange rate",0.1
+31511,Spain,2016,4,C01A-Cardiac glycosides,Million US$ at exchange rate,3.1
+31512,Spain,2016,4,B-Blood and blood forming organs,"/capita, US$ purchasing power parity",24.4
+31513,Spain,2016,4,C01A-Cardiac glycosides,Million of national currency units,2.8
+31514,Spain,2016,4,G-Genito urinary system and sex hormones,% of total sales,4.8
+31515,Spain,2016,4,G-Genito urinary system and sex hormones,"/capita, US$ purchasing power parity",19.1
+31516,Spain,2016,4,C01A-Cardiac glycosides,"/capita, US$ purchasing power parity",0.1
+31517,Spain,2016,4,C01A-Cardiac glycosides,% of total sales,0.0
+31518,Spain,2016,4,B-Blood and blood forming organs,"/capita, US$ exchange rate",17.4
+31519,Spain,2016,4,N05C-Hypnotics and sedatives,"/capita, US$ exchange rate",1.1
+31520,Spain,2016,4,N05C-Hypnotics and sedatives,"Million US$, purchasing power parity",73.0
+31521,Spain,2016,4,N05C-Hypnotics and sedatives,Million US$ at exchange rate,51.9
+31522,Spain,2016,4,N05C-Hypnotics and sedatives,% of total sales,0.4
+31523,Spain,2016,4,N05C-Hypnotics and sedatives,"/capita, US$ purchasing power parity",1.6
+31524,Spain,2016,4,G-Genito urinary system and sex hormones,"/capita, US$ exchange rate",13.6
+31525,Spain,2016,4,B-Blood and blood forming organs,Million US$ at exchange rate,806.9
+31526,Spain,2016,4,B-Blood and blood forming organs,"Million US$, purchasing power parity",1134.4
+31527,Spain,2016,4,N05C-Hypnotics and sedatives,Million of national currency units,46.9
+31528,Spain,2016,4,B-Blood and blood forming organs,Million of national currency units,729.0
+31529,Spain,2016,4,N06A-Antidepressants,"/capita, US$ exchange rate",11.5
+31530,Spain,2016,4,N06A-Antidepressants,"/capita, US$ purchasing power parity",16.2
+31531,Spain,2016,4,N06A-Antidepressants,Million of national currency units,483.9
+31532,Spain,2016,4,N06A-Antidepressants,Million US$ at exchange rate,535.6
+31533,Spain,2016,4,N06A-Antidepressants,"Million US$, purchasing power parity",753.0
+31534,Spain,2016,4,M01A-Antiinflammatory and antirheumatic products non-steroids,"Million US$, purchasing power parity",420.0
+31535,Spain,2016,4,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ exchange rate",6.4
+31536,Spain,2016,4,M01A-Antiinflammatory and antirheumatic products non-steroids,Million US$ at exchange rate,298.7
+31537,Spain,2016,4,N06A-Antidepressants,% of total sales,4.1
+31538,Spain,2016,4,M01A-Antiinflammatory and antirheumatic products non-steroids,Million of national currency units,269.9
+31539,Spain,2016,4,G-Genito urinary system and sex hormones,Million of national currency units,571.4
+31540,Spain,2016,4,G03-Sex hormones and modulators of the genital system,Million of national currency units,99.3
+31541,Spain,2016,4,G-Genito urinary system and sex hormones,"Million US$, purchasing power parity",889.2
+31542,Spain,2016,4,G-Genito urinary system and sex hormones,Million US$ at exchange rate,632.5
+31543,Spain,2016,4,G03-Sex hormones and modulators of the genital system,"/capita, US$ purchasing power parity",3.3
+31544,Spain,2016,4,G03-Sex hormones and modulators of the genital system,% of total sales,0.8
+31545,Spain,2016,4,G03-Sex hormones and modulators of the genital system,"Million US$, purchasing power parity",154.6
+31546,Spain,2016,4,G03-Sex hormones and modulators of the genital system,Million US$ at exchange rate,110.0
+31547,Spain,2016,4,G03-Sex hormones and modulators of the genital system,"/capita, US$ exchange rate",2.4
+31548,Spain,2016,4,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ purchasing power parity",14.2
+31549,Spain,2016,4,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),% of total sales,3.6
+31550,Spain,2016,4,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"Million US$, purchasing power parity",657.9
+31551,Spain,2016,4,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ exchange rate",10.1
+31552,Spain,2016,4,A-Alimentary tract and metabolism,"Million US$, purchasing power parity",3274.4
+31553,Spain,2016,4,A-Alimentary tract and metabolism,"/capita, US$ exchange rate",50.1
+31554,Spain,2016,4,A-Alimentary tract and metabolism,Million of national currency units,2104.3
+31555,Spain,2016,4,A-Alimentary tract and metabolism,Million US$ at exchange rate,2329.2
+31556,Spain,2016,4,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ exchange rate",21.1
+31557,Spain,2016,4,C09-Agents acting on the Renin-Angiotensin system,"Million US$, purchasing power parity",1375.6
+31558,Spain,2016,4,C09-Agents acting on the Renin-Angiotensin system,% of total sales,7.5
+31559,Spain,2016,4,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ purchasing power parity",29.6
+31560,Spain,2016,4,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million of national currency units,422.8
+31561,Spain,2016,4,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million US$ at exchange rate,468.0
+31562,Spain,2016,4,C09-Agents acting on the Renin-Angiotensin system,Million US$ at exchange rate,978.5
+31563,Spain,2016,4,C09-Agents acting on the Renin-Angiotensin system,Million of national currency units,884.0
+31564,Spain,2016,4,N02-Analgesics,"/capita, US$ exchange rate",16.4
+31565,Spain,2016,4,N02-Analgesics,% of total sales,5.8
+31566,Spain,2016,4,N02-Analgesics,"Million US$, purchasing power parity",1069.4
+31567,Spain,2016,4,N02-Analgesics,"/capita, US$ purchasing power parity",23.0
+31568,Spain,2016,4,C02-Antihypertensives,Million of national currency units,41.1
+31569,Spain,2016,4,N02-Analgesics,Million of national currency units,687.3
+31570,Spain,2016,4,N02-Analgesics,Million US$ at exchange rate,760.7
+31571,Spain,2016,4,R03-Drugs for obstructive airway diseases,Million of national currency units,981.7
+31572,Spain,2016,4,R03-Drugs for obstructive airway diseases,Million US$ at exchange rate,1086.6
+31573,Spain,2016,4,A-Alimentary tract and metabolism,"/capita, US$ purchasing power parity",70.4
+31574,Spain,2016,4,A-Alimentary tract and metabolism,% of total sales,17.8
+31575,Spain,2016,4,R03-Drugs for obstructive airway diseases,"/capita, US$ purchasing power parity",32.9
+31576,Spain,2016,4,R03-Drugs for obstructive airway diseases,% of total sales,8.3
+31577,Spain,2016,4,R03-Drugs for obstructive airway diseases,"Million US$, purchasing power parity",1527.5
+31578,Spain,2016,4,R03-Drugs for obstructive airway diseases,"/capita, US$ exchange rate",23.4
+31579,Spain,2016,4,A10-Drugs used in diabetes,Million of national currency units,1383.9
+31580,Spain,2016,4,"C01B-Antiarrhythmics, Class I and III",% of total sales,0.3
+31581,Spain,2016,4,A10-Drugs used in diabetes,Million US$ at exchange rate,1531.8
+31582,Spain,2016,4,A10-Drugs used in diabetes,"/capita, US$ purchasing power parity",46.3
+31583,Spain,2016,4,A10-Drugs used in diabetes,% of total sales,11.7
+31584,Spain,2016,4,A10-Drugs used in diabetes,"Million US$, purchasing power parity",2153.4
+31585,Spain,2016,4,A10-Drugs used in diabetes,"/capita, US$ exchange rate",33.0
+31586,Spain,2016,4,"C01B-Antiarrhythmics, Class I and III","/capita, US$ purchasing power parity",1.2
+31587,Spain,2016,4,"C01B-Antiarrhythmics, Class I and III",Million US$ at exchange rate,39.2
+31588,Spain,2016,4,"C01B-Antiarrhythmics, Class I and III","Million US$, purchasing power parity",55.1
+31589,Spain,2016,4,"C01B-Antiarrhythmics, Class I and III",Million of national currency units,35.4
+31590,Spain,2016,4,"C01B-Antiarrhythmics, Class I and III","/capita, US$ exchange rate",0.8
+31591,Spain,2017,4,J01-Antibacterials for systemic use,"/capita, US$ purchasing power parity",8.1
+31592,Spain,2017,4,J01-Antibacterials for systemic use,% of total sales,2.0
+31593,Spain,2017,4,J01-Antibacterials for systemic use,"/capita, US$ exchange rate",5.8
+31594,Spain,2017,4,J01-Antibacterials for systemic use,Million US$ at exchange rate,268.2
+31595,Spain,2017,4,J01-Antibacterials for systemic use,"Million US$, purchasing power parity",376.3
+31596,Spain,2017,4,J01-Antibacterials for systemic use,Million of national currency units,237.4
+31597,Spain,2017,4,C02-Antihypertensives,"Million US$, purchasing power parity",71.7
+31598,Spain,2017,4,C02-Antihypertensives,"/capita, US$ purchasing power parity",1.5
+31599,Spain,2017,4,C-Cardiovascular system,"Million US$, purchasing power parity",3491.4
+31600,Spain,2017,4,C02-Antihypertensives,"/capita, US$ exchange rate",1.1
+31601,Spain,2017,4,C08-Calcium channel blockers,"/capita, US$ purchasing power parity",3.7
+31602,Spain,2017,4,C08-Calcium channel blockers,"/capita, US$ exchange rate",2.6
+31603,Spain,2017,4,C02-Antihypertensives,% of total sales,0.4
+31604,Spain,2017,4,C08-Calcium channel blockers,% of total sales,0.9
+31605,Spain,2017,4,J-Antiinfectives for systemic use,"/capita, US$ exchange rate",7.1
+31606,Spain,2017,4,J-Antiinfectives for systemic use,"/capita, US$ purchasing power parity",10.0
+31607,Spain,2017,4,J-Antiinfectives for systemic use,Million US$ at exchange rate,331.2
+31608,Spain,2017,4,J-Antiinfectives for systemic use,"Million US$, purchasing power parity",464.8
+31609,Spain,2017,4,C03-Diuretics,Million US$ at exchange rate,108.5
+31610,Spain,2017,4,C03-Diuretics,"Million US$, purchasing power parity",152.2
+31611,Spain,2017,4,J-Antiinfectives for systemic use,% of total sales,2.4
+31612,Spain,2017,4,C03-Diuretics,Million of national currency units,96.0
+31613,Spain,2017,4,C07-Beta blocking agents,"/capita, US$ purchasing power parity",3.0
+31614,Spain,2017,4,C07-Beta blocking agents,"/capita, US$ exchange rate",2.1
+31615,Spain,2017,4,N-Nervous system,Million of national currency units,3070.2
+31616,Spain,2017,4,C07-Beta blocking agents,% of total sales,0.7
+31617,Spain,2017,4,C07-Beta blocking agents,Million of national currency units,88.5
+31618,Spain,2017,4,J-Antiinfectives for systemic use,Million of national currency units,293.2
+31619,Spain,2017,4,C07-Beta blocking agents,"Million US$, purchasing power parity",140.4
+31620,Spain,2017,4,C07-Beta blocking agents,Million US$ at exchange rate,100.0
+31621,Spain,2017,4,N-Nervous system,"/capita, US$ purchasing power parity",104.5
+31622,Spain,2017,4,N-Nervous system,"/capita, US$ exchange rate",74.4
+31623,Spain,2017,4,N-Nervous system,% of total sales,25.4
+31624,Spain,2017,4,C08-Calcium channel blockers,"Million US$, purchasing power parity",170.7
+31625,Spain,2017,4,C-Cardiovascular system,Million of national currency units,2202.5
+31626,Spain,2017,4,C-Cardiovascular system,Million US$ at exchange rate,2488.1
+31627,Spain,2017,4,N-Nervous system,"Million US$, purchasing power parity",4866.9
+31628,Spain,2017,4,N-Nervous system,Million US$ at exchange rate,3468.4
+31629,Spain,2017,4,C08-Calcium channel blockers,Million US$ at exchange rate,121.6
+31630,Spain,2017,4,C03-Diuretics,% of total sales,0.8
+31631,Spain,2017,4,C-Cardiovascular system,% of total sales,18.3
+31632,Spain,2017,4,C03-Diuretics,"/capita, US$ exchange rate",2.3
+31633,Spain,2017,4,C03-Diuretics,"/capita, US$ purchasing power parity",3.3
+31634,Spain,2017,4,C08-Calcium channel blockers,Million of national currency units,107.7
+31635,Spain,2017,4,C-Cardiovascular system,"/capita, US$ purchasing power parity",74.9
+31636,Spain,2017,4,C-Cardiovascular system,"/capita, US$ exchange rate",53.4
+31637,Spain,2017,4,C02-Antihypertensives,Million US$ at exchange rate,51.1
+31638,Spain,2017,4,C10-Lipid modifying agents,Million US$ at exchange rate,969.4
+31639,Spain,2017,4,C10-Lipid modifying agents,Million of national currency units,858.1
+31640,Spain,2017,4,C10-Lipid modifying agents,"/capita, US$ purchasing power parity",29.2
+31641,Spain,2017,4,C10-Lipid modifying agents,"/capita, US$ exchange rate",20.8
+31642,Spain,2017,4,C10-Lipid modifying agents,"Million US$, purchasing power parity",1360.3
+31643,Spain,2017,4,M-Musculo-skeletal system,"Million US$, purchasing power parity",710.4
+31644,Spain,2017,4,N05B-Anxiolytics,% of total sales,0.8
+31645,Spain,2017,4,M-Musculo-skeletal system,"/capita, US$ exchange rate",10.9
+31646,Spain,2017,4,M-Musculo-skeletal system,% of total sales,3.7
+31647,Spain,2017,4,M-Musculo-skeletal system,"/capita, US$ purchasing power parity",15.2
+31648,Spain,2017,4,B-Blood and blood forming organs,% of total sales,6.7
+31649,Spain,2017,4,Total pharmaceutical sales,Million of national currency units,12064.9
+31650,Spain,2017,4,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ purchasing power parity",8.4
+31651,Spain,2017,4,M01A-Antiinflammatory and antirheumatic products non-steroids,% of total sales,2.0
+31652,Spain,2017,4,B-Blood and blood forming organs,"/capita, US$ purchasing power parity",27.4
+31653,Spain,2017,4,Total pharmaceutical sales,"/capita, US$ purchasing power parity",410.5
+31654,Spain,2017,4,C10-Lipid modifying agents,% of total sales,7.1
+31655,Spain,2017,4,Total pharmaceutical sales,Million US$ at exchange rate,13629.5
+31656,Spain,2017,4,Total pharmaceutical sales,"Million US$, purchasing power parity",19125.2
+31657,Spain,2017,4,Total pharmaceutical sales,"/capita, US$ exchange rate",292.5
+31658,Spain,2017,4,M-Musculo-skeletal system,Million of national currency units,448.2
+31659,Spain,2017,4,R-Respiratory system,Million of national currency units,1134.8
+31660,Spain,2017,4,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ purchasing power parity",8.4
+31661,Spain,2017,4,"H-Systemic hormonal preparations, excluding sex hormones and insulins",% of total sales,2.1
+31662,Spain,2017,4,M-Musculo-skeletal system,Million US$ at exchange rate,506.3
+31663,Spain,2017,4,R-Respiratory system,"/capita, US$ purchasing power parity",38.6
+31664,Spain,2017,4,R-Respiratory system,% of total sales,9.4
+31665,Spain,2017,4,R-Respiratory system,Million US$ at exchange rate,1281.9
+31666,Spain,2017,4,R-Respiratory system,"/capita, US$ exchange rate",27.5
+31667,Spain,2017,4,R-Respiratory system,"Million US$, purchasing power parity",1798.8
+31668,Spain,2017,4,N05B-Anxiolytics,"Million US$, purchasing power parity",159.1
+31669,Spain,2017,4,N05B-Anxiolytics,Million US$ at exchange rate,113.4
+31670,Spain,2017,4,N05B-Anxiolytics,"/capita, US$ purchasing power parity",3.4
+31671,Spain,2017,4,N05B-Anxiolytics,"/capita, US$ exchange rate",2.4
+31672,Spain,2017,4,N05B-Anxiolytics,Million of national currency units,100.4
+31673,Spain,2017,4,"H-Systemic hormonal preparations, excluding sex hormones and insulins","Million US$, purchasing power parity",392.1
+31674,Spain,2017,4,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ exchange rate",6.0
+31675,Spain,2017,4,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million of national currency units,247.3
+31676,Spain,2017,4,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million US$ at exchange rate,279.4
+31677,Spain,2017,4,C01A-Cardiac glycosides,Million US$ at exchange rate,2.9
+31678,Spain,2017,4,C01A-Cardiac glycosides,"Million US$, purchasing power parity",4.0
+31679,Spain,2017,4,C01A-Cardiac glycosides,"/capita, US$ exchange rate",0.1
+31680,Spain,2017,4,C01A-Cardiac glycosides,Million of national currency units,2.5
+31681,Spain,2017,4,G-Genito urinary system and sex hormones,% of total sales,5.0
+31682,Spain,2017,4,G-Genito urinary system and sex hormones,"/capita, US$ purchasing power parity",20.4
+31683,Spain,2017,4,G-Genito urinary system and sex hormones,"/capita, US$ exchange rate",14.5
+31684,Spain,2017,4,C01A-Cardiac glycosides,"/capita, US$ purchasing power parity",0.1
+31685,Spain,2017,4,C01A-Cardiac glycosides,% of total sales,0.0
+31686,Spain,2017,4,B-Blood and blood forming organs,"/capita, US$ exchange rate",19.5
+31687,Spain,2017,4,N05C-Hypnotics and sedatives,"Million US$, purchasing power parity",75.5
+31688,Spain,2017,4,N05C-Hypnotics and sedatives,Million US$ at exchange rate,53.8
+31689,Spain,2017,4,N05C-Hypnotics and sedatives,"/capita, US$ exchange rate",1.2
+31690,Spain,2017,4,N05C-Hypnotics and sedatives,% of total sales,0.4
+31691,Spain,2017,4,N05C-Hypnotics and sedatives,"/capita, US$ purchasing power parity",1.6
+31692,Spain,2017,4,B-Blood and blood forming organs,Million US$ at exchange rate,910.7
+31693,Spain,2017,4,B-Blood and blood forming organs,"Million US$, purchasing power parity",1277.9
+31694,Spain,2017,4,N05C-Hypnotics and sedatives,Million of national currency units,47.6
+31695,Spain,2017,4,B-Blood and blood forming organs,Million of national currency units,806.2
+31696,Spain,2017,4,N06A-Antidepressants,"/capita, US$ exchange rate",12.1
+31697,Spain,2017,4,N06A-Antidepressants,"/capita, US$ purchasing power parity",17.0
+31698,Spain,2017,4,N06A-Antidepressants,Million of national currency units,500.8
+31699,Spain,2017,4,N06A-Antidepressants,"Million US$, purchasing power parity",793.8
+31700,Spain,2017,4,N06A-Antidepressants,Million US$ at exchange rate,565.7
+31701,Spain,2017,4,M01A-Antiinflammatory and antirheumatic products non-steroids,"Million US$, purchasing power parity",391.1
+31702,Spain,2017,4,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ exchange rate",6.0
+31703,Spain,2017,4,M01A-Antiinflammatory and antirheumatic products non-steroids,Million US$ at exchange rate,278.7
+31704,Spain,2017,4,N06A-Antidepressants,% of total sales,4.2
+31705,Spain,2017,4,M01A-Antiinflammatory and antirheumatic products non-steroids,Million of national currency units,246.7
+31706,Spain,2017,4,G-Genito urinary system and sex hormones,Million of national currency units,600.1
+31707,Spain,2017,4,G03-Sex hormones and modulators of the genital system,Million of national currency units,107.7
+31708,Spain,2017,4,G-Genito urinary system and sex hormones,"Million US$, purchasing power parity",951.3
+31709,Spain,2017,4,G-Genito urinary system and sex hormones,Million US$ at exchange rate,677.9
+31710,Spain,2017,4,G03-Sex hormones and modulators of the genital system,Million US$ at exchange rate,121.7
+31711,Spain,2017,4,G03-Sex hormones and modulators of the genital system,"/capita, US$ purchasing power parity",3.7
+31712,Spain,2017,4,G03-Sex hormones and modulators of the genital system,% of total sales,0.9
+31713,Spain,2017,4,G03-Sex hormones and modulators of the genital system,"Million US$, purchasing power parity",170.7
+31714,Spain,2017,4,G03-Sex hormones and modulators of the genital system,"/capita, US$ exchange rate",2.6
+31715,Spain,2017,4,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ purchasing power parity",14.4
+31716,Spain,2017,4,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),% of total sales,3.5
+31717,Spain,2017,4,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"Million US$, purchasing power parity",671.5
+31718,Spain,2017,4,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ exchange rate",10.3
+31719,Spain,2017,4,A-Alimentary tract and metabolism,"Million US$, purchasing power parity",3512.0
+31720,Spain,2017,4,A-Alimentary tract and metabolism,"/capita, US$ exchange rate",53.7
+31721,Spain,2017,4,A-Alimentary tract and metabolism,Million of national currency units,2215.5
+31722,Spain,2017,4,A-Alimentary tract and metabolism,Million US$ at exchange rate,2502.8
+31723,Spain,2017,4,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ exchange rate",20.3
+31724,Spain,2017,4,C09-Agents acting on the Renin-Angiotensin system,"Million US$, purchasing power parity",1328.0
+31725,Spain,2017,4,C09-Agents acting on the Renin-Angiotensin system,% of total sales,6.9
+31726,Spain,2017,4,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ purchasing power parity",28.5
+31727,Spain,2017,4,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million of national currency units,423.6
+31728,Spain,2017,4,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million US$ at exchange rate,478.6
+31729,Spain,2017,4,C09-Agents acting on the Renin-Angiotensin system,Million US$ at exchange rate,946.4
+31730,Spain,2017,4,C09-Agents acting on the Renin-Angiotensin system,Million of national currency units,837.8
+31731,Spain,2017,4,N02-Analgesics,"/capita, US$ exchange rate",17.4
+31732,Spain,2017,4,N02-Analgesics,"Million US$, purchasing power parity",1138.5
+31733,Spain,2017,4,N02-Analgesics,% of total sales,6.0
+31734,Spain,2017,4,N02-Analgesics,"/capita, US$ purchasing power parity",24.4
+31735,Spain,2017,4,C02-Antihypertensives,Million of national currency units,45.2
+31736,Spain,2017,4,N02-Analgesics,Million US$ at exchange rate,811.4
+31737,Spain,2017,4,N02-Analgesics,Million of national currency units,718.2
+31738,Spain,2017,4,R03-Drugs for obstructive airway diseases,% of total sales,8.0
+31739,Spain,2017,4,R03-Drugs for obstructive airway diseases,Million of national currency units,961.2
+31740,Spain,2017,4,A-Alimentary tract and metabolism,"/capita, US$ purchasing power parity",75.4
+31741,Spain,2017,4,R03-Drugs for obstructive airway diseases,Million US$ at exchange rate,1085.8
+31742,Spain,2017,4,A-Alimentary tract and metabolism,% of total sales,18.4
+31743,Spain,2017,4,R03-Drugs for obstructive airway diseases,"/capita, US$ purchasing power parity",32.7
+31744,Spain,2017,4,R03-Drugs for obstructive airway diseases,"/capita, US$ exchange rate",23.3
+31745,Spain,2017,4,R03-Drugs for obstructive airway diseases,"Million US$, purchasing power parity",1523.6
+31746,Spain,2017,4,A10-Drugs used in diabetes,Million of national currency units,1467.1
+31747,Spain,2017,4,"C01B-Antiarrhythmics, Class I and III",% of total sales,0.2
+31748,Spain,2017,4,A10-Drugs used in diabetes,"/capita, US$ purchasing power parity",49.9
+31749,Spain,2017,4,A10-Drugs used in diabetes,% of total sales,12.2
+31750,Spain,2017,4,A10-Drugs used in diabetes,Million US$ at exchange rate,1657.4
+31751,Spain,2017,4,A10-Drugs used in diabetes,"Million US$, purchasing power parity",2325.7
+31752,Spain,2017,4,A10-Drugs used in diabetes,"/capita, US$ exchange rate",35.6
+31753,Spain,2017,4,"C01B-Antiarrhythmics, Class I and III",Million US$ at exchange rate,33.5
+31754,Spain,2017,4,"C01B-Antiarrhythmics, Class I and III","Million US$, purchasing power parity",47.0
+31755,Spain,2017,4,"C01B-Antiarrhythmics, Class I and III","/capita, US$ purchasing power parity",1.0
+31756,Spain,2017,4,"C01B-Antiarrhythmics, Class I and III","/capita, US$ exchange rate",0.7
+31757,Spain,2017,4,"C01B-Antiarrhythmics, Class I and III",Million of national currency units,29.6
+31758,Spain,2014,4,J01-Antibacterials for systemic use,"/capita, US$ purchasing power parity",8.1
+31759,Spain,2014,4,J01-Antibacterials for systemic use,% of total sales,2.2
+31760,Spain,2014,4,J01-Antibacterials for systemic use,Million US$ at exchange rate,333.1
+31761,Spain,2014,4,J01-Antibacterials for systemic use,"Million US$, purchasing power parity",378.6
+31762,Spain,2014,4,J01-Antibacterials for systemic use,"/capita, US$ exchange rate",7.2
+31763,Spain,2014,4,J01-Antibacterials for systemic use,Million of national currency units,250.8
+31764,Spain,2014,4,C02-Antihypertensives,"/capita, US$ exchange rate",1.2
+31765,Spain,2014,4,C02-Antihypertensives,"Million US$, purchasing power parity",62.4
+31766,Spain,2014,4,C02-Antihypertensives,"/capita, US$ purchasing power parity",1.3
+31767,Spain,2014,4,C-Cardiovascular system,"Million US$, purchasing power parity",3232.1
+31768,Spain,2014,4,C08-Calcium channel blockers,"/capita, US$ purchasing power parity",3.7
+31769,Spain,2014,4,C08-Calcium channel blockers,"/capita, US$ exchange rate",3.2
+31770,Spain,2014,4,C02-Antihypertensives,% of total sales,0.4
+31771,Spain,2014,4,C08-Calcium channel blockers,% of total sales,1.0
+31772,Spain,2014,4,J-Antiinfectives for systemic use,"/capita, US$ exchange rate",8.6
+31773,Spain,2014,4,J-Antiinfectives for systemic use,"/capita, US$ purchasing power parity",9.8
+31774,Spain,2014,4,J-Antiinfectives for systemic use,Million US$ at exchange rate,401.5
+31775,Spain,2014,4,J-Antiinfectives for systemic use,"Million US$, purchasing power parity",456.2
+31776,Spain,2014,4,C03-Diuretics,Million US$ at exchange rate,136.6
+31777,Spain,2014,4,C03-Diuretics,"Million US$, purchasing power parity",155.2
+31778,Spain,2014,4,J-Antiinfectives for systemic use,% of total sales,2.7
+31779,Spain,2014,4,C03-Diuretics,Million of national currency units,102.8
+31780,Spain,2014,4,C07-Beta blocking agents,"/capita, US$ purchasing power parity",2.7
+31781,Spain,2014,4,N-Nervous system,Million of national currency units,3043.9
+31782,Spain,2014,4,C07-Beta blocking agents,% of total sales,0.7
+31783,Spain,2014,4,C07-Beta blocking agents,"/capita, US$ exchange rate",2.4
+31784,Spain,2014,4,C07-Beta blocking agents,Million of national currency units,84.4
+31785,Spain,2014,4,J-Antiinfectives for systemic use,Million of national currency units,302.2
+31786,Spain,2014,4,C07-Beta blocking agents,Million US$ at exchange rate,112.1
+31787,Spain,2014,4,C07-Beta blocking agents,"Million US$, purchasing power parity",127.4
+31788,Spain,2014,4,N-Nervous system,"/capita, US$ purchasing power parity",98.9
+31789,Spain,2014,4,N-Nervous system,"/capita, US$ exchange rate",87.0
+31790,Spain,2014,4,C08-Calcium channel blockers,"Million US$, purchasing power parity",169.9
+31791,Spain,2014,4,N-Nervous system,% of total sales,26.9
+31792,Spain,2014,4,C-Cardiovascular system,Million of national currency units,2140.8
+31793,Spain,2014,4,C-Cardiovascular system,Million US$ at exchange rate,2844.1
+31794,Spain,2014,4,N-Nervous system,"Million US$, purchasing power parity",4595.6
+31795,Spain,2014,4,N-Nervous system,Million US$ at exchange rate,4043.9
+31796,Spain,2014,4,C03-Diuretics,% of total sales,0.9
+31797,Spain,2014,4,C-Cardiovascular system,% of total sales,18.9
+31798,Spain,2014,4,C03-Diuretics,"/capita, US$ exchange rate",2.9
+31799,Spain,2014,4,C03-Diuretics,"/capita, US$ purchasing power parity",3.3
+31800,Spain,2014,4,C08-Calcium channel blockers,Million of national currency units,112.6
+31801,Spain,2014,4,C08-Calcium channel blockers,Million US$ at exchange rate,149.5
+31802,Spain,2014,4,C-Cardiovascular system,"/capita, US$ purchasing power parity",69.5
+31803,Spain,2014,4,C-Cardiovascular system,"/capita, US$ exchange rate",61.2
+31804,Spain,2014,4,C10-Lipid modifying agents,Million US$ at exchange rate,950.3
+31805,Spain,2014,4,C10-Lipid modifying agents,Million of national currency units,715.3
+31806,Spain,2014,4,C10-Lipid modifying agents,"Million US$, purchasing power parity",1080.0
+31807,Spain,2014,4,C10-Lipid modifying agents,"/capita, US$ purchasing power parity",23.2
+31808,Spain,2014,4,C10-Lipid modifying agents,"/capita, US$ exchange rate",20.4
+31809,Spain,2014,4,M-Musculo-skeletal system,"/capita, US$ exchange rate",14.6
+31810,Spain,2014,4,M-Musculo-skeletal system,"Million US$, purchasing power parity",769.1
+31811,Spain,2014,4,M-Musculo-skeletal system,% of total sales,4.5
+31812,Spain,2014,4,M-Musculo-skeletal system,"/capita, US$ purchasing power parity",16.5
+31813,Spain,2014,4,B-Blood and blood forming organs,% of total sales,5.3
+31814,Spain,2014,4,Total pharmaceutical sales,Million of national currency units,11302.6
+31815,Spain,2014,4,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ purchasing power parity",10.0
+31816,Spain,2014,4,M01A-Antiinflammatory and antirheumatic products non-steroids,% of total sales,2.7
+31817,Spain,2014,4,Total pharmaceutical sales,Million US$ at exchange rate,15015.6
+31818,Spain,2014,4,Total pharmaceutical sales,"/capita, US$ purchasing power parity",367.1
+31819,Spain,2014,4,C10-Lipid modifying agents,% of total sales,6.3
+31820,Spain,2014,4,Total pharmaceutical sales,"Million US$, purchasing power parity",17064.2
+31821,Spain,2014,4,Total pharmaceutical sales,"/capita, US$ exchange rate",323.0
+31822,Spain,2014,4,M-Musculo-skeletal system,Million of national currency units,509.4
+31823,Spain,2014,4,R-Respiratory system,Million of national currency units,1150.2
+31824,Spain,2014,4,"H-Systemic hormonal preparations, excluding sex hormones and insulins",% of total sales,2.0
+31825,Spain,2014,4,M-Musculo-skeletal system,Million US$ at exchange rate,676.7
+31826,Spain,2014,4,R-Respiratory system,Million US$ at exchange rate,1528.0
+31827,Spain,2014,4,R-Respiratory system,"/capita, US$ purchasing power parity",37.4
+31828,Spain,2014,4,R-Respiratory system,% of total sales,10.2
+31829,Spain,2014,4,R-Respiratory system,"Million US$, purchasing power parity",1736.5
+31830,Spain,2014,4,R-Respiratory system,"/capita, US$ exchange rate",32.9
+31831,Spain,2014,4,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ purchasing power parity",7.3
+31832,Spain,2014,4,N05B-Anxiolytics,"Million US$, purchasing power parity",156.8
+31833,Spain,2014,4,N05B-Anxiolytics,Million US$ at exchange rate,137.9
+31834,Spain,2014,4,N05B-Anxiolytics,"/capita, US$ purchasing power parity",3.4
+31835,Spain,2014,4,N05B-Anxiolytics,"/capita, US$ exchange rate",3.0
+31836,Spain,2014,4,N05B-Anxiolytics,% of total sales,0.9
+31837,Spain,2014,4,"H-Systemic hormonal preparations, excluding sex hormones and insulins","Million US$, purchasing power parity",338.9
+31838,Spain,2014,4,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ exchange rate",6.4
+31839,Spain,2014,4,N05B-Anxiolytics,Million of national currency units,103.8
+31840,Spain,2014,4,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million of national currency units,224.5
+31841,Spain,2014,4,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million US$ at exchange rate,298.2
+31842,Spain,2014,4,C01A-Cardiac glycosides,"Million US$, purchasing power parity",4.8
+31843,Spain,2014,4,C01A-Cardiac glycosides,"/capita, US$ exchange rate",0.1
+31844,Spain,2014,4,B-Blood and blood forming organs,"/capita, US$ purchasing power parity",19.3
+31845,Spain,2014,4,C01A-Cardiac glycosides,Million of national currency units,3.2
+31846,Spain,2014,4,C01A-Cardiac glycosides,Million US$ at exchange rate,4.2
+31847,Spain,2014,4,G-Genito urinary system and sex hormones,% of total sales,4.6
+31848,Spain,2014,4,G-Genito urinary system and sex hormones,"/capita, US$ purchasing power parity",16.7
+31849,Spain,2014,4,C01A-Cardiac glycosides,"/capita, US$ purchasing power parity",0.1
+31850,Spain,2014,4,C01A-Cardiac glycosides,% of total sales,0.0
+31851,Spain,2014,4,N05C-Hypnotics and sedatives,"/capita, US$ exchange rate",1.3
+31852,Spain,2014,4,N05C-Hypnotics and sedatives,"Million US$, purchasing power parity",67.6
+31853,Spain,2014,4,N05C-Hypnotics and sedatives,% of total sales,0.4
+31854,Spain,2014,4,N05C-Hypnotics and sedatives,"/capita, US$ purchasing power parity",1.5
+31855,Spain,2014,4,N05C-Hypnotics and sedatives,Million US$ at exchange rate,59.4
+31856,Spain,2014,4,B-Blood and blood forming organs,Million US$ at exchange rate,788.8
+31857,Spain,2014,4,B-Blood and blood forming organs,"Million US$, purchasing power parity",896.4
+31858,Spain,2014,4,B-Blood and blood forming organs,"/capita, US$ exchange rate",17.0
+31859,Spain,2014,4,N05C-Hypnotics and sedatives,Million of national currency units,44.7
+31860,Spain,2014,4,B-Blood and blood forming organs,Million of national currency units,593.7
+31861,Spain,2014,4,G-Genito urinary system and sex hormones,"/capita, US$ exchange rate",14.7
+31862,Spain,2014,4,N06A-Antidepressants,"/capita, US$ exchange rate",15.3
+31863,Spain,2014,4,N06A-Antidepressants,"/capita, US$ purchasing power parity",17.4
+31864,Spain,2014,4,N06A-Antidepressants,Million US$ at exchange rate,711.2
+31865,Spain,2014,4,N06A-Antidepressants,"Million US$, purchasing power parity",808.2
+31866,Spain,2014,4,M01A-Antiinflammatory and antirheumatic products non-steroids,"Million US$, purchasing power parity",467.0
+31867,Spain,2014,4,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ exchange rate",8.8
+31868,Spain,2014,4,N06A-Antidepressants,% of total sales,4.7
+31869,Spain,2014,4,M01A-Antiinflammatory and antirheumatic products non-steroids,Million of national currency units,309.3
+31870,Spain,2014,4,M01A-Antiinflammatory and antirheumatic products non-steroids,Million US$ at exchange rate,410.9
+31871,Spain,2014,4,N06A-Antidepressants,Million of national currency units,535.3
+31872,Spain,2014,4,G-Genito urinary system and sex hormones,Million of national currency units,515.1
+31873,Spain,2014,4,G03-Sex hormones and modulators of the genital system,Million of national currency units,103.4
+31874,Spain,2014,4,G-Genito urinary system and sex hormones,"Million US$, purchasing power parity",777.6
+31875,Spain,2014,4,G03-Sex hormones and modulators of the genital system,Million US$ at exchange rate,137.4
+31876,Spain,2014,4,G-Genito urinary system and sex hormones,Million US$ at exchange rate,684.3
+31877,Spain,2014,4,G03-Sex hormones and modulators of the genital system,"/capita, US$ purchasing power parity",3.4
+31878,Spain,2014,4,G03-Sex hormones and modulators of the genital system,% of total sales,0.9
+31879,Spain,2014,4,G03-Sex hormones and modulators of the genital system,"Million US$, purchasing power parity",156.1
+31880,Spain,2014,4,G03-Sex hormones and modulators of the genital system,"/capita, US$ exchange rate",3.0
+31881,Spain,2014,4,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ purchasing power parity",13.7
+31882,Spain,2014,4,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),% of total sales,3.7
+31883,Spain,2014,4,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"Million US$, purchasing power parity",635.4
+31884,Spain,2014,4,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ exchange rate",12.0
+31885,Spain,2014,4,A-Alimentary tract and metabolism,"Million US$, purchasing power parity",2796.7
+31886,Spain,2014,4,A-Alimentary tract and metabolism,"/capita, US$ exchange rate",52.9
+31887,Spain,2014,4,A-Alimentary tract and metabolism,Million of national currency units,1852.4
+31888,Spain,2014,4,A-Alimentary tract and metabolism,Million US$ at exchange rate,2460.9
+31889,Spain,2014,4,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ exchange rate",25.6
+31890,Spain,2014,4,C09-Agents acting on the Renin-Angiotensin system,"Million US$, purchasing power parity",1350.6
+31891,Spain,2014,4,C09-Agents acting on the Renin-Angiotensin system,% of total sales,7.9
+31892,Spain,2014,4,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ purchasing power parity",29.1
+31893,Spain,2014,4,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million of national currency units,420.8
+31894,Spain,2014,4,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million US$ at exchange rate,559.1
+31895,Spain,2014,4,C09-Agents acting on the Renin-Angiotensin system,Million US$ at exchange rate,1188.4
+31896,Spain,2014,4,C09-Agents acting on the Renin-Angiotensin system,Million of national currency units,894.6
+31897,Spain,2014,4,N02-Analgesics,"/capita, US$ exchange rate",16.3
+31898,Spain,2014,4,N02-Analgesics,"/capita, US$ purchasing power parity",18.5
+31899,Spain,2014,4,N02-Analgesics,% of total sales,5.0
+31900,Spain,2014,4,C02-Antihypertensives,Million of national currency units,41.3
+31901,Spain,2014,4,C02-Antihypertensives,Million US$ at exchange rate,54.9
+31902,Spain,2014,4,N02-Analgesics,Million of national currency units,570.2
+31903,Spain,2014,4,N02-Analgesics,"Million US$, purchasing power parity",860.9
+31904,Spain,2014,4,N02-Analgesics,Million US$ at exchange rate,757.6
+31905,Spain,2014,4,R03-Drugs for obstructive airway diseases,Million of national currency units,985.8
+31906,Spain,2014,4,R03-Drugs for obstructive airway diseases,Million US$ at exchange rate,1309.6
+31907,Spain,2014,4,A-Alimentary tract and metabolism,"/capita, US$ purchasing power parity",60.2
+31908,Spain,2014,4,A-Alimentary tract and metabolism,% of total sales,16.4
+31909,Spain,2014,4,R03-Drugs for obstructive airway diseases,"/capita, US$ purchasing power parity",32.0
+31910,Spain,2014,4,R03-Drugs for obstructive airway diseases,% of total sales,8.7
+31911,Spain,2014,4,R03-Drugs for obstructive airway diseases,"Million US$, purchasing power parity",1488.3
+31912,Spain,2014,4,R03-Drugs for obstructive airway diseases,"/capita, US$ exchange rate",28.2
+31913,Spain,2014,4,A10-Drugs used in diabetes,Million of national currency units,1167.2
+31914,Spain,2014,4,A10-Drugs used in diabetes,Million US$ at exchange rate,1550.7
+31915,Spain,2014,4,"C01B-Antiarrhythmics, Class I and III",% of total sales,0.3
+31916,Spain,2014,4,A10-Drugs used in diabetes,"/capita, US$ purchasing power parity",37.9
+31917,Spain,2014,4,A10-Drugs used in diabetes,"Million US$, purchasing power parity",1762.2
+31918,Spain,2014,4,A10-Drugs used in diabetes,"/capita, US$ exchange rate",33.4
+31919,Spain,2014,4,A10-Drugs used in diabetes,% of total sales,10.3
+31920,Spain,2014,4,"C01B-Antiarrhythmics, Class I and III","Million US$, purchasing power parity",53.5
+31921,Spain,2014,4,"C01B-Antiarrhythmics, Class I and III",Million US$ at exchange rate,47.1
+31922,Spain,2014,4,"C01B-Antiarrhythmics, Class I and III",Million of national currency units,35.5
+31923,Spain,2014,4,"C01B-Antiarrhythmics, Class I and III","/capita, US$ exchange rate",1.0
+31924,Spain,2014,4,"C01B-Antiarrhythmics, Class I and III","/capita, US$ purchasing power parity",1.2
+31925,Sweden,2017,4,"C01B-Antiarrhythmics, Class I and III","/capita, US$ purchasing power parity",0.9
+31926,Sweden,2017,4,"C01B-Antiarrhythmics, Class I and III","/capita, US$ exchange rate",0.9
+31927,Sweden,2017,4,J01-Antibacterials for systemic use,"Million US$, purchasing power parity",78.4
+31928,Sweden,2017,4,A-Alimentary tract and metabolism,"Million US$, purchasing power parity",521.7
+31929,Sweden,2017,4,J01-Antibacterials for systemic use,Million US$ at exchange rate,81.2
+31930,Sweden,2017,4,C03-Diuretics,"Million US$, purchasing power parity",25.0
+31931,Sweden,2017,4,C03-Diuretics,Million US$ at exchange rate,25.9
+31932,Sweden,2017,4,C03-Diuretics,Million of national currency units,221.4
+31933,Sweden,2017,4,C03-Diuretics,% of total sales,0.5
+31934,Sweden,2017,4,C-Cardiovascular system,Million US$ at exchange rate,294.2
+31935,Sweden,2017,4,C03-Diuretics,"/capita, US$ exchange rate",2.6
+31936,Sweden,2017,4,C03-Diuretics,"/capita, US$ purchasing power parity",2.5
+31937,Sweden,2017,4,A-Alimentary tract and metabolism,"/capita, US$ purchasing power parity",51.9
+31938,Sweden,2017,4,A-Alimentary tract and metabolism,% of total sales,10.6
+31939,Sweden,2017,4,"C01B-Antiarrhythmics, Class I and III",Million of national currency units,80.9
+31940,Sweden,2017,4,A-Alimentary tract and metabolism,"/capita, US$ exchange rate",53.7
+31941,Sweden,2017,4,C02-Antihypertensives,Million of national currency units,226.1
+31942,Sweden,2017,4,J01-Antibacterials for systemic use,Million of national currency units,694.2
+31943,Sweden,2017,4,C02-Antihypertensives,"Million US$, purchasing power parity",25.5
+31944,Sweden,2017,4,C02-Antihypertensives,Million US$ at exchange rate,26.5
+31945,Sweden,2017,4,C01A-Cardiac glycosides,"/capita, US$ purchasing power parity",0.1
+31946,Sweden,2017,4,C01A-Cardiac glycosides,"/capita, US$ exchange rate",0.1
+31947,Sweden,2017,4,C-Cardiovascular system,Million of national currency units,2515.4
+31948,Sweden,2017,4,C01A-Cardiac glycosides,% of total sales,0.0
+31949,Sweden,2017,4,C01A-Cardiac glycosides,"Million US$, purchasing power parity",1.4
+31950,Sweden,2017,4,"C01B-Antiarrhythmics, Class I and III","Million US$, purchasing power parity",9.1
+31951,Sweden,2017,4,"C01B-Antiarrhythmics, Class I and III",Million US$ at exchange rate,9.5
+31952,Sweden,2017,4,C01A-Cardiac glycosides,Million US$ at exchange rate,1.5
+31953,Sweden,2017,4,C01A-Cardiac glycosides,Million of national currency units,12.5
+31954,Sweden,2017,4,C02-Antihypertensives,"/capita, US$ purchasing power parity",2.5
+31955,Sweden,2017,4,A10-Drugs used in diabetes,Million US$ at exchange rate,217.0
+31956,Sweden,2017,4,C02-Antihypertensives,"/capita, US$ exchange rate",2.6
+31957,Sweden,2017,4,Total pharmaceutical sales,Million US$ at exchange rate,5112.2
+31958,Sweden,2017,4,Total pharmaceutical sales,Million of national currency units,43703.1
+31959,Sweden,2017,4,M01A-Antiinflammatory and antirheumatic products non-steroids,% of total sales,1.7
+31960,Sweden,2017,4,C02-Antihypertensives,% of total sales,0.5
+31961,Sweden,2017,4,A10-Drugs used in diabetes,"Million US$, purchasing power parity",209.6
+31962,Sweden,2017,4,A10-Drugs used in diabetes,"/capita, US$ exchange rate",21.6
+31963,Sweden,2017,4,M-Musculo-skeletal system,"Million US$, purchasing power parity",180.2
+31964,Sweden,2017,4,M-Musculo-skeletal system,"/capita, US$ exchange rate",18.6
+31965,Sweden,2017,4,M-Musculo-skeletal system,Million of national currency units,1595.2
+31966,Sweden,2017,4,M-Musculo-skeletal system,Million US$ at exchange rate,186.6
+31967,Sweden,2017,4,M-Musculo-skeletal system,"/capita, US$ purchasing power parity",17.9
+31968,Sweden,2017,4,Total pharmaceutical sales,"/capita, US$ exchange rate",508.3
+31969,Sweden,2017,4,Total pharmaceutical sales,"Million US$, purchasing power parity",4937.0
+31970,Sweden,2017,4,M-Musculo-skeletal system,% of total sales,3.7
+31971,Sweden,2017,4,Total pharmaceutical sales,"/capita, US$ purchasing power parity",490.9
+31972,Sweden,2017,4,C-Cardiovascular system,"/capita, US$ exchange rate",29.3
+31973,Sweden,2017,4,C-Cardiovascular system,"Million US$, purchasing power parity",284.2
+31974,Sweden,2017,4,A10-Drugs used in diabetes,% of total sales,4.2
+31975,Sweden,2017,4,C-Cardiovascular system,"/capita, US$ purchasing power parity",28.3
+31976,Sweden,2017,4,J01-Antibacterials for systemic use,% of total sales,1.6
+31977,Sweden,2017,4,A-Alimentary tract and metabolism,Million of national currency units,4618.1
+31978,Sweden,2017,4,J01-Antibacterials for systemic use,"/capita, US$ purchasing power parity",7.8
+31979,Sweden,2017,4,J01-Antibacterials for systemic use,"/capita, US$ exchange rate",8.1
+31980,Sweden,2017,4,M01A-Antiinflammatory and antirheumatic products non-steroids,"Million US$, purchasing power parity",86.0
+31981,Sweden,2017,4,M01A-Antiinflammatory and antirheumatic products non-steroids,Million US$ at exchange rate,89.0
+31982,Sweden,2017,4,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ exchange rate",8.9
+31983,Sweden,2017,4,A10-Drugs used in diabetes,Million of national currency units,1855.0
+31984,Sweden,2017,4,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ purchasing power parity",8.6
+31985,Sweden,2017,4,A-Alimentary tract and metabolism,Million US$ at exchange rate,540.2
+31986,Sweden,2017,4,C-Cardiovascular system,% of total sales,5.8
+31987,Sweden,2017,4,A10-Drugs used in diabetes,"/capita, US$ purchasing power parity",20.8
+31988,Sweden,2017,4,M01A-Antiinflammatory and antirheumatic products non-steroids,Million of national currency units,761.3
+31989,Sweden,2017,4,"C01B-Antiarrhythmics, Class I and III",% of total sales,0.2
+31990,Sweden,2017,4,C09-Agents acting on the Renin-Angiotensin system,% of total sales,1.0
+31991,Sweden,2017,4,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ purchasing power parity",4.9
+31992,Sweden,2017,4,A02A-Antacids,Million of national currency units,98.3
+31993,Sweden,2017,4,A02A-Antacids,"Million US$, purchasing power parity",11.1
+31994,Sweden,2017,4,A02A-Antacids,Million US$ at exchange rate,11.5
+31995,Sweden,2017,4,C09-Agents acting on the Renin-Angiotensin system,Million of national currency units,440.6
+31996,Sweden,2017,4,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million US$ at exchange rate,56.5
+31997,Sweden,2017,4,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million of national currency units,482.8
+31998,Sweden,2017,4,C09-Agents acting on the Renin-Angiotensin system,"Million US$, purchasing power parity",49.8
+31999,Sweden,2017,4,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ exchange rate",5.1
+32000,Sweden,2017,4,C09-Agents acting on the Renin-Angiotensin system,Million US$ at exchange rate,51.5
+32001,Sweden,2017,4,A02A-Antacids,"/capita, US$ exchange rate",1.1
+32002,Sweden,2017,4,R-Respiratory system,Million of national currency units,3523.8
+32003,Sweden,2017,4,R-Respiratory system,Million US$ at exchange rate,412.2
+32004,Sweden,2017,4,R-Respiratory system,"Million US$, purchasing power parity",398.1
+32005,Sweden,2017,4,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ exchange rate",12.3
+32006,Sweden,2017,4,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ purchasing power parity",11.8
+32007,Sweden,2017,4,"H-Systemic hormonal preparations, excluding sex hormones and insulins",% of total sales,2.4
+32008,Sweden,2017,4,A02A-Antacids,% of total sales,0.2
+32009,Sweden,2017,4,A02A-Antacids,"/capita, US$ purchasing power parity",1.1
+32010,Sweden,2017,4,R-Respiratory system,% of total sales,8.1
+32011,Sweden,2017,4,R-Respiratory system,"/capita, US$ exchange rate",41.0
+32012,Sweden,2017,4,R-Respiratory system,"/capita, US$ purchasing power parity",39.6
+32013,Sweden,2017,4,N02-Analgesics,Million US$ at exchange rate,230.4
+32014,Sweden,2017,4,C08-Calcium channel blockers,% of total sales,0.5
+32015,Sweden,2017,4,N02-Analgesics,Million of national currency units,1969.4
+32016,Sweden,2017,4,N02-Analgesics,"/capita, US$ exchange rate",22.9
+32017,Sweden,2017,4,N02-Analgesics,"/capita, US$ purchasing power parity",22.1
+32018,Sweden,2017,4,N02-Analgesics,"Million US$, purchasing power parity",222.5
+32019,Sweden,2017,4,C08-Calcium channel blockers,Million US$ at exchange rate,23.6
+32020,Sweden,2017,4,C08-Calcium channel blockers,Million of national currency units,202.1
+32021,Sweden,2017,4,C08-Calcium channel blockers,"/capita, US$ purchasing power parity",2.3
+32022,Sweden,2017,4,C08-Calcium channel blockers,"Million US$, purchasing power parity",22.8
+32023,Sweden,2017,4,C08-Calcium channel blockers,"/capita, US$ exchange rate",2.4
+32024,Sweden,2017,4,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),% of total sales,1.1
+32025,Sweden,2017,4,R03-Drugs for obstructive airway diseases,Million of national currency units,1731.2
+32026,Sweden,2017,4,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ purchasing power parity",5.4
+32027,Sweden,2017,4,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"Million US$, purchasing power parity",54.5
+32028,Sweden,2017,4,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ exchange rate",5.6
+32029,Sweden,2017,4,R03-Drugs for obstructive airway diseases,Million US$ at exchange rate,202.5
+32030,Sweden,2017,4,R03-Drugs for obstructive airway diseases,% of total sales,4.0
+32031,Sweden,2017,4,R03-Drugs for obstructive airway diseases,"/capita, US$ purchasing power parity",19.4
+32032,Sweden,2017,4,N02-Analgesics,% of total sales,4.5
+32033,Sweden,2017,4,R03-Drugs for obstructive airway diseases,"Million US$, purchasing power parity",195.6
+32034,Sweden,2017,4,R03-Drugs for obstructive airway diseases,"/capita, US$ exchange rate",20.1
+32035,Sweden,2017,4,G03-Sex hormones and modulators of the genital system,"Million US$, purchasing power parity",104.7
+32036,Sweden,2017,4,G03-Sex hormones and modulators of the genital system,"/capita, US$ purchasing power parity",10.4
+32037,Sweden,2017,4,G03-Sex hormones and modulators of the genital system,"/capita, US$ exchange rate",10.8
+32038,Sweden,2017,4,G-Genito urinary system and sex hormones,Million of national currency units,1719.5
+32039,Sweden,2017,4,G03-Sex hormones and modulators of the genital system,Million of national currency units,927.0
+32040,Sweden,2017,4,G03-Sex hormones and modulators of the genital system,Million US$ at exchange rate,108.4
+32041,Sweden,2017,4,N06A-Antidepressants,"Million US$, purchasing power parity",69.9
+32042,Sweden,2017,4,N06A-Antidepressants,"/capita, US$ exchange rate",7.2
+32043,Sweden,2017,4,G03-Sex hormones and modulators of the genital system,% of total sales,2.1
+32044,Sweden,2017,4,N06A-Antidepressants,Million of national currency units,618.9
+32045,Sweden,2017,4,N06A-Antidepressants,Million US$ at exchange rate,72.4
+32046,Sweden,2017,4,N05C-Hypnotics and sedatives,"Million US$, purchasing power parity",59.2
+32047,Sweden,2017,4,N05C-Hypnotics and sedatives,Million US$ at exchange rate,61.3
+32048,Sweden,2017,4,N05C-Hypnotics and sedatives,% of total sales,1.2
+32049,Sweden,2017,4,N05C-Hypnotics and sedatives,"/capita, US$ exchange rate",6.1
+32050,Sweden,2017,4,N05C-Hypnotics and sedatives,"/capita, US$ purchasing power parity",5.9
+32051,Sweden,2017,4,N05C-Hypnotics and sedatives,Million of national currency units,523.8
+32052,Sweden,2017,4,G-Genito urinary system and sex hormones,"Million US$, purchasing power parity",194.2
+32053,Sweden,2017,4,G-Genito urinary system and sex hormones,Million US$ at exchange rate,201.1
+32054,Sweden,2017,4,G-Genito urinary system and sex hormones,"/capita, US$ exchange rate",20.0
+32055,Sweden,2017,4,G-Genito urinary system and sex hormones,% of total sales,3.9
+32056,Sweden,2017,4,G-Genito urinary system and sex hormones,"/capita, US$ purchasing power parity",19.3
+32057,Sweden,2017,4,N06A-Antidepressants,"/capita, US$ purchasing power parity",7.0
+32058,Sweden,2017,4,N05B-Anxiolytics,"/capita, US$ purchasing power parity",2.2
+32059,Sweden,2017,4,N05B-Anxiolytics,"/capita, US$ exchange rate",2.3
+32060,Sweden,2017,4,C10-Lipid modifying agents,Million US$ at exchange rate,68.7
+32061,Sweden,2017,4,C10-Lipid modifying agents,Million of national currency units,587.3
+32062,Sweden,2017,4,N05B-Anxiolytics,% of total sales,0.5
+32063,Sweden,2017,4,N05B-Anxiolytics,"Million US$, purchasing power parity",22.3
+32064,Sweden,2017,4,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million US$ at exchange rate,123.4
+32065,Sweden,2017,4,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million of national currency units,1054.6
+32066,Sweden,2017,4,"H-Systemic hormonal preparations, excluding sex hormones and insulins","Million US$, purchasing power parity",119.1
+32067,Sweden,2017,4,N05B-Anxiolytics,Million US$ at exchange rate,23.0
+32068,Sweden,2017,4,N05B-Anxiolytics,Million of national currency units,197.0
+32069,Sweden,2017,4,B-Blood and blood forming organs,"Million US$, purchasing power parity",485.1
+32070,Sweden,2017,4,B-Blood and blood forming organs,Million US$ at exchange rate,502.3
+32071,Sweden,2017,4,B-Blood and blood forming organs,"/capita, US$ exchange rate",49.9
+32072,Sweden,2017,4,N06A-Antidepressants,% of total sales,1.4
+32073,Sweden,2017,4,B-Blood and blood forming organs,Million of national currency units,4294.4
+32074,Sweden,2017,4,C10-Lipid modifying agents,"/capita, US$ purchasing power parity",6.6
+32075,Sweden,2017,4,C10-Lipid modifying agents,"/capita, US$ exchange rate",6.8
+32076,Sweden,2017,4,C10-Lipid modifying agents,"Million US$, purchasing power parity",66.3
+32077,Sweden,2017,4,B-Blood and blood forming organs,"/capita, US$ purchasing power parity",48.2
+32078,Sweden,2017,4,B-Blood and blood forming organs,% of total sales,9.8
+32079,Sweden,2017,4,C10-Lipid modifying agents,% of total sales,1.3
+32080,Sweden,2017,4,J-Antiinfectives for systemic use,Million of national currency units,3285.5
+32081,Sweden,2017,4,J-Antiinfectives for systemic use,"/capita, US$ exchange rate",38.2
+32082,Sweden,2017,4,J-Antiinfectives for systemic use,"/capita, US$ purchasing power parity",36.9
+32083,Sweden,2017,4,N-Nervous system,"/capita, US$ exchange rate",88.1
+32084,Sweden,2017,4,N-Nervous system,"/capita, US$ purchasing power parity",85.1
+32085,Sweden,2017,4,C07-Beta blocking agents,Million of national currency units,397.1
+32086,Sweden,2017,4,N-Nervous system,% of total sales,17.3
+32087,Sweden,2017,4,C07-Beta blocking agents,Million US$ at exchange rate,46.4
+32088,Sweden,2017,4,C07-Beta blocking agents,"/capita, US$ exchange rate",4.6
+32089,Sweden,2017,4,J-Antiinfectives for systemic use,% of total sales,7.5
+32090,Sweden,2017,4,C07-Beta blocking agents,"Million US$, purchasing power parity",44.9
+32091,Sweden,2017,4,C07-Beta blocking agents,"/capita, US$ purchasing power parity",4.5
+32092,Sweden,2017,4,C07-Beta blocking agents,% of total sales,0.9
+32093,Sweden,2017,4,J-Antiinfectives for systemic use,Million US$ at exchange rate,384.3
+32094,Sweden,2017,4,J-Antiinfectives for systemic use,"Million US$, purchasing power parity",371.1
+32095,Sweden,2017,4,N-Nervous system,Million of national currency units,7573.2
+32096,Sweden,2017,4,N-Nervous system,Million US$ at exchange rate,885.9
+32097,Sweden,2017,4,N-Nervous system,"Million US$, purchasing power parity",855.5
+32098,Sweden,2011,5,"C01B-Antiarrhythmics, Class I and III","/capita, US$ purchasing power parity",0.6
+32099,Sweden,2011,5,A-Alimentary tract and metabolism,"Million US$, purchasing power parity",415.6
+32100,Sweden,2011,5,J01-Antibacterials for systemic use,"Million US$, purchasing power parity",105.6
+32101,Sweden,2011,5,C03-Diuretics,"Million US$, purchasing power parity",30.0
+32102,Sweden,2011,5,C03-Diuretics,Million of national currency units,265.3
+32103,Sweden,2011,5,C03-Diuretics,"/capita, US$ exchange rate",4.3
+32104,Sweden,2011,5,C03-Diuretics,Million US$ at exchange rate,40.9
+32105,Sweden,2011,5,C-Cardiovascular system,"Million US$, purchasing power parity",343.3
+32106,Sweden,2011,5,"C01B-Antiarrhythmics, Class I and III","/capita, US$ exchange rate",0.8
+32107,Sweden,2011,5,C03-Diuretics,% of total sales,0.7
+32108,Sweden,2011,5,C03-Diuretics,"/capita, US$ purchasing power parity",3.2
+32109,Sweden,2011,5,A-Alimentary tract and metabolism,% of total sales,10.0
+32110,Sweden,2011,5,"C01B-Antiarrhythmics, Class I and III",Million of national currency units,49.4
+32111,Sweden,2011,5,A-Alimentary tract and metabolism,"/capita, US$ exchange rate",59.9
+32112,Sweden,2011,5,A-Alimentary tract and metabolism,"/capita, US$ purchasing power parity",44.0
+32113,Sweden,2011,5,C02-Antihypertensives,"/capita, US$ exchange rate",2.4
+32114,Sweden,2011,5,C02-Antihypertensives,Million of national currency units,145.3
+32115,Sweden,2011,5,J01-Antibacterials for systemic use,Million of national currency units,934.3
+32116,Sweden,2011,5,J01-Antibacterials for systemic use,Million US$ at exchange rate,143.9
+32117,Sweden,2011,5,C02-Antihypertensives,"Million US$, purchasing power parity",16.4
+32118,Sweden,2011,5,C02-Antihypertensives,Million US$ at exchange rate,22.4
+32119,Sweden,2011,5,"C01B-Antiarrhythmics, Class I and III",Million US$ at exchange rate,7.6
+32120,Sweden,2011,5,C01A-Cardiac glycosides,"/capita, US$ purchasing power parity",0.2
+32121,Sweden,2011,5,C01A-Cardiac glycosides,"/capita, US$ exchange rate",0.2
+32122,Sweden,2011,5,C-Cardiovascular system,Million US$ at exchange rate,467.5
+32123,Sweden,2011,5,C-Cardiovascular system,Million of national currency units,3035.7
+32124,Sweden,2011,5,C01A-Cardiac glycosides,% of total sales,0.0
+32125,Sweden,2011,5,C01A-Cardiac glycosides,Million of national currency units,13.1
+32126,Sweden,2011,5,"C01B-Antiarrhythmics, Class I and III","Million US$, purchasing power parity",5.6
+32127,Sweden,2011,5,C01A-Cardiac glycosides,"Million US$, purchasing power parity",1.5
+32128,Sweden,2011,5,C01A-Cardiac glycosides,Million US$ at exchange rate,2.0
+32129,Sweden,2011,5,C02-Antihypertensives,"/capita, US$ purchasing power parity",1.7
+32130,Sweden,2011,5,Total pharmaceutical sales,Million US$ at exchange rate,5664.4
+32131,Sweden,2011,5,Total pharmaceutical sales,Million of national currency units,36781.9
+32132,Sweden,2011,5,A10-Drugs used in diabetes,"Million US$, purchasing power parity",149.5
+32133,Sweden,2011,5,C02-Antihypertensives,% of total sales,0.4
+32134,Sweden,2011,5,M01A-Antiinflammatory and antirheumatic products non-steroids,% of total sales,1.9
+32135,Sweden,2011,5,A10-Drugs used in diabetes,"/capita, US$ exchange rate",21.6
+32136,Sweden,2011,5,A10-Drugs used in diabetes,"/capita, US$ purchasing power parity",15.8
+32137,Sweden,2011,5,M-Musculo-skeletal system,"/capita, US$ exchange rate",19.3
+32138,Sweden,2011,5,M-Musculo-skeletal system,"/capita, US$ purchasing power parity",14.1
+32139,Sweden,2011,5,M-Musculo-skeletal system,Million US$ at exchange rate,182.0
+32140,Sweden,2011,5,M-Musculo-skeletal system,"Million US$, purchasing power parity",133.6
+32141,Sweden,2011,5,Total pharmaceutical sales,"/capita, US$ purchasing power parity",440.1
+32142,Sweden,2011,5,Total pharmaceutical sales,"/capita, US$ exchange rate",599.5
+32143,Sweden,2011,5,Total pharmaceutical sales,"Million US$, purchasing power parity",4158.9
+32144,Sweden,2011,5,M-Musculo-skeletal system,% of total sales,3.2
+32145,Sweden,2011,5,A10-Drugs used in diabetes,Million US$ at exchange rate,203.7
+32146,Sweden,2011,5,C-Cardiovascular system,"/capita, US$ exchange rate",49.5
+32147,Sweden,2011,5,A10-Drugs used in diabetes,% of total sales,3.6
+32148,Sweden,2011,5,C-Cardiovascular system,"/capita, US$ purchasing power parity",36.3
+32149,Sweden,2011,5,A-Alimentary tract and metabolism,Million of national currency units,3675.8
+32150,Sweden,2011,5,A-Alimentary tract and metabolism,Million US$ at exchange rate,566.1
+32151,Sweden,2011,5,J01-Antibacterials for systemic use,"/capita, US$ exchange rate",15.2
+32152,Sweden,2011,5,J01-Antibacterials for systemic use,% of total sales,2.5
+32153,Sweden,2011,5,M-Musculo-skeletal system,Million of national currency units,1181.9
+32154,Sweden,2011,5,J01-Antibacterials for systemic use,"/capita, US$ purchasing power parity",11.2
+32155,Sweden,2011,5,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ exchange rate",11.6
+32156,Sweden,2011,5,M01A-Antiinflammatory and antirheumatic products non-steroids,"Million US$, purchasing power parity",80.3
+32157,Sweden,2011,5,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ purchasing power parity",8.5
+32158,Sweden,2011,5,M01A-Antiinflammatory and antirheumatic products non-steroids,Million US$ at exchange rate,109.3
+32159,Sweden,2011,5,"C01B-Antiarrhythmics, Class I and III",% of total sales,0.1
+32160,Sweden,2011,5,C-Cardiovascular system,% of total sales,8.3
+32161,Sweden,2011,5,M01A-Antiinflammatory and antirheumatic products non-steroids,Million of national currency units,710.0
+32162,Sweden,2011,5,A10-Drugs used in diabetes,Million of national currency units,1322.4
+32163,Sweden,2011,5,N-Nervous system,Million of national currency units,7595.8
+32164,Sweden,2011,5,A02A-Antacids,Million of national currency units,70.7
+32165,Sweden,2011,5,C09-Agents acting on the Renin-Angiotensin system,% of total sales,2.4
+32166,Sweden,2011,5,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ purchasing power parity",10.6
+32167,Sweden,2011,5,A02A-Antacids,"/capita, US$ exchange rate",1.2
+32168,Sweden,2011,5,A02A-Antacids,"Million US$, purchasing power parity",8.0
+32169,Sweden,2011,5,A02A-Antacids,Million US$ at exchange rate,10.9
+32170,Sweden,2011,5,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million of national currency units,560.8
+32171,Sweden,2011,5,C09-Agents acting on the Renin-Angiotensin system,Million of national currency units,885.6
+32172,Sweden,2011,5,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million US$ at exchange rate,86.4
+32173,Sweden,2011,5,C09-Agents acting on the Renin-Angiotensin system,Million US$ at exchange rate,136.4
+32174,Sweden,2011,5,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ exchange rate",14.4
+32175,Sweden,2011,5,C09-Agents acting on the Renin-Angiotensin system,"Million US$, purchasing power parity",100.1
+32176,Sweden,2011,5,R-Respiratory system,Million US$ at exchange rate,530.9
+32177,Sweden,2011,5,R-Respiratory system,"Million US$, purchasing power parity",389.8
+32178,Sweden,2011,5,R-Respiratory system,Million of national currency units,3447.6
+32179,Sweden,2011,5,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ purchasing power parity",11.2
+32180,Sweden,2011,5,"H-Systemic hormonal preparations, excluding sex hormones and insulins",% of total sales,2.5
+32181,Sweden,2011,5,A02A-Antacids,% of total sales,0.2
+32182,Sweden,2011,5,R-Respiratory system,"/capita, US$ purchasing power parity",41.3
+32183,Sweden,2011,5,R-Respiratory system,"/capita, US$ exchange rate",56.2
+32184,Sweden,2011,5,R-Respiratory system,% of total sales,9.4
+32185,Sweden,2011,5,N02-Analgesics,Million US$ at exchange rate,310.5
+32186,Sweden,2011,5,N02-Analgesics,Million of national currency units,2016.5
+32187,Sweden,2011,5,N02-Analgesics,"Million US$, purchasing power parity",228.0
+32188,Sweden,2011,5,N02-Analgesics,"/capita, US$ purchasing power parity",24.1
+32189,Sweden,2011,5,N02-Analgesics,"/capita, US$ exchange rate",32.9
+32190,Sweden,2011,5,C08-Calcium channel blockers,% of total sales,0.5
+32191,Sweden,2011,5,C08-Calcium channel blockers,Million US$ at exchange rate,30.2
+32192,Sweden,2011,5,C08-Calcium channel blockers,"Million US$, purchasing power parity",22.1
+32193,Sweden,2011,5,J-Antiinfectives for systemic use,Million of national currency units,2551.0
+32194,Sweden,2011,5,C08-Calcium channel blockers,Million of national currency units,195.8
+32195,Sweden,2011,5,C08-Calcium channel blockers,"/capita, US$ purchasing power parity",2.3
+32196,Sweden,2011,5,C08-Calcium channel blockers,"/capita, US$ exchange rate",3.2
+32197,Sweden,2011,5,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),% of total sales,1.5
+32198,Sweden,2011,5,R03-Drugs for obstructive airway diseases,Million US$ at exchange rate,308.0
+32199,Sweden,2011,5,R03-Drugs for obstructive airway diseases,Million of national currency units,1999.8
+32200,Sweden,2011,5,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ exchange rate",9.1
+32201,Sweden,2011,5,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"Million US$, purchasing power parity",63.4
+32202,Sweden,2011,5,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ purchasing power parity",6.7
+32203,Sweden,2011,5,R03-Drugs for obstructive airway diseases,% of total sales,5.4
+32204,Sweden,2011,5,N02-Analgesics,% of total sales,5.5
+32205,Sweden,2011,5,R03-Drugs for obstructive airway diseases,"Million US$, purchasing power parity",226.1
+32206,Sweden,2011,5,R03-Drugs for obstructive airway diseases,"/capita, US$ purchasing power parity",23.9
+32207,Sweden,2011,5,R03-Drugs for obstructive airway diseases,"/capita, US$ exchange rate",32.6
+32208,Sweden,2011,5,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ exchange rate",15.2
+32209,Sweden,2011,5,G03-Sex hormones and modulators of the genital system,"/capita, US$ exchange rate",14.6
+32210,Sweden,2011,5,G03-Sex hormones and modulators of the genital system,"Million US$, purchasing power parity",101.6
+32211,Sweden,2011,5,G03-Sex hormones and modulators of the genital system,"/capita, US$ purchasing power parity",10.8
+32212,Sweden,2011,5,G03-Sex hormones and modulators of the genital system,Million of national currency units,898.8
+32213,Sweden,2011,5,G-Genito urinary system and sex hormones,Million of national currency units,1722.7
+32214,Sweden,2011,5,G03-Sex hormones and modulators of the genital system,Million US$ at exchange rate,138.4
+32215,Sweden,2011,5,N06A-Antidepressants,"Million US$, purchasing power parity",74.7
+32216,Sweden,2011,5,N06A-Antidepressants,"/capita, US$ exchange rate",10.8
+32217,Sweden,2011,5,N06A-Antidepressants,"/capita, US$ purchasing power parity",7.9
+32218,Sweden,2011,5,G03-Sex hormones and modulators of the genital system,% of total sales,2.4
+32219,Sweden,2011,5,N06A-Antidepressants,Million of national currency units,660.8
+32220,Sweden,2011,5,N06A-Antidepressants,Million US$ at exchange rate,101.8
+32221,Sweden,2011,5,N05C-Hypnotics and sedatives,"Million US$, purchasing power parity",31.7
+32222,Sweden,2011,5,N05C-Hypnotics and sedatives,"/capita, US$ exchange rate",4.6
+32223,Sweden,2011,5,N05C-Hypnotics and sedatives,Million US$ at exchange rate,43.2
+32224,Sweden,2011,5,N05C-Hypnotics and sedatives,% of total sales,0.8
+32225,Sweden,2011,5,N05C-Hypnotics and sedatives,"/capita, US$ purchasing power parity",3.4
+32226,Sweden,2011,5,G-Genito urinary system and sex hormones,"/capita, US$ exchange rate",28.1
+32227,Sweden,2011,5,G-Genito urinary system and sex hormones,Million US$ at exchange rate,265.3
+32228,Sweden,2011,5,G-Genito urinary system and sex hormones,"Million US$, purchasing power parity",194.8
+32229,Sweden,2011,5,N05C-Hypnotics and sedatives,Million of national currency units,280.4
+32230,Sweden,2011,5,G-Genito urinary system and sex hormones,% of total sales,4.7
+32231,Sweden,2011,5,G-Genito urinary system and sex hormones,"/capita, US$ purchasing power parity",20.6
+32232,Sweden,2011,5,N05B-Anxiolytics,"/capita, US$ purchasing power parity",2.3
+32233,Sweden,2011,5,N05B-Anxiolytics,% of total sales,0.5
+32234,Sweden,2011,5,N05B-Anxiolytics,"/capita, US$ exchange rate",3.1
+32235,Sweden,2011,5,C10-Lipid modifying agents,Million US$ at exchange rate,118.2
+32236,Sweden,2011,5,C10-Lipid modifying agents,Million of national currency units,767.3
+32237,Sweden,2011,5,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million US$ at exchange rate,144.0
+32238,Sweden,2011,5,"H-Systemic hormonal preparations, excluding sex hormones and insulins","Million US$, purchasing power parity",105.7
+32239,Sweden,2011,5,N05B-Anxiolytics,"Million US$, purchasing power parity",21.5
+32240,Sweden,2011,5,N05B-Anxiolytics,Million US$ at exchange rate,29.3
+32241,Sweden,2011,5,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million of national currency units,934.9
+32242,Sweden,2011,5,N05B-Anxiolytics,Million of national currency units,190.1
+32243,Sweden,2011,5,C10-Lipid modifying agents,"Million US$, purchasing power parity",86.8
+32244,Sweden,2011,5,B-Blood and blood forming organs,"Million US$, purchasing power parity",358.4
+32245,Sweden,2011,5,B-Blood and blood forming organs,"/capita, US$ exchange rate",51.7
+32246,Sweden,2011,5,N06A-Antidepressants,% of total sales,1.8
+32247,Sweden,2011,5,B-Blood and blood forming organs,Million US$ at exchange rate,488.1
+32248,Sweden,2011,5,B-Blood and blood forming organs,Million of national currency units,3169.6
+32249,Sweden,2011,5,B-Blood and blood forming organs,"/capita, US$ purchasing power parity",37.9
+32250,Sweden,2011,5,C10-Lipid modifying agents,"/capita, US$ purchasing power parity",9.2
+32251,Sweden,2011,5,C10-Lipid modifying agents,"/capita, US$ exchange rate",12.5
+32252,Sweden,2011,5,B-Blood and blood forming organs,% of total sales,8.6
+32253,Sweden,2011,5,C10-Lipid modifying agents,% of total sales,2.1
+32254,Sweden,2011,5,A02A-Antacids,"/capita, US$ purchasing power parity",0.8
+32255,Sweden,2011,5,J-Antiinfectives for systemic use,"/capita, US$ purchasing power parity",30.5
+32256,Sweden,2011,5,N-Nervous system,% of total sales,20.7
+32257,Sweden,2011,5,J-Antiinfectives for systemic use,% of total sales,6.9
+32258,Sweden,2011,5,N-Nervous system,"/capita, US$ exchange rate",123.8
+32259,Sweden,2011,5,N-Nervous system,"/capita, US$ purchasing power parity",90.9
+32260,Sweden,2011,5,J-Antiinfectives for systemic use,"/capita, US$ exchange rate",41.6
+32261,Sweden,2011,5,C07-Beta blocking agents,Million US$ at exchange rate,62.1
+32262,Sweden,2011,5,C07-Beta blocking agents,Million of national currency units,403.0
+32263,Sweden,2011,5,C07-Beta blocking agents,"/capita, US$ exchange rate",6.6
+32264,Sweden,2011,5,C07-Beta blocking agents,"Million US$, purchasing power parity",45.6
+32265,Sweden,2011,5,C07-Beta blocking agents,% of total sales,1.1
+32266,Sweden,2011,5,C07-Beta blocking agents,"/capita, US$ purchasing power parity",4.8
+32267,Sweden,2011,5,J-Antiinfectives for systemic use,"Million US$, purchasing power parity",288.4
+32268,Sweden,2011,5,N-Nervous system,Million US$ at exchange rate,1169.7
+32269,Sweden,2011,5,J-Antiinfectives for systemic use,Million US$ at exchange rate,392.9
+32270,Sweden,2011,5,N-Nervous system,"Million US$, purchasing power parity",858.9
+32271,Sweden,2012,5,"C01B-Antiarrhythmics, Class I and III","/capita, US$ purchasing power parity",0.6
+32272,Sweden,2012,5,A-Alimentary tract and metabolism,"Million US$, purchasing power parity",431.2
+32273,Sweden,2012,5,J01-Antibacterials for systemic use,"Million US$, purchasing power parity",98.3
+32274,Sweden,2012,5,"C01B-Antiarrhythmics, Class I and III","/capita, US$ exchange rate",0.8
+32275,Sweden,2012,5,C03-Diuretics,"Million US$, purchasing power parity",29.9
+32276,Sweden,2012,5,C03-Diuretics,Million of national currency units,259.0
+32277,Sweden,2012,5,C03-Diuretics,Million US$ at exchange rate,38.2
+32278,Sweden,2012,5,C03-Diuretics,"/capita, US$ exchange rate",4.0
+32279,Sweden,2012,5,C-Cardiovascular system,"Million US$, purchasing power parity",293.9
+32280,Sweden,2012,5,C03-Diuretics,% of total sales,0.7
+32281,Sweden,2012,5,C03-Diuretics,"/capita, US$ purchasing power parity",3.1
+32282,Sweden,2012,5,A-Alimentary tract and metabolism,% of total sales,10.3
+32283,Sweden,2012,5,"C01B-Antiarrhythmics, Class I and III",Million of national currency units,50.6
+32284,Sweden,2012,5,A-Alimentary tract and metabolism,"/capita, US$ purchasing power parity",45.3
+32285,Sweden,2012,5,C02-Antihypertensives,"/capita, US$ exchange rate",2.3
+32286,Sweden,2012,5,A-Alimentary tract and metabolism,"/capita, US$ exchange rate",57.9
+32287,Sweden,2012,5,C02-Antihypertensives,Million of national currency units,147.5
+32288,Sweden,2012,5,J01-Antibacterials for systemic use,Million of national currency units,850.4
+32289,Sweden,2012,5,J01-Antibacterials for systemic use,Million US$ at exchange rate,125.5
+32290,Sweden,2012,5,C02-Antihypertensives,"Million US$, purchasing power parity",17.0
+32291,Sweden,2012,5,C02-Antihypertensives,Million US$ at exchange rate,21.8
+32292,Sweden,2012,5,"C01B-Antiarrhythmics, Class I and III",Million US$ at exchange rate,7.5
+32293,Sweden,2012,5,C01A-Cardiac glycosides,"/capita, US$ purchasing power parity",0.2
+32294,Sweden,2012,5,C01A-Cardiac glycosides,"/capita, US$ exchange rate",0.2
+32295,Sweden,2012,5,C-Cardiovascular system,Million US$ at exchange rate,375.4
+32296,Sweden,2012,5,C-Cardiovascular system,Million of national currency units,2543.6
+32297,Sweden,2012,5,C01A-Cardiac glycosides,% of total sales,0.0
+32298,Sweden,2012,5,C01A-Cardiac glycosides,Million of national currency units,13.4
+32299,Sweden,2012,5,"C01B-Antiarrhythmics, Class I and III","Million US$, purchasing power parity",5.8
+32300,Sweden,2012,5,C01A-Cardiac glycosides,"Million US$, purchasing power parity",1.5
+32301,Sweden,2012,5,C01A-Cardiac glycosides,Million US$ at exchange rate,2.0
+32302,Sweden,2012,5,M-Musculo-skeletal system,Million of national currency units,1188.3
+32303,Sweden,2012,5,C02-Antihypertensives,"/capita, US$ purchasing power parity",1.8
+32304,Sweden,2012,5,Total pharmaceutical sales,Million US$ at exchange rate,5330.8
+32305,Sweden,2012,5,Total pharmaceutical sales,Million of national currency units,36116.2
+32306,Sweden,2012,5,C02-Antihypertensives,% of total sales,0.4
+32307,Sweden,2012,5,M01A-Antiinflammatory and antirheumatic products non-steroids,% of total sales,2.0
+32308,Sweden,2012,5,A10-Drugs used in diabetes,"Million US$, purchasing power parity",159.9
+32309,Sweden,2012,5,A10-Drugs used in diabetes,"/capita, US$ exchange rate",21.5
+32310,Sweden,2012,5,Total pharmaceutical sales,"Million US$, purchasing power parity",4173.0
+32311,Sweden,2012,5,M-Musculo-skeletal system,"/capita, US$ exchange rate",18.4
+32312,Sweden,2012,5,M-Musculo-skeletal system,"/capita, US$ purchasing power parity",14.4
+32313,Sweden,2012,5,M-Musculo-skeletal system,"Million US$, purchasing power parity",137.3
+32314,Sweden,2012,5,M-Musculo-skeletal system,Million US$ at exchange rate,175.4
+32315,Sweden,2012,5,Total pharmaceutical sales,"/capita, US$ exchange rate",560.0
+32316,Sweden,2012,5,Total pharmaceutical sales,"/capita, US$ purchasing power parity",438.4
+32317,Sweden,2012,5,M-Musculo-skeletal system,% of total sales,3.3
+32318,Sweden,2012,5,A10-Drugs used in diabetes,Million US$ at exchange rate,204.3
+32319,Sweden,2012,5,C-Cardiovascular system,"/capita, US$ exchange rate",39.4
+32320,Sweden,2012,5,A10-Drugs used in diabetes,% of total sales,3.8
+32321,Sweden,2012,5,C-Cardiovascular system,"/capita, US$ purchasing power parity",30.9
+32322,Sweden,2012,5,A-Alimentary tract and metabolism,Million of national currency units,3732.0
+32323,Sweden,2012,5,A-Alimentary tract and metabolism,Million US$ at exchange rate,550.8
+32324,Sweden,2012,5,J01-Antibacterials for systemic use,"/capita, US$ exchange rate",13.2
+32325,Sweden,2012,5,J01-Antibacterials for systemic use,% of total sales,2.4
+32326,Sweden,2012,5,J01-Antibacterials for systemic use,"/capita, US$ purchasing power parity",10.3
+32327,Sweden,2012,5,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ exchange rate",11.2
+32328,Sweden,2012,5,M01A-Antiinflammatory and antirheumatic products non-steroids,"Million US$, purchasing power parity",83.4
+32329,Sweden,2012,5,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ purchasing power parity",8.8
+32330,Sweden,2012,5,"C01B-Antiarrhythmics, Class I and III",% of total sales,0.1
+32331,Sweden,2012,5,C-Cardiovascular system,% of total sales,7.0
+32332,Sweden,2012,5,A10-Drugs used in diabetes,"/capita, US$ purchasing power parity",16.8
+32333,Sweden,2012,5,M01A-Antiinflammatory and antirheumatic products non-steroids,Million US$ at exchange rate,106.6
+32334,Sweden,2012,5,M01A-Antiinflammatory and antirheumatic products non-steroids,Million of national currency units,722.2
+32335,Sweden,2012,5,A10-Drugs used in diabetes,Million of national currency units,1384.0
+32336,Sweden,2012,5,A02A-Antacids,Million of national currency units,70.3
+32337,Sweden,2012,5,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ purchasing power parity",7.6
+32338,Sweden,2012,5,C09-Agents acting on the Renin-Angiotensin system,% of total sales,1.7
+32339,Sweden,2012,5,A02A-Antacids,"Million US$, purchasing power parity",8.1
+32340,Sweden,2012,5,A02A-Antacids,"/capita, US$ exchange rate",1.1
+32341,Sweden,2012,5,A02A-Antacids,Million US$ at exchange rate,10.4
+32342,Sweden,2012,5,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million of national currency units,536.8
+32343,Sweden,2012,5,C09-Agents acting on the Renin-Angiotensin system,Million of national currency units,627.9
+32344,Sweden,2012,5,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million US$ at exchange rate,79.2
+32345,Sweden,2012,5,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ exchange rate",9.7
+32346,Sweden,2012,5,C09-Agents acting on the Renin-Angiotensin system,Million US$ at exchange rate,92.7
+32347,Sweden,2012,5,C09-Agents acting on the Renin-Angiotensin system,"Million US$, purchasing power parity",72.5
+32348,Sweden,2012,5,R-Respiratory system,Million US$ at exchange rate,527.3
+32349,Sweden,2012,5,R-Respiratory system,Million of national currency units,3572.8
+32350,Sweden,2012,5,R-Respiratory system,"Million US$, purchasing power parity",412.8
+32351,Sweden,2012,5,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ purchasing power parity",11.7
+32352,Sweden,2012,5,"H-Systemic hormonal preparations, excluding sex hormones and insulins",% of total sales,2.7
+32353,Sweden,2012,5,A02A-Antacids,% of total sales,0.2
+32354,Sweden,2012,5,A02A-Antacids,"/capita, US$ purchasing power parity",0.9
+32355,Sweden,2012,5,R-Respiratory system,"/capita, US$ exchange rate",55.4
+32356,Sweden,2012,5,R-Respiratory system,"/capita, US$ purchasing power parity",43.4
+32357,Sweden,2012,5,R-Respiratory system,% of total sales,9.9
+32358,Sweden,2012,5,N02-Analgesics,Million US$ at exchange rate,285.8
+32359,Sweden,2012,5,N02-Analgesics,Million of national currency units,1936.1
+32360,Sweden,2012,5,N02-Analgesics,"/capita, US$ purchasing power parity",23.5
+32361,Sweden,2012,5,N02-Analgesics,"Million US$, purchasing power parity",223.7
+32362,Sweden,2012,5,N02-Analgesics,"/capita, US$ exchange rate",30.0
+32363,Sweden,2012,5,C08-Calcium channel blockers,% of total sales,0.5
+32364,Sweden,2012,5,C08-Calcium channel blockers,Million US$ at exchange rate,28.5
+32365,Sweden,2012,5,C08-Calcium channel blockers,"Million US$, purchasing power parity",22.3
+32366,Sweden,2012,5,J-Antiinfectives for systemic use,Million of national currency units,2540.3
+32367,Sweden,2012,5,C08-Calcium channel blockers,Million of national currency units,193.0
+32368,Sweden,2012,5,C08-Calcium channel blockers,"/capita, US$ purchasing power parity",2.3
+32369,Sweden,2012,5,C08-Calcium channel blockers,"/capita, US$ exchange rate",3.0
+32370,Sweden,2012,5,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),% of total sales,1.5
+32371,Sweden,2012,5,R03-Drugs for obstructive airway diseases,Million of national currency units,2058.9
+32372,Sweden,2012,5,R03-Drugs for obstructive airway diseases,Million US$ at exchange rate,303.9
+32373,Sweden,2012,5,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"Million US$, purchasing power parity",62.0
+32374,Sweden,2012,5,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ exchange rate",8.3
+32375,Sweden,2012,5,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ purchasing power parity",6.5
+32376,Sweden,2012,5,R03-Drugs for obstructive airway diseases,% of total sales,5.7
+32377,Sweden,2012,5,N02-Analgesics,% of total sales,5.4
+32378,Sweden,2012,5,R03-Drugs for obstructive airway diseases,"/capita, US$ purchasing power parity",25.0
+32379,Sweden,2012,5,R03-Drugs for obstructive airway diseases,"Million US$, purchasing power parity",237.9
+32380,Sweden,2012,5,R03-Drugs for obstructive airway diseases,"/capita, US$ exchange rate",31.9
+32381,Sweden,2012,5,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ exchange rate",15.0
+32382,Sweden,2012,5,G03-Sex hormones and modulators of the genital system,"/capita, US$ exchange rate",14.3
+32383,Sweden,2012,5,G03-Sex hormones and modulators of the genital system,"Million US$, purchasing power parity",106.6
+32384,Sweden,2012,5,G03-Sex hormones and modulators of the genital system,"/capita, US$ purchasing power parity",11.2
+32385,Sweden,2012,5,G03-Sex hormones and modulators of the genital system,Million of national currency units,922.9
+32386,Sweden,2012,5,G-Genito urinary system and sex hormones,Million of national currency units,1757.1
+32387,Sweden,2012,5,G03-Sex hormones and modulators of the genital system,Million US$ at exchange rate,136.2
+32388,Sweden,2012,5,N06A-Antidepressants,"Million US$, purchasing power parity",78.4
+32389,Sweden,2012,5,N06A-Antidepressants,"/capita, US$ purchasing power parity",8.2
+32390,Sweden,2012,5,N06A-Antidepressants,"/capita, US$ exchange rate",10.5
+32391,Sweden,2012,5,G03-Sex hormones and modulators of the genital system,% of total sales,2.6
+32392,Sweden,2012,5,N06A-Antidepressants,Million of national currency units,678.8
+32393,Sweden,2012,5,N06A-Antidepressants,Million US$ at exchange rate,100.2
+32394,Sweden,2012,5,N05C-Hypnotics and sedatives,"Million US$, purchasing power parity",34.5
+32395,Sweden,2012,5,N05C-Hypnotics and sedatives,"/capita, US$ exchange rate",4.6
+32396,Sweden,2012,5,N05C-Hypnotics and sedatives,Million US$ at exchange rate,44.0
+32397,Sweden,2012,5,N05C-Hypnotics and sedatives,% of total sales,0.8
+32398,Sweden,2012,5,N05C-Hypnotics and sedatives,"/capita, US$ purchasing power parity",3.6
+32399,Sweden,2012,5,G-Genito urinary system and sex hormones,"/capita, US$ exchange rate",27.2
+32400,Sweden,2012,5,G-Genito urinary system and sex hormones,"Million US$, purchasing power parity",203.0
+32401,Sweden,2012,5,G-Genito urinary system and sex hormones,Million US$ at exchange rate,259.3
+32402,Sweden,2012,5,N05C-Hypnotics and sedatives,Million of national currency units,298.3
+32403,Sweden,2012,5,G-Genito urinary system and sex hormones,% of total sales,4.9
+32404,Sweden,2012,5,G-Genito urinary system and sex hormones,"/capita, US$ purchasing power parity",21.3
+32405,Sweden,2012,5,N05B-Anxiolytics,"/capita, US$ purchasing power parity",2.3
+32406,Sweden,2012,5,N05B-Anxiolytics,"/capita, US$ exchange rate",3.0
+32407,Sweden,2012,5,N05B-Anxiolytics,% of total sales,0.5
+32408,Sweden,2012,5,C10-Lipid modifying agents,Million US$ at exchange rate,82.4
+32409,Sweden,2012,5,C10-Lipid modifying agents,Million of national currency units,558.3
+32410,Sweden,2012,5,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million US$ at exchange rate,142.5
+32411,Sweden,2012,5,"H-Systemic hormonal preparations, excluding sex hormones and insulins","Million US$, purchasing power parity",111.6
+32412,Sweden,2012,5,N05B-Anxiolytics,Million US$ at exchange rate,28.3
+32413,Sweden,2012,5,N05B-Anxiolytics,"Million US$, purchasing power parity",22.1
+32414,Sweden,2012,5,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million of national currency units,965.5
+32415,Sweden,2012,5,N05B-Anxiolytics,Million of national currency units,191.6
+32416,Sweden,2012,5,C10-Lipid modifying agents,"Million US$, purchasing power parity",64.5
+32417,Sweden,2012,5,B-Blood and blood forming organs,"Million US$, purchasing power parity",366.5
+32418,Sweden,2012,5,B-Blood and blood forming organs,"/capita, US$ exchange rate",49.2
+32419,Sweden,2012,5,B-Blood and blood forming organs,Million US$ at exchange rate,468.2
+32420,Sweden,2012,5,N06A-Antidepressants,% of total sales,1.9
+32421,Sweden,2012,5,B-Blood and blood forming organs,Million of national currency units,3172.3
+32422,Sweden,2012,5,C10-Lipid modifying agents,"/capita, US$ purchasing power parity",6.8
+32423,Sweden,2012,5,C10-Lipid modifying agents,"/capita, US$ exchange rate",8.7
+32424,Sweden,2012,5,B-Blood and blood forming organs,"/capita, US$ purchasing power parity",38.5
+32425,Sweden,2012,5,B-Blood and blood forming organs,% of total sales,8.8
+32426,Sweden,2012,5,C10-Lipid modifying agents,% of total sales,1.5
+32427,Sweden,2012,5,J-Antiinfectives for systemic use,"/capita, US$ purchasing power parity",30.8
+32428,Sweden,2012,5,N-Nervous system,% of total sales,20.0
+32429,Sweden,2012,5,J-Antiinfectives for systemic use,% of total sales,7.0
+32430,Sweden,2012,5,N-Nervous system,"/capita, US$ exchange rate",112.2
+32431,Sweden,2012,5,N-Nervous system,"/capita, US$ purchasing power parity",87.8
+32432,Sweden,2012,5,J-Antiinfectives for systemic use,"/capita, US$ exchange rate",39.4
+32433,Sweden,2012,5,C07-Beta blocking agents,Million US$ at exchange rate,58.0
+32434,Sweden,2012,5,C07-Beta blocking agents,Million of national currency units,393.0
+32435,Sweden,2012,5,C07-Beta blocking agents,"/capita, US$ exchange rate",6.1
+32436,Sweden,2012,5,C07-Beta blocking agents,"Million US$, purchasing power parity",45.4
+32437,Sweden,2012,5,C07-Beta blocking agents,% of total sales,1.1
+32438,Sweden,2012,5,C07-Beta blocking agents,"/capita, US$ purchasing power parity",4.8
+32439,Sweden,2012,5,J-Antiinfectives for systemic use,"Million US$, purchasing power parity",293.5
+32440,Sweden,2012,5,N-Nervous system,Million US$ at exchange rate,1067.8
+32441,Sweden,2012,5,N-Nervous system,Million of national currency units,7234.7
+32442,Sweden,2012,5,J-Antiinfectives for systemic use,Million US$ at exchange rate,374.9
+32443,Sweden,2012,5,N-Nervous system,"Million US$, purchasing power parity",835.9
+32444,Sweden,2016,4,"C01B-Antiarrhythmics, Class I and III","/capita, US$ purchasing power parity",0.8
+32445,Sweden,2016,4,"C01B-Antiarrhythmics, Class I and III","/capita, US$ exchange rate",0.9
+32446,Sweden,2016,4,J01-Antibacterials for systemic use,Million US$ at exchange rate,84.6
+32447,Sweden,2016,4,J01-Antibacterials for systemic use,"Million US$, purchasing power parity",82.1
+32448,Sweden,2016,4,A-Alimentary tract and metabolism,"Million US$, purchasing power parity",498.4
+32449,Sweden,2016,4,C03-Diuretics,"Million US$, purchasing power parity",25.3
+32450,Sweden,2016,4,C03-Diuretics,Million US$ at exchange rate,26.0
+32451,Sweden,2016,4,C03-Diuretics,Million of national currency units,223.0
+32452,Sweden,2016,4,C03-Diuretics,% of total sales,0.5
+32453,Sweden,2016,4,C03-Diuretics,"/capita, US$ exchange rate",2.6
+32454,Sweden,2016,4,C03-Diuretics,"/capita, US$ purchasing power parity",2.5
+32455,Sweden,2016,4,A-Alimentary tract and metabolism,"/capita, US$ purchasing power parity",50.2
+32456,Sweden,2016,4,A-Alimentary tract and metabolism,% of total sales,10.4
+32457,Sweden,2016,4,"C01B-Antiarrhythmics, Class I and III",Million of national currency units,74.4
+32458,Sweden,2016,4,A-Alimentary tract and metabolism,"/capita, US$ exchange rate",51.8
+32459,Sweden,2016,4,C02-Antihypertensives,Million of national currency units,211.9
+32460,Sweden,2016,4,J01-Antibacterials for systemic use,Million of national currency units,724.5
+32461,Sweden,2016,4,C02-Antihypertensives,"Million US$, purchasing power parity",24.0
+32462,Sweden,2016,4,C02-Antihypertensives,Million US$ at exchange rate,24.7
+32463,Sweden,2016,4,C01A-Cardiac glycosides,"/capita, US$ purchasing power parity",0.1
+32464,Sweden,2016,4,C01A-Cardiac glycosides,"/capita, US$ exchange rate",0.1
+32465,Sweden,2016,4,C-Cardiovascular system,Million of national currency units,2398.2
+32466,Sweden,2016,4,C01A-Cardiac glycosides,% of total sales,0.0
+32467,Sweden,2016,4,"C01B-Antiarrhythmics, Class I and III","Million US$, purchasing power parity",8.4
+32468,Sweden,2016,4,"C01B-Antiarrhythmics, Class I and III",Million US$ at exchange rate,8.7
+32469,Sweden,2016,4,C-Cardiovascular system,Million US$ at exchange rate,280.1
+32470,Sweden,2016,4,C01A-Cardiac glycosides,Million of national currency units,12.7
+32471,Sweden,2016,4,C01A-Cardiac glycosides,"Million US$, purchasing power parity",1.4
+32472,Sweden,2016,4,C01A-Cardiac glycosides,Million US$ at exchange rate,1.5
+32473,Sweden,2016,4,A-Alimentary tract and metabolism,Million US$ at exchange rate,513.6
+32474,Sweden,2016,4,C02-Antihypertensives,"/capita, US$ purchasing power parity",2.4
+32475,Sweden,2016,4,C02-Antihypertensives,"/capita, US$ exchange rate",2.5
+32476,Sweden,2016,4,A10-Drugs used in diabetes,Million US$ at exchange rate,197.1
+32477,Sweden,2016,4,Total pharmaceutical sales,Million US$ at exchange rate,4945.8
+32478,Sweden,2016,4,Total pharmaceutical sales,Million of national currency units,42346.3
+32479,Sweden,2016,4,M01A-Antiinflammatory and antirheumatic products non-steroids,% of total sales,1.9
+32480,Sweden,2016,4,C02-Antihypertensives,% of total sales,0.5
+32481,Sweden,2016,4,A10-Drugs used in diabetes,"Million US$, purchasing power parity",191.3
+32482,Sweden,2016,4,A10-Drugs used in diabetes,"/capita, US$ exchange rate",19.9
+32483,Sweden,2016,4,M-Musculo-skeletal system,"Million US$, purchasing power parity",170.3
+32484,Sweden,2016,4,M-Musculo-skeletal system,"/capita, US$ exchange rate",17.7
+32485,Sweden,2016,4,M-Musculo-skeletal system,Million of national currency units,1502.6
+32486,Sweden,2016,4,M-Musculo-skeletal system,Million US$ at exchange rate,175.5
+32487,Sweden,2016,4,M-Musculo-skeletal system,"/capita, US$ purchasing power parity",17.2
+32488,Sweden,2016,4,Total pharmaceutical sales,"/capita, US$ exchange rate",498.4
+32489,Sweden,2016,4,Total pharmaceutical sales,"Million US$, purchasing power parity",4799.8
+32490,Sweden,2016,4,M-Musculo-skeletal system,% of total sales,3.5
+32491,Sweden,2016,4,Total pharmaceutical sales,"/capita, US$ purchasing power parity",483.7
+32492,Sweden,2016,4,C-Cardiovascular system,"/capita, US$ exchange rate",28.2
+32493,Sweden,2016,4,C-Cardiovascular system,"Million US$, purchasing power parity",271.8
+32494,Sweden,2016,4,A10-Drugs used in diabetes,% of total sales,4.0
+32495,Sweden,2016,4,C-Cardiovascular system,"/capita, US$ purchasing power parity",27.4
+32496,Sweden,2016,4,J01-Antibacterials for systemic use,% of total sales,1.7
+32497,Sweden,2016,4,A-Alimentary tract and metabolism,Million of national currency units,4397.3
+32498,Sweden,2016,4,J01-Antibacterials for systemic use,"/capita, US$ purchasing power parity",8.3
+32499,Sweden,2016,4,J01-Antibacterials for systemic use,"/capita, US$ exchange rate",8.5
+32500,Sweden,2016,4,M01A-Antiinflammatory and antirheumatic products non-steroids,"Million US$, purchasing power parity",90.7
+32501,Sweden,2016,4,M01A-Antiinflammatory and antirheumatic products non-steroids,Million US$ at exchange rate,93.5
+32502,Sweden,2016,4,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ purchasing power parity",9.1
+32503,Sweden,2016,4,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ exchange rate",9.4
+32504,Sweden,2016,4,C-Cardiovascular system,% of total sales,5.7
+32505,Sweden,2016,4,A10-Drugs used in diabetes,"/capita, US$ purchasing power parity",19.3
+32506,Sweden,2016,4,"C01B-Antiarrhythmics, Class I and III",% of total sales,0.2
+32507,Sweden,2016,4,M01A-Antiinflammatory and antirheumatic products non-steroids,Million of national currency units,800.6
+32508,Sweden,2016,4,A10-Drugs used in diabetes,Million of national currency units,1687.7
+32509,Sweden,2016,4,C09-Agents acting on the Renin-Angiotensin system,% of total sales,1.0
+32510,Sweden,2016,4,A02A-Antacids,Million of national currency units,95.9
+32511,Sweden,2016,4,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ purchasing power parity",4.7
+32512,Sweden,2016,4,A02A-Antacids,"Million US$, purchasing power parity",10.9
+32513,Sweden,2016,4,A02A-Antacids,Million US$ at exchange rate,11.2
+32514,Sweden,2016,4,C09-Agents acting on the Renin-Angiotensin system,Million of national currency units,414.0
+32515,Sweden,2016,4,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million of national currency units,493.9
+32516,Sweden,2016,4,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million US$ at exchange rate,57.7
+32517,Sweden,2016,4,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ exchange rate",4.9
+32518,Sweden,2016,4,C09-Agents acting on the Renin-Angiotensin system,"Million US$, purchasing power parity",46.9
+32519,Sweden,2016,4,C09-Agents acting on the Renin-Angiotensin system,Million US$ at exchange rate,48.4
+32520,Sweden,2016,4,R-Respiratory system,Million of national currency units,3456.4
+32521,Sweden,2016,4,R-Respiratory system,"Million US$, purchasing power parity",391.8
+32522,Sweden,2016,4,R-Respiratory system,Million US$ at exchange rate,403.7
+32523,Sweden,2016,4,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ purchasing power parity",11.7
+32524,Sweden,2016,4,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ exchange rate",12.1
+32525,Sweden,2016,4,"H-Systemic hormonal preparations, excluding sex hormones and insulins",% of total sales,2.4
+32526,Sweden,2016,4,A02A-Antacids,% of total sales,0.2
+32527,Sweden,2016,4,A02A-Antacids,"/capita, US$ purchasing power parity",1.1
+32528,Sweden,2016,4,A02A-Antacids,"/capita, US$ exchange rate",1.1
+32529,Sweden,2016,4,R-Respiratory system,"/capita, US$ exchange rate",40.7
+32530,Sweden,2016,4,R-Respiratory system,% of total sales,8.2
+32531,Sweden,2016,4,R-Respiratory system,"/capita, US$ purchasing power parity",39.5
+32532,Sweden,2016,4,N02-Analgesics,Million US$ at exchange rate,235.9
+32533,Sweden,2016,4,N02-Analgesics,Million of national currency units,2020.0
+32534,Sweden,2016,4,C08-Calcium channel blockers,% of total sales,0.5
+32535,Sweden,2016,4,N02-Analgesics,"/capita, US$ purchasing power parity",23.1
+32536,Sweden,2016,4,N02-Analgesics,"/capita, US$ exchange rate",23.8
+32537,Sweden,2016,4,N02-Analgesics,"Million US$, purchasing power parity",229.0
+32538,Sweden,2016,4,C08-Calcium channel blockers,Million US$ at exchange rate,23.4
+32539,Sweden,2016,4,C08-Calcium channel blockers,Million of national currency units,200.3
+32540,Sweden,2016,4,C08-Calcium channel blockers,"Million US$, purchasing power parity",22.7
+32541,Sweden,2016,4,C08-Calcium channel blockers,"/capita, US$ purchasing power parity",2.3
+32542,Sweden,2016,4,C08-Calcium channel blockers,"/capita, US$ exchange rate",2.4
+32543,Sweden,2016,4,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),% of total sales,1.2
+32544,Sweden,2016,4,R03-Drugs for obstructive airway diseases,Million of national currency units,1741.7
+32545,Sweden,2016,4,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"Million US$, purchasing power parity",56.0
+32546,Sweden,2016,4,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ purchasing power parity",5.6
+32547,Sweden,2016,4,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ exchange rate",5.8
+32548,Sweden,2016,4,R03-Drugs for obstructive airway diseases,Million US$ at exchange rate,203.4
+32549,Sweden,2016,4,R03-Drugs for obstructive airway diseases,% of total sales,4.1
+32550,Sweden,2016,4,R03-Drugs for obstructive airway diseases,"/capita, US$ purchasing power parity",19.9
+32551,Sweden,2016,4,N02-Analgesics,% of total sales,4.8
+32552,Sweden,2016,4,R03-Drugs for obstructive airway diseases,"Million US$, purchasing power parity",197.4
+32553,Sweden,2016,4,R03-Drugs for obstructive airway diseases,"/capita, US$ exchange rate",20.5
+32554,Sweden,2016,4,G03-Sex hormones and modulators of the genital system,"Million US$, purchasing power parity",104.8
+32555,Sweden,2016,4,G03-Sex hormones and modulators of the genital system,"/capita, US$ exchange rate",10.9
+32556,Sweden,2016,4,G03-Sex hormones and modulators of the genital system,"/capita, US$ purchasing power parity",10.6
+32557,Sweden,2016,4,G-Genito urinary system and sex hormones,Million of national currency units,1693.7
+32558,Sweden,2016,4,G03-Sex hormones and modulators of the genital system,Million of national currency units,924.5
+32559,Sweden,2016,4,G03-Sex hormones and modulators of the genital system,Million US$ at exchange rate,108.0
+32560,Sweden,2016,4,N06A-Antidepressants,"Million US$, purchasing power parity",66.9
+32561,Sweden,2016,4,N06A-Antidepressants,"/capita, US$ exchange rate",6.9
+32562,Sweden,2016,4,N06A-Antidepressants,Million US$ at exchange rate,68.9
+32563,Sweden,2016,4,G03-Sex hormones and modulators of the genital system,% of total sales,2.2
+32564,Sweden,2016,4,N06A-Antidepressants,Million of national currency units,590.1
+32565,Sweden,2016,4,N05C-Hypnotics and sedatives,"Million US$, purchasing power parity",49.1
+32566,Sweden,2016,4,N05C-Hypnotics and sedatives,Million US$ at exchange rate,50.6
+32567,Sweden,2016,4,N05C-Hypnotics and sedatives,% of total sales,1.0
+32568,Sweden,2016,4,N05C-Hypnotics and sedatives,"/capita, US$ exchange rate",5.1
+32569,Sweden,2016,4,N05C-Hypnotics and sedatives,"/capita, US$ purchasing power parity",5.0
+32570,Sweden,2016,4,N05C-Hypnotics and sedatives,Million of national currency units,433.4
+32571,Sweden,2016,4,G-Genito urinary system and sex hormones,"Million US$, purchasing power parity",192.0
+32572,Sweden,2016,4,G-Genito urinary system and sex hormones,"/capita, US$ exchange rate",19.9
+32573,Sweden,2016,4,G-Genito urinary system and sex hormones,Million US$ at exchange rate,197.8
+32574,Sweden,2016,4,G-Genito urinary system and sex hormones,% of total sales,4.0
+32575,Sweden,2016,4,G-Genito urinary system and sex hormones,"/capita, US$ purchasing power parity",19.3
+32576,Sweden,2016,4,N06A-Antidepressants,"/capita, US$ purchasing power parity",6.7
+32577,Sweden,2016,4,N05B-Anxiolytics,"/capita, US$ purchasing power parity",2.3
+32578,Sweden,2016,4,N05B-Anxiolytics,"/capita, US$ exchange rate",2.3
+32579,Sweden,2016,4,C10-Lipid modifying agents,Million US$ at exchange rate,61.0
+32580,Sweden,2016,4,N05B-Anxiolytics,% of total sales,0.5
+32581,Sweden,2016,4,C10-Lipid modifying agents,Million of national currency units,522.1
+32582,Sweden,2016,4,N05B-Anxiolytics,"Million US$, purchasing power parity",22.5
+32583,Sweden,2016,4,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million US$ at exchange rate,119.9
+32584,Sweden,2016,4,"H-Systemic hormonal preparations, excluding sex hormones and insulins","Million US$, purchasing power parity",116.4
+32585,Sweden,2016,4,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million of national currency units,1026.8
+32586,Sweden,2016,4,N05B-Anxiolytics,Million US$ at exchange rate,23.2
+32587,Sweden,2016,4,N05B-Anxiolytics,Million of national currency units,198.3
+32588,Sweden,2016,4,B-Blood and blood forming organs,"Million US$, purchasing power parity",440.6
+32589,Sweden,2016,4,B-Blood and blood forming organs,Million US$ at exchange rate,454.0
+32590,Sweden,2016,4,B-Blood and blood forming organs,"/capita, US$ exchange rate",45.8
+32591,Sweden,2016,4,N06A-Antidepressants,% of total sales,1.4
+32592,Sweden,2016,4,B-Blood and blood forming organs,Million of national currency units,3887.5
+32593,Sweden,2016,4,C10-Lipid modifying agents,"/capita, US$ purchasing power parity",6.0
+32594,Sweden,2016,4,C10-Lipid modifying agents,"/capita, US$ exchange rate",6.1
+32595,Sweden,2016,4,C10-Lipid modifying agents,"Million US$, purchasing power parity",59.2
+32596,Sweden,2016,4,B-Blood and blood forming organs,"/capita, US$ purchasing power parity",44.4
+32597,Sweden,2016,4,B-Blood and blood forming organs,% of total sales,9.2
+32598,Sweden,2016,4,C10-Lipid modifying agents,% of total sales,1.2
+32599,Sweden,2016,4,J-Antiinfectives for systemic use,"/capita, US$ purchasing power parity",44.4
+32600,Sweden,2016,4,J-Antiinfectives for systemic use,"/capita, US$ exchange rate",45.8
+32601,Sweden,2016,4,N-Nervous system,"/capita, US$ exchange rate",87.2
+32602,Sweden,2016,4,N-Nervous system,"/capita, US$ purchasing power parity",84.7
+32603,Sweden,2016,4,J-Antiinfectives for systemic use,% of total sales,9.2
+32604,Sweden,2016,4,C07-Beta blocking agents,Million of national currency units,394.3
+32605,Sweden,2016,4,N-Nervous system,% of total sales,17.5
+32606,Sweden,2016,4,C07-Beta blocking agents,Million US$ at exchange rate,46.0
+32607,Sweden,2016,4,C07-Beta blocking agents,"/capita, US$ exchange rate",4.6
+32608,Sweden,2016,4,C07-Beta blocking agents,"Million US$, purchasing power parity",44.7
+32609,Sweden,2016,4,C07-Beta blocking agents,"/capita, US$ purchasing power parity",4.5
+32610,Sweden,2016,4,C07-Beta blocking agents,% of total sales,0.9
+32611,Sweden,2016,4,J-Antiinfectives for systemic use,Million US$ at exchange rate,454.2
+32612,Sweden,2016,4,J-Antiinfectives for systemic use,"Million US$, purchasing power parity",440.8
+32613,Sweden,2016,4,J-Antiinfectives for systemic use,Million of national currency units,3888.6
+32614,Sweden,2016,4,N-Nervous system,Million of national currency units,7411.8
+32615,Sweden,2016,4,N-Nervous system,"Million US$, purchasing power parity",840.1
+32616,Sweden,2016,4,N-Nervous system,Million US$ at exchange rate,865.7
+32617,Sweden,2014,5,J01-Antibacterials for systemic use,"Million US$, purchasing power parity",81.4
+32618,Sweden,2014,5,J01-Antibacterials for systemic use,Million US$ at exchange rate,103.5
+32619,Sweden,2014,5,"C01B-Antiarrhythmics, Class I and III","/capita, US$ purchasing power parity",0.7
+32620,Sweden,2014,5,A-Alimentary tract and metabolism,"Million US$, purchasing power parity",440.2
+32621,Sweden,2014,5,"C01B-Antiarrhythmics, Class I and III","/capita, US$ exchange rate",0.9
+32622,Sweden,2014,5,C03-Diuretics,"Million US$, purchasing power parity",29.2
+32623,Sweden,2014,5,C03-Diuretics,Million US$ at exchange rate,37.2
+32624,Sweden,2014,5,C03-Diuretics,Million of national currency units,255.1
+32625,Sweden,2014,5,C03-Diuretics,"/capita, US$ exchange rate",3.8
+32626,Sweden,2014,5,C03-Diuretics,% of total sales,0.7
+32627,Sweden,2014,5,C03-Diuretics,"/capita, US$ purchasing power parity",3.0
+32628,Sweden,2014,5,A-Alimentary tract and metabolism,% of total sales,10.2
+32629,Sweden,2014,5,"C01B-Antiarrhythmics, Class I and III",Million of national currency units,60.5
+32630,Sweden,2014,5,A-Alimentary tract and metabolism,"/capita, US$ purchasing power parity",45.4
+32631,Sweden,2014,5,A-Alimentary tract and metabolism,"/capita, US$ exchange rate",57.8
+32632,Sweden,2014,5,C02-Antihypertensives,Million of national currency units,181.4
+32633,Sweden,2014,5,J01-Antibacterials for systemic use,Million of national currency units,710.3
+32634,Sweden,2014,5,C02-Antihypertensives,"Million US$, purchasing power parity",20.8
+32635,Sweden,2014,5,C02-Antihypertensives,Million US$ at exchange rate,26.4
+32636,Sweden,2014,5,C01A-Cardiac glycosides,"/capita, US$ purchasing power parity",0.2
+32637,Sweden,2014,5,C01A-Cardiac glycosides,"/capita, US$ exchange rate",0.2
+32638,Sweden,2014,5,C-Cardiovascular system,Million US$ at exchange rate,340.8
+32639,Sweden,2014,5,C01A-Cardiac glycosides,% of total sales,0.0
+32640,Sweden,2014,5,C-Cardiovascular system,Million of national currency units,2338.4
+32641,Sweden,2014,5,"C01B-Antiarrhythmics, Class I and III","Million US$, purchasing power parity",6.9
+32642,Sweden,2014,5,"C01B-Antiarrhythmics, Class I and III",Million US$ at exchange rate,8.8
+32643,Sweden,2014,5,C01A-Cardiac glycosides,Million of national currency units,15.9
+32644,Sweden,2014,5,C01A-Cardiac glycosides,"Million US$, purchasing power parity",1.8
+32645,Sweden,2014,5,C01A-Cardiac glycosides,Million US$ at exchange rate,2.3
+32646,Sweden,2014,5,C02-Antihypertensives,"/capita, US$ purchasing power parity",2.1
+32647,Sweden,2014,5,C02-Antihypertensives,"/capita, US$ exchange rate",2.7
+32648,Sweden,2014,5,A10-Drugs used in diabetes,Million US$ at exchange rate,205.6
+32649,Sweden,2014,5,Total pharmaceutical sales,Million US$ at exchange rate,5510.9
+32650,Sweden,2014,5,Total pharmaceutical sales,Million of national currency units,37808.8
+32651,Sweden,2014,5,M01A-Antiinflammatory and antirheumatic products non-steroids,% of total sales,1.9
+32652,Sweden,2014,5,C02-Antihypertensives,% of total sales,0.5
+32653,Sweden,2014,5,A10-Drugs used in diabetes,"Million US$, purchasing power parity",161.7
+32654,Sweden,2014,5,A10-Drugs used in diabetes,"/capita, US$ exchange rate",21.2
+32655,Sweden,2014,5,M-Musculo-skeletal system,"/capita, US$ exchange rate",19.4
+32656,Sweden,2014,5,M-Musculo-skeletal system,"Million US$, purchasing power parity",147.5
+32657,Sweden,2014,5,M-Musculo-skeletal system,Million of national currency units,1287.3
+32658,Sweden,2014,5,M-Musculo-skeletal system,Million US$ at exchange rate,187.6
+32659,Sweden,2014,5,M-Musculo-skeletal system,"/capita, US$ purchasing power parity",15.2
+32660,Sweden,2014,5,Total pharmaceutical sales,"/capita, US$ exchange rate",568.4
+32661,Sweden,2014,5,Total pharmaceutical sales,"Million US$, purchasing power parity",4332.3
+32662,Sweden,2014,5,M-Musculo-skeletal system,% of total sales,3.4
+32663,Sweden,2014,5,Total pharmaceutical sales,"/capita, US$ purchasing power parity",446.8
+32664,Sweden,2014,5,C-Cardiovascular system,"/capita, US$ exchange rate",35.2
+32665,Sweden,2014,5,C-Cardiovascular system,"Million US$, purchasing power parity",267.9
+32666,Sweden,2014,5,A10-Drugs used in diabetes,% of total sales,3.7
+32667,Sweden,2014,5,C-Cardiovascular system,"/capita, US$ purchasing power parity",27.6
+32668,Sweden,2014,5,J01-Antibacterials for systemic use,% of total sales,1.9
+32669,Sweden,2014,5,A-Alimentary tract and metabolism,Million of national currency units,3841.9
+32670,Sweden,2014,5,A-Alimentary tract and metabolism,Million US$ at exchange rate,560.0
+32671,Sweden,2014,5,J01-Antibacterials for systemic use,"/capita, US$ exchange rate",10.7
+32672,Sweden,2014,5,J01-Antibacterials for systemic use,"/capita, US$ purchasing power parity",8.4
+32673,Sweden,2014,5,M01A-Antiinflammatory and antirheumatic products non-steroids,"Million US$, purchasing power parity",82.4
+32674,Sweden,2014,5,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ exchange rate",10.8
+32675,Sweden,2014,5,M01A-Antiinflammatory and antirheumatic products non-steroids,Million US$ at exchange rate,104.8
+32676,Sweden,2014,5,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ purchasing power parity",8.5
+32677,Sweden,2014,5,"C01B-Antiarrhythmics, Class I and III",% of total sales,0.2
+32678,Sweden,2014,5,C-Cardiovascular system,% of total sales,6.2
+32679,Sweden,2014,5,A10-Drugs used in diabetes,"/capita, US$ purchasing power parity",16.7
+32680,Sweden,2014,5,M01A-Antiinflammatory and antirheumatic products non-steroids,Million of national currency units,718.9
+32681,Sweden,2014,5,A10-Drugs used in diabetes,Million of national currency units,1410.9
+32682,Sweden,2014,5,C09-Agents acting on the Renin-Angiotensin system,% of total sales,1.1
+32683,Sweden,2014,5,A02A-Antacids,Million of national currency units,81.7
+32684,Sweden,2014,5,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ purchasing power parity",4.9
+32685,Sweden,2014,5,A02A-Antacids,"Million US$, purchasing power parity",9.4
+32686,Sweden,2014,5,A02A-Antacids,Million US$ at exchange rate,11.9
+32687,Sweden,2014,5,C09-Agents acting on the Renin-Angiotensin system,Million of national currency units,413.6
+32688,Sweden,2014,5,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million of national currency units,474.1
+32689,Sweden,2014,5,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million US$ at exchange rate,69.1
+32690,Sweden,2014,5,A02A-Antacids,"/capita, US$ exchange rate",1.2
+32691,Sweden,2014,5,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ exchange rate",6.2
+32692,Sweden,2014,5,C09-Agents acting on the Renin-Angiotensin system,"Million US$, purchasing power parity",47.4
+32693,Sweden,2014,5,C09-Agents acting on the Renin-Angiotensin system,Million US$ at exchange rate,60.3
+32694,Sweden,2014,5,R-Respiratory system,Million US$ at exchange rate,515.1
+32695,Sweden,2014,5,R-Respiratory system,Million of national currency units,3534.1
+32696,Sweden,2014,5,R-Respiratory system,"Million US$, purchasing power parity",405.0
+32697,Sweden,2014,5,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ purchasing power parity",11.4
+32698,Sweden,2014,5,"H-Systemic hormonal preparations, excluding sex hormones and insulins",% of total sales,2.6
+32699,Sweden,2014,5,A02A-Antacids,% of total sales,0.2
+32700,Sweden,2014,5,A02A-Antacids,"/capita, US$ purchasing power parity",1.0
+32701,Sweden,2014,5,R-Respiratory system,"/capita, US$ exchange rate",53.1
+32702,Sweden,2014,5,R-Respiratory system,"/capita, US$ purchasing power parity",41.8
+32703,Sweden,2014,5,R-Respiratory system,% of total sales,9.3
+32704,Sweden,2014,5,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ exchange rate",14.5
+32705,Sweden,2014,5,N02-Analgesics,Million US$ at exchange rate,289.5
+32706,Sweden,2014,5,N02-Analgesics,Million of national currency units,1985.9
+32707,Sweden,2014,5,N02-Analgesics,"/capita, US$ purchasing power parity",23.5
+32708,Sweden,2014,5,N02-Analgesics,"/capita, US$ exchange rate",29.9
+32709,Sweden,2014,5,N02-Analgesics,"Million US$, purchasing power parity",227.6
+32710,Sweden,2014,5,C08-Calcium channel blockers,% of total sales,0.5
+32711,Sweden,2014,5,C08-Calcium channel blockers,Million US$ at exchange rate,29.4
+32712,Sweden,2014,5,C08-Calcium channel blockers,Million of national currency units,202.0
+32713,Sweden,2014,5,C08-Calcium channel blockers,"Million US$, purchasing power parity",23.1
+32714,Sweden,2014,5,C08-Calcium channel blockers,"/capita, US$ purchasing power parity",2.4
+32715,Sweden,2014,5,C08-Calcium channel blockers,"/capita, US$ exchange rate",3.0
+32716,Sweden,2014,5,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),% of total sales,1.3
+32717,Sweden,2014,5,R03-Drugs for obstructive airway diseases,Million of national currency units,1982.6
+32718,Sweden,2014,5,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"Million US$, purchasing power parity",54.3
+32719,Sweden,2014,5,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ exchange rate",7.1
+32720,Sweden,2014,5,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ purchasing power parity",5.6
+32721,Sweden,2014,5,R03-Drugs for obstructive airway diseases,Million US$ at exchange rate,289.0
+32722,Sweden,2014,5,R03-Drugs for obstructive airway diseases,% of total sales,5.2
+32723,Sweden,2014,5,N02-Analgesics,% of total sales,5.3
+32724,Sweden,2014,5,R03-Drugs for obstructive airway diseases,"/capita, US$ purchasing power parity",23.4
+32725,Sweden,2014,5,R03-Drugs for obstructive airway diseases,"Million US$, purchasing power parity",227.2
+32726,Sweden,2014,5,R03-Drugs for obstructive airway diseases,"/capita, US$ exchange rate",29.8
+32727,Sweden,2014,5,G03-Sex hormones and modulators of the genital system,"Million US$, purchasing power parity",105.8
+32728,Sweden,2014,5,G03-Sex hormones and modulators of the genital system,"/capita, US$ exchange rate",13.9
+32729,Sweden,2014,5,G03-Sex hormones and modulators of the genital system,"/capita, US$ purchasing power parity",10.9
+32730,Sweden,2014,5,G03-Sex hormones and modulators of the genital system,Million of national currency units,923.3
+32731,Sweden,2014,5,G-Genito urinary system and sex hormones,Million of national currency units,1684.8
+32732,Sweden,2014,5,G03-Sex hormones and modulators of the genital system,Million US$ at exchange rate,134.6
+32733,Sweden,2014,5,N06A-Antidepressants,"Million US$, purchasing power parity",82.7
+32734,Sweden,2014,5,N06A-Antidepressants,"/capita, US$ exchange rate",10.8
+32735,Sweden,2014,5,G03-Sex hormones and modulators of the genital system,% of total sales,2.4
+32736,Sweden,2014,5,N06A-Antidepressants,Million US$ at exchange rate,105.1
+32737,Sweden,2014,5,N06A-Antidepressants,Million of national currency units,721.3
+32738,Sweden,2014,5,N06A-Antidepressants,"/capita, US$ purchasing power parity",8.5
+32739,Sweden,2014,5,N05C-Hypnotics and sedatives,"Million US$, purchasing power parity",39.3
+32740,Sweden,2014,5,N05C-Hypnotics and sedatives,Million US$ at exchange rate,49.9
+32741,Sweden,2014,5,N05C-Hypnotics and sedatives,"/capita, US$ exchange rate",5.1
+32742,Sweden,2014,5,N05C-Hypnotics and sedatives,% of total sales,0.9
+32743,Sweden,2014,5,N05C-Hypnotics and sedatives,"/capita, US$ purchasing power parity",4.0
+32744,Sweden,2014,5,G-Genito urinary system and sex hormones,"/capita, US$ exchange rate",25.3
+32745,Sweden,2014,5,G-Genito urinary system and sex hormones,"Million US$, purchasing power parity",193.0
+32746,Sweden,2014,5,G-Genito urinary system and sex hormones,Million US$ at exchange rate,245.6
+32747,Sweden,2014,5,G-Genito urinary system and sex hormones,% of total sales,4.5
+32748,Sweden,2014,5,N05C-Hypnotics and sedatives,Million of national currency units,342.5
+32749,Sweden,2014,5,G-Genito urinary system and sex hormones,"/capita, US$ purchasing power parity",19.9
+32750,Sweden,2014,5,N05B-Anxiolytics,"/capita, US$ purchasing power parity",2.4
+32751,Sweden,2014,5,N05B-Anxiolytics,"/capita, US$ exchange rate",3.0
+32752,Sweden,2014,5,N05B-Anxiolytics,% of total sales,0.5
+32753,Sweden,2014,5,C10-Lipid modifying agents,Million US$ at exchange rate,70.1
+32754,Sweden,2014,5,C10-Lipid modifying agents,Million of national currency units,480.8
+32755,Sweden,2014,5,N05B-Anxiolytics,"Million US$, purchasing power parity",23.1
+32756,Sweden,2014,5,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million US$ at exchange rate,141.0
+32757,Sweden,2014,5,"H-Systemic hormonal preparations, excluding sex hormones and insulins","Million US$, purchasing power parity",110.9
+32758,Sweden,2014,5,N05B-Anxiolytics,Million US$ at exchange rate,29.4
+32759,Sweden,2014,5,N05B-Anxiolytics,Million of national currency units,201.4
+32760,Sweden,2014,5,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million of national currency units,967.4
+32761,Sweden,2014,5,B-Blood and blood forming organs,"Million US$, purchasing power parity",369.3
+32762,Sweden,2014,5,B-Blood and blood forming organs,"/capita, US$ exchange rate",48.4
+32763,Sweden,2014,5,B-Blood and blood forming organs,Million US$ at exchange rate,469.8
+32764,Sweden,2014,5,N06A-Antidepressants,% of total sales,1.9
+32765,Sweden,2014,5,B-Blood and blood forming organs,Million of national currency units,3223.0
+32766,Sweden,2014,5,J-Antiinfectives for systemic use,Million of national currency units,3029.8
+32767,Sweden,2014,5,C10-Lipid modifying agents,"/capita, US$ purchasing power parity",5.7
+32768,Sweden,2014,5,C10-Lipid modifying agents,"Million US$, purchasing power parity",55.1
+32769,Sweden,2014,5,C10-Lipid modifying agents,"/capita, US$ exchange rate",7.2
+32770,Sweden,2014,5,B-Blood and blood forming organs,% of total sales,8.5
+32771,Sweden,2014,5,B-Blood and blood forming organs,"/capita, US$ purchasing power parity",38.1
+32772,Sweden,2014,5,C10-Lipid modifying agents,% of total sales,1.3
+32773,Sweden,2014,5,J-Antiinfectives for systemic use,"/capita, US$ purchasing power parity",35.8
+32774,Sweden,2014,5,J-Antiinfectives for systemic use,% of total sales,8.0
+32775,Sweden,2014,5,J-Antiinfectives for systemic use,"/capita, US$ exchange rate",45.5
+32776,Sweden,2014,5,N-Nervous system,"/capita, US$ exchange rate",110.4
+32777,Sweden,2014,5,N-Nervous system,"/capita, US$ purchasing power parity",86.8
+32778,Sweden,2014,5,C07-Beta blocking agents,Million US$ at exchange rate,61.1
+32779,Sweden,2014,5,C07-Beta blocking agents,Million of national currency units,419.1
+32780,Sweden,2014,5,N-Nervous system,% of total sales,19.4
+32781,Sweden,2014,5,C07-Beta blocking agents,"/capita, US$ exchange rate",6.3
+32782,Sweden,2014,5,C07-Beta blocking agents,"Million US$, purchasing power parity",48.0
+32783,Sweden,2014,5,C07-Beta blocking agents,% of total sales,1.1
+32784,Sweden,2014,5,C07-Beta blocking agents,"/capita, US$ purchasing power parity",5.0
+32785,Sweden,2014,5,J-Antiinfectives for systemic use,Million US$ at exchange rate,441.6
+32786,Sweden,2014,5,J-Antiinfectives for systemic use,"Million US$, purchasing power parity",347.2
+32787,Sweden,2014,5,N-Nervous system,Million of national currency units,7342.3
+32788,Sweden,2014,5,N-Nervous system,Million US$ at exchange rate,1070.2
+32789,Sweden,2014,5,N-Nervous system,"Million US$, purchasing power parity",841.3
+32790,Sweden,2015,4,"C01B-Antiarrhythmics, Class I and III","/capita, US$ purchasing power parity",0.8
+32791,Sweden,2015,4,J01-Antibacterials for systemic use,Million US$ at exchange rate,88.9
+32792,Sweden,2015,4,"C01B-Antiarrhythmics, Class I and III","/capita, US$ exchange rate",0.8
+32793,Sweden,2015,4,A-Alimentary tract and metabolism,"Million US$, purchasing power parity",464.8
+32794,Sweden,2015,4,J01-Antibacterials for systemic use,"Million US$, purchasing power parity",84.6
+32795,Sweden,2015,4,C03-Diuretics,"Million US$, purchasing power parity",27.3
+32796,Sweden,2015,4,C03-Diuretics,Million US$ at exchange rate,28.7
+32797,Sweden,2015,4,C03-Diuretics,Million of national currency units,241.9
+32798,Sweden,2015,4,C03-Diuretics,% of total sales,0.6
+32799,Sweden,2015,4,C03-Diuretics,"/capita, US$ exchange rate",2.9
+32800,Sweden,2015,4,C03-Diuretics,"/capita, US$ purchasing power parity",2.8
+32801,Sweden,2015,4,C-Cardiovascular system,Million US$ at exchange rate,285.0
+32802,Sweden,2015,4,A-Alimentary tract and metabolism,% of total sales,10.1
+32803,Sweden,2015,4,A-Alimentary tract and metabolism,"/capita, US$ purchasing power parity",47.4
+32804,Sweden,2015,4,"C01B-Antiarrhythmics, Class I and III",Million of national currency units,66.6
+32805,Sweden,2015,4,A-Alimentary tract and metabolism,"/capita, US$ exchange rate",49.8
+32806,Sweden,2015,4,C02-Antihypertensives,Million of national currency units,214.2
+32807,Sweden,2015,4,J01-Antibacterials for systemic use,Million of national currency units,749.5
+32808,Sweden,2015,4,C02-Antihypertensives,"Million US$, purchasing power parity",24.2
+32809,Sweden,2015,4,C02-Antihypertensives,Million US$ at exchange rate,25.4
+32810,Sweden,2015,4,C01A-Cardiac glycosides,"/capita, US$ purchasing power parity",0.2
+32811,Sweden,2015,4,C01A-Cardiac glycosides,"/capita, US$ exchange rate",0.2
+32812,Sweden,2015,4,C-Cardiovascular system,Million of national currency units,2404.2
+32813,Sweden,2015,4,C01A-Cardiac glycosides,% of total sales,0.0
+32814,Sweden,2015,4,"C01B-Antiarrhythmics, Class I and III","Million US$, purchasing power parity",7.5
+32815,Sweden,2015,4,"C01B-Antiarrhythmics, Class I and III",Million US$ at exchange rate,7.9
+32816,Sweden,2015,4,C01A-Cardiac glycosides,"Million US$, purchasing power parity",1.5
+32817,Sweden,2015,4,C01A-Cardiac glycosides,Million of national currency units,13.2
+32818,Sweden,2015,4,C01A-Cardiac glycosides,Million US$ at exchange rate,1.6
+32819,Sweden,2015,4,C02-Antihypertensives,"/capita, US$ purchasing power parity",2.5
+32820,Sweden,2015,4,C02-Antihypertensives,"/capita, US$ exchange rate",2.6
+32821,Sweden,2015,4,A10-Drugs used in diabetes,Million US$ at exchange rate,182.1
+32822,Sweden,2015,4,Total pharmaceutical sales,Million US$ at exchange rate,4808.3
+32823,Sweden,2015,4,Total pharmaceutical sales,Million of national currency units,40557.2
+32824,Sweden,2015,4,M01A-Antiinflammatory and antirheumatic products non-steroids,% of total sales,1.9
+32825,Sweden,2015,4,C02-Antihypertensives,% of total sales,0.5
+32826,Sweden,2015,4,A10-Drugs used in diabetes,"Million US$, purchasing power parity",173.4
+32827,Sweden,2015,4,A10-Drugs used in diabetes,"/capita, US$ exchange rate",18.6
+32828,Sweden,2015,4,M-Musculo-skeletal system,"Million US$, purchasing power parity",155.3
+32829,Sweden,2015,4,M-Musculo-skeletal system,"/capita, US$ exchange rate",16.6
+32830,Sweden,2015,4,M-Musculo-skeletal system,Million of national currency units,1375.3
+32831,Sweden,2015,4,M-Musculo-skeletal system,Million US$ at exchange rate,163.0
+32832,Sweden,2015,4,M-Musculo-skeletal system,"/capita, US$ purchasing power parity",15.9
+32833,Sweden,2015,4,Total pharmaceutical sales,"/capita, US$ exchange rate",490.7
+32834,Sweden,2015,4,Total pharmaceutical sales,"Million US$, purchasing power parity",4580.5
+32835,Sweden,2015,4,Total pharmaceutical sales,"/capita, US$ purchasing power parity",467.4
+32836,Sweden,2015,4,M-Musculo-skeletal system,% of total sales,3.4
+32837,Sweden,2015,4,C-Cardiovascular system,"/capita, US$ exchange rate",29.1
+32838,Sweden,2015,4,C-Cardiovascular system,"Million US$, purchasing power parity",271.5
+32839,Sweden,2015,4,A10-Drugs used in diabetes,% of total sales,3.8
+32840,Sweden,2015,4,C-Cardiovascular system,"/capita, US$ purchasing power parity",27.7
+32841,Sweden,2015,4,J01-Antibacterials for systemic use,% of total sales,1.8
+32842,Sweden,2015,4,A-Alimentary tract and metabolism,Million of national currency units,4115.1
+32843,Sweden,2015,4,A-Alimentary tract and metabolism,Million US$ at exchange rate,487.9
+32844,Sweden,2015,4,J01-Antibacterials for systemic use,"/capita, US$ purchasing power parity",8.6
+32845,Sweden,2015,4,J01-Antibacterials for systemic use,"/capita, US$ exchange rate",9.1
+32846,Sweden,2015,4,M01A-Antiinflammatory and antirheumatic products non-steroids,"Million US$, purchasing power parity",85.0
+32847,Sweden,2015,4,M01A-Antiinflammatory and antirheumatic products non-steroids,Million US$ at exchange rate,89.2
+32848,Sweden,2015,4,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ exchange rate",9.1
+32849,Sweden,2015,4,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ purchasing power parity",8.7
+32850,Sweden,2015,4,C-Cardiovascular system,% of total sales,5.9
+32851,Sweden,2015,4,A10-Drugs used in diabetes,"/capita, US$ purchasing power parity",17.7
+32852,Sweden,2015,4,"C01B-Antiarrhythmics, Class I and III",% of total sales,0.2
+32853,Sweden,2015,4,M01A-Antiinflammatory and antirheumatic products non-steroids,Million of national currency units,752.3
+32854,Sweden,2015,4,A10-Drugs used in diabetes,Million of national currency units,1535.6
+32855,Sweden,2015,4,C09-Agents acting on the Renin-Angiotensin system,% of total sales,1.0
+32856,Sweden,2015,4,A02A-Antacids,Million of national currency units,92.4
+32857,Sweden,2015,4,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ purchasing power parity",4.9
+32858,Sweden,2015,4,A02A-Antacids,"Million US$, purchasing power parity",10.4
+32859,Sweden,2015,4,A02A-Antacids,Million US$ at exchange rate,11.0
+32860,Sweden,2015,4,C09-Agents acting on the Renin-Angiotensin system,Million of national currency units,422.0
+32861,Sweden,2015,4,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million of national currency units,493.7
+32862,Sweden,2015,4,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million US$ at exchange rate,58.5
+32863,Sweden,2015,4,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ exchange rate",5.1
+32864,Sweden,2015,4,C09-Agents acting on the Renin-Angiotensin system,"Million US$, purchasing power parity",47.7
+32865,Sweden,2015,4,C09-Agents acting on the Renin-Angiotensin system,Million US$ at exchange rate,50.0
+32866,Sweden,2015,4,A02A-Antacids,"/capita, US$ exchange rate",1.1
+32867,Sweden,2015,4,R-Respiratory system,Million of national currency units,3332.4
+32868,Sweden,2015,4,R-Respiratory system,Million US$ at exchange rate,395.1
+32869,Sweden,2015,4,R-Respiratory system,"Million US$, purchasing power parity",376.4
+32870,Sweden,2015,4,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ purchasing power parity",11.3
+32871,Sweden,2015,4,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ exchange rate",11.9
+32872,Sweden,2015,4,"H-Systemic hormonal preparations, excluding sex hormones and insulins",% of total sales,2.4
+32873,Sweden,2015,4,A02A-Antacids,% of total sales,0.2
+32874,Sweden,2015,4,A02A-Antacids,"/capita, US$ purchasing power parity",1.1
+32875,Sweden,2015,4,R-Respiratory system,"/capita, US$ exchange rate",40.3
+32876,Sweden,2015,4,R-Respiratory system,% of total sales,8.2
+32877,Sweden,2015,4,R-Respiratory system,"/capita, US$ purchasing power parity",38.4
+32878,Sweden,2015,4,N02-Analgesics,Million US$ at exchange rate,242.4
+32879,Sweden,2015,4,C08-Calcium channel blockers,% of total sales,0.5
+32880,Sweden,2015,4,N02-Analgesics,Million of national currency units,2044.8
+32881,Sweden,2015,4,N02-Analgesics,"/capita, US$ purchasing power parity",23.6
+32882,Sweden,2015,4,N02-Analgesics,"/capita, US$ exchange rate",24.7
+32883,Sweden,2015,4,N02-Analgesics,"Million US$, purchasing power parity",230.9
+32884,Sweden,2015,4,C08-Calcium channel blockers,Million US$ at exchange rate,24.1
+32885,Sweden,2015,4,C08-Calcium channel blockers,Million of national currency units,203.5
+32886,Sweden,2015,4,C08-Calcium channel blockers,"/capita, US$ purchasing power parity",2.3
+32887,Sweden,2015,4,C08-Calcium channel blockers,"/capita, US$ exchange rate",2.5
+32888,Sweden,2015,4,C08-Calcium channel blockers,"Million US$, purchasing power parity",23.0
+32889,Sweden,2015,4,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),% of total sales,1.2
+32890,Sweden,2015,4,R03-Drugs for obstructive airway diseases,Million of national currency units,1702.5
+32891,Sweden,2015,4,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"Million US$, purchasing power parity",55.8
+32892,Sweden,2015,4,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ purchasing power parity",5.7
+32893,Sweden,2015,4,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ exchange rate",6.0
+32894,Sweden,2015,4,R03-Drugs for obstructive airway diseases,Million US$ at exchange rate,201.8
+32895,Sweden,2015,4,R03-Drugs for obstructive airway diseases,% of total sales,4.2
+32896,Sweden,2015,4,N02-Analgesics,% of total sales,5.0
+32897,Sweden,2015,4,R03-Drugs for obstructive airway diseases,"/capita, US$ purchasing power parity",19.6
+32898,Sweden,2015,4,R03-Drugs for obstructive airway diseases,"Million US$, purchasing power parity",192.3
+32899,Sweden,2015,4,R03-Drugs for obstructive airway diseases,"/capita, US$ exchange rate",20.6
+32900,Sweden,2015,4,G03-Sex hormones and modulators of the genital system,"Million US$, purchasing power parity",104.5
+32901,Sweden,2015,4,G03-Sex hormones and modulators of the genital system,"/capita, US$ purchasing power parity",10.7
+32902,Sweden,2015,4,G03-Sex hormones and modulators of the genital system,"/capita, US$ exchange rate",11.2
+32903,Sweden,2015,4,G03-Sex hormones and modulators of the genital system,Million of national currency units,925.1
+32904,Sweden,2015,4,G-Genito urinary system and sex hormones,Million of national currency units,1676.9
+32905,Sweden,2015,4,G03-Sex hormones and modulators of the genital system,Million US$ at exchange rate,109.7
+32906,Sweden,2015,4,N06A-Antidepressants,"Million US$, purchasing power parity",75.5
+32907,Sweden,2015,4,N06A-Antidepressants,"/capita, US$ exchange rate",8.1
+32908,Sweden,2015,4,G03-Sex hormones and modulators of the genital system,% of total sales,2.3
+32909,Sweden,2015,4,N06A-Antidepressants,Million US$ at exchange rate,79.2
+32910,Sweden,2015,4,N06A-Antidepressants,Million of national currency units,668.4
+32911,Sweden,2015,4,N05C-Hypnotics and sedatives,"Million US$, purchasing power parity",41.1
+32912,Sweden,2015,4,N05C-Hypnotics and sedatives,Million US$ at exchange rate,43.2
+32913,Sweden,2015,4,N05C-Hypnotics and sedatives,"/capita, US$ exchange rate",4.4
+32914,Sweden,2015,4,N05C-Hypnotics and sedatives,% of total sales,0.9
+32915,Sweden,2015,4,N05C-Hypnotics and sedatives,"/capita, US$ purchasing power parity",4.2
+32916,Sweden,2015,4,N05C-Hypnotics and sedatives,Million of national currency units,364.1
+32917,Sweden,2015,4,G-Genito urinary system and sex hormones,"Million US$, purchasing power parity",189.4
+32918,Sweden,2015,4,G-Genito urinary system and sex hormones,"/capita, US$ exchange rate",20.3
+32919,Sweden,2015,4,G-Genito urinary system and sex hormones,Million US$ at exchange rate,198.8
+32920,Sweden,2015,4,G-Genito urinary system and sex hormones,% of total sales,4.1
+32921,Sweden,2015,4,G-Genito urinary system and sex hormones,"/capita, US$ purchasing power parity",19.3
+32922,Sweden,2015,4,N06A-Antidepressants,"/capita, US$ purchasing power parity",7.7
+32923,Sweden,2015,4,N05B-Anxiolytics,"/capita, US$ purchasing power parity",2.3
+32924,Sweden,2015,4,N05B-Anxiolytics,"/capita, US$ exchange rate",2.4
+32925,Sweden,2015,4,C10-Lipid modifying agents,Million US$ at exchange rate,57.2
+32926,Sweden,2015,4,N05B-Anxiolytics,% of total sales,0.5
+32927,Sweden,2015,4,C10-Lipid modifying agents,Million of national currency units,482.1
+32928,Sweden,2015,4,N05B-Anxiolytics,"Million US$, purchasing power parity",22.6
+32929,Sweden,2015,4,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million US$ at exchange rate,116.6
+32930,Sweden,2015,4,"H-Systemic hormonal preparations, excluding sex hormones and insulins","Million US$, purchasing power parity",111.1
+32931,Sweden,2015,4,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million of national currency units,983.4
+32932,Sweden,2015,4,N05B-Anxiolytics,Million US$ at exchange rate,23.7
+32933,Sweden,2015,4,N05B-Anxiolytics,Million of national currency units,199.8
+32934,Sweden,2015,4,B-Blood and blood forming organs,"Million US$, purchasing power parity",397.6
+32935,Sweden,2015,4,B-Blood and blood forming organs,"/capita, US$ exchange rate",42.6
+32936,Sweden,2015,4,B-Blood and blood forming organs,Million US$ at exchange rate,417.4
+32937,Sweden,2015,4,N06A-Antidepressants,% of total sales,1.6
+32938,Sweden,2015,4,B-Blood and blood forming organs,Million of national currency units,3520.9
+32939,Sweden,2015,4,C10-Lipid modifying agents,"/capita, US$ purchasing power parity",5.6
+32940,Sweden,2015,4,C10-Lipid modifying agents,"/capita, US$ exchange rate",5.8
+32941,Sweden,2015,4,C10-Lipid modifying agents,"Million US$, purchasing power parity",54.5
+32942,Sweden,2015,4,B-Blood and blood forming organs,% of total sales,8.7
+32943,Sweden,2015,4,B-Blood and blood forming organs,"/capita, US$ purchasing power parity",40.6
+32944,Sweden,2015,4,C10-Lipid modifying agents,% of total sales,1.2
+32945,Sweden,2015,4,J-Antiinfectives for systemic use,Million of national currency units,3983.5
+32946,Sweden,2015,4,J-Antiinfectives for systemic use,"/capita, US$ purchasing power parity",45.9
+32947,Sweden,2015,4,J-Antiinfectives for systemic use,"/capita, US$ exchange rate",48.2
+32948,Sweden,2015,4,N-Nervous system,"/capita, US$ exchange rate",90.6
+32949,Sweden,2015,4,J-Antiinfectives for systemic use,% of total sales,9.8
+32950,Sweden,2015,4,N-Nervous system,"/capita, US$ purchasing power parity",86.3
+32951,Sweden,2015,4,C07-Beta blocking agents,Million US$ at exchange rate,50.9
+32952,Sweden,2015,4,C07-Beta blocking agents,Million of national currency units,429.4
+32953,Sweden,2015,4,N-Nervous system,% of total sales,18.5
+32954,Sweden,2015,4,C07-Beta blocking agents,"/capita, US$ exchange rate",5.2
+32955,Sweden,2015,4,C07-Beta blocking agents,"Million US$, purchasing power parity",48.5
+32956,Sweden,2015,4,C07-Beta blocking agents,% of total sales,1.1
+32957,Sweden,2015,4,C07-Beta blocking agents,"/capita, US$ purchasing power parity",4.9
+32958,Sweden,2015,4,J-Antiinfectives for systemic use,Million US$ at exchange rate,472.3
+32959,Sweden,2015,4,J-Antiinfectives for systemic use,"Million US$, purchasing power parity",449.9
+32960,Sweden,2015,4,N-Nervous system,Million of national currency units,7485.8
+32961,Sweden,2015,4,N-Nervous system,Million US$ at exchange rate,887.5
+32962,Sweden,2015,4,N-Nervous system,"Million US$, purchasing power parity",845.4
+32963,Sweden,2010,4,"C01B-Antiarrhythmics, Class I and III",% of total sales,0.1
+32964,Sweden,2010,4,"C01B-Antiarrhythmics, Class I and III","/capita, US$ purchasing power parity",0.4
+32965,Sweden,2010,4,J01-Antibacterials for systemic use,"Million US$, purchasing power parity",111.1
+32966,Sweden,2010,4,A-Alimentary tract and metabolism,"Million US$, purchasing power parity",414.0
+32967,Sweden,2010,4,C03-Diuretics,"Million US$, purchasing power parity",29.8
+32968,Sweden,2010,4,C03-Diuretics,"/capita, US$ exchange rate",4.0
+32969,Sweden,2010,4,C03-Diuretics,Million of national currency units,269.1
+32970,Sweden,2010,4,C03-Diuretics,Million US$ at exchange rate,37.3
+32971,Sweden,2010,4,C-Cardiovascular system,"Million US$, purchasing power parity",345.5
+32972,Sweden,2010,4,C03-Diuretics,% of total sales,0.7
+32973,Sweden,2010,4,C03-Diuretics,"/capita, US$ purchasing power parity",3.2
+32974,Sweden,2010,4,A-Alimentary tract and metabolism,% of total sales,10.4
+32975,Sweden,2010,4,"C01B-Antiarrhythmics, Class I and III",Million of national currency units,36.1
+32976,Sweden,2010,4,A-Alimentary tract and metabolism,"/capita, US$ exchange rate",55.3
+32977,Sweden,2010,4,A-Alimentary tract and metabolism,"/capita, US$ purchasing power parity",44.1
+32978,Sweden,2010,4,"C01B-Antiarrhythmics, Class I and III",Million US$ at exchange rate,5.0
+32979,Sweden,2010,4,C02-Antihypertensives,Million of national currency units,137.8
+32980,Sweden,2010,4,J01-Antibacterials for systemic use,Million of national currency units,1003.0
+32981,Sweden,2010,4,J01-Antibacterials for systemic use,Million US$ at exchange rate,139.2
+32982,Sweden,2010,4,C02-Antihypertensives,"Million US$, purchasing power parity",15.3
+32983,Sweden,2010,4,C02-Antihypertensives,"/capita, US$ exchange rate",2.0
+32984,Sweden,2010,4,C02-Antihypertensives,Million US$ at exchange rate,19.1
+32985,Sweden,2010,4,C01A-Cardiac glycosides,"/capita, US$ purchasing power parity",0.2
+32986,Sweden,2010,4,C01A-Cardiac glycosides,"/capita, US$ exchange rate",0.2
+32987,Sweden,2010,4,C01A-Cardiac glycosides,% of total sales,0.0
+32988,Sweden,2010,4,C-Cardiovascular system,Million US$ at exchange rate,432.6
+32989,Sweden,2010,4,C-Cardiovascular system,Million of national currency units,3118.3
+32990,Sweden,2010,4,C01A-Cardiac glycosides,Million of national currency units,14.1
+32991,Sweden,2010,4,"C01B-Antiarrhythmics, Class I and III","/capita, US$ exchange rate",0.5
+32992,Sweden,2010,4,"C01B-Antiarrhythmics, Class I and III","Million US$, purchasing power parity",4.0
+32993,Sweden,2010,4,C01A-Cardiac glycosides,"Million US$, purchasing power parity",1.6
+32994,Sweden,2010,4,C01A-Cardiac glycosides,Million US$ at exchange rate,2.0
+32995,Sweden,2010,4,C02-Antihypertensives,"/capita, US$ purchasing power parity",1.6
+32996,Sweden,2010,4,Total pharmaceutical sales,Million US$ at exchange rate,5003.0
+32997,Sweden,2010,4,Total pharmaceutical sales,Million of national currency units,36059.4
+32998,Sweden,2010,4,A10-Drugs used in diabetes,"Million US$, purchasing power parity",143.3
+32999,Sweden,2010,4,C02-Antihypertensives,% of total sales,0.4
+33000,Sweden,2010,4,M-Musculo-skeletal system,Million of national currency units,1241.2
+33001,Sweden,2010,4,A10-Drugs used in diabetes,"/capita, US$ purchasing power parity",15.3
+33002,Sweden,2010,4,A10-Drugs used in diabetes,"/capita, US$ exchange rate",19.1
+33003,Sweden,2010,4,Total pharmaceutical sales,"Million US$, purchasing power parity",3995.5
+33004,Sweden,2010,4,M-Musculo-skeletal system,"/capita, US$ exchange rate",18.4
+33005,Sweden,2010,4,M-Musculo-skeletal system,"/capita, US$ purchasing power parity",14.7
+33006,Sweden,2010,4,M-Musculo-skeletal system,Million US$ at exchange rate,172.2
+33007,Sweden,2010,4,M-Musculo-skeletal system,"Million US$, purchasing power parity",137.5
+33008,Sweden,2010,4,Total pharmaceutical sales,"/capita, US$ purchasing power parity",426.0
+33009,Sweden,2010,4,Total pharmaceutical sales,"/capita, US$ exchange rate",533.5
+33010,Sweden,2010,4,M-Musculo-skeletal system,% of total sales,3.4
+33011,Sweden,2010,4,A10-Drugs used in diabetes,Million US$ at exchange rate,179.4
+33012,Sweden,2010,4,C-Cardiovascular system,"/capita, US$ exchange rate",46.1
+33013,Sweden,2010,4,A10-Drugs used in diabetes,% of total sales,3.6
+33014,Sweden,2010,4,C-Cardiovascular system,"/capita, US$ purchasing power parity",36.8
+33015,Sweden,2010,4,J01-Antibacterials for systemic use,"/capita, US$ exchange rate",14.8
+33016,Sweden,2010,4,A-Alimentary tract and metabolism,Million of national currency units,3736.4
+33017,Sweden,2010,4,A-Alimentary tract and metabolism,Million US$ at exchange rate,518.4
+33018,Sweden,2010,4,J01-Antibacterials for systemic use,% of total sales,2.8
+33019,Sweden,2010,4,J01-Antibacterials for systemic use,"/capita, US$ purchasing power parity",11.9
+33020,Sweden,2010,4,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ exchange rate",10.9
+33021,Sweden,2010,4,M01A-Antiinflammatory and antirheumatic products non-steroids,"Million US$, purchasing power parity",82.0
+33022,Sweden,2010,4,M01A-Antiinflammatory and antirheumatic products non-steroids,% of total sales,2.1
+33023,Sweden,2010,4,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ purchasing power parity",8.7
+33024,Sweden,2010,4,C-Cardiovascular system,% of total sales,8.6
+33025,Sweden,2010,4,M01A-Antiinflammatory and antirheumatic products non-steroids,Million US$ at exchange rate,102.6
+33026,Sweden,2010,4,M01A-Antiinflammatory and antirheumatic products non-steroids,Million of national currency units,739.8
+33027,Sweden,2010,4,A10-Drugs used in diabetes,Million of national currency units,1293.3
+33028,Sweden,2010,4,A02A-Antacids,Million of national currency units,62.4
+33029,Sweden,2010,4,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ purchasing power parity",11.8
+33030,Sweden,2010,4,C09-Agents acting on the Renin-Angiotensin system,% of total sales,2.8
+33031,Sweden,2010,4,A02A-Antacids,"/capita, US$ exchange rate",0.9
+33032,Sweden,2010,4,A02A-Antacids,"Million US$, purchasing power parity",6.9
+33033,Sweden,2010,4,A02A-Antacids,Million US$ at exchange rate,8.7
+33034,Sweden,2010,4,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million of national currency units,727.7
+33035,Sweden,2010,4,C09-Agents acting on the Renin-Angiotensin system,Million of national currency units,998.7
+33036,Sweden,2010,4,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million US$ at exchange rate,101.0
+33037,Sweden,2010,4,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ exchange rate",14.8
+33038,Sweden,2010,4,C09-Agents acting on the Renin-Angiotensin system,"Million US$, purchasing power parity",110.7
+33039,Sweden,2010,4,C09-Agents acting on the Renin-Angiotensin system,Million US$ at exchange rate,138.6
+33040,Sweden,2010,4,R-Respiratory system,Million US$ at exchange rate,461.2
+33041,Sweden,2010,4,R-Respiratory system,"Million US$, purchasing power parity",368.3
+33042,Sweden,2010,4,R-Respiratory system,Million of national currency units,3323.9
+33043,Sweden,2010,4,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ purchasing power parity",10.9
+33044,Sweden,2010,4,"H-Systemic hormonal preparations, excluding sex hormones and insulins",% of total sales,2.5
+33045,Sweden,2010,4,A02A-Antacids,% of total sales,0.2
+33046,Sweden,2010,4,A02A-Antacids,"/capita, US$ purchasing power parity",0.7
+33047,Sweden,2010,4,N-Nervous system,Million of national currency units,7256.9
+33048,Sweden,2010,4,R-Respiratory system,"/capita, US$ purchasing power parity",39.3
+33049,Sweden,2010,4,R-Respiratory system,"/capita, US$ exchange rate",49.2
+33050,Sweden,2010,4,R-Respiratory system,% of total sales,9.2
+33051,Sweden,2010,4,N02-Analgesics,Million US$ at exchange rate,280.4
+33052,Sweden,2010,4,N02-Analgesics,Million of national currency units,2021.1
+33053,Sweden,2010,4,N02-Analgesics,"Million US$, purchasing power parity",223.9
+33054,Sweden,2010,4,N02-Analgesics,"/capita, US$ purchasing power parity",23.9
+33055,Sweden,2010,4,N02-Analgesics,"/capita, US$ exchange rate",29.9
+33056,Sweden,2010,4,C08-Calcium channel blockers,"Million US$, purchasing power parity",22.9
+33057,Sweden,2010,4,C08-Calcium channel blockers,Million US$ at exchange rate,28.7
+33058,Sweden,2010,4,J-Antiinfectives for systemic use,Million of national currency units,2649.2
+33059,Sweden,2010,4,C08-Calcium channel blockers,Million of national currency units,206.8
+33060,Sweden,2010,4,C08-Calcium channel blockers,"/capita, US$ purchasing power parity",2.4
+33061,Sweden,2010,4,C08-Calcium channel blockers,% of total sales,0.6
+33062,Sweden,2010,4,C08-Calcium channel blockers,"/capita, US$ exchange rate",3.1
+33063,Sweden,2010,4,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),% of total sales,2.0
+33064,Sweden,2010,4,R03-Drugs for obstructive airway diseases,Million of national currency units,1932.4
+33065,Sweden,2010,4,R03-Drugs for obstructive airway diseases,Million US$ at exchange rate,268.1
+33066,Sweden,2010,4,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ exchange rate",10.8
+33067,Sweden,2010,4,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"Million US$, purchasing power parity",80.6
+33068,Sweden,2010,4,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ purchasing power parity",8.6
+33069,Sweden,2010,4,R03-Drugs for obstructive airway diseases,% of total sales,5.4
+33070,Sweden,2010,4,N02-Analgesics,% of total sales,5.6
+33071,Sweden,2010,4,R03-Drugs for obstructive airway diseases,"Million US$, purchasing power parity",214.1
+33072,Sweden,2010,4,R03-Drugs for obstructive airway diseases,"/capita, US$ purchasing power parity",22.8
+33073,Sweden,2010,4,R03-Drugs for obstructive airway diseases,"/capita, US$ exchange rate",28.6
+33074,Sweden,2010,4,G03-Sex hormones and modulators of the genital system,"/capita, US$ exchange rate",13.2
+33075,Sweden,2010,4,G03-Sex hormones and modulators of the genital system,"/capita, US$ purchasing power parity",10.6
+33076,Sweden,2010,4,G03-Sex hormones and modulators of the genital system,"Million US$, purchasing power parity",99.2
+33077,Sweden,2010,4,G03-Sex hormones and modulators of the genital system,Million of national currency units,895.5
+33078,Sweden,2010,4,G-Genito urinary system and sex hormones,Million of national currency units,1715.4
+33079,Sweden,2010,4,G03-Sex hormones and modulators of the genital system,Million US$ at exchange rate,124.2
+33080,Sweden,2010,4,N06A-Antidepressants,"Million US$, purchasing power parity",69.3
+33081,Sweden,2010,4,N06A-Antidepressants,"/capita, US$ exchange rate",9.3
+33082,Sweden,2010,4,N06A-Antidepressants,"/capita, US$ purchasing power parity",7.4
+33083,Sweden,2010,4,N06A-Antidepressants,Million of national currency units,625.7
+33084,Sweden,2010,4,G03-Sex hormones and modulators of the genital system,% of total sales,2.5
+33085,Sweden,2010,4,N06A-Antidepressants,Million US$ at exchange rate,86.8
+33086,Sweden,2010,4,N05C-Hypnotics and sedatives,"Million US$, purchasing power parity",30.1
+33087,Sweden,2010,4,N05C-Hypnotics and sedatives,"/capita, US$ exchange rate",4.0
+33088,Sweden,2010,4,N05C-Hypnotics and sedatives,Million US$ at exchange rate,37.7
+33089,Sweden,2010,4,N05C-Hypnotics and sedatives,% of total sales,0.8
+33090,Sweden,2010,4,N05C-Hypnotics and sedatives,"/capita, US$ purchasing power parity",3.2
+33091,Sweden,2010,4,G-Genito urinary system and sex hormones,"/capita, US$ exchange rate",25.4
+33092,Sweden,2010,4,G-Genito urinary system and sex hormones,Million US$ at exchange rate,238.0
+33093,Sweden,2010,4,G-Genito urinary system and sex hormones,"Million US$, purchasing power parity",190.1
+33094,Sweden,2010,4,N05C-Hypnotics and sedatives,Million of national currency units,271.6
+33095,Sweden,2010,4,G-Genito urinary system and sex hormones,% of total sales,4.8
+33096,Sweden,2010,4,G-Genito urinary system and sex hormones,"/capita, US$ purchasing power parity",20.3
+33097,Sweden,2010,4,N05B-Anxiolytics,"/capita, US$ purchasing power parity",2.2
+33098,Sweden,2010,4,N05B-Anxiolytics,% of total sales,0.5
+33099,Sweden,2010,4,N05B-Anxiolytics,"/capita, US$ exchange rate",2.8
+33100,Sweden,2010,4,C10-Lipid modifying agents,Million US$ at exchange rate,100.3
+33101,Sweden,2010,4,C10-Lipid modifying agents,Million of national currency units,722.6
+33102,Sweden,2010,4,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million US$ at exchange rate,127.6
+33103,Sweden,2010,4,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ exchange rate",13.6
+33104,Sweden,2010,4,"H-Systemic hormonal preparations, excluding sex hormones and insulins","Million US$, purchasing power parity",101.9
+33105,Sweden,2010,4,N05B-Anxiolytics,"Million US$, purchasing power parity",20.8
+33106,Sweden,2010,4,N05B-Anxiolytics,Million US$ at exchange rate,26.0
+33107,Sweden,2010,4,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million of national currency units,919.4
+33108,Sweden,2010,4,N05B-Anxiolytics,Million of national currency units,187.6
+33109,Sweden,2010,4,C10-Lipid modifying agents,"Million US$, purchasing power parity",80.1
+33110,Sweden,2010,4,B-Blood and blood forming organs,"Million US$, purchasing power parity",341.2
+33111,Sweden,2010,4,B-Blood and blood forming organs,"/capita, US$ exchange rate",45.6
+33112,Sweden,2010,4,B-Blood and blood forming organs,"/capita, US$ purchasing power parity",36.4
+33113,Sweden,2010,4,N06A-Antidepressants,% of total sales,1.7
+33114,Sweden,2010,4,B-Blood and blood forming organs,Million US$ at exchange rate,427.3
+33115,Sweden,2010,4,B-Blood and blood forming organs,Million of national currency units,3079.7
+33116,Sweden,2010,4,C10-Lipid modifying agents,"/capita, US$ purchasing power parity",8.5
+33117,Sweden,2010,4,C10-Lipid modifying agents,"/capita, US$ exchange rate",10.7
+33118,Sweden,2010,4,C10-Lipid modifying agents,% of total sales,2.0
+33119,Sweden,2010,4,B-Blood and blood forming organs,% of total sales,8.5
+33120,Sweden,2010,4,J-Antiinfectives for systemic use,"/capita, US$ purchasing power parity",31.3
+33121,Sweden,2010,4,N-Nervous system,% of total sales,20.1
+33122,Sweden,2010,4,J-Antiinfectives for systemic use,% of total sales,7.3
+33123,Sweden,2010,4,N-Nervous system,"/capita, US$ purchasing power parity",85.7
+33124,Sweden,2010,4,J-Antiinfectives for systemic use,"/capita, US$ exchange rate",39.2
+33125,Sweden,2010,4,N-Nervous system,"/capita, US$ exchange rate",107.4
+33126,Sweden,2010,4,C07-Beta blocking agents,Million US$ at exchange rate,59.7
+33127,Sweden,2010,4,C07-Beta blocking agents,Million of national currency units,430.0
+33128,Sweden,2010,4,C07-Beta blocking agents,"/capita, US$ exchange rate",6.4
+33129,Sweden,2010,4,C07-Beta blocking agents,"Million US$, purchasing power parity",47.6
+33130,Sweden,2010,4,C07-Beta blocking agents,% of total sales,1.2
+33131,Sweden,2010,4,C07-Beta blocking agents,"/capita, US$ purchasing power parity",5.1
+33132,Sweden,2010,4,J-Antiinfectives for systemic use,"Million US$, purchasing power parity",293.5
+33133,Sweden,2010,4,J-Antiinfectives for systemic use,Million US$ at exchange rate,367.6
+33134,Sweden,2010,4,N-Nervous system,Million US$ at exchange rate,1006.9
+33135,Sweden,2010,4,N-Nervous system,"Million US$, purchasing power parity",804.1
+33136,Sweden,2013,5,"C01B-Antiarrhythmics, Class I and III","/capita, US$ purchasing power parity",0.7
+33137,Sweden,2013,5,A-Alimentary tract and metabolism,"Million US$, purchasing power parity",436.2
+33138,Sweden,2013,5,J01-Antibacterials for systemic use,"Million US$, purchasing power parity",83.8
+33139,Sweden,2013,5,C03-Diuretics,"Million US$, purchasing power parity",29.9
+33140,Sweden,2013,5,C03-Diuretics,Million of national currency units,257.0
+33141,Sweden,2013,5,C03-Diuretics,Million US$ at exchange rate,39.5
+33142,Sweden,2013,5,"C01B-Antiarrhythmics, Class I and III","/capita, US$ exchange rate",0.9
+33143,Sweden,2013,5,C03-Diuretics,% of total sales,0.7
+33144,Sweden,2013,5,C03-Diuretics,"/capita, US$ exchange rate",4.1
+33145,Sweden,2013,5,C03-Diuretics,"/capita, US$ purchasing power parity",3.1
+33146,Sweden,2013,5,A-Alimentary tract and metabolism,% of total sales,10.3
+33147,Sweden,2013,5,"C01B-Antiarrhythmics, Class I and III",Million of national currency units,54.1
+33148,Sweden,2013,5,A-Alimentary tract and metabolism,"/capita, US$ purchasing power parity",45.4
+33149,Sweden,2013,5,A-Alimentary tract and metabolism,"/capita, US$ exchange rate",60.0
+33150,Sweden,2013,5,C02-Antihypertensives,Million of national currency units,154.1
+33151,Sweden,2013,5,J01-Antibacterials for systemic use,Million of national currency units,720.8
+33152,Sweden,2013,5,J01-Antibacterials for systemic use,Million US$ at exchange rate,110.7
+33153,Sweden,2013,5,C02-Antihypertensives,"Million US$, purchasing power parity",17.9
+33154,Sweden,2013,5,C02-Antihypertensives,Million US$ at exchange rate,23.7
+33155,Sweden,2013,5,"C01B-Antiarrhythmics, Class I and III",Million US$ at exchange rate,8.3
+33156,Sweden,2013,5,C01A-Cardiac glycosides,"/capita, US$ purchasing power parity",0.2
+33157,Sweden,2013,5,C01A-Cardiac glycosides,"/capita, US$ exchange rate",0.2
+33158,Sweden,2013,5,C-Cardiovascular system,Million US$ at exchange rate,352.4
+33159,Sweden,2013,5,C-Cardiovascular system,Million of national currency units,2295.4
+33160,Sweden,2013,5,C01A-Cardiac glycosides,% of total sales,0.0
+33161,Sweden,2013,5,C01A-Cardiac glycosides,Million of national currency units,14.5
+33162,Sweden,2013,5,"C01B-Antiarrhythmics, Class I and III","Million US$, purchasing power parity",6.3
+33163,Sweden,2013,5,C01A-Cardiac glycosides,"Million US$, purchasing power parity",1.7
+33164,Sweden,2013,5,C01A-Cardiac glycosides,Million US$ at exchange rate,2.2
+33165,Sweden,2013,5,C02-Antihypertensives,"/capita, US$ purchasing power parity",1.9
+33166,Sweden,2013,5,A10-Drugs used in diabetes,Million US$ at exchange rate,209.8
+33167,Sweden,2013,5,Total pharmaceutical sales,Million US$ at exchange rate,5578.4
+33168,Sweden,2013,5,Total pharmaceutical sales,Million of national currency units,36337.4
+33169,Sweden,2013,5,M01A-Antiinflammatory and antirheumatic products non-steroids,% of total sales,2.0
+33170,Sweden,2013,5,C02-Antihypertensives,% of total sales,0.4
+33171,Sweden,2013,5,A10-Drugs used in diabetes,"Million US$, purchasing power parity",159.0
+33172,Sweden,2013,5,C02-Antihypertensives,"/capita, US$ exchange rate",2.5
+33173,Sweden,2013,5,A10-Drugs used in diabetes,"/capita, US$ exchange rate",21.9
+33174,Sweden,2013,5,M-Musculo-skeletal system,"/capita, US$ exchange rate",20.0
+33175,Sweden,2013,5,M-Musculo-skeletal system,"/capita, US$ purchasing power parity",15.1
+33176,Sweden,2013,5,M-Musculo-skeletal system,"Million US$, purchasing power parity",145.4
+33177,Sweden,2013,5,M-Musculo-skeletal system,Million of national currency units,1249.9
+33178,Sweden,2013,5,M-Musculo-skeletal system,Million US$ at exchange rate,191.9
+33179,Sweden,2013,5,Total pharmaceutical sales,"/capita, US$ exchange rate",581.1
+33180,Sweden,2013,5,Total pharmaceutical sales,"Million US$, purchasing power parity",4226.4
+33181,Sweden,2013,5,Total pharmaceutical sales,"/capita, US$ purchasing power parity",440.2
+33182,Sweden,2013,5,M-Musculo-skeletal system,% of total sales,3.4
+33183,Sweden,2013,5,C-Cardiovascular system,"/capita, US$ exchange rate",36.7
+33184,Sweden,2013,5,C-Cardiovascular system,"Million US$, purchasing power parity",267.0
+33185,Sweden,2013,5,A10-Drugs used in diabetes,% of total sales,3.8
+33186,Sweden,2013,5,C-Cardiovascular system,"/capita, US$ purchasing power parity",27.8
+33187,Sweden,2013,5,A-Alimentary tract and metabolism,Million of national currency units,3749.9
+33188,Sweden,2013,5,A-Alimentary tract and metabolism,Million US$ at exchange rate,575.7
+33189,Sweden,2013,5,J01-Antibacterials for systemic use,% of total sales,2.0
+33190,Sweden,2013,5,J01-Antibacterials for systemic use,"/capita, US$ purchasing power parity",8.7
+33191,Sweden,2013,5,J01-Antibacterials for systemic use,"/capita, US$ exchange rate",11.5
+33192,Sweden,2013,5,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ exchange rate",11.4
+33193,Sweden,2013,5,M01A-Antiinflammatory and antirheumatic products non-steroids,"Million US$, purchasing power parity",83.2
+33194,Sweden,2013,5,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ purchasing power parity",8.7
+33195,Sweden,2013,5,M01A-Antiinflammatory and antirheumatic products non-steroids,Million US$ at exchange rate,109.8
+33196,Sweden,2013,5,"C01B-Antiarrhythmics, Class I and III",% of total sales,0.1
+33197,Sweden,2013,5,C-Cardiovascular system,% of total sales,6.3
+33198,Sweden,2013,5,A10-Drugs used in diabetes,"/capita, US$ purchasing power parity",16.6
+33199,Sweden,2013,5,M01A-Antiinflammatory and antirheumatic products non-steroids,Million of national currency units,715.4
+33200,Sweden,2013,5,A10-Drugs used in diabetes,Million of national currency units,1366.8
+33201,Sweden,2013,5,A02A-Antacids,Million of national currency units,75.9
+33202,Sweden,2013,5,C09-Agents acting on the Renin-Angiotensin system,% of total sales,1.3
+33203,Sweden,2013,5,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ purchasing power parity",5.5
+33204,Sweden,2013,5,A02A-Antacids,"Million US$, purchasing power parity",8.8
+33205,Sweden,2013,5,A02A-Antacids,"/capita, US$ exchange rate",1.2
+33206,Sweden,2013,5,A02A-Antacids,Million US$ at exchange rate,11.7
+33207,Sweden,2013,5,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million of national currency units,500.4
+33208,Sweden,2013,5,C09-Agents acting on the Renin-Angiotensin system,Million of national currency units,457.3
+33209,Sweden,2013,5,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million US$ at exchange rate,76.8
+33210,Sweden,2013,5,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ exchange rate",7.3
+33211,Sweden,2013,5,C09-Agents acting on the Renin-Angiotensin system,Million US$ at exchange rate,70.2
+33212,Sweden,2013,5,C09-Agents acting on the Renin-Angiotensin system,"Million US$, purchasing power parity",53.2
+33213,Sweden,2013,5,R-Respiratory system,Million US$ at exchange rate,545.2
+33214,Sweden,2013,5,R-Respiratory system,Million of national currency units,3551.1
+33215,Sweden,2013,5,R-Respiratory system,"Million US$, purchasing power parity",413.0
+33216,Sweden,2013,5,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ purchasing power parity",11.8
+33217,Sweden,2013,5,"H-Systemic hormonal preparations, excluding sex hormones and insulins",% of total sales,2.7
+33218,Sweden,2013,5,A02A-Antacids,% of total sales,0.2
+33219,Sweden,2013,5,A02A-Antacids,"/capita, US$ purchasing power parity",0.9
+33220,Sweden,2013,5,R-Respiratory system,"/capita, US$ exchange rate",56.8
+33221,Sweden,2013,5,R-Respiratory system,"/capita, US$ purchasing power parity",43.0
+33222,Sweden,2013,5,R-Respiratory system,% of total sales,9.8
+33223,Sweden,2013,5,N02-Analgesics,Million US$ at exchange rate,302.7
+33224,Sweden,2013,5,N02-Analgesics,Million of national currency units,1972.0
+33225,Sweden,2013,5,N02-Analgesics,"/capita, US$ purchasing power parity",23.9
+33226,Sweden,2013,5,N02-Analgesics,"Million US$, purchasing power parity",229.4
+33227,Sweden,2013,5,N02-Analgesics,"/capita, US$ exchange rate",31.5
+33228,Sweden,2013,5,C08-Calcium channel blockers,% of total sales,0.5
+33229,Sweden,2013,5,C08-Calcium channel blockers,Million US$ at exchange rate,30.5
+33230,Sweden,2013,5,J-Antiinfectives for systemic use,Million of national currency units,2367.4
+33231,Sweden,2013,5,C08-Calcium channel blockers,Million of national currency units,198.7
+33232,Sweden,2013,5,C08-Calcium channel blockers,"Million US$, purchasing power parity",23.1
+33233,Sweden,2013,5,C08-Calcium channel blockers,"/capita, US$ purchasing power parity",2.4
+33234,Sweden,2013,5,C08-Calcium channel blockers,"/capita, US$ exchange rate",3.2
+33235,Sweden,2013,5,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),% of total sales,1.4
+33236,Sweden,2013,5,R03-Drugs for obstructive airway diseases,Million US$ at exchange rate,311.5
+33237,Sweden,2013,5,R03-Drugs for obstructive airway diseases,Million of national currency units,2029.1
+33238,Sweden,2013,5,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"Million US$, purchasing power parity",58.2
+33239,Sweden,2013,5,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ exchange rate",8.0
+33240,Sweden,2013,5,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ purchasing power parity",6.1
+33241,Sweden,2013,5,R03-Drugs for obstructive airway diseases,% of total sales,5.6
+33242,Sweden,2013,5,N02-Analgesics,% of total sales,5.4
+33243,Sweden,2013,5,R03-Drugs for obstructive airway diseases,"Million US$, purchasing power parity",236.0
+33244,Sweden,2013,5,R03-Drugs for obstructive airway diseases,"/capita, US$ exchange rate",32.4
+33245,Sweden,2013,5,R03-Drugs for obstructive airway diseases,"/capita, US$ purchasing power parity",24.6
+33246,Sweden,2013,5,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ exchange rate",15.6
+33247,Sweden,2013,5,G03-Sex hormones and modulators of the genital system,"/capita, US$ exchange rate",14.8
+33248,Sweden,2013,5,G03-Sex hormones and modulators of the genital system,"Million US$, purchasing power parity",108.0
+33249,Sweden,2013,5,G03-Sex hormones and modulators of the genital system,"/capita, US$ purchasing power parity",11.2
+33250,Sweden,2013,5,G03-Sex hormones and modulators of the genital system,Million of national currency units,928.4
+33251,Sweden,2013,5,G-Genito urinary system and sex hormones,Million of national currency units,1729.0
+33252,Sweden,2013,5,G03-Sex hormones and modulators of the genital system,Million US$ at exchange rate,142.5
+33253,Sweden,2013,5,N06A-Antidepressants,"Million US$, purchasing power parity",86.6
+33254,Sweden,2013,5,N06A-Antidepressants,"/capita, US$ purchasing power parity",9.0
+33255,Sweden,2013,5,N06A-Antidepressants,"/capita, US$ exchange rate",11.9
+33256,Sweden,2013,5,G03-Sex hormones and modulators of the genital system,% of total sales,2.6
+33257,Sweden,2013,5,N06A-Antidepressants,Million of national currency units,744.4
+33258,Sweden,2013,5,N06A-Antidepressants,Million US$ at exchange rate,114.3
+33259,Sweden,2013,5,N05C-Hypnotics and sedatives,"Million US$, purchasing power parity",36.6
+33260,Sweden,2013,5,N05C-Hypnotics and sedatives,Million US$ at exchange rate,48.3
+33261,Sweden,2013,5,N05C-Hypnotics and sedatives,"/capita, US$ exchange rate",5.0
+33262,Sweden,2013,5,N05C-Hypnotics and sedatives,% of total sales,0.9
+33263,Sweden,2013,5,N05C-Hypnotics and sedatives,"/capita, US$ purchasing power parity",3.8
+33264,Sweden,2013,5,G-Genito urinary system and sex hormones,"/capita, US$ exchange rate",27.6
+33265,Sweden,2013,5,G-Genito urinary system and sex hormones,"Million US$, purchasing power parity",201.1
+33266,Sweden,2013,5,G-Genito urinary system and sex hormones,Million US$ at exchange rate,265.4
+33267,Sweden,2013,5,G-Genito urinary system and sex hormones,% of total sales,4.8
+33268,Sweden,2013,5,N05C-Hypnotics and sedatives,Million of national currency units,314.9
+33269,Sweden,2013,5,G-Genito urinary system and sex hormones,"/capita, US$ purchasing power parity",20.9
+33270,Sweden,2013,5,N05B-Anxiolytics,"/capita, US$ purchasing power parity",2.4
+33271,Sweden,2013,5,N05B-Anxiolytics,"/capita, US$ exchange rate",3.2
+33272,Sweden,2013,5,N05B-Anxiolytics,% of total sales,0.6
+33273,Sweden,2013,5,C10-Lipid modifying agents,Million US$ at exchange rate,67.7
+33274,Sweden,2013,5,C10-Lipid modifying agents,Million of national currency units,440.8
+33275,Sweden,2013,5,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million US$ at exchange rate,149.4
+33276,Sweden,2013,5,"H-Systemic hormonal preparations, excluding sex hormones and insulins","Million US$, purchasing power parity",113.2
+33277,Sweden,2013,5,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million of national currency units,973.5
+33278,Sweden,2013,5,N05B-Anxiolytics,Million US$ at exchange rate,30.8
+33279,Sweden,2013,5,N05B-Anxiolytics,"Million US$, purchasing power parity",23.3
+33280,Sweden,2013,5,N05B-Anxiolytics,Million of national currency units,200.7
+33281,Sweden,2013,5,B-Blood and blood forming organs,"Million US$, purchasing power parity",366.2
+33282,Sweden,2013,5,B-Blood and blood forming organs,"/capita, US$ exchange rate",50.3
+33283,Sweden,2013,5,N06A-Antidepressants,% of total sales,2.0
+33284,Sweden,2013,5,B-Blood and blood forming organs,Million of national currency units,3148.6
+33285,Sweden,2013,5,B-Blood and blood forming organs,Million US$ at exchange rate,483.4
+33286,Sweden,2013,5,B-Blood and blood forming organs,"/capita, US$ purchasing power parity",38.1
+33287,Sweden,2013,5,C10-Lipid modifying agents,"/capita, US$ purchasing power parity",5.3
+33288,Sweden,2013,5,C10-Lipid modifying agents,"Million US$, purchasing power parity",51.3
+33289,Sweden,2013,5,C10-Lipid modifying agents,"/capita, US$ exchange rate",7.0
+33290,Sweden,2013,5,B-Blood and blood forming organs,% of total sales,8.7
+33291,Sweden,2013,5,C10-Lipid modifying agents,% of total sales,1.2
+33292,Sweden,2013,5,J-Antiinfectives for systemic use,"/capita, US$ purchasing power parity",28.7
+33293,Sweden,2013,5,J-Antiinfectives for systemic use,% of total sales,6.5
+33294,Sweden,2013,5,J-Antiinfectives for systemic use,"/capita, US$ exchange rate",37.9
+33295,Sweden,2013,5,N-Nervous system,"/capita, US$ exchange rate",116.7
+33296,Sweden,2013,5,N-Nervous system,"/capita, US$ purchasing power parity",88.4
+33297,Sweden,2013,5,C07-Beta blocking agents,Million US$ at exchange rate,63.1
+33298,Sweden,2013,5,C07-Beta blocking agents,Million of national currency units,411.0
+33299,Sweden,2013,5,C07-Beta blocking agents,"/capita, US$ exchange rate",6.6
+33300,Sweden,2013,5,C07-Beta blocking agents,"Million US$, purchasing power parity",47.8
+33301,Sweden,2013,5,N-Nervous system,% of total sales,20.1
+33302,Sweden,2013,5,C07-Beta blocking agents,% of total sales,1.1
+33303,Sweden,2013,5,C07-Beta blocking agents,"/capita, US$ purchasing power parity",5.0
+33304,Sweden,2013,5,J-Antiinfectives for systemic use,Million US$ at exchange rate,363.4
+33305,Sweden,2013,5,J-Antiinfectives for systemic use,"Million US$, purchasing power parity",275.3
+33306,Sweden,2013,5,N-Nervous system,Million US$ at exchange rate,1119.9
+33307,Sweden,2013,5,N-Nervous system,Million of national currency units,7295.0
+33308,Sweden,2013,5,N-Nervous system,"Million US$, purchasing power parity",848.5
+33309,Switzerland,2017,5,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ purchasing power parity",9.3
+33310,Switzerland,2017,5,"H-Systemic hormonal preparations, excluding sex hormones and insulins",% of total sales,1.4
+33311,Switzerland,2017,5,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ exchange rate",11.2
+33312,Switzerland,2017,5,B-Blood and blood forming organs,Million of national currency units,354.0
+33313,Switzerland,2017,5,B-Blood and blood forming organs,Million US$ at exchange rate,359.5
+33314,Switzerland,2017,5,B-Blood and blood forming organs,"Million US$, purchasing power parity",298.0
+33315,Switzerland,2017,5,"H-Systemic hormonal preparations, excluding sex hormones and insulins","Million US$, purchasing power parity",78.3
+33316,Switzerland,2017,5,C-Cardiovascular system,Million of national currency units,792.0
+33317,Switzerland,2017,5,N-Nervous system,"/capita, US$ exchange rate",145.9
+33318,Switzerland,2017,5,N-Nervous system,"/capita, US$ purchasing power parity",120.9
+33319,Switzerland,2017,5,N-Nervous system,"Million US$, purchasing power parity",1022.1
+33320,Switzerland,2017,5,N-Nervous system,Million of national currency units,1214.0
+33321,Switzerland,2017,5,N-Nervous system,Million US$ at exchange rate,1232.9
+33322,Switzerland,2017,5,N-Nervous system,% of total sales,18.6
+33323,Switzerland,2017,5,C-Cardiovascular system,"Million US$, purchasing power parity",666.8
+33324,Switzerland,2017,5,C-Cardiovascular system,Million US$ at exchange rate,804.3
+33325,Switzerland,2017,5,C-Cardiovascular system,"/capita, US$ exchange rate",95.2
+33326,Switzerland,2017,5,C-Cardiovascular system,% of total sales,12.1
+33327,Switzerland,2017,5,C-Cardiovascular system,"/capita, US$ purchasing power parity",78.9
+33328,Switzerland,2017,5,Products not elsewhere classified,Million of national currency units,1298.0
+33329,Switzerland,2017,5,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million US$ at exchange rate,94.4
+33330,Switzerland,2017,5,M-Musculo-skeletal system,Million of national currency units,427.0
+33331,Switzerland,2017,5,M-Musculo-skeletal system,Million US$ at exchange rate,433.6
+33332,Switzerland,2017,5,R-Respiratory system,Million of national currency units,507.0
+33333,Switzerland,2017,5,R-Respiratory system,Million US$ at exchange rate,514.9
+33334,Switzerland,2017,5,Products not elsewhere classified,% of total sales,19.9
+33335,Switzerland,2017,5,Products not elsewhere classified,"/capita, US$ purchasing power parity",129.3
+33336,Switzerland,2017,5,Products not elsewhere classified,"/capita, US$ exchange rate",156.0
+33337,Switzerland,2017,5,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million of national currency units,93.0
+33338,Switzerland,2017,5,Products not elsewhere classified,Million US$ at exchange rate,1318.2
+33339,Switzerland,2017,5,Products not elsewhere classified,"Million US$, purchasing power parity",1092.8
+33340,Switzerland,2017,5,Total pharmaceutical sales,Million US$ at exchange rate,6621.4
+33341,Switzerland,2017,5,Total pharmaceutical sales,Million of national currency units,6520.0
+33342,Switzerland,2017,5,Total pharmaceutical sales,"Million US$, purchasing power parity",5489.5
+33343,Switzerland,2017,5,B-Blood and blood forming organs,"/capita, US$ exchange rate",42.5
+33344,Switzerland,2017,5,B-Blood and blood forming organs,"/capita, US$ purchasing power parity",35.3
+33345,Switzerland,2017,5,B-Blood and blood forming organs,% of total sales,5.4
+33346,Switzerland,2017,5,R-Respiratory system,"/capita, US$ exchange rate",60.9
+33347,Switzerland,2017,5,R-Respiratory system,"/capita, US$ purchasing power parity",50.5
+33348,Switzerland,2017,5,R-Respiratory system,"Million US$, purchasing power parity",426.9
+33349,Switzerland,2017,5,Total pharmaceutical sales,"/capita, US$ exchange rate",783.4
+33350,Switzerland,2017,5,Total pharmaceutical sales,"/capita, US$ purchasing power parity",649.5
+33351,Switzerland,2017,5,R-Respiratory system,% of total sales,7.8
+33352,Switzerland,2017,5,A-Alimentary tract and metabolism,"/capita, US$ purchasing power parity",93.0
+33353,Switzerland,2017,5,A-Alimentary tract and metabolism,% of total sales,14.3
+33354,Switzerland,2017,5,M-Musculo-skeletal system,% of total sales,6.5
+33355,Switzerland,2017,5,A-Alimentary tract and metabolism,"/capita, US$ exchange rate",112.2
+33356,Switzerland,2017,5,J-Antiinfectives for systemic use,% of total sales,8.5
+33357,Switzerland,2017,5,A-Alimentary tract and metabolism,Million of national currency units,934.0
+33358,Switzerland,2017,5,J-Antiinfectives for systemic use,"/capita, US$ purchasing power parity",55.2
+33359,Switzerland,2017,5,A-Alimentary tract and metabolism,Million US$ at exchange rate,948.5
+33360,Switzerland,2017,5,M-Musculo-skeletal system,"/capita, US$ exchange rate",51.3
+33361,Switzerland,2017,5,M-Musculo-skeletal system,"/capita, US$ purchasing power parity",42.5
+33362,Switzerland,2017,5,A-Alimentary tract and metabolism,"Million US$, purchasing power parity",786.4
+33363,Switzerland,2017,5,M-Musculo-skeletal system,"Million US$, purchasing power parity",359.5
+33364,Switzerland,2017,5,J-Antiinfectives for systemic use,Million of national currency units,554.0
+33365,Switzerland,2017,5,G-Genito urinary system and sex hormones,Million of national currency units,347.0
+33366,Switzerland,2017,5,G-Genito urinary system and sex hormones,% of total sales,5.3
+33367,Switzerland,2017,5,G-Genito urinary system and sex hormones,"/capita, US$ purchasing power parity",34.6
+33368,Switzerland,2017,5,J-Antiinfectives for systemic use,Million US$ at exchange rate,562.6
+33369,Switzerland,2017,5,J-Antiinfectives for systemic use,"Million US$, purchasing power parity",466.4
+33370,Switzerland,2017,5,J-Antiinfectives for systemic use,"/capita, US$ exchange rate",66.6
+33371,Switzerland,2017,5,G-Genito urinary system and sex hormones,Million US$ at exchange rate,352.4
+33372,Switzerland,2017,5,G-Genito urinary system and sex hormones,"Million US$, purchasing power parity",292.2
+33373,Switzerland,2017,5,G-Genito urinary system and sex hormones,"/capita, US$ exchange rate",41.7
+33374,Switzerland,2016,5,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ purchasing power parity",9.0
+33375,Switzerland,2016,5,"H-Systemic hormonal preparations, excluding sex hormones and insulins",% of total sales,1.4
+33376,Switzerland,2016,5,B-Blood and blood forming organs,Million US$ at exchange rate,324.7
+33377,Switzerland,2016,5,B-Blood and blood forming organs,"Million US$, purchasing power parity",266.2
+33378,Switzerland,2016,5,B-Blood and blood forming organs,Million of national currency units,320.0
+33379,Switzerland,2016,5,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ exchange rate",11.0
+33380,Switzerland,2016,5,"H-Systemic hormonal preparations, excluding sex hormones and insulins","Million US$, purchasing power parity",75.7
+33381,Switzerland,2016,5,C-Cardiovascular system,Million of national currency units,799.0
+33382,Switzerland,2016,5,N-Nervous system,"/capita, US$ exchange rate",148.0
+33383,Switzerland,2016,5,N-Nervous system,"/capita, US$ purchasing power parity",121.3
+33384,Switzerland,2016,5,N-Nervous system,Million of national currency units,1221.0
+33385,Switzerland,2016,5,N-Nervous system,"Million US$, purchasing power parity",1015.8
+33386,Switzerland,2016,5,N-Nervous system,Million US$ at exchange rate,1239.1
+33387,Switzerland,2016,5,N-Nervous system,% of total sales,19.1
+33388,Switzerland,2016,5,C-Cardiovascular system,"Million US$, purchasing power parity",664.7
+33389,Switzerland,2016,5,C-Cardiovascular system,Million US$ at exchange rate,810.8
+33390,Switzerland,2016,5,C-Cardiovascular system,"/capita, US$ exchange rate",96.8
+33391,Switzerland,2016,5,C-Cardiovascular system,% of total sales,12.5
+33392,Switzerland,2016,5,C-Cardiovascular system,"/capita, US$ purchasing power parity",79.4
+33393,Switzerland,2016,5,Products not elsewhere classified,Million of national currency units,1218.0
+33394,Switzerland,2016,5,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million US$ at exchange rate,92.3
+33395,Switzerland,2016,5,M-Musculo-skeletal system,Million of national currency units,416.0
+33396,Switzerland,2016,5,M-Musculo-skeletal system,Million US$ at exchange rate,422.2
+33397,Switzerland,2016,5,R-Respiratory system,Million of national currency units,497.0
+33398,Switzerland,2016,5,R-Respiratory system,Million US$ at exchange rate,504.4
+33399,Switzerland,2016,5,Products not elsewhere classified,% of total sales,19.1
+33400,Switzerland,2016,5,Products not elsewhere classified,"/capita, US$ exchange rate",147.6
+33401,Switzerland,2016,5,Products not elsewhere classified,"/capita, US$ purchasing power parity",121.0
+33402,Switzerland,2016,5,Products not elsewhere classified,Million US$ at exchange rate,1236.1
+33403,Switzerland,2016,5,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million of national currency units,91.0
+33404,Switzerland,2016,5,Products not elsewhere classified,"Million US$, purchasing power parity",1013.3
+33405,Switzerland,2016,5,Total pharmaceutical sales,Million US$ at exchange rate,6474.6
+33406,Switzerland,2016,5,Total pharmaceutical sales,Million of national currency units,6380.0
+33407,Switzerland,2016,5,Total pharmaceutical sales,"Million US$, purchasing power parity",5308.0
+33408,Switzerland,2016,5,B-Blood and blood forming organs,"/capita, US$ purchasing power parity",31.8
+33409,Switzerland,2016,5,B-Blood and blood forming organs,"/capita, US$ exchange rate",38.8
+33410,Switzerland,2016,5,B-Blood and blood forming organs,% of total sales,5.0
+33411,Switzerland,2016,5,R-Respiratory system,"/capita, US$ exchange rate",60.2
+33412,Switzerland,2016,5,R-Respiratory system,"/capita, US$ purchasing power parity",49.4
+33413,Switzerland,2016,5,R-Respiratory system,"Million US$, purchasing power parity",413.5
+33414,Switzerland,2016,5,Total pharmaceutical sales,"/capita, US$ purchasing power parity",633.9
+33415,Switzerland,2016,5,Total pharmaceutical sales,"/capita, US$ exchange rate",773.2
+33416,Switzerland,2016,5,R-Respiratory system,% of total sales,7.8
+33417,Switzerland,2016,5,A-Alimentary tract and metabolism,"/capita, US$ purchasing power parity",91.7
+33418,Switzerland,2016,5,A-Alimentary tract and metabolism,% of total sales,14.5
+33419,Switzerland,2016,5,M-Musculo-skeletal system,% of total sales,6.5
+33420,Switzerland,2016,5,A-Alimentary tract and metabolism,"/capita, US$ exchange rate",111.9
+33421,Switzerland,2016,5,J-Antiinfectives for systemic use,% of total sales,8.6
+33422,Switzerland,2016,5,A-Alimentary tract and metabolism,Million of national currency units,923.0
+33423,Switzerland,2016,5,J-Antiinfectives for systemic use,"/capita, US$ purchasing power parity",54.3
+33424,Switzerland,2016,5,A-Alimentary tract and metabolism,Million US$ at exchange rate,936.7
+33425,Switzerland,2016,5,J-Antiinfectives for systemic use,Million of national currency units,546.0
+33426,Switzerland,2016,5,M-Musculo-skeletal system,"/capita, US$ exchange rate",50.4
+33427,Switzerland,2016,5,M-Musculo-skeletal system,"/capita, US$ purchasing power parity",41.3
+33428,Switzerland,2016,5,M-Musculo-skeletal system,"Million US$, purchasing power parity",346.1
+33429,Switzerland,2016,5,A-Alimentary tract and metabolism,"Million US$, purchasing power parity",767.9
+33430,Switzerland,2016,5,G-Genito urinary system and sex hormones,Million of national currency units,351.0
+33431,Switzerland,2016,5,G-Genito urinary system and sex hormones,% of total sales,5.5
+33432,Switzerland,2016,5,G-Genito urinary system and sex hormones,"/capita, US$ purchasing power parity",34.9
+33433,Switzerland,2016,5,J-Antiinfectives for systemic use,Million US$ at exchange rate,554.1
+33434,Switzerland,2016,5,J-Antiinfectives for systemic use,"Million US$, purchasing power parity",454.3
+33435,Switzerland,2016,5,J-Antiinfectives for systemic use,"/capita, US$ exchange rate",66.2
+33436,Switzerland,2016,5,G-Genito urinary system and sex hormones,Million US$ at exchange rate,356.2
+33437,Switzerland,2016,5,G-Genito urinary system and sex hormones,"Million US$, purchasing power parity",292.0
+33438,Switzerland,2016,5,G-Genito urinary system and sex hormones,"/capita, US$ exchange rate",42.5
+33439,Switzerland,2014,5,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ purchasing power parity",8.1
+33440,Switzerland,2014,5,C-Cardiovascular system,Million of national currency units,770.0
+33441,Switzerland,2014,5,"H-Systemic hormonal preparations, excluding sex hormones and insulins",% of total sales,1.4
+33442,Switzerland,2014,5,B-Blood and blood forming organs,Million US$ at exchange rate,287.1
+33443,Switzerland,2014,5,B-Blood and blood forming organs,"Million US$, purchasing power parity",205.2
+33444,Switzerland,2014,5,B-Blood and blood forming organs,Million of national currency units,263.0
+33445,Switzerland,2014,5,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ exchange rate",11.3
+33446,Switzerland,2014,5,"H-Systemic hormonal preparations, excluding sex hormones and insulins","Million US$, purchasing power parity",66.3
+33447,Switzerland,2014,5,C-Cardiovascular system,"Million US$, purchasing power parity",600.7
+33448,Switzerland,2014,5,N-Nervous system,"/capita, US$ exchange rate",137.0
+33449,Switzerland,2014,5,N-Nervous system,% of total sales,17.3
+33450,Switzerland,2014,5,N-Nervous system,"/capita, US$ purchasing power parity",97.9
+33451,Switzerland,2014,5,N-Nervous system,Million of national currency units,1028.0
+33452,Switzerland,2014,5,N-Nervous system,Million US$ at exchange rate,1122.1
+33453,Switzerland,2014,5,N-Nervous system,"Million US$, purchasing power parity",802.0
+33454,Switzerland,2014,5,C-Cardiovascular system,Million US$ at exchange rate,840.5
+33455,Switzerland,2014,5,C-Cardiovascular system,% of total sales,13.0
+33456,Switzerland,2014,5,C-Cardiovascular system,"/capita, US$ purchasing power parity",73.4
+33457,Switzerland,2014,5,B-Blood and blood forming organs,"/capita, US$ exchange rate",35.1
+33458,Switzerland,2014,5,Products not elsewhere classified,Million of national currency units,1258.0
+33459,Switzerland,2014,5,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million US$ at exchange rate,92.8
+33460,Switzerland,2014,5,M-Musculo-skeletal system,Million US$ at exchange rate,418.1
+33461,Switzerland,2014,5,M-Musculo-skeletal system,Million of national currency units,383.0
+33462,Switzerland,2014,5,R-Respiratory system,Million of national currency units,476.0
+33463,Switzerland,2014,5,R-Respiratory system,Million US$ at exchange rate,519.6
+33464,Switzerland,2014,5,Products not elsewhere classified,% of total sales,21.2
+33465,Switzerland,2014,5,Products not elsewhere classified,"/capita, US$ exchange rate",167.7
+33466,Switzerland,2014,5,Products not elsewhere classified,"/capita, US$ purchasing power parity",119.9
+33467,Switzerland,2014,5,Products not elsewhere classified,Million US$ at exchange rate,1373.1
+33468,Switzerland,2014,5,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million of national currency units,85.0
+33469,Switzerland,2014,5,Products not elsewhere classified,"Million US$, purchasing power parity",981.5
+33470,Switzerland,2014,5,Total pharmaceutical sales,Million US$ at exchange rate,6473.8
+33471,Switzerland,2014,5,Total pharmaceutical sales,"Million US$, purchasing power parity",4627.2
+33472,Switzerland,2014,5,Total pharmaceutical sales,Million of national currency units,5931.0
+33473,Switzerland,2014,5,B-Blood and blood forming organs,"/capita, US$ purchasing power parity",25.1
+33474,Switzerland,2014,5,B-Blood and blood forming organs,% of total sales,4.4
+33475,Switzerland,2014,5,Total pharmaceutical sales,"/capita, US$ exchange rate",790.6
+33476,Switzerland,2014,5,R-Respiratory system,"/capita, US$ purchasing power parity",45.4
+33477,Switzerland,2014,5,R-Respiratory system,"/capita, US$ exchange rate",63.4
+33478,Switzerland,2014,5,R-Respiratory system,"Million US$, purchasing power parity",371.4
+33479,Switzerland,2014,5,Total pharmaceutical sales,"/capita, US$ purchasing power parity",565.1
+33480,Switzerland,2014,5,R-Respiratory system,% of total sales,8.0
+33481,Switzerland,2014,5,C-Cardiovascular system,"/capita, US$ exchange rate",102.6
+33482,Switzerland,2014,5,A-Alimentary tract and metabolism,"/capita, US$ purchasing power parity",82.2
+33483,Switzerland,2014,5,A-Alimentary tract and metabolism,% of total sales,14.6
+33484,Switzerland,2014,5,M-Musculo-skeletal system,% of total sales,6.5
+33485,Switzerland,2014,5,A-Alimentary tract and metabolism,"/capita, US$ exchange rate",115.0
+33486,Switzerland,2014,5,J-Antiinfectives for systemic use,% of total sales,7.7
+33487,Switzerland,2014,5,M-Musculo-skeletal system,"/capita, US$ exchange rate",51.1
+33488,Switzerland,2014,5,A-Alimentary tract and metabolism,Million of national currency units,863.0
+33489,Switzerland,2014,5,J-Antiinfectives for systemic use,"/capita, US$ purchasing power parity",43.7
+33490,Switzerland,2014,5,G-Genito urinary system and sex hormones,Million of national currency units,346.0
+33491,Switzerland,2014,5,A-Alimentary tract and metabolism,Million US$ at exchange rate,942.0
+33492,Switzerland,2014,5,J-Antiinfectives for systemic use,Million of national currency units,459.0
+33493,Switzerland,2014,5,M-Musculo-skeletal system,"/capita, US$ purchasing power parity",36.5
+33494,Switzerland,2014,5,A-Alimentary tract and metabolism,"Million US$, purchasing power parity",673.3
+33495,Switzerland,2014,5,M-Musculo-skeletal system,"Million US$, purchasing power parity",298.8
+33496,Switzerland,2014,5,J-Antiinfectives for systemic use,Million US$ at exchange rate,501.0
+33497,Switzerland,2014,5,G-Genito urinary system and sex hormones,% of total sales,5.8
+33498,Switzerland,2014,5,G-Genito urinary system and sex hormones,"/capita, US$ purchasing power parity",33.0
+33499,Switzerland,2014,5,J-Antiinfectives for systemic use,"Million US$, purchasing power parity",358.1
+33500,Switzerland,2014,5,J-Antiinfectives for systemic use,"/capita, US$ exchange rate",61.2
+33501,Switzerland,2014,5,G-Genito urinary system and sex hormones,Million US$ at exchange rate,377.7
+33502,Switzerland,2014,5,G-Genito urinary system and sex hormones,"Million US$, purchasing power parity",269.9
+33503,Switzerland,2014,5,G-Genito urinary system and sex hormones,"/capita, US$ exchange rate",46.1
+33504,Switzerland,2013,6,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ purchasing power parity",7.9
+33505,Switzerland,2013,6,C-Cardiovascular system,Million of national currency units,791.0
+33506,Switzerland,2013,6,"H-Systemic hormonal preparations, excluding sex hormones and insulins",% of total sales,1.4
+33507,Switzerland,2013,6,B-Blood and blood forming organs,Million US$ at exchange rate,264.3
+33508,Switzerland,2013,6,B-Blood and blood forming organs,"Million US$, purchasing power parity",186.7
+33509,Switzerland,2013,6,B-Blood and blood forming organs,Million of national currency units,245.0
+33510,Switzerland,2013,6,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ exchange rate",11.2
+33511,Switzerland,2013,6,M-Musculo-skeletal system,Million of national currency units,355.0
+33512,Switzerland,2013,6,N-Nervous system,"/capita, US$ exchange rate",139.4
+33513,Switzerland,2013,6,N-Nervous system,% of total sales,17.6
+33514,Switzerland,2013,6,N-Nervous system,"/capita, US$ purchasing power parity",98.4
+33515,Switzerland,2013,6,N-Nervous system,Million of national currency units,1045.0
+33516,Switzerland,2013,6,N-Nervous system,Million US$ at exchange rate,1127.4
+33517,Switzerland,2013,6,N-Nervous system,"Million US$, purchasing power parity",796.2
+33518,Switzerland,2013,6,C-Cardiovascular system,"Million US$, purchasing power parity",602.7
+33519,Switzerland,2013,6,C-Cardiovascular system,"/capita, US$ exchange rate",105.5
+33520,Switzerland,2013,6,C-Cardiovascular system,Million US$ at exchange rate,853.4
+33521,Switzerland,2013,6,C-Cardiovascular system,% of total sales,13.3
+33522,Switzerland,2013,6,C-Cardiovascular system,"/capita, US$ purchasing power parity",74.5
+33523,Switzerland,2013,6,Products not elsewhere classified,Million of national currency units,1238.0
+33524,Switzerland,2013,6,Products not elsewhere classified,Million US$ at exchange rate,1335.6
+33525,Switzerland,2013,6,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million US$ at exchange rate,90.6
+33526,Switzerland,2013,6,"H-Systemic hormonal preparations, excluding sex hormones and insulins","Million US$, purchasing power parity",64.0
+33527,Switzerland,2013,6,R-Respiratory system,Million of national currency units,513.0
+33528,Switzerland,2013,6,M-Musculo-skeletal system,Million US$ at exchange rate,383.0
+33529,Switzerland,2013,6,R-Respiratory system,Million US$ at exchange rate,553.5
+33530,Switzerland,2013,6,Products not elsewhere classified,% of total sales,20.9
+33531,Switzerland,2013,6,Products not elsewhere classified,"/capita, US$ exchange rate",165.1
+33532,Switzerland,2013,6,Products not elsewhere classified,"/capita, US$ purchasing power parity",116.6
+33533,Switzerland,2013,6,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million of national currency units,84.0
+33534,Switzerland,2013,6,Products not elsewhere classified,"Million US$, purchasing power parity",943.3
+33535,Switzerland,2013,6,Total pharmaceutical sales,Million US$ at exchange rate,6398.7
+33536,Switzerland,2013,6,Total pharmaceutical sales,"Million US$, purchasing power parity",4518.9
+33537,Switzerland,2013,6,Total pharmaceutical sales,Million of national currency units,5931.0
+33538,Switzerland,2013,6,B-Blood and blood forming organs,"/capita, US$ purchasing power parity",23.1
+33539,Switzerland,2013,6,B-Blood and blood forming organs,% of total sales,4.1
+33540,Switzerland,2013,6,B-Blood and blood forming organs,"/capita, US$ exchange rate",32.7
+33541,Switzerland,2013,6,R-Respiratory system,"/capita, US$ purchasing power parity",48.3
+33542,Switzerland,2013,6,R-Respiratory system,"Million US$, purchasing power parity",390.9
+33543,Switzerland,2013,6,R-Respiratory system,"/capita, US$ exchange rate",68.4
+33544,Switzerland,2013,6,Total pharmaceutical sales,"/capita, US$ purchasing power parity",558.6
+33545,Switzerland,2013,6,R-Respiratory system,% of total sales,8.6
+33546,Switzerland,2013,6,Total pharmaceutical sales,"/capita, US$ exchange rate",791.0
+33547,Switzerland,2013,6,A-Alimentary tract and metabolism,"/capita, US$ purchasing power parity",80.8
+33548,Switzerland,2013,6,A-Alimentary tract and metabolism,% of total sales,14.5
+33549,Switzerland,2013,6,M-Musculo-skeletal system,% of total sales,6.0
+33550,Switzerland,2013,6,J-Antiinfectives for systemic use,% of total sales,7.6
+33551,Switzerland,2013,6,G-Genito urinary system and sex hormones,Million of national currency units,353.0
+33552,Switzerland,2013,6,A-Alimentary tract and metabolism,Million of national currency units,858.0
+33553,Switzerland,2013,6,J-Antiinfectives for systemic use,"/capita, US$ purchasing power parity",42.3
+33554,Switzerland,2013,6,A-Alimentary tract and metabolism,Million US$ at exchange rate,925.7
+33555,Switzerland,2013,6,A-Alimentary tract and metabolism,"Million US$, purchasing power parity",653.7
+33556,Switzerland,2013,6,J-Antiinfectives for systemic use,Million of national currency units,449.0
+33557,Switzerland,2013,6,M-Musculo-skeletal system,"/capita, US$ purchasing power parity",33.4
+33558,Switzerland,2013,6,M-Musculo-skeletal system,"Million US$, purchasing power parity",270.5
+33559,Switzerland,2013,6,A-Alimentary tract and metabolism,"/capita, US$ exchange rate",114.4
+33560,Switzerland,2013,6,J-Antiinfectives for systemic use,Million US$ at exchange rate,484.4
+33561,Switzerland,2013,6,G-Genito urinary system and sex hormones,% of total sales,6.0
+33562,Switzerland,2013,6,G-Genito urinary system and sex hormones,"/capita, US$ purchasing power parity",33.2
+33563,Switzerland,2013,6,J-Antiinfectives for systemic use,"Million US$, purchasing power parity",342.1
+33564,Switzerland,2013,6,J-Antiinfectives for systemic use,"/capita, US$ exchange rate",59.9
+33565,Switzerland,2013,6,M-Musculo-skeletal system,"/capita, US$ exchange rate",47.3
+33566,Switzerland,2013,6,G-Genito urinary system and sex hormones,Million US$ at exchange rate,380.8
+33567,Switzerland,2013,6,G-Genito urinary system and sex hormones,"Million US$, purchasing power parity",269.0
+33568,Switzerland,2013,6,G-Genito urinary system and sex hormones,"/capita, US$ exchange rate",47.1
+33569,Switzerland,2012,6,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ purchasing power parity",7.7
+33570,Switzerland,2012,6,C-Cardiovascular system,Million of national currency units,876.0
+33571,Switzerland,2012,6,"H-Systemic hormonal preparations, excluding sex hormones and insulins",% of total sales,1.4
+33572,Switzerland,2012,6,B-Blood and blood forming organs,Million US$ at exchange rate,236.8
+33573,Switzerland,2012,6,B-Blood and blood forming organs,"Million US$, purchasing power parity",163.9
+33574,Switzerland,2012,6,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ exchange rate",11.1
+33575,Switzerland,2012,6,M-Musculo-skeletal system,Million of national currency units,356.0
+33576,Switzerland,2012,6,B-Blood and blood forming organs,Million of national currency units,222.0
+33577,Switzerland,2012,6,N-Nervous system,"/capita, US$ exchange rate",141.4
+33578,Switzerland,2012,6,N-Nervous system,"/capita, US$ purchasing power parity",97.9
+33579,Switzerland,2012,6,N-Nervous system,% of total sales,17.9
+33580,Switzerland,2012,6,N-Nervous system,Million of national currency units,1060.0
+33581,Switzerland,2012,6,N-Nervous system,Million US$ at exchange rate,1130.4
+33582,Switzerland,2012,6,N-Nervous system,"Million US$, purchasing power parity",782.8
+33583,Switzerland,2012,6,C-Cardiovascular system,"Million US$, purchasing power parity",646.9
+33584,Switzerland,2012,6,C-Cardiovascular system,"/capita, US$ exchange rate",116.8
+33585,Switzerland,2012,6,C-Cardiovascular system,Million US$ at exchange rate,934.2
+33586,Switzerland,2012,6,C-Cardiovascular system,% of total sales,14.8
+33587,Switzerland,2012,6,C-Cardiovascular system,"/capita, US$ purchasing power parity",80.9
+33588,Switzerland,2012,6,B-Blood and blood forming organs,"/capita, US$ exchange rate",29.6
+33589,Switzerland,2012,6,Products not elsewhere classified,Million of national currency units,1180.0
+33590,Switzerland,2012,6,R-Respiratory system,Million of national currency units,494.0
+33591,Switzerland,2012,6,"H-Systemic hormonal preparations, excluding sex hormones and insulins","Million US$, purchasing power parity",61.3
+33592,Switzerland,2012,6,Products not elsewhere classified,Million US$ at exchange rate,1258.4
+33593,Switzerland,2012,6,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million US$ at exchange rate,88.5
+33594,Switzerland,2012,6,M-Musculo-skeletal system,Million US$ at exchange rate,379.7
+33595,Switzerland,2012,6,R-Respiratory system,Million US$ at exchange rate,526.8
+33596,Switzerland,2012,6,Products not elsewhere classified,% of total sales,19.9
+33597,Switzerland,2012,6,Products not elsewhere classified,"/capita, US$ purchasing power parity",109.0
+33598,Switzerland,2012,6,Products not elsewhere classified,"/capita, US$ exchange rate",157.4
+33599,Switzerland,2012,6,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million of national currency units,83.0
+33600,Switzerland,2012,6,Products not elsewhere classified,"Million US$, purchasing power parity",871.4
+33601,Switzerland,2012,6,Total pharmaceutical sales,Million US$ at exchange rate,6331.6
+33602,Switzerland,2012,6,Total pharmaceutical sales,"Million US$, purchasing power parity",4384.6
+33603,Switzerland,2012,6,Total pharmaceutical sales,Million of national currency units,5937.0
+33604,Switzerland,2012,6,B-Blood and blood forming organs,"/capita, US$ purchasing power parity",20.5
+33605,Switzerland,2012,6,B-Blood and blood forming organs,% of total sales,3.7
+33606,Switzerland,2012,6,Total pharmaceutical sales,"/capita, US$ exchange rate",791.8
+33607,Switzerland,2012,6,R-Respiratory system,"/capita, US$ purchasing power parity",45.6
+33608,Switzerland,2012,6,R-Respiratory system,"/capita, US$ exchange rate",65.9
+33609,Switzerland,2012,6,R-Respiratory system,"Million US$, purchasing power parity",364.8
+33610,Switzerland,2012,6,Total pharmaceutical sales,"/capita, US$ purchasing power parity",548.3
+33611,Switzerland,2012,6,R-Respiratory system,% of total sales,8.3
+33612,Switzerland,2012,6,A-Alimentary tract and metabolism,"/capita, US$ purchasing power parity",78.6
+33613,Switzerland,2012,6,A-Alimentary tract and metabolism,% of total sales,14.3
+33614,Switzerland,2012,6,J-Antiinfectives for systemic use,% of total sales,7.8
+33615,Switzerland,2012,6,G-Genito urinary system and sex hormones,Million of national currency units,353.0
+33616,Switzerland,2012,6,A-Alimentary tract and metabolism,Million of national currency units,851.0
+33617,Switzerland,2012,6,J-Antiinfectives for systemic use,"/capita, US$ purchasing power parity",42.8
+33618,Switzerland,2012,6,M-Musculo-skeletal system,% of total sales,6.0
+33619,Switzerland,2012,6,A-Alimentary tract and metabolism,Million US$ at exchange rate,907.6
+33620,Switzerland,2012,6,A-Alimentary tract and metabolism,"Million US$, purchasing power parity",628.5
+33621,Switzerland,2012,6,M-Musculo-skeletal system,"/capita, US$ purchasing power parity",32.9
+33622,Switzerland,2012,6,J-Antiinfectives for systemic use,Million of national currency units,463.0
+33623,Switzerland,2012,6,M-Musculo-skeletal system,"Million US$, purchasing power parity",262.9
+33624,Switzerland,2012,6,A-Alimentary tract and metabolism,"/capita, US$ exchange rate",113.5
+33625,Switzerland,2012,6,J-Antiinfectives for systemic use,Million US$ at exchange rate,493.8
+33626,Switzerland,2012,6,M-Musculo-skeletal system,"/capita, US$ exchange rate",47.5
+33627,Switzerland,2012,6,G-Genito urinary system and sex hormones,% of total sales,5.9
+33628,Switzerland,2012,6,G-Genito urinary system and sex hormones,"/capita, US$ purchasing power parity",32.6
+33629,Switzerland,2012,6,J-Antiinfectives for systemic use,"Million US$, purchasing power parity",341.9
+33630,Switzerland,2012,6,J-Antiinfectives for systemic use,"/capita, US$ exchange rate",61.7
+33631,Switzerland,2012,6,G-Genito urinary system and sex hormones,"Million US$, purchasing power parity",260.7
+33632,Switzerland,2012,6,G-Genito urinary system and sex hormones,Million US$ at exchange rate,376.5
+33633,Switzerland,2012,6,G-Genito urinary system and sex hormones,"/capita, US$ exchange rate",47.1
+33634,Switzerland,2011,6,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ purchasing power parity",6.6
+33635,Switzerland,2011,6,C-Cardiovascular system,Million of national currency units,929.0
+33636,Switzerland,2011,6,"H-Systemic hormonal preparations, excluding sex hormones and insulins",% of total sales,1.3
+33637,Switzerland,2011,6,B-Blood and blood forming organs,Million US$ at exchange rate,234.2
+33638,Switzerland,2011,6,B-Blood and blood forming organs,"Million US$, purchasing power parity",148.8
+33639,Switzerland,2011,6,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ exchange rate",10.4
+33640,Switzerland,2011,6,M-Musculo-skeletal system,Million of national currency units,345.0
+33641,Switzerland,2011,6,B-Blood and blood forming organs,Million of national currency units,208.0
+33642,Switzerland,2011,6,N-Nervous system,"/capita, US$ exchange rate",151.3
+33643,Switzerland,2011,6,N-Nervous system,"/capita, US$ purchasing power parity",96.1
+33644,Switzerland,2011,6,N-Nervous system,% of total sales,18.4
+33645,Switzerland,2011,6,N-Nervous system,Million US$ at exchange rate,1197.0
+33646,Switzerland,2011,6,N-Nervous system,Million of national currency units,1063.0
+33647,Switzerland,2011,6,N-Nervous system,"Million US$, purchasing power parity",760.6
+33648,Switzerland,2011,6,B-Blood and blood forming organs,"/capita, US$ exchange rate",29.6
+33649,Switzerland,2011,6,C-Cardiovascular system,"/capita, US$ exchange rate",132.2
+33650,Switzerland,2011,6,C-Cardiovascular system,"Million US$, purchasing power parity",664.8
+33651,Switzerland,2011,6,C-Cardiovascular system,Million US$ at exchange rate,1046.1
+33652,Switzerland,2011,6,C-Cardiovascular system,% of total sales,16.1
+33653,Switzerland,2011,6,C-Cardiovascular system,"/capita, US$ purchasing power parity",84.0
+33654,Switzerland,2011,6,Products not elsewhere classified,Million of national currency units,1030.0
+33655,Switzerland,2011,6,R-Respiratory system,Million of national currency units,487.0
+33656,Switzerland,2011,6,Products not elsewhere classified,Million US$ at exchange rate,1159.9
+33657,Switzerland,2011,6,"H-Systemic hormonal preparations, excluding sex hormones and insulins","Million US$, purchasing power parity",52.2
+33658,Switzerland,2011,6,M-Musculo-skeletal system,Million US$ at exchange rate,388.5
+33659,Switzerland,2011,6,R-Respiratory system,Million US$ at exchange rate,548.4
+33660,Switzerland,2011,6,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million US$ at exchange rate,82.2
+33661,Switzerland,2011,6,Products not elsewhere classified,% of total sales,17.8
+33662,Switzerland,2011,6,Products not elsewhere classified,"/capita, US$ purchasing power parity",93.1
+33663,Switzerland,2011,6,Products not elsewhere classified,"/capita, US$ exchange rate",146.6
+33664,Switzerland,2011,6,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million of national currency units,73.0
+33665,Switzerland,2011,6,Products not elsewhere classified,"Million US$, purchasing power parity",737.0
+33666,Switzerland,2011,6,Total pharmaceutical sales,Million US$ at exchange rate,6504.2
+33667,Switzerland,2011,6,Total pharmaceutical sales,"Million US$, purchasing power parity",4133.1
+33668,Switzerland,2011,6,B-Blood and blood forming organs,"/capita, US$ purchasing power parity",18.8
+33669,Switzerland,2011,6,Total pharmaceutical sales,Million of national currency units,5776.0
+33670,Switzerland,2011,6,Total pharmaceutical sales,"/capita, US$ exchange rate",822.0
+33671,Switzerland,2011,6,B-Blood and blood forming organs,% of total sales,3.6
+33672,Switzerland,2011,6,R-Respiratory system,"/capita, US$ purchasing power parity",44.0
+33673,Switzerland,2011,6,R-Respiratory system,"Million US$, purchasing power parity",348.5
+33674,Switzerland,2011,6,R-Respiratory system,"/capita, US$ exchange rate",69.3
+33675,Switzerland,2011,6,Total pharmaceutical sales,"/capita, US$ purchasing power parity",522.4
+33676,Switzerland,2011,6,R-Respiratory system,% of total sales,8.4
+33677,Switzerland,2011,6,A-Alimentary tract and metabolism,% of total sales,14.7
+33678,Switzerland,2011,6,A-Alimentary tract and metabolism,"/capita, US$ purchasing power parity",76.6
+33679,Switzerland,2011,6,J-Antiinfectives for systemic use,% of total sales,7.7
+33680,Switzerland,2011,6,G-Genito urinary system and sex hormones,Million of national currency units,349.0
+33681,Switzerland,2011,6,A-Alimentary tract and metabolism,Million of national currency units,847.0
+33682,Switzerland,2011,6,A-Alimentary tract and metabolism,Million US$ at exchange rate,953.8
+33683,Switzerland,2011,6,A-Alimentary tract and metabolism,"Million US$, purchasing power parity",606.1
+33684,Switzerland,2011,6,M-Musculo-skeletal system,"/capita, US$ purchasing power parity",31.2
+33685,Switzerland,2011,6,J-Antiinfectives for systemic use,Million of national currency units,445.0
+33686,Switzerland,2011,6,M-Musculo-skeletal system,% of total sales,6.0
+33687,Switzerland,2011,6,M-Musculo-skeletal system,"Million US$, purchasing power parity",246.9
+33688,Switzerland,2011,6,A-Alimentary tract and metabolism,"/capita, US$ exchange rate",120.5
+33689,Switzerland,2011,6,J-Antiinfectives for systemic use,Million US$ at exchange rate,501.1
+33690,Switzerland,2011,6,M-Musculo-skeletal system,"/capita, US$ exchange rate",49.1
+33691,Switzerland,2011,6,J-Antiinfectives for systemic use,"/capita, US$ purchasing power parity",40.2
+33692,Switzerland,2011,6,G-Genito urinary system and sex hormones,% of total sales,6.0
+33693,Switzerland,2011,6,G-Genito urinary system and sex hormones,"/capita, US$ purchasing power parity",31.6
+33694,Switzerland,2011,6,J-Antiinfectives for systemic use,"Million US$, purchasing power parity",318.4
+33695,Switzerland,2011,6,J-Antiinfectives for systemic use,"/capita, US$ exchange rate",63.3
+33696,Switzerland,2011,6,G-Genito urinary system and sex hormones,Million US$ at exchange rate,393.0
+33697,Switzerland,2011,6,G-Genito urinary system and sex hormones,"Million US$, purchasing power parity",249.7
+33698,Switzerland,2011,6,G-Genito urinary system and sex hormones,"/capita, US$ exchange rate",49.7
+33699,Switzerland,2010,6,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ purchasing power parity",6.2
+33700,Switzerland,2010,6,"H-Systemic hormonal preparations, excluding sex hormones and insulins",% of total sales,1.2
+33701,Switzerland,2010,6,C-Cardiovascular system,Million of national currency units,946.1
+33702,Switzerland,2010,6,B-Blood and blood forming organs,Million US$ at exchange rate,206.6
+33703,Switzerland,2010,6,B-Blood and blood forming organs,"Million US$, purchasing power parity",147.0
+33704,Switzerland,2010,6,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ exchange rate",8.8
+33705,Switzerland,2010,6,B-Blood and blood forming organs,"/capita, US$ exchange rate",26.4
+33706,Switzerland,2010,6,M-Musculo-skeletal system,Million of national currency units,346.2
+33707,Switzerland,2010,6,B-Blood and blood forming organs,Million of national currency units,215.5
+33708,Switzerland,2010,6,N-Nervous system,"/capita, US$ exchange rate",127.7
+33709,Switzerland,2010,6,N-Nervous system,"/capita, US$ purchasing power parity",90.9
+33710,Switzerland,2010,6,N-Nervous system,% of total sales,18.1
+33711,Switzerland,2010,6,N-Nervous system,Million US$ at exchange rate,999.4
+33712,Switzerland,2010,6,N-Nervous system,Million of national currency units,1042.3
+33713,Switzerland,2010,6,N-Nervous system,"Million US$, purchasing power parity",710.9
+33714,Switzerland,2010,6,C-Cardiovascular system,"/capita, US$ exchange rate",115.9
+33715,Switzerland,2010,6,C-Cardiovascular system,"Million US$, purchasing power parity",645.3
+33716,Switzerland,2010,6,C-Cardiovascular system,Million US$ at exchange rate,907.2
+33717,Switzerland,2010,6,C-Cardiovascular system,% of total sales,16.5
+33718,Switzerland,2010,6,C-Cardiovascular system,"/capita, US$ purchasing power parity",82.5
+33719,Switzerland,2010,6,Products not elsewhere classified,Million of national currency units,980.6
+33720,Switzerland,2010,6,R-Respiratory system,Million of national currency units,484.8
+33721,Switzerland,2010,6,Products not elsewhere classified,Million US$ at exchange rate,940.2
+33722,Switzerland,2010,6,"H-Systemic hormonal preparations, excluding sex hormones and insulins","Million US$, purchasing power parity",48.7
+33723,Switzerland,2010,6,M-Musculo-skeletal system,Million US$ at exchange rate,331.9
+33724,Switzerland,2010,6,R-Respiratory system,Million US$ at exchange rate,464.8
+33725,Switzerland,2010,6,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million US$ at exchange rate,68.5
+33726,Switzerland,2010,6,Products not elsewhere classified,% of total sales,17.1
+33727,Switzerland,2010,6,Products not elsewhere classified,"/capita, US$ purchasing power parity",85.5
+33728,Switzerland,2010,6,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million of national currency units,71.4
+33729,Switzerland,2010,6,Products not elsewhere classified,"/capita, US$ exchange rate",120.2
+33730,Switzerland,2010,6,Products not elsewhere classified,"Million US$, purchasing power parity",668.8
+33731,Switzerland,2010,6,Total pharmaceutical sales,Million US$ at exchange rate,5507.8
+33732,Switzerland,2010,6,Total pharmaceutical sales,"/capita, US$ exchange rate",703.9
+33733,Switzerland,2010,6,Total pharmaceutical sales,"Million US$, purchasing power parity",3917.9
+33734,Switzerland,2010,6,B-Blood and blood forming organs,"/capita, US$ purchasing power parity",18.8
+33735,Switzerland,2010,6,Total pharmaceutical sales,Million of national currency units,5744.2
+33736,Switzerland,2010,6,B-Blood and blood forming organs,% of total sales,3.8
+33737,Switzerland,2010,6,R-Respiratory system,"/capita, US$ purchasing power parity",42.3
+33738,Switzerland,2010,6,R-Respiratory system,"Million US$, purchasing power parity",330.6
+33739,Switzerland,2010,6,R-Respiratory system,"/capita, US$ exchange rate",59.4
+33740,Switzerland,2010,6,Total pharmaceutical sales,"/capita, US$ purchasing power parity",500.7
+33741,Switzerland,2010,6,R-Respiratory system,% of total sales,8.4
+33742,Switzerland,2010,6,A-Alimentary tract and metabolism,% of total sales,15.2
+33743,Switzerland,2010,6,A-Alimentary tract and metabolism,"/capita, US$ purchasing power parity",76.3
+33744,Switzerland,2010,6,J-Antiinfectives for systemic use,% of total sales,7.6
+33745,Switzerland,2010,6,G-Genito urinary system and sex hormones,Million of national currency units,344.2
+33746,Switzerland,2010,6,A-Alimentary tract and metabolism,Million of national currency units,875.8
+33747,Switzerland,2010,6,M-Musculo-skeletal system,% of total sales,6.0
+33748,Switzerland,2010,6,A-Alimentary tract and metabolism,Million US$ at exchange rate,839.8
+33749,Switzerland,2010,6,A-Alimentary tract and metabolism,"Million US$, purchasing power parity",597.4
+33750,Switzerland,2010,6,J-Antiinfectives for systemic use,Million of national currency units,437.3
+33751,Switzerland,2010,6,M-Musculo-skeletal system,"/capita, US$ purchasing power parity",30.2
+33752,Switzerland,2010,6,M-Musculo-skeletal system,"Million US$, purchasing power parity",236.1
+33753,Switzerland,2010,6,A-Alimentary tract and metabolism,"/capita, US$ exchange rate",107.3
+33754,Switzerland,2010,6,J-Antiinfectives for systemic use,Million US$ at exchange rate,419.3
+33755,Switzerland,2010,6,M-Musculo-skeletal system,"/capita, US$ exchange rate",42.4
+33756,Switzerland,2010,6,J-Antiinfectives for systemic use,"/capita, US$ purchasing power parity",38.1
+33757,Switzerland,2010,6,G-Genito urinary system and sex hormones,% of total sales,6.0
+33758,Switzerland,2010,6,G-Genito urinary system and sex hormones,"/capita, US$ purchasing power parity",30.0
+33759,Switzerland,2010,6,J-Antiinfectives for systemic use,"Million US$, purchasing power parity",298.3
+33760,Switzerland,2010,6,J-Antiinfectives for systemic use,"/capita, US$ exchange rate",53.6
+33761,Switzerland,2010,6,G-Genito urinary system and sex hormones,"/capita, US$ exchange rate",42.2
+33762,Switzerland,2010,6,G-Genito urinary system and sex hormones,"Million US$, purchasing power parity",234.8
+33763,Switzerland,2010,6,G-Genito urinary system and sex hormones,Million US$ at exchange rate,330.0
+33764,Switzerland,2015,5,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ purchasing power parity",8.5
+33765,Switzerland,2015,5,"H-Systemic hormonal preparations, excluding sex hormones and insulins",% of total sales,1.4
+33766,Switzerland,2015,5,C-Cardiovascular system,Million of national currency units,777.0
+33767,Switzerland,2015,5,B-Blood and blood forming organs,Million US$ at exchange rate,296.1
+33768,Switzerland,2015,5,B-Blood and blood forming organs,"Million US$, purchasing power parity",230.6
+33769,Switzerland,2015,5,B-Blood and blood forming organs,Million of national currency units,285.0
+33770,Switzerland,2015,5,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ exchange rate",10.9
+33771,Switzerland,2015,5,"H-Systemic hormonal preparations, excluding sex hormones and insulins","Million US$, purchasing power parity",70.4
+33772,Switzerland,2015,5,N-Nervous system,"/capita, US$ exchange rate",130.0
+33773,Switzerland,2015,5,N-Nervous system,"/capita, US$ purchasing power parity",101.2
+33774,Switzerland,2015,5,N-Nervous system,% of total sales,16.8
+33775,Switzerland,2015,5,N-Nervous system,Million of national currency units,1036.0
+33776,Switzerland,2015,5,N-Nervous system,"Million US$, purchasing power parity",838.3
+33777,Switzerland,2015,5,N-Nervous system,Million US$ at exchange rate,1076.5
+33778,Switzerland,2015,5,C-Cardiovascular system,"Million US$, purchasing power parity",628.7
+33779,Switzerland,2015,5,C-Cardiovascular system,Million US$ at exchange rate,807.4
+33780,Switzerland,2015,5,C-Cardiovascular system,"/capita, US$ exchange rate",97.5
+33781,Switzerland,2015,5,C-Cardiovascular system,% of total sales,12.6
+33782,Switzerland,2015,5,C-Cardiovascular system,"/capita, US$ purchasing power parity",75.9
+33783,Switzerland,2015,5,Products not elsewhere classified,Million of national currency units,1291.0
+33784,Switzerland,2015,5,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million US$ at exchange rate,90.4
+33785,Switzerland,2015,5,R-Respiratory system,Million of national currency units,503.0
+33786,Switzerland,2015,5,M-Musculo-skeletal system,Million US$ at exchange rate,413.6
+33787,Switzerland,2015,5,M-Musculo-skeletal system,Million of national currency units,398.0
+33788,Switzerland,2015,5,R-Respiratory system,Million US$ at exchange rate,522.7
+33789,Switzerland,2015,5,Products not elsewhere classified,% of total sales,20.9
+33790,Switzerland,2015,5,Products not elsewhere classified,"/capita, US$ exchange rate",162.0
+33791,Switzerland,2015,5,Products not elsewhere classified,"/capita, US$ purchasing power parity",126.1
+33792,Switzerland,2015,5,Products not elsewhere classified,Million US$ at exchange rate,1341.5
+33793,Switzerland,2015,5,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million of national currency units,87.0
+33794,Switzerland,2015,5,Products not elsewhere classified,"Million US$, purchasing power parity",1044.7
+33795,Switzerland,2015,5,Total pharmaceutical sales,Million US$ at exchange rate,6425.7
+33796,Switzerland,2015,5,Total pharmaceutical sales,Million of national currency units,6184.0
+33797,Switzerland,2015,5,Total pharmaceutical sales,"Million US$, purchasing power parity",5004.1
+33798,Switzerland,2015,5,B-Blood and blood forming organs,"/capita, US$ purchasing power parity",27.8
+33799,Switzerland,2015,5,B-Blood and blood forming organs,"/capita, US$ exchange rate",35.8
+33800,Switzerland,2015,5,B-Blood and blood forming organs,% of total sales,4.6
+33801,Switzerland,2015,5,R-Respiratory system,"/capita, US$ purchasing power parity",49.1
+33802,Switzerland,2015,5,R-Respiratory system,"/capita, US$ exchange rate",63.1
+33803,Switzerland,2015,5,R-Respiratory system,"Million US$, purchasing power parity",407.0
+33804,Switzerland,2015,5,Total pharmaceutical sales,"/capita, US$ purchasing power parity",604.2
+33805,Switzerland,2015,5,Total pharmaceutical sales,"/capita, US$ exchange rate",775.8
+33806,Switzerland,2015,5,R-Respiratory system,% of total sales,8.1
+33807,Switzerland,2015,5,A-Alimentary tract and metabolism,"/capita, US$ purchasing power parity",87.0
+33808,Switzerland,2015,5,A-Alimentary tract and metabolism,% of total sales,14.4
+33809,Switzerland,2015,5,M-Musculo-skeletal system,% of total sales,6.4
+33810,Switzerland,2015,5,A-Alimentary tract and metabolism,"/capita, US$ exchange rate",111.7
+33811,Switzerland,2015,5,J-Antiinfectives for systemic use,% of total sales,9.2
+33812,Switzerland,2015,5,A-Alimentary tract and metabolism,Million of national currency units,890.0
+33813,Switzerland,2015,5,J-Antiinfectives for systemic use,"/capita, US$ purchasing power parity",55.6
+33814,Switzerland,2015,5,A-Alimentary tract and metabolism,Million US$ at exchange rate,924.8
+33815,Switzerland,2015,5,J-Antiinfectives for systemic use,Million of national currency units,569.0
+33816,Switzerland,2015,5,M-Musculo-skeletal system,"/capita, US$ exchange rate",49.9
+33817,Switzerland,2015,5,M-Musculo-skeletal system,"/capita, US$ purchasing power parity",38.9
+33818,Switzerland,2015,5,A-Alimentary tract and metabolism,"Million US$, purchasing power parity",720.2
+33819,Switzerland,2015,5,M-Musculo-skeletal system,"Million US$, purchasing power parity",322.1
+33820,Switzerland,2015,5,G-Genito urinary system and sex hormones,Million of national currency units,348.0
+33821,Switzerland,2015,5,G-Genito urinary system and sex hormones,% of total sales,5.6
+33822,Switzerland,2015,5,G-Genito urinary system and sex hormones,"/capita, US$ purchasing power parity",34.0
+33823,Switzerland,2015,5,J-Antiinfectives for systemic use,Million US$ at exchange rate,591.2
+33824,Switzerland,2015,5,J-Antiinfectives for systemic use,"Million US$, purchasing power parity",460.4
+33825,Switzerland,2015,5,J-Antiinfectives for systemic use,"/capita, US$ exchange rate",71.4
+33826,Switzerland,2015,5,G-Genito urinary system and sex hormones,Million US$ at exchange rate,361.6
+33827,Switzerland,2015,5,G-Genito urinary system and sex hormones,"Million US$, purchasing power parity",281.6
+33828,Switzerland,2015,5,G-Genito urinary system and sex hormones,"/capita, US$ exchange rate",43.7
+33829,United Kingdom,2012,8,J-Antiinfectives for systemic use,"/capita, US$ exchange rate",39.8
+33830,United Kingdom,2012,8,M-Musculo-skeletal system,Million US$ at exchange rate,568.4
+33831,United Kingdom,2012,8,M-Musculo-skeletal system,Million of national currency units,359.8
+33832,United Kingdom,2012,8,B-Blood and blood forming organs,"/capita, US$ exchange rate",14.4
+33833,United Kingdom,2012,8,B-Blood and blood forming organs,"/capita, US$ purchasing power parity",13.0
+33834,United Kingdom,2012,8,J-Antiinfectives for systemic use,"/capita, US$ purchasing power parity",35.9
+33835,United Kingdom,2012,8,N-Nervous system,% of total sales,18.7
+33836,United Kingdom,2012,8,N-Nervous system,"/capita, US$ purchasing power parity",57.8
+33837,United Kingdom,2012,8,B-Blood and blood forming organs,% of total sales,4.2
+33838,United Kingdom,2012,8,J-Antiinfectives for systemic use,% of total sales,11.7
+33839,United Kingdom,2012,8,M-Musculo-skeletal system,"Million US$, purchasing power parity",512.8
+33840,United Kingdom,2012,8,"H-Systemic hormonal preparations, excluding sex hormones and insulins",% of total sales,2.5
+33841,United Kingdom,2012,8,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million of national currency units,338.3
+33842,United Kingdom,2012,8,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ purchasing power parity",7.6
+33843,United Kingdom,2012,8,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million US$ at exchange rate,534.4
+33844,United Kingdom,2012,8,"H-Systemic hormonal preparations, excluding sex hormones and insulins","Million US$, purchasing power parity",482.2
+33845,United Kingdom,2012,8,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ exchange rate",8.4
+33846,United Kingdom,2012,8,N-Nervous system,"/capita, US$ exchange rate",64.0
+33847,United Kingdom,2012,8,M-Musculo-skeletal system,"/capita, US$ purchasing power parity",8.0
+33848,United Kingdom,2012,8,M-Musculo-skeletal system,"/capita, US$ exchange rate",8.9
+33849,United Kingdom,2012,8,M-Musculo-skeletal system,% of total sales,2.6
+33850,United Kingdom,2012,8,N-Nervous system,Million US$ at exchange rate,4078.4
+33851,United Kingdom,2012,8,N-Nervous system,Million of national currency units,2581.8
+33852,United Kingdom,2012,8,N-Nervous system,"Million US$, purchasing power parity",3679.7
+33853,United Kingdom,2012,8,A-Alimentary tract and metabolism,Million of national currency units,1384.3
+33854,United Kingdom,2012,8,C-Cardiovascular system,Million of national currency units,1332.3
+33855,United Kingdom,2012,8,C-Cardiovascular system,Million US$ at exchange rate,2104.6
+33856,United Kingdom,2012,8,C-Cardiovascular system,"Million US$, purchasing power parity",1898.9
+33857,United Kingdom,2012,8,A-Alimentary tract and metabolism,Million US$ at exchange rate,2186.7
+33858,United Kingdom,2012,8,A-Alimentary tract and metabolism,% of total sales,10.1
+33859,United Kingdom,2012,8,A-Alimentary tract and metabolism,"/capita, US$ purchasing power parity",31.0
+33860,United Kingdom,2012,8,A-Alimentary tract and metabolism,"/capita, US$ exchange rate",34.3
+33861,United Kingdom,2012,8,A-Alimentary tract and metabolism,"Million US$, purchasing power parity",1973.0
+33862,United Kingdom,2012,8,R-Respiratory system,% of total sales,10.5
+33863,United Kingdom,2012,8,R-Respiratory system,"Million US$, purchasing power parity",2052.8
+33864,United Kingdom,2012,8,R-Respiratory system,"/capita, US$ purchasing power parity",32.2
+33865,United Kingdom,2012,8,R-Respiratory system,"/capita, US$ exchange rate",35.7
+33866,United Kingdom,2012,8,C-Cardiovascular system,"/capita, US$ purchasing power parity",29.8
+33867,United Kingdom,2012,8,R-Respiratory system,Million of national currency units,1440.3
+33868,United Kingdom,2012,8,R-Respiratory system,Million US$ at exchange rate,2275.2
+33869,United Kingdom,2012,8,C-Cardiovascular system,"/capita, US$ exchange rate",33.0
+33870,United Kingdom,2012,8,C-Cardiovascular system,% of total sales,9.7
+33871,United Kingdom,2012,8,J-Antiinfectives for systemic use,Million of national currency units,1606.0
+33872,United Kingdom,2012,8,Total pharmaceutical sales,"/capita, US$ exchange rate",341.5
+33873,United Kingdom,2012,8,Total pharmaceutical sales,"Million US$, purchasing power parity",19629.2
+33874,United Kingdom,2012,8,Total pharmaceutical sales,Million US$ at exchange rate,21755.9
+33875,United Kingdom,2012,8,B-Blood and blood forming organs,"Million US$, purchasing power parity",826.6
+33876,United Kingdom,2012,8,B-Blood and blood forming organs,Million US$ at exchange rate,916.2
+33877,United Kingdom,2012,8,Total pharmaceutical sales,"/capita, US$ purchasing power parity",308.1
+33878,United Kingdom,2012,8,B-Blood and blood forming organs,Million of national currency units,580.0
+33879,United Kingdom,2012,8,G-Genito urinary system and sex hormones,Million US$ at exchange rate,1081.0
+33880,United Kingdom,2012,8,G-Genito urinary system and sex hormones,Million of national currency units,684.3
+33881,United Kingdom,2012,8,J-Antiinfectives for systemic use,"Million US$, purchasing power parity",2288.9
+33882,United Kingdom,2012,8,J-Antiinfectives for systemic use,Million US$ at exchange rate,2536.9
+33883,United Kingdom,2012,8,G-Genito urinary system and sex hormones,"Million US$, purchasing power parity",975.3
+33884,United Kingdom,2012,8,G-Genito urinary system and sex hormones,% of total sales,5.0
+33885,United Kingdom,2012,8,Total pharmaceutical sales,Million of national currency units,13772.5
+33886,United Kingdom,2012,8,G-Genito urinary system and sex hormones,"/capita, US$ purchasing power parity",15.3
+33887,United Kingdom,2012,8,G-Genito urinary system and sex hormones,"/capita, US$ exchange rate",17.0
+33888,United Kingdom,2011,9,Total pharmaceutical sales,Million US$ at exchange rate,20802.4
+33889,United Kingdom,2011,9,Total pharmaceutical sales,"/capita, US$ exchange rate",328.7
+33890,United Kingdom,2011,9,Total pharmaceutical sales,"Million US$, purchasing power parity",18389.0
+33891,United Kingdom,2011,9,Total pharmaceutical sales,"/capita, US$ purchasing power parity",290.6
+33892,United Kingdom,2011,9,Total pharmaceutical sales,Million of national currency units,12983.6
+33893,United Kingdom,2017,7,J-Antiinfectives for systemic use,"/capita, US$ exchange rate",51.0
+33894,United Kingdom,2017,7,B-Blood and blood forming organs,"/capita, US$ purchasing power parity",26.2
+33895,United Kingdom,2017,7,J-Antiinfectives for systemic use,"Million US$, purchasing power parity",3820.8
+33896,United Kingdom,2017,7,M-Musculo-skeletal system,Million US$ at exchange rate,634.1
+33897,United Kingdom,2017,7,M-Musculo-skeletal system,Million of national currency units,492.7
+33898,United Kingdom,2017,7,N-Nervous system,"/capita, US$ exchange rate",62.2
+33899,United Kingdom,2017,7,B-Blood and blood forming organs,"/capita, US$ exchange rate",23.1
+33900,United Kingdom,2017,7,N-Nervous system,"/capita, US$ purchasing power parity",70.6
+33901,United Kingdom,2017,7,N-Nervous system,% of total sales,16.3
+33902,United Kingdom,2017,7,J-Antiinfectives for systemic use,"/capita, US$ purchasing power parity",57.9
+33903,United Kingdom,2017,7,B-Blood and blood forming organs,% of total sales,6.1
+33904,United Kingdom,2017,7,J-Antiinfectives for systemic use,% of total sales,13.4
+33905,United Kingdom,2017,7,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ purchasing power parity",11.8
+33906,United Kingdom,2017,7,"H-Systemic hormonal preparations, excluding sex hormones and insulins",% of total sales,2.7
+33907,United Kingdom,2017,7,N-Nervous system,Million US$ at exchange rate,4107.6
+33908,United Kingdom,2017,7,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ exchange rate",10.4
+33909,United Kingdom,2017,7,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million US$ at exchange rate,685.7
+33910,United Kingdom,2017,7,"H-Systemic hormonal preparations, excluding sex hormones and insulins","Million US$, purchasing power parity",778.3
+33911,United Kingdom,2017,7,N-Nervous system,"Million US$, purchasing power parity",4661.8
+33912,United Kingdom,2017,7,M-Musculo-skeletal system,"/capita, US$ exchange rate",9.6
+33913,United Kingdom,2017,7,M-Musculo-skeletal system,"Million US$, purchasing power parity",719.7
+33914,United Kingdom,2017,7,M-Musculo-skeletal system,"/capita, US$ purchasing power parity",10.9
+33915,United Kingdom,2017,7,N-Nervous system,Million of national currency units,3191.5
+33916,United Kingdom,2017,7,M-Musculo-skeletal system,% of total sales,2.5
+33917,United Kingdom,2017,7,B-Blood and blood forming organs,"Million US$, purchasing power parity",1727.9
+33918,United Kingdom,2017,7,A-Alimentary tract and metabolism,Million of national currency units,1854.8
+33919,United Kingdom,2017,7,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million of national currency units,532.8
+33920,United Kingdom,2017,7,C-Cardiovascular system,Million of national currency units,1301.0
+33921,United Kingdom,2017,7,C-Cardiovascular system,Million US$ at exchange rate,1674.4
+33922,United Kingdom,2017,7,A-Alimentary tract and metabolism,"/capita, US$ purchasing power parity",41.0
+33923,United Kingdom,2017,7,A-Alimentary tract and metabolism,"/capita, US$ exchange rate",36.1
+33924,United Kingdom,2017,7,C-Cardiovascular system,"Million US$, purchasing power parity",1900.4
+33925,United Kingdom,2017,7,A-Alimentary tract and metabolism,"Million US$, purchasing power parity",2709.3
+33926,United Kingdom,2017,7,A-Alimentary tract and metabolism,Million US$ at exchange rate,2387.2
+33927,United Kingdom,2017,7,R-Respiratory system,% of total sales,8.5
+33928,United Kingdom,2017,7,R-Respiratory system,"/capita, US$ purchasing power parity",36.9
+33929,United Kingdom,2017,7,R-Respiratory system,"/capita, US$ exchange rate",32.5
+33930,United Kingdom,2017,7,R-Respiratory system,"Million US$, purchasing power parity",2433.7
+33931,United Kingdom,2017,7,R-Respiratory system,Million US$ at exchange rate,2144.3
+33932,United Kingdom,2017,7,C-Cardiovascular system,"/capita, US$ exchange rate",25.4
+33933,United Kingdom,2017,7,R-Respiratory system,Million of national currency units,1666.1
+33934,United Kingdom,2017,7,C-Cardiovascular system,% of total sales,6.7
+33935,United Kingdom,2017,7,C-Cardiovascular system,"/capita, US$ purchasing power parity",28.8
+33936,United Kingdom,2017,7,A-Alimentary tract and metabolism,% of total sales,9.5
+33937,United Kingdom,2017,7,Total pharmaceutical sales,"Million US$, purchasing power parity",28520.4
+33938,United Kingdom,2017,7,Total pharmaceutical sales,Million US$ at exchange rate,25129.6
+33939,United Kingdom,2017,7,Total pharmaceutical sales,Million of national currency units,19525.1
+33940,United Kingdom,2017,7,Total pharmaceutical sales,"/capita, US$ exchange rate",380.5
+33941,United Kingdom,2017,7,B-Blood and blood forming organs,Million US$ at exchange rate,1522.4
+33942,United Kingdom,2017,7,B-Blood and blood forming organs,Million of national currency units,1182.9
+33943,United Kingdom,2017,7,Total pharmaceutical sales,"/capita, US$ purchasing power parity",431.9
+33944,United Kingdom,2017,7,G-Genito urinary system and sex hormones,Million of national currency units,757.8
+33945,United Kingdom,2017,7,J-Antiinfectives for systemic use,Million US$ at exchange rate,3366.5
+33946,United Kingdom,2017,7,J-Antiinfectives for systemic use,Million of national currency units,2615.7
+33947,United Kingdom,2017,7,G-Genito urinary system and sex hormones,Million US$ at exchange rate,975.3
+33948,United Kingdom,2017,7,G-Genito urinary system and sex hormones,% of total sales,3.9
+33949,United Kingdom,2017,7,G-Genito urinary system and sex hormones,"/capita, US$ purchasing power parity",16.8
+33950,United Kingdom,2017,7,G-Genito urinary system and sex hormones,"/capita, US$ exchange rate",14.8
+33951,United Kingdom,2017,7,G-Genito urinary system and sex hormones,"Million US$, purchasing power parity",1106.9
+33952,United Kingdom,2010,10,Total pharmaceutical sales,"/capita, US$ exchange rate",323.9
+33953,United Kingdom,2010,10,Total pharmaceutical sales,"Million US$, purchasing power parity",18733.4
+33954,United Kingdom,2010,10,Total pharmaceutical sales,Million US$ at exchange rate,20328.4
+33955,United Kingdom,2010,10,Total pharmaceutical sales,"/capita, US$ purchasing power parity",298.5
+33956,United Kingdom,2010,10,Total pharmaceutical sales,Million of national currency units,13156.1
+33957,United Kingdom,2014,8,J-Antiinfectives for systemic use,"/capita, US$ exchange rate",47.0
+33958,United Kingdom,2014,8,M-Musculo-skeletal system,Million US$ at exchange rate,661.6
+33959,United Kingdom,2014,8,M-Musculo-skeletal system,Million of national currency units,402.1
+33960,United Kingdom,2014,8,N-Nervous system,"/capita, US$ exchange rate",75.3
+33961,United Kingdom,2014,8,B-Blood and blood forming organs,"/capita, US$ exchange rate",19.4
+33962,United Kingdom,2014,8,J-Antiinfectives for systemic use,"/capita, US$ purchasing power parity",40.9
+33963,United Kingdom,2014,8,N-Nervous system,% of total sales,18.5
+33964,United Kingdom,2014,8,N-Nervous system,"/capita, US$ purchasing power parity",65.5
+33965,United Kingdom,2014,8,B-Blood and blood forming organs,"/capita, US$ purchasing power parity",16.9
+33966,United Kingdom,2014,8,B-Blood and blood forming organs,% of total sales,4.8
+33967,United Kingdom,2014,8,J-Antiinfectives for systemic use,% of total sales,11.5
+33968,United Kingdom,2014,8,M-Musculo-skeletal system,"Million US$, purchasing power parity",575.7
+33969,United Kingdom,2014,8,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ purchasing power parity",10.6
+33970,United Kingdom,2014,8,"H-Systemic hormonal preparations, excluding sex hormones and insulins",% of total sales,3.0
+33971,United Kingdom,2014,8,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million of national currency units,478.3
+33972,United Kingdom,2014,8,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million US$ at exchange rate,787.0
+33973,United Kingdom,2014,8,"H-Systemic hormonal preparations, excluding sex hormones and insulins","Million US$, purchasing power parity",684.8
+33974,United Kingdom,2014,8,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ exchange rate",12.2
+33975,United Kingdom,2014,8,N-Nervous system,Million US$ at exchange rate,4863.8
+33976,United Kingdom,2014,8,M-Musculo-skeletal system,"/capita, US$ purchasing power parity",8.9
+33977,United Kingdom,2014,8,M-Musculo-skeletal system,"/capita, US$ exchange rate",10.2
+33978,United Kingdom,2014,8,N-Nervous system,Million of national currency units,2955.9
+33979,United Kingdom,2014,8,N-Nervous system,"Million US$, purchasing power parity",4232.1
+33980,United Kingdom,2014,8,M-Musculo-skeletal system,% of total sales,2.5
+33981,United Kingdom,2014,8,A-Alimentary tract and metabolism,Million of national currency units,1537.2
+33982,United Kingdom,2014,8,C-Cardiovascular system,Million of national currency units,1186.8
+33983,United Kingdom,2014,8,C-Cardiovascular system,Million US$ at exchange rate,1952.8
+33984,United Kingdom,2014,8,C-Cardiovascular system,"Million US$, purchasing power parity",1699.2
+33985,United Kingdom,2014,8,A-Alimentary tract and metabolism,Million US$ at exchange rate,2529.4
+33986,United Kingdom,2014,8,A-Alimentary tract and metabolism,% of total sales,9.6
+33987,United Kingdom,2014,8,A-Alimentary tract and metabolism,"/capita, US$ purchasing power parity",34.1
+33988,United Kingdom,2014,8,A-Alimentary tract and metabolism,"/capita, US$ exchange rate",39.2
+33989,United Kingdom,2014,8,A-Alimentary tract and metabolism,"Million US$, purchasing power parity",2200.9
+33990,United Kingdom,2014,8,R-Respiratory system,% of total sales,9.9
+33991,United Kingdom,2014,8,R-Respiratory system,"/capita, US$ purchasing power parity",35.0
+33992,United Kingdom,2014,8,R-Respiratory system,"/capita, US$ exchange rate",40.3
+33993,United Kingdom,2014,8,R-Respiratory system,"Million US$, purchasing power parity",2263.7
+33994,United Kingdom,2014,8,C-Cardiovascular system,"/capita, US$ exchange rate",30.2
+33995,United Kingdom,2014,8,R-Respiratory system,Million of national currency units,1581.1
+33996,United Kingdom,2014,8,C-Cardiovascular system,% of total sales,7.4
+33997,United Kingdom,2014,8,C-Cardiovascular system,"/capita, US$ purchasing power parity",26.3
+33998,United Kingdom,2014,8,R-Respiratory system,Million US$ at exchange rate,2601.6
+33999,United Kingdom,2014,8,Total pharmaceutical sales,"/capita, US$ exchange rate",407.4
+34000,United Kingdom,2014,8,Total pharmaceutical sales,"Million US$, purchasing power parity",22901.2
+34001,United Kingdom,2014,8,Total pharmaceutical sales,Million US$ at exchange rate,26319.6
+34002,United Kingdom,2014,8,B-Blood and blood forming organs,"Million US$, purchasing power parity",1090.1
+34003,United Kingdom,2014,8,B-Blood and blood forming organs,Million US$ at exchange rate,1252.9
+34004,United Kingdom,2014,8,Total pharmaceutical sales,Million of national currency units,15995.2
+34005,United Kingdom,2014,8,Total pharmaceutical sales,"/capita, US$ purchasing power parity",354.5
+34006,United Kingdom,2014,8,B-Blood and blood forming organs,Million of national currency units,761.4
+34007,United Kingdom,2014,8,G-Genito urinary system and sex hormones,Million US$ at exchange rate,1120.1
+34008,United Kingdom,2014,8,G-Genito urinary system and sex hormones,Million of national currency units,680.7
+34009,United Kingdom,2014,8,J-Antiinfectives for systemic use,Million US$ at exchange rate,3034.6
+34010,United Kingdom,2014,8,J-Antiinfectives for systemic use,Million of national currency units,1844.2
+34011,United Kingdom,2014,8,J-Antiinfectives for systemic use,"Million US$, purchasing power parity",2640.4
+34012,United Kingdom,2014,8,G-Genito urinary system and sex hormones,% of total sales,4.3
+34013,United Kingdom,2014,8,G-Genito urinary system and sex hormones,"/capita, US$ purchasing power parity",15.1
+34014,United Kingdom,2014,8,G-Genito urinary system and sex hormones,"/capita, US$ exchange rate",17.3
+34015,United Kingdom,2014,8,G-Genito urinary system and sex hormones,"Million US$, purchasing power parity",974.6
+34016,United Kingdom,2015,8,J-Antiinfectives for systemic use,"/capita, US$ exchange rate",48.8
+34017,United Kingdom,2015,8,M-Musculo-skeletal system,Million US$ at exchange rate,672.8
+34018,United Kingdom,2015,8,M-Musculo-skeletal system,Million of national currency units,440.4
+34019,United Kingdom,2015,8,N-Nervous system,"/capita, US$ exchange rate",75.6
+34020,United Kingdom,2015,8,B-Blood and blood forming organs,"/capita, US$ exchange rate",21.1
+34021,United Kingdom,2015,8,N-Nervous system,"/capita, US$ purchasing power parity",71.5
+34022,United Kingdom,2015,8,B-Blood and blood forming organs,"/capita, US$ purchasing power parity",20.0
+34023,United Kingdom,2015,8,N-Nervous system,% of total sales,18.2
+34024,United Kingdom,2015,8,J-Antiinfectives for systemic use,"/capita, US$ purchasing power parity",46.1
+34025,United Kingdom,2015,8,J-Antiinfectives for systemic use,% of total sales,11.8
+34026,United Kingdom,2015,8,B-Blood and blood forming organs,% of total sales,5.1
+34027,United Kingdom,2015,8,R-Respiratory system,"Million US$, purchasing power parity",2337.6
+34028,United Kingdom,2015,8,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ purchasing power parity",13.1
+34029,United Kingdom,2015,8,"H-Systemic hormonal preparations, excluding sex hormones and insulins",% of total sales,3.3
+34030,United Kingdom,2015,8,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million of national currency units,589.6
+34031,United Kingdom,2015,8,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million US$ at exchange rate,900.8
+34032,United Kingdom,2015,8,"H-Systemic hormonal preparations, excluding sex hormones and insulins","Million US$, purchasing power parity",851.3
+34033,United Kingdom,2015,8,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ exchange rate",13.8
+34034,United Kingdom,2015,8,N-Nervous system,Million US$ at exchange rate,4923.1
+34035,United Kingdom,2015,8,M-Musculo-skeletal system,"/capita, US$ purchasing power parity",9.8
+34036,United Kingdom,2015,8,M-Musculo-skeletal system,"/capita, US$ exchange rate",10.3
+34037,United Kingdom,2015,8,M-Musculo-skeletal system,"Million US$, purchasing power parity",635.9
+34038,United Kingdom,2015,8,N-Nervous system,Million of national currency units,3222.4
+34039,United Kingdom,2015,8,N-Nervous system,"Million US$, purchasing power parity",4652.9
+34040,United Kingdom,2015,8,M-Musculo-skeletal system,% of total sales,2.5
+34041,United Kingdom,2015,8,B-Blood and blood forming organs,"Million US$, purchasing power parity",1300.7
+34042,United Kingdom,2015,8,A-Alimentary tract and metabolism,Million of national currency units,1710.8
+34043,United Kingdom,2015,8,C-Cardiovascular system,Million of national currency units,1267.8
+34044,United Kingdom,2015,8,C-Cardiovascular system,Million US$ at exchange rate,1936.9
+34045,United Kingdom,2015,8,C-Cardiovascular system,"Million US$, purchasing power parity",1830.6
+34046,United Kingdom,2015,8,A-Alimentary tract and metabolism,Million US$ at exchange rate,2613.7
+34047,United Kingdom,2015,8,A-Alimentary tract and metabolism,% of total sales,9.7
+34048,United Kingdom,2015,8,A-Alimentary tract and metabolism,"/capita, US$ purchasing power parity",37.9
+34049,United Kingdom,2015,8,A-Alimentary tract and metabolism,"Million US$, purchasing power parity",2470.3
+34050,United Kingdom,2015,8,A-Alimentary tract and metabolism,"/capita, US$ exchange rate",40.1
+34051,United Kingdom,2015,8,R-Respiratory system,% of total sales,9.2
+34052,United Kingdom,2015,8,R-Respiratory system,"/capita, US$ purchasing power parity",35.9
+34053,United Kingdom,2015,8,R-Respiratory system,"/capita, US$ exchange rate",38.0
+34054,United Kingdom,2015,8,C-Cardiovascular system,"/capita, US$ exchange rate",29.7
+34055,United Kingdom,2015,8,R-Respiratory system,Million of national currency units,1618.9
+34056,United Kingdom,2015,8,R-Respiratory system,Million US$ at exchange rate,2473.3
+34057,United Kingdom,2015,8,C-Cardiovascular system,% of total sales,7.2
+34058,United Kingdom,2015,8,C-Cardiovascular system,"/capita, US$ purchasing power parity",28.1
+34059,United Kingdom,2015,8,Total pharmaceutical sales,"Million US$, purchasing power parity",25538.8
+34060,United Kingdom,2015,8,Total pharmaceutical sales,Million US$ at exchange rate,27021.7
+34061,United Kingdom,2015,8,Total pharmaceutical sales,Million of national currency units,17686.9
+34062,United Kingdom,2015,8,Total pharmaceutical sales,"/capita, US$ exchange rate",415.0
+34063,United Kingdom,2015,8,B-Blood and blood forming organs,Million US$ at exchange rate,1376.2
+34064,United Kingdom,2015,8,B-Blood and blood forming organs,Million of national currency units,900.8
+34065,United Kingdom,2015,8,Total pharmaceutical sales,"/capita, US$ purchasing power parity",392.2
+34066,United Kingdom,2015,8,J-Antiinfectives for systemic use,"Million US$, purchasing power parity",3002.7
+34067,United Kingdom,2015,8,G-Genito urinary system and sex hormones,Million US$ at exchange rate,1081.5
+34068,United Kingdom,2015,8,G-Genito urinary system and sex hormones,Million of national currency units,707.9
+34069,United Kingdom,2015,8,J-Antiinfectives for systemic use,Million US$ at exchange rate,3177.0
+34070,United Kingdom,2015,8,J-Antiinfectives for systemic use,Million of national currency units,2079.5
+34071,United Kingdom,2015,8,G-Genito urinary system and sex hormones,% of total sales,4.0
+34072,United Kingdom,2015,8,G-Genito urinary system and sex hormones,"/capita, US$ purchasing power parity",15.7
+34073,United Kingdom,2015,8,G-Genito urinary system and sex hormones,"/capita, US$ exchange rate",16.6
+34074,United Kingdom,2015,8,G-Genito urinary system and sex hormones,"Million US$, purchasing power parity",1022.2
+34075,United Kingdom,2016,7,J-Antiinfectives for systemic use,"/capita, US$ exchange rate",48.3
+34076,United Kingdom,2016,7,N-Nervous system,"/capita, US$ exchange rate",66.9
+34077,United Kingdom,2016,7,M-Musculo-skeletal system,Million US$ at exchange rate,618.1
+34078,United Kingdom,2016,7,M-Musculo-skeletal system,Million of national currency units,457.8
+34079,United Kingdom,2016,7,B-Blood and blood forming organs,"/capita, US$ exchange rate",21.2
+34080,United Kingdom,2016,7,N-Nervous system,"/capita, US$ purchasing power parity",72.0
+34081,United Kingdom,2016,7,J-Antiinfectives for systemic use,"/capita, US$ purchasing power parity",51.9
+34082,United Kingdom,2016,7,N-Nervous system,% of total sales,17.5
+34083,United Kingdom,2016,7,B-Blood and blood forming organs,% of total sales,5.5
+34084,United Kingdom,2016,7,J-Antiinfectives for systemic use,% of total sales,12.6
+34085,United Kingdom,2016,7,B-Blood and blood forming organs,"/capita, US$ purchasing power parity",22.8
+34086,United Kingdom,2016,7,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ purchasing power parity",13.4
+34087,United Kingdom,2016,7,"H-Systemic hormonal preparations, excluding sex hormones and insulins",% of total sales,3.3
+34088,United Kingdom,2016,7,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million of national currency units,607.3
+34089,United Kingdom,2016,7,N-Nervous system,Million US$ at exchange rate,4392.2
+34090,United Kingdom,2016,7,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million US$ at exchange rate,820.0
+34091,United Kingdom,2016,7,"H-Systemic hormonal preparations, excluding sex hormones and insulins","Million US$, purchasing power parity",881.9
+34092,United Kingdom,2016,7,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ exchange rate",12.5
+34093,United Kingdom,2016,7,M-Musculo-skeletal system,"/capita, US$ exchange rate",9.4
+34094,United Kingdom,2016,7,M-Musculo-skeletal system,"Million US$, purchasing power parity",664.8
+34095,United Kingdom,2016,7,M-Musculo-skeletal system,"/capita, US$ purchasing power parity",10.1
+34096,United Kingdom,2016,7,N-Nervous system,Million of national currency units,3253.0
+34097,United Kingdom,2016,7,N-Nervous system,"Million US$, purchasing power parity",4724.1
+34098,United Kingdom,2016,7,M-Musculo-skeletal system,% of total sales,2.5
+34099,United Kingdom,2016,7,A-Alimentary tract and metabolism,Million of national currency units,1773.2
+34100,United Kingdom,2016,7,C-Cardiovascular system,Million of national currency units,1280.2
+34101,United Kingdom,2016,7,C-Cardiovascular system,Million US$ at exchange rate,1728.5
+34102,United Kingdom,2016,7,C-Cardiovascular system,"Million US$, purchasing power parity",1859.1
+34103,United Kingdom,2016,7,A-Alimentary tract and metabolism,"/capita, US$ purchasing power parity",39.2
+34104,United Kingdom,2016,7,A-Alimentary tract and metabolism,"/capita, US$ exchange rate",36.5
+34105,United Kingdom,2016,7,A-Alimentary tract and metabolism,"Million US$, purchasing power parity",2575.1
+34106,United Kingdom,2016,7,A-Alimentary tract and metabolism,Million US$ at exchange rate,2394.2
+34107,United Kingdom,2016,7,A-Alimentary tract and metabolism,% of total sales,9.6
+34108,United Kingdom,2016,7,R-Respiratory system,% of total sales,8.9
+34109,United Kingdom,2016,7,R-Respiratory system,"/capita, US$ purchasing power parity",36.6
+34110,United Kingdom,2016,7,R-Respiratory system,"/capita, US$ exchange rate",34.0
+34111,United Kingdom,2016,7,R-Respiratory system,Million US$ at exchange rate,2231.9
+34112,United Kingdom,2016,7,C-Cardiovascular system,"/capita, US$ exchange rate",26.3
+34113,United Kingdom,2016,7,R-Respiratory system,Million of national currency units,1653.0
+34114,United Kingdom,2016,7,C-Cardiovascular system,% of total sales,6.9
+34115,United Kingdom,2016,7,C-Cardiovascular system,"/capita, US$ purchasing power parity",28.3
+34116,United Kingdom,2016,7,B-Blood and blood forming organs,"Million US$, purchasing power parity",1495.3
+34117,United Kingdom,2016,7,Total pharmaceutical sales,"Million US$, purchasing power parity",26944.6
+34118,United Kingdom,2016,7,Total pharmaceutical sales,Million US$ at exchange rate,25051.6
+34119,United Kingdom,2016,7,R-Respiratory system,"Million US$, purchasing power parity",2400.5
+34120,United Kingdom,2016,7,Total pharmaceutical sales,Million of national currency units,18554.1
+34121,United Kingdom,2016,7,Total pharmaceutical sales,"/capita, US$ exchange rate",381.6
+34122,United Kingdom,2016,7,B-Blood and blood forming organs,Million US$ at exchange rate,1390.3
+34123,United Kingdom,2016,7,B-Blood and blood forming organs,Million of national currency units,1029.7
+34124,United Kingdom,2016,7,Total pharmaceutical sales,"/capita, US$ purchasing power parity",410.4
+34125,United Kingdom,2016,7,J-Antiinfectives for systemic use,"Million US$, purchasing power parity",3408.2
+34126,United Kingdom,2016,7,G-Genito urinary system and sex hormones,Million US$ at exchange rate,960.1
+34127,United Kingdom,2016,7,G-Genito urinary system and sex hormones,Million of national currency units,711.1
+34128,United Kingdom,2016,7,J-Antiinfectives for systemic use,Million US$ at exchange rate,3168.8
+34129,United Kingdom,2016,7,J-Antiinfectives for systemic use,Million of national currency units,2346.9
+34130,United Kingdom,2016,7,G-Genito urinary system and sex hormones,% of total sales,3.8
+34131,United Kingdom,2016,7,G-Genito urinary system and sex hormones,"/capita, US$ purchasing power parity",15.7
+34132,United Kingdom,2016,7,G-Genito urinary system and sex hormones,"/capita, US$ exchange rate",14.6
+34133,United Kingdom,2016,7,G-Genito urinary system and sex hormones,"Million US$, purchasing power parity",1032.7
+34134,United Kingdom,2013,8,J-Antiinfectives for systemic use,"/capita, US$ exchange rate",42.2
+34135,United Kingdom,2013,8,M-Musculo-skeletal system,Million US$ at exchange rate,585.3
+34136,United Kingdom,2013,8,M-Musculo-skeletal system,Million of national currency units,374.4
+34137,United Kingdom,2013,8,B-Blood and blood forming organs,"/capita, US$ exchange rate",15.8
+34138,United Kingdom,2013,8,B-Blood and blood forming organs,"/capita, US$ purchasing power parity",14.6
+34139,United Kingdom,2013,8,N-Nervous system,% of total sales,18.9
+34140,United Kingdom,2013,8,B-Blood and blood forming organs,% of total sales,4.4
+34141,United Kingdom,2013,8,N-Nervous system,"/capita, US$ purchasing power parity",61.9
+34142,United Kingdom,2013,8,J-Antiinfectives for systemic use,"/capita, US$ purchasing power parity",38.8
+34143,United Kingdom,2013,8,J-Antiinfectives for systemic use,% of total sales,11.8
+34144,United Kingdom,2013,8,"H-Systemic hormonal preparations, excluding sex hormones and insulins",% of total sales,2.7
+34145,United Kingdom,2013,8,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million of national currency units,391.9
+34146,United Kingdom,2013,8,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ purchasing power parity",8.8
+34147,United Kingdom,2013,8,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million US$ at exchange rate,612.7
+34148,United Kingdom,2013,8,"H-Systemic hormonal preparations, excluding sex hormones and insulins","Million US$, purchasing power parity",563.7
+34149,United Kingdom,2013,8,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ exchange rate",9.6
+34150,United Kingdom,2013,8,N-Nervous system,Million US$ at exchange rate,4315.1
+34151,United Kingdom,2013,8,N-Nervous system,"/capita, US$ exchange rate",67.3
+34152,United Kingdom,2013,8,M-Musculo-skeletal system,"/capita, US$ purchasing power parity",8.4
+34153,United Kingdom,2013,8,M-Musculo-skeletal system,"/capita, US$ exchange rate",9.1
+34154,United Kingdom,2013,8,N-Nervous system,Million of national currency units,2760.2
+34155,United Kingdom,2013,8,M-Musculo-skeletal system,"Million US$, purchasing power parity",538.5
+34156,United Kingdom,2013,8,M-Musculo-skeletal system,% of total sales,2.6
+34157,United Kingdom,2013,8,N-Nervous system,"Million US$, purchasing power parity",3970.1
+34158,United Kingdom,2013,8,A-Alimentary tract and metabolism,Million of national currency units,1410.4
+34159,United Kingdom,2013,8,C-Cardiovascular system,Million of national currency units,1156.4
+34160,United Kingdom,2013,8,C-Cardiovascular system,Million US$ at exchange rate,1807.8
+34161,United Kingdom,2013,8,C-Cardiovascular system,"Million US$, purchasing power parity",1663.3
+34162,United Kingdom,2013,8,A-Alimentary tract and metabolism,Million US$ at exchange rate,2204.9
+34163,United Kingdom,2013,8,A-Alimentary tract and metabolism,% of total sales,9.7
+34164,United Kingdom,2013,8,A-Alimentary tract and metabolism,"/capita, US$ purchasing power parity",31.6
+34165,United Kingdom,2013,8,A-Alimentary tract and metabolism,"/capita, US$ exchange rate",34.4
+34166,United Kingdom,2013,8,A-Alimentary tract and metabolism,"Million US$, purchasing power parity",2028.6
+34167,United Kingdom,2013,8,C-Cardiovascular system,"/capita, US$ exchange rate",28.2
+34168,United Kingdom,2013,8,R-Respiratory system,% of total sales,10.5
+34169,United Kingdom,2013,8,R-Respiratory system,"Million US$, purchasing power parity",2195.6
+34170,United Kingdom,2013,8,R-Respiratory system,"/capita, US$ purchasing power parity",34.3
+34171,United Kingdom,2013,8,R-Respiratory system,"/capita, US$ exchange rate",37.2
+34172,United Kingdom,2013,8,C-Cardiovascular system,"/capita, US$ purchasing power parity",25.9
+34173,United Kingdom,2013,8,R-Respiratory system,Million of national currency units,1526.5
+34174,United Kingdom,2013,8,R-Respiratory system,Million US$ at exchange rate,2386.4
+34175,United Kingdom,2013,8,C-Cardiovascular system,% of total sales,7.9
+34176,United Kingdom,2013,8,Total pharmaceutical sales,"/capita, US$ exchange rate",356.1
+34177,United Kingdom,2013,8,Total pharmaceutical sales,"Million US$, purchasing power parity",21002.7
+34178,United Kingdom,2013,8,Total pharmaceutical sales,Million US$ at exchange rate,22827.9
+34179,United Kingdom,2013,8,B-Blood and blood forming organs,"Million US$, purchasing power parity",934.2
+34180,United Kingdom,2013,8,B-Blood and blood forming organs,Million US$ at exchange rate,1015.4
+34181,United Kingdom,2013,8,B-Blood and blood forming organs,Million of national currency units,649.5
+34182,United Kingdom,2013,8,Total pharmaceutical sales,"/capita, US$ purchasing power parity",327.6
+34183,United Kingdom,2013,8,Total pharmaceutical sales,Million of national currency units,14602.1
+34184,United Kingdom,2013,8,G-Genito urinary system and sex hormones,Million US$ at exchange rate,1063.2
+34185,United Kingdom,2013,8,G-Genito urinary system and sex hormones,Million of national currency units,680.1
+34186,United Kingdom,2013,8,J-Antiinfectives for systemic use,"Million US$, purchasing power parity",2487.5
+34187,United Kingdom,2013,8,J-Antiinfectives for systemic use,Million US$ at exchange rate,2703.6
+34188,United Kingdom,2013,8,J-Antiinfectives for systemic use,Million of national currency units,1729.4
+34189,United Kingdom,2013,8,G-Genito urinary system and sex hormones,"Million US$, purchasing power parity",978.2
+34190,United Kingdom,2013,8,G-Genito urinary system and sex hormones,% of total sales,4.7
+34191,United Kingdom,2013,8,G-Genito urinary system and sex hormones,"/capita, US$ exchange rate",16.6
+34192,United Kingdom,2013,8,G-Genito urinary system and sex hormones,"/capita, US$ purchasing power parity",15.3
diff --git a/exercicios/para-casa/exercicioCrisPereiraS11/analiseCEIS.ipynb b/exercicios/para-casa/exercicioCrisPereiraS11/analiseCEIS.ipynb
new file mode 100644
index 0000000..4afa1df
--- /dev/null
+++ b/exercicios/para-casa/exercicioCrisPereiraS11/analiseCEIS.ipynb
@@ -0,0 +1,1306 @@
+{
+ "cells": [
+  {
+   "cell_type": "markdown",
+   "metadata": {},
+   "source": [
+    "# Projeto Semana 11 - Python Reprograma - Cris Pereira\n",
+    "\n",
+    "## Introdução\n",
+    "Nesse notebook realizo edições e faço uma análise inicial de dois bancos de dados, um de morte materna ao redor do mundo e outro relacionado à receita da indústria farmacêutica em diversos países (tema que tem a ver com a minha pesquisa de pós-graduação sobre o Complexo Industrial da Saúde - CEIS).  "
+   ]
+  },
+  {
+   "cell_type": "markdown",
+   "metadata": {},
+   "source": [
+    "## Processamento"
+   ]
+  },
+  {
+   "cell_type": "code",
+   "execution_count": 5,
+   "metadata": {},
+   "outputs": [],
+   "source": [
+    "import pandas as pd"
+   ]
+  },
+  {
+   "cell_type": "code",
+   "execution_count": 6,
+   "metadata": {},
+   "outputs": [],
+   "source": [
+    "df_health = pd.read_csv(\"health_indicators_ocde.csv\")\n",
+    "df_mortality = pd.read_csv(\"maternal-mortality-who.csv\")"
+   ]
+  },
+  {
+   "cell_type": "code",
+   "execution_count": 7,
+   "metadata": {},
+   "outputs": [
+    {
+     "data": {
+      "text/html": [
+       "<div>\n",
+       "<style scoped>\n",
+       "    .dataframe tbody tr th:only-of-type {\n",
+       "        vertical-align: middle;\n",
+       "    }\n",
+       "\n",
+       "    .dataframe tbody tr th {\n",
+       "        vertical-align: top;\n",
+       "    }\n",
+       "\n",
+       "    .dataframe thead th {\n",
+       "        text-align: right;\n",
+       "    }\n",
+       "</style>\n",
+       "<table border=\"1\" class=\"dataframe\">\n",
+       "  <thead>\n",
+       "    <tr style=\"text-align: right;\">\n",
+       "      <th></th>\n",
+       "      <th>VAR</th>\n",
+       "      <th>Variable</th>\n",
+       "      <th>UNIT</th>\n",
+       "      <th>Measure</th>\n",
+       "      <th>COU</th>\n",
+       "      <th>Country</th>\n",
+       "      <th>YEA</th>\n",
+       "      <th>Year</th>\n",
+       "      <th>Value</th>\n",
+       "      <th>Flag Codes</th>\n",
+       "      <th>Flags</th>\n",
+       "    </tr>\n",
+       "  </thead>\n",
+       "  <tbody>\n",
+       "    <tr>\n",
+       "      <th>0</th>\n",
+       "      <td>PATCTOTT</td>\n",
+       "      <td>Total pharmaceutical sales</td>\n",
+       "      <td>MLLNCUMT</td>\n",
+       "      <td>Million of national currency units</td>\n",
+       "      <td>AUS</td>\n",
+       "      <td>Australia</td>\n",
+       "      <td>2010</td>\n",
+       "      <td>2010</td>\n",
+       "      <td>9795.0</td>\n",
+       "      <td>D</td>\n",
+       "      <td>Difference in methodology</td>\n",
+       "    </tr>\n",
+       "    <tr>\n",
+       "      <th>1</th>\n",
+       "      <td>PATCTOTT</td>\n",
+       "      <td>Total pharmaceutical sales</td>\n",
+       "      <td>MLLNCUMT</td>\n",
+       "      <td>Million of national currency units</td>\n",
+       "      <td>AUS</td>\n",
+       "      <td>Australia</td>\n",
+       "      <td>2011</td>\n",
+       "      <td>2011</td>\n",
+       "      <td>10261.0</td>\n",
+       "      <td>D</td>\n",
+       "      <td>Difference in methodology</td>\n",
+       "    </tr>\n",
+       "    <tr>\n",
+       "      <th>2</th>\n",
+       "      <td>PATCTOTT</td>\n",
+       "      <td>Total pharmaceutical sales</td>\n",
+       "      <td>MLLNCUMT</td>\n",
+       "      <td>Million of national currency units</td>\n",
+       "      <td>AUS</td>\n",
+       "      <td>Australia</td>\n",
+       "      <td>2012</td>\n",
+       "      <td>2012</td>\n",
+       "      <td>10355.0</td>\n",
+       "      <td>D</td>\n",
+       "      <td>Difference in methodology</td>\n",
+       "    </tr>\n",
+       "  </tbody>\n",
+       "</table>\n",
+       "</div>"
+      ],
+      "text/plain": [
+       "        VAR                    Variable      UNIT  \\\n",
+       "0  PATCTOTT  Total pharmaceutical sales  MLLNCUMT   \n",
+       "1  PATCTOTT  Total pharmaceutical sales  MLLNCUMT   \n",
+       "2  PATCTOTT  Total pharmaceutical sales  MLLNCUMT   \n",
+       "\n",
+       "                              Measure  COU    Country   YEA  Year    Value  \\\n",
+       "0  Million of national currency units  AUS  Australia  2010  2010   9795.0   \n",
+       "1  Million of national currency units  AUS  Australia  2011  2011  10261.0   \n",
+       "2  Million of national currency units  AUS  Australia  2012  2012  10355.0   \n",
+       "\n",
+       "  Flag Codes                      Flags  \n",
+       "0          D  Difference in methodology  \n",
+       "1          D  Difference in methodology  \n",
+       "2          D  Difference in methodology  "
+      ]
+     },
+     "execution_count": 7,
+     "metadata": {},
+     "output_type": "execute_result"
+    }
+   ],
+   "source": [
+    "df_health.head(3)"
+   ]
+  },
+  {
+   "cell_type": "code",
+   "execution_count": 8,
+   "metadata": {},
+   "outputs": [
+    {
+     "data": {
+      "text/html": [
+       "<div>\n",
+       "<style scoped>\n",
+       "    .dataframe tbody tr th:only-of-type {\n",
+       "        vertical-align: middle;\n",
+       "    }\n",
+       "\n",
+       "    .dataframe tbody tr th {\n",
+       "        vertical-align: top;\n",
+       "    }\n",
+       "\n",
+       "    .dataframe thead th {\n",
+       "        text-align: right;\n",
+       "    }\n",
+       "</style>\n",
+       "<table border=\"1\" class=\"dataframe\">\n",
+       "  <thead>\n",
+       "    <tr style=\"text-align: right;\">\n",
+       "      <th></th>\n",
+       "      <th>Entity</th>\n",
+       "      <th>Code</th>\n",
+       "      <th>Year</th>\n",
+       "      <th>Indicator:Maternal mortality ratio (per 100 000 live births)</th>\n",
+       "    </tr>\n",
+       "  </thead>\n",
+       "  <tbody>\n",
+       "    <tr>\n",
+       "      <th>0</th>\n",
+       "      <td>Afghanistan</td>\n",
+       "      <td>AFG</td>\n",
+       "      <td>2000</td>\n",
+       "      <td>1450</td>\n",
+       "    </tr>\n",
+       "    <tr>\n",
+       "      <th>1</th>\n",
+       "      <td>Afghanistan</td>\n",
+       "      <td>AFG</td>\n",
+       "      <td>2001</td>\n",
+       "      <td>1390</td>\n",
+       "    </tr>\n",
+       "    <tr>\n",
+       "      <th>2</th>\n",
+       "      <td>Afghanistan</td>\n",
+       "      <td>AFG</td>\n",
+       "      <td>2002</td>\n",
+       "      <td>1300</td>\n",
+       "    </tr>\n",
+       "  </tbody>\n",
+       "</table>\n",
+       "</div>"
+      ],
+      "text/plain": [
+       "        Entity Code  Year  \\\n",
+       "0  Afghanistan  AFG  2000   \n",
+       "1  Afghanistan  AFG  2001   \n",
+       "2  Afghanistan  AFG  2002   \n",
+       "\n",
+       "   Indicator:Maternal mortality ratio (per 100 000 live births)  \n",
+       "0                                               1450             \n",
+       "1                                               1390             \n",
+       "2                                               1300             "
+      ]
+     },
+     "execution_count": 8,
+     "metadata": {},
+     "output_type": "execute_result"
+    }
+   ],
+   "source": [
+    "df_mortality.head(3)"
+   ]
+  },
+  {
+   "cell_type": "code",
+   "execution_count": 9,
+   "metadata": {},
+   "outputs": [],
+   "source": [
+    "# Decidi colocar o dataframe com novas colunas em um novo objeto\n",
+    "df_newhealth = df_health.drop(columns= ['VAR', 'UNIT','COU','YEA','Flag Codes', 'Flags'])"
+   ]
+  },
+  {
+   "cell_type": "code",
+   "execution_count": 10,
+   "metadata": {},
+   "outputs": [
+    {
+     "data": {
+      "text/plain": [
+       "Index(['Variable', 'Measure', 'Country', 'Year', 'Value'], dtype='object')"
+      ]
+     },
+     "execution_count": 10,
+     "metadata": {},
+     "output_type": "execute_result"
+    }
+   ],
+   "source": [
+    "# Verificando remoção das colunas\n",
+    "df_newhealth.columns"
+   ]
+  },
+  {
+   "cell_type": "code",
+   "execution_count": 11,
+   "metadata": {},
+   "outputs": [],
+   "source": [
+    "# Decidi colocar o dataframe com novas colunas em um novo objeto\n",
+    "df_newmortality = df_mortality.drop(columns=[\"Code\"])"
+   ]
+  },
+  {
+   "cell_type": "code",
+   "execution_count": 12,
+   "metadata": {},
+   "outputs": [
+    {
+     "data": {
+      "text/plain": [
+       "Index(['Entity', 'Year',\n",
+       "       'Indicator:Maternal mortality ratio (per 100 000 live births)'],\n",
+       "      dtype='object')"
+      ]
+     },
+     "execution_count": 12,
+     "metadata": {},
+     "output_type": "execute_result"
+    }
+   ],
+   "source": [
+    "# Verificando remoção das colunas\n",
+    "df_newmortality.columns"
+   ]
+  },
+  {
+   "cell_type": "code",
+   "execution_count": 13,
+   "metadata": {},
+   "outputs": [
+    {
+     "data": {
+      "text/html": [
+       "<div>\n",
+       "<style scoped>\n",
+       "    .dataframe tbody tr th:only-of-type {\n",
+       "        vertical-align: middle;\n",
+       "    }\n",
+       "\n",
+       "    .dataframe tbody tr th {\n",
+       "        vertical-align: top;\n",
+       "    }\n",
+       "\n",
+       "    .dataframe thead th {\n",
+       "        text-align: right;\n",
+       "    }\n",
+       "</style>\n",
+       "<table border=\"1\" class=\"dataframe\">\n",
+       "  <thead>\n",
+       "    <tr style=\"text-align: right;\">\n",
+       "      <th></th>\n",
+       "      <th>Variable</th>\n",
+       "      <th>Measure</th>\n",
+       "      <th>Country</th>\n",
+       "      <th>Year</th>\n",
+       "      <th>Value</th>\n",
+       "    </tr>\n",
+       "  </thead>\n",
+       "  <tbody>\n",
+       "    <tr>\n",
+       "      <th>0</th>\n",
+       "      <td>Total pharmaceutical sales</td>\n",
+       "      <td>Million of national currency units</td>\n",
+       "      <td>Australia</td>\n",
+       "      <td>2010</td>\n",
+       "      <td>9795.0</td>\n",
+       "    </tr>\n",
+       "    <tr>\n",
+       "      <th>37893</th>\n",
+       "      <td>M-Musculo-skeletal system</td>\n",
+       "      <td>Million of national currency units</td>\n",
+       "      <td>Australia</td>\n",
+       "      <td>2013</td>\n",
+       "      <td>378.0</td>\n",
+       "    </tr>\n",
+       "    <tr>\n",
+       "      <th>37892</th>\n",
+       "      <td>M-Musculo-skeletal system</td>\n",
+       "      <td>Million of national currency units</td>\n",
+       "      <td>Australia</td>\n",
+       "      <td>2012</td>\n",
+       "      <td>312.0</td>\n",
+       "    </tr>\n",
+       "    <tr>\n",
+       "      <th>37891</th>\n",
+       "      <td>M-Musculo-skeletal system</td>\n",
+       "      <td>Million of national currency units</td>\n",
+       "      <td>Australia</td>\n",
+       "      <td>2011</td>\n",
+       "      <td>309.0</td>\n",
+       "    </tr>\n",
+       "    <tr>\n",
+       "      <th>37890</th>\n",
+       "      <td>M-Musculo-skeletal system</td>\n",
+       "      <td>Million of national currency units</td>\n",
+       "      <td>Australia</td>\n",
+       "      <td>2010</td>\n",
+       "      <td>324.0</td>\n",
+       "    </tr>\n",
+       "    <tr>\n",
+       "      <th>...</th>\n",
+       "      <td>...</td>\n",
+       "      <td>...</td>\n",
+       "      <td>...</td>\n",
+       "      <td>...</td>\n",
+       "      <td>...</td>\n",
+       "    </tr>\n",
+       "    <tr>\n",
+       "      <th>29781</th>\n",
+       "      <td>G-Genito urinary system and sex hormones</td>\n",
+       "      <td>Million US$, purchasing power parity</td>\n",
+       "      <td>United Kingdom</td>\n",
+       "      <td>2016</td>\n",
+       "      <td>1032.7</td>\n",
+       "    </tr>\n",
+       "    <tr>\n",
+       "      <th>29780</th>\n",
+       "      <td>G-Genito urinary system and sex hormones</td>\n",
+       "      <td>Million US$, purchasing power parity</td>\n",
+       "      <td>United Kingdom</td>\n",
+       "      <td>2015</td>\n",
+       "      <td>1022.2</td>\n",
+       "    </tr>\n",
+       "    <tr>\n",
+       "      <th>29779</th>\n",
+       "      <td>G-Genito urinary system and sex hormones</td>\n",
+       "      <td>Million US$, purchasing power parity</td>\n",
+       "      <td>United Kingdom</td>\n",
+       "      <td>2014</td>\n",
+       "      <td>974.6</td>\n",
+       "    </tr>\n",
+       "    <tr>\n",
+       "      <th>29792</th>\n",
+       "      <td>G-Genito urinary system and sex hormones</td>\n",
+       "      <td>/capita, US$ purchasing power parity</td>\n",
+       "      <td>United Kingdom</td>\n",
+       "      <td>2013</td>\n",
+       "      <td>15.3</td>\n",
+       "    </tr>\n",
+       "    <tr>\n",
+       "      <th>33661</th>\n",
+       "      <td>H-Systemic hormonal preparations, excluding se...</td>\n",
+       "      <td>Million of national currency units</td>\n",
+       "      <td>United Kingdom</td>\n",
+       "      <td>2018</td>\n",
+       "      <td>442.9</td>\n",
+       "    </tr>\n",
+       "  </tbody>\n",
+       "</table>\n",
+       "<p>62544 rows × 5 columns</p>\n",
+       "</div>"
+      ],
+      "text/plain": [
+       "                                                Variable  \\\n",
+       "0                             Total pharmaceutical sales   \n",
+       "37893                          M-Musculo-skeletal system   \n",
+       "37892                          M-Musculo-skeletal system   \n",
+       "37891                          M-Musculo-skeletal system   \n",
+       "37890                          M-Musculo-skeletal system   \n",
+       "...                                                  ...   \n",
+       "29781           G-Genito urinary system and sex hormones   \n",
+       "29780           G-Genito urinary system and sex hormones   \n",
+       "29779           G-Genito urinary system and sex hormones   \n",
+       "29792           G-Genito urinary system and sex hormones   \n",
+       "33661  H-Systemic hormonal preparations, excluding se...   \n",
+       "\n",
+       "                                    Measure         Country  Year   Value  \n",
+       "0        Million of national currency units       Australia  2010  9795.0  \n",
+       "37893    Million of national currency units       Australia  2013   378.0  \n",
+       "37892    Million of national currency units       Australia  2012   312.0  \n",
+       "37891    Million of national currency units       Australia  2011   309.0  \n",
+       "37890    Million of national currency units       Australia  2010   324.0  \n",
+       "...                                     ...             ...   ...     ...  \n",
+       "29781  Million US$, purchasing power parity  United Kingdom  2016  1032.7  \n",
+       "29780  Million US$, purchasing power parity  United Kingdom  2015  1022.2  \n",
+       "29779  Million US$, purchasing power parity  United Kingdom  2014   974.6  \n",
+       "29792  /capita, US$ purchasing power parity  United Kingdom  2013    15.3  \n",
+       "33661    Million of national currency units  United Kingdom  2018   442.9  \n",
+       "\n",
+       "[62544 rows x 5 columns]"
+      ]
+     },
+     "execution_count": 13,
+     "metadata": {},
+     "output_type": "execute_result"
+    }
+   ],
+   "source": [
+    "# Organizando pela coluna \"Country\"\n",
+    "df_newhealth = df_newhealth.sort_values([\"Country\"])\n",
+    "df_newhealth"
+   ]
+  },
+  {
+   "cell_type": "code",
+   "execution_count": 14,
+   "metadata": {},
+   "outputs": [
+    {
+     "data": {
+      "text/html": [
+       "<div>\n",
+       "<style scoped>\n",
+       "    .dataframe tbody tr th:only-of-type {\n",
+       "        vertical-align: middle;\n",
+       "    }\n",
+       "\n",
+       "    .dataframe tbody tr th {\n",
+       "        vertical-align: top;\n",
+       "    }\n",
+       "\n",
+       "    .dataframe thead th {\n",
+       "        text-align: right;\n",
+       "    }\n",
+       "</style>\n",
+       "<table border=\"1\" class=\"dataframe\">\n",
+       "  <thead>\n",
+       "    <tr style=\"text-align: right;\">\n",
+       "      <th></th>\n",
+       "      <th>Entity</th>\n",
+       "      <th>Year</th>\n",
+       "      <th>Indicator:Maternal mortality ratio (per 100 000 live births)</th>\n",
+       "    </tr>\n",
+       "  </thead>\n",
+       "  <tbody>\n",
+       "    <tr>\n",
+       "      <th>0</th>\n",
+       "      <td>Afghanistan</td>\n",
+       "      <td>2000</td>\n",
+       "      <td>1450</td>\n",
+       "    </tr>\n",
+       "    <tr>\n",
+       "      <th>17</th>\n",
+       "      <td>Afghanistan</td>\n",
+       "      <td>2017</td>\n",
+       "      <td>638</td>\n",
+       "    </tr>\n",
+       "    <tr>\n",
+       "      <th>16</th>\n",
+       "      <td>Afghanistan</td>\n",
+       "      <td>2016</td>\n",
+       "      <td>673</td>\n",
+       "    </tr>\n",
+       "    <tr>\n",
+       "      <th>15</th>\n",
+       "      <td>Afghanistan</td>\n",
+       "      <td>2015</td>\n",
+       "      <td>701</td>\n",
+       "    </tr>\n",
+       "    <tr>\n",
+       "      <th>14</th>\n",
+       "      <td>Afghanistan</td>\n",
+       "      <td>2014</td>\n",
+       "      <td>786</td>\n",
+       "    </tr>\n",
+       "    <tr>\n",
+       "      <th>...</th>\n",
+       "      <td>...</td>\n",
+       "      <td>...</td>\n",
+       "      <td>...</td>\n",
+       "    </tr>\n",
+       "    <tr>\n",
+       "      <th>3403</th>\n",
+       "      <td>Zimbabwe</td>\n",
+       "      <td>2001</td>\n",
+       "      <td>629</td>\n",
+       "    </tr>\n",
+       "    <tr>\n",
+       "      <th>3402</th>\n",
+       "      <td>Zimbabwe</td>\n",
+       "      <td>2000</td>\n",
+       "      <td>579</td>\n",
+       "    </tr>\n",
+       "    <tr>\n",
+       "      <th>3418</th>\n",
+       "      <td>Zimbabwe</td>\n",
+       "      <td>2016</td>\n",
+       "      <td>468</td>\n",
+       "    </tr>\n",
+       "    <tr>\n",
+       "      <th>3409</th>\n",
+       "      <td>Zimbabwe</td>\n",
+       "      <td>2007</td>\n",
+       "      <td>671</td>\n",
+       "    </tr>\n",
+       "    <tr>\n",
+       "      <th>3419</th>\n",
+       "      <td>Zimbabwe</td>\n",
+       "      <td>2017</td>\n",
+       "      <td>458</td>\n",
+       "    </tr>\n",
+       "  </tbody>\n",
+       "</table>\n",
+       "<p>3420 rows × 3 columns</p>\n",
+       "</div>"
+      ],
+      "text/plain": [
+       "           Entity  Year  \\\n",
+       "0     Afghanistan  2000   \n",
+       "17    Afghanistan  2017   \n",
+       "16    Afghanistan  2016   \n",
+       "15    Afghanistan  2015   \n",
+       "14    Afghanistan  2014   \n",
+       "...           ...   ...   \n",
+       "3403     Zimbabwe  2001   \n",
+       "3402     Zimbabwe  2000   \n",
+       "3418     Zimbabwe  2016   \n",
+       "3409     Zimbabwe  2007   \n",
+       "3419     Zimbabwe  2017   \n",
+       "\n",
+       "      Indicator:Maternal mortality ratio (per 100 000 live births)  \n",
+       "0                                                  1450             \n",
+       "17                                                  638             \n",
+       "16                                                  673             \n",
+       "15                                                  701             \n",
+       "14                                                  786             \n",
+       "...                                                 ...             \n",
+       "3403                                                629             \n",
+       "3402                                                579             \n",
+       "3418                                                468             \n",
+       "3409                                                671             \n",
+       "3419                                                458             \n",
+       "\n",
+       "[3420 rows x 3 columns]"
+      ]
+     },
+     "execution_count": 14,
+     "metadata": {},
+     "output_type": "execute_result"
+    }
+   ],
+   "source": [
+    "# Organizando pela coluna \"Entity\" \n",
+    "df_newmortality.sort_values([\"Entity\"], inplace=True)\n",
+    "df_newmortality"
+   ]
+  },
+  {
+   "cell_type": "code",
+   "execution_count": 15,
+   "metadata": {},
+   "outputs": [
+    {
+     "name": "stdout",
+     "output_type": "stream",
+     "text": [
+      "Valores nulos por coluna do dataframe:\n",
+      "Variable    0\n",
+      "Measure     0\n",
+      "Country     0\n",
+      "Year        0\n",
+      "Value       0\n",
+      "dtype: int64\n"
+     ]
+    }
+   ],
+   "source": [
+    "# Não irei realizar a remoção de nulos, porque a pesquisa abaixo indica que não há valores nulos\n",
+    "print(\"Valores nulos por coluna do dataframe:\")\n",
+    "print(df_newhealth.isnull().sum())"
+   ]
+  },
+  {
+   "cell_type": "code",
+   "execution_count": 16,
+   "metadata": {},
+   "outputs": [
+    {
+     "name": "stdout",
+     "output_type": "stream",
+     "text": [
+      "Valores nulos por coluna do dataframe:\n",
+      "Entity                                                          0\n",
+      "Year                                                            0\n",
+      "Indicator:Maternal mortality ratio (per 100 000 live births)    0\n",
+      "dtype: int64\n"
+     ]
+    }
+   ],
+   "source": [
+    "# Não irei realizar a remoção de nulos, porque a pesquisa abaixo indica que não há valores nulos\n",
+    "print(\"Valores nulos por coluna do dataframe:\")\n",
+    "print(df_newmortality.isnull().sum())"
+   ]
+  },
+  {
+   "cell_type": "code",
+   "execution_count": 17,
+   "metadata": {},
+   "outputs": [],
+   "source": [
+    "# Resetando o index de cada banco de dados\n",
+    "df_newhealth.reset_index(drop=True, inplace=True)"
+   ]
+  },
+  {
+   "cell_type": "code",
+   "execution_count": 18,
+   "metadata": {},
+   "outputs": [],
+   "source": [
+    "# Resetando o index de cada banco de dados\n",
+    "df_newmortality.reset_index(drop=True, inplace=True)"
+   ]
+  },
+  {
+   "cell_type": "markdown",
+   "metadata": {},
+   "source": [
+    "# Conclusão\n",
+    "Irei tentar verificar se há correlação entre vendas farmacêuticas e mortalidade materna."
+   ]
+  },
+  {
+   "cell_type": "code",
+   "execution_count": 19,
+   "metadata": {},
+   "outputs": [],
+   "source": [
+    "import seaborn as sn"
+   ]
+  },
+  {
+   "cell_type": "markdown",
+   "metadata": {},
+   "source": [
+    "Vou unir os dois dataframes em um só para fazer uma análise de correlação, mas antes vou editar o df de mortalidade mudando o nome da coluna Entity para Country - para ficar igual ao df de saúde. "
+   ]
+  },
+  {
+   "cell_type": "code",
+   "execution_count": 20,
+   "metadata": {},
+   "outputs": [
+    {
+     "data": {
+      "text/html": [
+       "<div>\n",
+       "<style scoped>\n",
+       "    .dataframe tbody tr th:only-of-type {\n",
+       "        vertical-align: middle;\n",
+       "    }\n",
+       "\n",
+       "    .dataframe tbody tr th {\n",
+       "        vertical-align: top;\n",
+       "    }\n",
+       "\n",
+       "    .dataframe thead th {\n",
+       "        text-align: right;\n",
+       "    }\n",
+       "</style>\n",
+       "<table border=\"1\" class=\"dataframe\">\n",
+       "  <thead>\n",
+       "    <tr style=\"text-align: right;\">\n",
+       "      <th></th>\n",
+       "      <th>Country</th>\n",
+       "      <th>Year</th>\n",
+       "      <th>Indicator:Maternal mortality ratio (per 100 000 live births)</th>\n",
+       "    </tr>\n",
+       "  </thead>\n",
+       "  <tbody>\n",
+       "    <tr>\n",
+       "      <th>0</th>\n",
+       "      <td>Afghanistan</td>\n",
+       "      <td>2000</td>\n",
+       "      <td>1450</td>\n",
+       "    </tr>\n",
+       "    <tr>\n",
+       "      <th>1</th>\n",
+       "      <td>Afghanistan</td>\n",
+       "      <td>2017</td>\n",
+       "      <td>638</td>\n",
+       "    </tr>\n",
+       "    <tr>\n",
+       "      <th>2</th>\n",
+       "      <td>Afghanistan</td>\n",
+       "      <td>2016</td>\n",
+       "      <td>673</td>\n",
+       "    </tr>\n",
+       "    <tr>\n",
+       "      <th>3</th>\n",
+       "      <td>Afghanistan</td>\n",
+       "      <td>2015</td>\n",
+       "      <td>701</td>\n",
+       "    </tr>\n",
+       "    <tr>\n",
+       "      <th>4</th>\n",
+       "      <td>Afghanistan</td>\n",
+       "      <td>2014</td>\n",
+       "      <td>786</td>\n",
+       "    </tr>\n",
+       "    <tr>\n",
+       "      <th>...</th>\n",
+       "      <td>...</td>\n",
+       "      <td>...</td>\n",
+       "      <td>...</td>\n",
+       "    </tr>\n",
+       "    <tr>\n",
+       "      <th>3415</th>\n",
+       "      <td>Zimbabwe</td>\n",
+       "      <td>2001</td>\n",
+       "      <td>629</td>\n",
+       "    </tr>\n",
+       "    <tr>\n",
+       "      <th>3416</th>\n",
+       "      <td>Zimbabwe</td>\n",
+       "      <td>2000</td>\n",
+       "      <td>579</td>\n",
+       "    </tr>\n",
+       "    <tr>\n",
+       "      <th>3417</th>\n",
+       "      <td>Zimbabwe</td>\n",
+       "      <td>2016</td>\n",
+       "      <td>468</td>\n",
+       "    </tr>\n",
+       "    <tr>\n",
+       "      <th>3418</th>\n",
+       "      <td>Zimbabwe</td>\n",
+       "      <td>2007</td>\n",
+       "      <td>671</td>\n",
+       "    </tr>\n",
+       "    <tr>\n",
+       "      <th>3419</th>\n",
+       "      <td>Zimbabwe</td>\n",
+       "      <td>2017</td>\n",
+       "      <td>458</td>\n",
+       "    </tr>\n",
+       "  </tbody>\n",
+       "</table>\n",
+       "<p>3420 rows × 3 columns</p>\n",
+       "</div>"
+      ],
+      "text/plain": [
+       "          Country  Year  \\\n",
+       "0     Afghanistan  2000   \n",
+       "1     Afghanistan  2017   \n",
+       "2     Afghanistan  2016   \n",
+       "3     Afghanistan  2015   \n",
+       "4     Afghanistan  2014   \n",
+       "...           ...   ...   \n",
+       "3415     Zimbabwe  2001   \n",
+       "3416     Zimbabwe  2000   \n",
+       "3417     Zimbabwe  2016   \n",
+       "3418     Zimbabwe  2007   \n",
+       "3419     Zimbabwe  2017   \n",
+       "\n",
+       "      Indicator:Maternal mortality ratio (per 100 000 live births)  \n",
+       "0                                                  1450             \n",
+       "1                                                   638             \n",
+       "2                                                   673             \n",
+       "3                                                   701             \n",
+       "4                                                   786             \n",
+       "...                                                 ...             \n",
+       "3415                                                629             \n",
+       "3416                                                579             \n",
+       "3417                                                468             \n",
+       "3418                                                671             \n",
+       "3419                                                458             \n",
+       "\n",
+       "[3420 rows x 3 columns]"
+      ]
+     },
+     "execution_count": 20,
+     "metadata": {},
+     "output_type": "execute_result"
+    }
+   ],
+   "source": [
+    "# Primeiro uma cópia do df de mortalidade materna\n",
+    "df_mortalitycopy = df_newmortality.copy()\n",
+    "df_mortalitycopy.rename(columns={'Entity': 'Country'}, inplace = True)\n",
+    "df_mortalitycopy"
+   ]
+  },
+  {
+   "cell_type": "code",
+   "execution_count": 21,
+   "metadata": {},
+   "outputs": [
+    {
+     "data": {
+      "text/html": [
+       "<div>\n",
+       "<style scoped>\n",
+       "    .dataframe tbody tr th:only-of-type {\n",
+       "        vertical-align: middle;\n",
+       "    }\n",
+       "\n",
+       "    .dataframe tbody tr th {\n",
+       "        vertical-align: top;\n",
+       "    }\n",
+       "\n",
+       "    .dataframe thead th {\n",
+       "        text-align: right;\n",
+       "    }\n",
+       "</style>\n",
+       "<table border=\"1\" class=\"dataframe\">\n",
+       "  <thead>\n",
+       "    <tr style=\"text-align: right;\">\n",
+       "      <th></th>\n",
+       "      <th>Country</th>\n",
+       "      <th>Year</th>\n",
+       "      <th>Indicator:Maternal mortality ratio (per 100 000 live births)</th>\n",
+       "      <th>Variable</th>\n",
+       "      <th>Measure</th>\n",
+       "      <th>Value</th>\n",
+       "    </tr>\n",
+       "  </thead>\n",
+       "  <tbody>\n",
+       "    <tr>\n",
+       "      <th>0</th>\n",
+       "      <td>Australia</td>\n",
+       "      <td>2016</td>\n",
+       "      <td>6</td>\n",
+       "      <td>B-Blood and blood forming organs</td>\n",
+       "      <td>Million of national currency units</td>\n",
+       "      <td>667.0</td>\n",
+       "    </tr>\n",
+       "    <tr>\n",
+       "      <th>1</th>\n",
+       "      <td>Australia</td>\n",
+       "      <td>2016</td>\n",
+       "      <td>6</td>\n",
+       "      <td>M-Musculo-skeletal system</td>\n",
+       "      <td>Million US$ at exchange rate</td>\n",
+       "      <td>316.7</td>\n",
+       "    </tr>\n",
+       "    <tr>\n",
+       "      <th>2</th>\n",
+       "      <td>Australia</td>\n",
+       "      <td>2016</td>\n",
+       "      <td>6</td>\n",
+       "      <td>M-Musculo-skeletal system</td>\n",
+       "      <td>Million of national currency units</td>\n",
+       "      <td>426.0</td>\n",
+       "    </tr>\n",
+       "  </tbody>\n",
+       "</table>\n",
+       "</div>"
+      ],
+      "text/plain": [
+       "     Country  Year  \\\n",
+       "0  Australia  2016   \n",
+       "1  Australia  2016   \n",
+       "2  Australia  2016   \n",
+       "\n",
+       "   Indicator:Maternal mortality ratio (per 100 000 live births)  \\\n",
+       "0                                                  6              \n",
+       "1                                                  6              \n",
+       "2                                                  6              \n",
+       "\n",
+       "                           Variable                             Measure  Value  \n",
+       "0  B-Blood and blood forming organs  Million of national currency units  667.0  \n",
+       "1         M-Musculo-skeletal system        Million US$ at exchange rate  316.7  \n",
+       "2         M-Musculo-skeletal system  Million of national currency units  426.0  "
+      ]
+     },
+     "execution_count": 21,
+     "metadata": {},
+     "output_type": "execute_result"
+    }
+   ],
+   "source": [
+    "# Unindos os dataframes em um só\n",
+    "df_correlation = pd.merge(df_mortalitycopy, df_newhealth, how = 'inner', on = ('Country','Year'))\n",
+    "df_correlation.head(3)"
+   ]
+  },
+  {
+   "cell_type": "code",
+   "execution_count": 22,
+   "metadata": {},
+   "outputs": [
+    {
+     "data": {
+      "text/plain": [
+       "Index(['Country', 'Year',\n",
+       "       'Indicator:Maternal mortality ratio (per 100 000 live births)',\n",
+       "       'Variable', 'Measure', 'Value'],\n",
+       "      dtype='object')"
+      ]
+     },
+     "execution_count": 22,
+     "metadata": {},
+     "output_type": "execute_result"
+    }
+   ],
+   "source": [
+    "df_correlation.columns"
+   ]
+  },
+  {
+   "cell_type": "code",
+   "execution_count": 23,
+   "metadata": {},
+   "outputs": [
+    {
+     "data": {
+      "text/html": [
+       "<div>\n",
+       "<style scoped>\n",
+       "    .dataframe tbody tr th:only-of-type {\n",
+       "        vertical-align: middle;\n",
+       "    }\n",
+       "\n",
+       "    .dataframe tbody tr th {\n",
+       "        vertical-align: top;\n",
+       "    }\n",
+       "\n",
+       "    .dataframe thead th {\n",
+       "        text-align: right;\n",
+       "    }\n",
+       "</style>\n",
+       "<table border=\"1\" class=\"dataframe\">\n",
+       "  <thead>\n",
+       "    <tr style=\"text-align: right;\">\n",
+       "      <th></th>\n",
+       "      <th>Country</th>\n",
+       "      <th>Year</th>\n",
+       "      <th>Indicator:Maternal mortality ratio (per 100 000 live births)</th>\n",
+       "      <th>Variable</th>\n",
+       "      <th>Measure</th>\n",
+       "      <th>Value</th>\n",
+       "    </tr>\n",
+       "  </thead>\n",
+       "  <tbody>\n",
+       "    <tr>\n",
+       "      <th>0</th>\n",
+       "      <td>Australia</td>\n",
+       "      <td>2016</td>\n",
+       "      <td>6</td>\n",
+       "      <td>B-Blood and blood forming organs</td>\n",
+       "      <td>Million of national currency units</td>\n",
+       "      <td>667.0</td>\n",
+       "    </tr>\n",
+       "    <tr>\n",
+       "      <th>1</th>\n",
+       "      <td>Australia</td>\n",
+       "      <td>2016</td>\n",
+       "      <td>6</td>\n",
+       "      <td>M-Musculo-skeletal system</td>\n",
+       "      <td>Million US$ at exchange rate</td>\n",
+       "      <td>316.7</td>\n",
+       "    </tr>\n",
+       "    <tr>\n",
+       "      <th>2</th>\n",
+       "      <td>Australia</td>\n",
+       "      <td>2016</td>\n",
+       "      <td>6</td>\n",
+       "      <td>M-Musculo-skeletal system</td>\n",
+       "      <td>Million of national currency units</td>\n",
+       "      <td>426.0</td>\n",
+       "    </tr>\n",
+       "  </tbody>\n",
+       "</table>\n",
+       "</div>"
+      ],
+      "text/plain": [
+       "     Country  Year  \\\n",
+       "0  Australia  2016   \n",
+       "1  Australia  2016   \n",
+       "2  Australia  2016   \n",
+       "\n",
+       "   Indicator:Maternal mortality ratio (per 100 000 live births)  \\\n",
+       "0                                                  6              \n",
+       "1                                                  6              \n",
+       "2                                                  6              \n",
+       "\n",
+       "                           Variable                             Measure  Value  \n",
+       "0  B-Blood and blood forming organs  Million of national currency units  667.0  \n",
+       "1         M-Musculo-skeletal system        Million US$ at exchange rate  316.7  \n",
+       "2         M-Musculo-skeletal system  Million of national currency units  426.0  "
+      ]
+     },
+     "execution_count": 23,
+     "metadata": {},
+     "output_type": "execute_result"
+    }
+   ],
+   "source": [
+    "df_correlation.head(3)"
+   ]
+  },
+  {
+   "cell_type": "code",
+   "execution_count": 24,
+   "metadata": {},
+   "outputs": [],
+   "source": [
+    "# Vou mudar o nome das colunas para fazerem mais sentido \n",
+    "df_correlation.rename(columns={'Variable': 'Type_of_Medicine'}, inplace = True)\n",
+    "df_correlation.rename(columns={'Value': 'Total_Sales_Value'}, inplace = True)"
+   ]
+  },
+  {
+   "cell_type": "code",
+   "execution_count": 26,
+   "metadata": {},
+   "outputs": [
+    {
+     "data": {
+      "text/html": [
+       "<div>\n",
+       "<style scoped>\n",
+       "    .dataframe tbody tr th:only-of-type {\n",
+       "        vertical-align: middle;\n",
+       "    }\n",
+       "\n",
+       "    .dataframe tbody tr th {\n",
+       "        vertical-align: top;\n",
+       "    }\n",
+       "\n",
+       "    .dataframe thead th {\n",
+       "        text-align: right;\n",
+       "    }\n",
+       "</style>\n",
+       "<table border=\"1\" class=\"dataframe\">\n",
+       "  <thead>\n",
+       "    <tr style=\"text-align: right;\">\n",
+       "      <th></th>\n",
+       "      <th>Year</th>\n",
+       "      <th>Indicator:Maternal mortality ratio (per 100 000 live births)</th>\n",
+       "      <th>Total_Sales_Value</th>\n",
+       "    </tr>\n",
+       "  </thead>\n",
+       "  <tbody>\n",
+       "    <tr>\n",
+       "      <th>count</th>\n",
+       "      <td>34193.000000</td>\n",
+       "      <td>34193.000000</td>\n",
+       "      <td>3.419300e+04</td>\n",
+       "    </tr>\n",
+       "    <tr>\n",
+       "      <th>mean</th>\n",
+       "      <td>2013.515135</td>\n",
+       "      <td>8.310385</td>\n",
+       "      <td>4.743234e+03</td>\n",
+       "    </tr>\n",
+       "    <tr>\n",
+       "      <th>std</th>\n",
+       "      <td>2.266302</td>\n",
+       "      <td>6.548559</td>\n",
+       "      <td>1.202409e+05</td>\n",
+       "    </tr>\n",
+       "    <tr>\n",
+       "      <th>min</th>\n",
+       "      <td>2010.000000</td>\n",
+       "      <td>2.000000</td>\n",
+       "      <td>0.000000e+00</td>\n",
+       "    </tr>\n",
+       "    <tr>\n",
+       "      <th>25%</th>\n",
+       "      <td>2012.000000</td>\n",
+       "      <td>5.000000</td>\n",
+       "      <td>4.600000e+00</td>\n",
+       "    </tr>\n",
+       "    <tr>\n",
+       "      <th>50%</th>\n",
+       "      <td>2014.000000</td>\n",
+       "      <td>6.000000</td>\n",
+       "      <td>2.050000e+01</td>\n",
+       "    </tr>\n",
+       "    <tr>\n",
+       "      <th>75%</th>\n",
+       "      <td>2015.000000</td>\n",
+       "      <td>10.000000</td>\n",
+       "      <td>1.518000e+02</td>\n",
+       "    </tr>\n",
+       "    <tr>\n",
+       "      <th>max</th>\n",
+       "      <td>2017.000000</td>\n",
+       "      <td>46.000000</td>\n",
+       "      <td>6.987367e+06</td>\n",
+       "    </tr>\n",
+       "  </tbody>\n",
+       "</table>\n",
+       "</div>"
+      ],
+      "text/plain": [
+       "               Year  \\\n",
+       "count  34193.000000   \n",
+       "mean    2013.515135   \n",
+       "std        2.266302   \n",
+       "min     2010.000000   \n",
+       "25%     2012.000000   \n",
+       "50%     2014.000000   \n",
+       "75%     2015.000000   \n",
+       "max     2017.000000   \n",
+       "\n",
+       "       Indicator:Maternal mortality ratio (per 100 000 live births)  \\\n",
+       "count                                       34193.000000              \n",
+       "mean                                            8.310385              \n",
+       "std                                             6.548559              \n",
+       "min                                             2.000000              \n",
+       "25%                                             5.000000              \n",
+       "50%                                             6.000000              \n",
+       "75%                                            10.000000              \n",
+       "max                                            46.000000              \n",
+       "\n",
+       "       Total_Sales_Value  \n",
+       "count       3.419300e+04  \n",
+       "mean        4.743234e+03  \n",
+       "std         1.202409e+05  \n",
+       "min         0.000000e+00  \n",
+       "25%         4.600000e+00  \n",
+       "50%         2.050000e+01  \n",
+       "75%         1.518000e+02  \n",
+       "max         6.987367e+06  "
+      ]
+     },
+     "execution_count": 26,
+     "metadata": {},
+     "output_type": "execute_result"
+    }
+   ],
+   "source": [
+    "# Dando uma verificada nos dados\n",
+    "df_correlation.describe()"
+   ]
+  },
+  {
+   "cell_type": "code",
+   "execution_count": 27,
+   "metadata": {},
+   "outputs": [],
+   "source": [
+    "# Vou excluir as colunas com dados string e manter só valores que quero relacionar\n",
+    "df_correlationvalues = df_correlation.drop(columns= [\"Measure\",\"Country\", \"Year\", \"Type_of_Medicine\"])\n"
+   ]
+  },
+  {
+   "cell_type": "code",
+   "execution_count": 28,
+   "metadata": {},
+   "outputs": [
+    {
+     "data": {
+      "text/plain": [
+       "Index(['Indicator:Maternal mortality ratio (per 100 000 live births)', 'Total_Sales_Value'], dtype='object')"
+      ]
+     },
+     "execution_count": 28,
+     "metadata": {},
+     "output_type": "execute_result"
+    }
+   ],
+   "source": [
+    "df_correlationvalues.columns"
+   ]
+  },
+  {
+   "cell_type": "code",
+   "execution_count": 29,
+   "metadata": {},
+   "outputs": [],
+   "source": [
+    "# Testando criar a correlação\n",
+    "correlation = df_correlationvalues.corr()"
+   ]
+  },
+  {
+   "cell_type": "code",
+   "execution_count": 30,
+   "metadata": {},
+   "outputs": [
+    {
+     "data": {
+      "text/plain": [
+       "<Axes: >"
+      ]
+     },
+     "execution_count": 30,
+     "metadata": {},
+     "output_type": "execute_result"
+    },
+    {
+     "data": {
+      "image/png": "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",
+      "text/plain": [
+       "<Figure size 640x480 with 2 Axes>"
+      ]
+     },
+     "metadata": {},
+     "output_type": "display_data"
+    }
+   ],
+   "source": [
+    "#Plot da matriz de correlação \n",
+    "plot = sn.heatmap(correlation, annot = True, fmt=\".1f\", linewidths=.6)\n",
+    "plot"
+   ]
+  },
+  {
+   "cell_type": "markdown",
+   "metadata": {},
+   "source": [
+    "O insight por enquanto é que não tem correlação nenhuma, mas preciso limpar mais os dados, pensei em selecionar uma lista de países num ano específico ou um país ao longo do tempo - tentei fazer e não consegui :/"
+   ]
+  },
+  {
+   "cell_type": "markdown",
+   "metadata": {},
+   "source": [
+    "# Finalizando salvando dataframe de correlação em csv"
+   ]
+  },
+  {
+   "cell_type": "code",
+   "execution_count": 32,
+   "metadata": {},
+   "outputs": [],
+   "source": [
+    "df_correlation.to_csv(\"MaternalMortality_HealthIndicators.csv\")"
+   ]
+  }
+ ],
+ "metadata": {
+  "kernelspec": {
+   "display_name": "Python 3",
+   "language": "python",
+   "name": "python3"
+  },
+  "language_info": {
+   "codemirror_mode": {
+    "name": "ipython",
+    "version": 3
+   },
+   "file_extension": ".py",
+   "mimetype": "text/x-python",
+   "name": "python",
+   "nbconvert_exporter": "python",
+   "pygments_lexer": "ipython3",
+   "version": "3.11.4"
+  }
+ },
+ "nbformat": 4,
+ "nbformat_minor": 2
+}
diff --git a/exercicios/para-casa/exercicioCrisPereiraS11/health_indicators_ocde.csv b/exercicios/para-casa/exercicioCrisPereiraS11/health_indicators_ocde.csv
new file mode 100644
index 0000000..aeffb0c
--- /dev/null
+++ b/exercicios/para-casa/exercicioCrisPereiraS11/health_indicators_ocde.csv
@@ -0,0 +1,62545 @@
+"VAR","Variable","UNIT","Measure","COU","Country","YEA","Year","Value","Flag Codes","Flags"
+"PATCTOTT","Total pharmaceutical sales","MLLNCUMT","Million of national currency units","AUS","Australia","2010","2010",9795,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","MLLNCUMT","Million of national currency units","AUS","Australia","2011","2011",10261,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","MLLNCUMT","Million of national currency units","AUS","Australia","2012","2012",10355,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","MLLNCUMT","Million of national currency units","AUS","Australia","2013","2013",11820,"B; D","Break; Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","MLLNCUMT","Million of national currency units","AUS","Australia","2014","2014",11888,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","MLLNCUMT","Million of national currency units","AUS","Australia","2015","2015",12284,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","MLLNCUMT","Million of national currency units","AUS","Australia","2016","2016",15305,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","MLLNCUMT","Million of national currency units","AUS","Australia","2017","2017",14774,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","MLLNCUMT","Million of national currency units","AUS","Australia","2018","2018",14905,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","MLLNCUMT","Million of national currency units","AUS","Australia","2019","2019",15559,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","MLLNCUMT","Million of national currency units","AUS","Australia","2020","2020",16614,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","MLLNCUMT","Million of national currency units","AUS","Australia","2021","2021",17556,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","MTMOTCMT","Million US$ at exchange rate","AUS","Australia","2010","2010",8984.9,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","MTMOTCMT","Million US$ at exchange rate","AUS","Australia","2011","2011",10584.2,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","MTMOTCMT","Million US$ at exchange rate","AUS","Australia","2012","2012",10721.7,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","MTMOTCMT","Million US$ at exchange rate","AUS","Australia","2013","2013",11411,"B; D","Break; Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","MTMOTCMT","Million US$ at exchange rate","AUS","Australia","2014","2014",10716.1,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","MTMOTCMT","Million US$ at exchange rate","AUS","Australia","2015","2015",9228.5,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","MTMOTCMT","Million US$ at exchange rate","AUS","Australia","2016","2016",11377.4,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","MTMOTCMT","Million US$ at exchange rate","AUS","Australia","2017","2017",11323.2,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","MTMOTCMT","Million US$ at exchange rate","AUS","Australia","2018","2018",11136.3,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","MTMOTCMT","Million US$ at exchange rate","AUS","Australia","2019","2019",10816.1,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","MTMOTCMT","Million US$ at exchange rate","AUS","Australia","2020","2020",11433.6,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","MTMOTCMT","Million US$ at exchange rate","AUS","Australia","2021","2021",13187.9,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","MTMOPPMT","Million US$, purchasing power parity","AUS","Australia","2010","2010",6514.3,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","MTMOPPMT","Million US$, purchasing power parity","AUS","Australia","2011","2011",6790.6,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","MTMOPPMT","Million US$, purchasing power parity","AUS","Australia","2012","2012",6723.5,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","MTMOPPMT","Million US$, purchasing power parity","AUS","Australia","2013","2013",8167.9,"B; D","Break; Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","MTMOPPMT","Million US$, purchasing power parity","AUS","Australia","2014","2014",8184.6,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","MTMOPPMT","Million US$, purchasing power parity","AUS","Australia","2015","2015",8335.5,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","MTMOPPMT","Million US$, purchasing power parity","AUS","Australia","2016","2016",10554,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","MTMOPPMT","Million US$, purchasing power parity","AUS","Australia","2017","2017",9999,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","MTMOPPMT","Million US$, purchasing power parity","AUS","Australia","2018","2018",10136.7,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","MTMOPPMT","Million US$, purchasing power parity","AUS","Australia","2019","2019",10513.7,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","MTMOPPMT","Million US$, purchasing power parity","AUS","Australia","2020","2020",11426.7,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","MTMOPPMT","Million US$, purchasing power parity","AUS","Australia","2021","2021",12127.8,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","TCPPERMT","/capita, US$ exchange rate","AUS","Australia","2010","2010",407.8,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","TCPPERMT","/capita, US$ exchange rate","AUS","Australia","2011","2011",473.8,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","TCPPERMT","/capita, US$ exchange rate","AUS","Australia","2012","2012",471.6,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","TCPPERMT","/capita, US$ exchange rate","AUS","Australia","2013","2013",493.4,"B; D","Break; Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","TCPPERMT","/capita, US$ exchange rate","AUS","Australia","2014","2014",456.5,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","TCPPERMT","/capita, US$ exchange rate","AUS","Australia","2015","2015",387.5,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","TCPPERMT","/capita, US$ exchange rate","AUS","Australia","2016","2016",470.3,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","TCPPERMT","/capita, US$ exchange rate","AUS","Australia","2017","2017",460.4,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","TCPPERMT","/capita, US$ exchange rate","AUS","Australia","2018","2018",446,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","TCPPERMT","/capita, US$ exchange rate","AUS","Australia","2019","2019",426.8,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","TCPPERMT","/capita, US$ exchange rate","AUS","Australia","2020","2020",445.7,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","TCPPERMT","/capita, US$ exchange rate","AUS","Australia","2021","2021",513.4,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2010","2010",295.7,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2011","2011",304,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2012","2012",295.8,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2013","2013",353.2,"B; D","Break; Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2014","2014",348.6,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2015","2015",350,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2016","2016",436.3,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2017","2017",406.6,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2018","2018",406,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2019","2019",414.9,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2020","2020",445.4,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2021","2021",472.1,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","MLLNCUMT","Million of national currency units","AUT","Austria","2010","2010",2493,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","MLLNCUMT","Million of national currency units","AUT","Austria","2011","2011",2549.6,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","MLLNCUMT","Million of national currency units","AUT","Austria","2012","2012",2613,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","MLLNCUMT","Million of national currency units","AUT","Austria","2013","2013",2635.2,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","MLLNCUMT","Million of national currency units","AUT","Austria","2014","2014",2787.4,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","MLLNCUMT","Million of national currency units","AUT","Austria","2015","2015",2928.9,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","MLLNCUMT","Million of national currency units","AUT","Austria","2016","2016",3006.4,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","MLLNCUMT","Million of national currency units","AUT","Austria","2017","2017",3127.2,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","MLLNCUMT","Million of national currency units","AUT","Austria","2018","2018",3213.6,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","MLLNCUMT","Million of national currency units","AUT","Austria","2019","2019",3312.6,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","MLLNCUMT","Million of national currency units","AUT","Austria","2020","2020",3475.9,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","MLLNCUMT","Million of national currency units","AUT","Austria","2021","2021",3711.7,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","MTMOTCMT","Million US$ at exchange rate","AUT","Austria","2010","2010",3305,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","MTMOTCMT","Million US$ at exchange rate","AUT","Austria","2011","2011",3548.9,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","MTMOTCMT","Million US$ at exchange rate","AUT","Austria","2012","2012",3357.1,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","MTMOTCMT","Million US$ at exchange rate","AUT","Austria","2013","2013",3499.8,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","MTMOTCMT","Million US$ at exchange rate","AUT","Austria","2014","2014",3703.1,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","MTMOTCMT","Million US$ at exchange rate","AUT","Austria","2015","2015",3249.6,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","MTMOTCMT","Million US$ at exchange rate","AUT","Austria","2016","2016",3327.8,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","MTMOTCMT","Million US$ at exchange rate","AUT","Austria","2017","2017",3532.8,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","MTMOTCMT","Million US$ at exchange rate","AUT","Austria","2018","2018",3795.2,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","MTMOTCMT","Million US$ at exchange rate","AUT","Austria","2019","2019",3708.3,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","MTMOTCMT","Million US$ at exchange rate","AUT","Austria","2020","2020",3970.1,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","MTMOTCMT","Million US$ at exchange rate","AUT","Austria","2021","2021",4390,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","MTMOPPMT","Million US$, purchasing power parity","AUT","Austria","2010","2010",2959.9,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","MTMOPPMT","Million US$, purchasing power parity","AUT","Austria","2011","2011",3066.7,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","MTMOPPMT","Million US$, purchasing power parity","AUT","Austria","2012","2012",3211.4,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","MTMOPPMT","Million US$, purchasing power parity","AUT","Austria","2013","2013",3306,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","MTMOPPMT","Million US$, purchasing power parity","AUT","Austria","2014","2014",3489.5,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","MTMOPPMT","Million US$, purchasing power parity","AUT","Austria","2015","2015",3666.5,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","MTMOPPMT","Million US$, purchasing power parity","AUT","Austria","2016","2016",3869.5,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","MTMOPPMT","Million US$, purchasing power parity","AUT","Austria","2017","2017",4035.1,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","MTMOPPMT","Million US$, purchasing power parity","AUT","Austria","2018","2018",4198.6,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","MTMOPPMT","Million US$, purchasing power parity","AUT","Austria","2019","2019",4421.8,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","MTMOPPMT","Million US$, purchasing power parity","AUT","Austria","2020","2020",4657.4,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","MTMOPPMT","Million US$, purchasing power parity","AUT","Austria","2021","2021",4907.6,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","TCPPERMT","/capita, US$ exchange rate","AUT","Austria","2010","2010",395.2,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","TCPPERMT","/capita, US$ exchange rate","AUT","Austria","2011","2011",422.9,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","TCPPERMT","/capita, US$ exchange rate","AUT","Austria","2012","2012",398.2,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","TCPPERMT","/capita, US$ exchange rate","AUT","Austria","2013","2013",412.7,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","TCPPERMT","/capita, US$ exchange rate","AUT","Austria","2014","2014",433.3,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","TCPPERMT","/capita, US$ exchange rate","AUT","Austria","2015","2015",376,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","TCPPERMT","/capita, US$ exchange rate","AUT","Austria","2016","2016",380.9,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","TCPPERMT","/capita, US$ exchange rate","AUT","Austria","2017","2017",401.6,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","TCPPERMT","/capita, US$ exchange rate","AUT","Austria","2018","2018",429.3,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","TCPPERMT","/capita, US$ exchange rate","AUT","Austria","2019","2019",417.6,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","TCPPERMT","/capita, US$ exchange rate","AUT","Austria","2020","2020",445.2,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","TCPPERMT","/capita, US$ exchange rate","AUT","Austria","2021","2021",490.2,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2010","2010",353.9,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2011","2011",365.4,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2012","2012",381,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2013","2013",389.9,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2014","2014",408.3,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2015","2015",424.2,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2016","2016",442.9,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2017","2017",458.7,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2018","2018",474.9,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2019","2019",498,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2020","2020",522.3,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2021","2021",548,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","MLLNCUMT","Million of national currency units","BEL","Belgium","2010","2010",5881.5,,
+"PATCTOTT","Total pharmaceutical sales","MLLNCUMT","Million of national currency units","BEL","Belgium","2011","2011",5993.3,,
+"PATCTOTT","Total pharmaceutical sales","MLLNCUMT","Million of national currency units","BEL","Belgium","2012","2012",5939.4,,
+"PATCTOTT","Total pharmaceutical sales","MLLNCUMT","Million of national currency units","BEL","Belgium","2013","2013",5947.9,,
+"PATCTOTT","Total pharmaceutical sales","MLLNCUMT","Million of national currency units","BEL","Belgium","2014","2014",5947.5,,
+"PATCTOTT","Total pharmaceutical sales","MLLNCUMT","Million of national currency units","BEL","Belgium","2015","2015",6191.6,,
+"PATCTOTT","Total pharmaceutical sales","MLLNCUMT","Million of national currency units","BEL","Belgium","2016","2016",6242.6,,
+"PATCTOTT","Total pharmaceutical sales","MLLNCUMT","Million of national currency units","BEL","Belgium","2017","2017",6543.2,,
+"PATCTOTT","Total pharmaceutical sales","MLLNCUMT","Million of national currency units","BEL","Belgium","2018","2018",6681.1,,
+"PATCTOTT","Total pharmaceutical sales","MLLNCUMT","Million of national currency units","BEL","Belgium","2019","2019",7355.3,,
+"PATCTOTT","Total pharmaceutical sales","MLLNCUMT","Million of national currency units","BEL","Belgium","2020","2020",7662,,
+"PATCTOTT","Total pharmaceutical sales","MLLNCUMT","Million of national currency units","BEL","Belgium","2021","2021",8051.6,,
+"PATCTOTT","Total pharmaceutical sales","MLLNCUMT","Million of national currency units","BEL","Belgium","2022","2022",9006.9,"E","Estimated value"
+"PATCTOTT","Total pharmaceutical sales","MTMOTCMT","Million US$ at exchange rate","BEL","Belgium","2010","2010",7797.2,,
+"PATCTOTT","Total pharmaceutical sales","MTMOTCMT","Million US$ at exchange rate","BEL","Belgium","2011","2011",8342.4,,
+"PATCTOTT","Total pharmaceutical sales","MTMOTCMT","Million US$ at exchange rate","BEL","Belgium","2012","2012",7630.9,,
+"PATCTOTT","Total pharmaceutical sales","MTMOTCMT","Million US$ at exchange rate","BEL","Belgium","2013","2013",7899.5,,
+"PATCTOTT","Total pharmaceutical sales","MTMOTCMT","Million US$ at exchange rate","BEL","Belgium","2014","2014",7901.2,,
+"PATCTOTT","Total pharmaceutical sales","MTMOTCMT","Million US$ at exchange rate","BEL","Belgium","2015","2015",6869.7,,
+"PATCTOTT","Total pharmaceutical sales","MTMOTCMT","Million US$ at exchange rate","BEL","Belgium","2016","2016",6910,,
+"PATCTOTT","Total pharmaceutical sales","MTMOTCMT","Million US$ at exchange rate","BEL","Belgium","2017","2017",7391.7,,
+"PATCTOTT","Total pharmaceutical sales","MTMOTCMT","Million US$ at exchange rate","BEL","Belgium","2018","2018",7890,,
+"PATCTOTT","Total pharmaceutical sales","MTMOTCMT","Million US$ at exchange rate","BEL","Belgium","2019","2019",8234.1,,
+"PATCTOTT","Total pharmaceutical sales","MTMOTCMT","Million US$ at exchange rate","BEL","Belgium","2020","2020",8751.5,,
+"PATCTOTT","Total pharmaceutical sales","MTMOTCMT","Million US$ at exchange rate","BEL","Belgium","2021","2021",9523,,
+"PATCTOTT","Total pharmaceutical sales","MTMOTCMT","Million US$ at exchange rate","BEL","Belgium","2022","2022",9484.8,"E","Estimated value"
+"PATCTOTT","Total pharmaceutical sales","MTMOPPMT","Million US$, purchasing power parity","BEL","Belgium","2010","2010",7030.2,,
+"PATCTOTT","Total pharmaceutical sales","MTMOPPMT","Million US$, purchasing power parity","BEL","Belgium","2011","2011",7204.3,,
+"PATCTOTT","Total pharmaceutical sales","MTMOPPMT","Million US$, purchasing power parity","BEL","Belgium","2012","2012",7224.3,,
+"PATCTOTT","Total pharmaceutical sales","MTMOPPMT","Million US$, purchasing power parity","BEL","Belgium","2013","2013",7378,,
+"PATCTOTT","Total pharmaceutical sales","MTMOPPMT","Million US$, purchasing power parity","BEL","Belgium","2014","2014",7432.3,,
+"PATCTOTT","Total pharmaceutical sales","MTMOPPMT","Million US$, purchasing power parity","BEL","Belgium","2015","2015",7739.6,,
+"PATCTOTT","Total pharmaceutical sales","MTMOPPMT","Million US$, purchasing power parity","BEL","Belgium","2016","2016",7993,,
+"PATCTOTT","Total pharmaceutical sales","MTMOPPMT","Million US$, purchasing power parity","BEL","Belgium","2017","2017",8435.9,,
+"PATCTOTT","Total pharmaceutical sales","MTMOPPMT","Million US$, purchasing power parity","BEL","Belgium","2018","2018",8717.4,,
+"PATCTOTT","Total pharmaceutical sales","MTMOPPMT","Million US$, purchasing power parity","BEL","Belgium","2019","2019",9851.7,,
+"PATCTOTT","Total pharmaceutical sales","MTMOPPMT","Million US$, purchasing power parity","BEL","Belgium","2020","2020",10491.9,,
+"PATCTOTT","Total pharmaceutical sales","MTMOPPMT","Million US$, purchasing power parity","BEL","Belgium","2021","2021",10929.5,,
+"PATCTOTT","Total pharmaceutical sales","MTMOPPMT","Million US$, purchasing power parity","BEL","Belgium","2022","2022",12615.9,"E","Estimated value"
+"PATCTOTT","Total pharmaceutical sales","TCPPERMT","/capita, US$ exchange rate","BEL","Belgium","2010","2010",715.6,,
+"PATCTOTT","Total pharmaceutical sales","TCPPERMT","/capita, US$ exchange rate","BEL","Belgium","2011","2011",755.8,,
+"PATCTOTT","Total pharmaceutical sales","TCPPERMT","/capita, US$ exchange rate","BEL","Belgium","2012","2012",687,,
+"PATCTOTT","Total pharmaceutical sales","TCPPERMT","/capita, US$ exchange rate","BEL","Belgium","2013","2013",707.9,,
+"PATCTOTT","Total pharmaceutical sales","TCPPERMT","/capita, US$ exchange rate","BEL","Belgium","2014","2014",704.9,,
+"PATCTOTT","Total pharmaceutical sales","TCPPERMT","/capita, US$ exchange rate","BEL","Belgium","2015","2015",609.3,,
+"PATCTOTT","Total pharmaceutical sales","TCPPERMT","/capita, US$ exchange rate","BEL","Belgium","2016","2016",609.8,,
+"PATCTOTT","Total pharmaceutical sales","TCPPERMT","/capita, US$ exchange rate","BEL","Belgium","2017","2017",649.8,,
+"PATCTOTT","Total pharmaceutical sales","TCPPERMT","/capita, US$ exchange rate","BEL","Belgium","2018","2018",690.5,,
+"PATCTOTT","Total pharmaceutical sales","TCPPERMT","/capita, US$ exchange rate","BEL","Belgium","2019","2019",716.7,,
+"PATCTOTT","Total pharmaceutical sales","TCPPERMT","/capita, US$ exchange rate","BEL","Belgium","2020","2020",758.5,,
+"PATCTOTT","Total pharmaceutical sales","TCPPERMT","/capita, US$ exchange rate","BEL","Belgium","2021","2021",821.9,,
+"PATCTOTT","Total pharmaceutical sales","TCPPERMT","/capita, US$ exchange rate","BEL","Belgium","2022","2022",816.4,"E","Estimated value"
+"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2010","2010",645.2,,
+"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2011","2011",652.7,,
+"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2012","2012",650.4,,
+"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2013","2013",661.1,,
+"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2014","2014",663.1,,
+"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2015","2015",686.5,,
+"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2016","2016",705.4,,
+"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2017","2017",741.6,,
+"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2018","2018",762.9,,
+"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2019","2019",857.5,,
+"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2020","2020",909.3,,
+"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2021","2021",943.3,,
+"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2022","2022",1085.9,"E","Estimated value"
+"PATCTOTT","Total pharmaceutical sales","MLLNCUMT","Million of national currency units","CAN","Canada","2012","2012",24297.8,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","MLLNCUMT","Million of national currency units","CAN","Canada","2013","2013",24579.2,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","MLLNCUMT","Million of national currency units","CAN","Canada","2014","2014",25517,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","MLLNCUMT","Million of national currency units","CAN","Canada","2015","2015",27126.4,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","MLLNCUMT","Million of national currency units","CAN","Canada","2016","2016",28334.3,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","MLLNCUMT","Million of national currency units","CAN","Canada","2017","2017",29776.2,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","MLLNCUMT","Million of national currency units","CAN","Canada","2018","2018",30603.7,"E; B; D","Estimated value; Break; Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","MLLNCUMT","Million of national currency units","CAN","Canada","2019","2019",31829.5,"E; D","Estimated value; Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","MLLNCUMT","Million of national currency units","CAN","Canada","2020","2020",34260.5,"E; D","Estimated value; Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","MLLNCUMT","Million of national currency units","CAN","Canada","2021","2021",36839.6,"E; D","Estimated value; Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","MLLNCUMT","Million of national currency units","CAN","Canada","2022","2022",39943.9,"E; D","Estimated value; Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","MTMOTCMT","Million US$ at exchange rate","CAN","Canada","2012","2012",24313.2,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","MTMOTCMT","Million US$ at exchange rate","CAN","Canada","2013","2013",23860.1,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","MTMOTCMT","Million US$ at exchange rate","CAN","Canada","2014","2014",23097.6,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","MTMOTCMT","Million US$ at exchange rate","CAN","Canada","2015","2015",21212.6,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","MTMOTCMT","Million US$ at exchange rate","CAN","Canada","2016","2016",21374.5,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","MTMOTCMT","Million US$ at exchange rate","CAN","Canada","2017","2017",22941.2,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","MTMOTCMT","Million US$ at exchange rate","CAN","Canada","2018","2018",23617.3,"E; B; D","Estimated value; Break; Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","MTMOTCMT","Million US$ at exchange rate","CAN","Canada","2019","2019",23989.8,"E; D","Estimated value; Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","MTMOTCMT","Million US$ at exchange rate","CAN","Canada","2020","2020",25545.5,"E; D","Estimated value; Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","MTMOTCMT","Million US$ at exchange rate","CAN","Canada","2021","2021",29380.5,"E; D","Estimated value; Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","MTMOTCMT","Million US$ at exchange rate","CAN","Canada","2022","2022",30689.3,"E; D","Estimated value; Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","MTMOPPMT","Million US$, purchasing power parity","CAN","Canada","2012","2012",19522.5,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","MTMOPPMT","Million US$, purchasing power parity","CAN","Canada","2013","2013",20081,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","MTMOPPMT","Million US$, purchasing power parity","CAN","Canada","2014","2014",20739.5,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","MTMOPPMT","Million US$, purchasing power parity","CAN","Canada","2015","2015",21735.2,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","MTMOPPMT","Million US$, purchasing power parity","CAN","Canada","2016","2016",23474.1,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","MTMOPPMT","Million US$, purchasing power parity","CAN","Canada","2017","2017",24561.7,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","MTMOPPMT","Million US$, purchasing power parity","CAN","Canada","2018","2018",25365.2,"E; B; D","Estimated value; Break; Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","MTMOPPMT","Million US$, purchasing power parity","CAN","Canada","2019","2019",25778.8,"E; D","Estimated value; Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","MTMOPPMT","Million US$, purchasing power parity","CAN","Canada","2020","2020",27830,"E; D","Estimated value; Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","MTMOPPMT","Million US$, purchasing power parity","CAN","Canada","2021","2021",29753.6,"E; D","Estimated value; Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","MTMOPPMT","Million US$, purchasing power parity","CAN","Canada","2022","2022",31857.3,"E; D","Estimated value; Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","TCPPERMT","/capita, US$ exchange rate","CAN","Canada","2012","2012",700.4,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","TCPPERMT","/capita, US$ exchange rate","CAN","Canada","2013","2013",680.1,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","TCPPERMT","/capita, US$ exchange rate","CAN","Canada","2014","2014",651.8,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","TCPPERMT","/capita, US$ exchange rate","CAN","Canada","2015","2015",594.1,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","TCPPERMT","/capita, US$ exchange rate","CAN","Canada","2016","2016",591.9,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","TCPPERMT","/capita, US$ exchange rate","CAN","Canada","2017","2017",627.7,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","TCPPERMT","/capita, US$ exchange rate","CAN","Canada","2018","2018",637.2,"E; B; D","Estimated value; Break; Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","TCPPERMT","/capita, US$ exchange rate","CAN","Canada","2019","2019",638,"E; D","Estimated value; Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","TCPPERMT","/capita, US$ exchange rate","CAN","Canada","2020","2020",671.6,"E; D","Estimated value; Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","TCPPERMT","/capita, US$ exchange rate","CAN","Canada","2021","2021",768.2,"E; D","Estimated value; Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","TCPPERMT","/capita, US$ exchange rate","CAN","Canada","2022","2022",789.3,"E; D","Estimated value; Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2012","2012",562.4,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2013","2013",572.4,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2014","2014",585.2,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2015","2015",608.8,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2016","2016",650.1,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2017","2017",672.1,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2018","2018",684.3,"E; B; D","Estimated value; Break; Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2019","2019",685.6,"E; D","Estimated value; Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2020","2020",731.7,"E; D","Estimated value; Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2021","2021",778,"E; D","Estimated value; Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2022","2022",819.3,"E; D","Estimated value; Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","MLLNCUMT","Million of national currency units","CZE","Czech Republic","2010","2010",81467.5,,
+"PATCTOTT","Total pharmaceutical sales","MLLNCUMT","Million of national currency units","CZE","Czech Republic","2011","2011",80927.9,,
+"PATCTOTT","Total pharmaceutical sales","MLLNCUMT","Million of national currency units","CZE","Czech Republic","2012","2012",83749.3,,
+"PATCTOTT","Total pharmaceutical sales","MLLNCUMT","Million of national currency units","CZE","Czech Republic","2013","2013",79711.5,,
+"PATCTOTT","Total pharmaceutical sales","MLLNCUMT","Million of national currency units","CZE","Czech Republic","2014","2014",81080.3,,
+"PATCTOTT","Total pharmaceutical sales","MLLNCUMT","Million of national currency units","CZE","Czech Republic","2015","2015",84444.6,,
+"PATCTOTT","Total pharmaceutical sales","MLLNCUMT","Million of national currency units","CZE","Czech Republic","2016","2016",87267.5,,
+"PATCTOTT","Total pharmaceutical sales","MLLNCUMT","Million of national currency units","CZE","Czech Republic","2017","2017",92013.1,,
+"PATCTOTT","Total pharmaceutical sales","MLLNCUMT","Million of national currency units","CZE","Czech Republic","2018","2018",97984.5,,
+"PATCTOTT","Total pharmaceutical sales","MLLNCUMT","Million of national currency units","CZE","Czech Republic","2019","2019",103398.9,,
+"PATCTOTT","Total pharmaceutical sales","MLLNCUMT","Million of national currency units","CZE","Czech Republic","2020","2020",87781.9,"B","Break"
+"PATCTOTT","Total pharmaceutical sales","MLLNCUMT","Million of national currency units","CZE","Czech Republic","2021","2021",93006.5,,
+"PATCTOTT","Total pharmaceutical sales","MTMOTCMT","Million US$ at exchange rate","CZE","Czech Republic","2010","2010",4265.7,,
+"PATCTOTT","Total pharmaceutical sales","MTMOTCMT","Million US$ at exchange rate","CZE","Czech Republic","2011","2011",4573.2,,
+"PATCTOTT","Total pharmaceutical sales","MTMOTCMT","Million US$ at exchange rate","CZE","Czech Republic","2012","2012",4277.8,,
+"PATCTOTT","Total pharmaceutical sales","MTMOTCMT","Million US$ at exchange rate","CZE","Czech Republic","2013","2013",4073,,
+"PATCTOTT","Total pharmaceutical sales","MTMOTCMT","Million US$ at exchange rate","CZE","Czech Republic","2014","2014",3906.1,,
+"PATCTOTT","Total pharmaceutical sales","MTMOTCMT","Million US$ at exchange rate","CZE","Czech Republic","2015","2015",3432.9,,
+"PATCTOTT","Total pharmaceutical sales","MTMOTCMT","Million US$ at exchange rate","CZE","Czech Republic","2016","2016",3570.7,,
+"PATCTOTT","Total pharmaceutical sales","MTMOTCMT","Million US$ at exchange rate","CZE","Czech Republic","2017","2017",3936.2,,
+"PATCTOTT","Total pharmaceutical sales","MTMOTCMT","Million US$ at exchange rate","CZE","Czech Republic","2018","2018",4509.2,,
+"PATCTOTT","Total pharmaceutical sales","MTMOTCMT","Million US$ at exchange rate","CZE","Czech Republic","2019","2019",4508.9,,
+"PATCTOTT","Total pharmaceutical sales","MTMOTCMT","Million US$ at exchange rate","CZE","Czech Republic","2020","2020",3782,"B","Break"
+"PATCTOTT","Total pharmaceutical sales","MTMOTCMT","Million US$ at exchange rate","CZE","Czech Republic","2021","2021",4290.3,,
+"PATCTOTT","Total pharmaceutical sales","MTMOPPMT","Million US$, purchasing power parity","CZE","Czech Republic","2010","2010",5958.4,,
+"PATCTOTT","Total pharmaceutical sales","MTMOPPMT","Million US$, purchasing power parity","CZE","Czech Republic","2011","2011",6064.1,,
+"PATCTOTT","Total pharmaceutical sales","MTMOPPMT","Million US$, purchasing power parity","CZE","Czech Republic","2012","2012",6298,,
+"PATCTOTT","Total pharmaceutical sales","MTMOPPMT","Million US$, purchasing power parity","CZE","Czech Republic","2013","2013",6234.6,,
+"PATCTOTT","Total pharmaceutical sales","MTMOPPMT","Million US$, purchasing power parity","CZE","Czech Republic","2014","2014",6382.7,,
+"PATCTOTT","Total pharmaceutical sales","MTMOPPMT","Million US$, purchasing power parity","CZE","Czech Republic","2015","2015",6526.9,,
+"PATCTOTT","Total pharmaceutical sales","MTMOPPMT","Million US$, purchasing power parity","CZE","Czech Republic","2016","2016",6939,,
+"PATCTOTT","Total pharmaceutical sales","MTMOPPMT","Million US$, purchasing power parity","CZE","Czech Republic","2017","2017",7405.5,,
+"PATCTOTT","Total pharmaceutical sales","MTMOPPMT","Million US$, purchasing power parity","CZE","Czech Republic","2018","2018",7920.2,,
+"PATCTOTT","Total pharmaceutical sales","MTMOPPMT","Million US$, purchasing power parity","CZE","Czech Republic","2019","2019",8423.9,,
+"PATCTOTT","Total pharmaceutical sales","MTMOPPMT","Million US$, purchasing power parity","CZE","Czech Republic","2020","2020",7044.5,"B","Break"
+"PATCTOTT","Total pharmaceutical sales","MTMOPPMT","Million US$, purchasing power parity","CZE","Czech Republic","2021","2021",7298.6,,
+"PATCTOTT","Total pharmaceutical sales","TCPPERMT","/capita, US$ exchange rate","CZE","Czech Republic","2010","2010",407.2,,
+"PATCTOTT","Total pharmaceutical sales","TCPPERMT","/capita, US$ exchange rate","CZE","Czech Republic","2011","2011",435.7,,
+"PATCTOTT","Total pharmaceutical sales","TCPPERMT","/capita, US$ exchange rate","CZE","Czech Republic","2012","2012",407,,
+"PATCTOTT","Total pharmaceutical sales","TCPPERMT","/capita, US$ exchange rate","CZE","Czech Republic","2013","2013",387.4,,
+"PATCTOTT","Total pharmaceutical sales","TCPPERMT","/capita, US$ exchange rate","CZE","Czech Republic","2014","2014",371.1,,
+"PATCTOTT","Total pharmaceutical sales","TCPPERMT","/capita, US$ exchange rate","CZE","Czech Republic","2015","2015",325.5,,
+"PATCTOTT","Total pharmaceutical sales","TCPPERMT","/capita, US$ exchange rate","CZE","Czech Republic","2016","2016",337.9,,
+"PATCTOTT","Total pharmaceutical sales","TCPPERMT","/capita, US$ exchange rate","CZE","Czech Republic","2017","2017",371.5,,
+"PATCTOTT","Total pharmaceutical sales","TCPPERMT","/capita, US$ exchange rate","CZE","Czech Republic","2018","2018",424.2,,
+"PATCTOTT","Total pharmaceutical sales","TCPPERMT","/capita, US$ exchange rate","CZE","Czech Republic","2019","2019",422.5,,
+"PATCTOTT","Total pharmaceutical sales","TCPPERMT","/capita, US$ exchange rate","CZE","Czech Republic","2020","2020",353.5,"B","Break"
+"PATCTOTT","Total pharmaceutical sales","TCPPERMT","/capita, US$ exchange rate","CZE","Czech Republic","2021","2021",408.4,,
+"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czech Republic","2010","2010",568.9,,
+"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czech Republic","2011","2011",577.8,,
+"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czech Republic","2012","2012",599.2,,
+"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czech Republic","2013","2013",593,,
+"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czech Republic","2014","2014",606.4,,
+"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czech Republic","2015","2015",618.9,,
+"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czech Republic","2016","2016",656.7,,
+"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czech Republic","2017","2017",699,,
+"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czech Republic","2018","2018",745.1,,
+"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czech Republic","2019","2019",789.4,,
+"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czech Republic","2020","2020",658.5,"B","Break"
+"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czech Republic","2021","2021",694.7,,
+"PATCTOTT","Total pharmaceutical sales","MLLNCUMT","Million of national currency units","DNK","Denmark","2010","2010",21171.2,,
+"PATCTOTT","Total pharmaceutical sales","MLLNCUMT","Million of national currency units","DNK","Denmark","2011","2011",20540.2,,
+"PATCTOTT","Total pharmaceutical sales","MLLNCUMT","Million of national currency units","DNK","Denmark","2012","2012",20459.8,,
+"PATCTOTT","Total pharmaceutical sales","MLLNCUMT","Million of national currency units","DNK","Denmark","2013","2013",20422.2,,
+"PATCTOTT","Total pharmaceutical sales","MLLNCUMT","Million of national currency units","DNK","Denmark","2014","2014",21418.1,,
+"PATCTOTT","Total pharmaceutical sales","MLLNCUMT","Million of national currency units","DNK","Denmark","2015","2015",21897.7,,
+"PATCTOTT","Total pharmaceutical sales","MLLNCUMT","Million of national currency units","DNK","Denmark","2016","2016",22110,,
+"PATCTOTT","Total pharmaceutical sales","MLLNCUMT","Million of national currency units","DNK","Denmark","2017","2017",22941.5,,
+"PATCTOTT","Total pharmaceutical sales","MLLNCUMT","Million of national currency units","DNK","Denmark","2018","2018",23831.6,,
+"PATCTOTT","Total pharmaceutical sales","MLLNCUMT","Million of national currency units","DNK","Denmark","2019","2019",24553.2,,
+"PATCTOTT","Total pharmaceutical sales","MLLNCUMT","Million of national currency units","DNK","Denmark","2020","2020",25270.8,,
+"PATCTOTT","Total pharmaceutical sales","MLLNCUMT","Million of national currency units","DNK","Denmark","2021","2021",25516.2,,
+"PATCTOTT","Total pharmaceutical sales","MTMOTCMT","Million US$ at exchange rate","DNK","Denmark","2010","2010",3764.4,,
+"PATCTOTT","Total pharmaceutical sales","MTMOTCMT","Million US$ at exchange rate","DNK","Denmark","2011","2011",3825.9,,
+"PATCTOTT","Total pharmaceutical sales","MTMOTCMT","Million US$ at exchange rate","DNK","Denmark","2012","2012",3532.1,,
+"PATCTOTT","Total pharmaceutical sales","MTMOTCMT","Million US$ at exchange rate","DNK","Denmark","2013","2013",3636.2,,
+"PATCTOTT","Total pharmaceutical sales","MTMOTCMT","Million US$ at exchange rate","DNK","Denmark","2014","2014",3816.2,,
+"PATCTOTT","Total pharmaceutical sales","MTMOTCMT","Million US$ at exchange rate","DNK","Denmark","2015","2015",3254.8,,
+"PATCTOTT","Total pharmaceutical sales","MTMOTCMT","Million US$ at exchange rate","DNK","Denmark","2016","2016",3284.5,,
+"PATCTOTT","Total pharmaceutical sales","MTMOTCMT","Million US$ at exchange rate","DNK","Denmark","2017","2017",3474.5,,
+"PATCTOTT","Total pharmaceutical sales","MTMOTCMT","Million US$ at exchange rate","DNK","Denmark","2018","2018",3774,,
+"PATCTOTT","Total pharmaceutical sales","MTMOTCMT","Million US$ at exchange rate","DNK","Denmark","2019","2019",3681.4,,
+"PATCTOTT","Total pharmaceutical sales","MTMOTCMT","Million US$ at exchange rate","DNK","Denmark","2020","2020",3862.8,,
+"PATCTOTT","Total pharmaceutical sales","MTMOTCMT","Million US$ at exchange rate","DNK","Denmark","2021","2021",4058.5,,
+"PATCTOTT","Total pharmaceutical sales","MTMOPPMT","Million US$, purchasing power parity","DNK","Denmark","2010","2010",2788.9,,
+"PATCTOTT","Total pharmaceutical sales","MTMOPPMT","Million US$, purchasing power parity","DNK","Denmark","2011","2011",2751,,
+"PATCTOTT","Total pharmaceutical sales","MTMOPPMT","Million US$, purchasing power parity","DNK","Denmark","2012","2012",2704.8,,
+"PATCTOTT","Total pharmaceutical sales","MTMOPPMT","Million US$, purchasing power parity","DNK","Denmark","2013","2013",2776.7,,
+"PATCTOTT","Total pharmaceutical sales","MTMOPPMT","Million US$, purchasing power parity","DNK","Denmark","2014","2014",2922.5,,
+"PATCTOTT","Total pharmaceutical sales","MTMOPPMT","Million US$, purchasing power parity","DNK","Denmark","2015","2015",2997.5,,
+"PATCTOTT","Total pharmaceutical sales","MTMOPPMT","Million US$, purchasing power parity","DNK","Denmark","2016","2016",3122.9,,
+"PATCTOTT","Total pharmaceutical sales","MTMOPPMT","Million US$, purchasing power parity","DNK","Denmark","2017","2017",3338.6,,
+"PATCTOTT","Total pharmaceutical sales","MTMOPPMT","Million US$, purchasing power parity","DNK","Denmark","2018","2018",3522.3,,
+"PATCTOTT","Total pharmaceutical sales","MTMOPPMT","Million US$, purchasing power parity","DNK","Denmark","2019","2019",3701.1,,
+"PATCTOTT","Total pharmaceutical sales","MTMOPPMT","Million US$, purchasing power parity","DNK","Denmark","2020","2020",3857.5,,
+"PATCTOTT","Total pharmaceutical sales","MTMOPPMT","Million US$, purchasing power parity","DNK","Denmark","2021","2021",3872.1,,
+"PATCTOTT","Total pharmaceutical sales","TCPPERMT","/capita, US$ exchange rate","DNK","Denmark","2010","2010",678.6,,
+"PATCTOTT","Total pharmaceutical sales","TCPPERMT","/capita, US$ exchange rate","DNK","Denmark","2011","2011",686.8,,
+"PATCTOTT","Total pharmaceutical sales","TCPPERMT","/capita, US$ exchange rate","DNK","Denmark","2012","2012",631.7,,
+"PATCTOTT","Total pharmaceutical sales","TCPPERMT","/capita, US$ exchange rate","DNK","Denmark","2013","2013",647.6,,
+"PATCTOTT","Total pharmaceutical sales","TCPPERMT","/capita, US$ exchange rate","DNK","Denmark","2014","2014",676.2,,
+"PATCTOTT","Total pharmaceutical sales","TCPPERMT","/capita, US$ exchange rate","DNK","Denmark","2015","2015",572.7,,
+"PATCTOTT","Total pharmaceutical sales","TCPPERMT","/capita, US$ exchange rate","DNK","Denmark","2016","2016",573.4,,
+"PATCTOTT","Total pharmaceutical sales","TCPPERMT","/capita, US$ exchange rate","DNK","Denmark","2017","2017",602.7,,
+"PATCTOTT","Total pharmaceutical sales","TCPPERMT","/capita, US$ exchange rate","DNK","Denmark","2018","2018",651.4,,
+"PATCTOTT","Total pharmaceutical sales","TCPPERMT","/capita, US$ exchange rate","DNK","Denmark","2019","2019",633.2,,
+"PATCTOTT","Total pharmaceutical sales","TCPPERMT","/capita, US$ exchange rate","DNK","Denmark","2020","2020",662.4,,
+"PATCTOTT","Total pharmaceutical sales","TCPPERMT","/capita, US$ exchange rate","DNK","Denmark","2021","2021",693,,
+"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","DNK","Denmark","2010","2010",502.7,,
+"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","DNK","Denmark","2011","2011",493.8,,
+"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","DNK","Denmark","2012","2012",483.7,,
+"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","DNK","Denmark","2013","2013",494.5,,
+"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","DNK","Denmark","2014","2014",517.9,,
+"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","DNK","Denmark","2015","2015",527.4,,
+"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","DNK","Denmark","2016","2016",545.2,,
+"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","DNK","Denmark","2017","2017",579.1,,
+"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","DNK","Denmark","2018","2018",608,,
+"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","DNK","Denmark","2019","2019",636.5,,
+"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","DNK","Denmark","2020","2020",661.5,,
+"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","DNK","Denmark","2021","2021",661.1,,
+"PATCTOTT","Total pharmaceutical sales","MLLNCUMT","Million of national currency units","FIN","Finland","2010","2010",1880.2,,
+"PATCTOTT","Total pharmaceutical sales","MLLNCUMT","Million of national currency units","FIN","Finland","2011","2011",1927.6,,
+"PATCTOTT","Total pharmaceutical sales","MLLNCUMT","Million of national currency units","FIN","Finland","2012","2012",1964.8,,
+"PATCTOTT","Total pharmaceutical sales","MLLNCUMT","Million of national currency units","FIN","Finland","2013","2013",2012.7,,
+"PATCTOTT","Total pharmaceutical sales","MLLNCUMT","Million of national currency units","FIN","Finland","2014","2014",2093.5,,
+"PATCTOTT","Total pharmaceutical sales","MLLNCUMT","Million of national currency units","FIN","Finland","2015","2015",2200.1,,
+"PATCTOTT","Total pharmaceutical sales","MLLNCUMT","Million of national currency units","FIN","Finland","2016","2016",2288.8,,
+"PATCTOTT","Total pharmaceutical sales","MLLNCUMT","Million of national currency units","FIN","Finland","2017","2017",2313.7,,
+"PATCTOTT","Total pharmaceutical sales","MLLNCUMT","Million of national currency units","FIN","Finland","2018","2018",2502.3,,
+"PATCTOTT","Total pharmaceutical sales","MLLNCUMT","Million of national currency units","FIN","Finland","2019","2019",2658.7,,
+"PATCTOTT","Total pharmaceutical sales","MLLNCUMT","Million of national currency units","FIN","Finland","2020","2020",2693.9,,
+"PATCTOTT","Total pharmaceutical sales","MLLNCUMT","Million of national currency units","FIN","Finland","2021","2021",2852.5,,
+"PATCTOTT","Total pharmaceutical sales","MTMOTCMT","Million US$ at exchange rate","FIN","Finland","2010","2010",2492.6,,
+"PATCTOTT","Total pharmaceutical sales","MTMOTCMT","Million US$ at exchange rate","FIN","Finland","2011","2011",2683.1,,
+"PATCTOTT","Total pharmaceutical sales","MTMOTCMT","Million US$ at exchange rate","FIN","Finland","2012","2012",2524.4,,
+"PATCTOTT","Total pharmaceutical sales","MTMOTCMT","Million US$ at exchange rate","FIN","Finland","2013","2013",2673.1,,
+"PATCTOTT","Total pharmaceutical sales","MTMOTCMT","Million US$ at exchange rate","FIN","Finland","2014","2014",2781.2,,
+"PATCTOTT","Total pharmaceutical sales","MTMOTCMT","Million US$ at exchange rate","FIN","Finland","2015","2015",2441,,
+"PATCTOTT","Total pharmaceutical sales","MTMOTCMT","Million US$ at exchange rate","FIN","Finland","2016","2016",2533.5,,
+"PATCTOTT","Total pharmaceutical sales","MTMOTCMT","Million US$ at exchange rate","FIN","Finland","2017","2017",2613.7,,
+"PATCTOTT","Total pharmaceutical sales","MTMOTCMT","Million US$ at exchange rate","FIN","Finland","2018","2018",2955.1,,
+"PATCTOTT","Total pharmaceutical sales","MTMOTCMT","Million US$ at exchange rate","FIN","Finland","2019","2019",2976.3,,
+"PATCTOTT","Total pharmaceutical sales","MTMOTCMT","Million US$ at exchange rate","FIN","Finland","2020","2020",3077,,
+"PATCTOTT","Total pharmaceutical sales","MTMOTCMT","Million US$ at exchange rate","FIN","Finland","2021","2021",3373.8,,
+"PATCTOTT","Total pharmaceutical sales","MTMOPPMT","Million US$, purchasing power parity","FIN","Finland","2010","2010",2087.9,,
+"PATCTOTT","Total pharmaceutical sales","MTMOPPMT","Million US$, purchasing power parity","FIN","Finland","2011","2011",2146.4,,
+"PATCTOTT","Total pharmaceutical sales","MTMOPPMT","Million US$, purchasing power parity","FIN","Finland","2012","2012",2162.7,,
+"PATCTOTT","Total pharmaceutical sales","MTMOPPMT","Million US$, purchasing power parity","FIN","Finland","2013","2013",2223.1,,
+"PATCTOTT","Total pharmaceutical sales","MTMOPPMT","Million US$, purchasing power parity","FIN","Finland","2014","2014",2307.6,,
+"PATCTOTT","Total pharmaceutical sales","MTMOPPMT","Million US$, purchasing power parity","FIN","Finland","2015","2015",2423.7,,
+"PATCTOTT","Total pharmaceutical sales","MTMOPPMT","Million US$, purchasing power parity","FIN","Finland","2016","2016",2598.3,,
+"PATCTOTT","Total pharmaceutical sales","MTMOPPMT","Million US$, purchasing power parity","FIN","Finland","2017","2017",2679,,
+"PATCTOTT","Total pharmaceutical sales","MTMOPPMT","Million US$, purchasing power parity","FIN","Finland","2018","2018",2931,,
+"PATCTOTT","Total pharmaceutical sales","MTMOPPMT","Million US$, purchasing power parity","FIN","Finland","2019","2019",3171.1,,
+"PATCTOTT","Total pharmaceutical sales","MTMOPPMT","Million US$, purchasing power parity","FIN","Finland","2020","2020",3273.2,,
+"PATCTOTT","Total pharmaceutical sales","MTMOPPMT","Million US$, purchasing power parity","FIN","Finland","2021","2021",3450.5,,
+"PATCTOTT","Total pharmaceutical sales","TCPPERMT","/capita, US$ exchange rate","FIN","Finland","2010","2010",464.7,,
+"PATCTOTT","Total pharmaceutical sales","TCPPERMT","/capita, US$ exchange rate","FIN","Finland","2011","2011",498,,
+"PATCTOTT","Total pharmaceutical sales","TCPPERMT","/capita, US$ exchange rate","FIN","Finland","2012","2012",466.3,,
+"PATCTOTT","Total pharmaceutical sales","TCPPERMT","/capita, US$ exchange rate","FIN","Finland","2013","2013",491.5,,
+"PATCTOTT","Total pharmaceutical sales","TCPPERMT","/capita, US$ exchange rate","FIN","Finland","2014","2014",509.2,,
+"PATCTOTT","Total pharmaceutical sales","TCPPERMT","/capita, US$ exchange rate","FIN","Finland","2015","2015",445.5,,
+"PATCTOTT","Total pharmaceutical sales","TCPPERMT","/capita, US$ exchange rate","FIN","Finland","2016","2016",461,,
+"PATCTOTT","Total pharmaceutical sales","TCPPERMT","/capita, US$ exchange rate","FIN","Finland","2017","2017",474.5,,
+"PATCTOTT","Total pharmaceutical sales","TCPPERMT","/capita, US$ exchange rate","FIN","Finland","2018","2018",535.8,,
+"PATCTOTT","Total pharmaceutical sales","TCPPERMT","/capita, US$ exchange rate","FIN","Finland","2019","2019",539,,
+"PATCTOTT","Total pharmaceutical sales","TCPPERMT","/capita, US$ exchange rate","FIN","Finland","2020","2020",556.5,,
+"PATCTOTT","Total pharmaceutical sales","TCPPERMT","/capita, US$ exchange rate","FIN","Finland","2021","2021",608.9,,
+"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2010","2010",389.3,,
+"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2011","2011",398.3,,
+"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2012","2012",399.5,,
+"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2013","2013",408.7,,
+"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2014","2014",422.5,,
+"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2015","2015",442.3,,
+"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2016","2016",472.8,,
+"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2017","2017",486.4,,
+"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2018","2018",531.4,,
+"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2019","2019",574.3,,
+"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2020","2020",591.9,,
+"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2021","2021",622.7,,
+"PATCTOTT","Total pharmaceutical sales","MLLNCUMT","Million of national currency units","FRA","France","2010","2010",27539,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","MLLNCUMT","Million of national currency units","FRA","France","2011","2011",27600,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","MLLNCUMT","Million of national currency units","FRA","France","2012","2012",27200,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","MLLNCUMT","Million of national currency units","FRA","France","2013","2013",26800,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","MTMOTCMT","Million US$ at exchange rate","FRA","France","2010","2010",36508.9,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","MTMOTCMT","Million US$ at exchange rate","FRA","France","2011","2011",38418,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","MTMOTCMT","Million US$ at exchange rate","FRA","France","2012","2012",34946.3,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","MTMOTCMT","Million US$ at exchange rate","FRA","France","2013","2013",35593.6,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","MTMOPPMT","Million US$, purchasing power parity","FRA","France","2010","2010",32221.6,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","MTMOPPMT","Million US$, purchasing power parity","FRA","France","2011","2011",32804,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","MTMOPPMT","Million US$, purchasing power parity","FRA","France","2012","2012",32216,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","MTMOPPMT","Million US$, purchasing power parity","FRA","France","2013","2013",33019.4,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","TCPPERMT","/capita, US$ exchange rate","FRA","France","2010","2010",563.2,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","TCPPERMT","/capita, US$ exchange rate","FRA","France","2011","2011",589.9,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","TCPPERMT","/capita, US$ exchange rate","FRA","France","2012","2012",534,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","TCPPERMT","/capita, US$ exchange rate","FRA","France","2013","2013",541.2,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","FRA","France","2010","2010",497.1,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","FRA","France","2011","2011",503.7,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","FRA","France","2012","2012",492.3,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","FRA","France","2013","2013",502,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","MLLNCUMT","Million of national currency units","DEU","Germany","2010","2010",29724.7,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","MLLNCUMT","Million of national currency units","DEU","Germany","2011","2011",29716.2,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","MLLNCUMT","Million of national currency units","DEU","Germany","2012","2012",30442,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","MLLNCUMT","Million of national currency units","DEU","Germany","2013","2013",31524.1,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","MLLNCUMT","Million of national currency units","DEU","Germany","2014","2014",33564.8,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","MLLNCUMT","Million of national currency units","DEU","Germany","2015","2015",35349.7,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","MLLNCUMT","Million of national currency units","DEU","Germany","2016","2016",36118.6,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","MLLNCUMT","Million of national currency units","DEU","Germany","2017","2017",37188.6,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","MLLNCUMT","Million of national currency units","DEU","Germany","2018","2018",44230.1,"B; D","Break; Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","MLLNCUMT","Million of national currency units","DEU","Germany","2019","2019",46853.4,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","MLLNCUMT","Million of national currency units","DEU","Germany","2020","2020",49155.4,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","MLLNCUMT","Million of national currency units","DEU","Germany","2021","2021",53299.9,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","MTMOTCMT","Million US$ at exchange rate","DEU","Germany","2010","2010",39406.5,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","MTMOTCMT","Million US$ at exchange rate","DEU","Germany","2011","2011",41363.6,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","MTMOTCMT","Million US$ at exchange rate","DEU","Germany","2012","2012",39111.5,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","MTMOTCMT","Million US$ at exchange rate","DEU","Germany","2013","2013",41867.7,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","MTMOTCMT","Million US$ at exchange rate","DEU","Germany","2014","2014",44590.9,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","MTMOTCMT","Million US$ at exchange rate","DEU","Germany","2015","2015",39221,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","MTMOTCMT","Million US$ at exchange rate","DEU","Germany","2016","2016",39979.8,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","MTMOTCMT","Million US$ at exchange rate","DEU","Germany","2017","2017",42011.2,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","MTMOTCMT","Million US$ at exchange rate","DEU","Germany","2018","2018",52233.7,"B; D","Break; Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","MTMOTCMT","Million US$ at exchange rate","DEU","Germany","2019","2019",52451.2,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","MTMOTCMT","Million US$ at exchange rate","DEU","Germany","2020","2020",56145.1,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","MTMOTCMT","Million US$ at exchange rate","DEU","Germany","2021","2021",63040,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","MTMOPPMT","Million US$, purchasing power parity","DEU","Germany","2010","2010",36921.4,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","MTMOPPMT","Million US$, purchasing power parity","DEU","Germany","2011","2011",37675.6,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","MTMOPPMT","Million US$, purchasing power parity","DEU","Germany","2012","2012",38669,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","MTMOPPMT","Million US$, purchasing power parity","DEU","Germany","2013","2013",40687.6,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","MTMOPPMT","Million US$, purchasing power parity","DEU","Germany","2014","2014",43650.9,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","MTMOPPMT","Million US$, purchasing power parity","DEU","Germany","2015","2015",45429.5,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","MTMOPPMT","Million US$, purchasing power parity","DEU","Germany","2016","2016",47991.3,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","MTMOPPMT","Million US$, purchasing power parity","DEU","Germany","2017","2017",49932.1,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","MTMOPPMT","Million US$, purchasing power parity","DEU","Germany","2018","2018",60140.3,"B; D","Break; Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","MTMOPPMT","Million US$, purchasing power parity","DEU","Germany","2019","2019",64337.1,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","MTMOPPMT","Million US$, purchasing power parity","DEU","Germany","2020","2020",67800.4,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","MTMOPPMT","Million US$, purchasing power parity","DEU","Germany","2021","2021",72391.1,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","TCPPERMT","/capita, US$ exchange rate","DEU","Germany","2010","2010",481.9,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","TCPPERMT","/capita, US$ exchange rate","DEU","Germany","2011","2011",515.3,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","TCPPERMT","/capita, US$ exchange rate","DEU","Germany","2012","2012",486.3,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","TCPPERMT","/capita, US$ exchange rate","DEU","Germany","2013","2013",519.2,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","TCPPERMT","/capita, US$ exchange rate","DEU","Germany","2014","2014",550.6,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","TCPPERMT","/capita, US$ exchange rate","DEU","Germany","2015","2015",480.1,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","TCPPERMT","/capita, US$ exchange rate","DEU","Germany","2016","2016",485.5,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","TCPPERMT","/capita, US$ exchange rate","DEU","Germany","2017","2017",508.3,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","TCPPERMT","/capita, US$ exchange rate","DEU","Germany","2018","2018",630,"B; D","Break; Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","TCPPERMT","/capita, US$ exchange rate","DEU","Germany","2019","2019",631.2,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","TCPPERMT","/capita, US$ exchange rate","DEU","Germany","2020","2020",675.1,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","TCPPERMT","/capita, US$ exchange rate","DEU","Germany","2021","2021",757.7,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2010","2010",451.5,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2011","2011",469.3,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2012","2012",480.8,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2013","2013",504.5,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2014","2014",539,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2015","2015",556.1,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2016","2016",582.8,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2017","2017",604.1,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2018","2018",725.4,"B; D","Break; Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2019","2019",774.3,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2020","2020",815.3,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2021","2021",870.1,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","MLLNCUMT","Million of national currency units","HUN","Hungary","2010","2010",498140.3,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","MLLNCUMT","Million of national currency units","HUN","Hungary","2011","2011",515299.2,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","MLLNCUMT","Million of national currency units","HUN","Hungary","2012","2012",444548.6,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","MLLNCUMT","Million of national currency units","HUN","Hungary","2013","2013",430163.5,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","MLLNCUMT","Million of national currency units","HUN","Hungary","2014","2014",442945.7,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","MLLNCUMT","Million of national currency units","HUN","Hungary","2015","2015",466411.6,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","MLLNCUMT","Million of national currency units","HUN","Hungary","2016","2016",498866.9,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","MLLNCUMT","Million of national currency units","HUN","Hungary","2017","2017",493022.1,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","MLLNCUMT","Million of national currency units","HUN","Hungary","2018","2018",500762.1,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","MLLNCUMT","Million of national currency units","HUN","Hungary","2019","2019",527613.5,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","MLLNCUMT","Million of national currency units","HUN","Hungary","2020","2020",557449.8,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","MLLNCUMT","Million of national currency units","HUN","Hungary","2021","2021",568039.5,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","MLLNCUMT","Million of national currency units","HUN","Hungary","2022","2022",597360.3,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","MTMOTCMT","Million US$ at exchange rate","HUN","Hungary","2010","2010",2395.5,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","MTMOTCMT","Million US$ at exchange rate","HUN","Hungary","2011","2011",2563,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","MTMOTCMT","Million US$ at exchange rate","HUN","Hungary","2012","2012",1974.9,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","MTMOTCMT","Million US$ at exchange rate","HUN","Hungary","2013","2013",1923,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","MTMOTCMT","Million US$ at exchange rate","HUN","Hungary","2014","2014",1904.3,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","MTMOTCMT","Million US$ at exchange rate","HUN","Hungary","2015","2015",1669.7,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","MTMOTCMT","Million US$ at exchange rate","HUN","Hungary","2016","2016",1772,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","MTMOTCMT","Million US$ at exchange rate","HUN","Hungary","2017","2017",1796.5,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","MTMOTCMT","Million US$ at exchange rate","HUN","Hungary","2018","2018",1853.2,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","MTMOTCMT","Million US$ at exchange rate","HUN","Hungary","2019","2019",1815.2,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","MTMOTCMT","Million US$ at exchange rate","HUN","Hungary","2020","2020",1809.9,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","MTMOTCMT","Million US$ at exchange rate","HUN","Hungary","2021","2021",1873.8,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","MTMOTCMT","Million US$ at exchange rate","HUN","Hungary","2022","2022",1603.2,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","MTMOPPMT","Million US$, purchasing power parity","HUN","Hungary","2010","2010",3940.5,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","MTMOPPMT","Million US$, purchasing power parity","HUN","Hungary","2011","2011",4146.5,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","MTMOPPMT","Million US$, purchasing power parity","HUN","Hungary","2012","2012",3538.7,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","MTMOPPMT","Million US$, purchasing power parity","HUN","Hungary","2013","2013",3441.9,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","MTMOPPMT","Million US$, purchasing power parity","HUN","Hungary","2014","2014",3422.7,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","MTMOPPMT","Million US$, purchasing power parity","HUN","Hungary","2015","2015",3518.7,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","MTMOPPMT","Million US$, purchasing power parity","HUN","Hungary","2016","2016",3778.3,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","MTMOPPMT","Million US$, purchasing power parity","HUN","Hungary","2017","2017",3624.2,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","MTMOPPMT","Million US$, purchasing power parity","HUN","Hungary","2018","2018",3600.2,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","MTMOPPMT","Million US$, purchasing power parity","HUN","Hungary","2019","2019",3746.5,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","MTMOPPMT","Million US$, purchasing power parity","HUN","Hungary","2020","2020",3835.2,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","MTMOPPMT","Million US$, purchasing power parity","HUN","Hungary","2021","2021",3670.7,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","MTMOPPMT","Million US$, purchasing power parity","HUN","Hungary","2022","2022",3704.8,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","TCPPERMT","/capita, US$ exchange rate","HUN","Hungary","2010","2010",239.6,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","TCPPERMT","/capita, US$ exchange rate","HUN","Hungary","2011","2011",257,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","TCPPERMT","/capita, US$ exchange rate","HUN","Hungary","2012","2012",199.1,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","TCPPERMT","/capita, US$ exchange rate","HUN","Hungary","2013","2013",194.4,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","TCPPERMT","/capita, US$ exchange rate","HUN","Hungary","2014","2014",193,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","TCPPERMT","/capita, US$ exchange rate","HUN","Hungary","2015","2015",169.6,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","TCPPERMT","/capita, US$ exchange rate","HUN","Hungary","2016","2016",180.6,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","TCPPERMT","/capita, US$ exchange rate","HUN","Hungary","2017","2017",183.5,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","TCPPERMT","/capita, US$ exchange rate","HUN","Hungary","2018","2018",189.6,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","TCPPERMT","/capita, US$ exchange rate","HUN","Hungary","2019","2019",185.8,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","TCPPERMT","/capita, US$ exchange rate","HUN","Hungary","2020","2020",185.6,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","TCPPERMT","/capita, US$ exchange rate","HUN","Hungary","2021","2021",193,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","TCPPERMT","/capita, US$ exchange rate","HUN","Hungary","2022","2022",165.5,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2010","2010",394,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2011","2011",415.8,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2012","2012",356.7,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2013","2013",347.9,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2014","2014",346.9,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2015","2015",357.5,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2016","2016",385,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2017","2017",370.3,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2018","2018",368.3,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2019","2019",383.4,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2020","2020",393.3,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2021","2021",378,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2022","2022",382.4,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","MLLNCUMT","Million of national currency units","ISL","Iceland","2010","2010",25011.6,,
+"PATCTOTT","Total pharmaceutical sales","MLLNCUMT","Million of national currency units","ISL","Iceland","2011","2011",26083.5,,
+"PATCTOTT","Total pharmaceutical sales","MLLNCUMT","Million of national currency units","ISL","Iceland","2012","2012",24278,,
+"PATCTOTT","Total pharmaceutical sales","MLLNCUMT","Million of national currency units","ISL","Iceland","2013","2013",26023.1,,
+"PATCTOTT","Total pharmaceutical sales","MLLNCUMT","Million of national currency units","ISL","Iceland","2014","2014",23689.8,,
+"PATCTOTT","Total pharmaceutical sales","MLLNCUMT","Million of national currency units","ISL","Iceland","2015","2015",24403.4,,
+"PATCTOTT","Total pharmaceutical sales","MLLNCUMT","Million of national currency units","ISL","Iceland","2016","2016",25384.8,,
+"PATCTOTT","Total pharmaceutical sales","MLLNCUMT","Million of national currency units","ISL","Iceland","2017","2017",26522.3,,
+"PATCTOTT","Total pharmaceutical sales","MLLNCUMT","Million of national currency units","ISL","Iceland","2018","2018",30184.3,,
+"PATCTOTT","Total pharmaceutical sales","MLLNCUMT","Million of national currency units","ISL","Iceland","2019","2019",33635,,
+"PATCTOTT","Total pharmaceutical sales","MLLNCUMT","Million of national currency units","ISL","Iceland","2020","2020",39846.8,,
+"PATCTOTT","Total pharmaceutical sales","MLLNCUMT","Million of national currency units","ISL","Iceland","2021","2021",45105.3,,
+"PATCTOTT","Total pharmaceutical sales","MTMOTCMT","Million US$ at exchange rate","ISL","Iceland","2010","2010",204.6,,
+"PATCTOTT","Total pharmaceutical sales","MTMOTCMT","Million US$ at exchange rate","ISL","Iceland","2011","2011",224.9,,
+"PATCTOTT","Total pharmaceutical sales","MTMOTCMT","Million US$ at exchange rate","ISL","Iceland","2012","2012",194.1,,
+"PATCTOTT","Total pharmaceutical sales","MTMOTCMT","Million US$ at exchange rate","ISL","Iceland","2013","2013",213,,
+"PATCTOTT","Total pharmaceutical sales","MTMOTCMT","Million US$ at exchange rate","ISL","Iceland","2014","2014",202.9,,
+"PATCTOTT","Total pharmaceutical sales","MTMOTCMT","Million US$ at exchange rate","ISL","Iceland","2015","2015",185,,
+"PATCTOTT","Total pharmaceutical sales","MTMOTCMT","Million US$ at exchange rate","ISL","Iceland","2016","2016",210.1,,
+"PATCTOTT","Total pharmaceutical sales","MTMOTCMT","Million US$ at exchange rate","ISL","Iceland","2017","2017",248.2,,
+"PATCTOTT","Total pharmaceutical sales","MTMOTCMT","Million US$ at exchange rate","ISL","Iceland","2018","2018",278.7,,
+"PATCTOTT","Total pharmaceutical sales","MTMOTCMT","Million US$ at exchange rate","ISL","Iceland","2019","2019",274.3,,
+"PATCTOTT","Total pharmaceutical sales","MTMOTCMT","Million US$ at exchange rate","ISL","Iceland","2020","2020",294.2,,
+"PATCTOTT","Total pharmaceutical sales","MTMOTCMT","Million US$ at exchange rate","ISL","Iceland","2021","2021",355.2,,
+"PATCTOTT","Total pharmaceutical sales","MTMOPPMT","Million US$, purchasing power parity","ISL","Iceland","2010","2010",188.2,,
+"PATCTOTT","Total pharmaceutical sales","MTMOPPMT","Million US$, purchasing power parity","ISL","Iceland","2011","2011",193,,
+"PATCTOTT","Total pharmaceutical sales","MTMOPPMT","Million US$, purchasing power parity","ISL","Iceland","2012","2012",177.3,,
+"PATCTOTT","Total pharmaceutical sales","MTMOPPMT","Million US$, purchasing power parity","ISL","Iceland","2013","2013",189.9,,
+"PATCTOTT","Total pharmaceutical sales","MTMOPPMT","Million US$, purchasing power parity","ISL","Iceland","2014","2014",171,,
+"PATCTOTT","Total pharmaceutical sales","MTMOPPMT","Million US$, purchasing power parity","ISL","Iceland","2015","2015",171.9,,
+"PATCTOTT","Total pharmaceutical sales","MTMOPPMT","Million US$, purchasing power parity","ISL","Iceland","2016","2016",181.3,,
+"PATCTOTT","Total pharmaceutical sales","MTMOPPMT","Million US$, purchasing power parity","ISL","Iceland","2017","2017",191.8,,
+"PATCTOTT","Total pharmaceutical sales","MTMOPPMT","Million US$, purchasing power parity","ISL","Iceland","2018","2018",214.1,,
+"PATCTOTT","Total pharmaceutical sales","MTMOPPMT","Million US$, purchasing power parity","ISL","Iceland","2019","2019",239.1,,
+"PATCTOTT","Total pharmaceutical sales","MTMOPPMT","Million US$, purchasing power parity","ISL","Iceland","2020","2020",271.7,,
+"PATCTOTT","Total pharmaceutical sales","MTMOPPMT","Million US$, purchasing power parity","ISL","Iceland","2021","2021",301.3,,
+"PATCTOTT","Total pharmaceutical sales","TCPPERMT","/capita, US$ exchange rate","ISL","Iceland","2010","2010",643.3,,
+"PATCTOTT","Total pharmaceutical sales","TCPPERMT","/capita, US$ exchange rate","ISL","Iceland","2011","2011",705.1,,
+"PATCTOTT","Total pharmaceutical sales","TCPPERMT","/capita, US$ exchange rate","ISL","Iceland","2012","2012",605.2,,
+"PATCTOTT","Total pharmaceutical sales","TCPPERMT","/capita, US$ exchange rate","ISL","Iceland","2013","2013",657.9,,
+"PATCTOTT","Total pharmaceutical sales","TCPPERMT","/capita, US$ exchange rate","ISL","Iceland","2014","2014",619.7,,
+"PATCTOTT","Total pharmaceutical sales","TCPPERMT","/capita, US$ exchange rate","ISL","Iceland","2015","2015",559.2,,
+"PATCTOTT","Total pharmaceutical sales","TCPPERMT","/capita, US$ exchange rate","ISL","Iceland","2016","2016",626.4,,
+"PATCTOTT","Total pharmaceutical sales","TCPPERMT","/capita, US$ exchange rate","ISL","Iceland","2017","2017",722.9,,
+"PATCTOTT","Total pharmaceutical sales","TCPPERMT","/capita, US$ exchange rate","ISL","Iceland","2018","2018",790.2,,
+"PATCTOTT","Total pharmaceutical sales","TCPPERMT","/capita, US$ exchange rate","ISL","Iceland","2019","2019",760.8,,
+"PATCTOTT","Total pharmaceutical sales","TCPPERMT","/capita, US$ exchange rate","ISL","Iceland","2020","2020",802.9,,
+"PATCTOTT","Total pharmaceutical sales","TCPPERMT","/capita, US$ exchange rate","ISL","Iceland","2021","2021",953.5,,
+"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2010","2010",591.8,,
+"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2011","2011",605,,
+"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2012","2012",552.7,,
+"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2013","2013",586.6,,
+"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2014","2014",522.3,,
+"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2015","2015",519.6,,
+"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2016","2016",540.4,,
+"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2017","2017",558.5,,
+"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2018","2018",607,,
+"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2019","2019",663,,
+"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2020","2020",741.4,,
+"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2021","2021",808.9,,
+"PATCTOTT","Total pharmaceutical sales","MLLNCUMT","Million of national currency units","IRL","Ireland","2010","2010",2050,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","MLLNCUMT","Million of national currency units","IRL","Ireland","2011","2011",1956.6,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","MLLNCUMT","Million of national currency units","IRL","Ireland","2012","2012",2044.7,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","MLLNCUMT","Million of national currency units","IRL","Ireland","2013","2013",1959.6,"B; D","Break; Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","MLLNCUMT","Million of national currency units","IRL","Ireland","2014","2014",1913.8,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","MLLNCUMT","Million of national currency units","IRL","Ireland","2015","2015",1985.1,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","MLLNCUMT","Million of national currency units","IRL","Ireland","2016","2016",2076,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","MLLNCUMT","Million of national currency units","IRL","Ireland","2017","2017",2124.4,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","MLLNCUMT","Million of national currency units","IRL","Ireland","2018","2018",2264.8,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","MLLNCUMT","Million of national currency units","IRL","Ireland","2019","2019",2406.2,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","MLLNCUMT","Million of national currency units","IRL","Ireland","2020","2020",2458.6,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","MLLNCUMT","Million of national currency units","IRL","Ireland","2021","2021",2621.4,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","MTMOTCMT","Million US$ at exchange rate","IRL","Ireland","2010","2010",2717.7,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","MTMOTCMT","Million US$ at exchange rate","IRL","Ireland","2011","2011",2723.5,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","MTMOTCMT","Million US$ at exchange rate","IRL","Ireland","2012","2012",2627.1,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","MTMOTCMT","Million US$ at exchange rate","IRL","Ireland","2013","2013",2602.6,"B; D","Break; Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","MTMOTCMT","Million US$ at exchange rate","IRL","Ireland","2014","2014",2542.4,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","MTMOTCMT","Million US$ at exchange rate","IRL","Ireland","2015","2015",2202.5,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","MTMOTCMT","Million US$ at exchange rate","IRL","Ireland","2016","2016",2298,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","MTMOTCMT","Million US$ at exchange rate","IRL","Ireland","2017","2017",2399.9,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","MTMOTCMT","Million US$ at exchange rate","IRL","Ireland","2018","2018",2674.6,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","MTMOTCMT","Million US$ at exchange rate","IRL","Ireland","2019","2019",2693.7,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","MTMOTCMT","Million US$ at exchange rate","IRL","Ireland","2020","2020",2808.2,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","MTMOTCMT","Million US$ at exchange rate","IRL","Ireland","2021","2021",3100.5,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","MTMOPPMT","Million US$, purchasing power parity","IRL","Ireland","2010","2010",2413,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","MTMOPPMT","Million US$, purchasing power parity","IRL","Ireland","2011","2011",2353.1,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","MTMOPPMT","Million US$, purchasing power parity","IRL","Ireland","2012","2012",2484.3,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","MTMOPPMT","Million US$, purchasing power parity","IRL","Ireland","2013","2013",2415.6,"B; D","Break; Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","MTMOPPMT","Million US$, purchasing power parity","IRL","Ireland","2014","2014",2336.6,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","MTMOPPMT","Million US$, purchasing power parity","IRL","Ireland","2015","2015",2451.7,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","MTMOPPMT","Million US$, purchasing power parity","IRL","Ireland","2016","2016",2613.7,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","MTMOPPMT","Million US$, purchasing power parity","IRL","Ireland","2017","2017",2674.3,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","MTMOPPMT","Million US$, purchasing power parity","IRL","Ireland","2018","2018",2858.8,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","MTMOPPMT","Million US$, purchasing power parity","IRL","Ireland","2019","2019",2986.2,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","MTMOPPMT","Million US$, purchasing power parity","IRL","Ireland","2020","2020",3088.4,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","MTMOPPMT","Million US$, purchasing power parity","IRL","Ireland","2021","2021",3298.5,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","TCPPERMT","/capita, US$ exchange rate","IRL","Ireland","2010","2010",596,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","TCPPERMT","/capita, US$ exchange rate","IRL","Ireland","2011","2011",594.6,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","TCPPERMT","/capita, US$ exchange rate","IRL","Ireland","2012","2012",571.2,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","TCPPERMT","/capita, US$ exchange rate","IRL","Ireland","2013","2013",562.9,"B; D","Break; Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","TCPPERMT","/capita, US$ exchange rate","IRL","Ireland","2014","2014",545.9,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","TCPPERMT","/capita, US$ exchange rate","IRL","Ireland","2015","2015",468.4,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","TCPPERMT","/capita, US$ exchange rate","IRL","Ireland","2016","2016",483.2,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","TCPPERMT","/capita, US$ exchange rate","IRL","Ireland","2017","2017",499.2,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","TCPPERMT","/capita, US$ exchange rate","IRL","Ireland","2018","2018",549.5,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","TCPPERMT","/capita, US$ exchange rate","IRL","Ireland","2019","2019",545.9,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","TCPPERMT","/capita, US$ exchange rate","IRL","Ireland","2020","2020",563.3,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","TCPPERMT","/capita, US$ exchange rate","IRL","Ireland","2021","2021",616,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2010","2010",529.1,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2011","2011",513.8,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2012","2012",540.1,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2013","2013",522.4,"B; D","Break; Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2014","2014",501.7,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2015","2015",521.4,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2016","2016",549.6,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2017","2017",556.3,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2018","2018",587.3,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2019","2019",605.2,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2020","2020",619.5,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2021","2021",655.4,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","MLLNCUMT","Million of national currency units","ITA","Italy","2011","2011",19514,,
+"PATCTOTT","Total pharmaceutical sales","MLLNCUMT","Million of national currency units","ITA","Italy","2012","2012",19077.9,,
+"PATCTOTT","Total pharmaceutical sales","MLLNCUMT","Million of national currency units","ITA","Italy","2013","2013",19445,,
+"PATCTOTT","Total pharmaceutical sales","MLLNCUMT","Million of national currency units","ITA","Italy","2014","2014",19887.5,,
+"PATCTOTT","Total pharmaceutical sales","MLLNCUMT","Million of national currency units","ITA","Italy","2015","2015",22615.3,,
+"PATCTOTT","Total pharmaceutical sales","MLLNCUMT","Million of national currency units","ITA","Italy","2016","2016",22780.6,,
+"PATCTOTT","Total pharmaceutical sales","MLLNCUMT","Million of national currency units","ITA","Italy","2017","2017",22618.8,,
+"PATCTOTT","Total pharmaceutical sales","MLLNCUMT","Million of national currency units","ITA","Italy","2018","2018",22361.5,,
+"PATCTOTT","Total pharmaceutical sales","MLLNCUMT","Million of national currency units","ITA","Italy","2019","2019",22859.9,,
+"PATCTOTT","Total pharmaceutical sales","MLLNCUMT","Million of national currency units","ITA","Italy","2020","2020",23151.9,,
+"PATCTOTT","Total pharmaceutical sales","MLLNCUMT","Million of national currency units","ITA","Italy","2021","2021",23842.1,,
+"PATCTOTT","Total pharmaceutical sales","MLLNCUMT","Million of national currency units","ITA","Italy","2022","2022",24798.5,"E","Estimated value"
+"PATCTOTT","Total pharmaceutical sales","MTMOTCMT","Million US$ at exchange rate","ITA","Italy","2011","2011",27162.7,,
+"PATCTOTT","Total pharmaceutical sales","MTMOTCMT","Million US$ at exchange rate","ITA","Italy","2012","2012",24511,,
+"PATCTOTT","Total pharmaceutical sales","MTMOTCMT","Million US$ at exchange rate","ITA","Italy","2013","2013",25825.3,,
+"PATCTOTT","Total pharmaceutical sales","MTMOTCMT","Million US$ at exchange rate","ITA","Italy","2014","2014",26420.6,,
+"PATCTOTT","Total pharmaceutical sales","MTMOTCMT","Million US$ at exchange rate","ITA","Italy","2015","2015",25092,,
+"PATCTOTT","Total pharmaceutical sales","MTMOTCMT","Million US$ at exchange rate","ITA","Italy","2016","2016",25215.9,,
+"PATCTOTT","Total pharmaceutical sales","MTMOTCMT","Million US$ at exchange rate","ITA","Italy","2017","2017",25552,,
+"PATCTOTT","Total pharmaceutical sales","MTMOTCMT","Million US$ at exchange rate","ITA","Italy","2018","2018",26408,,
+"PATCTOTT","Total pharmaceutical sales","MTMOTCMT","Million US$ at exchange rate","ITA","Italy","2019","2019",25591.1,,
+"PATCTOTT","Total pharmaceutical sales","MTMOTCMT","Million US$ at exchange rate","ITA","Italy","2020","2020",26444,,
+"PATCTOTT","Total pharmaceutical sales","MTMOTCMT","Million US$ at exchange rate","ITA","Italy","2021","2021",28199.1,,
+"PATCTOTT","Total pharmaceutical sales","MTMOTCMT","Million US$ at exchange rate","ITA","Italy","2022","2022",26114,"E","Estimated value"
+"PATCTOTT","Total pharmaceutical sales","MTMOPPMT","Million US$, purchasing power parity","ITA","Italy","2011","2011",25720.8,,
+"PATCTOTT","Total pharmaceutical sales","MTMOPPMT","Million US$, purchasing power parity","ITA","Italy","2012","2012",25514.3,,
+"PATCTOTT","Total pharmaceutical sales","MTMOPPMT","Million US$, purchasing power parity","ITA","Italy","2013","2013",26373.3,,
+"PATCTOTT","Total pharmaceutical sales","MTMOPPMT","Million US$, purchasing power parity","ITA","Italy","2014","2014",26888,,
+"PATCTOTT","Total pharmaceutical sales","MTMOPPMT","Million US$, purchasing power parity","ITA","Italy","2015","2015",30615.3,,
+"PATCTOTT","Total pharmaceutical sales","MTMOPPMT","Million US$, purchasing power parity","ITA","Italy","2016","2016",32518.4,,
+"PATCTOTT","Total pharmaceutical sales","MTMOPPMT","Million US$, purchasing power parity","ITA","Italy","2017","2017",32785.9,,
+"PATCTOTT","Total pharmaceutical sales","MTMOPPMT","Million US$, purchasing power parity","ITA","Italy","2018","2018",32825.8,,
+"PATCTOTT","Total pharmaceutical sales","MTMOPPMT","Million US$, purchasing power parity","ITA","Italy","2019","2019",34806.6,,
+"PATCTOTT","Total pharmaceutical sales","MTMOPPMT","Million US$, purchasing power parity","ITA","Italy","2020","2020",35744.3,,
+"PATCTOTT","Total pharmaceutical sales","MTMOPPMT","Million US$, purchasing power parity","ITA","Italy","2021","2021",36819.5,,
+"PATCTOTT","Total pharmaceutical sales","MTMOPPMT","Million US$, purchasing power parity","ITA","Italy","2022","2022",40164.8,"E","Estimated value"
+"PATCTOTT","Total pharmaceutical sales","TCPPERMT","/capita, US$ exchange rate","ITA","Italy","2011","2011",457.4,,
+"PATCTOTT","Total pharmaceutical sales","TCPPERMT","/capita, US$ exchange rate","ITA","Italy","2012","2012",411.7,,
+"PATCTOTT","Total pharmaceutical sales","TCPPERMT","/capita, US$ exchange rate","ITA","Italy","2013","2013",428.7,,
+"PATCTOTT","Total pharmaceutical sales","TCPPERMT","/capita, US$ exchange rate","ITA","Italy","2014","2014",434.6,,
+"PATCTOTT","Total pharmaceutical sales","TCPPERMT","/capita, US$ exchange rate","ITA","Italy","2015","2015",413.2,,
+"PATCTOTT","Total pharmaceutical sales","TCPPERMT","/capita, US$ exchange rate","ITA","Italy","2016","2016",415.9,,
+"PATCTOTT","Total pharmaceutical sales","TCPPERMT","/capita, US$ exchange rate","ITA","Italy","2017","2017",422.1,,
+"PATCTOTT","Total pharmaceutical sales","TCPPERMT","/capita, US$ exchange rate","ITA","Italy","2018","2018",437.1,,
+"PATCTOTT","Total pharmaceutical sales","TCPPERMT","/capita, US$ exchange rate","ITA","Italy","2019","2019",428.5,,
+"PATCTOTT","Total pharmaceutical sales","TCPPERMT","/capita, US$ exchange rate","ITA","Italy","2020","2020",444.9,,
+"PATCTOTT","Total pharmaceutical sales","TCPPERMT","/capita, US$ exchange rate","ITA","Italy","2021","2021",476.9,,
+"PATCTOTT","Total pharmaceutical sales","TCPPERMT","/capita, US$ exchange rate","ITA","Italy","2022","2022",442.4,"E","Estimated value"
+"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2011","2011",433.2,,
+"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2012","2012",428.5,,
+"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2013","2013",437.8,,
+"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2014","2014",442.3,,
+"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2015","2015",504.1,,
+"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2016","2016",536.4,,
+"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2017","2017",541.6,,
+"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2018","2018",543.3,,
+"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2019","2019",582.7,,
+"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2020","2020",601.4,,
+"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2021","2021",622.7,,
+"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2022","2022",680.4,"E","Estimated value"
+"PATCTOTT","Total pharmaceutical sales","MLLNCUMT","Million of national currency units","JPN","Japan","2010","2010",6779099,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","MLLNCUMT","Million of national currency units","JPN","Japan","2011","2011",6987367,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","MLLNCUMT","Million of national currency units","JPN","Japan","2012","2012",6976712,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","MLLNCUMT","Million of national currency units","JPN","Japan","2013","2013",6894014,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","MLLNCUMT","Million of national currency units","JPN","Japan","2014","2014",6589762,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","MLLNCUMT","Million of national currency units","JPN","Japan","2015","2015",6748121,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","MLLNCUMT","Million of national currency units","JPN","Japan","2016","2016",6623860,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","MLLNCUMT","Million of national currency units","JPN","Japan","2017","2017",6721317,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","MLLNCUMT","Million of national currency units","JPN","Japan","2018","2018",6907722,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","MLLNCUMT","Million of national currency units","JPN","Japan","2019","2019",9489305,"B; D","Break; Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","MLLNCUMT","Million of national currency units","JPN","Japan","2020","2020",9264066,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","MLLNCUMT","Million of national currency units","JPN","Japan","2021","2021",9180180,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","MTMOTCMT","Million US$ at exchange rate","JPN","Japan","2010","2010",77228.4,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","MTMOTCMT","Million US$ at exchange rate","JPN","Japan","2011","2011",87553.3,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","MTMOTCMT","Million US$ at exchange rate","JPN","Japan","2012","2012",87437.9,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","MTMOTCMT","Million US$ at exchange rate","JPN","Japan","2013","2013",70638.5,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","MTMOTCMT","Million US$ at exchange rate","JPN","Japan","2014","2014",62200,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","MTMOTCMT","Million US$ at exchange rate","JPN","Japan","2015","2015",55749.3,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","MTMOTCMT","Million US$ at exchange rate","JPN","Japan","2016","2016",60885,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","MTMOTCMT","Million US$ at exchange rate","JPN","Japan","2017","2017",59922.9,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","MTMOTCMT","Million US$ at exchange rate","JPN","Japan","2018","2018",62556.8,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","MTMOTCMT","Million US$ at exchange rate","JPN","Japan","2019","2019",87050.1,"B; D","Break; Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","MTMOTCMT","Million US$ at exchange rate","JPN","Japan","2020","2020",86762.8,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","MTMOTCMT","Million US$ at exchange rate","JPN","Japan","2021","2021",83643,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","MTMOPPMT","Million US$, purchasing power parity","JPN","Japan","2010","2010",60685,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","MTMOPPMT","Million US$, purchasing power parity","JPN","Japan","2011","2011",65026.4,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","MTMOPPMT","Million US$, purchasing power parity","JPN","Japan","2012","2012",66907.5,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","MTMOPPMT","Million US$, purchasing power parity","JPN","Japan","2013","2013",68053.6,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","MTMOPPMT","Million US$, purchasing power parity","JPN","Japan","2014","2014",63945.9,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","MTMOPPMT","Million US$, purchasing power parity","JPN","Japan","2015","2015",65218.5,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","MTMOPPMT","Million US$, purchasing power parity","JPN","Japan","2016","2016",62773.8,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","MTMOPPMT","Million US$, purchasing power parity","JPN","Japan","2017","2017",63950.5,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","MTMOPPMT","Million US$, purchasing power parity","JPN","Japan","2018","2018",66319.2,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","MTMOPPMT","Million US$, purchasing power parity","JPN","Japan","2019","2019",91045.5,"B; D","Break; Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","MTMOPPMT","Million US$, purchasing power parity","JPN","Japan","2020","2020",90444.9,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","MTMOPPMT","Million US$, purchasing power parity","JPN","Japan","2021","2021",89957.6,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","TCPPERMT","/capita, US$ exchange rate","JPN","Japan","2010","2010",603.1,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","TCPPERMT","/capita, US$ exchange rate","JPN","Japan","2011","2011",684.9,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","TCPPERMT","/capita, US$ exchange rate","JPN","Japan","2012","2012",685.3,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","TCPPERMT","/capita, US$ exchange rate","JPN","Japan","2013","2013",554.4,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","TCPPERMT","/capita, US$ exchange rate","JPN","Japan","2014","2014",488.9,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","TCPPERMT","/capita, US$ exchange rate","JPN","Japan","2015","2015",438.6,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","TCPPERMT","/capita, US$ exchange rate","JPN","Japan","2016","2016",479.7,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","TCPPERMT","/capita, US$ exchange rate","JPN","Japan","2017","2017",472.9,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","TCPPERMT","/capita, US$ exchange rate","JPN","Japan","2018","2018",494.7,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","TCPPERMT","/capita, US$ exchange rate","JPN","Japan","2019","2019",690,"B; D","Break; Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","TCPPERMT","/capita, US$ exchange rate","JPN","Japan","2020","2020",687.8,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","TCPPERMT","/capita, US$ exchange rate","JPN","Japan","2021","2021",666.5,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","JPN","Japan","2010","2010",473.9,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","JPN","Japan","2011","2011",508.7,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","JPN","Japan","2012","2012",524.4,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","JPN","Japan","2013","2013",534.1,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","JPN","Japan","2014","2014",502.6,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","JPN","Japan","2015","2015",513.1,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","JPN","Japan","2016","2016",494.5,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","JPN","Japan","2017","2017",504.7,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","JPN","Japan","2018","2018",524.5,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","JPN","Japan","2019","2019",721.6,"B; D","Break; Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","JPN","Japan","2020","2020",717,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","JPN","Japan","2021","2021",716.8,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","MLLNCUMT","Million of national currency units","KOR","Korea","2010","2010",20322863,,
+"PATCTOTT","Total pharmaceutical sales","MLLNCUMT","Million of national currency units","KOR","Korea","2011","2011",22054640,"B","Break"
+"PATCTOTT","Total pharmaceutical sales","MLLNCUMT","Million of national currency units","KOR","Korea","2012","2012",21735937.7,,
+"PATCTOTT","Total pharmaceutical sales","MLLNCUMT","Million of national currency units","KOR","Korea","2013","2013",22556709.9,,
+"PATCTOTT","Total pharmaceutical sales","MLLNCUMT","Million of national currency units","KOR","Korea","2014","2014",23669148,,
+"PATCTOTT","Total pharmaceutical sales","MLLNCUMT","Million of national currency units","KOR","Korea","2015","2015",24607410,,
+"PATCTOTT","Total pharmaceutical sales","MLLNCUMT","Million of national currency units","KOR","Korea","2016","2016",25393661.2,"B","Break"
+"PATCTOTT","Total pharmaceutical sales","MLLNCUMT","Million of national currency units","KOR","Korea","2017","2017",26957165.1,,
+"PATCTOTT","Total pharmaceutical sales","MLLNCUMT","Million of national currency units","KOR","Korea","2018","2018",28893231.7,,
+"PATCTOTT","Total pharmaceutical sales","MLLNCUMT","Million of national currency units","KOR","Korea","2019","2019",31031450.2,,
+"PATCTOTT","Total pharmaceutical sales","MLLNCUMT","Million of national currency units","KOR","Korea","2020","2020",32522204.3,,
+"PATCTOTT","Total pharmaceutical sales","MLLNCUMT","Million of national currency units","KOR","Korea","2021","2021",34704585,,
+"PATCTOTT","Total pharmaceutical sales","MTMOTCMT","Million US$ at exchange rate","KOR","Korea","2010","2010",17573.3,,
+"PATCTOTT","Total pharmaceutical sales","MTMOTCMT","Million US$ at exchange rate","KOR","Korea","2011","2011",19900.7,"B","Break"
+"PATCTOTT","Total pharmaceutical sales","MTMOTCMT","Million US$ at exchange rate","KOR","Korea","2012","2012",19289.9,,
+"PATCTOTT","Total pharmaceutical sales","MTMOTCMT","Million US$ at exchange rate","KOR","Korea","2013","2013",20600.1,,
+"PATCTOTT","Total pharmaceutical sales","MTMOTCMT","Million US$ at exchange rate","KOR","Korea","2014","2014",22481.2,,
+"PATCTOTT","Total pharmaceutical sales","MTMOTCMT","Million US$ at exchange rate","KOR","Korea","2015","2015",21758.1,,
+"PATCTOTT","Total pharmaceutical sales","MTMOTCMT","Million US$ at exchange rate","KOR","Korea","2016","2016",21876.6,"B","Break"
+"PATCTOTT","Total pharmaceutical sales","MTMOTCMT","Million US$ at exchange rate","KOR","Korea","2017","2017",23834.8,,
+"PATCTOTT","Total pharmaceutical sales","MTMOTCMT","Million US$ at exchange rate","KOR","Korea","2018","2018",26262.7,,
+"PATCTOTT","Total pharmaceutical sales","MTMOTCMT","Million US$ at exchange rate","KOR","Korea","2019","2019",26628.3,,
+"PATCTOTT","Total pharmaceutical sales","MTMOTCMT","Million US$ at exchange rate","KOR","Korea","2020","2020",27555,,
+"PATCTOTT","Total pharmaceutical sales","MTMOTCMT","Million US$ at exchange rate","KOR","Korea","2021","2021",30337.5,,
+"PATCTOTT","Total pharmaceutical sales","MTMOPPMT","Million US$, purchasing power parity","KOR","Korea","2010","2010",24165.4,,
+"PATCTOTT","Total pharmaceutical sales","MTMOPPMT","Million US$, purchasing power parity","KOR","Korea","2011","2011",25807.4,"B","Break"
+"PATCTOTT","Total pharmaceutical sales","MTMOPPMT","Million US$, purchasing power parity","KOR","Korea","2012","2012",25425.5,,
+"PATCTOTT","Total pharmaceutical sales","MTMOPPMT","Million US$, purchasing power parity","KOR","Korea","2013","2013",25954.7,,
+"PATCTOTT","Total pharmaceutical sales","MTMOPPMT","Million US$, purchasing power parity","KOR","Korea","2014","2014",27147.3,,
+"PATCTOTT","Total pharmaceutical sales","MTMOPPMT","Million US$, purchasing power parity","KOR","Korea","2015","2015",28697.2,,
+"PATCTOTT","Total pharmaceutical sales","MTMOPPMT","Million US$, purchasing power parity","KOR","Korea","2016","2016",29568.4,"B","Break"
+"PATCTOTT","Total pharmaceutical sales","MTMOPPMT","Million US$, purchasing power parity","KOR","Korea","2017","2017",30892,,
+"PATCTOTT","Total pharmaceutical sales","MTMOPPMT","Million US$, purchasing power parity","KOR","Korea","2018","2018",33798.3,,
+"PATCTOTT","Total pharmaceutical sales","MTMOPPMT","Million US$, purchasing power parity","KOR","Korea","2019","2019",36233.7,,
+"PATCTOTT","Total pharmaceutical sales","MTMOPPMT","Million US$, purchasing power parity","KOR","Korea","2020","2020",38824.5,,
+"PATCTOTT","Total pharmaceutical sales","MTMOPPMT","Million US$, purchasing power parity","KOR","Korea","2021","2021",40633.1,,
+"PATCTOTT","Total pharmaceutical sales","TCPPERMT","/capita, US$ exchange rate","KOR","Korea","2010","2010",354.6,,
+"PATCTOTT","Total pharmaceutical sales","TCPPERMT","/capita, US$ exchange rate","KOR","Korea","2011","2011",398.5,"B","Break"
+"PATCTOTT","Total pharmaceutical sales","TCPPERMT","/capita, US$ exchange rate","KOR","Korea","2012","2012",384.3,,
+"PATCTOTT","Total pharmaceutical sales","TCPPERMT","/capita, US$ exchange rate","KOR","Korea","2013","2013",408.5,,
+"PATCTOTT","Total pharmaceutical sales","TCPPERMT","/capita, US$ exchange rate","KOR","Korea","2014","2014",443,,
+"PATCTOTT","Total pharmaceutical sales","TCPPERMT","/capita, US$ exchange rate","KOR","Korea","2015","2015",426.5,,
+"PATCTOTT","Total pharmaceutical sales","TCPPERMT","/capita, US$ exchange rate","KOR","Korea","2016","2016",427.1,"B","Break"
+"PATCTOTT","Total pharmaceutical sales","TCPPERMT","/capita, US$ exchange rate","KOR","Korea","2017","2017",464.1,,
+"PATCTOTT","Total pharmaceutical sales","TCPPERMT","/capita, US$ exchange rate","KOR","Korea","2018","2018",509.1,,
+"PATCTOTT","Total pharmaceutical sales","TCPPERMT","/capita, US$ exchange rate","KOR","Korea","2019","2019",514.4,,
+"PATCTOTT","Total pharmaceutical sales","TCPPERMT","/capita, US$ exchange rate","KOR","Korea","2020","2020",531.6,,
+"PATCTOTT","Total pharmaceutical sales","TCPPERMT","/capita, US$ exchange rate","KOR","Korea","2021","2021",586.3,,
+"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2010","2010",487.7,,
+"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2011","2011",516.8,"B","Break"
+"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2012","2012",506.5,,
+"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2013","2013",514.7,,
+"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2014","2014",535,,
+"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2015","2015",562.5,,
+"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2016","2016",577.3,"B","Break"
+"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2017","2017",601.5,,
+"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2018","2018",655.2,,
+"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2019","2019",700,,
+"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2020","2020",749,,
+"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2021","2021",785.3,,
+"PATCTOTT","Total pharmaceutical sales","MLLNCUMT","Million of national currency units","LUX","Luxembourg","2010","2010",189.4,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","MLLNCUMT","Million of national currency units","LUX","Luxembourg","2011","2011",190.4,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","MLLNCUMT","Million of national currency units","LUX","Luxembourg","2012","2012",195.8,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","MLLNCUMT","Million of national currency units","LUX","Luxembourg","2013","2013",194.9,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","MLLNCUMT","Million of national currency units","LUX","Luxembourg","2014","2014",191.3,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","MLLNCUMT","Million of national currency units","LUX","Luxembourg","2015","2015",192.6,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","MLLNCUMT","Million of national currency units","LUX","Luxembourg","2016","2016",194.9,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","MLLNCUMT","Million of national currency units","LUX","Luxembourg","2017","2017",194.1,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","MLLNCUMT","Million of national currency units","LUX","Luxembourg","2018","2018",198.6,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","MLLNCUMT","Million of national currency units","LUX","Luxembourg","2019","2019",204.4,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","MLLNCUMT","Million of national currency units","LUX","Luxembourg","2020","2020",209.2,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","MLLNCUMT","Million of national currency units","LUX","Luxembourg","2021","2021",239.7,"B; D; P","Break; Difference in methodology; Provisional value"
+"PATCTOTT","Total pharmaceutical sales","MLLNCUMT","Million of national currency units","LUX","Luxembourg","2022","2022",257.3,"D; P","Difference in methodology; Provisional value"
+"PATCTOTT","Total pharmaceutical sales","MTMOTCMT","Million US$ at exchange rate","LUX","Luxembourg","2010","2010",251.1,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","MTMOTCMT","Million US$ at exchange rate","LUX","Luxembourg","2011","2011",265,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","MTMOTCMT","Million US$ at exchange rate","LUX","Luxembourg","2012","2012",251.5,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","MTMOTCMT","Million US$ at exchange rate","LUX","Luxembourg","2013","2013",258.9,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","MTMOTCMT","Million US$ at exchange rate","LUX","Luxembourg","2014","2014",254.1,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","MTMOTCMT","Million US$ at exchange rate","LUX","Luxembourg","2015","2015",213.7,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","MTMOTCMT","Million US$ at exchange rate","LUX","Luxembourg","2016","2016",215.7,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","MTMOTCMT","Million US$ at exchange rate","LUX","Luxembourg","2017","2017",219.2,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","MTMOTCMT","Million US$ at exchange rate","LUX","Luxembourg","2018","2018",234.6,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","MTMOTCMT","Million US$ at exchange rate","LUX","Luxembourg","2019","2019",228.9,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","MTMOTCMT","Million US$ at exchange rate","LUX","Luxembourg","2020","2020",238.9,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","MTMOTCMT","Million US$ at exchange rate","LUX","Luxembourg","2021","2021",283.5,"B; D; P","Break; Difference in methodology; Provisional value"
+"PATCTOTT","Total pharmaceutical sales","MTMOTCMT","Million US$ at exchange rate","LUX","Luxembourg","2022","2022",270.9,"D; P","Difference in methodology; Provisional value"
+"PATCTOTT","Total pharmaceutical sales","MTMOPPMT","Million US$, purchasing power parity","LUX","Luxembourg","2010","2010",204.6,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","MTMOPPMT","Million US$, purchasing power parity","LUX","Luxembourg","2011","2011",210.4,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","MTMOPPMT","Million US$, purchasing power parity","LUX","Luxembourg","2012","2012",215.9,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","MTMOPPMT","Million US$, purchasing power parity","LUX","Luxembourg","2013","2013",217.7,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","MTMOPPMT","Million US$, purchasing power parity","LUX","Luxembourg","2014","2014",216.3,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","MTMOPPMT","Million US$, purchasing power parity","LUX","Luxembourg","2015","2015",218.6,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","MTMOPPMT","Million US$, purchasing power parity","LUX","Luxembourg","2016","2016",228.8,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","MTMOPPMT","Million US$, purchasing power parity","LUX","Luxembourg","2017","2017",228.8,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","MTMOPPMT","Million US$, purchasing power parity","LUX","Luxembourg","2018","2018",234,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","MTMOPPMT","Million US$, purchasing power parity","LUX","Luxembourg","2019","2019",242.9,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","MTMOPPMT","Million US$, purchasing power parity","LUX","Luxembourg","2020","2020",244.3,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","MTMOPPMT","Million US$, purchasing power parity","LUX","Luxembourg","2021","2021",279.1,"B; D; P","Break; Difference in methodology; Provisional value"
+"PATCTOTT","Total pharmaceutical sales","MTMOPPMT","Million US$, purchasing power parity","LUX","Luxembourg","2022","2022",309.4,"D; P","Difference in methodology; Provisional value"
+"PATCTOTT","Total pharmaceutical sales","TCPPERMT","/capita, US$ exchange rate","LUX","Luxembourg","2010","2010",530.7,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","TCPPERMT","/capita, US$ exchange rate","LUX","Luxembourg","2011","2011",549.9,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","TCPPERMT","/capita, US$ exchange rate","LUX","Luxembourg","2012","2012",510.7,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","TCPPERMT","/capita, US$ exchange rate","LUX","Luxembourg","2013","2013",515.8,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","TCPPERMT","/capita, US$ exchange rate","LUX","Luxembourg","2014","2014",497.5,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","TCPPERMT","/capita, US$ exchange rate","LUX","Luxembourg","2015","2015",412.5,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","TCPPERMT","/capita, US$ exchange rate","LUX","Luxembourg","2016","2016",409.6,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","TCPPERMT","/capita, US$ exchange rate","LUX","Luxembourg","2017","2017",409,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","TCPPERMT","/capita, US$ exchange rate","LUX","Luxembourg","2018","2018",429.7,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","TCPPERMT","/capita, US$ exchange rate","LUX","Luxembourg","2019","2019",411.1,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","TCPPERMT","/capita, US$ exchange rate","LUX","Luxembourg","2020","2020",421.3,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","TCPPERMT","/capita, US$ exchange rate","LUX","Luxembourg","2021","2021",492.8,"B; D; P","Break; Difference in methodology; Provisional value"
+"PATCTOTT","Total pharmaceutical sales","TCPPERMT","/capita, US$ exchange rate","LUX","Luxembourg","2022","2022",461.9,"D; P","Difference in methodology; Provisional value"
+"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2010","2010",432.5,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2011","2011",436.5,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2012","2012",438.3,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2013","2013",433.8,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2014","2014",423.6,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2015","2015",421.8,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2016","2016",434.3,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2017","2017",426.8,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2018","2018",428.7,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2019","2019",436.4,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2020","2020",430.7,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2021","2021",485.1,"B; D; P","Break; Difference in methodology; Provisional value"
+"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2022","2022",527.5,"D; P","Difference in methodology; Provisional value"
+"PATCTOTT","Total pharmaceutical sales","MLLNCUMT","Million of national currency units","MEX","Mexico","2013","2013",141748.4,,
+"PATCTOTT","Total pharmaceutical sales","MLLNCUMT","Million of national currency units","MEX","Mexico","2018","2018",228114.8,,
+"PATCTOTT","Total pharmaceutical sales","MTMOTCMT","Million US$ at exchange rate","MEX","Mexico","2013","2013",11098.4,,
+"PATCTOTT","Total pharmaceutical sales","MTMOTCMT","Million US$ at exchange rate","MEX","Mexico","2018","2018",11853.6,,
+"PATCTOTT","Total pharmaceutical sales","MTMOPPMT","Million US$, purchasing power parity","MEX","Mexico","2013","2013",17978.4,,
+"PATCTOTT","Total pharmaceutical sales","MTMOPPMT","Million US$, purchasing power parity","MEX","Mexico","2018","2018",24591,,
+"PATCTOTT","Total pharmaceutical sales","TCPPERMT","/capita, US$ exchange rate","MEX","Mexico","2013","2013",93.7,,
+"PATCTOTT","Total pharmaceutical sales","TCPPERMT","/capita, US$ exchange rate","MEX","Mexico","2018","2018",94.6,,
+"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","MEX","Mexico","2013","2013",151.8,,
+"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","MEX","Mexico","2018","2018",196.2,,
+"PATCTOTT","Total pharmaceutical sales","MLLNCUMT","Million of national currency units","NLD","Netherlands","2010","2010",5213.1,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","MLLNCUMT","Million of national currency units","NLD","Netherlands","2011","2011",5210,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","MLLNCUMT","Million of national currency units","NLD","Netherlands","2012","2012",4608.3,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","MLLNCUMT","Million of national currency units","NLD","Netherlands","2013","2013",4301.1,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","MLLNCUMT","Million of national currency units","NLD","Netherlands","2014","2014",4328.4,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","MLLNCUMT","Million of national currency units","NLD","Netherlands","2015","2015",4463.3,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","MLLNCUMT","Million of national currency units","NLD","Netherlands","2016","2016",4532.2,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","MLLNCUMT","Million of national currency units","NLD","Netherlands","2017","2017",4561.2,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","MLLNCUMT","Million of national currency units","NLD","Netherlands","2018","2018",4624,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","MLLNCUMT","Million of national currency units","NLD","Netherlands","2019","2019",4846.5,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","MLLNCUMT","Million of national currency units","NLD","Netherlands","2020","2020",4971.9,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","MLLNCUMT","Million of national currency units","NLD","Netherlands","2021","2021",4860.8,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","MTMOTCMT","Million US$ at exchange rate","NLD","Netherlands","2010","2010",6911.1,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","MTMOTCMT","Million US$ at exchange rate","NLD","Netherlands","2011","2011",7252.1,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","MTMOTCMT","Million US$ at exchange rate","NLD","Netherlands","2012","2012",5920.7,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","MTMOTCMT","Million US$ at exchange rate","NLD","Netherlands","2013","2013",5712.3,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","MTMOTCMT","Million US$ at exchange rate","NLD","Netherlands","2014","2014",5750.2,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","MTMOTCMT","Million US$ at exchange rate","NLD","Netherlands","2015","2015",4952.1,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","MTMOTCMT","Million US$ at exchange rate","NLD","Netherlands","2016","2016",5016.8,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","MTMOTCMT","Million US$ at exchange rate","NLD","Netherlands","2017","2017",5152.7,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","MTMOTCMT","Million US$ at exchange rate","NLD","Netherlands","2018","2018",5460.7,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","MTMOTCMT","Million US$ at exchange rate","NLD","Netherlands","2019","2019",5425.5,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","MTMOTCMT","Million US$ at exchange rate","NLD","Netherlands","2020","2020",5678.9,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","MTMOTCMT","Million US$ at exchange rate","NLD","Netherlands","2021","2021",5749.1,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","MTMOPPMT","Million US$, purchasing power parity","NLD","Netherlands","2010","2010",6103.7,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","MTMOPPMT","Million US$, purchasing power parity","NLD","Netherlands","2011","2011",6231.5,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","MTMOPPMT","Million US$, purchasing power parity","NLD","Netherlands","2012","2012",5589.9,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","MTMOPPMT","Million US$, purchasing power parity","NLD","Netherlands","2013","2013",5388.7,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","MTMOPPMT","Million US$, purchasing power parity","NLD","Netherlands","2014","2014",5351.6,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","MTMOPPMT","Million US$, purchasing power parity","NLD","Netherlands","2015","2015",5510.4,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","MTMOPPMT","Million US$, purchasing power parity","NLD","Netherlands","2016","2016",5697.7,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","MTMOPPMT","Million US$, purchasing power parity","NLD","Netherlands","2017","2017",5831.7,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","MTMOPPMT","Million US$, purchasing power parity","NLD","Netherlands","2018","2018",5953,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","MTMOPPMT","Million US$, purchasing power parity","NLD","Netherlands","2019","2019",6225,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","MTMOPPMT","Million US$, purchasing power parity","NLD","Netherlands","2020","2020",6512.9,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","MTMOPPMT","Million US$, purchasing power parity","NLD","Netherlands","2021","2021",6313,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","TCPPERMT","/capita, US$ exchange rate","NLD","Netherlands","2010","2010",415.9,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","TCPPERMT","/capita, US$ exchange rate","NLD","Netherlands","2011","2011",434.4,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","TCPPERMT","/capita, US$ exchange rate","NLD","Netherlands","2012","2012",353.4,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","TCPPERMT","/capita, US$ exchange rate","NLD","Netherlands","2013","2013",339.9,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","TCPPERMT","/capita, US$ exchange rate","NLD","Netherlands","2014","2014",341,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","TCPPERMT","/capita, US$ exchange rate","NLD","Netherlands","2015","2015",292.3,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","TCPPERMT","/capita, US$ exchange rate","NLD","Netherlands","2016","2016",294.6,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","TCPPERMT","/capita, US$ exchange rate","NLD","Netherlands","2017","2017",300.8,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","TCPPERMT","/capita, US$ exchange rate","NLD","Netherlands","2018","2018",316.9,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","TCPPERMT","/capita, US$ exchange rate","NLD","Netherlands","2019","2019",312.8,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","TCPPERMT","/capita, US$ exchange rate","NLD","Netherlands","2020","2020",325.6,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","TCPPERMT","/capita, US$ exchange rate","NLD","Netherlands","2021","2021",327.9,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","NLD","Netherlands","2010","2010",367.4,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","NLD","Netherlands","2011","2011",373.3,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","NLD","Netherlands","2012","2012",333.6,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","NLD","Netherlands","2013","2013",320.7,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","NLD","Netherlands","2014","2014",317.3,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","NLD","Netherlands","2015","2015",325.3,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","NLD","Netherlands","2016","2016",334.6,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","NLD","Netherlands","2017","2017",340.4,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","NLD","Netherlands","2018","2018",345.5,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","NLD","Netherlands","2019","2019",358.9,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","NLD","Netherlands","2020","2020",373.4,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","NLD","Netherlands","2021","2021",360.1,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","MLLNCUMT","Million of national currency units","NZL","New Zealand","2010","2010",748.7,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","MLLNCUMT","Million of national currency units","NZL","New Zealand","2011","2011",817,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","MLLNCUMT","Million of national currency units","NZL","New Zealand","2012","2012",924.1,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","MLLNCUMT","Million of national currency units","NZL","New Zealand","2013","2013",922.9,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","MLLNCUMT","Million of national currency units","NZL","New Zealand","2014","2014",959.5,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","MLLNCUMT","Million of national currency units","NZL","New Zealand","2015","2015",987.6,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","MLLNCUMT","Million of national currency units","NZL","New Zealand","2016","2016",1072.1,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","MLLNCUMT","Million of national currency units","NZL","New Zealand","2017","2017",1262.2,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","MLLNCUMT","Million of national currency units","NZL","New Zealand","2018","2018",1321.1,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","MLLNCUMT","Million of national currency units","NZL","New Zealand","2019","2019",1492,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","MLLNCUMT","Million of national currency units","NZL","New Zealand","2020","2020",1652,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","MLLNCUMT","Million of national currency units","NZL","New Zealand","2021","2021",1777,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","MLLNCUMT","Million of national currency units","NZL","New Zealand","2022","2022",1903,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","MTMOTCMT","Million US$ at exchange rate","NZL","New Zealand","2010","2010",539.5,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","MTMOTCMT","Million US$ at exchange rate","NZL","New Zealand","2011","2011",645.4,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","MTMOTCMT","Million US$ at exchange rate","NZL","New Zealand","2012","2012",748.7,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","MTMOTCMT","Million US$ at exchange rate","NZL","New Zealand","2013","2013",756.8,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","MTMOTCMT","Million US$ at exchange rate","NZL","New Zealand","2014","2014",796,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","MTMOTCMT","Million US$ at exchange rate","NZL","New Zealand","2015","2015",688.7,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","MTMOTCMT","Million US$ at exchange rate","NZL","New Zealand","2016","2016",746.3,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","MTMOTCMT","Million US$ at exchange rate","NZL","New Zealand","2017","2017",896.8,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","MTMOTCMT","Million US$ at exchange rate","NZL","New Zealand","2018","2018",914.1,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","MTMOTCMT","Million US$ at exchange rate","NZL","New Zealand","2019","2019",983,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","MTMOTCMT","Million US$ at exchange rate","NZL","New Zealand","2020","2020",1071.3,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","MTMOTCMT","Million US$ at exchange rate","NZL","New Zealand","2021","2021",1256.9,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","MTMOTCMT","Million US$ at exchange rate","NZL","New Zealand","2022","2022",1206.6,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","MTMOPPMT","Million US$, purchasing power parity","NZL","New Zealand","2010","2010",500.2,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","MTMOPPMT","Million US$, purchasing power parity","NZL","New Zealand","2011","2011",549.8,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","MTMOPPMT","Million US$, purchasing power parity","NZL","New Zealand","2012","2012",617.9,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","MTMOPPMT","Million US$, purchasing power parity","NZL","New Zealand","2013","2013",638.2,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","MTMOPPMT","Million US$, purchasing power parity","NZL","New Zealand","2014","2014",666,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","MTMOPPMT","Million US$, purchasing power parity","NZL","New Zealand","2015","2015",668.2,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","MTMOPPMT","Million US$, purchasing power parity","NZL","New Zealand","2016","2016",744,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","MTMOPPMT","Million US$, purchasing power parity","NZL","New Zealand","2017","2017",882.1,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","MTMOPPMT","Million US$, purchasing power parity","NZL","New Zealand","2018","2018",898.7,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","MTMOPPMT","Million US$, purchasing power parity","NZL","New Zealand","2019","2019",1053.1,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","MTMOPPMT","Million US$, purchasing power parity","NZL","New Zealand","2020","2020",1168.6,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","MTMOPPMT","Million US$, purchasing power parity","NZL","New Zealand","2021","2021",1217.9,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","MTMOPPMT","Million US$, purchasing power parity","NZL","New Zealand","2022","2022",1319.4,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","TCPPERMT","/capita, US$ exchange rate","NZL","New Zealand","2010","2010",124,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","TCPPERMT","/capita, US$ exchange rate","NZL","New Zealand","2011","2011",147.2,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","TCPPERMT","/capita, US$ exchange rate","NZL","New Zealand","2012","2012",169.8,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","TCPPERMT","/capita, US$ exchange rate","NZL","New Zealand","2013","2013",170.4,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","TCPPERMT","/capita, US$ exchange rate","NZL","New Zealand","2014","2014",176.2,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","TCPPERMT","/capita, US$ exchange rate","NZL","New Zealand","2015","2015",149.4,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","TCPPERMT","/capita, US$ exchange rate","NZL","New Zealand","2016","2016",158.3,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","TCPPERMT","/capita, US$ exchange rate","NZL","New Zealand","2017","2017",186.3,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","TCPPERMT","/capita, US$ exchange rate","NZL","New Zealand","2018","2018",186.5,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","TCPPERMT","/capita, US$ exchange rate","NZL","New Zealand","2019","2019",197.4,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","TCPPERMT","/capita, US$ exchange rate","NZL","New Zealand","2020","2020",210.5,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","TCPPERMT","/capita, US$ exchange rate","NZL","New Zealand","2021","2021",245.9,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","TCPPERMT","/capita, US$ exchange rate","NZL","New Zealand","2022","2022",235.5,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2010","2010",115,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2011","2011",125.4,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2012","2012",140.2,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2013","2013",143.7,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2014","2014",147.5,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2015","2015",145,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2016","2016",157.8,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2017","2017",183.2,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2018","2018",183.4,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2019","2019",211.5,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2020","2020",229.6,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2021","2021",238.3,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2022","2022",257.5,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","MLLNCUMT","Million of national currency units","NOR","Norway","2010","2010",17890,,
+"PATCTOTT","Total pharmaceutical sales","MLLNCUMT","Million of national currency units","NOR","Norway","2011","2011",18200,,
+"PATCTOTT","Total pharmaceutical sales","MLLNCUMT","Million of national currency units","NOR","Norway","2012","2012",18800,,
+"PATCTOTT","Total pharmaceutical sales","MLLNCUMT","Million of national currency units","NOR","Norway","2013","2013",19300,,
+"PATCTOTT","Total pharmaceutical sales","MLLNCUMT","Million of national currency units","NOR","Norway","2014","2014",21077,,
+"PATCTOTT","Total pharmaceutical sales","MLLNCUMT","Million of national currency units","NOR","Norway","2015","2015",22769,,
+"PATCTOTT","Total pharmaceutical sales","MLLNCUMT","Million of national currency units","NOR","Norway","2016","2016",24769,,
+"PATCTOTT","Total pharmaceutical sales","MLLNCUMT","Million of national currency units","NOR","Norway","2017","2017",26650,,
+"PATCTOTT","Total pharmaceutical sales","MLLNCUMT","Million of national currency units","NOR","Norway","2018","2018",27494,,
+"PATCTOTT","Total pharmaceutical sales","MLLNCUMT","Million of national currency units","NOR","Norway","2019","2019",28400,,
+"PATCTOTT","Total pharmaceutical sales","MLLNCUMT","Million of national currency units","NOR","Norway","2020","2020",29708,,
+"PATCTOTT","Total pharmaceutical sales","MLLNCUMT","Million of national currency units","NOR","Norway","2021","2021",33559,,
+"PATCTOTT","Total pharmaceutical sales","MLLNCUMT","Million of national currency units","NOR","Norway","2022","2022",36008,,
+"PATCTOTT","Total pharmaceutical sales","MTMOTCMT","Million US$ at exchange rate","NOR","Norway","2010","2010",2959.9,,
+"PATCTOTT","Total pharmaceutical sales","MTMOTCMT","Million US$ at exchange rate","NOR","Norway","2011","2011",3247.3,,
+"PATCTOTT","Total pharmaceutical sales","MTMOTCMT","Million US$ at exchange rate","NOR","Norway","2012","2012",3231.6,,
+"PATCTOTT","Total pharmaceutical sales","MTMOTCMT","Million US$ at exchange rate","NOR","Norway","2013","2013",3285.1,,
+"PATCTOTT","Total pharmaceutical sales","MTMOTCMT","Million US$ at exchange rate","NOR","Norway","2014","2014",3344.7,,
+"PATCTOTT","Total pharmaceutical sales","MTMOTCMT","Million US$ at exchange rate","NOR","Norway","2015","2015",2823.5,,
+"PATCTOTT","Total pharmaceutical sales","MTMOTCMT","Million US$ at exchange rate","NOR","Norway","2016","2016",2948.7,,
+"PATCTOTT","Total pharmaceutical sales","MTMOTCMT","Million US$ at exchange rate","NOR","Norway","2017","2017",3221.8,,
+"PATCTOTT","Total pharmaceutical sales","MTMOTCMT","Million US$ at exchange rate","NOR","Norway","2018","2018",3380.8,,
+"PATCTOTT","Total pharmaceutical sales","MTMOTCMT","Million US$ at exchange rate","NOR","Norway","2019","2019",3227.3,,
+"PATCTOTT","Total pharmaceutical sales","MTMOTCMT","Million US$ at exchange rate","NOR","Norway","2020","2020",3155.1,,
+"PATCTOTT","Total pharmaceutical sales","MTMOTCMT","Million US$ at exchange rate","NOR","Norway","2021","2021",3906.8,,
+"PATCTOTT","Total pharmaceutical sales","MTMOTCMT","Million US$ at exchange rate","NOR","Norway","2022","2022",3745.3,,
+"PATCTOTT","Total pharmaceutical sales","MTMOPPMT","Million US$, purchasing power parity","NOR","Norway","2010","2010",1954.8,,
+"PATCTOTT","Total pharmaceutical sales","MTMOPPMT","Million US$, purchasing power parity","NOR","Norway","2011","2011",2003.8,,
+"PATCTOTT","Total pharmaceutical sales","MTMOPPMT","Million US$, purchasing power parity","NOR","Norway","2012","2012",2080.3,,
+"PATCTOTT","Total pharmaceutical sales","MTMOPPMT","Million US$, purchasing power parity","NOR","Norway","2013","2013",2137.5,,
+"PATCTOTT","Total pharmaceutical sales","MTMOPPMT","Million US$, purchasing power parity","NOR","Norway","2014","2014",2271.6,,
+"PATCTOTT","Total pharmaceutical sales","MTMOPPMT","Million US$, purchasing power parity","NOR","Norway","2015","2015",2292.4,,
+"PATCTOTT","Total pharmaceutical sales","MTMOPPMT","Million US$, purchasing power parity","NOR","Norway","2016","2016",2466.6,,
+"PATCTOTT","Total pharmaceutical sales","MTMOPPMT","Million US$, purchasing power parity","NOR","Norway","2017","2017",2733.4,,
+"PATCTOTT","Total pharmaceutical sales","MTMOPPMT","Million US$, purchasing power parity","NOR","Norway","2018","2018",2868.7,,
+"PATCTOTT","Total pharmaceutical sales","MTMOPPMT","Million US$, purchasing power parity","NOR","Norway","2019","2019",2952.2,,
+"PATCTOTT","Total pharmaceutical sales","MTMOPPMT","Million US$, purchasing power parity","NOR","Norway","2020","2020",3006.9,,
+"PATCTOTT","Total pharmaceutical sales","MTMOPPMT","Million US$, purchasing power parity","NOR","Norway","2021","2021",3528,,
+"PATCTOTT","Total pharmaceutical sales","MTMOPPMT","Million US$, purchasing power parity","NOR","Norway","2022","2022",3352.8,,
+"PATCTOTT","Total pharmaceutical sales","TCPPERMT","/capita, US$ exchange rate","NOR","Norway","2010","2010",605.4,,
+"PATCTOTT","Total pharmaceutical sales","TCPPERMT","/capita, US$ exchange rate","NOR","Norway","2011","2011",655.6,,
+"PATCTOTT","Total pharmaceutical sales","TCPPERMT","/capita, US$ exchange rate","NOR","Norway","2012","2012",643.9,,
+"PATCTOTT","Total pharmaceutical sales","TCPPERMT","/capita, US$ exchange rate","NOR","Norway","2013","2013",646.7,,
+"PATCTOTT","Total pharmaceutical sales","TCPPERMT","/capita, US$ exchange rate","NOR","Norway","2014","2014",651.1,,
+"PATCTOTT","Total pharmaceutical sales","TCPPERMT","/capita, US$ exchange rate","NOR","Norway","2015","2015",544.2,,
+"PATCTOTT","Total pharmaceutical sales","TCPPERMT","/capita, US$ exchange rate","NOR","Norway","2016","2016",563.3,,
+"PATCTOTT","Total pharmaceutical sales","TCPPERMT","/capita, US$ exchange rate","NOR","Norway","2017","2017",610.5,,
+"PATCTOTT","Total pharmaceutical sales","TCPPERMT","/capita, US$ exchange rate","NOR","Norway","2018","2018",636.4,,
+"PATCTOTT","Total pharmaceutical sales","TCPPERMT","/capita, US$ exchange rate","NOR","Norway","2019","2019",603.5,,
+"PATCTOTT","Total pharmaceutical sales","TCPPERMT","/capita, US$ exchange rate","NOR","Norway","2020","2020",586.5,,
+"PATCTOTT","Total pharmaceutical sales","TCPPERMT","/capita, US$ exchange rate","NOR","Norway","2021","2021",722.4,,
+"PATCTOTT","Total pharmaceutical sales","TCPPERMT","/capita, US$ exchange rate","NOR","Norway","2022","2022",690.3,,
+"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2010","2010",399.8,,
+"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2011","2011",404.6,,
+"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2012","2012",414.5,,
+"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2013","2013",420.8,,
+"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2014","2014",442.2,,
+"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2015","2015",441.8,,
+"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2016","2016",471.2,,
+"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2017","2017",518,,
+"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2018","2018",540.1,,
+"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2019","2019",552,,
+"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2020","2020",559,,
+"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2021","2021",652.3,,
+"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2022","2022",618,,
+"PATCTOTT","Total pharmaceutical sales","MLLNCUMT","Million of national currency units","PRT","Portugal","2010","2010",3237.9,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","MLLNCUMT","Million of national currency units","PRT","Portugal","2011","2011",2942.6,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","MLLNCUMT","Million of national currency units","PRT","Portugal","2012","2012",2614,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","MLLNCUMT","Million of national currency units","PRT","Portugal","2013","2013",2409.5,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","MLLNCUMT","Million of national currency units","PRT","Portugal","2014","2014",2397.6,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","MLLNCUMT","Million of national currency units","PRT","Portugal","2015","2015",2491.3,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","MLLNCUMT","Million of national currency units","PRT","Portugal","2016","2016",2530.4,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","MLLNCUMT","Million of national currency units","PRT","Portugal","2017","2017",2555.3,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","MLLNCUMT","Million of national currency units","PRT","Portugal","2018","2018",2627.9,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","MLLNCUMT","Million of national currency units","PRT","Portugal","2019","2019",2789.8,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","MLLNCUMT","Million of national currency units","PRT","Portugal","2020","2020",2809.2,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","MLLNCUMT","Million of national currency units","PRT","Portugal","2021","2021",2923,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","MLLNCUMT","Million of national currency units","PRT","Portugal","2022","2022",3187.9,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","MTMOTCMT","Million US$ at exchange rate","PRT","Portugal","2010","2010",4292.5,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","MTMOTCMT","Million US$ at exchange rate","PRT","Portugal","2011","2011",4096,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","MTMOTCMT","Million US$ at exchange rate","PRT","Portugal","2012","2012",3358.4,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","MTMOTCMT","Million US$ at exchange rate","PRT","Portugal","2013","2013",3200.1,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","MTMOTCMT","Million US$ at exchange rate","PRT","Portugal","2014","2014",3185.2,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","MTMOTCMT","Million US$ at exchange rate","PRT","Portugal","2015","2015",2764.1,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","MTMOTCMT","Million US$ at exchange rate","PRT","Portugal","2016","2016",2800.9,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","MTMOTCMT","Million US$ at exchange rate","PRT","Portugal","2017","2017",2886.6,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","MTMOTCMT","Million US$ at exchange rate","PRT","Portugal","2018","2018",3103.4,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","MTMOTCMT","Million US$ at exchange rate","PRT","Portugal","2019","2019",3123.1,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","MTMOTCMT","Million US$ at exchange rate","PRT","Portugal","2020","2020",3208.7,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","MTMOTCMT","Million US$ at exchange rate","PRT","Portugal","2021","2021",3457.2,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","MTMOTCMT","Million US$ at exchange rate","PRT","Portugal","2022","2022",3357,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","MTMOPPMT","Million US$, purchasing power parity","PRT","Portugal","2010","2010",5195.9,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","MTMOPPMT","Million US$, purchasing power parity","PRT","Portugal","2011","2011",4722.6,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","MTMOPPMT","Million US$, purchasing power parity","PRT","Portugal","2012","2012",4317.7,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","MTMOPPMT","Million US$, purchasing power parity","PRT","Portugal","2013","2013",4128.6,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","MTMOPPMT","Million US$, purchasing power parity","PRT","Portugal","2014","2014",4141.9,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","MTMOPPMT","Million US$, purchasing power parity","PRT","Portugal","2015","2015",4259,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","MTMOPPMT","Million US$, purchasing power parity","PRT","Portugal","2016","2016",4428.3,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","MTMOPPMT","Million US$, purchasing power parity","PRT","Portugal","2017","2017",4438.6,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","MTMOPPMT","Million US$, purchasing power parity","PRT","Portugal","2018","2018",4600.4,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","MTMOPPMT","Million US$, purchasing power parity","PRT","Portugal","2019","2019",4993,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","MTMOPPMT","Million US$, purchasing power parity","PRT","Portugal","2020","2020",5042.7,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","MTMOPPMT","Million US$, purchasing power parity","PRT","Portugal","2021","2021",5149.2,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","MTMOPPMT","Million US$, purchasing power parity","PRT","Portugal","2022","2022",5796.4,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","TCPPERMT","/capita, US$ exchange rate","PRT","Portugal","2010","2010",406,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","TCPPERMT","/capita, US$ exchange rate","PRT","Portugal","2011","2011",388,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","TCPPERMT","/capita, US$ exchange rate","PRT","Portugal","2012","2012",319.4,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","TCPPERMT","/capita, US$ exchange rate","PRT","Portugal","2013","2013",306,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","TCPPERMT","/capita, US$ exchange rate","PRT","Portugal","2014","2014",306.2,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","TCPPERMT","/capita, US$ exchange rate","PRT","Portugal","2015","2015",266.9,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","TCPPERMT","/capita, US$ exchange rate","PRT","Portugal","2016","2016",271.3,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","TCPPERMT","/capita, US$ exchange rate","PRT","Portugal","2017","2017",280.2,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","TCPPERMT","/capita, US$ exchange rate","PRT","Portugal","2018","2018",301.8,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","TCPPERMT","/capita, US$ exchange rate","PRT","Portugal","2019","2019",303.6,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","TCPPERMT","/capita, US$ exchange rate","PRT","Portugal","2020","2020",311.6,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","TCPPERMT","/capita, US$ exchange rate","PRT","Portugal","2021","2021",333.6,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","TCPPERMT","/capita, US$ exchange rate","PRT","Portugal","2022","2022",324.3,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2010","2010",491.4,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2011","2011",447.3,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2012","2012",410.6,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2013","2013",394.8,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2014","2014",398.2,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2015","2015",411.2,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2016","2016",428.9,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2017","2017",430.9,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2018","2018",447.3,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2019","2019",485.4,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2020","2020",489.7,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2021","2021",496.9,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2022","2022",559.9,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","MLLNCUMT","Million of national currency units","SVK","Slovak Republic","2010","2010",1115.7,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","MLLNCUMT","Million of national currency units","SVK","Slovak Republic","2011","2011",1128.6,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","MLLNCUMT","Million of national currency units","SVK","Slovak Republic","2012","2012",1104.2,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","MLLNCUMT","Million of national currency units","SVK","Slovak Republic","2013","2013",1229.2,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","MLLNCUMT","Million of national currency units","SVK","Slovak Republic","2014","2014",1317.2,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","MLLNCUMT","Million of national currency units","SVK","Slovak Republic","2015","2015",1384.5,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","MLLNCUMT","Million of national currency units","SVK","Slovak Republic","2016","2016",1573.3,"B","Break"
+"PATCTOTT","Total pharmaceutical sales","MLLNCUMT","Million of national currency units","SVK","Slovak Republic","2017","2017",1563,,
+"PATCTOTT","Total pharmaceutical sales","MLLNCUMT","Million of national currency units","SVK","Slovak Republic","2018","2018",1629.3,,
+"PATCTOTT","Total pharmaceutical sales","MLLNCUMT","Million of national currency units","SVK","Slovak Republic","2019","2019",1730.2,,
+"PATCTOTT","Total pharmaceutical sales","MLLNCUMT","Million of national currency units","SVK","Slovak Republic","2020","2020",1661.7,,
+"PATCTOTT","Total pharmaceutical sales","MLLNCUMT","Million of national currency units","SVK","Slovak Republic","2021","2021",1789.3,,
+"PATCTOTT","Total pharmaceutical sales","MTMOTCMT","Million US$ at exchange rate","SVK","Slovak Republic","2010","2010",1479.1,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","MTMOTCMT","Million US$ at exchange rate","SVK","Slovak Republic","2011","2011",1570.9,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","MTMOTCMT","Million US$ at exchange rate","SVK","Slovak Republic","2012","2012",1418.7,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","MTMOTCMT","Million US$ at exchange rate","SVK","Slovak Republic","2013","2013",1632.5,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","MTMOTCMT","Million US$ at exchange rate","SVK","Slovak Republic","2014","2014",1749.9,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","MTMOTCMT","Million US$ at exchange rate","SVK","Slovak Republic","2015","2015",1536.2,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","MTMOTCMT","Million US$ at exchange rate","SVK","Slovak Republic","2016","2016",1741.5,"B","Break"
+"PATCTOTT","Total pharmaceutical sales","MTMOTCMT","Million US$ at exchange rate","SVK","Slovak Republic","2017","2017",1765.7,,
+"PATCTOTT","Total pharmaceutical sales","MTMOTCMT","Million US$ at exchange rate","SVK","Slovak Republic","2018","2018",1924.1,,
+"PATCTOTT","Total pharmaceutical sales","MTMOTCMT","Million US$ at exchange rate","SVK","Slovak Republic","2019","2019",1936.9,,
+"PATCTOTT","Total pharmaceutical sales","MTMOTCMT","Million US$ at exchange rate","SVK","Slovak Republic","2020","2020",1898,,
+"PATCTOTT","Total pharmaceutical sales","MTMOTCMT","Million US$ at exchange rate","SVK","Slovak Republic","2021","2021",2116.3,,
+"PATCTOTT","Total pharmaceutical sales","MTMOPPMT","Million US$, purchasing power parity","SVK","Slovak Republic","2010","2010",2222,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","MTMOPPMT","Million US$, purchasing power parity","SVK","Slovak Republic","2011","2011",2228.6,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","MTMOPPMT","Million US$, purchasing power parity","SVK","Slovak Republic","2012","2012",2188.6,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","MTMOPPMT","Million US$, purchasing power parity","SVK","Slovak Republic","2013","2013",2502.8,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","MTMOPPMT","Million US$, purchasing power parity","SVK","Slovak Republic","2014","2014",2713.5,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","MTMOPPMT","Million US$, purchasing power parity","SVK","Slovak Republic","2015","2015",2816.7,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","MTMOPPMT","Million US$, purchasing power parity","SVK","Slovak Republic","2016","2016",3126.6,"B","Break"
+"PATCTOTT","Total pharmaceutical sales","MTMOPPMT","Million US$, purchasing power parity","SVK","Slovak Republic","2017","2017",3026.6,,
+"PATCTOTT","Total pharmaceutical sales","MTMOPPMT","Million US$, purchasing power parity","SVK","Slovak Republic","2018","2018",3097.5,,
+"PATCTOTT","Total pharmaceutical sales","MTMOPPMT","Million US$, purchasing power parity","SVK","Slovak Republic","2019","2019",3343.2,,
+"PATCTOTT","Total pharmaceutical sales","MTMOPPMT","Million US$, purchasing power parity","SVK","Slovak Republic","2020","2020",3195.9,,
+"PATCTOTT","Total pharmaceutical sales","MTMOPPMT","Million US$, purchasing power parity","SVK","Slovak Republic","2021","2021",3354.7,,
+"PATCTOTT","Total pharmaceutical sales","TCPPERMT","/capita, US$ exchange rate","SVK","Slovak Republic","2010","2010",274.3,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","TCPPERMT","/capita, US$ exchange rate","SVK","Slovak Republic","2011","2011",291,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","TCPPERMT","/capita, US$ exchange rate","SVK","Slovak Republic","2012","2012",262.4,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","TCPPERMT","/capita, US$ exchange rate","SVK","Slovak Republic","2013","2013",301.6,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","TCPPERMT","/capita, US$ exchange rate","SVK","Slovak Republic","2014","2014",322.9,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","TCPPERMT","/capita, US$ exchange rate","SVK","Slovak Republic","2015","2015",283.2,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","TCPPERMT","/capita, US$ exchange rate","SVK","Slovak Republic","2016","2016",320.7,"B","Break"
+"PATCTOTT","Total pharmaceutical sales","TCPPERMT","/capita, US$ exchange rate","SVK","Slovak Republic","2017","2017",324.6,,
+"PATCTOTT","Total pharmaceutical sales","TCPPERMT","/capita, US$ exchange rate","SVK","Slovak Republic","2018","2018",353.3,,
+"PATCTOTT","Total pharmaceutical sales","TCPPERMT","/capita, US$ exchange rate","SVK","Slovak Republic","2019","2019",355.1,,
+"PATCTOTT","Total pharmaceutical sales","TCPPERMT","/capita, US$ exchange rate","SVK","Slovak Republic","2020","2020",347.7,,
+"PATCTOTT","Total pharmaceutical sales","TCPPERMT","/capita, US$ exchange rate","SVK","Slovak Republic","2021","2021",388.5,,
+"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2010","2010",412.1,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2011","2011",412.8,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2012","2012",404.7,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2013","2013",462.3,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2014","2014",500.8,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2015","2015",519.3,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2016","2016",575.7,"B","Break"
+"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2017","2017",556.4,,
+"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2018","2018",568.7,,
+"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2019","2019",613,,
+"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2020","2020",585.5,,
+"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2021","2021",615.8,,
+"PATCTOTT","Total pharmaceutical sales","MLLNCUMT","Million of national currency units","ESP","Spain","2010","2010",13238.8,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","MLLNCUMT","Million of national currency units","ESP","Spain","2011","2011",12356.1,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","MLLNCUMT","Million of national currency units","ESP","Spain","2012","2012",11072,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","MLLNCUMT","Million of national currency units","ESP","Spain","2013","2013",10669.9,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","MLLNCUMT","Million of national currency units","ESP","Spain","2014","2014",11302.6,"B; D","Break; Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","MLLNCUMT","Million of national currency units","ESP","Spain","2015","2015",11403.6,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","MLLNCUMT","Million of national currency units","ESP","Spain","2016","2016",11833,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","MLLNCUMT","Million of national currency units","ESP","Spain","2017","2017",12064.9,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","MLLNCUMT","Million of national currency units","ESP","Spain","2018","2018",18994,"B","Break"
+"PATCTOTT","Total pharmaceutical sales","MLLNCUMT","Million of national currency units","ESP","Spain","2019","2019",20007.5,,
+"PATCTOTT","Total pharmaceutical sales","MLLNCUMT","Million of national currency units","ESP","Spain","2020","2020",20802.2,,
+"PATCTOTT","Total pharmaceutical sales","MLLNCUMT","Million of national currency units","ESP","Spain","2021","2021",22020.8,,
+"PATCTOTT","Total pharmaceutical sales","MLLNCUMT","Million of national currency units","ESP","Spain","2022","2022",22932.1,"P","Provisional value"
+"PATCTOTT","Total pharmaceutical sales","MTMOTCMT","Million US$ at exchange rate","ESP","Spain","2010","2010",17550.9,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","MTMOTCMT","Million US$ at exchange rate","ESP","Spain","2011","2011",17199.1,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","MTMOTCMT","Million US$ at exchange rate","ESP","Spain","2012","2012",14225.2,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","MTMOTCMT","Million US$ at exchange rate","ESP","Spain","2013","2013",14170.8,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","MTMOTCMT","Million US$ at exchange rate","ESP","Spain","2014","2014",15015.6,"B; D","Break; Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","MTMOTCMT","Million US$ at exchange rate","ESP","Spain","2015","2015",12652.5,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","MTMOTCMT","Million US$ at exchange rate","ESP","Spain","2016","2016",13098,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","MTMOTCMT","Million US$ at exchange rate","ESP","Spain","2017","2017",13629.5,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","MTMOTCMT","Million US$ at exchange rate","ESP","Spain","2018","2018",22431.1,"B","Break"
+"PATCTOTT","Total pharmaceutical sales","MTMOTCMT","Million US$ at exchange rate","ESP","Spain","2019","2019",22397.9,,
+"PATCTOTT","Total pharmaceutical sales","MTMOTCMT","Million US$ at exchange rate","ESP","Spain","2020","2020",23760.2,,
+"PATCTOTT","Total pharmaceutical sales","MTMOTCMT","Million US$ at exchange rate","ESP","Spain","2021","2021",26044.9,,
+"PATCTOTT","Total pharmaceutical sales","MTMOTCMT","Million US$ at exchange rate","ESP","Spain","2022","2022",24148.6,"P","Provisional value"
+"PATCTOTT","Total pharmaceutical sales","MTMOPPMT","Million US$, purchasing power parity","ESP","Spain","2010","2010",18211.2,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","MTMOPPMT","Million US$, purchasing power parity","ESP","Spain","2011","2011",17302.4,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","MTMOPPMT","Million US$, purchasing power parity","ESP","Spain","2012","2012",15931.5,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","MTMOPPMT","Million US$, purchasing power parity","ESP","Spain","2013","2013",15811.9,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","MTMOPPMT","Million US$, purchasing power parity","ESP","Spain","2014","2014",17064.2,"B; D","Break; Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","MTMOPPMT","Million US$, purchasing power parity","ESP","Spain","2015","2015",17155,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","MTMOPPMT","Million US$, purchasing power parity","ESP","Spain","2016","2016",18412.9,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","MTMOPPMT","Million US$, purchasing power parity","ESP","Spain","2017","2017",19125.2,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","MTMOPPMT","Million US$, purchasing power parity","ESP","Spain","2018","2018",30063.4,"B","Break"
+"PATCTOTT","Total pharmaceutical sales","MTMOPPMT","Million US$, purchasing power parity","ESP","Spain","2019","2019",32640.2,,
+"PATCTOTT","Total pharmaceutical sales","MTMOPPMT","Million US$, purchasing power parity","ESP","Spain","2020","2020",33479.8,,
+"PATCTOTT","Total pharmaceutical sales","MTMOPPMT","Million US$, purchasing power parity","ESP","Spain","2021","2021",35179.8,,
+"PATCTOTT","Total pharmaceutical sales","MTMOPPMT","Million US$, purchasing power parity","ESP","Spain","2022","2022",38462.8,"P","Provisional value"
+"PATCTOTT","Total pharmaceutical sales","TCPPERMT","/capita, US$ exchange rate","ESP","Spain","2010","2010",376.8,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","TCPPERMT","/capita, US$ exchange rate","ESP","Spain","2011","2011",368,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","TCPPERMT","/capita, US$ exchange rate","ESP","Spain","2012","2012",304.1,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","TCPPERMT","/capita, US$ exchange rate","ESP","Spain","2013","2013",304,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","TCPPERMT","/capita, US$ exchange rate","ESP","Spain","2014","2014",323,"B; D","Break; Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","TCPPERMT","/capita, US$ exchange rate","ESP","Spain","2015","2015",272.4,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","TCPPERMT","/capita, US$ exchange rate","ESP","Spain","2016","2016",281.8,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","TCPPERMT","/capita, US$ exchange rate","ESP","Spain","2017","2017",292.5,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","TCPPERMT","/capita, US$ exchange rate","ESP","Spain","2018","2018",479.3,"B","Break"
+"PATCTOTT","Total pharmaceutical sales","TCPPERMT","/capita, US$ exchange rate","ESP","Spain","2019","2019",475.2,,
+"PATCTOTT","Total pharmaceutical sales","TCPPERMT","/capita, US$ exchange rate","ESP","Spain","2020","2020",501.6,,
+"PATCTOTT","Total pharmaceutical sales","TCPPERMT","/capita, US$ exchange rate","ESP","Spain","2021","2021",549.3,,
+"PATCTOTT","Total pharmaceutical sales","TCPPERMT","/capita, US$ exchange rate","ESP","Spain","2022","2022",509.1,"P","Provisional value"
+"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2010","2010",391,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2011","2011",370.2,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2012","2012",340.6,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2013","2013",339.2,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2014","2014",367.1,"B; D","Break; Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2015","2015",369.4,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2016","2016",396.1,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2017","2017",410.5,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2018","2018",642.4,"B","Break"
+"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2019","2019",692.5,,
+"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2020","2020",706.8,,
+"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2021","2021",741.9,,
+"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2022","2022",810.9,"P","Provisional value"
+"PATCTOTT","Total pharmaceutical sales","MLLNCUMT","Million of national currency units","SWE","Sweden","2010","2010",36059.4,,
+"PATCTOTT","Total pharmaceutical sales","MLLNCUMT","Million of national currency units","SWE","Sweden","2011","2011",36781.9,,
+"PATCTOTT","Total pharmaceutical sales","MLLNCUMT","Million of national currency units","SWE","Sweden","2012","2012",36116.2,,
+"PATCTOTT","Total pharmaceutical sales","MLLNCUMT","Million of national currency units","SWE","Sweden","2013","2013",36337.4,,
+"PATCTOTT","Total pharmaceutical sales","MLLNCUMT","Million of national currency units","SWE","Sweden","2014","2014",37808.8,,
+"PATCTOTT","Total pharmaceutical sales","MLLNCUMT","Million of national currency units","SWE","Sweden","2015","2015",40557.2,,
+"PATCTOTT","Total pharmaceutical sales","MLLNCUMT","Million of national currency units","SWE","Sweden","2016","2016",42346.3,,
+"PATCTOTT","Total pharmaceutical sales","MLLNCUMT","Million of national currency units","SWE","Sweden","2017","2017",43703.1,,
+"PATCTOTT","Total pharmaceutical sales","MLLNCUMT","Million of national currency units","SWE","Sweden","2018","2018",47840.5,,
+"PATCTOTT","Total pharmaceutical sales","MLLNCUMT","Million of national currency units","SWE","Sweden","2019","2019",50523.2,,
+"PATCTOTT","Total pharmaceutical sales","MLLNCUMT","Million of national currency units","SWE","Sweden","2020","2020",52438.3,,
+"PATCTOTT","Total pharmaceutical sales","MLLNCUMT","Million of national currency units","SWE","Sweden","2021","2021",53870.1,,
+"PATCTOTT","Total pharmaceutical sales","MLLNCUMT","Million of national currency units","SWE","Sweden","2022","2022",57795.3,,
+"PATCTOTT","Total pharmaceutical sales","MTMOTCMT","Million US$ at exchange rate","SWE","Sweden","2010","2010",5003,,
+"PATCTOTT","Total pharmaceutical sales","MTMOTCMT","Million US$ at exchange rate","SWE","Sweden","2011","2011",5664.4,,
+"PATCTOTT","Total pharmaceutical sales","MTMOTCMT","Million US$ at exchange rate","SWE","Sweden","2012","2012",5330.8,,
+"PATCTOTT","Total pharmaceutical sales","MTMOTCMT","Million US$ at exchange rate","SWE","Sweden","2013","2013",5578.4,,
+"PATCTOTT","Total pharmaceutical sales","MTMOTCMT","Million US$ at exchange rate","SWE","Sweden","2014","2014",5510.9,,
+"PATCTOTT","Total pharmaceutical sales","MTMOTCMT","Million US$ at exchange rate","SWE","Sweden","2015","2015",4808.3,,
+"PATCTOTT","Total pharmaceutical sales","MTMOTCMT","Million US$ at exchange rate","SWE","Sweden","2016","2016",4945.8,,
+"PATCTOTT","Total pharmaceutical sales","MTMOTCMT","Million US$ at exchange rate","SWE","Sweden","2017","2017",5112.2,,
+"PATCTOTT","Total pharmaceutical sales","MTMOTCMT","Million US$ at exchange rate","SWE","Sweden","2018","2018",5503.6,,
+"PATCTOTT","Total pharmaceutical sales","MTMOTCMT","Million US$ at exchange rate","SWE","Sweden","2019","2019",5341.7,,
+"PATCTOTT","Total pharmaceutical sales","MTMOTCMT","Million US$ at exchange rate","SWE","Sweden","2020","2020",5693.4,,
+"PATCTOTT","Total pharmaceutical sales","MTMOTCMT","Million US$ at exchange rate","SWE","Sweden","2021","2021",6281.1,,
+"PATCTOTT","Total pharmaceutical sales","MTMOTCMT","Million US$ at exchange rate","SWE","Sweden","2022","2022",5714.2,,
+"PATCTOTT","Total pharmaceutical sales","MTMOPPMT","Million US$, purchasing power parity","SWE","Sweden","2010","2010",3995.5,,
+"PATCTOTT","Total pharmaceutical sales","MTMOPPMT","Million US$, purchasing power parity","SWE","Sweden","2011","2011",4158.9,,
+"PATCTOTT","Total pharmaceutical sales","MTMOPPMT","Million US$, purchasing power parity","SWE","Sweden","2012","2012",4173,,
+"PATCTOTT","Total pharmaceutical sales","MTMOPPMT","Million US$, purchasing power parity","SWE","Sweden","2013","2013",4226.4,,
+"PATCTOTT","Total pharmaceutical sales","MTMOPPMT","Million US$, purchasing power parity","SWE","Sweden","2014","2014",4332.3,,
+"PATCTOTT","Total pharmaceutical sales","MTMOPPMT","Million US$, purchasing power parity","SWE","Sweden","2015","2015",4580.5,,
+"PATCTOTT","Total pharmaceutical sales","MTMOPPMT","Million US$, purchasing power parity","SWE","Sweden","2016","2016",4799.8,,
+"PATCTOTT","Total pharmaceutical sales","MTMOPPMT","Million US$, purchasing power parity","SWE","Sweden","2017","2017",4937,,
+"PATCTOTT","Total pharmaceutical sales","MTMOPPMT","Million US$, purchasing power parity","SWE","Sweden","2018","2018",5396,,
+"PATCTOTT","Total pharmaceutical sales","MTMOPPMT","Million US$, purchasing power parity","SWE","Sweden","2019","2019",5800.8,,
+"PATCTOTT","Total pharmaceutical sales","MTMOPPMT","Million US$, purchasing power parity","SWE","Sweden","2020","2020",6049.3,,
+"PATCTOTT","Total pharmaceutical sales","MTMOPPMT","Million US$, purchasing power parity","SWE","Sweden","2021","2021",6176.7,,
+"PATCTOTT","Total pharmaceutical sales","MTMOPPMT","Million US$, purchasing power parity","SWE","Sweden","2022","2022",6669,,
+"PATCTOTT","Total pharmaceutical sales","TCPPERMT","/capita, US$ exchange rate","SWE","Sweden","2010","2010",533.5,,
+"PATCTOTT","Total pharmaceutical sales","TCPPERMT","/capita, US$ exchange rate","SWE","Sweden","2011","2011",599.5,,
+"PATCTOTT","Total pharmaceutical sales","TCPPERMT","/capita, US$ exchange rate","SWE","Sweden","2012","2012",560,,
+"PATCTOTT","Total pharmaceutical sales","TCPPERMT","/capita, US$ exchange rate","SWE","Sweden","2013","2013",581.1,,
+"PATCTOTT","Total pharmaceutical sales","TCPPERMT","/capita, US$ exchange rate","SWE","Sweden","2014","2014",568.4,,
+"PATCTOTT","Total pharmaceutical sales","TCPPERMT","/capita, US$ exchange rate","SWE","Sweden","2015","2015",490.7,,
+"PATCTOTT","Total pharmaceutical sales","TCPPERMT","/capita, US$ exchange rate","SWE","Sweden","2016","2016",498.4,,
+"PATCTOTT","Total pharmaceutical sales","TCPPERMT","/capita, US$ exchange rate","SWE","Sweden","2017","2017",508.3,,
+"PATCTOTT","Total pharmaceutical sales","TCPPERMT","/capita, US$ exchange rate","SWE","Sweden","2018","2018",540.9,,
+"PATCTOTT","Total pharmaceutical sales","TCPPERMT","/capita, US$ exchange rate","SWE","Sweden","2019","2019",519.7,,
+"PATCTOTT","Total pharmaceutical sales","TCPPERMT","/capita, US$ exchange rate","SWE","Sweden","2020","2020",549.9,,
+"PATCTOTT","Total pharmaceutical sales","TCPPERMT","/capita, US$ exchange rate","SWE","Sweden","2021","2021",603,,
+"PATCTOTT","Total pharmaceutical sales","TCPPERMT","/capita, US$ exchange rate","SWE","Sweden","2022","2022",546.7,,
+"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2010","2010",426,,
+"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2011","2011",440.1,,
+"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2012","2012",438.4,,
+"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2013","2013",440.2,,
+"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2014","2014",446.8,,
+"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2015","2015",467.4,,
+"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2016","2016",483.7,,
+"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2017","2017",490.9,,
+"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2018","2018",530.3,,
+"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2019","2019",564.3,,
+"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2020","2020",584.3,,
+"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2021","2021",593,,
+"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2022","2022",638,,
+"PATCTOTT","Total pharmaceutical sales","MLLNCUMT","Million of national currency units","CHE","Switzerland","2010","2010",5744.2,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","MLLNCUMT","Million of national currency units","CHE","Switzerland","2011","2011",5776,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","MLLNCUMT","Million of national currency units","CHE","Switzerland","2012","2012",5937,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","MLLNCUMT","Million of national currency units","CHE","Switzerland","2013","2013",5931,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","MLLNCUMT","Million of national currency units","CHE","Switzerland","2014","2014",5931,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","MLLNCUMT","Million of national currency units","CHE","Switzerland","2015","2015",6184,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","MLLNCUMT","Million of national currency units","CHE","Switzerland","2016","2016",6380,"B; D","Break; Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","MLLNCUMT","Million of national currency units","CHE","Switzerland","2017","2017",6520,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","MLLNCUMT","Million of national currency units","CHE","Switzerland","2018","2018",6605,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","MLLNCUMT","Million of national currency units","CHE","Switzerland","2019","2019",6696,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","MLLNCUMT","Million of national currency units","CHE","Switzerland","2020","2020",6836,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","MLLNCUMT","Million of national currency units","CHE","Switzerland","2021","2021",7116,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","MLLNCUMT","Million of national currency units","CHE","Switzerland","2022","2022",7596,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","MTMOTCMT","Million US$ at exchange rate","CHE","Switzerland","2010","2010",5507.8,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","MTMOTCMT","Million US$ at exchange rate","CHE","Switzerland","2011","2011",6504.2,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","MTMOTCMT","Million US$ at exchange rate","CHE","Switzerland","2012","2012",6331.6,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","MTMOTCMT","Million US$ at exchange rate","CHE","Switzerland","2013","2013",6398.7,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","MTMOTCMT","Million US$ at exchange rate","CHE","Switzerland","2014","2014",6473.8,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","MTMOTCMT","Million US$ at exchange rate","CHE","Switzerland","2015","2015",6425.7,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","MTMOTCMT","Million US$ at exchange rate","CHE","Switzerland","2016","2016",6474.6,"B; D","Break; Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","MTMOTCMT","Million US$ at exchange rate","CHE","Switzerland","2017","2017",6621.4,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","MTMOTCMT","Million US$ at exchange rate","CHE","Switzerland","2018","2018",6754.3,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","MTMOTCMT","Million US$ at exchange rate","CHE","Switzerland","2019","2019",6738.4,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","MTMOTCMT","Million US$ at exchange rate","CHE","Switzerland","2020","2020",7280.4,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","MTMOTCMT","Million US$ at exchange rate","CHE","Switzerland","2021","2021",7786.9,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","MTMOTCMT","Million US$ at exchange rate","CHE","Switzerland","2022","2022",7955.3,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","MTMOPPMT","Million US$, purchasing power parity","CHE","Switzerland","2010","2010",3917.9,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","MTMOPPMT","Million US$, purchasing power parity","CHE","Switzerland","2011","2011",4133.1,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","MTMOPPMT","Million US$, purchasing power parity","CHE","Switzerland","2012","2012",4384.6,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","MTMOPPMT","Million US$, purchasing power parity","CHE","Switzerland","2013","2013",4518.9,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","MTMOPPMT","Million US$, purchasing power parity","CHE","Switzerland","2014","2014",4627.2,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","MTMOPPMT","Million US$, purchasing power parity","CHE","Switzerland","2015","2015",5004.1,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","MTMOPPMT","Million US$, purchasing power parity","CHE","Switzerland","2016","2016",5308,"B; D","Break; Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","MTMOPPMT","Million US$, purchasing power parity","CHE","Switzerland","2017","2017",5489.5,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","MTMOPPMT","Million US$, purchasing power parity","CHE","Switzerland","2018","2018",5602.8,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","MTMOPPMT","Million US$, purchasing power parity","CHE","Switzerland","2019","2019",5820.6,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","MTMOPPMT","Million US$, purchasing power parity","CHE","Switzerland","2020","2020",6019.4,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","MTMOPPMT","Million US$, purchasing power parity","CHE","Switzerland","2021","2021",6431.5,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","MTMOPPMT","Million US$, purchasing power parity","CHE","Switzerland","2022","2022",7126.1,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","TCPPERMT","/capita, US$ exchange rate","CHE","Switzerland","2010","2010",703.9,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","TCPPERMT","/capita, US$ exchange rate","CHE","Switzerland","2011","2011",822,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","TCPPERMT","/capita, US$ exchange rate","CHE","Switzerland","2012","2012",791.8,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","TCPPERMT","/capita, US$ exchange rate","CHE","Switzerland","2013","2013",791,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","TCPPERMT","/capita, US$ exchange rate","CHE","Switzerland","2014","2014",790.6,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","TCPPERMT","/capita, US$ exchange rate","CHE","Switzerland","2015","2015",775.8,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","TCPPERMT","/capita, US$ exchange rate","CHE","Switzerland","2016","2016",773.2,"B; D","Break; Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","TCPPERMT","/capita, US$ exchange rate","CHE","Switzerland","2017","2017",783.4,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","TCPPERMT","/capita, US$ exchange rate","CHE","Switzerland","2018","2018",793.3,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","TCPPERMT","/capita, US$ exchange rate","CHE","Switzerland","2019","2019",785.8,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","TCPPERMT","/capita, US$ exchange rate","CHE","Switzerland","2020","2020",842.8,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","TCPPERMT","/capita, US$ exchange rate","CHE","Switzerland","2021","2021",894.6,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","TCPPERMT","/capita, US$ exchange rate","CHE","Switzerland","2022","2022",910.3,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","CHE","Switzerland","2010","2010",500.7,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","CHE","Switzerland","2011","2011",522.4,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","CHE","Switzerland","2012","2012",548.3,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","CHE","Switzerland","2013","2013",558.6,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","CHE","Switzerland","2014","2014",565.1,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","CHE","Switzerland","2015","2015",604.2,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","CHE","Switzerland","2016","2016",633.9,"B; D","Break; Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","CHE","Switzerland","2017","2017",649.5,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","CHE","Switzerland","2018","2018",658,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","CHE","Switzerland","2019","2019",678.8,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","CHE","Switzerland","2020","2020",696.8,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","CHE","Switzerland","2021","2021",738.9,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","CHE","Switzerland","2022","2022",815.5,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","MLLNCUMT","Million of national currency units","TUR","Türkiye","2010","2010",15588.8,,
+"PATCTOTT","Total pharmaceutical sales","MLLNCUMT","Million of national currency units","TUR","Türkiye","2011","2011",14167,,
+"PATCTOTT","Total pharmaceutical sales","MLLNCUMT","Million of national currency units","TUR","Türkiye","2012","2012",13519.8,,
+"PATCTOTT","Total pharmaceutical sales","MLLNCUMT","Million of national currency units","TUR","Türkiye","2013","2013",14335.5,,
+"PATCTOTT","Total pharmaceutical sales","MLLNCUMT","Million of national currency units","TUR","Türkiye","2014","2014",15698.7,,
+"PATCTOTT","Total pharmaceutical sales","MLLNCUMT","Million of national currency units","TUR","Türkiye","2015","2015",18303.6,,
+"PATCTOTT","Total pharmaceutical sales","MLLNCUMT","Million of national currency units","TUR","Türkiye","2016","2016",21893.4,,
+"PATCTOTT","Total pharmaceutical sales","MLLNCUMT","Million of national currency units","TUR","Türkiye","2017","2017",25447.6,,
+"PATCTOTT","Total pharmaceutical sales","MLLNCUMT","Million of national currency units","TUR","Türkiye","2018","2018",32038,,
+"PATCTOTT","Total pharmaceutical sales","MLLNCUMT","Million of national currency units","TUR","Türkiye","2019","2019",42070.5,,
+"PATCTOTT","Total pharmaceutical sales","MLLNCUMT","Million of national currency units","TUR","Türkiye","2020","2020",49965.3,,
+"PATCTOTT","Total pharmaceutical sales","MLLNCUMT","Million of national currency units","TUR","Türkiye","2021","2021",64807.1,,
+"PATCTOTT","Total pharmaceutical sales","MTMOTCMT","Million US$ at exchange rate","TUR","Türkiye","2010","2010",10372.8,,
+"PATCTOTT","Total pharmaceutical sales","MTMOTCMT","Million US$ at exchange rate","TUR","Türkiye","2011","2011",8458.2,,
+"PATCTOTT","Total pharmaceutical sales","MTMOTCMT","Million US$ at exchange rate","TUR","Türkiye","2012","2012",7527.7,,
+"PATCTOTT","Total pharmaceutical sales","MTMOTCMT","Million US$ at exchange rate","TUR","Türkiye","2013","2013",7530.1,,
+"PATCTOTT","Total pharmaceutical sales","MTMOTCMT","Million US$ at exchange rate","TUR","Türkiye","2014","2014",7173.1,,
+"PATCTOTT","Total pharmaceutical sales","MTMOTCMT","Million US$ at exchange rate","TUR","Türkiye","2015","2015",6729.2,,
+"PATCTOTT","Total pharmaceutical sales","MTMOTCMT","Million US$ at exchange rate","TUR","Türkiye","2016","2016",7249.1,,
+"PATCTOTT","Total pharmaceutical sales","MTMOTCMT","Million US$ at exchange rate","TUR","Türkiye","2017","2017",6975.5,,
+"PATCTOTT","Total pharmaceutical sales","MTMOTCMT","Million US$ at exchange rate","TUR","Türkiye","2018","2018",6635.4,,
+"PATCTOTT","Total pharmaceutical sales","MTMOTCMT","Million US$ at exchange rate","TUR","Türkiye","2019","2019",7414.8,,
+"PATCTOTT","Total pharmaceutical sales","MTMOTCMT","Million US$ at exchange rate","TUR","Türkiye","2020","2020",7129.1,,
+"PATCTOTT","Total pharmaceutical sales","MTMOTCMT","Million US$ at exchange rate","TUR","Türkiye","2021","2021",7322.5,,
+"PATCTOTT","Total pharmaceutical sales","MTMOPPMT","Million US$, purchasing power parity","TUR","Türkiye","2010","2010",16937.8,,
+"PATCTOTT","Total pharmaceutical sales","MTMOPPMT","Million US$, purchasing power parity","TUR","Türkiye","2011","2011",14663,,
+"PATCTOTT","Total pharmaceutical sales","MTMOPPMT","Million US$, purchasing power parity","TUR","Türkiye","2012","2012",13256.6,,
+"PATCTOTT","Total pharmaceutical sales","MTMOPPMT","Million US$, purchasing power parity","TUR","Türkiye","2013","2013",13394,,
+"PATCTOTT","Total pharmaceutical sales","MTMOPPMT","Million US$, purchasing power parity","TUR","Türkiye","2014","2014",14213.3,,
+"PATCTOTT","Total pharmaceutical sales","MTMOPPMT","Million US$, purchasing power parity","TUR","Türkiye","2015","2015",15745.7,,
+"PATCTOTT","Total pharmaceutical sales","MTMOPPMT","Million US$, purchasing power parity","TUR","Türkiye","2016","2016",17641,,
+"PATCTOTT","Total pharmaceutical sales","MTMOPPMT","Million US$, purchasing power parity","TUR","Türkiye","2017","2017",18387.2,,
+"PATCTOTT","Total pharmaceutical sales","MTMOPPMT","Million US$, purchasing power parity","TUR","Türkiye","2018","2018",19623.8,,
+"PATCTOTT","Total pharmaceutical sales","MTMOPPMT","Million US$, purchasing power parity","TUR","Türkiye","2019","2019",22569.9,,
+"PATCTOTT","Total pharmaceutical sales","MTMOPPMT","Million US$, purchasing power parity","TUR","Türkiye","2020","2020",23087.2,,
+"PATCTOTT","Total pharmaceutical sales","MTMOPPMT","Million US$, purchasing power parity","TUR","Türkiye","2021","2021",23080.4,,
+"PATCTOTT","Total pharmaceutical sales","TCPPERMT","/capita, US$ exchange rate","TUR","Türkiye","2010","2010",141.8,,
+"PATCTOTT","Total pharmaceutical sales","TCPPERMT","/capita, US$ exchange rate","TUR","Türkiye","2011","2011",114,,
+"PATCTOTT","Total pharmaceutical sales","TCPPERMT","/capita, US$ exchange rate","TUR","Türkiye","2012","2012",100.1,,
+"PATCTOTT","Total pharmaceutical sales","TCPPERMT","/capita, US$ exchange rate","TUR","Türkiye","2013","2013",98.9,,
+"PATCTOTT","Total pharmaceutical sales","TCPPERMT","/capita, US$ exchange rate","TUR","Türkiye","2014","2014",92.9,,
+"PATCTOTT","Total pharmaceutical sales","TCPPERMT","/capita, US$ exchange rate","TUR","Türkiye","2015","2015",86,,
+"PATCTOTT","Total pharmaceutical sales","TCPPERMT","/capita, US$ exchange rate","TUR","Türkiye","2016","2016",91.4,,
+"PATCTOTT","Total pharmaceutical sales","TCPPERMT","/capita, US$ exchange rate","TUR","Türkiye","2017","2017",86.9,,
+"PATCTOTT","Total pharmaceutical sales","TCPPERMT","/capita, US$ exchange rate","TUR","Türkiye","2018","2018",81.5,,
+"PATCTOTT","Total pharmaceutical sales","TCPPERMT","/capita, US$ exchange rate","TUR","Türkiye","2019","2019",89.8,,
+"PATCTOTT","Total pharmaceutical sales","TCPPERMT","/capita, US$ exchange rate","TUR","Türkiye","2020","2020",85.5,,
+"PATCTOTT","Total pharmaceutical sales","TCPPERMT","/capita, US$ exchange rate","TUR","Türkiye","2021","2021",87,,
+"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2010","2010",231.6,,
+"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2011","2011",197.6,,
+"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2012","2012",176.3,,
+"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2013","2013",175.9,,
+"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2014","2014",184.2,,
+"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2015","2015",201.3,,
+"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2016","2016",222.5,,
+"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2017","2017",228.9,,
+"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2018","2018",241.1,,
+"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2019","2019",273.3,,
+"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2020","2020",276.9,,
+"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2021","2021",274.3,,
+"PATCTOTT","Total pharmaceutical sales","MLLNCUMT","Million of national currency units","GBR","United Kingdom","2010","2010",13156.1,"B","Break"
+"PATCTOTT","Total pharmaceutical sales","MLLNCUMT","Million of national currency units","GBR","United Kingdom","2011","2011",12983.6,,
+"PATCTOTT","Total pharmaceutical sales","MLLNCUMT","Million of national currency units","GBR","United Kingdom","2012","2012",13772.5,,
+"PATCTOTT","Total pharmaceutical sales","MLLNCUMT","Million of national currency units","GBR","United Kingdom","2013","2013",14602.1,,
+"PATCTOTT","Total pharmaceutical sales","MLLNCUMT","Million of national currency units","GBR","United Kingdom","2014","2014",15995.2,,
+"PATCTOTT","Total pharmaceutical sales","MLLNCUMT","Million of national currency units","GBR","United Kingdom","2015","2015",17686.9,,
+"PATCTOTT","Total pharmaceutical sales","MLLNCUMT","Million of national currency units","GBR","United Kingdom","2016","2016",18554.1,,
+"PATCTOTT","Total pharmaceutical sales","MLLNCUMT","Million of national currency units","GBR","United Kingdom","2017","2017",19525.1,,
+"PATCTOTT","Total pharmaceutical sales","MLLNCUMT","Million of national currency units","GBR","United Kingdom","2018","2018",20446.5,,
+"PATCTOTT","Total pharmaceutical sales","MTMOTCMT","Million US$ at exchange rate","GBR","United Kingdom","2010","2010",20328.4,"B","Break"
+"PATCTOTT","Total pharmaceutical sales","MTMOTCMT","Million US$ at exchange rate","GBR","United Kingdom","2011","2011",20802.4,,
+"PATCTOTT","Total pharmaceutical sales","MTMOTCMT","Million US$ at exchange rate","GBR","United Kingdom","2012","2012",21755.9,,
+"PATCTOTT","Total pharmaceutical sales","MTMOTCMT","Million US$ at exchange rate","GBR","United Kingdom","2013","2013",22827.9,,
+"PATCTOTT","Total pharmaceutical sales","MTMOTCMT","Million US$ at exchange rate","GBR","United Kingdom","2014","2014",26319.6,,
+"PATCTOTT","Total pharmaceutical sales","MTMOTCMT","Million US$ at exchange rate","GBR","United Kingdom","2015","2015",27021.7,,
+"PATCTOTT","Total pharmaceutical sales","MTMOTCMT","Million US$ at exchange rate","GBR","United Kingdom","2016","2016",25051.6,,
+"PATCTOTT","Total pharmaceutical sales","MTMOTCMT","Million US$ at exchange rate","GBR","United Kingdom","2017","2017",25129.6,,
+"PATCTOTT","Total pharmaceutical sales","MTMOTCMT","Million US$ at exchange rate","GBR","United Kingdom","2018","2018",27279,,
+"PATCTOTT","Total pharmaceutical sales","MTMOPPMT","Million US$, purchasing power parity","GBR","United Kingdom","2010","2010",18733.4,"B","Break"
+"PATCTOTT","Total pharmaceutical sales","MTMOPPMT","Million US$, purchasing power parity","GBR","United Kingdom","2011","2011",18389,,
+"PATCTOTT","Total pharmaceutical sales","MTMOPPMT","Million US$, purchasing power parity","GBR","United Kingdom","2012","2012",19629.2,,
+"PATCTOTT","Total pharmaceutical sales","MTMOPPMT","Million US$, purchasing power parity","GBR","United Kingdom","2013","2013",21002.7,,
+"PATCTOTT","Total pharmaceutical sales","MTMOPPMT","Million US$, purchasing power parity","GBR","United Kingdom","2014","2014",22901.2,,
+"PATCTOTT","Total pharmaceutical sales","MTMOPPMT","Million US$, purchasing power parity","GBR","United Kingdom","2015","2015",25538.8,,
+"PATCTOTT","Total pharmaceutical sales","MTMOPPMT","Million US$, purchasing power parity","GBR","United Kingdom","2016","2016",26944.6,,
+"PATCTOTT","Total pharmaceutical sales","MTMOPPMT","Million US$, purchasing power parity","GBR","United Kingdom","2017","2017",28520.4,,
+"PATCTOTT","Total pharmaceutical sales","MTMOPPMT","Million US$, purchasing power parity","GBR","United Kingdom","2018","2018",29731.1,,
+"PATCTOTT","Total pharmaceutical sales","TCPPERMT","/capita, US$ exchange rate","GBR","United Kingdom","2010","2010",323.9,"B","Break"
+"PATCTOTT","Total pharmaceutical sales","TCPPERMT","/capita, US$ exchange rate","GBR","United Kingdom","2011","2011",328.7,,
+"PATCTOTT","Total pharmaceutical sales","TCPPERMT","/capita, US$ exchange rate","GBR","United Kingdom","2012","2012",341.5,,
+"PATCTOTT","Total pharmaceutical sales","TCPPERMT","/capita, US$ exchange rate","GBR","United Kingdom","2013","2013",356.1,,
+"PATCTOTT","Total pharmaceutical sales","TCPPERMT","/capita, US$ exchange rate","GBR","United Kingdom","2014","2014",407.4,,
+"PATCTOTT","Total pharmaceutical sales","TCPPERMT","/capita, US$ exchange rate","GBR","United Kingdom","2015","2015",415,,
+"PATCTOTT","Total pharmaceutical sales","TCPPERMT","/capita, US$ exchange rate","GBR","United Kingdom","2016","2016",381.6,,
+"PATCTOTT","Total pharmaceutical sales","TCPPERMT","/capita, US$ exchange rate","GBR","United Kingdom","2017","2017",380.5,,
+"PATCTOTT","Total pharmaceutical sales","TCPPERMT","/capita, US$ exchange rate","GBR","United Kingdom","2018","2018",410.6,,
+"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","GBR","United Kingdom","2010","2010",298.5,"B","Break"
+"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","GBR","United Kingdom","2011","2011",290.6,,
+"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","GBR","United Kingdom","2012","2012",308.1,,
+"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","GBR","United Kingdom","2013","2013",327.6,,
+"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","GBR","United Kingdom","2014","2014",354.5,,
+"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","GBR","United Kingdom","2015","2015",392.2,,
+"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","GBR","United Kingdom","2016","2016",410.4,,
+"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","GBR","United Kingdom","2017","2017",431.9,,
+"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","GBR","United Kingdom","2018","2018",447.5,,
+"PATCTOTT","Total pharmaceutical sales","MLLNCUMT","Million of national currency units","CHL","Chile","2010","2010",826115.8,,
+"PATCTOTT","Total pharmaceutical sales","MLLNCUMT","Million of national currency units","CHL","Chile","2011","2011",1179279,"B","Break"
+"PATCTOTT","Total pharmaceutical sales","MLLNCUMT","Million of national currency units","CHL","Chile","2012","2012",1248234.6,,
+"PATCTOTT","Total pharmaceutical sales","MLLNCUMT","Million of national currency units","CHL","Chile","2013","2013",1446986.6,,
+"PATCTOTT","Total pharmaceutical sales","MLLNCUMT","Million of national currency units","CHL","Chile","2014","2014",1546451.1,,
+"PATCTOTT","Total pharmaceutical sales","MLLNCUMT","Million of national currency units","CHL","Chile","2015","2015",1823693.1,,
+"PATCTOTT","Total pharmaceutical sales","MLLNCUMT","Million of national currency units","CHL","Chile","2016","2016",2023878.4,,
+"PATCTOTT","Total pharmaceutical sales","MLLNCUMT","Million of national currency units","CHL","Chile","2017","2017",2067820.4,,
+"PATCTOTT","Total pharmaceutical sales","MLLNCUMT","Million of national currency units","CHL","Chile","2018","2018",2296898.5,,
+"PATCTOTT","Total pharmaceutical sales","MLLNCUMT","Million of national currency units","CHL","Chile","2019","2019",2522481.4,,
+"PATCTOTT","Total pharmaceutical sales","MLLNCUMT","Million of national currency units","CHL","Chile","2020","2020",2689451.6,,
+"PATCTOTT","Total pharmaceutical sales","MLLNCUMT","Million of national currency units","CHL","Chile","2021","2021",2813418,,
+"PATCTOTT","Total pharmaceutical sales","MLLNCUMT","Million of national currency units","CHL","Chile","2022","2022",2817224.7,,
+"PATCTOTT","Total pharmaceutical sales","MTMOTCMT","Million US$ at exchange rate","CHL","Chile","2010","2010",1619,,
+"PATCTOTT","Total pharmaceutical sales","MTMOTCMT","Million US$ at exchange rate","CHL","Chile","2011","2011",2438.2,"B","Break"
+"PATCTOTT","Total pharmaceutical sales","MTMOTCMT","Million US$ at exchange rate","CHL","Chile","2012","2012",2565.9,,
+"PATCTOTT","Total pharmaceutical sales","MTMOTCMT","Million US$ at exchange rate","CHL","Chile","2013","2013",2921.6,,
+"PATCTOTT","Total pharmaceutical sales","MTMOTCMT","Million US$ at exchange rate","CHL","Chile","2014","2014",2711.4,,
+"PATCTOTT","Total pharmaceutical sales","MTMOTCMT","Million US$ at exchange rate","CHL","Chile","2015","2015",2788,,
+"PATCTOTT","Total pharmaceutical sales","MTMOTCMT","Million US$ at exchange rate","CHL","Chile","2016","2016",2989.7,,
+"PATCTOTT","Total pharmaceutical sales","MTMOTCMT","Million US$ at exchange rate","CHL","Chile","2017","2017",3187,,
+"PATCTOTT","Total pharmaceutical sales","MTMOTCMT","Million US$ at exchange rate","CHL","Chile","2018","2018",3581.8,,
+"PATCTOTT","Total pharmaceutical sales","MTMOTCMT","Million US$ at exchange rate","CHL","Chile","2019","2019",3588.7,,
+"PATCTOTT","Total pharmaceutical sales","MTMOTCMT","Million US$ at exchange rate","CHL","Chile","2020","2020",3392.7,,
+"PATCTOTT","Total pharmaceutical sales","MTMOTCMT","Million US$ at exchange rate","CHL","Chile","2021","2021",3707,,
+"PATCTOTT","Total pharmaceutical sales","MTMOTCMT","Million US$ at exchange rate","CHL","Chile","2022","2022",3225.9,,
+"PATCTOTT","Total pharmaceutical sales","MTMOPPMT","Million US$, purchasing power parity","CHL","Chile","2010","2010",2295.8,,
+"PATCTOTT","Total pharmaceutical sales","MTMOPPMT","Million US$, purchasing power parity","CHL","Chile","2011","2011",3388.6,"B","Break"
+"PATCTOTT","Total pharmaceutical sales","MTMOPPMT","Million US$, purchasing power parity","CHL","Chile","2012","2012",3594.9,,
+"PATCTOTT","Total pharmaceutical sales","MTMOPPMT","Million US$, purchasing power parity","CHL","Chile","2013","2013",4138,,
+"PATCTOTT","Total pharmaceutical sales","MTMOPPMT","Million US$, purchasing power parity","CHL","Chile","2014","2014",4211.3,,
+"PATCTOTT","Total pharmaceutical sales","MTMOPPMT","Million US$, purchasing power parity","CHL","Chile","2015","2015",4662,,
+"PATCTOTT","Total pharmaceutical sales","MTMOPPMT","Million US$, purchasing power parity","CHL","Chile","2016","2016",5094.7,,
+"PATCTOTT","Total pharmaceutical sales","MTMOPPMT","Million US$, purchasing power parity","CHL","Chile","2017","2017",5199.6,,
+"PATCTOTT","Total pharmaceutical sales","MTMOPPMT","Million US$, purchasing power parity","CHL","Chile","2018","2018",5796.9,,
+"PATCTOTT","Total pharmaceutical sales","MTMOPPMT","Million US$, purchasing power parity","CHL","Chile","2019","2019",6280.9,,
+"PATCTOTT","Total pharmaceutical sales","MTMOPPMT","Million US$, purchasing power parity","CHL","Chile","2020","2020",6427.2,,
+"PATCTOTT","Total pharmaceutical sales","MTMOPPMT","Million US$, purchasing power parity","CHL","Chile","2021","2021",6465.3,,
+"PATCTOTT","Total pharmaceutical sales","MTMOPPMT","Million US$, purchasing power parity","CHL","Chile","2022","2022",6438.5,,
+"PATCTOTT","Total pharmaceutical sales","TCPPERMT","/capita, US$ exchange rate","CHL","Chile","2010","2010",94.9,,
+"PATCTOTT","Total pharmaceutical sales","TCPPERMT","/capita, US$ exchange rate","CHL","Chile","2011","2011",141.3,"B","Break"
+"PATCTOTT","Total pharmaceutical sales","TCPPERMT","/capita, US$ exchange rate","CHL","Chile","2012","2012",147.1,,
+"PATCTOTT","Total pharmaceutical sales","TCPPERMT","/capita, US$ exchange rate","CHL","Chile","2013","2013",165.9,,
+"PATCTOTT","Total pharmaceutical sales","TCPPERMT","/capita, US$ exchange rate","CHL","Chile","2014","2014",152.4,,
+"PATCTOTT","Total pharmaceutical sales","TCPPERMT","/capita, US$ exchange rate","CHL","Chile","2015","2015",155.1,,
+"PATCTOTT","Total pharmaceutical sales","TCPPERMT","/capita, US$ exchange rate","CHL","Chile","2016","2016",164.6,,
+"PATCTOTT","Total pharmaceutical sales","TCPPERMT","/capita, US$ exchange rate","CHL","Chile","2017","2017",173,,
+"PATCTOTT","Total pharmaceutical sales","TCPPERMT","/capita, US$ exchange rate","CHL","Chile","2018","2018",191,,
+"PATCTOTT","Total pharmaceutical sales","TCPPERMT","/capita, US$ exchange rate","CHL","Chile","2019","2019",187.8,,
+"PATCTOTT","Total pharmaceutical sales","TCPPERMT","/capita, US$ exchange rate","CHL","Chile","2020","2020",174.4,,
+"PATCTOTT","Total pharmaceutical sales","TCPPERMT","/capita, US$ exchange rate","CHL","Chile","2021","2021",188.4,,
+"PATCTOTT","Total pharmaceutical sales","TCPPERMT","/capita, US$ exchange rate","CHL","Chile","2022","2022",162.7,,
+"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2010","2010",134.5,,
+"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2011","2011",196.4,"B","Break"
+"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2012","2012",206.1,,
+"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2013","2013",235,,
+"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2014","2014",236.8,,
+"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2015","2015",259.4,,
+"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2016","2016",280.4,,
+"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2017","2017",282.3,,
+"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2018","2018",309.1,,
+"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2019","2019",328.7,,
+"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2020","2020",330.3,,
+"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2021","2021",328.5,,
+"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2022","2022",324.7,,
+"PATCTOTT","Total pharmaceutical sales","MLLNCUMT","Million of national currency units","EST","Estonia","2010","2010",194.1,,
+"PATCTOTT","Total pharmaceutical sales","MLLNCUMT","Million of national currency units","EST","Estonia","2011","2011",204.4,,
+"PATCTOTT","Total pharmaceutical sales","MLLNCUMT","Million of national currency units","EST","Estonia","2012","2012",221.7,,
+"PATCTOTT","Total pharmaceutical sales","MLLNCUMT","Million of national currency units","EST","Estonia","2013","2013",231,,
+"PATCTOTT","Total pharmaceutical sales","MLLNCUMT","Million of national currency units","EST","Estonia","2014","2014",249.4,,
+"PATCTOTT","Total pharmaceutical sales","MLLNCUMT","Million of national currency units","EST","Estonia","2015","2015",265.2,,
+"PATCTOTT","Total pharmaceutical sales","MLLNCUMT","Million of national currency units","EST","Estonia","2016","2016",289.9,,
+"PATCTOTT","Total pharmaceutical sales","MLLNCUMT","Million of national currency units","EST","Estonia","2017","2017",301,,
+"PATCTOTT","Total pharmaceutical sales","MLLNCUMT","Million of national currency units","EST","Estonia","2018","2018",325.4,,
+"PATCTOTT","Total pharmaceutical sales","MLLNCUMT","Million of national currency units","EST","Estonia","2019","2019",344.4,,
+"PATCTOTT","Total pharmaceutical sales","MLLNCUMT","Million of national currency units","EST","Estonia","2020","2020",358.6,,
+"PATCTOTT","Total pharmaceutical sales","MLLNCUMT","Million of national currency units","EST","Estonia","2021","2021",408.8,,
+"PATCTOTT","Total pharmaceutical sales","MLLNCUMT","Million of national currency units","EST","Estonia","2022","2022",431.3,,
+"PATCTOTT","Total pharmaceutical sales","MTMOTCMT","Million US$ at exchange rate","EST","Estonia","2010","2010",257.2,,
+"PATCTOTT","Total pharmaceutical sales","MTMOTCMT","Million US$ at exchange rate","EST","Estonia","2011","2011",284.5,,
+"PATCTOTT","Total pharmaceutical sales","MTMOTCMT","Million US$ at exchange rate","EST","Estonia","2012","2012",284.9,,
+"PATCTOTT","Total pharmaceutical sales","MTMOTCMT","Million US$ at exchange rate","EST","Estonia","2013","2013",306.7,,
+"PATCTOTT","Total pharmaceutical sales","MTMOTCMT","Million US$ at exchange rate","EST","Estonia","2014","2014",331.4,,
+"PATCTOTT","Total pharmaceutical sales","MTMOTCMT","Million US$ at exchange rate","EST","Estonia","2015","2015",294.2,,
+"PATCTOTT","Total pharmaceutical sales","MTMOTCMT","Million US$ at exchange rate","EST","Estonia","2016","2016",320.9,,
+"PATCTOTT","Total pharmaceutical sales","MTMOTCMT","Million US$ at exchange rate","EST","Estonia","2017","2017",340,,
+"PATCTOTT","Total pharmaceutical sales","MTMOTCMT","Million US$ at exchange rate","EST","Estonia","2018","2018",384.3,,
+"PATCTOTT","Total pharmaceutical sales","MTMOTCMT","Million US$ at exchange rate","EST","Estonia","2019","2019",385.5,,
+"PATCTOTT","Total pharmaceutical sales","MTMOTCMT","Million US$ at exchange rate","EST","Estonia","2020","2020",409.6,,
+"PATCTOTT","Total pharmaceutical sales","MTMOTCMT","Million US$ at exchange rate","EST","Estonia","2021","2021",483.5,,
+"PATCTOTT","Total pharmaceutical sales","MTMOTCMT","Million US$ at exchange rate","EST","Estonia","2022","2022",454.2,,
+"PATCTOTT","Total pharmaceutical sales","MTMOPPMT","Million US$, purchasing power parity","EST","Estonia","2010","2010",379,,
+"PATCTOTT","Total pharmaceutical sales","MTMOPPMT","Million US$, purchasing power parity","EST","Estonia","2011","2011",399.5,,
+"PATCTOTT","Total pharmaceutical sales","MTMOPPMT","Million US$, purchasing power parity","EST","Estonia","2012","2012",425.5,,
+"PATCTOTT","Total pharmaceutical sales","MTMOPPMT","Million US$, purchasing power parity","EST","Estonia","2013","2013",442.1,,
+"PATCTOTT","Total pharmaceutical sales","MTMOPPMT","Million US$, purchasing power parity","EST","Estonia","2014","2014",473.4,,
+"PATCTOTT","Total pharmaceutical sales","MTMOPPMT","Million US$, purchasing power parity","EST","Estonia","2015","2015",493.2,,
+"PATCTOTT","Total pharmaceutical sales","MTMOPPMT","Million US$, purchasing power parity","EST","Estonia","2016","2016",549.2,,
+"PATCTOTT","Total pharmaceutical sales","MTMOPPMT","Million US$, purchasing power parity","EST","Estonia","2017","2017",562.6,,
+"PATCTOTT","Total pharmaceutical sales","MTMOPPMT","Million US$, purchasing power parity","EST","Estonia","2018","2018",604,,
+"PATCTOTT","Total pharmaceutical sales","MTMOPPMT","Million US$, purchasing power parity","EST","Estonia","2019","2019",641.9,,
+"PATCTOTT","Total pharmaceutical sales","MTMOPPMT","Million US$, purchasing power parity","EST","Estonia","2020","2020",684.8,,
+"PATCTOTT","Total pharmaceutical sales","MTMOPPMT","Million US$, purchasing power parity","EST","Estonia","2021","2021",752.2,,
+"PATCTOTT","Total pharmaceutical sales","MTMOPPMT","Million US$, purchasing power parity","EST","Estonia","2022","2022",757.6,,
+"PATCTOTT","Total pharmaceutical sales","TCPPERMT","/capita, US$ exchange rate","EST","Estonia","2010","2010",193.2,,
+"PATCTOTT","Total pharmaceutical sales","TCPPERMT","/capita, US$ exchange rate","EST","Estonia","2011","2011",214.3,,
+"PATCTOTT","Total pharmaceutical sales","TCPPERMT","/capita, US$ exchange rate","EST","Estonia","2012","2012",215.4,,
+"PATCTOTT","Total pharmaceutical sales","TCPPERMT","/capita, US$ exchange rate","EST","Estonia","2013","2013",232.7,,
+"PATCTOTT","Total pharmaceutical sales","TCPPERMT","/capita, US$ exchange rate","EST","Estonia","2014","2014",252.1,,
+"PATCTOTT","Total pharmaceutical sales","TCPPERMT","/capita, US$ exchange rate","EST","Estonia","2015","2015",223.6,,
+"PATCTOTT","Total pharmaceutical sales","TCPPERMT","/capita, US$ exchange rate","EST","Estonia","2016","2016",243.9,,
+"PATCTOTT","Total pharmaceutical sales","TCPPERMT","/capita, US$ exchange rate","EST","Estonia","2017","2017",258.1,,
+"PATCTOTT","Total pharmaceutical sales","TCPPERMT","/capita, US$ exchange rate","EST","Estonia","2018","2018",290.7,,
+"PATCTOTT","Total pharmaceutical sales","TCPPERMT","/capita, US$ exchange rate","EST","Estonia","2019","2019",290.5,,
+"PATCTOTT","Total pharmaceutical sales","TCPPERMT","/capita, US$ exchange rate","EST","Estonia","2020","2020",308.1,,
+"PATCTOTT","Total pharmaceutical sales","TCPPERMT","/capita, US$ exchange rate","EST","Estonia","2021","2021",363.3,,
+"PATCTOTT","Total pharmaceutical sales","TCPPERMT","/capita, US$ exchange rate","EST","Estonia","2022","2022",341,,
+"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2010","2010",284.6,,
+"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2011","2011",301,,
+"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2012","2012",321.7,,
+"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2013","2013",335.4,,
+"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2014","2014",360.1,,
+"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2015","2015",375,,
+"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2016","2016",417.4,,
+"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2017","2017",427.1,,
+"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2018","2018",456.9,,
+"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2019","2019",483.8,,
+"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2020","2020",515,,
+"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2021","2021",565.2,,
+"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2022","2022",568.8,,
+"PATCTOTT","Total pharmaceutical sales","MLLNCUMT","Million of national currency units","SVN","Slovenia","2010","2010",474.4,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","MLLNCUMT","Million of national currency units","SVN","Slovenia","2011","2011",470,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","MLLNCUMT","Million of national currency units","SVN","Slovenia","2012","2012",454.4,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","MLLNCUMT","Million of national currency units","SVN","Slovenia","2013","2013",451.1,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","MLLNCUMT","Million of national currency units","SVN","Slovenia","2014","2014",432.3,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","MLLNCUMT","Million of national currency units","SVN","Slovenia","2015","2015",446,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","MLLNCUMT","Million of national currency units","SVN","Slovenia","2016","2016",466.7,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","MLLNCUMT","Million of national currency units","SVN","Slovenia","2017","2017",484.2,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","MLLNCUMT","Million of national currency units","SVN","Slovenia","2018","2018",516.7,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","MLLNCUMT","Million of national currency units","SVN","Slovenia","2019","2019",542.1,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","MLLNCUMT","Million of national currency units","SVN","Slovenia","2020","2020",568.2,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","MLLNCUMT","Million of national currency units","SVN","Slovenia","2021","2021",613.2,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","MLLNCUMT","Million of national currency units","SVN","Slovenia","2022","2022",679.5,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","MTMOTCMT","Million US$ at exchange rate","SVN","Slovenia","2010","2010",628.9,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","MTMOTCMT","Million US$ at exchange rate","SVN","Slovenia","2011","2011",654.3,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","MTMOTCMT","Million US$ at exchange rate","SVN","Slovenia","2012","2012",583.8,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","MTMOTCMT","Million US$ at exchange rate","SVN","Slovenia","2013","2013",599.1,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","MTMOTCMT","Million US$ at exchange rate","SVN","Slovenia","2014","2014",574.3,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","MTMOTCMT","Million US$ at exchange rate","SVN","Slovenia","2015","2015",494.9,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","MTMOTCMT","Million US$ at exchange rate","SVN","Slovenia","2016","2016",516.6,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","MTMOTCMT","Million US$ at exchange rate","SVN","Slovenia","2017","2017",547,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","MTMOTCMT","Million US$ at exchange rate","SVN","Slovenia","2018","2018",610.2,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","MTMOTCMT","Million US$ at exchange rate","SVN","Slovenia","2019","2019",606.9,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","MTMOTCMT","Million US$ at exchange rate","SVN","Slovenia","2020","2020",649,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","MTMOTCMT","Million US$ at exchange rate","SVN","Slovenia","2021","2021",725.3,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","MTMOTCMT","Million US$ at exchange rate","SVN","Slovenia","2022","2022",715.5,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","MTMOPPMT","Million US$, purchasing power parity","SVN","Slovenia","2010","2010",743.6,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","MTMOPPMT","Million US$, purchasing power parity","SVN","Slovenia","2011","2011",753.3,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","MTMOPPMT","Million US$, purchasing power parity","SVN","Slovenia","2012","2012",748.8,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","MTMOPPMT","Million US$, purchasing power parity","SVN","Slovenia","2013","2013",764,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","MTMOPPMT","Million US$, purchasing power parity","SVN","Slovenia","2014","2014",731.2,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","MTMOPPMT","Million US$, purchasing power parity","SVN","Slovenia","2015","2015",749.3,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","MTMOPPMT","Million US$, purchasing power parity","SVN","Slovenia","2016","2016",808.7,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","MTMOPPMT","Million US$, purchasing power parity","SVN","Slovenia","2017","2017",849.3,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","MTMOPPMT","Million US$, purchasing power parity","SVN","Slovenia","2018","2018",910.4,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","MTMOPPMT","Million US$, purchasing power parity","SVN","Slovenia","2019","2019",981.8,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","MTMOPPMT","Million US$, purchasing power parity","SVN","Slovenia","2020","2020",1038.5,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","MTMOPPMT","Million US$, purchasing power parity","SVN","Slovenia","2021","2021",1088.9,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","MTMOPPMT","Million US$, purchasing power parity","SVN","Slovenia","2022","2022",1231.8,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","TCPPERMT","/capita, US$ exchange rate","SVN","Slovenia","2010","2010",307,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","TCPPERMT","/capita, US$ exchange rate","SVN","Slovenia","2011","2011",318.7,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","TCPPERMT","/capita, US$ exchange rate","SVN","Slovenia","2012","2012",283.8,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","TCPPERMT","/capita, US$ exchange rate","SVN","Slovenia","2013","2013",290.8,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","TCPPERMT","/capita, US$ exchange rate","SVN","Slovenia","2014","2014",278.5,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","TCPPERMT","/capita, US$ exchange rate","SVN","Slovenia","2015","2015",239.8,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","TCPPERMT","/capita, US$ exchange rate","SVN","Slovenia","2016","2016",250.2,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","TCPPERMT","/capita, US$ exchange rate","SVN","Slovenia","2017","2017",264.7,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","TCPPERMT","/capita, US$ exchange rate","SVN","Slovenia","2018","2018",294.2,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","TCPPERMT","/capita, US$ exchange rate","SVN","Slovenia","2019","2019",290.6,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","TCPPERMT","/capita, US$ exchange rate","SVN","Slovenia","2020","2020",308.7,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","TCPPERMT","/capita, US$ exchange rate","SVN","Slovenia","2021","2021",344.1,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","TCPPERMT","/capita, US$ exchange rate","SVN","Slovenia","2022","2022",339.6,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2010","2010",363,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2011","2011",367,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2012","2012",364,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2013","2013",370.9,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2014","2014",354.6,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2015","2015",363.1,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2016","2016",391.6,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2017","2017",411,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2018","2018",439,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2019","2019",470.1,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2020","2020",493.9,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2021","2021",516.5,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2022","2022",584.6,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","MLLNCUMT","Million of national currency units","AUS","Australia","2010","2010",1227,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","MLLNCUMT","Million of national currency units","AUS","Australia","2011","2011",1218,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","MLLNCUMT","Million of national currency units","AUS","Australia","2012","2012",1214,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","MLLNCUMT","Million of national currency units","AUS","Australia","2013","2013",1399,"B; D","Break; Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","MLLNCUMT","Million of national currency units","AUS","Australia","2014","2014",1351,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","MLLNCUMT","Million of national currency units","AUS","Australia","2015","2015",1353,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","MLLNCUMT","Million of national currency units","AUS","Australia","2016","2016",1383,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","MLLNCUMT","Million of national currency units","AUS","Australia","2017","2017",1424,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","MLLNCUMT","Million of national currency units","AUS","Australia","2018","2018",1410,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","MLLNCUMT","Million of national currency units","AUS","Australia","2019","2019",1415,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","MLLNCUMT","Million of national currency units","AUS","Australia","2020","2020",1493,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","MLLNCUMT","Million of national currency units","AUS","Australia","2021","2021",1634,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","MTMOTCMT","Million US$ at exchange rate","AUS","Australia","2010","2010",1125.5,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","MTMOTCMT","Million US$ at exchange rate","AUS","Australia","2011","2011",1256.4,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","MTMOTCMT","Million US$ at exchange rate","AUS","Australia","2012","2012",1257,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","MTMOTCMT","Million US$ at exchange rate","AUS","Australia","2013","2013",1350.6,"B; D","Break; Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","MTMOTCMT","Million US$ at exchange rate","AUS","Australia","2014","2014",1217.8,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","MTMOTCMT","Million US$ at exchange rate","AUS","Australia","2015","2015",1016.5,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","MTMOTCMT","Million US$ at exchange rate","AUS","Australia","2016","2016",1028.1,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","MTMOTCMT","Million US$ at exchange rate","AUS","Australia","2017","2017",1091.4,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","MTMOTCMT","Million US$ at exchange rate","AUS","Australia","2018","2018",1053.5,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","MTMOTCMT","Million US$ at exchange rate","AUS","Australia","2019","2019",983.7,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","MTMOTCMT","Million US$ at exchange rate","AUS","Australia","2020","2020",1027.5,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","MTMOTCMT","Million US$ at exchange rate","AUS","Australia","2021","2021",1227.4,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","MTMOPPMT","Million US$, purchasing power parity","AUS","Australia","2010","2010",816,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","MTMOPPMT","Million US$, purchasing power parity","AUS","Australia","2011","2011",806.1,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","MTMOPPMT","Million US$, purchasing power parity","AUS","Australia","2012","2012",788.3,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","MTMOPPMT","Million US$, purchasing power parity","AUS","Australia","2013","2013",966.7,"B; D","Break; Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","MTMOPPMT","Million US$, purchasing power parity","AUS","Australia","2014","2014",930.1,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","MTMOPPMT","Million US$, purchasing power parity","AUS","Australia","2015","2015",918.1,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","MTMOPPMT","Million US$, purchasing power parity","AUS","Australia","2016","2016",953.7,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","MTMOPPMT","Million US$, purchasing power parity","AUS","Australia","2017","2017",963.8,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","MTMOPPMT","Million US$, purchasing power parity","AUS","Australia","2018","2018",958.9,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","MTMOPPMT","Million US$, purchasing power parity","AUS","Australia","2019","2019",956.2,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","MTMOPPMT","Million US$, purchasing power parity","AUS","Australia","2020","2020",1026.9,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","MTMOPPMT","Million US$, purchasing power parity","AUS","Australia","2021","2021",1128.8,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","TCPPERMT","/capita, US$ exchange rate","AUS","Australia","2010","2010",51.1,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","TCPPERMT","/capita, US$ exchange rate","AUS","Australia","2011","2011",56.2,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","TCPPERMT","/capita, US$ exchange rate","AUS","Australia","2012","2012",55.3,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","TCPPERMT","/capita, US$ exchange rate","AUS","Australia","2013","2013",58.4,"B; D","Break; Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","TCPPERMT","/capita, US$ exchange rate","AUS","Australia","2014","2014",51.9,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","TCPPERMT","/capita, US$ exchange rate","AUS","Australia","2015","2015",42.7,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","TCPPERMT","/capita, US$ exchange rate","AUS","Australia","2016","2016",42.5,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","TCPPERMT","/capita, US$ exchange rate","AUS","Australia","2017","2017",44.4,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","TCPPERMT","/capita, US$ exchange rate","AUS","Australia","2018","2018",42.2,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","TCPPERMT","/capita, US$ exchange rate","AUS","Australia","2019","2019",38.8,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","TCPPERMT","/capita, US$ exchange rate","AUS","Australia","2020","2020",40,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","TCPPERMT","/capita, US$ exchange rate","AUS","Australia","2021","2021",47.8,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2010","2010",37,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2011","2011",36.1,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2012","2012",34.7,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2013","2013",41.8,"B; D","Break; Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2014","2014",39.6,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2015","2015",38.5,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2016","2016",39.4,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2017","2017",39.2,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2018","2018",38.4,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2019","2019",37.7,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2020","2020",40,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2021","2021",43.9,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","ATCPTTMT","% of total sales","AUS","Australia","2010","2010",12.5,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","ATCPTTMT","% of total sales","AUS","Australia","2011","2011",11.9,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","ATCPTTMT","% of total sales","AUS","Australia","2012","2012",11.7,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","ATCPTTMT","% of total sales","AUS","Australia","2013","2013",11.8,"B; D","Break; Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","ATCPTTMT","% of total sales","AUS","Australia","2014","2014",11.4,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","ATCPTTMT","% of total sales","AUS","Australia","2015","2015",11,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","ATCPTTMT","% of total sales","AUS","Australia","2016","2016",9,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","ATCPTTMT","% of total sales","AUS","Australia","2017","2017",9.6,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","ATCPTTMT","% of total sales","AUS","Australia","2018","2018",9.5,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","ATCPTTMT","% of total sales","AUS","Australia","2019","2019",9.1,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","ATCPTTMT","% of total sales","AUS","Australia","2020","2020",9,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","ATCPTTMT","% of total sales","AUS","Australia","2021","2021",9.3,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","MLLNCUMT","Million of national currency units","AUT","Austria","2010","2010",274.4,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","MLLNCUMT","Million of national currency units","AUT","Austria","2011","2011",272.4,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","MLLNCUMT","Million of national currency units","AUT","Austria","2012","2012",273,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","MLLNCUMT","Million of national currency units","AUT","Austria","2013","2013",275.5,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","MLLNCUMT","Million of national currency units","AUT","Austria","2014","2014",287.1,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","MLLNCUMT","Million of national currency units","AUT","Austria","2015","2015",297.1,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","MLLNCUMT","Million of national currency units","AUT","Austria","2016","2016",296.9,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","MLLNCUMT","Million of national currency units","AUT","Austria","2017","2017",304.2,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","MLLNCUMT","Million of national currency units","AUT","Austria","2018","2018",316.3,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","MLLNCUMT","Million of national currency units","AUT","Austria","2019","2019",343,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","MLLNCUMT","Million of national currency units","AUT","Austria","2020","2020",368.1,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","MLLNCUMT","Million of national currency units","AUT","Austria","2021","2021",391.2,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","MTMOTCMT","Million US$ at exchange rate","AUT","Austria","2010","2010",363.8,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","MTMOTCMT","Million US$ at exchange rate","AUT","Austria","2011","2011",379.2,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","MTMOTCMT","Million US$ at exchange rate","AUT","Austria","2012","2012",350.8,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","MTMOTCMT","Million US$ at exchange rate","AUT","Austria","2013","2013",365.9,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","MTMOTCMT","Million US$ at exchange rate","AUT","Austria","2014","2014",381.4,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","MTMOTCMT","Million US$ at exchange rate","AUT","Austria","2015","2015",329.7,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","MTMOTCMT","Million US$ at exchange rate","AUT","Austria","2016","2016",328.7,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","MTMOTCMT","Million US$ at exchange rate","AUT","Austria","2017","2017",343.6,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","MTMOTCMT","Million US$ at exchange rate","AUT","Austria","2018","2018",373.5,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","MTMOTCMT","Million US$ at exchange rate","AUT","Austria","2019","2019",384,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","MTMOTCMT","Million US$ at exchange rate","AUT","Austria","2020","2020",420.5,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","MTMOTCMT","Million US$ at exchange rate","AUT","Austria","2021","2021",462.7,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","MTMOPPMT","Million US$, purchasing power parity","AUT","Austria","2010","2010",325.9,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","MTMOPPMT","Million US$, purchasing power parity","AUT","Austria","2011","2011",327.7,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","MTMOPPMT","Million US$, purchasing power parity","AUT","Austria","2012","2012",335.6,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","MTMOPPMT","Million US$, purchasing power parity","AUT","Austria","2013","2013",345.6,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","MTMOPPMT","Million US$, purchasing power parity","AUT","Austria","2014","2014",359.4,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","MTMOPPMT","Million US$, purchasing power parity","AUT","Austria","2015","2015",372,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","MTMOPPMT","Million US$, purchasing power parity","AUT","Austria","2016","2016",382.2,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","MTMOPPMT","Million US$, purchasing power parity","AUT","Austria","2017","2017",392.5,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","MTMOPPMT","Million US$, purchasing power parity","AUT","Austria","2018","2018",413.2,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","MTMOPPMT","Million US$, purchasing power parity","AUT","Austria","2019","2019",457.8,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","MTMOPPMT","Million US$, purchasing power parity","AUT","Austria","2020","2020",493.3,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","MTMOPPMT","Million US$, purchasing power parity","AUT","Austria","2021","2021",517.2,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","TCPPERMT","/capita, US$ exchange rate","AUT","Austria","2010","2010",43.5,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","TCPPERMT","/capita, US$ exchange rate","AUT","Austria","2011","2011",45.2,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","TCPPERMT","/capita, US$ exchange rate","AUT","Austria","2012","2012",41.6,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","TCPPERMT","/capita, US$ exchange rate","AUT","Austria","2013","2013",43.1,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","TCPPERMT","/capita, US$ exchange rate","AUT","Austria","2014","2014",44.6,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","TCPPERMT","/capita, US$ exchange rate","AUT","Austria","2015","2015",38.1,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","TCPPERMT","/capita, US$ exchange rate","AUT","Austria","2016","2016",37.6,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","TCPPERMT","/capita, US$ exchange rate","AUT","Austria","2017","2017",39.1,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","TCPPERMT","/capita, US$ exchange rate","AUT","Austria","2018","2018",42.2,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","TCPPERMT","/capita, US$ exchange rate","AUT","Austria","2019","2019",43.2,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","TCPPERMT","/capita, US$ exchange rate","AUT","Austria","2020","2020",47.2,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","TCPPERMT","/capita, US$ exchange rate","AUT","Austria","2021","2021",51.7,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2010","2010",39,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2011","2011",39,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2012","2012",39.8,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2013","2013",40.8,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2014","2014",42,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2015","2015",43,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2016","2016",43.7,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2017","2017",44.6,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2018","2018",46.7,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2019","2019",51.6,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2020","2020",55.3,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2021","2021",57.8,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","ATCPTTMT","% of total sales","AUT","Austria","2010","2010",11,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","ATCPTTMT","% of total sales","AUT","Austria","2011","2011",10.7,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","ATCPTTMT","% of total sales","AUT","Austria","2012","2012",10.4,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","ATCPTTMT","% of total sales","AUT","Austria","2013","2013",10.5,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","ATCPTTMT","% of total sales","AUT","Austria","2014","2014",10.3,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","ATCPTTMT","% of total sales","AUT","Austria","2015","2015",10.1,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","ATCPTTMT","% of total sales","AUT","Austria","2016","2016",9.9,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","ATCPTTMT","% of total sales","AUT","Austria","2017","2017",9.7,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","ATCPTTMT","% of total sales","AUT","Austria","2018","2018",9.8,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","ATCPTTMT","% of total sales","AUT","Austria","2019","2019",10.4,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","ATCPTTMT","% of total sales","AUT","Austria","2020","2020",10.6,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","ATCPTTMT","% of total sales","AUT","Austria","2021","2021",10.5,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","MLLNCUMT","Million of national currency units","BEL","Belgium","2010","2010",627,,
+"PATCALIM","A-Alimentary tract and metabolism","MLLNCUMT","Million of national currency units","BEL","Belgium","2011","2011",647.7,,
+"PATCALIM","A-Alimentary tract and metabolism","MLLNCUMT","Million of national currency units","BEL","Belgium","2012","2012",647.4,,
+"PATCALIM","A-Alimentary tract and metabolism","MLLNCUMT","Million of national currency units","BEL","Belgium","2013","2013",649.7,,
+"PATCALIM","A-Alimentary tract and metabolism","MLLNCUMT","Million of national currency units","BEL","Belgium","2014","2014",633.4,,
+"PATCALIM","A-Alimentary tract and metabolism","MLLNCUMT","Million of national currency units","BEL","Belgium","2015","2015",651.4,,
+"PATCALIM","A-Alimentary tract and metabolism","MLLNCUMT","Million of national currency units","BEL","Belgium","2016","2016",677.6,,
+"PATCALIM","A-Alimentary tract and metabolism","MLLNCUMT","Million of national currency units","BEL","Belgium","2017","2017",697.5,,
+"PATCALIM","A-Alimentary tract and metabolism","MLLNCUMT","Million of national currency units","BEL","Belgium","2018","2018",699.1,,
+"PATCALIM","A-Alimentary tract and metabolism","MLLNCUMT","Million of national currency units","BEL","Belgium","2019","2019",750.8,,
+"PATCALIM","A-Alimentary tract and metabolism","MLLNCUMT","Million of national currency units","BEL","Belgium","2020","2020",772.2,,
+"PATCALIM","A-Alimentary tract and metabolism","MLLNCUMT","Million of national currency units","BEL","Belgium","2021","2021",802.4,,
+"PATCALIM","A-Alimentary tract and metabolism","MLLNCUMT","Million of national currency units","BEL","Belgium","2022","2022",876.6,"E","Estimated value"
+"PATCALIM","A-Alimentary tract and metabolism","MTMOTCMT","Million US$ at exchange rate","BEL","Belgium","2010","2010",831.3,,
+"PATCALIM","A-Alimentary tract and metabolism","MTMOTCMT","Million US$ at exchange rate","BEL","Belgium","2011","2011",901.6,,
+"PATCALIM","A-Alimentary tract and metabolism","MTMOTCMT","Million US$ at exchange rate","BEL","Belgium","2012","2012",831.8,,
+"PATCALIM","A-Alimentary tract and metabolism","MTMOTCMT","Million US$ at exchange rate","BEL","Belgium","2013","2013",862.9,,
+"PATCALIM","A-Alimentary tract and metabolism","MTMOTCMT","Million US$ at exchange rate","BEL","Belgium","2014","2014",841.4,,
+"PATCALIM","A-Alimentary tract and metabolism","MTMOTCMT","Million US$ at exchange rate","BEL","Belgium","2015","2015",722.7,,
+"PATCALIM","A-Alimentary tract and metabolism","MTMOTCMT","Million US$ at exchange rate","BEL","Belgium","2016","2016",750.1,,
+"PATCALIM","A-Alimentary tract and metabolism","MTMOTCMT","Million US$ at exchange rate","BEL","Belgium","2017","2017",788,,
+"PATCALIM","A-Alimentary tract and metabolism","MTMOTCMT","Million US$ at exchange rate","BEL","Belgium","2018","2018",825.6,,
+"PATCALIM","A-Alimentary tract and metabolism","MTMOTCMT","Million US$ at exchange rate","BEL","Belgium","2019","2019",840.5,,
+"PATCALIM","A-Alimentary tract and metabolism","MTMOTCMT","Million US$ at exchange rate","BEL","Belgium","2020","2020",882,,
+"PATCALIM","A-Alimentary tract and metabolism","MTMOTCMT","Million US$ at exchange rate","BEL","Belgium","2021","2021",949,,
+"PATCALIM","A-Alimentary tract and metabolism","MTMOTCMT","Million US$ at exchange rate","BEL","Belgium","2022","2022",923.1,"E","Estimated value"
+"PATCALIM","A-Alimentary tract and metabolism","MTMOPPMT","Million US$, purchasing power parity","BEL","Belgium","2010","2010",749.5,,
+"PATCALIM","A-Alimentary tract and metabolism","MTMOPPMT","Million US$, purchasing power parity","BEL","Belgium","2011","2011",778.6,,
+"PATCALIM","A-Alimentary tract and metabolism","MTMOPPMT","Million US$, purchasing power parity","BEL","Belgium","2012","2012",787.5,,
+"PATCALIM","A-Alimentary tract and metabolism","MTMOPPMT","Million US$, purchasing power parity","BEL","Belgium","2013","2013",805.9,,
+"PATCALIM","A-Alimentary tract and metabolism","MTMOPPMT","Million US$, purchasing power parity","BEL","Belgium","2014","2014",791.5,,
+"PATCALIM","A-Alimentary tract and metabolism","MTMOPPMT","Million US$, purchasing power parity","BEL","Belgium","2015","2015",814.2,,
+"PATCALIM","A-Alimentary tract and metabolism","MTMOPPMT","Million US$, purchasing power parity","BEL","Belgium","2016","2016",867.6,,
+"PATCALIM","A-Alimentary tract and metabolism","MTMOPPMT","Million US$, purchasing power parity","BEL","Belgium","2017","2017",899.3,,
+"PATCALIM","A-Alimentary tract and metabolism","MTMOPPMT","Million US$, purchasing power parity","BEL","Belgium","2018","2018",912.2,,
+"PATCALIM","A-Alimentary tract and metabolism","MTMOPPMT","Million US$, purchasing power parity","BEL","Belgium","2019","2019",1005.6,,
+"PATCALIM","A-Alimentary tract and metabolism","MTMOPPMT","Million US$, purchasing power parity","BEL","Belgium","2020","2020",1057.4,,
+"PATCALIM","A-Alimentary tract and metabolism","MTMOPPMT","Million US$, purchasing power parity","BEL","Belgium","2021","2021",1089.2,,
+"PATCALIM","A-Alimentary tract and metabolism","MTMOPPMT","Million US$, purchasing power parity","BEL","Belgium","2022","2022",1227.8,"E","Estimated value"
+"PATCALIM","A-Alimentary tract and metabolism","TCPPERMT","/capita, US$ exchange rate","BEL","Belgium","2010","2010",76.3,,
+"PATCALIM","A-Alimentary tract and metabolism","TCPPERMT","/capita, US$ exchange rate","BEL","Belgium","2011","2011",81.7,,
+"PATCALIM","A-Alimentary tract and metabolism","TCPPERMT","/capita, US$ exchange rate","BEL","Belgium","2012","2012",74.9,,
+"PATCALIM","A-Alimentary tract and metabolism","TCPPERMT","/capita, US$ exchange rate","BEL","Belgium","2013","2013",77.3,,
+"PATCALIM","A-Alimentary tract and metabolism","TCPPERMT","/capita, US$ exchange rate","BEL","Belgium","2014","2014",75.1,,
+"PATCALIM","A-Alimentary tract and metabolism","TCPPERMT","/capita, US$ exchange rate","BEL","Belgium","2015","2015",64.1,,
+"PATCALIM","A-Alimentary tract and metabolism","TCPPERMT","/capita, US$ exchange rate","BEL","Belgium","2016","2016",66.2,,
+"PATCALIM","A-Alimentary tract and metabolism","TCPPERMT","/capita, US$ exchange rate","BEL","Belgium","2017","2017",69.3,,
+"PATCALIM","A-Alimentary tract and metabolism","TCPPERMT","/capita, US$ exchange rate","BEL","Belgium","2018","2018",72.3,,
+"PATCALIM","A-Alimentary tract and metabolism","TCPPERMT","/capita, US$ exchange rate","BEL","Belgium","2019","2019",73.2,,
+"PATCALIM","A-Alimentary tract and metabolism","TCPPERMT","/capita, US$ exchange rate","BEL","Belgium","2020","2020",76.4,,
+"PATCALIM","A-Alimentary tract and metabolism","TCPPERMT","/capita, US$ exchange rate","BEL","Belgium","2021","2021",81.9,,
+"PATCALIM","A-Alimentary tract and metabolism","TCPPERMT","/capita, US$ exchange rate","BEL","Belgium","2022","2022",79.5,"E","Estimated value"
+"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2010","2010",68.8,,
+"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2011","2011",70.5,,
+"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2012","2012",70.9,,
+"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2013","2013",72.2,,
+"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2014","2014",70.6,,
+"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2015","2015",72.2,,
+"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2016","2016",76.6,,
+"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2017","2017",79.1,,
+"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2018","2018",79.8,,
+"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2019","2019",87.5,,
+"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2020","2020",91.6,,
+"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2021","2021",94,,
+"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2022","2022",105.7,"E","Estimated value"
+"PATCALIM","A-Alimentary tract and metabolism","ATCPTTMT","% of total sales","BEL","Belgium","2010","2010",10.7,,
+"PATCALIM","A-Alimentary tract and metabolism","ATCPTTMT","% of total sales","BEL","Belgium","2011","2011",10.8,,
+"PATCALIM","A-Alimentary tract and metabolism","ATCPTTMT","% of total sales","BEL","Belgium","2012","2012",10.9,,
+"PATCALIM","A-Alimentary tract and metabolism","ATCPTTMT","% of total sales","BEL","Belgium","2013","2013",10.9,,
+"PATCALIM","A-Alimentary tract and metabolism","ATCPTTMT","% of total sales","BEL","Belgium","2014","2014",10.6,,
+"PATCALIM","A-Alimentary tract and metabolism","ATCPTTMT","% of total sales","BEL","Belgium","2015","2015",10.5,,
+"PATCALIM","A-Alimentary tract and metabolism","ATCPTTMT","% of total sales","BEL","Belgium","2016","2016",10.9,,
+"PATCALIM","A-Alimentary tract and metabolism","ATCPTTMT","% of total sales","BEL","Belgium","2017","2017",10.7,,
+"PATCALIM","A-Alimentary tract and metabolism","ATCPTTMT","% of total sales","BEL","Belgium","2018","2018",10.5,,
+"PATCALIM","A-Alimentary tract and metabolism","ATCPTTMT","% of total sales","BEL","Belgium","2019","2019",10.2,,
+"PATCALIM","A-Alimentary tract and metabolism","ATCPTTMT","% of total sales","BEL","Belgium","2020","2020",10.1,,
+"PATCALIM","A-Alimentary tract and metabolism","ATCPTTMT","% of total sales","BEL","Belgium","2021","2021",10,,
+"PATCALIM","A-Alimentary tract and metabolism","ATCPTTMT","% of total sales","BEL","Belgium","2022","2022",9.7,"E","Estimated value"
+"PATCALIM","A-Alimentary tract and metabolism","MLLNCUMT","Million of national currency units","CAN","Canada","2012","2012",3199.5,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","MLLNCUMT","Million of national currency units","CAN","Canada","2013","2013",3245.2,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","MLLNCUMT","Million of national currency units","CAN","Canada","2014","2014",3377.5,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","MLLNCUMT","Million of national currency units","CAN","Canada","2015","2015",3825,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","MLLNCUMT","Million of national currency units","CAN","Canada","2016","2016",3822.6,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","MLLNCUMT","Million of national currency units","CAN","Canada","2017","2017",4045.8,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","MLLNCUMT","Million of national currency units","CAN","Canada","2018","2018",4288.4,"E; B; D","Estimated value; Break; Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","MLLNCUMT","Million of national currency units","CAN","Canada","2019","2019",4648.8,"E; D","Estimated value; Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","MLLNCUMT","Million of national currency units","CAN","Canada","2020","2020",5292.6,"E; D","Estimated value; Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","MLLNCUMT","Million of national currency units","CAN","Canada","2021","2021",5971.9,"E; D","Estimated value; Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","MLLNCUMT","Million of national currency units","CAN","Canada","2022","2022",6932.4,"E; D","Estimated value; Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","MTMOTCMT","Million US$ at exchange rate","CAN","Canada","2012","2012",3201.5,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","MTMOTCMT","Million US$ at exchange rate","CAN","Canada","2013","2013",3150.3,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","MTMOTCMT","Million US$ at exchange rate","CAN","Canada","2014","2014",3057.3,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","MTMOTCMT","Million US$ at exchange rate","CAN","Canada","2015","2015",2991.1,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","MTMOTCMT","Million US$ at exchange rate","CAN","Canada","2016","2016",2883.6,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","MTMOTCMT","Million US$ at exchange rate","CAN","Canada","2017","2017",3117.1,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","MTMOTCMT","Million US$ at exchange rate","CAN","Canada","2018","2018",3309.4,"E; B; D","Estimated value; Break; Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","MTMOTCMT","Million US$ at exchange rate","CAN","Canada","2019","2019",3503.8,"E; D","Estimated value; Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","MTMOTCMT","Million US$ at exchange rate","CAN","Canada","2020","2020",3946.3,"E; D","Estimated value; Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","MTMOTCMT","Million US$ at exchange rate","CAN","Canada","2021","2021",4762.7,"E; D","Estimated value; Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","MTMOTCMT","Million US$ at exchange rate","CAN","Canada","2022","2022",5326.3,"E; D","Estimated value; Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","MTMOPPMT","Million US$, purchasing power parity","CAN","Canada","2012","2012",2570.7,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","MTMOPPMT","Million US$, purchasing power parity","CAN","Canada","2013","2013",2651.3,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","MTMOPPMT","Million US$, purchasing power parity","CAN","Canada","2014","2014",2745.1,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","MTMOPPMT","Million US$, purchasing power parity","CAN","Canada","2015","2015",3064.8,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","MTMOPPMT","Million US$, purchasing power parity","CAN","Canada","2016","2016",3166.9,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","MTMOPPMT","Million US$, purchasing power parity","CAN","Canada","2017","2017",3337.3,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","MTMOPPMT","Million US$, purchasing power parity","CAN","Canada","2018","2018",3554.3,"E; B; D","Estimated value; Break; Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","MTMOPPMT","Million US$, purchasing power parity","CAN","Canada","2019","2019",3765.1,"E; D","Estimated value; Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","MTMOPPMT","Million US$, purchasing power parity","CAN","Canada","2020","2020",4299.2,"E; D","Estimated value; Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","MTMOPPMT","Million US$, purchasing power parity","CAN","Canada","2021","2021",4823.2,"E; D","Estimated value; Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","MTMOPPMT","Million US$, purchasing power parity","CAN","Canada","2022","2022",5529,"E; D","Estimated value; Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","TCPPERMT","/capita, US$ exchange rate","CAN","Canada","2012","2012",92.2,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","TCPPERMT","/capita, US$ exchange rate","CAN","Canada","2013","2013",89.8,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","TCPPERMT","/capita, US$ exchange rate","CAN","Canada","2014","2014",86.3,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","TCPPERMT","/capita, US$ exchange rate","CAN","Canada","2015","2015",83.8,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","TCPPERMT","/capita, US$ exchange rate","CAN","Canada","2016","2016",79.9,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","TCPPERMT","/capita, US$ exchange rate","CAN","Canada","2017","2017",85.3,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","TCPPERMT","/capita, US$ exchange rate","CAN","Canada","2018","2018",89.3,"E; B; D","Estimated value; Break; Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","TCPPERMT","/capita, US$ exchange rate","CAN","Canada","2019","2019",93.2,"E; D","Estimated value; Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","TCPPERMT","/capita, US$ exchange rate","CAN","Canada","2020","2020",103.7,"E; D","Estimated value; Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","TCPPERMT","/capita, US$ exchange rate","CAN","Canada","2021","2021",124.5,"E; D","Estimated value; Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","TCPPERMT","/capita, US$ exchange rate","CAN","Canada","2022","2022",137,"E; D","Estimated value; Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2012","2012",74.1,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2013","2013",75.6,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2014","2014",77.5,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2015","2015",85.8,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2016","2016",87.7,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2017","2017",91.3,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2018","2018",95.9,"E; B; D","Estimated value; Break; Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2019","2019",100.1,"E; D","Estimated value; Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2020","2020",113,"E; D","Estimated value; Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2021","2021",126.1,"E; D","Estimated value; Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2022","2022",142.2,"E; D","Estimated value; Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","ATCPTTMT","% of total sales","CAN","Canada","2012","2012",13.2,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","ATCPTTMT","% of total sales","CAN","Canada","2013","2013",13.2,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","ATCPTTMT","% of total sales","CAN","Canada","2014","2014",13.2,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","ATCPTTMT","% of total sales","CAN","Canada","2015","2015",14.1,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","ATCPTTMT","% of total sales","CAN","Canada","2016","2016",13.5,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","ATCPTTMT","% of total sales","CAN","Canada","2017","2017",13.6,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","ATCPTTMT","% of total sales","CAN","Canada","2018","2018",14,"E; B; D","Estimated value; Break; Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","ATCPTTMT","% of total sales","CAN","Canada","2019","2019",14.6,"E; D","Estimated value; Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","ATCPTTMT","% of total sales","CAN","Canada","2020","2020",15.4,"E; D","Estimated value; Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","ATCPTTMT","% of total sales","CAN","Canada","2021","2021",16.2,"E; D","Estimated value; Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","ATCPTTMT","% of total sales","CAN","Canada","2022","2022",17.4,"E; D","Estimated value; Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","MLLNCUMT","Million of national currency units","CZE","Czech Republic","2010","2010",8968.6,,
+"PATCALIM","A-Alimentary tract and metabolism","MLLNCUMT","Million of national currency units","CZE","Czech Republic","2011","2011",9060.3,,
+"PATCALIM","A-Alimentary tract and metabolism","MLLNCUMT","Million of national currency units","CZE","Czech Republic","2012","2012",9641.7,,
+"PATCALIM","A-Alimentary tract and metabolism","MLLNCUMT","Million of national currency units","CZE","Czech Republic","2013","2013",9350.8,,
+"PATCALIM","A-Alimentary tract and metabolism","MLLNCUMT","Million of national currency units","CZE","Czech Republic","2014","2014",9917.4,,
+"PATCALIM","A-Alimentary tract and metabolism","MLLNCUMT","Million of national currency units","CZE","Czech Republic","2015","2015",10350,,
+"PATCALIM","A-Alimentary tract and metabolism","MLLNCUMT","Million of national currency units","CZE","Czech Republic","2016","2016",11002.3,,
+"PATCALIM","A-Alimentary tract and metabolism","MLLNCUMT","Million of national currency units","CZE","Czech Republic","2017","2017",11476.3,,
+"PATCALIM","A-Alimentary tract and metabolism","MLLNCUMT","Million of national currency units","CZE","Czech Republic","2018","2018",12131.3,,
+"PATCALIM","A-Alimentary tract and metabolism","MLLNCUMT","Million of national currency units","CZE","Czech Republic","2019","2019",12817.6,,
+"PATCALIM","A-Alimentary tract and metabolism","MLLNCUMT","Million of national currency units","CZE","Czech Republic","2020","2020",11067.1,"B","Break"
+"PATCALIM","A-Alimentary tract and metabolism","MLLNCUMT","Million of national currency units","CZE","Czech Republic","2021","2021",11646.5,,
+"PATCALIM","A-Alimentary tract and metabolism","MTMOTCMT","Million US$ at exchange rate","CZE","Czech Republic","2010","2010",469.6,,
+"PATCALIM","A-Alimentary tract and metabolism","MTMOTCMT","Million US$ at exchange rate","CZE","Czech Republic","2011","2011",512,,
+"PATCALIM","A-Alimentary tract and metabolism","MTMOTCMT","Million US$ at exchange rate","CZE","Czech Republic","2012","2012",492.5,,
+"PATCALIM","A-Alimentary tract and metabolism","MTMOTCMT","Million US$ at exchange rate","CZE","Czech Republic","2013","2013",477.8,,
+"PATCALIM","A-Alimentary tract and metabolism","MTMOTCMT","Million US$ at exchange rate","CZE","Czech Republic","2014","2014",477.8,,
+"PATCALIM","A-Alimentary tract and metabolism","MTMOTCMT","Million US$ at exchange rate","CZE","Czech Republic","2015","2015",420.8,,
+"PATCALIM","A-Alimentary tract and metabolism","MTMOTCMT","Million US$ at exchange rate","CZE","Czech Republic","2016","2016",450.2,,
+"PATCALIM","A-Alimentary tract and metabolism","MTMOTCMT","Million US$ at exchange rate","CZE","Czech Republic","2017","2017",490.9,,
+"PATCALIM","A-Alimentary tract and metabolism","MTMOTCMT","Million US$ at exchange rate","CZE","Czech Republic","2018","2018",558.3,,
+"PATCALIM","A-Alimentary tract and metabolism","MTMOTCMT","Million US$ at exchange rate","CZE","Czech Republic","2019","2019",558.9,,
+"PATCALIM","A-Alimentary tract and metabolism","MTMOTCMT","Million US$ at exchange rate","CZE","Czech Republic","2020","2020",476.8,"B","Break"
+"PATCALIM","A-Alimentary tract and metabolism","MTMOTCMT","Million US$ at exchange rate","CZE","Czech Republic","2021","2021",537.2,,
+"PATCALIM","A-Alimentary tract and metabolism","MTMOPPMT","Million US$, purchasing power parity","CZE","Czech Republic","2010","2010",656,,
+"PATCALIM","A-Alimentary tract and metabolism","MTMOPPMT","Million US$, purchasing power parity","CZE","Czech Republic","2011","2011",678.9,,
+"PATCALIM","A-Alimentary tract and metabolism","MTMOPPMT","Million US$, purchasing power parity","CZE","Czech Republic","2012","2012",725.1,,
+"PATCALIM","A-Alimentary tract and metabolism","MTMOPPMT","Million US$, purchasing power parity","CZE","Czech Republic","2013","2013",731.4,,
+"PATCALIM","A-Alimentary tract and metabolism","MTMOPPMT","Million US$, purchasing power parity","CZE","Czech Republic","2014","2014",780.7,,
+"PATCALIM","A-Alimentary tract and metabolism","MTMOPPMT","Million US$, purchasing power parity","CZE","Czech Republic","2015","2015",800,,
+"PATCALIM","A-Alimentary tract and metabolism","MTMOPPMT","Million US$, purchasing power parity","CZE","Czech Republic","2016","2016",874.8,,
+"PATCALIM","A-Alimentary tract and metabolism","MTMOPPMT","Million US$, purchasing power parity","CZE","Czech Republic","2017","2017",923.6,,
+"PATCALIM","A-Alimentary tract and metabolism","MTMOPPMT","Million US$, purchasing power parity","CZE","Czech Republic","2018","2018",980.6,,
+"PATCALIM","A-Alimentary tract and metabolism","MTMOPPMT","Million US$, purchasing power parity","CZE","Czech Republic","2019","2019",1044.3,,
+"PATCALIM","A-Alimentary tract and metabolism","MTMOPPMT","Million US$, purchasing power parity","CZE","Czech Republic","2020","2020",888.1,"B","Break"
+"PATCALIM","A-Alimentary tract and metabolism","MTMOPPMT","Million US$, purchasing power parity","CZE","Czech Republic","2021","2021",914,,
+"PATCALIM","A-Alimentary tract and metabolism","TCPPERMT","/capita, US$ exchange rate","CZE","Czech Republic","2010","2010",44.8,,
+"PATCALIM","A-Alimentary tract and metabolism","TCPPERMT","/capita, US$ exchange rate","CZE","Czech Republic","2011","2011",48.8,,
+"PATCALIM","A-Alimentary tract and metabolism","TCPPERMT","/capita, US$ exchange rate","CZE","Czech Republic","2012","2012",46.9,,
+"PATCALIM","A-Alimentary tract and metabolism","TCPPERMT","/capita, US$ exchange rate","CZE","Czech Republic","2013","2013",45.4,,
+"PATCALIM","A-Alimentary tract and metabolism","TCPPERMT","/capita, US$ exchange rate","CZE","Czech Republic","2014","2014",45.4,,
+"PATCALIM","A-Alimentary tract and metabolism","TCPPERMT","/capita, US$ exchange rate","CZE","Czech Republic","2015","2015",39.9,,
+"PATCALIM","A-Alimentary tract and metabolism","TCPPERMT","/capita, US$ exchange rate","CZE","Czech Republic","2016","2016",42.6,,
+"PATCALIM","A-Alimentary tract and metabolism","TCPPERMT","/capita, US$ exchange rate","CZE","Czech Republic","2017","2017",46.3,,
+"PATCALIM","A-Alimentary tract and metabolism","TCPPERMT","/capita, US$ exchange rate","CZE","Czech Republic","2018","2018",52.5,,
+"PATCALIM","A-Alimentary tract and metabolism","TCPPERMT","/capita, US$ exchange rate","CZE","Czech Republic","2019","2019",52.4,,
+"PATCALIM","A-Alimentary tract and metabolism","TCPPERMT","/capita, US$ exchange rate","CZE","Czech Republic","2020","2020",44.6,"B","Break"
+"PATCALIM","A-Alimentary tract and metabolism","TCPPERMT","/capita, US$ exchange rate","CZE","Czech Republic","2021","2021",51.1,,
+"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czech Republic","2010","2010",62.6,,
+"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czech Republic","2011","2011",64.7,,
+"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czech Republic","2012","2012",69,,
+"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czech Republic","2013","2013",69.6,,
+"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czech Republic","2014","2014",74.2,,
+"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czech Republic","2015","2015",75.9,,
+"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czech Republic","2016","2016",82.8,,
+"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czech Republic","2017","2017",87.2,,
+"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czech Republic","2018","2018",92.2,,
+"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czech Republic","2019","2019",97.9,,
+"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czech Republic","2020","2020",83,"B","Break"
+"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czech Republic","2021","2021",87,,
+"PATCALIM","A-Alimentary tract and metabolism","ATCPTTMT","% of total sales","CZE","Czech Republic","2010","2010",11,,
+"PATCALIM","A-Alimentary tract and metabolism","ATCPTTMT","% of total sales","CZE","Czech Republic","2011","2011",11.2,,
+"PATCALIM","A-Alimentary tract and metabolism","ATCPTTMT","% of total sales","CZE","Czech Republic","2012","2012",11.5,,
+"PATCALIM","A-Alimentary tract and metabolism","ATCPTTMT","% of total sales","CZE","Czech Republic","2013","2013",11.7,,
+"PATCALIM","A-Alimentary tract and metabolism","ATCPTTMT","% of total sales","CZE","Czech Republic","2014","2014",12.2,,
+"PATCALIM","A-Alimentary tract and metabolism","ATCPTTMT","% of total sales","CZE","Czech Republic","2015","2015",12.3,,
+"PATCALIM","A-Alimentary tract and metabolism","ATCPTTMT","% of total sales","CZE","Czech Republic","2016","2016",12.6,,
+"PATCALIM","A-Alimentary tract and metabolism","ATCPTTMT","% of total sales","CZE","Czech Republic","2017","2017",12.5,,
+"PATCALIM","A-Alimentary tract and metabolism","ATCPTTMT","% of total sales","CZE","Czech Republic","2018","2018",12.4,,
+"PATCALIM","A-Alimentary tract and metabolism","ATCPTTMT","% of total sales","CZE","Czech Republic","2019","2019",12.4,,
+"PATCALIM","A-Alimentary tract and metabolism","ATCPTTMT","% of total sales","CZE","Czech Republic","2020","2020",12.6,"B","Break"
+"PATCALIM","A-Alimentary tract and metabolism","ATCPTTMT","% of total sales","CZE","Czech Republic","2021","2021",12.5,,
+"PATCALIM","A-Alimentary tract and metabolism","MLLNCUMT","Million of national currency units","DNK","Denmark","2010","2010",1740,,
+"PATCALIM","A-Alimentary tract and metabolism","MLLNCUMT","Million of national currency units","DNK","Denmark","2011","2011",1682.9,,
+"PATCALIM","A-Alimentary tract and metabolism","MLLNCUMT","Million of national currency units","DNK","Denmark","2012","2012",1777,,
+"PATCALIM","A-Alimentary tract and metabolism","MLLNCUMT","Million of national currency units","DNK","Denmark","2013","2013",1825.1,,
+"PATCALIM","A-Alimentary tract and metabolism","MLLNCUMT","Million of national currency units","DNK","Denmark","2014","2014",1954.7,,
+"PATCALIM","A-Alimentary tract and metabolism","MLLNCUMT","Million of national currency units","DNK","Denmark","2015","2015",2086.5,,
+"PATCALIM","A-Alimentary tract and metabolism","MLLNCUMT","Million of national currency units","DNK","Denmark","2016","2016",2214.3,,
+"PATCALIM","A-Alimentary tract and metabolism","MLLNCUMT","Million of national currency units","DNK","Denmark","2017","2017",2320.4,,
+"PATCALIM","A-Alimentary tract and metabolism","MLLNCUMT","Million of national currency units","DNK","Denmark","2018","2018",2492.3,,
+"PATCALIM","A-Alimentary tract and metabolism","MLLNCUMT","Million of national currency units","DNK","Denmark","2019","2019",2721,,
+"PATCALIM","A-Alimentary tract and metabolism","MLLNCUMT","Million of national currency units","DNK","Denmark","2020","2020",2800.5,,
+"PATCALIM","A-Alimentary tract and metabolism","MLLNCUMT","Million of national currency units","DNK","Denmark","2021","2021",3036,,
+"PATCALIM","A-Alimentary tract and metabolism","MTMOTCMT","Million US$ at exchange rate","DNK","Denmark","2010","2010",309.4,,
+"PATCALIM","A-Alimentary tract and metabolism","MTMOTCMT","Million US$ at exchange rate","DNK","Denmark","2011","2011",313.5,,
+"PATCALIM","A-Alimentary tract and metabolism","MTMOTCMT","Million US$ at exchange rate","DNK","Denmark","2012","2012",306.8,,
+"PATCALIM","A-Alimentary tract and metabolism","MTMOTCMT","Million US$ at exchange rate","DNK","Denmark","2013","2013",325,,
+"PATCALIM","A-Alimentary tract and metabolism","MTMOTCMT","Million US$ at exchange rate","DNK","Denmark","2014","2014",348.3,,
+"PATCALIM","A-Alimentary tract and metabolism","MTMOTCMT","Million US$ at exchange rate","DNK","Denmark","2015","2015",310.1,,
+"PATCALIM","A-Alimentary tract and metabolism","MTMOTCMT","Million US$ at exchange rate","DNK","Denmark","2016","2016",328.9,,
+"PATCALIM","A-Alimentary tract and metabolism","MTMOTCMT","Million US$ at exchange rate","DNK","Denmark","2017","2017",351.4,,
+"PATCALIM","A-Alimentary tract and metabolism","MTMOTCMT","Million US$ at exchange rate","DNK","Denmark","2018","2018",394.7,,
+"PATCALIM","A-Alimentary tract and metabolism","MTMOTCMT","Million US$ at exchange rate","DNK","Denmark","2019","2019",408,,
+"PATCALIM","A-Alimentary tract and metabolism","MTMOTCMT","Million US$ at exchange rate","DNK","Denmark","2020","2020",428.1,,
+"PATCALIM","A-Alimentary tract and metabolism","MTMOTCMT","Million US$ at exchange rate","DNK","Denmark","2021","2021",482.9,,
+"PATCALIM","A-Alimentary tract and metabolism","MTMOPPMT","Million US$, purchasing power parity","DNK","Denmark","2010","2010",229.2,,
+"PATCALIM","A-Alimentary tract and metabolism","MTMOPPMT","Million US$, purchasing power parity","DNK","Denmark","2011","2011",225.4,,
+"PATCALIM","A-Alimentary tract and metabolism","MTMOPPMT","Million US$, purchasing power parity","DNK","Denmark","2012","2012",234.9,,
+"PATCALIM","A-Alimentary tract and metabolism","MTMOPPMT","Million US$, purchasing power parity","DNK","Denmark","2013","2013",248.2,,
+"PATCALIM","A-Alimentary tract and metabolism","MTMOPPMT","Million US$, purchasing power parity","DNK","Denmark","2014","2014",266.7,,
+"PATCALIM","A-Alimentary tract and metabolism","MTMOPPMT","Million US$, purchasing power parity","DNK","Denmark","2015","2015",285.6,,
+"PATCALIM","A-Alimentary tract and metabolism","MTMOPPMT","Million US$, purchasing power parity","DNK","Denmark","2016","2016",312.8,,
+"PATCALIM","A-Alimentary tract and metabolism","MTMOPPMT","Million US$, purchasing power parity","DNK","Denmark","2017","2017",337.7,,
+"PATCALIM","A-Alimentary tract and metabolism","MTMOPPMT","Million US$, purchasing power parity","DNK","Denmark","2018","2018",368.4,,
+"PATCALIM","A-Alimentary tract and metabolism","MTMOPPMT","Million US$, purchasing power parity","DNK","Denmark","2019","2019",410.2,,
+"PATCALIM","A-Alimentary tract and metabolism","MTMOPPMT","Million US$, purchasing power parity","DNK","Denmark","2020","2020",427.5,,
+"PATCALIM","A-Alimentary tract and metabolism","MTMOPPMT","Million US$, purchasing power parity","DNK","Denmark","2021","2021",460.7,,
+"PATCALIM","A-Alimentary tract and metabolism","TCPPERMT","/capita, US$ exchange rate","DNK","Denmark","2010","2010",55.8,,
+"PATCALIM","A-Alimentary tract and metabolism","TCPPERMT","/capita, US$ exchange rate","DNK","Denmark","2011","2011",56.3,,
+"PATCALIM","A-Alimentary tract and metabolism","TCPPERMT","/capita, US$ exchange rate","DNK","Denmark","2012","2012",54.9,,
+"PATCALIM","A-Alimentary tract and metabolism","TCPPERMT","/capita, US$ exchange rate","DNK","Denmark","2013","2013",57.9,,
+"PATCALIM","A-Alimentary tract and metabolism","TCPPERMT","/capita, US$ exchange rate","DNK","Denmark","2014","2014",61.7,,
+"PATCALIM","A-Alimentary tract and metabolism","TCPPERMT","/capita, US$ exchange rate","DNK","Denmark","2015","2015",54.6,,
+"PATCALIM","A-Alimentary tract and metabolism","TCPPERMT","/capita, US$ exchange rate","DNK","Denmark","2016","2016",57.4,,
+"PATCALIM","A-Alimentary tract and metabolism","TCPPERMT","/capita, US$ exchange rate","DNK","Denmark","2017","2017",61,,
+"PATCALIM","A-Alimentary tract and metabolism","TCPPERMT","/capita, US$ exchange rate","DNK","Denmark","2018","2018",68.1,,
+"PATCALIM","A-Alimentary tract and metabolism","TCPPERMT","/capita, US$ exchange rate","DNK","Denmark","2019","2019",70.2,,
+"PATCALIM","A-Alimentary tract and metabolism","TCPPERMT","/capita, US$ exchange rate","DNK","Denmark","2020","2020",73.4,,
+"PATCALIM","A-Alimentary tract and metabolism","TCPPERMT","/capita, US$ exchange rate","DNK","Denmark","2021","2021",82.5,,
+"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","DNK","Denmark","2010","2010",41.3,,
+"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","DNK","Denmark","2011","2011",40.5,,
+"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","DNK","Denmark","2012","2012",42,,
+"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","DNK","Denmark","2013","2013",44.2,,
+"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","DNK","Denmark","2014","2014",47.3,,
+"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","DNK","Denmark","2015","2015",50.3,,
+"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","DNK","Denmark","2016","2016",54.6,,
+"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","DNK","Denmark","2017","2017",58.6,,
+"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","DNK","Denmark","2018","2018",63.6,,
+"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","DNK","Denmark","2019","2019",70.5,,
+"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","DNK","Denmark","2020","2020",73.3,,
+"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","DNK","Denmark","2021","2021",78.7,,
+"PATCALIM","A-Alimentary tract and metabolism","ATCPTTMT","% of total sales","DNK","Denmark","2010","2010",8.2,,
+"PATCALIM","A-Alimentary tract and metabolism","ATCPTTMT","% of total sales","DNK","Denmark","2011","2011",8.2,,
+"PATCALIM","A-Alimentary tract and metabolism","ATCPTTMT","% of total sales","DNK","Denmark","2012","2012",8.7,,
+"PATCALIM","A-Alimentary tract and metabolism","ATCPTTMT","% of total sales","DNK","Denmark","2013","2013",8.9,,
+"PATCALIM","A-Alimentary tract and metabolism","ATCPTTMT","% of total sales","DNK","Denmark","2014","2014",9.1,,
+"PATCALIM","A-Alimentary tract and metabolism","ATCPTTMT","% of total sales","DNK","Denmark","2015","2015",9.5,,
+"PATCALIM","A-Alimentary tract and metabolism","ATCPTTMT","% of total sales","DNK","Denmark","2016","2016",10,,
+"PATCALIM","A-Alimentary tract and metabolism","ATCPTTMT","% of total sales","DNK","Denmark","2017","2017",10.1,,
+"PATCALIM","A-Alimentary tract and metabolism","ATCPTTMT","% of total sales","DNK","Denmark","2018","2018",10.5,,
+"PATCALIM","A-Alimentary tract and metabolism","ATCPTTMT","% of total sales","DNK","Denmark","2019","2019",11.1,,
+"PATCALIM","A-Alimentary tract and metabolism","ATCPTTMT","% of total sales","DNK","Denmark","2020","2020",11.1,,
+"PATCALIM","A-Alimentary tract and metabolism","ATCPTTMT","% of total sales","DNK","Denmark","2021","2021",11.9,,
+"PATCALIM","A-Alimentary tract and metabolism","MLLNCUMT","Million of national currency units","FIN","Finland","2010","2010",227.5,,
+"PATCALIM","A-Alimentary tract and metabolism","MLLNCUMT","Million of national currency units","FIN","Finland","2011","2011",241.9,,
+"PATCALIM","A-Alimentary tract and metabolism","MLLNCUMT","Million of national currency units","FIN","Finland","2012","2012",254.7,,
+"PATCALIM","A-Alimentary tract and metabolism","MLLNCUMT","Million of national currency units","FIN","Finland","2013","2013",265,,
+"PATCALIM","A-Alimentary tract and metabolism","MLLNCUMT","Million of national currency units","FIN","Finland","2014","2014",279.3,,
+"PATCALIM","A-Alimentary tract and metabolism","MLLNCUMT","Million of national currency units","FIN","Finland","2015","2015",293,,
+"PATCALIM","A-Alimentary tract and metabolism","MLLNCUMT","Million of national currency units","FIN","Finland","2016","2016",302.4,,
+"PATCALIM","A-Alimentary tract and metabolism","MLLNCUMT","Million of national currency units","FIN","Finland","2017","2017",295.1,,
+"PATCALIM","A-Alimentary tract and metabolism","MLLNCUMT","Million of national currency units","FIN","Finland","2018","2018",300.3,,
+"PATCALIM","A-Alimentary tract and metabolism","MLLNCUMT","Million of national currency units","FIN","Finland","2019","2019",309.6,,
+"PATCALIM","A-Alimentary tract and metabolism","MLLNCUMT","Million of national currency units","FIN","Finland","2020","2020",321.6,,
+"PATCALIM","A-Alimentary tract and metabolism","MLLNCUMT","Million of national currency units","FIN","Finland","2021","2021",334.6,,
+"PATCALIM","A-Alimentary tract and metabolism","MTMOTCMT","Million US$ at exchange rate","FIN","Finland","2010","2010",301.6,,
+"PATCALIM","A-Alimentary tract and metabolism","MTMOTCMT","Million US$ at exchange rate","FIN","Finland","2011","2011",336.7,,
+"PATCALIM","A-Alimentary tract and metabolism","MTMOTCMT","Million US$ at exchange rate","FIN","Finland","2012","2012",327.2,,
+"PATCALIM","A-Alimentary tract and metabolism","MTMOTCMT","Million US$ at exchange rate","FIN","Finland","2013","2013",352,,
+"PATCALIM","A-Alimentary tract and metabolism","MTMOTCMT","Million US$ at exchange rate","FIN","Finland","2014","2014",371.1,,
+"PATCALIM","A-Alimentary tract and metabolism","MTMOTCMT","Million US$ at exchange rate","FIN","Finland","2015","2015",325.1,,
+"PATCALIM","A-Alimentary tract and metabolism","MTMOTCMT","Million US$ at exchange rate","FIN","Finland","2016","2016",334.7,,
+"PATCALIM","A-Alimentary tract and metabolism","MTMOTCMT","Million US$ at exchange rate","FIN","Finland","2017","2017",333.4,,
+"PATCALIM","A-Alimentary tract and metabolism","MTMOTCMT","Million US$ at exchange rate","FIN","Finland","2018","2018",354.6,,
+"PATCALIM","A-Alimentary tract and metabolism","MTMOTCMT","Million US$ at exchange rate","FIN","Finland","2019","2019",346.6,,
+"PATCALIM","A-Alimentary tract and metabolism","MTMOTCMT","Million US$ at exchange rate","FIN","Finland","2020","2020",367.3,,
+"PATCALIM","A-Alimentary tract and metabolism","MTMOTCMT","Million US$ at exchange rate","FIN","Finland","2021","2021",395.7,,
+"PATCALIM","A-Alimentary tract and metabolism","MTMOPPMT","Million US$, purchasing power parity","FIN","Finland","2010","2010",252.6,,
+"PATCALIM","A-Alimentary tract and metabolism","MTMOPPMT","Million US$, purchasing power parity","FIN","Finland","2011","2011",269.4,,
+"PATCALIM","A-Alimentary tract and metabolism","MTMOPPMT","Million US$, purchasing power parity","FIN","Finland","2012","2012",280.4,,
+"PATCALIM","A-Alimentary tract and metabolism","MTMOPPMT","Million US$, purchasing power parity","FIN","Finland","2013","2013",292.7,,
+"PATCALIM","A-Alimentary tract and metabolism","MTMOPPMT","Million US$, purchasing power parity","FIN","Finland","2014","2014",307.9,,
+"PATCALIM","A-Alimentary tract and metabolism","MTMOPPMT","Million US$, purchasing power parity","FIN","Finland","2015","2015",322.8,,
+"PATCALIM","A-Alimentary tract and metabolism","MTMOPPMT","Million US$, purchasing power parity","FIN","Finland","2016","2016",343.3,,
+"PATCALIM","A-Alimentary tract and metabolism","MTMOPPMT","Million US$, purchasing power parity","FIN","Finland","2017","2017",341.7,,
+"PATCALIM","A-Alimentary tract and metabolism","MTMOPPMT","Million US$, purchasing power parity","FIN","Finland","2018","2018",351.7,,
+"PATCALIM","A-Alimentary tract and metabolism","MTMOPPMT","Million US$, purchasing power parity","FIN","Finland","2019","2019",369.3,,
+"PATCALIM","A-Alimentary tract and metabolism","MTMOPPMT","Million US$, purchasing power parity","FIN","Finland","2020","2020",390.8,,
+"PATCALIM","A-Alimentary tract and metabolism","MTMOPPMT","Million US$, purchasing power parity","FIN","Finland","2021","2021",404.7,,
+"PATCALIM","A-Alimentary tract and metabolism","TCPPERMT","/capita, US$ exchange rate","FIN","Finland","2010","2010",56.2,,
+"PATCALIM","A-Alimentary tract and metabolism","TCPPERMT","/capita, US$ exchange rate","FIN","Finland","2011","2011",62.5,,
+"PATCALIM","A-Alimentary tract and metabolism","TCPPERMT","/capita, US$ exchange rate","FIN","Finland","2012","2012",60.4,,
+"PATCALIM","A-Alimentary tract and metabolism","TCPPERMT","/capita, US$ exchange rate","FIN","Finland","2013","2013",64.7,,
+"PATCALIM","A-Alimentary tract and metabolism","TCPPERMT","/capita, US$ exchange rate","FIN","Finland","2014","2014",67.9,,
+"PATCALIM","A-Alimentary tract and metabolism","TCPPERMT","/capita, US$ exchange rate","FIN","Finland","2015","2015",59.3,,
+"PATCALIM","A-Alimentary tract and metabolism","TCPPERMT","/capita, US$ exchange rate","FIN","Finland","2016","2016",60.9,,
+"PATCALIM","A-Alimentary tract and metabolism","TCPPERMT","/capita, US$ exchange rate","FIN","Finland","2017","2017",60.5,,
+"PATCALIM","A-Alimentary tract and metabolism","TCPPERMT","/capita, US$ exchange rate","FIN","Finland","2018","2018",64.3,,
+"PATCALIM","A-Alimentary tract and metabolism","TCPPERMT","/capita, US$ exchange rate","FIN","Finland","2019","2019",62.8,,
+"PATCALIM","A-Alimentary tract and metabolism","TCPPERMT","/capita, US$ exchange rate","FIN","Finland","2020","2020",66.4,,
+"PATCALIM","A-Alimentary tract and metabolism","TCPPERMT","/capita, US$ exchange rate","FIN","Finland","2021","2021",71.4,,
+"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2010","2010",47.1,,
+"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2011","2011",50,,
+"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2012","2012",51.8,,
+"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2013","2013",53.8,,
+"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2014","2014",56.4,,
+"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2015","2015",58.9,,
+"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2016","2016",62.5,,
+"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2017","2017",62,,
+"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2018","2018",63.8,,
+"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2019","2019",66.9,,
+"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2020","2020",70.7,,
+"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2021","2021",73,,
+"PATCALIM","A-Alimentary tract and metabolism","ATCPTTMT","% of total sales","FIN","Finland","2010","2010",12.1,,
+"PATCALIM","A-Alimentary tract and metabolism","ATCPTTMT","% of total sales","FIN","Finland","2011","2011",12.5,,
+"PATCALIM","A-Alimentary tract and metabolism","ATCPTTMT","% of total sales","FIN","Finland","2012","2012",13,,
+"PATCALIM","A-Alimentary tract and metabolism","ATCPTTMT","% of total sales","FIN","Finland","2013","2013",13.2,,
+"PATCALIM","A-Alimentary tract and metabolism","ATCPTTMT","% of total sales","FIN","Finland","2014","2014",13.3,,
+"PATCALIM","A-Alimentary tract and metabolism","ATCPTTMT","% of total sales","FIN","Finland","2015","2015",13.3,,
+"PATCALIM","A-Alimentary tract and metabolism","ATCPTTMT","% of total sales","FIN","Finland","2016","2016",13.2,,
+"PATCALIM","A-Alimentary tract and metabolism","ATCPTTMT","% of total sales","FIN","Finland","2017","2017",12.8,,
+"PATCALIM","A-Alimentary tract and metabolism","ATCPTTMT","% of total sales","FIN","Finland","2018","2018",12,,
+"PATCALIM","A-Alimentary tract and metabolism","ATCPTTMT","% of total sales","FIN","Finland","2019","2019",11.6,,
+"PATCALIM","A-Alimentary tract and metabolism","ATCPTTMT","% of total sales","FIN","Finland","2020","2020",11.9,,
+"PATCALIM","A-Alimentary tract and metabolism","ATCPTTMT","% of total sales","FIN","Finland","2021","2021",11.7,,
+"PATCALIM","A-Alimentary tract and metabolism","MLLNCUMT","Million of national currency units","FRA","France","2011","2011",2952.3,,
+"PATCALIM","A-Alimentary tract and metabolism","MTMOTCMT","Million US$ at exchange rate","FRA","France","2011","2011",4109.5,,
+"PATCALIM","A-Alimentary tract and metabolism","MTMOPPMT","Million US$, purchasing power parity","FRA","France","2011","2011",3509,,
+"PATCALIM","A-Alimentary tract and metabolism","TCPPERMT","/capita, US$ exchange rate","FRA","France","2011","2011",63.1,,
+"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","FRA","France","2011","2011",53.9,,
+"PATCALIM","A-Alimentary tract and metabolism","ATCPTTMT","% of total sales","FRA","France","2011","2011",10.7,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","MLLNCUMT","Million of national currency units","DEU","Germany","2010","2010",3714.8,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","MLLNCUMT","Million of national currency units","DEU","Germany","2011","2011",3704,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","MLLNCUMT","Million of national currency units","DEU","Germany","2012","2012",3894.1,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","MLLNCUMT","Million of national currency units","DEU","Germany","2013","2013",4031.6,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","MLLNCUMT","Million of national currency units","DEU","Germany","2014","2014",4132.3,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","MLLNCUMT","Million of national currency units","DEU","Germany","2015","2015",4253.2,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","MLLNCUMT","Million of national currency units","DEU","Germany","2016","2016",4404.3,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","MLLNCUMT","Million of national currency units","DEU","Germany","2017","2017",4483.3,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","MLLNCUMT","Million of national currency units","DEU","Germany","2018","2018",4775.5,"B; D","Break; Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","MLLNCUMT","Million of national currency units","DEU","Germany","2019","2019",5025.5,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","MLLNCUMT","Million of national currency units","DEU","Germany","2020","2020",5246,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","MLLNCUMT","Million of national currency units","DEU","Germany","2021","2021",5597.1,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","MTMOTCMT","Million US$ at exchange rate","DEU","Germany","2010","2010",4924.8,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","MTMOTCMT","Million US$ at exchange rate","DEU","Germany","2011","2011",5155.8,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","MTMOTCMT","Million US$ at exchange rate","DEU","Germany","2012","2012",5003.1,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","MTMOTCMT","Million US$ at exchange rate","DEU","Germany","2013","2013",5354.4,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","MTMOTCMT","Million US$ at exchange rate","DEU","Germany","2014","2014",5489.8,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","MTMOTCMT","Million US$ at exchange rate","DEU","Germany","2015","2015",4719,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","MTMOTCMT","Million US$ at exchange rate","DEU","Germany","2016","2016",4875.1,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","MTMOTCMT","Million US$ at exchange rate","DEU","Germany","2017","2017",5064.7,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","MTMOTCMT","Million US$ at exchange rate","DEU","Germany","2018","2018",5639.6,"B; D","Break; Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","MTMOTCMT","Million US$ at exchange rate","DEU","Germany","2019","2019",5625.9,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","MTMOTCMT","Million US$ at exchange rate","DEU","Germany","2020","2020",5992,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","MTMOTCMT","Million US$ at exchange rate","DEU","Germany","2021","2021",6619.9,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","MTMOPPMT","Million US$, purchasing power parity","DEU","Germany","2010","2010",4614.2,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","MTMOPPMT","Million US$, purchasing power parity","DEU","Germany","2011","2011",4696.1,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","MTMOPPMT","Million US$, purchasing power parity","DEU","Germany","2012","2012",4946.5,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","MTMOPPMT","Million US$, purchasing power parity","DEU","Germany","2013","2013",5203.5,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","MTMOPPMT","Million US$, purchasing power parity","DEU","Germany","2014","2014",5374,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","MTMOPPMT","Million US$, purchasing power parity","DEU","Germany","2015","2015",5466,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","MTMOPPMT","Million US$, purchasing power parity","DEU","Germany","2016","2016",5852.1,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","MTMOPPMT","Million US$, purchasing power parity","DEU","Germany","2017","2017",6019.6,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","MTMOPPMT","Million US$, purchasing power parity","DEU","Germany","2018","2018",6493.3,"B; D","Break; Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","MTMOPPMT","Million US$, purchasing power parity","DEU","Germany","2019","2019",6900.8,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","MTMOPPMT","Million US$, purchasing power parity","DEU","Germany","2020","2020",7235.8,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","MTMOPPMT","Million US$, purchasing power parity","DEU","Germany","2021","2021",7601.9,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","TCPPERMT","/capita, US$ exchange rate","DEU","Germany","2010","2010",60.2,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","TCPPERMT","/capita, US$ exchange rate","DEU","Germany","2011","2011",64.2,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","TCPPERMT","/capita, US$ exchange rate","DEU","Germany","2012","2012",62.2,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","TCPPERMT","/capita, US$ exchange rate","DEU","Germany","2013","2013",66.4,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","TCPPERMT","/capita, US$ exchange rate","DEU","Germany","2014","2014",67.8,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","TCPPERMT","/capita, US$ exchange rate","DEU","Germany","2015","2015",57.8,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","TCPPERMT","/capita, US$ exchange rate","DEU","Germany","2016","2016",59.2,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","TCPPERMT","/capita, US$ exchange rate","DEU","Germany","2017","2017",61.3,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","TCPPERMT","/capita, US$ exchange rate","DEU","Germany","2018","2018",68,"B; D","Break; Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","TCPPERMT","/capita, US$ exchange rate","DEU","Germany","2019","2019",67.7,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","TCPPERMT","/capita, US$ exchange rate","DEU","Germany","2020","2020",72.1,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","TCPPERMT","/capita, US$ exchange rate","DEU","Germany","2021","2021",79.6,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2010","2010",56.4,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2011","2011",58.5,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2012","2012",61.5,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2013","2013",64.5,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2014","2014",66.4,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2015","2015",66.9,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2016","2016",71.1,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2017","2017",72.8,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2018","2018",78.3,"B; D","Break; Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2019","2019",83,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2020","2020",87,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2021","2021",91.4,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","ATCPTTMT","% of total sales","DEU","Germany","2010","2010",12.5,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","ATCPTTMT","% of total sales","DEU","Germany","2011","2011",12.5,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","ATCPTTMT","% of total sales","DEU","Germany","2012","2012",12.8,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","ATCPTTMT","% of total sales","DEU","Germany","2013","2013",12.8,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","ATCPTTMT","% of total sales","DEU","Germany","2014","2014",12.3,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","ATCPTTMT","% of total sales","DEU","Germany","2015","2015",12,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","ATCPTTMT","% of total sales","DEU","Germany","2016","2016",12.2,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","ATCPTTMT","% of total sales","DEU","Germany","2017","2017",12.1,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","ATCPTTMT","% of total sales","DEU","Germany","2018","2018",10.8,"B; D","Break; Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","ATCPTTMT","% of total sales","DEU","Germany","2019","2019",10.7,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","ATCPTTMT","% of total sales","DEU","Germany","2020","2020",10.7,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","ATCPTTMT","% of total sales","DEU","Germany","2021","2021",10.5,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","MLLNCUMT","Million of national currency units","GRC","Greece","2010","2010",856,,
+"PATCALIM","A-Alimentary tract and metabolism","MLLNCUMT","Million of national currency units","GRC","Greece","2011","2011",743.9,,
+"PATCALIM","A-Alimentary tract and metabolism","MLLNCUMT","Million of national currency units","GRC","Greece","2012","2012",678.3,,
+"PATCALIM","A-Alimentary tract and metabolism","MLLNCUMT","Million of national currency units","GRC","Greece","2013","2013",630.1,,
+"PATCALIM","A-Alimentary tract and metabolism","MLLNCUMT","Million of national currency units","GRC","Greece","2014","2014",634.9,,
+"PATCALIM","A-Alimentary tract and metabolism","MLLNCUMT","Million of national currency units","GRC","Greece","2015","2015",594.7,,
+"PATCALIM","A-Alimentary tract and metabolism","MLLNCUMT","Million of national currency units","GRC","Greece","2016","2016",749.2,,
+"PATCALIM","A-Alimentary tract and metabolism","MLLNCUMT","Million of national currency units","GRC","Greece","2017","2017",760.9,,
+"PATCALIM","A-Alimentary tract and metabolism","MLLNCUMT","Million of national currency units","GRC","Greece","2018","2018",805,,
+"PATCALIM","A-Alimentary tract and metabolism","MLLNCUMT","Million of national currency units","GRC","Greece","2019","2019",833.8,,
+"PATCALIM","A-Alimentary tract and metabolism","MLLNCUMT","Million of national currency units","GRC","Greece","2020","2020",874.6,,
+"PATCALIM","A-Alimentary tract and metabolism","MLLNCUMT","Million of national currency units","GRC","Greece","2021","2021",944.3,,
+"PATCALIM","A-Alimentary tract and metabolism","MLLNCUMT","Million of national currency units","GRC","Greece","2022","2022",813,,
+"PATCALIM","A-Alimentary tract and metabolism","MTMOTCMT","Million US$ at exchange rate","GRC","Greece","2010","2010",1134.8,,
+"PATCALIM","A-Alimentary tract and metabolism","MTMOTCMT","Million US$ at exchange rate","GRC","Greece","2011","2011",1035.5,,
+"PATCALIM","A-Alimentary tract and metabolism","MTMOTCMT","Million US$ at exchange rate","GRC","Greece","2012","2012",871.5,,
+"PATCALIM","A-Alimentary tract and metabolism","MTMOTCMT","Million US$ at exchange rate","GRC","Greece","2013","2013",836.8,,
+"PATCALIM","A-Alimentary tract and metabolism","MTMOTCMT","Million US$ at exchange rate","GRC","Greece","2014","2014",843.5,,
+"PATCALIM","A-Alimentary tract and metabolism","MTMOTCMT","Million US$ at exchange rate","GRC","Greece","2015","2015",659.8,,
+"PATCALIM","A-Alimentary tract and metabolism","MTMOTCMT","Million US$ at exchange rate","GRC","Greece","2016","2016",829.3,,
+"PATCALIM","A-Alimentary tract and metabolism","MTMOTCMT","Million US$ at exchange rate","GRC","Greece","2017","2017",859.6,,
+"PATCALIM","A-Alimentary tract and metabolism","MTMOTCMT","Million US$ at exchange rate","GRC","Greece","2018","2018",950.6,,
+"PATCALIM","A-Alimentary tract and metabolism","MTMOTCMT","Million US$ at exchange rate","GRC","Greece","2019","2019",933.4,,
+"PATCALIM","A-Alimentary tract and metabolism","MTMOTCMT","Million US$ at exchange rate","GRC","Greece","2020","2020",998.9,,
+"PATCALIM","A-Alimentary tract and metabolism","MTMOTCMT","Million US$ at exchange rate","GRC","Greece","2021","2021",1116.8,,
+"PATCALIM","A-Alimentary tract and metabolism","MTMOTCMT","Million US$ at exchange rate","GRC","Greece","2022","2022",856.1,,
+"PATCALIM","A-Alimentary tract and metabolism","MTMOPPMT","Million US$, purchasing power parity","GRC","Greece","2010","2010",1185.5,,
+"PATCALIM","A-Alimentary tract and metabolism","MTMOPPMT","Million US$, purchasing power parity","GRC","Greece","2011","2011",1043.1,,
+"PATCALIM","A-Alimentary tract and metabolism","MTMOPPMT","Million US$, purchasing power parity","GRC","Greece","2012","2012",990.7,,
+"PATCALIM","A-Alimentary tract and metabolism","MTMOPPMT","Million US$, purchasing power parity","GRC","Greece","2013","2013",998.1,,
+"PATCALIM","A-Alimentary tract and metabolism","MTMOPPMT","Million US$, purchasing power parity","GRC","Greece","2014","2014",1038.9,,
+"PATCALIM","A-Alimentary tract and metabolism","MTMOPPMT","Million US$, purchasing power parity","GRC","Greece","2015","2015",976.4,,
+"PATCALIM","A-Alimentary tract and metabolism","MTMOPPMT","Million US$, purchasing power parity","GRC","Greece","2016","2016",1272.9,,
+"PATCALIM","A-Alimentary tract and metabolism","MTMOPPMT","Million US$, purchasing power parity","GRC","Greece","2017","2017",1323.2,,
+"PATCALIM","A-Alimentary tract and metabolism","MTMOPPMT","Million US$, purchasing power parity","GRC","Greece","2018","2018",1425.1,,
+"PATCALIM","A-Alimentary tract and metabolism","MTMOPPMT","Million US$, purchasing power parity","GRC","Greece","2019","2019",1519.1,,
+"PATCALIM","A-Alimentary tract and metabolism","MTMOPPMT","Million US$, purchasing power parity","GRC","Greece","2020","2020",1607.5,,
+"PATCALIM","A-Alimentary tract and metabolism","MTMOPPMT","Million US$, purchasing power parity","GRC","Greece","2021","2021",1730.9,,
+"PATCALIM","A-Alimentary tract and metabolism","MTMOPPMT","Million US$, purchasing power parity","GRC","Greece","2022","2022",1538.3,,
+"PATCALIM","A-Alimentary tract and metabolism","TCPPERMT","/capita, US$ exchange rate","GRC","Greece","2010","2010",102,,
+"PATCALIM","A-Alimentary tract and metabolism","TCPPERMT","/capita, US$ exchange rate","GRC","Greece","2011","2011",93.2,,
+"PATCALIM","A-Alimentary tract and metabolism","TCPPERMT","/capita, US$ exchange rate","GRC","Greece","2012","2012",78.9,,
+"PATCALIM","A-Alimentary tract and metabolism","TCPPERMT","/capita, US$ exchange rate","GRC","Greece","2013","2013",76.3,,
+"PATCALIM","A-Alimentary tract and metabolism","TCPPERMT","/capita, US$ exchange rate","GRC","Greece","2014","2014",77.4,,
+"PATCALIM","A-Alimentary tract and metabolism","TCPPERMT","/capita, US$ exchange rate","GRC","Greece","2015","2015",61,,
+"PATCALIM","A-Alimentary tract and metabolism","TCPPERMT","/capita, US$ exchange rate","GRC","Greece","2016","2016",77,,
+"PATCALIM","A-Alimentary tract and metabolism","TCPPERMT","/capita, US$ exchange rate","GRC","Greece","2017","2017",79.9,,
+"PATCALIM","A-Alimentary tract and metabolism","TCPPERMT","/capita, US$ exchange rate","GRC","Greece","2018","2018",88.6,,
+"PATCALIM","A-Alimentary tract and metabolism","TCPPERMT","/capita, US$ exchange rate","GRC","Greece","2019","2019",87.1,,
+"PATCALIM","A-Alimentary tract and metabolism","TCPPERMT","/capita, US$ exchange rate","GRC","Greece","2020","2020",93.4,,
+"PATCALIM","A-Alimentary tract and metabolism","TCPPERMT","/capita, US$ exchange rate","GRC","Greece","2021","2021",105.7,,
+"PATCALIM","A-Alimentary tract and metabolism","TCPPERMT","/capita, US$ exchange rate","GRC","Greece","2022","2022",81.8,,
+"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2010","2010",106.6,,
+"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2011","2011",93.9,,
+"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2012","2012",89.7,,
+"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2013","2013",91,,
+"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2014","2014",95.4,,
+"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2015","2015",90.2,,
+"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2016","2016",118.1,,
+"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2017","2017",123,,
+"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2018","2018",132.8,,
+"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2019","2019",141.7,,
+"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2020","2020",150.3,,
+"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2021","2021",163.8,,
+"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2022","2022",147.1,,
+"PATCALIM","A-Alimentary tract and metabolism","MLLNCUMT","Million of national currency units","HUN","Hungary","2010","2010",64095.7,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","MLLNCUMT","Million of national currency units","HUN","Hungary","2011","2011",68963.5,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","MLLNCUMT","Million of national currency units","HUN","Hungary","2012","2012",64446.7,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","MLLNCUMT","Million of national currency units","HUN","Hungary","2013","2013",60613.7,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","MLLNCUMT","Million of national currency units","HUN","Hungary","2014","2014",64320.4,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","MLLNCUMT","Million of national currency units","HUN","Hungary","2015","2015",67533,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","MLLNCUMT","Million of national currency units","HUN","Hungary","2016","2016",73066.7,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","MLLNCUMT","Million of national currency units","HUN","Hungary","2017","2017",78667.7,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","MLLNCUMT","Million of national currency units","HUN","Hungary","2018","2018",85394.6,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","MLLNCUMT","Million of national currency units","HUN","Hungary","2019","2019",94664.5,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","MLLNCUMT","Million of national currency units","HUN","Hungary","2020","2020",107184.2,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","MLLNCUMT","Million of national currency units","HUN","Hungary","2021","2021",109798.9,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","MLLNCUMT","Million of national currency units","HUN","Hungary","2022","2022",117157,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","MTMOTCMT","Million US$ at exchange rate","HUN","Hungary","2010","2010",308.2,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","MTMOTCMT","Million US$ at exchange rate","HUN","Hungary","2011","2011",343,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","MTMOTCMT","Million US$ at exchange rate","HUN","Hungary","2012","2012",286.3,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","MTMOTCMT","Million US$ at exchange rate","HUN","Hungary","2013","2013",271,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","MTMOTCMT","Million US$ at exchange rate","HUN","Hungary","2014","2014",276.5,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","MTMOTCMT","Million US$ at exchange rate","HUN","Hungary","2015","2015",241.8,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","MTMOTCMT","Million US$ at exchange rate","HUN","Hungary","2016","2016",259.5,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","MTMOTCMT","Million US$ at exchange rate","HUN","Hungary","2017","2017",286.7,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","MTMOTCMT","Million US$ at exchange rate","HUN","Hungary","2018","2018",316,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","MTMOTCMT","Million US$ at exchange rate","HUN","Hungary","2019","2019",325.7,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","MTMOTCMT","Million US$ at exchange rate","HUN","Hungary","2020","2020",348,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","MTMOTCMT","Million US$ at exchange rate","HUN","Hungary","2021","2021",362.2,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","MTMOTCMT","Million US$ at exchange rate","HUN","Hungary","2022","2022",314.4,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","MTMOPPMT","Million US$, purchasing power parity","HUN","Hungary","2010","2010",507,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","MTMOPPMT","Million US$, purchasing power parity","HUN","Hungary","2011","2011",554.9,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","MTMOPPMT","Million US$, purchasing power parity","HUN","Hungary","2012","2012",513,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","MTMOPPMT","Million US$, purchasing power parity","HUN","Hungary","2013","2013",485,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","MTMOPPMT","Million US$, purchasing power parity","HUN","Hungary","2014","2014",497,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","MTMOPPMT","Million US$, purchasing power parity","HUN","Hungary","2015","2015",509.5,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","MTMOPPMT","Million US$, purchasing power parity","HUN","Hungary","2016","2016",553.4,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","MTMOPPMT","Million US$, purchasing power parity","HUN","Hungary","2017","2017",578.3,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","MTMOPPMT","Million US$, purchasing power parity","HUN","Hungary","2018","2018",613.9,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","MTMOPPMT","Million US$, purchasing power parity","HUN","Hungary","2019","2019",672.2,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","MTMOPPMT","Million US$, purchasing power parity","HUN","Hungary","2020","2020",737.4,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","MTMOPPMT","Million US$, purchasing power parity","HUN","Hungary","2021","2021",709.5,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","MTMOPPMT","Million US$, purchasing power parity","HUN","Hungary","2022","2022",726.6,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","TCPPERMT","/capita, US$ exchange rate","HUN","Hungary","2010","2010",30.8,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","TCPPERMT","/capita, US$ exchange rate","HUN","Hungary","2011","2011",34.4,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","TCPPERMT","/capita, US$ exchange rate","HUN","Hungary","2012","2012",28.9,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","TCPPERMT","/capita, US$ exchange rate","HUN","Hungary","2013","2013",27.4,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","TCPPERMT","/capita, US$ exchange rate","HUN","Hungary","2014","2014",28,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","TCPPERMT","/capita, US$ exchange rate","HUN","Hungary","2015","2015",24.6,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","TCPPERMT","/capita, US$ exchange rate","HUN","Hungary","2016","2016",26.4,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","TCPPERMT","/capita, US$ exchange rate","HUN","Hungary","2017","2017",29.3,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","TCPPERMT","/capita, US$ exchange rate","HUN","Hungary","2018","2018",32.3,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","TCPPERMT","/capita, US$ exchange rate","HUN","Hungary","2019","2019",33.3,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","TCPPERMT","/capita, US$ exchange rate","HUN","Hungary","2020","2020",35.7,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","TCPPERMT","/capita, US$ exchange rate","HUN","Hungary","2021","2021",37.3,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","TCPPERMT","/capita, US$ exchange rate","HUN","Hungary","2022","2022",32.5,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2010","2010",50.7,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2011","2011",55.7,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2012","2012",51.7,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2013","2013",49,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2014","2014",50.4,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2015","2015",51.8,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2016","2016",56.4,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2017","2017",59.1,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2018","2018",62.8,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2019","2019",68.8,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2020","2020",75.6,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2021","2021",73.1,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2022","2022",75,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","ATCPTTMT","% of total sales","HUN","Hungary","2010","2010",12.9,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","ATCPTTMT","% of total sales","HUN","Hungary","2011","2011",13.4,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","ATCPTTMT","% of total sales","HUN","Hungary","2012","2012",14.5,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","ATCPTTMT","% of total sales","HUN","Hungary","2013","2013",14.1,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","ATCPTTMT","% of total sales","HUN","Hungary","2014","2014",14.5,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","ATCPTTMT","% of total sales","HUN","Hungary","2015","2015",14.5,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","ATCPTTMT","% of total sales","HUN","Hungary","2016","2016",14.6,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","ATCPTTMT","% of total sales","HUN","Hungary","2017","2017",16,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","ATCPTTMT","% of total sales","HUN","Hungary","2018","2018",17.1,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","ATCPTTMT","% of total sales","HUN","Hungary","2019","2019",17.9,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","ATCPTTMT","% of total sales","HUN","Hungary","2020","2020",19.2,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","ATCPTTMT","% of total sales","HUN","Hungary","2021","2021",19.3,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","ATCPTTMT","% of total sales","HUN","Hungary","2022","2022",19.6,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","MLLNCUMT","Million of national currency units","ISL","Iceland","2010","2010",2071.3,,
+"PATCALIM","A-Alimentary tract and metabolism","MLLNCUMT","Million of national currency units","ISL","Iceland","2011","2011",1894.8,,
+"PATCALIM","A-Alimentary tract and metabolism","MLLNCUMT","Million of national currency units","ISL","Iceland","2012","2012",1700.3,,
+"PATCALIM","A-Alimentary tract and metabolism","MLLNCUMT","Million of national currency units","ISL","Iceland","2013","2013",2134,,
+"PATCALIM","A-Alimentary tract and metabolism","MLLNCUMT","Million of national currency units","ISL","Iceland","2014","2014",1897.2,,
+"PATCALIM","A-Alimentary tract and metabolism","MLLNCUMT","Million of national currency units","ISL","Iceland","2015","2015",2003.7,,
+"PATCALIM","A-Alimentary tract and metabolism","MLLNCUMT","Million of national currency units","ISL","Iceland","2016","2016",2188.8,,
+"PATCALIM","A-Alimentary tract and metabolism","MLLNCUMT","Million of national currency units","ISL","Iceland","2017","2017",2159.5,,
+"PATCALIM","A-Alimentary tract and metabolism","MLLNCUMT","Million of national currency units","ISL","Iceland","2018","2018",2463.9,,
+"PATCALIM","A-Alimentary tract and metabolism","MLLNCUMT","Million of national currency units","ISL","Iceland","2019","2019",2929.2,,
+"PATCALIM","A-Alimentary tract and metabolism","MLLNCUMT","Million of national currency units","ISL","Iceland","2020","2020",3578.1,,
+"PATCALIM","A-Alimentary tract and metabolism","MLLNCUMT","Million of national currency units","ISL","Iceland","2021","2021",4281.3,,
+"PATCALIM","A-Alimentary tract and metabolism","MTMOTCMT","Million US$ at exchange rate","ISL","Iceland","2010","2010",16.9,,
+"PATCALIM","A-Alimentary tract and metabolism","MTMOTCMT","Million US$ at exchange rate","ISL","Iceland","2011","2011",16.3,,
+"PATCALIM","A-Alimentary tract and metabolism","MTMOTCMT","Million US$ at exchange rate","ISL","Iceland","2012","2012",13.6,,
+"PATCALIM","A-Alimentary tract and metabolism","MTMOTCMT","Million US$ at exchange rate","ISL","Iceland","2013","2013",17.5,,
+"PATCALIM","A-Alimentary tract and metabolism","MTMOTCMT","Million US$ at exchange rate","ISL","Iceland","2014","2014",16.2,,
+"PATCALIM","A-Alimentary tract and metabolism","MTMOTCMT","Million US$ at exchange rate","ISL","Iceland","2015","2015",15.2,,
+"PATCALIM","A-Alimentary tract and metabolism","MTMOTCMT","Million US$ at exchange rate","ISL","Iceland","2016","2016",18.1,,
+"PATCALIM","A-Alimentary tract and metabolism","MTMOTCMT","Million US$ at exchange rate","ISL","Iceland","2017","2017",20.2,,
+"PATCALIM","A-Alimentary tract and metabolism","MTMOTCMT","Million US$ at exchange rate","ISL","Iceland","2018","2018",22.8,,
+"PATCALIM","A-Alimentary tract and metabolism","MTMOTCMT","Million US$ at exchange rate","ISL","Iceland","2019","2019",23.9,,
+"PATCALIM","A-Alimentary tract and metabolism","MTMOTCMT","Million US$ at exchange rate","ISL","Iceland","2020","2020",26.4,,
+"PATCALIM","A-Alimentary tract and metabolism","MTMOTCMT","Million US$ at exchange rate","ISL","Iceland","2021","2021",33.7,,
+"PATCALIM","A-Alimentary tract and metabolism","MTMOPPMT","Million US$, purchasing power parity","ISL","Iceland","2010","2010",15.6,,
+"PATCALIM","A-Alimentary tract and metabolism","MTMOPPMT","Million US$, purchasing power parity","ISL","Iceland","2011","2011",14,,
+"PATCALIM","A-Alimentary tract and metabolism","MTMOPPMT","Million US$, purchasing power parity","ISL","Iceland","2012","2012",12.4,,
+"PATCALIM","A-Alimentary tract and metabolism","MTMOPPMT","Million US$, purchasing power parity","ISL","Iceland","2013","2013",15.6,,
+"PATCALIM","A-Alimentary tract and metabolism","MTMOPPMT","Million US$, purchasing power parity","ISL","Iceland","2014","2014",13.7,,
+"PATCALIM","A-Alimentary tract and metabolism","MTMOPPMT","Million US$, purchasing power parity","ISL","Iceland","2015","2015",14.1,,
+"PATCALIM","A-Alimentary tract and metabolism","MTMOPPMT","Million US$, purchasing power parity","ISL","Iceland","2016","2016",15.6,,
+"PATCALIM","A-Alimentary tract and metabolism","MTMOPPMT","Million US$, purchasing power parity","ISL","Iceland","2017","2017",15.6,,
+"PATCALIM","A-Alimentary tract and metabolism","MTMOPPMT","Million US$, purchasing power parity","ISL","Iceland","2018","2018",17.5,,
+"PATCALIM","A-Alimentary tract and metabolism","MTMOPPMT","Million US$, purchasing power parity","ISL","Iceland","2019","2019",20.8,,
+"PATCALIM","A-Alimentary tract and metabolism","MTMOPPMT","Million US$, purchasing power parity","ISL","Iceland","2020","2020",24.4,,
+"PATCALIM","A-Alimentary tract and metabolism","MTMOPPMT","Million US$, purchasing power parity","ISL","Iceland","2021","2021",28.6,,
+"PATCALIM","A-Alimentary tract and metabolism","TCPPERMT","/capita, US$ exchange rate","ISL","Iceland","2010","2010",53.3,,
+"PATCALIM","A-Alimentary tract and metabolism","TCPPERMT","/capita, US$ exchange rate","ISL","Iceland","2011","2011",51.2,,
+"PATCALIM","A-Alimentary tract and metabolism","TCPPERMT","/capita, US$ exchange rate","ISL","Iceland","2012","2012",42.4,,
+"PATCALIM","A-Alimentary tract and metabolism","TCPPERMT","/capita, US$ exchange rate","ISL","Iceland","2013","2013",53.9,,
+"PATCALIM","A-Alimentary tract and metabolism","TCPPERMT","/capita, US$ exchange rate","ISL","Iceland","2014","2014",49.6,,
+"PATCALIM","A-Alimentary tract and metabolism","TCPPERMT","/capita, US$ exchange rate","ISL","Iceland","2015","2015",45.9,,
+"PATCALIM","A-Alimentary tract and metabolism","TCPPERMT","/capita, US$ exchange rate","ISL","Iceland","2016","2016",54,,
+"PATCALIM","A-Alimentary tract and metabolism","TCPPERMT","/capita, US$ exchange rate","ISL","Iceland","2017","2017",58.9,,
+"PATCALIM","A-Alimentary tract and metabolism","TCPPERMT","/capita, US$ exchange rate","ISL","Iceland","2018","2018",64.5,,
+"PATCALIM","A-Alimentary tract and metabolism","TCPPERMT","/capita, US$ exchange rate","ISL","Iceland","2019","2019",66.3,,
+"PATCALIM","A-Alimentary tract and metabolism","TCPPERMT","/capita, US$ exchange rate","ISL","Iceland","2020","2020",72.1,,
+"PATCALIM","A-Alimentary tract and metabolism","TCPPERMT","/capita, US$ exchange rate","ISL","Iceland","2021","2021",90.5,,
+"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2010","2010",49,,
+"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2011","2011",43.9,,
+"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2012","2012",38.7,,
+"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2013","2013",48.1,,
+"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2014","2014",41.8,,
+"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2015","2015",42.7,,
+"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2016","2016",46.6,,
+"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2017","2017",45.5,,
+"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2018","2018",49.6,,
+"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2019","2019",57.7,,
+"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2020","2020",66.6,,
+"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2021","2021",76.8,,
+"PATCALIM","A-Alimentary tract and metabolism","ATCPTTMT","% of total sales","ISL","Iceland","2010","2010",8.3,,
+"PATCALIM","A-Alimentary tract and metabolism","ATCPTTMT","% of total sales","ISL","Iceland","2011","2011",7.3,,
+"PATCALIM","A-Alimentary tract and metabolism","ATCPTTMT","% of total sales","ISL","Iceland","2012","2012",7,,
+"PATCALIM","A-Alimentary tract and metabolism","ATCPTTMT","% of total sales","ISL","Iceland","2013","2013",8.2,,
+"PATCALIM","A-Alimentary tract and metabolism","ATCPTTMT","% of total sales","ISL","Iceland","2014","2014",8,,
+"PATCALIM","A-Alimentary tract and metabolism","ATCPTTMT","% of total sales","ISL","Iceland","2015","2015",8.2,,
+"PATCALIM","A-Alimentary tract and metabolism","ATCPTTMT","% of total sales","ISL","Iceland","2016","2016",8.6,,
+"PATCALIM","A-Alimentary tract and metabolism","ATCPTTMT","% of total sales","ISL","Iceland","2017","2017",8.1,,
+"PATCALIM","A-Alimentary tract and metabolism","ATCPTTMT","% of total sales","ISL","Iceland","2018","2018",8.2,,
+"PATCALIM","A-Alimentary tract and metabolism","ATCPTTMT","% of total sales","ISL","Iceland","2019","2019",8.7,,
+"PATCALIM","A-Alimentary tract and metabolism","ATCPTTMT","% of total sales","ISL","Iceland","2020","2020",9,,
+"PATCALIM","A-Alimentary tract and metabolism","ATCPTTMT","% of total sales","ISL","Iceland","2021","2021",9.5,,
+"PATCALIM","A-Alimentary tract and metabolism","MLLNCUMT","Million of national currency units","IRL","Ireland","2010","2010",263.4,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","MLLNCUMT","Million of national currency units","IRL","Ireland","2011","2011",239,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","MLLNCUMT","Million of national currency units","IRL","Ireland","2012","2012",248.8,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","MLLNCUMT","Million of national currency units","IRL","Ireland","2013","2013",233.4,"B; D","Break; Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","MLLNCUMT","Million of national currency units","IRL","Ireland","2014","2014",207.4,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","MLLNCUMT","Million of national currency units","IRL","Ireland","2015","2015",206,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","MLLNCUMT","Million of national currency units","IRL","Ireland","2016","2016",210.4,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","MLLNCUMT","Million of national currency units","IRL","Ireland","2017","2017",215.6,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","MLLNCUMT","Million of national currency units","IRL","Ireland","2018","2018",227,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","MLLNCUMT","Million of national currency units","IRL","Ireland","2019","2019",242,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","MLLNCUMT","Million of national currency units","IRL","Ireland","2020","2020",260.7,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","MLLNCUMT","Million of national currency units","IRL","Ireland","2021","2021",282,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","MTMOTCMT","Million US$ at exchange rate","IRL","Ireland","2010","2010",349.2,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","MTMOTCMT","Million US$ at exchange rate","IRL","Ireland","2011","2011",332.6,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","MTMOTCMT","Million US$ at exchange rate","IRL","Ireland","2012","2012",319.6,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","MTMOTCMT","Million US$ at exchange rate","IRL","Ireland","2013","2013",310,"B; D","Break; Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","MTMOTCMT","Million US$ at exchange rate","IRL","Ireland","2014","2014",275.5,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","MTMOTCMT","Million US$ at exchange rate","IRL","Ireland","2015","2015",228.6,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","MTMOTCMT","Million US$ at exchange rate","IRL","Ireland","2016","2016",232.9,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","MTMOTCMT","Million US$ at exchange rate","IRL","Ireland","2017","2017",243.5,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","MTMOTCMT","Million US$ at exchange rate","IRL","Ireland","2018","2018",268,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","MTMOTCMT","Million US$ at exchange rate","IRL","Ireland","2019","2019",270.9,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","MTMOTCMT","Million US$ at exchange rate","IRL","Ireland","2020","2020",297.8,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","MTMOTCMT","Million US$ at exchange rate","IRL","Ireland","2021","2021",333.6,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","MTMOPPMT","Million US$, purchasing power parity","IRL","Ireland","2010","2010",310,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","MTMOPPMT","Million US$, purchasing power parity","IRL","Ireland","2011","2011",287.4,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","MTMOPPMT","Million US$, purchasing power parity","IRL","Ireland","2012","2012",302.3,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","MTMOPPMT","Million US$, purchasing power parity","IRL","Ireland","2013","2013",287.7,"B; D","Break; Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","MTMOPPMT","Million US$, purchasing power parity","IRL","Ireland","2014","2014",253.2,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","MTMOPPMT","Million US$, purchasing power parity","IRL","Ireland","2015","2015",254.4,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","MTMOPPMT","Million US$, purchasing power parity","IRL","Ireland","2016","2016",264.9,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","MTMOPPMT","Million US$, purchasing power parity","IRL","Ireland","2017","2017",271.4,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","MTMOPPMT","Million US$, purchasing power parity","IRL","Ireland","2018","2018",286.5,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","MTMOPPMT","Million US$, purchasing power parity","IRL","Ireland","2019","2019",300.3,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","MTMOPPMT","Million US$, purchasing power parity","IRL","Ireland","2020","2020",327.5,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","MTMOPPMT","Million US$, purchasing power parity","IRL","Ireland","2021","2021",354.9,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","TCPPERMT","/capita, US$ exchange rate","IRL","Ireland","2010","2010",76.6,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","TCPPERMT","/capita, US$ exchange rate","IRL","Ireland","2011","2011",72.6,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","TCPPERMT","/capita, US$ exchange rate","IRL","Ireland","2012","2012",69.5,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","TCPPERMT","/capita, US$ exchange rate","IRL","Ireland","2013","2013",67,"B; D","Break; Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","TCPPERMT","/capita, US$ exchange rate","IRL","Ireland","2014","2014",59.1,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","TCPPERMT","/capita, US$ exchange rate","IRL","Ireland","2015","2015",48.6,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","TCPPERMT","/capita, US$ exchange rate","IRL","Ireland","2016","2016",49,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","TCPPERMT","/capita, US$ exchange rate","IRL","Ireland","2017","2017",50.7,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","TCPPERMT","/capita, US$ exchange rate","IRL","Ireland","2018","2018",55.1,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","TCPPERMT","/capita, US$ exchange rate","IRL","Ireland","2019","2019",54.9,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","TCPPERMT","/capita, US$ exchange rate","IRL","Ireland","2020","2020",59.7,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","TCPPERMT","/capita, US$ exchange rate","IRL","Ireland","2021","2021",66.3,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2010","2010",68,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2011","2011",62.7,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2012","2012",65.7,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2013","2013",62.2,"B; D","Break; Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2014","2014",54.4,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2015","2015",54.1,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2016","2016",55.7,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2017","2017",56.4,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2018","2018",58.9,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2019","2019",60.9,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2020","2020",65.7,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2021","2021",70.5,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","ATCPTTMT","% of total sales","IRL","Ireland","2010","2010",12.8,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","ATCPTTMT","% of total sales","IRL","Ireland","2011","2011",12.2,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","ATCPTTMT","% of total sales","IRL","Ireland","2012","2012",12.2,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","ATCPTTMT","% of total sales","IRL","Ireland","2013","2013",11.9,"B; D","Break; Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","ATCPTTMT","% of total sales","IRL","Ireland","2014","2014",10.8,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","ATCPTTMT","% of total sales","IRL","Ireland","2015","2015",10.4,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","ATCPTTMT","% of total sales","IRL","Ireland","2016","2016",10.1,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","ATCPTTMT","% of total sales","IRL","Ireland","2017","2017",10.1,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","ATCPTTMT","% of total sales","IRL","Ireland","2018","2018",10,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","ATCPTTMT","% of total sales","IRL","Ireland","2019","2019",10.1,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","ATCPTTMT","% of total sales","IRL","Ireland","2020","2020",10.6,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","ATCPTTMT","% of total sales","IRL","Ireland","2021","2021",10.8,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","MLLNCUMT","Million of national currency units","ITA","Italy","2011","2011",2281.9,,
+"PATCALIM","A-Alimentary tract and metabolism","MLLNCUMT","Million of national currency units","ITA","Italy","2012","2012",2363.1,,
+"PATCALIM","A-Alimentary tract and metabolism","MLLNCUMT","Million of national currency units","ITA","Italy","2013","2013",2478.7,,
+"PATCALIM","A-Alimentary tract and metabolism","MLLNCUMT","Million of national currency units","ITA","Italy","2014","2014",2584.4,,
+"PATCALIM","A-Alimentary tract and metabolism","MLLNCUMT","Million of national currency units","ITA","Italy","2015","2015",2654.9,,
+"PATCALIM","A-Alimentary tract and metabolism","MLLNCUMT","Million of national currency units","ITA","Italy","2016","2016",2695.4,,
+"PATCALIM","A-Alimentary tract and metabolism","MLLNCUMT","Million of national currency units","ITA","Italy","2017","2017",2754,,
+"PATCALIM","A-Alimentary tract and metabolism","MLLNCUMT","Million of national currency units","ITA","Italy","2018","2018",2837.4,,
+"PATCALIM","A-Alimentary tract and metabolism","MLLNCUMT","Million of national currency units","ITA","Italy","2019","2019",2901.1,,
+"PATCALIM","A-Alimentary tract and metabolism","MLLNCUMT","Million of national currency units","ITA","Italy","2020","2020",2878.6,,
+"PATCALIM","A-Alimentary tract and metabolism","MLLNCUMT","Million of national currency units","ITA","Italy","2021","2021",3064.2,,
+"PATCALIM","A-Alimentary tract and metabolism","MLLNCUMT","Million of national currency units","ITA","Italy","2022","2022",3258.6,"E","Estimated value"
+"PATCALIM","A-Alimentary tract and metabolism","MTMOTCMT","Million US$ at exchange rate","ITA","Italy","2011","2011",3176.3,,
+"PATCALIM","A-Alimentary tract and metabolism","MTMOTCMT","Million US$ at exchange rate","ITA","Italy","2012","2012",3036.1,,
+"PATCALIM","A-Alimentary tract and metabolism","MTMOTCMT","Million US$ at exchange rate","ITA","Italy","2013","2013",3292,,
+"PATCALIM","A-Alimentary tract and metabolism","MTMOTCMT","Million US$ at exchange rate","ITA","Italy","2014","2014",3433.3,,
+"PATCALIM","A-Alimentary tract and metabolism","MTMOTCMT","Million US$ at exchange rate","ITA","Italy","2015","2015",2945.6,,
+"PATCALIM","A-Alimentary tract and metabolism","MTMOTCMT","Million US$ at exchange rate","ITA","Italy","2016","2016",2983.5,,
+"PATCALIM","A-Alimentary tract and metabolism","MTMOTCMT","Million US$ at exchange rate","ITA","Italy","2017","2017",3111.2,,
+"PATCALIM","A-Alimentary tract and metabolism","MTMOTCMT","Million US$ at exchange rate","ITA","Italy","2018","2018",3350.8,,
+"PATCALIM","A-Alimentary tract and metabolism","MTMOTCMT","Million US$ at exchange rate","ITA","Italy","2019","2019",3247.7,,
+"PATCALIM","A-Alimentary tract and metabolism","MTMOTCMT","Million US$ at exchange rate","ITA","Italy","2020","2020",3287.9,,
+"PATCALIM","A-Alimentary tract and metabolism","MTMOTCMT","Million US$ at exchange rate","ITA","Italy","2021","2021",3624.2,,
+"PATCALIM","A-Alimentary tract and metabolism","MTMOTCMT","Million US$ at exchange rate","ITA","Italy","2022","2022",3431.5,"E","Estimated value"
+"PATCALIM","A-Alimentary tract and metabolism","MTMOPPMT","Million US$, purchasing power parity","ITA","Italy","2011","2011",3007.7,,
+"PATCALIM","A-Alimentary tract and metabolism","MTMOPPMT","Million US$, purchasing power parity","ITA","Italy","2012","2012",3160.4,,
+"PATCALIM","A-Alimentary tract and metabolism","MTMOPPMT","Million US$, purchasing power parity","ITA","Italy","2013","2013",3361.9,,
+"PATCALIM","A-Alimentary tract and metabolism","MTMOPPMT","Million US$, purchasing power parity","ITA","Italy","2014","2014",3494.1,,
+"PATCALIM","A-Alimentary tract and metabolism","MTMOPPMT","Million US$, purchasing power parity","ITA","Italy","2015","2015",3594,,
+"PATCALIM","A-Alimentary tract and metabolism","MTMOPPMT","Million US$, purchasing power parity","ITA","Italy","2016","2016",3847.5,,
+"PATCALIM","A-Alimentary tract and metabolism","MTMOPPMT","Million US$, purchasing power parity","ITA","Italy","2017","2017",3992,,
+"PATCALIM","A-Alimentary tract and metabolism","MTMOPPMT","Million US$, purchasing power parity","ITA","Italy","2018","2018",4165.2,,
+"PATCALIM","A-Alimentary tract and metabolism","MTMOPPMT","Million US$, purchasing power parity","ITA","Italy","2019","2019",4417.2,,
+"PATCALIM","A-Alimentary tract and metabolism","MTMOPPMT","Million US$, purchasing power parity","ITA","Italy","2020","2020",4444.3,,
+"PATCALIM","A-Alimentary tract and metabolism","MTMOPPMT","Million US$, purchasing power parity","ITA","Italy","2021","2021",4732.1,,
+"PATCALIM","A-Alimentary tract and metabolism","MTMOPPMT","Million US$, purchasing power parity","ITA","Italy","2022","2022",5277.8,"E","Estimated value"
+"PATCALIM","A-Alimentary tract and metabolism","TCPPERMT","/capita, US$ exchange rate","ITA","Italy","2011","2011",53.5,,
+"PATCALIM","A-Alimentary tract and metabolism","TCPPERMT","/capita, US$ exchange rate","ITA","Italy","2012","2012",51,,
+"PATCALIM","A-Alimentary tract and metabolism","TCPPERMT","/capita, US$ exchange rate","ITA","Italy","2013","2013",54.7,,
+"PATCALIM","A-Alimentary tract and metabolism","TCPPERMT","/capita, US$ exchange rate","ITA","Italy","2014","2014",56.5,,
+"PATCALIM","A-Alimentary tract and metabolism","TCPPERMT","/capita, US$ exchange rate","ITA","Italy","2015","2015",48.5,,
+"PATCALIM","A-Alimentary tract and metabolism","TCPPERMT","/capita, US$ exchange rate","ITA","Italy","2016","2016",49.2,,
+"PATCALIM","A-Alimentary tract and metabolism","TCPPERMT","/capita, US$ exchange rate","ITA","Italy","2017","2017",51.4,,
+"PATCALIM","A-Alimentary tract and metabolism","TCPPERMT","/capita, US$ exchange rate","ITA","Italy","2018","2018",55.5,,
+"PATCALIM","A-Alimentary tract and metabolism","TCPPERMT","/capita, US$ exchange rate","ITA","Italy","2019","2019",54.4,,
+"PATCALIM","A-Alimentary tract and metabolism","TCPPERMT","/capita, US$ exchange rate","ITA","Italy","2020","2020",55.3,,
+"PATCALIM","A-Alimentary tract and metabolism","TCPPERMT","/capita, US$ exchange rate","ITA","Italy","2021","2021",61.3,,
+"PATCALIM","A-Alimentary tract and metabolism","TCPPERMT","/capita, US$ exchange rate","ITA","Italy","2022","2022",58.1,"E","Estimated value"
+"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2011","2011",50.7,,
+"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2012","2012",53.1,,
+"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2013","2013",55.8,,
+"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2014","2014",57.5,,
+"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2015","2015",59.2,,
+"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2016","2016",63.5,,
+"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2017","2017",65.9,,
+"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2018","2018",68.9,,
+"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2019","2019",74,,
+"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2020","2020",74.8,,
+"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2021","2021",80,,
+"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2022","2022",89.4,"E","Estimated value"
+"PATCALIM","A-Alimentary tract and metabolism","ATCPTTMT","% of total sales","ITA","Italy","2011","2011",11.7,,
+"PATCALIM","A-Alimentary tract and metabolism","ATCPTTMT","% of total sales","ITA","Italy","2012","2012",12.4,,
+"PATCALIM","A-Alimentary tract and metabolism","ATCPTTMT","% of total sales","ITA","Italy","2013","2013",12.7,,
+"PATCALIM","A-Alimentary tract and metabolism","ATCPTTMT","% of total sales","ITA","Italy","2014","2014",13,,
+"PATCALIM","A-Alimentary tract and metabolism","ATCPTTMT","% of total sales","ITA","Italy","2015","2015",11.7,,
+"PATCALIM","A-Alimentary tract and metabolism","ATCPTTMT","% of total sales","ITA","Italy","2016","2016",11.8,,
+"PATCALIM","A-Alimentary tract and metabolism","ATCPTTMT","% of total sales","ITA","Italy","2017","2017",12.2,,
+"PATCALIM","A-Alimentary tract and metabolism","ATCPTTMT","% of total sales","ITA","Italy","2018","2018",12.7,,
+"PATCALIM","A-Alimentary tract and metabolism","ATCPTTMT","% of total sales","ITA","Italy","2019","2019",12.7,,
+"PATCALIM","A-Alimentary tract and metabolism","ATCPTTMT","% of total sales","ITA","Italy","2020","2020",12.4,,
+"PATCALIM","A-Alimentary tract and metabolism","ATCPTTMT","% of total sales","ITA","Italy","2021","2021",12.9,,
+"PATCALIM","A-Alimentary tract and metabolism","ATCPTTMT","% of total sales","ITA","Italy","2022","2022",13.1,"E","Estimated value"
+"PATCALIM","A-Alimentary tract and metabolism","MLLNCUMT","Million of national currency units","JPN","Japan","2010","2010",581966,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","MLLNCUMT","Million of national currency units","JPN","Japan","2011","2011",570135,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","MLLNCUMT","Million of national currency units","JPN","Japan","2012","2012",572354,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","MLLNCUMT","Million of national currency units","JPN","Japan","2013","2013",532593,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","MLLNCUMT","Million of national currency units","JPN","Japan","2014","2014",484331,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","MLLNCUMT","Million of national currency units","JPN","Japan","2015","2015",464073,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","MLLNCUMT","Million of national currency units","JPN","Japan","2016","2016",400328,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","MLLNCUMT","Million of national currency units","JPN","Japan","2017","2017",403493,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","MLLNCUMT","Million of national currency units","JPN","Japan","2018","2018",375517,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","MLLNCUMT","Million of national currency units","JPN","Japan","2019","2019",561901,"B; D","Break; Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","MLLNCUMT","Million of national currency units","JPN","Japan","2020","2020",560631,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","MLLNCUMT","Million of national currency units","JPN","Japan","2021","2021",540915,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","MTMOTCMT","Million US$ at exchange rate","JPN","Japan","2010","2010",6629.8,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","MTMOTCMT","Million US$ at exchange rate","JPN","Japan","2011","2011",7143.9,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","MTMOTCMT","Million US$ at exchange rate","JPN","Japan","2012","2012",7173.2,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","MTMOTCMT","Million US$ at exchange rate","JPN","Japan","2013","2013",5457.1,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","MTMOTCMT","Million US$ at exchange rate","JPN","Japan","2014","2014",4571.5,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","MTMOTCMT","Million US$ at exchange rate","JPN","Japan","2015","2015",3833.9,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","MTMOTCMT","Million US$ at exchange rate","JPN","Japan","2016","2016",3679.7,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","MTMOTCMT","Million US$ at exchange rate","JPN","Japan","2017","2017",3597.3,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","MTMOTCMT","Million US$ at exchange rate","JPN","Japan","2018","2018",3400.7,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","MTMOTCMT","Million US$ at exchange rate","JPN","Japan","2019","2019",5154.6,"B; D","Break; Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","MTMOTCMT","Million US$ at exchange rate","JPN","Japan","2020","2020",5250.6,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","MTMOTCMT","Million US$ at exchange rate","JPN","Japan","2021","2021",4928.4,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","MTMOPPMT","Million US$, purchasing power parity","JPN","Japan","2010","2010",5209.6,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","MTMOPPMT","Million US$, purchasing power parity","JPN","Japan","2011","2011",5305.8,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","MTMOPPMT","Million US$, purchasing power parity","JPN","Japan","2012","2012",5488.9,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","MTMOPPMT","Million US$, purchasing power parity","JPN","Japan","2013","2013",5257.4,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","MTMOPPMT","Million US$, purchasing power parity","JPN","Japan","2014","2014",4699.9,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","MTMOPPMT","Million US$, purchasing power parity","JPN","Japan","2015","2015",4485.1,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","MTMOPPMT","Million US$, purchasing power parity","JPN","Japan","2016","2016",3793.9,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","MTMOPPMT","Million US$, purchasing power parity","JPN","Japan","2017","2017",3839.1,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","MTMOPPMT","Million US$, purchasing power parity","JPN","Japan","2018","2018",3605.2,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","MTMOPPMT","Million US$, purchasing power parity","JPN","Japan","2019","2019",5391.2,"B; D","Break; Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","MTMOPPMT","Million US$, purchasing power parity","JPN","Japan","2020","2020",5473.4,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","MTMOPPMT","Million US$, purchasing power parity","JPN","Japan","2021","2021",5300.5,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","TCPPERMT","/capita, US$ exchange rate","JPN","Japan","2010","2010",51.8,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","TCPPERMT","/capita, US$ exchange rate","JPN","Japan","2011","2011",55.9,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","TCPPERMT","/capita, US$ exchange rate","JPN","Japan","2012","2012",56.2,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","TCPPERMT","/capita, US$ exchange rate","JPN","Japan","2013","2013",42.8,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","TCPPERMT","/capita, US$ exchange rate","JPN","Japan","2014","2014",35.9,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","TCPPERMT","/capita, US$ exchange rate","JPN","Japan","2015","2015",30.2,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","TCPPERMT","/capita, US$ exchange rate","JPN","Japan","2016","2016",29,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","TCPPERMT","/capita, US$ exchange rate","JPN","Japan","2017","2017",28.4,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","TCPPERMT","/capita, US$ exchange rate","JPN","Japan","2018","2018",26.9,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","TCPPERMT","/capita, US$ exchange rate","JPN","Japan","2019","2019",40.9,"B; D","Break; Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","TCPPERMT","/capita, US$ exchange rate","JPN","Japan","2020","2020",41.6,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","TCPPERMT","/capita, US$ exchange rate","JPN","Japan","2021","2021",39.3,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","JPN","Japan","2010","2010",40.7,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","JPN","Japan","2011","2011",41.5,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","JPN","Japan","2012","2012",43,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","JPN","Japan","2013","2013",41.3,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","JPN","Japan","2014","2014",36.9,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","JPN","Japan","2015","2015",35.3,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","JPN","Japan","2016","2016",29.9,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","JPN","Japan","2017","2017",30.3,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","JPN","Japan","2018","2018",28.5,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","JPN","Japan","2019","2019",42.7,"B; D","Break; Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","JPN","Japan","2020","2020",43.4,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","JPN","Japan","2021","2021",42.2,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","ATCPTTMT","% of total sales","JPN","Japan","2010","2010",8.6,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","ATCPTTMT","% of total sales","JPN","Japan","2011","2011",8.2,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","ATCPTTMT","% of total sales","JPN","Japan","2012","2012",8.2,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","ATCPTTMT","% of total sales","JPN","Japan","2013","2013",7.7,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","ATCPTTMT","% of total sales","JPN","Japan","2014","2014",7.3,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","ATCPTTMT","% of total sales","JPN","Japan","2015","2015",6.9,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","ATCPTTMT","% of total sales","JPN","Japan","2016","2016",6,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","ATCPTTMT","% of total sales","JPN","Japan","2017","2017",6,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","ATCPTTMT","% of total sales","JPN","Japan","2018","2018",5.4,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","ATCPTTMT","% of total sales","JPN","Japan","2019","2019",5.9,"B; D","Break; Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","ATCPTTMT","% of total sales","JPN","Japan","2020","2020",6.1,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","ATCPTTMT","% of total sales","JPN","Japan","2021","2021",5.9,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","MLLNCUMT","Million of national currency units","KOR","Korea","2010","2010",3258189,,
+"PATCALIM","A-Alimentary tract and metabolism","MLLNCUMT","Million of national currency units","KOR","Korea","2011","2011",3370253.9,"B","Break"
+"PATCALIM","A-Alimentary tract and metabolism","MLLNCUMT","Million of national currency units","KOR","Korea","2012","2012",3197570.2,,
+"PATCALIM","A-Alimentary tract and metabolism","MLLNCUMT","Million of national currency units","KOR","Korea","2013","2013",3351225.1,,
+"PATCALIM","A-Alimentary tract and metabolism","MLLNCUMT","Million of national currency units","KOR","Korea","2014","2014",3508305.2,,
+"PATCALIM","A-Alimentary tract and metabolism","MLLNCUMT","Million of national currency units","KOR","Korea","2015","2015",3705647.1,,
+"PATCALIM","A-Alimentary tract and metabolism","MLLNCUMT","Million of national currency units","KOR","Korea","2016","2016",3857818.7,"B","Break"
+"PATCALIM","A-Alimentary tract and metabolism","MLLNCUMT","Million of national currency units","KOR","Korea","2017","2017",4137071.1,,
+"PATCALIM","A-Alimentary tract and metabolism","MLLNCUMT","Million of national currency units","KOR","Korea","2018","2018",4431342.5,,
+"PATCALIM","A-Alimentary tract and metabolism","MLLNCUMT","Million of national currency units","KOR","Korea","2019","2019",4752462.9,,
+"PATCALIM","A-Alimentary tract and metabolism","MLLNCUMT","Million of national currency units","KOR","Korea","2020","2020",5102463.6,,
+"PATCALIM","A-Alimentary tract and metabolism","MLLNCUMT","Million of national currency units","KOR","Korea","2021","2021",5476282.6,,
+"PATCALIM","A-Alimentary tract and metabolism","MTMOTCMT","Million US$ at exchange rate","KOR","Korea","2010","2010",2817.4,,
+"PATCALIM","A-Alimentary tract and metabolism","MTMOTCMT","Million US$ at exchange rate","KOR","Korea","2011","2011",3041.1,"B","Break"
+"PATCALIM","A-Alimentary tract and metabolism","MTMOTCMT","Million US$ at exchange rate","KOR","Korea","2012","2012",2837.7,,
+"PATCALIM","A-Alimentary tract and metabolism","MTMOTCMT","Million US$ at exchange rate","KOR","Korea","2013","2013",3060.5,,
+"PATCALIM","A-Alimentary tract and metabolism","MTMOTCMT","Million US$ at exchange rate","KOR","Korea","2014","2014",3332.2,,
+"PATCALIM","A-Alimentary tract and metabolism","MTMOTCMT","Million US$ at exchange rate","KOR","Korea","2015","2015",3276.6,,
+"PATCALIM","A-Alimentary tract and metabolism","MTMOTCMT","Million US$ at exchange rate","KOR","Korea","2016","2016",3323.5,"B","Break"
+"PATCALIM","A-Alimentary tract and metabolism","MTMOTCMT","Million US$ at exchange rate","KOR","Korea","2017","2017",3657.9,,
+"PATCALIM","A-Alimentary tract and metabolism","MTMOTCMT","Million US$ at exchange rate","KOR","Korea","2018","2018",4027.9,,
+"PATCALIM","A-Alimentary tract and metabolism","MTMOTCMT","Million US$ at exchange rate","KOR","Korea","2019","2019",4078.1,,
+"PATCALIM","A-Alimentary tract and metabolism","MTMOTCMT","Million US$ at exchange rate","KOR","Korea","2020","2020",4323.1,,
+"PATCALIM","A-Alimentary tract and metabolism","MTMOTCMT","Million US$ at exchange rate","KOR","Korea","2021","2021",4787.2,,
+"PATCALIM","A-Alimentary tract and metabolism","MTMOPPMT","Million US$, purchasing power parity","KOR","Korea","2010","2010",3874.2,,
+"PATCALIM","A-Alimentary tract and metabolism","MTMOPPMT","Million US$, purchasing power parity","KOR","Korea","2011","2011",3943.7,"B","Break"
+"PATCALIM","A-Alimentary tract and metabolism","MTMOPPMT","Million US$, purchasing power parity","KOR","Korea","2012","2012",3740.3,,
+"PATCALIM","A-Alimentary tract and metabolism","MTMOPPMT","Million US$, purchasing power parity","KOR","Korea","2013","2013",3856.1,,
+"PATCALIM","A-Alimentary tract and metabolism","MTMOPPMT","Million US$, purchasing power parity","KOR","Korea","2014","2014",4023.8,,
+"PATCALIM","A-Alimentary tract and metabolism","MTMOPPMT","Million US$, purchasing power parity","KOR","Korea","2015","2015",4321.5,,
+"PATCALIM","A-Alimentary tract and metabolism","MTMOPPMT","Million US$, purchasing power parity","KOR","Korea","2016","2016",4492.1,"B","Break"
+"PATCALIM","A-Alimentary tract and metabolism","MTMOPPMT","Million US$, purchasing power parity","KOR","Korea","2017","2017",4741,,
+"PATCALIM","A-Alimentary tract and metabolism","MTMOPPMT","Million US$, purchasing power parity","KOR","Korea","2018","2018",5183.6,,
+"PATCALIM","A-Alimentary tract and metabolism","MTMOPPMT","Million US$, purchasing power parity","KOR","Korea","2019","2019",5549.2,,
+"PATCALIM","A-Alimentary tract and metabolism","MTMOPPMT","Million US$, purchasing power parity","KOR","Korea","2020","2020",6091.2,,
+"PATCALIM","A-Alimentary tract and metabolism","MTMOPPMT","Million US$, purchasing power parity","KOR","Korea","2021","2021",6411.8,,
+"PATCALIM","A-Alimentary tract and metabolism","TCPPERMT","/capita, US$ exchange rate","KOR","Korea","2010","2010",56.9,,
+"PATCALIM","A-Alimentary tract and metabolism","TCPPERMT","/capita, US$ exchange rate","KOR","Korea","2011","2011",60.9,"B","Break"
+"PATCALIM","A-Alimentary tract and metabolism","TCPPERMT","/capita, US$ exchange rate","KOR","Korea","2012","2012",56.5,,
+"PATCALIM","A-Alimentary tract and metabolism","TCPPERMT","/capita, US$ exchange rate","KOR","Korea","2013","2013",60.7,,
+"PATCALIM","A-Alimentary tract and metabolism","TCPPERMT","/capita, US$ exchange rate","KOR","Korea","2014","2014",65.7,,
+"PATCALIM","A-Alimentary tract and metabolism","TCPPERMT","/capita, US$ exchange rate","KOR","Korea","2015","2015",64.2,,
+"PATCALIM","A-Alimentary tract and metabolism","TCPPERMT","/capita, US$ exchange rate","KOR","Korea","2016","2016",64.9,"B","Break"
+"PATCALIM","A-Alimentary tract and metabolism","TCPPERMT","/capita, US$ exchange rate","KOR","Korea","2017","2017",71.2,,
+"PATCALIM","A-Alimentary tract and metabolism","TCPPERMT","/capita, US$ exchange rate","KOR","Korea","2018","2018",78.1,,
+"PATCALIM","A-Alimentary tract and metabolism","TCPPERMT","/capita, US$ exchange rate","KOR","Korea","2019","2019",78.8,,
+"PATCALIM","A-Alimentary tract and metabolism","TCPPERMT","/capita, US$ exchange rate","KOR","Korea","2020","2020",83.4,,
+"PATCALIM","A-Alimentary tract and metabolism","TCPPERMT","/capita, US$ exchange rate","KOR","Korea","2021","2021",92.5,,
+"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2010","2010",78.2,,
+"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2011","2011",79,"B","Break"
+"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2012","2012",74.5,,
+"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2013","2013",76.5,,
+"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2014","2014",79.3,,
+"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2015","2015",84.7,,
+"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2016","2016",87.7,"B","Break"
+"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2017","2017",92.3,,
+"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2018","2018",100.5,,
+"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2019","2019",107.2,,
+"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2020","2020",117.5,,
+"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2021","2021",123.9,,
+"PATCALIM","A-Alimentary tract and metabolism","ATCPTTMT","% of total sales","KOR","Korea","2010","2010",16,,
+"PATCALIM","A-Alimentary tract and metabolism","ATCPTTMT","% of total sales","KOR","Korea","2011","2011",15.3,"B","Break"
+"PATCALIM","A-Alimentary tract and metabolism","ATCPTTMT","% of total sales","KOR","Korea","2012","2012",14.7,,
+"PATCALIM","A-Alimentary tract and metabolism","ATCPTTMT","% of total sales","KOR","Korea","2013","2013",14.9,,
+"PATCALIM","A-Alimentary tract and metabolism","ATCPTTMT","% of total sales","KOR","Korea","2014","2014",14.8,,
+"PATCALIM","A-Alimentary tract and metabolism","ATCPTTMT","% of total sales","KOR","Korea","2015","2015",15.1,,
+"PATCALIM","A-Alimentary tract and metabolism","ATCPTTMT","% of total sales","KOR","Korea","2016","2016",15.2,"B","Break"
+"PATCALIM","A-Alimentary tract and metabolism","ATCPTTMT","% of total sales","KOR","Korea","2017","2017",15.3,,
+"PATCALIM","A-Alimentary tract and metabolism","ATCPTTMT","% of total sales","KOR","Korea","2018","2018",15.3,,
+"PATCALIM","A-Alimentary tract and metabolism","ATCPTTMT","% of total sales","KOR","Korea","2019","2019",15.3,,
+"PATCALIM","A-Alimentary tract and metabolism","ATCPTTMT","% of total sales","KOR","Korea","2020","2020",15.7,,
+"PATCALIM","A-Alimentary tract and metabolism","ATCPTTMT","% of total sales","KOR","Korea","2021","2021",15.8,,
+"PATCALIM","A-Alimentary tract and metabolism","MLLNCUMT","Million of national currency units","LUX","Luxembourg","2010","2010",28.5,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","MLLNCUMT","Million of national currency units","LUX","Luxembourg","2011","2011",28.4,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","MLLNCUMT","Million of national currency units","LUX","Luxembourg","2012","2012",29.9,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","MLLNCUMT","Million of national currency units","LUX","Luxembourg","2013","2013",31.6,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","MLLNCUMT","Million of national currency units","LUX","Luxembourg","2014","2014",32.9,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","MLLNCUMT","Million of national currency units","LUX","Luxembourg","2015","2015",33.3,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","MLLNCUMT","Million of national currency units","LUX","Luxembourg","2016","2016",34.4,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","MLLNCUMT","Million of national currency units","LUX","Luxembourg","2017","2017",35.2,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","MLLNCUMT","Million of national currency units","LUX","Luxembourg","2018","2018",36.6,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","MLLNCUMT","Million of national currency units","LUX","Luxembourg","2019","2019",38.2,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","MLLNCUMT","Million of national currency units","LUX","Luxembourg","2020","2020",39.2,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","MLLNCUMT","Million of national currency units","LUX","Luxembourg","2021","2021",42.3,"B; D; P","Break; Difference in methodology; Provisional value"
+"PATCALIM","A-Alimentary tract and metabolism","MLLNCUMT","Million of national currency units","LUX","Luxembourg","2022","2022",42.7,"D; P","Difference in methodology; Provisional value"
+"PATCALIM","A-Alimentary tract and metabolism","MTMOTCMT","Million US$ at exchange rate","LUX","Luxembourg","2010","2010",37.8,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","MTMOTCMT","Million US$ at exchange rate","LUX","Luxembourg","2011","2011",39.5,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","MTMOTCMT","Million US$ at exchange rate","LUX","Luxembourg","2012","2012",38.4,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","MTMOTCMT","Million US$ at exchange rate","LUX","Luxembourg","2013","2013",42,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","MTMOTCMT","Million US$ at exchange rate","LUX","Luxembourg","2014","2014",43.7,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","MTMOTCMT","Million US$ at exchange rate","LUX","Luxembourg","2015","2015",36.9,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","MTMOTCMT","Million US$ at exchange rate","LUX","Luxembourg","2016","2016",38,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","MTMOTCMT","Million US$ at exchange rate","LUX","Luxembourg","2017","2017",39.8,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","MTMOTCMT","Million US$ at exchange rate","LUX","Luxembourg","2018","2018",43.2,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","MTMOTCMT","Million US$ at exchange rate","LUX","Luxembourg","2019","2019",42.8,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","MTMOTCMT","Million US$ at exchange rate","LUX","Luxembourg","2020","2020",44.8,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","MTMOTCMT","Million US$ at exchange rate","LUX","Luxembourg","2021","2021",50,"B; D; P","Break; Difference in methodology; Provisional value"
+"PATCALIM","A-Alimentary tract and metabolism","MTMOTCMT","Million US$ at exchange rate","LUX","Luxembourg","2022","2022",45,"D; P","Difference in methodology; Provisional value"
+"PATCALIM","A-Alimentary tract and metabolism","MTMOPPMT","Million US$, purchasing power parity","LUX","Luxembourg","2010","2010",30.8,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","MTMOPPMT","Million US$, purchasing power parity","LUX","Luxembourg","2011","2011",31.4,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","MTMOPPMT","Million US$, purchasing power parity","LUX","Luxembourg","2012","2012",33,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","MTMOPPMT","Million US$, purchasing power parity","LUX","Luxembourg","2013","2013",35.3,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","MTMOPPMT","Million US$, purchasing power parity","LUX","Luxembourg","2014","2014",37.2,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","MTMOPPMT","Million US$, purchasing power parity","LUX","Luxembourg","2015","2015",37.8,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","MTMOPPMT","Million US$, purchasing power parity","LUX","Luxembourg","2016","2016",40.3,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","MTMOPPMT","Million US$, purchasing power parity","LUX","Luxembourg","2017","2017",41.5,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","MTMOPPMT","Million US$, purchasing power parity","LUX","Luxembourg","2018","2018",43.1,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","MTMOPPMT","Million US$, purchasing power parity","LUX","Luxembourg","2019","2019",45.4,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","MTMOPPMT","Million US$, purchasing power parity","LUX","Luxembourg","2020","2020",45.8,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","MTMOPPMT","Million US$, purchasing power parity","LUX","Luxembourg","2021","2021",49.3,"B; D; P","Break; Difference in methodology; Provisional value"
+"PATCALIM","A-Alimentary tract and metabolism","MTMOPPMT","Million US$, purchasing power parity","LUX","Luxembourg","2022","2022",51.3,"D; P","Difference in methodology; Provisional value"
+"PATCALIM","A-Alimentary tract and metabolism","TCPPERMT","/capita, US$ exchange rate","LUX","Luxembourg","2010","2010",79.9,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","TCPPERMT","/capita, US$ exchange rate","LUX","Luxembourg","2011","2011",82,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","TCPPERMT","/capita, US$ exchange rate","LUX","Luxembourg","2012","2012",78,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","TCPPERMT","/capita, US$ exchange rate","LUX","Luxembourg","2013","2013",83.6,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","TCPPERMT","/capita, US$ exchange rate","LUX","Luxembourg","2014","2014",85.5,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","TCPPERMT","/capita, US$ exchange rate","LUX","Luxembourg","2015","2015",71.2,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","TCPPERMT","/capita, US$ exchange rate","LUX","Luxembourg","2016","2016",72.2,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","TCPPERMT","/capita, US$ exchange rate","LUX","Luxembourg","2017","2017",74.3,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","TCPPERMT","/capita, US$ exchange rate","LUX","Luxembourg","2018","2018",79.1,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","TCPPERMT","/capita, US$ exchange rate","LUX","Luxembourg","2019","2019",76.9,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","TCPPERMT","/capita, US$ exchange rate","LUX","Luxembourg","2020","2020",79,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","TCPPERMT","/capita, US$ exchange rate","LUX","Luxembourg","2021","2021",87,"B; D; P","Break; Difference in methodology; Provisional value"
+"PATCALIM","A-Alimentary tract and metabolism","TCPPERMT","/capita, US$ exchange rate","LUX","Luxembourg","2022","2022",76.6,"D; P","Difference in methodology; Provisional value"
+"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2010","2010",65.1,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2011","2011",65.1,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2012","2012",66.9,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2013","2013",70.3,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2014","2014",72.8,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2015","2015",72.9,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2016","2016",76.6,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2017","2017",77.5,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2018","2018",78.9,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2019","2019",81.6,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2020","2020",80.7,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2021","2021",85.6,"B; D; P","Break; Difference in methodology; Provisional value"
+"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2022","2022",87.5,"D; P","Difference in methodology; Provisional value"
+"PATCALIM","A-Alimentary tract and metabolism","ATCPTTMT","% of total sales","LUX","Luxembourg","2010","2010",15.1,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","ATCPTTMT","% of total sales","LUX","Luxembourg","2011","2011",14.9,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","ATCPTTMT","% of total sales","LUX","Luxembourg","2012","2012",15.3,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","ATCPTTMT","% of total sales","LUX","Luxembourg","2013","2013",16.2,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","ATCPTTMT","% of total sales","LUX","Luxembourg","2014","2014",17.2,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","ATCPTTMT","% of total sales","LUX","Luxembourg","2015","2015",17.3,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","ATCPTTMT","% of total sales","LUX","Luxembourg","2016","2016",17.6,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","ATCPTTMT","% of total sales","LUX","Luxembourg","2017","2017",18.2,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","ATCPTTMT","% of total sales","LUX","Luxembourg","2018","2018",18.4,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","ATCPTTMT","% of total sales","LUX","Luxembourg","2019","2019",18.7,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","ATCPTTMT","% of total sales","LUX","Luxembourg","2020","2020",18.7,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","ATCPTTMT","% of total sales","LUX","Luxembourg","2021","2021",17.7,"B; D; P","Break; Difference in methodology; Provisional value"
+"PATCALIM","A-Alimentary tract and metabolism","ATCPTTMT","% of total sales","LUX","Luxembourg","2022","2022",16.6,"D; P","Difference in methodology; Provisional value"
+"PATCALIM","A-Alimentary tract and metabolism","MLLNCUMT","Million of national currency units","NLD","Netherlands","2010","2010",668,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","MLLNCUMT","Million of national currency units","NLD","Netherlands","2011","2011",684.3,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","MLLNCUMT","Million of national currency units","NLD","Netherlands","2012","2012",646.6,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","MLLNCUMT","Million of national currency units","NLD","Netherlands","2013","2013",651.8,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","MLLNCUMT","Million of national currency units","NLD","Netherlands","2014","2014",651.6,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","MTMOTCMT","Million US$ at exchange rate","NLD","Netherlands","2010","2010",885.6,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","MTMOTCMT","Million US$ at exchange rate","NLD","Netherlands","2011","2011",952.6,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","MTMOTCMT","Million US$ at exchange rate","NLD","Netherlands","2012","2012",830.8,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","MTMOTCMT","Million US$ at exchange rate","NLD","Netherlands","2013","2013",865.6,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","MTMOTCMT","Million US$ at exchange rate","NLD","Netherlands","2014","2014",865.6,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","MTMOPPMT","Million US$, purchasing power parity","NLD","Netherlands","2010","2010",782.1,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","MTMOPPMT","Million US$, purchasing power parity","NLD","Netherlands","2011","2011",818.5,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","MTMOPPMT","Million US$, purchasing power parity","NLD","Netherlands","2012","2012",784.3,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","MTMOPPMT","Million US$, purchasing power parity","NLD","Netherlands","2013","2013",816.6,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","MTMOPPMT","Million US$, purchasing power parity","NLD","Netherlands","2014","2014",805.6,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","TCPPERMT","/capita, US$ exchange rate","NLD","Netherlands","2010","2010",53.3,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","TCPPERMT","/capita, US$ exchange rate","NLD","Netherlands","2011","2011",57.1,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","TCPPERMT","/capita, US$ exchange rate","NLD","Netherlands","2012","2012",49.6,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","TCPPERMT","/capita, US$ exchange rate","NLD","Netherlands","2013","2013",51.5,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","TCPPERMT","/capita, US$ exchange rate","NLD","Netherlands","2014","2014",51.3,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","NLD","Netherlands","2010","2010",47.1,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","NLD","Netherlands","2011","2011",49,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","NLD","Netherlands","2012","2012",46.8,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","NLD","Netherlands","2013","2013",48.6,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","NLD","Netherlands","2014","2014",47.8,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","ATCPTTMT","% of total sales","NLD","Netherlands","2010","2010",12.8,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","ATCPTTMT","% of total sales","NLD","Netherlands","2011","2011",13.1,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","ATCPTTMT","% of total sales","NLD","Netherlands","2012","2012",14,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","ATCPTTMT","% of total sales","NLD","Netherlands","2013","2013",15.2,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","ATCPTTMT","% of total sales","NLD","Netherlands","2014","2014",15.1,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","MLLNCUMT","Million of national currency units","NZL","New Zealand","2010","2010",68.2,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","MLLNCUMT","Million of national currency units","NZL","New Zealand","2011","2011",71.7,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","MLLNCUMT","Million of national currency units","NZL","New Zealand","2012","2012",71.7,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","MLLNCUMT","Million of national currency units","NZL","New Zealand","2013","2013",75.2,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","MLLNCUMT","Million of national currency units","NZL","New Zealand","2014","2014",79.2,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","MLLNCUMT","Million of national currency units","NZL","New Zealand","2015","2015",90.2,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","MLLNCUMT","Million of national currency units","NZL","New Zealand","2016","2016",91.1,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","MLLNCUMT","Million of national currency units","NZL","New Zealand","2017","2017",88.7,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","MLLNCUMT","Million of national currency units","NZL","New Zealand","2018","2018",97.8,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","MLLNCUMT","Million of national currency units","NZL","New Zealand","2019","2019",98.3,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","MLLNCUMT","Million of national currency units","NZL","New Zealand","2020","2020",116.3,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","MLLNCUMT","Million of national currency units","NZL","New Zealand","2021","2021",132.3,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","MLLNCUMT","Million of national currency units","NZL","New Zealand","2022","2022",174,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","MTMOTCMT","Million US$ at exchange rate","NZL","New Zealand","2010","2010",49.2,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","MTMOTCMT","Million US$ at exchange rate","NZL","New Zealand","2011","2011",56.6,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","MTMOTCMT","Million US$ at exchange rate","NZL","New Zealand","2012","2012",58.1,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","MTMOTCMT","Million US$ at exchange rate","NZL","New Zealand","2013","2013",61.7,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","MTMOTCMT","Million US$ at exchange rate","NZL","New Zealand","2014","2014",65.7,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","MTMOTCMT","Million US$ at exchange rate","NZL","New Zealand","2015","2015",62.9,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","MTMOTCMT","Million US$ at exchange rate","NZL","New Zealand","2016","2016",63.4,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","MTMOTCMT","Million US$ at exchange rate","NZL","New Zealand","2017","2017",63,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","MTMOTCMT","Million US$ at exchange rate","NZL","New Zealand","2018","2018",67.7,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","MTMOTCMT","Million US$ at exchange rate","NZL","New Zealand","2019","2019",64.8,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","MTMOTCMT","Million US$ at exchange rate","NZL","New Zealand","2020","2020",75.4,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","MTMOTCMT","Million US$ at exchange rate","NZL","New Zealand","2021","2021",93.5,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","MTMOTCMT","Million US$ at exchange rate","NZL","New Zealand","2022","2022",110.3,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","MTMOPPMT","Million US$, purchasing power parity","NZL","New Zealand","2010","2010",45.6,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","MTMOPPMT","Million US$, purchasing power parity","NZL","New Zealand","2011","2011",48.2,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","MTMOPPMT","Million US$, purchasing power parity","NZL","New Zealand","2012","2012",48,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","MTMOPPMT","Million US$, purchasing power parity","NZL","New Zealand","2013","2013",52,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","MTMOPPMT","Million US$, purchasing power parity","NZL","New Zealand","2014","2014",55,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","MTMOPPMT","Million US$, purchasing power parity","NZL","New Zealand","2015","2015",61,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","MTMOPPMT","Million US$, purchasing power parity","NZL","New Zealand","2016","2016",63.2,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","MTMOPPMT","Million US$, purchasing power parity","NZL","New Zealand","2017","2017",62,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","MTMOPPMT","Million US$, purchasing power parity","NZL","New Zealand","2018","2018",66.5,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","MTMOPPMT","Million US$, purchasing power parity","NZL","New Zealand","2019","2019",69.4,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","MTMOPPMT","Million US$, purchasing power parity","NZL","New Zealand","2020","2020",82.2,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","MTMOPPMT","Million US$, purchasing power parity","NZL","New Zealand","2021","2021",90.6,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","MTMOPPMT","Million US$, purchasing power parity","NZL","New Zealand","2022","2022",120.7,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","TCPPERMT","/capita, US$ exchange rate","NZL","New Zealand","2010","2010",11.3,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","TCPPERMT","/capita, US$ exchange rate","NZL","New Zealand","2011","2011",12.9,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","TCPPERMT","/capita, US$ exchange rate","NZL","New Zealand","2012","2012",13.2,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","TCPPERMT","/capita, US$ exchange rate","NZL","New Zealand","2013","2013",13.9,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","TCPPERMT","/capita, US$ exchange rate","NZL","New Zealand","2014","2014",14.5,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","TCPPERMT","/capita, US$ exchange rate","NZL","New Zealand","2015","2015",13.6,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","TCPPERMT","/capita, US$ exchange rate","NZL","New Zealand","2016","2016",13.5,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","TCPPERMT","/capita, US$ exchange rate","NZL","New Zealand","2017","2017",13.1,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","TCPPERMT","/capita, US$ exchange rate","NZL","New Zealand","2018","2018",13.8,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","TCPPERMT","/capita, US$ exchange rate","NZL","New Zealand","2019","2019",13,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","TCPPERMT","/capita, US$ exchange rate","NZL","New Zealand","2020","2020",14.8,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","TCPPERMT","/capita, US$ exchange rate","NZL","New Zealand","2021","2021",18.3,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","TCPPERMT","/capita, US$ exchange rate","NZL","New Zealand","2022","2022",21.5,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2010","2010",10.5,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2011","2011",11,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2012","2012",10.9,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2013","2013",11.7,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2014","2014",12.2,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2015","2015",13.2,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2016","2016",13.4,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2017","2017",12.9,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2018","2018",13.6,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2019","2019",13.9,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2020","2020",16.2,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2021","2021",17.7,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2022","2022",23.5,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","ATCPTTMT","% of total sales","NZL","New Zealand","2010","2010",9.1,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","ATCPTTMT","% of total sales","NZL","New Zealand","2011","2011",8.8,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","ATCPTTMT","% of total sales","NZL","New Zealand","2012","2012",7.8,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","ATCPTTMT","% of total sales","NZL","New Zealand","2013","2013",8.1,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","ATCPTTMT","% of total sales","NZL","New Zealand","2014","2014",8.3,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","ATCPTTMT","% of total sales","NZL","New Zealand","2015","2015",9.1,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","ATCPTTMT","% of total sales","NZL","New Zealand","2016","2016",8.5,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","ATCPTTMT","% of total sales","NZL","New Zealand","2017","2017",7,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","ATCPTTMT","% of total sales","NZL","New Zealand","2018","2018",7.4,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","ATCPTTMT","% of total sales","NZL","New Zealand","2019","2019",6.6,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","ATCPTTMT","% of total sales","NZL","New Zealand","2020","2020",7,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","ATCPTTMT","% of total sales","NZL","New Zealand","2021","2021",7.4,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","ATCPTTMT","% of total sales","NZL","New Zealand","2022","2022",9.1,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","MLLNCUMT","Million of national currency units","NOR","Norway","2010","2010",1829,,
+"PATCALIM","A-Alimentary tract and metabolism","MLLNCUMT","Million of national currency units","NOR","Norway","2011","2011",1886,,
+"PATCALIM","A-Alimentary tract and metabolism","MLLNCUMT","Million of national currency units","NOR","Norway","2012","2012",1910,,
+"PATCALIM","A-Alimentary tract and metabolism","MLLNCUMT","Million of national currency units","NOR","Norway","2013","2013",1915,,
+"PATCALIM","A-Alimentary tract and metabolism","MLLNCUMT","Million of national currency units","NOR","Norway","2014","2014",2061,,
+"PATCALIM","A-Alimentary tract and metabolism","MLLNCUMT","Million of national currency units","NOR","Norway","2015","2015",2224,,
+"PATCALIM","A-Alimentary tract and metabolism","MLLNCUMT","Million of national currency units","NOR","Norway","2016","2016",2559,,
+"PATCALIM","A-Alimentary tract and metabolism","MLLNCUMT","Million of national currency units","NOR","Norway","2017","2017",2775,,
+"PATCALIM","A-Alimentary tract and metabolism","MLLNCUMT","Million of national currency units","NOR","Norway","2018","2018",2944,,
+"PATCALIM","A-Alimentary tract and metabolism","MLLNCUMT","Million of national currency units","NOR","Norway","2019","2019",3134,,
+"PATCALIM","A-Alimentary tract and metabolism","MLLNCUMT","Million of national currency units","NOR","Norway","2020","2020",3470,,
+"PATCALIM","A-Alimentary tract and metabolism","MLLNCUMT","Million of national currency units","NOR","Norway","2021","2021",4141,,
+"PATCALIM","A-Alimentary tract and metabolism","MLLNCUMT","Million of national currency units","NOR","Norway","2022","2022",5090,,
+"PATCALIM","A-Alimentary tract and metabolism","MTMOTCMT","Million US$ at exchange rate","NOR","Norway","2010","2010",302.6,,
+"PATCALIM","A-Alimentary tract and metabolism","MTMOTCMT","Million US$ at exchange rate","NOR","Norway","2011","2011",336.5,,
+"PATCALIM","A-Alimentary tract and metabolism","MTMOTCMT","Million US$ at exchange rate","NOR","Norway","2012","2012",328.3,,
+"PATCALIM","A-Alimentary tract and metabolism","MTMOTCMT","Million US$ at exchange rate","NOR","Norway","2013","2013",326,,
+"PATCALIM","A-Alimentary tract and metabolism","MTMOTCMT","Million US$ at exchange rate","NOR","Norway","2014","2014",327.1,,
+"PATCALIM","A-Alimentary tract and metabolism","MTMOTCMT","Million US$ at exchange rate","NOR","Norway","2015","2015",275.8,,
+"PATCALIM","A-Alimentary tract and metabolism","MTMOTCMT","Million US$ at exchange rate","NOR","Norway","2016","2016",304.6,,
+"PATCALIM","A-Alimentary tract and metabolism","MTMOTCMT","Million US$ at exchange rate","NOR","Norway","2017","2017",335.5,,
+"PATCALIM","A-Alimentary tract and metabolism","MTMOTCMT","Million US$ at exchange rate","NOR","Norway","2018","2018",362,,
+"PATCALIM","A-Alimentary tract and metabolism","MTMOTCMT","Million US$ at exchange rate","NOR","Norway","2019","2019",356.1,,
+"PATCALIM","A-Alimentary tract and metabolism","MTMOTCMT","Million US$ at exchange rate","NOR","Norway","2020","2020",368.5,,
+"PATCALIM","A-Alimentary tract and metabolism","MTMOTCMT","Million US$ at exchange rate","NOR","Norway","2021","2021",482.1,,
+"PATCALIM","A-Alimentary tract and metabolism","MTMOTCMT","Million US$ at exchange rate","NOR","Norway","2022","2022",529.4,,
+"PATCALIM","A-Alimentary tract and metabolism","MTMOPPMT","Million US$, purchasing power parity","NOR","Norway","2010","2010",199.9,,
+"PATCALIM","A-Alimentary tract and metabolism","MTMOPPMT","Million US$, purchasing power parity","NOR","Norway","2011","2011",207.6,,
+"PATCALIM","A-Alimentary tract and metabolism","MTMOPPMT","Million US$, purchasing power parity","NOR","Norway","2012","2012",211.4,,
+"PATCALIM","A-Alimentary tract and metabolism","MTMOPPMT","Million US$, purchasing power parity","NOR","Norway","2013","2013",212.1,,
+"PATCALIM","A-Alimentary tract and metabolism","MTMOPPMT","Million US$, purchasing power parity","NOR","Norway","2014","2014",222.1,,
+"PATCALIM","A-Alimentary tract and metabolism","MTMOPPMT","Million US$, purchasing power parity","NOR","Norway","2015","2015",223.9,,
+"PATCALIM","A-Alimentary tract and metabolism","MTMOPPMT","Million US$, purchasing power parity","NOR","Norway","2016","2016",254.8,,
+"PATCALIM","A-Alimentary tract and metabolism","MTMOPPMT","Million US$, purchasing power parity","NOR","Norway","2017","2017",284.6,,
+"PATCALIM","A-Alimentary tract and metabolism","MTMOPPMT","Million US$, purchasing power parity","NOR","Norway","2018","2018",307.2,,
+"PATCALIM","A-Alimentary tract and metabolism","MTMOPPMT","Million US$, purchasing power parity","NOR","Norway","2019","2019",325.8,,
+"PATCALIM","A-Alimentary tract and metabolism","MTMOPPMT","Million US$, purchasing power parity","NOR","Norway","2020","2020",351.2,,
+"PATCALIM","A-Alimentary tract and metabolism","MTMOPPMT","Million US$, purchasing power parity","NOR","Norway","2021","2021",435.3,,
+"PATCALIM","A-Alimentary tract and metabolism","MTMOPPMT","Million US$, purchasing power parity","NOR","Norway","2022","2022",473.9,,
+"PATCALIM","A-Alimentary tract and metabolism","TCPPERMT","/capita, US$ exchange rate","NOR","Norway","2010","2010",61.9,,
+"PATCALIM","A-Alimentary tract and metabolism","TCPPERMT","/capita, US$ exchange rate","NOR","Norway","2011","2011",67.9,,
+"PATCALIM","A-Alimentary tract and metabolism","TCPPERMT","/capita, US$ exchange rate","NOR","Norway","2012","2012",65.4,,
+"PATCALIM","A-Alimentary tract and metabolism","TCPPERMT","/capita, US$ exchange rate","NOR","Norway","2013","2013",64.2,,
+"PATCALIM","A-Alimentary tract and metabolism","TCPPERMT","/capita, US$ exchange rate","NOR","Norway","2014","2014",63.7,,
+"PATCALIM","A-Alimentary tract and metabolism","TCPPERMT","/capita, US$ exchange rate","NOR","Norway","2015","2015",53.2,,
+"PATCALIM","A-Alimentary tract and metabolism","TCPPERMT","/capita, US$ exchange rate","NOR","Norway","2016","2016",58.2,,
+"PATCALIM","A-Alimentary tract and metabolism","TCPPERMT","/capita, US$ exchange rate","NOR","Norway","2017","2017",63.6,,
+"PATCALIM","A-Alimentary tract and metabolism","TCPPERMT","/capita, US$ exchange rate","NOR","Norway","2018","2018",68.1,,
+"PATCALIM","A-Alimentary tract and metabolism","TCPPERMT","/capita, US$ exchange rate","NOR","Norway","2019","2019",66.6,,
+"PATCALIM","A-Alimentary tract and metabolism","TCPPERMT","/capita, US$ exchange rate","NOR","Norway","2020","2020",68.5,,
+"PATCALIM","A-Alimentary tract and metabolism","TCPPERMT","/capita, US$ exchange rate","NOR","Norway","2021","2021",89.1,,
+"PATCALIM","A-Alimentary tract and metabolism","TCPPERMT","/capita, US$ exchange rate","NOR","Norway","2022","2022",97.6,,
+"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2010","2010",40.9,,
+"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2011","2011",41.9,,
+"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2012","2012",42.1,,
+"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2013","2013",41.8,,
+"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2014","2014",43.2,,
+"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2015","2015",43.2,,
+"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2016","2016",48.7,,
+"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2017","2017",53.9,,
+"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2018","2018",57.8,,
+"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2019","2019",60.9,,
+"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2020","2020",65.3,,
+"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2021","2021",80.5,,
+"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2022","2022",87.4,,
+"PATCALIM","A-Alimentary tract and metabolism","ATCPTTMT","% of total sales","NOR","Norway","2010","2010",10.2,,
+"PATCALIM","A-Alimentary tract and metabolism","ATCPTTMT","% of total sales","NOR","Norway","2011","2011",10.4,,
+"PATCALIM","A-Alimentary tract and metabolism","ATCPTTMT","% of total sales","NOR","Norway","2012","2012",10.2,,
+"PATCALIM","A-Alimentary tract and metabolism","ATCPTTMT","% of total sales","NOR","Norway","2013","2013",9.9,,
+"PATCALIM","A-Alimentary tract and metabolism","ATCPTTMT","% of total sales","NOR","Norway","2014","2014",9.8,,
+"PATCALIM","A-Alimentary tract and metabolism","ATCPTTMT","% of total sales","NOR","Norway","2015","2015",9.8,,
+"PATCALIM","A-Alimentary tract and metabolism","ATCPTTMT","% of total sales","NOR","Norway","2016","2016",10.3,,
+"PATCALIM","A-Alimentary tract and metabolism","ATCPTTMT","% of total sales","NOR","Norway","2017","2017",10.4,,
+"PATCALIM","A-Alimentary tract and metabolism","ATCPTTMT","% of total sales","NOR","Norway","2018","2018",10.7,,
+"PATCALIM","A-Alimentary tract and metabolism","ATCPTTMT","% of total sales","NOR","Norway","2019","2019",11,,
+"PATCALIM","A-Alimentary tract and metabolism","ATCPTTMT","% of total sales","NOR","Norway","2020","2020",11.7,,
+"PATCALIM","A-Alimentary tract and metabolism","ATCPTTMT","% of total sales","NOR","Norway","2021","2021",12.3,,
+"PATCALIM","A-Alimentary tract and metabolism","ATCPTTMT","% of total sales","NOR","Norway","2022","2022",14.1,,
+"PATCALIM","A-Alimentary tract and metabolism","MLLNCUMT","Million of national currency units","PRT","Portugal","2010","2010",511.4,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","MLLNCUMT","Million of national currency units","PRT","Portugal","2011","2011",455.8,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","MLLNCUMT","Million of national currency units","PRT","Portugal","2012","2012",400.8,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","MLLNCUMT","Million of national currency units","PRT","Portugal","2013","2013",396.1,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","MLLNCUMT","Million of national currency units","PRT","Portugal","2014","2014",404.8,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","MLLNCUMT","Million of national currency units","PRT","Portugal","2015","2015",440,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","MLLNCUMT","Million of national currency units","PRT","Portugal","2016","2016",460.6,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","MLLNCUMT","Million of national currency units","PRT","Portugal","2017","2017",478,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","MLLNCUMT","Million of national currency units","PRT","Portugal","2018","2018",513,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","MLLNCUMT","Million of national currency units","PRT","Portugal","2019","2019",561.8,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","MLLNCUMT","Million of national currency units","PRT","Portugal","2020","2020",596.2,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","MLLNCUMT","Million of national currency units","PRT","Portugal","2021","2021",658.7,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","MLLNCUMT","Million of national currency units","PRT","Portugal","2022","2022",747.7,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","MTMOTCMT","Million US$ at exchange rate","PRT","Portugal","2010","2010",677.9,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","MTMOTCMT","Million US$ at exchange rate","PRT","Portugal","2011","2011",634.4,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","MTMOTCMT","Million US$ at exchange rate","PRT","Portugal","2012","2012",515,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","MTMOTCMT","Million US$ at exchange rate","PRT","Portugal","2013","2013",526,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","MTMOTCMT","Million US$ at exchange rate","PRT","Portugal","2014","2014",537.8,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","MTMOTCMT","Million US$ at exchange rate","PRT","Portugal","2015","2015",488.2,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","MTMOTCMT","Million US$ at exchange rate","PRT","Portugal","2016","2016",509.8,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","MTMOTCMT","Million US$ at exchange rate","PRT","Portugal","2017","2017",540,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","MTMOTCMT","Million US$ at exchange rate","PRT","Portugal","2018","2018",605.9,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","MTMOTCMT","Million US$ at exchange rate","PRT","Portugal","2019","2019",629,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","MTMOTCMT","Million US$ at exchange rate","PRT","Portugal","2020","2020",681,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","MTMOTCMT","Million US$ at exchange rate","PRT","Portugal","2021","2021",779.1,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","MTMOTCMT","Million US$ at exchange rate","PRT","Portugal","2022","2022",787.4,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","MTMOPPMT","Million US$, purchasing power parity","PRT","Portugal","2010","2010",820.6,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","MTMOPPMT","Million US$, purchasing power parity","PRT","Portugal","2011","2011",731.5,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","MTMOPPMT","Million US$, purchasing power parity","PRT","Portugal","2012","2012",662.1,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","MTMOPPMT","Million US$, purchasing power parity","PRT","Portugal","2013","2013",678.6,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","MTMOPPMT","Million US$, purchasing power parity","PRT","Portugal","2014","2014",699.3,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","MTMOPPMT","Million US$, purchasing power parity","PRT","Portugal","2015","2015",752.2,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","MTMOPPMT","Million US$, purchasing power parity","PRT","Portugal","2016","2016",806,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","MTMOPPMT","Million US$, purchasing power parity","PRT","Portugal","2017","2017",830.4,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","MTMOPPMT","Million US$, purchasing power parity","PRT","Portugal","2018","2018",898.1,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","MTMOPPMT","Million US$, purchasing power parity","PRT","Portugal","2019","2019",1005.5,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","MTMOPPMT","Million US$, purchasing power parity","PRT","Portugal","2020","2020",1070.2,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","MTMOPPMT","Million US$, purchasing power parity","PRT","Portugal","2021","2021",1160.5,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","MTMOPPMT","Million US$, purchasing power parity","PRT","Portugal","2022","2022",1359.5,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","TCPPERMT","/capita, US$ exchange rate","PRT","Portugal","2010","2010",64.1,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","TCPPERMT","/capita, US$ exchange rate","PRT","Portugal","2011","2011",60.1,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","TCPPERMT","/capita, US$ exchange rate","PRT","Portugal","2012","2012",49,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","TCPPERMT","/capita, US$ exchange rate","PRT","Portugal","2013","2013",50.3,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","TCPPERMT","/capita, US$ exchange rate","PRT","Portugal","2014","2014",51.7,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","TCPPERMT","/capita, US$ exchange rate","PRT","Portugal","2015","2015",47.1,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","TCPPERMT","/capita, US$ exchange rate","PRT","Portugal","2016","2016",49.4,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","TCPPERMT","/capita, US$ exchange rate","PRT","Portugal","2017","2017",52.4,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","TCPPERMT","/capita, US$ exchange rate","PRT","Portugal","2018","2018",58.9,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","TCPPERMT","/capita, US$ exchange rate","PRT","Portugal","2019","2019",61.1,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","TCPPERMT","/capita, US$ exchange rate","PRT","Portugal","2020","2020",66.1,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","TCPPERMT","/capita, US$ exchange rate","PRT","Portugal","2021","2021",75.2,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","TCPPERMT","/capita, US$ exchange rate","PRT","Portugal","2022","2022",76.1,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2010","2010",77.6,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2011","2011",69.3,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2012","2012",63,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2013","2013",64.9,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2014","2014",67.2,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2015","2015",72.6,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2016","2016",78.1,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2017","2017",80.6,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2018","2018",87.3,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2019","2019",97.8,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2020","2020",103.9,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2021","2021",112,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2022","2022",131.3,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","ATCPTTMT","% of total sales","PRT","Portugal","2010","2010",15.8,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","ATCPTTMT","% of total sales","PRT","Portugal","2011","2011",15.5,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","ATCPTTMT","% of total sales","PRT","Portugal","2012","2012",15.3,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","ATCPTTMT","% of total sales","PRT","Portugal","2013","2013",16.4,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","ATCPTTMT","% of total sales","PRT","Portugal","2014","2014",16.9,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","ATCPTTMT","% of total sales","PRT","Portugal","2015","2015",17.7,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","ATCPTTMT","% of total sales","PRT","Portugal","2016","2016",18.2,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","ATCPTTMT","% of total sales","PRT","Portugal","2017","2017",18.7,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","ATCPTTMT","% of total sales","PRT","Portugal","2018","2018",19.5,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","ATCPTTMT","% of total sales","PRT","Portugal","2019","2019",20.1,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","ATCPTTMT","% of total sales","PRT","Portugal","2020","2020",21.2,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","ATCPTTMT","% of total sales","PRT","Portugal","2021","2021",22.5,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","ATCPTTMT","% of total sales","PRT","Portugal","2022","2022",23.5,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","MLLNCUMT","Million of national currency units","SVK","Slovak Republic","2010","2010",116.4,,
+"PATCALIM","A-Alimentary tract and metabolism","MLLNCUMT","Million of national currency units","SVK","Slovak Republic","2011","2011",120.2,,
+"PATCALIM","A-Alimentary tract and metabolism","MLLNCUMT","Million of national currency units","SVK","Slovak Republic","2012","2012",112.7,,
+"PATCALIM","A-Alimentary tract and metabolism","MLLNCUMT","Million of national currency units","SVK","Slovak Republic","2013","2013",127.1,,
+"PATCALIM","A-Alimentary tract and metabolism","MLLNCUMT","Million of national currency units","SVK","Slovak Republic","2014","2014",136.7,,
+"PATCALIM","A-Alimentary tract and metabolism","MLLNCUMT","Million of national currency units","SVK","Slovak Republic","2015","2015",152.6,,
+"PATCALIM","A-Alimentary tract and metabolism","MLLNCUMT","Million of national currency units","SVK","Slovak Republic","2016","2016",186,"B","Break"
+"PATCALIM","A-Alimentary tract and metabolism","MLLNCUMT","Million of national currency units","SVK","Slovak Republic","2017","2017",186.6,,
+"PATCALIM","A-Alimentary tract and metabolism","MLLNCUMT","Million of national currency units","SVK","Slovak Republic","2018","2018",196.9,,
+"PATCALIM","A-Alimentary tract and metabolism","MLLNCUMT","Million of national currency units","SVK","Slovak Republic","2019","2019",211.2,,
+"PATCALIM","A-Alimentary tract and metabolism","MLLNCUMT","Million of national currency units","SVK","Slovak Republic","2020","2020",216,,
+"PATCALIM","A-Alimentary tract and metabolism","MLLNCUMT","Million of national currency units","SVK","Slovak Republic","2021","2021",238.6,,
+"PATCALIM","A-Alimentary tract and metabolism","MTMOTCMT","Million US$ at exchange rate","SVK","Slovak Republic","2010","2010",154.3,,
+"PATCALIM","A-Alimentary tract and metabolism","MTMOTCMT","Million US$ at exchange rate","SVK","Slovak Republic","2011","2011",167.3,,
+"PATCALIM","A-Alimentary tract and metabolism","MTMOTCMT","Million US$ at exchange rate","SVK","Slovak Republic","2012","2012",144.8,,
+"PATCALIM","A-Alimentary tract and metabolism","MTMOTCMT","Million US$ at exchange rate","SVK","Slovak Republic","2013","2013",168.8,,
+"PATCALIM","A-Alimentary tract and metabolism","MTMOTCMT","Million US$ at exchange rate","SVK","Slovak Republic","2014","2014",181.5,,
+"PATCALIM","A-Alimentary tract and metabolism","MTMOTCMT","Million US$ at exchange rate","SVK","Slovak Republic","2015","2015",169.4,,
+"PATCALIM","A-Alimentary tract and metabolism","MTMOTCMT","Million US$ at exchange rate","SVK","Slovak Republic","2016","2016",205.8,"B","Break"
+"PATCALIM","A-Alimentary tract and metabolism","MTMOTCMT","Million US$ at exchange rate","SVK","Slovak Republic","2017","2017",210.8,,
+"PATCALIM","A-Alimentary tract and metabolism","MTMOTCMT","Million US$ at exchange rate","SVK","Slovak Republic","2018","2018",232.5,,
+"PATCALIM","A-Alimentary tract and metabolism","MTMOTCMT","Million US$ at exchange rate","SVK","Slovak Republic","2019","2019",236.4,,
+"PATCALIM","A-Alimentary tract and metabolism","MTMOTCMT","Million US$ at exchange rate","SVK","Slovak Republic","2020","2020",246.7,,
+"PATCALIM","A-Alimentary tract and metabolism","MTMOTCMT","Million US$ at exchange rate","SVK","Slovak Republic","2021","2021",282.2,,
+"PATCALIM","A-Alimentary tract and metabolism","MTMOPPMT","Million US$, purchasing power parity","SVK","Slovak Republic","2010","2010",231.8,,
+"PATCALIM","A-Alimentary tract and metabolism","MTMOPPMT","Million US$, purchasing power parity","SVK","Slovak Republic","2011","2011",237.4,,
+"PATCALIM","A-Alimentary tract and metabolism","MTMOPPMT","Million US$, purchasing power parity","SVK","Slovak Republic","2012","2012",223.4,,
+"PATCALIM","A-Alimentary tract and metabolism","MTMOPPMT","Million US$, purchasing power parity","SVK","Slovak Republic","2013","2013",258.8,,
+"PATCALIM","A-Alimentary tract and metabolism","MTMOPPMT","Million US$, purchasing power parity","SVK","Slovak Republic","2014","2014",281.5,,
+"PATCALIM","A-Alimentary tract and metabolism","MTMOPPMT","Million US$, purchasing power parity","SVK","Slovak Republic","2015","2015",310.5,,
+"PATCALIM","A-Alimentary tract and metabolism","MTMOPPMT","Million US$, purchasing power parity","SVK","Slovak Republic","2016","2016",369.6,"B","Break"
+"PATCALIM","A-Alimentary tract and metabolism","MTMOPPMT","Million US$, purchasing power parity","SVK","Slovak Republic","2017","2017",361.3,,
+"PATCALIM","A-Alimentary tract and metabolism","MTMOPPMT","Million US$, purchasing power parity","SVK","Slovak Republic","2018","2018",374.4,,
+"PATCALIM","A-Alimentary tract and metabolism","MTMOPPMT","Million US$, purchasing power parity","SVK","Slovak Republic","2019","2019",408.1,,
+"PATCALIM","A-Alimentary tract and metabolism","MTMOPPMT","Million US$, purchasing power parity","SVK","Slovak Republic","2020","2020",415.4,,
+"PATCALIM","A-Alimentary tract and metabolism","MTMOPPMT","Million US$, purchasing power parity","SVK","Slovak Republic","2021","2021",447.3,,
+"PATCALIM","A-Alimentary tract and metabolism","TCPPERMT","/capita, US$ exchange rate","SVK","Slovak Republic","2010","2010",28.6,,
+"PATCALIM","A-Alimentary tract and metabolism","TCPPERMT","/capita, US$ exchange rate","SVK","Slovak Republic","2011","2011",31,,
+"PATCALIM","A-Alimentary tract and metabolism","TCPPERMT","/capita, US$ exchange rate","SVK","Slovak Republic","2012","2012",26.8,,
+"PATCALIM","A-Alimentary tract and metabolism","TCPPERMT","/capita, US$ exchange rate","SVK","Slovak Republic","2013","2013",31.2,,
+"PATCALIM","A-Alimentary tract and metabolism","TCPPERMT","/capita, US$ exchange rate","SVK","Slovak Republic","2014","2014",33.5,,
+"PATCALIM","A-Alimentary tract and metabolism","TCPPERMT","/capita, US$ exchange rate","SVK","Slovak Republic","2015","2015",31.2,,
+"PATCALIM","A-Alimentary tract and metabolism","TCPPERMT","/capita, US$ exchange rate","SVK","Slovak Republic","2016","2016",37.9,"B","Break"
+"PATCALIM","A-Alimentary tract and metabolism","TCPPERMT","/capita, US$ exchange rate","SVK","Slovak Republic","2017","2017",38.7,,
+"PATCALIM","A-Alimentary tract and metabolism","TCPPERMT","/capita, US$ exchange rate","SVK","Slovak Republic","2018","2018",42.7,,
+"PATCALIM","A-Alimentary tract and metabolism","TCPPERMT","/capita, US$ exchange rate","SVK","Slovak Republic","2019","2019",43.3,,
+"PATCALIM","A-Alimentary tract and metabolism","TCPPERMT","/capita, US$ exchange rate","SVK","Slovak Republic","2020","2020",45.2,,
+"PATCALIM","A-Alimentary tract and metabolism","TCPPERMT","/capita, US$ exchange rate","SVK","Slovak Republic","2021","2021",51.8,,
+"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2010","2010",43,,
+"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2011","2011",44,,
+"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2012","2012",41.3,,
+"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2013","2013",47.8,,
+"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2014","2014",52,,
+"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2015","2015",57.3,,
+"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2016","2016",68,"B","Break"
+"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2017","2017",66.4,,
+"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2018","2018",68.7,,
+"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2019","2019",74.8,,
+"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2020","2020",76.1,,
+"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2021","2021",82.1,,
+"PATCALIM","A-Alimentary tract and metabolism","ATCPTTMT","% of total sales","SVK","Slovak Republic","2010","2010",10.4,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","ATCPTTMT","% of total sales","SVK","Slovak Republic","2011","2011",10.7,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","ATCPTTMT","% of total sales","SVK","Slovak Republic","2012","2012",10.2,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","ATCPTTMT","% of total sales","SVK","Slovak Republic","2013","2013",10.3,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","ATCPTTMT","% of total sales","SVK","Slovak Republic","2014","2014",10.4,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","ATCPTTMT","% of total sales","SVK","Slovak Republic","2015","2015",11,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","ATCPTTMT","% of total sales","SVK","Slovak Republic","2016","2016",11.8,"B","Break"
+"PATCALIM","A-Alimentary tract and metabolism","ATCPTTMT","% of total sales","SVK","Slovak Republic","2017","2017",11.9,,
+"PATCALIM","A-Alimentary tract and metabolism","ATCPTTMT","% of total sales","SVK","Slovak Republic","2018","2018",12.1,,
+"PATCALIM","A-Alimentary tract and metabolism","ATCPTTMT","% of total sales","SVK","Slovak Republic","2019","2019",12.2,,
+"PATCALIM","A-Alimentary tract and metabolism","ATCPTTMT","% of total sales","SVK","Slovak Republic","2020","2020",13,,
+"PATCALIM","A-Alimentary tract and metabolism","ATCPTTMT","% of total sales","SVK","Slovak Republic","2021","2021",13.3,,
+"PATCALIM","A-Alimentary tract and metabolism","MLLNCUMT","Million of national currency units","ESP","Spain","2010","2010",1778.6,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","MLLNCUMT","Million of national currency units","ESP","Spain","2011","2011",1777.5,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","MLLNCUMT","Million of national currency units","ESP","Spain","2012","2012",1678.8,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","MLLNCUMT","Million of national currency units","ESP","Spain","2013","2013",1685.3,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","MLLNCUMT","Million of national currency units","ESP","Spain","2014","2014",1852.4,"B; D","Break; Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","MLLNCUMT","Million of national currency units","ESP","Spain","2015","2015",1958,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","MLLNCUMT","Million of national currency units","ESP","Spain","2016","2016",2104.3,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","MLLNCUMT","Million of national currency units","ESP","Spain","2017","2017",2215.5,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","MLLNCUMT","Million of national currency units","ESP","Spain","2018","2018",2612.3,"B","Break"
+"PATCALIM","A-Alimentary tract and metabolism","MLLNCUMT","Million of national currency units","ESP","Spain","2019","2019",2797,,
+"PATCALIM","A-Alimentary tract and metabolism","MLLNCUMT","Million of national currency units","ESP","Spain","2020","2020",2955,,
+"PATCALIM","A-Alimentary tract and metabolism","MLLNCUMT","Million of national currency units","ESP","Spain","2021","2021",3246.2,,
+"PATCALIM","A-Alimentary tract and metabolism","MLLNCUMT","Million of national currency units","ESP","Spain","2022","2022",3474.2,"P","Provisional value"
+"PATCALIM","A-Alimentary tract and metabolism","MTMOTCMT","Million US$ at exchange rate","ESP","Spain","2010","2010",2358,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","MTMOTCMT","Million US$ at exchange rate","ESP","Spain","2011","2011",2474.2,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","MTMOTCMT","Million US$ at exchange rate","ESP","Spain","2012","2012",2156.9,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","MTMOTCMT","Million US$ at exchange rate","ESP","Spain","2013","2013",2238.2,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","MTMOTCMT","Million US$ at exchange rate","ESP","Spain","2014","2014",2460.9,"B; D","Break; Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","MTMOTCMT","Million US$ at exchange rate","ESP","Spain","2015","2015",2172.4,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","MTMOTCMT","Million US$ at exchange rate","ESP","Spain","2016","2016",2329.2,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","MTMOTCMT","Million US$ at exchange rate","ESP","Spain","2017","2017",2502.8,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","MTMOTCMT","Million US$ at exchange rate","ESP","Spain","2018","2018",3085,"B","Break"
+"PATCALIM","A-Alimentary tract and metabolism","MTMOTCMT","Million US$ at exchange rate","ESP","Spain","2019","2019",3131.2,,
+"PATCALIM","A-Alimentary tract and metabolism","MTMOTCMT","Million US$ at exchange rate","ESP","Spain","2020","2020",3375.1,,
+"PATCALIM","A-Alimentary tract and metabolism","MTMOTCMT","Million US$ at exchange rate","ESP","Spain","2021","2021",3839.4,,
+"PATCALIM","A-Alimentary tract and metabolism","MTMOTCMT","Million US$ at exchange rate","ESP","Spain","2022","2022",3658.5,"P","Provisional value"
+"PATCALIM","A-Alimentary tract and metabolism","MTMOPPMT","Million US$, purchasing power parity","ESP","Spain","2010","2010",2446.7,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","MTMOPPMT","Million US$, purchasing power parity","ESP","Spain","2011","2011",2489,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","MTMOPPMT","Million US$, purchasing power parity","ESP","Spain","2012","2012",2415.6,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","MTMOPPMT","Million US$, purchasing power parity","ESP","Spain","2013","2013",2497.4,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","MTMOPPMT","Million US$, purchasing power parity","ESP","Spain","2014","2014",2796.7,"B; D","Break; Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","MTMOPPMT","Million US$, purchasing power parity","ESP","Spain","2015","2015",2945.5,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","MTMOPPMT","Million US$, purchasing power parity","ESP","Spain","2016","2016",3274.4,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","MTMOPPMT","Million US$, purchasing power parity","ESP","Spain","2017","2017",3512,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","MTMOPPMT","Million US$, purchasing power parity","ESP","Spain","2018","2018",4134.7,"B","Break"
+"PATCALIM","A-Alimentary tract and metabolism","MTMOPPMT","Million US$, purchasing power parity","ESP","Spain","2019","2019",4563,,
+"PATCALIM","A-Alimentary tract and metabolism","MTMOPPMT","Million US$, purchasing power parity","ESP","Spain","2020","2020",4755.8,,
+"PATCALIM","A-Alimentary tract and metabolism","MTMOPPMT","Million US$, purchasing power parity","ESP","Spain","2021","2021",5186,,
+"PATCALIM","A-Alimentary tract and metabolism","MTMOPPMT","Million US$, purchasing power parity","ESP","Spain","2022","2022",5827.1,"P","Provisional value"
+"PATCALIM","A-Alimentary tract and metabolism","TCPPERMT","/capita, US$ exchange rate","ESP","Spain","2010","2010",50.6,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","TCPPERMT","/capita, US$ exchange rate","ESP","Spain","2011","2011",52.9,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","TCPPERMT","/capita, US$ exchange rate","ESP","Spain","2012","2012",46.1,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","TCPPERMT","/capita, US$ exchange rate","ESP","Spain","2013","2013",48,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","TCPPERMT","/capita, US$ exchange rate","ESP","Spain","2014","2014",52.9,"B; D","Break; Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","TCPPERMT","/capita, US$ exchange rate","ESP","Spain","2015","2015",46.8,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","TCPPERMT","/capita, US$ exchange rate","ESP","Spain","2016","2016",50.1,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","TCPPERMT","/capita, US$ exchange rate","ESP","Spain","2017","2017",53.7,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","TCPPERMT","/capita, US$ exchange rate","ESP","Spain","2018","2018",65.9,"B","Break"
+"PATCALIM","A-Alimentary tract and metabolism","TCPPERMT","/capita, US$ exchange rate","ESP","Spain","2019","2019",66.4,,
+"PATCALIM","A-Alimentary tract and metabolism","TCPPERMT","/capita, US$ exchange rate","ESP","Spain","2020","2020",71.3,,
+"PATCALIM","A-Alimentary tract and metabolism","TCPPERMT","/capita, US$ exchange rate","ESP","Spain","2021","2021",81,,
+"PATCALIM","A-Alimentary tract and metabolism","TCPPERMT","/capita, US$ exchange rate","ESP","Spain","2022","2022",77.1,"P","Provisional value"
+"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2010","2010",52.5,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2011","2011",53.2,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2012","2012",51.6,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2013","2013",53.6,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2014","2014",60.2,"B; D","Break; Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2015","2015",63.4,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2016","2016",70.4,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2017","2017",75.4,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2018","2018",88.4,"B","Break"
+"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2019","2019",96.8,,
+"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2020","2020",100.4,,
+"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2021","2021",109.4,,
+"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2022","2022",122.8,"P","Provisional value"
+"PATCALIM","A-Alimentary tract and metabolism","ATCPTTMT","% of total sales","ESP","Spain","2010","2010",13.4,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","ATCPTTMT","% of total sales","ESP","Spain","2011","2011",14.4,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","ATCPTTMT","% of total sales","ESP","Spain","2012","2012",15.2,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","ATCPTTMT","% of total sales","ESP","Spain","2013","2013",15.8,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","ATCPTTMT","% of total sales","ESP","Spain","2014","2014",16.4,"B; D","Break; Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","ATCPTTMT","% of total sales","ESP","Spain","2015","2015",17.2,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","ATCPTTMT","% of total sales","ESP","Spain","2016","2016",17.8,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","ATCPTTMT","% of total sales","ESP","Spain","2017","2017",18.4,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","ATCPTTMT","% of total sales","ESP","Spain","2018","2018",13.8,"B","Break"
+"PATCALIM","A-Alimentary tract and metabolism","ATCPTTMT","% of total sales","ESP","Spain","2019","2019",14,,
+"PATCALIM","A-Alimentary tract and metabolism","ATCPTTMT","% of total sales","ESP","Spain","2020","2020",14.2,,
+"PATCALIM","A-Alimentary tract and metabolism","ATCPTTMT","% of total sales","ESP","Spain","2021","2021",14.7,,
+"PATCALIM","A-Alimentary tract and metabolism","ATCPTTMT","% of total sales","ESP","Spain","2022","2022",15.2,"P","Provisional value"
+"PATCALIM","A-Alimentary tract and metabolism","MLLNCUMT","Million of national currency units","SWE","Sweden","2010","2010",3736.4,,
+"PATCALIM","A-Alimentary tract and metabolism","MLLNCUMT","Million of national currency units","SWE","Sweden","2011","2011",3675.8,,
+"PATCALIM","A-Alimentary tract and metabolism","MLLNCUMT","Million of national currency units","SWE","Sweden","2012","2012",3732,,
+"PATCALIM","A-Alimentary tract and metabolism","MLLNCUMT","Million of national currency units","SWE","Sweden","2013","2013",3749.9,,
+"PATCALIM","A-Alimentary tract and metabolism","MLLNCUMT","Million of national currency units","SWE","Sweden","2014","2014",3841.9,,
+"PATCALIM","A-Alimentary tract and metabolism","MLLNCUMT","Million of national currency units","SWE","Sweden","2015","2015",4115.1,,
+"PATCALIM","A-Alimentary tract and metabolism","MLLNCUMT","Million of national currency units","SWE","Sweden","2016","2016",4397.3,,
+"PATCALIM","A-Alimentary tract and metabolism","MLLNCUMT","Million of national currency units","SWE","Sweden","2017","2017",4618.1,,
+"PATCALIM","A-Alimentary tract and metabolism","MLLNCUMT","Million of national currency units","SWE","Sweden","2018","2018",4954,,
+"PATCALIM","A-Alimentary tract and metabolism","MLLNCUMT","Million of national currency units","SWE","Sweden","2019","2019",5382.5,,
+"PATCALIM","A-Alimentary tract and metabolism","MLLNCUMT","Million of national currency units","SWE","Sweden","2020","2020",5723.2,,
+"PATCALIM","A-Alimentary tract and metabolism","MLLNCUMT","Million of national currency units","SWE","Sweden","2021","2021",6118.8,,
+"PATCALIM","A-Alimentary tract and metabolism","MLLNCUMT","Million of national currency units","SWE","Sweden","2022","2022",6826,,
+"PATCALIM","A-Alimentary tract and metabolism","MTMOTCMT","Million US$ at exchange rate","SWE","Sweden","2010","2010",518.4,,
+"PATCALIM","A-Alimentary tract and metabolism","MTMOTCMT","Million US$ at exchange rate","SWE","Sweden","2011","2011",566.1,,
+"PATCALIM","A-Alimentary tract and metabolism","MTMOTCMT","Million US$ at exchange rate","SWE","Sweden","2012","2012",550.8,,
+"PATCALIM","A-Alimentary tract and metabolism","MTMOTCMT","Million US$ at exchange rate","SWE","Sweden","2013","2013",575.7,,
+"PATCALIM","A-Alimentary tract and metabolism","MTMOTCMT","Million US$ at exchange rate","SWE","Sweden","2014","2014",560,,
+"PATCALIM","A-Alimentary tract and metabolism","MTMOTCMT","Million US$ at exchange rate","SWE","Sweden","2015","2015",487.9,,
+"PATCALIM","A-Alimentary tract and metabolism","MTMOTCMT","Million US$ at exchange rate","SWE","Sweden","2016","2016",513.6,,
+"PATCALIM","A-Alimentary tract and metabolism","MTMOTCMT","Million US$ at exchange rate","SWE","Sweden","2017","2017",540.2,,
+"PATCALIM","A-Alimentary tract and metabolism","MTMOTCMT","Million US$ at exchange rate","SWE","Sweden","2018","2018",569.9,,
+"PATCALIM","A-Alimentary tract and metabolism","MTMOTCMT","Million US$ at exchange rate","SWE","Sweden","2019","2019",569.1,,
+"PATCALIM","A-Alimentary tract and metabolism","MTMOTCMT","Million US$ at exchange rate","SWE","Sweden","2020","2020",621.4,,
+"PATCALIM","A-Alimentary tract and metabolism","MTMOTCMT","Million US$ at exchange rate","SWE","Sweden","2021","2021",713.4,,
+"PATCALIM","A-Alimentary tract and metabolism","MTMOTCMT","Million US$ at exchange rate","SWE","Sweden","2022","2022",674.9,,
+"PATCALIM","A-Alimentary tract and metabolism","MTMOPPMT","Million US$, purchasing power parity","SWE","Sweden","2010","2010",414,,
+"PATCALIM","A-Alimentary tract and metabolism","MTMOPPMT","Million US$, purchasing power parity","SWE","Sweden","2011","2011",415.6,,
+"PATCALIM","A-Alimentary tract and metabolism","MTMOPPMT","Million US$, purchasing power parity","SWE","Sweden","2012","2012",431.2,,
+"PATCALIM","A-Alimentary tract and metabolism","MTMOPPMT","Million US$, purchasing power parity","SWE","Sweden","2013","2013",436.2,,
+"PATCALIM","A-Alimentary tract and metabolism","MTMOPPMT","Million US$, purchasing power parity","SWE","Sweden","2014","2014",440.2,,
+"PATCALIM","A-Alimentary tract and metabolism","MTMOPPMT","Million US$, purchasing power parity","SWE","Sweden","2015","2015",464.8,,
+"PATCALIM","A-Alimentary tract and metabolism","MTMOPPMT","Million US$, purchasing power parity","SWE","Sweden","2016","2016",498.4,,
+"PATCALIM","A-Alimentary tract and metabolism","MTMOPPMT","Million US$, purchasing power parity","SWE","Sweden","2017","2017",521.7,,
+"PATCALIM","A-Alimentary tract and metabolism","MTMOPPMT","Million US$, purchasing power parity","SWE","Sweden","2018","2018",558.8,,
+"PATCALIM","A-Alimentary tract and metabolism","MTMOPPMT","Million US$, purchasing power parity","SWE","Sweden","2019","2019",618,,
+"PATCALIM","A-Alimentary tract and metabolism","MTMOPPMT","Million US$, purchasing power parity","SWE","Sweden","2020","2020",660.2,,
+"PATCALIM","A-Alimentary tract and metabolism","MTMOPPMT","Million US$, purchasing power parity","SWE","Sweden","2021","2021",701.6,,
+"PATCALIM","A-Alimentary tract and metabolism","MTMOPPMT","Million US$, purchasing power parity","SWE","Sweden","2022","2022",787.7,,
+"PATCALIM","A-Alimentary tract and metabolism","TCPPERMT","/capita, US$ exchange rate","SWE","Sweden","2010","2010",55.3,,
+"PATCALIM","A-Alimentary tract and metabolism","TCPPERMT","/capita, US$ exchange rate","SWE","Sweden","2011","2011",59.9,,
+"PATCALIM","A-Alimentary tract and metabolism","TCPPERMT","/capita, US$ exchange rate","SWE","Sweden","2012","2012",57.9,,
+"PATCALIM","A-Alimentary tract and metabolism","TCPPERMT","/capita, US$ exchange rate","SWE","Sweden","2013","2013",60,,
+"PATCALIM","A-Alimentary tract and metabolism","TCPPERMT","/capita, US$ exchange rate","SWE","Sweden","2014","2014",57.8,,
+"PATCALIM","A-Alimentary tract and metabolism","TCPPERMT","/capita, US$ exchange rate","SWE","Sweden","2015","2015",49.8,,
+"PATCALIM","A-Alimentary tract and metabolism","TCPPERMT","/capita, US$ exchange rate","SWE","Sweden","2016","2016",51.8,,
+"PATCALIM","A-Alimentary tract and metabolism","TCPPERMT","/capita, US$ exchange rate","SWE","Sweden","2017","2017",53.7,,
+"PATCALIM","A-Alimentary tract and metabolism","TCPPERMT","/capita, US$ exchange rate","SWE","Sweden","2018","2018",56,,
+"PATCALIM","A-Alimentary tract and metabolism","TCPPERMT","/capita, US$ exchange rate","SWE","Sweden","2019","2019",55.4,,
+"PATCALIM","A-Alimentary tract and metabolism","TCPPERMT","/capita, US$ exchange rate","SWE","Sweden","2020","2020",60,,
+"PATCALIM","A-Alimentary tract and metabolism","TCPPERMT","/capita, US$ exchange rate","SWE","Sweden","2021","2021",68.5,,
+"PATCALIM","A-Alimentary tract and metabolism","TCPPERMT","/capita, US$ exchange rate","SWE","Sweden","2022","2022",64.6,,
+"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2010","2010",44.1,,
+"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2011","2011",44,,
+"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2012","2012",45.3,,
+"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2013","2013",45.4,,
+"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2014","2014",45.4,,
+"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2015","2015",47.4,,
+"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2016","2016",50.2,,
+"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2017","2017",51.9,,
+"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2018","2018",54.9,,
+"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2019","2019",60.1,,
+"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2020","2020",63.8,,
+"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2021","2021",67.4,,
+"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2022","2022",75.4,,
+"PATCALIM","A-Alimentary tract and metabolism","ATCPTTMT","% of total sales","SWE","Sweden","2010","2010",10.4,,
+"PATCALIM","A-Alimentary tract and metabolism","ATCPTTMT","% of total sales","SWE","Sweden","2011","2011",10,,
+"PATCALIM","A-Alimentary tract and metabolism","ATCPTTMT","% of total sales","SWE","Sweden","2012","2012",10.3,,
+"PATCALIM","A-Alimentary tract and metabolism","ATCPTTMT","% of total sales","SWE","Sweden","2013","2013",10.3,,
+"PATCALIM","A-Alimentary tract and metabolism","ATCPTTMT","% of total sales","SWE","Sweden","2014","2014",10.2,,
+"PATCALIM","A-Alimentary tract and metabolism","ATCPTTMT","% of total sales","SWE","Sweden","2015","2015",10.1,,
+"PATCALIM","A-Alimentary tract and metabolism","ATCPTTMT","% of total sales","SWE","Sweden","2016","2016",10.4,,
+"PATCALIM","A-Alimentary tract and metabolism","ATCPTTMT","% of total sales","SWE","Sweden","2017","2017",10.6,,
+"PATCALIM","A-Alimentary tract and metabolism","ATCPTTMT","% of total sales","SWE","Sweden","2018","2018",10.4,,
+"PATCALIM","A-Alimentary tract and metabolism","ATCPTTMT","% of total sales","SWE","Sweden","2019","2019",10.7,,
+"PATCALIM","A-Alimentary tract and metabolism","ATCPTTMT","% of total sales","SWE","Sweden","2020","2020",10.9,,
+"PATCALIM","A-Alimentary tract and metabolism","ATCPTTMT","% of total sales","SWE","Sweden","2021","2021",11.4,,
+"PATCALIM","A-Alimentary tract and metabolism","ATCPTTMT","% of total sales","SWE","Sweden","2022","2022",11.8,,
+"PATCALIM","A-Alimentary tract and metabolism","MLLNCUMT","Million of national currency units","CHE","Switzerland","2010","2010",875.8,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","MLLNCUMT","Million of national currency units","CHE","Switzerland","2011","2011",847,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","MLLNCUMT","Million of national currency units","CHE","Switzerland","2012","2012",851,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","MLLNCUMT","Million of national currency units","CHE","Switzerland","2013","2013",858,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","MLLNCUMT","Million of national currency units","CHE","Switzerland","2014","2014",863,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","MLLNCUMT","Million of national currency units","CHE","Switzerland","2015","2015",890,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","MLLNCUMT","Million of national currency units","CHE","Switzerland","2016","2016",923,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","MLLNCUMT","Million of national currency units","CHE","Switzerland","2017","2017",934,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","MLLNCUMT","Million of national currency units","CHE","Switzerland","2018","2018",925,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","MLLNCUMT","Million of national currency units","CHE","Switzerland","2019","2019",943,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","MLLNCUMT","Million of national currency units","CHE","Switzerland","2020","2020",987,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","MLLNCUMT","Million of national currency units","CHE","Switzerland","2021","2021",1037,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","MLLNCUMT","Million of national currency units","CHE","Switzerland","2022","2022",1112,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","MTMOTCMT","Million US$ at exchange rate","CHE","Switzerland","2010","2010",839.8,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","MTMOTCMT","Million US$ at exchange rate","CHE","Switzerland","2011","2011",953.8,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","MTMOTCMT","Million US$ at exchange rate","CHE","Switzerland","2012","2012",907.6,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","MTMOTCMT","Million US$ at exchange rate","CHE","Switzerland","2013","2013",925.7,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","MTMOTCMT","Million US$ at exchange rate","CHE","Switzerland","2014","2014",942,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","MTMOTCMT","Million US$ at exchange rate","CHE","Switzerland","2015","2015",924.8,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","MTMOTCMT","Million US$ at exchange rate","CHE","Switzerland","2016","2016",936.7,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","MTMOTCMT","Million US$ at exchange rate","CHE","Switzerland","2017","2017",948.5,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","MTMOTCMT","Million US$ at exchange rate","CHE","Switzerland","2018","2018",945.9,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","MTMOTCMT","Million US$ at exchange rate","CHE","Switzerland","2019","2019",949,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","MTMOTCMT","Million US$ at exchange rate","CHE","Switzerland","2020","2020",1051.2,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","MTMOTCMT","Million US$ at exchange rate","CHE","Switzerland","2021","2021",1134.8,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","MTMOTCMT","Million US$ at exchange rate","CHE","Switzerland","2022","2022",1164.6,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","MTMOPPMT","Million US$, purchasing power parity","CHE","Switzerland","2010","2010",597.4,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","MTMOPPMT","Million US$, purchasing power parity","CHE","Switzerland","2011","2011",606.1,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","MTMOPPMT","Million US$, purchasing power parity","CHE","Switzerland","2012","2012",628.5,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","MTMOPPMT","Million US$, purchasing power parity","CHE","Switzerland","2013","2013",653.7,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","MTMOPPMT","Million US$, purchasing power parity","CHE","Switzerland","2014","2014",673.3,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","MTMOPPMT","Million US$, purchasing power parity","CHE","Switzerland","2015","2015",720.2,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","MTMOPPMT","Million US$, purchasing power parity","CHE","Switzerland","2016","2016",767.9,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","MTMOPPMT","Million US$, purchasing power parity","CHE","Switzerland","2017","2017",786.4,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","MTMOPPMT","Million US$, purchasing power parity","CHE","Switzerland","2018","2018",784.7,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","MTMOPPMT","Million US$, purchasing power parity","CHE","Switzerland","2019","2019",819.7,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","MTMOPPMT","Million US$, purchasing power parity","CHE","Switzerland","2020","2020",869.1,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","MTMOPPMT","Million US$, purchasing power parity","CHE","Switzerland","2021","2021",937.3,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","MTMOPPMT","Million US$, purchasing power parity","CHE","Switzerland","2022","2022",1043.2,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","TCPPERMT","/capita, US$ exchange rate","CHE","Switzerland","2010","2010",107.3,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","TCPPERMT","/capita, US$ exchange rate","CHE","Switzerland","2011","2011",120.5,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","TCPPERMT","/capita, US$ exchange rate","CHE","Switzerland","2012","2012",113.5,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","TCPPERMT","/capita, US$ exchange rate","CHE","Switzerland","2013","2013",114.4,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","TCPPERMT","/capita, US$ exchange rate","CHE","Switzerland","2014","2014",115,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","TCPPERMT","/capita, US$ exchange rate","CHE","Switzerland","2015","2015",111.7,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","TCPPERMT","/capita, US$ exchange rate","CHE","Switzerland","2016","2016",111.9,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","TCPPERMT","/capita, US$ exchange rate","CHE","Switzerland","2017","2017",112.2,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","TCPPERMT","/capita, US$ exchange rate","CHE","Switzerland","2018","2018",111.1,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","TCPPERMT","/capita, US$ exchange rate","CHE","Switzerland","2019","2019",110.7,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","TCPPERMT","/capita, US$ exchange rate","CHE","Switzerland","2020","2020",121.7,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","TCPPERMT","/capita, US$ exchange rate","CHE","Switzerland","2021","2021",130.4,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","TCPPERMT","/capita, US$ exchange rate","CHE","Switzerland","2022","2022",133.3,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","CHE","Switzerland","2010","2010",76.3,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","CHE","Switzerland","2011","2011",76.6,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","CHE","Switzerland","2012","2012",78.6,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","CHE","Switzerland","2013","2013",80.8,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","CHE","Switzerland","2014","2014",82.2,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","CHE","Switzerland","2015","2015",87,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","CHE","Switzerland","2016","2016",91.7,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","CHE","Switzerland","2017","2017",93,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","CHE","Switzerland","2018","2018",92.2,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","CHE","Switzerland","2019","2019",95.6,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","CHE","Switzerland","2020","2020",100.6,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","CHE","Switzerland","2021","2021",107.7,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","CHE","Switzerland","2022","2022",119.4,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","ATCPTTMT","% of total sales","CHE","Switzerland","2010","2010",15.2,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","ATCPTTMT","% of total sales","CHE","Switzerland","2011","2011",14.7,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","ATCPTTMT","% of total sales","CHE","Switzerland","2012","2012",14.3,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","ATCPTTMT","% of total sales","CHE","Switzerland","2013","2013",14.5,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","ATCPTTMT","% of total sales","CHE","Switzerland","2014","2014",14.6,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","ATCPTTMT","% of total sales","CHE","Switzerland","2015","2015",14.4,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","ATCPTTMT","% of total sales","CHE","Switzerland","2016","2016",14.5,"B; D","Break; Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","ATCPTTMT","% of total sales","CHE","Switzerland","2017","2017",14.3,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","ATCPTTMT","% of total sales","CHE","Switzerland","2018","2018",14,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","ATCPTTMT","% of total sales","CHE","Switzerland","2019","2019",14.1,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","ATCPTTMT","% of total sales","CHE","Switzerland","2020","2020",14.4,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","ATCPTTMT","% of total sales","CHE","Switzerland","2021","2021",14.6,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","ATCPTTMT","% of total sales","CHE","Switzerland","2022","2022",14.6,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","MLLNCUMT","Million of national currency units","TUR","Türkiye","2010","2010",2158.8,,
+"PATCALIM","A-Alimentary tract and metabolism","MLLNCUMT","Million of national currency units","TUR","Türkiye","2011","2011",1965.4,,
+"PATCALIM","A-Alimentary tract and metabolism","MLLNCUMT","Million of national currency units","TUR","Türkiye","2012","2012",1947.3,,
+"PATCALIM","A-Alimentary tract and metabolism","MLLNCUMT","Million of national currency units","TUR","Türkiye","2013","2013",2115.4,,
+"PATCALIM","A-Alimentary tract and metabolism","MLLNCUMT","Million of national currency units","TUR","Türkiye","2014","2014",2328.7,,
+"PATCALIM","A-Alimentary tract and metabolism","MLLNCUMT","Million of national currency units","TUR","Türkiye","2015","2015",2779.4,,
+"PATCALIM","A-Alimentary tract and metabolism","MLLNCUMT","Million of national currency units","TUR","Türkiye","2016","2016",3349.9,,
+"PATCALIM","A-Alimentary tract and metabolism","MLLNCUMT","Million of national currency units","TUR","Türkiye","2017","2017",4164.3,,
+"PATCALIM","A-Alimentary tract and metabolism","MLLNCUMT","Million of national currency units","TUR","Türkiye","2018","2018",5223.5,,
+"PATCALIM","A-Alimentary tract and metabolism","MLLNCUMT","Million of national currency units","TUR","Türkiye","2019","2019",6893.8,,
+"PATCALIM","A-Alimentary tract and metabolism","MLLNCUMT","Million of national currency units","TUR","Türkiye","2020","2020",9117.7,,
+"PATCALIM","A-Alimentary tract and metabolism","MLLNCUMT","Million of national currency units","TUR","Türkiye","2021","2021",12158.5,,
+"PATCALIM","A-Alimentary tract and metabolism","MTMOTCMT","Million US$ at exchange rate","TUR","Türkiye","2010","2010",1436.5,,
+"PATCALIM","A-Alimentary tract and metabolism","MTMOTCMT","Million US$ at exchange rate","TUR","Türkiye","2011","2011",1173.4,,
+"PATCALIM","A-Alimentary tract and metabolism","MTMOTCMT","Million US$ at exchange rate","TUR","Türkiye","2012","2012",1084.3,,
+"PATCALIM","A-Alimentary tract and metabolism","MTMOTCMT","Million US$ at exchange rate","TUR","Türkiye","2013","2013",1111.2,,
+"PATCALIM","A-Alimentary tract and metabolism","MTMOTCMT","Million US$ at exchange rate","TUR","Türkiye","2014","2014",1064,,
+"PATCALIM","A-Alimentary tract and metabolism","MTMOTCMT","Million US$ at exchange rate","TUR","Türkiye","2015","2015",1021.8,,
+"PATCALIM","A-Alimentary tract and metabolism","MTMOTCMT","Million US$ at exchange rate","TUR","Türkiye","2016","2016",1109.2,,
+"PATCALIM","A-Alimentary tract and metabolism","MTMOTCMT","Million US$ at exchange rate","TUR","Türkiye","2017","2017",1141.5,,
+"PATCALIM","A-Alimentary tract and metabolism","MTMOTCMT","Million US$ at exchange rate","TUR","Türkiye","2018","2018",1081.8,,
+"PATCALIM","A-Alimentary tract and metabolism","MTMOTCMT","Million US$ at exchange rate","TUR","Türkiye","2019","2019",1215,,
+"PATCALIM","A-Alimentary tract and metabolism","MTMOTCMT","Million US$ at exchange rate","TUR","Türkiye","2020","2020",1300.9,,
+"PATCALIM","A-Alimentary tract and metabolism","MTMOTCMT","Million US$ at exchange rate","TUR","Türkiye","2021","2021",1373.8,,
+"PATCALIM","A-Alimentary tract and metabolism","MTMOPPMT","Million US$, purchasing power parity","TUR","Türkiye","2010","2010",2345.6,,
+"PATCALIM","A-Alimentary tract and metabolism","MTMOPPMT","Million US$, purchasing power parity","TUR","Türkiye","2011","2011",2034.2,,
+"PATCALIM","A-Alimentary tract and metabolism","MTMOPPMT","Million US$, purchasing power parity","TUR","Türkiye","2012","2012",1909.4,,
+"PATCALIM","A-Alimentary tract and metabolism","MTMOPPMT","Million US$, purchasing power parity","TUR","Türkiye","2013","2013",1976.5,,
+"PATCALIM","A-Alimentary tract and metabolism","MTMOPPMT","Million US$, purchasing power parity","TUR","Türkiye","2014","2014",2108.4,,
+"PATCALIM","A-Alimentary tract and metabolism","MTMOPPMT","Million US$, purchasing power parity","TUR","Türkiye","2015","2015",2390.9,,
+"PATCALIM","A-Alimentary tract and metabolism","MTMOPPMT","Million US$, purchasing power parity","TUR","Türkiye","2016","2016",2699.3,,
+"PATCALIM","A-Alimentary tract and metabolism","MTMOPPMT","Million US$, purchasing power parity","TUR","Türkiye","2017","2017",3008.9,,
+"PATCALIM","A-Alimentary tract and metabolism","MTMOPPMT","Million US$, purchasing power parity","TUR","Türkiye","2018","2018",3199.5,,
+"PATCALIM","A-Alimentary tract and metabolism","MTMOPPMT","Million US$, purchasing power parity","TUR","Türkiye","2019","2019",3698.4,,
+"PATCALIM","A-Alimentary tract and metabolism","MTMOPPMT","Million US$, purchasing power parity","TUR","Türkiye","2020","2020",4213,,
+"PATCALIM","A-Alimentary tract and metabolism","MTMOPPMT","Million US$, purchasing power parity","TUR","Türkiye","2021","2021",4330.1,,
+"PATCALIM","A-Alimentary tract and metabolism","TCPPERMT","/capita, US$ exchange rate","TUR","Türkiye","2010","2010",19.6,,
+"PATCALIM","A-Alimentary tract and metabolism","TCPPERMT","/capita, US$ exchange rate","TUR","Türkiye","2011","2011",15.8,,
+"PATCALIM","A-Alimentary tract and metabolism","TCPPERMT","/capita, US$ exchange rate","TUR","Türkiye","2012","2012",14.4,,
+"PATCALIM","A-Alimentary tract and metabolism","TCPPERMT","/capita, US$ exchange rate","TUR","Türkiye","2013","2013",14.6,,
+"PATCALIM","A-Alimentary tract and metabolism","TCPPERMT","/capita, US$ exchange rate","TUR","Türkiye","2014","2014",13.8,,
+"PATCALIM","A-Alimentary tract and metabolism","TCPPERMT","/capita, US$ exchange rate","TUR","Türkiye","2015","2015",13.1,,
+"PATCALIM","A-Alimentary tract and metabolism","TCPPERMT","/capita, US$ exchange rate","TUR","Türkiye","2016","2016",14,,
+"PATCALIM","A-Alimentary tract and metabolism","TCPPERMT","/capita, US$ exchange rate","TUR","Türkiye","2017","2017",14.2,,
+"PATCALIM","A-Alimentary tract and metabolism","TCPPERMT","/capita, US$ exchange rate","TUR","Türkiye","2018","2018",13.3,,
+"PATCALIM","A-Alimentary tract and metabolism","TCPPERMT","/capita, US$ exchange rate","TUR","Türkiye","2019","2019",14.7,,
+"PATCALIM","A-Alimentary tract and metabolism","TCPPERMT","/capita, US$ exchange rate","TUR","Türkiye","2020","2020",15.6,,
+"PATCALIM","A-Alimentary tract and metabolism","TCPPERMT","/capita, US$ exchange rate","TUR","Türkiye","2021","2021",16.3,,
+"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2010","2010",32.1,,
+"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2011","2011",27.4,,
+"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2012","2012",25.4,,
+"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2013","2013",26,,
+"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2014","2014",27.3,,
+"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2015","2015",30.6,,
+"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2016","2016",34,,
+"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2017","2017",37.5,,
+"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2018","2018",39.3,,
+"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2019","2019",44.8,,
+"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2020","2020",50.5,,
+"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2021","2021",51.5,,
+"PATCALIM","A-Alimentary tract and metabolism","ATCPTTMT","% of total sales","TUR","Türkiye","2010","2010",13.8,,
+"PATCALIM","A-Alimentary tract and metabolism","ATCPTTMT","% of total sales","TUR","Türkiye","2011","2011",13.9,,
+"PATCALIM","A-Alimentary tract and metabolism","ATCPTTMT","% of total sales","TUR","Türkiye","2012","2012",14.4,,
+"PATCALIM","A-Alimentary tract and metabolism","ATCPTTMT","% of total sales","TUR","Türkiye","2013","2013",14.8,,
+"PATCALIM","A-Alimentary tract and metabolism","ATCPTTMT","% of total sales","TUR","Türkiye","2014","2014",14.8,,
+"PATCALIM","A-Alimentary tract and metabolism","ATCPTTMT","% of total sales","TUR","Türkiye","2015","2015",15.2,,
+"PATCALIM","A-Alimentary tract and metabolism","ATCPTTMT","% of total sales","TUR","Türkiye","2016","2016",15.3,,
+"PATCALIM","A-Alimentary tract and metabolism","ATCPTTMT","% of total sales","TUR","Türkiye","2017","2017",16.4,,
+"PATCALIM","A-Alimentary tract and metabolism","ATCPTTMT","% of total sales","TUR","Türkiye","2018","2018",16.3,,
+"PATCALIM","A-Alimentary tract and metabolism","ATCPTTMT","% of total sales","TUR","Türkiye","2019","2019",16.4,,
+"PATCALIM","A-Alimentary tract and metabolism","ATCPTTMT","% of total sales","TUR","Türkiye","2020","2020",18.2,,
+"PATCALIM","A-Alimentary tract and metabolism","ATCPTTMT","% of total sales","TUR","Türkiye","2021","2021",18.8,,
+"PATCALIM","A-Alimentary tract and metabolism","MLLNCUMT","Million of national currency units","GBR","United Kingdom","2012","2012",1384.3,"B","Break"
+"PATCALIM","A-Alimentary tract and metabolism","MLLNCUMT","Million of national currency units","GBR","United Kingdom","2013","2013",1410.4,,
+"PATCALIM","A-Alimentary tract and metabolism","MLLNCUMT","Million of national currency units","GBR","United Kingdom","2014","2014",1537.2,,
+"PATCALIM","A-Alimentary tract and metabolism","MLLNCUMT","Million of national currency units","GBR","United Kingdom","2015","2015",1710.8,,
+"PATCALIM","A-Alimentary tract and metabolism","MLLNCUMT","Million of national currency units","GBR","United Kingdom","2016","2016",1773.2,,
+"PATCALIM","A-Alimentary tract and metabolism","MLLNCUMT","Million of national currency units","GBR","United Kingdom","2017","2017",1854.8,,
+"PATCALIM","A-Alimentary tract and metabolism","MLLNCUMT","Million of national currency units","GBR","United Kingdom","2018","2018",1981.1,,
+"PATCALIM","A-Alimentary tract and metabolism","MTMOTCMT","Million US$ at exchange rate","GBR","United Kingdom","2012","2012",2186.7,"B","Break"
+"PATCALIM","A-Alimentary tract and metabolism","MTMOTCMT","Million US$ at exchange rate","GBR","United Kingdom","2013","2013",2204.9,,
+"PATCALIM","A-Alimentary tract and metabolism","MTMOTCMT","Million US$ at exchange rate","GBR","United Kingdom","2014","2014",2529.4,,
+"PATCALIM","A-Alimentary tract and metabolism","MTMOTCMT","Million US$ at exchange rate","GBR","United Kingdom","2015","2015",2613.7,,
+"PATCALIM","A-Alimentary tract and metabolism","MTMOTCMT","Million US$ at exchange rate","GBR","United Kingdom","2016","2016",2394.2,,
+"PATCALIM","A-Alimentary tract and metabolism","MTMOTCMT","Million US$ at exchange rate","GBR","United Kingdom","2017","2017",2387.2,,
+"PATCALIM","A-Alimentary tract and metabolism","MTMOTCMT","Million US$ at exchange rate","GBR","United Kingdom","2018","2018",2643.1,,
+"PATCALIM","A-Alimentary tract and metabolism","MTMOPPMT","Million US$, purchasing power parity","GBR","United Kingdom","2012","2012",1973,"B","Break"
+"PATCALIM","A-Alimentary tract and metabolism","MTMOPPMT","Million US$, purchasing power parity","GBR","United Kingdom","2013","2013",2028.6,,
+"PATCALIM","A-Alimentary tract and metabolism","MTMOPPMT","Million US$, purchasing power parity","GBR","United Kingdom","2014","2014",2200.9,,
+"PATCALIM","A-Alimentary tract and metabolism","MTMOPPMT","Million US$, purchasing power parity","GBR","United Kingdom","2015","2015",2470.3,,
+"PATCALIM","A-Alimentary tract and metabolism","MTMOPPMT","Million US$, purchasing power parity","GBR","United Kingdom","2016","2016",2575.1,,
+"PATCALIM","A-Alimentary tract and metabolism","MTMOPPMT","Million US$, purchasing power parity","GBR","United Kingdom","2017","2017",2709.3,,
+"PATCALIM","A-Alimentary tract and metabolism","MTMOPPMT","Million US$, purchasing power parity","GBR","United Kingdom","2018","2018",2880.7,,
+"PATCALIM","A-Alimentary tract and metabolism","TCPPERMT","/capita, US$ exchange rate","GBR","United Kingdom","2012","2012",34.3,"B","Break"
+"PATCALIM","A-Alimentary tract and metabolism","TCPPERMT","/capita, US$ exchange rate","GBR","United Kingdom","2013","2013",34.4,,
+"PATCALIM","A-Alimentary tract and metabolism","TCPPERMT","/capita, US$ exchange rate","GBR","United Kingdom","2014","2014",39.2,,
+"PATCALIM","A-Alimentary tract and metabolism","TCPPERMT","/capita, US$ exchange rate","GBR","United Kingdom","2015","2015",40.1,,
+"PATCALIM","A-Alimentary tract and metabolism","TCPPERMT","/capita, US$ exchange rate","GBR","United Kingdom","2016","2016",36.5,,
+"PATCALIM","A-Alimentary tract and metabolism","TCPPERMT","/capita, US$ exchange rate","GBR","United Kingdom","2017","2017",36.1,,
+"PATCALIM","A-Alimentary tract and metabolism","TCPPERMT","/capita, US$ exchange rate","GBR","United Kingdom","2018","2018",39.8,,
+"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","GBR","United Kingdom","2012","2012",31,"B","Break"
+"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","GBR","United Kingdom","2013","2013",31.6,,
+"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","GBR","United Kingdom","2014","2014",34.1,,
+"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","GBR","United Kingdom","2015","2015",37.9,,
+"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","GBR","United Kingdom","2016","2016",39.2,,
+"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","GBR","United Kingdom","2017","2017",41,,
+"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","GBR","United Kingdom","2018","2018",43.4,,
+"PATCALIM","A-Alimentary tract and metabolism","ATCPTTMT","% of total sales","GBR","United Kingdom","2012","2012",10.1,"B","Break"
+"PATCALIM","A-Alimentary tract and metabolism","ATCPTTMT","% of total sales","GBR","United Kingdom","2013","2013",9.7,,
+"PATCALIM","A-Alimentary tract and metabolism","ATCPTTMT","% of total sales","GBR","United Kingdom","2014","2014",9.6,,
+"PATCALIM","A-Alimentary tract and metabolism","ATCPTTMT","% of total sales","GBR","United Kingdom","2015","2015",9.7,,
+"PATCALIM","A-Alimentary tract and metabolism","ATCPTTMT","% of total sales","GBR","United Kingdom","2016","2016",9.6,,
+"PATCALIM","A-Alimentary tract and metabolism","ATCPTTMT","% of total sales","GBR","United Kingdom","2017","2017",9.5,,
+"PATCALIM","A-Alimentary tract and metabolism","ATCPTTMT","% of total sales","GBR","United Kingdom","2018","2018",9.7,,
+"PATCALIM","A-Alimentary tract and metabolism","MLLNCUMT","Million of national currency units","CHL","Chile","2010","2010",151311.4,,
+"PATCALIM","A-Alimentary tract and metabolism","MLLNCUMT","Million of national currency units","CHL","Chile","2011","2011",184612.6,"B","Break"
+"PATCALIM","A-Alimentary tract and metabolism","MLLNCUMT","Million of national currency units","CHL","Chile","2012","2012",203569.3,,
+"PATCALIM","A-Alimentary tract and metabolism","MLLNCUMT","Million of national currency units","CHL","Chile","2013","2013",220594,,
+"PATCALIM","A-Alimentary tract and metabolism","MLLNCUMT","Million of national currency units","CHL","Chile","2014","2014",260015,,
+"PATCALIM","A-Alimentary tract and metabolism","MLLNCUMT","Million of national currency units","CHL","Chile","2015","2015",317777.7,,
+"PATCALIM","A-Alimentary tract and metabolism","MLLNCUMT","Million of national currency units","CHL","Chile","2016","2016",361148.7,,
+"PATCALIM","A-Alimentary tract and metabolism","MLLNCUMT","Million of national currency units","CHL","Chile","2017","2017",385291.1,,
+"PATCALIM","A-Alimentary tract and metabolism","MLLNCUMT","Million of national currency units","CHL","Chile","2018","2018",397573.8,,
+"PATCALIM","A-Alimentary tract and metabolism","MLLNCUMT","Million of national currency units","CHL","Chile","2019","2019",479315.8,,
+"PATCALIM","A-Alimentary tract and metabolism","MLLNCUMT","Million of national currency units","CHL","Chile","2020","2020",508617,,
+"PATCALIM","A-Alimentary tract and metabolism","MLLNCUMT","Million of national currency units","CHL","Chile","2021","2021",542926.4,,
+"PATCALIM","A-Alimentary tract and metabolism","MLLNCUMT","Million of national currency units","CHL","Chile","2022","2022",498922,,
+"PATCALIM","A-Alimentary tract and metabolism","MTMOTCMT","Million US$ at exchange rate","CHL","Chile","2010","2010",296.5,,
+"PATCALIM","A-Alimentary tract and metabolism","MTMOTCMT","Million US$ at exchange rate","CHL","Chile","2011","2011",381.7,"B","Break"
+"PATCALIM","A-Alimentary tract and metabolism","MTMOTCMT","Million US$ at exchange rate","CHL","Chile","2012","2012",418.5,,
+"PATCALIM","A-Alimentary tract and metabolism","MTMOTCMT","Million US$ at exchange rate","CHL","Chile","2013","2013",445.4,,
+"PATCALIM","A-Alimentary tract and metabolism","MTMOTCMT","Million US$ at exchange rate","CHL","Chile","2014","2014",455.9,,
+"PATCALIM","A-Alimentary tract and metabolism","MTMOTCMT","Million US$ at exchange rate","CHL","Chile","2015","2015",485.8,,
+"PATCALIM","A-Alimentary tract and metabolism","MTMOTCMT","Million US$ at exchange rate","CHL","Chile","2016","2016",533.5,,
+"PATCALIM","A-Alimentary tract and metabolism","MTMOTCMT","Million US$ at exchange rate","CHL","Chile","2017","2017",593.8,,
+"PATCALIM","A-Alimentary tract and metabolism","MTMOTCMT","Million US$ at exchange rate","CHL","Chile","2018","2018",620,,
+"PATCALIM","A-Alimentary tract and metabolism","MTMOTCMT","Million US$ at exchange rate","CHL","Chile","2019","2019",681.9,,
+"PATCALIM","A-Alimentary tract and metabolism","MTMOTCMT","Million US$ at exchange rate","CHL","Chile","2020","2020",641.6,,
+"PATCALIM","A-Alimentary tract and metabolism","MTMOTCMT","Million US$ at exchange rate","CHL","Chile","2021","2021",715.4,,
+"PATCALIM","A-Alimentary tract and metabolism","MTMOTCMT","Million US$ at exchange rate","CHL","Chile","2022","2022",571.3,,
+"PATCALIM","A-Alimentary tract and metabolism","MTMOPPMT","Million US$, purchasing power parity","CHL","Chile","2010","2010",420.5,,
+"PATCALIM","A-Alimentary tract and metabolism","MTMOPPMT","Million US$, purchasing power parity","CHL","Chile","2011","2011",530.5,"B","Break"
+"PATCALIM","A-Alimentary tract and metabolism","MTMOPPMT","Million US$, purchasing power parity","CHL","Chile","2012","2012",586.3,,
+"PATCALIM","A-Alimentary tract and metabolism","MTMOPPMT","Million US$, purchasing power parity","CHL","Chile","2013","2013",630.8,,
+"PATCALIM","A-Alimentary tract and metabolism","MTMOPPMT","Million US$, purchasing power parity","CHL","Chile","2014","2014",708.1,,
+"PATCALIM","A-Alimentary tract and metabolism","MTMOPPMT","Million US$, purchasing power parity","CHL","Chile","2015","2015",812.4,,
+"PATCALIM","A-Alimentary tract and metabolism","MTMOPPMT","Million US$, purchasing power parity","CHL","Chile","2016","2016",909.1,,
+"PATCALIM","A-Alimentary tract and metabolism","MTMOPPMT","Million US$, purchasing power parity","CHL","Chile","2017","2017",968.8,,
+"PATCALIM","A-Alimentary tract and metabolism","MTMOPPMT","Million US$, purchasing power parity","CHL","Chile","2018","2018",1003.4,,
+"PATCALIM","A-Alimentary tract and metabolism","MTMOPPMT","Million US$, purchasing power parity","CHL","Chile","2019","2019",1193.5,,
+"PATCALIM","A-Alimentary tract and metabolism","MTMOPPMT","Million US$, purchasing power parity","CHL","Chile","2020","2020",1215.5,,
+"PATCALIM","A-Alimentary tract and metabolism","MTMOPPMT","Million US$, purchasing power parity","CHL","Chile","2021","2021",1247.7,,
+"PATCALIM","A-Alimentary tract and metabolism","MTMOPPMT","Million US$, purchasing power parity","CHL","Chile","2022","2022",1140.2,,
+"PATCALIM","A-Alimentary tract and metabolism","TCPPERMT","/capita, US$ exchange rate","CHL","Chile","2010","2010",17.4,,
+"PATCALIM","A-Alimentary tract and metabolism","TCPPERMT","/capita, US$ exchange rate","CHL","Chile","2011","2011",22.1,"B","Break"
+"PATCALIM","A-Alimentary tract and metabolism","TCPPERMT","/capita, US$ exchange rate","CHL","Chile","2012","2012",24,,
+"PATCALIM","A-Alimentary tract and metabolism","TCPPERMT","/capita, US$ exchange rate","CHL","Chile","2013","2013",25.3,,
+"PATCALIM","A-Alimentary tract and metabolism","TCPPERMT","/capita, US$ exchange rate","CHL","Chile","2014","2014",25.6,,
+"PATCALIM","A-Alimentary tract and metabolism","TCPPERMT","/capita, US$ exchange rate","CHL","Chile","2015","2015",27,,
+"PATCALIM","A-Alimentary tract and metabolism","TCPPERMT","/capita, US$ exchange rate","CHL","Chile","2016","2016",29.4,,
+"PATCALIM","A-Alimentary tract and metabolism","TCPPERMT","/capita, US$ exchange rate","CHL","Chile","2017","2017",32.2,,
+"PATCALIM","A-Alimentary tract and metabolism","TCPPERMT","/capita, US$ exchange rate","CHL","Chile","2018","2018",33.1,,
+"PATCALIM","A-Alimentary tract and metabolism","TCPPERMT","/capita, US$ exchange rate","CHL","Chile","2019","2019",35.7,,
+"PATCALIM","A-Alimentary tract and metabolism","TCPPERMT","/capita, US$ exchange rate","CHL","Chile","2020","2020",33,,
+"PATCALIM","A-Alimentary tract and metabolism","TCPPERMT","/capita, US$ exchange rate","CHL","Chile","2021","2021",36.4,,
+"PATCALIM","A-Alimentary tract and metabolism","TCPPERMT","/capita, US$ exchange rate","CHL","Chile","2022","2022",28.8,,
+"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2010","2010",24.6,,
+"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2011","2011",30.7,"B","Break"
+"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2012","2012",33.6,,
+"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2013","2013",35.8,,
+"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2014","2014",39.8,,
+"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2015","2015",45.2,,
+"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2016","2016",50,,
+"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2017","2017",52.6,,
+"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2018","2018",53.5,,
+"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2019","2019",62.5,,
+"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2020","2020",62.5,,
+"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2021","2021",63.4,,
+"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2022","2022",57.5,,
+"PATCALIM","A-Alimentary tract and metabolism","ATCPTTMT","% of total sales","CHL","Chile","2010","2010",18.3,,
+"PATCALIM","A-Alimentary tract and metabolism","ATCPTTMT","% of total sales","CHL","Chile","2011","2011",15.7,"B","Break"
+"PATCALIM","A-Alimentary tract and metabolism","ATCPTTMT","% of total sales","CHL","Chile","2012","2012",16.3,,
+"PATCALIM","A-Alimentary tract and metabolism","ATCPTTMT","% of total sales","CHL","Chile","2013","2013",15.2,,
+"PATCALIM","A-Alimentary tract and metabolism","ATCPTTMT","% of total sales","CHL","Chile","2014","2014",16.8,,
+"PATCALIM","A-Alimentary tract and metabolism","ATCPTTMT","% of total sales","CHL","Chile","2015","2015",17.4,,
+"PATCALIM","A-Alimentary tract and metabolism","ATCPTTMT","% of total sales","CHL","Chile","2016","2016",17.8,,
+"PATCALIM","A-Alimentary tract and metabolism","ATCPTTMT","% of total sales","CHL","Chile","2017","2017",18.6,,
+"PATCALIM","A-Alimentary tract and metabolism","ATCPTTMT","% of total sales","CHL","Chile","2018","2018",17.3,,
+"PATCALIM","A-Alimentary tract and metabolism","ATCPTTMT","% of total sales","CHL","Chile","2019","2019",19,,
+"PATCALIM","A-Alimentary tract and metabolism","ATCPTTMT","% of total sales","CHL","Chile","2020","2020",18.9,,
+"PATCALIM","A-Alimentary tract and metabolism","ATCPTTMT","% of total sales","CHL","Chile","2021","2021",19.3,,
+"PATCALIM","A-Alimentary tract and metabolism","ATCPTTMT","% of total sales","CHL","Chile","2022","2022",17.7,,
+"PATCALIM","A-Alimentary tract and metabolism","MLLNCUMT","Million of national currency units","EST","Estonia","2010","2010",23.5,,
+"PATCALIM","A-Alimentary tract and metabolism","MLLNCUMT","Million of national currency units","EST","Estonia","2011","2011",24.3,,
+"PATCALIM","A-Alimentary tract and metabolism","MLLNCUMT","Million of national currency units","EST","Estonia","2012","2012",26.9,,
+"PATCALIM","A-Alimentary tract and metabolism","MLLNCUMT","Million of national currency units","EST","Estonia","2013","2013",28.7,,
+"PATCALIM","A-Alimentary tract and metabolism","MLLNCUMT","Million of national currency units","EST","Estonia","2014","2014",30.7,,
+"PATCALIM","A-Alimentary tract and metabolism","MLLNCUMT","Million of national currency units","EST","Estonia","2015","2015",32.7,,
+"PATCALIM","A-Alimentary tract and metabolism","MLLNCUMT","Million of national currency units","EST","Estonia","2016","2016",34.3,,
+"PATCALIM","A-Alimentary tract and metabolism","MLLNCUMT","Million of national currency units","EST","Estonia","2017","2017",35.6,,
+"PATCALIM","A-Alimentary tract and metabolism","MLLNCUMT","Million of national currency units","EST","Estonia","2018","2018",38.1,,
+"PATCALIM","A-Alimentary tract and metabolism","MLLNCUMT","Million of national currency units","EST","Estonia","2019","2019",39.6,,
+"PATCALIM","A-Alimentary tract and metabolism","MLLNCUMT","Million of national currency units","EST","Estonia","2020","2020",41.3,,
+"PATCALIM","A-Alimentary tract and metabolism","MLLNCUMT","Million of national currency units","EST","Estonia","2021","2021",43.4,,
+"PATCALIM","A-Alimentary tract and metabolism","MLLNCUMT","Million of national currency units","EST","Estonia","2022","2022",50,,
+"PATCALIM","A-Alimentary tract and metabolism","MTMOTCMT","Million US$ at exchange rate","EST","Estonia","2010","2010",31.2,,
+"PATCALIM","A-Alimentary tract and metabolism","MTMOTCMT","Million US$ at exchange rate","EST","Estonia","2011","2011",33.9,,
+"PATCALIM","A-Alimentary tract and metabolism","MTMOTCMT","Million US$ at exchange rate","EST","Estonia","2012","2012",34.5,,
+"PATCALIM","A-Alimentary tract and metabolism","MTMOTCMT","Million US$ at exchange rate","EST","Estonia","2013","2013",38.1,,
+"PATCALIM","A-Alimentary tract and metabolism","MTMOTCMT","Million US$ at exchange rate","EST","Estonia","2014","2014",40.8,,
+"PATCALIM","A-Alimentary tract and metabolism","MTMOTCMT","Million US$ at exchange rate","EST","Estonia","2015","2015",36.3,,
+"PATCALIM","A-Alimentary tract and metabolism","MTMOTCMT","Million US$ at exchange rate","EST","Estonia","2016","2016",38,,
+"PATCALIM","A-Alimentary tract and metabolism","MTMOTCMT","Million US$ at exchange rate","EST","Estonia","2017","2017",40.2,,
+"PATCALIM","A-Alimentary tract and metabolism","MTMOTCMT","Million US$ at exchange rate","EST","Estonia","2018","2018",45,,
+"PATCALIM","A-Alimentary tract and metabolism","MTMOTCMT","Million US$ at exchange rate","EST","Estonia","2019","2019",44.3,,
+"PATCALIM","A-Alimentary tract and metabolism","MTMOTCMT","Million US$ at exchange rate","EST","Estonia","2020","2020",47.2,,
+"PATCALIM","A-Alimentary tract and metabolism","MTMOTCMT","Million US$ at exchange rate","EST","Estonia","2021","2021",51.4,,
+"PATCALIM","A-Alimentary tract and metabolism","MTMOTCMT","Million US$ at exchange rate","EST","Estonia","2022","2022",52.7,,
+"PATCALIM","A-Alimentary tract and metabolism","MTMOPPMT","Million US$, purchasing power parity","EST","Estonia","2010","2010",46,,
+"PATCALIM","A-Alimentary tract and metabolism","MTMOPPMT","Million US$, purchasing power parity","EST","Estonia","2011","2011",47.6,,
+"PATCALIM","A-Alimentary tract and metabolism","MTMOPPMT","Million US$, purchasing power parity","EST","Estonia","2012","2012",51.6,,
+"PATCALIM","A-Alimentary tract and metabolism","MTMOPPMT","Million US$, purchasing power parity","EST","Estonia","2013","2013",54.9,,
+"PATCALIM","A-Alimentary tract and metabolism","MTMOPPMT","Million US$, purchasing power parity","EST","Estonia","2014","2014",58.3,,
+"PATCALIM","A-Alimentary tract and metabolism","MTMOPPMT","Million US$, purchasing power parity","EST","Estonia","2015","2015",60.9,,
+"PATCALIM","A-Alimentary tract and metabolism","MTMOPPMT","Million US$, purchasing power parity","EST","Estonia","2016","2016",65.1,,
+"PATCALIM","A-Alimentary tract and metabolism","MTMOPPMT","Million US$, purchasing power parity","EST","Estonia","2017","2017",66.5,,
+"PATCALIM","A-Alimentary tract and metabolism","MTMOPPMT","Million US$, purchasing power parity","EST","Estonia","2018","2018",70.8,,
+"PATCALIM","A-Alimentary tract and metabolism","MTMOPPMT","Million US$, purchasing power parity","EST","Estonia","2019","2019",73.8,,
+"PATCALIM","A-Alimentary tract and metabolism","MTMOPPMT","Million US$, purchasing power parity","EST","Estonia","2020","2020",78.8,,
+"PATCALIM","A-Alimentary tract and metabolism","MTMOPPMT","Million US$, purchasing power parity","EST","Estonia","2021","2021",79.9,,
+"PATCALIM","A-Alimentary tract and metabolism","MTMOPPMT","Million US$, purchasing power parity","EST","Estonia","2022","2022",87.8,,
+"PATCALIM","A-Alimentary tract and metabolism","TCPPERMT","/capita, US$ exchange rate","EST","Estonia","2010","2010",23.4,,
+"PATCALIM","A-Alimentary tract and metabolism","TCPPERMT","/capita, US$ exchange rate","EST","Estonia","2011","2011",25.5,,
+"PATCALIM","A-Alimentary tract and metabolism","TCPPERMT","/capita, US$ exchange rate","EST","Estonia","2012","2012",26.1,,
+"PATCALIM","A-Alimentary tract and metabolism","TCPPERMT","/capita, US$ exchange rate","EST","Estonia","2013","2013",28.9,,
+"PATCALIM","A-Alimentary tract and metabolism","TCPPERMT","/capita, US$ exchange rate","EST","Estonia","2014","2014",31.1,,
+"PATCALIM","A-Alimentary tract and metabolism","TCPPERMT","/capita, US$ exchange rate","EST","Estonia","2015","2015",27.6,,
+"PATCALIM","A-Alimentary tract and metabolism","TCPPERMT","/capita, US$ exchange rate","EST","Estonia","2016","2016",28.9,,
+"PATCALIM","A-Alimentary tract and metabolism","TCPPERMT","/capita, US$ exchange rate","EST","Estonia","2017","2017",30.5,,
+"PATCALIM","A-Alimentary tract and metabolism","TCPPERMT","/capita, US$ exchange rate","EST","Estonia","2018","2018",34.1,,
+"PATCALIM","A-Alimentary tract and metabolism","TCPPERMT","/capita, US$ exchange rate","EST","Estonia","2019","2019",33.4,,
+"PATCALIM","A-Alimentary tract and metabolism","TCPPERMT","/capita, US$ exchange rate","EST","Estonia","2020","2020",35.5,,
+"PATCALIM","A-Alimentary tract and metabolism","TCPPERMT","/capita, US$ exchange rate","EST","Estonia","2021","2021",38.6,,
+"PATCALIM","A-Alimentary tract and metabolism","TCPPERMT","/capita, US$ exchange rate","EST","Estonia","2022","2022",39.5,,
+"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2010","2010",34.5,,
+"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2011","2011",35.8,,
+"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2012","2012",39,,
+"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2013","2013",41.7,,
+"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2014","2014",44.4,,
+"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2015","2015",46.3,,
+"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2016","2016",49.4,,
+"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2017","2017",50.5,,
+"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2018","2018",53.5,,
+"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2019","2019",55.6,,
+"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2020","2020",59.3,,
+"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2021","2021",60,,
+"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2022","2022",66,,
+"PATCALIM","A-Alimentary tract and metabolism","ATCPTTMT","% of total sales","EST","Estonia","2010","2010",12.1,,
+"PATCALIM","A-Alimentary tract and metabolism","ATCPTTMT","% of total sales","EST","Estonia","2011","2011",11.9,,
+"PATCALIM","A-Alimentary tract and metabolism","ATCPTTMT","% of total sales","EST","Estonia","2012","2012",12.1,,
+"PATCALIM","A-Alimentary tract and metabolism","ATCPTTMT","% of total sales","EST","Estonia","2013","2013",12.4,,
+"PATCALIM","A-Alimentary tract and metabolism","ATCPTTMT","% of total sales","EST","Estonia","2014","2014",12.3,,
+"PATCALIM","A-Alimentary tract and metabolism","ATCPTTMT","% of total sales","EST","Estonia","2015","2015",12.3,,
+"PATCALIM","A-Alimentary tract and metabolism","ATCPTTMT","% of total sales","EST","Estonia","2016","2016",11.8,,
+"PATCALIM","A-Alimentary tract and metabolism","ATCPTTMT","% of total sales","EST","Estonia","2017","2017",11.8,,
+"PATCALIM","A-Alimentary tract and metabolism","ATCPTTMT","% of total sales","EST","Estonia","2018","2018",11.7,,
+"PATCALIM","A-Alimentary tract and metabolism","ATCPTTMT","% of total sales","EST","Estonia","2019","2019",11.5,,
+"PATCALIM","A-Alimentary tract and metabolism","ATCPTTMT","% of total sales","EST","Estonia","2020","2020",11.5,,
+"PATCALIM","A-Alimentary tract and metabolism","ATCPTTMT","% of total sales","EST","Estonia","2021","2021",10.6,,
+"PATCALIM","A-Alimentary tract and metabolism","ATCPTTMT","% of total sales","EST","Estonia","2022","2022",11.6,,
+"PATCALIM","A-Alimentary tract and metabolism","MLLNCUMT","Million of national currency units","SVN","Slovenia","2010","2010",55.5,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","MLLNCUMT","Million of national currency units","SVN","Slovenia","2011","2011",55.2,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","MLLNCUMT","Million of national currency units","SVN","Slovenia","2012","2012",51.8,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","MLLNCUMT","Million of national currency units","SVN","Slovenia","2013","2013",49.9,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","MLLNCUMT","Million of national currency units","SVN","Slovenia","2014","2014",50.1,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","MLLNCUMT","Million of national currency units","SVN","Slovenia","2015","2015",52.8,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","MLLNCUMT","Million of national currency units","SVN","Slovenia","2016","2016",56.1,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","MLLNCUMT","Million of national currency units","SVN","Slovenia","2017","2017",57.8,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","MLLNCUMT","Million of national currency units","SVN","Slovenia","2018","2018",62.1,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","MLLNCUMT","Million of national currency units","SVN","Slovenia","2019","2019",67.2,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","MLLNCUMT","Million of national currency units","SVN","Slovenia","2020","2020",72.2,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","MLLNCUMT","Million of national currency units","SVN","Slovenia","2021","2021",76.8,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","MLLNCUMT","Million of national currency units","SVN","Slovenia","2022","2022",87.5,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","MTMOTCMT","Million US$ at exchange rate","SVN","Slovenia","2010","2010",73.5,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","MTMOTCMT","Million US$ at exchange rate","SVN","Slovenia","2011","2011",76.8,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","MTMOTCMT","Million US$ at exchange rate","SVN","Slovenia","2012","2012",66.6,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","MTMOTCMT","Million US$ at exchange rate","SVN","Slovenia","2013","2013",66.3,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","MTMOTCMT","Million US$ at exchange rate","SVN","Slovenia","2014","2014",66.6,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","MTMOTCMT","Million US$ at exchange rate","SVN","Slovenia","2015","2015",58.5,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","MTMOTCMT","Million US$ at exchange rate","SVN","Slovenia","2016","2016",62.1,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","MTMOTCMT","Million US$ at exchange rate","SVN","Slovenia","2017","2017",65.3,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","MTMOTCMT","Million US$ at exchange rate","SVN","Slovenia","2018","2018",73.3,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","MTMOTCMT","Million US$ at exchange rate","SVN","Slovenia","2019","2019",75.2,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","MTMOTCMT","Million US$ at exchange rate","SVN","Slovenia","2020","2020",82.5,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","MTMOTCMT","Million US$ at exchange rate","SVN","Slovenia","2021","2021",90.8,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","MTMOTCMT","Million US$ at exchange rate","SVN","Slovenia","2022","2022",92.1,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","MTMOPPMT","Million US$, purchasing power parity","SVN","Slovenia","2010","2010",86.9,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","MTMOPPMT","Million US$, purchasing power parity","SVN","Slovenia","2011","2011",88.4,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","MTMOPPMT","Million US$, purchasing power parity","SVN","Slovenia","2012","2012",85.4,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","MTMOPPMT","Million US$, purchasing power parity","SVN","Slovenia","2013","2013",84.5,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","MTMOPPMT","Million US$, purchasing power parity","SVN","Slovenia","2014","2014",84.8,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","MTMOPPMT","Million US$, purchasing power parity","SVN","Slovenia","2015","2015",88.6,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","MTMOPPMT","Million US$, purchasing power parity","SVN","Slovenia","2016","2016",97.3,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","MTMOPPMT","Million US$, purchasing power parity","SVN","Slovenia","2017","2017",101.3,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","MTMOPPMT","Million US$, purchasing power parity","SVN","Slovenia","2018","2018",109.4,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","MTMOPPMT","Million US$, purchasing power parity","SVN","Slovenia","2019","2019",121.7,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","MTMOPPMT","Million US$, purchasing power parity","SVN","Slovenia","2020","2020",132,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","MTMOPPMT","Million US$, purchasing power parity","SVN","Slovenia","2021","2021",136.3,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","MTMOPPMT","Million US$, purchasing power parity","SVN","Slovenia","2022","2022",158.6,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","TCPPERMT","/capita, US$ exchange rate","SVN","Slovenia","2010","2010",35.9,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","TCPPERMT","/capita, US$ exchange rate","SVN","Slovenia","2011","2011",37.4,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","TCPPERMT","/capita, US$ exchange rate","SVN","Slovenia","2012","2012",32.4,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","TCPPERMT","/capita, US$ exchange rate","SVN","Slovenia","2013","2013",32.2,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","TCPPERMT","/capita, US$ exchange rate","SVN","Slovenia","2014","2014",32.3,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","TCPPERMT","/capita, US$ exchange rate","SVN","Slovenia","2015","2015",28.4,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","TCPPERMT","/capita, US$ exchange rate","SVN","Slovenia","2016","2016",30.1,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","TCPPERMT","/capita, US$ exchange rate","SVN","Slovenia","2017","2017",31.6,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","TCPPERMT","/capita, US$ exchange rate","SVN","Slovenia","2018","2018",35.4,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","TCPPERMT","/capita, US$ exchange rate","SVN","Slovenia","2019","2019",36,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","TCPPERMT","/capita, US$ exchange rate","SVN","Slovenia","2020","2020",39.3,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","TCPPERMT","/capita, US$ exchange rate","SVN","Slovenia","2021","2021",43.1,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","TCPPERMT","/capita, US$ exchange rate","SVN","Slovenia","2022","2022",43.7,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2010","2010",42.4,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2011","2011",43.1,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2012","2012",41.5,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2013","2013",41,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2014","2014",41.1,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2015","2015",43,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2016","2016",47.1,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2017","2017",49,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2018","2018",52.8,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2019","2019",58.3,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2020","2020",62.8,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2021","2021",64.7,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2022","2022",75.2,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","ATCPTTMT","% of total sales","SVN","Slovenia","2010","2010",11.7,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","ATCPTTMT","% of total sales","SVN","Slovenia","2011","2011",11.7,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","ATCPTTMT","% of total sales","SVN","Slovenia","2012","2012",11.4,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","ATCPTTMT","% of total sales","SVN","Slovenia","2013","2013",11.1,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","ATCPTTMT","% of total sales","SVN","Slovenia","2014","2014",11.6,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","ATCPTTMT","% of total sales","SVN","Slovenia","2015","2015",11.8,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","ATCPTTMT","% of total sales","SVN","Slovenia","2016","2016",12,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","ATCPTTMT","% of total sales","SVN","Slovenia","2017","2017",11.9,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","ATCPTTMT","% of total sales","SVN","Slovenia","2018","2018",12,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","ATCPTTMT","% of total sales","SVN","Slovenia","2019","2019",12.4,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","ATCPTTMT","% of total sales","SVN","Slovenia","2020","2020",12.7,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","ATCPTTMT","% of total sales","SVN","Slovenia","2021","2021",12.5,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","ATCPTTMT","% of total sales","SVN","Slovenia","2022","2022",12.9,"D","Difference in methodology"
+"PATCACID","A02A-Antacids","MLLNCUMT","Million of national currency units","AUS","Australia","2010","2010",2,"D","Difference in methodology"
+"PATCACID","A02A-Antacids","MLLNCUMT","Million of national currency units","AUS","Australia","2011","2011",2,"D","Difference in methodology"
+"PATCACID","A02A-Antacids","MLLNCUMT","Million of national currency units","AUS","Australia","2012","2012",2,"D","Difference in methodology"
+"PATCACID","A02A-Antacids","MLLNCUMT","Million of national currency units","AUS","Australia","2013","2013",2,"B; D","Break; Difference in methodology"
+"PATCACID","A02A-Antacids","MLLNCUMT","Million of national currency units","AUS","Australia","2014","2014",1,"D","Difference in methodology"
+"PATCACID","A02A-Antacids","MLLNCUMT","Million of national currency units","AUS","Australia","2015","2015",2,"D","Difference in methodology"
+"PATCACID","A02A-Antacids","MLLNCUMT","Million of national currency units","AUS","Australia","2016","2016",0,"D","Difference in methodology"
+"PATCACID","A02A-Antacids","MLLNCUMT","Million of national currency units","AUS","Australia","2017","2017",0,"D","Difference in methodology"
+"PATCACID","A02A-Antacids","MLLNCUMT","Million of national currency units","AUS","Australia","2018","2018",0,"D","Difference in methodology"
+"PATCACID","A02A-Antacids","MLLNCUMT","Million of national currency units","AUS","Australia","2019","2019",0,"D","Difference in methodology"
+"PATCACID","A02A-Antacids","MLLNCUMT","Million of national currency units","AUS","Australia","2020","2020",0,"D","Difference in methodology"
+"PATCACID","A02A-Antacids","MLLNCUMT","Million of national currency units","AUS","Australia","2021","2021",0,"D","Difference in methodology"
+"PATCACID","A02A-Antacids","MTMOTCMT","Million US$ at exchange rate","AUS","Australia","2010","2010",1.8,"D","Difference in methodology"
+"PATCACID","A02A-Antacids","MTMOTCMT","Million US$ at exchange rate","AUS","Australia","2011","2011",2.1,"D","Difference in methodology"
+"PATCACID","A02A-Antacids","MTMOTCMT","Million US$ at exchange rate","AUS","Australia","2012","2012",2.1,"D","Difference in methodology"
+"PATCACID","A02A-Antacids","MTMOTCMT","Million US$ at exchange rate","AUS","Australia","2013","2013",1.9,"B; D","Break; Difference in methodology"
+"PATCACID","A02A-Antacids","MTMOTCMT","Million US$ at exchange rate","AUS","Australia","2014","2014",0.9,"D","Difference in methodology"
+"PATCACID","A02A-Antacids","MTMOTCMT","Million US$ at exchange rate","AUS","Australia","2015","2015",1.5,"D","Difference in methodology"
+"PATCACID","A02A-Antacids","MTMOTCMT","Million US$ at exchange rate","AUS","Australia","2016","2016",0,"D","Difference in methodology"
+"PATCACID","A02A-Antacids","MTMOTCMT","Million US$ at exchange rate","AUS","Australia","2017","2017",0,"D","Difference in methodology"
+"PATCACID","A02A-Antacids","MTMOTCMT","Million US$ at exchange rate","AUS","Australia","2018","2018",0,"D","Difference in methodology"
+"PATCACID","A02A-Antacids","MTMOTCMT","Million US$ at exchange rate","AUS","Australia","2019","2019",0,"D","Difference in methodology"
+"PATCACID","A02A-Antacids","MTMOTCMT","Million US$ at exchange rate","AUS","Australia","2020","2020",0,"D","Difference in methodology"
+"PATCACID","A02A-Antacids","MTMOTCMT","Million US$ at exchange rate","AUS","Australia","2021","2021",0,"D","Difference in methodology"
+"PATCACID","A02A-Antacids","MTMOPPMT","Million US$, purchasing power parity","AUS","Australia","2010","2010",1.3,"D","Difference in methodology"
+"PATCACID","A02A-Antacids","MTMOPPMT","Million US$, purchasing power parity","AUS","Australia","2011","2011",1.3,"D","Difference in methodology"
+"PATCACID","A02A-Antacids","MTMOPPMT","Million US$, purchasing power parity","AUS","Australia","2012","2012",1.3,"D","Difference in methodology"
+"PATCACID","A02A-Antacids","MTMOPPMT","Million US$, purchasing power parity","AUS","Australia","2013","2013",1.4,"B; D","Break; Difference in methodology"
+"PATCACID","A02A-Antacids","MTMOPPMT","Million US$, purchasing power parity","AUS","Australia","2014","2014",0.7,"D","Difference in methodology"
+"PATCACID","A02A-Antacids","MTMOPPMT","Million US$, purchasing power parity","AUS","Australia","2015","2015",1.4,"D","Difference in methodology"
+"PATCACID","A02A-Antacids","MTMOPPMT","Million US$, purchasing power parity","AUS","Australia","2016","2016",0,"D","Difference in methodology"
+"PATCACID","A02A-Antacids","MTMOPPMT","Million US$, purchasing power parity","AUS","Australia","2017","2017",0,"D","Difference in methodology"
+"PATCACID","A02A-Antacids","MTMOPPMT","Million US$, purchasing power parity","AUS","Australia","2018","2018",0,"D","Difference in methodology"
+"PATCACID","A02A-Antacids","MTMOPPMT","Million US$, purchasing power parity","AUS","Australia","2019","2019",0,"D","Difference in methodology"
+"PATCACID","A02A-Antacids","MTMOPPMT","Million US$, purchasing power parity","AUS","Australia","2020","2020",0,"D","Difference in methodology"
+"PATCACID","A02A-Antacids","MTMOPPMT","Million US$, purchasing power parity","AUS","Australia","2021","2021",0,"D","Difference in methodology"
+"PATCACID","A02A-Antacids","TCPPERMT","/capita, US$ exchange rate","AUS","Australia","2010","2010",0.1,"D","Difference in methodology"
+"PATCACID","A02A-Antacids","TCPPERMT","/capita, US$ exchange rate","AUS","Australia","2011","2011",0.1,"D","Difference in methodology"
+"PATCACID","A02A-Antacids","TCPPERMT","/capita, US$ exchange rate","AUS","Australia","2012","2012",0.1,"D","Difference in methodology"
+"PATCACID","A02A-Antacids","TCPPERMT","/capita, US$ exchange rate","AUS","Australia","2013","2013",0.1,"B; D","Break; Difference in methodology"
+"PATCACID","A02A-Antacids","TCPPERMT","/capita, US$ exchange rate","AUS","Australia","2014","2014",0,"D","Difference in methodology"
+"PATCACID","A02A-Antacids","TCPPERMT","/capita, US$ exchange rate","AUS","Australia","2015","2015",0.1,"D","Difference in methodology"
+"PATCACID","A02A-Antacids","TCPPERMT","/capita, US$ exchange rate","AUS","Australia","2016","2016",0,"D","Difference in methodology"
+"PATCACID","A02A-Antacids","TCPPERMT","/capita, US$ exchange rate","AUS","Australia","2017","2017",0,"D","Difference in methodology"
+"PATCACID","A02A-Antacids","TCPPERMT","/capita, US$ exchange rate","AUS","Australia","2018","2018",0,"D","Difference in methodology"
+"PATCACID","A02A-Antacids","TCPPERMT","/capita, US$ exchange rate","AUS","Australia","2019","2019",0,"D","Difference in methodology"
+"PATCACID","A02A-Antacids","TCPPERMT","/capita, US$ exchange rate","AUS","Australia","2020","2020",0,"D","Difference in methodology"
+"PATCACID","A02A-Antacids","TCPPERMT","/capita, US$ exchange rate","AUS","Australia","2021","2021",0,"D","Difference in methodology"
+"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2010","2010",0.1,"D","Difference in methodology"
+"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2011","2011",0.1,"D","Difference in methodology"
+"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2012","2012",0.1,"D","Difference in methodology"
+"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2013","2013",0.1,"B; D","Break; Difference in methodology"
+"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2014","2014",0,"D","Difference in methodology"
+"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2015","2015",0.1,"D","Difference in methodology"
+"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2016","2016",0,"D","Difference in methodology"
+"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2017","2017",0,"D","Difference in methodology"
+"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2018","2018",0,"D","Difference in methodology"
+"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2019","2019",0,"D","Difference in methodology"
+"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2020","2020",0,"D","Difference in methodology"
+"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2021","2021",0,"D","Difference in methodology"
+"PATCACID","A02A-Antacids","ATCPTTMT","% of total sales","AUS","Australia","2010","2010",0,"D","Difference in methodology"
+"PATCACID","A02A-Antacids","ATCPTTMT","% of total sales","AUS","Australia","2011","2011",0,"D","Difference in methodology"
+"PATCACID","A02A-Antacids","ATCPTTMT","% of total sales","AUS","Australia","2012","2012",0,"D","Difference in methodology"
+"PATCACID","A02A-Antacids","ATCPTTMT","% of total sales","AUS","Australia","2013","2013",0,"B; D","Break; Difference in methodology"
+"PATCACID","A02A-Antacids","ATCPTTMT","% of total sales","AUS","Australia","2014","2014",0,"D","Difference in methodology"
+"PATCACID","A02A-Antacids","ATCPTTMT","% of total sales","AUS","Australia","2015","2015",0,"D","Difference in methodology"
+"PATCACID","A02A-Antacids","ATCPTTMT","% of total sales","AUS","Australia","2016","2016",0,"D","Difference in methodology"
+"PATCACID","A02A-Antacids","ATCPTTMT","% of total sales","AUS","Australia","2017","2017",0,"D","Difference in methodology"
+"PATCACID","A02A-Antacids","ATCPTTMT","% of total sales","AUS","Australia","2018","2018",0,"D","Difference in methodology"
+"PATCACID","A02A-Antacids","ATCPTTMT","% of total sales","AUS","Australia","2019","2019",0,"D","Difference in methodology"
+"PATCACID","A02A-Antacids","ATCPTTMT","% of total sales","AUS","Australia","2020","2020",0,"D","Difference in methodology"
+"PATCACID","A02A-Antacids","ATCPTTMT","% of total sales","AUS","Australia","2021","2021",0,"D","Difference in methodology"
+"PATCACID","A02A-Antacids","MLLNCUMT","Million of national currency units","AUT","Austria","2010","2010",0.2,"D","Difference in methodology"
+"PATCACID","A02A-Antacids","MLLNCUMT","Million of national currency units","AUT","Austria","2011","2011",0.1,"D","Difference in methodology"
+"PATCACID","A02A-Antacids","MLLNCUMT","Million of national currency units","AUT","Austria","2012","2012",0.1,"D","Difference in methodology"
+"PATCACID","A02A-Antacids","MLLNCUMT","Million of national currency units","AUT","Austria","2013","2013",0.1,"D","Difference in methodology"
+"PATCACID","A02A-Antacids","MLLNCUMT","Million of national currency units","AUT","Austria","2014","2014",0.1,"D","Difference in methodology"
+"PATCACID","A02A-Antacids","MLLNCUMT","Million of national currency units","AUT","Austria","2015","2015",0.2,"D","Difference in methodology"
+"PATCACID","A02A-Antacids","MLLNCUMT","Million of national currency units","AUT","Austria","2016","2016",0.6,"D","Difference in methodology"
+"PATCACID","A02A-Antacids","MLLNCUMT","Million of national currency units","AUT","Austria","2017","2017",0.9,"D","Difference in methodology"
+"PATCACID","A02A-Antacids","MLLNCUMT","Million of national currency units","AUT","Austria","2018","2018",1,"D","Difference in methodology"
+"PATCACID","A02A-Antacids","MLLNCUMT","Million of national currency units","AUT","Austria","2019","2019",1.2,"D","Difference in methodology"
+"PATCACID","A02A-Antacids","MLLNCUMT","Million of national currency units","AUT","Austria","2020","2020",1.3,"D","Difference in methodology"
+"PATCACID","A02A-Antacids","MLLNCUMT","Million of national currency units","AUT","Austria","2021","2021",1.4,"D","Difference in methodology"
+"PATCACID","A02A-Antacids","MTMOTCMT","Million US$ at exchange rate","AUT","Austria","2010","2010",0.3,"D","Difference in methodology"
+"PATCACID","A02A-Antacids","MTMOTCMT","Million US$ at exchange rate","AUT","Austria","2011","2011",0.2,"D","Difference in methodology"
+"PATCACID","A02A-Antacids","MTMOTCMT","Million US$ at exchange rate","AUT","Austria","2012","2012",0.2,"D","Difference in methodology"
+"PATCACID","A02A-Antacids","MTMOTCMT","Million US$ at exchange rate","AUT","Austria","2013","2013",0.2,"D","Difference in methodology"
+"PATCACID","A02A-Antacids","MTMOTCMT","Million US$ at exchange rate","AUT","Austria","2014","2014",0.2,"D","Difference in methodology"
+"PATCACID","A02A-Antacids","MTMOTCMT","Million US$ at exchange rate","AUT","Austria","2015","2015",0.2,"D","Difference in methodology"
+"PATCACID","A02A-Antacids","MTMOTCMT","Million US$ at exchange rate","AUT","Austria","2016","2016",0.6,"D","Difference in methodology"
+"PATCACID","A02A-Antacids","MTMOTCMT","Million US$ at exchange rate","AUT","Austria","2017","2017",1,"D","Difference in methodology"
+"PATCACID","A02A-Antacids","MTMOTCMT","Million US$ at exchange rate","AUT","Austria","2018","2018",1.2,"D","Difference in methodology"
+"PATCACID","A02A-Antacids","MTMOTCMT","Million US$ at exchange rate","AUT","Austria","2019","2019",1.3,"D","Difference in methodology"
+"PATCACID","A02A-Antacids","MTMOTCMT","Million US$ at exchange rate","AUT","Austria","2020","2020",1.4,"D","Difference in methodology"
+"PATCACID","A02A-Antacids","MTMOTCMT","Million US$ at exchange rate","AUT","Austria","2021","2021",1.6,"D","Difference in methodology"
+"PATCACID","A02A-Antacids","MTMOPPMT","Million US$, purchasing power parity","AUT","Austria","2010","2010",0.2,"D","Difference in methodology"
+"PATCACID","A02A-Antacids","MTMOPPMT","Million US$, purchasing power parity","AUT","Austria","2011","2011",0.2,"D","Difference in methodology"
+"PATCACID","A02A-Antacids","MTMOPPMT","Million US$, purchasing power parity","AUT","Austria","2012","2012",0.2,"D","Difference in methodology"
+"PATCACID","A02A-Antacids","MTMOPPMT","Million US$, purchasing power parity","AUT","Austria","2013","2013",0.2,"D","Difference in methodology"
+"PATCACID","A02A-Antacids","MTMOPPMT","Million US$, purchasing power parity","AUT","Austria","2014","2014",0.2,"D","Difference in methodology"
+"PATCACID","A02A-Antacids","MTMOPPMT","Million US$, purchasing power parity","AUT","Austria","2015","2015",0.3,"D","Difference in methodology"
+"PATCACID","A02A-Antacids","MTMOPPMT","Million US$, purchasing power parity","AUT","Austria","2016","2016",0.8,"D","Difference in methodology"
+"PATCACID","A02A-Antacids","MTMOPPMT","Million US$, purchasing power parity","AUT","Austria","2017","2017",1.1,"D","Difference in methodology"
+"PATCACID","A02A-Antacids","MTMOPPMT","Million US$, purchasing power parity","AUT","Austria","2018","2018",1.3,"D","Difference in methodology"
+"PATCACID","A02A-Antacids","MTMOPPMT","Million US$, purchasing power parity","AUT","Austria","2019","2019",1.5,"D","Difference in methodology"
+"PATCACID","A02A-Antacids","MTMOPPMT","Million US$, purchasing power parity","AUT","Austria","2020","2020",1.7,"D","Difference in methodology"
+"PATCACID","A02A-Antacids","MTMOPPMT","Million US$, purchasing power parity","AUT","Austria","2021","2021",1.8,"D","Difference in methodology"
+"PATCACID","A02A-Antacids","TCPPERMT","/capita, US$ exchange rate","AUT","Austria","2010","2010",0,"D","Difference in methodology"
+"PATCACID","A02A-Antacids","TCPPERMT","/capita, US$ exchange rate","AUT","Austria","2011","2011",0,"D","Difference in methodology"
+"PATCACID","A02A-Antacids","TCPPERMT","/capita, US$ exchange rate","AUT","Austria","2012","2012",0,"D","Difference in methodology"
+"PATCACID","A02A-Antacids","TCPPERMT","/capita, US$ exchange rate","AUT","Austria","2013","2013",0,"D","Difference in methodology"
+"PATCACID","A02A-Antacids","TCPPERMT","/capita, US$ exchange rate","AUT","Austria","2014","2014",0,"D","Difference in methodology"
+"PATCACID","A02A-Antacids","TCPPERMT","/capita, US$ exchange rate","AUT","Austria","2015","2015",0,"D","Difference in methodology"
+"PATCACID","A02A-Antacids","TCPPERMT","/capita, US$ exchange rate","AUT","Austria","2016","2016",0.1,"D","Difference in methodology"
+"PATCACID","A02A-Antacids","TCPPERMT","/capita, US$ exchange rate","AUT","Austria","2017","2017",0.1,"D","Difference in methodology"
+"PATCACID","A02A-Antacids","TCPPERMT","/capita, US$ exchange rate","AUT","Austria","2018","2018",0.1,"D","Difference in methodology"
+"PATCACID","A02A-Antacids","TCPPERMT","/capita, US$ exchange rate","AUT","Austria","2019","2019",0.1,"D","Difference in methodology"
+"PATCACID","A02A-Antacids","TCPPERMT","/capita, US$ exchange rate","AUT","Austria","2020","2020",0.2,"D","Difference in methodology"
+"PATCACID","A02A-Antacids","TCPPERMT","/capita, US$ exchange rate","AUT","Austria","2021","2021",0.2,"D","Difference in methodology"
+"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2010","2010",0,"D","Difference in methodology"
+"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2011","2011",0,"D","Difference in methodology"
+"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2012","2012",0,"D","Difference in methodology"
+"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2013","2013",0,"D","Difference in methodology"
+"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2014","2014",0,"D","Difference in methodology"
+"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2015","2015",0,"D","Difference in methodology"
+"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2016","2016",0.1,"D","Difference in methodology"
+"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2017","2017",0.1,"D","Difference in methodology"
+"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2018","2018",0.1,"D","Difference in methodology"
+"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2019","2019",0.2,"D","Difference in methodology"
+"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2020","2020",0.2,"D","Difference in methodology"
+"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2021","2021",0.2,"D","Difference in methodology"
+"PATCACID","A02A-Antacids","ATCPTTMT","% of total sales","AUT","Austria","2010","2010",0,"D","Difference in methodology"
+"PATCACID","A02A-Antacids","ATCPTTMT","% of total sales","AUT","Austria","2011","2011",0,"D","Difference in methodology"
+"PATCACID","A02A-Antacids","ATCPTTMT","% of total sales","AUT","Austria","2012","2012",0,"D","Difference in methodology"
+"PATCACID","A02A-Antacids","ATCPTTMT","% of total sales","AUT","Austria","2013","2013",0,"D","Difference in methodology"
+"PATCACID","A02A-Antacids","ATCPTTMT","% of total sales","AUT","Austria","2014","2014",0,"D","Difference in methodology"
+"PATCACID","A02A-Antacids","ATCPTTMT","% of total sales","AUT","Austria","2015","2015",0,"D","Difference in methodology"
+"PATCACID","A02A-Antacids","ATCPTTMT","% of total sales","AUT","Austria","2016","2016",0,"D","Difference in methodology"
+"PATCACID","A02A-Antacids","ATCPTTMT","% of total sales","AUT","Austria","2017","2017",0,"D","Difference in methodology"
+"PATCACID","A02A-Antacids","ATCPTTMT","% of total sales","AUT","Austria","2018","2018",0,"D","Difference in methodology"
+"PATCACID","A02A-Antacids","ATCPTTMT","% of total sales","AUT","Austria","2019","2019",0,"D","Difference in methodology"
+"PATCACID","A02A-Antacids","ATCPTTMT","% of total sales","AUT","Austria","2020","2020",0,"D","Difference in methodology"
+"PATCACID","A02A-Antacids","ATCPTTMT","% of total sales","AUT","Austria","2021","2021",0,"D","Difference in methodology"
+"PATCACID","A02A-Antacids","MLLNCUMT","Million of national currency units","BEL","Belgium","2010","2010",10.7,,
+"PATCACID","A02A-Antacids","MLLNCUMT","Million of national currency units","BEL","Belgium","2011","2011",11.5,,
+"PATCACID","A02A-Antacids","MLLNCUMT","Million of national currency units","BEL","Belgium","2012","2012",11.6,,
+"PATCACID","A02A-Antacids","MLLNCUMT","Million of national currency units","BEL","Belgium","2013","2013",11.1,,
+"PATCACID","A02A-Antacids","MLLNCUMT","Million of national currency units","BEL","Belgium","2014","2014",10.5,,
+"PATCACID","A02A-Antacids","MLLNCUMT","Million of national currency units","BEL","Belgium","2015","2015",10,,
+"PATCACID","A02A-Antacids","MLLNCUMT","Million of national currency units","BEL","Belgium","2016","2016",9.8,,
+"PATCACID","A02A-Antacids","MLLNCUMT","Million of national currency units","BEL","Belgium","2017","2017",9.5,,
+"PATCACID","A02A-Antacids","MLLNCUMT","Million of national currency units","BEL","Belgium","2018","2018",9.4,,
+"PATCACID","A02A-Antacids","MLLNCUMT","Million of national currency units","BEL","Belgium","2019","2019",9.9,,
+"PATCACID","A02A-Antacids","MLLNCUMT","Million of national currency units","BEL","Belgium","2020","2020",10.4,,
+"PATCACID","A02A-Antacids","MLLNCUMT","Million of national currency units","BEL","Belgium","2021","2021",10,,
+"PATCACID","A02A-Antacids","MLLNCUMT","Million of national currency units","BEL","Belgium","2022","2022",9.8,"E","Estimated value"
+"PATCACID","A02A-Antacids","MTMOTCMT","Million US$ at exchange rate","BEL","Belgium","2010","2010",14.2,,
+"PATCACID","A02A-Antacids","MTMOTCMT","Million US$ at exchange rate","BEL","Belgium","2011","2011",16,,
+"PATCACID","A02A-Antacids","MTMOTCMT","Million US$ at exchange rate","BEL","Belgium","2012","2012",14.9,,
+"PATCACID","A02A-Antacids","MTMOTCMT","Million US$ at exchange rate","BEL","Belgium","2013","2013",14.7,,
+"PATCACID","A02A-Antacids","MTMOTCMT","Million US$ at exchange rate","BEL","Belgium","2014","2014",13.9,,
+"PATCACID","A02A-Antacids","MTMOTCMT","Million US$ at exchange rate","BEL","Belgium","2015","2015",11.1,,
+"PATCACID","A02A-Antacids","MTMOTCMT","Million US$ at exchange rate","BEL","Belgium","2016","2016",10.8,,
+"PATCACID","A02A-Antacids","MTMOTCMT","Million US$ at exchange rate","BEL","Belgium","2017","2017",10.8,,
+"PATCACID","A02A-Antacids","MTMOTCMT","Million US$ at exchange rate","BEL","Belgium","2018","2018",11.1,,
+"PATCACID","A02A-Antacids","MTMOTCMT","Million US$ at exchange rate","BEL","Belgium","2019","2019",11.1,,
+"PATCACID","A02A-Antacids","MTMOTCMT","Million US$ at exchange rate","BEL","Belgium","2020","2020",11.9,,
+"PATCACID","A02A-Antacids","MTMOTCMT","Million US$ at exchange rate","BEL","Belgium","2021","2021",11.8,,
+"PATCACID","A02A-Antacids","MTMOTCMT","Million US$ at exchange rate","BEL","Belgium","2022","2022",10.3,"E","Estimated value"
+"PATCACID","A02A-Antacids","MTMOPPMT","Million US$, purchasing power parity","BEL","Belgium","2010","2010",12.8,,
+"PATCACID","A02A-Antacids","MTMOPPMT","Million US$, purchasing power parity","BEL","Belgium","2011","2011",13.8,,
+"PATCACID","A02A-Antacids","MTMOPPMT","Million US$, purchasing power parity","BEL","Belgium","2012","2012",14.1,,
+"PATCACID","A02A-Antacids","MTMOPPMT","Million US$, purchasing power parity","BEL","Belgium","2013","2013",13.8,,
+"PATCACID","A02A-Antacids","MTMOPPMT","Million US$, purchasing power parity","BEL","Belgium","2014","2014",13.1,,
+"PATCACID","A02A-Antacids","MTMOPPMT","Million US$, purchasing power parity","BEL","Belgium","2015","2015",12.5,,
+"PATCACID","A02A-Antacids","MTMOPPMT","Million US$, purchasing power parity","BEL","Belgium","2016","2016",12.5,,
+"PATCACID","A02A-Antacids","MTMOPPMT","Million US$, purchasing power parity","BEL","Belgium","2017","2017",12.3,,
+"PATCACID","A02A-Antacids","MTMOPPMT","Million US$, purchasing power parity","BEL","Belgium","2018","2018",12.3,,
+"PATCACID","A02A-Antacids","MTMOPPMT","Million US$, purchasing power parity","BEL","Belgium","2019","2019",13.2,,
+"PATCACID","A02A-Antacids","MTMOPPMT","Million US$, purchasing power parity","BEL","Belgium","2020","2020",14.3,,
+"PATCACID","A02A-Antacids","MTMOPPMT","Million US$, purchasing power parity","BEL","Belgium","2021","2021",13.6,,
+"PATCACID","A02A-Antacids","MTMOPPMT","Million US$, purchasing power parity","BEL","Belgium","2022","2022",13.7,"E","Estimated value"
+"PATCACID","A02A-Antacids","TCPPERMT","/capita, US$ exchange rate","BEL","Belgium","2010","2010",1.3,,
+"PATCACID","A02A-Antacids","TCPPERMT","/capita, US$ exchange rate","BEL","Belgium","2011","2011",1.4,,
+"PATCACID","A02A-Antacids","TCPPERMT","/capita, US$ exchange rate","BEL","Belgium","2012","2012",1.3,,
+"PATCACID","A02A-Antacids","TCPPERMT","/capita, US$ exchange rate","BEL","Belgium","2013","2013",1.3,,
+"PATCACID","A02A-Antacids","TCPPERMT","/capita, US$ exchange rate","BEL","Belgium","2014","2014",1.2,,
+"PATCACID","A02A-Antacids","TCPPERMT","/capita, US$ exchange rate","BEL","Belgium","2015","2015",1,,
+"PATCACID","A02A-Antacids","TCPPERMT","/capita, US$ exchange rate","BEL","Belgium","2016","2016",1,,
+"PATCACID","A02A-Antacids","TCPPERMT","/capita, US$ exchange rate","BEL","Belgium","2017","2017",0.9,,
+"PATCACID","A02A-Antacids","TCPPERMT","/capita, US$ exchange rate","BEL","Belgium","2018","2018",1,,
+"PATCACID","A02A-Antacids","TCPPERMT","/capita, US$ exchange rate","BEL","Belgium","2019","2019",1,,
+"PATCACID","A02A-Antacids","TCPPERMT","/capita, US$ exchange rate","BEL","Belgium","2020","2020",1,,
+"PATCACID","A02A-Antacids","TCPPERMT","/capita, US$ exchange rate","BEL","Belgium","2021","2021",1,,
+"PATCACID","A02A-Antacids","TCPPERMT","/capita, US$ exchange rate","BEL","Belgium","2022","2022",0.9,"E","Estimated value"
+"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2010","2010",1.2,,
+"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2011","2011",1.3,,
+"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2012","2012",1.3,,
+"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2013","2013",1.2,,
+"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2014","2014",1.2,,
+"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2015","2015",1.1,,
+"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2016","2016",1.1,,
+"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2017","2017",1.1,,
+"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2018","2018",1.1,,
+"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2019","2019",1.2,,
+"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2020","2020",1.2,,
+"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2021","2021",1.2,,
+"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2022","2022",1.2,"E","Estimated value"
+"PATCACID","A02A-Antacids","ATCPTTMT","% of total sales","BEL","Belgium","2010","2010",0.2,,
+"PATCACID","A02A-Antacids","ATCPTTMT","% of total sales","BEL","Belgium","2011","2011",0.2,,
+"PATCACID","A02A-Antacids","ATCPTTMT","% of total sales","BEL","Belgium","2012","2012",0.2,,
+"PATCACID","A02A-Antacids","ATCPTTMT","% of total sales","BEL","Belgium","2013","2013",0.2,,
+"PATCACID","A02A-Antacids","ATCPTTMT","% of total sales","BEL","Belgium","2014","2014",0.2,,
+"PATCACID","A02A-Antacids","ATCPTTMT","% of total sales","BEL","Belgium","2015","2015",0.2,,
+"PATCACID","A02A-Antacids","ATCPTTMT","% of total sales","BEL","Belgium","2016","2016",0.2,,
+"PATCACID","A02A-Antacids","ATCPTTMT","% of total sales","BEL","Belgium","2017","2017",0.1,,
+"PATCACID","A02A-Antacids","ATCPTTMT","% of total sales","BEL","Belgium","2018","2018",0.1,,
+"PATCACID","A02A-Antacids","ATCPTTMT","% of total sales","BEL","Belgium","2019","2019",0.1,,
+"PATCACID","A02A-Antacids","ATCPTTMT","% of total sales","BEL","Belgium","2020","2020",0.1,,
+"PATCACID","A02A-Antacids","ATCPTTMT","% of total sales","BEL","Belgium","2021","2021",0.1,,
+"PATCACID","A02A-Antacids","ATCPTTMT","% of total sales","BEL","Belgium","2022","2022",0.1,"E","Estimated value"
+"PATCACID","A02A-Antacids","MLLNCUMT","Million of national currency units","CAN","Canada","2012","2012",1.4,"D","Difference in methodology"
+"PATCACID","A02A-Antacids","MLLNCUMT","Million of national currency units","CAN","Canada","2013","2013",1.3,"D","Difference in methodology"
+"PATCACID","A02A-Antacids","MLLNCUMT","Million of national currency units","CAN","Canada","2014","2014",1.3,"D","Difference in methodology"
+"PATCACID","A02A-Antacids","MLLNCUMT","Million of national currency units","CAN","Canada","2015","2015",1.4,"D","Difference in methodology"
+"PATCACID","A02A-Antacids","MLLNCUMT","Million of national currency units","CAN","Canada","2016","2016",1.5,"D","Difference in methodology"
+"PATCACID","A02A-Antacids","MLLNCUMT","Million of national currency units","CAN","Canada","2017","2017",1.6,"D","Difference in methodology"
+"PATCACID","A02A-Antacids","MTMOTCMT","Million US$ at exchange rate","CAN","Canada","2012","2012",1.4,"D","Difference in methodology"
+"PATCACID","A02A-Antacids","MTMOTCMT","Million US$ at exchange rate","CAN","Canada","2013","2013",1.3,"D","Difference in methodology"
+"PATCACID","A02A-Antacids","MTMOTCMT","Million US$ at exchange rate","CAN","Canada","2014","2014",1.2,"D","Difference in methodology"
+"PATCACID","A02A-Antacids","MTMOTCMT","Million US$ at exchange rate","CAN","Canada","2015","2015",1.1,"D","Difference in methodology"
+"PATCACID","A02A-Antacids","MTMOTCMT","Million US$ at exchange rate","CAN","Canada","2016","2016",1.1,"D","Difference in methodology"
+"PATCACID","A02A-Antacids","MTMOTCMT","Million US$ at exchange rate","CAN","Canada","2017","2017",1.2,"D","Difference in methodology"
+"PATCACID","A02A-Antacids","MTMOPPMT","Million US$, purchasing power parity","CAN","Canada","2012","2012",1.1,"D","Difference in methodology"
+"PATCACID","A02A-Antacids","MTMOPPMT","Million US$, purchasing power parity","CAN","Canada","2013","2013",1.1,"D","Difference in methodology"
+"PATCACID","A02A-Antacids","MTMOPPMT","Million US$, purchasing power parity","CAN","Canada","2014","2014",1.1,"D","Difference in methodology"
+"PATCACID","A02A-Antacids","MTMOPPMT","Million US$, purchasing power parity","CAN","Canada","2015","2015",1.1,"D","Difference in methodology"
+"PATCACID","A02A-Antacids","MTMOPPMT","Million US$, purchasing power parity","CAN","Canada","2016","2016",1.2,"D","Difference in methodology"
+"PATCACID","A02A-Antacids","MTMOPPMT","Million US$, purchasing power parity","CAN","Canada","2017","2017",1.3,"D","Difference in methodology"
+"PATCACID","A02A-Antacids","TCPPERMT","/capita, US$ exchange rate","CAN","Canada","2012","2012",0,"D","Difference in methodology"
+"PATCACID","A02A-Antacids","TCPPERMT","/capita, US$ exchange rate","CAN","Canada","2013","2013",0,"D","Difference in methodology"
+"PATCACID","A02A-Antacids","TCPPERMT","/capita, US$ exchange rate","CAN","Canada","2014","2014",0,"D","Difference in methodology"
+"PATCACID","A02A-Antacids","TCPPERMT","/capita, US$ exchange rate","CAN","Canada","2015","2015",0,"D","Difference in methodology"
+"PATCACID","A02A-Antacids","TCPPERMT","/capita, US$ exchange rate","CAN","Canada","2016","2016",0,"D","Difference in methodology"
+"PATCACID","A02A-Antacids","TCPPERMT","/capita, US$ exchange rate","CAN","Canada","2017","2017",0,"D","Difference in methodology"
+"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2012","2012",0,"D","Difference in methodology"
+"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2013","2013",0,"D","Difference in methodology"
+"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2014","2014",0,"D","Difference in methodology"
+"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2015","2015",0,"D","Difference in methodology"
+"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2016","2016",0,"D","Difference in methodology"
+"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2017","2017",0,"D","Difference in methodology"
+"PATCACID","A02A-Antacids","ATCPTTMT","% of total sales","CAN","Canada","2012","2012",0,"D","Difference in methodology"
+"PATCACID","A02A-Antacids","ATCPTTMT","% of total sales","CAN","Canada","2013","2013",0,"D","Difference in methodology"
+"PATCACID","A02A-Antacids","ATCPTTMT","% of total sales","CAN","Canada","2014","2014",0,"D","Difference in methodology"
+"PATCACID","A02A-Antacids","ATCPTTMT","% of total sales","CAN","Canada","2015","2015",0,"D","Difference in methodology"
+"PATCACID","A02A-Antacids","ATCPTTMT","% of total sales","CAN","Canada","2016","2016",0,"D","Difference in methodology"
+"PATCACID","A02A-Antacids","ATCPTTMT","% of total sales","CAN","Canada","2017","2017",0,"D","Difference in methodology"
+"PATCACID","A02A-Antacids","MLLNCUMT","Million of national currency units","CZE","Czech Republic","2010","2010",103.9,,
+"PATCACID","A02A-Antacids","MLLNCUMT","Million of national currency units","CZE","Czech Republic","2011","2011",101.5,,
+"PATCACID","A02A-Antacids","MLLNCUMT","Million of national currency units","CZE","Czech Republic","2012","2012",102.2,,
+"PATCACID","A02A-Antacids","MLLNCUMT","Million of national currency units","CZE","Czech Republic","2013","2013",110.2,,
+"PATCACID","A02A-Antacids","MLLNCUMT","Million of national currency units","CZE","Czech Republic","2014","2014",100.8,,
+"PATCACID","A02A-Antacids","MLLNCUMT","Million of national currency units","CZE","Czech Republic","2015","2015",97.4,,
+"PATCACID","A02A-Antacids","MLLNCUMT","Million of national currency units","CZE","Czech Republic","2016","2016",101,,
+"PATCACID","A02A-Antacids","MLLNCUMT","Million of national currency units","CZE","Czech Republic","2017","2017",100.7,,
+"PATCACID","A02A-Antacids","MLLNCUMT","Million of national currency units","CZE","Czech Republic","2018","2018",100.2,,
+"PATCACID","A02A-Antacids","MLLNCUMT","Million of national currency units","CZE","Czech Republic","2019","2019",98.2,,
+"PATCACID","A02A-Antacids","MLLNCUMT","Million of national currency units","CZE","Czech Republic","2020","2020",0,"B","Break"
+"PATCACID","A02A-Antacids","MLLNCUMT","Million of national currency units","CZE","Czech Republic","2021","2021",0,,
+"PATCACID","A02A-Antacids","MTMOTCMT","Million US$ at exchange rate","CZE","Czech Republic","2010","2010",5.4,,
+"PATCACID","A02A-Antacids","MTMOTCMT","Million US$ at exchange rate","CZE","Czech Republic","2011","2011",5.7,,
+"PATCACID","A02A-Antacids","MTMOTCMT","Million US$ at exchange rate","CZE","Czech Republic","2012","2012",5.2,,
+"PATCACID","A02A-Antacids","MTMOTCMT","Million US$ at exchange rate","CZE","Czech Republic","2013","2013",5.6,,
+"PATCACID","A02A-Antacids","MTMOTCMT","Million US$ at exchange rate","CZE","Czech Republic","2014","2014",4.9,,
+"PATCACID","A02A-Antacids","MTMOTCMT","Million US$ at exchange rate","CZE","Czech Republic","2015","2015",4,,
+"PATCACID","A02A-Antacids","MTMOTCMT","Million US$ at exchange rate","CZE","Czech Republic","2016","2016",4.1,,
+"PATCACID","A02A-Antacids","MTMOTCMT","Million US$ at exchange rate","CZE","Czech Republic","2017","2017",4.3,,
+"PATCACID","A02A-Antacids","MTMOTCMT","Million US$ at exchange rate","CZE","Czech Republic","2018","2018",4.6,,
+"PATCACID","A02A-Antacids","MTMOTCMT","Million US$ at exchange rate","CZE","Czech Republic","2019","2019",4.3,,
+"PATCACID","A02A-Antacids","MTMOTCMT","Million US$ at exchange rate","CZE","Czech Republic","2020","2020",0,"B","Break"
+"PATCACID","A02A-Antacids","MTMOTCMT","Million US$ at exchange rate","CZE","Czech Republic","2021","2021",0,,
+"PATCACID","A02A-Antacids","MTMOPPMT","Million US$, purchasing power parity","CZE","Czech Republic","2010","2010",7.6,,
+"PATCACID","A02A-Antacids","MTMOPPMT","Million US$, purchasing power parity","CZE","Czech Republic","2011","2011",7.6,,
+"PATCACID","A02A-Antacids","MTMOPPMT","Million US$, purchasing power parity","CZE","Czech Republic","2012","2012",7.7,,
+"PATCACID","A02A-Antacids","MTMOPPMT","Million US$, purchasing power parity","CZE","Czech Republic","2013","2013",8.6,,
+"PATCACID","A02A-Antacids","MTMOPPMT","Million US$, purchasing power parity","CZE","Czech Republic","2014","2014",7.9,,
+"PATCACID","A02A-Antacids","MTMOPPMT","Million US$, purchasing power parity","CZE","Czech Republic","2015","2015",7.5,,
+"PATCACID","A02A-Antacids","MTMOPPMT","Million US$, purchasing power parity","CZE","Czech Republic","2016","2016",8,,
+"PATCACID","A02A-Antacids","MTMOPPMT","Million US$, purchasing power parity","CZE","Czech Republic","2017","2017",8.1,,
+"PATCACID","A02A-Antacids","MTMOPPMT","Million US$, purchasing power parity","CZE","Czech Republic","2018","2018",8.1,,
+"PATCACID","A02A-Antacids","MTMOPPMT","Million US$, purchasing power parity","CZE","Czech Republic","2019","2019",8,,
+"PATCACID","A02A-Antacids","MTMOPPMT","Million US$, purchasing power parity","CZE","Czech Republic","2020","2020",0,"B","Break"
+"PATCACID","A02A-Antacids","MTMOPPMT","Million US$, purchasing power parity","CZE","Czech Republic","2021","2021",0,,
+"PATCACID","A02A-Antacids","TCPPERMT","/capita, US$ exchange rate","CZE","Czech Republic","2010","2010",0.5,,
+"PATCACID","A02A-Antacids","TCPPERMT","/capita, US$ exchange rate","CZE","Czech Republic","2011","2011",0.5,,
+"PATCACID","A02A-Antacids","TCPPERMT","/capita, US$ exchange rate","CZE","Czech Republic","2012","2012",0.5,,
+"PATCACID","A02A-Antacids","TCPPERMT","/capita, US$ exchange rate","CZE","Czech Republic","2013","2013",0.5,,
+"PATCACID","A02A-Antacids","TCPPERMT","/capita, US$ exchange rate","CZE","Czech Republic","2014","2014",0.5,,
+"PATCACID","A02A-Antacids","TCPPERMT","/capita, US$ exchange rate","CZE","Czech Republic","2015","2015",0.4,,
+"PATCACID","A02A-Antacids","TCPPERMT","/capita, US$ exchange rate","CZE","Czech Republic","2016","2016",0.4,,
+"PATCACID","A02A-Antacids","TCPPERMT","/capita, US$ exchange rate","CZE","Czech Republic","2017","2017",0.4,,
+"PATCACID","A02A-Antacids","TCPPERMT","/capita, US$ exchange rate","CZE","Czech Republic","2018","2018",0.4,,
+"PATCACID","A02A-Antacids","TCPPERMT","/capita, US$ exchange rate","CZE","Czech Republic","2019","2019",0.4,,
+"PATCACID","A02A-Antacids","TCPPERMT","/capita, US$ exchange rate","CZE","Czech Republic","2020","2020",0,"B","Break"
+"PATCACID","A02A-Antacids","TCPPERMT","/capita, US$ exchange rate","CZE","Czech Republic","2021","2021",0,,
+"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czech Republic","2010","2010",0.7,,
+"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czech Republic","2011","2011",0.7,,
+"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czech Republic","2012","2012",0.7,,
+"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czech Republic","2013","2013",0.8,,
+"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czech Republic","2014","2014",0.8,,
+"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czech Republic","2015","2015",0.7,,
+"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czech Republic","2016","2016",0.8,,
+"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czech Republic","2017","2017",0.8,,
+"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czech Republic","2018","2018",0.8,,
+"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czech Republic","2019","2019",0.7,,
+"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czech Republic","2020","2020",0,"B","Break"
+"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czech Republic","2021","2021",0,,
+"PATCACID","A02A-Antacids","ATCPTTMT","% of total sales","CZE","Czech Republic","2010","2010",0.1,,
+"PATCACID","A02A-Antacids","ATCPTTMT","% of total sales","CZE","Czech Republic","2011","2011",0.1,,
+"PATCACID","A02A-Antacids","ATCPTTMT","% of total sales","CZE","Czech Republic","2012","2012",0.1,,
+"PATCACID","A02A-Antacids","ATCPTTMT","% of total sales","CZE","Czech Republic","2013","2013",0.1,,
+"PATCACID","A02A-Antacids","ATCPTTMT","% of total sales","CZE","Czech Republic","2014","2014",0.1,,
+"PATCACID","A02A-Antacids","ATCPTTMT","% of total sales","CZE","Czech Republic","2015","2015",0.1,,
+"PATCACID","A02A-Antacids","ATCPTTMT","% of total sales","CZE","Czech Republic","2016","2016",0.1,,
+"PATCACID","A02A-Antacids","ATCPTTMT","% of total sales","CZE","Czech Republic","2017","2017",0.1,,
+"PATCACID","A02A-Antacids","ATCPTTMT","% of total sales","CZE","Czech Republic","2018","2018",0.1,,
+"PATCACID","A02A-Antacids","ATCPTTMT","% of total sales","CZE","Czech Republic","2019","2019",0.1,,
+"PATCACID","A02A-Antacids","ATCPTTMT","% of total sales","CZE","Czech Republic","2020","2020",0,"B","Break"
+"PATCACID","A02A-Antacids","ATCPTTMT","% of total sales","CZE","Czech Republic","2021","2021",0,,
+"PATCACID","A02A-Antacids","MLLNCUMT","Million of national currency units","FIN","Finland","2010","2010",2.7,,
+"PATCACID","A02A-Antacids","MLLNCUMT","Million of national currency units","FIN","Finland","2011","2011",2.8,,
+"PATCACID","A02A-Antacids","MLLNCUMT","Million of national currency units","FIN","Finland","2012","2012",3,,
+"PATCACID","A02A-Antacids","MLLNCUMT","Million of national currency units","FIN","Finland","2013","2013",3,,
+"PATCACID","A02A-Antacids","MLLNCUMT","Million of national currency units","FIN","Finland","2014","2014",3.1,,
+"PATCACID","A02A-Antacids","MLLNCUMT","Million of national currency units","FIN","Finland","2015","2015",3.2,,
+"PATCACID","A02A-Antacids","MLLNCUMT","Million of national currency units","FIN","Finland","2016","2016",3.2,,
+"PATCACID","A02A-Antacids","MLLNCUMT","Million of national currency units","FIN","Finland","2017","2017",3.4,,
+"PATCACID","A02A-Antacids","MLLNCUMT","Million of national currency units","FIN","Finland","2018","2018",3.4,,
+"PATCACID","A02A-Antacids","MLLNCUMT","Million of national currency units","FIN","Finland","2019","2019",3.6,,
+"PATCACID","A02A-Antacids","MLLNCUMT","Million of national currency units","FIN","Finland","2020","2020",3.7,,
+"PATCACID","A02A-Antacids","MLLNCUMT","Million of national currency units","FIN","Finland","2021","2021",3.9,,
+"PATCACID","A02A-Antacids","MTMOTCMT","Million US$ at exchange rate","FIN","Finland","2010","2010",3.6,,
+"PATCACID","A02A-Antacids","MTMOTCMT","Million US$ at exchange rate","FIN","Finland","2011","2011",3.9,,
+"PATCACID","A02A-Antacids","MTMOTCMT","Million US$ at exchange rate","FIN","Finland","2012","2012",3.9,,
+"PATCACID","A02A-Antacids","MTMOTCMT","Million US$ at exchange rate","FIN","Finland","2013","2013",4,,
+"PATCACID","A02A-Antacids","MTMOTCMT","Million US$ at exchange rate","FIN","Finland","2014","2014",4.1,,
+"PATCACID","A02A-Antacids","MTMOTCMT","Million US$ at exchange rate","FIN","Finland","2015","2015",3.6,,
+"PATCACID","A02A-Antacids","MTMOTCMT","Million US$ at exchange rate","FIN","Finland","2016","2016",3.5,,
+"PATCACID","A02A-Antacids","MTMOTCMT","Million US$ at exchange rate","FIN","Finland","2017","2017",3.8,,
+"PATCACID","A02A-Antacids","MTMOTCMT","Million US$ at exchange rate","FIN","Finland","2018","2018",4,,
+"PATCACID","A02A-Antacids","MTMOTCMT","Million US$ at exchange rate","FIN","Finland","2019","2019",4,,
+"PATCACID","A02A-Antacids","MTMOTCMT","Million US$ at exchange rate","FIN","Finland","2020","2020",4.2,,
+"PATCACID","A02A-Antacids","MTMOTCMT","Million US$ at exchange rate","FIN","Finland","2021","2021",4.6,,
+"PATCACID","A02A-Antacids","MTMOPPMT","Million US$, purchasing power parity","FIN","Finland","2010","2010",3,,
+"PATCACID","A02A-Antacids","MTMOPPMT","Million US$, purchasing power parity","FIN","Finland","2011","2011",3.1,,
+"PATCACID","A02A-Antacids","MTMOPPMT","Million US$, purchasing power parity","FIN","Finland","2012","2012",3.3,,
+"PATCACID","A02A-Antacids","MTMOPPMT","Million US$, purchasing power parity","FIN","Finland","2013","2013",3.3,,
+"PATCACID","A02A-Antacids","MTMOPPMT","Million US$, purchasing power parity","FIN","Finland","2014","2014",3.4,,
+"PATCACID","A02A-Antacids","MTMOPPMT","Million US$, purchasing power parity","FIN","Finland","2015","2015",3.5,,
+"PATCACID","A02A-Antacids","MTMOPPMT","Million US$, purchasing power parity","FIN","Finland","2016","2016",3.6,,
+"PATCACID","A02A-Antacids","MTMOPPMT","Million US$, purchasing power parity","FIN","Finland","2017","2017",3.9,,
+"PATCACID","A02A-Antacids","MTMOPPMT","Million US$, purchasing power parity","FIN","Finland","2018","2018",4,,
+"PATCACID","A02A-Antacids","MTMOPPMT","Million US$, purchasing power parity","FIN","Finland","2019","2019",4.3,,
+"PATCACID","A02A-Antacids","MTMOPPMT","Million US$, purchasing power parity","FIN","Finland","2020","2020",4.5,,
+"PATCACID","A02A-Antacids","MTMOPPMT","Million US$, purchasing power parity","FIN","Finland","2021","2021",4.7,,
+"PATCACID","A02A-Antacids","TCPPERMT","/capita, US$ exchange rate","FIN","Finland","2010","2010",0.7,,
+"PATCACID","A02A-Antacids","TCPPERMT","/capita, US$ exchange rate","FIN","Finland","2011","2011",0.7,,
+"PATCACID","A02A-Antacids","TCPPERMT","/capita, US$ exchange rate","FIN","Finland","2012","2012",0.7,,
+"PATCACID","A02A-Antacids","TCPPERMT","/capita, US$ exchange rate","FIN","Finland","2013","2013",0.7,,
+"PATCACID","A02A-Antacids","TCPPERMT","/capita, US$ exchange rate","FIN","Finland","2014","2014",0.8,,
+"PATCACID","A02A-Antacids","TCPPERMT","/capita, US$ exchange rate","FIN","Finland","2015","2015",0.6,,
+"PATCACID","A02A-Antacids","TCPPERMT","/capita, US$ exchange rate","FIN","Finland","2016","2016",0.6,,
+"PATCACID","A02A-Antacids","TCPPERMT","/capita, US$ exchange rate","FIN","Finland","2017","2017",0.7,,
+"PATCACID","A02A-Antacids","TCPPERMT","/capita, US$ exchange rate","FIN","Finland","2018","2018",0.7,,
+"PATCACID","A02A-Antacids","TCPPERMT","/capita, US$ exchange rate","FIN","Finland","2019","2019",0.7,,
+"PATCACID","A02A-Antacids","TCPPERMT","/capita, US$ exchange rate","FIN","Finland","2020","2020",0.8,,
+"PATCACID","A02A-Antacids","TCPPERMT","/capita, US$ exchange rate","FIN","Finland","2021","2021",0.8,,
+"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2010","2010",0.6,,
+"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2011","2011",0.6,,
+"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2012","2012",0.6,,
+"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2013","2013",0.6,,
+"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2014","2014",0.6,,
+"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2015","2015",0.6,,
+"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2016","2016",0.7,,
+"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2017","2017",0.7,,
+"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2018","2018",0.7,,
+"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2019","2019",0.8,,
+"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2020","2020",0.8,,
+"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2021","2021",0.9,,
+"PATCACID","A02A-Antacids","ATCPTTMT","% of total sales","FIN","Finland","2010","2010",0.1,,
+"PATCACID","A02A-Antacids","ATCPTTMT","% of total sales","FIN","Finland","2011","2011",0.1,,
+"PATCACID","A02A-Antacids","ATCPTTMT","% of total sales","FIN","Finland","2012","2012",0.2,,
+"PATCACID","A02A-Antacids","ATCPTTMT","% of total sales","FIN","Finland","2013","2013",0.1,,
+"PATCACID","A02A-Antacids","ATCPTTMT","% of total sales","FIN","Finland","2014","2014",0.1,,
+"PATCACID","A02A-Antacids","ATCPTTMT","% of total sales","FIN","Finland","2015","2015",0.1,,
+"PATCACID","A02A-Antacids","ATCPTTMT","% of total sales","FIN","Finland","2016","2016",0.1,,
+"PATCACID","A02A-Antacids","ATCPTTMT","% of total sales","FIN","Finland","2017","2017",0.1,,
+"PATCACID","A02A-Antacids","ATCPTTMT","% of total sales","FIN","Finland","2018","2018",0.1,,
+"PATCACID","A02A-Antacids","ATCPTTMT","% of total sales","FIN","Finland","2019","2019",0.1,,
+"PATCACID","A02A-Antacids","ATCPTTMT","% of total sales","FIN","Finland","2020","2020",0.1,,
+"PATCACID","A02A-Antacids","ATCPTTMT","% of total sales","FIN","Finland","2021","2021",0.1,,
+"PATCACID","A02A-Antacids","MLLNCUMT","Million of national currency units","DEU","Germany","2010","2010",14.5,"D","Difference in methodology"
+"PATCACID","A02A-Antacids","MLLNCUMT","Million of national currency units","DEU","Germany","2011","2011",14.7,"D","Difference in methodology"
+"PATCACID","A02A-Antacids","MLLNCUMT","Million of national currency units","DEU","Germany","2012","2012",14.9,"D","Difference in methodology"
+"PATCACID","A02A-Antacids","MLLNCUMT","Million of national currency units","DEU","Germany","2013","2013",15.1,"D","Difference in methodology"
+"PATCACID","A02A-Antacids","MLLNCUMT","Million of national currency units","DEU","Germany","2014","2014",17.1,"D","Difference in methodology"
+"PATCACID","A02A-Antacids","MLLNCUMT","Million of national currency units","DEU","Germany","2015","2015",17.8,"D","Difference in methodology"
+"PATCACID","A02A-Antacids","MLLNCUMT","Million of national currency units","DEU","Germany","2016","2016",19.1,"D","Difference in methodology"
+"PATCACID","A02A-Antacids","MLLNCUMT","Million of national currency units","DEU","Germany","2017","2017",19.1,"D","Difference in methodology"
+"PATCACID","A02A-Antacids","MLLNCUMT","Million of national currency units","DEU","Germany","2018","2018",21,"B; D","Break; Difference in methodology"
+"PATCACID","A02A-Antacids","MLLNCUMT","Million of national currency units","DEU","Germany","2019","2019",23.4,"D","Difference in methodology"
+"PATCACID","A02A-Antacids","MLLNCUMT","Million of national currency units","DEU","Germany","2020","2020",25.2,"D","Difference in methodology"
+"PATCACID","A02A-Antacids","MLLNCUMT","Million of national currency units","DEU","Germany","2021","2021",27.4,"D","Difference in methodology"
+"PATCACID","A02A-Antacids","MTMOTCMT","Million US$ at exchange rate","DEU","Germany","2010","2010",19.2,"D","Difference in methodology"
+"PATCACID","A02A-Antacids","MTMOTCMT","Million US$ at exchange rate","DEU","Germany","2011","2011",20.5,"D","Difference in methodology"
+"PATCACID","A02A-Antacids","MTMOTCMT","Million US$ at exchange rate","DEU","Germany","2012","2012",19.1,"D","Difference in methodology"
+"PATCACID","A02A-Antacids","MTMOTCMT","Million US$ at exchange rate","DEU","Germany","2013","2013",20.1,"D","Difference in methodology"
+"PATCACID","A02A-Antacids","MTMOTCMT","Million US$ at exchange rate","DEU","Germany","2014","2014",22.7,"D","Difference in methodology"
+"PATCACID","A02A-Antacids","MTMOTCMT","Million US$ at exchange rate","DEU","Germany","2015","2015",19.7,"D","Difference in methodology"
+"PATCACID","A02A-Antacids","MTMOTCMT","Million US$ at exchange rate","DEU","Germany","2016","2016",21.1,"D","Difference in methodology"
+"PATCACID","A02A-Antacids","MTMOTCMT","Million US$ at exchange rate","DEU","Germany","2017","2017",21.6,"D","Difference in methodology"
+"PATCACID","A02A-Antacids","MTMOTCMT","Million US$ at exchange rate","DEU","Germany","2018","2018",24.8,"B; D","Break; Difference in methodology"
+"PATCACID","A02A-Antacids","MTMOTCMT","Million US$ at exchange rate","DEU","Germany","2019","2019",26.2,"D","Difference in methodology"
+"PATCACID","A02A-Antacids","MTMOTCMT","Million US$ at exchange rate","DEU","Germany","2020","2020",28.8,"D","Difference in methodology"
+"PATCACID","A02A-Antacids","MTMOTCMT","Million US$ at exchange rate","DEU","Germany","2021","2021",32.4,"D","Difference in methodology"
+"PATCACID","A02A-Antacids","MTMOPPMT","Million US$, purchasing power parity","DEU","Germany","2010","2010",18,"D","Difference in methodology"
+"PATCACID","A02A-Antacids","MTMOPPMT","Million US$, purchasing power parity","DEU","Germany","2011","2011",18.6,"D","Difference in methodology"
+"PATCACID","A02A-Antacids","MTMOPPMT","Million US$, purchasing power parity","DEU","Germany","2012","2012",18.9,"D","Difference in methodology"
+"PATCACID","A02A-Antacids","MTMOPPMT","Million US$, purchasing power parity","DEU","Germany","2013","2013",19.5,"D","Difference in methodology"
+"PATCACID","A02A-Antacids","MTMOPPMT","Million US$, purchasing power parity","DEU","Germany","2014","2014",22.2,"D","Difference in methodology"
+"PATCACID","A02A-Antacids","MTMOPPMT","Million US$, purchasing power parity","DEU","Germany","2015","2015",22.9,"D","Difference in methodology"
+"PATCACID","A02A-Antacids","MTMOPPMT","Million US$, purchasing power parity","DEU","Germany","2016","2016",25.4,"D","Difference in methodology"
+"PATCACID","A02A-Antacids","MTMOPPMT","Million US$, purchasing power parity","DEU","Germany","2017","2017",25.6,"D","Difference in methodology"
+"PATCACID","A02A-Antacids","MTMOPPMT","Million US$, purchasing power parity","DEU","Germany","2018","2018",28.6,"B; D","Break; Difference in methodology"
+"PATCACID","A02A-Antacids","MTMOPPMT","Million US$, purchasing power parity","DEU","Germany","2019","2019",32.1,"D","Difference in methodology"
+"PATCACID","A02A-Antacids","MTMOPPMT","Million US$, purchasing power parity","DEU","Germany","2020","2020",34.8,"D","Difference in methodology"
+"PATCACID","A02A-Antacids","MTMOPPMT","Million US$, purchasing power parity","DEU","Germany","2021","2021",37.2,"D","Difference in methodology"
+"PATCACID","A02A-Antacids","TCPPERMT","/capita, US$ exchange rate","DEU","Germany","2010","2010",0.2,"D","Difference in methodology"
+"PATCACID","A02A-Antacids","TCPPERMT","/capita, US$ exchange rate","DEU","Germany","2011","2011",0.3,"D","Difference in methodology"
+"PATCACID","A02A-Antacids","TCPPERMT","/capita, US$ exchange rate","DEU","Germany","2012","2012",0.2,"D","Difference in methodology"
+"PATCACID","A02A-Antacids","TCPPERMT","/capita, US$ exchange rate","DEU","Germany","2013","2013",0.2,"D","Difference in methodology"
+"PATCACID","A02A-Antacids","TCPPERMT","/capita, US$ exchange rate","DEU","Germany","2014","2014",0.3,"D","Difference in methodology"
+"PATCACID","A02A-Antacids","TCPPERMT","/capita, US$ exchange rate","DEU","Germany","2015","2015",0.2,"D","Difference in methodology"
+"PATCACID","A02A-Antacids","TCPPERMT","/capita, US$ exchange rate","DEU","Germany","2016","2016",0.3,"D","Difference in methodology"
+"PATCACID","A02A-Antacids","TCPPERMT","/capita, US$ exchange rate","DEU","Germany","2017","2017",0.3,"D","Difference in methodology"
+"PATCACID","A02A-Antacids","TCPPERMT","/capita, US$ exchange rate","DEU","Germany","2018","2018",0.3,"B; D","Break; Difference in methodology"
+"PATCACID","A02A-Antacids","TCPPERMT","/capita, US$ exchange rate","DEU","Germany","2019","2019",0.3,"D","Difference in methodology"
+"PATCACID","A02A-Antacids","TCPPERMT","/capita, US$ exchange rate","DEU","Germany","2020","2020",0.3,"D","Difference in methodology"
+"PATCACID","A02A-Antacids","TCPPERMT","/capita, US$ exchange rate","DEU","Germany","2021","2021",0.4,"D","Difference in methodology"
+"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2010","2010",0.2,"D","Difference in methodology"
+"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2011","2011",0.2,"D","Difference in methodology"
+"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2012","2012",0.2,"D","Difference in methodology"
+"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2013","2013",0.2,"D","Difference in methodology"
+"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2014","2014",0.3,"D","Difference in methodology"
+"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2015","2015",0.3,"D","Difference in methodology"
+"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2016","2016",0.3,"D","Difference in methodology"
+"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2017","2017",0.3,"D","Difference in methodology"
+"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2018","2018",0.3,"B; D","Break; Difference in methodology"
+"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2019","2019",0.4,"D","Difference in methodology"
+"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2020","2020",0.4,"D","Difference in methodology"
+"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2021","2021",0.4,"D","Difference in methodology"
+"PATCACID","A02A-Antacids","ATCPTTMT","% of total sales","DEU","Germany","2010","2010",0,"D","Difference in methodology"
+"PATCACID","A02A-Antacids","ATCPTTMT","% of total sales","DEU","Germany","2011","2011",0,"D","Difference in methodology"
+"PATCACID","A02A-Antacids","ATCPTTMT","% of total sales","DEU","Germany","2012","2012",0,"D","Difference in methodology"
+"PATCACID","A02A-Antacids","ATCPTTMT","% of total sales","DEU","Germany","2013","2013",0,"D","Difference in methodology"
+"PATCACID","A02A-Antacids","ATCPTTMT","% of total sales","DEU","Germany","2014","2014",0.1,"D","Difference in methodology"
+"PATCACID","A02A-Antacids","ATCPTTMT","% of total sales","DEU","Germany","2015","2015",0.1,"D","Difference in methodology"
+"PATCACID","A02A-Antacids","ATCPTTMT","% of total sales","DEU","Germany","2016","2016",0.1,"D","Difference in methodology"
+"PATCACID","A02A-Antacids","ATCPTTMT","% of total sales","DEU","Germany","2017","2017",0.1,"D","Difference in methodology"
+"PATCACID","A02A-Antacids","ATCPTTMT","% of total sales","DEU","Germany","2018","2018",0,"B; D","Break; Difference in methodology"
+"PATCACID","A02A-Antacids","ATCPTTMT","% of total sales","DEU","Germany","2019","2019",0,"D","Difference in methodology"
+"PATCACID","A02A-Antacids","ATCPTTMT","% of total sales","DEU","Germany","2020","2020",0.1,"D","Difference in methodology"
+"PATCACID","A02A-Antacids","ATCPTTMT","% of total sales","DEU","Germany","2021","2021",0.1,"D","Difference in methodology"
+"PATCACID","A02A-Antacids","MLLNCUMT","Million of national currency units","GRC","Greece","2010","2010",5.8,,
+"PATCACID","A02A-Antacids","MLLNCUMT","Million of national currency units","GRC","Greece","2011","2011",6,,
+"PATCACID","A02A-Antacids","MLLNCUMT","Million of national currency units","GRC","Greece","2012","2012",5.3,,
+"PATCACID","A02A-Antacids","MLLNCUMT","Million of national currency units","GRC","Greece","2013","2013",5.6,,
+"PATCACID","A02A-Antacids","MLLNCUMT","Million of national currency units","GRC","Greece","2014","2014",5.5,,
+"PATCACID","A02A-Antacids","MLLNCUMT","Million of national currency units","GRC","Greece","2015","2015",5.2,,
+"PATCACID","A02A-Antacids","MLLNCUMT","Million of national currency units","GRC","Greece","2016","2016",4.3,,
+"PATCACID","A02A-Antacids","MLLNCUMT","Million of national currency units","GRC","Greece","2017","2017",4.4,,
+"PATCACID","A02A-Antacids","MLLNCUMT","Million of national currency units","GRC","Greece","2018","2018",4.9,,
+"PATCACID","A02A-Antacids","MLLNCUMT","Million of national currency units","GRC","Greece","2019","2019",5.3,,
+"PATCACID","A02A-Antacids","MLLNCUMT","Million of national currency units","GRC","Greece","2020","2020",5.6,,
+"PATCACID","A02A-Antacids","MLLNCUMT","Million of national currency units","GRC","Greece","2021","2021",5.3,,
+"PATCACID","A02A-Antacids","MLLNCUMT","Million of national currency units","GRC","Greece","2022","2022",5.5,,
+"PATCACID","A02A-Antacids","MTMOTCMT","Million US$ at exchange rate","GRC","Greece","2010","2010",7.7,,
+"PATCACID","A02A-Antacids","MTMOTCMT","Million US$ at exchange rate","GRC","Greece","2011","2011",8.4,,
+"PATCACID","A02A-Antacids","MTMOTCMT","Million US$ at exchange rate","GRC","Greece","2012","2012",6.9,,
+"PATCACID","A02A-Antacids","MTMOTCMT","Million US$ at exchange rate","GRC","Greece","2013","2013",7.4,,
+"PATCACID","A02A-Antacids","MTMOTCMT","Million US$ at exchange rate","GRC","Greece","2014","2014",7.2,,
+"PATCACID","A02A-Antacids","MTMOTCMT","Million US$ at exchange rate","GRC","Greece","2015","2015",5.7,,
+"PATCACID","A02A-Antacids","MTMOTCMT","Million US$ at exchange rate","GRC","Greece","2016","2016",4.8,,
+"PATCACID","A02A-Antacids","MTMOTCMT","Million US$ at exchange rate","GRC","Greece","2017","2017",5,,
+"PATCACID","A02A-Antacids","MTMOTCMT","Million US$ at exchange rate","GRC","Greece","2018","2018",5.8,,
+"PATCACID","A02A-Antacids","MTMOTCMT","Million US$ at exchange rate","GRC","Greece","2019","2019",5.9,,
+"PATCACID","A02A-Antacids","MTMOTCMT","Million US$ at exchange rate","GRC","Greece","2020","2020",6.4,,
+"PATCACID","A02A-Antacids","MTMOTCMT","Million US$ at exchange rate","GRC","Greece","2021","2021",6.2,,
+"PATCACID","A02A-Antacids","MTMOTCMT","Million US$ at exchange rate","GRC","Greece","2022","2022",5.8,,
+"PATCACID","A02A-Antacids","MTMOPPMT","Million US$, purchasing power parity","GRC","Greece","2010","2010",8,,
+"PATCACID","A02A-Antacids","MTMOPPMT","Million US$, purchasing power parity","GRC","Greece","2011","2011",8.4,,
+"PATCACID","A02A-Antacids","MTMOPPMT","Million US$, purchasing power parity","GRC","Greece","2012","2012",7.8,,
+"PATCACID","A02A-Antacids","MTMOPPMT","Million US$, purchasing power parity","GRC","Greece","2013","2013",8.9,,
+"PATCACID","A02A-Antacids","MTMOPPMT","Million US$, purchasing power parity","GRC","Greece","2014","2014",8.9,,
+"PATCACID","A02A-Antacids","MTMOPPMT","Million US$, purchasing power parity","GRC","Greece","2015","2015",8.5,,
+"PATCACID","A02A-Antacids","MTMOPPMT","Million US$, purchasing power parity","GRC","Greece","2016","2016",7.3,,
+"PATCACID","A02A-Antacids","MTMOPPMT","Million US$, purchasing power parity","GRC","Greece","2017","2017",7.6,,
+"PATCACID","A02A-Antacids","MTMOPPMT","Million US$, purchasing power parity","GRC","Greece","2018","2018",8.6,,
+"PATCACID","A02A-Antacids","MTMOPPMT","Million US$, purchasing power parity","GRC","Greece","2019","2019",9.6,,
+"PATCACID","A02A-Antacids","MTMOPPMT","Million US$, purchasing power parity","GRC","Greece","2020","2020",10.2,,
+"PATCACID","A02A-Antacids","MTMOPPMT","Million US$, purchasing power parity","GRC","Greece","2021","2021",9.6,,
+"PATCACID","A02A-Antacids","MTMOPPMT","Million US$, purchasing power parity","GRC","Greece","2022","2022",10.5,,
+"PATCACID","A02A-Antacids","TCPPERMT","/capita, US$ exchange rate","GRC","Greece","2010","2010",0.7,,
+"PATCACID","A02A-Antacids","TCPPERMT","/capita, US$ exchange rate","GRC","Greece","2011","2011",0.8,,
+"PATCACID","A02A-Antacids","TCPPERMT","/capita, US$ exchange rate","GRC","Greece","2012","2012",0.6,,
+"PATCACID","A02A-Antacids","TCPPERMT","/capita, US$ exchange rate","GRC","Greece","2013","2013",0.7,,
+"PATCACID","A02A-Antacids","TCPPERMT","/capita, US$ exchange rate","GRC","Greece","2014","2014",0.7,,
+"PATCACID","A02A-Antacids","TCPPERMT","/capita, US$ exchange rate","GRC","Greece","2015","2015",0.5,,
+"PATCACID","A02A-Antacids","TCPPERMT","/capita, US$ exchange rate","GRC","Greece","2016","2016",0.4,,
+"PATCACID","A02A-Antacids","TCPPERMT","/capita, US$ exchange rate","GRC","Greece","2017","2017",0.5,,
+"PATCACID","A02A-Antacids","TCPPERMT","/capita, US$ exchange rate","GRC","Greece","2018","2018",0.5,,
+"PATCACID","A02A-Antacids","TCPPERMT","/capita, US$ exchange rate","GRC","Greece","2019","2019",0.5,,
+"PATCACID","A02A-Antacids","TCPPERMT","/capita, US$ exchange rate","GRC","Greece","2020","2020",0.6,,
+"PATCACID","A02A-Antacids","TCPPERMT","/capita, US$ exchange rate","GRC","Greece","2021","2021",0.6,,
+"PATCACID","A02A-Antacids","TCPPERMT","/capita, US$ exchange rate","GRC","Greece","2022","2022",0.6,,
+"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2010","2010",0.7,,
+"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2011","2011",0.8,,
+"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2012","2012",0.7,,
+"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2013","2013",0.8,,
+"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2014","2014",0.8,,
+"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2015","2015",0.8,,
+"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2016","2016",0.7,,
+"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2017","2017",0.7,,
+"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2018","2018",0.8,,
+"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2019","2019",0.9,,
+"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2020","2020",1,,
+"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2021","2021",0.9,,
+"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2022","2022",1,,
+"PATCACID","A02A-Antacids","MLLNCUMT","Million of national currency units","HUN","Hungary","2010","2010",0,"D","Difference in methodology"
+"PATCACID","A02A-Antacids","MLLNCUMT","Million of national currency units","HUN","Hungary","2011","2011",0,"D","Difference in methodology"
+"PATCACID","A02A-Antacids","MLLNCUMT","Million of national currency units","HUN","Hungary","2012","2012",0,"D","Difference in methodology"
+"PATCACID","A02A-Antacids","MLLNCUMT","Million of national currency units","HUN","Hungary","2013","2013",0,"D","Difference in methodology"
+"PATCACID","A02A-Antacids","MLLNCUMT","Million of national currency units","HUN","Hungary","2014","2014",0,"D","Difference in methodology"
+"PATCACID","A02A-Antacids","MLLNCUMT","Million of national currency units","HUN","Hungary","2015","2015",0,"D","Difference in methodology"
+"PATCACID","A02A-Antacids","MLLNCUMT","Million of national currency units","HUN","Hungary","2016","2016",0,"D","Difference in methodology"
+"PATCACID","A02A-Antacids","MLLNCUMT","Million of national currency units","HUN","Hungary","2017","2017",0,"D","Difference in methodology"
+"PATCACID","A02A-Antacids","MLLNCUMT","Million of national currency units","HUN","Hungary","2018","2018",0,"D","Difference in methodology"
+"PATCACID","A02A-Antacids","MLLNCUMT","Million of national currency units","HUN","Hungary","2019","2019",0,"D","Difference in methodology"
+"PATCACID","A02A-Antacids","MLLNCUMT","Million of national currency units","HUN","Hungary","2020","2020",0,"D","Difference in methodology"
+"PATCACID","A02A-Antacids","MLLNCUMT","Million of national currency units","HUN","Hungary","2021","2021",0,"D","Difference in methodology"
+"PATCACID","A02A-Antacids","MLLNCUMT","Million of national currency units","HUN","Hungary","2022","2022",0,"D","Difference in methodology"
+"PATCACID","A02A-Antacids","MTMOTCMT","Million US$ at exchange rate","HUN","Hungary","2010","2010",0,"D","Difference in methodology"
+"PATCACID","A02A-Antacids","MTMOTCMT","Million US$ at exchange rate","HUN","Hungary","2011","2011",0,"D","Difference in methodology"
+"PATCACID","A02A-Antacids","MTMOTCMT","Million US$ at exchange rate","HUN","Hungary","2012","2012",0,"D","Difference in methodology"
+"PATCACID","A02A-Antacids","MTMOTCMT","Million US$ at exchange rate","HUN","Hungary","2013","2013",0,"D","Difference in methodology"
+"PATCACID","A02A-Antacids","MTMOTCMT","Million US$ at exchange rate","HUN","Hungary","2014","2014",0,"D","Difference in methodology"
+"PATCACID","A02A-Antacids","MTMOTCMT","Million US$ at exchange rate","HUN","Hungary","2015","2015",0,"D","Difference in methodology"
+"PATCACID","A02A-Antacids","MTMOTCMT","Million US$ at exchange rate","HUN","Hungary","2016","2016",0,"D","Difference in methodology"
+"PATCACID","A02A-Antacids","MTMOTCMT","Million US$ at exchange rate","HUN","Hungary","2017","2017",0,"D","Difference in methodology"
+"PATCACID","A02A-Antacids","MTMOTCMT","Million US$ at exchange rate","HUN","Hungary","2018","2018",0,"D","Difference in methodology"
+"PATCACID","A02A-Antacids","MTMOTCMT","Million US$ at exchange rate","HUN","Hungary","2019","2019",0,"D","Difference in methodology"
+"PATCACID","A02A-Antacids","MTMOTCMT","Million US$ at exchange rate","HUN","Hungary","2020","2020",0,"D","Difference in methodology"
+"PATCACID","A02A-Antacids","MTMOTCMT","Million US$ at exchange rate","HUN","Hungary","2021","2021",0,"D","Difference in methodology"
+"PATCACID","A02A-Antacids","MTMOTCMT","Million US$ at exchange rate","HUN","Hungary","2022","2022",0,"D","Difference in methodology"
+"PATCACID","A02A-Antacids","MTMOPPMT","Million US$, purchasing power parity","HUN","Hungary","2010","2010",0,"D","Difference in methodology"
+"PATCACID","A02A-Antacids","MTMOPPMT","Million US$, purchasing power parity","HUN","Hungary","2011","2011",0,"D","Difference in methodology"
+"PATCACID","A02A-Antacids","MTMOPPMT","Million US$, purchasing power parity","HUN","Hungary","2012","2012",0,"D","Difference in methodology"
+"PATCACID","A02A-Antacids","MTMOPPMT","Million US$, purchasing power parity","HUN","Hungary","2013","2013",0,"D","Difference in methodology"
+"PATCACID","A02A-Antacids","MTMOPPMT","Million US$, purchasing power parity","HUN","Hungary","2014","2014",0,"D","Difference in methodology"
+"PATCACID","A02A-Antacids","MTMOPPMT","Million US$, purchasing power parity","HUN","Hungary","2015","2015",0,"D","Difference in methodology"
+"PATCACID","A02A-Antacids","MTMOPPMT","Million US$, purchasing power parity","HUN","Hungary","2016","2016",0,"D","Difference in methodology"
+"PATCACID","A02A-Antacids","MTMOPPMT","Million US$, purchasing power parity","HUN","Hungary","2017","2017",0,"D","Difference in methodology"
+"PATCACID","A02A-Antacids","MTMOPPMT","Million US$, purchasing power parity","HUN","Hungary","2018","2018",0,"D","Difference in methodology"
+"PATCACID","A02A-Antacids","MTMOPPMT","Million US$, purchasing power parity","HUN","Hungary","2019","2019",0,"D","Difference in methodology"
+"PATCACID","A02A-Antacids","MTMOPPMT","Million US$, purchasing power parity","HUN","Hungary","2020","2020",0,"D","Difference in methodology"
+"PATCACID","A02A-Antacids","MTMOPPMT","Million US$, purchasing power parity","HUN","Hungary","2021","2021",0,"D","Difference in methodology"
+"PATCACID","A02A-Antacids","MTMOPPMT","Million US$, purchasing power parity","HUN","Hungary","2022","2022",0,"D","Difference in methodology"
+"PATCACID","A02A-Antacids","TCPPERMT","/capita, US$ exchange rate","HUN","Hungary","2010","2010",0,"D","Difference in methodology"
+"PATCACID","A02A-Antacids","TCPPERMT","/capita, US$ exchange rate","HUN","Hungary","2011","2011",0,"D","Difference in methodology"
+"PATCACID","A02A-Antacids","TCPPERMT","/capita, US$ exchange rate","HUN","Hungary","2012","2012",0,"D","Difference in methodology"
+"PATCACID","A02A-Antacids","TCPPERMT","/capita, US$ exchange rate","HUN","Hungary","2013","2013",0,"D","Difference in methodology"
+"PATCACID","A02A-Antacids","TCPPERMT","/capita, US$ exchange rate","HUN","Hungary","2014","2014",0,"D","Difference in methodology"
+"PATCACID","A02A-Antacids","TCPPERMT","/capita, US$ exchange rate","HUN","Hungary","2015","2015",0,"D","Difference in methodology"
+"PATCACID","A02A-Antacids","TCPPERMT","/capita, US$ exchange rate","HUN","Hungary","2016","2016",0,"D","Difference in methodology"
+"PATCACID","A02A-Antacids","TCPPERMT","/capita, US$ exchange rate","HUN","Hungary","2017","2017",0,"D","Difference in methodology"
+"PATCACID","A02A-Antacids","TCPPERMT","/capita, US$ exchange rate","HUN","Hungary","2018","2018",0,"D","Difference in methodology"
+"PATCACID","A02A-Antacids","TCPPERMT","/capita, US$ exchange rate","HUN","Hungary","2019","2019",0,"D","Difference in methodology"
+"PATCACID","A02A-Antacids","TCPPERMT","/capita, US$ exchange rate","HUN","Hungary","2020","2020",0,"D","Difference in methodology"
+"PATCACID","A02A-Antacids","TCPPERMT","/capita, US$ exchange rate","HUN","Hungary","2021","2021",0,"D","Difference in methodology"
+"PATCACID","A02A-Antacids","TCPPERMT","/capita, US$ exchange rate","HUN","Hungary","2022","2022",0,"D","Difference in methodology"
+"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2010","2010",0,"D","Difference in methodology"
+"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2011","2011",0,"D","Difference in methodology"
+"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2012","2012",0,"D","Difference in methodology"
+"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2013","2013",0,"D","Difference in methodology"
+"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2014","2014",0,"D","Difference in methodology"
+"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2015","2015",0,"D","Difference in methodology"
+"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2016","2016",0,"D","Difference in methodology"
+"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2017","2017",0,"D","Difference in methodology"
+"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2018","2018",0,"D","Difference in methodology"
+"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2019","2019",0,"D","Difference in methodology"
+"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2020","2020",0,"D","Difference in methodology"
+"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2021","2021",0,"D","Difference in methodology"
+"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2022","2022",0,"D","Difference in methodology"
+"PATCACID","A02A-Antacids","ATCPTTMT","% of total sales","HUN","Hungary","2010","2010",0,"D","Difference in methodology"
+"PATCACID","A02A-Antacids","ATCPTTMT","% of total sales","HUN","Hungary","2011","2011",0,"D","Difference in methodology"
+"PATCACID","A02A-Antacids","ATCPTTMT","% of total sales","HUN","Hungary","2012","2012",0,"D","Difference in methodology"
+"PATCACID","A02A-Antacids","ATCPTTMT","% of total sales","HUN","Hungary","2013","2013",0,"D","Difference in methodology"
+"PATCACID","A02A-Antacids","ATCPTTMT","% of total sales","HUN","Hungary","2014","2014",0,"D","Difference in methodology"
+"PATCACID","A02A-Antacids","ATCPTTMT","% of total sales","HUN","Hungary","2015","2015",0,"D","Difference in methodology"
+"PATCACID","A02A-Antacids","ATCPTTMT","% of total sales","HUN","Hungary","2016","2016",0,"D","Difference in methodology"
+"PATCACID","A02A-Antacids","ATCPTTMT","% of total sales","HUN","Hungary","2017","2017",0,"D","Difference in methodology"
+"PATCACID","A02A-Antacids","ATCPTTMT","% of total sales","HUN","Hungary","2018","2018",0,"D","Difference in methodology"
+"PATCACID","A02A-Antacids","ATCPTTMT","% of total sales","HUN","Hungary","2019","2019",0,"D","Difference in methodology"
+"PATCACID","A02A-Antacids","ATCPTTMT","% of total sales","HUN","Hungary","2020","2020",0,"D","Difference in methodology"
+"PATCACID","A02A-Antacids","ATCPTTMT","% of total sales","HUN","Hungary","2021","2021",0,"D","Difference in methodology"
+"PATCACID","A02A-Antacids","ATCPTTMT","% of total sales","HUN","Hungary","2022","2022",0,"D","Difference in methodology"
+"PATCACID","A02A-Antacids","MLLNCUMT","Million of national currency units","ISL","Iceland","2010","2010",53.9,,
+"PATCACID","A02A-Antacids","MLLNCUMT","Million of national currency units","ISL","Iceland","2011","2011",0,,
+"PATCACID","A02A-Antacids","MLLNCUMT","Million of national currency units","ISL","Iceland","2012","2012",0,,
+"PATCACID","A02A-Antacids","MLLNCUMT","Million of national currency units","ISL","Iceland","2013","2013",0,,
+"PATCACID","A02A-Antacids","MLLNCUMT","Million of national currency units","ISL","Iceland","2014","2014",0,,
+"PATCACID","A02A-Antacids","MLLNCUMT","Million of national currency units","ISL","Iceland","2015","2015",0,,
+"PATCACID","A02A-Antacids","MLLNCUMT","Million of national currency units","ISL","Iceland","2016","2016",0,,
+"PATCACID","A02A-Antacids","MLLNCUMT","Million of national currency units","ISL","Iceland","2017","2017",0,,
+"PATCACID","A02A-Antacids","MLLNCUMT","Million of national currency units","ISL","Iceland","2018","2018",0,,
+"PATCACID","A02A-Antacids","MLLNCUMT","Million of national currency units","ISL","Iceland","2019","2019",0,,
+"PATCACID","A02A-Antacids","MLLNCUMT","Million of national currency units","ISL","Iceland","2020","2020",0,,
+"PATCACID","A02A-Antacids","MLLNCUMT","Million of national currency units","ISL","Iceland","2021","2021",0,,
+"PATCACID","A02A-Antacids","MTMOTCMT","Million US$ at exchange rate","ISL","Iceland","2010","2010",0.4,,
+"PATCACID","A02A-Antacids","MTMOTCMT","Million US$ at exchange rate","ISL","Iceland","2011","2011",0,,
+"PATCACID","A02A-Antacids","MTMOTCMT","Million US$ at exchange rate","ISL","Iceland","2012","2012",0,,
+"PATCACID","A02A-Antacids","MTMOTCMT","Million US$ at exchange rate","ISL","Iceland","2013","2013",0,,
+"PATCACID","A02A-Antacids","MTMOTCMT","Million US$ at exchange rate","ISL","Iceland","2014","2014",0,,
+"PATCACID","A02A-Antacids","MTMOTCMT","Million US$ at exchange rate","ISL","Iceland","2015","2015",0,,
+"PATCACID","A02A-Antacids","MTMOTCMT","Million US$ at exchange rate","ISL","Iceland","2016","2016",0,,
+"PATCACID","A02A-Antacids","MTMOTCMT","Million US$ at exchange rate","ISL","Iceland","2017","2017",0,,
+"PATCACID","A02A-Antacids","MTMOTCMT","Million US$ at exchange rate","ISL","Iceland","2018","2018",0,,
+"PATCACID","A02A-Antacids","MTMOTCMT","Million US$ at exchange rate","ISL","Iceland","2019","2019",0,,
+"PATCACID","A02A-Antacids","MTMOTCMT","Million US$ at exchange rate","ISL","Iceland","2020","2020",0,,
+"PATCACID","A02A-Antacids","MTMOTCMT","Million US$ at exchange rate","ISL","Iceland","2021","2021",0,,
+"PATCACID","A02A-Antacids","MTMOPPMT","Million US$, purchasing power parity","ISL","Iceland","2010","2010",0.4,,
+"PATCACID","A02A-Antacids","MTMOPPMT","Million US$, purchasing power parity","ISL","Iceland","2011","2011",0,,
+"PATCACID","A02A-Antacids","MTMOPPMT","Million US$, purchasing power parity","ISL","Iceland","2012","2012",0,,
+"PATCACID","A02A-Antacids","MTMOPPMT","Million US$, purchasing power parity","ISL","Iceland","2013","2013",0,,
+"PATCACID","A02A-Antacids","MTMOPPMT","Million US$, purchasing power parity","ISL","Iceland","2014","2014",0,,
+"PATCACID","A02A-Antacids","MTMOPPMT","Million US$, purchasing power parity","ISL","Iceland","2015","2015",0,,
+"PATCACID","A02A-Antacids","MTMOPPMT","Million US$, purchasing power parity","ISL","Iceland","2016","2016",0,,
+"PATCACID","A02A-Antacids","MTMOPPMT","Million US$, purchasing power parity","ISL","Iceland","2017","2017",0,,
+"PATCACID","A02A-Antacids","MTMOPPMT","Million US$, purchasing power parity","ISL","Iceland","2018","2018",0,,
+"PATCACID","A02A-Antacids","MTMOPPMT","Million US$, purchasing power parity","ISL","Iceland","2019","2019",0,,
+"PATCACID","A02A-Antacids","MTMOPPMT","Million US$, purchasing power parity","ISL","Iceland","2020","2020",0,,
+"PATCACID","A02A-Antacids","MTMOPPMT","Million US$, purchasing power parity","ISL","Iceland","2021","2021",0,,
+"PATCACID","A02A-Antacids","TCPPERMT","/capita, US$ exchange rate","ISL","Iceland","2010","2010",1.4,,
+"PATCACID","A02A-Antacids","TCPPERMT","/capita, US$ exchange rate","ISL","Iceland","2011","2011",0,,
+"PATCACID","A02A-Antacids","TCPPERMT","/capita, US$ exchange rate","ISL","Iceland","2012","2012",0,,
+"PATCACID","A02A-Antacids","TCPPERMT","/capita, US$ exchange rate","ISL","Iceland","2013","2013",0,,
+"PATCACID","A02A-Antacids","TCPPERMT","/capita, US$ exchange rate","ISL","Iceland","2014","2014",0,,
+"PATCACID","A02A-Antacids","TCPPERMT","/capita, US$ exchange rate","ISL","Iceland","2015","2015",0,,
+"PATCACID","A02A-Antacids","TCPPERMT","/capita, US$ exchange rate","ISL","Iceland","2016","2016",0,,
+"PATCACID","A02A-Antacids","TCPPERMT","/capita, US$ exchange rate","ISL","Iceland","2017","2017",0,,
+"PATCACID","A02A-Antacids","TCPPERMT","/capita, US$ exchange rate","ISL","Iceland","2018","2018",0,,
+"PATCACID","A02A-Antacids","TCPPERMT","/capita, US$ exchange rate","ISL","Iceland","2019","2019",0,,
+"PATCACID","A02A-Antacids","TCPPERMT","/capita, US$ exchange rate","ISL","Iceland","2020","2020",0,,
+"PATCACID","A02A-Antacids","TCPPERMT","/capita, US$ exchange rate","ISL","Iceland","2021","2021",0,,
+"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2010","2010",1.3,,
+"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2011","2011",0,,
+"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2012","2012",0,,
+"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2013","2013",0,,
+"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2014","2014",0,,
+"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2015","2015",0,,
+"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2016","2016",0,,
+"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2017","2017",0,,
+"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2018","2018",0,,
+"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2019","2019",0,,
+"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2020","2020",0,,
+"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2021","2021",0,,
+"PATCACID","A02A-Antacids","ATCPTTMT","% of total sales","ISL","Iceland","2010","2010",0.2,,
+"PATCACID","A02A-Antacids","ATCPTTMT","% of total sales","ISL","Iceland","2011","2011",0,,
+"PATCACID","A02A-Antacids","ATCPTTMT","% of total sales","ISL","Iceland","2012","2012",0,,
+"PATCACID","A02A-Antacids","ATCPTTMT","% of total sales","ISL","Iceland","2013","2013",0,,
+"PATCACID","A02A-Antacids","ATCPTTMT","% of total sales","ISL","Iceland","2014","2014",0,,
+"PATCACID","A02A-Antacids","ATCPTTMT","% of total sales","ISL","Iceland","2015","2015",0,,
+"PATCACID","A02A-Antacids","ATCPTTMT","% of total sales","ISL","Iceland","2016","2016",0,,
+"PATCACID","A02A-Antacids","ATCPTTMT","% of total sales","ISL","Iceland","2017","2017",0,,
+"PATCACID","A02A-Antacids","ATCPTTMT","% of total sales","ISL","Iceland","2018","2018",0,,
+"PATCACID","A02A-Antacids","ATCPTTMT","% of total sales","ISL","Iceland","2019","2019",0,,
+"PATCACID","A02A-Antacids","ATCPTTMT","% of total sales","ISL","Iceland","2020","2020",0,,
+"PATCACID","A02A-Antacids","ATCPTTMT","% of total sales","ISL","Iceland","2021","2021",0,,
+"PATCACID","A02A-Antacids","MLLNCUMT","Million of national currency units","IRL","Ireland","2010","2010",0.1,"D","Difference in methodology"
+"PATCACID","A02A-Antacids","MLLNCUMT","Million of national currency units","IRL","Ireland","2011","2011",0.1,"D","Difference in methodology"
+"PATCACID","A02A-Antacids","MLLNCUMT","Million of national currency units","IRL","Ireland","2012","2012",0.1,"D","Difference in methodology"
+"PATCACID","A02A-Antacids","MLLNCUMT","Million of national currency units","IRL","Ireland","2013","2013",0.1,"B; D","Break; Difference in methodology"
+"PATCACID","A02A-Antacids","MLLNCUMT","Million of national currency units","IRL","Ireland","2014","2014",0.1,"D","Difference in methodology"
+"PATCACID","A02A-Antacids","MLLNCUMT","Million of national currency units","IRL","Ireland","2015","2015",0.1,"D","Difference in methodology"
+"PATCACID","A02A-Antacids","MLLNCUMT","Million of national currency units","IRL","Ireland","2016","2016",0,"D","Difference in methodology"
+"PATCACID","A02A-Antacids","MLLNCUMT","Million of national currency units","IRL","Ireland","2017","2017",0,"D","Difference in methodology"
+"PATCACID","A02A-Antacids","MLLNCUMT","Million of national currency units","IRL","Ireland","2018","2018",0,"D","Difference in methodology"
+"PATCACID","A02A-Antacids","MLLNCUMT","Million of national currency units","IRL","Ireland","2019","2019",0,"D","Difference in methodology"
+"PATCACID","A02A-Antacids","MLLNCUMT","Million of national currency units","IRL","Ireland","2020","2020",0,"D","Difference in methodology"
+"PATCACID","A02A-Antacids","MLLNCUMT","Million of national currency units","IRL","Ireland","2021","2021",0,"D","Difference in methodology"
+"PATCACID","A02A-Antacids","MTMOTCMT","Million US$ at exchange rate","IRL","Ireland","2010","2010",0.2,"D","Difference in methodology"
+"PATCACID","A02A-Antacids","MTMOTCMT","Million US$ at exchange rate","IRL","Ireland","2011","2011",0.2,"D","Difference in methodology"
+"PATCACID","A02A-Antacids","MTMOTCMT","Million US$ at exchange rate","IRL","Ireland","2012","2012",0.1,"D","Difference in methodology"
+"PATCACID","A02A-Antacids","MTMOTCMT","Million US$ at exchange rate","IRL","Ireland","2013","2013",0.1,"B; D","Break; Difference in methodology"
+"PATCACID","A02A-Antacids","MTMOTCMT","Million US$ at exchange rate","IRL","Ireland","2014","2014",0.1,"D","Difference in methodology"
+"PATCACID","A02A-Antacids","MTMOTCMT","Million US$ at exchange rate","IRL","Ireland","2015","2015",0.1,"D","Difference in methodology"
+"PATCACID","A02A-Antacids","MTMOTCMT","Million US$ at exchange rate","IRL","Ireland","2016","2016",0,"D","Difference in methodology"
+"PATCACID","A02A-Antacids","MTMOTCMT","Million US$ at exchange rate","IRL","Ireland","2017","2017",0,"D","Difference in methodology"
+"PATCACID","A02A-Antacids","MTMOTCMT","Million US$ at exchange rate","IRL","Ireland","2018","2018",0,"D","Difference in methodology"
+"PATCACID","A02A-Antacids","MTMOTCMT","Million US$ at exchange rate","IRL","Ireland","2019","2019",0,"D","Difference in methodology"
+"PATCACID","A02A-Antacids","MTMOTCMT","Million US$ at exchange rate","IRL","Ireland","2020","2020",0,"D","Difference in methodology"
+"PATCACID","A02A-Antacids","MTMOTCMT","Million US$ at exchange rate","IRL","Ireland","2021","2021",0,"D","Difference in methodology"
+"PATCACID","A02A-Antacids","MTMOPPMT","Million US$, purchasing power parity","IRL","Ireland","2010","2010",0.2,"D","Difference in methodology"
+"PATCACID","A02A-Antacids","MTMOPPMT","Million US$, purchasing power parity","IRL","Ireland","2011","2011",0.1,"D","Difference in methodology"
+"PATCACID","A02A-Antacids","MTMOPPMT","Million US$, purchasing power parity","IRL","Ireland","2012","2012",0.1,"D","Difference in methodology"
+"PATCACID","A02A-Antacids","MTMOPPMT","Million US$, purchasing power parity","IRL","Ireland","2013","2013",0.1,"B; D","Break; Difference in methodology"
+"PATCACID","A02A-Antacids","MTMOPPMT","Million US$, purchasing power parity","IRL","Ireland","2014","2014",0.1,"D","Difference in methodology"
+"PATCACID","A02A-Antacids","MTMOPPMT","Million US$, purchasing power parity","IRL","Ireland","2015","2015",0.1,"D","Difference in methodology"
+"PATCACID","A02A-Antacids","MTMOPPMT","Million US$, purchasing power parity","IRL","Ireland","2016","2016",0.1,"D","Difference in methodology"
+"PATCACID","A02A-Antacids","MTMOPPMT","Million US$, purchasing power parity","IRL","Ireland","2017","2017",0,"D","Difference in methodology"
+"PATCACID","A02A-Antacids","MTMOPPMT","Million US$, purchasing power parity","IRL","Ireland","2018","2018",0,"D","Difference in methodology"
+"PATCACID","A02A-Antacids","MTMOPPMT","Million US$, purchasing power parity","IRL","Ireland","2019","2019",0,"D","Difference in methodology"
+"PATCACID","A02A-Antacids","MTMOPPMT","Million US$, purchasing power parity","IRL","Ireland","2020","2020",0,"D","Difference in methodology"
+"PATCACID","A02A-Antacids","MTMOPPMT","Million US$, purchasing power parity","IRL","Ireland","2021","2021",0,"D","Difference in methodology"
+"PATCACID","A02A-Antacids","TCPPERMT","/capita, US$ exchange rate","IRL","Ireland","2010","2010",0,"D","Difference in methodology"
+"PATCACID","A02A-Antacids","TCPPERMT","/capita, US$ exchange rate","IRL","Ireland","2011","2011",0,"D","Difference in methodology"
+"PATCACID","A02A-Antacids","TCPPERMT","/capita, US$ exchange rate","IRL","Ireland","2012","2012",0,"D","Difference in methodology"
+"PATCACID","A02A-Antacids","TCPPERMT","/capita, US$ exchange rate","IRL","Ireland","2013","2013",0,"B; D","Break; Difference in methodology"
+"PATCACID","A02A-Antacids","TCPPERMT","/capita, US$ exchange rate","IRL","Ireland","2014","2014",0,"D","Difference in methodology"
+"PATCACID","A02A-Antacids","TCPPERMT","/capita, US$ exchange rate","IRL","Ireland","2015","2015",0,"D","Difference in methodology"
+"PATCACID","A02A-Antacids","TCPPERMT","/capita, US$ exchange rate","IRL","Ireland","2016","2016",0,"D","Difference in methodology"
+"PATCACID","A02A-Antacids","TCPPERMT","/capita, US$ exchange rate","IRL","Ireland","2017","2017",0,"D","Difference in methodology"
+"PATCACID","A02A-Antacids","TCPPERMT","/capita, US$ exchange rate","IRL","Ireland","2018","2018",0,"D","Difference in methodology"
+"PATCACID","A02A-Antacids","TCPPERMT","/capita, US$ exchange rate","IRL","Ireland","2019","2019",0,"D","Difference in methodology"
+"PATCACID","A02A-Antacids","TCPPERMT","/capita, US$ exchange rate","IRL","Ireland","2020","2020",0,"D","Difference in methodology"
+"PATCACID","A02A-Antacids","TCPPERMT","/capita, US$ exchange rate","IRL","Ireland","2021","2021",0,"D","Difference in methodology"
+"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2010","2010",0,"D","Difference in methodology"
+"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2011","2011",0,"D","Difference in methodology"
+"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2012","2012",0,"D","Difference in methodology"
+"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2013","2013",0,"B; D","Break; Difference in methodology"
+"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2014","2014",0,"D","Difference in methodology"
+"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2015","2015",0,"D","Difference in methodology"
+"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2016","2016",0,"D","Difference in methodology"
+"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2017","2017",0,"D","Difference in methodology"
+"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2018","2018",0,"D","Difference in methodology"
+"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2019","2019",0,"D","Difference in methodology"
+"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2020","2020",0,"D","Difference in methodology"
+"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2021","2021",0,"D","Difference in methodology"
+"PATCACID","A02A-Antacids","ATCPTTMT","% of total sales","IRL","Ireland","2010","2010",0,"D","Difference in methodology"
+"PATCACID","A02A-Antacids","ATCPTTMT","% of total sales","IRL","Ireland","2011","2011",0,"D","Difference in methodology"
+"PATCACID","A02A-Antacids","ATCPTTMT","% of total sales","IRL","Ireland","2012","2012",0,"D","Difference in methodology"
+"PATCACID","A02A-Antacids","ATCPTTMT","% of total sales","IRL","Ireland","2013","2013",0,"B; D","Break; Difference in methodology"
+"PATCACID","A02A-Antacids","ATCPTTMT","% of total sales","IRL","Ireland","2014","2014",0,"D","Difference in methodology"
+"PATCACID","A02A-Antacids","ATCPTTMT","% of total sales","IRL","Ireland","2015","2015",0,"D","Difference in methodology"
+"PATCACID","A02A-Antacids","ATCPTTMT","% of total sales","IRL","Ireland","2016","2016",0,"D","Difference in methodology"
+"PATCACID","A02A-Antacids","ATCPTTMT","% of total sales","IRL","Ireland","2017","2017",0,"D","Difference in methodology"
+"PATCACID","A02A-Antacids","ATCPTTMT","% of total sales","IRL","Ireland","2018","2018",0,"D","Difference in methodology"
+"PATCACID","A02A-Antacids","ATCPTTMT","% of total sales","IRL","Ireland","2019","2019",0,"D","Difference in methodology"
+"PATCACID","A02A-Antacids","ATCPTTMT","% of total sales","IRL","Ireland","2020","2020",0,"D","Difference in methodology"
+"PATCACID","A02A-Antacids","ATCPTTMT","% of total sales","IRL","Ireland","2021","2021",0,"D","Difference in methodology"
+"PATCACID","A02A-Antacids","MLLNCUMT","Million of national currency units","ITA","Italy","2011","2011",21.9,,
+"PATCACID","A02A-Antacids","MLLNCUMT","Million of national currency units","ITA","Italy","2012","2012",21.7,,
+"PATCACID","A02A-Antacids","MLLNCUMT","Million of national currency units","ITA","Italy","2013","2013",22.1,,
+"PATCACID","A02A-Antacids","MLLNCUMT","Million of national currency units","ITA","Italy","2014","2014",24.2,,
+"PATCACID","A02A-Antacids","MLLNCUMT","Million of national currency units","ITA","Italy","2015","2015",24.6,,
+"PATCACID","A02A-Antacids","MLLNCUMT","Million of national currency units","ITA","Italy","2016","2016",25.3,,
+"PATCACID","A02A-Antacids","MLLNCUMT","Million of national currency units","ITA","Italy","2017","2017",25.4,,
+"PATCACID","A02A-Antacids","MLLNCUMT","Million of national currency units","ITA","Italy","2018","2018",26,,
+"PATCACID","A02A-Antacids","MLLNCUMT","Million of national currency units","ITA","Italy","2019","2019",23.9,,
+"PATCACID","A02A-Antacids","MLLNCUMT","Million of national currency units","ITA","Italy","2020","2020",24.9,,
+"PATCACID","A02A-Antacids","MLLNCUMT","Million of national currency units","ITA","Italy","2021","2021",25,,
+"PATCACID","A02A-Antacids","MLLNCUMT","Million of national currency units","ITA","Italy","2022","2022",32.8,"E","Estimated value"
+"PATCACID","A02A-Antacids","MTMOTCMT","Million US$ at exchange rate","ITA","Italy","2011","2011",30.5,,
+"PATCACID","A02A-Antacids","MTMOTCMT","Million US$ at exchange rate","ITA","Italy","2012","2012",27.9,,
+"PATCACID","A02A-Antacids","MTMOTCMT","Million US$ at exchange rate","ITA","Italy","2013","2013",29.4,,
+"PATCACID","A02A-Antacids","MTMOTCMT","Million US$ at exchange rate","ITA","Italy","2014","2014",32.2,,
+"PATCACID","A02A-Antacids","MTMOTCMT","Million US$ at exchange rate","ITA","Italy","2015","2015",27.3,,
+"PATCACID","A02A-Antacids","MTMOTCMT","Million US$ at exchange rate","ITA","Italy","2016","2016",28,,
+"PATCACID","A02A-Antacids","MTMOTCMT","Million US$ at exchange rate","ITA","Italy","2017","2017",28.7,,
+"PATCACID","A02A-Antacids","MTMOTCMT","Million US$ at exchange rate","ITA","Italy","2018","2018",30.7,,
+"PATCACID","A02A-Antacids","MTMOTCMT","Million US$ at exchange rate","ITA","Italy","2019","2019",26.8,,
+"PATCACID","A02A-Antacids","MTMOTCMT","Million US$ at exchange rate","ITA","Italy","2020","2020",28.5,,
+"PATCACID","A02A-Antacids","MTMOTCMT","Million US$ at exchange rate","ITA","Italy","2021","2021",29.6,,
+"PATCACID","A02A-Antacids","MTMOTCMT","Million US$ at exchange rate","ITA","Italy","2022","2022",34.6,"E","Estimated value"
+"PATCACID","A02A-Antacids","MTMOPPMT","Million US$, purchasing power parity","ITA","Italy","2011","2011",28.9,,
+"PATCACID","A02A-Antacids","MTMOPPMT","Million US$, purchasing power parity","ITA","Italy","2012","2012",29.1,,
+"PATCACID","A02A-Antacids","MTMOPPMT","Million US$, purchasing power parity","ITA","Italy","2013","2013",30,,
+"PATCACID","A02A-Antacids","MTMOPPMT","Million US$, purchasing power parity","ITA","Italy","2014","2014",32.7,,
+"PATCACID","A02A-Antacids","MTMOPPMT","Million US$, purchasing power parity","ITA","Italy","2015","2015",33.4,,
+"PATCACID","A02A-Antacids","MTMOPPMT","Million US$, purchasing power parity","ITA","Italy","2016","2016",36.1,,
+"PATCACID","A02A-Antacids","MTMOPPMT","Million US$, purchasing power parity","ITA","Italy","2017","2017",36.9,,
+"PATCACID","A02A-Antacids","MTMOPPMT","Million US$, purchasing power parity","ITA","Italy","2018","2018",38.2,,
+"PATCACID","A02A-Antacids","MTMOPPMT","Million US$, purchasing power parity","ITA","Italy","2019","2019",36.4,,
+"PATCACID","A02A-Antacids","MTMOPPMT","Million US$, purchasing power parity","ITA","Italy","2020","2020",38.5,,
+"PATCACID","A02A-Antacids","MTMOPPMT","Million US$, purchasing power parity","ITA","Italy","2021","2021",38.6,,
+"PATCACID","A02A-Antacids","MTMOPPMT","Million US$, purchasing power parity","ITA","Italy","2022","2022",53.2,"E","Estimated value"
+"PATCACID","A02A-Antacids","TCPPERMT","/capita, US$ exchange rate","ITA","Italy","2011","2011",0.5,,
+"PATCACID","A02A-Antacids","TCPPERMT","/capita, US$ exchange rate","ITA","Italy","2012","2012",0.5,,
+"PATCACID","A02A-Antacids","TCPPERMT","/capita, US$ exchange rate","ITA","Italy","2013","2013",0.5,,
+"PATCACID","A02A-Antacids","TCPPERMT","/capita, US$ exchange rate","ITA","Italy","2014","2014",0.5,,
+"PATCACID","A02A-Antacids","TCPPERMT","/capita, US$ exchange rate","ITA","Italy","2015","2015",0.5,,
+"PATCACID","A02A-Antacids","TCPPERMT","/capita, US$ exchange rate","ITA","Italy","2016","2016",0.5,,
+"PATCACID","A02A-Antacids","TCPPERMT","/capita, US$ exchange rate","ITA","Italy","2017","2017",0.5,,
+"PATCACID","A02A-Antacids","TCPPERMT","/capita, US$ exchange rate","ITA","Italy","2018","2018",0.5,,
+"PATCACID","A02A-Antacids","TCPPERMT","/capita, US$ exchange rate","ITA","Italy","2019","2019",0.4,,
+"PATCACID","A02A-Antacids","TCPPERMT","/capita, US$ exchange rate","ITA","Italy","2020","2020",0.5,,
+"PATCACID","A02A-Antacids","TCPPERMT","/capita, US$ exchange rate","ITA","Italy","2021","2021",0.5,,
+"PATCACID","A02A-Antacids","TCPPERMT","/capita, US$ exchange rate","ITA","Italy","2022","2022",0.6,"E","Estimated value"
+"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2011","2011",0.5,,
+"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2012","2012",0.5,,
+"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2013","2013",0.5,,
+"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2014","2014",0.5,,
+"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2015","2015",0.5,,
+"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2016","2016",0.6,,
+"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2017","2017",0.6,,
+"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2018","2018",0.6,,
+"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2019","2019",0.6,,
+"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2020","2020",0.6,,
+"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2021","2021",0.7,,
+"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2022","2022",0.9,"E","Estimated value"
+"PATCACID","A02A-Antacids","ATCPTTMT","% of total sales","ITA","Italy","2011","2011",0.1,,
+"PATCACID","A02A-Antacids","ATCPTTMT","% of total sales","ITA","Italy","2012","2012",0.1,,
+"PATCACID","A02A-Antacids","ATCPTTMT","% of total sales","ITA","Italy","2013","2013",0.1,,
+"PATCACID","A02A-Antacids","ATCPTTMT","% of total sales","ITA","Italy","2014","2014",0.1,,
+"PATCACID","A02A-Antacids","ATCPTTMT","% of total sales","ITA","Italy","2015","2015",0.1,,
+"PATCACID","A02A-Antacids","ATCPTTMT","% of total sales","ITA","Italy","2016","2016",0.1,,
+"PATCACID","A02A-Antacids","ATCPTTMT","% of total sales","ITA","Italy","2017","2017",0.1,,
+"PATCACID","A02A-Antacids","ATCPTTMT","% of total sales","ITA","Italy","2018","2018",0.1,,
+"PATCACID","A02A-Antacids","ATCPTTMT","% of total sales","ITA","Italy","2019","2019",0.1,,
+"PATCACID","A02A-Antacids","ATCPTTMT","% of total sales","ITA","Italy","2020","2020",0.1,,
+"PATCACID","A02A-Antacids","ATCPTTMT","% of total sales","ITA","Italy","2021","2021",0.1,,
+"PATCACID","A02A-Antacids","ATCPTTMT","% of total sales","ITA","Italy","2022","2022",0.1,"E","Estimated value"
+"PATCACID","A02A-Antacids","MLLNCUMT","Million of national currency units","KOR","Korea","2010","2010",107888,,
+"PATCACID","A02A-Antacids","MLLNCUMT","Million of national currency units","KOR","Korea","2011","2011",94392,"B","Break"
+"PATCACID","A02A-Antacids","MLLNCUMT","Million of national currency units","KOR","Korea","2012","2012",83934.6,,
+"PATCACID","A02A-Antacids","MLLNCUMT","Million of national currency units","KOR","Korea","2013","2013",79360.9,,
+"PATCACID","A02A-Antacids","MLLNCUMT","Million of national currency units","KOR","Korea","2014","2014",78601.3,,
+"PATCACID","A02A-Antacids","MLLNCUMT","Million of national currency units","KOR","Korea","2015","2015",75437.3,,
+"PATCACID","A02A-Antacids","MLLNCUMT","Million of national currency units","KOR","Korea","2016","2016",68368.6,"B","Break"
+"PATCACID","A02A-Antacids","MLLNCUMT","Million of national currency units","KOR","Korea","2017","2017",68847,,
+"PATCACID","A02A-Antacids","MLLNCUMT","Million of national currency units","KOR","Korea","2018","2018",70990.6,,
+"PATCACID","A02A-Antacids","MLLNCUMT","Million of national currency units","KOR","Korea","2019","2019",73827.3,,
+"PATCACID","A02A-Antacids","MLLNCUMT","Million of national currency units","KOR","Korea","2020","2020",80978.9,,
+"PATCACID","A02A-Antacids","MLLNCUMT","Million of national currency units","KOR","Korea","2021","2021",79702.3,,
+"PATCACID","A02A-Antacids","MTMOTCMT","Million US$ at exchange rate","KOR","Korea","2010","2010",93.3,,
+"PATCACID","A02A-Antacids","MTMOTCMT","Million US$ at exchange rate","KOR","Korea","2011","2011",85.2,"B","Break"
+"PATCACID","A02A-Antacids","MTMOTCMT","Million US$ at exchange rate","KOR","Korea","2012","2012",74.5,,
+"PATCACID","A02A-Antacids","MTMOTCMT","Million US$ at exchange rate","KOR","Korea","2013","2013",72.5,,
+"PATCACID","A02A-Antacids","MTMOTCMT","Million US$ at exchange rate","KOR","Korea","2014","2014",74.7,,
+"PATCACID","A02A-Antacids","MTMOTCMT","Million US$ at exchange rate","KOR","Korea","2015","2015",66.7,,
+"PATCACID","A02A-Antacids","MTMOTCMT","Million US$ at exchange rate","KOR","Korea","2016","2016",58.9,"B","Break"
+"PATCACID","A02A-Antacids","MTMOTCMT","Million US$ at exchange rate","KOR","Korea","2017","2017",60.9,,
+"PATCACID","A02A-Antacids","MTMOTCMT","Million US$ at exchange rate","KOR","Korea","2018","2018",64.5,,
+"PATCACID","A02A-Antacids","MTMOTCMT","Million US$ at exchange rate","KOR","Korea","2019","2019",63.4,,
+"PATCACID","A02A-Antacids","MTMOTCMT","Million US$ at exchange rate","KOR","Korea","2020","2020",68.6,,
+"PATCACID","A02A-Antacids","MTMOTCMT","Million US$ at exchange rate","KOR","Korea","2021","2021",69.7,,
+"PATCACID","A02A-Antacids","MTMOPPMT","Million US$, purchasing power parity","KOR","Korea","2010","2010",128.3,,
+"PATCACID","A02A-Antacids","MTMOPPMT","Million US$, purchasing power parity","KOR","Korea","2011","2011",110.5,"B","Break"
+"PATCACID","A02A-Antacids","MTMOPPMT","Million US$, purchasing power parity","KOR","Korea","2012","2012",98.2,,
+"PATCACID","A02A-Antacids","MTMOPPMT","Million US$, purchasing power parity","KOR","Korea","2013","2013",91.3,,
+"PATCACID","A02A-Antacids","MTMOPPMT","Million US$, purchasing power parity","KOR","Korea","2014","2014",90.2,,
+"PATCACID","A02A-Antacids","MTMOPPMT","Million US$, purchasing power parity","KOR","Korea","2015","2015",88,,
+"PATCACID","A02A-Antacids","MTMOPPMT","Million US$, purchasing power parity","KOR","Korea","2016","2016",79.6,"B","Break"
+"PATCACID","A02A-Antacids","MTMOPPMT","Million US$, purchasing power parity","KOR","Korea","2017","2017",78.9,,
+"PATCACID","A02A-Antacids","MTMOPPMT","Million US$, purchasing power parity","KOR","Korea","2018","2018",83,,
+"PATCACID","A02A-Antacids","MTMOPPMT","Million US$, purchasing power parity","KOR","Korea","2019","2019",86.2,,
+"PATCACID","A02A-Antacids","MTMOPPMT","Million US$, purchasing power parity","KOR","Korea","2020","2020",96.7,,
+"PATCACID","A02A-Antacids","MTMOPPMT","Million US$, purchasing power parity","KOR","Korea","2021","2021",93.3,,
+"PATCACID","A02A-Antacids","TCPPERMT","/capita, US$ exchange rate","KOR","Korea","2010","2010",1.9,,
+"PATCACID","A02A-Antacids","TCPPERMT","/capita, US$ exchange rate","KOR","Korea","2011","2011",1.7,"B","Break"
+"PATCACID","A02A-Antacids","TCPPERMT","/capita, US$ exchange rate","KOR","Korea","2012","2012",1.5,,
+"PATCACID","A02A-Antacids","TCPPERMT","/capita, US$ exchange rate","KOR","Korea","2013","2013",1.4,,
+"PATCACID","A02A-Antacids","TCPPERMT","/capita, US$ exchange rate","KOR","Korea","2014","2014",1.5,,
+"PATCACID","A02A-Antacids","TCPPERMT","/capita, US$ exchange rate","KOR","Korea","2015","2015",1.3,,
+"PATCACID","A02A-Antacids","TCPPERMT","/capita, US$ exchange rate","KOR","Korea","2016","2016",1.1,"B","Break"
+"PATCACID","A02A-Antacids","TCPPERMT","/capita, US$ exchange rate","KOR","Korea","2017","2017",1.2,,
+"PATCACID","A02A-Antacids","TCPPERMT","/capita, US$ exchange rate","KOR","Korea","2018","2018",1.3,,
+"PATCACID","A02A-Antacids","TCPPERMT","/capita, US$ exchange rate","KOR","Korea","2019","2019",1.2,,
+"PATCACID","A02A-Antacids","TCPPERMT","/capita, US$ exchange rate","KOR","Korea","2020","2020",1.3,,
+"PATCACID","A02A-Antacids","TCPPERMT","/capita, US$ exchange rate","KOR","Korea","2021","2021",1.3,,
+"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2010","2010",2.6,,
+"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2011","2011",2.2,"B","Break"
+"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2012","2012",2,,
+"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2013","2013",1.8,,
+"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2014","2014",1.8,,
+"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2015","2015",1.7,,
+"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2016","2016",1.6,"B","Break"
+"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2017","2017",1.5,,
+"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2018","2018",1.6,,
+"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2019","2019",1.7,,
+"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2020","2020",1.9,,
+"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2021","2021",1.8,,
+"PATCACID","A02A-Antacids","ATCPTTMT","% of total sales","KOR","Korea","2010","2010",0.5,,
+"PATCACID","A02A-Antacids","ATCPTTMT","% of total sales","KOR","Korea","2011","2011",0.4,"B","Break"
+"PATCACID","A02A-Antacids","ATCPTTMT","% of total sales","KOR","Korea","2012","2012",0.4,,
+"PATCACID","A02A-Antacids","ATCPTTMT","% of total sales","KOR","Korea","2013","2013",0.4,,
+"PATCACID","A02A-Antacids","ATCPTTMT","% of total sales","KOR","Korea","2014","2014",0.3,,
+"PATCACID","A02A-Antacids","ATCPTTMT","% of total sales","KOR","Korea","2015","2015",0.3,,
+"PATCACID","A02A-Antacids","ATCPTTMT","% of total sales","KOR","Korea","2016","2016",0.3,"B","Break"
+"PATCACID","A02A-Antacids","ATCPTTMT","% of total sales","KOR","Korea","2017","2017",0.3,,
+"PATCACID","A02A-Antacids","ATCPTTMT","% of total sales","KOR","Korea","2018","2018",0.2,,
+"PATCACID","A02A-Antacids","ATCPTTMT","% of total sales","KOR","Korea","2019","2019",0.2,,
+"PATCACID","A02A-Antacids","ATCPTTMT","% of total sales","KOR","Korea","2020","2020",0.2,,
+"PATCACID","A02A-Antacids","ATCPTTMT","% of total sales","KOR","Korea","2021","2021",0.2,,
+"PATCACID","A02A-Antacids","MLLNCUMT","Million of national currency units","LUX","Luxembourg","2010","2010",0.3,"D","Difference in methodology"
+"PATCACID","A02A-Antacids","MLLNCUMT","Million of national currency units","LUX","Luxembourg","2011","2011",0.3,"D","Difference in methodology"
+"PATCACID","A02A-Antacids","MLLNCUMT","Million of national currency units","LUX","Luxembourg","2012","2012",0.3,"D","Difference in methodology"
+"PATCACID","A02A-Antacids","MLLNCUMT","Million of national currency units","LUX","Luxembourg","2013","2013",0.3,"D","Difference in methodology"
+"PATCACID","A02A-Antacids","MLLNCUMT","Million of national currency units","LUX","Luxembourg","2014","2014",0.4,"D","Difference in methodology"
+"PATCACID","A02A-Antacids","MLLNCUMT","Million of national currency units","LUX","Luxembourg","2015","2015",0.4,"D","Difference in methodology"
+"PATCACID","A02A-Antacids","MLLNCUMT","Million of national currency units","LUX","Luxembourg","2016","2016",0.4,"D","Difference in methodology"
+"PATCACID","A02A-Antacids","MLLNCUMT","Million of national currency units","LUX","Luxembourg","2017","2017",0.4,"D","Difference in methodology"
+"PATCACID","A02A-Antacids","MLLNCUMT","Million of national currency units","LUX","Luxembourg","2018","2018",0.4,"D","Difference in methodology"
+"PATCACID","A02A-Antacids","MLLNCUMT","Million of national currency units","LUX","Luxembourg","2019","2019",0.4,"D","Difference in methodology"
+"PATCACID","A02A-Antacids","MLLNCUMT","Million of national currency units","LUX","Luxembourg","2020","2020",0.4,"D","Difference in methodology"
+"PATCACID","A02A-Antacids","MLLNCUMT","Million of national currency units","LUX","Luxembourg","2021","2021",0.4,"B; D; P","Break; Difference in methodology; Provisional value"
+"PATCACID","A02A-Antacids","MLLNCUMT","Million of national currency units","LUX","Luxembourg","2022","2022",0.3,"D; P","Difference in methodology; Provisional value"
+"PATCACID","A02A-Antacids","MTMOTCMT","Million US$ at exchange rate","LUX","Luxembourg","2010","2010",0.4,"D","Difference in methodology"
+"PATCACID","A02A-Antacids","MTMOTCMT","Million US$ at exchange rate","LUX","Luxembourg","2011","2011",0.4,"D","Difference in methodology"
+"PATCACID","A02A-Antacids","MTMOTCMT","Million US$ at exchange rate","LUX","Luxembourg","2012","2012",0.4,"D","Difference in methodology"
+"PATCACID","A02A-Antacids","MTMOTCMT","Million US$ at exchange rate","LUX","Luxembourg","2013","2013",0.4,"D","Difference in methodology"
+"PATCACID","A02A-Antacids","MTMOTCMT","Million US$ at exchange rate","LUX","Luxembourg","2014","2014",0.5,"D","Difference in methodology"
+"PATCACID","A02A-Antacids","MTMOTCMT","Million US$ at exchange rate","LUX","Luxembourg","2015","2015",0.4,"D","Difference in methodology"
+"PATCACID","A02A-Antacids","MTMOTCMT","Million US$ at exchange rate","LUX","Luxembourg","2016","2016",0.4,"D","Difference in methodology"
+"PATCACID","A02A-Antacids","MTMOTCMT","Million US$ at exchange rate","LUX","Luxembourg","2017","2017",0.4,"D","Difference in methodology"
+"PATCACID","A02A-Antacids","MTMOTCMT","Million US$ at exchange rate","LUX","Luxembourg","2018","2018",0.4,"D","Difference in methodology"
+"PATCACID","A02A-Antacids","MTMOTCMT","Million US$ at exchange rate","LUX","Luxembourg","2019","2019",0.4,"D","Difference in methodology"
+"PATCACID","A02A-Antacids","MTMOTCMT","Million US$ at exchange rate","LUX","Luxembourg","2020","2020",0.4,"D","Difference in methodology"
+"PATCACID","A02A-Antacids","MTMOTCMT","Million US$ at exchange rate","LUX","Luxembourg","2021","2021",0.4,"B; D; P","Break; Difference in methodology; Provisional value"
+"PATCACID","A02A-Antacids","MTMOTCMT","Million US$ at exchange rate","LUX","Luxembourg","2022","2022",0.3,"D; P","Difference in methodology; Provisional value"
+"PATCACID","A02A-Antacids","MTMOPPMT","Million US$, purchasing power parity","LUX","Luxembourg","2010","2010",0.3,"D","Difference in methodology"
+"PATCACID","A02A-Antacids","MTMOPPMT","Million US$, purchasing power parity","LUX","Luxembourg","2011","2011",0.3,"D","Difference in methodology"
+"PATCACID","A02A-Antacids","MTMOPPMT","Million US$, purchasing power parity","LUX","Luxembourg","2012","2012",0.4,"D","Difference in methodology"
+"PATCACID","A02A-Antacids","MTMOPPMT","Million US$, purchasing power parity","LUX","Luxembourg","2013","2013",0.4,"D","Difference in methodology"
+"PATCACID","A02A-Antacids","MTMOPPMT","Million US$, purchasing power parity","LUX","Luxembourg","2014","2014",0.4,"D","Difference in methodology"
+"PATCACID","A02A-Antacids","MTMOPPMT","Million US$, purchasing power parity","LUX","Luxembourg","2015","2015",0.4,"D","Difference in methodology"
+"PATCACID","A02A-Antacids","MTMOPPMT","Million US$, purchasing power parity","LUX","Luxembourg","2016","2016",0.4,"D","Difference in methodology"
+"PATCACID","A02A-Antacids","MTMOPPMT","Million US$, purchasing power parity","LUX","Luxembourg","2017","2017",0.4,"D","Difference in methodology"
+"PATCACID","A02A-Antacids","MTMOPPMT","Million US$, purchasing power parity","LUX","Luxembourg","2018","2018",0.4,"D","Difference in methodology"
+"PATCACID","A02A-Antacids","MTMOPPMT","Million US$, purchasing power parity","LUX","Luxembourg","2019","2019",0.5,"D","Difference in methodology"
+"PATCACID","A02A-Antacids","MTMOPPMT","Million US$, purchasing power parity","LUX","Luxembourg","2020","2020",0.4,"D","Difference in methodology"
+"PATCACID","A02A-Antacids","MTMOPPMT","Million US$, purchasing power parity","LUX","Luxembourg","2021","2021",0.4,"B; D; P","Break; Difference in methodology; Provisional value"
+"PATCACID","A02A-Antacids","MTMOPPMT","Million US$, purchasing power parity","LUX","Luxembourg","2022","2022",0.4,"D; P","Difference in methodology; Provisional value"
+"PATCACID","A02A-Antacids","TCPPERMT","/capita, US$ exchange rate","LUX","Luxembourg","2010","2010",0.8,"D","Difference in methodology"
+"PATCACID","A02A-Antacids","TCPPERMT","/capita, US$ exchange rate","LUX","Luxembourg","2011","2011",0.9,"D","Difference in methodology"
+"PATCACID","A02A-Antacids","TCPPERMT","/capita, US$ exchange rate","LUX","Luxembourg","2012","2012",0.9,"D","Difference in methodology"
+"PATCACID","A02A-Antacids","TCPPERMT","/capita, US$ exchange rate","LUX","Luxembourg","2013","2013",0.8,"D","Difference in methodology"
+"PATCACID","A02A-Antacids","TCPPERMT","/capita, US$ exchange rate","LUX","Luxembourg","2014","2014",0.9,"D","Difference in methodology"
+"PATCACID","A02A-Antacids","TCPPERMT","/capita, US$ exchange rate","LUX","Luxembourg","2015","2015",0.8,"D","Difference in methodology"
+"PATCACID","A02A-Antacids","TCPPERMT","/capita, US$ exchange rate","LUX","Luxembourg","2016","2016",0.8,"D","Difference in methodology"
+"PATCACID","A02A-Antacids","TCPPERMT","/capita, US$ exchange rate","LUX","Luxembourg","2017","2017",0.8,"D","Difference in methodology"
+"PATCACID","A02A-Antacids","TCPPERMT","/capita, US$ exchange rate","LUX","Luxembourg","2018","2018",0.8,"D","Difference in methodology"
+"PATCACID","A02A-Antacids","TCPPERMT","/capita, US$ exchange rate","LUX","Luxembourg","2019","2019",0.8,"D","Difference in methodology"
+"PATCACID","A02A-Antacids","TCPPERMT","/capita, US$ exchange rate","LUX","Luxembourg","2020","2020",0.8,"D","Difference in methodology"
+"PATCACID","A02A-Antacids","TCPPERMT","/capita, US$ exchange rate","LUX","Luxembourg","2021","2021",0.7,"B; D; P","Break; Difference in methodology; Provisional value"
+"PATCACID","A02A-Antacids","TCPPERMT","/capita, US$ exchange rate","LUX","Luxembourg","2022","2022",0.6,"D; P","Difference in methodology; Provisional value"
+"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2010","2010",0.6,"D","Difference in methodology"
+"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2011","2011",0.7,"D","Difference in methodology"
+"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2012","2012",0.8,"D","Difference in methodology"
+"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2013","2013",0.7,"D","Difference in methodology"
+"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2014","2014",0.8,"D","Difference in methodology"
+"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2015","2015",0.8,"D","Difference in methodology"
+"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2016","2016",0.8,"D","Difference in methodology"
+"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2017","2017",0.8,"D","Difference in methodology"
+"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2018","2018",0.8,"D","Difference in methodology"
+"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2019","2019",0.8,"D","Difference in methodology"
+"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2020","2020",0.8,"D","Difference in methodology"
+"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2021","2021",0.7,"B; D; P","Break; Difference in methodology; Provisional value"
+"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2022","2022",0.7,"D; P","Difference in methodology; Provisional value"
+"PATCACID","A02A-Antacids","ATCPTTMT","% of total sales","LUX","Luxembourg","2010","2010",0.1,"D","Difference in methodology"
+"PATCACID","A02A-Antacids","ATCPTTMT","% of total sales","LUX","Luxembourg","2011","2011",0.2,"D","Difference in methodology"
+"PATCACID","A02A-Antacids","ATCPTTMT","% of total sales","LUX","Luxembourg","2012","2012",0.2,"D","Difference in methodology"
+"PATCACID","A02A-Antacids","ATCPTTMT","% of total sales","LUX","Luxembourg","2013","2013",0.2,"D","Difference in methodology"
+"PATCACID","A02A-Antacids","ATCPTTMT","% of total sales","LUX","Luxembourg","2014","2014",0.2,"D","Difference in methodology"
+"PATCACID","A02A-Antacids","ATCPTTMT","% of total sales","LUX","Luxembourg","2015","2015",0.2,"D","Difference in methodology"
+"PATCACID","A02A-Antacids","ATCPTTMT","% of total sales","LUX","Luxembourg","2016","2016",0.2,"D","Difference in methodology"
+"PATCACID","A02A-Antacids","ATCPTTMT","% of total sales","LUX","Luxembourg","2017","2017",0.2,"D","Difference in methodology"
+"PATCACID","A02A-Antacids","ATCPTTMT","% of total sales","LUX","Luxembourg","2018","2018",0.2,"D","Difference in methodology"
+"PATCACID","A02A-Antacids","ATCPTTMT","% of total sales","LUX","Luxembourg","2019","2019",0.2,"D","Difference in methodology"
+"PATCACID","A02A-Antacids","ATCPTTMT","% of total sales","LUX","Luxembourg","2020","2020",0.2,"D","Difference in methodology"
+"PATCACID","A02A-Antacids","ATCPTTMT","% of total sales","LUX","Luxembourg","2021","2021",0.2,"B; D; P","Break; Difference in methodology; Provisional value"
+"PATCACID","A02A-Antacids","ATCPTTMT","% of total sales","LUX","Luxembourg","2022","2022",0.1,"D; P","Difference in methodology; Provisional value"
+"PATCACID","A02A-Antacids","MLLNCUMT","Million of national currency units","NLD","Netherlands","2010","2010",0,"D","Difference in methodology"
+"PATCACID","A02A-Antacids","MLLNCUMT","Million of national currency units","NLD","Netherlands","2011","2011",0,"D","Difference in methodology"
+"PATCACID","A02A-Antacids","MLLNCUMT","Million of national currency units","NLD","Netherlands","2012","2012",0,"D","Difference in methodology"
+"PATCACID","A02A-Antacids","MLLNCUMT","Million of national currency units","NLD","Netherlands","2013","2013",0,"D","Difference in methodology"
+"PATCACID","A02A-Antacids","MLLNCUMT","Million of national currency units","NLD","Netherlands","2014","2014",0,"D","Difference in methodology"
+"PATCACID","A02A-Antacids","MTMOTCMT","Million US$ at exchange rate","NLD","Netherlands","2010","2010",0,"D","Difference in methodology"
+"PATCACID","A02A-Antacids","MTMOTCMT","Million US$ at exchange rate","NLD","Netherlands","2011","2011",0,"D","Difference in methodology"
+"PATCACID","A02A-Antacids","MTMOTCMT","Million US$ at exchange rate","NLD","Netherlands","2012","2012",0,"D","Difference in methodology"
+"PATCACID","A02A-Antacids","MTMOTCMT","Million US$ at exchange rate","NLD","Netherlands","2013","2013",0,"D","Difference in methodology"
+"PATCACID","A02A-Antacids","MTMOTCMT","Million US$ at exchange rate","NLD","Netherlands","2014","2014",0,"D","Difference in methodology"
+"PATCACID","A02A-Antacids","MTMOPPMT","Million US$, purchasing power parity","NLD","Netherlands","2010","2010",0,"D","Difference in methodology"
+"PATCACID","A02A-Antacids","MTMOPPMT","Million US$, purchasing power parity","NLD","Netherlands","2011","2011",0,"D","Difference in methodology"
+"PATCACID","A02A-Antacids","MTMOPPMT","Million US$, purchasing power parity","NLD","Netherlands","2012","2012",0,"D","Difference in methodology"
+"PATCACID","A02A-Antacids","MTMOPPMT","Million US$, purchasing power parity","NLD","Netherlands","2013","2013",0,"D","Difference in methodology"
+"PATCACID","A02A-Antacids","MTMOPPMT","Million US$, purchasing power parity","NLD","Netherlands","2014","2014",0,"D","Difference in methodology"
+"PATCACID","A02A-Antacids","TCPPERMT","/capita, US$ exchange rate","NLD","Netherlands","2010","2010",0,"D","Difference in methodology"
+"PATCACID","A02A-Antacids","TCPPERMT","/capita, US$ exchange rate","NLD","Netherlands","2011","2011",0,"D","Difference in methodology"
+"PATCACID","A02A-Antacids","TCPPERMT","/capita, US$ exchange rate","NLD","Netherlands","2012","2012",0,"D","Difference in methodology"
+"PATCACID","A02A-Antacids","TCPPERMT","/capita, US$ exchange rate","NLD","Netherlands","2013","2013",0,"D","Difference in methodology"
+"PATCACID","A02A-Antacids","TCPPERMT","/capita, US$ exchange rate","NLD","Netherlands","2014","2014",0,"D","Difference in methodology"
+"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","NLD","Netherlands","2010","2010",0,"D","Difference in methodology"
+"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","NLD","Netherlands","2011","2011",0,"D","Difference in methodology"
+"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","NLD","Netherlands","2012","2012",0,"D","Difference in methodology"
+"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","NLD","Netherlands","2013","2013",0,"D","Difference in methodology"
+"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","NLD","Netherlands","2014","2014",0,"D","Difference in methodology"
+"PATCACID","A02A-Antacids","ATCPTTMT","% of total sales","NLD","Netherlands","2010","2010",0,"D","Difference in methodology"
+"PATCACID","A02A-Antacids","ATCPTTMT","% of total sales","NLD","Netherlands","2011","2011",0,"D","Difference in methodology"
+"PATCACID","A02A-Antacids","ATCPTTMT","% of total sales","NLD","Netherlands","2012","2012",0,"D","Difference in methodology"
+"PATCACID","A02A-Antacids","ATCPTTMT","% of total sales","NLD","Netherlands","2013","2013",0,"D","Difference in methodology"
+"PATCACID","A02A-Antacids","ATCPTTMT","% of total sales","NLD","Netherlands","2014","2014",0,"D","Difference in methodology"
+"PATCACID","A02A-Antacids","MLLNCUMT","Million of national currency units","NZL","New Zealand","2010","2010",0.2,"D","Difference in methodology"
+"PATCACID","A02A-Antacids","MLLNCUMT","Million of national currency units","NZL","New Zealand","2011","2011",0.3,"D","Difference in methodology"
+"PATCACID","A02A-Antacids","MLLNCUMT","Million of national currency units","NZL","New Zealand","2012","2012",0.3,"D","Difference in methodology"
+"PATCACID","A02A-Antacids","MLLNCUMT","Million of national currency units","NZL","New Zealand","2013","2013",0.3,"D","Difference in methodology"
+"PATCACID","A02A-Antacids","MLLNCUMT","Million of national currency units","NZL","New Zealand","2014","2014",0.3,"D","Difference in methodology"
+"PATCACID","A02A-Antacids","MLLNCUMT","Million of national currency units","NZL","New Zealand","2015","2015",0.4,"D","Difference in methodology"
+"PATCACID","A02A-Antacids","MLLNCUMT","Million of national currency units","NZL","New Zealand","2016","2016",0.4,"D","Difference in methodology"
+"PATCACID","A02A-Antacids","MLLNCUMT","Million of national currency units","NZL","New Zealand","2017","2017",0.3,"D","Difference in methodology"
+"PATCACID","A02A-Antacids","MLLNCUMT","Million of national currency units","NZL","New Zealand","2018","2018",0.3,"D","Difference in methodology"
+"PATCACID","A02A-Antacids","MLLNCUMT","Million of national currency units","NZL","New Zealand","2019","2019",0.3,"D","Difference in methodology"
+"PATCACID","A02A-Antacids","MLLNCUMT","Million of national currency units","NZL","New Zealand","2020","2020",0.3,"D","Difference in methodology"
+"PATCACID","A02A-Antacids","MLLNCUMT","Million of national currency units","NZL","New Zealand","2021","2021",0.3,"D","Difference in methodology"
+"PATCACID","A02A-Antacids","MLLNCUMT","Million of national currency units","NZL","New Zealand","2022","2022",0.6,"D","Difference in methodology"
+"PATCACID","A02A-Antacids","MTMOTCMT","Million US$ at exchange rate","NZL","New Zealand","2010","2010",0.2,"D","Difference in methodology"
+"PATCACID","A02A-Antacids","MTMOTCMT","Million US$ at exchange rate","NZL","New Zealand","2011","2011",0.2,"D","Difference in methodology"
+"PATCACID","A02A-Antacids","MTMOTCMT","Million US$ at exchange rate","NZL","New Zealand","2012","2012",0.2,"D","Difference in methodology"
+"PATCACID","A02A-Antacids","MTMOTCMT","Million US$ at exchange rate","NZL","New Zealand","2013","2013",0.2,"D","Difference in methodology"
+"PATCACID","A02A-Antacids","MTMOTCMT","Million US$ at exchange rate","NZL","New Zealand","2014","2014",0.2,"D","Difference in methodology"
+"PATCACID","A02A-Antacids","MTMOTCMT","Million US$ at exchange rate","NZL","New Zealand","2015","2015",0.3,"D","Difference in methodology"
+"PATCACID","A02A-Antacids","MTMOTCMT","Million US$ at exchange rate","NZL","New Zealand","2016","2016",0.3,"D","Difference in methodology"
+"PATCACID","A02A-Antacids","MTMOTCMT","Million US$ at exchange rate","NZL","New Zealand","2017","2017",0.2,"D","Difference in methodology"
+"PATCACID","A02A-Antacids","MTMOTCMT","Million US$ at exchange rate","NZL","New Zealand","2018","2018",0.2,"D","Difference in methodology"
+"PATCACID","A02A-Antacids","MTMOTCMT","Million US$ at exchange rate","NZL","New Zealand","2019","2019",0.2,"D","Difference in methodology"
+"PATCACID","A02A-Antacids","MTMOTCMT","Million US$ at exchange rate","NZL","New Zealand","2020","2020",0.2,"D","Difference in methodology"
+"PATCACID","A02A-Antacids","MTMOTCMT","Million US$ at exchange rate","NZL","New Zealand","2021","2021",0.2,"D","Difference in methodology"
+"PATCACID","A02A-Antacids","MTMOTCMT","Million US$ at exchange rate","NZL","New Zealand","2022","2022",0.4,"D","Difference in methodology"
+"PATCACID","A02A-Antacids","MTMOPPMT","Million US$, purchasing power parity","NZL","New Zealand","2010","2010",0.2,"D","Difference in methodology"
+"PATCACID","A02A-Antacids","MTMOPPMT","Million US$, purchasing power parity","NZL","New Zealand","2011","2011",0.2,"D","Difference in methodology"
+"PATCACID","A02A-Antacids","MTMOPPMT","Million US$, purchasing power parity","NZL","New Zealand","2012","2012",0.2,"D","Difference in methodology"
+"PATCACID","A02A-Antacids","MTMOPPMT","Million US$, purchasing power parity","NZL","New Zealand","2013","2013",0.2,"D","Difference in methodology"
+"PATCACID","A02A-Antacids","MTMOPPMT","Million US$, purchasing power parity","NZL","New Zealand","2014","2014",0.2,"D","Difference in methodology"
+"PATCACID","A02A-Antacids","MTMOPPMT","Million US$, purchasing power parity","NZL","New Zealand","2015","2015",0.3,"D","Difference in methodology"
+"PATCACID","A02A-Antacids","MTMOPPMT","Million US$, purchasing power parity","NZL","New Zealand","2016","2016",0.3,"D","Difference in methodology"
+"PATCACID","A02A-Antacids","MTMOPPMT","Million US$, purchasing power parity","NZL","New Zealand","2017","2017",0.2,"D","Difference in methodology"
+"PATCACID","A02A-Antacids","MTMOPPMT","Million US$, purchasing power parity","NZL","New Zealand","2018","2018",0.2,"D","Difference in methodology"
+"PATCACID","A02A-Antacids","MTMOPPMT","Million US$, purchasing power parity","NZL","New Zealand","2019","2019",0.2,"D","Difference in methodology"
+"PATCACID","A02A-Antacids","MTMOPPMT","Million US$, purchasing power parity","NZL","New Zealand","2020","2020",0.2,"D","Difference in methodology"
+"PATCACID","A02A-Antacids","MTMOPPMT","Million US$, purchasing power parity","NZL","New Zealand","2021","2021",0.2,"D","Difference in methodology"
+"PATCACID","A02A-Antacids","MTMOPPMT","Million US$, purchasing power parity","NZL","New Zealand","2022","2022",0.4,"D","Difference in methodology"
+"PATCACID","A02A-Antacids","TCPPERMT","/capita, US$ exchange rate","NZL","New Zealand","2010","2010",0,"D","Difference in methodology"
+"PATCACID","A02A-Antacids","TCPPERMT","/capita, US$ exchange rate","NZL","New Zealand","2011","2011",0,"D","Difference in methodology"
+"PATCACID","A02A-Antacids","TCPPERMT","/capita, US$ exchange rate","NZL","New Zealand","2012","2012",0.1,"D","Difference in methodology"
+"PATCACID","A02A-Antacids","TCPPERMT","/capita, US$ exchange rate","NZL","New Zealand","2013","2013",0.1,"D","Difference in methodology"
+"PATCACID","A02A-Antacids","TCPPERMT","/capita, US$ exchange rate","NZL","New Zealand","2014","2014",0.1,"D","Difference in methodology"
+"PATCACID","A02A-Antacids","TCPPERMT","/capita, US$ exchange rate","NZL","New Zealand","2015","2015",0.1,"D","Difference in methodology"
+"PATCACID","A02A-Antacids","TCPPERMT","/capita, US$ exchange rate","NZL","New Zealand","2016","2016",0.1,"D","Difference in methodology"
+"PATCACID","A02A-Antacids","TCPPERMT","/capita, US$ exchange rate","NZL","New Zealand","2017","2017",0,"D","Difference in methodology"
+"PATCACID","A02A-Antacids","TCPPERMT","/capita, US$ exchange rate","NZL","New Zealand","2018","2018",0,"D","Difference in methodology"
+"PATCACID","A02A-Antacids","TCPPERMT","/capita, US$ exchange rate","NZL","New Zealand","2019","2019",0,"D","Difference in methodology"
+"PATCACID","A02A-Antacids","TCPPERMT","/capita, US$ exchange rate","NZL","New Zealand","2020","2020",0,"D","Difference in methodology"
+"PATCACID","A02A-Antacids","TCPPERMT","/capita, US$ exchange rate","NZL","New Zealand","2021","2021",0,"D","Difference in methodology"
+"PATCACID","A02A-Antacids","TCPPERMT","/capita, US$ exchange rate","NZL","New Zealand","2022","2022",0.1,"D","Difference in methodology"
+"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2010","2010",0,"D","Difference in methodology"
+"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2011","2011",0,"D","Difference in methodology"
+"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2012","2012",0,"D","Difference in methodology"
+"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2013","2013",0,"D","Difference in methodology"
+"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2014","2014",0,"D","Difference in methodology"
+"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2015","2015",0.1,"D","Difference in methodology"
+"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2016","2016",0.1,"D","Difference in methodology"
+"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2017","2017",0,"D","Difference in methodology"
+"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2018","2018",0,"D","Difference in methodology"
+"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2019","2019",0,"D","Difference in methodology"
+"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2020","2020",0,"D","Difference in methodology"
+"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2021","2021",0,"D","Difference in methodology"
+"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2022","2022",0.1,"D","Difference in methodology"
+"PATCACID","A02A-Antacids","ATCPTTMT","% of total sales","NZL","New Zealand","2010","2010",0,"D","Difference in methodology"
+"PATCACID","A02A-Antacids","ATCPTTMT","% of total sales","NZL","New Zealand","2011","2011",0,"D","Difference in methodology"
+"PATCACID","A02A-Antacids","ATCPTTMT","% of total sales","NZL","New Zealand","2012","2012",0,"D","Difference in methodology"
+"PATCACID","A02A-Antacids","ATCPTTMT","% of total sales","NZL","New Zealand","2013","2013",0,"D","Difference in methodology"
+"PATCACID","A02A-Antacids","ATCPTTMT","% of total sales","NZL","New Zealand","2014","2014",0,"D","Difference in methodology"
+"PATCACID","A02A-Antacids","ATCPTTMT","% of total sales","NZL","New Zealand","2015","2015",0,"D","Difference in methodology"
+"PATCACID","A02A-Antacids","ATCPTTMT","% of total sales","NZL","New Zealand","2016","2016",0,"D","Difference in methodology"
+"PATCACID","A02A-Antacids","ATCPTTMT","% of total sales","NZL","New Zealand","2017","2017",0,"D","Difference in methodology"
+"PATCACID","A02A-Antacids","ATCPTTMT","% of total sales","NZL","New Zealand","2018","2018",0,"D","Difference in methodology"
+"PATCACID","A02A-Antacids","ATCPTTMT","% of total sales","NZL","New Zealand","2019","2019",0,"D","Difference in methodology"
+"PATCACID","A02A-Antacids","ATCPTTMT","% of total sales","NZL","New Zealand","2020","2020",0,"D","Difference in methodology"
+"PATCACID","A02A-Antacids","ATCPTTMT","% of total sales","NZL","New Zealand","2021","2021",0,"D","Difference in methodology"
+"PATCACID","A02A-Antacids","ATCPTTMT","% of total sales","NZL","New Zealand","2022","2022",0,"D","Difference in methodology"
+"PATCACID","A02A-Antacids","MLLNCUMT","Million of national currency units","NOR","Norway","2010","2010",28,,
+"PATCACID","A02A-Antacids","MLLNCUMT","Million of national currency units","NOR","Norway","2011","2011",28,,
+"PATCACID","A02A-Antacids","MLLNCUMT","Million of national currency units","NOR","Norway","2012","2012",28,,
+"PATCACID","A02A-Antacids","MLLNCUMT","Million of national currency units","NOR","Norway","2013","2013",29,,
+"PATCACID","A02A-Antacids","MLLNCUMT","Million of national currency units","NOR","Norway","2014","2014",28,,
+"PATCACID","A02A-Antacids","MLLNCUMT","Million of national currency units","NOR","Norway","2015","2015",28,,
+"PATCACID","A02A-Antacids","MLLNCUMT","Million of national currency units","NOR","Norway","2016","2016",30,,
+"PATCACID","A02A-Antacids","MLLNCUMT","Million of national currency units","NOR","Norway","2017","2017",29,,
+"PATCACID","A02A-Antacids","MLLNCUMT","Million of national currency units","NOR","Norway","2018","2018",28,,
+"PATCACID","A02A-Antacids","MLLNCUMT","Million of national currency units","NOR","Norway","2019","2019",29,,
+"PATCACID","A02A-Antacids","MLLNCUMT","Million of national currency units","NOR","Norway","2020","2020",33,,
+"PATCACID","A02A-Antacids","MLLNCUMT","Million of national currency units","NOR","Norway","2021","2021",36,,
+"PATCACID","A02A-Antacids","MLLNCUMT","Million of national currency units","NOR","Norway","2022","2022",35,,
+"PATCACID","A02A-Antacids","MTMOTCMT","Million US$ at exchange rate","NOR","Norway","2010","2010",4.6,,
+"PATCACID","A02A-Antacids","MTMOTCMT","Million US$ at exchange rate","NOR","Norway","2011","2011",5,,
+"PATCACID","A02A-Antacids","MTMOTCMT","Million US$ at exchange rate","NOR","Norway","2012","2012",4.8,,
+"PATCACID","A02A-Antacids","MTMOTCMT","Million US$ at exchange rate","NOR","Norway","2013","2013",4.9,,
+"PATCACID","A02A-Antacids","MTMOTCMT","Million US$ at exchange rate","NOR","Norway","2014","2014",4.4,,
+"PATCACID","A02A-Antacids","MTMOTCMT","Million US$ at exchange rate","NOR","Norway","2015","2015",3.5,,
+"PATCACID","A02A-Antacids","MTMOTCMT","Million US$ at exchange rate","NOR","Norway","2016","2016",3.6,,
+"PATCACID","A02A-Antacids","MTMOTCMT","Million US$ at exchange rate","NOR","Norway","2017","2017",3.5,,
+"PATCACID","A02A-Antacids","MTMOTCMT","Million US$ at exchange rate","NOR","Norway","2018","2018",3.4,,
+"PATCACID","A02A-Antacids","MTMOTCMT","Million US$ at exchange rate","NOR","Norway","2019","2019",3.3,,
+"PATCACID","A02A-Antacids","MTMOTCMT","Million US$ at exchange rate","NOR","Norway","2020","2020",3.5,,
+"PATCACID","A02A-Antacids","MTMOTCMT","Million US$ at exchange rate","NOR","Norway","2021","2021",4.2,,
+"PATCACID","A02A-Antacids","MTMOTCMT","Million US$ at exchange rate","NOR","Norway","2022","2022",3.6,,
+"PATCACID","A02A-Antacids","MTMOPPMT","Million US$, purchasing power parity","NOR","Norway","2010","2010",3.1,,
+"PATCACID","A02A-Antacids","MTMOPPMT","Million US$, purchasing power parity","NOR","Norway","2011","2011",3.1,,
+"PATCACID","A02A-Antacids","MTMOPPMT","Million US$, purchasing power parity","NOR","Norway","2012","2012",3.1,,
+"PATCACID","A02A-Antacids","MTMOPPMT","Million US$, purchasing power parity","NOR","Norway","2013","2013",3.2,,
+"PATCACID","A02A-Antacids","MTMOPPMT","Million US$, purchasing power parity","NOR","Norway","2014","2014",3,,
+"PATCACID","A02A-Antacids","MTMOPPMT","Million US$, purchasing power parity","NOR","Norway","2015","2015",2.8,,
+"PATCACID","A02A-Antacids","MTMOPPMT","Million US$, purchasing power parity","NOR","Norway","2016","2016",3,,
+"PATCACID","A02A-Antacids","MTMOPPMT","Million US$, purchasing power parity","NOR","Norway","2017","2017",3,,
+"PATCACID","A02A-Antacids","MTMOPPMT","Million US$, purchasing power parity","NOR","Norway","2018","2018",2.9,,
+"PATCACID","A02A-Antacids","MTMOPPMT","Million US$, purchasing power parity","NOR","Norway","2019","2019",3,,
+"PATCACID","A02A-Antacids","MTMOPPMT","Million US$, purchasing power parity","NOR","Norway","2020","2020",3.3,,
+"PATCACID","A02A-Antacids","MTMOPPMT","Million US$, purchasing power parity","NOR","Norway","2021","2021",3.8,,
+"PATCACID","A02A-Antacids","MTMOPPMT","Million US$, purchasing power parity","NOR","Norway","2022","2022",3.3,,
+"PATCACID","A02A-Antacids","TCPPERMT","/capita, US$ exchange rate","NOR","Norway","2010","2010",0.9,,
+"PATCACID","A02A-Antacids","TCPPERMT","/capita, US$ exchange rate","NOR","Norway","2011","2011",1,,
+"PATCACID","A02A-Antacids","TCPPERMT","/capita, US$ exchange rate","NOR","Norway","2012","2012",1,,
+"PATCACID","A02A-Antacids","TCPPERMT","/capita, US$ exchange rate","NOR","Norway","2013","2013",1,,
+"PATCACID","A02A-Antacids","TCPPERMT","/capita, US$ exchange rate","NOR","Norway","2014","2014",0.9,,
+"PATCACID","A02A-Antacids","TCPPERMT","/capita, US$ exchange rate","NOR","Norway","2015","2015",0.7,,
+"PATCACID","A02A-Antacids","TCPPERMT","/capita, US$ exchange rate","NOR","Norway","2016","2016",0.7,,
+"PATCACID","A02A-Antacids","TCPPERMT","/capita, US$ exchange rate","NOR","Norway","2017","2017",0.7,,
+"PATCACID","A02A-Antacids","TCPPERMT","/capita, US$ exchange rate","NOR","Norway","2018","2018",0.6,,
+"PATCACID","A02A-Antacids","TCPPERMT","/capita, US$ exchange rate","NOR","Norway","2019","2019",0.6,,
+"PATCACID","A02A-Antacids","TCPPERMT","/capita, US$ exchange rate","NOR","Norway","2020","2020",0.7,,
+"PATCACID","A02A-Antacids","TCPPERMT","/capita, US$ exchange rate","NOR","Norway","2021","2021",0.8,,
+"PATCACID","A02A-Antacids","TCPPERMT","/capita, US$ exchange rate","NOR","Norway","2022","2022",0.7,,
+"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2010","2010",0.6,,
+"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2011","2011",0.6,,
+"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2012","2012",0.6,,
+"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2013","2013",0.6,,
+"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2014","2014",0.6,,
+"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2015","2015",0.5,,
+"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2016","2016",0.6,,
+"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2017","2017",0.6,,
+"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2018","2018",0.5,,
+"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2019","2019",0.6,,
+"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2020","2020",0.6,,
+"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2021","2021",0.7,,
+"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2022","2022",0.6,,
+"PATCACID","A02A-Antacids","ATCPTTMT","% of total sales","NOR","Norway","2010","2010",0.2,,
+"PATCACID","A02A-Antacids","ATCPTTMT","% of total sales","NOR","Norway","2011","2011",0.2,,
+"PATCACID","A02A-Antacids","ATCPTTMT","% of total sales","NOR","Norway","2012","2012",0.1,,
+"PATCACID","A02A-Antacids","ATCPTTMT","% of total sales","NOR","Norway","2013","2013",0.2,,
+"PATCACID","A02A-Antacids","ATCPTTMT","% of total sales","NOR","Norway","2014","2014",0.1,,
+"PATCACID","A02A-Antacids","ATCPTTMT","% of total sales","NOR","Norway","2015","2015",0.1,,
+"PATCACID","A02A-Antacids","ATCPTTMT","% of total sales","NOR","Norway","2016","2016",0.1,,
+"PATCACID","A02A-Antacids","ATCPTTMT","% of total sales","NOR","Norway","2017","2017",0.1,,
+"PATCACID","A02A-Antacids","ATCPTTMT","% of total sales","NOR","Norway","2018","2018",0.1,,
+"PATCACID","A02A-Antacids","ATCPTTMT","% of total sales","NOR","Norway","2019","2019",0.1,,
+"PATCACID","A02A-Antacids","ATCPTTMT","% of total sales","NOR","Norway","2020","2020",0.1,,
+"PATCACID","A02A-Antacids","ATCPTTMT","% of total sales","NOR","Norway","2021","2021",0.1,,
+"PATCACID","A02A-Antacids","ATCPTTMT","% of total sales","NOR","Norway","2022","2022",0.1,,
+"PATCACID","A02A-Antacids","MLLNCUMT","Million of national currency units","PRT","Portugal","2010","2010",6.4,"D","Difference in methodology"
+"PATCACID","A02A-Antacids","MLLNCUMT","Million of national currency units","PRT","Portugal","2011","2011",6,"D","Difference in methodology"
+"PATCACID","A02A-Antacids","MLLNCUMT","Million of national currency units","PRT","Portugal","2012","2012",6.1,"D","Difference in methodology"
+"PATCACID","A02A-Antacids","MLLNCUMT","Million of national currency units","PRT","Portugal","2013","2013",5.1,"D","Difference in methodology"
+"PATCACID","A02A-Antacids","MLLNCUMT","Million of national currency units","PRT","Portugal","2014","2014",4.7,"D","Difference in methodology"
+"PATCACID","A02A-Antacids","MLLNCUMT","Million of national currency units","PRT","Portugal","2015","2015",5.6,"D","Difference in methodology"
+"PATCACID","A02A-Antacids","MLLNCUMT","Million of national currency units","PRT","Portugal","2016","2016",5.3,"D","Difference in methodology"
+"PATCACID","A02A-Antacids","MLLNCUMT","Million of national currency units","PRT","Portugal","2017","2017",6,"D","Difference in methodology"
+"PATCACID","A02A-Antacids","MLLNCUMT","Million of national currency units","PRT","Portugal","2018","2018",5.8,"D","Difference in methodology"
+"PATCACID","A02A-Antacids","MLLNCUMT","Million of national currency units","PRT","Portugal","2019","2019",5.7,"D","Difference in methodology"
+"PATCACID","A02A-Antacids","MLLNCUMT","Million of national currency units","PRT","Portugal","2020","2020",5.7,"D","Difference in methodology"
+"PATCACID","A02A-Antacids","MLLNCUMT","Million of national currency units","PRT","Portugal","2021","2021",5.6,"D","Difference in methodology"
+"PATCACID","A02A-Antacids","MLLNCUMT","Million of national currency units","PRT","Portugal","2022","2022",5.4,"D","Difference in methodology"
+"PATCACID","A02A-Antacids","MTMOTCMT","Million US$ at exchange rate","PRT","Portugal","2010","2010",8.5,"D","Difference in methodology"
+"PATCACID","A02A-Antacids","MTMOTCMT","Million US$ at exchange rate","PRT","Portugal","2011","2011",8.4,"D","Difference in methodology"
+"PATCACID","A02A-Antacids","MTMOTCMT","Million US$ at exchange rate","PRT","Portugal","2012","2012",7.8,"D","Difference in methodology"
+"PATCACID","A02A-Antacids","MTMOTCMT","Million US$ at exchange rate","PRT","Portugal","2013","2013",6.8,"D","Difference in methodology"
+"PATCACID","A02A-Antacids","MTMOTCMT","Million US$ at exchange rate","PRT","Portugal","2014","2014",6.2,"D","Difference in methodology"
+"PATCACID","A02A-Antacids","MTMOTCMT","Million US$ at exchange rate","PRT","Portugal","2015","2015",6.2,"D","Difference in methodology"
+"PATCACID","A02A-Antacids","MTMOTCMT","Million US$ at exchange rate","PRT","Portugal","2016","2016",5.9,"D","Difference in methodology"
+"PATCACID","A02A-Antacids","MTMOTCMT","Million US$ at exchange rate","PRT","Portugal","2017","2017",6.8,"D","Difference in methodology"
+"PATCACID","A02A-Antacids","MTMOTCMT","Million US$ at exchange rate","PRT","Portugal","2018","2018",6.9,"D","Difference in methodology"
+"PATCACID","A02A-Antacids","MTMOTCMT","Million US$ at exchange rate","PRT","Portugal","2019","2019",6.4,"D","Difference in methodology"
+"PATCACID","A02A-Antacids","MTMOTCMT","Million US$ at exchange rate","PRT","Portugal","2020","2020",6.5,"D","Difference in methodology"
+"PATCACID","A02A-Antacids","MTMOTCMT","Million US$ at exchange rate","PRT","Portugal","2021","2021",6.6,"D","Difference in methodology"
+"PATCACID","A02A-Antacids","MTMOTCMT","Million US$ at exchange rate","PRT","Portugal","2022","2022",5.7,"D","Difference in methodology"
+"PATCACID","A02A-Antacids","MTMOPPMT","Million US$, purchasing power parity","PRT","Portugal","2010","2010",10.2,"D","Difference in methodology"
+"PATCACID","A02A-Antacids","MTMOPPMT","Million US$, purchasing power parity","PRT","Portugal","2011","2011",9.7,"D","Difference in methodology"
+"PATCACID","A02A-Antacids","MTMOPPMT","Million US$, purchasing power parity","PRT","Portugal","2012","2012",10,"D","Difference in methodology"
+"PATCACID","A02A-Antacids","MTMOPPMT","Million US$, purchasing power parity","PRT","Portugal","2013","2013",8.8,"D","Difference in methodology"
+"PATCACID","A02A-Antacids","MTMOPPMT","Million US$, purchasing power parity","PRT","Portugal","2014","2014",8.1,"D","Difference in methodology"
+"PATCACID","A02A-Antacids","MTMOPPMT","Million US$, purchasing power parity","PRT","Portugal","2015","2015",9.6,"D","Difference in methodology"
+"PATCACID","A02A-Antacids","MTMOPPMT","Million US$, purchasing power parity","PRT","Portugal","2016","2016",9.3,"D","Difference in methodology"
+"PATCACID","A02A-Antacids","MTMOPPMT","Million US$, purchasing power parity","PRT","Portugal","2017","2017",10.5,"D","Difference in methodology"
+"PATCACID","A02A-Antacids","MTMOPPMT","Million US$, purchasing power parity","PRT","Portugal","2018","2018",10.2,"D","Difference in methodology"
+"PATCACID","A02A-Antacids","MTMOPPMT","Million US$, purchasing power parity","PRT","Portugal","2019","2019",10.2,"D","Difference in methodology"
+"PATCACID","A02A-Antacids","MTMOPPMT","Million US$, purchasing power parity","PRT","Portugal","2020","2020",10.2,"D","Difference in methodology"
+"PATCACID","A02A-Antacids","MTMOPPMT","Million US$, purchasing power parity","PRT","Portugal","2021","2021",9.9,"D","Difference in methodology"
+"PATCACID","A02A-Antacids","MTMOPPMT","Million US$, purchasing power parity","PRT","Portugal","2022","2022",9.8,"D","Difference in methodology"
+"PATCACID","A02A-Antacids","TCPPERMT","/capita, US$ exchange rate","PRT","Portugal","2010","2010",0.8,"D","Difference in methodology"
+"PATCACID","A02A-Antacids","TCPPERMT","/capita, US$ exchange rate","PRT","Portugal","2011","2011",0.8,"D","Difference in methodology"
+"PATCACID","A02A-Antacids","TCPPERMT","/capita, US$ exchange rate","PRT","Portugal","2012","2012",0.7,"D","Difference in methodology"
+"PATCACID","A02A-Antacids","TCPPERMT","/capita, US$ exchange rate","PRT","Portugal","2013","2013",0.7,"D","Difference in methodology"
+"PATCACID","A02A-Antacids","TCPPERMT","/capita, US$ exchange rate","PRT","Portugal","2014","2014",0.6,"D","Difference in methodology"
+"PATCACID","A02A-Antacids","TCPPERMT","/capita, US$ exchange rate","PRT","Portugal","2015","2015",0.6,"D","Difference in methodology"
+"PATCACID","A02A-Antacids","TCPPERMT","/capita, US$ exchange rate","PRT","Portugal","2016","2016",0.6,"D","Difference in methodology"
+"PATCACID","A02A-Antacids","TCPPERMT","/capita, US$ exchange rate","PRT","Portugal","2017","2017",0.7,"D","Difference in methodology"
+"PATCACID","A02A-Antacids","TCPPERMT","/capita, US$ exchange rate","PRT","Portugal","2018","2018",0.7,"D","Difference in methodology"
+"PATCACID","A02A-Antacids","TCPPERMT","/capita, US$ exchange rate","PRT","Portugal","2019","2019",0.6,"D","Difference in methodology"
+"PATCACID","A02A-Antacids","TCPPERMT","/capita, US$ exchange rate","PRT","Portugal","2020","2020",0.6,"D","Difference in methodology"
+"PATCACID","A02A-Antacids","TCPPERMT","/capita, US$ exchange rate","PRT","Portugal","2021","2021",0.6,"D","Difference in methodology"
+"PATCACID","A02A-Antacids","TCPPERMT","/capita, US$ exchange rate","PRT","Portugal","2022","2022",0.5,"D","Difference in methodology"
+"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2010","2010",1,"D","Difference in methodology"
+"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2011","2011",0.9,"D","Difference in methodology"
+"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2012","2012",1,"D","Difference in methodology"
+"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2013","2013",0.8,"D","Difference in methodology"
+"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2014","2014",0.8,"D","Difference in methodology"
+"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2015","2015",0.9,"D","Difference in methodology"
+"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2016","2016",0.9,"D","Difference in methodology"
+"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2017","2017",1,"D","Difference in methodology"
+"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2018","2018",1,"D","Difference in methodology"
+"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2019","2019",1,"D","Difference in methodology"
+"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2020","2020",1,"D","Difference in methodology"
+"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2021","2021",1,"D","Difference in methodology"
+"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2022","2022",0.9,"D","Difference in methodology"
+"PATCACID","A02A-Antacids","ATCPTTMT","% of total sales","PRT","Portugal","2010","2010",0.2,"D","Difference in methodology"
+"PATCACID","A02A-Antacids","ATCPTTMT","% of total sales","PRT","Portugal","2011","2011",0.2,"D","Difference in methodology"
+"PATCACID","A02A-Antacids","ATCPTTMT","% of total sales","PRT","Portugal","2012","2012",0.2,"D","Difference in methodology"
+"PATCACID","A02A-Antacids","ATCPTTMT","% of total sales","PRT","Portugal","2013","2013",0.2,"D","Difference in methodology"
+"PATCACID","A02A-Antacids","ATCPTTMT","% of total sales","PRT","Portugal","2014","2014",0.2,"D","Difference in methodology"
+"PATCACID","A02A-Antacids","ATCPTTMT","% of total sales","PRT","Portugal","2015","2015",0.2,"D","Difference in methodology"
+"PATCACID","A02A-Antacids","ATCPTTMT","% of total sales","PRT","Portugal","2016","2016",0.2,"D","Difference in methodology"
+"PATCACID","A02A-Antacids","ATCPTTMT","% of total sales","PRT","Portugal","2017","2017",0.2,"D","Difference in methodology"
+"PATCACID","A02A-Antacids","ATCPTTMT","% of total sales","PRT","Portugal","2018","2018",0.2,"D","Difference in methodology"
+"PATCACID","A02A-Antacids","ATCPTTMT","% of total sales","PRT","Portugal","2019","2019",0.2,"D","Difference in methodology"
+"PATCACID","A02A-Antacids","ATCPTTMT","% of total sales","PRT","Portugal","2020","2020",0.2,"D","Difference in methodology"
+"PATCACID","A02A-Antacids","ATCPTTMT","% of total sales","PRT","Portugal","2021","2021",0.2,"D","Difference in methodology"
+"PATCACID","A02A-Antacids","ATCPTTMT","% of total sales","PRT","Portugal","2022","2022",0.2,"D","Difference in methodology"
+"PATCACID","A02A-Antacids","MLLNCUMT","Million of national currency units","SVK","Slovak Republic","2010","2010",0.7,,
+"PATCACID","A02A-Antacids","MLLNCUMT","Million of national currency units","SVK","Slovak Republic","2011","2011",0.8,,
+"PATCACID","A02A-Antacids","MLLNCUMT","Million of national currency units","SVK","Slovak Republic","2012","2012",0.7,,
+"PATCACID","A02A-Antacids","MLLNCUMT","Million of national currency units","SVK","Slovak Republic","2013","2013",0.8,,
+"PATCACID","A02A-Antacids","MLLNCUMT","Million of national currency units","SVK","Slovak Republic","2014","2014",0.8,,
+"PATCACID","A02A-Antacids","MLLNCUMT","Million of national currency units","SVK","Slovak Republic","2015","2015",0.7,,
+"PATCACID","A02A-Antacids","MLLNCUMT","Million of national currency units","SVK","Slovak Republic","2016","2016",0.9,"B","Break"
+"PATCACID","A02A-Antacids","MLLNCUMT","Million of national currency units","SVK","Slovak Republic","2017","2017",0,,
+"PATCACID","A02A-Antacids","MLLNCUMT","Million of national currency units","SVK","Slovak Republic","2018","2018",0.8,,
+"PATCACID","A02A-Antacids","MLLNCUMT","Million of national currency units","SVK","Slovak Republic","2019","2019",0.8,,
+"PATCACID","A02A-Antacids","MLLNCUMT","Million of national currency units","SVK","Slovak Republic","2020","2020",0.8,,
+"PATCACID","A02A-Antacids","MLLNCUMT","Million of national currency units","SVK","Slovak Republic","2021","2021",0.9,,
+"PATCACID","A02A-Antacids","MTMOTCMT","Million US$ at exchange rate","SVK","Slovak Republic","2010","2010",1,,
+"PATCACID","A02A-Antacids","MTMOTCMT","Million US$ at exchange rate","SVK","Slovak Republic","2011","2011",1.1,,
+"PATCACID","A02A-Antacids","MTMOTCMT","Million US$ at exchange rate","SVK","Slovak Republic","2012","2012",0.9,,
+"PATCACID","A02A-Antacids","MTMOTCMT","Million US$ at exchange rate","SVK","Slovak Republic","2013","2013",1,,
+"PATCACID","A02A-Antacids","MTMOTCMT","Million US$ at exchange rate","SVK","Slovak Republic","2014","2014",1,,
+"PATCACID","A02A-Antacids","MTMOTCMT","Million US$ at exchange rate","SVK","Slovak Republic","2015","2015",0.8,,
+"PATCACID","A02A-Antacids","MTMOTCMT","Million US$ at exchange rate","SVK","Slovak Republic","2016","2016",1,"B","Break"
+"PATCACID","A02A-Antacids","MTMOTCMT","Million US$ at exchange rate","SVK","Slovak Republic","2017","2017",0,,
+"PATCACID","A02A-Antacids","MTMOTCMT","Million US$ at exchange rate","SVK","Slovak Republic","2018","2018",1,,
+"PATCACID","A02A-Antacids","MTMOTCMT","Million US$ at exchange rate","SVK","Slovak Republic","2019","2019",0.9,,
+"PATCACID","A02A-Antacids","MTMOTCMT","Million US$ at exchange rate","SVK","Slovak Republic","2020","2020",1,,
+"PATCACID","A02A-Antacids","MTMOTCMT","Million US$ at exchange rate","SVK","Slovak Republic","2021","2021",1.1,,
+"PATCACID","A02A-Antacids","MTMOPPMT","Million US$, purchasing power parity","SVK","Slovak Republic","2010","2010",1.5,,
+"PATCACID","A02A-Antacids","MTMOPPMT","Million US$, purchasing power parity","SVK","Slovak Republic","2011","2011",1.5,,
+"PATCACID","A02A-Antacids","MTMOPPMT","Million US$, purchasing power parity","SVK","Slovak Republic","2012","2012",1.4,,
+"PATCACID","A02A-Antacids","MTMOPPMT","Million US$, purchasing power parity","SVK","Slovak Republic","2013","2013",1.6,,
+"PATCACID","A02A-Antacids","MTMOPPMT","Million US$, purchasing power parity","SVK","Slovak Republic","2014","2014",1.6,,
+"PATCACID","A02A-Antacids","MTMOPPMT","Million US$, purchasing power parity","SVK","Slovak Republic","2015","2015",1.5,,
+"PATCACID","A02A-Antacids","MTMOPPMT","Million US$, purchasing power parity","SVK","Slovak Republic","2016","2016",1.8,"B","Break"
+"PATCACID","A02A-Antacids","MTMOPPMT","Million US$, purchasing power parity","SVK","Slovak Republic","2017","2017",0,,
+"PATCACID","A02A-Antacids","MTMOPPMT","Million US$, purchasing power parity","SVK","Slovak Republic","2018","2018",1.6,,
+"PATCACID","A02A-Antacids","MTMOPPMT","Million US$, purchasing power parity","SVK","Slovak Republic","2019","2019",1.6,,
+"PATCACID","A02A-Antacids","MTMOPPMT","Million US$, purchasing power parity","SVK","Slovak Republic","2020","2020",1.6,,
+"PATCACID","A02A-Antacids","MTMOPPMT","Million US$, purchasing power parity","SVK","Slovak Republic","2021","2021",1.8,,
+"PATCACID","A02A-Antacids","TCPPERMT","/capita, US$ exchange rate","SVK","Slovak Republic","2010","2010",0.2,,
+"PATCACID","A02A-Antacids","TCPPERMT","/capita, US$ exchange rate","SVK","Slovak Republic","2011","2011",0.2,,
+"PATCACID","A02A-Antacids","TCPPERMT","/capita, US$ exchange rate","SVK","Slovak Republic","2012","2012",0.2,,
+"PATCACID","A02A-Antacids","TCPPERMT","/capita, US$ exchange rate","SVK","Slovak Republic","2013","2013",0.2,,
+"PATCACID","A02A-Antacids","TCPPERMT","/capita, US$ exchange rate","SVK","Slovak Republic","2014","2014",0.2,,
+"PATCACID","A02A-Antacids","TCPPERMT","/capita, US$ exchange rate","SVK","Slovak Republic","2015","2015",0.2,,
+"PATCACID","A02A-Antacids","TCPPERMT","/capita, US$ exchange rate","SVK","Slovak Republic","2016","2016",0.2,"B","Break"
+"PATCACID","A02A-Antacids","TCPPERMT","/capita, US$ exchange rate","SVK","Slovak Republic","2017","2017",0,,
+"PATCACID","A02A-Antacids","TCPPERMT","/capita, US$ exchange rate","SVK","Slovak Republic","2018","2018",0.2,,
+"PATCACID","A02A-Antacids","TCPPERMT","/capita, US$ exchange rate","SVK","Slovak Republic","2019","2019",0.2,,
+"PATCACID","A02A-Antacids","TCPPERMT","/capita, US$ exchange rate","SVK","Slovak Republic","2020","2020",0.2,,
+"PATCACID","A02A-Antacids","TCPPERMT","/capita, US$ exchange rate","SVK","Slovak Republic","2021","2021",0.2,,
+"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2010","2010",0.3,,
+"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2011","2011",0.3,,
+"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2012","2012",0.3,,
+"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2013","2013",0.3,,
+"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2014","2014",0.3,,
+"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2015","2015",0.3,,
+"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2016","2016",0.3,"B","Break"
+"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2017","2017",0,,
+"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2018","2018",0.3,,
+"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2019","2019",0.3,,
+"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2020","2020",0.3,,
+"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2021","2021",0.3,,
+"PATCACID","A02A-Antacids","ATCPTTMT","% of total sales","SVK","Slovak Republic","2010","2010",0.1,"D","Difference in methodology"
+"PATCACID","A02A-Antacids","ATCPTTMT","% of total sales","SVK","Slovak Republic","2011","2011",0.1,"D","Difference in methodology"
+"PATCACID","A02A-Antacids","ATCPTTMT","% of total sales","SVK","Slovak Republic","2012","2012",0.1,"D","Difference in methodology"
+"PATCACID","A02A-Antacids","ATCPTTMT","% of total sales","SVK","Slovak Republic","2013","2013",0.1,"D","Difference in methodology"
+"PATCACID","A02A-Antacids","ATCPTTMT","% of total sales","SVK","Slovak Republic","2014","2014",0.1,"D","Difference in methodology"
+"PATCACID","A02A-Antacids","ATCPTTMT","% of total sales","SVK","Slovak Republic","2015","2015",0.1,"D","Difference in methodology"
+"PATCACID","A02A-Antacids","ATCPTTMT","% of total sales","SVK","Slovak Republic","2016","2016",0.1,"B","Break"
+"PATCACID","A02A-Antacids","ATCPTTMT","% of total sales","SVK","Slovak Republic","2017","2017",0,,
+"PATCACID","A02A-Antacids","ATCPTTMT","% of total sales","SVK","Slovak Republic","2018","2018",0.1,,
+"PATCACID","A02A-Antacids","ATCPTTMT","% of total sales","SVK","Slovak Republic","2019","2019",0,,
+"PATCACID","A02A-Antacids","ATCPTTMT","% of total sales","SVK","Slovak Republic","2020","2020",0.1,,
+"PATCACID","A02A-Antacids","ATCPTTMT","% of total sales","SVK","Slovak Republic","2021","2021",0.1,,
+"PATCACID","A02A-Antacids","MLLNCUMT","Million of national currency units","ESP","Spain","2010","2010",19.3,"D","Difference in methodology"
+"PATCACID","A02A-Antacids","MLLNCUMT","Million of national currency units","ESP","Spain","2011","2011",17.9,"D","Difference in methodology"
+"PATCACID","A02A-Antacids","MLLNCUMT","Million of national currency units","ESP","Spain","2012","2012",11.7,"D","Difference in methodology"
+"PATCACID","A02A-Antacids","MTMOTCMT","Million US$ at exchange rate","ESP","Spain","2010","2010",25.6,"D","Difference in methodology"
+"PATCACID","A02A-Antacids","MTMOTCMT","Million US$ at exchange rate","ESP","Spain","2011","2011",24.9,"D","Difference in methodology"
+"PATCACID","A02A-Antacids","MTMOTCMT","Million US$ at exchange rate","ESP","Spain","2012","2012",15,"D","Difference in methodology"
+"PATCACID","A02A-Antacids","MTMOPPMT","Million US$, purchasing power parity","ESP","Spain","2010","2010",26.6,"D","Difference in methodology"
+"PATCACID","A02A-Antacids","MTMOPPMT","Million US$, purchasing power parity","ESP","Spain","2011","2011",25,"D","Difference in methodology"
+"PATCACID","A02A-Antacids","MTMOPPMT","Million US$, purchasing power parity","ESP","Spain","2012","2012",16.8,"D","Difference in methodology"
+"PATCACID","A02A-Antacids","TCPPERMT","/capita, US$ exchange rate","ESP","Spain","2010","2010",0.6,"D","Difference in methodology"
+"PATCACID","A02A-Antacids","TCPPERMT","/capita, US$ exchange rate","ESP","Spain","2011","2011",0.5,"D","Difference in methodology"
+"PATCACID","A02A-Antacids","TCPPERMT","/capita, US$ exchange rate","ESP","Spain","2012","2012",0.3,"D","Difference in methodology"
+"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2010","2010",0.6,"D","Difference in methodology"
+"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2011","2011",0.5,"D","Difference in methodology"
+"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2012","2012",0.4,"D","Difference in methodology"
+"PATCACID","A02A-Antacids","ATCPTTMT","% of total sales","ESP","Spain","2010","2010",0.1,"D","Difference in methodology"
+"PATCACID","A02A-Antacids","ATCPTTMT","% of total sales","ESP","Spain","2011","2011",0.1,"D","Difference in methodology"
+"PATCACID","A02A-Antacids","ATCPTTMT","% of total sales","ESP","Spain","2012","2012",0.1,"D","Difference in methodology"
+"PATCACID","A02A-Antacids","MLLNCUMT","Million of national currency units","SWE","Sweden","2010","2010",62.4,,
+"PATCACID","A02A-Antacids","MLLNCUMT","Million of national currency units","SWE","Sweden","2011","2011",70.7,,
+"PATCACID","A02A-Antacids","MLLNCUMT","Million of national currency units","SWE","Sweden","2012","2012",70.3,,
+"PATCACID","A02A-Antacids","MLLNCUMT","Million of national currency units","SWE","Sweden","2013","2013",75.9,,
+"PATCACID","A02A-Antacids","MLLNCUMT","Million of national currency units","SWE","Sweden","2014","2014",81.7,,
+"PATCACID","A02A-Antacids","MLLNCUMT","Million of national currency units","SWE","Sweden","2015","2015",92.4,,
+"PATCACID","A02A-Antacids","MLLNCUMT","Million of national currency units","SWE","Sweden","2016","2016",95.9,,
+"PATCACID","A02A-Antacids","MLLNCUMT","Million of national currency units","SWE","Sweden","2017","2017",98.3,,
+"PATCACID","A02A-Antacids","MLLNCUMT","Million of national currency units","SWE","Sweden","2018","2018",99,,
+"PATCACID","A02A-Antacids","MLLNCUMT","Million of national currency units","SWE","Sweden","2019","2019",104.1,,
+"PATCACID","A02A-Antacids","MLLNCUMT","Million of national currency units","SWE","Sweden","2020","2020",104.1,,
+"PATCACID","A02A-Antacids","MLLNCUMT","Million of national currency units","SWE","Sweden","2021","2021",108,,
+"PATCACID","A02A-Antacids","MLLNCUMT","Million of national currency units","SWE","Sweden","2022","2022",107.8,,
+"PATCACID","A02A-Antacids","MTMOTCMT","Million US$ at exchange rate","SWE","Sweden","2010","2010",8.7,,
+"PATCACID","A02A-Antacids","MTMOTCMT","Million US$ at exchange rate","SWE","Sweden","2011","2011",10.9,,
+"PATCACID","A02A-Antacids","MTMOTCMT","Million US$ at exchange rate","SWE","Sweden","2012","2012",10.4,,
+"PATCACID","A02A-Antacids","MTMOTCMT","Million US$ at exchange rate","SWE","Sweden","2013","2013",11.7,,
+"PATCACID","A02A-Antacids","MTMOTCMT","Million US$ at exchange rate","SWE","Sweden","2014","2014",11.9,,
+"PATCACID","A02A-Antacids","MTMOTCMT","Million US$ at exchange rate","SWE","Sweden","2015","2015",11,,
+"PATCACID","A02A-Antacids","MTMOTCMT","Million US$ at exchange rate","SWE","Sweden","2016","2016",11.2,,
+"PATCACID","A02A-Antacids","MTMOTCMT","Million US$ at exchange rate","SWE","Sweden","2017","2017",11.5,,
+"PATCACID","A02A-Antacids","MTMOTCMT","Million US$ at exchange rate","SWE","Sweden","2018","2018",11.4,,
+"PATCACID","A02A-Antacids","MTMOTCMT","Million US$ at exchange rate","SWE","Sweden","2019","2019",11,,
+"PATCACID","A02A-Antacids","MTMOTCMT","Million US$ at exchange rate","SWE","Sweden","2020","2020",11.3,,
+"PATCACID","A02A-Antacids","MTMOTCMT","Million US$ at exchange rate","SWE","Sweden","2021","2021",12.6,,
+"PATCACID","A02A-Antacids","MTMOTCMT","Million US$ at exchange rate","SWE","Sweden","2022","2022",10.7,,
+"PATCACID","A02A-Antacids","MTMOPPMT","Million US$, purchasing power parity","SWE","Sweden","2010","2010",6.9,,
+"PATCACID","A02A-Antacids","MTMOPPMT","Million US$, purchasing power parity","SWE","Sweden","2011","2011",8,,
+"PATCACID","A02A-Antacids","MTMOPPMT","Million US$, purchasing power parity","SWE","Sweden","2012","2012",8.1,,
+"PATCACID","A02A-Antacids","MTMOPPMT","Million US$, purchasing power parity","SWE","Sweden","2013","2013",8.8,,
+"PATCACID","A02A-Antacids","MTMOPPMT","Million US$, purchasing power parity","SWE","Sweden","2014","2014",9.4,,
+"PATCACID","A02A-Antacids","MTMOPPMT","Million US$, purchasing power parity","SWE","Sweden","2015","2015",10.4,,
+"PATCACID","A02A-Antacids","MTMOPPMT","Million US$, purchasing power parity","SWE","Sweden","2016","2016",10.9,,
+"PATCACID","A02A-Antacids","MTMOPPMT","Million US$, purchasing power parity","SWE","Sweden","2017","2017",11.1,,
+"PATCACID","A02A-Antacids","MTMOPPMT","Million US$, purchasing power parity","SWE","Sweden","2018","2018",11.2,,
+"PATCACID","A02A-Antacids","MTMOPPMT","Million US$, purchasing power parity","SWE","Sweden","2019","2019",11.9,,
+"PATCACID","A02A-Antacids","MTMOPPMT","Million US$, purchasing power parity","SWE","Sweden","2020","2020",12,,
+"PATCACID","A02A-Antacids","MTMOPPMT","Million US$, purchasing power parity","SWE","Sweden","2021","2021",12.4,,
+"PATCACID","A02A-Antacids","MTMOPPMT","Million US$, purchasing power parity","SWE","Sweden","2022","2022",12.4,,
+"PATCACID","A02A-Antacids","TCPPERMT","/capita, US$ exchange rate","SWE","Sweden","2010","2010",0.9,,
+"PATCACID","A02A-Antacids","TCPPERMT","/capita, US$ exchange rate","SWE","Sweden","2011","2011",1.2,,
+"PATCACID","A02A-Antacids","TCPPERMT","/capita, US$ exchange rate","SWE","Sweden","2012","2012",1.1,,
+"PATCACID","A02A-Antacids","TCPPERMT","/capita, US$ exchange rate","SWE","Sweden","2013","2013",1.2,,
+"PATCACID","A02A-Antacids","TCPPERMT","/capita, US$ exchange rate","SWE","Sweden","2014","2014",1.2,,
+"PATCACID","A02A-Antacids","TCPPERMT","/capita, US$ exchange rate","SWE","Sweden","2015","2015",1.1,,
+"PATCACID","A02A-Antacids","TCPPERMT","/capita, US$ exchange rate","SWE","Sweden","2016","2016",1.1,,
+"PATCACID","A02A-Antacids","TCPPERMT","/capita, US$ exchange rate","SWE","Sweden","2017","2017",1.1,,
+"PATCACID","A02A-Antacids","TCPPERMT","/capita, US$ exchange rate","SWE","Sweden","2018","2018",1.1,,
+"PATCACID","A02A-Antacids","TCPPERMT","/capita, US$ exchange rate","SWE","Sweden","2019","2019",1.1,,
+"PATCACID","A02A-Antacids","TCPPERMT","/capita, US$ exchange rate","SWE","Sweden","2020","2020",1.1,,
+"PATCACID","A02A-Antacids","TCPPERMT","/capita, US$ exchange rate","SWE","Sweden","2021","2021",1.2,,
+"PATCACID","A02A-Antacids","TCPPERMT","/capita, US$ exchange rate","SWE","Sweden","2022","2022",1,,
+"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2010","2010",0.7,,
+"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2011","2011",0.8,,
+"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2012","2012",0.9,,
+"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2013","2013",0.9,,
+"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2014","2014",1,,
+"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2015","2015",1.1,,
+"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2016","2016",1.1,,
+"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2017","2017",1.1,,
+"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2018","2018",1.1,,
+"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2019","2019",1.2,,
+"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2020","2020",1.2,,
+"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2021","2021",1.2,,
+"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2022","2022",1.2,,
+"PATCACID","A02A-Antacids","ATCPTTMT","% of total sales","SWE","Sweden","2010","2010",0.2,,
+"PATCACID","A02A-Antacids","ATCPTTMT","% of total sales","SWE","Sweden","2011","2011",0.2,,
+"PATCACID","A02A-Antacids","ATCPTTMT","% of total sales","SWE","Sweden","2012","2012",0.2,,
+"PATCACID","A02A-Antacids","ATCPTTMT","% of total sales","SWE","Sweden","2013","2013",0.2,,
+"PATCACID","A02A-Antacids","ATCPTTMT","% of total sales","SWE","Sweden","2014","2014",0.2,,
+"PATCACID","A02A-Antacids","ATCPTTMT","% of total sales","SWE","Sweden","2015","2015",0.2,,
+"PATCACID","A02A-Antacids","ATCPTTMT","% of total sales","SWE","Sweden","2016","2016",0.2,,
+"PATCACID","A02A-Antacids","ATCPTTMT","% of total sales","SWE","Sweden","2017","2017",0.2,,
+"PATCACID","A02A-Antacids","ATCPTTMT","% of total sales","SWE","Sweden","2018","2018",0.2,,
+"PATCACID","A02A-Antacids","ATCPTTMT","% of total sales","SWE","Sweden","2019","2019",0.2,,
+"PATCACID","A02A-Antacids","ATCPTTMT","% of total sales","SWE","Sweden","2020","2020",0.2,,
+"PATCACID","A02A-Antacids","ATCPTTMT","% of total sales","SWE","Sweden","2021","2021",0.2,,
+"PATCACID","A02A-Antacids","ATCPTTMT","% of total sales","SWE","Sweden","2022","2022",0.2,,
+"PATCACID","A02A-Antacids","MLLNCUMT","Million of national currency units","TUR","Türkiye","2010","2010",94.1,,
+"PATCACID","A02A-Antacids","MLLNCUMT","Million of national currency units","TUR","Türkiye","2011","2011",102.1,,
+"PATCACID","A02A-Antacids","MLLNCUMT","Million of national currency units","TUR","Türkiye","2012","2012",101.7,,
+"PATCACID","A02A-Antacids","MLLNCUMT","Million of national currency units","TUR","Türkiye","2013","2013",93.6,,
+"PATCACID","A02A-Antacids","MLLNCUMT","Million of national currency units","TUR","Türkiye","2014","2014",99,,
+"PATCACID","A02A-Antacids","MLLNCUMT","Million of national currency units","TUR","Türkiye","2015","2015",125.5,,
+"PATCACID","A02A-Antacids","MLLNCUMT","Million of national currency units","TUR","Türkiye","2016","2016",161.8,,
+"PATCACID","A02A-Antacids","MLLNCUMT","Million of national currency units","TUR","Türkiye","2017","2017",198.8,,
+"PATCACID","A02A-Antacids","MLLNCUMT","Million of national currency units","TUR","Türkiye","2018","2018",221.2,,
+"PATCACID","A02A-Antacids","MLLNCUMT","Million of national currency units","TUR","Türkiye","2019","2019",265.6,,
+"PATCACID","A02A-Antacids","MLLNCUMT","Million of national currency units","TUR","Türkiye","2020","2020",333.2,,
+"PATCACID","A02A-Antacids","MLLNCUMT","Million of national currency units","TUR","Türkiye","2021","2021",424,,
+"PATCACID","A02A-Antacids","MTMOTCMT","Million US$ at exchange rate","TUR","Türkiye","2010","2010",62.6,,
+"PATCACID","A02A-Antacids","MTMOTCMT","Million US$ at exchange rate","TUR","Türkiye","2011","2011",61,,
+"PATCACID","A02A-Antacids","MTMOTCMT","Million US$ at exchange rate","TUR","Türkiye","2012","2012",56.6,,
+"PATCACID","A02A-Antacids","MTMOTCMT","Million US$ at exchange rate","TUR","Türkiye","2013","2013",49.2,,
+"PATCACID","A02A-Antacids","MTMOTCMT","Million US$ at exchange rate","TUR","Türkiye","2014","2014",45.2,,
+"PATCACID","A02A-Antacids","MTMOTCMT","Million US$ at exchange rate","TUR","Türkiye","2015","2015",46.1,,
+"PATCACID","A02A-Antacids","MTMOTCMT","Million US$ at exchange rate","TUR","Türkiye","2016","2016",53.6,,
+"PATCACID","A02A-Antacids","MTMOTCMT","Million US$ at exchange rate","TUR","Türkiye","2017","2017",54.5,,
+"PATCACID","A02A-Antacids","MTMOTCMT","Million US$ at exchange rate","TUR","Türkiye","2018","2018",45.8,,
+"PATCACID","A02A-Antacids","MTMOTCMT","Million US$ at exchange rate","TUR","Türkiye","2019","2019",46.8,,
+"PATCACID","A02A-Antacids","MTMOTCMT","Million US$ at exchange rate","TUR","Türkiye","2020","2020",47.5,,
+"PATCACID","A02A-Antacids","MTMOTCMT","Million US$ at exchange rate","TUR","Türkiye","2021","2021",47.9,,
+"PATCACID","A02A-Antacids","MTMOPPMT","Million US$, purchasing power parity","TUR","Türkiye","2010","2010",102.2,,
+"PATCACID","A02A-Antacids","MTMOPPMT","Million US$, purchasing power parity","TUR","Türkiye","2011","2011",105.7,,
+"PATCACID","A02A-Antacids","MTMOPPMT","Million US$, purchasing power parity","TUR","Türkiye","2012","2012",99.7,,
+"PATCACID","A02A-Antacids","MTMOPPMT","Million US$, purchasing power parity","TUR","Türkiye","2013","2013",87.4,,
+"PATCACID","A02A-Antacids","MTMOPPMT","Million US$, purchasing power parity","TUR","Türkiye","2014","2014",89.6,,
+"PATCACID","A02A-Antacids","MTMOPPMT","Million US$, purchasing power parity","TUR","Türkiye","2015","2015",108,,
+"PATCACID","A02A-Antacids","MTMOPPMT","Million US$, purchasing power parity","TUR","Türkiye","2016","2016",130.4,,
+"PATCACID","A02A-Antacids","MTMOPPMT","Million US$, purchasing power parity","TUR","Türkiye","2017","2017",143.7,,
+"PATCACID","A02A-Antacids","MTMOPPMT","Million US$, purchasing power parity","TUR","Türkiye","2018","2018",135.5,,
+"PATCACID","A02A-Antacids","MTMOPPMT","Million US$, purchasing power parity","TUR","Türkiye","2019","2019",142.5,,
+"PATCACID","A02A-Antacids","MTMOPPMT","Million US$, purchasing power parity","TUR","Türkiye","2020","2020",154,,
+"PATCACID","A02A-Antacids","MTMOPPMT","Million US$, purchasing power parity","TUR","Türkiye","2021","2021",151,,
+"PATCACID","A02A-Antacids","TCPPERMT","/capita, US$ exchange rate","TUR","Türkiye","2010","2010",0.9,,
+"PATCACID","A02A-Antacids","TCPPERMT","/capita, US$ exchange rate","TUR","Türkiye","2011","2011",0.8,,
+"PATCACID","A02A-Antacids","TCPPERMT","/capita, US$ exchange rate","TUR","Türkiye","2012","2012",0.8,,
+"PATCACID","A02A-Antacids","TCPPERMT","/capita, US$ exchange rate","TUR","Türkiye","2013","2013",0.6,,
+"PATCACID","A02A-Antacids","TCPPERMT","/capita, US$ exchange rate","TUR","Türkiye","2014","2014",0.6,,
+"PATCACID","A02A-Antacids","TCPPERMT","/capita, US$ exchange rate","TUR","Türkiye","2015","2015",0.6,,
+"PATCACID","A02A-Antacids","TCPPERMT","/capita, US$ exchange rate","TUR","Türkiye","2016","2016",0.7,,
+"PATCACID","A02A-Antacids","TCPPERMT","/capita, US$ exchange rate","TUR","Türkiye","2017","2017",0.7,,
+"PATCACID","A02A-Antacids","TCPPERMT","/capita, US$ exchange rate","TUR","Türkiye","2018","2018",0.6,,
+"PATCACID","A02A-Antacids","TCPPERMT","/capita, US$ exchange rate","TUR","Türkiye","2019","2019",0.6,,
+"PATCACID","A02A-Antacids","TCPPERMT","/capita, US$ exchange rate","TUR","Türkiye","2020","2020",0.6,,
+"PATCACID","A02A-Antacids","TCPPERMT","/capita, US$ exchange rate","TUR","Türkiye","2021","2021",0.6,,
+"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2010","2010",1.4,,
+"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2011","2011",1.4,,
+"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2012","2012",1.3,,
+"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2013","2013",1.1,,
+"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2014","2014",1.2,,
+"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2015","2015",1.4,,
+"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2016","2016",1.6,,
+"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2017","2017",1.8,,
+"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2018","2018",1.7,,
+"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2019","2019",1.7,,
+"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2020","2020",1.8,,
+"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2021","2021",1.8,,
+"PATCACID","A02A-Antacids","ATCPTTMT","% of total sales","TUR","Türkiye","2010","2010",0.6,,
+"PATCACID","A02A-Antacids","ATCPTTMT","% of total sales","TUR","Türkiye","2011","2011",0.7,,
+"PATCACID","A02A-Antacids","ATCPTTMT","% of total sales","TUR","Türkiye","2012","2012",0.8,,
+"PATCACID","A02A-Antacids","ATCPTTMT","% of total sales","TUR","Türkiye","2013","2013",0.7,,
+"PATCACID","A02A-Antacids","ATCPTTMT","% of total sales","TUR","Türkiye","2014","2014",0.6,,
+"PATCACID","A02A-Antacids","ATCPTTMT","% of total sales","TUR","Türkiye","2015","2015",0.7,,
+"PATCACID","A02A-Antacids","ATCPTTMT","% of total sales","TUR","Türkiye","2016","2016",0.7,,
+"PATCACID","A02A-Antacids","ATCPTTMT","% of total sales","TUR","Türkiye","2017","2017",0.8,,
+"PATCACID","A02A-Antacids","ATCPTTMT","% of total sales","TUR","Türkiye","2018","2018",0.7,,
+"PATCACID","A02A-Antacids","ATCPTTMT","% of total sales","TUR","Türkiye","2019","2019",0.6,,
+"PATCACID","A02A-Antacids","ATCPTTMT","% of total sales","TUR","Türkiye","2020","2020",0.7,,
+"PATCACID","A02A-Antacids","ATCPTTMT","% of total sales","TUR","Türkiye","2021","2021",0.7,,
+"PATCACID","A02A-Antacids","MLLNCUMT","Million of national currency units","CHL","Chile","2010","2010",8337.3,,
+"PATCACID","A02A-Antacids","MLLNCUMT","Million of national currency units","CHL","Chile","2011","2011",9337.8,"B","Break"
+"PATCACID","A02A-Antacids","MLLNCUMT","Million of national currency units","CHL","Chile","2012","2012",9204.3,,
+"PATCACID","A02A-Antacids","MLLNCUMT","Million of national currency units","CHL","Chile","2013","2013",9763.4,,
+"PATCACID","A02A-Antacids","MLLNCUMT","Million of national currency units","CHL","Chile","2014","2014",10396.9,,
+"PATCACID","A02A-Antacids","MLLNCUMT","Million of national currency units","CHL","Chile","2015","2015",11322.5,,
+"PATCACID","A02A-Antacids","MLLNCUMT","Million of national currency units","CHL","Chile","2016","2016",11264.6,,
+"PATCACID","A02A-Antacids","MLLNCUMT","Million of national currency units","CHL","Chile","2017","2017",11617,,
+"PATCACID","A02A-Antacids","MLLNCUMT","Million of national currency units","CHL","Chile","2018","2018",12658.9,,
+"PATCACID","A02A-Antacids","MLLNCUMT","Million of national currency units","CHL","Chile","2019","2019",11513.9,,
+"PATCACID","A02A-Antacids","MLLNCUMT","Million of national currency units","CHL","Chile","2020","2020",11755.4,,
+"PATCACID","A02A-Antacids","MLLNCUMT","Million of national currency units","CHL","Chile","2021","2021",9854.6,,
+"PATCACID","A02A-Antacids","MLLNCUMT","Million of national currency units","CHL","Chile","2022","2022",10301.3,,
+"PATCACID","A02A-Antacids","MTMOTCMT","Million US$ at exchange rate","CHL","Chile","2010","2010",16.3,,
+"PATCACID","A02A-Antacids","MTMOTCMT","Million US$ at exchange rate","CHL","Chile","2011","2011",19.3,"B","Break"
+"PATCACID","A02A-Antacids","MTMOTCMT","Million US$ at exchange rate","CHL","Chile","2012","2012",18.9,,
+"PATCACID","A02A-Antacids","MTMOTCMT","Million US$ at exchange rate","CHL","Chile","2013","2013",19.7,,
+"PATCACID","A02A-Antacids","MTMOTCMT","Million US$ at exchange rate","CHL","Chile","2014","2014",18.2,,
+"PATCACID","A02A-Antacids","MTMOTCMT","Million US$ at exchange rate","CHL","Chile","2015","2015",17.3,,
+"PATCACID","A02A-Antacids","MTMOTCMT","Million US$ at exchange rate","CHL","Chile","2016","2016",16.6,,
+"PATCACID","A02A-Antacids","MTMOTCMT","Million US$ at exchange rate","CHL","Chile","2017","2017",17.9,,
+"PATCACID","A02A-Antacids","MTMOTCMT","Million US$ at exchange rate","CHL","Chile","2018","2018",19.7,,
+"PATCACID","A02A-Antacids","MTMOTCMT","Million US$ at exchange rate","CHL","Chile","2019","2019",16.4,,
+"PATCACID","A02A-Antacids","MTMOTCMT","Million US$ at exchange rate","CHL","Chile","2020","2020",14.8,,
+"PATCACID","A02A-Antacids","MTMOTCMT","Million US$ at exchange rate","CHL","Chile","2021","2021",13,,
+"PATCACID","A02A-Antacids","MTMOTCMT","Million US$ at exchange rate","CHL","Chile","2022","2022",11.8,,
+"PATCACID","A02A-Antacids","MTMOPPMT","Million US$, purchasing power parity","CHL","Chile","2010","2010",23.2,,
+"PATCACID","A02A-Antacids","MTMOPPMT","Million US$, purchasing power parity","CHL","Chile","2011","2011",26.8,"B","Break"
+"PATCACID","A02A-Antacids","MTMOPPMT","Million US$, purchasing power parity","CHL","Chile","2012","2012",26.5,,
+"PATCACID","A02A-Antacids","MTMOPPMT","Million US$, purchasing power parity","CHL","Chile","2013","2013",27.9,,
+"PATCACID","A02A-Antacids","MTMOPPMT","Million US$, purchasing power parity","CHL","Chile","2014","2014",28.3,,
+"PATCACID","A02A-Antacids","MTMOPPMT","Million US$, purchasing power parity","CHL","Chile","2015","2015",28.9,,
+"PATCACID","A02A-Antacids","MTMOPPMT","Million US$, purchasing power parity","CHL","Chile","2016","2016",28.4,,
+"PATCACID","A02A-Antacids","MTMOPPMT","Million US$, purchasing power parity","CHL","Chile","2017","2017",29.2,,
+"PATCACID","A02A-Antacids","MTMOPPMT","Million US$, purchasing power parity","CHL","Chile","2018","2018",31.9,,
+"PATCACID","A02A-Antacids","MTMOPPMT","Million US$, purchasing power parity","CHL","Chile","2019","2019",28.7,,
+"PATCACID","A02A-Antacids","MTMOPPMT","Million US$, purchasing power parity","CHL","Chile","2020","2020",28.1,,
+"PATCACID","A02A-Antacids","MTMOPPMT","Million US$, purchasing power parity","CHL","Chile","2021","2021",22.6,,
+"PATCACID","A02A-Antacids","MTMOPPMT","Million US$, purchasing power parity","CHL","Chile","2022","2022",23.5,,
+"PATCACID","A02A-Antacids","TCPPERMT","/capita, US$ exchange rate","CHL","Chile","2010","2010",1,,
+"PATCACID","A02A-Antacids","TCPPERMT","/capita, US$ exchange rate","CHL","Chile","2011","2011",1.1,"B","Break"
+"PATCACID","A02A-Antacids","TCPPERMT","/capita, US$ exchange rate","CHL","Chile","2012","2012",1.1,,
+"PATCACID","A02A-Antacids","TCPPERMT","/capita, US$ exchange rate","CHL","Chile","2013","2013",1.1,,
+"PATCACID","A02A-Antacids","TCPPERMT","/capita, US$ exchange rate","CHL","Chile","2014","2014",1,,
+"PATCACID","A02A-Antacids","TCPPERMT","/capita, US$ exchange rate","CHL","Chile","2015","2015",1,,
+"PATCACID","A02A-Antacids","TCPPERMT","/capita, US$ exchange rate","CHL","Chile","2016","2016",0.9,,
+"PATCACID","A02A-Antacids","TCPPERMT","/capita, US$ exchange rate","CHL","Chile","2017","2017",1,,
+"PATCACID","A02A-Antacids","TCPPERMT","/capita, US$ exchange rate","CHL","Chile","2018","2018",1.1,,
+"PATCACID","A02A-Antacids","TCPPERMT","/capita, US$ exchange rate","CHL","Chile","2019","2019",0.9,,
+"PATCACID","A02A-Antacids","TCPPERMT","/capita, US$ exchange rate","CHL","Chile","2020","2020",0.8,,
+"PATCACID","A02A-Antacids","TCPPERMT","/capita, US$ exchange rate","CHL","Chile","2021","2021",0.7,,
+"PATCACID","A02A-Antacids","TCPPERMT","/capita, US$ exchange rate","CHL","Chile","2022","2022",0.6,,
+"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2010","2010",1.4,,
+"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2011","2011",1.6,"B","Break"
+"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2012","2012",1.5,,
+"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2013","2013",1.6,,
+"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2014","2014",1.6,,
+"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2015","2015",1.6,,
+"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2016","2016",1.6,,
+"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2017","2017",1.6,,
+"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2018","2018",1.7,,
+"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2019","2019",1.5,,
+"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2020","2020",1.4,,
+"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2021","2021",1.2,,
+"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2022","2022",1.2,,
+"PATCACID","A02A-Antacids","ATCPTTMT","% of total sales","CHL","Chile","2010","2010",1,,
+"PATCACID","A02A-Antacids","ATCPTTMT","% of total sales","CHL","Chile","2011","2011",0.8,"B","Break"
+"PATCACID","A02A-Antacids","ATCPTTMT","% of total sales","CHL","Chile","2012","2012",0.7,,
+"PATCACID","A02A-Antacids","ATCPTTMT","% of total sales","CHL","Chile","2013","2013",0.7,,
+"PATCACID","A02A-Antacids","ATCPTTMT","% of total sales","CHL","Chile","2014","2014",0.7,,
+"PATCACID","A02A-Antacids","ATCPTTMT","% of total sales","CHL","Chile","2015","2015",0.6,,
+"PATCACID","A02A-Antacids","ATCPTTMT","% of total sales","CHL","Chile","2016","2016",0.6,,
+"PATCACID","A02A-Antacids","ATCPTTMT","% of total sales","CHL","Chile","2017","2017",0.6,,
+"PATCACID","A02A-Antacids","ATCPTTMT","% of total sales","CHL","Chile","2018","2018",0.6,,
+"PATCACID","A02A-Antacids","ATCPTTMT","% of total sales","CHL","Chile","2019","2019",0.5,,
+"PATCACID","A02A-Antacids","ATCPTTMT","% of total sales","CHL","Chile","2020","2020",0.4,,
+"PATCACID","A02A-Antacids","ATCPTTMT","% of total sales","CHL","Chile","2021","2021",0.4,,
+"PATCACID","A02A-Antacids","ATCPTTMT","% of total sales","CHL","Chile","2022","2022",0.4,,
+"PATCACID","A02A-Antacids","MLLNCUMT","Million of national currency units","EST","Estonia","2010","2010",0.3,,
+"PATCACID","A02A-Antacids","MLLNCUMT","Million of national currency units","EST","Estonia","2011","2011",0.3,,
+"PATCACID","A02A-Antacids","MLLNCUMT","Million of national currency units","EST","Estonia","2012","2012",0.3,,
+"PATCACID","A02A-Antacids","MLLNCUMT","Million of national currency units","EST","Estonia","2013","2013",0.3,,
+"PATCACID","A02A-Antacids","MLLNCUMT","Million of national currency units","EST","Estonia","2014","2014",0.4,,
+"PATCACID","A02A-Antacids","MLLNCUMT","Million of national currency units","EST","Estonia","2015","2015",0.4,,
+"PATCACID","A02A-Antacids","MLLNCUMT","Million of national currency units","EST","Estonia","2016","2016",0.4,,
+"PATCACID","A02A-Antacids","MLLNCUMT","Million of national currency units","EST","Estonia","2017","2017",0.4,,
+"PATCACID","A02A-Antacids","MLLNCUMT","Million of national currency units","EST","Estonia","2018","2018",0.4,,
+"PATCACID","A02A-Antacids","MLLNCUMT","Million of national currency units","EST","Estonia","2019","2019",0.5,,
+"PATCACID","A02A-Antacids","MLLNCUMT","Million of national currency units","EST","Estonia","2020","2020",0.5,,
+"PATCACID","A02A-Antacids","MLLNCUMT","Million of national currency units","EST","Estonia","2021","2021",0.5,,
+"PATCACID","A02A-Antacids","MLLNCUMT","Million of national currency units","EST","Estonia","2022","2022",0.7,,
+"PATCACID","A02A-Antacids","MTMOTCMT","Million US$ at exchange rate","EST","Estonia","2010","2010",0.4,,
+"PATCACID","A02A-Antacids","MTMOTCMT","Million US$ at exchange rate","EST","Estonia","2011","2011",0.4,,
+"PATCACID","A02A-Antacids","MTMOTCMT","Million US$ at exchange rate","EST","Estonia","2012","2012",0.4,,
+"PATCACID","A02A-Antacids","MTMOTCMT","Million US$ at exchange rate","EST","Estonia","2013","2013",0.4,,
+"PATCACID","A02A-Antacids","MTMOTCMT","Million US$ at exchange rate","EST","Estonia","2014","2014",0.5,,
+"PATCACID","A02A-Antacids","MTMOTCMT","Million US$ at exchange rate","EST","Estonia","2015","2015",0.4,,
+"PATCACID","A02A-Antacids","MTMOTCMT","Million US$ at exchange rate","EST","Estonia","2016","2016",0.4,,
+"PATCACID","A02A-Antacids","MTMOTCMT","Million US$ at exchange rate","EST","Estonia","2017","2017",0.4,,
+"PATCACID","A02A-Antacids","MTMOTCMT","Million US$ at exchange rate","EST","Estonia","2018","2018",0.5,,
+"PATCACID","A02A-Antacids","MTMOTCMT","Million US$ at exchange rate","EST","Estonia","2019","2019",0.6,,
+"PATCACID","A02A-Antacids","MTMOTCMT","Million US$ at exchange rate","EST","Estonia","2020","2020",0.6,,
+"PATCACID","A02A-Antacids","MTMOTCMT","Million US$ at exchange rate","EST","Estonia","2021","2021",0.6,,
+"PATCACID","A02A-Antacids","MTMOTCMT","Million US$ at exchange rate","EST","Estonia","2022","2022",0.7,,
+"PATCACID","A02A-Antacids","MTMOPPMT","Million US$, purchasing power parity","EST","Estonia","2010","2010",0.5,,
+"PATCACID","A02A-Antacids","MTMOPPMT","Million US$, purchasing power parity","EST","Estonia","2011","2011",0.6,,
+"PATCACID","A02A-Antacids","MTMOPPMT","Million US$, purchasing power parity","EST","Estonia","2012","2012",0.6,,
+"PATCACID","A02A-Antacids","MTMOPPMT","Million US$, purchasing power parity","EST","Estonia","2013","2013",0.6,,
+"PATCACID","A02A-Antacids","MTMOPPMT","Million US$, purchasing power parity","EST","Estonia","2014","2014",0.7,,
+"PATCACID","A02A-Antacids","MTMOPPMT","Million US$, purchasing power parity","EST","Estonia","2015","2015",0.7,,
+"PATCACID","A02A-Antacids","MTMOPPMT","Million US$, purchasing power parity","EST","Estonia","2016","2016",0.7,,
+"PATCACID","A02A-Antacids","MTMOPPMT","Million US$, purchasing power parity","EST","Estonia","2017","2017",0.7,,
+"PATCACID","A02A-Antacids","MTMOPPMT","Million US$, purchasing power parity","EST","Estonia","2018","2018",0.8,,
+"PATCACID","A02A-Antacids","MTMOPPMT","Million US$, purchasing power parity","EST","Estonia","2019","2019",0.9,,
+"PATCACID","A02A-Antacids","MTMOPPMT","Million US$, purchasing power parity","EST","Estonia","2020","2020",1,,
+"PATCACID","A02A-Antacids","MTMOPPMT","Million US$, purchasing power parity","EST","Estonia","2021","2021",1,,
+"PATCACID","A02A-Antacids","MTMOPPMT","Million US$, purchasing power parity","EST","Estonia","2022","2022",1.2,,
+"PATCACID","A02A-Antacids","TCPPERMT","/capita, US$ exchange rate","EST","Estonia","2010","2010",0.3,,
+"PATCACID","A02A-Antacids","TCPPERMT","/capita, US$ exchange rate","EST","Estonia","2011","2011",0.3,,
+"PATCACID","A02A-Antacids","TCPPERMT","/capita, US$ exchange rate","EST","Estonia","2012","2012",0.3,,
+"PATCACID","A02A-Antacids","TCPPERMT","/capita, US$ exchange rate","EST","Estonia","2013","2013",0.3,,
+"PATCACID","A02A-Antacids","TCPPERMT","/capita, US$ exchange rate","EST","Estonia","2014","2014",0.4,,
+"PATCACID","A02A-Antacids","TCPPERMT","/capita, US$ exchange rate","EST","Estonia","2015","2015",0.3,,
+"PATCACID","A02A-Antacids","TCPPERMT","/capita, US$ exchange rate","EST","Estonia","2016","2016",0.3,,
+"PATCACID","A02A-Antacids","TCPPERMT","/capita, US$ exchange rate","EST","Estonia","2017","2017",0.3,,
+"PATCACID","A02A-Antacids","TCPPERMT","/capita, US$ exchange rate","EST","Estonia","2018","2018",0.4,,
+"PATCACID","A02A-Antacids","TCPPERMT","/capita, US$ exchange rate","EST","Estonia","2019","2019",0.4,,
+"PATCACID","A02A-Antacids","TCPPERMT","/capita, US$ exchange rate","EST","Estonia","2020","2020",0.5,,
+"PATCACID","A02A-Antacids","TCPPERMT","/capita, US$ exchange rate","EST","Estonia","2021","2021",0.5,,
+"PATCACID","A02A-Antacids","TCPPERMT","/capita, US$ exchange rate","EST","Estonia","2022","2022",0.5,,
+"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2010","2010",0.4,,
+"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2011","2011",0.4,,
+"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2012","2012",0.5,,
+"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2013","2013",0.5,,
+"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2014","2014",0.5,,
+"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2015","2015",0.5,,
+"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2016","2016",0.5,,
+"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2017","2017",0.6,,
+"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2018","2018",0.6,,
+"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2019","2019",0.7,,
+"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2020","2020",0.8,,
+"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2021","2021",0.7,,
+"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2022","2022",0.9,,
+"PATCACID","A02A-Antacids","ATCPTTMT","% of total sales","EST","Estonia","2010","2010",0.1,,
+"PATCACID","A02A-Antacids","ATCPTTMT","% of total sales","EST","Estonia","2011","2011",0.1,,
+"PATCACID","A02A-Antacids","ATCPTTMT","% of total sales","EST","Estonia","2012","2012",0.1,,
+"PATCACID","A02A-Antacids","ATCPTTMT","% of total sales","EST","Estonia","2013","2013",0.1,,
+"PATCACID","A02A-Antacids","ATCPTTMT","% of total sales","EST","Estonia","2014","2014",0.1,,
+"PATCACID","A02A-Antacids","ATCPTTMT","% of total sales","EST","Estonia","2015","2015",0.1,,
+"PATCACID","A02A-Antacids","ATCPTTMT","% of total sales","EST","Estonia","2016","2016",0.1,,
+"PATCACID","A02A-Antacids","ATCPTTMT","% of total sales","EST","Estonia","2017","2017",0.1,,
+"PATCACID","A02A-Antacids","ATCPTTMT","% of total sales","EST","Estonia","2018","2018",0.1,,
+"PATCACID","A02A-Antacids","ATCPTTMT","% of total sales","EST","Estonia","2019","2019",0.1,,
+"PATCACID","A02A-Antacids","ATCPTTMT","% of total sales","EST","Estonia","2020","2020",0.2,,
+"PATCACID","A02A-Antacids","ATCPTTMT","% of total sales","EST","Estonia","2021","2021",0.1,,
+"PATCACID","A02A-Antacids","ATCPTTMT","% of total sales","EST","Estonia","2022","2022",0.2,,
+"PATCACID","A02A-Antacids","MLLNCUMT","Million of national currency units","SVN","Slovenia","2010","2010",0.3,"D","Difference in methodology"
+"PATCACID","A02A-Antacids","MLLNCUMT","Million of national currency units","SVN","Slovenia","2011","2011",0.4,"D","Difference in methodology"
+"PATCACID","A02A-Antacids","MLLNCUMT","Million of national currency units","SVN","Slovenia","2012","2012",0.5,"D","Difference in methodology"
+"PATCACID","A02A-Antacids","MLLNCUMT","Million of national currency units","SVN","Slovenia","2013","2013",0.5,"D","Difference in methodology"
+"PATCACID","A02A-Antacids","MLLNCUMT","Million of national currency units","SVN","Slovenia","2014","2014",0.6,"D","Difference in methodology"
+"PATCACID","A02A-Antacids","MLLNCUMT","Million of national currency units","SVN","Slovenia","2015","2015",0.7,"D","Difference in methodology"
+"PATCACID","A02A-Antacids","MLLNCUMT","Million of national currency units","SVN","Slovenia","2016","2016",0.7,"D","Difference in methodology"
+"PATCACID","A02A-Antacids","MLLNCUMT","Million of national currency units","SVN","Slovenia","2017","2017",0.8,"D","Difference in methodology"
+"PATCACID","A02A-Antacids","MLLNCUMT","Million of national currency units","SVN","Slovenia","2018","2018",0.9,"D","Difference in methodology"
+"PATCACID","A02A-Antacids","MLLNCUMT","Million of national currency units","SVN","Slovenia","2019","2019",0.9,"D","Difference in methodology"
+"PATCACID","A02A-Antacids","MLLNCUMT","Million of national currency units","SVN","Slovenia","2020","2020",1,"D","Difference in methodology"
+"PATCACID","A02A-Antacids","MLLNCUMT","Million of national currency units","SVN","Slovenia","2021","2021",1,"D","Difference in methodology"
+"PATCACID","A02A-Antacids","MLLNCUMT","Million of national currency units","SVN","Slovenia","2022","2022",1,"D","Difference in methodology"
+"PATCACID","A02A-Antacids","MTMOTCMT","Million US$ at exchange rate","SVN","Slovenia","2010","2010",0.5,"D","Difference in methodology"
+"PATCACID","A02A-Antacids","MTMOTCMT","Million US$ at exchange rate","SVN","Slovenia","2011","2011",0.6,"D","Difference in methodology"
+"PATCACID","A02A-Antacids","MTMOTCMT","Million US$ at exchange rate","SVN","Slovenia","2012","2012",0.6,"D","Difference in methodology"
+"PATCACID","A02A-Antacids","MTMOTCMT","Million US$ at exchange rate","SVN","Slovenia","2013","2013",0.7,"D","Difference in methodology"
+"PATCACID","A02A-Antacids","MTMOTCMT","Million US$ at exchange rate","SVN","Slovenia","2014","2014",0.8,"D","Difference in methodology"
+"PATCACID","A02A-Antacids","MTMOTCMT","Million US$ at exchange rate","SVN","Slovenia","2015","2015",0.7,"D","Difference in methodology"
+"PATCACID","A02A-Antacids","MTMOTCMT","Million US$ at exchange rate","SVN","Slovenia","2016","2016",0.8,"D","Difference in methodology"
+"PATCACID","A02A-Antacids","MTMOTCMT","Million US$ at exchange rate","SVN","Slovenia","2017","2017",0.9,"D","Difference in methodology"
+"PATCACID","A02A-Antacids","MTMOTCMT","Million US$ at exchange rate","SVN","Slovenia","2018","2018",1,"D","Difference in methodology"
+"PATCACID","A02A-Antacids","MTMOTCMT","Million US$ at exchange rate","SVN","Slovenia","2019","2019",1.1,"D","Difference in methodology"
+"PATCACID","A02A-Antacids","MTMOTCMT","Million US$ at exchange rate","SVN","Slovenia","2020","2020",1.1,"D","Difference in methodology"
+"PATCACID","A02A-Antacids","MTMOTCMT","Million US$ at exchange rate","SVN","Slovenia","2021","2021",1.2,"D","Difference in methodology"
+"PATCACID","A02A-Antacids","MTMOTCMT","Million US$ at exchange rate","SVN","Slovenia","2022","2022",1.1,"D","Difference in methodology"
+"PATCACID","A02A-Antacids","MTMOPPMT","Million US$, purchasing power parity","SVN","Slovenia","2010","2010",0.5,"D","Difference in methodology"
+"PATCACID","A02A-Antacids","MTMOPPMT","Million US$, purchasing power parity","SVN","Slovenia","2011","2011",0.7,"D","Difference in methodology"
+"PATCACID","A02A-Antacids","MTMOPPMT","Million US$, purchasing power parity","SVN","Slovenia","2012","2012",0.8,"D","Difference in methodology"
+"PATCACID","A02A-Antacids","MTMOPPMT","Million US$, purchasing power parity","SVN","Slovenia","2013","2013",0.9,"D","Difference in methodology"
+"PATCACID","A02A-Antacids","MTMOPPMT","Million US$, purchasing power parity","SVN","Slovenia","2014","2014",1,"D","Difference in methodology"
+"PATCACID","A02A-Antacids","MTMOPPMT","Million US$, purchasing power parity","SVN","Slovenia","2015","2015",1.1,"D","Difference in methodology"
+"PATCACID","A02A-Antacids","MTMOPPMT","Million US$, purchasing power parity","SVN","Slovenia","2016","2016",1.3,"D","Difference in methodology"
+"PATCACID","A02A-Antacids","MTMOPPMT","Million US$, purchasing power parity","SVN","Slovenia","2017","2017",1.3,"D","Difference in methodology"
+"PATCACID","A02A-Antacids","MTMOPPMT","Million US$, purchasing power parity","SVN","Slovenia","2018","2018",1.6,"D","Difference in methodology"
+"PATCACID","A02A-Antacids","MTMOPPMT","Million US$, purchasing power parity","SVN","Slovenia","2019","2019",1.7,"D","Difference in methodology"
+"PATCACID","A02A-Antacids","MTMOPPMT","Million US$, purchasing power parity","SVN","Slovenia","2020","2020",1.8,"D","Difference in methodology"
+"PATCACID","A02A-Antacids","MTMOPPMT","Million US$, purchasing power parity","SVN","Slovenia","2021","2021",1.7,"D","Difference in methodology"
+"PATCACID","A02A-Antacids","MTMOPPMT","Million US$, purchasing power parity","SVN","Slovenia","2022","2022",1.9,"D","Difference in methodology"
+"PATCACID","A02A-Antacids","TCPPERMT","/capita, US$ exchange rate","SVN","Slovenia","2010","2010",0.2,"D","Difference in methodology"
+"PATCACID","A02A-Antacids","TCPPERMT","/capita, US$ exchange rate","SVN","Slovenia","2011","2011",0.3,"D","Difference in methodology"
+"PATCACID","A02A-Antacids","TCPPERMT","/capita, US$ exchange rate","SVN","Slovenia","2012","2012",0.3,"D","Difference in methodology"
+"PATCACID","A02A-Antacids","TCPPERMT","/capita, US$ exchange rate","SVN","Slovenia","2013","2013",0.4,"D","Difference in methodology"
+"PATCACID","A02A-Antacids","TCPPERMT","/capita, US$ exchange rate","SVN","Slovenia","2014","2014",0.4,"D","Difference in methodology"
+"PATCACID","A02A-Antacids","TCPPERMT","/capita, US$ exchange rate","SVN","Slovenia","2015","2015",0.4,"D","Difference in methodology"
+"PATCACID","A02A-Antacids","TCPPERMT","/capita, US$ exchange rate","SVN","Slovenia","2016","2016",0.4,"D","Difference in methodology"
+"PATCACID","A02A-Antacids","TCPPERMT","/capita, US$ exchange rate","SVN","Slovenia","2017","2017",0.4,"D","Difference in methodology"
+"PATCACID","A02A-Antacids","TCPPERMT","/capita, US$ exchange rate","SVN","Slovenia","2018","2018",0.5,"D","Difference in methodology"
+"PATCACID","A02A-Antacids","TCPPERMT","/capita, US$ exchange rate","SVN","Slovenia","2019","2019",0.5,"D","Difference in methodology"
+"PATCACID","A02A-Antacids","TCPPERMT","/capita, US$ exchange rate","SVN","Slovenia","2020","2020",0.5,"D","Difference in methodology"
+"PATCACID","A02A-Antacids","TCPPERMT","/capita, US$ exchange rate","SVN","Slovenia","2021","2021",0.5,"D","Difference in methodology"
+"PATCACID","A02A-Antacids","TCPPERMT","/capita, US$ exchange rate","SVN","Slovenia","2022","2022",0.5,"D","Difference in methodology"
+"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2010","2010",0.3,"D","Difference in methodology"
+"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2011","2011",0.3,"D","Difference in methodology"
+"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2012","2012",0.4,"D","Difference in methodology"
+"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2013","2013",0.4,"D","Difference in methodology"
+"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2014","2014",0.5,"D","Difference in methodology"
+"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2015","2015",0.5,"D","Difference in methodology"
+"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2016","2016",0.6,"D","Difference in methodology"
+"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2017","2017",0.6,"D","Difference in methodology"
+"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2018","2018",0.8,"D","Difference in methodology"
+"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2019","2019",0.8,"D","Difference in methodology"
+"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2020","2020",0.9,"D","Difference in methodology"
+"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2021","2021",0.8,"D","Difference in methodology"
+"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2022","2022",0.9,"D","Difference in methodology"
+"PATCACID","A02A-Antacids","ATCPTTMT","% of total sales","SVN","Slovenia","2010","2010",0.1,"D","Difference in methodology"
+"PATCACID","A02A-Antacids","ATCPTTMT","% of total sales","SVN","Slovenia","2011","2011",0.1,"D","Difference in methodology"
+"PATCACID","A02A-Antacids","ATCPTTMT","% of total sales","SVN","Slovenia","2012","2012",0.1,"D","Difference in methodology"
+"PATCACID","A02A-Antacids","ATCPTTMT","% of total sales","SVN","Slovenia","2013","2013",0.1,"D","Difference in methodology"
+"PATCACID","A02A-Antacids","ATCPTTMT","% of total sales","SVN","Slovenia","2014","2014",0.1,"D","Difference in methodology"
+"PATCACID","A02A-Antacids","ATCPTTMT","% of total sales","SVN","Slovenia","2015","2015",0.1,"D","Difference in methodology"
+"PATCACID","A02A-Antacids","ATCPTTMT","% of total sales","SVN","Slovenia","2016","2016",0.2,"D","Difference in methodology"
+"PATCACID","A02A-Antacids","ATCPTTMT","% of total sales","SVN","Slovenia","2017","2017",0.2,"D","Difference in methodology"
+"PATCACID","A02A-Antacids","ATCPTTMT","% of total sales","SVN","Slovenia","2018","2018",0.2,"D","Difference in methodology"
+"PATCACID","A02A-Antacids","ATCPTTMT","% of total sales","SVN","Slovenia","2019","2019",0.2,"D","Difference in methodology"
+"PATCACID","A02A-Antacids","ATCPTTMT","% of total sales","SVN","Slovenia","2020","2020",0.2,"D","Difference in methodology"
+"PATCACID","A02A-Antacids","ATCPTTMT","% of total sales","SVN","Slovenia","2021","2021",0.2,"D","Difference in methodology"
+"PATCACID","A02A-Antacids","ATCPTTMT","% of total sales","SVN","Slovenia","2022","2022",0.2,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MLLNCUMT","Million of national currency units","AUS","Australia","2010","2010",628,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MLLNCUMT","Million of national currency units","AUS","Australia","2011","2011",567,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MLLNCUMT","Million of national currency units","AUS","Australia","2012","2012",502,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MLLNCUMT","Million of national currency units","AUS","Australia","2013","2013",589,"B; D","Break; Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MLLNCUMT","Million of national currency units","AUS","Australia","2014","2014",532,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MLLNCUMT","Million of national currency units","AUS","Australia","2015","2015",492,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MLLNCUMT","Million of national currency units","AUS","Australia","2016","2016",486,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MLLNCUMT","Million of national currency units","AUS","Australia","2017","2017",452,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MLLNCUMT","Million of national currency units","AUS","Australia","2018","2018",406,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MLLNCUMT","Million of national currency units","AUS","Australia","2019","2019",378,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MLLNCUMT","Million of national currency units","AUS","Australia","2020","2020",376,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MLLNCUMT","Million of national currency units","AUS","Australia","2021","2021",394,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOTCMT","Million US$ at exchange rate","AUS","Australia","2010","2010",576.1,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOTCMT","Million US$ at exchange rate","AUS","Australia","2011","2011",584.9,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOTCMT","Million US$ at exchange rate","AUS","Australia","2012","2012",519.8,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOTCMT","Million US$ at exchange rate","AUS","Australia","2013","2013",568.6,"B; D","Break; Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOTCMT","Million US$ at exchange rate","AUS","Australia","2014","2014",479.6,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOTCMT","Million US$ at exchange rate","AUS","Australia","2015","2015",369.6,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOTCMT","Million US$ at exchange rate","AUS","Australia","2016","2016",361.3,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOTCMT","Million US$ at exchange rate","AUS","Australia","2017","2017",346.4,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOTCMT","Million US$ at exchange rate","AUS","Australia","2018","2018",303.3,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOTCMT","Million US$ at exchange rate","AUS","Australia","2019","2019",262.8,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOTCMT","Million US$ at exchange rate","AUS","Australia","2020","2020",258.8,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOTCMT","Million US$ at exchange rate","AUS","Australia","2021","2021",296,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOPPMT","Million US$, purchasing power parity","AUS","Australia","2010","2010",417.7,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOPPMT","Million US$, purchasing power parity","AUS","Australia","2011","2011",375.2,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOPPMT","Million US$, purchasing power parity","AUS","Australia","2012","2012",325.9,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOPPMT","Million US$, purchasing power parity","AUS","Australia","2013","2013",407,"B; D","Break; Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOPPMT","Million US$, purchasing power parity","AUS","Australia","2014","2014",366.3,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOPPMT","Million US$, purchasing power parity","AUS","Australia","2015","2015",333.9,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOPPMT","Million US$, purchasing power parity","AUS","Australia","2016","2016",335.1,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOPPMT","Million US$, purchasing power parity","AUS","Australia","2017","2017",305.9,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOPPMT","Million US$, purchasing power parity","AUS","Australia","2018","2018",276.1,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOPPMT","Million US$, purchasing power parity","AUS","Australia","2019","2019",255.4,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOPPMT","Million US$, purchasing power parity","AUS","Australia","2020","2020",258.6,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOPPMT","Million US$, purchasing power parity","AUS","Australia","2021","2021",272.2,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","TCPPERMT","/capita, US$ exchange rate","AUS","Australia","2010","2010",26.1,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","TCPPERMT","/capita, US$ exchange rate","AUS","Australia","2011","2011",26.2,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","TCPPERMT","/capita, US$ exchange rate","AUS","Australia","2012","2012",22.9,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","TCPPERMT","/capita, US$ exchange rate","AUS","Australia","2013","2013",24.6,"B; D","Break; Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","TCPPERMT","/capita, US$ exchange rate","AUS","Australia","2014","2014",20.4,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","TCPPERMT","/capita, US$ exchange rate","AUS","Australia","2015","2015",15.5,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","TCPPERMT","/capita, US$ exchange rate","AUS","Australia","2016","2016",14.9,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","TCPPERMT","/capita, US$ exchange rate","AUS","Australia","2017","2017",14.1,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","TCPPERMT","/capita, US$ exchange rate","AUS","Australia","2018","2018",12.1,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","TCPPERMT","/capita, US$ exchange rate","AUS","Australia","2019","2019",10.4,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","TCPPERMT","/capita, US$ exchange rate","AUS","Australia","2020","2020",10.1,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","TCPPERMT","/capita, US$ exchange rate","AUS","Australia","2021","2021",11.5,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2010","2010",19,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2011","2011",16.8,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2012","2012",14.3,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2013","2013",17.6,"B; D","Break; Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2014","2014",15.6,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2015","2015",14,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2016","2016",13.9,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2017","2017",12.4,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2018","2018",11.1,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2019","2019",10.1,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2020","2020",10.1,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2021","2021",10.6,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","ATCPTTMT","% of total sales","AUS","Australia","2010","2010",6.4,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","ATCPTTMT","% of total sales","AUS","Australia","2011","2011",5.5,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","ATCPTTMT","% of total sales","AUS","Australia","2012","2012",4.8,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","ATCPTTMT","% of total sales","AUS","Australia","2013","2013",5,"B; D","Break; Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","ATCPTTMT","% of total sales","AUS","Australia","2014","2014",4.5,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","ATCPTTMT","% of total sales","AUS","Australia","2015","2015",4,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","ATCPTTMT","% of total sales","AUS","Australia","2016","2016",3.2,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","ATCPTTMT","% of total sales","AUS","Australia","2017","2017",3.1,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","ATCPTTMT","% of total sales","AUS","Australia","2018","2018",2.7,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","ATCPTTMT","% of total sales","AUS","Australia","2019","2019",2.4,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","ATCPTTMT","% of total sales","AUS","Australia","2020","2020",2.3,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","ATCPTTMT","% of total sales","AUS","Australia","2021","2021",2.2,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MLLNCUMT","Million of national currency units","AUT","Austria","2010","2010",107.7,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MLLNCUMT","Million of national currency units","AUT","Austria","2011","2011",96.2,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MLLNCUMT","Million of national currency units","AUT","Austria","2012","2012",88.3,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MLLNCUMT","Million of national currency units","AUT","Austria","2013","2013",83,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MLLNCUMT","Million of national currency units","AUT","Austria","2014","2014",79.6,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MLLNCUMT","Million of national currency units","AUT","Austria","2015","2015",76.5,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MLLNCUMT","Million of national currency units","AUT","Austria","2016","2016",51.7,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MLLNCUMT","Million of national currency units","AUT","Austria","2017","2017",38.5,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MLLNCUMT","Million of national currency units","AUT","Austria","2018","2018",35.1,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MLLNCUMT","Million of national currency units","AUT","Austria","2019","2019",33.5,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MLLNCUMT","Million of national currency units","AUT","Austria","2020","2020",31,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MLLNCUMT","Million of national currency units","AUT","Austria","2021","2021",30.3,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOTCMT","Million US$ at exchange rate","AUT","Austria","2010","2010",142.8,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOTCMT","Million US$ at exchange rate","AUT","Austria","2011","2011",134,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOTCMT","Million US$ at exchange rate","AUT","Austria","2012","2012",113.4,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOTCMT","Million US$ at exchange rate","AUT","Austria","2013","2013",110.3,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOTCMT","Million US$ at exchange rate","AUT","Austria","2014","2014",105.8,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOTCMT","Million US$ at exchange rate","AUT","Austria","2015","2015",84.8,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOTCMT","Million US$ at exchange rate","AUT","Austria","2016","2016",57.3,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOTCMT","Million US$ at exchange rate","AUT","Austria","2017","2017",43.5,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOTCMT","Million US$ at exchange rate","AUT","Austria","2018","2018",41.4,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOTCMT","Million US$ at exchange rate","AUT","Austria","2019","2019",37.5,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOTCMT","Million US$ at exchange rate","AUT","Austria","2020","2020",35.4,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOTCMT","Million US$ at exchange rate","AUT","Austria","2021","2021",35.8,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOPPMT","Million US$, purchasing power parity","AUT","Austria","2010","2010",127.9,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOPPMT","Million US$, purchasing power parity","AUT","Austria","2011","2011",115.8,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOPPMT","Million US$, purchasing power parity","AUT","Austria","2012","2012",108.5,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOPPMT","Million US$, purchasing power parity","AUT","Austria","2013","2013",104.2,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOPPMT","Million US$, purchasing power parity","AUT","Austria","2014","2014",99.7,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOPPMT","Million US$, purchasing power parity","AUT","Austria","2015","2015",95.7,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOPPMT","Million US$, purchasing power parity","AUT","Austria","2016","2016",66.6,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOPPMT","Million US$, purchasing power parity","AUT","Austria","2017","2017",49.7,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOPPMT","Million US$, purchasing power parity","AUT","Austria","2018","2018",45.8,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOPPMT","Million US$, purchasing power parity","AUT","Austria","2019","2019",44.7,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOPPMT","Million US$, purchasing power parity","AUT","Austria","2020","2020",41.5,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOPPMT","Million US$, purchasing power parity","AUT","Austria","2021","2021",40,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","TCPPERMT","/capita, US$ exchange rate","AUT","Austria","2010","2010",17.1,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","TCPPERMT","/capita, US$ exchange rate","AUT","Austria","2011","2011",16,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","TCPPERMT","/capita, US$ exchange rate","AUT","Austria","2012","2012",13.5,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","TCPPERMT","/capita, US$ exchange rate","AUT","Austria","2013","2013",13,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","TCPPERMT","/capita, US$ exchange rate","AUT","Austria","2014","2014",12.4,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","TCPPERMT","/capita, US$ exchange rate","AUT","Austria","2015","2015",9.8,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","TCPPERMT","/capita, US$ exchange rate","AUT","Austria","2016","2016",6.6,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","TCPPERMT","/capita, US$ exchange rate","AUT","Austria","2017","2017",4.9,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","TCPPERMT","/capita, US$ exchange rate","AUT","Austria","2018","2018",4.7,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","TCPPERMT","/capita, US$ exchange rate","AUT","Austria","2019","2019",4.2,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","TCPPERMT","/capita, US$ exchange rate","AUT","Austria","2020","2020",4,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","TCPPERMT","/capita, US$ exchange rate","AUT","Austria","2021","2021",4,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2010","2010",15.3,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2011","2011",13.8,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2012","2012",12.9,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2013","2013",12.3,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2014","2014",11.7,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2015","2015",11.1,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2016","2016",7.6,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2017","2017",5.7,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2018","2018",5.2,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2019","2019",5,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2020","2020",4.7,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2021","2021",4.5,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","ATCPTTMT","% of total sales","AUT","Austria","2010","2010",4.3,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","ATCPTTMT","% of total sales","AUT","Austria","2011","2011",3.8,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","ATCPTTMT","% of total sales","AUT","Austria","2012","2012",3.4,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","ATCPTTMT","% of total sales","AUT","Austria","2013","2013",3.2,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","ATCPTTMT","% of total sales","AUT","Austria","2014","2014",2.9,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","ATCPTTMT","% of total sales","AUT","Austria","2015","2015",2.6,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","ATCPTTMT","% of total sales","AUT","Austria","2016","2016",1.7,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","ATCPTTMT","% of total sales","AUT","Austria","2017","2017",1.2,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","ATCPTTMT","% of total sales","AUT","Austria","2018","2018",1.1,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","ATCPTTMT","% of total sales","AUT","Austria","2019","2019",1,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","ATCPTTMT","% of total sales","AUT","Austria","2020","2020",0.9,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","ATCPTTMT","% of total sales","AUT","Austria","2021","2021",0.8,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MLLNCUMT","Million of national currency units","BEL","Belgium","2010","2010",177.4,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MLLNCUMT","Million of national currency units","BEL","Belgium","2011","2011",176.7,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MLLNCUMT","Million of national currency units","BEL","Belgium","2012","2012",158.3,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MLLNCUMT","Million of national currency units","BEL","Belgium","2013","2013",142.9,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MLLNCUMT","Million of national currency units","BEL","Belgium","2014","2014",144.1,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MLLNCUMT","Million of national currency units","BEL","Belgium","2015","2015",154.7,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MLLNCUMT","Million of national currency units","BEL","Belgium","2016","2016",163.2,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MLLNCUMT","Million of national currency units","BEL","Belgium","2017","2017",155.3,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MLLNCUMT","Million of national currency units","BEL","Belgium","2018","2018",157.3,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MLLNCUMT","Million of national currency units","BEL","Belgium","2019","2019",166.2,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MLLNCUMT","Million of national currency units","BEL","Belgium","2020","2020",163.7,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MLLNCUMT","Million of national currency units","BEL","Belgium","2021","2021",159.1,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MLLNCUMT","Million of national currency units","BEL","Belgium","2022","2022",155.3,"E","Estimated value"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOTCMT","Million US$ at exchange rate","BEL","Belgium","2010","2010",235.2,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOTCMT","Million US$ at exchange rate","BEL","Belgium","2011","2011",246,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOTCMT","Million US$ at exchange rate","BEL","Belgium","2012","2012",203.4,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOTCMT","Million US$ at exchange rate","BEL","Belgium","2013","2013",189.8,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOTCMT","Million US$ at exchange rate","BEL","Belgium","2014","2014",191.4,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOTCMT","Million US$ at exchange rate","BEL","Belgium","2015","2015",171.7,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOTCMT","Million US$ at exchange rate","BEL","Belgium","2016","2016",180.7,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOTCMT","Million US$ at exchange rate","BEL","Belgium","2017","2017",175.4,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOTCMT","Million US$ at exchange rate","BEL","Belgium","2018","2018",185.8,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOTCMT","Million US$ at exchange rate","BEL","Belgium","2019","2019",186.1,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOTCMT","Million US$ at exchange rate","BEL","Belgium","2020","2020",186.9,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOTCMT","Million US$ at exchange rate","BEL","Belgium","2021","2021",188.2,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOTCMT","Million US$ at exchange rate","BEL","Belgium","2022","2022",163.6,"E","Estimated value"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOPPMT","Million US$, purchasing power parity","BEL","Belgium","2010","2010",212,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOPPMT","Million US$, purchasing power parity","BEL","Belgium","2011","2011",212.4,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOPPMT","Million US$, purchasing power parity","BEL","Belgium","2012","2012",192.6,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOPPMT","Million US$, purchasing power parity","BEL","Belgium","2013","2013",177.2,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOPPMT","Million US$, purchasing power parity","BEL","Belgium","2014","2014",180,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOPPMT","Million US$, purchasing power parity","BEL","Belgium","2015","2015",193.4,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOPPMT","Million US$, purchasing power parity","BEL","Belgium","2016","2016",209,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOPPMT","Million US$, purchasing power parity","BEL","Belgium","2017","2017",200.2,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOPPMT","Million US$, purchasing power parity","BEL","Belgium","2018","2018",205.3,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOPPMT","Million US$, purchasing power parity","BEL","Belgium","2019","2019",222.6,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOPPMT","Million US$, purchasing power parity","BEL","Belgium","2020","2020",224.1,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOPPMT","Million US$, purchasing power parity","BEL","Belgium","2021","2021",216,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOPPMT","Million US$, purchasing power parity","BEL","Belgium","2022","2022",217.6,"E","Estimated value"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","TCPPERMT","/capita, US$ exchange rate","BEL","Belgium","2010","2010",21.6,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","TCPPERMT","/capita, US$ exchange rate","BEL","Belgium","2011","2011",22.3,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","TCPPERMT","/capita, US$ exchange rate","BEL","Belgium","2012","2012",18.3,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","TCPPERMT","/capita, US$ exchange rate","BEL","Belgium","2013","2013",17,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","TCPPERMT","/capita, US$ exchange rate","BEL","Belgium","2014","2014",17.1,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","TCPPERMT","/capita, US$ exchange rate","BEL","Belgium","2015","2015",15.2,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","TCPPERMT","/capita, US$ exchange rate","BEL","Belgium","2016","2016",15.9,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","TCPPERMT","/capita, US$ exchange rate","BEL","Belgium","2017","2017",15.4,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","TCPPERMT","/capita, US$ exchange rate","BEL","Belgium","2018","2018",16.3,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","TCPPERMT","/capita, US$ exchange rate","BEL","Belgium","2019","2019",16.2,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","TCPPERMT","/capita, US$ exchange rate","BEL","Belgium","2020","2020",16.2,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","TCPPERMT","/capita, US$ exchange rate","BEL","Belgium","2021","2021",16.2,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","TCPPERMT","/capita, US$ exchange rate","BEL","Belgium","2022","2022",14.1,"E","Estimated value"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2010","2010",19.5,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2011","2011",19.2,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2012","2012",17.3,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2013","2013",15.9,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2014","2014",16.1,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2015","2015",17.2,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2016","2016",18.4,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2017","2017",17.6,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2018","2018",18,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2019","2019",19.4,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2020","2020",19.4,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2021","2021",18.6,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2022","2022",18.7,"E","Estimated value"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","ATCPTTMT","% of total sales","BEL","Belgium","2010","2010",3,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","ATCPTTMT","% of total sales","BEL","Belgium","2011","2011",2.9,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","ATCPTTMT","% of total sales","BEL","Belgium","2012","2012",2.7,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","ATCPTTMT","% of total sales","BEL","Belgium","2013","2013",2.4,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","ATCPTTMT","% of total sales","BEL","Belgium","2014","2014",2.4,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","ATCPTTMT","% of total sales","BEL","Belgium","2015","2015",2.5,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","ATCPTTMT","% of total sales","BEL","Belgium","2016","2016",2.6,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","ATCPTTMT","% of total sales","BEL","Belgium","2017","2017",2.4,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","ATCPTTMT","% of total sales","BEL","Belgium","2018","2018",2.4,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","ATCPTTMT","% of total sales","BEL","Belgium","2019","2019",2.3,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","ATCPTTMT","% of total sales","BEL","Belgium","2020","2020",2.1,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","ATCPTTMT","% of total sales","BEL","Belgium","2021","2021",2,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","ATCPTTMT","% of total sales","BEL","Belgium","2022","2022",1.7,"E","Estimated value"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MLLNCUMT","Million of national currency units","CAN","Canada","2012","2012",1298.2,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MLLNCUMT","Million of national currency units","CAN","Canada","2013","2013",1195.7,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MLLNCUMT","Million of national currency units","CAN","Canada","2014","2014",1134.9,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MLLNCUMT","Million of national currency units","CAN","Canada","2015","2015",1146.9,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MLLNCUMT","Million of national currency units","CAN","Canada","2016","2016",1037.1,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MLLNCUMT","Million of national currency units","CAN","Canada","2017","2017",994,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MLLNCUMT","Million of national currency units","CAN","Canada","2018","2018",854.6,"E; B; D","Estimated value; Break; Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MLLNCUMT","Million of national currency units","CAN","Canada","2019","2019",835.9,"E; D","Estimated value; Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MLLNCUMT","Million of national currency units","CAN","Canada","2020","2020",889.5,"E; D","Estimated value; Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MLLNCUMT","Million of national currency units","CAN","Canada","2021","2021",892.8,"E; D","Estimated value; Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MLLNCUMT","Million of national currency units","CAN","Canada","2022","2022",890.1,"E; D","Estimated value; Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOTCMT","Million US$ at exchange rate","CAN","Canada","2012","2012",1299,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOTCMT","Million US$ at exchange rate","CAN","Canada","2013","2013",1160.7,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOTCMT","Million US$ at exchange rate","CAN","Canada","2014","2014",1027.3,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOTCMT","Million US$ at exchange rate","CAN","Canada","2015","2015",896.9,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOTCMT","Million US$ at exchange rate","CAN","Canada","2016","2016",782.4,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOTCMT","Million US$ at exchange rate","CAN","Canada","2017","2017",765.8,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOTCMT","Million US$ at exchange rate","CAN","Canada","2018","2018",659.5,"E; B; D","Estimated value; Break; Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOTCMT","Million US$ at exchange rate","CAN","Canada","2019","2019",630,"E; D","Estimated value; Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOTCMT","Million US$ at exchange rate","CAN","Canada","2020","2020",663.2,"E; D","Estimated value; Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOTCMT","Million US$ at exchange rate","CAN","Canada","2021","2021",712.1,"E; D","Estimated value; Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOTCMT","Million US$ at exchange rate","CAN","Canada","2022","2022",683.9,"E; D","Estimated value; Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOPPMT","Million US$, purchasing power parity","CAN","Canada","2012","2012",1043.1,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOPPMT","Million US$, purchasing power parity","CAN","Canada","2013","2013",976.9,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOPPMT","Million US$, purchasing power parity","CAN","Canada","2014","2014",922.4,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOPPMT","Million US$, purchasing power parity","CAN","Canada","2015","2015",919,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOPPMT","Million US$, purchasing power parity","CAN","Canada","2016","2016",859.2,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOPPMT","Million US$, purchasing power parity","CAN","Canada","2017","2017",819.9,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOPPMT","Million US$, purchasing power parity","CAN","Canada","2018","2018",708.3,"E; B; D","Estimated value; Break; Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOPPMT","Million US$, purchasing power parity","CAN","Canada","2019","2019",677,"E; D","Estimated value; Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOPPMT","Million US$, purchasing power parity","CAN","Canada","2020","2020",722.6,"E; D","Estimated value; Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOPPMT","Million US$, purchasing power parity","CAN","Canada","2021","2021",721.1,"E; D","Estimated value; Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOPPMT","Million US$, purchasing power parity","CAN","Canada","2022","2022",709.9,"E; D","Estimated value; Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","TCPPERMT","/capita, US$ exchange rate","CAN","Canada","2012","2012",37.4,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","TCPPERMT","/capita, US$ exchange rate","CAN","Canada","2013","2013",33.1,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","TCPPERMT","/capita, US$ exchange rate","CAN","Canada","2014","2014",29,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","TCPPERMT","/capita, US$ exchange rate","CAN","Canada","2015","2015",25.1,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","TCPPERMT","/capita, US$ exchange rate","CAN","Canada","2016","2016",21.7,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","TCPPERMT","/capita, US$ exchange rate","CAN","Canada","2017","2017",21,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","TCPPERMT","/capita, US$ exchange rate","CAN","Canada","2018","2018",17.8,"E; B; D","Estimated value; Break; Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","TCPPERMT","/capita, US$ exchange rate","CAN","Canada","2019","2019",16.8,"E; D","Estimated value; Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","TCPPERMT","/capita, US$ exchange rate","CAN","Canada","2020","2020",17.4,"E; D","Estimated value; Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","TCPPERMT","/capita, US$ exchange rate","CAN","Canada","2021","2021",18.6,"E; D","Estimated value; Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","TCPPERMT","/capita, US$ exchange rate","CAN","Canada","2022","2022",17.6,"E; D","Estimated value; Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2012","2012",30,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2013","2013",27.8,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2014","2014",26,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2015","2015",25.7,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2016","2016",23.8,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2017","2017",22.4,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2018","2018",19.1,"E; B; D","Estimated value; Break; Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2019","2019",18,"E; D","Estimated value; Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2020","2020",19,"E; D","Estimated value; Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2021","2021",18.9,"E; D","Estimated value; Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2022","2022",18.3,"E; D","Estimated value; Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","ATCPTTMT","% of total sales","CAN","Canada","2012","2012",5.3,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","ATCPTTMT","% of total sales","CAN","Canada","2013","2013",4.9,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","ATCPTTMT","% of total sales","CAN","Canada","2014","2014",4.4,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","ATCPTTMT","% of total sales","CAN","Canada","2015","2015",4.2,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","ATCPTTMT","% of total sales","CAN","Canada","2016","2016",3.7,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","ATCPTTMT","% of total sales","CAN","Canada","2017","2017",3.3,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","ATCPTTMT","% of total sales","CAN","Canada","2018","2018",2.8,"E; B; D","Estimated value; Break; Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","ATCPTTMT","% of total sales","CAN","Canada","2019","2019",2.6,"E; D","Estimated value; Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","ATCPTTMT","% of total sales","CAN","Canada","2020","2020",2.6,"E; D","Estimated value; Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","ATCPTTMT","% of total sales","CAN","Canada","2021","2021",2.4,"E; D","Estimated value; Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","ATCPTTMT","% of total sales","CAN","Canada","2022","2022",2.2,"E; D","Estimated value; Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MLLNCUMT","Million of national currency units","CZE","Czech Republic","2010","2010",1324,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MLLNCUMT","Million of national currency units","CZE","Czech Republic","2011","2011",1357.6,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MLLNCUMT","Million of national currency units","CZE","Czech Republic","2012","2012",1465.4,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MLLNCUMT","Million of national currency units","CZE","Czech Republic","2013","2013",1250.2,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MLLNCUMT","Million of national currency units","CZE","Czech Republic","2014","2014",1081.3,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MLLNCUMT","Million of national currency units","CZE","Czech Republic","2015","2015",915.1,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MLLNCUMT","Million of national currency units","CZE","Czech Republic","2016","2016",955.7,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MLLNCUMT","Million of national currency units","CZE","Czech Republic","2017","2017",823.1,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MLLNCUMT","Million of national currency units","CZE","Czech Republic","2018","2018",775.9,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MLLNCUMT","Million of national currency units","CZE","Czech Republic","2019","2019",808.5,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MLLNCUMT","Million of national currency units","CZE","Czech Republic","2020","2020",739.4,"B","Break"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MLLNCUMT","Million of national currency units","CZE","Czech Republic","2021","2021",747.6,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOTCMT","Million US$ at exchange rate","CZE","Czech Republic","2010","2010",69.3,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOTCMT","Million US$ at exchange rate","CZE","Czech Republic","2011","2011",76.7,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOTCMT","Million US$ at exchange rate","CZE","Czech Republic","2012","2012",74.9,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOTCMT","Million US$ at exchange rate","CZE","Czech Republic","2013","2013",63.9,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOTCMT","Million US$ at exchange rate","CZE","Czech Republic","2014","2014",52.1,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOTCMT","Million US$ at exchange rate","CZE","Czech Republic","2015","2015",37.2,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOTCMT","Million US$ at exchange rate","CZE","Czech Republic","2016","2016",39.1,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOTCMT","Million US$ at exchange rate","CZE","Czech Republic","2017","2017",35.2,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOTCMT","Million US$ at exchange rate","CZE","Czech Republic","2018","2018",35.7,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOTCMT","Million US$ at exchange rate","CZE","Czech Republic","2019","2019",35.3,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOTCMT","Million US$ at exchange rate","CZE","Czech Republic","2020","2020",31.9,"B","Break"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOTCMT","Million US$ at exchange rate","CZE","Czech Republic","2021","2021",34.5,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOPPMT","Million US$, purchasing power parity","CZE","Czech Republic","2010","2010",96.8,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOPPMT","Million US$, purchasing power parity","CZE","Czech Republic","2011","2011",101.7,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOPPMT","Million US$, purchasing power parity","CZE","Czech Republic","2012","2012",110.2,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOPPMT","Million US$, purchasing power parity","CZE","Czech Republic","2013","2013",97.8,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOPPMT","Million US$, purchasing power parity","CZE","Czech Republic","2014","2014",85.1,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOPPMT","Million US$, purchasing power parity","CZE","Czech Republic","2015","2015",70.7,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOPPMT","Million US$, purchasing power parity","CZE","Czech Republic","2016","2016",76,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOPPMT","Million US$, purchasing power parity","CZE","Czech Republic","2017","2017",66.2,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOPPMT","Million US$, purchasing power parity","CZE","Czech Republic","2018","2018",62.7,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOPPMT","Million US$, purchasing power parity","CZE","Czech Republic","2019","2019",65.9,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOPPMT","Million US$, purchasing power parity","CZE","Czech Republic","2020","2020",59.3,"B","Break"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOPPMT","Million US$, purchasing power parity","CZE","Czech Republic","2021","2021",58.7,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","TCPPERMT","/capita, US$ exchange rate","CZE","Czech Republic","2010","2010",6.6,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","TCPPERMT","/capita, US$ exchange rate","CZE","Czech Republic","2011","2011",7.3,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","TCPPERMT","/capita, US$ exchange rate","CZE","Czech Republic","2012","2012",7.1,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","TCPPERMT","/capita, US$ exchange rate","CZE","Czech Republic","2013","2013",6.1,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","TCPPERMT","/capita, US$ exchange rate","CZE","Czech Republic","2014","2014",4.9,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","TCPPERMT","/capita, US$ exchange rate","CZE","Czech Republic","2015","2015",3.5,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","TCPPERMT","/capita, US$ exchange rate","CZE","Czech Republic","2016","2016",3.7,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","TCPPERMT","/capita, US$ exchange rate","CZE","Czech Republic","2017","2017",3.3,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","TCPPERMT","/capita, US$ exchange rate","CZE","Czech Republic","2018","2018",3.4,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","TCPPERMT","/capita, US$ exchange rate","CZE","Czech Republic","2019","2019",3.3,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","TCPPERMT","/capita, US$ exchange rate","CZE","Czech Republic","2020","2020",3,"B","Break"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","TCPPERMT","/capita, US$ exchange rate","CZE","Czech Republic","2021","2021",3.3,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czech Republic","2010","2010",9.2,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czech Republic","2011","2011",9.7,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czech Republic","2012","2012",10.5,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czech Republic","2013","2013",9.3,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czech Republic","2014","2014",8.1,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czech Republic","2015","2015",6.7,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czech Republic","2016","2016",7.2,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czech Republic","2017","2017",6.3,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czech Republic","2018","2018",5.9,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czech Republic","2019","2019",6.2,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czech Republic","2020","2020",5.5,"B","Break"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czech Republic","2021","2021",5.6,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","ATCPTTMT","% of total sales","CZE","Czech Republic","2010","2010",1.6,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","ATCPTTMT","% of total sales","CZE","Czech Republic","2011","2011",1.7,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","ATCPTTMT","% of total sales","CZE","Czech Republic","2012","2012",1.7,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","ATCPTTMT","% of total sales","CZE","Czech Republic","2013","2013",1.6,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","ATCPTTMT","% of total sales","CZE","Czech Republic","2014","2014",1.3,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","ATCPTTMT","% of total sales","CZE","Czech Republic","2015","2015",1.1,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","ATCPTTMT","% of total sales","CZE","Czech Republic","2016","2016",1.1,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","ATCPTTMT","% of total sales","CZE","Czech Republic","2017","2017",0.9,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","ATCPTTMT","% of total sales","CZE","Czech Republic","2018","2018",0.8,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","ATCPTTMT","% of total sales","CZE","Czech Republic","2019","2019",0.8,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","ATCPTTMT","% of total sales","CZE","Czech Republic","2020","2020",0.8,"B","Break"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","ATCPTTMT","% of total sales","CZE","Czech Republic","2021","2021",0.8,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MLLNCUMT","Million of national currency units","FIN","Finland","2010","2010",33.2,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MLLNCUMT","Million of national currency units","FIN","Finland","2011","2011",29.4,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MLLNCUMT","Million of national currency units","FIN","Finland","2012","2012",30.7,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MLLNCUMT","Million of national currency units","FIN","Finland","2013","2013",32,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MLLNCUMT","Million of national currency units","FIN","Finland","2014","2014",33,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MLLNCUMT","Million of national currency units","FIN","Finland","2015","2015",35.4,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MLLNCUMT","Million of national currency units","FIN","Finland","2016","2016",35.3,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MLLNCUMT","Million of national currency units","FIN","Finland","2017","2017",34.3,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MLLNCUMT","Million of national currency units","FIN","Finland","2018","2018",31.7,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MLLNCUMT","Million of national currency units","FIN","Finland","2019","2019",29.1,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MLLNCUMT","Million of national currency units","FIN","Finland","2020","2020",27.2,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MLLNCUMT","Million of national currency units","FIN","Finland","2021","2021",26.3,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOTCMT","Million US$ at exchange rate","FIN","Finland","2010","2010",44,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOTCMT","Million US$ at exchange rate","FIN","Finland","2011","2011",40.9,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOTCMT","Million US$ at exchange rate","FIN","Finland","2012","2012",39.4,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOTCMT","Million US$ at exchange rate","FIN","Finland","2013","2013",42.5,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOTCMT","Million US$ at exchange rate","FIN","Finland","2014","2014",43.8,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOTCMT","Million US$ at exchange rate","FIN","Finland","2015","2015",39.3,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOTCMT","Million US$ at exchange rate","FIN","Finland","2016","2016",39.1,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOTCMT","Million US$ at exchange rate","FIN","Finland","2017","2017",38.7,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOTCMT","Million US$ at exchange rate","FIN","Finland","2018","2018",37.4,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOTCMT","Million US$ at exchange rate","FIN","Finland","2019","2019",32.6,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOTCMT","Million US$ at exchange rate","FIN","Finland","2020","2020",31.1,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOTCMT","Million US$ at exchange rate","FIN","Finland","2021","2021",31.1,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOPPMT","Million US$, purchasing power parity","FIN","Finland","2010","2010",36.9,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOPPMT","Million US$, purchasing power parity","FIN","Finland","2011","2011",32.7,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOPPMT","Million US$, purchasing power parity","FIN","Finland","2012","2012",33.8,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOPPMT","Million US$, purchasing power parity","FIN","Finland","2013","2013",35.3,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOPPMT","Million US$, purchasing power parity","FIN","Finland","2014","2014",36.4,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOPPMT","Million US$, purchasing power parity","FIN","Finland","2015","2015",39,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOPPMT","Million US$, purchasing power parity","FIN","Finland","2016","2016",40.1,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOPPMT","Million US$, purchasing power parity","FIN","Finland","2017","2017",39.7,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOPPMT","Million US$, purchasing power parity","FIN","Finland","2018","2018",37.1,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOPPMT","Million US$, purchasing power parity","FIN","Finland","2019","2019",34.7,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOPPMT","Million US$, purchasing power parity","FIN","Finland","2020","2020",33,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOPPMT","Million US$, purchasing power parity","FIN","Finland","2021","2021",31.8,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","TCPPERMT","/capita, US$ exchange rate","FIN","Finland","2010","2010",8.2,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","TCPPERMT","/capita, US$ exchange rate","FIN","Finland","2011","2011",7.6,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","TCPPERMT","/capita, US$ exchange rate","FIN","Finland","2012","2012",7.3,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","TCPPERMT","/capita, US$ exchange rate","FIN","Finland","2013","2013",7.8,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","TCPPERMT","/capita, US$ exchange rate","FIN","Finland","2014","2014",8,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","TCPPERMT","/capita, US$ exchange rate","FIN","Finland","2015","2015",7.2,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","TCPPERMT","/capita, US$ exchange rate","FIN","Finland","2016","2016",7.1,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","TCPPERMT","/capita, US$ exchange rate","FIN","Finland","2017","2017",7,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","TCPPERMT","/capita, US$ exchange rate","FIN","Finland","2018","2018",6.8,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","TCPPERMT","/capita, US$ exchange rate","FIN","Finland","2019","2019",5.9,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","TCPPERMT","/capita, US$ exchange rate","FIN","Finland","2020","2020",5.6,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","TCPPERMT","/capita, US$ exchange rate","FIN","Finland","2021","2021",5.6,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2010","2010",6.9,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2011","2011",6.1,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2012","2012",6.2,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2013","2013",6.5,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2014","2014",6.7,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2015","2015",7.1,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2016","2016",7.3,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2017","2017",7.2,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2018","2018",6.7,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2019","2019",6.3,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2020","2020",6,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2021","2021",5.7,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","ATCPTTMT","% of total sales","FIN","Finland","2010","2010",1.8,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","ATCPTTMT","% of total sales","FIN","Finland","2011","2011",1.5,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","ATCPTTMT","% of total sales","FIN","Finland","2012","2012",1.6,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","ATCPTTMT","% of total sales","FIN","Finland","2013","2013",1.6,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","ATCPTTMT","% of total sales","FIN","Finland","2014","2014",1.6,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","ATCPTTMT","% of total sales","FIN","Finland","2015","2015",1.6,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","ATCPTTMT","% of total sales","FIN","Finland","2016","2016",1.5,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","ATCPTTMT","% of total sales","FIN","Finland","2017","2017",1.5,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","ATCPTTMT","% of total sales","FIN","Finland","2018","2018",1.3,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","ATCPTTMT","% of total sales","FIN","Finland","2019","2019",1.1,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","ATCPTTMT","% of total sales","FIN","Finland","2020","2020",1,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","ATCPTTMT","% of total sales","FIN","Finland","2021","2021",0.9,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MLLNCUMT","Million of national currency units","DEU","Germany","2010","2010",912,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MLLNCUMT","Million of national currency units","DEU","Germany","2011","2011",796.7,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MLLNCUMT","Million of national currency units","DEU","Germany","2012","2012",805.4,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MLLNCUMT","Million of national currency units","DEU","Germany","2013","2013",778.8,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MLLNCUMT","Million of national currency units","DEU","Germany","2014","2014",795.5,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MLLNCUMT","Million of national currency units","DEU","Germany","2015","2015",796.2,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MLLNCUMT","Million of national currency units","DEU","Germany","2016","2016",772.4,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MLLNCUMT","Million of national currency units","DEU","Germany","2017","2017",695.7,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MLLNCUMT","Million of national currency units","DEU","Germany","2018","2018",687,"B; D","Break; Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MLLNCUMT","Million of national currency units","DEU","Germany","2019","2019",670.7,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MLLNCUMT","Million of national currency units","DEU","Germany","2020","2020",620,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MLLNCUMT","Million of national currency units","DEU","Germany","2021","2021",595.9,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOTCMT","Million US$ at exchange rate","DEU","Germany","2010","2010",1209.1,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOTCMT","Million US$ at exchange rate","DEU","Germany","2011","2011",1109,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOTCMT","Million US$ at exchange rate","DEU","Germany","2012","2012",1034.8,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOTCMT","Million US$ at exchange rate","DEU","Germany","2013","2013",1034.3,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOTCMT","Million US$ at exchange rate","DEU","Germany","2014","2014",1056.8,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOTCMT","Million US$ at exchange rate","DEU","Germany","2015","2015",883.4,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOTCMT","Million US$ at exchange rate","DEU","Germany","2016","2016",855,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOTCMT","Million US$ at exchange rate","DEU","Germany","2017","2017",785.9,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOTCMT","Million US$ at exchange rate","DEU","Germany","2018","2018",811.3,"B; D","Break; Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOTCMT","Million US$ at exchange rate","DEU","Germany","2019","2019",750.8,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOTCMT","Million US$ at exchange rate","DEU","Germany","2020","2020",708.2,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOTCMT","Million US$ at exchange rate","DEU","Germany","2021","2021",704.8,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOPPMT","Million US$, purchasing power parity","DEU","Germany","2010","2010",1132.8,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOPPMT","Million US$, purchasing power parity","DEU","Germany","2011","2011",1010.1,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOPPMT","Million US$, purchasing power parity","DEU","Germany","2012","2012",1023.1,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOPPMT","Million US$, purchasing power parity","DEU","Germany","2013","2013",1005.2,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOPPMT","Million US$, purchasing power parity","DEU","Germany","2014","2014",1034.5,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOPPMT","Million US$, purchasing power parity","DEU","Germany","2015","2015",1023.2,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOPPMT","Million US$, purchasing power parity","DEU","Germany","2016","2016",1026.3,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOPPMT","Million US$, purchasing power parity","DEU","Germany","2017","2017",934.1,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOPPMT","Million US$, purchasing power parity","DEU","Germany","2018","2018",934.1,"B; D","Break; Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOPPMT","Million US$, purchasing power parity","DEU","Germany","2019","2019",921,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOPPMT","Million US$, purchasing power parity","DEU","Germany","2020","2020",855.2,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOPPMT","Million US$, purchasing power parity","DEU","Germany","2021","2021",809.3,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","TCPPERMT","/capita, US$ exchange rate","DEU","Germany","2010","2010",14.8,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","TCPPERMT","/capita, US$ exchange rate","DEU","Germany","2011","2011",13.8,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","TCPPERMT","/capita, US$ exchange rate","DEU","Germany","2012","2012",12.9,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","TCPPERMT","/capita, US$ exchange rate","DEU","Germany","2013","2013",12.8,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","TCPPERMT","/capita, US$ exchange rate","DEU","Germany","2014","2014",13.1,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","TCPPERMT","/capita, US$ exchange rate","DEU","Germany","2015","2015",10.8,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","TCPPERMT","/capita, US$ exchange rate","DEU","Germany","2016","2016",10.4,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","TCPPERMT","/capita, US$ exchange rate","DEU","Germany","2017","2017",9.5,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","TCPPERMT","/capita, US$ exchange rate","DEU","Germany","2018","2018",9.8,"B; D","Break; Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","TCPPERMT","/capita, US$ exchange rate","DEU","Germany","2019","2019",9,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","TCPPERMT","/capita, US$ exchange rate","DEU","Germany","2020","2020",8.5,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","TCPPERMT","/capita, US$ exchange rate","DEU","Germany","2021","2021",8.5,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2010","2010",13.9,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2011","2011",12.6,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2012","2012",12.7,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2013","2013",12.5,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2014","2014",12.8,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2015","2015",12.5,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2016","2016",12.5,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2017","2017",11.3,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2018","2018",11.3,"B; D","Break; Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2019","2019",11.1,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2020","2020",10.3,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2021","2021",9.7,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","ATCPTTMT","% of total sales","DEU","Germany","2010","2010",3.1,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","ATCPTTMT","% of total sales","DEU","Germany","2011","2011",2.7,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","ATCPTTMT","% of total sales","DEU","Germany","2012","2012",2.6,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","ATCPTTMT","% of total sales","DEU","Germany","2013","2013",2.5,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","ATCPTTMT","% of total sales","DEU","Germany","2014","2014",2.4,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","ATCPTTMT","% of total sales","DEU","Germany","2015","2015",2.3,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","ATCPTTMT","% of total sales","DEU","Germany","2016","2016",2.1,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","ATCPTTMT","% of total sales","DEU","Germany","2017","2017",1.9,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","ATCPTTMT","% of total sales","DEU","Germany","2018","2018",1.6,"B; D","Break; Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","ATCPTTMT","% of total sales","DEU","Germany","2019","2019",1.4,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","ATCPTTMT","% of total sales","DEU","Germany","2020","2020",1.3,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","ATCPTTMT","% of total sales","DEU","Germany","2021","2021",1.1,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MLLNCUMT","Million of national currency units","GRC","Greece","2010","2010",321.2,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MLLNCUMT","Million of national currency units","GRC","Greece","2011","2011",264.7,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MLLNCUMT","Million of national currency units","GRC","Greece","2012","2012",222.9,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MLLNCUMT","Million of national currency units","GRC","Greece","2013","2013",180,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MLLNCUMT","Million of national currency units","GRC","Greece","2014","2014",161.5,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MLLNCUMT","Million of national currency units","GRC","Greece","2015","2015",155.1,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MLLNCUMT","Million of national currency units","GRC","Greece","2016","2016",166.8,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MLLNCUMT","Million of national currency units","GRC","Greece","2017","2017",152.5,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MLLNCUMT","Million of national currency units","GRC","Greece","2018","2018",150.7,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MLLNCUMT","Million of national currency units","GRC","Greece","2019","2019",146.6,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MLLNCUMT","Million of national currency units","GRC","Greece","2020","2020",144.1,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MLLNCUMT","Million of national currency units","GRC","Greece","2021","2021",154.6,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MLLNCUMT","Million of national currency units","GRC","Greece","2022","2022",118.2,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOTCMT","Million US$ at exchange rate","GRC","Greece","2010","2010",425.8,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOTCMT","Million US$ at exchange rate","GRC","Greece","2011","2011",368.5,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOTCMT","Million US$ at exchange rate","GRC","Greece","2012","2012",286.4,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOTCMT","Million US$ at exchange rate","GRC","Greece","2013","2013",239,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOTCMT","Million US$ at exchange rate","GRC","Greece","2014","2014",214.6,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOTCMT","Million US$ at exchange rate","GRC","Greece","2015","2015",172,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOTCMT","Million US$ at exchange rate","GRC","Greece","2016","2016",184.6,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOTCMT","Million US$ at exchange rate","GRC","Greece","2017","2017",172.3,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOTCMT","Million US$ at exchange rate","GRC","Greece","2018","2018",177.9,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOTCMT","Million US$ at exchange rate","GRC","Greece","2019","2019",164.1,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOTCMT","Million US$ at exchange rate","GRC","Greece","2020","2020",164.6,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOTCMT","Million US$ at exchange rate","GRC","Greece","2021","2021",182.8,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOTCMT","Million US$ at exchange rate","GRC","Greece","2022","2022",124.5,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOPPMT","Million US$, purchasing power parity","GRC","Greece","2010","2010",444.8,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOPPMT","Million US$, purchasing power parity","GRC","Greece","2011","2011",371.2,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOPPMT","Million US$, purchasing power parity","GRC","Greece","2012","2012",325.6,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOPPMT","Million US$, purchasing power parity","GRC","Greece","2013","2013",285.1,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOPPMT","Million US$, purchasing power parity","GRC","Greece","2014","2014",264.3,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOPPMT","Million US$, purchasing power parity","GRC","Greece","2015","2015",254.6,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOPPMT","Million US$, purchasing power parity","GRC","Greece","2016","2016",283.4,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOPPMT","Million US$, purchasing power parity","GRC","Greece","2017","2017",265.3,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOPPMT","Million US$, purchasing power parity","GRC","Greece","2018","2018",266.7,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOPPMT","Million US$, purchasing power parity","GRC","Greece","2019","2019",267.1,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOPPMT","Million US$, purchasing power parity","GRC","Greece","2020","2020",264.8,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOPPMT","Million US$, purchasing power parity","GRC","Greece","2021","2021",283.3,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOPPMT","Million US$, purchasing power parity","GRC","Greece","2022","2022",223.7,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","TCPPERMT","/capita, US$ exchange rate","GRC","Greece","2010","2010",38.3,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","TCPPERMT","/capita, US$ exchange rate","GRC","Greece","2011","2011",33.2,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","TCPPERMT","/capita, US$ exchange rate","GRC","Greece","2012","2012",25.9,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","TCPPERMT","/capita, US$ exchange rate","GRC","Greece","2013","2013",21.8,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","TCPPERMT","/capita, US$ exchange rate","GRC","Greece","2014","2014",19.7,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","TCPPERMT","/capita, US$ exchange rate","GRC","Greece","2015","2015",15.9,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","TCPPERMT","/capita, US$ exchange rate","GRC","Greece","2016","2016",17.1,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","TCPPERMT","/capita, US$ exchange rate","GRC","Greece","2017","2017",16,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","TCPPERMT","/capita, US$ exchange rate","GRC","Greece","2018","2018",16.6,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","TCPPERMT","/capita, US$ exchange rate","GRC","Greece","2019","2019",15.3,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","TCPPERMT","/capita, US$ exchange rate","GRC","Greece","2020","2020",15.4,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","TCPPERMT","/capita, US$ exchange rate","GRC","Greece","2021","2021",17.3,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","TCPPERMT","/capita, US$ exchange rate","GRC","Greece","2022","2022",11.9,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2010","2010",40,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2011","2011",33.4,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2012","2012",29.5,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2013","2013",26,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2014","2014",24.3,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2015","2015",23.5,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2016","2016",26.3,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2017","2017",24.7,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2018","2018",24.9,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2019","2019",24.9,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2020","2020",24.8,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2021","2021",26.8,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2022","2022",21.4,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MLLNCUMT","Million of national currency units","HUN","Hungary","2010","2010",18687.7,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MLLNCUMT","Million of national currency units","HUN","Hungary","2011","2011",18507.6,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MLLNCUMT","Million of national currency units","HUN","Hungary","2012","2012",12740.4,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MLLNCUMT","Million of national currency units","HUN","Hungary","2013","2013",9057.7,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MLLNCUMT","Million of national currency units","HUN","Hungary","2014","2014",8814.9,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MLLNCUMT","Million of national currency units","HUN","Hungary","2015","2015",8905.5,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MLLNCUMT","Million of national currency units","HUN","Hungary","2016","2016",8548.3,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MLLNCUMT","Million of national currency units","HUN","Hungary","2017","2017",8825.9,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MLLNCUMT","Million of national currency units","HUN","Hungary","2018","2018",9239.6,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MLLNCUMT","Million of national currency units","HUN","Hungary","2019","2019",11030.9,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MLLNCUMT","Million of national currency units","HUN","Hungary","2020","2020",13882.7,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MLLNCUMT","Million of national currency units","HUN","Hungary","2021","2021",13825.2,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MLLNCUMT","Million of national currency units","HUN","Hungary","2022","2022",14075.3,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOTCMT","Million US$ at exchange rate","HUN","Hungary","2010","2010",89.9,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOTCMT","Million US$ at exchange rate","HUN","Hungary","2011","2011",92.1,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOTCMT","Million US$ at exchange rate","HUN","Hungary","2012","2012",56.6,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOTCMT","Million US$ at exchange rate","HUN","Hungary","2013","2013",40.5,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOTCMT","Million US$ at exchange rate","HUN","Hungary","2014","2014",37.9,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOTCMT","Million US$ at exchange rate","HUN","Hungary","2015","2015",31.9,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOTCMT","Million US$ at exchange rate","HUN","Hungary","2016","2016",30.4,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOTCMT","Million US$ at exchange rate","HUN","Hungary","2017","2017",32.2,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOTCMT","Million US$ at exchange rate","HUN","Hungary","2018","2018",34.2,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOTCMT","Million US$ at exchange rate","HUN","Hungary","2019","2019",38,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOTCMT","Million US$ at exchange rate","HUN","Hungary","2020","2020",45.1,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOTCMT","Million US$ at exchange rate","HUN","Hungary","2021","2021",45.6,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOTCMT","Million US$ at exchange rate","HUN","Hungary","2022","2022",37.8,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOPPMT","Million US$, purchasing power parity","HUN","Hungary","2010","2010",147.8,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOPPMT","Million US$, purchasing power parity","HUN","Hungary","2011","2011",148.9,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOPPMT","Million US$, purchasing power parity","HUN","Hungary","2012","2012",101.4,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOPPMT","Million US$, purchasing power parity","HUN","Hungary","2013","2013",72.5,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOPPMT","Million US$, purchasing power parity","HUN","Hungary","2014","2014",68.1,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOPPMT","Million US$, purchasing power parity","HUN","Hungary","2015","2015",67.2,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOPPMT","Million US$, purchasing power parity","HUN","Hungary","2016","2016",64.7,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOPPMT","Million US$, purchasing power parity","HUN","Hungary","2017","2017",64.9,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOPPMT","Million US$, purchasing power parity","HUN","Hungary","2018","2018",66.4,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOPPMT","Million US$, purchasing power parity","HUN","Hungary","2019","2019",78.3,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOPPMT","Million US$, purchasing power parity","HUN","Hungary","2020","2020",95.5,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOPPMT","Million US$, purchasing power parity","HUN","Hungary","2021","2021",89.3,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOPPMT","Million US$, purchasing power parity","HUN","Hungary","2022","2022",87.3,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","TCPPERMT","/capita, US$ exchange rate","HUN","Hungary","2010","2010",9,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","TCPPERMT","/capita, US$ exchange rate","HUN","Hungary","2011","2011",9.2,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","TCPPERMT","/capita, US$ exchange rate","HUN","Hungary","2012","2012",5.7,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","TCPPERMT","/capita, US$ exchange rate","HUN","Hungary","2013","2013",4.1,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","TCPPERMT","/capita, US$ exchange rate","HUN","Hungary","2014","2014",3.8,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","TCPPERMT","/capita, US$ exchange rate","HUN","Hungary","2015","2015",3.2,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","TCPPERMT","/capita, US$ exchange rate","HUN","Hungary","2016","2016",3.1,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","TCPPERMT","/capita, US$ exchange rate","HUN","Hungary","2017","2017",3.3,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","TCPPERMT","/capita, US$ exchange rate","HUN","Hungary","2018","2018",3.5,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","TCPPERMT","/capita, US$ exchange rate","HUN","Hungary","2019","2019",3.9,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","TCPPERMT","/capita, US$ exchange rate","HUN","Hungary","2020","2020",4.6,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","TCPPERMT","/capita, US$ exchange rate","HUN","Hungary","2021","2021",4.7,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","TCPPERMT","/capita, US$ exchange rate","HUN","Hungary","2022","2022",3.9,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2010","2010",14.8,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2011","2011",14.9,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2012","2012",10.2,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2013","2013",7.3,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2014","2014",6.9,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2015","2015",6.8,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2016","2016",6.6,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2017","2017",6.6,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2018","2018",6.8,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2019","2019",8,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2020","2020",9.8,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2021","2021",9.2,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2022","2022",9,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","ATCPTTMT","% of total sales","HUN","Hungary","2010","2010",3.8,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","ATCPTTMT","% of total sales","HUN","Hungary","2011","2011",3.6,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","ATCPTTMT","% of total sales","HUN","Hungary","2012","2012",2.9,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","ATCPTTMT","% of total sales","HUN","Hungary","2013","2013",2.1,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","ATCPTTMT","% of total sales","HUN","Hungary","2014","2014",2,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","ATCPTTMT","% of total sales","HUN","Hungary","2015","2015",1.9,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","ATCPTTMT","% of total sales","HUN","Hungary","2016","2016",1.7,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","ATCPTTMT","% of total sales","HUN","Hungary","2017","2017",1.8,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","ATCPTTMT","% of total sales","HUN","Hungary","2018","2018",1.8,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","ATCPTTMT","% of total sales","HUN","Hungary","2019","2019",2.1,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","ATCPTTMT","% of total sales","HUN","Hungary","2020","2020",2.5,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","ATCPTTMT","% of total sales","HUN","Hungary","2021","2021",2.4,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","ATCPTTMT","% of total sales","HUN","Hungary","2022","2022",2.4,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MLLNCUMT","Million of national currency units","ISL","Iceland","2010","2010",853.4,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MLLNCUMT","Million of national currency units","ISL","Iceland","2011","2011",808.1,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MLLNCUMT","Million of national currency units","ISL","Iceland","2012","2012",581,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MLLNCUMT","Million of national currency units","ISL","Iceland","2013","2013",621,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MLLNCUMT","Million of national currency units","ISL","Iceland","2014","2014",569.9,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MLLNCUMT","Million of national currency units","ISL","Iceland","2015","2015",561.1,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MLLNCUMT","Million of national currency units","ISL","Iceland","2016","2016",596.9,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MLLNCUMT","Million of national currency units","ISL","Iceland","2017","2017",626.3,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MLLNCUMT","Million of national currency units","ISL","Iceland","2018","2018",666.8,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MLLNCUMT","Million of national currency units","ISL","Iceland","2019","2019",700.7,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MLLNCUMT","Million of national currency units","ISL","Iceland","2020","2020",778.7,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MLLNCUMT","Million of national currency units","ISL","Iceland","2021","2021",838.1,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOTCMT","Million US$ at exchange rate","ISL","Iceland","2010","2010",7,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOTCMT","Million US$ at exchange rate","ISL","Iceland","2011","2011",7,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOTCMT","Million US$ at exchange rate","ISL","Iceland","2012","2012",4.6,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOTCMT","Million US$ at exchange rate","ISL","Iceland","2013","2013",5.1,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOTCMT","Million US$ at exchange rate","ISL","Iceland","2014","2014",4.9,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOTCMT","Million US$ at exchange rate","ISL","Iceland","2015","2015",4.3,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOTCMT","Million US$ at exchange rate","ISL","Iceland","2016","2016",4.9,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOTCMT","Million US$ at exchange rate","ISL","Iceland","2017","2017",5.9,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOTCMT","Million US$ at exchange rate","ISL","Iceland","2018","2018",6.2,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOTCMT","Million US$ at exchange rate","ISL","Iceland","2019","2019",5.7,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOTCMT","Million US$ at exchange rate","ISL","Iceland","2020","2020",5.8,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOTCMT","Million US$ at exchange rate","ISL","Iceland","2021","2021",6.6,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOPPMT","Million US$, purchasing power parity","ISL","Iceland","2010","2010",6.4,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOPPMT","Million US$, purchasing power parity","ISL","Iceland","2011","2011",6,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOPPMT","Million US$, purchasing power parity","ISL","Iceland","2012","2012",4.2,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOPPMT","Million US$, purchasing power parity","ISL","Iceland","2013","2013",4.5,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOPPMT","Million US$, purchasing power parity","ISL","Iceland","2014","2014",4.1,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOPPMT","Million US$, purchasing power parity","ISL","Iceland","2015","2015",4,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOPPMT","Million US$, purchasing power parity","ISL","Iceland","2016","2016",4.3,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOPPMT","Million US$, purchasing power parity","ISL","Iceland","2017","2017",4.5,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOPPMT","Million US$, purchasing power parity","ISL","Iceland","2018","2018",4.7,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOPPMT","Million US$, purchasing power parity","ISL","Iceland","2019","2019",5,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOPPMT","Million US$, purchasing power parity","ISL","Iceland","2020","2020",5.3,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOPPMT","Million US$, purchasing power parity","ISL","Iceland","2021","2021",5.6,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","TCPPERMT","/capita, US$ exchange rate","ISL","Iceland","2010","2010",22,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","TCPPERMT","/capita, US$ exchange rate","ISL","Iceland","2011","2011",21.8,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","TCPPERMT","/capita, US$ exchange rate","ISL","Iceland","2012","2012",14.5,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","TCPPERMT","/capita, US$ exchange rate","ISL","Iceland","2013","2013",15.7,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","TCPPERMT","/capita, US$ exchange rate","ISL","Iceland","2014","2014",14.9,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","TCPPERMT","/capita, US$ exchange rate","ISL","Iceland","2015","2015",12.9,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","TCPPERMT","/capita, US$ exchange rate","ISL","Iceland","2016","2016",14.7,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","TCPPERMT","/capita, US$ exchange rate","ISL","Iceland","2017","2017",17.1,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","TCPPERMT","/capita, US$ exchange rate","ISL","Iceland","2018","2018",17.5,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","TCPPERMT","/capita, US$ exchange rate","ISL","Iceland","2019","2019",15.9,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","TCPPERMT","/capita, US$ exchange rate","ISL","Iceland","2020","2020",15.7,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","TCPPERMT","/capita, US$ exchange rate","ISL","Iceland","2021","2021",17.7,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2010","2010",20.2,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2011","2011",18.7,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2012","2012",13.2,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2013","2013",14,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2014","2014",12.6,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2015","2015",11.9,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2016","2016",12.7,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2017","2017",13.2,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2018","2018",13.4,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2019","2019",13.8,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2020","2020",14.5,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2021","2021",15,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","ATCPTTMT","% of total sales","ISL","Iceland","2010","2010",3.4,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","ATCPTTMT","% of total sales","ISL","Iceland","2011","2011",3.1,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","ATCPTTMT","% of total sales","ISL","Iceland","2012","2012",2.4,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","ATCPTTMT","% of total sales","ISL","Iceland","2013","2013",2.4,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","ATCPTTMT","% of total sales","ISL","Iceland","2014","2014",2.4,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","ATCPTTMT","% of total sales","ISL","Iceland","2015","2015",2.3,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","ATCPTTMT","% of total sales","ISL","Iceland","2016","2016",2.4,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","ATCPTTMT","% of total sales","ISL","Iceland","2017","2017",2.4,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","ATCPTTMT","% of total sales","ISL","Iceland","2018","2018",2.2,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","ATCPTTMT","% of total sales","ISL","Iceland","2019","2019",2.1,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","ATCPTTMT","% of total sales","ISL","Iceland","2020","2020",2,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","ATCPTTMT","% of total sales","ISL","Iceland","2021","2021",1.9,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MLLNCUMT","Million of national currency units","IRL","Ireland","2010","2010",135,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MLLNCUMT","Million of national currency units","IRL","Ireland","2011","2011",107.7,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MLLNCUMT","Million of national currency units","IRL","Ireland","2012","2012",108.5,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MLLNCUMT","Million of national currency units","IRL","Ireland","2013","2013",95,"B; D","Break; Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MLLNCUMT","Million of national currency units","IRL","Ireland","2014","2014",66.3,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MLLNCUMT","Million of national currency units","IRL","Ireland","2015","2015",55.6,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MLLNCUMT","Million of national currency units","IRL","Ireland","2016","2016",52.4,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MLLNCUMT","Million of national currency units","IRL","Ireland","2017","2017",51.7,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MLLNCUMT","Million of national currency units","IRL","Ireland","2018","2018",52,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MLLNCUMT","Million of national currency units","IRL","Ireland","2019","2019",53,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MLLNCUMT","Million of national currency units","IRL","Ireland","2020","2020",54.2,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MLLNCUMT","Million of national currency units","IRL","Ireland","2021","2021",56.2,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOTCMT","Million US$ at exchange rate","IRL","Ireland","2010","2010",178.9,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOTCMT","Million US$ at exchange rate","IRL","Ireland","2011","2011",150,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOTCMT","Million US$ at exchange rate","IRL","Ireland","2012","2012",139.4,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOTCMT","Million US$ at exchange rate","IRL","Ireland","2013","2013",126.2,"B; D","Break; Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOTCMT","Million US$ at exchange rate","IRL","Ireland","2014","2014",88.1,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOTCMT","Million US$ at exchange rate","IRL","Ireland","2015","2015",61.7,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOTCMT","Million US$ at exchange rate","IRL","Ireland","2016","2016",58,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOTCMT","Million US$ at exchange rate","IRL","Ireland","2017","2017",58.4,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOTCMT","Million US$ at exchange rate","IRL","Ireland","2018","2018",61.4,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOTCMT","Million US$ at exchange rate","IRL","Ireland","2019","2019",59.3,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOTCMT","Million US$ at exchange rate","IRL","Ireland","2020","2020",61.9,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOTCMT","Million US$ at exchange rate","IRL","Ireland","2021","2021",66.4,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOPPMT","Million US$, purchasing power parity","IRL","Ireland","2010","2010",158.9,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOPPMT","Million US$, purchasing power parity","IRL","Ireland","2011","2011",129.6,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOPPMT","Million US$, purchasing power parity","IRL","Ireland","2012","2012",131.8,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOPPMT","Million US$, purchasing power parity","IRL","Ireland","2013","2013",117.2,"B; D","Break; Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOPPMT","Million US$, purchasing power parity","IRL","Ireland","2014","2014",81,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOPPMT","Million US$, purchasing power parity","IRL","Ireland","2015","2015",68.6,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOPPMT","Million US$, purchasing power parity","IRL","Ireland","2016","2016",66,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOPPMT","Million US$, purchasing power parity","IRL","Ireland","2017","2017",65.1,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOPPMT","Million US$, purchasing power parity","IRL","Ireland","2018","2018",65.6,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOPPMT","Million US$, purchasing power parity","IRL","Ireland","2019","2019",65.7,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOPPMT","Million US$, purchasing power parity","IRL","Ireland","2020","2020",68.1,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOPPMT","Million US$, purchasing power parity","IRL","Ireland","2021","2021",70.7,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","TCPPERMT","/capita, US$ exchange rate","IRL","Ireland","2010","2010",39.2,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","TCPPERMT","/capita, US$ exchange rate","IRL","Ireland","2011","2011",32.7,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","TCPPERMT","/capita, US$ exchange rate","IRL","Ireland","2012","2012",30.3,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","TCPPERMT","/capita, US$ exchange rate","IRL","Ireland","2013","2013",27.3,"B; D","Break; Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","TCPPERMT","/capita, US$ exchange rate","IRL","Ireland","2014","2014",18.9,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","TCPPERMT","/capita, US$ exchange rate","IRL","Ireland","2015","2015",13.1,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","TCPPERMT","/capita, US$ exchange rate","IRL","Ireland","2016","2016",12.2,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","TCPPERMT","/capita, US$ exchange rate","IRL","Ireland","2017","2017",12.1,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","TCPPERMT","/capita, US$ exchange rate","IRL","Ireland","2018","2018",12.6,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","TCPPERMT","/capita, US$ exchange rate","IRL","Ireland","2019","2019",12,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","TCPPERMT","/capita, US$ exchange rate","IRL","Ireland","2020","2020",12.4,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","TCPPERMT","/capita, US$ exchange rate","IRL","Ireland","2021","2021",13.2,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2010","2010",34.8,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2011","2011",28.3,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2012","2012",28.7,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2013","2013",25.3,"B; D","Break; Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2014","2014",17.4,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2015","2015",14.6,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2016","2016",13.9,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2017","2017",13.5,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2018","2018",13.5,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2019","2019",13.3,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2020","2020",13.7,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2021","2021",14,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","ATCPTTMT","% of total sales","IRL","Ireland","2010","2010",6.6,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","ATCPTTMT","% of total sales","IRL","Ireland","2011","2011",5.5,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","ATCPTTMT","% of total sales","IRL","Ireland","2012","2012",5.3,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","ATCPTTMT","% of total sales","IRL","Ireland","2013","2013",4.8,"B; D","Break; Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","ATCPTTMT","% of total sales","IRL","Ireland","2014","2014",3.5,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","ATCPTTMT","% of total sales","IRL","Ireland","2015","2015",2.8,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","ATCPTTMT","% of total sales","IRL","Ireland","2016","2016",2.5,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","ATCPTTMT","% of total sales","IRL","Ireland","2017","2017",2.4,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","ATCPTTMT","% of total sales","IRL","Ireland","2018","2018",2.3,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","ATCPTTMT","% of total sales","IRL","Ireland","2019","2019",2.2,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","ATCPTTMT","% of total sales","IRL","Ireland","2020","2020",2.2,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","ATCPTTMT","% of total sales","IRL","Ireland","2021","2021",2.1,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MLLNCUMT","Million of national currency units","ITA","Italy","2011","2011",987.4,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MLLNCUMT","Million of national currency units","ITA","Italy","2012","2012",979.9,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MLLNCUMT","Million of national currency units","ITA","Italy","2013","2013",997.3,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MLLNCUMT","Million of national currency units","ITA","Italy","2014","2014",1037,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MLLNCUMT","Million of national currency units","ITA","Italy","2015","2015",981.7,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MLLNCUMT","Million of national currency units","ITA","Italy","2016","2016",907.1,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MLLNCUMT","Million of national currency units","ITA","Italy","2017","2017",889.8,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MLLNCUMT","Million of national currency units","ITA","Italy","2018","2018",843.2,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MLLNCUMT","Million of national currency units","ITA","Italy","2019","2019",791.4,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MLLNCUMT","Million of national currency units","ITA","Italy","2020","2020",753.4,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MLLNCUMT","Million of national currency units","ITA","Italy","2021","2021",753,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MLLNCUMT","Million of national currency units","ITA","Italy","2022","2022",720,"E","Estimated value"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOTCMT","Million US$ at exchange rate","ITA","Italy","2011","2011",1374.5,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOTCMT","Million US$ at exchange rate","ITA","Italy","2012","2012",1259,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOTCMT","Million US$ at exchange rate","ITA","Italy","2013","2013",1324.5,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOTCMT","Million US$ at exchange rate","ITA","Italy","2014","2014",1377.7,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOTCMT","Million US$ at exchange rate","ITA","Italy","2015","2015",1089.2,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOTCMT","Million US$ at exchange rate","ITA","Italy","2016","2016",1004.1,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOTCMT","Million US$ at exchange rate","ITA","Italy","2017","2017",1005.2,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOTCMT","Million US$ at exchange rate","ITA","Italy","2018","2018",995.8,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOTCMT","Million US$ at exchange rate","ITA","Italy","2019","2019",886,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOTCMT","Million US$ at exchange rate","ITA","Italy","2020","2020",860.5,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOTCMT","Million US$ at exchange rate","ITA","Italy","2021","2021",890.6,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOTCMT","Million US$ at exchange rate","ITA","Italy","2022","2022",758.2,"E","Estimated value"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOPPMT","Million US$, purchasing power parity","ITA","Italy","2011","2011",1301.5,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOPPMT","Million US$, purchasing power parity","ITA","Italy","2012","2012",1310.5,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOPPMT","Million US$, purchasing power parity","ITA","Italy","2013","2013",1352.6,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOPPMT","Million US$, purchasing power parity","ITA","Italy","2014","2014",1402,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOPPMT","Million US$, purchasing power parity","ITA","Italy","2015","2015",1328.9,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOPPMT","Million US$, purchasing power parity","ITA","Italy","2016","2016",1294.9,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOPPMT","Million US$, purchasing power parity","ITA","Italy","2017","2017",1289.8,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOPPMT","Million US$, purchasing power parity","ITA","Italy","2018","2018",1237.8,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOPPMT","Million US$, purchasing power parity","ITA","Italy","2019","2019",1205,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOPPMT","Million US$, purchasing power parity","ITA","Italy","2020","2020",1163.1,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOPPMT","Million US$, purchasing power parity","ITA","Italy","2021","2021",1162.8,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOPPMT","Million US$, purchasing power parity","ITA","Italy","2022","2022",1166.2,"E","Estimated value"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","TCPPERMT","/capita, US$ exchange rate","ITA","Italy","2011","2011",23.1,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","TCPPERMT","/capita, US$ exchange rate","ITA","Italy","2012","2012",21.1,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","TCPPERMT","/capita, US$ exchange rate","ITA","Italy","2013","2013",22,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","TCPPERMT","/capita, US$ exchange rate","ITA","Italy","2014","2014",22.7,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","TCPPERMT","/capita, US$ exchange rate","ITA","Italy","2015","2015",17.9,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","TCPPERMT","/capita, US$ exchange rate","ITA","Italy","2016","2016",16.6,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","TCPPERMT","/capita, US$ exchange rate","ITA","Italy","2017","2017",16.6,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","TCPPERMT","/capita, US$ exchange rate","ITA","Italy","2018","2018",16.5,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","TCPPERMT","/capita, US$ exchange rate","ITA","Italy","2019","2019",14.8,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","TCPPERMT","/capita, US$ exchange rate","ITA","Italy","2020","2020",14.5,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","TCPPERMT","/capita, US$ exchange rate","ITA","Italy","2021","2021",15.1,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","TCPPERMT","/capita, US$ exchange rate","ITA","Italy","2022","2022",12.8,"E","Estimated value"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2011","2011",21.9,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2012","2012",22,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2013","2013",22.5,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2014","2014",23.1,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2015","2015",21.9,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2016","2016",21.4,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2017","2017",21.3,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2018","2018",20.5,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2019","2019",20.2,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2020","2020",19.6,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2021","2021",19.7,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2022","2022",19.8,"E","Estimated value"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","ATCPTTMT","% of total sales","ITA","Italy","2011","2011",5.1,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","ATCPTTMT","% of total sales","ITA","Italy","2012","2012",5.1,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","ATCPTTMT","% of total sales","ITA","Italy","2013","2013",5.1,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","ATCPTTMT","% of total sales","ITA","Italy","2014","2014",5.2,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","ATCPTTMT","% of total sales","ITA","Italy","2015","2015",4.3,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","ATCPTTMT","% of total sales","ITA","Italy","2016","2016",4,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","ATCPTTMT","% of total sales","ITA","Italy","2017","2017",3.9,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","ATCPTTMT","% of total sales","ITA","Italy","2018","2018",3.8,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","ATCPTTMT","% of total sales","ITA","Italy","2019","2019",3.5,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","ATCPTTMT","% of total sales","ITA","Italy","2020","2020",3.3,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","ATCPTTMT","% of total sales","ITA","Italy","2021","2021",3.2,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","ATCPTTMT","% of total sales","ITA","Italy","2022","2022",2.9,"E","Estimated value"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MLLNCUMT","Million of national currency units","KOR","Korea","2010","2010",727243,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MLLNCUMT","Million of national currency units","KOR","Korea","2011","2011",785646.1,"B","Break"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MLLNCUMT","Million of national currency units","KOR","Korea","2012","2012",750318.6,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MLLNCUMT","Million of national currency units","KOR","Korea","2013","2013",779352.5,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MLLNCUMT","Million of national currency units","KOR","Korea","2014","2014",824285.9,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MLLNCUMT","Million of national currency units","KOR","Korea","2015","2015",872847.8,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MLLNCUMT","Million of national currency units","KOR","Korea","2016","2016",900276.8,"B","Break"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MLLNCUMT","Million of national currency units","KOR","Korea","2017","2017",961820.6,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MLLNCUMT","Million of national currency units","KOR","Korea","2018","2018",1039828.3,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MLLNCUMT","Million of national currency units","KOR","Korea","2019","2019",1070467.7,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MLLNCUMT","Million of national currency units","KOR","Korea","2020","2020",1093712,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MLLNCUMT","Million of national currency units","KOR","Korea","2021","2021",1225994.3,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOTCMT","Million US$ at exchange rate","KOR","Korea","2010","2010",628.9,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOTCMT","Million US$ at exchange rate","KOR","Korea","2011","2011",708.9,"B","Break"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOTCMT","Million US$ at exchange rate","KOR","Korea","2012","2012",665.9,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOTCMT","Million US$ at exchange rate","KOR","Korea","2013","2013",711.7,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOTCMT","Million US$ at exchange rate","KOR","Korea","2014","2014",782.9,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOTCMT","Million US$ at exchange rate","KOR","Korea","2015","2015",771.8,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOTCMT","Million US$ at exchange rate","KOR","Korea","2016","2016",775.6,"B","Break"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOTCMT","Million US$ at exchange rate","KOR","Korea","2017","2017",850.4,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOTCMT","Million US$ at exchange rate","KOR","Korea","2018","2018",945.2,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOTCMT","Million US$ at exchange rate","KOR","Korea","2019","2019",918.6,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOTCMT","Million US$ at exchange rate","KOR","Korea","2020","2020",926.7,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOTCMT","Million US$ at exchange rate","KOR","Korea","2021","2021",1071.7,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOPPMT","Million US$, purchasing power parity","KOR","Korea","2010","2010",864.7,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOPPMT","Million US$, purchasing power parity","KOR","Korea","2011","2011",919.3,"B","Break"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOPPMT","Million US$, purchasing power parity","KOR","Korea","2012","2012",877.7,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOPPMT","Million US$, purchasing power parity","KOR","Korea","2013","2013",896.8,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOPPMT","Million US$, purchasing power parity","KOR","Korea","2014","2014",945.4,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOPPMT","Million US$, purchasing power parity","KOR","Korea","2015","2015",1017.9,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOPPMT","Million US$, purchasing power parity","KOR","Korea","2016","2016",1048.3,"B","Break"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOPPMT","Million US$, purchasing power parity","KOR","Korea","2017","2017",1102.2,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOPPMT","Million US$, purchasing power parity","KOR","Korea","2018","2018",1216.4,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOPPMT","Million US$, purchasing power parity","KOR","Korea","2019","2019",1249.9,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOPPMT","Million US$, purchasing power parity","KOR","Korea","2020","2020",1305.7,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOPPMT","Million US$, purchasing power parity","KOR","Korea","2021","2021",1435.4,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","TCPPERMT","/capita, US$ exchange rate","KOR","Korea","2010","2010",12.7,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","TCPPERMT","/capita, US$ exchange rate","KOR","Korea","2011","2011",14.2,"B","Break"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","TCPPERMT","/capita, US$ exchange rate","KOR","Korea","2012","2012",13.3,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","TCPPERMT","/capita, US$ exchange rate","KOR","Korea","2013","2013",14.1,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","TCPPERMT","/capita, US$ exchange rate","KOR","Korea","2014","2014",15.4,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","TCPPERMT","/capita, US$ exchange rate","KOR","Korea","2015","2015",15.1,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","TCPPERMT","/capita, US$ exchange rate","KOR","Korea","2016","2016",15.1,"B","Break"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","TCPPERMT","/capita, US$ exchange rate","KOR","Korea","2017","2017",16.6,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","TCPPERMT","/capita, US$ exchange rate","KOR","Korea","2018","2018",18.3,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","TCPPERMT","/capita, US$ exchange rate","KOR","Korea","2019","2019",17.7,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","TCPPERMT","/capita, US$ exchange rate","KOR","Korea","2020","2020",17.9,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","TCPPERMT","/capita, US$ exchange rate","KOR","Korea","2021","2021",20.7,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2010","2010",17.5,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2011","2011",18.4,"B","Break"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2012","2012",17.5,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2013","2013",17.8,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2014","2014",18.6,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2015","2015",20,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2016","2016",20.5,"B","Break"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2017","2017",21.5,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2018","2018",23.6,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2019","2019",24.1,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2020","2020",25.2,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2021","2021",27.7,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","ATCPTTMT","% of total sales","KOR","Korea","2010","2010",3.6,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","ATCPTTMT","% of total sales","KOR","Korea","2011","2011",3.6,"B","Break"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","ATCPTTMT","% of total sales","KOR","Korea","2012","2012",3.5,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","ATCPTTMT","% of total sales","KOR","Korea","2013","2013",3.5,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","ATCPTTMT","% of total sales","KOR","Korea","2014","2014",3.5,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","ATCPTTMT","% of total sales","KOR","Korea","2015","2015",3.5,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","ATCPTTMT","% of total sales","KOR","Korea","2016","2016",3.5,"B","Break"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","ATCPTTMT","% of total sales","KOR","Korea","2017","2017",3.6,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","ATCPTTMT","% of total sales","KOR","Korea","2018","2018",3.6,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","ATCPTTMT","% of total sales","KOR","Korea","2019","2019",3.4,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","ATCPTTMT","% of total sales","KOR","Korea","2020","2020",3.4,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","ATCPTTMT","% of total sales","KOR","Korea","2021","2021",3.5,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MLLNCUMT","Million of national currency units","LUX","Luxembourg","2010","2010",10.6,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MLLNCUMT","Million of national currency units","LUX","Luxembourg","2011","2011",8.6,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MLLNCUMT","Million of national currency units","LUX","Luxembourg","2012","2012",8.8,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MLLNCUMT","Million of national currency units","LUX","Luxembourg","2013","2013",8.9,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MLLNCUMT","Million of national currency units","LUX","Luxembourg","2014","2014",8.3,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MLLNCUMT","Million of national currency units","LUX","Luxembourg","2015","2015",7.2,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MLLNCUMT","Million of national currency units","LUX","Luxembourg","2016","2016",7.3,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MLLNCUMT","Million of national currency units","LUX","Luxembourg","2017","2017",7,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MLLNCUMT","Million of national currency units","LUX","Luxembourg","2018","2018",6.9,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MLLNCUMT","Million of national currency units","LUX","Luxembourg","2019","2019",6.8,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MLLNCUMT","Million of national currency units","LUX","Luxembourg","2020","2020",6.5,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MLLNCUMT","Million of national currency units","LUX","Luxembourg","2021","2021",6.2,"B; D; P","Break; Difference in methodology; Provisional value"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MLLNCUMT","Million of national currency units","LUX","Luxembourg","2022","2022",5.8,"D; P","Difference in methodology; Provisional value"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOTCMT","Million US$ at exchange rate","LUX","Luxembourg","2010","2010",14,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOTCMT","Million US$ at exchange rate","LUX","Luxembourg","2011","2011",12,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOTCMT","Million US$ at exchange rate","LUX","Luxembourg","2012","2012",11.2,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOTCMT","Million US$ at exchange rate","LUX","Luxembourg","2013","2013",11.8,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOTCMT","Million US$ at exchange rate","LUX","Luxembourg","2014","2014",11.1,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOTCMT","Million US$ at exchange rate","LUX","Luxembourg","2015","2015",8,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOTCMT","Million US$ at exchange rate","LUX","Luxembourg","2016","2016",8.1,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOTCMT","Million US$ at exchange rate","LUX","Luxembourg","2017","2017",7.9,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOTCMT","Million US$ at exchange rate","LUX","Luxembourg","2018","2018",8.2,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOTCMT","Million US$ at exchange rate","LUX","Luxembourg","2019","2019",7.6,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOTCMT","Million US$ at exchange rate","LUX","Luxembourg","2020","2020",7.4,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOTCMT","Million US$ at exchange rate","LUX","Luxembourg","2021","2021",7.3,"B; D; P","Break; Difference in methodology; Provisional value"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOTCMT","Million US$ at exchange rate","LUX","Luxembourg","2022","2022",6.1,"D; P","Difference in methodology; Provisional value"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOPPMT","Million US$, purchasing power parity","LUX","Luxembourg","2010","2010",11.4,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOPPMT","Million US$, purchasing power parity","LUX","Luxembourg","2011","2011",9.5,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOPPMT","Million US$, purchasing power parity","LUX","Luxembourg","2012","2012",9.6,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOPPMT","Million US$, purchasing power parity","LUX","Luxembourg","2013","2013",10,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOPPMT","Million US$, purchasing power parity","LUX","Luxembourg","2014","2014",9.4,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOPPMT","Million US$, purchasing power parity","LUX","Luxembourg","2015","2015",8.2,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOPPMT","Million US$, purchasing power parity","LUX","Luxembourg","2016","2016",8.5,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOPPMT","Million US$, purchasing power parity","LUX","Luxembourg","2017","2017",8.3,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOPPMT","Million US$, purchasing power parity","LUX","Luxembourg","2018","2018",8.2,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOPPMT","Million US$, purchasing power parity","LUX","Luxembourg","2019","2019",8.1,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOPPMT","Million US$, purchasing power parity","LUX","Luxembourg","2020","2020",7.5,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOPPMT","Million US$, purchasing power parity","LUX","Luxembourg","2021","2021",7.2,"B; D; P","Break; Difference in methodology; Provisional value"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOPPMT","Million US$, purchasing power parity","LUX","Luxembourg","2022","2022",6.9,"D; P","Difference in methodology; Provisional value"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","TCPPERMT","/capita, US$ exchange rate","LUX","Luxembourg","2010","2010",29.6,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","TCPPERMT","/capita, US$ exchange rate","LUX","Luxembourg","2011","2011",25,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","TCPPERMT","/capita, US$ exchange rate","LUX","Luxembourg","2012","2012",22.8,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","TCPPERMT","/capita, US$ exchange rate","LUX","Luxembourg","2013","2013",23.6,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","TCPPERMT","/capita, US$ exchange rate","LUX","Luxembourg","2014","2014",21.6,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","TCPPERMT","/capita, US$ exchange rate","LUX","Luxembourg","2015","2015",15.5,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","TCPPERMT","/capita, US$ exchange rate","LUX","Luxembourg","2016","2016",15.3,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","TCPPERMT","/capita, US$ exchange rate","LUX","Luxembourg","2017","2017",14.8,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","TCPPERMT","/capita, US$ exchange rate","LUX","Luxembourg","2018","2018",15,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","TCPPERMT","/capita, US$ exchange rate","LUX","Luxembourg","2019","2019",13.7,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","TCPPERMT","/capita, US$ exchange rate","LUX","Luxembourg","2020","2020",13,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","TCPPERMT","/capita, US$ exchange rate","LUX","Luxembourg","2021","2021",12.7,"B; D; P","Break; Difference in methodology; Provisional value"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","TCPPERMT","/capita, US$ exchange rate","LUX","Luxembourg","2022","2022",10.4,"D; P","Difference in methodology; Provisional value"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2010","2010",24.1,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2011","2011",19.8,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2012","2012",19.6,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2013","2013",19.9,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2014","2014",18.4,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2015","2015",15.9,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2016","2016",16.2,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2017","2017",15.4,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2018","2018",15,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2019","2019",14.5,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2020","2020",13.3,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2021","2021",12.5,"B; D; P","Break; Difference in methodology; Provisional value"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2022","2022",11.8,"D; P","Difference in methodology; Provisional value"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","ATCPTTMT","% of total sales","LUX","Luxembourg","2010","2010",5.6,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","ATCPTTMT","% of total sales","LUX","Luxembourg","2011","2011",4.5,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","ATCPTTMT","% of total sales","LUX","Luxembourg","2012","2012",4.5,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","ATCPTTMT","% of total sales","LUX","Luxembourg","2013","2013",4.6,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","ATCPTTMT","% of total sales","LUX","Luxembourg","2014","2014",4.4,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","ATCPTTMT","% of total sales","LUX","Luxembourg","2015","2015",3.8,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","ATCPTTMT","% of total sales","LUX","Luxembourg","2016","2016",3.7,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","ATCPTTMT","% of total sales","LUX","Luxembourg","2017","2017",3.6,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","ATCPTTMT","% of total sales","LUX","Luxembourg","2018","2018",3.5,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","ATCPTTMT","% of total sales","LUX","Luxembourg","2019","2019",3.3,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","ATCPTTMT","% of total sales","LUX","Luxembourg","2020","2020",3.1,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","ATCPTTMT","% of total sales","LUX","Luxembourg","2021","2021",2.6,"B; D; P","Break; Difference in methodology; Provisional value"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","ATCPTTMT","% of total sales","LUX","Luxembourg","2022","2022",2.2,"D; P","Difference in methodology; Provisional value"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MLLNCUMT","Million of national currency units","NLD","Netherlands","2010","2010",202.1,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MLLNCUMT","Million of national currency units","NLD","Netherlands","2011","2011",185.2,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MLLNCUMT","Million of national currency units","NLD","Netherlands","2012","2012",125.8,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MLLNCUMT","Million of national currency units","NLD","Netherlands","2013","2013",118.4,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MLLNCUMT","Million of national currency units","NLD","Netherlands","2014","2014",117.1,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOTCMT","Million US$ at exchange rate","NLD","Netherlands","2010","2010",268,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOTCMT","Million US$ at exchange rate","NLD","Netherlands","2011","2011",257.8,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOTCMT","Million US$ at exchange rate","NLD","Netherlands","2012","2012",161.7,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOTCMT","Million US$ at exchange rate","NLD","Netherlands","2013","2013",157.3,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOTCMT","Million US$ at exchange rate","NLD","Netherlands","2014","2014",155.6,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOPPMT","Million US$, purchasing power parity","NLD","Netherlands","2010","2010",236.7,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOPPMT","Million US$, purchasing power parity","NLD","Netherlands","2011","2011",221.5,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOPPMT","Million US$, purchasing power parity","NLD","Netherlands","2012","2012",152.6,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOPPMT","Million US$, purchasing power parity","NLD","Netherlands","2013","2013",148.3,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOPPMT","Million US$, purchasing power parity","NLD","Netherlands","2014","2014",144.8,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","TCPPERMT","/capita, US$ exchange rate","NLD","Netherlands","2010","2010",16.1,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","TCPPERMT","/capita, US$ exchange rate","NLD","Netherlands","2011","2011",15.4,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","TCPPERMT","/capita, US$ exchange rate","NLD","Netherlands","2012","2012",9.6,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","TCPPERMT","/capita, US$ exchange rate","NLD","Netherlands","2013","2013",9.4,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","TCPPERMT","/capita, US$ exchange rate","NLD","Netherlands","2014","2014",9.2,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","NLD","Netherlands","2010","2010",14.2,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","NLD","Netherlands","2011","2011",13.3,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","NLD","Netherlands","2012","2012",9.1,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","NLD","Netherlands","2013","2013",8.8,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","NLD","Netherlands","2014","2014",8.6,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","ATCPTTMT","% of total sales","NLD","Netherlands","2010","2010",3.9,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","ATCPTTMT","% of total sales","NLD","Netherlands","2011","2011",3.6,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","ATCPTTMT","% of total sales","NLD","Netherlands","2012","2012",2.7,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","ATCPTTMT","% of total sales","NLD","Netherlands","2013","2013",2.8,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","ATCPTTMT","% of total sales","NLD","Netherlands","2014","2014",2.7,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MLLNCUMT","Million of national currency units","NZL","New Zealand","2010","2010",12.5,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MLLNCUMT","Million of national currency units","NZL","New Zealand","2011","2011",11.9,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MLLNCUMT","Million of national currency units","NZL","New Zealand","2012","2012",7.8,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MLLNCUMT","Million of national currency units","NZL","New Zealand","2013","2013",6.9,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MLLNCUMT","Million of national currency units","NZL","New Zealand","2014","2014",7,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MLLNCUMT","Million of national currency units","NZL","New Zealand","2015","2015",6.3,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MLLNCUMT","Million of national currency units","NZL","New Zealand","2016","2016",6,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MLLNCUMT","Million of national currency units","NZL","New Zealand","2017","2017",5.9,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MLLNCUMT","Million of national currency units","NZL","New Zealand","2018","2018",5.3,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MLLNCUMT","Million of national currency units","NZL","New Zealand","2019","2019",4.9,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MLLNCUMT","Million of national currency units","NZL","New Zealand","2020","2020",4.5,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MLLNCUMT","Million of national currency units","NZL","New Zealand","2021","2021",5.1,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MLLNCUMT","Million of national currency units","NZL","New Zealand","2022","2022",5.4,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOTCMT","Million US$ at exchange rate","NZL","New Zealand","2010","2010",9,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOTCMT","Million US$ at exchange rate","NZL","New Zealand","2011","2011",9.4,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOTCMT","Million US$ at exchange rate","NZL","New Zealand","2012","2012",6.3,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOTCMT","Million US$ at exchange rate","NZL","New Zealand","2013","2013",5.7,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOTCMT","Million US$ at exchange rate","NZL","New Zealand","2014","2014",5.8,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOTCMT","Million US$ at exchange rate","NZL","New Zealand","2015","2015",4.4,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOTCMT","Million US$ at exchange rate","NZL","New Zealand","2016","2016",4.2,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOTCMT","Million US$ at exchange rate","NZL","New Zealand","2017","2017",4.2,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOTCMT","Million US$ at exchange rate","NZL","New Zealand","2018","2018",3.7,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOTCMT","Million US$ at exchange rate","NZL","New Zealand","2019","2019",3.2,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOTCMT","Million US$ at exchange rate","NZL","New Zealand","2020","2020",2.9,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOTCMT","Million US$ at exchange rate","NZL","New Zealand","2021","2021",3.6,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOTCMT","Million US$ at exchange rate","NZL","New Zealand","2022","2022",3.4,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOPPMT","Million US$, purchasing power parity","NZL","New Zealand","2010","2010",8.4,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOPPMT","Million US$, purchasing power parity","NZL","New Zealand","2011","2011",8,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOPPMT","Million US$, purchasing power parity","NZL","New Zealand","2012","2012",5.2,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOPPMT","Million US$, purchasing power parity","NZL","New Zealand","2013","2013",4.8,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOPPMT","Million US$, purchasing power parity","NZL","New Zealand","2014","2014",4.8,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOPPMT","Million US$, purchasing power parity","NZL","New Zealand","2015","2015",4.3,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOPPMT","Million US$, purchasing power parity","NZL","New Zealand","2016","2016",4.2,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOPPMT","Million US$, purchasing power parity","NZL","New Zealand","2017","2017",4.1,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOPPMT","Million US$, purchasing power parity","NZL","New Zealand","2018","2018",3.6,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOPPMT","Million US$, purchasing power parity","NZL","New Zealand","2019","2019",3.4,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOPPMT","Million US$, purchasing power parity","NZL","New Zealand","2020","2020",3.2,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOPPMT","Million US$, purchasing power parity","NZL","New Zealand","2021","2021",3.5,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOPPMT","Million US$, purchasing power parity","NZL","New Zealand","2022","2022",3.7,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","TCPPERMT","/capita, US$ exchange rate","NZL","New Zealand","2010","2010",2.1,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","TCPPERMT","/capita, US$ exchange rate","NZL","New Zealand","2011","2011",2.1,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","TCPPERMT","/capita, US$ exchange rate","NZL","New Zealand","2012","2012",1.4,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","TCPPERMT","/capita, US$ exchange rate","NZL","New Zealand","2013","2013",1.3,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","TCPPERMT","/capita, US$ exchange rate","NZL","New Zealand","2014","2014",1.3,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","TCPPERMT","/capita, US$ exchange rate","NZL","New Zealand","2015","2015",1,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","TCPPERMT","/capita, US$ exchange rate","NZL","New Zealand","2016","2016",0.9,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","TCPPERMT","/capita, US$ exchange rate","NZL","New Zealand","2017","2017",0.9,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","TCPPERMT","/capita, US$ exchange rate","NZL","New Zealand","2018","2018",0.8,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","TCPPERMT","/capita, US$ exchange rate","NZL","New Zealand","2019","2019",0.6,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","TCPPERMT","/capita, US$ exchange rate","NZL","New Zealand","2020","2020",0.6,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","TCPPERMT","/capita, US$ exchange rate","NZL","New Zealand","2021","2021",0.7,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","TCPPERMT","/capita, US$ exchange rate","NZL","New Zealand","2022","2022",0.7,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2010","2010",1.9,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2011","2011",1.8,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2012","2012",1.2,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2013","2013",1.1,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2014","2014",1.1,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2015","2015",0.9,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2016","2016",0.9,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2017","2017",0.9,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2018","2018",0.7,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2019","2019",0.7,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2020","2020",0.6,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2021","2021",0.7,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2022","2022",0.7,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","ATCPTTMT","% of total sales","NZL","New Zealand","2010","2010",1.7,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","ATCPTTMT","% of total sales","NZL","New Zealand","2011","2011",1.5,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","ATCPTTMT","% of total sales","NZL","New Zealand","2012","2012",0.8,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","ATCPTTMT","% of total sales","NZL","New Zealand","2013","2013",0.7,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","ATCPTTMT","% of total sales","NZL","New Zealand","2014","2014",0.7,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","ATCPTTMT","% of total sales","NZL","New Zealand","2015","2015",0.6,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","ATCPTTMT","% of total sales","NZL","New Zealand","2016","2016",0.6,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","ATCPTTMT","% of total sales","NZL","New Zealand","2017","2017",0.5,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","ATCPTTMT","% of total sales","NZL","New Zealand","2018","2018",0.4,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","ATCPTTMT","% of total sales","NZL","New Zealand","2019","2019",0.3,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","ATCPTTMT","% of total sales","NZL","New Zealand","2020","2020",0.3,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","ATCPTTMT","% of total sales","NZL","New Zealand","2021","2021",0.3,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","ATCPTTMT","% of total sales","NZL","New Zealand","2022","2022",0.3,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MLLNCUMT","Million of national currency units","NOR","Norway","2010","2010",459,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MLLNCUMT","Million of national currency units","NOR","Norway","2011","2011",447,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MLLNCUMT","Million of national currency units","NOR","Norway","2012","2012",414,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MLLNCUMT","Million of national currency units","NOR","Norway","2013","2013",387,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MLLNCUMT","Million of national currency units","NOR","Norway","2014","2014",373,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MLLNCUMT","Million of national currency units","NOR","Norway","2015","2015",320,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MLLNCUMT","Million of national currency units","NOR","Norway","2016","2016",329,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MLLNCUMT","Million of national currency units","NOR","Norway","2017","2017",330,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MLLNCUMT","Million of national currency units","NOR","Norway","2018","2018",329,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MLLNCUMT","Million of national currency units","NOR","Norway","2019","2019",327,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MLLNCUMT","Million of national currency units","NOR","Norway","2020","2020",368,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MLLNCUMT","Million of national currency units","NOR","Norway","2021","2021",383,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MLLNCUMT","Million of national currency units","NOR","Norway","2022","2022",405,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOTCMT","Million US$ at exchange rate","NOR","Norway","2010","2010",75.9,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOTCMT","Million US$ at exchange rate","NOR","Norway","2011","2011",79.8,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOTCMT","Million US$ at exchange rate","NOR","Norway","2012","2012",71.2,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOTCMT","Million US$ at exchange rate","NOR","Norway","2013","2013",65.9,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOTCMT","Million US$ at exchange rate","NOR","Norway","2014","2014",59.2,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOTCMT","Million US$ at exchange rate","NOR","Norway","2015","2015",39.7,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOTCMT","Million US$ at exchange rate","NOR","Norway","2016","2016",39.2,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOTCMT","Million US$ at exchange rate","NOR","Norway","2017","2017",39.9,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOTCMT","Million US$ at exchange rate","NOR","Norway","2018","2018",40.5,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOTCMT","Million US$ at exchange rate","NOR","Norway","2019","2019",37.2,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOTCMT","Million US$ at exchange rate","NOR","Norway","2020","2020",39.1,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOTCMT","Million US$ at exchange rate","NOR","Norway","2021","2021",44.6,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOTCMT","Million US$ at exchange rate","NOR","Norway","2022","2022",42.1,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOPPMT","Million US$, purchasing power parity","NOR","Norway","2010","2010",50.2,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOPPMT","Million US$, purchasing power parity","NOR","Norway","2011","2011",49.2,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOPPMT","Million US$, purchasing power parity","NOR","Norway","2012","2012",45.8,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOPPMT","Million US$, purchasing power parity","NOR","Norway","2013","2013",42.9,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOPPMT","Million US$, purchasing power parity","NOR","Norway","2014","2014",40.2,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOPPMT","Million US$, purchasing power parity","NOR","Norway","2015","2015",32.2,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOPPMT","Million US$, purchasing power parity","NOR","Norway","2016","2016",32.8,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOPPMT","Million US$, purchasing power parity","NOR","Norway","2017","2017",33.8,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOPPMT","Million US$, purchasing power parity","NOR","Norway","2018","2018",34.3,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOPPMT","Million US$, purchasing power parity","NOR","Norway","2019","2019",34,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOPPMT","Million US$, purchasing power parity","NOR","Norway","2020","2020",37.2,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOPPMT","Million US$, purchasing power parity","NOR","Norway","2021","2021",40.3,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOPPMT","Million US$, purchasing power parity","NOR","Norway","2022","2022",37.7,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","TCPPERMT","/capita, US$ exchange rate","NOR","Norway","2010","2010",15.5,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","TCPPERMT","/capita, US$ exchange rate","NOR","Norway","2011","2011",16.1,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","TCPPERMT","/capita, US$ exchange rate","NOR","Norway","2012","2012",14.2,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","TCPPERMT","/capita, US$ exchange rate","NOR","Norway","2013","2013",13,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","TCPPERMT","/capita, US$ exchange rate","NOR","Norway","2014","2014",11.5,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","TCPPERMT","/capita, US$ exchange rate","NOR","Norway","2015","2015",7.6,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","TCPPERMT","/capita, US$ exchange rate","NOR","Norway","2016","2016",7.5,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","TCPPERMT","/capita, US$ exchange rate","NOR","Norway","2017","2017",7.6,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","TCPPERMT","/capita, US$ exchange rate","NOR","Norway","2018","2018",7.6,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","TCPPERMT","/capita, US$ exchange rate","NOR","Norway","2019","2019",6.9,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","TCPPERMT","/capita, US$ exchange rate","NOR","Norway","2020","2020",7.3,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","TCPPERMT","/capita, US$ exchange rate","NOR","Norway","2021","2021",8.2,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","TCPPERMT","/capita, US$ exchange rate","NOR","Norway","2022","2022",7.8,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2010","2010",10.3,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2011","2011",9.9,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2012","2012",9.1,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2013","2013",8.4,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2014","2014",7.8,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2015","2015",6.2,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2016","2016",6.3,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2017","2017",6.4,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2018","2018",6.5,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2019","2019",6.4,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2020","2020",6.9,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2021","2021",7.4,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2022","2022",7,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","ATCPTTMT","% of total sales","NOR","Norway","2010","2010",2.6,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","ATCPTTMT","% of total sales","NOR","Norway","2011","2011",2.5,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","ATCPTTMT","% of total sales","NOR","Norway","2012","2012",2.2,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","ATCPTTMT","% of total sales","NOR","Norway","2013","2013",2,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","ATCPTTMT","% of total sales","NOR","Norway","2014","2014",1.8,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","ATCPTTMT","% of total sales","NOR","Norway","2015","2015",1.4,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","ATCPTTMT","% of total sales","NOR","Norway","2016","2016",1.3,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","ATCPTTMT","% of total sales","NOR","Norway","2017","2017",1.2,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","ATCPTTMT","% of total sales","NOR","Norway","2018","2018",1.2,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","ATCPTTMT","% of total sales","NOR","Norway","2019","2019",1.2,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","ATCPTTMT","% of total sales","NOR","Norway","2020","2020",1.2,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","ATCPTTMT","% of total sales","NOR","Norway","2021","2021",1.1,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","ATCPTTMT","% of total sales","NOR","Norway","2022","2022",1.1,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MLLNCUMT","Million of national currency units","PRT","Portugal","2010","2010",186.5,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MLLNCUMT","Million of national currency units","PRT","Portugal","2011","2011",124.6,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MLLNCUMT","Million of national currency units","PRT","Portugal","2012","2012",66.9,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MLLNCUMT","Million of national currency units","PRT","Portugal","2013","2013",62.6,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MLLNCUMT","Million of national currency units","PRT","Portugal","2014","2014",62.7,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MLLNCUMT","Million of national currency units","PRT","Portugal","2015","2015",62.8,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MLLNCUMT","Million of national currency units","PRT","Portugal","2016","2016",64.8,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MLLNCUMT","Million of national currency units","PRT","Portugal","2017","2017",61.6,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MLLNCUMT","Million of national currency units","PRT","Portugal","2018","2018",63.5,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MLLNCUMT","Million of national currency units","PRT","Portugal","2019","2019",70,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MLLNCUMT","Million of national currency units","PRT","Portugal","2020","2020",70.4,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MLLNCUMT","Million of national currency units","PRT","Portugal","2021","2021",75.1,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MLLNCUMT","Million of national currency units","PRT","Portugal","2022","2022",78.5,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOTCMT","Million US$ at exchange rate","PRT","Portugal","2010","2010",247.2,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOTCMT","Million US$ at exchange rate","PRT","Portugal","2011","2011",173.4,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOTCMT","Million US$ at exchange rate","PRT","Portugal","2012","2012",86,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOTCMT","Million US$ at exchange rate","PRT","Portugal","2013","2013",83.1,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOTCMT","Million US$ at exchange rate","PRT","Portugal","2014","2014",83.3,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOTCMT","Million US$ at exchange rate","PRT","Portugal","2015","2015",69.6,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOTCMT","Million US$ at exchange rate","PRT","Portugal","2016","2016",71.7,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOTCMT","Million US$ at exchange rate","PRT","Portugal","2017","2017",69.6,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOTCMT","Million US$ at exchange rate","PRT","Portugal","2018","2018",75,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOTCMT","Million US$ at exchange rate","PRT","Portugal","2019","2019",78.4,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOTCMT","Million US$ at exchange rate","PRT","Portugal","2020","2020",80.4,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOTCMT","Million US$ at exchange rate","PRT","Portugal","2021","2021",88.8,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOTCMT","Million US$ at exchange rate","PRT","Portugal","2022","2022",82.6,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOPPMT","Million US$, purchasing power parity","PRT","Portugal","2010","2010",299.3,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOPPMT","Million US$, purchasing power parity","PRT","Portugal","2011","2011",199.9,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOPPMT","Million US$, purchasing power parity","PRT","Portugal","2012","2012",110.5,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOPPMT","Million US$, purchasing power parity","PRT","Portugal","2013","2013",107.2,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOPPMT","Million US$, purchasing power parity","PRT","Portugal","2014","2014",108.4,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOPPMT","Million US$, purchasing power parity","PRT","Portugal","2015","2015",107.3,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOPPMT","Million US$, purchasing power parity","PRT","Portugal","2016","2016",113.4,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOPPMT","Million US$, purchasing power parity","PRT","Portugal","2017","2017",107,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOPPMT","Million US$, purchasing power parity","PRT","Portugal","2018","2018",111.2,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOPPMT","Million US$, purchasing power parity","PRT","Portugal","2019","2019",125.3,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOPPMT","Million US$, purchasing power parity","PRT","Portugal","2020","2020",126.3,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOPPMT","Million US$, purchasing power parity","PRT","Portugal","2021","2021",132.3,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOPPMT","Million US$, purchasing power parity","PRT","Portugal","2022","2022",142.7,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","TCPPERMT","/capita, US$ exchange rate","PRT","Portugal","2010","2010",23.4,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","TCPPERMT","/capita, US$ exchange rate","PRT","Portugal","2011","2011",16.4,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","TCPPERMT","/capita, US$ exchange rate","PRT","Portugal","2012","2012",8.2,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","TCPPERMT","/capita, US$ exchange rate","PRT","Portugal","2013","2013",7.9,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","TCPPERMT","/capita, US$ exchange rate","PRT","Portugal","2014","2014",8,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","TCPPERMT","/capita, US$ exchange rate","PRT","Portugal","2015","2015",6.7,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","TCPPERMT","/capita, US$ exchange rate","PRT","Portugal","2016","2016",6.9,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","TCPPERMT","/capita, US$ exchange rate","PRT","Portugal","2017","2017",6.8,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","TCPPERMT","/capita, US$ exchange rate","PRT","Portugal","2018","2018",7.3,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","TCPPERMT","/capita, US$ exchange rate","PRT","Portugal","2019","2019",7.6,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","TCPPERMT","/capita, US$ exchange rate","PRT","Portugal","2020","2020",7.8,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","TCPPERMT","/capita, US$ exchange rate","PRT","Portugal","2021","2021",8.6,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","TCPPERMT","/capita, US$ exchange rate","PRT","Portugal","2022","2022",8,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2010","2010",28.3,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2011","2011",18.9,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2012","2012",10.5,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2013","2013",10.3,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2014","2014",10.4,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2015","2015",10.4,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2016","2016",11,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2017","2017",10.4,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2018","2018",10.8,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2019","2019",12.2,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2020","2020",12.3,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2021","2021",12.8,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2022","2022",13.8,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","ATCPTTMT","% of total sales","PRT","Portugal","2010","2010",5.8,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","ATCPTTMT","% of total sales","PRT","Portugal","2011","2011",4.2,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","ATCPTTMT","% of total sales","PRT","Portugal","2012","2012",2.6,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","ATCPTTMT","% of total sales","PRT","Portugal","2013","2013",2.6,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","ATCPTTMT","% of total sales","PRT","Portugal","2014","2014",2.6,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","ATCPTTMT","% of total sales","PRT","Portugal","2015","2015",2.5,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","ATCPTTMT","% of total sales","PRT","Portugal","2016","2016",2.6,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","ATCPTTMT","% of total sales","PRT","Portugal","2017","2017",2.4,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","ATCPTTMT","% of total sales","PRT","Portugal","2018","2018",2.4,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","ATCPTTMT","% of total sales","PRT","Portugal","2019","2019",2.5,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","ATCPTTMT","% of total sales","PRT","Portugal","2020","2020",2.5,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","ATCPTTMT","% of total sales","PRT","Portugal","2021","2021",2.6,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","ATCPTTMT","% of total sales","PRT","Portugal","2022","2022",2.5,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MLLNCUMT","Million of national currency units","SVK","Slovak Republic","2010","2010",9.6,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MLLNCUMT","Million of national currency units","SVK","Slovak Republic","2011","2011",8.6,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MLLNCUMT","Million of national currency units","SVK","Slovak Republic","2012","2012",7.7,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MLLNCUMT","Million of national currency units","SVK","Slovak Republic","2013","2013",8.5,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MLLNCUMT","Million of national currency units","SVK","Slovak Republic","2014","2014",8.9,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MLLNCUMT","Million of national currency units","SVK","Slovak Republic","2015","2015",9.3,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MLLNCUMT","Million of national currency units","SVK","Slovak Republic","2016","2016",10.4,"B","Break"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MLLNCUMT","Million of national currency units","SVK","Slovak Republic","2017","2017",10,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MLLNCUMT","Million of national currency units","SVK","Slovak Republic","2018","2018",10.7,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MLLNCUMT","Million of national currency units","SVK","Slovak Republic","2019","2019",11.1,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MLLNCUMT","Million of national currency units","SVK","Slovak Republic","2020","2020",11.5,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MLLNCUMT","Million of national currency units","SVK","Slovak Republic","2021","2021",12.2,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOTCMT","Million US$ at exchange rate","SVK","Slovak Republic","2010","2010",12.7,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOTCMT","Million US$ at exchange rate","SVK","Slovak Republic","2011","2011",12,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOTCMT","Million US$ at exchange rate","SVK","Slovak Republic","2012","2012",9.9,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOTCMT","Million US$ at exchange rate","SVK","Slovak Republic","2013","2013",11.3,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOTCMT","Million US$ at exchange rate","SVK","Slovak Republic","2014","2014",11.9,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOTCMT","Million US$ at exchange rate","SVK","Slovak Republic","2015","2015",10.3,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOTCMT","Million US$ at exchange rate","SVK","Slovak Republic","2016","2016",11.5,"B","Break"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOTCMT","Million US$ at exchange rate","SVK","Slovak Republic","2017","2017",11.3,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOTCMT","Million US$ at exchange rate","SVK","Slovak Republic","2018","2018",12.7,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOTCMT","Million US$ at exchange rate","SVK","Slovak Republic","2019","2019",12.5,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOTCMT","Million US$ at exchange rate","SVK","Slovak Republic","2020","2020",13.2,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOTCMT","Million US$ at exchange rate","SVK","Slovak Republic","2021","2021",14.5,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOPPMT","Million US$, purchasing power parity","SVK","Slovak Republic","2010","2010",19.1,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOPPMT","Million US$, purchasing power parity","SVK","Slovak Republic","2011","2011",17,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOPPMT","Million US$, purchasing power parity","SVK","Slovak Republic","2012","2012",15.3,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOPPMT","Million US$, purchasing power parity","SVK","Slovak Republic","2013","2013",17.3,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOPPMT","Million US$, purchasing power parity","SVK","Slovak Republic","2014","2014",18.4,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOPPMT","Million US$, purchasing power parity","SVK","Slovak Republic","2015","2015",18.8,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOPPMT","Million US$, purchasing power parity","SVK","Slovak Republic","2016","2016",20.7,"B","Break"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOPPMT","Million US$, purchasing power parity","SVK","Slovak Republic","2017","2017",19.4,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOPPMT","Million US$, purchasing power parity","SVK","Slovak Republic","2018","2018",20.4,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOPPMT","Million US$, purchasing power parity","SVK","Slovak Republic","2019","2019",21.5,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOPPMT","Million US$, purchasing power parity","SVK","Slovak Republic","2020","2020",22.2,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOPPMT","Million US$, purchasing power parity","SVK","Slovak Republic","2021","2021",22.9,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","TCPPERMT","/capita, US$ exchange rate","SVK","Slovak Republic","2010","2010",2.4,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","TCPPERMT","/capita, US$ exchange rate","SVK","Slovak Republic","2011","2011",2.2,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","TCPPERMT","/capita, US$ exchange rate","SVK","Slovak Republic","2012","2012",1.8,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","TCPPERMT","/capita, US$ exchange rate","SVK","Slovak Republic","2013","2013",2.1,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","TCPPERMT","/capita, US$ exchange rate","SVK","Slovak Republic","2014","2014",2.2,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","TCPPERMT","/capita, US$ exchange rate","SVK","Slovak Republic","2015","2015",1.9,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","TCPPERMT","/capita, US$ exchange rate","SVK","Slovak Republic","2016","2016",2.1,"B","Break"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","TCPPERMT","/capita, US$ exchange rate","SVK","Slovak Republic","2017","2017",2.1,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","TCPPERMT","/capita, US$ exchange rate","SVK","Slovak Republic","2018","2018",2.3,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","TCPPERMT","/capita, US$ exchange rate","SVK","Slovak Republic","2019","2019",2.3,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","TCPPERMT","/capita, US$ exchange rate","SVK","Slovak Republic","2020","2020",2.4,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","TCPPERMT","/capita, US$ exchange rate","SVK","Slovak Republic","2021","2021",2.7,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2010","2010",3.5,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2011","2011",3.1,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2012","2012",2.8,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2013","2013",3.2,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2014","2014",3.4,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2015","2015",3.5,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2016","2016",3.8,"B","Break"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2017","2017",3.6,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2018","2018",3.7,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2019","2019",3.9,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2020","2020",4.1,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2021","2021",4.2,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","ATCPTTMT","% of total sales","SVK","Slovak Republic","2010","2010",0.9,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","ATCPTTMT","% of total sales","SVK","Slovak Republic","2011","2011",0.8,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","ATCPTTMT","% of total sales","SVK","Slovak Republic","2012","2012",0.7,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","ATCPTTMT","% of total sales","SVK","Slovak Republic","2013","2013",0.7,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","ATCPTTMT","% of total sales","SVK","Slovak Republic","2014","2014",0.7,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","ATCPTTMT","% of total sales","SVK","Slovak Republic","2015","2015",0.7,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","ATCPTTMT","% of total sales","SVK","Slovak Republic","2016","2016",0.7,"B","Break"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","ATCPTTMT","% of total sales","SVK","Slovak Republic","2017","2017",0.6,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","ATCPTTMT","% of total sales","SVK","Slovak Republic","2018","2018",0.7,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","ATCPTTMT","% of total sales","SVK","Slovak Republic","2019","2019",0.6,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","ATCPTTMT","% of total sales","SVK","Slovak Republic","2020","2020",0.7,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","ATCPTTMT","% of total sales","SVK","Slovak Republic","2021","2021",0.7,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MLLNCUMT","Million of national currency units","ESP","Spain","2010","2010",655.4,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MLLNCUMT","Million of national currency units","ESP","Spain","2011","2011",562.8,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MLLNCUMT","Million of national currency units","ESP","Spain","2012","2012",449.2,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MLLNCUMT","Million of national currency units","ESP","Spain","2013","2013",419.3,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MLLNCUMT","Million of national currency units","ESP","Spain","2014","2014",420.8,"B; D","Break; Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MLLNCUMT","Million of national currency units","ESP","Spain","2015","2015",414.5,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MLLNCUMT","Million of national currency units","ESP","Spain","2016","2016",422.8,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MLLNCUMT","Million of national currency units","ESP","Spain","2017","2017",423.6,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MLLNCUMT","Million of national currency units","ESP","Spain","2018","2018",449.5,"B","Break"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MLLNCUMT","Million of national currency units","ESP","Spain","2019","2019",463.4,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MLLNCUMT","Million of national currency units","ESP","Spain","2020","2020",472,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MLLNCUMT","Million of national currency units","ESP","Spain","2021","2021",505.1,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MLLNCUMT","Million of national currency units","ESP","Spain","2022","2022",526.7,"P","Provisional value"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOTCMT","Million US$ at exchange rate","ESP","Spain","2010","2010",868.9,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOTCMT","Million US$ at exchange rate","ESP","Spain","2011","2011",783.4,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOTCMT","Million US$ at exchange rate","ESP","Spain","2012","2012",577.1,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOTCMT","Million US$ at exchange rate","ESP","Spain","2013","2013",556.9,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOTCMT","Million US$ at exchange rate","ESP","Spain","2014","2014",559.1,"B; D","Break; Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOTCMT","Million US$ at exchange rate","ESP","Spain","2015","2015",459.8,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOTCMT","Million US$ at exchange rate","ESP","Spain","2016","2016",468,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOTCMT","Million US$ at exchange rate","ESP","Spain","2017","2017",478.6,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOTCMT","Million US$ at exchange rate","ESP","Spain","2018","2018",530.9,"B","Break"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOTCMT","Million US$ at exchange rate","ESP","Spain","2019","2019",518.7,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOTCMT","Million US$ at exchange rate","ESP","Spain","2020","2020",539.1,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOTCMT","Million US$ at exchange rate","ESP","Spain","2021","2021",597.5,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOTCMT","Million US$ at exchange rate","ESP","Spain","2022","2022",554.6,"P","Provisional value"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOPPMT","Million US$, purchasing power parity","ESP","Spain","2010","2010",901.5,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOPPMT","Million US$, purchasing power parity","ESP","Spain","2011","2011",788.1,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOPPMT","Million US$, purchasing power parity","ESP","Spain","2012","2012",646.3,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOPPMT","Million US$, purchasing power parity","ESP","Spain","2013","2013",621.4,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOPPMT","Million US$, purchasing power parity","ESP","Spain","2014","2014",635.4,"B; D","Break; Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOPPMT","Million US$, purchasing power parity","ESP","Spain","2015","2015",623.5,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOPPMT","Million US$, purchasing power parity","ESP","Spain","2016","2016",657.9,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOPPMT","Million US$, purchasing power parity","ESP","Spain","2017","2017",671.5,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOPPMT","Million US$, purchasing power parity","ESP","Spain","2018","2018",711.5,"B","Break"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOPPMT","Million US$, purchasing power parity","ESP","Spain","2019","2019",755.9,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOPPMT","Million US$, purchasing power parity","ESP","Spain","2020","2020",759.6,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOPPMT","Million US$, purchasing power parity","ESP","Spain","2021","2021",807,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOPPMT","Million US$, purchasing power parity","ESP","Spain","2022","2022",883.4,"P","Provisional value"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","TCPPERMT","/capita, US$ exchange rate","ESP","Spain","2010","2010",18.7,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","TCPPERMT","/capita, US$ exchange rate","ESP","Spain","2011","2011",16.8,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","TCPPERMT","/capita, US$ exchange rate","ESP","Spain","2012","2012",12.3,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","TCPPERMT","/capita, US$ exchange rate","ESP","Spain","2013","2013",11.9,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","TCPPERMT","/capita, US$ exchange rate","ESP","Spain","2014","2014",12,"B; D","Break; Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","TCPPERMT","/capita, US$ exchange rate","ESP","Spain","2015","2015",9.9,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","TCPPERMT","/capita, US$ exchange rate","ESP","Spain","2016","2016",10.1,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","TCPPERMT","/capita, US$ exchange rate","ESP","Spain","2017","2017",10.3,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","TCPPERMT","/capita, US$ exchange rate","ESP","Spain","2018","2018",11.3,"B","Break"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","TCPPERMT","/capita, US$ exchange rate","ESP","Spain","2019","2019",11,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","TCPPERMT","/capita, US$ exchange rate","ESP","Spain","2020","2020",11.4,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","TCPPERMT","/capita, US$ exchange rate","ESP","Spain","2021","2021",12.6,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","TCPPERMT","/capita, US$ exchange rate","ESP","Spain","2022","2022",11.7,"P","Provisional value"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2010","2010",19.4,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2011","2011",16.9,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2012","2012",13.8,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2013","2013",13.3,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2014","2014",13.7,"B; D","Break; Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2015","2015",13.4,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2016","2016",14.2,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2017","2017",14.4,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2018","2018",15.2,"B","Break"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2019","2019",16,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2020","2020",16,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2021","2021",17,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2022","2022",18.6,"P","Provisional value"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","ATCPTTMT","% of total sales","ESP","Spain","2010","2010",5,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","ATCPTTMT","% of total sales","ESP","Spain","2011","2011",4.6,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","ATCPTTMT","% of total sales","ESP","Spain","2012","2012",4.1,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","ATCPTTMT","% of total sales","ESP","Spain","2013","2013",3.9,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","ATCPTTMT","% of total sales","ESP","Spain","2014","2014",3.7,"B; D","Break; Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","ATCPTTMT","% of total sales","ESP","Spain","2015","2015",3.6,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","ATCPTTMT","% of total sales","ESP","Spain","2016","2016",3.6,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","ATCPTTMT","% of total sales","ESP","Spain","2017","2017",3.5,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","ATCPTTMT","% of total sales","ESP","Spain","2018","2018",2.4,"B","Break"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","ATCPTTMT","% of total sales","ESP","Spain","2019","2019",2.3,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","ATCPTTMT","% of total sales","ESP","Spain","2020","2020",2.3,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","ATCPTTMT","% of total sales","ESP","Spain","2021","2021",2.3,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","ATCPTTMT","% of total sales","ESP","Spain","2022","2022",2.3,"P","Provisional value"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MLLNCUMT","Million of national currency units","SWE","Sweden","2010","2010",727.7,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MLLNCUMT","Million of national currency units","SWE","Sweden","2011","2011",560.8,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MLLNCUMT","Million of national currency units","SWE","Sweden","2012","2012",536.8,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MLLNCUMT","Million of national currency units","SWE","Sweden","2013","2013",500.4,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MLLNCUMT","Million of national currency units","SWE","Sweden","2014","2014",474.1,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MLLNCUMT","Million of national currency units","SWE","Sweden","2015","2015",493.7,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MLLNCUMT","Million of national currency units","SWE","Sweden","2016","2016",493.9,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MLLNCUMT","Million of national currency units","SWE","Sweden","2017","2017",482.8,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MLLNCUMT","Million of national currency units","SWE","Sweden","2018","2018",492.4,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MLLNCUMT","Million of national currency units","SWE","Sweden","2019","2019",528.3,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MLLNCUMT","Million of national currency units","SWE","Sweden","2020","2020",523.8,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MLLNCUMT","Million of national currency units","SWE","Sweden","2021","2021",500.6,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MLLNCUMT","Million of national currency units","SWE","Sweden","2022","2022",534.7,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOTCMT","Million US$ at exchange rate","SWE","Sweden","2010","2010",101,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOTCMT","Million US$ at exchange rate","SWE","Sweden","2011","2011",86.4,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOTCMT","Million US$ at exchange rate","SWE","Sweden","2012","2012",79.2,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOTCMT","Million US$ at exchange rate","SWE","Sweden","2013","2013",76.8,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOTCMT","Million US$ at exchange rate","SWE","Sweden","2014","2014",69.1,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOTCMT","Million US$ at exchange rate","SWE","Sweden","2015","2015",58.5,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOTCMT","Million US$ at exchange rate","SWE","Sweden","2016","2016",57.7,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOTCMT","Million US$ at exchange rate","SWE","Sweden","2017","2017",56.5,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOTCMT","Million US$ at exchange rate","SWE","Sweden","2018","2018",56.6,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOTCMT","Million US$ at exchange rate","SWE","Sweden","2019","2019",55.9,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOTCMT","Million US$ at exchange rate","SWE","Sweden","2020","2020",56.9,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOTCMT","Million US$ at exchange rate","SWE","Sweden","2021","2021",58.4,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOTCMT","Million US$ at exchange rate","SWE","Sweden","2022","2022",52.9,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOPPMT","Million US$, purchasing power parity","SWE","Sweden","2010","2010",80.6,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOPPMT","Million US$, purchasing power parity","SWE","Sweden","2011","2011",63.4,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOPPMT","Million US$, purchasing power parity","SWE","Sweden","2012","2012",62,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOPPMT","Million US$, purchasing power parity","SWE","Sweden","2013","2013",58.2,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOPPMT","Million US$, purchasing power parity","SWE","Sweden","2014","2014",54.3,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOPPMT","Million US$, purchasing power parity","SWE","Sweden","2015","2015",55.8,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOPPMT","Million US$, purchasing power parity","SWE","Sweden","2016","2016",56,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOPPMT","Million US$, purchasing power parity","SWE","Sweden","2017","2017",54.5,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOPPMT","Million US$, purchasing power parity","SWE","Sweden","2018","2018",55.5,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOPPMT","Million US$, purchasing power parity","SWE","Sweden","2019","2019",60.7,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOPPMT","Million US$, purchasing power parity","SWE","Sweden","2020","2020",60.4,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOPPMT","Million US$, purchasing power parity","SWE","Sweden","2021","2021",57.4,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOPPMT","Million US$, purchasing power parity","SWE","Sweden","2022","2022",61.7,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","TCPPERMT","/capita, US$ exchange rate","SWE","Sweden","2010","2010",10.8,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","TCPPERMT","/capita, US$ exchange rate","SWE","Sweden","2011","2011",9.1,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","TCPPERMT","/capita, US$ exchange rate","SWE","Sweden","2012","2012",8.3,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","TCPPERMT","/capita, US$ exchange rate","SWE","Sweden","2013","2013",8,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","TCPPERMT","/capita, US$ exchange rate","SWE","Sweden","2014","2014",7.1,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","TCPPERMT","/capita, US$ exchange rate","SWE","Sweden","2015","2015",6,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","TCPPERMT","/capita, US$ exchange rate","SWE","Sweden","2016","2016",5.8,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","TCPPERMT","/capita, US$ exchange rate","SWE","Sweden","2017","2017",5.6,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","TCPPERMT","/capita, US$ exchange rate","SWE","Sweden","2018","2018",5.6,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","TCPPERMT","/capita, US$ exchange rate","SWE","Sweden","2019","2019",5.4,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","TCPPERMT","/capita, US$ exchange rate","SWE","Sweden","2020","2020",5.5,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","TCPPERMT","/capita, US$ exchange rate","SWE","Sweden","2021","2021",5.6,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","TCPPERMT","/capita, US$ exchange rate","SWE","Sweden","2022","2022",5.1,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2010","2010",8.6,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2011","2011",6.7,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2012","2012",6.5,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2013","2013",6.1,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2014","2014",5.6,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2015","2015",5.7,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2016","2016",5.6,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2017","2017",5.4,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2018","2018",5.5,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2019","2019",5.9,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2020","2020",5.8,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2021","2021",5.5,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2022","2022",5.9,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","ATCPTTMT","% of total sales","SWE","Sweden","2010","2010",2,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","ATCPTTMT","% of total sales","SWE","Sweden","2011","2011",1.5,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","ATCPTTMT","% of total sales","SWE","Sweden","2012","2012",1.5,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","ATCPTTMT","% of total sales","SWE","Sweden","2013","2013",1.4,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","ATCPTTMT","% of total sales","SWE","Sweden","2014","2014",1.3,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","ATCPTTMT","% of total sales","SWE","Sweden","2015","2015",1.2,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","ATCPTTMT","% of total sales","SWE","Sweden","2016","2016",1.2,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","ATCPTTMT","% of total sales","SWE","Sweden","2017","2017",1.1,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","ATCPTTMT","% of total sales","SWE","Sweden","2018","2018",1,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","ATCPTTMT","% of total sales","SWE","Sweden","2019","2019",1,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","ATCPTTMT","% of total sales","SWE","Sweden","2020","2020",1,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","ATCPTTMT","% of total sales","SWE","Sweden","2021","2021",0.9,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","ATCPTTMT","% of total sales","SWE","Sweden","2022","2022",0.9,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MLLNCUMT","Million of national currency units","TUR","Türkiye","2010","2010",633.3,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MLLNCUMT","Million of national currency units","TUR","Türkiye","2011","2011",429.8,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MLLNCUMT","Million of national currency units","TUR","Türkiye","2012","2012",424.9,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MLLNCUMT","Million of national currency units","TUR","Türkiye","2013","2013",416,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MLLNCUMT","Million of national currency units","TUR","Türkiye","2014","2014",423.1,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MLLNCUMT","Million of national currency units","TUR","Türkiye","2015","2015",517.6,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MLLNCUMT","Million of national currency units","TUR","Türkiye","2016","2016",595.1,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MLLNCUMT","Million of national currency units","TUR","Türkiye","2017","2017",671.4,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MLLNCUMT","Million of national currency units","TUR","Türkiye","2018","2018",739.5,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MLLNCUMT","Million of national currency units","TUR","Türkiye","2019","2019",824.9,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MLLNCUMT","Million of national currency units","TUR","Türkiye","2020","2020",854.2,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MLLNCUMT","Million of national currency units","TUR","Türkiye","2021","2021",1162.9,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOTCMT","Million US$ at exchange rate","TUR","Türkiye","2010","2010",421.4,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOTCMT","Million US$ at exchange rate","TUR","Türkiye","2011","2011",256.6,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOTCMT","Million US$ at exchange rate","TUR","Türkiye","2012","2012",236.6,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOTCMT","Million US$ at exchange rate","TUR","Türkiye","2013","2013",218.5,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOTCMT","Million US$ at exchange rate","TUR","Türkiye","2014","2014",193.3,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOTCMT","Million US$ at exchange rate","TUR","Türkiye","2015","2015",190.3,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOTCMT","Million US$ at exchange rate","TUR","Türkiye","2016","2016",197.1,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOTCMT","Million US$ at exchange rate","TUR","Türkiye","2017","2017",184,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOTCMT","Million US$ at exchange rate","TUR","Türkiye","2018","2018",153.2,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOTCMT","Million US$ at exchange rate","TUR","Türkiye","2019","2019",145.4,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOTCMT","Million US$ at exchange rate","TUR","Türkiye","2020","2020",121.9,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOTCMT","Million US$ at exchange rate","TUR","Türkiye","2021","2021",131.4,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOPPMT","Million US$, purchasing power parity","TUR","Türkiye","2010","2010",688.1,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOPPMT","Million US$, purchasing power parity","TUR","Türkiye","2011","2011",444.9,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOPPMT","Million US$, purchasing power parity","TUR","Türkiye","2012","2012",416.6,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOPPMT","Million US$, purchasing power parity","TUR","Türkiye","2013","2013",388.6,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOPPMT","Million US$, purchasing power parity","TUR","Türkiye","2014","2014",383,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOPPMT","Million US$, purchasing power parity","TUR","Türkiye","2015","2015",445.2,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOPPMT","Million US$, purchasing power parity","TUR","Türkiye","2016","2016",479.5,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOPPMT","Million US$, purchasing power parity","TUR","Türkiye","2017","2017",485.1,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOPPMT","Million US$, purchasing power parity","TUR","Türkiye","2018","2018",453,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOPPMT","Million US$, purchasing power parity","TUR","Türkiye","2019","2019",442.5,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOPPMT","Million US$, purchasing power parity","TUR","Türkiye","2020","2020",394.7,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOPPMT","Million US$, purchasing power parity","TUR","Türkiye","2021","2021",414.1,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","TCPPERMT","/capita, US$ exchange rate","TUR","Türkiye","2010","2010",5.8,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","TCPPERMT","/capita, US$ exchange rate","TUR","Türkiye","2011","2011",3.5,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","TCPPERMT","/capita, US$ exchange rate","TUR","Türkiye","2012","2012",3.1,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","TCPPERMT","/capita, US$ exchange rate","TUR","Türkiye","2013","2013",2.9,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","TCPPERMT","/capita, US$ exchange rate","TUR","Türkiye","2014","2014",2.5,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","TCPPERMT","/capita, US$ exchange rate","TUR","Türkiye","2015","2015",2.4,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","TCPPERMT","/capita, US$ exchange rate","TUR","Türkiye","2016","2016",2.5,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","TCPPERMT","/capita, US$ exchange rate","TUR","Türkiye","2017","2017",2.3,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","TCPPERMT","/capita, US$ exchange rate","TUR","Türkiye","2018","2018",1.9,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","TCPPERMT","/capita, US$ exchange rate","TUR","Türkiye","2019","2019",1.8,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","TCPPERMT","/capita, US$ exchange rate","TUR","Türkiye","2020","2020",1.5,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","TCPPERMT","/capita, US$ exchange rate","TUR","Türkiye","2021","2021",1.6,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2010","2010",9.4,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2011","2011",6,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2012","2012",5.5,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2013","2013",5.1,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2014","2014",5,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2015","2015",5.7,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2016","2016",6,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2017","2017",6,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2018","2018",5.6,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2019","2019",5.4,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2020","2020",4.7,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2021","2021",4.9,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","ATCPTTMT","% of total sales","TUR","Türkiye","2010","2010",4.1,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","ATCPTTMT","% of total sales","TUR","Türkiye","2011","2011",3,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","ATCPTTMT","% of total sales","TUR","Türkiye","2012","2012",3.1,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","ATCPTTMT","% of total sales","TUR","Türkiye","2013","2013",2.9,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","ATCPTTMT","% of total sales","TUR","Türkiye","2014","2014",2.7,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","ATCPTTMT","% of total sales","TUR","Türkiye","2015","2015",2.8,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","ATCPTTMT","% of total sales","TUR","Türkiye","2016","2016",2.7,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","ATCPTTMT","% of total sales","TUR","Türkiye","2017","2017",2.6,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","ATCPTTMT","% of total sales","TUR","Türkiye","2018","2018",2.3,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","ATCPTTMT","% of total sales","TUR","Türkiye","2019","2019",2,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","ATCPTTMT","% of total sales","TUR","Türkiye","2020","2020",1.7,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","ATCPTTMT","% of total sales","TUR","Türkiye","2021","2021",1.8,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MLLNCUMT","Million of national currency units","CHL","Chile","2010","2010",16183.9,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MLLNCUMT","Million of national currency units","CHL","Chile","2011","2011",21124.4,"B","Break"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MLLNCUMT","Million of national currency units","CHL","Chile","2012","2012",22320.2,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MLLNCUMT","Million of national currency units","CHL","Chile","2013","2013",24042.2,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MLLNCUMT","Million of national currency units","CHL","Chile","2014","2014",26581.9,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MLLNCUMT","Million of national currency units","CHL","Chile","2015","2015",30504,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MLLNCUMT","Million of national currency units","CHL","Chile","2016","2016",27671.1,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MLLNCUMT","Million of national currency units","CHL","Chile","2017","2017",31943,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MLLNCUMT","Million of national currency units","CHL","Chile","2018","2018",28521.8,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MLLNCUMT","Million of national currency units","CHL","Chile","2019","2019",32593.6,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MLLNCUMT","Million of national currency units","CHL","Chile","2020","2020",31750.8,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MLLNCUMT","Million of national currency units","CHL","Chile","2021","2021",44395.8,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MLLNCUMT","Million of national currency units","CHL","Chile","2022","2022",45021.7,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOTCMT","Million US$ at exchange rate","CHL","Chile","2010","2010",31.7,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOTCMT","Million US$ at exchange rate","CHL","Chile","2011","2011",43.7,"B","Break"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOTCMT","Million US$ at exchange rate","CHL","Chile","2012","2012",45.9,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOTCMT","Million US$ at exchange rate","CHL","Chile","2013","2013",48.5,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOTCMT","Million US$ at exchange rate","CHL","Chile","2014","2014",46.6,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOTCMT","Million US$ at exchange rate","CHL","Chile","2015","2015",46.6,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOTCMT","Million US$ at exchange rate","CHL","Chile","2016","2016",40.9,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOTCMT","Million US$ at exchange rate","CHL","Chile","2017","2017",49.2,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOTCMT","Million US$ at exchange rate","CHL","Chile","2018","2018",44.5,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOTCMT","Million US$ at exchange rate","CHL","Chile","2019","2019",46.4,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOTCMT","Million US$ at exchange rate","CHL","Chile","2020","2020",40.1,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOTCMT","Million US$ at exchange rate","CHL","Chile","2021","2021",58.5,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOTCMT","Million US$ at exchange rate","CHL","Chile","2022","2022",51.6,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOPPMT","Million US$, purchasing power parity","CHL","Chile","2010","2010",45,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOPPMT","Million US$, purchasing power parity","CHL","Chile","2011","2011",60.7,"B","Break"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOPPMT","Million US$, purchasing power parity","CHL","Chile","2012","2012",64.3,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOPPMT","Million US$, purchasing power parity","CHL","Chile","2013","2013",68.8,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOPPMT","Million US$, purchasing power parity","CHL","Chile","2014","2014",72.4,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOPPMT","Million US$, purchasing power parity","CHL","Chile","2015","2015",78,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOPPMT","Million US$, purchasing power parity","CHL","Chile","2016","2016",69.7,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOPPMT","Million US$, purchasing power parity","CHL","Chile","2017","2017",80.3,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOPPMT","Million US$, purchasing power parity","CHL","Chile","2018","2018",72,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOPPMT","Million US$, purchasing power parity","CHL","Chile","2019","2019",81.2,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOPPMT","Million US$, purchasing power parity","CHL","Chile","2020","2020",75.9,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOPPMT","Million US$, purchasing power parity","CHL","Chile","2021","2021",102,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOPPMT","Million US$, purchasing power parity","CHL","Chile","2022","2022",102.9,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","TCPPERMT","/capita, US$ exchange rate","CHL","Chile","2010","2010",1.9,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","TCPPERMT","/capita, US$ exchange rate","CHL","Chile","2011","2011",2.5,"B","Break"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","TCPPERMT","/capita, US$ exchange rate","CHL","Chile","2012","2012",2.6,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","TCPPERMT","/capita, US$ exchange rate","CHL","Chile","2013","2013",2.8,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","TCPPERMT","/capita, US$ exchange rate","CHL","Chile","2014","2014",2.6,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","TCPPERMT","/capita, US$ exchange rate","CHL","Chile","2015","2015",2.6,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","TCPPERMT","/capita, US$ exchange rate","CHL","Chile","2016","2016",2.2,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","TCPPERMT","/capita, US$ exchange rate","CHL","Chile","2017","2017",2.7,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","TCPPERMT","/capita, US$ exchange rate","CHL","Chile","2018","2018",2.4,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","TCPPERMT","/capita, US$ exchange rate","CHL","Chile","2019","2019",2.4,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","TCPPERMT","/capita, US$ exchange rate","CHL","Chile","2020","2020",2.1,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","TCPPERMT","/capita, US$ exchange rate","CHL","Chile","2021","2021",3,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","TCPPERMT","/capita, US$ exchange rate","CHL","Chile","2022","2022",2.6,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2010","2010",2.6,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2011","2011",3.5,"B","Break"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2012","2012",3.7,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2013","2013",3.9,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2014","2014",4.1,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2015","2015",4.3,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2016","2016",3.8,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2017","2017",4.4,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2018","2018",3.8,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2019","2019",4.2,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2020","2020",3.9,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2021","2021",5.2,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2022","2022",5.2,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","ATCPTTMT","% of total sales","CHL","Chile","2010","2010",2,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","ATCPTTMT","% of total sales","CHL","Chile","2011","2011",1.8,"B","Break"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","ATCPTTMT","% of total sales","CHL","Chile","2012","2012",1.8,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","ATCPTTMT","% of total sales","CHL","Chile","2013","2013",1.7,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","ATCPTTMT","% of total sales","CHL","Chile","2014","2014",1.7,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","ATCPTTMT","% of total sales","CHL","Chile","2015","2015",1.7,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","ATCPTTMT","% of total sales","CHL","Chile","2016","2016",1.4,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","ATCPTTMT","% of total sales","CHL","Chile","2017","2017",1.5,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","ATCPTTMT","% of total sales","CHL","Chile","2018","2018",1.2,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","ATCPTTMT","% of total sales","CHL","Chile","2019","2019",1.3,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","ATCPTTMT","% of total sales","CHL","Chile","2020","2020",1.2,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","ATCPTTMT","% of total sales","CHL","Chile","2021","2021",1.6,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","ATCPTTMT","% of total sales","CHL","Chile","2022","2022",1.6,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MLLNCUMT","Million of national currency units","EST","Estonia","2010","2010",3.6,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MLLNCUMT","Million of national currency units","EST","Estonia","2011","2011",3.2,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MLLNCUMT","Million of national currency units","EST","Estonia","2012","2012",3.4,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MLLNCUMT","Million of national currency units","EST","Estonia","2013","2013",3.5,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MLLNCUMT","Million of national currency units","EST","Estonia","2014","2014",3.4,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MLLNCUMT","Million of national currency units","EST","Estonia","2015","2015",3.5,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MLLNCUMT","Million of national currency units","EST","Estonia","2016","2016",3.7,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MLLNCUMT","Million of national currency units","EST","Estonia","2017","2017",3.7,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MLLNCUMT","Million of national currency units","EST","Estonia","2018","2018",4,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MLLNCUMT","Million of national currency units","EST","Estonia","2019","2019",4.4,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MLLNCUMT","Million of national currency units","EST","Estonia","2020","2020",4.6,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MLLNCUMT","Million of national currency units","EST","Estonia","2021","2021",4.6,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MLLNCUMT","Million of national currency units","EST","Estonia","2022","2022",4.9,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOTCMT","Million US$ at exchange rate","EST","Estonia","2010","2010",4.8,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOTCMT","Million US$ at exchange rate","EST","Estonia","2011","2011",4.5,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOTCMT","Million US$ at exchange rate","EST","Estonia","2012","2012",4.4,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOTCMT","Million US$ at exchange rate","EST","Estonia","2013","2013",4.7,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOTCMT","Million US$ at exchange rate","EST","Estonia","2014","2014",4.5,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOTCMT","Million US$ at exchange rate","EST","Estonia","2015","2015",3.8,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOTCMT","Million US$ at exchange rate","EST","Estonia","2016","2016",4.1,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOTCMT","Million US$ at exchange rate","EST","Estonia","2017","2017",4.2,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOTCMT","Million US$ at exchange rate","EST","Estonia","2018","2018",4.8,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOTCMT","Million US$ at exchange rate","EST","Estonia","2019","2019",4.9,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOTCMT","Million US$ at exchange rate","EST","Estonia","2020","2020",5.2,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOTCMT","Million US$ at exchange rate","EST","Estonia","2021","2021",5.5,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOTCMT","Million US$ at exchange rate","EST","Estonia","2022","2022",5.2,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOPPMT","Million US$, purchasing power parity","EST","Estonia","2010","2010",7.1,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOPPMT","Million US$, purchasing power parity","EST","Estonia","2011","2011",6.3,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOPPMT","Million US$, purchasing power parity","EST","Estonia","2012","2012",6.6,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOPPMT","Million US$, purchasing power parity","EST","Estonia","2013","2013",6.8,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOPPMT","Million US$, purchasing power parity","EST","Estonia","2014","2014",6.4,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOPPMT","Million US$, purchasing power parity","EST","Estonia","2015","2015",6.4,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOPPMT","Million US$, purchasing power parity","EST","Estonia","2016","2016",7,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOPPMT","Million US$, purchasing power parity","EST","Estonia","2017","2017",7,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOPPMT","Million US$, purchasing power parity","EST","Estonia","2018","2018",7.5,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOPPMT","Million US$, purchasing power parity","EST","Estonia","2019","2019",8.2,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOPPMT","Million US$, purchasing power parity","EST","Estonia","2020","2020",8.7,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOPPMT","Million US$, purchasing power parity","EST","Estonia","2021","2021",8.5,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOPPMT","Million US$, purchasing power parity","EST","Estonia","2022","2022",8.6,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","TCPPERMT","/capita, US$ exchange rate","EST","Estonia","2010","2010",3.6,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","TCPPERMT","/capita, US$ exchange rate","EST","Estonia","2011","2011",3.4,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","TCPPERMT","/capita, US$ exchange rate","EST","Estonia","2012","2012",3.3,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","TCPPERMT","/capita, US$ exchange rate","EST","Estonia","2013","2013",3.6,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","TCPPERMT","/capita, US$ exchange rate","EST","Estonia","2014","2014",3.4,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","TCPPERMT","/capita, US$ exchange rate","EST","Estonia","2015","2015",2.9,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","TCPPERMT","/capita, US$ exchange rate","EST","Estonia","2016","2016",3.1,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","TCPPERMT","/capita, US$ exchange rate","EST","Estonia","2017","2017",3.2,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","TCPPERMT","/capita, US$ exchange rate","EST","Estonia","2018","2018",3.6,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","TCPPERMT","/capita, US$ exchange rate","EST","Estonia","2019","2019",3.7,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","TCPPERMT","/capita, US$ exchange rate","EST","Estonia","2020","2020",3.9,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","TCPPERMT","/capita, US$ exchange rate","EST","Estonia","2021","2021",4.1,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","TCPPERMT","/capita, US$ exchange rate","EST","Estonia","2022","2022",3.9,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2010","2010",5.3,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2011","2011",4.7,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2012","2012",5,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2013","2013",5.1,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2014","2014",4.8,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2015","2015",4.9,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2016","2016",5.3,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2017","2017",5.3,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2018","2018",5.7,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2019","2019",6.2,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2020","2020",6.6,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2021","2021",6.4,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2022","2022",6.5,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","ATCPTTMT","% of total sales","EST","Estonia","2010","2010",1.9,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","ATCPTTMT","% of total sales","EST","Estonia","2011","2011",1.6,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","ATCPTTMT","% of total sales","EST","Estonia","2012","2012",1.5,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","ATCPTTMT","% of total sales","EST","Estonia","2013","2013",1.5,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","ATCPTTMT","% of total sales","EST","Estonia","2014","2014",1.3,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","ATCPTTMT","% of total sales","EST","Estonia","2015","2015",1.3,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","ATCPTTMT","% of total sales","EST","Estonia","2016","2016",1.3,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","ATCPTTMT","% of total sales","EST","Estonia","2017","2017",1.2,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","ATCPTTMT","% of total sales","EST","Estonia","2018","2018",1.2,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","ATCPTTMT","% of total sales","EST","Estonia","2019","2019",1.3,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","ATCPTTMT","% of total sales","EST","Estonia","2020","2020",1.3,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","ATCPTTMT","% of total sales","EST","Estonia","2021","2021",1.1,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","ATCPTTMT","% of total sales","EST","Estonia","2022","2022",1.1,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MLLNCUMT","Million of national currency units","SVN","Slovenia","2010","2010",19.9,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MLLNCUMT","Million of national currency units","SVN","Slovenia","2011","2011",17.9,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MLLNCUMT","Million of national currency units","SVN","Slovenia","2012","2012",13.4,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MLLNCUMT","Million of national currency units","SVN","Slovenia","2013","2013",11.7,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MLLNCUMT","Million of national currency units","SVN","Slovenia","2014","2014",10.9,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MLLNCUMT","Million of national currency units","SVN","Slovenia","2015","2015",10.7,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MLLNCUMT","Million of national currency units","SVN","Slovenia","2016","2016",10.6,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MLLNCUMT","Million of national currency units","SVN","Slovenia","2017","2017",9.5,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MLLNCUMT","Million of national currency units","SVN","Slovenia","2018","2018",9.8,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MLLNCUMT","Million of national currency units","SVN","Slovenia","2019","2019",9.9,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MLLNCUMT","Million of national currency units","SVN","Slovenia","2020","2020",9.6,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MLLNCUMT","Million of national currency units","SVN","Slovenia","2021","2021",9.9,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MLLNCUMT","Million of national currency units","SVN","Slovenia","2022","2022",10.3,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOTCMT","Million US$ at exchange rate","SVN","Slovenia","2010","2010",26.4,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOTCMT","Million US$ at exchange rate","SVN","Slovenia","2011","2011",24.9,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOTCMT","Million US$ at exchange rate","SVN","Slovenia","2012","2012",17.3,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOTCMT","Million US$ at exchange rate","SVN","Slovenia","2013","2013",15.5,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOTCMT","Million US$ at exchange rate","SVN","Slovenia","2014","2014",14.5,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOTCMT","Million US$ at exchange rate","SVN","Slovenia","2015","2015",11.9,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOTCMT","Million US$ at exchange rate","SVN","Slovenia","2016","2016",11.7,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOTCMT","Million US$ at exchange rate","SVN","Slovenia","2017","2017",10.8,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOTCMT","Million US$ at exchange rate","SVN","Slovenia","2018","2018",11.6,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOTCMT","Million US$ at exchange rate","SVN","Slovenia","2019","2019",11.1,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOTCMT","Million US$ at exchange rate","SVN","Slovenia","2020","2020",10.9,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOTCMT","Million US$ at exchange rate","SVN","Slovenia","2021","2021",11.7,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOTCMT","Million US$ at exchange rate","SVN","Slovenia","2022","2022",10.8,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOPPMT","Million US$, purchasing power parity","SVN","Slovenia","2010","2010",31.2,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOPPMT","Million US$, purchasing power parity","SVN","Slovenia","2011","2011",28.7,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOPPMT","Million US$, purchasing power parity","SVN","Slovenia","2012","2012",22.1,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOPPMT","Million US$, purchasing power parity","SVN","Slovenia","2013","2013",19.8,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOPPMT","Million US$, purchasing power parity","SVN","Slovenia","2014","2014",18.5,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOPPMT","Million US$, purchasing power parity","SVN","Slovenia","2015","2015",18,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOPPMT","Million US$, purchasing power parity","SVN","Slovenia","2016","2016",18.3,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOPPMT","Million US$, purchasing power parity","SVN","Slovenia","2017","2017",16.7,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOPPMT","Million US$, purchasing power parity","SVN","Slovenia","2018","2018",17.2,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOPPMT","Million US$, purchasing power parity","SVN","Slovenia","2019","2019",18,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOPPMT","Million US$, purchasing power parity","SVN","Slovenia","2020","2020",17.5,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOPPMT","Million US$, purchasing power parity","SVN","Slovenia","2021","2021",17.5,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOPPMT","Million US$, purchasing power parity","SVN","Slovenia","2022","2022",18.6,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","TCPPERMT","/capita, US$ exchange rate","SVN","Slovenia","2010","2010",12.9,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","TCPPERMT","/capita, US$ exchange rate","SVN","Slovenia","2011","2011",12.1,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","TCPPERMT","/capita, US$ exchange rate","SVN","Slovenia","2012","2012",8.4,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","TCPPERMT","/capita, US$ exchange rate","SVN","Slovenia","2013","2013",7.5,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","TCPPERMT","/capita, US$ exchange rate","SVN","Slovenia","2014","2014",7,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","TCPPERMT","/capita, US$ exchange rate","SVN","Slovenia","2015","2015",5.7,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","TCPPERMT","/capita, US$ exchange rate","SVN","Slovenia","2016","2016",5.7,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","TCPPERMT","/capita, US$ exchange rate","SVN","Slovenia","2017","2017",5.2,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","TCPPERMT","/capita, US$ exchange rate","SVN","Slovenia","2018","2018",5.6,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","TCPPERMT","/capita, US$ exchange rate","SVN","Slovenia","2019","2019",5.3,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","TCPPERMT","/capita, US$ exchange rate","SVN","Slovenia","2020","2020",5.2,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","TCPPERMT","/capita, US$ exchange rate","SVN","Slovenia","2021","2021",5.5,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","TCPPERMT","/capita, US$ exchange rate","SVN","Slovenia","2022","2022",5.1,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2010","2010",15.2,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2011","2011",14,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2012","2012",10.8,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2013","2013",9.6,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2014","2014",8.9,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2015","2015",8.7,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2016","2016",8.9,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2017","2017",8.1,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2018","2018",8.3,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2019","2019",8.6,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2020","2020",8.3,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2021","2021",8.3,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2022","2022",8.9,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","ATCPTTMT","% of total sales","SVN","Slovenia","2010","2010",4.2,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","ATCPTTMT","% of total sales","SVN","Slovenia","2011","2011",3.8,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","ATCPTTMT","% of total sales","SVN","Slovenia","2012","2012",3,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","ATCPTTMT","% of total sales","SVN","Slovenia","2013","2013",2.6,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","ATCPTTMT","% of total sales","SVN","Slovenia","2014","2014",2.5,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","ATCPTTMT","% of total sales","SVN","Slovenia","2015","2015",2.4,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","ATCPTTMT","% of total sales","SVN","Slovenia","2016","2016",2.3,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","ATCPTTMT","% of total sales","SVN","Slovenia","2017","2017",2,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","ATCPTTMT","% of total sales","SVN","Slovenia","2018","2018",1.9,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","ATCPTTMT","% of total sales","SVN","Slovenia","2019","2019",1.8,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","ATCPTTMT","% of total sales","SVN","Slovenia","2020","2020",1.7,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","ATCPTTMT","% of total sales","SVN","Slovenia","2021","2021",1.6,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","ATCPTTMT","% of total sales","SVN","Slovenia","2022","2022",1.5,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","MLLNCUMT","Million of national currency units","AUS","Australia","2010","2010",424,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","MLLNCUMT","Million of national currency units","AUS","Australia","2011","2011",470,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","MLLNCUMT","Million of national currency units","AUS","Australia","2012","2012",519,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","MLLNCUMT","Million of national currency units","AUS","Australia","2013","2013",594,"B; D","Break; Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","MLLNCUMT","Million of national currency units","AUS","Australia","2014","2014",589,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","MLLNCUMT","Million of national currency units","AUS","Australia","2015","2015",617,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","MLLNCUMT","Million of national currency units","AUS","Australia","2016","2016",648,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","MLLNCUMT","Million of national currency units","AUS","Australia","2017","2017",718,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","MLLNCUMT","Million of national currency units","AUS","Australia","2018","2018",747,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","MLLNCUMT","Million of national currency units","AUS","Australia","2019","2019",784,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","MLLNCUMT","Million of national currency units","AUS","Australia","2020","2020",868,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","MLLNCUMT","Million of national currency units","AUS","Australia","2021","2021",977,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","MTMOTCMT","Million US$ at exchange rate","AUS","Australia","2010","2010",388.9,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","MTMOTCMT","Million US$ at exchange rate","AUS","Australia","2011","2011",484.8,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","MTMOTCMT","Million US$ at exchange rate","AUS","Australia","2012","2012",537.4,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","MTMOTCMT","Million US$ at exchange rate","AUS","Australia","2013","2013",573.4,"B; D","Break; Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","MTMOTCMT","Million US$ at exchange rate","AUS","Australia","2014","2014",530.9,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","MTMOTCMT","Million US$ at exchange rate","AUS","Australia","2015","2015",463.5,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","MTMOTCMT","Million US$ at exchange rate","AUS","Australia","2016","2016",481.7,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","MTMOTCMT","Million US$ at exchange rate","AUS","Australia","2017","2017",550.3,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","MTMOTCMT","Million US$ at exchange rate","AUS","Australia","2018","2018",558.1,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","MTMOTCMT","Million US$ at exchange rate","AUS","Australia","2019","2019",545,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","MTMOTCMT","Million US$ at exchange rate","AUS","Australia","2020","2020",597.3,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","MTMOTCMT","Million US$ at exchange rate","AUS","Australia","2021","2021",733.9,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","MTMOPPMT","Million US$, purchasing power parity","AUS","Australia","2010","2010",282,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","MTMOPPMT","Million US$, purchasing power parity","AUS","Australia","2011","2011",311,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","MTMOPPMT","Million US$, purchasing power parity","AUS","Australia","2012","2012",337,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","MTMOPPMT","Million US$, purchasing power parity","AUS","Australia","2013","2013",410.5,"B; D","Break; Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","MTMOPPMT","Million US$, purchasing power parity","AUS","Australia","2014","2014",405.5,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","MTMOPPMT","Million US$, purchasing power parity","AUS","Australia","2015","2015",418.7,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","MTMOPPMT","Million US$, purchasing power parity","AUS","Australia","2016","2016",446.8,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","MTMOPPMT","Million US$, purchasing power parity","AUS","Australia","2017","2017",485.9,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","MTMOPPMT","Million US$, purchasing power parity","AUS","Australia","2018","2018",508,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","MTMOPPMT","Million US$, purchasing power parity","AUS","Australia","2019","2019",529.8,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","MTMOPPMT","Million US$, purchasing power parity","AUS","Australia","2020","2020",597,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","MTMOPPMT","Million US$, purchasing power parity","AUS","Australia","2021","2021",674.9,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","TCPPERMT","/capita, US$ exchange rate","AUS","Australia","2010","2010",17.7,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","TCPPERMT","/capita, US$ exchange rate","AUS","Australia","2011","2011",21.7,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","TCPPERMT","/capita, US$ exchange rate","AUS","Australia","2012","2012",23.6,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","TCPPERMT","/capita, US$ exchange rate","AUS","Australia","2013","2013",24.8,"B; D","Break; Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","TCPPERMT","/capita, US$ exchange rate","AUS","Australia","2014","2014",22.6,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","TCPPERMT","/capita, US$ exchange rate","AUS","Australia","2015","2015",19.5,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","TCPPERMT","/capita, US$ exchange rate","AUS","Australia","2016","2016",19.9,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","TCPPERMT","/capita, US$ exchange rate","AUS","Australia","2017","2017",22.4,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","TCPPERMT","/capita, US$ exchange rate","AUS","Australia","2018","2018",22.4,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","TCPPERMT","/capita, US$ exchange rate","AUS","Australia","2019","2019",21.5,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","TCPPERMT","/capita, US$ exchange rate","AUS","Australia","2020","2020",23.3,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","TCPPERMT","/capita, US$ exchange rate","AUS","Australia","2021","2021",28.6,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2010","2010",12.8,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2011","2011",13.9,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2012","2012",14.8,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2013","2013",17.7,"B; D","Break; Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2014","2014",17.3,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2015","2015",17.6,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2016","2016",18.5,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2017","2017",19.8,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2018","2018",20.3,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2019","2019",20.9,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2020","2020",23.3,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2021","2021",26.3,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","ATCPTTMT","% of total sales","AUS","Australia","2010","2010",4.3,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","ATCPTTMT","% of total sales","AUS","Australia","2011","2011",4.6,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","ATCPTTMT","% of total sales","AUS","Australia","2012","2012",5,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","ATCPTTMT","% of total sales","AUS","Australia","2013","2013",5,"B; D","Break; Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","ATCPTTMT","% of total sales","AUS","Australia","2014","2014",5,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","ATCPTTMT","% of total sales","AUS","Australia","2015","2015",5,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","ATCPTTMT","% of total sales","AUS","Australia","2016","2016",4.2,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","ATCPTTMT","% of total sales","AUS","Australia","2017","2017",4.9,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","ATCPTTMT","% of total sales","AUS","Australia","2018","2018",5,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","ATCPTTMT","% of total sales","AUS","Australia","2019","2019",5,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","ATCPTTMT","% of total sales","AUS","Australia","2020","2020",5.2,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","ATCPTTMT","% of total sales","AUS","Australia","2021","2021",5.6,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","MLLNCUMT","Million of national currency units","AUT","Austria","2010","2010",96.6,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","MLLNCUMT","Million of national currency units","AUT","Austria","2011","2011",104.1,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","MLLNCUMT","Million of national currency units","AUT","Austria","2012","2012",110.5,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","MLLNCUMT","Million of national currency units","AUT","Austria","2013","2013",115.2,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","MLLNCUMT","Million of national currency units","AUT","Austria","2014","2014",123.8,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","MLLNCUMT","Million of national currency units","AUT","Austria","2015","2015",134,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","MLLNCUMT","Million of national currency units","AUT","Austria","2016","2016",149.7,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","MLLNCUMT","Million of national currency units","AUT","Austria","2017","2017",165.7,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","MLLNCUMT","Million of national currency units","AUT","Austria","2018","2018",179.1,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","MLLNCUMT","Million of national currency units","AUT","Austria","2019","2019",195.9,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","MLLNCUMT","Million of national currency units","AUT","Austria","2020","2020",214.6,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","MLLNCUMT","Million of national currency units","AUT","Austria","2021","2021",228.6,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","MTMOTCMT","Million US$ at exchange rate","AUT","Austria","2010","2010",128.1,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","MTMOTCMT","Million US$ at exchange rate","AUT","Austria","2011","2011",144.9,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","MTMOTCMT","Million US$ at exchange rate","AUT","Austria","2012","2012",142,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","MTMOTCMT","Million US$ at exchange rate","AUT","Austria","2013","2013",152.9,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","MTMOTCMT","Million US$ at exchange rate","AUT","Austria","2014","2014",164.5,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","MTMOTCMT","Million US$ at exchange rate","AUT","Austria","2015","2015",148.7,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","MTMOTCMT","Million US$ at exchange rate","AUT","Austria","2016","2016",165.8,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","MTMOTCMT","Million US$ at exchange rate","AUT","Austria","2017","2017",187.2,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","MTMOTCMT","Million US$ at exchange rate","AUT","Austria","2018","2018",211.5,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","MTMOTCMT","Million US$ at exchange rate","AUT","Austria","2019","2019",219.3,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","MTMOTCMT","Million US$ at exchange rate","AUT","Austria","2020","2020",245.1,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","MTMOTCMT","Million US$ at exchange rate","AUT","Austria","2021","2021",270.3,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","MTMOPPMT","Million US$, purchasing power parity","AUT","Austria","2010","2010",114.7,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","MTMOPPMT","Million US$, purchasing power parity","AUT","Austria","2011","2011",125.2,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","MTMOPPMT","Million US$, purchasing power parity","AUT","Austria","2012","2012",135.8,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","MTMOPPMT","Million US$, purchasing power parity","AUT","Austria","2013","2013",144.5,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","MTMOPPMT","Million US$, purchasing power parity","AUT","Austria","2014","2014",155,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","MTMOPPMT","Million US$, purchasing power parity","AUT","Austria","2015","2015",167.8,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","MTMOPPMT","Million US$, purchasing power parity","AUT","Austria","2016","2016",192.7,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","MTMOPPMT","Million US$, purchasing power parity","AUT","Austria","2017","2017",213.8,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","MTMOPPMT","Million US$, purchasing power parity","AUT","Austria","2018","2018",234,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","MTMOPPMT","Million US$, purchasing power parity","AUT","Austria","2019","2019",261.5,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","MTMOPPMT","Million US$, purchasing power parity","AUT","Austria","2020","2020",287.6,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","MTMOPPMT","Million US$, purchasing power parity","AUT","Austria","2021","2021",302.2,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","TCPPERMT","/capita, US$ exchange rate","AUT","Austria","2010","2010",15.3,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","TCPPERMT","/capita, US$ exchange rate","AUT","Austria","2011","2011",17.3,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","TCPPERMT","/capita, US$ exchange rate","AUT","Austria","2012","2012",16.8,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","TCPPERMT","/capita, US$ exchange rate","AUT","Austria","2013","2013",18,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","TCPPERMT","/capita, US$ exchange rate","AUT","Austria","2014","2014",19.2,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","TCPPERMT","/capita, US$ exchange rate","AUT","Austria","2015","2015",17.2,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","TCPPERMT","/capita, US$ exchange rate","AUT","Austria","2016","2016",19,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","TCPPERMT","/capita, US$ exchange rate","AUT","Austria","2017","2017",21.3,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","TCPPERMT","/capita, US$ exchange rate","AUT","Austria","2018","2018",23.9,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","TCPPERMT","/capita, US$ exchange rate","AUT","Austria","2019","2019",24.7,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","TCPPERMT","/capita, US$ exchange rate","AUT","Austria","2020","2020",27.5,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","TCPPERMT","/capita, US$ exchange rate","AUT","Austria","2021","2021",30.2,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2010","2010",13.7,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2011","2011",14.9,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2012","2012",16.1,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2013","2013",17,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2014","2014",18.1,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2015","2015",19.4,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2016","2016",22.1,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2017","2017",24.3,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2018","2018",26.5,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2019","2019",29.5,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2020","2020",32.2,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2021","2021",33.7,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","ATCPTTMT","% of total sales","AUT","Austria","2010","2010",3.9,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","ATCPTTMT","% of total sales","AUT","Austria","2011","2011",4.1,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","ATCPTTMT","% of total sales","AUT","Austria","2012","2012",4.2,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","ATCPTTMT","% of total sales","AUT","Austria","2013","2013",4.4,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","ATCPTTMT","% of total sales","AUT","Austria","2014","2014",4.4,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","ATCPTTMT","% of total sales","AUT","Austria","2015","2015",4.6,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","ATCPTTMT","% of total sales","AUT","Austria","2016","2016",5,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","ATCPTTMT","% of total sales","AUT","Austria","2017","2017",5.3,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","ATCPTTMT","% of total sales","AUT","Austria","2018","2018",5.6,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","ATCPTTMT","% of total sales","AUT","Austria","2019","2019",5.9,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","ATCPTTMT","% of total sales","AUT","Austria","2020","2020",6.2,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","ATCPTTMT","% of total sales","AUT","Austria","2021","2021",6.2,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","MLLNCUMT","Million of national currency units","BEL","Belgium","2010","2010",139.5,,
+"PATCDIAB","A10-Drugs used in diabetes","MLLNCUMT","Million of national currency units","BEL","Belgium","2011","2011",150.4,,
+"PATCDIAB","A10-Drugs used in diabetes","MLLNCUMT","Million of national currency units","BEL","Belgium","2012","2012",155.2,,
+"PATCDIAB","A10-Drugs used in diabetes","MLLNCUMT","Million of national currency units","BEL","Belgium","2013","2013",163.2,,
+"PATCDIAB","A10-Drugs used in diabetes","MLLNCUMT","Million of national currency units","BEL","Belgium","2014","2014",171.4,,
+"PATCDIAB","A10-Drugs used in diabetes","MLLNCUMT","Million of national currency units","BEL","Belgium","2015","2015",178.8,,
+"PATCDIAB","A10-Drugs used in diabetes","MLLNCUMT","Million of national currency units","BEL","Belgium","2016","2016",191.8,,
+"PATCDIAB","A10-Drugs used in diabetes","MLLNCUMT","Million of national currency units","BEL","Belgium","2017","2017",201.6,,
+"PATCDIAB","A10-Drugs used in diabetes","MLLNCUMT","Million of national currency units","BEL","Belgium","2018","2018",210.9,,
+"PATCDIAB","A10-Drugs used in diabetes","MLLNCUMT","Million of national currency units","BEL","Belgium","2019","2019",237.7,,
+"PATCDIAB","A10-Drugs used in diabetes","MLLNCUMT","Million of national currency units","BEL","Belgium","2020","2020",258.2,,
+"PATCDIAB","A10-Drugs used in diabetes","MLLNCUMT","Million of national currency units","BEL","Belgium","2021","2021",287.2,,
+"PATCDIAB","A10-Drugs used in diabetes","MLLNCUMT","Million of national currency units","BEL","Belgium","2022","2022",330.6,"E","Estimated value"
+"PATCDIAB","A10-Drugs used in diabetes","MTMOTCMT","Million US$ at exchange rate","BEL","Belgium","2010","2010",184.9,,
+"PATCDIAB","A10-Drugs used in diabetes","MTMOTCMT","Million US$ at exchange rate","BEL","Belgium","2011","2011",209.4,,
+"PATCDIAB","A10-Drugs used in diabetes","MTMOTCMT","Million US$ at exchange rate","BEL","Belgium","2012","2012",199.4,,
+"PATCDIAB","A10-Drugs used in diabetes","MTMOTCMT","Million US$ at exchange rate","BEL","Belgium","2013","2013",216.8,,
+"PATCDIAB","A10-Drugs used in diabetes","MTMOTCMT","Million US$ at exchange rate","BEL","Belgium","2014","2014",227.7,,
+"PATCDIAB","A10-Drugs used in diabetes","MTMOTCMT","Million US$ at exchange rate","BEL","Belgium","2015","2015",198.4,,
+"PATCDIAB","A10-Drugs used in diabetes","MTMOTCMT","Million US$ at exchange rate","BEL","Belgium","2016","2016",212.4,,
+"PATCDIAB","A10-Drugs used in diabetes","MTMOTCMT","Million US$ at exchange rate","BEL","Belgium","2017","2017",227.8,,
+"PATCDIAB","A10-Drugs used in diabetes","MTMOTCMT","Million US$ at exchange rate","BEL","Belgium","2018","2018",249.1,,
+"PATCDIAB","A10-Drugs used in diabetes","MTMOTCMT","Million US$ at exchange rate","BEL","Belgium","2019","2019",266.2,,
+"PATCDIAB","A10-Drugs used in diabetes","MTMOTCMT","Million US$ at exchange rate","BEL","Belgium","2020","2020",295,,
+"PATCDIAB","A10-Drugs used in diabetes","MTMOTCMT","Million US$ at exchange rate","BEL","Belgium","2021","2021",339.6,,
+"PATCDIAB","A10-Drugs used in diabetes","MTMOTCMT","Million US$ at exchange rate","BEL","Belgium","2022","2022",348.2,"E","Estimated value"
+"PATCDIAB","A10-Drugs used in diabetes","MTMOPPMT","Million US$, purchasing power parity","BEL","Belgium","2010","2010",166.8,,
+"PATCDIAB","A10-Drugs used in diabetes","MTMOPPMT","Million US$, purchasing power parity","BEL","Belgium","2011","2011",180.8,,
+"PATCDIAB","A10-Drugs used in diabetes","MTMOPPMT","Million US$, purchasing power parity","BEL","Belgium","2012","2012",188.8,,
+"PATCDIAB","A10-Drugs used in diabetes","MTMOPPMT","Million US$, purchasing power parity","BEL","Belgium","2013","2013",202.5,,
+"PATCDIAB","A10-Drugs used in diabetes","MTMOPPMT","Million US$, purchasing power parity","BEL","Belgium","2014","2014",214.2,,
+"PATCDIAB","A10-Drugs used in diabetes","MTMOPPMT","Million US$, purchasing power parity","BEL","Belgium","2015","2015",223.5,,
+"PATCDIAB","A10-Drugs used in diabetes","MTMOPPMT","Million US$, purchasing power parity","BEL","Belgium","2016","2016",245.6,,
+"PATCDIAB","A10-Drugs used in diabetes","MTMOPPMT","Million US$, purchasing power parity","BEL","Belgium","2017","2017",259.9,,
+"PATCDIAB","A10-Drugs used in diabetes","MTMOPPMT","Million US$, purchasing power parity","BEL","Belgium","2018","2018",275.2,,
+"PATCDIAB","A10-Drugs used in diabetes","MTMOPPMT","Million US$, purchasing power parity","BEL","Belgium","2019","2019",318.4,,
+"PATCDIAB","A10-Drugs used in diabetes","MTMOPPMT","Million US$, purchasing power parity","BEL","Belgium","2020","2020",353.6,,
+"PATCDIAB","A10-Drugs used in diabetes","MTMOPPMT","Million US$, purchasing power parity","BEL","Belgium","2021","2021",389.8,,
+"PATCDIAB","A10-Drugs used in diabetes","MTMOPPMT","Million US$, purchasing power parity","BEL","Belgium","2022","2022",463.1,"E","Estimated value"
+"PATCDIAB","A10-Drugs used in diabetes","TCPPERMT","/capita, US$ exchange rate","BEL","Belgium","2010","2010",17,,
+"PATCDIAB","A10-Drugs used in diabetes","TCPPERMT","/capita, US$ exchange rate","BEL","Belgium","2011","2011",19,,
+"PATCDIAB","A10-Drugs used in diabetes","TCPPERMT","/capita, US$ exchange rate","BEL","Belgium","2012","2012",18,,
+"PATCDIAB","A10-Drugs used in diabetes","TCPPERMT","/capita, US$ exchange rate","BEL","Belgium","2013","2013",19.4,,
+"PATCDIAB","A10-Drugs used in diabetes","TCPPERMT","/capita, US$ exchange rate","BEL","Belgium","2014","2014",20.3,,
+"PATCDIAB","A10-Drugs used in diabetes","TCPPERMT","/capita, US$ exchange rate","BEL","Belgium","2015","2015",17.6,,
+"PATCDIAB","A10-Drugs used in diabetes","TCPPERMT","/capita, US$ exchange rate","BEL","Belgium","2016","2016",18.7,,
+"PATCDIAB","A10-Drugs used in diabetes","TCPPERMT","/capita, US$ exchange rate","BEL","Belgium","2017","2017",20,,
+"PATCDIAB","A10-Drugs used in diabetes","TCPPERMT","/capita, US$ exchange rate","BEL","Belgium","2018","2018",21.8,,
+"PATCDIAB","A10-Drugs used in diabetes","TCPPERMT","/capita, US$ exchange rate","BEL","Belgium","2019","2019",23.2,,
+"PATCDIAB","A10-Drugs used in diabetes","TCPPERMT","/capita, US$ exchange rate","BEL","Belgium","2020","2020",25.6,,
+"PATCDIAB","A10-Drugs used in diabetes","TCPPERMT","/capita, US$ exchange rate","BEL","Belgium","2021","2021",29.3,,
+"PATCDIAB","A10-Drugs used in diabetes","TCPPERMT","/capita, US$ exchange rate","BEL","Belgium","2022","2022",30,"E","Estimated value"
+"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2010","2010",15.3,,
+"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2011","2011",16.4,,
+"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2012","2012",17,,
+"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2013","2013",18.1,,
+"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2014","2014",19.1,,
+"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2015","2015",19.8,,
+"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2016","2016",21.7,,
+"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2017","2017",22.9,,
+"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2018","2018",24.1,,
+"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2019","2019",27.7,,
+"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2020","2020",30.6,,
+"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2021","2021",33.6,,
+"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2022","2022",39.9,"E","Estimated value"
+"PATCDIAB","A10-Drugs used in diabetes","ATCPTTMT","% of total sales","BEL","Belgium","2010","2010",2.4,,
+"PATCDIAB","A10-Drugs used in diabetes","ATCPTTMT","% of total sales","BEL","Belgium","2011","2011",2.5,,
+"PATCDIAB","A10-Drugs used in diabetes","ATCPTTMT","% of total sales","BEL","Belgium","2012","2012",2.6,,
+"PATCDIAB","A10-Drugs used in diabetes","ATCPTTMT","% of total sales","BEL","Belgium","2013","2013",2.7,,
+"PATCDIAB","A10-Drugs used in diabetes","ATCPTTMT","% of total sales","BEL","Belgium","2014","2014",2.9,,
+"PATCDIAB","A10-Drugs used in diabetes","ATCPTTMT","% of total sales","BEL","Belgium","2015","2015",2.9,,
+"PATCDIAB","A10-Drugs used in diabetes","ATCPTTMT","% of total sales","BEL","Belgium","2016","2016",3.1,,
+"PATCDIAB","A10-Drugs used in diabetes","ATCPTTMT","% of total sales","BEL","Belgium","2017","2017",3.1,,
+"PATCDIAB","A10-Drugs used in diabetes","ATCPTTMT","% of total sales","BEL","Belgium","2018","2018",3.2,,
+"PATCDIAB","A10-Drugs used in diabetes","ATCPTTMT","% of total sales","BEL","Belgium","2019","2019",3.2,,
+"PATCDIAB","A10-Drugs used in diabetes","ATCPTTMT","% of total sales","BEL","Belgium","2020","2020",3.4,,
+"PATCDIAB","A10-Drugs used in diabetes","ATCPTTMT","% of total sales","BEL","Belgium","2021","2021",3.6,,
+"PATCDIAB","A10-Drugs used in diabetes","ATCPTTMT","% of total sales","BEL","Belgium","2022","2022",3.7,"E","Estimated value"
+"PATCDIAB","A10-Drugs used in diabetes","MLLNCUMT","Million of national currency units","CAN","Canada","2012","2012",1233.7,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","MLLNCUMT","Million of national currency units","CAN","Canada","2013","2013",1369,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","MLLNCUMT","Million of national currency units","CAN","Canada","2014","2014",1514.1,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","MLLNCUMT","Million of national currency units","CAN","Canada","2015","2015",1702.1,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","MLLNCUMT","Million of national currency units","CAN","Canada","2016","2016",1947.1,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","MLLNCUMT","Million of national currency units","CAN","Canada","2017","2017",2175.7,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","MLLNCUMT","Million of national currency units","CAN","Canada","2018","2018",2402.5,"E; B; D","Estimated value; Break; Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","MLLNCUMT","Million of national currency units","CAN","Canada","2019","2019",2673.1,"E; D","Estimated value; Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","MLLNCUMT","Million of national currency units","CAN","Canada","2020","2020",3086.4,"E; D","Estimated value; Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","MLLNCUMT","Million of national currency units","CAN","Canada","2021","2021",3536.2,"E; D","Estimated value; Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","MLLNCUMT","Million of national currency units","CAN","Canada","2022","2022",4299.2,"E; D","Estimated value; Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","MTMOTCMT","Million US$ at exchange rate","CAN","Canada","2012","2012",1234.5,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","MTMOTCMT","Million US$ at exchange rate","CAN","Canada","2013","2013",1328.9,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","MTMOTCMT","Million US$ at exchange rate","CAN","Canada","2014","2014",1370.5,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","MTMOTCMT","Million US$ at exchange rate","CAN","Canada","2015","2015",1331,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","MTMOTCMT","Million US$ at exchange rate","CAN","Canada","2016","2016",1468.8,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","MTMOTCMT","Million US$ at exchange rate","CAN","Canada","2017","2017",1676.3,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","MTMOTCMT","Million US$ at exchange rate","CAN","Canada","2018","2018",1854.1,"E; B; D","Estimated value; Break; Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","MTMOTCMT","Million US$ at exchange rate","CAN","Canada","2019","2019",2014.7,"E; D","Estimated value; Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","MTMOTCMT","Million US$ at exchange rate","CAN","Canada","2020","2020",2301.3,"E; D","Estimated value; Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","MTMOTCMT","Million US$ at exchange rate","CAN","Canada","2021","2021",2820.2,"E; D","Estimated value; Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","MTMOTCMT","Million US$ at exchange rate","CAN","Canada","2022","2022",3303.1,"E; D","Estimated value; Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","MTMOPPMT","Million US$, purchasing power parity","CAN","Canada","2012","2012",991.2,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","MTMOPPMT","Million US$, purchasing power parity","CAN","Canada","2013","2013",1118.5,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","MTMOPPMT","Million US$, purchasing power parity","CAN","Canada","2014","2014",1230.6,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","MTMOPPMT","Million US$, purchasing power parity","CAN","Canada","2015","2015",1363.8,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","MTMOPPMT","Million US$, purchasing power parity","CAN","Canada","2016","2016",1613.1,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","MTMOPPMT","Million US$, purchasing power parity","CAN","Canada","2017","2017",1794.7,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","MTMOPPMT","Million US$, purchasing power parity","CAN","Canada","2018","2018",1991.3,"E; B; D","Estimated value; Break; Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","MTMOPPMT","Million US$, purchasing power parity","CAN","Canada","2019","2019",2164.9,"E; D","Estimated value; Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","MTMOPPMT","Million US$, purchasing power parity","CAN","Canada","2020","2020",2507.1,"E; D","Estimated value; Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","MTMOPPMT","Million US$, purchasing power parity","CAN","Canada","2021","2021",2856,"E; D","Estimated value; Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","MTMOPPMT","Million US$, purchasing power parity","CAN","Canada","2022","2022",3428.9,"E; D","Estimated value; Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","TCPPERMT","/capita, US$ exchange rate","CAN","Canada","2012","2012",35.6,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","TCPPERMT","/capita, US$ exchange rate","CAN","Canada","2013","2013",37.9,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","TCPPERMT","/capita, US$ exchange rate","CAN","Canada","2014","2014",38.7,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","TCPPERMT","/capita, US$ exchange rate","CAN","Canada","2015","2015",37.3,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","TCPPERMT","/capita, US$ exchange rate","CAN","Canada","2016","2016",40.7,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","TCPPERMT","/capita, US$ exchange rate","CAN","Canada","2017","2017",45.9,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","TCPPERMT","/capita, US$ exchange rate","CAN","Canada","2018","2018",50,"E; B; D","Estimated value; Break; Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","TCPPERMT","/capita, US$ exchange rate","CAN","Canada","2019","2019",53.6,"E; D","Estimated value; Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","TCPPERMT","/capita, US$ exchange rate","CAN","Canada","2020","2020",60.5,"E; D","Estimated value; Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","TCPPERMT","/capita, US$ exchange rate","CAN","Canada","2021","2021",73.7,"E; D","Estimated value; Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","TCPPERMT","/capita, US$ exchange rate","CAN","Canada","2022","2022",85,"E; D","Estimated value; Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2012","2012",28.6,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2013","2013",31.9,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2014","2014",34.7,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2015","2015",38.2,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2016","2016",44.7,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2017","2017",49.1,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2018","2018",53.7,"E; B; D","Estimated value; Break; Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2019","2019",57.6,"E; D","Estimated value; Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2020","2020",65.9,"E; D","Estimated value; Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2021","2021",74.7,"E; D","Estimated value; Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2022","2022",88.2,"E; D","Estimated value; Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","ATCPTTMT","% of total sales","CAN","Canada","2012","2012",5.1,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","ATCPTTMT","% of total sales","CAN","Canada","2013","2013",5.6,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","ATCPTTMT","% of total sales","CAN","Canada","2014","2014",5.9,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","ATCPTTMT","% of total sales","CAN","Canada","2015","2015",6.3,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","ATCPTTMT","% of total sales","CAN","Canada","2016","2016",6.9,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","ATCPTTMT","% of total sales","CAN","Canada","2017","2017",7.3,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","ATCPTTMT","% of total sales","CAN","Canada","2018","2018",7.9,"E; B; D","Estimated value; Break; Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","ATCPTTMT","% of total sales","CAN","Canada","2019","2019",8.4,"E; D","Estimated value; Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","ATCPTTMT","% of total sales","CAN","Canada","2020","2020",9,"E; D","Estimated value; Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","ATCPTTMT","% of total sales","CAN","Canada","2021","2021",9.6,"E; D","Estimated value; Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","ATCPTTMT","% of total sales","CAN","Canada","2022","2022",10.8,"E; D","Estimated value; Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","MLLNCUMT","Million of national currency units","CZE","Czech Republic","2010","2010",3639.3,,
+"PATCDIAB","A10-Drugs used in diabetes","MLLNCUMT","Million of national currency units","CZE","Czech Republic","2011","2011",3775,,
+"PATCDIAB","A10-Drugs used in diabetes","MLLNCUMT","Million of national currency units","CZE","Czech Republic","2012","2012",4194.7,,
+"PATCDIAB","A10-Drugs used in diabetes","MLLNCUMT","Million of national currency units","CZE","Czech Republic","2013","2013",4098.3,,
+"PATCDIAB","A10-Drugs used in diabetes","MLLNCUMT","Million of national currency units","CZE","Czech Republic","2014","2014",4614,,
+"PATCDIAB","A10-Drugs used in diabetes","MLLNCUMT","Million of national currency units","CZE","Czech Republic","2015","2015",5120.1,,
+"PATCDIAB","A10-Drugs used in diabetes","MLLNCUMT","Million of national currency units","CZE","Czech Republic","2016","2016",5517.5,,
+"PATCDIAB","A10-Drugs used in diabetes","MLLNCUMT","Million of national currency units","CZE","Czech Republic","2017","2017",5999.4,,
+"PATCDIAB","A10-Drugs used in diabetes","MLLNCUMT","Million of national currency units","CZE","Czech Republic","2018","2018",6345,,
+"PATCDIAB","A10-Drugs used in diabetes","MLLNCUMT","Million of national currency units","CZE","Czech Republic","2019","2019",6768.9,,
+"PATCDIAB","A10-Drugs used in diabetes","MLLNCUMT","Million of national currency units","CZE","Czech Republic","2020","2020",7133.6,"B","Break"
+"PATCDIAB","A10-Drugs used in diabetes","MLLNCUMT","Million of national currency units","CZE","Czech Republic","2021","2021",7499.7,,
+"PATCDIAB","A10-Drugs used in diabetes","MTMOTCMT","Million US$ at exchange rate","CZE","Czech Republic","2010","2010",190.6,,
+"PATCDIAB","A10-Drugs used in diabetes","MTMOTCMT","Million US$ at exchange rate","CZE","Czech Republic","2011","2011",213.3,,
+"PATCDIAB","A10-Drugs used in diabetes","MTMOTCMT","Million US$ at exchange rate","CZE","Czech Republic","2012","2012",214.3,,
+"PATCDIAB","A10-Drugs used in diabetes","MTMOTCMT","Million US$ at exchange rate","CZE","Czech Republic","2013","2013",209.4,,
+"PATCDIAB","A10-Drugs used in diabetes","MTMOTCMT","Million US$ at exchange rate","CZE","Czech Republic","2014","2014",222.3,,
+"PATCDIAB","A10-Drugs used in diabetes","MTMOTCMT","Million US$ at exchange rate","CZE","Czech Republic","2015","2015",208.1,,
+"PATCDIAB","A10-Drugs used in diabetes","MTMOTCMT","Million US$ at exchange rate","CZE","Czech Republic","2016","2016",225.8,,
+"PATCDIAB","A10-Drugs used in diabetes","MTMOTCMT","Million US$ at exchange rate","CZE","Czech Republic","2017","2017",256.6,,
+"PATCDIAB","A10-Drugs used in diabetes","MTMOTCMT","Million US$ at exchange rate","CZE","Czech Republic","2018","2018",292,,
+"PATCDIAB","A10-Drugs used in diabetes","MTMOTCMT","Million US$ at exchange rate","CZE","Czech Republic","2019","2019",295.2,,
+"PATCDIAB","A10-Drugs used in diabetes","MTMOTCMT","Million US$ at exchange rate","CZE","Czech Republic","2020","2020",307.3,"B","Break"
+"PATCDIAB","A10-Drugs used in diabetes","MTMOTCMT","Million US$ at exchange rate","CZE","Czech Republic","2021","2021",346,,
+"PATCDIAB","A10-Drugs used in diabetes","MTMOPPMT","Million US$, purchasing power parity","CZE","Czech Republic","2010","2010",266.2,,
+"PATCDIAB","A10-Drugs used in diabetes","MTMOPPMT","Million US$, purchasing power parity","CZE","Czech Republic","2011","2011",282.9,,
+"PATCDIAB","A10-Drugs used in diabetes","MTMOPPMT","Million US$, purchasing power parity","CZE","Czech Republic","2012","2012",315.4,,
+"PATCDIAB","A10-Drugs used in diabetes","MTMOPPMT","Million US$, purchasing power parity","CZE","Czech Republic","2013","2013",320.5,,
+"PATCDIAB","A10-Drugs used in diabetes","MTMOPPMT","Million US$, purchasing power parity","CZE","Czech Republic","2014","2014",363.2,,
+"PATCDIAB","A10-Drugs used in diabetes","MTMOPPMT","Million US$, purchasing power parity","CZE","Czech Republic","2015","2015",395.7,,
+"PATCDIAB","A10-Drugs used in diabetes","MTMOPPMT","Million US$, purchasing power parity","CZE","Czech Republic","2016","2016",438.7,,
+"PATCDIAB","A10-Drugs used in diabetes","MTMOPPMT","Million US$, purchasing power parity","CZE","Czech Republic","2017","2017",482.9,,
+"PATCDIAB","A10-Drugs used in diabetes","MTMOPPMT","Million US$, purchasing power parity","CZE","Czech Republic","2018","2018",512.9,,
+"PATCDIAB","A10-Drugs used in diabetes","MTMOPPMT","Million US$, purchasing power parity","CZE","Czech Republic","2019","2019",551.5,,
+"PATCDIAB","A10-Drugs used in diabetes","MTMOPPMT","Million US$, purchasing power parity","CZE","Czech Republic","2020","2020",572.5,"B","Break"
+"PATCDIAB","A10-Drugs used in diabetes","MTMOPPMT","Million US$, purchasing power parity","CZE","Czech Republic","2021","2021",588.5,,
+"PATCDIAB","A10-Drugs used in diabetes","TCPPERMT","/capita, US$ exchange rate","CZE","Czech Republic","2010","2010",18.2,,
+"PATCDIAB","A10-Drugs used in diabetes","TCPPERMT","/capita, US$ exchange rate","CZE","Czech Republic","2011","2011",20.3,,
+"PATCDIAB","A10-Drugs used in diabetes","TCPPERMT","/capita, US$ exchange rate","CZE","Czech Republic","2012","2012",20.4,,
+"PATCDIAB","A10-Drugs used in diabetes","TCPPERMT","/capita, US$ exchange rate","CZE","Czech Republic","2013","2013",19.9,,
+"PATCDIAB","A10-Drugs used in diabetes","TCPPERMT","/capita, US$ exchange rate","CZE","Czech Republic","2014","2014",21.1,,
+"PATCDIAB","A10-Drugs used in diabetes","TCPPERMT","/capita, US$ exchange rate","CZE","Czech Republic","2015","2015",19.7,,
+"PATCDIAB","A10-Drugs used in diabetes","TCPPERMT","/capita, US$ exchange rate","CZE","Czech Republic","2016","2016",21.4,,
+"PATCDIAB","A10-Drugs used in diabetes","TCPPERMT","/capita, US$ exchange rate","CZE","Czech Republic","2017","2017",24.2,,
+"PATCDIAB","A10-Drugs used in diabetes","TCPPERMT","/capita, US$ exchange rate","CZE","Czech Republic","2018","2018",27.5,,
+"PATCDIAB","A10-Drugs used in diabetes","TCPPERMT","/capita, US$ exchange rate","CZE","Czech Republic","2019","2019",27.7,,
+"PATCDIAB","A10-Drugs used in diabetes","TCPPERMT","/capita, US$ exchange rate","CZE","Czech Republic","2020","2020",28.7,"B","Break"
+"PATCDIAB","A10-Drugs used in diabetes","TCPPERMT","/capita, US$ exchange rate","CZE","Czech Republic","2021","2021",32.9,,
+"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czech Republic","2010","2010",25.4,,
+"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czech Republic","2011","2011",26.9,,
+"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czech Republic","2012","2012",30,,
+"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czech Republic","2013","2013",30.5,,
+"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czech Republic","2014","2014",34.5,,
+"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czech Republic","2015","2015",37.5,,
+"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czech Republic","2016","2016",41.5,,
+"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czech Republic","2017","2017",45.6,,
+"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czech Republic","2018","2018",48.2,,
+"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czech Republic","2019","2019",51.7,,
+"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czech Republic","2020","2020",53.5,"B","Break"
+"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czech Republic","2021","2021",56,,
+"PATCDIAB","A10-Drugs used in diabetes","ATCPTTMT","% of total sales","CZE","Czech Republic","2010","2010",4.5,,
+"PATCDIAB","A10-Drugs used in diabetes","ATCPTTMT","% of total sales","CZE","Czech Republic","2011","2011",4.7,,
+"PATCDIAB","A10-Drugs used in diabetes","ATCPTTMT","% of total sales","CZE","Czech Republic","2012","2012",5,,
+"PATCDIAB","A10-Drugs used in diabetes","ATCPTTMT","% of total sales","CZE","Czech Republic","2013","2013",5.1,,
+"PATCDIAB","A10-Drugs used in diabetes","ATCPTTMT","% of total sales","CZE","Czech Republic","2014","2014",5.7,,
+"PATCDIAB","A10-Drugs used in diabetes","ATCPTTMT","% of total sales","CZE","Czech Republic","2015","2015",6.1,,
+"PATCDIAB","A10-Drugs used in diabetes","ATCPTTMT","% of total sales","CZE","Czech Republic","2016","2016",6.3,,
+"PATCDIAB","A10-Drugs used in diabetes","ATCPTTMT","% of total sales","CZE","Czech Republic","2017","2017",6.5,,
+"PATCDIAB","A10-Drugs used in diabetes","ATCPTTMT","% of total sales","CZE","Czech Republic","2018","2018",6.5,,
+"PATCDIAB","A10-Drugs used in diabetes","ATCPTTMT","% of total sales","CZE","Czech Republic","2019","2019",6.5,,
+"PATCDIAB","A10-Drugs used in diabetes","ATCPTTMT","% of total sales","CZE","Czech Republic","2020","2020",8.1,"B","Break"
+"PATCDIAB","A10-Drugs used in diabetes","ATCPTTMT","% of total sales","CZE","Czech Republic","2021","2021",8.1,,
+"PATCDIAB","A10-Drugs used in diabetes","MLLNCUMT","Million of national currency units","FIN","Finland","2010","2010",104.6,,
+"PATCDIAB","A10-Drugs used in diabetes","MLLNCUMT","Million of national currency units","FIN","Finland","2011","2011",117.1,,
+"PATCDIAB","A10-Drugs used in diabetes","MLLNCUMT","Million of national currency units","FIN","Finland","2012","2012",127.2,,
+"PATCDIAB","A10-Drugs used in diabetes","MLLNCUMT","Million of national currency units","FIN","Finland","2013","2013",131,,
+"PATCDIAB","A10-Drugs used in diabetes","MLLNCUMT","Million of national currency units","FIN","Finland","2014","2014",140,,
+"PATCDIAB","A10-Drugs used in diabetes","MLLNCUMT","Million of national currency units","FIN","Finland","2015","2015",148.2,,
+"PATCDIAB","A10-Drugs used in diabetes","MLLNCUMT","Million of national currency units","FIN","Finland","2016","2016",153.5,,
+"PATCDIAB","A10-Drugs used in diabetes","MLLNCUMT","Million of national currency units","FIN","Finland","2017","2017",148,,
+"PATCDIAB","A10-Drugs used in diabetes","MLLNCUMT","Million of national currency units","FIN","Finland","2018","2018",154.9,,
+"PATCDIAB","A10-Drugs used in diabetes","MLLNCUMT","Million of national currency units","FIN","Finland","2019","2019",161.3,,
+"PATCDIAB","A10-Drugs used in diabetes","MLLNCUMT","Million of national currency units","FIN","Finland","2020","2020",170.9,,
+"PATCDIAB","A10-Drugs used in diabetes","MLLNCUMT","Million of national currency units","FIN","Finland","2021","2021",180.8,,
+"PATCDIAB","A10-Drugs used in diabetes","MTMOTCMT","Million US$ at exchange rate","FIN","Finland","2010","2010",138.7,,
+"PATCDIAB","A10-Drugs used in diabetes","MTMOTCMT","Million US$ at exchange rate","FIN","Finland","2011","2011",163,,
+"PATCDIAB","A10-Drugs used in diabetes","MTMOTCMT","Million US$ at exchange rate","FIN","Finland","2012","2012",163.4,,
+"PATCDIAB","A10-Drugs used in diabetes","MTMOTCMT","Million US$ at exchange rate","FIN","Finland","2013","2013",174,,
+"PATCDIAB","A10-Drugs used in diabetes","MTMOTCMT","Million US$ at exchange rate","FIN","Finland","2014","2014",186,,
+"PATCDIAB","A10-Drugs used in diabetes","MTMOTCMT","Million US$ at exchange rate","FIN","Finland","2015","2015",164.4,,
+"PATCDIAB","A10-Drugs used in diabetes","MTMOTCMT","Million US$ at exchange rate","FIN","Finland","2016","2016",169.9,,
+"PATCDIAB","A10-Drugs used in diabetes","MTMOTCMT","Million US$ at exchange rate","FIN","Finland","2017","2017",167.2,,
+"PATCDIAB","A10-Drugs used in diabetes","MTMOTCMT","Million US$ at exchange rate","FIN","Finland","2018","2018",182.9,,
+"PATCDIAB","A10-Drugs used in diabetes","MTMOTCMT","Million US$ at exchange rate","FIN","Finland","2019","2019",180.6,,
+"PATCDIAB","A10-Drugs used in diabetes","MTMOTCMT","Million US$ at exchange rate","FIN","Finland","2020","2020",195.2,,
+"PATCDIAB","A10-Drugs used in diabetes","MTMOTCMT","Million US$ at exchange rate","FIN","Finland","2021","2021",213.8,,
+"PATCDIAB","A10-Drugs used in diabetes","MTMOPPMT","Million US$, purchasing power parity","FIN","Finland","2010","2010",116.2,,
+"PATCDIAB","A10-Drugs used in diabetes","MTMOPPMT","Million US$, purchasing power parity","FIN","Finland","2011","2011",130.4,,
+"PATCDIAB","A10-Drugs used in diabetes","MTMOPPMT","Million US$, purchasing power parity","FIN","Finland","2012","2012",140,,
+"PATCDIAB","A10-Drugs used in diabetes","MTMOPPMT","Million US$, purchasing power parity","FIN","Finland","2013","2013",144.7,,
+"PATCDIAB","A10-Drugs used in diabetes","MTMOPPMT","Million US$, purchasing power parity","FIN","Finland","2014","2014",154.3,,
+"PATCDIAB","A10-Drugs used in diabetes","MTMOPPMT","Million US$, purchasing power parity","FIN","Finland","2015","2015",163.3,,
+"PATCDIAB","A10-Drugs used in diabetes","MTMOPPMT","Million US$, purchasing power parity","FIN","Finland","2016","2016",174.3,,
+"PATCDIAB","A10-Drugs used in diabetes","MTMOPPMT","Million US$, purchasing power parity","FIN","Finland","2017","2017",171.4,,
+"PATCDIAB","A10-Drugs used in diabetes","MTMOPPMT","Million US$, purchasing power parity","FIN","Finland","2018","2018",181.4,,
+"PATCDIAB","A10-Drugs used in diabetes","MTMOPPMT","Million US$, purchasing power parity","FIN","Finland","2019","2019",192.4,,
+"PATCDIAB","A10-Drugs used in diabetes","MTMOPPMT","Million US$, purchasing power parity","FIN","Finland","2020","2020",207.6,,
+"PATCDIAB","A10-Drugs used in diabetes","MTMOPPMT","Million US$, purchasing power parity","FIN","Finland","2021","2021",218.7,,
+"PATCDIAB","A10-Drugs used in diabetes","TCPPERMT","/capita, US$ exchange rate","FIN","Finland","2010","2010",25.9,,
+"PATCDIAB","A10-Drugs used in diabetes","TCPPERMT","/capita, US$ exchange rate","FIN","Finland","2011","2011",30.3,,
+"PATCDIAB","A10-Drugs used in diabetes","TCPPERMT","/capita, US$ exchange rate","FIN","Finland","2012","2012",30.2,,
+"PATCDIAB","A10-Drugs used in diabetes","TCPPERMT","/capita, US$ exchange rate","FIN","Finland","2013","2013",32,,
+"PATCDIAB","A10-Drugs used in diabetes","TCPPERMT","/capita, US$ exchange rate","FIN","Finland","2014","2014",34.1,,
+"PATCDIAB","A10-Drugs used in diabetes","TCPPERMT","/capita, US$ exchange rate","FIN","Finland","2015","2015",30,,
+"PATCDIAB","A10-Drugs used in diabetes","TCPPERMT","/capita, US$ exchange rate","FIN","Finland","2016","2016",30.9,,
+"PATCDIAB","A10-Drugs used in diabetes","TCPPERMT","/capita, US$ exchange rate","FIN","Finland","2017","2017",30.4,,
+"PATCDIAB","A10-Drugs used in diabetes","TCPPERMT","/capita, US$ exchange rate","FIN","Finland","2018","2018",33.2,,
+"PATCDIAB","A10-Drugs used in diabetes","TCPPERMT","/capita, US$ exchange rate","FIN","Finland","2019","2019",32.7,,
+"PATCDIAB","A10-Drugs used in diabetes","TCPPERMT","/capita, US$ exchange rate","FIN","Finland","2020","2020",35.3,,
+"PATCDIAB","A10-Drugs used in diabetes","TCPPERMT","/capita, US$ exchange rate","FIN","Finland","2021","2021",38.6,,
+"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2010","2010",21.7,,
+"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2011","2011",24.2,,
+"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2012","2012",25.9,,
+"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2013","2013",26.6,,
+"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2014","2014",28.3,,
+"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2015","2015",29.8,,
+"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2016","2016",31.7,,
+"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2017","2017",31.1,,
+"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2018","2018",32.9,,
+"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2019","2019",34.8,,
+"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2020","2020",37.6,,
+"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2021","2021",39.5,,
+"PATCDIAB","A10-Drugs used in diabetes","ATCPTTMT","% of total sales","FIN","Finland","2010","2010",5.6,,
+"PATCDIAB","A10-Drugs used in diabetes","ATCPTTMT","% of total sales","FIN","Finland","2011","2011",6.1,,
+"PATCDIAB","A10-Drugs used in diabetes","ATCPTTMT","% of total sales","FIN","Finland","2012","2012",6.5,,
+"PATCDIAB","A10-Drugs used in diabetes","ATCPTTMT","% of total sales","FIN","Finland","2013","2013",6.5,,
+"PATCDIAB","A10-Drugs used in diabetes","ATCPTTMT","% of total sales","FIN","Finland","2014","2014",6.7,,
+"PATCDIAB","A10-Drugs used in diabetes","ATCPTTMT","% of total sales","FIN","Finland","2015","2015",6.7,,
+"PATCDIAB","A10-Drugs used in diabetes","ATCPTTMT","% of total sales","FIN","Finland","2016","2016",6.7,,
+"PATCDIAB","A10-Drugs used in diabetes","ATCPTTMT","% of total sales","FIN","Finland","2017","2017",6.4,,
+"PATCDIAB","A10-Drugs used in diabetes","ATCPTTMT","% of total sales","FIN","Finland","2018","2018",6.2,,
+"PATCDIAB","A10-Drugs used in diabetes","ATCPTTMT","% of total sales","FIN","Finland","2019","2019",6.1,,
+"PATCDIAB","A10-Drugs used in diabetes","ATCPTTMT","% of total sales","FIN","Finland","2020","2020",6.3,,
+"PATCDIAB","A10-Drugs used in diabetes","ATCPTTMT","% of total sales","FIN","Finland","2021","2021",6.3,,
+"PATCDIAB","A10-Drugs used in diabetes","MLLNCUMT","Million of national currency units","DEU","Germany","2010","2010",1888.9,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","MLLNCUMT","Million of national currency units","DEU","Germany","2011","2011",1947.1,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","MLLNCUMT","Million of national currency units","DEU","Germany","2012","2012",2068.8,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","MLLNCUMT","Million of national currency units","DEU","Germany","2013","2013",2203,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","MLLNCUMT","Million of national currency units","DEU","Germany","2014","2014",2229.6,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","MLLNCUMT","Million of national currency units","DEU","Germany","2015","2015",2303.5,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","MLLNCUMT","Million of national currency units","DEU","Germany","2016","2016",2416.9,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","MLLNCUMT","Million of national currency units","DEU","Germany","2017","2017",2502,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","MLLNCUMT","Million of national currency units","DEU","Germany","2018","2018",2635.8,"B; D","Break; Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","MLLNCUMT","Million of national currency units","DEU","Germany","2019","2019",2791.6,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","MLLNCUMT","Million of national currency units","DEU","Germany","2020","2020",2972,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","MLLNCUMT","Million of national currency units","DEU","Germany","2021","2021",3234.2,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","MTMOTCMT","Million US$ at exchange rate","DEU","Germany","2010","2010",2504.1,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","MTMOTCMT","Million US$ at exchange rate","DEU","Germany","2011","2011",2710.3,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","MTMOTCMT","Million US$ at exchange rate","DEU","Germany","2012","2012",2658,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","MTMOTCMT","Million US$ at exchange rate","DEU","Germany","2013","2013",2925.8,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","MTMOTCMT","Million US$ at exchange rate","DEU","Germany","2014","2014",2962,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","MTMOTCMT","Million US$ at exchange rate","DEU","Germany","2015","2015",2555.8,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","MTMOTCMT","Million US$ at exchange rate","DEU","Germany","2016","2016",2675.3,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","MTMOTCMT","Million US$ at exchange rate","DEU","Germany","2017","2017",2826.5,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","MTMOTCMT","Million US$ at exchange rate","DEU","Germany","2018","2018",3112.8,"B; D","Break; Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","MTMOTCMT","Million US$ at exchange rate","DEU","Germany","2019","2019",3125.1,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","MTMOTCMT","Million US$ at exchange rate","DEU","Germany","2020","2020",3394.6,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","MTMOTCMT","Million US$ at exchange rate","DEU","Germany","2021","2021",3825.2,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","MTMOPPMT","Million US$, purchasing power parity","DEU","Germany","2010","2010",2346.2,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","MTMOPPMT","Million US$, purchasing power parity","DEU","Germany","2011","2011",2468.6,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","MTMOPPMT","Million US$, purchasing power parity","DEU","Germany","2012","2012",2627.9,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","MTMOPPMT","Million US$, purchasing power parity","DEU","Germany","2013","2013",2843.4,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","MTMOPPMT","Million US$, purchasing power parity","DEU","Germany","2014","2014",2899.6,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","MTMOPPMT","Million US$, purchasing power parity","DEU","Germany","2015","2015",2960.3,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","MTMOPPMT","Million US$, purchasing power parity","DEU","Germany","2016","2016",3211.4,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","MTMOPPMT","Million US$, purchasing power parity","DEU","Germany","2017","2017",3359.4,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","MTMOPPMT","Million US$, purchasing power parity","DEU","Germany","2018","2018",3583.9,"B; D","Break; Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","MTMOPPMT","Million US$, purchasing power parity","DEU","Germany","2019","2019",3833.3,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","MTMOPPMT","Million US$, purchasing power parity","DEU","Germany","2020","2020",4099.3,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","MTMOPPMT","Million US$, purchasing power parity","DEU","Germany","2021","2021",4392.6,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","TCPPERMT","/capita, US$ exchange rate","DEU","Germany","2010","2010",30.6,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","TCPPERMT","/capita, US$ exchange rate","DEU","Germany","2011","2011",33.8,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","TCPPERMT","/capita, US$ exchange rate","DEU","Germany","2012","2012",33,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","TCPPERMT","/capita, US$ exchange rate","DEU","Germany","2013","2013",36.3,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","TCPPERMT","/capita, US$ exchange rate","DEU","Germany","2014","2014",36.6,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","TCPPERMT","/capita, US$ exchange rate","DEU","Germany","2015","2015",31.3,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","TCPPERMT","/capita, US$ exchange rate","DEU","Germany","2016","2016",32.5,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","TCPPERMT","/capita, US$ exchange rate","DEU","Germany","2017","2017",34.2,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","TCPPERMT","/capita, US$ exchange rate","DEU","Germany","2018","2018",37.5,"B; D","Break; Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","TCPPERMT","/capita, US$ exchange rate","DEU","Germany","2019","2019",37.6,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","TCPPERMT","/capita, US$ exchange rate","DEU","Germany","2020","2020",40.8,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","TCPPERMT","/capita, US$ exchange rate","DEU","Germany","2021","2021",46,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2010","2010",28.7,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2011","2011",30.8,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2012","2012",32.7,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2013","2013",35.3,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2014","2014",35.8,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2015","2015",36.2,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2016","2016",39,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2017","2017",40.6,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2018","2018",43.2,"B; D","Break; Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2019","2019",46.1,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2020","2020",49.3,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2021","2021",52.8,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","ATCPTTMT","% of total sales","DEU","Germany","2010","2010",6.4,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","ATCPTTMT","% of total sales","DEU","Germany","2011","2011",6.6,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","ATCPTTMT","% of total sales","DEU","Germany","2012","2012",6.8,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","ATCPTTMT","% of total sales","DEU","Germany","2013","2013",7,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","ATCPTTMT","% of total sales","DEU","Germany","2014","2014",6.6,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","ATCPTTMT","% of total sales","DEU","Germany","2015","2015",6.5,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","ATCPTTMT","% of total sales","DEU","Germany","2016","2016",6.7,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","ATCPTTMT","% of total sales","DEU","Germany","2017","2017",6.7,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","ATCPTTMT","% of total sales","DEU","Germany","2018","2018",6,"B; D","Break; Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","ATCPTTMT","% of total sales","DEU","Germany","2019","2019",6,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","ATCPTTMT","% of total sales","DEU","Germany","2020","2020",6,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","ATCPTTMT","% of total sales","DEU","Germany","2021","2021",6.1,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","MLLNCUMT","Million of national currency units","GRC","Greece","2010","2010",303.2,,
+"PATCDIAB","A10-Drugs used in diabetes","MLLNCUMT","Million of national currency units","GRC","Greece","2011","2011",277.3,,
+"PATCDIAB","A10-Drugs used in diabetes","MLLNCUMT","Million of national currency units","GRC","Greece","2012","2012",281.1,,
+"PATCDIAB","A10-Drugs used in diabetes","MLLNCUMT","Million of national currency units","GRC","Greece","2013","2013",286.4,,
+"PATCDIAB","A10-Drugs used in diabetes","MLLNCUMT","Million of national currency units","GRC","Greece","2014","2014",306.1,,
+"PATCDIAB","A10-Drugs used in diabetes","MLLNCUMT","Million of national currency units","GRC","Greece","2015","2015",283.8,,
+"PATCDIAB","A10-Drugs used in diabetes","MLLNCUMT","Million of national currency units","GRC","Greece","2016","2016",398.2,,
+"PATCDIAB","A10-Drugs used in diabetes","MLLNCUMT","Million of national currency units","GRC","Greece","2017","2017",408.7,,
+"PATCDIAB","A10-Drugs used in diabetes","MLLNCUMT","Million of national currency units","GRC","Greece","2018","2018",418,,
+"PATCDIAB","A10-Drugs used in diabetes","MLLNCUMT","Million of national currency units","GRC","Greece","2019","2019",442.3,,
+"PATCDIAB","A10-Drugs used in diabetes","MLLNCUMT","Million of national currency units","GRC","Greece","2020","2020",426.9,,
+"PATCDIAB","A10-Drugs used in diabetes","MLLNCUMT","Million of national currency units","GRC","Greece","2021","2021",513.7,,
+"PATCDIAB","A10-Drugs used in diabetes","MLLNCUMT","Million of national currency units","GRC","Greece","2022","2022",472.1,,
+"PATCDIAB","A10-Drugs used in diabetes","MTMOTCMT","Million US$ at exchange rate","GRC","Greece","2010","2010",401.9,,
+"PATCDIAB","A10-Drugs used in diabetes","MTMOTCMT","Million US$ at exchange rate","GRC","Greece","2011","2011",386.1,,
+"PATCDIAB","A10-Drugs used in diabetes","MTMOTCMT","Million US$ at exchange rate","GRC","Greece","2012","2012",361.1,,
+"PATCDIAB","A10-Drugs used in diabetes","MTMOTCMT","Million US$ at exchange rate","GRC","Greece","2013","2013",380.4,,
+"PATCDIAB","A10-Drugs used in diabetes","MTMOTCMT","Million US$ at exchange rate","GRC","Greece","2014","2014",406.6,,
+"PATCDIAB","A10-Drugs used in diabetes","MTMOTCMT","Million US$ at exchange rate","GRC","Greece","2015","2015",314.8,,
+"PATCDIAB","A10-Drugs used in diabetes","MTMOTCMT","Million US$ at exchange rate","GRC","Greece","2016","2016",440.7,,
+"PATCDIAB","A10-Drugs used in diabetes","MTMOTCMT","Million US$ at exchange rate","GRC","Greece","2017","2017",461.7,,
+"PATCDIAB","A10-Drugs used in diabetes","MTMOTCMT","Million US$ at exchange rate","GRC","Greece","2018","2018",493.7,,
+"PATCDIAB","A10-Drugs used in diabetes","MTMOTCMT","Million US$ at exchange rate","GRC","Greece","2019","2019",495.1,,
+"PATCDIAB","A10-Drugs used in diabetes","MTMOTCMT","Million US$ at exchange rate","GRC","Greece","2020","2020",487.6,,
+"PATCDIAB","A10-Drugs used in diabetes","MTMOTCMT","Million US$ at exchange rate","GRC","Greece","2021","2021",607.6,,
+"PATCDIAB","A10-Drugs used in diabetes","MTMOTCMT","Million US$ at exchange rate","GRC","Greece","2022","2022",497.1,,
+"PATCDIAB","A10-Drugs used in diabetes","MTMOPPMT","Million US$, purchasing power parity","GRC","Greece","2010","2010",419.9,,
+"PATCDIAB","A10-Drugs used in diabetes","MTMOPPMT","Million US$, purchasing power parity","GRC","Greece","2011","2011",388.9,,
+"PATCDIAB","A10-Drugs used in diabetes","MTMOPPMT","Million US$, purchasing power parity","GRC","Greece","2012","2012",410.6,,
+"PATCDIAB","A10-Drugs used in diabetes","MTMOPPMT","Million US$, purchasing power parity","GRC","Greece","2013","2013",453.7,,
+"PATCDIAB","A10-Drugs used in diabetes","MTMOPPMT","Million US$, purchasing power parity","GRC","Greece","2014","2014",500.8,,
+"PATCDIAB","A10-Drugs used in diabetes","MTMOPPMT","Million US$, purchasing power parity","GRC","Greece","2015","2015",465.9,,
+"PATCDIAB","A10-Drugs used in diabetes","MTMOPPMT","Million US$, purchasing power parity","GRC","Greece","2016","2016",676.5,,
+"PATCDIAB","A10-Drugs used in diabetes","MTMOPPMT","Million US$, purchasing power parity","GRC","Greece","2017","2017",710.7,,
+"PATCDIAB","A10-Drugs used in diabetes","MTMOPPMT","Million US$, purchasing power parity","GRC","Greece","2018","2018",740.1,,
+"PATCDIAB","A10-Drugs used in diabetes","MTMOPPMT","Million US$, purchasing power parity","GRC","Greece","2019","2019",805.8,,
+"PATCDIAB","A10-Drugs used in diabetes","MTMOPPMT","Million US$, purchasing power parity","GRC","Greece","2020","2020",784.7,,
+"PATCDIAB","A10-Drugs used in diabetes","MTMOPPMT","Million US$, purchasing power parity","GRC","Greece","2021","2021",941.7,,
+"PATCDIAB","A10-Drugs used in diabetes","MTMOPPMT","Million US$, purchasing power parity","GRC","Greece","2022","2022",893.3,,
+"PATCDIAB","A10-Drugs used in diabetes","TCPPERMT","/capita, US$ exchange rate","GRC","Greece","2010","2010",36.1,,
+"PATCDIAB","A10-Drugs used in diabetes","TCPPERMT","/capita, US$ exchange rate","GRC","Greece","2011","2011",34.8,,
+"PATCDIAB","A10-Drugs used in diabetes","TCPPERMT","/capita, US$ exchange rate","GRC","Greece","2012","2012",32.7,,
+"PATCDIAB","A10-Drugs used in diabetes","TCPPERMT","/capita, US$ exchange rate","GRC","Greece","2013","2013",34.7,,
+"PATCDIAB","A10-Drugs used in diabetes","TCPPERMT","/capita, US$ exchange rate","GRC","Greece","2014","2014",37.3,,
+"PATCDIAB","A10-Drugs used in diabetes","TCPPERMT","/capita, US$ exchange rate","GRC","Greece","2015","2015",29.1,,
+"PATCDIAB","A10-Drugs used in diabetes","TCPPERMT","/capita, US$ exchange rate","GRC","Greece","2016","2016",40.9,,
+"PATCDIAB","A10-Drugs used in diabetes","TCPPERMT","/capita, US$ exchange rate","GRC","Greece","2017","2017",42.9,,
+"PATCDIAB","A10-Drugs used in diabetes","TCPPERMT","/capita, US$ exchange rate","GRC","Greece","2018","2018",46,,
+"PATCDIAB","A10-Drugs used in diabetes","TCPPERMT","/capita, US$ exchange rate","GRC","Greece","2019","2019",46.2,,
+"PATCDIAB","A10-Drugs used in diabetes","TCPPERMT","/capita, US$ exchange rate","GRC","Greece","2020","2020",45.6,,
+"PATCDIAB","A10-Drugs used in diabetes","TCPPERMT","/capita, US$ exchange rate","GRC","Greece","2021","2021",57.5,,
+"PATCDIAB","A10-Drugs used in diabetes","TCPPERMT","/capita, US$ exchange rate","GRC","Greece","2022","2022",47.5,,
+"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2010","2010",37.8,,
+"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2011","2011",35,,
+"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2012","2012",37.2,,
+"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2013","2013",41.4,,
+"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2014","2014",46,,
+"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2015","2015",43.1,,
+"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2016","2016",62.8,,
+"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2017","2017",66.1,,
+"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2018","2018",69,,
+"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2019","2019",75.2,,
+"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2020","2020",73.3,,
+"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2021","2021",89.1,,
+"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2022","2022",85.4,,
+"PATCDIAB","A10-Drugs used in diabetes","MLLNCUMT","Million of national currency units","HUN","Hungary","2010","2010",30573.8,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","MLLNCUMT","Million of national currency units","HUN","Hungary","2011","2011",33416.2,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","MLLNCUMT","Million of national currency units","HUN","Hungary","2012","2012",34389.1,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","MLLNCUMT","Million of national currency units","HUN","Hungary","2013","2013",35559.7,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","MLLNCUMT","Million of national currency units","HUN","Hungary","2014","2014",38486.2,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","MLLNCUMT","Million of national currency units","HUN","Hungary","2015","2015",40546,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","MLLNCUMT","Million of national currency units","HUN","Hungary","2016","2016",45267.9,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","MLLNCUMT","Million of national currency units","HUN","Hungary","2017","2017",50037.2,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","MLLNCUMT","Million of national currency units","HUN","Hungary","2018","2018",55484.4,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","MLLNCUMT","Million of national currency units","HUN","Hungary","2019","2019",61900.9,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","MLLNCUMT","Million of national currency units","HUN","Hungary","2020","2020",69245.7,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","MLLNCUMT","Million of national currency units","HUN","Hungary","2021","2021",71161.5,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","MLLNCUMT","Million of national currency units","HUN","Hungary","2022","2022",78318.5,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","MTMOTCMT","Million US$ at exchange rate","HUN","Hungary","2010","2010",147,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","MTMOTCMT","Million US$ at exchange rate","HUN","Hungary","2011","2011",166.2,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","MTMOTCMT","Million US$ at exchange rate","HUN","Hungary","2012","2012",152.8,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","MTMOTCMT","Million US$ at exchange rate","HUN","Hungary","2013","2013",159,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","MTMOTCMT","Million US$ at exchange rate","HUN","Hungary","2014","2014",165.5,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","MTMOTCMT","Million US$ at exchange rate","HUN","Hungary","2015","2015",145.2,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","MTMOTCMT","Million US$ at exchange rate","HUN","Hungary","2016","2016",160.8,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","MTMOTCMT","Million US$ at exchange rate","HUN","Hungary","2017","2017",182.3,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","MTMOTCMT","Million US$ at exchange rate","HUN","Hungary","2018","2018",205.3,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","MTMOTCMT","Million US$ at exchange rate","HUN","Hungary","2019","2019",213,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","MTMOTCMT","Million US$ at exchange rate","HUN","Hungary","2020","2020",224.8,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","MTMOTCMT","Million US$ at exchange rate","HUN","Hungary","2021","2021",234.7,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","MTMOTCMT","Million US$ at exchange rate","HUN","Hungary","2022","2022",210.2,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","MTMOPPMT","Million US$, purchasing power parity","HUN","Hungary","2010","2010",241.8,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","MTMOPPMT","Million US$, purchasing power parity","HUN","Hungary","2011","2011",268.9,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","MTMOPPMT","Million US$, purchasing power parity","HUN","Hungary","2012","2012",273.7,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","MTMOPPMT","Million US$, purchasing power parity","HUN","Hungary","2013","2013",284.5,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","MTMOPPMT","Million US$, purchasing power parity","HUN","Hungary","2014","2014",297.4,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","MTMOPPMT","Million US$, purchasing power parity","HUN","Hungary","2015","2015",305.9,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","MTMOPPMT","Million US$, purchasing power parity","HUN","Hungary","2016","2016",342.9,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","MTMOPPMT","Million US$, purchasing power parity","HUN","Hungary","2017","2017",367.8,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","MTMOPPMT","Million US$, purchasing power parity","HUN","Hungary","2018","2018",398.9,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","MTMOPPMT","Million US$, purchasing power parity","HUN","Hungary","2019","2019",439.5,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","MTMOPPMT","Million US$, purchasing power parity","HUN","Hungary","2020","2020",476.4,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","MTMOPPMT","Million US$, purchasing power parity","HUN","Hungary","2021","2021",459.9,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","MTMOPPMT","Million US$, purchasing power parity","HUN","Hungary","2022","2022",485.7,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","TCPPERMT","/capita, US$ exchange rate","HUN","Hungary","2010","2010",14.7,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","TCPPERMT","/capita, US$ exchange rate","HUN","Hungary","2011","2011",16.7,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","TCPPERMT","/capita, US$ exchange rate","HUN","Hungary","2012","2012",15.4,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","TCPPERMT","/capita, US$ exchange rate","HUN","Hungary","2013","2013",16.1,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","TCPPERMT","/capita, US$ exchange rate","HUN","Hungary","2014","2014",16.8,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","TCPPERMT","/capita, US$ exchange rate","HUN","Hungary","2015","2015",14.7,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","TCPPERMT","/capita, US$ exchange rate","HUN","Hungary","2016","2016",16.4,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","TCPPERMT","/capita, US$ exchange rate","HUN","Hungary","2017","2017",18.6,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","TCPPERMT","/capita, US$ exchange rate","HUN","Hungary","2018","2018",21,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","TCPPERMT","/capita, US$ exchange rate","HUN","Hungary","2019","2019",21.8,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","TCPPERMT","/capita, US$ exchange rate","HUN","Hungary","2020","2020",23.1,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","TCPPERMT","/capita, US$ exchange rate","HUN","Hungary","2021","2021",24.2,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","TCPPERMT","/capita, US$ exchange rate","HUN","Hungary","2022","2022",21.7,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2010","2010",24.2,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2011","2011",27,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2012","2012",27.6,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2013","2013",28.8,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2014","2014",30.1,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2015","2015",31.1,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2016","2016",34.9,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2017","2017",37.6,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2018","2018",40.8,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2019","2019",45,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2020","2020",48.9,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2021","2021",47.4,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2022","2022",50.1,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","ATCPTTMT","% of total sales","HUN","Hungary","2010","2010",6.1,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","ATCPTTMT","% of total sales","HUN","Hungary","2011","2011",6.5,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","ATCPTTMT","% of total sales","HUN","Hungary","2012","2012",7.7,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","ATCPTTMT","% of total sales","HUN","Hungary","2013","2013",8.3,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","ATCPTTMT","% of total sales","HUN","Hungary","2014","2014",8.7,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","ATCPTTMT","% of total sales","HUN","Hungary","2015","2015",8.7,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","ATCPTTMT","% of total sales","HUN","Hungary","2016","2016",9.1,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","ATCPTTMT","% of total sales","HUN","Hungary","2017","2017",10.1,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","ATCPTTMT","% of total sales","HUN","Hungary","2018","2018",11.1,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","ATCPTTMT","% of total sales","HUN","Hungary","2019","2019",11.7,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","ATCPTTMT","% of total sales","HUN","Hungary","2020","2020",12.4,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","ATCPTTMT","% of total sales","HUN","Hungary","2021","2021",12.5,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","ATCPTTMT","% of total sales","HUN","Hungary","2022","2022",13.1,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","MLLNCUMT","Million of national currency units","ISL","Iceland","2010","2010",612.6,,
+"PATCDIAB","A10-Drugs used in diabetes","MLLNCUMT","Million of national currency units","ISL","Iceland","2011","2011",645.2,,
+"PATCDIAB","A10-Drugs used in diabetes","MLLNCUMT","Million of national currency units","ISL","Iceland","2012","2012",673.1,,
+"PATCDIAB","A10-Drugs used in diabetes","MLLNCUMT","Million of national currency units","ISL","Iceland","2013","2013",738,,
+"PATCDIAB","A10-Drugs used in diabetes","MLLNCUMT","Million of national currency units","ISL","Iceland","2014","2014",726.7,,
+"PATCDIAB","A10-Drugs used in diabetes","MLLNCUMT","Million of national currency units","ISL","Iceland","2015","2015",731.1,,
+"PATCDIAB","A10-Drugs used in diabetes","MLLNCUMT","Million of national currency units","ISL","Iceland","2016","2016",838.3,,
+"PATCDIAB","A10-Drugs used in diabetes","MLLNCUMT","Million of national currency units","ISL","Iceland","2017","2017",845.8,,
+"PATCDIAB","A10-Drugs used in diabetes","MLLNCUMT","Million of national currency units","ISL","Iceland","2018","2018",1057.2,,
+"PATCDIAB","A10-Drugs used in diabetes","MLLNCUMT","Million of national currency units","ISL","Iceland","2019","2019",1327.2,,
+"PATCDIAB","A10-Drugs used in diabetes","MLLNCUMT","Million of national currency units","ISL","Iceland","2020","2020",1834.7,,
+"PATCDIAB","A10-Drugs used in diabetes","MLLNCUMT","Million of national currency units","ISL","Iceland","2021","2021",2435.6,,
+"PATCDIAB","A10-Drugs used in diabetes","MTMOTCMT","Million US$ at exchange rate","ISL","Iceland","2010","2010",5,,
+"PATCDIAB","A10-Drugs used in diabetes","MTMOTCMT","Million US$ at exchange rate","ISL","Iceland","2011","2011",5.6,,
+"PATCDIAB","A10-Drugs used in diabetes","MTMOTCMT","Million US$ at exchange rate","ISL","Iceland","2012","2012",5.4,,
+"PATCDIAB","A10-Drugs used in diabetes","MTMOTCMT","Million US$ at exchange rate","ISL","Iceland","2013","2013",6,,
+"PATCDIAB","A10-Drugs used in diabetes","MTMOTCMT","Million US$ at exchange rate","ISL","Iceland","2014","2014",6.2,,
+"PATCDIAB","A10-Drugs used in diabetes","MTMOTCMT","Million US$ at exchange rate","ISL","Iceland","2015","2015",5.5,,
+"PATCDIAB","A10-Drugs used in diabetes","MTMOTCMT","Million US$ at exchange rate","ISL","Iceland","2016","2016",6.9,,
+"PATCDIAB","A10-Drugs used in diabetes","MTMOTCMT","Million US$ at exchange rate","ISL","Iceland","2017","2017",7.9,,
+"PATCDIAB","A10-Drugs used in diabetes","MTMOTCMT","Million US$ at exchange rate","ISL","Iceland","2018","2018",9.8,,
+"PATCDIAB","A10-Drugs used in diabetes","MTMOTCMT","Million US$ at exchange rate","ISL","Iceland","2019","2019",10.8,,
+"PATCDIAB","A10-Drugs used in diabetes","MTMOTCMT","Million US$ at exchange rate","ISL","Iceland","2020","2020",13.5,,
+"PATCDIAB","A10-Drugs used in diabetes","MTMOTCMT","Million US$ at exchange rate","ISL","Iceland","2021","2021",19.2,,
+"PATCDIAB","A10-Drugs used in diabetes","MTMOPPMT","Million US$, purchasing power parity","ISL","Iceland","2010","2010",4.6,,
+"PATCDIAB","A10-Drugs used in diabetes","MTMOPPMT","Million US$, purchasing power parity","ISL","Iceland","2011","2011",4.8,,
+"PATCDIAB","A10-Drugs used in diabetes","MTMOPPMT","Million US$, purchasing power parity","ISL","Iceland","2012","2012",4.9,,
+"PATCDIAB","A10-Drugs used in diabetes","MTMOPPMT","Million US$, purchasing power parity","ISL","Iceland","2013","2013",5.4,,
+"PATCDIAB","A10-Drugs used in diabetes","MTMOPPMT","Million US$, purchasing power parity","ISL","Iceland","2014","2014",5.2,,
+"PATCDIAB","A10-Drugs used in diabetes","MTMOPPMT","Million US$, purchasing power parity","ISL","Iceland","2015","2015",5.1,,
+"PATCDIAB","A10-Drugs used in diabetes","MTMOPPMT","Million US$, purchasing power parity","ISL","Iceland","2016","2016",6,,
+"PATCDIAB","A10-Drugs used in diabetes","MTMOPPMT","Million US$, purchasing power parity","ISL","Iceland","2017","2017",6.1,,
+"PATCDIAB","A10-Drugs used in diabetes","MTMOPPMT","Million US$, purchasing power parity","ISL","Iceland","2018","2018",7.5,,
+"PATCDIAB","A10-Drugs used in diabetes","MTMOPPMT","Million US$, purchasing power parity","ISL","Iceland","2019","2019",9.4,,
+"PATCDIAB","A10-Drugs used in diabetes","MTMOPPMT","Million US$, purchasing power parity","ISL","Iceland","2020","2020",12.5,,
+"PATCDIAB","A10-Drugs used in diabetes","MTMOPPMT","Million US$, purchasing power parity","ISL","Iceland","2021","2021",16.3,,
+"PATCDIAB","A10-Drugs used in diabetes","TCPPERMT","/capita, US$ exchange rate","ISL","Iceland","2010","2010",15.8,,
+"PATCDIAB","A10-Drugs used in diabetes","TCPPERMT","/capita, US$ exchange rate","ISL","Iceland","2011","2011",17.4,,
+"PATCDIAB","A10-Drugs used in diabetes","TCPPERMT","/capita, US$ exchange rate","ISL","Iceland","2012","2012",16.8,,
+"PATCDIAB","A10-Drugs used in diabetes","TCPPERMT","/capita, US$ exchange rate","ISL","Iceland","2013","2013",18.7,,
+"PATCDIAB","A10-Drugs used in diabetes","TCPPERMT","/capita, US$ exchange rate","ISL","Iceland","2014","2014",19,,
+"PATCDIAB","A10-Drugs used in diabetes","TCPPERMT","/capita, US$ exchange rate","ISL","Iceland","2015","2015",16.8,,
+"PATCDIAB","A10-Drugs used in diabetes","TCPPERMT","/capita, US$ exchange rate","ISL","Iceland","2016","2016",20.7,,
+"PATCDIAB","A10-Drugs used in diabetes","TCPPERMT","/capita, US$ exchange rate","ISL","Iceland","2017","2017",23.1,,
+"PATCDIAB","A10-Drugs used in diabetes","TCPPERMT","/capita, US$ exchange rate","ISL","Iceland","2018","2018",27.7,,
+"PATCDIAB","A10-Drugs used in diabetes","TCPPERMT","/capita, US$ exchange rate","ISL","Iceland","2019","2019",30,,
+"PATCDIAB","A10-Drugs used in diabetes","TCPPERMT","/capita, US$ exchange rate","ISL","Iceland","2020","2020",37,,
+"PATCDIAB","A10-Drugs used in diabetes","TCPPERMT","/capita, US$ exchange rate","ISL","Iceland","2021","2021",51.5,,
+"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2010","2010",14.5,,
+"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2011","2011",15,,
+"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2012","2012",15.3,,
+"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2013","2013",16.6,,
+"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2014","2014",16,,
+"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2015","2015",15.6,,
+"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2016","2016",17.8,,
+"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2017","2017",17.8,,
+"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2018","2018",21.3,,
+"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2019","2019",26.2,,
+"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2020","2020",34.1,,
+"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2021","2021",43.7,,
+"PATCDIAB","A10-Drugs used in diabetes","ATCPTTMT","% of total sales","ISL","Iceland","2010","2010",2.4,,
+"PATCDIAB","A10-Drugs used in diabetes","ATCPTTMT","% of total sales","ISL","Iceland","2011","2011",2.5,,
+"PATCDIAB","A10-Drugs used in diabetes","ATCPTTMT","% of total sales","ISL","Iceland","2012","2012",2.8,,
+"PATCDIAB","A10-Drugs used in diabetes","ATCPTTMT","% of total sales","ISL","Iceland","2013","2013",2.8,,
+"PATCDIAB","A10-Drugs used in diabetes","ATCPTTMT","% of total sales","ISL","Iceland","2014","2014",3.1,,
+"PATCDIAB","A10-Drugs used in diabetes","ATCPTTMT","% of total sales","ISL","Iceland","2015","2015",3,,
+"PATCDIAB","A10-Drugs used in diabetes","ATCPTTMT","% of total sales","ISL","Iceland","2016","2016",3.3,,
+"PATCDIAB","A10-Drugs used in diabetes","ATCPTTMT","% of total sales","ISL","Iceland","2017","2017",3.2,,
+"PATCDIAB","A10-Drugs used in diabetes","ATCPTTMT","% of total sales","ISL","Iceland","2018","2018",3.5,,
+"PATCDIAB","A10-Drugs used in diabetes","ATCPTTMT","% of total sales","ISL","Iceland","2019","2019",3.9,,
+"PATCDIAB","A10-Drugs used in diabetes","ATCPTTMT","% of total sales","ISL","Iceland","2020","2020",4.6,,
+"PATCDIAB","A10-Drugs used in diabetes","ATCPTTMT","% of total sales","ISL","Iceland","2021","2021",5.4,,
+"PATCDIAB","A10-Drugs used in diabetes","MLLNCUMT","Million of national currency units","IRL","Ireland","2010","2010",68,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","MLLNCUMT","Million of national currency units","IRL","Ireland","2011","2011",73.5,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","MLLNCUMT","Million of national currency units","IRL","Ireland","2012","2012",81.4,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","MLLNCUMT","Million of national currency units","IRL","Ireland","2013","2013",82,"B; D","Break; Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","MLLNCUMT","Million of national currency units","IRL","Ireland","2014","2014",83.6,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","MLLNCUMT","Million of national currency units","IRL","Ireland","2015","2015",89.3,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","MLLNCUMT","Million of national currency units","IRL","Ireland","2016","2016",94,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","MLLNCUMT","Million of national currency units","IRL","Ireland","2017","2017",97.8,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","MLLNCUMT","Million of national currency units","IRL","Ireland","2018","2018",104.9,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","MLLNCUMT","Million of national currency units","IRL","Ireland","2019","2019",114.4,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","MLLNCUMT","Million of national currency units","IRL","Ireland","2020","2020",124.3,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","MLLNCUMT","Million of national currency units","IRL","Ireland","2021","2021",134.8,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","MTMOTCMT","Million US$ at exchange rate","IRL","Ireland","2010","2010",90.1,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","MTMOTCMT","Million US$ at exchange rate","IRL","Ireland","2011","2011",102.2,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","MTMOTCMT","Million US$ at exchange rate","IRL","Ireland","2012","2012",104.5,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","MTMOTCMT","Million US$ at exchange rate","IRL","Ireland","2013","2013",108.9,"B; D","Break; Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","MTMOTCMT","Million US$ at exchange rate","IRL","Ireland","2014","2014",111.1,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","MTMOTCMT","Million US$ at exchange rate","IRL","Ireland","2015","2015",99.1,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","MTMOTCMT","Million US$ at exchange rate","IRL","Ireland","2016","2016",104,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","MTMOTCMT","Million US$ at exchange rate","IRL","Ireland","2017","2017",110.5,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","MTMOTCMT","Million US$ at exchange rate","IRL","Ireland","2018","2018",123.8,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","MTMOTCMT","Million US$ at exchange rate","IRL","Ireland","2019","2019",128.1,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","MTMOTCMT","Million US$ at exchange rate","IRL","Ireland","2020","2020",142,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","MTMOTCMT","Million US$ at exchange rate","IRL","Ireland","2021","2021",159.4,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","MTMOPPMT","Million US$, purchasing power parity","IRL","Ireland","2010","2010",80,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","MTMOPPMT","Million US$, purchasing power parity","IRL","Ireland","2011","2011",88.3,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","MTMOPPMT","Million US$, purchasing power parity","IRL","Ireland","2012","2012",98.8,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","MTMOPPMT","Million US$, purchasing power parity","IRL","Ireland","2013","2013",101,"B; D","Break; Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","MTMOPPMT","Million US$, purchasing power parity","IRL","Ireland","2014","2014",102.1,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","MTMOPPMT","Million US$, purchasing power parity","IRL","Ireland","2015","2015",110.3,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","MTMOPPMT","Million US$, purchasing power parity","IRL","Ireland","2016","2016",118.3,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","MTMOPPMT","Million US$, purchasing power parity","IRL","Ireland","2017","2017",123.2,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","MTMOPPMT","Million US$, purchasing power parity","IRL","Ireland","2018","2018",132.4,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","MTMOPPMT","Million US$, purchasing power parity","IRL","Ireland","2019","2019",142,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","MTMOPPMT","Million US$, purchasing power parity","IRL","Ireland","2020","2020",156.2,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","MTMOPPMT","Million US$, purchasing power parity","IRL","Ireland","2021","2021",169.6,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","TCPPERMT","/capita, US$ exchange rate","IRL","Ireland","2010","2010",19.8,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","TCPPERMT","/capita, US$ exchange rate","IRL","Ireland","2011","2011",22.3,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","TCPPERMT","/capita, US$ exchange rate","IRL","Ireland","2012","2012",22.7,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","TCPPERMT","/capita, US$ exchange rate","IRL","Ireland","2013","2013",23.5,"B; D","Break; Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","TCPPERMT","/capita, US$ exchange rate","IRL","Ireland","2014","2014",23.8,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","TCPPERMT","/capita, US$ exchange rate","IRL","Ireland","2015","2015",21.1,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","TCPPERMT","/capita, US$ exchange rate","IRL","Ireland","2016","2016",21.9,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","TCPPERMT","/capita, US$ exchange rate","IRL","Ireland","2017","2017",23,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","TCPPERMT","/capita, US$ exchange rate","IRL","Ireland","2018","2018",25.4,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","TCPPERMT","/capita, US$ exchange rate","IRL","Ireland","2019","2019",26,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","TCPPERMT","/capita, US$ exchange rate","IRL","Ireland","2020","2020",28.5,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","TCPPERMT","/capita, US$ exchange rate","IRL","Ireland","2021","2021",31.7,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2010","2010",17.5,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2011","2011",19.3,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2012","2012",21.5,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2013","2013",21.9,"B; D","Break; Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2014","2014",21.9,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2015","2015",23.5,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2016","2016",24.9,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2017","2017",25.6,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2018","2018",27.2,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2019","2019",28.8,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2020","2020",31.3,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2021","2021",33.7,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","ATCPTTMT","% of total sales","IRL","Ireland","2010","2010",3.3,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","ATCPTTMT","% of total sales","IRL","Ireland","2011","2011",3.8,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","ATCPTTMT","% of total sales","IRL","Ireland","2012","2012",4,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","ATCPTTMT","% of total sales","IRL","Ireland","2013","2013",4.2,"B; D","Break; Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","ATCPTTMT","% of total sales","IRL","Ireland","2014","2014",4.4,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","ATCPTTMT","% of total sales","IRL","Ireland","2015","2015",4.5,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","ATCPTTMT","% of total sales","IRL","Ireland","2016","2016",4.5,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","ATCPTTMT","% of total sales","IRL","Ireland","2017","2017",4.6,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","ATCPTTMT","% of total sales","IRL","Ireland","2018","2018",4.6,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","ATCPTTMT","% of total sales","IRL","Ireland","2019","2019",4.8,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","ATCPTTMT","% of total sales","IRL","Ireland","2020","2020",5.1,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","ATCPTTMT","% of total sales","IRL","Ireland","2021","2021",5.1,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","MLLNCUMT","Million of national currency units","ITA","Italy","2011","2011",742.4,,
+"PATCDIAB","A10-Drugs used in diabetes","MLLNCUMT","Million of national currency units","ITA","Italy","2012","2012",779.7,,
+"PATCDIAB","A10-Drugs used in diabetes","MLLNCUMT","Million of national currency units","ITA","Italy","2013","2013",812,,
+"PATCDIAB","A10-Drugs used in diabetes","MLLNCUMT","Million of national currency units","ITA","Italy","2014","2014",809.7,,
+"PATCDIAB","A10-Drugs used in diabetes","MLLNCUMT","Million of national currency units","ITA","Italy","2015","2015",869.9,,
+"PATCDIAB","A10-Drugs used in diabetes","MLLNCUMT","Million of national currency units","ITA","Italy","2016","2016",898.2,,
+"PATCDIAB","A10-Drugs used in diabetes","MLLNCUMT","Million of national currency units","ITA","Italy","2017","2017",904.1,,
+"PATCDIAB","A10-Drugs used in diabetes","MLLNCUMT","Million of national currency units","ITA","Italy","2018","2018",945.4,,
+"PATCDIAB","A10-Drugs used in diabetes","MLLNCUMT","Million of national currency units","ITA","Italy","2019","2019",1010,,
+"PATCDIAB","A10-Drugs used in diabetes","MLLNCUMT","Million of national currency units","ITA","Italy","2020","2020",1095,,
+"PATCDIAB","A10-Drugs used in diabetes","MLLNCUMT","Million of national currency units","ITA","Italy","2021","2021",1178.4,,
+"PATCDIAB","A10-Drugs used in diabetes","MLLNCUMT","Million of national currency units","ITA","Italy","2022","2022",1346.6,"E","Estimated value"
+"PATCDIAB","A10-Drugs used in diabetes","MTMOTCMT","Million US$ at exchange rate","ITA","Italy","2011","2011",1033.4,,
+"PATCDIAB","A10-Drugs used in diabetes","MTMOTCMT","Million US$ at exchange rate","ITA","Italy","2012","2012",1001.8,,
+"PATCDIAB","A10-Drugs used in diabetes","MTMOTCMT","Million US$ at exchange rate","ITA","Italy","2013","2013",1078.4,,
+"PATCDIAB","A10-Drugs used in diabetes","MTMOTCMT","Million US$ at exchange rate","ITA","Italy","2014","2014",1075.6,,
+"PATCDIAB","A10-Drugs used in diabetes","MTMOTCMT","Million US$ at exchange rate","ITA","Italy","2015","2015",965.1,,
+"PATCDIAB","A10-Drugs used in diabetes","MTMOTCMT","Million US$ at exchange rate","ITA","Italy","2016","2016",994.2,,
+"PATCDIAB","A10-Drugs used in diabetes","MTMOTCMT","Million US$ at exchange rate","ITA","Italy","2017","2017",1021.3,,
+"PATCDIAB","A10-Drugs used in diabetes","MTMOTCMT","Million US$ at exchange rate","ITA","Italy","2018","2018",1116.5,,
+"PATCDIAB","A10-Drugs used in diabetes","MTMOTCMT","Million US$ at exchange rate","ITA","Italy","2019","2019",1130.7,,
+"PATCDIAB","A10-Drugs used in diabetes","MTMOTCMT","Million US$ at exchange rate","ITA","Italy","2020","2020",1250.7,,
+"PATCDIAB","A10-Drugs used in diabetes","MTMOTCMT","Million US$ at exchange rate","ITA","Italy","2021","2021",1393.7,,
+"PATCDIAB","A10-Drugs used in diabetes","MTMOTCMT","Million US$ at exchange rate","ITA","Italy","2022","2022",1418,"E","Estimated value"
+"PATCDIAB","A10-Drugs used in diabetes","MTMOPPMT","Million US$, purchasing power parity","ITA","Italy","2011","2011",978.5,,
+"PATCDIAB","A10-Drugs used in diabetes","MTMOPPMT","Million US$, purchasing power parity","ITA","Italy","2012","2012",1042.8,,
+"PATCDIAB","A10-Drugs used in diabetes","MTMOPPMT","Million US$, purchasing power parity","ITA","Italy","2013","2013",1101.3,,
+"PATCDIAB","A10-Drugs used in diabetes","MTMOPPMT","Million US$, purchasing power parity","ITA","Italy","2014","2014",1094.7,,
+"PATCDIAB","A10-Drugs used in diabetes","MTMOPPMT","Million US$, purchasing power parity","ITA","Italy","2015","2015",1177.6,,
+"PATCDIAB","A10-Drugs used in diabetes","MTMOPPMT","Million US$, purchasing power parity","ITA","Italy","2016","2016",1282.1,,
+"PATCDIAB","A10-Drugs used in diabetes","MTMOPPMT","Million US$, purchasing power parity","ITA","Italy","2017","2017",1310.5,,
+"PATCDIAB","A10-Drugs used in diabetes","MTMOPPMT","Million US$, purchasing power parity","ITA","Italy","2018","2018",1387.9,,
+"PATCDIAB","A10-Drugs used in diabetes","MTMOPPMT","Million US$, purchasing power parity","ITA","Italy","2019","2019",1537.9,,
+"PATCDIAB","A10-Drugs used in diabetes","MTMOPPMT","Million US$, purchasing power parity","ITA","Italy","2020","2020",1690.5,,
+"PATCDIAB","A10-Drugs used in diabetes","MTMOPPMT","Million US$, purchasing power parity","ITA","Italy","2021","2021",1819.8,,
+"PATCDIAB","A10-Drugs used in diabetes","MTMOPPMT","Million US$, purchasing power parity","ITA","Italy","2022","2022",2180.9,"E","Estimated value"
+"PATCDIAB","A10-Drugs used in diabetes","TCPPERMT","/capita, US$ exchange rate","ITA","Italy","2011","2011",17.4,,
+"PATCDIAB","A10-Drugs used in diabetes","TCPPERMT","/capita, US$ exchange rate","ITA","Italy","2012","2012",16.8,,
+"PATCDIAB","A10-Drugs used in diabetes","TCPPERMT","/capita, US$ exchange rate","ITA","Italy","2013","2013",17.9,,
+"PATCDIAB","A10-Drugs used in diabetes","TCPPERMT","/capita, US$ exchange rate","ITA","Italy","2014","2014",17.7,,
+"PATCDIAB","A10-Drugs used in diabetes","TCPPERMT","/capita, US$ exchange rate","ITA","Italy","2015","2015",15.9,,
+"PATCDIAB","A10-Drugs used in diabetes","TCPPERMT","/capita, US$ exchange rate","ITA","Italy","2016","2016",16.4,,
+"PATCDIAB","A10-Drugs used in diabetes","TCPPERMT","/capita, US$ exchange rate","ITA","Italy","2017","2017",16.9,,
+"PATCDIAB","A10-Drugs used in diabetes","TCPPERMT","/capita, US$ exchange rate","ITA","Italy","2018","2018",18.5,,
+"PATCDIAB","A10-Drugs used in diabetes","TCPPERMT","/capita, US$ exchange rate","ITA","Italy","2019","2019",18.9,,
+"PATCDIAB","A10-Drugs used in diabetes","TCPPERMT","/capita, US$ exchange rate","ITA","Italy","2020","2020",21,,
+"PATCDIAB","A10-Drugs used in diabetes","TCPPERMT","/capita, US$ exchange rate","ITA","Italy","2021","2021",23.6,,
+"PATCDIAB","A10-Drugs used in diabetes","TCPPERMT","/capita, US$ exchange rate","ITA","Italy","2022","2022",24,"E","Estimated value"
+"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2011","2011",16.5,,
+"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2012","2012",17.5,,
+"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2013","2013",18.3,,
+"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2014","2014",18,,
+"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2015","2015",19.4,,
+"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2016","2016",21.1,,
+"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2017","2017",21.6,,
+"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2018","2018",23,,
+"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2019","2019",25.7,,
+"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2020","2020",28.4,,
+"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2021","2021",30.8,,
+"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2022","2022",36.9,"E","Estimated value"
+"PATCDIAB","A10-Drugs used in diabetes","ATCPTTMT","% of total sales","ITA","Italy","2011","2011",3.8,,
+"PATCDIAB","A10-Drugs used in diabetes","ATCPTTMT","% of total sales","ITA","Italy","2012","2012",4.1,,
+"PATCDIAB","A10-Drugs used in diabetes","ATCPTTMT","% of total sales","ITA","Italy","2013","2013",4.2,,
+"PATCDIAB","A10-Drugs used in diabetes","ATCPTTMT","% of total sales","ITA","Italy","2014","2014",4.1,,
+"PATCDIAB","A10-Drugs used in diabetes","ATCPTTMT","% of total sales","ITA","Italy","2015","2015",3.8,,
+"PATCDIAB","A10-Drugs used in diabetes","ATCPTTMT","% of total sales","ITA","Italy","2016","2016",3.9,,
+"PATCDIAB","A10-Drugs used in diabetes","ATCPTTMT","% of total sales","ITA","Italy","2017","2017",4,,
+"PATCDIAB","A10-Drugs used in diabetes","ATCPTTMT","% of total sales","ITA","Italy","2018","2018",4.2,,
+"PATCDIAB","A10-Drugs used in diabetes","ATCPTTMT","% of total sales","ITA","Italy","2019","2019",4.4,,
+"PATCDIAB","A10-Drugs used in diabetes","ATCPTTMT","% of total sales","ITA","Italy","2020","2020",4.7,,
+"PATCDIAB","A10-Drugs used in diabetes","ATCPTTMT","% of total sales","ITA","Italy","2021","2021",4.9,,
+"PATCDIAB","A10-Drugs used in diabetes","ATCPTTMT","% of total sales","ITA","Italy","2022","2022",5.4,"E","Estimated value"
+"PATCDIAB","A10-Drugs used in diabetes","MLLNCUMT","Million of national currency units","KOR","Korea","2010","2010",554852,,
+"PATCDIAB","A10-Drugs used in diabetes","MLLNCUMT","Million of national currency units","KOR","Korea","2011","2011",585107.5,"B","Break"
+"PATCDIAB","A10-Drugs used in diabetes","MLLNCUMT","Million of national currency units","KOR","Korea","2012","2012",573474.6,,
+"PATCDIAB","A10-Drugs used in diabetes","MLLNCUMT","Million of national currency units","KOR","Korea","2013","2013",634317.8,,
+"PATCDIAB","A10-Drugs used in diabetes","MLLNCUMT","Million of national currency units","KOR","Korea","2014","2014",690951.6,,
+"PATCDIAB","A10-Drugs used in diabetes","MLLNCUMT","Million of national currency units","KOR","Korea","2015","2015",772617.8,,
+"PATCDIAB","A10-Drugs used in diabetes","MLLNCUMT","Million of national currency units","KOR","Korea","2016","2016",845488.9,"B","Break"
+"PATCDIAB","A10-Drugs used in diabetes","MLLNCUMT","Million of national currency units","KOR","Korea","2017","2017",954874.1,,
+"PATCDIAB","A10-Drugs used in diabetes","MLLNCUMT","Million of national currency units","KOR","Korea","2018","2018",1087093.5,,
+"PATCDIAB","A10-Drugs used in diabetes","MLLNCUMT","Million of national currency units","KOR","Korea","2019","2019",1193608.8,,
+"PATCDIAB","A10-Drugs used in diabetes","MLLNCUMT","Million of national currency units","KOR","Korea","2020","2020",1310982.2,,
+"PATCDIAB","A10-Drugs used in diabetes","MLLNCUMT","Million of national currency units","KOR","Korea","2021","2021",1419692.7,,
+"PATCDIAB","A10-Drugs used in diabetes","MTMOTCMT","Million US$ at exchange rate","KOR","Korea","2010","2010",479.8,,
+"PATCDIAB","A10-Drugs used in diabetes","MTMOTCMT","Million US$ at exchange rate","KOR","Korea","2011","2011",528,"B","Break"
+"PATCDIAB","A10-Drugs used in diabetes","MTMOTCMT","Million US$ at exchange rate","KOR","Korea","2012","2012",508.9,,
+"PATCDIAB","A10-Drugs used in diabetes","MTMOTCMT","Million US$ at exchange rate","KOR","Korea","2013","2013",579.3,,
+"PATCDIAB","A10-Drugs used in diabetes","MTMOTCMT","Million US$ at exchange rate","KOR","Korea","2014","2014",656.3,,
+"PATCDIAB","A10-Drugs used in diabetes","MTMOTCMT","Million US$ at exchange rate","KOR","Korea","2015","2015",683.2,,
+"PATCDIAB","A10-Drugs used in diabetes","MTMOTCMT","Million US$ at exchange rate","KOR","Korea","2016","2016",728.4,"B","Break"
+"PATCDIAB","A10-Drugs used in diabetes","MTMOTCMT","Million US$ at exchange rate","KOR","Korea","2017","2017",844.3,,
+"PATCDIAB","A10-Drugs used in diabetes","MTMOTCMT","Million US$ at exchange rate","KOR","Korea","2018","2018",988.1,,
+"PATCDIAB","A10-Drugs used in diabetes","MTMOTCMT","Million US$ at exchange rate","KOR","Korea","2019","2019",1024.2,,
+"PATCDIAB","A10-Drugs used in diabetes","MTMOTCMT","Million US$ at exchange rate","KOR","Korea","2020","2020",1110.8,,
+"PATCDIAB","A10-Drugs used in diabetes","MTMOTCMT","Million US$ at exchange rate","KOR","Korea","2021","2021",1241,,
+"PATCDIAB","A10-Drugs used in diabetes","MTMOPPMT","Million US$, purchasing power parity","KOR","Korea","2010","2010",659.8,,
+"PATCDIAB","A10-Drugs used in diabetes","MTMOPPMT","Million US$, purchasing power parity","KOR","Korea","2011","2011",684.7,"B","Break"
+"PATCDIAB","A10-Drugs used in diabetes","MTMOPPMT","Million US$, purchasing power parity","KOR","Korea","2012","2012",670.8,,
+"PATCDIAB","A10-Drugs used in diabetes","MTMOPPMT","Million US$, purchasing power parity","KOR","Korea","2013","2013",729.9,,
+"PATCDIAB","A10-Drugs used in diabetes","MTMOPPMT","Million US$, purchasing power parity","KOR","Korea","2014","2014",792.5,,
+"PATCDIAB","A10-Drugs used in diabetes","MTMOPPMT","Million US$, purchasing power parity","KOR","Korea","2015","2015",901,,
+"PATCDIAB","A10-Drugs used in diabetes","MTMOPPMT","Million US$, purchasing power parity","KOR","Korea","2016","2016",984.5,"B","Break"
+"PATCDIAB","A10-Drugs used in diabetes","MTMOPPMT","Million US$, purchasing power parity","KOR","Korea","2017","2017",1094.3,,
+"PATCDIAB","A10-Drugs used in diabetes","MTMOPPMT","Million US$, purchasing power parity","KOR","Korea","2018","2018",1271.6,,
+"PATCDIAB","A10-Drugs used in diabetes","MTMOPPMT","Million US$, purchasing power parity","KOR","Korea","2019","2019",1393.7,,
+"PATCDIAB","A10-Drugs used in diabetes","MTMOPPMT","Million US$, purchasing power parity","KOR","Korea","2020","2020",1565,,
+"PATCDIAB","A10-Drugs used in diabetes","MTMOPPMT","Million US$, purchasing power parity","KOR","Korea","2021","2021",1662.2,,
+"PATCDIAB","A10-Drugs used in diabetes","TCPPERMT","/capita, US$ exchange rate","KOR","Korea","2010","2010",9.7,,
+"PATCDIAB","A10-Drugs used in diabetes","TCPPERMT","/capita, US$ exchange rate","KOR","Korea","2011","2011",10.6,"B","Break"
+"PATCDIAB","A10-Drugs used in diabetes","TCPPERMT","/capita, US$ exchange rate","KOR","Korea","2012","2012",10.1,,
+"PATCDIAB","A10-Drugs used in diabetes","TCPPERMT","/capita, US$ exchange rate","KOR","Korea","2013","2013",11.5,,
+"PATCDIAB","A10-Drugs used in diabetes","TCPPERMT","/capita, US$ exchange rate","KOR","Korea","2014","2014",12.9,,
+"PATCDIAB","A10-Drugs used in diabetes","TCPPERMT","/capita, US$ exchange rate","KOR","Korea","2015","2015",13.4,,
+"PATCDIAB","A10-Drugs used in diabetes","TCPPERMT","/capita, US$ exchange rate","KOR","Korea","2016","2016",14.2,"B","Break"
+"PATCDIAB","A10-Drugs used in diabetes","TCPPERMT","/capita, US$ exchange rate","KOR","Korea","2017","2017",16.4,,
+"PATCDIAB","A10-Drugs used in diabetes","TCPPERMT","/capita, US$ exchange rate","KOR","Korea","2018","2018",19.2,,
+"PATCDIAB","A10-Drugs used in diabetes","TCPPERMT","/capita, US$ exchange rate","KOR","Korea","2019","2019",19.8,,
+"PATCDIAB","A10-Drugs used in diabetes","TCPPERMT","/capita, US$ exchange rate","KOR","Korea","2020","2020",21.4,,
+"PATCDIAB","A10-Drugs used in diabetes","TCPPERMT","/capita, US$ exchange rate","KOR","Korea","2021","2021",24,,
+"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2010","2010",13.3,,
+"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2011","2011",13.7,"B","Break"
+"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2012","2012",13.4,,
+"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2013","2013",14.5,,
+"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2014","2014",15.6,,
+"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2015","2015",17.7,,
+"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2016","2016",19.2,"B","Break"
+"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2017","2017",21.3,,
+"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2018","2018",24.7,,
+"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2019","2019",26.9,,
+"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2020","2020",30.2,,
+"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2021","2021",32.1,,
+"PATCDIAB","A10-Drugs used in diabetes","ATCPTTMT","% of total sales","KOR","Korea","2010","2010",2.7,,
+"PATCDIAB","A10-Drugs used in diabetes","ATCPTTMT","% of total sales","KOR","Korea","2011","2011",2.7,"B","Break"
+"PATCDIAB","A10-Drugs used in diabetes","ATCPTTMT","% of total sales","KOR","Korea","2012","2012",2.6,,
+"PATCDIAB","A10-Drugs used in diabetes","ATCPTTMT","% of total sales","KOR","Korea","2013","2013",2.8,,
+"PATCDIAB","A10-Drugs used in diabetes","ATCPTTMT","% of total sales","KOR","Korea","2014","2014",2.9,,
+"PATCDIAB","A10-Drugs used in diabetes","ATCPTTMT","% of total sales","KOR","Korea","2015","2015",3.1,,
+"PATCDIAB","A10-Drugs used in diabetes","ATCPTTMT","% of total sales","KOR","Korea","2016","2016",3.3,"B","Break"
+"PATCDIAB","A10-Drugs used in diabetes","ATCPTTMT","% of total sales","KOR","Korea","2017","2017",3.5,,
+"PATCDIAB","A10-Drugs used in diabetes","ATCPTTMT","% of total sales","KOR","Korea","2018","2018",3.8,,
+"PATCDIAB","A10-Drugs used in diabetes","ATCPTTMT","% of total sales","KOR","Korea","2019","2019",3.8,,
+"PATCDIAB","A10-Drugs used in diabetes","ATCPTTMT","% of total sales","KOR","Korea","2020","2020",4,,
+"PATCDIAB","A10-Drugs used in diabetes","ATCPTTMT","% of total sales","KOR","Korea","2021","2021",4.1,,
+"PATCDIAB","A10-Drugs used in diabetes","MLLNCUMT","Million of national currency units","LUX","Luxembourg","2010","2010",9.1,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","MLLNCUMT","Million of national currency units","LUX","Luxembourg","2011","2011",10.3,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","MLLNCUMT","Million of national currency units","LUX","Luxembourg","2012","2012",11,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","MLLNCUMT","Million of national currency units","LUX","Luxembourg","2013","2013",12.1,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","MLLNCUMT","Million of national currency units","LUX","Luxembourg","2014","2014",13.8,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","MLLNCUMT","Million of national currency units","LUX","Luxembourg","2015","2015",15.1,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","MLLNCUMT","Million of national currency units","LUX","Luxembourg","2016","2016",15.8,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","MLLNCUMT","Million of national currency units","LUX","Luxembourg","2017","2017",17.1,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","MLLNCUMT","Million of national currency units","LUX","Luxembourg","2018","2018",18.1,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","MLLNCUMT","Million of national currency units","LUX","Luxembourg","2019","2019",19.6,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","MLLNCUMT","Million of national currency units","LUX","Luxembourg","2020","2020",21,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","MLLNCUMT","Million of national currency units","LUX","Luxembourg","2021","2021",22.4,"B; D; P","Break; Difference in methodology; Provisional value"
+"PATCDIAB","A10-Drugs used in diabetes","MLLNCUMT","Million of national currency units","LUX","Luxembourg","2022","2022",22.6,"D; P","Difference in methodology; Provisional value"
+"PATCDIAB","A10-Drugs used in diabetes","MTMOTCMT","Million US$ at exchange rate","LUX","Luxembourg","2010","2010",12.1,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","MTMOTCMT","Million US$ at exchange rate","LUX","Luxembourg","2011","2011",14.4,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","MTMOTCMT","Million US$ at exchange rate","LUX","Luxembourg","2012","2012",14.2,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","MTMOTCMT","Million US$ at exchange rate","LUX","Luxembourg","2013","2013",16.1,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","MTMOTCMT","Million US$ at exchange rate","LUX","Luxembourg","2014","2014",18.4,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","MTMOTCMT","Million US$ at exchange rate","LUX","Luxembourg","2015","2015",16.8,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","MTMOTCMT","Million US$ at exchange rate","LUX","Luxembourg","2016","2016",17.5,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","MTMOTCMT","Million US$ at exchange rate","LUX","Luxembourg","2017","2017",19.3,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","MTMOTCMT","Million US$ at exchange rate","LUX","Luxembourg","2018","2018",21.4,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","MTMOTCMT","Million US$ at exchange rate","LUX","Luxembourg","2019","2019",21.9,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","MTMOTCMT","Million US$ at exchange rate","LUX","Luxembourg","2020","2020",24,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","MTMOTCMT","Million US$ at exchange rate","LUX","Luxembourg","2021","2021",26.5,"B; D; P","Break; Difference in methodology; Provisional value"
+"PATCDIAB","A10-Drugs used in diabetes","MTMOTCMT","Million US$ at exchange rate","LUX","Luxembourg","2022","2022",23.8,"D; P","Difference in methodology; Provisional value"
+"PATCDIAB","A10-Drugs used in diabetes","MTMOPPMT","Million US$, purchasing power parity","LUX","Luxembourg","2010","2010",9.9,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","MTMOPPMT","Million US$, purchasing power parity","LUX","Luxembourg","2011","2011",11.4,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","MTMOPPMT","Million US$, purchasing power parity","LUX","Luxembourg","2012","2012",12.2,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","MTMOPPMT","Million US$, purchasing power parity","LUX","Luxembourg","2013","2013",13.5,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","MTMOPPMT","Million US$, purchasing power parity","LUX","Luxembourg","2014","2014",15.7,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","MTMOPPMT","Million US$, purchasing power parity","LUX","Luxembourg","2015","2015",17.2,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","MTMOPPMT","Million US$, purchasing power parity","LUX","Luxembourg","2016","2016",18.6,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","MTMOPPMT","Million US$, purchasing power parity","LUX","Luxembourg","2017","2017",20.1,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","MTMOPPMT","Million US$, purchasing power parity","LUX","Luxembourg","2018","2018",21.3,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","MTMOPPMT","Million US$, purchasing power parity","LUX","Luxembourg","2019","2019",23.3,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","MTMOPPMT","Million US$, purchasing power parity","LUX","Luxembourg","2020","2020",24.5,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","MTMOPPMT","Million US$, purchasing power parity","LUX","Luxembourg","2021","2021",26,"B; D; P","Break; Difference in methodology; Provisional value"
+"PATCDIAB","A10-Drugs used in diabetes","MTMOPPMT","Million US$, purchasing power parity","LUX","Luxembourg","2022","2022",27.1,"D; P","Difference in methodology; Provisional value"
+"PATCDIAB","A10-Drugs used in diabetes","TCPPERMT","/capita, US$ exchange rate","LUX","Luxembourg","2010","2010",25.6,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","TCPPERMT","/capita, US$ exchange rate","LUX","Luxembourg","2011","2011",29.8,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","TCPPERMT","/capita, US$ exchange rate","LUX","Luxembourg","2012","2012",28.8,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","TCPPERMT","/capita, US$ exchange rate","LUX","Luxembourg","2013","2013",32,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","TCPPERMT","/capita, US$ exchange rate","LUX","Luxembourg","2014","2014",36,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","TCPPERMT","/capita, US$ exchange rate","LUX","Luxembourg","2015","2015",32.4,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","TCPPERMT","/capita, US$ exchange rate","LUX","Luxembourg","2016","2016",33.3,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","TCPPERMT","/capita, US$ exchange rate","LUX","Luxembourg","2017","2017",36,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","TCPPERMT","/capita, US$ exchange rate","LUX","Luxembourg","2018","2018",39.1,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","TCPPERMT","/capita, US$ exchange rate","LUX","Luxembourg","2019","2019",39.4,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","TCPPERMT","/capita, US$ exchange rate","LUX","Luxembourg","2020","2020",42.2,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","TCPPERMT","/capita, US$ exchange rate","LUX","Luxembourg","2021","2021",46,"B; D; P","Break; Difference in methodology; Provisional value"
+"PATCDIAB","A10-Drugs used in diabetes","TCPPERMT","/capita, US$ exchange rate","LUX","Luxembourg","2022","2022",40.5,"D; P","Difference in methodology; Provisional value"
+"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2010","2010",20.9,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2011","2011",23.6,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2012","2012",24.7,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2013","2013",26.9,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2014","2014",30.7,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2015","2015",33.1,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2016","2016",35.3,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2017","2017",37.6,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2018","2018",39,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2019","2019",41.8,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2020","2020",43.2,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2021","2021",45.3,"B; D; P","Break; Difference in methodology; Provisional value"
+"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2022","2022",46.3,"D; P","Difference in methodology; Provisional value"
+"PATCDIAB","A10-Drugs used in diabetes","ATCPTTMT","% of total sales","LUX","Luxembourg","2010","2010",4.8,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","ATCPTTMT","% of total sales","LUX","Luxembourg","2011","2011",5.4,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","ATCPTTMT","% of total sales","LUX","Luxembourg","2012","2012",5.6,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","ATCPTTMT","% of total sales","LUX","Luxembourg","2013","2013",6.2,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","ATCPTTMT","% of total sales","LUX","Luxembourg","2014","2014",7.2,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","ATCPTTMT","% of total sales","LUX","Luxembourg","2015","2015",7.8,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","ATCPTTMT","% of total sales","LUX","Luxembourg","2016","2016",8.1,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","ATCPTTMT","% of total sales","LUX","Luxembourg","2017","2017",8.8,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","ATCPTTMT","% of total sales","LUX","Luxembourg","2018","2018",9.1,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","ATCPTTMT","% of total sales","LUX","Luxembourg","2019","2019",9.6,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","ATCPTTMT","% of total sales","LUX","Luxembourg","2020","2020",10,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","ATCPTTMT","% of total sales","LUX","Luxembourg","2021","2021",9.3,"B; D; P","Break; Difference in methodology; Provisional value"
+"PATCDIAB","A10-Drugs used in diabetes","ATCPTTMT","% of total sales","LUX","Luxembourg","2022","2022",8.8,"D; P","Difference in methodology; Provisional value"
+"PATCDIAB","A10-Drugs used in diabetes","MLLNCUMT","Million of national currency units","NLD","Netherlands","2010","2010",242.2,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","MLLNCUMT","Million of national currency units","NLD","Netherlands","2011","2011",252,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","MLLNCUMT","Million of national currency units","NLD","Netherlands","2012","2012",260.2,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","MLLNCUMT","Million of national currency units","NLD","Netherlands","2013","2013",269.8,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","MLLNCUMT","Million of national currency units","NLD","Netherlands","2014","2014",268.1,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","MTMOTCMT","Million US$ at exchange rate","NLD","Netherlands","2010","2010",321.1,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","MTMOTCMT","Million US$ at exchange rate","NLD","Netherlands","2011","2011",350.8,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","MTMOTCMT","Million US$ at exchange rate","NLD","Netherlands","2012","2012",334.2,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","MTMOTCMT","Million US$ at exchange rate","NLD","Netherlands","2013","2013",358.3,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","MTMOTCMT","Million US$ at exchange rate","NLD","Netherlands","2014","2014",356.2,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","MTMOPPMT","Million US$, purchasing power parity","NLD","Netherlands","2010","2010",283.6,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","MTMOPPMT","Million US$, purchasing power parity","NLD","Netherlands","2011","2011",301.5,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","MTMOPPMT","Million US$, purchasing power parity","NLD","Netherlands","2012","2012",315.6,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","MTMOPPMT","Million US$, purchasing power parity","NLD","Netherlands","2013","2013",338,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","MTMOPPMT","Million US$, purchasing power parity","NLD","Netherlands","2014","2014",331.5,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","TCPPERMT","/capita, US$ exchange rate","NLD","Netherlands","2010","2010",19.3,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","TCPPERMT","/capita, US$ exchange rate","NLD","Netherlands","2011","2011",21,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","TCPPERMT","/capita, US$ exchange rate","NLD","Netherlands","2012","2012",19.9,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","TCPPERMT","/capita, US$ exchange rate","NLD","Netherlands","2013","2013",21.3,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","TCPPERMT","/capita, US$ exchange rate","NLD","Netherlands","2014","2014",21.1,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","NLD","Netherlands","2010","2010",17.1,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","NLD","Netherlands","2011","2011",18.1,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","NLD","Netherlands","2012","2012",18.8,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","NLD","Netherlands","2013","2013",20.1,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","NLD","Netherlands","2014","2014",19.7,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","ATCPTTMT","% of total sales","NLD","Netherlands","2010","2010",4.6,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","ATCPTTMT","% of total sales","NLD","Netherlands","2011","2011",4.8,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","ATCPTTMT","% of total sales","NLD","Netherlands","2012","2012",5.6,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","ATCPTTMT","% of total sales","NLD","Netherlands","2013","2013",6.3,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","ATCPTTMT","% of total sales","NLD","Netherlands","2014","2014",6.2,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","MLLNCUMT","Million of national currency units","NZL","New Zealand","2010","2010",29.7,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","MLLNCUMT","Million of national currency units","NZL","New Zealand","2011","2011",32.4,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","MLLNCUMT","Million of national currency units","NZL","New Zealand","2012","2012",35.5,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","MLLNCUMT","Million of national currency units","NZL","New Zealand","2013","2013",39.1,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","MLLNCUMT","Million of national currency units","NZL","New Zealand","2014","2014",42.5,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","MLLNCUMT","Million of national currency units","NZL","New Zealand","2015","2015",46.4,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","MLLNCUMT","Million of national currency units","NZL","New Zealand","2016","2016",50,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","MLLNCUMT","Million of national currency units","NZL","New Zealand","2017","2017",53.2,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","MLLNCUMT","Million of national currency units","NZL","New Zealand","2018","2018",57.5,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","MLLNCUMT","Million of national currency units","NZL","New Zealand","2019","2019",60.7,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","MLLNCUMT","Million of national currency units","NZL","New Zealand","2020","2020",75.1,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","MLLNCUMT","Million of national currency units","NZL","New Zealand","2021","2021",86.3,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","MLLNCUMT","Million of national currency units","NZL","New Zealand","2022","2022",123,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","MTMOTCMT","Million US$ at exchange rate","NZL","New Zealand","2010","2010",21.4,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","MTMOTCMT","Million US$ at exchange rate","NZL","New Zealand","2011","2011",25.6,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","MTMOTCMT","Million US$ at exchange rate","NZL","New Zealand","2012","2012",28.7,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","MTMOTCMT","Million US$ at exchange rate","NZL","New Zealand","2013","2013",32.1,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","MTMOTCMT","Million US$ at exchange rate","NZL","New Zealand","2014","2014",35.3,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","MTMOTCMT","Million US$ at exchange rate","NZL","New Zealand","2015","2015",32.3,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","MTMOTCMT","Million US$ at exchange rate","NZL","New Zealand","2016","2016",34.8,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","MTMOTCMT","Million US$ at exchange rate","NZL","New Zealand","2017","2017",37.8,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","MTMOTCMT","Million US$ at exchange rate","NZL","New Zealand","2018","2018",39.8,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","MTMOTCMT","Million US$ at exchange rate","NZL","New Zealand","2019","2019",40,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","MTMOTCMT","Million US$ at exchange rate","NZL","New Zealand","2020","2020",48.7,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","MTMOTCMT","Million US$ at exchange rate","NZL","New Zealand","2021","2021",61,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","MTMOTCMT","Million US$ at exchange rate","NZL","New Zealand","2022","2022",78,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","MTMOPPMT","Million US$, purchasing power parity","NZL","New Zealand","2010","2010",19.8,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","MTMOPPMT","Million US$, purchasing power parity","NZL","New Zealand","2011","2011",21.8,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","MTMOPPMT","Million US$, purchasing power parity","NZL","New Zealand","2012","2012",23.7,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","MTMOPPMT","Million US$, purchasing power parity","NZL","New Zealand","2013","2013",27,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","MTMOPPMT","Million US$, purchasing power parity","NZL","New Zealand","2014","2014",29.5,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","MTMOPPMT","Million US$, purchasing power parity","NZL","New Zealand","2015","2015",31.4,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","MTMOPPMT","Million US$, purchasing power parity","NZL","New Zealand","2016","2016",34.7,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","MTMOPPMT","Million US$, purchasing power parity","NZL","New Zealand","2017","2017",37.2,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","MTMOPPMT","Million US$, purchasing power parity","NZL","New Zealand","2018","2018",39.1,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","MTMOPPMT","Million US$, purchasing power parity","NZL","New Zealand","2019","2019",42.9,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","MTMOPPMT","Million US$, purchasing power parity","NZL","New Zealand","2020","2020",53.1,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","MTMOPPMT","Million US$, purchasing power parity","NZL","New Zealand","2021","2021",59.1,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","MTMOPPMT","Million US$, purchasing power parity","NZL","New Zealand","2022","2022",85.3,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","TCPPERMT","/capita, US$ exchange rate","NZL","New Zealand","2010","2010",4.9,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","TCPPERMT","/capita, US$ exchange rate","NZL","New Zealand","2011","2011",5.8,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","TCPPERMT","/capita, US$ exchange rate","NZL","New Zealand","2012","2012",6.5,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","TCPPERMT","/capita, US$ exchange rate","NZL","New Zealand","2013","2013",7.2,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","TCPPERMT","/capita, US$ exchange rate","NZL","New Zealand","2014","2014",7.8,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","TCPPERMT","/capita, US$ exchange rate","NZL","New Zealand","2015","2015",7,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","TCPPERMT","/capita, US$ exchange rate","NZL","New Zealand","2016","2016",7.4,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","TCPPERMT","/capita, US$ exchange rate","NZL","New Zealand","2017","2017",7.9,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","TCPPERMT","/capita, US$ exchange rate","NZL","New Zealand","2018","2018",8.1,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","TCPPERMT","/capita, US$ exchange rate","NZL","New Zealand","2019","2019",8,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","TCPPERMT","/capita, US$ exchange rate","NZL","New Zealand","2020","2020",9.6,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","TCPPERMT","/capita, US$ exchange rate","NZL","New Zealand","2021","2021",11.9,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","TCPPERMT","/capita, US$ exchange rate","NZL","New Zealand","2022","2022",15.2,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2010","2010",4.6,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2011","2011",5,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2012","2012",5.4,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2013","2013",6.1,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2014","2014",6.5,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2015","2015",6.8,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2016","2016",7.4,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2017","2017",7.7,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2018","2018",8,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2019","2019",8.6,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2020","2020",10.4,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2021","2021",11.6,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2022","2022",16.6,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","ATCPTTMT","% of total sales","NZL","New Zealand","2010","2010",4,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","ATCPTTMT","% of total sales","NZL","New Zealand","2011","2011",4,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","ATCPTTMT","% of total sales","NZL","New Zealand","2012","2012",3.8,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","ATCPTTMT","% of total sales","NZL","New Zealand","2013","2013",4.2,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","ATCPTTMT","% of total sales","NZL","New Zealand","2014","2014",4.4,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","ATCPTTMT","% of total sales","NZL","New Zealand","2015","2015",4.7,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","ATCPTTMT","% of total sales","NZL","New Zealand","2016","2016",4.7,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","ATCPTTMT","% of total sales","NZL","New Zealand","2017","2017",4.2,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","ATCPTTMT","% of total sales","NZL","New Zealand","2018","2018",4.4,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","ATCPTTMT","% of total sales","NZL","New Zealand","2019","2019",4.1,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","ATCPTTMT","% of total sales","NZL","New Zealand","2020","2020",4.5,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","ATCPTTMT","% of total sales","NZL","New Zealand","2021","2021",4.9,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","ATCPTTMT","% of total sales","NZL","New Zealand","2022","2022",6.5,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","MLLNCUMT","Million of national currency units","NOR","Norway","2010","2010",517,,
+"PATCDIAB","A10-Drugs used in diabetes","MLLNCUMT","Million of national currency units","NOR","Norway","2011","2011",556,,
+"PATCDIAB","A10-Drugs used in diabetes","MLLNCUMT","Million of national currency units","NOR","Norway","2012","2012",596,,
+"PATCDIAB","A10-Drugs used in diabetes","MLLNCUMT","Million of national currency units","NOR","Norway","2013","2013",601,,
+"PATCDIAB","A10-Drugs used in diabetes","MLLNCUMT","Million of national currency units","NOR","Norway","2014","2014",683,,
+"PATCDIAB","A10-Drugs used in diabetes","MLLNCUMT","Million of national currency units","NOR","Norway","2015","2015",786,,
+"PATCDIAB","A10-Drugs used in diabetes","MLLNCUMT","Million of national currency units","NOR","Norway","2016","2016",913,,
+"PATCDIAB","A10-Drugs used in diabetes","MLLNCUMT","Million of national currency units","NOR","Norway","2017","2017",1001,,
+"PATCDIAB","A10-Drugs used in diabetes","MLLNCUMT","Million of national currency units","NOR","Norway","2018","2018",1099,,
+"PATCDIAB","A10-Drugs used in diabetes","MLLNCUMT","Million of national currency units","NOR","Norway","2019","2019",1218,,
+"PATCDIAB","A10-Drugs used in diabetes","MLLNCUMT","Million of national currency units","NOR","Norway","2020","2020",1405,,
+"PATCDIAB","A10-Drugs used in diabetes","MLLNCUMT","Million of national currency units","NOR","Norway","2021","2021",1907,,
+"PATCDIAB","A10-Drugs used in diabetes","MLLNCUMT","Million of national currency units","NOR","Norway","2022","2022",2663,,
+"PATCDIAB","A10-Drugs used in diabetes","MTMOTCMT","Million US$ at exchange rate","NOR","Norway","2010","2010",85.5,,
+"PATCDIAB","A10-Drugs used in diabetes","MTMOTCMT","Million US$ at exchange rate","NOR","Norway","2011","2011",99.2,,
+"PATCDIAB","A10-Drugs used in diabetes","MTMOTCMT","Million US$ at exchange rate","NOR","Norway","2012","2012",102.4,,
+"PATCDIAB","A10-Drugs used in diabetes","MTMOTCMT","Million US$ at exchange rate","NOR","Norway","2013","2013",102.3,,
+"PATCDIAB","A10-Drugs used in diabetes","MTMOTCMT","Million US$ at exchange rate","NOR","Norway","2014","2014",108.4,,
+"PATCDIAB","A10-Drugs used in diabetes","MTMOTCMT","Million US$ at exchange rate","NOR","Norway","2015","2015",97.5,,
+"PATCDIAB","A10-Drugs used in diabetes","MTMOTCMT","Million US$ at exchange rate","NOR","Norway","2016","2016",108.7,,
+"PATCDIAB","A10-Drugs used in diabetes","MTMOTCMT","Million US$ at exchange rate","NOR","Norway","2017","2017",121,,
+"PATCDIAB","A10-Drugs used in diabetes","MTMOTCMT","Million US$ at exchange rate","NOR","Norway","2018","2018",135.1,,
+"PATCDIAB","A10-Drugs used in diabetes","MTMOTCMT","Million US$ at exchange rate","NOR","Norway","2019","2019",138.4,,
+"PATCDIAB","A10-Drugs used in diabetes","MTMOTCMT","Million US$ at exchange rate","NOR","Norway","2020","2020",149.2,,
+"PATCDIAB","A10-Drugs used in diabetes","MTMOTCMT","Million US$ at exchange rate","NOR","Norway","2021","2021",222,,
+"PATCDIAB","A10-Drugs used in diabetes","MTMOTCMT","Million US$ at exchange rate","NOR","Norway","2022","2022",277,,
+"PATCDIAB","A10-Drugs used in diabetes","MTMOPPMT","Million US$, purchasing power parity","NOR","Norway","2010","2010",56.5,,
+"PATCDIAB","A10-Drugs used in diabetes","MTMOPPMT","Million US$, purchasing power parity","NOR","Norway","2011","2011",61.2,,
+"PATCDIAB","A10-Drugs used in diabetes","MTMOPPMT","Million US$, purchasing power parity","NOR","Norway","2012","2012",66,,
+"PATCDIAB","A10-Drugs used in diabetes","MTMOPPMT","Million US$, purchasing power parity","NOR","Norway","2013","2013",66.6,,
+"PATCDIAB","A10-Drugs used in diabetes","MTMOPPMT","Million US$, purchasing power parity","NOR","Norway","2014","2014",73.6,,
+"PATCDIAB","A10-Drugs used in diabetes","MTMOPPMT","Million US$, purchasing power parity","NOR","Norway","2015","2015",79.1,,
+"PATCDIAB","A10-Drugs used in diabetes","MTMOPPMT","Million US$, purchasing power parity","NOR","Norway","2016","2016",90.9,,
+"PATCDIAB","A10-Drugs used in diabetes","MTMOPPMT","Million US$, purchasing power parity","NOR","Norway","2017","2017",102.7,,
+"PATCDIAB","A10-Drugs used in diabetes","MTMOPPMT","Million US$, purchasing power parity","NOR","Norway","2018","2018",114.7,,
+"PATCDIAB","A10-Drugs used in diabetes","MTMOPPMT","Million US$, purchasing power parity","NOR","Norway","2019","2019",126.6,,
+"PATCDIAB","A10-Drugs used in diabetes","MTMOPPMT","Million US$, purchasing power parity","NOR","Norway","2020","2020",142.2,,
+"PATCDIAB","A10-Drugs used in diabetes","MTMOPPMT","Million US$, purchasing power parity","NOR","Norway","2021","2021",200.5,,
+"PATCDIAB","A10-Drugs used in diabetes","MTMOPPMT","Million US$, purchasing power parity","NOR","Norway","2022","2022",248,,
+"PATCDIAB","A10-Drugs used in diabetes","TCPPERMT","/capita, US$ exchange rate","NOR","Norway","2010","2010",17.5,,
+"PATCDIAB","A10-Drugs used in diabetes","TCPPERMT","/capita, US$ exchange rate","NOR","Norway","2011","2011",20,,
+"PATCDIAB","A10-Drugs used in diabetes","TCPPERMT","/capita, US$ exchange rate","NOR","Norway","2012","2012",20.4,,
+"PATCDIAB","A10-Drugs used in diabetes","TCPPERMT","/capita, US$ exchange rate","NOR","Norway","2013","2013",20.1,,
+"PATCDIAB","A10-Drugs used in diabetes","TCPPERMT","/capita, US$ exchange rate","NOR","Norway","2014","2014",21.1,,
+"PATCDIAB","A10-Drugs used in diabetes","TCPPERMT","/capita, US$ exchange rate","NOR","Norway","2015","2015",18.8,,
+"PATCDIAB","A10-Drugs used in diabetes","TCPPERMT","/capita, US$ exchange rate","NOR","Norway","2016","2016",20.8,,
+"PATCDIAB","A10-Drugs used in diabetes","TCPPERMT","/capita, US$ exchange rate","NOR","Norway","2017","2017",22.9,,
+"PATCDIAB","A10-Drugs used in diabetes","TCPPERMT","/capita, US$ exchange rate","NOR","Norway","2018","2018",25.4,,
+"PATCDIAB","A10-Drugs used in diabetes","TCPPERMT","/capita, US$ exchange rate","NOR","Norway","2019","2019",25.9,,
+"PATCDIAB","A10-Drugs used in diabetes","TCPPERMT","/capita, US$ exchange rate","NOR","Norway","2020","2020",27.7,,
+"PATCDIAB","A10-Drugs used in diabetes","TCPPERMT","/capita, US$ exchange rate","NOR","Norway","2021","2021",41,,
+"PATCDIAB","A10-Drugs used in diabetes","TCPPERMT","/capita, US$ exchange rate","NOR","Norway","2022","2022",51.1,,
+"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2010","2010",11.6,,
+"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2011","2011",12.4,,
+"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2012","2012",13.1,,
+"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2013","2013",13.1,,
+"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2014","2014",14.3,,
+"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2015","2015",15.3,,
+"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2016","2016",17.4,,
+"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2017","2017",19.5,,
+"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2018","2018",21.6,,
+"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2019","2019",23.7,,
+"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2020","2020",26.4,,
+"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2021","2021",37.1,,
+"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2022","2022",45.7,,
+"PATCDIAB","A10-Drugs used in diabetes","ATCPTTMT","% of total sales","NOR","Norway","2010","2010",2.9,,
+"PATCDIAB","A10-Drugs used in diabetes","ATCPTTMT","% of total sales","NOR","Norway","2011","2011",3.1,,
+"PATCDIAB","A10-Drugs used in diabetes","ATCPTTMT","% of total sales","NOR","Norway","2012","2012",3.2,,
+"PATCDIAB","A10-Drugs used in diabetes","ATCPTTMT","% of total sales","NOR","Norway","2013","2013",3.1,,
+"PATCDIAB","A10-Drugs used in diabetes","ATCPTTMT","% of total sales","NOR","Norway","2014","2014",3.2,,
+"PATCDIAB","A10-Drugs used in diabetes","ATCPTTMT","% of total sales","NOR","Norway","2015","2015",3.5,,
+"PATCDIAB","A10-Drugs used in diabetes","ATCPTTMT","% of total sales","NOR","Norway","2016","2016",3.7,,
+"PATCDIAB","A10-Drugs used in diabetes","ATCPTTMT","% of total sales","NOR","Norway","2017","2017",3.8,,
+"PATCDIAB","A10-Drugs used in diabetes","ATCPTTMT","% of total sales","NOR","Norway","2018","2018",4,,
+"PATCDIAB","A10-Drugs used in diabetes","ATCPTTMT","% of total sales","NOR","Norway","2019","2019",4.3,,
+"PATCDIAB","A10-Drugs used in diabetes","ATCPTTMT","% of total sales","NOR","Norway","2020","2020",4.7,,
+"PATCDIAB","A10-Drugs used in diabetes","ATCPTTMT","% of total sales","NOR","Norway","2021","2021",5.7,,
+"PATCDIAB","A10-Drugs used in diabetes","ATCPTTMT","% of total sales","NOR","Norway","2022","2022",7.4,,
+"PATCDIAB","A10-Drugs used in diabetes","MLLNCUMT","Million of national currency units","PRT","Portugal","2010","2010",208.6,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","MLLNCUMT","Million of national currency units","PRT","Portugal","2011","2011",222.3,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","MLLNCUMT","Million of national currency units","PRT","Portugal","2012","2012",224.2,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","MLLNCUMT","Million of national currency units","PRT","Portugal","2013","2013",228.4,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","MLLNCUMT","Million of national currency units","PRT","Portugal","2014","2014",238.9,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","MLLNCUMT","Million of national currency units","PRT","Portugal","2015","2015",265,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","MLLNCUMT","Million of national currency units","PRT","Portugal","2016","2016",279.2,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","MLLNCUMT","Million of national currency units","PRT","Portugal","2017","2017",291.8,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","MLLNCUMT","Million of national currency units","PRT","Portugal","2018","2018",322,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","MLLNCUMT","Million of national currency units","PRT","Portugal","2019","2019",359.8,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","MLLNCUMT","Million of national currency units","PRT","Portugal","2020","2020",395.9,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","MLLNCUMT","Million of national currency units","PRT","Portugal","2021","2021",440.5,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","MLLNCUMT","Million of national currency units","PRT","Portugal","2022","2022",515.8,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","MTMOTCMT","Million US$ at exchange rate","PRT","Portugal","2010","2010",276.5,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","MTMOTCMT","Million US$ at exchange rate","PRT","Portugal","2011","2011",309.5,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","MTMOTCMT","Million US$ at exchange rate","PRT","Portugal","2012","2012",288.1,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","MTMOTCMT","Million US$ at exchange rate","PRT","Portugal","2013","2013",303.4,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","MTMOTCMT","Million US$ at exchange rate","PRT","Portugal","2014","2014",317.3,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","MTMOTCMT","Million US$ at exchange rate","PRT","Portugal","2015","2015",294,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","MTMOTCMT","Million US$ at exchange rate","PRT","Portugal","2016","2016",309.1,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","MTMOTCMT","Million US$ at exchange rate","PRT","Portugal","2017","2017",329.7,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","MTMOTCMT","Million US$ at exchange rate","PRT","Portugal","2018","2018",380.3,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","MTMOTCMT","Million US$ at exchange rate","PRT","Portugal","2019","2019",402.8,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","MTMOTCMT","Million US$ at exchange rate","PRT","Portugal","2020","2020",452.2,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","MTMOTCMT","Million US$ at exchange rate","PRT","Portugal","2021","2021",521,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","MTMOTCMT","Million US$ at exchange rate","PRT","Portugal","2022","2022",543.1,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","MTMOPPMT","Million US$, purchasing power parity","PRT","Portugal","2010","2010",334.7,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","MTMOPPMT","Million US$, purchasing power parity","PRT","Portugal","2011","2011",356.8,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","MTMOPPMT","Million US$, purchasing power parity","PRT","Portugal","2012","2012",370.4,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","MTMOPPMT","Million US$, purchasing power parity","PRT","Portugal","2013","2013",391.4,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","MTMOPPMT","Million US$, purchasing power parity","PRT","Portugal","2014","2014",412.6,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","MTMOPPMT","Million US$, purchasing power parity","PRT","Portugal","2015","2015",453,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","MTMOPPMT","Million US$, purchasing power parity","PRT","Portugal","2016","2016",488.7,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","MTMOPPMT","Million US$, purchasing power parity","PRT","Portugal","2017","2017",506.9,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","MTMOPPMT","Million US$, purchasing power parity","PRT","Portugal","2018","2018",563.8,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","MTMOPPMT","Million US$, purchasing power parity","PRT","Portugal","2019","2019",644,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","MTMOPPMT","Million US$, purchasing power parity","PRT","Portugal","2020","2020",710.6,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","MTMOPPMT","Million US$, purchasing power parity","PRT","Portugal","2021","2021",775.9,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","MTMOPPMT","Million US$, purchasing power parity","PRT","Portugal","2022","2022",937.8,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","TCPPERMT","/capita, US$ exchange rate","PRT","Portugal","2010","2010",26.2,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","TCPPERMT","/capita, US$ exchange rate","PRT","Portugal","2011","2011",29.3,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","TCPPERMT","/capita, US$ exchange rate","PRT","Portugal","2012","2012",27.4,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","TCPPERMT","/capita, US$ exchange rate","PRT","Portugal","2013","2013",29,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","TCPPERMT","/capita, US$ exchange rate","PRT","Portugal","2014","2014",30.5,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","TCPPERMT","/capita, US$ exchange rate","PRT","Portugal","2015","2015",28.4,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","TCPPERMT","/capita, US$ exchange rate","PRT","Portugal","2016","2016",29.9,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","TCPPERMT","/capita, US$ exchange rate","PRT","Portugal","2017","2017",32,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","TCPPERMT","/capita, US$ exchange rate","PRT","Portugal","2018","2018",37,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","TCPPERMT","/capita, US$ exchange rate","PRT","Portugal","2019","2019",39.2,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","TCPPERMT","/capita, US$ exchange rate","PRT","Portugal","2020","2020",43.9,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","TCPPERMT","/capita, US$ exchange rate","PRT","Portugal","2021","2021",50.3,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","TCPPERMT","/capita, US$ exchange rate","PRT","Portugal","2022","2022",52.5,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2010","2010",31.7,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2011","2011",33.8,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2012","2012",35.2,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2013","2013",37.4,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2014","2014",39.7,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2015","2015",43.7,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2016","2016",47.3,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2017","2017",49.2,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2018","2018",54.8,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2019","2019",62.6,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2020","2020",69,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2021","2021",74.9,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2022","2022",90.6,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","ATCPTTMT","% of total sales","PRT","Portugal","2010","2010",6.4,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","ATCPTTMT","% of total sales","PRT","Portugal","2011","2011",7.6,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","ATCPTTMT","% of total sales","PRT","Portugal","2012","2012",8.6,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","ATCPTTMT","% of total sales","PRT","Portugal","2013","2013",9.5,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","ATCPTTMT","% of total sales","PRT","Portugal","2014","2014",10,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","ATCPTTMT","% of total sales","PRT","Portugal","2015","2015",10.6,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","ATCPTTMT","% of total sales","PRT","Portugal","2016","2016",11,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","ATCPTTMT","% of total sales","PRT","Portugal","2017","2017",11.4,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","ATCPTTMT","% of total sales","PRT","Portugal","2018","2018",12.3,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","ATCPTTMT","% of total sales","PRT","Portugal","2019","2019",12.9,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","ATCPTTMT","% of total sales","PRT","Portugal","2020","2020",14.1,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","ATCPTTMT","% of total sales","PRT","Portugal","2021","2021",15.1,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","ATCPTTMT","% of total sales","PRT","Portugal","2022","2022",16.2,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","MLLNCUMT","Million of national currency units","SVK","Slovak Republic","2010","2010",39.4,,
+"PATCDIAB","A10-Drugs used in diabetes","MLLNCUMT","Million of national currency units","SVK","Slovak Republic","2011","2011",43,,
+"PATCDIAB","A10-Drugs used in diabetes","MLLNCUMT","Million of national currency units","SVK","Slovak Republic","2012","2012",39.7,,
+"PATCDIAB","A10-Drugs used in diabetes","MLLNCUMT","Million of national currency units","SVK","Slovak Republic","2013","2013",45.6,,
+"PATCDIAB","A10-Drugs used in diabetes","MLLNCUMT","Million of national currency units","SVK","Slovak Republic","2014","2014",52.3,,
+"PATCDIAB","A10-Drugs used in diabetes","MLLNCUMT","Million of national currency units","SVK","Slovak Republic","2015","2015",62.7,,
+"PATCDIAB","A10-Drugs used in diabetes","MLLNCUMT","Million of national currency units","SVK","Slovak Republic","2016","2016",67.6,"B","Break"
+"PATCDIAB","A10-Drugs used in diabetes","MLLNCUMT","Million of national currency units","SVK","Slovak Republic","2017","2017",67.3,,
+"PATCDIAB","A10-Drugs used in diabetes","MLLNCUMT","Million of national currency units","SVK","Slovak Republic","2018","2018",69.7,,
+"PATCDIAB","A10-Drugs used in diabetes","MLLNCUMT","Million of national currency units","SVK","Slovak Republic","2019","2019",74.9,,
+"PATCDIAB","A10-Drugs used in diabetes","MLLNCUMT","Million of national currency units","SVK","Slovak Republic","2020","2020",80.6,,
+"PATCDIAB","A10-Drugs used in diabetes","MLLNCUMT","Million of national currency units","SVK","Slovak Republic","2021","2021",84.4,,
+"PATCDIAB","A10-Drugs used in diabetes","MTMOTCMT","Million US$ at exchange rate","SVK","Slovak Republic","2010","2010",52.2,,
+"PATCDIAB","A10-Drugs used in diabetes","MTMOTCMT","Million US$ at exchange rate","SVK","Slovak Republic","2011","2011",59.8,,
+"PATCDIAB","A10-Drugs used in diabetes","MTMOTCMT","Million US$ at exchange rate","SVK","Slovak Republic","2012","2012",51,,
+"PATCDIAB","A10-Drugs used in diabetes","MTMOTCMT","Million US$ at exchange rate","SVK","Slovak Republic","2013","2013",60.6,,
+"PATCDIAB","A10-Drugs used in diabetes","MTMOTCMT","Million US$ at exchange rate","SVK","Slovak Republic","2014","2014",69.5,,
+"PATCDIAB","A10-Drugs used in diabetes","MTMOTCMT","Million US$ at exchange rate","SVK","Slovak Republic","2015","2015",69.6,,
+"PATCDIAB","A10-Drugs used in diabetes","MTMOTCMT","Million US$ at exchange rate","SVK","Slovak Republic","2016","2016",74.8,"B","Break"
+"PATCDIAB","A10-Drugs used in diabetes","MTMOTCMT","Million US$ at exchange rate","SVK","Slovak Republic","2017","2017",76,,
+"PATCDIAB","A10-Drugs used in diabetes","MTMOTCMT","Million US$ at exchange rate","SVK","Slovak Republic","2018","2018",82.3,,
+"PATCDIAB","A10-Drugs used in diabetes","MTMOTCMT","Million US$ at exchange rate","SVK","Slovak Republic","2019","2019",83.8,,
+"PATCDIAB","A10-Drugs used in diabetes","MTMOTCMT","Million US$ at exchange rate","SVK","Slovak Republic","2020","2020",92.1,,
+"PATCDIAB","A10-Drugs used in diabetes","MTMOTCMT","Million US$ at exchange rate","SVK","Slovak Republic","2021","2021",99.8,,
+"PATCDIAB","A10-Drugs used in diabetes","MTMOPPMT","Million US$, purchasing power parity","SVK","Slovak Republic","2010","2010",78.4,,
+"PATCDIAB","A10-Drugs used in diabetes","MTMOPPMT","Million US$, purchasing power parity","SVK","Slovak Republic","2011","2011",84.8,,
+"PATCDIAB","A10-Drugs used in diabetes","MTMOPPMT","Million US$, purchasing power parity","SVK","Slovak Republic","2012","2012",78.7,,
+"PATCDIAB","A10-Drugs used in diabetes","MTMOPPMT","Million US$, purchasing power parity","SVK","Slovak Republic","2013","2013",92.9,,
+"PATCDIAB","A10-Drugs used in diabetes","MTMOPPMT","Million US$, purchasing power parity","SVK","Slovak Republic","2014","2014",107.8,,
+"PATCDIAB","A10-Drugs used in diabetes","MTMOPPMT","Million US$, purchasing power parity","SVK","Slovak Republic","2015","2015",127.6,,
+"PATCDIAB","A10-Drugs used in diabetes","MTMOPPMT","Million US$, purchasing power parity","SVK","Slovak Republic","2016","2016",134.4,"B","Break"
+"PATCDIAB","A10-Drugs used in diabetes","MTMOPPMT","Million US$, purchasing power parity","SVK","Slovak Republic","2017","2017",130.2,,
+"PATCDIAB","A10-Drugs used in diabetes","MTMOPPMT","Million US$, purchasing power parity","SVK","Slovak Republic","2018","2018",132.5,,
+"PATCDIAB","A10-Drugs used in diabetes","MTMOPPMT","Million US$, purchasing power parity","SVK","Slovak Republic","2019","2019",144.7,,
+"PATCDIAB","A10-Drugs used in diabetes","MTMOPPMT","Million US$, purchasing power parity","SVK","Slovak Republic","2020","2020",155.1,,
+"PATCDIAB","A10-Drugs used in diabetes","MTMOPPMT","Million US$, purchasing power parity","SVK","Slovak Republic","2021","2021",158.1,,
+"PATCDIAB","A10-Drugs used in diabetes","TCPPERMT","/capita, US$ exchange rate","SVK","Slovak Republic","2010","2010",9.7,,
+"PATCDIAB","A10-Drugs used in diabetes","TCPPERMT","/capita, US$ exchange rate","SVK","Slovak Republic","2011","2011",11.1,,
+"PATCDIAB","A10-Drugs used in diabetes","TCPPERMT","/capita, US$ exchange rate","SVK","Slovak Republic","2012","2012",9.4,,
+"PATCDIAB","A10-Drugs used in diabetes","TCPPERMT","/capita, US$ exchange rate","SVK","Slovak Republic","2013","2013",11.2,,
+"PATCDIAB","A10-Drugs used in diabetes","TCPPERMT","/capita, US$ exchange rate","SVK","Slovak Republic","2014","2014",12.8,,
+"PATCDIAB","A10-Drugs used in diabetes","TCPPERMT","/capita, US$ exchange rate","SVK","Slovak Republic","2015","2015",12.8,,
+"PATCDIAB","A10-Drugs used in diabetes","TCPPERMT","/capita, US$ exchange rate","SVK","Slovak Republic","2016","2016",13.8,"B","Break"
+"PATCDIAB","A10-Drugs used in diabetes","TCPPERMT","/capita, US$ exchange rate","SVK","Slovak Republic","2017","2017",14,,
+"PATCDIAB","A10-Drugs used in diabetes","TCPPERMT","/capita, US$ exchange rate","SVK","Slovak Republic","2018","2018",15.1,,
+"PATCDIAB","A10-Drugs used in diabetes","TCPPERMT","/capita, US$ exchange rate","SVK","Slovak Republic","2019","2019",15.4,,
+"PATCDIAB","A10-Drugs used in diabetes","TCPPERMT","/capita, US$ exchange rate","SVK","Slovak Republic","2020","2020",16.9,,
+"PATCDIAB","A10-Drugs used in diabetes","TCPPERMT","/capita, US$ exchange rate","SVK","Slovak Republic","2021","2021",18.3,,
+"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2010","2010",14.5,,
+"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2011","2011",15.7,,
+"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2012","2012",14.6,,
+"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2013","2013",17.2,,
+"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2014","2014",19.9,,
+"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2015","2015",23.5,,
+"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2016","2016",24.7,"B","Break"
+"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2017","2017",23.9,,
+"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2018","2018",24.3,,
+"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2019","2019",26.5,,
+"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2020","2020",28.4,,
+"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2021","2021",29,,
+"PATCDIAB","A10-Drugs used in diabetes","ATCPTTMT","% of total sales","SVK","Slovak Republic","2010","2010",3.5,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","ATCPTTMT","% of total sales","SVK","Slovak Republic","2011","2011",3.8,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","ATCPTTMT","% of total sales","SVK","Slovak Republic","2012","2012",3.6,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","ATCPTTMT","% of total sales","SVK","Slovak Republic","2013","2013",3.7,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","ATCPTTMT","% of total sales","SVK","Slovak Republic","2014","2014",4,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","ATCPTTMT","% of total sales","SVK","Slovak Republic","2015","2015",4.5,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","ATCPTTMT","% of total sales","SVK","Slovak Republic","2016","2016",4.3,"B","Break"
+"PATCDIAB","A10-Drugs used in diabetes","ATCPTTMT","% of total sales","SVK","Slovak Republic","2017","2017",4.3,,
+"PATCDIAB","A10-Drugs used in diabetes","ATCPTTMT","% of total sales","SVK","Slovak Republic","2018","2018",4.3,,
+"PATCDIAB","A10-Drugs used in diabetes","ATCPTTMT","% of total sales","SVK","Slovak Republic","2019","2019",4.3,,
+"PATCDIAB","A10-Drugs used in diabetes","ATCPTTMT","% of total sales","SVK","Slovak Republic","2020","2020",4.9,,
+"PATCDIAB","A10-Drugs used in diabetes","ATCPTTMT","% of total sales","SVK","Slovak Republic","2021","2021",4.7,,
+"PATCDIAB","A10-Drugs used in diabetes","MLLNCUMT","Million of national currency units","ESP","Spain","2010","2010",802.4,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","MLLNCUMT","Million of national currency units","ESP","Spain","2011","2011",890.8,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","MLLNCUMT","Million of national currency units","ESP","Spain","2012","2012",941.9,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","MLLNCUMT","Million of national currency units","ESP","Spain","2013","2013",1024.7,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","MLLNCUMT","Million of national currency units","ESP","Spain","2014","2014",1167.2,"B; D","Break; Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","MLLNCUMT","Million of national currency units","ESP","Spain","2015","2015",1269.7,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","MLLNCUMT","Million of national currency units","ESP","Spain","2016","2016",1383.9,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","MLLNCUMT","Million of national currency units","ESP","Spain","2017","2017",1467.1,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","MLLNCUMT","Million of national currency units","ESP","Spain","2018","2018",1594.8,"B","Break"
+"PATCDIAB","A10-Drugs used in diabetes","MLLNCUMT","Million of national currency units","ESP","Spain","2019","2019",1711.5,,
+"PATCDIAB","A10-Drugs used in diabetes","MLLNCUMT","Million of national currency units","ESP","Spain","2020","2020",1834.1,,
+"PATCDIAB","A10-Drugs used in diabetes","MLLNCUMT","Million of national currency units","ESP","Spain","2021","2021",2012.6,,
+"PATCDIAB","A10-Drugs used in diabetes","MLLNCUMT","Million of national currency units","ESP","Spain","2022","2022",2175.3,"P","Provisional value"
+"PATCDIAB","A10-Drugs used in diabetes","MTMOTCMT","Million US$ at exchange rate","ESP","Spain","2010","2010",1063.8,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","MTMOTCMT","Million US$ at exchange rate","ESP","Spain","2011","2011",1239.9,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","MTMOTCMT","Million US$ at exchange rate","ESP","Spain","2012","2012",1210.1,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","MTMOTCMT","Million US$ at exchange rate","ESP","Spain","2013","2013",1361,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","MTMOTCMT","Million US$ at exchange rate","ESP","Spain","2014","2014",1550.7,"B; D","Break; Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","MTMOTCMT","Million US$ at exchange rate","ESP","Spain","2015","2015",1408.7,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","MTMOTCMT","Million US$ at exchange rate","ESP","Spain","2016","2016",1531.8,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","MTMOTCMT","Million US$ at exchange rate","ESP","Spain","2017","2017",1657.4,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","MTMOTCMT","Million US$ at exchange rate","ESP","Spain","2018","2018",1883.4,"B","Break"
+"PATCDIAB","A10-Drugs used in diabetes","MTMOTCMT","Million US$ at exchange rate","ESP","Spain","2019","2019",1915.9,,
+"PATCDIAB","A10-Drugs used in diabetes","MTMOTCMT","Million US$ at exchange rate","ESP","Spain","2020","2020",2094.9,,
+"PATCDIAB","A10-Drugs used in diabetes","MTMOTCMT","Million US$ at exchange rate","ESP","Spain","2021","2021",2380.4,,
+"PATCDIAB","A10-Drugs used in diabetes","MTMOTCMT","Million US$ at exchange rate","ESP","Spain","2022","2022",2290.7,"P","Provisional value"
+"PATCDIAB","A10-Drugs used in diabetes","MTMOPPMT","Million US$, purchasing power parity","ESP","Spain","2010","2010",1103.8,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","MTMOPPMT","Million US$, purchasing power parity","ESP","Spain","2011","2011",1247.4,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","MTMOPPMT","Million US$, purchasing power parity","ESP","Spain","2012","2012",1355.3,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","MTMOPPMT","Million US$, purchasing power parity","ESP","Spain","2013","2013",1518.6,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","MTMOPPMT","Million US$, purchasing power parity","ESP","Spain","2014","2014",1762.2,"B; D","Break; Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","MTMOPPMT","Million US$, purchasing power parity","ESP","Spain","2015","2015",1910,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","MTMOPPMT","Million US$, purchasing power parity","ESP","Spain","2016","2016",2153.4,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","MTMOPPMT","Million US$, purchasing power parity","ESP","Spain","2017","2017",2325.7,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","MTMOPPMT","Million US$, purchasing power parity","ESP","Spain","2018","2018",2524.2,"B","Break"
+"PATCDIAB","A10-Drugs used in diabetes","MTMOPPMT","Million US$, purchasing power parity","ESP","Spain","2019","2019",2792.1,,
+"PATCDIAB","A10-Drugs used in diabetes","MTMOPPMT","Million US$, purchasing power parity","ESP","Spain","2020","2020",2951.9,,
+"PATCDIAB","A10-Drugs used in diabetes","MTMOPPMT","Million US$, purchasing power parity","ESP","Spain","2021","2021",3215.4,,
+"PATCDIAB","A10-Drugs used in diabetes","MTMOPPMT","Million US$, purchasing power parity","ESP","Spain","2022","2022",3648.6,"P","Provisional value"
+"PATCDIAB","A10-Drugs used in diabetes","TCPPERMT","/capita, US$ exchange rate","ESP","Spain","2010","2010",22.8,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","TCPPERMT","/capita, US$ exchange rate","ESP","Spain","2011","2011",26.5,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","TCPPERMT","/capita, US$ exchange rate","ESP","Spain","2012","2012",25.9,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","TCPPERMT","/capita, US$ exchange rate","ESP","Spain","2013","2013",29.2,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","TCPPERMT","/capita, US$ exchange rate","ESP","Spain","2014","2014",33.4,"B; D","Break; Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","TCPPERMT","/capita, US$ exchange rate","ESP","Spain","2015","2015",30.3,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","TCPPERMT","/capita, US$ exchange rate","ESP","Spain","2016","2016",33,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","TCPPERMT","/capita, US$ exchange rate","ESP","Spain","2017","2017",35.6,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","TCPPERMT","/capita, US$ exchange rate","ESP","Spain","2018","2018",40.2,"B","Break"
+"PATCDIAB","A10-Drugs used in diabetes","TCPPERMT","/capita, US$ exchange rate","ESP","Spain","2019","2019",40.6,,
+"PATCDIAB","A10-Drugs used in diabetes","TCPPERMT","/capita, US$ exchange rate","ESP","Spain","2020","2020",44.2,,
+"PATCDIAB","A10-Drugs used in diabetes","TCPPERMT","/capita, US$ exchange rate","ESP","Spain","2021","2021",50.2,,
+"PATCDIAB","A10-Drugs used in diabetes","TCPPERMT","/capita, US$ exchange rate","ESP","Spain","2022","2022",48.3,"P","Provisional value"
+"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2010","2010",23.7,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2011","2011",26.7,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2012","2012",29,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2013","2013",32.6,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2014","2014",37.9,"B; D","Break; Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2015","2015",41.1,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2016","2016",46.3,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2017","2017",49.9,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2018","2018",53.9,"B","Break"
+"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2019","2019",59.2,,
+"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2020","2020",62.3,,
+"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2021","2021",67.8,,
+"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2022","2022",76.9,"P","Provisional value"
+"PATCDIAB","A10-Drugs used in diabetes","ATCPTTMT","% of total sales","ESP","Spain","2010","2010",6.1,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","ATCPTTMT","% of total sales","ESP","Spain","2011","2011",7.2,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","ATCPTTMT","% of total sales","ESP","Spain","2012","2012",8.5,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","ATCPTTMT","% of total sales","ESP","Spain","2013","2013",9.6,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","ATCPTTMT","% of total sales","ESP","Spain","2014","2014",10.3,"B; D","Break; Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","ATCPTTMT","% of total sales","ESP","Spain","2015","2015",11.1,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","ATCPTTMT","% of total sales","ESP","Spain","2016","2016",11.7,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","ATCPTTMT","% of total sales","ESP","Spain","2017","2017",12.2,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","ATCPTTMT","% of total sales","ESP","Spain","2018","2018",8.4,"B","Break"
+"PATCDIAB","A10-Drugs used in diabetes","ATCPTTMT","% of total sales","ESP","Spain","2019","2019",8.6,,
+"PATCDIAB","A10-Drugs used in diabetes","ATCPTTMT","% of total sales","ESP","Spain","2020","2020",8.8,,
+"PATCDIAB","A10-Drugs used in diabetes","ATCPTTMT","% of total sales","ESP","Spain","2021","2021",9.1,,
+"PATCDIAB","A10-Drugs used in diabetes","ATCPTTMT","% of total sales","ESP","Spain","2022","2022",9.5,"P","Provisional value"
+"PATCDIAB","A10-Drugs used in diabetes","MLLNCUMT","Million of national currency units","SWE","Sweden","2010","2010",1293.3,,
+"PATCDIAB","A10-Drugs used in diabetes","MLLNCUMT","Million of national currency units","SWE","Sweden","2011","2011",1322.4,,
+"PATCDIAB","A10-Drugs used in diabetes","MLLNCUMT","Million of national currency units","SWE","Sweden","2012","2012",1384,,
+"PATCDIAB","A10-Drugs used in diabetes","MLLNCUMT","Million of national currency units","SWE","Sweden","2013","2013",1366.8,,
+"PATCDIAB","A10-Drugs used in diabetes","MLLNCUMT","Million of national currency units","SWE","Sweden","2014","2014",1410.9,,
+"PATCDIAB","A10-Drugs used in diabetes","MLLNCUMT","Million of national currency units","SWE","Sweden","2015","2015",1535.6,,
+"PATCDIAB","A10-Drugs used in diabetes","MLLNCUMT","Million of national currency units","SWE","Sweden","2016","2016",1687.7,,
+"PATCDIAB","A10-Drugs used in diabetes","MLLNCUMT","Million of national currency units","SWE","Sweden","2017","2017",1855,,
+"PATCDIAB","A10-Drugs used in diabetes","MLLNCUMT","Million of national currency units","SWE","Sweden","2018","2018",2100,,
+"PATCDIAB","A10-Drugs used in diabetes","MLLNCUMT","Million of national currency units","SWE","Sweden","2019","2019",2372.9,,
+"PATCDIAB","A10-Drugs used in diabetes","MLLNCUMT","Million of national currency units","SWE","Sweden","2020","2020",2640.6,,
+"PATCDIAB","A10-Drugs used in diabetes","MLLNCUMT","Million of national currency units","SWE","Sweden","2021","2021",2951.7,,
+"PATCDIAB","A10-Drugs used in diabetes","MLLNCUMT","Million of national currency units","SWE","Sweden","2022","2022",3474.4,,
+"PATCDIAB","A10-Drugs used in diabetes","MTMOTCMT","Million US$ at exchange rate","SWE","Sweden","2010","2010",179.4,,
+"PATCDIAB","A10-Drugs used in diabetes","MTMOTCMT","Million US$ at exchange rate","SWE","Sweden","2011","2011",203.7,,
+"PATCDIAB","A10-Drugs used in diabetes","MTMOTCMT","Million US$ at exchange rate","SWE","Sweden","2012","2012",204.3,,
+"PATCDIAB","A10-Drugs used in diabetes","MTMOTCMT","Million US$ at exchange rate","SWE","Sweden","2013","2013",209.8,,
+"PATCDIAB","A10-Drugs used in diabetes","MTMOTCMT","Million US$ at exchange rate","SWE","Sweden","2014","2014",205.6,,
+"PATCDIAB","A10-Drugs used in diabetes","MTMOTCMT","Million US$ at exchange rate","SWE","Sweden","2015","2015",182.1,,
+"PATCDIAB","A10-Drugs used in diabetes","MTMOTCMT","Million US$ at exchange rate","SWE","Sweden","2016","2016",197.1,,
+"PATCDIAB","A10-Drugs used in diabetes","MTMOTCMT","Million US$ at exchange rate","SWE","Sweden","2017","2017",217,,
+"PATCDIAB","A10-Drugs used in diabetes","MTMOTCMT","Million US$ at exchange rate","SWE","Sweden","2018","2018",241.6,,
+"PATCDIAB","A10-Drugs used in diabetes","MTMOTCMT","Million US$ at exchange rate","SWE","Sweden","2019","2019",250.9,,
+"PATCDIAB","A10-Drugs used in diabetes","MTMOTCMT","Million US$ at exchange rate","SWE","Sweden","2020","2020",286.7,,
+"PATCDIAB","A10-Drugs used in diabetes","MTMOTCMT","Million US$ at exchange rate","SWE","Sweden","2021","2021",344.2,,
+"PATCDIAB","A10-Drugs used in diabetes","MTMOTCMT","Million US$ at exchange rate","SWE","Sweden","2022","2022",343.5,,
+"PATCDIAB","A10-Drugs used in diabetes","MTMOPPMT","Million US$, purchasing power parity","SWE","Sweden","2010","2010",143.3,,
+"PATCDIAB","A10-Drugs used in diabetes","MTMOPPMT","Million US$, purchasing power parity","SWE","Sweden","2011","2011",149.5,,
+"PATCDIAB","A10-Drugs used in diabetes","MTMOPPMT","Million US$, purchasing power parity","SWE","Sweden","2012","2012",159.9,,
+"PATCDIAB","A10-Drugs used in diabetes","MTMOPPMT","Million US$, purchasing power parity","SWE","Sweden","2013","2013",159,,
+"PATCDIAB","A10-Drugs used in diabetes","MTMOPPMT","Million US$, purchasing power parity","SWE","Sweden","2014","2014",161.7,,
+"PATCDIAB","A10-Drugs used in diabetes","MTMOPPMT","Million US$, purchasing power parity","SWE","Sweden","2015","2015",173.4,,
+"PATCDIAB","A10-Drugs used in diabetes","MTMOPPMT","Million US$, purchasing power parity","SWE","Sweden","2016","2016",191.3,,
+"PATCDIAB","A10-Drugs used in diabetes","MTMOPPMT","Million US$, purchasing power parity","SWE","Sweden","2017","2017",209.6,,
+"PATCDIAB","A10-Drugs used in diabetes","MTMOPPMT","Million US$, purchasing power parity","SWE","Sweden","2018","2018",236.9,,
+"PATCDIAB","A10-Drugs used in diabetes","MTMOPPMT","Million US$, purchasing power parity","SWE","Sweden","2019","2019",272.4,,
+"PATCDIAB","A10-Drugs used in diabetes","MTMOPPMT","Million US$, purchasing power parity","SWE","Sweden","2020","2020",304.6,,
+"PATCDIAB","A10-Drugs used in diabetes","MTMOPPMT","Million US$, purchasing power parity","SWE","Sweden","2021","2021",338.4,,
+"PATCDIAB","A10-Drugs used in diabetes","MTMOPPMT","Million US$, purchasing power parity","SWE","Sweden","2022","2022",400.9,,
+"PATCDIAB","A10-Drugs used in diabetes","TCPPERMT","/capita, US$ exchange rate","SWE","Sweden","2010","2010",19.1,,
+"PATCDIAB","A10-Drugs used in diabetes","TCPPERMT","/capita, US$ exchange rate","SWE","Sweden","2011","2011",21.6,,
+"PATCDIAB","A10-Drugs used in diabetes","TCPPERMT","/capita, US$ exchange rate","SWE","Sweden","2012","2012",21.5,,
+"PATCDIAB","A10-Drugs used in diabetes","TCPPERMT","/capita, US$ exchange rate","SWE","Sweden","2013","2013",21.9,,
+"PATCDIAB","A10-Drugs used in diabetes","TCPPERMT","/capita, US$ exchange rate","SWE","Sweden","2014","2014",21.2,,
+"PATCDIAB","A10-Drugs used in diabetes","TCPPERMT","/capita, US$ exchange rate","SWE","Sweden","2015","2015",18.6,,
+"PATCDIAB","A10-Drugs used in diabetes","TCPPERMT","/capita, US$ exchange rate","SWE","Sweden","2016","2016",19.9,,
+"PATCDIAB","A10-Drugs used in diabetes","TCPPERMT","/capita, US$ exchange rate","SWE","Sweden","2017","2017",21.6,,
+"PATCDIAB","A10-Drugs used in diabetes","TCPPERMT","/capita, US$ exchange rate","SWE","Sweden","2018","2018",23.7,,
+"PATCDIAB","A10-Drugs used in diabetes","TCPPERMT","/capita, US$ exchange rate","SWE","Sweden","2019","2019",24.4,,
+"PATCDIAB","A10-Drugs used in diabetes","TCPPERMT","/capita, US$ exchange rate","SWE","Sweden","2020","2020",27.7,,
+"PATCDIAB","A10-Drugs used in diabetes","TCPPERMT","/capita, US$ exchange rate","SWE","Sweden","2021","2021",33,,
+"PATCDIAB","A10-Drugs used in diabetes","TCPPERMT","/capita, US$ exchange rate","SWE","Sweden","2022","2022",32.9,,
+"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2010","2010",15.3,,
+"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2011","2011",15.8,,
+"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2012","2012",16.8,,
+"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2013","2013",16.6,,
+"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2014","2014",16.7,,
+"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2015","2015",17.7,,
+"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2016","2016",19.3,,
+"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2017","2017",20.8,,
+"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2018","2018",23.3,,
+"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2019","2019",26.5,,
+"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2020","2020",29.4,,
+"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2021","2021",32.5,,
+"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2022","2022",38.4,,
+"PATCDIAB","A10-Drugs used in diabetes","ATCPTTMT","% of total sales","SWE","Sweden","2010","2010",3.6,,
+"PATCDIAB","A10-Drugs used in diabetes","ATCPTTMT","% of total sales","SWE","Sweden","2011","2011",3.6,,
+"PATCDIAB","A10-Drugs used in diabetes","ATCPTTMT","% of total sales","SWE","Sweden","2012","2012",3.8,,
+"PATCDIAB","A10-Drugs used in diabetes","ATCPTTMT","% of total sales","SWE","Sweden","2013","2013",3.8,,
+"PATCDIAB","A10-Drugs used in diabetes","ATCPTTMT","% of total sales","SWE","Sweden","2014","2014",3.7,,
+"PATCDIAB","A10-Drugs used in diabetes","ATCPTTMT","% of total sales","SWE","Sweden","2015","2015",3.8,,
+"PATCDIAB","A10-Drugs used in diabetes","ATCPTTMT","% of total sales","SWE","Sweden","2016","2016",4,,
+"PATCDIAB","A10-Drugs used in diabetes","ATCPTTMT","% of total sales","SWE","Sweden","2017","2017",4.2,,
+"PATCDIAB","A10-Drugs used in diabetes","ATCPTTMT","% of total sales","SWE","Sweden","2018","2018",4.4,,
+"PATCDIAB","A10-Drugs used in diabetes","ATCPTTMT","% of total sales","SWE","Sweden","2019","2019",4.7,,
+"PATCDIAB","A10-Drugs used in diabetes","ATCPTTMT","% of total sales","SWE","Sweden","2020","2020",5,,
+"PATCDIAB","A10-Drugs used in diabetes","ATCPTTMT","% of total sales","SWE","Sweden","2021","2021",5.5,,
+"PATCDIAB","A10-Drugs used in diabetes","ATCPTTMT","% of total sales","SWE","Sweden","2022","2022",6,,
+"PATCDIAB","A10-Drugs used in diabetes","MLLNCUMT","Million of national currency units","TUR","Türkiye","2010","2010",699.2,,
+"PATCDIAB","A10-Drugs used in diabetes","MLLNCUMT","Million of national currency units","TUR","Türkiye","2011","2011",658,,
+"PATCDIAB","A10-Drugs used in diabetes","MLLNCUMT","Million of national currency units","TUR","Türkiye","2012","2012",658.1,,
+"PATCDIAB","A10-Drugs used in diabetes","MLLNCUMT","Million of national currency units","TUR","Türkiye","2013","2013",798,,
+"PATCDIAB","A10-Drugs used in diabetes","MLLNCUMT","Million of national currency units","TUR","Türkiye","2014","2014",913.5,,
+"PATCDIAB","A10-Drugs used in diabetes","MLLNCUMT","Million of national currency units","TUR","Türkiye","2015","2015",1051.5,,
+"PATCDIAB","A10-Drugs used in diabetes","MLLNCUMT","Million of national currency units","TUR","Türkiye","2016","2016",1234.5,,
+"PATCDIAB","A10-Drugs used in diabetes","MLLNCUMT","Million of national currency units","TUR","Türkiye","2017","2017",1534.3,,
+"PATCDIAB","A10-Drugs used in diabetes","MLLNCUMT","Million of national currency units","TUR","Türkiye","2018","2018",1933.1,,
+"PATCDIAB","A10-Drugs used in diabetes","MLLNCUMT","Million of national currency units","TUR","Türkiye","2019","2019",2630.7,,
+"PATCDIAB","A10-Drugs used in diabetes","MLLNCUMT","Million of national currency units","TUR","Türkiye","2020","2020",3713.4,,
+"PATCDIAB","A10-Drugs used in diabetes","MLLNCUMT","Million of national currency units","TUR","Türkiye","2021","2021",4640.6,,
+"PATCDIAB","A10-Drugs used in diabetes","MTMOTCMT","Million US$ at exchange rate","TUR","Türkiye","2010","2010",465.3,,
+"PATCDIAB","A10-Drugs used in diabetes","MTMOTCMT","Million US$ at exchange rate","TUR","Türkiye","2011","2011",392.8,,
+"PATCDIAB","A10-Drugs used in diabetes","MTMOTCMT","Million US$ at exchange rate","TUR","Türkiye","2012","2012",366.4,,
+"PATCDIAB","A10-Drugs used in diabetes","MTMOTCMT","Million US$ at exchange rate","TUR","Türkiye","2013","2013",419.2,,
+"PATCDIAB","A10-Drugs used in diabetes","MTMOTCMT","Million US$ at exchange rate","TUR","Türkiye","2014","2014",417.4,,
+"PATCDIAB","A10-Drugs used in diabetes","MTMOTCMT","Million US$ at exchange rate","TUR","Türkiye","2015","2015",386.6,,
+"PATCDIAB","A10-Drugs used in diabetes","MTMOTCMT","Million US$ at exchange rate","TUR","Türkiye","2016","2016",408.8,,
+"PATCDIAB","A10-Drugs used in diabetes","MTMOTCMT","Million US$ at exchange rate","TUR","Türkiye","2017","2017",420.6,,
+"PATCDIAB","A10-Drugs used in diabetes","MTMOTCMT","Million US$ at exchange rate","TUR","Türkiye","2018","2018",400.4,,
+"PATCDIAB","A10-Drugs used in diabetes","MTMOTCMT","Million US$ at exchange rate","TUR","Türkiye","2019","2019",463.7,,
+"PATCDIAB","A10-Drugs used in diabetes","MTMOTCMT","Million US$ at exchange rate","TUR","Türkiye","2020","2020",529.8,,
+"PATCDIAB","A10-Drugs used in diabetes","MTMOTCMT","Million US$ at exchange rate","TUR","Türkiye","2021","2021",524.3,,
+"PATCDIAB","A10-Drugs used in diabetes","MTMOPPMT","Million US$, purchasing power parity","TUR","Türkiye","2010","2010",759.8,,
+"PATCDIAB","A10-Drugs used in diabetes","MTMOPPMT","Million US$, purchasing power parity","TUR","Türkiye","2011","2011",681,,
+"PATCDIAB","A10-Drugs used in diabetes","MTMOPPMT","Million US$, purchasing power parity","TUR","Türkiye","2012","2012",645.3,,
+"PATCDIAB","A10-Drugs used in diabetes","MTMOPPMT","Million US$, purchasing power parity","TUR","Türkiye","2013","2013",745.6,,
+"PATCDIAB","A10-Drugs used in diabetes","MTMOPPMT","Million US$, purchasing power parity","TUR","Türkiye","2014","2014",827.1,,
+"PATCDIAB","A10-Drugs used in diabetes","MTMOPPMT","Million US$, purchasing power parity","TUR","Türkiye","2015","2015",904.5,,
+"PATCDIAB","A10-Drugs used in diabetes","MTMOPPMT","Million US$, purchasing power parity","TUR","Türkiye","2016","2016",994.7,,
+"PATCDIAB","A10-Drugs used in diabetes","MTMOPPMT","Million US$, purchasing power parity","TUR","Türkiye","2017","2017",1108.6,,
+"PATCDIAB","A10-Drugs used in diabetes","MTMOPPMT","Million US$, purchasing power parity","TUR","Türkiye","2018","2018",1184.1,,
+"PATCDIAB","A10-Drugs used in diabetes","MTMOPPMT","Million US$, purchasing power parity","TUR","Türkiye","2019","2019",1411.3,,
+"PATCDIAB","A10-Drugs used in diabetes","MTMOPPMT","Million US$, purchasing power parity","TUR","Türkiye","2020","2020",1715.8,,
+"PATCDIAB","A10-Drugs used in diabetes","MTMOPPMT","Million US$, purchasing power parity","TUR","Türkiye","2021","2021",1652.7,,
+"PATCDIAB","A10-Drugs used in diabetes","TCPPERMT","/capita, US$ exchange rate","TUR","Türkiye","2010","2010",6.4,,
+"PATCDIAB","A10-Drugs used in diabetes","TCPPERMT","/capita, US$ exchange rate","TUR","Türkiye","2011","2011",5.3,,
+"PATCDIAB","A10-Drugs used in diabetes","TCPPERMT","/capita, US$ exchange rate","TUR","Türkiye","2012","2012",4.9,,
+"PATCDIAB","A10-Drugs used in diabetes","TCPPERMT","/capita, US$ exchange rate","TUR","Türkiye","2013","2013",5.5,,
+"PATCDIAB","A10-Drugs used in diabetes","TCPPERMT","/capita, US$ exchange rate","TUR","Türkiye","2014","2014",5.4,,
+"PATCDIAB","A10-Drugs used in diabetes","TCPPERMT","/capita, US$ exchange rate","TUR","Türkiye","2015","2015",4.9,,
+"PATCDIAB","A10-Drugs used in diabetes","TCPPERMT","/capita, US$ exchange rate","TUR","Türkiye","2016","2016",5.2,,
+"PATCDIAB","A10-Drugs used in diabetes","TCPPERMT","/capita, US$ exchange rate","TUR","Türkiye","2017","2017",5.2,,
+"PATCDIAB","A10-Drugs used in diabetes","TCPPERMT","/capita, US$ exchange rate","TUR","Türkiye","2018","2018",4.9,,
+"PATCDIAB","A10-Drugs used in diabetes","TCPPERMT","/capita, US$ exchange rate","TUR","Türkiye","2019","2019",5.6,,
+"PATCDIAB","A10-Drugs used in diabetes","TCPPERMT","/capita, US$ exchange rate","TUR","Türkiye","2020","2020",6.4,,
+"PATCDIAB","A10-Drugs used in diabetes","TCPPERMT","/capita, US$ exchange rate","TUR","Türkiye","2021","2021",6.2,,
+"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2010","2010",10.4,,
+"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2011","2011",9.2,,
+"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2012","2012",8.6,,
+"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2013","2013",9.8,,
+"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2014","2014",10.7,,
+"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2015","2015",11.6,,
+"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2016","2016",12.5,,
+"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2017","2017",13.8,,
+"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2018","2018",14.5,,
+"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2019","2019",17.1,,
+"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2020","2020",20.6,,
+"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2021","2021",19.6,,
+"PATCDIAB","A10-Drugs used in diabetes","ATCPTTMT","% of total sales","TUR","Türkiye","2010","2010",4.5,,
+"PATCDIAB","A10-Drugs used in diabetes","ATCPTTMT","% of total sales","TUR","Türkiye","2011","2011",4.6,,
+"PATCDIAB","A10-Drugs used in diabetes","ATCPTTMT","% of total sales","TUR","Türkiye","2012","2012",4.9,,
+"PATCDIAB","A10-Drugs used in diabetes","ATCPTTMT","% of total sales","TUR","Türkiye","2013","2013",5.6,,
+"PATCDIAB","A10-Drugs used in diabetes","ATCPTTMT","% of total sales","TUR","Türkiye","2014","2014",5.8,,
+"PATCDIAB","A10-Drugs used in diabetes","ATCPTTMT","% of total sales","TUR","Türkiye","2015","2015",5.7,,
+"PATCDIAB","A10-Drugs used in diabetes","ATCPTTMT","% of total sales","TUR","Türkiye","2016","2016",5.6,,
+"PATCDIAB","A10-Drugs used in diabetes","ATCPTTMT","% of total sales","TUR","Türkiye","2017","2017",6,,
+"PATCDIAB","A10-Drugs used in diabetes","ATCPTTMT","% of total sales","TUR","Türkiye","2018","2018",6,,
+"PATCDIAB","A10-Drugs used in diabetes","ATCPTTMT","% of total sales","TUR","Türkiye","2019","2019",6.3,,
+"PATCDIAB","A10-Drugs used in diabetes","ATCPTTMT","% of total sales","TUR","Türkiye","2020","2020",7.4,,
+"PATCDIAB","A10-Drugs used in diabetes","ATCPTTMT","% of total sales","TUR","Türkiye","2021","2021",7.2,,
+"PATCDIAB","A10-Drugs used in diabetes","MLLNCUMT","Million of national currency units","CHL","Chile","2010","2010",21597.9,,
+"PATCDIAB","A10-Drugs used in diabetes","MLLNCUMT","Million of national currency units","CHL","Chile","2011","2011",34618.4,"B","Break"
+"PATCDIAB","A10-Drugs used in diabetes","MLLNCUMT","Million of national currency units","CHL","Chile","2012","2012",41736.2,,
+"PATCDIAB","A10-Drugs used in diabetes","MLLNCUMT","Million of national currency units","CHL","Chile","2013","2013",50330.5,,
+"PATCDIAB","A10-Drugs used in diabetes","MLLNCUMT","Million of national currency units","CHL","Chile","2014","2014",66175.6,,
+"PATCDIAB","A10-Drugs used in diabetes","MLLNCUMT","Million of national currency units","CHL","Chile","2015","2015",87238.4,,
+"PATCDIAB","A10-Drugs used in diabetes","MLLNCUMT","Million of national currency units","CHL","Chile","2016","2016",96716.5,,
+"PATCDIAB","A10-Drugs used in diabetes","MLLNCUMT","Million of national currency units","CHL","Chile","2017","2017",111563.3,,
+"PATCDIAB","A10-Drugs used in diabetes","MLLNCUMT","Million of national currency units","CHL","Chile","2018","2018",105573.4,,
+"PATCDIAB","A10-Drugs used in diabetes","MLLNCUMT","Million of national currency units","CHL","Chile","2019","2019",138703.4,,
+"PATCDIAB","A10-Drugs used in diabetes","MLLNCUMT","Million of national currency units","CHL","Chile","2020","2020",180033.4,,
+"PATCDIAB","A10-Drugs used in diabetes","MLLNCUMT","Million of national currency units","CHL","Chile","2021","2021",219396.2,,
+"PATCDIAB","A10-Drugs used in diabetes","MLLNCUMT","Million of national currency units","CHL","Chile","2022","2022",249712.5,,
+"PATCDIAB","A10-Drugs used in diabetes","MTMOTCMT","Million US$ at exchange rate","CHL","Chile","2010","2010",42.3,,
+"PATCDIAB","A10-Drugs used in diabetes","MTMOTCMT","Million US$ at exchange rate","CHL","Chile","2011","2011",71.6,"B","Break"
+"PATCDIAB","A10-Drugs used in diabetes","MTMOTCMT","Million US$ at exchange rate","CHL","Chile","2012","2012",85.8,,
+"PATCDIAB","A10-Drugs used in diabetes","MTMOTCMT","Million US$ at exchange rate","CHL","Chile","2013","2013",101.6,,
+"PATCDIAB","A10-Drugs used in diabetes","MTMOTCMT","Million US$ at exchange rate","CHL","Chile","2014","2014",116,,
+"PATCDIAB","A10-Drugs used in diabetes","MTMOTCMT","Million US$ at exchange rate","CHL","Chile","2015","2015",133.4,,
+"PATCDIAB","A10-Drugs used in diabetes","MTMOTCMT","Million US$ at exchange rate","CHL","Chile","2016","2016",142.9,,
+"PATCDIAB","A10-Drugs used in diabetes","MTMOTCMT","Million US$ at exchange rate","CHL","Chile","2017","2017",171.9,,
+"PATCDIAB","A10-Drugs used in diabetes","MTMOTCMT","Million US$ at exchange rate","CHL","Chile","2018","2018",164.6,,
+"PATCDIAB","A10-Drugs used in diabetes","MTMOTCMT","Million US$ at exchange rate","CHL","Chile","2019","2019",197.3,,
+"PATCDIAB","A10-Drugs used in diabetes","MTMOTCMT","Million US$ at exchange rate","CHL","Chile","2020","2020",227.1,,
+"PATCDIAB","A10-Drugs used in diabetes","MTMOTCMT","Million US$ at exchange rate","CHL","Chile","2021","2021",289.1,,
+"PATCDIAB","A10-Drugs used in diabetes","MTMOTCMT","Million US$ at exchange rate","CHL","Chile","2022","2022",285.9,,
+"PATCDIAB","A10-Drugs used in diabetes","MTMOPPMT","Million US$, purchasing power parity","CHL","Chile","2010","2010",60,,
+"PATCDIAB","A10-Drugs used in diabetes","MTMOPPMT","Million US$, purchasing power parity","CHL","Chile","2011","2011",99.5,"B","Break"
+"PATCDIAB","A10-Drugs used in diabetes","MTMOPPMT","Million US$, purchasing power parity","CHL","Chile","2012","2012",120.2,,
+"PATCDIAB","A10-Drugs used in diabetes","MTMOPPMT","Million US$, purchasing power parity","CHL","Chile","2013","2013",143.9,,
+"PATCDIAB","A10-Drugs used in diabetes","MTMOPPMT","Million US$, purchasing power parity","CHL","Chile","2014","2014",180.2,,
+"PATCDIAB","A10-Drugs used in diabetes","MTMOPPMT","Million US$, purchasing power parity","CHL","Chile","2015","2015",223,,
+"PATCDIAB","A10-Drugs used in diabetes","MTMOPPMT","Million US$, purchasing power parity","CHL","Chile","2016","2016",243.5,,
+"PATCDIAB","A10-Drugs used in diabetes","MTMOPPMT","Million US$, purchasing power parity","CHL","Chile","2017","2017",280.5,,
+"PATCDIAB","A10-Drugs used in diabetes","MTMOPPMT","Million US$, purchasing power parity","CHL","Chile","2018","2018",266.4,,
+"PATCDIAB","A10-Drugs used in diabetes","MTMOPPMT","Million US$, purchasing power parity","CHL","Chile","2019","2019",345.4,,
+"PATCDIAB","A10-Drugs used in diabetes","MTMOPPMT","Million US$, purchasing power parity","CHL","Chile","2020","2020",430.2,,
+"PATCDIAB","A10-Drugs used in diabetes","MTMOPPMT","Million US$, purchasing power parity","CHL","Chile","2021","2021",504.2,,
+"PATCDIAB","A10-Drugs used in diabetes","MTMOPPMT","Million US$, purchasing power parity","CHL","Chile","2022","2022",570.7,,
+"PATCDIAB","A10-Drugs used in diabetes","TCPPERMT","/capita, US$ exchange rate","CHL","Chile","2010","2010",2.5,,
+"PATCDIAB","A10-Drugs used in diabetes","TCPPERMT","/capita, US$ exchange rate","CHL","Chile","2011","2011",4.1,"B","Break"
+"PATCDIAB","A10-Drugs used in diabetes","TCPPERMT","/capita, US$ exchange rate","CHL","Chile","2012","2012",4.9,,
+"PATCDIAB","A10-Drugs used in diabetes","TCPPERMT","/capita, US$ exchange rate","CHL","Chile","2013","2013",5.8,,
+"PATCDIAB","A10-Drugs used in diabetes","TCPPERMT","/capita, US$ exchange rate","CHL","Chile","2014","2014",6.5,,
+"PATCDIAB","A10-Drugs used in diabetes","TCPPERMT","/capita, US$ exchange rate","CHL","Chile","2015","2015",7.4,,
+"PATCDIAB","A10-Drugs used in diabetes","TCPPERMT","/capita, US$ exchange rate","CHL","Chile","2016","2016",7.9,,
+"PATCDIAB","A10-Drugs used in diabetes","TCPPERMT","/capita, US$ exchange rate","CHL","Chile","2017","2017",9.3,,
+"PATCDIAB","A10-Drugs used in diabetes","TCPPERMT","/capita, US$ exchange rate","CHL","Chile","2018","2018",8.8,,
+"PATCDIAB","A10-Drugs used in diabetes","TCPPERMT","/capita, US$ exchange rate","CHL","Chile","2019","2019",10.3,,
+"PATCDIAB","A10-Drugs used in diabetes","TCPPERMT","/capita, US$ exchange rate","CHL","Chile","2020","2020",11.7,,
+"PATCDIAB","A10-Drugs used in diabetes","TCPPERMT","/capita, US$ exchange rate","CHL","Chile","2021","2021",14.7,,
+"PATCDIAB","A10-Drugs used in diabetes","TCPPERMT","/capita, US$ exchange rate","CHL","Chile","2022","2022",14.4,,
+"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2010","2010",3.5,,
+"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2011","2011",5.8,"B","Break"
+"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2012","2012",6.9,,
+"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2013","2013",8.2,,
+"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2014","2014",10.1,,
+"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2015","2015",12.4,,
+"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2016","2016",13.4,,
+"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2017","2017",15.2,,
+"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2018","2018",14.2,,
+"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2019","2019",18.1,,
+"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2020","2020",22.1,,
+"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2021","2021",25.6,,
+"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2022","2022",28.8,,
+"PATCDIAB","A10-Drugs used in diabetes","ATCPTTMT","% of total sales","CHL","Chile","2010","2010",2.6,,
+"PATCDIAB","A10-Drugs used in diabetes","ATCPTTMT","% of total sales","CHL","Chile","2011","2011",2.9,"B","Break"
+"PATCDIAB","A10-Drugs used in diabetes","ATCPTTMT","% of total sales","CHL","Chile","2012","2012",3.3,,
+"PATCDIAB","A10-Drugs used in diabetes","ATCPTTMT","% of total sales","CHL","Chile","2013","2013",3.5,,
+"PATCDIAB","A10-Drugs used in diabetes","ATCPTTMT","% of total sales","CHL","Chile","2014","2014",4.3,,
+"PATCDIAB","A10-Drugs used in diabetes","ATCPTTMT","% of total sales","CHL","Chile","2015","2015",4.8,,
+"PATCDIAB","A10-Drugs used in diabetes","ATCPTTMT","% of total sales","CHL","Chile","2016","2016",4.8,,
+"PATCDIAB","A10-Drugs used in diabetes","ATCPTTMT","% of total sales","CHL","Chile","2017","2017",5.4,,
+"PATCDIAB","A10-Drugs used in diabetes","ATCPTTMT","% of total sales","CHL","Chile","2018","2018",4.6,,
+"PATCDIAB","A10-Drugs used in diabetes","ATCPTTMT","% of total sales","CHL","Chile","2019","2019",5.5,,
+"PATCDIAB","A10-Drugs used in diabetes","ATCPTTMT","% of total sales","CHL","Chile","2020","2020",6.7,,
+"PATCDIAB","A10-Drugs used in diabetes","ATCPTTMT","% of total sales","CHL","Chile","2021","2021",7.8,,
+"PATCDIAB","A10-Drugs used in diabetes","ATCPTTMT","% of total sales","CHL","Chile","2022","2022",8.9,,
+"PATCDIAB","A10-Drugs used in diabetes","MLLNCUMT","Million of national currency units","EST","Estonia","2010","2010",11.5,,
+"PATCDIAB","A10-Drugs used in diabetes","MLLNCUMT","Million of national currency units","EST","Estonia","2011","2011",11.9,,
+"PATCDIAB","A10-Drugs used in diabetes","MLLNCUMT","Million of national currency units","EST","Estonia","2012","2012",13.4,,
+"PATCDIAB","A10-Drugs used in diabetes","MLLNCUMT","Million of national currency units","EST","Estonia","2013","2013",14.1,,
+"PATCDIAB","A10-Drugs used in diabetes","MLLNCUMT","Million of national currency units","EST","Estonia","2014","2014",15.4,,
+"PATCDIAB","A10-Drugs used in diabetes","MLLNCUMT","Million of national currency units","EST","Estonia","2015","2015",16.4,,
+"PATCDIAB","A10-Drugs used in diabetes","MLLNCUMT","Million of national currency units","EST","Estonia","2016","2016",17.3,,
+"PATCDIAB","A10-Drugs used in diabetes","MLLNCUMT","Million of national currency units","EST","Estonia","2017","2017",18,,
+"PATCDIAB","A10-Drugs used in diabetes","MLLNCUMT","Million of national currency units","EST","Estonia","2018","2018",19.7,,
+"PATCDIAB","A10-Drugs used in diabetes","MLLNCUMT","Million of national currency units","EST","Estonia","2019","2019",20.9,,
+"PATCDIAB","A10-Drugs used in diabetes","MLLNCUMT","Million of national currency units","EST","Estonia","2020","2020",22.4,,
+"PATCDIAB","A10-Drugs used in diabetes","MLLNCUMT","Million of national currency units","EST","Estonia","2021","2021",24.2,,
+"PATCDIAB","A10-Drugs used in diabetes","MLLNCUMT","Million of national currency units","EST","Estonia","2022","2022",29.4,,
+"PATCDIAB","A10-Drugs used in diabetes","MTMOTCMT","Million US$ at exchange rate","EST","Estonia","2010","2010",15.2,,
+"PATCDIAB","A10-Drugs used in diabetes","MTMOTCMT","Million US$ at exchange rate","EST","Estonia","2011","2011",16.6,,
+"PATCDIAB","A10-Drugs used in diabetes","MTMOTCMT","Million US$ at exchange rate","EST","Estonia","2012","2012",17.2,,
+"PATCDIAB","A10-Drugs used in diabetes","MTMOTCMT","Million US$ at exchange rate","EST","Estonia","2013","2013",18.8,,
+"PATCDIAB","A10-Drugs used in diabetes","MTMOTCMT","Million US$ at exchange rate","EST","Estonia","2014","2014",20.4,,
+"PATCDIAB","A10-Drugs used in diabetes","MTMOTCMT","Million US$ at exchange rate","EST","Estonia","2015","2015",18.2,,
+"PATCDIAB","A10-Drugs used in diabetes","MTMOTCMT","Million US$ at exchange rate","EST","Estonia","2016","2016",19.1,,
+"PATCDIAB","A10-Drugs used in diabetes","MTMOTCMT","Million US$ at exchange rate","EST","Estonia","2017","2017",20.3,,
+"PATCDIAB","A10-Drugs used in diabetes","MTMOTCMT","Million US$ at exchange rate","EST","Estonia","2018","2018",23.3,,
+"PATCDIAB","A10-Drugs used in diabetes","MTMOTCMT","Million US$ at exchange rate","EST","Estonia","2019","2019",23.4,,
+"PATCDIAB","A10-Drugs used in diabetes","MTMOTCMT","Million US$ at exchange rate","EST","Estonia","2020","2020",25.6,,
+"PATCDIAB","A10-Drugs used in diabetes","MTMOTCMT","Million US$ at exchange rate","EST","Estonia","2021","2021",28.6,,
+"PATCDIAB","A10-Drugs used in diabetes","MTMOTCMT","Million US$ at exchange rate","EST","Estonia","2022","2022",30.9,,
+"PATCDIAB","A10-Drugs used in diabetes","MTMOPPMT","Million US$, purchasing power parity","EST","Estonia","2010","2010",22.4,,
+"PATCDIAB","A10-Drugs used in diabetes","MTMOPPMT","Million US$, purchasing power parity","EST","Estonia","2011","2011",23.3,,
+"PATCDIAB","A10-Drugs used in diabetes","MTMOPPMT","Million US$, purchasing power parity","EST","Estonia","2012","2012",25.7,,
+"PATCDIAB","A10-Drugs used in diabetes","MTMOPPMT","Million US$, purchasing power parity","EST","Estonia","2013","2013",27.1,,
+"PATCDIAB","A10-Drugs used in diabetes","MTMOPPMT","Million US$, purchasing power parity","EST","Estonia","2014","2014",29.2,,
+"PATCDIAB","A10-Drugs used in diabetes","MTMOPPMT","Million US$, purchasing power parity","EST","Estonia","2015","2015",30.4,,
+"PATCDIAB","A10-Drugs used in diabetes","MTMOPPMT","Million US$, purchasing power parity","EST","Estonia","2016","2016",32.7,,
+"PATCDIAB","A10-Drugs used in diabetes","MTMOPPMT","Million US$, purchasing power parity","EST","Estonia","2017","2017",33.6,,
+"PATCDIAB","A10-Drugs used in diabetes","MTMOPPMT","Million US$, purchasing power parity","EST","Estonia","2018","2018",36.5,,
+"PATCDIAB","A10-Drugs used in diabetes","MTMOPPMT","Million US$, purchasing power parity","EST","Estonia","2019","2019",38.9,,
+"PATCDIAB","A10-Drugs used in diabetes","MTMOPPMT","Million US$, purchasing power parity","EST","Estonia","2020","2020",42.8,,
+"PATCDIAB","A10-Drugs used in diabetes","MTMOPPMT","Million US$, purchasing power parity","EST","Estonia","2021","2021",44.5,,
+"PATCDIAB","A10-Drugs used in diabetes","MTMOPPMT","Million US$, purchasing power parity","EST","Estonia","2022","2022",51.6,,
+"PATCDIAB","A10-Drugs used in diabetes","TCPPERMT","/capita, US$ exchange rate","EST","Estonia","2010","2010",11.4,,
+"PATCDIAB","A10-Drugs used in diabetes","TCPPERMT","/capita, US$ exchange rate","EST","Estonia","2011","2011",12.5,,
+"PATCDIAB","A10-Drugs used in diabetes","TCPPERMT","/capita, US$ exchange rate","EST","Estonia","2012","2012",13,,
+"PATCDIAB","A10-Drugs used in diabetes","TCPPERMT","/capita, US$ exchange rate","EST","Estonia","2013","2013",14.3,,
+"PATCDIAB","A10-Drugs used in diabetes","TCPPERMT","/capita, US$ exchange rate","EST","Estonia","2014","2014",15.5,,
+"PATCDIAB","A10-Drugs used in diabetes","TCPPERMT","/capita, US$ exchange rate","EST","Estonia","2015","2015",13.8,,
+"PATCDIAB","A10-Drugs used in diabetes","TCPPERMT","/capita, US$ exchange rate","EST","Estonia","2016","2016",14.5,,
+"PATCDIAB","A10-Drugs used in diabetes","TCPPERMT","/capita, US$ exchange rate","EST","Estonia","2017","2017",15.4,,
+"PATCDIAB","A10-Drugs used in diabetes","TCPPERMT","/capita, US$ exchange rate","EST","Estonia","2018","2018",17.6,,
+"PATCDIAB","A10-Drugs used in diabetes","TCPPERMT","/capita, US$ exchange rate","EST","Estonia","2019","2019",17.6,,
+"PATCDIAB","A10-Drugs used in diabetes","TCPPERMT","/capita, US$ exchange rate","EST","Estonia","2020","2020",19.3,,
+"PATCDIAB","A10-Drugs used in diabetes","TCPPERMT","/capita, US$ exchange rate","EST","Estonia","2021","2021",21.5,,
+"PATCDIAB","A10-Drugs used in diabetes","TCPPERMT","/capita, US$ exchange rate","EST","Estonia","2022","2022",23.2,,
+"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2010","2010",16.8,,
+"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2011","2011",17.6,,
+"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2012","2012",19.4,,
+"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2013","2013",20.5,,
+"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2014","2014",22.2,,
+"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2015","2015",23.1,,
+"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2016","2016",24.8,,
+"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2017","2017",25.5,,
+"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2018","2018",27.6,,
+"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2019","2019",29.3,,
+"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2020","2020",32.2,,
+"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2021","2021",33.4,,
+"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2022","2022",38.8,,
+"PATCDIAB","A10-Drugs used in diabetes","ATCPTTMT","% of total sales","EST","Estonia","2010","2010",5.9,,
+"PATCDIAB","A10-Drugs used in diabetes","ATCPTTMT","% of total sales","EST","Estonia","2011","2011",5.8,,
+"PATCDIAB","A10-Drugs used in diabetes","ATCPTTMT","% of total sales","EST","Estonia","2012","2012",6,,
+"PATCDIAB","A10-Drugs used in diabetes","ATCPTTMT","% of total sales","EST","Estonia","2013","2013",6.1,,
+"PATCDIAB","A10-Drugs used in diabetes","ATCPTTMT","% of total sales","EST","Estonia","2014","2014",6.2,,
+"PATCDIAB","A10-Drugs used in diabetes","ATCPTTMT","% of total sales","EST","Estonia","2015","2015",6.2,,
+"PATCDIAB","A10-Drugs used in diabetes","ATCPTTMT","% of total sales","EST","Estonia","2016","2016",6,,
+"PATCDIAB","A10-Drugs used in diabetes","ATCPTTMT","% of total sales","EST","Estonia","2017","2017",6,,
+"PATCDIAB","A10-Drugs used in diabetes","ATCPTTMT","% of total sales","EST","Estonia","2018","2018",6.1,,
+"PATCDIAB","A10-Drugs used in diabetes","ATCPTTMT","% of total sales","EST","Estonia","2019","2019",6.1,,
+"PATCDIAB","A10-Drugs used in diabetes","ATCPTTMT","% of total sales","EST","Estonia","2020","2020",6.3,,
+"PATCDIAB","A10-Drugs used in diabetes","ATCPTTMT","% of total sales","EST","Estonia","2021","2021",5.9,,
+"PATCDIAB","A10-Drugs used in diabetes","ATCPTTMT","% of total sales","EST","Estonia","2022","2022",6.8,,
+"PATCDIAB","A10-Drugs used in diabetes","MLLNCUMT","Million of national currency units","SVN","Slovenia","2010","2010",25.6,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","MLLNCUMT","Million of national currency units","SVN","Slovenia","2011","2011",26.9,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","MLLNCUMT","Million of national currency units","SVN","Slovenia","2012","2012",28.2,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","MLLNCUMT","Million of national currency units","SVN","Slovenia","2013","2013",28,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","MLLNCUMT","Million of national currency units","SVN","Slovenia","2014","2014",28.3,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","MLLNCUMT","Million of national currency units","SVN","Slovenia","2015","2015",28.8,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","MLLNCUMT","Million of national currency units","SVN","Slovenia","2016","2016",30.4,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","MLLNCUMT","Million of national currency units","SVN","Slovenia","2017","2017",31.5,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","MLLNCUMT","Million of national currency units","SVN","Slovenia","2018","2018",34,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","MLLNCUMT","Million of national currency units","SVN","Slovenia","2019","2019",36.6,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","MLLNCUMT","Million of national currency units","SVN","Slovenia","2020","2020",39.4,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","MLLNCUMT","Million of national currency units","SVN","Slovenia","2021","2021",43.7,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","MLLNCUMT","Million of national currency units","SVN","Slovenia","2022","2022",52.5,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","MTMOTCMT","Million US$ at exchange rate","SVN","Slovenia","2010","2010",34,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","MTMOTCMT","Million US$ at exchange rate","SVN","Slovenia","2011","2011",37.5,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","MTMOTCMT","Million US$ at exchange rate","SVN","Slovenia","2012","2012",36.2,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","MTMOTCMT","Million US$ at exchange rate","SVN","Slovenia","2013","2013",37.1,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","MTMOTCMT","Million US$ at exchange rate","SVN","Slovenia","2014","2014",37.6,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","MTMOTCMT","Million US$ at exchange rate","SVN","Slovenia","2015","2015",32,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","MTMOTCMT","Million US$ at exchange rate","SVN","Slovenia","2016","2016",33.6,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","MTMOTCMT","Million US$ at exchange rate","SVN","Slovenia","2017","2017",35.6,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","MTMOTCMT","Million US$ at exchange rate","SVN","Slovenia","2018","2018",40.1,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","MTMOTCMT","Million US$ at exchange rate","SVN","Slovenia","2019","2019",41,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","MTMOTCMT","Million US$ at exchange rate","SVN","Slovenia","2020","2020",45,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","MTMOTCMT","Million US$ at exchange rate","SVN","Slovenia","2021","2021",51.7,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","MTMOTCMT","Million US$ at exchange rate","SVN","Slovenia","2022","2022",55.2,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","MTMOPPMT","Million US$, purchasing power parity","SVN","Slovenia","2010","2010",40.2,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","MTMOPPMT","Million US$, purchasing power parity","SVN","Slovenia","2011","2011",43.2,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","MTMOPPMT","Million US$, purchasing power parity","SVN","Slovenia","2012","2012",46.4,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","MTMOPPMT","Million US$, purchasing power parity","SVN","Slovenia","2013","2013",47.4,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","MTMOPPMT","Million US$, purchasing power parity","SVN","Slovenia","2014","2014",47.9,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","MTMOPPMT","Million US$, purchasing power parity","SVN","Slovenia","2015","2015",48.4,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","MTMOPPMT","Million US$, purchasing power parity","SVN","Slovenia","2016","2016",52.6,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","MTMOPPMT","Million US$, purchasing power parity","SVN","Slovenia","2017","2017",55.2,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","MTMOPPMT","Million US$, purchasing power parity","SVN","Slovenia","2018","2018",59.9,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","MTMOPPMT","Million US$, purchasing power parity","SVN","Slovenia","2019","2019",66.3,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","MTMOPPMT","Million US$, purchasing power parity","SVN","Slovenia","2020","2020",72,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","MTMOPPMT","Million US$, purchasing power parity","SVN","Slovenia","2021","2021",77.6,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","MTMOPPMT","Million US$, purchasing power parity","SVN","Slovenia","2022","2022",95.1,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","TCPPERMT","/capita, US$ exchange rate","SVN","Slovenia","2010","2010",16.6,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","TCPPERMT","/capita, US$ exchange rate","SVN","Slovenia","2011","2011",18.3,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","TCPPERMT","/capita, US$ exchange rate","SVN","Slovenia","2012","2012",17.6,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","TCPPERMT","/capita, US$ exchange rate","SVN","Slovenia","2013","2013",18,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","TCPPERMT","/capita, US$ exchange rate","SVN","Slovenia","2014","2014",18.2,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","TCPPERMT","/capita, US$ exchange rate","SVN","Slovenia","2015","2015",15.5,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","TCPPERMT","/capita, US$ exchange rate","SVN","Slovenia","2016","2016",16.3,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","TCPPERMT","/capita, US$ exchange rate","SVN","Slovenia","2017","2017",17.2,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","TCPPERMT","/capita, US$ exchange rate","SVN","Slovenia","2018","2018",19.3,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","TCPPERMT","/capita, US$ exchange rate","SVN","Slovenia","2019","2019",19.6,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","TCPPERMT","/capita, US$ exchange rate","SVN","Slovenia","2020","2020",21.4,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","TCPPERMT","/capita, US$ exchange rate","SVN","Slovenia","2021","2021",24.5,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","TCPPERMT","/capita, US$ exchange rate","SVN","Slovenia","2022","2022",26.2,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2010","2010",19.6,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2011","2011",21,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2012","2012",22.6,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2013","2013",23,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2014","2014",23.2,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2015","2015",23.5,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2016","2016",25.5,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2017","2017",26.7,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2018","2018",28.9,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2019","2019",31.8,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2020","2020",34.3,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2021","2021",36.8,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2022","2022",45.1,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","ATCPTTMT","% of total sales","SVN","Slovenia","2010","2010",5.4,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","ATCPTTMT","% of total sales","SVN","Slovenia","2011","2011",5.7,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","ATCPTTMT","% of total sales","SVN","Slovenia","2012","2012",6.2,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","ATCPTTMT","% of total sales","SVN","Slovenia","2013","2013",6.2,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","ATCPTTMT","% of total sales","SVN","Slovenia","2014","2014",6.5,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","ATCPTTMT","% of total sales","SVN","Slovenia","2015","2015",6.5,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","ATCPTTMT","% of total sales","SVN","Slovenia","2016","2016",6.5,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","ATCPTTMT","% of total sales","SVN","Slovenia","2017","2017",6.5,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","ATCPTTMT","% of total sales","SVN","Slovenia","2018","2018",6.6,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","ATCPTTMT","% of total sales","SVN","Slovenia","2019","2019",6.8,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","ATCPTTMT","% of total sales","SVN","Slovenia","2020","2020",6.9,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","ATCPTTMT","% of total sales","SVN","Slovenia","2021","2021",7.1,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","ATCPTTMT","% of total sales","SVN","Slovenia","2022","2022",7.7,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","MLLNCUMT","Million of national currency units","AUS","Australia","2010","2010",406,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","MLLNCUMT","Million of national currency units","AUS","Australia","2011","2011",417,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","MLLNCUMT","Million of national currency units","AUS","Australia","2012","2012",405,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","MLLNCUMT","Million of national currency units","AUS","Australia","2013","2013",481,"B; D","Break; Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","MLLNCUMT","Million of national currency units","AUS","Australia","2014","2014",545,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","MLLNCUMT","Million of national currency units","AUS","Australia","2015","2015",617,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","MLLNCUMT","Million of national currency units","AUS","Australia","2016","2016",667,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","MLLNCUMT","Million of national currency units","AUS","Australia","2017","2017",748,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","MLLNCUMT","Million of national currency units","AUS","Australia","2018","2018",816,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","MLLNCUMT","Million of national currency units","AUS","Australia","2019","2019",880,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","MLLNCUMT","Million of national currency units","AUS","Australia","2020","2020",947,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","MLLNCUMT","Million of national currency units","AUS","Australia","2021","2021",1022,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","MTMOTCMT","Million US$ at exchange rate","AUS","Australia","2010","2010",372.4,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","MTMOTCMT","Million US$ at exchange rate","AUS","Australia","2011","2011",430.1,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","MTMOTCMT","Million US$ at exchange rate","AUS","Australia","2012","2012",419.3,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","MTMOTCMT","Million US$ at exchange rate","AUS","Australia","2013","2013",464.4,"B; D","Break; Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","MTMOTCMT","Million US$ at exchange rate","AUS","Australia","2014","2014",491.3,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","MTMOTCMT","Million US$ at exchange rate","AUS","Australia","2015","2015",463.5,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","MTMOTCMT","Million US$ at exchange rate","AUS","Australia","2016","2016",495.8,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","MTMOTCMT","Million US$ at exchange rate","AUS","Australia","2017","2017",573.3,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","MTMOTCMT","Million US$ at exchange rate","AUS","Australia","2018","2018",609.7,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","MTMOTCMT","Million US$ at exchange rate","AUS","Australia","2019","2019",611.7,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","MTMOTCMT","Million US$ at exchange rate","AUS","Australia","2020","2020",651.7,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","MTMOTCMT","Million US$ at exchange rate","AUS","Australia","2021","2021",767.7,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","MTMOPPMT","Million US$, purchasing power parity","AUS","Australia","2010","2010",270,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","MTMOPPMT","Million US$, purchasing power parity","AUS","Australia","2011","2011",276,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","MTMOPPMT","Million US$, purchasing power parity","AUS","Australia","2012","2012",263,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","MTMOPPMT","Million US$, purchasing power parity","AUS","Australia","2013","2013",332.4,"B; D","Break; Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","MTMOPPMT","Million US$, purchasing power parity","AUS","Australia","2014","2014",375.2,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","MTMOPPMT","Million US$, purchasing power parity","AUS","Australia","2015","2015",418.7,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","MTMOPPMT","Million US$, purchasing power parity","AUS","Australia","2016","2016",460,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","MTMOPPMT","Million US$, purchasing power parity","AUS","Australia","2017","2017",506.2,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","MTMOPPMT","Million US$, purchasing power parity","AUS","Australia","2018","2018",554.9,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","MTMOPPMT","Million US$, purchasing power parity","AUS","Australia","2019","2019",594.6,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","MTMOPPMT","Million US$, purchasing power parity","AUS","Australia","2020","2020",651.3,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","MTMOPPMT","Million US$, purchasing power parity","AUS","Australia","2021","2021",706,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","TCPPERMT","/capita, US$ exchange rate","AUS","Australia","2010","2010",16.9,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","TCPPERMT","/capita, US$ exchange rate","AUS","Australia","2011","2011",19.3,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","TCPPERMT","/capita, US$ exchange rate","AUS","Australia","2012","2012",18.4,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","TCPPERMT","/capita, US$ exchange rate","AUS","Australia","2013","2013",20.1,"B; D","Break; Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","TCPPERMT","/capita, US$ exchange rate","AUS","Australia","2014","2014",20.9,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","TCPPERMT","/capita, US$ exchange rate","AUS","Australia","2015","2015",19.5,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","TCPPERMT","/capita, US$ exchange rate","AUS","Australia","2016","2016",20.5,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","TCPPERMT","/capita, US$ exchange rate","AUS","Australia","2017","2017",23.3,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","TCPPERMT","/capita, US$ exchange rate","AUS","Australia","2018","2018",24.4,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","TCPPERMT","/capita, US$ exchange rate","AUS","Australia","2019","2019",24.1,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","TCPPERMT","/capita, US$ exchange rate","AUS","Australia","2020","2020",25.4,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","TCPPERMT","/capita, US$ exchange rate","AUS","Australia","2021","2021",29.9,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2010","2010",12.3,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2011","2011",12.4,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2012","2012",11.6,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2013","2013",14.4,"B; D","Break; Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2014","2014",16,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2015","2015",17.6,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2016","2016",19,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2017","2017",20.6,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2018","2018",22.2,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2019","2019",23.5,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2020","2020",25.4,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2021","2021",27.5,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","ATCPTTMT","% of total sales","AUS","Australia","2010","2010",4.1,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","ATCPTTMT","% of total sales","AUS","Australia","2011","2011",4.1,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","ATCPTTMT","% of total sales","AUS","Australia","2012","2012",3.9,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","ATCPTTMT","% of total sales","AUS","Australia","2013","2013",4.1,"B; D","Break; Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","ATCPTTMT","% of total sales","AUS","Australia","2014","2014",4.6,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","ATCPTTMT","% of total sales","AUS","Australia","2015","2015",5,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","ATCPTTMT","% of total sales","AUS","Australia","2016","2016",4.4,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","ATCPTTMT","% of total sales","AUS","Australia","2017","2017",5.1,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","ATCPTTMT","% of total sales","AUS","Australia","2018","2018",5.5,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","ATCPTTMT","% of total sales","AUS","Australia","2019","2019",5.7,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","ATCPTTMT","% of total sales","AUS","Australia","2020","2020",5.7,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","ATCPTTMT","% of total sales","AUS","Australia","2021","2021",5.8,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","MLLNCUMT","Million of national currency units","AUT","Austria","2010","2010",151.2,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","MLLNCUMT","Million of national currency units","AUT","Austria","2011","2011",145.8,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","MLLNCUMT","Million of national currency units","AUT","Austria","2012","2012",164.8,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","MLLNCUMT","Million of national currency units","AUT","Austria","2013","2013",191.4,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","MLLNCUMT","Million of national currency units","AUT","Austria","2014","2014",220.1,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","MLLNCUMT","Million of national currency units","AUT","Austria","2015","2015",246.3,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","MLLNCUMT","Million of national currency units","AUT","Austria","2016","2016",280.4,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","MLLNCUMT","Million of national currency units","AUT","Austria","2017","2017",309.8,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","MLLNCUMT","Million of national currency units","AUT","Austria","2018","2018",335,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","MLLNCUMT","Million of national currency units","AUT","Austria","2019","2019",355.9,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","MLLNCUMT","Million of national currency units","AUT","Austria","2020","2020",381.5,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","MLLNCUMT","Million of national currency units","AUT","Austria","2021","2021",406.9,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","MTMOTCMT","Million US$ at exchange rate","AUT","Austria","2010","2010",200.4,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","MTMOTCMT","Million US$ at exchange rate","AUT","Austria","2011","2011",203,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","MTMOTCMT","Million US$ at exchange rate","AUT","Austria","2012","2012",211.7,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","MTMOTCMT","Million US$ at exchange rate","AUT","Austria","2013","2013",254.2,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","MTMOTCMT","Million US$ at exchange rate","AUT","Austria","2014","2014",292.4,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","MTMOTCMT","Million US$ at exchange rate","AUT","Austria","2015","2015",273.2,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","MTMOTCMT","Million US$ at exchange rate","AUT","Austria","2016","2016",310.3,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","MTMOTCMT","Million US$ at exchange rate","AUT","Austria","2017","2017",350,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","MTMOTCMT","Million US$ at exchange rate","AUT","Austria","2018","2018",395.7,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","MTMOTCMT","Million US$ at exchange rate","AUT","Austria","2019","2019",398.4,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","MTMOTCMT","Million US$ at exchange rate","AUT","Austria","2020","2020",435.7,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","MTMOTCMT","Million US$ at exchange rate","AUT","Austria","2021","2021",481.3,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","MTMOPPMT","Million US$, purchasing power parity","AUT","Austria","2010","2010",179.5,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","MTMOPPMT","Million US$, purchasing power parity","AUT","Austria","2011","2011",175.4,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","MTMOPPMT","Million US$, purchasing power parity","AUT","Austria","2012","2012",202.5,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","MTMOPPMT","Million US$, purchasing power parity","AUT","Austria","2013","2013",240.2,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","MTMOPPMT","Million US$, purchasing power parity","AUT","Austria","2014","2014",275.5,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","MTMOPPMT","Million US$, purchasing power parity","AUT","Austria","2015","2015",308.3,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","MTMOPPMT","Million US$, purchasing power parity","AUT","Austria","2016","2016",360.9,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","MTMOPPMT","Million US$, purchasing power parity","AUT","Austria","2017","2017",399.7,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","MTMOPPMT","Million US$, purchasing power parity","AUT","Austria","2018","2018",437.7,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","MTMOPPMT","Million US$, purchasing power parity","AUT","Austria","2019","2019",475.1,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","MTMOPPMT","Million US$, purchasing power parity","AUT","Austria","2020","2020",511.2,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","MTMOPPMT","Million US$, purchasing power parity","AUT","Austria","2021","2021",538,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","TCPPERMT","/capita, US$ exchange rate","AUT","Austria","2010","2010",24,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","TCPPERMT","/capita, US$ exchange rate","AUT","Austria","2011","2011",24.2,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","TCPPERMT","/capita, US$ exchange rate","AUT","Austria","2012","2012",25.1,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","TCPPERMT","/capita, US$ exchange rate","AUT","Austria","2013","2013",30,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","TCPPERMT","/capita, US$ exchange rate","AUT","Austria","2014","2014",34.2,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","TCPPERMT","/capita, US$ exchange rate","AUT","Austria","2015","2015",31.6,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","TCPPERMT","/capita, US$ exchange rate","AUT","Austria","2016","2016",35.5,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","TCPPERMT","/capita, US$ exchange rate","AUT","Austria","2017","2017",39.8,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","TCPPERMT","/capita, US$ exchange rate","AUT","Austria","2018","2018",44.8,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","TCPPERMT","/capita, US$ exchange rate","AUT","Austria","2019","2019",44.9,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","TCPPERMT","/capita, US$ exchange rate","AUT","Austria","2020","2020",48.9,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","TCPPERMT","/capita, US$ exchange rate","AUT","Austria","2021","2021",53.7,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2010","2010",21.5,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2011","2011",20.9,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2012","2012",24,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2013","2013",28.3,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2014","2014",32.2,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2015","2015",35.7,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2016","2016",41.3,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2017","2017",45.4,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2018","2018",49.5,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2019","2019",53.5,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2020","2020",57.3,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2021","2021",60.1,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","ATCPTTMT","% of total sales","AUT","Austria","2010","2010",6.1,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","ATCPTTMT","% of total sales","AUT","Austria","2011","2011",5.7,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","ATCPTTMT","% of total sales","AUT","Austria","2012","2012",6.3,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","ATCPTTMT","% of total sales","AUT","Austria","2013","2013",7.3,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","ATCPTTMT","% of total sales","AUT","Austria","2014","2014",7.9,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","ATCPTTMT","% of total sales","AUT","Austria","2015","2015",8.4,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","ATCPTTMT","% of total sales","AUT","Austria","2016","2016",9.3,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","ATCPTTMT","% of total sales","AUT","Austria","2017","2017",9.9,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","ATCPTTMT","% of total sales","AUT","Austria","2018","2018",10.4,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","ATCPTTMT","% of total sales","AUT","Austria","2019","2019",10.7,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","ATCPTTMT","% of total sales","AUT","Austria","2020","2020",11,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","ATCPTTMT","% of total sales","AUT","Austria","2021","2021",11,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","MLLNCUMT","Million of national currency units","BEL","Belgium","2010","2010",448.9,,
+"PATCBLOO","B-Blood and blood forming organs","MLLNCUMT","Million of national currency units","BEL","Belgium","2011","2011",444.1,,
+"PATCBLOO","B-Blood and blood forming organs","MLLNCUMT","Million of national currency units","BEL","Belgium","2012","2012",450.6,,
+"PATCBLOO","B-Blood and blood forming organs","MLLNCUMT","Million of national currency units","BEL","Belgium","2013","2013",491.1,,
+"PATCBLOO","B-Blood and blood forming organs","MLLNCUMT","Million of national currency units","BEL","Belgium","2014","2014",501.4,,
+"PATCBLOO","B-Blood and blood forming organs","MLLNCUMT","Million of national currency units","BEL","Belgium","2015","2015",522.8,,
+"PATCBLOO","B-Blood and blood forming organs","MLLNCUMT","Million of national currency units","BEL","Belgium","2016","2016",559.7,,
+"PATCBLOO","B-Blood and blood forming organs","MLLNCUMT","Million of national currency units","BEL","Belgium","2017","2017",595,,
+"PATCBLOO","B-Blood and blood forming organs","MLLNCUMT","Million of national currency units","BEL","Belgium","2018","2018",611.6,,
+"PATCBLOO","B-Blood and blood forming organs","MLLNCUMT","Million of national currency units","BEL","Belgium","2019","2019",683,,
+"PATCBLOO","B-Blood and blood forming organs","MLLNCUMT","Million of national currency units","BEL","Belgium","2020","2020",745.4,,
+"PATCBLOO","B-Blood and blood forming organs","MLLNCUMT","Million of national currency units","BEL","Belgium","2021","2021",816.8,,
+"PATCBLOO","B-Blood and blood forming organs","MLLNCUMT","Million of national currency units","BEL","Belgium","2022","2022",891.1,"E","Estimated value"
+"PATCBLOO","B-Blood and blood forming organs","MTMOTCMT","Million US$ at exchange rate","BEL","Belgium","2010","2010",595.2,,
+"PATCBLOO","B-Blood and blood forming organs","MTMOTCMT","Million US$ at exchange rate","BEL","Belgium","2011","2011",618.2,,
+"PATCBLOO","B-Blood and blood forming organs","MTMOTCMT","Million US$ at exchange rate","BEL","Belgium","2012","2012",578.9,,
+"PATCBLOO","B-Blood and blood forming organs","MTMOTCMT","Million US$ at exchange rate","BEL","Belgium","2013","2013",652.3,,
+"PATCBLOO","B-Blood and blood forming organs","MTMOTCMT","Million US$ at exchange rate","BEL","Belgium","2014","2014",666.1,,
+"PATCBLOO","B-Blood and blood forming organs","MTMOTCMT","Million US$ at exchange rate","BEL","Belgium","2015","2015",580,,
+"PATCBLOO","B-Blood and blood forming organs","MTMOTCMT","Million US$ at exchange rate","BEL","Belgium","2016","2016",619.5,,
+"PATCBLOO","B-Blood and blood forming organs","MTMOTCMT","Million US$ at exchange rate","BEL","Belgium","2017","2017",672.1,,
+"PATCBLOO","B-Blood and blood forming organs","MTMOTCMT","Million US$ at exchange rate","BEL","Belgium","2018","2018",722.2,,
+"PATCBLOO","B-Blood and blood forming organs","MTMOTCMT","Million US$ at exchange rate","BEL","Belgium","2019","2019",764.6,,
+"PATCBLOO","B-Blood and blood forming organs","MTMOTCMT","Million US$ at exchange rate","BEL","Belgium","2020","2020",851.4,,
+"PATCBLOO","B-Blood and blood forming organs","MTMOTCMT","Million US$ at exchange rate","BEL","Belgium","2021","2021",966,,
+"PATCBLOO","B-Blood and blood forming organs","MTMOTCMT","Million US$ at exchange rate","BEL","Belgium","2022","2022",938.4,"E","Estimated value"
+"PATCBLOO","B-Blood and blood forming organs","MTMOPPMT","Million US$, purchasing power parity","BEL","Belgium","2010","2010",536.6,,
+"PATCBLOO","B-Blood and blood forming organs","MTMOPPMT","Million US$, purchasing power parity","BEL","Belgium","2011","2011",533.9,,
+"PATCBLOO","B-Blood and blood forming organs","MTMOPPMT","Million US$, purchasing power parity","BEL","Belgium","2012","2012",548,,
+"PATCBLOO","B-Blood and blood forming organs","MTMOPPMT","Million US$, purchasing power parity","BEL","Belgium","2013","2013",609.2,,
+"PATCBLOO","B-Blood and blood forming organs","MTMOPPMT","Million US$, purchasing power parity","BEL","Belgium","2014","2014",626.5,,
+"PATCBLOO","B-Blood and blood forming organs","MTMOPPMT","Million US$, purchasing power parity","BEL","Belgium","2015","2015",653.4,,
+"PATCBLOO","B-Blood and blood forming organs","MTMOPPMT","Million US$, purchasing power parity","BEL","Belgium","2016","2016",716.6,,
+"PATCBLOO","B-Blood and blood forming organs","MTMOPPMT","Million US$, purchasing power parity","BEL","Belgium","2017","2017",767.1,,
+"PATCBLOO","B-Blood and blood forming organs","MTMOPPMT","Million US$, purchasing power parity","BEL","Belgium","2018","2018",797.9,,
+"PATCBLOO","B-Blood and blood forming organs","MTMOPPMT","Million US$, purchasing power parity","BEL","Belgium","2019","2019",914.9,,
+"PATCBLOO","B-Blood and blood forming organs","MTMOPPMT","Million US$, purchasing power parity","BEL","Belgium","2020","2020",1020.7,,
+"PATCBLOO","B-Blood and blood forming organs","MTMOPPMT","Million US$, purchasing power parity","BEL","Belgium","2021","2021",1108.7,,
+"PATCBLOO","B-Blood and blood forming organs","MTMOPPMT","Million US$, purchasing power parity","BEL","Belgium","2022","2022",1248.2,"E","Estimated value"
+"PATCBLOO","B-Blood and blood forming organs","TCPPERMT","/capita, US$ exchange rate","BEL","Belgium","2010","2010",54.6,,
+"PATCBLOO","B-Blood and blood forming organs","TCPPERMT","/capita, US$ exchange rate","BEL","Belgium","2011","2011",56,,
+"PATCBLOO","B-Blood and blood forming organs","TCPPERMT","/capita, US$ exchange rate","BEL","Belgium","2012","2012",52.1,,
+"PATCBLOO","B-Blood and blood forming organs","TCPPERMT","/capita, US$ exchange rate","BEL","Belgium","2013","2013",58.5,,
+"PATCBLOO","B-Blood and blood forming organs","TCPPERMT","/capita, US$ exchange rate","BEL","Belgium","2014","2014",59.4,,
+"PATCBLOO","B-Blood and blood forming organs","TCPPERMT","/capita, US$ exchange rate","BEL","Belgium","2015","2015",51.4,,
+"PATCBLOO","B-Blood and blood forming organs","TCPPERMT","/capita, US$ exchange rate","BEL","Belgium","2016","2016",54.7,,
+"PATCBLOO","B-Blood and blood forming organs","TCPPERMT","/capita, US$ exchange rate","BEL","Belgium","2017","2017",59.1,,
+"PATCBLOO","B-Blood and blood forming organs","TCPPERMT","/capita, US$ exchange rate","BEL","Belgium","2018","2018",63.2,,
+"PATCBLOO","B-Blood and blood forming organs","TCPPERMT","/capita, US$ exchange rate","BEL","Belgium","2019","2019",66.6,,
+"PATCBLOO","B-Blood and blood forming organs","TCPPERMT","/capita, US$ exchange rate","BEL","Belgium","2020","2020",73.8,,
+"PATCBLOO","B-Blood and blood forming organs","TCPPERMT","/capita, US$ exchange rate","BEL","Belgium","2021","2021",83.4,,
+"PATCBLOO","B-Blood and blood forming organs","TCPPERMT","/capita, US$ exchange rate","BEL","Belgium","2022","2022",80.8,"E","Estimated value"
+"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2010","2010",49.3,,
+"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2011","2011",48.4,,
+"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2012","2012",49.3,,
+"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2013","2013",54.6,,
+"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2014","2014",55.9,,
+"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2015","2015",58,,
+"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2016","2016",63.2,,
+"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2017","2017",67.4,,
+"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2018","2018",69.8,,
+"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2019","2019",79.6,,
+"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2020","2020",88.5,,
+"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2021","2021",95.7,,
+"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2022","2022",107.4,"E","Estimated value"
+"PATCBLOO","B-Blood and blood forming organs","ATCPTTMT","% of total sales","BEL","Belgium","2010","2010",7.6,,
+"PATCBLOO","B-Blood and blood forming organs","ATCPTTMT","% of total sales","BEL","Belgium","2011","2011",7.4,,
+"PATCBLOO","B-Blood and blood forming organs","ATCPTTMT","% of total sales","BEL","Belgium","2012","2012",7.6,,
+"PATCBLOO","B-Blood and blood forming organs","ATCPTTMT","% of total sales","BEL","Belgium","2013","2013",8.3,,
+"PATCBLOO","B-Blood and blood forming organs","ATCPTTMT","% of total sales","BEL","Belgium","2014","2014",8.4,,
+"PATCBLOO","B-Blood and blood forming organs","ATCPTTMT","% of total sales","BEL","Belgium","2015","2015",8.4,,
+"PATCBLOO","B-Blood and blood forming organs","ATCPTTMT","% of total sales","BEL","Belgium","2016","2016",9,,
+"PATCBLOO","B-Blood and blood forming organs","ATCPTTMT","% of total sales","BEL","Belgium","2017","2017",9.1,,
+"PATCBLOO","B-Blood and blood forming organs","ATCPTTMT","% of total sales","BEL","Belgium","2018","2018",9.2,,
+"PATCBLOO","B-Blood and blood forming organs","ATCPTTMT","% of total sales","BEL","Belgium","2019","2019",9.3,,
+"PATCBLOO","B-Blood and blood forming organs","ATCPTTMT","% of total sales","BEL","Belgium","2020","2020",9.7,,
+"PATCBLOO","B-Blood and blood forming organs","ATCPTTMT","% of total sales","BEL","Belgium","2021","2021",10.1,,
+"PATCBLOO","B-Blood and blood forming organs","ATCPTTMT","% of total sales","BEL","Belgium","2022","2022",9.9,"E","Estimated value"
+"PATCBLOO","B-Blood and blood forming organs","MLLNCUMT","Million of national currency units","CAN","Canada","2012","2012",742.9,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","MLLNCUMT","Million of national currency units","CAN","Canada","2013","2013",774.2,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","MLLNCUMT","Million of national currency units","CAN","Canada","2014","2014",870.2,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","MLLNCUMT","Million of national currency units","CAN","Canada","2015","2015",954.8,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","MLLNCUMT","Million of national currency units","CAN","Canada","2016","2016",1064.2,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","MLLNCUMT","Million of national currency units","CAN","Canada","2017","2017",1161.9,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","MLLNCUMT","Million of national currency units","CAN","Canada","2018","2018",1246.1,"E; B; D","Estimated value; Break; Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","MLLNCUMT","Million of national currency units","CAN","Canada","2019","2019",1345.5,"E; D","Estimated value; Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","MLLNCUMT","Million of national currency units","CAN","Canada","2020","2020",1476.1,"E; D","Estimated value; Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","MLLNCUMT","Million of national currency units","CAN","Canada","2021","2021",1572.2,"E; D","Estimated value; Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","MLLNCUMT","Million of national currency units","CAN","Canada","2022","2022",1611.6,"E; D","Estimated value; Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","MTMOTCMT","Million US$ at exchange rate","CAN","Canada","2012","2012",743.4,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","MTMOTCMT","Million US$ at exchange rate","CAN","Canada","2013","2013",751.6,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","MTMOTCMT","Million US$ at exchange rate","CAN","Canada","2014","2014",787.7,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","MTMOTCMT","Million US$ at exchange rate","CAN","Canada","2015","2015",746.6,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","MTMOTCMT","Million US$ at exchange rate","CAN","Canada","2016","2016",802.8,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","MTMOTCMT","Million US$ at exchange rate","CAN","Canada","2017","2017",895.2,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","MTMOTCMT","Million US$ at exchange rate","CAN","Canada","2018","2018",961.6,"E; B; D","Estimated value; Break; Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","MTMOTCMT","Million US$ at exchange rate","CAN","Canada","2019","2019",1014.1,"E; D","Estimated value; Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","MTMOTCMT","Million US$ at exchange rate","CAN","Canada","2020","2020",1100.6,"E; D","Estimated value; Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","MTMOTCMT","Million US$ at exchange rate","CAN","Canada","2021","2021",1253.9,"E; D","Estimated value; Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","MTMOTCMT","Million US$ at exchange rate","CAN","Canada","2022","2022",1238.2,"E; D","Estimated value; Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","MTMOPPMT","Million US$, purchasing power parity","CAN","Canada","2012","2012",596.9,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","MTMOPPMT","Million US$, purchasing power parity","CAN","Canada","2013","2013",632.5,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","MTMOPPMT","Million US$, purchasing power parity","CAN","Canada","2014","2014",707.3,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","MTMOPPMT","Million US$, purchasing power parity","CAN","Canada","2015","2015",765,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","MTMOPPMT","Million US$, purchasing power parity","CAN","Canada","2016","2016",881.7,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","MTMOPPMT","Million US$, purchasing power parity","CAN","Canada","2017","2017",958.4,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","MTMOPPMT","Million US$, purchasing power parity","CAN","Canada","2018","2018",1032.8,"E; B; D","Estimated value; Break; Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","MTMOPPMT","Million US$, purchasing power parity","CAN","Canada","2019","2019",1089.7,"E; D","Estimated value; Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","MTMOPPMT","Million US$, purchasing power parity","CAN","Canada","2020","2020",1199.1,"E; D","Estimated value; Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","MTMOPPMT","Million US$, purchasing power parity","CAN","Canada","2021","2021",1269.8,"E; D","Estimated value; Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","MTMOPPMT","Million US$, purchasing power parity","CAN","Canada","2022","2022",1285.4,"E; D","Estimated value; Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","TCPPERMT","/capita, US$ exchange rate","CAN","Canada","2012","2012",21.4,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","TCPPERMT","/capita, US$ exchange rate","CAN","Canada","2013","2013",21.4,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","TCPPERMT","/capita, US$ exchange rate","CAN","Canada","2014","2014",22.2,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","TCPPERMT","/capita, US$ exchange rate","CAN","Canada","2015","2015",20.9,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","TCPPERMT","/capita, US$ exchange rate","CAN","Canada","2016","2016",22.2,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","TCPPERMT","/capita, US$ exchange rate","CAN","Canada","2017","2017",24.5,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","TCPPERMT","/capita, US$ exchange rate","CAN","Canada","2018","2018",25.9,"E; B; D","Estimated value; Break; Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","TCPPERMT","/capita, US$ exchange rate","CAN","Canada","2019","2019",27,"E; D","Estimated value; Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","TCPPERMT","/capita, US$ exchange rate","CAN","Canada","2020","2020",28.9,"E; D","Estimated value; Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","TCPPERMT","/capita, US$ exchange rate","CAN","Canada","2021","2021",32.8,"E; D","Estimated value; Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","TCPPERMT","/capita, US$ exchange rate","CAN","Canada","2022","2022",31.8,"E; D","Estimated value; Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2012","2012",17.2,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2013","2013",18,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2014","2014",20,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2015","2015",21.4,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2016","2016",24.4,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2017","2017",26.2,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2018","2018",27.9,"E; B; D","Estimated value; Break; Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2019","2019",29,"E; D","Estimated value; Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2020","2020",31.5,"E; D","Estimated value; Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2021","2021",33.2,"E; D","Estimated value; Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2022","2022",33.1,"E; D","Estimated value; Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","ATCPTTMT","% of total sales","CAN","Canada","2012","2012",3.1,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","ATCPTTMT","% of total sales","CAN","Canada","2013","2013",3.1,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","ATCPTTMT","% of total sales","CAN","Canada","2014","2014",3.4,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","ATCPTTMT","% of total sales","CAN","Canada","2015","2015",3.5,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","ATCPTTMT","% of total sales","CAN","Canada","2016","2016",3.8,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","ATCPTTMT","% of total sales","CAN","Canada","2017","2017",3.9,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","ATCPTTMT","% of total sales","CAN","Canada","2018","2018",4.1,"E; B; D","Estimated value; Break; Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","ATCPTTMT","% of total sales","CAN","Canada","2019","2019",4.2,"E; D","Estimated value; Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","ATCPTTMT","% of total sales","CAN","Canada","2020","2020",4.3,"E; D","Estimated value; Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","ATCPTTMT","% of total sales","CAN","Canada","2021","2021",4.3,"E; D","Estimated value; Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","ATCPTTMT","% of total sales","CAN","Canada","2022","2022",4,"E; D","Estimated value; Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","MLLNCUMT","Million of national currency units","CZE","Czech Republic","2010","2010",5259.8,,
+"PATCBLOO","B-Blood and blood forming organs","MLLNCUMT","Million of national currency units","CZE","Czech Republic","2011","2011",5429,,
+"PATCBLOO","B-Blood and blood forming organs","MLLNCUMT","Million of national currency units","CZE","Czech Republic","2012","2012",6184.9,,
+"PATCBLOO","B-Blood and blood forming organs","MLLNCUMT","Million of national currency units","CZE","Czech Republic","2013","2013",6193.4,,
+"PATCBLOO","B-Blood and blood forming organs","MLLNCUMT","Million of national currency units","CZE","Czech Republic","2014","2014",6890.5,,
+"PATCBLOO","B-Blood and blood forming organs","MLLNCUMT","Million of national currency units","CZE","Czech Republic","2015","2015",7422.6,,
+"PATCBLOO","B-Blood and blood forming organs","MLLNCUMT","Million of national currency units","CZE","Czech Republic","2016","2016",7961.9,,
+"PATCBLOO","B-Blood and blood forming organs","MLLNCUMT","Million of national currency units","CZE","Czech Republic","2017","2017",8615.1,,
+"PATCBLOO","B-Blood and blood forming organs","MLLNCUMT","Million of national currency units","CZE","Czech Republic","2018","2018",9450.5,,
+"PATCBLOO","B-Blood and blood forming organs","MLLNCUMT","Million of national currency units","CZE","Czech Republic","2019","2019",9824.2,,
+"PATCBLOO","B-Blood and blood forming organs","MLLNCUMT","Million of national currency units","CZE","Czech Republic","2020","2020",9517.8,"B","Break"
+"PATCBLOO","B-Blood and blood forming organs","MLLNCUMT","Million of national currency units","CZE","Czech Republic","2021","2021",10694.6,,
+"PATCBLOO","B-Blood and blood forming organs","MTMOTCMT","Million US$ at exchange rate","CZE","Czech Republic","2010","2010",275.4,,
+"PATCBLOO","B-Blood and blood forming organs","MTMOTCMT","Million US$ at exchange rate","CZE","Czech Republic","2011","2011",306.8,,
+"PATCBLOO","B-Blood and blood forming organs","MTMOTCMT","Million US$ at exchange rate","CZE","Czech Republic","2012","2012",315.9,,
+"PATCBLOO","B-Blood and blood forming organs","MTMOTCMT","Million US$ at exchange rate","CZE","Czech Republic","2013","2013",316.5,,
+"PATCBLOO","B-Blood and blood forming organs","MTMOTCMT","Million US$ at exchange rate","CZE","Czech Republic","2014","2014",332,,
+"PATCBLOO","B-Blood and blood forming organs","MTMOTCMT","Million US$ at exchange rate","CZE","Czech Republic","2015","2015",301.7,,
+"PATCBLOO","B-Blood and blood forming organs","MTMOTCMT","Million US$ at exchange rate","CZE","Czech Republic","2016","2016",325.8,,
+"PATCBLOO","B-Blood and blood forming organs","MTMOTCMT","Million US$ at exchange rate","CZE","Czech Republic","2017","2017",368.5,,
+"PATCBLOO","B-Blood and blood forming organs","MTMOTCMT","Million US$ at exchange rate","CZE","Czech Republic","2018","2018",434.9,,
+"PATCBLOO","B-Blood and blood forming organs","MTMOTCMT","Million US$ at exchange rate","CZE","Czech Republic","2019","2019",428.4,,
+"PATCBLOO","B-Blood and blood forming organs","MTMOTCMT","Million US$ at exchange rate","CZE","Czech Republic","2020","2020",410.1,"B","Break"
+"PATCBLOO","B-Blood and blood forming organs","MTMOTCMT","Million US$ at exchange rate","CZE","Czech Republic","2021","2021",493.3,,
+"PATCBLOO","B-Blood and blood forming organs","MTMOPPMT","Million US$, purchasing power parity","CZE","Czech Republic","2010","2010",384.7,,
+"PATCBLOO","B-Blood and blood forming organs","MTMOPPMT","Million US$, purchasing power parity","CZE","Czech Republic","2011","2011",406.8,,
+"PATCBLOO","B-Blood and blood forming organs","MTMOPPMT","Million US$, purchasing power parity","CZE","Czech Republic","2012","2012",465.1,,
+"PATCBLOO","B-Blood and blood forming organs","MTMOPPMT","Million US$, purchasing power parity","CZE","Czech Republic","2013","2013",484.4,,
+"PATCBLOO","B-Blood and blood forming organs","MTMOPPMT","Million US$, purchasing power parity","CZE","Czech Republic","2014","2014",542.4,,
+"PATCBLOO","B-Blood and blood forming organs","MTMOPPMT","Million US$, purchasing power parity","CZE","Czech Republic","2015","2015",573.7,,
+"PATCBLOO","B-Blood and blood forming organs","MTMOPPMT","Million US$, purchasing power parity","CZE","Czech Republic","2016","2016",633.1,,
+"PATCBLOO","B-Blood and blood forming organs","MTMOPPMT","Million US$, purchasing power parity","CZE","Czech Republic","2017","2017",693.4,,
+"PATCBLOO","B-Blood and blood forming organs","MTMOPPMT","Million US$, purchasing power parity","CZE","Czech Republic","2018","2018",763.9,,
+"PATCBLOO","B-Blood and blood forming organs","MTMOPPMT","Million US$, purchasing power parity","CZE","Czech Republic","2019","2019",800.4,,
+"PATCBLOO","B-Blood and blood forming organs","MTMOPPMT","Million US$, purchasing power parity","CZE","Czech Republic","2020","2020",763.8,"B","Break"
+"PATCBLOO","B-Blood and blood forming organs","MTMOPPMT","Million US$, purchasing power parity","CZE","Czech Republic","2021","2021",839.3,,
+"PATCBLOO","B-Blood and blood forming organs","TCPPERMT","/capita, US$ exchange rate","CZE","Czech Republic","2010","2010",26.3,,
+"PATCBLOO","B-Blood and blood forming organs","TCPPERMT","/capita, US$ exchange rate","CZE","Czech Republic","2011","2011",29.2,,
+"PATCBLOO","B-Blood and blood forming organs","TCPPERMT","/capita, US$ exchange rate","CZE","Czech Republic","2012","2012",30.1,,
+"PATCBLOO","B-Blood and blood forming organs","TCPPERMT","/capita, US$ exchange rate","CZE","Czech Republic","2013","2013",30.1,,
+"PATCBLOO","B-Blood and blood forming organs","TCPPERMT","/capita, US$ exchange rate","CZE","Czech Republic","2014","2014",31.5,,
+"PATCBLOO","B-Blood and blood forming organs","TCPPERMT","/capita, US$ exchange rate","CZE","Czech Republic","2015","2015",28.6,,
+"PATCBLOO","B-Blood and blood forming organs","TCPPERMT","/capita, US$ exchange rate","CZE","Czech Republic","2016","2016",30.8,,
+"PATCBLOO","B-Blood and blood forming organs","TCPPERMT","/capita, US$ exchange rate","CZE","Czech Republic","2017","2017",34.8,,
+"PATCBLOO","B-Blood and blood forming organs","TCPPERMT","/capita, US$ exchange rate","CZE","Czech Republic","2018","2018",40.9,,
+"PATCBLOO","B-Blood and blood forming organs","TCPPERMT","/capita, US$ exchange rate","CZE","Czech Republic","2019","2019",40.1,,
+"PATCBLOO","B-Blood and blood forming organs","TCPPERMT","/capita, US$ exchange rate","CZE","Czech Republic","2020","2020",38.3,"B","Break"
+"PATCBLOO","B-Blood and blood forming organs","TCPPERMT","/capita, US$ exchange rate","CZE","Czech Republic","2021","2021",47,,
+"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czech Republic","2010","2010",36.7,,
+"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czech Republic","2011","2011",38.8,,
+"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czech Republic","2012","2012",44.3,,
+"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czech Republic","2013","2013",46.1,,
+"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czech Republic","2014","2014",51.5,,
+"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czech Republic","2015","2015",54.4,,
+"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czech Republic","2016","2016",59.9,,
+"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czech Republic","2017","2017",65.4,,
+"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czech Republic","2018","2018",71.9,,
+"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czech Republic","2019","2019",75,,
+"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czech Republic","2020","2020",71.4,"B","Break"
+"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czech Republic","2021","2021",79.9,,
+"PATCBLOO","B-Blood and blood forming organs","ATCPTTMT","% of total sales","CZE","Czech Republic","2010","2010",6.5,,
+"PATCBLOO","B-Blood and blood forming organs","ATCPTTMT","% of total sales","CZE","Czech Republic","2011","2011",6.7,,
+"PATCBLOO","B-Blood and blood forming organs","ATCPTTMT","% of total sales","CZE","Czech Republic","2012","2012",7.4,,
+"PATCBLOO","B-Blood and blood forming organs","ATCPTTMT","% of total sales","CZE","Czech Republic","2013","2013",7.8,,
+"PATCBLOO","B-Blood and blood forming organs","ATCPTTMT","% of total sales","CZE","Czech Republic","2014","2014",8.5,,
+"PATCBLOO","B-Blood and blood forming organs","ATCPTTMT","% of total sales","CZE","Czech Republic","2015","2015",8.8,,
+"PATCBLOO","B-Blood and blood forming organs","ATCPTTMT","% of total sales","CZE","Czech Republic","2016","2016",9.1,,
+"PATCBLOO","B-Blood and blood forming organs","ATCPTTMT","% of total sales","CZE","Czech Republic","2017","2017",9.4,,
+"PATCBLOO","B-Blood and blood forming organs","ATCPTTMT","% of total sales","CZE","Czech Republic","2018","2018",9.6,,
+"PATCBLOO","B-Blood and blood forming organs","ATCPTTMT","% of total sales","CZE","Czech Republic","2019","2019",9.5,,
+"PATCBLOO","B-Blood and blood forming organs","ATCPTTMT","% of total sales","CZE","Czech Republic","2020","2020",10.8,"B","Break"
+"PATCBLOO","B-Blood and blood forming organs","ATCPTTMT","% of total sales","CZE","Czech Republic","2021","2021",11.5,,
+"PATCBLOO","B-Blood and blood forming organs","MLLNCUMT","Million of national currency units","DNK","Denmark","2010","2010",1243.4,,
+"PATCBLOO","B-Blood and blood forming organs","MLLNCUMT","Million of national currency units","DNK","Denmark","2011","2011",1206,,
+"PATCBLOO","B-Blood and blood forming organs","MLLNCUMT","Million of national currency units","DNK","Denmark","2012","2012",1344.1,,
+"PATCBLOO","B-Blood and blood forming organs","MLLNCUMT","Million of national currency units","DNK","Denmark","2013","2013",1405.3,,
+"PATCBLOO","B-Blood and blood forming organs","MLLNCUMT","Million of national currency units","DNK","Denmark","2014","2014",1593.7,,
+"PATCBLOO","B-Blood and blood forming organs","MLLNCUMT","Million of national currency units","DNK","Denmark","2015","2015",1721.2,,
+"PATCBLOO","B-Blood and blood forming organs","MLLNCUMT","Million of national currency units","DNK","Denmark","2016","2016",1851.8,,
+"PATCBLOO","B-Blood and blood forming organs","MLLNCUMT","Million of national currency units","DNK","Denmark","2017","2017",1993.8,,
+"PATCBLOO","B-Blood and blood forming organs","MLLNCUMT","Million of national currency units","DNK","Denmark","2018","2018",2168.8,,
+"PATCBLOO","B-Blood and blood forming organs","MLLNCUMT","Million of national currency units","DNK","Denmark","2019","2019",2239,,
+"PATCBLOO","B-Blood and blood forming organs","MLLNCUMT","Million of national currency units","DNK","Denmark","2020","2020",2370.1,,
+"PATCBLOO","B-Blood and blood forming organs","MLLNCUMT","Million of national currency units","DNK","Denmark","2021","2021",2521,,
+"PATCBLOO","B-Blood and blood forming organs","MTMOTCMT","Million US$ at exchange rate","DNK","Denmark","2010","2010",221.1,,
+"PATCBLOO","B-Blood and blood forming organs","MTMOTCMT","Million US$ at exchange rate","DNK","Denmark","2011","2011",224.6,,
+"PATCBLOO","B-Blood and blood forming organs","MTMOTCMT","Million US$ at exchange rate","DNK","Denmark","2012","2012",232,,
+"PATCBLOO","B-Blood and blood forming organs","MTMOTCMT","Million US$ at exchange rate","DNK","Denmark","2013","2013",250.2,,
+"PATCBLOO","B-Blood and blood forming organs","MTMOTCMT","Million US$ at exchange rate","DNK","Denmark","2014","2014",284,,
+"PATCBLOO","B-Blood and blood forming organs","MTMOTCMT","Million US$ at exchange rate","DNK","Denmark","2015","2015",255.8,,
+"PATCBLOO","B-Blood and blood forming organs","MTMOTCMT","Million US$ at exchange rate","DNK","Denmark","2016","2016",275.1,,
+"PATCBLOO","B-Blood and blood forming organs","MTMOTCMT","Million US$ at exchange rate","DNK","Denmark","2017","2017",302,,
+"PATCBLOO","B-Blood and blood forming organs","MTMOTCMT","Million US$ at exchange rate","DNK","Denmark","2018","2018",343.5,,
+"PATCBLOO","B-Blood and blood forming organs","MTMOTCMT","Million US$ at exchange rate","DNK","Denmark","2019","2019",335.7,,
+"PATCBLOO","B-Blood and blood forming organs","MTMOTCMT","Million US$ at exchange rate","DNK","Denmark","2020","2020",362.3,,
+"PATCBLOO","B-Blood and blood forming organs","MTMOTCMT","Million US$ at exchange rate","DNK","Denmark","2021","2021",401,,
+"PATCBLOO","B-Blood and blood forming organs","MTMOPPMT","Million US$, purchasing power parity","DNK","Denmark","2010","2010",163.8,,
+"PATCBLOO","B-Blood and blood forming organs","MTMOPPMT","Million US$, purchasing power parity","DNK","Denmark","2011","2011",161.5,,
+"PATCBLOO","B-Blood and blood forming organs","MTMOPPMT","Million US$, purchasing power parity","DNK","Denmark","2012","2012",177.7,,
+"PATCBLOO","B-Blood and blood forming organs","MTMOPPMT","Million US$, purchasing power parity","DNK","Denmark","2013","2013",191.1,,
+"PATCBLOO","B-Blood and blood forming organs","MTMOPPMT","Million US$, purchasing power parity","DNK","Denmark","2014","2014",217.5,,
+"PATCBLOO","B-Blood and blood forming organs","MTMOPPMT","Million US$, purchasing power parity","DNK","Denmark","2015","2015",235.6,,
+"PATCBLOO","B-Blood and blood forming organs","MTMOPPMT","Million US$, purchasing power parity","DNK","Denmark","2016","2016",261.6,,
+"PATCBLOO","B-Blood and blood forming organs","MTMOPPMT","Million US$, purchasing power parity","DNK","Denmark","2017","2017",290.1,,
+"PATCBLOO","B-Blood and blood forming organs","MTMOPPMT","Million US$, purchasing power parity","DNK","Denmark","2018","2018",320.5,,
+"PATCBLOO","B-Blood and blood forming organs","MTMOPPMT","Million US$, purchasing power parity","DNK","Denmark","2019","2019",337.5,,
+"PATCBLOO","B-Blood and blood forming organs","MTMOPPMT","Million US$, purchasing power parity","DNK","Denmark","2020","2020",361.8,,
+"PATCBLOO","B-Blood and blood forming organs","MTMOPPMT","Million US$, purchasing power parity","DNK","Denmark","2021","2021",382.6,,
+"PATCBLOO","B-Blood and blood forming organs","TCPPERMT","/capita, US$ exchange rate","DNK","Denmark","2010","2010",39.9,,
+"PATCBLOO","B-Blood and blood forming organs","TCPPERMT","/capita, US$ exchange rate","DNK","Denmark","2011","2011",40.3,,
+"PATCBLOO","B-Blood and blood forming organs","TCPPERMT","/capita, US$ exchange rate","DNK","Denmark","2012","2012",41.5,,
+"PATCBLOO","B-Blood and blood forming organs","TCPPERMT","/capita, US$ exchange rate","DNK","Denmark","2013","2013",44.6,,
+"PATCBLOO","B-Blood and blood forming organs","TCPPERMT","/capita, US$ exchange rate","DNK","Denmark","2014","2014",50.3,,
+"PATCBLOO","B-Blood and blood forming organs","TCPPERMT","/capita, US$ exchange rate","DNK","Denmark","2015","2015",45,,
+"PATCBLOO","B-Blood and blood forming organs","TCPPERMT","/capita, US$ exchange rate","DNK","Denmark","2016","2016",48,,
+"PATCBLOO","B-Blood and blood forming organs","TCPPERMT","/capita, US$ exchange rate","DNK","Denmark","2017","2017",52.4,,
+"PATCBLOO","B-Blood and blood forming organs","TCPPERMT","/capita, US$ exchange rate","DNK","Denmark","2018","2018",59.3,,
+"PATCBLOO","B-Blood and blood forming organs","TCPPERMT","/capita, US$ exchange rate","DNK","Denmark","2019","2019",57.7,,
+"PATCBLOO","B-Blood and blood forming organs","TCPPERMT","/capita, US$ exchange rate","DNK","Denmark","2020","2020",62.1,,
+"PATCBLOO","B-Blood and blood forming organs","TCPPERMT","/capita, US$ exchange rate","DNK","Denmark","2021","2021",68.5,,
+"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","DNK","Denmark","2010","2010",29.5,,
+"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","DNK","Denmark","2011","2011",29,,
+"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","DNK","Denmark","2012","2012",31.8,,
+"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","DNK","Denmark","2013","2013",34,,
+"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","DNK","Denmark","2014","2014",38.5,,
+"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","DNK","Denmark","2015","2015",41.5,,
+"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","DNK","Denmark","2016","2016",45.7,,
+"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","DNK","Denmark","2017","2017",50.3,,
+"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","DNK","Denmark","2018","2018",55.3,,
+"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","DNK","Denmark","2019","2019",58,,
+"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","DNK","Denmark","2020","2020",62,,
+"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","DNK","Denmark","2021","2021",65.3,,
+"PATCBLOO","B-Blood and blood forming organs","ATCPTTMT","% of total sales","DNK","Denmark","2010","2010",5.9,,
+"PATCBLOO","B-Blood and blood forming organs","ATCPTTMT","% of total sales","DNK","Denmark","2011","2011",5.9,,
+"PATCBLOO","B-Blood and blood forming organs","ATCPTTMT","% of total sales","DNK","Denmark","2012","2012",6.6,,
+"PATCBLOO","B-Blood and blood forming organs","ATCPTTMT","% of total sales","DNK","Denmark","2013","2013",6.9,,
+"PATCBLOO","B-Blood and blood forming organs","ATCPTTMT","% of total sales","DNK","Denmark","2014","2014",7.4,,
+"PATCBLOO","B-Blood and blood forming organs","ATCPTTMT","% of total sales","DNK","Denmark","2015","2015",7.9,,
+"PATCBLOO","B-Blood and blood forming organs","ATCPTTMT","% of total sales","DNK","Denmark","2016","2016",8.4,,
+"PATCBLOO","B-Blood and blood forming organs","ATCPTTMT","% of total sales","DNK","Denmark","2017","2017",8.7,,
+"PATCBLOO","B-Blood and blood forming organs","ATCPTTMT","% of total sales","DNK","Denmark","2018","2018",9.1,,
+"PATCBLOO","B-Blood and blood forming organs","ATCPTTMT","% of total sales","DNK","Denmark","2019","2019",9.1,,
+"PATCBLOO","B-Blood and blood forming organs","ATCPTTMT","% of total sales","DNK","Denmark","2020","2020",9.4,,
+"PATCBLOO","B-Blood and blood forming organs","ATCPTTMT","% of total sales","DNK","Denmark","2021","2021",9.9,,
+"PATCBLOO","B-Blood and blood forming organs","MLLNCUMT","Million of national currency units","FIN","Finland","2010","2010",131.3,,
+"PATCBLOO","B-Blood and blood forming organs","MLLNCUMT","Million of national currency units","FIN","Finland","2011","2011",138.5,,
+"PATCBLOO","B-Blood and blood forming organs","MLLNCUMT","Million of national currency units","FIN","Finland","2012","2012",152.4,,
+"PATCBLOO","B-Blood and blood forming organs","MLLNCUMT","Million of national currency units","FIN","Finland","2013","2013",156.2,,
+"PATCBLOO","B-Blood and blood forming organs","MLLNCUMT","Million of national currency units","FIN","Finland","2014","2014",162.1,,
+"PATCBLOO","B-Blood and blood forming organs","MLLNCUMT","Million of national currency units","FIN","Finland","2015","2015",177.4,,
+"PATCBLOO","B-Blood and blood forming organs","MLLNCUMT","Million of national currency units","FIN","Finland","2016","2016",195.9,,
+"PATCBLOO","B-Blood and blood forming organs","MLLNCUMT","Million of national currency units","FIN","Finland","2017","2017",217.5,,
+"PATCBLOO","B-Blood and blood forming organs","MLLNCUMT","Million of national currency units","FIN","Finland","2018","2018",237.9,,
+"PATCBLOO","B-Blood and blood forming organs","MLLNCUMT","Million of national currency units","FIN","Finland","2019","2019",268.3,,
+"PATCBLOO","B-Blood and blood forming organs","MLLNCUMT","Million of national currency units","FIN","Finland","2020","2020",284.6,,
+"PATCBLOO","B-Blood and blood forming organs","MLLNCUMT","Million of national currency units","FIN","Finland","2021","2021",296.2,,
+"PATCBLOO","B-Blood and blood forming organs","MTMOTCMT","Million US$ at exchange rate","FIN","Finland","2010","2010",174.1,,
+"PATCBLOO","B-Blood and blood forming organs","MTMOTCMT","Million US$ at exchange rate","FIN","Finland","2011","2011",192.8,,
+"PATCBLOO","B-Blood and blood forming organs","MTMOTCMT","Million US$ at exchange rate","FIN","Finland","2012","2012",195.8,,
+"PATCBLOO","B-Blood and blood forming organs","MTMOTCMT","Million US$ at exchange rate","FIN","Finland","2013","2013",207.5,,
+"PATCBLOO","B-Blood and blood forming organs","MTMOTCMT","Million US$ at exchange rate","FIN","Finland","2014","2014",215.4,,
+"PATCBLOO","B-Blood and blood forming organs","MTMOTCMT","Million US$ at exchange rate","FIN","Finland","2015","2015",196.8,,
+"PATCBLOO","B-Blood and blood forming organs","MTMOTCMT","Million US$ at exchange rate","FIN","Finland","2016","2016",216.8,,
+"PATCBLOO","B-Blood and blood forming organs","MTMOTCMT","Million US$ at exchange rate","FIN","Finland","2017","2017",245.7,,
+"PATCBLOO","B-Blood and blood forming organs","MTMOTCMT","Million US$ at exchange rate","FIN","Finland","2018","2018",280.9,,
+"PATCBLOO","B-Blood and blood forming organs","MTMOTCMT","Million US$ at exchange rate","FIN","Finland","2019","2019",300.4,,
+"PATCBLOO","B-Blood and blood forming organs","MTMOTCMT","Million US$ at exchange rate","FIN","Finland","2020","2020",325.1,,
+"PATCBLOO","B-Blood and blood forming organs","MTMOTCMT","Million US$ at exchange rate","FIN","Finland","2021","2021",350.3,,
+"PATCBLOO","B-Blood and blood forming organs","MTMOPPMT","Million US$, purchasing power parity","FIN","Finland","2010","2010",145.8,,
+"PATCBLOO","B-Blood and blood forming organs","MTMOPPMT","Million US$, purchasing power parity","FIN","Finland","2011","2011",154.2,,
+"PATCBLOO","B-Blood and blood forming organs","MTMOPPMT","Million US$, purchasing power parity","FIN","Finland","2012","2012",167.7,,
+"PATCBLOO","B-Blood and blood forming organs","MTMOPPMT","Million US$, purchasing power parity","FIN","Finland","2013","2013",172.5,,
+"PATCBLOO","B-Blood and blood forming organs","MTMOPPMT","Million US$, purchasing power parity","FIN","Finland","2014","2014",178.7,,
+"PATCBLOO","B-Blood and blood forming organs","MTMOPPMT","Million US$, purchasing power parity","FIN","Finland","2015","2015",195.4,,
+"PATCBLOO","B-Blood and blood forming organs","MTMOPPMT","Million US$, purchasing power parity","FIN","Finland","2016","2016",222.4,,
+"PATCBLOO","B-Blood and blood forming organs","MTMOPPMT","Million US$, purchasing power parity","FIN","Finland","2017","2017",251.8,,
+"PATCBLOO","B-Blood and blood forming organs","MTMOPPMT","Million US$, purchasing power parity","FIN","Finland","2018","2018",278.7,,
+"PATCBLOO","B-Blood and blood forming organs","MTMOPPMT","Million US$, purchasing power parity","FIN","Finland","2019","2019",320,,
+"PATCBLOO","B-Blood and blood forming organs","MTMOPPMT","Million US$, purchasing power parity","FIN","Finland","2020","2020",345.8,,
+"PATCBLOO","B-Blood and blood forming organs","MTMOPPMT","Million US$, purchasing power parity","FIN","Finland","2021","2021",358.3,,
+"PATCBLOO","B-Blood and blood forming organs","TCPPERMT","/capita, US$ exchange rate","FIN","Finland","2010","2010",32.5,,
+"PATCBLOO","B-Blood and blood forming organs","TCPPERMT","/capita, US$ exchange rate","FIN","Finland","2011","2011",35.8,,
+"PATCBLOO","B-Blood and blood forming organs","TCPPERMT","/capita, US$ exchange rate","FIN","Finland","2012","2012",36.2,,
+"PATCBLOO","B-Blood and blood forming organs","TCPPERMT","/capita, US$ exchange rate","FIN","Finland","2013","2013",38.1,,
+"PATCBLOO","B-Blood and blood forming organs","TCPPERMT","/capita, US$ exchange rate","FIN","Finland","2014","2014",39.4,,
+"PATCBLOO","B-Blood and blood forming organs","TCPPERMT","/capita, US$ exchange rate","FIN","Finland","2015","2015",35.9,,
+"PATCBLOO","B-Blood and blood forming organs","TCPPERMT","/capita, US$ exchange rate","FIN","Finland","2016","2016",39.5,,
+"PATCBLOO","B-Blood and blood forming organs","TCPPERMT","/capita, US$ exchange rate","FIN","Finland","2017","2017",44.6,,
+"PATCBLOO","B-Blood and blood forming organs","TCPPERMT","/capita, US$ exchange rate","FIN","Finland","2018","2018",50.9,,
+"PATCBLOO","B-Blood and blood forming organs","TCPPERMT","/capita, US$ exchange rate","FIN","Finland","2019","2019",54.4,,
+"PATCBLOO","B-Blood and blood forming organs","TCPPERMT","/capita, US$ exchange rate","FIN","Finland","2020","2020",58.8,,
+"PATCBLOO","B-Blood and blood forming organs","TCPPERMT","/capita, US$ exchange rate","FIN","Finland","2021","2021",63.2,,
+"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2010","2010",27.2,,
+"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2011","2011",28.6,,
+"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2012","2012",31,,
+"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2013","2013",31.7,,
+"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2014","2014",32.7,,
+"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2015","2015",35.7,,
+"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2016","2016",40.5,,
+"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2017","2017",45.7,,
+"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2018","2018",50.5,,
+"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2019","2019",58,,
+"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2020","2020",62.5,,
+"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2021","2021",64.7,,
+"PATCBLOO","B-Blood and blood forming organs","ATCPTTMT","% of total sales","FIN","Finland","2010","2010",7,,
+"PATCBLOO","B-Blood and blood forming organs","ATCPTTMT","% of total sales","FIN","Finland","2011","2011",7.2,,
+"PATCBLOO","B-Blood and blood forming organs","ATCPTTMT","% of total sales","FIN","Finland","2012","2012",7.8,,
+"PATCBLOO","B-Blood and blood forming organs","ATCPTTMT","% of total sales","FIN","Finland","2013","2013",7.8,,
+"PATCBLOO","B-Blood and blood forming organs","ATCPTTMT","% of total sales","FIN","Finland","2014","2014",7.7,,
+"PATCBLOO","B-Blood and blood forming organs","ATCPTTMT","% of total sales","FIN","Finland","2015","2015",8.1,,
+"PATCBLOO","B-Blood and blood forming organs","ATCPTTMT","% of total sales","FIN","Finland","2016","2016",8.6,,
+"PATCBLOO","B-Blood and blood forming organs","ATCPTTMT","% of total sales","FIN","Finland","2017","2017",9.4,,
+"PATCBLOO","B-Blood and blood forming organs","ATCPTTMT","% of total sales","FIN","Finland","2018","2018",9.5,,
+"PATCBLOO","B-Blood and blood forming organs","ATCPTTMT","% of total sales","FIN","Finland","2019","2019",10.1,,
+"PATCBLOO","B-Blood and blood forming organs","ATCPTTMT","% of total sales","FIN","Finland","2020","2020",10.6,,
+"PATCBLOO","B-Blood and blood forming organs","ATCPTTMT","% of total sales","FIN","Finland","2021","2021",10.4,,
+"PATCBLOO","B-Blood and blood forming organs","MLLNCUMT","Million of national currency units","FRA","France","2011","2011",2128.9,,
+"PATCBLOO","B-Blood and blood forming organs","MTMOTCMT","Million US$ at exchange rate","FRA","France","2011","2011",2963.3,,
+"PATCBLOO","B-Blood and blood forming organs","MTMOPPMT","Million US$, purchasing power parity","FRA","France","2011","2011",2530.3,,
+"PATCBLOO","B-Blood and blood forming organs","TCPPERMT","/capita, US$ exchange rate","FRA","France","2011","2011",45.5,,
+"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","FRA","France","2011","2011",38.9,,
+"PATCBLOO","B-Blood and blood forming organs","ATCPTTMT","% of total sales","FRA","France","2011","2011",7.7,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","MLLNCUMT","Million of national currency units","DEU","Germany","2010","2010",1650.5,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","MLLNCUMT","Million of national currency units","DEU","Germany","2011","2011",1592.7,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","MLLNCUMT","Million of national currency units","DEU","Germany","2012","2012",1758.1,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","MLLNCUMT","Million of national currency units","DEU","Germany","2013","2013",2013.5,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","MLLNCUMT","Million of national currency units","DEU","Germany","2014","2014",2317.8,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","MLLNCUMT","Million of national currency units","DEU","Germany","2015","2015",2564.2,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","MLLNCUMT","Million of national currency units","DEU","Germany","2016","2016",2837.3,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","MLLNCUMT","Million of national currency units","DEU","Germany","2017","2017",3168.4,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","MLLNCUMT","Million of national currency units","DEU","Germany","2018","2018",3675,"B; D","Break; Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","MLLNCUMT","Million of national currency units","DEU","Germany","2019","2019",4064.8,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","MLLNCUMT","Million of national currency units","DEU","Germany","2020","2020",4566.6,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","MLLNCUMT","Million of national currency units","DEU","Germany","2021","2021",5290.7,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","MTMOTCMT","Million US$ at exchange rate","DEU","Germany","2010","2010",2188.1,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","MTMOTCMT","Million US$ at exchange rate","DEU","Germany","2011","2011",2217,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","MTMOTCMT","Million US$ at exchange rate","DEU","Germany","2012","2012",2258.8,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","MTMOTCMT","Million US$ at exchange rate","DEU","Germany","2013","2013",2674.2,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","MTMOTCMT","Million US$ at exchange rate","DEU","Germany","2014","2014",3079.2,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","MTMOTCMT","Million US$ at exchange rate","DEU","Germany","2015","2015",2845,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","MTMOTCMT","Million US$ at exchange rate","DEU","Germany","2016","2016",3140.6,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","MTMOTCMT","Million US$ at exchange rate","DEU","Germany","2017","2017",3579.3,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","MTMOTCMT","Million US$ at exchange rate","DEU","Germany","2018","2018",4340,"B; D","Break; Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","MTMOTCMT","Million US$ at exchange rate","DEU","Germany","2019","2019",4550.4,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","MTMOTCMT","Million US$ at exchange rate","DEU","Germany","2020","2020",5216,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","MTMOTCMT","Million US$ at exchange rate","DEU","Germany","2021","2021",6257.5,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","MTMOPPMT","Million US$, purchasing power parity","DEU","Germany","2010","2010",2050.1,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","MTMOPPMT","Million US$, purchasing power parity","DEU","Germany","2011","2011",2019.3,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","MTMOPPMT","Million US$, purchasing power parity","DEU","Germany","2012","2012",2233.2,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","MTMOPPMT","Million US$, purchasing power parity","DEU","Germany","2013","2013",2598.8,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","MTMOPPMT","Million US$, purchasing power parity","DEU","Germany","2014","2014",3014.3,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","MTMOPPMT","Million US$, purchasing power parity","DEU","Germany","2015","2015",3295.4,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","MTMOPPMT","Million US$, purchasing power parity","DEU","Germany","2016","2016",3770,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","MTMOPPMT","Million US$, purchasing power parity","DEU","Germany","2017","2017",4254.1,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","MTMOPPMT","Million US$, purchasing power parity","DEU","Germany","2018","2018",4997,"B; D","Break; Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","MTMOPPMT","Million US$, purchasing power parity","DEU","Germany","2019","2019",5581.6,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","MTMOPPMT","Million US$, purchasing power parity","DEU","Germany","2020","2020",6298.7,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","MTMOPPMT","Million US$, purchasing power parity","DEU","Germany","2021","2021",7185.7,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","TCPPERMT","/capita, US$ exchange rate","DEU","Germany","2010","2010",26.8,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","TCPPERMT","/capita, US$ exchange rate","DEU","Germany","2011","2011",27.6,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","TCPPERMT","/capita, US$ exchange rate","DEU","Germany","2012","2012",28.1,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","TCPPERMT","/capita, US$ exchange rate","DEU","Germany","2013","2013",33.2,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","TCPPERMT","/capita, US$ exchange rate","DEU","Germany","2014","2014",38,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","TCPPERMT","/capita, US$ exchange rate","DEU","Germany","2015","2015",34.8,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","TCPPERMT","/capita, US$ exchange rate","DEU","Germany","2016","2016",38.1,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","TCPPERMT","/capita, US$ exchange rate","DEU","Germany","2017","2017",43.3,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","TCPPERMT","/capita, US$ exchange rate","DEU","Germany","2018","2018",52.3,"B; D","Break; Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","TCPPERMT","/capita, US$ exchange rate","DEU","Germany","2019","2019",54.8,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","TCPPERMT","/capita, US$ exchange rate","DEU","Germany","2020","2020",62.7,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","TCPPERMT","/capita, US$ exchange rate","DEU","Germany","2021","2021",75.2,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2010","2010",25.1,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2011","2011",25.2,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2012","2012",27.8,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2013","2013",32.2,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2014","2014",37.2,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2015","2015",40.3,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2016","2016",45.8,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2017","2017",51.5,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2018","2018",60.3,"B; D","Break; Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2019","2019",67.2,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2020","2020",75.7,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2021","2021",86.4,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","ATCPTTMT","% of total sales","DEU","Germany","2010","2010",5.6,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","ATCPTTMT","% of total sales","DEU","Germany","2011","2011",5.4,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","ATCPTTMT","% of total sales","DEU","Germany","2012","2012",5.8,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","ATCPTTMT","% of total sales","DEU","Germany","2013","2013",6.4,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","ATCPTTMT","% of total sales","DEU","Germany","2014","2014",6.9,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","ATCPTTMT","% of total sales","DEU","Germany","2015","2015",7.3,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","ATCPTTMT","% of total sales","DEU","Germany","2016","2016",7.9,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","ATCPTTMT","% of total sales","DEU","Germany","2017","2017",8.5,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","ATCPTTMT","% of total sales","DEU","Germany","2018","2018",8.3,"B; D","Break; Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","ATCPTTMT","% of total sales","DEU","Germany","2019","2019",8.7,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","ATCPTTMT","% of total sales","DEU","Germany","2020","2020",9.3,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","ATCPTTMT","% of total sales","DEU","Germany","2021","2021",9.9,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","MLLNCUMT","Million of national currency units","GRC","Greece","2010","2010",643.7,,
+"PATCBLOO","B-Blood and blood forming organs","MLLNCUMT","Million of national currency units","GRC","Greece","2011","2011",579.4,,
+"PATCBLOO","B-Blood and blood forming organs","MLLNCUMT","Million of national currency units","GRC","Greece","2012","2012",509.9,,
+"PATCBLOO","B-Blood and blood forming organs","MLLNCUMT","Million of national currency units","GRC","Greece","2013","2013",463.7,,
+"PATCBLOO","B-Blood and blood forming organs","MLLNCUMT","Million of national currency units","GRC","Greece","2014","2014",492,,
+"PATCBLOO","B-Blood and blood forming organs","MLLNCUMT","Million of national currency units","GRC","Greece","2015","2015",449.2,,
+"PATCBLOO","B-Blood and blood forming organs","MLLNCUMT","Million of national currency units","GRC","Greece","2016","2016",1701.7,,
+"PATCBLOO","B-Blood and blood forming organs","MLLNCUMT","Million of national currency units","GRC","Greece","2017","2017",1024.6,,
+"PATCBLOO","B-Blood and blood forming organs","MLLNCUMT","Million of national currency units","GRC","Greece","2018","2018",1090.7,,
+"PATCBLOO","B-Blood and blood forming organs","MLLNCUMT","Million of national currency units","GRC","Greece","2019","2019",809.9,,
+"PATCBLOO","B-Blood and blood forming organs","MLLNCUMT","Million of national currency units","GRC","Greece","2020","2020",765,,
+"PATCBLOO","B-Blood and blood forming organs","MLLNCUMT","Million of national currency units","GRC","Greece","2021","2021",819.3,,
+"PATCBLOO","B-Blood and blood forming organs","MLLNCUMT","Million of national currency units","GRC","Greece","2022","2022",810.8,,
+"PATCBLOO","B-Blood and blood forming organs","MTMOTCMT","Million US$ at exchange rate","GRC","Greece","2010","2010",853.4,,
+"PATCBLOO","B-Blood and blood forming organs","MTMOTCMT","Million US$ at exchange rate","GRC","Greece","2011","2011",806.5,,
+"PATCBLOO","B-Blood and blood forming organs","MTMOTCMT","Million US$ at exchange rate","GRC","Greece","2012","2012",655.1,,
+"PATCBLOO","B-Blood and blood forming organs","MTMOTCMT","Million US$ at exchange rate","GRC","Greece","2013","2013",615.8,,
+"PATCBLOO","B-Blood and blood forming organs","MTMOTCMT","Million US$ at exchange rate","GRC","Greece","2014","2014",653.6,,
+"PATCBLOO","B-Blood and blood forming organs","MTMOTCMT","Million US$ at exchange rate","GRC","Greece","2015","2015",498.4,,
+"PATCBLOO","B-Blood and blood forming organs","MTMOTCMT","Million US$ at exchange rate","GRC","Greece","2016","2016",1883.7,,
+"PATCBLOO","B-Blood and blood forming organs","MTMOTCMT","Million US$ at exchange rate","GRC","Greece","2017","2017",1157.5,,
+"PATCBLOO","B-Blood and blood forming organs","MTMOTCMT","Million US$ at exchange rate","GRC","Greece","2018","2018",1288.1,,
+"PATCBLOO","B-Blood and blood forming organs","MTMOTCMT","Million US$ at exchange rate","GRC","Greece","2019","2019",906.7,,
+"PATCBLOO","B-Blood and blood forming organs","MTMOTCMT","Million US$ at exchange rate","GRC","Greece","2020","2020",873.8,,
+"PATCBLOO","B-Blood and blood forming organs","MTMOTCMT","Million US$ at exchange rate","GRC","Greece","2021","2021",969,,
+"PATCBLOO","B-Blood and blood forming organs","MTMOTCMT","Million US$ at exchange rate","GRC","Greece","2022","2022",853.8,,
+"PATCBLOO","B-Blood and blood forming organs","MTMOPPMT","Million US$, purchasing power parity","GRC","Greece","2010","2010",891.6,,
+"PATCBLOO","B-Blood and blood forming organs","MTMOPPMT","Million US$, purchasing power parity","GRC","Greece","2011","2011",812.5,,
+"PATCBLOO","B-Blood and blood forming organs","MTMOPPMT","Million US$, purchasing power parity","GRC","Greece","2012","2012",744.8,,
+"PATCBLOO","B-Blood and blood forming organs","MTMOPPMT","Million US$, purchasing power parity","GRC","Greece","2013","2013",734.5,,
+"PATCBLOO","B-Blood and blood forming organs","MTMOPPMT","Million US$, purchasing power parity","GRC","Greece","2014","2014",805.1,,
+"PATCBLOO","B-Blood and blood forming organs","MTMOPPMT","Million US$, purchasing power parity","GRC","Greece","2015","2015",737.5,,
+"PATCBLOO","B-Blood and blood forming organs","MTMOPPMT","Million US$, purchasing power parity","GRC","Greece","2016","2016",2891.3,,
+"PATCBLOO","B-Blood and blood forming organs","MTMOPPMT","Million US$, purchasing power parity","GRC","Greece","2017","2017",1781.9,,
+"PATCBLOO","B-Blood and blood forming organs","MTMOPPMT","Million US$, purchasing power parity","GRC","Greece","2018","2018",1931,,
+"PATCBLOO","B-Blood and blood forming organs","MTMOPPMT","Million US$, purchasing power parity","GRC","Greece","2019","2019",1475.5,,
+"PATCBLOO","B-Blood and blood forming organs","MTMOPPMT","Million US$, purchasing power parity","GRC","Greece","2020","2020",1406.1,,
+"PATCBLOO","B-Blood and blood forming organs","MTMOPPMT","Million US$, purchasing power parity","GRC","Greece","2021","2021",1501.8,,
+"PATCBLOO","B-Blood and blood forming organs","MTMOPPMT","Million US$, purchasing power parity","GRC","Greece","2022","2022",1534.1,,
+"PATCBLOO","B-Blood and blood forming organs","TCPPERMT","/capita, US$ exchange rate","GRC","Greece","2010","2010",76.7,,
+"PATCBLOO","B-Blood and blood forming organs","TCPPERMT","/capita, US$ exchange rate","GRC","Greece","2011","2011",72.6,,
+"PATCBLOO","B-Blood and blood forming organs","TCPPERMT","/capita, US$ exchange rate","GRC","Greece","2012","2012",59.3,,
+"PATCBLOO","B-Blood and blood forming organs","TCPPERMT","/capita, US$ exchange rate","GRC","Greece","2013","2013",56.2,,
+"PATCBLOO","B-Blood and blood forming organs","TCPPERMT","/capita, US$ exchange rate","GRC","Greece","2014","2014",60,,
+"PATCBLOO","B-Blood and blood forming organs","TCPPERMT","/capita, US$ exchange rate","GRC","Greece","2015","2015",46.1,,
+"PATCBLOO","B-Blood and blood forming organs","TCPPERMT","/capita, US$ exchange rate","GRC","Greece","2016","2016",174.8,,
+"PATCBLOO","B-Blood and blood forming organs","TCPPERMT","/capita, US$ exchange rate","GRC","Greece","2017","2017",107.6,,
+"PATCBLOO","B-Blood and blood forming organs","TCPPERMT","/capita, US$ exchange rate","GRC","Greece","2018","2018",120,,
+"PATCBLOO","B-Blood and blood forming organs","TCPPERMT","/capita, US$ exchange rate","GRC","Greece","2019","2019",84.6,,
+"PATCBLOO","B-Blood and blood forming organs","TCPPERMT","/capita, US$ exchange rate","GRC","Greece","2020","2020",81.7,,
+"PATCBLOO","B-Blood and blood forming organs","TCPPERMT","/capita, US$ exchange rate","GRC","Greece","2021","2021",91.7,,
+"PATCBLOO","B-Blood and blood forming organs","TCPPERMT","/capita, US$ exchange rate","GRC","Greece","2022","2022",81.6,,
+"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2010","2010",80.2,,
+"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2011","2011",73.2,,
+"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2012","2012",67.4,,
+"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2013","2013",67,,
+"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2014","2014",73.9,,
+"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2015","2015",68.2,,
+"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2016","2016",268.3,,
+"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2017","2017",165.7,,
+"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2018","2018",179.9,,
+"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2019","2019",137.6,,
+"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2020","2020",131.4,,
+"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2021","2021",142.1,,
+"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2022","2022",146.7,,
+"PATCBLOO","B-Blood and blood forming organs","MLLNCUMT","Million of national currency units","HUN","Hungary","2010","2010",39342.1,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","MLLNCUMT","Million of national currency units","HUN","Hungary","2011","2011",40274.7,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","MLLNCUMT","Million of national currency units","HUN","Hungary","2012","2012",39070,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","MLLNCUMT","Million of national currency units","HUN","Hungary","2013","2013",38973.8,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","MLLNCUMT","Million of national currency units","HUN","Hungary","2014","2014",43658.2,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","MLLNCUMT","Million of national currency units","HUN","Hungary","2015","2015",48375.2,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","MLLNCUMT","Million of national currency units","HUN","Hungary","2016","2016",53187.8,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","MLLNCUMT","Million of national currency units","HUN","Hungary","2017","2017",50338.2,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","MLLNCUMT","Million of national currency units","HUN","Hungary","2018","2018",46539.5,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","MLLNCUMT","Million of national currency units","HUN","Hungary","2019","2019",53924.7,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","MLLNCUMT","Million of national currency units","HUN","Hungary","2020","2020",61036.6,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","MLLNCUMT","Million of national currency units","HUN","Hungary","2021","2021",67066,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","MLLNCUMT","Million of national currency units","HUN","Hungary","2022","2022",72200.3,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","MTMOTCMT","Million US$ at exchange rate","HUN","Hungary","2010","2010",189.2,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","MTMOTCMT","Million US$ at exchange rate","HUN","Hungary","2011","2011",200.3,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","MTMOTCMT","Million US$ at exchange rate","HUN","Hungary","2012","2012",173.6,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","MTMOTCMT","Million US$ at exchange rate","HUN","Hungary","2013","2013",174.2,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","MTMOTCMT","Million US$ at exchange rate","HUN","Hungary","2014","2014",187.7,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","MTMOTCMT","Million US$ at exchange rate","HUN","Hungary","2015","2015",173.2,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","MTMOTCMT","Million US$ at exchange rate","HUN","Hungary","2016","2016",188.9,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","MTMOTCMT","Million US$ at exchange rate","HUN","Hungary","2017","2017",183.4,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","MTMOTCMT","Million US$ at exchange rate","HUN","Hungary","2018","2018",172.2,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","MTMOTCMT","Million US$ at exchange rate","HUN","Hungary","2019","2019",185.5,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","MTMOTCMT","Million US$ at exchange rate","HUN","Hungary","2020","2020",198.2,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","MTMOTCMT","Million US$ at exchange rate","HUN","Hungary","2021","2021",221.2,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","MTMOTCMT","Million US$ at exchange rate","HUN","Hungary","2022","2022",193.8,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","MTMOPPMT","Million US$, purchasing power parity","HUN","Hungary","2010","2010",311.2,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","MTMOPPMT","Million US$, purchasing power parity","HUN","Hungary","2011","2011",324.1,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","MTMOPPMT","Million US$, purchasing power parity","HUN","Hungary","2012","2012",311,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","MTMOPPMT","Million US$, purchasing power parity","HUN","Hungary","2013","2013",311.8,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","MTMOPPMT","Million US$, purchasing power parity","HUN","Hungary","2014","2014",337.4,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","MTMOPPMT","Million US$, purchasing power parity","HUN","Hungary","2015","2015",364.9,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","MTMOPPMT","Million US$, purchasing power parity","HUN","Hungary","2016","2016",402.8,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","MTMOPPMT","Million US$, purchasing power parity","HUN","Hungary","2017","2017",370,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","MTMOPPMT","Million US$, purchasing power parity","HUN","Hungary","2018","2018",334.6,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","MTMOPPMT","Million US$, purchasing power parity","HUN","Hungary","2019","2019",382.9,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","MTMOPPMT","Million US$, purchasing power parity","HUN","Hungary","2020","2020",419.9,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","MTMOPPMT","Million US$, purchasing power parity","HUN","Hungary","2021","2021",433.4,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","MTMOPPMT","Million US$, purchasing power parity","HUN","Hungary","2022","2022",447.8,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","TCPPERMT","/capita, US$ exchange rate","HUN","Hungary","2010","2010",18.9,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","TCPPERMT","/capita, US$ exchange rate","HUN","Hungary","2011","2011",20.1,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","TCPPERMT","/capita, US$ exchange rate","HUN","Hungary","2012","2012",17.5,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","TCPPERMT","/capita, US$ exchange rate","HUN","Hungary","2013","2013",17.6,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","TCPPERMT","/capita, US$ exchange rate","HUN","Hungary","2014","2014",19,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","TCPPERMT","/capita, US$ exchange rate","HUN","Hungary","2015","2015",17.6,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","TCPPERMT","/capita, US$ exchange rate","HUN","Hungary","2016","2016",19.3,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","TCPPERMT","/capita, US$ exchange rate","HUN","Hungary","2017","2017",18.7,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","TCPPERMT","/capita, US$ exchange rate","HUN","Hungary","2018","2018",17.6,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","TCPPERMT","/capita, US$ exchange rate","HUN","Hungary","2019","2019",19,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","TCPPERMT","/capita, US$ exchange rate","HUN","Hungary","2020","2020",20.3,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","TCPPERMT","/capita, US$ exchange rate","HUN","Hungary","2021","2021",22.8,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","TCPPERMT","/capita, US$ exchange rate","HUN","Hungary","2022","2022",20,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2010","2010",31.1,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2011","2011",32.5,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2012","2012",31.4,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2013","2013",31.5,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2014","2014",34.2,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2015","2015",37.1,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2016","2016",41,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2017","2017",37.8,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2018","2018",34.2,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2019","2019",39.2,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2020","2020",43.1,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2021","2021",44.6,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2022","2022",46.2,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","ATCPTTMT","% of total sales","HUN","Hungary","2010","2010",7.9,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","ATCPTTMT","% of total sales","HUN","Hungary","2011","2011",7.8,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","ATCPTTMT","% of total sales","HUN","Hungary","2012","2012",8.8,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","ATCPTTMT","% of total sales","HUN","Hungary","2013","2013",9.1,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","ATCPTTMT","% of total sales","HUN","Hungary","2014","2014",9.9,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","ATCPTTMT","% of total sales","HUN","Hungary","2015","2015",10.4,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","ATCPTTMT","% of total sales","HUN","Hungary","2016","2016",10.7,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","ATCPTTMT","% of total sales","HUN","Hungary","2017","2017",10.2,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","ATCPTTMT","% of total sales","HUN","Hungary","2018","2018",9.3,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","ATCPTTMT","% of total sales","HUN","Hungary","2019","2019",10.2,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","ATCPTTMT","% of total sales","HUN","Hungary","2020","2020",10.9,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","ATCPTTMT","% of total sales","HUN","Hungary","2021","2021",11.8,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","ATCPTTMT","% of total sales","HUN","Hungary","2022","2022",12.1,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","MLLNCUMT","Million of national currency units","ISL","Iceland","2010","2010",1316,,
+"PATCBLOO","B-Blood and blood forming organs","MLLNCUMT","Million of national currency units","ISL","Iceland","2011","2011",1283.9,,
+"PATCBLOO","B-Blood and blood forming organs","MLLNCUMT","Million of national currency units","ISL","Iceland","2012","2012",1325.5,,
+"PATCBLOO","B-Blood and blood forming organs","MLLNCUMT","Million of national currency units","ISL","Iceland","2013","2013",1557,,
+"PATCBLOO","B-Blood and blood forming organs","MLLNCUMT","Million of national currency units","ISL","Iceland","2014","2014",1526.6,,
+"PATCBLOO","B-Blood and blood forming organs","MLLNCUMT","Million of national currency units","ISL","Iceland","2015","2015",1575.9,,
+"PATCBLOO","B-Blood and blood forming organs","MLLNCUMT","Million of national currency units","ISL","Iceland","2016","2016",1922.6,,
+"PATCBLOO","B-Blood and blood forming organs","MLLNCUMT","Million of national currency units","ISL","Iceland","2017","2017",1768.1,,
+"PATCBLOO","B-Blood and blood forming organs","MLLNCUMT","Million of national currency units","ISL","Iceland","2018","2018",1992.3,,
+"PATCBLOO","B-Blood and blood forming organs","MLLNCUMT","Million of national currency units","ISL","Iceland","2019","2019",2454,,
+"PATCBLOO","B-Blood and blood forming organs","MLLNCUMT","Million of national currency units","ISL","Iceland","2020","2020",2952.6,,
+"PATCBLOO","B-Blood and blood forming organs","MLLNCUMT","Million of national currency units","ISL","Iceland","2021","2021",3356.2,,
+"PATCBLOO","B-Blood and blood forming organs","MTMOTCMT","Million US$ at exchange rate","ISL","Iceland","2010","2010",10.8,,
+"PATCBLOO","B-Blood and blood forming organs","MTMOTCMT","Million US$ at exchange rate","ISL","Iceland","2011","2011",11.1,,
+"PATCBLOO","B-Blood and blood forming organs","MTMOTCMT","Million US$ at exchange rate","ISL","Iceland","2012","2012",10.6,,
+"PATCBLOO","B-Blood and blood forming organs","MTMOTCMT","Million US$ at exchange rate","ISL","Iceland","2013","2013",12.7,,
+"PATCBLOO","B-Blood and blood forming organs","MTMOTCMT","Million US$ at exchange rate","ISL","Iceland","2014","2014",13.1,,
+"PATCBLOO","B-Blood and blood forming organs","MTMOTCMT","Million US$ at exchange rate","ISL","Iceland","2015","2015",11.9,,
+"PATCBLOO","B-Blood and blood forming organs","MTMOTCMT","Million US$ at exchange rate","ISL","Iceland","2016","2016",15.9,,
+"PATCBLOO","B-Blood and blood forming organs","MTMOTCMT","Million US$ at exchange rate","ISL","Iceland","2017","2017",16.5,,
+"PATCBLOO","B-Blood and blood forming organs","MTMOTCMT","Million US$ at exchange rate","ISL","Iceland","2018","2018",18.4,,
+"PATCBLOO","B-Blood and blood forming organs","MTMOTCMT","Million US$ at exchange rate","ISL","Iceland","2019","2019",20,,
+"PATCBLOO","B-Blood and blood forming organs","MTMOTCMT","Million US$ at exchange rate","ISL","Iceland","2020","2020",21.8,,
+"PATCBLOO","B-Blood and blood forming organs","MTMOTCMT","Million US$ at exchange rate","ISL","Iceland","2021","2021",26.4,,
+"PATCBLOO","B-Blood and blood forming organs","MTMOPPMT","Million US$, purchasing power parity","ISL","Iceland","2010","2010",9.9,,
+"PATCBLOO","B-Blood and blood forming organs","MTMOPPMT","Million US$, purchasing power parity","ISL","Iceland","2011","2011",9.5,,
+"PATCBLOO","B-Blood and blood forming organs","MTMOPPMT","Million US$, purchasing power parity","ISL","Iceland","2012","2012",9.7,,
+"PATCBLOO","B-Blood and blood forming organs","MTMOPPMT","Million US$, purchasing power parity","ISL","Iceland","2013","2013",11.4,,
+"PATCBLOO","B-Blood and blood forming organs","MTMOPPMT","Million US$, purchasing power parity","ISL","Iceland","2014","2014",11,,
+"PATCBLOO","B-Blood and blood forming organs","MTMOPPMT","Million US$, purchasing power parity","ISL","Iceland","2015","2015",11.1,,
+"PATCBLOO","B-Blood and blood forming organs","MTMOPPMT","Million US$, purchasing power parity","ISL","Iceland","2016","2016",13.7,,
+"PATCBLOO","B-Blood and blood forming organs","MTMOPPMT","Million US$, purchasing power parity","ISL","Iceland","2017","2017",12.8,,
+"PATCBLOO","B-Blood and blood forming organs","MTMOPPMT","Million US$, purchasing power parity","ISL","Iceland","2018","2018",14.1,,
+"PATCBLOO","B-Blood and blood forming organs","MTMOPPMT","Million US$, purchasing power parity","ISL","Iceland","2019","2019",17.4,,
+"PATCBLOO","B-Blood and blood forming organs","MTMOPPMT","Million US$, purchasing power parity","ISL","Iceland","2020","2020",20.1,,
+"PATCBLOO","B-Blood and blood forming organs","MTMOPPMT","Million US$, purchasing power parity","ISL","Iceland","2021","2021",22.4,,
+"PATCBLOO","B-Blood and blood forming organs","TCPPERMT","/capita, US$ exchange rate","ISL","Iceland","2010","2010",33.8,,
+"PATCBLOO","B-Blood and blood forming organs","TCPPERMT","/capita, US$ exchange rate","ISL","Iceland","2011","2011",34.7,,
+"PATCBLOO","B-Blood and blood forming organs","TCPPERMT","/capita, US$ exchange rate","ISL","Iceland","2012","2012",33,,
+"PATCBLOO","B-Blood and blood forming organs","TCPPERMT","/capita, US$ exchange rate","ISL","Iceland","2013","2013",39.4,,
+"PATCBLOO","B-Blood and blood forming organs","TCPPERMT","/capita, US$ exchange rate","ISL","Iceland","2014","2014",39.9,,
+"PATCBLOO","B-Blood and blood forming organs","TCPPERMT","/capita, US$ exchange rate","ISL","Iceland","2015","2015",36.1,,
+"PATCBLOO","B-Blood and blood forming organs","TCPPERMT","/capita, US$ exchange rate","ISL","Iceland","2016","2016",47.4,,
+"PATCBLOO","B-Blood and blood forming organs","TCPPERMT","/capita, US$ exchange rate","ISL","Iceland","2017","2017",48.2,,
+"PATCBLOO","B-Blood and blood forming organs","TCPPERMT","/capita, US$ exchange rate","ISL","Iceland","2018","2018",52.2,,
+"PATCBLOO","B-Blood and blood forming organs","TCPPERMT","/capita, US$ exchange rate","ISL","Iceland","2019","2019",55.5,,
+"PATCBLOO","B-Blood and blood forming organs","TCPPERMT","/capita, US$ exchange rate","ISL","Iceland","2020","2020",59.5,,
+"PATCBLOO","B-Blood and blood forming organs","TCPPERMT","/capita, US$ exchange rate","ISL","Iceland","2021","2021",70.9,,
+"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2010","2010",31.1,,
+"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2011","2011",29.8,,
+"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2012","2012",30.2,,
+"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2013","2013",35.1,,
+"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2014","2014",33.7,,
+"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2015","2015",33.6,,
+"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2016","2016",40.9,,
+"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2017","2017",37.2,,
+"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2018","2018",40.1,,
+"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2019","2019",48.4,,
+"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2020","2020",54.9,,
+"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2021","2021",60.2,,
+"PATCBLOO","B-Blood and blood forming organs","ATCPTTMT","% of total sales","ISL","Iceland","2010","2010",5.3,,
+"PATCBLOO","B-Blood and blood forming organs","ATCPTTMT","% of total sales","ISL","Iceland","2011","2011",4.9,,
+"PATCBLOO","B-Blood and blood forming organs","ATCPTTMT","% of total sales","ISL","Iceland","2012","2012",5.5,,
+"PATCBLOO","B-Blood and blood forming organs","ATCPTTMT","% of total sales","ISL","Iceland","2013","2013",6,,
+"PATCBLOO","B-Blood and blood forming organs","ATCPTTMT","% of total sales","ISL","Iceland","2014","2014",6.4,,
+"PATCBLOO","B-Blood and blood forming organs","ATCPTTMT","% of total sales","ISL","Iceland","2015","2015",6.5,,
+"PATCBLOO","B-Blood and blood forming organs","ATCPTTMT","% of total sales","ISL","Iceland","2016","2016",7.6,,
+"PATCBLOO","B-Blood and blood forming organs","ATCPTTMT","% of total sales","ISL","Iceland","2017","2017",6.7,,
+"PATCBLOO","B-Blood and blood forming organs","ATCPTTMT","% of total sales","ISL","Iceland","2018","2018",6.6,,
+"PATCBLOO","B-Blood and blood forming organs","ATCPTTMT","% of total sales","ISL","Iceland","2019","2019",7.3,,
+"PATCBLOO","B-Blood and blood forming organs","ATCPTTMT","% of total sales","ISL","Iceland","2020","2020",7.4,,
+"PATCBLOO","B-Blood and blood forming organs","ATCPTTMT","% of total sales","ISL","Iceland","2021","2021",7.4,,
+"PATCBLOO","B-Blood and blood forming organs","MLLNCUMT","Million of national currency units","IRL","Ireland","2010","2010",93.9,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","MLLNCUMT","Million of national currency units","IRL","Ireland","2011","2011",89.8,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","MLLNCUMT","Million of national currency units","IRL","Ireland","2012","2012",91.6,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","MLLNCUMT","Million of national currency units","IRL","Ireland","2013","2013",89.7,"B; D","Break; Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","MLLNCUMT","Million of national currency units","IRL","Ireland","2014","2014",90.5,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","MLLNCUMT","Million of national currency units","IRL","Ireland","2015","2015",95.2,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","MLLNCUMT","Million of national currency units","IRL","Ireland","2016","2016",104.9,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","MLLNCUMT","Million of national currency units","IRL","Ireland","2017","2017",113.1,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","MLLNCUMT","Million of national currency units","IRL","Ireland","2018","2018",123.7,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","MLLNCUMT","Million of national currency units","IRL","Ireland","2019","2019",132.1,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","MLLNCUMT","Million of national currency units","IRL","Ireland","2020","2020",141.4,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","MLLNCUMT","Million of national currency units","IRL","Ireland","2021","2021",148.3,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","MTMOTCMT","Million US$ at exchange rate","IRL","Ireland","2010","2010",124.5,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","MTMOTCMT","Million US$ at exchange rate","IRL","Ireland","2011","2011",124.9,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","MTMOTCMT","Million US$ at exchange rate","IRL","Ireland","2012","2012",117.7,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","MTMOTCMT","Million US$ at exchange rate","IRL","Ireland","2013","2013",119.2,"B; D","Break; Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","MTMOTCMT","Million US$ at exchange rate","IRL","Ireland","2014","2014",120.2,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","MTMOTCMT","Million US$ at exchange rate","IRL","Ireland","2015","2015",105.6,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","MTMOTCMT","Million US$ at exchange rate","IRL","Ireland","2016","2016",116.1,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","MTMOTCMT","Million US$ at exchange rate","IRL","Ireland","2017","2017",127.8,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","MTMOTCMT","Million US$ at exchange rate","IRL","Ireland","2018","2018",146.1,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","MTMOTCMT","Million US$ at exchange rate","IRL","Ireland","2019","2019",147.9,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","MTMOTCMT","Million US$ at exchange rate","IRL","Ireland","2020","2020",161.5,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","MTMOTCMT","Million US$ at exchange rate","IRL","Ireland","2021","2021",175.4,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","MTMOPPMT","Million US$, purchasing power parity","IRL","Ireland","2010","2010",110.6,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","MTMOPPMT","Million US$, purchasing power parity","IRL","Ireland","2011","2011",107.9,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","MTMOPPMT","Million US$, purchasing power parity","IRL","Ireland","2012","2012",111.3,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","MTMOPPMT","Million US$, purchasing power parity","IRL","Ireland","2013","2013",110.6,"B; D","Break; Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","MTMOPPMT","Million US$, purchasing power parity","IRL","Ireland","2014","2014",110.5,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","MTMOPPMT","Million US$, purchasing power parity","IRL","Ireland","2015","2015",117.5,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","MTMOPPMT","Million US$, purchasing power parity","IRL","Ireland","2016","2016",132.1,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","MTMOPPMT","Million US$, purchasing power parity","IRL","Ireland","2017","2017",142.4,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","MTMOPPMT","Million US$, purchasing power parity","IRL","Ireland","2018","2018",156.1,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","MTMOPPMT","Million US$, purchasing power parity","IRL","Ireland","2019","2019",164,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","MTMOPPMT","Million US$, purchasing power parity","IRL","Ireland","2020","2020",177.6,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","MTMOPPMT","Million US$, purchasing power parity","IRL","Ireland","2021","2021",186.6,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","TCPPERMT","/capita, US$ exchange rate","IRL","Ireland","2010","2010",27.3,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","TCPPERMT","/capita, US$ exchange rate","IRL","Ireland","2011","2011",27.3,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","TCPPERMT","/capita, US$ exchange rate","IRL","Ireland","2012","2012",25.6,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","TCPPERMT","/capita, US$ exchange rate","IRL","Ireland","2013","2013",25.8,"B; D","Break; Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","TCPPERMT","/capita, US$ exchange rate","IRL","Ireland","2014","2014",25.8,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","TCPPERMT","/capita, US$ exchange rate","IRL","Ireland","2015","2015",22.5,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","TCPPERMT","/capita, US$ exchange rate","IRL","Ireland","2016","2016",24.4,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","TCPPERMT","/capita, US$ exchange rate","IRL","Ireland","2017","2017",26.6,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","TCPPERMT","/capita, US$ exchange rate","IRL","Ireland","2018","2018",30,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","TCPPERMT","/capita, US$ exchange rate","IRL","Ireland","2019","2019",30,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","TCPPERMT","/capita, US$ exchange rate","IRL","Ireland","2020","2020",32.4,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","TCPPERMT","/capita, US$ exchange rate","IRL","Ireland","2021","2021",34.9,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2010","2010",24.2,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2011","2011",23.6,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2012","2012",24.2,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2013","2013",23.9,"B; D","Break; Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2014","2014",23.7,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2015","2015",25,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2016","2016",27.8,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2017","2017",29.6,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2018","2018",32.1,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2019","2019",33.2,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2020","2020",35.6,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2021","2021",37.1,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","ATCPTTMT","% of total sales","IRL","Ireland","2010","2010",4.6,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","ATCPTTMT","% of total sales","IRL","Ireland","2011","2011",4.6,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","ATCPTTMT","% of total sales","IRL","Ireland","2012","2012",4.5,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","ATCPTTMT","% of total sales","IRL","Ireland","2013","2013",4.6,"B; D","Break; Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","ATCPTTMT","% of total sales","IRL","Ireland","2014","2014",4.7,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","ATCPTTMT","% of total sales","IRL","Ireland","2015","2015",4.8,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","ATCPTTMT","% of total sales","IRL","Ireland","2016","2016",5.1,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","ATCPTTMT","% of total sales","IRL","Ireland","2017","2017",5.3,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","ATCPTTMT","% of total sales","IRL","Ireland","2018","2018",5.5,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","ATCPTTMT","% of total sales","IRL","Ireland","2019","2019",5.5,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","ATCPTTMT","% of total sales","IRL","Ireland","2020","2020",5.7,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","ATCPTTMT","% of total sales","IRL","Ireland","2021","2021",5.7,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","MLLNCUMT","Million of national currency units","ITA","Italy","2011","2011",1775.5,,
+"PATCBLOO","B-Blood and blood forming organs","MLLNCUMT","Million of national currency units","ITA","Italy","2012","2012",1764.8,,
+"PATCBLOO","B-Blood and blood forming organs","MLLNCUMT","Million of national currency units","ITA","Italy","2013","2013",1717.3,,
+"PATCBLOO","B-Blood and blood forming organs","MLLNCUMT","Million of national currency units","ITA","Italy","2014","2014",1853.9,,
+"PATCBLOO","B-Blood and blood forming organs","MLLNCUMT","Million of national currency units","ITA","Italy","2015","2015",1981.9,,
+"PATCBLOO","B-Blood and blood forming organs","MLLNCUMT","Million of national currency units","ITA","Italy","2016","2016",2027,,
+"PATCBLOO","B-Blood and blood forming organs","MLLNCUMT","Million of national currency units","ITA","Italy","2017","2017",2088.3,,
+"PATCBLOO","B-Blood and blood forming organs","MLLNCUMT","Million of national currency units","ITA","Italy","2018","2018",2082.5,,
+"PATCBLOO","B-Blood and blood forming organs","MLLNCUMT","Million of national currency units","ITA","Italy","2019","2019",2178.9,,
+"PATCBLOO","B-Blood and blood forming organs","MLLNCUMT","Million of national currency units","ITA","Italy","2020","2020",2304.7,,
+"PATCBLOO","B-Blood and blood forming organs","MLLNCUMT","Million of national currency units","ITA","Italy","2021","2021",2349.4,,
+"PATCBLOO","B-Blood and blood forming organs","MLLNCUMT","Million of national currency units","ITA","Italy","2022","2022",2406.8,"E","Estimated value"
+"PATCBLOO","B-Blood and blood forming organs","MTMOTCMT","Million US$ at exchange rate","ITA","Italy","2011","2011",2471.4,,
+"PATCBLOO","B-Blood and blood forming organs","MTMOTCMT","Million US$ at exchange rate","ITA","Italy","2012","2012",2267.4,,
+"PATCBLOO","B-Blood and blood forming organs","MTMOTCMT","Million US$ at exchange rate","ITA","Italy","2013","2013",2280.7,,
+"PATCBLOO","B-Blood and blood forming organs","MTMOTCMT","Million US$ at exchange rate","ITA","Italy","2014","2014",2462.9,,
+"PATCBLOO","B-Blood and blood forming organs","MTMOTCMT","Million US$ at exchange rate","ITA","Italy","2015","2015",2198.9,,
+"PATCBLOO","B-Blood and blood forming organs","MTMOTCMT","Million US$ at exchange rate","ITA","Italy","2016","2016",2243.7,,
+"PATCBLOO","B-Blood and blood forming organs","MTMOTCMT","Million US$ at exchange rate","ITA","Italy","2017","2017",2359.1,,
+"PATCBLOO","B-Blood and blood forming organs","MTMOTCMT","Million US$ at exchange rate","ITA","Italy","2018","2018",2459.4,,
+"PATCBLOO","B-Blood and blood forming organs","MTMOTCMT","Million US$ at exchange rate","ITA","Italy","2019","2019",2439.2,,
+"PATCBLOO","B-Blood and blood forming organs","MTMOTCMT","Million US$ at exchange rate","ITA","Italy","2020","2020",2632.4,,
+"PATCBLOO","B-Blood and blood forming organs","MTMOTCMT","Million US$ at exchange rate","ITA","Italy","2021","2021",2778.7,,
+"PATCBLOO","B-Blood and blood forming organs","MTMOTCMT","Million US$ at exchange rate","ITA","Italy","2022","2022",2534.4,"E","Estimated value"
+"PATCBLOO","B-Blood and blood forming organs","MTMOPPMT","Million US$, purchasing power parity","ITA","Italy","2011","2011",2340.2,,
+"PATCBLOO","B-Blood and blood forming organs","MTMOPPMT","Million US$, purchasing power parity","ITA","Italy","2012","2012",2360.2,,
+"PATCBLOO","B-Blood and blood forming organs","MTMOPPMT","Million US$, purchasing power parity","ITA","Italy","2013","2013",2329.1,,
+"PATCBLOO","B-Blood and blood forming organs","MTMOPPMT","Million US$, purchasing power parity","ITA","Italy","2014","2014",2506.4,,
+"PATCBLOO","B-Blood and blood forming organs","MTMOPPMT","Million US$, purchasing power parity","ITA","Italy","2015","2015",2683,,
+"PATCBLOO","B-Blood and blood forming organs","MTMOPPMT","Million US$, purchasing power parity","ITA","Italy","2016","2016",2893.5,,
+"PATCBLOO","B-Blood and blood forming organs","MTMOPPMT","Million US$, purchasing power parity","ITA","Italy","2017","2017",3027,,
+"PATCBLOO","B-Blood and blood forming organs","MTMOPPMT","Million US$, purchasing power parity","ITA","Italy","2018","2018",3057.1,,
+"PATCBLOO","B-Blood and blood forming organs","MTMOPPMT","Million US$, purchasing power parity","ITA","Italy","2019","2019",3317.5,,
+"PATCBLOO","B-Blood and blood forming organs","MTMOPPMT","Million US$, purchasing power parity","ITA","Italy","2020","2020",3558.2,,
+"PATCBLOO","B-Blood and blood forming organs","MTMOPPMT","Million US$, purchasing power parity","ITA","Italy","2021","2021",3628.1,,
+"PATCBLOO","B-Blood and blood forming organs","MTMOPPMT","Million US$, purchasing power parity","ITA","Italy","2022","2022",3898.1,"E","Estimated value"
+"PATCBLOO","B-Blood and blood forming organs","TCPPERMT","/capita, US$ exchange rate","ITA","Italy","2011","2011",41.6,,
+"PATCBLOO","B-Blood and blood forming organs","TCPPERMT","/capita, US$ exchange rate","ITA","Italy","2012","2012",38.1,,
+"PATCBLOO","B-Blood and blood forming organs","TCPPERMT","/capita, US$ exchange rate","ITA","Italy","2013","2013",37.9,,
+"PATCBLOO","B-Blood and blood forming organs","TCPPERMT","/capita, US$ exchange rate","ITA","Italy","2014","2014",40.5,,
+"PATCBLOO","B-Blood and blood forming organs","TCPPERMT","/capita, US$ exchange rate","ITA","Italy","2015","2015",36.2,,
+"PATCBLOO","B-Blood and blood forming organs","TCPPERMT","/capita, US$ exchange rate","ITA","Italy","2016","2016",37,,
+"PATCBLOO","B-Blood and blood forming organs","TCPPERMT","/capita, US$ exchange rate","ITA","Italy","2017","2017",39,,
+"PATCBLOO","B-Blood and blood forming organs","TCPPERMT","/capita, US$ exchange rate","ITA","Italy","2018","2018",40.7,,
+"PATCBLOO","B-Blood and blood forming organs","TCPPERMT","/capita, US$ exchange rate","ITA","Italy","2019","2019",40.8,,
+"PATCBLOO","B-Blood and blood forming organs","TCPPERMT","/capita, US$ exchange rate","ITA","Italy","2020","2020",44.3,,
+"PATCBLOO","B-Blood and blood forming organs","TCPPERMT","/capita, US$ exchange rate","ITA","Italy","2021","2021",47,,
+"PATCBLOO","B-Blood and blood forming organs","TCPPERMT","/capita, US$ exchange rate","ITA","Italy","2022","2022",42.9,"E","Estimated value"
+"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2011","2011",39.4,,
+"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2012","2012",39.6,,
+"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2013","2013",38.7,,
+"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2014","2014",41.2,,
+"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2015","2015",44.2,,
+"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2016","2016",47.7,,
+"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2017","2017",50,,
+"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2018","2018",50.6,,
+"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2019","2019",55.5,,
+"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2020","2020",59.9,,
+"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2021","2021",61.4,,
+"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2022","2022",66,"E","Estimated value"
+"PATCBLOO","B-Blood and blood forming organs","ATCPTTMT","% of total sales","ITA","Italy","2011","2011",9.1,,
+"PATCBLOO","B-Blood and blood forming organs","ATCPTTMT","% of total sales","ITA","Italy","2012","2012",9.3,,
+"PATCBLOO","B-Blood and blood forming organs","ATCPTTMT","% of total sales","ITA","Italy","2013","2013",8.8,,
+"PATCBLOO","B-Blood and blood forming organs","ATCPTTMT","% of total sales","ITA","Italy","2014","2014",9.3,,
+"PATCBLOO","B-Blood and blood forming organs","ATCPTTMT","% of total sales","ITA","Italy","2015","2015",8.8,,
+"PATCBLOO","B-Blood and blood forming organs","ATCPTTMT","% of total sales","ITA","Italy","2016","2016",8.9,,
+"PATCBLOO","B-Blood and blood forming organs","ATCPTTMT","% of total sales","ITA","Italy","2017","2017",9.2,,
+"PATCBLOO","B-Blood and blood forming organs","ATCPTTMT","% of total sales","ITA","Italy","2018","2018",9.3,,
+"PATCBLOO","B-Blood and blood forming organs","ATCPTTMT","% of total sales","ITA","Italy","2019","2019",9.5,,
+"PATCBLOO","B-Blood and blood forming organs","ATCPTTMT","% of total sales","ITA","Italy","2020","2020",10,,
+"PATCBLOO","B-Blood and blood forming organs","ATCPTTMT","% of total sales","ITA","Italy","2021","2021",9.9,,
+"PATCBLOO","B-Blood and blood forming organs","ATCPTTMT","% of total sales","ITA","Italy","2022","2022",9.7,"E","Estimated value"
+"PATCBLOO","B-Blood and blood forming organs","MLLNCUMT","Million of national currency units","JPN","Japan","2010","2010",446699,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","MLLNCUMT","Million of national currency units","JPN","Japan","2011","2011",463919,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","MLLNCUMT","Million of national currency units","JPN","Japan","2012","2012",510891,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","MLLNCUMT","Million of national currency units","JPN","Japan","2013","2013",497196,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","MLLNCUMT","Million of national currency units","JPN","Japan","2014","2014",448987,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","MLLNCUMT","Million of national currency units","JPN","Japan","2015","2015",461825,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","MLLNCUMT","Million of national currency units","JPN","Japan","2016","2016",425618,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","MLLNCUMT","Million of national currency units","JPN","Japan","2017","2017",420896,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","MLLNCUMT","Million of national currency units","JPN","Japan","2018","2018",469262,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","MLLNCUMT","Million of national currency units","JPN","Japan","2019","2019",683211,"B; D","Break; Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","MLLNCUMT","Million of national currency units","JPN","Japan","2020","2020",641276,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","MLLNCUMT","Million of national currency units","JPN","Japan","2021","2021",616820,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","MTMOTCMT","Million US$ at exchange rate","JPN","Japan","2010","2010",5088.9,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","MTMOTCMT","Million US$ at exchange rate","JPN","Japan","2011","2011",5813,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","MTMOTCMT","Million US$ at exchange rate","JPN","Japan","2012","2012",6402.9,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","MTMOTCMT","Million US$ at exchange rate","JPN","Japan","2013","2013",5094.4,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","MTMOTCMT","Million US$ at exchange rate","JPN","Japan","2014","2014",4237.9,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","MTMOTCMT","Million US$ at exchange rate","JPN","Japan","2015","2015",3815.3,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","MTMOTCMT","Million US$ at exchange rate","JPN","Japan","2016","2016",3912.2,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","MTMOTCMT","Million US$ at exchange rate","JPN","Japan","2017","2017",3752.4,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","MTMOTCMT","Million US$ at exchange rate","JPN","Japan","2018","2018",4249.7,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","MTMOTCMT","Million US$ at exchange rate","JPN","Japan","2019","2019",6267.4,"B; D","Break; Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","MTMOTCMT","Million US$ at exchange rate","JPN","Japan","2020","2020",6005.9,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","MTMOTCMT","Million US$ at exchange rate","JPN","Japan","2021","2021",5620,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","MTMOPPMT","Million US$, purchasing power parity","JPN","Japan","2010","2010",3998.8,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","MTMOPPMT","Million US$, purchasing power parity","JPN","Japan","2011","2011",4317.4,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","MTMOPPMT","Million US$, purchasing power parity","JPN","Japan","2012","2012",4899.5,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","MTMOPPMT","Million US$, purchasing power parity","JPN","Japan","2013","2013",4908,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","MTMOPPMT","Million US$, purchasing power parity","JPN","Japan","2014","2014",4356.9,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","MTMOPPMT","Million US$, purchasing power parity","JPN","Japan","2015","2015",4463.4,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","MTMOPPMT","Million US$, purchasing power parity","JPN","Japan","2016","2016",4033.5,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","MTMOPPMT","Million US$, purchasing power parity","JPN","Japan","2017","2017",4004.6,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","MTMOPPMT","Million US$, purchasing power parity","JPN","Japan","2018","2018",4505.3,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","MTMOPPMT","Million US$, purchasing power parity","JPN","Japan","2019","2019",6555.1,"B; D","Break; Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","MTMOPPMT","Million US$, purchasing power parity","JPN","Japan","2020","2020",6260.8,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","MTMOPPMT","Million US$, purchasing power parity","JPN","Japan","2021","2021",6044.3,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","TCPPERMT","/capita, US$ exchange rate","JPN","Japan","2010","2010",39.7,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","TCPPERMT","/capita, US$ exchange rate","JPN","Japan","2011","2011",45.5,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","TCPPERMT","/capita, US$ exchange rate","JPN","Japan","2012","2012",50.2,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","TCPPERMT","/capita, US$ exchange rate","JPN","Japan","2013","2013",40,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","TCPPERMT","/capita, US$ exchange rate","JPN","Japan","2014","2014",33.3,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","TCPPERMT","/capita, US$ exchange rate","JPN","Japan","2015","2015",30,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","TCPPERMT","/capita, US$ exchange rate","JPN","Japan","2016","2016",30.8,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","TCPPERMT","/capita, US$ exchange rate","JPN","Japan","2017","2017",29.6,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","TCPPERMT","/capita, US$ exchange rate","JPN","Japan","2018","2018",33.6,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","TCPPERMT","/capita, US$ exchange rate","JPN","Japan","2019","2019",49.7,"B; D","Break; Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","TCPPERMT","/capita, US$ exchange rate","JPN","Japan","2020","2020",47.6,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","TCPPERMT","/capita, US$ exchange rate","JPN","Japan","2021","2021",44.8,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","JPN","Japan","2010","2010",31.2,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","JPN","Japan","2011","2011",33.8,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","JPN","Japan","2012","2012",38.4,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","JPN","Japan","2013","2013",38.5,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","JPN","Japan","2014","2014",34.2,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","JPN","Japan","2015","2015",35.1,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","JPN","Japan","2016","2016",31.8,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","JPN","Japan","2017","2017",31.6,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","JPN","Japan","2018","2018",35.6,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","JPN","Japan","2019","2019",52,"B; D","Break; Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","JPN","Japan","2020","2020",49.6,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","JPN","Japan","2021","2021",48.2,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","ATCPTTMT","% of total sales","JPN","Japan","2010","2010",6.6,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","ATCPTTMT","% of total sales","JPN","Japan","2011","2011",6.6,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","ATCPTTMT","% of total sales","JPN","Japan","2012","2012",7.3,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","ATCPTTMT","% of total sales","JPN","Japan","2013","2013",7.2,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","ATCPTTMT","% of total sales","JPN","Japan","2014","2014",6.8,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","ATCPTTMT","% of total sales","JPN","Japan","2015","2015",6.8,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","ATCPTTMT","% of total sales","JPN","Japan","2016","2016",6.4,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","ATCPTTMT","% of total sales","JPN","Japan","2017","2017",6.3,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","ATCPTTMT","% of total sales","JPN","Japan","2018","2018",6.8,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","ATCPTTMT","% of total sales","JPN","Japan","2019","2019",7.2,"B; D","Break; Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","ATCPTTMT","% of total sales","JPN","Japan","2020","2020",6.9,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","ATCPTTMT","% of total sales","JPN","Japan","2021","2021",6.7,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","MLLNCUMT","Million of national currency units","KOR","Korea","2010","2010",1647148,,
+"PATCBLOO","B-Blood and blood forming organs","MLLNCUMT","Million of national currency units","KOR","Korea","2011","2011",1767579.5,"B","Break"
+"PATCBLOO","B-Blood and blood forming organs","MLLNCUMT","Million of national currency units","KOR","Korea","2012","2012",1782148.1,,
+"PATCBLOO","B-Blood and blood forming organs","MLLNCUMT","Million of national currency units","KOR","Korea","2013","2013",1852464.8,,
+"PATCBLOO","B-Blood and blood forming organs","MLLNCUMT","Million of national currency units","KOR","Korea","2014","2014",1967406.1,,
+"PATCBLOO","B-Blood and blood forming organs","MLLNCUMT","Million of national currency units","KOR","Korea","2015","2015",2093006.8,,
+"PATCBLOO","B-Blood and blood forming organs","MLLNCUMT","Million of national currency units","KOR","Korea","2016","2016",2000397.8,"B","Break"
+"PATCBLOO","B-Blood and blood forming organs","MLLNCUMT","Million of national currency units","KOR","Korea","2017","2017",2107041.8,,
+"PATCBLOO","B-Blood and blood forming organs","MLLNCUMT","Million of national currency units","KOR","Korea","2018","2018",2300183.1,,
+"PATCBLOO","B-Blood and blood forming organs","MLLNCUMT","Million of national currency units","KOR","Korea","2019","2019",2470833.2,,
+"PATCBLOO","B-Blood and blood forming organs","MLLNCUMT","Million of national currency units","KOR","Korea","2020","2020",2608157,,
+"PATCBLOO","B-Blood and blood forming organs","MLLNCUMT","Million of national currency units","KOR","Korea","2021","2021",2786025.4,,
+"PATCBLOO","B-Blood and blood forming organs","MTMOTCMT","Million US$ at exchange rate","KOR","Korea","2010","2010",1424.3,,
+"PATCBLOO","B-Blood and blood forming organs","MTMOTCMT","Million US$ at exchange rate","KOR","Korea","2011","2011",1595,"B","Break"
+"PATCBLOO","B-Blood and blood forming organs","MTMOTCMT","Million US$ at exchange rate","KOR","Korea","2012","2012",1581.6,,
+"PATCBLOO","B-Blood and blood forming organs","MTMOTCMT","Million US$ at exchange rate","KOR","Korea","2013","2013",1691.8,,
+"PATCBLOO","B-Blood and blood forming organs","MTMOTCMT","Million US$ at exchange rate","KOR","Korea","2014","2014",1868.7,,
+"PATCBLOO","B-Blood and blood forming organs","MTMOTCMT","Million US$ at exchange rate","KOR","Korea","2015","2015",1850.7,,
+"PATCBLOO","B-Blood and blood forming organs","MTMOTCMT","Million US$ at exchange rate","KOR","Korea","2016","2016",1723.3,"B","Break"
+"PATCBLOO","B-Blood and blood forming organs","MTMOTCMT","Million US$ at exchange rate","KOR","Korea","2017","2017",1863,,
+"PATCBLOO","B-Blood and blood forming organs","MTMOTCMT","Million US$ at exchange rate","KOR","Korea","2018","2018",2090.8,,
+"PATCBLOO","B-Blood and blood forming organs","MTMOTCMT","Million US$ at exchange rate","KOR","Korea","2019","2019",2120.2,,
+"PATCBLOO","B-Blood and blood forming organs","MTMOTCMT","Million US$ at exchange rate","KOR","Korea","2020","2020",2209.8,,
+"PATCBLOO","B-Blood and blood forming organs","MTMOTCMT","Million US$ at exchange rate","KOR","Korea","2021","2021",2435.4,,
+"PATCBLOO","B-Blood and blood forming organs","MTMOPPMT","Million US$, purchasing power parity","KOR","Korea","2010","2010",1958.6,,
+"PATCBLOO","B-Blood and blood forming organs","MTMOPPMT","Million US$, purchasing power parity","KOR","Korea","2011","2011",2068.3,"B","Break"
+"PATCBLOO","B-Blood and blood forming organs","MTMOPPMT","Million US$, purchasing power parity","KOR","Korea","2012","2012",2084.7,,
+"PATCBLOO","B-Blood and blood forming organs","MTMOPPMT","Million US$, purchasing power parity","KOR","Korea","2013","2013",2131.5,,
+"PATCBLOO","B-Blood and blood forming organs","MTMOPPMT","Million US$, purchasing power parity","KOR","Korea","2014","2014",2256.5,,
+"PATCBLOO","B-Blood and blood forming organs","MTMOPPMT","Million US$, purchasing power parity","KOR","Korea","2015","2015",2440.9,,
+"PATCBLOO","B-Blood and blood forming organs","MTMOPPMT","Million US$, purchasing power parity","KOR","Korea","2016","2016",2329.3,"B","Break"
+"PATCBLOO","B-Blood and blood forming organs","MTMOPPMT","Million US$, purchasing power parity","KOR","Korea","2017","2017",2414.6,,
+"PATCBLOO","B-Blood and blood forming organs","MTMOPPMT","Million US$, purchasing power parity","KOR","Korea","2018","2018",2690.7,,
+"PATCBLOO","B-Blood and blood forming organs","MTMOPPMT","Million US$, purchasing power parity","KOR","Korea","2019","2019",2885.1,,
+"PATCBLOO","B-Blood and blood forming organs","MTMOPPMT","Million US$, purchasing power parity","KOR","Korea","2020","2020",3113.6,,
+"PATCBLOO","B-Blood and blood forming organs","MTMOPPMT","Million US$, purchasing power parity","KOR","Korea","2021","2021",3262,,
+"PATCBLOO","B-Blood and blood forming organs","TCPPERMT","/capita, US$ exchange rate","KOR","Korea","2010","2010",28.7,,
+"PATCBLOO","B-Blood and blood forming organs","TCPPERMT","/capita, US$ exchange rate","KOR","Korea","2011","2011",31.9,"B","Break"
+"PATCBLOO","B-Blood and blood forming organs","TCPPERMT","/capita, US$ exchange rate","KOR","Korea","2012","2012",31.5,,
+"PATCBLOO","B-Blood and blood forming organs","TCPPERMT","/capita, US$ exchange rate","KOR","Korea","2013","2013",33.5,,
+"PATCBLOO","B-Blood and blood forming organs","TCPPERMT","/capita, US$ exchange rate","KOR","Korea","2014","2014",36.8,,
+"PATCBLOO","B-Blood and blood forming organs","TCPPERMT","/capita, US$ exchange rate","KOR","Korea","2015","2015",36.3,,
+"PATCBLOO","B-Blood and blood forming organs","TCPPERMT","/capita, US$ exchange rate","KOR","Korea","2016","2016",33.6,"B","Break"
+"PATCBLOO","B-Blood and blood forming organs","TCPPERMT","/capita, US$ exchange rate","KOR","Korea","2017","2017",36.3,,
+"PATCBLOO","B-Blood and blood forming organs","TCPPERMT","/capita, US$ exchange rate","KOR","Korea","2018","2018",40.5,,
+"PATCBLOO","B-Blood and blood forming organs","TCPPERMT","/capita, US$ exchange rate","KOR","Korea","2019","2019",41,,
+"PATCBLOO","B-Blood and blood forming organs","TCPPERMT","/capita, US$ exchange rate","KOR","Korea","2020","2020",42.6,,
+"PATCBLOO","B-Blood and blood forming organs","TCPPERMT","/capita, US$ exchange rate","KOR","Korea","2021","2021",47.1,,
+"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2010","2010",39.5,,
+"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2011","2011",41.4,"B","Break"
+"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2012","2012",41.5,,
+"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2013","2013",42.3,,
+"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2014","2014",44.5,,
+"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2015","2015",47.8,,
+"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2016","2016",45.5,"B","Break"
+"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2017","2017",47,,
+"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2018","2018",52.2,,
+"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2019","2019",55.7,,
+"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2020","2020",60.1,,
+"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2021","2021",63,,
+"PATCBLOO","B-Blood and blood forming organs","ATCPTTMT","% of total sales","KOR","Korea","2010","2010",8.1,,
+"PATCBLOO","B-Blood and blood forming organs","ATCPTTMT","% of total sales","KOR","Korea","2011","2011",8,"B","Break"
+"PATCBLOO","B-Blood and blood forming organs","ATCPTTMT","% of total sales","KOR","Korea","2012","2012",8.2,,
+"PATCBLOO","B-Blood and blood forming organs","ATCPTTMT","% of total sales","KOR","Korea","2013","2013",8.2,,
+"PATCBLOO","B-Blood and blood forming organs","ATCPTTMT","% of total sales","KOR","Korea","2014","2014",8.3,,
+"PATCBLOO","B-Blood and blood forming organs","ATCPTTMT","% of total sales","KOR","Korea","2015","2015",8.5,,
+"PATCBLOO","B-Blood and blood forming organs","ATCPTTMT","% of total sales","KOR","Korea","2016","2016",7.9,"B","Break"
+"PATCBLOO","B-Blood and blood forming organs","ATCPTTMT","% of total sales","KOR","Korea","2017","2017",7.8,,
+"PATCBLOO","B-Blood and blood forming organs","ATCPTTMT","% of total sales","KOR","Korea","2018","2018",8,,
+"PATCBLOO","B-Blood and blood forming organs","ATCPTTMT","% of total sales","KOR","Korea","2019","2019",8,,
+"PATCBLOO","B-Blood and blood forming organs","ATCPTTMT","% of total sales","KOR","Korea","2020","2020",8,,
+"PATCBLOO","B-Blood and blood forming organs","ATCPTTMT","% of total sales","KOR","Korea","2021","2021",8,,
+"PATCBLOO","B-Blood and blood forming organs","MLLNCUMT","Million of national currency units","LUX","Luxembourg","2010","2010",9.6,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","MLLNCUMT","Million of national currency units","LUX","Luxembourg","2011","2011",9.2,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","MLLNCUMT","Million of national currency units","LUX","Luxembourg","2012","2012",10.1,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","MLLNCUMT","Million of national currency units","LUX","Luxembourg","2013","2013",10.8,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","MLLNCUMT","Million of national currency units","LUX","Luxembourg","2014","2014",11.9,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","MLLNCUMT","Million of national currency units","LUX","Luxembourg","2015","2015",13,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","MLLNCUMT","Million of national currency units","LUX","Luxembourg","2016","2016",14.4,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","MLLNCUMT","Million of national currency units","LUX","Luxembourg","2017","2017",15.6,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","MLLNCUMT","Million of national currency units","LUX","Luxembourg","2018","2018",16.9,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","MLLNCUMT","Million of national currency units","LUX","Luxembourg","2019","2019",18.4,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","MLLNCUMT","Million of national currency units","LUX","Luxembourg","2020","2020",19.9,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","MLLNCUMT","Million of national currency units","LUX","Luxembourg","2021","2021",22.5,"B; D; P","Break; Difference in methodology; Provisional value"
+"PATCBLOO","B-Blood and blood forming organs","MLLNCUMT","Million of national currency units","LUX","Luxembourg","2022","2022",22.6,"D; P","Difference in methodology; Provisional value"
+"PATCBLOO","B-Blood and blood forming organs","MTMOTCMT","Million US$ at exchange rate","LUX","Luxembourg","2010","2010",12.7,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","MTMOTCMT","Million US$ at exchange rate","LUX","Luxembourg","2011","2011",12.7,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","MTMOTCMT","Million US$ at exchange rate","LUX","Luxembourg","2012","2012",12.9,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","MTMOTCMT","Million US$ at exchange rate","LUX","Luxembourg","2013","2013",14.4,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","MTMOTCMT","Million US$ at exchange rate","LUX","Luxembourg","2014","2014",15.7,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","MTMOTCMT","Million US$ at exchange rate","LUX","Luxembourg","2015","2015",14.5,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","MTMOTCMT","Million US$ at exchange rate","LUX","Luxembourg","2016","2016",15.9,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","MTMOTCMT","Million US$ at exchange rate","LUX","Luxembourg","2017","2017",17.6,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","MTMOTCMT","Million US$ at exchange rate","LUX","Luxembourg","2018","2018",19.9,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","MTMOTCMT","Million US$ at exchange rate","LUX","Luxembourg","2019","2019",20.6,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","MTMOTCMT","Million US$ at exchange rate","LUX","Luxembourg","2020","2020",22.7,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","MTMOTCMT","Million US$ at exchange rate","LUX","Luxembourg","2021","2021",26.6,"B; D; P","Break; Difference in methodology; Provisional value"
+"PATCBLOO","B-Blood and blood forming organs","MTMOTCMT","Million US$ at exchange rate","LUX","Luxembourg","2022","2022",23.8,"D; P","Difference in methodology; Provisional value"
+"PATCBLOO","B-Blood and blood forming organs","MTMOPPMT","Million US$, purchasing power parity","LUX","Luxembourg","2010","2010",10.4,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","MTMOPPMT","Million US$, purchasing power parity","LUX","Luxembourg","2011","2011",10.1,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","MTMOPPMT","Million US$, purchasing power parity","LUX","Luxembourg","2012","2012",11.1,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","MTMOPPMT","Million US$, purchasing power parity","LUX","Luxembourg","2013","2013",12.1,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","MTMOPPMT","Million US$, purchasing power parity","LUX","Luxembourg","2014","2014",13.4,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","MTMOPPMT","Million US$, purchasing power parity","LUX","Luxembourg","2015","2015",14.8,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","MTMOPPMT","Million US$, purchasing power parity","LUX","Luxembourg","2016","2016",16.9,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","MTMOPPMT","Million US$, purchasing power parity","LUX","Luxembourg","2017","2017",18.4,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","MTMOPPMT","Million US$, purchasing power parity","LUX","Luxembourg","2018","2018",19.9,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","MTMOPPMT","Million US$, purchasing power parity","LUX","Luxembourg","2019","2019",21.8,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","MTMOPPMT","Million US$, purchasing power parity","LUX","Luxembourg","2020","2020",23.2,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","MTMOPPMT","Million US$, purchasing power parity","LUX","Luxembourg","2021","2021",26.2,"B; D; P","Break; Difference in methodology; Provisional value"
+"PATCBLOO","B-Blood and blood forming organs","MTMOPPMT","Million US$, purchasing power parity","LUX","Luxembourg","2022","2022",27.2,"D; P","Difference in methodology; Provisional value"
+"PATCBLOO","B-Blood and blood forming organs","TCPPERMT","/capita, US$ exchange rate","LUX","Luxembourg","2010","2010",26.9,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","TCPPERMT","/capita, US$ exchange rate","LUX","Luxembourg","2011","2011",26.4,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","TCPPERMT","/capita, US$ exchange rate","LUX","Luxembourg","2012","2012",26.2,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","TCPPERMT","/capita, US$ exchange rate","LUX","Luxembourg","2013","2013",28.6,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","TCPPERMT","/capita, US$ exchange rate","LUX","Luxembourg","2014","2014",30.8,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","TCPPERMT","/capita, US$ exchange rate","LUX","Luxembourg","2015","2015",27.9,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","TCPPERMT","/capita, US$ exchange rate","LUX","Luxembourg","2016","2016",30.3,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","TCPPERMT","/capita, US$ exchange rate","LUX","Luxembourg","2017","2017",32.9,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","TCPPERMT","/capita, US$ exchange rate","LUX","Luxembourg","2018","2018",36.5,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","TCPPERMT","/capita, US$ exchange rate","LUX","Luxembourg","2019","2019",37,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","TCPPERMT","/capita, US$ exchange rate","LUX","Luxembourg","2020","2020",40.1,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","TCPPERMT","/capita, US$ exchange rate","LUX","Luxembourg","2021","2021",46.2,"B; D; P","Break; Difference in methodology; Provisional value"
+"PATCBLOO","B-Blood and blood forming organs","TCPPERMT","/capita, US$ exchange rate","LUX","Luxembourg","2022","2022",40.6,"D; P","Difference in methodology; Provisional value"
+"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2010","2010",21.9,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2011","2011",21,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2012","2012",22.5,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2013","2013",24.1,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2014","2014",26.2,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2015","2015",28.6,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2016","2016",32.1,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2017","2017",34.4,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2018","2018",36.4,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2019","2019",39.2,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2020","2020",41,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2021","2021",45.5,"B; D; P","Break; Difference in methodology; Provisional value"
+"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2022","2022",46.4,"D; P","Difference in methodology; Provisional value"
+"PATCBLOO","B-Blood and blood forming organs","ATCPTTMT","% of total sales","LUX","Luxembourg","2010","2010",5.1,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","ATCPTTMT","% of total sales","LUX","Luxembourg","2011","2011",4.8,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","ATCPTTMT","% of total sales","LUX","Luxembourg","2012","2012",5.1,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","ATCPTTMT","% of total sales","LUX","Luxembourg","2013","2013",5.6,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","ATCPTTMT","% of total sales","LUX","Luxembourg","2014","2014",6.2,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","ATCPTTMT","% of total sales","LUX","Luxembourg","2015","2015",6.8,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","ATCPTTMT","% of total sales","LUX","Luxembourg","2016","2016",7.4,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","ATCPTTMT","% of total sales","LUX","Luxembourg","2017","2017",8,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","ATCPTTMT","% of total sales","LUX","Luxembourg","2018","2018",8.5,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","ATCPTTMT","% of total sales","LUX","Luxembourg","2019","2019",9,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","ATCPTTMT","% of total sales","LUX","Luxembourg","2020","2020",9.5,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","ATCPTTMT","% of total sales","LUX","Luxembourg","2021","2021",9.4,"B; D; P","Break; Difference in methodology; Provisional value"
+"PATCBLOO","B-Blood and blood forming organs","ATCPTTMT","% of total sales","LUX","Luxembourg","2022","2022",8.8,"D; P","Difference in methodology; Provisional value"
+"PATCBLOO","B-Blood and blood forming organs","MLLNCUMT","Million of national currency units","MEX","Mexico","2010","2010",3930,,
+"PATCBLOO","B-Blood and blood forming organs","MLLNCUMT","Million of national currency units","MEX","Mexico","2011","2011",2231,,
+"PATCBLOO","B-Blood and blood forming organs","MLLNCUMT","Million of national currency units","MEX","Mexico","2012","2012",4172,,
+"PATCBLOO","B-Blood and blood forming organs","MLLNCUMT","Million of national currency units","MEX","Mexico","2013","2013",2218,,
+"PATCBLOO","B-Blood and blood forming organs","MLLNCUMT","Million of national currency units","MEX","Mexico","2014","2014",2176,,
+"PATCBLOO","B-Blood and blood forming organs","MLLNCUMT","Million of national currency units","MEX","Mexico","2015","2015",2320,,
+"PATCBLOO","B-Blood and blood forming organs","MLLNCUMT","Million of national currency units","MEX","Mexico","2016","2016",1766,,
+"PATCBLOO","B-Blood and blood forming organs","MLLNCUMT","Million of national currency units","MEX","Mexico","2017","2017",1640,,
+"PATCBLOO","B-Blood and blood forming organs","MLLNCUMT","Million of national currency units","MEX","Mexico","2018","2018",1401,,
+"PATCBLOO","B-Blood and blood forming organs","MLLNCUMT","Million of national currency units","MEX","Mexico","2019","2019",1889,,
+"PATCBLOO","B-Blood and blood forming organs","MLLNCUMT","Million of national currency units","MEX","Mexico","2020","2020",2109,,
+"PATCBLOO","B-Blood and blood forming organs","MLLNCUMT","Million of national currency units","MEX","Mexico","2021","2021",2435.9,,
+"PATCBLOO","B-Blood and blood forming organs","MLLNCUMT","Million of national currency units","MEX","Mexico","2022","2022",2290.7,"E","Estimated value"
+"PATCBLOO","B-Blood and blood forming organs","MTMOTCMT","Million US$ at exchange rate","MEX","Mexico","2010","2010",311,,
+"PATCBLOO","B-Blood and blood forming organs","MTMOTCMT","Million US$ at exchange rate","MEX","Mexico","2011","2011",179.6,,
+"PATCBLOO","B-Blood and blood forming organs","MTMOTCMT","Million US$ at exchange rate","MEX","Mexico","2012","2012",316.8,,
+"PATCBLOO","B-Blood and blood forming organs","MTMOTCMT","Million US$ at exchange rate","MEX","Mexico","2013","2013",173.7,,
+"PATCBLOO","B-Blood and blood forming organs","MTMOTCMT","Million US$ at exchange rate","MEX","Mexico","2014","2014",163.7,,
+"PATCBLOO","B-Blood and blood forming organs","MTMOTCMT","Million US$ at exchange rate","MEX","Mexico","2015","2015",146.4,,
+"PATCBLOO","B-Blood and blood forming organs","MTMOTCMT","Million US$ at exchange rate","MEX","Mexico","2016","2016",94.6,,
+"PATCBLOO","B-Blood and blood forming organs","MTMOTCMT","Million US$ at exchange rate","MEX","Mexico","2017","2017",86.7,,
+"PATCBLOO","B-Blood and blood forming organs","MTMOTCMT","Million US$ at exchange rate","MEX","Mexico","2018","2018",72.8,,
+"PATCBLOO","B-Blood and blood forming organs","MTMOTCMT","Million US$ at exchange rate","MEX","Mexico","2019","2019",98.1,,
+"PATCBLOO","B-Blood and blood forming organs","MTMOTCMT","Million US$ at exchange rate","MEX","Mexico","2020","2020",98.2,,
+"PATCBLOO","B-Blood and blood forming organs","MTMOTCMT","Million US$ at exchange rate","MEX","Mexico","2021","2021",120.2,,
+"PATCBLOO","B-Blood and blood forming organs","MTMOTCMT","Million US$ at exchange rate","MEX","Mexico","2022","2022",113.8,"E","Estimated value"
+"PATCBLOO","B-Blood and blood forming organs","MTMOPPMT","Million US$, purchasing power parity","MEX","Mexico","2010","2010",511.7,,
+"PATCBLOO","B-Blood and blood forming organs","MTMOPPMT","Million US$, purchasing power parity","MEX","Mexico","2011","2011",290.8,,
+"PATCBLOO","B-Blood and blood forming organs","MTMOPPMT","Million US$, purchasing power parity","MEX","Mexico","2012","2012",530.9,,
+"PATCBLOO","B-Blood and blood forming organs","MTMOPPMT","Million US$, purchasing power parity","MEX","Mexico","2013","2013",281.3,,
+"PATCBLOO","B-Blood and blood forming organs","MTMOPPMT","Million US$, purchasing power parity","MEX","Mexico","2014","2014",270.5,,
+"PATCBLOO","B-Blood and blood forming organs","MTMOPPMT","Million US$, purchasing power parity","MEX","Mexico","2015","2015",278.6,,
+"PATCBLOO","B-Blood and blood forming organs","MTMOPPMT","Million US$, purchasing power parity","MEX","Mexico","2016","2016",209.1,,
+"PATCBLOO","B-Blood and blood forming organs","MTMOPPMT","Million US$, purchasing power parity","MEX","Mexico","2017","2017",184,,
+"PATCBLOO","B-Blood and blood forming organs","MTMOPPMT","Million US$, purchasing power parity","MEX","Mexico","2018","2018",151,,
+"PATCBLOO","B-Blood and blood forming organs","MTMOPPMT","Million US$, purchasing power parity","MEX","Mexico","2019","2019",195.5,,
+"PATCBLOO","B-Blood and blood forming organs","MTMOPPMT","Million US$, purchasing power parity","MEX","Mexico","2020","2020",210.1,,
+"PATCBLOO","B-Blood and blood forming organs","MTMOPPMT","Million US$, purchasing power parity","MEX","Mexico","2021","2021",234.2,,
+"PATCBLOO","B-Blood and blood forming organs","MTMOPPMT","Million US$, purchasing power parity","MEX","Mexico","2022","2022",216.6,"E","Estimated value"
+"PATCBLOO","B-Blood and blood forming organs","TCPPERMT","/capita, US$ exchange rate","MEX","Mexico","2010","2010",2.7,,
+"PATCBLOO","B-Blood and blood forming organs","TCPPERMT","/capita, US$ exchange rate","MEX","Mexico","2011","2011",1.6,,
+"PATCBLOO","B-Blood and blood forming organs","TCPPERMT","/capita, US$ exchange rate","MEX","Mexico","2012","2012",2.7,,
+"PATCBLOO","B-Blood and blood forming organs","TCPPERMT","/capita, US$ exchange rate","MEX","Mexico","2013","2013",1.5,,
+"PATCBLOO","B-Blood and blood forming organs","TCPPERMT","/capita, US$ exchange rate","MEX","Mexico","2014","2014",1.4,,
+"PATCBLOO","B-Blood and blood forming organs","TCPPERMT","/capita, US$ exchange rate","MEX","Mexico","2015","2015",1.2,,
+"PATCBLOO","B-Blood and blood forming organs","TCPPERMT","/capita, US$ exchange rate","MEX","Mexico","2016","2016",0.8,,
+"PATCBLOO","B-Blood and blood forming organs","TCPPERMT","/capita, US$ exchange rate","MEX","Mexico","2017","2017",0.7,,
+"PATCBLOO","B-Blood and blood forming organs","TCPPERMT","/capita, US$ exchange rate","MEX","Mexico","2018","2018",0.6,,
+"PATCBLOO","B-Blood and blood forming organs","TCPPERMT","/capita, US$ exchange rate","MEX","Mexico","2019","2019",0.8,,
+"PATCBLOO","B-Blood and blood forming organs","TCPPERMT","/capita, US$ exchange rate","MEX","Mexico","2020","2020",0.8,,
+"PATCBLOO","B-Blood and blood forming organs","TCPPERMT","/capita, US$ exchange rate","MEX","Mexico","2021","2021",0.9,,
+"PATCBLOO","B-Blood and blood forming organs","TCPPERMT","/capita, US$ exchange rate","MEX","Mexico","2022","2022",0.9,"E","Estimated value"
+"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","MEX","Mexico","2010","2010",4.5,,
+"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","MEX","Mexico","2011","2011",2.5,,
+"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","MEX","Mexico","2012","2012",4.5,,
+"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","MEX","Mexico","2013","2013",2.4,,
+"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","MEX","Mexico","2014","2014",2.3,,
+"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","MEX","Mexico","2015","2015",2.3,,
+"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","MEX","Mexico","2016","2016",1.7,,
+"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","MEX","Mexico","2017","2017",1.5,,
+"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","MEX","Mexico","2018","2018",1.2,,
+"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","MEX","Mexico","2019","2019",1.5,,
+"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","MEX","Mexico","2020","2020",1.6,,
+"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","MEX","Mexico","2021","2021",1.8,,
+"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","MEX","Mexico","2022","2022",1.7,"E","Estimated value"
+"PATCBLOO","B-Blood and blood forming organs","ATCPTTMT","% of total sales","MEX","Mexico","2013","2013",1.6,,
+"PATCBLOO","B-Blood and blood forming organs","ATCPTTMT","% of total sales","MEX","Mexico","2018","2018",0.6,,
+"PATCBLOO","B-Blood and blood forming organs","MLLNCUMT","Million of national currency units","NLD","Netherlands","2010","2010",245.7,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","MLLNCUMT","Million of national currency units","NLD","Netherlands","2011","2011",242.7,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","MLLNCUMT","Million of national currency units","NLD","Netherlands","2012","2012",244.3,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","MLLNCUMT","Million of national currency units","NLD","Netherlands","2013","2013",258.1,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","MLLNCUMT","Million of national currency units","NLD","Netherlands","2014","2014",267.6,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","MTMOTCMT","Million US$ at exchange rate","NLD","Netherlands","2010","2010",325.8,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","MTMOTCMT","Million US$ at exchange rate","NLD","Netherlands","2011","2011",337.8,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","MTMOTCMT","Million US$ at exchange rate","NLD","Netherlands","2012","2012",313.9,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","MTMOTCMT","Million US$ at exchange rate","NLD","Netherlands","2013","2013",342.8,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","MTMOTCMT","Million US$ at exchange rate","NLD","Netherlands","2014","2014",355.5,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","MTMOPPMT","Million US$, purchasing power parity","NLD","Netherlands","2010","2010",287.7,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","MTMOPPMT","Million US$, purchasing power parity","NLD","Netherlands","2011","2011",290.3,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","MTMOPPMT","Million US$, purchasing power parity","NLD","Netherlands","2012","2012",296.4,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","MTMOPPMT","Million US$, purchasing power parity","NLD","Netherlands","2013","2013",323.4,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","MTMOPPMT","Million US$, purchasing power parity","NLD","Netherlands","2014","2014",330.9,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","TCPPERMT","/capita, US$ exchange rate","NLD","Netherlands","2010","2010",19.6,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","TCPPERMT","/capita, US$ exchange rate","NLD","Netherlands","2011","2011",20.2,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","TCPPERMT","/capita, US$ exchange rate","NLD","Netherlands","2012","2012",18.7,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","TCPPERMT","/capita, US$ exchange rate","NLD","Netherlands","2013","2013",20.4,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","TCPPERMT","/capita, US$ exchange rate","NLD","Netherlands","2014","2014",21.1,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","NLD","Netherlands","2010","2010",17.3,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","NLD","Netherlands","2011","2011",17.4,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","NLD","Netherlands","2012","2012",17.7,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","NLD","Netherlands","2013","2013",19.2,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","NLD","Netherlands","2014","2014",19.6,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","ATCPTTMT","% of total sales","NLD","Netherlands","2010","2010",4.7,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","ATCPTTMT","% of total sales","NLD","Netherlands","2011","2011",4.7,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","ATCPTTMT","% of total sales","NLD","Netherlands","2012","2012",5.3,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","ATCPTTMT","% of total sales","NLD","Netherlands","2013","2013",6,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","ATCPTTMT","% of total sales","NLD","Netherlands","2014","2014",6.2,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","MLLNCUMT","Million of national currency units","NZL","New Zealand","2010","2010",26.2,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","MLLNCUMT","Million of national currency units","NZL","New Zealand","2011","2011",26.3,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","MLLNCUMT","Million of national currency units","NZL","New Zealand","2012","2012",42.8,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","MLLNCUMT","Million of national currency units","NZL","New Zealand","2013","2013",48.2,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","MLLNCUMT","Million of national currency units","NZL","New Zealand","2014","2014",87.1,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","MLLNCUMT","Million of national currency units","NZL","New Zealand","2015","2015",99,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","MLLNCUMT","Million of national currency units","NZL","New Zealand","2016","2016",84.8,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","MLLNCUMT","Million of national currency units","NZL","New Zealand","2017","2017",68.3,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","MLLNCUMT","Million of national currency units","NZL","New Zealand","2018","2018",80,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","MLLNCUMT","Million of national currency units","NZL","New Zealand","2019","2019",81,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","MLLNCUMT","Million of national currency units","NZL","New Zealand","2020","2020",99.9,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","MLLNCUMT","Million of national currency units","NZL","New Zealand","2021","2021",113.4,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","MLLNCUMT","Million of national currency units","NZL","New Zealand","2022","2022",126,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","MTMOTCMT","Million US$ at exchange rate","NZL","New Zealand","2010","2010",18.9,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","MTMOTCMT","Million US$ at exchange rate","NZL","New Zealand","2011","2011",20.7,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","MTMOTCMT","Million US$ at exchange rate","NZL","New Zealand","2012","2012",34.7,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","MTMOTCMT","Million US$ at exchange rate","NZL","New Zealand","2013","2013",39.5,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","MTMOTCMT","Million US$ at exchange rate","NZL","New Zealand","2014","2014",72.3,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","MTMOTCMT","Million US$ at exchange rate","NZL","New Zealand","2015","2015",69.1,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","MTMOTCMT","Million US$ at exchange rate","NZL","New Zealand","2016","2016",59,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","MTMOTCMT","Million US$ at exchange rate","NZL","New Zealand","2017","2017",48.5,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","MTMOTCMT","Million US$ at exchange rate","NZL","New Zealand","2018","2018",55.3,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","MTMOTCMT","Million US$ at exchange rate","NZL","New Zealand","2019","2019",53.4,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","MTMOTCMT","Million US$ at exchange rate","NZL","New Zealand","2020","2020",64.8,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","MTMOTCMT","Million US$ at exchange rate","NZL","New Zealand","2021","2021",80.2,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","MTMOTCMT","Million US$ at exchange rate","NZL","New Zealand","2022","2022",79.9,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","MTMOPPMT","Million US$, purchasing power parity","NZL","New Zealand","2010","2010",17.5,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","MTMOPPMT","Million US$, purchasing power parity","NZL","New Zealand","2011","2011",17.7,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","MTMOPPMT","Million US$, purchasing power parity","NZL","New Zealand","2012","2012",28.6,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","MTMOPPMT","Million US$, purchasing power parity","NZL","New Zealand","2013","2013",33.3,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","MTMOPPMT","Million US$, purchasing power parity","NZL","New Zealand","2014","2014",60.5,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","MTMOPPMT","Million US$, purchasing power parity","NZL","New Zealand","2015","2015",67,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","MTMOPPMT","Million US$, purchasing power parity","NZL","New Zealand","2016","2016",58.8,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","MTMOPPMT","Million US$, purchasing power parity","NZL","New Zealand","2017","2017",47.7,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","MTMOPPMT","Million US$, purchasing power parity","NZL","New Zealand","2018","2018",54.4,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","MTMOPPMT","Million US$, purchasing power parity","NZL","New Zealand","2019","2019",57.2,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","MTMOPPMT","Million US$, purchasing power parity","NZL","New Zealand","2020","2020",70.7,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","MTMOPPMT","Million US$, purchasing power parity","NZL","New Zealand","2021","2021",77.7,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","MTMOPPMT","Million US$, purchasing power parity","NZL","New Zealand","2022","2022",87.3,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","TCPPERMT","/capita, US$ exchange rate","NZL","New Zealand","2010","2010",4.3,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","TCPPERMT","/capita, US$ exchange rate","NZL","New Zealand","2011","2011",4.7,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","TCPPERMT","/capita, US$ exchange rate","NZL","New Zealand","2012","2012",7.9,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","TCPPERMT","/capita, US$ exchange rate","NZL","New Zealand","2013","2013",8.9,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","TCPPERMT","/capita, US$ exchange rate","NZL","New Zealand","2014","2014",16,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","TCPPERMT","/capita, US$ exchange rate","NZL","New Zealand","2015","2015",15,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","TCPPERMT","/capita, US$ exchange rate","NZL","New Zealand","2016","2016",12.5,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","TCPPERMT","/capita, US$ exchange rate","NZL","New Zealand","2017","2017",10.1,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","TCPPERMT","/capita, US$ exchange rate","NZL","New Zealand","2018","2018",11.3,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","TCPPERMT","/capita, US$ exchange rate","NZL","New Zealand","2019","2019",10.7,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","TCPPERMT","/capita, US$ exchange rate","NZL","New Zealand","2020","2020",12.7,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","TCPPERMT","/capita, US$ exchange rate","NZL","New Zealand","2021","2021",15.7,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","TCPPERMT","/capita, US$ exchange rate","NZL","New Zealand","2022","2022",15.6,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2010","2010",4,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2011","2011",4,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2012","2012",6.5,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2013","2013",7.5,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2014","2014",13.4,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2015","2015",14.5,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2016","2016",12.5,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2017","2017",9.9,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2018","2018",11.1,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2019","2019",11.5,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2020","2020",13.9,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2021","2021",15.2,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2022","2022",17,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","ATCPTTMT","% of total sales","NZL","New Zealand","2010","2010",3.5,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","ATCPTTMT","% of total sales","NZL","New Zealand","2011","2011",3.2,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","ATCPTTMT","% of total sales","NZL","New Zealand","2012","2012",4.6,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","ATCPTTMT","% of total sales","NZL","New Zealand","2013","2013",5.2,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","ATCPTTMT","% of total sales","NZL","New Zealand","2014","2014",9.1,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","ATCPTTMT","% of total sales","NZL","New Zealand","2015","2015",10,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","ATCPTTMT","% of total sales","NZL","New Zealand","2016","2016",7.9,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","ATCPTTMT","% of total sales","NZL","New Zealand","2017","2017",5.4,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","ATCPTTMT","% of total sales","NZL","New Zealand","2018","2018",6.1,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","ATCPTTMT","% of total sales","NZL","New Zealand","2019","2019",5.4,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","ATCPTTMT","% of total sales","NZL","New Zealand","2020","2020",6,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","ATCPTTMT","% of total sales","NZL","New Zealand","2021","2021",6.4,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","ATCPTTMT","% of total sales","NZL","New Zealand","2022","2022",6.6,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","MLLNCUMT","Million of national currency units","NOR","Norway","2010","2010",1188,,
+"PATCBLOO","B-Blood and blood forming organs","MLLNCUMT","Million of national currency units","NOR","Norway","2011","2011",1203,,
+"PATCBLOO","B-Blood and blood forming organs","MLLNCUMT","Million of national currency units","NOR","Norway","2012","2012",1274,,
+"PATCBLOO","B-Blood and blood forming organs","MLLNCUMT","Million of national currency units","NOR","Norway","2013","2013",1498,,
+"PATCBLOO","B-Blood and blood forming organs","MLLNCUMT","Million of national currency units","NOR","Norway","2014","2014",1654,,
+"PATCBLOO","B-Blood and blood forming organs","MLLNCUMT","Million of national currency units","NOR","Norway","2015","2015",1846,,
+"PATCBLOO","B-Blood and blood forming organs","MLLNCUMT","Million of national currency units","NOR","Norway","2016","2016",2127,,
+"PATCBLOO","B-Blood and blood forming organs","MLLNCUMT","Million of national currency units","NOR","Norway","2017","2017",2330,,
+"PATCBLOO","B-Blood and blood forming organs","MLLNCUMT","Million of national currency units","NOR","Norway","2018","2018",2510,,
+"PATCBLOO","B-Blood and blood forming organs","MLLNCUMT","Million of national currency units","NOR","Norway","2019","2019",2679,,
+"PATCBLOO","B-Blood and blood forming organs","MLLNCUMT","Million of national currency units","NOR","Norway","2020","2020",2762,,
+"PATCBLOO","B-Blood and blood forming organs","MLLNCUMT","Million of national currency units","NOR","Norway","2021","2021",2931,,
+"PATCBLOO","B-Blood and blood forming organs","MLLNCUMT","Million of national currency units","NOR","Norway","2022","2022",3082,,
+"PATCBLOO","B-Blood and blood forming organs","MTMOTCMT","Million US$ at exchange rate","NOR","Norway","2010","2010",196.6,,
+"PATCBLOO","B-Blood and blood forming organs","MTMOTCMT","Million US$ at exchange rate","NOR","Norway","2011","2011",214.6,,
+"PATCBLOO","B-Blood and blood forming organs","MTMOTCMT","Million US$ at exchange rate","NOR","Norway","2012","2012",219,,
+"PATCBLOO","B-Blood and blood forming organs","MTMOTCMT","Million US$ at exchange rate","NOR","Norway","2013","2013",255,,
+"PATCBLOO","B-Blood and blood forming organs","MTMOTCMT","Million US$ at exchange rate","NOR","Norway","2014","2014",262.5,,
+"PATCBLOO","B-Blood and blood forming organs","MTMOTCMT","Million US$ at exchange rate","NOR","Norway","2015","2015",228.9,,
+"PATCBLOO","B-Blood and blood forming organs","MTMOTCMT","Million US$ at exchange rate","NOR","Norway","2016","2016",253.2,,
+"PATCBLOO","B-Blood and blood forming organs","MTMOTCMT","Million US$ at exchange rate","NOR","Norway","2017","2017",281.7,,
+"PATCBLOO","B-Blood and blood forming organs","MTMOTCMT","Million US$ at exchange rate","NOR","Norway","2018","2018",308.6,,
+"PATCBLOO","B-Blood and blood forming organs","MTMOTCMT","Million US$ at exchange rate","NOR","Norway","2019","2019",304.4,,
+"PATCBLOO","B-Blood and blood forming organs","MTMOTCMT","Million US$ at exchange rate","NOR","Norway","2020","2020",293.3,,
+"PATCBLOO","B-Blood and blood forming organs","MTMOTCMT","Million US$ at exchange rate","NOR","Norway","2021","2021",341.2,,
+"PATCBLOO","B-Blood and blood forming organs","MTMOTCMT","Million US$ at exchange rate","NOR","Norway","2022","2022",320.6,,
+"PATCBLOO","B-Blood and blood forming organs","MTMOPPMT","Million US$, purchasing power parity","NOR","Norway","2010","2010",129.8,,
+"PATCBLOO","B-Blood and blood forming organs","MTMOPPMT","Million US$, purchasing power parity","NOR","Norway","2011","2011",132.4,,
+"PATCBLOO","B-Blood and blood forming organs","MTMOPPMT","Million US$, purchasing power parity","NOR","Norway","2012","2012",141,,
+"PATCBLOO","B-Blood and blood forming organs","MTMOPPMT","Million US$, purchasing power parity","NOR","Norway","2013","2013",165.9,,
+"PATCBLOO","B-Blood and blood forming organs","MTMOPPMT","Million US$, purchasing power parity","NOR","Norway","2014","2014",178.3,,
+"PATCBLOO","B-Blood and blood forming organs","MTMOPPMT","Million US$, purchasing power parity","NOR","Norway","2015","2015",185.9,,
+"PATCBLOO","B-Blood and blood forming organs","MTMOPPMT","Million US$, purchasing power parity","NOR","Norway","2016","2016",211.8,,
+"PATCBLOO","B-Blood and blood forming organs","MTMOPPMT","Million US$, purchasing power parity","NOR","Norway","2017","2017",239,,
+"PATCBLOO","B-Blood and blood forming organs","MTMOPPMT","Million US$, purchasing power parity","NOR","Norway","2018","2018",261.9,,
+"PATCBLOO","B-Blood and blood forming organs","MTMOPPMT","Million US$, purchasing power parity","NOR","Norway","2019","2019",278.5,,
+"PATCBLOO","B-Blood and blood forming organs","MTMOPPMT","Million US$, purchasing power parity","NOR","Norway","2020","2020",279.6,,
+"PATCBLOO","B-Blood and blood forming organs","MTMOPPMT","Million US$, purchasing power parity","NOR","Norway","2021","2021",308.1,,
+"PATCBLOO","B-Blood and blood forming organs","MTMOPPMT","Million US$, purchasing power parity","NOR","Norway","2022","2022",287,,
+"PATCBLOO","B-Blood and blood forming organs","TCPPERMT","/capita, US$ exchange rate","NOR","Norway","2010","2010",40.2,,
+"PATCBLOO","B-Blood and blood forming organs","TCPPERMT","/capita, US$ exchange rate","NOR","Norway","2011","2011",43.3,,
+"PATCBLOO","B-Blood and blood forming organs","TCPPERMT","/capita, US$ exchange rate","NOR","Norway","2012","2012",43.6,,
+"PATCBLOO","B-Blood and blood forming organs","TCPPERMT","/capita, US$ exchange rate","NOR","Norway","2013","2013",50.2,,
+"PATCBLOO","B-Blood and blood forming organs","TCPPERMT","/capita, US$ exchange rate","NOR","Norway","2014","2014",51.1,,
+"PATCBLOO","B-Blood and blood forming organs","TCPPERMT","/capita, US$ exchange rate","NOR","Norway","2015","2015",44.1,,
+"PATCBLOO","B-Blood and blood forming organs","TCPPERMT","/capita, US$ exchange rate","NOR","Norway","2016","2016",48.4,,
+"PATCBLOO","B-Blood and blood forming organs","TCPPERMT","/capita, US$ exchange rate","NOR","Norway","2017","2017",53.4,,
+"PATCBLOO","B-Blood and blood forming organs","TCPPERMT","/capita, US$ exchange rate","NOR","Norway","2018","2018",58.1,,
+"PATCBLOO","B-Blood and blood forming organs","TCPPERMT","/capita, US$ exchange rate","NOR","Norway","2019","2019",56.9,,
+"PATCBLOO","B-Blood and blood forming organs","TCPPERMT","/capita, US$ exchange rate","NOR","Norway","2020","2020",54.5,,
+"PATCBLOO","B-Blood and blood forming organs","TCPPERMT","/capita, US$ exchange rate","NOR","Norway","2021","2021",63.1,,
+"PATCBLOO","B-Blood and blood forming organs","TCPPERMT","/capita, US$ exchange rate","NOR","Norway","2022","2022",59.1,,
+"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2010","2010",26.6,,
+"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2011","2011",26.7,,
+"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2012","2012",28.1,,
+"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2013","2013",32.7,,
+"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2014","2014",34.7,,
+"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2015","2015",35.8,,
+"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2016","2016",40.5,,
+"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2017","2017",45.3,,
+"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2018","2018",49.3,,
+"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2019","2019",52.1,,
+"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2020","2020",52,,
+"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2021","2021",57,,
+"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2022","2022",52.9,,
+"PATCBLOO","B-Blood and blood forming organs","ATCPTTMT","% of total sales","NOR","Norway","2010","2010",6.6,,
+"PATCBLOO","B-Blood and blood forming organs","ATCPTTMT","% of total sales","NOR","Norway","2011","2011",6.6,,
+"PATCBLOO","B-Blood and blood forming organs","ATCPTTMT","% of total sales","NOR","Norway","2012","2012",6.8,,
+"PATCBLOO","B-Blood and blood forming organs","ATCPTTMT","% of total sales","NOR","Norway","2013","2013",7.8,,
+"PATCBLOO","B-Blood and blood forming organs","ATCPTTMT","% of total sales","NOR","Norway","2014","2014",7.8,,
+"PATCBLOO","B-Blood and blood forming organs","ATCPTTMT","% of total sales","NOR","Norway","2015","2015",8.1,,
+"PATCBLOO","B-Blood and blood forming organs","ATCPTTMT","% of total sales","NOR","Norway","2016","2016",8.6,,
+"PATCBLOO","B-Blood and blood forming organs","ATCPTTMT","% of total sales","NOR","Norway","2017","2017",8.7,,
+"PATCBLOO","B-Blood and blood forming organs","ATCPTTMT","% of total sales","NOR","Norway","2018","2018",9.1,,
+"PATCBLOO","B-Blood and blood forming organs","ATCPTTMT","% of total sales","NOR","Norway","2019","2019",9.4,,
+"PATCBLOO","B-Blood and blood forming organs","ATCPTTMT","% of total sales","NOR","Norway","2020","2020",9.3,,
+"PATCBLOO","B-Blood and blood forming organs","ATCPTTMT","% of total sales","NOR","Norway","2021","2021",8.7,,
+"PATCBLOO","B-Blood and blood forming organs","ATCPTTMT","% of total sales","NOR","Norway","2022","2022",8.6,,
+"PATCBLOO","B-Blood and blood forming organs","MLLNCUMT","Million of national currency units","PRT","Portugal","2010","2010",120.5,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","MLLNCUMT","Million of national currency units","PRT","Portugal","2011","2011",105.7,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","MLLNCUMT","Million of national currency units","PRT","Portugal","2012","2012",87.4,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","MLLNCUMT","Million of national currency units","PRT","Portugal","2013","2013",91.8,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","MLLNCUMT","Million of national currency units","PRT","Portugal","2014","2014",110.9,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","MLLNCUMT","Million of national currency units","PRT","Portugal","2015","2015",140.5,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","MLLNCUMT","Million of national currency units","PRT","Portugal","2016","2016",175.5,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","MLLNCUMT","Million of national currency units","PRT","Portugal","2017","2017",192.1,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","MLLNCUMT","Million of national currency units","PRT","Portugal","2018","2018",225.4,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","MLLNCUMT","Million of national currency units","PRT","Portugal","2019","2019",258.8,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","MLLNCUMT","Million of national currency units","PRT","Portugal","2020","2020",262.4,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","MLLNCUMT","Million of national currency units","PRT","Portugal","2021","2021",283.5,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","MLLNCUMT","Million of national currency units","PRT","Portugal","2022","2022",303,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","MTMOTCMT","Million US$ at exchange rate","PRT","Portugal","2010","2010",159.8,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","MTMOTCMT","Million US$ at exchange rate","PRT","Portugal","2011","2011",147.1,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","MTMOTCMT","Million US$ at exchange rate","PRT","Portugal","2012","2012",112.3,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","MTMOTCMT","Million US$ at exchange rate","PRT","Portugal","2013","2013",121.9,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","MTMOTCMT","Million US$ at exchange rate","PRT","Portugal","2014","2014",147.4,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","MTMOTCMT","Million US$ at exchange rate","PRT","Portugal","2015","2015",155.9,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","MTMOTCMT","Million US$ at exchange rate","PRT","Portugal","2016","2016",194.3,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","MTMOTCMT","Million US$ at exchange rate","PRT","Portugal","2017","2017",217,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","MTMOTCMT","Million US$ at exchange rate","PRT","Portugal","2018","2018",266.2,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","MTMOTCMT","Million US$ at exchange rate","PRT","Portugal","2019","2019",289.7,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","MTMOTCMT","Million US$ at exchange rate","PRT","Portugal","2020","2020",299.7,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","MTMOTCMT","Million US$ at exchange rate","PRT","Portugal","2021","2021",335.3,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","MTMOTCMT","Million US$ at exchange rate","PRT","Portugal","2022","2022",319.1,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","MTMOPPMT","Million US$, purchasing power parity","PRT","Portugal","2010","2010",193.4,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","MTMOPPMT","Million US$, purchasing power parity","PRT","Portugal","2011","2011",169.6,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","MTMOPPMT","Million US$, purchasing power parity","PRT","Portugal","2012","2012",144.4,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","MTMOPPMT","Million US$, purchasing power parity","PRT","Portugal","2013","2013",157.3,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","MTMOPPMT","Million US$, purchasing power parity","PRT","Portugal","2014","2014",191.7,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","MTMOPPMT","Million US$, purchasing power parity","PRT","Portugal","2015","2015",240.3,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","MTMOPPMT","Million US$, purchasing power parity","PRT","Portugal","2016","2016",307.2,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","MTMOPPMT","Million US$, purchasing power parity","PRT","Portugal","2017","2017",333.6,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","MTMOPPMT","Million US$, purchasing power parity","PRT","Portugal","2018","2018",394.5,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","MTMOPPMT","Million US$, purchasing power parity","PRT","Portugal","2019","2019",463.2,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","MTMOPPMT","Million US$, purchasing power parity","PRT","Portugal","2020","2020",470.9,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","MTMOPPMT","Million US$, purchasing power parity","PRT","Portugal","2021","2021",499.4,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","MTMOPPMT","Million US$, purchasing power parity","PRT","Portugal","2022","2022",551,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","TCPPERMT","/capita, US$ exchange rate","PRT","Portugal","2010","2010",15.1,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","TCPPERMT","/capita, US$ exchange rate","PRT","Portugal","2011","2011",13.9,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","TCPPERMT","/capita, US$ exchange rate","PRT","Portugal","2012","2012",10.7,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","TCPPERMT","/capita, US$ exchange rate","PRT","Portugal","2013","2013",11.7,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","TCPPERMT","/capita, US$ exchange rate","PRT","Portugal","2014","2014",14.2,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","TCPPERMT","/capita, US$ exchange rate","PRT","Portugal","2015","2015",15.1,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","TCPPERMT","/capita, US$ exchange rate","PRT","Portugal","2016","2016",18.8,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","TCPPERMT","/capita, US$ exchange rate","PRT","Portugal","2017","2017",21.1,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","TCPPERMT","/capita, US$ exchange rate","PRT","Portugal","2018","2018",25.9,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","TCPPERMT","/capita, US$ exchange rate","PRT","Portugal","2019","2019",28.2,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","TCPPERMT","/capita, US$ exchange rate","PRT","Portugal","2020","2020",29.1,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","TCPPERMT","/capita, US$ exchange rate","PRT","Portugal","2021","2021",32.4,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","TCPPERMT","/capita, US$ exchange rate","PRT","Portugal","2022","2022",30.8,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2010","2010",18.3,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2011","2011",16.1,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2012","2012",13.7,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2013","2013",15,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2014","2014",18.4,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2015","2015",23.2,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2016","2016",29.7,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2017","2017",32.4,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2018","2018",38.4,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2019","2019",45,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2020","2020",45.7,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2021","2021",48.2,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2022","2022",53.2,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","ATCPTTMT","% of total sales","PRT","Portugal","2010","2010",3.7,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","ATCPTTMT","% of total sales","PRT","Portugal","2011","2011",3.6,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","ATCPTTMT","% of total sales","PRT","Portugal","2012","2012",3.3,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","ATCPTTMT","% of total sales","PRT","Portugal","2013","2013",3.8,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","ATCPTTMT","% of total sales","PRT","Portugal","2014","2014",4.6,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","ATCPTTMT","% of total sales","PRT","Portugal","2015","2015",5.6,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","ATCPTTMT","% of total sales","PRT","Portugal","2016","2016",6.9,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","ATCPTTMT","% of total sales","PRT","Portugal","2017","2017",7.5,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","ATCPTTMT","% of total sales","PRT","Portugal","2018","2018",8.6,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","ATCPTTMT","% of total sales","PRT","Portugal","2019","2019",9.3,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","ATCPTTMT","% of total sales","PRT","Portugal","2020","2020",9.3,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","ATCPTTMT","% of total sales","PRT","Portugal","2021","2021",9.7,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","ATCPTTMT","% of total sales","PRT","Portugal","2022","2022",9.5,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","MLLNCUMT","Million of national currency units","SVK","Slovak Republic","2010","2010",102.4,,
+"PATCBLOO","B-Blood and blood forming organs","MLLNCUMT","Million of national currency units","SVK","Slovak Republic","2011","2011",97.7,,
+"PATCBLOO","B-Blood and blood forming organs","MLLNCUMT","Million of national currency units","SVK","Slovak Republic","2012","2012",106.9,,
+"PATCBLOO","B-Blood and blood forming organs","MLLNCUMT","Million of national currency units","SVK","Slovak Republic","2013","2013",118.7,,
+"PATCBLOO","B-Blood and blood forming organs","MLLNCUMT","Million of national currency units","SVK","Slovak Republic","2014","2014",134.1,,
+"PATCBLOO","B-Blood and blood forming organs","MLLNCUMT","Million of national currency units","SVK","Slovak Republic","2015","2015",146.8,,
+"PATCBLOO","B-Blood and blood forming organs","MLLNCUMT","Million of national currency units","SVK","Slovak Republic","2016","2016",180.7,"B","Break"
+"PATCBLOO","B-Blood and blood forming organs","MLLNCUMT","Million of national currency units","SVK","Slovak Republic","2017","2017",191.1,,
+"PATCBLOO","B-Blood and blood forming organs","MLLNCUMT","Million of national currency units","SVK","Slovak Republic","2018","2018",213.8,,
+"PATCBLOO","B-Blood and blood forming organs","MLLNCUMT","Million of national currency units","SVK","Slovak Republic","2019","2019",217.1,,
+"PATCBLOO","B-Blood and blood forming organs","MLLNCUMT","Million of national currency units","SVK","Slovak Republic","2020","2020",203.8,,
+"PATCBLOO","B-Blood and blood forming organs","MLLNCUMT","Million of national currency units","SVK","Slovak Republic","2021","2021",176,,
+"PATCBLOO","B-Blood and blood forming organs","MTMOTCMT","Million US$ at exchange rate","SVK","Slovak Republic","2010","2010",135.7,,
+"PATCBLOO","B-Blood and blood forming organs","MTMOTCMT","Million US$ at exchange rate","SVK","Slovak Republic","2011","2011",136,,
+"PATCBLOO","B-Blood and blood forming organs","MTMOTCMT","Million US$ at exchange rate","SVK","Slovak Republic","2012","2012",137.3,,
+"PATCBLOO","B-Blood and blood forming organs","MTMOTCMT","Million US$ at exchange rate","SVK","Slovak Republic","2013","2013",157.6,,
+"PATCBLOO","B-Blood and blood forming organs","MTMOTCMT","Million US$ at exchange rate","SVK","Slovak Republic","2014","2014",178.1,,
+"PATCBLOO","B-Blood and blood forming organs","MTMOTCMT","Million US$ at exchange rate","SVK","Slovak Republic","2015","2015",162.8,,
+"PATCBLOO","B-Blood and blood forming organs","MTMOTCMT","Million US$ at exchange rate","SVK","Slovak Republic","2016","2016",200,"B","Break"
+"PATCBLOO","B-Blood and blood forming organs","MTMOTCMT","Million US$ at exchange rate","SVK","Slovak Republic","2017","2017",215.9,,
+"PATCBLOO","B-Blood and blood forming organs","MTMOTCMT","Million US$ at exchange rate","SVK","Slovak Republic","2018","2018",252.5,,
+"PATCBLOO","B-Blood and blood forming organs","MTMOTCMT","Million US$ at exchange rate","SVK","Slovak Republic","2019","2019",243,,
+"PATCBLOO","B-Blood and blood forming organs","MTMOTCMT","Million US$ at exchange rate","SVK","Slovak Republic","2020","2020",232.8,,
+"PATCBLOO","B-Blood and blood forming organs","MTMOTCMT","Million US$ at exchange rate","SVK","Slovak Republic","2021","2021",208.1,,
+"PATCBLOO","B-Blood and blood forming organs","MTMOPPMT","Million US$, purchasing power parity","SVK","Slovak Republic","2010","2010",203.8,,
+"PATCBLOO","B-Blood and blood forming organs","MTMOPPMT","Million US$, purchasing power parity","SVK","Slovak Republic","2011","2011",193,,
+"PATCBLOO","B-Blood and blood forming organs","MTMOPPMT","Million US$, purchasing power parity","SVK","Slovak Republic","2012","2012",211.9,,
+"PATCBLOO","B-Blood and blood forming organs","MTMOPPMT","Million US$, purchasing power parity","SVK","Slovak Republic","2013","2013",241.6,,
+"PATCBLOO","B-Blood and blood forming organs","MTMOPPMT","Million US$, purchasing power parity","SVK","Slovak Republic","2014","2014",276.2,,
+"PATCBLOO","B-Blood and blood forming organs","MTMOPPMT","Million US$, purchasing power parity","SVK","Slovak Republic","2015","2015",298.6,,
+"PATCBLOO","B-Blood and blood forming organs","MTMOPPMT","Million US$, purchasing power parity","SVK","Slovak Republic","2016","2016",359.1,"B","Break"
+"PATCBLOO","B-Blood and blood forming organs","MTMOPPMT","Million US$, purchasing power parity","SVK","Slovak Republic","2017","2017",370,,
+"PATCBLOO","B-Blood and blood forming organs","MTMOPPMT","Million US$, purchasing power parity","SVK","Slovak Republic","2018","2018",406.6,,
+"PATCBLOO","B-Blood and blood forming organs","MTMOPPMT","Million US$, purchasing power parity","SVK","Slovak Republic","2019","2019",419.5,,
+"PATCBLOO","B-Blood and blood forming organs","MTMOPPMT","Million US$, purchasing power parity","SVK","Slovak Republic","2020","2020",392,,
+"PATCBLOO","B-Blood and blood forming organs","MTMOPPMT","Million US$, purchasing power parity","SVK","Slovak Republic","2021","2021",329.9,,
+"PATCBLOO","B-Blood and blood forming organs","TCPPERMT","/capita, US$ exchange rate","SVK","Slovak Republic","2010","2010",25.2,,
+"PATCBLOO","B-Blood and blood forming organs","TCPPERMT","/capita, US$ exchange rate","SVK","Slovak Republic","2011","2011",25.2,,
+"PATCBLOO","B-Blood and blood forming organs","TCPPERMT","/capita, US$ exchange rate","SVK","Slovak Republic","2012","2012",25.4,,
+"PATCBLOO","B-Blood and blood forming organs","TCPPERMT","/capita, US$ exchange rate","SVK","Slovak Republic","2013","2013",29.1,,
+"PATCBLOO","B-Blood and blood forming organs","TCPPERMT","/capita, US$ exchange rate","SVK","Slovak Republic","2014","2014",32.9,,
+"PATCBLOO","B-Blood and blood forming organs","TCPPERMT","/capita, US$ exchange rate","SVK","Slovak Republic","2015","2015",30,,
+"PATCBLOO","B-Blood and blood forming organs","TCPPERMT","/capita, US$ exchange rate","SVK","Slovak Republic","2016","2016",36.8,"B","Break"
+"PATCBLOO","B-Blood and blood forming organs","TCPPERMT","/capita, US$ exchange rate","SVK","Slovak Republic","2017","2017",39.7,,
+"PATCBLOO","B-Blood and blood forming organs","TCPPERMT","/capita, US$ exchange rate","SVK","Slovak Republic","2018","2018",46.4,,
+"PATCBLOO","B-Blood and blood forming organs","TCPPERMT","/capita, US$ exchange rate","SVK","Slovak Republic","2019","2019",44.6,,
+"PATCBLOO","B-Blood and blood forming organs","TCPPERMT","/capita, US$ exchange rate","SVK","Slovak Republic","2020","2020",42.6,,
+"PATCBLOO","B-Blood and blood forming organs","TCPPERMT","/capita, US$ exchange rate","SVK","Slovak Republic","2021","2021",38.2,,
+"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2010","2010",37.8,,
+"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2011","2011",35.8,,
+"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2012","2012",39.2,,
+"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2013","2013",44.6,,
+"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2014","2014",51,,
+"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2015","2015",55.1,,
+"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2016","2016",66.1,"B","Break"
+"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2017","2017",68,,
+"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2018","2018",74.6,,
+"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2019","2019",76.9,,
+"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2020","2020",71.8,,
+"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2021","2021",60.6,,
+"PATCBLOO","B-Blood and blood forming organs","ATCPTTMT","% of total sales","SVK","Slovak Republic","2010","2010",9.2,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","ATCPTTMT","% of total sales","SVK","Slovak Republic","2011","2011",8.7,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","ATCPTTMT","% of total sales","SVK","Slovak Republic","2012","2012",9.7,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","ATCPTTMT","% of total sales","SVK","Slovak Republic","2013","2013",9.7,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","ATCPTTMT","% of total sales","SVK","Slovak Republic","2014","2014",10.2,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","ATCPTTMT","% of total sales","SVK","Slovak Republic","2015","2015",10.6,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","ATCPTTMT","% of total sales","SVK","Slovak Republic","2016","2016",11.5,"B","Break"
+"PATCBLOO","B-Blood and blood forming organs","ATCPTTMT","% of total sales","SVK","Slovak Republic","2017","2017",12.2,,
+"PATCBLOO","B-Blood and blood forming organs","ATCPTTMT","% of total sales","SVK","Slovak Republic","2018","2018",13.1,,
+"PATCBLOO","B-Blood and blood forming organs","ATCPTTMT","% of total sales","SVK","Slovak Republic","2019","2019",12.5,,
+"PATCBLOO","B-Blood and blood forming organs","ATCPTTMT","% of total sales","SVK","Slovak Republic","2020","2020",12.3,,
+"PATCBLOO","B-Blood and blood forming organs","ATCPTTMT","% of total sales","SVK","Slovak Republic","2021","2021",9.8,,
+"PATCBLOO","B-Blood and blood forming organs","MLLNCUMT","Million of national currency units","ESP","Spain","2010","2010",612.6,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","MLLNCUMT","Million of national currency units","ESP","Spain","2011","2011",529.6,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","MLLNCUMT","Million of national currency units","ESP","Spain","2012","2012",501.8,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","MLLNCUMT","Million of national currency units","ESP","Spain","2013","2013",526.8,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","MLLNCUMT","Million of national currency units","ESP","Spain","2014","2014",593.7,"B; D","Break; Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","MLLNCUMT","Million of national currency units","ESP","Spain","2015","2015",652.8,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","MLLNCUMT","Million of national currency units","ESP","Spain","2016","2016",729,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","MLLNCUMT","Million of national currency units","ESP","Spain","2017","2017",806.2,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","MLLNCUMT","Million of national currency units","ESP","Spain","2018","2018",1638.6,"B","Break"
+"PATCBLOO","B-Blood and blood forming organs","MLLNCUMT","Million of national currency units","ESP","Spain","2019","2019",1746.3,,
+"PATCBLOO","B-Blood and blood forming organs","MLLNCUMT","Million of national currency units","ESP","Spain","2020","2020",1847.2,,
+"PATCBLOO","B-Blood and blood forming organs","MLLNCUMT","Million of national currency units","ESP","Spain","2021","2021",2023.3,,
+"PATCBLOO","B-Blood and blood forming organs","MLLNCUMT","Million of national currency units","ESP","Spain","2022","2022",2090.9,"P","Provisional value"
+"PATCBLOO","B-Blood and blood forming organs","MTMOTCMT","Million US$ at exchange rate","ESP","Spain","2010","2010",812.1,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","MTMOTCMT","Million US$ at exchange rate","ESP","Spain","2011","2011",737.2,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","MTMOTCMT","Million US$ at exchange rate","ESP","Spain","2012","2012",644.7,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","MTMOTCMT","Million US$ at exchange rate","ESP","Spain","2013","2013",699.7,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","MTMOTCMT","Million US$ at exchange rate","ESP","Spain","2014","2014",788.8,"B; D","Break; Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","MTMOTCMT","Million US$ at exchange rate","ESP","Spain","2015","2015",724.3,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","MTMOTCMT","Million US$ at exchange rate","ESP","Spain","2016","2016",806.9,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","MTMOTCMT","Million US$ at exchange rate","ESP","Spain","2017","2017",910.7,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","MTMOTCMT","Million US$ at exchange rate","ESP","Spain","2018","2018",1935.2,"B","Break"
+"PATCBLOO","B-Blood and blood forming organs","MTMOTCMT","Million US$ at exchange rate","ESP","Spain","2019","2019",1954.9,,
+"PATCBLOO","B-Blood and blood forming organs","MTMOTCMT","Million US$ at exchange rate","ESP","Spain","2020","2020",2109.9,,
+"PATCBLOO","B-Blood and blood forming organs","MTMOTCMT","Million US$ at exchange rate","ESP","Spain","2021","2021",2393,,
+"PATCBLOO","B-Blood and blood forming organs","MTMOTCMT","Million US$ at exchange rate","ESP","Spain","2022","2022",2201.8,"P","Provisional value"
+"PATCBLOO","B-Blood and blood forming organs","MTMOPPMT","Million US$, purchasing power parity","ESP","Spain","2010","2010",842.7,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","MTMOPPMT","Million US$, purchasing power parity","ESP","Spain","2011","2011",741.7,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","MTMOPPMT","Million US$, purchasing power parity","ESP","Spain","2012","2012",722,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","MTMOPPMT","Million US$, purchasing power parity","ESP","Spain","2013","2013",780.7,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","MTMOPPMT","Million US$, purchasing power parity","ESP","Spain","2014","2014",896.4,"B; D","Break; Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","MTMOPPMT","Million US$, purchasing power parity","ESP","Spain","2015","2015",982,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","MTMOPPMT","Million US$, purchasing power parity","ESP","Spain","2016","2016",1134.4,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","MTMOPPMT","Million US$, purchasing power parity","ESP","Spain","2017","2017",1277.9,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","MTMOPPMT","Million US$, purchasing power parity","ESP","Spain","2018","2018",2593.6,"B","Break"
+"PATCBLOO","B-Blood and blood forming organs","MTMOPPMT","Million US$, purchasing power parity","ESP","Spain","2019","2019",2848.9,,
+"PATCBLOO","B-Blood and blood forming organs","MTMOPPMT","Million US$, purchasing power parity","ESP","Spain","2020","2020",2973,,
+"PATCBLOO","B-Blood and blood forming organs","MTMOPPMT","Million US$, purchasing power parity","ESP","Spain","2021","2021",3232.4,,
+"PATCBLOO","B-Blood and blood forming organs","MTMOPPMT","Million US$, purchasing power parity","ESP","Spain","2022","2022",3507,"P","Provisional value"
+"PATCBLOO","B-Blood and blood forming organs","TCPPERMT","/capita, US$ exchange rate","ESP","Spain","2010","2010",17.4,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","TCPPERMT","/capita, US$ exchange rate","ESP","Spain","2011","2011",15.8,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","TCPPERMT","/capita, US$ exchange rate","ESP","Spain","2012","2012",13.8,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","TCPPERMT","/capita, US$ exchange rate","ESP","Spain","2013","2013",15,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","TCPPERMT","/capita, US$ exchange rate","ESP","Spain","2014","2014",17,"B; D","Break; Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","TCPPERMT","/capita, US$ exchange rate","ESP","Spain","2015","2015",15.6,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","TCPPERMT","/capita, US$ exchange rate","ESP","Spain","2016","2016",17.4,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","TCPPERMT","/capita, US$ exchange rate","ESP","Spain","2017","2017",19.5,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","TCPPERMT","/capita, US$ exchange rate","ESP","Spain","2018","2018",41.4,"B","Break"
+"PATCBLOO","B-Blood and blood forming organs","TCPPERMT","/capita, US$ exchange rate","ESP","Spain","2019","2019",41.5,,
+"PATCBLOO","B-Blood and blood forming organs","TCPPERMT","/capita, US$ exchange rate","ESP","Spain","2020","2020",44.5,,
+"PATCBLOO","B-Blood and blood forming organs","TCPPERMT","/capita, US$ exchange rate","ESP","Spain","2021","2021",50.5,,
+"PATCBLOO","B-Blood and blood forming organs","TCPPERMT","/capita, US$ exchange rate","ESP","Spain","2022","2022",46.4,"P","Provisional value"
+"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2010","2010",18.1,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2011","2011",15.9,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2012","2012",15.4,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2013","2013",16.7,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2014","2014",19.3,"B; D","Break; Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2015","2015",21.1,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2016","2016",24.4,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2017","2017",27.4,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2018","2018",55.4,"B","Break"
+"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2019","2019",60.4,,
+"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2020","2020",62.8,,
+"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2021","2021",68.2,,
+"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2022","2022",73.9,"P","Provisional value"
+"PATCBLOO","B-Blood and blood forming organs","ATCPTTMT","% of total sales","ESP","Spain","2010","2010",4.6,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","ATCPTTMT","% of total sales","ESP","Spain","2011","2011",4.3,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","ATCPTTMT","% of total sales","ESP","Spain","2012","2012",4.5,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","ATCPTTMT","% of total sales","ESP","Spain","2013","2013",4.9,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","ATCPTTMT","% of total sales","ESP","Spain","2014","2014",5.3,"B; D","Break; Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","ATCPTTMT","% of total sales","ESP","Spain","2015","2015",5.7,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","ATCPTTMT","% of total sales","ESP","Spain","2016","2016",6.2,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","ATCPTTMT","% of total sales","ESP","Spain","2017","2017",6.7,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","ATCPTTMT","% of total sales","ESP","Spain","2018","2018",8.6,"B","Break"
+"PATCBLOO","B-Blood and blood forming organs","ATCPTTMT","% of total sales","ESP","Spain","2019","2019",8.7,,
+"PATCBLOO","B-Blood and blood forming organs","ATCPTTMT","% of total sales","ESP","Spain","2020","2020",8.9,,
+"PATCBLOO","B-Blood and blood forming organs","ATCPTTMT","% of total sales","ESP","Spain","2021","2021",9.2,,
+"PATCBLOO","B-Blood and blood forming organs","ATCPTTMT","% of total sales","ESP","Spain","2022","2022",9.1,"P","Provisional value"
+"PATCBLOO","B-Blood and blood forming organs","MLLNCUMT","Million of national currency units","SWE","Sweden","2010","2010",3079.7,,
+"PATCBLOO","B-Blood and blood forming organs","MLLNCUMT","Million of national currency units","SWE","Sweden","2011","2011",3169.6,,
+"PATCBLOO","B-Blood and blood forming organs","MLLNCUMT","Million of national currency units","SWE","Sweden","2012","2012",3172.3,,
+"PATCBLOO","B-Blood and blood forming organs","MLLNCUMT","Million of national currency units","SWE","Sweden","2013","2013",3148.6,,
+"PATCBLOO","B-Blood and blood forming organs","MLLNCUMT","Million of national currency units","SWE","Sweden","2014","2014",3223,,
+"PATCBLOO","B-Blood and blood forming organs","MLLNCUMT","Million of national currency units","SWE","Sweden","2015","2015",3520.9,,
+"PATCBLOO","B-Blood and blood forming organs","MLLNCUMT","Million of national currency units","SWE","Sweden","2016","2016",3887.5,,
+"PATCBLOO","B-Blood and blood forming organs","MLLNCUMT","Million of national currency units","SWE","Sweden","2017","2017",4294.4,,
+"PATCBLOO","B-Blood and blood forming organs","MLLNCUMT","Million of national currency units","SWE","Sweden","2018","2018",4641.8,,
+"PATCBLOO","B-Blood and blood forming organs","MLLNCUMT","Million of national currency units","SWE","Sweden","2019","2019",5018.9,,
+"PATCBLOO","B-Blood and blood forming organs","MLLNCUMT","Million of national currency units","SWE","Sweden","2020","2020",5405,,
+"PATCBLOO","B-Blood and blood forming organs","MLLNCUMT","Million of national currency units","SWE","Sweden","2021","2021",5630.8,,
+"PATCBLOO","B-Blood and blood forming organs","MLLNCUMT","Million of national currency units","SWE","Sweden","2022","2022",5980.5,,
+"PATCBLOO","B-Blood and blood forming organs","MTMOTCMT","Million US$ at exchange rate","SWE","Sweden","2010","2010",427.3,,
+"PATCBLOO","B-Blood and blood forming organs","MTMOTCMT","Million US$ at exchange rate","SWE","Sweden","2011","2011",488.1,,
+"PATCBLOO","B-Blood and blood forming organs","MTMOTCMT","Million US$ at exchange rate","SWE","Sweden","2012","2012",468.2,,
+"PATCBLOO","B-Blood and blood forming organs","MTMOTCMT","Million US$ at exchange rate","SWE","Sweden","2013","2013",483.4,,
+"PATCBLOO","B-Blood and blood forming organs","MTMOTCMT","Million US$ at exchange rate","SWE","Sweden","2014","2014",469.8,,
+"PATCBLOO","B-Blood and blood forming organs","MTMOTCMT","Million US$ at exchange rate","SWE","Sweden","2015","2015",417.4,,
+"PATCBLOO","B-Blood and blood forming organs","MTMOTCMT","Million US$ at exchange rate","SWE","Sweden","2016","2016",454,,
+"PATCBLOO","B-Blood and blood forming organs","MTMOTCMT","Million US$ at exchange rate","SWE","Sweden","2017","2017",502.3,,
+"PATCBLOO","B-Blood and blood forming organs","MTMOTCMT","Million US$ at exchange rate","SWE","Sweden","2018","2018",534,,
+"PATCBLOO","B-Blood and blood forming organs","MTMOTCMT","Million US$ at exchange rate","SWE","Sweden","2019","2019",530.6,,
+"PATCBLOO","B-Blood and blood forming organs","MTMOTCMT","Million US$ at exchange rate","SWE","Sweden","2020","2020",586.8,,
+"PATCBLOO","B-Blood and blood forming organs","MTMOTCMT","Million US$ at exchange rate","SWE","Sweden","2021","2021",656.5,,
+"PATCBLOO","B-Blood and blood forming organs","MTMOTCMT","Million US$ at exchange rate","SWE","Sweden","2022","2022",591.3,,
+"PATCBLOO","B-Blood and blood forming organs","MTMOPPMT","Million US$, purchasing power parity","SWE","Sweden","2010","2010",341.2,,
+"PATCBLOO","B-Blood and blood forming organs","MTMOPPMT","Million US$, purchasing power parity","SWE","Sweden","2011","2011",358.4,,
+"PATCBLOO","B-Blood and blood forming organs","MTMOPPMT","Million US$, purchasing power parity","SWE","Sweden","2012","2012",366.5,,
+"PATCBLOO","B-Blood and blood forming organs","MTMOPPMT","Million US$, purchasing power parity","SWE","Sweden","2013","2013",366.2,,
+"PATCBLOO","B-Blood and blood forming organs","MTMOPPMT","Million US$, purchasing power parity","SWE","Sweden","2014","2014",369.3,,
+"PATCBLOO","B-Blood and blood forming organs","MTMOPPMT","Million US$, purchasing power parity","SWE","Sweden","2015","2015",397.6,,
+"PATCBLOO","B-Blood and blood forming organs","MTMOPPMT","Million US$, purchasing power parity","SWE","Sweden","2016","2016",440.6,,
+"PATCBLOO","B-Blood and blood forming organs","MTMOPPMT","Million US$, purchasing power parity","SWE","Sweden","2017","2017",485.1,,
+"PATCBLOO","B-Blood and blood forming organs","MTMOPPMT","Million US$, purchasing power parity","SWE","Sweden","2018","2018",523.6,,
+"PATCBLOO","B-Blood and blood forming organs","MTMOPPMT","Million US$, purchasing power parity","SWE","Sweden","2019","2019",576.2,,
+"PATCBLOO","B-Blood and blood forming organs","MTMOPPMT","Million US$, purchasing power parity","SWE","Sweden","2020","2020",623.5,,
+"PATCBLOO","B-Blood and blood forming organs","MTMOPPMT","Million US$, purchasing power parity","SWE","Sweden","2021","2021",645.6,,
+"PATCBLOO","B-Blood and blood forming organs","MTMOPPMT","Million US$, purchasing power parity","SWE","Sweden","2022","2022",690.1,,
+"PATCBLOO","B-Blood and blood forming organs","TCPPERMT","/capita, US$ exchange rate","SWE","Sweden","2010","2010",45.6,,
+"PATCBLOO","B-Blood and blood forming organs","TCPPERMT","/capita, US$ exchange rate","SWE","Sweden","2011","2011",51.7,,
+"PATCBLOO","B-Blood and blood forming organs","TCPPERMT","/capita, US$ exchange rate","SWE","Sweden","2012","2012",49.2,,
+"PATCBLOO","B-Blood and blood forming organs","TCPPERMT","/capita, US$ exchange rate","SWE","Sweden","2013","2013",50.3,,
+"PATCBLOO","B-Blood and blood forming organs","TCPPERMT","/capita, US$ exchange rate","SWE","Sweden","2014","2014",48.4,,
+"PATCBLOO","B-Blood and blood forming organs","TCPPERMT","/capita, US$ exchange rate","SWE","Sweden","2015","2015",42.6,,
+"PATCBLOO","B-Blood and blood forming organs","TCPPERMT","/capita, US$ exchange rate","SWE","Sweden","2016","2016",45.8,,
+"PATCBLOO","B-Blood and blood forming organs","TCPPERMT","/capita, US$ exchange rate","SWE","Sweden","2017","2017",49.9,,
+"PATCBLOO","B-Blood and blood forming organs","TCPPERMT","/capita, US$ exchange rate","SWE","Sweden","2018","2018",52.5,,
+"PATCBLOO","B-Blood and blood forming organs","TCPPERMT","/capita, US$ exchange rate","SWE","Sweden","2019","2019",51.6,,
+"PATCBLOO","B-Blood and blood forming organs","TCPPERMT","/capita, US$ exchange rate","SWE","Sweden","2020","2020",56.7,,
+"PATCBLOO","B-Blood and blood forming organs","TCPPERMT","/capita, US$ exchange rate","SWE","Sweden","2021","2021",63,,
+"PATCBLOO","B-Blood and blood forming organs","TCPPERMT","/capita, US$ exchange rate","SWE","Sweden","2022","2022",56.6,,
+"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2010","2010",36.4,,
+"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2011","2011",37.9,,
+"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2012","2012",38.5,,
+"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2013","2013",38.1,,
+"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2014","2014",38.1,,
+"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2015","2015",40.6,,
+"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2016","2016",44.4,,
+"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2017","2017",48.2,,
+"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2018","2018",51.5,,
+"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2019","2019",56.1,,
+"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2020","2020",60.2,,
+"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2021","2021",62,,
+"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2022","2022",66,,
+"PATCBLOO","B-Blood and blood forming organs","ATCPTTMT","% of total sales","SWE","Sweden","2010","2010",8.5,,
+"PATCBLOO","B-Blood and blood forming organs","ATCPTTMT","% of total sales","SWE","Sweden","2011","2011",8.6,,
+"PATCBLOO","B-Blood and blood forming organs","ATCPTTMT","% of total sales","SWE","Sweden","2012","2012",8.8,,
+"PATCBLOO","B-Blood and blood forming organs","ATCPTTMT","% of total sales","SWE","Sweden","2013","2013",8.7,,
+"PATCBLOO","B-Blood and blood forming organs","ATCPTTMT","% of total sales","SWE","Sweden","2014","2014",8.5,,
+"PATCBLOO","B-Blood and blood forming organs","ATCPTTMT","% of total sales","SWE","Sweden","2015","2015",8.7,,
+"PATCBLOO","B-Blood and blood forming organs","ATCPTTMT","% of total sales","SWE","Sweden","2016","2016",9.2,,
+"PATCBLOO","B-Blood and blood forming organs","ATCPTTMT","% of total sales","SWE","Sweden","2017","2017",9.8,,
+"PATCBLOO","B-Blood and blood forming organs","ATCPTTMT","% of total sales","SWE","Sweden","2018","2018",9.7,,
+"PATCBLOO","B-Blood and blood forming organs","ATCPTTMT","% of total sales","SWE","Sweden","2019","2019",9.9,,
+"PATCBLOO","B-Blood and blood forming organs","ATCPTTMT","% of total sales","SWE","Sweden","2020","2020",10.3,,
+"PATCBLOO","B-Blood and blood forming organs","ATCPTTMT","% of total sales","SWE","Sweden","2021","2021",10.5,,
+"PATCBLOO","B-Blood and blood forming organs","ATCPTTMT","% of total sales","SWE","Sweden","2022","2022",10.3,,
+"PATCBLOO","B-Blood and blood forming organs","MLLNCUMT","Million of national currency units","CHE","Switzerland","2010","2010",215.5,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","MLLNCUMT","Million of national currency units","CHE","Switzerland","2011","2011",208,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","MLLNCUMT","Million of national currency units","CHE","Switzerland","2012","2012",222,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","MLLNCUMT","Million of national currency units","CHE","Switzerland","2013","2013",245,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","MLLNCUMT","Million of national currency units","CHE","Switzerland","2014","2014",263,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","MLLNCUMT","Million of national currency units","CHE","Switzerland","2015","2015",285,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","MLLNCUMT","Million of national currency units","CHE","Switzerland","2016","2016",320,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","MLLNCUMT","Million of national currency units","CHE","Switzerland","2017","2017",354,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","MLLNCUMT","Million of national currency units","CHE","Switzerland","2018","2018",387,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","MLLNCUMT","Million of national currency units","CHE","Switzerland","2019","2019",397,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","MLLNCUMT","Million of national currency units","CHE","Switzerland","2020","2020",422,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","MLLNCUMT","Million of national currency units","CHE","Switzerland","2021","2021",453,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","MLLNCUMT","Million of national currency units","CHE","Switzerland","2022","2022",455,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","MTMOTCMT","Million US$ at exchange rate","CHE","Switzerland","2010","2010",206.6,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","MTMOTCMT","Million US$ at exchange rate","CHE","Switzerland","2011","2011",234.2,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","MTMOTCMT","Million US$ at exchange rate","CHE","Switzerland","2012","2012",236.8,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","MTMOTCMT","Million US$ at exchange rate","CHE","Switzerland","2013","2013",264.3,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","MTMOTCMT","Million US$ at exchange rate","CHE","Switzerland","2014","2014",287.1,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","MTMOTCMT","Million US$ at exchange rate","CHE","Switzerland","2015","2015",296.1,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","MTMOTCMT","Million US$ at exchange rate","CHE","Switzerland","2016","2016",324.7,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","MTMOTCMT","Million US$ at exchange rate","CHE","Switzerland","2017","2017",359.5,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","MTMOTCMT","Million US$ at exchange rate","CHE","Switzerland","2018","2018",395.7,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","MTMOTCMT","Million US$ at exchange rate","CHE","Switzerland","2019","2019",399.5,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","MTMOTCMT","Million US$ at exchange rate","CHE","Switzerland","2020","2020",449.4,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","MTMOTCMT","Million US$ at exchange rate","CHE","Switzerland","2021","2021",495.7,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","MTMOTCMT","Million US$ at exchange rate","CHE","Switzerland","2022","2022",476.5,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","MTMOPPMT","Million US$, purchasing power parity","CHE","Switzerland","2010","2010",147,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","MTMOPPMT","Million US$, purchasing power parity","CHE","Switzerland","2011","2011",148.8,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","MTMOPPMT","Million US$, purchasing power parity","CHE","Switzerland","2012","2012",163.9,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","MTMOPPMT","Million US$, purchasing power parity","CHE","Switzerland","2013","2013",186.7,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","MTMOPPMT","Million US$, purchasing power parity","CHE","Switzerland","2014","2014",205.2,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","MTMOPPMT","Million US$, purchasing power parity","CHE","Switzerland","2015","2015",230.6,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","MTMOPPMT","Million US$, purchasing power parity","CHE","Switzerland","2016","2016",266.2,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","MTMOPPMT","Million US$, purchasing power parity","CHE","Switzerland","2017","2017",298,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","MTMOPPMT","Million US$, purchasing power parity","CHE","Switzerland","2018","2018",328.3,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","MTMOPPMT","Million US$, purchasing power parity","CHE","Switzerland","2019","2019",345.1,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","MTMOPPMT","Million US$, purchasing power parity","CHE","Switzerland","2020","2020",371.6,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","MTMOPPMT","Million US$, purchasing power parity","CHE","Switzerland","2021","2021",409.4,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","MTMOPPMT","Million US$, purchasing power parity","CHE","Switzerland","2022","2022",426.9,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","TCPPERMT","/capita, US$ exchange rate","CHE","Switzerland","2010","2010",26.4,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","TCPPERMT","/capita, US$ exchange rate","CHE","Switzerland","2011","2011",29.6,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","TCPPERMT","/capita, US$ exchange rate","CHE","Switzerland","2012","2012",29.6,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","TCPPERMT","/capita, US$ exchange rate","CHE","Switzerland","2013","2013",32.7,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","TCPPERMT","/capita, US$ exchange rate","CHE","Switzerland","2014","2014",35.1,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","TCPPERMT","/capita, US$ exchange rate","CHE","Switzerland","2015","2015",35.8,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","TCPPERMT","/capita, US$ exchange rate","CHE","Switzerland","2016","2016",38.8,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","TCPPERMT","/capita, US$ exchange rate","CHE","Switzerland","2017","2017",42.5,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","TCPPERMT","/capita, US$ exchange rate","CHE","Switzerland","2018","2018",46.5,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","TCPPERMT","/capita, US$ exchange rate","CHE","Switzerland","2019","2019",46.6,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","TCPPERMT","/capita, US$ exchange rate","CHE","Switzerland","2020","2020",52,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","TCPPERMT","/capita, US$ exchange rate","CHE","Switzerland","2021","2021",56.9,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","TCPPERMT","/capita, US$ exchange rate","CHE","Switzerland","2022","2022",54.5,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","CHE","Switzerland","2010","2010",18.8,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","CHE","Switzerland","2011","2011",18.8,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","CHE","Switzerland","2012","2012",20.5,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","CHE","Switzerland","2013","2013",23.1,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","CHE","Switzerland","2014","2014",25.1,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","CHE","Switzerland","2015","2015",27.8,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","CHE","Switzerland","2016","2016",31.8,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","CHE","Switzerland","2017","2017",35.3,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","CHE","Switzerland","2018","2018",38.6,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","CHE","Switzerland","2019","2019",40.2,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","CHE","Switzerland","2020","2020",43,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","CHE","Switzerland","2021","2021",47,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","CHE","Switzerland","2022","2022",48.8,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","ATCPTTMT","% of total sales","CHE","Switzerland","2010","2010",3.8,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","ATCPTTMT","% of total sales","CHE","Switzerland","2011","2011",3.6,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","ATCPTTMT","% of total sales","CHE","Switzerland","2012","2012",3.7,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","ATCPTTMT","% of total sales","CHE","Switzerland","2013","2013",4.1,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","ATCPTTMT","% of total sales","CHE","Switzerland","2014","2014",4.4,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","ATCPTTMT","% of total sales","CHE","Switzerland","2015","2015",4.6,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","ATCPTTMT","% of total sales","CHE","Switzerland","2016","2016",5,"B; D","Break; Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","ATCPTTMT","% of total sales","CHE","Switzerland","2017","2017",5.4,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","ATCPTTMT","% of total sales","CHE","Switzerland","2018","2018",5.9,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","ATCPTTMT","% of total sales","CHE","Switzerland","2019","2019",5.9,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","ATCPTTMT","% of total sales","CHE","Switzerland","2020","2020",6.2,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","ATCPTTMT","% of total sales","CHE","Switzerland","2021","2021",6.4,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","ATCPTTMT","% of total sales","CHE","Switzerland","2022","2022",6,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","MLLNCUMT","Million of national currency units","TUR","Türkiye","2010","2010",716.2,,
+"PATCBLOO","B-Blood and blood forming organs","MLLNCUMT","Million of national currency units","TUR","Türkiye","2011","2011",739,,
+"PATCBLOO","B-Blood and blood forming organs","MLLNCUMT","Million of national currency units","TUR","Türkiye","2012","2012",744.3,,
+"PATCBLOO","B-Blood and blood forming organs","MLLNCUMT","Million of national currency units","TUR","Türkiye","2013","2013",824.5,,
+"PATCBLOO","B-Blood and blood forming organs","MLLNCUMT","Million of national currency units","TUR","Türkiye","2014","2014",959.9,,
+"PATCBLOO","B-Blood and blood forming organs","MLLNCUMT","Million of national currency units","TUR","Türkiye","2015","2015",1179,,
+"PATCBLOO","B-Blood and blood forming organs","MLLNCUMT","Million of national currency units","TUR","Türkiye","2016","2016",1410.9,,
+"PATCBLOO","B-Blood and blood forming organs","MLLNCUMT","Million of national currency units","TUR","Türkiye","2017","2017",1774.8,,
+"PATCBLOO","B-Blood and blood forming organs","MLLNCUMT","Million of national currency units","TUR","Türkiye","2018","2018",2309.3,,
+"PATCBLOO","B-Blood and blood forming organs","MLLNCUMT","Million of national currency units","TUR","Türkiye","2019","2019",3114.7,,
+"PATCBLOO","B-Blood and blood forming organs","MLLNCUMT","Million of national currency units","TUR","Türkiye","2020","2020",3935,,
+"PATCBLOO","B-Blood and blood forming organs","MLLNCUMT","Million of national currency units","TUR","Türkiye","2021","2021",5042,,
+"PATCBLOO","B-Blood and blood forming organs","MTMOTCMT","Million US$ at exchange rate","TUR","Türkiye","2010","2010",476.6,,
+"PATCBLOO","B-Blood and blood forming organs","MTMOTCMT","Million US$ at exchange rate","TUR","Türkiye","2011","2011",441.2,,
+"PATCBLOO","B-Blood and blood forming organs","MTMOTCMT","Million US$ at exchange rate","TUR","Türkiye","2012","2012",414.4,,
+"PATCBLOO","B-Blood and blood forming organs","MTMOTCMT","Million US$ at exchange rate","TUR","Türkiye","2013","2013",433.1,,
+"PATCBLOO","B-Blood and blood forming organs","MTMOTCMT","Million US$ at exchange rate","TUR","Türkiye","2014","2014",438.6,,
+"PATCBLOO","B-Blood and blood forming organs","MTMOTCMT","Million US$ at exchange rate","TUR","Türkiye","2015","2015",433.5,,
+"PATCBLOO","B-Blood and blood forming organs","MTMOTCMT","Million US$ at exchange rate","TUR","Türkiye","2016","2016",467.2,,
+"PATCBLOO","B-Blood and blood forming organs","MTMOTCMT","Million US$ at exchange rate","TUR","Türkiye","2017","2017",486.5,,
+"PATCBLOO","B-Blood and blood forming organs","MTMOTCMT","Million US$ at exchange rate","TUR","Türkiye","2018","2018",478.3,,
+"PATCBLOO","B-Blood and blood forming organs","MTMOTCMT","Million US$ at exchange rate","TUR","Türkiye","2019","2019",549,,
+"PATCBLOO","B-Blood and blood forming organs","MTMOTCMT","Million US$ at exchange rate","TUR","Türkiye","2020","2020",561.5,,
+"PATCBLOO","B-Blood and blood forming organs","MTMOTCMT","Million US$ at exchange rate","TUR","Türkiye","2021","2021",569.7,,
+"PATCBLOO","B-Blood and blood forming organs","MTMOPPMT","Million US$, purchasing power parity","TUR","Türkiye","2010","2010",778.2,,
+"PATCBLOO","B-Blood and blood forming organs","MTMOPPMT","Million US$, purchasing power parity","TUR","Türkiye","2011","2011",764.9,,
+"PATCBLOO","B-Blood and blood forming organs","MTMOPPMT","Million US$, purchasing power parity","TUR","Türkiye","2012","2012",729.8,,
+"PATCBLOO","B-Blood and blood forming organs","MTMOPPMT","Million US$, purchasing power parity","TUR","Türkiye","2013","2013",770.3,,
+"PATCBLOO","B-Blood and blood forming organs","MTMOPPMT","Million US$, purchasing power parity","TUR","Türkiye","2014","2014",869.1,,
+"PATCBLOO","B-Blood and blood forming organs","MTMOPPMT","Million US$, purchasing power parity","TUR","Türkiye","2015","2015",1014.3,,
+"PATCBLOO","B-Blood and blood forming organs","MTMOPPMT","Million US$, purchasing power parity","TUR","Türkiye","2016","2016",1136.9,,
+"PATCBLOO","B-Blood and blood forming organs","MTMOPPMT","Million US$, purchasing power parity","TUR","Türkiye","2017","2017",1282.4,,
+"PATCBLOO","B-Blood and blood forming organs","MTMOPPMT","Million US$, purchasing power parity","TUR","Türkiye","2018","2018",1414.5,,
+"PATCBLOO","B-Blood and blood forming organs","MTMOPPMT","Million US$, purchasing power parity","TUR","Türkiye","2019","2019",1671,,
+"PATCBLOO","B-Blood and blood forming organs","MTMOPPMT","Million US$, purchasing power parity","TUR","Türkiye","2020","2020",1818.2,,
+"PATCBLOO","B-Blood and blood forming organs","MTMOPPMT","Million US$, purchasing power parity","TUR","Türkiye","2021","2021",1795.7,,
+"PATCBLOO","B-Blood and blood forming organs","TCPPERMT","/capita, US$ exchange rate","TUR","Türkiye","2010","2010",6.5,,
+"PATCBLOO","B-Blood and blood forming organs","TCPPERMT","/capita, US$ exchange rate","TUR","Türkiye","2011","2011",5.9,,
+"PATCBLOO","B-Blood and blood forming organs","TCPPERMT","/capita, US$ exchange rate","TUR","Türkiye","2012","2012",5.5,,
+"PATCBLOO","B-Blood and blood forming organs","TCPPERMT","/capita, US$ exchange rate","TUR","Türkiye","2013","2013",5.7,,
+"PATCBLOO","B-Blood and blood forming organs","TCPPERMT","/capita, US$ exchange rate","TUR","Türkiye","2014","2014",5.7,,
+"PATCBLOO","B-Blood and blood forming organs","TCPPERMT","/capita, US$ exchange rate","TUR","Türkiye","2015","2015",5.5,,
+"PATCBLOO","B-Blood and blood forming organs","TCPPERMT","/capita, US$ exchange rate","TUR","Türkiye","2016","2016",5.9,,
+"PATCBLOO","B-Blood and blood forming organs","TCPPERMT","/capita, US$ exchange rate","TUR","Türkiye","2017","2017",6.1,,
+"PATCBLOO","B-Blood and blood forming organs","TCPPERMT","/capita, US$ exchange rate","TUR","Türkiye","2018","2018",5.9,,
+"PATCBLOO","B-Blood and blood forming organs","TCPPERMT","/capita, US$ exchange rate","TUR","Türkiye","2019","2019",6.6,,
+"PATCBLOO","B-Blood and blood forming organs","TCPPERMT","/capita, US$ exchange rate","TUR","Türkiye","2020","2020",6.7,,
+"PATCBLOO","B-Blood and blood forming organs","TCPPERMT","/capita, US$ exchange rate","TUR","Türkiye","2021","2021",6.8,,
+"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2010","2010",10.6,,
+"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2011","2011",10.3,,
+"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2012","2012",9.7,,
+"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2013","2013",10.1,,
+"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2014","2014",11.3,,
+"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2015","2015",13,,
+"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2016","2016",14.3,,
+"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2017","2017",16,,
+"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2018","2018",17.4,,
+"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2019","2019",20.2,,
+"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2020","2020",21.8,,
+"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2021","2021",21.3,,
+"PATCBLOO","B-Blood and blood forming organs","ATCPTTMT","% of total sales","TUR","Türkiye","2010","2010",4.6,,
+"PATCBLOO","B-Blood and blood forming organs","ATCPTTMT","% of total sales","TUR","Türkiye","2011","2011",5.2,,
+"PATCBLOO","B-Blood and blood forming organs","ATCPTTMT","% of total sales","TUR","Türkiye","2012","2012",5.5,,
+"PATCBLOO","B-Blood and blood forming organs","ATCPTTMT","% of total sales","TUR","Türkiye","2013","2013",5.8,,
+"PATCBLOO","B-Blood and blood forming organs","ATCPTTMT","% of total sales","TUR","Türkiye","2014","2014",6.1,,
+"PATCBLOO","B-Blood and blood forming organs","ATCPTTMT","% of total sales","TUR","Türkiye","2015","2015",6.4,,
+"PATCBLOO","B-Blood and blood forming organs","ATCPTTMT","% of total sales","TUR","Türkiye","2016","2016",6.4,,
+"PATCBLOO","B-Blood and blood forming organs","ATCPTTMT","% of total sales","TUR","Türkiye","2017","2017",7,,
+"PATCBLOO","B-Blood and blood forming organs","ATCPTTMT","% of total sales","TUR","Türkiye","2018","2018",7.2,,
+"PATCBLOO","B-Blood and blood forming organs","ATCPTTMT","% of total sales","TUR","Türkiye","2019","2019",7.4,,
+"PATCBLOO","B-Blood and blood forming organs","ATCPTTMT","% of total sales","TUR","Türkiye","2020","2020",7.9,,
+"PATCBLOO","B-Blood and blood forming organs","ATCPTTMT","% of total sales","TUR","Türkiye","2021","2021",7.8,,
+"PATCBLOO","B-Blood and blood forming organs","MLLNCUMT","Million of national currency units","GBR","United Kingdom","2012","2012",580,"B","Break"
+"PATCBLOO","B-Blood and blood forming organs","MLLNCUMT","Million of national currency units","GBR","United Kingdom","2013","2013",649.5,,
+"PATCBLOO","B-Blood and blood forming organs","MLLNCUMT","Million of national currency units","GBR","United Kingdom","2014","2014",761.4,,
+"PATCBLOO","B-Blood and blood forming organs","MLLNCUMT","Million of national currency units","GBR","United Kingdom","2015","2015",900.8,,
+"PATCBLOO","B-Blood and blood forming organs","MLLNCUMT","Million of national currency units","GBR","United Kingdom","2016","2016",1029.7,,
+"PATCBLOO","B-Blood and blood forming organs","MLLNCUMT","Million of national currency units","GBR","United Kingdom","2017","2017",1182.9,,
+"PATCBLOO","B-Blood and blood forming organs","MLLNCUMT","Million of national currency units","GBR","United Kingdom","2018","2018",1335,,
+"PATCBLOO","B-Blood and blood forming organs","MTMOTCMT","Million US$ at exchange rate","GBR","United Kingdom","2012","2012",916.2,"B","Break"
+"PATCBLOO","B-Blood and blood forming organs","MTMOTCMT","Million US$ at exchange rate","GBR","United Kingdom","2013","2013",1015.4,,
+"PATCBLOO","B-Blood and blood forming organs","MTMOTCMT","Million US$ at exchange rate","GBR","United Kingdom","2014","2014",1252.9,,
+"PATCBLOO","B-Blood and blood forming organs","MTMOTCMT","Million US$ at exchange rate","GBR","United Kingdom","2015","2015",1376.2,,
+"PATCBLOO","B-Blood and blood forming organs","MTMOTCMT","Million US$ at exchange rate","GBR","United Kingdom","2016","2016",1390.3,,
+"PATCBLOO","B-Blood and blood forming organs","MTMOTCMT","Million US$ at exchange rate","GBR","United Kingdom","2017","2017",1522.4,,
+"PATCBLOO","B-Blood and blood forming organs","MTMOTCMT","Million US$ at exchange rate","GBR","United Kingdom","2018","2018",1781.1,,
+"PATCBLOO","B-Blood and blood forming organs","MTMOPPMT","Million US$, purchasing power parity","GBR","United Kingdom","2012","2012",826.6,"B","Break"
+"PATCBLOO","B-Blood and blood forming organs","MTMOPPMT","Million US$, purchasing power parity","GBR","United Kingdom","2013","2013",934.2,,
+"PATCBLOO","B-Blood and blood forming organs","MTMOPPMT","Million US$, purchasing power parity","GBR","United Kingdom","2014","2014",1090.1,,
+"PATCBLOO","B-Blood and blood forming organs","MTMOPPMT","Million US$, purchasing power parity","GBR","United Kingdom","2015","2015",1300.7,,
+"PATCBLOO","B-Blood and blood forming organs","MTMOPPMT","Million US$, purchasing power parity","GBR","United Kingdom","2016","2016",1495.3,,
+"PATCBLOO","B-Blood and blood forming organs","MTMOPPMT","Million US$, purchasing power parity","GBR","United Kingdom","2017","2017",1727.9,,
+"PATCBLOO","B-Blood and blood forming organs","MTMOPPMT","Million US$, purchasing power parity","GBR","United Kingdom","2018","2018",1941.2,,
+"PATCBLOO","B-Blood and blood forming organs","TCPPERMT","/capita, US$ exchange rate","GBR","United Kingdom","2012","2012",14.4,"B","Break"
+"PATCBLOO","B-Blood and blood forming organs","TCPPERMT","/capita, US$ exchange rate","GBR","United Kingdom","2013","2013",15.8,,
+"PATCBLOO","B-Blood and blood forming organs","TCPPERMT","/capita, US$ exchange rate","GBR","United Kingdom","2014","2014",19.4,,
+"PATCBLOO","B-Blood and blood forming organs","TCPPERMT","/capita, US$ exchange rate","GBR","United Kingdom","2015","2015",21.1,,
+"PATCBLOO","B-Blood and blood forming organs","TCPPERMT","/capita, US$ exchange rate","GBR","United Kingdom","2016","2016",21.2,,
+"PATCBLOO","B-Blood and blood forming organs","TCPPERMT","/capita, US$ exchange rate","GBR","United Kingdom","2017","2017",23.1,,
+"PATCBLOO","B-Blood and blood forming organs","TCPPERMT","/capita, US$ exchange rate","GBR","United Kingdom","2018","2018",26.8,,
+"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","GBR","United Kingdom","2012","2012",13,"B","Break"
+"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","GBR","United Kingdom","2013","2013",14.6,,
+"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","GBR","United Kingdom","2014","2014",16.9,,
+"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","GBR","United Kingdom","2015","2015",20,,
+"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","GBR","United Kingdom","2016","2016",22.8,,
+"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","GBR","United Kingdom","2017","2017",26.2,,
+"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","GBR","United Kingdom","2018","2018",29.2,,
+"PATCBLOO","B-Blood and blood forming organs","ATCPTTMT","% of total sales","GBR","United Kingdom","2012","2012",4.2,"B","Break"
+"PATCBLOO","B-Blood and blood forming organs","ATCPTTMT","% of total sales","GBR","United Kingdom","2013","2013",4.4,,
+"PATCBLOO","B-Blood and blood forming organs","ATCPTTMT","% of total sales","GBR","United Kingdom","2014","2014",4.8,,
+"PATCBLOO","B-Blood and blood forming organs","ATCPTTMT","% of total sales","GBR","United Kingdom","2015","2015",5.1,,
+"PATCBLOO","B-Blood and blood forming organs","ATCPTTMT","% of total sales","GBR","United Kingdom","2016","2016",5.5,,
+"PATCBLOO","B-Blood and blood forming organs","ATCPTTMT","% of total sales","GBR","United Kingdom","2017","2017",6.1,,
+"PATCBLOO","B-Blood and blood forming organs","ATCPTTMT","% of total sales","GBR","United Kingdom","2018","2018",6.5,,
+"PATCBLOO","B-Blood and blood forming organs","MLLNCUMT","Million of national currency units","CHL","Chile","2010","2010",19663.6,,
+"PATCBLOO","B-Blood and blood forming organs","MLLNCUMT","Million of national currency units","CHL","Chile","2011","2011",55202.5,"B","Break"
+"PATCBLOO","B-Blood and blood forming organs","MLLNCUMT","Million of national currency units","CHL","Chile","2012","2012",66082.9,,
+"PATCBLOO","B-Blood and blood forming organs","MLLNCUMT","Million of national currency units","CHL","Chile","2013","2013",75138.6,,
+"PATCBLOO","B-Blood and blood forming organs","MLLNCUMT","Million of national currency units","CHL","Chile","2014","2014",68583.3,,
+"PATCBLOO","B-Blood and blood forming organs","MLLNCUMT","Million of national currency units","CHL","Chile","2015","2015",92673.7,,
+"PATCBLOO","B-Blood and blood forming organs","MLLNCUMT","Million of national currency units","CHL","Chile","2016","2016",99840,,
+"PATCBLOO","B-Blood and blood forming organs","MLLNCUMT","Million of national currency units","CHL","Chile","2017","2017",93218.1,,
+"PATCBLOO","B-Blood and blood forming organs","MLLNCUMT","Million of national currency units","CHL","Chile","2018","2018",117343.5,,
+"PATCBLOO","B-Blood and blood forming organs","MLLNCUMT","Million of national currency units","CHL","Chile","2019","2019",137320.8,,
+"PATCBLOO","B-Blood and blood forming organs","MLLNCUMT","Million of national currency units","CHL","Chile","2020","2020",139350.2,,
+"PATCBLOO","B-Blood and blood forming organs","MLLNCUMT","Million of national currency units","CHL","Chile","2021","2021",199401.4,,
+"PATCBLOO","B-Blood and blood forming organs","MLLNCUMT","Million of national currency units","CHL","Chile","2022","2022",178790.7,,
+"PATCBLOO","B-Blood and blood forming organs","MTMOTCMT","Million US$ at exchange rate","CHL","Chile","2010","2010",38.5,,
+"PATCBLOO","B-Blood and blood forming organs","MTMOTCMT","Million US$ at exchange rate","CHL","Chile","2011","2011",114.1,"B","Break"
+"PATCBLOO","B-Blood and blood forming organs","MTMOTCMT","Million US$ at exchange rate","CHL","Chile","2012","2012",135.8,,
+"PATCBLOO","B-Blood and blood forming organs","MTMOTCMT","Million US$ at exchange rate","CHL","Chile","2013","2013",151.7,,
+"PATCBLOO","B-Blood and blood forming organs","MTMOTCMT","Million US$ at exchange rate","CHL","Chile","2014","2014",120.2,,
+"PATCBLOO","B-Blood and blood forming organs","MTMOTCMT","Million US$ at exchange rate","CHL","Chile","2015","2015",141.7,,
+"PATCBLOO","B-Blood and blood forming organs","MTMOTCMT","Million US$ at exchange rate","CHL","Chile","2016","2016",147.5,,
+"PATCBLOO","B-Blood and blood forming organs","MTMOTCMT","Million US$ at exchange rate","CHL","Chile","2017","2017",143.7,,
+"PATCBLOO","B-Blood and blood forming organs","MTMOTCMT","Million US$ at exchange rate","CHL","Chile","2018","2018",183,,
+"PATCBLOO","B-Blood and blood forming organs","MTMOTCMT","Million US$ at exchange rate","CHL","Chile","2019","2019",195.4,,
+"PATCBLOO","B-Blood and blood forming organs","MTMOTCMT","Million US$ at exchange rate","CHL","Chile","2020","2020",175.8,,
+"PATCBLOO","B-Blood and blood forming organs","MTMOTCMT","Million US$ at exchange rate","CHL","Chile","2021","2021",262.7,,
+"PATCBLOO","B-Blood and blood forming organs","MTMOTCMT","Million US$ at exchange rate","CHL","Chile","2022","2022",204.7,,
+"PATCBLOO","B-Blood and blood forming organs","MTMOPPMT","Million US$, purchasing power parity","CHL","Chile","2010","2010",54.6,,
+"PATCBLOO","B-Blood and blood forming organs","MTMOPPMT","Million US$, purchasing power parity","CHL","Chile","2011","2011",158.6,"B","Break"
+"PATCBLOO","B-Blood and blood forming organs","MTMOPPMT","Million US$, purchasing power parity","CHL","Chile","2012","2012",190.3,,
+"PATCBLOO","B-Blood and blood forming organs","MTMOPPMT","Million US$, purchasing power parity","CHL","Chile","2013","2013",214.9,,
+"PATCBLOO","B-Blood and blood forming organs","MTMOPPMT","Million US$, purchasing power parity","CHL","Chile","2014","2014",186.8,,
+"PATCBLOO","B-Blood and blood forming organs","MTMOPPMT","Million US$, purchasing power parity","CHL","Chile","2015","2015",236.9,,
+"PATCBLOO","B-Blood and blood forming organs","MTMOPPMT","Million US$, purchasing power parity","CHL","Chile","2016","2016",251.3,,
+"PATCBLOO","B-Blood and blood forming organs","MTMOPPMT","Million US$, purchasing power parity","CHL","Chile","2017","2017",234.4,,
+"PATCBLOO","B-Blood and blood forming organs","MTMOPPMT","Million US$, purchasing power parity","CHL","Chile","2018","2018",296.2,,
+"PATCBLOO","B-Blood and blood forming organs","MTMOPPMT","Million US$, purchasing power parity","CHL","Chile","2019","2019",341.9,,
+"PATCBLOO","B-Blood and blood forming organs","MTMOPPMT","Million US$, purchasing power parity","CHL","Chile","2020","2020",333,,
+"PATCBLOO","B-Blood and blood forming organs","MTMOPPMT","Million US$, purchasing power parity","CHL","Chile","2021","2021",458.2,,
+"PATCBLOO","B-Blood and blood forming organs","MTMOPPMT","Million US$, purchasing power parity","CHL","Chile","2022","2022",408.6,,
+"PATCBLOO","B-Blood and blood forming organs","TCPPERMT","/capita, US$ exchange rate","CHL","Chile","2010","2010",2.3,,
+"PATCBLOO","B-Blood and blood forming organs","TCPPERMT","/capita, US$ exchange rate","CHL","Chile","2011","2011",6.6,"B","Break"
+"PATCBLOO","B-Blood and blood forming organs","TCPPERMT","/capita, US$ exchange rate","CHL","Chile","2012","2012",7.8,,
+"PATCBLOO","B-Blood and blood forming organs","TCPPERMT","/capita, US$ exchange rate","CHL","Chile","2013","2013",8.6,,
+"PATCBLOO","B-Blood and blood forming organs","TCPPERMT","/capita, US$ exchange rate","CHL","Chile","2014","2014",6.8,,
+"PATCBLOO","B-Blood and blood forming organs","TCPPERMT","/capita, US$ exchange rate","CHL","Chile","2015","2015",7.9,,
+"PATCBLOO","B-Blood and blood forming organs","TCPPERMT","/capita, US$ exchange rate","CHL","Chile","2016","2016",8.1,,
+"PATCBLOO","B-Blood and blood forming organs","TCPPERMT","/capita, US$ exchange rate","CHL","Chile","2017","2017",7.8,,
+"PATCBLOO","B-Blood and blood forming organs","TCPPERMT","/capita, US$ exchange rate","CHL","Chile","2018","2018",9.8,,
+"PATCBLOO","B-Blood and blood forming organs","TCPPERMT","/capita, US$ exchange rate","CHL","Chile","2019","2019",10.2,,
+"PATCBLOO","B-Blood and blood forming organs","TCPPERMT","/capita, US$ exchange rate","CHL","Chile","2020","2020",9,,
+"PATCBLOO","B-Blood and blood forming organs","TCPPERMT","/capita, US$ exchange rate","CHL","Chile","2021","2021",13.4,,
+"PATCBLOO","B-Blood and blood forming organs","TCPPERMT","/capita, US$ exchange rate","CHL","Chile","2022","2022",10.3,,
+"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2010","2010",3.2,,
+"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2011","2011",9.2,"B","Break"
+"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2012","2012",10.9,,
+"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2013","2013",12.2,,
+"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2014","2014",10.5,,
+"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2015","2015",13.2,,
+"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2016","2016",13.8,,
+"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2017","2017",12.7,,
+"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2018","2018",15.8,,
+"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2019","2019",17.9,,
+"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2020","2020",17.1,,
+"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2021","2021",23.3,,
+"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2022","2022",20.6,,
+"PATCBLOO","B-Blood and blood forming organs","ATCPTTMT","% of total sales","CHL","Chile","2010","2010",2.4,,
+"PATCBLOO","B-Blood and blood forming organs","ATCPTTMT","% of total sales","CHL","Chile","2011","2011",4.7,"B","Break"
+"PATCBLOO","B-Blood and blood forming organs","ATCPTTMT","% of total sales","CHL","Chile","2012","2012",5.3,,
+"PATCBLOO","B-Blood and blood forming organs","ATCPTTMT","% of total sales","CHL","Chile","2013","2013",5.2,,
+"PATCBLOO","B-Blood and blood forming organs","ATCPTTMT","% of total sales","CHL","Chile","2014","2014",4.4,,
+"PATCBLOO","B-Blood and blood forming organs","ATCPTTMT","% of total sales","CHL","Chile","2015","2015",5.1,,
+"PATCBLOO","B-Blood and blood forming organs","ATCPTTMT","% of total sales","CHL","Chile","2016","2016",4.9,,
+"PATCBLOO","B-Blood and blood forming organs","ATCPTTMT","% of total sales","CHL","Chile","2017","2017",4.5,,
+"PATCBLOO","B-Blood and blood forming organs","ATCPTTMT","% of total sales","CHL","Chile","2018","2018",5.1,,
+"PATCBLOO","B-Blood and blood forming organs","ATCPTTMT","% of total sales","CHL","Chile","2019","2019",5.4,,
+"PATCBLOO","B-Blood and blood forming organs","ATCPTTMT","% of total sales","CHL","Chile","2020","2020",5.2,,
+"PATCBLOO","B-Blood and blood forming organs","ATCPTTMT","% of total sales","CHL","Chile","2021","2021",7.1,,
+"PATCBLOO","B-Blood and blood forming organs","ATCPTTMT","% of total sales","CHL","Chile","2022","2022",6.3,,
+"PATCBLOO","B-Blood and blood forming organs","MLLNCUMT","Million of national currency units","EST","Estonia","2010","2010",10.3,,
+"PATCBLOO","B-Blood and blood forming organs","MLLNCUMT","Million of national currency units","EST","Estonia","2011","2011",11.4,,
+"PATCBLOO","B-Blood and blood forming organs","MLLNCUMT","Million of national currency units","EST","Estonia","2012","2012",13.1,,
+"PATCBLOO","B-Blood and blood forming organs","MLLNCUMT","Million of national currency units","EST","Estonia","2013","2013",14.1,,
+"PATCBLOO","B-Blood and blood forming organs","MLLNCUMT","Million of national currency units","EST","Estonia","2014","2014",17.4,,
+"PATCBLOO","B-Blood and blood forming organs","MLLNCUMT","Million of national currency units","EST","Estonia","2015","2015",21.3,,
+"PATCBLOO","B-Blood and blood forming organs","MLLNCUMT","Million of national currency units","EST","Estonia","2016","2016",25.4,,
+"PATCBLOO","B-Blood and blood forming organs","MLLNCUMT","Million of national currency units","EST","Estonia","2017","2017",29.4,,
+"PATCBLOO","B-Blood and blood forming organs","MLLNCUMT","Million of national currency units","EST","Estonia","2018","2018",35.6,,
+"PATCBLOO","B-Blood and blood forming organs","MLLNCUMT","Million of national currency units","EST","Estonia","2019","2019",37.8,,
+"PATCBLOO","B-Blood and blood forming organs","MLLNCUMT","Million of national currency units","EST","Estonia","2020","2020",40.4,,
+"PATCBLOO","B-Blood and blood forming organs","MLLNCUMT","Million of national currency units","EST","Estonia","2021","2021",42.7,,
+"PATCBLOO","B-Blood and blood forming organs","MLLNCUMT","Million of national currency units","EST","Estonia","2022","2022",46,,
+"PATCBLOO","B-Blood and blood forming organs","MTMOTCMT","Million US$ at exchange rate","EST","Estonia","2010","2010",13.7,,
+"PATCBLOO","B-Blood and blood forming organs","MTMOTCMT","Million US$ at exchange rate","EST","Estonia","2011","2011",15.8,,
+"PATCBLOO","B-Blood and blood forming organs","MTMOTCMT","Million US$ at exchange rate","EST","Estonia","2012","2012",16.9,,
+"PATCBLOO","B-Blood and blood forming organs","MTMOTCMT","Million US$ at exchange rate","EST","Estonia","2013","2013",18.7,,
+"PATCBLOO","B-Blood and blood forming organs","MTMOTCMT","Million US$ at exchange rate","EST","Estonia","2014","2014",23.1,,
+"PATCBLOO","B-Blood and blood forming organs","MTMOTCMT","Million US$ at exchange rate","EST","Estonia","2015","2015",23.6,,
+"PATCBLOO","B-Blood and blood forming organs","MTMOTCMT","Million US$ at exchange rate","EST","Estonia","2016","2016",28.1,,
+"PATCBLOO","B-Blood and blood forming organs","MTMOTCMT","Million US$ at exchange rate","EST","Estonia","2017","2017",33.2,,
+"PATCBLOO","B-Blood and blood forming organs","MTMOTCMT","Million US$ at exchange rate","EST","Estonia","2018","2018",42,,
+"PATCBLOO","B-Blood and blood forming organs","MTMOTCMT","Million US$ at exchange rate","EST","Estonia","2019","2019",42.3,,
+"PATCBLOO","B-Blood and blood forming organs","MTMOTCMT","Million US$ at exchange rate","EST","Estonia","2020","2020",46.1,,
+"PATCBLOO","B-Blood and blood forming organs","MTMOTCMT","Million US$ at exchange rate","EST","Estonia","2021","2021",50.6,,
+"PATCBLOO","B-Blood and blood forming organs","MTMOTCMT","Million US$ at exchange rate","EST","Estonia","2022","2022",48.4,,
+"PATCBLOO","B-Blood and blood forming organs","MTMOPPMT","Million US$, purchasing power parity","EST","Estonia","2010","2010",20.2,,
+"PATCBLOO","B-Blood and blood forming organs","MTMOPPMT","Million US$, purchasing power parity","EST","Estonia","2011","2011",22.2,,
+"PATCBLOO","B-Blood and blood forming organs","MTMOPPMT","Million US$, purchasing power parity","EST","Estonia","2012","2012",25.2,,
+"PATCBLOO","B-Blood and blood forming organs","MTMOPPMT","Million US$, purchasing power parity","EST","Estonia","2013","2013",27,,
+"PATCBLOO","B-Blood and blood forming organs","MTMOPPMT","Million US$, purchasing power parity","EST","Estonia","2014","2014",33,,
+"PATCBLOO","B-Blood and blood forming organs","MTMOPPMT","Million US$, purchasing power parity","EST","Estonia","2015","2015",39.6,,
+"PATCBLOO","B-Blood and blood forming organs","MTMOPPMT","Million US$, purchasing power parity","EST","Estonia","2016","2016",48,,
+"PATCBLOO","B-Blood and blood forming organs","MTMOPPMT","Million US$, purchasing power parity","EST","Estonia","2017","2017",54.9,,
+"PATCBLOO","B-Blood and blood forming organs","MTMOPPMT","Million US$, purchasing power parity","EST","Estonia","2018","2018",66,,
+"PATCBLOO","B-Blood and blood forming organs","MTMOPPMT","Million US$, purchasing power parity","EST","Estonia","2019","2019",70.5,,
+"PATCBLOO","B-Blood and blood forming organs","MTMOPPMT","Million US$, purchasing power parity","EST","Estonia","2020","2020",77.1,,
+"PATCBLOO","B-Blood and blood forming organs","MTMOPPMT","Million US$, purchasing power parity","EST","Estonia","2021","2021",78.7,,
+"PATCBLOO","B-Blood and blood forming organs","MTMOPPMT","Million US$, purchasing power parity","EST","Estonia","2022","2022",80.8,,
+"PATCBLOO","B-Blood and blood forming organs","TCPPERMT","/capita, US$ exchange rate","EST","Estonia","2010","2010",10.3,,
+"PATCBLOO","B-Blood and blood forming organs","TCPPERMT","/capita, US$ exchange rate","EST","Estonia","2011","2011",11.9,,
+"PATCBLOO","B-Blood and blood forming organs","TCPPERMT","/capita, US$ exchange rate","EST","Estonia","2012","2012",12.8,,
+"PATCBLOO","B-Blood and blood forming organs","TCPPERMT","/capita, US$ exchange rate","EST","Estonia","2013","2013",14.2,,
+"PATCBLOO","B-Blood and blood forming organs","TCPPERMT","/capita, US$ exchange rate","EST","Estonia","2014","2014",17.6,,
+"PATCBLOO","B-Blood and blood forming organs","TCPPERMT","/capita, US$ exchange rate","EST","Estonia","2015","2015",17.9,,
+"PATCBLOO","B-Blood and blood forming organs","TCPPERMT","/capita, US$ exchange rate","EST","Estonia","2016","2016",21.3,,
+"PATCBLOO","B-Blood and blood forming organs","TCPPERMT","/capita, US$ exchange rate","EST","Estonia","2017","2017",25.2,,
+"PATCBLOO","B-Blood and blood forming organs","TCPPERMT","/capita, US$ exchange rate","EST","Estonia","2018","2018",31.8,,
+"PATCBLOO","B-Blood and blood forming organs","TCPPERMT","/capita, US$ exchange rate","EST","Estonia","2019","2019",31.9,,
+"PATCBLOO","B-Blood and blood forming organs","TCPPERMT","/capita, US$ exchange rate","EST","Estonia","2020","2020",34.7,,
+"PATCBLOO","B-Blood and blood forming organs","TCPPERMT","/capita, US$ exchange rate","EST","Estonia","2021","2021",38,,
+"PATCBLOO","B-Blood and blood forming organs","TCPPERMT","/capita, US$ exchange rate","EST","Estonia","2022","2022",36.4,,
+"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2010","2010",15.2,,
+"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2011","2011",16.7,,
+"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2012","2012",19.1,,
+"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2013","2013",20.5,,
+"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2014","2014",25.1,,
+"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2015","2015",30.1,,
+"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2016","2016",36.5,,
+"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2017","2017",41.7,,
+"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2018","2018",50,,
+"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2019","2019",53.1,,
+"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2020","2020",58,,
+"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2021","2021",59.1,,
+"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2022","2022",60.6,,
+"PATCBLOO","B-Blood and blood forming organs","ATCPTTMT","% of total sales","EST","Estonia","2010","2010",5.3,,
+"PATCBLOO","B-Blood and blood forming organs","ATCPTTMT","% of total sales","EST","Estonia","2011","2011",5.6,,
+"PATCBLOO","B-Blood and blood forming organs","ATCPTTMT","% of total sales","EST","Estonia","2012","2012",5.9,,
+"PATCBLOO","B-Blood and blood forming organs","ATCPTTMT","% of total sales","EST","Estonia","2013","2013",6.1,,
+"PATCBLOO","B-Blood and blood forming organs","ATCPTTMT","% of total sales","EST","Estonia","2014","2014",7,,
+"PATCBLOO","B-Blood and blood forming organs","ATCPTTMT","% of total sales","EST","Estonia","2015","2015",8,,
+"PATCBLOO","B-Blood and blood forming organs","ATCPTTMT","% of total sales","EST","Estonia","2016","2016",8.7,,
+"PATCBLOO","B-Blood and blood forming organs","ATCPTTMT","% of total sales","EST","Estonia","2017","2017",9.8,,
+"PATCBLOO","B-Blood and blood forming organs","ATCPTTMT","% of total sales","EST","Estonia","2018","2018",10.9,,
+"PATCBLOO","B-Blood and blood forming organs","ATCPTTMT","% of total sales","EST","Estonia","2019","2019",11,,
+"PATCBLOO","B-Blood and blood forming organs","ATCPTTMT","% of total sales","EST","Estonia","2020","2020",11.3,,
+"PATCBLOO","B-Blood and blood forming organs","ATCPTTMT","% of total sales","EST","Estonia","2021","2021",10.5,,
+"PATCBLOO","B-Blood and blood forming organs","ATCPTTMT","% of total sales","EST","Estonia","2022","2022",10.7,,
+"PATCBLOO","B-Blood and blood forming organs","MLLNCUMT","Million of national currency units","SVN","Slovenia","2010","2010",25.5,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","MLLNCUMT","Million of national currency units","SVN","Slovenia","2011","2011",25.2,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","MLLNCUMT","Million of national currency units","SVN","Slovenia","2012","2012",25.4,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","MLLNCUMT","Million of national currency units","SVN","Slovenia","2013","2013",28.7,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","MLLNCUMT","Million of national currency units","SVN","Slovenia","2014","2014",31.3,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","MLLNCUMT","Million of national currency units","SVN","Slovenia","2015","2015",35,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","MLLNCUMT","Million of national currency units","SVN","Slovenia","2016","2016",40,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","MLLNCUMT","Million of national currency units","SVN","Slovenia","2017","2017",46.7,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","MLLNCUMT","Million of national currency units","SVN","Slovenia","2018","2018",54.5,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","MLLNCUMT","Million of national currency units","SVN","Slovenia","2019","2019",60.9,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","MLLNCUMT","Million of national currency units","SVN","Slovenia","2020","2020",67.7,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","MLLNCUMT","Million of national currency units","SVN","Slovenia","2021","2021",74.5,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","MLLNCUMT","Million of national currency units","SVN","Slovenia","2022","2022",79.2,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","MTMOTCMT","Million US$ at exchange rate","SVN","Slovenia","2010","2010",33.8,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","MTMOTCMT","Million US$ at exchange rate","SVN","Slovenia","2011","2011",35,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","MTMOTCMT","Million US$ at exchange rate","SVN","Slovenia","2012","2012",32.6,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","MTMOTCMT","Million US$ at exchange rate","SVN","Slovenia","2013","2013",38.1,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","MTMOTCMT","Million US$ at exchange rate","SVN","Slovenia","2014","2014",41.5,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","MTMOTCMT","Million US$ at exchange rate","SVN","Slovenia","2015","2015",38.8,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","MTMOTCMT","Million US$ at exchange rate","SVN","Slovenia","2016","2016",44.3,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","MTMOTCMT","Million US$ at exchange rate","SVN","Slovenia","2017","2017",52.7,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","MTMOTCMT","Million US$ at exchange rate","SVN","Slovenia","2018","2018",64.3,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","MTMOTCMT","Million US$ at exchange rate","SVN","Slovenia","2019","2019",68.1,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","MTMOTCMT","Million US$ at exchange rate","SVN","Slovenia","2020","2020",77.3,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","MTMOTCMT","Million US$ at exchange rate","SVN","Slovenia","2021","2021",88.1,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","MTMOTCMT","Million US$ at exchange rate","SVN","Slovenia","2022","2022",83.4,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","MTMOPPMT","Million US$, purchasing power parity","SVN","Slovenia","2010","2010",39.9,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","MTMOPPMT","Million US$, purchasing power parity","SVN","Slovenia","2011","2011",40.3,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","MTMOPPMT","Million US$, purchasing power parity","SVN","Slovenia","2012","2012",41.9,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","MTMOPPMT","Million US$, purchasing power parity","SVN","Slovenia","2013","2013",48.5,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","MTMOPPMT","Million US$, purchasing power parity","SVN","Slovenia","2014","2014",52.9,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","MTMOPPMT","Million US$, purchasing power parity","SVN","Slovenia","2015","2015",58.8,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","MTMOPPMT","Million US$, purchasing power parity","SVN","Slovenia","2016","2016",69.3,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","MTMOPPMT","Million US$, purchasing power parity","SVN","Slovenia","2017","2017",81.8,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","MTMOPPMT","Million US$, purchasing power parity","SVN","Slovenia","2018","2018",95.9,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","MTMOPPMT","Million US$, purchasing power parity","SVN","Slovenia","2019","2019",110.2,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","MTMOPPMT","Million US$, purchasing power parity","SVN","Slovenia","2020","2020",123.7,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","MTMOPPMT","Million US$, purchasing power parity","SVN","Slovenia","2021","2021",132.3,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","MTMOPPMT","Million US$, purchasing power parity","SVN","Slovenia","2022","2022",143.5,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","TCPPERMT","/capita, US$ exchange rate","SVN","Slovenia","2010","2010",16.5,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","TCPPERMT","/capita, US$ exchange rate","SVN","Slovenia","2011","2011",17.1,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","TCPPERMT","/capita, US$ exchange rate","SVN","Slovenia","2012","2012",15.9,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","TCPPERMT","/capita, US$ exchange rate","SVN","Slovenia","2013","2013",18.5,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","TCPPERMT","/capita, US$ exchange rate","SVN","Slovenia","2014","2014",20.1,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","TCPPERMT","/capita, US$ exchange rate","SVN","Slovenia","2015","2015",18.8,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","TCPPERMT","/capita, US$ exchange rate","SVN","Slovenia","2016","2016",21.4,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","TCPPERMT","/capita, US$ exchange rate","SVN","Slovenia","2017","2017",25.5,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","TCPPERMT","/capita, US$ exchange rate","SVN","Slovenia","2018","2018",31,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","TCPPERMT","/capita, US$ exchange rate","SVN","Slovenia","2019","2019",32.6,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","TCPPERMT","/capita, US$ exchange rate","SVN","Slovenia","2020","2020",36.8,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","TCPPERMT","/capita, US$ exchange rate","SVN","Slovenia","2021","2021",41.8,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","TCPPERMT","/capita, US$ exchange rate","SVN","Slovenia","2022","2022",39.6,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2010","2010",19.5,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2011","2011",19.6,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2012","2012",20.3,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2013","2013",23.6,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2014","2014",25.6,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2015","2015",28.5,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2016","2016",33.6,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2017","2017",39.6,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2018","2018",46.3,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2019","2019",52.8,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2020","2020",58.8,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2021","2021",62.8,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2022","2022",68.1,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","ATCPTTMT","% of total sales","SVN","Slovenia","2010","2010",5.4,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","ATCPTTMT","% of total sales","SVN","Slovenia","2011","2011",5.4,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","ATCPTTMT","% of total sales","SVN","Slovenia","2012","2012",5.6,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","ATCPTTMT","% of total sales","SVN","Slovenia","2013","2013",6.4,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","ATCPTTMT","% of total sales","SVN","Slovenia","2014","2014",7.2,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","ATCPTTMT","% of total sales","SVN","Slovenia","2015","2015",7.8,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","ATCPTTMT","% of total sales","SVN","Slovenia","2016","2016",8.6,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","ATCPTTMT","% of total sales","SVN","Slovenia","2017","2017",9.6,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","ATCPTTMT","% of total sales","SVN","Slovenia","2018","2018",10.5,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","ATCPTTMT","% of total sales","SVN","Slovenia","2019","2019",11.2,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","ATCPTTMT","% of total sales","SVN","Slovenia","2020","2020",11.9,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","ATCPTTMT","% of total sales","SVN","Slovenia","2021","2021",12.2,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","ATCPTTMT","% of total sales","SVN","Slovenia","2022","2022",11.7,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","MLLNCUMT","Million of national currency units","AUS","Australia","2010","2010",2744,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","MLLNCUMT","Million of national currency units","AUS","Australia","2011","2011",2825,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","MLLNCUMT","Million of national currency units","AUS","Australia","2012","2012",2538,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","MLLNCUMT","Million of national currency units","AUS","Australia","2013","2013",2516,"B; D","Break; Difference in methodology"
+"PATCCARV","C-Cardiovascular system","MLLNCUMT","Million of national currency units","AUS","Australia","2014","2014",2200,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","MLLNCUMT","Million of national currency units","AUS","Australia","2015","2015",1992,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","MLLNCUMT","Million of national currency units","AUS","Australia","2016","2016",1860,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","MLLNCUMT","Million of national currency units","AUS","Australia","2017","2017",1798,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","MLLNCUMT","Million of national currency units","AUS","Australia","2018","2018",1822,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","MLLNCUMT","Million of national currency units","AUS","Australia","2019","2019",1862,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","MLLNCUMT","Million of national currency units","AUS","Australia","2020","2020",1962,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","MLLNCUMT","Million of national currency units","AUS","Australia","2021","2021",2061,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","MTMOTCMT","Million US$ at exchange rate","AUS","Australia","2010","2010",2517.1,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","MTMOTCMT","Million US$ at exchange rate","AUS","Australia","2011","2011",2914,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","MTMOTCMT","Million US$ at exchange rate","AUS","Australia","2012","2012",2627.9,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","MTMOTCMT","Million US$ at exchange rate","AUS","Australia","2013","2013",2428.9,"B; D","Break; Difference in methodology"
+"PATCCARV","C-Cardiovascular system","MTMOTCMT","Million US$ at exchange rate","AUS","Australia","2014","2014",1983.1,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","MTMOTCMT","Million US$ at exchange rate","AUS","Australia","2015","2015",1496.5,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","MTMOTCMT","Million US$ at exchange rate","AUS","Australia","2016","2016",1382.7,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","MTMOTCMT","Million US$ at exchange rate","AUS","Australia","2017","2017",1378,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","MTMOTCMT","Million US$ at exchange rate","AUS","Australia","2018","2018",1361.3,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","MTMOTCMT","Million US$ at exchange rate","AUS","Australia","2019","2019",1294.4,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","MTMOTCMT","Million US$ at exchange rate","AUS","Australia","2020","2020",1350.2,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","MTMOTCMT","Million US$ at exchange rate","AUS","Australia","2021","2021",1548.2,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","MTMOPPMT","Million US$, purchasing power parity","AUS","Australia","2010","2010",1824.9,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","MTMOPPMT","Million US$, purchasing power parity","AUS","Australia","2011","2011",1869.6,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","MTMOPPMT","Million US$, purchasing power parity","AUS","Australia","2012","2012",1647.9,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","MTMOPPMT","Million US$, purchasing power parity","AUS","Australia","2013","2013",1738.6,"B; D","Break; Difference in methodology"
+"PATCCARV","C-Cardiovascular system","MTMOPPMT","Million US$, purchasing power parity","AUS","Australia","2014","2014",1514.6,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","MTMOPPMT","Million US$, purchasing power parity","AUS","Australia","2015","2015",1351.7,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","MTMOPPMT","Million US$, purchasing power parity","AUS","Australia","2016","2016",1282.6,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","MTMOPPMT","Million US$, purchasing power parity","AUS","Australia","2017","2017",1216.9,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","MTMOPPMT","Million US$, purchasing power parity","AUS","Australia","2018","2018",1239.1,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","MTMOPPMT","Million US$, purchasing power parity","AUS","Australia","2019","2019",1258.2,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","MTMOPPMT","Million US$, purchasing power parity","AUS","Australia","2020","2020",1349.4,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","MTMOPPMT","Million US$, purchasing power parity","AUS","Australia","2021","2021",1423.8,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","TCPPERMT","/capita, US$ exchange rate","AUS","Australia","2010","2010",114.2,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","TCPPERMT","/capita, US$ exchange rate","AUS","Australia","2011","2011",130.4,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","TCPPERMT","/capita, US$ exchange rate","AUS","Australia","2012","2012",115.6,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","TCPPERMT","/capita, US$ exchange rate","AUS","Australia","2013","2013",105,"B; D","Break; Difference in methodology"
+"PATCCARV","C-Cardiovascular system","TCPPERMT","/capita, US$ exchange rate","AUS","Australia","2014","2014",84.5,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","TCPPERMT","/capita, US$ exchange rate","AUS","Australia","2015","2015",62.8,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","TCPPERMT","/capita, US$ exchange rate","AUS","Australia","2016","2016",57.2,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","TCPPERMT","/capita, US$ exchange rate","AUS","Australia","2017","2017",56,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","TCPPERMT","/capita, US$ exchange rate","AUS","Australia","2018","2018",54.5,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","TCPPERMT","/capita, US$ exchange rate","AUS","Australia","2019","2019",51.1,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","TCPPERMT","/capita, US$ exchange rate","AUS","Australia","2020","2020",52.6,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","TCPPERMT","/capita, US$ exchange rate","AUS","Australia","2021","2021",60.3,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2010","2010",82.8,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2011","2011",83.7,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2012","2012",72.5,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2013","2013",75.2,"B; D","Break; Difference in methodology"
+"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2014","2014",64.5,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2015","2015",56.8,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2016","2016",53,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2017","2017",49.5,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2018","2018",49.6,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2019","2019",49.7,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2020","2020",52.6,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2021","2021",55.4,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","ATCPTTMT","% of total sales","AUS","Australia","2010","2010",28,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","ATCPTTMT","% of total sales","AUS","Australia","2011","2011",27.5,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","ATCPTTMT","% of total sales","AUS","Australia","2012","2012",24.5,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","ATCPTTMT","% of total sales","AUS","Australia","2013","2013",21.3,"B; D","Break; Difference in methodology"
+"PATCCARV","C-Cardiovascular system","ATCPTTMT","% of total sales","AUS","Australia","2014","2014",18.5,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","ATCPTTMT","% of total sales","AUS","Australia","2015","2015",16.2,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","ATCPTTMT","% of total sales","AUS","Australia","2016","2016",12.2,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","ATCPTTMT","% of total sales","AUS","Australia","2017","2017",12.2,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","ATCPTTMT","% of total sales","AUS","Australia","2018","2018",12.2,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","ATCPTTMT","% of total sales","AUS","Australia","2019","2019",12,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","ATCPTTMT","% of total sales","AUS","Australia","2020","2020",11.8,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","ATCPTTMT","% of total sales","AUS","Australia","2021","2021",11.7,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","MLLNCUMT","Million of national currency units","AUT","Austria","2010","2010",498,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","MLLNCUMT","Million of national currency units","AUT","Austria","2011","2011",495.9,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","MLLNCUMT","Million of national currency units","AUT","Austria","2012","2012",483.2,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","MLLNCUMT","Million of national currency units","AUT","Austria","2013","2013",437.7,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","MLLNCUMT","Million of national currency units","AUT","Austria","2014","2014",432.8,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","MLLNCUMT","Million of national currency units","AUT","Austria","2015","2015",426.9,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","MLLNCUMT","Million of national currency units","AUT","Austria","2016","2016",427.9,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","MLLNCUMT","Million of national currency units","AUT","Austria","2017","2017",434.7,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","MLLNCUMT","Million of national currency units","AUT","Austria","2018","2018",415.8,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","MLLNCUMT","Million of national currency units","AUT","Austria","2019","2019",394.4,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","MLLNCUMT","Million of national currency units","AUT","Austria","2020","2020",388.7,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","MLLNCUMT","Million of national currency units","AUT","Austria","2021","2021",380.6,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","MTMOTCMT","Million US$ at exchange rate","AUT","Austria","2010","2010",660.2,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","MTMOTCMT","Million US$ at exchange rate","AUT","Austria","2011","2011",690.3,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","MTMOTCMT","Million US$ at exchange rate","AUT","Austria","2012","2012",620.8,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","MTMOTCMT","Million US$ at exchange rate","AUT","Austria","2013","2013",581.3,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","MTMOTCMT","Million US$ at exchange rate","AUT","Austria","2014","2014",574.9,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","MTMOTCMT","Million US$ at exchange rate","AUT","Austria","2015","2015",473.6,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","MTMOTCMT","Million US$ at exchange rate","AUT","Austria","2016","2016",473.7,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","MTMOTCMT","Million US$ at exchange rate","AUT","Austria","2017","2017",491,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","MTMOTCMT","Million US$ at exchange rate","AUT","Austria","2018","2018",491.1,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","MTMOTCMT","Million US$ at exchange rate","AUT","Austria","2019","2019",441.5,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","MTMOTCMT","Million US$ at exchange rate","AUT","Austria","2020","2020",443.9,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","MTMOTCMT","Million US$ at exchange rate","AUT","Austria","2021","2021",450.1,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","MTMOPPMT","Million US$, purchasing power parity","AUT","Austria","2010","2010",591.3,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","MTMOPPMT","Million US$, purchasing power parity","AUT","Austria","2011","2011",596.5,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","MTMOPPMT","Million US$, purchasing power parity","AUT","Austria","2012","2012",593.9,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","MTMOPPMT","Million US$, purchasing power parity","AUT","Austria","2013","2013",549.1,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","MTMOPPMT","Million US$, purchasing power parity","AUT","Austria","2014","2014",541.8,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","MTMOPPMT","Million US$, purchasing power parity","AUT","Austria","2015","2015",534.4,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","MTMOPPMT","Million US$, purchasing power parity","AUT","Austria","2016","2016",550.8,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","MTMOPPMT","Million US$, purchasing power parity","AUT","Austria","2017","2017",560.8,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","MTMOPPMT","Million US$, purchasing power parity","AUT","Austria","2018","2018",543.3,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","MTMOPPMT","Million US$, purchasing power parity","AUT","Austria","2019","2019",526.5,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","MTMOPPMT","Million US$, purchasing power parity","AUT","Austria","2020","2020",520.8,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","MTMOPPMT","Million US$, purchasing power parity","AUT","Austria","2021","2021",503.2,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","TCPPERMT","/capita, US$ exchange rate","AUT","Austria","2010","2010",78.9,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","TCPPERMT","/capita, US$ exchange rate","AUT","Austria","2011","2011",82.3,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","TCPPERMT","/capita, US$ exchange rate","AUT","Austria","2012","2012",73.6,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","TCPPERMT","/capita, US$ exchange rate","AUT","Austria","2013","2013",68.6,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","TCPPERMT","/capita, US$ exchange rate","AUT","Austria","2014","2014",67.3,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","TCPPERMT","/capita, US$ exchange rate","AUT","Austria","2015","2015",54.8,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","TCPPERMT","/capita, US$ exchange rate","AUT","Austria","2016","2016",54.2,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","TCPPERMT","/capita, US$ exchange rate","AUT","Austria","2017","2017",55.8,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","TCPPERMT","/capita, US$ exchange rate","AUT","Austria","2018","2018",55.5,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","TCPPERMT","/capita, US$ exchange rate","AUT","Austria","2019","2019",49.7,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","TCPPERMT","/capita, US$ exchange rate","AUT","Austria","2020","2020",49.8,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","TCPPERMT","/capita, US$ exchange rate","AUT","Austria","2021","2021",50.3,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2010","2010",70.7,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2011","2011",71.1,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2012","2012",70.4,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2013","2013",64.8,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2014","2014",63.4,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2015","2015",61.8,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2016","2016",63,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2017","2017",63.8,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2018","2018",61.5,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2019","2019",59.3,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2020","2020",58.4,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2021","2021",56.2,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","ATCPTTMT","% of total sales","AUT","Austria","2010","2010",20,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","ATCPTTMT","% of total sales","AUT","Austria","2011","2011",19.5,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","ATCPTTMT","% of total sales","AUT","Austria","2012","2012",18.5,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","ATCPTTMT","% of total sales","AUT","Austria","2013","2013",16.6,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","ATCPTTMT","% of total sales","AUT","Austria","2014","2014",15.5,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","ATCPTTMT","% of total sales","AUT","Austria","2015","2015",14.6,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","ATCPTTMT","% of total sales","AUT","Austria","2016","2016",14.2,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","ATCPTTMT","% of total sales","AUT","Austria","2017","2017",13.9,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","ATCPTTMT","% of total sales","AUT","Austria","2018","2018",12.9,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","ATCPTTMT","% of total sales","AUT","Austria","2019","2019",11.9,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","ATCPTTMT","% of total sales","AUT","Austria","2020","2020",11.2,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","ATCPTTMT","% of total sales","AUT","Austria","2021","2021",10.3,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","MLLNCUMT","Million of national currency units","BEL","Belgium","2010","2010",893.8,,
+"PATCCARV","C-Cardiovascular system","MLLNCUMT","Million of national currency units","BEL","Belgium","2011","2011",889.8,,
+"PATCCARV","C-Cardiovascular system","MLLNCUMT","Million of national currency units","BEL","Belgium","2012","2012",840.1,,
+"PATCCARV","C-Cardiovascular system","MLLNCUMT","Million of national currency units","BEL","Belgium","2013","2013",782.9,,
+"PATCCARV","C-Cardiovascular system","MLLNCUMT","Million of national currency units","BEL","Belgium","2014","2014",724.2,,
+"PATCCARV","C-Cardiovascular system","MLLNCUMT","Million of national currency units","BEL","Belgium","2015","2015",701.7,,
+"PATCCARV","C-Cardiovascular system","MLLNCUMT","Million of national currency units","BEL","Belgium","2016","2016",686.7,,
+"PATCCARV","C-Cardiovascular system","MLLNCUMT","Million of national currency units","BEL","Belgium","2017","2017",655.8,,
+"PATCCARV","C-Cardiovascular system","MLLNCUMT","Million of national currency units","BEL","Belgium","2018","2018",586.6,,
+"PATCCARV","C-Cardiovascular system","MLLNCUMT","Million of national currency units","BEL","Belgium","2019","2019",596.4,,
+"PATCCARV","C-Cardiovascular system","MLLNCUMT","Million of national currency units","BEL","Belgium","2020","2020",581.4,,
+"PATCCARV","C-Cardiovascular system","MLLNCUMT","Million of national currency units","BEL","Belgium","2021","2021",569.9,,
+"PATCCARV","C-Cardiovascular system","MLLNCUMT","Million of national currency units","BEL","Belgium","2022","2022",595.3,"E","Estimated value"
+"PATCCARV","C-Cardiovascular system","MTMOTCMT","Million US$ at exchange rate","BEL","Belgium","2010","2010",1184.9,,
+"PATCCARV","C-Cardiovascular system","MTMOTCMT","Million US$ at exchange rate","BEL","Belgium","2011","2011",1238.6,,
+"PATCCARV","C-Cardiovascular system","MTMOTCMT","Million US$ at exchange rate","BEL","Belgium","2012","2012",1079.3,,
+"PATCCARV","C-Cardiovascular system","MTMOTCMT","Million US$ at exchange rate","BEL","Belgium","2013","2013",1039.8,,
+"PATCCARV","C-Cardiovascular system","MTMOTCMT","Million US$ at exchange rate","BEL","Belgium","2014","2014",962.1,,
+"PATCCARV","C-Cardiovascular system","MTMOTCMT","Million US$ at exchange rate","BEL","Belgium","2015","2015",778.5,,
+"PATCCARV","C-Cardiovascular system","MTMOTCMT","Million US$ at exchange rate","BEL","Belgium","2016","2016",760.2,,
+"PATCCARV","C-Cardiovascular system","MTMOTCMT","Million US$ at exchange rate","BEL","Belgium","2017","2017",740.9,,
+"PATCCARV","C-Cardiovascular system","MTMOTCMT","Million US$ at exchange rate","BEL","Belgium","2018","2018",692.8,,
+"PATCCARV","C-Cardiovascular system","MTMOTCMT","Million US$ at exchange rate","BEL","Belgium","2019","2019",667.7,,
+"PATCCARV","C-Cardiovascular system","MTMOTCMT","Million US$ at exchange rate","BEL","Belgium","2020","2020",664,,
+"PATCCARV","C-Cardiovascular system","MTMOTCMT","Million US$ at exchange rate","BEL","Belgium","2021","2021",674,,
+"PATCCARV","C-Cardiovascular system","MTMOTCMT","Million US$ at exchange rate","BEL","Belgium","2022","2022",626.9,"E","Estimated value"
+"PATCCARV","C-Cardiovascular system","MTMOPPMT","Million US$, purchasing power parity","BEL","Belgium","2010","2010",1068.3,,
+"PATCCARV","C-Cardiovascular system","MTMOPPMT","Million US$, purchasing power parity","BEL","Belgium","2011","2011",1069.6,,
+"PATCCARV","C-Cardiovascular system","MTMOPPMT","Million US$, purchasing power parity","BEL","Belgium","2012","2012",1021.8,,
+"PATCCARV","C-Cardiovascular system","MTMOPPMT","Million US$, purchasing power parity","BEL","Belgium","2013","2013",971.2,,
+"PATCCARV","C-Cardiovascular system","MTMOPPMT","Million US$, purchasing power parity","BEL","Belgium","2014","2014",905,,
+"PATCCARV","C-Cardiovascular system","MTMOPPMT","Million US$, purchasing power parity","BEL","Belgium","2015","2015",877.1,,
+"PATCCARV","C-Cardiovascular system","MTMOPPMT","Million US$, purchasing power parity","BEL","Belgium","2016","2016",879.3,,
+"PATCCARV","C-Cardiovascular system","MTMOPPMT","Million US$, purchasing power parity","BEL","Belgium","2017","2017",845.5,,
+"PATCCARV","C-Cardiovascular system","MTMOPPMT","Million US$, purchasing power parity","BEL","Belgium","2018","2018",765.4,,
+"PATCCARV","C-Cardiovascular system","MTMOPPMT","Million US$, purchasing power parity","BEL","Belgium","2019","2019",798.9,,
+"PATCCARV","C-Cardiovascular system","MTMOPPMT","Million US$, purchasing power parity","BEL","Belgium","2020","2020",796.1,,
+"PATCCARV","C-Cardiovascular system","MTMOPPMT","Million US$, purchasing power parity","BEL","Belgium","2021","2021",773.6,,
+"PATCCARV","C-Cardiovascular system","MTMOPPMT","Million US$, purchasing power parity","BEL","Belgium","2022","2022",833.9,"E","Estimated value"
+"PATCCARV","C-Cardiovascular system","TCPPERMT","/capita, US$ exchange rate","BEL","Belgium","2010","2010",108.7,,
+"PATCCARV","C-Cardiovascular system","TCPPERMT","/capita, US$ exchange rate","BEL","Belgium","2011","2011",112.2,,
+"PATCCARV","C-Cardiovascular system","TCPPERMT","/capita, US$ exchange rate","BEL","Belgium","2012","2012",97.2,,
+"PATCCARV","C-Cardiovascular system","TCPPERMT","/capita, US$ exchange rate","BEL","Belgium","2013","2013",93.2,,
+"PATCCARV","C-Cardiovascular system","TCPPERMT","/capita, US$ exchange rate","BEL","Belgium","2014","2014",85.8,,
+"PATCCARV","C-Cardiovascular system","TCPPERMT","/capita, US$ exchange rate","BEL","Belgium","2015","2015",69.1,,
+"PATCCARV","C-Cardiovascular system","TCPPERMT","/capita, US$ exchange rate","BEL","Belgium","2016","2016",67.1,,
+"PATCCARV","C-Cardiovascular system","TCPPERMT","/capita, US$ exchange rate","BEL","Belgium","2017","2017",65.1,,
+"PATCCARV","C-Cardiovascular system","TCPPERMT","/capita, US$ exchange rate","BEL","Belgium","2018","2018",60.6,,
+"PATCCARV","C-Cardiovascular system","TCPPERMT","/capita, US$ exchange rate","BEL","Belgium","2019","2019",58.1,,
+"PATCCARV","C-Cardiovascular system","TCPPERMT","/capita, US$ exchange rate","BEL","Belgium","2020","2020",57.5,,
+"PATCCARV","C-Cardiovascular system","TCPPERMT","/capita, US$ exchange rate","BEL","Belgium","2021","2021",58.2,,
+"PATCCARV","C-Cardiovascular system","TCPPERMT","/capita, US$ exchange rate","BEL","Belgium","2022","2022",54,"E","Estimated value"
+"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2010","2010",98.1,,
+"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2011","2011",96.9,,
+"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2012","2012",92,,
+"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2013","2013",87,,
+"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2014","2014",80.7,,
+"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2015","2015",77.8,,
+"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2016","2016",77.6,,
+"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2017","2017",74.3,,
+"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2018","2018",67,,
+"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2019","2019",69.5,,
+"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2020","2020",69,,
+"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2021","2021",66.8,,
+"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2022","2022",71.8,"E","Estimated value"
+"PATCCARV","C-Cardiovascular system","ATCPTTMT","% of total sales","BEL","Belgium","2010","2010",15.2,,
+"PATCCARV","C-Cardiovascular system","ATCPTTMT","% of total sales","BEL","Belgium","2011","2011",14.8,,
+"PATCCARV","C-Cardiovascular system","ATCPTTMT","% of total sales","BEL","Belgium","2012","2012",14.1,,
+"PATCCARV","C-Cardiovascular system","ATCPTTMT","% of total sales","BEL","Belgium","2013","2013",13.2,,
+"PATCCARV","C-Cardiovascular system","ATCPTTMT","% of total sales","BEL","Belgium","2014","2014",12.2,,
+"PATCCARV","C-Cardiovascular system","ATCPTTMT","% of total sales","BEL","Belgium","2015","2015",11.3,,
+"PATCCARV","C-Cardiovascular system","ATCPTTMT","% of total sales","BEL","Belgium","2016","2016",11,,
+"PATCCARV","C-Cardiovascular system","ATCPTTMT","% of total sales","BEL","Belgium","2017","2017",10,,
+"PATCCARV","C-Cardiovascular system","ATCPTTMT","% of total sales","BEL","Belgium","2018","2018",8.8,,
+"PATCCARV","C-Cardiovascular system","ATCPTTMT","% of total sales","BEL","Belgium","2019","2019",8.1,,
+"PATCCARV","C-Cardiovascular system","ATCPTTMT","% of total sales","BEL","Belgium","2020","2020",7.6,,
+"PATCCARV","C-Cardiovascular system","ATCPTTMT","% of total sales","BEL","Belgium","2021","2021",7.1,,
+"PATCCARV","C-Cardiovascular system","ATCPTTMT","% of total sales","BEL","Belgium","2022","2022",6.6,"E","Estimated value"
+"PATCCARV","C-Cardiovascular system","MLLNCUMT","Million of national currency units","CAN","Canada","2012","2012",4627.3,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","MLLNCUMT","Million of national currency units","CAN","Canada","2013","2013",4082.7,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","MLLNCUMT","Million of national currency units","CAN","Canada","2014","2014",3973.2,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","MLLNCUMT","Million of national currency units","CAN","Canada","2015","2015",3888.7,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","MLLNCUMT","Million of national currency units","CAN","Canada","2016","2016",3942.4,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","MLLNCUMT","Million of national currency units","CAN","Canada","2017","2017",3999.3,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","MLLNCUMT","Million of national currency units","CAN","Canada","2018","2018",3386.8,"E; B; D","Estimated value; Break; Difference in methodology"
+"PATCCARV","C-Cardiovascular system","MLLNCUMT","Million of national currency units","CAN","Canada","2019","2019",3162.5,"E; D","Estimated value; Difference in methodology"
+"PATCCARV","C-Cardiovascular system","MLLNCUMT","Million of national currency units","CAN","Canada","2020","2020",3318.3,"E; D","Estimated value; Difference in methodology"
+"PATCCARV","C-Cardiovascular system","MLLNCUMT","Million of national currency units","CAN","Canada","2021","2021",3394.2,"E; D","Estimated value; Difference in methodology"
+"PATCCARV","C-Cardiovascular system","MLLNCUMT","Million of national currency units","CAN","Canada","2022","2022",3557.2,"E; D","Estimated value; Difference in methodology"
+"PATCCARV","C-Cardiovascular system","MTMOTCMT","Million US$ at exchange rate","CAN","Canada","2012","2012",4630.2,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","MTMOTCMT","Million US$ at exchange rate","CAN","Canada","2013","2013",3963.3,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","MTMOTCMT","Million US$ at exchange rate","CAN","Canada","2014","2014",3596.5,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","MTMOTCMT","Million US$ at exchange rate","CAN","Canada","2015","2015",3040.9,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","MTMOTCMT","Million US$ at exchange rate","CAN","Canada","2016","2016",2974,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","MTMOTCMT","Million US$ at exchange rate","CAN","Canada","2017","2017",3081.3,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","MTMOTCMT","Million US$ at exchange rate","CAN","Canada","2018","2018",2613.6,"E; B; D","Estimated value; Break; Difference in methodology"
+"PATCCARV","C-Cardiovascular system","MTMOTCMT","Million US$ at exchange rate","CAN","Canada","2019","2019",2383.6,"E; D","Estimated value; Difference in methodology"
+"PATCCARV","C-Cardiovascular system","MTMOTCMT","Million US$ at exchange rate","CAN","Canada","2020","2020",2474.2,"E; D","Estimated value; Difference in methodology"
+"PATCCARV","C-Cardiovascular system","MTMOTCMT","Million US$ at exchange rate","CAN","Canada","2021","2021",2707,"E; D","Estimated value; Difference in methodology"
+"PATCCARV","C-Cardiovascular system","MTMOTCMT","Million US$ at exchange rate","CAN","Canada","2022","2022",2733,"E; D","Estimated value; Difference in methodology"
+"PATCCARV","C-Cardiovascular system","MTMOPPMT","Million US$, purchasing power parity","CAN","Canada","2012","2012",3717.9,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","MTMOPPMT","Million US$, purchasing power parity","CAN","Canada","2013","2013",3335.5,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","MTMOPPMT","Million US$, purchasing power parity","CAN","Canada","2014","2014",3229.3,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","MTMOPPMT","Million US$, purchasing power parity","CAN","Canada","2015","2015",3115.8,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","MTMOPPMT","Million US$, purchasing power parity","CAN","Canada","2016","2016",3266.2,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","MTMOPPMT","Million US$, purchasing power parity","CAN","Canada","2017","2017",3298.9,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","MTMOPPMT","Million US$, purchasing power parity","CAN","Canada","2018","2018",2807,"E; B; D","Estimated value; Break; Difference in methodology"
+"PATCCARV","C-Cardiovascular system","MTMOPPMT","Million US$, purchasing power parity","CAN","Canada","2019","2019",2561.3,"E; D","Estimated value; Difference in methodology"
+"PATCCARV","C-Cardiovascular system","MTMOPPMT","Million US$, purchasing power parity","CAN","Canada","2020","2020",2695.4,"E; D","Estimated value; Difference in methodology"
+"PATCCARV","C-Cardiovascular system","MTMOPPMT","Million US$, purchasing power parity","CAN","Canada","2021","2021",2741.4,"E; D","Estimated value; Difference in methodology"
+"PATCCARV","C-Cardiovascular system","MTMOPPMT","Million US$, purchasing power parity","CAN","Canada","2022","2022",2837,"E; D","Estimated value; Difference in methodology"
+"PATCCARV","C-Cardiovascular system","TCPPERMT","/capita, US$ exchange rate","CAN","Canada","2012","2012",133.4,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","TCPPERMT","/capita, US$ exchange rate","CAN","Canada","2013","2013",113,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","TCPPERMT","/capita, US$ exchange rate","CAN","Canada","2014","2014",101.5,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","TCPPERMT","/capita, US$ exchange rate","CAN","Canada","2015","2015",85.2,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","TCPPERMT","/capita, US$ exchange rate","CAN","Canada","2016","2016",82.4,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","TCPPERMT","/capita, US$ exchange rate","CAN","Canada","2017","2017",84.3,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","TCPPERMT","/capita, US$ exchange rate","CAN","Canada","2018","2018",70.5,"E; B; D","Estimated value; Break; Difference in methodology"
+"PATCCARV","C-Cardiovascular system","TCPPERMT","/capita, US$ exchange rate","CAN","Canada","2019","2019",63.4,"E; D","Estimated value; Difference in methodology"
+"PATCCARV","C-Cardiovascular system","TCPPERMT","/capita, US$ exchange rate","CAN","Canada","2020","2020",65,"E; D","Estimated value; Difference in methodology"
+"PATCCARV","C-Cardiovascular system","TCPPERMT","/capita, US$ exchange rate","CAN","Canada","2021","2021",70.8,"E; D","Estimated value; Difference in methodology"
+"PATCCARV","C-Cardiovascular system","TCPPERMT","/capita, US$ exchange rate","CAN","Canada","2022","2022",70.3,"E; D","Estimated value; Difference in methodology"
+"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2012","2012",107.1,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2013","2013",95.1,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2014","2014",91.1,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2015","2015",87.3,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2016","2016",90.5,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2017","2017",90.3,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2018","2018",75.7,"E; B; D","Estimated value; Break; Difference in methodology"
+"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2019","2019",68.1,"E; D","Estimated value; Difference in methodology"
+"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2020","2020",70.9,"E; D","Estimated value; Difference in methodology"
+"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2021","2021",71.7,"E; D","Estimated value; Difference in methodology"
+"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2022","2022",73,"E; D","Estimated value; Difference in methodology"
+"PATCCARV","C-Cardiovascular system","ATCPTTMT","% of total sales","CAN","Canada","2012","2012",19,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","ATCPTTMT","% of total sales","CAN","Canada","2013","2013",16.6,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","ATCPTTMT","% of total sales","CAN","Canada","2014","2014",15.6,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","ATCPTTMT","% of total sales","CAN","Canada","2015","2015",14.3,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","ATCPTTMT","% of total sales","CAN","Canada","2016","2016",13.9,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","ATCPTTMT","% of total sales","CAN","Canada","2017","2017",13.4,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","ATCPTTMT","% of total sales","CAN","Canada","2018","2018",11.1,"E; B; D","Estimated value; Break; Difference in methodology"
+"PATCCARV","C-Cardiovascular system","ATCPTTMT","% of total sales","CAN","Canada","2019","2019",9.9,"E; D","Estimated value; Difference in methodology"
+"PATCCARV","C-Cardiovascular system","ATCPTTMT","% of total sales","CAN","Canada","2020","2020",9.7,"E; D","Estimated value; Difference in methodology"
+"PATCCARV","C-Cardiovascular system","ATCPTTMT","% of total sales","CAN","Canada","2021","2021",9.2,"E; D","Estimated value; Difference in methodology"
+"PATCCARV","C-Cardiovascular system","ATCPTTMT","% of total sales","CAN","Canada","2022","2022",8.9,"E; D","Estimated value; Difference in methodology"
+"PATCCARV","C-Cardiovascular system","MLLNCUMT","Million of national currency units","CZE","Czech Republic","2010","2010",12949.9,,
+"PATCCARV","C-Cardiovascular system","MLLNCUMT","Million of national currency units","CZE","Czech Republic","2011","2011",12647.3,,
+"PATCCARV","C-Cardiovascular system","MLLNCUMT","Million of national currency units","CZE","Czech Republic","2012","2012",12682.4,,
+"PATCCARV","C-Cardiovascular system","MLLNCUMT","Million of national currency units","CZE","Czech Republic","2013","2013",11618.1,,
+"PATCCARV","C-Cardiovascular system","MLLNCUMT","Million of national currency units","CZE","Czech Republic","2014","2014",10632.6,,
+"PATCCARV","C-Cardiovascular system","MLLNCUMT","Million of national currency units","CZE","Czech Republic","2015","2015",10160.6,,
+"PATCCARV","C-Cardiovascular system","MLLNCUMT","Million of national currency units","CZE","Czech Republic","2016","2016",10153,,
+"PATCCARV","C-Cardiovascular system","MLLNCUMT","Million of national currency units","CZE","Czech Republic","2017","2017",10372.5,,
+"PATCCARV","C-Cardiovascular system","MLLNCUMT","Million of national currency units","CZE","Czech Republic","2018","2018",10425.4,,
+"PATCCARV","C-Cardiovascular system","MLLNCUMT","Million of national currency units","CZE","Czech Republic","2019","2019",10754.3,,
+"PATCCARV","C-Cardiovascular system","MLLNCUMT","Million of national currency units","CZE","Czech Republic","2020","2020",9837.8,"B","Break"
+"PATCCARV","C-Cardiovascular system","MLLNCUMT","Million of national currency units","CZE","Czech Republic","2021","2021",9928.7,,
+"PATCCARV","C-Cardiovascular system","MTMOTCMT","Million US$ at exchange rate","CZE","Czech Republic","2010","2010",678.1,,
+"PATCCARV","C-Cardiovascular system","MTMOTCMT","Million US$ at exchange rate","CZE","Czech Republic","2011","2011",714.7,,
+"PATCCARV","C-Cardiovascular system","MTMOTCMT","Million US$ at exchange rate","CZE","Czech Republic","2012","2012",647.8,,
+"PATCCARV","C-Cardiovascular system","MTMOTCMT","Million US$ at exchange rate","CZE","Czech Republic","2013","2013",593.7,,
+"PATCCARV","C-Cardiovascular system","MTMOTCMT","Million US$ at exchange rate","CZE","Czech Republic","2014","2014",512.2,,
+"PATCCARV","C-Cardiovascular system","MTMOTCMT","Million US$ at exchange rate","CZE","Czech Republic","2015","2015",413.1,,
+"PATCCARV","C-Cardiovascular system","MTMOTCMT","Million US$ at exchange rate","CZE","Czech Republic","2016","2016",415.4,,
+"PATCCARV","C-Cardiovascular system","MTMOTCMT","Million US$ at exchange rate","CZE","Czech Republic","2017","2017",443.7,,
+"PATCCARV","C-Cardiovascular system","MTMOTCMT","Million US$ at exchange rate","CZE","Czech Republic","2018","2018",479.8,,
+"PATCCARV","C-Cardiovascular system","MTMOTCMT","Million US$ at exchange rate","CZE","Czech Republic","2019","2019",469,,
+"PATCCARV","C-Cardiovascular system","MTMOTCMT","Million US$ at exchange rate","CZE","Czech Republic","2020","2020",423.9,"B","Break"
+"PATCCARV","C-Cardiovascular system","MTMOTCMT","Million US$ at exchange rate","CZE","Czech Republic","2021","2021",458,,
+"PATCCARV","C-Cardiovascular system","MTMOPPMT","Million US$, purchasing power parity","CZE","Czech Republic","2010","2010",947.1,,
+"PATCCARV","C-Cardiovascular system","MTMOPPMT","Million US$, purchasing power parity","CZE","Czech Republic","2011","2011",947.7,,
+"PATCCARV","C-Cardiovascular system","MTMOPPMT","Million US$, purchasing power parity","CZE","Czech Republic","2012","2012",953.7,,
+"PATCCARV","C-Cardiovascular system","MTMOPPMT","Million US$, purchasing power parity","CZE","Czech Republic","2013","2013",908.7,,
+"PATCCARV","C-Cardiovascular system","MTMOPPMT","Million US$, purchasing power parity","CZE","Czech Republic","2014","2014",837,,
+"PATCCARV","C-Cardiovascular system","MTMOPPMT","Million US$, purchasing power parity","CZE","Czech Republic","2015","2015",785.3,,
+"PATCCARV","C-Cardiovascular system","MTMOPPMT","Million US$, purchasing power parity","CZE","Czech Republic","2016","2016",807.3,,
+"PATCCARV","C-Cardiovascular system","MTMOPPMT","Million US$, purchasing power parity","CZE","Czech Republic","2017","2017",834.8,,
+"PATCCARV","C-Cardiovascular system","MTMOPPMT","Million US$, purchasing power parity","CZE","Czech Republic","2018","2018",842.7,,
+"PATCCARV","C-Cardiovascular system","MTMOPPMT","Million US$, purchasing power parity","CZE","Czech Republic","2019","2019",876.1,,
+"PATCCARV","C-Cardiovascular system","MTMOPPMT","Million US$, purchasing power parity","CZE","Czech Republic","2020","2020",789.5,"B","Break"
+"PATCCARV","C-Cardiovascular system","MTMOPPMT","Million US$, purchasing power parity","CZE","Czech Republic","2021","2021",779.1,,
+"PATCCARV","C-Cardiovascular system","TCPPERMT","/capita, US$ exchange rate","CZE","Czech Republic","2010","2010",64.7,,
+"PATCCARV","C-Cardiovascular system","TCPPERMT","/capita, US$ exchange rate","CZE","Czech Republic","2011","2011",68.1,,
+"PATCCARV","C-Cardiovascular system","TCPPERMT","/capita, US$ exchange rate","CZE","Czech Republic","2012","2012",61.6,,
+"PATCCARV","C-Cardiovascular system","TCPPERMT","/capita, US$ exchange rate","CZE","Czech Republic","2013","2013",56.5,,
+"PATCCARV","C-Cardiovascular system","TCPPERMT","/capita, US$ exchange rate","CZE","Czech Republic","2014","2014",48.7,,
+"PATCCARV","C-Cardiovascular system","TCPPERMT","/capita, US$ exchange rate","CZE","Czech Republic","2015","2015",39.2,,
+"PATCCARV","C-Cardiovascular system","TCPPERMT","/capita, US$ exchange rate","CZE","Czech Republic","2016","2016",39.3,,
+"PATCCARV","C-Cardiovascular system","TCPPERMT","/capita, US$ exchange rate","CZE","Czech Republic","2017","2017",41.9,,
+"PATCCARV","C-Cardiovascular system","TCPPERMT","/capita, US$ exchange rate","CZE","Czech Republic","2018","2018",45.1,,
+"PATCCARV","C-Cardiovascular system","TCPPERMT","/capita, US$ exchange rate","CZE","Czech Republic","2019","2019",43.9,,
+"PATCCARV","C-Cardiovascular system","TCPPERMT","/capita, US$ exchange rate","CZE","Czech Republic","2020","2020",39.6,"B","Break"
+"PATCCARV","C-Cardiovascular system","TCPPERMT","/capita, US$ exchange rate","CZE","Czech Republic","2021","2021",43.6,,
+"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czech Republic","2010","2010",90.4,,
+"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czech Republic","2011","2011",90.3,,
+"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czech Republic","2012","2012",90.7,,
+"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czech Republic","2013","2013",86.4,,
+"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czech Republic","2014","2014",79.5,,
+"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czech Republic","2015","2015",74.5,,
+"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czech Republic","2016","2016",76.4,,
+"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czech Republic","2017","2017",78.8,,
+"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czech Republic","2018","2018",79.3,,
+"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czech Republic","2019","2019",82.1,,
+"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czech Republic","2020","2020",73.8,"B","Break"
+"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czech Republic","2021","2021",74.2,,
+"PATCCARV","C-Cardiovascular system","ATCPTTMT","% of total sales","CZE","Czech Republic","2010","2010",15.9,,
+"PATCCARV","C-Cardiovascular system","ATCPTTMT","% of total sales","CZE","Czech Republic","2011","2011",15.6,,
+"PATCCARV","C-Cardiovascular system","ATCPTTMT","% of total sales","CZE","Czech Republic","2012","2012",15.1,,
+"PATCCARV","C-Cardiovascular system","ATCPTTMT","% of total sales","CZE","Czech Republic","2013","2013",14.6,,
+"PATCCARV","C-Cardiovascular system","ATCPTTMT","% of total sales","CZE","Czech Republic","2014","2014",13.1,,
+"PATCCARV","C-Cardiovascular system","ATCPTTMT","% of total sales","CZE","Czech Republic","2015","2015",12,,
+"PATCCARV","C-Cardiovascular system","ATCPTTMT","% of total sales","CZE","Czech Republic","2016","2016",11.6,,
+"PATCCARV","C-Cardiovascular system","ATCPTTMT","% of total sales","CZE","Czech Republic","2017","2017",11.3,,
+"PATCCARV","C-Cardiovascular system","ATCPTTMT","% of total sales","CZE","Czech Republic","2018","2018",10.6,,
+"PATCCARV","C-Cardiovascular system","ATCPTTMT","% of total sales","CZE","Czech Republic","2019","2019",10.4,,
+"PATCCARV","C-Cardiovascular system","ATCPTTMT","% of total sales","CZE","Czech Republic","2020","2020",11.2,"B","Break"
+"PATCCARV","C-Cardiovascular system","ATCPTTMT","% of total sales","CZE","Czech Republic","2021","2021",10.7,,
+"PATCCARV","C-Cardiovascular system","MLLNCUMT","Million of national currency units","DNK","Denmark","2010","2010",1722,,
+"PATCCARV","C-Cardiovascular system","MLLNCUMT","Million of national currency units","DNK","Denmark","2011","2011",1418.5,,
+"PATCCARV","C-Cardiovascular system","MLLNCUMT","Million of national currency units","DNK","Denmark","2012","2012",1273.3,,
+"PATCCARV","C-Cardiovascular system","MLLNCUMT","Million of national currency units","DNK","Denmark","2013","2013",1128.6,,
+"PATCCARV","C-Cardiovascular system","MLLNCUMT","Million of national currency units","DNK","Denmark","2014","2014",1153.2,,
+"PATCCARV","C-Cardiovascular system","MLLNCUMT","Million of national currency units","DNK","Denmark","2015","2015",1152.3,,
+"PATCCARV","C-Cardiovascular system","MLLNCUMT","Million of national currency units","DNK","Denmark","2016","2016",1084.4,,
+"PATCCARV","C-Cardiovascular system","MLLNCUMT","Million of national currency units","DNK","Denmark","2017","2017",1079.3,,
+"PATCCARV","C-Cardiovascular system","MLLNCUMT","Million of national currency units","DNK","Denmark","2018","2018",978.7,,
+"PATCCARV","C-Cardiovascular system","MLLNCUMT","Million of national currency units","DNK","Denmark","2019","2019",1192.4,,
+"PATCCARV","C-Cardiovascular system","MLLNCUMT","Million of national currency units","DNK","Denmark","2020","2020",1217.3,,
+"PATCCARV","C-Cardiovascular system","MLLNCUMT","Million of national currency units","DNK","Denmark","2021","2021",1051,,
+"PATCCARV","C-Cardiovascular system","MTMOTCMT","Million US$ at exchange rate","DNK","Denmark","2010","2010",306.2,,
+"PATCCARV","C-Cardiovascular system","MTMOTCMT","Million US$ at exchange rate","DNK","Denmark","2011","2011",264.2,,
+"PATCCARV","C-Cardiovascular system","MTMOTCMT","Million US$ at exchange rate","DNK","Denmark","2012","2012",219.8,,
+"PATCCARV","C-Cardiovascular system","MTMOTCMT","Million US$ at exchange rate","DNK","Denmark","2013","2013",200.9,,
+"PATCCARV","C-Cardiovascular system","MTMOTCMT","Million US$ at exchange rate","DNK","Denmark","2014","2014",205.5,,
+"PATCCARV","C-Cardiovascular system","MTMOTCMT","Million US$ at exchange rate","DNK","Denmark","2015","2015",171.3,,
+"PATCCARV","C-Cardiovascular system","MTMOTCMT","Million US$ at exchange rate","DNK","Denmark","2016","2016",161.1,,
+"PATCCARV","C-Cardiovascular system","MTMOTCMT","Million US$ at exchange rate","DNK","Denmark","2017","2017",163.5,,
+"PATCCARV","C-Cardiovascular system","MTMOTCMT","Million US$ at exchange rate","DNK","Denmark","2018","2018",155,,
+"PATCCARV","C-Cardiovascular system","MTMOTCMT","Million US$ at exchange rate","DNK","Denmark","2019","2019",178.8,,
+"PATCCARV","C-Cardiovascular system","MTMOTCMT","Million US$ at exchange rate","DNK","Denmark","2020","2020",186.1,,
+"PATCCARV","C-Cardiovascular system","MTMOTCMT","Million US$ at exchange rate","DNK","Denmark","2021","2021",167.2,,
+"PATCCARV","C-Cardiovascular system","MTMOPPMT","Million US$, purchasing power parity","DNK","Denmark","2010","2010",226.8,,
+"PATCCARV","C-Cardiovascular system","MTMOPPMT","Million US$, purchasing power parity","DNK","Denmark","2011","2011",190,,
+"PATCCARV","C-Cardiovascular system","MTMOPPMT","Million US$, purchasing power parity","DNK","Denmark","2012","2012",168.3,,
+"PATCCARV","C-Cardiovascular system","MTMOPPMT","Million US$, purchasing power parity","DNK","Denmark","2013","2013",153.4,,
+"PATCCARV","C-Cardiovascular system","MTMOPPMT","Million US$, purchasing power parity","DNK","Denmark","2014","2014",157.4,,
+"PATCCARV","C-Cardiovascular system","MTMOPPMT","Million US$, purchasing power parity","DNK","Denmark","2015","2015",157.7,,
+"PATCCARV","C-Cardiovascular system","MTMOPPMT","Million US$, purchasing power parity","DNK","Denmark","2016","2016",153.2,,
+"PATCCARV","C-Cardiovascular system","MTMOPPMT","Million US$, purchasing power parity","DNK","Denmark","2017","2017",157.1,,
+"PATCCARV","C-Cardiovascular system","MTMOPPMT","Million US$, purchasing power parity","DNK","Denmark","2018","2018",144.6,,
+"PATCCARV","C-Cardiovascular system","MTMOPPMT","Million US$, purchasing power parity","DNK","Denmark","2019","2019",179.7,,
+"PATCCARV","C-Cardiovascular system","MTMOPPMT","Million US$, purchasing power parity","DNK","Denmark","2020","2020",185.8,,
+"PATCCARV","C-Cardiovascular system","MTMOPPMT","Million US$, purchasing power parity","DNK","Denmark","2021","2021",159.5,,
+"PATCCARV","C-Cardiovascular system","TCPPERMT","/capita, US$ exchange rate","DNK","Denmark","2010","2010",55.2,,
+"PATCCARV","C-Cardiovascular system","TCPPERMT","/capita, US$ exchange rate","DNK","Denmark","2011","2011",47.4,,
+"PATCCARV","C-Cardiovascular system","TCPPERMT","/capita, US$ exchange rate","DNK","Denmark","2012","2012",39.3,,
+"PATCCARV","C-Cardiovascular system","TCPPERMT","/capita, US$ exchange rate","DNK","Denmark","2013","2013",35.8,,
+"PATCCARV","C-Cardiovascular system","TCPPERMT","/capita, US$ exchange rate","DNK","Denmark","2014","2014",36.4,,
+"PATCCARV","C-Cardiovascular system","TCPPERMT","/capita, US$ exchange rate","DNK","Denmark","2015","2015",30.1,,
+"PATCCARV","C-Cardiovascular system","TCPPERMT","/capita, US$ exchange rate","DNK","Denmark","2016","2016",28.1,,
+"PATCCARV","C-Cardiovascular system","TCPPERMT","/capita, US$ exchange rate","DNK","Denmark","2017","2017",28.4,,
+"PATCCARV","C-Cardiovascular system","TCPPERMT","/capita, US$ exchange rate","DNK","Denmark","2018","2018",26.8,,
+"PATCCARV","C-Cardiovascular system","TCPPERMT","/capita, US$ exchange rate","DNK","Denmark","2019","2019",30.7,,
+"PATCCARV","C-Cardiovascular system","TCPPERMT","/capita, US$ exchange rate","DNK","Denmark","2020","2020",31.9,,
+"PATCCARV","C-Cardiovascular system","TCPPERMT","/capita, US$ exchange rate","DNK","Denmark","2021","2021",28.5,,
+"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","DNK","Denmark","2010","2010",40.9,,
+"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","DNK","Denmark","2011","2011",34.1,,
+"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","DNK","Denmark","2012","2012",30.1,,
+"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","DNK","Denmark","2013","2013",27.3,,
+"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","DNK","Denmark","2014","2014",27.9,,
+"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","DNK","Denmark","2015","2015",27.8,,
+"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","DNK","Denmark","2016","2016",26.7,,
+"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","DNK","Denmark","2017","2017",27.2,,
+"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","DNK","Denmark","2018","2018",25,,
+"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","DNK","Denmark","2019","2019",30.9,,
+"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","DNK","Denmark","2020","2020",31.9,,
+"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","DNK","Denmark","2021","2021",27.2,,
+"PATCCARV","C-Cardiovascular system","ATCPTTMT","% of total sales","DNK","Denmark","2010","2010",8.1,,
+"PATCCARV","C-Cardiovascular system","ATCPTTMT","% of total sales","DNK","Denmark","2011","2011",6.9,,
+"PATCCARV","C-Cardiovascular system","ATCPTTMT","% of total sales","DNK","Denmark","2012","2012",6.2,,
+"PATCCARV","C-Cardiovascular system","ATCPTTMT","% of total sales","DNK","Denmark","2013","2013",5.5,,
+"PATCCARV","C-Cardiovascular system","ATCPTTMT","% of total sales","DNK","Denmark","2014","2014",5.4,,
+"PATCCARV","C-Cardiovascular system","ATCPTTMT","% of total sales","DNK","Denmark","2015","2015",5.3,,
+"PATCCARV","C-Cardiovascular system","ATCPTTMT","% of total sales","DNK","Denmark","2016","2016",4.9,,
+"PATCCARV","C-Cardiovascular system","ATCPTTMT","% of total sales","DNK","Denmark","2017","2017",4.7,,
+"PATCCARV","C-Cardiovascular system","ATCPTTMT","% of total sales","DNK","Denmark","2018","2018",4.1,,
+"PATCCARV","C-Cardiovascular system","ATCPTTMT","% of total sales","DNK","Denmark","2019","2019",4.9,,
+"PATCCARV","C-Cardiovascular system","ATCPTTMT","% of total sales","DNK","Denmark","2020","2020",4.8,,
+"PATCCARV","C-Cardiovascular system","ATCPTTMT","% of total sales","DNK","Denmark","2021","2021",4.1,,
+"PATCCARV","C-Cardiovascular system","MLLNCUMT","Million of national currency units","FIN","Finland","2010","2010",195,,
+"PATCCARV","C-Cardiovascular system","MLLNCUMT","Million of national currency units","FIN","Finland","2011","2011",178.2,,
+"PATCCARV","C-Cardiovascular system","MLLNCUMT","Million of national currency units","FIN","Finland","2012","2012",176.2,,
+"PATCCARV","C-Cardiovascular system","MLLNCUMT","Million of national currency units","FIN","Finland","2013","2013",181.9,,
+"PATCCARV","C-Cardiovascular system","MLLNCUMT","Million of national currency units","FIN","Finland","2014","2014",190.9,,
+"PATCCARV","C-Cardiovascular system","MLLNCUMT","Million of national currency units","FIN","Finland","2015","2015",203.2,,
+"PATCCARV","C-Cardiovascular system","MLLNCUMT","Million of national currency units","FIN","Finland","2016","2016",210.1,,
+"PATCCARV","C-Cardiovascular system","MLLNCUMT","Million of national currency units","FIN","Finland","2017","2017",197.7,,
+"PATCCARV","C-Cardiovascular system","MLLNCUMT","Million of national currency units","FIN","Finland","2018","2018",172.4,,
+"PATCCARV","C-Cardiovascular system","MLLNCUMT","Million of national currency units","FIN","Finland","2019","2019",150.7,,
+"PATCCARV","C-Cardiovascular system","MLLNCUMT","Million of national currency units","FIN","Finland","2020","2020",138.3,,
+"PATCCARV","C-Cardiovascular system","MLLNCUMT","Million of national currency units","FIN","Finland","2021","2021",130.7,,
+"PATCCARV","C-Cardiovascular system","MTMOTCMT","Million US$ at exchange rate","FIN","Finland","2010","2010",258.5,,
+"PATCCARV","C-Cardiovascular system","MTMOTCMT","Million US$ at exchange rate","FIN","Finland","2011","2011",248,,
+"PATCCARV","C-Cardiovascular system","MTMOTCMT","Million US$ at exchange rate","FIN","Finland","2012","2012",226.4,,
+"PATCCARV","C-Cardiovascular system","MTMOTCMT","Million US$ at exchange rate","FIN","Finland","2013","2013",241.6,,
+"PATCCARV","C-Cardiovascular system","MTMOTCMT","Million US$ at exchange rate","FIN","Finland","2014","2014",253.6,,
+"PATCCARV","C-Cardiovascular system","MTMOTCMT","Million US$ at exchange rate","FIN","Finland","2015","2015",225.5,,
+"PATCCARV","C-Cardiovascular system","MTMOTCMT","Million US$ at exchange rate","FIN","Finland","2016","2016",232.6,,
+"PATCCARV","C-Cardiovascular system","MTMOTCMT","Million US$ at exchange rate","FIN","Finland","2017","2017",223.3,,
+"PATCCARV","C-Cardiovascular system","MTMOTCMT","Million US$ at exchange rate","FIN","Finland","2018","2018",203.6,,
+"PATCCARV","C-Cardiovascular system","MTMOTCMT","Million US$ at exchange rate","FIN","Finland","2019","2019",168.7,,
+"PATCCARV","C-Cardiovascular system","MTMOTCMT","Million US$ at exchange rate","FIN","Finland","2020","2020",158,,
+"PATCCARV","C-Cardiovascular system","MTMOTCMT","Million US$ at exchange rate","FIN","Finland","2021","2021",154.6,,
+"PATCCARV","C-Cardiovascular system","MTMOPPMT","Million US$, purchasing power parity","FIN","Finland","2010","2010",216.5,,
+"PATCCARV","C-Cardiovascular system","MTMOPPMT","Million US$, purchasing power parity","FIN","Finland","2011","2011",198.4,,
+"PATCCARV","C-Cardiovascular system","MTMOPPMT","Million US$, purchasing power parity","FIN","Finland","2012","2012",193.9,,
+"PATCCARV","C-Cardiovascular system","MTMOPPMT","Million US$, purchasing power parity","FIN","Finland","2013","2013",200.9,,
+"PATCCARV","C-Cardiovascular system","MTMOPPMT","Million US$, purchasing power parity","FIN","Finland","2014","2014",210.4,,
+"PATCCARV","C-Cardiovascular system","MTMOPPMT","Million US$, purchasing power parity","FIN","Finland","2015","2015",223.9,,
+"PATCCARV","C-Cardiovascular system","MTMOPPMT","Million US$, purchasing power parity","FIN","Finland","2016","2016",238.5,,
+"PATCCARV","C-Cardiovascular system","MTMOPPMT","Million US$, purchasing power parity","FIN","Finland","2017","2017",228.9,,
+"PATCCARV","C-Cardiovascular system","MTMOPPMT","Million US$, purchasing power parity","FIN","Finland","2018","2018",201.9,,
+"PATCCARV","C-Cardiovascular system","MTMOPPMT","Million US$, purchasing power parity","FIN","Finland","2019","2019",179.7,,
+"PATCCARV","C-Cardiovascular system","MTMOPPMT","Million US$, purchasing power parity","FIN","Finland","2020","2020",168,,
+"PATCCARV","C-Cardiovascular system","MTMOPPMT","Million US$, purchasing power parity","FIN","Finland","2021","2021",158.1,,
+"PATCCARV","C-Cardiovascular system","TCPPERMT","/capita, US$ exchange rate","FIN","Finland","2010","2010",48.2,,
+"PATCCARV","C-Cardiovascular system","TCPPERMT","/capita, US$ exchange rate","FIN","Finland","2011","2011",46,,
+"PATCCARV","C-Cardiovascular system","TCPPERMT","/capita, US$ exchange rate","FIN","Finland","2012","2012",41.8,,
+"PATCCARV","C-Cardiovascular system","TCPPERMT","/capita, US$ exchange rate","FIN","Finland","2013","2013",44.4,,
+"PATCCARV","C-Cardiovascular system","TCPPERMT","/capita, US$ exchange rate","FIN","Finland","2014","2014",46.4,,
+"PATCCARV","C-Cardiovascular system","TCPPERMT","/capita, US$ exchange rate","FIN","Finland","2015","2015",41.1,,
+"PATCCARV","C-Cardiovascular system","TCPPERMT","/capita, US$ exchange rate","FIN","Finland","2016","2016",42.3,,
+"PATCCARV","C-Cardiovascular system","TCPPERMT","/capita, US$ exchange rate","FIN","Finland","2017","2017",40.5,,
+"PATCCARV","C-Cardiovascular system","TCPPERMT","/capita, US$ exchange rate","FIN","Finland","2018","2018",36.9,,
+"PATCCARV","C-Cardiovascular system","TCPPERMT","/capita, US$ exchange rate","FIN","Finland","2019","2019",30.6,,
+"PATCCARV","C-Cardiovascular system","TCPPERMT","/capita, US$ exchange rate","FIN","Finland","2020","2020",28.6,,
+"PATCCARV","C-Cardiovascular system","TCPPERMT","/capita, US$ exchange rate","FIN","Finland","2021","2021",27.9,,
+"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2010","2010",40.4,,
+"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2011","2011",36.8,,
+"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2012","2012",35.8,,
+"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2013","2013",36.9,,
+"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2014","2014",38.5,,
+"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2015","2015",40.9,,
+"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2016","2016",43.4,,
+"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2017","2017",41.6,,
+"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2018","2018",36.6,,
+"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2019","2019",32.6,,
+"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2020","2020",30.4,,
+"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2021","2021",28.5,,
+"PATCCARV","C-Cardiovascular system","ATCPTTMT","% of total sales","FIN","Finland","2010","2010",10.4,,
+"PATCCARV","C-Cardiovascular system","ATCPTTMT","% of total sales","FIN","Finland","2011","2011",9.2,,
+"PATCCARV","C-Cardiovascular system","ATCPTTMT","% of total sales","FIN","Finland","2012","2012",9,,
+"PATCCARV","C-Cardiovascular system","ATCPTTMT","% of total sales","FIN","Finland","2013","2013",9,,
+"PATCCARV","C-Cardiovascular system","ATCPTTMT","% of total sales","FIN","Finland","2014","2014",9.1,,
+"PATCCARV","C-Cardiovascular system","ATCPTTMT","% of total sales","FIN","Finland","2015","2015",9.2,,
+"PATCCARV","C-Cardiovascular system","ATCPTTMT","% of total sales","FIN","Finland","2016","2016",9.2,,
+"PATCCARV","C-Cardiovascular system","ATCPTTMT","% of total sales","FIN","Finland","2017","2017",8.5,,
+"PATCCARV","C-Cardiovascular system","ATCPTTMT","% of total sales","FIN","Finland","2018","2018",6.9,,
+"PATCCARV","C-Cardiovascular system","ATCPTTMT","% of total sales","FIN","Finland","2019","2019",5.7,,
+"PATCCARV","C-Cardiovascular system","ATCPTTMT","% of total sales","FIN","Finland","2020","2020",5.1,,
+"PATCCARV","C-Cardiovascular system","ATCPTTMT","% of total sales","FIN","Finland","2021","2021",4.6,,
+"PATCCARV","C-Cardiovascular system","MLLNCUMT","Million of national currency units","FRA","France","2011","2011",3937,,
+"PATCCARV","C-Cardiovascular system","MTMOTCMT","Million US$ at exchange rate","FRA","France","2011","2011",5480.1,,
+"PATCCARV","C-Cardiovascular system","MTMOPPMT","Million US$, purchasing power parity","FRA","France","2011","2011",4679.3,,
+"PATCCARV","C-Cardiovascular system","TCPPERMT","/capita, US$ exchange rate","FRA","France","2011","2011",84.1,,
+"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","FRA","France","2011","2011",71.8,,
+"PATCCARV","C-Cardiovascular system","ATCPTTMT","% of total sales","FRA","France","2011","2011",14.3,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","MLLNCUMT","Million of national currency units","DEU","Germany","2010","2010",4869.6,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","MLLNCUMT","Million of national currency units","DEU","Germany","2011","2011",4794.3,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","MLLNCUMT","Million of national currency units","DEU","Germany","2012","2012",4529.2,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","MLLNCUMT","Million of national currency units","DEU","Germany","2013","2013",4455.9,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","MLLNCUMT","Million of national currency units","DEU","Germany","2014","2014",4399.7,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","MLLNCUMT","Million of national currency units","DEU","Germany","2015","2015",4273.6,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","MLLNCUMT","Million of national currency units","DEU","Germany","2016","2016",4366.6,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","MLLNCUMT","Million of national currency units","DEU","Germany","2017","2017",4431.4,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","MLLNCUMT","Million of national currency units","DEU","Germany","2018","2018",4541.9,"B; D","Break; Difference in methodology"
+"PATCCARV","C-Cardiovascular system","MLLNCUMT","Million of national currency units","DEU","Germany","2019","2019",4692.5,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","MLLNCUMT","Million of national currency units","DEU","Germany","2020","2020",4771.1,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","MLLNCUMT","Million of national currency units","DEU","Germany","2021","2021",4907.4,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","MTMOTCMT","Million US$ at exchange rate","DEU","Germany","2010","2010",6455.7,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","MTMOTCMT","Million US$ at exchange rate","DEU","Germany","2011","2011",6673.5,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","MTMOTCMT","Million US$ at exchange rate","DEU","Germany","2012","2012",5819.1,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","MTMOTCMT","Million US$ at exchange rate","DEU","Germany","2013","2013",5918,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","MTMOTCMT","Million US$ at exchange rate","DEU","Germany","2014","2014",5845,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","MTMOTCMT","Million US$ at exchange rate","DEU","Germany","2015","2015",4741.6,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","MTMOTCMT","Million US$ at exchange rate","DEU","Germany","2016","2016",4833.4,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","MTMOTCMT","Million US$ at exchange rate","DEU","Germany","2017","2017",5006.1,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","MTMOTCMT","Million US$ at exchange rate","DEU","Germany","2018","2018",5363.8,"B; D","Break; Difference in methodology"
+"PATCCARV","C-Cardiovascular system","MTMOTCMT","Million US$ at exchange rate","DEU","Germany","2019","2019",5253.1,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","MTMOTCMT","Million US$ at exchange rate","DEU","Germany","2020","2020",5449.5,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","MTMOTCMT","Million US$ at exchange rate","DEU","Germany","2021","2021",5804.2,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","MTMOPPMT","Million US$, purchasing power parity","DEU","Germany","2010","2010",6048.6,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","MTMOPPMT","Million US$, purchasing power parity","DEU","Germany","2011","2011",6078.4,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","MTMOPPMT","Million US$, purchasing power parity","DEU","Germany","2012","2012",5753.2,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","MTMOPPMT","Million US$, purchasing power parity","DEU","Germany","2013","2013",5751.2,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","MTMOPPMT","Million US$, purchasing power parity","DEU","Germany","2014","2014",5721.8,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","MTMOPPMT","Million US$, purchasing power parity","DEU","Germany","2015","2015",5492.2,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","MTMOPPMT","Million US$, purchasing power parity","DEU","Germany","2016","2016",5802,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","MTMOPPMT","Million US$, purchasing power parity","DEU","Germany","2017","2017",5949.9,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","MTMOPPMT","Million US$, purchasing power parity","DEU","Germany","2018","2018",6175.7,"B; D","Break; Difference in methodology"
+"PATCCARV","C-Cardiovascular system","MTMOPPMT","Million US$, purchasing power parity","DEU","Germany","2019","2019",6443.5,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","MTMOPPMT","Million US$, purchasing power parity","DEU","Germany","2020","2020",6580.8,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","MTMOPPMT","Million US$, purchasing power parity","DEU","Germany","2021","2021",6665.2,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","TCPPERMT","/capita, US$ exchange rate","DEU","Germany","2010","2010",78.9,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","TCPPERMT","/capita, US$ exchange rate","DEU","Germany","2011","2011",83.1,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","TCPPERMT","/capita, US$ exchange rate","DEU","Germany","2012","2012",72.4,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","TCPPERMT","/capita, US$ exchange rate","DEU","Germany","2013","2013",73.4,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","TCPPERMT","/capita, US$ exchange rate","DEU","Germany","2014","2014",72.2,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","TCPPERMT","/capita, US$ exchange rate","DEU","Germany","2015","2015",58,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","TCPPERMT","/capita, US$ exchange rate","DEU","Germany","2016","2016",58.7,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","TCPPERMT","/capita, US$ exchange rate","DEU","Germany","2017","2017",60.6,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","TCPPERMT","/capita, US$ exchange rate","DEU","Germany","2018","2018",64.7,"B; D","Break; Difference in methodology"
+"PATCCARV","C-Cardiovascular system","TCPPERMT","/capita, US$ exchange rate","DEU","Germany","2019","2019",63.2,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","TCPPERMT","/capita, US$ exchange rate","DEU","Germany","2020","2020",65.5,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","TCPPERMT","/capita, US$ exchange rate","DEU","Germany","2021","2021",69.8,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2010","2010",74,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2011","2011",75.7,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2012","2012",71.5,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2013","2013",71.3,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2014","2014",70.7,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2015","2015",67.2,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2016","2016",70.5,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2017","2017",72,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2018","2018",74.5,"B; D","Break; Difference in methodology"
+"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2019","2019",77.5,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2020","2020",79.1,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2021","2021",80.1,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","ATCPTTMT","% of total sales","DEU","Germany","2010","2010",16.4,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","ATCPTTMT","% of total sales","DEU","Germany","2011","2011",16.1,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","ATCPTTMT","% of total sales","DEU","Germany","2012","2012",14.9,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","ATCPTTMT","% of total sales","DEU","Germany","2013","2013",14.1,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","ATCPTTMT","% of total sales","DEU","Germany","2014","2014",13.1,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","ATCPTTMT","% of total sales","DEU","Germany","2015","2015",12.1,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","ATCPTTMT","% of total sales","DEU","Germany","2016","2016",12.1,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","ATCPTTMT","% of total sales","DEU","Germany","2017","2017",11.9,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","ATCPTTMT","% of total sales","DEU","Germany","2018","2018",10.3,"B; D","Break; Difference in methodology"
+"PATCCARV","C-Cardiovascular system","ATCPTTMT","% of total sales","DEU","Germany","2019","2019",10,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","ATCPTTMT","% of total sales","DEU","Germany","2020","2020",9.7,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","ATCPTTMT","% of total sales","DEU","Germany","2021","2021",9.2,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","MLLNCUMT","Million of national currency units","GRC","Greece","2010","2010",1425.5,,
+"PATCCARV","C-Cardiovascular system","MLLNCUMT","Million of national currency units","GRC","Greece","2011","2011",1314.5,,
+"PATCCARV","C-Cardiovascular system","MLLNCUMT","Million of national currency units","GRC","Greece","2012","2012",1196.9,,
+"PATCCARV","C-Cardiovascular system","MLLNCUMT","Million of national currency units","GRC","Greece","2013","2013",1018,,
+"PATCCARV","C-Cardiovascular system","MLLNCUMT","Million of national currency units","GRC","Greece","2014","2014",953.9,,
+"PATCCARV","C-Cardiovascular system","MLLNCUMT","Million of national currency units","GRC","Greece","2015","2015",885.9,,
+"PATCCARV","C-Cardiovascular system","MLLNCUMT","Million of national currency units","GRC","Greece","2016","2016",939.4,,
+"PATCCARV","C-Cardiovascular system","MLLNCUMT","Million of national currency units","GRC","Greece","2017","2017",873.7,,
+"PATCCARV","C-Cardiovascular system","MLLNCUMT","Million of national currency units","GRC","Greece","2018","2018",853,,
+"PATCCARV","C-Cardiovascular system","MLLNCUMT","Million of national currency units","GRC","Greece","2019","2019",850.9,,
+"PATCCARV","C-Cardiovascular system","MLLNCUMT","Million of national currency units","GRC","Greece","2020","2020",810.6,,
+"PATCCARV","C-Cardiovascular system","MLLNCUMT","Million of national currency units","GRC","Greece","2021","2021",829,,
+"PATCCARV","C-Cardiovascular system","MLLNCUMT","Million of national currency units","GRC","Greece","2022","2022",650.5,,
+"PATCCARV","C-Cardiovascular system","MTMOTCMT","Million US$ at exchange rate","GRC","Greece","2010","2010",1889.8,,
+"PATCCARV","C-Cardiovascular system","MTMOTCMT","Million US$ at exchange rate","GRC","Greece","2011","2011",1829.7,,
+"PATCCARV","C-Cardiovascular system","MTMOTCMT","Million US$ at exchange rate","GRC","Greece","2012","2012",1537.7,,
+"PATCCARV","C-Cardiovascular system","MTMOTCMT","Million US$ at exchange rate","GRC","Greece","2013","2013",1352,,
+"PATCCARV","C-Cardiovascular system","MTMOTCMT","Million US$ at exchange rate","GRC","Greece","2014","2014",1267.2,,
+"PATCCARV","C-Cardiovascular system","MTMOTCMT","Million US$ at exchange rate","GRC","Greece","2015","2015",982.9,,
+"PATCCARV","C-Cardiovascular system","MTMOTCMT","Million US$ at exchange rate","GRC","Greece","2016","2016",1039.8,,
+"PATCCARV","C-Cardiovascular system","MTMOTCMT","Million US$ at exchange rate","GRC","Greece","2017","2017",987,,
+"PATCCARV","C-Cardiovascular system","MTMOTCMT","Million US$ at exchange rate","GRC","Greece","2018","2018",1007.4,,
+"PATCCARV","C-Cardiovascular system","MTMOTCMT","Million US$ at exchange rate","GRC","Greece","2019","2019",952.6,,
+"PATCCARV","C-Cardiovascular system","MTMOTCMT","Million US$ at exchange rate","GRC","Greece","2020","2020",925.9,,
+"PATCCARV","C-Cardiovascular system","MTMOTCMT","Million US$ at exchange rate","GRC","Greece","2021","2021",980.5,,
+"PATCCARV","C-Cardiovascular system","MTMOTCMT","Million US$ at exchange rate","GRC","Greece","2022","2022",685,,
+"PATCCARV","C-Cardiovascular system","MTMOPPMT","Million US$, purchasing power parity","GRC","Greece","2010","2010",1974.4,,
+"PATCCARV","C-Cardiovascular system","MTMOPPMT","Million US$, purchasing power parity","GRC","Greece","2011","2011",1843.2,,
+"PATCCARV","C-Cardiovascular system","MTMOPPMT","Million US$, purchasing power parity","GRC","Greece","2012","2012",1748.1,,
+"PATCCARV","C-Cardiovascular system","MTMOPPMT","Million US$, purchasing power parity","GRC","Greece","2013","2013",1612.5,,
+"PATCCARV","C-Cardiovascular system","MTMOPPMT","Million US$, purchasing power parity","GRC","Greece","2014","2014",1560.8,,
+"PATCCARV","C-Cardiovascular system","MTMOPPMT","Million US$, purchasing power parity","GRC","Greece","2015","2015",1454.5,,
+"PATCCARV","C-Cardiovascular system","MTMOPPMT","Million US$, purchasing power parity","GRC","Greece","2016","2016",1596.1,,
+"PATCCARV","C-Cardiovascular system","MTMOPPMT","Million US$, purchasing power parity","GRC","Greece","2017","2017",1519.4,,
+"PATCCARV","C-Cardiovascular system","MTMOPPMT","Million US$, purchasing power parity","GRC","Greece","2018","2018",1510.2,,
+"PATCCARV","C-Cardiovascular system","MTMOPPMT","Million US$, purchasing power parity","GRC","Greece","2019","2019",1550.3,,
+"PATCCARV","C-Cardiovascular system","MTMOPPMT","Million US$, purchasing power parity","GRC","Greece","2020","2020",1489.9,,
+"PATCCARV","C-Cardiovascular system","MTMOPPMT","Million US$, purchasing power parity","GRC","Greece","2021","2021",1519.6,,
+"PATCCARV","C-Cardiovascular system","MTMOPPMT","Million US$, purchasing power parity","GRC","Greece","2022","2022",1230.9,,
+"PATCCARV","C-Cardiovascular system","TCPPERMT","/capita, US$ exchange rate","GRC","Greece","2010","2010",169.9,,
+"PATCCARV","C-Cardiovascular system","TCPPERMT","/capita, US$ exchange rate","GRC","Greece","2011","2011",164.8,,
+"PATCCARV","C-Cardiovascular system","TCPPERMT","/capita, US$ exchange rate","GRC","Greece","2012","2012",139.2,,
+"PATCCARV","C-Cardiovascular system","TCPPERMT","/capita, US$ exchange rate","GRC","Greece","2013","2013",123.3,,
+"PATCCARV","C-Cardiovascular system","TCPPERMT","/capita, US$ exchange rate","GRC","Greece","2014","2014",116.3,,
+"PATCCARV","C-Cardiovascular system","TCPPERMT","/capita, US$ exchange rate","GRC","Greece","2015","2015",90.8,,
+"PATCCARV","C-Cardiovascular system","TCPPERMT","/capita, US$ exchange rate","GRC","Greece","2016","2016",96.5,,
+"PATCCARV","C-Cardiovascular system","TCPPERMT","/capita, US$ exchange rate","GRC","Greece","2017","2017",91.8,,
+"PATCCARV","C-Cardiovascular system","TCPPERMT","/capita, US$ exchange rate","GRC","Greece","2018","2018",93.9,,
+"PATCCARV","C-Cardiovascular system","TCPPERMT","/capita, US$ exchange rate","GRC","Greece","2019","2019",88.8,,
+"PATCCARV","C-Cardiovascular system","TCPPERMT","/capita, US$ exchange rate","GRC","Greece","2020","2020",86.5,,
+"PATCCARV","C-Cardiovascular system","TCPPERMT","/capita, US$ exchange rate","GRC","Greece","2021","2021",92.8,,
+"PATCCARV","C-Cardiovascular system","TCPPERMT","/capita, US$ exchange rate","GRC","Greece","2022","2022",65.5,,
+"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2010","2010",177.5,,
+"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2011","2011",166,,
+"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2012","2012",158.3,,
+"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2013","2013",147.1,,
+"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2014","2014",143.3,,
+"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2015","2015",134.4,,
+"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2016","2016",148.1,,
+"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2017","2017",141.3,,
+"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2018","2018",140.7,,
+"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2019","2019",144.6,,
+"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2020","2020",139.3,,
+"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2021","2021",143.8,,
+"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2022","2022",117.7,,
+"PATCCARV","C-Cardiovascular system","MLLNCUMT","Million of national currency units","HUN","Hungary","2010","2010",129978.7,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","MLLNCUMT","Million of national currency units","HUN","Hungary","2011","2011",127453,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","MLLNCUMT","Million of national currency units","HUN","Hungary","2012","2012",105895,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","MLLNCUMT","Million of national currency units","HUN","Hungary","2013","2013",95396.2,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","MLLNCUMT","Million of national currency units","HUN","Hungary","2014","2014",90647.4,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","MLLNCUMT","Million of national currency units","HUN","Hungary","2015","2015",90577.6,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","MLLNCUMT","Million of national currency units","HUN","Hungary","2016","2016",92167.6,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","MLLNCUMT","Million of national currency units","HUN","Hungary","2017","2017",92973.4,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","MLLNCUMT","Million of national currency units","HUN","Hungary","2018","2018",93271.8,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","MLLNCUMT","Million of national currency units","HUN","Hungary","2019","2019",94477.5,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","MLLNCUMT","Million of national currency units","HUN","Hungary","2020","2020",99352.5,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","MLLNCUMT","Million of national currency units","HUN","Hungary","2021","2021",96764.1,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","MLLNCUMT","Million of national currency units","HUN","Hungary","2022","2022",100396.9,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","MTMOTCMT","Million US$ at exchange rate","HUN","Hungary","2010","2010",625.1,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","MTMOTCMT","Million US$ at exchange rate","HUN","Hungary","2011","2011",633.9,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","MTMOTCMT","Million US$ at exchange rate","HUN","Hungary","2012","2012",470.4,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","MTMOTCMT","Million US$ at exchange rate","HUN","Hungary","2013","2013",426.5,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","MTMOTCMT","Million US$ at exchange rate","HUN","Hungary","2014","2014",389.7,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","MTMOTCMT","Million US$ at exchange rate","HUN","Hungary","2015","2015",324.3,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","MTMOTCMT","Million US$ at exchange rate","HUN","Hungary","2016","2016",327.4,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","MTMOTCMT","Million US$ at exchange rate","HUN","Hungary","2017","2017",338.8,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","MTMOTCMT","Million US$ at exchange rate","HUN","Hungary","2018","2018",345.2,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","MTMOTCMT","Million US$ at exchange rate","HUN","Hungary","2019","2019",325,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","MTMOTCMT","Million US$ at exchange rate","HUN","Hungary","2020","2020",322.6,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","MTMOTCMT","Million US$ at exchange rate","HUN","Hungary","2021","2021",319.2,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","MTMOTCMT","Million US$ at exchange rate","HUN","Hungary","2022","2022",269.5,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","MTMOPPMT","Million US$, purchasing power parity","HUN","Hungary","2010","2010",1028.2,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","MTMOPPMT","Million US$, purchasing power parity","HUN","Hungary","2011","2011",1025.6,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","MTMOPPMT","Million US$, purchasing power parity","HUN","Hungary","2012","2012",843,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","MTMOPPMT","Million US$, purchasing power parity","HUN","Hungary","2013","2013",763.3,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","MTMOPPMT","Million US$, purchasing power parity","HUN","Hungary","2014","2014",700.4,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","MTMOPPMT","Million US$, purchasing power parity","HUN","Hungary","2015","2015",683.3,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","MTMOPPMT","Million US$, purchasing power parity","HUN","Hungary","2016","2016",698.1,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","MTMOPPMT","Million US$, purchasing power parity","HUN","Hungary","2017","2017",683.4,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","MTMOPPMT","Million US$, purchasing power parity","HUN","Hungary","2018","2018",670.6,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","MTMOPPMT","Million US$, purchasing power parity","HUN","Hungary","2019","2019",670.9,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","MTMOPPMT","Million US$, purchasing power parity","HUN","Hungary","2020","2020",683.5,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","MTMOPPMT","Million US$, purchasing power parity","HUN","Hungary","2021","2021",625.3,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","MTMOPPMT","Million US$, purchasing power parity","HUN","Hungary","2022","2022",622.7,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","TCPPERMT","/capita, US$ exchange rate","HUN","Hungary","2010","2010",62.5,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","TCPPERMT","/capita, US$ exchange rate","HUN","Hungary","2011","2011",63.6,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","TCPPERMT","/capita, US$ exchange rate","HUN","Hungary","2012","2012",47.4,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","TCPPERMT","/capita, US$ exchange rate","HUN","Hungary","2013","2013",43.1,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","TCPPERMT","/capita, US$ exchange rate","HUN","Hungary","2014","2014",39.5,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","TCPPERMT","/capita, US$ exchange rate","HUN","Hungary","2015","2015",32.9,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","TCPPERMT","/capita, US$ exchange rate","HUN","Hungary","2016","2016",33.4,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","TCPPERMT","/capita, US$ exchange rate","HUN","Hungary","2017","2017",34.6,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","TCPPERMT","/capita, US$ exchange rate","HUN","Hungary","2018","2018",35.3,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","TCPPERMT","/capita, US$ exchange rate","HUN","Hungary","2019","2019",33.3,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","TCPPERMT","/capita, US$ exchange rate","HUN","Hungary","2020","2020",33.1,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","TCPPERMT","/capita, US$ exchange rate","HUN","Hungary","2021","2021",32.9,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","TCPPERMT","/capita, US$ exchange rate","HUN","Hungary","2022","2022",27.8,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2010","2010",102.8,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2011","2011",102.9,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2012","2012",85,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2013","2013",77.2,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2014","2014",71,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2015","2015",69.4,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2016","2016",71.1,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2017","2017",69.8,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2018","2018",68.6,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2019","2019",68.7,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2020","2020",70.1,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2021","2021",64.4,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2022","2022",64.3,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","ATCPTTMT","% of total sales","HUN","Hungary","2010","2010",26.1,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","ATCPTTMT","% of total sales","HUN","Hungary","2011","2011",24.7,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","ATCPTTMT","% of total sales","HUN","Hungary","2012","2012",23.8,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","ATCPTTMT","% of total sales","HUN","Hungary","2013","2013",22.2,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","ATCPTTMT","% of total sales","HUN","Hungary","2014","2014",20.5,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","ATCPTTMT","% of total sales","HUN","Hungary","2015","2015",19.4,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","ATCPTTMT","% of total sales","HUN","Hungary","2016","2016",18.5,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","ATCPTTMT","% of total sales","HUN","Hungary","2017","2017",18.9,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","ATCPTTMT","% of total sales","HUN","Hungary","2018","2018",18.6,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","ATCPTTMT","% of total sales","HUN","Hungary","2019","2019",17.9,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","ATCPTTMT","% of total sales","HUN","Hungary","2020","2020",17.8,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","ATCPTTMT","% of total sales","HUN","Hungary","2021","2021",17,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","ATCPTTMT","% of total sales","HUN","Hungary","2022","2022",16.8,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","MLLNCUMT","Million of national currency units","ISL","Iceland","2010","2010",1906.8,,
+"PATCCARV","C-Cardiovascular system","MLLNCUMT","Million of national currency units","ISL","Iceland","2011","2011",1946.3,,
+"PATCCARV","C-Cardiovascular system","MLLNCUMT","Million of national currency units","ISL","Iceland","2012","2012",1866.2,,
+"PATCCARV","C-Cardiovascular system","MLLNCUMT","Million of national currency units","ISL","Iceland","2013","2013",1814,,
+"PATCCARV","C-Cardiovascular system","MLLNCUMT","Million of national currency units","ISL","Iceland","2014","2014",1783.8,,
+"PATCCARV","C-Cardiovascular system","MLLNCUMT","Million of national currency units","ISL","Iceland","2015","2015",1713.3,,
+"PATCCARV","C-Cardiovascular system","MLLNCUMT","Million of national currency units","ISL","Iceland","2016","2016",1734.6,,
+"PATCCARV","C-Cardiovascular system","MLLNCUMT","Million of national currency units","ISL","Iceland","2017","2017",1827.3,,
+"PATCCARV","C-Cardiovascular system","MLLNCUMT","Million of national currency units","ISL","Iceland","2018","2018",1998.7,,
+"PATCCARV","C-Cardiovascular system","MLLNCUMT","Million of national currency units","ISL","Iceland","2019","2019",2169.4,,
+"PATCCARV","C-Cardiovascular system","MLLNCUMT","Million of national currency units","ISL","Iceland","2020","2020",2440.8,,
+"PATCCARV","C-Cardiovascular system","MLLNCUMT","Million of national currency units","ISL","Iceland","2021","2021",2639.6,,
+"PATCCARV","C-Cardiovascular system","MTMOTCMT","Million US$ at exchange rate","ISL","Iceland","2010","2010",15.6,,
+"PATCCARV","C-Cardiovascular system","MTMOTCMT","Million US$ at exchange rate","ISL","Iceland","2011","2011",16.8,,
+"PATCCARV","C-Cardiovascular system","MTMOTCMT","Million US$ at exchange rate","ISL","Iceland","2012","2012",14.9,,
+"PATCCARV","C-Cardiovascular system","MTMOTCMT","Million US$ at exchange rate","ISL","Iceland","2013","2013",14.8,,
+"PATCCARV","C-Cardiovascular system","MTMOTCMT","Million US$ at exchange rate","ISL","Iceland","2014","2014",15.3,,
+"PATCCARV","C-Cardiovascular system","MTMOTCMT","Million US$ at exchange rate","ISL","Iceland","2015","2015",13,,
+"PATCCARV","C-Cardiovascular system","MTMOTCMT","Million US$ at exchange rate","ISL","Iceland","2016","2016",14.4,,
+"PATCCARV","C-Cardiovascular system","MTMOTCMT","Million US$ at exchange rate","ISL","Iceland","2017","2017",17.1,,
+"PATCCARV","C-Cardiovascular system","MTMOTCMT","Million US$ at exchange rate","ISL","Iceland","2018","2018",18.5,,
+"PATCCARV","C-Cardiovascular system","MTMOTCMT","Million US$ at exchange rate","ISL","Iceland","2019","2019",17.7,,
+"PATCCARV","C-Cardiovascular system","MTMOTCMT","Million US$ at exchange rate","ISL","Iceland","2020","2020",18,,
+"PATCCARV","C-Cardiovascular system","MTMOTCMT","Million US$ at exchange rate","ISL","Iceland","2021","2021",20.8,,
+"PATCCARV","C-Cardiovascular system","MTMOPPMT","Million US$, purchasing power parity","ISL","Iceland","2010","2010",14.3,,
+"PATCCARV","C-Cardiovascular system","MTMOPPMT","Million US$, purchasing power parity","ISL","Iceland","2011","2011",14.4,,
+"PATCCARV","C-Cardiovascular system","MTMOPPMT","Million US$, purchasing power parity","ISL","Iceland","2012","2012",13.6,,
+"PATCCARV","C-Cardiovascular system","MTMOPPMT","Million US$, purchasing power parity","ISL","Iceland","2013","2013",13.2,,
+"PATCCARV","C-Cardiovascular system","MTMOPPMT","Million US$, purchasing power parity","ISL","Iceland","2014","2014",12.9,,
+"PATCCARV","C-Cardiovascular system","MTMOPPMT","Million US$, purchasing power parity","ISL","Iceland","2015","2015",12.1,,
+"PATCCARV","C-Cardiovascular system","MTMOPPMT","Million US$, purchasing power parity","ISL","Iceland","2016","2016",12.4,,
+"PATCCARV","C-Cardiovascular system","MTMOPPMT","Million US$, purchasing power parity","ISL","Iceland","2017","2017",13.2,,
+"PATCCARV","C-Cardiovascular system","MTMOPPMT","Million US$, purchasing power parity","ISL","Iceland","2018","2018",14.2,,
+"PATCCARV","C-Cardiovascular system","MTMOPPMT","Million US$, purchasing power parity","ISL","Iceland","2019","2019",15.4,,
+"PATCCARV","C-Cardiovascular system","MTMOPPMT","Million US$, purchasing power parity","ISL","Iceland","2020","2020",16.6,,
+"PATCCARV","C-Cardiovascular system","MTMOPPMT","Million US$, purchasing power parity","ISL","Iceland","2021","2021",17.6,,
+"PATCCARV","C-Cardiovascular system","TCPPERMT","/capita, US$ exchange rate","ISL","Iceland","2010","2010",49,,
+"PATCCARV","C-Cardiovascular system","TCPPERMT","/capita, US$ exchange rate","ISL","Iceland","2011","2011",52.6,,
+"PATCCARV","C-Cardiovascular system","TCPPERMT","/capita, US$ exchange rate","ISL","Iceland","2012","2012",46.5,,
+"PATCCARV","C-Cardiovascular system","TCPPERMT","/capita, US$ exchange rate","ISL","Iceland","2013","2013",45.9,,
+"PATCCARV","C-Cardiovascular system","TCPPERMT","/capita, US$ exchange rate","ISL","Iceland","2014","2014",46.7,,
+"PATCCARV","C-Cardiovascular system","TCPPERMT","/capita, US$ exchange rate","ISL","Iceland","2015","2015",39.3,,
+"PATCCARV","C-Cardiovascular system","TCPPERMT","/capita, US$ exchange rate","ISL","Iceland","2016","2016",42.8,,
+"PATCCARV","C-Cardiovascular system","TCPPERMT","/capita, US$ exchange rate","ISL","Iceland","2017","2017",49.8,,
+"PATCCARV","C-Cardiovascular system","TCPPERMT","/capita, US$ exchange rate","ISL","Iceland","2018","2018",52.3,,
+"PATCCARV","C-Cardiovascular system","TCPPERMT","/capita, US$ exchange rate","ISL","Iceland","2019","2019",49.1,,
+"PATCCARV","C-Cardiovascular system","TCPPERMT","/capita, US$ exchange rate","ISL","Iceland","2020","2020",49.2,,
+"PATCCARV","C-Cardiovascular system","TCPPERMT","/capita, US$ exchange rate","ISL","Iceland","2021","2021",55.8,,
+"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2010","2010",45.1,,
+"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2011","2011",45.1,,
+"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2012","2012",42.5,,
+"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2013","2013",40.9,,
+"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2014","2014",39.3,,
+"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2015","2015",36.5,,
+"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2016","2016",36.9,,
+"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2017","2017",38.5,,
+"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2018","2018",40.2,,
+"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2019","2019",42.8,,
+"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2020","2020",45.4,,
+"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2021","2021",47.3,,
+"PATCCARV","C-Cardiovascular system","ATCPTTMT","% of total sales","ISL","Iceland","2010","2010",7.6,,
+"PATCCARV","C-Cardiovascular system","ATCPTTMT","% of total sales","ISL","Iceland","2011","2011",7.5,,
+"PATCCARV","C-Cardiovascular system","ATCPTTMT","% of total sales","ISL","Iceland","2012","2012",7.7,,
+"PATCCARV","C-Cardiovascular system","ATCPTTMT","% of total sales","ISL","Iceland","2013","2013",7,,
+"PATCCARV","C-Cardiovascular system","ATCPTTMT","% of total sales","ISL","Iceland","2014","2014",7.5,,
+"PATCCARV","C-Cardiovascular system","ATCPTTMT","% of total sales","ISL","Iceland","2015","2015",7,,
+"PATCCARV","C-Cardiovascular system","ATCPTTMT","% of total sales","ISL","Iceland","2016","2016",6.8,,
+"PATCCARV","C-Cardiovascular system","ATCPTTMT","% of total sales","ISL","Iceland","2017","2017",6.9,,
+"PATCCARV","C-Cardiovascular system","ATCPTTMT","% of total sales","ISL","Iceland","2018","2018",6.6,,
+"PATCCARV","C-Cardiovascular system","ATCPTTMT","% of total sales","ISL","Iceland","2019","2019",6.4,,
+"PATCCARV","C-Cardiovascular system","ATCPTTMT","% of total sales","ISL","Iceland","2020","2020",6.1,,
+"PATCCARV","C-Cardiovascular system","ATCPTTMT","% of total sales","ISL","Iceland","2021","2021",5.9,,
+"PATCCARV","C-Cardiovascular system","MLLNCUMT","Million of national currency units","IRL","Ireland","2010","2010",398.5,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","MLLNCUMT","Million of national currency units","IRL","Ireland","2011","2011",339.9,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","MLLNCUMT","Million of national currency units","IRL","Ireland","2012","2012",337.5,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","MLLNCUMT","Million of national currency units","IRL","Ireland","2013","2013",288.4,"B; D","Break; Difference in methodology"
+"PATCCARV","C-Cardiovascular system","MLLNCUMT","Million of national currency units","IRL","Ireland","2014","2014",233.7,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","MLLNCUMT","Million of national currency units","IRL","Ireland","2015","2015",217.8,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","MLLNCUMT","Million of national currency units","IRL","Ireland","2016","2016",218.3,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","MLLNCUMT","Million of national currency units","IRL","Ireland","2017","2017",211.3,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","MLLNCUMT","Million of national currency units","IRL","Ireland","2018","2018",209.2,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","MLLNCUMT","Million of national currency units","IRL","Ireland","2019","2019",203.5,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","MLLNCUMT","Million of national currency units","IRL","Ireland","2020","2020",207.5,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","MLLNCUMT","Million of national currency units","IRL","Ireland","2021","2021",214.6,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","MTMOTCMT","Million US$ at exchange rate","IRL","Ireland","2010","2010",528.2,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","MTMOTCMT","Million US$ at exchange rate","IRL","Ireland","2011","2011",473.1,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","MTMOTCMT","Million US$ at exchange rate","IRL","Ireland","2012","2012",433.6,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","MTMOTCMT","Million US$ at exchange rate","IRL","Ireland","2013","2013",383,"B; D","Break; Difference in methodology"
+"PATCCARV","C-Cardiovascular system","MTMOTCMT","Million US$ at exchange rate","IRL","Ireland","2014","2014",310.5,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","MTMOTCMT","Million US$ at exchange rate","IRL","Ireland","2015","2015",241.7,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","MTMOTCMT","Million US$ at exchange rate","IRL","Ireland","2016","2016",241.6,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","MTMOTCMT","Million US$ at exchange rate","IRL","Ireland","2017","2017",238.7,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","MTMOTCMT","Million US$ at exchange rate","IRL","Ireland","2018","2018",247.1,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","MTMOTCMT","Million US$ at exchange rate","IRL","Ireland","2019","2019",227.8,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","MTMOTCMT","Million US$ at exchange rate","IRL","Ireland","2020","2020",237.1,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","MTMOTCMT","Million US$ at exchange rate","IRL","Ireland","2021","2021",253.8,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","MTMOPPMT","Million US$, purchasing power parity","IRL","Ireland","2010","2010",469,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","MTMOPPMT","Million US$, purchasing power parity","IRL","Ireland","2011","2011",408.7,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","MTMOPPMT","Million US$, purchasing power parity","IRL","Ireland","2012","2012",410,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","MTMOPPMT","Million US$, purchasing power parity","IRL","Ireland","2013","2013",355.5,"B; D","Break; Difference in methodology"
+"PATCCARV","C-Cardiovascular system","MTMOPPMT","Million US$, purchasing power parity","IRL","Ireland","2014","2014",285.4,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","MTMOPPMT","Million US$, purchasing power parity","IRL","Ireland","2015","2015",269,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","MTMOPPMT","Million US$, purchasing power parity","IRL","Ireland","2016","2016",274.8,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","MTMOPPMT","Million US$, purchasing power parity","IRL","Ireland","2017","2017",266,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","MTMOPPMT","Million US$, purchasing power parity","IRL","Ireland","2018","2018",264.1,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","MTMOPPMT","Million US$, purchasing power parity","IRL","Ireland","2019","2019",252.6,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","MTMOPPMT","Million US$, purchasing power parity","IRL","Ireland","2020","2020",260.7,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","MTMOPPMT","Million US$, purchasing power parity","IRL","Ireland","2021","2021",270,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","TCPPERMT","/capita, US$ exchange rate","IRL","Ireland","2010","2010",115.8,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","TCPPERMT","/capita, US$ exchange rate","IRL","Ireland","2011","2011",103.3,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","TCPPERMT","/capita, US$ exchange rate","IRL","Ireland","2012","2012",94.3,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","TCPPERMT","/capita, US$ exchange rate","IRL","Ireland","2013","2013",82.8,"B; D","Break; Difference in methodology"
+"PATCCARV","C-Cardiovascular system","TCPPERMT","/capita, US$ exchange rate","IRL","Ireland","2014","2014",66.7,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","TCPPERMT","/capita, US$ exchange rate","IRL","Ireland","2015","2015",51.4,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","TCPPERMT","/capita, US$ exchange rate","IRL","Ireland","2016","2016",50.8,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","TCPPERMT","/capita, US$ exchange rate","IRL","Ireland","2017","2017",49.7,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","TCPPERMT","/capita, US$ exchange rate","IRL","Ireland","2018","2018",50.8,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","TCPPERMT","/capita, US$ exchange rate","IRL","Ireland","2019","2019",46.2,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","TCPPERMT","/capita, US$ exchange rate","IRL","Ireland","2020","2020",47.6,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","TCPPERMT","/capita, US$ exchange rate","IRL","Ireland","2021","2021",50.4,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2010","2010",102.9,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2011","2011",89.2,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2012","2012",89.1,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2013","2013",76.9,"B; D","Break; Difference in methodology"
+"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2014","2014",61.3,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2015","2015",57.2,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2016","2016",57.8,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2017","2017",55.3,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2018","2018",54.3,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2019","2019",51.2,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2020","2020",52.3,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2021","2021",53.6,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","ATCPTTMT","% of total sales","IRL","Ireland","2010","2010",19.4,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","ATCPTTMT","% of total sales","IRL","Ireland","2011","2011",17.4,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","ATCPTTMT","% of total sales","IRL","Ireland","2012","2012",16.5,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","ATCPTTMT","% of total sales","IRL","Ireland","2013","2013",14.7,"B; D","Break; Difference in methodology"
+"PATCCARV","C-Cardiovascular system","ATCPTTMT","% of total sales","IRL","Ireland","2014","2014",12.2,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","ATCPTTMT","% of total sales","IRL","Ireland","2015","2015",11,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","ATCPTTMT","% of total sales","IRL","Ireland","2016","2016",10.5,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","ATCPTTMT","% of total sales","IRL","Ireland","2017","2017",9.9,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","ATCPTTMT","% of total sales","IRL","Ireland","2018","2018",9.2,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","ATCPTTMT","% of total sales","IRL","Ireland","2019","2019",8.5,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","ATCPTTMT","% of total sales","IRL","Ireland","2020","2020",8.4,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","ATCPTTMT","% of total sales","IRL","Ireland","2021","2021",8.2,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","MLLNCUMT","Million of national currency units","ITA","Italy","2011","2011",4542.7,,
+"PATCCARV","C-Cardiovascular system","MLLNCUMT","Million of national currency units","ITA","Italy","2012","2012",3968.6,,
+"PATCCARV","C-Cardiovascular system","MLLNCUMT","Million of national currency units","ITA","Italy","2013","2013",3769.3,,
+"PATCCARV","C-Cardiovascular system","MLLNCUMT","Million of national currency units","ITA","Italy","2014","2014",3624,,
+"PATCCARV","C-Cardiovascular system","MLLNCUMT","Million of national currency units","ITA","Italy","2015","2015",3617.5,,
+"PATCCARV","C-Cardiovascular system","MLLNCUMT","Million of national currency units","ITA","Italy","2016","2016",3629.5,,
+"PATCCARV","C-Cardiovascular system","MLLNCUMT","Million of national currency units","ITA","Italy","2017","2017",3549.6,,
+"PATCCARV","C-Cardiovascular system","MLLNCUMT","Million of national currency units","ITA","Italy","2018","2018",3241.2,,
+"PATCCARV","C-Cardiovascular system","MLLNCUMT","Million of national currency units","ITA","Italy","2019","2019",3182.4,,
+"PATCCARV","C-Cardiovascular system","MLLNCUMT","Million of national currency units","ITA","Italy","2020","2020",3276.6,,
+"PATCCARV","C-Cardiovascular system","MLLNCUMT","Million of national currency units","ITA","Italy","2021","2021",3318.1,,
+"PATCCARV","C-Cardiovascular system","MLLNCUMT","Million of national currency units","ITA","Italy","2022","2022",3393.8,"E","Estimated value"
+"PATCCARV","C-Cardiovascular system","MTMOTCMT","Million US$ at exchange rate","ITA","Italy","2011","2011",6323.2,,
+"PATCCARV","C-Cardiovascular system","MTMOTCMT","Million US$ at exchange rate","ITA","Italy","2012","2012",5098.8,,
+"PATCCARV","C-Cardiovascular system","MTMOTCMT","Million US$ at exchange rate","ITA","Italy","2013","2013",5006.1,,
+"PATCCARV","C-Cardiovascular system","MTMOTCMT","Million US$ at exchange rate","ITA","Italy","2014","2014",4814.5,,
+"PATCCARV","C-Cardiovascular system","MTMOTCMT","Million US$ at exchange rate","ITA","Italy","2015","2015",4013.6,,
+"PATCCARV","C-Cardiovascular system","MTMOTCMT","Million US$ at exchange rate","ITA","Italy","2016","2016",4017.5,,
+"PATCCARV","C-Cardiovascular system","MTMOTCMT","Million US$ at exchange rate","ITA","Italy","2017","2017",4010,,
+"PATCCARV","C-Cardiovascular system","MTMOTCMT","Million US$ at exchange rate","ITA","Italy","2018","2018",3827.7,,
+"PATCCARV","C-Cardiovascular system","MTMOTCMT","Million US$ at exchange rate","ITA","Italy","2019","2019",3562.6,,
+"PATCCARV","C-Cardiovascular system","MTMOTCMT","Million US$ at exchange rate","ITA","Italy","2020","2020",3742.5,,
+"PATCCARV","C-Cardiovascular system","MTMOTCMT","Million US$ at exchange rate","ITA","Italy","2021","2021",3924.4,,
+"PATCCARV","C-Cardiovascular system","MTMOTCMT","Million US$ at exchange rate","ITA","Italy","2022","2022",3573.9,"E","Estimated value"
+"PATCCARV","C-Cardiovascular system","MTMOPPMT","Million US$, purchasing power parity","ITA","Italy","2011","2011",5987.5,,
+"PATCCARV","C-Cardiovascular system","MTMOPPMT","Million US$, purchasing power parity","ITA","Italy","2012","2012",5307.5,,
+"PATCCARV","C-Cardiovascular system","MTMOPPMT","Million US$, purchasing power parity","ITA","Italy","2013","2013",5112.3,,
+"PATCCARV","C-Cardiovascular system","MTMOPPMT","Million US$, purchasing power parity","ITA","Italy","2014","2014",4899.6,,
+"PATCCARV","C-Cardiovascular system","MTMOPPMT","Million US$, purchasing power parity","ITA","Italy","2015","2015",4897.1,,
+"PATCCARV","C-Cardiovascular system","MTMOPPMT","Million US$, purchasing power parity","ITA","Italy","2016","2016",5181,,
+"PATCCARV","C-Cardiovascular system","MTMOPPMT","Million US$, purchasing power parity","ITA","Italy","2017","2017",5145.2,,
+"PATCCARV","C-Cardiovascular system","MTMOPPMT","Million US$, purchasing power parity","ITA","Italy","2018","2018",4758,,
+"PATCCARV","C-Cardiovascular system","MTMOPPMT","Million US$, purchasing power parity","ITA","Italy","2019","2019",4845.5,,
+"PATCCARV","C-Cardiovascular system","MTMOPPMT","Million US$, purchasing power parity","ITA","Italy","2020","2020",5058.7,,
+"PATCCARV","C-Cardiovascular system","MTMOPPMT","Million US$, purchasing power parity","ITA","Italy","2021","2021",5124.1,,
+"PATCCARV","C-Cardiovascular system","MTMOPPMT","Million US$, purchasing power parity","ITA","Italy","2022","2022",5496.8,"E","Estimated value"
+"PATCCARV","C-Cardiovascular system","TCPPERMT","/capita, US$ exchange rate","ITA","Italy","2011","2011",106.5,,
+"PATCCARV","C-Cardiovascular system","TCPPERMT","/capita, US$ exchange rate","ITA","Italy","2012","2012",85.6,,
+"PATCCARV","C-Cardiovascular system","TCPPERMT","/capita, US$ exchange rate","ITA","Italy","2013","2013",83.1,,
+"PATCCARV","C-Cardiovascular system","TCPPERMT","/capita, US$ exchange rate","ITA","Italy","2014","2014",79.2,,
+"PATCCARV","C-Cardiovascular system","TCPPERMT","/capita, US$ exchange rate","ITA","Italy","2015","2015",66.1,,
+"PATCCARV","C-Cardiovascular system","TCPPERMT","/capita, US$ exchange rate","ITA","Italy","2016","2016",66.3,,
+"PATCCARV","C-Cardiovascular system","TCPPERMT","/capita, US$ exchange rate","ITA","Italy","2017","2017",66.2,,
+"PATCCARV","C-Cardiovascular system","TCPPERMT","/capita, US$ exchange rate","ITA","Italy","2018","2018",63.4,,
+"PATCCARV","C-Cardiovascular system","TCPPERMT","/capita, US$ exchange rate","ITA","Italy","2019","2019",59.6,,
+"PATCCARV","C-Cardiovascular system","TCPPERMT","/capita, US$ exchange rate","ITA","Italy","2020","2020",63,,
+"PATCCARV","C-Cardiovascular system","TCPPERMT","/capita, US$ exchange rate","ITA","Italy","2021","2021",66.4,,
+"PATCCARV","C-Cardiovascular system","TCPPERMT","/capita, US$ exchange rate","ITA","Italy","2022","2022",60.5,"E","Estimated value"
+"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2011","2011",100.8,,
+"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2012","2012",89.1,,
+"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2013","2013",84.9,,
+"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2014","2014",80.6,,
+"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2015","2015",80.6,,
+"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2016","2016",85.5,,
+"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2017","2017",85,,
+"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2018","2018",78.7,,
+"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2019","2019",81.1,,
+"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2020","2020",85.1,,
+"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2021","2021",86.7,,
+"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2022","2022",93.1,"E","Estimated value"
+"PATCCARV","C-Cardiovascular system","ATCPTTMT","% of total sales","ITA","Italy","2011","2011",23.3,,
+"PATCCARV","C-Cardiovascular system","ATCPTTMT","% of total sales","ITA","Italy","2012","2012",20.8,,
+"PATCCARV","C-Cardiovascular system","ATCPTTMT","% of total sales","ITA","Italy","2013","2013",19.4,,
+"PATCCARV","C-Cardiovascular system","ATCPTTMT","% of total sales","ITA","Italy","2014","2014",18.2,,
+"PATCCARV","C-Cardiovascular system","ATCPTTMT","% of total sales","ITA","Italy","2015","2015",16,,
+"PATCCARV","C-Cardiovascular system","ATCPTTMT","% of total sales","ITA","Italy","2016","2016",15.9,,
+"PATCCARV","C-Cardiovascular system","ATCPTTMT","% of total sales","ITA","Italy","2017","2017",15.7,,
+"PATCCARV","C-Cardiovascular system","ATCPTTMT","% of total sales","ITA","Italy","2018","2018",14.5,,
+"PATCCARV","C-Cardiovascular system","ATCPTTMT","% of total sales","ITA","Italy","2019","2019",13.9,,
+"PATCCARV","C-Cardiovascular system","ATCPTTMT","% of total sales","ITA","Italy","2020","2020",14.2,,
+"PATCCARV","C-Cardiovascular system","ATCPTTMT","% of total sales","ITA","Italy","2021","2021",13.9,,
+"PATCCARV","C-Cardiovascular system","ATCPTTMT","% of total sales","ITA","Italy","2022","2022",13.7,"E","Estimated value"
+"PATCCARV","C-Cardiovascular system","MLLNCUMT","Million of national currency units","JPN","Japan","2010","2010",1401736,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","MLLNCUMT","Million of national currency units","JPN","Japan","2011","2011",1347996,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","MLLNCUMT","Million of national currency units","JPN","Japan","2012","2012",1297037,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","MLLNCUMT","Million of national currency units","JPN","Japan","2013","2013",1255017,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","MLLNCUMT","Million of national currency units","JPN","Japan","2014","2014",1157221,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","MLLNCUMT","Million of national currency units","JPN","Japan","2015","2015",1088475,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","MLLNCUMT","Million of national currency units","JPN","Japan","2016","2016",1007745,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","MLLNCUMT","Million of national currency units","JPN","Japan","2017","2017",934437,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","MLLNCUMT","Million of national currency units","JPN","Japan","2018","2018",802634,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","MLLNCUMT","Million of national currency units","JPN","Japan","2019","2019",996769,"B; D","Break; Difference in methodology"
+"PATCCARV","C-Cardiovascular system","MLLNCUMT","Million of national currency units","JPN","Japan","2020","2020",939361,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","MLLNCUMT","Million of national currency units","JPN","Japan","2021","2021",898665,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","MTMOTCMT","Million US$ at exchange rate","JPN","Japan","2010","2010",15968.8,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","MTMOTCMT","Million US$ at exchange rate","JPN","Japan","2011","2011",16890.7,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","MTMOTCMT","Million US$ at exchange rate","JPN","Japan","2012","2012",16255.5,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","MTMOTCMT","Million US$ at exchange rate","JPN","Japan","2013","2013",12859.4,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","MTMOTCMT","Million US$ at exchange rate","JPN","Japan","2014","2014",10922.9,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","MTMOTCMT","Million US$ at exchange rate","JPN","Japan","2015","2015",8992.4,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","MTMOTCMT","Million US$ at exchange rate","JPN","Japan","2016","2016",9263,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","MTMOTCMT","Million US$ at exchange rate","JPN","Japan","2017","2017",8330.8,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","MTMOTCMT","Million US$ at exchange rate","JPN","Japan","2018","2018",7268.7,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","MTMOTCMT","Million US$ at exchange rate","JPN","Japan","2019","2019",9143.9,"B; D","Break; Difference in methodology"
+"PATCCARV","C-Cardiovascular system","MTMOTCMT","Million US$ at exchange rate","JPN","Japan","2020","2020",8797.6,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","MTMOTCMT","Million US$ at exchange rate","JPN","Japan","2021","2021",8188,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","MTMOPPMT","Million US$, purchasing power parity","JPN","Japan","2010","2010",12548,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","MTMOPPMT","Million US$, purchasing power parity","JPN","Japan","2011","2011",12544.8,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","MTMOPPMT","Million US$, purchasing power parity","JPN","Japan","2012","2012",12438.7,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","MTMOPPMT","Million US$, purchasing power parity","JPN","Japan","2013","2013",12388.8,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","MTMOPPMT","Million US$, purchasing power parity","JPN","Japan","2014","2014",11229.5,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","MTMOPPMT","Million US$, purchasing power parity","JPN","Japan","2015","2015",10519.8,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","MTMOPPMT","Million US$, purchasing power parity","JPN","Japan","2016","2016",9550.3,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","MTMOPPMT","Million US$, purchasing power parity","JPN","Japan","2017","2017",8890.8,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","MTMOPPMT","Million US$, purchasing power parity","JPN","Japan","2018","2018",7705.9,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","MTMOPPMT","Million US$, purchasing power parity","JPN","Japan","2019","2019",9563.5,"B; D","Break; Difference in methodology"
+"PATCCARV","C-Cardiovascular system","MTMOPPMT","Million US$, purchasing power parity","JPN","Japan","2020","2020",9171,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","MTMOPPMT","Million US$, purchasing power parity","JPN","Japan","2021","2021",8806.1,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","TCPPERMT","/capita, US$ exchange rate","JPN","Japan","2010","2010",124.7,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","TCPPERMT","/capita, US$ exchange rate","JPN","Japan","2011","2011",132.1,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","TCPPERMT","/capita, US$ exchange rate","JPN","Japan","2012","2012",127.4,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","TCPPERMT","/capita, US$ exchange rate","JPN","Japan","2013","2013",100.9,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","TCPPERMT","/capita, US$ exchange rate","JPN","Japan","2014","2014",85.8,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","TCPPERMT","/capita, US$ exchange rate","JPN","Japan","2015","2015",70.8,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","TCPPERMT","/capita, US$ exchange rate","JPN","Japan","2016","2016",73,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","TCPPERMT","/capita, US$ exchange rate","JPN","Japan","2017","2017",65.7,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","TCPPERMT","/capita, US$ exchange rate","JPN","Japan","2018","2018",57.5,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","TCPPERMT","/capita, US$ exchange rate","JPN","Japan","2019","2019",72.5,"B; D","Break; Difference in methodology"
+"PATCCARV","C-Cardiovascular system","TCPPERMT","/capita, US$ exchange rate","JPN","Japan","2020","2020",69.7,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","TCPPERMT","/capita, US$ exchange rate","JPN","Japan","2021","2021",65.2,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","JPN","Japan","2010","2010",98,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","JPN","Japan","2011","2011",98.1,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","JPN","Japan","2012","2012",97.5,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","JPN","Japan","2013","2013",97.2,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","JPN","Japan","2014","2014",88.3,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","JPN","Japan","2015","2015",82.8,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","JPN","Japan","2016","2016",75.2,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","JPN","Japan","2017","2017",70.2,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","JPN","Japan","2018","2018",60.9,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","JPN","Japan","2019","2019",75.8,"B; D","Break; Difference in methodology"
+"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","JPN","Japan","2020","2020",72.7,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","JPN","Japan","2021","2021",70.2,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","ATCPTTMT","% of total sales","JPN","Japan","2010","2010",20.7,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","ATCPTTMT","% of total sales","JPN","Japan","2011","2011",19.3,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","ATCPTTMT","% of total sales","JPN","Japan","2012","2012",18.6,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","ATCPTTMT","% of total sales","JPN","Japan","2013","2013",18.2,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","ATCPTTMT","% of total sales","JPN","Japan","2014","2014",17.6,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","ATCPTTMT","% of total sales","JPN","Japan","2015","2015",16.1,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","ATCPTTMT","% of total sales","JPN","Japan","2016","2016",15.2,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","ATCPTTMT","% of total sales","JPN","Japan","2017","2017",13.9,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","ATCPTTMT","% of total sales","JPN","Japan","2018","2018",11.6,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","ATCPTTMT","% of total sales","JPN","Japan","2019","2019",10.5,"B; D","Break; Difference in methodology"
+"PATCCARV","C-Cardiovascular system","ATCPTTMT","% of total sales","JPN","Japan","2020","2020",10.1,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","ATCPTTMT","% of total sales","JPN","Japan","2021","2021",9.8,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","MLLNCUMT","Million of national currency units","KOR","Korea","2010","2010",2801238,,
+"PATCCARV","C-Cardiovascular system","MLLNCUMT","Million of national currency units","KOR","Korea","2011","2011",2980199.5,"B","Break"
+"PATCCARV","C-Cardiovascular system","MLLNCUMT","Million of national currency units","KOR","Korea","2012","2012",2861087.1,,
+"PATCCARV","C-Cardiovascular system","MLLNCUMT","Million of national currency units","KOR","Korea","2013","2013",2909973.6,,
+"PATCCARV","C-Cardiovascular system","MLLNCUMT","Million of national currency units","KOR","Korea","2014","2014",2959711.6,,
+"PATCCARV","C-Cardiovascular system","MLLNCUMT","Million of national currency units","KOR","Korea","2015","2015",3047770.9,,
+"PATCCARV","C-Cardiovascular system","MLLNCUMT","Million of national currency units","KOR","Korea","2016","2016",3208747.7,"B","Break"
+"PATCCARV","C-Cardiovascular system","MLLNCUMT","Million of national currency units","KOR","Korea","2017","2017",3475580.5,,
+"PATCCARV","C-Cardiovascular system","MLLNCUMT","Million of national currency units","KOR","Korea","2018","2018",3753638.1,,
+"PATCCARV","C-Cardiovascular system","MLLNCUMT","Million of national currency units","KOR","Korea","2019","2019",3981146.8,,
+"PATCCARV","C-Cardiovascular system","MLLNCUMT","Million of national currency units","KOR","Korea","2020","2020",4466464.9,,
+"PATCCARV","C-Cardiovascular system","MLLNCUMT","Million of national currency units","KOR","Korea","2021","2021",4922786,,
+"PATCCARV","C-Cardiovascular system","MTMOTCMT","Million US$ at exchange rate","KOR","Korea","2010","2010",2422.3,,
+"PATCCARV","C-Cardiovascular system","MTMOTCMT","Million US$ at exchange rate","KOR","Korea","2011","2011",2689.1,"B","Break"
+"PATCCARV","C-Cardiovascular system","MTMOTCMT","Million US$ at exchange rate","KOR","Korea","2012","2012",2539.1,,
+"PATCCARV","C-Cardiovascular system","MTMOTCMT","Million US$ at exchange rate","KOR","Korea","2013","2013",2657.6,,
+"PATCCARV","C-Cardiovascular system","MTMOTCMT","Million US$ at exchange rate","KOR","Korea","2014","2014",2811.2,,
+"PATCCARV","C-Cardiovascular system","MTMOTCMT","Million US$ at exchange rate","KOR","Korea","2015","2015",2694.9,,
+"PATCCARV","C-Cardiovascular system","MTMOTCMT","Million US$ at exchange rate","KOR","Korea","2016","2016",2764.3,"B","Break"
+"PATCCARV","C-Cardiovascular system","MTMOTCMT","Million US$ at exchange rate","KOR","Korea","2017","2017",3073,,
+"PATCCARV","C-Cardiovascular system","MTMOTCMT","Million US$ at exchange rate","KOR","Korea","2018","2018",3411.9,,
+"PATCCARV","C-Cardiovascular system","MTMOTCMT","Million US$ at exchange rate","KOR","Korea","2019","2019",3416.2,,
+"PATCCARV","C-Cardiovascular system","MTMOTCMT","Million US$ at exchange rate","KOR","Korea","2020","2020",3784.3,,
+"PATCCARV","C-Cardiovascular system","MTMOTCMT","Million US$ at exchange rate","KOR","Korea","2021","2021",4303.3,,
+"PATCCARV","C-Cardiovascular system","MTMOPPMT","Million US$, purchasing power parity","KOR","Korea","2010","2010",3330.9,,
+"PATCCARV","C-Cardiovascular system","MTMOPPMT","Million US$, purchasing power parity","KOR","Korea","2011","2011",3487.3,"B","Break"
+"PATCCARV","C-Cardiovascular system","MTMOPPMT","Million US$, purchasing power parity","KOR","Korea","2012","2012",3346.7,,
+"PATCCARV","C-Cardiovascular system","MTMOPPMT","Million US$, purchasing power parity","KOR","Korea","2013","2013",3348.3,,
+"PATCCARV","C-Cardiovascular system","MTMOPPMT","Million US$, purchasing power parity","KOR","Korea","2014","2014",3394.6,,
+"PATCCARV","C-Cardiovascular system","MTMOPPMT","Million US$, purchasing power parity","KOR","Korea","2015","2015",3554.3,,
+"PATCCARV","C-Cardiovascular system","MTMOPPMT","Million US$, purchasing power parity","KOR","Korea","2016","2016",3736.3,"B","Break"
+"PATCCARV","C-Cardiovascular system","MTMOPPMT","Million US$, purchasing power parity","KOR","Korea","2017","2017",3982.9,,
+"PATCCARV","C-Cardiovascular system","MTMOPPMT","Million US$, purchasing power parity","KOR","Korea","2018","2018",4390.9,,
+"PATCCARV","C-Cardiovascular system","MTMOPPMT","Million US$, purchasing power parity","KOR","Korea","2019","2019",4648.6,,
+"PATCCARV","C-Cardiovascular system","MTMOPPMT","Million US$, purchasing power parity","KOR","Korea","2020","2020",5332,,
+"PATCCARV","C-Cardiovascular system","MTMOPPMT","Million US$, purchasing power parity","KOR","Korea","2021","2021",5763.7,,
+"PATCCARV","C-Cardiovascular system","TCPPERMT","/capita, US$ exchange rate","KOR","Korea","2010","2010",48.9,,
+"PATCCARV","C-Cardiovascular system","TCPPERMT","/capita, US$ exchange rate","KOR","Korea","2011","2011",53.9,"B","Break"
+"PATCCARV","C-Cardiovascular system","TCPPERMT","/capita, US$ exchange rate","KOR","Korea","2012","2012",50.6,,
+"PATCCARV","C-Cardiovascular system","TCPPERMT","/capita, US$ exchange rate","KOR","Korea","2013","2013",52.7,,
+"PATCCARV","C-Cardiovascular system","TCPPERMT","/capita, US$ exchange rate","KOR","Korea","2014","2014",55.4,,
+"PATCCARV","C-Cardiovascular system","TCPPERMT","/capita, US$ exchange rate","KOR","Korea","2015","2015",52.8,,
+"PATCCARV","C-Cardiovascular system","TCPPERMT","/capita, US$ exchange rate","KOR","Korea","2016","2016",54,"B","Break"
+"PATCCARV","C-Cardiovascular system","TCPPERMT","/capita, US$ exchange rate","KOR","Korea","2017","2017",59.8,,
+"PATCCARV","C-Cardiovascular system","TCPPERMT","/capita, US$ exchange rate","KOR","Korea","2018","2018",66.1,,
+"PATCCARV","C-Cardiovascular system","TCPPERMT","/capita, US$ exchange rate","KOR","Korea","2019","2019",66,,
+"PATCCARV","C-Cardiovascular system","TCPPERMT","/capita, US$ exchange rate","KOR","Korea","2020","2020",73,,
+"PATCCARV","C-Cardiovascular system","TCPPERMT","/capita, US$ exchange rate","KOR","Korea","2021","2021",83.2,,
+"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2010","2010",67.2,,
+"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2011","2011",69.8,"B","Break"
+"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2012","2012",66.7,,
+"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2013","2013",66.4,,
+"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2014","2014",66.9,,
+"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2015","2015",69.7,,
+"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2016","2016",72.9,"B","Break"
+"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2017","2017",77.5,,
+"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2018","2018",85.1,,
+"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2019","2019",89.8,,
+"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2020","2020",102.9,,
+"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2021","2021",111.4,,
+"PATCCARV","C-Cardiovascular system","ATCPTTMT","% of total sales","KOR","Korea","2010","2010",13.8,,
+"PATCCARV","C-Cardiovascular system","ATCPTTMT","% of total sales","KOR","Korea","2011","2011",13.5,"B","Break"
+"PATCCARV","C-Cardiovascular system","ATCPTTMT","% of total sales","KOR","Korea","2012","2012",13.2,,
+"PATCCARV","C-Cardiovascular system","ATCPTTMT","% of total sales","KOR","Korea","2013","2013",12.9,,
+"PATCCARV","C-Cardiovascular system","ATCPTTMT","% of total sales","KOR","Korea","2014","2014",12.5,,
+"PATCCARV","C-Cardiovascular system","ATCPTTMT","% of total sales","KOR","Korea","2015","2015",12.4,,
+"PATCCARV","C-Cardiovascular system","ATCPTTMT","% of total sales","KOR","Korea","2016","2016",12.6,"B","Break"
+"PATCCARV","C-Cardiovascular system","ATCPTTMT","% of total sales","KOR","Korea","2017","2017",12.9,,
+"PATCCARV","C-Cardiovascular system","ATCPTTMT","% of total sales","KOR","Korea","2018","2018",13,,
+"PATCCARV","C-Cardiovascular system","ATCPTTMT","% of total sales","KOR","Korea","2019","2019",12.8,,
+"PATCCARV","C-Cardiovascular system","ATCPTTMT","% of total sales","KOR","Korea","2020","2020",13.7,,
+"PATCCARV","C-Cardiovascular system","ATCPTTMT","% of total sales","KOR","Korea","2021","2021",14.2,,
+"PATCCARV","C-Cardiovascular system","MLLNCUMT","Million of national currency units","LUX","Luxembourg","2010","2010",41.1,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","MLLNCUMT","Million of national currency units","LUX","Luxembourg","2011","2011",42,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","MLLNCUMT","Million of national currency units","LUX","Luxembourg","2012","2012",41.7,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","MLLNCUMT","Million of national currency units","LUX","Luxembourg","2013","2013",38.7,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","MLLNCUMT","Million of national currency units","LUX","Luxembourg","2014","2014",34.2,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","MLLNCUMT","Million of national currency units","LUX","Luxembourg","2015","2015",33,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","MLLNCUMT","Million of national currency units","LUX","Luxembourg","2016","2016",32.5,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","MLLNCUMT","Million of national currency units","LUX","Luxembourg","2017","2017",30.2,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","MLLNCUMT","Million of national currency units","LUX","Luxembourg","2018","2018",26.6,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","MLLNCUMT","Million of national currency units","LUX","Luxembourg","2019","2019",26.2,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","MLLNCUMT","Million of national currency units","LUX","Luxembourg","2020","2020",26.4,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","MLLNCUMT","Million of national currency units","LUX","Luxembourg","2021","2021",26.9,"B; D; P","Break; Difference in methodology; Provisional value"
+"PATCCARV","C-Cardiovascular system","MLLNCUMT","Million of national currency units","LUX","Luxembourg","2022","2022",27.3,"D; P","Difference in methodology; Provisional value"
+"PATCCARV","C-Cardiovascular system","MTMOTCMT","Million US$ at exchange rate","LUX","Luxembourg","2010","2010",54.4,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","MTMOTCMT","Million US$ at exchange rate","LUX","Luxembourg","2011","2011",58.4,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","MTMOTCMT","Million US$ at exchange rate","LUX","Luxembourg","2012","2012",53.6,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","MTMOTCMT","Million US$ at exchange rate","LUX","Luxembourg","2013","2013",51.4,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","MTMOTCMT","Million US$ at exchange rate","LUX","Luxembourg","2014","2014",45.4,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","MTMOTCMT","Million US$ at exchange rate","LUX","Luxembourg","2015","2015",36.6,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","MTMOTCMT","Million US$ at exchange rate","LUX","Luxembourg","2016","2016",36,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","MTMOTCMT","Million US$ at exchange rate","LUX","Luxembourg","2017","2017",34.2,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","MTMOTCMT","Million US$ at exchange rate","LUX","Luxembourg","2018","2018",31.4,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","MTMOTCMT","Million US$ at exchange rate","LUX","Luxembourg","2019","2019",29.3,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","MTMOTCMT","Million US$ at exchange rate","LUX","Luxembourg","2020","2020",30.1,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","MTMOTCMT","Million US$ at exchange rate","LUX","Luxembourg","2021","2021",31.8,"B; D; P","Break; Difference in methodology; Provisional value"
+"PATCCARV","C-Cardiovascular system","MTMOTCMT","Million US$ at exchange rate","LUX","Luxembourg","2022","2022",28.7,"D; P","Difference in methodology; Provisional value"
+"PATCCARV","C-Cardiovascular system","MTMOPPMT","Million US$, purchasing power parity","LUX","Luxembourg","2010","2010",44.4,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","MTMOPPMT","Million US$, purchasing power parity","LUX","Luxembourg","2011","2011",46.3,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","MTMOPPMT","Million US$, purchasing power parity","LUX","Luxembourg","2012","2012",46,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","MTMOPPMT","Million US$, purchasing power parity","LUX","Luxembourg","2013","2013",43.2,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","MTMOPPMT","Million US$, purchasing power parity","LUX","Luxembourg","2014","2014",38.7,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","MTMOPPMT","Million US$, purchasing power parity","LUX","Luxembourg","2015","2015",37.4,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","MTMOPPMT","Million US$, purchasing power parity","LUX","Luxembourg","2016","2016",38.1,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","MTMOPPMT","Million US$, purchasing power parity","LUX","Luxembourg","2017","2017",35.6,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","MTMOPPMT","Million US$, purchasing power parity","LUX","Luxembourg","2018","2018",31.3,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","MTMOPPMT","Million US$, purchasing power parity","LUX","Luxembourg","2019","2019",31.1,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","MTMOPPMT","Million US$, purchasing power parity","LUX","Luxembourg","2020","2020",30.8,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","MTMOPPMT","Million US$, purchasing power parity","LUX","Luxembourg","2021","2021",31.3,"B; D; P","Break; Difference in methodology; Provisional value"
+"PATCCARV","C-Cardiovascular system","MTMOPPMT","Million US$, purchasing power parity","LUX","Luxembourg","2022","2022",32.8,"D; P","Difference in methodology; Provisional value"
+"PATCCARV","C-Cardiovascular system","TCPPERMT","/capita, US$ exchange rate","LUX","Luxembourg","2010","2010",115.1,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","TCPPERMT","/capita, US$ exchange rate","LUX","Luxembourg","2011","2011",121.2,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","TCPPERMT","/capita, US$ exchange rate","LUX","Luxembourg","2012","2012",108.8,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","TCPPERMT","/capita, US$ exchange rate","LUX","Luxembourg","2013","2013",102.4,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","TCPPERMT","/capita, US$ exchange rate","LUX","Luxembourg","2014","2014",88.9,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","TCPPERMT","/capita, US$ exchange rate","LUX","Luxembourg","2015","2015",70.6,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","TCPPERMT","/capita, US$ exchange rate","LUX","Luxembourg","2016","2016",68.3,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","TCPPERMT","/capita, US$ exchange rate","LUX","Luxembourg","2017","2017",63.7,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","TCPPERMT","/capita, US$ exchange rate","LUX","Luxembourg","2018","2018",57.5,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","TCPPERMT","/capita, US$ exchange rate","LUX","Luxembourg","2019","2019",52.6,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","TCPPERMT","/capita, US$ exchange rate","LUX","Luxembourg","2020","2020",53.1,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","TCPPERMT","/capita, US$ exchange rate","LUX","Luxembourg","2021","2021",55.3,"B; D; P","Break; Difference in methodology; Provisional value"
+"PATCCARV","C-Cardiovascular system","TCPPERMT","/capita, US$ exchange rate","LUX","Luxembourg","2022","2022",49,"D; P","Difference in methodology; Provisional value"
+"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2010","2010",93.8,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2011","2011",96.2,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2012","2012",93.4,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2013","2013",86.1,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2014","2014",75.7,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2015","2015",72.2,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2016","2016",72.4,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2017","2017",66.5,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2018","2018",57.4,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2019","2019",55.8,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2020","2020",54.3,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2021","2021",54.4,"B; D; P","Break; Difference in methodology; Provisional value"
+"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2022","2022",55.9,"D; P","Difference in methodology; Provisional value"
+"PATCCARV","C-Cardiovascular system","ATCPTTMT","% of total sales","LUX","Luxembourg","2010","2010",21.7,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","ATCPTTMT","% of total sales","LUX","Luxembourg","2011","2011",22,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","ATCPTTMT","% of total sales","LUX","Luxembourg","2012","2012",21.3,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","ATCPTTMT","% of total sales","LUX","Luxembourg","2013","2013",19.8,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","ATCPTTMT","% of total sales","LUX","Luxembourg","2014","2014",17.9,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","ATCPTTMT","% of total sales","LUX","Luxembourg","2015","2015",17.1,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","ATCPTTMT","% of total sales","LUX","Luxembourg","2016","2016",16.7,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","ATCPTTMT","% of total sales","LUX","Luxembourg","2017","2017",15.6,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","ATCPTTMT","% of total sales","LUX","Luxembourg","2018","2018",13.4,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","ATCPTTMT","% of total sales","LUX","Luxembourg","2019","2019",12.8,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","ATCPTTMT","% of total sales","LUX","Luxembourg","2020","2020",12.6,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","ATCPTTMT","% of total sales","LUX","Luxembourg","2021","2021",11.2,"B; D; P","Break; Difference in methodology; Provisional value"
+"PATCCARV","C-Cardiovascular system","ATCPTTMT","% of total sales","LUX","Luxembourg","2022","2022",10.6,"D; P","Difference in methodology; Provisional value"
+"PATCCARV","C-Cardiovascular system","MLLNCUMT","Million of national currency units","MEX","Mexico","2010","2010",10123,,
+"PATCCARV","C-Cardiovascular system","MLLNCUMT","Million of national currency units","MEX","Mexico","2011","2011",10277,,
+"PATCCARV","C-Cardiovascular system","MLLNCUMT","Million of national currency units","MEX","Mexico","2012","2012",9747,,
+"PATCCARV","C-Cardiovascular system","MLLNCUMT","Million of national currency units","MEX","Mexico","2013","2013",9926,,
+"PATCCARV","C-Cardiovascular system","MLLNCUMT","Million of national currency units","MEX","Mexico","2014","2014",8388,,
+"PATCCARV","C-Cardiovascular system","MLLNCUMT","Million of national currency units","MEX","Mexico","2015","2015",9583,,
+"PATCCARV","C-Cardiovascular system","MLLNCUMT","Million of national currency units","MEX","Mexico","2016","2016",11846,,
+"PATCCARV","C-Cardiovascular system","MLLNCUMT","Million of national currency units","MEX","Mexico","2017","2017",10490,,
+"PATCCARV","C-Cardiovascular system","MLLNCUMT","Million of national currency units","MEX","Mexico","2018","2018",10015,,
+"PATCCARV","C-Cardiovascular system","MLLNCUMT","Million of national currency units","MEX","Mexico","2019","2019",9183.1,,
+"PATCCARV","C-Cardiovascular system","MLLNCUMT","Million of national currency units","MEX","Mexico","2020","2020",9090,,
+"PATCCARV","C-Cardiovascular system","MLLNCUMT","Million of national currency units","MEX","Mexico","2021","2021",7824.2,,
+"PATCCARV","C-Cardiovascular system","MLLNCUMT","Million of national currency units","MEX","Mexico","2022","2022",7963.2,"E","Estimated value"
+"PATCCARV","C-Cardiovascular system","MTMOTCMT","Million US$ at exchange rate","MEX","Mexico","2010","2010",801.1,,
+"PATCCARV","C-Cardiovascular system","MTMOTCMT","Million US$ at exchange rate","MEX","Mexico","2011","2011",827.2,,
+"PATCCARV","C-Cardiovascular system","MTMOTCMT","Million US$ at exchange rate","MEX","Mexico","2012","2012",740.1,,
+"PATCCARV","C-Cardiovascular system","MTMOTCMT","Million US$ at exchange rate","MEX","Mexico","2013","2013",777.2,,
+"PATCCARV","C-Cardiovascular system","MTMOTCMT","Million US$ at exchange rate","MEX","Mexico","2014","2014",631,,
+"PATCCARV","C-Cardiovascular system","MTMOTCMT","Million US$ at exchange rate","MEX","Mexico","2015","2015",604.7,,
+"PATCCARV","C-Cardiovascular system","MTMOTCMT","Million US$ at exchange rate","MEX","Mexico","2016","2016",634.7,,
+"PATCCARV","C-Cardiovascular system","MTMOTCMT","Million US$ at exchange rate","MEX","Mexico","2017","2017",554.2,,
+"PATCCARV","C-Cardiovascular system","MTMOTCMT","Million US$ at exchange rate","MEX","Mexico","2018","2018",520.4,,
+"PATCCARV","C-Cardiovascular system","MTMOTCMT","Million US$ at exchange rate","MEX","Mexico","2019","2019",476.7,,
+"PATCCARV","C-Cardiovascular system","MTMOTCMT","Million US$ at exchange rate","MEX","Mexico","2020","2020",423.1,,
+"PATCCARV","C-Cardiovascular system","MTMOTCMT","Million US$ at exchange rate","MEX","Mexico","2021","2021",386,,
+"PATCCARV","C-Cardiovascular system","MTMOTCMT","Million US$ at exchange rate","MEX","Mexico","2022","2022",395.6,"E","Estimated value"
+"PATCCARV","C-Cardiovascular system","MTMOPPMT","Million US$, purchasing power parity","MEX","Mexico","2010","2010",1318.2,,
+"PATCCARV","C-Cardiovascular system","MTMOPPMT","Million US$, purchasing power parity","MEX","Mexico","2011","2011",1339.4,,
+"PATCCARV","C-Cardiovascular system","MTMOPPMT","Million US$, purchasing power parity","MEX","Mexico","2012","2012",1240.3,,
+"PATCCARV","C-Cardiovascular system","MTMOPPMT","Million US$, purchasing power parity","MEX","Mexico","2013","2013",1258.9,,
+"PATCCARV","C-Cardiovascular system","MTMOPPMT","Million US$, purchasing power parity","MEX","Mexico","2014","2014",1042.6,,
+"PATCCARV","C-Cardiovascular system","MTMOPPMT","Million US$, purchasing power parity","MEX","Mexico","2015","2015",1150.8,,
+"PATCCARV","C-Cardiovascular system","MTMOPPMT","Million US$, purchasing power parity","MEX","Mexico","2016","2016",1402.6,,
+"PATCCARV","C-Cardiovascular system","MTMOPPMT","Million US$, purchasing power parity","MEX","Mexico","2017","2017",1176.9,,
+"PATCCARV","C-Cardiovascular system","MTMOPPMT","Million US$, purchasing power parity","MEX","Mexico","2018","2018",1079.6,,
+"PATCCARV","C-Cardiovascular system","MTMOPPMT","Million US$, purchasing power parity","MEX","Mexico","2019","2019",950.3,,
+"PATCCARV","C-Cardiovascular system","MTMOPPMT","Million US$, purchasing power parity","MEX","Mexico","2020","2020",905.4,,
+"PATCCARV","C-Cardiovascular system","MTMOPPMT","Million US$, purchasing power parity","MEX","Mexico","2021","2021",752.2,,
+"PATCCARV","C-Cardiovascular system","MTMOPPMT","Million US$, purchasing power parity","MEX","Mexico","2022","2022",752.9,"E","Estimated value"
+"PATCCARV","C-Cardiovascular system","TCPPERMT","/capita, US$ exchange rate","MEX","Mexico","2010","2010",7,,
+"PATCCARV","C-Cardiovascular system","TCPPERMT","/capita, US$ exchange rate","MEX","Mexico","2011","2011",7.2,,
+"PATCCARV","C-Cardiovascular system","TCPPERMT","/capita, US$ exchange rate","MEX","Mexico","2012","2012",6.3,,
+"PATCCARV","C-Cardiovascular system","TCPPERMT","/capita, US$ exchange rate","MEX","Mexico","2013","2013",6.6,,
+"PATCCARV","C-Cardiovascular system","TCPPERMT","/capita, US$ exchange rate","MEX","Mexico","2014","2014",5.3,,
+"PATCCARV","C-Cardiovascular system","TCPPERMT","/capita, US$ exchange rate","MEX","Mexico","2015","2015",5,,
+"PATCCARV","C-Cardiovascular system","TCPPERMT","/capita, US$ exchange rate","MEX","Mexico","2016","2016",5.2,,
+"PATCCARV","C-Cardiovascular system","TCPPERMT","/capita, US$ exchange rate","MEX","Mexico","2017","2017",4.5,,
+"PATCCARV","C-Cardiovascular system","TCPPERMT","/capita, US$ exchange rate","MEX","Mexico","2018","2018",4.2,,
+"PATCCARV","C-Cardiovascular system","TCPPERMT","/capita, US$ exchange rate","MEX","Mexico","2019","2019",3.8,,
+"PATCCARV","C-Cardiovascular system","TCPPERMT","/capita, US$ exchange rate","MEX","Mexico","2020","2020",3.3,,
+"PATCCARV","C-Cardiovascular system","TCPPERMT","/capita, US$ exchange rate","MEX","Mexico","2021","2021",3,,
+"PATCCARV","C-Cardiovascular system","TCPPERMT","/capita, US$ exchange rate","MEX","Mexico","2022","2022",3,"E","Estimated value"
+"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","MEX","Mexico","2010","2010",11.6,,
+"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","MEX","Mexico","2011","2011",11.6,,
+"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","MEX","Mexico","2012","2012",10.6,,
+"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","MEX","Mexico","2013","2013",10.6,,
+"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","MEX","Mexico","2014","2014",8.7,,
+"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","MEX","Mexico","2015","2015",9.5,,
+"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","MEX","Mexico","2016","2016",11.4,,
+"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","MEX","Mexico","2017","2017",9.5,,
+"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","MEX","Mexico","2018","2018",8.6,,
+"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","MEX","Mexico","2019","2019",7.5,,
+"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","MEX","Mexico","2020","2020",7.1,,
+"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","MEX","Mexico","2021","2021",5.8,,
+"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","MEX","Mexico","2022","2022",5.8,"E","Estimated value"
+"PATCCARV","C-Cardiovascular system","ATCPTTMT","% of total sales","MEX","Mexico","2013","2013",7,,
+"PATCCARV","C-Cardiovascular system","ATCPTTMT","% of total sales","MEX","Mexico","2018","2018",4.4,,
+"PATCCARV","C-Cardiovascular system","MLLNCUMT","Million of national currency units","NLD","Netherlands","2010","2010",906.4,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","MLLNCUMT","Million of national currency units","NLD","Netherlands","2011","2011",896.2,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","MLLNCUMT","Million of national currency units","NLD","Netherlands","2012","2012",776.6,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","MLLNCUMT","Million of national currency units","NLD","Netherlands","2013","2013",714.1,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","MLLNCUMT","Million of national currency units","NLD","Netherlands","2014","2014",682.1,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","MTMOTCMT","Million US$ at exchange rate","NLD","Netherlands","2010","2010",1201.6,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","MTMOTCMT","Million US$ at exchange rate","NLD","Netherlands","2011","2011",1247.4,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","MTMOTCMT","Million US$ at exchange rate","NLD","Netherlands","2012","2012",997.8,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","MTMOTCMT","Million US$ at exchange rate","NLD","Netherlands","2013","2013",948.4,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","MTMOTCMT","Million US$ at exchange rate","NLD","Netherlands","2014","2014",906.2,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","MTMOPPMT","Million US$, purchasing power parity","NLD","Netherlands","2010","2010",1061.2,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","MTMOPPMT","Million US$, purchasing power parity","NLD","Netherlands","2011","2011",1071.9,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","MTMOPPMT","Million US$, purchasing power parity","NLD","Netherlands","2012","2012",942,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","MTMOPPMT","Million US$, purchasing power parity","NLD","Netherlands","2013","2013",894.7,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","MTMOPPMT","Million US$, purchasing power parity","NLD","Netherlands","2014","2014",843.4,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","TCPPERMT","/capita, US$ exchange rate","NLD","Netherlands","2010","2010",72.3,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","TCPPERMT","/capita, US$ exchange rate","NLD","Netherlands","2011","2011",74.7,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","TCPPERMT","/capita, US$ exchange rate","NLD","Netherlands","2012","2012",59.6,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","TCPPERMT","/capita, US$ exchange rate","NLD","Netherlands","2013","2013",56.4,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","TCPPERMT","/capita, US$ exchange rate","NLD","Netherlands","2014","2014",53.7,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","NLD","Netherlands","2010","2010",63.9,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","NLD","Netherlands","2011","2011",64.2,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","NLD","Netherlands","2012","2012",56.2,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","NLD","Netherlands","2013","2013",53.2,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","NLD","Netherlands","2014","2014",50,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","ATCPTTMT","% of total sales","NLD","Netherlands","2010","2010",17.4,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","ATCPTTMT","% of total sales","NLD","Netherlands","2011","2011",17.2,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","ATCPTTMT","% of total sales","NLD","Netherlands","2012","2012",16.9,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","ATCPTTMT","% of total sales","NLD","Netherlands","2013","2013",16.6,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","ATCPTTMT","% of total sales","NLD","Netherlands","2014","2014",15.8,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","MLLNCUMT","Million of national currency units","NZL","New Zealand","2010","2010",122.4,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","MLLNCUMT","Million of national currency units","NZL","New Zealand","2011","2011",134.6,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","MLLNCUMT","Million of national currency units","NZL","New Zealand","2012","2012",153.7,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","MLLNCUMT","Million of national currency units","NZL","New Zealand","2013","2013",86.4,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","MLLNCUMT","Million of national currency units","NZL","New Zealand","2014","2014",69.9,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","MLLNCUMT","Million of national currency units","NZL","New Zealand","2015","2015",66.6,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","MLLNCUMT","Million of national currency units","NZL","New Zealand","2016","2016",51,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","MLLNCUMT","Million of national currency units","NZL","New Zealand","2017","2017",51.6,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","MLLNCUMT","Million of national currency units","NZL","New Zealand","2018","2018",46.8,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","MLLNCUMT","Million of national currency units","NZL","New Zealand","2019","2019",45.9,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","MLLNCUMT","Million of national currency units","NZL","New Zealand","2020","2020",47.9,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","MLLNCUMT","Million of national currency units","NZL","New Zealand","2021","2021",59.3,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","MLLNCUMT","Million of national currency units","NZL","New Zealand","2022","2022",71.6,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","MTMOTCMT","Million US$ at exchange rate","NZL","New Zealand","2010","2010",88.2,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","MTMOTCMT","Million US$ at exchange rate","NZL","New Zealand","2011","2011",106.3,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","MTMOTCMT","Million US$ at exchange rate","NZL","New Zealand","2012","2012",124.5,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","MTMOTCMT","Million US$ at exchange rate","NZL","New Zealand","2013","2013",70.9,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","MTMOTCMT","Million US$ at exchange rate","NZL","New Zealand","2014","2014",58,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","MTMOTCMT","Million US$ at exchange rate","NZL","New Zealand","2015","2015",46.5,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","MTMOTCMT","Million US$ at exchange rate","NZL","New Zealand","2016","2016",35.5,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","MTMOTCMT","Million US$ at exchange rate","NZL","New Zealand","2017","2017",36.7,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","MTMOTCMT","Million US$ at exchange rate","NZL","New Zealand","2018","2018",32.4,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","MTMOTCMT","Million US$ at exchange rate","NZL","New Zealand","2019","2019",30.2,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","MTMOTCMT","Million US$ at exchange rate","NZL","New Zealand","2020","2020",31.1,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","MTMOTCMT","Million US$ at exchange rate","NZL","New Zealand","2021","2021",41.9,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","MTMOTCMT","Million US$ at exchange rate","NZL","New Zealand","2022","2022",45.4,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","MTMOPPMT","Million US$, purchasing power parity","NZL","New Zealand","2010","2010",81.8,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","MTMOPPMT","Million US$, purchasing power parity","NZL","New Zealand","2011","2011",90.6,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","MTMOPPMT","Million US$, purchasing power parity","NZL","New Zealand","2012","2012",102.8,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","MTMOPPMT","Million US$, purchasing power parity","NZL","New Zealand","2013","2013",59.8,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","MTMOPPMT","Million US$, purchasing power parity","NZL","New Zealand","2014","2014",48.5,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","MTMOPPMT","Million US$, purchasing power parity","NZL","New Zealand","2015","2015",45.1,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","MTMOPPMT","Million US$, purchasing power parity","NZL","New Zealand","2016","2016",35.4,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","MTMOPPMT","Million US$, purchasing power parity","NZL","New Zealand","2017","2017",36.1,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","MTMOPPMT","Million US$, purchasing power parity","NZL","New Zealand","2018","2018",31.8,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","MTMOPPMT","Million US$, purchasing power parity","NZL","New Zealand","2019","2019",32.4,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","MTMOPPMT","Million US$, purchasing power parity","NZL","New Zealand","2020","2020",33.9,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","MTMOPPMT","Million US$, purchasing power parity","NZL","New Zealand","2021","2021",40.6,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","MTMOPPMT","Million US$, purchasing power parity","NZL","New Zealand","2022","2022",49.6,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","TCPPERMT","/capita, US$ exchange rate","NZL","New Zealand","2010","2010",20.3,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","TCPPERMT","/capita, US$ exchange rate","NZL","New Zealand","2011","2011",24.2,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","TCPPERMT","/capita, US$ exchange rate","NZL","New Zealand","2012","2012",28.2,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","TCPPERMT","/capita, US$ exchange rate","NZL","New Zealand","2013","2013",16,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","TCPPERMT","/capita, US$ exchange rate","NZL","New Zealand","2014","2014",12.8,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","TCPPERMT","/capita, US$ exchange rate","NZL","New Zealand","2015","2015",10.1,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","TCPPERMT","/capita, US$ exchange rate","NZL","New Zealand","2016","2016",7.5,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","TCPPERMT","/capita, US$ exchange rate","NZL","New Zealand","2017","2017",7.6,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","TCPPERMT","/capita, US$ exchange rate","NZL","New Zealand","2018","2018",6.6,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","TCPPERMT","/capita, US$ exchange rate","NZL","New Zealand","2019","2019",6.1,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","TCPPERMT","/capita, US$ exchange rate","NZL","New Zealand","2020","2020",6.1,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","TCPPERMT","/capita, US$ exchange rate","NZL","New Zealand","2021","2021",8.2,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","TCPPERMT","/capita, US$ exchange rate","NZL","New Zealand","2022","2022",8.9,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2010","2010",18.8,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2011","2011",20.7,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2012","2012",23.3,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2013","2013",13.5,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2014","2014",10.7,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2015","2015",9.8,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2016","2016",7.5,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2017","2017",7.5,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2018","2018",6.5,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2019","2019",6.5,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2020","2020",6.7,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2021","2021",8,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2022","2022",9.7,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","ATCPTTMT","% of total sales","NZL","New Zealand","2010","2010",16.3,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","ATCPTTMT","% of total sales","NZL","New Zealand","2011","2011",16.5,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","ATCPTTMT","% of total sales","NZL","New Zealand","2012","2012",16.6,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","ATCPTTMT","% of total sales","NZL","New Zealand","2013","2013",9.4,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","ATCPTTMT","% of total sales","NZL","New Zealand","2014","2014",7.3,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","ATCPTTMT","% of total sales","NZL","New Zealand","2015","2015",6.7,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","ATCPTTMT","% of total sales","NZL","New Zealand","2016","2016",4.8,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","ATCPTTMT","% of total sales","NZL","New Zealand","2017","2017",4.1,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","ATCPTTMT","% of total sales","NZL","New Zealand","2018","2018",3.5,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","ATCPTTMT","% of total sales","NZL","New Zealand","2019","2019",3.1,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","ATCPTTMT","% of total sales","NZL","New Zealand","2020","2020",2.9,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","ATCPTTMT","% of total sales","NZL","New Zealand","2021","2021",3.3,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","ATCPTTMT","% of total sales","NZL","New Zealand","2022","2022",3.8,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","MLLNCUMT","Million of national currency units","NOR","Norway","2010","2010",1869,,
+"PATCCARV","C-Cardiovascular system","MLLNCUMT","Million of national currency units","NOR","Norway","2011","2011",1797,,
+"PATCCARV","C-Cardiovascular system","MLLNCUMT","Million of national currency units","NOR","Norway","2012","2012",1631,,
+"PATCCARV","C-Cardiovascular system","MLLNCUMT","Million of national currency units","NOR","Norway","2013","2013",1481,,
+"PATCCARV","C-Cardiovascular system","MLLNCUMT","Million of national currency units","NOR","Norway","2014","2014",1477,,
+"PATCCARV","C-Cardiovascular system","MLLNCUMT","Million of national currency units","NOR","Norway","2015","2015",1508,,
+"PATCCARV","C-Cardiovascular system","MLLNCUMT","Million of national currency units","NOR","Norway","2016","2016",1632,,
+"PATCCARV","C-Cardiovascular system","MLLNCUMT","Million of national currency units","NOR","Norway","2017","2017",1708,,
+"PATCCARV","C-Cardiovascular system","MLLNCUMT","Million of national currency units","NOR","Norway","2018","2018",1732,,
+"PATCCARV","C-Cardiovascular system","MLLNCUMT","Million of national currency units","NOR","Norway","2019","2019",1793,,
+"PATCCARV","C-Cardiovascular system","MLLNCUMT","Million of national currency units","NOR","Norway","2020","2020",1825,,
+"PATCCARV","C-Cardiovascular system","MLLNCUMT","Million of national currency units","NOR","Norway","2021","2021",1873,,
+"PATCCARV","C-Cardiovascular system","MLLNCUMT","Million of national currency units","NOR","Norway","2022","2022",1974,,
+"PATCCARV","C-Cardiovascular system","MTMOTCMT","Million US$ at exchange rate","NOR","Norway","2010","2010",309.2,,
+"PATCCARV","C-Cardiovascular system","MTMOTCMT","Million US$ at exchange rate","NOR","Norway","2011","2011",320.6,,
+"PATCCARV","C-Cardiovascular system","MTMOTCMT","Million US$ at exchange rate","NOR","Norway","2012","2012",280.4,,
+"PATCCARV","C-Cardiovascular system","MTMOTCMT","Million US$ at exchange rate","NOR","Norway","2013","2013",252.1,,
+"PATCCARV","C-Cardiovascular system","MTMOTCMT","Million US$ at exchange rate","NOR","Norway","2014","2014",234.4,,
+"PATCCARV","C-Cardiovascular system","MTMOTCMT","Million US$ at exchange rate","NOR","Norway","2015","2015",187,,
+"PATCCARV","C-Cardiovascular system","MTMOTCMT","Million US$ at exchange rate","NOR","Norway","2016","2016",194.3,,
+"PATCCARV","C-Cardiovascular system","MTMOTCMT","Million US$ at exchange rate","NOR","Norway","2017","2017",206.5,,
+"PATCCARV","C-Cardiovascular system","MTMOTCMT","Million US$ at exchange rate","NOR","Norway","2018","2018",213,,
+"PATCCARV","C-Cardiovascular system","MTMOTCMT","Million US$ at exchange rate","NOR","Norway","2019","2019",203.8,,
+"PATCCARV","C-Cardiovascular system","MTMOTCMT","Million US$ at exchange rate","NOR","Norway","2020","2020",193.8,,
+"PATCCARV","C-Cardiovascular system","MTMOTCMT","Million US$ at exchange rate","NOR","Norway","2021","2021",218,,
+"PATCCARV","C-Cardiovascular system","MTMOTCMT","Million US$ at exchange rate","NOR","Norway","2022","2022",205.3,,
+"PATCCARV","C-Cardiovascular system","MTMOPPMT","Million US$, purchasing power parity","NOR","Norway","2010","2010",204.2,,
+"PATCCARV","C-Cardiovascular system","MTMOPPMT","Million US$, purchasing power parity","NOR","Norway","2011","2011",197.8,,
+"PATCCARV","C-Cardiovascular system","MTMOPPMT","Million US$, purchasing power parity","NOR","Norway","2012","2012",180.5,,
+"PATCCARV","C-Cardiovascular system","MTMOPPMT","Million US$, purchasing power parity","NOR","Norway","2013","2013",164,,
+"PATCCARV","C-Cardiovascular system","MTMOPPMT","Million US$, purchasing power parity","NOR","Norway","2014","2014",159.2,,
+"PATCCARV","C-Cardiovascular system","MTMOPPMT","Million US$, purchasing power parity","NOR","Norway","2015","2015",151.8,,
+"PATCCARV","C-Cardiovascular system","MTMOPPMT","Million US$, purchasing power parity","NOR","Norway","2016","2016",162.5,,
+"PATCCARV","C-Cardiovascular system","MTMOPPMT","Million US$, purchasing power parity","NOR","Norway","2017","2017",175.2,,
+"PATCCARV","C-Cardiovascular system","MTMOPPMT","Million US$, purchasing power parity","NOR","Norway","2018","2018",180.7,,
+"PATCCARV","C-Cardiovascular system","MTMOPPMT","Million US$, purchasing power parity","NOR","Norway","2019","2019",186.4,,
+"PATCCARV","C-Cardiovascular system","MTMOPPMT","Million US$, purchasing power parity","NOR","Norway","2020","2020",184.7,,
+"PATCCARV","C-Cardiovascular system","MTMOPPMT","Million US$, purchasing power parity","NOR","Norway","2021","2021",196.9,,
+"PATCCARV","C-Cardiovascular system","MTMOPPMT","Million US$, purchasing power parity","NOR","Norway","2022","2022",183.8,,
+"PATCCARV","C-Cardiovascular system","TCPPERMT","/capita, US$ exchange rate","NOR","Norway","2010","2010",63.2,,
+"PATCCARV","C-Cardiovascular system","TCPPERMT","/capita, US$ exchange rate","NOR","Norway","2011","2011",64.7,,
+"PATCCARV","C-Cardiovascular system","TCPPERMT","/capita, US$ exchange rate","NOR","Norway","2012","2012",55.9,,
+"PATCCARV","C-Cardiovascular system","TCPPERMT","/capita, US$ exchange rate","NOR","Norway","2013","2013",49.6,,
+"PATCCARV","C-Cardiovascular system","TCPPERMT","/capita, US$ exchange rate","NOR","Norway","2014","2014",45.6,,
+"PATCCARV","C-Cardiovascular system","TCPPERMT","/capita, US$ exchange rate","NOR","Norway","2015","2015",36,,
+"PATCCARV","C-Cardiovascular system","TCPPERMT","/capita, US$ exchange rate","NOR","Norway","2016","2016",37.1,,
+"PATCCARV","C-Cardiovascular system","TCPPERMT","/capita, US$ exchange rate","NOR","Norway","2017","2017",39.1,,
+"PATCCARV","C-Cardiovascular system","TCPPERMT","/capita, US$ exchange rate","NOR","Norway","2018","2018",40.1,,
+"PATCCARV","C-Cardiovascular system","TCPPERMT","/capita, US$ exchange rate","NOR","Norway","2019","2019",38.1,,
+"PATCCARV","C-Cardiovascular system","TCPPERMT","/capita, US$ exchange rate","NOR","Norway","2020","2020",36,,
+"PATCCARV","C-Cardiovascular system","TCPPERMT","/capita, US$ exchange rate","NOR","Norway","2021","2021",40.3,,
+"PATCCARV","C-Cardiovascular system","TCPPERMT","/capita, US$ exchange rate","NOR","Norway","2022","2022",37.8,,
+"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2010","2010",41.8,,
+"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2011","2011",39.9,,
+"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2012","2012",36,,
+"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2013","2013",32.3,,
+"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2014","2014",31,,
+"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2015","2015",29.3,,
+"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2016","2016",31,,
+"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2017","2017",33.2,,
+"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2018","2018",34,,
+"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2019","2019",34.9,,
+"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2020","2020",34.3,,
+"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2021","2021",36.4,,
+"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2022","2022",33.9,,
+"PATCCARV","C-Cardiovascular system","ATCPTTMT","% of total sales","NOR","Norway","2010","2010",10.4,,
+"PATCCARV","C-Cardiovascular system","ATCPTTMT","% of total sales","NOR","Norway","2011","2011",9.9,,
+"PATCCARV","C-Cardiovascular system","ATCPTTMT","% of total sales","NOR","Norway","2012","2012",8.7,,
+"PATCCARV","C-Cardiovascular system","ATCPTTMT","% of total sales","NOR","Norway","2013","2013",7.7,,
+"PATCCARV","C-Cardiovascular system","ATCPTTMT","% of total sales","NOR","Norway","2014","2014",7,,
+"PATCCARV","C-Cardiovascular system","ATCPTTMT","% of total sales","NOR","Norway","2015","2015",6.6,,
+"PATCCARV","C-Cardiovascular system","ATCPTTMT","% of total sales","NOR","Norway","2016","2016",6.6,,
+"PATCCARV","C-Cardiovascular system","ATCPTTMT","% of total sales","NOR","Norway","2017","2017",6.4,,
+"PATCCARV","C-Cardiovascular system","ATCPTTMT","% of total sales","NOR","Norway","2018","2018",6.3,,
+"PATCCARV","C-Cardiovascular system","ATCPTTMT","% of total sales","NOR","Norway","2019","2019",6.3,,
+"PATCCARV","C-Cardiovascular system","ATCPTTMT","% of total sales","NOR","Norway","2020","2020",6.1,,
+"PATCCARV","C-Cardiovascular system","ATCPTTMT","% of total sales","NOR","Norway","2021","2021",5.6,,
+"PATCCARV","C-Cardiovascular system","ATCPTTMT","% of total sales","NOR","Norway","2022","2022",5.5,,
+"PATCCARV","C-Cardiovascular system","MLLNCUMT","Million of national currency units","PRT","Portugal","2010","2010",892.1,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","MLLNCUMT","Million of national currency units","PRT","Portugal","2011","2011",781.6,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","MLLNCUMT","Million of national currency units","PRT","Portugal","2012","2012",668.8,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","MLLNCUMT","Million of national currency units","PRT","Portugal","2013","2013",591.2,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","MLLNCUMT","Million of national currency units","PRT","Portugal","2014","2014",568.4,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","MLLNCUMT","Million of national currency units","PRT","Portugal","2015","2015",554.5,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","MLLNCUMT","Million of national currency units","PRT","Portugal","2016","2016",539.9,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","MLLNCUMT","Million of national currency units","PRT","Portugal","2017","2017",519.6,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","MLLNCUMT","Million of national currency units","PRT","Portugal","2018","2018",493.3,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","MLLNCUMT","Million of national currency units","PRT","Portugal","2019","2019",507.8,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","MLLNCUMT","Million of national currency units","PRT","Portugal","2020","2020",532.7,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","MLLNCUMT","Million of national currency units","PRT","Portugal","2021","2021",556.8,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","MLLNCUMT","Million of national currency units","PRT","Portugal","2022","2022",590.1,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","MTMOTCMT","Million US$ at exchange rate","PRT","Portugal","2010","2010",1182.7,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","MTMOTCMT","Million US$ at exchange rate","PRT","Portugal","2011","2011",1088,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","MTMOTCMT","Million US$ at exchange rate","PRT","Portugal","2012","2012",859.3,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","MTMOTCMT","Million US$ at exchange rate","PRT","Portugal","2013","2013",785.2,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","MTMOTCMT","Million US$ at exchange rate","PRT","Portugal","2014","2014",755.1,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","MTMOTCMT","Million US$ at exchange rate","PRT","Portugal","2015","2015",615.2,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","MTMOTCMT","Million US$ at exchange rate","PRT","Portugal","2016","2016",597.6,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","MTMOTCMT","Million US$ at exchange rate","PRT","Portugal","2017","2017",587,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","MTMOTCMT","Million US$ at exchange rate","PRT","Portugal","2018","2018",582.6,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","MTMOTCMT","Million US$ at exchange rate","PRT","Portugal","2019","2019",568.4,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","MTMOTCMT","Million US$ at exchange rate","PRT","Portugal","2020","2020",608.4,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","MTMOTCMT","Million US$ at exchange rate","PRT","Portugal","2021","2021",658.6,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","MTMOTCMT","Million US$ at exchange rate","PRT","Portugal","2022","2022",621.4,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","MTMOPPMT","Million US$, purchasing power parity","PRT","Portugal","2010","2010",1431.7,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","MTMOPPMT","Million US$, purchasing power parity","PRT","Portugal","2011","2011",1254.5,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","MTMOPPMT","Million US$, purchasing power parity","PRT","Portugal","2012","2012",1104.8,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","MTMOPPMT","Million US$, purchasing power parity","PRT","Portugal","2013","2013",1013,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","MTMOPPMT","Million US$, purchasing power parity","PRT","Portugal","2014","2014",981.9,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","MTMOPPMT","Million US$, purchasing power parity","PRT","Portugal","2015","2015",947.9,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","MTMOPPMT","Million US$, purchasing power parity","PRT","Portugal","2016","2016",944.9,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","MTMOPPMT","Million US$, purchasing power parity","PRT","Portugal","2017","2017",902.5,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","MTMOPPMT","Million US$, purchasing power parity","PRT","Portugal","2018","2018",863.6,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","MTMOPPMT","Million US$, purchasing power parity","PRT","Portugal","2019","2019",908.8,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","MTMOPPMT","Million US$, purchasing power parity","PRT","Portugal","2020","2020",956.2,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","MTMOPPMT","Million US$, purchasing power parity","PRT","Portugal","2021","2021",980.9,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","MTMOPPMT","Million US$, purchasing power parity","PRT","Portugal","2022","2022",1072.9,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","TCPPERMT","/capita, US$ exchange rate","PRT","Portugal","2010","2010",111.9,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","TCPPERMT","/capita, US$ exchange rate","PRT","Portugal","2011","2011",103.1,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","TCPPERMT","/capita, US$ exchange rate","PRT","Portugal","2012","2012",81.7,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","TCPPERMT","/capita, US$ exchange rate","PRT","Portugal","2013","2013",75.1,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","TCPPERMT","/capita, US$ exchange rate","PRT","Portugal","2014","2014",72.6,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","TCPPERMT","/capita, US$ exchange rate","PRT","Portugal","2015","2015",59.4,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","TCPPERMT","/capita, US$ exchange rate","PRT","Portugal","2016","2016",57.9,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","TCPPERMT","/capita, US$ exchange rate","PRT","Portugal","2017","2017",57,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","TCPPERMT","/capita, US$ exchange rate","PRT","Portugal","2018","2018",56.6,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","TCPPERMT","/capita, US$ exchange rate","PRT","Portugal","2019","2019",55.3,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","TCPPERMT","/capita, US$ exchange rate","PRT","Portugal","2020","2020",59.1,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","TCPPERMT","/capita, US$ exchange rate","PRT","Portugal","2021","2021",63.6,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","TCPPERMT","/capita, US$ exchange rate","PRT","Portugal","2022","2022",60,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2010","2010",135.4,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2011","2011",118.8,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2012","2012",105.1,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2013","2013",96.9,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2014","2014",94.4,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2015","2015",91.5,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2016","2016",91.5,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2017","2017",87.6,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2018","2018",84,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2019","2019",88.3,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2020","2020",92.9,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2021","2021",94.7,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2022","2022",103.6,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","ATCPTTMT","% of total sales","PRT","Portugal","2010","2010",27.6,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","ATCPTTMT","% of total sales","PRT","Portugal","2011","2011",26.6,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","ATCPTTMT","% of total sales","PRT","Portugal","2012","2012",25.6,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","ATCPTTMT","% of total sales","PRT","Portugal","2013","2013",24.5,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","ATCPTTMT","% of total sales","PRT","Portugal","2014","2014",23.7,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","ATCPTTMT","% of total sales","PRT","Portugal","2015","2015",22.3,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","ATCPTTMT","% of total sales","PRT","Portugal","2016","2016",21.3,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","ATCPTTMT","% of total sales","PRT","Portugal","2017","2017",20.3,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","ATCPTTMT","% of total sales","PRT","Portugal","2018","2018",18.8,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","ATCPTTMT","% of total sales","PRT","Portugal","2019","2019",18.2,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","ATCPTTMT","% of total sales","PRT","Portugal","2020","2020",19,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","ATCPTTMT","% of total sales","PRT","Portugal","2021","2021",19.1,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","ATCPTTMT","% of total sales","PRT","Portugal","2022","2022",18.5,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","MLLNCUMT","Million of national currency units","SVK","Slovak Republic","2010","2010",183.3,,
+"PATCCARV","C-Cardiovascular system","MLLNCUMT","Million of national currency units","SVK","Slovak Republic","2011","2011",189.4,,
+"PATCCARV","C-Cardiovascular system","MLLNCUMT","Million of national currency units","SVK","Slovak Republic","2012","2012",165,,
+"PATCCARV","C-Cardiovascular system","MLLNCUMT","Million of national currency units","SVK","Slovak Republic","2013","2013",159.1,,
+"PATCCARV","C-Cardiovascular system","MLLNCUMT","Million of national currency units","SVK","Slovak Republic","2014","2014",155.9,,
+"PATCCARV","C-Cardiovascular system","MLLNCUMT","Million of national currency units","SVK","Slovak Republic","2015","2015",154.8,,
+"PATCCARV","C-Cardiovascular system","MLLNCUMT","Million of national currency units","SVK","Slovak Republic","2016","2016",194.1,"B","Break"
+"PATCCARV","C-Cardiovascular system","MLLNCUMT","Million of national currency units","SVK","Slovak Republic","2017","2017",188.7,,
+"PATCCARV","C-Cardiovascular system","MLLNCUMT","Million of national currency units","SVK","Slovak Republic","2018","2018",187.8,,
+"PATCCARV","C-Cardiovascular system","MLLNCUMT","Million of national currency units","SVK","Slovak Republic","2019","2019",191.3,,
+"PATCCARV","C-Cardiovascular system","MLLNCUMT","Million of national currency units","SVK","Slovak Republic","2020","2020",199.7,,
+"PATCCARV","C-Cardiovascular system","MLLNCUMT","Million of national currency units","SVK","Slovak Republic","2021","2021",207.9,,
+"PATCCARV","C-Cardiovascular system","MTMOTCMT","Million US$ at exchange rate","SVK","Slovak Republic","2010","2010",242.9,,
+"PATCCARV","C-Cardiovascular system","MTMOTCMT","Million US$ at exchange rate","SVK","Slovak Republic","2011","2011",263.6,,
+"PATCCARV","C-Cardiovascular system","MTMOTCMT","Million US$ at exchange rate","SVK","Slovak Republic","2012","2012",212,,
+"PATCCARV","C-Cardiovascular system","MTMOTCMT","Million US$ at exchange rate","SVK","Slovak Republic","2013","2013",211.3,,
+"PATCCARV","C-Cardiovascular system","MTMOTCMT","Million US$ at exchange rate","SVK","Slovak Republic","2014","2014",207.1,,
+"PATCCARV","C-Cardiovascular system","MTMOTCMT","Million US$ at exchange rate","SVK","Slovak Republic","2015","2015",171.7,,
+"PATCCARV","C-Cardiovascular system","MTMOTCMT","Million US$ at exchange rate","SVK","Slovak Republic","2016","2016",214.9,"B","Break"
+"PATCCARV","C-Cardiovascular system","MTMOTCMT","Million US$ at exchange rate","SVK","Slovak Republic","2017","2017",213.2,,
+"PATCCARV","C-Cardiovascular system","MTMOTCMT","Million US$ at exchange rate","SVK","Slovak Republic","2018","2018",221.7,,
+"PATCCARV","C-Cardiovascular system","MTMOTCMT","Million US$ at exchange rate","SVK","Slovak Republic","2019","2019",214.1,,
+"PATCCARV","C-Cardiovascular system","MTMOTCMT","Million US$ at exchange rate","SVK","Slovak Republic","2020","2020",228,,
+"PATCCARV","C-Cardiovascular system","MTMOTCMT","Million US$ at exchange rate","SVK","Slovak Republic","2021","2021",245.9,,
+"PATCCARV","C-Cardiovascular system","MTMOPPMT","Million US$, purchasing power parity","SVK","Slovak Republic","2010","2010",365,,
+"PATCCARV","C-Cardiovascular system","MTMOPPMT","Million US$, purchasing power parity","SVK","Slovak Republic","2011","2011",373.9,,
+"PATCCARV","C-Cardiovascular system","MTMOPPMT","Million US$, purchasing power parity","SVK","Slovak Republic","2012","2012",327,,
+"PATCCARV","C-Cardiovascular system","MTMOPPMT","Million US$, purchasing power parity","SVK","Slovak Republic","2013","2013",324,,
+"PATCCARV","C-Cardiovascular system","MTMOPPMT","Million US$, purchasing power parity","SVK","Slovak Republic","2014","2014",321.1,,
+"PATCCARV","C-Cardiovascular system","MTMOPPMT","Million US$, purchasing power parity","SVK","Slovak Republic","2015","2015",314.9,,
+"PATCCARV","C-Cardiovascular system","MTMOPPMT","Million US$, purchasing power parity","SVK","Slovak Republic","2016","2016",385.8,"B","Break"
+"PATCCARV","C-Cardiovascular system","MTMOPPMT","Million US$, purchasing power parity","SVK","Slovak Republic","2017","2017",365.5,,
+"PATCCARV","C-Cardiovascular system","MTMOPPMT","Million US$, purchasing power parity","SVK","Slovak Republic","2018","2018",357,,
+"PATCCARV","C-Cardiovascular system","MTMOPPMT","Million US$, purchasing power parity","SVK","Slovak Republic","2019","2019",369.6,,
+"PATCCARV","C-Cardiovascular system","MTMOPPMT","Million US$, purchasing power parity","SVK","Slovak Republic","2020","2020",384,,
+"PATCCARV","C-Cardiovascular system","MTMOPPMT","Million US$, purchasing power parity","SVK","Slovak Republic","2021","2021",389.8,,
+"PATCCARV","C-Cardiovascular system","TCPPERMT","/capita, US$ exchange rate","SVK","Slovak Republic","2010","2010",45.1,,
+"PATCCARV","C-Cardiovascular system","TCPPERMT","/capita, US$ exchange rate","SVK","Slovak Republic","2011","2011",48.8,,
+"PATCCARV","C-Cardiovascular system","TCPPERMT","/capita, US$ exchange rate","SVK","Slovak Republic","2012","2012",39.2,,
+"PATCCARV","C-Cardiovascular system","TCPPERMT","/capita, US$ exchange rate","SVK","Slovak Republic","2013","2013",39,,
+"PATCCARV","C-Cardiovascular system","TCPPERMT","/capita, US$ exchange rate","SVK","Slovak Republic","2014","2014",38.2,,
+"PATCCARV","C-Cardiovascular system","TCPPERMT","/capita, US$ exchange rate","SVK","Slovak Republic","2015","2015",31.7,,
+"PATCCARV","C-Cardiovascular system","TCPPERMT","/capita, US$ exchange rate","SVK","Slovak Republic","2016","2016",39.6,"B","Break"
+"PATCCARV","C-Cardiovascular system","TCPPERMT","/capita, US$ exchange rate","SVK","Slovak Republic","2017","2017",39.2,,
+"PATCCARV","C-Cardiovascular system","TCPPERMT","/capita, US$ exchange rate","SVK","Slovak Republic","2018","2018",40.7,,
+"PATCCARV","C-Cardiovascular system","TCPPERMT","/capita, US$ exchange rate","SVK","Slovak Republic","2019","2019",39.3,,
+"PATCCARV","C-Cardiovascular system","TCPPERMT","/capita, US$ exchange rate","SVK","Slovak Republic","2020","2020",41.8,,
+"PATCCARV","C-Cardiovascular system","TCPPERMT","/capita, US$ exchange rate","SVK","Slovak Republic","2021","2021",45.1,,
+"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2010","2010",67.7,,
+"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2011","2011",69.3,,
+"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2012","2012",60.5,,
+"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2013","2013",59.9,,
+"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2014","2014",59.3,,
+"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2015","2015",58.1,,
+"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2016","2016",71,"B","Break"
+"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2017","2017",67.2,,
+"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2018","2018",65.5,,
+"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2019","2019",67.8,,
+"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2020","2020",70.3,,
+"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2021","2021",71.6,,
+"PATCCARV","C-Cardiovascular system","ATCPTTMT","% of total sales","SVK","Slovak Republic","2010","2010",16.4,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","ATCPTTMT","% of total sales","SVK","Slovak Republic","2011","2011",16.8,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","ATCPTTMT","% of total sales","SVK","Slovak Republic","2012","2012",14.9,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","ATCPTTMT","% of total sales","SVK","Slovak Republic","2013","2013",12.9,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","ATCPTTMT","% of total sales","SVK","Slovak Republic","2014","2014",11.8,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","ATCPTTMT","% of total sales","SVK","Slovak Republic","2015","2015",11.2,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","ATCPTTMT","% of total sales","SVK","Slovak Republic","2016","2016",12.3,"B","Break"
+"PATCCARV","C-Cardiovascular system","ATCPTTMT","% of total sales","SVK","Slovak Republic","2017","2017",12.1,,
+"PATCCARV","C-Cardiovascular system","ATCPTTMT","% of total sales","SVK","Slovak Republic","2018","2018",11.5,,
+"PATCCARV","C-Cardiovascular system","ATCPTTMT","% of total sales","SVK","Slovak Republic","2019","2019",11.1,,
+"PATCCARV","C-Cardiovascular system","ATCPTTMT","% of total sales","SVK","Slovak Republic","2020","2020",12,,
+"PATCCARV","C-Cardiovascular system","ATCPTTMT","% of total sales","SVK","Slovak Republic","2021","2021",11.6,,
+"PATCCARV","C-Cardiovascular system","MLLNCUMT","Million of national currency units","ESP","Spain","2010","2010",3077.7,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","MLLNCUMT","Million of national currency units","ESP","Spain","2011","2011",2591,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","MLLNCUMT","Million of national currency units","ESP","Spain","2012","2012",2209.6,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","MLLNCUMT","Million of national currency units","ESP","Spain","2013","2013",2078.7,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","MLLNCUMT","Million of national currency units","ESP","Spain","2014","2014",2140.8,"B; D","Break; Difference in methodology"
+"PATCCARV","C-Cardiovascular system","MLLNCUMT","Million of national currency units","ESP","Spain","2015","2015",2151.8,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","MLLNCUMT","Million of national currency units","ESP","Spain","2016","2016",2235.6,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","MLLNCUMT","Million of national currency units","ESP","Spain","2017","2017",2202.5,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","MLLNCUMT","Million of national currency units","ESP","Spain","2018","2018",2299.8,"B","Break"
+"PATCCARV","C-Cardiovascular system","MLLNCUMT","Million of national currency units","ESP","Spain","2019","2019",2363.2,,
+"PATCCARV","C-Cardiovascular system","MLLNCUMT","Million of national currency units","ESP","Spain","2020","2020",2438.5,,
+"PATCCARV","C-Cardiovascular system","MLLNCUMT","Million of national currency units","ESP","Spain","2021","2021",2443.9,,
+"PATCCARV","C-Cardiovascular system","MLLNCUMT","Million of national currency units","ESP","Spain","2022","2022",2540,"P","Provisional value"
+"PATCCARV","C-Cardiovascular system","MTMOTCMT","Million US$ at exchange rate","ESP","Spain","2010","2010",4080.1,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","MTMOTCMT","Million US$ at exchange rate","ESP","Spain","2011","2011",3606.5,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","MTMOTCMT","Million US$ at exchange rate","ESP","Spain","2012","2012",2838.9,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","MTMOTCMT","Million US$ at exchange rate","ESP","Spain","2013","2013",2760.7,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","MTMOTCMT","Million US$ at exchange rate","ESP","Spain","2014","2014",2844.1,"B; D","Break; Difference in methodology"
+"PATCCARV","C-Cardiovascular system","MTMOTCMT","Million US$ at exchange rate","ESP","Spain","2015","2015",2387.5,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","MTMOTCMT","Million US$ at exchange rate","ESP","Spain","2016","2016",2474.6,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","MTMOTCMT","Million US$ at exchange rate","ESP","Spain","2017","2017",2488.1,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","MTMOTCMT","Million US$ at exchange rate","ESP","Spain","2018","2018",2716,"B","Break"
+"PATCCARV","C-Cardiovascular system","MTMOTCMT","Million US$ at exchange rate","ESP","Spain","2019","2019",2645.6,,
+"PATCCARV","C-Cardiovascular system","MTMOTCMT","Million US$ at exchange rate","ESP","Spain","2020","2020",2785.2,,
+"PATCCARV","C-Cardiovascular system","MTMOTCMT","Million US$ at exchange rate","ESP","Spain","2021","2021",2890.5,,
+"PATCCARV","C-Cardiovascular system","MTMOTCMT","Million US$ at exchange rate","ESP","Spain","2022","2022",2674.8,"P","Provisional value"
+"PATCCARV","C-Cardiovascular system","MTMOPPMT","Million US$, purchasing power parity","ESP","Spain","2010","2010",4233.6,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","MTMOPPMT","Million US$, purchasing power parity","ESP","Spain","2011","2011",3628.2,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","MTMOPPMT","Million US$, purchasing power parity","ESP","Spain","2012","2012",3179.4,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","MTMOPPMT","Million US$, purchasing power parity","ESP","Spain","2013","2013",3080.4,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","MTMOPPMT","Million US$, purchasing power parity","ESP","Spain","2014","2014",3232.1,"B; D","Break; Difference in methodology"
+"PATCCARV","C-Cardiovascular system","MTMOPPMT","Million US$, purchasing power parity","ESP","Spain","2015","2015",3237.1,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","MTMOPPMT","Million US$, purchasing power parity","ESP","Spain","2016","2016",3478.8,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","MTMOPPMT","Million US$, purchasing power parity","ESP","Spain","2017","2017",3491.4,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","MTMOPPMT","Million US$, purchasing power parity","ESP","Spain","2018","2018",3640.1,"B","Break"
+"PATCCARV","C-Cardiovascular system","MTMOPPMT","Million US$, purchasing power parity","ESP","Spain","2019","2019",3855.4,,
+"PATCCARV","C-Cardiovascular system","MTMOPPMT","Million US$, purchasing power parity","ESP","Spain","2020","2020",3924.6,,
+"PATCCARV","C-Cardiovascular system","MTMOPPMT","Million US$, purchasing power parity","ESP","Spain","2021","2021",3904.3,,
+"PATCCARV","C-Cardiovascular system","MTMOPPMT","Million US$, purchasing power parity","ESP","Spain","2022","2022",4260.3,"P","Provisional value"
+"PATCCARV","C-Cardiovascular system","TCPPERMT","/capita, US$ exchange rate","ESP","Spain","2010","2010",87.6,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","TCPPERMT","/capita, US$ exchange rate","ESP","Spain","2011","2011",77.2,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","TCPPERMT","/capita, US$ exchange rate","ESP","Spain","2012","2012",60.7,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","TCPPERMT","/capita, US$ exchange rate","ESP","Spain","2013","2013",59.2,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","TCPPERMT","/capita, US$ exchange rate","ESP","Spain","2014","2014",61.2,"B; D","Break; Difference in methodology"
+"PATCCARV","C-Cardiovascular system","TCPPERMT","/capita, US$ exchange rate","ESP","Spain","2015","2015",51.4,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","TCPPERMT","/capita, US$ exchange rate","ESP","Spain","2016","2016",53.2,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","TCPPERMT","/capita, US$ exchange rate","ESP","Spain","2017","2017",53.4,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","TCPPERMT","/capita, US$ exchange rate","ESP","Spain","2018","2018",58,"B","Break"
+"PATCCARV","C-Cardiovascular system","TCPPERMT","/capita, US$ exchange rate","ESP","Spain","2019","2019",56.1,,
+"PATCCARV","C-Cardiovascular system","TCPPERMT","/capita, US$ exchange rate","ESP","Spain","2020","2020",58.8,,
+"PATCCARV","C-Cardiovascular system","TCPPERMT","/capita, US$ exchange rate","ESP","Spain","2021","2021",61,,
+"PATCCARV","C-Cardiovascular system","TCPPERMT","/capita, US$ exchange rate","ESP","Spain","2022","2022",56.4,"P","Provisional value"
+"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2010","2010",90.9,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2011","2011",77.6,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2012","2012",68,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2013","2013",66.1,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2014","2014",69.5,"B; D","Break; Difference in methodology"
+"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2015","2015",69.7,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2016","2016",74.8,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2017","2017",74.9,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2018","2018",77.8,"B","Break"
+"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2019","2019",81.8,,
+"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2020","2020",82.9,,
+"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2021","2021",82.3,,
+"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2022","2022",89.8,"P","Provisional value"
+"PATCCARV","C-Cardiovascular system","ATCPTTMT","% of total sales","ESP","Spain","2010","2010",23.2,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","ATCPTTMT","% of total sales","ESP","Spain","2011","2011",21,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","ATCPTTMT","% of total sales","ESP","Spain","2012","2012",20,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","ATCPTTMT","% of total sales","ESP","Spain","2013","2013",19.5,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","ATCPTTMT","% of total sales","ESP","Spain","2014","2014",18.9,"B; D","Break; Difference in methodology"
+"PATCCARV","C-Cardiovascular system","ATCPTTMT","% of total sales","ESP","Spain","2015","2015",18.9,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","ATCPTTMT","% of total sales","ESP","Spain","2016","2016",18.9,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","ATCPTTMT","% of total sales","ESP","Spain","2017","2017",18.3,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","ATCPTTMT","% of total sales","ESP","Spain","2018","2018",12.1,"B","Break"
+"PATCCARV","C-Cardiovascular system","ATCPTTMT","% of total sales","ESP","Spain","2019","2019",11.8,,
+"PATCCARV","C-Cardiovascular system","ATCPTTMT","% of total sales","ESP","Spain","2020","2020",11.7,,
+"PATCCARV","C-Cardiovascular system","ATCPTTMT","% of total sales","ESP","Spain","2021","2021",11.1,,
+"PATCCARV","C-Cardiovascular system","ATCPTTMT","% of total sales","ESP","Spain","2022","2022",11.1,"P","Provisional value"
+"PATCCARV","C-Cardiovascular system","MLLNCUMT","Million of national currency units","SWE","Sweden","2010","2010",3118.3,,
+"PATCCARV","C-Cardiovascular system","MLLNCUMT","Million of national currency units","SWE","Sweden","2011","2011",3035.7,,
+"PATCCARV","C-Cardiovascular system","MLLNCUMT","Million of national currency units","SWE","Sweden","2012","2012",2543.6,,
+"PATCCARV","C-Cardiovascular system","MLLNCUMT","Million of national currency units","SWE","Sweden","2013","2013",2295.4,,
+"PATCCARV","C-Cardiovascular system","MLLNCUMT","Million of national currency units","SWE","Sweden","2014","2014",2338.4,,
+"PATCCARV","C-Cardiovascular system","MLLNCUMT","Million of national currency units","SWE","Sweden","2015","2015",2404.2,,
+"PATCCARV","C-Cardiovascular system","MLLNCUMT","Million of national currency units","SWE","Sweden","2016","2016",2398.2,,
+"PATCCARV","C-Cardiovascular system","MLLNCUMT","Million of national currency units","SWE","Sweden","2017","2017",2515.4,,
+"PATCCARV","C-Cardiovascular system","MLLNCUMT","Million of national currency units","SWE","Sweden","2018","2018",2545.8,,
+"PATCCARV","C-Cardiovascular system","MLLNCUMT","Million of national currency units","SWE","Sweden","2019","2019",2802.5,,
+"PATCCARV","C-Cardiovascular system","MLLNCUMT","Million of national currency units","SWE","Sweden","2020","2020",3029.7,,
+"PATCCARV","C-Cardiovascular system","MLLNCUMT","Million of national currency units","SWE","Sweden","2021","2021",2993.1,,
+"PATCCARV","C-Cardiovascular system","MLLNCUMT","Million of national currency units","SWE","Sweden","2022","2022",3235.8,,
+"PATCCARV","C-Cardiovascular system","MTMOTCMT","Million US$ at exchange rate","SWE","Sweden","2010","2010",432.6,,
+"PATCCARV","C-Cardiovascular system","MTMOTCMT","Million US$ at exchange rate","SWE","Sweden","2011","2011",467.5,,
+"PATCCARV","C-Cardiovascular system","MTMOTCMT","Million US$ at exchange rate","SWE","Sweden","2012","2012",375.4,,
+"PATCCARV","C-Cardiovascular system","MTMOTCMT","Million US$ at exchange rate","SWE","Sweden","2013","2013",352.4,,
+"PATCCARV","C-Cardiovascular system","MTMOTCMT","Million US$ at exchange rate","SWE","Sweden","2014","2014",340.8,,
+"PATCCARV","C-Cardiovascular system","MTMOTCMT","Million US$ at exchange rate","SWE","Sweden","2015","2015",285,,
+"PATCCARV","C-Cardiovascular system","MTMOTCMT","Million US$ at exchange rate","SWE","Sweden","2016","2016",280.1,,
+"PATCCARV","C-Cardiovascular system","MTMOTCMT","Million US$ at exchange rate","SWE","Sweden","2017","2017",294.2,,
+"PATCCARV","C-Cardiovascular system","MTMOTCMT","Million US$ at exchange rate","SWE","Sweden","2018","2018",292.9,,
+"PATCCARV","C-Cardiovascular system","MTMOTCMT","Million US$ at exchange rate","SWE","Sweden","2019","2019",296.3,,
+"PATCCARV","C-Cardiovascular system","MTMOTCMT","Million US$ at exchange rate","SWE","Sweden","2020","2020",328.9,,
+"PATCCARV","C-Cardiovascular system","MTMOTCMT","Million US$ at exchange rate","SWE","Sweden","2021","2021",349,,
+"PATCCARV","C-Cardiovascular system","MTMOTCMT","Million US$ at exchange rate","SWE","Sweden","2022","2022",319.9,,
+"PATCCARV","C-Cardiovascular system","MTMOPPMT","Million US$, purchasing power parity","SWE","Sweden","2010","2010",345.5,,
+"PATCCARV","C-Cardiovascular system","MTMOPPMT","Million US$, purchasing power parity","SWE","Sweden","2011","2011",343.3,,
+"PATCCARV","C-Cardiovascular system","MTMOPPMT","Million US$, purchasing power parity","SWE","Sweden","2012","2012",293.9,,
+"PATCCARV","C-Cardiovascular system","MTMOPPMT","Million US$, purchasing power parity","SWE","Sweden","2013","2013",267,,
+"PATCCARV","C-Cardiovascular system","MTMOPPMT","Million US$, purchasing power parity","SWE","Sweden","2014","2014",267.9,,
+"PATCCARV","C-Cardiovascular system","MTMOPPMT","Million US$, purchasing power parity","SWE","Sweden","2015","2015",271.5,,
+"PATCCARV","C-Cardiovascular system","MTMOPPMT","Million US$, purchasing power parity","SWE","Sweden","2016","2016",271.8,,
+"PATCCARV","C-Cardiovascular system","MTMOPPMT","Million US$, purchasing power parity","SWE","Sweden","2017","2017",284.2,,
+"PATCCARV","C-Cardiovascular system","MTMOPPMT","Million US$, purchasing power parity","SWE","Sweden","2018","2018",287.1,,
+"PATCCARV","C-Cardiovascular system","MTMOPPMT","Million US$, purchasing power parity","SWE","Sweden","2019","2019",321.8,,
+"PATCCARV","C-Cardiovascular system","MTMOPPMT","Million US$, purchasing power parity","SWE","Sweden","2020","2020",349.5,,
+"PATCCARV","C-Cardiovascular system","MTMOPPMT","Million US$, purchasing power parity","SWE","Sweden","2021","2021",343.2,,
+"PATCCARV","C-Cardiovascular system","MTMOPPMT","Million US$, purchasing power parity","SWE","Sweden","2022","2022",373.4,,
+"PATCCARV","C-Cardiovascular system","TCPPERMT","/capita, US$ exchange rate","SWE","Sweden","2010","2010",46.1,,
+"PATCCARV","C-Cardiovascular system","TCPPERMT","/capita, US$ exchange rate","SWE","Sweden","2011","2011",49.5,,
+"PATCCARV","C-Cardiovascular system","TCPPERMT","/capita, US$ exchange rate","SWE","Sweden","2012","2012",39.4,,
+"PATCCARV","C-Cardiovascular system","TCPPERMT","/capita, US$ exchange rate","SWE","Sweden","2013","2013",36.7,,
+"PATCCARV","C-Cardiovascular system","TCPPERMT","/capita, US$ exchange rate","SWE","Sweden","2014","2014",35.2,,
+"PATCCARV","C-Cardiovascular system","TCPPERMT","/capita, US$ exchange rate","SWE","Sweden","2015","2015",29.1,,
+"PATCCARV","C-Cardiovascular system","TCPPERMT","/capita, US$ exchange rate","SWE","Sweden","2016","2016",28.2,,
+"PATCCARV","C-Cardiovascular system","TCPPERMT","/capita, US$ exchange rate","SWE","Sweden","2017","2017",29.3,,
+"PATCCARV","C-Cardiovascular system","TCPPERMT","/capita, US$ exchange rate","SWE","Sweden","2018","2018",28.8,,
+"PATCCARV","C-Cardiovascular system","TCPPERMT","/capita, US$ exchange rate","SWE","Sweden","2019","2019",28.8,,
+"PATCCARV","C-Cardiovascular system","TCPPERMT","/capita, US$ exchange rate","SWE","Sweden","2020","2020",31.8,,
+"PATCCARV","C-Cardiovascular system","TCPPERMT","/capita, US$ exchange rate","SWE","Sweden","2021","2021",33.5,,
+"PATCCARV","C-Cardiovascular system","TCPPERMT","/capita, US$ exchange rate","SWE","Sweden","2022","2022",30.6,,
+"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2010","2010",36.8,,
+"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2011","2011",36.3,,
+"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2012","2012",30.9,,
+"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2013","2013",27.8,,
+"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2014","2014",27.6,,
+"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2015","2015",27.7,,
+"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2016","2016",27.4,,
+"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2017","2017",28.3,,
+"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2018","2018",28.2,,
+"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2019","2019",31.3,,
+"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2020","2020",33.8,,
+"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2021","2021",32.9,,
+"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2022","2022",35.7,,
+"PATCCARV","C-Cardiovascular system","ATCPTTMT","% of total sales","SWE","Sweden","2010","2010",8.6,,
+"PATCCARV","C-Cardiovascular system","ATCPTTMT","% of total sales","SWE","Sweden","2011","2011",8.3,,
+"PATCCARV","C-Cardiovascular system","ATCPTTMT","% of total sales","SWE","Sweden","2012","2012",7,,
+"PATCCARV","C-Cardiovascular system","ATCPTTMT","% of total sales","SWE","Sweden","2013","2013",6.3,,
+"PATCCARV","C-Cardiovascular system","ATCPTTMT","% of total sales","SWE","Sweden","2014","2014",6.2,,
+"PATCCARV","C-Cardiovascular system","ATCPTTMT","% of total sales","SWE","Sweden","2015","2015",5.9,,
+"PATCCARV","C-Cardiovascular system","ATCPTTMT","% of total sales","SWE","Sweden","2016","2016",5.7,,
+"PATCCARV","C-Cardiovascular system","ATCPTTMT","% of total sales","SWE","Sweden","2017","2017",5.8,,
+"PATCCARV","C-Cardiovascular system","ATCPTTMT","% of total sales","SWE","Sweden","2018","2018",5.3,,
+"PATCCARV","C-Cardiovascular system","ATCPTTMT","% of total sales","SWE","Sweden","2019","2019",5.5,,
+"PATCCARV","C-Cardiovascular system","ATCPTTMT","% of total sales","SWE","Sweden","2020","2020",5.8,,
+"PATCCARV","C-Cardiovascular system","ATCPTTMT","% of total sales","SWE","Sweden","2021","2021",5.6,,
+"PATCCARV","C-Cardiovascular system","ATCPTTMT","% of total sales","SWE","Sweden","2022","2022",5.6,,
+"PATCCARV","C-Cardiovascular system","MLLNCUMT","Million of national currency units","CHE","Switzerland","2010","2010",946.1,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","MLLNCUMT","Million of national currency units","CHE","Switzerland","2011","2011",929,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","MLLNCUMT","Million of national currency units","CHE","Switzerland","2012","2012",876,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","MLLNCUMT","Million of national currency units","CHE","Switzerland","2013","2013",791,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","MLLNCUMT","Million of national currency units","CHE","Switzerland","2014","2014",770,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","MLLNCUMT","Million of national currency units","CHE","Switzerland","2015","2015",777,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","MLLNCUMT","Million of national currency units","CHE","Switzerland","2016","2016",799,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","MLLNCUMT","Million of national currency units","CHE","Switzerland","2017","2017",792,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","MLLNCUMT","Million of national currency units","CHE","Switzerland","2018","2018",774,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","MLLNCUMT","Million of national currency units","CHE","Switzerland","2019","2019",797,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","MLLNCUMT","Million of national currency units","CHE","Switzerland","2020","2020",797,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","MLLNCUMT","Million of national currency units","CHE","Switzerland","2021","2021",865,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","MLLNCUMT","Million of national currency units","CHE","Switzerland","2022","2022",900,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","MTMOTCMT","Million US$ at exchange rate","CHE","Switzerland","2010","2010",907.2,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","MTMOTCMT","Million US$ at exchange rate","CHE","Switzerland","2011","2011",1046.1,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","MTMOTCMT","Million US$ at exchange rate","CHE","Switzerland","2012","2012",934.2,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","MTMOTCMT","Million US$ at exchange rate","CHE","Switzerland","2013","2013",853.4,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","MTMOTCMT","Million US$ at exchange rate","CHE","Switzerland","2014","2014",840.5,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","MTMOTCMT","Million US$ at exchange rate","CHE","Switzerland","2015","2015",807.4,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","MTMOTCMT","Million US$ at exchange rate","CHE","Switzerland","2016","2016",810.8,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","MTMOTCMT","Million US$ at exchange rate","CHE","Switzerland","2017","2017",804.3,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","MTMOTCMT","Million US$ at exchange rate","CHE","Switzerland","2018","2018",791.5,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","MTMOTCMT","Million US$ at exchange rate","CHE","Switzerland","2019","2019",802,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","MTMOTCMT","Million US$ at exchange rate","CHE","Switzerland","2020","2020",848.8,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","MTMOTCMT","Million US$ at exchange rate","CHE","Switzerland","2021","2021",946.5,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","MTMOTCMT","Million US$ at exchange rate","CHE","Switzerland","2022","2022",942.6,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","MTMOPPMT","Million US$, purchasing power parity","CHE","Switzerland","2010","2010",645.3,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","MTMOPPMT","Million US$, purchasing power parity","CHE","Switzerland","2011","2011",664.8,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","MTMOPPMT","Million US$, purchasing power parity","CHE","Switzerland","2012","2012",646.9,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","MTMOPPMT","Million US$, purchasing power parity","CHE","Switzerland","2013","2013",602.7,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","MTMOPPMT","Million US$, purchasing power parity","CHE","Switzerland","2014","2014",600.7,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","MTMOPPMT","Million US$, purchasing power parity","CHE","Switzerland","2015","2015",628.7,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","MTMOPPMT","Million US$, purchasing power parity","CHE","Switzerland","2016","2016",664.7,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","MTMOPPMT","Million US$, purchasing power parity","CHE","Switzerland","2017","2017",666.8,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","MTMOPPMT","Million US$, purchasing power parity","CHE","Switzerland","2018","2018",656.6,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","MTMOPPMT","Million US$, purchasing power parity","CHE","Switzerland","2019","2019",692.8,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","MTMOPPMT","Million US$, purchasing power parity","CHE","Switzerland","2020","2020",701.8,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","MTMOPPMT","Million US$, purchasing power parity","CHE","Switzerland","2021","2021",781.8,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","MTMOPPMT","Million US$, purchasing power parity","CHE","Switzerland","2022","2022",844.3,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","TCPPERMT","/capita, US$ exchange rate","CHE","Switzerland","2010","2010",115.9,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","TCPPERMT","/capita, US$ exchange rate","CHE","Switzerland","2011","2011",132.2,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","TCPPERMT","/capita, US$ exchange rate","CHE","Switzerland","2012","2012",116.8,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","TCPPERMT","/capita, US$ exchange rate","CHE","Switzerland","2013","2013",105.5,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","TCPPERMT","/capita, US$ exchange rate","CHE","Switzerland","2014","2014",102.6,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","TCPPERMT","/capita, US$ exchange rate","CHE","Switzerland","2015","2015",97.5,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","TCPPERMT","/capita, US$ exchange rate","CHE","Switzerland","2016","2016",96.8,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","TCPPERMT","/capita, US$ exchange rate","CHE","Switzerland","2017","2017",95.2,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","TCPPERMT","/capita, US$ exchange rate","CHE","Switzerland","2018","2018",93,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","TCPPERMT","/capita, US$ exchange rate","CHE","Switzerland","2019","2019",93.5,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","TCPPERMT","/capita, US$ exchange rate","CHE","Switzerland","2020","2020",98.3,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","TCPPERMT","/capita, US$ exchange rate","CHE","Switzerland","2021","2021",108.7,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","TCPPERMT","/capita, US$ exchange rate","CHE","Switzerland","2022","2022",107.9,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","CHE","Switzerland","2010","2010",82.5,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","CHE","Switzerland","2011","2011",84,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","CHE","Switzerland","2012","2012",80.9,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","CHE","Switzerland","2013","2013",74.5,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","CHE","Switzerland","2014","2014",73.4,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","CHE","Switzerland","2015","2015",75.9,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","CHE","Switzerland","2016","2016",79.4,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","CHE","Switzerland","2017","2017",78.9,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","CHE","Switzerland","2018","2018",77.1,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","CHE","Switzerland","2019","2019",80.8,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","CHE","Switzerland","2020","2020",81.2,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","CHE","Switzerland","2021","2021",89.8,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","CHE","Switzerland","2022","2022",96.6,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","ATCPTTMT","% of total sales","CHE","Switzerland","2010","2010",16.5,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","ATCPTTMT","% of total sales","CHE","Switzerland","2011","2011",16.1,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","ATCPTTMT","% of total sales","CHE","Switzerland","2012","2012",14.8,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","ATCPTTMT","% of total sales","CHE","Switzerland","2013","2013",13.3,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","ATCPTTMT","% of total sales","CHE","Switzerland","2014","2014",13,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","ATCPTTMT","% of total sales","CHE","Switzerland","2015","2015",12.6,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","ATCPTTMT","% of total sales","CHE","Switzerland","2016","2016",12.5,"B; D","Break; Difference in methodology"
+"PATCCARV","C-Cardiovascular system","ATCPTTMT","% of total sales","CHE","Switzerland","2017","2017",12.1,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","ATCPTTMT","% of total sales","CHE","Switzerland","2018","2018",11.7,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","ATCPTTMT","% of total sales","CHE","Switzerland","2019","2019",11.9,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","ATCPTTMT","% of total sales","CHE","Switzerland","2020","2020",11.7,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","ATCPTTMT","% of total sales","CHE","Switzerland","2021","2021",12.2,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","ATCPTTMT","% of total sales","CHE","Switzerland","2022","2022",11.8,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","MLLNCUMT","Million of national currency units","TUR","Türkiye","2010","2010",1834.5,,
+"PATCCARV","C-Cardiovascular system","MLLNCUMT","Million of national currency units","TUR","Türkiye","2011","2011",1624.3,,
+"PATCCARV","C-Cardiovascular system","MLLNCUMT","Million of national currency units","TUR","Türkiye","2012","2012",1396.8,,
+"PATCCARV","C-Cardiovascular system","MLLNCUMT","Million of national currency units","TUR","Türkiye","2013","2013",1389.4,,
+"PATCCARV","C-Cardiovascular system","MLLNCUMT","Million of national currency units","TUR","Türkiye","2014","2014",1434.6,,
+"PATCCARV","C-Cardiovascular system","MLLNCUMT","Million of national currency units","TUR","Türkiye","2015","2015",1541.6,,
+"PATCCARV","C-Cardiovascular system","MLLNCUMT","Million of national currency units","TUR","Türkiye","2016","2016",1743.9,,
+"PATCCARV","C-Cardiovascular system","MLLNCUMT","Million of national currency units","TUR","Türkiye","2017","2017",2133.4,,
+"PATCCARV","C-Cardiovascular system","MLLNCUMT","Million of national currency units","TUR","Türkiye","2018","2018",2609,,
+"PATCCARV","C-Cardiovascular system","MLLNCUMT","Million of national currency units","TUR","Türkiye","2019","2019",3441.1,,
+"PATCCARV","C-Cardiovascular system","MLLNCUMT","Million of national currency units","TUR","Türkiye","2020","2020",4375.4,,
+"PATCCARV","C-Cardiovascular system","MLLNCUMT","Million of national currency units","TUR","Türkiye","2021","2021",5358,,
+"PATCCARV","C-Cardiovascular system","MTMOTCMT","Million US$ at exchange rate","TUR","Türkiye","2010","2010",1220.7,,
+"PATCCARV","C-Cardiovascular system","MTMOTCMT","Million US$ at exchange rate","TUR","Türkiye","2011","2011",969.7,,
+"PATCCARV","C-Cardiovascular system","MTMOTCMT","Million US$ at exchange rate","TUR","Türkiye","2012","2012",777.7,,
+"PATCCARV","C-Cardiovascular system","MTMOTCMT","Million US$ at exchange rate","TUR","Türkiye","2013","2013",729.8,,
+"PATCCARV","C-Cardiovascular system","MTMOTCMT","Million US$ at exchange rate","TUR","Türkiye","2014","2014",655.5,,
+"PATCCARV","C-Cardiovascular system","MTMOTCMT","Million US$ at exchange rate","TUR","Türkiye","2015","2015",566.7,,
+"PATCCARV","C-Cardiovascular system","MTMOTCMT","Million US$ at exchange rate","TUR","Türkiye","2016","2016",577.4,,
+"PATCCARV","C-Cardiovascular system","MTMOTCMT","Million US$ at exchange rate","TUR","Türkiye","2017","2017",584.8,,
+"PATCCARV","C-Cardiovascular system","MTMOTCMT","Million US$ at exchange rate","TUR","Türkiye","2018","2018",540.3,,
+"PATCCARV","C-Cardiovascular system","MTMOTCMT","Million US$ at exchange rate","TUR","Türkiye","2019","2019",606.5,,
+"PATCCARV","C-Cardiovascular system","MTMOTCMT","Million US$ at exchange rate","TUR","Türkiye","2020","2020",624.3,,
+"PATCCARV","C-Cardiovascular system","MTMOTCMT","Million US$ at exchange rate","TUR","Türkiye","2021","2021",605.4,,
+"PATCCARV","C-Cardiovascular system","MTMOPPMT","Million US$, purchasing power parity","TUR","Türkiye","2010","2010",1993.3,,
+"PATCCARV","C-Cardiovascular system","MTMOPPMT","Million US$, purchasing power parity","TUR","Türkiye","2011","2011",1681.1,,
+"PATCCARV","C-Cardiovascular system","MTMOPPMT","Million US$, purchasing power parity","TUR","Türkiye","2012","2012",1369.6,,
+"PATCCARV","C-Cardiovascular system","MTMOPPMT","Million US$, purchasing power parity","TUR","Türkiye","2013","2013",1298.1,,
+"PATCCARV","C-Cardiovascular system","MTMOPPMT","Million US$, purchasing power parity","TUR","Türkiye","2014","2014",1298.8,,
+"PATCCARV","C-Cardiovascular system","MTMOPPMT","Million US$, purchasing power parity","TUR","Türkiye","2015","2015",1326.1,,
+"PATCCARV","C-Cardiovascular system","MTMOPPMT","Million US$, purchasing power parity","TUR","Türkiye","2016","2016",1405.2,,
+"PATCCARV","C-Cardiovascular system","MTMOPPMT","Million US$, purchasing power parity","TUR","Türkiye","2017","2017",1541.5,,
+"PATCCARV","C-Cardiovascular system","MTMOPPMT","Million US$, purchasing power parity","TUR","Türkiye","2018","2018",1598.1,,
+"PATCCARV","C-Cardiovascular system","MTMOPPMT","Million US$, purchasing power parity","TUR","Türkiye","2019","2019",1846.1,,
+"PATCCARV","C-Cardiovascular system","MTMOPPMT","Million US$, purchasing power parity","TUR","Türkiye","2020","2020",2021.7,,
+"PATCCARV","C-Cardiovascular system","MTMOPPMT","Million US$, purchasing power parity","TUR","Türkiye","2021","2021",1908.2,,
+"PATCCARV","C-Cardiovascular system","TCPPERMT","/capita, US$ exchange rate","TUR","Türkiye","2010","2010",16.7,,
+"PATCCARV","C-Cardiovascular system","TCPPERMT","/capita, US$ exchange rate","TUR","Türkiye","2011","2011",13.1,,
+"PATCCARV","C-Cardiovascular system","TCPPERMT","/capita, US$ exchange rate","TUR","Türkiye","2012","2012",10.3,,
+"PATCCARV","C-Cardiovascular system","TCPPERMT","/capita, US$ exchange rate","TUR","Türkiye","2013","2013",9.6,,
+"PATCCARV","C-Cardiovascular system","TCPPERMT","/capita, US$ exchange rate","TUR","Türkiye","2014","2014",8.5,,
+"PATCCARV","C-Cardiovascular system","TCPPERMT","/capita, US$ exchange rate","TUR","Türkiye","2015","2015",7.2,,
+"PATCCARV","C-Cardiovascular system","TCPPERMT","/capita, US$ exchange rate","TUR","Türkiye","2016","2016",7.3,,
+"PATCCARV","C-Cardiovascular system","TCPPERMT","/capita, US$ exchange rate","TUR","Türkiye","2017","2017",7.3,,
+"PATCCARV","C-Cardiovascular system","TCPPERMT","/capita, US$ exchange rate","TUR","Türkiye","2018","2018",6.6,,
+"PATCCARV","C-Cardiovascular system","TCPPERMT","/capita, US$ exchange rate","TUR","Türkiye","2019","2019",7.3,,
+"PATCCARV","C-Cardiovascular system","TCPPERMT","/capita, US$ exchange rate","TUR","Türkiye","2020","2020",7.5,,
+"PATCCARV","C-Cardiovascular system","TCPPERMT","/capita, US$ exchange rate","TUR","Türkiye","2021","2021",7.2,,
+"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2010","2010",27.3,,
+"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2011","2011",22.6,,
+"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2012","2012",18.2,,
+"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2013","2013",17,,
+"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2014","2014",16.8,,
+"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2015","2015",17,,
+"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2016","2016",17.7,,
+"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2017","2017",19.2,,
+"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2018","2018",19.6,,
+"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2019","2019",22.4,,
+"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2020","2020",24.2,,
+"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2021","2021",22.7,,
+"PATCCARV","C-Cardiovascular system","ATCPTTMT","% of total sales","TUR","Türkiye","2010","2010",11.8,,
+"PATCCARV","C-Cardiovascular system","ATCPTTMT","% of total sales","TUR","Türkiye","2011","2011",11.5,,
+"PATCCARV","C-Cardiovascular system","ATCPTTMT","% of total sales","TUR","Türkiye","2012","2012",10.3,,
+"PATCCARV","C-Cardiovascular system","ATCPTTMT","% of total sales","TUR","Türkiye","2013","2013",9.7,,
+"PATCCARV","C-Cardiovascular system","ATCPTTMT","% of total sales","TUR","Türkiye","2014","2014",9.1,,
+"PATCCARV","C-Cardiovascular system","ATCPTTMT","% of total sales","TUR","Türkiye","2015","2015",8.4,,
+"PATCCARV","C-Cardiovascular system","ATCPTTMT","% of total sales","TUR","Türkiye","2016","2016",8,,
+"PATCCARV","C-Cardiovascular system","ATCPTTMT","% of total sales","TUR","Türkiye","2017","2017",8.4,,
+"PATCCARV","C-Cardiovascular system","ATCPTTMT","% of total sales","TUR","Türkiye","2018","2018",8.1,,
+"PATCCARV","C-Cardiovascular system","ATCPTTMT","% of total sales","TUR","Türkiye","2019","2019",8.2,,
+"PATCCARV","C-Cardiovascular system","ATCPTTMT","% of total sales","TUR","Türkiye","2020","2020",8.8,,
+"PATCCARV","C-Cardiovascular system","ATCPTTMT","% of total sales","TUR","Türkiye","2021","2021",8.3,,
+"PATCCARV","C-Cardiovascular system","MLLNCUMT","Million of national currency units","GBR","United Kingdom","2012","2012",1332.3,"B","Break"
+"PATCCARV","C-Cardiovascular system","MLLNCUMT","Million of national currency units","GBR","United Kingdom","2013","2013",1156.4,,
+"PATCCARV","C-Cardiovascular system","MLLNCUMT","Million of national currency units","GBR","United Kingdom","2014","2014",1186.8,,
+"PATCCARV","C-Cardiovascular system","MLLNCUMT","Million of national currency units","GBR","United Kingdom","2015","2015",1267.8,,
+"PATCCARV","C-Cardiovascular system","MLLNCUMT","Million of national currency units","GBR","United Kingdom","2016","2016",1280.2,,
+"PATCCARV","C-Cardiovascular system","MLLNCUMT","Million of national currency units","GBR","United Kingdom","2017","2017",1301,,
+"PATCCARV","C-Cardiovascular system","MLLNCUMT","Million of national currency units","GBR","United Kingdom","2018","2018",1287.2,,
+"PATCCARV","C-Cardiovascular system","MTMOTCMT","Million US$ at exchange rate","GBR","United Kingdom","2012","2012",2104.6,"B","Break"
+"PATCCARV","C-Cardiovascular system","MTMOTCMT","Million US$ at exchange rate","GBR","United Kingdom","2013","2013",1807.8,,
+"PATCCARV","C-Cardiovascular system","MTMOTCMT","Million US$ at exchange rate","GBR","United Kingdom","2014","2014",1952.8,,
+"PATCCARV","C-Cardiovascular system","MTMOTCMT","Million US$ at exchange rate","GBR","United Kingdom","2015","2015",1936.9,,
+"PATCCARV","C-Cardiovascular system","MTMOTCMT","Million US$ at exchange rate","GBR","United Kingdom","2016","2016",1728.5,,
+"PATCCARV","C-Cardiovascular system","MTMOTCMT","Million US$ at exchange rate","GBR","United Kingdom","2017","2017",1674.4,,
+"PATCCARV","C-Cardiovascular system","MTMOTCMT","Million US$ at exchange rate","GBR","United Kingdom","2018","2018",1717.3,,
+"PATCCARV","C-Cardiovascular system","MTMOPPMT","Million US$, purchasing power parity","GBR","United Kingdom","2012","2012",1898.9,"B","Break"
+"PATCCARV","C-Cardiovascular system","MTMOPPMT","Million US$, purchasing power parity","GBR","United Kingdom","2013","2013",1663.3,,
+"PATCCARV","C-Cardiovascular system","MTMOPPMT","Million US$, purchasing power parity","GBR","United Kingdom","2014","2014",1699.2,,
+"PATCCARV","C-Cardiovascular system","MTMOPPMT","Million US$, purchasing power parity","GBR","United Kingdom","2015","2015",1830.6,,
+"PATCCARV","C-Cardiovascular system","MTMOPPMT","Million US$, purchasing power parity","GBR","United Kingdom","2016","2016",1859.1,,
+"PATCCARV","C-Cardiovascular system","MTMOPPMT","Million US$, purchasing power parity","GBR","United Kingdom","2017","2017",1900.4,,
+"PATCCARV","C-Cardiovascular system","MTMOPPMT","Million US$, purchasing power parity","GBR","United Kingdom","2018","2018",1871.7,,
+"PATCCARV","C-Cardiovascular system","TCPPERMT","/capita, US$ exchange rate","GBR","United Kingdom","2012","2012",33,"B","Break"
+"PATCCARV","C-Cardiovascular system","TCPPERMT","/capita, US$ exchange rate","GBR","United Kingdom","2013","2013",28.2,,
+"PATCCARV","C-Cardiovascular system","TCPPERMT","/capita, US$ exchange rate","GBR","United Kingdom","2014","2014",30.2,,
+"PATCCARV","C-Cardiovascular system","TCPPERMT","/capita, US$ exchange rate","GBR","United Kingdom","2015","2015",29.7,,
+"PATCCARV","C-Cardiovascular system","TCPPERMT","/capita, US$ exchange rate","GBR","United Kingdom","2016","2016",26.3,,
+"PATCCARV","C-Cardiovascular system","TCPPERMT","/capita, US$ exchange rate","GBR","United Kingdom","2017","2017",25.4,,
+"PATCCARV","C-Cardiovascular system","TCPPERMT","/capita, US$ exchange rate","GBR","United Kingdom","2018","2018",25.8,,
+"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","GBR","United Kingdom","2012","2012",29.8,"B","Break"
+"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","GBR","United Kingdom","2013","2013",25.9,,
+"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","GBR","United Kingdom","2014","2014",26.3,,
+"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","GBR","United Kingdom","2015","2015",28.1,,
+"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","GBR","United Kingdom","2016","2016",28.3,,
+"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","GBR","United Kingdom","2017","2017",28.8,,
+"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","GBR","United Kingdom","2018","2018",28.2,,
+"PATCCARV","C-Cardiovascular system","ATCPTTMT","% of total sales","GBR","United Kingdom","2012","2012",9.7,"B","Break"
+"PATCCARV","C-Cardiovascular system","ATCPTTMT","% of total sales","GBR","United Kingdom","2013","2013",7.9,,
+"PATCCARV","C-Cardiovascular system","ATCPTTMT","% of total sales","GBR","United Kingdom","2014","2014",7.4,,
+"PATCCARV","C-Cardiovascular system","ATCPTTMT","% of total sales","GBR","United Kingdom","2015","2015",7.2,,
+"PATCCARV","C-Cardiovascular system","ATCPTTMT","% of total sales","GBR","United Kingdom","2016","2016",6.9,,
+"PATCCARV","C-Cardiovascular system","ATCPTTMT","% of total sales","GBR","United Kingdom","2017","2017",6.7,,
+"PATCCARV","C-Cardiovascular system","ATCPTTMT","% of total sales","GBR","United Kingdom","2018","2018",6.3,,
+"PATCCARV","C-Cardiovascular system","MLLNCUMT","Million of national currency units","CHL","Chile","2010","2010",74875.9,,
+"PATCCARV","C-Cardiovascular system","MLLNCUMT","Million of national currency units","CHL","Chile","2011","2011",91532.1,"B","Break"
+"PATCCARV","C-Cardiovascular system","MLLNCUMT","Million of national currency units","CHL","Chile","2012","2012",100837.7,,
+"PATCCARV","C-Cardiovascular system","MLLNCUMT","Million of national currency units","CHL","Chile","2013","2013",105559,,
+"PATCCARV","C-Cardiovascular system","MLLNCUMT","Million of national currency units","CHL","Chile","2014","2014",124399.3,,
+"PATCCARV","C-Cardiovascular system","MLLNCUMT","Million of national currency units","CHL","Chile","2015","2015",138496.2,,
+"PATCCARV","C-Cardiovascular system","MLLNCUMT","Million of national currency units","CHL","Chile","2016","2016",152031.5,,
+"PATCCARV","C-Cardiovascular system","MLLNCUMT","Million of national currency units","CHL","Chile","2017","2017",146723.5,,
+"PATCCARV","C-Cardiovascular system","MLLNCUMT","Million of national currency units","CHL","Chile","2018","2018",154799.9,,
+"PATCCARV","C-Cardiovascular system","MLLNCUMT","Million of national currency units","CHL","Chile","2019","2019",184317.7,,
+"PATCCARV","C-Cardiovascular system","MLLNCUMT","Million of national currency units","CHL","Chile","2020","2020",193006.7,,
+"PATCCARV","C-Cardiovascular system","MLLNCUMT","Million of national currency units","CHL","Chile","2021","2021",179534.6,,
+"PATCCARV","C-Cardiovascular system","MLLNCUMT","Million of national currency units","CHL","Chile","2022","2022",213450.7,,
+"PATCCARV","C-Cardiovascular system","MTMOTCMT","Million US$ at exchange rate","CHL","Chile","2010","2010",146.7,,
+"PATCCARV","C-Cardiovascular system","MTMOTCMT","Million US$ at exchange rate","CHL","Chile","2011","2011",189.2,"B","Break"
+"PATCCARV","C-Cardiovascular system","MTMOTCMT","Million US$ at exchange rate","CHL","Chile","2012","2012",207.3,,
+"PATCCARV","C-Cardiovascular system","MTMOTCMT","Million US$ at exchange rate","CHL","Chile","2013","2013",213.1,,
+"PATCCARV","C-Cardiovascular system","MTMOTCMT","Million US$ at exchange rate","CHL","Chile","2014","2014",218.1,,
+"PATCCARV","C-Cardiovascular system","MTMOTCMT","Million US$ at exchange rate","CHL","Chile","2015","2015",211.7,,
+"PATCCARV","C-Cardiovascular system","MTMOTCMT","Million US$ at exchange rate","CHL","Chile","2016","2016",224.6,,
+"PATCCARV","C-Cardiovascular system","MTMOTCMT","Million US$ at exchange rate","CHL","Chile","2017","2017",226.1,,
+"PATCCARV","C-Cardiovascular system","MTMOTCMT","Million US$ at exchange rate","CHL","Chile","2018","2018",241.4,,
+"PATCCARV","C-Cardiovascular system","MTMOTCMT","Million US$ at exchange rate","CHL","Chile","2019","2019",262.2,,
+"PATCCARV","C-Cardiovascular system","MTMOTCMT","Million US$ at exchange rate","CHL","Chile","2020","2020",243.5,,
+"PATCCARV","C-Cardiovascular system","MTMOTCMT","Million US$ at exchange rate","CHL","Chile","2021","2021",236.6,,
+"PATCCARV","C-Cardiovascular system","MTMOTCMT","Million US$ at exchange rate","CHL","Chile","2022","2022",244.4,,
+"PATCCARV","C-Cardiovascular system","MTMOPPMT","Million US$, purchasing power parity","CHL","Chile","2010","2010",208.1,,
+"PATCCARV","C-Cardiovascular system","MTMOPPMT","Million US$, purchasing power parity","CHL","Chile","2011","2011",263,"B","Break"
+"PATCCARV","C-Cardiovascular system","MTMOPPMT","Million US$, purchasing power parity","CHL","Chile","2012","2012",290.4,,
+"PATCCARV","C-Cardiovascular system","MTMOPPMT","Million US$, purchasing power parity","CHL","Chile","2013","2013",301.9,,
+"PATCCARV","C-Cardiovascular system","MTMOPPMT","Million US$, purchasing power parity","CHL","Chile","2014","2014",338.8,,
+"PATCCARV","C-Cardiovascular system","MTMOPPMT","Million US$, purchasing power parity","CHL","Chile","2015","2015",354,,
+"PATCCARV","C-Cardiovascular system","MTMOPPMT","Million US$, purchasing power parity","CHL","Chile","2016","2016",382.7,,
+"PATCCARV","C-Cardiovascular system","MTMOPPMT","Million US$, purchasing power parity","CHL","Chile","2017","2017",368.9,,
+"PATCCARV","C-Cardiovascular system","MTMOPPMT","Million US$, purchasing power parity","CHL","Chile","2018","2018",390.7,,
+"PATCCARV","C-Cardiovascular system","MTMOPPMT","Million US$, purchasing power parity","CHL","Chile","2019","2019",458.9,,
+"PATCCARV","C-Cardiovascular system","MTMOPPMT","Million US$, purchasing power parity","CHL","Chile","2020","2020",461.2,,
+"PATCCARV","C-Cardiovascular system","MTMOPPMT","Million US$, purchasing power parity","CHL","Chile","2021","2021",412.6,,
+"PATCCARV","C-Cardiovascular system","MTMOPPMT","Million US$, purchasing power parity","CHL","Chile","2022","2022",487.8,,
+"PATCCARV","C-Cardiovascular system","TCPPERMT","/capita, US$ exchange rate","CHL","Chile","2010","2010",8.6,,
+"PATCCARV","C-Cardiovascular system","TCPPERMT","/capita, US$ exchange rate","CHL","Chile","2011","2011",11,"B","Break"
+"PATCCARV","C-Cardiovascular system","TCPPERMT","/capita, US$ exchange rate","CHL","Chile","2012","2012",11.9,,
+"PATCCARV","C-Cardiovascular system","TCPPERMT","/capita, US$ exchange rate","CHL","Chile","2013","2013",12.1,,
+"PATCCARV","C-Cardiovascular system","TCPPERMT","/capita, US$ exchange rate","CHL","Chile","2014","2014",12.3,,
+"PATCCARV","C-Cardiovascular system","TCPPERMT","/capita, US$ exchange rate","CHL","Chile","2015","2015",11.8,,
+"PATCCARV","C-Cardiovascular system","TCPPERMT","/capita, US$ exchange rate","CHL","Chile","2016","2016",12.4,,
+"PATCCARV","C-Cardiovascular system","TCPPERMT","/capita, US$ exchange rate","CHL","Chile","2017","2017",12.3,,
+"PATCCARV","C-Cardiovascular system","TCPPERMT","/capita, US$ exchange rate","CHL","Chile","2018","2018",12.9,,
+"PATCCARV","C-Cardiovascular system","TCPPERMT","/capita, US$ exchange rate","CHL","Chile","2019","2019",13.7,,
+"PATCCARV","C-Cardiovascular system","TCPPERMT","/capita, US$ exchange rate","CHL","Chile","2020","2020",12.5,,
+"PATCCARV","C-Cardiovascular system","TCPPERMT","/capita, US$ exchange rate","CHL","Chile","2021","2021",12,,
+"PATCCARV","C-Cardiovascular system","TCPPERMT","/capita, US$ exchange rate","CHL","Chile","2022","2022",12.3,,
+"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2010","2010",12.2,,
+"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2011","2011",15.2,"B","Break"
+"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2012","2012",16.6,,
+"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2013","2013",17.1,,
+"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2014","2014",19,,
+"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2015","2015",19.7,,
+"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2016","2016",21.1,,
+"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2017","2017",20,,
+"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2018","2018",20.8,,
+"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2019","2019",24,,
+"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2020","2020",23.7,,
+"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2021","2021",21,,
+"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2022","2022",24.6,,
+"PATCCARV","C-Cardiovascular system","ATCPTTMT","% of total sales","CHL","Chile","2010","2010",9.1,,
+"PATCCARV","C-Cardiovascular system","ATCPTTMT","% of total sales","CHL","Chile","2011","2011",7.8,"B","Break"
+"PATCCARV","C-Cardiovascular system","ATCPTTMT","% of total sales","CHL","Chile","2012","2012",8.1,,
+"PATCCARV","C-Cardiovascular system","ATCPTTMT","% of total sales","CHL","Chile","2013","2013",7.3,,
+"PATCCARV","C-Cardiovascular system","ATCPTTMT","% of total sales","CHL","Chile","2014","2014",8,,
+"PATCCARV","C-Cardiovascular system","ATCPTTMT","% of total sales","CHL","Chile","2015","2015",7.6,,
+"PATCCARV","C-Cardiovascular system","ATCPTTMT","% of total sales","CHL","Chile","2016","2016",7.5,,
+"PATCCARV","C-Cardiovascular system","ATCPTTMT","% of total sales","CHL","Chile","2017","2017",7.1,,
+"PATCCARV","C-Cardiovascular system","ATCPTTMT","% of total sales","CHL","Chile","2018","2018",6.7,,
+"PATCCARV","C-Cardiovascular system","ATCPTTMT","% of total sales","CHL","Chile","2019","2019",7.3,,
+"PATCCARV","C-Cardiovascular system","ATCPTTMT","% of total sales","CHL","Chile","2020","2020",7.2,,
+"PATCCARV","C-Cardiovascular system","ATCPTTMT","% of total sales","CHL","Chile","2021","2021",6.4,,
+"PATCCARV","C-Cardiovascular system","ATCPTTMT","% of total sales","CHL","Chile","2022","2022",7.6,,
+"PATCCARV","C-Cardiovascular system","MLLNCUMT","Million of national currency units","EST","Estonia","2010","2010",35,,
+"PATCCARV","C-Cardiovascular system","MLLNCUMT","Million of national currency units","EST","Estonia","2011","2011",31.2,,
+"PATCCARV","C-Cardiovascular system","MLLNCUMT","Million of national currency units","EST","Estonia","2012","2012",32.6,,
+"PATCCARV","C-Cardiovascular system","MLLNCUMT","Million of national currency units","EST","Estonia","2013","2013",31.7,,
+"PATCCARV","C-Cardiovascular system","MLLNCUMT","Million of national currency units","EST","Estonia","2014","2014",32,,
+"PATCCARV","C-Cardiovascular system","MLLNCUMT","Million of national currency units","EST","Estonia","2015","2015",31.5,,
+"PATCCARV","C-Cardiovascular system","MLLNCUMT","Million of national currency units","EST","Estonia","2016","2016",30.8,,
+"PATCCARV","C-Cardiovascular system","MLLNCUMT","Million of national currency units","EST","Estonia","2017","2017",29.9,,
+"PATCCARV","C-Cardiovascular system","MLLNCUMT","Million of national currency units","EST","Estonia","2018","2018",30.9,,
+"PATCCARV","C-Cardiovascular system","MLLNCUMT","Million of national currency units","EST","Estonia","2019","2019",31.8,,
+"PATCCARV","C-Cardiovascular system","MLLNCUMT","Million of national currency units","EST","Estonia","2020","2020",34.3,,
+"PATCCARV","C-Cardiovascular system","MLLNCUMT","Million of national currency units","EST","Estonia","2021","2021",34.5,,
+"PATCCARV","C-Cardiovascular system","MLLNCUMT","Million of national currency units","EST","Estonia","2022","2022",36.3,,
+"PATCCARV","C-Cardiovascular system","MTMOTCMT","Million US$ at exchange rate","EST","Estonia","2010","2010",46.3,,
+"PATCCARV","C-Cardiovascular system","MTMOTCMT","Million US$ at exchange rate","EST","Estonia","2011","2011",43.4,,
+"PATCCARV","C-Cardiovascular system","MTMOTCMT","Million US$ at exchange rate","EST","Estonia","2012","2012",41.8,,
+"PATCCARV","C-Cardiovascular system","MTMOTCMT","Million US$ at exchange rate","EST","Estonia","2013","2013",42.1,,
+"PATCCARV","C-Cardiovascular system","MTMOTCMT","Million US$ at exchange rate","EST","Estonia","2014","2014",42.5,,
+"PATCCARV","C-Cardiovascular system","MTMOTCMT","Million US$ at exchange rate","EST","Estonia","2015","2015",34.9,,
+"PATCCARV","C-Cardiovascular system","MTMOTCMT","Million US$ at exchange rate","EST","Estonia","2016","2016",34.1,,
+"PATCCARV","C-Cardiovascular system","MTMOTCMT","Million US$ at exchange rate","EST","Estonia","2017","2017",33.8,,
+"PATCCARV","C-Cardiovascular system","MTMOTCMT","Million US$ at exchange rate","EST","Estonia","2018","2018",36.4,,
+"PATCCARV","C-Cardiovascular system","MTMOTCMT","Million US$ at exchange rate","EST","Estonia","2019","2019",35.6,,
+"PATCCARV","C-Cardiovascular system","MTMOTCMT","Million US$ at exchange rate","EST","Estonia","2020","2020",39.2,,
+"PATCCARV","C-Cardiovascular system","MTMOTCMT","Million US$ at exchange rate","EST","Estonia","2021","2021",40.8,,
+"PATCCARV","C-Cardiovascular system","MTMOTCMT","Million US$ at exchange rate","EST","Estonia","2022","2022",38.2,,
+"PATCCARV","C-Cardiovascular system","MTMOPPMT","Million US$, purchasing power parity","EST","Estonia","2010","2010",68.3,,
+"PATCCARV","C-Cardiovascular system","MTMOPPMT","Million US$, purchasing power parity","EST","Estonia","2011","2011",60.9,,
+"PATCCARV","C-Cardiovascular system","MTMOPPMT","Million US$, purchasing power parity","EST","Estonia","2012","2012",62.5,,
+"PATCCARV","C-Cardiovascular system","MTMOPPMT","Million US$, purchasing power parity","EST","Estonia","2013","2013",60.7,,
+"PATCCARV","C-Cardiovascular system","MTMOPPMT","Million US$, purchasing power parity","EST","Estonia","2014","2014",60.8,,
+"PATCCARV","C-Cardiovascular system","MTMOPPMT","Million US$, purchasing power parity","EST","Estonia","2015","2015",58.5,,
+"PATCCARV","C-Cardiovascular system","MTMOPPMT","Million US$, purchasing power parity","EST","Estonia","2016","2016",58.3,,
+"PATCCARV","C-Cardiovascular system","MTMOPPMT","Million US$, purchasing power parity","EST","Estonia","2017","2017",56,,
+"PATCCARV","C-Cardiovascular system","MTMOPPMT","Million US$, purchasing power parity","EST","Estonia","2018","2018",57.3,,
+"PATCCARV","C-Cardiovascular system","MTMOPPMT","Million US$, purchasing power parity","EST","Estonia","2019","2019",59.3,,
+"PATCCARV","C-Cardiovascular system","MTMOPPMT","Million US$, purchasing power parity","EST","Estonia","2020","2020",65.5,,
+"PATCCARV","C-Cardiovascular system","MTMOPPMT","Million US$, purchasing power parity","EST","Estonia","2021","2021",63.5,,
+"PATCCARV","C-Cardiovascular system","MTMOPPMT","Million US$, purchasing power parity","EST","Estonia","2022","2022",63.8,,
+"PATCCARV","C-Cardiovascular system","TCPPERMT","/capita, US$ exchange rate","EST","Estonia","2010","2010",34.8,,
+"PATCCARV","C-Cardiovascular system","TCPPERMT","/capita, US$ exchange rate","EST","Estonia","2011","2011",32.7,,
+"PATCCARV","C-Cardiovascular system","TCPPERMT","/capita, US$ exchange rate","EST","Estonia","2012","2012",31.6,,
+"PATCCARV","C-Cardiovascular system","TCPPERMT","/capita, US$ exchange rate","EST","Estonia","2013","2013",31.9,,
+"PATCCARV","C-Cardiovascular system","TCPPERMT","/capita, US$ exchange rate","EST","Estonia","2014","2014",32.4,,
+"PATCCARV","C-Cardiovascular system","TCPPERMT","/capita, US$ exchange rate","EST","Estonia","2015","2015",26.5,,
+"PATCCARV","C-Cardiovascular system","TCPPERMT","/capita, US$ exchange rate","EST","Estonia","2016","2016",25.9,,
+"PATCCARV","C-Cardiovascular system","TCPPERMT","/capita, US$ exchange rate","EST","Estonia","2017","2017",25.7,,
+"PATCCARV","C-Cardiovascular system","TCPPERMT","/capita, US$ exchange rate","EST","Estonia","2018","2018",27.6,,
+"PATCCARV","C-Cardiovascular system","TCPPERMT","/capita, US$ exchange rate","EST","Estonia","2019","2019",26.8,,
+"PATCCARV","C-Cardiovascular system","TCPPERMT","/capita, US$ exchange rate","EST","Estonia","2020","2020",29.5,,
+"PATCCARV","C-Cardiovascular system","TCPPERMT","/capita, US$ exchange rate","EST","Estonia","2021","2021",30.7,,
+"PATCCARV","C-Cardiovascular system","TCPPERMT","/capita, US$ exchange rate","EST","Estonia","2022","2022",28.7,,
+"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2010","2010",51.3,,
+"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2011","2011",45.9,,
+"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2012","2012",47.2,,
+"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2013","2013",46,,
+"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2014","2014",46.2,,
+"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2015","2015",44.5,,
+"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2016","2016",44.3,,
+"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2017","2017",42.5,,
+"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2018","2018",43.3,,
+"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2019","2019",44.7,,
+"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2020","2020",49.2,,
+"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2021","2021",47.7,,
+"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2022","2022",47.9,,
+"PATCCARV","C-Cardiovascular system","ATCPTTMT","% of total sales","EST","Estonia","2010","2010",18,,
+"PATCCARV","C-Cardiovascular system","ATCPTTMT","% of total sales","EST","Estonia","2011","2011",15.3,,
+"PATCCARV","C-Cardiovascular system","ATCPTTMT","% of total sales","EST","Estonia","2012","2012",14.7,,
+"PATCCARV","C-Cardiovascular system","ATCPTTMT","% of total sales","EST","Estonia","2013","2013",13.7,,
+"PATCCARV","C-Cardiovascular system","ATCPTTMT","% of total sales","EST","Estonia","2014","2014",12.8,,
+"PATCCARV","C-Cardiovascular system","ATCPTTMT","% of total sales","EST","Estonia","2015","2015",11.9,,
+"PATCCARV","C-Cardiovascular system","ATCPTTMT","% of total sales","EST","Estonia","2016","2016",10.6,,
+"PATCCARV","C-Cardiovascular system","ATCPTTMT","% of total sales","EST","Estonia","2017","2017",9.9,,
+"PATCCARV","C-Cardiovascular system","ATCPTTMT","% of total sales","EST","Estonia","2018","2018",9.5,,
+"PATCCARV","C-Cardiovascular system","ATCPTTMT","% of total sales","EST","Estonia","2019","2019",9.2,,
+"PATCCARV","C-Cardiovascular system","ATCPTTMT","% of total sales","EST","Estonia","2020","2020",9.6,,
+"PATCCARV","C-Cardiovascular system","ATCPTTMT","% of total sales","EST","Estonia","2021","2021",8.4,,
+"PATCCARV","C-Cardiovascular system","ATCPTTMT","% of total sales","EST","Estonia","2022","2022",8.4,,
+"PATCCARV","C-Cardiovascular system","MLLNCUMT","Million of national currency units","SVN","Slovenia","2010","2010",122.5,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","MLLNCUMT","Million of national currency units","SVN","Slovenia","2011","2011",113.7,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","MLLNCUMT","Million of national currency units","SVN","Slovenia","2012","2012",105.4,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","MLLNCUMT","Million of national currency units","SVN","Slovenia","2013","2013",100.7,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","MLLNCUMT","Million of national currency units","SVN","Slovenia","2014","2014",81.2,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","MLLNCUMT","Million of national currency units","SVN","Slovenia","2015","2015",77,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","MLLNCUMT","Million of national currency units","SVN","Slovenia","2016","2016",75.6,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","MLLNCUMT","Million of national currency units","SVN","Slovenia","2017","2017",75.9,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","MLLNCUMT","Million of national currency units","SVN","Slovenia","2018","2018",76,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","MLLNCUMT","Million of national currency units","SVN","Slovenia","2019","2019",78.6,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","MLLNCUMT","Million of national currency units","SVN","Slovenia","2020","2020",83.4,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","MLLNCUMT","Million of national currency units","SVN","Slovenia","2021","2021",85.2,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","MLLNCUMT","Million of national currency units","SVN","Slovenia","2022","2022",90.1,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","MTMOTCMT","Million US$ at exchange rate","SVN","Slovenia","2010","2010",162.4,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","MTMOTCMT","Million US$ at exchange rate","SVN","Slovenia","2011","2011",158.2,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","MTMOTCMT","Million US$ at exchange rate","SVN","Slovenia","2012","2012",135.4,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","MTMOTCMT","Million US$ at exchange rate","SVN","Slovenia","2013","2013",133.7,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","MTMOTCMT","Million US$ at exchange rate","SVN","Slovenia","2014","2014",107.8,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","MTMOTCMT","Million US$ at exchange rate","SVN","Slovenia","2015","2015",85.5,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","MTMOTCMT","Million US$ at exchange rate","SVN","Slovenia","2016","2016",83.7,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","MTMOTCMT","Million US$ at exchange rate","SVN","Slovenia","2017","2017",85.7,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","MTMOTCMT","Million US$ at exchange rate","SVN","Slovenia","2018","2018",89.7,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","MTMOTCMT","Million US$ at exchange rate","SVN","Slovenia","2019","2019",88,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","MTMOTCMT","Million US$ at exchange rate","SVN","Slovenia","2020","2020",95.3,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","MTMOTCMT","Million US$ at exchange rate","SVN","Slovenia","2021","2021",100.8,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","MTMOTCMT","Million US$ at exchange rate","SVN","Slovenia","2022","2022",94.8,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","MTMOPPMT","Million US$, purchasing power parity","SVN","Slovenia","2010","2010",192,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","MTMOPPMT","Million US$, purchasing power parity","SVN","Slovenia","2011","2011",182.1,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","MTMOPPMT","Million US$, purchasing power parity","SVN","Slovenia","2012","2012",173.6,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","MTMOPPMT","Million US$, purchasing power parity","SVN","Slovenia","2013","2013",170.5,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","MTMOPPMT","Million US$, purchasing power parity","SVN","Slovenia","2014","2014",137.3,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","MTMOPPMT","Million US$, purchasing power parity","SVN","Slovenia","2015","2015",129.4,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","MTMOPPMT","Million US$, purchasing power parity","SVN","Slovenia","2016","2016",130.9,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","MTMOPPMT","Million US$, purchasing power parity","SVN","Slovenia","2017","2017",133.1,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","MTMOPPMT","Million US$, purchasing power parity","SVN","Slovenia","2018","2018",133.8,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","MTMOPPMT","Million US$, purchasing power parity","SVN","Slovenia","2019","2019",142.4,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","MTMOPPMT","Million US$, purchasing power parity","SVN","Slovenia","2020","2020",152.5,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","MTMOPPMT","Million US$, purchasing power parity","SVN","Slovenia","2021","2021",151.4,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","MTMOPPMT","Million US$, purchasing power parity","SVN","Slovenia","2022","2022",163.3,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","TCPPERMT","/capita, US$ exchange rate","SVN","Slovenia","2010","2010",79.3,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","TCPPERMT","/capita, US$ exchange rate","SVN","Slovenia","2011","2011",77.1,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","TCPPERMT","/capita, US$ exchange rate","SVN","Slovenia","2012","2012",65.8,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","TCPPERMT","/capita, US$ exchange rate","SVN","Slovenia","2013","2013",64.9,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","TCPPERMT","/capita, US$ exchange rate","SVN","Slovenia","2014","2014",52.3,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","TCPPERMT","/capita, US$ exchange rate","SVN","Slovenia","2015","2015",41.4,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","TCPPERMT","/capita, US$ exchange rate","SVN","Slovenia","2016","2016",40.5,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","TCPPERMT","/capita, US$ exchange rate","SVN","Slovenia","2017","2017",41.5,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","TCPPERMT","/capita, US$ exchange rate","SVN","Slovenia","2018","2018",43.3,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","TCPPERMT","/capita, US$ exchange rate","SVN","Slovenia","2019","2019",42.1,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","TCPPERMT","/capita, US$ exchange rate","SVN","Slovenia","2020","2020",45.3,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","TCPPERMT","/capita, US$ exchange rate","SVN","Slovenia","2021","2021",47.8,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","TCPPERMT","/capita, US$ exchange rate","SVN","Slovenia","2022","2022",45,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2010","2010",93.7,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2011","2011",88.7,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2012","2012",84.4,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2013","2013",82.8,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2014","2014",66.6,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2015","2015",62.7,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2016","2016",63.4,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2017","2017",64.4,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2018","2018",64.5,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2019","2019",68.2,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2020","2020",72.5,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2021","2021",71.8,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2022","2022",77.5,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","ATCPTTMT","% of total sales","SVN","Slovenia","2010","2010",25.8,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","ATCPTTMT","% of total sales","SVN","Slovenia","2011","2011",24.2,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","ATCPTTMT","% of total sales","SVN","Slovenia","2012","2012",23.2,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","ATCPTTMT","% of total sales","SVN","Slovenia","2013","2013",22.3,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","ATCPTTMT","% of total sales","SVN","Slovenia","2014","2014",18.8,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","ATCPTTMT","% of total sales","SVN","Slovenia","2015","2015",17.3,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","ATCPTTMT","% of total sales","SVN","Slovenia","2016","2016",16.2,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","ATCPTTMT","% of total sales","SVN","Slovenia","2017","2017",15.7,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","ATCPTTMT","% of total sales","SVN","Slovenia","2018","2018",14.7,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","ATCPTTMT","% of total sales","SVN","Slovenia","2019","2019",14.5,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","ATCPTTMT","% of total sales","SVN","Slovenia","2020","2020",14.7,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","ATCPTTMT","% of total sales","SVN","Slovenia","2021","2021",13.9,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","ATCPTTMT","% of total sales","SVN","Slovenia","2022","2022",13.3,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","MLLNCUMT","Million of national currency units","AUS","Australia","2010","2010",4,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","MLLNCUMT","Million of national currency units","AUS","Australia","2011","2011",4,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","MLLNCUMT","Million of national currency units","AUS","Australia","2012","2012",4,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","MLLNCUMT","Million of national currency units","AUS","Australia","2013","2013",4,"B; D","Break; Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","MLLNCUMT","Million of national currency units","AUS","Australia","2014","2014",4,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","MLLNCUMT","Million of national currency units","AUS","Australia","2015","2015",5,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","MLLNCUMT","Million of national currency units","AUS","Australia","2016","2016",5,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","MLLNCUMT","Million of national currency units","AUS","Australia","2017","2017",5,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","MLLNCUMT","Million of national currency units","AUS","Australia","2018","2018",5,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","MLLNCUMT","Million of national currency units","AUS","Australia","2019","2019",5,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","MLLNCUMT","Million of national currency units","AUS","Australia","2020","2020",5,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","MLLNCUMT","Million of national currency units","AUS","Australia","2021","2021",5,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","MTMOTCMT","Million US$ at exchange rate","AUS","Australia","2010","2010",3.7,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","MTMOTCMT","Million US$ at exchange rate","AUS","Australia","2011","2011",4.1,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","MTMOTCMT","Million US$ at exchange rate","AUS","Australia","2012","2012",4.1,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","MTMOTCMT","Million US$ at exchange rate","AUS","Australia","2013","2013",3.9,"B; D","Break; Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","MTMOTCMT","Million US$ at exchange rate","AUS","Australia","2014","2014",3.6,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","MTMOTCMT","Million US$ at exchange rate","AUS","Australia","2015","2015",3.8,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","MTMOTCMT","Million US$ at exchange rate","AUS","Australia","2016","2016",3.7,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","MTMOTCMT","Million US$ at exchange rate","AUS","Australia","2017","2017",3.8,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","MTMOTCMT","Million US$ at exchange rate","AUS","Australia","2018","2018",3.7,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","MTMOTCMT","Million US$ at exchange rate","AUS","Australia","2019","2019",3.5,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","MTMOTCMT","Million US$ at exchange rate","AUS","Australia","2020","2020",3.4,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","MTMOTCMT","Million US$ at exchange rate","AUS","Australia","2021","2021",3.8,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","MTMOPPMT","Million US$, purchasing power parity","AUS","Australia","2010","2010",2.7,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","MTMOPPMT","Million US$, purchasing power parity","AUS","Australia","2011","2011",2.6,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","MTMOPPMT","Million US$, purchasing power parity","AUS","Australia","2012","2012",2.6,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","MTMOPPMT","Million US$, purchasing power parity","AUS","Australia","2013","2013",2.8,"B; D","Break; Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","MTMOPPMT","Million US$, purchasing power parity","AUS","Australia","2014","2014",2.8,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","MTMOPPMT","Million US$, purchasing power parity","AUS","Australia","2015","2015",3.4,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","MTMOPPMT","Million US$, purchasing power parity","AUS","Australia","2016","2016",3.4,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","MTMOPPMT","Million US$, purchasing power parity","AUS","Australia","2017","2017",3.4,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","MTMOPPMT","Million US$, purchasing power parity","AUS","Australia","2018","2018",3.4,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","MTMOPPMT","Million US$, purchasing power parity","AUS","Australia","2019","2019",3.4,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","MTMOPPMT","Million US$, purchasing power parity","AUS","Australia","2020","2020",3.4,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","MTMOPPMT","Million US$, purchasing power parity","AUS","Australia","2021","2021",3.5,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","TCPPERMT","/capita, US$ exchange rate","AUS","Australia","2010","2010",0.2,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","TCPPERMT","/capita, US$ exchange rate","AUS","Australia","2011","2011",0.2,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","TCPPERMT","/capita, US$ exchange rate","AUS","Australia","2012","2012",0.2,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","TCPPERMT","/capita, US$ exchange rate","AUS","Australia","2013","2013",0.2,"B; D","Break; Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","TCPPERMT","/capita, US$ exchange rate","AUS","Australia","2014","2014",0.2,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","TCPPERMT","/capita, US$ exchange rate","AUS","Australia","2015","2015",0.2,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","TCPPERMT","/capita, US$ exchange rate","AUS","Australia","2016","2016",0.2,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","TCPPERMT","/capita, US$ exchange rate","AUS","Australia","2017","2017",0.2,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","TCPPERMT","/capita, US$ exchange rate","AUS","Australia","2018","2018",0.1,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","TCPPERMT","/capita, US$ exchange rate","AUS","Australia","2019","2019",0.1,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","TCPPERMT","/capita, US$ exchange rate","AUS","Australia","2020","2020",0.1,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","TCPPERMT","/capita, US$ exchange rate","AUS","Australia","2021","2021",0.1,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2010","2010",0.1,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2011","2011",0.1,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2012","2012",0.1,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2013","2013",0.1,"B; D","Break; Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2014","2014",0.1,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2015","2015",0.1,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2016","2016",0.1,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2017","2017",0.1,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2018","2018",0.1,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2019","2019",0.1,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2020","2020",0.1,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2021","2021",0.1,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","ATCPTTMT","% of total sales","AUS","Australia","2010","2010",0,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","ATCPTTMT","% of total sales","AUS","Australia","2011","2011",0,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","ATCPTTMT","% of total sales","AUS","Australia","2012","2012",0,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","ATCPTTMT","% of total sales","AUS","Australia","2013","2013",0,"B; D","Break; Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","ATCPTTMT","% of total sales","AUS","Australia","2014","2014",0,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","ATCPTTMT","% of total sales","AUS","Australia","2015","2015",0,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","ATCPTTMT","% of total sales","AUS","Australia","2016","2016",0,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","ATCPTTMT","% of total sales","AUS","Australia","2017","2017",0,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","ATCPTTMT","% of total sales","AUS","Australia","2018","2018",0,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","ATCPTTMT","% of total sales","AUS","Australia","2019","2019",0,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","ATCPTTMT","% of total sales","AUS","Australia","2020","2020",0,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","ATCPTTMT","% of total sales","AUS","Australia","2021","2021",0,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","MLLNCUMT","Million of national currency units","AUT","Austria","2010","2010",0.7,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","MLLNCUMT","Million of national currency units","AUT","Austria","2011","2011",0.7,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","MLLNCUMT","Million of national currency units","AUT","Austria","2012","2012",0.6,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","MLLNCUMT","Million of national currency units","AUT","Austria","2013","2013",0.6,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","MLLNCUMT","Million of national currency units","AUT","Austria","2014","2014",0.6,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","MLLNCUMT","Million of national currency units","AUT","Austria","2015","2015",0.5,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","MLLNCUMT","Million of national currency units","AUT","Austria","2016","2016",0.5,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","MLLNCUMT","Million of national currency units","AUT","Austria","2017","2017",0.4,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","MLLNCUMT","Million of national currency units","AUT","Austria","2018","2018",0.4,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","MLLNCUMT","Million of national currency units","AUT","Austria","2019","2019",0.3,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","MLLNCUMT","Million of national currency units","AUT","Austria","2020","2020",0.3,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","MLLNCUMT","Million of national currency units","AUT","Austria","2021","2021",0.3,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","MTMOTCMT","Million US$ at exchange rate","AUT","Austria","2010","2010",1,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","MTMOTCMT","Million US$ at exchange rate","AUT","Austria","2011","2011",0.9,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","MTMOTCMT","Million US$ at exchange rate","AUT","Austria","2012","2012",0.8,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","MTMOTCMT","Million US$ at exchange rate","AUT","Austria","2013","2013",0.7,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","MTMOTCMT","Million US$ at exchange rate","AUT","Austria","2014","2014",0.8,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","MTMOTCMT","Million US$ at exchange rate","AUT","Austria","2015","2015",0.6,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","MTMOTCMT","Million US$ at exchange rate","AUT","Austria","2016","2016",0.5,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","MTMOTCMT","Million US$ at exchange rate","AUT","Austria","2017","2017",0.5,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","MTMOTCMT","Million US$ at exchange rate","AUT","Austria","2018","2018",0.4,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","MTMOTCMT","Million US$ at exchange rate","AUT","Austria","2019","2019",0.4,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","MTMOTCMT","Million US$ at exchange rate","AUT","Austria","2020","2020",0.4,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","MTMOTCMT","Million US$ at exchange rate","AUT","Austria","2021","2021",0.3,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","MTMOPPMT","Million US$, purchasing power parity","AUT","Austria","2010","2010",0.9,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","MTMOPPMT","Million US$, purchasing power parity","AUT","Austria","2011","2011",0.8,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","MTMOPPMT","Million US$, purchasing power parity","AUT","Austria","2012","2012",0.8,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","MTMOPPMT","Million US$, purchasing power parity","AUT","Austria","2013","2013",0.7,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","MTMOPPMT","Million US$, purchasing power parity","AUT","Austria","2014","2014",0.7,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","MTMOPPMT","Million US$, purchasing power parity","AUT","Austria","2015","2015",0.7,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","MTMOPPMT","Million US$, purchasing power parity","AUT","Austria","2016","2016",0.6,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","MTMOPPMT","Million US$, purchasing power parity","AUT","Austria","2017","2017",0.6,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","MTMOPPMT","Million US$, purchasing power parity","AUT","Austria","2018","2018",0.5,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","MTMOPPMT","Million US$, purchasing power parity","AUT","Austria","2019","2019",0.4,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","MTMOPPMT","Million US$, purchasing power parity","AUT","Austria","2020","2020",0.4,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","MTMOPPMT","Million US$, purchasing power parity","AUT","Austria","2021","2021",0.4,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","TCPPERMT","/capita, US$ exchange rate","AUT","Austria","2010","2010",0.1,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","TCPPERMT","/capita, US$ exchange rate","AUT","Austria","2011","2011",0.1,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","TCPPERMT","/capita, US$ exchange rate","AUT","Austria","2012","2012",0.1,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","TCPPERMT","/capita, US$ exchange rate","AUT","Austria","2013","2013",0.1,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","TCPPERMT","/capita, US$ exchange rate","AUT","Austria","2014","2014",0.1,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","TCPPERMT","/capita, US$ exchange rate","AUT","Austria","2015","2015",0.1,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","TCPPERMT","/capita, US$ exchange rate","AUT","Austria","2016","2016",0.1,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","TCPPERMT","/capita, US$ exchange rate","AUT","Austria","2017","2017",0.1,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","TCPPERMT","/capita, US$ exchange rate","AUT","Austria","2018","2018",0.1,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","TCPPERMT","/capita, US$ exchange rate","AUT","Austria","2019","2019",0,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","TCPPERMT","/capita, US$ exchange rate","AUT","Austria","2020","2020",0,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","TCPPERMT","/capita, US$ exchange rate","AUT","Austria","2021","2021",0,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2010","2010",0.1,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2011","2011",0.1,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2012","2012",0.1,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2013","2013",0.1,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2014","2014",0.1,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2015","2015",0.1,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2016","2016",0.1,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2017","2017",0.1,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2018","2018",0.1,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2019","2019",0.1,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2020","2020",0,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2021","2021",0,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","ATCPTTMT","% of total sales","AUT","Austria","2010","2010",0,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","ATCPTTMT","% of total sales","AUT","Austria","2011","2011",0,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","ATCPTTMT","% of total sales","AUT","Austria","2012","2012",0,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","ATCPTTMT","% of total sales","AUT","Austria","2013","2013",0,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","ATCPTTMT","% of total sales","AUT","Austria","2014","2014",0,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","ATCPTTMT","% of total sales","AUT","Austria","2015","2015",0,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","ATCPTTMT","% of total sales","AUT","Austria","2016","2016",0,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","ATCPTTMT","% of total sales","AUT","Austria","2017","2017",0,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","ATCPTTMT","% of total sales","AUT","Austria","2018","2018",0,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","ATCPTTMT","% of total sales","AUT","Austria","2019","2019",0,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","ATCPTTMT","% of total sales","AUT","Austria","2020","2020",0,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","ATCPTTMT","% of total sales","AUT","Austria","2021","2021",0,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","MLLNCUMT","Million of national currency units","BEL","Belgium","2010","2010",1.3,,
+"PATCGLYC","C01A-Cardiac glycosides","MLLNCUMT","Million of national currency units","BEL","Belgium","2011","2011",1.5,,
+"PATCGLYC","C01A-Cardiac glycosides","MLLNCUMT","Million of national currency units","BEL","Belgium","2012","2012",1.4,,
+"PATCGLYC","C01A-Cardiac glycosides","MLLNCUMT","Million of national currency units","BEL","Belgium","2013","2013",1.2,,
+"PATCGLYC","C01A-Cardiac glycosides","MLLNCUMT","Million of national currency units","BEL","Belgium","2014","2014",1.1,,
+"PATCGLYC","C01A-Cardiac glycosides","MLLNCUMT","Million of national currency units","BEL","Belgium","2015","2015",1,,
+"PATCGLYC","C01A-Cardiac glycosides","MLLNCUMT","Million of national currency units","BEL","Belgium","2016","2016",0.9,,
+"PATCGLYC","C01A-Cardiac glycosides","MLLNCUMT","Million of national currency units","BEL","Belgium","2017","2017",0.8,,
+"PATCGLYC","C01A-Cardiac glycosides","MLLNCUMT","Million of national currency units","BEL","Belgium","2018","2018",0.7,,
+"PATCGLYC","C01A-Cardiac glycosides","MLLNCUMT","Million of national currency units","BEL","Belgium","2019","2019",0.7,,
+"PATCGLYC","C01A-Cardiac glycosides","MLLNCUMT","Million of national currency units","BEL","Belgium","2020","2020",0.6,,
+"PATCGLYC","C01A-Cardiac glycosides","MLLNCUMT","Million of national currency units","BEL","Belgium","2021","2021",0.6,,
+"PATCGLYC","C01A-Cardiac glycosides","MLLNCUMT","Million of national currency units","BEL","Belgium","2022","2022",0.6,"E","Estimated value"
+"PATCGLYC","C01A-Cardiac glycosides","MTMOTCMT","Million US$ at exchange rate","BEL","Belgium","2010","2010",1.8,,
+"PATCGLYC","C01A-Cardiac glycosides","MTMOTCMT","Million US$ at exchange rate","BEL","Belgium","2011","2011",2,,
+"PATCGLYC","C01A-Cardiac glycosides","MTMOTCMT","Million US$ at exchange rate","BEL","Belgium","2012","2012",1.8,,
+"PATCGLYC","C01A-Cardiac glycosides","MTMOTCMT","Million US$ at exchange rate","BEL","Belgium","2013","2013",1.6,,
+"PATCGLYC","C01A-Cardiac glycosides","MTMOTCMT","Million US$ at exchange rate","BEL","Belgium","2014","2014",1.5,,
+"PATCGLYC","C01A-Cardiac glycosides","MTMOTCMT","Million US$ at exchange rate","BEL","Belgium","2015","2015",1.1,,
+"PATCGLYC","C01A-Cardiac glycosides","MTMOTCMT","Million US$ at exchange rate","BEL","Belgium","2016","2016",1,,
+"PATCGLYC","C01A-Cardiac glycosides","MTMOTCMT","Million US$ at exchange rate","BEL","Belgium","2017","2017",1,,
+"PATCGLYC","C01A-Cardiac glycosides","MTMOTCMT","Million US$ at exchange rate","BEL","Belgium","2018","2018",0.9,,
+"PATCGLYC","C01A-Cardiac glycosides","MTMOTCMT","Million US$ at exchange rate","BEL","Belgium","2019","2019",0.8,,
+"PATCGLYC","C01A-Cardiac glycosides","MTMOTCMT","Million US$ at exchange rate","BEL","Belgium","2020","2020",0.7,,
+"PATCGLYC","C01A-Cardiac glycosides","MTMOTCMT","Million US$ at exchange rate","BEL","Belgium","2021","2021",0.7,,
+"PATCGLYC","C01A-Cardiac glycosides","MTMOTCMT","Million US$ at exchange rate","BEL","Belgium","2022","2022",0.6,"E","Estimated value"
+"PATCGLYC","C01A-Cardiac glycosides","MTMOPPMT","Million US$, purchasing power parity","BEL","Belgium","2010","2010",1.6,,
+"PATCGLYC","C01A-Cardiac glycosides","MTMOPPMT","Million US$, purchasing power parity","BEL","Belgium","2011","2011",1.8,,
+"PATCGLYC","C01A-Cardiac glycosides","MTMOPPMT","Million US$, purchasing power parity","BEL","Belgium","2012","2012",1.7,,
+"PATCGLYC","C01A-Cardiac glycosides","MTMOPPMT","Million US$, purchasing power parity","BEL","Belgium","2013","2013",1.5,,
+"PATCGLYC","C01A-Cardiac glycosides","MTMOPPMT","Million US$, purchasing power parity","BEL","Belgium","2014","2014",1.4,,
+"PATCGLYC","C01A-Cardiac glycosides","MTMOPPMT","Million US$, purchasing power parity","BEL","Belgium","2015","2015",1.2,,
+"PATCGLYC","C01A-Cardiac glycosides","MTMOPPMT","Million US$, purchasing power parity","BEL","Belgium","2016","2016",1.1,,
+"PATCGLYC","C01A-Cardiac glycosides","MTMOPPMT","Million US$, purchasing power parity","BEL","Belgium","2017","2017",1.1,,
+"PATCGLYC","C01A-Cardiac glycosides","MTMOPPMT","Million US$, purchasing power parity","BEL","Belgium","2018","2018",1,,
+"PATCGLYC","C01A-Cardiac glycosides","MTMOPPMT","Million US$, purchasing power parity","BEL","Belgium","2019","2019",0.9,,
+"PATCGLYC","C01A-Cardiac glycosides","MTMOPPMT","Million US$, purchasing power parity","BEL","Belgium","2020","2020",0.8,,
+"PATCGLYC","C01A-Cardiac glycosides","MTMOPPMT","Million US$, purchasing power parity","BEL","Belgium","2021","2021",0.8,,
+"PATCGLYC","C01A-Cardiac glycosides","MTMOPPMT","Million US$, purchasing power parity","BEL","Belgium","2022","2022",0.8,"E","Estimated value"
+"PATCGLYC","C01A-Cardiac glycosides","TCPPERMT","/capita, US$ exchange rate","BEL","Belgium","2010","2010",0.2,,
+"PATCGLYC","C01A-Cardiac glycosides","TCPPERMT","/capita, US$ exchange rate","BEL","Belgium","2011","2011",0.2,,
+"PATCGLYC","C01A-Cardiac glycosides","TCPPERMT","/capita, US$ exchange rate","BEL","Belgium","2012","2012",0.2,,
+"PATCGLYC","C01A-Cardiac glycosides","TCPPERMT","/capita, US$ exchange rate","BEL","Belgium","2013","2013",0.1,,
+"PATCGLYC","C01A-Cardiac glycosides","TCPPERMT","/capita, US$ exchange rate","BEL","Belgium","2014","2014",0.1,,
+"PATCGLYC","C01A-Cardiac glycosides","TCPPERMT","/capita, US$ exchange rate","BEL","Belgium","2015","2015",0.1,,
+"PATCGLYC","C01A-Cardiac glycosides","TCPPERMT","/capita, US$ exchange rate","BEL","Belgium","2016","2016",0.1,,
+"PATCGLYC","C01A-Cardiac glycosides","TCPPERMT","/capita, US$ exchange rate","BEL","Belgium","2017","2017",0.1,,
+"PATCGLYC","C01A-Cardiac glycosides","TCPPERMT","/capita, US$ exchange rate","BEL","Belgium","2018","2018",0.1,,
+"PATCGLYC","C01A-Cardiac glycosides","TCPPERMT","/capita, US$ exchange rate","BEL","Belgium","2019","2019",0.1,,
+"PATCGLYC","C01A-Cardiac glycosides","TCPPERMT","/capita, US$ exchange rate","BEL","Belgium","2020","2020",0.1,,
+"PATCGLYC","C01A-Cardiac glycosides","TCPPERMT","/capita, US$ exchange rate","BEL","Belgium","2021","2021",0.1,,
+"PATCGLYC","C01A-Cardiac glycosides","TCPPERMT","/capita, US$ exchange rate","BEL","Belgium","2022","2022",0.1,"E","Estimated value"
+"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2010","2010",0.1,,
+"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2011","2011",0.2,,
+"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2012","2012",0.2,,
+"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2013","2013",0.1,,
+"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2014","2014",0.1,,
+"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2015","2015",0.1,,
+"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2016","2016",0.1,,
+"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2017","2017",0.1,,
+"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2018","2018",0.1,,
+"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2019","2019",0.1,,
+"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2020","2020",0.1,,
+"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2021","2021",0.1,,
+"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2022","2022",0.1,"E","Estimated value"
+"PATCGLYC","C01A-Cardiac glycosides","ATCPTTMT","% of total sales","BEL","Belgium","2010","2010",0,,
+"PATCGLYC","C01A-Cardiac glycosides","ATCPTTMT","% of total sales","BEL","Belgium","2011","2011",0,,
+"PATCGLYC","C01A-Cardiac glycosides","ATCPTTMT","% of total sales","BEL","Belgium","2012","2012",0,,
+"PATCGLYC","C01A-Cardiac glycosides","ATCPTTMT","% of total sales","BEL","Belgium","2013","2013",0,,
+"PATCGLYC","C01A-Cardiac glycosides","ATCPTTMT","% of total sales","BEL","Belgium","2014","2014",0,,
+"PATCGLYC","C01A-Cardiac glycosides","ATCPTTMT","% of total sales","BEL","Belgium","2015","2015",0,,
+"PATCGLYC","C01A-Cardiac glycosides","ATCPTTMT","% of total sales","BEL","Belgium","2016","2016",0,,
+"PATCGLYC","C01A-Cardiac glycosides","ATCPTTMT","% of total sales","BEL","Belgium","2017","2017",0,,
+"PATCGLYC","C01A-Cardiac glycosides","ATCPTTMT","% of total sales","BEL","Belgium","2018","2018",0,,
+"PATCGLYC","C01A-Cardiac glycosides","ATCPTTMT","% of total sales","BEL","Belgium","2019","2019",0,,
+"PATCGLYC","C01A-Cardiac glycosides","ATCPTTMT","% of total sales","BEL","Belgium","2020","2020",0,,
+"PATCGLYC","C01A-Cardiac glycosides","ATCPTTMT","% of total sales","BEL","Belgium","2021","2021",0,,
+"PATCGLYC","C01A-Cardiac glycosides","ATCPTTMT","% of total sales","BEL","Belgium","2022","2022",0,"E","Estimated value"
+"PATCGLYC","C01A-Cardiac glycosides","MLLNCUMT","Million of national currency units","CAN","Canada","2012","2012",22.3,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","MLLNCUMT","Million of national currency units","CAN","Canada","2013","2013",21.7,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","MLLNCUMT","Million of national currency units","CAN","Canada","2014","2014",20.5,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","MLLNCUMT","Million of national currency units","CAN","Canada","2015","2015",19,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","MLLNCUMT","Million of national currency units","CAN","Canada","2016","2016",17.6,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","MLLNCUMT","Million of national currency units","CAN","Canada","2017","2017",16.6,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","MLLNCUMT","Million of national currency units","CAN","Canada","2018","2018",16.4,"E; B; D","Estimated value; Break; Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","MLLNCUMT","Million of national currency units","CAN","Canada","2019","2019",16,"E; D","Estimated value; Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","MLLNCUMT","Million of national currency units","CAN","Canada","2020","2020",16.8,"E; D","Estimated value; Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","MLLNCUMT","Million of national currency units","CAN","Canada","2021","2021",15.3,"E; D","Estimated value; Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","MLLNCUMT","Million of national currency units","CAN","Canada","2022","2022",14.3,"E; D","Estimated value; Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","MTMOTCMT","Million US$ at exchange rate","CAN","Canada","2012","2012",22.3,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","MTMOTCMT","Million US$ at exchange rate","CAN","Canada","2013","2013",21.1,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","MTMOTCMT","Million US$ at exchange rate","CAN","Canada","2014","2014",18.6,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","MTMOTCMT","Million US$ at exchange rate","CAN","Canada","2015","2015",14.9,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","MTMOTCMT","Million US$ at exchange rate","CAN","Canada","2016","2016",13.3,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","MTMOTCMT","Million US$ at exchange rate","CAN","Canada","2017","2017",12.8,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","MTMOTCMT","Million US$ at exchange rate","CAN","Canada","2018","2018",12.7,"E; B; D","Estimated value; Break; Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","MTMOTCMT","Million US$ at exchange rate","CAN","Canada","2019","2019",12.1,"E; D","Estimated value; Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","MTMOTCMT","Million US$ at exchange rate","CAN","Canada","2020","2020",12.5,"E; D","Estimated value; Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","MTMOTCMT","Million US$ at exchange rate","CAN","Canada","2021","2021",12.2,"E; D","Estimated value; Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","MTMOTCMT","Million US$ at exchange rate","CAN","Canada","2022","2022",11,"E; D","Estimated value; Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","MTMOPPMT","Million US$, purchasing power parity","CAN","Canada","2012","2012",17.9,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","MTMOPPMT","Million US$, purchasing power parity","CAN","Canada","2013","2013",17.7,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","MTMOPPMT","Million US$, purchasing power parity","CAN","Canada","2014","2014",16.7,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","MTMOPPMT","Million US$, purchasing power parity","CAN","Canada","2015","2015",15.2,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","MTMOPPMT","Million US$, purchasing power parity","CAN","Canada","2016","2016",14.6,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","MTMOPPMT","Million US$, purchasing power parity","CAN","Canada","2017","2017",13.7,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","MTMOPPMT","Million US$, purchasing power parity","CAN","Canada","2018","2018",13.6,"E; B; D","Estimated value; Break; Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","MTMOPPMT","Million US$, purchasing power parity","CAN","Canada","2019","2019",13,"E; D","Estimated value; Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","MTMOPPMT","Million US$, purchasing power parity","CAN","Canada","2020","2020",13.6,"E; D","Estimated value; Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","MTMOPPMT","Million US$, purchasing power parity","CAN","Canada","2021","2021",12.4,"E; D","Estimated value; Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","MTMOPPMT","Million US$, purchasing power parity","CAN","Canada","2022","2022",11.4,"E; D","Estimated value; Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","TCPPERMT","/capita, US$ exchange rate","CAN","Canada","2012","2012",0.6,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","TCPPERMT","/capita, US$ exchange rate","CAN","Canada","2013","2013",0.6,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","TCPPERMT","/capita, US$ exchange rate","CAN","Canada","2014","2014",0.5,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","TCPPERMT","/capita, US$ exchange rate","CAN","Canada","2015","2015",0.4,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","TCPPERMT","/capita, US$ exchange rate","CAN","Canada","2016","2016",0.4,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","TCPPERMT","/capita, US$ exchange rate","CAN","Canada","2017","2017",0.3,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","TCPPERMT","/capita, US$ exchange rate","CAN","Canada","2018","2018",0.3,"E; B; D","Estimated value; Break; Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","TCPPERMT","/capita, US$ exchange rate","CAN","Canada","2019","2019",0.3,"E; D","Estimated value; Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","TCPPERMT","/capita, US$ exchange rate","CAN","Canada","2020","2020",0.3,"E; D","Estimated value; Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","TCPPERMT","/capita, US$ exchange rate","CAN","Canada","2021","2021",0.3,"E; D","Estimated value; Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","TCPPERMT","/capita, US$ exchange rate","CAN","Canada","2022","2022",0.3,"E; D","Estimated value; Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2012","2012",0.5,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2013","2013",0.5,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2014","2014",0.5,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2015","2015",0.4,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2016","2016",0.4,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2017","2017",0.4,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2018","2018",0.4,"E; B; D","Estimated value; Break; Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2019","2019",0.3,"E; D","Estimated value; Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2020","2020",0.4,"E; D","Estimated value; Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2021","2021",0.3,"E; D","Estimated value; Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2022","2022",0.3,"E; D","Estimated value; Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","ATCPTTMT","% of total sales","CAN","Canada","2012","2012",0.1,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","ATCPTTMT","% of total sales","CAN","Canada","2013","2013",0.1,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","ATCPTTMT","% of total sales","CAN","Canada","2014","2014",0.1,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","ATCPTTMT","% of total sales","CAN","Canada","2015","2015",0.1,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","ATCPTTMT","% of total sales","CAN","Canada","2016","2016",0.1,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","ATCPTTMT","% of total sales","CAN","Canada","2017","2017",0.1,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","ATCPTTMT","% of total sales","CAN","Canada","2018","2018",0.1,"E; B; D","Estimated value; Break; Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","ATCPTTMT","% of total sales","CAN","Canada","2019","2019",0.1,"E; D","Estimated value; Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","ATCPTTMT","% of total sales","CAN","Canada","2020","2020",0,"E; D","Estimated value; Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","ATCPTTMT","% of total sales","CAN","Canada","2021","2021",0,"E; D","Estimated value; Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","ATCPTTMT","% of total sales","CAN","Canada","2022","2022",0,"E; D","Estimated value; Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","MLLNCUMT","Million of national currency units","CZE","Czech Republic","2010","2010",22.6,,
+"PATCGLYC","C01A-Cardiac glycosides","MLLNCUMT","Million of national currency units","CZE","Czech Republic","2011","2011",21.3,,
+"PATCGLYC","C01A-Cardiac glycosides","MLLNCUMT","Million of national currency units","CZE","Czech Republic","2012","2012",23.5,,
+"PATCGLYC","C01A-Cardiac glycosides","MLLNCUMT","Million of national currency units","CZE","Czech Republic","2013","2013",22.2,,
+"PATCGLYC","C01A-Cardiac glycosides","MLLNCUMT","Million of national currency units","CZE","Czech Republic","2014","2014",20.7,,
+"PATCGLYC","C01A-Cardiac glycosides","MLLNCUMT","Million of national currency units","CZE","Czech Republic","2015","2015",19,,
+"PATCGLYC","C01A-Cardiac glycosides","MLLNCUMT","Million of national currency units","CZE","Czech Republic","2016","2016",18.8,,
+"PATCGLYC","C01A-Cardiac glycosides","MLLNCUMT","Million of national currency units","CZE","Czech Republic","2017","2017",20.4,,
+"PATCGLYC","C01A-Cardiac glycosides","MLLNCUMT","Million of national currency units","CZE","Czech Republic","2018","2018",19.5,,
+"PATCGLYC","C01A-Cardiac glycosides","MLLNCUMT","Million of national currency units","CZE","Czech Republic","2019","2019",21.5,,
+"PATCGLYC","C01A-Cardiac glycosides","MLLNCUMT","Million of national currency units","CZE","Czech Republic","2020","2020",19.5,"B","Break"
+"PATCGLYC","C01A-Cardiac glycosides","MLLNCUMT","Million of national currency units","CZE","Czech Republic","2021","2021",18.5,,
+"PATCGLYC","C01A-Cardiac glycosides","MTMOTCMT","Million US$ at exchange rate","CZE","Czech Republic","2010","2010",1.2,,
+"PATCGLYC","C01A-Cardiac glycosides","MTMOTCMT","Million US$ at exchange rate","CZE","Czech Republic","2011","2011",1.2,,
+"PATCGLYC","C01A-Cardiac glycosides","MTMOTCMT","Million US$ at exchange rate","CZE","Czech Republic","2012","2012",1.2,,
+"PATCGLYC","C01A-Cardiac glycosides","MTMOTCMT","Million US$ at exchange rate","CZE","Czech Republic","2013","2013",1.1,,
+"PATCGLYC","C01A-Cardiac glycosides","MTMOTCMT","Million US$ at exchange rate","CZE","Czech Republic","2014","2014",1,,
+"PATCGLYC","C01A-Cardiac glycosides","MTMOTCMT","Million US$ at exchange rate","CZE","Czech Republic","2015","2015",0.8,,
+"PATCGLYC","C01A-Cardiac glycosides","MTMOTCMT","Million US$ at exchange rate","CZE","Czech Republic","2016","2016",0.8,,
+"PATCGLYC","C01A-Cardiac glycosides","MTMOTCMT","Million US$ at exchange rate","CZE","Czech Republic","2017","2017",0.9,,
+"PATCGLYC","C01A-Cardiac glycosides","MTMOTCMT","Million US$ at exchange rate","CZE","Czech Republic","2018","2018",0.9,,
+"PATCGLYC","C01A-Cardiac glycosides","MTMOTCMT","Million US$ at exchange rate","CZE","Czech Republic","2019","2019",0.9,,
+"PATCGLYC","C01A-Cardiac glycosides","MTMOTCMT","Million US$ at exchange rate","CZE","Czech Republic","2020","2020",0.8,"B","Break"
+"PATCGLYC","C01A-Cardiac glycosides","MTMOTCMT","Million US$ at exchange rate","CZE","Czech Republic","2021","2021",0.9,,
+"PATCGLYC","C01A-Cardiac glycosides","MTMOPPMT","Million US$, purchasing power parity","CZE","Czech Republic","2010","2010",1.7,,
+"PATCGLYC","C01A-Cardiac glycosides","MTMOPPMT","Million US$, purchasing power parity","CZE","Czech Republic","2011","2011",1.6,,
+"PATCGLYC","C01A-Cardiac glycosides","MTMOPPMT","Million US$, purchasing power parity","CZE","Czech Republic","2012","2012",1.8,,
+"PATCGLYC","C01A-Cardiac glycosides","MTMOPPMT","Million US$, purchasing power parity","CZE","Czech Republic","2013","2013",1.7,,
+"PATCGLYC","C01A-Cardiac glycosides","MTMOPPMT","Million US$, purchasing power parity","CZE","Czech Republic","2014","2014",1.6,,
+"PATCGLYC","C01A-Cardiac glycosides","MTMOPPMT","Million US$, purchasing power parity","CZE","Czech Republic","2015","2015",1.5,,
+"PATCGLYC","C01A-Cardiac glycosides","MTMOPPMT","Million US$, purchasing power parity","CZE","Czech Republic","2016","2016",1.5,,
+"PATCGLYC","C01A-Cardiac glycosides","MTMOPPMT","Million US$, purchasing power parity","CZE","Czech Republic","2017","2017",1.6,,
+"PATCGLYC","C01A-Cardiac glycosides","MTMOPPMT","Million US$, purchasing power parity","CZE","Czech Republic","2018","2018",1.6,,
+"PATCGLYC","C01A-Cardiac glycosides","MTMOPPMT","Million US$, purchasing power parity","CZE","Czech Republic","2019","2019",1.7,,
+"PATCGLYC","C01A-Cardiac glycosides","MTMOPPMT","Million US$, purchasing power parity","CZE","Czech Republic","2020","2020",1.6,"B","Break"
+"PATCGLYC","C01A-Cardiac glycosides","MTMOPPMT","Million US$, purchasing power parity","CZE","Czech Republic","2021","2021",1.5,,
+"PATCGLYC","C01A-Cardiac glycosides","TCPPERMT","/capita, US$ exchange rate","CZE","Czech Republic","2010","2010",0.1,,
+"PATCGLYC","C01A-Cardiac glycosides","TCPPERMT","/capita, US$ exchange rate","CZE","Czech Republic","2011","2011",0.1,,
+"PATCGLYC","C01A-Cardiac glycosides","TCPPERMT","/capita, US$ exchange rate","CZE","Czech Republic","2012","2012",0.1,,
+"PATCGLYC","C01A-Cardiac glycosides","TCPPERMT","/capita, US$ exchange rate","CZE","Czech Republic","2013","2013",0.1,,
+"PATCGLYC","C01A-Cardiac glycosides","TCPPERMT","/capita, US$ exchange rate","CZE","Czech Republic","2014","2014",0.1,,
+"PATCGLYC","C01A-Cardiac glycosides","TCPPERMT","/capita, US$ exchange rate","CZE","Czech Republic","2015","2015",0.1,,
+"PATCGLYC","C01A-Cardiac glycosides","TCPPERMT","/capita, US$ exchange rate","CZE","Czech Republic","2016","2016",0.1,,
+"PATCGLYC","C01A-Cardiac glycosides","TCPPERMT","/capita, US$ exchange rate","CZE","Czech Republic","2017","2017",0.1,,
+"PATCGLYC","C01A-Cardiac glycosides","TCPPERMT","/capita, US$ exchange rate","CZE","Czech Republic","2018","2018",0.1,,
+"PATCGLYC","C01A-Cardiac glycosides","TCPPERMT","/capita, US$ exchange rate","CZE","Czech Republic","2019","2019",0.1,,
+"PATCGLYC","C01A-Cardiac glycosides","TCPPERMT","/capita, US$ exchange rate","CZE","Czech Republic","2020","2020",0.1,"B","Break"
+"PATCGLYC","C01A-Cardiac glycosides","TCPPERMT","/capita, US$ exchange rate","CZE","Czech Republic","2021","2021",0.1,,
+"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czech Republic","2010","2010",0.2,,
+"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czech Republic","2011","2011",0.2,,
+"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czech Republic","2012","2012",0.2,,
+"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czech Republic","2013","2013",0.2,,
+"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czech Republic","2014","2014",0.2,,
+"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czech Republic","2015","2015",0.1,,
+"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czech Republic","2016","2016",0.1,,
+"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czech Republic","2017","2017",0.2,,
+"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czech Republic","2018","2018",0.1,,
+"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czech Republic","2019","2019",0.2,,
+"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czech Republic","2020","2020",0.1,"B","Break"
+"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czech Republic","2021","2021",0.1,,
+"PATCGLYC","C01A-Cardiac glycosides","ATCPTTMT","% of total sales","CZE","Czech Republic","2010","2010",0,,
+"PATCGLYC","C01A-Cardiac glycosides","ATCPTTMT","% of total sales","CZE","Czech Republic","2011","2011",0,,
+"PATCGLYC","C01A-Cardiac glycosides","ATCPTTMT","% of total sales","CZE","Czech Republic","2012","2012",0,,
+"PATCGLYC","C01A-Cardiac glycosides","ATCPTTMT","% of total sales","CZE","Czech Republic","2013","2013",0,,
+"PATCGLYC","C01A-Cardiac glycosides","ATCPTTMT","% of total sales","CZE","Czech Republic","2014","2014",0,,
+"PATCGLYC","C01A-Cardiac glycosides","ATCPTTMT","% of total sales","CZE","Czech Republic","2015","2015",0,,
+"PATCGLYC","C01A-Cardiac glycosides","ATCPTTMT","% of total sales","CZE","Czech Republic","2016","2016",0,,
+"PATCGLYC","C01A-Cardiac glycosides","ATCPTTMT","% of total sales","CZE","Czech Republic","2017","2017",0,,
+"PATCGLYC","C01A-Cardiac glycosides","ATCPTTMT","% of total sales","CZE","Czech Republic","2018","2018",0,,
+"PATCGLYC","C01A-Cardiac glycosides","ATCPTTMT","% of total sales","CZE","Czech Republic","2019","2019",0,,
+"PATCGLYC","C01A-Cardiac glycosides","ATCPTTMT","% of total sales","CZE","Czech Republic","2020","2020",0,"B","Break"
+"PATCGLYC","C01A-Cardiac glycosides","ATCPTTMT","% of total sales","CZE","Czech Republic","2021","2021",0,,
+"PATCGLYC","C01A-Cardiac glycosides","MLLNCUMT","Million of national currency units","FIN","Finland","2010","2010",0.5,,
+"PATCGLYC","C01A-Cardiac glycosides","MLLNCUMT","Million of national currency units","FIN","Finland","2011","2011",0.4,,
+"PATCGLYC","C01A-Cardiac glycosides","MLLNCUMT","Million of national currency units","FIN","Finland","2012","2012",0.4,,
+"PATCGLYC","C01A-Cardiac glycosides","MLLNCUMT","Million of national currency units","FIN","Finland","2013","2013",0.6,,
+"PATCGLYC","C01A-Cardiac glycosides","MLLNCUMT","Million of national currency units","FIN","Finland","2014","2014",1.1,,
+"PATCGLYC","C01A-Cardiac glycosides","MLLNCUMT","Million of national currency units","FIN","Finland","2015","2015",1.3,,
+"PATCGLYC","C01A-Cardiac glycosides","MLLNCUMT","Million of national currency units","FIN","Finland","2016","2016",1.2,,
+"PATCGLYC","C01A-Cardiac glycosides","MLLNCUMT","Million of national currency units","FIN","Finland","2017","2017",1.2,,
+"PATCGLYC","C01A-Cardiac glycosides","MLLNCUMT","Million of national currency units","FIN","Finland","2018","2018",1.1,,
+"PATCGLYC","C01A-Cardiac glycosides","MLLNCUMT","Million of national currency units","FIN","Finland","2019","2019",1.1,,
+"PATCGLYC","C01A-Cardiac glycosides","MLLNCUMT","Million of national currency units","FIN","Finland","2020","2020",1.1,,
+"PATCGLYC","C01A-Cardiac glycosides","MLLNCUMT","Million of national currency units","FIN","Finland","2021","2021",1.1,,
+"PATCGLYC","C01A-Cardiac glycosides","MTMOTCMT","Million US$ at exchange rate","FIN","Finland","2010","2010",0.7,,
+"PATCGLYC","C01A-Cardiac glycosides","MTMOTCMT","Million US$ at exchange rate","FIN","Finland","2011","2011",0.6,,
+"PATCGLYC","C01A-Cardiac glycosides","MTMOTCMT","Million US$ at exchange rate","FIN","Finland","2012","2012",0.5,,
+"PATCGLYC","C01A-Cardiac glycosides","MTMOTCMT","Million US$ at exchange rate","FIN","Finland","2013","2013",0.8,,
+"PATCGLYC","C01A-Cardiac glycosides","MTMOTCMT","Million US$ at exchange rate","FIN","Finland","2014","2014",1.5,,
+"PATCGLYC","C01A-Cardiac glycosides","MTMOTCMT","Million US$ at exchange rate","FIN","Finland","2015","2015",1.4,,
+"PATCGLYC","C01A-Cardiac glycosides","MTMOTCMT","Million US$ at exchange rate","FIN","Finland","2016","2016",1.3,,
+"PATCGLYC","C01A-Cardiac glycosides","MTMOTCMT","Million US$ at exchange rate","FIN","Finland","2017","2017",1.4,,
+"PATCGLYC","C01A-Cardiac glycosides","MTMOTCMT","Million US$ at exchange rate","FIN","Finland","2018","2018",1.3,,
+"PATCGLYC","C01A-Cardiac glycosides","MTMOTCMT","Million US$ at exchange rate","FIN","Finland","2019","2019",1.2,,
+"PATCGLYC","C01A-Cardiac glycosides","MTMOTCMT","Million US$ at exchange rate","FIN","Finland","2020","2020",1.3,,
+"PATCGLYC","C01A-Cardiac glycosides","MTMOTCMT","Million US$ at exchange rate","FIN","Finland","2021","2021",1.3,,
+"PATCGLYC","C01A-Cardiac glycosides","MTMOPPMT","Million US$, purchasing power parity","FIN","Finland","2010","2010",0.6,,
+"PATCGLYC","C01A-Cardiac glycosides","MTMOPPMT","Million US$, purchasing power parity","FIN","Finland","2011","2011",0.4,,
+"PATCGLYC","C01A-Cardiac glycosides","MTMOPPMT","Million US$, purchasing power parity","FIN","Finland","2012","2012",0.4,,
+"PATCGLYC","C01A-Cardiac glycosides","MTMOPPMT","Million US$, purchasing power parity","FIN","Finland","2013","2013",0.7,,
+"PATCGLYC","C01A-Cardiac glycosides","MTMOPPMT","Million US$, purchasing power parity","FIN","Finland","2014","2014",1.2,,
+"PATCGLYC","C01A-Cardiac glycosides","MTMOPPMT","Million US$, purchasing power parity","FIN","Finland","2015","2015",1.4,,
+"PATCGLYC","C01A-Cardiac glycosides","MTMOPPMT","Million US$, purchasing power parity","FIN","Finland","2016","2016",1.4,,
+"PATCGLYC","C01A-Cardiac glycosides","MTMOPPMT","Million US$, purchasing power parity","FIN","Finland","2017","2017",1.4,,
+"PATCGLYC","C01A-Cardiac glycosides","MTMOPPMT","Million US$, purchasing power parity","FIN","Finland","2018","2018",1.3,,
+"PATCGLYC","C01A-Cardiac glycosides","MTMOPPMT","Million US$, purchasing power parity","FIN","Finland","2019","2019",1.3,,
+"PATCGLYC","C01A-Cardiac glycosides","MTMOPPMT","Million US$, purchasing power parity","FIN","Finland","2020","2020",1.3,,
+"PATCGLYC","C01A-Cardiac glycosides","MTMOPPMT","Million US$, purchasing power parity","FIN","Finland","2021","2021",1.3,,
+"PATCGLYC","C01A-Cardiac glycosides","TCPPERMT","/capita, US$ exchange rate","FIN","Finland","2010","2010",0.1,,
+"PATCGLYC","C01A-Cardiac glycosides","TCPPERMT","/capita, US$ exchange rate","FIN","Finland","2011","2011",0.1,,
+"PATCGLYC","C01A-Cardiac glycosides","TCPPERMT","/capita, US$ exchange rate","FIN","Finland","2012","2012",0.1,,
+"PATCGLYC","C01A-Cardiac glycosides","TCPPERMT","/capita, US$ exchange rate","FIN","Finland","2013","2013",0.1,,
+"PATCGLYC","C01A-Cardiac glycosides","TCPPERMT","/capita, US$ exchange rate","FIN","Finland","2014","2014",0.3,,
+"PATCGLYC","C01A-Cardiac glycosides","TCPPERMT","/capita, US$ exchange rate","FIN","Finland","2015","2015",0.3,,
+"PATCGLYC","C01A-Cardiac glycosides","TCPPERMT","/capita, US$ exchange rate","FIN","Finland","2016","2016",0.2,,
+"PATCGLYC","C01A-Cardiac glycosides","TCPPERMT","/capita, US$ exchange rate","FIN","Finland","2017","2017",0.2,,
+"PATCGLYC","C01A-Cardiac glycosides","TCPPERMT","/capita, US$ exchange rate","FIN","Finland","2018","2018",0.2,,
+"PATCGLYC","C01A-Cardiac glycosides","TCPPERMT","/capita, US$ exchange rate","FIN","Finland","2019","2019",0.2,,
+"PATCGLYC","C01A-Cardiac glycosides","TCPPERMT","/capita, US$ exchange rate","FIN","Finland","2020","2020",0.2,,
+"PATCGLYC","C01A-Cardiac glycosides","TCPPERMT","/capita, US$ exchange rate","FIN","Finland","2021","2021",0.2,,
+"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2010","2010",0.1,,
+"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2011","2011",0.1,,
+"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2012","2012",0.1,,
+"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2013","2013",0.1,,
+"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2014","2014",0.2,,
+"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2015","2015",0.3,,
+"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2016","2016",0.2,,
+"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2017","2017",0.3,,
+"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2018","2018",0.2,,
+"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2019","2019",0.2,,
+"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2020","2020",0.2,,
+"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2021","2021",0.2,,
+"PATCGLYC","C01A-Cardiac glycosides","ATCPTTMT","% of total sales","FIN","Finland","2010","2010",0,,
+"PATCGLYC","C01A-Cardiac glycosides","ATCPTTMT","% of total sales","FIN","Finland","2011","2011",0,,
+"PATCGLYC","C01A-Cardiac glycosides","ATCPTTMT","% of total sales","FIN","Finland","2012","2012",0,,
+"PATCGLYC","C01A-Cardiac glycosides","ATCPTTMT","% of total sales","FIN","Finland","2013","2013",0,,
+"PATCGLYC","C01A-Cardiac glycosides","ATCPTTMT","% of total sales","FIN","Finland","2014","2014",0.1,,
+"PATCGLYC","C01A-Cardiac glycosides","ATCPTTMT","% of total sales","FIN","Finland","2015","2015",0.1,,
+"PATCGLYC","C01A-Cardiac glycosides","ATCPTTMT","% of total sales","FIN","Finland","2016","2016",0.1,,
+"PATCGLYC","C01A-Cardiac glycosides","ATCPTTMT","% of total sales","FIN","Finland","2017","2017",0.1,,
+"PATCGLYC","C01A-Cardiac glycosides","ATCPTTMT","% of total sales","FIN","Finland","2018","2018",0,,
+"PATCGLYC","C01A-Cardiac glycosides","ATCPTTMT","% of total sales","FIN","Finland","2019","2019",0,,
+"PATCGLYC","C01A-Cardiac glycosides","ATCPTTMT","% of total sales","FIN","Finland","2020","2020",0,,
+"PATCGLYC","C01A-Cardiac glycosides","ATCPTTMT","% of total sales","FIN","Finland","2021","2021",0,,
+"PATCGLYC","C01A-Cardiac glycosides","MLLNCUMT","Million of national currency units","DEU","Germany","2010","2010",39.3,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","MLLNCUMT","Million of national currency units","DEU","Germany","2011","2011",35.8,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","MLLNCUMT","Million of national currency units","DEU","Germany","2012","2012",33.6,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","MLLNCUMT","Million of national currency units","DEU","Germany","2013","2013",30.8,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","MLLNCUMT","Million of national currency units","DEU","Germany","2014","2014",28.7,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","MLLNCUMT","Million of national currency units","DEU","Germany","2015","2015",26.4,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","MLLNCUMT","Million of national currency units","DEU","Germany","2016","2016",23.6,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","MLLNCUMT","Million of national currency units","DEU","Germany","2017","2017",21.7,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","MLLNCUMT","Million of national currency units","DEU","Germany","2018","2018",20.8,"B; D","Break; Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","MLLNCUMT","Million of national currency units","DEU","Germany","2019","2019",19.9,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","MLLNCUMT","Million of national currency units","DEU","Germany","2020","2020",18.9,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","MLLNCUMT","Million of national currency units","DEU","Germany","2021","2021",18.1,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","MTMOTCMT","Million US$ at exchange rate","DEU","Germany","2010","2010",52.1,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","MTMOTCMT","Million US$ at exchange rate","DEU","Germany","2011","2011",49.8,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","MTMOTCMT","Million US$ at exchange rate","DEU","Germany","2012","2012",43.2,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","MTMOTCMT","Million US$ at exchange rate","DEU","Germany","2013","2013",40.9,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","MTMOTCMT","Million US$ at exchange rate","DEU","Germany","2014","2014",38.1,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","MTMOTCMT","Million US$ at exchange rate","DEU","Germany","2015","2015",29.3,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","MTMOTCMT","Million US$ at exchange rate","DEU","Germany","2016","2016",26.1,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","MTMOTCMT","Million US$ at exchange rate","DEU","Germany","2017","2017",24.5,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","MTMOTCMT","Million US$ at exchange rate","DEU","Germany","2018","2018",24.6,"B; D","Break; Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","MTMOTCMT","Million US$ at exchange rate","DEU","Germany","2019","2019",22.3,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","MTMOTCMT","Million US$ at exchange rate","DEU","Germany","2020","2020",21.6,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","MTMOTCMT","Million US$ at exchange rate","DEU","Germany","2021","2021",21.4,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","MTMOPPMT","Million US$, purchasing power parity","DEU","Germany","2010","2010",48.8,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","MTMOPPMT","Million US$, purchasing power parity","DEU","Germany","2011","2011",45.4,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","MTMOPPMT","Million US$, purchasing power parity","DEU","Germany","2012","2012",42.7,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","MTMOPPMT","Million US$, purchasing power parity","DEU","Germany","2013","2013",39.8,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","MTMOPPMT","Million US$, purchasing power parity","DEU","Germany","2014","2014",37.3,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","MTMOPPMT","Million US$, purchasing power parity","DEU","Germany","2015","2015",33.9,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","MTMOPPMT","Million US$, purchasing power parity","DEU","Germany","2016","2016",31.4,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","MTMOPPMT","Million US$, purchasing power parity","DEU","Germany","2017","2017",29.1,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","MTMOPPMT","Million US$, purchasing power parity","DEU","Germany","2018","2018",28.3,"B; D","Break; Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","MTMOPPMT","Million US$, purchasing power parity","DEU","Germany","2019","2019",27.3,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","MTMOPPMT","Million US$, purchasing power parity","DEU","Germany","2020","2020",26.1,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","MTMOPPMT","Million US$, purchasing power parity","DEU","Germany","2021","2021",24.6,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","TCPPERMT","/capita, US$ exchange rate","DEU","Germany","2010","2010",0.6,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","TCPPERMT","/capita, US$ exchange rate","DEU","Germany","2011","2011",0.6,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","TCPPERMT","/capita, US$ exchange rate","DEU","Germany","2012","2012",0.5,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","TCPPERMT","/capita, US$ exchange rate","DEU","Germany","2013","2013",0.5,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","TCPPERMT","/capita, US$ exchange rate","DEU","Germany","2014","2014",0.5,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","TCPPERMT","/capita, US$ exchange rate","DEU","Germany","2015","2015",0.4,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","TCPPERMT","/capita, US$ exchange rate","DEU","Germany","2016","2016",0.3,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","TCPPERMT","/capita, US$ exchange rate","DEU","Germany","2017","2017",0.3,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","TCPPERMT","/capita, US$ exchange rate","DEU","Germany","2018","2018",0.3,"B; D","Break; Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","TCPPERMT","/capita, US$ exchange rate","DEU","Germany","2019","2019",0.3,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","TCPPERMT","/capita, US$ exchange rate","DEU","Germany","2020","2020",0.3,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","TCPPERMT","/capita, US$ exchange rate","DEU","Germany","2021","2021",0.3,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2010","2010",0.6,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2011","2011",0.6,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2012","2012",0.5,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2013","2013",0.5,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2014","2014",0.5,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2015","2015",0.4,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2016","2016",0.4,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2017","2017",0.4,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2018","2018",0.3,"B; D","Break; Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2019","2019",0.3,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2020","2020",0.3,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2021","2021",0.3,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","ATCPTTMT","% of total sales","DEU","Germany","2010","2010",0.1,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","ATCPTTMT","% of total sales","DEU","Germany","2011","2011",0.1,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","ATCPTTMT","% of total sales","DEU","Germany","2012","2012",0.1,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","ATCPTTMT","% of total sales","DEU","Germany","2013","2013",0.1,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","ATCPTTMT","% of total sales","DEU","Germany","2014","2014",0.1,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","ATCPTTMT","% of total sales","DEU","Germany","2015","2015",0.1,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","ATCPTTMT","% of total sales","DEU","Germany","2016","2016",0.1,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","ATCPTTMT","% of total sales","DEU","Germany","2017","2017",0.1,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","ATCPTTMT","% of total sales","DEU","Germany","2018","2018",0,"B; D","Break; Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","ATCPTTMT","% of total sales","DEU","Germany","2019","2019",0,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","ATCPTTMT","% of total sales","DEU","Germany","2020","2020",0,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","ATCPTTMT","% of total sales","DEU","Germany","2021","2021",0,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","MLLNCUMT","Million of national currency units","GRC","Greece","2010","2010",1.2,,
+"PATCGLYC","C01A-Cardiac glycosides","MLLNCUMT","Million of national currency units","GRC","Greece","2011","2011",1.2,,
+"PATCGLYC","C01A-Cardiac glycosides","MLLNCUMT","Million of national currency units","GRC","Greece","2012","2012",1.2,,
+"PATCGLYC","C01A-Cardiac glycosides","MLLNCUMT","Million of national currency units","GRC","Greece","2013","2013",1,,
+"PATCGLYC","C01A-Cardiac glycosides","MLLNCUMT","Million of national currency units","GRC","Greece","2014","2014",0.9,,
+"PATCGLYC","C01A-Cardiac glycosides","MLLNCUMT","Million of national currency units","GRC","Greece","2015","2015",0.7,,
+"PATCGLYC","C01A-Cardiac glycosides","MLLNCUMT","Million of national currency units","GRC","Greece","2016","2016",0.7,,
+"PATCGLYC","C01A-Cardiac glycosides","MLLNCUMT","Million of national currency units","GRC","Greece","2017","2017",0.6,,
+"PATCGLYC","C01A-Cardiac glycosides","MLLNCUMT","Million of national currency units","GRC","Greece","2018","2018",0.7,,
+"PATCGLYC","C01A-Cardiac glycosides","MLLNCUMT","Million of national currency units","GRC","Greece","2019","2019",0.4,,
+"PATCGLYC","C01A-Cardiac glycosides","MLLNCUMT","Million of national currency units","GRC","Greece","2020","2020",0.5,,
+"PATCGLYC","C01A-Cardiac glycosides","MLLNCUMT","Million of national currency units","GRC","Greece","2021","2021",0.4,,
+"PATCGLYC","C01A-Cardiac glycosides","MLLNCUMT","Million of national currency units","GRC","Greece","2022","2022",0.3,,
+"PATCGLYC","C01A-Cardiac glycosides","MTMOTCMT","Million US$ at exchange rate","GRC","Greece","2010","2010",1.6,,
+"PATCGLYC","C01A-Cardiac glycosides","MTMOTCMT","Million US$ at exchange rate","GRC","Greece","2011","2011",1.6,,
+"PATCGLYC","C01A-Cardiac glycosides","MTMOTCMT","Million US$ at exchange rate","GRC","Greece","2012","2012",1.5,,
+"PATCGLYC","C01A-Cardiac glycosides","MTMOTCMT","Million US$ at exchange rate","GRC","Greece","2013","2013",1.3,,
+"PATCGLYC","C01A-Cardiac glycosides","MTMOTCMT","Million US$ at exchange rate","GRC","Greece","2014","2014",1.2,,
+"PATCGLYC","C01A-Cardiac glycosides","MTMOTCMT","Million US$ at exchange rate","GRC","Greece","2015","2015",0.8,,
+"PATCGLYC","C01A-Cardiac glycosides","MTMOTCMT","Million US$ at exchange rate","GRC","Greece","2016","2016",0.8,,
+"PATCGLYC","C01A-Cardiac glycosides","MTMOTCMT","Million US$ at exchange rate","GRC","Greece","2017","2017",0.7,,
+"PATCGLYC","C01A-Cardiac glycosides","MTMOTCMT","Million US$ at exchange rate","GRC","Greece","2018","2018",0.9,,
+"PATCGLYC","C01A-Cardiac glycosides","MTMOTCMT","Million US$ at exchange rate","GRC","Greece","2019","2019",0.4,,
+"PATCGLYC","C01A-Cardiac glycosides","MTMOTCMT","Million US$ at exchange rate","GRC","Greece","2020","2020",0.6,,
+"PATCGLYC","C01A-Cardiac glycosides","MTMOTCMT","Million US$ at exchange rate","GRC","Greece","2021","2021",0.5,,
+"PATCGLYC","C01A-Cardiac glycosides","MTMOTCMT","Million US$ at exchange rate","GRC","Greece","2022","2022",0.3,,
+"PATCGLYC","C01A-Cardiac glycosides","MTMOPPMT","Million US$, purchasing power parity","GRC","Greece","2010","2010",1.7,,
+"PATCGLYC","C01A-Cardiac glycosides","MTMOPPMT","Million US$, purchasing power parity","GRC","Greece","2011","2011",1.6,,
+"PATCGLYC","C01A-Cardiac glycosides","MTMOPPMT","Million US$, purchasing power parity","GRC","Greece","2012","2012",1.7,,
+"PATCGLYC","C01A-Cardiac glycosides","MTMOPPMT","Million US$, purchasing power parity","GRC","Greece","2013","2013",1.5,,
+"PATCGLYC","C01A-Cardiac glycosides","MTMOPPMT","Million US$, purchasing power parity","GRC","Greece","2014","2014",1.5,,
+"PATCGLYC","C01A-Cardiac glycosides","MTMOPPMT","Million US$, purchasing power parity","GRC","Greece","2015","2015",1.2,,
+"PATCGLYC","C01A-Cardiac glycosides","MTMOPPMT","Million US$, purchasing power parity","GRC","Greece","2016","2016",1.2,,
+"PATCGLYC","C01A-Cardiac glycosides","MTMOPPMT","Million US$, purchasing power parity","GRC","Greece","2017","2017",1,,
+"PATCGLYC","C01A-Cardiac glycosides","MTMOPPMT","Million US$, purchasing power parity","GRC","Greece","2018","2018",1.3,,
+"PATCGLYC","C01A-Cardiac glycosides","MTMOPPMT","Million US$, purchasing power parity","GRC","Greece","2019","2019",0.7,,
+"PATCGLYC","C01A-Cardiac glycosides","MTMOPPMT","Million US$, purchasing power parity","GRC","Greece","2020","2020",0.9,,
+"PATCGLYC","C01A-Cardiac glycosides","MTMOPPMT","Million US$, purchasing power parity","GRC","Greece","2021","2021",0.7,,
+"PATCGLYC","C01A-Cardiac glycosides","MTMOPPMT","Million US$, purchasing power parity","GRC","Greece","2022","2022",0.5,,
+"PATCGLYC","C01A-Cardiac glycosides","TCPPERMT","/capita, US$ exchange rate","GRC","Greece","2010","2010",0.1,,
+"PATCGLYC","C01A-Cardiac glycosides","TCPPERMT","/capita, US$ exchange rate","GRC","Greece","2011","2011",0.1,,
+"PATCGLYC","C01A-Cardiac glycosides","TCPPERMT","/capita, US$ exchange rate","GRC","Greece","2012","2012",0.1,,
+"PATCGLYC","C01A-Cardiac glycosides","TCPPERMT","/capita, US$ exchange rate","GRC","Greece","2013","2013",0.1,,
+"PATCGLYC","C01A-Cardiac glycosides","TCPPERMT","/capita, US$ exchange rate","GRC","Greece","2014","2014",0.1,,
+"PATCGLYC","C01A-Cardiac glycosides","TCPPERMT","/capita, US$ exchange rate","GRC","Greece","2015","2015",0.1,,
+"PATCGLYC","C01A-Cardiac glycosides","TCPPERMT","/capita, US$ exchange rate","GRC","Greece","2016","2016",0.1,,
+"PATCGLYC","C01A-Cardiac glycosides","TCPPERMT","/capita, US$ exchange rate","GRC","Greece","2017","2017",0.1,,
+"PATCGLYC","C01A-Cardiac glycosides","TCPPERMT","/capita, US$ exchange rate","GRC","Greece","2018","2018",0.1,,
+"PATCGLYC","C01A-Cardiac glycosides","TCPPERMT","/capita, US$ exchange rate","GRC","Greece","2019","2019",0,,
+"PATCGLYC","C01A-Cardiac glycosides","TCPPERMT","/capita, US$ exchange rate","GRC","Greece","2020","2020",0.1,,
+"PATCGLYC","C01A-Cardiac glycosides","TCPPERMT","/capita, US$ exchange rate","GRC","Greece","2021","2021",0,,
+"PATCGLYC","C01A-Cardiac glycosides","TCPPERMT","/capita, US$ exchange rate","GRC","Greece","2022","2022",0,,
+"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2010","2010",0.2,,
+"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2011","2011",0.1,,
+"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2012","2012",0.2,,
+"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2013","2013",0.1,,
+"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2014","2014",0.1,,
+"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2015","2015",0.1,,
+"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2016","2016",0.1,,
+"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2017","2017",0.1,,
+"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2018","2018",0.1,,
+"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2019","2019",0.1,,
+"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2020","2020",0.1,,
+"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2021","2021",0.1,,
+"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2022","2022",0,,
+"PATCGLYC","C01A-Cardiac glycosides","MLLNCUMT","Million of national currency units","HUN","Hungary","2010","2010",279.1,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","MLLNCUMT","Million of national currency units","HUN","Hungary","2011","2011",260.8,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","MLLNCUMT","Million of national currency units","HUN","Hungary","2012","2012",234.3,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","MLLNCUMT","Million of national currency units","HUN","Hungary","2013","2013",219.9,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","MLLNCUMT","Million of national currency units","HUN","Hungary","2014","2014",204,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","MLLNCUMT","Million of national currency units","HUN","Hungary","2015","2015",188.4,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","MLLNCUMT","Million of national currency units","HUN","Hungary","2016","2016",174.1,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","MLLNCUMT","Million of national currency units","HUN","Hungary","2017","2017",162.2,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","MLLNCUMT","Million of national currency units","HUN","Hungary","2018","2018",149.8,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","MLLNCUMT","Million of national currency units","HUN","Hungary","2019","2019",134.6,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","MLLNCUMT","Million of national currency units","HUN","Hungary","2020","2020",132.7,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","MLLNCUMT","Million of national currency units","HUN","Hungary","2021","2021",115.1,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","MLLNCUMT","Million of national currency units","HUN","Hungary","2022","2022",101.4,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","MTMOTCMT","Million US$ at exchange rate","HUN","Hungary","2010","2010",1.3,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","MTMOTCMT","Million US$ at exchange rate","HUN","Hungary","2011","2011",1.3,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","MTMOTCMT","Million US$ at exchange rate","HUN","Hungary","2012","2012",1,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","MTMOTCMT","Million US$ at exchange rate","HUN","Hungary","2013","2013",1,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","MTMOTCMT","Million US$ at exchange rate","HUN","Hungary","2014","2014",0.9,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","MTMOTCMT","Million US$ at exchange rate","HUN","Hungary","2015","2015",0.7,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","MTMOTCMT","Million US$ at exchange rate","HUN","Hungary","2016","2016",0.6,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","MTMOTCMT","Million US$ at exchange rate","HUN","Hungary","2017","2017",0.6,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","MTMOTCMT","Million US$ at exchange rate","HUN","Hungary","2018","2018",0.6,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","MTMOTCMT","Million US$ at exchange rate","HUN","Hungary","2019","2019",0.5,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","MTMOTCMT","Million US$ at exchange rate","HUN","Hungary","2020","2020",0.4,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","MTMOTCMT","Million US$ at exchange rate","HUN","Hungary","2021","2021",0.4,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","MTMOTCMT","Million US$ at exchange rate","HUN","Hungary","2022","2022",0.3,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","MTMOPPMT","Million US$, purchasing power parity","HUN","Hungary","2010","2010",2.2,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","MTMOPPMT","Million US$, purchasing power parity","HUN","Hungary","2011","2011",2.1,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","MTMOPPMT","Million US$, purchasing power parity","HUN","Hungary","2012","2012",1.9,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","MTMOPPMT","Million US$, purchasing power parity","HUN","Hungary","2013","2013",1.8,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","MTMOPPMT","Million US$, purchasing power parity","HUN","Hungary","2014","2014",1.6,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","MTMOPPMT","Million US$, purchasing power parity","HUN","Hungary","2015","2015",1.4,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","MTMOPPMT","Million US$, purchasing power parity","HUN","Hungary","2016","2016",1.3,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","MTMOPPMT","Million US$, purchasing power parity","HUN","Hungary","2017","2017",1.2,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","MTMOPPMT","Million US$, purchasing power parity","HUN","Hungary","2018","2018",1.1,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","MTMOPPMT","Million US$, purchasing power parity","HUN","Hungary","2019","2019",1,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","MTMOPPMT","Million US$, purchasing power parity","HUN","Hungary","2020","2020",0.9,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","MTMOPPMT","Million US$, purchasing power parity","HUN","Hungary","2021","2021",0.7,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","MTMOPPMT","Million US$, purchasing power parity","HUN","Hungary","2022","2022",0.6,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","TCPPERMT","/capita, US$ exchange rate","HUN","Hungary","2010","2010",0.1,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","TCPPERMT","/capita, US$ exchange rate","HUN","Hungary","2011","2011",0.1,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","TCPPERMT","/capita, US$ exchange rate","HUN","Hungary","2012","2012",0.1,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","TCPPERMT","/capita, US$ exchange rate","HUN","Hungary","2013","2013",0.1,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","TCPPERMT","/capita, US$ exchange rate","HUN","Hungary","2014","2014",0.1,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","TCPPERMT","/capita, US$ exchange rate","HUN","Hungary","2015","2015",0.1,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","TCPPERMT","/capita, US$ exchange rate","HUN","Hungary","2016","2016",0.1,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","TCPPERMT","/capita, US$ exchange rate","HUN","Hungary","2017","2017",0.1,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","TCPPERMT","/capita, US$ exchange rate","HUN","Hungary","2018","2018",0.1,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","TCPPERMT","/capita, US$ exchange rate","HUN","Hungary","2019","2019",0,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","TCPPERMT","/capita, US$ exchange rate","HUN","Hungary","2020","2020",0,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","TCPPERMT","/capita, US$ exchange rate","HUN","Hungary","2021","2021",0,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","TCPPERMT","/capita, US$ exchange rate","HUN","Hungary","2022","2022",0,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2010","2010",0.2,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2011","2011",0.2,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2012","2012",0.2,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2013","2013",0.2,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2014","2014",0.2,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2015","2015",0.1,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2016","2016",0.1,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2017","2017",0.1,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2018","2018",0.1,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2019","2019",0.1,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2020","2020",0.1,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2021","2021",0.1,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2022","2022",0.1,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","ATCPTTMT","% of total sales","HUN","Hungary","2010","2010",0.1,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","ATCPTTMT","% of total sales","HUN","Hungary","2011","2011",0.1,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","ATCPTTMT","% of total sales","HUN","Hungary","2012","2012",0.1,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","ATCPTTMT","% of total sales","HUN","Hungary","2013","2013",0.1,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","ATCPTTMT","% of total sales","HUN","Hungary","2014","2014",0,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","ATCPTTMT","% of total sales","HUN","Hungary","2015","2015",0,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","ATCPTTMT","% of total sales","HUN","Hungary","2016","2016",0,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","ATCPTTMT","% of total sales","HUN","Hungary","2017","2017",0,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","ATCPTTMT","% of total sales","HUN","Hungary","2018","2018",0,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","ATCPTTMT","% of total sales","HUN","Hungary","2019","2019",0,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","ATCPTTMT","% of total sales","HUN","Hungary","2020","2020",0,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","ATCPTTMT","% of total sales","HUN","Hungary","2021","2021",0,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","ATCPTTMT","% of total sales","HUN","Hungary","2022","2022",0,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","MLLNCUMT","Million of national currency units","ISL","Iceland","2010","2010",9.4,,
+"PATCGLYC","C01A-Cardiac glycosides","MLLNCUMT","Million of national currency units","ISL","Iceland","2011","2011",10,,
+"PATCGLYC","C01A-Cardiac glycosides","MLLNCUMT","Million of national currency units","ISL","Iceland","2012","2012",10.6,,
+"PATCGLYC","C01A-Cardiac glycosides","MLLNCUMT","Million of national currency units","ISL","Iceland","2013","2013",11.3,,
+"PATCGLYC","C01A-Cardiac glycosides","MLLNCUMT","Million of national currency units","ISL","Iceland","2014","2014",11.6,,
+"PATCGLYC","C01A-Cardiac glycosides","MLLNCUMT","Million of national currency units","ISL","Iceland","2015","2015",11.7,,
+"PATCGLYC","C01A-Cardiac glycosides","MLLNCUMT","Million of national currency units","ISL","Iceland","2016","2016",11.5,,
+"PATCGLYC","C01A-Cardiac glycosides","MLLNCUMT","Million of national currency units","ISL","Iceland","2017","2017",11.3,,
+"PATCGLYC","C01A-Cardiac glycosides","MLLNCUMT","Million of national currency units","ISL","Iceland","2018","2018",10.2,,
+"PATCGLYC","C01A-Cardiac glycosides","MLLNCUMT","Million of national currency units","ISL","Iceland","2019","2019",10.1,,
+"PATCGLYC","C01A-Cardiac glycosides","MLLNCUMT","Million of national currency units","ISL","Iceland","2020","2020",9.8,,
+"PATCGLYC","C01A-Cardiac glycosides","MLLNCUMT","Million of national currency units","ISL","Iceland","2021","2021",9.3,,
+"PATCGLYC","C01A-Cardiac glycosides","MTMOTCMT","Million US$ at exchange rate","ISL","Iceland","2010","2010",0.1,,
+"PATCGLYC","C01A-Cardiac glycosides","MTMOTCMT","Million US$ at exchange rate","ISL","Iceland","2011","2011",0.1,,
+"PATCGLYC","C01A-Cardiac glycosides","MTMOTCMT","Million US$ at exchange rate","ISL","Iceland","2012","2012",0.1,,
+"PATCGLYC","C01A-Cardiac glycosides","MTMOTCMT","Million US$ at exchange rate","ISL","Iceland","2013","2013",0.1,,
+"PATCGLYC","C01A-Cardiac glycosides","MTMOTCMT","Million US$ at exchange rate","ISL","Iceland","2014","2014",0.1,,
+"PATCGLYC","C01A-Cardiac glycosides","MTMOTCMT","Million US$ at exchange rate","ISL","Iceland","2015","2015",0.1,,
+"PATCGLYC","C01A-Cardiac glycosides","MTMOTCMT","Million US$ at exchange rate","ISL","Iceland","2016","2016",0.1,,
+"PATCGLYC","C01A-Cardiac glycosides","MTMOTCMT","Million US$ at exchange rate","ISL","Iceland","2017","2017",0.1,,
+"PATCGLYC","C01A-Cardiac glycosides","MTMOTCMT","Million US$ at exchange rate","ISL","Iceland","2018","2018",0.1,,
+"PATCGLYC","C01A-Cardiac glycosides","MTMOTCMT","Million US$ at exchange rate","ISL","Iceland","2019","2019",0.1,,
+"PATCGLYC","C01A-Cardiac glycosides","MTMOTCMT","Million US$ at exchange rate","ISL","Iceland","2020","2020",0.1,,
+"PATCGLYC","C01A-Cardiac glycosides","MTMOTCMT","Million US$ at exchange rate","ISL","Iceland","2021","2021",0.1,,
+"PATCGLYC","C01A-Cardiac glycosides","MTMOPPMT","Million US$, purchasing power parity","ISL","Iceland","2010","2010",0.1,,
+"PATCGLYC","C01A-Cardiac glycosides","MTMOPPMT","Million US$, purchasing power parity","ISL","Iceland","2011","2011",0.1,,
+"PATCGLYC","C01A-Cardiac glycosides","MTMOPPMT","Million US$, purchasing power parity","ISL","Iceland","2012","2012",0.1,,
+"PATCGLYC","C01A-Cardiac glycosides","MTMOPPMT","Million US$, purchasing power parity","ISL","Iceland","2013","2013",0.1,,
+"PATCGLYC","C01A-Cardiac glycosides","MTMOPPMT","Million US$, purchasing power parity","ISL","Iceland","2014","2014",0.1,,
+"PATCGLYC","C01A-Cardiac glycosides","MTMOPPMT","Million US$, purchasing power parity","ISL","Iceland","2015","2015",0.1,,
+"PATCGLYC","C01A-Cardiac glycosides","MTMOPPMT","Million US$, purchasing power parity","ISL","Iceland","2016","2016",0.1,,
+"PATCGLYC","C01A-Cardiac glycosides","MTMOPPMT","Million US$, purchasing power parity","ISL","Iceland","2017","2017",0.1,,
+"PATCGLYC","C01A-Cardiac glycosides","MTMOPPMT","Million US$, purchasing power parity","ISL","Iceland","2018","2018",0.1,,
+"PATCGLYC","C01A-Cardiac glycosides","MTMOPPMT","Million US$, purchasing power parity","ISL","Iceland","2019","2019",0.1,,
+"PATCGLYC","C01A-Cardiac glycosides","MTMOPPMT","Million US$, purchasing power parity","ISL","Iceland","2020","2020",0.1,,
+"PATCGLYC","C01A-Cardiac glycosides","MTMOPPMT","Million US$, purchasing power parity","ISL","Iceland","2021","2021",0.1,,
+"PATCGLYC","C01A-Cardiac glycosides","TCPPERMT","/capita, US$ exchange rate","ISL","Iceland","2010","2010",0.2,,
+"PATCGLYC","C01A-Cardiac glycosides","TCPPERMT","/capita, US$ exchange rate","ISL","Iceland","2011","2011",0.3,,
+"PATCGLYC","C01A-Cardiac glycosides","TCPPERMT","/capita, US$ exchange rate","ISL","Iceland","2012","2012",0.3,,
+"PATCGLYC","C01A-Cardiac glycosides","TCPPERMT","/capita, US$ exchange rate","ISL","Iceland","2013","2013",0.3,,
+"PATCGLYC","C01A-Cardiac glycosides","TCPPERMT","/capita, US$ exchange rate","ISL","Iceland","2014","2014",0.3,,
+"PATCGLYC","C01A-Cardiac glycosides","TCPPERMT","/capita, US$ exchange rate","ISL","Iceland","2015","2015",0.3,,
+"PATCGLYC","C01A-Cardiac glycosides","TCPPERMT","/capita, US$ exchange rate","ISL","Iceland","2016","2016",0.3,,
+"PATCGLYC","C01A-Cardiac glycosides","TCPPERMT","/capita, US$ exchange rate","ISL","Iceland","2017","2017",0.3,,
+"PATCGLYC","C01A-Cardiac glycosides","TCPPERMT","/capita, US$ exchange rate","ISL","Iceland","2018","2018",0.3,,
+"PATCGLYC","C01A-Cardiac glycosides","TCPPERMT","/capita, US$ exchange rate","ISL","Iceland","2019","2019",0.2,,
+"PATCGLYC","C01A-Cardiac glycosides","TCPPERMT","/capita, US$ exchange rate","ISL","Iceland","2020","2020",0.2,,
+"PATCGLYC","C01A-Cardiac glycosides","TCPPERMT","/capita, US$ exchange rate","ISL","Iceland","2021","2021",0.2,,
+"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2010","2010",0.2,,
+"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2011","2011",0.2,,
+"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2012","2012",0.2,,
+"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2013","2013",0.3,,
+"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2014","2014",0.3,,
+"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2015","2015",0.2,,
+"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2016","2016",0.2,,
+"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2017","2017",0.2,,
+"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2018","2018",0.2,,
+"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2019","2019",0.2,,
+"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2020","2020",0.2,,
+"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2021","2021",0.2,,
+"PATCGLYC","C01A-Cardiac glycosides","ATCPTTMT","% of total sales","ISL","Iceland","2010","2010",0,,
+"PATCGLYC","C01A-Cardiac glycosides","ATCPTTMT","% of total sales","ISL","Iceland","2011","2011",0,,
+"PATCGLYC","C01A-Cardiac glycosides","ATCPTTMT","% of total sales","ISL","Iceland","2012","2012",0,,
+"PATCGLYC","C01A-Cardiac glycosides","ATCPTTMT","% of total sales","ISL","Iceland","2013","2013",0,,
+"PATCGLYC","C01A-Cardiac glycosides","ATCPTTMT","% of total sales","ISL","Iceland","2014","2014",0,,
+"PATCGLYC","C01A-Cardiac glycosides","ATCPTTMT","% of total sales","ISL","Iceland","2015","2015",0,,
+"PATCGLYC","C01A-Cardiac glycosides","ATCPTTMT","% of total sales","ISL","Iceland","2016","2016",0,,
+"PATCGLYC","C01A-Cardiac glycosides","ATCPTTMT","% of total sales","ISL","Iceland","2017","2017",0,,
+"PATCGLYC","C01A-Cardiac glycosides","ATCPTTMT","% of total sales","ISL","Iceland","2018","2018",0,,
+"PATCGLYC","C01A-Cardiac glycosides","ATCPTTMT","% of total sales","ISL","Iceland","2019","2019",0,,
+"PATCGLYC","C01A-Cardiac glycosides","ATCPTTMT","% of total sales","ISL","Iceland","2020","2020",0,,
+"PATCGLYC","C01A-Cardiac glycosides","ATCPTTMT","% of total sales","ISL","Iceland","2021","2021",0,,
+"PATCGLYC","C01A-Cardiac glycosides","MLLNCUMT","Million of national currency units","IRL","Ireland","2010","2010",1.6,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","MLLNCUMT","Million of national currency units","IRL","Ireland","2011","2011",1.5,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","MLLNCUMT","Million of national currency units","IRL","Ireland","2012","2012",1.5,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","MLLNCUMT","Million of national currency units","IRL","Ireland","2013","2013",1.5,"B; D","Break; Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","MLLNCUMT","Million of national currency units","IRL","Ireland","2014","2014",1.4,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","MLLNCUMT","Million of national currency units","IRL","Ireland","2015","2015",1.3,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","MLLNCUMT","Million of national currency units","IRL","Ireland","2016","2016",1.2,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","MLLNCUMT","Million of national currency units","IRL","Ireland","2017","2017",1.1,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","MLLNCUMT","Million of national currency units","IRL","Ireland","2018","2018",1,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","MLLNCUMT","Million of national currency units","IRL","Ireland","2019","2019",0.9,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","MLLNCUMT","Million of national currency units","IRL","Ireland","2020","2020",0.8,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","MLLNCUMT","Million of national currency units","IRL","Ireland","2021","2021",0.7,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","MTMOTCMT","Million US$ at exchange rate","IRL","Ireland","2010","2010",2.1,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","MTMOTCMT","Million US$ at exchange rate","IRL","Ireland","2011","2011",2.1,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","MTMOTCMT","Million US$ at exchange rate","IRL","Ireland","2012","2012",2,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","MTMOTCMT","Million US$ at exchange rate","IRL","Ireland","2013","2013",2,"B; D","Break; Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","MTMOTCMT","Million US$ at exchange rate","IRL","Ireland","2014","2014",1.9,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","MTMOTCMT","Million US$ at exchange rate","IRL","Ireland","2015","2015",1.5,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","MTMOTCMT","Million US$ at exchange rate","IRL","Ireland","2016","2016",1.4,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","MTMOTCMT","Million US$ at exchange rate","IRL","Ireland","2017","2017",1.2,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","MTMOTCMT","Million US$ at exchange rate","IRL","Ireland","2018","2018",1.1,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","MTMOTCMT","Million US$ at exchange rate","IRL","Ireland","2019","2019",1,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","MTMOTCMT","Million US$ at exchange rate","IRL","Ireland","2020","2020",0.9,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","MTMOTCMT","Million US$ at exchange rate","IRL","Ireland","2021","2021",0.8,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","MTMOPPMT","Million US$, purchasing power parity","IRL","Ireland","2010","2010",1.8,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","MTMOPPMT","Million US$, purchasing power parity","IRL","Ireland","2011","2011",1.9,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","MTMOPPMT","Million US$, purchasing power parity","IRL","Ireland","2012","2012",1.9,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","MTMOPPMT","Million US$, purchasing power parity","IRL","Ireland","2013","2013",1.9,"B; D","Break; Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","MTMOPPMT","Million US$, purchasing power parity","IRL","Ireland","2014","2014",1.7,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","MTMOPPMT","Million US$, purchasing power parity","IRL","Ireland","2015","2015",1.7,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","MTMOPPMT","Million US$, purchasing power parity","IRL","Ireland","2016","2016",1.6,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","MTMOPPMT","Million US$, purchasing power parity","IRL","Ireland","2017","2017",1.4,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","MTMOPPMT","Million US$, purchasing power parity","IRL","Ireland","2018","2018",1.2,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","MTMOPPMT","Million US$, purchasing power parity","IRL","Ireland","2019","2019",1.1,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","MTMOPPMT","Million US$, purchasing power parity","IRL","Ireland","2020","2020",0.9,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","MTMOPPMT","Million US$, purchasing power parity","IRL","Ireland","2021","2021",0.9,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","TCPPERMT","/capita, US$ exchange rate","IRL","Ireland","2010","2010",0.5,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","TCPPERMT","/capita, US$ exchange rate","IRL","Ireland","2011","2011",0.5,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","TCPPERMT","/capita, US$ exchange rate","IRL","Ireland","2012","2012",0.4,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","TCPPERMT","/capita, US$ exchange rate","IRL","Ireland","2013","2013",0.4,"B; D","Break; Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","TCPPERMT","/capita, US$ exchange rate","IRL","Ireland","2014","2014",0.4,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","TCPPERMT","/capita, US$ exchange rate","IRL","Ireland","2015","2015",0.3,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","TCPPERMT","/capita, US$ exchange rate","IRL","Ireland","2016","2016",0.3,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","TCPPERMT","/capita, US$ exchange rate","IRL","Ireland","2017","2017",0.3,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","TCPPERMT","/capita, US$ exchange rate","IRL","Ireland","2018","2018",0.2,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","TCPPERMT","/capita, US$ exchange rate","IRL","Ireland","2019","2019",0.2,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","TCPPERMT","/capita, US$ exchange rate","IRL","Ireland","2020","2020",0.2,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","TCPPERMT","/capita, US$ exchange rate","IRL","Ireland","2021","2021",0.2,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2010","2010",0.4,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2011","2011",0.4,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2012","2012",0.4,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2013","2013",0.4,"B; D","Break; Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2014","2014",0.4,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2015","2015",0.4,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2016","2016",0.3,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2017","2017",0.3,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2018","2018",0.3,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2019","2019",0.2,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2020","2020",0.2,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2021","2021",0.2,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","ATCPTTMT","% of total sales","IRL","Ireland","2010","2010",0.1,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","ATCPTTMT","% of total sales","IRL","Ireland","2011","2011",0.1,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","ATCPTTMT","% of total sales","IRL","Ireland","2012","2012",0.1,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","ATCPTTMT","% of total sales","IRL","Ireland","2013","2013",0.1,"B; D","Break; Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","ATCPTTMT","% of total sales","IRL","Ireland","2014","2014",0.1,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","ATCPTTMT","% of total sales","IRL","Ireland","2015","2015",0.1,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","ATCPTTMT","% of total sales","IRL","Ireland","2016","2016",0.1,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","ATCPTTMT","% of total sales","IRL","Ireland","2017","2017",0.1,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","ATCPTTMT","% of total sales","IRL","Ireland","2018","2018",0,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","ATCPTTMT","% of total sales","IRL","Ireland","2019","2019",0,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","ATCPTTMT","% of total sales","IRL","Ireland","2020","2020",0,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","ATCPTTMT","% of total sales","IRL","Ireland","2021","2021",0,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","MLLNCUMT","Million of national currency units","ITA","Italy","2011","2011",10.6,,
+"PATCGLYC","C01A-Cardiac glycosides","MLLNCUMT","Million of national currency units","ITA","Italy","2012","2012",9.7,,
+"PATCGLYC","C01A-Cardiac glycosides","MLLNCUMT","Million of national currency units","ITA","Italy","2013","2013",8.8,,
+"PATCGLYC","C01A-Cardiac glycosides","MLLNCUMT","Million of national currency units","ITA","Italy","2014","2014",8.1,,
+"PATCGLYC","C01A-Cardiac glycosides","MLLNCUMT","Million of national currency units","ITA","Italy","2015","2015",7.2,,
+"PATCGLYC","C01A-Cardiac glycosides","MLLNCUMT","Million of national currency units","ITA","Italy","2016","2016",6.5,,
+"PATCGLYC","C01A-Cardiac glycosides","MLLNCUMT","Million of national currency units","ITA","Italy","2017","2017",5.9,,
+"PATCGLYC","C01A-Cardiac glycosides","MLLNCUMT","Million of national currency units","ITA","Italy","2018","2018",5.4,,
+"PATCGLYC","C01A-Cardiac glycosides","MLLNCUMT","Million of national currency units","ITA","Italy","2019","2019",4.9,,
+"PATCGLYC","C01A-Cardiac glycosides","MLLNCUMT","Million of national currency units","ITA","Italy","2020","2020",4.5,,
+"PATCGLYC","C01A-Cardiac glycosides","MLLNCUMT","Million of national currency units","ITA","Italy","2021","2021",4.2,,
+"PATCGLYC","C01A-Cardiac glycosides","MLLNCUMT","Million of national currency units","ITA","Italy","2022","2022",3.9,"E","Estimated value"
+"PATCGLYC","C01A-Cardiac glycosides","MTMOTCMT","Million US$ at exchange rate","ITA","Italy","2011","2011",14.7,,
+"PATCGLYC","C01A-Cardiac glycosides","MTMOTCMT","Million US$ at exchange rate","ITA","Italy","2012","2012",12.5,,
+"PATCGLYC","C01A-Cardiac glycosides","MTMOTCMT","Million US$ at exchange rate","ITA","Italy","2013","2013",11.7,,
+"PATCGLYC","C01A-Cardiac glycosides","MTMOTCMT","Million US$ at exchange rate","ITA","Italy","2014","2014",10.7,,
+"PATCGLYC","C01A-Cardiac glycosides","MTMOTCMT","Million US$ at exchange rate","ITA","Italy","2015","2015",8,,
+"PATCGLYC","C01A-Cardiac glycosides","MTMOTCMT","Million US$ at exchange rate","ITA","Italy","2016","2016",7.2,,
+"PATCGLYC","C01A-Cardiac glycosides","MTMOTCMT","Million US$ at exchange rate","ITA","Italy","2017","2017",6.7,,
+"PATCGLYC","C01A-Cardiac glycosides","MTMOTCMT","Million US$ at exchange rate","ITA","Italy","2018","2018",6.3,,
+"PATCGLYC","C01A-Cardiac glycosides","MTMOTCMT","Million US$ at exchange rate","ITA","Italy","2019","2019",5.5,,
+"PATCGLYC","C01A-Cardiac glycosides","MTMOTCMT","Million US$ at exchange rate","ITA","Italy","2020","2020",5.2,,
+"PATCGLYC","C01A-Cardiac glycosides","MTMOTCMT","Million US$ at exchange rate","ITA","Italy","2021","2021",5,,
+"PATCGLYC","C01A-Cardiac glycosides","MTMOTCMT","Million US$ at exchange rate","ITA","Italy","2022","2022",4.1,"E","Estimated value"
+"PATCGLYC","C01A-Cardiac glycosides","MTMOPPMT","Million US$, purchasing power parity","ITA","Italy","2011","2011",14,,
+"PATCGLYC","C01A-Cardiac glycosides","MTMOPPMT","Million US$, purchasing power parity","ITA","Italy","2012","2012",13,,
+"PATCGLYC","C01A-Cardiac glycosides","MTMOPPMT","Million US$, purchasing power parity","ITA","Italy","2013","2013",11.9,,
+"PATCGLYC","C01A-Cardiac glycosides","MTMOPPMT","Million US$, purchasing power parity","ITA","Italy","2014","2014",10.9,,
+"PATCGLYC","C01A-Cardiac glycosides","MTMOPPMT","Million US$, purchasing power parity","ITA","Italy","2015","2015",9.8,,
+"PATCGLYC","C01A-Cardiac glycosides","MTMOPPMT","Million US$, purchasing power parity","ITA","Italy","2016","2016",9.3,,
+"PATCGLYC","C01A-Cardiac glycosides","MTMOPPMT","Million US$, purchasing power parity","ITA","Italy","2017","2017",8.6,,
+"PATCGLYC","C01A-Cardiac glycosides","MTMOPPMT","Million US$, purchasing power parity","ITA","Italy","2018","2018",7.9,,
+"PATCGLYC","C01A-Cardiac glycosides","MTMOPPMT","Million US$, purchasing power parity","ITA","Italy","2019","2019",7.5,,
+"PATCGLYC","C01A-Cardiac glycosides","MTMOPPMT","Million US$, purchasing power parity","ITA","Italy","2020","2020",7,,
+"PATCGLYC","C01A-Cardiac glycosides","MTMOPPMT","Million US$, purchasing power parity","ITA","Italy","2021","2021",6.5,,
+"PATCGLYC","C01A-Cardiac glycosides","MTMOPPMT","Million US$, purchasing power parity","ITA","Italy","2022","2022",6.3,"E","Estimated value"
+"PATCGLYC","C01A-Cardiac glycosides","TCPPERMT","/capita, US$ exchange rate","ITA","Italy","2011","2011",0.2,,
+"PATCGLYC","C01A-Cardiac glycosides","TCPPERMT","/capita, US$ exchange rate","ITA","Italy","2012","2012",0.2,,
+"PATCGLYC","C01A-Cardiac glycosides","TCPPERMT","/capita, US$ exchange rate","ITA","Italy","2013","2013",0.2,,
+"PATCGLYC","C01A-Cardiac glycosides","TCPPERMT","/capita, US$ exchange rate","ITA","Italy","2014","2014",0.2,,
+"PATCGLYC","C01A-Cardiac glycosides","TCPPERMT","/capita, US$ exchange rate","ITA","Italy","2015","2015",0.1,,
+"PATCGLYC","C01A-Cardiac glycosides","TCPPERMT","/capita, US$ exchange rate","ITA","Italy","2016","2016",0.1,,
+"PATCGLYC","C01A-Cardiac glycosides","TCPPERMT","/capita, US$ exchange rate","ITA","Italy","2017","2017",0.1,,
+"PATCGLYC","C01A-Cardiac glycosides","TCPPERMT","/capita, US$ exchange rate","ITA","Italy","2018","2018",0.1,,
+"PATCGLYC","C01A-Cardiac glycosides","TCPPERMT","/capita, US$ exchange rate","ITA","Italy","2019","2019",0.1,,
+"PATCGLYC","C01A-Cardiac glycosides","TCPPERMT","/capita, US$ exchange rate","ITA","Italy","2020","2020",0.1,,
+"PATCGLYC","C01A-Cardiac glycosides","TCPPERMT","/capita, US$ exchange rate","ITA","Italy","2021","2021",0.1,,
+"PATCGLYC","C01A-Cardiac glycosides","TCPPERMT","/capita, US$ exchange rate","ITA","Italy","2022","2022",0.1,"E","Estimated value"
+"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2011","2011",0.2,,
+"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2012","2012",0.2,,
+"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2013","2013",0.2,,
+"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2014","2014",0.2,,
+"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2015","2015",0.2,,
+"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2016","2016",0.2,,
+"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2017","2017",0.1,,
+"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2018","2018",0.1,,
+"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2019","2019",0.1,,
+"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2020","2020",0.1,,
+"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2021","2021",0.1,,
+"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2022","2022",0.1,"E","Estimated value"
+"PATCGLYC","C01A-Cardiac glycosides","ATCPTTMT","% of total sales","ITA","Italy","2011","2011",0.1,,
+"PATCGLYC","C01A-Cardiac glycosides","ATCPTTMT","% of total sales","ITA","Italy","2012","2012",0.1,,
+"PATCGLYC","C01A-Cardiac glycosides","ATCPTTMT","% of total sales","ITA","Italy","2013","2013",0,,
+"PATCGLYC","C01A-Cardiac glycosides","ATCPTTMT","% of total sales","ITA","Italy","2014","2014",0,,
+"PATCGLYC","C01A-Cardiac glycosides","ATCPTTMT","% of total sales","ITA","Italy","2015","2015",0,,
+"PATCGLYC","C01A-Cardiac glycosides","ATCPTTMT","% of total sales","ITA","Italy","2016","2016",0,,
+"PATCGLYC","C01A-Cardiac glycosides","ATCPTTMT","% of total sales","ITA","Italy","2017","2017",0,,
+"PATCGLYC","C01A-Cardiac glycosides","ATCPTTMT","% of total sales","ITA","Italy","2018","2018",0,,
+"PATCGLYC","C01A-Cardiac glycosides","ATCPTTMT","% of total sales","ITA","Italy","2019","2019",0,,
+"PATCGLYC","C01A-Cardiac glycosides","ATCPTTMT","% of total sales","ITA","Italy","2020","2020",0,,
+"PATCGLYC","C01A-Cardiac glycosides","ATCPTTMT","% of total sales","ITA","Italy","2021","2021",0,,
+"PATCGLYC","C01A-Cardiac glycosides","ATCPTTMT","% of total sales","ITA","Italy","2022","2022",0,"E","Estimated value"
+"PATCGLYC","C01A-Cardiac glycosides","MLLNCUMT","Million of national currency units","KOR","Korea","2010","2010",781,,
+"PATCGLYC","C01A-Cardiac glycosides","MLLNCUMT","Million of national currency units","KOR","Korea","2011","2011",788.4,"B","Break"
+"PATCGLYC","C01A-Cardiac glycosides","MLLNCUMT","Million of national currency units","KOR","Korea","2012","2012",770.1,,
+"PATCGLYC","C01A-Cardiac glycosides","MLLNCUMT","Million of national currency units","KOR","Korea","2013","2013",952.5,,
+"PATCGLYC","C01A-Cardiac glycosides","MLLNCUMT","Million of national currency units","KOR","Korea","2014","2014",883.4,,
+"PATCGLYC","C01A-Cardiac glycosides","MLLNCUMT","Million of national currency units","KOR","Korea","2015","2015",864,,
+"PATCGLYC","C01A-Cardiac glycosides","MLLNCUMT","Million of national currency units","KOR","Korea","2016","2016",740.8,"B","Break"
+"PATCGLYC","C01A-Cardiac glycosides","MLLNCUMT","Million of national currency units","KOR","Korea","2017","2017",704.1,,
+"PATCGLYC","C01A-Cardiac glycosides","MLLNCUMT","Million of national currency units","KOR","Korea","2018","2018",667.4,,
+"PATCGLYC","C01A-Cardiac glycosides","MLLNCUMT","Million of national currency units","KOR","Korea","2019","2019",625.8,,
+"PATCGLYC","C01A-Cardiac glycosides","MLLNCUMT","Million of national currency units","KOR","Korea","2020","2020",679.7,,
+"PATCGLYC","C01A-Cardiac glycosides","MLLNCUMT","Million of national currency units","KOR","Korea","2021","2021",620,,
+"PATCGLYC","C01A-Cardiac glycosides","MTMOTCMT","Million US$ at exchange rate","KOR","Korea","2010","2010",0.7,,
+"PATCGLYC","C01A-Cardiac glycosides","MTMOTCMT","Million US$ at exchange rate","KOR","Korea","2011","2011",0.7,"B","Break"
+"PATCGLYC","C01A-Cardiac glycosides","MTMOTCMT","Million US$ at exchange rate","KOR","Korea","2012","2012",0.7,,
+"PATCGLYC","C01A-Cardiac glycosides","MTMOTCMT","Million US$ at exchange rate","KOR","Korea","2013","2013",0.9,,
+"PATCGLYC","C01A-Cardiac glycosides","MTMOTCMT","Million US$ at exchange rate","KOR","Korea","2014","2014",0.8,,
+"PATCGLYC","C01A-Cardiac glycosides","MTMOTCMT","Million US$ at exchange rate","KOR","Korea","2015","2015",0.8,,
+"PATCGLYC","C01A-Cardiac glycosides","MTMOTCMT","Million US$ at exchange rate","KOR","Korea","2016","2016",0.6,"B","Break"
+"PATCGLYC","C01A-Cardiac glycosides","MTMOTCMT","Million US$ at exchange rate","KOR","Korea","2017","2017",0.6,,
+"PATCGLYC","C01A-Cardiac glycosides","MTMOTCMT","Million US$ at exchange rate","KOR","Korea","2018","2018",0.6,,
+"PATCGLYC","C01A-Cardiac glycosides","MTMOTCMT","Million US$ at exchange rate","KOR","Korea","2019","2019",0.5,,
+"PATCGLYC","C01A-Cardiac glycosides","MTMOTCMT","Million US$ at exchange rate","KOR","Korea","2020","2020",0.6,,
+"PATCGLYC","C01A-Cardiac glycosides","MTMOTCMT","Million US$ at exchange rate","KOR","Korea","2021","2021",0.5,,
+"PATCGLYC","C01A-Cardiac glycosides","MTMOPPMT","Million US$, purchasing power parity","KOR","Korea","2010","2010",0.9,,
+"PATCGLYC","C01A-Cardiac glycosides","MTMOPPMT","Million US$, purchasing power parity","KOR","Korea","2011","2011",0.9,"B","Break"
+"PATCGLYC","C01A-Cardiac glycosides","MTMOPPMT","Million US$, purchasing power parity","KOR","Korea","2012","2012",0.9,,
+"PATCGLYC","C01A-Cardiac glycosides","MTMOPPMT","Million US$, purchasing power parity","KOR","Korea","2013","2013",1.1,,
+"PATCGLYC","C01A-Cardiac glycosides","MTMOPPMT","Million US$, purchasing power parity","KOR","Korea","2014","2014",1,,
+"PATCGLYC","C01A-Cardiac glycosides","MTMOPPMT","Million US$, purchasing power parity","KOR","Korea","2015","2015",1,,
+"PATCGLYC","C01A-Cardiac glycosides","MTMOPPMT","Million US$, purchasing power parity","KOR","Korea","2016","2016",0.9,"B","Break"
+"PATCGLYC","C01A-Cardiac glycosides","MTMOPPMT","Million US$, purchasing power parity","KOR","Korea","2017","2017",0.8,,
+"PATCGLYC","C01A-Cardiac glycosides","MTMOPPMT","Million US$, purchasing power parity","KOR","Korea","2018","2018",0.8,,
+"PATCGLYC","C01A-Cardiac glycosides","MTMOPPMT","Million US$, purchasing power parity","KOR","Korea","2019","2019",0.7,,
+"PATCGLYC","C01A-Cardiac glycosides","MTMOPPMT","Million US$, purchasing power parity","KOR","Korea","2020","2020",0.8,,
+"PATCGLYC","C01A-Cardiac glycosides","MTMOPPMT","Million US$, purchasing power parity","KOR","Korea","2021","2021",0.7,,
+"PATCGLYC","C01A-Cardiac glycosides","TCPPERMT","/capita, US$ exchange rate","KOR","Korea","2010","2010",0,,
+"PATCGLYC","C01A-Cardiac glycosides","TCPPERMT","/capita, US$ exchange rate","KOR","Korea","2011","2011",0,"B","Break"
+"PATCGLYC","C01A-Cardiac glycosides","TCPPERMT","/capita, US$ exchange rate","KOR","Korea","2012","2012",0,,
+"PATCGLYC","C01A-Cardiac glycosides","TCPPERMT","/capita, US$ exchange rate","KOR","Korea","2013","2013",0,,
+"PATCGLYC","C01A-Cardiac glycosides","TCPPERMT","/capita, US$ exchange rate","KOR","Korea","2014","2014",0,,
+"PATCGLYC","C01A-Cardiac glycosides","TCPPERMT","/capita, US$ exchange rate","KOR","Korea","2015","2015",0,,
+"PATCGLYC","C01A-Cardiac glycosides","TCPPERMT","/capita, US$ exchange rate","KOR","Korea","2016","2016",0,"B","Break"
+"PATCGLYC","C01A-Cardiac glycosides","TCPPERMT","/capita, US$ exchange rate","KOR","Korea","2017","2017",0,,
+"PATCGLYC","C01A-Cardiac glycosides","TCPPERMT","/capita, US$ exchange rate","KOR","Korea","2018","2018",0,,
+"PATCGLYC","C01A-Cardiac glycosides","TCPPERMT","/capita, US$ exchange rate","KOR","Korea","2019","2019",0,,
+"PATCGLYC","C01A-Cardiac glycosides","TCPPERMT","/capita, US$ exchange rate","KOR","Korea","2020","2020",0,,
+"PATCGLYC","C01A-Cardiac glycosides","TCPPERMT","/capita, US$ exchange rate","KOR","Korea","2021","2021",0,,
+"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2010","2010",0,,
+"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2011","2011",0,"B","Break"
+"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2012","2012",0,,
+"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2013","2013",0,,
+"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2014","2014",0,,
+"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2015","2015",0,,
+"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2016","2016",0,"B","Break"
+"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2017","2017",0,,
+"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2018","2018",0,,
+"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2019","2019",0,,
+"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2020","2020",0,,
+"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2021","2021",0,,
+"PATCGLYC","C01A-Cardiac glycosides","ATCPTTMT","% of total sales","KOR","Korea","2010","2010",0,,
+"PATCGLYC","C01A-Cardiac glycosides","ATCPTTMT","% of total sales","KOR","Korea","2011","2011",0,"B","Break"
+"PATCGLYC","C01A-Cardiac glycosides","ATCPTTMT","% of total sales","KOR","Korea","2012","2012",0,,
+"PATCGLYC","C01A-Cardiac glycosides","ATCPTTMT","% of total sales","KOR","Korea","2013","2013",0,,
+"PATCGLYC","C01A-Cardiac glycosides","ATCPTTMT","% of total sales","KOR","Korea","2014","2014",0,,
+"PATCGLYC","C01A-Cardiac glycosides","ATCPTTMT","% of total sales","KOR","Korea","2015","2015",0,,
+"PATCGLYC","C01A-Cardiac glycosides","ATCPTTMT","% of total sales","KOR","Korea","2016","2016",0,"B","Break"
+"PATCGLYC","C01A-Cardiac glycosides","ATCPTTMT","% of total sales","KOR","Korea","2017","2017",0,,
+"PATCGLYC","C01A-Cardiac glycosides","ATCPTTMT","% of total sales","KOR","Korea","2018","2018",0,,
+"PATCGLYC","C01A-Cardiac glycosides","ATCPTTMT","% of total sales","KOR","Korea","2019","2019",0,,
+"PATCGLYC","C01A-Cardiac glycosides","ATCPTTMT","% of total sales","KOR","Korea","2020","2020",0,,
+"PATCGLYC","C01A-Cardiac glycosides","ATCPTTMT","% of total sales","KOR","Korea","2021","2021",0,,
+"PATCGLYC","C01A-Cardiac glycosides","MLLNCUMT","Million of national currency units","LUX","Luxembourg","2010","2010",0,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","MLLNCUMT","Million of national currency units","LUX","Luxembourg","2011","2011",0.1,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","MLLNCUMT","Million of national currency units","LUX","Luxembourg","2012","2012",0.1,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","MLLNCUMT","Million of national currency units","LUX","Luxembourg","2013","2013",0.1,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","MLLNCUMT","Million of national currency units","LUX","Luxembourg","2014","2014",0,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","MLLNCUMT","Million of national currency units","LUX","Luxembourg","2015","2015",0,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","MLLNCUMT","Million of national currency units","LUX","Luxembourg","2016","2016",0,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","MLLNCUMT","Million of national currency units","LUX","Luxembourg","2017","2017",0,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","MLLNCUMT","Million of national currency units","LUX","Luxembourg","2018","2018",0,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","MLLNCUMT","Million of national currency units","LUX","Luxembourg","2019","2019",0,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","MLLNCUMT","Million of national currency units","LUX","Luxembourg","2020","2020",0,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","MLLNCUMT","Million of national currency units","LUX","Luxembourg","2021","2021",0,"B; D; P","Break; Difference in methodology; Provisional value"
+"PATCGLYC","C01A-Cardiac glycosides","MLLNCUMT","Million of national currency units","LUX","Luxembourg","2022","2022",0,"D; P","Difference in methodology; Provisional value"
+"PATCGLYC","C01A-Cardiac glycosides","MTMOTCMT","Million US$ at exchange rate","LUX","Luxembourg","2010","2010",0,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","MTMOTCMT","Million US$ at exchange rate","LUX","Luxembourg","2011","2011",0.1,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","MTMOTCMT","Million US$ at exchange rate","LUX","Luxembourg","2012","2012",0.1,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","MTMOTCMT","Million US$ at exchange rate","LUX","Luxembourg","2013","2013",0.1,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","MTMOTCMT","Million US$ at exchange rate","LUX","Luxembourg","2014","2014",0.1,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","MTMOTCMT","Million US$ at exchange rate","LUX","Luxembourg","2015","2015",0,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","MTMOTCMT","Million US$ at exchange rate","LUX","Luxembourg","2016","2016",0,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","MTMOTCMT","Million US$ at exchange rate","LUX","Luxembourg","2017","2017",0,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","MTMOTCMT","Million US$ at exchange rate","LUX","Luxembourg","2018","2018",0,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","MTMOTCMT","Million US$ at exchange rate","LUX","Luxembourg","2019","2019",0,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","MTMOTCMT","Million US$ at exchange rate","LUX","Luxembourg","2020","2020",0,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","MTMOTCMT","Million US$ at exchange rate","LUX","Luxembourg","2021","2021",0,"B; D; P","Break; Difference in methodology; Provisional value"
+"PATCGLYC","C01A-Cardiac glycosides","MTMOTCMT","Million US$ at exchange rate","LUX","Luxembourg","2022","2022",0,"D; P","Difference in methodology; Provisional value"
+"PATCGLYC","C01A-Cardiac glycosides","MTMOPPMT","Million US$, purchasing power parity","LUX","Luxembourg","2010","2010",0,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","MTMOPPMT","Million US$, purchasing power parity","LUX","Luxembourg","2011","2011",0.1,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","MTMOPPMT","Million US$, purchasing power parity","LUX","Luxembourg","2012","2012",0.1,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","MTMOPPMT","Million US$, purchasing power parity","LUX","Luxembourg","2013","2013",0.1,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","MTMOPPMT","Million US$, purchasing power parity","LUX","Luxembourg","2014","2014",0,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","MTMOPPMT","Million US$, purchasing power parity","LUX","Luxembourg","2015","2015",0,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","MTMOPPMT","Million US$, purchasing power parity","LUX","Luxembourg","2016","2016",0,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","MTMOPPMT","Million US$, purchasing power parity","LUX","Luxembourg","2017","2017",0,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","MTMOPPMT","Million US$, purchasing power parity","LUX","Luxembourg","2018","2018",0,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","MTMOPPMT","Million US$, purchasing power parity","LUX","Luxembourg","2019","2019",0,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","MTMOPPMT","Million US$, purchasing power parity","LUX","Luxembourg","2020","2020",0,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","MTMOPPMT","Million US$, purchasing power parity","LUX","Luxembourg","2021","2021",0,"B; D; P","Break; Difference in methodology; Provisional value"
+"PATCGLYC","C01A-Cardiac glycosides","MTMOPPMT","Million US$, purchasing power parity","LUX","Luxembourg","2022","2022",0,"D; P","Difference in methodology; Provisional value"
+"PATCGLYC","C01A-Cardiac glycosides","TCPPERMT","/capita, US$ exchange rate","LUX","Luxembourg","2010","2010",0.1,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","TCPPERMT","/capita, US$ exchange rate","LUX","Luxembourg","2011","2011",0.1,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","TCPPERMT","/capita, US$ exchange rate","LUX","Luxembourg","2012","2012",0.1,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","TCPPERMT","/capita, US$ exchange rate","LUX","Luxembourg","2013","2013",0.1,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","TCPPERMT","/capita, US$ exchange rate","LUX","Luxembourg","2014","2014",0.1,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","TCPPERMT","/capita, US$ exchange rate","LUX","Luxembourg","2015","2015",0.1,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","TCPPERMT","/capita, US$ exchange rate","LUX","Luxembourg","2016","2016",0.1,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","TCPPERMT","/capita, US$ exchange rate","LUX","Luxembourg","2017","2017",0.1,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","TCPPERMT","/capita, US$ exchange rate","LUX","Luxembourg","2018","2018",0.1,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","TCPPERMT","/capita, US$ exchange rate","LUX","Luxembourg","2019","2019",0.1,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","TCPPERMT","/capita, US$ exchange rate","LUX","Luxembourg","2020","2020",0.1,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","TCPPERMT","/capita, US$ exchange rate","LUX","Luxembourg","2021","2021",0.1,"B; D; P","Break; Difference in methodology; Provisional value"
+"PATCGLYC","C01A-Cardiac glycosides","TCPPERMT","/capita, US$ exchange rate","LUX","Luxembourg","2022","2022",0.1,"D; P","Difference in methodology; Provisional value"
+"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2010","2010",0.1,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2011","2011",0.1,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2012","2012",0.1,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2013","2013",0.1,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2014","2014",0.1,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2015","2015",0.1,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2016","2016",0.1,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2017","2017",0.1,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2018","2018",0.1,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2019","2019",0.1,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2020","2020",0.1,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2021","2021",0.1,"B; D; P","Break; Difference in methodology; Provisional value"
+"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2022","2022",0.1,"D; P","Difference in methodology; Provisional value"
+"PATCGLYC","C01A-Cardiac glycosides","ATCPTTMT","% of total sales","LUX","Luxembourg","2010","2010",0,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","ATCPTTMT","% of total sales","LUX","Luxembourg","2011","2011",0,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","ATCPTTMT","% of total sales","LUX","Luxembourg","2012","2012",0,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","ATCPTTMT","% of total sales","LUX","Luxembourg","2013","2013",0,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","ATCPTTMT","% of total sales","LUX","Luxembourg","2014","2014",0,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","ATCPTTMT","% of total sales","LUX","Luxembourg","2015","2015",0,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","ATCPTTMT","% of total sales","LUX","Luxembourg","2016","2016",0,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","ATCPTTMT","% of total sales","LUX","Luxembourg","2017","2017",0,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","ATCPTTMT","% of total sales","LUX","Luxembourg","2018","2018",0,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","ATCPTTMT","% of total sales","LUX","Luxembourg","2019","2019",0,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","ATCPTTMT","% of total sales","LUX","Luxembourg","2020","2020",0,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","ATCPTTMT","% of total sales","LUX","Luxembourg","2021","2021",0,"B; D; P","Break; Difference in methodology; Provisional value"
+"PATCGLYC","C01A-Cardiac glycosides","ATCPTTMT","% of total sales","LUX","Luxembourg","2022","2022",0,"D; P","Difference in methodology; Provisional value"
+"PATCGLYC","C01A-Cardiac glycosides","MLLNCUMT","Million of national currency units","NLD","Netherlands","2010","2010",6.4,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","MLLNCUMT","Million of national currency units","NLD","Netherlands","2011","2011",6.5,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","MLLNCUMT","Million of national currency units","NLD","Netherlands","2012","2012",6.5,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","MLLNCUMT","Million of national currency units","NLD","Netherlands","2013","2013",6.4,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","MLLNCUMT","Million of national currency units","NLD","Netherlands","2014","2014",6,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","MTMOTCMT","Million US$ at exchange rate","NLD","Netherlands","2010","2010",8.4,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","MTMOTCMT","Million US$ at exchange rate","NLD","Netherlands","2011","2011",9,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","MTMOTCMT","Million US$ at exchange rate","NLD","Netherlands","2012","2012",8.3,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","MTMOTCMT","Million US$ at exchange rate","NLD","Netherlands","2013","2013",8.6,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","MTMOTCMT","Million US$ at exchange rate","NLD","Netherlands","2014","2014",7.9,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","MTMOPPMT","Million US$, purchasing power parity","NLD","Netherlands","2010","2010",7.4,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","MTMOPPMT","Million US$, purchasing power parity","NLD","Netherlands","2011","2011",7.7,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","MTMOPPMT","Million US$, purchasing power parity","NLD","Netherlands","2012","2012",7.8,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","MTMOPPMT","Million US$, purchasing power parity","NLD","Netherlands","2013","2013",8.1,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","MTMOPPMT","Million US$, purchasing power parity","NLD","Netherlands","2014","2014",7.4,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","TCPPERMT","/capita, US$ exchange rate","NLD","Netherlands","2010","2010",0.5,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","TCPPERMT","/capita, US$ exchange rate","NLD","Netherlands","2011","2011",0.5,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","TCPPERMT","/capita, US$ exchange rate","NLD","Netherlands","2012","2012",0.5,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","TCPPERMT","/capita, US$ exchange rate","NLD","Netherlands","2013","2013",0.5,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","TCPPERMT","/capita, US$ exchange rate","NLD","Netherlands","2014","2014",0.5,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","NLD","Netherlands","2010","2010",0.4,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","NLD","Netherlands","2011","2011",0.5,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","NLD","Netherlands","2012","2012",0.5,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","NLD","Netherlands","2013","2013",0.5,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","NLD","Netherlands","2014","2014",0.4,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","ATCPTTMT","% of total sales","NLD","Netherlands","2010","2010",0.1,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","ATCPTTMT","% of total sales","NLD","Netherlands","2011","2011",0.1,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","ATCPTTMT","% of total sales","NLD","Netherlands","2012","2012",0.1,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","ATCPTTMT","% of total sales","NLD","Netherlands","2013","2013",0.1,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","ATCPTTMT","% of total sales","NLD","Netherlands","2014","2014",0.1,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","MLLNCUMT","Million of national currency units","NZL","New Zealand","2010","2010",0.4,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","MLLNCUMT","Million of national currency units","NZL","New Zealand","2011","2011",0.4,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","MLLNCUMT","Million of national currency units","NZL","New Zealand","2012","2012",0.4,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","MLLNCUMT","Million of national currency units","NZL","New Zealand","2013","2013",0.4,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","MLLNCUMT","Million of national currency units","NZL","New Zealand","2014","2014",0.4,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","MLLNCUMT","Million of national currency units","NZL","New Zealand","2015","2015",0.4,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","MLLNCUMT","Million of national currency units","NZL","New Zealand","2016","2016",0.3,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","MLLNCUMT","Million of national currency units","NZL","New Zealand","2017","2017",0.4,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","MLLNCUMT","Million of national currency units","NZL","New Zealand","2018","2018",0.3,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","MLLNCUMT","Million of national currency units","NZL","New Zealand","2019","2019",0.3,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","MLLNCUMT","Million of national currency units","NZL","New Zealand","2020","2020",0.3,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","MLLNCUMT","Million of national currency units","NZL","New Zealand","2021","2021",0.3,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","MLLNCUMT","Million of national currency units","NZL","New Zealand","2022","2022",0.3,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","MTMOTCMT","Million US$ at exchange rate","NZL","New Zealand","2010","2010",0.3,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","MTMOTCMT","Million US$ at exchange rate","NZL","New Zealand","2011","2011",0.3,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","MTMOTCMT","Million US$ at exchange rate","NZL","New Zealand","2012","2012",0.3,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","MTMOTCMT","Million US$ at exchange rate","NZL","New Zealand","2013","2013",0.3,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","MTMOTCMT","Million US$ at exchange rate","NZL","New Zealand","2014","2014",0.3,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","MTMOTCMT","Million US$ at exchange rate","NZL","New Zealand","2015","2015",0.2,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","MTMOTCMT","Million US$ at exchange rate","NZL","New Zealand","2016","2016",0.2,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","MTMOTCMT","Million US$ at exchange rate","NZL","New Zealand","2017","2017",0.2,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","MTMOTCMT","Million US$ at exchange rate","NZL","New Zealand","2018","2018",0.2,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","MTMOTCMT","Million US$ at exchange rate","NZL","New Zealand","2019","2019",0.2,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","MTMOTCMT","Million US$ at exchange rate","NZL","New Zealand","2020","2020",0.2,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","MTMOTCMT","Million US$ at exchange rate","NZL","New Zealand","2021","2021",0.2,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","MTMOTCMT","Million US$ at exchange rate","NZL","New Zealand","2022","2022",0.2,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","MTMOPPMT","Million US$, purchasing power parity","NZL","New Zealand","2010","2010",0.3,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","MTMOPPMT","Million US$, purchasing power parity","NZL","New Zealand","2011","2011",0.3,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","MTMOPPMT","Million US$, purchasing power parity","NZL","New Zealand","2012","2012",0.3,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","MTMOPPMT","Million US$, purchasing power parity","NZL","New Zealand","2013","2013",0.3,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","MTMOPPMT","Million US$, purchasing power parity","NZL","New Zealand","2014","2014",0.3,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","MTMOPPMT","Million US$, purchasing power parity","NZL","New Zealand","2015","2015",0.2,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","MTMOPPMT","Million US$, purchasing power parity","NZL","New Zealand","2016","2016",0.2,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","MTMOPPMT","Million US$, purchasing power parity","NZL","New Zealand","2017","2017",0.2,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","MTMOPPMT","Million US$, purchasing power parity","NZL","New Zealand","2018","2018",0.2,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","MTMOPPMT","Million US$, purchasing power parity","NZL","New Zealand","2019","2019",0.2,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","MTMOPPMT","Million US$, purchasing power parity","NZL","New Zealand","2020","2020",0.2,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","MTMOPPMT","Million US$, purchasing power parity","NZL","New Zealand","2021","2021",0.2,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","MTMOPPMT","Million US$, purchasing power parity","NZL","New Zealand","2022","2022",0.2,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","TCPPERMT","/capita, US$ exchange rate","NZL","New Zealand","2010","2010",0.1,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","TCPPERMT","/capita, US$ exchange rate","NZL","New Zealand","2011","2011",0.1,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","TCPPERMT","/capita, US$ exchange rate","NZL","New Zealand","2012","2012",0.1,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","TCPPERMT","/capita, US$ exchange rate","NZL","New Zealand","2013","2013",0.1,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","TCPPERMT","/capita, US$ exchange rate","NZL","New Zealand","2014","2014",0.1,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","TCPPERMT","/capita, US$ exchange rate","NZL","New Zealand","2015","2015",0.1,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","TCPPERMT","/capita, US$ exchange rate","NZL","New Zealand","2016","2016",0,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","TCPPERMT","/capita, US$ exchange rate","NZL","New Zealand","2017","2017",0.1,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","TCPPERMT","/capita, US$ exchange rate","NZL","New Zealand","2018","2018",0,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","TCPPERMT","/capita, US$ exchange rate","NZL","New Zealand","2019","2019",0,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","TCPPERMT","/capita, US$ exchange rate","NZL","New Zealand","2020","2020",0,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","TCPPERMT","/capita, US$ exchange rate","NZL","New Zealand","2021","2021",0,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","TCPPERMT","/capita, US$ exchange rate","NZL","New Zealand","2022","2022",0,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2010","2010",0.1,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2011","2011",0.1,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2012","2012",0.1,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2013","2013",0.1,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2014","2014",0.1,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2015","2015",0.1,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2016","2016",0,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2017","2017",0.1,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2018","2018",0,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2019","2019",0,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2020","2020",0,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2021","2021",0,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2022","2022",0,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","ATCPTTMT","% of total sales","NZL","New Zealand","2010","2010",0.1,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","ATCPTTMT","% of total sales","NZL","New Zealand","2011","2011",0,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","ATCPTTMT","% of total sales","NZL","New Zealand","2012","2012",0,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","ATCPTTMT","% of total sales","NZL","New Zealand","2013","2013",0,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","ATCPTTMT","% of total sales","NZL","New Zealand","2014","2014",0,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","ATCPTTMT","% of total sales","NZL","New Zealand","2015","2015",0,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","ATCPTTMT","% of total sales","NZL","New Zealand","2016","2016",0,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","ATCPTTMT","% of total sales","NZL","New Zealand","2017","2017",0,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","ATCPTTMT","% of total sales","NZL","New Zealand","2018","2018",0,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","ATCPTTMT","% of total sales","NZL","New Zealand","2019","2019",0,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","ATCPTTMT","% of total sales","NZL","New Zealand","2020","2020",0,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","ATCPTTMT","% of total sales","NZL","New Zealand","2021","2021",0,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","ATCPTTMT","% of total sales","NZL","New Zealand","2022","2022",0,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","MLLNCUMT","Million of national currency units","NOR","Norway","2010","2010",5,,
+"PATCGLYC","C01A-Cardiac glycosides","MLLNCUMT","Million of national currency units","NOR","Norway","2011","2011",3,,
+"PATCGLYC","C01A-Cardiac glycosides","MLLNCUMT","Million of national currency units","NOR","Norway","2012","2012",3,,
+"PATCGLYC","C01A-Cardiac glycosides","MLLNCUMT","Million of national currency units","NOR","Norway","2013","2013",5,,
+"PATCGLYC","C01A-Cardiac glycosides","MLLNCUMT","Million of national currency units","NOR","Norway","2014","2014",5,,
+"PATCGLYC","C01A-Cardiac glycosides","MLLNCUMT","Million of national currency units","NOR","Norway","2015","2015",5,,
+"PATCGLYC","C01A-Cardiac glycosides","MLLNCUMT","Million of national currency units","NOR","Norway","2016","2016",5,,
+"PATCGLYC","C01A-Cardiac glycosides","MLLNCUMT","Million of national currency units","NOR","Norway","2017","2017",5,,
+"PATCGLYC","C01A-Cardiac glycosides","MLLNCUMT","Million of national currency units","NOR","Norway","2018","2018",6,,
+"PATCGLYC","C01A-Cardiac glycosides","MLLNCUMT","Million of national currency units","NOR","Norway","2019","2019",6,,
+"PATCGLYC","C01A-Cardiac glycosides","MLLNCUMT","Million of national currency units","NOR","Norway","2020","2020",6,,
+"PATCGLYC","C01A-Cardiac glycosides","MLLNCUMT","Million of national currency units","NOR","Norway","2021","2021",6,,
+"PATCGLYC","C01A-Cardiac glycosides","MLLNCUMT","Million of national currency units","NOR","Norway","2022","2022",7,,
+"PATCGLYC","C01A-Cardiac glycosides","MTMOTCMT","Million US$ at exchange rate","NOR","Norway","2010","2010",0.8,,
+"PATCGLYC","C01A-Cardiac glycosides","MTMOTCMT","Million US$ at exchange rate","NOR","Norway","2011","2011",0.5,,
+"PATCGLYC","C01A-Cardiac glycosides","MTMOTCMT","Million US$ at exchange rate","NOR","Norway","2012","2012",0.5,,
+"PATCGLYC","C01A-Cardiac glycosides","MTMOTCMT","Million US$ at exchange rate","NOR","Norway","2013","2013",0.9,,
+"PATCGLYC","C01A-Cardiac glycosides","MTMOTCMT","Million US$ at exchange rate","NOR","Norway","2014","2014",0.8,,
+"PATCGLYC","C01A-Cardiac glycosides","MTMOTCMT","Million US$ at exchange rate","NOR","Norway","2015","2015",0.6,,
+"PATCGLYC","C01A-Cardiac glycosides","MTMOTCMT","Million US$ at exchange rate","NOR","Norway","2016","2016",0.6,,
+"PATCGLYC","C01A-Cardiac glycosides","MTMOTCMT","Million US$ at exchange rate","NOR","Norway","2017","2017",0.6,,
+"PATCGLYC","C01A-Cardiac glycosides","MTMOTCMT","Million US$ at exchange rate","NOR","Norway","2018","2018",0.7,,
+"PATCGLYC","C01A-Cardiac glycosides","MTMOTCMT","Million US$ at exchange rate","NOR","Norway","2019","2019",0.7,,
+"PATCGLYC","C01A-Cardiac glycosides","MTMOTCMT","Million US$ at exchange rate","NOR","Norway","2020","2020",0.6,,
+"PATCGLYC","C01A-Cardiac glycosides","MTMOTCMT","Million US$ at exchange rate","NOR","Norway","2021","2021",0.7,,
+"PATCGLYC","C01A-Cardiac glycosides","MTMOTCMT","Million US$ at exchange rate","NOR","Norway","2022","2022",0.7,,
+"PATCGLYC","C01A-Cardiac glycosides","MTMOPPMT","Million US$, purchasing power parity","NOR","Norway","2010","2010",0.5,,
+"PATCGLYC","C01A-Cardiac glycosides","MTMOPPMT","Million US$, purchasing power parity","NOR","Norway","2011","2011",0.3,,
+"PATCGLYC","C01A-Cardiac glycosides","MTMOPPMT","Million US$, purchasing power parity","NOR","Norway","2012","2012",0.3,,
+"PATCGLYC","C01A-Cardiac glycosides","MTMOPPMT","Million US$, purchasing power parity","NOR","Norway","2013","2013",0.6,,
+"PATCGLYC","C01A-Cardiac glycosides","MTMOPPMT","Million US$, purchasing power parity","NOR","Norway","2014","2014",0.5,,
+"PATCGLYC","C01A-Cardiac glycosides","MTMOPPMT","Million US$, purchasing power parity","NOR","Norway","2015","2015",0.5,,
+"PATCGLYC","C01A-Cardiac glycosides","MTMOPPMT","Million US$, purchasing power parity","NOR","Norway","2016","2016",0.5,,
+"PATCGLYC","C01A-Cardiac glycosides","MTMOPPMT","Million US$, purchasing power parity","NOR","Norway","2017","2017",0.5,,
+"PATCGLYC","C01A-Cardiac glycosides","MTMOPPMT","Million US$, purchasing power parity","NOR","Norway","2018","2018",0.6,,
+"PATCGLYC","C01A-Cardiac glycosides","MTMOPPMT","Million US$, purchasing power parity","NOR","Norway","2019","2019",0.6,,
+"PATCGLYC","C01A-Cardiac glycosides","MTMOPPMT","Million US$, purchasing power parity","NOR","Norway","2020","2020",0.6,,
+"PATCGLYC","C01A-Cardiac glycosides","MTMOPPMT","Million US$, purchasing power parity","NOR","Norway","2021","2021",0.6,,
+"PATCGLYC","C01A-Cardiac glycosides","MTMOPPMT","Million US$, purchasing power parity","NOR","Norway","2022","2022",0.7,,
+"PATCGLYC","C01A-Cardiac glycosides","TCPPERMT","/capita, US$ exchange rate","NOR","Norway","2010","2010",0.2,,
+"PATCGLYC","C01A-Cardiac glycosides","TCPPERMT","/capita, US$ exchange rate","NOR","Norway","2011","2011",0.1,,
+"PATCGLYC","C01A-Cardiac glycosides","TCPPERMT","/capita, US$ exchange rate","NOR","Norway","2012","2012",0.1,,
+"PATCGLYC","C01A-Cardiac glycosides","TCPPERMT","/capita, US$ exchange rate","NOR","Norway","2013","2013",0.2,,
+"PATCGLYC","C01A-Cardiac glycosides","TCPPERMT","/capita, US$ exchange rate","NOR","Norway","2014","2014",0.2,,
+"PATCGLYC","C01A-Cardiac glycosides","TCPPERMT","/capita, US$ exchange rate","NOR","Norway","2015","2015",0.1,,
+"PATCGLYC","C01A-Cardiac glycosides","TCPPERMT","/capita, US$ exchange rate","NOR","Norway","2016","2016",0.1,,
+"PATCGLYC","C01A-Cardiac glycosides","TCPPERMT","/capita, US$ exchange rate","NOR","Norway","2017","2017",0.1,,
+"PATCGLYC","C01A-Cardiac glycosides","TCPPERMT","/capita, US$ exchange rate","NOR","Norway","2018","2018",0.1,,
+"PATCGLYC","C01A-Cardiac glycosides","TCPPERMT","/capita, US$ exchange rate","NOR","Norway","2019","2019",0.1,,
+"PATCGLYC","C01A-Cardiac glycosides","TCPPERMT","/capita, US$ exchange rate","NOR","Norway","2020","2020",0.1,,
+"PATCGLYC","C01A-Cardiac glycosides","TCPPERMT","/capita, US$ exchange rate","NOR","Norway","2021","2021",0.1,,
+"PATCGLYC","C01A-Cardiac glycosides","TCPPERMT","/capita, US$ exchange rate","NOR","Norway","2022","2022",0.1,,
+"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2010","2010",0.1,,
+"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2011","2011",0.1,,
+"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2012","2012",0.1,,
+"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2013","2013",0.1,,
+"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2014","2014",0.1,,
+"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2015","2015",0.1,,
+"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2016","2016",0.1,,
+"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2017","2017",0.1,,
+"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2018","2018",0.1,,
+"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2019","2019",0.1,,
+"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2020","2020",0.1,,
+"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2021","2021",0.1,,
+"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2022","2022",0.1,,
+"PATCGLYC","C01A-Cardiac glycosides","ATCPTTMT","% of total sales","NOR","Norway","2010","2010",0,,
+"PATCGLYC","C01A-Cardiac glycosides","ATCPTTMT","% of total sales","NOR","Norway","2011","2011",0,,
+"PATCGLYC","C01A-Cardiac glycosides","ATCPTTMT","% of total sales","NOR","Norway","2012","2012",0,,
+"PATCGLYC","C01A-Cardiac glycosides","ATCPTTMT","% of total sales","NOR","Norway","2013","2013",0,,
+"PATCGLYC","C01A-Cardiac glycosides","ATCPTTMT","% of total sales","NOR","Norway","2014","2014",0,,
+"PATCGLYC","C01A-Cardiac glycosides","ATCPTTMT","% of total sales","NOR","Norway","2015","2015",0,,
+"PATCGLYC","C01A-Cardiac glycosides","ATCPTTMT","% of total sales","NOR","Norway","2016","2016",0,,
+"PATCGLYC","C01A-Cardiac glycosides","ATCPTTMT","% of total sales","NOR","Norway","2017","2017",0,,
+"PATCGLYC","C01A-Cardiac glycosides","ATCPTTMT","% of total sales","NOR","Norway","2018","2018",0,,
+"PATCGLYC","C01A-Cardiac glycosides","ATCPTTMT","% of total sales","NOR","Norway","2019","2019",0,,
+"PATCGLYC","C01A-Cardiac glycosides","ATCPTTMT","% of total sales","NOR","Norway","2020","2020",0,,
+"PATCGLYC","C01A-Cardiac glycosides","ATCPTTMT","% of total sales","NOR","Norway","2021","2021",0,,
+"PATCGLYC","C01A-Cardiac glycosides","ATCPTTMT","% of total sales","NOR","Norway","2022","2022",0,,
+"PATCGLYC","C01A-Cardiac glycosides","MLLNCUMT","Million of national currency units","PRT","Portugal","2010","2010",1,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","MLLNCUMT","Million of national currency units","PRT","Portugal","2011","2011",0.9,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","MLLNCUMT","Million of national currency units","PRT","Portugal","2012","2012",0.9,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","MLLNCUMT","Million of national currency units","PRT","Portugal","2013","2013",0.8,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","MLLNCUMT","Million of national currency units","PRT","Portugal","2014","2014",0.9,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","MLLNCUMT","Million of national currency units","PRT","Portugal","2015","2015",0.9,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","MLLNCUMT","Million of national currency units","PRT","Portugal","2016","2016",0.8,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","MLLNCUMT","Million of national currency units","PRT","Portugal","2017","2017",0.7,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","MLLNCUMT","Million of national currency units","PRT","Portugal","2018","2018",0.7,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","MLLNCUMT","Million of national currency units","PRT","Portugal","2019","2019",0.7,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","MLLNCUMT","Million of national currency units","PRT","Portugal","2020","2020",0.6,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","MLLNCUMT","Million of national currency units","PRT","Portugal","2021","2021",0.6,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","MLLNCUMT","Million of national currency units","PRT","Portugal","2022","2022",0.5,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","MTMOTCMT","Million US$ at exchange rate","PRT","Portugal","2010","2010",1.3,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","MTMOTCMT","Million US$ at exchange rate","PRT","Portugal","2011","2011",1.3,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","MTMOTCMT","Million US$ at exchange rate","PRT","Portugal","2012","2012",1.1,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","MTMOTCMT","Million US$ at exchange rate","PRT","Portugal","2013","2013",1.1,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","MTMOTCMT","Million US$ at exchange rate","PRT","Portugal","2014","2014",1.2,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","MTMOTCMT","Million US$ at exchange rate","PRT","Portugal","2015","2015",1,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","MTMOTCMT","Million US$ at exchange rate","PRT","Portugal","2016","2016",0.9,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","MTMOTCMT","Million US$ at exchange rate","PRT","Portugal","2017","2017",0.8,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","MTMOTCMT","Million US$ at exchange rate","PRT","Portugal","2018","2018",0.8,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","MTMOTCMT","Million US$ at exchange rate","PRT","Portugal","2019","2019",0.8,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","MTMOTCMT","Million US$ at exchange rate","PRT","Portugal","2020","2020",0.7,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","MTMOTCMT","Million US$ at exchange rate","PRT","Portugal","2021","2021",0.7,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","MTMOTCMT","Million US$ at exchange rate","PRT","Portugal","2022","2022",0.5,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","MTMOPPMT","Million US$, purchasing power parity","PRT","Portugal","2010","2010",1.6,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","MTMOPPMT","Million US$, purchasing power parity","PRT","Portugal","2011","2011",1.4,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","MTMOPPMT","Million US$, purchasing power parity","PRT","Portugal","2012","2012",1.5,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","MTMOPPMT","Million US$, purchasing power parity","PRT","Portugal","2013","2013",1.4,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","MTMOPPMT","Million US$, purchasing power parity","PRT","Portugal","2014","2014",1.6,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","MTMOPPMT","Million US$, purchasing power parity","PRT","Portugal","2015","2015",1.5,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","MTMOPPMT","Million US$, purchasing power parity","PRT","Portugal","2016","2016",1.4,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","MTMOPPMT","Million US$, purchasing power parity","PRT","Portugal","2017","2017",1.3,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","MTMOPPMT","Million US$, purchasing power parity","PRT","Portugal","2018","2018",1.2,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","MTMOPPMT","Million US$, purchasing power parity","PRT","Portugal","2019","2019",1.2,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","MTMOPPMT","Million US$, purchasing power parity","PRT","Portugal","2020","2020",1.1,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","MTMOPPMT","Million US$, purchasing power parity","PRT","Portugal","2021","2021",1,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","MTMOPPMT","Million US$, purchasing power parity","PRT","Portugal","2022","2022",0.9,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","TCPPERMT","/capita, US$ exchange rate","PRT","Portugal","2010","2010",0.1,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","TCPPERMT","/capita, US$ exchange rate","PRT","Portugal","2011","2011",0.1,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","TCPPERMT","/capita, US$ exchange rate","PRT","Portugal","2012","2012",0.1,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","TCPPERMT","/capita, US$ exchange rate","PRT","Portugal","2013","2013",0.1,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","TCPPERMT","/capita, US$ exchange rate","PRT","Portugal","2014","2014",0.1,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","TCPPERMT","/capita, US$ exchange rate","PRT","Portugal","2015","2015",0.1,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","TCPPERMT","/capita, US$ exchange rate","PRT","Portugal","2016","2016",0.1,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","TCPPERMT","/capita, US$ exchange rate","PRT","Portugal","2017","2017",0.1,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","TCPPERMT","/capita, US$ exchange rate","PRT","Portugal","2018","2018",0.1,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","TCPPERMT","/capita, US$ exchange rate","PRT","Portugal","2019","2019",0.1,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","TCPPERMT","/capita, US$ exchange rate","PRT","Portugal","2020","2020",0.1,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","TCPPERMT","/capita, US$ exchange rate","PRT","Portugal","2021","2021",0.1,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","TCPPERMT","/capita, US$ exchange rate","PRT","Portugal","2022","2022",0.1,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2010","2010",0.2,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2011","2011",0.1,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2012","2012",0.1,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2013","2013",0.1,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2014","2014",0.2,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2015","2015",0.1,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2016","2016",0.1,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2017","2017",0.1,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2018","2018",0.1,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2019","2019",0.1,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2020","2020",0.1,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2021","2021",0.1,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2022","2022",0.1,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","ATCPTTMT","% of total sales","PRT","Portugal","2010","2010",0,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","ATCPTTMT","% of total sales","PRT","Portugal","2011","2011",0,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","ATCPTTMT","% of total sales","PRT","Portugal","2012","2012",0,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","ATCPTTMT","% of total sales","PRT","Portugal","2013","2013",0,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","ATCPTTMT","% of total sales","PRT","Portugal","2014","2014",0,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","ATCPTTMT","% of total sales","PRT","Portugal","2015","2015",0,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","ATCPTTMT","% of total sales","PRT","Portugal","2016","2016",0,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","ATCPTTMT","% of total sales","PRT","Portugal","2017","2017",0,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","ATCPTTMT","% of total sales","PRT","Portugal","2018","2018",0,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","ATCPTTMT","% of total sales","PRT","Portugal","2019","2019",0,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","ATCPTTMT","% of total sales","PRT","Portugal","2020","2020",0,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","ATCPTTMT","% of total sales","PRT","Portugal","2021","2021",0,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","ATCPTTMT","% of total sales","PRT","Portugal","2022","2022",0,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","MLLNCUMT","Million of national currency units","SVK","Slovak Republic","2010","2010",0.4,,
+"PATCGLYC","C01A-Cardiac glycosides","MLLNCUMT","Million of national currency units","SVK","Slovak Republic","2011","2011",0.3,,
+"PATCGLYC","C01A-Cardiac glycosides","MLLNCUMT","Million of national currency units","SVK","Slovak Republic","2012","2012",0.3,,
+"PATCGLYC","C01A-Cardiac glycosides","MLLNCUMT","Million of national currency units","SVK","Slovak Republic","2013","2013",0.3,,
+"PATCGLYC","C01A-Cardiac glycosides","MLLNCUMT","Million of national currency units","SVK","Slovak Republic","2014","2014",0.3,,
+"PATCGLYC","C01A-Cardiac glycosides","MLLNCUMT","Million of national currency units","SVK","Slovak Republic","2015","2015",0.2,,
+"PATCGLYC","C01A-Cardiac glycosides","MLLNCUMT","Million of national currency units","SVK","Slovak Republic","2016","2016",0.3,"B","Break"
+"PATCGLYC","C01A-Cardiac glycosides","MLLNCUMT","Million of national currency units","SVK","Slovak Republic","2017","2017",0.3,,
+"PATCGLYC","C01A-Cardiac glycosides","MLLNCUMT","Million of national currency units","SVK","Slovak Republic","2018","2018",0.3,,
+"PATCGLYC","C01A-Cardiac glycosides","MLLNCUMT","Million of national currency units","SVK","Slovak Republic","2019","2019",0.3,,
+"PATCGLYC","C01A-Cardiac glycosides","MLLNCUMT","Million of national currency units","SVK","Slovak Republic","2020","2020",0.3,,
+"PATCGLYC","C01A-Cardiac glycosides","MLLNCUMT","Million of national currency units","SVK","Slovak Republic","2021","2021",0.2,,
+"PATCGLYC","C01A-Cardiac glycosides","MTMOTCMT","Million US$ at exchange rate","SVK","Slovak Republic","2010","2010",0.5,,
+"PATCGLYC","C01A-Cardiac glycosides","MTMOTCMT","Million US$ at exchange rate","SVK","Slovak Republic","2011","2011",0.5,,
+"PATCGLYC","C01A-Cardiac glycosides","MTMOTCMT","Million US$ at exchange rate","SVK","Slovak Republic","2012","2012",0.4,,
+"PATCGLYC","C01A-Cardiac glycosides","MTMOTCMT","Million US$ at exchange rate","SVK","Slovak Republic","2013","2013",0.4,,
+"PATCGLYC","C01A-Cardiac glycosides","MTMOTCMT","Million US$ at exchange rate","SVK","Slovak Republic","2014","2014",0.4,,
+"PATCGLYC","C01A-Cardiac glycosides","MTMOTCMT","Million US$ at exchange rate","SVK","Slovak Republic","2015","2015",0.3,,
+"PATCGLYC","C01A-Cardiac glycosides","MTMOTCMT","Million US$ at exchange rate","SVK","Slovak Republic","2016","2016",0.4,"B","Break"
+"PATCGLYC","C01A-Cardiac glycosides","MTMOTCMT","Million US$ at exchange rate","SVK","Slovak Republic","2017","2017",0.3,,
+"PATCGLYC","C01A-Cardiac glycosides","MTMOTCMT","Million US$ at exchange rate","SVK","Slovak Republic","2018","2018",0.3,,
+"PATCGLYC","C01A-Cardiac glycosides","MTMOTCMT","Million US$ at exchange rate","SVK","Slovak Republic","2019","2019",0.3,,
+"PATCGLYC","C01A-Cardiac glycosides","MTMOTCMT","Million US$ at exchange rate","SVK","Slovak Republic","2020","2020",0.3,,
+"PATCGLYC","C01A-Cardiac glycosides","MTMOTCMT","Million US$ at exchange rate","SVK","Slovak Republic","2021","2021",0.3,,
+"PATCGLYC","C01A-Cardiac glycosides","MTMOPPMT","Million US$, purchasing power parity","SVK","Slovak Republic","2010","2010",0.7,,
+"PATCGLYC","C01A-Cardiac glycosides","MTMOPPMT","Million US$, purchasing power parity","SVK","Slovak Republic","2011","2011",0.7,,
+"PATCGLYC","C01A-Cardiac glycosides","MTMOPPMT","Million US$, purchasing power parity","SVK","Slovak Republic","2012","2012",0.6,,
+"PATCGLYC","C01A-Cardiac glycosides","MTMOPPMT","Million US$, purchasing power parity","SVK","Slovak Republic","2013","2013",0.6,,
+"PATCGLYC","C01A-Cardiac glycosides","MTMOPPMT","Million US$, purchasing power parity","SVK","Slovak Republic","2014","2014",0.5,,
+"PATCGLYC","C01A-Cardiac glycosides","MTMOPPMT","Million US$, purchasing power parity","SVK","Slovak Republic","2015","2015",0.5,,
+"PATCGLYC","C01A-Cardiac glycosides","MTMOPPMT","Million US$, purchasing power parity","SVK","Slovak Republic","2016","2016",0.6,"B","Break"
+"PATCGLYC","C01A-Cardiac glycosides","MTMOPPMT","Million US$, purchasing power parity","SVK","Slovak Republic","2017","2017",0.6,,
+"PATCGLYC","C01A-Cardiac glycosides","MTMOPPMT","Million US$, purchasing power parity","SVK","Slovak Republic","2018","2018",0.5,,
+"PATCGLYC","C01A-Cardiac glycosides","MTMOPPMT","Million US$, purchasing power parity","SVK","Slovak Republic","2019","2019",0.5,,
+"PATCGLYC","C01A-Cardiac glycosides","MTMOPPMT","Million US$, purchasing power parity","SVK","Slovak Republic","2020","2020",0.5,,
+"PATCGLYC","C01A-Cardiac glycosides","MTMOPPMT","Million US$, purchasing power parity","SVK","Slovak Republic","2021","2021",0.4,,
+"PATCGLYC","C01A-Cardiac glycosides","TCPPERMT","/capita, US$ exchange rate","SVK","Slovak Republic","2010","2010",0.1,,
+"PATCGLYC","C01A-Cardiac glycosides","TCPPERMT","/capita, US$ exchange rate","SVK","Slovak Republic","2011","2011",0.1,,
+"PATCGLYC","C01A-Cardiac glycosides","TCPPERMT","/capita, US$ exchange rate","SVK","Slovak Republic","2012","2012",0.1,,
+"PATCGLYC","C01A-Cardiac glycosides","TCPPERMT","/capita, US$ exchange rate","SVK","Slovak Republic","2013","2013",0.1,,
+"PATCGLYC","C01A-Cardiac glycosides","TCPPERMT","/capita, US$ exchange rate","SVK","Slovak Republic","2014","2014",0.1,,
+"PATCGLYC","C01A-Cardiac glycosides","TCPPERMT","/capita, US$ exchange rate","SVK","Slovak Republic","2015","2015",0.1,,
+"PATCGLYC","C01A-Cardiac glycosides","TCPPERMT","/capita, US$ exchange rate","SVK","Slovak Republic","2016","2016",0.1,"B","Break"
+"PATCGLYC","C01A-Cardiac glycosides","TCPPERMT","/capita, US$ exchange rate","SVK","Slovak Republic","2017","2017",0.1,,
+"PATCGLYC","C01A-Cardiac glycosides","TCPPERMT","/capita, US$ exchange rate","SVK","Slovak Republic","2018","2018",0.1,,
+"PATCGLYC","C01A-Cardiac glycosides","TCPPERMT","/capita, US$ exchange rate","SVK","Slovak Republic","2019","2019",0.1,,
+"PATCGLYC","C01A-Cardiac glycosides","TCPPERMT","/capita, US$ exchange rate","SVK","Slovak Republic","2020","2020",0.1,,
+"PATCGLYC","C01A-Cardiac glycosides","TCPPERMT","/capita, US$ exchange rate","SVK","Slovak Republic","2021","2021",0.1,,
+"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2010","2010",0.1,,
+"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2011","2011",0.1,,
+"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2012","2012",0.1,,
+"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2013","2013",0.1,,
+"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2014","2014",0.1,,
+"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2015","2015",0.1,,
+"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2016","2016",0.1,"B","Break"
+"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2017","2017",0.1,,
+"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2018","2018",0.1,,
+"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2019","2019",0.1,,
+"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2020","2020",0.1,,
+"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2021","2021",0.1,,
+"PATCGLYC","C01A-Cardiac glycosides","ATCPTTMT","% of total sales","SVK","Slovak Republic","2010","2010",0,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","ATCPTTMT","% of total sales","SVK","Slovak Republic","2011","2011",0,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","ATCPTTMT","% of total sales","SVK","Slovak Republic","2012","2012",0,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","ATCPTTMT","% of total sales","SVK","Slovak Republic","2013","2013",0,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","ATCPTTMT","% of total sales","SVK","Slovak Republic","2014","2014",0,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","ATCPTTMT","% of total sales","SVK","Slovak Republic","2015","2015",0,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","ATCPTTMT","% of total sales","SVK","Slovak Republic","2016","2016",0,"B","Break"
+"PATCGLYC","C01A-Cardiac glycosides","ATCPTTMT","% of total sales","SVK","Slovak Republic","2017","2017",0,,
+"PATCGLYC","C01A-Cardiac glycosides","ATCPTTMT","% of total sales","SVK","Slovak Republic","2018","2018",0,,
+"PATCGLYC","C01A-Cardiac glycosides","ATCPTTMT","% of total sales","SVK","Slovak Republic","2019","2019",0,,
+"PATCGLYC","C01A-Cardiac glycosides","ATCPTTMT","% of total sales","SVK","Slovak Republic","2020","2020",0,,
+"PATCGLYC","C01A-Cardiac glycosides","ATCPTTMT","% of total sales","SVK","Slovak Republic","2021","2021",0,,
+"PATCGLYC","C01A-Cardiac glycosides","MLLNCUMT","Million of national currency units","ESP","Spain","2010","2010",4,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","MLLNCUMT","Million of national currency units","ESP","Spain","2011","2011",3.7,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","MLLNCUMT","Million of national currency units","ESP","Spain","2012","2012",3.4,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","MLLNCUMT","Million of national currency units","ESP","Spain","2013","2013",3.1,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","MLLNCUMT","Million of national currency units","ESP","Spain","2014","2014",3.2,"B; D","Break; Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","MLLNCUMT","Million of national currency units","ESP","Spain","2015","2015",3,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","MLLNCUMT","Million of national currency units","ESP","Spain","2016","2016",2.8,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","MLLNCUMT","Million of national currency units","ESP","Spain","2017","2017",2.5,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","MLLNCUMT","Million of national currency units","ESP","Spain","2018","2018",2.3,"B","Break"
+"PATCGLYC","C01A-Cardiac glycosides","MLLNCUMT","Million of national currency units","ESP","Spain","2019","2019",2.1,,
+"PATCGLYC","C01A-Cardiac glycosides","MLLNCUMT","Million of national currency units","ESP","Spain","2020","2020",1.9,,
+"PATCGLYC","C01A-Cardiac glycosides","MLLNCUMT","Million of national currency units","ESP","Spain","2021","2021",1.8,,
+"PATCGLYC","C01A-Cardiac glycosides","MLLNCUMT","Million of national currency units","ESP","Spain","2022","2022",1.6,"P","Provisional value"
+"PATCGLYC","C01A-Cardiac glycosides","MTMOTCMT","Million US$ at exchange rate","ESP","Spain","2010","2010",5.2,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","MTMOTCMT","Million US$ at exchange rate","ESP","Spain","2011","2011",5.2,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","MTMOTCMT","Million US$ at exchange rate","ESP","Spain","2012","2012",4.3,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","MTMOTCMT","Million US$ at exchange rate","ESP","Spain","2013","2013",4.1,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","MTMOTCMT","Million US$ at exchange rate","ESP","Spain","2014","2014",4.2,"B; D","Break; Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","MTMOTCMT","Million US$ at exchange rate","ESP","Spain","2015","2015",3.3,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","MTMOTCMT","Million US$ at exchange rate","ESP","Spain","2016","2016",3.1,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","MTMOTCMT","Million US$ at exchange rate","ESP","Spain","2017","2017",2.9,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","MTMOTCMT","Million US$ at exchange rate","ESP","Spain","2018","2018",2.7,"B","Break"
+"PATCGLYC","C01A-Cardiac glycosides","MTMOTCMT","Million US$ at exchange rate","ESP","Spain","2019","2019",2.3,,
+"PATCGLYC","C01A-Cardiac glycosides","MTMOTCMT","Million US$ at exchange rate","ESP","Spain","2020","2020",2.2,,
+"PATCGLYC","C01A-Cardiac glycosides","MTMOTCMT","Million US$ at exchange rate","ESP","Spain","2021","2021",2.1,,
+"PATCGLYC","C01A-Cardiac glycosides","MTMOTCMT","Million US$ at exchange rate","ESP","Spain","2022","2022",1.7,"P","Provisional value"
+"PATCGLYC","C01A-Cardiac glycosides","MTMOPPMT","Million US$, purchasing power parity","ESP","Spain","2010","2010",5.4,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","MTMOPPMT","Million US$, purchasing power parity","ESP","Spain","2011","2011",5.2,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","MTMOPPMT","Million US$, purchasing power parity","ESP","Spain","2012","2012",4.8,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","MTMOPPMT","Million US$, purchasing power parity","ESP","Spain","2013","2013",4.6,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","MTMOPPMT","Million US$, purchasing power parity","ESP","Spain","2014","2014",4.8,"B; D","Break; Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","MTMOPPMT","Million US$, purchasing power parity","ESP","Spain","2015","2015",4.5,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","MTMOPPMT","Million US$, purchasing power parity","ESP","Spain","2016","2016",4.3,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","MTMOPPMT","Million US$, purchasing power parity","ESP","Spain","2017","2017",4,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","MTMOPPMT","Million US$, purchasing power parity","ESP","Spain","2018","2018",3.6,"B","Break"
+"PATCGLYC","C01A-Cardiac glycosides","MTMOPPMT","Million US$, purchasing power parity","ESP","Spain","2019","2019",3.4,,
+"PATCGLYC","C01A-Cardiac glycosides","MTMOPPMT","Million US$, purchasing power parity","ESP","Spain","2020","2020",3.1,,
+"PATCGLYC","C01A-Cardiac glycosides","MTMOPPMT","Million US$, purchasing power parity","ESP","Spain","2021","2021",2.8,,
+"PATCGLYC","C01A-Cardiac glycosides","MTMOPPMT","Million US$, purchasing power parity","ESP","Spain","2022","2022",2.7,"P","Provisional value"
+"PATCGLYC","C01A-Cardiac glycosides","TCPPERMT","/capita, US$ exchange rate","ESP","Spain","2010","2010",0.1,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","TCPPERMT","/capita, US$ exchange rate","ESP","Spain","2011","2011",0.1,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","TCPPERMT","/capita, US$ exchange rate","ESP","Spain","2012","2012",0.1,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","TCPPERMT","/capita, US$ exchange rate","ESP","Spain","2013","2013",0.1,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","TCPPERMT","/capita, US$ exchange rate","ESP","Spain","2014","2014",0.1,"B; D","Break; Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","TCPPERMT","/capita, US$ exchange rate","ESP","Spain","2015","2015",0.1,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","TCPPERMT","/capita, US$ exchange rate","ESP","Spain","2016","2016",0.1,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","TCPPERMT","/capita, US$ exchange rate","ESP","Spain","2017","2017",0.1,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","TCPPERMT","/capita, US$ exchange rate","ESP","Spain","2018","2018",0.1,"B","Break"
+"PATCGLYC","C01A-Cardiac glycosides","TCPPERMT","/capita, US$ exchange rate","ESP","Spain","2019","2019",0,,
+"PATCGLYC","C01A-Cardiac glycosides","TCPPERMT","/capita, US$ exchange rate","ESP","Spain","2020","2020",0,,
+"PATCGLYC","C01A-Cardiac glycosides","TCPPERMT","/capita, US$ exchange rate","ESP","Spain","2021","2021",0,,
+"PATCGLYC","C01A-Cardiac glycosides","TCPPERMT","/capita, US$ exchange rate","ESP","Spain","2022","2022",0,"P","Provisional value"
+"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2010","2010",0.1,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2011","2011",0.1,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2012","2012",0.1,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2013","2013",0.1,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2014","2014",0.1,"B; D","Break; Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2015","2015",0.1,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2016","2016",0.1,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2017","2017",0.1,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2018","2018",0.1,"B","Break"
+"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2019","2019",0.1,,
+"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2020","2020",0.1,,
+"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2021","2021",0.1,,
+"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2022","2022",0.1,"P","Provisional value"
+"PATCGLYC","C01A-Cardiac glycosides","ATCPTTMT","% of total sales","ESP","Spain","2010","2010",0,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","ATCPTTMT","% of total sales","ESP","Spain","2011","2011",0,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","ATCPTTMT","% of total sales","ESP","Spain","2012","2012",0,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","ATCPTTMT","% of total sales","ESP","Spain","2013","2013",0,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","ATCPTTMT","% of total sales","ESP","Spain","2014","2014",0,"B; D","Break; Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","ATCPTTMT","% of total sales","ESP","Spain","2015","2015",0,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","ATCPTTMT","% of total sales","ESP","Spain","2016","2016",0,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","ATCPTTMT","% of total sales","ESP","Spain","2017","2017",0,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","ATCPTTMT","% of total sales","ESP","Spain","2018","2018",0,"B","Break"
+"PATCGLYC","C01A-Cardiac glycosides","ATCPTTMT","% of total sales","ESP","Spain","2019","2019",0,,
+"PATCGLYC","C01A-Cardiac glycosides","ATCPTTMT","% of total sales","ESP","Spain","2020","2020",0,,
+"PATCGLYC","C01A-Cardiac glycosides","ATCPTTMT","% of total sales","ESP","Spain","2021","2021",0,,
+"PATCGLYC","C01A-Cardiac glycosides","ATCPTTMT","% of total sales","ESP","Spain","2022","2022",0,"P","Provisional value"
+"PATCGLYC","C01A-Cardiac glycosides","MLLNCUMT","Million of national currency units","SWE","Sweden","2010","2010",14.1,,
+"PATCGLYC","C01A-Cardiac glycosides","MLLNCUMT","Million of national currency units","SWE","Sweden","2011","2011",13.1,,
+"PATCGLYC","C01A-Cardiac glycosides","MLLNCUMT","Million of national currency units","SWE","Sweden","2012","2012",13.4,,
+"PATCGLYC","C01A-Cardiac glycosides","MLLNCUMT","Million of national currency units","SWE","Sweden","2013","2013",14.5,,
+"PATCGLYC","C01A-Cardiac glycosides","MLLNCUMT","Million of national currency units","SWE","Sweden","2014","2014",15.9,,
+"PATCGLYC","C01A-Cardiac glycosides","MLLNCUMT","Million of national currency units","SWE","Sweden","2015","2015",13.2,,
+"PATCGLYC","C01A-Cardiac glycosides","MLLNCUMT","Million of national currency units","SWE","Sweden","2016","2016",12.7,,
+"PATCGLYC","C01A-Cardiac glycosides","MLLNCUMT","Million of national currency units","SWE","Sweden","2017","2017",12.5,,
+"PATCGLYC","C01A-Cardiac glycosides","MLLNCUMT","Million of national currency units","SWE","Sweden","2018","2018",12.1,,
+"PATCGLYC","C01A-Cardiac glycosides","MLLNCUMT","Million of national currency units","SWE","Sweden","2019","2019",11.8,,
+"PATCGLYC","C01A-Cardiac glycosides","MLLNCUMT","Million of national currency units","SWE","Sweden","2020","2020",11.1,,
+"PATCGLYC","C01A-Cardiac glycosides","MLLNCUMT","Million of national currency units","SWE","Sweden","2021","2021",10.7,,
+"PATCGLYC","C01A-Cardiac glycosides","MLLNCUMT","Million of national currency units","SWE","Sweden","2022","2022",13.3,,
+"PATCGLYC","C01A-Cardiac glycosides","MTMOTCMT","Million US$ at exchange rate","SWE","Sweden","2010","2010",2,,
+"PATCGLYC","C01A-Cardiac glycosides","MTMOTCMT","Million US$ at exchange rate","SWE","Sweden","2011","2011",2,,
+"PATCGLYC","C01A-Cardiac glycosides","MTMOTCMT","Million US$ at exchange rate","SWE","Sweden","2012","2012",2,,
+"PATCGLYC","C01A-Cardiac glycosides","MTMOTCMT","Million US$ at exchange rate","SWE","Sweden","2013","2013",2.2,,
+"PATCGLYC","C01A-Cardiac glycosides","MTMOTCMT","Million US$ at exchange rate","SWE","Sweden","2014","2014",2.3,,
+"PATCGLYC","C01A-Cardiac glycosides","MTMOTCMT","Million US$ at exchange rate","SWE","Sweden","2015","2015",1.6,,
+"PATCGLYC","C01A-Cardiac glycosides","MTMOTCMT","Million US$ at exchange rate","SWE","Sweden","2016","2016",1.5,,
+"PATCGLYC","C01A-Cardiac glycosides","MTMOTCMT","Million US$ at exchange rate","SWE","Sweden","2017","2017",1.5,,
+"PATCGLYC","C01A-Cardiac glycosides","MTMOTCMT","Million US$ at exchange rate","SWE","Sweden","2018","2018",1.4,,
+"PATCGLYC","C01A-Cardiac glycosides","MTMOTCMT","Million US$ at exchange rate","SWE","Sweden","2019","2019",1.2,,
+"PATCGLYC","C01A-Cardiac glycosides","MTMOTCMT","Million US$ at exchange rate","SWE","Sweden","2020","2020",1.2,,
+"PATCGLYC","C01A-Cardiac glycosides","MTMOTCMT","Million US$ at exchange rate","SWE","Sweden","2021","2021",1.2,,
+"PATCGLYC","C01A-Cardiac glycosides","MTMOTCMT","Million US$ at exchange rate","SWE","Sweden","2022","2022",1.3,,
+"PATCGLYC","C01A-Cardiac glycosides","MTMOPPMT","Million US$, purchasing power parity","SWE","Sweden","2010","2010",1.6,,
+"PATCGLYC","C01A-Cardiac glycosides","MTMOPPMT","Million US$, purchasing power parity","SWE","Sweden","2011","2011",1.5,,
+"PATCGLYC","C01A-Cardiac glycosides","MTMOPPMT","Million US$, purchasing power parity","SWE","Sweden","2012","2012",1.5,,
+"PATCGLYC","C01A-Cardiac glycosides","MTMOPPMT","Million US$, purchasing power parity","SWE","Sweden","2013","2013",1.7,,
+"PATCGLYC","C01A-Cardiac glycosides","MTMOPPMT","Million US$, purchasing power parity","SWE","Sweden","2014","2014",1.8,,
+"PATCGLYC","C01A-Cardiac glycosides","MTMOPPMT","Million US$, purchasing power parity","SWE","Sweden","2015","2015",1.5,,
+"PATCGLYC","C01A-Cardiac glycosides","MTMOPPMT","Million US$, purchasing power parity","SWE","Sweden","2016","2016",1.4,,
+"PATCGLYC","C01A-Cardiac glycosides","MTMOPPMT","Million US$, purchasing power parity","SWE","Sweden","2017","2017",1.4,,
+"PATCGLYC","C01A-Cardiac glycosides","MTMOPPMT","Million US$, purchasing power parity","SWE","Sweden","2018","2018",1.4,,
+"PATCGLYC","C01A-Cardiac glycosides","MTMOPPMT","Million US$, purchasing power parity","SWE","Sweden","2019","2019",1.4,,
+"PATCGLYC","C01A-Cardiac glycosides","MTMOPPMT","Million US$, purchasing power parity","SWE","Sweden","2020","2020",1.3,,
+"PATCGLYC","C01A-Cardiac glycosides","MTMOPPMT","Million US$, purchasing power parity","SWE","Sweden","2021","2021",1.2,,
+"PATCGLYC","C01A-Cardiac glycosides","MTMOPPMT","Million US$, purchasing power parity","SWE","Sweden","2022","2022",1.5,,
+"PATCGLYC","C01A-Cardiac glycosides","TCPPERMT","/capita, US$ exchange rate","SWE","Sweden","2010","2010",0.2,,
+"PATCGLYC","C01A-Cardiac glycosides","TCPPERMT","/capita, US$ exchange rate","SWE","Sweden","2011","2011",0.2,,
+"PATCGLYC","C01A-Cardiac glycosides","TCPPERMT","/capita, US$ exchange rate","SWE","Sweden","2012","2012",0.2,,
+"PATCGLYC","C01A-Cardiac glycosides","TCPPERMT","/capita, US$ exchange rate","SWE","Sweden","2013","2013",0.2,,
+"PATCGLYC","C01A-Cardiac glycosides","TCPPERMT","/capita, US$ exchange rate","SWE","Sweden","2014","2014",0.2,,
+"PATCGLYC","C01A-Cardiac glycosides","TCPPERMT","/capita, US$ exchange rate","SWE","Sweden","2015","2015",0.2,,
+"PATCGLYC","C01A-Cardiac glycosides","TCPPERMT","/capita, US$ exchange rate","SWE","Sweden","2016","2016",0.1,,
+"PATCGLYC","C01A-Cardiac glycosides","TCPPERMT","/capita, US$ exchange rate","SWE","Sweden","2017","2017",0.1,,
+"PATCGLYC","C01A-Cardiac glycosides","TCPPERMT","/capita, US$ exchange rate","SWE","Sweden","2018","2018",0.1,,
+"PATCGLYC","C01A-Cardiac glycosides","TCPPERMT","/capita, US$ exchange rate","SWE","Sweden","2019","2019",0.1,,
+"PATCGLYC","C01A-Cardiac glycosides","TCPPERMT","/capita, US$ exchange rate","SWE","Sweden","2020","2020",0.1,,
+"PATCGLYC","C01A-Cardiac glycosides","TCPPERMT","/capita, US$ exchange rate","SWE","Sweden","2021","2021",0.1,,
+"PATCGLYC","C01A-Cardiac glycosides","TCPPERMT","/capita, US$ exchange rate","SWE","Sweden","2022","2022",0.1,,
+"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2010","2010",0.2,,
+"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2011","2011",0.2,,
+"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2012","2012",0.2,,
+"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2013","2013",0.2,,
+"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2014","2014",0.2,,
+"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2015","2015",0.2,,
+"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2016","2016",0.1,,
+"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2017","2017",0.1,,
+"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2018","2018",0.1,,
+"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2019","2019",0.1,,
+"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2020","2020",0.1,,
+"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2021","2021",0.1,,
+"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2022","2022",0.1,,
+"PATCGLYC","C01A-Cardiac glycosides","ATCPTTMT","% of total sales","SWE","Sweden","2010","2010",0,,
+"PATCGLYC","C01A-Cardiac glycosides","ATCPTTMT","% of total sales","SWE","Sweden","2011","2011",0,,
+"PATCGLYC","C01A-Cardiac glycosides","ATCPTTMT","% of total sales","SWE","Sweden","2012","2012",0,,
+"PATCGLYC","C01A-Cardiac glycosides","ATCPTTMT","% of total sales","SWE","Sweden","2013","2013",0,,
+"PATCGLYC","C01A-Cardiac glycosides","ATCPTTMT","% of total sales","SWE","Sweden","2014","2014",0,,
+"PATCGLYC","C01A-Cardiac glycosides","ATCPTTMT","% of total sales","SWE","Sweden","2015","2015",0,,
+"PATCGLYC","C01A-Cardiac glycosides","ATCPTTMT","% of total sales","SWE","Sweden","2016","2016",0,,
+"PATCGLYC","C01A-Cardiac glycosides","ATCPTTMT","% of total sales","SWE","Sweden","2017","2017",0,,
+"PATCGLYC","C01A-Cardiac glycosides","ATCPTTMT","% of total sales","SWE","Sweden","2018","2018",0,,
+"PATCGLYC","C01A-Cardiac glycosides","ATCPTTMT","% of total sales","SWE","Sweden","2019","2019",0,,
+"PATCGLYC","C01A-Cardiac glycosides","ATCPTTMT","% of total sales","SWE","Sweden","2020","2020",0,,
+"PATCGLYC","C01A-Cardiac glycosides","ATCPTTMT","% of total sales","SWE","Sweden","2021","2021",0,,
+"PATCGLYC","C01A-Cardiac glycosides","ATCPTTMT","% of total sales","SWE","Sweden","2022","2022",0,,
+"PATCGLYC","C01A-Cardiac glycosides","MLLNCUMT","Million of national currency units","TUR","Türkiye","2010","2010",1.2,,
+"PATCGLYC","C01A-Cardiac glycosides","MLLNCUMT","Million of national currency units","TUR","Türkiye","2011","2011",1.2,,
+"PATCGLYC","C01A-Cardiac glycosides","MLLNCUMT","Million of national currency units","TUR","Türkiye","2012","2012",1.1,,
+"PATCGLYC","C01A-Cardiac glycosides","MLLNCUMT","Million of national currency units","TUR","Türkiye","2013","2013",1.2,,
+"PATCGLYC","C01A-Cardiac glycosides","MLLNCUMT","Million of national currency units","TUR","Türkiye","2014","2014",1.2,,
+"PATCGLYC","C01A-Cardiac glycosides","MLLNCUMT","Million of national currency units","TUR","Türkiye","2015","2015",1.4,,
+"PATCGLYC","C01A-Cardiac glycosides","MLLNCUMT","Million of national currency units","TUR","Türkiye","2016","2016",1.5,,
+"PATCGLYC","C01A-Cardiac glycosides","MLLNCUMT","Million of national currency units","TUR","Türkiye","2017","2017",1.7,,
+"PATCGLYC","C01A-Cardiac glycosides","MLLNCUMT","Million of national currency units","TUR","Türkiye","2018","2018",2.1,,
+"PATCGLYC","C01A-Cardiac glycosides","MLLNCUMT","Million of national currency units","TUR","Türkiye","2019","2019",4.1,,
+"PATCGLYC","C01A-Cardiac glycosides","MLLNCUMT","Million of national currency units","TUR","Türkiye","2020","2020",4.9,,
+"PATCGLYC","C01A-Cardiac glycosides","MLLNCUMT","Million of national currency units","TUR","Türkiye","2021","2021",5.9,,
+"PATCGLYC","C01A-Cardiac glycosides","MTMOTCMT","Million US$ at exchange rate","TUR","Türkiye","2010","2010",0.8,,
+"PATCGLYC","C01A-Cardiac glycosides","MTMOTCMT","Million US$ at exchange rate","TUR","Türkiye","2011","2011",0.7,,
+"PATCGLYC","C01A-Cardiac glycosides","MTMOTCMT","Million US$ at exchange rate","TUR","Türkiye","2012","2012",0.6,,
+"PATCGLYC","C01A-Cardiac glycosides","MTMOTCMT","Million US$ at exchange rate","TUR","Türkiye","2013","2013",0.6,,
+"PATCGLYC","C01A-Cardiac glycosides","MTMOTCMT","Million US$ at exchange rate","TUR","Türkiye","2014","2014",0.6,,
+"PATCGLYC","C01A-Cardiac glycosides","MTMOTCMT","Million US$ at exchange rate","TUR","Türkiye","2015","2015",0.5,,
+"PATCGLYC","C01A-Cardiac glycosides","MTMOTCMT","Million US$ at exchange rate","TUR","Türkiye","2016","2016",0.5,,
+"PATCGLYC","C01A-Cardiac glycosides","MTMOTCMT","Million US$ at exchange rate","TUR","Türkiye","2017","2017",0.5,,
+"PATCGLYC","C01A-Cardiac glycosides","MTMOTCMT","Million US$ at exchange rate","TUR","Türkiye","2018","2018",0.4,,
+"PATCGLYC","C01A-Cardiac glycosides","MTMOTCMT","Million US$ at exchange rate","TUR","Türkiye","2019","2019",0.7,,
+"PATCGLYC","C01A-Cardiac glycosides","MTMOTCMT","Million US$ at exchange rate","TUR","Türkiye","2020","2020",0.7,,
+"PATCGLYC","C01A-Cardiac glycosides","MTMOTCMT","Million US$ at exchange rate","TUR","Türkiye","2021","2021",0.7,,
+"PATCGLYC","C01A-Cardiac glycosides","MTMOPPMT","Million US$, purchasing power parity","TUR","Türkiye","2010","2010",1.3,,
+"PATCGLYC","C01A-Cardiac glycosides","MTMOPPMT","Million US$, purchasing power parity","TUR","Türkiye","2011","2011",1.2,,
+"PATCGLYC","C01A-Cardiac glycosides","MTMOPPMT","Million US$, purchasing power parity","TUR","Türkiye","2012","2012",1.1,,
+"PATCGLYC","C01A-Cardiac glycosides","MTMOPPMT","Million US$, purchasing power parity","TUR","Türkiye","2013","2013",1.1,,
+"PATCGLYC","C01A-Cardiac glycosides","MTMOPPMT","Million US$, purchasing power parity","TUR","Türkiye","2014","2014",1.1,,
+"PATCGLYC","C01A-Cardiac glycosides","MTMOPPMT","Million US$, purchasing power parity","TUR","Türkiye","2015","2015",1.2,,
+"PATCGLYC","C01A-Cardiac glycosides","MTMOPPMT","Million US$, purchasing power parity","TUR","Türkiye","2016","2016",1.2,,
+"PATCGLYC","C01A-Cardiac glycosides","MTMOPPMT","Million US$, purchasing power parity","TUR","Türkiye","2017","2017",1.3,,
+"PATCGLYC","C01A-Cardiac glycosides","MTMOPPMT","Million US$, purchasing power parity","TUR","Türkiye","2018","2018",1.3,,
+"PATCGLYC","C01A-Cardiac glycosides","MTMOPPMT","Million US$, purchasing power parity","TUR","Türkiye","2019","2019",2.2,,
+"PATCGLYC","C01A-Cardiac glycosides","MTMOPPMT","Million US$, purchasing power parity","TUR","Türkiye","2020","2020",2.2,,
+"PATCGLYC","C01A-Cardiac glycosides","MTMOPPMT","Million US$, purchasing power parity","TUR","Türkiye","2021","2021",2.1,,
+"PATCGLYC","C01A-Cardiac glycosides","TCPPERMT","/capita, US$ exchange rate","TUR","Türkiye","2010","2010",0,,
+"PATCGLYC","C01A-Cardiac glycosides","TCPPERMT","/capita, US$ exchange rate","TUR","Türkiye","2011","2011",0,,
+"PATCGLYC","C01A-Cardiac glycosides","TCPPERMT","/capita, US$ exchange rate","TUR","Türkiye","2012","2012",0,,
+"PATCGLYC","C01A-Cardiac glycosides","TCPPERMT","/capita, US$ exchange rate","TUR","Türkiye","2013","2013",0,,
+"PATCGLYC","C01A-Cardiac glycosides","TCPPERMT","/capita, US$ exchange rate","TUR","Türkiye","2014","2014",0,,
+"PATCGLYC","C01A-Cardiac glycosides","TCPPERMT","/capita, US$ exchange rate","TUR","Türkiye","2015","2015",0,,
+"PATCGLYC","C01A-Cardiac glycosides","TCPPERMT","/capita, US$ exchange rate","TUR","Türkiye","2016","2016",0,,
+"PATCGLYC","C01A-Cardiac glycosides","TCPPERMT","/capita, US$ exchange rate","TUR","Türkiye","2017","2017",0,,
+"PATCGLYC","C01A-Cardiac glycosides","TCPPERMT","/capita, US$ exchange rate","TUR","Türkiye","2018","2018",0,,
+"PATCGLYC","C01A-Cardiac glycosides","TCPPERMT","/capita, US$ exchange rate","TUR","Türkiye","2019","2019",0,,
+"PATCGLYC","C01A-Cardiac glycosides","TCPPERMT","/capita, US$ exchange rate","TUR","Türkiye","2020","2020",0,,
+"PATCGLYC","C01A-Cardiac glycosides","TCPPERMT","/capita, US$ exchange rate","TUR","Türkiye","2021","2021",0,,
+"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2010","2010",0,,
+"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2011","2011",0,,
+"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2012","2012",0,,
+"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2013","2013",0,,
+"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2014","2014",0,,
+"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2015","2015",0,,
+"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2016","2016",0,,
+"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2017","2017",0,,
+"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2018","2018",0,,
+"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2019","2019",0,,
+"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2020","2020",0,,
+"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2021","2021",0,,
+"PATCGLYC","C01A-Cardiac glycosides","ATCPTTMT","% of total sales","TUR","Türkiye","2010","2010",0,,
+"PATCGLYC","C01A-Cardiac glycosides","ATCPTTMT","% of total sales","TUR","Türkiye","2011","2011",0,,
+"PATCGLYC","C01A-Cardiac glycosides","ATCPTTMT","% of total sales","TUR","Türkiye","2012","2012",0,,
+"PATCGLYC","C01A-Cardiac glycosides","ATCPTTMT","% of total sales","TUR","Türkiye","2013","2013",0,,
+"PATCGLYC","C01A-Cardiac glycosides","ATCPTTMT","% of total sales","TUR","Türkiye","2014","2014",0,,
+"PATCGLYC","C01A-Cardiac glycosides","ATCPTTMT","% of total sales","TUR","Türkiye","2015","2015",0,,
+"PATCGLYC","C01A-Cardiac glycosides","ATCPTTMT","% of total sales","TUR","Türkiye","2016","2016",0,,
+"PATCGLYC","C01A-Cardiac glycosides","ATCPTTMT","% of total sales","TUR","Türkiye","2017","2017",0,,
+"PATCGLYC","C01A-Cardiac glycosides","ATCPTTMT","% of total sales","TUR","Türkiye","2018","2018",0,,
+"PATCGLYC","C01A-Cardiac glycosides","ATCPTTMT","% of total sales","TUR","Türkiye","2019","2019",0,,
+"PATCGLYC","C01A-Cardiac glycosides","ATCPTTMT","% of total sales","TUR","Türkiye","2020","2020",0,,
+"PATCGLYC","C01A-Cardiac glycosides","ATCPTTMT","% of total sales","TUR","Türkiye","2021","2021",0,,
+"PATCGLYC","C01A-Cardiac glycosides","MLLNCUMT","Million of national currency units","CHL","Chile","2010","2010",49,,
+"PATCGLYC","C01A-Cardiac glycosides","MLLNCUMT","Million of national currency units","CHL","Chile","2011","2011",91.5,"B","Break"
+"PATCGLYC","C01A-Cardiac glycosides","MLLNCUMT","Million of national currency units","CHL","Chile","2012","2012",185.5,,
+"PATCGLYC","C01A-Cardiac glycosides","MLLNCUMT","Million of national currency units","CHL","Chile","2013","2013",136,,
+"PATCGLYC","C01A-Cardiac glycosides","MLLNCUMT","Million of national currency units","CHL","Chile","2014","2014",247.9,,
+"PATCGLYC","C01A-Cardiac glycosides","MLLNCUMT","Million of national currency units","CHL","Chile","2015","2015",173.5,,
+"PATCGLYC","C01A-Cardiac glycosides","MLLNCUMT","Million of national currency units","CHL","Chile","2016","2016",335.1,,
+"PATCGLYC","C01A-Cardiac glycosides","MLLNCUMT","Million of national currency units","CHL","Chile","2017","2017",198.3,,
+"PATCGLYC","C01A-Cardiac glycosides","MLLNCUMT","Million of national currency units","CHL","Chile","2018","2018",337.5,,
+"PATCGLYC","C01A-Cardiac glycosides","MLLNCUMT","Million of national currency units","CHL","Chile","2019","2019",304.4,,
+"PATCGLYC","C01A-Cardiac glycosides","MLLNCUMT","Million of national currency units","CHL","Chile","2020","2020",361.7,,
+"PATCGLYC","C01A-Cardiac glycosides","MLLNCUMT","Million of national currency units","CHL","Chile","2021","2021",438.2,,
+"PATCGLYC","C01A-Cardiac glycosides","MLLNCUMT","Million of national currency units","CHL","Chile","2022","2022",691.9,,
+"PATCGLYC","C01A-Cardiac glycosides","MTMOTCMT","Million US$ at exchange rate","CHL","Chile","2010","2010",0.1,,
+"PATCGLYC","C01A-Cardiac glycosides","MTMOTCMT","Million US$ at exchange rate","CHL","Chile","2011","2011",0.2,"B","Break"
+"PATCGLYC","C01A-Cardiac glycosides","MTMOTCMT","Million US$ at exchange rate","CHL","Chile","2012","2012",0.4,,
+"PATCGLYC","C01A-Cardiac glycosides","MTMOTCMT","Million US$ at exchange rate","CHL","Chile","2013","2013",0.3,,
+"PATCGLYC","C01A-Cardiac glycosides","MTMOTCMT","Million US$ at exchange rate","CHL","Chile","2014","2014",0.4,,
+"PATCGLYC","C01A-Cardiac glycosides","MTMOTCMT","Million US$ at exchange rate","CHL","Chile","2015","2015",0.3,,
+"PATCGLYC","C01A-Cardiac glycosides","MTMOTCMT","Million US$ at exchange rate","CHL","Chile","2016","2016",0.5,,
+"PATCGLYC","C01A-Cardiac glycosides","MTMOTCMT","Million US$ at exchange rate","CHL","Chile","2017","2017",0.3,,
+"PATCGLYC","C01A-Cardiac glycosides","MTMOTCMT","Million US$ at exchange rate","CHL","Chile","2018","2018",0.5,,
+"PATCGLYC","C01A-Cardiac glycosides","MTMOTCMT","Million US$ at exchange rate","CHL","Chile","2019","2019",0.4,,
+"PATCGLYC","C01A-Cardiac glycosides","MTMOTCMT","Million US$ at exchange rate","CHL","Chile","2020","2020",0.5,,
+"PATCGLYC","C01A-Cardiac glycosides","MTMOTCMT","Million US$ at exchange rate","CHL","Chile","2021","2021",0.6,,
+"PATCGLYC","C01A-Cardiac glycosides","MTMOTCMT","Million US$ at exchange rate","CHL","Chile","2022","2022",0.8,,
+"PATCGLYC","C01A-Cardiac glycosides","MTMOPPMT","Million US$, purchasing power parity","CHL","Chile","2010","2010",0.1,,
+"PATCGLYC","C01A-Cardiac glycosides","MTMOPPMT","Million US$, purchasing power parity","CHL","Chile","2011","2011",0.3,"B","Break"
+"PATCGLYC","C01A-Cardiac glycosides","MTMOPPMT","Million US$, purchasing power parity","CHL","Chile","2012","2012",0.5,,
+"PATCGLYC","C01A-Cardiac glycosides","MTMOPPMT","Million US$, purchasing power parity","CHL","Chile","2013","2013",0.4,,
+"PATCGLYC","C01A-Cardiac glycosides","MTMOPPMT","Million US$, purchasing power parity","CHL","Chile","2014","2014",0.7,,
+"PATCGLYC","C01A-Cardiac glycosides","MTMOPPMT","Million US$, purchasing power parity","CHL","Chile","2015","2015",0.4,,
+"PATCGLYC","C01A-Cardiac glycosides","MTMOPPMT","Million US$, purchasing power parity","CHL","Chile","2016","2016",0.8,,
+"PATCGLYC","C01A-Cardiac glycosides","MTMOPPMT","Million US$, purchasing power parity","CHL","Chile","2017","2017",0.5,,
+"PATCGLYC","C01A-Cardiac glycosides","MTMOPPMT","Million US$, purchasing power parity","CHL","Chile","2018","2018",0.9,,
+"PATCGLYC","C01A-Cardiac glycosides","MTMOPPMT","Million US$, purchasing power parity","CHL","Chile","2019","2019",0.8,,
+"PATCGLYC","C01A-Cardiac glycosides","MTMOPPMT","Million US$, purchasing power parity","CHL","Chile","2020","2020",0.9,,
+"PATCGLYC","C01A-Cardiac glycosides","MTMOPPMT","Million US$, purchasing power parity","CHL","Chile","2021","2021",1,,
+"PATCGLYC","C01A-Cardiac glycosides","MTMOPPMT","Million US$, purchasing power parity","CHL","Chile","2022","2022",1.6,,
+"PATCGLYC","C01A-Cardiac glycosides","TCPPERMT","/capita, US$ exchange rate","CHL","Chile","2010","2010",0,,
+"PATCGLYC","C01A-Cardiac glycosides","TCPPERMT","/capita, US$ exchange rate","CHL","Chile","2011","2011",0,"B","Break"
+"PATCGLYC","C01A-Cardiac glycosides","TCPPERMT","/capita, US$ exchange rate","CHL","Chile","2012","2012",0,,
+"PATCGLYC","C01A-Cardiac glycosides","TCPPERMT","/capita, US$ exchange rate","CHL","Chile","2013","2013",0,,
+"PATCGLYC","C01A-Cardiac glycosides","TCPPERMT","/capita, US$ exchange rate","CHL","Chile","2014","2014",0,,
+"PATCGLYC","C01A-Cardiac glycosides","TCPPERMT","/capita, US$ exchange rate","CHL","Chile","2015","2015",0,,
+"PATCGLYC","C01A-Cardiac glycosides","TCPPERMT","/capita, US$ exchange rate","CHL","Chile","2016","2016",0,,
+"PATCGLYC","C01A-Cardiac glycosides","TCPPERMT","/capita, US$ exchange rate","CHL","Chile","2017","2017",0,,
+"PATCGLYC","C01A-Cardiac glycosides","TCPPERMT","/capita, US$ exchange rate","CHL","Chile","2018","2018",0,,
+"PATCGLYC","C01A-Cardiac glycosides","TCPPERMT","/capita, US$ exchange rate","CHL","Chile","2019","2019",0,,
+"PATCGLYC","C01A-Cardiac glycosides","TCPPERMT","/capita, US$ exchange rate","CHL","Chile","2020","2020",0,,
+"PATCGLYC","C01A-Cardiac glycosides","TCPPERMT","/capita, US$ exchange rate","CHL","Chile","2021","2021",0,,
+"PATCGLYC","C01A-Cardiac glycosides","TCPPERMT","/capita, US$ exchange rate","CHL","Chile","2022","2022",0,,
+"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2010","2010",0,,
+"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2011","2011",0,"B","Break"
+"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2012","2012",0,,
+"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2013","2013",0,,
+"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2014","2014",0,,
+"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2015","2015",0,,
+"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2016","2016",0,,
+"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2017","2017",0,,
+"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2018","2018",0,,
+"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2019","2019",0,,
+"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2020","2020",0,,
+"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2021","2021",0.1,,
+"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2022","2022",0.1,,
+"PATCGLYC","C01A-Cardiac glycosides","ATCPTTMT","% of total sales","CHL","Chile","2010","2010",0,,
+"PATCGLYC","C01A-Cardiac glycosides","ATCPTTMT","% of total sales","CHL","Chile","2011","2011",0,"B","Break"
+"PATCGLYC","C01A-Cardiac glycosides","ATCPTTMT","% of total sales","CHL","Chile","2012","2012",0,,
+"PATCGLYC","C01A-Cardiac glycosides","ATCPTTMT","% of total sales","CHL","Chile","2013","2013",0,,
+"PATCGLYC","C01A-Cardiac glycosides","ATCPTTMT","% of total sales","CHL","Chile","2014","2014",0,,
+"PATCGLYC","C01A-Cardiac glycosides","ATCPTTMT","% of total sales","CHL","Chile","2015","2015",0,,
+"PATCGLYC","C01A-Cardiac glycosides","ATCPTTMT","% of total sales","CHL","Chile","2016","2016",0,,
+"PATCGLYC","C01A-Cardiac glycosides","ATCPTTMT","% of total sales","CHL","Chile","2017","2017",0,,
+"PATCGLYC","C01A-Cardiac glycosides","ATCPTTMT","% of total sales","CHL","Chile","2018","2018",0,,
+"PATCGLYC","C01A-Cardiac glycosides","ATCPTTMT","% of total sales","CHL","Chile","2019","2019",0,,
+"PATCGLYC","C01A-Cardiac glycosides","ATCPTTMT","% of total sales","CHL","Chile","2020","2020",0,,
+"PATCGLYC","C01A-Cardiac glycosides","ATCPTTMT","% of total sales","CHL","Chile","2021","2021",0,,
+"PATCGLYC","C01A-Cardiac glycosides","ATCPTTMT","% of total sales","CHL","Chile","2022","2022",0,,
+"PATCGLYC","C01A-Cardiac glycosides","MLLNCUMT","Million of national currency units","EST","Estonia","2010","2010",0.2,,
+"PATCGLYC","C01A-Cardiac glycosides","MLLNCUMT","Million of national currency units","EST","Estonia","2011","2011",0.2,,
+"PATCGLYC","C01A-Cardiac glycosides","MLLNCUMT","Million of national currency units","EST","Estonia","2012","2012",0.2,,
+"PATCGLYC","C01A-Cardiac glycosides","MLLNCUMT","Million of national currency units","EST","Estonia","2013","2013",0.2,,
+"PATCGLYC","C01A-Cardiac glycosides","MLLNCUMT","Million of national currency units","EST","Estonia","2014","2014",0.2,,
+"PATCGLYC","C01A-Cardiac glycosides","MLLNCUMT","Million of national currency units","EST","Estonia","2015","2015",0.1,,
+"PATCGLYC","C01A-Cardiac glycosides","MLLNCUMT","Million of national currency units","EST","Estonia","2016","2016",0.1,,
+"PATCGLYC","C01A-Cardiac glycosides","MLLNCUMT","Million of national currency units","EST","Estonia","2017","2017",0.1,,
+"PATCGLYC","C01A-Cardiac glycosides","MLLNCUMT","Million of national currency units","EST","Estonia","2018","2018",0.1,,
+"PATCGLYC","C01A-Cardiac glycosides","MLLNCUMT","Million of national currency units","EST","Estonia","2019","2019",0.1,,
+"PATCGLYC","C01A-Cardiac glycosides","MLLNCUMT","Million of national currency units","EST","Estonia","2020","2020",0.1,,
+"PATCGLYC","C01A-Cardiac glycosides","MLLNCUMT","Million of national currency units","EST","Estonia","2021","2021",0.1,,
+"PATCGLYC","C01A-Cardiac glycosides","MLLNCUMT","Million of national currency units","EST","Estonia","2022","2022",0.1,,
+"PATCGLYC","C01A-Cardiac glycosides","MTMOTCMT","Million US$ at exchange rate","EST","Estonia","2010","2010",0.2,,
+"PATCGLYC","C01A-Cardiac glycosides","MTMOTCMT","Million US$ at exchange rate","EST","Estonia","2011","2011",0.2,,
+"PATCGLYC","C01A-Cardiac glycosides","MTMOTCMT","Million US$ at exchange rate","EST","Estonia","2012","2012",0.2,,
+"PATCGLYC","C01A-Cardiac glycosides","MTMOTCMT","Million US$ at exchange rate","EST","Estonia","2013","2013",0.2,,
+"PATCGLYC","C01A-Cardiac glycosides","MTMOTCMT","Million US$ at exchange rate","EST","Estonia","2014","2014",0.2,,
+"PATCGLYC","C01A-Cardiac glycosides","MTMOTCMT","Million US$ at exchange rate","EST","Estonia","2015","2015",0.2,,
+"PATCGLYC","C01A-Cardiac glycosides","MTMOTCMT","Million US$ at exchange rate","EST","Estonia","2016","2016",0.1,,
+"PATCGLYC","C01A-Cardiac glycosides","MTMOTCMT","Million US$ at exchange rate","EST","Estonia","2017","2017",0.1,,
+"PATCGLYC","C01A-Cardiac glycosides","MTMOTCMT","Million US$ at exchange rate","EST","Estonia","2018","2018",0.1,,
+"PATCGLYC","C01A-Cardiac glycosides","MTMOTCMT","Million US$ at exchange rate","EST","Estonia","2019","2019",0.1,,
+"PATCGLYC","C01A-Cardiac glycosides","MTMOTCMT","Million US$ at exchange rate","EST","Estonia","2020","2020",0.1,,
+"PATCGLYC","C01A-Cardiac glycosides","MTMOTCMT","Million US$ at exchange rate","EST","Estonia","2021","2021",0.1,,
+"PATCGLYC","C01A-Cardiac glycosides","MTMOTCMT","Million US$ at exchange rate","EST","Estonia","2022","2022",0.1,,
+"PATCGLYC","C01A-Cardiac glycosides","MTMOPPMT","Million US$, purchasing power parity","EST","Estonia","2010","2010",0.3,,
+"PATCGLYC","C01A-Cardiac glycosides","MTMOPPMT","Million US$, purchasing power parity","EST","Estonia","2011","2011",0.3,,
+"PATCGLYC","C01A-Cardiac glycosides","MTMOPPMT","Million US$, purchasing power parity","EST","Estonia","2012","2012",0.3,,
+"PATCGLYC","C01A-Cardiac glycosides","MTMOPPMT","Million US$, purchasing power parity","EST","Estonia","2013","2013",0.3,,
+"PATCGLYC","C01A-Cardiac glycosides","MTMOPPMT","Million US$, purchasing power parity","EST","Estonia","2014","2014",0.3,,
+"PATCGLYC","C01A-Cardiac glycosides","MTMOPPMT","Million US$, purchasing power parity","EST","Estonia","2015","2015",0.3,,
+"PATCGLYC","C01A-Cardiac glycosides","MTMOPPMT","Million US$, purchasing power parity","EST","Estonia","2016","2016",0.2,,
+"PATCGLYC","C01A-Cardiac glycosides","MTMOPPMT","Million US$, purchasing power parity","EST","Estonia","2017","2017",0.2,,
+"PATCGLYC","C01A-Cardiac glycosides","MTMOPPMT","Million US$, purchasing power parity","EST","Estonia","2018","2018",0.2,,
+"PATCGLYC","C01A-Cardiac glycosides","MTMOPPMT","Million US$, purchasing power parity","EST","Estonia","2019","2019",0.2,,
+"PATCGLYC","C01A-Cardiac glycosides","MTMOPPMT","Million US$, purchasing power parity","EST","Estonia","2020","2020",0.2,,
+"PATCGLYC","C01A-Cardiac glycosides","MTMOPPMT","Million US$, purchasing power parity","EST","Estonia","2021","2021",0.2,,
+"PATCGLYC","C01A-Cardiac glycosides","MTMOPPMT","Million US$, purchasing power parity","EST","Estonia","2022","2022",0.1,,
+"PATCGLYC","C01A-Cardiac glycosides","TCPPERMT","/capita, US$ exchange rate","EST","Estonia","2010","2010",0.2,,
+"PATCGLYC","C01A-Cardiac glycosides","TCPPERMT","/capita, US$ exchange rate","EST","Estonia","2011","2011",0.2,,
+"PATCGLYC","C01A-Cardiac glycosides","TCPPERMT","/capita, US$ exchange rate","EST","Estonia","2012","2012",0.2,,
+"PATCGLYC","C01A-Cardiac glycosides","TCPPERMT","/capita, US$ exchange rate","EST","Estonia","2013","2013",0.2,,
+"PATCGLYC","C01A-Cardiac glycosides","TCPPERMT","/capita, US$ exchange rate","EST","Estonia","2014","2014",0.2,,
+"PATCGLYC","C01A-Cardiac glycosides","TCPPERMT","/capita, US$ exchange rate","EST","Estonia","2015","2015",0.1,,
+"PATCGLYC","C01A-Cardiac glycosides","TCPPERMT","/capita, US$ exchange rate","EST","Estonia","2016","2016",0.1,,
+"PATCGLYC","C01A-Cardiac glycosides","TCPPERMT","/capita, US$ exchange rate","EST","Estonia","2017","2017",0.1,,
+"PATCGLYC","C01A-Cardiac glycosides","TCPPERMT","/capita, US$ exchange rate","EST","Estonia","2018","2018",0.1,,
+"PATCGLYC","C01A-Cardiac glycosides","TCPPERMT","/capita, US$ exchange rate","EST","Estonia","2019","2019",0.1,,
+"PATCGLYC","C01A-Cardiac glycosides","TCPPERMT","/capita, US$ exchange rate","EST","Estonia","2020","2020",0.1,,
+"PATCGLYC","C01A-Cardiac glycosides","TCPPERMT","/capita, US$ exchange rate","EST","Estonia","2021","2021",0.1,,
+"PATCGLYC","C01A-Cardiac glycosides","TCPPERMT","/capita, US$ exchange rate","EST","Estonia","2022","2022",0.1,,
+"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2010","2010",0.2,,
+"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2011","2011",0.2,,
+"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2012","2012",0.2,,
+"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2013","2013",0.2,,
+"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2014","2014",0.2,,
+"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2015","2015",0.2,,
+"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2016","2016",0.2,,
+"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2017","2017",0.2,,
+"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2018","2018",0.2,,
+"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2019","2019",0.1,,
+"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2020","2020",0.1,,
+"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2021","2021",0.1,,
+"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2022","2022",0.1,,
+"PATCGLYC","C01A-Cardiac glycosides","ATCPTTMT","% of total sales","EST","Estonia","2010","2010",0.1,,
+"PATCGLYC","C01A-Cardiac glycosides","ATCPTTMT","% of total sales","EST","Estonia","2011","2011",0.1,,
+"PATCGLYC","C01A-Cardiac glycosides","ATCPTTMT","% of total sales","EST","Estonia","2012","2012",0.1,,
+"PATCGLYC","C01A-Cardiac glycosides","ATCPTTMT","% of total sales","EST","Estonia","2013","2013",0.1,,
+"PATCGLYC","C01A-Cardiac glycosides","ATCPTTMT","% of total sales","EST","Estonia","2014","2014",0.1,,
+"PATCGLYC","C01A-Cardiac glycosides","ATCPTTMT","% of total sales","EST","Estonia","2015","2015",0.1,,
+"PATCGLYC","C01A-Cardiac glycosides","ATCPTTMT","% of total sales","EST","Estonia","2016","2016",0,,
+"PATCGLYC","C01A-Cardiac glycosides","ATCPTTMT","% of total sales","EST","Estonia","2017","2017",0,,
+"PATCGLYC","C01A-Cardiac glycosides","ATCPTTMT","% of total sales","EST","Estonia","2018","2018",0,,
+"PATCGLYC","C01A-Cardiac glycosides","ATCPTTMT","% of total sales","EST","Estonia","2019","2019",0,,
+"PATCGLYC","C01A-Cardiac glycosides","ATCPTTMT","% of total sales","EST","Estonia","2020","2020",0,,
+"PATCGLYC","C01A-Cardiac glycosides","ATCPTTMT","% of total sales","EST","Estonia","2021","2021",0,,
+"PATCGLYC","C01A-Cardiac glycosides","ATCPTTMT","% of total sales","EST","Estonia","2022","2022",0,,
+"PATCGLYC","C01A-Cardiac glycosides","MLLNCUMT","Million of national currency units","SVN","Slovenia","2010","2010",0.3,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","MLLNCUMT","Million of national currency units","SVN","Slovenia","2011","2011",0.3,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","MLLNCUMT","Million of national currency units","SVN","Slovenia","2012","2012",0.3,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","MLLNCUMT","Million of national currency units","SVN","Slovenia","2013","2013",0.3,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","MLLNCUMT","Million of national currency units","SVN","Slovenia","2014","2014",0.3,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","MLLNCUMT","Million of national currency units","SVN","Slovenia","2015","2015",0.3,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","MLLNCUMT","Million of national currency units","SVN","Slovenia","2016","2016",0.3,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","MLLNCUMT","Million of national currency units","SVN","Slovenia","2017","2017",0.3,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","MLLNCUMT","Million of national currency units","SVN","Slovenia","2018","2018",0.3,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","MLLNCUMT","Million of national currency units","SVN","Slovenia","2019","2019",0.3,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","MLLNCUMT","Million of national currency units","SVN","Slovenia","2020","2020",0.3,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","MLLNCUMT","Million of national currency units","SVN","Slovenia","2021","2021",0.3,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","MLLNCUMT","Million of national currency units","SVN","Slovenia","2022","2022",0.3,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","MTMOTCMT","Million US$ at exchange rate","SVN","Slovenia","2010","2010",0.4,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","MTMOTCMT","Million US$ at exchange rate","SVN","Slovenia","2011","2011",0.4,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","MTMOTCMT","Million US$ at exchange rate","SVN","Slovenia","2012","2012",0.4,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","MTMOTCMT","Million US$ at exchange rate","SVN","Slovenia","2013","2013",0.4,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","MTMOTCMT","Million US$ at exchange rate","SVN","Slovenia","2014","2014",0.4,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","MTMOTCMT","Million US$ at exchange rate","SVN","Slovenia","2015","2015",0.3,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","MTMOTCMT","Million US$ at exchange rate","SVN","Slovenia","2016","2016",0.3,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","MTMOTCMT","Million US$ at exchange rate","SVN","Slovenia","2017","2017",0.4,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","MTMOTCMT","Million US$ at exchange rate","SVN","Slovenia","2018","2018",0.4,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","MTMOTCMT","Million US$ at exchange rate","SVN","Slovenia","2019","2019",0.3,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","MTMOTCMT","Million US$ at exchange rate","SVN","Slovenia","2020","2020",0.4,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","MTMOTCMT","Million US$ at exchange rate","SVN","Slovenia","2021","2021",0.4,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","MTMOTCMT","Million US$ at exchange rate","SVN","Slovenia","2022","2022",0.3,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","MTMOPPMT","Million US$, purchasing power parity","SVN","Slovenia","2010","2010",0.5,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","MTMOPPMT","Million US$, purchasing power parity","SVN","Slovenia","2011","2011",0.5,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","MTMOPPMT","Million US$, purchasing power parity","SVN","Slovenia","2012","2012",0.5,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","MTMOPPMT","Million US$, purchasing power parity","SVN","Slovenia","2013","2013",0.5,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","MTMOPPMT","Million US$, purchasing power parity","SVN","Slovenia","2014","2014",0.5,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","MTMOPPMT","Million US$, purchasing power parity","SVN","Slovenia","2015","2015",0.5,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","MTMOPPMT","Million US$, purchasing power parity","SVN","Slovenia","2016","2016",0.5,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","MTMOPPMT","Million US$, purchasing power parity","SVN","Slovenia","2017","2017",0.6,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","MTMOPPMT","Million US$, purchasing power parity","SVN","Slovenia","2018","2018",0.6,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","MTMOPPMT","Million US$, purchasing power parity","SVN","Slovenia","2019","2019",0.5,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","MTMOPPMT","Million US$, purchasing power parity","SVN","Slovenia","2020","2020",0.6,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","MTMOPPMT","Million US$, purchasing power parity","SVN","Slovenia","2021","2021",0.5,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","MTMOPPMT","Million US$, purchasing power parity","SVN","Slovenia","2022","2022",0.5,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","TCPPERMT","/capita, US$ exchange rate","SVN","Slovenia","2010","2010",0.2,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","TCPPERMT","/capita, US$ exchange rate","SVN","Slovenia","2011","2011",0.2,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","TCPPERMT","/capita, US$ exchange rate","SVN","Slovenia","2012","2012",0.2,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","TCPPERMT","/capita, US$ exchange rate","SVN","Slovenia","2013","2013",0.2,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","TCPPERMT","/capita, US$ exchange rate","SVN","Slovenia","2014","2014",0.2,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","TCPPERMT","/capita, US$ exchange rate","SVN","Slovenia","2015","2015",0.2,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","TCPPERMT","/capita, US$ exchange rate","SVN","Slovenia","2016","2016",0.2,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","TCPPERMT","/capita, US$ exchange rate","SVN","Slovenia","2017","2017",0.2,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","TCPPERMT","/capita, US$ exchange rate","SVN","Slovenia","2018","2018",0.2,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","TCPPERMT","/capita, US$ exchange rate","SVN","Slovenia","2019","2019",0.2,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","TCPPERMT","/capita, US$ exchange rate","SVN","Slovenia","2020","2020",0.2,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","TCPPERMT","/capita, US$ exchange rate","SVN","Slovenia","2021","2021",0.2,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","TCPPERMT","/capita, US$ exchange rate","SVN","Slovenia","2022","2022",0.1,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2010","2010",0.3,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2011","2011",0.2,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2012","2012",0.3,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2013","2013",0.3,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2014","2014",0.2,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2015","2015",0.2,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2016","2016",0.2,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2017","2017",0.3,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2018","2018",0.3,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2019","2019",0.2,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2020","2020",0.3,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2021","2021",0.3,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2022","2022",0.3,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","ATCPTTMT","% of total sales","SVN","Slovenia","2010","2010",0.1,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","ATCPTTMT","% of total sales","SVN","Slovenia","2011","2011",0.1,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","ATCPTTMT","% of total sales","SVN","Slovenia","2012","2012",0.1,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","ATCPTTMT","% of total sales","SVN","Slovenia","2013","2013",0.1,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","ATCPTTMT","% of total sales","SVN","Slovenia","2014","2014",0.1,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","ATCPTTMT","% of total sales","SVN","Slovenia","2015","2015",0.1,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","ATCPTTMT","% of total sales","SVN","Slovenia","2016","2016",0.1,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","ATCPTTMT","% of total sales","SVN","Slovenia","2017","2017",0.1,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","ATCPTTMT","% of total sales","SVN","Slovenia","2018","2018",0.1,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","ATCPTTMT","% of total sales","SVN","Slovenia","2019","2019",0.1,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","ATCPTTMT","% of total sales","SVN","Slovenia","2020","2020",0.1,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","ATCPTTMT","% of total sales","SVN","Slovenia","2021","2021",0.1,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","ATCPTTMT","% of total sales","SVN","Slovenia","2022","2022",0,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MLLNCUMT","Million of national currency units","AUS","Australia","2010","2010",17,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MLLNCUMT","Million of national currency units","AUS","Australia","2011","2011",17,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MLLNCUMT","Million of national currency units","AUS","Australia","2012","2012",17,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MLLNCUMT","Million of national currency units","AUS","Australia","2013","2013",18,"B; D","Break; Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MLLNCUMT","Million of national currency units","AUS","Australia","2014","2014",19,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MLLNCUMT","Million of national currency units","AUS","Australia","2015","2015",19,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MLLNCUMT","Million of national currency units","AUS","Australia","2016","2016",20,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MLLNCUMT","Million of national currency units","AUS","Australia","2017","2017",20,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MLLNCUMT","Million of national currency units","AUS","Australia","2018","2018",21,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MLLNCUMT","Million of national currency units","AUS","Australia","2019","2019",22,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MLLNCUMT","Million of national currency units","AUS","Australia","2020","2020",24,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MLLNCUMT","Million of national currency units","AUS","Australia","2021","2021",26,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOTCMT","Million US$ at exchange rate","AUS","Australia","2010","2010",15.6,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOTCMT","Million US$ at exchange rate","AUS","Australia","2011","2011",17.5,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOTCMT","Million US$ at exchange rate","AUS","Australia","2012","2012",17.6,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOTCMT","Million US$ at exchange rate","AUS","Australia","2013","2013",17.4,"B; D","Break; Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOTCMT","Million US$ at exchange rate","AUS","Australia","2014","2014",17.1,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOTCMT","Million US$ at exchange rate","AUS","Australia","2015","2015",14.3,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOTCMT","Million US$ at exchange rate","AUS","Australia","2016","2016",14.9,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOTCMT","Million US$ at exchange rate","AUS","Australia","2017","2017",15.3,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOTCMT","Million US$ at exchange rate","AUS","Australia","2018","2018",15.7,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOTCMT","Million US$ at exchange rate","AUS","Australia","2019","2019",15.3,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOTCMT","Million US$ at exchange rate","AUS","Australia","2020","2020",16.5,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOTCMT","Million US$ at exchange rate","AUS","Australia","2021","2021",19.5,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOPPMT","Million US$, purchasing power parity","AUS","Australia","2010","2010",11.3,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOPPMT","Million US$, purchasing power parity","AUS","Australia","2011","2011",11.3,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOPPMT","Million US$, purchasing power parity","AUS","Australia","2012","2012",11,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOPPMT","Million US$, purchasing power parity","AUS","Australia","2013","2013",12.4,"B; D","Break; Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOPPMT","Million US$, purchasing power parity","AUS","Australia","2014","2014",13.1,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOPPMT","Million US$, purchasing power parity","AUS","Australia","2015","2015",12.9,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOPPMT","Million US$, purchasing power parity","AUS","Australia","2016","2016",13.8,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOPPMT","Million US$, purchasing power parity","AUS","Australia","2017","2017",13.5,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOPPMT","Million US$, purchasing power parity","AUS","Australia","2018","2018",14.3,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOPPMT","Million US$, purchasing power parity","AUS","Australia","2019","2019",14.9,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOPPMT","Million US$, purchasing power parity","AUS","Australia","2020","2020",16.5,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOPPMT","Million US$, purchasing power parity","AUS","Australia","2021","2021",18,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","TCPPERMT","/capita, US$ exchange rate","AUS","Australia","2010","2010",0.7,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","TCPPERMT","/capita, US$ exchange rate","AUS","Australia","2011","2011",0.8,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","TCPPERMT","/capita, US$ exchange rate","AUS","Australia","2012","2012",0.8,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","TCPPERMT","/capita, US$ exchange rate","AUS","Australia","2013","2013",0.8,"B; D","Break; Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","TCPPERMT","/capita, US$ exchange rate","AUS","Australia","2014","2014",0.7,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","TCPPERMT","/capita, US$ exchange rate","AUS","Australia","2015","2015",0.6,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","TCPPERMT","/capita, US$ exchange rate","AUS","Australia","2016","2016",0.6,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","TCPPERMT","/capita, US$ exchange rate","AUS","Australia","2017","2017",0.6,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","TCPPERMT","/capita, US$ exchange rate","AUS","Australia","2018","2018",0.6,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","TCPPERMT","/capita, US$ exchange rate","AUS","Australia","2019","2019",0.6,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","TCPPERMT","/capita, US$ exchange rate","AUS","Australia","2020","2020",0.6,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","TCPPERMT","/capita, US$ exchange rate","AUS","Australia","2021","2021",0.8,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2010","2010",0.5,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2011","2011",0.5,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2012","2012",0.5,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2013","2013",0.5,"B; D","Break; Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2014","2014",0.6,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2015","2015",0.5,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2016","2016",0.6,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2017","2017",0.6,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2018","2018",0.6,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2019","2019",0.6,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2020","2020",0.6,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2021","2021",0.7,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","ATCPTTMT","% of total sales","AUS","Australia","2010","2010",0.2,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","ATCPTTMT","% of total sales","AUS","Australia","2011","2011",0.2,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","ATCPTTMT","% of total sales","AUS","Australia","2012","2012",0.2,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","ATCPTTMT","% of total sales","AUS","Australia","2013","2013",0.2,"B; D","Break; Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","ATCPTTMT","% of total sales","AUS","Australia","2014","2014",0.2,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","ATCPTTMT","% of total sales","AUS","Australia","2015","2015",0.2,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","ATCPTTMT","% of total sales","AUS","Australia","2016","2016",0.1,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","ATCPTTMT","% of total sales","AUS","Australia","2017","2017",0.1,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","ATCPTTMT","% of total sales","AUS","Australia","2018","2018",0.1,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","ATCPTTMT","% of total sales","AUS","Australia","2019","2019",0.1,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","ATCPTTMT","% of total sales","AUS","Australia","2020","2020",0.1,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","ATCPTTMT","% of total sales","AUS","Australia","2021","2021",0.1,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MLLNCUMT","Million of national currency units","AUT","Austria","2010","2010",6.8,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MLLNCUMT","Million of national currency units","AUT","Austria","2011","2011",7.6,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MLLNCUMT","Million of national currency units","AUT","Austria","2012","2012",7.3,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MLLNCUMT","Million of national currency units","AUT","Austria","2013","2013",7.3,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MLLNCUMT","Million of national currency units","AUT","Austria","2014","2014",7.2,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MLLNCUMT","Million of national currency units","AUT","Austria","2015","2015",7,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MLLNCUMT","Million of national currency units","AUT","Austria","2016","2016",6.8,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MLLNCUMT","Million of national currency units","AUT","Austria","2017","2017",6.6,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MLLNCUMT","Million of national currency units","AUT","Austria","2018","2018",6.4,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MLLNCUMT","Million of national currency units","AUT","Austria","2019","2019",5.5,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MLLNCUMT","Million of national currency units","AUT","Austria","2020","2020",4.8,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MLLNCUMT","Million of national currency units","AUT","Austria","2021","2021",4.2,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOTCMT","Million US$ at exchange rate","AUT","Austria","2010","2010",9,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOTCMT","Million US$ at exchange rate","AUT","Austria","2011","2011",10.6,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOTCMT","Million US$ at exchange rate","AUT","Austria","2012","2012",9.4,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOTCMT","Million US$ at exchange rate","AUT","Austria","2013","2013",9.7,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOTCMT","Million US$ at exchange rate","AUT","Austria","2014","2014",9.6,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOTCMT","Million US$ at exchange rate","AUT","Austria","2015","2015",7.8,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOTCMT","Million US$ at exchange rate","AUT","Austria","2016","2016",7.5,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOTCMT","Million US$ at exchange rate","AUT","Austria","2017","2017",7.4,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOTCMT","Million US$ at exchange rate","AUT","Austria","2018","2018",7.6,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOTCMT","Million US$ at exchange rate","AUT","Austria","2019","2019",6.2,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOTCMT","Million US$ at exchange rate","AUT","Austria","2020","2020",5.4,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOTCMT","Million US$ at exchange rate","AUT","Austria","2021","2021",5,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOPPMT","Million US$, purchasing power parity","AUT","Austria","2010","2010",8.1,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOPPMT","Million US$, purchasing power parity","AUT","Austria","2011","2011",9.2,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOPPMT","Million US$, purchasing power parity","AUT","Austria","2012","2012",9,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOPPMT","Million US$, purchasing power parity","AUT","Austria","2013","2013",9.1,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOPPMT","Million US$, purchasing power parity","AUT","Austria","2014","2014",9,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOPPMT","Million US$, purchasing power parity","AUT","Austria","2015","2015",8.8,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOPPMT","Million US$, purchasing power parity","AUT","Austria","2016","2016",8.8,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOPPMT","Million US$, purchasing power parity","AUT","Austria","2017","2017",8.5,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOPPMT","Million US$, purchasing power parity","AUT","Austria","2018","2018",8.4,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOPPMT","Million US$, purchasing power parity","AUT","Austria","2019","2019",7.4,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOPPMT","Million US$, purchasing power parity","AUT","Austria","2020","2020",6.4,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOPPMT","Million US$, purchasing power parity","AUT","Austria","2021","2021",5.6,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","TCPPERMT","/capita, US$ exchange rate","AUT","Austria","2010","2010",1.1,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","TCPPERMT","/capita, US$ exchange rate","AUT","Austria","2011","2011",1.3,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","TCPPERMT","/capita, US$ exchange rate","AUT","Austria","2012","2012",1.1,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","TCPPERMT","/capita, US$ exchange rate","AUT","Austria","2013","2013",1.1,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","TCPPERMT","/capita, US$ exchange rate","AUT","Austria","2014","2014",1.1,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","TCPPERMT","/capita, US$ exchange rate","AUT","Austria","2015","2015",0.9,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","TCPPERMT","/capita, US$ exchange rate","AUT","Austria","2016","2016",0.9,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","TCPPERMT","/capita, US$ exchange rate","AUT","Austria","2017","2017",0.8,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","TCPPERMT","/capita, US$ exchange rate","AUT","Austria","2018","2018",0.9,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","TCPPERMT","/capita, US$ exchange rate","AUT","Austria","2019","2019",0.7,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","TCPPERMT","/capita, US$ exchange rate","AUT","Austria","2020","2020",0.6,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","TCPPERMT","/capita, US$ exchange rate","AUT","Austria","2021","2021",0.6,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2010","2010",1,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2011","2011",1.1,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2012","2012",1.1,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2013","2013",1.1,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2014","2014",1.1,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2015","2015",1,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2016","2016",1,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2017","2017",1,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2018","2018",0.9,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2019","2019",0.8,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2020","2020",0.7,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2021","2021",0.6,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","ATCPTTMT","% of total sales","AUT","Austria","2010","2010",0.3,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","ATCPTTMT","% of total sales","AUT","Austria","2011","2011",0.3,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","ATCPTTMT","% of total sales","AUT","Austria","2012","2012",0.3,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","ATCPTTMT","% of total sales","AUT","Austria","2013","2013",0.3,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","ATCPTTMT","% of total sales","AUT","Austria","2014","2014",0.3,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","ATCPTTMT","% of total sales","AUT","Austria","2015","2015",0.2,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","ATCPTTMT","% of total sales","AUT","Austria","2016","2016",0.2,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","ATCPTTMT","% of total sales","AUT","Austria","2017","2017",0.2,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","ATCPTTMT","% of total sales","AUT","Austria","2018","2018",0.2,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","ATCPTTMT","% of total sales","AUT","Austria","2019","2019",0.2,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","ATCPTTMT","% of total sales","AUT","Austria","2020","2020",0.1,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","ATCPTTMT","% of total sales","AUT","Austria","2021","2021",0.1,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MLLNCUMT","Million of national currency units","BEL","Belgium","2010","2010",16,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MLLNCUMT","Million of national currency units","BEL","Belgium","2011","2011",15.1,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MLLNCUMT","Million of national currency units","BEL","Belgium","2012","2012",15.1,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MLLNCUMT","Million of national currency units","BEL","Belgium","2013","2013",15.4,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MLLNCUMT","Million of national currency units","BEL","Belgium","2014","2014",15.5,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MLLNCUMT","Million of national currency units","BEL","Belgium","2015","2015",15.3,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MLLNCUMT","Million of national currency units","BEL","Belgium","2016","2016",14.8,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MLLNCUMT","Million of national currency units","BEL","Belgium","2017","2017",14.9,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MLLNCUMT","Million of national currency units","BEL","Belgium","2018","2018",14.9,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MLLNCUMT","Million of national currency units","BEL","Belgium","2019","2019",14.9,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MLLNCUMT","Million of national currency units","BEL","Belgium","2020","2020",14,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MLLNCUMT","Million of national currency units","BEL","Belgium","2021","2021",13.6,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MLLNCUMT","Million of national currency units","BEL","Belgium","2022","2022",13.4,"E","Estimated value"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOTCMT","Million US$ at exchange rate","BEL","Belgium","2010","2010",21.2,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOTCMT","Million US$ at exchange rate","BEL","Belgium","2011","2011",21,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOTCMT","Million US$ at exchange rate","BEL","Belgium","2012","2012",19.4,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOTCMT","Million US$ at exchange rate","BEL","Belgium","2013","2013",20.5,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOTCMT","Million US$ at exchange rate","BEL","Belgium","2014","2014",20.6,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOTCMT","Million US$ at exchange rate","BEL","Belgium","2015","2015",16.9,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOTCMT","Million US$ at exchange rate","BEL","Belgium","2016","2016",16.4,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOTCMT","Million US$ at exchange rate","BEL","Belgium","2017","2017",16.8,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOTCMT","Million US$ at exchange rate","BEL","Belgium","2018","2018",17.6,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOTCMT","Million US$ at exchange rate","BEL","Belgium","2019","2019",16.7,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOTCMT","Million US$ at exchange rate","BEL","Belgium","2020","2020",15.9,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOTCMT","Million US$ at exchange rate","BEL","Belgium","2021","2021",16.1,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOTCMT","Million US$ at exchange rate","BEL","Belgium","2022","2022",14.1,"E","Estimated value"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOPPMT","Million US$, purchasing power parity","BEL","Belgium","2010","2010",19.1,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOPPMT","Million US$, purchasing power parity","BEL","Belgium","2011","2011",18.1,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOPPMT","Million US$, purchasing power parity","BEL","Belgium","2012","2012",18.4,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOPPMT","Million US$, purchasing power parity","BEL","Belgium","2013","2013",19.1,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOPPMT","Million US$, purchasing power parity","BEL","Belgium","2014","2014",19.4,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOPPMT","Million US$, purchasing power parity","BEL","Belgium","2015","2015",19.1,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOPPMT","Million US$, purchasing power parity","BEL","Belgium","2016","2016",19,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOPPMT","Million US$, purchasing power parity","BEL","Belgium","2017","2017",19.2,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOPPMT","Million US$, purchasing power parity","BEL","Belgium","2018","2018",19.5,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOPPMT","Million US$, purchasing power parity","BEL","Belgium","2019","2019",20,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOPPMT","Million US$, purchasing power parity","BEL","Belgium","2020","2020",19.1,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOPPMT","Million US$, purchasing power parity","BEL","Belgium","2021","2021",18.5,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOPPMT","Million US$, purchasing power parity","BEL","Belgium","2022","2022",18.7,"E","Estimated value"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","TCPPERMT","/capita, US$ exchange rate","BEL","Belgium","2010","2010",1.9,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","TCPPERMT","/capita, US$ exchange rate","BEL","Belgium","2011","2011",1.9,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","TCPPERMT","/capita, US$ exchange rate","BEL","Belgium","2012","2012",1.7,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","TCPPERMT","/capita, US$ exchange rate","BEL","Belgium","2013","2013",1.8,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","TCPPERMT","/capita, US$ exchange rate","BEL","Belgium","2014","2014",1.8,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","TCPPERMT","/capita, US$ exchange rate","BEL","Belgium","2015","2015",1.5,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","TCPPERMT","/capita, US$ exchange rate","BEL","Belgium","2016","2016",1.4,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","TCPPERMT","/capita, US$ exchange rate","BEL","Belgium","2017","2017",1.5,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","TCPPERMT","/capita, US$ exchange rate","BEL","Belgium","2018","2018",1.5,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","TCPPERMT","/capita, US$ exchange rate","BEL","Belgium","2019","2019",1.5,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","TCPPERMT","/capita, US$ exchange rate","BEL","Belgium","2020","2020",1.4,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","TCPPERMT","/capita, US$ exchange rate","BEL","Belgium","2021","2021",1.4,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","TCPPERMT","/capita, US$ exchange rate","BEL","Belgium","2022","2022",1.2,"E","Estimated value"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2010","2010",1.8,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2011","2011",1.6,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2012","2012",1.7,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2013","2013",1.7,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2014","2014",1.7,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2015","2015",1.7,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2016","2016",1.7,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2017","2017",1.7,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2018","2018",1.7,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2019","2019",1.7,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2020","2020",1.7,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2021","2021",1.6,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2022","2022",1.6,"E","Estimated value"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","ATCPTTMT","% of total sales","BEL","Belgium","2010","2010",0.3,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","ATCPTTMT","% of total sales","BEL","Belgium","2011","2011",0.3,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","ATCPTTMT","% of total sales","BEL","Belgium","2012","2012",0.3,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","ATCPTTMT","% of total sales","BEL","Belgium","2013","2013",0.3,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","ATCPTTMT","% of total sales","BEL","Belgium","2014","2014",0.3,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","ATCPTTMT","% of total sales","BEL","Belgium","2015","2015",0.2,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","ATCPTTMT","% of total sales","BEL","Belgium","2016","2016",0.2,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","ATCPTTMT","% of total sales","BEL","Belgium","2017","2017",0.2,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","ATCPTTMT","% of total sales","BEL","Belgium","2018","2018",0.2,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","ATCPTTMT","% of total sales","BEL","Belgium","2019","2019",0.2,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","ATCPTTMT","% of total sales","BEL","Belgium","2020","2020",0.2,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","ATCPTTMT","% of total sales","BEL","Belgium","2021","2021",0.2,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","ATCPTTMT","% of total sales","BEL","Belgium","2022","2022",0.1,"E","Estimated value"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MLLNCUMT","Million of national currency units","CAN","Canada","2012","2012",30.6,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MLLNCUMT","Million of national currency units","CAN","Canada","2013","2013",28.5,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MLLNCUMT","Million of national currency units","CAN","Canada","2014","2014",28.9,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MLLNCUMT","Million of national currency units","CAN","Canada","2015","2015",28.3,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MLLNCUMT","Million of national currency units","CAN","Canada","2016","2016",29,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MLLNCUMT","Million of national currency units","CAN","Canada","2017","2017",29.5,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MLLNCUMT","Million of national currency units","CAN","Canada","2018","2018",25.4,"E; B; D","Estimated value; Break; Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MLLNCUMT","Million of national currency units","CAN","Canada","2019","2019",23.7,"E; D","Estimated value; Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MLLNCUMT","Million of national currency units","CAN","Canada","2020","2020",25.2,"E; D","Estimated value; Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MLLNCUMT","Million of national currency units","CAN","Canada","2021","2021",22.8,"E; D","Estimated value; Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MLLNCUMT","Million of national currency units","CAN","Canada","2022","2022",23.4,"E; D","Estimated value; Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOTCMT","Million US$ at exchange rate","CAN","Canada","2012","2012",30.6,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOTCMT","Million US$ at exchange rate","CAN","Canada","2013","2013",27.7,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOTCMT","Million US$ at exchange rate","CAN","Canada","2014","2014",26.2,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOTCMT","Million US$ at exchange rate","CAN","Canada","2015","2015",22.1,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOTCMT","Million US$ at exchange rate","CAN","Canada","2016","2016",21.9,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOTCMT","Million US$ at exchange rate","CAN","Canada","2017","2017",22.7,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOTCMT","Million US$ at exchange rate","CAN","Canada","2018","2018",19.6,"E; B; D","Estimated value; Break; Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOTCMT","Million US$ at exchange rate","CAN","Canada","2019","2019",17.8,"E; D","Estimated value; Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOTCMT","Million US$ at exchange rate","CAN","Canada","2020","2020",18.8,"E; D","Estimated value; Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOTCMT","Million US$ at exchange rate","CAN","Canada","2021","2021",18.2,"E; D","Estimated value; Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOTCMT","Million US$ at exchange rate","CAN","Canada","2022","2022",18,"E; D","Estimated value; Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOPPMT","Million US$, purchasing power parity","CAN","Canada","2012","2012",24.6,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOPPMT","Million US$, purchasing power parity","CAN","Canada","2013","2013",23.3,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOPPMT","Million US$, purchasing power parity","CAN","Canada","2014","2014",23.5,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOPPMT","Million US$, purchasing power parity","CAN","Canada","2015","2015",22.7,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOPPMT","Million US$, purchasing power parity","CAN","Canada","2016","2016",24,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOPPMT","Million US$, purchasing power parity","CAN","Canada","2017","2017",24.3,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOPPMT","Million US$, purchasing power parity","CAN","Canada","2018","2018",21,"E; B; D","Estimated value; Break; Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOPPMT","Million US$, purchasing power parity","CAN","Canada","2019","2019",19.2,"E; D","Estimated value; Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOPPMT","Million US$, purchasing power parity","CAN","Canada","2020","2020",20.5,"E; D","Estimated value; Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOPPMT","Million US$, purchasing power parity","CAN","Canada","2021","2021",18.4,"E; D","Estimated value; Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOPPMT","Million US$, purchasing power parity","CAN","Canada","2022","2022",18.6,"E; D","Estimated value; Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","TCPPERMT","/capita, US$ exchange rate","CAN","Canada","2012","2012",0.9,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","TCPPERMT","/capita, US$ exchange rate","CAN","Canada","2013","2013",0.8,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","TCPPERMT","/capita, US$ exchange rate","CAN","Canada","2014","2014",0.7,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","TCPPERMT","/capita, US$ exchange rate","CAN","Canada","2015","2015",0.6,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","TCPPERMT","/capita, US$ exchange rate","CAN","Canada","2016","2016",0.6,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","TCPPERMT","/capita, US$ exchange rate","CAN","Canada","2017","2017",0.6,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","TCPPERMT","/capita, US$ exchange rate","CAN","Canada","2018","2018",0.5,"E; B; D","Estimated value; Break; Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","TCPPERMT","/capita, US$ exchange rate","CAN","Canada","2019","2019",0.5,"E; D","Estimated value; Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","TCPPERMT","/capita, US$ exchange rate","CAN","Canada","2020","2020",0.5,"E; D","Estimated value; Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","TCPPERMT","/capita, US$ exchange rate","CAN","Canada","2021","2021",0.5,"E; D","Estimated value; Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","TCPPERMT","/capita, US$ exchange rate","CAN","Canada","2022","2022",0.5,"E; D","Estimated value; Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2012","2012",0.7,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2013","2013",0.7,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2014","2014",0.7,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2015","2015",0.6,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2016","2016",0.7,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2017","2017",0.7,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2018","2018",0.6,"E; B; D","Estimated value; Break; Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2019","2019",0.5,"E; D","Estimated value; Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2020","2020",0.5,"E; D","Estimated value; Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2021","2021",0.5,"E; D","Estimated value; Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2022","2022",0.5,"E; D","Estimated value; Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","ATCPTTMT","% of total sales","CAN","Canada","2012","2012",0.1,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","ATCPTTMT","% of total sales","CAN","Canada","2013","2013",0.1,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","ATCPTTMT","% of total sales","CAN","Canada","2014","2014",0.1,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","ATCPTTMT","% of total sales","CAN","Canada","2015","2015",0.1,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","ATCPTTMT","% of total sales","CAN","Canada","2016","2016",0.1,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","ATCPTTMT","% of total sales","CAN","Canada","2017","2017",0.1,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","ATCPTTMT","% of total sales","CAN","Canada","2018","2018",0.1,"E; B; D","Estimated value; Break; Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","ATCPTTMT","% of total sales","CAN","Canada","2019","2019",0.1,"E; D","Estimated value; Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","ATCPTTMT","% of total sales","CAN","Canada","2020","2020",0.1,"E; D","Estimated value; Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","ATCPTTMT","% of total sales","CAN","Canada","2021","2021",0.1,"E; D","Estimated value; Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","ATCPTTMT","% of total sales","CAN","Canada","2022","2022",0.1,"E; D","Estimated value; Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MLLNCUMT","Million of national currency units","CZE","Czech Republic","2010","2010",176.5,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MLLNCUMT","Million of national currency units","CZE","Czech Republic","2011","2011",222.9,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MLLNCUMT","Million of national currency units","CZE","Czech Republic","2012","2012",233.7,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MLLNCUMT","Million of national currency units","CZE","Czech Republic","2013","2013",206.8,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MLLNCUMT","Million of national currency units","CZE","Czech Republic","2014","2014",198.2,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MLLNCUMT","Million of national currency units","CZE","Czech Republic","2015","2015",195.9,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MLLNCUMT","Million of national currency units","CZE","Czech Republic","2016","2016",194.2,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MLLNCUMT","Million of national currency units","CZE","Czech Republic","2017","2017",197.4,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MLLNCUMT","Million of national currency units","CZE","Czech Republic","2018","2018",200.9,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MLLNCUMT","Million of national currency units","CZE","Czech Republic","2019","2019",208.5,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MLLNCUMT","Million of national currency units","CZE","Czech Republic","2020","2020",209.1,"B","Break"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MLLNCUMT","Million of national currency units","CZE","Czech Republic","2021","2021",212.4,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOTCMT","Million US$ at exchange rate","CZE","Czech Republic","2010","2010",9.2,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOTCMT","Million US$ at exchange rate","CZE","Czech Republic","2011","2011",12.6,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOTCMT","Million US$ at exchange rate","CZE","Czech Republic","2012","2012",11.9,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOTCMT","Million US$ at exchange rate","CZE","Czech Republic","2013","2013",10.6,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOTCMT","Million US$ at exchange rate","CZE","Czech Republic","2014","2014",9.5,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOTCMT","Million US$ at exchange rate","CZE","Czech Republic","2015","2015",8,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOTCMT","Million US$ at exchange rate","CZE","Czech Republic","2016","2016",7.9,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOTCMT","Million US$ at exchange rate","CZE","Czech Republic","2017","2017",8.4,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOTCMT","Million US$ at exchange rate","CZE","Czech Republic","2018","2018",9.2,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOTCMT","Million US$ at exchange rate","CZE","Czech Republic","2019","2019",9.1,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOTCMT","Million US$ at exchange rate","CZE","Czech Republic","2020","2020",9,"B","Break"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOTCMT","Million US$ at exchange rate","CZE","Czech Republic","2021","2021",9.8,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOPPMT","Million US$, purchasing power parity","CZE","Czech Republic","2010","2010",12.9,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOPPMT","Million US$, purchasing power parity","CZE","Czech Republic","2011","2011",16.7,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOPPMT","Million US$, purchasing power parity","CZE","Czech Republic","2012","2012",17.6,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOPPMT","Million US$, purchasing power parity","CZE","Czech Republic","2013","2013",16.2,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOPPMT","Million US$, purchasing power parity","CZE","Czech Republic","2014","2014",15.6,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOPPMT","Million US$, purchasing power parity","CZE","Czech Republic","2015","2015",15.1,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOPPMT","Million US$, purchasing power parity","CZE","Czech Republic","2016","2016",15.4,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOPPMT","Million US$, purchasing power parity","CZE","Czech Republic","2017","2017",15.9,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOPPMT","Million US$, purchasing power parity","CZE","Czech Republic","2018","2018",16.2,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOPPMT","Million US$, purchasing power parity","CZE","Czech Republic","2019","2019",17,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOPPMT","Million US$, purchasing power parity","CZE","Czech Republic","2020","2020",16.8,"B","Break"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOPPMT","Million US$, purchasing power parity","CZE","Czech Republic","2021","2021",16.7,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","TCPPERMT","/capita, US$ exchange rate","CZE","Czech Republic","2010","2010",0.9,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","TCPPERMT","/capita, US$ exchange rate","CZE","Czech Republic","2011","2011",1.2,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","TCPPERMT","/capita, US$ exchange rate","CZE","Czech Republic","2012","2012",1.1,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","TCPPERMT","/capita, US$ exchange rate","CZE","Czech Republic","2013","2013",1,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","TCPPERMT","/capita, US$ exchange rate","CZE","Czech Republic","2014","2014",0.9,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","TCPPERMT","/capita, US$ exchange rate","CZE","Czech Republic","2015","2015",0.8,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","TCPPERMT","/capita, US$ exchange rate","CZE","Czech Republic","2016","2016",0.8,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","TCPPERMT","/capita, US$ exchange rate","CZE","Czech Republic","2017","2017",0.8,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","TCPPERMT","/capita, US$ exchange rate","CZE","Czech Republic","2018","2018",0.9,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","TCPPERMT","/capita, US$ exchange rate","CZE","Czech Republic","2019","2019",0.9,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","TCPPERMT","/capita, US$ exchange rate","CZE","Czech Republic","2020","2020",0.8,"B","Break"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","TCPPERMT","/capita, US$ exchange rate","CZE","Czech Republic","2021","2021",0.9,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czech Republic","2010","2010",1.2,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czech Republic","2011","2011",1.6,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czech Republic","2012","2012",1.7,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czech Republic","2013","2013",1.5,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czech Republic","2014","2014",1.5,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czech Republic","2015","2015",1.4,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czech Republic","2016","2016",1.5,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czech Republic","2017","2017",1.5,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czech Republic","2018","2018",1.5,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czech Republic","2019","2019",1.6,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czech Republic","2020","2020",1.6,"B","Break"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czech Republic","2021","2021",1.6,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","ATCPTTMT","% of total sales","CZE","Czech Republic","2010","2010",0.2,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","ATCPTTMT","% of total sales","CZE","Czech Republic","2011","2011",0.3,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","ATCPTTMT","% of total sales","CZE","Czech Republic","2012","2012",0.3,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","ATCPTTMT","% of total sales","CZE","Czech Republic","2013","2013",0.3,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","ATCPTTMT","% of total sales","CZE","Czech Republic","2014","2014",0.2,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","ATCPTTMT","% of total sales","CZE","Czech Republic","2015","2015",0.2,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","ATCPTTMT","% of total sales","CZE","Czech Republic","2016","2016",0.2,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","ATCPTTMT","% of total sales","CZE","Czech Republic","2017","2017",0.2,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","ATCPTTMT","% of total sales","CZE","Czech Republic","2018","2018",0.2,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","ATCPTTMT","% of total sales","CZE","Czech Republic","2019","2019",0.2,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","ATCPTTMT","% of total sales","CZE","Czech Republic","2020","2020",0.2,"B","Break"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","ATCPTTMT","% of total sales","CZE","Czech Republic","2021","2021",0.2,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MLLNCUMT","Million of national currency units","FIN","Finland","2010","2010",3.2,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MLLNCUMT","Million of national currency units","FIN","Finland","2011","2011",4.2,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MLLNCUMT","Million of national currency units","FIN","Finland","2012","2012",3.8,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MLLNCUMT","Million of national currency units","FIN","Finland","2013","2013",3.7,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MLLNCUMT","Million of national currency units","FIN","Finland","2014","2014",3.6,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MLLNCUMT","Million of national currency units","FIN","Finland","2015","2015",4,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MLLNCUMT","Million of national currency units","FIN","Finland","2016","2016",4.2,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MLLNCUMT","Million of national currency units","FIN","Finland","2017","2017",4.2,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MLLNCUMT","Million of national currency units","FIN","Finland","2018","2018",4.1,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MLLNCUMT","Million of national currency units","FIN","Finland","2019","2019",3.7,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MLLNCUMT","Million of national currency units","FIN","Finland","2020","2020",2.9,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MLLNCUMT","Million of national currency units","FIN","Finland","2021","2021",2.5,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOTCMT","Million US$ at exchange rate","FIN","Finland","2010","2010",4.2,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOTCMT","Million US$ at exchange rate","FIN","Finland","2011","2011",5.8,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOTCMT","Million US$ at exchange rate","FIN","Finland","2012","2012",4.9,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOTCMT","Million US$ at exchange rate","FIN","Finland","2013","2013",4.9,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOTCMT","Million US$ at exchange rate","FIN","Finland","2014","2014",4.8,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOTCMT","Million US$ at exchange rate","FIN","Finland","2015","2015",4.4,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOTCMT","Million US$ at exchange rate","FIN","Finland","2016","2016",4.6,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOTCMT","Million US$ at exchange rate","FIN","Finland","2017","2017",4.7,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOTCMT","Million US$ at exchange rate","FIN","Finland","2018","2018",4.8,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOTCMT","Million US$ at exchange rate","FIN","Finland","2019","2019",4.1,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOTCMT","Million US$ at exchange rate","FIN","Finland","2020","2020",3.3,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOTCMT","Million US$ at exchange rate","FIN","Finland","2021","2021",3,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOPPMT","Million US$, purchasing power parity","FIN","Finland","2010","2010",3.6,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOPPMT","Million US$, purchasing power parity","FIN","Finland","2011","2011",4.7,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOPPMT","Million US$, purchasing power parity","FIN","Finland","2012","2012",4.2,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOPPMT","Million US$, purchasing power parity","FIN","Finland","2013","2013",4.1,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOPPMT","Million US$, purchasing power parity","FIN","Finland","2014","2014",4,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOPPMT","Million US$, purchasing power parity","FIN","Finland","2015","2015",4.4,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOPPMT","Million US$, purchasing power parity","FIN","Finland","2016","2016",4.8,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOPPMT","Million US$, purchasing power parity","FIN","Finland","2017","2017",4.9,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOPPMT","Million US$, purchasing power parity","FIN","Finland","2018","2018",4.8,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOPPMT","Million US$, purchasing power parity","FIN","Finland","2019","2019",4.4,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOPPMT","Million US$, purchasing power parity","FIN","Finland","2020","2020",3.5,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOPPMT","Million US$, purchasing power parity","FIN","Finland","2021","2021",3,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","TCPPERMT","/capita, US$ exchange rate","FIN","Finland","2010","2010",0.8,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","TCPPERMT","/capita, US$ exchange rate","FIN","Finland","2011","2011",1.1,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","TCPPERMT","/capita, US$ exchange rate","FIN","Finland","2012","2012",0.9,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","TCPPERMT","/capita, US$ exchange rate","FIN","Finland","2013","2013",0.9,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","TCPPERMT","/capita, US$ exchange rate","FIN","Finland","2014","2014",0.9,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","TCPPERMT","/capita, US$ exchange rate","FIN","Finland","2015","2015",0.8,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","TCPPERMT","/capita, US$ exchange rate","FIN","Finland","2016","2016",0.8,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","TCPPERMT","/capita, US$ exchange rate","FIN","Finland","2017","2017",0.9,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","TCPPERMT","/capita, US$ exchange rate","FIN","Finland","2018","2018",0.9,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","TCPPERMT","/capita, US$ exchange rate","FIN","Finland","2019","2019",0.8,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","TCPPERMT","/capita, US$ exchange rate","FIN","Finland","2020","2020",0.6,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","TCPPERMT","/capita, US$ exchange rate","FIN","Finland","2021","2021",0.5,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2010","2010",0.7,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2011","2011",0.9,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2012","2012",0.8,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2013","2013",0.8,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2014","2014",0.7,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2015","2015",0.8,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2016","2016",0.9,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2017","2017",0.9,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2018","2018",0.9,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2019","2019",0.8,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2020","2020",0.6,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2021","2021",0.5,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","ATCPTTMT","% of total sales","FIN","Finland","2010","2010",0.2,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","ATCPTTMT","% of total sales","FIN","Finland","2011","2011",0.2,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","ATCPTTMT","% of total sales","FIN","Finland","2012","2012",0.2,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","ATCPTTMT","% of total sales","FIN","Finland","2013","2013",0.2,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","ATCPTTMT","% of total sales","FIN","Finland","2014","2014",0.2,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","ATCPTTMT","% of total sales","FIN","Finland","2015","2015",0.2,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","ATCPTTMT","% of total sales","FIN","Finland","2016","2016",0.2,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","ATCPTTMT","% of total sales","FIN","Finland","2017","2017",0.2,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","ATCPTTMT","% of total sales","FIN","Finland","2018","2018",0.2,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","ATCPTTMT","% of total sales","FIN","Finland","2019","2019",0.1,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","ATCPTTMT","% of total sales","FIN","Finland","2020","2020",0.1,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","ATCPTTMT","% of total sales","FIN","Finland","2021","2021",0.1,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MLLNCUMT","Million of national currency units","DEU","Germany","2010","2010",76.1,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MLLNCUMT","Million of national currency units","DEU","Germany","2011","2011",87.7,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MLLNCUMT","Million of national currency units","DEU","Germany","2012","2012",79.3,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MLLNCUMT","Million of national currency units","DEU","Germany","2013","2013",79.1,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MLLNCUMT","Million of national currency units","DEU","Germany","2014","2014",80.4,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MLLNCUMT","Million of national currency units","DEU","Germany","2015","2015",77.9,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MLLNCUMT","Million of national currency units","DEU","Germany","2016","2016",75.5,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MLLNCUMT","Million of national currency units","DEU","Germany","2017","2017",71.2,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MLLNCUMT","Million of national currency units","DEU","Germany","2018","2018",68.3,"B; D","Break; Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MLLNCUMT","Million of national currency units","DEU","Germany","2019","2019",68.1,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MLLNCUMT","Million of national currency units","DEU","Germany","2020","2020",61.5,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MLLNCUMT","Million of national currency units","DEU","Germany","2021","2021",59.2,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOTCMT","Million US$ at exchange rate","DEU","Germany","2010","2010",100.9,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOTCMT","Million US$ at exchange rate","DEU","Germany","2011","2011",122.1,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOTCMT","Million US$ at exchange rate","DEU","Germany","2012","2012",101.9,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOTCMT","Million US$ at exchange rate","DEU","Germany","2013","2013",105.1,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOTCMT","Million US$ at exchange rate","DEU","Germany","2014","2014",106.8,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOTCMT","Million US$ at exchange rate","DEU","Germany","2015","2015",86.4,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOTCMT","Million US$ at exchange rate","DEU","Germany","2016","2016",83.6,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOTCMT","Million US$ at exchange rate","DEU","Germany","2017","2017",80.4,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOTCMT","Million US$ at exchange rate","DEU","Germany","2018","2018",80.7,"B; D","Break; Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOTCMT","Million US$ at exchange rate","DEU","Germany","2019","2019",76.2,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOTCMT","Million US$ at exchange rate","DEU","Germany","2020","2020",70.2,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOTCMT","Million US$ at exchange rate","DEU","Germany","2021","2021",70,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOPPMT","Million US$, purchasing power parity","DEU","Germany","2010","2010",94.5,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOPPMT","Million US$, purchasing power parity","DEU","Germany","2011","2011",111.2,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOPPMT","Million US$, purchasing power parity","DEU","Germany","2012","2012",100.7,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOPPMT","Million US$, purchasing power parity","DEU","Germany","2013","2013",102.1,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOPPMT","Million US$, purchasing power parity","DEU","Germany","2014","2014",104.6,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOPPMT","Million US$, purchasing power parity","DEU","Germany","2015","2015",100.1,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOPPMT","Million US$, purchasing power parity","DEU","Germany","2016","2016",100.3,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOPPMT","Million US$, purchasing power parity","DEU","Germany","2017","2017",95.6,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOPPMT","Million US$, purchasing power parity","DEU","Germany","2018","2018",92.9,"B; D","Break; Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOPPMT","Million US$, purchasing power parity","DEU","Germany","2019","2019",93.5,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOPPMT","Million US$, purchasing power parity","DEU","Germany","2020","2020",84.8,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOPPMT","Million US$, purchasing power parity","DEU","Germany","2021","2021",80.4,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","TCPPERMT","/capita, US$ exchange rate","DEU","Germany","2010","2010",1.2,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","TCPPERMT","/capita, US$ exchange rate","DEU","Germany","2011","2011",1.5,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","TCPPERMT","/capita, US$ exchange rate","DEU","Germany","2012","2012",1.3,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","TCPPERMT","/capita, US$ exchange rate","DEU","Germany","2013","2013",1.3,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","TCPPERMT","/capita, US$ exchange rate","DEU","Germany","2014","2014",1.3,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","TCPPERMT","/capita, US$ exchange rate","DEU","Germany","2015","2015",1.1,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","TCPPERMT","/capita, US$ exchange rate","DEU","Germany","2016","2016",1,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","TCPPERMT","/capita, US$ exchange rate","DEU","Germany","2017","2017",1,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","TCPPERMT","/capita, US$ exchange rate","DEU","Germany","2018","2018",1,"B; D","Break; Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","TCPPERMT","/capita, US$ exchange rate","DEU","Germany","2019","2019",0.9,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","TCPPERMT","/capita, US$ exchange rate","DEU","Germany","2020","2020",0.8,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","TCPPERMT","/capita, US$ exchange rate","DEU","Germany","2021","2021",0.8,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2010","2010",1.2,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2011","2011",1.4,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2012","2012",1.3,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2013","2013",1.3,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2014","2014",1.3,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2015","2015",1.2,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2016","2016",1.2,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2017","2017",1.2,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2018","2018",1.1,"B; D","Break; Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2019","2019",1.1,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2020","2020",1,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2021","2021",1,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","ATCPTTMT","% of total sales","DEU","Germany","2010","2010",0.3,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","ATCPTTMT","% of total sales","DEU","Germany","2011","2011",0.3,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","ATCPTTMT","% of total sales","DEU","Germany","2012","2012",0.3,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","ATCPTTMT","% of total sales","DEU","Germany","2013","2013",0.3,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","ATCPTTMT","% of total sales","DEU","Germany","2014","2014",0.2,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","ATCPTTMT","% of total sales","DEU","Germany","2015","2015",0.2,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","ATCPTTMT","% of total sales","DEU","Germany","2016","2016",0.2,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","ATCPTTMT","% of total sales","DEU","Germany","2017","2017",0.2,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","ATCPTTMT","% of total sales","DEU","Germany","2018","2018",0.2,"B; D","Break; Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","ATCPTTMT","% of total sales","DEU","Germany","2019","2019",0.1,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","ATCPTTMT","% of total sales","DEU","Germany","2020","2020",0.1,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","ATCPTTMT","% of total sales","DEU","Germany","2021","2021",0.1,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MLLNCUMT","Million of national currency units","GRC","Greece","2010","2010",5.5,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MLLNCUMT","Million of national currency units","GRC","Greece","2011","2011",6.2,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MLLNCUMT","Million of national currency units","GRC","Greece","2012","2012",5.8,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MLLNCUMT","Million of national currency units","GRC","Greece","2013","2013",6.5,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MLLNCUMT","Million of national currency units","GRC","Greece","2014","2014",6.4,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MLLNCUMT","Million of national currency units","GRC","Greece","2015","2015",6.6,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MLLNCUMT","Million of national currency units","GRC","Greece","2016","2016",7.4,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MLLNCUMT","Million of national currency units","GRC","Greece","2017","2017",7.6,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MLLNCUMT","Million of national currency units","GRC","Greece","2018","2018",8.1,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MLLNCUMT","Million of national currency units","GRC","Greece","2019","2019",8.5,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MLLNCUMT","Million of national currency units","GRC","Greece","2020","2020",8.6,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MLLNCUMT","Million of national currency units","GRC","Greece","2021","2021",8.5,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MLLNCUMT","Million of national currency units","GRC","Greece","2022","2022",6.1,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOTCMT","Million US$ at exchange rate","GRC","Greece","2010","2010",7.3,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOTCMT","Million US$ at exchange rate","GRC","Greece","2011","2011",8.7,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOTCMT","Million US$ at exchange rate","GRC","Greece","2012","2012",7.5,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOTCMT","Million US$ at exchange rate","GRC","Greece","2013","2013",8.6,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOTCMT","Million US$ at exchange rate","GRC","Greece","2014","2014",8.4,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOTCMT","Million US$ at exchange rate","GRC","Greece","2015","2015",7.3,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOTCMT","Million US$ at exchange rate","GRC","Greece","2016","2016",8.2,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOTCMT","Million US$ at exchange rate","GRC","Greece","2017","2017",8.6,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOTCMT","Million US$ at exchange rate","GRC","Greece","2018","2018",9.6,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOTCMT","Million US$ at exchange rate","GRC","Greece","2019","2019",9.5,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOTCMT","Million US$ at exchange rate","GRC","Greece","2020","2020",9.8,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOTCMT","Million US$ at exchange rate","GRC","Greece","2021","2021",10.1,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOTCMT","Million US$ at exchange rate","GRC","Greece","2022","2022",6.4,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOPPMT","Million US$, purchasing power parity","GRC","Greece","2010","2010",7.6,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOPPMT","Million US$, purchasing power parity","GRC","Greece","2011","2011",8.7,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOPPMT","Million US$, purchasing power parity","GRC","Greece","2012","2012",8.5,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOPPMT","Million US$, purchasing power parity","GRC","Greece","2013","2013",10.3,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOPPMT","Million US$, purchasing power parity","GRC","Greece","2014","2014",10.4,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOPPMT","Million US$, purchasing power parity","GRC","Greece","2015","2015",10.9,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOPPMT","Million US$, purchasing power parity","GRC","Greece","2016","2016",12.5,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOPPMT","Million US$, purchasing power parity","GRC","Greece","2017","2017",13.2,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOPPMT","Million US$, purchasing power parity","GRC","Greece","2018","2018",14.4,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOPPMT","Million US$, purchasing power parity","GRC","Greece","2019","2019",15.5,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOPPMT","Million US$, purchasing power parity","GRC","Greece","2020","2020",15.8,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOPPMT","Million US$, purchasing power parity","GRC","Greece","2021","2021",15.6,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOPPMT","Million US$, purchasing power parity","GRC","Greece","2022","2022",11.5,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","TCPPERMT","/capita, US$ exchange rate","GRC","Greece","2010","2010",0.7,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","TCPPERMT","/capita, US$ exchange rate","GRC","Greece","2011","2011",0.8,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","TCPPERMT","/capita, US$ exchange rate","GRC","Greece","2012","2012",0.7,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","TCPPERMT","/capita, US$ exchange rate","GRC","Greece","2013","2013",0.8,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","TCPPERMT","/capita, US$ exchange rate","GRC","Greece","2014","2014",0.8,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","TCPPERMT","/capita, US$ exchange rate","GRC","Greece","2015","2015",0.7,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","TCPPERMT","/capita, US$ exchange rate","GRC","Greece","2016","2016",0.8,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","TCPPERMT","/capita, US$ exchange rate","GRC","Greece","2017","2017",0.8,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","TCPPERMT","/capita, US$ exchange rate","GRC","Greece","2018","2018",0.9,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","TCPPERMT","/capita, US$ exchange rate","GRC","Greece","2019","2019",0.9,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","TCPPERMT","/capita, US$ exchange rate","GRC","Greece","2020","2020",0.9,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","TCPPERMT","/capita, US$ exchange rate","GRC","Greece","2021","2021",1,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","TCPPERMT","/capita, US$ exchange rate","GRC","Greece","2022","2022",0.6,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2010","2010",0.7,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2011","2011",0.8,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2012","2012",0.8,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2013","2013",0.9,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2014","2014",1,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2015","2015",1,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2016","2016",1.2,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2017","2017",1.2,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2018","2018",1.3,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2019","2019",1.4,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2020","2020",1.5,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2021","2021",1.5,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2022","2022",1.1,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MLLNCUMT","Million of national currency units","HUN","Hungary","2010","2010",1511.2,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MLLNCUMT","Million of national currency units","HUN","Hungary","2011","2011",1522.8,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MLLNCUMT","Million of national currency units","HUN","Hungary","2012","2012",1427.3,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MLLNCUMT","Million of national currency units","HUN","Hungary","2013","2013",1406.9,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MLLNCUMT","Million of national currency units","HUN","Hungary","2014","2014",1405,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MLLNCUMT","Million of national currency units","HUN","Hungary","2015","2015",1391.1,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MLLNCUMT","Million of national currency units","HUN","Hungary","2016","2016",1384.4,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MLLNCUMT","Million of national currency units","HUN","Hungary","2017","2017",1380.3,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MLLNCUMT","Million of national currency units","HUN","Hungary","2018","2018",1362.5,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MLLNCUMT","Million of national currency units","HUN","Hungary","2019","2019",1378.7,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MLLNCUMT","Million of national currency units","HUN","Hungary","2020","2020",1571.7,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MLLNCUMT","Million of national currency units","HUN","Hungary","2021","2021",1469.2,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MLLNCUMT","Million of national currency units","HUN","Hungary","2022","2022",1451.8,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOTCMT","Million US$ at exchange rate","HUN","Hungary","2010","2010",7.3,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOTCMT","Million US$ at exchange rate","HUN","Hungary","2011","2011",7.6,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOTCMT","Million US$ at exchange rate","HUN","Hungary","2012","2012",6.3,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOTCMT","Million US$ at exchange rate","HUN","Hungary","2013","2013",6.3,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOTCMT","Million US$ at exchange rate","HUN","Hungary","2014","2014",6,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOTCMT","Million US$ at exchange rate","HUN","Hungary","2015","2015",5,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOTCMT","Million US$ at exchange rate","HUN","Hungary","2016","2016",4.9,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOTCMT","Million US$ at exchange rate","HUN","Hungary","2017","2017",5,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOTCMT","Million US$ at exchange rate","HUN","Hungary","2018","2018",5,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOTCMT","Million US$ at exchange rate","HUN","Hungary","2019","2019",4.7,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOTCMT","Million US$ at exchange rate","HUN","Hungary","2020","2020",5.1,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOTCMT","Million US$ at exchange rate","HUN","Hungary","2021","2021",4.8,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOTCMT","Million US$ at exchange rate","HUN","Hungary","2022","2022",3.9,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOPPMT","Million US$, purchasing power parity","HUN","Hungary","2010","2010",12,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOPPMT","Million US$, purchasing power parity","HUN","Hungary","2011","2011",12.3,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOPPMT","Million US$, purchasing power parity","HUN","Hungary","2012","2012",11.4,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOPPMT","Million US$, purchasing power parity","HUN","Hungary","2013","2013",11.3,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOPPMT","Million US$, purchasing power parity","HUN","Hungary","2014","2014",10.9,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOPPMT","Million US$, purchasing power parity","HUN","Hungary","2015","2015",10.5,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOPPMT","Million US$, purchasing power parity","HUN","Hungary","2016","2016",10.5,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOPPMT","Million US$, purchasing power parity","HUN","Hungary","2017","2017",10.1,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOPPMT","Million US$, purchasing power parity","HUN","Hungary","2018","2018",9.8,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOPPMT","Million US$, purchasing power parity","HUN","Hungary","2019","2019",9.8,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOPPMT","Million US$, purchasing power parity","HUN","Hungary","2020","2020",10.8,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOPPMT","Million US$, purchasing power parity","HUN","Hungary","2021","2021",9.5,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOPPMT","Million US$, purchasing power parity","HUN","Hungary","2022","2022",9,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","TCPPERMT","/capita, US$ exchange rate","HUN","Hungary","2010","2010",0.7,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","TCPPERMT","/capita, US$ exchange rate","HUN","Hungary","2011","2011",0.8,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","TCPPERMT","/capita, US$ exchange rate","HUN","Hungary","2012","2012",0.6,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","TCPPERMT","/capita, US$ exchange rate","HUN","Hungary","2013","2013",0.6,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","TCPPERMT","/capita, US$ exchange rate","HUN","Hungary","2014","2014",0.6,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","TCPPERMT","/capita, US$ exchange rate","HUN","Hungary","2015","2015",0.5,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","TCPPERMT","/capita, US$ exchange rate","HUN","Hungary","2016","2016",0.5,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","TCPPERMT","/capita, US$ exchange rate","HUN","Hungary","2017","2017",0.5,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","TCPPERMT","/capita, US$ exchange rate","HUN","Hungary","2018","2018",0.5,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","TCPPERMT","/capita, US$ exchange rate","HUN","Hungary","2019","2019",0.5,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","TCPPERMT","/capita, US$ exchange rate","HUN","Hungary","2020","2020",0.5,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","TCPPERMT","/capita, US$ exchange rate","HUN","Hungary","2021","2021",0.5,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","TCPPERMT","/capita, US$ exchange rate","HUN","Hungary","2022","2022",0.4,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2010","2010",1.2,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2011","2011",1.2,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2012","2012",1.1,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2013","2013",1.1,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2014","2014",1.1,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2015","2015",1.1,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2016","2016",1.1,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2017","2017",1,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2018","2018",1,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2019","2019",1,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2020","2020",1.1,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2021","2021",1,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2022","2022",0.9,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","ATCPTTMT","% of total sales","HUN","Hungary","2010","2010",0.3,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","ATCPTTMT","% of total sales","HUN","Hungary","2011","2011",0.3,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","ATCPTTMT","% of total sales","HUN","Hungary","2012","2012",0.3,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","ATCPTTMT","% of total sales","HUN","Hungary","2013","2013",0.3,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","ATCPTTMT","% of total sales","HUN","Hungary","2014","2014",0.3,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","ATCPTTMT","% of total sales","HUN","Hungary","2015","2015",0.3,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","ATCPTTMT","% of total sales","HUN","Hungary","2016","2016",0.3,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","ATCPTTMT","% of total sales","HUN","Hungary","2017","2017",0.3,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","ATCPTTMT","% of total sales","HUN","Hungary","2018","2018",0.3,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","ATCPTTMT","% of total sales","HUN","Hungary","2019","2019",0.3,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","ATCPTTMT","% of total sales","HUN","Hungary","2020","2020",0.3,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","ATCPTTMT","% of total sales","HUN","Hungary","2021","2021",0.3,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","ATCPTTMT","% of total sales","HUN","Hungary","2022","2022",0.2,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MLLNCUMT","Million of national currency units","ISL","Iceland","2010","2010",61.4,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MLLNCUMT","Million of national currency units","ISL","Iceland","2011","2011",69.6,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MLLNCUMT","Million of national currency units","ISL","Iceland","2012","2012",77.4,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MLLNCUMT","Million of national currency units","ISL","Iceland","2013","2013",79.2,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MLLNCUMT","Million of national currency units","ISL","Iceland","2014","2014",73,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MLLNCUMT","Million of national currency units","ISL","Iceland","2015","2015",69.1,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MLLNCUMT","Million of national currency units","ISL","Iceland","2016","2016",77.9,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MLLNCUMT","Million of national currency units","ISL","Iceland","2017","2017",83.5,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MLLNCUMT","Million of national currency units","ISL","Iceland","2018","2018",92.8,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MLLNCUMT","Million of national currency units","ISL","Iceland","2019","2019",104.5,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MLLNCUMT","Million of national currency units","ISL","Iceland","2020","2020",126.5,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MLLNCUMT","Million of national currency units","ISL","Iceland","2021","2021",121.8,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOTCMT","Million US$ at exchange rate","ISL","Iceland","2010","2010",0.5,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOTCMT","Million US$ at exchange rate","ISL","Iceland","2011","2011",0.6,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOTCMT","Million US$ at exchange rate","ISL","Iceland","2012","2012",0.6,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOTCMT","Million US$ at exchange rate","ISL","Iceland","2013","2013",0.6,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOTCMT","Million US$ at exchange rate","ISL","Iceland","2014","2014",0.6,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOTCMT","Million US$ at exchange rate","ISL","Iceland","2015","2015",0.5,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOTCMT","Million US$ at exchange rate","ISL","Iceland","2016","2016",0.6,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOTCMT","Million US$ at exchange rate","ISL","Iceland","2017","2017",0.8,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOTCMT","Million US$ at exchange rate","ISL","Iceland","2018","2018",0.9,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOTCMT","Million US$ at exchange rate","ISL","Iceland","2019","2019",0.9,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOTCMT","Million US$ at exchange rate","ISL","Iceland","2020","2020",0.9,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOTCMT","Million US$ at exchange rate","ISL","Iceland","2021","2021",1,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOPPMT","Million US$, purchasing power parity","ISL","Iceland","2010","2010",0.5,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOPPMT","Million US$, purchasing power parity","ISL","Iceland","2011","2011",0.5,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOPPMT","Million US$, purchasing power parity","ISL","Iceland","2012","2012",0.6,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOPPMT","Million US$, purchasing power parity","ISL","Iceland","2013","2013",0.6,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOPPMT","Million US$, purchasing power parity","ISL","Iceland","2014","2014",0.5,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOPPMT","Million US$, purchasing power parity","ISL","Iceland","2015","2015",0.5,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOPPMT","Million US$, purchasing power parity","ISL","Iceland","2016","2016",0.6,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOPPMT","Million US$, purchasing power parity","ISL","Iceland","2017","2017",0.6,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOPPMT","Million US$, purchasing power parity","ISL","Iceland","2018","2018",0.7,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOPPMT","Million US$, purchasing power parity","ISL","Iceland","2019","2019",0.7,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOPPMT","Million US$, purchasing power parity","ISL","Iceland","2020","2020",0.9,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOPPMT","Million US$, purchasing power parity","ISL","Iceland","2021","2021",0.8,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","TCPPERMT","/capita, US$ exchange rate","ISL","Iceland","2010","2010",1.6,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","TCPPERMT","/capita, US$ exchange rate","ISL","Iceland","2011","2011",1.9,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","TCPPERMT","/capita, US$ exchange rate","ISL","Iceland","2012","2012",1.9,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","TCPPERMT","/capita, US$ exchange rate","ISL","Iceland","2013","2013",2,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","TCPPERMT","/capita, US$ exchange rate","ISL","Iceland","2014","2014",1.9,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","TCPPERMT","/capita, US$ exchange rate","ISL","Iceland","2015","2015",1.6,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","TCPPERMT","/capita, US$ exchange rate","ISL","Iceland","2016","2016",1.9,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","TCPPERMT","/capita, US$ exchange rate","ISL","Iceland","2017","2017",2.3,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","TCPPERMT","/capita, US$ exchange rate","ISL","Iceland","2018","2018",2.4,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","TCPPERMT","/capita, US$ exchange rate","ISL","Iceland","2019","2019",2.4,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","TCPPERMT","/capita, US$ exchange rate","ISL","Iceland","2020","2020",2.5,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","TCPPERMT","/capita, US$ exchange rate","ISL","Iceland","2021","2021",2.6,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2010","2010",1.5,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2011","2011",1.6,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2012","2012",1.8,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2013","2013",1.8,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2014","2014",1.6,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2015","2015",1.5,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2016","2016",1.7,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2017","2017",1.8,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2018","2018",1.9,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2019","2019",2.1,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2020","2020",2.4,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2021","2021",2.2,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","ATCPTTMT","% of total sales","ISL","Iceland","2010","2010",0.2,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","ATCPTTMT","% of total sales","ISL","Iceland","2011","2011",0.3,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","ATCPTTMT","% of total sales","ISL","Iceland","2012","2012",0.3,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","ATCPTTMT","% of total sales","ISL","Iceland","2013","2013",0.3,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","ATCPTTMT","% of total sales","ISL","Iceland","2014","2014",0.3,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","ATCPTTMT","% of total sales","ISL","Iceland","2015","2015",0.3,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","ATCPTTMT","% of total sales","ISL","Iceland","2016","2016",0.3,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","ATCPTTMT","% of total sales","ISL","Iceland","2017","2017",0.3,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","ATCPTTMT","% of total sales","ISL","Iceland","2018","2018",0.3,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","ATCPTTMT","% of total sales","ISL","Iceland","2019","2019",0.3,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","ATCPTTMT","% of total sales","ISL","Iceland","2020","2020",0.3,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","ATCPTTMT","% of total sales","ISL","Iceland","2021","2021",0.3,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MLLNCUMT","Million of national currency units","IRL","Ireland","2010","2010",2.6,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MLLNCUMT","Million of national currency units","IRL","Ireland","2011","2011",3.3,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MLLNCUMT","Million of national currency units","IRL","Ireland","2012","2012",3.1,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MLLNCUMT","Million of national currency units","IRL","Ireland","2013","2013",3,"B; D","Break; Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MLLNCUMT","Million of national currency units","IRL","Ireland","2014","2014",2.3,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MLLNCUMT","Million of national currency units","IRL","Ireland","2015","2015",3,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MLLNCUMT","Million of national currency units","IRL","Ireland","2016","2016",3.1,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MLLNCUMT","Million of national currency units","IRL","Ireland","2017","2017",3.1,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MLLNCUMT","Million of national currency units","IRL","Ireland","2018","2018",3.1,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MLLNCUMT","Million of national currency units","IRL","Ireland","2019","2019",3.1,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MLLNCUMT","Million of national currency units","IRL","Ireland","2020","2020",3.2,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MLLNCUMT","Million of national currency units","IRL","Ireland","2021","2021",3.1,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOTCMT","Million US$ at exchange rate","IRL","Ireland","2010","2010",3.4,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOTCMT","Million US$ at exchange rate","IRL","Ireland","2011","2011",4.6,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOTCMT","Million US$ at exchange rate","IRL","Ireland","2012","2012",3.9,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOTCMT","Million US$ at exchange rate","IRL","Ireland","2013","2013",3.9,"B; D","Break; Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOTCMT","Million US$ at exchange rate","IRL","Ireland","2014","2014",3,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOTCMT","Million US$ at exchange rate","IRL","Ireland","2015","2015",3.3,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOTCMT","Million US$ at exchange rate","IRL","Ireland","2016","2016",3.4,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOTCMT","Million US$ at exchange rate","IRL","Ireland","2017","2017",3.4,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOTCMT","Million US$ at exchange rate","IRL","Ireland","2018","2018",3.7,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOTCMT","Million US$ at exchange rate","IRL","Ireland","2019","2019",3.5,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOTCMT","Million US$ at exchange rate","IRL","Ireland","2020","2020",3.6,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOTCMT","Million US$ at exchange rate","IRL","Ireland","2021","2021",3.7,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOPPMT","Million US$, purchasing power parity","IRL","Ireland","2010","2010",3.1,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOPPMT","Million US$, purchasing power parity","IRL","Ireland","2011","2011",3.9,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOPPMT","Million US$, purchasing power parity","IRL","Ireland","2012","2012",3.7,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOPPMT","Million US$, purchasing power parity","IRL","Ireland","2013","2013",3.6,"B; D","Break; Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOPPMT","Million US$, purchasing power parity","IRL","Ireland","2014","2014",2.8,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOPPMT","Million US$, purchasing power parity","IRL","Ireland","2015","2015",3.7,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOPPMT","Million US$, purchasing power parity","IRL","Ireland","2016","2016",3.9,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOPPMT","Million US$, purchasing power parity","IRL","Ireland","2017","2017",3.8,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOPPMT","Million US$, purchasing power parity","IRL","Ireland","2018","2018",3.9,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOPPMT","Million US$, purchasing power parity","IRL","Ireland","2019","2019",3.9,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOPPMT","Million US$, purchasing power parity","IRL","Ireland","2020","2020",4,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOPPMT","Million US$, purchasing power parity","IRL","Ireland","2021","2021",3.9,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","TCPPERMT","/capita, US$ exchange rate","IRL","Ireland","2010","2010",0.8,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","TCPPERMT","/capita, US$ exchange rate","IRL","Ireland","2011","2011",1,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","TCPPERMT","/capita, US$ exchange rate","IRL","Ireland","2012","2012",0.9,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","TCPPERMT","/capita, US$ exchange rate","IRL","Ireland","2013","2013",0.8,"B; D","Break; Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","TCPPERMT","/capita, US$ exchange rate","IRL","Ireland","2014","2014",0.7,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","TCPPERMT","/capita, US$ exchange rate","IRL","Ireland","2015","2015",0.7,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","TCPPERMT","/capita, US$ exchange rate","IRL","Ireland","2016","2016",0.7,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","TCPPERMT","/capita, US$ exchange rate","IRL","Ireland","2017","2017",0.7,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","TCPPERMT","/capita, US$ exchange rate","IRL","Ireland","2018","2018",0.8,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","TCPPERMT","/capita, US$ exchange rate","IRL","Ireland","2019","2019",0.7,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","TCPPERMT","/capita, US$ exchange rate","IRL","Ireland","2020","2020",0.7,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","TCPPERMT","/capita, US$ exchange rate","IRL","Ireland","2021","2021",0.7,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2010","2010",0.7,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2011","2011",0.9,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2012","2012",0.8,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2013","2013",0.8,"B; D","Break; Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2014","2014",0.6,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2015","2015",0.8,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2016","2016",0.8,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2017","2017",0.8,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2018","2018",0.8,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2019","2019",0.8,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2020","2020",0.8,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2021","2021",0.8,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","ATCPTTMT","% of total sales","IRL","Ireland","2010","2010",0.1,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","ATCPTTMT","% of total sales","IRL","Ireland","2011","2011",0.2,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","ATCPTTMT","% of total sales","IRL","Ireland","2012","2012",0.1,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","ATCPTTMT","% of total sales","IRL","Ireland","2013","2013",0.2,"B; D","Break; Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","ATCPTTMT","% of total sales","IRL","Ireland","2014","2014",0.1,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","ATCPTTMT","% of total sales","IRL","Ireland","2015","2015",0.1,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","ATCPTTMT","% of total sales","IRL","Ireland","2016","2016",0.1,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","ATCPTTMT","% of total sales","IRL","Ireland","2017","2017",0.1,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","ATCPTTMT","% of total sales","IRL","Ireland","2018","2018",0.1,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","ATCPTTMT","% of total sales","IRL","Ireland","2019","2019",0.1,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","ATCPTTMT","% of total sales","IRL","Ireland","2020","2020",0.1,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","ATCPTTMT","% of total sales","IRL","Ireland","2021","2021",0.1,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MLLNCUMT","Million of national currency units","ITA","Italy","2011","2011",75.3,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MLLNCUMT","Million of national currency units","ITA","Italy","2012","2012",73.4,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MLLNCUMT","Million of national currency units","ITA","Italy","2013","2013",74.8,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MLLNCUMT","Million of national currency units","ITA","Italy","2014","2014",75.7,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MLLNCUMT","Million of national currency units","ITA","Italy","2015","2015",77.1,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MLLNCUMT","Million of national currency units","ITA","Italy","2016","2016",77.7,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MLLNCUMT","Million of national currency units","ITA","Italy","2017","2017",79,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MLLNCUMT","Million of national currency units","ITA","Italy","2018","2018",80.4,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MLLNCUMT","Million of national currency units","ITA","Italy","2019","2019",81.8,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MLLNCUMT","Million of national currency units","ITA","Italy","2020","2020",83.3,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MLLNCUMT","Million of national currency units","ITA","Italy","2021","2021",82.4,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MLLNCUMT","Million of national currency units","ITA","Italy","2022","2022",82,"E","Estimated value"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOTCMT","Million US$ at exchange rate","ITA","Italy","2011","2011",104.8,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOTCMT","Million US$ at exchange rate","ITA","Italy","2012","2012",94.3,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOTCMT","Million US$ at exchange rate","ITA","Italy","2013","2013",99.3,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOTCMT","Million US$ at exchange rate","ITA","Italy","2014","2014",100.5,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOTCMT","Million US$ at exchange rate","ITA","Italy","2015","2015",85.5,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOTCMT","Million US$ at exchange rate","ITA","Italy","2016","2016",86,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOTCMT","Million US$ at exchange rate","ITA","Italy","2017","2017",89.2,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOTCMT","Million US$ at exchange rate","ITA","Italy","2018","2018",95,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOTCMT","Million US$ at exchange rate","ITA","Italy","2019","2019",91.6,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOTCMT","Million US$ at exchange rate","ITA","Italy","2020","2020",95.2,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOTCMT","Million US$ at exchange rate","ITA","Italy","2021","2021",97.5,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOTCMT","Million US$ at exchange rate","ITA","Italy","2022","2022",86.4,"E","Estimated value"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOPPMT","Million US$, purchasing power parity","ITA","Italy","2011","2011",99.2,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOPPMT","Million US$, purchasing power parity","ITA","Italy","2012","2012",98.1,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOPPMT","Million US$, purchasing power parity","ITA","Italy","2013","2013",101.4,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOPPMT","Million US$, purchasing power parity","ITA","Italy","2014","2014",102.3,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOPPMT","Million US$, purchasing power parity","ITA","Italy","2015","2015",104.3,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOPPMT","Million US$, purchasing power parity","ITA","Italy","2016","2016",110.9,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOPPMT","Million US$, purchasing power parity","ITA","Italy","2017","2017",114.5,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOPPMT","Million US$, purchasing power parity","ITA","Italy","2018","2018",118.1,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOPPMT","Million US$, purchasing power parity","ITA","Italy","2019","2019",124.5,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOPPMT","Million US$, purchasing power parity","ITA","Italy","2020","2020",128.7,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOPPMT","Million US$, purchasing power parity","ITA","Italy","2021","2021",127.2,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOPPMT","Million US$, purchasing power parity","ITA","Italy","2022","2022",132.9,"E","Estimated value"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","TCPPERMT","/capita, US$ exchange rate","ITA","Italy","2011","2011",1.8,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","TCPPERMT","/capita, US$ exchange rate","ITA","Italy","2012","2012",1.6,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","TCPPERMT","/capita, US$ exchange rate","ITA","Italy","2013","2013",1.6,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","TCPPERMT","/capita, US$ exchange rate","ITA","Italy","2014","2014",1.7,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","TCPPERMT","/capita, US$ exchange rate","ITA","Italy","2015","2015",1.4,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","TCPPERMT","/capita, US$ exchange rate","ITA","Italy","2016","2016",1.4,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","TCPPERMT","/capita, US$ exchange rate","ITA","Italy","2017","2017",1.5,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","TCPPERMT","/capita, US$ exchange rate","ITA","Italy","2018","2018",1.6,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","TCPPERMT","/capita, US$ exchange rate","ITA","Italy","2019","2019",1.5,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","TCPPERMT","/capita, US$ exchange rate","ITA","Italy","2020","2020",1.6,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","TCPPERMT","/capita, US$ exchange rate","ITA","Italy","2021","2021",1.6,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","TCPPERMT","/capita, US$ exchange rate","ITA","Italy","2022","2022",1.5,"E","Estimated value"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2011","2011",1.7,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2012","2012",1.6,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2013","2013",1.7,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2014","2014",1.7,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2015","2015",1.7,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2016","2016",1.8,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2017","2017",1.9,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2018","2018",2,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2019","2019",2.1,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2020","2020",2.2,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2021","2021",2.2,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2022","2022",2.3,"E","Estimated value"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","ATCPTTMT","% of total sales","ITA","Italy","2011","2011",0.4,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","ATCPTTMT","% of total sales","ITA","Italy","2012","2012",0.4,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","ATCPTTMT","% of total sales","ITA","Italy","2013","2013",0.4,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","ATCPTTMT","% of total sales","ITA","Italy","2014","2014",0.4,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","ATCPTTMT","% of total sales","ITA","Italy","2015","2015",0.3,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","ATCPTTMT","% of total sales","ITA","Italy","2016","2016",0.3,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","ATCPTTMT","% of total sales","ITA","Italy","2017","2017",0.3,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","ATCPTTMT","% of total sales","ITA","Italy","2018","2018",0.4,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","ATCPTTMT","% of total sales","ITA","Italy","2019","2019",0.4,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","ATCPTTMT","% of total sales","ITA","Italy","2020","2020",0.4,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","ATCPTTMT","% of total sales","ITA","Italy","2021","2021",0.3,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","ATCPTTMT","% of total sales","ITA","Italy","2022","2022",0.3,"E","Estimated value"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MLLNCUMT","Million of national currency units","KOR","Korea","2010","2010",8636,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MLLNCUMT","Million of national currency units","KOR","Korea","2011","2011",11558.9,"B","Break"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MLLNCUMT","Million of national currency units","KOR","Korea","2012","2012",11018.4,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MLLNCUMT","Million of national currency units","KOR","Korea","2013","2013",11041.1,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MLLNCUMT","Million of national currency units","KOR","Korea","2014","2014",11754,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MLLNCUMT","Million of national currency units","KOR","Korea","2015","2015",12980.3,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MLLNCUMT","Million of national currency units","KOR","Korea","2016","2016",14174.3,"B","Break"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MLLNCUMT","Million of national currency units","KOR","Korea","2017","2017",16183.7,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MLLNCUMT","Million of national currency units","KOR","Korea","2018","2018",18654.4,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MLLNCUMT","Million of national currency units","KOR","Korea","2019","2019",21623.1,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MLLNCUMT","Million of national currency units","KOR","Korea","2020","2020",25886.5,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MLLNCUMT","Million of national currency units","KOR","Korea","2021","2021",28729.7,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOTCMT","Million US$ at exchange rate","KOR","Korea","2010","2010",7.5,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOTCMT","Million US$ at exchange rate","KOR","Korea","2011","2011",10.4,"B","Break"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOTCMT","Million US$ at exchange rate","KOR","Korea","2012","2012",9.8,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOTCMT","Million US$ at exchange rate","KOR","Korea","2013","2013",10.1,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOTCMT","Million US$ at exchange rate","KOR","Korea","2014","2014",11.2,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOTCMT","Million US$ at exchange rate","KOR","Korea","2015","2015",11.5,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOTCMT","Million US$ at exchange rate","KOR","Korea","2016","2016",12.2,"B","Break"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOTCMT","Million US$ at exchange rate","KOR","Korea","2017","2017",14.3,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOTCMT","Million US$ at exchange rate","KOR","Korea","2018","2018",17,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOTCMT","Million US$ at exchange rate","KOR","Korea","2019","2019",18.6,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOTCMT","Million US$ at exchange rate","KOR","Korea","2020","2020",21.9,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOTCMT","Million US$ at exchange rate","KOR","Korea","2021","2021",25.1,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOPPMT","Million US$, purchasing power parity","KOR","Korea","2010","2010",10.3,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOPPMT","Million US$, purchasing power parity","KOR","Korea","2011","2011",13.5,"B","Break"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOPPMT","Million US$, purchasing power parity","KOR","Korea","2012","2012",12.9,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOPPMT","Million US$, purchasing power parity","KOR","Korea","2013","2013",12.7,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOPPMT","Million US$, purchasing power parity","KOR","Korea","2014","2014",13.5,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOPPMT","Million US$, purchasing power parity","KOR","Korea","2015","2015",15.1,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOPPMT","Million US$, purchasing power parity","KOR","Korea","2016","2016",16.5,"B","Break"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOPPMT","Million US$, purchasing power parity","KOR","Korea","2017","2017",18.5,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOPPMT","Million US$, purchasing power parity","KOR","Korea","2018","2018",21.8,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOPPMT","Million US$, purchasing power parity","KOR","Korea","2019","2019",25.2,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOPPMT","Million US$, purchasing power parity","KOR","Korea","2020","2020",30.9,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOPPMT","Million US$, purchasing power parity","KOR","Korea","2021","2021",33.6,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","TCPPERMT","/capita, US$ exchange rate","KOR","Korea","2010","2010",0.2,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","TCPPERMT","/capita, US$ exchange rate","KOR","Korea","2011","2011",0.2,"B","Break"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","TCPPERMT","/capita, US$ exchange rate","KOR","Korea","2012","2012",0.2,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","TCPPERMT","/capita, US$ exchange rate","KOR","Korea","2013","2013",0.2,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","TCPPERMT","/capita, US$ exchange rate","KOR","Korea","2014","2014",0.2,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","TCPPERMT","/capita, US$ exchange rate","KOR","Korea","2015","2015",0.2,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","TCPPERMT","/capita, US$ exchange rate","KOR","Korea","2016","2016",0.2,"B","Break"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","TCPPERMT","/capita, US$ exchange rate","KOR","Korea","2017","2017",0.3,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","TCPPERMT","/capita, US$ exchange rate","KOR","Korea","2018","2018",0.3,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","TCPPERMT","/capita, US$ exchange rate","KOR","Korea","2019","2019",0.4,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","TCPPERMT","/capita, US$ exchange rate","KOR","Korea","2020","2020",0.4,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","TCPPERMT","/capita, US$ exchange rate","KOR","Korea","2021","2021",0.5,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2010","2010",0.2,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2011","2011",0.3,"B","Break"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2012","2012",0.3,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2013","2013",0.3,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2014","2014",0.3,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2015","2015",0.3,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2016","2016",0.3,"B","Break"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2017","2017",0.4,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2018","2018",0.4,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2019","2019",0.5,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2020","2020",0.6,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2021","2021",0.7,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","ATCPTTMT","% of total sales","KOR","Korea","2010","2010",0,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","ATCPTTMT","% of total sales","KOR","Korea","2011","2011",0.1,"B","Break"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","ATCPTTMT","% of total sales","KOR","Korea","2012","2012",0.1,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","ATCPTTMT","% of total sales","KOR","Korea","2013","2013",0,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","ATCPTTMT","% of total sales","KOR","Korea","2014","2014",0,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","ATCPTTMT","% of total sales","KOR","Korea","2015","2015",0.1,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","ATCPTTMT","% of total sales","KOR","Korea","2016","2016",0.1,"B","Break"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","ATCPTTMT","% of total sales","KOR","Korea","2017","2017",0.1,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","ATCPTTMT","% of total sales","KOR","Korea","2018","2018",0.1,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","ATCPTTMT","% of total sales","KOR","Korea","2019","2019",0.1,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","ATCPTTMT","% of total sales","KOR","Korea","2020","2020",0.1,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","ATCPTTMT","% of total sales","KOR","Korea","2021","2021",0.1,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MLLNCUMT","Million of national currency units","LUX","Luxembourg","2010","2010",0.6,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MLLNCUMT","Million of national currency units","LUX","Luxembourg","2011","2011",0.6,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MLLNCUMT","Million of national currency units","LUX","Luxembourg","2012","2012",0.6,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MLLNCUMT","Million of national currency units","LUX","Luxembourg","2013","2013",0.6,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MLLNCUMT","Million of national currency units","LUX","Luxembourg","2014","2014",0.6,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MLLNCUMT","Million of national currency units","LUX","Luxembourg","2015","2015",0.6,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MLLNCUMT","Million of national currency units","LUX","Luxembourg","2016","2016",0.5,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MLLNCUMT","Million of national currency units","LUX","Luxembourg","2017","2017",0.5,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MLLNCUMT","Million of national currency units","LUX","Luxembourg","2018","2018",0.5,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MLLNCUMT","Million of national currency units","LUX","Luxembourg","2019","2019",0.5,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MLLNCUMT","Million of national currency units","LUX","Luxembourg","2020","2020",0.5,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MLLNCUMT","Million of national currency units","LUX","Luxembourg","2021","2021",0.5,"B; D; P","Break; Difference in methodology; Provisional value"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MLLNCUMT","Million of national currency units","LUX","Luxembourg","2022","2022",0.4,"D; P","Difference in methodology; Provisional value"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOTCMT","Million US$ at exchange rate","LUX","Luxembourg","2010","2010",0.7,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOTCMT","Million US$ at exchange rate","LUX","Luxembourg","2011","2011",0.8,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOTCMT","Million US$ at exchange rate","LUX","Luxembourg","2012","2012",0.7,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOTCMT","Million US$ at exchange rate","LUX","Luxembourg","2013","2013",0.8,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOTCMT","Million US$ at exchange rate","LUX","Luxembourg","2014","2014",0.8,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOTCMT","Million US$ at exchange rate","LUX","Luxembourg","2015","2015",0.6,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOTCMT","Million US$ at exchange rate","LUX","Luxembourg","2016","2016",0.6,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOTCMT","Million US$ at exchange rate","LUX","Luxembourg","2017","2017",0.6,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOTCMT","Million US$ at exchange rate","LUX","Luxembourg","2018","2018",0.6,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOTCMT","Million US$ at exchange rate","LUX","Luxembourg","2019","2019",0.6,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOTCMT","Million US$ at exchange rate","LUX","Luxembourg","2020","2020",0.6,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOTCMT","Million US$ at exchange rate","LUX","Luxembourg","2021","2021",0.5,"B; D; P","Break; Difference in methodology; Provisional value"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOTCMT","Million US$ at exchange rate","LUX","Luxembourg","2022","2022",0.4,"D; P","Difference in methodology; Provisional value"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOPPMT","Million US$, purchasing power parity","LUX","Luxembourg","2010","2010",0.6,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOPPMT","Million US$, purchasing power parity","LUX","Luxembourg","2011","2011",0.6,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOPPMT","Million US$, purchasing power parity","LUX","Luxembourg","2012","2012",0.6,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOPPMT","Million US$, purchasing power parity","LUX","Luxembourg","2013","2013",0.6,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOPPMT","Million US$, purchasing power parity","LUX","Luxembourg","2014","2014",0.6,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOPPMT","Million US$, purchasing power parity","LUX","Luxembourg","2015","2015",0.6,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOPPMT","Million US$, purchasing power parity","LUX","Luxembourg","2016","2016",0.6,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOPPMT","Million US$, purchasing power parity","LUX","Luxembourg","2017","2017",0.6,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOPPMT","Million US$, purchasing power parity","LUX","Luxembourg","2018","2018",0.6,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOPPMT","Million US$, purchasing power parity","LUX","Luxembourg","2019","2019",0.6,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOPPMT","Million US$, purchasing power parity","LUX","Luxembourg","2020","2020",0.6,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOPPMT","Million US$, purchasing power parity","LUX","Luxembourg","2021","2021",0.5,"B; D; P","Break; Difference in methodology; Provisional value"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOPPMT","Million US$, purchasing power parity","LUX","Luxembourg","2022","2022",0.5,"D; P","Difference in methodology; Provisional value"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","TCPPERMT","/capita, US$ exchange rate","LUX","Luxembourg","2010","2010",1.6,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","TCPPERMT","/capita, US$ exchange rate","LUX","Luxembourg","2011","2011",1.6,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","TCPPERMT","/capita, US$ exchange rate","LUX","Luxembourg","2012","2012",1.5,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","TCPPERMT","/capita, US$ exchange rate","LUX","Luxembourg","2013","2013",1.5,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","TCPPERMT","/capita, US$ exchange rate","LUX","Luxembourg","2014","2014",1.5,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","TCPPERMT","/capita, US$ exchange rate","LUX","Luxembourg","2015","2015",1.2,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","TCPPERMT","/capita, US$ exchange rate","LUX","Luxembourg","2016","2016",1.1,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","TCPPERMT","/capita, US$ exchange rate","LUX","Luxembourg","2017","2017",1.1,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","TCPPERMT","/capita, US$ exchange rate","LUX","Luxembourg","2018","2018",1.1,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","TCPPERMT","/capita, US$ exchange rate","LUX","Luxembourg","2019","2019",1,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","TCPPERMT","/capita, US$ exchange rate","LUX","Luxembourg","2020","2020",1,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","TCPPERMT","/capita, US$ exchange rate","LUX","Luxembourg","2021","2021",0.9,"B; D; P","Break; Difference in methodology; Provisional value"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","TCPPERMT","/capita, US$ exchange rate","LUX","Luxembourg","2022","2022",0.7,"D; P","Difference in methodology; Provisional value"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2010","2010",1.3,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2011","2011",1.3,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2012","2012",1.3,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2013","2013",1.3,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2014","2014",1.3,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2015","2015",1.2,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2016","2016",1.2,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2017","2017",1.2,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2018","2018",1.1,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2019","2019",1.1,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2020","2020",1,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2021","2021",0.9,"B; D; P","Break; Difference in methodology; Provisional value"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2022","2022",0.8,"D; P","Difference in methodology; Provisional value"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","ATCPTTMT","% of total sales","LUX","Luxembourg","2010","2010",0.3,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","ATCPTTMT","% of total sales","LUX","Luxembourg","2011","2011",0.3,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","ATCPTTMT","% of total sales","LUX","Luxembourg","2012","2012",0.3,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","ATCPTTMT","% of total sales","LUX","Luxembourg","2013","2013",0.3,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","ATCPTTMT","% of total sales","LUX","Luxembourg","2014","2014",0.3,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","ATCPTTMT","% of total sales","LUX","Luxembourg","2015","2015",0.3,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","ATCPTTMT","% of total sales","LUX","Luxembourg","2016","2016",0.3,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","ATCPTTMT","% of total sales","LUX","Luxembourg","2017","2017",0.3,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","ATCPTTMT","% of total sales","LUX","Luxembourg","2018","2018",0.3,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","ATCPTTMT","% of total sales","LUX","Luxembourg","2019","2019",0.2,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","ATCPTTMT","% of total sales","LUX","Luxembourg","2020","2020",0.2,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","ATCPTTMT","% of total sales","LUX","Luxembourg","2021","2021",0.2,"B; D; P","Break; Difference in methodology; Provisional value"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","ATCPTTMT","% of total sales","LUX","Luxembourg","2022","2022",0.2,"D; P","Difference in methodology; Provisional value"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MLLNCUMT","Million of national currency units","NLD","Netherlands","2010","2010",10.7,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MLLNCUMT","Million of national currency units","NLD","Netherlands","2011","2011",10.2,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MLLNCUMT","Million of national currency units","NLD","Netherlands","2012","2012",9.7,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MLLNCUMT","Million of national currency units","NLD","Netherlands","2013","2013",9.7,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MLLNCUMT","Million of national currency units","NLD","Netherlands","2014","2014",9.6,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOTCMT","Million US$ at exchange rate","NLD","Netherlands","2010","2010",14.1,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOTCMT","Million US$ at exchange rate","NLD","Netherlands","2011","2011",14.3,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOTCMT","Million US$ at exchange rate","NLD","Netherlands","2012","2012",12.5,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOTCMT","Million US$ at exchange rate","NLD","Netherlands","2013","2013",12.9,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOTCMT","Million US$ at exchange rate","NLD","Netherlands","2014","2014",12.8,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOPPMT","Million US$, purchasing power parity","NLD","Netherlands","2010","2010",12.5,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOPPMT","Million US$, purchasing power parity","NLD","Netherlands","2011","2011",12.3,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOPPMT","Million US$, purchasing power parity","NLD","Netherlands","2012","2012",11.8,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOPPMT","Million US$, purchasing power parity","NLD","Netherlands","2013","2013",12.2,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOPPMT","Million US$, purchasing power parity","NLD","Netherlands","2014","2014",11.9,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","TCPPERMT","/capita, US$ exchange rate","NLD","Netherlands","2010","2010",0.9,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","TCPPERMT","/capita, US$ exchange rate","NLD","Netherlands","2011","2011",0.9,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","TCPPERMT","/capita, US$ exchange rate","NLD","Netherlands","2012","2012",0.7,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","TCPPERMT","/capita, US$ exchange rate","NLD","Netherlands","2013","2013",0.8,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","TCPPERMT","/capita, US$ exchange rate","NLD","Netherlands","2014","2014",0.8,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","NLD","Netherlands","2010","2010",0.8,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","NLD","Netherlands","2011","2011",0.7,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","NLD","Netherlands","2012","2012",0.7,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","NLD","Netherlands","2013","2013",0.7,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","NLD","Netherlands","2014","2014",0.7,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","ATCPTTMT","% of total sales","NLD","Netherlands","2010","2010",0.2,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","ATCPTTMT","% of total sales","NLD","Netherlands","2011","2011",0.2,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","ATCPTTMT","% of total sales","NLD","Netherlands","2012","2012",0.2,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","ATCPTTMT","% of total sales","NLD","Netherlands","2013","2013",0.2,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","ATCPTTMT","% of total sales","NLD","Netherlands","2014","2014",0.2,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MLLNCUMT","Million of national currency units","NZL","New Zealand","2010","2010",4.6,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MLLNCUMT","Million of national currency units","NZL","New Zealand","2011","2011",4.8,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MLLNCUMT","Million of national currency units","NZL","New Zealand","2012","2012",4.9,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MLLNCUMT","Million of national currency units","NZL","New Zealand","2013","2013",5,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MLLNCUMT","Million of national currency units","NZL","New Zealand","2014","2014",5.1,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MLLNCUMT","Million of national currency units","NZL","New Zealand","2015","2015",4.6,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MLLNCUMT","Million of national currency units","NZL","New Zealand","2016","2016",4.7,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MLLNCUMT","Million of national currency units","NZL","New Zealand","2017","2017",4.1,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MLLNCUMT","Million of national currency units","NZL","New Zealand","2018","2018",4.1,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MLLNCUMT","Million of national currency units","NZL","New Zealand","2019","2019",4.2,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MLLNCUMT","Million of national currency units","NZL","New Zealand","2020","2020",2.7,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MLLNCUMT","Million of national currency units","NZL","New Zealand","2021","2021",1.8,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MLLNCUMT","Million of national currency units","NZL","New Zealand","2022","2022",1.9,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOTCMT","Million US$ at exchange rate","NZL","New Zealand","2010","2010",3.3,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOTCMT","Million US$ at exchange rate","NZL","New Zealand","2011","2011",3.8,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOTCMT","Million US$ at exchange rate","NZL","New Zealand","2012","2012",3.9,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOTCMT","Million US$ at exchange rate","NZL","New Zealand","2013","2013",4.1,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOTCMT","Million US$ at exchange rate","NZL","New Zealand","2014","2014",4.2,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOTCMT","Million US$ at exchange rate","NZL","New Zealand","2015","2015",3.2,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOTCMT","Million US$ at exchange rate","NZL","New Zealand","2016","2016",3.3,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOTCMT","Million US$ at exchange rate","NZL","New Zealand","2017","2017",2.9,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOTCMT","Million US$ at exchange rate","NZL","New Zealand","2018","2018",2.9,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOTCMT","Million US$ at exchange rate","NZL","New Zealand","2019","2019",2.8,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOTCMT","Million US$ at exchange rate","NZL","New Zealand","2020","2020",1.8,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOTCMT","Million US$ at exchange rate","NZL","New Zealand","2021","2021",1.3,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOTCMT","Million US$ at exchange rate","NZL","New Zealand","2022","2022",1.2,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOPPMT","Million US$, purchasing power parity","NZL","New Zealand","2010","2010",3.1,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOPPMT","Million US$, purchasing power parity","NZL","New Zealand","2011","2011",3.2,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOPPMT","Million US$, purchasing power parity","NZL","New Zealand","2012","2012",3.3,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOPPMT","Million US$, purchasing power parity","NZL","New Zealand","2013","2013",3.5,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOPPMT","Million US$, purchasing power parity","NZL","New Zealand","2014","2014",3.5,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOPPMT","Million US$, purchasing power parity","NZL","New Zealand","2015","2015",3.1,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOPPMT","Million US$, purchasing power parity","NZL","New Zealand","2016","2016",3.3,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOPPMT","Million US$, purchasing power parity","NZL","New Zealand","2017","2017",2.9,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOPPMT","Million US$, purchasing power parity","NZL","New Zealand","2018","2018",2.8,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOPPMT","Million US$, purchasing power parity","NZL","New Zealand","2019","2019",3,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOPPMT","Million US$, purchasing power parity","NZL","New Zealand","2020","2020",1.9,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOPPMT","Million US$, purchasing power parity","NZL","New Zealand","2021","2021",1.2,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOPPMT","Million US$, purchasing power parity","NZL","New Zealand","2022","2022",1.3,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","TCPPERMT","/capita, US$ exchange rate","NZL","New Zealand","2010","2010",0.8,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","TCPPERMT","/capita, US$ exchange rate","NZL","New Zealand","2011","2011",0.9,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","TCPPERMT","/capita, US$ exchange rate","NZL","New Zealand","2012","2012",0.9,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","TCPPERMT","/capita, US$ exchange rate","NZL","New Zealand","2013","2013",0.9,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","TCPPERMT","/capita, US$ exchange rate","NZL","New Zealand","2014","2014",0.9,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","TCPPERMT","/capita, US$ exchange rate","NZL","New Zealand","2015","2015",0.7,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","TCPPERMT","/capita, US$ exchange rate","NZL","New Zealand","2016","2016",0.7,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","TCPPERMT","/capita, US$ exchange rate","NZL","New Zealand","2017","2017",0.6,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","TCPPERMT","/capita, US$ exchange rate","NZL","New Zealand","2018","2018",0.6,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","TCPPERMT","/capita, US$ exchange rate","NZL","New Zealand","2019","2019",0.6,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","TCPPERMT","/capita, US$ exchange rate","NZL","New Zealand","2020","2020",0.3,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","TCPPERMT","/capita, US$ exchange rate","NZL","New Zealand","2021","2021",0.2,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","TCPPERMT","/capita, US$ exchange rate","NZL","New Zealand","2022","2022",0.2,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2010","2010",0.7,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2011","2011",0.7,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2012","2012",0.7,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2013","2013",0.8,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2014","2014",0.8,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2015","2015",0.7,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2016","2016",0.7,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2017","2017",0.6,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2018","2018",0.6,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2019","2019",0.6,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2020","2020",0.4,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2021","2021",0.2,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2022","2022",0.3,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","ATCPTTMT","% of total sales","NZL","New Zealand","2010","2010",0.6,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","ATCPTTMT","% of total sales","NZL","New Zealand","2011","2011",0.6,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","ATCPTTMT","% of total sales","NZL","New Zealand","2012","2012",0.5,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","ATCPTTMT","% of total sales","NZL","New Zealand","2013","2013",0.5,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","ATCPTTMT","% of total sales","NZL","New Zealand","2014","2014",0.5,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","ATCPTTMT","% of total sales","NZL","New Zealand","2015","2015",0.5,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","ATCPTTMT","% of total sales","NZL","New Zealand","2016","2016",0.4,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","ATCPTTMT","% of total sales","NZL","New Zealand","2017","2017",0.3,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","ATCPTTMT","% of total sales","NZL","New Zealand","2018","2018",0.3,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","ATCPTTMT","% of total sales","NZL","New Zealand","2019","2019",0.3,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","ATCPTTMT","% of total sales","NZL","New Zealand","2020","2020",0.2,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","ATCPTTMT","% of total sales","NZL","New Zealand","2021","2021",0.1,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","ATCPTTMT","% of total sales","NZL","New Zealand","2022","2022",0.1,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MLLNCUMT","Million of national currency units","NOR","Norway","2010","2010",25,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MLLNCUMT","Million of national currency units","NOR","Norway","2011","2011",29,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MLLNCUMT","Million of national currency units","NOR","Norway","2012","2012",29,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MLLNCUMT","Million of national currency units","NOR","Norway","2013","2013",31,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MLLNCUMT","Million of national currency units","NOR","Norway","2014","2014",33,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MLLNCUMT","Million of national currency units","NOR","Norway","2015","2015",36,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MLLNCUMT","Million of national currency units","NOR","Norway","2016","2016",38,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MLLNCUMT","Million of national currency units","NOR","Norway","2017","2017",41,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MLLNCUMT","Million of national currency units","NOR","Norway","2018","2018",44,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MLLNCUMT","Million of national currency units","NOR","Norway","2019","2019",47,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MLLNCUMT","Million of national currency units","NOR","Norway","2020","2020",43,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MLLNCUMT","Million of national currency units","NOR","Norway","2021","2021",36,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MLLNCUMT","Million of national currency units","NOR","Norway","2022","2022",35,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOTCMT","Million US$ at exchange rate","NOR","Norway","2010","2010",4.1,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOTCMT","Million US$ at exchange rate","NOR","Norway","2011","2011",5.2,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOTCMT","Million US$ at exchange rate","NOR","Norway","2012","2012",5,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOTCMT","Million US$ at exchange rate","NOR","Norway","2013","2013",5.3,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOTCMT","Million US$ at exchange rate","NOR","Norway","2014","2014",5.2,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOTCMT","Million US$ at exchange rate","NOR","Norway","2015","2015",4.5,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOTCMT","Million US$ at exchange rate","NOR","Norway","2016","2016",4.5,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOTCMT","Million US$ at exchange rate","NOR","Norway","2017","2017",5,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOTCMT","Million US$ at exchange rate","NOR","Norway","2018","2018",5.4,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOTCMT","Million US$ at exchange rate","NOR","Norway","2019","2019",5.3,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOTCMT","Million US$ at exchange rate","NOR","Norway","2020","2020",4.6,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOTCMT","Million US$ at exchange rate","NOR","Norway","2021","2021",4.2,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOTCMT","Million US$ at exchange rate","NOR","Norway","2022","2022",3.6,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOPPMT","Million US$, purchasing power parity","NOR","Norway","2010","2010",2.7,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOPPMT","Million US$, purchasing power parity","NOR","Norway","2011","2011",3.2,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOPPMT","Million US$, purchasing power parity","NOR","Norway","2012","2012",3.2,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOPPMT","Million US$, purchasing power parity","NOR","Norway","2013","2013",3.4,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOPPMT","Million US$, purchasing power parity","NOR","Norway","2014","2014",3.6,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOPPMT","Million US$, purchasing power parity","NOR","Norway","2015","2015",3.6,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOPPMT","Million US$, purchasing power parity","NOR","Norway","2016","2016",3.8,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOPPMT","Million US$, purchasing power parity","NOR","Norway","2017","2017",4.2,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOPPMT","Million US$, purchasing power parity","NOR","Norway","2018","2018",4.6,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOPPMT","Million US$, purchasing power parity","NOR","Norway","2019","2019",4.9,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOPPMT","Million US$, purchasing power parity","NOR","Norway","2020","2020",4.4,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOPPMT","Million US$, purchasing power parity","NOR","Norway","2021","2021",3.8,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOPPMT","Million US$, purchasing power parity","NOR","Norway","2022","2022",3.3,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","TCPPERMT","/capita, US$ exchange rate","NOR","Norway","2010","2010",0.8,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","TCPPERMT","/capita, US$ exchange rate","NOR","Norway","2011","2011",1,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","TCPPERMT","/capita, US$ exchange rate","NOR","Norway","2012","2012",1,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","TCPPERMT","/capita, US$ exchange rate","NOR","Norway","2013","2013",1,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","TCPPERMT","/capita, US$ exchange rate","NOR","Norway","2014","2014",1,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","TCPPERMT","/capita, US$ exchange rate","NOR","Norway","2015","2015",0.9,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","TCPPERMT","/capita, US$ exchange rate","NOR","Norway","2016","2016",0.9,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","TCPPERMT","/capita, US$ exchange rate","NOR","Norway","2017","2017",0.9,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","TCPPERMT","/capita, US$ exchange rate","NOR","Norway","2018","2018",1,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","TCPPERMT","/capita, US$ exchange rate","NOR","Norway","2019","2019",1,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","TCPPERMT","/capita, US$ exchange rate","NOR","Norway","2020","2020",0.8,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","TCPPERMT","/capita, US$ exchange rate","NOR","Norway","2021","2021",0.8,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","TCPPERMT","/capita, US$ exchange rate","NOR","Norway","2022","2022",0.7,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2010","2010",0.6,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2011","2011",0.6,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2012","2012",0.6,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2013","2013",0.7,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2014","2014",0.7,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2015","2015",0.7,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2016","2016",0.7,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2017","2017",0.8,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2018","2018",0.9,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2019","2019",0.9,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2020","2020",0.8,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2021","2021",0.7,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2022","2022",0.6,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","ATCPTTMT","% of total sales","NOR","Norway","2010","2010",0.1,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","ATCPTTMT","% of total sales","NOR","Norway","2011","2011",0.2,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","ATCPTTMT","% of total sales","NOR","Norway","2012","2012",0.2,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","ATCPTTMT","% of total sales","NOR","Norway","2013","2013",0.2,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","ATCPTTMT","% of total sales","NOR","Norway","2014","2014",0.2,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","ATCPTTMT","% of total sales","NOR","Norway","2015","2015",0.2,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","ATCPTTMT","% of total sales","NOR","Norway","2016","2016",0.2,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","ATCPTTMT","% of total sales","NOR","Norway","2017","2017",0.2,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","ATCPTTMT","% of total sales","NOR","Norway","2018","2018",0.2,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","ATCPTTMT","% of total sales","NOR","Norway","2019","2019",0.2,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","ATCPTTMT","% of total sales","NOR","Norway","2020","2020",0.1,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","ATCPTTMT","% of total sales","NOR","Norway","2021","2021",0.1,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","ATCPTTMT","% of total sales","NOR","Norway","2022","2022",0.1,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MLLNCUMT","Million of national currency units","PRT","Portugal","2010","2010",4.8,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MLLNCUMT","Million of national currency units","PRT","Portugal","2011","2011",4.3,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MLLNCUMT","Million of national currency units","PRT","Portugal","2012","2012",4.2,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MLLNCUMT","Million of national currency units","PRT","Portugal","2013","2013",3.8,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MLLNCUMT","Million of national currency units","PRT","Portugal","2014","2014",3.7,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MLLNCUMT","Million of national currency units","PRT","Portugal","2015","2015",3.7,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MLLNCUMT","Million of national currency units","PRT","Portugal","2016","2016",3.7,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MLLNCUMT","Million of national currency units","PRT","Portugal","2017","2017",3.7,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MLLNCUMT","Million of national currency units","PRT","Portugal","2018","2018",3.8,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MLLNCUMT","Million of national currency units","PRT","Portugal","2019","2019",3.7,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MLLNCUMT","Million of national currency units","PRT","Portugal","2020","2020",3.7,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MLLNCUMT","Million of national currency units","PRT","Portugal","2021","2021",3.7,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MLLNCUMT","Million of national currency units","PRT","Portugal","2022","2022",3.8,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOTCMT","Million US$ at exchange rate","PRT","Portugal","2010","2010",6.4,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOTCMT","Million US$ at exchange rate","PRT","Portugal","2011","2011",5.9,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOTCMT","Million US$ at exchange rate","PRT","Portugal","2012","2012",5.3,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOTCMT","Million US$ at exchange rate","PRT","Portugal","2013","2013",5.1,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOTCMT","Million US$ at exchange rate","PRT","Portugal","2014","2014",5,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOTCMT","Million US$ at exchange rate","PRT","Portugal","2015","2015",4.1,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOTCMT","Million US$ at exchange rate","PRT","Portugal","2016","2016",4.1,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOTCMT","Million US$ at exchange rate","PRT","Portugal","2017","2017",4.2,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOTCMT","Million US$ at exchange rate","PRT","Portugal","2018","2018",4.4,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOTCMT","Million US$ at exchange rate","PRT","Portugal","2019","2019",4.1,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOTCMT","Million US$ at exchange rate","PRT","Portugal","2020","2020",4.3,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOTCMT","Million US$ at exchange rate","PRT","Portugal","2021","2021",4.4,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOTCMT","Million US$ at exchange rate","PRT","Portugal","2022","2022",4,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOPPMT","Million US$, purchasing power parity","PRT","Portugal","2010","2010",7.7,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOPPMT","Million US$, purchasing power parity","PRT","Portugal","2011","2011",6.9,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOPPMT","Million US$, purchasing power parity","PRT","Portugal","2012","2012",6.9,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOPPMT","Million US$, purchasing power parity","PRT","Portugal","2013","2013",6.6,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOPPMT","Million US$, purchasing power parity","PRT","Portugal","2014","2014",6.5,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOPPMT","Million US$, purchasing power parity","PRT","Portugal","2015","2015",6.3,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOPPMT","Million US$, purchasing power parity","PRT","Portugal","2016","2016",6.5,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOPPMT","Million US$, purchasing power parity","PRT","Portugal","2017","2017",6.4,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOPPMT","Million US$, purchasing power parity","PRT","Portugal","2018","2018",6.6,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOPPMT","Million US$, purchasing power parity","PRT","Portugal","2019","2019",6.6,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOPPMT","Million US$, purchasing power parity","PRT","Portugal","2020","2020",6.7,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOPPMT","Million US$, purchasing power parity","PRT","Portugal","2021","2021",6.5,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOPPMT","Million US$, purchasing power parity","PRT","Portugal","2022","2022",6.9,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","TCPPERMT","/capita, US$ exchange rate","PRT","Portugal","2010","2010",0.6,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","TCPPERMT","/capita, US$ exchange rate","PRT","Portugal","2011","2011",0.6,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","TCPPERMT","/capita, US$ exchange rate","PRT","Portugal","2012","2012",0.5,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","TCPPERMT","/capita, US$ exchange rate","PRT","Portugal","2013","2013",0.5,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","TCPPERMT","/capita, US$ exchange rate","PRT","Portugal","2014","2014",0.5,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","TCPPERMT","/capita, US$ exchange rate","PRT","Portugal","2015","2015",0.4,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","TCPPERMT","/capita, US$ exchange rate","PRT","Portugal","2016","2016",0.4,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","TCPPERMT","/capita, US$ exchange rate","PRT","Portugal","2017","2017",0.4,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","TCPPERMT","/capita, US$ exchange rate","PRT","Portugal","2018","2018",0.4,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","TCPPERMT","/capita, US$ exchange rate","PRT","Portugal","2019","2019",0.4,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","TCPPERMT","/capita, US$ exchange rate","PRT","Portugal","2020","2020",0.4,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","TCPPERMT","/capita, US$ exchange rate","PRT","Portugal","2021","2021",0.4,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","TCPPERMT","/capita, US$ exchange rate","PRT","Portugal","2022","2022",0.4,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2010","2010",0.7,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2011","2011",0.6,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2012","2012",0.7,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2013","2013",0.6,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2014","2014",0.6,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2015","2015",0.6,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2016","2016",0.6,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2017","2017",0.6,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2018","2018",0.6,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2019","2019",0.6,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2020","2020",0.7,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2021","2021",0.6,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2022","2022",0.7,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","ATCPTTMT","% of total sales","PRT","Portugal","2010","2010",0.1,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","ATCPTTMT","% of total sales","PRT","Portugal","2011","2011",0.1,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","ATCPTTMT","% of total sales","PRT","Portugal","2012","2012",0.2,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","ATCPTTMT","% of total sales","PRT","Portugal","2013","2013",0.2,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","ATCPTTMT","% of total sales","PRT","Portugal","2014","2014",0.2,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","ATCPTTMT","% of total sales","PRT","Portugal","2015","2015",0.1,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","ATCPTTMT","% of total sales","PRT","Portugal","2016","2016",0.1,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","ATCPTTMT","% of total sales","PRT","Portugal","2017","2017",0.1,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","ATCPTTMT","% of total sales","PRT","Portugal","2018","2018",0.1,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","ATCPTTMT","% of total sales","PRT","Portugal","2019","2019",0.1,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","ATCPTTMT","% of total sales","PRT","Portugal","2020","2020",0.1,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","ATCPTTMT","% of total sales","PRT","Portugal","2021","2021",0.1,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","ATCPTTMT","% of total sales","PRT","Portugal","2022","2022",0.1,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MLLNCUMT","Million of national currency units","SVK","Slovak Republic","2010","2010",3.4,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MLLNCUMT","Million of national currency units","SVK","Slovak Republic","2011","2011",4.4,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MLLNCUMT","Million of national currency units","SVK","Slovak Republic","2012","2012",4.3,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MLLNCUMT","Million of national currency units","SVK","Slovak Republic","2013","2013",5.1,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MLLNCUMT","Million of national currency units","SVK","Slovak Republic","2014","2014",5.2,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MLLNCUMT","Million of national currency units","SVK","Slovak Republic","2015","2015",5.5,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MLLNCUMT","Million of national currency units","SVK","Slovak Republic","2016","2016",6.1,"B","Break"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MLLNCUMT","Million of national currency units","SVK","Slovak Republic","2017","2017",5.9,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MLLNCUMT","Million of national currency units","SVK","Slovak Republic","2018","2018",5.6,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MLLNCUMT","Million of national currency units","SVK","Slovak Republic","2019","2019",5.7,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MLLNCUMT","Million of national currency units","SVK","Slovak Republic","2020","2020",5.9,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MLLNCUMT","Million of national currency units","SVK","Slovak Republic","2021","2021",5.8,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOTCMT","Million US$ at exchange rate","SVK","Slovak Republic","2010","2010",4.6,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOTCMT","Million US$ at exchange rate","SVK","Slovak Republic","2011","2011",6.1,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOTCMT","Million US$ at exchange rate","SVK","Slovak Republic","2012","2012",5.5,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOTCMT","Million US$ at exchange rate","SVK","Slovak Republic","2013","2013",6.7,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOTCMT","Million US$ at exchange rate","SVK","Slovak Republic","2014","2014",7,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOTCMT","Million US$ at exchange rate","SVK","Slovak Republic","2015","2015",6.1,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOTCMT","Million US$ at exchange rate","SVK","Slovak Republic","2016","2016",6.7,"B","Break"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOTCMT","Million US$ at exchange rate","SVK","Slovak Republic","2017","2017",6.7,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOTCMT","Million US$ at exchange rate","SVK","Slovak Republic","2018","2018",6.6,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOTCMT","Million US$ at exchange rate","SVK","Slovak Republic","2019","2019",6.4,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOTCMT","Million US$ at exchange rate","SVK","Slovak Republic","2020","2020",6.7,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOTCMT","Million US$ at exchange rate","SVK","Slovak Republic","2021","2021",6.9,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOPPMT","Million US$, purchasing power parity","SVK","Slovak Republic","2010","2010",6.9,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOPPMT","Million US$, purchasing power parity","SVK","Slovak Republic","2011","2011",8.6,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOPPMT","Million US$, purchasing power parity","SVK","Slovak Republic","2012","2012",8.5,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOPPMT","Million US$, purchasing power parity","SVK","Slovak Republic","2013","2013",10.3,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOPPMT","Million US$, purchasing power parity","SVK","Slovak Republic","2014","2014",10.8,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOPPMT","Million US$, purchasing power parity","SVK","Slovak Republic","2015","2015",11.1,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOPPMT","Million US$, purchasing power parity","SVK","Slovak Republic","2016","2016",12.1,"B","Break"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOPPMT","Million US$, purchasing power parity","SVK","Slovak Republic","2017","2017",11.4,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOPPMT","Million US$, purchasing power parity","SVK","Slovak Republic","2018","2018",10.6,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOPPMT","Million US$, purchasing power parity","SVK","Slovak Republic","2019","2019",11.1,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOPPMT","Million US$, purchasing power parity","SVK","Slovak Republic","2020","2020",11.3,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOPPMT","Million US$, purchasing power parity","SVK","Slovak Republic","2021","2021",11,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","TCPPERMT","/capita, US$ exchange rate","SVK","Slovak Republic","2010","2010",0.8,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","TCPPERMT","/capita, US$ exchange rate","SVK","Slovak Republic","2011","2011",1.1,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","TCPPERMT","/capita, US$ exchange rate","SVK","Slovak Republic","2012","2012",1,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","TCPPERMT","/capita, US$ exchange rate","SVK","Slovak Republic","2013","2013",1.2,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","TCPPERMT","/capita, US$ exchange rate","SVK","Slovak Republic","2014","2014",1.3,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","TCPPERMT","/capita, US$ exchange rate","SVK","Slovak Republic","2015","2015",1.1,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","TCPPERMT","/capita, US$ exchange rate","SVK","Slovak Republic","2016","2016",1.2,"B","Break"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","TCPPERMT","/capita, US$ exchange rate","SVK","Slovak Republic","2017","2017",1.2,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","TCPPERMT","/capita, US$ exchange rate","SVK","Slovak Republic","2018","2018",1.2,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","TCPPERMT","/capita, US$ exchange rate","SVK","Slovak Republic","2019","2019",1.2,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","TCPPERMT","/capita, US$ exchange rate","SVK","Slovak Republic","2020","2020",1.2,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","TCPPERMT","/capita, US$ exchange rate","SVK","Slovak Republic","2021","2021",1.3,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2010","2010",1.3,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2011","2011",1.6,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2012","2012",1.6,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2013","2013",1.9,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2014","2014",2,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2015","2015",2,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2016","2016",2.2,"B","Break"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2017","2017",2.1,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2018","2018",1.9,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2019","2019",2,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2020","2020",2.1,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2021","2021",2,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","ATCPTTMT","% of total sales","SVK","Slovak Republic","2010","2010",0.3,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","ATCPTTMT","% of total sales","SVK","Slovak Republic","2011","2011",0.4,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","ATCPTTMT","% of total sales","SVK","Slovak Republic","2012","2012",0.4,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","ATCPTTMT","% of total sales","SVK","Slovak Republic","2013","2013",0.4,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","ATCPTTMT","% of total sales","SVK","Slovak Republic","2014","2014",0.4,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","ATCPTTMT","% of total sales","SVK","Slovak Republic","2015","2015",0.4,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","ATCPTTMT","% of total sales","SVK","Slovak Republic","2016","2016",0.4,"B","Break"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","ATCPTTMT","% of total sales","SVK","Slovak Republic","2017","2017",0.4,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","ATCPTTMT","% of total sales","SVK","Slovak Republic","2018","2018",0.3,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","ATCPTTMT","% of total sales","SVK","Slovak Republic","2019","2019",0.3,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","ATCPTTMT","% of total sales","SVK","Slovak Republic","2020","2020",0.4,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","ATCPTTMT","% of total sales","SVK","Slovak Republic","2021","2021",0.3,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MLLNCUMT","Million of national currency units","ESP","Spain","2010","2010",22.8,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MLLNCUMT","Million of national currency units","ESP","Spain","2011","2011",33.6,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MLLNCUMT","Million of national currency units","ESP","Spain","2012","2012",31.2,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MLLNCUMT","Million of national currency units","ESP","Spain","2013","2013",31.7,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MLLNCUMT","Million of national currency units","ESP","Spain","2014","2014",35.5,"B; D","Break; Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MLLNCUMT","Million of national currency units","ESP","Spain","2015","2015",36.7,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MLLNCUMT","Million of national currency units","ESP","Spain","2016","2016",35.4,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MLLNCUMT","Million of national currency units","ESP","Spain","2017","2017",29.6,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MLLNCUMT","Million of national currency units","ESP","Spain","2018","2018",29.6,"B","Break"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MLLNCUMT","Million of national currency units","ESP","Spain","2019","2019",27.5,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MLLNCUMT","Million of national currency units","ESP","Spain","2020","2020",23,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MLLNCUMT","Million of national currency units","ESP","Spain","2021","2021",22.8,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MLLNCUMT","Million of national currency units","ESP","Spain","2022","2022",22.6,"P","Provisional value"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOTCMT","Million US$ at exchange rate","ESP","Spain","2010","2010",30.2,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOTCMT","Million US$ at exchange rate","ESP","Spain","2011","2011",46.8,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOTCMT","Million US$ at exchange rate","ESP","Spain","2012","2012",40.1,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOTCMT","Million US$ at exchange rate","ESP","Spain","2013","2013",42.1,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOTCMT","Million US$ at exchange rate","ESP","Spain","2014","2014",47.1,"B; D","Break; Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOTCMT","Million US$ at exchange rate","ESP","Spain","2015","2015",40.7,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOTCMT","Million US$ at exchange rate","ESP","Spain","2016","2016",39.2,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOTCMT","Million US$ at exchange rate","ESP","Spain","2017","2017",33.5,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOTCMT","Million US$ at exchange rate","ESP","Spain","2018","2018",35,"B","Break"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOTCMT","Million US$ at exchange rate","ESP","Spain","2019","2019",30.8,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOTCMT","Million US$ at exchange rate","ESP","Spain","2020","2020",26.2,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOTCMT","Million US$ at exchange rate","ESP","Spain","2021","2021",26.9,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOTCMT","Million US$ at exchange rate","ESP","Spain","2022","2022",23.8,"P","Provisional value"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOPPMT","Million US$, purchasing power parity","ESP","Spain","2010","2010",31.4,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOPPMT","Million US$, purchasing power parity","ESP","Spain","2011","2011",47.1,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOPPMT","Million US$, purchasing power parity","ESP","Spain","2012","2012",44.9,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOPPMT","Million US$, purchasing power parity","ESP","Spain","2013","2013",47,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOPPMT","Million US$, purchasing power parity","ESP","Spain","2014","2014",53.5,"B; D","Break; Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOPPMT","Million US$, purchasing power parity","ESP","Spain","2015","2015",55.2,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOPPMT","Million US$, purchasing power parity","ESP","Spain","2016","2016",55.1,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOPPMT","Million US$, purchasing power parity","ESP","Spain","2017","2017",47,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOPPMT","Million US$, purchasing power parity","ESP","Spain","2018","2018",46.9,"B","Break"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOPPMT","Million US$, purchasing power parity","ESP","Spain","2019","2019",44.9,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOPPMT","Million US$, purchasing power parity","ESP","Spain","2020","2020",36.9,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOPPMT","Million US$, purchasing power parity","ESP","Spain","2021","2021",36.4,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOPPMT","Million US$, purchasing power parity","ESP","Spain","2022","2022",37.9,"P","Provisional value"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","TCPPERMT","/capita, US$ exchange rate","ESP","Spain","2010","2010",0.6,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","TCPPERMT","/capita, US$ exchange rate","ESP","Spain","2011","2011",1,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","TCPPERMT","/capita, US$ exchange rate","ESP","Spain","2012","2012",0.9,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","TCPPERMT","/capita, US$ exchange rate","ESP","Spain","2013","2013",0.9,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","TCPPERMT","/capita, US$ exchange rate","ESP","Spain","2014","2014",1,"B; D","Break; Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","TCPPERMT","/capita, US$ exchange rate","ESP","Spain","2015","2015",0.9,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","TCPPERMT","/capita, US$ exchange rate","ESP","Spain","2016","2016",0.8,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","TCPPERMT","/capita, US$ exchange rate","ESP","Spain","2017","2017",0.7,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","TCPPERMT","/capita, US$ exchange rate","ESP","Spain","2018","2018",0.7,"B","Break"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","TCPPERMT","/capita, US$ exchange rate","ESP","Spain","2019","2019",0.7,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","TCPPERMT","/capita, US$ exchange rate","ESP","Spain","2020","2020",0.6,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","TCPPERMT","/capita, US$ exchange rate","ESP","Spain","2021","2021",0.6,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","TCPPERMT","/capita, US$ exchange rate","ESP","Spain","2022","2022",0.5,"P","Provisional value"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2010","2010",0.7,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2011","2011",1,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2012","2012",1,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2013","2013",1,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2014","2014",1.2,"B; D","Break; Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2015","2015",1.2,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2016","2016",1.2,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2017","2017",1,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2018","2018",1,"B","Break"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2019","2019",1,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2020","2020",0.8,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2021","2021",0.8,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2022","2022",0.8,"P","Provisional value"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","ATCPTTMT","% of total sales","ESP","Spain","2010","2010",0.2,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","ATCPTTMT","% of total sales","ESP","Spain","2011","2011",0.3,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","ATCPTTMT","% of total sales","ESP","Spain","2012","2012",0.3,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","ATCPTTMT","% of total sales","ESP","Spain","2013","2013",0.3,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","ATCPTTMT","% of total sales","ESP","Spain","2014","2014",0.3,"B; D","Break; Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","ATCPTTMT","% of total sales","ESP","Spain","2015","2015",0.3,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","ATCPTTMT","% of total sales","ESP","Spain","2016","2016",0.3,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","ATCPTTMT","% of total sales","ESP","Spain","2017","2017",0.2,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","ATCPTTMT","% of total sales","ESP","Spain","2018","2018",0.2,"B","Break"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","ATCPTTMT","% of total sales","ESP","Spain","2019","2019",0.1,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","ATCPTTMT","% of total sales","ESP","Spain","2020","2020",0.1,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","ATCPTTMT","% of total sales","ESP","Spain","2021","2021",0.1,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","ATCPTTMT","% of total sales","ESP","Spain","2022","2022",0.1,"P","Provisional value"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MLLNCUMT","Million of national currency units","SWE","Sweden","2010","2010",36.1,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MLLNCUMT","Million of national currency units","SWE","Sweden","2011","2011",49.4,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MLLNCUMT","Million of national currency units","SWE","Sweden","2012","2012",50.6,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MLLNCUMT","Million of national currency units","SWE","Sweden","2013","2013",54.1,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MLLNCUMT","Million of national currency units","SWE","Sweden","2014","2014",60.5,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MLLNCUMT","Million of national currency units","SWE","Sweden","2015","2015",66.6,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MLLNCUMT","Million of national currency units","SWE","Sweden","2016","2016",74.4,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MLLNCUMT","Million of national currency units","SWE","Sweden","2017","2017",80.9,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MLLNCUMT","Million of national currency units","SWE","Sweden","2018","2018",88.9,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MLLNCUMT","Million of national currency units","SWE","Sweden","2019","2019",97.6,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MLLNCUMT","Million of national currency units","SWE","Sweden","2020","2020",88.6,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MLLNCUMT","Million of national currency units","SWE","Sweden","2021","2021",88.8,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MLLNCUMT","Million of national currency units","SWE","Sweden","2022","2022",55.7,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOTCMT","Million US$ at exchange rate","SWE","Sweden","2010","2010",5,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOTCMT","Million US$ at exchange rate","SWE","Sweden","2011","2011",7.6,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOTCMT","Million US$ at exchange rate","SWE","Sweden","2012","2012",7.5,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOTCMT","Million US$ at exchange rate","SWE","Sweden","2013","2013",8.3,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOTCMT","Million US$ at exchange rate","SWE","Sweden","2014","2014",8.8,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOTCMT","Million US$ at exchange rate","SWE","Sweden","2015","2015",7.9,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOTCMT","Million US$ at exchange rate","SWE","Sweden","2016","2016",8.7,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOTCMT","Million US$ at exchange rate","SWE","Sweden","2017","2017",9.5,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOTCMT","Million US$ at exchange rate","SWE","Sweden","2018","2018",10.2,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOTCMT","Million US$ at exchange rate","SWE","Sweden","2019","2019",10.3,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOTCMT","Million US$ at exchange rate","SWE","Sweden","2020","2020",9.6,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOTCMT","Million US$ at exchange rate","SWE","Sweden","2021","2021",10.4,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOTCMT","Million US$ at exchange rate","SWE","Sweden","2022","2022",5.5,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOPPMT","Million US$, purchasing power parity","SWE","Sweden","2010","2010",4,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOPPMT","Million US$, purchasing power parity","SWE","Sweden","2011","2011",5.6,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOPPMT","Million US$, purchasing power parity","SWE","Sweden","2012","2012",5.8,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOPPMT","Million US$, purchasing power parity","SWE","Sweden","2013","2013",6.3,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOPPMT","Million US$, purchasing power parity","SWE","Sweden","2014","2014",6.9,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOPPMT","Million US$, purchasing power parity","SWE","Sweden","2015","2015",7.5,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOPPMT","Million US$, purchasing power parity","SWE","Sweden","2016","2016",8.4,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOPPMT","Million US$, purchasing power parity","SWE","Sweden","2017","2017",9.1,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOPPMT","Million US$, purchasing power parity","SWE","Sweden","2018","2018",10,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOPPMT","Million US$, purchasing power parity","SWE","Sweden","2019","2019",11.2,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOPPMT","Million US$, purchasing power parity","SWE","Sweden","2020","2020",10.2,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOPPMT","Million US$, purchasing power parity","SWE","Sweden","2021","2021",10.2,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOPPMT","Million US$, purchasing power parity","SWE","Sweden","2022","2022",6.4,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","TCPPERMT","/capita, US$ exchange rate","SWE","Sweden","2010","2010",0.5,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","TCPPERMT","/capita, US$ exchange rate","SWE","Sweden","2011","2011",0.8,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","TCPPERMT","/capita, US$ exchange rate","SWE","Sweden","2012","2012",0.8,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","TCPPERMT","/capita, US$ exchange rate","SWE","Sweden","2013","2013",0.9,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","TCPPERMT","/capita, US$ exchange rate","SWE","Sweden","2014","2014",0.9,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","TCPPERMT","/capita, US$ exchange rate","SWE","Sweden","2015","2015",0.8,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","TCPPERMT","/capita, US$ exchange rate","SWE","Sweden","2016","2016",0.9,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","TCPPERMT","/capita, US$ exchange rate","SWE","Sweden","2017","2017",0.9,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","TCPPERMT","/capita, US$ exchange rate","SWE","Sweden","2018","2018",1,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","TCPPERMT","/capita, US$ exchange rate","SWE","Sweden","2019","2019",1,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","TCPPERMT","/capita, US$ exchange rate","SWE","Sweden","2020","2020",0.9,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","TCPPERMT","/capita, US$ exchange rate","SWE","Sweden","2021","2021",1,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","TCPPERMT","/capita, US$ exchange rate","SWE","Sweden","2022","2022",0.5,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2010","2010",0.4,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2011","2011",0.6,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2012","2012",0.6,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2013","2013",0.7,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2014","2014",0.7,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2015","2015",0.8,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2016","2016",0.8,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2017","2017",0.9,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2018","2018",1,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2019","2019",1.1,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2020","2020",1,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2021","2021",1,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2022","2022",0.6,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","ATCPTTMT","% of total sales","SWE","Sweden","2010","2010",0.1,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","ATCPTTMT","% of total sales","SWE","Sweden","2011","2011",0.1,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","ATCPTTMT","% of total sales","SWE","Sweden","2012","2012",0.1,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","ATCPTTMT","% of total sales","SWE","Sweden","2013","2013",0.1,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","ATCPTTMT","% of total sales","SWE","Sweden","2014","2014",0.2,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","ATCPTTMT","% of total sales","SWE","Sweden","2015","2015",0.2,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","ATCPTTMT","% of total sales","SWE","Sweden","2016","2016",0.2,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","ATCPTTMT","% of total sales","SWE","Sweden","2017","2017",0.2,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","ATCPTTMT","% of total sales","SWE","Sweden","2018","2018",0.2,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","ATCPTTMT","% of total sales","SWE","Sweden","2019","2019",0.2,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","ATCPTTMT","% of total sales","SWE","Sweden","2020","2020",0.2,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","ATCPTTMT","% of total sales","SWE","Sweden","2021","2021",0.2,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","ATCPTTMT","% of total sales","SWE","Sweden","2022","2022",0.1,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MLLNCUMT","Million of national currency units","TUR","Türkiye","2010","2010",6.4,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MLLNCUMT","Million of national currency units","TUR","Türkiye","2011","2011",7,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MLLNCUMT","Million of national currency units","TUR","Türkiye","2012","2012",7.1,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MLLNCUMT","Million of national currency units","TUR","Türkiye","2013","2013",8,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MLLNCUMT","Million of national currency units","TUR","Türkiye","2014","2014",9.1,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MLLNCUMT","Million of national currency units","TUR","Türkiye","2015","2015",10.3,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MLLNCUMT","Million of national currency units","TUR","Türkiye","2016","2016",13.8,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MLLNCUMT","Million of national currency units","TUR","Türkiye","2017","2017",17.8,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MLLNCUMT","Million of national currency units","TUR","Türkiye","2018","2018",23.5,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MLLNCUMT","Million of national currency units","TUR","Türkiye","2019","2019",31.8,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MLLNCUMT","Million of national currency units","TUR","Türkiye","2020","2020",37.5,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MLLNCUMT","Million of national currency units","TUR","Türkiye","2021","2021",53.9,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOTCMT","Million US$ at exchange rate","TUR","Türkiye","2010","2010",4.2,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOTCMT","Million US$ at exchange rate","TUR","Türkiye","2011","2011",4.2,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOTCMT","Million US$ at exchange rate","TUR","Türkiye","2012","2012",4,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOTCMT","Million US$ at exchange rate","TUR","Türkiye","2013","2013",4.2,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOTCMT","Million US$ at exchange rate","TUR","Türkiye","2014","2014",4.2,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOTCMT","Million US$ at exchange rate","TUR","Türkiye","2015","2015",3.8,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOTCMT","Million US$ at exchange rate","TUR","Türkiye","2016","2016",4.6,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOTCMT","Million US$ at exchange rate","TUR","Türkiye","2017","2017",4.9,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOTCMT","Million US$ at exchange rate","TUR","Türkiye","2018","2018",4.9,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOTCMT","Million US$ at exchange rate","TUR","Türkiye","2019","2019",5.6,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOTCMT","Million US$ at exchange rate","TUR","Türkiye","2020","2020",5.3,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOTCMT","Million US$ at exchange rate","TUR","Türkiye","2021","2021",6.1,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOPPMT","Million US$, purchasing power parity","TUR","Türkiye","2010","2010",6.9,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOPPMT","Million US$, purchasing power parity","TUR","Türkiye","2011","2011",7.2,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOPPMT","Million US$, purchasing power parity","TUR","Türkiye","2012","2012",7,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOPPMT","Million US$, purchasing power parity","TUR","Türkiye","2013","2013",7.5,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOPPMT","Million US$, purchasing power parity","TUR","Türkiye","2014","2014",8.2,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOPPMT","Million US$, purchasing power parity","TUR","Türkiye","2015","2015",8.8,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOPPMT","Million US$, purchasing power parity","TUR","Türkiye","2016","2016",11.1,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOPPMT","Million US$, purchasing power parity","TUR","Türkiye","2017","2017",12.9,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOPPMT","Million US$, purchasing power parity","TUR","Türkiye","2018","2018",14.4,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOPPMT","Million US$, purchasing power parity","TUR","Türkiye","2019","2019",17.1,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOPPMT","Million US$, purchasing power parity","TUR","Türkiye","2020","2020",17.3,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOPPMT","Million US$, purchasing power parity","TUR","Türkiye","2021","2021",19.2,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","TCPPERMT","/capita, US$ exchange rate","TUR","Türkiye","2010","2010",0.1,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","TCPPERMT","/capita, US$ exchange rate","TUR","Türkiye","2011","2011",0.1,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","TCPPERMT","/capita, US$ exchange rate","TUR","Türkiye","2012","2012",0.1,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","TCPPERMT","/capita, US$ exchange rate","TUR","Türkiye","2013","2013",0.1,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","TCPPERMT","/capita, US$ exchange rate","TUR","Türkiye","2014","2014",0.1,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","TCPPERMT","/capita, US$ exchange rate","TUR","Türkiye","2015","2015",0,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","TCPPERMT","/capita, US$ exchange rate","TUR","Türkiye","2016","2016",0.1,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","TCPPERMT","/capita, US$ exchange rate","TUR","Türkiye","2017","2017",0.1,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","TCPPERMT","/capita, US$ exchange rate","TUR","Türkiye","2018","2018",0.1,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","TCPPERMT","/capita, US$ exchange rate","TUR","Türkiye","2019","2019",0.1,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","TCPPERMT","/capita, US$ exchange rate","TUR","Türkiye","2020","2020",0.1,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","TCPPERMT","/capita, US$ exchange rate","TUR","Türkiye","2021","2021",0.1,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2010","2010",0.1,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2011","2011",0.1,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2012","2012",0.1,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2013","2013",0.1,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2014","2014",0.1,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2015","2015",0.1,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2016","2016",0.1,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2017","2017",0.2,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2018","2018",0.2,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2019","2019",0.2,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2020","2020",0.2,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2021","2021",0.2,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","ATCPTTMT","% of total sales","TUR","Türkiye","2010","2010",0,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","ATCPTTMT","% of total sales","TUR","Türkiye","2011","2011",0,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","ATCPTTMT","% of total sales","TUR","Türkiye","2012","2012",0.1,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","ATCPTTMT","% of total sales","TUR","Türkiye","2013","2013",0.1,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","ATCPTTMT","% of total sales","TUR","Türkiye","2014","2014",0.1,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","ATCPTTMT","% of total sales","TUR","Türkiye","2015","2015",0.1,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","ATCPTTMT","% of total sales","TUR","Türkiye","2016","2016",0.1,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","ATCPTTMT","% of total sales","TUR","Türkiye","2017","2017",0.1,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","ATCPTTMT","% of total sales","TUR","Türkiye","2018","2018",0.1,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","ATCPTTMT","% of total sales","TUR","Türkiye","2019","2019",0.1,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","ATCPTTMT","% of total sales","TUR","Türkiye","2020","2020",0.1,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","ATCPTTMT","% of total sales","TUR","Türkiye","2021","2021",0.1,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MLLNCUMT","Million of national currency units","CHL","Chile","2010","2010",1169.2,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MLLNCUMT","Million of national currency units","CHL","Chile","2011","2011",1341.3,"B","Break"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MLLNCUMT","Million of national currency units","CHL","Chile","2012","2012",1457.1,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MLLNCUMT","Million of national currency units","CHL","Chile","2013","2013",1625.7,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MLLNCUMT","Million of national currency units","CHL","Chile","2014","2014",1688.5,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MLLNCUMT","Million of national currency units","CHL","Chile","2015","2015",1679.1,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MLLNCUMT","Million of national currency units","CHL","Chile","2016","2016",2214.9,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MLLNCUMT","Million of national currency units","CHL","Chile","2017","2017",2149.5,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MLLNCUMT","Million of national currency units","CHL","Chile","2018","2018",2166.8,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MLLNCUMT","Million of national currency units","CHL","Chile","2019","2019",3246.1,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MLLNCUMT","Million of national currency units","CHL","Chile","2020","2020",3705.1,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MLLNCUMT","Million of national currency units","CHL","Chile","2021","2021",4299.6,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MLLNCUMT","Million of national currency units","CHL","Chile","2022","2022",4747.2,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOTCMT","Million US$ at exchange rate","CHL","Chile","2010","2010",2.3,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOTCMT","Million US$ at exchange rate","CHL","Chile","2011","2011",2.8,"B","Break"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOTCMT","Million US$ at exchange rate","CHL","Chile","2012","2012",3,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOTCMT","Million US$ at exchange rate","CHL","Chile","2013","2013",3.3,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOTCMT","Million US$ at exchange rate","CHL","Chile","2014","2014",3,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOTCMT","Million US$ at exchange rate","CHL","Chile","2015","2015",2.6,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOTCMT","Million US$ at exchange rate","CHL","Chile","2016","2016",3.3,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOTCMT","Million US$ at exchange rate","CHL","Chile","2017","2017",3.3,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOTCMT","Million US$ at exchange rate","CHL","Chile","2018","2018",3.4,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOTCMT","Million US$ at exchange rate","CHL","Chile","2019","2019",4.6,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOTCMT","Million US$ at exchange rate","CHL","Chile","2020","2020",4.7,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOTCMT","Million US$ at exchange rate","CHL","Chile","2021","2021",5.7,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOTCMT","Million US$ at exchange rate","CHL","Chile","2022","2022",5.4,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOPPMT","Million US$, purchasing power parity","CHL","Chile","2010","2010",3.2,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOPPMT","Million US$, purchasing power parity","CHL","Chile","2011","2011",3.9,"B","Break"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOPPMT","Million US$, purchasing power parity","CHL","Chile","2012","2012",4.2,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOPPMT","Million US$, purchasing power parity","CHL","Chile","2013","2013",4.6,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOPPMT","Million US$, purchasing power parity","CHL","Chile","2014","2014",4.6,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOPPMT","Million US$, purchasing power parity","CHL","Chile","2015","2015",4.3,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOPPMT","Million US$, purchasing power parity","CHL","Chile","2016","2016",5.6,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOPPMT","Million US$, purchasing power parity","CHL","Chile","2017","2017",5.4,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOPPMT","Million US$, purchasing power parity","CHL","Chile","2018","2018",5.5,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOPPMT","Million US$, purchasing power parity","CHL","Chile","2019","2019",8.1,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOPPMT","Million US$, purchasing power parity","CHL","Chile","2020","2020",8.9,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOPPMT","Million US$, purchasing power parity","CHL","Chile","2021","2021",9.9,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOPPMT","Million US$, purchasing power parity","CHL","Chile","2022","2022",10.8,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","TCPPERMT","/capita, US$ exchange rate","CHL","Chile","2010","2010",0.1,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","TCPPERMT","/capita, US$ exchange rate","CHL","Chile","2011","2011",0.2,"B","Break"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","TCPPERMT","/capita, US$ exchange rate","CHL","Chile","2012","2012",0.2,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","TCPPERMT","/capita, US$ exchange rate","CHL","Chile","2013","2013",0.2,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","TCPPERMT","/capita, US$ exchange rate","CHL","Chile","2014","2014",0.2,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","TCPPERMT","/capita, US$ exchange rate","CHL","Chile","2015","2015",0.1,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","TCPPERMT","/capita, US$ exchange rate","CHL","Chile","2016","2016",0.2,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","TCPPERMT","/capita, US$ exchange rate","CHL","Chile","2017","2017",0.2,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","TCPPERMT","/capita, US$ exchange rate","CHL","Chile","2018","2018",0.2,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","TCPPERMT","/capita, US$ exchange rate","CHL","Chile","2019","2019",0.2,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","TCPPERMT","/capita, US$ exchange rate","CHL","Chile","2020","2020",0.2,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","TCPPERMT","/capita, US$ exchange rate","CHL","Chile","2021","2021",0.3,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","TCPPERMT","/capita, US$ exchange rate","CHL","Chile","2022","2022",0.3,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2010","2010",0.2,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2011","2011",0.2,"B","Break"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2012","2012",0.2,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2013","2013",0.3,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2014","2014",0.3,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2015","2015",0.2,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2016","2016",0.3,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2017","2017",0.3,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2018","2018",0.3,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2019","2019",0.4,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2020","2020",0.5,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2021","2021",0.5,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2022","2022",0.5,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","ATCPTTMT","% of total sales","CHL","Chile","2010","2010",0.1,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","ATCPTTMT","% of total sales","CHL","Chile","2011","2011",0.1,"B","Break"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","ATCPTTMT","% of total sales","CHL","Chile","2012","2012",0.1,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","ATCPTTMT","% of total sales","CHL","Chile","2013","2013",0.1,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","ATCPTTMT","% of total sales","CHL","Chile","2014","2014",0.1,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","ATCPTTMT","% of total sales","CHL","Chile","2015","2015",0.1,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","ATCPTTMT","% of total sales","CHL","Chile","2016","2016",0.1,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","ATCPTTMT","% of total sales","CHL","Chile","2017","2017",0.1,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","ATCPTTMT","% of total sales","CHL","Chile","2018","2018",0.1,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","ATCPTTMT","% of total sales","CHL","Chile","2019","2019",0.1,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","ATCPTTMT","% of total sales","CHL","Chile","2020","2020",0.1,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","ATCPTTMT","% of total sales","CHL","Chile","2021","2021",0.2,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","ATCPTTMT","% of total sales","CHL","Chile","2022","2022",0.2,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MLLNCUMT","Million of national currency units","EST","Estonia","2010","2010",0.8,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MLLNCUMT","Million of national currency units","EST","Estonia","2011","2011",0.8,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MLLNCUMT","Million of national currency units","EST","Estonia","2012","2012",0.9,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MLLNCUMT","Million of national currency units","EST","Estonia","2013","2013",0.9,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MLLNCUMT","Million of national currency units","EST","Estonia","2014","2014",1,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MLLNCUMT","Million of national currency units","EST","Estonia","2015","2015",1,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MLLNCUMT","Million of national currency units","EST","Estonia","2016","2016",1,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MLLNCUMT","Million of national currency units","EST","Estonia","2017","2017",0.8,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MLLNCUMT","Million of national currency units","EST","Estonia","2018","2018",0.8,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MLLNCUMT","Million of national currency units","EST","Estonia","2019","2019",0.7,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MLLNCUMT","Million of national currency units","EST","Estonia","2020","2020",0.6,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MLLNCUMT","Million of national currency units","EST","Estonia","2021","2021",0.5,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MLLNCUMT","Million of national currency units","EST","Estonia","2022","2022",0.6,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOTCMT","Million US$ at exchange rate","EST","Estonia","2010","2010",1,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOTCMT","Million US$ at exchange rate","EST","Estonia","2011","2011",1.1,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOTCMT","Million US$ at exchange rate","EST","Estonia","2012","2012",1.1,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOTCMT","Million US$ at exchange rate","EST","Estonia","2013","2013",1.2,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOTCMT","Million US$ at exchange rate","EST","Estonia","2014","2014",1.3,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOTCMT","Million US$ at exchange rate","EST","Estonia","2015","2015",1.1,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOTCMT","Million US$ at exchange rate","EST","Estonia","2016","2016",1.1,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOTCMT","Million US$ at exchange rate","EST","Estonia","2017","2017",0.9,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOTCMT","Million US$ at exchange rate","EST","Estonia","2018","2018",0.9,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOTCMT","Million US$ at exchange rate","EST","Estonia","2019","2019",0.7,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOTCMT","Million US$ at exchange rate","EST","Estonia","2020","2020",0.7,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOTCMT","Million US$ at exchange rate","EST","Estonia","2021","2021",0.6,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOTCMT","Million US$ at exchange rate","EST","Estonia","2022","2022",0.6,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOPPMT","Million US$, purchasing power parity","EST","Estonia","2010","2010",1.5,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOPPMT","Million US$, purchasing power parity","EST","Estonia","2011","2011",1.5,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOPPMT","Million US$, purchasing power parity","EST","Estonia","2012","2012",1.7,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOPPMT","Million US$, purchasing power parity","EST","Estonia","2013","2013",1.7,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOPPMT","Million US$, purchasing power parity","EST","Estonia","2014","2014",1.8,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOPPMT","Million US$, purchasing power parity","EST","Estonia","2015","2015",1.9,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOPPMT","Million US$, purchasing power parity","EST","Estonia","2016","2016",1.8,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOPPMT","Million US$, purchasing power parity","EST","Estonia","2017","2017",1.5,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOPPMT","Million US$, purchasing power parity","EST","Estonia","2018","2018",1.4,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOPPMT","Million US$, purchasing power parity","EST","Estonia","2019","2019",1.2,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOPPMT","Million US$, purchasing power parity","EST","Estonia","2020","2020",1.1,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOPPMT","Million US$, purchasing power parity","EST","Estonia","2021","2021",1,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOPPMT","Million US$, purchasing power parity","EST","Estonia","2022","2022",1,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","TCPPERMT","/capita, US$ exchange rate","EST","Estonia","2010","2010",0.7,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","TCPPERMT","/capita, US$ exchange rate","EST","Estonia","2011","2011",0.8,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","TCPPERMT","/capita, US$ exchange rate","EST","Estonia","2012","2012",0.8,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","TCPPERMT","/capita, US$ exchange rate","EST","Estonia","2013","2013",0.9,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","TCPPERMT","/capita, US$ exchange rate","EST","Estonia","2014","2014",1,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","TCPPERMT","/capita, US$ exchange rate","EST","Estonia","2015","2015",0.8,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","TCPPERMT","/capita, US$ exchange rate","EST","Estonia","2016","2016",0.8,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","TCPPERMT","/capita, US$ exchange rate","EST","Estonia","2017","2017",0.7,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","TCPPERMT","/capita, US$ exchange rate","EST","Estonia","2018","2018",0.7,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","TCPPERMT","/capita, US$ exchange rate","EST","Estonia","2019","2019",0.6,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","TCPPERMT","/capita, US$ exchange rate","EST","Estonia","2020","2020",0.5,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","TCPPERMT","/capita, US$ exchange rate","EST","Estonia","2021","2021",0.5,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","TCPPERMT","/capita, US$ exchange rate","EST","Estonia","2022","2022",0.4,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2010","2010",1.1,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2011","2011",1.2,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2012","2012",1.3,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2013","2013",1.3,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2014","2014",1.4,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2015","2015",1.4,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2016","2016",1.4,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2017","2017",1.1,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2018","2018",1.1,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2019","2019",0.9,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2020","2020",0.9,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2021","2021",0.8,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2022","2022",0.7,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","ATCPTTMT","% of total sales","EST","Estonia","2010","2010",0.4,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","ATCPTTMT","% of total sales","EST","Estonia","2011","2011",0.4,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","ATCPTTMT","% of total sales","EST","Estonia","2012","2012",0.4,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","ATCPTTMT","% of total sales","EST","Estonia","2013","2013",0.4,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","ATCPTTMT","% of total sales","EST","Estonia","2014","2014",0.4,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","ATCPTTMT","% of total sales","EST","Estonia","2015","2015",0.4,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","ATCPTTMT","% of total sales","EST","Estonia","2016","2016",0.3,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","ATCPTTMT","% of total sales","EST","Estonia","2017","2017",0.3,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","ATCPTTMT","% of total sales","EST","Estonia","2018","2018",0.2,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","ATCPTTMT","% of total sales","EST","Estonia","2019","2019",0.2,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","ATCPTTMT","% of total sales","EST","Estonia","2020","2020",0.2,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","ATCPTTMT","% of total sales","EST","Estonia","2021","2021",0.1,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","ATCPTTMT","% of total sales","EST","Estonia","2022","2022",0.1,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MLLNCUMT","Million of national currency units","SVN","Slovenia","2010","2010",1.1,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MLLNCUMT","Million of national currency units","SVN","Slovenia","2011","2011",1.2,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MLLNCUMT","Million of national currency units","SVN","Slovenia","2012","2012",1.1,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MLLNCUMT","Million of national currency units","SVN","Slovenia","2013","2013",1.1,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MLLNCUMT","Million of national currency units","SVN","Slovenia","2014","2014",1,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MLLNCUMT","Million of national currency units","SVN","Slovenia","2015","2015",1,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MLLNCUMT","Million of national currency units","SVN","Slovenia","2016","2016",1,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MLLNCUMT","Million of national currency units","SVN","Slovenia","2017","2017",1,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MLLNCUMT","Million of national currency units","SVN","Slovenia","2018","2018",1,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MLLNCUMT","Million of national currency units","SVN","Slovenia","2019","2019",1,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MLLNCUMT","Million of national currency units","SVN","Slovenia","2020","2020",0.9,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MLLNCUMT","Million of national currency units","SVN","Slovenia","2021","2021",0.9,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MLLNCUMT","Million of national currency units","SVN","Slovenia","2022","2022",0.9,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOTCMT","Million US$ at exchange rate","SVN","Slovenia","2010","2010",1.4,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOTCMT","Million US$ at exchange rate","SVN","Slovenia","2011","2011",1.7,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOTCMT","Million US$ at exchange rate","SVN","Slovenia","2012","2012",1.4,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOTCMT","Million US$ at exchange rate","SVN","Slovenia","2013","2013",1.5,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOTCMT","Million US$ at exchange rate","SVN","Slovenia","2014","2014",1.4,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOTCMT","Million US$ at exchange rate","SVN","Slovenia","2015","2015",1.2,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOTCMT","Million US$ at exchange rate","SVN","Slovenia","2016","2016",1.1,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOTCMT","Million US$ at exchange rate","SVN","Slovenia","2017","2017",1.1,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOTCMT","Million US$ at exchange rate","SVN","Slovenia","2018","2018",1.1,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOTCMT","Million US$ at exchange rate","SVN","Slovenia","2019","2019",1.1,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOTCMT","Million US$ at exchange rate","SVN","Slovenia","2020","2020",1.1,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOTCMT","Million US$ at exchange rate","SVN","Slovenia","2021","2021",1.1,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOTCMT","Million US$ at exchange rate","SVN","Slovenia","2022","2022",0.9,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOPPMT","Million US$, purchasing power parity","SVN","Slovenia","2010","2010",1.7,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOPPMT","Million US$, purchasing power parity","SVN","Slovenia","2011","2011",2,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOPPMT","Million US$, purchasing power parity","SVN","Slovenia","2012","2012",1.9,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOPPMT","Million US$, purchasing power parity","SVN","Slovenia","2013","2013",1.8,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOPPMT","Million US$, purchasing power parity","SVN","Slovenia","2014","2014",1.8,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOPPMT","Million US$, purchasing power parity","SVN","Slovenia","2015","2015",1.7,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOPPMT","Million US$, purchasing power parity","SVN","Slovenia","2016","2016",1.7,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOPPMT","Million US$, purchasing power parity","SVN","Slovenia","2017","2017",1.7,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOPPMT","Million US$, purchasing power parity","SVN","Slovenia","2018","2018",1.7,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOPPMT","Million US$, purchasing power parity","SVN","Slovenia","2019","2019",1.7,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOPPMT","Million US$, purchasing power parity","SVN","Slovenia","2020","2020",1.7,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOPPMT","Million US$, purchasing power parity","SVN","Slovenia","2021","2021",1.6,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOPPMT","Million US$, purchasing power parity","SVN","Slovenia","2022","2022",1.6,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","TCPPERMT","/capita, US$ exchange rate","SVN","Slovenia","2010","2010",0.7,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","TCPPERMT","/capita, US$ exchange rate","SVN","Slovenia","2011","2011",0.8,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","TCPPERMT","/capita, US$ exchange rate","SVN","Slovenia","2012","2012",0.7,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","TCPPERMT","/capita, US$ exchange rate","SVN","Slovenia","2013","2013",0.7,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","TCPPERMT","/capita, US$ exchange rate","SVN","Slovenia","2014","2014",0.7,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","TCPPERMT","/capita, US$ exchange rate","SVN","Slovenia","2015","2015",0.6,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","TCPPERMT","/capita, US$ exchange rate","SVN","Slovenia","2016","2016",0.5,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","TCPPERMT","/capita, US$ exchange rate","SVN","Slovenia","2017","2017",0.5,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","TCPPERMT","/capita, US$ exchange rate","SVN","Slovenia","2018","2018",0.5,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","TCPPERMT","/capita, US$ exchange rate","SVN","Slovenia","2019","2019",0.5,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","TCPPERMT","/capita, US$ exchange rate","SVN","Slovenia","2020","2020",0.5,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","TCPPERMT","/capita, US$ exchange rate","SVN","Slovenia","2021","2021",0.5,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","TCPPERMT","/capita, US$ exchange rate","SVN","Slovenia","2022","2022",0.4,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2010","2010",0.8,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2011","2011",1,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2012","2012",0.9,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2013","2013",0.9,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2014","2014",0.9,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2015","2015",0.8,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2016","2016",0.8,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2017","2017",0.8,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2018","2018",0.8,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2019","2019",0.8,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2020","2020",0.8,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2021","2021",0.8,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2022","2022",0.8,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","ATCPTTMT","% of total sales","SVN","Slovenia","2010","2010",0.2,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","ATCPTTMT","% of total sales","SVN","Slovenia","2011","2011",0.3,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","ATCPTTMT","% of total sales","SVN","Slovenia","2012","2012",0.2,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","ATCPTTMT","% of total sales","SVN","Slovenia","2013","2013",0.2,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","ATCPTTMT","% of total sales","SVN","Slovenia","2014","2014",0.2,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","ATCPTTMT","% of total sales","SVN","Slovenia","2015","2015",0.2,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","ATCPTTMT","% of total sales","SVN","Slovenia","2016","2016",0.2,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","ATCPTTMT","% of total sales","SVN","Slovenia","2017","2017",0.2,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","ATCPTTMT","% of total sales","SVN","Slovenia","2018","2018",0.2,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","ATCPTTMT","% of total sales","SVN","Slovenia","2019","2019",0.2,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","ATCPTTMT","% of total sales","SVN","Slovenia","2020","2020",0.2,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","ATCPTTMT","% of total sales","SVN","Slovenia","2021","2021",0.1,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","ATCPTTMT","% of total sales","SVN","Slovenia","2022","2022",0.1,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","MLLNCUMT","Million of national currency units","AUS","Australia","2010","2010",64,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","MLLNCUMT","Million of national currency units","AUS","Australia","2011","2011",72,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","MLLNCUMT","Million of national currency units","AUS","Australia","2012","2012",78,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","MLLNCUMT","Million of national currency units","AUS","Australia","2013","2013",88,"B; D","Break; Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","MLLNCUMT","Million of national currency units","AUS","Australia","2014","2014",83,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","MLLNCUMT","Million of national currency units","AUS","Australia","2015","2015",91,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","MLLNCUMT","Million of national currency units","AUS","Australia","2016","2016",98,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","MLLNCUMT","Million of national currency units","AUS","Australia","2017","2017",107,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","MLLNCUMT","Million of national currency units","AUS","Australia","2018","2018",116,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","MLLNCUMT","Million of national currency units","AUS","Australia","2019","2019",134,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","MLLNCUMT","Million of national currency units","AUS","Australia","2020","2020",150,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","MLLNCUMT","Million of national currency units","AUS","Australia","2021","2021",169,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","MTMOTCMT","Million US$ at exchange rate","AUS","Australia","2010","2010",58.7,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","MTMOTCMT","Million US$ at exchange rate","AUS","Australia","2011","2011",74.3,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","MTMOTCMT","Million US$ at exchange rate","AUS","Australia","2012","2012",80.8,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","MTMOTCMT","Million US$ at exchange rate","AUS","Australia","2013","2013",85,"B; D","Break; Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","MTMOTCMT","Million US$ at exchange rate","AUS","Australia","2014","2014",74.8,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","MTMOTCMT","Million US$ at exchange rate","AUS","Australia","2015","2015",68.4,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","MTMOTCMT","Million US$ at exchange rate","AUS","Australia","2016","2016",72.9,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","MTMOTCMT","Million US$ at exchange rate","AUS","Australia","2017","2017",82,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","MTMOTCMT","Million US$ at exchange rate","AUS","Australia","2018","2018",86.7,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","MTMOTCMT","Million US$ at exchange rate","AUS","Australia","2019","2019",93.2,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","MTMOTCMT","Million US$ at exchange rate","AUS","Australia","2020","2020",103.2,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","MTMOTCMT","Million US$ at exchange rate","AUS","Australia","2021","2021",127,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","MTMOPPMT","Million US$, purchasing power parity","AUS","Australia","2010","2010",42.6,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","MTMOPPMT","Million US$, purchasing power parity","AUS","Australia","2011","2011",47.6,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","MTMOPPMT","Million US$, purchasing power parity","AUS","Australia","2012","2012",50.6,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","MTMOPPMT","Million US$, purchasing power parity","AUS","Australia","2013","2013",60.8,"B; D","Break; Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","MTMOPPMT","Million US$, purchasing power parity","AUS","Australia","2014","2014",57.1,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","MTMOPPMT","Million US$, purchasing power parity","AUS","Australia","2015","2015",61.7,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","MTMOPPMT","Million US$, purchasing power parity","AUS","Australia","2016","2016",67.6,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","MTMOPPMT","Million US$, purchasing power parity","AUS","Australia","2017","2017",72.4,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","MTMOPPMT","Million US$, purchasing power parity","AUS","Australia","2018","2018",78.9,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","MTMOPPMT","Million US$, purchasing power parity","AUS","Australia","2019","2019",90.5,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","MTMOPPMT","Million US$, purchasing power parity","AUS","Australia","2020","2020",103.2,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","MTMOPPMT","Million US$, purchasing power parity","AUS","Australia","2021","2021",116.7,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","TCPPERMT","/capita, US$ exchange rate","AUS","Australia","2010","2010",2.7,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","TCPPERMT","/capita, US$ exchange rate","AUS","Australia","2011","2011",3.3,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","TCPPERMT","/capita, US$ exchange rate","AUS","Australia","2012","2012",3.6,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","TCPPERMT","/capita, US$ exchange rate","AUS","Australia","2013","2013",3.7,"B; D","Break; Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","TCPPERMT","/capita, US$ exchange rate","AUS","Australia","2014","2014",3.2,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","TCPPERMT","/capita, US$ exchange rate","AUS","Australia","2015","2015",2.9,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","TCPPERMT","/capita, US$ exchange rate","AUS","Australia","2016","2016",3,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","TCPPERMT","/capita, US$ exchange rate","AUS","Australia","2017","2017",3.3,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","TCPPERMT","/capita, US$ exchange rate","AUS","Australia","2018","2018",3.5,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","TCPPERMT","/capita, US$ exchange rate","AUS","Australia","2019","2019",3.7,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","TCPPERMT","/capita, US$ exchange rate","AUS","Australia","2020","2020",4,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","TCPPERMT","/capita, US$ exchange rate","AUS","Australia","2021","2021",4.9,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2010","2010",1.9,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2011","2011",2.1,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2012","2012",2.2,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2013","2013",2.6,"B; D","Break; Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2014","2014",2.4,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2015","2015",2.6,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2016","2016",2.8,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2017","2017",2.9,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2018","2018",3.2,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2019","2019",3.6,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2020","2020",4,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2021","2021",4.5,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","ATCPTTMT","% of total sales","AUS","Australia","2010","2010",0.7,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","ATCPTTMT","% of total sales","AUS","Australia","2011","2011",0.7,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","ATCPTTMT","% of total sales","AUS","Australia","2012","2012",0.8,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","ATCPTTMT","% of total sales","AUS","Australia","2013","2013",0.7,"B; D","Break; Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","ATCPTTMT","% of total sales","AUS","Australia","2014","2014",0.7,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","ATCPTTMT","% of total sales","AUS","Australia","2015","2015",0.7,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","ATCPTTMT","% of total sales","AUS","Australia","2016","2016",0.6,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","ATCPTTMT","% of total sales","AUS","Australia","2017","2017",0.7,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","ATCPTTMT","% of total sales","AUS","Australia","2018","2018",0.8,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","ATCPTTMT","% of total sales","AUS","Australia","2019","2019",0.9,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","ATCPTTMT","% of total sales","AUS","Australia","2020","2020",0.9,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","ATCPTTMT","% of total sales","AUS","Australia","2021","2021",1,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","MLLNCUMT","Million of national currency units","AUT","Austria","2010","2010",39.3,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","MLLNCUMT","Million of national currency units","AUT","Austria","2011","2011",39.6,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","MLLNCUMT","Million of national currency units","AUT","Austria","2012","2012",41.4,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","MLLNCUMT","Million of national currency units","AUT","Austria","2013","2013",42.1,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","MLLNCUMT","Million of national currency units","AUT","Austria","2014","2014",42.7,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","MLLNCUMT","Million of national currency units","AUT","Austria","2015","2015",45.7,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","MLLNCUMT","Million of national currency units","AUT","Austria","2016","2016",48.7,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","MLLNCUMT","Million of national currency units","AUT","Austria","2017","2017",49.6,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","MLLNCUMT","Million of national currency units","AUT","Austria","2018","2018",45.6,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","MLLNCUMT","Million of national currency units","AUT","Austria","2019","2019",47.2,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","MLLNCUMT","Million of national currency units","AUT","Austria","2020","2020",49.7,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","MLLNCUMT","Million of national currency units","AUT","Austria","2021","2021",50.1,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","MTMOTCMT","Million US$ at exchange rate","AUT","Austria","2010","2010",52.1,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","MTMOTCMT","Million US$ at exchange rate","AUT","Austria","2011","2011",55.2,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","MTMOTCMT","Million US$ at exchange rate","AUT","Austria","2012","2012",53.2,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","MTMOTCMT","Million US$ at exchange rate","AUT","Austria","2013","2013",55.9,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","MTMOTCMT","Million US$ at exchange rate","AUT","Austria","2014","2014",56.7,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","MTMOTCMT","Million US$ at exchange rate","AUT","Austria","2015","2015",50.7,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","MTMOTCMT","Million US$ at exchange rate","AUT","Austria","2016","2016",53.9,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","MTMOTCMT","Million US$ at exchange rate","AUT","Austria","2017","2017",56,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","MTMOTCMT","Million US$ at exchange rate","AUT","Austria","2018","2018",53.9,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","MTMOTCMT","Million US$ at exchange rate","AUT","Austria","2019","2019",52.8,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","MTMOTCMT","Million US$ at exchange rate","AUT","Austria","2020","2020",56.8,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","MTMOTCMT","Million US$ at exchange rate","AUT","Austria","2021","2021",59.3,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","MTMOPPMT","Million US$, purchasing power parity","AUT","Austria","2010","2010",46.6,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","MTMOPPMT","Million US$, purchasing power parity","AUT","Austria","2011","2011",47.7,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","MTMOPPMT","Million US$, purchasing power parity","AUT","Austria","2012","2012",50.9,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","MTMOPPMT","Million US$, purchasing power parity","AUT","Austria","2013","2013",52.8,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","MTMOPPMT","Million US$, purchasing power parity","AUT","Austria","2014","2014",53.4,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","MTMOPPMT","Million US$, purchasing power parity","AUT","Austria","2015","2015",57.2,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","MTMOPPMT","Million US$, purchasing power parity","AUT","Austria","2016","2016",62.7,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","MTMOPPMT","Million US$, purchasing power parity","AUT","Austria","2017","2017",64,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","MTMOPPMT","Million US$, purchasing power parity","AUT","Austria","2018","2018",59.6,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","MTMOPPMT","Million US$, purchasing power parity","AUT","Austria","2019","2019",63,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","MTMOPPMT","Million US$, purchasing power parity","AUT","Austria","2020","2020",66.6,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","MTMOPPMT","Million US$, purchasing power parity","AUT","Austria","2021","2021",66.2,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","TCPPERMT","/capita, US$ exchange rate","AUT","Austria","2010","2010",6.2,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","TCPPERMT","/capita, US$ exchange rate","AUT","Austria","2011","2011",6.6,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","TCPPERMT","/capita, US$ exchange rate","AUT","Austria","2012","2012",6.3,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","TCPPERMT","/capita, US$ exchange rate","AUT","Austria","2013","2013",6.6,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","TCPPERMT","/capita, US$ exchange rate","AUT","Austria","2014","2014",6.6,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","TCPPERMT","/capita, US$ exchange rate","AUT","Austria","2015","2015",5.9,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","TCPPERMT","/capita, US$ exchange rate","AUT","Austria","2016","2016",6.2,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","TCPPERMT","/capita, US$ exchange rate","AUT","Austria","2017","2017",6.4,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","TCPPERMT","/capita, US$ exchange rate","AUT","Austria","2018","2018",6.1,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","TCPPERMT","/capita, US$ exchange rate","AUT","Austria","2019","2019",5.9,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","TCPPERMT","/capita, US$ exchange rate","AUT","Austria","2020","2020",6.4,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","TCPPERMT","/capita, US$ exchange rate","AUT","Austria","2021","2021",6.6,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2010","2010",5.6,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2011","2011",5.7,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2012","2012",6,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2013","2013",6.2,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2014","2014",6.3,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2015","2015",6.6,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2016","2016",7.2,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2017","2017",7.3,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2018","2018",6.7,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2019","2019",7.1,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2020","2020",7.5,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2021","2021",7.4,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","ATCPTTMT","% of total sales","AUT","Austria","2010","2010",1.6,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","ATCPTTMT","% of total sales","AUT","Austria","2011","2011",1.6,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","ATCPTTMT","% of total sales","AUT","Austria","2012","2012",1.6,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","ATCPTTMT","% of total sales","AUT","Austria","2013","2013",1.6,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","ATCPTTMT","% of total sales","AUT","Austria","2014","2014",1.5,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","ATCPTTMT","% of total sales","AUT","Austria","2015","2015",1.6,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","ATCPTTMT","% of total sales","AUT","Austria","2016","2016",1.6,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","ATCPTTMT","% of total sales","AUT","Austria","2017","2017",1.6,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","ATCPTTMT","% of total sales","AUT","Austria","2018","2018",1.4,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","ATCPTTMT","% of total sales","AUT","Austria","2019","2019",1.4,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","ATCPTTMT","% of total sales","AUT","Austria","2020","2020",1.4,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","ATCPTTMT","% of total sales","AUT","Austria","2021","2021",1.3,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","MLLNCUMT","Million of national currency units","BEL","Belgium","2010","2010",17.7,,
+"PATCHYPO","C02-Antihypertensives","MLLNCUMT","Million of national currency units","BEL","Belgium","2011","2011",20.7,,
+"PATCHYPO","C02-Antihypertensives","MLLNCUMT","Million of national currency units","BEL","Belgium","2012","2012",19.6,,
+"PATCHYPO","C02-Antihypertensives","MLLNCUMT","Million of national currency units","BEL","Belgium","2013","2013",19.3,,
+"PATCHYPO","C02-Antihypertensives","MLLNCUMT","Million of national currency units","BEL","Belgium","2014","2014",20.2,,
+"PATCHYPO","C02-Antihypertensives","MLLNCUMT","Million of national currency units","BEL","Belgium","2015","2015",24.3,,
+"PATCHYPO","C02-Antihypertensives","MLLNCUMT","Million of national currency units","BEL","Belgium","2016","2016",25.9,,
+"PATCHYPO","C02-Antihypertensives","MLLNCUMT","Million of national currency units","BEL","Belgium","2017","2017",26.1,,
+"PATCHYPO","C02-Antihypertensives","MLLNCUMT","Million of national currency units","BEL","Belgium","2018","2018",26.2,,
+"PATCHYPO","C02-Antihypertensives","MLLNCUMT","Million of national currency units","BEL","Belgium","2019","2019",30.3,,
+"PATCHYPO","C02-Antihypertensives","MLLNCUMT","Million of national currency units","BEL","Belgium","2020","2020",33,,
+"PATCHYPO","C02-Antihypertensives","MLLNCUMT","Million of national currency units","BEL","Belgium","2021","2021",32.4,,
+"PATCHYPO","C02-Antihypertensives","MLLNCUMT","Million of national currency units","BEL","Belgium","2022","2022",36.2,"E","Estimated value"
+"PATCHYPO","C02-Antihypertensives","MTMOTCMT","Million US$ at exchange rate","BEL","Belgium","2010","2010",23.5,,
+"PATCHYPO","C02-Antihypertensives","MTMOTCMT","Million US$ at exchange rate","BEL","Belgium","2011","2011",28.8,,
+"PATCHYPO","C02-Antihypertensives","MTMOTCMT","Million US$ at exchange rate","BEL","Belgium","2012","2012",25.2,,
+"PATCHYPO","C02-Antihypertensives","MTMOTCMT","Million US$ at exchange rate","BEL","Belgium","2013","2013",25.7,,
+"PATCHYPO","C02-Antihypertensives","MTMOTCMT","Million US$ at exchange rate","BEL","Belgium","2014","2014",26.8,,
+"PATCHYPO","C02-Antihypertensives","MTMOTCMT","Million US$ at exchange rate","BEL","Belgium","2015","2015",27,,
+"PATCHYPO","C02-Antihypertensives","MTMOTCMT","Million US$ at exchange rate","BEL","Belgium","2016","2016",28.7,,
+"PATCHYPO","C02-Antihypertensives","MTMOTCMT","Million US$ at exchange rate","BEL","Belgium","2017","2017",29.5,,
+"PATCHYPO","C02-Antihypertensives","MTMOTCMT","Million US$ at exchange rate","BEL","Belgium","2018","2018",30.9,,
+"PATCHYPO","C02-Antihypertensives","MTMOTCMT","Million US$ at exchange rate","BEL","Belgium","2019","2019",33.9,,
+"PATCHYPO","C02-Antihypertensives","MTMOTCMT","Million US$ at exchange rate","BEL","Belgium","2020","2020",37.7,,
+"PATCHYPO","C02-Antihypertensives","MTMOTCMT","Million US$ at exchange rate","BEL","Belgium","2021","2021",38.3,,
+"PATCHYPO","C02-Antihypertensives","MTMOTCMT","Million US$ at exchange rate","BEL","Belgium","2022","2022",38.1,"E","Estimated value"
+"PATCHYPO","C02-Antihypertensives","MTMOPPMT","Million US$, purchasing power parity","BEL","Belgium","2010","2010",21.2,,
+"PATCHYPO","C02-Antihypertensives","MTMOPPMT","Million US$, purchasing power parity","BEL","Belgium","2011","2011",24.9,,
+"PATCHYPO","C02-Antihypertensives","MTMOPPMT","Million US$, purchasing power parity","BEL","Belgium","2012","2012",23.9,,
+"PATCHYPO","C02-Antihypertensives","MTMOPPMT","Million US$, purchasing power parity","BEL","Belgium","2013","2013",24,,
+"PATCHYPO","C02-Antihypertensives","MTMOPPMT","Million US$, purchasing power parity","BEL","Belgium","2014","2014",25.2,,
+"PATCHYPO","C02-Antihypertensives","MTMOPPMT","Million US$, purchasing power parity","BEL","Belgium","2015","2015",30.4,,
+"PATCHYPO","C02-Antihypertensives","MTMOPPMT","Million US$, purchasing power parity","BEL","Belgium","2016","2016",33.2,,
+"PATCHYPO","C02-Antihypertensives","MTMOPPMT","Million US$, purchasing power parity","BEL","Belgium","2017","2017",33.6,,
+"PATCHYPO","C02-Antihypertensives","MTMOPPMT","Million US$, purchasing power parity","BEL","Belgium","2018","2018",34.2,,
+"PATCHYPO","C02-Antihypertensives","MTMOPPMT","Million US$, purchasing power parity","BEL","Belgium","2019","2019",40.6,,
+"PATCHYPO","C02-Antihypertensives","MTMOPPMT","Million US$, purchasing power parity","BEL","Belgium","2020","2020",45.2,,
+"PATCHYPO","C02-Antihypertensives","MTMOPPMT","Million US$, purchasing power parity","BEL","Belgium","2021","2021",43.9,,
+"PATCHYPO","C02-Antihypertensives","MTMOPPMT","Million US$, purchasing power parity","BEL","Belgium","2022","2022",50.7,"E","Estimated value"
+"PATCHYPO","C02-Antihypertensives","TCPPERMT","/capita, US$ exchange rate","BEL","Belgium","2010","2010",2.2,,
+"PATCHYPO","C02-Antihypertensives","TCPPERMT","/capita, US$ exchange rate","BEL","Belgium","2011","2011",2.6,,
+"PATCHYPO","C02-Antihypertensives","TCPPERMT","/capita, US$ exchange rate","BEL","Belgium","2012","2012",2.3,,
+"PATCHYPO","C02-Antihypertensives","TCPPERMT","/capita, US$ exchange rate","BEL","Belgium","2013","2013",2.3,,
+"PATCHYPO","C02-Antihypertensives","TCPPERMT","/capita, US$ exchange rate","BEL","Belgium","2014","2014",2.4,,
+"PATCHYPO","C02-Antihypertensives","TCPPERMT","/capita, US$ exchange rate","BEL","Belgium","2015","2015",2.4,,
+"PATCHYPO","C02-Antihypertensives","TCPPERMT","/capita, US$ exchange rate","BEL","Belgium","2016","2016",2.5,,
+"PATCHYPO","C02-Antihypertensives","TCPPERMT","/capita, US$ exchange rate","BEL","Belgium","2017","2017",2.6,,
+"PATCHYPO","C02-Antihypertensives","TCPPERMT","/capita, US$ exchange rate","BEL","Belgium","2018","2018",2.7,,
+"PATCHYPO","C02-Antihypertensives","TCPPERMT","/capita, US$ exchange rate","BEL","Belgium","2019","2019",3,,
+"PATCHYPO","C02-Antihypertensives","TCPPERMT","/capita, US$ exchange rate","BEL","Belgium","2020","2020",3.3,,
+"PATCHYPO","C02-Antihypertensives","TCPPERMT","/capita, US$ exchange rate","BEL","Belgium","2021","2021",3.3,,
+"PATCHYPO","C02-Antihypertensives","TCPPERMT","/capita, US$ exchange rate","BEL","Belgium","2022","2022",3.3,"E","Estimated value"
+"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2010","2010",1.9,,
+"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2011","2011",2.3,,
+"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2012","2012",2.1,,
+"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2013","2013",2.1,,
+"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2014","2014",2.2,,
+"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2015","2015",2.7,,
+"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2016","2016",2.9,,
+"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2017","2017",3,,
+"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2018","2018",3,,
+"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2019","2019",3.5,,
+"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2020","2020",3.9,,
+"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2021","2021",3.8,,
+"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2022","2022",4.4,"E","Estimated value"
+"PATCHYPO","C02-Antihypertensives","ATCPTTMT","% of total sales","BEL","Belgium","2010","2010",0.3,,
+"PATCHYPO","C02-Antihypertensives","ATCPTTMT","% of total sales","BEL","Belgium","2011","2011",0.3,,
+"PATCHYPO","C02-Antihypertensives","ATCPTTMT","% of total sales","BEL","Belgium","2012","2012",0.3,,
+"PATCHYPO","C02-Antihypertensives","ATCPTTMT","% of total sales","BEL","Belgium","2013","2013",0.3,,
+"PATCHYPO","C02-Antihypertensives","ATCPTTMT","% of total sales","BEL","Belgium","2014","2014",0.3,,
+"PATCHYPO","C02-Antihypertensives","ATCPTTMT","% of total sales","BEL","Belgium","2015","2015",0.4,,
+"PATCHYPO","C02-Antihypertensives","ATCPTTMT","% of total sales","BEL","Belgium","2016","2016",0.4,,
+"PATCHYPO","C02-Antihypertensives","ATCPTTMT","% of total sales","BEL","Belgium","2017","2017",0.4,,
+"PATCHYPO","C02-Antihypertensives","ATCPTTMT","% of total sales","BEL","Belgium","2018","2018",0.4,,
+"PATCHYPO","C02-Antihypertensives","ATCPTTMT","% of total sales","BEL","Belgium","2019","2019",0.4,,
+"PATCHYPO","C02-Antihypertensives","ATCPTTMT","% of total sales","BEL","Belgium","2020","2020",0.4,,
+"PATCHYPO","C02-Antihypertensives","ATCPTTMT","% of total sales","BEL","Belgium","2021","2021",0.4,,
+"PATCHYPO","C02-Antihypertensives","ATCPTTMT","% of total sales","BEL","Belgium","2022","2022",0.4,"E","Estimated value"
+"PATCHYPO","C02-Antihypertensives","MLLNCUMT","Million of national currency units","CAN","Canada","2012","2012",73.4,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","MLLNCUMT","Million of national currency units","CAN","Canada","2013","2013",76.5,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","MLLNCUMT","Million of national currency units","CAN","Canada","2014","2014",92,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","MLLNCUMT","Million of national currency units","CAN","Canada","2015","2015",104.3,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","MLLNCUMT","Million of national currency units","CAN","Canada","2016","2016",119.2,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","MLLNCUMT","Million of national currency units","CAN","Canada","2017","2017",129.6,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","MLLNCUMT","Million of national currency units","CAN","Canada","2018","2018",107.2,"E; B; D","Estimated value; Break; Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","MLLNCUMT","Million of national currency units","CAN","Canada","2019","2019",116.5,"E; D","Estimated value; Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","MLLNCUMT","Million of national currency units","CAN","Canada","2020","2020",125.2,"E; D","Estimated value; Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","MLLNCUMT","Million of national currency units","CAN","Canada","2021","2021",127.2,"E; D","Estimated value; Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","MLLNCUMT","Million of national currency units","CAN","Canada","2022","2022",113.2,"E; D","Estimated value; Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","MTMOTCMT","Million US$ at exchange rate","CAN","Canada","2012","2012",73.4,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","MTMOTCMT","Million US$ at exchange rate","CAN","Canada","2013","2013",74.3,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","MTMOTCMT","Million US$ at exchange rate","CAN","Canada","2014","2014",83.3,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","MTMOTCMT","Million US$ at exchange rate","CAN","Canada","2015","2015",81.6,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","MTMOTCMT","Million US$ at exchange rate","CAN","Canada","2016","2016",89.9,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","MTMOTCMT","Million US$ at exchange rate","CAN","Canada","2017","2017",99.9,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","MTMOTCMT","Million US$ at exchange rate","CAN","Canada","2018","2018",82.7,"E; B; D","Estimated value; Break; Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","MTMOTCMT","Million US$ at exchange rate","CAN","Canada","2019","2019",87.8,"E; D","Estimated value; Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","MTMOTCMT","Million US$ at exchange rate","CAN","Canada","2020","2020",93.3,"E; D","Estimated value; Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","MTMOTCMT","Million US$ at exchange rate","CAN","Canada","2021","2021",101.4,"E; D","Estimated value; Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","MTMOTCMT","Million US$ at exchange rate","CAN","Canada","2022","2022",87,"E; D","Estimated value; Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","MTMOPPMT","Million US$, purchasing power parity","CAN","Canada","2012","2012",59,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","MTMOPPMT","Million US$, purchasing power parity","CAN","Canada","2013","2013",62.5,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","MTMOPPMT","Million US$, purchasing power parity","CAN","Canada","2014","2014",74.8,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","MTMOPPMT","Million US$, purchasing power parity","CAN","Canada","2015","2015",83.6,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","MTMOPPMT","Million US$, purchasing power parity","CAN","Canada","2016","2016",98.8,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","MTMOPPMT","Million US$, purchasing power parity","CAN","Canada","2017","2017",106.9,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","MTMOPPMT","Million US$, purchasing power parity","CAN","Canada","2018","2018",88.8,"E; B; D","Estimated value; Break; Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","MTMOPPMT","Million US$, purchasing power parity","CAN","Canada","2019","2019",94.3,"E; D","Estimated value; Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","MTMOPPMT","Million US$, purchasing power parity","CAN","Canada","2020","2020",101.7,"E; D","Estimated value; Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","MTMOPPMT","Million US$, purchasing power parity","CAN","Canada","2021","2021",102.7,"E; D","Estimated value; Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","MTMOPPMT","Million US$, purchasing power parity","CAN","Canada","2022","2022",90.3,"E; D","Estimated value; Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","TCPPERMT","/capita, US$ exchange rate","CAN","Canada","2012","2012",2.1,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","TCPPERMT","/capita, US$ exchange rate","CAN","Canada","2013","2013",2.1,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","TCPPERMT","/capita, US$ exchange rate","CAN","Canada","2014","2014",2.3,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","TCPPERMT","/capita, US$ exchange rate","CAN","Canada","2015","2015",2.3,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","TCPPERMT","/capita, US$ exchange rate","CAN","Canada","2016","2016",2.5,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","TCPPERMT","/capita, US$ exchange rate","CAN","Canada","2017","2017",2.7,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","TCPPERMT","/capita, US$ exchange rate","CAN","Canada","2018","2018",2.2,"E; B; D","Estimated value; Break; Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","TCPPERMT","/capita, US$ exchange rate","CAN","Canada","2019","2019",2.3,"E; D","Estimated value; Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","TCPPERMT","/capita, US$ exchange rate","CAN","Canada","2020","2020",2.5,"E; D","Estimated value; Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","TCPPERMT","/capita, US$ exchange rate","CAN","Canada","2021","2021",2.7,"E; D","Estimated value; Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","TCPPERMT","/capita, US$ exchange rate","CAN","Canada","2022","2022",2.2,"E; D","Estimated value; Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2012","2012",1.7,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2013","2013",1.8,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2014","2014",2.1,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2015","2015",2.3,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2016","2016",2.7,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2017","2017",2.9,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2018","2018",2.4,"E; B; D","Estimated value; Break; Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2019","2019",2.5,"E; D","Estimated value; Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2020","2020",2.7,"E; D","Estimated value; Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2021","2021",2.7,"E; D","Estimated value; Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2022","2022",2.3,"E; D","Estimated value; Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","ATCPTTMT","% of total sales","CAN","Canada","2012","2012",0.3,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","ATCPTTMT","% of total sales","CAN","Canada","2013","2013",0.3,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","ATCPTTMT","% of total sales","CAN","Canada","2014","2014",0.4,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","ATCPTTMT","% of total sales","CAN","Canada","2015","2015",0.4,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","ATCPTTMT","% of total sales","CAN","Canada","2016","2016",0.4,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","ATCPTTMT","% of total sales","CAN","Canada","2017","2017",0.4,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","ATCPTTMT","% of total sales","CAN","Canada","2018","2018",0.4,"E; B; D","Estimated value; Break; Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","ATCPTTMT","% of total sales","CAN","Canada","2019","2019",0.4,"E; D","Estimated value; Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","ATCPTTMT","% of total sales","CAN","Canada","2020","2020",0.4,"E; D","Estimated value; Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","ATCPTTMT","% of total sales","CAN","Canada","2021","2021",0.3,"E; D","Estimated value; Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","ATCPTTMT","% of total sales","CAN","Canada","2022","2022",0.3,"E; D","Estimated value; Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","MLLNCUMT","Million of national currency units","CZE","Czech Republic","2010","2010",879.9,,
+"PATCHYPO","C02-Antihypertensives","MLLNCUMT","Million of national currency units","CZE","Czech Republic","2011","2011",800.8,,
+"PATCHYPO","C02-Antihypertensives","MLLNCUMT","Million of national currency units","CZE","Czech Republic","2012","2012",796,,
+"PATCHYPO","C02-Antihypertensives","MLLNCUMT","Million of national currency units","CZE","Czech Republic","2013","2013",752.5,,
+"PATCHYPO","C02-Antihypertensives","MLLNCUMT","Million of national currency units","CZE","Czech Republic","2014","2014",734.4,,
+"PATCHYPO","C02-Antihypertensives","MLLNCUMT","Million of national currency units","CZE","Czech Republic","2015","2015",689.1,,
+"PATCHYPO","C02-Antihypertensives","MLLNCUMT","Million of national currency units","CZE","Czech Republic","2016","2016",690.3,,
+"PATCHYPO","C02-Antihypertensives","MLLNCUMT","Million of national currency units","CZE","Czech Republic","2017","2017",725.2,,
+"PATCHYPO","C02-Antihypertensives","MLLNCUMT","Million of national currency units","CZE","Czech Republic","2018","2018",733.3,,
+"PATCHYPO","C02-Antihypertensives","MLLNCUMT","Million of national currency units","CZE","Czech Republic","2019","2019",731.3,,
+"PATCHYPO","C02-Antihypertensives","MLLNCUMT","Million of national currency units","CZE","Czech Republic","2020","2020",682.8,"B","Break"
+"PATCHYPO","C02-Antihypertensives","MLLNCUMT","Million of national currency units","CZE","Czech Republic","2021","2021",625.3,,
+"PATCHYPO","C02-Antihypertensives","MTMOTCMT","Million US$ at exchange rate","CZE","Czech Republic","2010","2010",46.1,,
+"PATCHYPO","C02-Antihypertensives","MTMOTCMT","Million US$ at exchange rate","CZE","Czech Republic","2011","2011",45.3,,
+"PATCHYPO","C02-Antihypertensives","MTMOTCMT","Million US$ at exchange rate","CZE","Czech Republic","2012","2012",40.7,,
+"PATCHYPO","C02-Antihypertensives","MTMOTCMT","Million US$ at exchange rate","CZE","Czech Republic","2013","2013",38.4,,
+"PATCHYPO","C02-Antihypertensives","MTMOTCMT","Million US$ at exchange rate","CZE","Czech Republic","2014","2014",35.4,,
+"PATCHYPO","C02-Antihypertensives","MTMOTCMT","Million US$ at exchange rate","CZE","Czech Republic","2015","2015",28,,
+"PATCHYPO","C02-Antihypertensives","MTMOTCMT","Million US$ at exchange rate","CZE","Czech Republic","2016","2016",28.2,,
+"PATCHYPO","C02-Antihypertensives","MTMOTCMT","Million US$ at exchange rate","CZE","Czech Republic","2017","2017",31,,
+"PATCHYPO","C02-Antihypertensives","MTMOTCMT","Million US$ at exchange rate","CZE","Czech Republic","2018","2018",33.7,,
+"PATCHYPO","C02-Antihypertensives","MTMOTCMT","Million US$ at exchange rate","CZE","Czech Republic","2019","2019",31.9,,
+"PATCHYPO","C02-Antihypertensives","MTMOTCMT","Million US$ at exchange rate","CZE","Czech Republic","2020","2020",29.4,"B","Break"
+"PATCHYPO","C02-Antihypertensives","MTMOTCMT","Million US$ at exchange rate","CZE","Czech Republic","2021","2021",28.8,,
+"PATCHYPO","C02-Antihypertensives","MTMOPPMT","Million US$, purchasing power parity","CZE","Czech Republic","2010","2010",64.4,,
+"PATCHYPO","C02-Antihypertensives","MTMOPPMT","Million US$, purchasing power parity","CZE","Czech Republic","2011","2011",60,,
+"PATCHYPO","C02-Antihypertensives","MTMOPPMT","Million US$, purchasing power parity","CZE","Czech Republic","2012","2012",59.9,,
+"PATCHYPO","C02-Antihypertensives","MTMOPPMT","Million US$, purchasing power parity","CZE","Czech Republic","2013","2013",58.9,,
+"PATCHYPO","C02-Antihypertensives","MTMOPPMT","Million US$, purchasing power parity","CZE","Czech Republic","2014","2014",57.8,,
+"PATCHYPO","C02-Antihypertensives","MTMOPPMT","Million US$, purchasing power parity","CZE","Czech Republic","2015","2015",53.3,,
+"PATCHYPO","C02-Antihypertensives","MTMOPPMT","Million US$, purchasing power parity","CZE","Czech Republic","2016","2016",54.9,,
+"PATCHYPO","C02-Antihypertensives","MTMOPPMT","Million US$, purchasing power parity","CZE","Czech Republic","2017","2017",58.4,,
+"PATCHYPO","C02-Antihypertensives","MTMOPPMT","Million US$, purchasing power parity","CZE","Czech Republic","2018","2018",59.3,,
+"PATCHYPO","C02-Antihypertensives","MTMOPPMT","Million US$, purchasing power parity","CZE","Czech Republic","2019","2019",59.6,,
+"PATCHYPO","C02-Antihypertensives","MTMOPPMT","Million US$, purchasing power parity","CZE","Czech Republic","2020","2020",54.8,"B","Break"
+"PATCHYPO","C02-Antihypertensives","MTMOPPMT","Million US$, purchasing power parity","CZE","Czech Republic","2021","2021",49.1,,
+"PATCHYPO","C02-Antihypertensives","TCPPERMT","/capita, US$ exchange rate","CZE","Czech Republic","2010","2010",4.4,,
+"PATCHYPO","C02-Antihypertensives","TCPPERMT","/capita, US$ exchange rate","CZE","Czech Republic","2011","2011",4.3,,
+"PATCHYPO","C02-Antihypertensives","TCPPERMT","/capita, US$ exchange rate","CZE","Czech Republic","2012","2012",3.9,,
+"PATCHYPO","C02-Antihypertensives","TCPPERMT","/capita, US$ exchange rate","CZE","Czech Republic","2013","2013",3.7,,
+"PATCHYPO","C02-Antihypertensives","TCPPERMT","/capita, US$ exchange rate","CZE","Czech Republic","2014","2014",3.4,,
+"PATCHYPO","C02-Antihypertensives","TCPPERMT","/capita, US$ exchange rate","CZE","Czech Republic","2015","2015",2.7,,
+"PATCHYPO","C02-Antihypertensives","TCPPERMT","/capita, US$ exchange rate","CZE","Czech Republic","2016","2016",2.7,,
+"PATCHYPO","C02-Antihypertensives","TCPPERMT","/capita, US$ exchange rate","CZE","Czech Republic","2017","2017",2.9,,
+"PATCHYPO","C02-Antihypertensives","TCPPERMT","/capita, US$ exchange rate","CZE","Czech Republic","2018","2018",3.2,,
+"PATCHYPO","C02-Antihypertensives","TCPPERMT","/capita, US$ exchange rate","CZE","Czech Republic","2019","2019",3,,
+"PATCHYPO","C02-Antihypertensives","TCPPERMT","/capita, US$ exchange rate","CZE","Czech Republic","2020","2020",2.7,"B","Break"
+"PATCHYPO","C02-Antihypertensives","TCPPERMT","/capita, US$ exchange rate","CZE","Czech Republic","2021","2021",2.7,,
+"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czech Republic","2010","2010",6.1,,
+"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czech Republic","2011","2011",5.7,,
+"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czech Republic","2012","2012",5.7,,
+"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czech Republic","2013","2013",5.6,,
+"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czech Republic","2014","2014",5.5,,
+"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czech Republic","2015","2015",5.1,,
+"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czech Republic","2016","2016",5.2,,
+"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czech Republic","2017","2017",5.5,,
+"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czech Republic","2018","2018",5.6,,
+"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czech Republic","2019","2019",5.6,,
+"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czech Republic","2020","2020",5.1,"B","Break"
+"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czech Republic","2021","2021",4.7,,
+"PATCHYPO","C02-Antihypertensives","ATCPTTMT","% of total sales","CZE","Czech Republic","2010","2010",1.1,,
+"PATCHYPO","C02-Antihypertensives","ATCPTTMT","% of total sales","CZE","Czech Republic","2011","2011",1,,
+"PATCHYPO","C02-Antihypertensives","ATCPTTMT","% of total sales","CZE","Czech Republic","2012","2012",1,,
+"PATCHYPO","C02-Antihypertensives","ATCPTTMT","% of total sales","CZE","Czech Republic","2013","2013",0.9,,
+"PATCHYPO","C02-Antihypertensives","ATCPTTMT","% of total sales","CZE","Czech Republic","2014","2014",0.9,,
+"PATCHYPO","C02-Antihypertensives","ATCPTTMT","% of total sales","CZE","Czech Republic","2015","2015",0.8,,
+"PATCHYPO","C02-Antihypertensives","ATCPTTMT","% of total sales","CZE","Czech Republic","2016","2016",0.8,,
+"PATCHYPO","C02-Antihypertensives","ATCPTTMT","% of total sales","CZE","Czech Republic","2017","2017",0.8,,
+"PATCHYPO","C02-Antihypertensives","ATCPTTMT","% of total sales","CZE","Czech Republic","2018","2018",0.7,,
+"PATCHYPO","C02-Antihypertensives","ATCPTTMT","% of total sales","CZE","Czech Republic","2019","2019",0.7,,
+"PATCHYPO","C02-Antihypertensives","ATCPTTMT","% of total sales","CZE","Czech Republic","2020","2020",0.8,"B","Break"
+"PATCHYPO","C02-Antihypertensives","ATCPTTMT","% of total sales","CZE","Czech Republic","2021","2021",0.7,,
+"PATCHYPO","C02-Antihypertensives","MLLNCUMT","Million of national currency units","FIN","Finland","2010","2010",4.9,,
+"PATCHYPO","C02-Antihypertensives","MLLNCUMT","Million of national currency units","FIN","Finland","2011","2011",5.3,,
+"PATCHYPO","C02-Antihypertensives","MLLNCUMT","Million of national currency units","FIN","Finland","2012","2012",5.4,,
+"PATCHYPO","C02-Antihypertensives","MLLNCUMT","Million of national currency units","FIN","Finland","2013","2013",5.7,,
+"PATCHYPO","C02-Antihypertensives","MLLNCUMT","Million of national currency units","FIN","Finland","2014","2014",6.2,,
+"PATCHYPO","C02-Antihypertensives","MLLNCUMT","Million of national currency units","FIN","Finland","2015","2015",7.1,,
+"PATCHYPO","C02-Antihypertensives","MLLNCUMT","Million of national currency units","FIN","Finland","2016","2016",7.6,,
+"PATCHYPO","C02-Antihypertensives","MLLNCUMT","Million of national currency units","FIN","Finland","2017","2017",6.5,,
+"PATCHYPO","C02-Antihypertensives","MLLNCUMT","Million of national currency units","FIN","Finland","2018","2018",7,,
+"PATCHYPO","C02-Antihypertensives","MLLNCUMT","Million of national currency units","FIN","Finland","2019","2019",7.9,,
+"PATCHYPO","C02-Antihypertensives","MLLNCUMT","Million of national currency units","FIN","Finland","2020","2020",9.1,,
+"PATCHYPO","C02-Antihypertensives","MLLNCUMT","Million of national currency units","FIN","Finland","2021","2021",9.2,,
+"PATCHYPO","C02-Antihypertensives","MTMOTCMT","Million US$ at exchange rate","FIN","Finland","2010","2010",6.5,,
+"PATCHYPO","C02-Antihypertensives","MTMOTCMT","Million US$ at exchange rate","FIN","Finland","2011","2011",7.4,,
+"PATCHYPO","C02-Antihypertensives","MTMOTCMT","Million US$ at exchange rate","FIN","Finland","2012","2012",6.9,,
+"PATCHYPO","C02-Antihypertensives","MTMOTCMT","Million US$ at exchange rate","FIN","Finland","2013","2013",7.6,,
+"PATCHYPO","C02-Antihypertensives","MTMOTCMT","Million US$ at exchange rate","FIN","Finland","2014","2014",8.2,,
+"PATCHYPO","C02-Antihypertensives","MTMOTCMT","Million US$ at exchange rate","FIN","Finland","2015","2015",7.9,,
+"PATCHYPO","C02-Antihypertensives","MTMOTCMT","Million US$ at exchange rate","FIN","Finland","2016","2016",8.4,,
+"PATCHYPO","C02-Antihypertensives","MTMOTCMT","Million US$ at exchange rate","FIN","Finland","2017","2017",7.3,,
+"PATCHYPO","C02-Antihypertensives","MTMOTCMT","Million US$ at exchange rate","FIN","Finland","2018","2018",8.3,,
+"PATCHYPO","C02-Antihypertensives","MTMOTCMT","Million US$ at exchange rate","FIN","Finland","2019","2019",8.8,,
+"PATCHYPO","C02-Antihypertensives","MTMOTCMT","Million US$ at exchange rate","FIN","Finland","2020","2020",10.4,,
+"PATCHYPO","C02-Antihypertensives","MTMOTCMT","Million US$ at exchange rate","FIN","Finland","2021","2021",10.9,,
+"PATCHYPO","C02-Antihypertensives","MTMOPPMT","Million US$, purchasing power parity","FIN","Finland","2010","2010",5.4,,
+"PATCHYPO","C02-Antihypertensives","MTMOPPMT","Million US$, purchasing power parity","FIN","Finland","2011","2011",5.9,,
+"PATCHYPO","C02-Antihypertensives","MTMOPPMT","Million US$, purchasing power parity","FIN","Finland","2012","2012",5.9,,
+"PATCHYPO","C02-Antihypertensives","MTMOPPMT","Million US$, purchasing power parity","FIN","Finland","2013","2013",6.3,,
+"PATCHYPO","C02-Antihypertensives","MTMOPPMT","Million US$, purchasing power parity","FIN","Finland","2014","2014",6.8,,
+"PATCHYPO","C02-Antihypertensives","MTMOPPMT","Million US$, purchasing power parity","FIN","Finland","2015","2015",7.8,,
+"PATCHYPO","C02-Antihypertensives","MTMOPPMT","Million US$, purchasing power parity","FIN","Finland","2016","2016",8.6,,
+"PATCHYPO","C02-Antihypertensives","MTMOPPMT","Million US$, purchasing power parity","FIN","Finland","2017","2017",7.5,,
+"PATCHYPO","C02-Antihypertensives","MTMOPPMT","Million US$, purchasing power parity","FIN","Finland","2018","2018",8.2,,
+"PATCHYPO","C02-Antihypertensives","MTMOPPMT","Million US$, purchasing power parity","FIN","Finland","2019","2019",9.4,,
+"PATCHYPO","C02-Antihypertensives","MTMOPPMT","Million US$, purchasing power parity","FIN","Finland","2020","2020",11.1,,
+"PATCHYPO","C02-Antihypertensives","MTMOPPMT","Million US$, purchasing power parity","FIN","Finland","2021","2021",11.1,,
+"PATCHYPO","C02-Antihypertensives","TCPPERMT","/capita, US$ exchange rate","FIN","Finland","2010","2010",1.2,,
+"PATCHYPO","C02-Antihypertensives","TCPPERMT","/capita, US$ exchange rate","FIN","Finland","2011","2011",1.4,,
+"PATCHYPO","C02-Antihypertensives","TCPPERMT","/capita, US$ exchange rate","FIN","Finland","2012","2012",1.3,,
+"PATCHYPO","C02-Antihypertensives","TCPPERMT","/capita, US$ exchange rate","FIN","Finland","2013","2013",1.4,,
+"PATCHYPO","C02-Antihypertensives","TCPPERMT","/capita, US$ exchange rate","FIN","Finland","2014","2014",1.5,,
+"PATCHYPO","C02-Antihypertensives","TCPPERMT","/capita, US$ exchange rate","FIN","Finland","2015","2015",1.4,,
+"PATCHYPO","C02-Antihypertensives","TCPPERMT","/capita, US$ exchange rate","FIN","Finland","2016","2016",1.5,,
+"PATCHYPO","C02-Antihypertensives","TCPPERMT","/capita, US$ exchange rate","FIN","Finland","2017","2017",1.3,,
+"PATCHYPO","C02-Antihypertensives","TCPPERMT","/capita, US$ exchange rate","FIN","Finland","2018","2018",1.5,,
+"PATCHYPO","C02-Antihypertensives","TCPPERMT","/capita, US$ exchange rate","FIN","Finland","2019","2019",1.6,,
+"PATCHYPO","C02-Antihypertensives","TCPPERMT","/capita, US$ exchange rate","FIN","Finland","2020","2020",1.9,,
+"PATCHYPO","C02-Antihypertensives","TCPPERMT","/capita, US$ exchange rate","FIN","Finland","2021","2021",2,,
+"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2010","2010",1,,
+"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2011","2011",1.1,,
+"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2012","2012",1.1,,
+"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2013","2013",1.2,,
+"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2014","2014",1.3,,
+"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2015","2015",1.4,,
+"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2016","2016",1.6,,
+"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2017","2017",1.4,,
+"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2018","2018",1.5,,
+"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2019","2019",1.7,,
+"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2020","2020",2,,
+"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2021","2021",2,,
+"PATCHYPO","C02-Antihypertensives","ATCPTTMT","% of total sales","FIN","Finland","2010","2010",0.3,,
+"PATCHYPO","C02-Antihypertensives","ATCPTTMT","% of total sales","FIN","Finland","2011","2011",0.3,,
+"PATCHYPO","C02-Antihypertensives","ATCPTTMT","% of total sales","FIN","Finland","2012","2012",0.3,,
+"PATCHYPO","C02-Antihypertensives","ATCPTTMT","% of total sales","FIN","Finland","2013","2013",0.3,,
+"PATCHYPO","C02-Antihypertensives","ATCPTTMT","% of total sales","FIN","Finland","2014","2014",0.3,,
+"PATCHYPO","C02-Antihypertensives","ATCPTTMT","% of total sales","FIN","Finland","2015","2015",0.3,,
+"PATCHYPO","C02-Antihypertensives","ATCPTTMT","% of total sales","FIN","Finland","2016","2016",0.3,,
+"PATCHYPO","C02-Antihypertensives","ATCPTTMT","% of total sales","FIN","Finland","2017","2017",0.3,,
+"PATCHYPO","C02-Antihypertensives","ATCPTTMT","% of total sales","FIN","Finland","2018","2018",0.3,,
+"PATCHYPO","C02-Antihypertensives","ATCPTTMT","% of total sales","FIN","Finland","2019","2019",0.3,,
+"PATCHYPO","C02-Antihypertensives","ATCPTTMT","% of total sales","FIN","Finland","2020","2020",0.3,,
+"PATCHYPO","C02-Antihypertensives","ATCPTTMT","% of total sales","FIN","Finland","2021","2021",0.3,,
+"PATCHYPO","C02-Antihypertensives","MLLNCUMT","Million of national currency units","DEU","Germany","2010","2010",306.7,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","MLLNCUMT","Million of national currency units","DEU","Germany","2011","2011",299.2,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","MLLNCUMT","Million of national currency units","DEU","Germany","2012","2012",310.9,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","MLLNCUMT","Million of national currency units","DEU","Germany","2013","2013",326,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","MLLNCUMT","Million of national currency units","DEU","Germany","2014","2014",356.5,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","MLLNCUMT","Million of national currency units","DEU","Germany","2015","2015",371.6,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","MLLNCUMT","Million of national currency units","DEU","Germany","2016","2016",390.1,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","MLLNCUMT","Million of national currency units","DEU","Germany","2017","2017",391.3,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","MLLNCUMT","Million of national currency units","DEU","Germany","2018","2018",316,"B; D","Break; Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","MLLNCUMT","Million of national currency units","DEU","Germany","2019","2019",323.5,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","MLLNCUMT","Million of national currency units","DEU","Germany","2020","2020",305.5,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","MLLNCUMT","Million of national currency units","DEU","Germany","2021","2021",301.4,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","MTMOTCMT","Million US$ at exchange rate","DEU","Germany","2010","2010",406.6,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","MTMOTCMT","Million US$ at exchange rate","DEU","Germany","2011","2011",416.5,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","MTMOTCMT","Million US$ at exchange rate","DEU","Germany","2012","2012",399.4,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","MTMOTCMT","Million US$ at exchange rate","DEU","Germany","2013","2013",433,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","MTMOTCMT","Million US$ at exchange rate","DEU","Germany","2014","2014",473.6,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","MTMOTCMT","Million US$ at exchange rate","DEU","Germany","2015","2015",412.3,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","MTMOTCMT","Million US$ at exchange rate","DEU","Germany","2016","2016",431.8,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","MTMOTCMT","Million US$ at exchange rate","DEU","Germany","2017","2017",442,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","MTMOTCMT","Million US$ at exchange rate","DEU","Germany","2018","2018",373.2,"B; D","Break; Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","MTMOTCMT","Million US$ at exchange rate","DEU","Germany","2019","2019",362.2,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","MTMOTCMT","Million US$ at exchange rate","DEU","Germany","2020","2020",348.9,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","MTMOTCMT","Million US$ at exchange rate","DEU","Germany","2021","2021",356.5,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","MTMOPPMT","Million US$, purchasing power parity","DEU","Germany","2010","2010",381,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","MTMOPPMT","Million US$, purchasing power parity","DEU","Germany","2011","2011",379.3,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","MTMOPPMT","Million US$, purchasing power parity","DEU","Germany","2012","2012",394.9,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","MTMOPPMT","Million US$, purchasing power parity","DEU","Germany","2013","2013",420.8,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","MTMOPPMT","Million US$, purchasing power parity","DEU","Germany","2014","2014",463.6,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","MTMOPPMT","Million US$, purchasing power parity","DEU","Germany","2015","2015",477.6,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","MTMOPPMT","Million US$, purchasing power parity","DEU","Germany","2016","2016",518.3,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","MTMOPPMT","Million US$, purchasing power parity","DEU","Germany","2017","2017",525.4,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","MTMOPPMT","Million US$, purchasing power parity","DEU","Germany","2018","2018",429.7,"B; D","Break; Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","MTMOPPMT","Million US$, purchasing power parity","DEU","Germany","2019","2019",444.2,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","MTMOPPMT","Million US$, purchasing power parity","DEU","Germany","2020","2020",421.4,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","MTMOPPMT","Million US$, purchasing power parity","DEU","Germany","2021","2021",409.4,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","TCPPERMT","/capita, US$ exchange rate","DEU","Germany","2010","2010",5,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","TCPPERMT","/capita, US$ exchange rate","DEU","Germany","2011","2011",5.2,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","TCPPERMT","/capita, US$ exchange rate","DEU","Germany","2012","2012",5,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","TCPPERMT","/capita, US$ exchange rate","DEU","Germany","2013","2013",5.4,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","TCPPERMT","/capita, US$ exchange rate","DEU","Germany","2014","2014",5.8,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","TCPPERMT","/capita, US$ exchange rate","DEU","Germany","2015","2015",5,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","TCPPERMT","/capita, US$ exchange rate","DEU","Germany","2016","2016",5.2,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","TCPPERMT","/capita, US$ exchange rate","DEU","Germany","2017","2017",5.3,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","TCPPERMT","/capita, US$ exchange rate","DEU","Germany","2018","2018",4.5,"B; D","Break; Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","TCPPERMT","/capita, US$ exchange rate","DEU","Germany","2019","2019",4.4,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","TCPPERMT","/capita, US$ exchange rate","DEU","Germany","2020","2020",4.2,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","TCPPERMT","/capita, US$ exchange rate","DEU","Germany","2021","2021",4.3,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2010","2010",4.7,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2011","2011",4.7,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2012","2012",4.9,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2013","2013",5.2,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2014","2014",5.7,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2015","2015",5.8,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2016","2016",6.3,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2017","2017",6.4,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2018","2018",5.2,"B; D","Break; Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2019","2019",5.3,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2020","2020",5.1,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2021","2021",4.9,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","ATCPTTMT","% of total sales","DEU","Germany","2010","2010",1,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","ATCPTTMT","% of total sales","DEU","Germany","2011","2011",1,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","ATCPTTMT","% of total sales","DEU","Germany","2012","2012",1,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","ATCPTTMT","% of total sales","DEU","Germany","2013","2013",1,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","ATCPTTMT","% of total sales","DEU","Germany","2014","2014",1.1,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","ATCPTTMT","% of total sales","DEU","Germany","2015","2015",1.1,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","ATCPTTMT","% of total sales","DEU","Germany","2016","2016",1.1,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","ATCPTTMT","% of total sales","DEU","Germany","2017","2017",1.1,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","ATCPTTMT","% of total sales","DEU","Germany","2018","2018",0.7,"B; D","Break; Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","ATCPTTMT","% of total sales","DEU","Germany","2019","2019",0.7,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","ATCPTTMT","% of total sales","DEU","Germany","2020","2020",0.6,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","ATCPTTMT","% of total sales","DEU","Germany","2021","2021",0.6,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","MLLNCUMT","Million of national currency units","GRC","Greece","2010","2010",41.5,,
+"PATCHYPO","C02-Antihypertensives","MLLNCUMT","Million of national currency units","GRC","Greece","2011","2011",39.3,,
+"PATCHYPO","C02-Antihypertensives","MLLNCUMT","Million of national currency units","GRC","Greece","2012","2012",32.3,,
+"PATCHYPO","C02-Antihypertensives","MLLNCUMT","Million of national currency units","GRC","Greece","2013","2013",27,,
+"PATCHYPO","C02-Antihypertensives","MLLNCUMT","Million of national currency units","GRC","Greece","2014","2014",25.2,,
+"PATCHYPO","C02-Antihypertensives","MLLNCUMT","Million of national currency units","GRC","Greece","2015","2015",25.1,,
+"PATCHYPO","C02-Antihypertensives","MLLNCUMT","Million of national currency units","GRC","Greece","2016","2016",26,,
+"PATCHYPO","C02-Antihypertensives","MLLNCUMT","Million of national currency units","GRC","Greece","2017","2017",24.9,,
+"PATCHYPO","C02-Antihypertensives","MLLNCUMT","Million of national currency units","GRC","Greece","2018","2018",24.9,,
+"PATCHYPO","C02-Antihypertensives","MLLNCUMT","Million of national currency units","GRC","Greece","2019","2019",25.8,,
+"PATCHYPO","C02-Antihypertensives","MLLNCUMT","Million of national currency units","GRC","Greece","2020","2020",33.5,,
+"PATCHYPO","C02-Antihypertensives","MLLNCUMT","Million of national currency units","GRC","Greece","2021","2021",30.2,,
+"PATCHYPO","C02-Antihypertensives","MLLNCUMT","Million of national currency units","GRC","Greece","2022","2022",23,,
+"PATCHYPO","C02-Antihypertensives","MTMOTCMT","Million US$ at exchange rate","GRC","Greece","2010","2010",55.1,,
+"PATCHYPO","C02-Antihypertensives","MTMOTCMT","Million US$ at exchange rate","GRC","Greece","2011","2011",54.7,,
+"PATCHYPO","C02-Antihypertensives","MTMOTCMT","Million US$ at exchange rate","GRC","Greece","2012","2012",41.5,,
+"PATCHYPO","C02-Antihypertensives","MTMOTCMT","Million US$ at exchange rate","GRC","Greece","2013","2013",35.9,,
+"PATCHYPO","C02-Antihypertensives","MTMOTCMT","Million US$ at exchange rate","GRC","Greece","2014","2014",33.5,,
+"PATCHYPO","C02-Antihypertensives","MTMOTCMT","Million US$ at exchange rate","GRC","Greece","2015","2015",27.9,,
+"PATCHYPO","C02-Antihypertensives","MTMOTCMT","Million US$ at exchange rate","GRC","Greece","2016","2016",28.8,,
+"PATCHYPO","C02-Antihypertensives","MTMOTCMT","Million US$ at exchange rate","GRC","Greece","2017","2017",28.1,,
+"PATCHYPO","C02-Antihypertensives","MTMOTCMT","Million US$ at exchange rate","GRC","Greece","2018","2018",29.4,,
+"PATCHYPO","C02-Antihypertensives","MTMOTCMT","Million US$ at exchange rate","GRC","Greece","2019","2019",28.9,,
+"PATCHYPO","C02-Antihypertensives","MTMOTCMT","Million US$ at exchange rate","GRC","Greece","2020","2020",38.2,,
+"PATCHYPO","C02-Antihypertensives","MTMOTCMT","Million US$ at exchange rate","GRC","Greece","2021","2021",35.7,,
+"PATCHYPO","C02-Antihypertensives","MTMOTCMT","Million US$ at exchange rate","GRC","Greece","2022","2022",24.2,,
+"PATCHYPO","C02-Antihypertensives","MTMOPPMT","Million US$, purchasing power parity","GRC","Greece","2010","2010",57.5,,
+"PATCHYPO","C02-Antihypertensives","MTMOPPMT","Million US$, purchasing power parity","GRC","Greece","2011","2011",55.1,,
+"PATCHYPO","C02-Antihypertensives","MTMOPPMT","Million US$, purchasing power parity","GRC","Greece","2012","2012",47.2,,
+"PATCHYPO","C02-Antihypertensives","MTMOPPMT","Million US$, purchasing power parity","GRC","Greece","2013","2013",42.8,,
+"PATCHYPO","C02-Antihypertensives","MTMOPPMT","Million US$, purchasing power parity","GRC","Greece","2014","2014",41.2,,
+"PATCHYPO","C02-Antihypertensives","MTMOPPMT","Million US$, purchasing power parity","GRC","Greece","2015","2015",41.3,,
+"PATCHYPO","C02-Antihypertensives","MTMOPPMT","Million US$, purchasing power parity","GRC","Greece","2016","2016",44.2,,
+"PATCHYPO","C02-Antihypertensives","MTMOPPMT","Million US$, purchasing power parity","GRC","Greece","2017","2017",43.2,,
+"PATCHYPO","C02-Antihypertensives","MTMOPPMT","Million US$, purchasing power parity","GRC","Greece","2018","2018",44,,
+"PATCHYPO","C02-Antihypertensives","MTMOPPMT","Million US$, purchasing power parity","GRC","Greece","2019","2019",47,,
+"PATCHYPO","C02-Antihypertensives","MTMOPPMT","Million US$, purchasing power parity","GRC","Greece","2020","2020",61.5,,
+"PATCHYPO","C02-Antihypertensives","MTMOPPMT","Million US$, purchasing power parity","GRC","Greece","2021","2021",55.3,,
+"PATCHYPO","C02-Antihypertensives","MTMOPPMT","Million US$, purchasing power parity","GRC","Greece","2022","2022",43.5,,
+"PATCHYPO","C02-Antihypertensives","TCPPERMT","/capita, US$ exchange rate","GRC","Greece","2010","2010",5,,
+"PATCHYPO","C02-Antihypertensives","TCPPERMT","/capita, US$ exchange rate","GRC","Greece","2011","2011",4.9,,
+"PATCHYPO","C02-Antihypertensives","TCPPERMT","/capita, US$ exchange rate","GRC","Greece","2012","2012",3.8,,
+"PATCHYPO","C02-Antihypertensives","TCPPERMT","/capita, US$ exchange rate","GRC","Greece","2013","2013",3.3,,
+"PATCHYPO","C02-Antihypertensives","TCPPERMT","/capita, US$ exchange rate","GRC","Greece","2014","2014",3.1,,
+"PATCHYPO","C02-Antihypertensives","TCPPERMT","/capita, US$ exchange rate","GRC","Greece","2015","2015",2.6,,
+"PATCHYPO","C02-Antihypertensives","TCPPERMT","/capita, US$ exchange rate","GRC","Greece","2016","2016",2.7,,
+"PATCHYPO","C02-Antihypertensives","TCPPERMT","/capita, US$ exchange rate","GRC","Greece","2017","2017",2.6,,
+"PATCHYPO","C02-Antihypertensives","TCPPERMT","/capita, US$ exchange rate","GRC","Greece","2018","2018",2.7,,
+"PATCHYPO","C02-Antihypertensives","TCPPERMT","/capita, US$ exchange rate","GRC","Greece","2019","2019",2.7,,
+"PATCHYPO","C02-Antihypertensives","TCPPERMT","/capita, US$ exchange rate","GRC","Greece","2020","2020",3.6,,
+"PATCHYPO","C02-Antihypertensives","TCPPERMT","/capita, US$ exchange rate","GRC","Greece","2021","2021",3.4,,
+"PATCHYPO","C02-Antihypertensives","TCPPERMT","/capita, US$ exchange rate","GRC","Greece","2022","2022",2.3,,
+"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2010","2010",5.2,,
+"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2011","2011",5,,
+"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2012","2012",4.3,,
+"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2013","2013",3.9,,
+"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2014","2014",3.8,,
+"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2015","2015",3.8,,
+"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2016","2016",4.1,,
+"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2017","2017",4,,
+"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2018","2018",4.1,,
+"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2019","2019",4.4,,
+"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2020","2020",5.7,,
+"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2021","2021",5.2,,
+"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2022","2022",4.2,,
+"PATCHYPO","C02-Antihypertensives","MLLNCUMT","Million of national currency units","HUN","Hungary","2010","2010",7338.5,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","MLLNCUMT","Million of national currency units","HUN","Hungary","2011","2011",7703.6,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","MLLNCUMT","Million of national currency units","HUN","Hungary","2012","2012",7380.4,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","MLLNCUMT","Million of national currency units","HUN","Hungary","2013","2013",7583.8,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","MLLNCUMT","Million of national currency units","HUN","Hungary","2014","2014",8102.4,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","MLLNCUMT","Million of national currency units","HUN","Hungary","2015","2015",8633.8,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","MLLNCUMT","Million of national currency units","HUN","Hungary","2016","2016",9311.8,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","MLLNCUMT","Million of national currency units","HUN","Hungary","2017","2017",9804.7,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","MLLNCUMT","Million of national currency units","HUN","Hungary","2018","2018",9734.8,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","MLLNCUMT","Million of national currency units","HUN","Hungary","2019","2019",10135.7,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","MLLNCUMT","Million of national currency units","HUN","Hungary","2020","2020",10964.8,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","MLLNCUMT","Million of national currency units","HUN","Hungary","2021","2021",10709.3,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","MLLNCUMT","Million of national currency units","HUN","Hungary","2022","2022",11191.1,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","MTMOTCMT","Million US$ at exchange rate","HUN","Hungary","2010","2010",35.3,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","MTMOTCMT","Million US$ at exchange rate","HUN","Hungary","2011","2011",38.3,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","MTMOTCMT","Million US$ at exchange rate","HUN","Hungary","2012","2012",32.8,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","MTMOTCMT","Million US$ at exchange rate","HUN","Hungary","2013","2013",33.9,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","MTMOTCMT","Million US$ at exchange rate","HUN","Hungary","2014","2014",34.8,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","MTMOTCMT","Million US$ at exchange rate","HUN","Hungary","2015","2015",30.9,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","MTMOTCMT","Million US$ at exchange rate","HUN","Hungary","2016","2016",33.1,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","MTMOTCMT","Million US$ at exchange rate","HUN","Hungary","2017","2017",35.7,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","MTMOTCMT","Million US$ at exchange rate","HUN","Hungary","2018","2018",36,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","MTMOTCMT","Million US$ at exchange rate","HUN","Hungary","2019","2019",34.9,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","MTMOTCMT","Million US$ at exchange rate","HUN","Hungary","2020","2020",35.6,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","MTMOTCMT","Million US$ at exchange rate","HUN","Hungary","2021","2021",35.3,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","MTMOTCMT","Million US$ at exchange rate","HUN","Hungary","2022","2022",30,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","MTMOPPMT","Million US$, purchasing power parity","HUN","Hungary","2010","2010",58,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","MTMOPPMT","Million US$, purchasing power parity","HUN","Hungary","2011","2011",62,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","MTMOPPMT","Million US$, purchasing power parity","HUN","Hungary","2012","2012",58.8,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","MTMOPPMT","Million US$, purchasing power parity","HUN","Hungary","2013","2013",60.7,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","MTMOPPMT","Million US$, purchasing power parity","HUN","Hungary","2014","2014",62.6,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","MTMOPPMT","Million US$, purchasing power parity","HUN","Hungary","2015","2015",65.1,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","MTMOPPMT","Million US$, purchasing power parity","HUN","Hungary","2016","2016",70.5,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","MTMOPPMT","Million US$, purchasing power parity","HUN","Hungary","2017","2017",72.1,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","MTMOPPMT","Million US$, purchasing power parity","HUN","Hungary","2018","2018",70,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","MTMOPPMT","Million US$, purchasing power parity","HUN","Hungary","2019","2019",72,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","MTMOPPMT","Million US$, purchasing power parity","HUN","Hungary","2020","2020",75.4,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","MTMOPPMT","Million US$, purchasing power parity","HUN","Hungary","2021","2021",69.2,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","MTMOPPMT","Million US$, purchasing power parity","HUN","Hungary","2022","2022",69.4,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","TCPPERMT","/capita, US$ exchange rate","HUN","Hungary","2010","2010",3.5,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","TCPPERMT","/capita, US$ exchange rate","HUN","Hungary","2011","2011",3.8,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","TCPPERMT","/capita, US$ exchange rate","HUN","Hungary","2012","2012",3.3,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","TCPPERMT","/capita, US$ exchange rate","HUN","Hungary","2013","2013",3.4,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","TCPPERMT","/capita, US$ exchange rate","HUN","Hungary","2014","2014",3.5,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","TCPPERMT","/capita, US$ exchange rate","HUN","Hungary","2015","2015",3.1,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","TCPPERMT","/capita, US$ exchange rate","HUN","Hungary","2016","2016",3.4,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","TCPPERMT","/capita, US$ exchange rate","HUN","Hungary","2017","2017",3.7,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","TCPPERMT","/capita, US$ exchange rate","HUN","Hungary","2018","2018",3.7,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","TCPPERMT","/capita, US$ exchange rate","HUN","Hungary","2019","2019",3.6,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","TCPPERMT","/capita, US$ exchange rate","HUN","Hungary","2020","2020",3.7,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","TCPPERMT","/capita, US$ exchange rate","HUN","Hungary","2021","2021",3.6,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","TCPPERMT","/capita, US$ exchange rate","HUN","Hungary","2022","2022",3.1,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2010","2010",5.8,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2011","2011",6.2,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2012","2012",5.9,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2013","2013",6.1,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2014","2014",6.3,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2015","2015",6.6,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2016","2016",7.2,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2017","2017",7.4,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2018","2018",7.2,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2019","2019",7.4,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2020","2020",7.7,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2021","2021",7.1,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2022","2022",7.2,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","ATCPTTMT","% of total sales","HUN","Hungary","2010","2010",1.5,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","ATCPTTMT","% of total sales","HUN","Hungary","2011","2011",1.5,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","ATCPTTMT","% of total sales","HUN","Hungary","2012","2012",1.7,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","ATCPTTMT","% of total sales","HUN","Hungary","2013","2013",1.8,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","ATCPTTMT","% of total sales","HUN","Hungary","2014","2014",1.8,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","ATCPTTMT","% of total sales","HUN","Hungary","2015","2015",1.9,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","ATCPTTMT","% of total sales","HUN","Hungary","2016","2016",1.9,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","ATCPTTMT","% of total sales","HUN","Hungary","2017","2017",2,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","ATCPTTMT","% of total sales","HUN","Hungary","2018","2018",1.9,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","ATCPTTMT","% of total sales","HUN","Hungary","2019","2019",1.9,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","ATCPTTMT","% of total sales","HUN","Hungary","2020","2020",2,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","ATCPTTMT","% of total sales","HUN","Hungary","2021","2021",1.9,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","ATCPTTMT","% of total sales","HUN","Hungary","2022","2022",1.9,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","MLLNCUMT","Million of national currency units","ISL","Iceland","2010","2010",37.6,,
+"PATCHYPO","C02-Antihypertensives","MLLNCUMT","Million of national currency units","ISL","Iceland","2011","2011",48.9,,
+"PATCHYPO","C02-Antihypertensives","MLLNCUMT","Million of national currency units","ISL","Iceland","2012","2012",57.7,,
+"PATCHYPO","C02-Antihypertensives","MLLNCUMT","Million of national currency units","ISL","Iceland","2013","2013",50.8,,
+"PATCHYPO","C02-Antihypertensives","MLLNCUMT","Million of national currency units","ISL","Iceland","2014","2014",45.3,,
+"PATCHYPO","C02-Antihypertensives","MLLNCUMT","Million of national currency units","ISL","Iceland","2015","2015",50.5,,
+"PATCHYPO","C02-Antihypertensives","MLLNCUMT","Million of national currency units","ISL","Iceland","2016","2016",49,,
+"PATCHYPO","C02-Antihypertensives","MLLNCUMT","Million of national currency units","ISL","Iceland","2017","2017",51,,
+"PATCHYPO","C02-Antihypertensives","MLLNCUMT","Million of national currency units","ISL","Iceland","2018","2018",59.5,,
+"PATCHYPO","C02-Antihypertensives","MLLNCUMT","Million of national currency units","ISL","Iceland","2019","2019",76,,
+"PATCHYPO","C02-Antihypertensives","MLLNCUMT","Million of national currency units","ISL","Iceland","2020","2020",83.8,,
+"PATCHYPO","C02-Antihypertensives","MLLNCUMT","Million of national currency units","ISL","Iceland","2021","2021",103.7,,
+"PATCHYPO","C02-Antihypertensives","MTMOTCMT","Million US$ at exchange rate","ISL","Iceland","2010","2010",0.3,,
+"PATCHYPO","C02-Antihypertensives","MTMOTCMT","Million US$ at exchange rate","ISL","Iceland","2011","2011",0.4,,
+"PATCHYPO","C02-Antihypertensives","MTMOTCMT","Million US$ at exchange rate","ISL","Iceland","2012","2012",0.5,,
+"PATCHYPO","C02-Antihypertensives","MTMOTCMT","Million US$ at exchange rate","ISL","Iceland","2013","2013",0.4,,
+"PATCHYPO","C02-Antihypertensives","MTMOTCMT","Million US$ at exchange rate","ISL","Iceland","2014","2014",0.4,,
+"PATCHYPO","C02-Antihypertensives","MTMOTCMT","Million US$ at exchange rate","ISL","Iceland","2015","2015",0.4,,
+"PATCHYPO","C02-Antihypertensives","MTMOTCMT","Million US$ at exchange rate","ISL","Iceland","2016","2016",0.4,,
+"PATCHYPO","C02-Antihypertensives","MTMOTCMT","Million US$ at exchange rate","ISL","Iceland","2017","2017",0.5,,
+"PATCHYPO","C02-Antihypertensives","MTMOTCMT","Million US$ at exchange rate","ISL","Iceland","2018","2018",0.5,,
+"PATCHYPO","C02-Antihypertensives","MTMOTCMT","Million US$ at exchange rate","ISL","Iceland","2019","2019",0.6,,
+"PATCHYPO","C02-Antihypertensives","MTMOTCMT","Million US$ at exchange rate","ISL","Iceland","2020","2020",0.6,,
+"PATCHYPO","C02-Antihypertensives","MTMOTCMT","Million US$ at exchange rate","ISL","Iceland","2021","2021",0.8,,
+"PATCHYPO","C02-Antihypertensives","MTMOPPMT","Million US$, purchasing power parity","ISL","Iceland","2010","2010",0.3,,
+"PATCHYPO","C02-Antihypertensives","MTMOPPMT","Million US$, purchasing power parity","ISL","Iceland","2011","2011",0.4,,
+"PATCHYPO","C02-Antihypertensives","MTMOPPMT","Million US$, purchasing power parity","ISL","Iceland","2012","2012",0.4,,
+"PATCHYPO","C02-Antihypertensives","MTMOPPMT","Million US$, purchasing power parity","ISL","Iceland","2013","2013",0.4,,
+"PATCHYPO","C02-Antihypertensives","MTMOPPMT","Million US$, purchasing power parity","ISL","Iceland","2014","2014",0.3,,
+"PATCHYPO","C02-Antihypertensives","MTMOPPMT","Million US$, purchasing power parity","ISL","Iceland","2015","2015",0.4,,
+"PATCHYPO","C02-Antihypertensives","MTMOPPMT","Million US$, purchasing power parity","ISL","Iceland","2016","2016",0.3,,
+"PATCHYPO","C02-Antihypertensives","MTMOPPMT","Million US$, purchasing power parity","ISL","Iceland","2017","2017",0.4,,
+"PATCHYPO","C02-Antihypertensives","MTMOPPMT","Million US$, purchasing power parity","ISL","Iceland","2018","2018",0.4,,
+"PATCHYPO","C02-Antihypertensives","MTMOPPMT","Million US$, purchasing power parity","ISL","Iceland","2019","2019",0.5,,
+"PATCHYPO","C02-Antihypertensives","MTMOPPMT","Million US$, purchasing power parity","ISL","Iceland","2020","2020",0.6,,
+"PATCHYPO","C02-Antihypertensives","MTMOPPMT","Million US$, purchasing power parity","ISL","Iceland","2021","2021",0.7,,
+"PATCHYPO","C02-Antihypertensives","TCPPERMT","/capita, US$ exchange rate","ISL","Iceland","2010","2010",1,,
+"PATCHYPO","C02-Antihypertensives","TCPPERMT","/capita, US$ exchange rate","ISL","Iceland","2011","2011",1.3,,
+"PATCHYPO","C02-Antihypertensives","TCPPERMT","/capita, US$ exchange rate","ISL","Iceland","2012","2012",1.4,,
+"PATCHYPO","C02-Antihypertensives","TCPPERMT","/capita, US$ exchange rate","ISL","Iceland","2013","2013",1.3,,
+"PATCHYPO","C02-Antihypertensives","TCPPERMT","/capita, US$ exchange rate","ISL","Iceland","2014","2014",1.2,,
+"PATCHYPO","C02-Antihypertensives","TCPPERMT","/capita, US$ exchange rate","ISL","Iceland","2015","2015",1.2,,
+"PATCHYPO","C02-Antihypertensives","TCPPERMT","/capita, US$ exchange rate","ISL","Iceland","2016","2016",1.2,,
+"PATCHYPO","C02-Antihypertensives","TCPPERMT","/capita, US$ exchange rate","ISL","Iceland","2017","2017",1.4,,
+"PATCHYPO","C02-Antihypertensives","TCPPERMT","/capita, US$ exchange rate","ISL","Iceland","2018","2018",1.6,,
+"PATCHYPO","C02-Antihypertensives","TCPPERMT","/capita, US$ exchange rate","ISL","Iceland","2019","2019",1.7,,
+"PATCHYPO","C02-Antihypertensives","TCPPERMT","/capita, US$ exchange rate","ISL","Iceland","2020","2020",1.7,,
+"PATCHYPO","C02-Antihypertensives","TCPPERMT","/capita, US$ exchange rate","ISL","Iceland","2021","2021",2.2,,
+"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2010","2010",0.9,,
+"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2011","2011",1.1,,
+"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2012","2012",1.3,,
+"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2013","2013",1.1,,
+"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2014","2014",1,,
+"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2015","2015",1.1,,
+"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2016","2016",1,,
+"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2017","2017",1.1,,
+"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2018","2018",1.2,,
+"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2019","2019",1.5,,
+"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2020","2020",1.6,,
+"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2021","2021",1.9,,
+"PATCHYPO","C02-Antihypertensives","ATCPTTMT","% of total sales","ISL","Iceland","2010","2010",0.2,,
+"PATCHYPO","C02-Antihypertensives","ATCPTTMT","% of total sales","ISL","Iceland","2011","2011",0.2,,
+"PATCHYPO","C02-Antihypertensives","ATCPTTMT","% of total sales","ISL","Iceland","2012","2012",0.2,,
+"PATCHYPO","C02-Antihypertensives","ATCPTTMT","% of total sales","ISL","Iceland","2013","2013",0.2,,
+"PATCHYPO","C02-Antihypertensives","ATCPTTMT","% of total sales","ISL","Iceland","2014","2014",0.2,,
+"PATCHYPO","C02-Antihypertensives","ATCPTTMT","% of total sales","ISL","Iceland","2015","2015",0.2,,
+"PATCHYPO","C02-Antihypertensives","ATCPTTMT","% of total sales","ISL","Iceland","2016","2016",0.2,,
+"PATCHYPO","C02-Antihypertensives","ATCPTTMT","% of total sales","ISL","Iceland","2017","2017",0.2,,
+"PATCHYPO","C02-Antihypertensives","ATCPTTMT","% of total sales","ISL","Iceland","2018","2018",0.2,,
+"PATCHYPO","C02-Antihypertensives","ATCPTTMT","% of total sales","ISL","Iceland","2019","2019",0.2,,
+"PATCHYPO","C02-Antihypertensives","ATCPTTMT","% of total sales","ISL","Iceland","2020","2020",0.2,,
+"PATCHYPO","C02-Antihypertensives","ATCPTTMT","% of total sales","ISL","Iceland","2021","2021",0.2,,
+"PATCHYPO","C02-Antihypertensives","MLLNCUMT","Million of national currency units","IRL","Ireland","2010","2010",21.1,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","MLLNCUMT","Million of national currency units","IRL","Ireland","2011","2011",21.4,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","MLLNCUMT","Million of national currency units","IRL","Ireland","2012","2012",21.1,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","MLLNCUMT","Million of national currency units","IRL","Ireland","2013","2013",16.9,"B; D","Break; Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","MLLNCUMT","Million of national currency units","IRL","Ireland","2014","2014",16.6,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","MLLNCUMT","Million of national currency units","IRL","Ireland","2015","2015",17.2,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","MLLNCUMT","Million of national currency units","IRL","Ireland","2016","2016",18.3,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","MLLNCUMT","Million of national currency units","IRL","Ireland","2017","2017",17.8,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","MLLNCUMT","Million of national currency units","IRL","Ireland","2018","2018",17.2,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","MLLNCUMT","Million of national currency units","IRL","Ireland","2019","2019",17.2,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","MLLNCUMT","Million of national currency units","IRL","Ireland","2020","2020",17.8,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","MLLNCUMT","Million of national currency units","IRL","Ireland","2021","2021",17.9,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","MTMOTCMT","Million US$ at exchange rate","IRL","Ireland","2010","2010",28,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","MTMOTCMT","Million US$ at exchange rate","IRL","Ireland","2011","2011",29.8,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","MTMOTCMT","Million US$ at exchange rate","IRL","Ireland","2012","2012",27.1,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","MTMOTCMT","Million US$ at exchange rate","IRL","Ireland","2013","2013",22.4,"B; D","Break; Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","MTMOTCMT","Million US$ at exchange rate","IRL","Ireland","2014","2014",22,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","MTMOTCMT","Million US$ at exchange rate","IRL","Ireland","2015","2015",19.1,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","MTMOTCMT","Million US$ at exchange rate","IRL","Ireland","2016","2016",20.3,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","MTMOTCMT","Million US$ at exchange rate","IRL","Ireland","2017","2017",20.1,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","MTMOTCMT","Million US$ at exchange rate","IRL","Ireland","2018","2018",20.4,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","MTMOTCMT","Million US$ at exchange rate","IRL","Ireland","2019","2019",19.2,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","MTMOTCMT","Million US$ at exchange rate","IRL","Ireland","2020","2020",20.3,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","MTMOTCMT","Million US$ at exchange rate","IRL","Ireland","2021","2021",21.2,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","MTMOPPMT","Million US$, purchasing power parity","IRL","Ireland","2010","2010",24.8,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","MTMOPPMT","Million US$, purchasing power parity","IRL","Ireland","2011","2011",25.7,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","MTMOPPMT","Million US$, purchasing power parity","IRL","Ireland","2012","2012",25.7,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","MTMOPPMT","Million US$, purchasing power parity","IRL","Ireland","2013","2013",20.8,"B; D","Break; Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","MTMOPPMT","Million US$, purchasing power parity","IRL","Ireland","2014","2014",20.2,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","MTMOPPMT","Million US$, purchasing power parity","IRL","Ireland","2015","2015",21.2,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","MTMOPPMT","Million US$, purchasing power parity","IRL","Ireland","2016","2016",23.1,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","MTMOPPMT","Million US$, purchasing power parity","IRL","Ireland","2017","2017",22.4,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","MTMOPPMT","Million US$, purchasing power parity","IRL","Ireland","2018","2018",21.8,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","MTMOPPMT","Million US$, purchasing power parity","IRL","Ireland","2019","2019",21.3,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","MTMOPPMT","Million US$, purchasing power parity","IRL","Ireland","2020","2020",22.4,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","MTMOPPMT","Million US$, purchasing power parity","IRL","Ireland","2021","2021",22.6,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","TCPPERMT","/capita, US$ exchange rate","IRL","Ireland","2010","2010",6.1,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","TCPPERMT","/capita, US$ exchange rate","IRL","Ireland","2011","2011",6.5,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","TCPPERMT","/capita, US$ exchange rate","IRL","Ireland","2012","2012",5.9,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","TCPPERMT","/capita, US$ exchange rate","IRL","Ireland","2013","2013",4.8,"B; D","Break; Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","TCPPERMT","/capita, US$ exchange rate","IRL","Ireland","2014","2014",4.7,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","TCPPERMT","/capita, US$ exchange rate","IRL","Ireland","2015","2015",4.1,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","TCPPERMT","/capita, US$ exchange rate","IRL","Ireland","2016","2016",4.3,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","TCPPERMT","/capita, US$ exchange rate","IRL","Ireland","2017","2017",4.2,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","TCPPERMT","/capita, US$ exchange rate","IRL","Ireland","2018","2018",4.2,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","TCPPERMT","/capita, US$ exchange rate","IRL","Ireland","2019","2019",3.9,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","TCPPERMT","/capita, US$ exchange rate","IRL","Ireland","2020","2020",4.1,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","TCPPERMT","/capita, US$ exchange rate","IRL","Ireland","2021","2021",4.2,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2010","2010",5.4,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2011","2011",5.6,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2012","2012",5.6,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2013","2013",4.5,"B; D","Break; Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2014","2014",4.3,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2015","2015",4.5,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2016","2016",4.9,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2017","2017",4.7,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2018","2018",4.5,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2019","2019",4.3,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2020","2020",4.5,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2021","2021",4.5,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","ATCPTTMT","% of total sales","IRL","Ireland","2010","2010",1,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","ATCPTTMT","% of total sales","IRL","Ireland","2011","2011",1.1,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","ATCPTTMT","% of total sales","IRL","Ireland","2012","2012",1,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","ATCPTTMT","% of total sales","IRL","Ireland","2013","2013",0.9,"B; D","Break; Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","ATCPTTMT","% of total sales","IRL","Ireland","2014","2014",0.9,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","ATCPTTMT","% of total sales","IRL","Ireland","2015","2015",0.9,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","ATCPTTMT","% of total sales","IRL","Ireland","2016","2016",0.9,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","ATCPTTMT","% of total sales","IRL","Ireland","2017","2017",0.8,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","ATCPTTMT","% of total sales","IRL","Ireland","2018","2018",0.8,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","ATCPTTMT","% of total sales","IRL","Ireland","2019","2019",0.7,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","ATCPTTMT","% of total sales","IRL","Ireland","2020","2020",0.7,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","ATCPTTMT","% of total sales","IRL","Ireland","2021","2021",0.7,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","MLLNCUMT","Million of national currency units","ITA","Italy","2011","2011",197.3,,
+"PATCHYPO","C02-Antihypertensives","MLLNCUMT","Million of national currency units","ITA","Italy","2012","2012",194.5,,
+"PATCHYPO","C02-Antihypertensives","MLLNCUMT","Million of national currency units","ITA","Italy","2013","2013",189.3,,
+"PATCHYPO","C02-Antihypertensives","MLLNCUMT","Million of national currency units","ITA","Italy","2014","2014",197.8,,
+"PATCHYPO","C02-Antihypertensives","MLLNCUMT","Million of national currency units","ITA","Italy","2015","2015",224.1,,
+"PATCHYPO","C02-Antihypertensives","MLLNCUMT","Million of national currency units","ITA","Italy","2016","2016",227.5,,
+"PATCHYPO","C02-Antihypertensives","MLLNCUMT","Million of national currency units","ITA","Italy","2017","2017",221.7,,
+"PATCHYPO","C02-Antihypertensives","MLLNCUMT","Million of national currency units","ITA","Italy","2018","2018",177.7,,
+"PATCHYPO","C02-Antihypertensives","MLLNCUMT","Million of national currency units","ITA","Italy","2019","2019",175,,
+"PATCHYPO","C02-Antihypertensives","MLLNCUMT","Million of national currency units","ITA","Italy","2020","2020",177.1,,
+"PATCHYPO","C02-Antihypertensives","MLLNCUMT","Million of national currency units","ITA","Italy","2021","2021",165,,
+"PATCHYPO","C02-Antihypertensives","MLLNCUMT","Million of national currency units","ITA","Italy","2022","2022",166.7,"E","Estimated value"
+"PATCHYPO","C02-Antihypertensives","MTMOTCMT","Million US$ at exchange rate","ITA","Italy","2011","2011",274.6,,
+"PATCHYPO","C02-Antihypertensives","MTMOTCMT","Million US$ at exchange rate","ITA","Italy","2012","2012",249.9,,
+"PATCHYPO","C02-Antihypertensives","MTMOTCMT","Million US$ at exchange rate","ITA","Italy","2013","2013",251.4,,
+"PATCHYPO","C02-Antihypertensives","MTMOTCMT","Million US$ at exchange rate","ITA","Italy","2014","2014",262.8,,
+"PATCHYPO","C02-Antihypertensives","MTMOTCMT","Million US$ at exchange rate","ITA","Italy","2015","2015",248.6,,
+"PATCHYPO","C02-Antihypertensives","MTMOTCMT","Million US$ at exchange rate","ITA","Italy","2016","2016",251.8,,
+"PATCHYPO","C02-Antihypertensives","MTMOTCMT","Million US$ at exchange rate","ITA","Italy","2017","2017",250.4,,
+"PATCHYPO","C02-Antihypertensives","MTMOTCMT","Million US$ at exchange rate","ITA","Italy","2018","2018",209.9,,
+"PATCHYPO","C02-Antihypertensives","MTMOTCMT","Million US$ at exchange rate","ITA","Italy","2019","2019",195.9,,
+"PATCHYPO","C02-Antihypertensives","MTMOTCMT","Million US$ at exchange rate","ITA","Italy","2020","2020",202.3,,
+"PATCHYPO","C02-Antihypertensives","MTMOTCMT","Million US$ at exchange rate","ITA","Italy","2021","2021",195.2,,
+"PATCHYPO","C02-Antihypertensives","MTMOTCMT","Million US$ at exchange rate","ITA","Italy","2022","2022",175.6,"E","Estimated value"
+"PATCHYPO","C02-Antihypertensives","MTMOPPMT","Million US$, purchasing power parity","ITA","Italy","2011","2011",260.1,,
+"PATCHYPO","C02-Antihypertensives","MTMOPPMT","Million US$, purchasing power parity","ITA","Italy","2012","2012",260.2,,
+"PATCHYPO","C02-Antihypertensives","MTMOPPMT","Million US$, purchasing power parity","ITA","Italy","2013","2013",256.7,,
+"PATCHYPO","C02-Antihypertensives","MTMOPPMT","Million US$, purchasing power parity","ITA","Italy","2014","2014",267.4,,
+"PATCHYPO","C02-Antihypertensives","MTMOPPMT","Million US$, purchasing power parity","ITA","Italy","2015","2015",303.3,,
+"PATCHYPO","C02-Antihypertensives","MTMOPPMT","Million US$, purchasing power parity","ITA","Italy","2016","2016",324.7,,
+"PATCHYPO","C02-Antihypertensives","MTMOPPMT","Million US$, purchasing power parity","ITA","Italy","2017","2017",321.3,,
+"PATCHYPO","C02-Antihypertensives","MTMOPPMT","Million US$, purchasing power parity","ITA","Italy","2018","2018",260.9,,
+"PATCHYPO","C02-Antihypertensives","MTMOPPMT","Million US$, purchasing power parity","ITA","Italy","2019","2019",266.5,,
+"PATCHYPO","C02-Antihypertensives","MTMOPPMT","Million US$, purchasing power parity","ITA","Italy","2020","2020",273.5,,
+"PATCHYPO","C02-Antihypertensives","MTMOPPMT","Million US$, purchasing power parity","ITA","Italy","2021","2021",254.9,,
+"PATCHYPO","C02-Antihypertensives","MTMOPPMT","Million US$, purchasing power parity","ITA","Italy","2022","2022",270.1,"E","Estimated value"
+"PATCHYPO","C02-Antihypertensives","TCPPERMT","/capita, US$ exchange rate","ITA","Italy","2011","2011",4.6,,
+"PATCHYPO","C02-Antihypertensives","TCPPERMT","/capita, US$ exchange rate","ITA","Italy","2012","2012",4.2,,
+"PATCHYPO","C02-Antihypertensives","TCPPERMT","/capita, US$ exchange rate","ITA","Italy","2013","2013",4.2,,
+"PATCHYPO","C02-Antihypertensives","TCPPERMT","/capita, US$ exchange rate","ITA","Italy","2014","2014",4.3,,
+"PATCHYPO","C02-Antihypertensives","TCPPERMT","/capita, US$ exchange rate","ITA","Italy","2015","2015",4.1,,
+"PATCHYPO","C02-Antihypertensives","TCPPERMT","/capita, US$ exchange rate","ITA","Italy","2016","2016",4.2,,
+"PATCHYPO","C02-Antihypertensives","TCPPERMT","/capita, US$ exchange rate","ITA","Italy","2017","2017",4.1,,
+"PATCHYPO","C02-Antihypertensives","TCPPERMT","/capita, US$ exchange rate","ITA","Italy","2018","2018",3.5,,
+"PATCHYPO","C02-Antihypertensives","TCPPERMT","/capita, US$ exchange rate","ITA","Italy","2019","2019",3.3,,
+"PATCHYPO","C02-Antihypertensives","TCPPERMT","/capita, US$ exchange rate","ITA","Italy","2020","2020",3.4,,
+"PATCHYPO","C02-Antihypertensives","TCPPERMT","/capita, US$ exchange rate","ITA","Italy","2021","2021",3.3,,
+"PATCHYPO","C02-Antihypertensives","TCPPERMT","/capita, US$ exchange rate","ITA","Italy","2022","2022",3,"E","Estimated value"
+"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2011","2011",4.4,,
+"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2012","2012",4.4,,
+"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2013","2013",4.3,,
+"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2014","2014",4.4,,
+"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2015","2015",5,,
+"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2016","2016",5.4,,
+"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2017","2017",5.3,,
+"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2018","2018",4.3,,
+"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2019","2019",4.5,,
+"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2020","2020",4.6,,
+"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2021","2021",4.3,,
+"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2022","2022",4.6,"E","Estimated value"
+"PATCHYPO","C02-Antihypertensives","ATCPTTMT","% of total sales","ITA","Italy","2011","2011",1,,
+"PATCHYPO","C02-Antihypertensives","ATCPTTMT","% of total sales","ITA","Italy","2012","2012",1,,
+"PATCHYPO","C02-Antihypertensives","ATCPTTMT","% of total sales","ITA","Italy","2013","2013",1,,
+"PATCHYPO","C02-Antihypertensives","ATCPTTMT","% of total sales","ITA","Italy","2014","2014",1,,
+"PATCHYPO","C02-Antihypertensives","ATCPTTMT","% of total sales","ITA","Italy","2015","2015",1,,
+"PATCHYPO","C02-Antihypertensives","ATCPTTMT","% of total sales","ITA","Italy","2016","2016",1,,
+"PATCHYPO","C02-Antihypertensives","ATCPTTMT","% of total sales","ITA","Italy","2017","2017",1,,
+"PATCHYPO","C02-Antihypertensives","ATCPTTMT","% of total sales","ITA","Italy","2018","2018",0.8,,
+"PATCHYPO","C02-Antihypertensives","ATCPTTMT","% of total sales","ITA","Italy","2019","2019",0.8,,
+"PATCHYPO","C02-Antihypertensives","ATCPTTMT","% of total sales","ITA","Italy","2020","2020",0.8,,
+"PATCHYPO","C02-Antihypertensives","ATCPTTMT","% of total sales","ITA","Italy","2021","2021",0.7,,
+"PATCHYPO","C02-Antihypertensives","ATCPTTMT","% of total sales","ITA","Italy","2022","2022",0.7,"E","Estimated value"
+"PATCHYPO","C02-Antihypertensives","MLLNCUMT","Million of national currency units","KOR","Korea","2010","2010",35631,,
+"PATCHYPO","C02-Antihypertensives","MLLNCUMT","Million of national currency units","KOR","Korea","2011","2011",36901.8,"B","Break"
+"PATCHYPO","C02-Antihypertensives","MLLNCUMT","Million of national currency units","KOR","Korea","2012","2012",33694.2,,
+"PATCHYPO","C02-Antihypertensives","MLLNCUMT","Million of national currency units","KOR","Korea","2013","2013",33695.8,,
+"PATCHYPO","C02-Antihypertensives","MLLNCUMT","Million of national currency units","KOR","Korea","2014","2014",31250.4,,
+"PATCHYPO","C02-Antihypertensives","MLLNCUMT","Million of national currency units","KOR","Korea","2015","2015",29043.1,,
+"PATCHYPO","C02-Antihypertensives","MLLNCUMT","Million of national currency units","KOR","Korea","2016","2016",29877.4,"B","Break"
+"PATCHYPO","C02-Antihypertensives","MLLNCUMT","Million of national currency units","KOR","Korea","2017","2017",32908.9,,
+"PATCHYPO","C02-Antihypertensives","MLLNCUMT","Million of national currency units","KOR","Korea","2018","2018",35023.8,,
+"PATCHYPO","C02-Antihypertensives","MLLNCUMT","Million of national currency units","KOR","Korea","2019","2019",36730,,
+"PATCHYPO","C02-Antihypertensives","MLLNCUMT","Million of national currency units","KOR","Korea","2020","2020",39405.2,,
+"PATCHYPO","C02-Antihypertensives","MLLNCUMT","Million of national currency units","KOR","Korea","2021","2021",44689.5,,
+"PATCHYPO","C02-Antihypertensives","MTMOTCMT","Million US$ at exchange rate","KOR","Korea","2010","2010",30.8,,
+"PATCHYPO","C02-Antihypertensives","MTMOTCMT","Million US$ at exchange rate","KOR","Korea","2011","2011",33.3,"B","Break"
+"PATCHYPO","C02-Antihypertensives","MTMOTCMT","Million US$ at exchange rate","KOR","Korea","2012","2012",29.9,,
+"PATCHYPO","C02-Antihypertensives","MTMOTCMT","Million US$ at exchange rate","KOR","Korea","2013","2013",30.8,,
+"PATCHYPO","C02-Antihypertensives","MTMOTCMT","Million US$ at exchange rate","KOR","Korea","2014","2014",29.7,,
+"PATCHYPO","C02-Antihypertensives","MTMOTCMT","Million US$ at exchange rate","KOR","Korea","2015","2015",25.7,,
+"PATCHYPO","C02-Antihypertensives","MTMOTCMT","Million US$ at exchange rate","KOR","Korea","2016","2016",25.7,"B","Break"
+"PATCHYPO","C02-Antihypertensives","MTMOTCMT","Million US$ at exchange rate","KOR","Korea","2017","2017",29.1,,
+"PATCHYPO","C02-Antihypertensives","MTMOTCMT","Million US$ at exchange rate","KOR","Korea","2018","2018",31.8,,
+"PATCHYPO","C02-Antihypertensives","MTMOTCMT","Million US$ at exchange rate","KOR","Korea","2019","2019",31.5,,
+"PATCHYPO","C02-Antihypertensives","MTMOTCMT","Million US$ at exchange rate","KOR","Korea","2020","2020",33.4,,
+"PATCHYPO","C02-Antihypertensives","MTMOTCMT","Million US$ at exchange rate","KOR","Korea","2021","2021",39.1,,
+"PATCHYPO","C02-Antihypertensives","MTMOPPMT","Million US$, purchasing power parity","KOR","Korea","2010","2010",42.4,,
+"PATCHYPO","C02-Antihypertensives","MTMOPPMT","Million US$, purchasing power parity","KOR","Korea","2011","2011",43.2,"B","Break"
+"PATCHYPO","C02-Antihypertensives","MTMOPPMT","Million US$, purchasing power parity","KOR","Korea","2012","2012",39.4,,
+"PATCHYPO","C02-Antihypertensives","MTMOPPMT","Million US$, purchasing power parity","KOR","Korea","2013","2013",38.8,,
+"PATCHYPO","C02-Antihypertensives","MTMOPPMT","Million US$, purchasing power parity","KOR","Korea","2014","2014",35.8,,
+"PATCHYPO","C02-Antihypertensives","MTMOPPMT","Million US$, purchasing power parity","KOR","Korea","2015","2015",33.9,,
+"PATCHYPO","C02-Antihypertensives","MTMOPPMT","Million US$, purchasing power parity","KOR","Korea","2016","2016",34.8,"B","Break"
+"PATCHYPO","C02-Antihypertensives","MTMOPPMT","Million US$, purchasing power parity","KOR","Korea","2017","2017",37.7,,
+"PATCHYPO","C02-Antihypertensives","MTMOPPMT","Million US$, purchasing power parity","KOR","Korea","2018","2018",41,,
+"PATCHYPO","C02-Antihypertensives","MTMOPPMT","Million US$, purchasing power parity","KOR","Korea","2019","2019",42.9,,
+"PATCHYPO","C02-Antihypertensives","MTMOPPMT","Million US$, purchasing power parity","KOR","Korea","2020","2020",47,,
+"PATCHYPO","C02-Antihypertensives","MTMOPPMT","Million US$, purchasing power parity","KOR","Korea","2021","2021",52.3,,
+"PATCHYPO","C02-Antihypertensives","TCPPERMT","/capita, US$ exchange rate","KOR","Korea","2010","2010",0.6,,
+"PATCHYPO","C02-Antihypertensives","TCPPERMT","/capita, US$ exchange rate","KOR","Korea","2011","2011",0.7,"B","Break"
+"PATCHYPO","C02-Antihypertensives","TCPPERMT","/capita, US$ exchange rate","KOR","Korea","2012","2012",0.6,,
+"PATCHYPO","C02-Antihypertensives","TCPPERMT","/capita, US$ exchange rate","KOR","Korea","2013","2013",0.6,,
+"PATCHYPO","C02-Antihypertensives","TCPPERMT","/capita, US$ exchange rate","KOR","Korea","2014","2014",0.6,,
+"PATCHYPO","C02-Antihypertensives","TCPPERMT","/capita, US$ exchange rate","KOR","Korea","2015","2015",0.5,,
+"PATCHYPO","C02-Antihypertensives","TCPPERMT","/capita, US$ exchange rate","KOR","Korea","2016","2016",0.5,"B","Break"
+"PATCHYPO","C02-Antihypertensives","TCPPERMT","/capita, US$ exchange rate","KOR","Korea","2017","2017",0.6,,
+"PATCHYPO","C02-Antihypertensives","TCPPERMT","/capita, US$ exchange rate","KOR","Korea","2018","2018",0.6,,
+"PATCHYPO","C02-Antihypertensives","TCPPERMT","/capita, US$ exchange rate","KOR","Korea","2019","2019",0.6,,
+"PATCHYPO","C02-Antihypertensives","TCPPERMT","/capita, US$ exchange rate","KOR","Korea","2020","2020",0.6,,
+"PATCHYPO","C02-Antihypertensives","TCPPERMT","/capita, US$ exchange rate","KOR","Korea","2021","2021",0.8,,
+"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2010","2010",0.9,,
+"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2011","2011",0.9,"B","Break"
+"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2012","2012",0.8,,
+"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2013","2013",0.8,,
+"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2014","2014",0.7,,
+"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2015","2015",0.7,,
+"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2016","2016",0.7,"B","Break"
+"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2017","2017",0.7,,
+"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2018","2018",0.8,,
+"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2019","2019",0.8,,
+"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2020","2020",0.9,,
+"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2021","2021",1,,
+"PATCHYPO","C02-Antihypertensives","ATCPTTMT","% of total sales","KOR","Korea","2010","2010",0.2,,
+"PATCHYPO","C02-Antihypertensives","ATCPTTMT","% of total sales","KOR","Korea","2011","2011",0.2,"B","Break"
+"PATCHYPO","C02-Antihypertensives","ATCPTTMT","% of total sales","KOR","Korea","2012","2012",0.2,,
+"PATCHYPO","C02-Antihypertensives","ATCPTTMT","% of total sales","KOR","Korea","2013","2013",0.1,,
+"PATCHYPO","C02-Antihypertensives","ATCPTTMT","% of total sales","KOR","Korea","2014","2014",0.1,,
+"PATCHYPO","C02-Antihypertensives","ATCPTTMT","% of total sales","KOR","Korea","2015","2015",0.1,,
+"PATCHYPO","C02-Antihypertensives","ATCPTTMT","% of total sales","KOR","Korea","2016","2016",0.1,"B","Break"
+"PATCHYPO","C02-Antihypertensives","ATCPTTMT","% of total sales","KOR","Korea","2017","2017",0.1,,
+"PATCHYPO","C02-Antihypertensives","ATCPTTMT","% of total sales","KOR","Korea","2018","2018",0.1,,
+"PATCHYPO","C02-Antihypertensives","ATCPTTMT","% of total sales","KOR","Korea","2019","2019",0.1,,
+"PATCHYPO","C02-Antihypertensives","ATCPTTMT","% of total sales","KOR","Korea","2020","2020",0.1,,
+"PATCHYPO","C02-Antihypertensives","ATCPTTMT","% of total sales","KOR","Korea","2021","2021",0.1,,
+"PATCHYPO","C02-Antihypertensives","MLLNCUMT","Million of national currency units","LUX","Luxembourg","2010","2010",0.5,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","MLLNCUMT","Million of national currency units","LUX","Luxembourg","2011","2011",0.4,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","MLLNCUMT","Million of national currency units","LUX","Luxembourg","2012","2012",0.4,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","MLLNCUMT","Million of national currency units","LUX","Luxembourg","2013","2013",0.4,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","MLLNCUMT","Million of national currency units","LUX","Luxembourg","2014","2014",0.4,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","MLLNCUMT","Million of national currency units","LUX","Luxembourg","2015","2015",0.4,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","MLLNCUMT","Million of national currency units","LUX","Luxembourg","2016","2016",0.5,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","MLLNCUMT","Million of national currency units","LUX","Luxembourg","2017","2017",0.4,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","MLLNCUMT","Million of national currency units","LUX","Luxembourg","2018","2018",0.5,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","MLLNCUMT","Million of national currency units","LUX","Luxembourg","2019","2019",0.5,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","MLLNCUMT","Million of national currency units","LUX","Luxembourg","2020","2020",0.4,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","MLLNCUMT","Million of national currency units","LUX","Luxembourg","2021","2021",0.6,"B; D; P","Break; Difference in methodology; Provisional value"
+"PATCHYPO","C02-Antihypertensives","MLLNCUMT","Million of national currency units","LUX","Luxembourg","2022","2022",0.7,"D; P","Difference in methodology; Provisional value"
+"PATCHYPO","C02-Antihypertensives","MTMOTCMT","Million US$ at exchange rate","LUX","Luxembourg","2010","2010",0.6,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","MTMOTCMT","Million US$ at exchange rate","LUX","Luxembourg","2011","2011",0.6,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","MTMOTCMT","Million US$ at exchange rate","LUX","Luxembourg","2012","2012",0.5,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","MTMOTCMT","Million US$ at exchange rate","LUX","Luxembourg","2013","2013",0.5,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","MTMOTCMT","Million US$ at exchange rate","LUX","Luxembourg","2014","2014",0.6,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","MTMOTCMT","Million US$ at exchange rate","LUX","Luxembourg","2015","2015",0.5,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","MTMOTCMT","Million US$ at exchange rate","LUX","Luxembourg","2016","2016",0.5,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","MTMOTCMT","Million US$ at exchange rate","LUX","Luxembourg","2017","2017",0.5,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","MTMOTCMT","Million US$ at exchange rate","LUX","Luxembourg","2018","2018",0.5,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","MTMOTCMT","Million US$ at exchange rate","LUX","Luxembourg","2019","2019",0.5,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","MTMOTCMT","Million US$ at exchange rate","LUX","Luxembourg","2020","2020",0.4,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","MTMOTCMT","Million US$ at exchange rate","LUX","Luxembourg","2021","2021",0.7,"B; D; P","Break; Difference in methodology; Provisional value"
+"PATCHYPO","C02-Antihypertensives","MTMOTCMT","Million US$ at exchange rate","LUX","Luxembourg","2022","2022",0.7,"D; P","Difference in methodology; Provisional value"
+"PATCHYPO","C02-Antihypertensives","MTMOPPMT","Million US$, purchasing power parity","LUX","Luxembourg","2010","2010",0.5,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","MTMOPPMT","Million US$, purchasing power parity","LUX","Luxembourg","2011","2011",0.5,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","MTMOPPMT","Million US$, purchasing power parity","LUX","Luxembourg","2012","2012",0.4,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","MTMOPPMT","Million US$, purchasing power parity","LUX","Luxembourg","2013","2013",0.5,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","MTMOPPMT","Million US$, purchasing power parity","LUX","Luxembourg","2014","2014",0.5,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","MTMOPPMT","Million US$, purchasing power parity","LUX","Luxembourg","2015","2015",0.5,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","MTMOPPMT","Million US$, purchasing power parity","LUX","Luxembourg","2016","2016",0.5,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","MTMOPPMT","Million US$, purchasing power parity","LUX","Luxembourg","2017","2017",0.5,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","MTMOPPMT","Million US$, purchasing power parity","LUX","Luxembourg","2018","2018",0.5,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","MTMOPPMT","Million US$, purchasing power parity","LUX","Luxembourg","2019","2019",0.5,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","MTMOPPMT","Million US$, purchasing power parity","LUX","Luxembourg","2020","2020",0.4,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","MTMOPPMT","Million US$, purchasing power parity","LUX","Luxembourg","2021","2021",0.6,"B; D; P","Break; Difference in methodology; Provisional value"
+"PATCHYPO","C02-Antihypertensives","MTMOPPMT","Million US$, purchasing power parity","LUX","Luxembourg","2022","2022",0.8,"D; P","Difference in methodology; Provisional value"
+"PATCHYPO","C02-Antihypertensives","TCPPERMT","/capita, US$ exchange rate","LUX","Luxembourg","2010","2010",1.3,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","TCPPERMT","/capita, US$ exchange rate","LUX","Luxembourg","2011","2011",1.2,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","TCPPERMT","/capita, US$ exchange rate","LUX","Luxembourg","2012","2012",1,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","TCPPERMT","/capita, US$ exchange rate","LUX","Luxembourg","2013","2013",1.1,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","TCPPERMT","/capita, US$ exchange rate","LUX","Luxembourg","2014","2014",1.1,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","TCPPERMT","/capita, US$ exchange rate","LUX","Luxembourg","2015","2015",0.9,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","TCPPERMT","/capita, US$ exchange rate","LUX","Luxembourg","2016","2016",0.9,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","TCPPERMT","/capita, US$ exchange rate","LUX","Luxembourg","2017","2017",0.9,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","TCPPERMT","/capita, US$ exchange rate","LUX","Luxembourg","2018","2018",1,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","TCPPERMT","/capita, US$ exchange rate","LUX","Luxembourg","2019","2019",0.9,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","TCPPERMT","/capita, US$ exchange rate","LUX","Luxembourg","2020","2020",0.8,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","TCPPERMT","/capita, US$ exchange rate","LUX","Luxembourg","2021","2021",1.1,"B; D; P","Break; Difference in methodology; Provisional value"
+"PATCHYPO","C02-Antihypertensives","TCPPERMT","/capita, US$ exchange rate","LUX","Luxembourg","2022","2022",1.2,"D; P","Difference in methodology; Provisional value"
+"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2010","2010",1,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2011","2011",1,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2012","2012",0.9,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2013","2013",0.9,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2014","2014",1,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2015","2015",0.9,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2016","2016",1,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2017","2017",1,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2018","2018",1,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2019","2019",1,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2020","2020",0.8,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2021","2021",1.1,"B; D; P","Break; Difference in methodology; Provisional value"
+"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2022","2022",1.3,"D; P","Difference in methodology; Provisional value"
+"PATCHYPO","C02-Antihypertensives","ATCPTTMT","% of total sales","LUX","Luxembourg","2010","2010",0.2,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","ATCPTTMT","% of total sales","LUX","Luxembourg","2011","2011",0.2,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","ATCPTTMT","% of total sales","LUX","Luxembourg","2012","2012",0.2,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","ATCPTTMT","% of total sales","LUX","Luxembourg","2013","2013",0.2,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","ATCPTTMT","% of total sales","LUX","Luxembourg","2014","2014",0.2,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","ATCPTTMT","% of total sales","LUX","Luxembourg","2015","2015",0.2,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","ATCPTTMT","% of total sales","LUX","Luxembourg","2016","2016",0.2,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","ATCPTTMT","% of total sales","LUX","Luxembourg","2017","2017",0.2,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","ATCPTTMT","% of total sales","LUX","Luxembourg","2018","2018",0.2,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","ATCPTTMT","% of total sales","LUX","Luxembourg","2019","2019",0.2,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","ATCPTTMT","% of total sales","LUX","Luxembourg","2020","2020",0.2,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","ATCPTTMT","% of total sales","LUX","Luxembourg","2021","2021",0.2,"B; D; P","Break; Difference in methodology; Provisional value"
+"PATCHYPO","C02-Antihypertensives","ATCPTTMT","% of total sales","LUX","Luxembourg","2022","2022",0.3,"D; P","Difference in methodology; Provisional value"
+"PATCHYPO","C02-Antihypertensives","MLLNCUMT","Million of national currency units","NLD","Netherlands","2010","2010",35.6,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","MLLNCUMT","Million of national currency units","NLD","Netherlands","2011","2011",34.6,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","MLLNCUMT","Million of national currency units","NLD","Netherlands","2012","2012",34.7,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","MLLNCUMT","Million of national currency units","NLD","Netherlands","2013","2013",34.2,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","MLLNCUMT","Million of national currency units","NLD","Netherlands","2014","2014",35,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","MTMOTCMT","Million US$ at exchange rate","NLD","Netherlands","2010","2010",47.1,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","MTMOTCMT","Million US$ at exchange rate","NLD","Netherlands","2011","2011",48.2,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","MTMOTCMT","Million US$ at exchange rate","NLD","Netherlands","2012","2012",44.6,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","MTMOTCMT","Million US$ at exchange rate","NLD","Netherlands","2013","2013",45.5,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","MTMOTCMT","Million US$ at exchange rate","NLD","Netherlands","2014","2014",46.6,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","MTMOPPMT","Million US$, purchasing power parity","NLD","Netherlands","2010","2010",41.6,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","MTMOPPMT","Million US$, purchasing power parity","NLD","Netherlands","2011","2011",41.4,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","MTMOPPMT","Million US$, purchasing power parity","NLD","Netherlands","2012","2012",42.1,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","MTMOPPMT","Million US$, purchasing power parity","NLD","Netherlands","2013","2013",42.9,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","MTMOPPMT","Million US$, purchasing power parity","NLD","Netherlands","2014","2014",43.3,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","TCPPERMT","/capita, US$ exchange rate","NLD","Netherlands","2010","2010",2.8,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","TCPPERMT","/capita, US$ exchange rate","NLD","Netherlands","2011","2011",2.9,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","TCPPERMT","/capita, US$ exchange rate","NLD","Netherlands","2012","2012",2.7,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","TCPPERMT","/capita, US$ exchange rate","NLD","Netherlands","2013","2013",2.7,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","TCPPERMT","/capita, US$ exchange rate","NLD","Netherlands","2014","2014",2.8,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","NLD","Netherlands","2010","2010",2.5,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","NLD","Netherlands","2011","2011",2.5,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","NLD","Netherlands","2012","2012",2.5,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","NLD","Netherlands","2013","2013",2.6,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","NLD","Netherlands","2014","2014",2.6,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","ATCPTTMT","% of total sales","NLD","Netherlands","2010","2010",0.7,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","ATCPTTMT","% of total sales","NLD","Netherlands","2011","2011",0.7,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","ATCPTTMT","% of total sales","NLD","Netherlands","2012","2012",0.8,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","ATCPTTMT","% of total sales","NLD","Netherlands","2013","2013",0.8,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","ATCPTTMT","% of total sales","NLD","Netherlands","2014","2014",0.8,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","MLLNCUMT","Million of national currency units","NZL","New Zealand","2010","2010",2.8,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","MLLNCUMT","Million of national currency units","NZL","New Zealand","2011","2011",3,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","MLLNCUMT","Million of national currency units","NZL","New Zealand","2012","2012",2.9,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","MLLNCUMT","Million of national currency units","NZL","New Zealand","2013","2013",3.8,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","MLLNCUMT","Million of national currency units","NZL","New Zealand","2014","2014",3.9,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","MLLNCUMT","Million of national currency units","NZL","New Zealand","2015","2015",3.5,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","MLLNCUMT","Million of national currency units","NZL","New Zealand","2016","2016",2.6,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","MLLNCUMT","Million of national currency units","NZL","New Zealand","2017","2017",2.2,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","MLLNCUMT","Million of national currency units","NZL","New Zealand","2018","2018",2.4,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","MLLNCUMT","Million of national currency units","NZL","New Zealand","2019","2019",3,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","MLLNCUMT","Million of national currency units","NZL","New Zealand","2020","2020",3.2,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","MLLNCUMT","Million of national currency units","NZL","New Zealand","2021","2021",3.4,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","MLLNCUMT","Million of national currency units","NZL","New Zealand","2022","2022",3.5,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","MTMOTCMT","Million US$ at exchange rate","NZL","New Zealand","2010","2010",2,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","MTMOTCMT","Million US$ at exchange rate","NZL","New Zealand","2011","2011",2.4,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","MTMOTCMT","Million US$ at exchange rate","NZL","New Zealand","2012","2012",2.3,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","MTMOTCMT","Million US$ at exchange rate","NZL","New Zealand","2013","2013",3.1,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","MTMOTCMT","Million US$ at exchange rate","NZL","New Zealand","2014","2014",3.2,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","MTMOTCMT","Million US$ at exchange rate","NZL","New Zealand","2015","2015",2.5,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","MTMOTCMT","Million US$ at exchange rate","NZL","New Zealand","2016","2016",1.8,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","MTMOTCMT","Million US$ at exchange rate","NZL","New Zealand","2017","2017",1.6,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","MTMOTCMT","Million US$ at exchange rate","NZL","New Zealand","2018","2018",1.7,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","MTMOTCMT","Million US$ at exchange rate","NZL","New Zealand","2019","2019",2,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","MTMOTCMT","Million US$ at exchange rate","NZL","New Zealand","2020","2020",2.1,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","MTMOTCMT","Million US$ at exchange rate","NZL","New Zealand","2021","2021",2.4,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","MTMOTCMT","Million US$ at exchange rate","NZL","New Zealand","2022","2022",2.2,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","MTMOPPMT","Million US$, purchasing power parity","NZL","New Zealand","2010","2010",1.9,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","MTMOPPMT","Million US$, purchasing power parity","NZL","New Zealand","2011","2011",2,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","MTMOPPMT","Million US$, purchasing power parity","NZL","New Zealand","2012","2012",1.9,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","MTMOPPMT","Million US$, purchasing power parity","NZL","New Zealand","2013","2013",2.6,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","MTMOPPMT","Million US$, purchasing power parity","NZL","New Zealand","2014","2014",2.7,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","MTMOPPMT","Million US$, purchasing power parity","NZL","New Zealand","2015","2015",2.4,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","MTMOPPMT","Million US$, purchasing power parity","NZL","New Zealand","2016","2016",1.8,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","MTMOPPMT","Million US$, purchasing power parity","NZL","New Zealand","2017","2017",1.6,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","MTMOPPMT","Million US$, purchasing power parity","NZL","New Zealand","2018","2018",1.6,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","MTMOPPMT","Million US$, purchasing power parity","NZL","New Zealand","2019","2019",2.1,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","MTMOPPMT","Million US$, purchasing power parity","NZL","New Zealand","2020","2020",2.3,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","MTMOPPMT","Million US$, purchasing power parity","NZL","New Zealand","2021","2021",2.4,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","MTMOPPMT","Million US$, purchasing power parity","NZL","New Zealand","2022","2022",2.5,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","TCPPERMT","/capita, US$ exchange rate","NZL","New Zealand","2010","2010",0.5,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","TCPPERMT","/capita, US$ exchange rate","NZL","New Zealand","2011","2011",0.5,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","TCPPERMT","/capita, US$ exchange rate","NZL","New Zealand","2012","2012",0.5,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","TCPPERMT","/capita, US$ exchange rate","NZL","New Zealand","2013","2013",0.7,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","TCPPERMT","/capita, US$ exchange rate","NZL","New Zealand","2014","2014",0.7,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","TCPPERMT","/capita, US$ exchange rate","NZL","New Zealand","2015","2015",0.5,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","TCPPERMT","/capita, US$ exchange rate","NZL","New Zealand","2016","2016",0.4,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","TCPPERMT","/capita, US$ exchange rate","NZL","New Zealand","2017","2017",0.3,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","TCPPERMT","/capita, US$ exchange rate","NZL","New Zealand","2018","2018",0.3,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","TCPPERMT","/capita, US$ exchange rate","NZL","New Zealand","2019","2019",0.4,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","TCPPERMT","/capita, US$ exchange rate","NZL","New Zealand","2020","2020",0.4,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","TCPPERMT","/capita, US$ exchange rate","NZL","New Zealand","2021","2021",0.5,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","TCPPERMT","/capita, US$ exchange rate","NZL","New Zealand","2022","2022",0.4,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2010","2010",0.4,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2011","2011",0.5,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2012","2012",0.4,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2013","2013",0.6,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2014","2014",0.6,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2015","2015",0.5,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2016","2016",0.4,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2017","2017",0.3,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2018","2018",0.3,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2019","2019",0.4,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2020","2020",0.4,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2021","2021",0.5,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2022","2022",0.5,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","ATCPTTMT","% of total sales","NZL","New Zealand","2010","2010",0.4,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","ATCPTTMT","% of total sales","NZL","New Zealand","2011","2011",0.4,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","ATCPTTMT","% of total sales","NZL","New Zealand","2012","2012",0.3,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","ATCPTTMT","% of total sales","NZL","New Zealand","2013","2013",0.4,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","ATCPTTMT","% of total sales","NZL","New Zealand","2014","2014",0.4,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","ATCPTTMT","% of total sales","NZL","New Zealand","2015","2015",0.4,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","ATCPTTMT","% of total sales","NZL","New Zealand","2016","2016",0.2,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","ATCPTTMT","% of total sales","NZL","New Zealand","2017","2017",0.2,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","ATCPTTMT","% of total sales","NZL","New Zealand","2018","2018",0.2,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","ATCPTTMT","% of total sales","NZL","New Zealand","2019","2019",0.2,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","ATCPTTMT","% of total sales","NZL","New Zealand","2020","2020",0.2,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","ATCPTTMT","% of total sales","NZL","New Zealand","2021","2021",0.2,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","ATCPTTMT","% of total sales","NZL","New Zealand","2022","2022",0.2,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","MLLNCUMT","Million of national currency units","NOR","Norway","2010","2010",54,,
+"PATCHYPO","C02-Antihypertensives","MLLNCUMT","Million of national currency units","NOR","Norway","2011","2011",56,,
+"PATCHYPO","C02-Antihypertensives","MLLNCUMT","Million of national currency units","NOR","Norway","2012","2012",61,,
+"PATCHYPO","C02-Antihypertensives","MLLNCUMT","Million of national currency units","NOR","Norway","2013","2013",69,,
+"PATCHYPO","C02-Antihypertensives","MLLNCUMT","Million of national currency units","NOR","Norway","2014","2014",74,,
+"PATCHYPO","C02-Antihypertensives","MLLNCUMT","Million of national currency units","NOR","Norway","2015","2015",91,,
+"PATCHYPO","C02-Antihypertensives","MLLNCUMT","Million of national currency units","NOR","Norway","2016","2016",103,,
+"PATCHYPO","C02-Antihypertensives","MLLNCUMT","Million of national currency units","NOR","Norway","2017","2017",110,,
+"PATCHYPO","C02-Antihypertensives","MLLNCUMT","Million of national currency units","NOR","Norway","2018","2018",104,,
+"PATCHYPO","C02-Antihypertensives","MLLNCUMT","Million of national currency units","NOR","Norway","2019","2019",99,,
+"PATCHYPO","C02-Antihypertensives","MLLNCUMT","Million of national currency units","NOR","Norway","2020","2020",106,,
+"PATCHYPO","C02-Antihypertensives","MLLNCUMT","Million of national currency units","NOR","Norway","2021","2021",105,,
+"PATCHYPO","C02-Antihypertensives","MLLNCUMT","Million of national currency units","NOR","Norway","2022","2022",121,,
+"PATCHYPO","C02-Antihypertensives","MTMOTCMT","Million US$ at exchange rate","NOR","Norway","2010","2010",8.9,,
+"PATCHYPO","C02-Antihypertensives","MTMOTCMT","Million US$ at exchange rate","NOR","Norway","2011","2011",10,,
+"PATCHYPO","C02-Antihypertensives","MTMOTCMT","Million US$ at exchange rate","NOR","Norway","2012","2012",10.5,,
+"PATCHYPO","C02-Antihypertensives","MTMOTCMT","Million US$ at exchange rate","NOR","Norway","2013","2013",11.7,,
+"PATCHYPO","C02-Antihypertensives","MTMOTCMT","Million US$ at exchange rate","NOR","Norway","2014","2014",11.7,,
+"PATCHYPO","C02-Antihypertensives","MTMOTCMT","Million US$ at exchange rate","NOR","Norway","2015","2015",11.3,,
+"PATCHYPO","C02-Antihypertensives","MTMOTCMT","Million US$ at exchange rate","NOR","Norway","2016","2016",12.3,,
+"PATCHYPO","C02-Antihypertensives","MTMOTCMT","Million US$ at exchange rate","NOR","Norway","2017","2017",13.3,,
+"PATCHYPO","C02-Antihypertensives","MTMOTCMT","Million US$ at exchange rate","NOR","Norway","2018","2018",12.8,,
+"PATCHYPO","C02-Antihypertensives","MTMOTCMT","Million US$ at exchange rate","NOR","Norway","2019","2019",11.3,,
+"PATCHYPO","C02-Antihypertensives","MTMOTCMT","Million US$ at exchange rate","NOR","Norway","2020","2020",11.3,,
+"PATCHYPO","C02-Antihypertensives","MTMOTCMT","Million US$ at exchange rate","NOR","Norway","2021","2021",12.2,,
+"PATCHYPO","C02-Antihypertensives","MTMOTCMT","Million US$ at exchange rate","NOR","Norway","2022","2022",12.6,,
+"PATCHYPO","C02-Antihypertensives","MTMOPPMT","Million US$, purchasing power parity","NOR","Norway","2010","2010",5.9,,
+"PATCHYPO","C02-Antihypertensives","MTMOPPMT","Million US$, purchasing power parity","NOR","Norway","2011","2011",6.2,,
+"PATCHYPO","C02-Antihypertensives","MTMOPPMT","Million US$, purchasing power parity","NOR","Norway","2012","2012",6.7,,
+"PATCHYPO","C02-Antihypertensives","MTMOPPMT","Million US$, purchasing power parity","NOR","Norway","2013","2013",7.6,,
+"PATCHYPO","C02-Antihypertensives","MTMOPPMT","Million US$, purchasing power parity","NOR","Norway","2014","2014",8,,
+"PATCHYPO","C02-Antihypertensives","MTMOPPMT","Million US$, purchasing power parity","NOR","Norway","2015","2015",9.2,,
+"PATCHYPO","C02-Antihypertensives","MTMOPPMT","Million US$, purchasing power parity","NOR","Norway","2016","2016",10.3,,
+"PATCHYPO","C02-Antihypertensives","MTMOPPMT","Million US$, purchasing power parity","NOR","Norway","2017","2017",11.3,,
+"PATCHYPO","C02-Antihypertensives","MTMOPPMT","Million US$, purchasing power parity","NOR","Norway","2018","2018",10.9,,
+"PATCHYPO","C02-Antihypertensives","MTMOPPMT","Million US$, purchasing power parity","NOR","Norway","2019","2019",10.3,,
+"PATCHYPO","C02-Antihypertensives","MTMOPPMT","Million US$, purchasing power parity","NOR","Norway","2020","2020",10.7,,
+"PATCHYPO","C02-Antihypertensives","MTMOPPMT","Million US$, purchasing power parity","NOR","Norway","2021","2021",11,,
+"PATCHYPO","C02-Antihypertensives","MTMOPPMT","Million US$, purchasing power parity","NOR","Norway","2022","2022",11.3,,
+"PATCHYPO","C02-Antihypertensives","TCPPERMT","/capita, US$ exchange rate","NOR","Norway","2010","2010",1.8,,
+"PATCHYPO","C02-Antihypertensives","TCPPERMT","/capita, US$ exchange rate","NOR","Norway","2011","2011",2,,
+"PATCHYPO","C02-Antihypertensives","TCPPERMT","/capita, US$ exchange rate","NOR","Norway","2012","2012",2.1,,
+"PATCHYPO","C02-Antihypertensives","TCPPERMT","/capita, US$ exchange rate","NOR","Norway","2013","2013",2.3,,
+"PATCHYPO","C02-Antihypertensives","TCPPERMT","/capita, US$ exchange rate","NOR","Norway","2014","2014",2.3,,
+"PATCHYPO","C02-Antihypertensives","TCPPERMT","/capita, US$ exchange rate","NOR","Norway","2015","2015",2.2,,
+"PATCHYPO","C02-Antihypertensives","TCPPERMT","/capita, US$ exchange rate","NOR","Norway","2016","2016",2.3,,
+"PATCHYPO","C02-Antihypertensives","TCPPERMT","/capita, US$ exchange rate","NOR","Norway","2017","2017",2.5,,
+"PATCHYPO","C02-Antihypertensives","TCPPERMT","/capita, US$ exchange rate","NOR","Norway","2018","2018",2.4,,
+"PATCHYPO","C02-Antihypertensives","TCPPERMT","/capita, US$ exchange rate","NOR","Norway","2019","2019",2.1,,
+"PATCHYPO","C02-Antihypertensives","TCPPERMT","/capita, US$ exchange rate","NOR","Norway","2020","2020",2.1,,
+"PATCHYPO","C02-Antihypertensives","TCPPERMT","/capita, US$ exchange rate","NOR","Norway","2021","2021",2.3,,
+"PATCHYPO","C02-Antihypertensives","TCPPERMT","/capita, US$ exchange rate","NOR","Norway","2022","2022",2.3,,
+"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2010","2010",1.2,,
+"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2011","2011",1.2,,
+"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2012","2012",1.3,,
+"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2013","2013",1.5,,
+"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2014","2014",1.6,,
+"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2015","2015",1.8,,
+"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2016","2016",2,,
+"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2017","2017",2.1,,
+"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2018","2018",2,,
+"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2019","2019",1.9,,
+"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2020","2020",2,,
+"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2021","2021",2,,
+"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2022","2022",2.1,,
+"PATCHYPO","C02-Antihypertensives","ATCPTTMT","% of total sales","NOR","Norway","2010","2010",0.3,,
+"PATCHYPO","C02-Antihypertensives","ATCPTTMT","% of total sales","NOR","Norway","2011","2011",0.3,,
+"PATCHYPO","C02-Antihypertensives","ATCPTTMT","% of total sales","NOR","Norway","2012","2012",0.3,,
+"PATCHYPO","C02-Antihypertensives","ATCPTTMT","% of total sales","NOR","Norway","2013","2013",0.4,,
+"PATCHYPO","C02-Antihypertensives","ATCPTTMT","% of total sales","NOR","Norway","2014","2014",0.4,,
+"PATCHYPO","C02-Antihypertensives","ATCPTTMT","% of total sales","NOR","Norway","2015","2015",0.4,,
+"PATCHYPO","C02-Antihypertensives","ATCPTTMT","% of total sales","NOR","Norway","2016","2016",0.4,,
+"PATCHYPO","C02-Antihypertensives","ATCPTTMT","% of total sales","NOR","Norway","2017","2017",0.4,,
+"PATCHYPO","C02-Antihypertensives","ATCPTTMT","% of total sales","NOR","Norway","2018","2018",0.4,,
+"PATCHYPO","C02-Antihypertensives","ATCPTTMT","% of total sales","NOR","Norway","2019","2019",0.3,,
+"PATCHYPO","C02-Antihypertensives","ATCPTTMT","% of total sales","NOR","Norway","2020","2020",0.4,,
+"PATCHYPO","C02-Antihypertensives","ATCPTTMT","% of total sales","NOR","Norway","2021","2021",0.3,,
+"PATCHYPO","C02-Antihypertensives","ATCPTTMT","% of total sales","NOR","Norway","2022","2022",0.3,,
+"PATCHYPO","C02-Antihypertensives","MLLNCUMT","Million of national currency units","PRT","Portugal","2010","2010",4.5,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","MLLNCUMT","Million of national currency units","PRT","Portugal","2011","2011",4.1,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","MLLNCUMT","Million of national currency units","PRT","Portugal","2012","2012",3.9,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","MLLNCUMT","Million of national currency units","PRT","Portugal","2013","2013",3.6,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","MLLNCUMT","Million of national currency units","PRT","Portugal","2014","2014",3.6,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","MLLNCUMT","Million of national currency units","PRT","Portugal","2015","2015",3.6,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","MLLNCUMT","Million of national currency units","PRT","Portugal","2016","2016",3.1,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","MLLNCUMT","Million of national currency units","PRT","Portugal","2017","2017",3.1,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","MLLNCUMT","Million of national currency units","PRT","Portugal","2018","2018",2.9,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","MLLNCUMT","Million of national currency units","PRT","Portugal","2019","2019",2.9,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","MLLNCUMT","Million of national currency units","PRT","Portugal","2020","2020",2.8,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","MLLNCUMT","Million of national currency units","PRT","Portugal","2021","2021",2.8,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","MLLNCUMT","Million of national currency units","PRT","Portugal","2022","2022",2.8,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","MTMOTCMT","Million US$ at exchange rate","PRT","Portugal","2010","2010",6,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","MTMOTCMT","Million US$ at exchange rate","PRT","Portugal","2011","2011",5.8,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","MTMOTCMT","Million US$ at exchange rate","PRT","Portugal","2012","2012",5,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","MTMOTCMT","Million US$ at exchange rate","PRT","Portugal","2013","2013",4.8,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","MTMOTCMT","Million US$ at exchange rate","PRT","Portugal","2014","2014",4.8,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","MTMOTCMT","Million US$ at exchange rate","PRT","Portugal","2015","2015",4,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","MTMOTCMT","Million US$ at exchange rate","PRT","Portugal","2016","2016",3.5,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","MTMOTCMT","Million US$ at exchange rate","PRT","Portugal","2017","2017",3.5,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","MTMOTCMT","Million US$ at exchange rate","PRT","Portugal","2018","2018",3.5,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","MTMOTCMT","Million US$ at exchange rate","PRT","Portugal","2019","2019",3.3,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","MTMOTCMT","Million US$ at exchange rate","PRT","Portugal","2020","2020",3.2,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","MTMOTCMT","Million US$ at exchange rate","PRT","Portugal","2021","2021",3.3,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","MTMOTCMT","Million US$ at exchange rate","PRT","Portugal","2022","2022",2.9,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","MTMOPPMT","Million US$, purchasing power parity","PRT","Portugal","2010","2010",7.2,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","MTMOPPMT","Million US$, purchasing power parity","PRT","Portugal","2011","2011",6.6,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","MTMOPPMT","Million US$, purchasing power parity","PRT","Portugal","2012","2012",6.4,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","MTMOPPMT","Million US$, purchasing power parity","PRT","Portugal","2013","2013",6.1,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","MTMOPPMT","Million US$, purchasing power parity","PRT","Portugal","2014","2014",6.3,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","MTMOPPMT","Million US$, purchasing power parity","PRT","Portugal","2015","2015",6.1,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","MTMOPPMT","Million US$, purchasing power parity","PRT","Portugal","2016","2016",5.5,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","MTMOPPMT","Million US$, purchasing power parity","PRT","Portugal","2017","2017",5.4,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","MTMOPPMT","Million US$, purchasing power parity","PRT","Portugal","2018","2018",5.1,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","MTMOPPMT","Million US$, purchasing power parity","PRT","Portugal","2019","2019",5.2,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","MTMOPPMT","Million US$, purchasing power parity","PRT","Portugal","2020","2020",5.1,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","MTMOPPMT","Million US$, purchasing power parity","PRT","Portugal","2021","2021",4.9,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","MTMOPPMT","Million US$, purchasing power parity","PRT","Portugal","2022","2022",5.1,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","TCPPERMT","/capita, US$ exchange rate","PRT","Portugal","2010","2010",0.6,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","TCPPERMT","/capita, US$ exchange rate","PRT","Portugal","2011","2011",0.5,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","TCPPERMT","/capita, US$ exchange rate","PRT","Portugal","2012","2012",0.5,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","TCPPERMT","/capita, US$ exchange rate","PRT","Portugal","2013","2013",0.5,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","TCPPERMT","/capita, US$ exchange rate","PRT","Portugal","2014","2014",0.5,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","TCPPERMT","/capita, US$ exchange rate","PRT","Portugal","2015","2015",0.4,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","TCPPERMT","/capita, US$ exchange rate","PRT","Portugal","2016","2016",0.3,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","TCPPERMT","/capita, US$ exchange rate","PRT","Portugal","2017","2017",0.3,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","TCPPERMT","/capita, US$ exchange rate","PRT","Portugal","2018","2018",0.3,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","TCPPERMT","/capita, US$ exchange rate","PRT","Portugal","2019","2019",0.3,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","TCPPERMT","/capita, US$ exchange rate","PRT","Portugal","2020","2020",0.3,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","TCPPERMT","/capita, US$ exchange rate","PRT","Portugal","2021","2021",0.3,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","TCPPERMT","/capita, US$ exchange rate","PRT","Portugal","2022","2022",0.3,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2010","2010",0.7,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2011","2011",0.6,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2012","2012",0.6,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2013","2013",0.6,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2014","2014",0.6,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2015","2015",0.6,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2016","2016",0.5,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2017","2017",0.5,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2018","2018",0.5,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2019","2019",0.5,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2020","2020",0.5,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2021","2021",0.5,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2022","2022",0.5,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","ATCPTTMT","% of total sales","PRT","Portugal","2010","2010",0.1,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","ATCPTTMT","% of total sales","PRT","Portugal","2011","2011",0.1,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","ATCPTTMT","% of total sales","PRT","Portugal","2012","2012",0.1,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","ATCPTTMT","% of total sales","PRT","Portugal","2013","2013",0.1,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","ATCPTTMT","% of total sales","PRT","Portugal","2014","2014",0.2,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","ATCPTTMT","% of total sales","PRT","Portugal","2015","2015",0.1,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","ATCPTTMT","% of total sales","PRT","Portugal","2016","2016",0.1,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","ATCPTTMT","% of total sales","PRT","Portugal","2017","2017",0.1,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","ATCPTTMT","% of total sales","PRT","Portugal","2018","2018",0.1,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","ATCPTTMT","% of total sales","PRT","Portugal","2019","2019",0.1,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","ATCPTTMT","% of total sales","PRT","Portugal","2020","2020",0.1,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","ATCPTTMT","% of total sales","PRT","Portugal","2021","2021",0.1,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","ATCPTTMT","% of total sales","PRT","Portugal","2022","2022",0.1,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","MLLNCUMT","Million of national currency units","SVK","Slovak Republic","2010","2010",13.3,,
+"PATCHYPO","C02-Antihypertensives","MLLNCUMT","Million of national currency units","SVK","Slovak Republic","2011","2011",14.6,,
+"PATCHYPO","C02-Antihypertensives","MLLNCUMT","Million of national currency units","SVK","Slovak Republic","2012","2012",15,,
+"PATCHYPO","C02-Antihypertensives","MLLNCUMT","Million of national currency units","SVK","Slovak Republic","2013","2013",16.8,,
+"PATCHYPO","C02-Antihypertensives","MLLNCUMT","Million of national currency units","SVK","Slovak Republic","2014","2014",17.3,,
+"PATCHYPO","C02-Antihypertensives","MLLNCUMT","Million of national currency units","SVK","Slovak Republic","2015","2015",17.9,,
+"PATCHYPO","C02-Antihypertensives","MLLNCUMT","Million of national currency units","SVK","Slovak Republic","2016","2016",22.9,"B","Break"
+"PATCHYPO","C02-Antihypertensives","MLLNCUMT","Million of national currency units","SVK","Slovak Republic","2017","2017",20.3,,
+"PATCHYPO","C02-Antihypertensives","MLLNCUMT","Million of national currency units","SVK","Slovak Republic","2018","2018",18.8,,
+"PATCHYPO","C02-Antihypertensives","MLLNCUMT","Million of national currency units","SVK","Slovak Republic","2019","2019",18.5,,
+"PATCHYPO","C02-Antihypertensives","MLLNCUMT","Million of national currency units","SVK","Slovak Republic","2020","2020",18.3,,
+"PATCHYPO","C02-Antihypertensives","MLLNCUMT","Million of national currency units","SVK","Slovak Republic","2021","2021",17.5,,
+"PATCHYPO","C02-Antihypertensives","MTMOTCMT","Million US$ at exchange rate","SVK","Slovak Republic","2010","2010",17.7,,
+"PATCHYPO","C02-Antihypertensives","MTMOTCMT","Million US$ at exchange rate","SVK","Slovak Republic","2011","2011",20.3,,
+"PATCHYPO","C02-Antihypertensives","MTMOTCMT","Million US$ at exchange rate","SVK","Slovak Republic","2012","2012",19.3,,
+"PATCHYPO","C02-Antihypertensives","MTMOTCMT","Million US$ at exchange rate","SVK","Slovak Republic","2013","2013",22.3,,
+"PATCHYPO","C02-Antihypertensives","MTMOTCMT","Million US$ at exchange rate","SVK","Slovak Republic","2014","2014",23,,
+"PATCHYPO","C02-Antihypertensives","MTMOTCMT","Million US$ at exchange rate","SVK","Slovak Republic","2015","2015",19.9,,
+"PATCHYPO","C02-Antihypertensives","MTMOTCMT","Million US$ at exchange rate","SVK","Slovak Republic","2016","2016",25.3,"B","Break"
+"PATCHYPO","C02-Antihypertensives","MTMOTCMT","Million US$ at exchange rate","SVK","Slovak Republic","2017","2017",22.9,,
+"PATCHYPO","C02-Antihypertensives","MTMOTCMT","Million US$ at exchange rate","SVK","Slovak Republic","2018","2018",22.2,,
+"PATCHYPO","C02-Antihypertensives","MTMOTCMT","Million US$ at exchange rate","SVK","Slovak Republic","2019","2019",20.7,,
+"PATCHYPO","C02-Antihypertensives","MTMOTCMT","Million US$ at exchange rate","SVK","Slovak Republic","2020","2020",20.9,,
+"PATCHYPO","C02-Antihypertensives","MTMOTCMT","Million US$ at exchange rate","SVK","Slovak Republic","2021","2021",20.7,,
+"PATCHYPO","C02-Antihypertensives","MTMOPPMT","Million US$, purchasing power parity","SVK","Slovak Republic","2010","2010",26.5,,
+"PATCHYPO","C02-Antihypertensives","MTMOPPMT","Million US$, purchasing power parity","SVK","Slovak Republic","2011","2011",28.8,,
+"PATCHYPO","C02-Antihypertensives","MTMOPPMT","Million US$, purchasing power parity","SVK","Slovak Republic","2012","2012",29.7,,
+"PATCHYPO","C02-Antihypertensives","MTMOPPMT","Million US$, purchasing power parity","SVK","Slovak Republic","2013","2013",34.1,,
+"PATCHYPO","C02-Antihypertensives","MTMOPPMT","Million US$, purchasing power parity","SVK","Slovak Republic","2014","2014",35.6,,
+"PATCHYPO","C02-Antihypertensives","MTMOPPMT","Million US$, purchasing power parity","SVK","Slovak Republic","2015","2015",36.4,,
+"PATCHYPO","C02-Antihypertensives","MTMOPPMT","Million US$, purchasing power parity","SVK","Slovak Republic","2016","2016",45.5,"B","Break"
+"PATCHYPO","C02-Antihypertensives","MTMOPPMT","Million US$, purchasing power parity","SVK","Slovak Republic","2017","2017",39.3,,
+"PATCHYPO","C02-Antihypertensives","MTMOPPMT","Million US$, purchasing power parity","SVK","Slovak Republic","2018","2018",35.7,,
+"PATCHYPO","C02-Antihypertensives","MTMOPPMT","Million US$, purchasing power parity","SVK","Slovak Republic","2019","2019",35.7,,
+"PATCHYPO","C02-Antihypertensives","MTMOPPMT","Million US$, purchasing power parity","SVK","Slovak Republic","2020","2020",35.3,,
+"PATCHYPO","C02-Antihypertensives","MTMOPPMT","Million US$, purchasing power parity","SVK","Slovak Republic","2021","2021",32.8,,
+"PATCHYPO","C02-Antihypertensives","TCPPERMT","/capita, US$ exchange rate","SVK","Slovak Republic","2010","2010",3.3,,
+"PATCHYPO","C02-Antihypertensives","TCPPERMT","/capita, US$ exchange rate","SVK","Slovak Republic","2011","2011",3.8,,
+"PATCHYPO","C02-Antihypertensives","TCPPERMT","/capita, US$ exchange rate","SVK","Slovak Republic","2012","2012",3.6,,
+"PATCHYPO","C02-Antihypertensives","TCPPERMT","/capita, US$ exchange rate","SVK","Slovak Republic","2013","2013",4.1,,
+"PATCHYPO","C02-Antihypertensives","TCPPERMT","/capita, US$ exchange rate","SVK","Slovak Republic","2014","2014",4.2,,
+"PATCHYPO","C02-Antihypertensives","TCPPERMT","/capita, US$ exchange rate","SVK","Slovak Republic","2015","2015",3.7,,
+"PATCHYPO","C02-Antihypertensives","TCPPERMT","/capita, US$ exchange rate","SVK","Slovak Republic","2016","2016",4.7,"B","Break"
+"PATCHYPO","C02-Antihypertensives","TCPPERMT","/capita, US$ exchange rate","SVK","Slovak Republic","2017","2017",4.2,,
+"PATCHYPO","C02-Antihypertensives","TCPPERMT","/capita, US$ exchange rate","SVK","Slovak Republic","2018","2018",4.1,,
+"PATCHYPO","C02-Antihypertensives","TCPPERMT","/capita, US$ exchange rate","SVK","Slovak Republic","2019","2019",3.8,,
+"PATCHYPO","C02-Antihypertensives","TCPPERMT","/capita, US$ exchange rate","SVK","Slovak Republic","2020","2020",3.8,,
+"PATCHYPO","C02-Antihypertensives","TCPPERMT","/capita, US$ exchange rate","SVK","Slovak Republic","2021","2021",3.8,,
+"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2010","2010",4.9,,
+"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2011","2011",5.3,,
+"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2012","2012",5.5,,
+"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2013","2013",6.3,,
+"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2014","2014",6.6,,
+"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2015","2015",6.7,,
+"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2016","2016",8.4,"B","Break"
+"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2017","2017",7.2,,
+"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2018","2018",6.6,,
+"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2019","2019",6.5,,
+"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2020","2020",6.5,,
+"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2021","2021",6,,
+"PATCHYPO","C02-Antihypertensives","ATCPTTMT","% of total sales","SVK","Slovak Republic","2010","2010",1.2,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","ATCPTTMT","% of total sales","SVK","Slovak Republic","2011","2011",1.3,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","ATCPTTMT","% of total sales","SVK","Slovak Republic","2012","2012",1.4,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","ATCPTTMT","% of total sales","SVK","Slovak Republic","2013","2013",1.4,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","ATCPTTMT","% of total sales","SVK","Slovak Republic","2014","2014",1.3,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","ATCPTTMT","% of total sales","SVK","Slovak Republic","2015","2015",1.3,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","ATCPTTMT","% of total sales","SVK","Slovak Republic","2016","2016",1.5,"B","Break"
+"PATCHYPO","C02-Antihypertensives","ATCPTTMT","% of total sales","SVK","Slovak Republic","2017","2017",1.3,,
+"PATCHYPO","C02-Antihypertensives","ATCPTTMT","% of total sales","SVK","Slovak Republic","2018","2018",1.2,,
+"PATCHYPO","C02-Antihypertensives","ATCPTTMT","% of total sales","SVK","Slovak Republic","2019","2019",1.1,,
+"PATCHYPO","C02-Antihypertensives","ATCPTTMT","% of total sales","SVK","Slovak Republic","2020","2020",1.1,,
+"PATCHYPO","C02-Antihypertensives","ATCPTTMT","% of total sales","SVK","Slovak Republic","2021","2021",1,,
+"PATCHYPO","C02-Antihypertensives","MLLNCUMT","Million of national currency units","ESP","Spain","2010","2010",59.2,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","MLLNCUMT","Million of national currency units","ESP","Spain","2011","2011",45,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","MLLNCUMT","Million of national currency units","ESP","Spain","2012","2012",40.6,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","MLLNCUMT","Million of national currency units","ESP","Spain","2013","2013",40.1,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","MLLNCUMT","Million of national currency units","ESP","Spain","2014","2014",41.3,"B; D","Break; Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","MLLNCUMT","Million of national currency units","ESP","Spain","2015","2015",40.9,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","MLLNCUMT","Million of national currency units","ESP","Spain","2016","2016",41.1,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","MLLNCUMT","Million of national currency units","ESP","Spain","2017","2017",45.2,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","MLLNCUMT","Million of national currency units","ESP","Spain","2018","2018",116.8,,
+"PATCHYPO","C02-Antihypertensives","MLLNCUMT","Million of national currency units","ESP","Spain","2019","2019",128.4,,
+"PATCHYPO","C02-Antihypertensives","MLLNCUMT","Million of national currency units","ESP","Spain","2020","2020",128,,
+"PATCHYPO","C02-Antihypertensives","MLLNCUMT","Million of national currency units","ESP","Spain","2021","2021",100.9,,
+"PATCHYPO","C02-Antihypertensives","MLLNCUMT","Million of national currency units","ESP","Spain","2022","2022",103.5,"P","Provisional value"
+"PATCHYPO","C02-Antihypertensives","MTMOTCMT","Million US$ at exchange rate","ESP","Spain","2010","2010",78.5,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","MTMOTCMT","Million US$ at exchange rate","ESP","Spain","2011","2011",62.7,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","MTMOTCMT","Million US$ at exchange rate","ESP","Spain","2012","2012",52.2,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","MTMOTCMT","Million US$ at exchange rate","ESP","Spain","2013","2013",53.2,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","MTMOTCMT","Million US$ at exchange rate","ESP","Spain","2014","2014",54.9,"B; D","Break; Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","MTMOTCMT","Million US$ at exchange rate","ESP","Spain","2015","2015",45.4,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","MTMOTCMT","Million US$ at exchange rate","ESP","Spain","2016","2016",45.5,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","MTMOTCMT","Million US$ at exchange rate","ESP","Spain","2017","2017",51.1,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","MTMOTCMT","Million US$ at exchange rate","ESP","Spain","2018","2018",137.9,,
+"PATCHYPO","C02-Antihypertensives","MTMOTCMT","Million US$ at exchange rate","ESP","Spain","2019","2019",143.7,,
+"PATCHYPO","C02-Antihypertensives","MTMOTCMT","Million US$ at exchange rate","ESP","Spain","2020","2020",146.2,,
+"PATCHYPO","C02-Antihypertensives","MTMOTCMT","Million US$ at exchange rate","ESP","Spain","2021","2021",119.3,,
+"PATCHYPO","C02-Antihypertensives","MTMOTCMT","Million US$ at exchange rate","ESP","Spain","2022","2022",108.9,"P","Provisional value"
+"PATCHYPO","C02-Antihypertensives","MTMOPPMT","Million US$, purchasing power parity","ESP","Spain","2010","2010",81.5,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","MTMOPPMT","Million US$, purchasing power parity","ESP","Spain","2011","2011",63.1,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","MTMOPPMT","Million US$, purchasing power parity","ESP","Spain","2012","2012",58.4,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","MTMOPPMT","Million US$, purchasing power parity","ESP","Spain","2013","2013",59.4,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","MTMOPPMT","Million US$, purchasing power parity","ESP","Spain","2014","2014",62.4,"B; D","Break; Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","MTMOPPMT","Million US$, purchasing power parity","ESP","Spain","2015","2015",61.6,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","MTMOPPMT","Million US$, purchasing power parity","ESP","Spain","2016","2016",64,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","MTMOPPMT","Million US$, purchasing power parity","ESP","Spain","2017","2017",71.7,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","MTMOPPMT","Million US$, purchasing power parity","ESP","Spain","2018","2018",184.9,,
+"PATCHYPO","C02-Antihypertensives","MTMOPPMT","Million US$, purchasing power parity","ESP","Spain","2019","2019",209.4,,
+"PATCHYPO","C02-Antihypertensives","MTMOPPMT","Million US$, purchasing power parity","ESP","Spain","2020","2020",206,,
+"PATCHYPO","C02-Antihypertensives","MTMOPPMT","Million US$, purchasing power parity","ESP","Spain","2021","2021",161.1,,
+"PATCHYPO","C02-Antihypertensives","MTMOPPMT","Million US$, purchasing power parity","ESP","Spain","2022","2022",173.5,"P","Provisional value"
+"PATCHYPO","C02-Antihypertensives","TCPPERMT","/capita, US$ exchange rate","ESP","Spain","2010","2010",1.7,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","TCPPERMT","/capita, US$ exchange rate","ESP","Spain","2011","2011",1.3,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","TCPPERMT","/capita, US$ exchange rate","ESP","Spain","2012","2012",1.1,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","TCPPERMT","/capita, US$ exchange rate","ESP","Spain","2013","2013",1.1,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","TCPPERMT","/capita, US$ exchange rate","ESP","Spain","2014","2014",1.2,"B; D","Break; Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","TCPPERMT","/capita, US$ exchange rate","ESP","Spain","2015","2015",1,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","TCPPERMT","/capita, US$ exchange rate","ESP","Spain","2016","2016",1,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","TCPPERMT","/capita, US$ exchange rate","ESP","Spain","2017","2017",1.1,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","TCPPERMT","/capita, US$ exchange rate","ESP","Spain","2018","2018",2.9,,
+"PATCHYPO","C02-Antihypertensives","TCPPERMT","/capita, US$ exchange rate","ESP","Spain","2019","2019",3,,
+"PATCHYPO","C02-Antihypertensives","TCPPERMT","/capita, US$ exchange rate","ESP","Spain","2020","2020",3.1,,
+"PATCHYPO","C02-Antihypertensives","TCPPERMT","/capita, US$ exchange rate","ESP","Spain","2021","2021",2.5,,
+"PATCHYPO","C02-Antihypertensives","TCPPERMT","/capita, US$ exchange rate","ESP","Spain","2022","2022",2.3,"P","Provisional value"
+"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2010","2010",1.7,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2011","2011",1.3,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2012","2012",1.2,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2013","2013",1.3,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2014","2014",1.3,"B; D","Break; Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2015","2015",1.3,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2016","2016",1.4,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2017","2017",1.5,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2018","2018",4,,
+"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2019","2019",4.4,,
+"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2020","2020",4.3,,
+"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2021","2021",3.4,,
+"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2022","2022",3.7,"P","Provisional value"
+"PATCHYPO","C02-Antihypertensives","ATCPTTMT","% of total sales","ESP","Spain","2010","2010",0.4,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","ATCPTTMT","% of total sales","ESP","Spain","2011","2011",0.4,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","ATCPTTMT","% of total sales","ESP","Spain","2012","2012",0.4,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","ATCPTTMT","% of total sales","ESP","Spain","2013","2013",0.4,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","ATCPTTMT","% of total sales","ESP","Spain","2014","2014",0.4,"B; D","Break; Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","ATCPTTMT","% of total sales","ESP","Spain","2015","2015",0.4,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","ATCPTTMT","% of total sales","ESP","Spain","2016","2016",0.3,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","ATCPTTMT","% of total sales","ESP","Spain","2017","2017",0.4,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","ATCPTTMT","% of total sales","ESP","Spain","2018","2018",0.6,"B","Break"
+"PATCHYPO","C02-Antihypertensives","ATCPTTMT","% of total sales","ESP","Spain","2019","2019",0.6,,
+"PATCHYPO","C02-Antihypertensives","ATCPTTMT","% of total sales","ESP","Spain","2020","2020",0.6,,
+"PATCHYPO","C02-Antihypertensives","ATCPTTMT","% of total sales","ESP","Spain","2021","2021",0.5,,
+"PATCHYPO","C02-Antihypertensives","ATCPTTMT","% of total sales","ESP","Spain","2022","2022",0.5,"P","Provisional value"
+"PATCHYPO","C02-Antihypertensives","MLLNCUMT","Million of national currency units","SWE","Sweden","2010","2010",137.8,,
+"PATCHYPO","C02-Antihypertensives","MLLNCUMT","Million of national currency units","SWE","Sweden","2011","2011",145.3,,
+"PATCHYPO","C02-Antihypertensives","MLLNCUMT","Million of national currency units","SWE","Sweden","2012","2012",147.5,,
+"PATCHYPO","C02-Antihypertensives","MLLNCUMT","Million of national currency units","SWE","Sweden","2013","2013",154.1,,
+"PATCHYPO","C02-Antihypertensives","MLLNCUMT","Million of national currency units","SWE","Sweden","2014","2014",181.4,,
+"PATCHYPO","C02-Antihypertensives","MLLNCUMT","Million of national currency units","SWE","Sweden","2015","2015",214.2,,
+"PATCHYPO","C02-Antihypertensives","MLLNCUMT","Million of national currency units","SWE","Sweden","2016","2016",211.9,,
+"PATCHYPO","C02-Antihypertensives","MLLNCUMT","Million of national currency units","SWE","Sweden","2017","2017",226.1,,
+"PATCHYPO","C02-Antihypertensives","MLLNCUMT","Million of national currency units","SWE","Sweden","2018","2018",221.4,,
+"PATCHYPO","C02-Antihypertensives","MLLNCUMT","Million of national currency units","SWE","Sweden","2019","2019",251.8,,
+"PATCHYPO","C02-Antihypertensives","MLLNCUMT","Million of national currency units","SWE","Sweden","2020","2020",307.1,,
+"PATCHYPO","C02-Antihypertensives","MLLNCUMT","Million of national currency units","SWE","Sweden","2021","2021",299.7,,
+"PATCHYPO","C02-Antihypertensives","MLLNCUMT","Million of national currency units","SWE","Sweden","2022","2022",305.1,,
+"PATCHYPO","C02-Antihypertensives","MTMOTCMT","Million US$ at exchange rate","SWE","Sweden","2010","2010",19.1,,
+"PATCHYPO","C02-Antihypertensives","MTMOTCMT","Million US$ at exchange rate","SWE","Sweden","2011","2011",22.4,,
+"PATCHYPO","C02-Antihypertensives","MTMOTCMT","Million US$ at exchange rate","SWE","Sweden","2012","2012",21.8,,
+"PATCHYPO","C02-Antihypertensives","MTMOTCMT","Million US$ at exchange rate","SWE","Sweden","2013","2013",23.7,,
+"PATCHYPO","C02-Antihypertensives","MTMOTCMT","Million US$ at exchange rate","SWE","Sweden","2014","2014",26.4,,
+"PATCHYPO","C02-Antihypertensives","MTMOTCMT","Million US$ at exchange rate","SWE","Sweden","2015","2015",25.4,,
+"PATCHYPO","C02-Antihypertensives","MTMOTCMT","Million US$ at exchange rate","SWE","Sweden","2016","2016",24.7,,
+"PATCHYPO","C02-Antihypertensives","MTMOTCMT","Million US$ at exchange rate","SWE","Sweden","2017","2017",26.5,,
+"PATCHYPO","C02-Antihypertensives","MTMOTCMT","Million US$ at exchange rate","SWE","Sweden","2018","2018",25.5,,
+"PATCHYPO","C02-Antihypertensives","MTMOTCMT","Million US$ at exchange rate","SWE","Sweden","2019","2019",26.6,,
+"PATCHYPO","C02-Antihypertensives","MTMOTCMT","Million US$ at exchange rate","SWE","Sweden","2020","2020",33.3,,
+"PATCHYPO","C02-Antihypertensives","MTMOTCMT","Million US$ at exchange rate","SWE","Sweden","2021","2021",34.9,,
+"PATCHYPO","C02-Antihypertensives","MTMOTCMT","Million US$ at exchange rate","SWE","Sweden","2022","2022",30.2,,
+"PATCHYPO","C02-Antihypertensives","MTMOPPMT","Million US$, purchasing power parity","SWE","Sweden","2010","2010",15.3,,
+"PATCHYPO","C02-Antihypertensives","MTMOPPMT","Million US$, purchasing power parity","SWE","Sweden","2011","2011",16.4,,
+"PATCHYPO","C02-Antihypertensives","MTMOPPMT","Million US$, purchasing power parity","SWE","Sweden","2012","2012",17,,
+"PATCHYPO","C02-Antihypertensives","MTMOPPMT","Million US$, purchasing power parity","SWE","Sweden","2013","2013",17.9,,
+"PATCHYPO","C02-Antihypertensives","MTMOPPMT","Million US$, purchasing power parity","SWE","Sweden","2014","2014",20.8,,
+"PATCHYPO","C02-Antihypertensives","MTMOPPMT","Million US$, purchasing power parity","SWE","Sweden","2015","2015",24.2,,
+"PATCHYPO","C02-Antihypertensives","MTMOPPMT","Million US$, purchasing power parity","SWE","Sweden","2016","2016",24,,
+"PATCHYPO","C02-Antihypertensives","MTMOPPMT","Million US$, purchasing power parity","SWE","Sweden","2017","2017",25.5,,
+"PATCHYPO","C02-Antihypertensives","MTMOPPMT","Million US$, purchasing power parity","SWE","Sweden","2018","2018",25,,
+"PATCHYPO","C02-Antihypertensives","MTMOPPMT","Million US$, purchasing power parity","SWE","Sweden","2019","2019",28.9,,
+"PATCHYPO","C02-Antihypertensives","MTMOPPMT","Million US$, purchasing power parity","SWE","Sweden","2020","2020",35.4,,
+"PATCHYPO","C02-Antihypertensives","MTMOPPMT","Million US$, purchasing power parity","SWE","Sweden","2021","2021",34.4,,
+"PATCHYPO","C02-Antihypertensives","MTMOPPMT","Million US$, purchasing power parity","SWE","Sweden","2022","2022",35.2,,
+"PATCHYPO","C02-Antihypertensives","TCPPERMT","/capita, US$ exchange rate","SWE","Sweden","2010","2010",2,,
+"PATCHYPO","C02-Antihypertensives","TCPPERMT","/capita, US$ exchange rate","SWE","Sweden","2011","2011",2.4,,
+"PATCHYPO","C02-Antihypertensives","TCPPERMT","/capita, US$ exchange rate","SWE","Sweden","2012","2012",2.3,,
+"PATCHYPO","C02-Antihypertensives","TCPPERMT","/capita, US$ exchange rate","SWE","Sweden","2013","2013",2.5,,
+"PATCHYPO","C02-Antihypertensives","TCPPERMT","/capita, US$ exchange rate","SWE","Sweden","2014","2014",2.7,,
+"PATCHYPO","C02-Antihypertensives","TCPPERMT","/capita, US$ exchange rate","SWE","Sweden","2015","2015",2.6,,
+"PATCHYPO","C02-Antihypertensives","TCPPERMT","/capita, US$ exchange rate","SWE","Sweden","2016","2016",2.5,,
+"PATCHYPO","C02-Antihypertensives","TCPPERMT","/capita, US$ exchange rate","SWE","Sweden","2017","2017",2.6,,
+"PATCHYPO","C02-Antihypertensives","TCPPERMT","/capita, US$ exchange rate","SWE","Sweden","2018","2018",2.5,,
+"PATCHYPO","C02-Antihypertensives","TCPPERMT","/capita, US$ exchange rate","SWE","Sweden","2019","2019",2.6,,
+"PATCHYPO","C02-Antihypertensives","TCPPERMT","/capita, US$ exchange rate","SWE","Sweden","2020","2020",3.2,,
+"PATCHYPO","C02-Antihypertensives","TCPPERMT","/capita, US$ exchange rate","SWE","Sweden","2021","2021",3.4,,
+"PATCHYPO","C02-Antihypertensives","TCPPERMT","/capita, US$ exchange rate","SWE","Sweden","2022","2022",2.9,,
+"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2010","2010",1.6,,
+"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2011","2011",1.7,,
+"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2012","2012",1.8,,
+"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2013","2013",1.9,,
+"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2014","2014",2.1,,
+"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2015","2015",2.5,,
+"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2016","2016",2.4,,
+"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2017","2017",2.5,,
+"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2018","2018",2.5,,
+"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2019","2019",2.8,,
+"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2020","2020",3.4,,
+"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2021","2021",3.3,,
+"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2022","2022",3.4,,
+"PATCHYPO","C02-Antihypertensives","ATCPTTMT","% of total sales","SWE","Sweden","2010","2010",0.4,,
+"PATCHYPO","C02-Antihypertensives","ATCPTTMT","% of total sales","SWE","Sweden","2011","2011",0.4,,
+"PATCHYPO","C02-Antihypertensives","ATCPTTMT","% of total sales","SWE","Sweden","2012","2012",0.4,,
+"PATCHYPO","C02-Antihypertensives","ATCPTTMT","% of total sales","SWE","Sweden","2013","2013",0.4,,
+"PATCHYPO","C02-Antihypertensives","ATCPTTMT","% of total sales","SWE","Sweden","2014","2014",0.5,,
+"PATCHYPO","C02-Antihypertensives","ATCPTTMT","% of total sales","SWE","Sweden","2015","2015",0.5,,
+"PATCHYPO","C02-Antihypertensives","ATCPTTMT","% of total sales","SWE","Sweden","2016","2016",0.5,,
+"PATCHYPO","C02-Antihypertensives","ATCPTTMT","% of total sales","SWE","Sweden","2017","2017",0.5,,
+"PATCHYPO","C02-Antihypertensives","ATCPTTMT","% of total sales","SWE","Sweden","2018","2018",0.5,,
+"PATCHYPO","C02-Antihypertensives","ATCPTTMT","% of total sales","SWE","Sweden","2019","2019",0.5,,
+"PATCHYPO","C02-Antihypertensives","ATCPTTMT","% of total sales","SWE","Sweden","2020","2020",0.6,,
+"PATCHYPO","C02-Antihypertensives","ATCPTTMT","% of total sales","SWE","Sweden","2021","2021",0.6,,
+"PATCHYPO","C02-Antihypertensives","ATCPTTMT","% of total sales","SWE","Sweden","2022","2022",0.5,,
+"PATCHYPO","C02-Antihypertensives","MLLNCUMT","Million of national currency units","TUR","Türkiye","2010","2010",26.1,,
+"PATCHYPO","C02-Antihypertensives","MLLNCUMT","Million of national currency units","TUR","Türkiye","2011","2011",26.5,,
+"PATCHYPO","C02-Antihypertensives","MLLNCUMT","Million of national currency units","TUR","Türkiye","2012","2012",26.5,,
+"PATCHYPO","C02-Antihypertensives","MLLNCUMT","Million of national currency units","TUR","Türkiye","2013","2013",27.2,,
+"PATCHYPO","C02-Antihypertensives","MLLNCUMT","Million of national currency units","TUR","Türkiye","2014","2014",28.5,,
+"PATCHYPO","C02-Antihypertensives","MLLNCUMT","Million of national currency units","TUR","Türkiye","2015","2015",28.5,,
+"PATCHYPO","C02-Antihypertensives","MLLNCUMT","Million of national currency units","TUR","Türkiye","2016","2016",27.6,,
+"PATCHYPO","C02-Antihypertensives","MLLNCUMT","Million of national currency units","TUR","Türkiye","2017","2017",45,,
+"PATCHYPO","C02-Antihypertensives","MLLNCUMT","Million of national currency units","TUR","Türkiye","2018","2018",52.1,,
+"PATCHYPO","C02-Antihypertensives","MLLNCUMT","Million of national currency units","TUR","Türkiye","2019","2019",70.4,,
+"PATCHYPO","C02-Antihypertensives","MLLNCUMT","Million of national currency units","TUR","Türkiye","2020","2020",88.6,,
+"PATCHYPO","C02-Antihypertensives","MLLNCUMT","Million of national currency units","TUR","Türkiye","2021","2021",117.3,,
+"PATCHYPO","C02-Antihypertensives","MTMOTCMT","Million US$ at exchange rate","TUR","Türkiye","2010","2010",17.3,,
+"PATCHYPO","C02-Antihypertensives","MTMOTCMT","Million US$ at exchange rate","TUR","Türkiye","2011","2011",15.8,,
+"PATCHYPO","C02-Antihypertensives","MTMOTCMT","Million US$ at exchange rate","TUR","Türkiye","2012","2012",14.7,,
+"PATCHYPO","C02-Antihypertensives","MTMOTCMT","Million US$ at exchange rate","TUR","Türkiye","2013","2013",14.3,,
+"PATCHYPO","C02-Antihypertensives","MTMOTCMT","Million US$ at exchange rate","TUR","Türkiye","2014","2014",13,,
+"PATCHYPO","C02-Antihypertensives","MTMOTCMT","Million US$ at exchange rate","TUR","Türkiye","2015","2015",10.5,,
+"PATCHYPO","C02-Antihypertensives","MTMOTCMT","Million US$ at exchange rate","TUR","Türkiye","2016","2016",9.1,,
+"PATCHYPO","C02-Antihypertensives","MTMOTCMT","Million US$ at exchange rate","TUR","Türkiye","2017","2017",12.3,,
+"PATCHYPO","C02-Antihypertensives","MTMOTCMT","Million US$ at exchange rate","TUR","Türkiye","2018","2018",10.8,,
+"PATCHYPO","C02-Antihypertensives","MTMOTCMT","Million US$ at exchange rate","TUR","Türkiye","2019","2019",12.4,,
+"PATCHYPO","C02-Antihypertensives","MTMOTCMT","Million US$ at exchange rate","TUR","Türkiye","2020","2020",12.6,,
+"PATCHYPO","C02-Antihypertensives","MTMOTCMT","Million US$ at exchange rate","TUR","Türkiye","2021","2021",13.3,,
+"PATCHYPO","C02-Antihypertensives","MTMOPPMT","Million US$, purchasing power parity","TUR","Türkiye","2010","2010",28.3,,
+"PATCHYPO","C02-Antihypertensives","MTMOPPMT","Million US$, purchasing power parity","TUR","Türkiye","2011","2011",27.4,,
+"PATCHYPO","C02-Antihypertensives","MTMOPPMT","Million US$, purchasing power parity","TUR","Türkiye","2012","2012",26,,
+"PATCHYPO","C02-Antihypertensives","MTMOPPMT","Million US$, purchasing power parity","TUR","Türkiye","2013","2013",25.4,,
+"PATCHYPO","C02-Antihypertensives","MTMOPPMT","Million US$, purchasing power parity","TUR","Türkiye","2014","2014",25.8,,
+"PATCHYPO","C02-Antihypertensives","MTMOPPMT","Million US$, purchasing power parity","TUR","Türkiye","2015","2015",24.5,,
+"PATCHYPO","C02-Antihypertensives","MTMOPPMT","Million US$, purchasing power parity","TUR","Türkiye","2016","2016",22.3,,
+"PATCHYPO","C02-Antihypertensives","MTMOPPMT","Million US$, purchasing power parity","TUR","Türkiye","2017","2017",32.5,,
+"PATCHYPO","C02-Antihypertensives","MTMOPPMT","Million US$, purchasing power parity","TUR","Türkiye","2018","2018",31.9,,
+"PATCHYPO","C02-Antihypertensives","MTMOPPMT","Million US$, purchasing power parity","TUR","Türkiye","2019","2019",37.8,,
+"PATCHYPO","C02-Antihypertensives","MTMOPPMT","Million US$, purchasing power parity","TUR","Türkiye","2020","2020",40.9,,
+"PATCHYPO","C02-Antihypertensives","MTMOPPMT","Million US$, purchasing power parity","TUR","Türkiye","2021","2021",41.8,,
+"PATCHYPO","C02-Antihypertensives","TCPPERMT","/capita, US$ exchange rate","TUR","Türkiye","2010","2010",0.2,,
+"PATCHYPO","C02-Antihypertensives","TCPPERMT","/capita, US$ exchange rate","TUR","Türkiye","2011","2011",0.2,,
+"PATCHYPO","C02-Antihypertensives","TCPPERMT","/capita, US$ exchange rate","TUR","Türkiye","2012","2012",0.2,,
+"PATCHYPO","C02-Antihypertensives","TCPPERMT","/capita, US$ exchange rate","TUR","Türkiye","2013","2013",0.2,,
+"PATCHYPO","C02-Antihypertensives","TCPPERMT","/capita, US$ exchange rate","TUR","Türkiye","2014","2014",0.2,,
+"PATCHYPO","C02-Antihypertensives","TCPPERMT","/capita, US$ exchange rate","TUR","Türkiye","2015","2015",0.1,,
+"PATCHYPO","C02-Antihypertensives","TCPPERMT","/capita, US$ exchange rate","TUR","Türkiye","2016","2016",0.1,,
+"PATCHYPO","C02-Antihypertensives","TCPPERMT","/capita, US$ exchange rate","TUR","Türkiye","2017","2017",0.2,,
+"PATCHYPO","C02-Antihypertensives","TCPPERMT","/capita, US$ exchange rate","TUR","Türkiye","2018","2018",0.1,,
+"PATCHYPO","C02-Antihypertensives","TCPPERMT","/capita, US$ exchange rate","TUR","Türkiye","2019","2019",0.2,,
+"PATCHYPO","C02-Antihypertensives","TCPPERMT","/capita, US$ exchange rate","TUR","Türkiye","2020","2020",0.2,,
+"PATCHYPO","C02-Antihypertensives","TCPPERMT","/capita, US$ exchange rate","TUR","Türkiye","2021","2021",0.2,,
+"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2010","2010",0.4,,
+"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2011","2011",0.4,,
+"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2012","2012",0.3,,
+"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2013","2013",0.3,,
+"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2014","2014",0.3,,
+"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2015","2015",0.3,,
+"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2016","2016",0.3,,
+"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2017","2017",0.4,,
+"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2018","2018",0.4,,
+"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2019","2019",0.5,,
+"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2020","2020",0.5,,
+"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2021","2021",0.5,,
+"PATCHYPO","C02-Antihypertensives","ATCPTTMT","% of total sales","TUR","Türkiye","2010","2010",0.2,,
+"PATCHYPO","C02-Antihypertensives","ATCPTTMT","% of total sales","TUR","Türkiye","2011","2011",0.2,,
+"PATCHYPO","C02-Antihypertensives","ATCPTTMT","% of total sales","TUR","Türkiye","2012","2012",0.2,,
+"PATCHYPO","C02-Antihypertensives","ATCPTTMT","% of total sales","TUR","Türkiye","2013","2013",0.2,,
+"PATCHYPO","C02-Antihypertensives","ATCPTTMT","% of total sales","TUR","Türkiye","2014","2014",0.2,,
+"PATCHYPO","C02-Antihypertensives","ATCPTTMT","% of total sales","TUR","Türkiye","2015","2015",0.2,,
+"PATCHYPO","C02-Antihypertensives","ATCPTTMT","% of total sales","TUR","Türkiye","2016","2016",0.1,,
+"PATCHYPO","C02-Antihypertensives","ATCPTTMT","% of total sales","TUR","Türkiye","2017","2017",0.2,,
+"PATCHYPO","C02-Antihypertensives","ATCPTTMT","% of total sales","TUR","Türkiye","2018","2018",0.2,,
+"PATCHYPO","C02-Antihypertensives","ATCPTTMT","% of total sales","TUR","Türkiye","2019","2019",0.2,,
+"PATCHYPO","C02-Antihypertensives","ATCPTTMT","% of total sales","TUR","Türkiye","2020","2020",0.2,,
+"PATCHYPO","C02-Antihypertensives","ATCPTTMT","% of total sales","TUR","Türkiye","2021","2021",0.2,,
+"PATCHYPO","C02-Antihypertensives","MLLNCUMT","Million of national currency units","CHL","Chile","2010","2010",1699.3,,
+"PATCHYPO","C02-Antihypertensives","MLLNCUMT","Million of national currency units","CHL","Chile","2011","2011",2317.9,"B","Break"
+"PATCHYPO","C02-Antihypertensives","MLLNCUMT","Million of national currency units","CHL","Chile","2012","2012",2551.3,,
+"PATCHYPO","C02-Antihypertensives","MLLNCUMT","Million of national currency units","CHL","Chile","2013","2013",2861.8,,
+"PATCHYPO","C02-Antihypertensives","MLLNCUMT","Million of national currency units","CHL","Chile","2014","2014",3129,,
+"PATCHYPO","C02-Antihypertensives","MLLNCUMT","Million of national currency units","CHL","Chile","2015","2015",3557.7,,
+"PATCHYPO","C02-Antihypertensives","MLLNCUMT","Million of national currency units","CHL","Chile","2016","2016",4456.9,,
+"PATCHYPO","C02-Antihypertensives","MLLNCUMT","Million of national currency units","CHL","Chile","2017","2017",4932.3,,
+"PATCHYPO","C02-Antihypertensives","MLLNCUMT","Million of national currency units","CHL","Chile","2018","2018",6971.2,,
+"PATCHYPO","C02-Antihypertensives","MLLNCUMT","Million of national currency units","CHL","Chile","2019","2019",8295.7,,
+"PATCHYPO","C02-Antihypertensives","MLLNCUMT","Million of national currency units","CHL","Chile","2020","2020",7817.8,,
+"PATCHYPO","C02-Antihypertensives","MLLNCUMT","Million of national currency units","CHL","Chile","2021","2021",6964.7,,
+"PATCHYPO","C02-Antihypertensives","MLLNCUMT","Million of national currency units","CHL","Chile","2022","2022",7014.8,,
+"PATCHYPO","C02-Antihypertensives","MTMOTCMT","Million US$ at exchange rate","CHL","Chile","2010","2010",3.3,,
+"PATCHYPO","C02-Antihypertensives","MTMOTCMT","Million US$ at exchange rate","CHL","Chile","2011","2011",4.8,"B","Break"
+"PATCHYPO","C02-Antihypertensives","MTMOTCMT","Million US$ at exchange rate","CHL","Chile","2012","2012",5.2,,
+"PATCHYPO","C02-Antihypertensives","MTMOTCMT","Million US$ at exchange rate","CHL","Chile","2013","2013",5.8,,
+"PATCHYPO","C02-Antihypertensives","MTMOTCMT","Million US$ at exchange rate","CHL","Chile","2014","2014",5.5,,
+"PATCHYPO","C02-Antihypertensives","MTMOTCMT","Million US$ at exchange rate","CHL","Chile","2015","2015",5.4,,
+"PATCHYPO","C02-Antihypertensives","MTMOTCMT","Million US$ at exchange rate","CHL","Chile","2016","2016",6.6,,
+"PATCHYPO","C02-Antihypertensives","MTMOTCMT","Million US$ at exchange rate","CHL","Chile","2017","2017",7.6,,
+"PATCHYPO","C02-Antihypertensives","MTMOTCMT","Million US$ at exchange rate","CHL","Chile","2018","2018",10.9,,
+"PATCHYPO","C02-Antihypertensives","MTMOTCMT","Million US$ at exchange rate","CHL","Chile","2019","2019",11.8,,
+"PATCHYPO","C02-Antihypertensives","MTMOTCMT","Million US$ at exchange rate","CHL","Chile","2020","2020",9.9,,
+"PATCHYPO","C02-Antihypertensives","MTMOTCMT","Million US$ at exchange rate","CHL","Chile","2021","2021",9.2,,
+"PATCHYPO","C02-Antihypertensives","MTMOTCMT","Million US$ at exchange rate","CHL","Chile","2022","2022",8,,
+"PATCHYPO","C02-Antihypertensives","MTMOPPMT","Million US$, purchasing power parity","CHL","Chile","2010","2010",4.7,,
+"PATCHYPO","C02-Antihypertensives","MTMOPPMT","Million US$, purchasing power parity","CHL","Chile","2011","2011",6.7,"B","Break"
+"PATCHYPO","C02-Antihypertensives","MTMOPPMT","Million US$, purchasing power parity","CHL","Chile","2012","2012",7.3,,
+"PATCHYPO","C02-Antihypertensives","MTMOPPMT","Million US$, purchasing power parity","CHL","Chile","2013","2013",8.2,,
+"PATCHYPO","C02-Antihypertensives","MTMOPPMT","Million US$, purchasing power parity","CHL","Chile","2014","2014",8.5,,
+"PATCHYPO","C02-Antihypertensives","MTMOPPMT","Million US$, purchasing power parity","CHL","Chile","2015","2015",9.1,,
+"PATCHYPO","C02-Antihypertensives","MTMOPPMT","Million US$, purchasing power parity","CHL","Chile","2016","2016",11.2,,
+"PATCHYPO","C02-Antihypertensives","MTMOPPMT","Million US$, purchasing power parity","CHL","Chile","2017","2017",12.4,,
+"PATCHYPO","C02-Antihypertensives","MTMOPPMT","Million US$, purchasing power parity","CHL","Chile","2018","2018",17.6,,
+"PATCHYPO","C02-Antihypertensives","MTMOPPMT","Million US$, purchasing power parity","CHL","Chile","2019","2019",20.7,,
+"PATCHYPO","C02-Antihypertensives","MTMOPPMT","Million US$, purchasing power parity","CHL","Chile","2020","2020",18.7,,
+"PATCHYPO","C02-Antihypertensives","MTMOPPMT","Million US$, purchasing power parity","CHL","Chile","2021","2021",16,,
+"PATCHYPO","C02-Antihypertensives","MTMOPPMT","Million US$, purchasing power parity","CHL","Chile","2022","2022",16,,
+"PATCHYPO","C02-Antihypertensives","TCPPERMT","/capita, US$ exchange rate","CHL","Chile","2010","2010",0.2,,
+"PATCHYPO","C02-Antihypertensives","TCPPERMT","/capita, US$ exchange rate","CHL","Chile","2011","2011",0.3,"B","Break"
+"PATCHYPO","C02-Antihypertensives","TCPPERMT","/capita, US$ exchange rate","CHL","Chile","2012","2012",0.3,,
+"PATCHYPO","C02-Antihypertensives","TCPPERMT","/capita, US$ exchange rate","CHL","Chile","2013","2013",0.3,,
+"PATCHYPO","C02-Antihypertensives","TCPPERMT","/capita, US$ exchange rate","CHL","Chile","2014","2014",0.3,,
+"PATCHYPO","C02-Antihypertensives","TCPPERMT","/capita, US$ exchange rate","CHL","Chile","2015","2015",0.3,,
+"PATCHYPO","C02-Antihypertensives","TCPPERMT","/capita, US$ exchange rate","CHL","Chile","2016","2016",0.4,,
+"PATCHYPO","C02-Antihypertensives","TCPPERMT","/capita, US$ exchange rate","CHL","Chile","2017","2017",0.4,,
+"PATCHYPO","C02-Antihypertensives","TCPPERMT","/capita, US$ exchange rate","CHL","Chile","2018","2018",0.6,,
+"PATCHYPO","C02-Antihypertensives","TCPPERMT","/capita, US$ exchange rate","CHL","Chile","2019","2019",0.6,,
+"PATCHYPO","C02-Antihypertensives","TCPPERMT","/capita, US$ exchange rate","CHL","Chile","2020","2020",0.5,,
+"PATCHYPO","C02-Antihypertensives","TCPPERMT","/capita, US$ exchange rate","CHL","Chile","2021","2021",0.5,,
+"PATCHYPO","C02-Antihypertensives","TCPPERMT","/capita, US$ exchange rate","CHL","Chile","2022","2022",0.4,,
+"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2010","2010",0.3,,
+"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2011","2011",0.4,"B","Break"
+"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2012","2012",0.4,,
+"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2013","2013",0.5,,
+"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2014","2014",0.5,,
+"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2015","2015",0.5,,
+"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2016","2016",0.6,,
+"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2017","2017",0.7,,
+"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2018","2018",0.9,,
+"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2019","2019",1.1,,
+"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2020","2020",1,,
+"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2021","2021",0.8,,
+"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2022","2022",0.8,,
+"PATCHYPO","C02-Antihypertensives","ATCPTTMT","% of total sales","CHL","Chile","2010","2010",0.2,,
+"PATCHYPO","C02-Antihypertensives","ATCPTTMT","% of total sales","CHL","Chile","2011","2011",0.2,"B","Break"
+"PATCHYPO","C02-Antihypertensives","ATCPTTMT","% of total sales","CHL","Chile","2012","2012",0.2,,
+"PATCHYPO","C02-Antihypertensives","ATCPTTMT","% of total sales","CHL","Chile","2013","2013",0.2,,
+"PATCHYPO","C02-Antihypertensives","ATCPTTMT","% of total sales","CHL","Chile","2014","2014",0.2,,
+"PATCHYPO","C02-Antihypertensives","ATCPTTMT","% of total sales","CHL","Chile","2015","2015",0.2,,
+"PATCHYPO","C02-Antihypertensives","ATCPTTMT","% of total sales","CHL","Chile","2016","2016",0.2,,
+"PATCHYPO","C02-Antihypertensives","ATCPTTMT","% of total sales","CHL","Chile","2017","2017",0.2,,
+"PATCHYPO","C02-Antihypertensives","ATCPTTMT","% of total sales","CHL","Chile","2018","2018",0.3,,
+"PATCHYPO","C02-Antihypertensives","ATCPTTMT","% of total sales","CHL","Chile","2019","2019",0.3,,
+"PATCHYPO","C02-Antihypertensives","ATCPTTMT","% of total sales","CHL","Chile","2020","2020",0.3,,
+"PATCHYPO","C02-Antihypertensives","ATCPTTMT","% of total sales","CHL","Chile","2021","2021",0.2,,
+"PATCHYPO","C02-Antihypertensives","ATCPTTMT","% of total sales","CHL","Chile","2022","2022",0.2,,
+"PATCHYPO","C02-Antihypertensives","MLLNCUMT","Million of national currency units","EST","Estonia","2010","2010",0.9,,
+"PATCHYPO","C02-Antihypertensives","MLLNCUMT","Million of national currency units","EST","Estonia","2011","2011",0.9,,
+"PATCHYPO","C02-Antihypertensives","MLLNCUMT","Million of national currency units","EST","Estonia","2012","2012",0.9,,
+"PATCHYPO","C02-Antihypertensives","MLLNCUMT","Million of national currency units","EST","Estonia","2013","2013",0.9,,
+"PATCHYPO","C02-Antihypertensives","MLLNCUMT","Million of national currency units","EST","Estonia","2014","2014",0.8,,
+"PATCHYPO","C02-Antihypertensives","MLLNCUMT","Million of national currency units","EST","Estonia","2015","2015",0.8,,
+"PATCHYPO","C02-Antihypertensives","MLLNCUMT","Million of national currency units","EST","Estonia","2016","2016",0.8,,
+"PATCHYPO","C02-Antihypertensives","MLLNCUMT","Million of national currency units","EST","Estonia","2017","2017",0.9,,
+"PATCHYPO","C02-Antihypertensives","MLLNCUMT","Million of national currency units","EST","Estonia","2018","2018",1,,
+"PATCHYPO","C02-Antihypertensives","MLLNCUMT","Million of national currency units","EST","Estonia","2019","2019",1.2,,
+"PATCHYPO","C02-Antihypertensives","MLLNCUMT","Million of national currency units","EST","Estonia","2020","2020",1.4,,
+"PATCHYPO","C02-Antihypertensives","MLLNCUMT","Million of national currency units","EST","Estonia","2021","2021",1.2,,
+"PATCHYPO","C02-Antihypertensives","MLLNCUMT","Million of national currency units","EST","Estonia","2022","2022",1.3,,
+"PATCHYPO","C02-Antihypertensives","MTMOTCMT","Million US$ at exchange rate","EST","Estonia","2010","2010",1.2,,
+"PATCHYPO","C02-Antihypertensives","MTMOTCMT","Million US$ at exchange rate","EST","Estonia","2011","2011",1.2,,
+"PATCHYPO","C02-Antihypertensives","MTMOTCMT","Million US$ at exchange rate","EST","Estonia","2012","2012",1.2,,
+"PATCHYPO","C02-Antihypertensives","MTMOTCMT","Million US$ at exchange rate","EST","Estonia","2013","2013",1.1,,
+"PATCHYPO","C02-Antihypertensives","MTMOTCMT","Million US$ at exchange rate","EST","Estonia","2014","2014",1.1,,
+"PATCHYPO","C02-Antihypertensives","MTMOTCMT","Million US$ at exchange rate","EST","Estonia","2015","2015",0.9,,
+"PATCHYPO","C02-Antihypertensives","MTMOTCMT","Million US$ at exchange rate","EST","Estonia","2016","2016",0.8,,
+"PATCHYPO","C02-Antihypertensives","MTMOTCMT","Million US$ at exchange rate","EST","Estonia","2017","2017",1,,
+"PATCHYPO","C02-Antihypertensives","MTMOTCMT","Million US$ at exchange rate","EST","Estonia","2018","2018",1.2,,
+"PATCHYPO","C02-Antihypertensives","MTMOTCMT","Million US$ at exchange rate","EST","Estonia","2019","2019",1.4,,
+"PATCHYPO","C02-Antihypertensives","MTMOTCMT","Million US$ at exchange rate","EST","Estonia","2020","2020",1.6,,
+"PATCHYPO","C02-Antihypertensives","MTMOTCMT","Million US$ at exchange rate","EST","Estonia","2021","2021",1.4,,
+"PATCHYPO","C02-Antihypertensives","MTMOTCMT","Million US$ at exchange rate","EST","Estonia","2022","2022",1.4,,
+"PATCHYPO","C02-Antihypertensives","MTMOPPMT","Million US$, purchasing power parity","EST","Estonia","2010","2010",1.7,,
+"PATCHYPO","C02-Antihypertensives","MTMOPPMT","Million US$, purchasing power parity","EST","Estonia","2011","2011",1.7,,
+"PATCHYPO","C02-Antihypertensives","MTMOPPMT","Million US$, purchasing power parity","EST","Estonia","2012","2012",1.8,,
+"PATCHYPO","C02-Antihypertensives","MTMOPPMT","Million US$, purchasing power parity","EST","Estonia","2013","2013",1.6,,
+"PATCHYPO","C02-Antihypertensives","MTMOPPMT","Million US$, purchasing power parity","EST","Estonia","2014","2014",1.6,,
+"PATCHYPO","C02-Antihypertensives","MTMOPPMT","Million US$, purchasing power parity","EST","Estonia","2015","2015",1.5,,
+"PATCHYPO","C02-Antihypertensives","MTMOPPMT","Million US$, purchasing power parity","EST","Estonia","2016","2016",1.4,,
+"PATCHYPO","C02-Antihypertensives","MTMOPPMT","Million US$, purchasing power parity","EST","Estonia","2017","2017",1.7,,
+"PATCHYPO","C02-Antihypertensives","MTMOPPMT","Million US$, purchasing power parity","EST","Estonia","2018","2018",1.9,,
+"PATCHYPO","C02-Antihypertensives","MTMOPPMT","Million US$, purchasing power parity","EST","Estonia","2019","2019",2.3,,
+"PATCHYPO","C02-Antihypertensives","MTMOPPMT","Million US$, purchasing power parity","EST","Estonia","2020","2020",2.6,,
+"PATCHYPO","C02-Antihypertensives","MTMOPPMT","Million US$, purchasing power parity","EST","Estonia","2021","2021",2.1,,
+"PATCHYPO","C02-Antihypertensives","MTMOPPMT","Million US$, purchasing power parity","EST","Estonia","2022","2022",2.3,,
+"PATCHYPO","C02-Antihypertensives","TCPPERMT","/capita, US$ exchange rate","EST","Estonia","2010","2010",0.9,,
+"PATCHYPO","C02-Antihypertensives","TCPPERMT","/capita, US$ exchange rate","EST","Estonia","2011","2011",0.9,,
+"PATCHYPO","C02-Antihypertensives","TCPPERMT","/capita, US$ exchange rate","EST","Estonia","2012","2012",0.9,,
+"PATCHYPO","C02-Antihypertensives","TCPPERMT","/capita, US$ exchange rate","EST","Estonia","2013","2013",0.9,,
+"PATCHYPO","C02-Antihypertensives","TCPPERMT","/capita, US$ exchange rate","EST","Estonia","2014","2014",0.8,,
+"PATCHYPO","C02-Antihypertensives","TCPPERMT","/capita, US$ exchange rate","EST","Estonia","2015","2015",0.7,,
+"PATCHYPO","C02-Antihypertensives","TCPPERMT","/capita, US$ exchange rate","EST","Estonia","2016","2016",0.6,,
+"PATCHYPO","C02-Antihypertensives","TCPPERMT","/capita, US$ exchange rate","EST","Estonia","2017","2017",0.8,,
+"PATCHYPO","C02-Antihypertensives","TCPPERMT","/capita, US$ exchange rate","EST","Estonia","2018","2018",0.9,,
+"PATCHYPO","C02-Antihypertensives","TCPPERMT","/capita, US$ exchange rate","EST","Estonia","2019","2019",1,,
+"PATCHYPO","C02-Antihypertensives","TCPPERMT","/capita, US$ exchange rate","EST","Estonia","2020","2020",1.2,,
+"PATCHYPO","C02-Antihypertensives","TCPPERMT","/capita, US$ exchange rate","EST","Estonia","2021","2021",1,,
+"PATCHYPO","C02-Antihypertensives","TCPPERMT","/capita, US$ exchange rate","EST","Estonia","2022","2022",1,,
+"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2010","2010",1.3,,
+"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2011","2011",1.3,,
+"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2012","2012",1.3,,
+"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2013","2013",1.2,,
+"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2014","2014",1.2,,
+"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2015","2015",1.1,,
+"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2016","2016",1.1,,
+"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2017","2017",1.3,,
+"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2018","2018",1.4,,
+"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2019","2019",1.7,,
+"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2020","2020",2,,
+"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2021","2021",1.6,,
+"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2022","2022",1.7,,
+"PATCHYPO","C02-Antihypertensives","ATCPTTMT","% of total sales","EST","Estonia","2010","2010",0.5,,
+"PATCHYPO","C02-Antihypertensives","ATCPTTMT","% of total sales","EST","Estonia","2011","2011",0.4,,
+"PATCHYPO","C02-Antihypertensives","ATCPTTMT","% of total sales","EST","Estonia","2012","2012",0.4,,
+"PATCHYPO","C02-Antihypertensives","ATCPTTMT","% of total sales","EST","Estonia","2013","2013",0.4,,
+"PATCHYPO","C02-Antihypertensives","ATCPTTMT","% of total sales","EST","Estonia","2014","2014",0.3,,
+"PATCHYPO","C02-Antihypertensives","ATCPTTMT","% of total sales","EST","Estonia","2015","2015",0.3,,
+"PATCHYPO","C02-Antihypertensives","ATCPTTMT","% of total sales","EST","Estonia","2016","2016",0.3,,
+"PATCHYPO","C02-Antihypertensives","ATCPTTMT","% of total sales","EST","Estonia","2017","2017",0.3,,
+"PATCHYPO","C02-Antihypertensives","ATCPTTMT","% of total sales","EST","Estonia","2018","2018",0.3,,
+"PATCHYPO","C02-Antihypertensives","ATCPTTMT","% of total sales","EST","Estonia","2019","2019",0.4,,
+"PATCHYPO","C02-Antihypertensives","ATCPTTMT","% of total sales","EST","Estonia","2020","2020",0.4,,
+"PATCHYPO","C02-Antihypertensives","ATCPTTMT","% of total sales","EST","Estonia","2021","2021",0.3,,
+"PATCHYPO","C02-Antihypertensives","ATCPTTMT","% of total sales","EST","Estonia","2022","2022",0.3,,
+"PATCHYPO","C02-Antihypertensives","MLLNCUMT","Million of national currency units","SVN","Slovenia","2010","2010",4.1,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","MLLNCUMT","Million of national currency units","SVN","Slovenia","2011","2011",4.5,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","MLLNCUMT","Million of national currency units","SVN","Slovenia","2012","2012",4.3,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","MLLNCUMT","Million of national currency units","SVN","Slovenia","2013","2013",4.4,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","MLLNCUMT","Million of national currency units","SVN","Slovenia","2014","2014",4,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","MLLNCUMT","Million of national currency units","SVN","Slovenia","2015","2015",3.4,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","MLLNCUMT","Million of national currency units","SVN","Slovenia","2016","2016",3.2,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","MLLNCUMT","Million of national currency units","SVN","Slovenia","2017","2017",3.2,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","MLLNCUMT","Million of national currency units","SVN","Slovenia","2018","2018",3.5,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","MLLNCUMT","Million of national currency units","SVN","Slovenia","2019","2019",3.9,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","MLLNCUMT","Million of national currency units","SVN","Slovenia","2020","2020",4.5,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","MLLNCUMT","Million of national currency units","SVN","Slovenia","2021","2021",4.8,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","MLLNCUMT","Million of national currency units","SVN","Slovenia","2022","2022",4.9,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","MTMOTCMT","Million US$ at exchange rate","SVN","Slovenia","2010","2010",5.5,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","MTMOTCMT","Million US$ at exchange rate","SVN","Slovenia","2011","2011",6.2,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","MTMOTCMT","Million US$ at exchange rate","SVN","Slovenia","2012","2012",5.5,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","MTMOTCMT","Million US$ at exchange rate","SVN","Slovenia","2013","2013",5.8,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","MTMOTCMT","Million US$ at exchange rate","SVN","Slovenia","2014","2014",5.3,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","MTMOTCMT","Million US$ at exchange rate","SVN","Slovenia","2015","2015",3.8,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","MTMOTCMT","Million US$ at exchange rate","SVN","Slovenia","2016","2016",3.5,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","MTMOTCMT","Million US$ at exchange rate","SVN","Slovenia","2017","2017",3.6,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","MTMOTCMT","Million US$ at exchange rate","SVN","Slovenia","2018","2018",4.1,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","MTMOTCMT","Million US$ at exchange rate","SVN","Slovenia","2019","2019",4.4,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","MTMOTCMT","Million US$ at exchange rate","SVN","Slovenia","2020","2020",5.1,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","MTMOTCMT","Million US$ at exchange rate","SVN","Slovenia","2021","2021",5.7,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","MTMOTCMT","Million US$ at exchange rate","SVN","Slovenia","2022","2022",5.2,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","MTMOPPMT","Million US$, purchasing power parity","SVN","Slovenia","2010","2010",6.5,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","MTMOPPMT","Million US$, purchasing power parity","SVN","Slovenia","2011","2011",7.2,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","MTMOPPMT","Million US$, purchasing power parity","SVN","Slovenia","2012","2012",7.1,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","MTMOPPMT","Million US$, purchasing power parity","SVN","Slovenia","2013","2013",7.4,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","MTMOPPMT","Million US$, purchasing power parity","SVN","Slovenia","2014","2014",6.8,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","MTMOPPMT","Million US$, purchasing power parity","SVN","Slovenia","2015","2015",5.7,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","MTMOPPMT","Million US$, purchasing power parity","SVN","Slovenia","2016","2016",5.5,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","MTMOPPMT","Million US$, purchasing power parity","SVN","Slovenia","2017","2017",5.6,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","MTMOPPMT","Million US$, purchasing power parity","SVN","Slovenia","2018","2018",6.2,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","MTMOPPMT","Million US$, purchasing power parity","SVN","Slovenia","2019","2019",7.1,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","MTMOPPMT","Million US$, purchasing power parity","SVN","Slovenia","2020","2020",8.2,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","MTMOPPMT","Million US$, purchasing power parity","SVN","Slovenia","2021","2021",8.6,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","MTMOPPMT","Million US$, purchasing power parity","SVN","Slovenia","2022","2022",8.9,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","TCPPERMT","/capita, US$ exchange rate","SVN","Slovenia","2010","2010",2.7,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","TCPPERMT","/capita, US$ exchange rate","SVN","Slovenia","2011","2011",3,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","TCPPERMT","/capita, US$ exchange rate","SVN","Slovenia","2012","2012",2.7,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","TCPPERMT","/capita, US$ exchange rate","SVN","Slovenia","2013","2013",2.8,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","TCPPERMT","/capita, US$ exchange rate","SVN","Slovenia","2014","2014",2.6,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","TCPPERMT","/capita, US$ exchange rate","SVN","Slovenia","2015","2015",1.8,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","TCPPERMT","/capita, US$ exchange rate","SVN","Slovenia","2016","2016",1.7,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","TCPPERMT","/capita, US$ exchange rate","SVN","Slovenia","2017","2017",1.7,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","TCPPERMT","/capita, US$ exchange rate","SVN","Slovenia","2018","2018",2,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","TCPPERMT","/capita, US$ exchange rate","SVN","Slovenia","2019","2019",2.1,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","TCPPERMT","/capita, US$ exchange rate","SVN","Slovenia","2020","2020",2.4,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","TCPPERMT","/capita, US$ exchange rate","SVN","Slovenia","2021","2021",2.7,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","TCPPERMT","/capita, US$ exchange rate","SVN","Slovenia","2022","2022",2.5,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2010","2010",3.2,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2011","2011",3.5,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2012","2012",3.5,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2013","2013",3.6,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2014","2014",3.3,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2015","2015",2.8,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2016","2016",2.7,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2017","2017",2.7,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2018","2018",3,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2019","2019",3.4,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2020","2020",3.9,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2021","2021",4.1,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2022","2022",4.2,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","ATCPTTMT","% of total sales","SVN","Slovenia","2010","2010",0.9,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","ATCPTTMT","% of total sales","SVN","Slovenia","2011","2011",1,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","ATCPTTMT","% of total sales","SVN","Slovenia","2012","2012",0.9,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","ATCPTTMT","% of total sales","SVN","Slovenia","2013","2013",1,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","ATCPTTMT","% of total sales","SVN","Slovenia","2014","2014",0.9,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","ATCPTTMT","% of total sales","SVN","Slovenia","2015","2015",0.8,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","ATCPTTMT","% of total sales","SVN","Slovenia","2016","2016",0.7,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","ATCPTTMT","% of total sales","SVN","Slovenia","2017","2017",0.7,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","ATCPTTMT","% of total sales","SVN","Slovenia","2018","2018",0.7,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","ATCPTTMT","% of total sales","SVN","Slovenia","2019","2019",0.7,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","ATCPTTMT","% of total sales","SVN","Slovenia","2020","2020",0.8,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","ATCPTTMT","% of total sales","SVN","Slovenia","2021","2021",0.8,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","ATCPTTMT","% of total sales","SVN","Slovenia","2022","2022",0.7,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","MLLNCUMT","Million of national currency units","AUS","Australia","2010","2010",31,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","MLLNCUMT","Million of national currency units","AUS","Australia","2011","2011",30,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","MLLNCUMT","Million of national currency units","AUS","Australia","2012","2012",30,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","MLLNCUMT","Million of national currency units","AUS","Australia","2013","2013",37,"B; D","Break; Difference in methodology"
+"PATCDIUR","C03-Diuretics","MLLNCUMT","Million of national currency units","AUS","Australia","2014","2014",38,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","MLLNCUMT","Million of national currency units","AUS","Australia","2015","2015",43,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","MLLNCUMT","Million of national currency units","AUS","Australia","2016","2016",46,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","MLLNCUMT","Million of national currency units","AUS","Australia","2017","2017",48,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","MLLNCUMT","Million of national currency units","AUS","Australia","2018","2018",49,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","MLLNCUMT","Million of national currency units","AUS","Australia","2019","2019",54,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","MLLNCUMT","Million of national currency units","AUS","Australia","2020","2020",62,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","MLLNCUMT","Million of national currency units","AUS","Australia","2021","2021",65,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","MTMOTCMT","Million US$ at exchange rate","AUS","Australia","2010","2010",28.4,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","MTMOTCMT","Million US$ at exchange rate","AUS","Australia","2011","2011",30.9,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","MTMOTCMT","Million US$ at exchange rate","AUS","Australia","2012","2012",31.1,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","MTMOTCMT","Million US$ at exchange rate","AUS","Australia","2013","2013",35.7,"B; D","Break; Difference in methodology"
+"PATCDIUR","C03-Diuretics","MTMOTCMT","Million US$ at exchange rate","AUS","Australia","2014","2014",34.3,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","MTMOTCMT","Million US$ at exchange rate","AUS","Australia","2015","2015",32.3,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","MTMOTCMT","Million US$ at exchange rate","AUS","Australia","2016","2016",34.2,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","MTMOTCMT","Million US$ at exchange rate","AUS","Australia","2017","2017",36.8,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","MTMOTCMT","Million US$ at exchange rate","AUS","Australia","2018","2018",36.6,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","MTMOTCMT","Million US$ at exchange rate","AUS","Australia","2019","2019",37.5,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","MTMOTCMT","Million US$ at exchange rate","AUS","Australia","2020","2020",42.7,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","MTMOTCMT","Million US$ at exchange rate","AUS","Australia","2021","2021",48.8,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","MTMOPPMT","Million US$, purchasing power parity","AUS","Australia","2010","2010",20.6,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","MTMOPPMT","Million US$, purchasing power parity","AUS","Australia","2011","2011",19.9,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","MTMOPPMT","Million US$, purchasing power parity","AUS","Australia","2012","2012",19.5,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","MTMOPPMT","Million US$, purchasing power parity","AUS","Australia","2013","2013",25.6,"B; D","Break; Difference in methodology"
+"PATCDIUR","C03-Diuretics","MTMOPPMT","Million US$, purchasing power parity","AUS","Australia","2014","2014",26.2,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","MTMOPPMT","Million US$, purchasing power parity","AUS","Australia","2015","2015",29.2,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","MTMOPPMT","Million US$, purchasing power parity","AUS","Australia","2016","2016",31.7,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","MTMOPPMT","Million US$, purchasing power parity","AUS","Australia","2017","2017",32.5,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","MTMOPPMT","Million US$, purchasing power parity","AUS","Australia","2018","2018",33.3,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","MTMOPPMT","Million US$, purchasing power parity","AUS","Australia","2019","2019",36.5,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","MTMOPPMT","Million US$, purchasing power parity","AUS","Australia","2020","2020",42.6,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","MTMOPPMT","Million US$, purchasing power parity","AUS","Australia","2021","2021",44.9,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","TCPPERMT","/capita, US$ exchange rate","AUS","Australia","2010","2010",1.3,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","TCPPERMT","/capita, US$ exchange rate","AUS","Australia","2011","2011",1.4,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","TCPPERMT","/capita, US$ exchange rate","AUS","Australia","2012","2012",1.4,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","TCPPERMT","/capita, US$ exchange rate","AUS","Australia","2013","2013",1.5,"B; D","Break; Difference in methodology"
+"PATCDIUR","C03-Diuretics","TCPPERMT","/capita, US$ exchange rate","AUS","Australia","2014","2014",1.5,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","TCPPERMT","/capita, US$ exchange rate","AUS","Australia","2015","2015",1.4,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","TCPPERMT","/capita, US$ exchange rate","AUS","Australia","2016","2016",1.4,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","TCPPERMT","/capita, US$ exchange rate","AUS","Australia","2017","2017",1.5,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","TCPPERMT","/capita, US$ exchange rate","AUS","Australia","2018","2018",1.5,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","TCPPERMT","/capita, US$ exchange rate","AUS","Australia","2019","2019",1.5,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","TCPPERMT","/capita, US$ exchange rate","AUS","Australia","2020","2020",1.7,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","TCPPERMT","/capita, US$ exchange rate","AUS","Australia","2021","2021",1.9,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2010","2010",0.9,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2011","2011",0.9,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2012","2012",0.9,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2013","2013",1.1,"B; D","Break; Difference in methodology"
+"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2014","2014",1.1,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2015","2015",1.2,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2016","2016",1.3,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2017","2017",1.3,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2018","2018",1.3,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2019","2019",1.4,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2020","2020",1.7,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2021","2021",1.7,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","ATCPTTMT","% of total sales","AUS","Australia","2010","2010",0.3,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","ATCPTTMT","% of total sales","AUS","Australia","2011","2011",0.3,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","ATCPTTMT","% of total sales","AUS","Australia","2012","2012",0.3,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","ATCPTTMT","% of total sales","AUS","Australia","2013","2013",0.3,"B; D","Break; Difference in methodology"
+"PATCDIUR","C03-Diuretics","ATCPTTMT","% of total sales","AUS","Australia","2014","2014",0.3,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","ATCPTTMT","% of total sales","AUS","Australia","2015","2015",0.4,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","ATCPTTMT","% of total sales","AUS","Australia","2016","2016",0.3,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","ATCPTTMT","% of total sales","AUS","Australia","2017","2017",0.3,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","ATCPTTMT","% of total sales","AUS","Australia","2018","2018",0.3,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","ATCPTTMT","% of total sales","AUS","Australia","2019","2019",0.3,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","ATCPTTMT","% of total sales","AUS","Australia","2020","2020",0.4,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","ATCPTTMT","% of total sales","AUS","Australia","2021","2021",0.4,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","MLLNCUMT","Million of national currency units","AUT","Austria","2010","2010",15.8,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","MLLNCUMT","Million of national currency units","AUT","Austria","2011","2011",15.4,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","MLLNCUMT","Million of national currency units","AUT","Austria","2012","2012",15.6,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","MLLNCUMT","Million of national currency units","AUT","Austria","2013","2013",15.4,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","MLLNCUMT","Million of national currency units","AUT","Austria","2014","2014",16.5,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","MLLNCUMT","Million of national currency units","AUT","Austria","2015","2015",16.5,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","MLLNCUMT","Million of national currency units","AUT","Austria","2016","2016",16.9,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","MLLNCUMT","Million of national currency units","AUT","Austria","2017","2017",18.3,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","MLLNCUMT","Million of national currency units","AUT","Austria","2018","2018",20,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","MLLNCUMT","Million of national currency units","AUT","Austria","2019","2019",21.8,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","MLLNCUMT","Million of national currency units","AUT","Austria","2020","2020",24,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","MLLNCUMT","Million of national currency units","AUT","Austria","2021","2021",24.8,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","MTMOTCMT","Million US$ at exchange rate","AUT","Austria","2010","2010",21,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","MTMOTCMT","Million US$ at exchange rate","AUT","Austria","2011","2011",21.4,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","MTMOTCMT","Million US$ at exchange rate","AUT","Austria","2012","2012",20.1,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","MTMOTCMT","Million US$ at exchange rate","AUT","Austria","2013","2013",20.5,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","MTMOTCMT","Million US$ at exchange rate","AUT","Austria","2014","2014",21.9,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","MTMOTCMT","Million US$ at exchange rate","AUT","Austria","2015","2015",18.3,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","MTMOTCMT","Million US$ at exchange rate","AUT","Austria","2016","2016",18.7,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","MTMOTCMT","Million US$ at exchange rate","AUT","Austria","2017","2017",20.7,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","MTMOTCMT","Million US$ at exchange rate","AUT","Austria","2018","2018",23.6,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","MTMOTCMT","Million US$ at exchange rate","AUT","Austria","2019","2019",24.4,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","MTMOTCMT","Million US$ at exchange rate","AUT","Austria","2020","2020",27.4,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","MTMOTCMT","Million US$ at exchange rate","AUT","Austria","2021","2021",29.3,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","MTMOPPMT","Million US$, purchasing power parity","AUT","Austria","2010","2010",18.8,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","MTMOPPMT","Million US$, purchasing power parity","AUT","Austria","2011","2011",18.5,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","MTMOPPMT","Million US$, purchasing power parity","AUT","Austria","2012","2012",19.2,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","MTMOPPMT","Million US$, purchasing power parity","AUT","Austria","2013","2013",19.3,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","MTMOPPMT","Million US$, purchasing power parity","AUT","Austria","2014","2014",20.6,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","MTMOPPMT","Million US$, purchasing power parity","AUT","Austria","2015","2015",20.6,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","MTMOPPMT","Million US$, purchasing power parity","AUT","Austria","2016","2016",21.7,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","MTMOPPMT","Million US$, purchasing power parity","AUT","Austria","2017","2017",23.6,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","MTMOPPMT","Million US$, purchasing power parity","AUT","Austria","2018","2018",26.1,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","MTMOPPMT","Million US$, purchasing power parity","AUT","Austria","2019","2019",29,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","MTMOPPMT","Million US$, purchasing power parity","AUT","Austria","2020","2020",32.2,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","MTMOPPMT","Million US$, purchasing power parity","AUT","Austria","2021","2021",32.8,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","TCPPERMT","/capita, US$ exchange rate","AUT","Austria","2010","2010",2.5,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","TCPPERMT","/capita, US$ exchange rate","AUT","Austria","2011","2011",2.6,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","TCPPERMT","/capita, US$ exchange rate","AUT","Austria","2012","2012",2.4,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","TCPPERMT","/capita, US$ exchange rate","AUT","Austria","2013","2013",2.4,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","TCPPERMT","/capita, US$ exchange rate","AUT","Austria","2014","2014",2.6,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","TCPPERMT","/capita, US$ exchange rate","AUT","Austria","2015","2015",2.1,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","TCPPERMT","/capita, US$ exchange rate","AUT","Austria","2016","2016",2.1,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","TCPPERMT","/capita, US$ exchange rate","AUT","Austria","2017","2017",2.4,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","TCPPERMT","/capita, US$ exchange rate","AUT","Austria","2018","2018",2.7,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","TCPPERMT","/capita, US$ exchange rate","AUT","Austria","2019","2019",2.7,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","TCPPERMT","/capita, US$ exchange rate","AUT","Austria","2020","2020",3.1,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","TCPPERMT","/capita, US$ exchange rate","AUT","Austria","2021","2021",3.3,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2010","2010",2.2,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2011","2011",2.2,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2012","2012",2.3,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2013","2013",2.3,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2014","2014",2.4,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2015","2015",2.4,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2016","2016",2.5,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2017","2017",2.7,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2018","2018",3,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2019","2019",3.3,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2020","2020",3.6,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2021","2021",3.7,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","ATCPTTMT","% of total sales","AUT","Austria","2010","2010",0.6,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","ATCPTTMT","% of total sales","AUT","Austria","2011","2011",0.6,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","ATCPTTMT","% of total sales","AUT","Austria","2012","2012",0.6,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","ATCPTTMT","% of total sales","AUT","Austria","2013","2013",0.6,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","ATCPTTMT","% of total sales","AUT","Austria","2014","2014",0.6,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","ATCPTTMT","% of total sales","AUT","Austria","2015","2015",0.6,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","ATCPTTMT","% of total sales","AUT","Austria","2016","2016",0.6,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","ATCPTTMT","% of total sales","AUT","Austria","2017","2017",0.6,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","ATCPTTMT","% of total sales","AUT","Austria","2018","2018",0.6,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","ATCPTTMT","% of total sales","AUT","Austria","2019","2019",0.7,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","ATCPTTMT","% of total sales","AUT","Austria","2020","2020",0.7,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","ATCPTTMT","% of total sales","AUT","Austria","2021","2021",0.7,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","MLLNCUMT","Million of national currency units","BEL","Belgium","2010","2010",38.1,,
+"PATCDIUR","C03-Diuretics","MLLNCUMT","Million of national currency units","BEL","Belgium","2011","2011",36.9,,
+"PATCDIUR","C03-Diuretics","MLLNCUMT","Million of national currency units","BEL","Belgium","2012","2012",35.7,,
+"PATCDIUR","C03-Diuretics","MLLNCUMT","Million of national currency units","BEL","Belgium","2013","2013",35.2,,
+"PATCDIUR","C03-Diuretics","MLLNCUMT","Million of national currency units","BEL","Belgium","2014","2014",34.7,,
+"PATCDIUR","C03-Diuretics","MLLNCUMT","Million of national currency units","BEL","Belgium","2015","2015",33.5,,
+"PATCDIUR","C03-Diuretics","MLLNCUMT","Million of national currency units","BEL","Belgium","2016","2016",33,,
+"PATCDIUR","C03-Diuretics","MLLNCUMT","Million of national currency units","BEL","Belgium","2017","2017",32.8,,
+"PATCDIUR","C03-Diuretics","MLLNCUMT","Million of national currency units","BEL","Belgium","2018","2018",31.5,,
+"PATCDIUR","C03-Diuretics","MLLNCUMT","Million of national currency units","BEL","Belgium","2019","2019",29,,
+"PATCDIUR","C03-Diuretics","MLLNCUMT","Million of national currency units","BEL","Belgium","2020","2020",28.5,,
+"PATCDIUR","C03-Diuretics","MLLNCUMT","Million of national currency units","BEL","Belgium","2021","2021",27.7,,
+"PATCDIUR","C03-Diuretics","MLLNCUMT","Million of national currency units","BEL","Belgium","2022","2022",28.2,"E","Estimated value"
+"PATCDIUR","C03-Diuretics","MTMOTCMT","Million US$ at exchange rate","BEL","Belgium","2010","2010",50.5,,
+"PATCDIUR","C03-Diuretics","MTMOTCMT","Million US$ at exchange rate","BEL","Belgium","2011","2011",51.3,,
+"PATCDIUR","C03-Diuretics","MTMOTCMT","Million US$ at exchange rate","BEL","Belgium","2012","2012",45.8,,
+"PATCDIUR","C03-Diuretics","MTMOTCMT","Million US$ at exchange rate","BEL","Belgium","2013","2013",46.8,,
+"PATCDIUR","C03-Diuretics","MTMOTCMT","Million US$ at exchange rate","BEL","Belgium","2014","2014",46.1,,
+"PATCDIUR","C03-Diuretics","MTMOTCMT","Million US$ at exchange rate","BEL","Belgium","2015","2015",37.2,,
+"PATCDIUR","C03-Diuretics","MTMOTCMT","Million US$ at exchange rate","BEL","Belgium","2016","2016",36.5,,
+"PATCDIUR","C03-Diuretics","MTMOTCMT","Million US$ at exchange rate","BEL","Belgium","2017","2017",37.1,,
+"PATCDIUR","C03-Diuretics","MTMOTCMT","Million US$ at exchange rate","BEL","Belgium","2018","2018",37.2,,
+"PATCDIUR","C03-Diuretics","MTMOTCMT","Million US$ at exchange rate","BEL","Belgium","2019","2019",32.5,,
+"PATCDIUR","C03-Diuretics","MTMOTCMT","Million US$ at exchange rate","BEL","Belgium","2020","2020",32.6,,
+"PATCDIUR","C03-Diuretics","MTMOTCMT","Million US$ at exchange rate","BEL","Belgium","2021","2021",32.7,,
+"PATCDIUR","C03-Diuretics","MTMOTCMT","Million US$ at exchange rate","BEL","Belgium","2022","2022",29.7,"E","Estimated value"
+"PATCDIUR","C03-Diuretics","MTMOPPMT","Million US$, purchasing power parity","BEL","Belgium","2010","2010",45.6,,
+"PATCDIUR","C03-Diuretics","MTMOPPMT","Million US$, purchasing power parity","BEL","Belgium","2011","2011",44.3,,
+"PATCDIUR","C03-Diuretics","MTMOPPMT","Million US$, purchasing power parity","BEL","Belgium","2012","2012",43.4,,
+"PATCDIUR","C03-Diuretics","MTMOPPMT","Million US$, purchasing power parity","BEL","Belgium","2013","2013",43.7,,
+"PATCDIUR","C03-Diuretics","MTMOPPMT","Million US$, purchasing power parity","BEL","Belgium","2014","2014",43.4,,
+"PATCDIUR","C03-Diuretics","MTMOPPMT","Million US$, purchasing power parity","BEL","Belgium","2015","2015",41.9,,
+"PATCDIUR","C03-Diuretics","MTMOPPMT","Million US$, purchasing power parity","BEL","Belgium","2016","2016",42.2,,
+"PATCDIUR","C03-Diuretics","MTMOPPMT","Million US$, purchasing power parity","BEL","Belgium","2017","2017",42.3,,
+"PATCDIUR","C03-Diuretics","MTMOPPMT","Million US$, purchasing power parity","BEL","Belgium","2018","2018",41.1,,
+"PATCDIUR","C03-Diuretics","MTMOPPMT","Million US$, purchasing power parity","BEL","Belgium","2019","2019",38.9,,
+"PATCDIUR","C03-Diuretics","MTMOPPMT","Million US$, purchasing power parity","BEL","Belgium","2020","2020",39.1,,
+"PATCDIUR","C03-Diuretics","MTMOPPMT","Million US$, purchasing power parity","BEL","Belgium","2021","2021",37.6,,
+"PATCDIUR","C03-Diuretics","MTMOPPMT","Million US$, purchasing power parity","BEL","Belgium","2022","2022",39.6,"E","Estimated value"
+"PATCDIUR","C03-Diuretics","TCPPERMT","/capita, US$ exchange rate","BEL","Belgium","2010","2010",4.6,,
+"PATCDIUR","C03-Diuretics","TCPPERMT","/capita, US$ exchange rate","BEL","Belgium","2011","2011",4.6,,
+"PATCDIUR","C03-Diuretics","TCPPERMT","/capita, US$ exchange rate","BEL","Belgium","2012","2012",4.1,,
+"PATCDIUR","C03-Diuretics","TCPPERMT","/capita, US$ exchange rate","BEL","Belgium","2013","2013",4.2,,
+"PATCDIUR","C03-Diuretics","TCPPERMT","/capita, US$ exchange rate","BEL","Belgium","2014","2014",4.1,,
+"PATCDIUR","C03-Diuretics","TCPPERMT","/capita, US$ exchange rate","BEL","Belgium","2015","2015",3.3,,
+"PATCDIUR","C03-Diuretics","TCPPERMT","/capita, US$ exchange rate","BEL","Belgium","2016","2016",3.2,,
+"PATCDIUR","C03-Diuretics","TCPPERMT","/capita, US$ exchange rate","BEL","Belgium","2017","2017",3.3,,
+"PATCDIUR","C03-Diuretics","TCPPERMT","/capita, US$ exchange rate","BEL","Belgium","2018","2018",3.3,,
+"PATCDIUR","C03-Diuretics","TCPPERMT","/capita, US$ exchange rate","BEL","Belgium","2019","2019",2.8,,
+"PATCDIUR","C03-Diuretics","TCPPERMT","/capita, US$ exchange rate","BEL","Belgium","2020","2020",2.8,,
+"PATCDIUR","C03-Diuretics","TCPPERMT","/capita, US$ exchange rate","BEL","Belgium","2021","2021",2.8,,
+"PATCDIUR","C03-Diuretics","TCPPERMT","/capita, US$ exchange rate","BEL","Belgium","2022","2022",2.6,"E","Estimated value"
+"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2010","2010",4.2,,
+"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2011","2011",4,,
+"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2012","2012",3.9,,
+"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2013","2013",3.9,,
+"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2014","2014",3.9,,
+"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2015","2015",3.7,,
+"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2016","2016",3.7,,
+"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2017","2017",3.7,,
+"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2018","2018",3.6,,
+"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2019","2019",3.4,,
+"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2020","2020",3.4,,
+"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2021","2021",3.2,,
+"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2022","2022",3.4,"E","Estimated value"
+"PATCDIUR","C03-Diuretics","ATCPTTMT","% of total sales","BEL","Belgium","2010","2010",0.6,,
+"PATCDIUR","C03-Diuretics","ATCPTTMT","% of total sales","BEL","Belgium","2011","2011",0.6,,
+"PATCDIUR","C03-Diuretics","ATCPTTMT","% of total sales","BEL","Belgium","2012","2012",0.6,,
+"PATCDIUR","C03-Diuretics","ATCPTTMT","% of total sales","BEL","Belgium","2013","2013",0.6,,
+"PATCDIUR","C03-Diuretics","ATCPTTMT","% of total sales","BEL","Belgium","2014","2014",0.6,,
+"PATCDIUR","C03-Diuretics","ATCPTTMT","% of total sales","BEL","Belgium","2015","2015",0.5,,
+"PATCDIUR","C03-Diuretics","ATCPTTMT","% of total sales","BEL","Belgium","2016","2016",0.5,,
+"PATCDIUR","C03-Diuretics","ATCPTTMT","% of total sales","BEL","Belgium","2017","2017",0.5,,
+"PATCDIUR","C03-Diuretics","ATCPTTMT","% of total sales","BEL","Belgium","2018","2018",0.5,,
+"PATCDIUR","C03-Diuretics","ATCPTTMT","% of total sales","BEL","Belgium","2019","2019",0.4,,
+"PATCDIUR","C03-Diuretics","ATCPTTMT","% of total sales","BEL","Belgium","2020","2020",0.4,,
+"PATCDIUR","C03-Diuretics","ATCPTTMT","% of total sales","BEL","Belgium","2021","2021",0.3,,
+"PATCDIUR","C03-Diuretics","ATCPTTMT","% of total sales","BEL","Belgium","2022","2022",0.3,"E","Estimated value"
+"PATCDIUR","C03-Diuretics","MLLNCUMT","Million of national currency units","CAN","Canada","2012","2012",198.4,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","MLLNCUMT","Million of national currency units","CAN","Canada","2013","2013",200.1,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","MLLNCUMT","Million of national currency units","CAN","Canada","2014","2014",201.9,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","MLLNCUMT","Million of national currency units","CAN","Canada","2015","2015",207,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","MLLNCUMT","Million of national currency units","CAN","Canada","2016","2016",214.3,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","MLLNCUMT","Million of national currency units","CAN","Canada","2017","2017",226.7,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","MLLNCUMT","Million of national currency units","CAN","Canada","2018","2018",258.9,"E; B; D","Estimated value; Break; Difference in methodology"
+"PATCDIUR","C03-Diuretics","MLLNCUMT","Million of national currency units","CAN","Canada","2019","2019",265.8,"E; D","Estimated value; Difference in methodology"
+"PATCDIUR","C03-Diuretics","MLLNCUMT","Million of national currency units","CAN","Canada","2020","2020",298.5,"E; D","Estimated value; Difference in methodology"
+"PATCDIUR","C03-Diuretics","MLLNCUMT","Million of national currency units","CAN","Canada","2021","2021",342.8,"E; D","Estimated value; Difference in methodology"
+"PATCDIUR","C03-Diuretics","MLLNCUMT","Million of national currency units","CAN","Canada","2022","2022",365.6,"E; D","Estimated value; Difference in methodology"
+"PATCDIUR","C03-Diuretics","MTMOTCMT","Million US$ at exchange rate","CAN","Canada","2012","2012",198.5,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","MTMOTCMT","Million US$ at exchange rate","CAN","Canada","2013","2013",194.2,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","MTMOTCMT","Million US$ at exchange rate","CAN","Canada","2014","2014",182.8,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","MTMOTCMT","Million US$ at exchange rate","CAN","Canada","2015","2015",161.9,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","MTMOTCMT","Million US$ at exchange rate","CAN","Canada","2016","2016",161.7,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","MTMOTCMT","Million US$ at exchange rate","CAN","Canada","2017","2017",174.7,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","MTMOTCMT","Million US$ at exchange rate","CAN","Canada","2018","2018",199.8,"E; B; D","Estimated value; Break; Difference in methodology"
+"PATCDIUR","C03-Diuretics","MTMOTCMT","Million US$ at exchange rate","CAN","Canada","2019","2019",200.3,"E; D","Estimated value; Difference in methodology"
+"PATCDIUR","C03-Diuretics","MTMOTCMT","Million US$ at exchange rate","CAN","Canada","2020","2020",222.6,"E; D","Estimated value; Difference in methodology"
+"PATCDIUR","C03-Diuretics","MTMOTCMT","Million US$ at exchange rate","CAN","Canada","2021","2021",273.4,"E; D","Estimated value; Difference in methodology"
+"PATCDIUR","C03-Diuretics","MTMOTCMT","Million US$ at exchange rate","CAN","Canada","2022","2022",280.9,"E; D","Estimated value; Difference in methodology"
+"PATCDIUR","C03-Diuretics","MTMOPPMT","Million US$, purchasing power parity","CAN","Canada","2012","2012",159.4,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","MTMOPPMT","Million US$, purchasing power parity","CAN","Canada","2013","2013",163.5,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","MTMOPPMT","Million US$, purchasing power parity","CAN","Canada","2014","2014",164.1,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","MTMOPPMT","Million US$, purchasing power parity","CAN","Canada","2015","2015",165.9,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","MTMOPPMT","Million US$, purchasing power parity","CAN","Canada","2016","2016",177.5,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","MTMOPPMT","Million US$, purchasing power parity","CAN","Canada","2017","2017",187,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","MTMOPPMT","Million US$, purchasing power parity","CAN","Canada","2018","2018",214.6,"E; B; D","Estimated value; Break; Difference in methodology"
+"PATCDIUR","C03-Diuretics","MTMOPPMT","Million US$, purchasing power parity","CAN","Canada","2019","2019",215.3,"E; D","Estimated value; Difference in methodology"
+"PATCDIUR","C03-Diuretics","MTMOPPMT","Million US$, purchasing power parity","CAN","Canada","2020","2020",242.5,"E; D","Estimated value; Difference in methodology"
+"PATCDIUR","C03-Diuretics","MTMOPPMT","Million US$, purchasing power parity","CAN","Canada","2021","2021",276.9,"E; D","Estimated value; Difference in methodology"
+"PATCDIUR","C03-Diuretics","MTMOPPMT","Million US$, purchasing power parity","CAN","Canada","2022","2022",291.6,"E; D","Estimated value; Difference in methodology"
+"PATCDIUR","C03-Diuretics","TCPPERMT","/capita, US$ exchange rate","CAN","Canada","2012","2012",5.7,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","TCPPERMT","/capita, US$ exchange rate","CAN","Canada","2013","2013",5.5,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","TCPPERMT","/capita, US$ exchange rate","CAN","Canada","2014","2014",5.2,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","TCPPERMT","/capita, US$ exchange rate","CAN","Canada","2015","2015",4.5,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","TCPPERMT","/capita, US$ exchange rate","CAN","Canada","2016","2016",4.5,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","TCPPERMT","/capita, US$ exchange rate","CAN","Canada","2017","2017",4.8,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","TCPPERMT","/capita, US$ exchange rate","CAN","Canada","2018","2018",5.4,"E; B; D","Estimated value; Break; Difference in methodology"
+"PATCDIUR","C03-Diuretics","TCPPERMT","/capita, US$ exchange rate","CAN","Canada","2019","2019",5.3,"E; D","Estimated value; Difference in methodology"
+"PATCDIUR","C03-Diuretics","TCPPERMT","/capita, US$ exchange rate","CAN","Canada","2020","2020",5.9,"E; D","Estimated value; Difference in methodology"
+"PATCDIUR","C03-Diuretics","TCPPERMT","/capita, US$ exchange rate","CAN","Canada","2021","2021",7.1,"E; D","Estimated value; Difference in methodology"
+"PATCDIUR","C03-Diuretics","TCPPERMT","/capita, US$ exchange rate","CAN","Canada","2022","2022",7.2,"E; D","Estimated value; Difference in methodology"
+"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2012","2012",4.6,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2013","2013",4.7,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2014","2014",4.6,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2015","2015",4.6,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2016","2016",4.9,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2017","2017",5.1,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2018","2018",5.8,"E; B; D","Estimated value; Break; Difference in methodology"
+"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2019","2019",5.7,"E; D","Estimated value; Difference in methodology"
+"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2020","2020",6.4,"E; D","Estimated value; Difference in methodology"
+"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2021","2021",7.2,"E; D","Estimated value; Difference in methodology"
+"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2022","2022",7.5,"E; D","Estimated value; Difference in methodology"
+"PATCDIUR","C03-Diuretics","ATCPTTMT","% of total sales","CAN","Canada","2012","2012",0.8,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","ATCPTTMT","% of total sales","CAN","Canada","2013","2013",0.8,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","ATCPTTMT","% of total sales","CAN","Canada","2014","2014",0.8,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","ATCPTTMT","% of total sales","CAN","Canada","2015","2015",0.8,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","ATCPTTMT","% of total sales","CAN","Canada","2016","2016",0.8,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","ATCPTTMT","% of total sales","CAN","Canada","2017","2017",0.8,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","ATCPTTMT","% of total sales","CAN","Canada","2018","2018",0.8,"E; B; D","Estimated value; Break; Difference in methodology"
+"PATCDIUR","C03-Diuretics","ATCPTTMT","% of total sales","CAN","Canada","2019","2019",0.8,"E; D","Estimated value; Difference in methodology"
+"PATCDIUR","C03-Diuretics","ATCPTTMT","% of total sales","CAN","Canada","2020","2020",0.9,"E; D","Estimated value; Difference in methodology"
+"PATCDIUR","C03-Diuretics","ATCPTTMT","% of total sales","CAN","Canada","2021","2021",0.9,"E; D","Estimated value; Difference in methodology"
+"PATCDIUR","C03-Diuretics","ATCPTTMT","% of total sales","CAN","Canada","2022","2022",0.9,"E; D","Estimated value; Difference in methodology"
+"PATCDIUR","C03-Diuretics","MLLNCUMT","Million of national currency units","CZE","Czech Republic","2010","2010",433.7,,
+"PATCDIUR","C03-Diuretics","MLLNCUMT","Million of national currency units","CZE","Czech Republic","2011","2011",420.5,,
+"PATCDIUR","C03-Diuretics","MLLNCUMT","Million of national currency units","CZE","Czech Republic","2012","2012",476.2,,
+"PATCDIUR","C03-Diuretics","MLLNCUMT","Million of national currency units","CZE","Czech Republic","2013","2013",493.5,,
+"PATCDIUR","C03-Diuretics","MLLNCUMT","Million of national currency units","CZE","Czech Republic","2014","2014",534.4,,
+"PATCDIUR","C03-Diuretics","MLLNCUMT","Million of national currency units","CZE","Czech Republic","2015","2015",524.5,,
+"PATCDIUR","C03-Diuretics","MLLNCUMT","Million of national currency units","CZE","Czech Republic","2016","2016",530.9,,
+"PATCDIUR","C03-Diuretics","MLLNCUMT","Million of national currency units","CZE","Czech Republic","2017","2017",525.6,,
+"PATCDIUR","C03-Diuretics","MLLNCUMT","Million of national currency units","CZE","Czech Republic","2018","2018",535.4,,
+"PATCDIUR","C03-Diuretics","MLLNCUMT","Million of national currency units","CZE","Czech Republic","2019","2019",542.7,,
+"PATCDIUR","C03-Diuretics","MLLNCUMT","Million of national currency units","CZE","Czech Republic","2020","2020",531.2,"B","Break"
+"PATCDIUR","C03-Diuretics","MLLNCUMT","Million of national currency units","CZE","Czech Republic","2021","2021",547.6,,
+"PATCDIUR","C03-Diuretics","MTMOTCMT","Million US$ at exchange rate","CZE","Czech Republic","2010","2010",22.7,,
+"PATCDIUR","C03-Diuretics","MTMOTCMT","Million US$ at exchange rate","CZE","Czech Republic","2011","2011",23.8,,
+"PATCDIUR","C03-Diuretics","MTMOTCMT","Million US$ at exchange rate","CZE","Czech Republic","2012","2012",24.3,,
+"PATCDIUR","C03-Diuretics","MTMOTCMT","Million US$ at exchange rate","CZE","Czech Republic","2013","2013",25.2,,
+"PATCDIUR","C03-Diuretics","MTMOTCMT","Million US$ at exchange rate","CZE","Czech Republic","2014","2014",25.7,,
+"PATCDIUR","C03-Diuretics","MTMOTCMT","Million US$ at exchange rate","CZE","Czech Republic","2015","2015",21.3,,
+"PATCDIUR","C03-Diuretics","MTMOTCMT","Million US$ at exchange rate","CZE","Czech Republic","2016","2016",21.7,,
+"PATCDIUR","C03-Diuretics","MTMOTCMT","Million US$ at exchange rate","CZE","Czech Republic","2017","2017",22.5,,
+"PATCDIUR","C03-Diuretics","MTMOTCMT","Million US$ at exchange rate","CZE","Czech Republic","2018","2018",24.6,,
+"PATCDIUR","C03-Diuretics","MTMOTCMT","Million US$ at exchange rate","CZE","Czech Republic","2019","2019",23.7,,
+"PATCDIUR","C03-Diuretics","MTMOTCMT","Million US$ at exchange rate","CZE","Czech Republic","2020","2020",22.9,"B","Break"
+"PATCDIUR","C03-Diuretics","MTMOTCMT","Million US$ at exchange rate","CZE","Czech Republic","2021","2021",25.3,,
+"PATCDIUR","C03-Diuretics","MTMOPPMT","Million US$, purchasing power parity","CZE","Czech Republic","2010","2010",31.7,,
+"PATCDIUR","C03-Diuretics","MTMOPPMT","Million US$, purchasing power parity","CZE","Czech Republic","2011","2011",31.5,,
+"PATCDIUR","C03-Diuretics","MTMOPPMT","Million US$, purchasing power parity","CZE","Czech Republic","2012","2012",35.8,,
+"PATCDIUR","C03-Diuretics","MTMOPPMT","Million US$, purchasing power parity","CZE","Czech Republic","2013","2013",38.6,,
+"PATCDIUR","C03-Diuretics","MTMOPPMT","Million US$, purchasing power parity","CZE","Czech Republic","2014","2014",42.1,,
+"PATCDIUR","C03-Diuretics","MTMOPPMT","Million US$, purchasing power parity","CZE","Czech Republic","2015","2015",40.5,,
+"PATCDIUR","C03-Diuretics","MTMOPPMT","Million US$, purchasing power parity","CZE","Czech Republic","2016","2016",42.2,,
+"PATCDIUR","C03-Diuretics","MTMOPPMT","Million US$, purchasing power parity","CZE","Czech Republic","2017","2017",42.3,,
+"PATCDIUR","C03-Diuretics","MTMOPPMT","Million US$, purchasing power parity","CZE","Czech Republic","2018","2018",43.3,,
+"PATCDIUR","C03-Diuretics","MTMOPPMT","Million US$, purchasing power parity","CZE","Czech Republic","2019","2019",44.2,,
+"PATCDIUR","C03-Diuretics","MTMOPPMT","Million US$, purchasing power parity","CZE","Czech Republic","2020","2020",42.6,"B","Break"
+"PATCDIUR","C03-Diuretics","MTMOPPMT","Million US$, purchasing power parity","CZE","Czech Republic","2021","2021",43,,
+"PATCDIUR","C03-Diuretics","TCPPERMT","/capita, US$ exchange rate","CZE","Czech Republic","2010","2010",2.2,,
+"PATCDIUR","C03-Diuretics","TCPPERMT","/capita, US$ exchange rate","CZE","Czech Republic","2011","2011",2.3,,
+"PATCDIUR","C03-Diuretics","TCPPERMT","/capita, US$ exchange rate","CZE","Czech Republic","2012","2012",2.3,,
+"PATCDIUR","C03-Diuretics","TCPPERMT","/capita, US$ exchange rate","CZE","Czech Republic","2013","2013",2.4,,
+"PATCDIUR","C03-Diuretics","TCPPERMT","/capita, US$ exchange rate","CZE","Czech Republic","2014","2014",2.4,,
+"PATCDIUR","C03-Diuretics","TCPPERMT","/capita, US$ exchange rate","CZE","Czech Republic","2015","2015",2,,
+"PATCDIUR","C03-Diuretics","TCPPERMT","/capita, US$ exchange rate","CZE","Czech Republic","2016","2016",2.1,,
+"PATCDIUR","C03-Diuretics","TCPPERMT","/capita, US$ exchange rate","CZE","Czech Republic","2017","2017",2.1,,
+"PATCDIUR","C03-Diuretics","TCPPERMT","/capita, US$ exchange rate","CZE","Czech Republic","2018","2018",2.3,,
+"PATCDIUR","C03-Diuretics","TCPPERMT","/capita, US$ exchange rate","CZE","Czech Republic","2019","2019",2.2,,
+"PATCDIUR","C03-Diuretics","TCPPERMT","/capita, US$ exchange rate","CZE","Czech Republic","2020","2020",2.1,"B","Break"
+"PATCDIUR","C03-Diuretics","TCPPERMT","/capita, US$ exchange rate","CZE","Czech Republic","2021","2021",2.4,,
+"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czech Republic","2010","2010",3,,
+"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czech Republic","2011","2011",3,,
+"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czech Republic","2012","2012",3.4,,
+"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czech Republic","2013","2013",3.7,,
+"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czech Republic","2014","2014",4,,
+"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czech Republic","2015","2015",3.8,,
+"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czech Republic","2016","2016",4,,
+"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czech Republic","2017","2017",4,,
+"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czech Republic","2018","2018",4.1,,
+"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czech Republic","2019","2019",4.1,,
+"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czech Republic","2020","2020",4,"B","Break"
+"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czech Republic","2021","2021",4.1,,
+"PATCDIUR","C03-Diuretics","ATCPTTMT","% of total sales","CZE","Czech Republic","2010","2010",0.5,,
+"PATCDIUR","C03-Diuretics","ATCPTTMT","% of total sales","CZE","Czech Republic","2011","2011",0.5,,
+"PATCDIUR","C03-Diuretics","ATCPTTMT","% of total sales","CZE","Czech Republic","2012","2012",0.6,,
+"PATCDIUR","C03-Diuretics","ATCPTTMT","% of total sales","CZE","Czech Republic","2013","2013",0.6,,
+"PATCDIUR","C03-Diuretics","ATCPTTMT","% of total sales","CZE","Czech Republic","2014","2014",0.7,,
+"PATCDIUR","C03-Diuretics","ATCPTTMT","% of total sales","CZE","Czech Republic","2015","2015",0.6,,
+"PATCDIUR","C03-Diuretics","ATCPTTMT","% of total sales","CZE","Czech Republic","2016","2016",0.6,,
+"PATCDIUR","C03-Diuretics","ATCPTTMT","% of total sales","CZE","Czech Republic","2017","2017",0.6,,
+"PATCDIUR","C03-Diuretics","ATCPTTMT","% of total sales","CZE","Czech Republic","2018","2018",0.5,,
+"PATCDIUR","C03-Diuretics","ATCPTTMT","% of total sales","CZE","Czech Republic","2019","2019",0.5,,
+"PATCDIUR","C03-Diuretics","ATCPTTMT","% of total sales","CZE","Czech Republic","2020","2020",0.6,"B","Break"
+"PATCDIUR","C03-Diuretics","ATCPTTMT","% of total sales","CZE","Czech Republic","2021","2021",0.6,,
+"PATCDIUR","C03-Diuretics","MLLNCUMT","Million of national currency units","FIN","Finland","2010","2010",9,,
+"PATCDIUR","C03-Diuretics","MLLNCUMT","Million of national currency units","FIN","Finland","2011","2011",8.8,,
+"PATCDIUR","C03-Diuretics","MLLNCUMT","Million of national currency units","FIN","Finland","2012","2012",8.2,,
+"PATCDIUR","C03-Diuretics","MLLNCUMT","Million of national currency units","FIN","Finland","2013","2013",8.3,,
+"PATCDIUR","C03-Diuretics","MLLNCUMT","Million of national currency units","FIN","Finland","2014","2014",8.5,,
+"PATCDIUR","C03-Diuretics","MLLNCUMT","Million of national currency units","FIN","Finland","2015","2015",8.8,,
+"PATCDIUR","C03-Diuretics","MLLNCUMT","Million of national currency units","FIN","Finland","2016","2016",8,,
+"PATCDIUR","C03-Diuretics","MLLNCUMT","Million of national currency units","FIN","Finland","2017","2017",7.9,,
+"PATCDIUR","C03-Diuretics","MLLNCUMT","Million of national currency units","FIN","Finland","2018","2018",8.2,,
+"PATCDIUR","C03-Diuretics","MLLNCUMT","Million of national currency units","FIN","Finland","2019","2019",8.7,,
+"PATCDIUR","C03-Diuretics","MLLNCUMT","Million of national currency units","FIN","Finland","2020","2020",9.1,,
+"PATCDIUR","C03-Diuretics","MLLNCUMT","Million of national currency units","FIN","Finland","2021","2021",9.2,,
+"PATCDIUR","C03-Diuretics","MTMOTCMT","Million US$ at exchange rate","FIN","Finland","2010","2010",11.9,,
+"PATCDIUR","C03-Diuretics","MTMOTCMT","Million US$ at exchange rate","FIN","Finland","2011","2011",12.2,,
+"PATCDIUR","C03-Diuretics","MTMOTCMT","Million US$ at exchange rate","FIN","Finland","2012","2012",10.5,,
+"PATCDIUR","C03-Diuretics","MTMOTCMT","Million US$ at exchange rate","FIN","Finland","2013","2013",11,,
+"PATCDIUR","C03-Diuretics","MTMOTCMT","Million US$ at exchange rate","FIN","Finland","2014","2014",11.3,,
+"PATCDIUR","C03-Diuretics","MTMOTCMT","Million US$ at exchange rate","FIN","Finland","2015","2015",9.8,,
+"PATCDIUR","C03-Diuretics","MTMOTCMT","Million US$ at exchange rate","FIN","Finland","2016","2016",8.9,,
+"PATCDIUR","C03-Diuretics","MTMOTCMT","Million US$ at exchange rate","FIN","Finland","2017","2017",8.9,,
+"PATCDIUR","C03-Diuretics","MTMOTCMT","Million US$ at exchange rate","FIN","Finland","2018","2018",9.7,,
+"PATCDIUR","C03-Diuretics","MTMOTCMT","Million US$ at exchange rate","FIN","Finland","2019","2019",9.7,,
+"PATCDIUR","C03-Diuretics","MTMOTCMT","Million US$ at exchange rate","FIN","Finland","2020","2020",10.4,,
+"PATCDIUR","C03-Diuretics","MTMOTCMT","Million US$ at exchange rate","FIN","Finland","2021","2021",10.9,,
+"PATCDIUR","C03-Diuretics","MTMOPPMT","Million US$, purchasing power parity","FIN","Finland","2010","2010",10,,
+"PATCDIUR","C03-Diuretics","MTMOPPMT","Million US$, purchasing power parity","FIN","Finland","2011","2011",9.8,,
+"PATCDIUR","C03-Diuretics","MTMOPPMT","Million US$, purchasing power parity","FIN","Finland","2012","2012",9,,
+"PATCDIUR","C03-Diuretics","MTMOPPMT","Million US$, purchasing power parity","FIN","Finland","2013","2013",9.2,,
+"PATCDIUR","C03-Diuretics","MTMOPPMT","Million US$, purchasing power parity","FIN","Finland","2014","2014",9.4,,
+"PATCDIUR","C03-Diuretics","MTMOPPMT","Million US$, purchasing power parity","FIN","Finland","2015","2015",9.7,,
+"PATCDIUR","C03-Diuretics","MTMOPPMT","Million US$, purchasing power parity","FIN","Finland","2016","2016",9.1,,
+"PATCDIUR","C03-Diuretics","MTMOPPMT","Million US$, purchasing power parity","FIN","Finland","2017","2017",9.1,,
+"PATCDIUR","C03-Diuretics","MTMOPPMT","Million US$, purchasing power parity","FIN","Finland","2018","2018",9.6,,
+"PATCDIUR","C03-Diuretics","MTMOPPMT","Million US$, purchasing power parity","FIN","Finland","2019","2019",10.4,,
+"PATCDIUR","C03-Diuretics","MTMOPPMT","Million US$, purchasing power parity","FIN","Finland","2020","2020",11.1,,
+"PATCDIUR","C03-Diuretics","MTMOPPMT","Million US$, purchasing power parity","FIN","Finland","2021","2021",11.1,,
+"PATCDIUR","C03-Diuretics","TCPPERMT","/capita, US$ exchange rate","FIN","Finland","2010","2010",2.2,,
+"PATCDIUR","C03-Diuretics","TCPPERMT","/capita, US$ exchange rate","FIN","Finland","2011","2011",2.3,,
+"PATCDIUR","C03-Diuretics","TCPPERMT","/capita, US$ exchange rate","FIN","Finland","2012","2012",1.9,,
+"PATCDIUR","C03-Diuretics","TCPPERMT","/capita, US$ exchange rate","FIN","Finland","2013","2013",2,,
+"PATCDIUR","C03-Diuretics","TCPPERMT","/capita, US$ exchange rate","FIN","Finland","2014","2014",2.1,,
+"PATCDIUR","C03-Diuretics","TCPPERMT","/capita, US$ exchange rate","FIN","Finland","2015","2015",1.8,,
+"PATCDIUR","C03-Diuretics","TCPPERMT","/capita, US$ exchange rate","FIN","Finland","2016","2016",1.6,,
+"PATCDIUR","C03-Diuretics","TCPPERMT","/capita, US$ exchange rate","FIN","Finland","2017","2017",1.6,,
+"PATCDIUR","C03-Diuretics","TCPPERMT","/capita, US$ exchange rate","FIN","Finland","2018","2018",1.8,,
+"PATCDIUR","C03-Diuretics","TCPPERMT","/capita, US$ exchange rate","FIN","Finland","2019","2019",1.8,,
+"PATCDIUR","C03-Diuretics","TCPPERMT","/capita, US$ exchange rate","FIN","Finland","2020","2020",1.9,,
+"PATCDIUR","C03-Diuretics","TCPPERMT","/capita, US$ exchange rate","FIN","Finland","2021","2021",2,,
+"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2010","2010",1.9,,
+"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2011","2011",1.8,,
+"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2012","2012",1.7,,
+"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2013","2013",1.7,,
+"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2014","2014",1.7,,
+"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2015","2015",1.8,,
+"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2016","2016",1.7,,
+"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2017","2017",1.7,,
+"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2018","2018",1.7,,
+"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2019","2019",1.9,,
+"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2020","2020",2,,
+"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2021","2021",2,,
+"PATCDIUR","C03-Diuretics","ATCPTTMT","% of total sales","FIN","Finland","2010","2010",0.5,,
+"PATCDIUR","C03-Diuretics","ATCPTTMT","% of total sales","FIN","Finland","2011","2011",0.5,,
+"PATCDIUR","C03-Diuretics","ATCPTTMT","% of total sales","FIN","Finland","2012","2012",0.4,,
+"PATCDIUR","C03-Diuretics","ATCPTTMT","% of total sales","FIN","Finland","2013","2013",0.4,,
+"PATCDIUR","C03-Diuretics","ATCPTTMT","% of total sales","FIN","Finland","2014","2014",0.4,,
+"PATCDIUR","C03-Diuretics","ATCPTTMT","% of total sales","FIN","Finland","2015","2015",0.4,,
+"PATCDIUR","C03-Diuretics","ATCPTTMT","% of total sales","FIN","Finland","2016","2016",0.3,,
+"PATCDIUR","C03-Diuretics","ATCPTTMT","% of total sales","FIN","Finland","2017","2017",0.3,,
+"PATCDIUR","C03-Diuretics","ATCPTTMT","% of total sales","FIN","Finland","2018","2018",0.3,,
+"PATCDIUR","C03-Diuretics","ATCPTTMT","% of total sales","FIN","Finland","2019","2019",0.3,,
+"PATCDIUR","C03-Diuretics","ATCPTTMT","% of total sales","FIN","Finland","2020","2020",0.3,,
+"PATCDIUR","C03-Diuretics","ATCPTTMT","% of total sales","FIN","Finland","2021","2021",0.3,,
+"PATCDIUR","C03-Diuretics","MLLNCUMT","Million of national currency units","DEU","Germany","2010","2010",392.5,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","MLLNCUMT","Million of national currency units","DEU","Germany","2011","2011",389.1,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","MLLNCUMT","Million of national currency units","DEU","Germany","2012","2012",401.3,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","MLLNCUMT","Million of national currency units","DEU","Germany","2013","2013",418.9,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","MLLNCUMT","Million of national currency units","DEU","Germany","2014","2014",440.5,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","MLLNCUMT","Million of national currency units","DEU","Germany","2015","2015",443.3,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","MLLNCUMT","Million of national currency units","DEU","Germany","2016","2016",449.9,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","MLLNCUMT","Million of national currency units","DEU","Germany","2017","2017",448.5,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","MLLNCUMT","Million of national currency units","DEU","Germany","2018","2018",490.3,"B; D","Break; Difference in methodology"
+"PATCDIUR","C03-Diuretics","MLLNCUMT","Million of national currency units","DEU","Germany","2019","2019",531,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","MLLNCUMT","Million of national currency units","DEU","Germany","2020","2020",559.1,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","MLLNCUMT","Million of national currency units","DEU","Germany","2021","2021",586.6,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","MTMOTCMT","Million US$ at exchange rate","DEU","Germany","2010","2010",520.3,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","MTMOTCMT","Million US$ at exchange rate","DEU","Germany","2011","2011",541.6,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","MTMOTCMT","Million US$ at exchange rate","DEU","Germany","2012","2012",515.6,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","MTMOTCMT","Million US$ at exchange rate","DEU","Germany","2013","2013",556.3,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","MTMOTCMT","Million US$ at exchange rate","DEU","Germany","2014","2014",585.2,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","MTMOTCMT","Million US$ at exchange rate","DEU","Germany","2015","2015",491.8,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","MTMOTCMT","Million US$ at exchange rate","DEU","Germany","2016","2016",498,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","MTMOTCMT","Million US$ at exchange rate","DEU","Germany","2017","2017",506.7,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","MTMOTCMT","Million US$ at exchange rate","DEU","Germany","2018","2018",579,"B; D","Break; Difference in methodology"
+"PATCDIUR","C03-Diuretics","MTMOTCMT","Million US$ at exchange rate","DEU","Germany","2019","2019",594.4,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","MTMOTCMT","Million US$ at exchange rate","DEU","Germany","2020","2020",638.6,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","MTMOTCMT","Million US$ at exchange rate","DEU","Germany","2021","2021",693.8,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","MTMOPPMT","Million US$, purchasing power parity","DEU","Germany","2010","2010",487.5,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","MTMOPPMT","Million US$, purchasing power parity","DEU","Germany","2011","2011",493.3,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","MTMOPPMT","Million US$, purchasing power parity","DEU","Germany","2012","2012",509.8,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","MTMOPPMT","Million US$, purchasing power parity","DEU","Germany","2013","2013",540.7,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","MTMOPPMT","Million US$, purchasing power parity","DEU","Germany","2014","2014",572.9,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","MTMOPPMT","Million US$, purchasing power parity","DEU","Germany","2015","2015",569.7,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","MTMOPPMT","Million US$, purchasing power parity","DEU","Germany","2016","2016",597.8,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","MTMOPPMT","Million US$, purchasing power parity","DEU","Germany","2017","2017",602.2,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","MTMOPPMT","Million US$, purchasing power parity","DEU","Germany","2018","2018",666.7,"B; D","Break; Difference in methodology"
+"PATCDIUR","C03-Diuretics","MTMOPPMT","Million US$, purchasing power parity","DEU","Germany","2019","2019",729.1,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","MTMOPPMT","Million US$, purchasing power parity","DEU","Germany","2020","2020",771.2,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","MTMOPPMT","Million US$, purchasing power parity","DEU","Germany","2021","2021",796.7,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","TCPPERMT","/capita, US$ exchange rate","DEU","Germany","2010","2010",6.4,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","TCPPERMT","/capita, US$ exchange rate","DEU","Germany","2011","2011",6.7,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","TCPPERMT","/capita, US$ exchange rate","DEU","Germany","2012","2012",6.4,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","TCPPERMT","/capita, US$ exchange rate","DEU","Germany","2013","2013",6.9,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","TCPPERMT","/capita, US$ exchange rate","DEU","Germany","2014","2014",7.2,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","TCPPERMT","/capita, US$ exchange rate","DEU","Germany","2015","2015",6,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","TCPPERMT","/capita, US$ exchange rate","DEU","Germany","2016","2016",6,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","TCPPERMT","/capita, US$ exchange rate","DEU","Germany","2017","2017",6.1,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","TCPPERMT","/capita, US$ exchange rate","DEU","Germany","2018","2018",7,"B; D","Break; Difference in methodology"
+"PATCDIUR","C03-Diuretics","TCPPERMT","/capita, US$ exchange rate","DEU","Germany","2019","2019",7.2,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","TCPPERMT","/capita, US$ exchange rate","DEU","Germany","2020","2020",7.7,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","TCPPERMT","/capita, US$ exchange rate","DEU","Germany","2021","2021",8.3,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2010","2010",6,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2011","2011",6.1,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2012","2012",6.3,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2013","2013",6.7,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2014","2014",7.1,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2015","2015",7,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2016","2016",7.3,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2017","2017",7.3,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2018","2018",8,"B; D","Break; Difference in methodology"
+"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2019","2019",8.8,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2020","2020",9.3,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2021","2021",9.6,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","ATCPTTMT","% of total sales","DEU","Germany","2010","2010",1.3,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","ATCPTTMT","% of total sales","DEU","Germany","2011","2011",1.3,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","ATCPTTMT","% of total sales","DEU","Germany","2012","2012",1.3,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","ATCPTTMT","% of total sales","DEU","Germany","2013","2013",1.3,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","ATCPTTMT","% of total sales","DEU","Germany","2014","2014",1.3,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","ATCPTTMT","% of total sales","DEU","Germany","2015","2015",1.3,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","ATCPTTMT","% of total sales","DEU","Germany","2016","2016",1.2,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","ATCPTTMT","% of total sales","DEU","Germany","2017","2017",1.2,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","ATCPTTMT","% of total sales","DEU","Germany","2018","2018",1.1,"B; D","Break; Difference in methodology"
+"PATCDIUR","C03-Diuretics","ATCPTTMT","% of total sales","DEU","Germany","2019","2019",1.1,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","ATCPTTMT","% of total sales","DEU","Germany","2020","2020",1.1,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","ATCPTTMT","% of total sales","DEU","Germany","2021","2021",1.1,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","MLLNCUMT","Million of national currency units","GRC","Greece","2010","2010",36.7,,
+"PATCDIUR","C03-Diuretics","MLLNCUMT","Million of national currency units","GRC","Greece","2011","2011",35.7,,
+"PATCDIUR","C03-Diuretics","MLLNCUMT","Million of national currency units","GRC","Greece","2012","2012",36.9,,
+"PATCDIUR","C03-Diuretics","MLLNCUMT","Million of national currency units","GRC","Greece","2013","2013",38.2,,
+"PATCDIUR","C03-Diuretics","MLLNCUMT","Million of national currency units","GRC","Greece","2014","2014",36.3,,
+"PATCDIUR","C03-Diuretics","MLLNCUMT","Million of national currency units","GRC","Greece","2015","2015",30.8,,
+"PATCDIUR","C03-Diuretics","MLLNCUMT","Million of national currency units","GRC","Greece","2016","2016",34.5,,
+"PATCDIUR","C03-Diuretics","MLLNCUMT","Million of national currency units","GRC","Greece","2017","2017",34.7,,
+"PATCDIUR","C03-Diuretics","MLLNCUMT","Million of national currency units","GRC","Greece","2018","2018",33.4,,
+"PATCDIUR","C03-Diuretics","MLLNCUMT","Million of national currency units","GRC","Greece","2019","2019",32,,
+"PATCDIUR","C03-Diuretics","MLLNCUMT","Million of national currency units","GRC","Greece","2020","2020",29.8,,
+"PATCDIUR","C03-Diuretics","MLLNCUMT","Million of national currency units","GRC","Greece","2021","2021",30,,
+"PATCDIUR","C03-Diuretics","MLLNCUMT","Million of national currency units","GRC","Greece","2022","2022",23.1,,
+"PATCDIUR","C03-Diuretics","MTMOTCMT","Million US$ at exchange rate","GRC","Greece","2010","2010",48.7,,
+"PATCDIUR","C03-Diuretics","MTMOTCMT","Million US$ at exchange rate","GRC","Greece","2011","2011",49.7,,
+"PATCDIUR","C03-Diuretics","MTMOTCMT","Million US$ at exchange rate","GRC","Greece","2012","2012",47.4,,
+"PATCDIUR","C03-Diuretics","MTMOTCMT","Million US$ at exchange rate","GRC","Greece","2013","2013",50.7,,
+"PATCDIUR","C03-Diuretics","MTMOTCMT","Million US$ at exchange rate","GRC","Greece","2014","2014",48.3,,
+"PATCDIUR","C03-Diuretics","MTMOTCMT","Million US$ at exchange rate","GRC","Greece","2015","2015",34.2,,
+"PATCDIUR","C03-Diuretics","MTMOTCMT","Million US$ at exchange rate","GRC","Greece","2016","2016",38.2,,
+"PATCDIUR","C03-Diuretics","MTMOTCMT","Million US$ at exchange rate","GRC","Greece","2017","2017",39.2,,
+"PATCDIUR","C03-Diuretics","MTMOTCMT","Million US$ at exchange rate","GRC","Greece","2018","2018",39.5,,
+"PATCDIUR","C03-Diuretics","MTMOTCMT","Million US$ at exchange rate","GRC","Greece","2019","2019",35.8,,
+"PATCDIUR","C03-Diuretics","MTMOTCMT","Million US$ at exchange rate","GRC","Greece","2020","2020",34.1,,
+"PATCDIUR","C03-Diuretics","MTMOTCMT","Million US$ at exchange rate","GRC","Greece","2021","2021",35.5,,
+"PATCDIUR","C03-Diuretics","MTMOTCMT","Million US$ at exchange rate","GRC","Greece","2022","2022",24.3,,
+"PATCDIUR","C03-Diuretics","MTMOPPMT","Million US$, purchasing power parity","GRC","Greece","2010","2010",50.8,,
+"PATCDIUR","C03-Diuretics","MTMOPPMT","Million US$, purchasing power parity","GRC","Greece","2011","2011",50.1,,
+"PATCDIUR","C03-Diuretics","MTMOPPMT","Million US$, purchasing power parity","GRC","Greece","2012","2012",53.9,,
+"PATCDIUR","C03-Diuretics","MTMOPPMT","Million US$, purchasing power parity","GRC","Greece","2013","2013",60.5,,
+"PATCDIUR","C03-Diuretics","MTMOPPMT","Million US$, purchasing power parity","GRC","Greece","2014","2014",59.5,,
+"PATCDIUR","C03-Diuretics","MTMOPPMT","Million US$, purchasing power parity","GRC","Greece","2015","2015",50.6,,
+"PATCDIUR","C03-Diuretics","MTMOPPMT","Million US$, purchasing power parity","GRC","Greece","2016","2016",58.6,,
+"PATCDIUR","C03-Diuretics","MTMOPPMT","Million US$, purchasing power parity","GRC","Greece","2017","2017",60.3,,
+"PATCDIUR","C03-Diuretics","MTMOPPMT","Million US$, purchasing power parity","GRC","Greece","2018","2018",59.1,,
+"PATCDIUR","C03-Diuretics","MTMOPPMT","Million US$, purchasing power parity","GRC","Greece","2019","2019",58.2,,
+"PATCDIUR","C03-Diuretics","MTMOPPMT","Million US$, purchasing power parity","GRC","Greece","2020","2020",54.8,,
+"PATCDIUR","C03-Diuretics","MTMOPPMT","Million US$, purchasing power parity","GRC","Greece","2021","2021",55.1,,
+"PATCDIUR","C03-Diuretics","MTMOPPMT","Million US$, purchasing power parity","GRC","Greece","2022","2022",43.7,,
+"PATCDIUR","C03-Diuretics","TCPPERMT","/capita, US$ exchange rate","GRC","Greece","2010","2010",4.4,,
+"PATCDIUR","C03-Diuretics","TCPPERMT","/capita, US$ exchange rate","GRC","Greece","2011","2011",4.5,,
+"PATCDIUR","C03-Diuretics","TCPPERMT","/capita, US$ exchange rate","GRC","Greece","2012","2012",4.3,,
+"PATCDIUR","C03-Diuretics","TCPPERMT","/capita, US$ exchange rate","GRC","Greece","2013","2013",4.6,,
+"PATCDIUR","C03-Diuretics","TCPPERMT","/capita, US$ exchange rate","GRC","Greece","2014","2014",4.4,,
+"PATCDIUR","C03-Diuretics","TCPPERMT","/capita, US$ exchange rate","GRC","Greece","2015","2015",3.2,,
+"PATCDIUR","C03-Diuretics","TCPPERMT","/capita, US$ exchange rate","GRC","Greece","2016","2016",3.5,,
+"PATCDIUR","C03-Diuretics","TCPPERMT","/capita, US$ exchange rate","GRC","Greece","2017","2017",3.6,,
+"PATCDIUR","C03-Diuretics","TCPPERMT","/capita, US$ exchange rate","GRC","Greece","2018","2018",3.7,,
+"PATCDIUR","C03-Diuretics","TCPPERMT","/capita, US$ exchange rate","GRC","Greece","2019","2019",3.3,,
+"PATCDIUR","C03-Diuretics","TCPPERMT","/capita, US$ exchange rate","GRC","Greece","2020","2020",3.2,,
+"PATCDIUR","C03-Diuretics","TCPPERMT","/capita, US$ exchange rate","GRC","Greece","2021","2021",3.4,,
+"PATCDIUR","C03-Diuretics","TCPPERMT","/capita, US$ exchange rate","GRC","Greece","2022","2022",2.3,,
+"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2010","2010",4.6,,
+"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2011","2011",4.5,,
+"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2012","2012",4.9,,
+"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2013","2013",5.5,,
+"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2014","2014",5.5,,
+"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2015","2015",4.7,,
+"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2016","2016",5.4,,
+"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2017","2017",5.6,,
+"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2018","2018",5.5,,
+"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2019","2019",5.4,,
+"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2020","2020",5.1,,
+"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2021","2021",5.2,,
+"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2022","2022",4.2,,
+"PATCDIUR","C03-Diuretics","MLLNCUMT","Million of national currency units","HUN","Hungary","2010","2010",4641.1,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","MLLNCUMT","Million of national currency units","HUN","Hungary","2011","2011",4864.6,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","MLLNCUMT","Million of national currency units","HUN","Hungary","2012","2012",4833,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","MLLNCUMT","Million of national currency units","HUN","Hungary","2013","2013",4641.7,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","MLLNCUMT","Million of national currency units","HUN","Hungary","2014","2014",4504.9,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","MLLNCUMT","Million of national currency units","HUN","Hungary","2015","2015",4496.7,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","MLLNCUMT","Million of national currency units","HUN","Hungary","2016","2016",4527.3,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","MLLNCUMT","Million of national currency units","HUN","Hungary","2017","2017",4545.2,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","MLLNCUMT","Million of national currency units","HUN","Hungary","2018","2018",4568.8,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","MLLNCUMT","Million of national currency units","HUN","Hungary","2019","2019",4743.3,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","MLLNCUMT","Million of national currency units","HUN","Hungary","2020","2020",4975.3,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","MLLNCUMT","Million of national currency units","HUN","Hungary","2021","2021",4916.5,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","MLLNCUMT","Million of national currency units","HUN","Hungary","2022","2022",5138.6,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","MTMOTCMT","Million US$ at exchange rate","HUN","Hungary","2010","2010",22.3,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","MTMOTCMT","Million US$ at exchange rate","HUN","Hungary","2011","2011",24.2,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","MTMOTCMT","Million US$ at exchange rate","HUN","Hungary","2012","2012",21.5,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","MTMOTCMT","Million US$ at exchange rate","HUN","Hungary","2013","2013",20.8,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","MTMOTCMT","Million US$ at exchange rate","HUN","Hungary","2014","2014",19.4,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","MTMOTCMT","Million US$ at exchange rate","HUN","Hungary","2015","2015",16.1,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","MTMOTCMT","Million US$ at exchange rate","HUN","Hungary","2016","2016",16.1,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","MTMOTCMT","Million US$ at exchange rate","HUN","Hungary","2017","2017",16.6,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","MTMOTCMT","Million US$ at exchange rate","HUN","Hungary","2018","2018",16.9,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","MTMOTCMT","Million US$ at exchange rate","HUN","Hungary","2019","2019",16.3,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","MTMOTCMT","Million US$ at exchange rate","HUN","Hungary","2020","2020",16.2,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","MTMOTCMT","Million US$ at exchange rate","HUN","Hungary","2021","2021",16.2,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","MTMOTCMT","Million US$ at exchange rate","HUN","Hungary","2022","2022",13.8,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","MTMOPPMT","Million US$, purchasing power parity","HUN","Hungary","2010","2010",36.7,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","MTMOPPMT","Million US$, purchasing power parity","HUN","Hungary","2011","2011",39.1,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","MTMOPPMT","Million US$, purchasing power parity","HUN","Hungary","2012","2012",38.5,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","MTMOPPMT","Million US$, purchasing power parity","HUN","Hungary","2013","2013",37.1,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","MTMOPPMT","Million US$, purchasing power parity","HUN","Hungary","2014","2014",34.8,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","MTMOPPMT","Million US$, purchasing power parity","HUN","Hungary","2015","2015",33.9,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","MTMOPPMT","Million US$, purchasing power parity","HUN","Hungary","2016","2016",34.3,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","MTMOPPMT","Million US$, purchasing power parity","HUN","Hungary","2017","2017",33.4,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","MTMOPPMT","Million US$, purchasing power parity","HUN","Hungary","2018","2018",32.8,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","MTMOPPMT","Million US$, purchasing power parity","HUN","Hungary","2019","2019",33.7,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","MTMOPPMT","Million US$, purchasing power parity","HUN","Hungary","2020","2020",34.2,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","MTMOPPMT","Million US$, purchasing power parity","HUN","Hungary","2021","2021",31.8,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","MTMOPPMT","Million US$, purchasing power parity","HUN","Hungary","2022","2022",31.9,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","TCPPERMT","/capita, US$ exchange rate","HUN","Hungary","2010","2010",2.2,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","TCPPERMT","/capita, US$ exchange rate","HUN","Hungary","2011","2011",2.4,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","TCPPERMT","/capita, US$ exchange rate","HUN","Hungary","2012","2012",2.2,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","TCPPERMT","/capita, US$ exchange rate","HUN","Hungary","2013","2013",2.1,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","TCPPERMT","/capita, US$ exchange rate","HUN","Hungary","2014","2014",2,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","TCPPERMT","/capita, US$ exchange rate","HUN","Hungary","2015","2015",1.6,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","TCPPERMT","/capita, US$ exchange rate","HUN","Hungary","2016","2016",1.6,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","TCPPERMT","/capita, US$ exchange rate","HUN","Hungary","2017","2017",1.7,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","TCPPERMT","/capita, US$ exchange rate","HUN","Hungary","2018","2018",1.7,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","TCPPERMT","/capita, US$ exchange rate","HUN","Hungary","2019","2019",1.7,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","TCPPERMT","/capita, US$ exchange rate","HUN","Hungary","2020","2020",1.7,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","TCPPERMT","/capita, US$ exchange rate","HUN","Hungary","2021","2021",1.7,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","TCPPERMT","/capita, US$ exchange rate","HUN","Hungary","2022","2022",1.4,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2010","2010",3.7,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2011","2011",3.9,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2012","2012",3.9,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2013","2013",3.8,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2014","2014",3.5,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2015","2015",3.4,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2016","2016",3.5,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2017","2017",3.4,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2018","2018",3.4,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2019","2019",3.4,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2020","2020",3.5,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2021","2021",3.3,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2022","2022",3.3,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","ATCPTTMT","% of total sales","HUN","Hungary","2010","2010",0.9,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","ATCPTTMT","% of total sales","HUN","Hungary","2011","2011",0.9,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","ATCPTTMT","% of total sales","HUN","Hungary","2012","2012",1.1,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","ATCPTTMT","% of total sales","HUN","Hungary","2013","2013",1.1,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","ATCPTTMT","% of total sales","HUN","Hungary","2014","2014",1,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","ATCPTTMT","% of total sales","HUN","Hungary","2015","2015",1,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","ATCPTTMT","% of total sales","HUN","Hungary","2016","2016",0.9,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","ATCPTTMT","% of total sales","HUN","Hungary","2017","2017",0.9,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","ATCPTTMT","% of total sales","HUN","Hungary","2018","2018",0.9,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","ATCPTTMT","% of total sales","HUN","Hungary","2019","2019",0.9,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","ATCPTTMT","% of total sales","HUN","Hungary","2020","2020",0.9,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","ATCPTTMT","% of total sales","HUN","Hungary","2021","2021",0.9,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","ATCPTTMT","% of total sales","HUN","Hungary","2022","2022",0.9,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","MLLNCUMT","Million of national currency units","ISL","Iceland","2010","2010",204.5,,
+"PATCDIUR","C03-Diuretics","MLLNCUMT","Million of national currency units","ISL","Iceland","2011","2011",219.2,,
+"PATCDIUR","C03-Diuretics","MLLNCUMT","Million of national currency units","ISL","Iceland","2012","2012",221.6,,
+"PATCDIUR","C03-Diuretics","MLLNCUMT","Million of national currency units","ISL","Iceland","2013","2013",225,,
+"PATCDIUR","C03-Diuretics","MLLNCUMT","Million of national currency units","ISL","Iceland","2014","2014",206.8,,
+"PATCDIUR","C03-Diuretics","MLLNCUMT","Million of national currency units","ISL","Iceland","2015","2015",186.4,,
+"PATCDIUR","C03-Diuretics","MLLNCUMT","Million of national currency units","ISL","Iceland","2016","2016",205.6,,
+"PATCDIUR","C03-Diuretics","MLLNCUMT","Million of national currency units","ISL","Iceland","2017","2017",216.6,,
+"PATCDIUR","C03-Diuretics","MLLNCUMT","Million of national currency units","ISL","Iceland","2018","2018",202.5,,
+"PATCDIUR","C03-Diuretics","MLLNCUMT","Million of national currency units","ISL","Iceland","2019","2019",212.2,,
+"PATCDIUR","C03-Diuretics","MLLNCUMT","Million of national currency units","ISL","Iceland","2020","2020",232.8,,
+"PATCDIUR","C03-Diuretics","MLLNCUMT","Million of national currency units","ISL","Iceland","2021","2021",234.4,,
+"PATCDIUR","C03-Diuretics","MTMOTCMT","Million US$ at exchange rate","ISL","Iceland","2010","2010",1.7,,
+"PATCDIUR","C03-Diuretics","MTMOTCMT","Million US$ at exchange rate","ISL","Iceland","2011","2011",1.9,,
+"PATCDIUR","C03-Diuretics","MTMOTCMT","Million US$ at exchange rate","ISL","Iceland","2012","2012",1.8,,
+"PATCDIUR","C03-Diuretics","MTMOTCMT","Million US$ at exchange rate","ISL","Iceland","2013","2013",1.8,,
+"PATCDIUR","C03-Diuretics","MTMOTCMT","Million US$ at exchange rate","ISL","Iceland","2014","2014",1.8,,
+"PATCDIUR","C03-Diuretics","MTMOTCMT","Million US$ at exchange rate","ISL","Iceland","2015","2015",1.4,,
+"PATCDIUR","C03-Diuretics","MTMOTCMT","Million US$ at exchange rate","ISL","Iceland","2016","2016",1.7,,
+"PATCDIUR","C03-Diuretics","MTMOTCMT","Million US$ at exchange rate","ISL","Iceland","2017","2017",2,,
+"PATCDIUR","C03-Diuretics","MTMOTCMT","Million US$ at exchange rate","ISL","Iceland","2018","2018",1.9,,
+"PATCDIUR","C03-Diuretics","MTMOTCMT","Million US$ at exchange rate","ISL","Iceland","2019","2019",1.7,,
+"PATCDIUR","C03-Diuretics","MTMOTCMT","Million US$ at exchange rate","ISL","Iceland","2020","2020",1.7,,
+"PATCDIUR","C03-Diuretics","MTMOTCMT","Million US$ at exchange rate","ISL","Iceland","2021","2021",1.8,,
+"PATCDIUR","C03-Diuretics","MTMOPPMT","Million US$, purchasing power parity","ISL","Iceland","2010","2010",1.5,,
+"PATCDIUR","C03-Diuretics","MTMOPPMT","Million US$, purchasing power parity","ISL","Iceland","2011","2011",1.6,,
+"PATCDIUR","C03-Diuretics","MTMOPPMT","Million US$, purchasing power parity","ISL","Iceland","2012","2012",1.6,,
+"PATCDIUR","C03-Diuretics","MTMOPPMT","Million US$, purchasing power parity","ISL","Iceland","2013","2013",1.6,,
+"PATCDIUR","C03-Diuretics","MTMOPPMT","Million US$, purchasing power parity","ISL","Iceland","2014","2014",1.5,,
+"PATCDIUR","C03-Diuretics","MTMOPPMT","Million US$, purchasing power parity","ISL","Iceland","2015","2015",1.3,,
+"PATCDIUR","C03-Diuretics","MTMOPPMT","Million US$, purchasing power parity","ISL","Iceland","2016","2016",1.5,,
+"PATCDIUR","C03-Diuretics","MTMOPPMT","Million US$, purchasing power parity","ISL","Iceland","2017","2017",1.6,,
+"PATCDIUR","C03-Diuretics","MTMOPPMT","Million US$, purchasing power parity","ISL","Iceland","2018","2018",1.4,,
+"PATCDIUR","C03-Diuretics","MTMOPPMT","Million US$, purchasing power parity","ISL","Iceland","2019","2019",1.5,,
+"PATCDIUR","C03-Diuretics","MTMOPPMT","Million US$, purchasing power parity","ISL","Iceland","2020","2020",1.6,,
+"PATCDIUR","C03-Diuretics","MTMOPPMT","Million US$, purchasing power parity","ISL","Iceland","2021","2021",1.6,,
+"PATCDIUR","C03-Diuretics","TCPPERMT","/capita, US$ exchange rate","ISL","Iceland","2010","2010",5.3,,
+"PATCDIUR","C03-Diuretics","TCPPERMT","/capita, US$ exchange rate","ISL","Iceland","2011","2011",5.9,,
+"PATCDIUR","C03-Diuretics","TCPPERMT","/capita, US$ exchange rate","ISL","Iceland","2012","2012",5.5,,
+"PATCDIUR","C03-Diuretics","TCPPERMT","/capita, US$ exchange rate","ISL","Iceland","2013","2013",5.7,,
+"PATCDIUR","C03-Diuretics","TCPPERMT","/capita, US$ exchange rate","ISL","Iceland","2014","2014",5.4,,
+"PATCDIUR","C03-Diuretics","TCPPERMT","/capita, US$ exchange rate","ISL","Iceland","2015","2015",4.3,,
+"PATCDIUR","C03-Diuretics","TCPPERMT","/capita, US$ exchange rate","ISL","Iceland","2016","2016",5.1,,
+"PATCDIUR","C03-Diuretics","TCPPERMT","/capita, US$ exchange rate","ISL","Iceland","2017","2017",5.9,,
+"PATCDIUR","C03-Diuretics","TCPPERMT","/capita, US$ exchange rate","ISL","Iceland","2018","2018",5.3,,
+"PATCDIUR","C03-Diuretics","TCPPERMT","/capita, US$ exchange rate","ISL","Iceland","2019","2019",4.8,,
+"PATCDIUR","C03-Diuretics","TCPPERMT","/capita, US$ exchange rate","ISL","Iceland","2020","2020",4.7,,
+"PATCDIUR","C03-Diuretics","TCPPERMT","/capita, US$ exchange rate","ISL","Iceland","2021","2021",5,,
+"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2010","2010",4.8,,
+"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2011","2011",5.1,,
+"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2012","2012",5,,
+"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2013","2013",5.1,,
+"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2014","2014",4.6,,
+"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2015","2015",4,,
+"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2016","2016",4.4,,
+"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2017","2017",4.6,,
+"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2018","2018",4.1,,
+"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2019","2019",4.2,,
+"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2020","2020",4.3,,
+"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2021","2021",4.2,,
+"PATCDIUR","C03-Diuretics","ATCPTTMT","% of total sales","ISL","Iceland","2010","2010",0.8,,
+"PATCDIUR","C03-Diuretics","ATCPTTMT","% of total sales","ISL","Iceland","2011","2011",0.8,,
+"PATCDIUR","C03-Diuretics","ATCPTTMT","% of total sales","ISL","Iceland","2012","2012",0.9,,
+"PATCDIUR","C03-Diuretics","ATCPTTMT","% of total sales","ISL","Iceland","2013","2013",0.9,,
+"PATCDIUR","C03-Diuretics","ATCPTTMT","% of total sales","ISL","Iceland","2014","2014",0.9,,
+"PATCDIUR","C03-Diuretics","ATCPTTMT","% of total sales","ISL","Iceland","2015","2015",0.8,,
+"PATCDIUR","C03-Diuretics","ATCPTTMT","% of total sales","ISL","Iceland","2016","2016",0.8,,
+"PATCDIUR","C03-Diuretics","ATCPTTMT","% of total sales","ISL","Iceland","2017","2017",0.8,,
+"PATCDIUR","C03-Diuretics","ATCPTTMT","% of total sales","ISL","Iceland","2018","2018",0.7,,
+"PATCDIUR","C03-Diuretics","ATCPTTMT","% of total sales","ISL","Iceland","2019","2019",0.6,,
+"PATCDIUR","C03-Diuretics","ATCPTTMT","% of total sales","ISL","Iceland","2020","2020",0.6,,
+"PATCDIUR","C03-Diuretics","ATCPTTMT","% of total sales","ISL","Iceland","2021","2021",0.5,,
+"PATCDIUR","C03-Diuretics","MLLNCUMT","Million of national currency units","IRL","Ireland","2010","2010",15.7,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","MLLNCUMT","Million of national currency units","IRL","Ireland","2011","2011",15.8,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","MLLNCUMT","Million of national currency units","IRL","Ireland","2012","2012",16.4,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","MLLNCUMT","Million of national currency units","IRL","Ireland","2013","2013",16.4,"B; D","Break; Difference in methodology"
+"PATCDIUR","C03-Diuretics","MLLNCUMT","Million of national currency units","IRL","Ireland","2014","2014",15.9,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","MLLNCUMT","Million of national currency units","IRL","Ireland","2015","2015",15.4,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","MLLNCUMT","Million of national currency units","IRL","Ireland","2016","2016",14.7,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","MLLNCUMT","Million of national currency units","IRL","Ireland","2017","2017",14.3,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","MLLNCUMT","Million of national currency units","IRL","Ireland","2018","2018",14,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","MLLNCUMT","Million of national currency units","IRL","Ireland","2019","2019",13.9,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","MLLNCUMT","Million of national currency units","IRL","Ireland","2020","2020",13.9,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","MLLNCUMT","Million of national currency units","IRL","Ireland","2021","2021",14,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","MTMOTCMT","Million US$ at exchange rate","IRL","Ireland","2010","2010",20.8,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","MTMOTCMT","Million US$ at exchange rate","IRL","Ireland","2011","2011",22,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","MTMOTCMT","Million US$ at exchange rate","IRL","Ireland","2012","2012",21.1,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","MTMOTCMT","Million US$ at exchange rate","IRL","Ireland","2013","2013",21.8,"B; D","Break; Difference in methodology"
+"PATCDIUR","C03-Diuretics","MTMOTCMT","Million US$ at exchange rate","IRL","Ireland","2014","2014",21.2,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","MTMOTCMT","Million US$ at exchange rate","IRL","Ireland","2015","2015",17.1,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","MTMOTCMT","Million US$ at exchange rate","IRL","Ireland","2016","2016",16.3,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","MTMOTCMT","Million US$ at exchange rate","IRL","Ireland","2017","2017",16.1,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","MTMOTCMT","Million US$ at exchange rate","IRL","Ireland","2018","2018",16.6,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","MTMOTCMT","Million US$ at exchange rate","IRL","Ireland","2019","2019",15.5,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","MTMOTCMT","Million US$ at exchange rate","IRL","Ireland","2020","2020",15.9,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","MTMOTCMT","Million US$ at exchange rate","IRL","Ireland","2021","2021",16.6,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","MTMOPPMT","Million US$, purchasing power parity","IRL","Ireland","2010","2010",18.4,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","MTMOPPMT","Million US$, purchasing power parity","IRL","Ireland","2011","2011",19,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","MTMOPPMT","Million US$, purchasing power parity","IRL","Ireland","2012","2012",20,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","MTMOPPMT","Million US$, purchasing power parity","IRL","Ireland","2013","2013",20.2,"B; D","Break; Difference in methodology"
+"PATCDIUR","C03-Diuretics","MTMOPPMT","Million US$, purchasing power parity","IRL","Ireland","2014","2014",19.5,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","MTMOPPMT","Million US$, purchasing power parity","IRL","Ireland","2015","2015",19,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","MTMOPPMT","Million US$, purchasing power parity","IRL","Ireland","2016","2016",18.6,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","MTMOPPMT","Million US$, purchasing power parity","IRL","Ireland","2017","2017",18,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","MTMOPPMT","Million US$, purchasing power parity","IRL","Ireland","2018","2018",17.7,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","MTMOPPMT","Million US$, purchasing power parity","IRL","Ireland","2019","2019",17.2,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","MTMOPPMT","Million US$, purchasing power parity","IRL","Ireland","2020","2020",17.5,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","MTMOPPMT","Million US$, purchasing power parity","IRL","Ireland","2021","2021",17.6,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","TCPPERMT","/capita, US$ exchange rate","IRL","Ireland","2010","2010",4.6,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","TCPPERMT","/capita, US$ exchange rate","IRL","Ireland","2011","2011",4.8,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","TCPPERMT","/capita, US$ exchange rate","IRL","Ireland","2012","2012",4.6,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","TCPPERMT","/capita, US$ exchange rate","IRL","Ireland","2013","2013",4.7,"B; D","Break; Difference in methodology"
+"PATCDIUR","C03-Diuretics","TCPPERMT","/capita, US$ exchange rate","IRL","Ireland","2014","2014",4.5,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","TCPPERMT","/capita, US$ exchange rate","IRL","Ireland","2015","2015",3.6,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","TCPPERMT","/capita, US$ exchange rate","IRL","Ireland","2016","2016",3.4,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","TCPPERMT","/capita, US$ exchange rate","IRL","Ireland","2017","2017",3.4,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","TCPPERMT","/capita, US$ exchange rate","IRL","Ireland","2018","2018",3.4,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","TCPPERMT","/capita, US$ exchange rate","IRL","Ireland","2019","2019",3.1,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","TCPPERMT","/capita, US$ exchange rate","IRL","Ireland","2020","2020",3.2,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","TCPPERMT","/capita, US$ exchange rate","IRL","Ireland","2021","2021",3.3,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2010","2010",4,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2011","2011",4.1,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2012","2012",4.3,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2013","2013",4.4,"B; D","Break; Difference in methodology"
+"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2014","2014",4.2,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2015","2015",4,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2016","2016",3.9,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2017","2017",3.7,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2018","2018",3.6,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2019","2019",3.5,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2020","2020",3.5,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2021","2021",3.5,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","ATCPTTMT","% of total sales","IRL","Ireland","2010","2010",0.8,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","ATCPTTMT","% of total sales","IRL","Ireland","2011","2011",0.8,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","ATCPTTMT","% of total sales","IRL","Ireland","2012","2012",0.8,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","ATCPTTMT","% of total sales","IRL","Ireland","2013","2013",0.8,"B; D","Break; Difference in methodology"
+"PATCDIUR","C03-Diuretics","ATCPTTMT","% of total sales","IRL","Ireland","2014","2014",0.8,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","ATCPTTMT","% of total sales","IRL","Ireland","2015","2015",0.8,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","ATCPTTMT","% of total sales","IRL","Ireland","2016","2016",0.7,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","ATCPTTMT","% of total sales","IRL","Ireland","2017","2017",0.7,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","ATCPTTMT","% of total sales","IRL","Ireland","2018","2018",0.6,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","ATCPTTMT","% of total sales","IRL","Ireland","2019","2019",0.6,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","ATCPTTMT","% of total sales","IRL","Ireland","2020","2020",0.6,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","ATCPTTMT","% of total sales","IRL","Ireland","2021","2021",0.5,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","MLLNCUMT","Million of national currency units","ITA","Italy","2011","2011",108.7,,
+"PATCDIUR","C03-Diuretics","MLLNCUMT","Million of national currency units","ITA","Italy","2012","2012",108.5,,
+"PATCDIUR","C03-Diuretics","MLLNCUMT","Million of national currency units","ITA","Italy","2013","2013",110.2,,
+"PATCDIUR","C03-Diuretics","MLLNCUMT","Million of national currency units","ITA","Italy","2014","2014",115.9,,
+"PATCDIUR","C03-Diuretics","MLLNCUMT","Million of national currency units","ITA","Italy","2015","2015",114.5,,
+"PATCDIUR","C03-Diuretics","MLLNCUMT","Million of national currency units","ITA","Italy","2016","2016",109.9,,
+"PATCDIUR","C03-Diuretics","MLLNCUMT","Million of national currency units","ITA","Italy","2017","2017",113,,
+"PATCDIUR","C03-Diuretics","MLLNCUMT","Million of national currency units","ITA","Italy","2018","2018",115.3,,
+"PATCDIUR","C03-Diuretics","MLLNCUMT","Million of national currency units","ITA","Italy","2019","2019",121.7,,
+"PATCDIUR","C03-Diuretics","MLLNCUMT","Million of national currency units","ITA","Italy","2020","2020",122.9,,
+"PATCDIUR","C03-Diuretics","MLLNCUMT","Million of national currency units","ITA","Italy","2021","2021",120.6,,
+"PATCDIUR","C03-Diuretics","MLLNCUMT","Million of national currency units","ITA","Italy","2022","2022",117,"E","Estimated value"
+"PATCDIUR","C03-Diuretics","MTMOTCMT","Million US$ at exchange rate","ITA","Italy","2011","2011",151.3,,
+"PATCDIUR","C03-Diuretics","MTMOTCMT","Million US$ at exchange rate","ITA","Italy","2012","2012",139.3,,
+"PATCDIUR","C03-Diuretics","MTMOTCMT","Million US$ at exchange rate","ITA","Italy","2013","2013",146.3,,
+"PATCDIUR","C03-Diuretics","MTMOTCMT","Million US$ at exchange rate","ITA","Italy","2014","2014",153.9,,
+"PATCDIUR","C03-Diuretics","MTMOTCMT","Million US$ at exchange rate","ITA","Italy","2015","2015",127,,
+"PATCDIUR","C03-Diuretics","MTMOTCMT","Million US$ at exchange rate","ITA","Italy","2016","2016",121.7,,
+"PATCDIUR","C03-Diuretics","MTMOTCMT","Million US$ at exchange rate","ITA","Italy","2017","2017",127.7,,
+"PATCDIUR","C03-Diuretics","MTMOTCMT","Million US$ at exchange rate","ITA","Italy","2018","2018",136.2,,
+"PATCDIUR","C03-Diuretics","MTMOTCMT","Million US$ at exchange rate","ITA","Italy","2019","2019",136.3,,
+"PATCDIUR","C03-Diuretics","MTMOTCMT","Million US$ at exchange rate","ITA","Italy","2020","2020",140.3,,
+"PATCDIUR","C03-Diuretics","MTMOTCMT","Million US$ at exchange rate","ITA","Italy","2021","2021",142.7,,
+"PATCDIUR","C03-Diuretics","MTMOTCMT","Million US$ at exchange rate","ITA","Italy","2022","2022",123.2,"E","Estimated value"
+"PATCDIUR","C03-Diuretics","MTMOPPMT","Million US$, purchasing power parity","ITA","Italy","2011","2011",143.3,,
+"PATCDIUR","C03-Diuretics","MTMOPPMT","Million US$, purchasing power parity","ITA","Italy","2012","2012",145,,
+"PATCDIUR","C03-Diuretics","MTMOPPMT","Million US$, purchasing power parity","ITA","Italy","2013","2013",149.4,,
+"PATCDIUR","C03-Diuretics","MTMOPPMT","Million US$, purchasing power parity","ITA","Italy","2014","2014",156.7,,
+"PATCDIUR","C03-Diuretics","MTMOPPMT","Million US$, purchasing power parity","ITA","Italy","2015","2015",155,,
+"PATCDIUR","C03-Diuretics","MTMOPPMT","Million US$, purchasing power parity","ITA","Italy","2016","2016",156.9,,
+"PATCDIUR","C03-Diuretics","MTMOPPMT","Million US$, purchasing power parity","ITA","Italy","2017","2017",163.8,,
+"PATCDIUR","C03-Diuretics","MTMOPPMT","Million US$, purchasing power parity","ITA","Italy","2018","2018",169.3,,
+"PATCDIUR","C03-Diuretics","MTMOPPMT","Million US$, purchasing power parity","ITA","Italy","2019","2019",185.4,,
+"PATCDIUR","C03-Diuretics","MTMOPPMT","Million US$, purchasing power parity","ITA","Italy","2020","2020",189.7,,
+"PATCDIUR","C03-Diuretics","MTMOPPMT","Million US$, purchasing power parity","ITA","Italy","2021","2021",186.3,,
+"PATCDIUR","C03-Diuretics","MTMOPPMT","Million US$, purchasing power parity","ITA","Italy","2022","2022",189.5,"E","Estimated value"
+"PATCDIUR","C03-Diuretics","TCPPERMT","/capita, US$ exchange rate","ITA","Italy","2011","2011",2.5,,
+"PATCDIUR","C03-Diuretics","TCPPERMT","/capita, US$ exchange rate","ITA","Italy","2012","2012",2.3,,
+"PATCDIUR","C03-Diuretics","TCPPERMT","/capita, US$ exchange rate","ITA","Italy","2013","2013",2.4,,
+"PATCDIUR","C03-Diuretics","TCPPERMT","/capita, US$ exchange rate","ITA","Italy","2014","2014",2.5,,
+"PATCDIUR","C03-Diuretics","TCPPERMT","/capita, US$ exchange rate","ITA","Italy","2015","2015",2.1,,
+"PATCDIUR","C03-Diuretics","TCPPERMT","/capita, US$ exchange rate","ITA","Italy","2016","2016",2,,
+"PATCDIUR","C03-Diuretics","TCPPERMT","/capita, US$ exchange rate","ITA","Italy","2017","2017",2.1,,
+"PATCDIUR","C03-Diuretics","TCPPERMT","/capita, US$ exchange rate","ITA","Italy","2018","2018",2.3,,
+"PATCDIUR","C03-Diuretics","TCPPERMT","/capita, US$ exchange rate","ITA","Italy","2019","2019",2.3,,
+"PATCDIUR","C03-Diuretics","TCPPERMT","/capita, US$ exchange rate","ITA","Italy","2020","2020",2.4,,
+"PATCDIUR","C03-Diuretics","TCPPERMT","/capita, US$ exchange rate","ITA","Italy","2021","2021",2.4,,
+"PATCDIUR","C03-Diuretics","TCPPERMT","/capita, US$ exchange rate","ITA","Italy","2022","2022",2.1,"E","Estimated value"
+"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2011","2011",2.4,,
+"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2012","2012",2.4,,
+"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2013","2013",2.5,,
+"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2014","2014",2.6,,
+"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2015","2015",2.6,,
+"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2016","2016",2.6,,
+"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2017","2017",2.7,,
+"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2018","2018",2.8,,
+"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2019","2019",3.1,,
+"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2020","2020",3.2,,
+"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2021","2021",3.2,,
+"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2022","2022",3.2,"E","Estimated value"
+"PATCDIUR","C03-Diuretics","ATCPTTMT","% of total sales","ITA","Italy","2011","2011",0.6,,
+"PATCDIUR","C03-Diuretics","ATCPTTMT","% of total sales","ITA","Italy","2012","2012",0.6,,
+"PATCDIUR","C03-Diuretics","ATCPTTMT","% of total sales","ITA","Italy","2013","2013",0.6,,
+"PATCDIUR","C03-Diuretics","ATCPTTMT","% of total sales","ITA","Italy","2014","2014",0.6,,
+"PATCDIUR","C03-Diuretics","ATCPTTMT","% of total sales","ITA","Italy","2015","2015",0.5,,
+"PATCDIUR","C03-Diuretics","ATCPTTMT","% of total sales","ITA","Italy","2016","2016",0.5,,
+"PATCDIUR","C03-Diuretics","ATCPTTMT","% of total sales","ITA","Italy","2017","2017",0.5,,
+"PATCDIUR","C03-Diuretics","ATCPTTMT","% of total sales","ITA","Italy","2018","2018",0.5,,
+"PATCDIUR","C03-Diuretics","ATCPTTMT","% of total sales","ITA","Italy","2019","2019",0.5,,
+"PATCDIUR","C03-Diuretics","ATCPTTMT","% of total sales","ITA","Italy","2020","2020",0.5,,
+"PATCDIUR","C03-Diuretics","ATCPTTMT","% of total sales","ITA","Italy","2021","2021",0.5,,
+"PATCDIUR","C03-Diuretics","ATCPTTMT","% of total sales","ITA","Italy","2022","2022",0.5,"E","Estimated value"
+"PATCDIUR","C03-Diuretics","MLLNCUMT","Million of national currency units","KOR","Korea","2010","2010",25582,,
+"PATCDIUR","C03-Diuretics","MLLNCUMT","Million of national currency units","KOR","Korea","2011","2011",25540.4,"B","Break"
+"PATCDIUR","C03-Diuretics","MLLNCUMT","Million of national currency units","KOR","Korea","2012","2012",22108.2,,
+"PATCDIUR","C03-Diuretics","MLLNCUMT","Million of national currency units","KOR","Korea","2013","2013",22273.9,,
+"PATCDIUR","C03-Diuretics","MLLNCUMT","Million of national currency units","KOR","Korea","2014","2014",22818.7,,
+"PATCDIUR","C03-Diuretics","MLLNCUMT","Million of national currency units","KOR","Korea","2015","2015",22838.3,,
+"PATCDIUR","C03-Diuretics","MLLNCUMT","Million of national currency units","KOR","Korea","2016","2016",21289,"B","Break"
+"PATCDIUR","C03-Diuretics","MLLNCUMT","Million of national currency units","KOR","Korea","2017","2017",21832.8,,
+"PATCDIUR","C03-Diuretics","MLLNCUMT","Million of national currency units","KOR","Korea","2018","2018",22899.6,,
+"PATCDIUR","C03-Diuretics","MLLNCUMT","Million of national currency units","KOR","Korea","2019","2019",24483.1,,
+"PATCDIUR","C03-Diuretics","MLLNCUMT","Million of national currency units","KOR","Korea","2020","2020",29067.4,,
+"PATCDIUR","C03-Diuretics","MLLNCUMT","Million of national currency units","KOR","Korea","2021","2021",32086.1,,
+"PATCDIUR","C03-Diuretics","MTMOTCMT","Million US$ at exchange rate","KOR","Korea","2010","2010",22.1,,
+"PATCDIUR","C03-Diuretics","MTMOTCMT","Million US$ at exchange rate","KOR","Korea","2011","2011",23,"B","Break"
+"PATCDIUR","C03-Diuretics","MTMOTCMT","Million US$ at exchange rate","KOR","Korea","2012","2012",19.6,,
+"PATCDIUR","C03-Diuretics","MTMOTCMT","Million US$ at exchange rate","KOR","Korea","2013","2013",20.3,,
+"PATCDIUR","C03-Diuretics","MTMOTCMT","Million US$ at exchange rate","KOR","Korea","2014","2014",21.7,,
+"PATCDIUR","C03-Diuretics","MTMOTCMT","Million US$ at exchange rate","KOR","Korea","2015","2015",20.2,,
+"PATCDIUR","C03-Diuretics","MTMOTCMT","Million US$ at exchange rate","KOR","Korea","2016","2016",18.3,"B","Break"
+"PATCDIUR","C03-Diuretics","MTMOTCMT","Million US$ at exchange rate","KOR","Korea","2017","2017",19.3,,
+"PATCDIUR","C03-Diuretics","MTMOTCMT","Million US$ at exchange rate","KOR","Korea","2018","2018",20.8,,
+"PATCDIUR","C03-Diuretics","MTMOTCMT","Million US$ at exchange rate","KOR","Korea","2019","2019",21,,
+"PATCDIUR","C03-Diuretics","MTMOTCMT","Million US$ at exchange rate","KOR","Korea","2020","2020",24.6,,
+"PATCDIUR","C03-Diuretics","MTMOTCMT","Million US$ at exchange rate","KOR","Korea","2021","2021",28,,
+"PATCDIUR","C03-Diuretics","MTMOPPMT","Million US$, purchasing power parity","KOR","Korea","2010","2010",30.4,,
+"PATCDIUR","C03-Diuretics","MTMOPPMT","Million US$, purchasing power parity","KOR","Korea","2011","2011",29.9,"B","Break"
+"PATCDIUR","C03-Diuretics","MTMOPPMT","Million US$, purchasing power parity","KOR","Korea","2012","2012",25.9,,
+"PATCDIUR","C03-Diuretics","MTMOPPMT","Million US$, purchasing power parity","KOR","Korea","2013","2013",25.6,,
+"PATCDIUR","C03-Diuretics","MTMOPPMT","Million US$, purchasing power parity","KOR","Korea","2014","2014",26.2,,
+"PATCDIUR","C03-Diuretics","MTMOPPMT","Million US$, purchasing power parity","KOR","Korea","2015","2015",26.6,,
+"PATCDIUR","C03-Diuretics","MTMOPPMT","Million US$, purchasing power parity","KOR","Korea","2016","2016",24.8,"B","Break"
+"PATCDIUR","C03-Diuretics","MTMOPPMT","Million US$, purchasing power parity","KOR","Korea","2017","2017",25,,
+"PATCDIUR","C03-Diuretics","MTMOPPMT","Million US$, purchasing power parity","KOR","Korea","2018","2018",26.8,,
+"PATCDIUR","C03-Diuretics","MTMOPPMT","Million US$, purchasing power parity","KOR","Korea","2019","2019",28.6,,
+"PATCDIUR","C03-Diuretics","MTMOPPMT","Million US$, purchasing power parity","KOR","Korea","2020","2020",34.7,,
+"PATCDIUR","C03-Diuretics","MTMOPPMT","Million US$, purchasing power parity","KOR","Korea","2021","2021",37.6,,
+"PATCDIUR","C03-Diuretics","TCPPERMT","/capita, US$ exchange rate","KOR","Korea","2010","2010",0.4,,
+"PATCDIUR","C03-Diuretics","TCPPERMT","/capita, US$ exchange rate","KOR","Korea","2011","2011",0.5,"B","Break"
+"PATCDIUR","C03-Diuretics","TCPPERMT","/capita, US$ exchange rate","KOR","Korea","2012","2012",0.4,,
+"PATCDIUR","C03-Diuretics","TCPPERMT","/capita, US$ exchange rate","KOR","Korea","2013","2013",0.4,,
+"PATCDIUR","C03-Diuretics","TCPPERMT","/capita, US$ exchange rate","KOR","Korea","2014","2014",0.4,,
+"PATCDIUR","C03-Diuretics","TCPPERMT","/capita, US$ exchange rate","KOR","Korea","2015","2015",0.4,,
+"PATCDIUR","C03-Diuretics","TCPPERMT","/capita, US$ exchange rate","KOR","Korea","2016","2016",0.4,"B","Break"
+"PATCDIUR","C03-Diuretics","TCPPERMT","/capita, US$ exchange rate","KOR","Korea","2017","2017",0.4,,
+"PATCDIUR","C03-Diuretics","TCPPERMT","/capita, US$ exchange rate","KOR","Korea","2018","2018",0.4,,
+"PATCDIUR","C03-Diuretics","TCPPERMT","/capita, US$ exchange rate","KOR","Korea","2019","2019",0.4,,
+"PATCDIUR","C03-Diuretics","TCPPERMT","/capita, US$ exchange rate","KOR","Korea","2020","2020",0.5,,
+"PATCDIUR","C03-Diuretics","TCPPERMT","/capita, US$ exchange rate","KOR","Korea","2021","2021",0.5,,
+"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2010","2010",0.6,,
+"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2011","2011",0.6,"B","Break"
+"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2012","2012",0.5,,
+"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2013","2013",0.5,,
+"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2014","2014",0.5,,
+"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2015","2015",0.5,,
+"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2016","2016",0.5,"B","Break"
+"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2017","2017",0.5,,
+"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2018","2018",0.5,,
+"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2019","2019",0.6,,
+"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2020","2020",0.7,,
+"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2021","2021",0.7,,
+"PATCDIUR","C03-Diuretics","ATCPTTMT","% of total sales","KOR","Korea","2010","2010",0.1,,
+"PATCDIUR","C03-Diuretics","ATCPTTMT","% of total sales","KOR","Korea","2011","2011",0.1,"B","Break"
+"PATCDIUR","C03-Diuretics","ATCPTTMT","% of total sales","KOR","Korea","2012","2012",0.1,,
+"PATCDIUR","C03-Diuretics","ATCPTTMT","% of total sales","KOR","Korea","2013","2013",0.1,,
+"PATCDIUR","C03-Diuretics","ATCPTTMT","% of total sales","KOR","Korea","2014","2014",0.1,,
+"PATCDIUR","C03-Diuretics","ATCPTTMT","% of total sales","KOR","Korea","2015","2015",0.1,,
+"PATCDIUR","C03-Diuretics","ATCPTTMT","% of total sales","KOR","Korea","2016","2016",0.1,"B","Break"
+"PATCDIUR","C03-Diuretics","ATCPTTMT","% of total sales","KOR","Korea","2017","2017",0.1,,
+"PATCDIUR","C03-Diuretics","ATCPTTMT","% of total sales","KOR","Korea","2018","2018",0.1,,
+"PATCDIUR","C03-Diuretics","ATCPTTMT","% of total sales","KOR","Korea","2019","2019",0.1,,
+"PATCDIUR","C03-Diuretics","ATCPTTMT","% of total sales","KOR","Korea","2020","2020",0.1,,
+"PATCDIUR","C03-Diuretics","ATCPTTMT","% of total sales","KOR","Korea","2021","2021",0.1,,
+"PATCDIUR","C03-Diuretics","MLLNCUMT","Million of national currency units","LUX","Luxembourg","2010","2010",1.7,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","MLLNCUMT","Million of national currency units","LUX","Luxembourg","2011","2011",1.6,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","MLLNCUMT","Million of national currency units","LUX","Luxembourg","2012","2012",1.6,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","MLLNCUMT","Million of national currency units","LUX","Luxembourg","2013","2013",1.6,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","MLLNCUMT","Million of national currency units","LUX","Luxembourg","2014","2014",1.7,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","MLLNCUMT","Million of national currency units","LUX","Luxembourg","2015","2015",1.6,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","MLLNCUMT","Million of national currency units","LUX","Luxembourg","2016","2016",1.6,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","MLLNCUMT","Million of national currency units","LUX","Luxembourg","2017","2017",1.4,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","MLLNCUMT","Million of national currency units","LUX","Luxembourg","2018","2018",1.4,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","MLLNCUMT","Million of national currency units","LUX","Luxembourg","2019","2019",1.4,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","MLLNCUMT","Million of national currency units","LUX","Luxembourg","2020","2020",1.4,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","MLLNCUMT","Million of national currency units","LUX","Luxembourg","2021","2021",1.3,"B; D; P","Break; Difference in methodology; Provisional value"
+"PATCDIUR","C03-Diuretics","MLLNCUMT","Million of national currency units","LUX","Luxembourg","2022","2022",1.3,"D; P","Difference in methodology; Provisional value"
+"PATCDIUR","C03-Diuretics","MTMOTCMT","Million US$ at exchange rate","LUX","Luxembourg","2010","2010",2.3,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","MTMOTCMT","Million US$ at exchange rate","LUX","Luxembourg","2011","2011",2.3,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","MTMOTCMT","Million US$ at exchange rate","LUX","Luxembourg","2012","2012",2,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","MTMOTCMT","Million US$ at exchange rate","LUX","Luxembourg","2013","2013",2.2,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","MTMOTCMT","Million US$ at exchange rate","LUX","Luxembourg","2014","2014",2.2,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","MTMOTCMT","Million US$ at exchange rate","LUX","Luxembourg","2015","2015",1.8,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","MTMOTCMT","Million US$ at exchange rate","LUX","Luxembourg","2016","2016",1.7,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","MTMOTCMT","Million US$ at exchange rate","LUX","Luxembourg","2017","2017",1.6,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","MTMOTCMT","Million US$ at exchange rate","LUX","Luxembourg","2018","2018",1.7,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","MTMOTCMT","Million US$ at exchange rate","LUX","Luxembourg","2019","2019",1.5,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","MTMOTCMT","Million US$ at exchange rate","LUX","Luxembourg","2020","2020",1.6,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","MTMOTCMT","Million US$ at exchange rate","LUX","Luxembourg","2021","2021",1.6,"B; D; P","Break; Difference in methodology; Provisional value"
+"PATCDIUR","C03-Diuretics","MTMOTCMT","Million US$ at exchange rate","LUX","Luxembourg","2022","2022",1.3,"D; P","Difference in methodology; Provisional value"
+"PATCDIUR","C03-Diuretics","MTMOPPMT","Million US$, purchasing power parity","LUX","Luxembourg","2010","2010",1.8,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","MTMOPPMT","Million US$, purchasing power parity","LUX","Luxembourg","2011","2011",1.8,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","MTMOPPMT","Million US$, purchasing power parity","LUX","Luxembourg","2012","2012",1.7,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","MTMOPPMT","Million US$, purchasing power parity","LUX","Luxembourg","2013","2013",1.8,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","MTMOPPMT","Million US$, purchasing power parity","LUX","Luxembourg","2014","2014",1.9,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","MTMOPPMT","Million US$, purchasing power parity","LUX","Luxembourg","2015","2015",1.8,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","MTMOPPMT","Million US$, purchasing power parity","LUX","Luxembourg","2016","2016",1.8,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","MTMOPPMT","Million US$, purchasing power parity","LUX","Luxembourg","2017","2017",1.7,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","MTMOPPMT","Million US$, purchasing power parity","LUX","Luxembourg","2018","2018",1.7,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","MTMOPPMT","Million US$, purchasing power parity","LUX","Luxembourg","2019","2019",1.6,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","MTMOPPMT","Million US$, purchasing power parity","LUX","Luxembourg","2020","2020",1.6,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","MTMOPPMT","Million US$, purchasing power parity","LUX","Luxembourg","2021","2021",1.5,"B; D; P","Break; Difference in methodology; Provisional value"
+"PATCDIUR","C03-Diuretics","MTMOPPMT","Million US$, purchasing power parity","LUX","Luxembourg","2022","2022",1.5,"D; P","Difference in methodology; Provisional value"
+"PATCDIUR","C03-Diuretics","TCPPERMT","/capita, US$ exchange rate","LUX","Luxembourg","2010","2010",4.8,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","TCPPERMT","/capita, US$ exchange rate","LUX","Luxembourg","2011","2011",4.7,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","TCPPERMT","/capita, US$ exchange rate","LUX","Luxembourg","2012","2012",4.1,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","TCPPERMT","/capita, US$ exchange rate","LUX","Luxembourg","2013","2013",4.3,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","TCPPERMT","/capita, US$ exchange rate","LUX","Luxembourg","2014","2014",4.3,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","TCPPERMT","/capita, US$ exchange rate","LUX","Luxembourg","2015","2015",3.4,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","TCPPERMT","/capita, US$ exchange rate","LUX","Luxembourg","2016","2016",3.3,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","TCPPERMT","/capita, US$ exchange rate","LUX","Luxembourg","2017","2017",3,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","TCPPERMT","/capita, US$ exchange rate","LUX","Luxembourg","2018","2018",3.1,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","TCPPERMT","/capita, US$ exchange rate","LUX","Luxembourg","2019","2019",2.8,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","TCPPERMT","/capita, US$ exchange rate","LUX","Luxembourg","2020","2020",2.8,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","TCPPERMT","/capita, US$ exchange rate","LUX","Luxembourg","2021","2021",2.7,"B; D; P","Break; Difference in methodology; Provisional value"
+"PATCDIUR","C03-Diuretics","TCPPERMT","/capita, US$ exchange rate","LUX","Luxembourg","2022","2022",2.3,"D; P","Difference in methodology; Provisional value"
+"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2010","2010",3.9,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2011","2011",3.7,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2012","2012",3.5,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2013","2013",3.6,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2014","2014",3.7,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2015","2015",3.5,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2016","2016",3.5,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2017","2017",3.1,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2018","2018",3,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2019","2019",2.9,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2020","2020",2.9,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2021","2021",2.7,"B; D; P","Break; Difference in methodology; Provisional value"
+"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2022","2022",2.6,"D; P","Difference in methodology; Provisional value"
+"PATCDIUR","C03-Diuretics","ATCPTTMT","% of total sales","LUX","Luxembourg","2010","2010",0.9,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","ATCPTTMT","% of total sales","LUX","Luxembourg","2011","2011",0.9,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","ATCPTTMT","% of total sales","LUX","Luxembourg","2012","2012",0.8,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","ATCPTTMT","% of total sales","LUX","Luxembourg","2013","2013",0.8,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","ATCPTTMT","% of total sales","LUX","Luxembourg","2014","2014",0.9,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","ATCPTTMT","% of total sales","LUX","Luxembourg","2015","2015",0.8,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","ATCPTTMT","% of total sales","LUX","Luxembourg","2016","2016",0.8,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","ATCPTTMT","% of total sales","LUX","Luxembourg","2017","2017",0.7,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","ATCPTTMT","% of total sales","LUX","Luxembourg","2018","2018",0.7,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","ATCPTTMT","% of total sales","LUX","Luxembourg","2019","2019",0.7,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","ATCPTTMT","% of total sales","LUX","Luxembourg","2020","2020",0.7,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","ATCPTTMT","% of total sales","LUX","Luxembourg","2021","2021",0.6,"B; D; P","Break; Difference in methodology; Provisional value"
+"PATCDIUR","C03-Diuretics","ATCPTTMT","% of total sales","LUX","Luxembourg","2022","2022",0.5,"D; P","Difference in methodology; Provisional value"
+"PATCDIUR","C03-Diuretics","MLLNCUMT","Million of national currency units","NLD","Netherlands","2010","2010",74.5,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","MLLNCUMT","Million of national currency units","NLD","Netherlands","2011","2011",78,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","MLLNCUMT","Million of national currency units","NLD","Netherlands","2012","2012",79,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","MLLNCUMT","Million of national currency units","NLD","Netherlands","2013","2013",81.5,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","MLLNCUMT","Million of national currency units","NLD","Netherlands","2014","2014",80.5,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","MTMOTCMT","Million US$ at exchange rate","NLD","Netherlands","2010","2010",98.8,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","MTMOTCMT","Million US$ at exchange rate","NLD","Netherlands","2011","2011",108.5,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","MTMOTCMT","Million US$ at exchange rate","NLD","Netherlands","2012","2012",101.5,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","MTMOTCMT","Million US$ at exchange rate","NLD","Netherlands","2013","2013",108.3,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","MTMOTCMT","Million US$ at exchange rate","NLD","Netherlands","2014","2014",106.9,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","MTMOPPMT","Million US$, purchasing power parity","NLD","Netherlands","2010","2010",87.3,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","MTMOPPMT","Million US$, purchasing power parity","NLD","Netherlands","2011","2011",93.2,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","MTMOPPMT","Million US$, purchasing power parity","NLD","Netherlands","2012","2012",95.9,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","MTMOPPMT","Million US$, purchasing power parity","NLD","Netherlands","2013","2013",102.2,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","MTMOPPMT","Million US$, purchasing power parity","NLD","Netherlands","2014","2014",99.5,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","TCPPERMT","/capita, US$ exchange rate","NLD","Netherlands","2010","2010",5.9,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","TCPPERMT","/capita, US$ exchange rate","NLD","Netherlands","2011","2011",6.5,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","TCPPERMT","/capita, US$ exchange rate","NLD","Netherlands","2012","2012",6.1,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","TCPPERMT","/capita, US$ exchange rate","NLD","Netherlands","2013","2013",6.4,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","TCPPERMT","/capita, US$ exchange rate","NLD","Netherlands","2014","2014",6.3,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","NLD","Netherlands","2010","2010",5.3,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","NLD","Netherlands","2011","2011",5.6,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","NLD","Netherlands","2012","2012",5.7,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","NLD","Netherlands","2013","2013",6.1,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","NLD","Netherlands","2014","2014",5.9,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","ATCPTTMT","% of total sales","NLD","Netherlands","2010","2010",1.4,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","ATCPTTMT","% of total sales","NLD","Netherlands","2011","2011",1.5,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","ATCPTTMT","% of total sales","NLD","Netherlands","2012","2012",1.7,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","ATCPTTMT","% of total sales","NLD","Netherlands","2013","2013",1.9,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","ATCPTTMT","% of total sales","NLD","Netherlands","2014","2014",1.9,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","MLLNCUMT","Million of national currency units","NZL","New Zealand","2010","2010",2.7,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","MLLNCUMT","Million of national currency units","NZL","New Zealand","2011","2011",2.3,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","MLLNCUMT","Million of national currency units","NZL","New Zealand","2012","2012",2.3,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","MLLNCUMT","Million of national currency units","NZL","New Zealand","2013","2013",2.2,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","MLLNCUMT","Million of national currency units","NZL","New Zealand","2014","2014",2.2,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","MLLNCUMT","Million of national currency units","NZL","New Zealand","2015","2015",2.2,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","MLLNCUMT","Million of national currency units","NZL","New Zealand","2016","2016",2.2,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","MLLNCUMT","Million of national currency units","NZL","New Zealand","2017","2017",2.3,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","MLLNCUMT","Million of national currency units","NZL","New Zealand","2018","2018",2.6,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","MLLNCUMT","Million of national currency units","NZL","New Zealand","2019","2019",3,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","MLLNCUMT","Million of national currency units","NZL","New Zealand","2020","2020",3,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","MLLNCUMT","Million of national currency units","NZL","New Zealand","2021","2021",3.9,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","MLLNCUMT","Million of national currency units","NZL","New Zealand","2022","2022",4.3,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","MTMOTCMT","Million US$ at exchange rate","NZL","New Zealand","2010","2010",2,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","MTMOTCMT","Million US$ at exchange rate","NZL","New Zealand","2011","2011",1.8,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","MTMOTCMT","Million US$ at exchange rate","NZL","New Zealand","2012","2012",1.9,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","MTMOTCMT","Million US$ at exchange rate","NZL","New Zealand","2013","2013",1.8,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","MTMOTCMT","Million US$ at exchange rate","NZL","New Zealand","2014","2014",1.8,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","MTMOTCMT","Million US$ at exchange rate","NZL","New Zealand","2015","2015",1.5,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","MTMOTCMT","Million US$ at exchange rate","NZL","New Zealand","2016","2016",1.6,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","MTMOTCMT","Million US$ at exchange rate","NZL","New Zealand","2017","2017",1.7,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","MTMOTCMT","Million US$ at exchange rate","NZL","New Zealand","2018","2018",1.8,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","MTMOTCMT","Million US$ at exchange rate","NZL","New Zealand","2019","2019",2,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","MTMOTCMT","Million US$ at exchange rate","NZL","New Zealand","2020","2020",2,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","MTMOTCMT","Million US$ at exchange rate","NZL","New Zealand","2021","2021",2.8,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","MTMOTCMT","Million US$ at exchange rate","NZL","New Zealand","2022","2022",2.8,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","MTMOPPMT","Million US$, purchasing power parity","NZL","New Zealand","2010","2010",1.8,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","MTMOPPMT","Million US$, purchasing power parity","NZL","New Zealand","2011","2011",1.5,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","MTMOPPMT","Million US$, purchasing power parity","NZL","New Zealand","2012","2012",1.5,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","MTMOPPMT","Million US$, purchasing power parity","NZL","New Zealand","2013","2013",1.5,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","MTMOPPMT","Million US$, purchasing power parity","NZL","New Zealand","2014","2014",1.5,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","MTMOPPMT","Million US$, purchasing power parity","NZL","New Zealand","2015","2015",1.5,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","MTMOPPMT","Million US$, purchasing power parity","NZL","New Zealand","2016","2016",1.6,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","MTMOPPMT","Million US$, purchasing power parity","NZL","New Zealand","2017","2017",1.6,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","MTMOPPMT","Million US$, purchasing power parity","NZL","New Zealand","2018","2018",1.8,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","MTMOPPMT","Million US$, purchasing power parity","NZL","New Zealand","2019","2019",2.1,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","MTMOPPMT","Million US$, purchasing power parity","NZL","New Zealand","2020","2020",2.1,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","MTMOPPMT","Million US$, purchasing power parity","NZL","New Zealand","2021","2021",2.7,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","MTMOPPMT","Million US$, purchasing power parity","NZL","New Zealand","2022","2022",3,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","TCPPERMT","/capita, US$ exchange rate","NZL","New Zealand","2010","2010",0.5,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","TCPPERMT","/capita, US$ exchange rate","NZL","New Zealand","2011","2011",0.4,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","TCPPERMT","/capita, US$ exchange rate","NZL","New Zealand","2012","2012",0.4,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","TCPPERMT","/capita, US$ exchange rate","NZL","New Zealand","2013","2013",0.4,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","TCPPERMT","/capita, US$ exchange rate","NZL","New Zealand","2014","2014",0.4,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","TCPPERMT","/capita, US$ exchange rate","NZL","New Zealand","2015","2015",0.3,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","TCPPERMT","/capita, US$ exchange rate","NZL","New Zealand","2016","2016",0.3,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","TCPPERMT","/capita, US$ exchange rate","NZL","New Zealand","2017","2017",0.3,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","TCPPERMT","/capita, US$ exchange rate","NZL","New Zealand","2018","2018",0.4,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","TCPPERMT","/capita, US$ exchange rate","NZL","New Zealand","2019","2019",0.4,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","TCPPERMT","/capita, US$ exchange rate","NZL","New Zealand","2020","2020",0.4,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","TCPPERMT","/capita, US$ exchange rate","NZL","New Zealand","2021","2021",0.5,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","TCPPERMT","/capita, US$ exchange rate","NZL","New Zealand","2022","2022",0.5,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2010","2010",0.4,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2011","2011",0.4,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2012","2012",0.3,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2013","2013",0.3,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2014","2014",0.3,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2015","2015",0.3,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2016","2016",0.3,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2017","2017",0.3,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2018","2018",0.4,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2019","2019",0.4,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2020","2020",0.4,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2021","2021",0.5,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2022","2022",0.6,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","ATCPTTMT","% of total sales","NZL","New Zealand","2010","2010",0.4,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","ATCPTTMT","% of total sales","NZL","New Zealand","2011","2011",0.3,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","ATCPTTMT","% of total sales","NZL","New Zealand","2012","2012",0.2,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","ATCPTTMT","% of total sales","NZL","New Zealand","2013","2013",0.2,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","ATCPTTMT","% of total sales","NZL","New Zealand","2014","2014",0.2,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","ATCPTTMT","% of total sales","NZL","New Zealand","2015","2015",0.2,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","ATCPTTMT","% of total sales","NZL","New Zealand","2016","2016",0.2,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","ATCPTTMT","% of total sales","NZL","New Zealand","2017","2017",0.2,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","ATCPTTMT","% of total sales","NZL","New Zealand","2018","2018",0.2,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","ATCPTTMT","% of total sales","NZL","New Zealand","2019","2019",0.2,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","ATCPTTMT","% of total sales","NZL","New Zealand","2020","2020",0.2,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","ATCPTTMT","% of total sales","NZL","New Zealand","2021","2021",0.2,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","ATCPTTMT","% of total sales","NZL","New Zealand","2022","2022",0.2,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","MLLNCUMT","Million of national currency units","NOR","Norway","2010","2010",99,,
+"PATCDIUR","C03-Diuretics","MLLNCUMT","Million of national currency units","NOR","Norway","2011","2011",102,,
+"PATCDIUR","C03-Diuretics","MLLNCUMT","Million of national currency units","NOR","Norway","2012","2012",99,,
+"PATCDIUR","C03-Diuretics","MLLNCUMT","Million of national currency units","NOR","Norway","2013","2013",98,,
+"PATCDIUR","C03-Diuretics","MLLNCUMT","Million of national currency units","NOR","Norway","2014","2014",105,,
+"PATCDIUR","C03-Diuretics","MLLNCUMT","Million of national currency units","NOR","Norway","2015","2015",110,,
+"PATCDIUR","C03-Diuretics","MLLNCUMT","Million of national currency units","NOR","Norway","2016","2016",112,,
+"PATCDIUR","C03-Diuretics","MLLNCUMT","Million of national currency units","NOR","Norway","2017","2017",122,,
+"PATCDIUR","C03-Diuretics","MLLNCUMT","Million of national currency units","NOR","Norway","2018","2018",131,,
+"PATCDIUR","C03-Diuretics","MLLNCUMT","Million of national currency units","NOR","Norway","2019","2019",141,,
+"PATCDIUR","C03-Diuretics","MLLNCUMT","Million of national currency units","NOR","Norway","2020","2020",148,,
+"PATCDIUR","C03-Diuretics","MLLNCUMT","Million of national currency units","NOR","Norway","2021","2021",143,,
+"PATCDIUR","C03-Diuretics","MLLNCUMT","Million of national currency units","NOR","Norway","2022","2022",144,,
+"PATCDIUR","C03-Diuretics","MTMOTCMT","Million US$ at exchange rate","NOR","Norway","2010","2010",16.4,,
+"PATCDIUR","C03-Diuretics","MTMOTCMT","Million US$ at exchange rate","NOR","Norway","2011","2011",18.2,,
+"PATCDIUR","C03-Diuretics","MTMOTCMT","Million US$ at exchange rate","NOR","Norway","2012","2012",17,,
+"PATCDIUR","C03-Diuretics","MTMOTCMT","Million US$ at exchange rate","NOR","Norway","2013","2013",16.7,,
+"PATCDIUR","C03-Diuretics","MTMOTCMT","Million US$ at exchange rate","NOR","Norway","2014","2014",16.7,,
+"PATCDIUR","C03-Diuretics","MTMOTCMT","Million US$ at exchange rate","NOR","Norway","2015","2015",13.6,,
+"PATCDIUR","C03-Diuretics","MTMOTCMT","Million US$ at exchange rate","NOR","Norway","2016","2016",13.3,,
+"PATCDIUR","C03-Diuretics","MTMOTCMT","Million US$ at exchange rate","NOR","Norway","2017","2017",14.7,,
+"PATCDIUR","C03-Diuretics","MTMOTCMT","Million US$ at exchange rate","NOR","Norway","2018","2018",16.1,,
+"PATCDIUR","C03-Diuretics","MTMOTCMT","Million US$ at exchange rate","NOR","Norway","2019","2019",16,,
+"PATCDIUR","C03-Diuretics","MTMOTCMT","Million US$ at exchange rate","NOR","Norway","2020","2020",15.7,,
+"PATCDIUR","C03-Diuretics","MTMOTCMT","Million US$ at exchange rate","NOR","Norway","2021","2021",16.6,,
+"PATCDIUR","C03-Diuretics","MTMOTCMT","Million US$ at exchange rate","NOR","Norway","2022","2022",15,,
+"PATCDIUR","C03-Diuretics","MTMOPPMT","Million US$, purchasing power parity","NOR","Norway","2010","2010",10.8,,
+"PATCDIUR","C03-Diuretics","MTMOPPMT","Million US$, purchasing power parity","NOR","Norway","2011","2011",11.2,,
+"PATCDIUR","C03-Diuretics","MTMOPPMT","Million US$, purchasing power parity","NOR","Norway","2012","2012",11,,
+"PATCDIUR","C03-Diuretics","MTMOPPMT","Million US$, purchasing power parity","NOR","Norway","2013","2013",10.9,,
+"PATCDIUR","C03-Diuretics","MTMOPPMT","Million US$, purchasing power parity","NOR","Norway","2014","2014",11.3,,
+"PATCDIUR","C03-Diuretics","MTMOPPMT","Million US$, purchasing power parity","NOR","Norway","2015","2015",11.1,,
+"PATCDIUR","C03-Diuretics","MTMOPPMT","Million US$, purchasing power parity","NOR","Norway","2016","2016",11.2,,
+"PATCDIUR","C03-Diuretics","MTMOPPMT","Million US$, purchasing power parity","NOR","Norway","2017","2017",12.5,,
+"PATCDIUR","C03-Diuretics","MTMOPPMT","Million US$, purchasing power parity","NOR","Norway","2018","2018",13.7,,
+"PATCDIUR","C03-Diuretics","MTMOPPMT","Million US$, purchasing power parity","NOR","Norway","2019","2019",14.7,,
+"PATCDIUR","C03-Diuretics","MTMOPPMT","Million US$, purchasing power parity","NOR","Norway","2020","2020",15,,
+"PATCDIUR","C03-Diuretics","MTMOPPMT","Million US$, purchasing power parity","NOR","Norway","2021","2021",15,,
+"PATCDIUR","C03-Diuretics","MTMOPPMT","Million US$, purchasing power parity","NOR","Norway","2022","2022",13.4,,
+"PATCDIUR","C03-Diuretics","TCPPERMT","/capita, US$ exchange rate","NOR","Norway","2010","2010",3.4,,
+"PATCDIUR","C03-Diuretics","TCPPERMT","/capita, US$ exchange rate","NOR","Norway","2011","2011",3.7,,
+"PATCDIUR","C03-Diuretics","TCPPERMT","/capita, US$ exchange rate","NOR","Norway","2012","2012",3.4,,
+"PATCDIUR","C03-Diuretics","TCPPERMT","/capita, US$ exchange rate","NOR","Norway","2013","2013",3.3,,
+"PATCDIUR","C03-Diuretics","TCPPERMT","/capita, US$ exchange rate","NOR","Norway","2014","2014",3.2,,
+"PATCDIUR","C03-Diuretics","TCPPERMT","/capita, US$ exchange rate","NOR","Norway","2015","2015",2.6,,
+"PATCDIUR","C03-Diuretics","TCPPERMT","/capita, US$ exchange rate","NOR","Norway","2016","2016",2.5,,
+"PATCDIUR","C03-Diuretics","TCPPERMT","/capita, US$ exchange rate","NOR","Norway","2017","2017",2.8,,
+"PATCDIUR","C03-Diuretics","TCPPERMT","/capita, US$ exchange rate","NOR","Norway","2018","2018",3,,
+"PATCDIUR","C03-Diuretics","TCPPERMT","/capita, US$ exchange rate","NOR","Norway","2019","2019",3,,
+"PATCDIUR","C03-Diuretics","TCPPERMT","/capita, US$ exchange rate","NOR","Norway","2020","2020",2.9,,
+"PATCDIUR","C03-Diuretics","TCPPERMT","/capita, US$ exchange rate","NOR","Norway","2021","2021",3.1,,
+"PATCDIUR","C03-Diuretics","TCPPERMT","/capita, US$ exchange rate","NOR","Norway","2022","2022",2.8,,
+"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2010","2010",2.2,,
+"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2011","2011",2.3,,
+"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2012","2012",2.2,,
+"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2013","2013",2.1,,
+"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2014","2014",2.2,,
+"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2015","2015",2.1,,
+"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2016","2016",2.1,,
+"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2017","2017",2.4,,
+"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2018","2018",2.6,,
+"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2019","2019",2.7,,
+"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2020","2020",2.8,,
+"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2021","2021",2.8,,
+"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2022","2022",2.5,,
+"PATCDIUR","C03-Diuretics","ATCPTTMT","% of total sales","NOR","Norway","2010","2010",0.6,,
+"PATCDIUR","C03-Diuretics","ATCPTTMT","% of total sales","NOR","Norway","2011","2011",0.6,,
+"PATCDIUR","C03-Diuretics","ATCPTTMT","% of total sales","NOR","Norway","2012","2012",0.5,,
+"PATCDIUR","C03-Diuretics","ATCPTTMT","% of total sales","NOR","Norway","2013","2013",0.5,,
+"PATCDIUR","C03-Diuretics","ATCPTTMT","% of total sales","NOR","Norway","2014","2014",0.5,,
+"PATCDIUR","C03-Diuretics","ATCPTTMT","% of total sales","NOR","Norway","2015","2015",0.5,,
+"PATCDIUR","C03-Diuretics","ATCPTTMT","% of total sales","NOR","Norway","2016","2016",0.5,,
+"PATCDIUR","C03-Diuretics","ATCPTTMT","% of total sales","NOR","Norway","2017","2017",0.5,,
+"PATCDIUR","C03-Diuretics","ATCPTTMT","% of total sales","NOR","Norway","2018","2018",0.5,,
+"PATCDIUR","C03-Diuretics","ATCPTTMT","% of total sales","NOR","Norway","2019","2019",0.5,,
+"PATCDIUR","C03-Diuretics","ATCPTTMT","% of total sales","NOR","Norway","2020","2020",0.5,,
+"PATCDIUR","C03-Diuretics","ATCPTTMT","% of total sales","NOR","Norway","2021","2021",0.4,,
+"PATCDIUR","C03-Diuretics","ATCPTTMT","% of total sales","NOR","Norway","2022","2022",0.4,,
+"PATCDIUR","C03-Diuretics","MLLNCUMT","Million of national currency units","PRT","Portugal","2010","2010",28.9,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","MLLNCUMT","Million of national currency units","PRT","Portugal","2011","2011",24.9,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","MLLNCUMT","Million of national currency units","PRT","Portugal","2012","2012",23.8,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","MLLNCUMT","Million of national currency units","PRT","Portugal","2013","2013",22.6,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","MLLNCUMT","Million of national currency units","PRT","Portugal","2014","2014",22.5,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","MLLNCUMT","Million of national currency units","PRT","Portugal","2015","2015",22.3,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","MLLNCUMT","Million of national currency units","PRT","Portugal","2016","2016",21.9,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","MLLNCUMT","Million of national currency units","PRT","Portugal","2017","2017",21.8,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","MLLNCUMT","Million of national currency units","PRT","Portugal","2018","2018",21.6,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","MLLNCUMT","Million of national currency units","PRT","Portugal","2019","2019",21.9,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","MLLNCUMT","Million of national currency units","PRT","Portugal","2020","2020",22.1,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","MLLNCUMT","Million of national currency units","PRT","Portugal","2021","2021",21.6,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","MLLNCUMT","Million of national currency units","PRT","Portugal","2022","2022",21,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","MTMOTCMT","Million US$ at exchange rate","PRT","Portugal","2010","2010",38.3,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","MTMOTCMT","Million US$ at exchange rate","PRT","Portugal","2011","2011",34.6,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","MTMOTCMT","Million US$ at exchange rate","PRT","Portugal","2012","2012",30.6,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","MTMOTCMT","Million US$ at exchange rate","PRT","Portugal","2013","2013",30,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","MTMOTCMT","Million US$ at exchange rate","PRT","Portugal","2014","2014",29.8,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","MTMOTCMT","Million US$ at exchange rate","PRT","Portugal","2015","2015",24.7,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","MTMOTCMT","Million US$ at exchange rate","PRT","Portugal","2016","2016",24.3,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","MTMOTCMT","Million US$ at exchange rate","PRT","Portugal","2017","2017",24.6,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","MTMOTCMT","Million US$ at exchange rate","PRT","Portugal","2018","2018",25.5,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","MTMOTCMT","Million US$ at exchange rate","PRT","Portugal","2019","2019",24.5,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","MTMOTCMT","Million US$ at exchange rate","PRT","Portugal","2020","2020",25.2,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","MTMOTCMT","Million US$ at exchange rate","PRT","Portugal","2021","2021",25.5,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","MTMOTCMT","Million US$ at exchange rate","PRT","Portugal","2022","2022",22.1,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","MTMOPPMT","Million US$, purchasing power parity","PRT","Portugal","2010","2010",46.3,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","MTMOPPMT","Million US$, purchasing power parity","PRT","Portugal","2011","2011",39.9,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","MTMOPPMT","Million US$, purchasing power parity","PRT","Portugal","2012","2012",39.3,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","MTMOPPMT","Million US$, purchasing power parity","PRT","Portugal","2013","2013",38.8,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","MTMOPPMT","Million US$, purchasing power parity","PRT","Portugal","2014","2014",38.8,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","MTMOPPMT","Million US$, purchasing power parity","PRT","Portugal","2015","2015",38,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","MTMOPPMT","Million US$, purchasing power parity","PRT","Portugal","2016","2016",38.4,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","MTMOPPMT","Million US$, purchasing power parity","PRT","Portugal","2017","2017",37.8,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","MTMOPPMT","Million US$, purchasing power parity","PRT","Portugal","2018","2018",37.8,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","MTMOPPMT","Million US$, purchasing power parity","PRT","Portugal","2019","2019",39.2,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","MTMOPPMT","Million US$, purchasing power parity","PRT","Portugal","2020","2020",39.6,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","MTMOPPMT","Million US$, purchasing power parity","PRT","Portugal","2021","2021",38,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","MTMOPPMT","Million US$, purchasing power parity","PRT","Portugal","2022","2022",38.1,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","TCPPERMT","/capita, US$ exchange rate","PRT","Portugal","2010","2010",3.6,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","TCPPERMT","/capita, US$ exchange rate","PRT","Portugal","2011","2011",3.3,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","TCPPERMT","/capita, US$ exchange rate","PRT","Portugal","2012","2012",2.9,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","TCPPERMT","/capita, US$ exchange rate","PRT","Portugal","2013","2013",2.9,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","TCPPERMT","/capita, US$ exchange rate","PRT","Portugal","2014","2014",2.9,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","TCPPERMT","/capita, US$ exchange rate","PRT","Portugal","2015","2015",2.4,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","TCPPERMT","/capita, US$ exchange rate","PRT","Portugal","2016","2016",2.4,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","TCPPERMT","/capita, US$ exchange rate","PRT","Portugal","2017","2017",2.4,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","TCPPERMT","/capita, US$ exchange rate","PRT","Portugal","2018","2018",2.5,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","TCPPERMT","/capita, US$ exchange rate","PRT","Portugal","2019","2019",2.4,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","TCPPERMT","/capita, US$ exchange rate","PRT","Portugal","2020","2020",2.4,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","TCPPERMT","/capita, US$ exchange rate","PRT","Portugal","2021","2021",2.5,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","TCPPERMT","/capita, US$ exchange rate","PRT","Portugal","2022","2022",2.1,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2010","2010",4.4,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2011","2011",3.8,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2012","2012",3.7,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2013","2013",3.7,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2014","2014",3.7,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2015","2015",3.7,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2016","2016",3.7,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2017","2017",3.7,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2018","2018",3.7,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2019","2019",3.8,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2020","2020",3.8,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2021","2021",3.7,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2022","2022",3.7,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","ATCPTTMT","% of total sales","PRT","Portugal","2010","2010",0.9,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","ATCPTTMT","% of total sales","PRT","Portugal","2011","2011",0.8,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","ATCPTTMT","% of total sales","PRT","Portugal","2012","2012",0.9,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","ATCPTTMT","% of total sales","PRT","Portugal","2013","2013",0.9,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","ATCPTTMT","% of total sales","PRT","Portugal","2014","2014",0.9,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","ATCPTTMT","% of total sales","PRT","Portugal","2015","2015",0.9,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","ATCPTTMT","% of total sales","PRT","Portugal","2016","2016",0.9,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","ATCPTTMT","% of total sales","PRT","Portugal","2017","2017",0.9,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","ATCPTTMT","% of total sales","PRT","Portugal","2018","2018",0.8,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","ATCPTTMT","% of total sales","PRT","Portugal","2019","2019",0.8,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","ATCPTTMT","% of total sales","PRT","Portugal","2020","2020",0.8,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","ATCPTTMT","% of total sales","PRT","Portugal","2021","2021",0.7,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","ATCPTTMT","% of total sales","PRT","Portugal","2022","2022",0.7,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","MLLNCUMT","Million of national currency units","SVK","Slovak Republic","2010","2010",5,,
+"PATCDIUR","C03-Diuretics","MLLNCUMT","Million of national currency units","SVK","Slovak Republic","2011","2011",5.5,,
+"PATCDIUR","C03-Diuretics","MLLNCUMT","Million of national currency units","SVK","Slovak Republic","2012","2012",5.9,,
+"PATCDIUR","C03-Diuretics","MLLNCUMT","Million of national currency units","SVK","Slovak Republic","2013","2013",6.4,,
+"PATCDIUR","C03-Diuretics","MLLNCUMT","Million of national currency units","SVK","Slovak Republic","2014","2014",6.8,,
+"PATCDIUR","C03-Diuretics","MLLNCUMT","Million of national currency units","SVK","Slovak Republic","2015","2015",6.3,,
+"PATCDIUR","C03-Diuretics","MLLNCUMT","Million of national currency units","SVK","Slovak Republic","2016","2016",9,"B","Break"
+"PATCDIUR","C03-Diuretics","MLLNCUMT","Million of national currency units","SVK","Slovak Republic","2017","2017",8.7,,
+"PATCDIUR","C03-Diuretics","MLLNCUMT","Million of national currency units","SVK","Slovak Republic","2018","2018",9.1,,
+"PATCDIUR","C03-Diuretics","MLLNCUMT","Million of national currency units","SVK","Slovak Republic","2019","2019",9.1,,
+"PATCDIUR","C03-Diuretics","MLLNCUMT","Million of national currency units","SVK","Slovak Republic","2020","2020",9.2,,
+"PATCDIUR","C03-Diuretics","MLLNCUMT","Million of national currency units","SVK","Slovak Republic","2021","2021",9,,
+"PATCDIUR","C03-Diuretics","MTMOTCMT","Million US$ at exchange rate","SVK","Slovak Republic","2010","2010",6.6,,
+"PATCDIUR","C03-Diuretics","MTMOTCMT","Million US$ at exchange rate","SVK","Slovak Republic","2011","2011",7.7,,
+"PATCDIUR","C03-Diuretics","MTMOTCMT","Million US$ at exchange rate","SVK","Slovak Republic","2012","2012",7.5,,
+"PATCDIUR","C03-Diuretics","MTMOTCMT","Million US$ at exchange rate","SVK","Slovak Republic","2013","2013",8.4,,
+"PATCDIUR","C03-Diuretics","MTMOTCMT","Million US$ at exchange rate","SVK","Slovak Republic","2014","2014",9,,
+"PATCDIUR","C03-Diuretics","MTMOTCMT","Million US$ at exchange rate","SVK","Slovak Republic","2015","2015",7,,
+"PATCDIUR","C03-Diuretics","MTMOTCMT","Million US$ at exchange rate","SVK","Slovak Republic","2016","2016",9.9,"B","Break"
+"PATCDIUR","C03-Diuretics","MTMOTCMT","Million US$ at exchange rate","SVK","Slovak Republic","2017","2017",9.8,,
+"PATCDIUR","C03-Diuretics","MTMOTCMT","Million US$ at exchange rate","SVK","Slovak Republic","2018","2018",10.7,,
+"PATCDIUR","C03-Diuretics","MTMOTCMT","Million US$ at exchange rate","SVK","Slovak Republic","2019","2019",10.2,,
+"PATCDIUR","C03-Diuretics","MTMOTCMT","Million US$ at exchange rate","SVK","Slovak Republic","2020","2020",10.5,,
+"PATCDIUR","C03-Diuretics","MTMOTCMT","Million US$ at exchange rate","SVK","Slovak Republic","2021","2021",10.7,,
+"PATCDIUR","C03-Diuretics","MTMOPPMT","Million US$, purchasing power parity","SVK","Slovak Republic","2010","2010",9.9,,
+"PATCDIUR","C03-Diuretics","MTMOPPMT","Million US$, purchasing power parity","SVK","Slovak Republic","2011","2011",10.9,,
+"PATCDIUR","C03-Diuretics","MTMOPPMT","Million US$, purchasing power parity","SVK","Slovak Republic","2012","2012",11.6,,
+"PATCDIUR","C03-Diuretics","MTMOPPMT","Million US$, purchasing power parity","SVK","Slovak Republic","2013","2013",12.9,,
+"PATCDIUR","C03-Diuretics","MTMOPPMT","Million US$, purchasing power parity","SVK","Slovak Republic","2014","2014",14,,
+"PATCDIUR","C03-Diuretics","MTMOPPMT","Million US$, purchasing power parity","SVK","Slovak Republic","2015","2015",12.8,,
+"PATCDIUR","C03-Diuretics","MTMOPPMT","Million US$, purchasing power parity","SVK","Slovak Republic","2016","2016",17.8,"B","Break"
+"PATCDIUR","C03-Diuretics","MTMOPPMT","Million US$, purchasing power parity","SVK","Slovak Republic","2017","2017",16.8,,
+"PATCDIUR","C03-Diuretics","MTMOPPMT","Million US$, purchasing power parity","SVK","Slovak Republic","2018","2018",17.3,,
+"PATCDIUR","C03-Diuretics","MTMOPPMT","Million US$, purchasing power parity","SVK","Slovak Republic","2019","2019",17.5,,
+"PATCDIUR","C03-Diuretics","MTMOPPMT","Million US$, purchasing power parity","SVK","Slovak Republic","2020","2020",17.7,,
+"PATCDIUR","C03-Diuretics","MTMOPPMT","Million US$, purchasing power parity","SVK","Slovak Republic","2021","2021",16.9,,
+"PATCDIUR","C03-Diuretics","TCPPERMT","/capita, US$ exchange rate","SVK","Slovak Republic","2010","2010",1.2,,
+"PATCDIUR","C03-Diuretics","TCPPERMT","/capita, US$ exchange rate","SVK","Slovak Republic","2011","2011",1.4,,
+"PATCDIUR","C03-Diuretics","TCPPERMT","/capita, US$ exchange rate","SVK","Slovak Republic","2012","2012",1.4,,
+"PATCDIUR","C03-Diuretics","TCPPERMT","/capita, US$ exchange rate","SVK","Slovak Republic","2013","2013",1.6,,
+"PATCDIUR","C03-Diuretics","TCPPERMT","/capita, US$ exchange rate","SVK","Slovak Republic","2014","2014",1.7,,
+"PATCDIUR","C03-Diuretics","TCPPERMT","/capita, US$ exchange rate","SVK","Slovak Republic","2015","2015",1.3,,
+"PATCDIUR","C03-Diuretics","TCPPERMT","/capita, US$ exchange rate","SVK","Slovak Republic","2016","2016",1.8,"B","Break"
+"PATCDIUR","C03-Diuretics","TCPPERMT","/capita, US$ exchange rate","SVK","Slovak Republic","2017","2017",1.8,,
+"PATCDIUR","C03-Diuretics","TCPPERMT","/capita, US$ exchange rate","SVK","Slovak Republic","2018","2018",2,,
+"PATCDIUR","C03-Diuretics","TCPPERMT","/capita, US$ exchange rate","SVK","Slovak Republic","2019","2019",1.9,,
+"PATCDIUR","C03-Diuretics","TCPPERMT","/capita, US$ exchange rate","SVK","Slovak Republic","2020","2020",1.9,,
+"PATCDIUR","C03-Diuretics","TCPPERMT","/capita, US$ exchange rate","SVK","Slovak Republic","2021","2021",2,,
+"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2010","2010",1.8,,
+"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2011","2011",2,,
+"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2012","2012",2.1,,
+"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2013","2013",2.4,,
+"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2014","2014",2.6,,
+"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2015","2015",2.4,,
+"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2016","2016",3.3,"B","Break"
+"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2017","2017",3.1,,
+"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2018","2018",3.2,,
+"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2019","2019",3.2,,
+"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2020","2020",3.2,,
+"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2021","2021",3.1,,
+"PATCDIUR","C03-Diuretics","ATCPTTMT","% of total sales","SVK","Slovak Republic","2010","2010",0.4,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","ATCPTTMT","% of total sales","SVK","Slovak Republic","2011","2011",0.5,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","ATCPTTMT","% of total sales","SVK","Slovak Republic","2012","2012",0.5,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","ATCPTTMT","% of total sales","SVK","Slovak Republic","2013","2013",0.5,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","ATCPTTMT","% of total sales","SVK","Slovak Republic","2014","2014",0.5,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","ATCPTTMT","% of total sales","SVK","Slovak Republic","2015","2015",0.5,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","ATCPTTMT","% of total sales","SVK","Slovak Republic","2016","2016",0.6,"B","Break"
+"PATCDIUR","C03-Diuretics","ATCPTTMT","% of total sales","SVK","Slovak Republic","2017","2017",0.6,,
+"PATCDIUR","C03-Diuretics","ATCPTTMT","% of total sales","SVK","Slovak Republic","2018","2018",0.6,,
+"PATCDIUR","C03-Diuretics","ATCPTTMT","% of total sales","SVK","Slovak Republic","2019","2019",0.5,,
+"PATCDIUR","C03-Diuretics","ATCPTTMT","% of total sales","SVK","Slovak Republic","2020","2020",0.6,,
+"PATCDIUR","C03-Diuretics","ATCPTTMT","% of total sales","SVK","Slovak Republic","2021","2021",0.5,,
+"PATCDIUR","C03-Diuretics","MLLNCUMT","Million of national currency units","ESP","Spain","2010","2010",124.6,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","MLLNCUMT","Million of national currency units","ESP","Spain","2011","2011",120.2,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","MLLNCUMT","Million of national currency units","ESP","Spain","2012","2012",111.6,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","MLLNCUMT","Million of national currency units","ESP","Spain","2013","2013",101.6,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","MLLNCUMT","Million of national currency units","ESP","Spain","2014","2014",102.8,"B; D","Break; Difference in methodology"
+"PATCDIUR","C03-Diuretics","MLLNCUMT","Million of national currency units","ESP","Spain","2015","2015",92.6,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","MLLNCUMT","Million of national currency units","ESP","Spain","2016","2016",94.5,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","MLLNCUMT","Million of national currency units","ESP","Spain","2017","2017",96,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","MLLNCUMT","Million of national currency units","ESP","Spain","2018","2018",111.6,"B","Break"
+"PATCDIUR","C03-Diuretics","MLLNCUMT","Million of national currency units","ESP","Spain","2019","2019",119.1,,
+"PATCDIUR","C03-Diuretics","MLLNCUMT","Million of national currency units","ESP","Spain","2020","2020",125.4,,
+"PATCDIUR","C03-Diuretics","MLLNCUMT","Million of national currency units","ESP","Spain","2021","2021",126.6,,
+"PATCDIUR","C03-Diuretics","MLLNCUMT","Million of national currency units","ESP","Spain","2022","2022",120.3,"P","Provisional value"
+"PATCDIUR","C03-Diuretics","MTMOTCMT","Million US$ at exchange rate","ESP","Spain","2010","2010",165.2,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","MTMOTCMT","Million US$ at exchange rate","ESP","Spain","2011","2011",167.4,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","MTMOTCMT","Million US$ at exchange rate","ESP","Spain","2012","2012",143.3,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","MTMOTCMT","Million US$ at exchange rate","ESP","Spain","2013","2013",135,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","MTMOTCMT","Million US$ at exchange rate","ESP","Spain","2014","2014",136.6,"B; D","Break; Difference in methodology"
+"PATCDIUR","C03-Diuretics","MTMOTCMT","Million US$ at exchange rate","ESP","Spain","2015","2015",102.8,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","MTMOTCMT","Million US$ at exchange rate","ESP","Spain","2016","2016",104.6,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","MTMOTCMT","Million US$ at exchange rate","ESP","Spain","2017","2017",108.5,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","MTMOTCMT","Million US$ at exchange rate","ESP","Spain","2018","2018",131.8,"B","Break"
+"PATCDIUR","C03-Diuretics","MTMOTCMT","Million US$ at exchange rate","ESP","Spain","2019","2019",133.4,,
+"PATCDIUR","C03-Diuretics","MTMOTCMT","Million US$ at exchange rate","ESP","Spain","2020","2020",143.3,,
+"PATCDIUR","C03-Diuretics","MTMOTCMT","Million US$ at exchange rate","ESP","Spain","2021","2021",149.7,,
+"PATCDIUR","C03-Diuretics","MTMOTCMT","Million US$ at exchange rate","ESP","Spain","2022","2022",126.7,"P","Provisional value"
+"PATCDIUR","C03-Diuretics","MTMOPPMT","Million US$, purchasing power parity","ESP","Spain","2010","2010",171.4,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","MTMOPPMT","Million US$, purchasing power parity","ESP","Spain","2011","2011",168.4,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","MTMOPPMT","Million US$, purchasing power parity","ESP","Spain","2012","2012",160.5,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","MTMOPPMT","Million US$, purchasing power parity","ESP","Spain","2013","2013",150.6,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","MTMOPPMT","Million US$, purchasing power parity","ESP","Spain","2014","2014",155.2,"B; D","Break; Difference in methodology"
+"PATCDIUR","C03-Diuretics","MTMOPPMT","Million US$, purchasing power parity","ESP","Spain","2015","2015",139.4,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","MTMOPPMT","Million US$, purchasing power parity","ESP","Spain","2016","2016",147.1,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","MTMOPPMT","Million US$, purchasing power parity","ESP","Spain","2017","2017",152.2,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","MTMOPPMT","Million US$, purchasing power parity","ESP","Spain","2018","2018",176.6,"B","Break"
+"PATCDIUR","C03-Diuretics","MTMOPPMT","Million US$, purchasing power parity","ESP","Spain","2019","2019",194.3,,
+"PATCDIUR","C03-Diuretics","MTMOPPMT","Million US$, purchasing power parity","ESP","Spain","2020","2020",201.9,,
+"PATCDIUR","C03-Diuretics","MTMOPPMT","Million US$, purchasing power parity","ESP","Spain","2021","2021",202.2,,
+"PATCDIUR","C03-Diuretics","MTMOPPMT","Million US$, purchasing power parity","ESP","Spain","2022","2022",201.8,"P","Provisional value"
+"PATCDIUR","C03-Diuretics","TCPPERMT","/capita, US$ exchange rate","ESP","Spain","2010","2010",3.5,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","TCPPERMT","/capita, US$ exchange rate","ESP","Spain","2011","2011",3.6,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","TCPPERMT","/capita, US$ exchange rate","ESP","Spain","2012","2012",3.1,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","TCPPERMT","/capita, US$ exchange rate","ESP","Spain","2013","2013",2.9,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","TCPPERMT","/capita, US$ exchange rate","ESP","Spain","2014","2014",2.9,"B; D","Break; Difference in methodology"
+"PATCDIUR","C03-Diuretics","TCPPERMT","/capita, US$ exchange rate","ESP","Spain","2015","2015",2.2,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","TCPPERMT","/capita, US$ exchange rate","ESP","Spain","2016","2016",2.3,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","TCPPERMT","/capita, US$ exchange rate","ESP","Spain","2017","2017",2.3,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","TCPPERMT","/capita, US$ exchange rate","ESP","Spain","2018","2018",2.8,"B","Break"
+"PATCDIUR","C03-Diuretics","TCPPERMT","/capita, US$ exchange rate","ESP","Spain","2019","2019",2.8,,
+"PATCDIUR","C03-Diuretics","TCPPERMT","/capita, US$ exchange rate","ESP","Spain","2020","2020",3,,
+"PATCDIUR","C03-Diuretics","TCPPERMT","/capita, US$ exchange rate","ESP","Spain","2021","2021",3.2,,
+"PATCDIUR","C03-Diuretics","TCPPERMT","/capita, US$ exchange rate","ESP","Spain","2022","2022",2.7,"P","Provisional value"
+"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2010","2010",3.7,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2011","2011",3.6,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2012","2012",3.4,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2013","2013",3.2,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2014","2014",3.3,"B; D","Break; Difference in methodology"
+"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2015","2015",3,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2016","2016",3.2,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2017","2017",3.3,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2018","2018",3.8,"B","Break"
+"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2019","2019",4.1,,
+"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2020","2020",4.3,,
+"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2021","2021",4.3,,
+"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2022","2022",4.3,"P","Provisional value"
+"PATCDIUR","C03-Diuretics","ATCPTTMT","% of total sales","ESP","Spain","2010","2010",0.9,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","ATCPTTMT","% of total sales","ESP","Spain","2011","2011",1,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","ATCPTTMT","% of total sales","ESP","Spain","2012","2012",1,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","ATCPTTMT","% of total sales","ESP","Spain","2013","2013",1,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","ATCPTTMT","% of total sales","ESP","Spain","2014","2014",0.9,"B; D","Break; Difference in methodology"
+"PATCDIUR","C03-Diuretics","ATCPTTMT","% of total sales","ESP","Spain","2015","2015",0.8,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","ATCPTTMT","% of total sales","ESP","Spain","2016","2016",0.8,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","ATCPTTMT","% of total sales","ESP","Spain","2017","2017",0.8,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","ATCPTTMT","% of total sales","ESP","Spain","2018","2018",0.6,"B","Break"
+"PATCDIUR","C03-Diuretics","ATCPTTMT","% of total sales","ESP","Spain","2019","2019",0.6,,
+"PATCDIUR","C03-Diuretics","ATCPTTMT","% of total sales","ESP","Spain","2020","2020",0.6,,
+"PATCDIUR","C03-Diuretics","ATCPTTMT","% of total sales","ESP","Spain","2021","2021",0.6,,
+"PATCDIUR","C03-Diuretics","ATCPTTMT","% of total sales","ESP","Spain","2022","2022",0.5,"P","Provisional value"
+"PATCDIUR","C03-Diuretics","MLLNCUMT","Million of national currency units","SWE","Sweden","2010","2010",269.1,,
+"PATCDIUR","C03-Diuretics","MLLNCUMT","Million of national currency units","SWE","Sweden","2011","2011",265.3,,
+"PATCDIUR","C03-Diuretics","MLLNCUMT","Million of national currency units","SWE","Sweden","2012","2012",259,,
+"PATCDIUR","C03-Diuretics","MLLNCUMT","Million of national currency units","SWE","Sweden","2013","2013",257,,
+"PATCDIUR","C03-Diuretics","MLLNCUMT","Million of national currency units","SWE","Sweden","2014","2014",255.1,,
+"PATCDIUR","C03-Diuretics","MLLNCUMT","Million of national currency units","SWE","Sweden","2015","2015",241.9,,
+"PATCDIUR","C03-Diuretics","MLLNCUMT","Million of national currency units","SWE","Sweden","2016","2016",223,,
+"PATCDIUR","C03-Diuretics","MLLNCUMT","Million of national currency units","SWE","Sweden","2017","2017",221.4,,
+"PATCDIUR","C03-Diuretics","MLLNCUMT","Million of national currency units","SWE","Sweden","2018","2018",221,,
+"PATCDIUR","C03-Diuretics","MLLNCUMT","Million of national currency units","SWE","Sweden","2019","2019",218.2,,
+"PATCDIUR","C03-Diuretics","MLLNCUMT","Million of national currency units","SWE","Sweden","2020","2020",237.4,,
+"PATCDIUR","C03-Diuretics","MLLNCUMT","Million of national currency units","SWE","Sweden","2021","2021",227.2,,
+"PATCDIUR","C03-Diuretics","MLLNCUMT","Million of national currency units","SWE","Sweden","2022","2022",248.9,,
+"PATCDIUR","C03-Diuretics","MTMOTCMT","Million US$ at exchange rate","SWE","Sweden","2010","2010",37.3,,
+"PATCDIUR","C03-Diuretics","MTMOTCMT","Million US$ at exchange rate","SWE","Sweden","2011","2011",40.9,,
+"PATCDIUR","C03-Diuretics","MTMOTCMT","Million US$ at exchange rate","SWE","Sweden","2012","2012",38.2,,
+"PATCDIUR","C03-Diuretics","MTMOTCMT","Million US$ at exchange rate","SWE","Sweden","2013","2013",39.5,,
+"PATCDIUR","C03-Diuretics","MTMOTCMT","Million US$ at exchange rate","SWE","Sweden","2014","2014",37.2,,
+"PATCDIUR","C03-Diuretics","MTMOTCMT","Million US$ at exchange rate","SWE","Sweden","2015","2015",28.7,,
+"PATCDIUR","C03-Diuretics","MTMOTCMT","Million US$ at exchange rate","SWE","Sweden","2016","2016",26,,
+"PATCDIUR","C03-Diuretics","MTMOTCMT","Million US$ at exchange rate","SWE","Sweden","2017","2017",25.9,,
+"PATCDIUR","C03-Diuretics","MTMOTCMT","Million US$ at exchange rate","SWE","Sweden","2018","2018",25.4,,
+"PATCDIUR","C03-Diuretics","MTMOTCMT","Million US$ at exchange rate","SWE","Sweden","2019","2019",23.1,,
+"PATCDIUR","C03-Diuretics","MTMOTCMT","Million US$ at exchange rate","SWE","Sweden","2020","2020",25.8,,
+"PATCDIUR","C03-Diuretics","MTMOTCMT","Million US$ at exchange rate","SWE","Sweden","2021","2021",26.5,,
+"PATCDIUR","C03-Diuretics","MTMOTCMT","Million US$ at exchange rate","SWE","Sweden","2022","2022",24.6,,
+"PATCDIUR","C03-Diuretics","MTMOPPMT","Million US$, purchasing power parity","SWE","Sweden","2010","2010",29.8,,
+"PATCDIUR","C03-Diuretics","MTMOPPMT","Million US$, purchasing power parity","SWE","Sweden","2011","2011",30,,
+"PATCDIUR","C03-Diuretics","MTMOPPMT","Million US$, purchasing power parity","SWE","Sweden","2012","2012",29.9,,
+"PATCDIUR","C03-Diuretics","MTMOPPMT","Million US$, purchasing power parity","SWE","Sweden","2013","2013",29.9,,
+"PATCDIUR","C03-Diuretics","MTMOPPMT","Million US$, purchasing power parity","SWE","Sweden","2014","2014",29.2,,
+"PATCDIUR","C03-Diuretics","MTMOPPMT","Million US$, purchasing power parity","SWE","Sweden","2015","2015",27.3,,
+"PATCDIUR","C03-Diuretics","MTMOPPMT","Million US$, purchasing power parity","SWE","Sweden","2016","2016",25.3,,
+"PATCDIUR","C03-Diuretics","MTMOPPMT","Million US$, purchasing power parity","SWE","Sweden","2017","2017",25,,
+"PATCDIUR","C03-Diuretics","MTMOPPMT","Million US$, purchasing power parity","SWE","Sweden","2018","2018",24.9,,
+"PATCDIUR","C03-Diuretics","MTMOPPMT","Million US$, purchasing power parity","SWE","Sweden","2019","2019",25,,
+"PATCDIUR","C03-Diuretics","MTMOPPMT","Million US$, purchasing power parity","SWE","Sweden","2020","2020",27.4,,
+"PATCDIUR","C03-Diuretics","MTMOPPMT","Million US$, purchasing power parity","SWE","Sweden","2021","2021",26,,
+"PATCDIUR","C03-Diuretics","MTMOPPMT","Million US$, purchasing power parity","SWE","Sweden","2022","2022",28.7,,
+"PATCDIUR","C03-Diuretics","TCPPERMT","/capita, US$ exchange rate","SWE","Sweden","2010","2010",4,,
+"PATCDIUR","C03-Diuretics","TCPPERMT","/capita, US$ exchange rate","SWE","Sweden","2011","2011",4.3,,
+"PATCDIUR","C03-Diuretics","TCPPERMT","/capita, US$ exchange rate","SWE","Sweden","2012","2012",4,,
+"PATCDIUR","C03-Diuretics","TCPPERMT","/capita, US$ exchange rate","SWE","Sweden","2013","2013",4.1,,
+"PATCDIUR","C03-Diuretics","TCPPERMT","/capita, US$ exchange rate","SWE","Sweden","2014","2014",3.8,,
+"PATCDIUR","C03-Diuretics","TCPPERMT","/capita, US$ exchange rate","SWE","Sweden","2015","2015",2.9,,
+"PATCDIUR","C03-Diuretics","TCPPERMT","/capita, US$ exchange rate","SWE","Sweden","2016","2016",2.6,,
+"PATCDIUR","C03-Diuretics","TCPPERMT","/capita, US$ exchange rate","SWE","Sweden","2017","2017",2.6,,
+"PATCDIUR","C03-Diuretics","TCPPERMT","/capita, US$ exchange rate","SWE","Sweden","2018","2018",2.5,,
+"PATCDIUR","C03-Diuretics","TCPPERMT","/capita, US$ exchange rate","SWE","Sweden","2019","2019",2.2,,
+"PATCDIUR","C03-Diuretics","TCPPERMT","/capita, US$ exchange rate","SWE","Sweden","2020","2020",2.5,,
+"PATCDIUR","C03-Diuretics","TCPPERMT","/capita, US$ exchange rate","SWE","Sweden","2021","2021",2.5,,
+"PATCDIUR","C03-Diuretics","TCPPERMT","/capita, US$ exchange rate","SWE","Sweden","2022","2022",2.4,,
+"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2010","2010",3.2,,
+"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2011","2011",3.2,,
+"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2012","2012",3.1,,
+"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2013","2013",3.1,,
+"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2014","2014",3,,
+"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2015","2015",2.8,,
+"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2016","2016",2.5,,
+"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2017","2017",2.5,,
+"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2018","2018",2.5,,
+"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2019","2019",2.4,,
+"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2020","2020",2.6,,
+"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2021","2021",2.5,,
+"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2022","2022",2.7,,
+"PATCDIUR","C03-Diuretics","ATCPTTMT","% of total sales","SWE","Sweden","2010","2010",0.7,,
+"PATCDIUR","C03-Diuretics","ATCPTTMT","% of total sales","SWE","Sweden","2011","2011",0.7,,
+"PATCDIUR","C03-Diuretics","ATCPTTMT","% of total sales","SWE","Sweden","2012","2012",0.7,,
+"PATCDIUR","C03-Diuretics","ATCPTTMT","% of total sales","SWE","Sweden","2013","2013",0.7,,
+"PATCDIUR","C03-Diuretics","ATCPTTMT","% of total sales","SWE","Sweden","2014","2014",0.7,,
+"PATCDIUR","C03-Diuretics","ATCPTTMT","% of total sales","SWE","Sweden","2015","2015",0.6,,
+"PATCDIUR","C03-Diuretics","ATCPTTMT","% of total sales","SWE","Sweden","2016","2016",0.5,,
+"PATCDIUR","C03-Diuretics","ATCPTTMT","% of total sales","SWE","Sweden","2017","2017",0.5,,
+"PATCDIUR","C03-Diuretics","ATCPTTMT","% of total sales","SWE","Sweden","2018","2018",0.5,,
+"PATCDIUR","C03-Diuretics","ATCPTTMT","% of total sales","SWE","Sweden","2019","2019",0.4,,
+"PATCDIUR","C03-Diuretics","ATCPTTMT","% of total sales","SWE","Sweden","2020","2020",0.5,,
+"PATCDIUR","C03-Diuretics","ATCPTTMT","% of total sales","SWE","Sweden","2021","2021",0.4,,
+"PATCDIUR","C03-Diuretics","ATCPTTMT","% of total sales","SWE","Sweden","2022","2022",0.4,,
+"PATCDIUR","C03-Diuretics","MLLNCUMT","Million of national currency units","TUR","Türkiye","2010","2010",38.6,,
+"PATCDIUR","C03-Diuretics","MLLNCUMT","Million of national currency units","TUR","Türkiye","2011","2011",39.7,,
+"PATCDIUR","C03-Diuretics","MLLNCUMT","Million of national currency units","TUR","Türkiye","2012","2012",37.9,,
+"PATCDIUR","C03-Diuretics","MLLNCUMT","Million of national currency units","TUR","Türkiye","2013","2013",40.4,,
+"PATCDIUR","C03-Diuretics","MLLNCUMT","Million of national currency units","TUR","Türkiye","2014","2014",47.1,,
+"PATCDIUR","C03-Diuretics","MLLNCUMT","Million of national currency units","TUR","Türkiye","2015","2015",53.4,,
+"PATCDIUR","C03-Diuretics","MLLNCUMT","Million of national currency units","TUR","Türkiye","2016","2016",64.9,,
+"PATCDIUR","C03-Diuretics","MLLNCUMT","Million of national currency units","TUR","Türkiye","2017","2017",79.6,,
+"PATCDIUR","C03-Diuretics","MLLNCUMT","Million of national currency units","TUR","Türkiye","2018","2018",97.4,,
+"PATCDIUR","C03-Diuretics","MLLNCUMT","Million of national currency units","TUR","Türkiye","2019","2019",158.8,,
+"PATCDIUR","C03-Diuretics","MLLNCUMT","Million of national currency units","TUR","Türkiye","2020","2020",246.3,,
+"PATCDIUR","C03-Diuretics","MLLNCUMT","Million of national currency units","TUR","Türkiye","2021","2021",339,,
+"PATCDIUR","C03-Diuretics","MTMOTCMT","Million US$ at exchange rate","TUR","Türkiye","2010","2010",25.7,,
+"PATCDIUR","C03-Diuretics","MTMOTCMT","Million US$ at exchange rate","TUR","Türkiye","2011","2011",23.7,,
+"PATCDIUR","C03-Diuretics","MTMOTCMT","Million US$ at exchange rate","TUR","Türkiye","2012","2012",21.1,,
+"PATCDIUR","C03-Diuretics","MTMOTCMT","Million US$ at exchange rate","TUR","Türkiye","2013","2013",21.2,,
+"PATCDIUR","C03-Diuretics","MTMOTCMT","Million US$ at exchange rate","TUR","Türkiye","2014","2014",21.5,,
+"PATCDIUR","C03-Diuretics","MTMOTCMT","Million US$ at exchange rate","TUR","Türkiye","2015","2015",19.6,,
+"PATCDIUR","C03-Diuretics","MTMOTCMT","Million US$ at exchange rate","TUR","Türkiye","2016","2016",21.5,,
+"PATCDIUR","C03-Diuretics","MTMOTCMT","Million US$ at exchange rate","TUR","Türkiye","2017","2017",21.8,,
+"PATCDIUR","C03-Diuretics","MTMOTCMT","Million US$ at exchange rate","TUR","Türkiye","2018","2018",20.2,,
+"PATCDIUR","C03-Diuretics","MTMOTCMT","Million US$ at exchange rate","TUR","Türkiye","2019","2019",28,,
+"PATCDIUR","C03-Diuretics","MTMOTCMT","Million US$ at exchange rate","TUR","Türkiye","2020","2020",35.1,,
+"PATCDIUR","C03-Diuretics","MTMOTCMT","Million US$ at exchange rate","TUR","Türkiye","2021","2021",38.3,,
+"PATCDIUR","C03-Diuretics","MTMOPPMT","Million US$, purchasing power parity","TUR","Türkiye","2010","2010",41.9,,
+"PATCDIUR","C03-Diuretics","MTMOPPMT","Million US$, purchasing power parity","TUR","Türkiye","2011","2011",41.1,,
+"PATCDIUR","C03-Diuretics","MTMOPPMT","Million US$, purchasing power parity","TUR","Türkiye","2012","2012",37.1,,
+"PATCDIUR","C03-Diuretics","MTMOPPMT","Million US$, purchasing power parity","TUR","Türkiye","2013","2013",37.8,,
+"PATCDIUR","C03-Diuretics","MTMOPPMT","Million US$, purchasing power parity","TUR","Türkiye","2014","2014",42.7,,
+"PATCDIUR","C03-Diuretics","MTMOPPMT","Million US$, purchasing power parity","TUR","Türkiye","2015","2015",45.9,,
+"PATCDIUR","C03-Diuretics","MTMOPPMT","Million US$, purchasing power parity","TUR","Türkiye","2016","2016",52.3,,
+"PATCDIUR","C03-Diuretics","MTMOPPMT","Million US$, purchasing power parity","TUR","Türkiye","2017","2017",57.5,,
+"PATCDIUR","C03-Diuretics","MTMOPPMT","Million US$, purchasing power parity","TUR","Türkiye","2018","2018",59.6,,
+"PATCDIUR","C03-Diuretics","MTMOPPMT","Million US$, purchasing power parity","TUR","Türkiye","2019","2019",85.2,,
+"PATCDIUR","C03-Diuretics","MTMOPPMT","Million US$, purchasing power parity","TUR","Türkiye","2020","2020",113.8,,
+"PATCDIUR","C03-Diuretics","MTMOPPMT","Million US$, purchasing power parity","TUR","Türkiye","2021","2021",120.7,,
+"PATCDIUR","C03-Diuretics","TCPPERMT","/capita, US$ exchange rate","TUR","Türkiye","2010","2010",0.4,,
+"PATCDIUR","C03-Diuretics","TCPPERMT","/capita, US$ exchange rate","TUR","Türkiye","2011","2011",0.3,,
+"PATCDIUR","C03-Diuretics","TCPPERMT","/capita, US$ exchange rate","TUR","Türkiye","2012","2012",0.3,,
+"PATCDIUR","C03-Diuretics","TCPPERMT","/capita, US$ exchange rate","TUR","Türkiye","2013","2013",0.3,,
+"PATCDIUR","C03-Diuretics","TCPPERMT","/capita, US$ exchange rate","TUR","Türkiye","2014","2014",0.3,,
+"PATCDIUR","C03-Diuretics","TCPPERMT","/capita, US$ exchange rate","TUR","Türkiye","2015","2015",0.3,,
+"PATCDIUR","C03-Diuretics","TCPPERMT","/capita, US$ exchange rate","TUR","Türkiye","2016","2016",0.3,,
+"PATCDIUR","C03-Diuretics","TCPPERMT","/capita, US$ exchange rate","TUR","Türkiye","2017","2017",0.3,,
+"PATCDIUR","C03-Diuretics","TCPPERMT","/capita, US$ exchange rate","TUR","Türkiye","2018","2018",0.2,,
+"PATCDIUR","C03-Diuretics","TCPPERMT","/capita, US$ exchange rate","TUR","Türkiye","2019","2019",0.3,,
+"PATCDIUR","C03-Diuretics","TCPPERMT","/capita, US$ exchange rate","TUR","Türkiye","2020","2020",0.4,,
+"PATCDIUR","C03-Diuretics","TCPPERMT","/capita, US$ exchange rate","TUR","Türkiye","2021","2021",0.5,,
+"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2010","2010",0.6,,
+"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2011","2011",0.6,,
+"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2012","2012",0.5,,
+"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2013","2013",0.5,,
+"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2014","2014",0.6,,
+"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2015","2015",0.6,,
+"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2016","2016",0.7,,
+"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2017","2017",0.7,,
+"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2018","2018",0.7,,
+"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2019","2019",1,,
+"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2020","2020",1.4,,
+"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2021","2021",1.4,,
+"PATCDIUR","C03-Diuretics","ATCPTTMT","% of total sales","TUR","Türkiye","2010","2010",0.2,,
+"PATCDIUR","C03-Diuretics","ATCPTTMT","% of total sales","TUR","Türkiye","2011","2011",0.3,,
+"PATCDIUR","C03-Diuretics","ATCPTTMT","% of total sales","TUR","Türkiye","2012","2012",0.3,,
+"PATCDIUR","C03-Diuretics","ATCPTTMT","% of total sales","TUR","Türkiye","2013","2013",0.3,,
+"PATCDIUR","C03-Diuretics","ATCPTTMT","% of total sales","TUR","Türkiye","2014","2014",0.3,,
+"PATCDIUR","C03-Diuretics","ATCPTTMT","% of total sales","TUR","Türkiye","2015","2015",0.3,,
+"PATCDIUR","C03-Diuretics","ATCPTTMT","% of total sales","TUR","Türkiye","2016","2016",0.3,,
+"PATCDIUR","C03-Diuretics","ATCPTTMT","% of total sales","TUR","Türkiye","2017","2017",0.3,,
+"PATCDIUR","C03-Diuretics","ATCPTTMT","% of total sales","TUR","Türkiye","2018","2018",0.3,,
+"PATCDIUR","C03-Diuretics","ATCPTTMT","% of total sales","TUR","Türkiye","2019","2019",0.4,,
+"PATCDIUR","C03-Diuretics","ATCPTTMT","% of total sales","TUR","Türkiye","2020","2020",0.5,,
+"PATCDIUR","C03-Diuretics","ATCPTTMT","% of total sales","TUR","Türkiye","2021","2021",0.5,,
+"PATCDIUR","C03-Diuretics","MLLNCUMT","Million of national currency units","CHL","Chile","2010","2010",1770.5,,
+"PATCDIUR","C03-Diuretics","MLLNCUMT","Million of national currency units","CHL","Chile","2011","2011",2756,"B","Break"
+"PATCDIUR","C03-Diuretics","MLLNCUMT","Million of national currency units","CHL","Chile","2012","2012",3547.9,,
+"PATCDIUR","C03-Diuretics","MLLNCUMT","Million of national currency units","CHL","Chile","2013","2013",3467.2,,
+"PATCDIUR","C03-Diuretics","MLLNCUMT","Million of national currency units","CHL","Chile","2014","2014",4497.4,,
+"PATCDIUR","C03-Diuretics","MLLNCUMT","Million of national currency units","CHL","Chile","2015","2015",6793.5,,
+"PATCDIUR","C03-Diuretics","MLLNCUMT","Million of national currency units","CHL","Chile","2016","2016",6034.4,,
+"PATCDIUR","C03-Diuretics","MLLNCUMT","Million of national currency units","CHL","Chile","2017","2017",5534.7,,
+"PATCDIUR","C03-Diuretics","MLLNCUMT","Million of national currency units","CHL","Chile","2018","2018",6312.9,,
+"PATCDIUR","C03-Diuretics","MLLNCUMT","Million of national currency units","CHL","Chile","2019","2019",7955.7,,
+"PATCDIUR","C03-Diuretics","MLLNCUMT","Million of national currency units","CHL","Chile","2020","2020",6086,,
+"PATCDIUR","C03-Diuretics","MLLNCUMT","Million of national currency units","CHL","Chile","2021","2021",8160.7,,
+"PATCDIUR","C03-Diuretics","MLLNCUMT","Million of national currency units","CHL","Chile","2022","2022",9498.7,,
+"PATCDIUR","C03-Diuretics","MTMOTCMT","Million US$ at exchange rate","CHL","Chile","2010","2010",3.5,,
+"PATCDIUR","C03-Diuretics","MTMOTCMT","Million US$ at exchange rate","CHL","Chile","2011","2011",5.7,"B","Break"
+"PATCDIUR","C03-Diuretics","MTMOTCMT","Million US$ at exchange rate","CHL","Chile","2012","2012",7.3,,
+"PATCDIUR","C03-Diuretics","MTMOTCMT","Million US$ at exchange rate","CHL","Chile","2013","2013",7,,
+"PATCDIUR","C03-Diuretics","MTMOTCMT","Million US$ at exchange rate","CHL","Chile","2014","2014",7.9,,
+"PATCDIUR","C03-Diuretics","MTMOTCMT","Million US$ at exchange rate","CHL","Chile","2015","2015",10.4,,
+"PATCDIUR","C03-Diuretics","MTMOTCMT","Million US$ at exchange rate","CHL","Chile","2016","2016",8.9,,
+"PATCDIUR","C03-Diuretics","MTMOTCMT","Million US$ at exchange rate","CHL","Chile","2017","2017",8.5,,
+"PATCDIUR","C03-Diuretics","MTMOTCMT","Million US$ at exchange rate","CHL","Chile","2018","2018",9.8,,
+"PATCDIUR","C03-Diuretics","MTMOTCMT","Million US$ at exchange rate","CHL","Chile","2019","2019",11.3,,
+"PATCDIUR","C03-Diuretics","MTMOTCMT","Million US$ at exchange rate","CHL","Chile","2020","2020",7.7,,
+"PATCDIUR","C03-Diuretics","MTMOTCMT","Million US$ at exchange rate","CHL","Chile","2021","2021",10.8,,
+"PATCDIUR","C03-Diuretics","MTMOTCMT","Million US$ at exchange rate","CHL","Chile","2022","2022",10.9,,
+"PATCDIUR","C03-Diuretics","MTMOPPMT","Million US$, purchasing power parity","CHL","Chile","2010","2010",4.9,,
+"PATCDIUR","C03-Diuretics","MTMOPPMT","Million US$, purchasing power parity","CHL","Chile","2011","2011",7.9,"B","Break"
+"PATCDIUR","C03-Diuretics","MTMOPPMT","Million US$, purchasing power parity","CHL","Chile","2012","2012",10.2,,
+"PATCDIUR","C03-Diuretics","MTMOPPMT","Million US$, purchasing power parity","CHL","Chile","2013","2013",9.9,,
+"PATCDIUR","C03-Diuretics","MTMOPPMT","Million US$, purchasing power parity","CHL","Chile","2014","2014",12.2,,
+"PATCDIUR","C03-Diuretics","MTMOPPMT","Million US$, purchasing power parity","CHL","Chile","2015","2015",17.4,,
+"PATCDIUR","C03-Diuretics","MTMOPPMT","Million US$, purchasing power parity","CHL","Chile","2016","2016",15.2,,
+"PATCDIUR","C03-Diuretics","MTMOPPMT","Million US$, purchasing power parity","CHL","Chile","2017","2017",13.9,,
+"PATCDIUR","C03-Diuretics","MTMOPPMT","Million US$, purchasing power parity","CHL","Chile","2018","2018",15.9,,
+"PATCDIUR","C03-Diuretics","MTMOPPMT","Million US$, purchasing power parity","CHL","Chile","2019","2019",19.8,,
+"PATCDIUR","C03-Diuretics","MTMOPPMT","Million US$, purchasing power parity","CHL","Chile","2020","2020",14.5,,
+"PATCDIUR","C03-Diuretics","MTMOPPMT","Million US$, purchasing power parity","CHL","Chile","2021","2021",18.8,,
+"PATCDIUR","C03-Diuretics","MTMOPPMT","Million US$, purchasing power parity","CHL","Chile","2022","2022",21.7,,
+"PATCDIUR","C03-Diuretics","TCPPERMT","/capita, US$ exchange rate","CHL","Chile","2010","2010",0.2,,
+"PATCDIUR","C03-Diuretics","TCPPERMT","/capita, US$ exchange rate","CHL","Chile","2011","2011",0.3,"B","Break"
+"PATCDIUR","C03-Diuretics","TCPPERMT","/capita, US$ exchange rate","CHL","Chile","2012","2012",0.4,,
+"PATCDIUR","C03-Diuretics","TCPPERMT","/capita, US$ exchange rate","CHL","Chile","2013","2013",0.4,,
+"PATCDIUR","C03-Diuretics","TCPPERMT","/capita, US$ exchange rate","CHL","Chile","2014","2014",0.4,,
+"PATCDIUR","C03-Diuretics","TCPPERMT","/capita, US$ exchange rate","CHL","Chile","2015","2015",0.6,,
+"PATCDIUR","C03-Diuretics","TCPPERMT","/capita, US$ exchange rate","CHL","Chile","2016","2016",0.5,,
+"PATCDIUR","C03-Diuretics","TCPPERMT","/capita, US$ exchange rate","CHL","Chile","2017","2017",0.5,,
+"PATCDIUR","C03-Diuretics","TCPPERMT","/capita, US$ exchange rate","CHL","Chile","2018","2018",0.5,,
+"PATCDIUR","C03-Diuretics","TCPPERMT","/capita, US$ exchange rate","CHL","Chile","2019","2019",0.6,,
+"PATCDIUR","C03-Diuretics","TCPPERMT","/capita, US$ exchange rate","CHL","Chile","2020","2020",0.4,,
+"PATCDIUR","C03-Diuretics","TCPPERMT","/capita, US$ exchange rate","CHL","Chile","2021","2021",0.5,,
+"PATCDIUR","C03-Diuretics","TCPPERMT","/capita, US$ exchange rate","CHL","Chile","2022","2022",0.5,,
+"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2010","2010",0.3,,
+"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2011","2011",0.5,"B","Break"
+"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2012","2012",0.6,,
+"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2013","2013",0.6,,
+"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2014","2014",0.7,,
+"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2015","2015",1,,
+"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2016","2016",0.8,,
+"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2017","2017",0.8,,
+"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2018","2018",0.8,,
+"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2019","2019",1,,
+"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2020","2020",0.7,,
+"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2021","2021",1,,
+"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2022","2022",1.1,,
+"PATCDIUR","C03-Diuretics","ATCPTTMT","% of total sales","CHL","Chile","2010","2010",0.2,,
+"PATCDIUR","C03-Diuretics","ATCPTTMT","% of total sales","CHL","Chile","2011","2011",0.2,"B","Break"
+"PATCDIUR","C03-Diuretics","ATCPTTMT","% of total sales","CHL","Chile","2012","2012",0.3,,
+"PATCDIUR","C03-Diuretics","ATCPTTMT","% of total sales","CHL","Chile","2013","2013",0.2,,
+"PATCDIUR","C03-Diuretics","ATCPTTMT","% of total sales","CHL","Chile","2014","2014",0.3,,
+"PATCDIUR","C03-Diuretics","ATCPTTMT","% of total sales","CHL","Chile","2015","2015",0.4,,
+"PATCDIUR","C03-Diuretics","ATCPTTMT","% of total sales","CHL","Chile","2016","2016",0.3,,
+"PATCDIUR","C03-Diuretics","ATCPTTMT","% of total sales","CHL","Chile","2017","2017",0.3,,
+"PATCDIUR","C03-Diuretics","ATCPTTMT","% of total sales","CHL","Chile","2018","2018",0.3,,
+"PATCDIUR","C03-Diuretics","ATCPTTMT","% of total sales","CHL","Chile","2019","2019",0.3,,
+"PATCDIUR","C03-Diuretics","ATCPTTMT","% of total sales","CHL","Chile","2020","2020",0.2,,
+"PATCDIUR","C03-Diuretics","ATCPTTMT","% of total sales","CHL","Chile","2021","2021",0.3,,
+"PATCDIUR","C03-Diuretics","ATCPTTMT","% of total sales","CHL","Chile","2022","2022",0.3,,
+"PATCDIUR","C03-Diuretics","MLLNCUMT","Million of national currency units","EST","Estonia","2010","2010",1.6,,
+"PATCDIUR","C03-Diuretics","MLLNCUMT","Million of national currency units","EST","Estonia","2011","2011",1.6,,
+"PATCDIUR","C03-Diuretics","MLLNCUMT","Million of national currency units","EST","Estonia","2012","2012",1.7,,
+"PATCDIUR","C03-Diuretics","MLLNCUMT","Million of national currency units","EST","Estonia","2013","2013",1.6,,
+"PATCDIUR","C03-Diuretics","MLLNCUMT","Million of national currency units","EST","Estonia","2014","2014",1.8,,
+"PATCDIUR","C03-Diuretics","MLLNCUMT","Million of national currency units","EST","Estonia","2015","2015",1.8,,
+"PATCDIUR","C03-Diuretics","MLLNCUMT","Million of national currency units","EST","Estonia","2016","2016",1.9,,
+"PATCDIUR","C03-Diuretics","MLLNCUMT","Million of national currency units","EST","Estonia","2017","2017",1.9,,
+"PATCDIUR","C03-Diuretics","MLLNCUMT","Million of national currency units","EST","Estonia","2018","2018",2.1,,
+"PATCDIUR","C03-Diuretics","MLLNCUMT","Million of national currency units","EST","Estonia","2019","2019",2.1,,
+"PATCDIUR","C03-Diuretics","MLLNCUMT","Million of national currency units","EST","Estonia","2020","2020",2.3,,
+"PATCDIUR","C03-Diuretics","MLLNCUMT","Million of national currency units","EST","Estonia","2021","2021",2.2,,
+"PATCDIUR","C03-Diuretics","MLLNCUMT","Million of national currency units","EST","Estonia","2022","2022",2.3,,
+"PATCDIUR","C03-Diuretics","MTMOTCMT","Million US$ at exchange rate","EST","Estonia","2010","2010",2.1,,
+"PATCDIUR","C03-Diuretics","MTMOTCMT","Million US$ at exchange rate","EST","Estonia","2011","2011",2.2,,
+"PATCDIUR","C03-Diuretics","MTMOTCMT","Million US$ at exchange rate","EST","Estonia","2012","2012",2.2,,
+"PATCDIUR","C03-Diuretics","MTMOTCMT","Million US$ at exchange rate","EST","Estonia","2013","2013",2.2,,
+"PATCDIUR","C03-Diuretics","MTMOTCMT","Million US$ at exchange rate","EST","Estonia","2014","2014",2.3,,
+"PATCDIUR","C03-Diuretics","MTMOTCMT","Million US$ at exchange rate","EST","Estonia","2015","2015",2,,
+"PATCDIUR","C03-Diuretics","MTMOTCMT","Million US$ at exchange rate","EST","Estonia","2016","2016",2.1,,
+"PATCDIUR","C03-Diuretics","MTMOTCMT","Million US$ at exchange rate","EST","Estonia","2017","2017",2.2,,
+"PATCDIUR","C03-Diuretics","MTMOTCMT","Million US$ at exchange rate","EST","Estonia","2018","2018",2.5,,
+"PATCDIUR","C03-Diuretics","MTMOTCMT","Million US$ at exchange rate","EST","Estonia","2019","2019",2.3,,
+"PATCDIUR","C03-Diuretics","MTMOTCMT","Million US$ at exchange rate","EST","Estonia","2020","2020",2.6,,
+"PATCDIUR","C03-Diuretics","MTMOTCMT","Million US$ at exchange rate","EST","Estonia","2021","2021",2.7,,
+"PATCDIUR","C03-Diuretics","MTMOTCMT","Million US$ at exchange rate","EST","Estonia","2022","2022",2.4,,
+"PATCDIUR","C03-Diuretics","MTMOPPMT","Million US$, purchasing power parity","EST","Estonia","2010","2010",3.1,,
+"PATCDIUR","C03-Diuretics","MTMOPPMT","Million US$, purchasing power parity","EST","Estonia","2011","2011",3.1,,
+"PATCDIUR","C03-Diuretics","MTMOPPMT","Million US$, purchasing power parity","EST","Estonia","2012","2012",3.3,,
+"PATCDIUR","C03-Diuretics","MTMOPPMT","Million US$, purchasing power parity","EST","Estonia","2013","2013",3.2,,
+"PATCDIUR","C03-Diuretics","MTMOPPMT","Million US$, purchasing power parity","EST","Estonia","2014","2014",3.3,,
+"PATCDIUR","C03-Diuretics","MTMOPPMT","Million US$, purchasing power parity","EST","Estonia","2015","2015",3.4,,
+"PATCDIUR","C03-Diuretics","MTMOPPMT","Million US$, purchasing power parity","EST","Estonia","2016","2016",3.6,,
+"PATCDIUR","C03-Diuretics","MTMOPPMT","Million US$, purchasing power parity","EST","Estonia","2017","2017",3.6,,
+"PATCDIUR","C03-Diuretics","MTMOPPMT","Million US$, purchasing power parity","EST","Estonia","2018","2018",3.9,,
+"PATCDIUR","C03-Diuretics","MTMOPPMT","Million US$, purchasing power parity","EST","Estonia","2019","2019",3.9,,
+"PATCDIUR","C03-Diuretics","MTMOPPMT","Million US$, purchasing power parity","EST","Estonia","2020","2020",4.4,,
+"PATCDIUR","C03-Diuretics","MTMOPPMT","Million US$, purchasing power parity","EST","Estonia","2021","2021",4.1,,
+"PATCDIUR","C03-Diuretics","MTMOPPMT","Million US$, purchasing power parity","EST","Estonia","2022","2022",4,,
+"PATCDIUR","C03-Diuretics","TCPPERMT","/capita, US$ exchange rate","EST","Estonia","2010","2010",1.6,,
+"PATCDIUR","C03-Diuretics","TCPPERMT","/capita, US$ exchange rate","EST","Estonia","2011","2011",1.6,,
+"PATCDIUR","C03-Diuretics","TCPPERMT","/capita, US$ exchange rate","EST","Estonia","2012","2012",1.7,,
+"PATCDIUR","C03-Diuretics","TCPPERMT","/capita, US$ exchange rate","EST","Estonia","2013","2013",1.7,,
+"PATCDIUR","C03-Diuretics","TCPPERMT","/capita, US$ exchange rate","EST","Estonia","2014","2014",1.8,,
+"PATCDIUR","C03-Diuretics","TCPPERMT","/capita, US$ exchange rate","EST","Estonia","2015","2015",1.5,,
+"PATCDIUR","C03-Diuretics","TCPPERMT","/capita, US$ exchange rate","EST","Estonia","2016","2016",1.6,,
+"PATCDIUR","C03-Diuretics","TCPPERMT","/capita, US$ exchange rate","EST","Estonia","2017","2017",1.6,,
+"PATCDIUR","C03-Diuretics","TCPPERMT","/capita, US$ exchange rate","EST","Estonia","2018","2018",1.9,,
+"PATCDIUR","C03-Diuretics","TCPPERMT","/capita, US$ exchange rate","EST","Estonia","2019","2019",1.8,,
+"PATCDIUR","C03-Diuretics","TCPPERMT","/capita, US$ exchange rate","EST","Estonia","2020","2020",2,,
+"PATCDIUR","C03-Diuretics","TCPPERMT","/capita, US$ exchange rate","EST","Estonia","2021","2021",2,,
+"PATCDIUR","C03-Diuretics","TCPPERMT","/capita, US$ exchange rate","EST","Estonia","2022","2022",1.8,,
+"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2010","2010",2.3,,
+"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2011","2011",2.3,,
+"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2012","2012",2.5,,
+"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2013","2013",2.4,,
+"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2014","2014",2.5,,
+"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2015","2015",2.6,,
+"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2016","2016",2.7,,
+"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2017","2017",2.7,,
+"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2018","2018",2.9,,
+"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2019","2019",2.9,,
+"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2020","2020",3.3,,
+"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2021","2021",3.1,,
+"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2022","2022",3,,
+"PATCDIUR","C03-Diuretics","ATCPTTMT","% of total sales","EST","Estonia","2010","2010",0.8,,
+"PATCDIUR","C03-Diuretics","ATCPTTMT","% of total sales","EST","Estonia","2011","2011",0.8,,
+"PATCDIUR","C03-Diuretics","ATCPTTMT","% of total sales","EST","Estonia","2012","2012",0.8,,
+"PATCDIUR","C03-Diuretics","ATCPTTMT","% of total sales","EST","Estonia","2013","2013",0.7,,
+"PATCDIUR","C03-Diuretics","ATCPTTMT","% of total sales","EST","Estonia","2014","2014",0.7,,
+"PATCDIUR","C03-Diuretics","ATCPTTMT","% of total sales","EST","Estonia","2015","2015",0.7,,
+"PATCDIUR","C03-Diuretics","ATCPTTMT","% of total sales","EST","Estonia","2016","2016",0.7,,
+"PATCDIUR","C03-Diuretics","ATCPTTMT","% of total sales","EST","Estonia","2017","2017",0.6,,
+"PATCDIUR","C03-Diuretics","ATCPTTMT","% of total sales","EST","Estonia","2018","2018",0.6,,
+"PATCDIUR","C03-Diuretics","ATCPTTMT","% of total sales","EST","Estonia","2019","2019",0.6,,
+"PATCDIUR","C03-Diuretics","ATCPTTMT","% of total sales","EST","Estonia","2020","2020",0.6,,
+"PATCDIUR","C03-Diuretics","ATCPTTMT","% of total sales","EST","Estonia","2021","2021",0.6,,
+"PATCDIUR","C03-Diuretics","ATCPTTMT","% of total sales","EST","Estonia","2022","2022",0.5,,
+"PATCDIUR","C03-Diuretics","MLLNCUMT","Million of national currency units","SVN","Slovenia","2010","2010",6.3,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","MLLNCUMT","Million of national currency units","SVN","Slovenia","2011","2011",6.1,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","MLLNCUMT","Million of national currency units","SVN","Slovenia","2012","2012",6,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","MLLNCUMT","Million of national currency units","SVN","Slovenia","2013","2013",6.2,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","MLLNCUMT","Million of national currency units","SVN","Slovenia","2014","2014",6.1,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","MLLNCUMT","Million of national currency units","SVN","Slovenia","2015","2015",6.3,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","MLLNCUMT","Million of national currency units","SVN","Slovenia","2016","2016",6.4,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","MLLNCUMT","Million of national currency units","SVN","Slovenia","2017","2017",6.3,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","MLLNCUMT","Million of national currency units","SVN","Slovenia","2018","2018",6.2,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","MLLNCUMT","Million of national currency units","SVN","Slovenia","2019","2019",6.2,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","MLLNCUMT","Million of national currency units","SVN","Slovenia","2020","2020",6.4,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","MLLNCUMT","Million of national currency units","SVN","Slovenia","2021","2021",6.3,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","MLLNCUMT","Million of national currency units","SVN","Slovenia","2022","2022",6.4,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","MTMOTCMT","Million US$ at exchange rate","SVN","Slovenia","2010","2010",8.4,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","MTMOTCMT","Million US$ at exchange rate","SVN","Slovenia","2011","2011",8.5,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","MTMOTCMT","Million US$ at exchange rate","SVN","Slovenia","2012","2012",7.8,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","MTMOTCMT","Million US$ at exchange rate","SVN","Slovenia","2013","2013",8.2,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","MTMOTCMT","Million US$ at exchange rate","SVN","Slovenia","2014","2014",8.1,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","MTMOTCMT","Million US$ at exchange rate","SVN","Slovenia","2015","2015",7,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","MTMOTCMT","Million US$ at exchange rate","SVN","Slovenia","2016","2016",7,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","MTMOTCMT","Million US$ at exchange rate","SVN","Slovenia","2017","2017",7.1,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","MTMOTCMT","Million US$ at exchange rate","SVN","Slovenia","2018","2018",7.3,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","MTMOTCMT","Million US$ at exchange rate","SVN","Slovenia","2019","2019",7,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","MTMOTCMT","Million US$ at exchange rate","SVN","Slovenia","2020","2020",7.3,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","MTMOTCMT","Million US$ at exchange rate","SVN","Slovenia","2021","2021",7.5,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","MTMOTCMT","Million US$ at exchange rate","SVN","Slovenia","2022","2022",6.7,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","MTMOPPMT","Million US$, purchasing power parity","SVN","Slovenia","2010","2010",9.9,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","MTMOPPMT","Million US$, purchasing power parity","SVN","Slovenia","2011","2011",9.8,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","MTMOPPMT","Million US$, purchasing power parity","SVN","Slovenia","2012","2012",10,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","MTMOPPMT","Million US$, purchasing power parity","SVN","Slovenia","2013","2013",10.5,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","MTMOPPMT","Million US$, purchasing power parity","SVN","Slovenia","2014","2014",10.3,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","MTMOPPMT","Million US$, purchasing power parity","SVN","Slovenia","2015","2015",10.5,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","MTMOPPMT","Million US$, purchasing power parity","SVN","Slovenia","2016","2016",11,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","MTMOPPMT","Million US$, purchasing power parity","SVN","Slovenia","2017","2017",11,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","MTMOPPMT","Million US$, purchasing power parity","SVN","Slovenia","2018","2018",10.8,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","MTMOPPMT","Million US$, purchasing power parity","SVN","Slovenia","2019","2019",11.3,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","MTMOPPMT","Million US$, purchasing power parity","SVN","Slovenia","2020","2020",11.7,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","MTMOPPMT","Million US$, purchasing power parity","SVN","Slovenia","2021","2021",11.2,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","MTMOPPMT","Million US$, purchasing power parity","SVN","Slovenia","2022","2022",11.6,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","TCPPERMT","/capita, US$ exchange rate","SVN","Slovenia","2010","2010",4.1,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","TCPPERMT","/capita, US$ exchange rate","SVN","Slovenia","2011","2011",4.1,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","TCPPERMT","/capita, US$ exchange rate","SVN","Slovenia","2012","2012",3.8,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","TCPPERMT","/capita, US$ exchange rate","SVN","Slovenia","2013","2013",4,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","TCPPERMT","/capita, US$ exchange rate","SVN","Slovenia","2014","2014",3.9,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","TCPPERMT","/capita, US$ exchange rate","SVN","Slovenia","2015","2015",3.4,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","TCPPERMT","/capita, US$ exchange rate","SVN","Slovenia","2016","2016",3.4,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","TCPPERMT","/capita, US$ exchange rate","SVN","Slovenia","2017","2017",3.4,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","TCPPERMT","/capita, US$ exchange rate","SVN","Slovenia","2018","2018",3.5,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","TCPPERMT","/capita, US$ exchange rate","SVN","Slovenia","2019","2019",3.4,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","TCPPERMT","/capita, US$ exchange rate","SVN","Slovenia","2020","2020",3.5,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","TCPPERMT","/capita, US$ exchange rate","SVN","Slovenia","2021","2021",3.5,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","TCPPERMT","/capita, US$ exchange rate","SVN","Slovenia","2022","2022",3.2,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2010","2010",4.8,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2011","2011",4.8,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2012","2012",4.8,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2013","2013",5.1,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2014","2014",5,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2015","2015",5.1,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2016","2016",5.3,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2017","2017",5.3,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2018","2018",5.2,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2019","2019",5.4,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2020","2020",5.6,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2021","2021",5.3,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2022","2022",5.5,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","ATCPTTMT","% of total sales","SVN","Slovenia","2010","2010",1.3,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","ATCPTTMT","% of total sales","SVN","Slovenia","2011","2011",1.3,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","ATCPTTMT","% of total sales","SVN","Slovenia","2012","2012",1.3,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","ATCPTTMT","% of total sales","SVN","Slovenia","2013","2013",1.4,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","ATCPTTMT","% of total sales","SVN","Slovenia","2014","2014",1.4,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","ATCPTTMT","% of total sales","SVN","Slovenia","2015","2015",1.4,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","ATCPTTMT","% of total sales","SVN","Slovenia","2016","2016",1.4,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","ATCPTTMT","% of total sales","SVN","Slovenia","2017","2017",1.3,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","ATCPTTMT","% of total sales","SVN","Slovenia","2018","2018",1.2,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","ATCPTTMT","% of total sales","SVN","Slovenia","2019","2019",1.2,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","ATCPTTMT","% of total sales","SVN","Slovenia","2020","2020",1.1,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","ATCPTTMT","% of total sales","SVN","Slovenia","2021","2021",1,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","ATCPTTMT","% of total sales","SVN","Slovenia","2022","2022",0.9,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","MLLNCUMT","Million of national currency units","AUS","Australia","2010","2010",142,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","MLLNCUMT","Million of national currency units","AUS","Australia","2011","2011",141,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","MLLNCUMT","Million of national currency units","AUS","Australia","2012","2012",137,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","MLLNCUMT","Million of national currency units","AUS","Australia","2013","2013",151,"B; D","Break; Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","MLLNCUMT","Million of national currency units","AUS","Australia","2014","2014",142,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","MLLNCUMT","Million of national currency units","AUS","Australia","2015","2015",144,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","MLLNCUMT","Million of national currency units","AUS","Australia","2016","2016",153,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","MLLNCUMT","Million of national currency units","AUS","Australia","2017","2017",153,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","MLLNCUMT","Million of national currency units","AUS","Australia","2018","2018",158,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","MLLNCUMT","Million of national currency units","AUS","Australia","2019","2019",163,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","MLLNCUMT","Million of national currency units","AUS","Australia","2020","2020",176,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","MLLNCUMT","Million of national currency units","AUS","Australia","2021","2021",187,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","MTMOTCMT","Million US$ at exchange rate","AUS","Australia","2010","2010",130.3,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","MTMOTCMT","Million US$ at exchange rate","AUS","Australia","2011","2011",145.4,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","MTMOTCMT","Million US$ at exchange rate","AUS","Australia","2012","2012",141.9,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","MTMOTCMT","Million US$ at exchange rate","AUS","Australia","2013","2013",145.8,"B; D","Break; Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","MTMOTCMT","Million US$ at exchange rate","AUS","Australia","2014","2014",128,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","MTMOTCMT","Million US$ at exchange rate","AUS","Australia","2015","2015",108.2,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","MTMOTCMT","Million US$ at exchange rate","AUS","Australia","2016","2016",113.7,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","MTMOTCMT","Million US$ at exchange rate","AUS","Australia","2017","2017",117.3,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","MTMOTCMT","Million US$ at exchange rate","AUS","Australia","2018","2018",118.1,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","MTMOTCMT","Million US$ at exchange rate","AUS","Australia","2019","2019",113.3,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","MTMOTCMT","Million US$ at exchange rate","AUS","Australia","2020","2020",121.1,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","MTMOTCMT","Million US$ at exchange rate","AUS","Australia","2021","2021",140.5,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","MTMOPPMT","Million US$, purchasing power parity","AUS","Australia","2010","2010",94.4,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","MTMOPPMT","Million US$, purchasing power parity","AUS","Australia","2011","2011",93.3,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","MTMOPPMT","Million US$, purchasing power parity","AUS","Australia","2012","2012",89,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","MTMOPPMT","Million US$, purchasing power parity","AUS","Australia","2013","2013",104.3,"B; D","Break; Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","MTMOPPMT","Million US$, purchasing power parity","AUS","Australia","2014","2014",97.8,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","MTMOPPMT","Million US$, purchasing power parity","AUS","Australia","2015","2015",97.7,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","MTMOPPMT","Million US$, purchasing power parity","AUS","Australia","2016","2016",105.5,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","MTMOPPMT","Million US$, purchasing power parity","AUS","Australia","2017","2017",103.5,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","MTMOPPMT","Million US$, purchasing power parity","AUS","Australia","2018","2018",107.5,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","MTMOPPMT","Million US$, purchasing power parity","AUS","Australia","2019","2019",110.1,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","MTMOPPMT","Million US$, purchasing power parity","AUS","Australia","2020","2020",121,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","MTMOPPMT","Million US$, purchasing power parity","AUS","Australia","2021","2021",129.2,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","TCPPERMT","/capita, US$ exchange rate","AUS","Australia","2010","2010",5.9,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","TCPPERMT","/capita, US$ exchange rate","AUS","Australia","2011","2011",6.5,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","TCPPERMT","/capita, US$ exchange rate","AUS","Australia","2012","2012",6.2,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","TCPPERMT","/capita, US$ exchange rate","AUS","Australia","2013","2013",6.3,"B; D","Break; Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","TCPPERMT","/capita, US$ exchange rate","AUS","Australia","2014","2014",5.5,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","TCPPERMT","/capita, US$ exchange rate","AUS","Australia","2015","2015",4.5,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","TCPPERMT","/capita, US$ exchange rate","AUS","Australia","2016","2016",4.7,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","TCPPERMT","/capita, US$ exchange rate","AUS","Australia","2017","2017",4.8,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","TCPPERMT","/capita, US$ exchange rate","AUS","Australia","2018","2018",4.7,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","TCPPERMT","/capita, US$ exchange rate","AUS","Australia","2019","2019",4.5,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","TCPPERMT","/capita, US$ exchange rate","AUS","Australia","2020","2020",4.7,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","TCPPERMT","/capita, US$ exchange rate","AUS","Australia","2021","2021",5.5,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2010","2010",4.3,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2011","2011",4.2,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2012","2012",3.9,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2013","2013",4.5,"B; D","Break; Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2014","2014",4.2,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2015","2015",4.1,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2016","2016",4.4,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2017","2017",4.2,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2018","2018",4.3,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2019","2019",4.3,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2020","2020",4.7,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2021","2021",5,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","ATCPTTMT","% of total sales","AUS","Australia","2010","2010",1.4,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","ATCPTTMT","% of total sales","AUS","Australia","2011","2011",1.4,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","ATCPTTMT","% of total sales","AUS","Australia","2012","2012",1.3,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","ATCPTTMT","% of total sales","AUS","Australia","2013","2013",1.3,"B; D","Break; Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","ATCPTTMT","% of total sales","AUS","Australia","2014","2014",1.2,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","ATCPTTMT","% of total sales","AUS","Australia","2015","2015",1.2,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","ATCPTTMT","% of total sales","AUS","Australia","2016","2016",1,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","ATCPTTMT","% of total sales","AUS","Australia","2017","2017",1,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","ATCPTTMT","% of total sales","AUS","Australia","2018","2018",1.1,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","ATCPTTMT","% of total sales","AUS","Australia","2019","2019",1,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","ATCPTTMT","% of total sales","AUS","Australia","2020","2020",1.1,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","ATCPTTMT","% of total sales","AUS","Australia","2021","2021",1.1,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","MLLNCUMT","Million of national currency units","AUT","Austria","2010","2010",63.7,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","MLLNCUMT","Million of national currency units","AUT","Austria","2011","2011",57.4,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","MLLNCUMT","Million of national currency units","AUT","Austria","2012","2012",51.3,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","MLLNCUMT","Million of national currency units","AUT","Austria","2013","2013",46.5,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","MLLNCUMT","Million of national currency units","AUT","Austria","2014","2014",46.2,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","MLLNCUMT","Million of national currency units","AUT","Austria","2015","2015",44.5,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","MLLNCUMT","Million of national currency units","AUT","Austria","2016","2016",43.6,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","MLLNCUMT","Million of national currency units","AUT","Austria","2017","2017",41.1,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","MLLNCUMT","Million of national currency units","AUT","Austria","2018","2018",35.8,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","MLLNCUMT","Million of national currency units","AUT","Austria","2019","2019",34.7,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","MLLNCUMT","Million of national currency units","AUT","Austria","2020","2020",33.8,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","MLLNCUMT","Million of national currency units","AUT","Austria","2021","2021",31.4,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","MTMOTCMT","Million US$ at exchange rate","AUT","Austria","2010","2010",84.5,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","MTMOTCMT","Million US$ at exchange rate","AUT","Austria","2011","2011",79.9,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","MTMOTCMT","Million US$ at exchange rate","AUT","Austria","2012","2012",65.9,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","MTMOTCMT","Million US$ at exchange rate","AUT","Austria","2013","2013",61.8,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","MTMOTCMT","Million US$ at exchange rate","AUT","Austria","2014","2014",61.3,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","MTMOTCMT","Million US$ at exchange rate","AUT","Austria","2015","2015",49.4,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","MTMOTCMT","Million US$ at exchange rate","AUT","Austria","2016","2016",48.3,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","MTMOTCMT","Million US$ at exchange rate","AUT","Austria","2017","2017",46.4,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","MTMOTCMT","Million US$ at exchange rate","AUT","Austria","2018","2018",42.3,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","MTMOTCMT","Million US$ at exchange rate","AUT","Austria","2019","2019",38.9,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","MTMOTCMT","Million US$ at exchange rate","AUT","Austria","2020","2020",38.6,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","MTMOTCMT","Million US$ at exchange rate","AUT","Austria","2021","2021",37.2,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","MTMOPPMT","Million US$, purchasing power parity","AUT","Austria","2010","2010",75.7,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","MTMOPPMT","Million US$, purchasing power parity","AUT","Austria","2011","2011",69,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","MTMOPPMT","Million US$, purchasing power parity","AUT","Austria","2012","2012",63,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","MTMOPPMT","Million US$, purchasing power parity","AUT","Austria","2013","2013",58.4,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","MTMOPPMT","Million US$, purchasing power parity","AUT","Austria","2014","2014",57.8,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","MTMOPPMT","Million US$, purchasing power parity","AUT","Austria","2015","2015",55.7,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","MTMOPPMT","Million US$, purchasing power parity","AUT","Austria","2016","2016",56.1,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","MTMOPPMT","Million US$, purchasing power parity","AUT","Austria","2017","2017",53,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","MTMOPPMT","Million US$, purchasing power parity","AUT","Austria","2018","2018",46.8,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","MTMOPPMT","Million US$, purchasing power parity","AUT","Austria","2019","2019",46.3,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","MTMOPPMT","Million US$, purchasing power parity","AUT","Austria","2020","2020",45.3,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","MTMOPPMT","Million US$, purchasing power parity","AUT","Austria","2021","2021",41.5,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","TCPPERMT","/capita, US$ exchange rate","AUT","Austria","2010","2010",10.1,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","TCPPERMT","/capita, US$ exchange rate","AUT","Austria","2011","2011",9.5,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","TCPPERMT","/capita, US$ exchange rate","AUT","Austria","2012","2012",7.8,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","TCPPERMT","/capita, US$ exchange rate","AUT","Austria","2013","2013",7.3,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","TCPPERMT","/capita, US$ exchange rate","AUT","Austria","2014","2014",7.2,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","TCPPERMT","/capita, US$ exchange rate","AUT","Austria","2015","2015",5.7,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","TCPPERMT","/capita, US$ exchange rate","AUT","Austria","2016","2016",5.5,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","TCPPERMT","/capita, US$ exchange rate","AUT","Austria","2017","2017",5.3,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","TCPPERMT","/capita, US$ exchange rate","AUT","Austria","2018","2018",4.8,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","TCPPERMT","/capita, US$ exchange rate","AUT","Austria","2019","2019",4.4,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","TCPPERMT","/capita, US$ exchange rate","AUT","Austria","2020","2020",4.3,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","TCPPERMT","/capita, US$ exchange rate","AUT","Austria","2021","2021",4.1,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2010","2010",9,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2011","2011",8.2,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2012","2012",7.5,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2013","2013",6.9,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2014","2014",6.8,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2015","2015",6.4,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2016","2016",6.4,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2017","2017",6,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2018","2018",5.3,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2019","2019",5.2,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2020","2020",5.1,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2021","2021",4.6,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","ATCPTTMT","% of total sales","AUT","Austria","2010","2010",2.6,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","ATCPTTMT","% of total sales","AUT","Austria","2011","2011",2.3,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","ATCPTTMT","% of total sales","AUT","Austria","2012","2012",2,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","ATCPTTMT","% of total sales","AUT","Austria","2013","2013",1.8,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","ATCPTTMT","% of total sales","AUT","Austria","2014","2014",1.7,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","ATCPTTMT","% of total sales","AUT","Austria","2015","2015",1.5,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","ATCPTTMT","% of total sales","AUT","Austria","2016","2016",1.5,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","ATCPTTMT","% of total sales","AUT","Austria","2017","2017",1.3,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","ATCPTTMT","% of total sales","AUT","Austria","2018","2018",1.1,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","ATCPTTMT","% of total sales","AUT","Austria","2019","2019",1,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","ATCPTTMT","% of total sales","AUT","Austria","2020","2020",1,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","ATCPTTMT","% of total sales","AUT","Austria","2021","2021",0.8,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","MLLNCUMT","Million of national currency units","BEL","Belgium","2010","2010",108.4,,
+"PATCBETA","C07-Beta blocking agents","MLLNCUMT","Million of national currency units","BEL","Belgium","2011","2011",99.5,,
+"PATCBETA","C07-Beta blocking agents","MLLNCUMT","Million of national currency units","BEL","Belgium","2012","2012",97.8,,
+"PATCBETA","C07-Beta blocking agents","MLLNCUMT","Million of national currency units","BEL","Belgium","2013","2013",97.1,,
+"PATCBETA","C07-Beta blocking agents","MLLNCUMT","Million of national currency units","BEL","Belgium","2014","2014",91.9,,
+"PATCBETA","C07-Beta blocking agents","MLLNCUMT","Million of national currency units","BEL","Belgium","2015","2015",87.3,,
+"PATCBETA","C07-Beta blocking agents","MLLNCUMT","Million of national currency units","BEL","Belgium","2016","2016",86.1,,
+"PATCBETA","C07-Beta blocking agents","MLLNCUMT","Million of national currency units","BEL","Belgium","2017","2017",82.7,,
+"PATCBETA","C07-Beta blocking agents","MLLNCUMT","Million of national currency units","BEL","Belgium","2018","2018",78.3,,
+"PATCBETA","C07-Beta blocking agents","MLLNCUMT","Million of national currency units","BEL","Belgium","2019","2019",76.7,,
+"PATCBETA","C07-Beta blocking agents","MLLNCUMT","Million of national currency units","BEL","Belgium","2020","2020",69.6,,
+"PATCBETA","C07-Beta blocking agents","MLLNCUMT","Million of national currency units","BEL","Belgium","2021","2021",62.5,,
+"PATCBETA","C07-Beta blocking agents","MLLNCUMT","Million of national currency units","BEL","Belgium","2022","2022",60.4,"E","Estimated value"
+"PATCBETA","C07-Beta blocking agents","MTMOTCMT","Million US$ at exchange rate","BEL","Belgium","2010","2010",143.7,,
+"PATCBETA","C07-Beta blocking agents","MTMOTCMT","Million US$ at exchange rate","BEL","Belgium","2011","2011",138.5,,
+"PATCBETA","C07-Beta blocking agents","MTMOTCMT","Million US$ at exchange rate","BEL","Belgium","2012","2012",125.7,,
+"PATCBETA","C07-Beta blocking agents","MTMOTCMT","Million US$ at exchange rate","BEL","Belgium","2013","2013",128.9,,
+"PATCBETA","C07-Beta blocking agents","MTMOTCMT","Million US$ at exchange rate","BEL","Belgium","2014","2014",122.1,,
+"PATCBETA","C07-Beta blocking agents","MTMOTCMT","Million US$ at exchange rate","BEL","Belgium","2015","2015",96.9,,
+"PATCBETA","C07-Beta blocking agents","MTMOTCMT","Million US$ at exchange rate","BEL","Belgium","2016","2016",95.3,,
+"PATCBETA","C07-Beta blocking agents","MTMOTCMT","Million US$ at exchange rate","BEL","Belgium","2017","2017",93.4,,
+"PATCBETA","C07-Beta blocking agents","MTMOTCMT","Million US$ at exchange rate","BEL","Belgium","2018","2018",92.5,,
+"PATCBETA","C07-Beta blocking agents","MTMOTCMT","Million US$ at exchange rate","BEL","Belgium","2019","2019",85.8,,
+"PATCBETA","C07-Beta blocking agents","MTMOTCMT","Million US$ at exchange rate","BEL","Belgium","2020","2020",79.5,,
+"PATCBETA","C07-Beta blocking agents","MTMOTCMT","Million US$ at exchange rate","BEL","Belgium","2021","2021",73.9,,
+"PATCBETA","C07-Beta blocking agents","MTMOTCMT","Million US$ at exchange rate","BEL","Belgium","2022","2022",63.6,"E","Estimated value"
+"PATCBETA","C07-Beta blocking agents","MTMOPPMT","Million US$, purchasing power parity","BEL","Belgium","2010","2010",129.6,,
+"PATCBETA","C07-Beta blocking agents","MTMOPPMT","Million US$, purchasing power parity","BEL","Belgium","2011","2011",119.6,,
+"PATCBETA","C07-Beta blocking agents","MTMOPPMT","Million US$, purchasing power parity","BEL","Belgium","2012","2012",119,,
+"PATCBETA","C07-Beta blocking agents","MTMOPPMT","Million US$, purchasing power parity","BEL","Belgium","2013","2013",120.4,,
+"PATCBETA","C07-Beta blocking agents","MTMOPPMT","Million US$, purchasing power parity","BEL","Belgium","2014","2014",114.8,,
+"PATCBETA","C07-Beta blocking agents","MTMOPPMT","Million US$, purchasing power parity","BEL","Belgium","2015","2015",109.2,,
+"PATCBETA","C07-Beta blocking agents","MTMOPPMT","Million US$, purchasing power parity","BEL","Belgium","2016","2016",110.3,,
+"PATCBETA","C07-Beta blocking agents","MTMOPPMT","Million US$, purchasing power parity","BEL","Belgium","2017","2017",106.6,,
+"PATCBETA","C07-Beta blocking agents","MTMOPPMT","Million US$, purchasing power parity","BEL","Belgium","2018","2018",102.2,,
+"PATCBETA","C07-Beta blocking agents","MTMOPPMT","Million US$, purchasing power parity","BEL","Belgium","2019","2019",102.7,,
+"PATCBETA","C07-Beta blocking agents","MTMOPPMT","Million US$, purchasing power parity","BEL","Belgium","2020","2020",95.3,,
+"PATCBETA","C07-Beta blocking agents","MTMOPPMT","Million US$, purchasing power parity","BEL","Belgium","2021","2021",84.8,,
+"PATCBETA","C07-Beta blocking agents","MTMOPPMT","Million US$, purchasing power parity","BEL","Belgium","2022","2022",84.6,"E","Estimated value"
+"PATCBETA","C07-Beta blocking agents","TCPPERMT","/capita, US$ exchange rate","BEL","Belgium","2010","2010",13.2,,
+"PATCBETA","C07-Beta blocking agents","TCPPERMT","/capita, US$ exchange rate","BEL","Belgium","2011","2011",12.5,,
+"PATCBETA","C07-Beta blocking agents","TCPPERMT","/capita, US$ exchange rate","BEL","Belgium","2012","2012",11.3,,
+"PATCBETA","C07-Beta blocking agents","TCPPERMT","/capita, US$ exchange rate","BEL","Belgium","2013","2013",11.6,,
+"PATCBETA","C07-Beta blocking agents","TCPPERMT","/capita, US$ exchange rate","BEL","Belgium","2014","2014",10.9,,
+"PATCBETA","C07-Beta blocking agents","TCPPERMT","/capita, US$ exchange rate","BEL","Belgium","2015","2015",8.6,,
+"PATCBETA","C07-Beta blocking agents","TCPPERMT","/capita, US$ exchange rate","BEL","Belgium","2016","2016",8.4,,
+"PATCBETA","C07-Beta blocking agents","TCPPERMT","/capita, US$ exchange rate","BEL","Belgium","2017","2017",8.2,,
+"PATCBETA","C07-Beta blocking agents","TCPPERMT","/capita, US$ exchange rate","BEL","Belgium","2018","2018",8.1,,
+"PATCBETA","C07-Beta blocking agents","TCPPERMT","/capita, US$ exchange rate","BEL","Belgium","2019","2019",7.5,,
+"PATCBETA","C07-Beta blocking agents","TCPPERMT","/capita, US$ exchange rate","BEL","Belgium","2020","2020",6.9,,
+"PATCBETA","C07-Beta blocking agents","TCPPERMT","/capita, US$ exchange rate","BEL","Belgium","2021","2021",6.4,,
+"PATCBETA","C07-Beta blocking agents","TCPPERMT","/capita, US$ exchange rate","BEL","Belgium","2022","2022",5.5,"E","Estimated value"
+"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2010","2010",11.9,,
+"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2011","2011",10.8,,
+"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2012","2012",10.7,,
+"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2013","2013",10.8,,
+"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2014","2014",10.2,,
+"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2015","2015",9.7,,
+"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2016","2016",9.7,,
+"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2017","2017",9.4,,
+"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2018","2018",8.9,,
+"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2019","2019",8.9,,
+"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2020","2020",8.3,,
+"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2021","2021",7.3,,
+"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2022","2022",7.3,"E","Estimated value"
+"PATCBETA","C07-Beta blocking agents","ATCPTTMT","% of total sales","BEL","Belgium","2010","2010",1.8,,
+"PATCBETA","C07-Beta blocking agents","ATCPTTMT","% of total sales","BEL","Belgium","2011","2011",1.7,,
+"PATCBETA","C07-Beta blocking agents","ATCPTTMT","% of total sales","BEL","Belgium","2012","2012",1.6,,
+"PATCBETA","C07-Beta blocking agents","ATCPTTMT","% of total sales","BEL","Belgium","2013","2013",1.6,,
+"PATCBETA","C07-Beta blocking agents","ATCPTTMT","% of total sales","BEL","Belgium","2014","2014",1.5,,
+"PATCBETA","C07-Beta blocking agents","ATCPTTMT","% of total sales","BEL","Belgium","2015","2015",1.4,,
+"PATCBETA","C07-Beta blocking agents","ATCPTTMT","% of total sales","BEL","Belgium","2016","2016",1.4,,
+"PATCBETA","C07-Beta blocking agents","ATCPTTMT","% of total sales","BEL","Belgium","2017","2017",1.3,,
+"PATCBETA","C07-Beta blocking agents","ATCPTTMT","% of total sales","BEL","Belgium","2018","2018",1.2,,
+"PATCBETA","C07-Beta blocking agents","ATCPTTMT","% of total sales","BEL","Belgium","2019","2019",1,,
+"PATCBETA","C07-Beta blocking agents","ATCPTTMT","% of total sales","BEL","Belgium","2020","2020",0.9,,
+"PATCBETA","C07-Beta blocking agents","ATCPTTMT","% of total sales","BEL","Belgium","2021","2021",0.8,,
+"PATCBETA","C07-Beta blocking agents","ATCPTTMT","% of total sales","BEL","Belgium","2022","2022",0.7,"E","Estimated value"
+"PATCBETA","C07-Beta blocking agents","MLLNCUMT","Million of national currency units","CAN","Canada","2012","2012",321.5,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","MLLNCUMT","Million of national currency units","CAN","Canada","2013","2013",308.5,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","MLLNCUMT","Million of national currency units","CAN","Canada","2014","2014",311.6,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","MLLNCUMT","Million of national currency units","CAN","Canada","2015","2015",316.5,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","MLLNCUMT","Million of national currency units","CAN","Canada","2016","2016",320.7,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","MLLNCUMT","Million of national currency units","CAN","Canada","2017","2017",326.8,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","MLLNCUMT","Million of national currency units","CAN","Canada","2018","2018",299.6,"E; B; D","Estimated value; Break; Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","MLLNCUMT","Million of national currency units","CAN","Canada","2019","2019",288.8,"E; D","Estimated value; Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","MLLNCUMT","Million of national currency units","CAN","Canada","2020","2020",291.7,"E; D","Estimated value; Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","MLLNCUMT","Million of national currency units","CAN","Canada","2021","2021",281.6,"E; D","Estimated value; Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","MLLNCUMT","Million of national currency units","CAN","Canada","2022","2022",258.9,"E; D","Estimated value; Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","MTMOTCMT","Million US$ at exchange rate","CAN","Canada","2012","2012",321.7,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","MTMOTCMT","Million US$ at exchange rate","CAN","Canada","2013","2013",299.5,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","MTMOTCMT","Million US$ at exchange rate","CAN","Canada","2014","2014",282.1,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","MTMOTCMT","Million US$ at exchange rate","CAN","Canada","2015","2015",247.5,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","MTMOTCMT","Million US$ at exchange rate","CAN","Canada","2016","2016",241.9,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","MTMOTCMT","Million US$ at exchange rate","CAN","Canada","2017","2017",251.8,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","MTMOTCMT","Million US$ at exchange rate","CAN","Canada","2018","2018",231.2,"E; B; D","Estimated value; Break; Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","MTMOTCMT","Million US$ at exchange rate","CAN","Canada","2019","2019",217.7,"E; D","Estimated value; Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","MTMOTCMT","Million US$ at exchange rate","CAN","Canada","2020","2020",217.5,"E; D","Estimated value; Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","MTMOTCMT","Million US$ at exchange rate","CAN","Canada","2021","2021",224.6,"E; D","Estimated value; Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","MTMOTCMT","Million US$ at exchange rate","CAN","Canada","2022","2022",198.9,"E; D","Estimated value; Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","MTMOPPMT","Million US$, purchasing power parity","CAN","Canada","2012","2012",258.3,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","MTMOPPMT","Million US$, purchasing power parity","CAN","Canada","2013","2013",252,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","MTMOPPMT","Million US$, purchasing power parity","CAN","Canada","2014","2014",253.3,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","MTMOPPMT","Million US$, purchasing power parity","CAN","Canada","2015","2015",253.6,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","MTMOPPMT","Million US$, purchasing power parity","CAN","Canada","2016","2016",265.7,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","MTMOPPMT","Million US$, purchasing power parity","CAN","Canada","2017","2017",269.6,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","MTMOPPMT","Million US$, purchasing power parity","CAN","Canada","2018","2018",248.4,"E; B; D","Estimated value; Break; Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","MTMOPPMT","Million US$, purchasing power parity","CAN","Canada","2019","2019",233.9,"E; D","Estimated value; Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","MTMOPPMT","Million US$, purchasing power parity","CAN","Canada","2020","2020",237,"E; D","Estimated value; Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","MTMOPPMT","Million US$, purchasing power parity","CAN","Canada","2021","2021",227.4,"E; D","Estimated value; Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","MTMOPPMT","Million US$, purchasing power parity","CAN","Canada","2022","2022",206.4,"E; D","Estimated value; Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","TCPPERMT","/capita, US$ exchange rate","CAN","Canada","2012","2012",9.3,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","TCPPERMT","/capita, US$ exchange rate","CAN","Canada","2013","2013",8.5,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","TCPPERMT","/capita, US$ exchange rate","CAN","Canada","2014","2014",8,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","TCPPERMT","/capita, US$ exchange rate","CAN","Canada","2015","2015",6.9,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","TCPPERMT","/capita, US$ exchange rate","CAN","Canada","2016","2016",6.7,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","TCPPERMT","/capita, US$ exchange rate","CAN","Canada","2017","2017",6.9,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","TCPPERMT","/capita, US$ exchange rate","CAN","Canada","2018","2018",6.2,"E; B; D","Estimated value; Break; Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","TCPPERMT","/capita, US$ exchange rate","CAN","Canada","2019","2019",5.8,"E; D","Estimated value; Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","TCPPERMT","/capita, US$ exchange rate","CAN","Canada","2020","2020",5.7,"E; D","Estimated value; Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","TCPPERMT","/capita, US$ exchange rate","CAN","Canada","2021","2021",5.9,"E; D","Estimated value; Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","TCPPERMT","/capita, US$ exchange rate","CAN","Canada","2022","2022",5.1,"E; D","Estimated value; Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2012","2012",7.4,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2013","2013",7.2,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2014","2014",7.1,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2015","2015",7.1,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2016","2016",7.4,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2017","2017",7.4,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2018","2018",6.7,"E; B; D","Estimated value; Break; Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2019","2019",6.2,"E; D","Estimated value; Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2020","2020",6.2,"E; D","Estimated value; Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2021","2021",5.9,"E; D","Estimated value; Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2022","2022",5.3,"E; D","Estimated value; Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","ATCPTTMT","% of total sales","CAN","Canada","2012","2012",1.3,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","ATCPTTMT","% of total sales","CAN","Canada","2013","2013",1.3,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","ATCPTTMT","% of total sales","CAN","Canada","2014","2014",1.2,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","ATCPTTMT","% of total sales","CAN","Canada","2015","2015",1.2,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","ATCPTTMT","% of total sales","CAN","Canada","2016","2016",1.1,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","ATCPTTMT","% of total sales","CAN","Canada","2017","2017",1.1,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","ATCPTTMT","% of total sales","CAN","Canada","2018","2018",1,"E; B; D","Estimated value; Break; Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","ATCPTTMT","% of total sales","CAN","Canada","2019","2019",0.9,"E; D","Estimated value; Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","ATCPTTMT","% of total sales","CAN","Canada","2020","2020",0.9,"E; D","Estimated value; Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","ATCPTTMT","% of total sales","CAN","Canada","2021","2021",0.8,"E; D","Estimated value; Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","ATCPTTMT","% of total sales","CAN","Canada","2022","2022",0.6,"E; D","Estimated value; Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","MLLNCUMT","Million of national currency units","CZE","Czech Republic","2010","2010",1182.1,,
+"PATCBETA","C07-Beta blocking agents","MLLNCUMT","Million of national currency units","CZE","Czech Republic","2011","2011",1140,,
+"PATCBETA","C07-Beta blocking agents","MLLNCUMT","Million of national currency units","CZE","Czech Republic","2012","2012",1148.2,,
+"PATCBETA","C07-Beta blocking agents","MLLNCUMT","Million of national currency units","CZE","Czech Republic","2013","2013",1118.7,,
+"PATCBETA","C07-Beta blocking agents","MLLNCUMT","Million of national currency units","CZE","Czech Republic","2014","2014",1122.9,,
+"PATCBETA","C07-Beta blocking agents","MLLNCUMT","Million of national currency units","CZE","Czech Republic","2015","2015",1089.5,,
+"PATCBETA","C07-Beta blocking agents","MLLNCUMT","Million of national currency units","CZE","Czech Republic","2016","2016",1079.9,,
+"PATCBETA","C07-Beta blocking agents","MLLNCUMT","Million of national currency units","CZE","Czech Republic","2017","2017",1125.8,,
+"PATCBETA","C07-Beta blocking agents","MLLNCUMT","Million of national currency units","CZE","Czech Republic","2018","2018",1096.9,,
+"PATCBETA","C07-Beta blocking agents","MLLNCUMT","Million of national currency units","CZE","Czech Republic","2019","2019",1088.4,,
+"PATCBETA","C07-Beta blocking agents","MLLNCUMT","Million of national currency units","CZE","Czech Republic","2020","2020",1085.8,"B","Break"
+"PATCBETA","C07-Beta blocking agents","MLLNCUMT","Million of national currency units","CZE","Czech Republic","2021","2021",1100.8,,
+"PATCBETA","C07-Beta blocking agents","MTMOTCMT","Million US$ at exchange rate","CZE","Czech Republic","2010","2010",61.9,,
+"PATCBETA","C07-Beta blocking agents","MTMOTCMT","Million US$ at exchange rate","CZE","Czech Republic","2011","2011",64.4,,
+"PATCBETA","C07-Beta blocking agents","MTMOTCMT","Million US$ at exchange rate","CZE","Czech Republic","2012","2012",58.6,,
+"PATCBETA","C07-Beta blocking agents","MTMOTCMT","Million US$ at exchange rate","CZE","Czech Republic","2013","2013",57.2,,
+"PATCBETA","C07-Beta blocking agents","MTMOTCMT","Million US$ at exchange rate","CZE","Czech Republic","2014","2014",54.1,,
+"PATCBETA","C07-Beta blocking agents","MTMOTCMT","Million US$ at exchange rate","CZE","Czech Republic","2015","2015",44.3,,
+"PATCBETA","C07-Beta blocking agents","MTMOTCMT","Million US$ at exchange rate","CZE","Czech Republic","2016","2016",44.2,,
+"PATCBETA","C07-Beta blocking agents","MTMOTCMT","Million US$ at exchange rate","CZE","Czech Republic","2017","2017",48.2,,
+"PATCBETA","C07-Beta blocking agents","MTMOTCMT","Million US$ at exchange rate","CZE","Czech Republic","2018","2018",50.5,,
+"PATCBETA","C07-Beta blocking agents","MTMOTCMT","Million US$ at exchange rate","CZE","Czech Republic","2019","2019",47.5,,
+"PATCBETA","C07-Beta blocking agents","MTMOTCMT","Million US$ at exchange rate","CZE","Czech Republic","2020","2020",46.8,"B","Break"
+"PATCBETA","C07-Beta blocking agents","MTMOTCMT","Million US$ at exchange rate","CZE","Czech Republic","2021","2021",50.8,,
+"PATCBETA","C07-Beta blocking agents","MTMOPPMT","Million US$, purchasing power parity","CZE","Czech Republic","2010","2010",86.5,,
+"PATCBETA","C07-Beta blocking agents","MTMOPPMT","Million US$, purchasing power parity","CZE","Czech Republic","2011","2011",85.4,,
+"PATCBETA","C07-Beta blocking agents","MTMOPPMT","Million US$, purchasing power parity","CZE","Czech Republic","2012","2012",86.3,,
+"PATCBETA","C07-Beta blocking agents","MTMOPPMT","Million US$, purchasing power parity","CZE","Czech Republic","2013","2013",87.5,,
+"PATCBETA","C07-Beta blocking agents","MTMOPPMT","Million US$, purchasing power parity","CZE","Czech Republic","2014","2014",88.4,,
+"PATCBETA","C07-Beta blocking agents","MTMOPPMT","Million US$, purchasing power parity","CZE","Czech Republic","2015","2015",84.2,,
+"PATCBETA","C07-Beta blocking agents","MTMOPPMT","Million US$, purchasing power parity","CZE","Czech Republic","2016","2016",85.9,,
+"PATCBETA","C07-Beta blocking agents","MTMOPPMT","Million US$, purchasing power parity","CZE","Czech Republic","2017","2017",90.6,,
+"PATCBETA","C07-Beta blocking agents","MTMOPPMT","Million US$, purchasing power parity","CZE","Czech Republic","2018","2018",88.7,,
+"PATCBETA","C07-Beta blocking agents","MTMOPPMT","Million US$, purchasing power parity","CZE","Czech Republic","2019","2019",88.7,,
+"PATCBETA","C07-Beta blocking agents","MTMOPPMT","Million US$, purchasing power parity","CZE","Czech Republic","2020","2020",87.1,"B","Break"
+"PATCBETA","C07-Beta blocking agents","MTMOPPMT","Million US$, purchasing power parity","CZE","Czech Republic","2021","2021",86.4,,
+"PATCBETA","C07-Beta blocking agents","TCPPERMT","/capita, US$ exchange rate","CZE","Czech Republic","2010","2010",5.9,,
+"PATCBETA","C07-Beta blocking agents","TCPPERMT","/capita, US$ exchange rate","CZE","Czech Republic","2011","2011",6.1,,
+"PATCBETA","C07-Beta blocking agents","TCPPERMT","/capita, US$ exchange rate","CZE","Czech Republic","2012","2012",5.6,,
+"PATCBETA","C07-Beta blocking agents","TCPPERMT","/capita, US$ exchange rate","CZE","Czech Republic","2013","2013",5.4,,
+"PATCBETA","C07-Beta blocking agents","TCPPERMT","/capita, US$ exchange rate","CZE","Czech Republic","2014","2014",5.1,,
+"PATCBETA","C07-Beta blocking agents","TCPPERMT","/capita, US$ exchange rate","CZE","Czech Republic","2015","2015",4.2,,
+"PATCBETA","C07-Beta blocking agents","TCPPERMT","/capita, US$ exchange rate","CZE","Czech Republic","2016","2016",4.2,,
+"PATCBETA","C07-Beta blocking agents","TCPPERMT","/capita, US$ exchange rate","CZE","Czech Republic","2017","2017",4.5,,
+"PATCBETA","C07-Beta blocking agents","TCPPERMT","/capita, US$ exchange rate","CZE","Czech Republic","2018","2018",4.7,,
+"PATCBETA","C07-Beta blocking agents","TCPPERMT","/capita, US$ exchange rate","CZE","Czech Republic","2019","2019",4.4,,
+"PATCBETA","C07-Beta blocking agents","TCPPERMT","/capita, US$ exchange rate","CZE","Czech Republic","2020","2020",4.4,"B","Break"
+"PATCBETA","C07-Beta blocking agents","TCPPERMT","/capita, US$ exchange rate","CZE","Czech Republic","2021","2021",4.8,,
+"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czech Republic","2010","2010",8.3,,
+"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czech Republic","2011","2011",8.1,,
+"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czech Republic","2012","2012",8.2,,
+"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czech Republic","2013","2013",8.3,,
+"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czech Republic","2014","2014",8.4,,
+"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czech Republic","2015","2015",8,,
+"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czech Republic","2016","2016",8.1,,
+"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czech Republic","2017","2017",8.6,,
+"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czech Republic","2018","2018",8.3,,
+"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czech Republic","2019","2019",8.3,,
+"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czech Republic","2020","2020",8.1,"B","Break"
+"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czech Republic","2021","2021",8.2,,
+"PATCBETA","C07-Beta blocking agents","ATCPTTMT","% of total sales","CZE","Czech Republic","2010","2010",1.5,,
+"PATCBETA","C07-Beta blocking agents","ATCPTTMT","% of total sales","CZE","Czech Republic","2011","2011",1.4,,
+"PATCBETA","C07-Beta blocking agents","ATCPTTMT","% of total sales","CZE","Czech Republic","2012","2012",1.4,,
+"PATCBETA","C07-Beta blocking agents","ATCPTTMT","% of total sales","CZE","Czech Republic","2013","2013",1.4,,
+"PATCBETA","C07-Beta blocking agents","ATCPTTMT","% of total sales","CZE","Czech Republic","2014","2014",1.4,,
+"PATCBETA","C07-Beta blocking agents","ATCPTTMT","% of total sales","CZE","Czech Republic","2015","2015",1.3,,
+"PATCBETA","C07-Beta blocking agents","ATCPTTMT","% of total sales","CZE","Czech Republic","2016","2016",1.2,,
+"PATCBETA","C07-Beta blocking agents","ATCPTTMT","% of total sales","CZE","Czech Republic","2017","2017",1.2,,
+"PATCBETA","C07-Beta blocking agents","ATCPTTMT","% of total sales","CZE","Czech Republic","2018","2018",1.1,,
+"PATCBETA","C07-Beta blocking agents","ATCPTTMT","% of total sales","CZE","Czech Republic","2019","2019",1.1,,
+"PATCBETA","C07-Beta blocking agents","ATCPTTMT","% of total sales","CZE","Czech Republic","2020","2020",1.2,"B","Break"
+"PATCBETA","C07-Beta blocking agents","ATCPTTMT","% of total sales","CZE","Czech Republic","2021","2021",1.2,,
+"PATCBETA","C07-Beta blocking agents","MLLNCUMT","Million of national currency units","FIN","Finland","2010","2010",29.8,,
+"PATCBETA","C07-Beta blocking agents","MLLNCUMT","Million of national currency units","FIN","Finland","2011","2011",25,,
+"PATCBETA","C07-Beta blocking agents","MLLNCUMT","Million of national currency units","FIN","Finland","2012","2012",26.2,,
+"PATCBETA","C07-Beta blocking agents","MLLNCUMT","Million of national currency units","FIN","Finland","2013","2013",27.1,,
+"PATCBETA","C07-Beta blocking agents","MLLNCUMT","Million of national currency units","FIN","Finland","2014","2014",27.6,,
+"PATCBETA","C07-Beta blocking agents","MLLNCUMT","Million of national currency units","FIN","Finland","2015","2015",27.6,,
+"PATCBETA","C07-Beta blocking agents","MLLNCUMT","Million of national currency units","FIN","Finland","2016","2016",26.5,,
+"PATCBETA","C07-Beta blocking agents","MLLNCUMT","Million of national currency units","FIN","Finland","2017","2017",23.5,,
+"PATCBETA","C07-Beta blocking agents","MLLNCUMT","Million of national currency units","FIN","Finland","2018","2018",21.7,,
+"PATCBETA","C07-Beta blocking agents","MLLNCUMT","Million of national currency units","FIN","Finland","2019","2019",20.3,,
+"PATCBETA","C07-Beta blocking agents","MLLNCUMT","Million of national currency units","FIN","Finland","2020","2020",19.3,,
+"PATCBETA","C07-Beta blocking agents","MLLNCUMT","Million of national currency units","FIN","Finland","2021","2021",18.4,,
+"PATCBETA","C07-Beta blocking agents","MTMOTCMT","Million US$ at exchange rate","FIN","Finland","2010","2010",39.5,,
+"PATCBETA","C07-Beta blocking agents","MTMOTCMT","Million US$ at exchange rate","FIN","Finland","2011","2011",34.8,,
+"PATCBETA","C07-Beta blocking agents","MTMOTCMT","Million US$ at exchange rate","FIN","Finland","2012","2012",33.7,,
+"PATCBETA","C07-Beta blocking agents","MTMOTCMT","Million US$ at exchange rate","FIN","Finland","2013","2013",36,,
+"PATCBETA","C07-Beta blocking agents","MTMOTCMT","Million US$ at exchange rate","FIN","Finland","2014","2014",36.7,,
+"PATCBETA","C07-Beta blocking agents","MTMOTCMT","Million US$ at exchange rate","FIN","Finland","2015","2015",30.6,,
+"PATCBETA","C07-Beta blocking agents","MTMOTCMT","Million US$ at exchange rate","FIN","Finland","2016","2016",29.3,,
+"PATCBETA","C07-Beta blocking agents","MTMOTCMT","Million US$ at exchange rate","FIN","Finland","2017","2017",26.5,,
+"PATCBETA","C07-Beta blocking agents","MTMOTCMT","Million US$ at exchange rate","FIN","Finland","2018","2018",25.6,,
+"PATCBETA","C07-Beta blocking agents","MTMOTCMT","Million US$ at exchange rate","FIN","Finland","2019","2019",22.7,,
+"PATCBETA","C07-Beta blocking agents","MTMOTCMT","Million US$ at exchange rate","FIN","Finland","2020","2020",22,,
+"PATCBETA","C07-Beta blocking agents","MTMOTCMT","Million US$ at exchange rate","FIN","Finland","2021","2021",21.8,,
+"PATCBETA","C07-Beta blocking agents","MTMOPPMT","Million US$, purchasing power parity","FIN","Finland","2010","2010",33.1,,
+"PATCBETA","C07-Beta blocking agents","MTMOPPMT","Million US$, purchasing power parity","FIN","Finland","2011","2011",27.8,,
+"PATCBETA","C07-Beta blocking agents","MTMOPPMT","Million US$, purchasing power parity","FIN","Finland","2012","2012",28.8,,
+"PATCBETA","C07-Beta blocking agents","MTMOPPMT","Million US$, purchasing power parity","FIN","Finland","2013","2013",29.9,,
+"PATCBETA","C07-Beta blocking agents","MTMOPPMT","Million US$, purchasing power parity","FIN","Finland","2014","2014",30.4,,
+"PATCBETA","C07-Beta blocking agents","MTMOPPMT","Million US$, purchasing power parity","FIN","Finland","2015","2015",30.4,,
+"PATCBETA","C07-Beta blocking agents","MTMOPPMT","Million US$, purchasing power parity","FIN","Finland","2016","2016",30.1,,
+"PATCBETA","C07-Beta blocking agents","MTMOPPMT","Million US$, purchasing power parity","FIN","Finland","2017","2017",27.2,,
+"PATCBETA","C07-Beta blocking agents","MTMOPPMT","Million US$, purchasing power parity","FIN","Finland","2018","2018",25.4,,
+"PATCBETA","C07-Beta blocking agents","MTMOPPMT","Million US$, purchasing power parity","FIN","Finland","2019","2019",24.2,,
+"PATCBETA","C07-Beta blocking agents","MTMOPPMT","Million US$, purchasing power parity","FIN","Finland","2020","2020",23.5,,
+"PATCBETA","C07-Beta blocking agents","MTMOPPMT","Million US$, purchasing power parity","FIN","Finland","2021","2021",22.3,,
+"PATCBETA","C07-Beta blocking agents","TCPPERMT","/capita, US$ exchange rate","FIN","Finland","2010","2010",7.4,,
+"PATCBETA","C07-Beta blocking agents","TCPPERMT","/capita, US$ exchange rate","FIN","Finland","2011","2011",6.5,,
+"PATCBETA","C07-Beta blocking agents","TCPPERMT","/capita, US$ exchange rate","FIN","Finland","2012","2012",6.2,,
+"PATCBETA","C07-Beta blocking agents","TCPPERMT","/capita, US$ exchange rate","FIN","Finland","2013","2013",6.6,,
+"PATCBETA","C07-Beta blocking agents","TCPPERMT","/capita, US$ exchange rate","FIN","Finland","2014","2014",6.7,,
+"PATCBETA","C07-Beta blocking agents","TCPPERMT","/capita, US$ exchange rate","FIN","Finland","2015","2015",5.6,,
+"PATCBETA","C07-Beta blocking agents","TCPPERMT","/capita, US$ exchange rate","FIN","Finland","2016","2016",5.3,,
+"PATCBETA","C07-Beta blocking agents","TCPPERMT","/capita, US$ exchange rate","FIN","Finland","2017","2017",4.8,,
+"PATCBETA","C07-Beta blocking agents","TCPPERMT","/capita, US$ exchange rate","FIN","Finland","2018","2018",4.6,,
+"PATCBETA","C07-Beta blocking agents","TCPPERMT","/capita, US$ exchange rate","FIN","Finland","2019","2019",4.1,,
+"PATCBETA","C07-Beta blocking agents","TCPPERMT","/capita, US$ exchange rate","FIN","Finland","2020","2020",4,,
+"PATCBETA","C07-Beta blocking agents","TCPPERMT","/capita, US$ exchange rate","FIN","Finland","2021","2021",3.9,,
+"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2010","2010",6.2,,
+"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2011","2011",5.2,,
+"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2012","2012",5.3,,
+"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2013","2013",5.5,,
+"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2014","2014",5.6,,
+"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2015","2015",5.5,,
+"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2016","2016",5.5,,
+"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2017","2017",4.9,,
+"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2018","2018",4.6,,
+"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2019","2019",4.4,,
+"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2020","2020",4.2,,
+"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2021","2021",4,,
+"PATCBETA","C07-Beta blocking agents","ATCPTTMT","% of total sales","FIN","Finland","2010","2010",1.6,,
+"PATCBETA","C07-Beta blocking agents","ATCPTTMT","% of total sales","FIN","Finland","2011","2011",1.3,,
+"PATCBETA","C07-Beta blocking agents","ATCPTTMT","% of total sales","FIN","Finland","2012","2012",1.3,,
+"PATCBETA","C07-Beta blocking agents","ATCPTTMT","% of total sales","FIN","Finland","2013","2013",1.3,,
+"PATCBETA","C07-Beta blocking agents","ATCPTTMT","% of total sales","FIN","Finland","2014","2014",1.3,,
+"PATCBETA","C07-Beta blocking agents","ATCPTTMT","% of total sales","FIN","Finland","2015","2015",1.3,,
+"PATCBETA","C07-Beta blocking agents","ATCPTTMT","% of total sales","FIN","Finland","2016","2016",1.2,,
+"PATCBETA","C07-Beta blocking agents","ATCPTTMT","% of total sales","FIN","Finland","2017","2017",1,,
+"PATCBETA","C07-Beta blocking agents","ATCPTTMT","% of total sales","FIN","Finland","2018","2018",0.9,,
+"PATCBETA","C07-Beta blocking agents","ATCPTTMT","% of total sales","FIN","Finland","2019","2019",0.8,,
+"PATCBETA","C07-Beta blocking agents","ATCPTTMT","% of total sales","FIN","Finland","2020","2020",0.7,,
+"PATCBETA","C07-Beta blocking agents","ATCPTTMT","% of total sales","FIN","Finland","2021","2021",0.6,,
+"PATCBETA","C07-Beta blocking agents","MLLNCUMT","Million of national currency units","DEU","Germany","2010","2010",666,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","MLLNCUMT","Million of national currency units","DEU","Germany","2011","2011",647.2,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","MLLNCUMT","Million of national currency units","DEU","Germany","2012","2012",654.5,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","MLLNCUMT","Million of national currency units","DEU","Germany","2013","2013",661.4,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","MLLNCUMT","Million of national currency units","DEU","Germany","2014","2014",669.8,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","MLLNCUMT","Million of national currency units","DEU","Germany","2015","2015",668.9,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","MLLNCUMT","Million of national currency units","DEU","Germany","2016","2016",659.7,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","MLLNCUMT","Million of national currency units","DEU","Germany","2017","2017",654.9,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","MLLNCUMT","Million of national currency units","DEU","Germany","2018","2018",662.8,"B; D","Break; Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","MLLNCUMT","Million of national currency units","DEU","Germany","2019","2019",677.4,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","MLLNCUMT","Million of national currency units","DEU","Germany","2020","2020",681.3,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","MLLNCUMT","Million of national currency units","DEU","Germany","2021","2021",683,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","MTMOTCMT","Million US$ at exchange rate","DEU","Germany","2010","2010",882.9,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","MTMOTCMT","Million US$ at exchange rate","DEU","Germany","2011","2011",900.9,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","MTMOTCMT","Million US$ at exchange rate","DEU","Germany","2012","2012",840.9,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","MTMOTCMT","Million US$ at exchange rate","DEU","Germany","2013","2013",878.4,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","MTMOTCMT","Million US$ at exchange rate","DEU","Germany","2014","2014",889.8,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","MTMOTCMT","Million US$ at exchange rate","DEU","Germany","2015","2015",742.2,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","MTMOTCMT","Million US$ at exchange rate","DEU","Germany","2016","2016",730.2,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","MTMOTCMT","Million US$ at exchange rate","DEU","Germany","2017","2017",739.8,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","MTMOTCMT","Million US$ at exchange rate","DEU","Germany","2018","2018",782.7,"B; D","Break; Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","MTMOTCMT","Million US$ at exchange rate","DEU","Germany","2019","2019",758.3,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","MTMOTCMT","Million US$ at exchange rate","DEU","Germany","2020","2020",778.2,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","MTMOTCMT","Million US$ at exchange rate","DEU","Germany","2021","2021",807.8,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","MTMOPPMT","Million US$, purchasing power parity","DEU","Germany","2010","2010",827.2,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","MTMOPPMT","Million US$, purchasing power parity","DEU","Germany","2011","2011",820.6,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","MTMOPPMT","Million US$, purchasing power parity","DEU","Germany","2012","2012",831.4,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","MTMOPPMT","Million US$, purchasing power parity","DEU","Germany","2013","2013",853.7,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","MTMOPPMT","Million US$, purchasing power parity","DEU","Germany","2014","2014",871.1,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","MTMOPPMT","Million US$, purchasing power parity","DEU","Germany","2015","2015",859.6,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","MTMOPPMT","Million US$, purchasing power parity","DEU","Germany","2016","2016",876.6,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","MTMOPPMT","Million US$, purchasing power parity","DEU","Germany","2017","2017",879.3,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","MTMOPPMT","Million US$, purchasing power parity","DEU","Germany","2018","2018",901.2,"B; D","Break; Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","MTMOPPMT","Million US$, purchasing power parity","DEU","Germany","2019","2019",930.2,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","MTMOPPMT","Million US$, purchasing power parity","DEU","Germany","2020","2020",939.7,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","MTMOPPMT","Million US$, purchasing power parity","DEU","Germany","2021","2021",927.6,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","TCPPERMT","/capita, US$ exchange rate","DEU","Germany","2010","2010",10.8,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","TCPPERMT","/capita, US$ exchange rate","DEU","Germany","2011","2011",11.2,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","TCPPERMT","/capita, US$ exchange rate","DEU","Germany","2012","2012",10.5,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","TCPPERMT","/capita, US$ exchange rate","DEU","Germany","2013","2013",10.9,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","TCPPERMT","/capita, US$ exchange rate","DEU","Germany","2014","2014",11,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","TCPPERMT","/capita, US$ exchange rate","DEU","Germany","2015","2015",9.1,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","TCPPERMT","/capita, US$ exchange rate","DEU","Germany","2016","2016",8.9,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","TCPPERMT","/capita, US$ exchange rate","DEU","Germany","2017","2017",9,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","TCPPERMT","/capita, US$ exchange rate","DEU","Germany","2018","2018",9.4,"B; D","Break; Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","TCPPERMT","/capita, US$ exchange rate","DEU","Germany","2019","2019",9.1,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","TCPPERMT","/capita, US$ exchange rate","DEU","Germany","2020","2020",9.4,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","TCPPERMT","/capita, US$ exchange rate","DEU","Germany","2021","2021",9.7,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2010","2010",10.1,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2011","2011",10.2,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2012","2012",10.3,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2013","2013",10.6,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2014","2014",10.8,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2015","2015",10.5,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2016","2016",10.6,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2017","2017",10.6,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2018","2018",10.9,"B; D","Break; Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2019","2019",11.2,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2020","2020",11.3,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2021","2021",11.2,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","ATCPTTMT","% of total sales","DEU","Germany","2010","2010",2.2,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","ATCPTTMT","% of total sales","DEU","Germany","2011","2011",2.2,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","ATCPTTMT","% of total sales","DEU","Germany","2012","2012",2.1,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","ATCPTTMT","% of total sales","DEU","Germany","2013","2013",2.1,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","ATCPTTMT","% of total sales","DEU","Germany","2014","2014",2,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","ATCPTTMT","% of total sales","DEU","Germany","2015","2015",1.9,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","ATCPTTMT","% of total sales","DEU","Germany","2016","2016",1.8,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","ATCPTTMT","% of total sales","DEU","Germany","2017","2017",1.8,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","ATCPTTMT","% of total sales","DEU","Germany","2018","2018",1.5,"B; D","Break; Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","ATCPTTMT","% of total sales","DEU","Germany","2019","2019",1.4,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","ATCPTTMT","% of total sales","DEU","Germany","2020","2020",1.4,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","ATCPTTMT","% of total sales","DEU","Germany","2021","2021",1.3,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","MLLNCUMT","Million of national currency units","GRC","Greece","2010","2010",81.2,,
+"PATCBETA","C07-Beta blocking agents","MLLNCUMT","Million of national currency units","GRC","Greece","2011","2011",81.7,,
+"PATCBETA","C07-Beta blocking agents","MLLNCUMT","Million of national currency units","GRC","Greece","2012","2012",79.9,,
+"PATCBETA","C07-Beta blocking agents","MLLNCUMT","Million of national currency units","GRC","Greece","2013","2013",64.2,,
+"PATCBETA","C07-Beta blocking agents","MLLNCUMT","Million of national currency units","GRC","Greece","2014","2014",58.7,,
+"PATCBETA","C07-Beta blocking agents","MLLNCUMT","Million of national currency units","GRC","Greece","2015","2015",57.5,,
+"PATCBETA","C07-Beta blocking agents","MLLNCUMT","Million of national currency units","GRC","Greece","2016","2016",59.7,,
+"PATCBETA","C07-Beta blocking agents","MLLNCUMT","Million of national currency units","GRC","Greece","2017","2017",57.6,,
+"PATCBETA","C07-Beta blocking agents","MLLNCUMT","Million of national currency units","GRC","Greece","2018","2018",58.5,,
+"PATCBETA","C07-Beta blocking agents","MLLNCUMT","Million of national currency units","GRC","Greece","2019","2019",60.9,,
+"PATCBETA","C07-Beta blocking agents","MLLNCUMT","Million of national currency units","GRC","Greece","2020","2020",67.8,,
+"PATCBETA","C07-Beta blocking agents","MLLNCUMT","Million of national currency units","GRC","Greece","2021","2021",78,,
+"PATCBETA","C07-Beta blocking agents","MLLNCUMT","Million of national currency units","GRC","Greece","2022","2022",60.4,,
+"PATCBETA","C07-Beta blocking agents","MTMOTCMT","Million US$ at exchange rate","GRC","Greece","2010","2010",107.7,,
+"PATCBETA","C07-Beta blocking agents","MTMOTCMT","Million US$ at exchange rate","GRC","Greece","2011","2011",113.7,,
+"PATCBETA","C07-Beta blocking agents","MTMOTCMT","Million US$ at exchange rate","GRC","Greece","2012","2012",102.6,,
+"PATCBETA","C07-Beta blocking agents","MTMOTCMT","Million US$ at exchange rate","GRC","Greece","2013","2013",85.2,,
+"PATCBETA","C07-Beta blocking agents","MTMOTCMT","Million US$ at exchange rate","GRC","Greece","2014","2014",78,,
+"PATCBETA","C07-Beta blocking agents","MTMOTCMT","Million US$ at exchange rate","GRC","Greece","2015","2015",63.8,,
+"PATCBETA","C07-Beta blocking agents","MTMOTCMT","Million US$ at exchange rate","GRC","Greece","2016","2016",66.1,,
+"PATCBETA","C07-Beta blocking agents","MTMOTCMT","Million US$ at exchange rate","GRC","Greece","2017","2017",65,,
+"PATCBETA","C07-Beta blocking agents","MTMOTCMT","Million US$ at exchange rate","GRC","Greece","2018","2018",69,,
+"PATCBETA","C07-Beta blocking agents","MTMOTCMT","Million US$ at exchange rate","GRC","Greece","2019","2019",68.2,,
+"PATCBETA","C07-Beta blocking agents","MTMOTCMT","Million US$ at exchange rate","GRC","Greece","2020","2020",77.4,,
+"PATCBETA","C07-Beta blocking agents","MTMOTCMT","Million US$ at exchange rate","GRC","Greece","2021","2021",92.3,,
+"PATCBETA","C07-Beta blocking agents","MTMOTCMT","Million US$ at exchange rate","GRC","Greece","2022","2022",63.6,,
+"PATCBETA","C07-Beta blocking agents","MTMOPPMT","Million US$, purchasing power parity","GRC","Greece","2010","2010",112.5,,
+"PATCBETA","C07-Beta blocking agents","MTMOPPMT","Million US$, purchasing power parity","GRC","Greece","2011","2011",114.5,,
+"PATCBETA","C07-Beta blocking agents","MTMOPPMT","Million US$, purchasing power parity","GRC","Greece","2012","2012",116.7,,
+"PATCBETA","C07-Beta blocking agents","MTMOPPMT","Million US$, purchasing power parity","GRC","Greece","2013","2013",101.7,,
+"PATCBETA","C07-Beta blocking agents","MTMOPPMT","Million US$, purchasing power parity","GRC","Greece","2014","2014",96,,
+"PATCBETA","C07-Beta blocking agents","MTMOPPMT","Million US$, purchasing power parity","GRC","Greece","2015","2015",94.4,,
+"PATCBETA","C07-Beta blocking agents","MTMOPPMT","Million US$, purchasing power parity","GRC","Greece","2016","2016",101.5,,
+"PATCBETA","C07-Beta blocking agents","MTMOPPMT","Million US$, purchasing power parity","GRC","Greece","2017","2017",100.1,,
+"PATCBETA","C07-Beta blocking agents","MTMOPPMT","Million US$, purchasing power parity","GRC","Greece","2018","2018",103.5,,
+"PATCBETA","C07-Beta blocking agents","MTMOPPMT","Million US$, purchasing power parity","GRC","Greece","2019","2019",110.9,,
+"PATCBETA","C07-Beta blocking agents","MTMOPPMT","Million US$, purchasing power parity","GRC","Greece","2020","2020",124.6,,
+"PATCBETA","C07-Beta blocking agents","MTMOPPMT","Million US$, purchasing power parity","GRC","Greece","2021","2021",143,,
+"PATCBETA","C07-Beta blocking agents","MTMOPPMT","Million US$, purchasing power parity","GRC","Greece","2022","2022",114.4,,
+"PATCBETA","C07-Beta blocking agents","TCPPERMT","/capita, US$ exchange rate","GRC","Greece","2010","2010",9.7,,
+"PATCBETA","C07-Beta blocking agents","TCPPERMT","/capita, US$ exchange rate","GRC","Greece","2011","2011",10.2,,
+"PATCBETA","C07-Beta blocking agents","TCPPERMT","/capita, US$ exchange rate","GRC","Greece","2012","2012",9.3,,
+"PATCBETA","C07-Beta blocking agents","TCPPERMT","/capita, US$ exchange rate","GRC","Greece","2013","2013",7.8,,
+"PATCBETA","C07-Beta blocking agents","TCPPERMT","/capita, US$ exchange rate","GRC","Greece","2014","2014",7.2,,
+"PATCBETA","C07-Beta blocking agents","TCPPERMT","/capita, US$ exchange rate","GRC","Greece","2015","2015",5.9,,
+"PATCBETA","C07-Beta blocking agents","TCPPERMT","/capita, US$ exchange rate","GRC","Greece","2016","2016",6.1,,
+"PATCBETA","C07-Beta blocking agents","TCPPERMT","/capita, US$ exchange rate","GRC","Greece","2017","2017",6,,
+"PATCBETA","C07-Beta blocking agents","TCPPERMT","/capita, US$ exchange rate","GRC","Greece","2018","2018",6.4,,
+"PATCBETA","C07-Beta blocking agents","TCPPERMT","/capita, US$ exchange rate","GRC","Greece","2019","2019",6.4,,
+"PATCBETA","C07-Beta blocking agents","TCPPERMT","/capita, US$ exchange rate","GRC","Greece","2020","2020",7.2,,
+"PATCBETA","C07-Beta blocking agents","TCPPERMT","/capita, US$ exchange rate","GRC","Greece","2021","2021",8.7,,
+"PATCBETA","C07-Beta blocking agents","TCPPERMT","/capita, US$ exchange rate","GRC","Greece","2022","2022",6.1,,
+"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2010","2010",10.1,,
+"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2011","2011",10.3,,
+"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2012","2012",10.6,,
+"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2013","2013",9.3,,
+"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2014","2014",8.8,,
+"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2015","2015",8.7,,
+"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2016","2016",9.4,,
+"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2017","2017",9.3,,
+"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2018","2018",9.6,,
+"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2019","2019",10.3,,
+"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2020","2020",11.6,,
+"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2021","2021",13.5,,
+"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2022","2022",10.9,,
+"PATCBETA","C07-Beta blocking agents","MLLNCUMT","Million of national currency units","HUN","Hungary","2010","2010",12071.4,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","MLLNCUMT","Million of national currency units","HUN","Hungary","2011","2011",12185.1,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","MLLNCUMT","Million of national currency units","HUN","Hungary","2012","2012",10376.8,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","MLLNCUMT","Million of national currency units","HUN","Hungary","2013","2013",9953.6,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","MLLNCUMT","Million of national currency units","HUN","Hungary","2014","2014",9722.1,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","MLLNCUMT","Million of national currency units","HUN","Hungary","2015","2015",9746,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","MLLNCUMT","Million of national currency units","HUN","Hungary","2016","2016",9800,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","MLLNCUMT","Million of national currency units","HUN","Hungary","2017","2017",9854.4,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","MLLNCUMT","Million of national currency units","HUN","Hungary","2018","2018",9925.4,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","MLLNCUMT","Million of national currency units","HUN","Hungary","2019","2019",9790.5,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","MLLNCUMT","Million of national currency units","HUN","Hungary","2020","2020",10122.9,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","MLLNCUMT","Million of national currency units","HUN","Hungary","2021","2021",9312.5,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","MLLNCUMT","Million of national currency units","HUN","Hungary","2022","2022",9446.6,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","MTMOTCMT","Million US$ at exchange rate","HUN","Hungary","2010","2010",58.1,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","MTMOTCMT","Million US$ at exchange rate","HUN","Hungary","2011","2011",60.6,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","MTMOTCMT","Million US$ at exchange rate","HUN","Hungary","2012","2012",46.1,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","MTMOTCMT","Million US$ at exchange rate","HUN","Hungary","2013","2013",44.5,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","MTMOTCMT","Million US$ at exchange rate","HUN","Hungary","2014","2014",41.8,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","MTMOTCMT","Million US$ at exchange rate","HUN","Hungary","2015","2015",34.9,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","MTMOTCMT","Million US$ at exchange rate","HUN","Hungary","2016","2016",34.8,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","MTMOTCMT","Million US$ at exchange rate","HUN","Hungary","2017","2017",35.9,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","MTMOTCMT","Million US$ at exchange rate","HUN","Hungary","2018","2018",36.7,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","MTMOTCMT","Million US$ at exchange rate","HUN","Hungary","2019","2019",33.7,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","MTMOTCMT","Million US$ at exchange rate","HUN","Hungary","2020","2020",32.9,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","MTMOTCMT","Million US$ at exchange rate","HUN","Hungary","2021","2021",30.7,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","MTMOTCMT","Million US$ at exchange rate","HUN","Hungary","2022","2022",25.4,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","MTMOPPMT","Million US$, purchasing power parity","HUN","Hungary","2010","2010",95.5,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","MTMOPPMT","Million US$, purchasing power parity","HUN","Hungary","2011","2011",98.1,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","MTMOPPMT","Million US$, purchasing power parity","HUN","Hungary","2012","2012",82.6,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","MTMOPPMT","Million US$, purchasing power parity","HUN","Hungary","2013","2013",79.6,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","MTMOPPMT","Million US$, purchasing power parity","HUN","Hungary","2014","2014",75.1,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","MTMOPPMT","Million US$, purchasing power parity","HUN","Hungary","2015","2015",73.5,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","MTMOPPMT","Million US$, purchasing power parity","HUN","Hungary","2016","2016",74.2,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","MTMOPPMT","Million US$, purchasing power parity","HUN","Hungary","2017","2017",72.4,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","MTMOPPMT","Million US$, purchasing power parity","HUN","Hungary","2018","2018",71.4,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","MTMOPPMT","Million US$, purchasing power parity","HUN","Hungary","2019","2019",69.5,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","MTMOPPMT","Million US$, purchasing power parity","HUN","Hungary","2020","2020",69.6,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","MTMOPPMT","Million US$, purchasing power parity","HUN","Hungary","2021","2021",60.2,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","MTMOPPMT","Million US$, purchasing power parity","HUN","Hungary","2022","2022",58.6,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","TCPPERMT","/capita, US$ exchange rate","HUN","Hungary","2010","2010",5.8,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","TCPPERMT","/capita, US$ exchange rate","HUN","Hungary","2011","2011",6.1,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","TCPPERMT","/capita, US$ exchange rate","HUN","Hungary","2012","2012",4.6,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","TCPPERMT","/capita, US$ exchange rate","HUN","Hungary","2013","2013",4.5,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","TCPPERMT","/capita, US$ exchange rate","HUN","Hungary","2014","2014",4.2,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","TCPPERMT","/capita, US$ exchange rate","HUN","Hungary","2015","2015",3.5,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","TCPPERMT","/capita, US$ exchange rate","HUN","Hungary","2016","2016",3.5,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","TCPPERMT","/capita, US$ exchange rate","HUN","Hungary","2017","2017",3.7,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","TCPPERMT","/capita, US$ exchange rate","HUN","Hungary","2018","2018",3.8,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","TCPPERMT","/capita, US$ exchange rate","HUN","Hungary","2019","2019",3.4,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","TCPPERMT","/capita, US$ exchange rate","HUN","Hungary","2020","2020",3.4,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","TCPPERMT","/capita, US$ exchange rate","HUN","Hungary","2021","2021",3.2,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","TCPPERMT","/capita, US$ exchange rate","HUN","Hungary","2022","2022",2.6,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2010","2010",9.5,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2011","2011",9.8,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2012","2012",8.3,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2013","2013",8.1,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2014","2014",7.6,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2015","2015",7.5,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2016","2016",7.6,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2017","2017",7.4,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2018","2018",7.3,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2019","2019",7.1,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2020","2020",7.1,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2021","2021",6.2,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2022","2022",6,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","ATCPTTMT","% of total sales","HUN","Hungary","2010","2010",2.4,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","ATCPTTMT","% of total sales","HUN","Hungary","2011","2011",2.4,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","ATCPTTMT","% of total sales","HUN","Hungary","2012","2012",2.3,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","ATCPTTMT","% of total sales","HUN","Hungary","2013","2013",2.3,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","ATCPTTMT","% of total sales","HUN","Hungary","2014","2014",2.2,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","ATCPTTMT","% of total sales","HUN","Hungary","2015","2015",2.1,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","ATCPTTMT","% of total sales","HUN","Hungary","2016","2016",2,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","ATCPTTMT","% of total sales","HUN","Hungary","2017","2017",2,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","ATCPTTMT","% of total sales","HUN","Hungary","2018","2018",2,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","ATCPTTMT","% of total sales","HUN","Hungary","2019","2019",1.9,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","ATCPTTMT","% of total sales","HUN","Hungary","2020","2020",1.8,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","ATCPTTMT","% of total sales","HUN","Hungary","2021","2021",1.6,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","ATCPTTMT","% of total sales","HUN","Hungary","2022","2022",1.6,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","MLLNCUMT","Million of national currency units","ISL","Iceland","2010","2010",327.2,,
+"PATCBETA","C07-Beta blocking agents","MLLNCUMT","Million of national currency units","ISL","Iceland","2011","2011",346.8,,
+"PATCBETA","C07-Beta blocking agents","MLLNCUMT","Million of national currency units","ISL","Iceland","2012","2012",345.8,,
+"PATCBETA","C07-Beta blocking agents","MLLNCUMT","Million of national currency units","ISL","Iceland","2013","2013",353.3,,
+"PATCBETA","C07-Beta blocking agents","MLLNCUMT","Million of national currency units","ISL","Iceland","2014","2014",342.1,,
+"PATCBETA","C07-Beta blocking agents","MLLNCUMT","Million of national currency units","ISL","Iceland","2015","2015",339.2,,
+"PATCBETA","C07-Beta blocking agents","MLLNCUMT","Million of national currency units","ISL","Iceland","2016","2016",340.2,,
+"PATCBETA","C07-Beta blocking agents","MLLNCUMT","Million of national currency units","ISL","Iceland","2017","2017",349.6,,
+"PATCBETA","C07-Beta blocking agents","MLLNCUMT","Million of national currency units","ISL","Iceland","2018","2018",368.2,,
+"PATCBETA","C07-Beta blocking agents","MLLNCUMT","Million of national currency units","ISL","Iceland","2019","2019",380.2,,
+"PATCBETA","C07-Beta blocking agents","MLLNCUMT","Million of national currency units","ISL","Iceland","2020","2020",441.2,,
+"PATCBETA","C07-Beta blocking agents","MLLNCUMT","Million of national currency units","ISL","Iceland","2021","2021",482.3,,
+"PATCBETA","C07-Beta blocking agents","MTMOTCMT","Million US$ at exchange rate","ISL","Iceland","2010","2010",2.7,,
+"PATCBETA","C07-Beta blocking agents","MTMOTCMT","Million US$ at exchange rate","ISL","Iceland","2011","2011",3,,
+"PATCBETA","C07-Beta blocking agents","MTMOTCMT","Million US$ at exchange rate","ISL","Iceland","2012","2012",2.8,,
+"PATCBETA","C07-Beta blocking agents","MTMOTCMT","Million US$ at exchange rate","ISL","Iceland","2013","2013",2.9,,
+"PATCBETA","C07-Beta blocking agents","MTMOTCMT","Million US$ at exchange rate","ISL","Iceland","2014","2014",2.9,,
+"PATCBETA","C07-Beta blocking agents","MTMOTCMT","Million US$ at exchange rate","ISL","Iceland","2015","2015",2.6,,
+"PATCBETA","C07-Beta blocking agents","MTMOTCMT","Million US$ at exchange rate","ISL","Iceland","2016","2016",2.8,,
+"PATCBETA","C07-Beta blocking agents","MTMOTCMT","Million US$ at exchange rate","ISL","Iceland","2017","2017",3.3,,
+"PATCBETA","C07-Beta blocking agents","MTMOTCMT","Million US$ at exchange rate","ISL","Iceland","2018","2018",3.4,,
+"PATCBETA","C07-Beta blocking agents","MTMOTCMT","Million US$ at exchange rate","ISL","Iceland","2019","2019",3.1,,
+"PATCBETA","C07-Beta blocking agents","MTMOTCMT","Million US$ at exchange rate","ISL","Iceland","2020","2020",3.3,,
+"PATCBETA","C07-Beta blocking agents","MTMOTCMT","Million US$ at exchange rate","ISL","Iceland","2021","2021",3.8,,
+"PATCBETA","C07-Beta blocking agents","MTMOPPMT","Million US$, purchasing power parity","ISL","Iceland","2010","2010",2.5,,
+"PATCBETA","C07-Beta blocking agents","MTMOPPMT","Million US$, purchasing power parity","ISL","Iceland","2011","2011",2.6,,
+"PATCBETA","C07-Beta blocking agents","MTMOPPMT","Million US$, purchasing power parity","ISL","Iceland","2012","2012",2.5,,
+"PATCBETA","C07-Beta blocking agents","MTMOPPMT","Million US$, purchasing power parity","ISL","Iceland","2013","2013",2.6,,
+"PATCBETA","C07-Beta blocking agents","MTMOPPMT","Million US$, purchasing power parity","ISL","Iceland","2014","2014",2.5,,
+"PATCBETA","C07-Beta blocking agents","MTMOPPMT","Million US$, purchasing power parity","ISL","Iceland","2015","2015",2.4,,
+"PATCBETA","C07-Beta blocking agents","MTMOPPMT","Million US$, purchasing power parity","ISL","Iceland","2016","2016",2.4,,
+"PATCBETA","C07-Beta blocking agents","MTMOPPMT","Million US$, purchasing power parity","ISL","Iceland","2017","2017",2.5,,
+"PATCBETA","C07-Beta blocking agents","MTMOPPMT","Million US$, purchasing power parity","ISL","Iceland","2018","2018",2.6,,
+"PATCBETA","C07-Beta blocking agents","MTMOPPMT","Million US$, purchasing power parity","ISL","Iceland","2019","2019",2.7,,
+"PATCBETA","C07-Beta blocking agents","MTMOPPMT","Million US$, purchasing power parity","ISL","Iceland","2020","2020",3,,
+"PATCBETA","C07-Beta blocking agents","MTMOPPMT","Million US$, purchasing power parity","ISL","Iceland","2021","2021",3.2,,
+"PATCBETA","C07-Beta blocking agents","TCPPERMT","/capita, US$ exchange rate","ISL","Iceland","2010","2010",8.4,,
+"PATCBETA","C07-Beta blocking agents","TCPPERMT","/capita, US$ exchange rate","ISL","Iceland","2011","2011",9.4,,
+"PATCBETA","C07-Beta blocking agents","TCPPERMT","/capita, US$ exchange rate","ISL","Iceland","2012","2012",8.6,,
+"PATCBETA","C07-Beta blocking agents","TCPPERMT","/capita, US$ exchange rate","ISL","Iceland","2013","2013",8.9,,
+"PATCBETA","C07-Beta blocking agents","TCPPERMT","/capita, US$ exchange rate","ISL","Iceland","2014","2014",8.9,,
+"PATCBETA","C07-Beta blocking agents","TCPPERMT","/capita, US$ exchange rate","ISL","Iceland","2015","2015",7.8,,
+"PATCBETA","C07-Beta blocking agents","TCPPERMT","/capita, US$ exchange rate","ISL","Iceland","2016","2016",8.4,,
+"PATCBETA","C07-Beta blocking agents","TCPPERMT","/capita, US$ exchange rate","ISL","Iceland","2017","2017",9.5,,
+"PATCBETA","C07-Beta blocking agents","TCPPERMT","/capita, US$ exchange rate","ISL","Iceland","2018","2018",9.6,,
+"PATCBETA","C07-Beta blocking agents","TCPPERMT","/capita, US$ exchange rate","ISL","Iceland","2019","2019",8.6,,
+"PATCBETA","C07-Beta blocking agents","TCPPERMT","/capita, US$ exchange rate","ISL","Iceland","2020","2020",8.9,,
+"PATCBETA","C07-Beta blocking agents","TCPPERMT","/capita, US$ exchange rate","ISL","Iceland","2021","2021",10.2,,
+"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2010","2010",7.7,,
+"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2011","2011",8,,
+"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2012","2012",7.9,,
+"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2013","2013",8,,
+"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2014","2014",7.5,,
+"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2015","2015",7.2,,
+"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2016","2016",7.2,,
+"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2017","2017",7.4,,
+"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2018","2018",7.4,,
+"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2019","2019",7.5,,
+"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2020","2020",8.2,,
+"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2021","2021",8.6,,
+"PATCBETA","C07-Beta blocking agents","ATCPTTMT","% of total sales","ISL","Iceland","2010","2010",1.3,,
+"PATCBETA","C07-Beta blocking agents","ATCPTTMT","% of total sales","ISL","Iceland","2011","2011",1.3,,
+"PATCBETA","C07-Beta blocking agents","ATCPTTMT","% of total sales","ISL","Iceland","2012","2012",1.4,,
+"PATCBETA","C07-Beta blocking agents","ATCPTTMT","% of total sales","ISL","Iceland","2013","2013",1.4,,
+"PATCBETA","C07-Beta blocking agents","ATCPTTMT","% of total sales","ISL","Iceland","2014","2014",1.4,,
+"PATCBETA","C07-Beta blocking agents","ATCPTTMT","% of total sales","ISL","Iceland","2015","2015",1.4,,
+"PATCBETA","C07-Beta blocking agents","ATCPTTMT","% of total sales","ISL","Iceland","2016","2016",1.3,,
+"PATCBETA","C07-Beta blocking agents","ATCPTTMT","% of total sales","ISL","Iceland","2017","2017",1.3,,
+"PATCBETA","C07-Beta blocking agents","ATCPTTMT","% of total sales","ISL","Iceland","2018","2018",1.2,,
+"PATCBETA","C07-Beta blocking agents","ATCPTTMT","% of total sales","ISL","Iceland","2019","2019",1.1,,
+"PATCBETA","C07-Beta blocking agents","ATCPTTMT","% of total sales","ISL","Iceland","2020","2020",1.1,,
+"PATCBETA","C07-Beta blocking agents","ATCPTTMT","% of total sales","ISL","Iceland","2021","2021",1.1,,
+"PATCBETA","C07-Beta blocking agents","MLLNCUMT","Million of national currency units","IRL","Ireland","2010","2010",27.4,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","MLLNCUMT","Million of national currency units","IRL","Ireland","2011","2011",23.3,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","MLLNCUMT","Million of national currency units","IRL","Ireland","2012","2012",23.7,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","MLLNCUMT","Million of national currency units","IRL","Ireland","2013","2013",23.6,"B; D","Break; Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","MLLNCUMT","Million of national currency units","IRL","Ireland","2014","2014",23.4,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","MLLNCUMT","Million of national currency units","IRL","Ireland","2015","2015",22.7,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","MLLNCUMT","Million of national currency units","IRL","Ireland","2016","2016",22.9,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","MLLNCUMT","Million of national currency units","IRL","Ireland","2017","2017",22.5,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","MLLNCUMT","Million of national currency units","IRL","Ireland","2018","2018",21.9,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","MLLNCUMT","Million of national currency units","IRL","Ireland","2019","2019",21.4,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","MLLNCUMT","Million of national currency units","IRL","Ireland","2020","2020",21.4,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","MLLNCUMT","Million of national currency units","IRL","Ireland","2021","2021",21.6,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","MTMOTCMT","Million US$ at exchange rate","IRL","Ireland","2010","2010",36.3,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","MTMOTCMT","Million US$ at exchange rate","IRL","Ireland","2011","2011",32.4,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","MTMOTCMT","Million US$ at exchange rate","IRL","Ireland","2012","2012",30.4,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","MTMOTCMT","Million US$ at exchange rate","IRL","Ireland","2013","2013",31.3,"B; D","Break; Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","MTMOTCMT","Million US$ at exchange rate","IRL","Ireland","2014","2014",31,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","MTMOTCMT","Million US$ at exchange rate","IRL","Ireland","2015","2015",25.2,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","MTMOTCMT","Million US$ at exchange rate","IRL","Ireland","2016","2016",25.4,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","MTMOTCMT","Million US$ at exchange rate","IRL","Ireland","2017","2017",25.4,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","MTMOTCMT","Million US$ at exchange rate","IRL","Ireland","2018","2018",25.8,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","MTMOTCMT","Million US$ at exchange rate","IRL","Ireland","2019","2019",24,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","MTMOTCMT","Million US$ at exchange rate","IRL","Ireland","2020","2020",24.4,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","MTMOTCMT","Million US$ at exchange rate","IRL","Ireland","2021","2021",25.6,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","MTMOPPMT","Million US$, purchasing power parity","IRL","Ireland","2010","2010",32.2,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","MTMOPPMT","Million US$, purchasing power parity","IRL","Ireland","2011","2011",28,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","MTMOPPMT","Million US$, purchasing power parity","IRL","Ireland","2012","2012",28.7,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","MTMOPPMT","Million US$, purchasing power parity","IRL","Ireland","2013","2013",29,"B; D","Break; Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","MTMOPPMT","Million US$, purchasing power parity","IRL","Ireland","2014","2014",28.5,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","MTMOPPMT","Million US$, purchasing power parity","IRL","Ireland","2015","2015",28,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","MTMOPPMT","Million US$, purchasing power parity","IRL","Ireland","2016","2016",28.9,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","MTMOPPMT","Million US$, purchasing power parity","IRL","Ireland","2017","2017",28.3,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","MTMOPPMT","Million US$, purchasing power parity","IRL","Ireland","2018","2018",27.6,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","MTMOPPMT","Million US$, purchasing power parity","IRL","Ireland","2019","2019",26.6,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","MTMOPPMT","Million US$, purchasing power parity","IRL","Ireland","2020","2020",26.8,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","MTMOPPMT","Million US$, purchasing power parity","IRL","Ireland","2021","2021",27.2,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","TCPPERMT","/capita, US$ exchange rate","IRL","Ireland","2010","2010",8,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","TCPPERMT","/capita, US$ exchange rate","IRL","Ireland","2011","2011",7.1,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","TCPPERMT","/capita, US$ exchange rate","IRL","Ireland","2012","2012",6.6,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","TCPPERMT","/capita, US$ exchange rate","IRL","Ireland","2013","2013",6.8,"B; D","Break; Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","TCPPERMT","/capita, US$ exchange rate","IRL","Ireland","2014","2014",6.7,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","TCPPERMT","/capita, US$ exchange rate","IRL","Ireland","2015","2015",5.4,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","TCPPERMT","/capita, US$ exchange rate","IRL","Ireland","2016","2016",5.3,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","TCPPERMT","/capita, US$ exchange rate","IRL","Ireland","2017","2017",5.3,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","TCPPERMT","/capita, US$ exchange rate","IRL","Ireland","2018","2018",5.3,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","TCPPERMT","/capita, US$ exchange rate","IRL","Ireland","2019","2019",4.9,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","TCPPERMT","/capita, US$ exchange rate","IRL","Ireland","2020","2020",4.9,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","TCPPERMT","/capita, US$ exchange rate","IRL","Ireland","2021","2021",5.1,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2010","2010",7.1,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2011","2011",6.1,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2012","2012",6.2,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2013","2013",6.3,"B; D","Break; Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2014","2014",6.1,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2015","2015",6,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2016","2016",6.1,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2017","2017",5.9,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2018","2018",5.7,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2019","2019",5.4,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2020","2020",5.4,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2021","2021",5.4,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","ATCPTTMT","% of total sales","IRL","Ireland","2010","2010",1.3,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","ATCPTTMT","% of total sales","IRL","Ireland","2011","2011",1.2,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","ATCPTTMT","% of total sales","IRL","Ireland","2012","2012",1.2,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","ATCPTTMT","% of total sales","IRL","Ireland","2013","2013",1.2,"B; D","Break; Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","ATCPTTMT","% of total sales","IRL","Ireland","2014","2014",1.2,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","ATCPTTMT","% of total sales","IRL","Ireland","2015","2015",1.1,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","ATCPTTMT","% of total sales","IRL","Ireland","2016","2016",1.1,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","ATCPTTMT","% of total sales","IRL","Ireland","2017","2017",1.1,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","ATCPTTMT","% of total sales","IRL","Ireland","2018","2018",1,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","ATCPTTMT","% of total sales","IRL","Ireland","2019","2019",0.9,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","ATCPTTMT","% of total sales","IRL","Ireland","2020","2020",0.9,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","ATCPTTMT","% of total sales","IRL","Ireland","2021","2021",0.8,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","MLLNCUMT","Million of national currency units","ITA","Italy","2011","2011",284.5,,
+"PATCBETA","C07-Beta blocking agents","MLLNCUMT","Million of national currency units","ITA","Italy","2012","2012",289.7,,
+"PATCBETA","C07-Beta blocking agents","MLLNCUMT","Million of national currency units","ITA","Italy","2013","2013",302.8,,
+"PATCBETA","C07-Beta blocking agents","MLLNCUMT","Million of national currency units","ITA","Italy","2014","2014",323.3,,
+"PATCBETA","C07-Beta blocking agents","MLLNCUMT","Million of national currency units","ITA","Italy","2015","2015",333.3,,
+"PATCBETA","C07-Beta blocking agents","MLLNCUMT","Million of national currency units","ITA","Italy","2016","2016",343.2,,
+"PATCBETA","C07-Beta blocking agents","MLLNCUMT","Million of national currency units","ITA","Italy","2017","2017",347.7,,
+"PATCBETA","C07-Beta blocking agents","MLLNCUMT","Million of national currency units","ITA","Italy","2018","2018",352.2,,
+"PATCBETA","C07-Beta blocking agents","MLLNCUMT","Million of national currency units","ITA","Italy","2019","2019",359.6,,
+"PATCBETA","C07-Beta blocking agents","MLLNCUMT","Million of national currency units","ITA","Italy","2020","2020",369.2,,
+"PATCBETA","C07-Beta blocking agents","MLLNCUMT","Million of national currency units","ITA","Italy","2021","2021",373.6,,
+"PATCBETA","C07-Beta blocking agents","MLLNCUMT","Million of national currency units","ITA","Italy","2022","2022",375.1,"E","Estimated value"
+"PATCBETA","C07-Beta blocking agents","MTMOTCMT","Million US$ at exchange rate","ITA","Italy","2011","2011",396,,
+"PATCBETA","C07-Beta blocking agents","MTMOTCMT","Million US$ at exchange rate","ITA","Italy","2012","2012",372.2,,
+"PATCBETA","C07-Beta blocking agents","MTMOTCMT","Million US$ at exchange rate","ITA","Italy","2013","2013",402.1,,
+"PATCBETA","C07-Beta blocking agents","MTMOTCMT","Million US$ at exchange rate","ITA","Italy","2014","2014",429.5,,
+"PATCBETA","C07-Beta blocking agents","MTMOTCMT","Million US$ at exchange rate","ITA","Italy","2015","2015",369.8,,
+"PATCBETA","C07-Beta blocking agents","MTMOTCMT","Million US$ at exchange rate","ITA","Italy","2016","2016",379.9,,
+"PATCBETA","C07-Beta blocking agents","MTMOTCMT","Million US$ at exchange rate","ITA","Italy","2017","2017",392.8,,
+"PATCBETA","C07-Beta blocking agents","MTMOTCMT","Million US$ at exchange rate","ITA","Italy","2018","2018",416,,
+"PATCBETA","C07-Beta blocking agents","MTMOTCMT","Million US$ at exchange rate","ITA","Italy","2019","2019",402.5,,
+"PATCBETA","C07-Beta blocking agents","MTMOTCMT","Million US$ at exchange rate","ITA","Italy","2020","2020",421.7,,
+"PATCBETA","C07-Beta blocking agents","MTMOTCMT","Million US$ at exchange rate","ITA","Italy","2021","2021",441.9,,
+"PATCBETA","C07-Beta blocking agents","MTMOTCMT","Million US$ at exchange rate","ITA","Italy","2022","2022",395,"E","Estimated value"
+"PATCBETA","C07-Beta blocking agents","MTMOPPMT","Million US$, purchasing power parity","ITA","Italy","2011","2011",375,,
+"PATCBETA","C07-Beta blocking agents","MTMOPPMT","Million US$, purchasing power parity","ITA","Italy","2012","2012",387.4,,
+"PATCBETA","C07-Beta blocking agents","MTMOPPMT","Million US$, purchasing power parity","ITA","Italy","2013","2013",410.7,,
+"PATCBETA","C07-Beta blocking agents","MTMOPPMT","Million US$, purchasing power parity","ITA","Italy","2014","2014",437.1,,
+"PATCBETA","C07-Beta blocking agents","MTMOPPMT","Million US$, purchasing power parity","ITA","Italy","2015","2015",451.2,,
+"PATCBETA","C07-Beta blocking agents","MTMOPPMT","Million US$, purchasing power parity","ITA","Italy","2016","2016",489.9,,
+"PATCBETA","C07-Beta blocking agents","MTMOPPMT","Million US$, purchasing power parity","ITA","Italy","2017","2017",504,,
+"PATCBETA","C07-Beta blocking agents","MTMOPPMT","Million US$, purchasing power parity","ITA","Italy","2018","2018",517,,
+"PATCBETA","C07-Beta blocking agents","MTMOPPMT","Million US$, purchasing power parity","ITA","Italy","2019","2019",547.5,,
+"PATCBETA","C07-Beta blocking agents","MTMOPPMT","Million US$, purchasing power parity","ITA","Italy","2020","2020",570,,
+"PATCBETA","C07-Beta blocking agents","MTMOPPMT","Million US$, purchasing power parity","ITA","Italy","2021","2021",576.9,,
+"PATCBETA","C07-Beta blocking agents","MTMOPPMT","Million US$, purchasing power parity","ITA","Italy","2022","2022",607.5,"E","Estimated value"
+"PATCBETA","C07-Beta blocking agents","TCPPERMT","/capita, US$ exchange rate","ITA","Italy","2011","2011",6.7,,
+"PATCBETA","C07-Beta blocking agents","TCPPERMT","/capita, US$ exchange rate","ITA","Italy","2012","2012",6.3,,
+"PATCBETA","C07-Beta blocking agents","TCPPERMT","/capita, US$ exchange rate","ITA","Italy","2013","2013",6.7,,
+"PATCBETA","C07-Beta blocking agents","TCPPERMT","/capita, US$ exchange rate","ITA","Italy","2014","2014",7.1,,
+"PATCBETA","C07-Beta blocking agents","TCPPERMT","/capita, US$ exchange rate","ITA","Italy","2015","2015",6.1,,
+"PATCBETA","C07-Beta blocking agents","TCPPERMT","/capita, US$ exchange rate","ITA","Italy","2016","2016",6.3,,
+"PATCBETA","C07-Beta blocking agents","TCPPERMT","/capita, US$ exchange rate","ITA","Italy","2017","2017",6.5,,
+"PATCBETA","C07-Beta blocking agents","TCPPERMT","/capita, US$ exchange rate","ITA","Italy","2018","2018",6.9,,
+"PATCBETA","C07-Beta blocking agents","TCPPERMT","/capita, US$ exchange rate","ITA","Italy","2019","2019",6.7,,
+"PATCBETA","C07-Beta blocking agents","TCPPERMT","/capita, US$ exchange rate","ITA","Italy","2020","2020",7.1,,
+"PATCBETA","C07-Beta blocking agents","TCPPERMT","/capita, US$ exchange rate","ITA","Italy","2021","2021",7.5,,
+"PATCBETA","C07-Beta blocking agents","TCPPERMT","/capita, US$ exchange rate","ITA","Italy","2022","2022",6.7,"E","Estimated value"
+"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2011","2011",6.3,,
+"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2012","2012",6.5,,
+"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2013","2013",6.8,,
+"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2014","2014",7.2,,
+"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2015","2015",7.4,,
+"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2016","2016",8.1,,
+"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2017","2017",8.3,,
+"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2018","2018",8.6,,
+"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2019","2019",9.2,,
+"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2020","2020",9.6,,
+"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2021","2021",9.8,,
+"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2022","2022",10.3,"E","Estimated value"
+"PATCBETA","C07-Beta blocking agents","ATCPTTMT","% of total sales","ITA","Italy","2011","2011",1.5,,
+"PATCBETA","C07-Beta blocking agents","ATCPTTMT","% of total sales","ITA","Italy","2012","2012",1.5,,
+"PATCBETA","C07-Beta blocking agents","ATCPTTMT","% of total sales","ITA","Italy","2013","2013",1.6,,
+"PATCBETA","C07-Beta blocking agents","ATCPTTMT","% of total sales","ITA","Italy","2014","2014",1.6,,
+"PATCBETA","C07-Beta blocking agents","ATCPTTMT","% of total sales","ITA","Italy","2015","2015",1.5,,
+"PATCBETA","C07-Beta blocking agents","ATCPTTMT","% of total sales","ITA","Italy","2016","2016",1.5,,
+"PATCBETA","C07-Beta blocking agents","ATCPTTMT","% of total sales","ITA","Italy","2017","2017",1.5,,
+"PATCBETA","C07-Beta blocking agents","ATCPTTMT","% of total sales","ITA","Italy","2018","2018",1.6,,
+"PATCBETA","C07-Beta blocking agents","ATCPTTMT","% of total sales","ITA","Italy","2019","2019",1.6,,
+"PATCBETA","C07-Beta blocking agents","ATCPTTMT","% of total sales","ITA","Italy","2020","2020",1.6,,
+"PATCBETA","C07-Beta blocking agents","ATCPTTMT","% of total sales","ITA","Italy","2021","2021",1.6,,
+"PATCBETA","C07-Beta blocking agents","ATCPTTMT","% of total sales","ITA","Italy","2022","2022",1.5,"E","Estimated value"
+"PATCBETA","C07-Beta blocking agents","MLLNCUMT","Million of national currency units","KOR","Korea","2010","2010",200847,,
+"PATCBETA","C07-Beta blocking agents","MLLNCUMT","Million of national currency units","KOR","Korea","2011","2011",194869,"B","Break"
+"PATCBETA","C07-Beta blocking agents","MLLNCUMT","Million of national currency units","KOR","Korea","2012","2012",152919.7,,
+"PATCBETA","C07-Beta blocking agents","MLLNCUMT","Million of national currency units","KOR","Korea","2013","2013",133036.2,,
+"PATCBETA","C07-Beta blocking agents","MLLNCUMT","Million of national currency units","KOR","Korea","2014","2014",127839.8,,
+"PATCBETA","C07-Beta blocking agents","MLLNCUMT","Million of national currency units","KOR","Korea","2015","2015",127385.5,,
+"PATCBETA","C07-Beta blocking agents","MLLNCUMT","Million of national currency units","KOR","Korea","2016","2016",123930.9,"B","Break"
+"PATCBETA","C07-Beta blocking agents","MLLNCUMT","Million of national currency units","KOR","Korea","2017","2017",126933.9,,
+"PATCBETA","C07-Beta blocking agents","MLLNCUMT","Million of national currency units","KOR","Korea","2018","2018",132278.2,,
+"PATCBETA","C07-Beta blocking agents","MLLNCUMT","Million of national currency units","KOR","Korea","2019","2019",134990.7,,
+"PATCBETA","C07-Beta blocking agents","MLLNCUMT","Million of national currency units","KOR","Korea","2020","2020",145065.4,,
+"PATCBETA","C07-Beta blocking agents","MLLNCUMT","Million of national currency units","KOR","Korea","2021","2021",151300.6,,
+"PATCBETA","C07-Beta blocking agents","MTMOTCMT","Million US$ at exchange rate","KOR","Korea","2010","2010",173.7,,
+"PATCBETA","C07-Beta blocking agents","MTMOTCMT","Million US$ at exchange rate","KOR","Korea","2011","2011",175.8,"B","Break"
+"PATCBETA","C07-Beta blocking agents","MTMOTCMT","Million US$ at exchange rate","KOR","Korea","2012","2012",135.7,,
+"PATCBETA","C07-Beta blocking agents","MTMOTCMT","Million US$ at exchange rate","KOR","Korea","2013","2013",121.5,,
+"PATCBETA","C07-Beta blocking agents","MTMOTCMT","Million US$ at exchange rate","KOR","Korea","2014","2014",121.4,,
+"PATCBETA","C07-Beta blocking agents","MTMOTCMT","Million US$ at exchange rate","KOR","Korea","2015","2015",112.6,,
+"PATCBETA","C07-Beta blocking agents","MTMOTCMT","Million US$ at exchange rate","KOR","Korea","2016","2016",106.8,"B","Break"
+"PATCBETA","C07-Beta blocking agents","MTMOTCMT","Million US$ at exchange rate","KOR","Korea","2017","2017",112.2,,
+"PATCBETA","C07-Beta blocking agents","MTMOTCMT","Million US$ at exchange rate","KOR","Korea","2018","2018",120.2,,
+"PATCBETA","C07-Beta blocking agents","MTMOTCMT","Million US$ at exchange rate","KOR","Korea","2019","2019",115.8,,
+"PATCBETA","C07-Beta blocking agents","MTMOTCMT","Million US$ at exchange rate","KOR","Korea","2020","2020",122.9,,
+"PATCBETA","C07-Beta blocking agents","MTMOTCMT","Million US$ at exchange rate","KOR","Korea","2021","2021",132.3,,
+"PATCBETA","C07-Beta blocking agents","MTMOPPMT","Million US$, purchasing power parity","KOR","Korea","2010","2010",238.8,,
+"PATCBETA","C07-Beta blocking agents","MTMOPPMT","Million US$, purchasing power parity","KOR","Korea","2011","2011",228,"B","Break"
+"PATCBETA","C07-Beta blocking agents","MTMOPPMT","Million US$, purchasing power parity","KOR","Korea","2012","2012",178.9,,
+"PATCBETA","C07-Beta blocking agents","MTMOPPMT","Million US$, purchasing power parity","KOR","Korea","2013","2013",153.1,,
+"PATCBETA","C07-Beta blocking agents","MTMOPPMT","Million US$, purchasing power parity","KOR","Korea","2014","2014",146.6,,
+"PATCBETA","C07-Beta blocking agents","MTMOPPMT","Million US$, purchasing power parity","KOR","Korea","2015","2015",148.6,,
+"PATCBETA","C07-Beta blocking agents","MTMOPPMT","Million US$, purchasing power parity","KOR","Korea","2016","2016",144.3,"B","Break"
+"PATCBETA","C07-Beta blocking agents","MTMOPPMT","Million US$, purchasing power parity","KOR","Korea","2017","2017",145.5,,
+"PATCBETA","C07-Beta blocking agents","MTMOPPMT","Million US$, purchasing power parity","KOR","Korea","2018","2018",154.7,,
+"PATCBETA","C07-Beta blocking agents","MTMOPPMT","Million US$, purchasing power parity","KOR","Korea","2019","2019",157.6,,
+"PATCBETA","C07-Beta blocking agents","MTMOPPMT","Million US$, purchasing power parity","KOR","Korea","2020","2020",173.2,,
+"PATCBETA","C07-Beta blocking agents","MTMOPPMT","Million US$, purchasing power parity","KOR","Korea","2021","2021",177.1,,
+"PATCBETA","C07-Beta blocking agents","TCPPERMT","/capita, US$ exchange rate","KOR","Korea","2010","2010",3.5,,
+"PATCBETA","C07-Beta blocking agents","TCPPERMT","/capita, US$ exchange rate","KOR","Korea","2011","2011",3.5,"B","Break"
+"PATCBETA","C07-Beta blocking agents","TCPPERMT","/capita, US$ exchange rate","KOR","Korea","2012","2012",2.7,,
+"PATCBETA","C07-Beta blocking agents","TCPPERMT","/capita, US$ exchange rate","KOR","Korea","2013","2013",2.4,,
+"PATCBETA","C07-Beta blocking agents","TCPPERMT","/capita, US$ exchange rate","KOR","Korea","2014","2014",2.4,,
+"PATCBETA","C07-Beta blocking agents","TCPPERMT","/capita, US$ exchange rate","KOR","Korea","2015","2015",2.2,,
+"PATCBETA","C07-Beta blocking agents","TCPPERMT","/capita, US$ exchange rate","KOR","Korea","2016","2016",2.1,"B","Break"
+"PATCBETA","C07-Beta blocking agents","TCPPERMT","/capita, US$ exchange rate","KOR","Korea","2017","2017",2.2,,
+"PATCBETA","C07-Beta blocking agents","TCPPERMT","/capita, US$ exchange rate","KOR","Korea","2018","2018",2.3,,
+"PATCBETA","C07-Beta blocking agents","TCPPERMT","/capita, US$ exchange rate","KOR","Korea","2019","2019",2.2,,
+"PATCBETA","C07-Beta blocking agents","TCPPERMT","/capita, US$ exchange rate","KOR","Korea","2020","2020",2.4,,
+"PATCBETA","C07-Beta blocking agents","TCPPERMT","/capita, US$ exchange rate","KOR","Korea","2021","2021",2.6,,
+"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2010","2010",4.8,,
+"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2011","2011",4.6,"B","Break"
+"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2012","2012",3.6,,
+"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2013","2013",3,,
+"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2014","2014",2.9,,
+"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2015","2015",2.9,,
+"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2016","2016",2.8,"B","Break"
+"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2017","2017",2.8,,
+"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2018","2018",3,,
+"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2019","2019",3,,
+"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2020","2020",3.3,,
+"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2021","2021",3.4,,
+"PATCBETA","C07-Beta blocking agents","ATCPTTMT","% of total sales","KOR","Korea","2010","2010",1,,
+"PATCBETA","C07-Beta blocking agents","ATCPTTMT","% of total sales","KOR","Korea","2011","2011",0.9,"B","Break"
+"PATCBETA","C07-Beta blocking agents","ATCPTTMT","% of total sales","KOR","Korea","2012","2012",0.7,,
+"PATCBETA","C07-Beta blocking agents","ATCPTTMT","% of total sales","KOR","Korea","2013","2013",0.6,,
+"PATCBETA","C07-Beta blocking agents","ATCPTTMT","% of total sales","KOR","Korea","2014","2014",0.5,,
+"PATCBETA","C07-Beta blocking agents","ATCPTTMT","% of total sales","KOR","Korea","2015","2015",0.5,,
+"PATCBETA","C07-Beta blocking agents","ATCPTTMT","% of total sales","KOR","Korea","2016","2016",0.5,"B","Break"
+"PATCBETA","C07-Beta blocking agents","ATCPTTMT","% of total sales","KOR","Korea","2017","2017",0.5,,
+"PATCBETA","C07-Beta blocking agents","ATCPTTMT","% of total sales","KOR","Korea","2018","2018",0.5,,
+"PATCBETA","C07-Beta blocking agents","ATCPTTMT","% of total sales","KOR","Korea","2019","2019",0.4,,
+"PATCBETA","C07-Beta blocking agents","ATCPTTMT","% of total sales","KOR","Korea","2020","2020",0.4,,
+"PATCBETA","C07-Beta blocking agents","ATCPTTMT","% of total sales","KOR","Korea","2021","2021",0.4,,
+"PATCBETA","C07-Beta blocking agents","MLLNCUMT","Million of national currency units","LUX","Luxembourg","2010","2010",3.4,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","MLLNCUMT","Million of national currency units","LUX","Luxembourg","2011","2011",3.3,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","MLLNCUMT","Million of national currency units","LUX","Luxembourg","2012","2012",3.5,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","MLLNCUMT","Million of national currency units","LUX","Luxembourg","2013","2013",3.7,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","MLLNCUMT","Million of national currency units","LUX","Luxembourg","2014","2014",3.6,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","MLLNCUMT","Million of national currency units","LUX","Luxembourg","2015","2015",3.6,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","MLLNCUMT","Million of national currency units","LUX","Luxembourg","2016","2016",3.7,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","MLLNCUMT","Million of national currency units","LUX","Luxembourg","2017","2017",3.6,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","MLLNCUMT","Million of national currency units","LUX","Luxembourg","2018","2018",3.6,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","MLLNCUMT","Million of national currency units","LUX","Luxembourg","2019","2019",3.6,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","MLLNCUMT","Million of national currency units","LUX","Luxembourg","2020","2020",3.6,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","MLLNCUMT","Million of national currency units","LUX","Luxembourg","2021","2021",3.4,"B; D; P","Break; Difference in methodology; Provisional value"
+"PATCBETA","C07-Beta blocking agents","MLLNCUMT","Million of national currency units","LUX","Luxembourg","2022","2022",3,"D; P","Difference in methodology; Provisional value"
+"PATCBETA","C07-Beta blocking agents","MTMOTCMT","Million US$ at exchange rate","LUX","Luxembourg","2010","2010",4.5,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","MTMOTCMT","Million US$ at exchange rate","LUX","Luxembourg","2011","2011",4.6,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","MTMOTCMT","Million US$ at exchange rate","LUX","Luxembourg","2012","2012",4.5,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","MTMOTCMT","Million US$ at exchange rate","LUX","Luxembourg","2013","2013",4.9,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","MTMOTCMT","Million US$ at exchange rate","LUX","Luxembourg","2014","2014",4.8,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","MTMOTCMT","Million US$ at exchange rate","LUX","Luxembourg","2015","2015",4,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","MTMOTCMT","Million US$ at exchange rate","LUX","Luxembourg","2016","2016",4.1,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","MTMOTCMT","Million US$ at exchange rate","LUX","Luxembourg","2017","2017",4.1,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","MTMOTCMT","Million US$ at exchange rate","LUX","Luxembourg","2018","2018",4.3,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","MTMOTCMT","Million US$ at exchange rate","LUX","Luxembourg","2019","2019",4,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","MTMOTCMT","Million US$ at exchange rate","LUX","Luxembourg","2020","2020",4.1,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","MTMOTCMT","Million US$ at exchange rate","LUX","Luxembourg","2021","2021",4,"B; D; P","Break; Difference in methodology; Provisional value"
+"PATCBETA","C07-Beta blocking agents","MTMOTCMT","Million US$ at exchange rate","LUX","Luxembourg","2022","2022",3.2,"D; P","Difference in methodology; Provisional value"
+"PATCBETA","C07-Beta blocking agents","MTMOPPMT","Million US$, purchasing power parity","LUX","Luxembourg","2010","2010",3.7,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","MTMOPPMT","Million US$, purchasing power parity","LUX","Luxembourg","2011","2011",3.7,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","MTMOPPMT","Million US$, purchasing power parity","LUX","Luxembourg","2012","2012",3.9,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","MTMOPPMT","Million US$, purchasing power parity","LUX","Luxembourg","2013","2013",4.1,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","MTMOPPMT","Million US$, purchasing power parity","LUX","Luxembourg","2014","2014",4.1,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","MTMOPPMT","Million US$, purchasing power parity","LUX","Luxembourg","2015","2015",4.1,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","MTMOPPMT","Million US$, purchasing power parity","LUX","Luxembourg","2016","2016",4.3,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","MTMOPPMT","Million US$, purchasing power parity","LUX","Luxembourg","2017","2017",4.2,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","MTMOPPMT","Million US$, purchasing power parity","LUX","Luxembourg","2018","2018",4.3,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","MTMOPPMT","Million US$, purchasing power parity","LUX","Luxembourg","2019","2019",4.2,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","MTMOPPMT","Million US$, purchasing power parity","LUX","Luxembourg","2020","2020",4.2,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","MTMOPPMT","Million US$, purchasing power parity","LUX","Luxembourg","2021","2021",4,"B; D; P","Break; Difference in methodology; Provisional value"
+"PATCBETA","C07-Beta blocking agents","MTMOPPMT","Million US$, purchasing power parity","LUX","Luxembourg","2022","2022",3.6,"D; P","Difference in methodology; Provisional value"
+"PATCBETA","C07-Beta blocking agents","TCPPERMT","/capita, US$ exchange rate","LUX","Luxembourg","2010","2010",9.6,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","TCPPERMT","/capita, US$ exchange rate","LUX","Luxembourg","2011","2011",9.6,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","TCPPERMT","/capita, US$ exchange rate","LUX","Luxembourg","2012","2012",9.2,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","TCPPERMT","/capita, US$ exchange rate","LUX","Luxembourg","2013","2013",9.7,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","TCPPERMT","/capita, US$ exchange rate","LUX","Luxembourg","2014","2014",9.4,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","TCPPERMT","/capita, US$ exchange rate","LUX","Luxembourg","2015","2015",7.7,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","TCPPERMT","/capita, US$ exchange rate","LUX","Luxembourg","2016","2016",7.7,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","TCPPERMT","/capita, US$ exchange rate","LUX","Luxembourg","2017","2017",7.6,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","TCPPERMT","/capita, US$ exchange rate","LUX","Luxembourg","2018","2018",7.8,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","TCPPERMT","/capita, US$ exchange rate","LUX","Luxembourg","2019","2019",7.2,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","TCPPERMT","/capita, US$ exchange rate","LUX","Luxembourg","2020","2020",7.3,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","TCPPERMT","/capita, US$ exchange rate","LUX","Luxembourg","2021","2021",7,"B; D; P","Break; Difference in methodology; Provisional value"
+"PATCBETA","C07-Beta blocking agents","TCPPERMT","/capita, US$ exchange rate","LUX","Luxembourg","2022","2022",5.4,"D; P","Difference in methodology; Provisional value"
+"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2010","2010",7.8,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2011","2011",7.6,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2012","2012",7.9,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2013","2013",8.1,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2014","2014",8,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2015","2015",7.9,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2016","2016",8.2,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2017","2017",7.9,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2018","2018",7.8,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2019","2019",7.6,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2020","2020",7.4,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2021","2021",6.9,"B; D; P","Break; Difference in methodology; Provisional value"
+"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2022","2022",6.2,"D; P","Difference in methodology; Provisional value"
+"PATCBETA","C07-Beta blocking agents","ATCPTTMT","% of total sales","LUX","Luxembourg","2010","2010",1.8,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","ATCPTTMT","% of total sales","LUX","Luxembourg","2011","2011",1.7,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","ATCPTTMT","% of total sales","LUX","Luxembourg","2012","2012",1.8,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","ATCPTTMT","% of total sales","LUX","Luxembourg","2013","2013",1.9,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","ATCPTTMT","% of total sales","LUX","Luxembourg","2014","2014",1.9,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","ATCPTTMT","% of total sales","LUX","Luxembourg","2015","2015",1.9,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","ATCPTTMT","% of total sales","LUX","Luxembourg","2016","2016",1.9,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","ATCPTTMT","% of total sales","LUX","Luxembourg","2017","2017",1.8,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","ATCPTTMT","% of total sales","LUX","Luxembourg","2018","2018",1.8,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","ATCPTTMT","% of total sales","LUX","Luxembourg","2019","2019",1.7,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","ATCPTTMT","% of total sales","LUX","Luxembourg","2020","2020",1.7,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","ATCPTTMT","% of total sales","LUX","Luxembourg","2021","2021",1.4,"B; D; P","Break; Difference in methodology; Provisional value"
+"PATCBETA","C07-Beta blocking agents","ATCPTTMT","% of total sales","LUX","Luxembourg","2022","2022",1.2,"D; P","Difference in methodology; Provisional value"
+"PATCBETA","C07-Beta blocking agents","MLLNCUMT","Million of national currency units","NLD","Netherlands","2010","2010",110.5,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","MLLNCUMT","Million of national currency units","NLD","Netherlands","2011","2011",96.6,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","MLLNCUMT","Million of national currency units","NLD","Netherlands","2012","2012",93.9,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","MLLNCUMT","Million of national currency units","NLD","Netherlands","2013","2013",93.9,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","MLLNCUMT","Million of national currency units","NLD","Netherlands","2014","2014",93.3,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","MTMOTCMT","Million US$ at exchange rate","NLD","Netherlands","2010","2010",146.4,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","MTMOTCMT","Million US$ at exchange rate","NLD","Netherlands","2011","2011",134.4,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","MTMOTCMT","Million US$ at exchange rate","NLD","Netherlands","2012","2012",120.7,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","MTMOTCMT","Million US$ at exchange rate","NLD","Netherlands","2013","2013",124.7,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","MTMOTCMT","Million US$ at exchange rate","NLD","Netherlands","2014","2014",123.9,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","MTMOPPMT","Million US$, purchasing power parity","NLD","Netherlands","2010","2010",129.3,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","MTMOPPMT","Million US$, purchasing power parity","NLD","Netherlands","2011","2011",115.5,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","MTMOPPMT","Million US$, purchasing power parity","NLD","Netherlands","2012","2012",113.9,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","MTMOPPMT","Million US$, purchasing power parity","NLD","Netherlands","2013","2013",117.7,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","MTMOPPMT","Million US$, purchasing power parity","NLD","Netherlands","2014","2014",115.3,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","TCPPERMT","/capita, US$ exchange rate","NLD","Netherlands","2010","2010",8.8,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","TCPPERMT","/capita, US$ exchange rate","NLD","Netherlands","2011","2011",8.1,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","TCPPERMT","/capita, US$ exchange rate","NLD","Netherlands","2012","2012",7.2,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","TCPPERMT","/capita, US$ exchange rate","NLD","Netherlands","2013","2013",7.4,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","TCPPERMT","/capita, US$ exchange rate","NLD","Netherlands","2014","2014",7.3,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","NLD","Netherlands","2010","2010",7.8,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","NLD","Netherlands","2011","2011",6.9,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","NLD","Netherlands","2012","2012",6.8,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","NLD","Netherlands","2013","2013",7,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","NLD","Netherlands","2014","2014",6.8,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","ATCPTTMT","% of total sales","NLD","Netherlands","2010","2010",2.1,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","ATCPTTMT","% of total sales","NLD","Netherlands","2011","2011",1.9,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","ATCPTTMT","% of total sales","NLD","Netherlands","2012","2012",2,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","ATCPTTMT","% of total sales","NLD","Netherlands","2013","2013",2.2,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","ATCPTTMT","% of total sales","NLD","Netherlands","2014","2014",2.2,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","MLLNCUMT","Million of national currency units","NZL","New Zealand","2010","2010",23.3,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","MLLNCUMT","Million of national currency units","NZL","New Zealand","2011","2011",18.2,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","MLLNCUMT","Million of national currency units","NZL","New Zealand","2012","2012",18.5,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","MLLNCUMT","Million of national currency units","NZL","New Zealand","2013","2013",14.4,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","MLLNCUMT","Million of national currency units","NZL","New Zealand","2014","2014",14.7,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","MLLNCUMT","Million of national currency units","NZL","New Zealand","2015","2015",14.1,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","MLLNCUMT","Million of national currency units","NZL","New Zealand","2016","2016",7.9,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","MLLNCUMT","Million of national currency units","NZL","New Zealand","2017","2017",12.1,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","MLLNCUMT","Million of national currency units","NZL","New Zealand","2018","2018",7.8,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","MLLNCUMT","Million of national currency units","NZL","New Zealand","2019","2019",7.3,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","MLLNCUMT","Million of national currency units","NZL","New Zealand","2020","2020",6.9,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","MLLNCUMT","Million of national currency units","NZL","New Zealand","2021","2021",8.1,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","MLLNCUMT","Million of national currency units","NZL","New Zealand","2022","2022",7.8,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","MTMOTCMT","Million US$ at exchange rate","NZL","New Zealand","2010","2010",16.8,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","MTMOTCMT","Million US$ at exchange rate","NZL","New Zealand","2011","2011",14.4,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","MTMOTCMT","Million US$ at exchange rate","NZL","New Zealand","2012","2012",15,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","MTMOTCMT","Million US$ at exchange rate","NZL","New Zealand","2013","2013",11.8,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","MTMOTCMT","Million US$ at exchange rate","NZL","New Zealand","2014","2014",12.2,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","MTMOTCMT","Million US$ at exchange rate","NZL","New Zealand","2015","2015",9.9,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","MTMOTCMT","Million US$ at exchange rate","NZL","New Zealand","2016","2016",5.5,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","MTMOTCMT","Million US$ at exchange rate","NZL","New Zealand","2017","2017",8.6,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","MTMOTCMT","Million US$ at exchange rate","NZL","New Zealand","2018","2018",5.4,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","MTMOTCMT","Million US$ at exchange rate","NZL","New Zealand","2019","2019",4.8,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","MTMOTCMT","Million US$ at exchange rate","NZL","New Zealand","2020","2020",4.5,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","MTMOTCMT","Million US$ at exchange rate","NZL","New Zealand","2021","2021",5.7,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","MTMOTCMT","Million US$ at exchange rate","NZL","New Zealand","2022","2022",5,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","MTMOPPMT","Million US$, purchasing power parity","NZL","New Zealand","2010","2010",15.6,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","MTMOPPMT","Million US$, purchasing power parity","NZL","New Zealand","2011","2011",12.3,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","MTMOPPMT","Million US$, purchasing power parity","NZL","New Zealand","2012","2012",12.4,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","MTMOPPMT","Million US$, purchasing power parity","NZL","New Zealand","2013","2013",10,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","MTMOPPMT","Million US$, purchasing power parity","NZL","New Zealand","2014","2014",10.2,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","MTMOPPMT","Million US$, purchasing power parity","NZL","New Zealand","2015","2015",9.6,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","MTMOPPMT","Million US$, purchasing power parity","NZL","New Zealand","2016","2016",5.5,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","MTMOPPMT","Million US$, purchasing power parity","NZL","New Zealand","2017","2017",8.5,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","MTMOPPMT","Million US$, purchasing power parity","NZL","New Zealand","2018","2018",5.3,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","MTMOPPMT","Million US$, purchasing power parity","NZL","New Zealand","2019","2019",5.1,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","MTMOPPMT","Million US$, purchasing power parity","NZL","New Zealand","2020","2020",4.9,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","MTMOPPMT","Million US$, purchasing power parity","NZL","New Zealand","2021","2021",5.5,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","MTMOPPMT","Million US$, purchasing power parity","NZL","New Zealand","2022","2022",5.4,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","TCPPERMT","/capita, US$ exchange rate","NZL","New Zealand","2010","2010",3.9,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","TCPPERMT","/capita, US$ exchange rate","NZL","New Zealand","2011","2011",3.3,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","TCPPERMT","/capita, US$ exchange rate","NZL","New Zealand","2012","2012",3.4,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","TCPPERMT","/capita, US$ exchange rate","NZL","New Zealand","2013","2013",2.7,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","TCPPERMT","/capita, US$ exchange rate","NZL","New Zealand","2014","2014",2.7,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","TCPPERMT","/capita, US$ exchange rate","NZL","New Zealand","2015","2015",2.1,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","TCPPERMT","/capita, US$ exchange rate","NZL","New Zealand","2016","2016",1.2,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","TCPPERMT","/capita, US$ exchange rate","NZL","New Zealand","2017","2017",1.8,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","TCPPERMT","/capita, US$ exchange rate","NZL","New Zealand","2018","2018",1.1,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","TCPPERMT","/capita, US$ exchange rate","NZL","New Zealand","2019","2019",1,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","TCPPERMT","/capita, US$ exchange rate","NZL","New Zealand","2020","2020",0.9,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","TCPPERMT","/capita, US$ exchange rate","NZL","New Zealand","2021","2021",1.1,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","TCPPERMT","/capita, US$ exchange rate","NZL","New Zealand","2022","2022",1,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2010","2010",3.6,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2011","2011",2.8,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2012","2012",2.8,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2013","2013",2.2,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2014","2014",2.3,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2015","2015",2.1,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2016","2016",1.2,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2017","2017",1.8,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2018","2018",1.1,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2019","2019",1,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2020","2020",1,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2021","2021",1.1,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2022","2022",1.1,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","ATCPTTMT","% of total sales","NZL","New Zealand","2010","2010",3.1,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","ATCPTTMT","% of total sales","NZL","New Zealand","2011","2011",2.2,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","ATCPTTMT","% of total sales","NZL","New Zealand","2012","2012",2,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","ATCPTTMT","% of total sales","NZL","New Zealand","2013","2013",1.6,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","ATCPTTMT","% of total sales","NZL","New Zealand","2014","2014",1.5,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","ATCPTTMT","% of total sales","NZL","New Zealand","2015","2015",1.4,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","ATCPTTMT","% of total sales","NZL","New Zealand","2016","2016",0.7,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","ATCPTTMT","% of total sales","NZL","New Zealand","2017","2017",1,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","ATCPTTMT","% of total sales","NZL","New Zealand","2018","2018",0.6,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","ATCPTTMT","% of total sales","NZL","New Zealand","2019","2019",0.5,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","ATCPTTMT","% of total sales","NZL","New Zealand","2020","2020",0.4,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","ATCPTTMT","% of total sales","NZL","New Zealand","2021","2021",0.5,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","ATCPTTMT","% of total sales","NZL","New Zealand","2022","2022",0.4,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","MLLNCUMT","Million of national currency units","NOR","Norway","2010","2010",168,,
+"PATCBETA","C07-Beta blocking agents","MLLNCUMT","Million of national currency units","NOR","Norway","2011","2011",166,,
+"PATCBETA","C07-Beta blocking agents","MLLNCUMT","Million of national currency units","NOR","Norway","2012","2012",165,,
+"PATCBETA","C07-Beta blocking agents","MLLNCUMT","Million of national currency units","NOR","Norway","2013","2013",167,,
+"PATCBETA","C07-Beta blocking agents","MLLNCUMT","Million of national currency units","NOR","Norway","2014","2014",172,,
+"PATCBETA","C07-Beta blocking agents","MLLNCUMT","Million of national currency units","NOR","Norway","2015","2015",174,,
+"PATCBETA","C07-Beta blocking agents","MLLNCUMT","Million of national currency units","NOR","Norway","2016","2016",180,,
+"PATCBETA","C07-Beta blocking agents","MLLNCUMT","Million of national currency units","NOR","Norway","2017","2017",183,,
+"PATCBETA","C07-Beta blocking agents","MLLNCUMT","Million of national currency units","NOR","Norway","2018","2018",186,,
+"PATCBETA","C07-Beta blocking agents","MLLNCUMT","Million of national currency units","NOR","Norway","2019","2019",202,,
+"PATCBETA","C07-Beta blocking agents","MLLNCUMT","Million of national currency units","NOR","Norway","2020","2020",206,,
+"PATCBETA","C07-Beta blocking agents","MLLNCUMT","Million of national currency units","NOR","Norway","2021","2021",208,,
+"PATCBETA","C07-Beta blocking agents","MLLNCUMT","Million of national currency units","NOR","Norway","2022","2022",225,,
+"PATCBETA","C07-Beta blocking agents","MTMOTCMT","Million US$ at exchange rate","NOR","Norway","2010","2010",27.8,,
+"PATCBETA","C07-Beta blocking agents","MTMOTCMT","Million US$ at exchange rate","NOR","Norway","2011","2011",29.6,,
+"PATCBETA","C07-Beta blocking agents","MTMOTCMT","Million US$ at exchange rate","NOR","Norway","2012","2012",28.4,,
+"PATCBETA","C07-Beta blocking agents","MTMOTCMT","Million US$ at exchange rate","NOR","Norway","2013","2013",28.4,,
+"PATCBETA","C07-Beta blocking agents","MTMOTCMT","Million US$ at exchange rate","NOR","Norway","2014","2014",27.3,,
+"PATCBETA","C07-Beta blocking agents","MTMOTCMT","Million US$ at exchange rate","NOR","Norway","2015","2015",21.6,,
+"PATCBETA","C07-Beta blocking agents","MTMOTCMT","Million US$ at exchange rate","NOR","Norway","2016","2016",21.4,,
+"PATCBETA","C07-Beta blocking agents","MTMOTCMT","Million US$ at exchange rate","NOR","Norway","2017","2017",22.1,,
+"PATCBETA","C07-Beta blocking agents","MTMOTCMT","Million US$ at exchange rate","NOR","Norway","2018","2018",22.9,,
+"PATCBETA","C07-Beta blocking agents","MTMOTCMT","Million US$ at exchange rate","NOR","Norway","2019","2019",23,,
+"PATCBETA","C07-Beta blocking agents","MTMOTCMT","Million US$ at exchange rate","NOR","Norway","2020","2020",21.9,,
+"PATCBETA","C07-Beta blocking agents","MTMOTCMT","Million US$ at exchange rate","NOR","Norway","2021","2021",24.2,,
+"PATCBETA","C07-Beta blocking agents","MTMOTCMT","Million US$ at exchange rate","NOR","Norway","2022","2022",23.4,,
+"PATCBETA","C07-Beta blocking agents","MTMOPPMT","Million US$, purchasing power parity","NOR","Norway","2010","2010",18.4,,
+"PATCBETA","C07-Beta blocking agents","MTMOPPMT","Million US$, purchasing power parity","NOR","Norway","2011","2011",18.3,,
+"PATCBETA","C07-Beta blocking agents","MTMOPPMT","Million US$, purchasing power parity","NOR","Norway","2012","2012",18.3,,
+"PATCBETA","C07-Beta blocking agents","MTMOPPMT","Million US$, purchasing power parity","NOR","Norway","2013","2013",18.5,,
+"PATCBETA","C07-Beta blocking agents","MTMOPPMT","Million US$, purchasing power parity","NOR","Norway","2014","2014",18.5,,
+"PATCBETA","C07-Beta blocking agents","MTMOPPMT","Million US$, purchasing power parity","NOR","Norway","2015","2015",17.5,,
+"PATCBETA","C07-Beta blocking agents","MTMOPPMT","Million US$, purchasing power parity","NOR","Norway","2016","2016",17.9,,
+"PATCBETA","C07-Beta blocking agents","MTMOPPMT","Million US$, purchasing power parity","NOR","Norway","2017","2017",18.8,,
+"PATCBETA","C07-Beta blocking agents","MTMOPPMT","Million US$, purchasing power parity","NOR","Norway","2018","2018",19.4,,
+"PATCBETA","C07-Beta blocking agents","MTMOPPMT","Million US$, purchasing power parity","NOR","Norway","2019","2019",21,,
+"PATCBETA","C07-Beta blocking agents","MTMOPPMT","Million US$, purchasing power parity","NOR","Norway","2020","2020",20.9,,
+"PATCBETA","C07-Beta blocking agents","MTMOPPMT","Million US$, purchasing power parity","NOR","Norway","2021","2021",21.9,,
+"PATCBETA","C07-Beta blocking agents","MTMOPPMT","Million US$, purchasing power parity","NOR","Norway","2022","2022",21,,
+"PATCBETA","C07-Beta blocking agents","TCPPERMT","/capita, US$ exchange rate","NOR","Norway","2010","2010",5.7,,
+"PATCBETA","C07-Beta blocking agents","TCPPERMT","/capita, US$ exchange rate","NOR","Norway","2011","2011",6,,
+"PATCBETA","C07-Beta blocking agents","TCPPERMT","/capita, US$ exchange rate","NOR","Norway","2012","2012",5.7,,
+"PATCBETA","C07-Beta blocking agents","TCPPERMT","/capita, US$ exchange rate","NOR","Norway","2013","2013",5.6,,
+"PATCBETA","C07-Beta blocking agents","TCPPERMT","/capita, US$ exchange rate","NOR","Norway","2014","2014",5.3,,
+"PATCBETA","C07-Beta blocking agents","TCPPERMT","/capita, US$ exchange rate","NOR","Norway","2015","2015",4.2,,
+"PATCBETA","C07-Beta blocking agents","TCPPERMT","/capita, US$ exchange rate","NOR","Norway","2016","2016",4.1,,
+"PATCBETA","C07-Beta blocking agents","TCPPERMT","/capita, US$ exchange rate","NOR","Norway","2017","2017",4.2,,
+"PATCBETA","C07-Beta blocking agents","TCPPERMT","/capita, US$ exchange rate","NOR","Norway","2018","2018",4.3,,
+"PATCBETA","C07-Beta blocking agents","TCPPERMT","/capita, US$ exchange rate","NOR","Norway","2019","2019",4.3,,
+"PATCBETA","C07-Beta blocking agents","TCPPERMT","/capita, US$ exchange rate","NOR","Norway","2020","2020",4.1,,
+"PATCBETA","C07-Beta blocking agents","TCPPERMT","/capita, US$ exchange rate","NOR","Norway","2021","2021",4.5,,
+"PATCBETA","C07-Beta blocking agents","TCPPERMT","/capita, US$ exchange rate","NOR","Norway","2022","2022",4.3,,
+"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2010","2010",3.8,,
+"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2011","2011",3.7,,
+"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2012","2012",3.6,,
+"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2013","2013",3.6,,
+"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2014","2014",3.6,,
+"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2015","2015",3.4,,
+"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2016","2016",3.4,,
+"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2017","2017",3.6,,
+"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2018","2018",3.7,,
+"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2019","2019",3.9,,
+"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2020","2020",3.9,,
+"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2021","2021",4,,
+"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2022","2022",3.9,,
+"PATCBETA","C07-Beta blocking agents","ATCPTTMT","% of total sales","NOR","Norway","2010","2010",0.9,,
+"PATCBETA","C07-Beta blocking agents","ATCPTTMT","% of total sales","NOR","Norway","2011","2011",0.9,,
+"PATCBETA","C07-Beta blocking agents","ATCPTTMT","% of total sales","NOR","Norway","2012","2012",0.9,,
+"PATCBETA","C07-Beta blocking agents","ATCPTTMT","% of total sales","NOR","Norway","2013","2013",0.9,,
+"PATCBETA","C07-Beta blocking agents","ATCPTTMT","% of total sales","NOR","Norway","2014","2014",0.8,,
+"PATCBETA","C07-Beta blocking agents","ATCPTTMT","% of total sales","NOR","Norway","2015","2015",0.8,,
+"PATCBETA","C07-Beta blocking agents","ATCPTTMT","% of total sales","NOR","Norway","2016","2016",0.7,,
+"PATCBETA","C07-Beta blocking agents","ATCPTTMT","% of total sales","NOR","Norway","2017","2017",0.7,,
+"PATCBETA","C07-Beta blocking agents","ATCPTTMT","% of total sales","NOR","Norway","2018","2018",0.7,,
+"PATCBETA","C07-Beta blocking agents","ATCPTTMT","% of total sales","NOR","Norway","2019","2019",0.7,,
+"PATCBETA","C07-Beta blocking agents","ATCPTTMT","% of total sales","NOR","Norway","2020","2020",0.7,,
+"PATCBETA","C07-Beta blocking agents","ATCPTTMT","% of total sales","NOR","Norway","2021","2021",0.6,,
+"PATCBETA","C07-Beta blocking agents","ATCPTTMT","% of total sales","NOR","Norway","2022","2022",0.6,,
+"PATCBETA","C07-Beta blocking agents","MLLNCUMT","Million of national currency units","PRT","Portugal","2010","2010",34.4,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","MLLNCUMT","Million of national currency units","PRT","Portugal","2011","2011",31.4,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","MLLNCUMT","Million of national currency units","PRT","Portugal","2012","2012",29.4,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","MLLNCUMT","Million of national currency units","PRT","Portugal","2013","2013",30.1,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","MLLNCUMT","Million of national currency units","PRT","Portugal","2014","2014",30.4,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","MLLNCUMT","Million of national currency units","PRT","Portugal","2015","2015",31.5,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","MLLNCUMT","Million of national currency units","PRT","Portugal","2016","2016",32.5,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","MLLNCUMT","Million of national currency units","PRT","Portugal","2017","2017",32.8,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","MLLNCUMT","Million of national currency units","PRT","Portugal","2018","2018",34.2,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","MLLNCUMT","Million of national currency units","PRT","Portugal","2019","2019",36,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","MLLNCUMT","Million of national currency units","PRT","Portugal","2020","2020",37.8,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","MLLNCUMT","Million of national currency units","PRT","Portugal","2021","2021",38.2,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","MLLNCUMT","Million of national currency units","PRT","Portugal","2022","2022",39,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","MTMOTCMT","Million US$ at exchange rate","PRT","Portugal","2010","2010",45.6,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","MTMOTCMT","Million US$ at exchange rate","PRT","Portugal","2011","2011",43.6,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","MTMOTCMT","Million US$ at exchange rate","PRT","Portugal","2012","2012",37.8,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","MTMOTCMT","Million US$ at exchange rate","PRT","Portugal","2013","2013",40,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","MTMOTCMT","Million US$ at exchange rate","PRT","Portugal","2014","2014",40.4,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","MTMOTCMT","Million US$ at exchange rate","PRT","Portugal","2015","2015",35,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","MTMOTCMT","Million US$ at exchange rate","PRT","Portugal","2016","2016",36,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","MTMOTCMT","Million US$ at exchange rate","PRT","Portugal","2017","2017",37,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","MTMOTCMT","Million US$ at exchange rate","PRT","Portugal","2018","2018",40.4,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","MTMOTCMT","Million US$ at exchange rate","PRT","Portugal","2019","2019",40.3,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","MTMOTCMT","Million US$ at exchange rate","PRT","Portugal","2020","2020",43.1,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","MTMOTCMT","Million US$ at exchange rate","PRT","Portugal","2021","2021",45.1,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","MTMOTCMT","Million US$ at exchange rate","PRT","Portugal","2022","2022",41.1,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","MTMOPPMT","Million US$, purchasing power parity","PRT","Portugal","2010","2010",55.2,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","MTMOPPMT","Million US$, purchasing power parity","PRT","Portugal","2011","2011",50.3,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","MTMOPPMT","Million US$, purchasing power parity","PRT","Portugal","2012","2012",48.6,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","MTMOPPMT","Million US$, purchasing power parity","PRT","Portugal","2013","2013",51.6,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","MTMOPPMT","Million US$, purchasing power parity","PRT","Portugal","2014","2014",52.5,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","MTMOPPMT","Million US$, purchasing power parity","PRT","Portugal","2015","2015",53.9,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","MTMOPPMT","Million US$, purchasing power parity","PRT","Portugal","2016","2016",57,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","MTMOPPMT","Million US$, purchasing power parity","PRT","Portugal","2017","2017",56.9,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","MTMOPPMT","Million US$, purchasing power parity","PRT","Portugal","2018","2018",59.8,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","MTMOPPMT","Million US$, purchasing power parity","PRT","Portugal","2019","2019",64.4,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","MTMOPPMT","Million US$, purchasing power parity","PRT","Portugal","2020","2020",67.8,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","MTMOPPMT","Million US$, purchasing power parity","PRT","Portugal","2021","2021",67.2,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","MTMOPPMT","Million US$, purchasing power parity","PRT","Portugal","2022","2022",70.9,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","TCPPERMT","/capita, US$ exchange rate","PRT","Portugal","2010","2010",4.3,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","TCPPERMT","/capita, US$ exchange rate","PRT","Portugal","2011","2011",4.1,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","TCPPERMT","/capita, US$ exchange rate","PRT","Portugal","2012","2012",3.6,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","TCPPERMT","/capita, US$ exchange rate","PRT","Portugal","2013","2013",3.8,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","TCPPERMT","/capita, US$ exchange rate","PRT","Portugal","2014","2014",3.9,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","TCPPERMT","/capita, US$ exchange rate","PRT","Portugal","2015","2015",3.4,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","TCPPERMT","/capita, US$ exchange rate","PRT","Portugal","2016","2016",3.5,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","TCPPERMT","/capita, US$ exchange rate","PRT","Portugal","2017","2017",3.6,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","TCPPERMT","/capita, US$ exchange rate","PRT","Portugal","2018","2018",3.9,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","TCPPERMT","/capita, US$ exchange rate","PRT","Portugal","2019","2019",3.9,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","TCPPERMT","/capita, US$ exchange rate","PRT","Portugal","2020","2020",4.2,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","TCPPERMT","/capita, US$ exchange rate","PRT","Portugal","2021","2021",4.4,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","TCPPERMT","/capita, US$ exchange rate","PRT","Portugal","2022","2022",4,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2010","2010",5.2,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2011","2011",4.8,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2012","2012",4.6,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2013","2013",4.9,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2014","2014",5.1,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2015","2015",5.2,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2016","2016",5.5,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2017","2017",5.5,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2018","2018",5.8,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2019","2019",6.3,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2020","2020",6.6,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2021","2021",6.5,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2022","2022",6.8,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","ATCPTTMT","% of total sales","PRT","Portugal","2010","2010",1.1,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","ATCPTTMT","% of total sales","PRT","Portugal","2011","2011",1.1,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","ATCPTTMT","% of total sales","PRT","Portugal","2012","2012",1.1,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","ATCPTTMT","% of total sales","PRT","Portugal","2013","2013",1.2,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","ATCPTTMT","% of total sales","PRT","Portugal","2014","2014",1.3,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","ATCPTTMT","% of total sales","PRT","Portugal","2015","2015",1.3,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","ATCPTTMT","% of total sales","PRT","Portugal","2016","2016",1.3,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","ATCPTTMT","% of total sales","PRT","Portugal","2017","2017",1.3,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","ATCPTTMT","% of total sales","PRT","Portugal","2018","2018",1.3,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","ATCPTTMT","% of total sales","PRT","Portugal","2019","2019",1.3,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","ATCPTTMT","% of total sales","PRT","Portugal","2020","2020",1.3,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","ATCPTTMT","% of total sales","PRT","Portugal","2021","2021",1.3,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","ATCPTTMT","% of total sales","PRT","Portugal","2022","2022",1.2,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","MLLNCUMT","Million of national currency units","SVK","Slovak Republic","2010","2010",15.2,,
+"PATCBETA","C07-Beta blocking agents","MLLNCUMT","Million of national currency units","SVK","Slovak Republic","2011","2011",15.4,,
+"PATCBETA","C07-Beta blocking agents","MLLNCUMT","Million of national currency units","SVK","Slovak Republic","2012","2012",14,,
+"PATCBETA","C07-Beta blocking agents","MLLNCUMT","Million of national currency units","SVK","Slovak Republic","2013","2013",15.2,,
+"PATCBETA","C07-Beta blocking agents","MLLNCUMT","Million of national currency units","SVK","Slovak Republic","2014","2014",15,,
+"PATCBETA","C07-Beta blocking agents","MLLNCUMT","Million of national currency units","SVK","Slovak Republic","2015","2015",15,,
+"PATCBETA","C07-Beta blocking agents","MLLNCUMT","Million of national currency units","SVK","Slovak Republic","2016","2016",21.9,"B","Break"
+"PATCBETA","C07-Beta blocking agents","MLLNCUMT","Million of national currency units","SVK","Slovak Republic","2017","2017",22,,
+"PATCBETA","C07-Beta blocking agents","MLLNCUMT","Million of national currency units","SVK","Slovak Republic","2018","2018",22.2,,
+"PATCBETA","C07-Beta blocking agents","MLLNCUMT","Million of national currency units","SVK","Slovak Republic","2019","2019",23,,
+"PATCBETA","C07-Beta blocking agents","MLLNCUMT","Million of national currency units","SVK","Slovak Republic","2020","2020",24.3,,
+"PATCBETA","C07-Beta blocking agents","MLLNCUMT","Million of national currency units","SVK","Slovak Republic","2021","2021",24.3,,
+"PATCBETA","C07-Beta blocking agents","MTMOTCMT","Million US$ at exchange rate","SVK","Slovak Republic","2010","2010",20.1,,
+"PATCBETA","C07-Beta blocking agents","MTMOTCMT","Million US$ at exchange rate","SVK","Slovak Republic","2011","2011",21.4,,
+"PATCBETA","C07-Beta blocking agents","MTMOTCMT","Million US$ at exchange rate","SVK","Slovak Republic","2012","2012",18,,
+"PATCBETA","C07-Beta blocking agents","MTMOTCMT","Million US$ at exchange rate","SVK","Slovak Republic","2013","2013",20.2,,
+"PATCBETA","C07-Beta blocking agents","MTMOTCMT","Million US$ at exchange rate","SVK","Slovak Republic","2014","2014",19.9,,
+"PATCBETA","C07-Beta blocking agents","MTMOTCMT","Million US$ at exchange rate","SVK","Slovak Republic","2015","2015",16.6,,
+"PATCBETA","C07-Beta blocking agents","MTMOTCMT","Million US$ at exchange rate","SVK","Slovak Republic","2016","2016",24.2,"B","Break"
+"PATCBETA","C07-Beta blocking agents","MTMOTCMT","Million US$ at exchange rate","SVK","Slovak Republic","2017","2017",24.9,,
+"PATCBETA","C07-Beta blocking agents","MTMOTCMT","Million US$ at exchange rate","SVK","Slovak Republic","2018","2018",26.2,,
+"PATCBETA","C07-Beta blocking agents","MTMOTCMT","Million US$ at exchange rate","SVK","Slovak Republic","2019","2019",25.8,,
+"PATCBETA","C07-Beta blocking agents","MTMOTCMT","Million US$ at exchange rate","SVK","Slovak Republic","2020","2020",27.8,,
+"PATCBETA","C07-Beta blocking agents","MTMOTCMT","Million US$ at exchange rate","SVK","Slovak Republic","2021","2021",28.8,,
+"PATCBETA","C07-Beta blocking agents","MTMOPPMT","Million US$, purchasing power parity","SVK","Slovak Republic","2010","2010",30.2,,
+"PATCBETA","C07-Beta blocking agents","MTMOPPMT","Million US$, purchasing power parity","SVK","Slovak Republic","2011","2011",30.4,,
+"PATCBETA","C07-Beta blocking agents","MTMOPPMT","Million US$, purchasing power parity","SVK","Slovak Republic","2012","2012",27.8,,
+"PATCBETA","C07-Beta blocking agents","MTMOPPMT","Million US$, purchasing power parity","SVK","Slovak Republic","2013","2013",30.9,,
+"PATCBETA","C07-Beta blocking agents","MTMOPPMT","Million US$, purchasing power parity","SVK","Slovak Republic","2014","2014",30.9,,
+"PATCBETA","C07-Beta blocking agents","MTMOPPMT","Million US$, purchasing power parity","SVK","Slovak Republic","2015","2015",30.4,,
+"PATCBETA","C07-Beta blocking agents","MTMOPPMT","Million US$, purchasing power parity","SVK","Slovak Republic","2016","2016",43.5,"B","Break"
+"PATCBETA","C07-Beta blocking agents","MTMOPPMT","Million US$, purchasing power parity","SVK","Slovak Republic","2017","2017",42.6,,
+"PATCBETA","C07-Beta blocking agents","MTMOPPMT","Million US$, purchasing power parity","SVK","Slovak Republic","2018","2018",42.2,,
+"PATCBETA","C07-Beta blocking agents","MTMOPPMT","Million US$, purchasing power parity","SVK","Slovak Republic","2019","2019",44.4,,
+"PATCBETA","C07-Beta blocking agents","MTMOPPMT","Million US$, purchasing power parity","SVK","Slovak Republic","2020","2020",46.8,,
+"PATCBETA","C07-Beta blocking agents","MTMOPPMT","Million US$, purchasing power parity","SVK","Slovak Republic","2021","2021",45.6,,
+"PATCBETA","C07-Beta blocking agents","TCPPERMT","/capita, US$ exchange rate","SVK","Slovak Republic","2010","2010",3.7,,
+"PATCBETA","C07-Beta blocking agents","TCPPERMT","/capita, US$ exchange rate","SVK","Slovak Republic","2011","2011",4,,
+"PATCBETA","C07-Beta blocking agents","TCPPERMT","/capita, US$ exchange rate","SVK","Slovak Republic","2012","2012",3.3,,
+"PATCBETA","C07-Beta blocking agents","TCPPERMT","/capita, US$ exchange rate","SVK","Slovak Republic","2013","2013",3.7,,
+"PATCBETA","C07-Beta blocking agents","TCPPERMT","/capita, US$ exchange rate","SVK","Slovak Republic","2014","2014",3.7,,
+"PATCBETA","C07-Beta blocking agents","TCPPERMT","/capita, US$ exchange rate","SVK","Slovak Republic","2015","2015",3.1,,
+"PATCBETA","C07-Beta blocking agents","TCPPERMT","/capita, US$ exchange rate","SVK","Slovak Republic","2016","2016",4.5,"B","Break"
+"PATCBETA","C07-Beta blocking agents","TCPPERMT","/capita, US$ exchange rate","SVK","Slovak Republic","2017","2017",4.6,,
+"PATCBETA","C07-Beta blocking agents","TCPPERMT","/capita, US$ exchange rate","SVK","Slovak Republic","2018","2018",4.8,,
+"PATCBETA","C07-Beta blocking agents","TCPPERMT","/capita, US$ exchange rate","SVK","Slovak Republic","2019","2019",4.7,,
+"PATCBETA","C07-Beta blocking agents","TCPPERMT","/capita, US$ exchange rate","SVK","Slovak Republic","2020","2020",5.1,,
+"PATCBETA","C07-Beta blocking agents","TCPPERMT","/capita, US$ exchange rate","SVK","Slovak Republic","2021","2021",5.3,,
+"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2010","2010",5.6,,
+"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2011","2011",5.6,,
+"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2012","2012",5.1,,
+"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2013","2013",5.7,,
+"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2014","2014",5.7,,
+"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2015","2015",5.6,,
+"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2016","2016",8,"B","Break"
+"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2017","2017",7.8,,
+"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2018","2018",7.7,,
+"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2019","2019",8.1,,
+"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2020","2020",8.6,,
+"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2021","2021",8.4,,
+"PATCBETA","C07-Beta blocking agents","ATCPTTMT","% of total sales","SVK","Slovak Republic","2010","2010",1.4,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","ATCPTTMT","% of total sales","SVK","Slovak Republic","2011","2011",1.4,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","ATCPTTMT","% of total sales","SVK","Slovak Republic","2012","2012",1.3,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","ATCPTTMT","% of total sales","SVK","Slovak Republic","2013","2013",1.2,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","ATCPTTMT","% of total sales","SVK","Slovak Republic","2014","2014",1.1,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","ATCPTTMT","% of total sales","SVK","Slovak Republic","2015","2015",1.1,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","ATCPTTMT","% of total sales","SVK","Slovak Republic","2016","2016",1.4,"B","Break"
+"PATCBETA","C07-Beta blocking agents","ATCPTTMT","% of total sales","SVK","Slovak Republic","2017","2017",1.4,,
+"PATCBETA","C07-Beta blocking agents","ATCPTTMT","% of total sales","SVK","Slovak Republic","2018","2018",1.4,,
+"PATCBETA","C07-Beta blocking agents","ATCPTTMT","% of total sales","SVK","Slovak Republic","2019","2019",1.3,,
+"PATCBETA","C07-Beta blocking agents","ATCPTTMT","% of total sales","SVK","Slovak Republic","2020","2020",1.5,,
+"PATCBETA","C07-Beta blocking agents","ATCPTTMT","% of total sales","SVK","Slovak Republic","2021","2021",1.4,,
+"PATCBETA","C07-Beta blocking agents","MLLNCUMT","Million of national currency units","ESP","Spain","2010","2010",99,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","MLLNCUMT","Million of national currency units","ESP","Spain","2011","2011",84.9,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","MLLNCUMT","Million of national currency units","ESP","Spain","2012","2012",79.1,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","MLLNCUMT","Million of national currency units","ESP","Spain","2013","2013",80.7,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","MLLNCUMT","Million of national currency units","ESP","Spain","2014","2014",84.4,"B; D","Break; Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","MLLNCUMT","Million of national currency units","ESP","Spain","2015","2015",82.9,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","MLLNCUMT","Million of national currency units","ESP","Spain","2016","2016",85.9,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","MLLNCUMT","Million of national currency units","ESP","Spain","2017","2017",88.5,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","MLLNCUMT","Million of national currency units","ESP","Spain","2018","2018",92.7,"B","Break"
+"PATCBETA","C07-Beta blocking agents","MLLNCUMT","Million of national currency units","ESP","Spain","2019","2019",96.9,,
+"PATCBETA","C07-Beta blocking agents","MLLNCUMT","Million of national currency units","ESP","Spain","2020","2020",100.5,,
+"PATCBETA","C07-Beta blocking agents","MLLNCUMT","Million of national currency units","ESP","Spain","2021","2021",103.4,,
+"PATCBETA","C07-Beta blocking agents","MLLNCUMT","Million of national currency units","ESP","Spain","2022","2022",104.9,"P","Provisional value"
+"PATCBETA","C07-Beta blocking agents","MTMOTCMT","Million US$ at exchange rate","ESP","Spain","2010","2010",131.3,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","MTMOTCMT","Million US$ at exchange rate","ESP","Spain","2011","2011",118.1,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","MTMOTCMT","Million US$ at exchange rate","ESP","Spain","2012","2012",101.6,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","MTMOTCMT","Million US$ at exchange rate","ESP","Spain","2013","2013",107.2,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","MTMOTCMT","Million US$ at exchange rate","ESP","Spain","2014","2014",112.1,"B; D","Break; Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","MTMOTCMT","Million US$ at exchange rate","ESP","Spain","2015","2015",91.9,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","MTMOTCMT","Million US$ at exchange rate","ESP","Spain","2016","2016",95.1,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","MTMOTCMT","Million US$ at exchange rate","ESP","Spain","2017","2017",100,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","MTMOTCMT","Million US$ at exchange rate","ESP","Spain","2018","2018",109.4,"B","Break"
+"PATCBETA","C07-Beta blocking agents","MTMOTCMT","Million US$ at exchange rate","ESP","Spain","2019","2019",108.5,,
+"PATCBETA","C07-Beta blocking agents","MTMOTCMT","Million US$ at exchange rate","ESP","Spain","2020","2020",114.8,,
+"PATCBETA","C07-Beta blocking agents","MTMOTCMT","Million US$ at exchange rate","ESP","Spain","2021","2021",122.3,,
+"PATCBETA","C07-Beta blocking agents","MTMOTCMT","Million US$ at exchange rate","ESP","Spain","2022","2022",110.5,"P","Provisional value"
+"PATCBETA","C07-Beta blocking agents","MTMOPPMT","Million US$, purchasing power parity","ESP","Spain","2010","2010",136.2,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","MTMOPPMT","Million US$, purchasing power parity","ESP","Spain","2011","2011",118.8,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","MTMOPPMT","Million US$, purchasing power parity","ESP","Spain","2012","2012",113.8,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","MTMOPPMT","Million US$, purchasing power parity","ESP","Spain","2013","2013",119.6,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","MTMOPPMT","Million US$, purchasing power parity","ESP","Spain","2014","2014",127.4,"B; D","Break; Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","MTMOPPMT","Million US$, purchasing power parity","ESP","Spain","2015","2015",124.6,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","MTMOPPMT","Million US$, purchasing power parity","ESP","Spain","2016","2016",133.7,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","MTMOPPMT","Million US$, purchasing power parity","ESP","Spain","2017","2017",140.4,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","MTMOPPMT","Million US$, purchasing power parity","ESP","Spain","2018","2018",146.7,"B","Break"
+"PATCBETA","C07-Beta blocking agents","MTMOPPMT","Million US$, purchasing power parity","ESP","Spain","2019","2019",158.1,,
+"PATCBETA","C07-Beta blocking agents","MTMOPPMT","Million US$, purchasing power parity","ESP","Spain","2020","2020",161.8,,
+"PATCBETA","C07-Beta blocking agents","MTMOPPMT","Million US$, purchasing power parity","ESP","Spain","2021","2021",165.2,,
+"PATCBETA","C07-Beta blocking agents","MTMOPPMT","Million US$, purchasing power parity","ESP","Spain","2022","2022",175.9,"P","Provisional value"
+"PATCBETA","C07-Beta blocking agents","TCPPERMT","/capita, US$ exchange rate","ESP","Spain","2010","2010",2.8,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","TCPPERMT","/capita, US$ exchange rate","ESP","Spain","2011","2011",2.5,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","TCPPERMT","/capita, US$ exchange rate","ESP","Spain","2012","2012",2.2,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","TCPPERMT","/capita, US$ exchange rate","ESP","Spain","2013","2013",2.3,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","TCPPERMT","/capita, US$ exchange rate","ESP","Spain","2014","2014",2.4,"B; D","Break; Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","TCPPERMT","/capita, US$ exchange rate","ESP","Spain","2015","2015",2,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","TCPPERMT","/capita, US$ exchange rate","ESP","Spain","2016","2016",2,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","TCPPERMT","/capita, US$ exchange rate","ESP","Spain","2017","2017",2.1,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","TCPPERMT","/capita, US$ exchange rate","ESP","Spain","2018","2018",2.3,"B","Break"
+"PATCBETA","C07-Beta blocking agents","TCPPERMT","/capita, US$ exchange rate","ESP","Spain","2019","2019",2.3,,
+"PATCBETA","C07-Beta blocking agents","TCPPERMT","/capita, US$ exchange rate","ESP","Spain","2020","2020",2.4,,
+"PATCBETA","C07-Beta blocking agents","TCPPERMT","/capita, US$ exchange rate","ESP","Spain","2021","2021",2.6,,
+"PATCBETA","C07-Beta blocking agents","TCPPERMT","/capita, US$ exchange rate","ESP","Spain","2022","2022",2.3,"P","Provisional value"
+"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2010","2010",2.9,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2011","2011",2.5,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2012","2012",2.4,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2013","2013",2.6,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2014","2014",2.7,"B; D","Break; Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2015","2015",2.7,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2016","2016",2.9,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2017","2017",3,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2018","2018",3.1,"B","Break"
+"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2019","2019",3.4,,
+"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2020","2020",3.4,,
+"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2021","2021",3.5,,
+"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2022","2022",3.7,"P","Provisional value"
+"PATCBETA","C07-Beta blocking agents","ATCPTTMT","% of total sales","ESP","Spain","2010","2010",0.7,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","ATCPTTMT","% of total sales","ESP","Spain","2011","2011",0.7,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","ATCPTTMT","% of total sales","ESP","Spain","2012","2012",0.7,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","ATCPTTMT","% of total sales","ESP","Spain","2013","2013",0.8,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","ATCPTTMT","% of total sales","ESP","Spain","2014","2014",0.7,"B; D","Break; Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","ATCPTTMT","% of total sales","ESP","Spain","2015","2015",0.7,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","ATCPTTMT","% of total sales","ESP","Spain","2016","2016",0.7,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","ATCPTTMT","% of total sales","ESP","Spain","2017","2017",0.7,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","ATCPTTMT","% of total sales","ESP","Spain","2018","2018",0.5,"B","Break"
+"PATCBETA","C07-Beta blocking agents","ATCPTTMT","% of total sales","ESP","Spain","2019","2019",0.5,,
+"PATCBETA","C07-Beta blocking agents","ATCPTTMT","% of total sales","ESP","Spain","2020","2020",0.5,,
+"PATCBETA","C07-Beta blocking agents","ATCPTTMT","% of total sales","ESP","Spain","2021","2021",0.5,,
+"PATCBETA","C07-Beta blocking agents","ATCPTTMT","% of total sales","ESP","Spain","2022","2022",0.5,"P","Provisional value"
+"PATCBETA","C07-Beta blocking agents","MLLNCUMT","Million of national currency units","SWE","Sweden","2010","2010",430,,
+"PATCBETA","C07-Beta blocking agents","MLLNCUMT","Million of national currency units","SWE","Sweden","2011","2011",403,,
+"PATCBETA","C07-Beta blocking agents","MLLNCUMT","Million of national currency units","SWE","Sweden","2012","2012",393,,
+"PATCBETA","C07-Beta blocking agents","MLLNCUMT","Million of national currency units","SWE","Sweden","2013","2013",411,,
+"PATCBETA","C07-Beta blocking agents","MLLNCUMT","Million of national currency units","SWE","Sweden","2014","2014",419.1,,
+"PATCBETA","C07-Beta blocking agents","MLLNCUMT","Million of national currency units","SWE","Sweden","2015","2015",429.4,,
+"PATCBETA","C07-Beta blocking agents","MLLNCUMT","Million of national currency units","SWE","Sweden","2016","2016",394.3,,
+"PATCBETA","C07-Beta blocking agents","MLLNCUMT","Million of national currency units","SWE","Sweden","2017","2017",397.1,,
+"PATCBETA","C07-Beta blocking agents","MLLNCUMT","Million of national currency units","SWE","Sweden","2018","2018",419.9,,
+"PATCBETA","C07-Beta blocking agents","MLLNCUMT","Million of national currency units","SWE","Sweden","2019","2019",437.2,,
+"PATCBETA","C07-Beta blocking agents","MLLNCUMT","Million of national currency units","SWE","Sweden","2020","2020",475.8,,
+"PATCBETA","C07-Beta blocking agents","MLLNCUMT","Million of national currency units","SWE","Sweden","2021","2021",443.1,,
+"PATCBETA","C07-Beta blocking agents","MLLNCUMT","Million of national currency units","SWE","Sweden","2022","2022",454.1,,
+"PATCBETA","C07-Beta blocking agents","MTMOTCMT","Million US$ at exchange rate","SWE","Sweden","2010","2010",59.7,,
+"PATCBETA","C07-Beta blocking agents","MTMOTCMT","Million US$ at exchange rate","SWE","Sweden","2011","2011",62.1,,
+"PATCBETA","C07-Beta blocking agents","MTMOTCMT","Million US$ at exchange rate","SWE","Sweden","2012","2012",58,,
+"PATCBETA","C07-Beta blocking agents","MTMOTCMT","Million US$ at exchange rate","SWE","Sweden","2013","2013",63.1,,
+"PATCBETA","C07-Beta blocking agents","MTMOTCMT","Million US$ at exchange rate","SWE","Sweden","2014","2014",61.1,,
+"PATCBETA","C07-Beta blocking agents","MTMOTCMT","Million US$ at exchange rate","SWE","Sweden","2015","2015",50.9,,
+"PATCBETA","C07-Beta blocking agents","MTMOTCMT","Million US$ at exchange rate","SWE","Sweden","2016","2016",46,,
+"PATCBETA","C07-Beta blocking agents","MTMOTCMT","Million US$ at exchange rate","SWE","Sweden","2017","2017",46.4,,
+"PATCBETA","C07-Beta blocking agents","MTMOTCMT","Million US$ at exchange rate","SWE","Sweden","2018","2018",48.3,,
+"PATCBETA","C07-Beta blocking agents","MTMOTCMT","Million US$ at exchange rate","SWE","Sweden","2019","2019",46.2,,
+"PATCBETA","C07-Beta blocking agents","MTMOTCMT","Million US$ at exchange rate","SWE","Sweden","2020","2020",51.7,,
+"PATCBETA","C07-Beta blocking agents","MTMOTCMT","Million US$ at exchange rate","SWE","Sweden","2021","2021",51.7,,
+"PATCBETA","C07-Beta blocking agents","MTMOTCMT","Million US$ at exchange rate","SWE","Sweden","2022","2022",44.9,,
+"PATCBETA","C07-Beta blocking agents","MTMOPPMT","Million US$, purchasing power parity","SWE","Sweden","2010","2010",47.6,,
+"PATCBETA","C07-Beta blocking agents","MTMOPPMT","Million US$, purchasing power parity","SWE","Sweden","2011","2011",45.6,,
+"PATCBETA","C07-Beta blocking agents","MTMOPPMT","Million US$, purchasing power parity","SWE","Sweden","2012","2012",45.4,,
+"PATCBETA","C07-Beta blocking agents","MTMOPPMT","Million US$, purchasing power parity","SWE","Sweden","2013","2013",47.8,,
+"PATCBETA","C07-Beta blocking agents","MTMOPPMT","Million US$, purchasing power parity","SWE","Sweden","2014","2014",48,,
+"PATCBETA","C07-Beta blocking agents","MTMOPPMT","Million US$, purchasing power parity","SWE","Sweden","2015","2015",48.5,,
+"PATCBETA","C07-Beta blocking agents","MTMOPPMT","Million US$, purchasing power parity","SWE","Sweden","2016","2016",44.7,,
+"PATCBETA","C07-Beta blocking agents","MTMOPPMT","Million US$, purchasing power parity","SWE","Sweden","2017","2017",44.9,,
+"PATCBETA","C07-Beta blocking agents","MTMOPPMT","Million US$, purchasing power parity","SWE","Sweden","2018","2018",47.4,,
+"PATCBETA","C07-Beta blocking agents","MTMOPPMT","Million US$, purchasing power parity","SWE","Sweden","2019","2019",50.2,,
+"PATCBETA","C07-Beta blocking agents","MTMOPPMT","Million US$, purchasing power parity","SWE","Sweden","2020","2020",54.9,,
+"PATCBETA","C07-Beta blocking agents","MTMOPPMT","Million US$, purchasing power parity","SWE","Sweden","2021","2021",50.8,,
+"PATCBETA","C07-Beta blocking agents","MTMOPPMT","Million US$, purchasing power parity","SWE","Sweden","2022","2022",52.4,,
+"PATCBETA","C07-Beta blocking agents","TCPPERMT","/capita, US$ exchange rate","SWE","Sweden","2010","2010",6.4,,
+"PATCBETA","C07-Beta blocking agents","TCPPERMT","/capita, US$ exchange rate","SWE","Sweden","2011","2011",6.6,,
+"PATCBETA","C07-Beta blocking agents","TCPPERMT","/capita, US$ exchange rate","SWE","Sweden","2012","2012",6.1,,
+"PATCBETA","C07-Beta blocking agents","TCPPERMT","/capita, US$ exchange rate","SWE","Sweden","2013","2013",6.6,,
+"PATCBETA","C07-Beta blocking agents","TCPPERMT","/capita, US$ exchange rate","SWE","Sweden","2014","2014",6.3,,
+"PATCBETA","C07-Beta blocking agents","TCPPERMT","/capita, US$ exchange rate","SWE","Sweden","2015","2015",5.2,,
+"PATCBETA","C07-Beta blocking agents","TCPPERMT","/capita, US$ exchange rate","SWE","Sweden","2016","2016",4.6,,
+"PATCBETA","C07-Beta blocking agents","TCPPERMT","/capita, US$ exchange rate","SWE","Sweden","2017","2017",4.6,,
+"PATCBETA","C07-Beta blocking agents","TCPPERMT","/capita, US$ exchange rate","SWE","Sweden","2018","2018",4.7,,
+"PATCBETA","C07-Beta blocking agents","TCPPERMT","/capita, US$ exchange rate","SWE","Sweden","2019","2019",4.5,,
+"PATCBETA","C07-Beta blocking agents","TCPPERMT","/capita, US$ exchange rate","SWE","Sweden","2020","2020",5,,
+"PATCBETA","C07-Beta blocking agents","TCPPERMT","/capita, US$ exchange rate","SWE","Sweden","2021","2021",5,,
+"PATCBETA","C07-Beta blocking agents","TCPPERMT","/capita, US$ exchange rate","SWE","Sweden","2022","2022",4.3,,
+"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2010","2010",5.1,,
+"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2011","2011",4.8,,
+"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2012","2012",4.8,,
+"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2013","2013",5,,
+"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2014","2014",5,,
+"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2015","2015",4.9,,
+"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2016","2016",4.5,,
+"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2017","2017",4.5,,
+"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2018","2018",4.7,,
+"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2019","2019",4.9,,
+"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2020","2020",5.3,,
+"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2021","2021",4.9,,
+"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2022","2022",5,,
+"PATCBETA","C07-Beta blocking agents","ATCPTTMT","% of total sales","SWE","Sweden","2010","2010",1.2,,
+"PATCBETA","C07-Beta blocking agents","ATCPTTMT","% of total sales","SWE","Sweden","2011","2011",1.1,,
+"PATCBETA","C07-Beta blocking agents","ATCPTTMT","% of total sales","SWE","Sweden","2012","2012",1.1,,
+"PATCBETA","C07-Beta blocking agents","ATCPTTMT","% of total sales","SWE","Sweden","2013","2013",1.1,,
+"PATCBETA","C07-Beta blocking agents","ATCPTTMT","% of total sales","SWE","Sweden","2014","2014",1.1,,
+"PATCBETA","C07-Beta blocking agents","ATCPTTMT","% of total sales","SWE","Sweden","2015","2015",1.1,,
+"PATCBETA","C07-Beta blocking agents","ATCPTTMT","% of total sales","SWE","Sweden","2016","2016",0.9,,
+"PATCBETA","C07-Beta blocking agents","ATCPTTMT","% of total sales","SWE","Sweden","2017","2017",0.9,,
+"PATCBETA","C07-Beta blocking agents","ATCPTTMT","% of total sales","SWE","Sweden","2018","2018",0.9,,
+"PATCBETA","C07-Beta blocking agents","ATCPTTMT","% of total sales","SWE","Sweden","2019","2019",0.9,,
+"PATCBETA","C07-Beta blocking agents","ATCPTTMT","% of total sales","SWE","Sweden","2020","2020",0.9,,
+"PATCBETA","C07-Beta blocking agents","ATCPTTMT","% of total sales","SWE","Sweden","2021","2021",0.8,,
+"PATCBETA","C07-Beta blocking agents","ATCPTTMT","% of total sales","SWE","Sweden","2022","2022",0.8,,
+"PATCBETA","C07-Beta blocking agents","MLLNCUMT","Million of national currency units","TUR","Türkiye","2010","2010",161.2,,
+"PATCBETA","C07-Beta blocking agents","MLLNCUMT","Million of national currency units","TUR","Türkiye","2011","2011",167.3,,
+"PATCBETA","C07-Beta blocking agents","MLLNCUMT","Million of national currency units","TUR","Türkiye","2012","2012",176.3,,
+"PATCBETA","C07-Beta blocking agents","MLLNCUMT","Million of national currency units","TUR","Türkiye","2013","2013",196.2,,
+"PATCBETA","C07-Beta blocking agents","MLLNCUMT","Million of national currency units","TUR","Türkiye","2014","2014",223.4,,
+"PATCBETA","C07-Beta blocking agents","MLLNCUMT","Million of national currency units","TUR","Türkiye","2015","2015",246.6,,
+"PATCBETA","C07-Beta blocking agents","MLLNCUMT","Million of national currency units","TUR","Türkiye","2016","2016",293.8,,
+"PATCBETA","C07-Beta blocking agents","MLLNCUMT","Million of national currency units","TUR","Türkiye","2017","2017",347,,
+"PATCBETA","C07-Beta blocking agents","MLLNCUMT","Million of national currency units","TUR","Türkiye","2018","2018",409.6,,
+"PATCBETA","C07-Beta blocking agents","MLLNCUMT","Million of national currency units","TUR","Türkiye","2019","2019",545,,
+"PATCBETA","C07-Beta blocking agents","MLLNCUMT","Million of national currency units","TUR","Türkiye","2020","2020",682.5,,
+"PATCBETA","C07-Beta blocking agents","MLLNCUMT","Million of national currency units","TUR","Türkiye","2021","2021",827.6,,
+"PATCBETA","C07-Beta blocking agents","MTMOTCMT","Million US$ at exchange rate","TUR","Türkiye","2010","2010",107.3,,
+"PATCBETA","C07-Beta blocking agents","MTMOTCMT","Million US$ at exchange rate","TUR","Türkiye","2011","2011",99.9,,
+"PATCBETA","C07-Beta blocking agents","MTMOTCMT","Million US$ at exchange rate","TUR","Türkiye","2012","2012",98.2,,
+"PATCBETA","C07-Beta blocking agents","MTMOTCMT","Million US$ at exchange rate","TUR","Türkiye","2013","2013",103,,
+"PATCBETA","C07-Beta blocking agents","MTMOTCMT","Million US$ at exchange rate","TUR","Türkiye","2014","2014",102.1,,
+"PATCBETA","C07-Beta blocking agents","MTMOTCMT","Million US$ at exchange rate","TUR","Türkiye","2015","2015",90.6,,
+"PATCBETA","C07-Beta blocking agents","MTMOTCMT","Million US$ at exchange rate","TUR","Türkiye","2016","2016",97.3,,
+"PATCBETA","C07-Beta blocking agents","MTMOTCMT","Million US$ at exchange rate","TUR","Türkiye","2017","2017",95.1,,
+"PATCBETA","C07-Beta blocking agents","MTMOTCMT","Million US$ at exchange rate","TUR","Türkiye","2018","2018",84.8,,
+"PATCBETA","C07-Beta blocking agents","MTMOTCMT","Million US$ at exchange rate","TUR","Türkiye","2019","2019",96.1,,
+"PATCBETA","C07-Beta blocking agents","MTMOTCMT","Million US$ at exchange rate","TUR","Türkiye","2020","2020",97.4,,
+"PATCBETA","C07-Beta blocking agents","MTMOTCMT","Million US$ at exchange rate","TUR","Türkiye","2021","2021",93.5,,
+"PATCBETA","C07-Beta blocking agents","MTMOPPMT","Million US$, purchasing power parity","TUR","Türkiye","2010","2010",175.2,,
+"PATCBETA","C07-Beta blocking agents","MTMOPPMT","Million US$, purchasing power parity","TUR","Türkiye","2011","2011",173.2,,
+"PATCBETA","C07-Beta blocking agents","MTMOPPMT","Million US$, purchasing power parity","TUR","Türkiye","2012","2012",172.9,,
+"PATCBETA","C07-Beta blocking agents","MTMOPPMT","Million US$, purchasing power parity","TUR","Türkiye","2013","2013",183.3,,
+"PATCBETA","C07-Beta blocking agents","MTMOPPMT","Million US$, purchasing power parity","TUR","Türkiye","2014","2014",202.3,,
+"PATCBETA","C07-Beta blocking agents","MTMOPPMT","Million US$, purchasing power parity","TUR","Türkiye","2015","2015",212.1,,
+"PATCBETA","C07-Beta blocking agents","MTMOPPMT","Million US$, purchasing power parity","TUR","Türkiye","2016","2016",236.7,,
+"PATCBETA","C07-Beta blocking agents","MTMOPPMT","Million US$, purchasing power parity","TUR","Türkiye","2017","2017",250.7,,
+"PATCBETA","C07-Beta blocking agents","MTMOPPMT","Million US$, purchasing power parity","TUR","Türkiye","2018","2018",250.9,,
+"PATCBETA","C07-Beta blocking agents","MTMOPPMT","Million US$, purchasing power parity","TUR","Türkiye","2019","2019",292.4,,
+"PATCBETA","C07-Beta blocking agents","MTMOPPMT","Million US$, purchasing power parity","TUR","Türkiye","2020","2020",315.4,,
+"PATCBETA","C07-Beta blocking agents","MTMOPPMT","Million US$, purchasing power parity","TUR","Türkiye","2021","2021",294.7,,
+"PATCBETA","C07-Beta blocking agents","TCPPERMT","/capita, US$ exchange rate","TUR","Türkiye","2010","2010",1.5,,
+"PATCBETA","C07-Beta blocking agents","TCPPERMT","/capita, US$ exchange rate","TUR","Türkiye","2011","2011",1.3,,
+"PATCBETA","C07-Beta blocking agents","TCPPERMT","/capita, US$ exchange rate","TUR","Türkiye","2012","2012",1.3,,
+"PATCBETA","C07-Beta blocking agents","TCPPERMT","/capita, US$ exchange rate","TUR","Türkiye","2013","2013",1.4,,
+"PATCBETA","C07-Beta blocking agents","TCPPERMT","/capita, US$ exchange rate","TUR","Türkiye","2014","2014",1.3,,
+"PATCBETA","C07-Beta blocking agents","TCPPERMT","/capita, US$ exchange rate","TUR","Türkiye","2015","2015",1.2,,
+"PATCBETA","C07-Beta blocking agents","TCPPERMT","/capita, US$ exchange rate","TUR","Türkiye","2016","2016",1.2,,
+"PATCBETA","C07-Beta blocking agents","TCPPERMT","/capita, US$ exchange rate","TUR","Türkiye","2017","2017",1.2,,
+"PATCBETA","C07-Beta blocking agents","TCPPERMT","/capita, US$ exchange rate","TUR","Türkiye","2018","2018",1,,
+"PATCBETA","C07-Beta blocking agents","TCPPERMT","/capita, US$ exchange rate","TUR","Türkiye","2019","2019",1.2,,
+"PATCBETA","C07-Beta blocking agents","TCPPERMT","/capita, US$ exchange rate","TUR","Türkiye","2020","2020",1.2,,
+"PATCBETA","C07-Beta blocking agents","TCPPERMT","/capita, US$ exchange rate","TUR","Türkiye","2021","2021",1.1,,
+"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2010","2010",2.4,,
+"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2011","2011",2.3,,
+"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2012","2012",2.3,,
+"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2013","2013",2.4,,
+"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2014","2014",2.6,,
+"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2015","2015",2.7,,
+"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2016","2016",3,,
+"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2017","2017",3.1,,
+"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2018","2018",3.1,,
+"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2019","2019",3.5,,
+"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2020","2020",3.8,,
+"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2021","2021",3.5,,
+"PATCBETA","C07-Beta blocking agents","ATCPTTMT","% of total sales","TUR","Türkiye","2010","2010",1,,
+"PATCBETA","C07-Beta blocking agents","ATCPTTMT","% of total sales","TUR","Türkiye","2011","2011",1.2,,
+"PATCBETA","C07-Beta blocking agents","ATCPTTMT","% of total sales","TUR","Türkiye","2012","2012",1.3,,
+"PATCBETA","C07-Beta blocking agents","ATCPTTMT","% of total sales","TUR","Türkiye","2013","2013",1.4,,
+"PATCBETA","C07-Beta blocking agents","ATCPTTMT","% of total sales","TUR","Türkiye","2014","2014",1.4,,
+"PATCBETA","C07-Beta blocking agents","ATCPTTMT","% of total sales","TUR","Türkiye","2015","2015",1.3,,
+"PATCBETA","C07-Beta blocking agents","ATCPTTMT","% of total sales","TUR","Türkiye","2016","2016",1.3,,
+"PATCBETA","C07-Beta blocking agents","ATCPTTMT","% of total sales","TUR","Türkiye","2017","2017",1.4,,
+"PATCBETA","C07-Beta blocking agents","ATCPTTMT","% of total sales","TUR","Türkiye","2018","2018",1.3,,
+"PATCBETA","C07-Beta blocking agents","ATCPTTMT","% of total sales","TUR","Türkiye","2019","2019",1.3,,
+"PATCBETA","C07-Beta blocking agents","ATCPTTMT","% of total sales","TUR","Türkiye","2020","2020",1.4,,
+"PATCBETA","C07-Beta blocking agents","ATCPTTMT","% of total sales","TUR","Türkiye","2021","2021",1.3,,
+"PATCBETA","C07-Beta blocking agents","MLLNCUMT","Million of national currency units","CHL","Chile","2010","2010",8640.2,,
+"PATCBETA","C07-Beta blocking agents","MLLNCUMT","Million of national currency units","CHL","Chile","2011","2011",10586.3,"B","Break"
+"PATCBETA","C07-Beta blocking agents","MLLNCUMT","Million of national currency units","CHL","Chile","2012","2012",11971.2,,
+"PATCBETA","C07-Beta blocking agents","MLLNCUMT","Million of national currency units","CHL","Chile","2013","2013",12752.7,,
+"PATCBETA","C07-Beta blocking agents","MLLNCUMT","Million of national currency units","CHL","Chile","2014","2014",15358.9,,
+"PATCBETA","C07-Beta blocking agents","MLLNCUMT","Million of national currency units","CHL","Chile","2015","2015",16311,,
+"PATCBETA","C07-Beta blocking agents","MLLNCUMT","Million of national currency units","CHL","Chile","2016","2016",19105.1,,
+"PATCBETA","C07-Beta blocking agents","MLLNCUMT","Million of national currency units","CHL","Chile","2017","2017",18779.6,,
+"PATCBETA","C07-Beta blocking agents","MLLNCUMT","Million of national currency units","CHL","Chile","2018","2018",18941.2,,
+"PATCBETA","C07-Beta blocking agents","MLLNCUMT","Million of national currency units","CHL","Chile","2019","2019",21320.2,,
+"PATCBETA","C07-Beta blocking agents","MLLNCUMT","Million of national currency units","CHL","Chile","2020","2020",25554,,
+"PATCBETA","C07-Beta blocking agents","MLLNCUMT","Million of national currency units","CHL","Chile","2021","2021",22481.8,,
+"PATCBETA","C07-Beta blocking agents","MLLNCUMT","Million of national currency units","CHL","Chile","2022","2022",25660.1,,
+"PATCBETA","C07-Beta blocking agents","MTMOTCMT","Million US$ at exchange rate","CHL","Chile","2010","2010",16.9,,
+"PATCBETA","C07-Beta blocking agents","MTMOTCMT","Million US$ at exchange rate","CHL","Chile","2011","2011",21.9,"B","Break"
+"PATCBETA","C07-Beta blocking agents","MTMOTCMT","Million US$ at exchange rate","CHL","Chile","2012","2012",24.6,,
+"PATCBETA","C07-Beta blocking agents","MTMOTCMT","Million US$ at exchange rate","CHL","Chile","2013","2013",25.7,,
+"PATCBETA","C07-Beta blocking agents","MTMOTCMT","Million US$ at exchange rate","CHL","Chile","2014","2014",26.9,,
+"PATCBETA","C07-Beta blocking agents","MTMOTCMT","Million US$ at exchange rate","CHL","Chile","2015","2015",24.9,,
+"PATCBETA","C07-Beta blocking agents","MTMOTCMT","Million US$ at exchange rate","CHL","Chile","2016","2016",28.2,,
+"PATCBETA","C07-Beta blocking agents","MTMOTCMT","Million US$ at exchange rate","CHL","Chile","2017","2017",28.9,,
+"PATCBETA","C07-Beta blocking agents","MTMOTCMT","Million US$ at exchange rate","CHL","Chile","2018","2018",29.5,,
+"PATCBETA","C07-Beta blocking agents","MTMOTCMT","Million US$ at exchange rate","CHL","Chile","2019","2019",30.3,,
+"PATCBETA","C07-Beta blocking agents","MTMOTCMT","Million US$ at exchange rate","CHL","Chile","2020","2020",32.2,,
+"PATCBETA","C07-Beta blocking agents","MTMOTCMT","Million US$ at exchange rate","CHL","Chile","2021","2021",29.6,,
+"PATCBETA","C07-Beta blocking agents","MTMOTCMT","Million US$ at exchange rate","CHL","Chile","2022","2022",29.4,,
+"PATCBETA","C07-Beta blocking agents","MTMOPPMT","Million US$, purchasing power parity","CHL","Chile","2010","2010",24,,
+"PATCBETA","C07-Beta blocking agents","MTMOPPMT","Million US$, purchasing power parity","CHL","Chile","2011","2011",30.4,"B","Break"
+"PATCBETA","C07-Beta blocking agents","MTMOPPMT","Million US$, purchasing power parity","CHL","Chile","2012","2012",34.5,,
+"PATCBETA","C07-Beta blocking agents","MTMOPPMT","Million US$, purchasing power parity","CHL","Chile","2013","2013",36.5,,
+"PATCBETA","C07-Beta blocking agents","MTMOPPMT","Million US$, purchasing power parity","CHL","Chile","2014","2014",41.8,,
+"PATCBETA","C07-Beta blocking agents","MTMOPPMT","Million US$, purchasing power parity","CHL","Chile","2015","2015",41.7,,
+"PATCBETA","C07-Beta blocking agents","MTMOPPMT","Million US$, purchasing power parity","CHL","Chile","2016","2016",48.1,,
+"PATCBETA","C07-Beta blocking agents","MTMOPPMT","Million US$, purchasing power parity","CHL","Chile","2017","2017",47.2,,
+"PATCBETA","C07-Beta blocking agents","MTMOPPMT","Million US$, purchasing power parity","CHL","Chile","2018","2018",47.8,,
+"PATCBETA","C07-Beta blocking agents","MTMOPPMT","Million US$, purchasing power parity","CHL","Chile","2019","2019",53.1,,
+"PATCBETA","C07-Beta blocking agents","MTMOPPMT","Million US$, purchasing power parity","CHL","Chile","2020","2020",61.1,,
+"PATCBETA","C07-Beta blocking agents","MTMOPPMT","Million US$, purchasing power parity","CHL","Chile","2021","2021",51.7,,
+"PATCBETA","C07-Beta blocking agents","MTMOPPMT","Million US$, purchasing power parity","CHL","Chile","2022","2022",58.6,,
+"PATCBETA","C07-Beta blocking agents","TCPPERMT","/capita, US$ exchange rate","CHL","Chile","2010","2010",1,,
+"PATCBETA","C07-Beta blocking agents","TCPPERMT","/capita, US$ exchange rate","CHL","Chile","2011","2011",1.3,"B","Break"
+"PATCBETA","C07-Beta blocking agents","TCPPERMT","/capita, US$ exchange rate","CHL","Chile","2012","2012",1.4,,
+"PATCBETA","C07-Beta blocking agents","TCPPERMT","/capita, US$ exchange rate","CHL","Chile","2013","2013",1.5,,
+"PATCBETA","C07-Beta blocking agents","TCPPERMT","/capita, US$ exchange rate","CHL","Chile","2014","2014",1.5,,
+"PATCBETA","C07-Beta blocking agents","TCPPERMT","/capita, US$ exchange rate","CHL","Chile","2015","2015",1.4,,
+"PATCBETA","C07-Beta blocking agents","TCPPERMT","/capita, US$ exchange rate","CHL","Chile","2016","2016",1.6,,
+"PATCBETA","C07-Beta blocking agents","TCPPERMT","/capita, US$ exchange rate","CHL","Chile","2017","2017",1.6,,
+"PATCBETA","C07-Beta blocking agents","TCPPERMT","/capita, US$ exchange rate","CHL","Chile","2018","2018",1.6,,
+"PATCBETA","C07-Beta blocking agents","TCPPERMT","/capita, US$ exchange rate","CHL","Chile","2019","2019",1.6,,
+"PATCBETA","C07-Beta blocking agents","TCPPERMT","/capita, US$ exchange rate","CHL","Chile","2020","2020",1.7,,
+"PATCBETA","C07-Beta blocking agents","TCPPERMT","/capita, US$ exchange rate","CHL","Chile","2021","2021",1.5,,
+"PATCBETA","C07-Beta blocking agents","TCPPERMT","/capita, US$ exchange rate","CHL","Chile","2022","2022",1.5,,
+"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2010","2010",1.4,,
+"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2011","2011",1.8,"B","Break"
+"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2012","2012",2,,
+"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2013","2013",2.1,,
+"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2014","2014",2.4,,
+"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2015","2015",2.3,,
+"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2016","2016",2.6,,
+"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2017","2017",2.6,,
+"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2018","2018",2.5,,
+"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2019","2019",2.8,,
+"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2020","2020",3.1,,
+"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2021","2021",2.6,,
+"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2022","2022",3,,
+"PATCBETA","C07-Beta blocking agents","ATCPTTMT","% of total sales","CHL","Chile","2010","2010",1,,
+"PATCBETA","C07-Beta blocking agents","ATCPTTMT","% of total sales","CHL","Chile","2011","2011",0.9,"B","Break"
+"PATCBETA","C07-Beta blocking agents","ATCPTTMT","% of total sales","CHL","Chile","2012","2012",1,,
+"PATCBETA","C07-Beta blocking agents","ATCPTTMT","% of total sales","CHL","Chile","2013","2013",0.9,,
+"PATCBETA","C07-Beta blocking agents","ATCPTTMT","% of total sales","CHL","Chile","2014","2014",1,,
+"PATCBETA","C07-Beta blocking agents","ATCPTTMT","% of total sales","CHL","Chile","2015","2015",0.9,,
+"PATCBETA","C07-Beta blocking agents","ATCPTTMT","% of total sales","CHL","Chile","2016","2016",0.9,,
+"PATCBETA","C07-Beta blocking agents","ATCPTTMT","% of total sales","CHL","Chile","2017","2017",0.9,,
+"PATCBETA","C07-Beta blocking agents","ATCPTTMT","% of total sales","CHL","Chile","2018","2018",0.8,,
+"PATCBETA","C07-Beta blocking agents","ATCPTTMT","% of total sales","CHL","Chile","2019","2019",0.8,,
+"PATCBETA","C07-Beta blocking agents","ATCPTTMT","% of total sales","CHL","Chile","2020","2020",1,,
+"PATCBETA","C07-Beta blocking agents","ATCPTTMT","% of total sales","CHL","Chile","2021","2021",0.8,,
+"PATCBETA","C07-Beta blocking agents","ATCPTTMT","% of total sales","CHL","Chile","2022","2022",0.9,,
+"PATCBETA","C07-Beta blocking agents","MLLNCUMT","Million of national currency units","EST","Estonia","2010","2010",5.5,,
+"PATCBETA","C07-Beta blocking agents","MLLNCUMT","Million of national currency units","EST","Estonia","2011","2011",4.8,,
+"PATCBETA","C07-Beta blocking agents","MLLNCUMT","Million of national currency units","EST","Estonia","2012","2012",5.3,,
+"PATCBETA","C07-Beta blocking agents","MLLNCUMT","Million of national currency units","EST","Estonia","2013","2013",5.3,,
+"PATCBETA","C07-Beta blocking agents","MLLNCUMT","Million of national currency units","EST","Estonia","2014","2014",5.5,,
+"PATCBETA","C07-Beta blocking agents","MLLNCUMT","Million of national currency units","EST","Estonia","2015","2015",5.6,,
+"PATCBETA","C07-Beta blocking agents","MLLNCUMT","Million of national currency units","EST","Estonia","2016","2016",5.4,,
+"PATCBETA","C07-Beta blocking agents","MLLNCUMT","Million of national currency units","EST","Estonia","2017","2017",5.5,,
+"PATCBETA","C07-Beta blocking agents","MLLNCUMT","Million of national currency units","EST","Estonia","2018","2018",5.5,,
+"PATCBETA","C07-Beta blocking agents","MLLNCUMT","Million of national currency units","EST","Estonia","2019","2019",5.5,,
+"PATCBETA","C07-Beta blocking agents","MLLNCUMT","Million of national currency units","EST","Estonia","2020","2020",5.8,,
+"PATCBETA","C07-Beta blocking agents","MLLNCUMT","Million of national currency units","EST","Estonia","2021","2021",5.9,,
+"PATCBETA","C07-Beta blocking agents","MLLNCUMT","Million of national currency units","EST","Estonia","2022","2022",6,,
+"PATCBETA","C07-Beta blocking agents","MTMOTCMT","Million US$ at exchange rate","EST","Estonia","2010","2010",7.2,,
+"PATCBETA","C07-Beta blocking agents","MTMOTCMT","Million US$ at exchange rate","EST","Estonia","2011","2011",6.6,,
+"PATCBETA","C07-Beta blocking agents","MTMOTCMT","Million US$ at exchange rate","EST","Estonia","2012","2012",6.8,,
+"PATCBETA","C07-Beta blocking agents","MTMOTCMT","Million US$ at exchange rate","EST","Estonia","2013","2013",7.1,,
+"PATCBETA","C07-Beta blocking agents","MTMOTCMT","Million US$ at exchange rate","EST","Estonia","2014","2014",7.4,,
+"PATCBETA","C07-Beta blocking agents","MTMOTCMT","Million US$ at exchange rate","EST","Estonia","2015","2015",6.2,,
+"PATCBETA","C07-Beta blocking agents","MTMOTCMT","Million US$ at exchange rate","EST","Estonia","2016","2016",6,,
+"PATCBETA","C07-Beta blocking agents","MTMOTCMT","Million US$ at exchange rate","EST","Estonia","2017","2017",6.2,,
+"PATCBETA","C07-Beta blocking agents","MTMOTCMT","Million US$ at exchange rate","EST","Estonia","2018","2018",6.5,,
+"PATCBETA","C07-Beta blocking agents","MTMOTCMT","Million US$ at exchange rate","EST","Estonia","2019","2019",6.2,,
+"PATCBETA","C07-Beta blocking agents","MTMOTCMT","Million US$ at exchange rate","EST","Estonia","2020","2020",6.6,,
+"PATCBETA","C07-Beta blocking agents","MTMOTCMT","Million US$ at exchange rate","EST","Estonia","2021","2021",6.9,,
+"PATCBETA","C07-Beta blocking agents","MTMOTCMT","Million US$ at exchange rate","EST","Estonia","2022","2022",6.3,,
+"PATCBETA","C07-Beta blocking agents","MTMOPPMT","Million US$, purchasing power parity","EST","Estonia","2010","2010",10.7,,
+"PATCBETA","C07-Beta blocking agents","MTMOPPMT","Million US$, purchasing power parity","EST","Estonia","2011","2011",9.3,,
+"PATCBETA","C07-Beta blocking agents","MTMOPPMT","Million US$, purchasing power parity","EST","Estonia","2012","2012",10.2,,
+"PATCBETA","C07-Beta blocking agents","MTMOPPMT","Million US$, purchasing power parity","EST","Estonia","2013","2013",10.2,,
+"PATCBETA","C07-Beta blocking agents","MTMOPPMT","Million US$, purchasing power parity","EST","Estonia","2014","2014",10.5,,
+"PATCBETA","C07-Beta blocking agents","MTMOPPMT","Million US$, purchasing power parity","EST","Estonia","2015","2015",10.4,,
+"PATCBETA","C07-Beta blocking agents","MTMOPPMT","Million US$, purchasing power parity","EST","Estonia","2016","2016",10.3,,
+"PATCBETA","C07-Beta blocking agents","MTMOPPMT","Million US$, purchasing power parity","EST","Estonia","2017","2017",10.2,,
+"PATCBETA","C07-Beta blocking agents","MTMOPPMT","Million US$, purchasing power parity","EST","Estonia","2018","2018",10.3,,
+"PATCBETA","C07-Beta blocking agents","MTMOPPMT","Million US$, purchasing power parity","EST","Estonia","2019","2019",10.3,,
+"PATCBETA","C07-Beta blocking agents","MTMOPPMT","Million US$, purchasing power parity","EST","Estonia","2020","2020",11.1,,
+"PATCBETA","C07-Beta blocking agents","MTMOPPMT","Million US$, purchasing power parity","EST","Estonia","2021","2021",10.8,,
+"PATCBETA","C07-Beta blocking agents","MTMOPPMT","Million US$, purchasing power parity","EST","Estonia","2022","2022",10.6,,
+"PATCBETA","C07-Beta blocking agents","TCPPERMT","/capita, US$ exchange rate","EST","Estonia","2010","2010",5.4,,
+"PATCBETA","C07-Beta blocking agents","TCPPERMT","/capita, US$ exchange rate","EST","Estonia","2011","2011",5,,
+"PATCBETA","C07-Beta blocking agents","TCPPERMT","/capita, US$ exchange rate","EST","Estonia","2012","2012",5.2,,
+"PATCBETA","C07-Beta blocking agents","TCPPERMT","/capita, US$ exchange rate","EST","Estonia","2013","2013",5.4,,
+"PATCBETA","C07-Beta blocking agents","TCPPERMT","/capita, US$ exchange rate","EST","Estonia","2014","2014",5.6,,
+"PATCBETA","C07-Beta blocking agents","TCPPERMT","/capita, US$ exchange rate","EST","Estonia","2015","2015",4.7,,
+"PATCBETA","C07-Beta blocking agents","TCPPERMT","/capita, US$ exchange rate","EST","Estonia","2016","2016",4.6,,
+"PATCBETA","C07-Beta blocking agents","TCPPERMT","/capita, US$ exchange rate","EST","Estonia","2017","2017",4.7,,
+"PATCBETA","C07-Beta blocking agents","TCPPERMT","/capita, US$ exchange rate","EST","Estonia","2018","2018",4.9,,
+"PATCBETA","C07-Beta blocking agents","TCPPERMT","/capita, US$ exchange rate","EST","Estonia","2019","2019",4.7,,
+"PATCBETA","C07-Beta blocking agents","TCPPERMT","/capita, US$ exchange rate","EST","Estonia","2020","2020",5,,
+"PATCBETA","C07-Beta blocking agents","TCPPERMT","/capita, US$ exchange rate","EST","Estonia","2021","2021",5.2,,
+"PATCBETA","C07-Beta blocking agents","TCPPERMT","/capita, US$ exchange rate","EST","Estonia","2022","2022",4.8,,
+"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2010","2010",8,,
+"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2011","2011",7,,
+"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2012","2012",7.7,,
+"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2013","2013",7.7,,
+"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2014","2014",8,,
+"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2015","2015",7.9,,
+"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2016","2016",7.8,,
+"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2017","2017",7.7,,
+"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2018","2018",7.8,,
+"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2019","2019",7.8,,
+"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2020","2020",8.3,,
+"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2021","2021",8.1,,
+"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2022","2022",7.9,,
+"PATCBETA","C07-Beta blocking agents","ATCPTTMT","% of total sales","EST","Estonia","2010","2010",2.8,,
+"PATCBETA","C07-Beta blocking agents","ATCPTTMT","% of total sales","EST","Estonia","2011","2011",2.3,,
+"PATCBETA","C07-Beta blocking agents","ATCPTTMT","% of total sales","EST","Estonia","2012","2012",2.4,,
+"PATCBETA","C07-Beta blocking agents","ATCPTTMT","% of total sales","EST","Estonia","2013","2013",2.3,,
+"PATCBETA","C07-Beta blocking agents","ATCPTTMT","% of total sales","EST","Estonia","2014","2014",2.2,,
+"PATCBETA","C07-Beta blocking agents","ATCPTTMT","% of total sales","EST","Estonia","2015","2015",2.1,,
+"PATCBETA","C07-Beta blocking agents","ATCPTTMT","% of total sales","EST","Estonia","2016","2016",1.9,,
+"PATCBETA","C07-Beta blocking agents","ATCPTTMT","% of total sales","EST","Estonia","2017","2017",1.8,,
+"PATCBETA","C07-Beta blocking agents","ATCPTTMT","% of total sales","EST","Estonia","2018","2018",1.7,,
+"PATCBETA","C07-Beta blocking agents","ATCPTTMT","% of total sales","EST","Estonia","2019","2019",1.6,,
+"PATCBETA","C07-Beta blocking agents","ATCPTTMT","% of total sales","EST","Estonia","2020","2020",1.6,,
+"PATCBETA","C07-Beta blocking agents","ATCPTTMT","% of total sales","EST","Estonia","2021","2021",1.4,,
+"PATCBETA","C07-Beta blocking agents","ATCPTTMT","% of total sales","EST","Estonia","2022","2022",1.4,,
+"PATCBETA","C07-Beta blocking agents","MLLNCUMT","Million of national currency units","SVN","Slovenia","2010","2010",8.4,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","MLLNCUMT","Million of national currency units","SVN","Slovenia","2011","2011",7.8,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","MLLNCUMT","Million of national currency units","SVN","Slovenia","2012","2012",8.3,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","MLLNCUMT","Million of national currency units","SVN","Slovenia","2013","2013",8.7,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","MLLNCUMT","Million of national currency units","SVN","Slovenia","2014","2014",8.9,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","MLLNCUMT","Million of national currency units","SVN","Slovenia","2015","2015",9.5,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","MLLNCUMT","Million of national currency units","SVN","Slovenia","2016","2016",10.1,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","MLLNCUMT","Million of national currency units","SVN","Slovenia","2017","2017",10.2,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","MLLNCUMT","Million of national currency units","SVN","Slovenia","2018","2018",10.6,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","MLLNCUMT","Million of national currency units","SVN","Slovenia","2019","2019",10.8,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","MLLNCUMT","Million of national currency units","SVN","Slovenia","2020","2020",11.2,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","MLLNCUMT","Million of national currency units","SVN","Slovenia","2021","2021",11,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","MLLNCUMT","Million of national currency units","SVN","Slovenia","2022","2022",11.2,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","MTMOTCMT","Million US$ at exchange rate","SVN","Slovenia","2010","2010",11.1,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","MTMOTCMT","Million US$ at exchange rate","SVN","Slovenia","2011","2011",10.9,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","MTMOTCMT","Million US$ at exchange rate","SVN","Slovenia","2012","2012",10.7,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","MTMOTCMT","Million US$ at exchange rate","SVN","Slovenia","2013","2013",11.6,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","MTMOTCMT","Million US$ at exchange rate","SVN","Slovenia","2014","2014",11.9,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","MTMOTCMT","Million US$ at exchange rate","SVN","Slovenia","2015","2015",10.5,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","MTMOTCMT","Million US$ at exchange rate","SVN","Slovenia","2016","2016",11.1,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","MTMOTCMT","Million US$ at exchange rate","SVN","Slovenia","2017","2017",11.5,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","MTMOTCMT","Million US$ at exchange rate","SVN","Slovenia","2018","2018",12.5,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","MTMOTCMT","Million US$ at exchange rate","SVN","Slovenia","2019","2019",12.1,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","MTMOTCMT","Million US$ at exchange rate","SVN","Slovenia","2020","2020",12.7,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","MTMOTCMT","Million US$ at exchange rate","SVN","Slovenia","2021","2021",13,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","MTMOTCMT","Million US$ at exchange rate","SVN","Slovenia","2022","2022",11.8,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","MTMOPPMT","Million US$, purchasing power parity","SVN","Slovenia","2010","2010",13.1,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","MTMOPPMT","Million US$, purchasing power parity","SVN","Slovenia","2011","2011",12.6,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","MTMOPPMT","Million US$, purchasing power parity","SVN","Slovenia","2012","2012",13.8,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","MTMOPPMT","Million US$, purchasing power parity","SVN","Slovenia","2013","2013",14.7,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","MTMOPPMT","Million US$, purchasing power parity","SVN","Slovenia","2014","2014",15.1,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","MTMOPPMT","Million US$, purchasing power parity","SVN","Slovenia","2015","2015",15.9,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","MTMOPPMT","Million US$, purchasing power parity","SVN","Slovenia","2016","2016",17.4,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","MTMOPPMT","Million US$, purchasing power parity","SVN","Slovenia","2017","2017",17.9,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","MTMOPPMT","Million US$, purchasing power parity","SVN","Slovenia","2018","2018",18.7,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","MTMOPPMT","Million US$, purchasing power parity","SVN","Slovenia","2019","2019",19.6,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","MTMOPPMT","Million US$, purchasing power parity","SVN","Slovenia","2020","2020",20.4,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","MTMOPPMT","Million US$, purchasing power parity","SVN","Slovenia","2021","2021",19.5,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","MTMOPPMT","Million US$, purchasing power parity","SVN","Slovenia","2022","2022",20.3,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","TCPPERMT","/capita, US$ exchange rate","SVN","Slovenia","2010","2010",5.4,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","TCPPERMT","/capita, US$ exchange rate","SVN","Slovenia","2011","2011",5.3,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","TCPPERMT","/capita, US$ exchange rate","SVN","Slovenia","2012","2012",5.2,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","TCPPERMT","/capita, US$ exchange rate","SVN","Slovenia","2013","2013",5.6,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","TCPPERMT","/capita, US$ exchange rate","SVN","Slovenia","2014","2014",5.8,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","TCPPERMT","/capita, US$ exchange rate","SVN","Slovenia","2015","2015",5.1,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","TCPPERMT","/capita, US$ exchange rate","SVN","Slovenia","2016","2016",5.4,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","TCPPERMT","/capita, US$ exchange rate","SVN","Slovenia","2017","2017",5.6,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","TCPPERMT","/capita, US$ exchange rate","SVN","Slovenia","2018","2018",6,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","TCPPERMT","/capita, US$ exchange rate","SVN","Slovenia","2019","2019",5.8,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","TCPPERMT","/capita, US$ exchange rate","SVN","Slovenia","2020","2020",6.1,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","TCPPERMT","/capita, US$ exchange rate","SVN","Slovenia","2021","2021",6.2,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","TCPPERMT","/capita, US$ exchange rate","SVN","Slovenia","2022","2022",5.6,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2010","2010",6.4,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2011","2011",6.1,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2012","2012",6.7,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2013","2013",7.2,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2014","2014",7.3,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2015","2015",7.7,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2016","2016",8.4,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2017","2017",8.7,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2018","2018",9,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2019","2019",9.4,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2020","2020",9.7,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2021","2021",9.3,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2022","2022",9.6,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","ATCPTTMT","% of total sales","SVN","Slovenia","2010","2010",1.8,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","ATCPTTMT","% of total sales","SVN","Slovenia","2011","2011",1.7,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","ATCPTTMT","% of total sales","SVN","Slovenia","2012","2012",1.8,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","ATCPTTMT","% of total sales","SVN","Slovenia","2013","2013",1.9,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","ATCPTTMT","% of total sales","SVN","Slovenia","2014","2014",2.1,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","ATCPTTMT","% of total sales","SVN","Slovenia","2015","2015",2.1,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","ATCPTTMT","% of total sales","SVN","Slovenia","2016","2016",2.2,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","ATCPTTMT","% of total sales","SVN","Slovenia","2017","2017",2.1,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","ATCPTTMT","% of total sales","SVN","Slovenia","2018","2018",2.1,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","ATCPTTMT","% of total sales","SVN","Slovenia","2019","2019",2,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","ATCPTTMT","% of total sales","SVN","Slovenia","2020","2020",2,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","ATCPTTMT","% of total sales","SVN","Slovenia","2021","2021",1.8,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","ATCPTTMT","% of total sales","SVN","Slovenia","2022","2022",1.6,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","MLLNCUMT","Million of national currency units","AUS","Australia","2010","2010",159,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","MLLNCUMT","Million of national currency units","AUS","Australia","2011","2011",142,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","MLLNCUMT","Million of national currency units","AUS","Australia","2012","2012",118,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","MLLNCUMT","Million of national currency units","AUS","Australia","2013","2013",131,"B; D","Break; Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","MLLNCUMT","Million of national currency units","AUS","Australia","2014","2014",119,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","MLLNCUMT","Million of national currency units","AUS","Australia","2015","2015",124,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","MLLNCUMT","Million of national currency units","AUS","Australia","2016","2016",133,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","MLLNCUMT","Million of national currency units","AUS","Australia","2017","2017",130,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","MLLNCUMT","Million of national currency units","AUS","Australia","2018","2018",132,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","MLLNCUMT","Million of national currency units","AUS","Australia","2019","2019",134,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","MLLNCUMT","Million of national currency units","AUS","Australia","2020","2020",142,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","MLLNCUMT","Million of national currency units","AUS","Australia","2021","2021",148,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","MTMOTCMT","Million US$ at exchange rate","AUS","Australia","2010","2010",145.9,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","MTMOTCMT","Million US$ at exchange rate","AUS","Australia","2011","2011",146.5,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","MTMOTCMT","Million US$ at exchange rate","AUS","Australia","2012","2012",122.2,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","MTMOTCMT","Million US$ at exchange rate","AUS","Australia","2013","2013",126.5,"B; D","Break; Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","MTMOTCMT","Million US$ at exchange rate","AUS","Australia","2014","2014",107.3,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","MTMOTCMT","Million US$ at exchange rate","AUS","Australia","2015","2015",93.2,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","MTMOTCMT","Million US$ at exchange rate","AUS","Australia","2016","2016",98.9,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","MTMOTCMT","Million US$ at exchange rate","AUS","Australia","2017","2017",99.6,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","MTMOTCMT","Million US$ at exchange rate","AUS","Australia","2018","2018",98.6,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","MTMOTCMT","Million US$ at exchange rate","AUS","Australia","2019","2019",93.2,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","MTMOTCMT","Million US$ at exchange rate","AUS","Australia","2020","2020",97.7,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","MTMOTCMT","Million US$ at exchange rate","AUS","Australia","2021","2021",111.2,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","MTMOPPMT","Million US$, purchasing power parity","AUS","Australia","2010","2010",105.7,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","MTMOPPMT","Million US$, purchasing power parity","AUS","Australia","2011","2011",94,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","MTMOPPMT","Million US$, purchasing power parity","AUS","Australia","2012","2012",76.6,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","MTMOPPMT","Million US$, purchasing power parity","AUS","Australia","2013","2013",90.5,"B; D","Break; Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","MTMOPPMT","Million US$, purchasing power parity","AUS","Australia","2014","2014",81.9,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","MTMOPPMT","Million US$, purchasing power parity","AUS","Australia","2015","2015",84.1,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","MTMOPPMT","Million US$, purchasing power parity","AUS","Australia","2016","2016",91.7,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","MTMOPPMT","Million US$, purchasing power parity","AUS","Australia","2017","2017",88,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","MTMOPPMT","Million US$, purchasing power parity","AUS","Australia","2018","2018",89.8,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","MTMOPPMT","Million US$, purchasing power parity","AUS","Australia","2019","2019",90.5,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","MTMOPPMT","Million US$, purchasing power parity","AUS","Australia","2020","2020",97.7,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","MTMOPPMT","Million US$, purchasing power parity","AUS","Australia","2021","2021",102.2,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","TCPPERMT","/capita, US$ exchange rate","AUS","Australia","2010","2010",6.6,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","TCPPERMT","/capita, US$ exchange rate","AUS","Australia","2011","2011",6.6,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","TCPPERMT","/capita, US$ exchange rate","AUS","Australia","2012","2012",5.4,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","TCPPERMT","/capita, US$ exchange rate","AUS","Australia","2013","2013",5.5,"B; D","Break; Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","TCPPERMT","/capita, US$ exchange rate","AUS","Australia","2014","2014",4.6,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","TCPPERMT","/capita, US$ exchange rate","AUS","Australia","2015","2015",3.9,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","TCPPERMT","/capita, US$ exchange rate","AUS","Australia","2016","2016",4.1,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","TCPPERMT","/capita, US$ exchange rate","AUS","Australia","2017","2017",4.1,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","TCPPERMT","/capita, US$ exchange rate","AUS","Australia","2018","2018",4,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","TCPPERMT","/capita, US$ exchange rate","AUS","Australia","2019","2019",3.7,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","TCPPERMT","/capita, US$ exchange rate","AUS","Australia","2020","2020",3.8,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","TCPPERMT","/capita, US$ exchange rate","AUS","Australia","2021","2021",4.3,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2010","2010",4.8,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2011","2011",4.2,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2012","2012",3.4,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2013","2013",3.9,"B; D","Break; Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2014","2014",3.5,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2015","2015",3.5,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2016","2016",3.8,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2017","2017",3.6,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2018","2018",3.6,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2019","2019",3.6,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2020","2020",3.8,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2021","2021",4,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","ATCPTTMT","% of total sales","AUS","Australia","2010","2010",1.6,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","ATCPTTMT","% of total sales","AUS","Australia","2011","2011",1.4,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","ATCPTTMT","% of total sales","AUS","Australia","2012","2012",1.1,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","ATCPTTMT","% of total sales","AUS","Australia","2013","2013",1.1,"B; D","Break; Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","ATCPTTMT","% of total sales","AUS","Australia","2014","2014",1,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","ATCPTTMT","% of total sales","AUS","Australia","2015","2015",1,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","ATCPTTMT","% of total sales","AUS","Australia","2016","2016",0.9,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","ATCPTTMT","% of total sales","AUS","Australia","2017","2017",0.9,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","ATCPTTMT","% of total sales","AUS","Australia","2018","2018",0.9,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","ATCPTTMT","% of total sales","AUS","Australia","2019","2019",0.9,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","ATCPTTMT","% of total sales","AUS","Australia","2020","2020",0.9,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","ATCPTTMT","% of total sales","AUS","Australia","2021","2021",0.8,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","MLLNCUMT","Million of national currency units","AUT","Austria","2010","2010",34.5,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","MLLNCUMT","Million of national currency units","AUT","Austria","2011","2011",30.5,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","MLLNCUMT","Million of national currency units","AUT","Austria","2012","2012",29.5,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","MLLNCUMT","Million of national currency units","AUT","Austria","2013","2013",28.4,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","MLLNCUMT","Million of national currency units","AUT","Austria","2014","2014",27.6,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","MLLNCUMT","Million of national currency units","AUT","Austria","2015","2015",20.6,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","MLLNCUMT","Million of national currency units","AUT","Austria","2016","2016",10.9,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","MLLNCUMT","Million of national currency units","AUT","Austria","2017","2017",10.1,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","MLLNCUMT","Million of national currency units","AUT","Austria","2018","2018",9.7,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","MLLNCUMT","Million of national currency units","AUT","Austria","2019","2019",9.4,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","MLLNCUMT","Million of national currency units","AUT","Austria","2020","2020",8.9,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","MLLNCUMT","Million of national currency units","AUT","Austria","2021","2021",8.7,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","MTMOTCMT","Million US$ at exchange rate","AUT","Austria","2010","2010",45.7,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","MTMOTCMT","Million US$ at exchange rate","AUT","Austria","2011","2011",42.5,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","MTMOTCMT","Million US$ at exchange rate","AUT","Austria","2012","2012",37.8,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","MTMOTCMT","Million US$ at exchange rate","AUT","Austria","2013","2013",37.8,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","MTMOTCMT","Million US$ at exchange rate","AUT","Austria","2014","2014",36.7,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","MTMOTCMT","Million US$ at exchange rate","AUT","Austria","2015","2015",22.9,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","MTMOTCMT","Million US$ at exchange rate","AUT","Austria","2016","2016",12,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","MTMOTCMT","Million US$ at exchange rate","AUT","Austria","2017","2017",11.4,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","MTMOTCMT","Million US$ at exchange rate","AUT","Austria","2018","2018",11.5,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","MTMOTCMT","Million US$ at exchange rate","AUT","Austria","2019","2019",10.6,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","MTMOTCMT","Million US$ at exchange rate","AUT","Austria","2020","2020",10.1,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","MTMOTCMT","Million US$ at exchange rate","AUT","Austria","2021","2021",10.3,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","MTMOPPMT","Million US$, purchasing power parity","AUT","Austria","2010","2010",40.9,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","MTMOPPMT","Million US$, purchasing power parity","AUT","Austria","2011","2011",36.7,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","MTMOPPMT","Million US$, purchasing power parity","AUT","Austria","2012","2012",36.2,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","MTMOPPMT","Million US$, purchasing power parity","AUT","Austria","2013","2013",35.7,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","MTMOPPMT","Million US$, purchasing power parity","AUT","Austria","2014","2014",34.5,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","MTMOPPMT","Million US$, purchasing power parity","AUT","Austria","2015","2015",25.8,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","MTMOPPMT","Million US$, purchasing power parity","AUT","Austria","2016","2016",14,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","MTMOPPMT","Million US$, purchasing power parity","AUT","Austria","2017","2017",13,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","MTMOPPMT","Million US$, purchasing power parity","AUT","Austria","2018","2018",12.7,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","MTMOPPMT","Million US$, purchasing power parity","AUT","Austria","2019","2019",12.6,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","MTMOPPMT","Million US$, purchasing power parity","AUT","Austria","2020","2020",11.9,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","MTMOPPMT","Million US$, purchasing power parity","AUT","Austria","2021","2021",11.6,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","TCPPERMT","/capita, US$ exchange rate","AUT","Austria","2010","2010",5.5,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","TCPPERMT","/capita, US$ exchange rate","AUT","Austria","2011","2011",5.1,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","TCPPERMT","/capita, US$ exchange rate","AUT","Austria","2012","2012",4.5,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","TCPPERMT","/capita, US$ exchange rate","AUT","Austria","2013","2013",4.5,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","TCPPERMT","/capita, US$ exchange rate","AUT","Austria","2014","2014",4.3,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","TCPPERMT","/capita, US$ exchange rate","AUT","Austria","2015","2015",2.6,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","TCPPERMT","/capita, US$ exchange rate","AUT","Austria","2016","2016",1.4,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","TCPPERMT","/capita, US$ exchange rate","AUT","Austria","2017","2017",1.3,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","TCPPERMT","/capita, US$ exchange rate","AUT","Austria","2018","2018",1.3,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","TCPPERMT","/capita, US$ exchange rate","AUT","Austria","2019","2019",1.2,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","TCPPERMT","/capita, US$ exchange rate","AUT","Austria","2020","2020",1.1,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","TCPPERMT","/capita, US$ exchange rate","AUT","Austria","2021","2021",1.2,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2010","2010",4.9,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2011","2011",4.4,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2012","2012",4.3,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2013","2013",4.2,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2014","2014",4,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2015","2015",3,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2016","2016",1.6,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2017","2017",1.5,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2018","2018",1.4,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2019","2019",1.4,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2020","2020",1.3,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2021","2021",1.3,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","ATCPTTMT","% of total sales","AUT","Austria","2010","2010",1.4,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","ATCPTTMT","% of total sales","AUT","Austria","2011","2011",1.2,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","ATCPTTMT","% of total sales","AUT","Austria","2012","2012",1.1,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","ATCPTTMT","% of total sales","AUT","Austria","2013","2013",1.1,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","ATCPTTMT","% of total sales","AUT","Austria","2014","2014",1,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","ATCPTTMT","% of total sales","AUT","Austria","2015","2015",0.7,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","ATCPTTMT","% of total sales","AUT","Austria","2016","2016",0.4,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","ATCPTTMT","% of total sales","AUT","Austria","2017","2017",0.3,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","ATCPTTMT","% of total sales","AUT","Austria","2018","2018",0.3,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","ATCPTTMT","% of total sales","AUT","Austria","2019","2019",0.3,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","ATCPTTMT","% of total sales","AUT","Austria","2020","2020",0.3,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","ATCPTTMT","% of total sales","AUT","Austria","2021","2021",0.2,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","MLLNCUMT","Million of national currency units","BEL","Belgium","2010","2010",72.4,,
+"PATCCCBR","C08-Calcium channel blockers","MLLNCUMT","Million of national currency units","BEL","Belgium","2011","2011",67.8,,
+"PATCCCBR","C08-Calcium channel blockers","MLLNCUMT","Million of national currency units","BEL","Belgium","2012","2012",63.9,,
+"PATCCCBR","C08-Calcium channel blockers","MLLNCUMT","Million of national currency units","BEL","Belgium","2013","2013",57.9,,
+"PATCCCBR","C08-Calcium channel blockers","MLLNCUMT","Million of national currency units","BEL","Belgium","2014","2014",57.1,,
+"PATCCCBR","C08-Calcium channel blockers","MLLNCUMT","Million of national currency units","BEL","Belgium","2015","2015",48.6,,
+"PATCCCBR","C08-Calcium channel blockers","MLLNCUMT","Million of national currency units","BEL","Belgium","2016","2016",45.9,,
+"PATCCCBR","C08-Calcium channel blockers","MLLNCUMT","Million of national currency units","BEL","Belgium","2017","2017",43.1,,
+"PATCCCBR","C08-Calcium channel blockers","MLLNCUMT","Million of national currency units","BEL","Belgium","2018","2018",35.5,,
+"PATCCCBR","C08-Calcium channel blockers","MLLNCUMT","Million of national currency units","BEL","Belgium","2019","2019",35.4,,
+"PATCCCBR","C08-Calcium channel blockers","MLLNCUMT","Million of national currency units","BEL","Belgium","2020","2020",33.7,,
+"PATCCCBR","C08-Calcium channel blockers","MLLNCUMT","Million of national currency units","BEL","Belgium","2021","2021",31.7,,
+"PATCCCBR","C08-Calcium channel blockers","MLLNCUMT","Million of national currency units","BEL","Belgium","2022","2022",30.3,"E","Estimated value"
+"PATCCCBR","C08-Calcium channel blockers","MTMOTCMT","Million US$ at exchange rate","BEL","Belgium","2010","2010",95.9,,
+"PATCCCBR","C08-Calcium channel blockers","MTMOTCMT","Million US$ at exchange rate","BEL","Belgium","2011","2011",94.4,,
+"PATCCCBR","C08-Calcium channel blockers","MTMOTCMT","Million US$ at exchange rate","BEL","Belgium","2012","2012",82,,
+"PATCCCBR","C08-Calcium channel blockers","MTMOTCMT","Million US$ at exchange rate","BEL","Belgium","2013","2013",76.9,,
+"PATCCCBR","C08-Calcium channel blockers","MTMOTCMT","Million US$ at exchange rate","BEL","Belgium","2014","2014",75.9,,
+"PATCCCBR","C08-Calcium channel blockers","MTMOTCMT","Million US$ at exchange rate","BEL","Belgium","2015","2015",53.9,,
+"PATCCCBR","C08-Calcium channel blockers","MTMOTCMT","Million US$ at exchange rate","BEL","Belgium","2016","2016",50.9,,
+"PATCCCBR","C08-Calcium channel blockers","MTMOTCMT","Million US$ at exchange rate","BEL","Belgium","2017","2017",48.7,,
+"PATCCCBR","C08-Calcium channel blockers","MTMOTCMT","Million US$ at exchange rate","BEL","Belgium","2018","2018",41.9,,
+"PATCCCBR","C08-Calcium channel blockers","MTMOTCMT","Million US$ at exchange rate","BEL","Belgium","2019","2019",39.7,,
+"PATCCCBR","C08-Calcium channel blockers","MTMOTCMT","Million US$ at exchange rate","BEL","Belgium","2020","2020",38.5,,
+"PATCCCBR","C08-Calcium channel blockers","MTMOTCMT","Million US$ at exchange rate","BEL","Belgium","2021","2021",37.5,,
+"PATCCCBR","C08-Calcium channel blockers","MTMOTCMT","Million US$ at exchange rate","BEL","Belgium","2022","2022",31.9,"E","Estimated value"
+"PATCCCBR","C08-Calcium channel blockers","MTMOPPMT","Million US$, purchasing power parity","BEL","Belgium","2010","2010",86.5,,
+"PATCCCBR","C08-Calcium channel blockers","MTMOPPMT","Million US$, purchasing power parity","BEL","Belgium","2011","2011",81.5,,
+"PATCCCBR","C08-Calcium channel blockers","MTMOPPMT","Million US$, purchasing power parity","BEL","Belgium","2012","2012",77.7,,
+"PATCCCBR","C08-Calcium channel blockers","MTMOPPMT","Million US$, purchasing power parity","BEL","Belgium","2013","2013",71.8,,
+"PATCCCBR","C08-Calcium channel blockers","MTMOPPMT","Million US$, purchasing power parity","BEL","Belgium","2014","2014",71.4,,
+"PATCCCBR","C08-Calcium channel blockers","MTMOPPMT","Million US$, purchasing power parity","BEL","Belgium","2015","2015",60.7,,
+"PATCCCBR","C08-Calcium channel blockers","MTMOPPMT","Million US$, purchasing power parity","BEL","Belgium","2016","2016",58.8,,
+"PATCCCBR","C08-Calcium channel blockers","MTMOPPMT","Million US$, purchasing power parity","BEL","Belgium","2017","2017",55.6,,
+"PATCCCBR","C08-Calcium channel blockers","MTMOPPMT","Million US$, purchasing power parity","BEL","Belgium","2018","2018",46.3,,
+"PATCCCBR","C08-Calcium channel blockers","MTMOPPMT","Million US$, purchasing power parity","BEL","Belgium","2019","2019",47.5,,
+"PATCCCBR","C08-Calcium channel blockers","MTMOPPMT","Million US$, purchasing power parity","BEL","Belgium","2020","2020",46.2,,
+"PATCCCBR","C08-Calcium channel blockers","MTMOPPMT","Million US$, purchasing power parity","BEL","Belgium","2021","2021",43,,
+"PATCCCBR","C08-Calcium channel blockers","MTMOPPMT","Million US$, purchasing power parity","BEL","Belgium","2022","2022",42.4,"E","Estimated value"
+"PATCCCBR","C08-Calcium channel blockers","TCPPERMT","/capita, US$ exchange rate","BEL","Belgium","2010","2010",8.8,,
+"PATCCCBR","C08-Calcium channel blockers","TCPPERMT","/capita, US$ exchange rate","BEL","Belgium","2011","2011",8.5,,
+"PATCCCBR","C08-Calcium channel blockers","TCPPERMT","/capita, US$ exchange rate","BEL","Belgium","2012","2012",7.4,,
+"PATCCCBR","C08-Calcium channel blockers","TCPPERMT","/capita, US$ exchange rate","BEL","Belgium","2013","2013",6.9,,
+"PATCCCBR","C08-Calcium channel blockers","TCPPERMT","/capita, US$ exchange rate","BEL","Belgium","2014","2014",6.8,,
+"PATCCCBR","C08-Calcium channel blockers","TCPPERMT","/capita, US$ exchange rate","BEL","Belgium","2015","2015",4.8,,
+"PATCCCBR","C08-Calcium channel blockers","TCPPERMT","/capita, US$ exchange rate","BEL","Belgium","2016","2016",4.5,,
+"PATCCCBR","C08-Calcium channel blockers","TCPPERMT","/capita, US$ exchange rate","BEL","Belgium","2017","2017",4.3,,
+"PATCCCBR","C08-Calcium channel blockers","TCPPERMT","/capita, US$ exchange rate","BEL","Belgium","2018","2018",3.7,,
+"PATCCCBR","C08-Calcium channel blockers","TCPPERMT","/capita, US$ exchange rate","BEL","Belgium","2019","2019",3.5,,
+"PATCCCBR","C08-Calcium channel blockers","TCPPERMT","/capita, US$ exchange rate","BEL","Belgium","2020","2020",3.3,,
+"PATCCCBR","C08-Calcium channel blockers","TCPPERMT","/capita, US$ exchange rate","BEL","Belgium","2021","2021",3.2,,
+"PATCCCBR","C08-Calcium channel blockers","TCPPERMT","/capita, US$ exchange rate","BEL","Belgium","2022","2022",2.7,"E","Estimated value"
+"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2010","2010",7.9,,
+"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2011","2011",7.4,,
+"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2012","2012",7,,
+"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2013","2013",6.4,,
+"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2014","2014",6.4,,
+"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2015","2015",5.4,,
+"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2016","2016",5.2,,
+"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2017","2017",4.9,,
+"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2018","2018",4.1,,
+"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2019","2019",4.1,,
+"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2020","2020",4,,
+"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2021","2021",3.7,,
+"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2022","2022",3.7,"E","Estimated value"
+"PATCCCBR","C08-Calcium channel blockers","ATCPTTMT","% of total sales","BEL","Belgium","2010","2010",1.2,,
+"PATCCCBR","C08-Calcium channel blockers","ATCPTTMT","% of total sales","BEL","Belgium","2011","2011",1.1,,
+"PATCCCBR","C08-Calcium channel blockers","ATCPTTMT","% of total sales","BEL","Belgium","2012","2012",1.1,,
+"PATCCCBR","C08-Calcium channel blockers","ATCPTTMT","% of total sales","BEL","Belgium","2013","2013",1,,
+"PATCCCBR","C08-Calcium channel blockers","ATCPTTMT","% of total sales","BEL","Belgium","2014","2014",1,,
+"PATCCCBR","C08-Calcium channel blockers","ATCPTTMT","% of total sales","BEL","Belgium","2015","2015",0.8,,
+"PATCCCBR","C08-Calcium channel blockers","ATCPTTMT","% of total sales","BEL","Belgium","2016","2016",0.7,,
+"PATCCCBR","C08-Calcium channel blockers","ATCPTTMT","% of total sales","BEL","Belgium","2017","2017",0.7,,
+"PATCCCBR","C08-Calcium channel blockers","ATCPTTMT","% of total sales","BEL","Belgium","2018","2018",0.5,,
+"PATCCCBR","C08-Calcium channel blockers","ATCPTTMT","% of total sales","BEL","Belgium","2019","2019",0.5,,
+"PATCCCBR","C08-Calcium channel blockers","ATCPTTMT","% of total sales","BEL","Belgium","2020","2020",0.4,,
+"PATCCCBR","C08-Calcium channel blockers","ATCPTTMT","% of total sales","BEL","Belgium","2021","2021",0.4,,
+"PATCCCBR","C08-Calcium channel blockers","ATCPTTMT","% of total sales","BEL","Belgium","2022","2022",0.3,"E","Estimated value"
+"PATCCCBR","C08-Calcium channel blockers","MLLNCUMT","Million of national currency units","CAN","Canada","2012","2012",613.4,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","MLLNCUMT","Million of national currency units","CAN","Canada","2013","2013",562.3,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","MLLNCUMT","Million of national currency units","CAN","Canada","2014","2014",547.5,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","MLLNCUMT","Million of national currency units","CAN","Canada","2015","2015",545.6,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","MLLNCUMT","Million of national currency units","CAN","Canada","2016","2016",546.9,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","MLLNCUMT","Million of national currency units","CAN","Canada","2017","2017",531.6,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","MLLNCUMT","Million of national currency units","CAN","Canada","2018","2018",472,"E; B; D","Estimated value; Break; Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","MLLNCUMT","Million of national currency units","CAN","Canada","2019","2019",427.3,"E; D","Estimated value; Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","MLLNCUMT","Million of national currency units","CAN","Canada","2020","2020",422.5,"E; D","Estimated value; Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","MLLNCUMT","Million of national currency units","CAN","Canada","2021","2021",414.4,"E; D","Estimated value; Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","MLLNCUMT","Million of national currency units","CAN","Canada","2022","2022",417.4,"E; D","Estimated value; Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","MTMOTCMT","Million US$ at exchange rate","CAN","Canada","2012","2012",613.8,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","MTMOTCMT","Million US$ at exchange rate","CAN","Canada","2013","2013",545.8,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","MTMOTCMT","Million US$ at exchange rate","CAN","Canada","2014","2014",495.6,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","MTMOTCMT","Million US$ at exchange rate","CAN","Canada","2015","2015",426.7,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","MTMOTCMT","Million US$ at exchange rate","CAN","Canada","2016","2016",412.6,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","MTMOTCMT","Million US$ at exchange rate","CAN","Canada","2017","2017",409.6,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","MTMOTCMT","Million US$ at exchange rate","CAN","Canada","2018","2018",364.3,"E; B; D","Estimated value; Break; Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","MTMOTCMT","Million US$ at exchange rate","CAN","Canada","2019","2019",322,"E; D","Estimated value; Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","MTMOTCMT","Million US$ at exchange rate","CAN","Canada","2020","2020",315.1,"E; D","Estimated value; Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","MTMOTCMT","Million US$ at exchange rate","CAN","Canada","2021","2021",330.5,"E; D","Estimated value; Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","MTMOTCMT","Million US$ at exchange rate","CAN","Canada","2022","2022",320.7,"E; D","Estimated value; Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","MTMOPPMT","Million US$, purchasing power parity","CAN","Canada","2012","2012",492.8,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","MTMOPPMT","Million US$, purchasing power parity","CAN","Canada","2013","2013",459.4,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","MTMOPPMT","Million US$, purchasing power parity","CAN","Canada","2014","2014",445,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","MTMOPPMT","Million US$, purchasing power parity","CAN","Canada","2015","2015",437.2,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","MTMOPPMT","Million US$, purchasing power parity","CAN","Canada","2016","2016",453.1,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","MTMOPPMT","Million US$, purchasing power parity","CAN","Canada","2017","2017",438.5,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","MTMOPPMT","Million US$, purchasing power parity","CAN","Canada","2018","2018",391.2,"E; B; D","Estimated value; Break; Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","MTMOPPMT","Million US$, purchasing power parity","CAN","Canada","2019","2019",346.1,"E; D","Estimated value; Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","MTMOPPMT","Million US$, purchasing power parity","CAN","Canada","2020","2020",343.2,"E; D","Estimated value; Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","MTMOPPMT","Million US$, purchasing power parity","CAN","Canada","2021","2021",334.7,"E; D","Estimated value; Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","MTMOPPMT","Million US$, purchasing power parity","CAN","Canada","2022","2022",332.9,"E; D","Estimated value; Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","TCPPERMT","/capita, US$ exchange rate","CAN","Canada","2012","2012",17.7,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","TCPPERMT","/capita, US$ exchange rate","CAN","Canada","2013","2013",15.6,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","TCPPERMT","/capita, US$ exchange rate","CAN","Canada","2014","2014",14,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","TCPPERMT","/capita, US$ exchange rate","CAN","Canada","2015","2015",12,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","TCPPERMT","/capita, US$ exchange rate","CAN","Canada","2016","2016",11.4,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","TCPPERMT","/capita, US$ exchange rate","CAN","Canada","2017","2017",11.2,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","TCPPERMT","/capita, US$ exchange rate","CAN","Canada","2018","2018",9.8,"E; B; D","Estimated value; Break; Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","TCPPERMT","/capita, US$ exchange rate","CAN","Canada","2019","2019",8.6,"E; D","Estimated value; Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","TCPPERMT","/capita, US$ exchange rate","CAN","Canada","2020","2020",8.3,"E; D","Estimated value; Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","TCPPERMT","/capita, US$ exchange rate","CAN","Canada","2021","2021",8.6,"E; D","Estimated value; Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","TCPPERMT","/capita, US$ exchange rate","CAN","Canada","2022","2022",8.2,"E; D","Estimated value; Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2012","2012",14.2,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2013","2013",13.1,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2014","2014",12.6,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2015","2015",12.2,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2016","2016",12.5,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2017","2017",12,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2018","2018",10.6,"E; B; D","Estimated value; Break; Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2019","2019",9.2,"E; D","Estimated value; Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2020","2020",9,"E; D","Estimated value; Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2021","2021",8.8,"E; D","Estimated value; Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2022","2022",8.6,"E; D","Estimated value; Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","ATCPTTMT","% of total sales","CAN","Canada","2012","2012",2.5,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","ATCPTTMT","% of total sales","CAN","Canada","2013","2013",2.3,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","ATCPTTMT","% of total sales","CAN","Canada","2014","2014",2.1,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","ATCPTTMT","% of total sales","CAN","Canada","2015","2015",2,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","ATCPTTMT","% of total sales","CAN","Canada","2016","2016",1.9,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","ATCPTTMT","% of total sales","CAN","Canada","2017","2017",1.8,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","ATCPTTMT","% of total sales","CAN","Canada","2018","2018",1.5,"E; B; D","Estimated value; Break; Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","ATCPTTMT","% of total sales","CAN","Canada","2019","2019",1.3,"E; D","Estimated value; Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","ATCPTTMT","% of total sales","CAN","Canada","2020","2020",1.2,"E; D","Estimated value; Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","ATCPTTMT","% of total sales","CAN","Canada","2021","2021",1.1,"E; D","Estimated value; Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","ATCPTTMT","% of total sales","CAN","Canada","2022","2022",1,"E; D","Estimated value; Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","MLLNCUMT","Million of national currency units","CZE","Czech Republic","2010","2010",1005.7,,
+"PATCCCBR","C08-Calcium channel blockers","MLLNCUMT","Million of national currency units","CZE","Czech Republic","2011","2011",817.6,,
+"PATCCCBR","C08-Calcium channel blockers","MLLNCUMT","Million of national currency units","CZE","Czech Republic","2012","2012",765.1,,
+"PATCCCBR","C08-Calcium channel blockers","MLLNCUMT","Million of national currency units","CZE","Czech Republic","2013","2013",730.7,,
+"PATCCCBR","C08-Calcium channel blockers","MLLNCUMT","Million of national currency units","CZE","Czech Republic","2014","2014",710,,
+"PATCCCBR","C08-Calcium channel blockers","MLLNCUMT","Million of national currency units","CZE","Czech Republic","2015","2015",590.5,,
+"PATCCCBR","C08-Calcium channel blockers","MLLNCUMT","Million of national currency units","CZE","Czech Republic","2016","2016",515.7,,
+"PATCCCBR","C08-Calcium channel blockers","MLLNCUMT","Million of national currency units","CZE","Czech Republic","2017","2017",501.5,,
+"PATCCCBR","C08-Calcium channel blockers","MLLNCUMT","Million of national currency units","CZE","Czech Republic","2018","2018",445.4,,
+"PATCCCBR","C08-Calcium channel blockers","MLLNCUMT","Million of national currency units","CZE","Czech Republic","2019","2019",436.6,,
+"PATCCCBR","C08-Calcium channel blockers","MLLNCUMT","Million of national currency units","CZE","Czech Republic","2020","2020",395,"B","Break"
+"PATCCCBR","C08-Calcium channel blockers","MLLNCUMT","Million of national currency units","CZE","Czech Republic","2021","2021",373.2,,
+"PATCCCBR","C08-Calcium channel blockers","MTMOTCMT","Million US$ at exchange rate","CZE","Czech Republic","2010","2010",52.7,,
+"PATCCCBR","C08-Calcium channel blockers","MTMOTCMT","Million US$ at exchange rate","CZE","Czech Republic","2011","2011",46.2,,
+"PATCCCBR","C08-Calcium channel blockers","MTMOTCMT","Million US$ at exchange rate","CZE","Czech Republic","2012","2012",39.1,,
+"PATCCCBR","C08-Calcium channel blockers","MTMOTCMT","Million US$ at exchange rate","CZE","Czech Republic","2013","2013",37.3,,
+"PATCCCBR","C08-Calcium channel blockers","MTMOTCMT","Million US$ at exchange rate","CZE","Czech Republic","2014","2014",34.2,,
+"PATCCCBR","C08-Calcium channel blockers","MTMOTCMT","Million US$ at exchange rate","CZE","Czech Republic","2015","2015",24,,
+"PATCCCBR","C08-Calcium channel blockers","MTMOTCMT","Million US$ at exchange rate","CZE","Czech Republic","2016","2016",21.1,,
+"PATCCCBR","C08-Calcium channel blockers","MTMOTCMT","Million US$ at exchange rate","CZE","Czech Republic","2017","2017",21.5,,
+"PATCCCBR","C08-Calcium channel blockers","MTMOTCMT","Million US$ at exchange rate","CZE","Czech Republic","2018","2018",20.5,,
+"PATCCCBR","C08-Calcium channel blockers","MTMOTCMT","Million US$ at exchange rate","CZE","Czech Republic","2019","2019",19,,
+"PATCCCBR","C08-Calcium channel blockers","MTMOTCMT","Million US$ at exchange rate","CZE","Czech Republic","2020","2020",17,"B","Break"
+"PATCCCBR","C08-Calcium channel blockers","MTMOTCMT","Million US$ at exchange rate","CZE","Czech Republic","2021","2021",17.2,,
+"PATCCCBR","C08-Calcium channel blockers","MTMOPPMT","Million US$, purchasing power parity","CZE","Czech Republic","2010","2010",73.6,,
+"PATCCCBR","C08-Calcium channel blockers","MTMOPPMT","Million US$, purchasing power parity","CZE","Czech Republic","2011","2011",61.3,,
+"PATCCCBR","C08-Calcium channel blockers","MTMOPPMT","Million US$, purchasing power parity","CZE","Czech Republic","2012","2012",57.5,,
+"PATCCCBR","C08-Calcium channel blockers","MTMOPPMT","Million US$, purchasing power parity","CZE","Czech Republic","2013","2013",57.1,,
+"PATCCCBR","C08-Calcium channel blockers","MTMOPPMT","Million US$, purchasing power parity","CZE","Czech Republic","2014","2014",55.9,,
+"PATCCCBR","C08-Calcium channel blockers","MTMOPPMT","Million US$, purchasing power parity","CZE","Czech Republic","2015","2015",45.6,,
+"PATCCCBR","C08-Calcium channel blockers","MTMOPPMT","Million US$, purchasing power parity","CZE","Czech Republic","2016","2016",41,,
+"PATCCCBR","C08-Calcium channel blockers","MTMOPPMT","Million US$, purchasing power parity","CZE","Czech Republic","2017","2017",40.4,,
+"PATCCCBR","C08-Calcium channel blockers","MTMOPPMT","Million US$, purchasing power parity","CZE","Czech Republic","2018","2018",36,,
+"PATCCCBR","C08-Calcium channel blockers","MTMOPPMT","Million US$, purchasing power parity","CZE","Czech Republic","2019","2019",35.6,,
+"PATCCCBR","C08-Calcium channel blockers","MTMOPPMT","Million US$, purchasing power parity","CZE","Czech Republic","2020","2020",31.7,"B","Break"
+"PATCCCBR","C08-Calcium channel blockers","MTMOPPMT","Million US$, purchasing power parity","CZE","Czech Republic","2021","2021",29.3,,
+"PATCCCBR","C08-Calcium channel blockers","TCPPERMT","/capita, US$ exchange rate","CZE","Czech Republic","2010","2010",5,,
+"PATCCCBR","C08-Calcium channel blockers","TCPPERMT","/capita, US$ exchange rate","CZE","Czech Republic","2011","2011",4.4,,
+"PATCCCBR","C08-Calcium channel blockers","TCPPERMT","/capita, US$ exchange rate","CZE","Czech Republic","2012","2012",3.7,,
+"PATCCCBR","C08-Calcium channel blockers","TCPPERMT","/capita, US$ exchange rate","CZE","Czech Republic","2013","2013",3.6,,
+"PATCCCBR","C08-Calcium channel blockers","TCPPERMT","/capita, US$ exchange rate","CZE","Czech Republic","2014","2014",3.2,,
+"PATCCCBR","C08-Calcium channel blockers","TCPPERMT","/capita, US$ exchange rate","CZE","Czech Republic","2015","2015",2.3,,
+"PATCCCBR","C08-Calcium channel blockers","TCPPERMT","/capita, US$ exchange rate","CZE","Czech Republic","2016","2016",2,,
+"PATCCCBR","C08-Calcium channel blockers","TCPPERMT","/capita, US$ exchange rate","CZE","Czech Republic","2017","2017",2,,
+"PATCCCBR","C08-Calcium channel blockers","TCPPERMT","/capita, US$ exchange rate","CZE","Czech Republic","2018","2018",1.9,,
+"PATCCCBR","C08-Calcium channel blockers","TCPPERMT","/capita, US$ exchange rate","CZE","Czech Republic","2019","2019",1.8,,
+"PATCCCBR","C08-Calcium channel blockers","TCPPERMT","/capita, US$ exchange rate","CZE","Czech Republic","2020","2020",1.6,"B","Break"
+"PATCCCBR","C08-Calcium channel blockers","TCPPERMT","/capita, US$ exchange rate","CZE","Czech Republic","2021","2021",1.6,,
+"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czech Republic","2010","2010",7,,
+"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czech Republic","2011","2011",5.8,,
+"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czech Republic","2012","2012",5.5,,
+"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czech Republic","2013","2013",5.4,,
+"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czech Republic","2014","2014",5.3,,
+"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czech Republic","2015","2015",4.3,,
+"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czech Republic","2016","2016",3.9,,
+"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czech Republic","2017","2017",3.8,,
+"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czech Republic","2018","2018",3.4,,
+"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czech Republic","2019","2019",3.3,,
+"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czech Republic","2020","2020",3,"B","Break"
+"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czech Republic","2021","2021",2.8,,
+"PATCCCBR","C08-Calcium channel blockers","ATCPTTMT","% of total sales","CZE","Czech Republic","2010","2010",1.2,,
+"PATCCCBR","C08-Calcium channel blockers","ATCPTTMT","% of total sales","CZE","Czech Republic","2011","2011",1,,
+"PATCCCBR","C08-Calcium channel blockers","ATCPTTMT","% of total sales","CZE","Czech Republic","2012","2012",0.9,,
+"PATCCCBR","C08-Calcium channel blockers","ATCPTTMT","% of total sales","CZE","Czech Republic","2013","2013",0.9,,
+"PATCCCBR","C08-Calcium channel blockers","ATCPTTMT","% of total sales","CZE","Czech Republic","2014","2014",0.9,,
+"PATCCCBR","C08-Calcium channel blockers","ATCPTTMT","% of total sales","CZE","Czech Republic","2015","2015",0.7,,
+"PATCCCBR","C08-Calcium channel blockers","ATCPTTMT","% of total sales","CZE","Czech Republic","2016","2016",0.6,,
+"PATCCCBR","C08-Calcium channel blockers","ATCPTTMT","% of total sales","CZE","Czech Republic","2017","2017",0.5,,
+"PATCCCBR","C08-Calcium channel blockers","ATCPTTMT","% of total sales","CZE","Czech Republic","2018","2018",0.5,,
+"PATCCCBR","C08-Calcium channel blockers","ATCPTTMT","% of total sales","CZE","Czech Republic","2019","2019",0.4,,
+"PATCCCBR","C08-Calcium channel blockers","ATCPTTMT","% of total sales","CZE","Czech Republic","2020","2020",0.4,"B","Break"
+"PATCCCBR","C08-Calcium channel blockers","ATCPTTMT","% of total sales","CZE","Czech Republic","2021","2021",0.4,,
+"PATCCCBR","C08-Calcium channel blockers","MLLNCUMT","Million of national currency units","FIN","Finland","2010","2010",17,,
+"PATCCCBR","C08-Calcium channel blockers","MLLNCUMT","Million of national currency units","FIN","Finland","2011","2011",15.2,,
+"PATCCCBR","C08-Calcium channel blockers","MLLNCUMT","Million of national currency units","FIN","Finland","2012","2012",15.3,,
+"PATCCCBR","C08-Calcium channel blockers","MLLNCUMT","Million of national currency units","FIN","Finland","2013","2013",16.9,,
+"PATCCCBR","C08-Calcium channel blockers","MLLNCUMT","Million of national currency units","FIN","Finland","2014","2014",18.1,,
+"PATCCCBR","C08-Calcium channel blockers","MLLNCUMT","Million of national currency units","FIN","Finland","2015","2015",19,,
+"PATCCCBR","C08-Calcium channel blockers","MLLNCUMT","Million of national currency units","FIN","Finland","2016","2016",19.4,,
+"PATCCCBR","C08-Calcium channel blockers","MLLNCUMT","Million of national currency units","FIN","Finland","2017","2017",18.2,,
+"PATCCCBR","C08-Calcium channel blockers","MLLNCUMT","Million of national currency units","FIN","Finland","2018","2018",16.3,,
+"PATCCCBR","C08-Calcium channel blockers","MLLNCUMT","Million of national currency units","FIN","Finland","2019","2019",12.8,,
+"PATCCCBR","C08-Calcium channel blockers","MLLNCUMT","Million of national currency units","FIN","Finland","2020","2020",11.4,,
+"PATCCCBR","C08-Calcium channel blockers","MLLNCUMT","Million of national currency units","FIN","Finland","2021","2021",11.1,,
+"PATCCCBR","C08-Calcium channel blockers","MTMOTCMT","Million US$ at exchange rate","FIN","Finland","2010","2010",22.5,,
+"PATCCCBR","C08-Calcium channel blockers","MTMOTCMT","Million US$ at exchange rate","FIN","Finland","2011","2011",21.2,,
+"PATCCCBR","C08-Calcium channel blockers","MTMOTCMT","Million US$ at exchange rate","FIN","Finland","2012","2012",19.7,,
+"PATCCCBR","C08-Calcium channel blockers","MTMOTCMT","Million US$ at exchange rate","FIN","Finland","2013","2013",22.4,,
+"PATCCCBR","C08-Calcium channel blockers","MTMOTCMT","Million US$ at exchange rate","FIN","Finland","2014","2014",24,,
+"PATCCCBR","C08-Calcium channel blockers","MTMOTCMT","Million US$ at exchange rate","FIN","Finland","2015","2015",21.1,,
+"PATCCCBR","C08-Calcium channel blockers","MTMOTCMT","Million US$ at exchange rate","FIN","Finland","2016","2016",21.5,,
+"PATCCCBR","C08-Calcium channel blockers","MTMOTCMT","Million US$ at exchange rate","FIN","Finland","2017","2017",20.6,,
+"PATCCCBR","C08-Calcium channel blockers","MTMOTCMT","Million US$ at exchange rate","FIN","Finland","2018","2018",19.2,,
+"PATCCCBR","C08-Calcium channel blockers","MTMOTCMT","Million US$ at exchange rate","FIN","Finland","2019","2019",14.3,,
+"PATCCCBR","C08-Calcium channel blockers","MTMOTCMT","Million US$ at exchange rate","FIN","Finland","2020","2020",13,,
+"PATCCCBR","C08-Calcium channel blockers","MTMOTCMT","Million US$ at exchange rate","FIN","Finland","2021","2021",13.1,,
+"PATCCCBR","C08-Calcium channel blockers","MTMOPPMT","Million US$, purchasing power parity","FIN","Finland","2010","2010",18.9,,
+"PATCCCBR","C08-Calcium channel blockers","MTMOPPMT","Million US$, purchasing power parity","FIN","Finland","2011","2011",16.9,,
+"PATCCCBR","C08-Calcium channel blockers","MTMOPPMT","Million US$, purchasing power parity","FIN","Finland","2012","2012",16.8,,
+"PATCCCBR","C08-Calcium channel blockers","MTMOPPMT","Million US$, purchasing power parity","FIN","Finland","2013","2013",18.7,,
+"PATCCCBR","C08-Calcium channel blockers","MTMOPPMT","Million US$, purchasing power parity","FIN","Finland","2014","2014",20,,
+"PATCCCBR","C08-Calcium channel blockers","MTMOPPMT","Million US$, purchasing power parity","FIN","Finland","2015","2015",20.9,,
+"PATCCCBR","C08-Calcium channel blockers","MTMOPPMT","Million US$, purchasing power parity","FIN","Finland","2016","2016",22,,
+"PATCCCBR","C08-Calcium channel blockers","MTMOPPMT","Million US$, purchasing power parity","FIN","Finland","2017","2017",21.1,,
+"PATCCCBR","C08-Calcium channel blockers","MTMOPPMT","Million US$, purchasing power parity","FIN","Finland","2018","2018",19.1,,
+"PATCCCBR","C08-Calcium channel blockers","MTMOPPMT","Million US$, purchasing power parity","FIN","Finland","2019","2019",15.3,,
+"PATCCCBR","C08-Calcium channel blockers","MTMOPPMT","Million US$, purchasing power parity","FIN","Finland","2020","2020",13.9,,
+"PATCCCBR","C08-Calcium channel blockers","MTMOPPMT","Million US$, purchasing power parity","FIN","Finland","2021","2021",13.4,,
+"PATCCCBR","C08-Calcium channel blockers","TCPPERMT","/capita, US$ exchange rate","FIN","Finland","2010","2010",4.2,,
+"PATCCCBR","C08-Calcium channel blockers","TCPPERMT","/capita, US$ exchange rate","FIN","Finland","2011","2011",3.9,,
+"PATCCCBR","C08-Calcium channel blockers","TCPPERMT","/capita, US$ exchange rate","FIN","Finland","2012","2012",3.6,,
+"PATCCCBR","C08-Calcium channel blockers","TCPPERMT","/capita, US$ exchange rate","FIN","Finland","2013","2013",4.1,,
+"PATCCCBR","C08-Calcium channel blockers","TCPPERMT","/capita, US$ exchange rate","FIN","Finland","2014","2014",4.4,,
+"PATCCCBR","C08-Calcium channel blockers","TCPPERMT","/capita, US$ exchange rate","FIN","Finland","2015","2015",3.8,,
+"PATCCCBR","C08-Calcium channel blockers","TCPPERMT","/capita, US$ exchange rate","FIN","Finland","2016","2016",3.9,,
+"PATCCCBR","C08-Calcium channel blockers","TCPPERMT","/capita, US$ exchange rate","FIN","Finland","2017","2017",3.7,,
+"PATCCCBR","C08-Calcium channel blockers","TCPPERMT","/capita, US$ exchange rate","FIN","Finland","2018","2018",3.5,,
+"PATCCCBR","C08-Calcium channel blockers","TCPPERMT","/capita, US$ exchange rate","FIN","Finland","2019","2019",2.6,,
+"PATCCCBR","C08-Calcium channel blockers","TCPPERMT","/capita, US$ exchange rate","FIN","Finland","2020","2020",2.4,,
+"PATCCCBR","C08-Calcium channel blockers","TCPPERMT","/capita, US$ exchange rate","FIN","Finland","2021","2021",2.4,,
+"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2010","2010",3.5,,
+"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2011","2011",3.1,,
+"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2012","2012",3.1,,
+"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2013","2013",3.4,,
+"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2014","2014",3.7,,
+"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2015","2015",3.8,,
+"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2016","2016",4,,
+"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2017","2017",3.8,,
+"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2018","2018",3.5,,
+"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2019","2019",2.8,,
+"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2020","2020",2.5,,
+"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2021","2021",2.4,,
+"PATCCCBR","C08-Calcium channel blockers","ATCPTTMT","% of total sales","FIN","Finland","2010","2010",0.9,,
+"PATCCCBR","C08-Calcium channel blockers","ATCPTTMT","% of total sales","FIN","Finland","2011","2011",0.8,,
+"PATCCCBR","C08-Calcium channel blockers","ATCPTTMT","% of total sales","FIN","Finland","2012","2012",0.8,,
+"PATCCCBR","C08-Calcium channel blockers","ATCPTTMT","% of total sales","FIN","Finland","2013","2013",0.8,,
+"PATCCCBR","C08-Calcium channel blockers","ATCPTTMT","% of total sales","FIN","Finland","2014","2014",0.9,,
+"PATCCCBR","C08-Calcium channel blockers","ATCPTTMT","% of total sales","FIN","Finland","2015","2015",0.9,,
+"PATCCCBR","C08-Calcium channel blockers","ATCPTTMT","% of total sales","FIN","Finland","2016","2016",0.8,,
+"PATCCCBR","C08-Calcium channel blockers","ATCPTTMT","% of total sales","FIN","Finland","2017","2017",0.8,,
+"PATCCCBR","C08-Calcium channel blockers","ATCPTTMT","% of total sales","FIN","Finland","2018","2018",0.7,,
+"PATCCCBR","C08-Calcium channel blockers","ATCPTTMT","% of total sales","FIN","Finland","2019","2019",0.5,,
+"PATCCCBR","C08-Calcium channel blockers","ATCPTTMT","% of total sales","FIN","Finland","2020","2020",0.4,,
+"PATCCCBR","C08-Calcium channel blockers","ATCPTTMT","% of total sales","FIN","Finland","2021","2021",0.4,,
+"PATCCCBR","C08-Calcium channel blockers","MLLNCUMT","Million of national currency units","DEU","Germany","2010","2010",308,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","MLLNCUMT","Million of national currency units","DEU","Germany","2011","2011",292,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","MLLNCUMT","Million of national currency units","DEU","Germany","2012","2012",289.6,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","MLLNCUMT","Million of national currency units","DEU","Germany","2013","2013",283.4,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","MLLNCUMT","Million of national currency units","DEU","Germany","2014","2014",284.7,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","MLLNCUMT","Million of national currency units","DEU","Germany","2015","2015",284.9,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","MLLNCUMT","Million of national currency units","DEU","Germany","2016","2016",285,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","MLLNCUMT","Million of national currency units","DEU","Germany","2017","2017",287.2,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","MLLNCUMT","Million of national currency units","DEU","Germany","2018","2018",297.5,"B; D","Break; Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","MLLNCUMT","Million of national currency units","DEU","Germany","2019","2019",318.2,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","MLLNCUMT","Million of national currency units","DEU","Germany","2020","2020",330.8,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","MLLNCUMT","Million of national currency units","DEU","Germany","2021","2021",341.7,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","MTMOTCMT","Million US$ at exchange rate","DEU","Germany","2010","2010",408.3,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","MTMOTCMT","Million US$ at exchange rate","DEU","Germany","2011","2011",406.5,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","MTMOTCMT","Million US$ at exchange rate","DEU","Germany","2012","2012",372.1,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","MTMOTCMT","Million US$ at exchange rate","DEU","Germany","2013","2013",376.4,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","MTMOTCMT","Million US$ at exchange rate","DEU","Germany","2014","2014",378.2,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","MTMOTCMT","Million US$ at exchange rate","DEU","Germany","2015","2015",316.1,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","MTMOTCMT","Million US$ at exchange rate","DEU","Germany","2016","2016",315.5,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","MTMOTCMT","Million US$ at exchange rate","DEU","Germany","2017","2017",324.4,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","MTMOTCMT","Million US$ at exchange rate","DEU","Germany","2018","2018",351.3,"B; D","Break; Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","MTMOTCMT","Million US$ at exchange rate","DEU","Germany","2019","2019",356.2,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","MTMOTCMT","Million US$ at exchange rate","DEU","Germany","2020","2020",377.8,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","MTMOTCMT","Million US$ at exchange rate","DEU","Germany","2021","2021",404.1,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","MTMOPPMT","Million US$, purchasing power parity","DEU","Germany","2010","2010",382.6,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","MTMOPPMT","Million US$, purchasing power parity","DEU","Germany","2011","2011",370.2,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","MTMOPPMT","Million US$, purchasing power parity","DEU","Germany","2012","2012",367.9,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","MTMOPPMT","Million US$, purchasing power parity","DEU","Germany","2013","2013",365.8,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","MTMOPPMT","Million US$, purchasing power parity","DEU","Germany","2014","2014",370.3,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","MTMOPPMT","Million US$, purchasing power parity","DEU","Germany","2015","2015",366.1,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","MTMOPPMT","Million US$, purchasing power parity","DEU","Germany","2016","2016",378.7,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","MTMOPPMT","Million US$, purchasing power parity","DEU","Germany","2017","2017",385.6,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","MTMOPPMT","Million US$, purchasing power parity","DEU","Germany","2018","2018",404.5,"B; D","Break; Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","MTMOPPMT","Million US$, purchasing power parity","DEU","Germany","2019","2019",436.9,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","MTMOPPMT","Million US$, purchasing power parity","DEU","Germany","2020","2020",456.3,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","MTMOPPMT","Million US$, purchasing power parity","DEU","Germany","2021","2021",464.1,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","TCPPERMT","/capita, US$ exchange rate","DEU","Germany","2010","2010",5,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","TCPPERMT","/capita, US$ exchange rate","DEU","Germany","2011","2011",5.1,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","TCPPERMT","/capita, US$ exchange rate","DEU","Germany","2012","2012",4.6,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","TCPPERMT","/capita, US$ exchange rate","DEU","Germany","2013","2013",4.7,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","TCPPERMT","/capita, US$ exchange rate","DEU","Germany","2014","2014",4.7,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","TCPPERMT","/capita, US$ exchange rate","DEU","Germany","2015","2015",3.9,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","TCPPERMT","/capita, US$ exchange rate","DEU","Germany","2016","2016",3.8,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","TCPPERMT","/capita, US$ exchange rate","DEU","Germany","2017","2017",3.9,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","TCPPERMT","/capita, US$ exchange rate","DEU","Germany","2018","2018",4.2,"B; D","Break; Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","TCPPERMT","/capita, US$ exchange rate","DEU","Germany","2019","2019",4.3,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","TCPPERMT","/capita, US$ exchange rate","DEU","Germany","2020","2020",4.5,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","TCPPERMT","/capita, US$ exchange rate","DEU","Germany","2021","2021",4.9,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2010","2010",4.7,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2011","2011",4.6,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2012","2012",4.6,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2013","2013",4.5,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2014","2014",4.6,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2015","2015",4.5,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2016","2016",4.6,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2017","2017",4.7,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2018","2018",4.9,"B; D","Break; Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2019","2019",5.3,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2020","2020",5.5,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2021","2021",5.6,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","ATCPTTMT","% of total sales","DEU","Germany","2010","2010",1,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","ATCPTTMT","% of total sales","DEU","Germany","2011","2011",1,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","ATCPTTMT","% of total sales","DEU","Germany","2012","2012",1,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","ATCPTTMT","% of total sales","DEU","Germany","2013","2013",0.9,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","ATCPTTMT","% of total sales","DEU","Germany","2014","2014",0.8,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","ATCPTTMT","% of total sales","DEU","Germany","2015","2015",0.8,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","ATCPTTMT","% of total sales","DEU","Germany","2016","2016",0.8,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","ATCPTTMT","% of total sales","DEU","Germany","2017","2017",0.8,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","ATCPTTMT","% of total sales","DEU","Germany","2018","2018",0.7,"B; D","Break; Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","ATCPTTMT","% of total sales","DEU","Germany","2019","2019",0.7,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","ATCPTTMT","% of total sales","DEU","Germany","2020","2020",0.7,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","ATCPTTMT","% of total sales","DEU","Germany","2021","2021",0.6,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","MLLNCUMT","Million of national currency units","GRC","Greece","2010","2010",94.3,,
+"PATCCCBR","C08-Calcium channel blockers","MLLNCUMT","Million of national currency units","GRC","Greece","2011","2011",77.7,,
+"PATCCCBR","C08-Calcium channel blockers","MLLNCUMT","Million of national currency units","GRC","Greece","2012","2012",68.8,,
+"PATCCCBR","C08-Calcium channel blockers","MLLNCUMT","Million of national currency units","GRC","Greece","2013","2013",61,,
+"PATCCCBR","C08-Calcium channel blockers","MLLNCUMT","Million of national currency units","GRC","Greece","2014","2014",56,,
+"PATCCCBR","C08-Calcium channel blockers","MLLNCUMT","Million of national currency units","GRC","Greece","2015","2015",50.4,,
+"PATCCCBR","C08-Calcium channel blockers","MLLNCUMT","Million of national currency units","GRC","Greece","2016","2016",50.2,,
+"PATCCCBR","C08-Calcium channel blockers","MLLNCUMT","Million of national currency units","GRC","Greece","2017","2017",49.1,,
+"PATCCCBR","C08-Calcium channel blockers","MLLNCUMT","Million of national currency units","GRC","Greece","2018","2018",45.9,,
+"PATCCCBR","C08-Calcium channel blockers","MLLNCUMT","Million of national currency units","GRC","Greece","2019","2019",44.4,,
+"PATCCCBR","C08-Calcium channel blockers","MLLNCUMT","Million of national currency units","GRC","Greece","2020","2020",40.9,,
+"PATCCCBR","C08-Calcium channel blockers","MLLNCUMT","Million of national currency units","GRC","Greece","2021","2021",39.1,,
+"PATCCCBR","C08-Calcium channel blockers","MLLNCUMT","Million of national currency units","GRC","Greece","2022","2022",28.8,,
+"PATCCCBR","C08-Calcium channel blockers","MTMOTCMT","Million US$ at exchange rate","GRC","Greece","2010","2010",125,,
+"PATCCCBR","C08-Calcium channel blockers","MTMOTCMT","Million US$ at exchange rate","GRC","Greece","2011","2011",108.1,,
+"PATCCCBR","C08-Calcium channel blockers","MTMOTCMT","Million US$ at exchange rate","GRC","Greece","2012","2012",88.4,,
+"PATCCCBR","C08-Calcium channel blockers","MTMOTCMT","Million US$ at exchange rate","GRC","Greece","2013","2013",81,,
+"PATCCCBR","C08-Calcium channel blockers","MTMOTCMT","Million US$ at exchange rate","GRC","Greece","2014","2014",74.3,,
+"PATCCCBR","C08-Calcium channel blockers","MTMOTCMT","Million US$ at exchange rate","GRC","Greece","2015","2015",55.9,,
+"PATCCCBR","C08-Calcium channel blockers","MTMOTCMT","Million US$ at exchange rate","GRC","Greece","2016","2016",55.6,,
+"PATCCCBR","C08-Calcium channel blockers","MTMOTCMT","Million US$ at exchange rate","GRC","Greece","2017","2017",55.5,,
+"PATCCCBR","C08-Calcium channel blockers","MTMOTCMT","Million US$ at exchange rate","GRC","Greece","2018","2018",54.2,,
+"PATCCCBR","C08-Calcium channel blockers","MTMOTCMT","Million US$ at exchange rate","GRC","Greece","2019","2019",49.8,,
+"PATCCCBR","C08-Calcium channel blockers","MTMOTCMT","Million US$ at exchange rate","GRC","Greece","2020","2020",46.8,,
+"PATCCCBR","C08-Calcium channel blockers","MTMOTCMT","Million US$ at exchange rate","GRC","Greece","2021","2021",46.2,,
+"PATCCCBR","C08-Calcium channel blockers","MTMOTCMT","Million US$ at exchange rate","GRC","Greece","2022","2022",30.3,,
+"PATCCCBR","C08-Calcium channel blockers","MTMOPPMT","Million US$, purchasing power parity","GRC","Greece","2010","2010",130.6,,
+"PATCCCBR","C08-Calcium channel blockers","MTMOPPMT","Million US$, purchasing power parity","GRC","Greece","2011","2011",108.9,,
+"PATCCCBR","C08-Calcium channel blockers","MTMOPPMT","Million US$, purchasing power parity","GRC","Greece","2012","2012",100.5,,
+"PATCCCBR","C08-Calcium channel blockers","MTMOPPMT","Million US$, purchasing power parity","GRC","Greece","2013","2013",96.7,,
+"PATCCCBR","C08-Calcium channel blockers","MTMOPPMT","Million US$, purchasing power parity","GRC","Greece","2014","2014",91.6,,
+"PATCCCBR","C08-Calcium channel blockers","MTMOPPMT","Million US$, purchasing power parity","GRC","Greece","2015","2015",82.7,,
+"PATCCCBR","C08-Calcium channel blockers","MTMOPPMT","Million US$, purchasing power parity","GRC","Greece","2016","2016",85.3,,
+"PATCCCBR","C08-Calcium channel blockers","MTMOPPMT","Million US$, purchasing power parity","GRC","Greece","2017","2017",85.5,,
+"PATCCCBR","C08-Calcium channel blockers","MTMOPPMT","Million US$, purchasing power parity","GRC","Greece","2018","2018",81.2,,
+"PATCCCBR","C08-Calcium channel blockers","MTMOPPMT","Million US$, purchasing power parity","GRC","Greece","2019","2019",81,,
+"PATCCCBR","C08-Calcium channel blockers","MTMOPPMT","Million US$, purchasing power parity","GRC","Greece","2020","2020",75.3,,
+"PATCCCBR","C08-Calcium channel blockers","MTMOPPMT","Million US$, purchasing power parity","GRC","Greece","2021","2021",71.6,,
+"PATCCCBR","C08-Calcium channel blockers","MTMOPPMT","Million US$, purchasing power parity","GRC","Greece","2022","2022",54.5,,
+"PATCCCBR","C08-Calcium channel blockers","TCPPERMT","/capita, US$ exchange rate","GRC","Greece","2010","2010",11.2,,
+"PATCCCBR","C08-Calcium channel blockers","TCPPERMT","/capita, US$ exchange rate","GRC","Greece","2011","2011",9.7,,
+"PATCCCBR","C08-Calcium channel blockers","TCPPERMT","/capita, US$ exchange rate","GRC","Greece","2012","2012",8,,
+"PATCCCBR","C08-Calcium channel blockers","TCPPERMT","/capita, US$ exchange rate","GRC","Greece","2013","2013",7.4,,
+"PATCCCBR","C08-Calcium channel blockers","TCPPERMT","/capita, US$ exchange rate","GRC","Greece","2014","2014",6.8,,
+"PATCCCBR","C08-Calcium channel blockers","TCPPERMT","/capita, US$ exchange rate","GRC","Greece","2015","2015",5.2,,
+"PATCCCBR","C08-Calcium channel blockers","TCPPERMT","/capita, US$ exchange rate","GRC","Greece","2016","2016",5.2,,
+"PATCCCBR","C08-Calcium channel blockers","TCPPERMT","/capita, US$ exchange rate","GRC","Greece","2017","2017",5.2,,
+"PATCCCBR","C08-Calcium channel blockers","TCPPERMT","/capita, US$ exchange rate","GRC","Greece","2018","2018",5,,
+"PATCCCBR","C08-Calcium channel blockers","TCPPERMT","/capita, US$ exchange rate","GRC","Greece","2019","2019",4.6,,
+"PATCCCBR","C08-Calcium channel blockers","TCPPERMT","/capita, US$ exchange rate","GRC","Greece","2020","2020",4.4,,
+"PATCCCBR","C08-Calcium channel blockers","TCPPERMT","/capita, US$ exchange rate","GRC","Greece","2021","2021",4.4,,
+"PATCCCBR","C08-Calcium channel blockers","TCPPERMT","/capita, US$ exchange rate","GRC","Greece","2022","2022",2.9,,
+"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2010","2010",11.7,,
+"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2011","2011",9.8,,
+"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2012","2012",9.1,,
+"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2013","2013",8.8,,
+"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2014","2014",8.4,,
+"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2015","2015",7.6,,
+"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2016","2016",7.9,,
+"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2017","2017",7.9,,
+"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2018","2018",7.6,,
+"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2019","2019",7.6,,
+"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2020","2020",7,,
+"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2021","2021",6.8,,
+"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2022","2022",5.2,,
+"PATCCCBR","C08-Calcium channel blockers","MLLNCUMT","Million of national currency units","HUN","Hungary","2010","2010",6967.9,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","MLLNCUMT","Million of national currency units","HUN","Hungary","2011","2011",6798.9,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","MLLNCUMT","Million of national currency units","HUN","Hungary","2012","2012",5530.2,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","MLLNCUMT","Million of national currency units","HUN","Hungary","2013","2013",3769.8,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","MLLNCUMT","Million of national currency units","HUN","Hungary","2014","2014",3109.2,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","MLLNCUMT","Million of national currency units","HUN","Hungary","2015","2015",2946.5,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","MLLNCUMT","Million of national currency units","HUN","Hungary","2016","2016",2787.9,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","MLLNCUMT","Million of national currency units","HUN","Hungary","2017","2017",2649.1,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","MLLNCUMT","Million of national currency units","HUN","Hungary","2018","2018",2558.9,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","MLLNCUMT","Million of national currency units","HUN","Hungary","2019","2019",2496.8,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","MLLNCUMT","Million of national currency units","HUN","Hungary","2020","2020",2522.7,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","MLLNCUMT","Million of national currency units","HUN","Hungary","2021","2021",2313.6,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","MLLNCUMT","Million of national currency units","HUN","Hungary","2022","2022",2220.1,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","MTMOTCMT","Million US$ at exchange rate","HUN","Hungary","2010","2010",33.5,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","MTMOTCMT","Million US$ at exchange rate","HUN","Hungary","2011","2011",33.8,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","MTMOTCMT","Million US$ at exchange rate","HUN","Hungary","2012","2012",24.6,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","MTMOTCMT","Million US$ at exchange rate","HUN","Hungary","2013","2013",16.9,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","MTMOTCMT","Million US$ at exchange rate","HUN","Hungary","2014","2014",13.4,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","MTMOTCMT","Million US$ at exchange rate","HUN","Hungary","2015","2015",10.5,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","MTMOTCMT","Million US$ at exchange rate","HUN","Hungary","2016","2016",9.9,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","MTMOTCMT","Million US$ at exchange rate","HUN","Hungary","2017","2017",9.7,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","MTMOTCMT","Million US$ at exchange rate","HUN","Hungary","2018","2018",9.5,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","MTMOTCMT","Million US$ at exchange rate","HUN","Hungary","2019","2019",8.6,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","MTMOTCMT","Million US$ at exchange rate","HUN","Hungary","2020","2020",8.2,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","MTMOTCMT","Million US$ at exchange rate","HUN","Hungary","2021","2021",7.6,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","MTMOTCMT","Million US$ at exchange rate","HUN","Hungary","2022","2022",6,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","MTMOPPMT","Million US$, purchasing power parity","HUN","Hungary","2010","2010",55.1,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","MTMOPPMT","Million US$, purchasing power parity","HUN","Hungary","2011","2011",54.7,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","MTMOPPMT","Million US$, purchasing power parity","HUN","Hungary","2012","2012",44,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","MTMOPPMT","Million US$, purchasing power parity","HUN","Hungary","2013","2013",30.2,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","MTMOPPMT","Million US$, purchasing power parity","HUN","Hungary","2014","2014",24,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","MTMOPPMT","Million US$, purchasing power parity","HUN","Hungary","2015","2015",22.2,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","MTMOPPMT","Million US$, purchasing power parity","HUN","Hungary","2016","2016",21.1,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","MTMOPPMT","Million US$, purchasing power parity","HUN","Hungary","2017","2017",19.5,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","MTMOPPMT","Million US$, purchasing power parity","HUN","Hungary","2018","2018",18.4,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","MTMOPPMT","Million US$, purchasing power parity","HUN","Hungary","2019","2019",17.7,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","MTMOPPMT","Million US$, purchasing power parity","HUN","Hungary","2020","2020",17.4,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","MTMOPPMT","Million US$, purchasing power parity","HUN","Hungary","2021","2021",15,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","MTMOPPMT","Million US$, purchasing power parity","HUN","Hungary","2022","2022",13.8,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","TCPPERMT","/capita, US$ exchange rate","HUN","Hungary","2010","2010",3.4,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","TCPPERMT","/capita, US$ exchange rate","HUN","Hungary","2011","2011",3.4,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","TCPPERMT","/capita, US$ exchange rate","HUN","Hungary","2012","2012",2.5,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","TCPPERMT","/capita, US$ exchange rate","HUN","Hungary","2013","2013",1.7,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","TCPPERMT","/capita, US$ exchange rate","HUN","Hungary","2014","2014",1.4,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","TCPPERMT","/capita, US$ exchange rate","HUN","Hungary","2015","2015",1.1,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","TCPPERMT","/capita, US$ exchange rate","HUN","Hungary","2016","2016",1,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","TCPPERMT","/capita, US$ exchange rate","HUN","Hungary","2017","2017",1,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","TCPPERMT","/capita, US$ exchange rate","HUN","Hungary","2018","2018",1,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","TCPPERMT","/capita, US$ exchange rate","HUN","Hungary","2019","2019",0.9,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","TCPPERMT","/capita, US$ exchange rate","HUN","Hungary","2020","2020",0.8,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","TCPPERMT","/capita, US$ exchange rate","HUN","Hungary","2021","2021",0.8,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","TCPPERMT","/capita, US$ exchange rate","HUN","Hungary","2022","2022",0.6,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2010","2010",5.5,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2011","2011",5.5,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2012","2012",4.4,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2013","2013",3,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2014","2014",2.4,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2015","2015",2.3,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2016","2016",2.2,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2017","2017",2,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2018","2018",1.9,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2019","2019",1.8,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2020","2020",1.8,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2021","2021",1.5,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2022","2022",1.4,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","ATCPTTMT","% of total sales","HUN","Hungary","2010","2010",1.4,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","ATCPTTMT","% of total sales","HUN","Hungary","2011","2011",1.3,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","ATCPTTMT","% of total sales","HUN","Hungary","2012","2012",1.2,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","ATCPTTMT","% of total sales","HUN","Hungary","2013","2013",0.9,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","ATCPTTMT","% of total sales","HUN","Hungary","2014","2014",0.7,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","ATCPTTMT","% of total sales","HUN","Hungary","2015","2015",0.6,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","ATCPTTMT","% of total sales","HUN","Hungary","2016","2016",0.6,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","ATCPTTMT","% of total sales","HUN","Hungary","2017","2017",0.5,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","ATCPTTMT","% of total sales","HUN","Hungary","2018","2018",0.5,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","ATCPTTMT","% of total sales","HUN","Hungary","2019","2019",0.5,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","ATCPTTMT","% of total sales","HUN","Hungary","2020","2020",0.5,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","ATCPTTMT","% of total sales","HUN","Hungary","2021","2021",0.4,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","ATCPTTMT","% of total sales","HUN","Hungary","2022","2022",0.4,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","MLLNCUMT","Million of national currency units","ISL","Iceland","2010","2010",223.5,,
+"PATCCCBR","C08-Calcium channel blockers","MLLNCUMT","Million of national currency units","ISL","Iceland","2011","2011",229.8,,
+"PATCCCBR","C08-Calcium channel blockers","MLLNCUMT","Million of national currency units","ISL","Iceland","2012","2012",211.5,,
+"PATCCCBR","C08-Calcium channel blockers","MLLNCUMT","Million of national currency units","ISL","Iceland","2013","2013",198.8,,
+"PATCCCBR","C08-Calcium channel blockers","MLLNCUMT","Million of national currency units","ISL","Iceland","2014","2014",185.1,,
+"PATCCCBR","C08-Calcium channel blockers","MLLNCUMT","Million of national currency units","ISL","Iceland","2015","2015",156.8,,
+"PATCCCBR","C08-Calcium channel blockers","MLLNCUMT","Million of national currency units","ISL","Iceland","2016","2016",165.6,,
+"PATCCCBR","C08-Calcium channel blockers","MLLNCUMT","Million of national currency units","ISL","Iceland","2017","2017",164.6,,
+"PATCCCBR","C08-Calcium channel blockers","MLLNCUMT","Million of national currency units","ISL","Iceland","2018","2018",180.5,,
+"PATCCCBR","C08-Calcium channel blockers","MLLNCUMT","Million of national currency units","ISL","Iceland","2019","2019",199.5,,
+"PATCCCBR","C08-Calcium channel blockers","MLLNCUMT","Million of national currency units","ISL","Iceland","2020","2020",236.6,,
+"PATCCCBR","C08-Calcium channel blockers","MLLNCUMT","Million of national currency units","ISL","Iceland","2021","2021",289.9,,
+"PATCCCBR","C08-Calcium channel blockers","MTMOTCMT","Million US$ at exchange rate","ISL","Iceland","2010","2010",1.8,,
+"PATCCCBR","C08-Calcium channel blockers","MTMOTCMT","Million US$ at exchange rate","ISL","Iceland","2011","2011",2,,
+"PATCCCBR","C08-Calcium channel blockers","MTMOTCMT","Million US$ at exchange rate","ISL","Iceland","2012","2012",1.7,,
+"PATCCCBR","C08-Calcium channel blockers","MTMOTCMT","Million US$ at exchange rate","ISL","Iceland","2013","2013",1.6,,
+"PATCCCBR","C08-Calcium channel blockers","MTMOTCMT","Million US$ at exchange rate","ISL","Iceland","2014","2014",1.6,,
+"PATCCCBR","C08-Calcium channel blockers","MTMOTCMT","Million US$ at exchange rate","ISL","Iceland","2015","2015",1.2,,
+"PATCCCBR","C08-Calcium channel blockers","MTMOTCMT","Million US$ at exchange rate","ISL","Iceland","2016","2016",1.4,,
+"PATCCCBR","C08-Calcium channel blockers","MTMOTCMT","Million US$ at exchange rate","ISL","Iceland","2017","2017",1.5,,
+"PATCCCBR","C08-Calcium channel blockers","MTMOTCMT","Million US$ at exchange rate","ISL","Iceland","2018","2018",1.7,,
+"PATCCCBR","C08-Calcium channel blockers","MTMOTCMT","Million US$ at exchange rate","ISL","Iceland","2019","2019",1.6,,
+"PATCCCBR","C08-Calcium channel blockers","MTMOTCMT","Million US$ at exchange rate","ISL","Iceland","2020","2020",1.7,,
+"PATCCCBR","C08-Calcium channel blockers","MTMOTCMT","Million US$ at exchange rate","ISL","Iceland","2021","2021",2.3,,
+"PATCCCBR","C08-Calcium channel blockers","MTMOPPMT","Million US$, purchasing power parity","ISL","Iceland","2010","2010",1.7,,
+"PATCCCBR","C08-Calcium channel blockers","MTMOPPMT","Million US$, purchasing power parity","ISL","Iceland","2011","2011",1.7,,
+"PATCCCBR","C08-Calcium channel blockers","MTMOPPMT","Million US$, purchasing power parity","ISL","Iceland","2012","2012",1.5,,
+"PATCCCBR","C08-Calcium channel blockers","MTMOPPMT","Million US$, purchasing power parity","ISL","Iceland","2013","2013",1.5,,
+"PATCCCBR","C08-Calcium channel blockers","MTMOPPMT","Million US$, purchasing power parity","ISL","Iceland","2014","2014",1.3,,
+"PATCCCBR","C08-Calcium channel blockers","MTMOPPMT","Million US$, purchasing power parity","ISL","Iceland","2015","2015",1.1,,
+"PATCCCBR","C08-Calcium channel blockers","MTMOPPMT","Million US$, purchasing power parity","ISL","Iceland","2016","2016",1.2,,
+"PATCCCBR","C08-Calcium channel blockers","MTMOPPMT","Million US$, purchasing power parity","ISL","Iceland","2017","2017",1.2,,
+"PATCCCBR","C08-Calcium channel blockers","MTMOPPMT","Million US$, purchasing power parity","ISL","Iceland","2018","2018",1.3,,
+"PATCCCBR","C08-Calcium channel blockers","MTMOPPMT","Million US$, purchasing power parity","ISL","Iceland","2019","2019",1.4,,
+"PATCCCBR","C08-Calcium channel blockers","MTMOPPMT","Million US$, purchasing power parity","ISL","Iceland","2020","2020",1.6,,
+"PATCCCBR","C08-Calcium channel blockers","MTMOPPMT","Million US$, purchasing power parity","ISL","Iceland","2021","2021",1.9,,
+"PATCCCBR","C08-Calcium channel blockers","TCPPERMT","/capita, US$ exchange rate","ISL","Iceland","2010","2010",5.7,,
+"PATCCCBR","C08-Calcium channel blockers","TCPPERMT","/capita, US$ exchange rate","ISL","Iceland","2011","2011",6.2,,
+"PATCCCBR","C08-Calcium channel blockers","TCPPERMT","/capita, US$ exchange rate","ISL","Iceland","2012","2012",5.3,,
+"PATCCCBR","C08-Calcium channel blockers","TCPPERMT","/capita, US$ exchange rate","ISL","Iceland","2013","2013",5,,
+"PATCCCBR","C08-Calcium channel blockers","TCPPERMT","/capita, US$ exchange rate","ISL","Iceland","2014","2014",4.8,,
+"PATCCCBR","C08-Calcium channel blockers","TCPPERMT","/capita, US$ exchange rate","ISL","Iceland","2015","2015",3.6,,
+"PATCCCBR","C08-Calcium channel blockers","TCPPERMT","/capita, US$ exchange rate","ISL","Iceland","2016","2016",4.1,,
+"PATCCCBR","C08-Calcium channel blockers","TCPPERMT","/capita, US$ exchange rate","ISL","Iceland","2017","2017",4.5,,
+"PATCCCBR","C08-Calcium channel blockers","TCPPERMT","/capita, US$ exchange rate","ISL","Iceland","2018","2018",4.7,,
+"PATCCCBR","C08-Calcium channel blockers","TCPPERMT","/capita, US$ exchange rate","ISL","Iceland","2019","2019",4.5,,
+"PATCCCBR","C08-Calcium channel blockers","TCPPERMT","/capita, US$ exchange rate","ISL","Iceland","2020","2020",4.8,,
+"PATCCCBR","C08-Calcium channel blockers","TCPPERMT","/capita, US$ exchange rate","ISL","Iceland","2021","2021",6.1,,
+"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2010","2010",5.3,,
+"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2011","2011",5.3,,
+"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2012","2012",4.8,,
+"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2013","2013",4.5,,
+"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2014","2014",4.1,,
+"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2015","2015",3.3,,
+"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2016","2016",3.5,,
+"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2017","2017",3.5,,
+"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2018","2018",3.6,,
+"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2019","2019",3.9,,
+"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2020","2020",4.4,,
+"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2021","2021",5.2,,
+"PATCCCBR","C08-Calcium channel blockers","ATCPTTMT","% of total sales","ISL","Iceland","2010","2010",0.9,,
+"PATCCCBR","C08-Calcium channel blockers","ATCPTTMT","% of total sales","ISL","Iceland","2011","2011",0.9,,
+"PATCCCBR","C08-Calcium channel blockers","ATCPTTMT","% of total sales","ISL","Iceland","2012","2012",0.9,,
+"PATCCCBR","C08-Calcium channel blockers","ATCPTTMT","% of total sales","ISL","Iceland","2013","2013",0.8,,
+"PATCCCBR","C08-Calcium channel blockers","ATCPTTMT","% of total sales","ISL","Iceland","2014","2014",0.8,,
+"PATCCCBR","C08-Calcium channel blockers","ATCPTTMT","% of total sales","ISL","Iceland","2015","2015",0.6,,
+"PATCCCBR","C08-Calcium channel blockers","ATCPTTMT","% of total sales","ISL","Iceland","2016","2016",0.7,,
+"PATCCCBR","C08-Calcium channel blockers","ATCPTTMT","% of total sales","ISL","Iceland","2017","2017",0.6,,
+"PATCCCBR","C08-Calcium channel blockers","ATCPTTMT","% of total sales","ISL","Iceland","2018","2018",0.6,,
+"PATCCCBR","C08-Calcium channel blockers","ATCPTTMT","% of total sales","ISL","Iceland","2019","2019",0.6,,
+"PATCCCBR","C08-Calcium channel blockers","ATCPTTMT","% of total sales","ISL","Iceland","2020","2020",0.6,,
+"PATCCCBR","C08-Calcium channel blockers","ATCPTTMT","% of total sales","ISL","Iceland","2021","2021",0.6,,
+"PATCCCBR","C08-Calcium channel blockers","MLLNCUMT","Million of national currency units","IRL","Ireland","2010","2010",26.8,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","MLLNCUMT","Million of national currency units","IRL","Ireland","2011","2011",24.8,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","MLLNCUMT","Million of national currency units","IRL","Ireland","2012","2012",25.2,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","MLLNCUMT","Million of national currency units","IRL","Ireland","2013","2013",24,"B; D","Break; Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","MLLNCUMT","Million of national currency units","IRL","Ireland","2014","2014",22.3,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","MLLNCUMT","Million of national currency units","IRL","Ireland","2015","2015",18,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","MLLNCUMT","Million of national currency units","IRL","Ireland","2016","2016",18.1,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","MLLNCUMT","Million of national currency units","IRL","Ireland","2017","2017",17.6,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","MLLNCUMT","Million of national currency units","IRL","Ireland","2018","2018",17.6,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","MLLNCUMT","Million of national currency units","IRL","Ireland","2019","2019",17.5,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","MLLNCUMT","Million of national currency units","IRL","Ireland","2020","2020",18.1,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","MLLNCUMT","Million of national currency units","IRL","Ireland","2021","2021",18.8,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","MTMOTCMT","Million US$ at exchange rate","IRL","Ireland","2010","2010",35.5,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","MTMOTCMT","Million US$ at exchange rate","IRL","Ireland","2011","2011",34.5,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","MTMOTCMT","Million US$ at exchange rate","IRL","Ireland","2012","2012",32.4,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","MTMOTCMT","Million US$ at exchange rate","IRL","Ireland","2013","2013",31.8,"B; D","Break; Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","MTMOTCMT","Million US$ at exchange rate","IRL","Ireland","2014","2014",29.7,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","MTMOTCMT","Million US$ at exchange rate","IRL","Ireland","2015","2015",20,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","MTMOTCMT","Million US$ at exchange rate","IRL","Ireland","2016","2016",20,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","MTMOTCMT","Million US$ at exchange rate","IRL","Ireland","2017","2017",19.9,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","MTMOTCMT","Million US$ at exchange rate","IRL","Ireland","2018","2018",20.8,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","MTMOTCMT","Million US$ at exchange rate","IRL","Ireland","2019","2019",19.6,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","MTMOTCMT","Million US$ at exchange rate","IRL","Ireland","2020","2020",20.7,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","MTMOTCMT","Million US$ at exchange rate","IRL","Ireland","2021","2021",22.2,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","MTMOPPMT","Million US$, purchasing power parity","IRL","Ireland","2010","2010",31.5,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","MTMOPPMT","Million US$, purchasing power parity","IRL","Ireland","2011","2011",29.8,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","MTMOPPMT","Million US$, purchasing power parity","IRL","Ireland","2012","2012",30.6,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","MTMOPPMT","Million US$, purchasing power parity","IRL","Ireland","2013","2013",29.6,"B; D","Break; Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","MTMOPPMT","Million US$, purchasing power parity","IRL","Ireland","2014","2014",27.3,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","MTMOPPMT","Million US$, purchasing power parity","IRL","Ireland","2015","2015",22.2,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","MTMOPPMT","Million US$, purchasing power parity","IRL","Ireland","2016","2016",22.7,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","MTMOPPMT","Million US$, purchasing power parity","IRL","Ireland","2017","2017",22.2,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","MTMOPPMT","Million US$, purchasing power parity","IRL","Ireland","2018","2018",22.3,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","MTMOPPMT","Million US$, purchasing power parity","IRL","Ireland","2019","2019",21.7,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","MTMOPPMT","Million US$, purchasing power parity","IRL","Ireland","2020","2020",22.8,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","MTMOPPMT","Million US$, purchasing power parity","IRL","Ireland","2021","2021",23.7,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","TCPPERMT","/capita, US$ exchange rate","IRL","Ireland","2010","2010",7.8,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","TCPPERMT","/capita, US$ exchange rate","IRL","Ireland","2011","2011",7.5,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","TCPPERMT","/capita, US$ exchange rate","IRL","Ireland","2012","2012",7,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","TCPPERMT","/capita, US$ exchange rate","IRL","Ireland","2013","2013",6.9,"B; D","Break; Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","TCPPERMT","/capita, US$ exchange rate","IRL","Ireland","2014","2014",6.4,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","TCPPERMT","/capita, US$ exchange rate","IRL","Ireland","2015","2015",4.2,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","TCPPERMT","/capita, US$ exchange rate","IRL","Ireland","2016","2016",4.2,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","TCPPERMT","/capita, US$ exchange rate","IRL","Ireland","2017","2017",4.1,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","TCPPERMT","/capita, US$ exchange rate","IRL","Ireland","2018","2018",4.3,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","TCPPERMT","/capita, US$ exchange rate","IRL","Ireland","2019","2019",4,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","TCPPERMT","/capita, US$ exchange rate","IRL","Ireland","2020","2020",4.2,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","TCPPERMT","/capita, US$ exchange rate","IRL","Ireland","2021","2021",4.4,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2010","2010",6.9,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2011","2011",6.5,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2012","2012",6.7,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2013","2013",6.4,"B; D","Break; Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2014","2014",5.9,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2015","2015",4.7,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2016","2016",4.8,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2017","2017",4.6,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2018","2018",4.6,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2019","2019",4.4,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2020","2020",4.6,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2021","2021",4.7,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","ATCPTTMT","% of total sales","IRL","Ireland","2010","2010",1.3,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","ATCPTTMT","% of total sales","IRL","Ireland","2011","2011",1.3,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","ATCPTTMT","% of total sales","IRL","Ireland","2012","2012",1.2,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","ATCPTTMT","% of total sales","IRL","Ireland","2013","2013",1.2,"B; D","Break; Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","ATCPTTMT","% of total sales","IRL","Ireland","2014","2014",1.2,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","ATCPTTMT","% of total sales","IRL","Ireland","2015","2015",0.9,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","ATCPTTMT","% of total sales","IRL","Ireland","2016","2016",0.9,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","ATCPTTMT","% of total sales","IRL","Ireland","2017","2017",0.8,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","ATCPTTMT","% of total sales","IRL","Ireland","2018","2018",0.8,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","ATCPTTMT","% of total sales","IRL","Ireland","2019","2019",0.7,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","ATCPTTMT","% of total sales","IRL","Ireland","2020","2020",0.7,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","ATCPTTMT","% of total sales","IRL","Ireland","2021","2021",0.7,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","MLLNCUMT","Million of national currency units","ITA","Italy","2011","2011",389,,
+"PATCCCBR","C08-Calcium channel blockers","MLLNCUMT","Million of national currency units","ITA","Italy","2012","2012",332.6,,
+"PATCCCBR","C08-Calcium channel blockers","MLLNCUMT","Million of national currency units","ITA","Italy","2013","2013",323.3,,
+"PATCCCBR","C08-Calcium channel blockers","MLLNCUMT","Million of national currency units","ITA","Italy","2014","2014",318.3,,
+"PATCCCBR","C08-Calcium channel blockers","MLLNCUMT","Million of national currency units","ITA","Italy","2015","2015",301.9,,
+"PATCCCBR","C08-Calcium channel blockers","MLLNCUMT","Million of national currency units","ITA","Italy","2016","2016",296.4,,
+"PATCCCBR","C08-Calcium channel blockers","MLLNCUMT","Million of national currency units","ITA","Italy","2017","2017",286.7,,
+"PATCCCBR","C08-Calcium channel blockers","MLLNCUMT","Million of national currency units","ITA","Italy","2018","2018",281,,
+"PATCCCBR","C08-Calcium channel blockers","MLLNCUMT","Million of national currency units","ITA","Italy","2019","2019",274.6,,
+"PATCCCBR","C08-Calcium channel blockers","MLLNCUMT","Million of national currency units","ITA","Italy","2020","2020",271.9,,
+"PATCCCBR","C08-Calcium channel blockers","MLLNCUMT","Million of national currency units","ITA","Italy","2021","2021",264.5,,
+"PATCCCBR","C08-Calcium channel blockers","MLLNCUMT","Million of national currency units","ITA","Italy","2022","2022",256.5,"E","Estimated value"
+"PATCCCBR","C08-Calcium channel blockers","MTMOTCMT","Million US$ at exchange rate","ITA","Italy","2011","2011",541.5,,
+"PATCCCBR","C08-Calcium channel blockers","MTMOTCMT","Million US$ at exchange rate","ITA","Italy","2012","2012",427.3,,
+"PATCCCBR","C08-Calcium channel blockers","MTMOTCMT","Million US$ at exchange rate","ITA","Italy","2013","2013",429.4,,
+"PATCCCBR","C08-Calcium channel blockers","MTMOTCMT","Million US$ at exchange rate","ITA","Italy","2014","2014",422.8,,
+"PATCCCBR","C08-Calcium channel blockers","MTMOTCMT","Million US$ at exchange rate","ITA","Italy","2015","2015",335,,
+"PATCCCBR","C08-Calcium channel blockers","MTMOTCMT","Million US$ at exchange rate","ITA","Italy","2016","2016",328.1,,
+"PATCCCBR","C08-Calcium channel blockers","MTMOTCMT","Million US$ at exchange rate","ITA","Italy","2017","2017",323.9,,
+"PATCCCBR","C08-Calcium channel blockers","MTMOTCMT","Million US$ at exchange rate","ITA","Italy","2018","2018",331.8,,
+"PATCCCBR","C08-Calcium channel blockers","MTMOTCMT","Million US$ at exchange rate","ITA","Italy","2019","2019",307.4,,
+"PATCCCBR","C08-Calcium channel blockers","MTMOTCMT","Million US$ at exchange rate","ITA","Italy","2020","2020",310.6,,
+"PATCCCBR","C08-Calcium channel blockers","MTMOTCMT","Million US$ at exchange rate","ITA","Italy","2021","2021",312.8,,
+"PATCCCBR","C08-Calcium channel blockers","MTMOTCMT","Million US$ at exchange rate","ITA","Italy","2022","2022",270.1,"E","Estimated value"
+"PATCCCBR","C08-Calcium channel blockers","MTMOPPMT","Million US$, purchasing power parity","ITA","Italy","2011","2011",512.7,,
+"PATCCCBR","C08-Calcium channel blockers","MTMOPPMT","Million US$, purchasing power parity","ITA","Italy","2012","2012",444.8,,
+"PATCCCBR","C08-Calcium channel blockers","MTMOPPMT","Million US$, purchasing power parity","ITA","Italy","2013","2013",438.5,,
+"PATCCCBR","C08-Calcium channel blockers","MTMOPPMT","Million US$, purchasing power parity","ITA","Italy","2014","2014",430.3,,
+"PATCCCBR","C08-Calcium channel blockers","MTMOPPMT","Million US$, purchasing power parity","ITA","Italy","2015","2015",408.7,,
+"PATCCCBR","C08-Calcium channel blockers","MTMOPPMT","Million US$, purchasing power parity","ITA","Italy","2016","2016",423.1,,
+"PATCCCBR","C08-Calcium channel blockers","MTMOPPMT","Million US$, purchasing power parity","ITA","Italy","2017","2017",415.5,,
+"PATCCCBR","C08-Calcium channel blockers","MTMOPPMT","Million US$, purchasing power parity","ITA","Italy","2018","2018",412.4,,
+"PATCCCBR","C08-Calcium channel blockers","MTMOPPMT","Million US$, purchasing power parity","ITA","Italy","2019","2019",418.2,,
+"PATCCCBR","C08-Calcium channel blockers","MTMOPPMT","Million US$, purchasing power parity","ITA","Italy","2020","2020",419.8,,
+"PATCCCBR","C08-Calcium channel blockers","MTMOPPMT","Million US$, purchasing power parity","ITA","Italy","2021","2021",408.4,,
+"PATCCCBR","C08-Calcium channel blockers","MTMOPPMT","Million US$, purchasing power parity","ITA","Italy","2022","2022",415.4,"E","Estimated value"
+"PATCCCBR","C08-Calcium channel blockers","TCPPERMT","/capita, US$ exchange rate","ITA","Italy","2011","2011",9.1,,
+"PATCCCBR","C08-Calcium channel blockers","TCPPERMT","/capita, US$ exchange rate","ITA","Italy","2012","2012",7.2,,
+"PATCCCBR","C08-Calcium channel blockers","TCPPERMT","/capita, US$ exchange rate","ITA","Italy","2013","2013",7.1,,
+"PATCCCBR","C08-Calcium channel blockers","TCPPERMT","/capita, US$ exchange rate","ITA","Italy","2014","2014",7,,
+"PATCCCBR","C08-Calcium channel blockers","TCPPERMT","/capita, US$ exchange rate","ITA","Italy","2015","2015",5.5,,
+"PATCCCBR","C08-Calcium channel blockers","TCPPERMT","/capita, US$ exchange rate","ITA","Italy","2016","2016",5.4,,
+"PATCCCBR","C08-Calcium channel blockers","TCPPERMT","/capita, US$ exchange rate","ITA","Italy","2017","2017",5.3,,
+"PATCCCBR","C08-Calcium channel blockers","TCPPERMT","/capita, US$ exchange rate","ITA","Italy","2018","2018",5.5,,
+"PATCCCBR","C08-Calcium channel blockers","TCPPERMT","/capita, US$ exchange rate","ITA","Italy","2019","2019",5.1,,
+"PATCCCBR","C08-Calcium channel blockers","TCPPERMT","/capita, US$ exchange rate","ITA","Italy","2020","2020",5.2,,
+"PATCCCBR","C08-Calcium channel blockers","TCPPERMT","/capita, US$ exchange rate","ITA","Italy","2021","2021",5.3,,
+"PATCCCBR","C08-Calcium channel blockers","TCPPERMT","/capita, US$ exchange rate","ITA","Italy","2022","2022",4.6,"E","Estimated value"
+"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2011","2011",8.6,,
+"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2012","2012",7.5,,
+"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2013","2013",7.3,,
+"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2014","2014",7.1,,
+"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2015","2015",6.7,,
+"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2016","2016",7,,
+"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2017","2017",6.9,,
+"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2018","2018",6.8,,
+"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2019","2019",7,,
+"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2020","2020",7.1,,
+"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2021","2021",6.9,,
+"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2022","2022",7,"E","Estimated value"
+"PATCCCBR","C08-Calcium channel blockers","ATCPTTMT","% of total sales","ITA","Italy","2011","2011",2,,
+"PATCCCBR","C08-Calcium channel blockers","ATCPTTMT","% of total sales","ITA","Italy","2012","2012",1.7,,
+"PATCCCBR","C08-Calcium channel blockers","ATCPTTMT","% of total sales","ITA","Italy","2013","2013",1.7,,
+"PATCCCBR","C08-Calcium channel blockers","ATCPTTMT","% of total sales","ITA","Italy","2014","2014",1.6,,
+"PATCCCBR","C08-Calcium channel blockers","ATCPTTMT","% of total sales","ITA","Italy","2015","2015",1.3,,
+"PATCCCBR","C08-Calcium channel blockers","ATCPTTMT","% of total sales","ITA","Italy","2016","2016",1.3,,
+"PATCCCBR","C08-Calcium channel blockers","ATCPTTMT","% of total sales","ITA","Italy","2017","2017",1.3,,
+"PATCCCBR","C08-Calcium channel blockers","ATCPTTMT","% of total sales","ITA","Italy","2018","2018",1.3,,
+"PATCCCBR","C08-Calcium channel blockers","ATCPTTMT","% of total sales","ITA","Italy","2019","2019",1.2,,
+"PATCCCBR","C08-Calcium channel blockers","ATCPTTMT","% of total sales","ITA","Italy","2020","2020",1.2,,
+"PATCCCBR","C08-Calcium channel blockers","ATCPTTMT","% of total sales","ITA","Italy","2021","2021",1.1,,
+"PATCCCBR","C08-Calcium channel blockers","ATCPTTMT","% of total sales","ITA","Italy","2022","2022",1,"E","Estimated value"
+"PATCCCBR","C08-Calcium channel blockers","MLLNCUMT","Million of national currency units","KOR","Korea","2010","2010",514083,,
+"PATCCCBR","C08-Calcium channel blockers","MLLNCUMT","Million of national currency units","KOR","Korea","2011","2011",493836.7,"B","Break"
+"PATCCCBR","C08-Calcium channel blockers","MLLNCUMT","Million of national currency units","KOR","Korea","2012","2012",439045.3,,
+"PATCCCBR","C08-Calcium channel blockers","MLLNCUMT","Million of national currency units","KOR","Korea","2013","2013",412627,,
+"PATCCCBR","C08-Calcium channel blockers","MLLNCUMT","Million of national currency units","KOR","Korea","2014","2014",380517.9,,
+"PATCCCBR","C08-Calcium channel blockers","MLLNCUMT","Million of national currency units","KOR","Korea","2015","2015",364513.9,,
+"PATCCCBR","C08-Calcium channel blockers","MLLNCUMT","Million of national currency units","KOR","Korea","2016","2016",345301,"B","Break"
+"PATCCCBR","C08-Calcium channel blockers","MLLNCUMT","Million of national currency units","KOR","Korea","2017","2017",337442.8,,
+"PATCCCBR","C08-Calcium channel blockers","MLLNCUMT","Million of national currency units","KOR","Korea","2018","2018",334169.7,,
+"PATCCCBR","C08-Calcium channel blockers","MLLNCUMT","Million of national currency units","KOR","Korea","2019","2019",326138.1,,
+"PATCCCBR","C08-Calcium channel blockers","MLLNCUMT","Million of national currency units","KOR","Korea","2020","2020",344643.7,,
+"PATCCCBR","C08-Calcium channel blockers","MLLNCUMT","Million of national currency units","KOR","Korea","2021","2021",345302.9,,
+"PATCCCBR","C08-Calcium channel blockers","MTMOTCMT","Million US$ at exchange rate","KOR","Korea","2010","2010",444.5,,
+"PATCCCBR","C08-Calcium channel blockers","MTMOTCMT","Million US$ at exchange rate","KOR","Korea","2011","2011",445.6,"B","Break"
+"PATCCCBR","C08-Calcium channel blockers","MTMOTCMT","Million US$ at exchange rate","KOR","Korea","2012","2012",389.6,,
+"PATCCCBR","C08-Calcium channel blockers","MTMOTCMT","Million US$ at exchange rate","KOR","Korea","2013","2013",376.8,,
+"PATCCCBR","C08-Calcium channel blockers","MTMOTCMT","Million US$ at exchange rate","KOR","Korea","2014","2014",361.4,,
+"PATCCCBR","C08-Calcium channel blockers","MTMOTCMT","Million US$ at exchange rate","KOR","Korea","2015","2015",322.3,,
+"PATCCCBR","C08-Calcium channel blockers","MTMOTCMT","Million US$ at exchange rate","KOR","Korea","2016","2016",297.5,"B","Break"
+"PATCCCBR","C08-Calcium channel blockers","MTMOTCMT","Million US$ at exchange rate","KOR","Korea","2017","2017",298.4,,
+"PATCCCBR","C08-Calcium channel blockers","MTMOTCMT","Million US$ at exchange rate","KOR","Korea","2018","2018",303.7,,
+"PATCCCBR","C08-Calcium channel blockers","MTMOTCMT","Million US$ at exchange rate","KOR","Korea","2019","2019",279.9,,
+"PATCCCBR","C08-Calcium channel blockers","MTMOTCMT","Million US$ at exchange rate","KOR","Korea","2020","2020",292,,
+"PATCCCBR","C08-Calcium channel blockers","MTMOTCMT","Million US$ at exchange rate","KOR","Korea","2021","2021",301.9,,
+"PATCCCBR","C08-Calcium channel blockers","MTMOPPMT","Million US$, purchasing power parity","KOR","Korea","2010","2010",611.3,,
+"PATCCCBR","C08-Calcium channel blockers","MTMOPPMT","Million US$, purchasing power parity","KOR","Korea","2011","2011",577.9,"B","Break"
+"PATCCCBR","C08-Calcium channel blockers","MTMOPPMT","Million US$, purchasing power parity","KOR","Korea","2012","2012",513.6,,
+"PATCCCBR","C08-Calcium channel blockers","MTMOPPMT","Million US$, purchasing power parity","KOR","Korea","2013","2013",474.8,,
+"PATCCCBR","C08-Calcium channel blockers","MTMOPPMT","Million US$, purchasing power parity","KOR","Korea","2014","2014",436.4,,
+"PATCCCBR","C08-Calcium channel blockers","MTMOPPMT","Million US$, purchasing power parity","KOR","Korea","2015","2015",425.1,,
+"PATCCCBR","C08-Calcium channel blockers","MTMOPPMT","Million US$, purchasing power parity","KOR","Korea","2016","2016",402.1,"B","Break"
+"PATCCCBR","C08-Calcium channel blockers","MTMOPPMT","Million US$, purchasing power parity","KOR","Korea","2017","2017",386.7,,
+"PATCCCBR","C08-Calcium channel blockers","MTMOPPMT","Million US$, purchasing power parity","KOR","Korea","2018","2018",390.9,,
+"PATCCCBR","C08-Calcium channel blockers","MTMOPPMT","Million US$, purchasing power parity","KOR","Korea","2019","2019",380.8,,
+"PATCCCBR","C08-Calcium channel blockers","MTMOPPMT","Million US$, purchasing power parity","KOR","Korea","2020","2020",411.4,,
+"PATCCCBR","C08-Calcium channel blockers","MTMOPPMT","Million US$, purchasing power parity","KOR","Korea","2021","2021",404.3,,
+"PATCCCBR","C08-Calcium channel blockers","TCPPERMT","/capita, US$ exchange rate","KOR","Korea","2010","2010",9,,
+"PATCCCBR","C08-Calcium channel blockers","TCPPERMT","/capita, US$ exchange rate","KOR","Korea","2011","2011",8.9,"B","Break"
+"PATCCCBR","C08-Calcium channel blockers","TCPPERMT","/capita, US$ exchange rate","KOR","Korea","2012","2012",7.8,,
+"PATCCCBR","C08-Calcium channel blockers","TCPPERMT","/capita, US$ exchange rate","KOR","Korea","2013","2013",7.5,,
+"PATCCCBR","C08-Calcium channel blockers","TCPPERMT","/capita, US$ exchange rate","KOR","Korea","2014","2014",7.1,,
+"PATCCCBR","C08-Calcium channel blockers","TCPPERMT","/capita, US$ exchange rate","KOR","Korea","2015","2015",6.3,,
+"PATCCCBR","C08-Calcium channel blockers","TCPPERMT","/capita, US$ exchange rate","KOR","Korea","2016","2016",5.8,"B","Break"
+"PATCCCBR","C08-Calcium channel blockers","TCPPERMT","/capita, US$ exchange rate","KOR","Korea","2017","2017",5.8,,
+"PATCCCBR","C08-Calcium channel blockers","TCPPERMT","/capita, US$ exchange rate","KOR","Korea","2018","2018",5.9,,
+"PATCCCBR","C08-Calcium channel blockers","TCPPERMT","/capita, US$ exchange rate","KOR","Korea","2019","2019",5.4,,
+"PATCCCBR","C08-Calcium channel blockers","TCPPERMT","/capita, US$ exchange rate","KOR","Korea","2020","2020",5.6,,
+"PATCCCBR","C08-Calcium channel blockers","TCPPERMT","/capita, US$ exchange rate","KOR","Korea","2021","2021",5.8,,
+"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2010","2010",12.3,,
+"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2011","2011",11.6,"B","Break"
+"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2012","2012",10.2,,
+"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2013","2013",9.4,,
+"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2014","2014",8.6,,
+"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2015","2015",8.3,,
+"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2016","2016",7.9,"B","Break"
+"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2017","2017",7.5,,
+"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2018","2018",7.6,,
+"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2019","2019",7.4,,
+"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2020","2020",7.9,,
+"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2021","2021",7.8,,
+"PATCCCBR","C08-Calcium channel blockers","ATCPTTMT","% of total sales","KOR","Korea","2010","2010",2.5,,
+"PATCCCBR","C08-Calcium channel blockers","ATCPTTMT","% of total sales","KOR","Korea","2011","2011",2.2,"B","Break"
+"PATCCCBR","C08-Calcium channel blockers","ATCPTTMT","% of total sales","KOR","Korea","2012","2012",2,,
+"PATCCCBR","C08-Calcium channel blockers","ATCPTTMT","% of total sales","KOR","Korea","2013","2013",1.8,,
+"PATCCCBR","C08-Calcium channel blockers","ATCPTTMT","% of total sales","KOR","Korea","2014","2014",1.6,,
+"PATCCCBR","C08-Calcium channel blockers","ATCPTTMT","% of total sales","KOR","Korea","2015","2015",1.5,,
+"PATCCCBR","C08-Calcium channel blockers","ATCPTTMT","% of total sales","KOR","Korea","2016","2016",1.4,"B","Break"
+"PATCCCBR","C08-Calcium channel blockers","ATCPTTMT","% of total sales","KOR","Korea","2017","2017",1.3,,
+"PATCCCBR","C08-Calcium channel blockers","ATCPTTMT","% of total sales","KOR","Korea","2018","2018",1.2,,
+"PATCCCBR","C08-Calcium channel blockers","ATCPTTMT","% of total sales","KOR","Korea","2019","2019",1.1,,
+"PATCCCBR","C08-Calcium channel blockers","ATCPTTMT","% of total sales","KOR","Korea","2020","2020",1.1,,
+"PATCCCBR","C08-Calcium channel blockers","ATCPTTMT","% of total sales","KOR","Korea","2021","2021",1,,
+"PATCCCBR","C08-Calcium channel blockers","MLLNCUMT","Million of national currency units","LUX","Luxembourg","2010","2010",2.8,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","MLLNCUMT","Million of national currency units","LUX","Luxembourg","2011","2011",2.6,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","MLLNCUMT","Million of national currency units","LUX","Luxembourg","2012","2012",2.4,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","MLLNCUMT","Million of national currency units","LUX","Luxembourg","2013","2013",2.3,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","MLLNCUMT","Million of national currency units","LUX","Luxembourg","2014","2014",2.1,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","MLLNCUMT","Million of national currency units","LUX","Luxembourg","2015","2015",1.9,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","MLLNCUMT","Million of national currency units","LUX","Luxembourg","2016","2016",1.8,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","MLLNCUMT","Million of national currency units","LUX","Luxembourg","2017","2017",1.7,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","MLLNCUMT","Million of national currency units","LUX","Luxembourg","2018","2018",1.3,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","MLLNCUMT","Million of national currency units","LUX","Luxembourg","2019","2019",1.2,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","MLLNCUMT","Million of national currency units","LUX","Luxembourg","2020","2020",1.2,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","MLLNCUMT","Million of national currency units","LUX","Luxembourg","2021","2021",1.1,"B; D; P","Break; Difference in methodology; Provisional value"
+"PATCCCBR","C08-Calcium channel blockers","MLLNCUMT","Million of national currency units","LUX","Luxembourg","2022","2022",1,"D; P","Difference in methodology; Provisional value"
+"PATCCCBR","C08-Calcium channel blockers","MTMOTCMT","Million US$ at exchange rate","LUX","Luxembourg","2010","2010",3.6,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","MTMOTCMT","Million US$ at exchange rate","LUX","Luxembourg","2011","2011",3.6,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","MTMOTCMT","Million US$ at exchange rate","LUX","Luxembourg","2012","2012",3.1,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","MTMOTCMT","Million US$ at exchange rate","LUX","Luxembourg","2013","2013",3,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","MTMOTCMT","Million US$ at exchange rate","LUX","Luxembourg","2014","2014",2.8,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","MTMOTCMT","Million US$ at exchange rate","LUX","Luxembourg","2015","2015",2.1,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","MTMOTCMT","Million US$ at exchange rate","LUX","Luxembourg","2016","2016",2,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","MTMOTCMT","Million US$ at exchange rate","LUX","Luxembourg","2017","2017",2,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","MTMOTCMT","Million US$ at exchange rate","LUX","Luxembourg","2018","2018",1.5,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","MTMOTCMT","Million US$ at exchange rate","LUX","Luxembourg","2019","2019",1.4,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","MTMOTCMT","Million US$ at exchange rate","LUX","Luxembourg","2020","2020",1.4,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","MTMOTCMT","Million US$ at exchange rate","LUX","Luxembourg","2021","2021",1.3,"B; D; P","Break; Difference in methodology; Provisional value"
+"PATCCCBR","C08-Calcium channel blockers","MTMOTCMT","Million US$ at exchange rate","LUX","Luxembourg","2022","2022",1.1,"D; P","Difference in methodology; Provisional value"
+"PATCCCBR","C08-Calcium channel blockers","MTMOPPMT","Million US$, purchasing power parity","LUX","Luxembourg","2010","2010",3,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","MTMOPPMT","Million US$, purchasing power parity","LUX","Luxembourg","2011","2011",2.9,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","MTMOPPMT","Million US$, purchasing power parity","LUX","Luxembourg","2012","2012",2.6,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","MTMOPPMT","Million US$, purchasing power parity","LUX","Luxembourg","2013","2013",2.5,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","MTMOPPMT","Million US$, purchasing power parity","LUX","Luxembourg","2014","2014",2.4,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","MTMOPPMT","Million US$, purchasing power parity","LUX","Luxembourg","2015","2015",2.2,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","MTMOPPMT","Million US$, purchasing power parity","LUX","Luxembourg","2016","2016",2.1,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","MTMOPPMT","Million US$, purchasing power parity","LUX","Luxembourg","2017","2017",2,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","MTMOPPMT","Million US$, purchasing power parity","LUX","Luxembourg","2018","2018",1.5,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","MTMOPPMT","Million US$, purchasing power parity","LUX","Luxembourg","2019","2019",1.5,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","MTMOPPMT","Million US$, purchasing power parity","LUX","Luxembourg","2020","2020",1.4,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","MTMOPPMT","Million US$, purchasing power parity","LUX","Luxembourg","2021","2021",1.3,"B; D; P","Break; Difference in methodology; Provisional value"
+"PATCCCBR","C08-Calcium channel blockers","MTMOPPMT","Million US$, purchasing power parity","LUX","Luxembourg","2022","2022",1.2,"D; P","Difference in methodology; Provisional value"
+"PATCCCBR","C08-Calcium channel blockers","TCPPERMT","/capita, US$ exchange rate","LUX","Luxembourg","2010","2010",7.7,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","TCPPERMT","/capita, US$ exchange rate","LUX","Luxembourg","2011","2011",7.5,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","TCPPERMT","/capita, US$ exchange rate","LUX","Luxembourg","2012","2012",6.2,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","TCPPERMT","/capita, US$ exchange rate","LUX","Luxembourg","2013","2013",6,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","TCPPERMT","/capita, US$ exchange rate","LUX","Luxembourg","2014","2014",5.5,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","TCPPERMT","/capita, US$ exchange rate","LUX","Luxembourg","2015","2015",4.1,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","TCPPERMT","/capita, US$ exchange rate","LUX","Luxembourg","2016","2016",3.8,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","TCPPERMT","/capita, US$ exchange rate","LUX","Luxembourg","2017","2017",3.6,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","TCPPERMT","/capita, US$ exchange rate","LUX","Luxembourg","2018","2018",2.8,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","TCPPERMT","/capita, US$ exchange rate","LUX","Luxembourg","2019","2019",2.5,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","TCPPERMT","/capita, US$ exchange rate","LUX","Luxembourg","2020","2020",2.4,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","TCPPERMT","/capita, US$ exchange rate","LUX","Luxembourg","2021","2021",2.3,"B; D; P","Break; Difference in methodology; Provisional value"
+"PATCCCBR","C08-Calcium channel blockers","TCPPERMT","/capita, US$ exchange rate","LUX","Luxembourg","2022","2022",1.8,"D; P","Difference in methodology; Provisional value"
+"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2010","2010",6.3,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2011","2011",5.9,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2012","2012",5.4,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2013","2013",5,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2014","2014",4.7,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2015","2015",4.2,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2016","2016",4.1,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2017","2017",3.8,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2018","2018",2.8,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2019","2019",2.6,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2020","2020",2.5,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2021","2021",2.2,"B; D; P","Break; Difference in methodology; Provisional value"
+"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2022","2022",2.1,"D; P","Difference in methodology; Provisional value"
+"PATCCCBR","C08-Calcium channel blockers","ATCPTTMT","% of total sales","LUX","Luxembourg","2010","2010",1.5,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","ATCPTTMT","% of total sales","LUX","Luxembourg","2011","2011",1.4,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","ATCPTTMT","% of total sales","LUX","Luxembourg","2012","2012",1.2,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","ATCPTTMT","% of total sales","LUX","Luxembourg","2013","2013",1.2,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","ATCPTTMT","% of total sales","LUX","Luxembourg","2014","2014",1.1,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","ATCPTTMT","% of total sales","LUX","Luxembourg","2015","2015",1,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","ATCPTTMT","% of total sales","LUX","Luxembourg","2016","2016",0.9,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","ATCPTTMT","% of total sales","LUX","Luxembourg","2017","2017",0.9,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","ATCPTTMT","% of total sales","LUX","Luxembourg","2018","2018",0.7,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","ATCPTTMT","% of total sales","LUX","Luxembourg","2019","2019",0.6,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","ATCPTTMT","% of total sales","LUX","Luxembourg","2020","2020",0.6,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","ATCPTTMT","% of total sales","LUX","Luxembourg","2021","2021",0.5,"B; D; P","Break; Difference in methodology; Provisional value"
+"PATCCCBR","C08-Calcium channel blockers","ATCPTTMT","% of total sales","LUX","Luxembourg","2022","2022",0.4,"D; P","Difference in methodology; Provisional value"
+"PATCCCBR","C08-Calcium channel blockers","MLLNCUMT","Million of national currency units","NLD","Netherlands","2010","2010",62.2,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","MLLNCUMT","Million of national currency units","NLD","Netherlands","2011","2011",60.9,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","MLLNCUMT","Million of national currency units","NLD","Netherlands","2012","2012",60.9,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","MLLNCUMT","Million of national currency units","NLD","Netherlands","2013","2013",64.9,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","MLLNCUMT","Million of national currency units","NLD","Netherlands","2014","2014",65.8,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","MTMOTCMT","Million US$ at exchange rate","NLD","Netherlands","2010","2010",82.5,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","MTMOTCMT","Million US$ at exchange rate","NLD","Netherlands","2011","2011",84.7,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","MTMOTCMT","Million US$ at exchange rate","NLD","Netherlands","2012","2012",78.2,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","MTMOTCMT","Million US$ at exchange rate","NLD","Netherlands","2013","2013",86.2,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","MTMOTCMT","Million US$ at exchange rate","NLD","Netherlands","2014","2014",87.5,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","MTMOPPMT","Million US$, purchasing power parity","NLD","Netherlands","2010","2010",72.9,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","MTMOPPMT","Million US$, purchasing power parity","NLD","Netherlands","2011","2011",72.8,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","MTMOPPMT","Million US$, purchasing power parity","NLD","Netherlands","2012","2012",73.9,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","MTMOPPMT","Million US$, purchasing power parity","NLD","Netherlands","2013","2013",81.3,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","MTMOPPMT","Million US$, purchasing power parity","NLD","Netherlands","2014","2014",81.4,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","TCPPERMT","/capita, US$ exchange rate","NLD","Netherlands","2010","2010",5,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","TCPPERMT","/capita, US$ exchange rate","NLD","Netherlands","2011","2011",5.1,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","TCPPERMT","/capita, US$ exchange rate","NLD","Netherlands","2012","2012",4.7,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","TCPPERMT","/capita, US$ exchange rate","NLD","Netherlands","2013","2013",5.1,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","TCPPERMT","/capita, US$ exchange rate","NLD","Netherlands","2014","2014",5.2,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","NLD","Netherlands","2010","2010",4.4,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","NLD","Netherlands","2011","2011",4.4,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","NLD","Netherlands","2012","2012",4.4,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","NLD","Netherlands","2013","2013",4.8,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","NLD","Netherlands","2014","2014",4.8,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","ATCPTTMT","% of total sales","NLD","Netherlands","2010","2010",1.2,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","ATCPTTMT","% of total sales","NLD","Netherlands","2011","2011",1.2,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","ATCPTTMT","% of total sales","NLD","Netherlands","2012","2012",1.3,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","ATCPTTMT","% of total sales","NLD","Netherlands","2013","2013",1.5,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","ATCPTTMT","% of total sales","NLD","Netherlands","2014","2014",1.5,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","MLLNCUMT","Million of national currency units","NZL","New Zealand","2010","2010",13.3,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","MLLNCUMT","Million of national currency units","NZL","New Zealand","2011","2011",14.8,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","MLLNCUMT","Million of national currency units","NZL","New Zealand","2012","2012",13.5,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","MLLNCUMT","Million of national currency units","NZL","New Zealand","2013","2013",9.6,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","MLLNCUMT","Million of national currency units","NZL","New Zealand","2014","2014",8.3,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","MLLNCUMT","Million of national currency units","NZL","New Zealand","2015","2015",8.2,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","MLLNCUMT","Million of national currency units","NZL","New Zealand","2016","2016",5.7,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","MLLNCUMT","Million of national currency units","NZL","New Zealand","2017","2017",5.8,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","MLLNCUMT","Million of national currency units","NZL","New Zealand","2018","2018",5.4,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","MLLNCUMT","Million of national currency units","NZL","New Zealand","2019","2019",5.2,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","MLLNCUMT","Million of national currency units","NZL","New Zealand","2020","2020",5,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","MLLNCUMT","Million of national currency units","NZL","New Zealand","2021","2021",6.3,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","MLLNCUMT","Million of national currency units","NZL","New Zealand","2022","2022",7.8,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","MTMOTCMT","Million US$ at exchange rate","NZL","New Zealand","2010","2010",9.6,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","MTMOTCMT","Million US$ at exchange rate","NZL","New Zealand","2011","2011",11.7,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","MTMOTCMT","Million US$ at exchange rate","NZL","New Zealand","2012","2012",10.9,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","MTMOTCMT","Million US$ at exchange rate","NZL","New Zealand","2013","2013",7.8,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","MTMOTCMT","Million US$ at exchange rate","NZL","New Zealand","2014","2014",6.8,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","MTMOTCMT","Million US$ at exchange rate","NZL","New Zealand","2015","2015",5.7,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","MTMOTCMT","Million US$ at exchange rate","NZL","New Zealand","2016","2016",4,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","MTMOTCMT","Million US$ at exchange rate","NZL","New Zealand","2017","2017",4.1,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","MTMOTCMT","Million US$ at exchange rate","NZL","New Zealand","2018","2018",3.7,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","MTMOTCMT","Million US$ at exchange rate","NZL","New Zealand","2019","2019",3.4,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","MTMOTCMT","Million US$ at exchange rate","NZL","New Zealand","2020","2020",3.3,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","MTMOTCMT","Million US$ at exchange rate","NZL","New Zealand","2021","2021",4.4,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","MTMOTCMT","Million US$ at exchange rate","NZL","New Zealand","2022","2022",5,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","MTMOPPMT","Million US$, purchasing power parity","NZL","New Zealand","2010","2010",8.9,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","MTMOPPMT","Million US$, purchasing power parity","NZL","New Zealand","2011","2011",10,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","MTMOPPMT","Million US$, purchasing power parity","NZL","New Zealand","2012","2012",9,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","MTMOPPMT","Million US$, purchasing power parity","NZL","New Zealand","2013","2013",6.6,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","MTMOPPMT","Million US$, purchasing power parity","NZL","New Zealand","2014","2014",5.7,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","MTMOPPMT","Million US$, purchasing power parity","NZL","New Zealand","2015","2015",5.5,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","MTMOPPMT","Million US$, purchasing power parity","NZL","New Zealand","2016","2016",4,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","MTMOPPMT","Million US$, purchasing power parity","NZL","New Zealand","2017","2017",4,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","MTMOPPMT","Million US$, purchasing power parity","NZL","New Zealand","2018","2018",3.7,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","MTMOPPMT","Million US$, purchasing power parity","NZL","New Zealand","2019","2019",3.6,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","MTMOPPMT","Million US$, purchasing power parity","NZL","New Zealand","2020","2020",3.6,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","MTMOPPMT","Million US$, purchasing power parity","NZL","New Zealand","2021","2021",4.3,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","MTMOPPMT","Million US$, purchasing power parity","NZL","New Zealand","2022","2022",5.4,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","TCPPERMT","/capita, US$ exchange rate","NZL","New Zealand","2010","2010",2.2,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","TCPPERMT","/capita, US$ exchange rate","NZL","New Zealand","2011","2011",2.7,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","TCPPERMT","/capita, US$ exchange rate","NZL","New Zealand","2012","2012",2.5,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","TCPPERMT","/capita, US$ exchange rate","NZL","New Zealand","2013","2013",1.8,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","TCPPERMT","/capita, US$ exchange rate","NZL","New Zealand","2014","2014",1.5,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","TCPPERMT","/capita, US$ exchange rate","NZL","New Zealand","2015","2015",1.2,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","TCPPERMT","/capita, US$ exchange rate","NZL","New Zealand","2016","2016",0.8,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","TCPPERMT","/capita, US$ exchange rate","NZL","New Zealand","2017","2017",0.8,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","TCPPERMT","/capita, US$ exchange rate","NZL","New Zealand","2018","2018",0.8,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","TCPPERMT","/capita, US$ exchange rate","NZL","New Zealand","2019","2019",0.7,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","TCPPERMT","/capita, US$ exchange rate","NZL","New Zealand","2020","2020",0.6,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","TCPPERMT","/capita, US$ exchange rate","NZL","New Zealand","2021","2021",0.9,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","TCPPERMT","/capita, US$ exchange rate","NZL","New Zealand","2022","2022",1,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2010","2010",2,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2011","2011",2.3,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2012","2012",2,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2013","2013",1.5,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2014","2014",1.3,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2015","2015",1.2,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2016","2016",0.8,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2017","2017",0.8,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2018","2018",0.7,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2019","2019",0.7,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2020","2020",0.7,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2021","2021",0.8,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2022","2022",1.1,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","ATCPTTMT","% of total sales","NZL","New Zealand","2010","2010",1.8,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","ATCPTTMT","% of total sales","NZL","New Zealand","2011","2011",1.8,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","ATCPTTMT","% of total sales","NZL","New Zealand","2012","2012",1.5,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","ATCPTTMT","% of total sales","NZL","New Zealand","2013","2013",1,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","ATCPTTMT","% of total sales","NZL","New Zealand","2014","2014",0.9,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","ATCPTTMT","% of total sales","NZL","New Zealand","2015","2015",0.8,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","ATCPTTMT","% of total sales","NZL","New Zealand","2016","2016",0.5,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","ATCPTTMT","% of total sales","NZL","New Zealand","2017","2017",0.5,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","ATCPTTMT","% of total sales","NZL","New Zealand","2018","2018",0.4,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","ATCPTTMT","% of total sales","NZL","New Zealand","2019","2019",0.3,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","ATCPTTMT","% of total sales","NZL","New Zealand","2020","2020",0.3,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","ATCPTTMT","% of total sales","NZL","New Zealand","2021","2021",0.4,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","ATCPTTMT","% of total sales","NZL","New Zealand","2022","2022",0.4,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","MLLNCUMT","Million of national currency units","NOR","Norway","2010","2010",159,,
+"PATCCCBR","C08-Calcium channel blockers","MLLNCUMT","Million of national currency units","NOR","Norway","2011","2011",141,,
+"PATCCCBR","C08-Calcium channel blockers","MLLNCUMT","Million of national currency units","NOR","Norway","2012","2012",132,,
+"PATCCCBR","C08-Calcium channel blockers","MLLNCUMT","Million of national currency units","NOR","Norway","2013","2013",128,,
+"PATCCCBR","C08-Calcium channel blockers","MLLNCUMT","Million of national currency units","NOR","Norway","2014","2014",130,,
+"PATCCCBR","C08-Calcium channel blockers","MLLNCUMT","Million of national currency units","NOR","Norway","2015","2015",121,,
+"PATCCCBR","C08-Calcium channel blockers","MLLNCUMT","Million of national currency units","NOR","Norway","2016","2016",126,,
+"PATCCCBR","C08-Calcium channel blockers","MLLNCUMT","Million of national currency units","NOR","Norway","2017","2017",128,,
+"PATCCCBR","C08-Calcium channel blockers","MLLNCUMT","Million of national currency units","NOR","Norway","2018","2018",111,,
+"PATCCCBR","C08-Calcium channel blockers","MLLNCUMT","Million of national currency units","NOR","Norway","2019","2019",108,,
+"PATCCCBR","C08-Calcium channel blockers","MLLNCUMT","Million of national currency units","NOR","Norway","2020","2020",111,,
+"PATCCCBR","C08-Calcium channel blockers","MLLNCUMT","Million of national currency units","NOR","Norway","2021","2021",109,,
+"PATCCCBR","C08-Calcium channel blockers","MLLNCUMT","Million of national currency units","NOR","Norway","2022","2022",114,,
+"PATCCCBR","C08-Calcium channel blockers","MTMOTCMT","Million US$ at exchange rate","NOR","Norway","2010","2010",26.3,,
+"PATCCCBR","C08-Calcium channel blockers","MTMOTCMT","Million US$ at exchange rate","NOR","Norway","2011","2011",25.2,,
+"PATCCCBR","C08-Calcium channel blockers","MTMOTCMT","Million US$ at exchange rate","NOR","Norway","2012","2012",22.7,,
+"PATCCCBR","C08-Calcium channel blockers","MTMOTCMT","Million US$ at exchange rate","NOR","Norway","2013","2013",21.8,,
+"PATCCCBR","C08-Calcium channel blockers","MTMOTCMT","Million US$ at exchange rate","NOR","Norway","2014","2014",20.6,,
+"PATCCCBR","C08-Calcium channel blockers","MTMOTCMT","Million US$ at exchange rate","NOR","Norway","2015","2015",15,,
+"PATCCCBR","C08-Calcium channel blockers","MTMOTCMT","Million US$ at exchange rate","NOR","Norway","2016","2016",15,,
+"PATCCCBR","C08-Calcium channel blockers","MTMOTCMT","Million US$ at exchange rate","NOR","Norway","2017","2017",15.5,,
+"PATCCCBR","C08-Calcium channel blockers","MTMOTCMT","Million US$ at exchange rate","NOR","Norway","2018","2018",13.6,,
+"PATCCCBR","C08-Calcium channel blockers","MTMOTCMT","Million US$ at exchange rate","NOR","Norway","2019","2019",12.3,,
+"PATCCCBR","C08-Calcium channel blockers","MTMOTCMT","Million US$ at exchange rate","NOR","Norway","2020","2020",11.8,,
+"PATCCCBR","C08-Calcium channel blockers","MTMOTCMT","Million US$ at exchange rate","NOR","Norway","2021","2021",12.7,,
+"PATCCCBR","C08-Calcium channel blockers","MTMOTCMT","Million US$ at exchange rate","NOR","Norway","2022","2022",11.9,,
+"PATCCCBR","C08-Calcium channel blockers","MTMOPPMT","Million US$, purchasing power parity","NOR","Norway","2010","2010",17.4,,
+"PATCCCBR","C08-Calcium channel blockers","MTMOPPMT","Million US$, purchasing power parity","NOR","Norway","2011","2011",15.5,,
+"PATCCCBR","C08-Calcium channel blockers","MTMOPPMT","Million US$, purchasing power parity","NOR","Norway","2012","2012",14.6,,
+"PATCCCBR","C08-Calcium channel blockers","MTMOPPMT","Million US$, purchasing power parity","NOR","Norway","2013","2013",14.2,,
+"PATCCCBR","C08-Calcium channel blockers","MTMOPPMT","Million US$, purchasing power parity","NOR","Norway","2014","2014",14,,
+"PATCCCBR","C08-Calcium channel blockers","MTMOPPMT","Million US$, purchasing power parity","NOR","Norway","2015","2015",12.2,,
+"PATCCCBR","C08-Calcium channel blockers","MTMOPPMT","Million US$, purchasing power parity","NOR","Norway","2016","2016",12.5,,
+"PATCCCBR","C08-Calcium channel blockers","MTMOPPMT","Million US$, purchasing power parity","NOR","Norway","2017","2017",13.1,,
+"PATCCCBR","C08-Calcium channel blockers","MTMOPPMT","Million US$, purchasing power parity","NOR","Norway","2018","2018",11.6,,
+"PATCCCBR","C08-Calcium channel blockers","MTMOPPMT","Million US$, purchasing power parity","NOR","Norway","2019","2019",11.2,,
+"PATCCCBR","C08-Calcium channel blockers","MTMOPPMT","Million US$, purchasing power parity","NOR","Norway","2020","2020",11.2,,
+"PATCCCBR","C08-Calcium channel blockers","MTMOPPMT","Million US$, purchasing power parity","NOR","Norway","2021","2021",11.5,,
+"PATCCCBR","C08-Calcium channel blockers","MTMOPPMT","Million US$, purchasing power parity","NOR","Norway","2022","2022",10.6,,
+"PATCCCBR","C08-Calcium channel blockers","TCPPERMT","/capita, US$ exchange rate","NOR","Norway","2010","2010",5.4,,
+"PATCCCBR","C08-Calcium channel blockers","TCPPERMT","/capita, US$ exchange rate","NOR","Norway","2011","2011",5.1,,
+"PATCCCBR","C08-Calcium channel blockers","TCPPERMT","/capita, US$ exchange rate","NOR","Norway","2012","2012",4.5,,
+"PATCCCBR","C08-Calcium channel blockers","TCPPERMT","/capita, US$ exchange rate","NOR","Norway","2013","2013",4.3,,
+"PATCCCBR","C08-Calcium channel blockers","TCPPERMT","/capita, US$ exchange rate","NOR","Norway","2014","2014",4,,
+"PATCCCBR","C08-Calcium channel blockers","TCPPERMT","/capita, US$ exchange rate","NOR","Norway","2015","2015",2.9,,
+"PATCCCBR","C08-Calcium channel blockers","TCPPERMT","/capita, US$ exchange rate","NOR","Norway","2016","2016",2.9,,
+"PATCCCBR","C08-Calcium channel blockers","TCPPERMT","/capita, US$ exchange rate","NOR","Norway","2017","2017",2.9,,
+"PATCCCBR","C08-Calcium channel blockers","TCPPERMT","/capita, US$ exchange rate","NOR","Norway","2018","2018",2.6,,
+"PATCCCBR","C08-Calcium channel blockers","TCPPERMT","/capita, US$ exchange rate","NOR","Norway","2019","2019",2.3,,
+"PATCCCBR","C08-Calcium channel blockers","TCPPERMT","/capita, US$ exchange rate","NOR","Norway","2020","2020",2.2,,
+"PATCCCBR","C08-Calcium channel blockers","TCPPERMT","/capita, US$ exchange rate","NOR","Norway","2021","2021",2.3,,
+"PATCCCBR","C08-Calcium channel blockers","TCPPERMT","/capita, US$ exchange rate","NOR","Norway","2022","2022",2.2,,
+"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2010","2010",3.6,,
+"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2011","2011",3.1,,
+"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2012","2012",2.9,,
+"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2013","2013",2.8,,
+"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2014","2014",2.7,,
+"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2015","2015",2.3,,
+"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2016","2016",2.4,,
+"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2017","2017",2.5,,
+"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2018","2018",2.2,,
+"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2019","2019",2.1,,
+"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2020","2020",2.1,,
+"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2021","2021",2.1,,
+"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2022","2022",2,,
+"PATCCCBR","C08-Calcium channel blockers","ATCPTTMT","% of total sales","NOR","Norway","2010","2010",0.9,,
+"PATCCCBR","C08-Calcium channel blockers","ATCPTTMT","% of total sales","NOR","Norway","2011","2011",0.8,,
+"PATCCCBR","C08-Calcium channel blockers","ATCPTTMT","% of total sales","NOR","Norway","2012","2012",0.7,,
+"PATCCCBR","C08-Calcium channel blockers","ATCPTTMT","% of total sales","NOR","Norway","2013","2013",0.7,,
+"PATCCCBR","C08-Calcium channel blockers","ATCPTTMT","% of total sales","NOR","Norway","2014","2014",0.6,,
+"PATCCCBR","C08-Calcium channel blockers","ATCPTTMT","% of total sales","NOR","Norway","2015","2015",0.5,,
+"PATCCCBR","C08-Calcium channel blockers","ATCPTTMT","% of total sales","NOR","Norway","2016","2016",0.5,,
+"PATCCCBR","C08-Calcium channel blockers","ATCPTTMT","% of total sales","NOR","Norway","2017","2017",0.5,,
+"PATCCCBR","C08-Calcium channel blockers","ATCPTTMT","% of total sales","NOR","Norway","2018","2018",0.4,,
+"PATCCCBR","C08-Calcium channel blockers","ATCPTTMT","% of total sales","NOR","Norway","2019","2019",0.4,,
+"PATCCCBR","C08-Calcium channel blockers","ATCPTTMT","% of total sales","NOR","Norway","2020","2020",0.4,,
+"PATCCCBR","C08-Calcium channel blockers","ATCPTTMT","% of total sales","NOR","Norway","2021","2021",0.3,,
+"PATCCCBR","C08-Calcium channel blockers","ATCPTTMT","% of total sales","NOR","Norway","2022","2022",0.3,,
+"PATCCCBR","C08-Calcium channel blockers","MLLNCUMT","Million of national currency units","PRT","Portugal","2010","2010",54.4,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","MLLNCUMT","Million of national currency units","PRT","Portugal","2011","2011",44.4,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","MLLNCUMT","Million of national currency units","PRT","Portugal","2012","2012",35.1,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","MLLNCUMT","Million of national currency units","PRT","Portugal","2013","2013",29.3,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","MLLNCUMT","Million of national currency units","PRT","Portugal","2014","2014",27,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","MLLNCUMT","Million of national currency units","PRT","Portugal","2015","2015",26,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","MLLNCUMT","Million of national currency units","PRT","Portugal","2016","2016",25.1,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","MLLNCUMT","Million of national currency units","PRT","Portugal","2017","2017",24.3,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","MLLNCUMT","Million of national currency units","PRT","Portugal","2018","2018",23.8,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","MLLNCUMT","Million of national currency units","PRT","Portugal","2019","2019",23.5,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","MLLNCUMT","Million of national currency units","PRT","Portugal","2020","2020",23.3,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","MLLNCUMT","Million of national currency units","PRT","Portugal","2021","2021",23,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","MLLNCUMT","Million of national currency units","PRT","Portugal","2022","2022",23.2,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","MTMOTCMT","Million US$ at exchange rate","PRT","Portugal","2010","2010",72.1,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","MTMOTCMT","Million US$ at exchange rate","PRT","Portugal","2011","2011",61.8,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","MTMOTCMT","Million US$ at exchange rate","PRT","Portugal","2012","2012",45.1,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","MTMOTCMT","Million US$ at exchange rate","PRT","Portugal","2013","2013",38.9,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","MTMOTCMT","Million US$ at exchange rate","PRT","Portugal","2014","2014",35.8,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","MTMOTCMT","Million US$ at exchange rate","PRT","Portugal","2015","2015",28.8,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","MTMOTCMT","Million US$ at exchange rate","PRT","Portugal","2016","2016",27.8,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","MTMOTCMT","Million US$ at exchange rate","PRT","Portugal","2017","2017",27.5,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","MTMOTCMT","Million US$ at exchange rate","PRT","Portugal","2018","2018",28.1,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","MTMOTCMT","Million US$ at exchange rate","PRT","Portugal","2019","2019",26.3,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","MTMOTCMT","Million US$ at exchange rate","PRT","Portugal","2020","2020",26.7,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","MTMOTCMT","Million US$ at exchange rate","PRT","Portugal","2021","2021",27.2,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","MTMOTCMT","Million US$ at exchange rate","PRT","Portugal","2022","2022",24.4,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","MTMOPPMT","Million US$, purchasing power parity","PRT","Portugal","2010","2010",87.2,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","MTMOPPMT","Million US$, purchasing power parity","PRT","Portugal","2011","2011",71.2,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","MTMOPPMT","Million US$, purchasing power parity","PRT","Portugal","2012","2012",58,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","MTMOPPMT","Million US$, purchasing power parity","PRT","Portugal","2013","2013",50.2,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","MTMOPPMT","Million US$, purchasing power parity","PRT","Portugal","2014","2014",46.6,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","MTMOPPMT","Million US$, purchasing power parity","PRT","Portugal","2015","2015",44.4,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","MTMOPPMT","Million US$, purchasing power parity","PRT","Portugal","2016","2016",43.9,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","MTMOPPMT","Million US$, purchasing power parity","PRT","Portugal","2017","2017",42.2,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","MTMOPPMT","Million US$, purchasing power parity","PRT","Portugal","2018","2018",41.7,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","MTMOPPMT","Million US$, purchasing power parity","PRT","Portugal","2019","2019",42,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","MTMOPPMT","Million US$, purchasing power parity","PRT","Portugal","2020","2020",41.9,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","MTMOPPMT","Million US$, purchasing power parity","PRT","Portugal","2021","2021",40.6,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","MTMOPPMT","Million US$, purchasing power parity","PRT","Portugal","2022","2022",42.2,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","TCPPERMT","/capita, US$ exchange rate","PRT","Portugal","2010","2010",6.8,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","TCPPERMT","/capita, US$ exchange rate","PRT","Portugal","2011","2011",5.9,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","TCPPERMT","/capita, US$ exchange rate","PRT","Portugal","2012","2012",4.3,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","TCPPERMT","/capita, US$ exchange rate","PRT","Portugal","2013","2013",3.7,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","TCPPERMT","/capita, US$ exchange rate","PRT","Portugal","2014","2014",3.4,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","TCPPERMT","/capita, US$ exchange rate","PRT","Portugal","2015","2015",2.8,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","TCPPERMT","/capita, US$ exchange rate","PRT","Portugal","2016","2016",2.7,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","TCPPERMT","/capita, US$ exchange rate","PRT","Portugal","2017","2017",2.7,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","TCPPERMT","/capita, US$ exchange rate","PRT","Portugal","2018","2018",2.7,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","TCPPERMT","/capita, US$ exchange rate","PRT","Portugal","2019","2019",2.6,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","TCPPERMT","/capita, US$ exchange rate","PRT","Portugal","2020","2020",2.6,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","TCPPERMT","/capita, US$ exchange rate","PRT","Portugal","2021","2021",2.6,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","TCPPERMT","/capita, US$ exchange rate","PRT","Portugal","2022","2022",2.4,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2010","2010",8.3,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2011","2011",6.7,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2012","2012",5.5,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2013","2013",4.8,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2014","2014",4.5,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2015","2015",4.3,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2016","2016",4.3,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2017","2017",4.1,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2018","2018",4.1,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2019","2019",4.1,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2020","2020",4.1,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2021","2021",3.9,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2022","2022",4.1,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","ATCPTTMT","% of total sales","PRT","Portugal","2010","2010",1.7,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","ATCPTTMT","% of total sales","PRT","Portugal","2011","2011",1.5,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","ATCPTTMT","% of total sales","PRT","Portugal","2012","2012",1.3,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","ATCPTTMT","% of total sales","PRT","Portugal","2013","2013",1.2,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","ATCPTTMT","% of total sales","PRT","Portugal","2014","2014",1.1,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","ATCPTTMT","% of total sales","PRT","Portugal","2015","2015",1,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","ATCPTTMT","% of total sales","PRT","Portugal","2016","2016",1,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","ATCPTTMT","% of total sales","PRT","Portugal","2017","2017",1,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","ATCPTTMT","% of total sales","PRT","Portugal","2018","2018",0.9,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","ATCPTTMT","% of total sales","PRT","Portugal","2019","2019",0.8,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","ATCPTTMT","% of total sales","PRT","Portugal","2020","2020",0.8,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","ATCPTTMT","% of total sales","PRT","Portugal","2021","2021",0.8,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","ATCPTTMT","% of total sales","PRT","Portugal","2022","2022",0.7,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","MLLNCUMT","Million of national currency units","SVK","Slovak Republic","2010","2010",17.1,,
+"PATCCCBR","C08-Calcium channel blockers","MLLNCUMT","Million of national currency units","SVK","Slovak Republic","2011","2011",16.1,,
+"PATCCCBR","C08-Calcium channel blockers","MLLNCUMT","Million of national currency units","SVK","Slovak Republic","2012","2012",10.1,,
+"PATCCCBR","C08-Calcium channel blockers","MLLNCUMT","Million of national currency units","SVK","Slovak Republic","2013","2013",10,,
+"PATCCCBR","C08-Calcium channel blockers","MLLNCUMT","Million of national currency units","SVK","Slovak Republic","2014","2014",9,,
+"PATCCCBR","C08-Calcium channel blockers","MLLNCUMT","Million of national currency units","SVK","Slovak Republic","2015","2015",8.3,,
+"PATCCCBR","C08-Calcium channel blockers","MLLNCUMT","Million of national currency units","SVK","Slovak Republic","2016","2016",11.3,"B","Break"
+"PATCCCBR","C08-Calcium channel blockers","MLLNCUMT","Million of national currency units","SVK","Slovak Republic","2017","2017",10.5,,
+"PATCCCBR","C08-Calcium channel blockers","MLLNCUMT","Million of national currency units","SVK","Slovak Republic","2018","2018",9.7,,
+"PATCCCBR","C08-Calcium channel blockers","MLLNCUMT","Million of national currency units","SVK","Slovak Republic","2019","2019",9.2,,
+"PATCCCBR","C08-Calcium channel blockers","MLLNCUMT","Million of national currency units","SVK","Slovak Republic","2020","2020",9.2,,
+"PATCCCBR","C08-Calcium channel blockers","MLLNCUMT","Million of national currency units","SVK","Slovak Republic","2021","2021",8.5,,
+"PATCCCBR","C08-Calcium channel blockers","MTMOTCMT","Million US$ at exchange rate","SVK","Slovak Republic","2010","2010",22.7,,
+"PATCCCBR","C08-Calcium channel blockers","MTMOTCMT","Million US$ at exchange rate","SVK","Slovak Republic","2011","2011",22.4,,
+"PATCCCBR","C08-Calcium channel blockers","MTMOTCMT","Million US$ at exchange rate","SVK","Slovak Republic","2012","2012",12.9,,
+"PATCCCBR","C08-Calcium channel blockers","MTMOTCMT","Million US$ at exchange rate","SVK","Slovak Republic","2013","2013",13.3,,
+"PATCCCBR","C08-Calcium channel blockers","MTMOTCMT","Million US$ at exchange rate","SVK","Slovak Republic","2014","2014",12,,
+"PATCCCBR","C08-Calcium channel blockers","MTMOTCMT","Million US$ at exchange rate","SVK","Slovak Republic","2015","2015",9.2,,
+"PATCCCBR","C08-Calcium channel blockers","MTMOTCMT","Million US$ at exchange rate","SVK","Slovak Republic","2016","2016",12.6,"B","Break"
+"PATCCCBR","C08-Calcium channel blockers","MTMOTCMT","Million US$ at exchange rate","SVK","Slovak Republic","2017","2017",11.8,,
+"PATCCCBR","C08-Calcium channel blockers","MTMOTCMT","Million US$ at exchange rate","SVK","Slovak Republic","2018","2018",11.5,,
+"PATCCCBR","C08-Calcium channel blockers","MTMOTCMT","Million US$ at exchange rate","SVK","Slovak Republic","2019","2019",10.3,,
+"PATCCCBR","C08-Calcium channel blockers","MTMOTCMT","Million US$ at exchange rate","SVK","Slovak Republic","2020","2020",10.5,,
+"PATCCCBR","C08-Calcium channel blockers","MTMOTCMT","Million US$ at exchange rate","SVK","Slovak Republic","2021","2021",10.1,,
+"PATCCCBR","C08-Calcium channel blockers","MTMOPPMT","Million US$, purchasing power parity","SVK","Slovak Republic","2010","2010",34.1,,
+"PATCCCBR","C08-Calcium channel blockers","MTMOPPMT","Million US$, purchasing power parity","SVK","Slovak Republic","2011","2011",31.8,,
+"PATCCCBR","C08-Calcium channel blockers","MTMOPPMT","Million US$, purchasing power parity","SVK","Slovak Republic","2012","2012",19.9,,
+"PATCCCBR","C08-Calcium channel blockers","MTMOPPMT","Million US$, purchasing power parity","SVK","Slovak Republic","2013","2013",20.4,,
+"PATCCCBR","C08-Calcium channel blockers","MTMOPPMT","Million US$, purchasing power parity","SVK","Slovak Republic","2014","2014",18.6,,
+"PATCCCBR","C08-Calcium channel blockers","MTMOPPMT","Million US$, purchasing power parity","SVK","Slovak Republic","2015","2015",16.9,,
+"PATCCCBR","C08-Calcium channel blockers","MTMOPPMT","Million US$, purchasing power parity","SVK","Slovak Republic","2016","2016",22.5,"B","Break"
+"PATCCCBR","C08-Calcium channel blockers","MTMOPPMT","Million US$, purchasing power parity","SVK","Slovak Republic","2017","2017",20.3,,
+"PATCCCBR","C08-Calcium channel blockers","MTMOPPMT","Million US$, purchasing power parity","SVK","Slovak Republic","2018","2018",18.5,,
+"PATCCCBR","C08-Calcium channel blockers","MTMOPPMT","Million US$, purchasing power parity","SVK","Slovak Republic","2019","2019",17.8,,
+"PATCCCBR","C08-Calcium channel blockers","MTMOPPMT","Million US$, purchasing power parity","SVK","Slovak Republic","2020","2020",17.6,,
+"PATCCCBR","C08-Calcium channel blockers","MTMOPPMT","Million US$, purchasing power parity","SVK","Slovak Republic","2021","2021",15.9,,
+"PATCCCBR","C08-Calcium channel blockers","TCPPERMT","/capita, US$ exchange rate","SVK","Slovak Republic","2010","2010",4.2,,
+"PATCCCBR","C08-Calcium channel blockers","TCPPERMT","/capita, US$ exchange rate","SVK","Slovak Republic","2011","2011",4.1,,
+"PATCCCBR","C08-Calcium channel blockers","TCPPERMT","/capita, US$ exchange rate","SVK","Slovak Republic","2012","2012",2.4,,
+"PATCCCBR","C08-Calcium channel blockers","TCPPERMT","/capita, US$ exchange rate","SVK","Slovak Republic","2013","2013",2.5,,
+"PATCCCBR","C08-Calcium channel blockers","TCPPERMT","/capita, US$ exchange rate","SVK","Slovak Republic","2014","2014",2.2,,
+"PATCCCBR","C08-Calcium channel blockers","TCPPERMT","/capita, US$ exchange rate","SVK","Slovak Republic","2015","2015",1.7,,
+"PATCCCBR","C08-Calcium channel blockers","TCPPERMT","/capita, US$ exchange rate","SVK","Slovak Republic","2016","2016",2.3,"B","Break"
+"PATCCCBR","C08-Calcium channel blockers","TCPPERMT","/capita, US$ exchange rate","SVK","Slovak Republic","2017","2017",2.2,,
+"PATCCCBR","C08-Calcium channel blockers","TCPPERMT","/capita, US$ exchange rate","SVK","Slovak Republic","2018","2018",2.1,,
+"PATCCCBR","C08-Calcium channel blockers","TCPPERMT","/capita, US$ exchange rate","SVK","Slovak Republic","2019","2019",1.9,,
+"PATCCCBR","C08-Calcium channel blockers","TCPPERMT","/capita, US$ exchange rate","SVK","Slovak Republic","2020","2020",1.9,,
+"PATCCCBR","C08-Calcium channel blockers","TCPPERMT","/capita, US$ exchange rate","SVK","Slovak Republic","2021","2021",1.8,,
+"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2010","2010",6.3,,
+"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2011","2011",5.9,,
+"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2012","2012",3.7,,
+"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2013","2013",3.8,,
+"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2014","2014",3.4,,
+"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2015","2015",3.1,,
+"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2016","2016",4.1,"B","Break"
+"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2017","2017",3.7,,
+"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2018","2018",3.4,,
+"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2019","2019",3.3,,
+"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2020","2020",3.2,,
+"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2021","2021",2.9,,
+"PATCCCBR","C08-Calcium channel blockers","ATCPTTMT","% of total sales","SVK","Slovak Republic","2010","2010",1.5,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","ATCPTTMT","% of total sales","SVK","Slovak Republic","2011","2011",1.4,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","ATCPTTMT","% of total sales","SVK","Slovak Republic","2012","2012",0.9,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","ATCPTTMT","% of total sales","SVK","Slovak Republic","2013","2013",0.8,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","ATCPTTMT","% of total sales","SVK","Slovak Republic","2014","2014",0.7,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","ATCPTTMT","% of total sales","SVK","Slovak Republic","2015","2015",0.6,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","ATCPTTMT","% of total sales","SVK","Slovak Republic","2016","2016",0.7,"B","Break"
+"PATCCCBR","C08-Calcium channel blockers","ATCPTTMT","% of total sales","SVK","Slovak Republic","2017","2017",0.7,,
+"PATCCCBR","C08-Calcium channel blockers","ATCPTTMT","% of total sales","SVK","Slovak Republic","2018","2018",0.6,,
+"PATCCCBR","C08-Calcium channel blockers","ATCPTTMT","% of total sales","SVK","Slovak Republic","2019","2019",0.5,,
+"PATCCCBR","C08-Calcium channel blockers","ATCPTTMT","% of total sales","SVK","Slovak Republic","2020","2020",0.6,,
+"PATCCCBR","C08-Calcium channel blockers","ATCPTTMT","% of total sales","SVK","Slovak Republic","2021","2021",0.5,,
+"PATCCCBR","C08-Calcium channel blockers","MLLNCUMT","Million of national currency units","ESP","Spain","2010","2010",238.3,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","MLLNCUMT","Million of national currency units","ESP","Spain","2011","2011",187,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","MLLNCUMT","Million of national currency units","ESP","Spain","2012","2012",126.7,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","MLLNCUMT","Million of national currency units","ESP","Spain","2013","2013",110.8,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","MLLNCUMT","Million of national currency units","ESP","Spain","2014","2014",112.6,"B; D","Break; Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","MLLNCUMT","Million of national currency units","ESP","Spain","2015","2015",108.2,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","MLLNCUMT","Million of national currency units","ESP","Spain","2016","2016",108.6,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","MLLNCUMT","Million of national currency units","ESP","Spain","2017","2017",107.7,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","MLLNCUMT","Million of national currency units","ESP","Spain","2018","2018",109.5,"B","Break"
+"PATCCCBR","C08-Calcium channel blockers","MLLNCUMT","Million of national currency units","ESP","Spain","2019","2019",110.1,,
+"PATCCCBR","C08-Calcium channel blockers","MLLNCUMT","Million of national currency units","ESP","Spain","2020","2020",109.8,,
+"PATCCCBR","C08-Calcium channel blockers","MLLNCUMT","Million of national currency units","ESP","Spain","2021","2021",110,,
+"PATCCCBR","C08-Calcium channel blockers","MLLNCUMT","Million of national currency units","ESP","Spain","2022","2022",109.5,"P","Provisional value"
+"PATCCCBR","C08-Calcium channel blockers","MTMOTCMT","Million US$ at exchange rate","ESP","Spain","2010","2010",316,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","MTMOTCMT","Million US$ at exchange rate","ESP","Spain","2011","2011",260.2,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","MTMOTCMT","Million US$ at exchange rate","ESP","Spain","2012","2012",162.8,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","MTMOTCMT","Million US$ at exchange rate","ESP","Spain","2013","2013",147.2,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","MTMOTCMT","Million US$ at exchange rate","ESP","Spain","2014","2014",149.5,"B; D","Break; Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","MTMOTCMT","Million US$ at exchange rate","ESP","Spain","2015","2015",120.1,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","MTMOTCMT","Million US$ at exchange rate","ESP","Spain","2016","2016",120.2,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","MTMOTCMT","Million US$ at exchange rate","ESP","Spain","2017","2017",121.6,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","MTMOTCMT","Million US$ at exchange rate","ESP","Spain","2018","2018",129.3,"B","Break"
+"PATCCCBR","C08-Calcium channel blockers","MTMOTCMT","Million US$ at exchange rate","ESP","Spain","2019","2019",123.3,,
+"PATCCCBR","C08-Calcium channel blockers","MTMOTCMT","Million US$ at exchange rate","ESP","Spain","2020","2020",125.4,,
+"PATCCCBR","C08-Calcium channel blockers","MTMOTCMT","Million US$ at exchange rate","ESP","Spain","2021","2021",130.1,,
+"PATCCCBR","C08-Calcium channel blockers","MTMOTCMT","Million US$ at exchange rate","ESP","Spain","2022","2022",115.3,"P","Provisional value"
+"PATCCCBR","C08-Calcium channel blockers","MTMOPPMT","Million US$, purchasing power parity","ESP","Spain","2010","2010",327.9,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","MTMOPPMT","Million US$, purchasing power parity","ESP","Spain","2011","2011",261.8,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","MTMOPPMT","Million US$, purchasing power parity","ESP","Spain","2012","2012",182.3,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","MTMOPPMT","Million US$, purchasing power parity","ESP","Spain","2013","2013",164.3,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","MTMOPPMT","Million US$, purchasing power parity","ESP","Spain","2014","2014",169.9,"B; D","Break; Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","MTMOPPMT","Million US$, purchasing power parity","ESP","Spain","2015","2015",162.8,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","MTMOPPMT","Million US$, purchasing power parity","ESP","Spain","2016","2016",168.9,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","MTMOPPMT","Million US$, purchasing power parity","ESP","Spain","2017","2017",170.7,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","MTMOPPMT","Million US$, purchasing power parity","ESP","Spain","2018","2018",173.3,"B","Break"
+"PATCCCBR","C08-Calcium channel blockers","MTMOPPMT","Million US$, purchasing power parity","ESP","Spain","2019","2019",179.7,,
+"PATCCCBR","C08-Calcium channel blockers","MTMOPPMT","Million US$, purchasing power parity","ESP","Spain","2020","2020",176.7,,
+"PATCCCBR","C08-Calcium channel blockers","MTMOPPMT","Million US$, purchasing power parity","ESP","Spain","2021","2021",175.7,,
+"PATCCCBR","C08-Calcium channel blockers","MTMOPPMT","Million US$, purchasing power parity","ESP","Spain","2022","2022",183.7,"P","Provisional value"
+"PATCCCBR","C08-Calcium channel blockers","TCPPERMT","/capita, US$ exchange rate","ESP","Spain","2010","2010",6.8,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","TCPPERMT","/capita, US$ exchange rate","ESP","Spain","2011","2011",5.6,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","TCPPERMT","/capita, US$ exchange rate","ESP","Spain","2012","2012",3.5,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","TCPPERMT","/capita, US$ exchange rate","ESP","Spain","2013","2013",3.2,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","TCPPERMT","/capita, US$ exchange rate","ESP","Spain","2014","2014",3.2,"B; D","Break; Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","TCPPERMT","/capita, US$ exchange rate","ESP","Spain","2015","2015",2.6,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","TCPPERMT","/capita, US$ exchange rate","ESP","Spain","2016","2016",2.6,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","TCPPERMT","/capita, US$ exchange rate","ESP","Spain","2017","2017",2.6,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","TCPPERMT","/capita, US$ exchange rate","ESP","Spain","2018","2018",2.8,"B","Break"
+"PATCCCBR","C08-Calcium channel blockers","TCPPERMT","/capita, US$ exchange rate","ESP","Spain","2019","2019",2.6,,
+"PATCCCBR","C08-Calcium channel blockers","TCPPERMT","/capita, US$ exchange rate","ESP","Spain","2020","2020",2.6,,
+"PATCCCBR","C08-Calcium channel blockers","TCPPERMT","/capita, US$ exchange rate","ESP","Spain","2021","2021",2.7,,
+"PATCCCBR","C08-Calcium channel blockers","TCPPERMT","/capita, US$ exchange rate","ESP","Spain","2022","2022",2.4,"P","Provisional value"
+"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2010","2010",7,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2011","2011",5.6,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2012","2012",3.9,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2013","2013",3.5,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2014","2014",3.7,"B; D","Break; Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2015","2015",3.5,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2016","2016",3.6,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2017","2017",3.7,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2018","2018",3.7,"B","Break"
+"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2019","2019",3.8,,
+"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2020","2020",3.7,,
+"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2021","2021",3.7,,
+"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2022","2022",3.9,"P","Provisional value"
+"PATCCCBR","C08-Calcium channel blockers","ATCPTTMT","% of total sales","ESP","Spain","2010","2010",1.8,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","ATCPTTMT","% of total sales","ESP","Spain","2011","2011",1.5,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","ATCPTTMT","% of total sales","ESP","Spain","2012","2012",1.1,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","ATCPTTMT","% of total sales","ESP","Spain","2013","2013",1,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","ATCPTTMT","% of total sales","ESP","Spain","2014","2014",1,"B; D","Break; Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","ATCPTTMT","% of total sales","ESP","Spain","2015","2015",0.9,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","ATCPTTMT","% of total sales","ESP","Spain","2016","2016",0.9,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","ATCPTTMT","% of total sales","ESP","Spain","2017","2017",0.9,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","ATCPTTMT","% of total sales","ESP","Spain","2018","2018",0.6,"B","Break"
+"PATCCCBR","C08-Calcium channel blockers","ATCPTTMT","% of total sales","ESP","Spain","2019","2019",0.6,,
+"PATCCCBR","C08-Calcium channel blockers","ATCPTTMT","% of total sales","ESP","Spain","2020","2020",0.5,,
+"PATCCCBR","C08-Calcium channel blockers","ATCPTTMT","% of total sales","ESP","Spain","2021","2021",0.5,,
+"PATCCCBR","C08-Calcium channel blockers","ATCPTTMT","% of total sales","ESP","Spain","2022","2022",0.5,"P","Provisional value"
+"PATCCCBR","C08-Calcium channel blockers","MLLNCUMT","Million of national currency units","SWE","Sweden","2010","2010",206.8,,
+"PATCCCBR","C08-Calcium channel blockers","MLLNCUMT","Million of national currency units","SWE","Sweden","2011","2011",195.8,,
+"PATCCCBR","C08-Calcium channel blockers","MLLNCUMT","Million of national currency units","SWE","Sweden","2012","2012",193,,
+"PATCCCBR","C08-Calcium channel blockers","MLLNCUMT","Million of national currency units","SWE","Sweden","2013","2013",198.7,,
+"PATCCCBR","C08-Calcium channel blockers","MLLNCUMT","Million of national currency units","SWE","Sweden","2014","2014",202,,
+"PATCCCBR","C08-Calcium channel blockers","MLLNCUMT","Million of national currency units","SWE","Sweden","2015","2015",203.5,,
+"PATCCCBR","C08-Calcium channel blockers","MLLNCUMT","Million of national currency units","SWE","Sweden","2016","2016",200.3,,
+"PATCCCBR","C08-Calcium channel blockers","MLLNCUMT","Million of national currency units","SWE","Sweden","2017","2017",202.1,,
+"PATCCCBR","C08-Calcium channel blockers","MLLNCUMT","Million of national currency units","SWE","Sweden","2018","2018",209.2,,
+"PATCCCBR","C08-Calcium channel blockers","MLLNCUMT","Million of national currency units","SWE","Sweden","2019","2019",239.8,,
+"PATCCCBR","C08-Calcium channel blockers","MLLNCUMT","Million of national currency units","SWE","Sweden","2020","2020",275.3,,
+"PATCCCBR","C08-Calcium channel blockers","MLLNCUMT","Million of national currency units","SWE","Sweden","2021","2021",249.3,,
+"PATCCCBR","C08-Calcium channel blockers","MLLNCUMT","Million of national currency units","SWE","Sweden","2022","2022",254.2,,
+"PATCCCBR","C08-Calcium channel blockers","MTMOTCMT","Million US$ at exchange rate","SWE","Sweden","2010","2010",28.7,,
+"PATCCCBR","C08-Calcium channel blockers","MTMOTCMT","Million US$ at exchange rate","SWE","Sweden","2011","2011",30.2,,
+"PATCCCBR","C08-Calcium channel blockers","MTMOTCMT","Million US$ at exchange rate","SWE","Sweden","2012","2012",28.5,,
+"PATCCCBR","C08-Calcium channel blockers","MTMOTCMT","Million US$ at exchange rate","SWE","Sweden","2013","2013",30.5,,
+"PATCCCBR","C08-Calcium channel blockers","MTMOTCMT","Million US$ at exchange rate","SWE","Sweden","2014","2014",29.4,,
+"PATCCCBR","C08-Calcium channel blockers","MTMOTCMT","Million US$ at exchange rate","SWE","Sweden","2015","2015",24.1,,
+"PATCCCBR","C08-Calcium channel blockers","MTMOTCMT","Million US$ at exchange rate","SWE","Sweden","2016","2016",23.4,,
+"PATCCCBR","C08-Calcium channel blockers","MTMOTCMT","Million US$ at exchange rate","SWE","Sweden","2017","2017",23.6,,
+"PATCCCBR","C08-Calcium channel blockers","MTMOTCMT","Million US$ at exchange rate","SWE","Sweden","2018","2018",24.1,,
+"PATCCCBR","C08-Calcium channel blockers","MTMOTCMT","Million US$ at exchange rate","SWE","Sweden","2019","2019",25.3,,
+"PATCCCBR","C08-Calcium channel blockers","MTMOTCMT","Million US$ at exchange rate","SWE","Sweden","2020","2020",29.9,,
+"PATCCCBR","C08-Calcium channel blockers","MTMOTCMT","Million US$ at exchange rate","SWE","Sweden","2021","2021",29.1,,
+"PATCCCBR","C08-Calcium channel blockers","MTMOTCMT","Million US$ at exchange rate","SWE","Sweden","2022","2022",25.1,,
+"PATCCCBR","C08-Calcium channel blockers","MTMOPPMT","Million US$, purchasing power parity","SWE","Sweden","2010","2010",22.9,,
+"PATCCCBR","C08-Calcium channel blockers","MTMOPPMT","Million US$, purchasing power parity","SWE","Sweden","2011","2011",22.1,,
+"PATCCCBR","C08-Calcium channel blockers","MTMOPPMT","Million US$, purchasing power parity","SWE","Sweden","2012","2012",22.3,,
+"PATCCCBR","C08-Calcium channel blockers","MTMOPPMT","Million US$, purchasing power parity","SWE","Sweden","2013","2013",23.1,,
+"PATCCCBR","C08-Calcium channel blockers","MTMOPPMT","Million US$, purchasing power parity","SWE","Sweden","2014","2014",23.1,,
+"PATCCCBR","C08-Calcium channel blockers","MTMOPPMT","Million US$, purchasing power parity","SWE","Sweden","2015","2015",23,,
+"PATCCCBR","C08-Calcium channel blockers","MTMOPPMT","Million US$, purchasing power parity","SWE","Sweden","2016","2016",22.7,,
+"PATCCCBR","C08-Calcium channel blockers","MTMOPPMT","Million US$, purchasing power parity","SWE","Sweden","2017","2017",22.8,,
+"PATCCCBR","C08-Calcium channel blockers","MTMOPPMT","Million US$, purchasing power parity","SWE","Sweden","2018","2018",23.6,,
+"PATCCCBR","C08-Calcium channel blockers","MTMOPPMT","Million US$, purchasing power parity","SWE","Sweden","2019","2019",27.5,,
+"PATCCCBR","C08-Calcium channel blockers","MTMOPPMT","Million US$, purchasing power parity","SWE","Sweden","2020","2020",31.8,,
+"PATCCCBR","C08-Calcium channel blockers","MTMOPPMT","Million US$, purchasing power parity","SWE","Sweden","2021","2021",28.6,,
+"PATCCCBR","C08-Calcium channel blockers","MTMOPPMT","Million US$, purchasing power parity","SWE","Sweden","2022","2022",29.3,,
+"PATCCCBR","C08-Calcium channel blockers","TCPPERMT","/capita, US$ exchange rate","SWE","Sweden","2010","2010",3.1,,
+"PATCCCBR","C08-Calcium channel blockers","TCPPERMT","/capita, US$ exchange rate","SWE","Sweden","2011","2011",3.2,,
+"PATCCCBR","C08-Calcium channel blockers","TCPPERMT","/capita, US$ exchange rate","SWE","Sweden","2012","2012",3,,
+"PATCCCBR","C08-Calcium channel blockers","TCPPERMT","/capita, US$ exchange rate","SWE","Sweden","2013","2013",3.2,,
+"PATCCCBR","C08-Calcium channel blockers","TCPPERMT","/capita, US$ exchange rate","SWE","Sweden","2014","2014",3,,
+"PATCCCBR","C08-Calcium channel blockers","TCPPERMT","/capita, US$ exchange rate","SWE","Sweden","2015","2015",2.5,,
+"PATCCCBR","C08-Calcium channel blockers","TCPPERMT","/capita, US$ exchange rate","SWE","Sweden","2016","2016",2.4,,
+"PATCCCBR","C08-Calcium channel blockers","TCPPERMT","/capita, US$ exchange rate","SWE","Sweden","2017","2017",2.4,,
+"PATCCCBR","C08-Calcium channel blockers","TCPPERMT","/capita, US$ exchange rate","SWE","Sweden","2018","2018",2.4,,
+"PATCCCBR","C08-Calcium channel blockers","TCPPERMT","/capita, US$ exchange rate","SWE","Sweden","2019","2019",2.5,,
+"PATCCCBR","C08-Calcium channel blockers","TCPPERMT","/capita, US$ exchange rate","SWE","Sweden","2020","2020",2.9,,
+"PATCCCBR","C08-Calcium channel blockers","TCPPERMT","/capita, US$ exchange rate","SWE","Sweden","2021","2021",2.8,,
+"PATCCCBR","C08-Calcium channel blockers","TCPPERMT","/capita, US$ exchange rate","SWE","Sweden","2022","2022",2.4,,
+"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2010","2010",2.4,,
+"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2011","2011",2.3,,
+"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2012","2012",2.3,,
+"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2013","2013",2.4,,
+"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2014","2014",2.4,,
+"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2015","2015",2.3,,
+"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2016","2016",2.3,,
+"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2017","2017",2.3,,
+"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2018","2018",2.3,,
+"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2019","2019",2.7,,
+"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2020","2020",3.1,,
+"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2021","2021",2.7,,
+"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2022","2022",2.8,,
+"PATCCCBR","C08-Calcium channel blockers","ATCPTTMT","% of total sales","SWE","Sweden","2010","2010",0.6,,
+"PATCCCBR","C08-Calcium channel blockers","ATCPTTMT","% of total sales","SWE","Sweden","2011","2011",0.5,,
+"PATCCCBR","C08-Calcium channel blockers","ATCPTTMT","% of total sales","SWE","Sweden","2012","2012",0.5,,
+"PATCCCBR","C08-Calcium channel blockers","ATCPTTMT","% of total sales","SWE","Sweden","2013","2013",0.5,,
+"PATCCCBR","C08-Calcium channel blockers","ATCPTTMT","% of total sales","SWE","Sweden","2014","2014",0.5,,
+"PATCCCBR","C08-Calcium channel blockers","ATCPTTMT","% of total sales","SWE","Sweden","2015","2015",0.5,,
+"PATCCCBR","C08-Calcium channel blockers","ATCPTTMT","% of total sales","SWE","Sweden","2016","2016",0.5,,
+"PATCCCBR","C08-Calcium channel blockers","ATCPTTMT","% of total sales","SWE","Sweden","2017","2017",0.5,,
+"PATCCCBR","C08-Calcium channel blockers","ATCPTTMT","% of total sales","SWE","Sweden","2018","2018",0.4,,
+"PATCCCBR","C08-Calcium channel blockers","ATCPTTMT","% of total sales","SWE","Sweden","2019","2019",0.5,,
+"PATCCCBR","C08-Calcium channel blockers","ATCPTTMT","% of total sales","SWE","Sweden","2020","2020",0.5,,
+"PATCCCBR","C08-Calcium channel blockers","ATCPTTMT","% of total sales","SWE","Sweden","2021","2021",0.5,,
+"PATCCCBR","C08-Calcium channel blockers","ATCPTTMT","% of total sales","SWE","Sweden","2022","2022",0.4,,
+"PATCCCBR","C08-Calcium channel blockers","MLLNCUMT","Million of national currency units","TUR","Türkiye","2010","2010",131.6,,
+"PATCCCBR","C08-Calcium channel blockers","MLLNCUMT","Million of national currency units","TUR","Türkiye","2011","2011",121.6,,
+"PATCCCBR","C08-Calcium channel blockers","MLLNCUMT","Million of national currency units","TUR","Türkiye","2012","2012",112.9,,
+"PATCCCBR","C08-Calcium channel blockers","MLLNCUMT","Million of national currency units","TUR","Türkiye","2013","2013",126.6,,
+"PATCCCBR","C08-Calcium channel blockers","MLLNCUMT","Million of national currency units","TUR","Türkiye","2014","2014",127.6,,
+"PATCCCBR","C08-Calcium channel blockers","MLLNCUMT","Million of national currency units","TUR","Türkiye","2015","2015",140.7,,
+"PATCCCBR","C08-Calcium channel blockers","MLLNCUMT","Million of national currency units","TUR","Türkiye","2016","2016",158.9,,
+"PATCCCBR","C08-Calcium channel blockers","MLLNCUMT","Million of national currency units","TUR","Türkiye","2017","2017",197.5,,
+"PATCCCBR","C08-Calcium channel blockers","MLLNCUMT","Million of national currency units","TUR","Türkiye","2018","2018",240.1,,
+"PATCCCBR","C08-Calcium channel blockers","MLLNCUMT","Million of national currency units","TUR","Türkiye","2019","2019",286.9,,
+"PATCCCBR","C08-Calcium channel blockers","MLLNCUMT","Million of national currency units","TUR","Türkiye","2020","2020",368.2,,
+"PATCCCBR","C08-Calcium channel blockers","MLLNCUMT","Million of national currency units","TUR","Türkiye","2021","2021",424.6,,
+"PATCCCBR","C08-Calcium channel blockers","MTMOTCMT","Million US$ at exchange rate","TUR","Türkiye","2010","2010",87.6,,
+"PATCCCBR","C08-Calcium channel blockers","MTMOTCMT","Million US$ at exchange rate","TUR","Türkiye","2011","2011",72.6,,
+"PATCCCBR","C08-Calcium channel blockers","MTMOTCMT","Million US$ at exchange rate","TUR","Türkiye","2012","2012",62.9,,
+"PATCCCBR","C08-Calcium channel blockers","MTMOTCMT","Million US$ at exchange rate","TUR","Türkiye","2013","2013",66.5,,
+"PATCCCBR","C08-Calcium channel blockers","MTMOTCMT","Million US$ at exchange rate","TUR","Türkiye","2014","2014",58.3,,
+"PATCCCBR","C08-Calcium channel blockers","MTMOTCMT","Million US$ at exchange rate","TUR","Türkiye","2015","2015",51.7,,
+"PATCCCBR","C08-Calcium channel blockers","MTMOTCMT","Million US$ at exchange rate","TUR","Türkiye","2016","2016",52.6,,
+"PATCCCBR","C08-Calcium channel blockers","MTMOTCMT","Million US$ at exchange rate","TUR","Türkiye","2017","2017",54.1,,
+"PATCCCBR","C08-Calcium channel blockers","MTMOTCMT","Million US$ at exchange rate","TUR","Türkiye","2018","2018",49.7,,
+"PATCCCBR","C08-Calcium channel blockers","MTMOTCMT","Million US$ at exchange rate","TUR","Türkiye","2019","2019",50.6,,
+"PATCCCBR","C08-Calcium channel blockers","MTMOTCMT","Million US$ at exchange rate","TUR","Türkiye","2020","2020",52.5,,
+"PATCCCBR","C08-Calcium channel blockers","MTMOTCMT","Million US$ at exchange rate","TUR","Türkiye","2021","2021",48,,
+"PATCCCBR","C08-Calcium channel blockers","MTMOPPMT","Million US$, purchasing power parity","TUR","Türkiye","2010","2010",143,,
+"PATCCCBR","C08-Calcium channel blockers","MTMOPPMT","Million US$, purchasing power parity","TUR","Türkiye","2011","2011",125.9,,
+"PATCCCBR","C08-Calcium channel blockers","MTMOPPMT","Million US$, purchasing power parity","TUR","Türkiye","2012","2012",110.7,,
+"PATCCCBR","C08-Calcium channel blockers","MTMOPPMT","Million US$, purchasing power parity","TUR","Türkiye","2013","2013",118.3,,
+"PATCCCBR","C08-Calcium channel blockers","MTMOPPMT","Million US$, purchasing power parity","TUR","Türkiye","2014","2014",115.6,,
+"PATCCCBR","C08-Calcium channel blockers","MTMOPPMT","Million US$, purchasing power parity","TUR","Türkiye","2015","2015",121,,
+"PATCCCBR","C08-Calcium channel blockers","MTMOPPMT","Million US$, purchasing power parity","TUR","Türkiye","2016","2016",128,,
+"PATCCCBR","C08-Calcium channel blockers","MTMOPPMT","Million US$, purchasing power parity","TUR","Türkiye","2017","2017",142.7,,
+"PATCCCBR","C08-Calcium channel blockers","MTMOPPMT","Million US$, purchasing power parity","TUR","Türkiye","2018","2018",147,,
+"PATCCCBR","C08-Calcium channel blockers","MTMOPPMT","Million US$, purchasing power parity","TUR","Türkiye","2019","2019",153.9,,
+"PATCCCBR","C08-Calcium channel blockers","MTMOPPMT","Million US$, purchasing power parity","TUR","Türkiye","2020","2020",170.2,,
+"PATCCCBR","C08-Calcium channel blockers","MTMOPPMT","Million US$, purchasing power parity","TUR","Türkiye","2021","2021",151.2,,
+"PATCCCBR","C08-Calcium channel blockers","TCPPERMT","/capita, US$ exchange rate","TUR","Türkiye","2010","2010",1.2,,
+"PATCCCBR","C08-Calcium channel blockers","TCPPERMT","/capita, US$ exchange rate","TUR","Türkiye","2011","2011",1,,
+"PATCCCBR","C08-Calcium channel blockers","TCPPERMT","/capita, US$ exchange rate","TUR","Türkiye","2012","2012",0.8,,
+"PATCCCBR","C08-Calcium channel blockers","TCPPERMT","/capita, US$ exchange rate","TUR","Türkiye","2013","2013",0.9,,
+"PATCCCBR","C08-Calcium channel blockers","TCPPERMT","/capita, US$ exchange rate","TUR","Türkiye","2014","2014",0.8,,
+"PATCCCBR","C08-Calcium channel blockers","TCPPERMT","/capita, US$ exchange rate","TUR","Türkiye","2015","2015",0.7,,
+"PATCCCBR","C08-Calcium channel blockers","TCPPERMT","/capita, US$ exchange rate","TUR","Türkiye","2016","2016",0.7,,
+"PATCCCBR","C08-Calcium channel blockers","TCPPERMT","/capita, US$ exchange rate","TUR","Türkiye","2017","2017",0.7,,
+"PATCCCBR","C08-Calcium channel blockers","TCPPERMT","/capita, US$ exchange rate","TUR","Türkiye","2018","2018",0.6,,
+"PATCCCBR","C08-Calcium channel blockers","TCPPERMT","/capita, US$ exchange rate","TUR","Türkiye","2019","2019",0.6,,
+"PATCCCBR","C08-Calcium channel blockers","TCPPERMT","/capita, US$ exchange rate","TUR","Türkiye","2020","2020",0.6,,
+"PATCCCBR","C08-Calcium channel blockers","TCPPERMT","/capita, US$ exchange rate","TUR","Türkiye","2021","2021",0.6,,
+"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2010","2010",2,,
+"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2011","2011",1.7,,
+"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2012","2012",1.5,,
+"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2013","2013",1.6,,
+"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2014","2014",1.5,,
+"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2015","2015",1.5,,
+"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2016","2016",1.6,,
+"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2017","2017",1.8,,
+"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2018","2018",1.8,,
+"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2019","2019",1.9,,
+"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2020","2020",2,,
+"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2021","2021",1.8,,
+"PATCCCBR","C08-Calcium channel blockers","ATCPTTMT","% of total sales","TUR","Türkiye","2010","2010",0.8,,
+"PATCCCBR","C08-Calcium channel blockers","ATCPTTMT","% of total sales","TUR","Türkiye","2011","2011",0.9,,
+"PATCCCBR","C08-Calcium channel blockers","ATCPTTMT","% of total sales","TUR","Türkiye","2012","2012",0.8,,
+"PATCCCBR","C08-Calcium channel blockers","ATCPTTMT","% of total sales","TUR","Türkiye","2013","2013",0.9,,
+"PATCCCBR","C08-Calcium channel blockers","ATCPTTMT","% of total sales","TUR","Türkiye","2014","2014",0.8,,
+"PATCCCBR","C08-Calcium channel blockers","ATCPTTMT","% of total sales","TUR","Türkiye","2015","2015",0.8,,
+"PATCCCBR","C08-Calcium channel blockers","ATCPTTMT","% of total sales","TUR","Türkiye","2016","2016",0.7,,
+"PATCCCBR","C08-Calcium channel blockers","ATCPTTMT","% of total sales","TUR","Türkiye","2017","2017",0.8,,
+"PATCCCBR","C08-Calcium channel blockers","ATCPTTMT","% of total sales","TUR","Türkiye","2018","2018",0.7,,
+"PATCCCBR","C08-Calcium channel blockers","ATCPTTMT","% of total sales","TUR","Türkiye","2019","2019",0.7,,
+"PATCCCBR","C08-Calcium channel blockers","ATCPTTMT","% of total sales","TUR","Türkiye","2020","2020",0.7,,
+"PATCCCBR","C08-Calcium channel blockers","ATCPTTMT","% of total sales","TUR","Türkiye","2021","2021",0.7,,
+"PATCCCBR","C08-Calcium channel blockers","MLLNCUMT","Million of national currency units","CHL","Chile","2010","2010",4975.3,,
+"PATCCCBR","C08-Calcium channel blockers","MLLNCUMT","Million of national currency units","CHL","Chile","2011","2011",5881.7,"B","Break"
+"PATCCCBR","C08-Calcium channel blockers","MLLNCUMT","Million of national currency units","CHL","Chile","2012","2012",5913.9,,
+"PATCCCBR","C08-Calcium channel blockers","MLLNCUMT","Million of national currency units","CHL","Chile","2013","2013",5672.3,,
+"PATCCCBR","C08-Calcium channel blockers","MLLNCUMT","Million of national currency units","CHL","Chile","2014","2014",6613,,
+"PATCCCBR","C08-Calcium channel blockers","MLLNCUMT","Million of national currency units","CHL","Chile","2015","2015",6710.2,,
+"PATCCCBR","C08-Calcium channel blockers","MLLNCUMT","Million of national currency units","CHL","Chile","2016","2016",6996.6,,
+"PATCCCBR","C08-Calcium channel blockers","MLLNCUMT","Million of national currency units","CHL","Chile","2017","2017",8473.5,,
+"PATCCCBR","C08-Calcium channel blockers","MLLNCUMT","Million of national currency units","CHL","Chile","2018","2018",6690.4,,
+"PATCCCBR","C08-Calcium channel blockers","MLLNCUMT","Million of national currency units","CHL","Chile","2019","2019",7243.6,,
+"PATCCCBR","C08-Calcium channel blockers","MLLNCUMT","Million of national currency units","CHL","Chile","2020","2020",8829.6,,
+"PATCCCBR","C08-Calcium channel blockers","MLLNCUMT","Million of national currency units","CHL","Chile","2021","2021",7415.5,,
+"PATCCCBR","C08-Calcium channel blockers","MLLNCUMT","Million of national currency units","CHL","Chile","2022","2022",7600.1,,
+"PATCCCBR","C08-Calcium channel blockers","MTMOTCMT","Million US$ at exchange rate","CHL","Chile","2010","2010",9.8,,
+"PATCCCBR","C08-Calcium channel blockers","MTMOTCMT","Million US$ at exchange rate","CHL","Chile","2011","2011",12.2,"B","Break"
+"PATCCCBR","C08-Calcium channel blockers","MTMOTCMT","Million US$ at exchange rate","CHL","Chile","2012","2012",12.2,,
+"PATCCCBR","C08-Calcium channel blockers","MTMOTCMT","Million US$ at exchange rate","CHL","Chile","2013","2013",11.5,,
+"PATCCCBR","C08-Calcium channel blockers","MTMOTCMT","Million US$ at exchange rate","CHL","Chile","2014","2014",11.6,,
+"PATCCCBR","C08-Calcium channel blockers","MTMOTCMT","Million US$ at exchange rate","CHL","Chile","2015","2015",10.3,,
+"PATCCCBR","C08-Calcium channel blockers","MTMOTCMT","Million US$ at exchange rate","CHL","Chile","2016","2016",10.3,,
+"PATCCCBR","C08-Calcium channel blockers","MTMOTCMT","Million US$ at exchange rate","CHL","Chile","2017","2017",13.1,,
+"PATCCCBR","C08-Calcium channel blockers","MTMOTCMT","Million US$ at exchange rate","CHL","Chile","2018","2018",10.4,,
+"PATCCCBR","C08-Calcium channel blockers","MTMOTCMT","Million US$ at exchange rate","CHL","Chile","2019","2019",10.3,,
+"PATCCCBR","C08-Calcium channel blockers","MTMOTCMT","Million US$ at exchange rate","CHL","Chile","2020","2020",11.1,,
+"PATCCCBR","C08-Calcium channel blockers","MTMOTCMT","Million US$ at exchange rate","CHL","Chile","2021","2021",9.8,,
+"PATCCCBR","C08-Calcium channel blockers","MTMOTCMT","Million US$ at exchange rate","CHL","Chile","2022","2022",8.7,,
+"PATCCCBR","C08-Calcium channel blockers","MTMOPPMT","Million US$, purchasing power parity","CHL","Chile","2010","2010",13.8,,
+"PATCCCBR","C08-Calcium channel blockers","MTMOPPMT","Million US$, purchasing power parity","CHL","Chile","2011","2011",16.9,"B","Break"
+"PATCCCBR","C08-Calcium channel blockers","MTMOPPMT","Million US$, purchasing power parity","CHL","Chile","2012","2012",17,,
+"PATCCCBR","C08-Calcium channel blockers","MTMOPPMT","Million US$, purchasing power parity","CHL","Chile","2013","2013",16.2,,
+"PATCCCBR","C08-Calcium channel blockers","MTMOPPMT","Million US$, purchasing power parity","CHL","Chile","2014","2014",18,,
+"PATCCCBR","C08-Calcium channel blockers","MTMOPPMT","Million US$, purchasing power parity","CHL","Chile","2015","2015",17.2,,
+"PATCCCBR","C08-Calcium channel blockers","MTMOPPMT","Million US$, purchasing power parity","CHL","Chile","2016","2016",17.6,,
+"PATCCCBR","C08-Calcium channel blockers","MTMOPPMT","Million US$, purchasing power parity","CHL","Chile","2017","2017",21.3,,
+"PATCCCBR","C08-Calcium channel blockers","MTMOPPMT","Million US$, purchasing power parity","CHL","Chile","2018","2018",16.9,,
+"PATCCCBR","C08-Calcium channel blockers","MTMOPPMT","Million US$, purchasing power parity","CHL","Chile","2019","2019",18,,
+"PATCCCBR","C08-Calcium channel blockers","MTMOPPMT","Million US$, purchasing power parity","CHL","Chile","2020","2020",21.1,,
+"PATCCCBR","C08-Calcium channel blockers","MTMOPPMT","Million US$, purchasing power parity","CHL","Chile","2021","2021",17,,
+"PATCCCBR","C08-Calcium channel blockers","MTMOPPMT","Million US$, purchasing power parity","CHL","Chile","2022","2022",17.4,,
+"PATCCCBR","C08-Calcium channel blockers","TCPPERMT","/capita, US$ exchange rate","CHL","Chile","2010","2010",0.6,,
+"PATCCCBR","C08-Calcium channel blockers","TCPPERMT","/capita, US$ exchange rate","CHL","Chile","2011","2011",0.7,"B","Break"
+"PATCCCBR","C08-Calcium channel blockers","TCPPERMT","/capita, US$ exchange rate","CHL","Chile","2012","2012",0.7,,
+"PATCCCBR","C08-Calcium channel blockers","TCPPERMT","/capita, US$ exchange rate","CHL","Chile","2013","2013",0.7,,
+"PATCCCBR","C08-Calcium channel blockers","TCPPERMT","/capita, US$ exchange rate","CHL","Chile","2014","2014",0.7,,
+"PATCCCBR","C08-Calcium channel blockers","TCPPERMT","/capita, US$ exchange rate","CHL","Chile","2015","2015",0.6,,
+"PATCCCBR","C08-Calcium channel blockers","TCPPERMT","/capita, US$ exchange rate","CHL","Chile","2016","2016",0.6,,
+"PATCCCBR","C08-Calcium channel blockers","TCPPERMT","/capita, US$ exchange rate","CHL","Chile","2017","2017",0.7,,
+"PATCCCBR","C08-Calcium channel blockers","TCPPERMT","/capita, US$ exchange rate","CHL","Chile","2018","2018",0.6,,
+"PATCCCBR","C08-Calcium channel blockers","TCPPERMT","/capita, US$ exchange rate","CHL","Chile","2019","2019",0.5,,
+"PATCCCBR","C08-Calcium channel blockers","TCPPERMT","/capita, US$ exchange rate","CHL","Chile","2020","2020",0.6,,
+"PATCCCBR","C08-Calcium channel blockers","TCPPERMT","/capita, US$ exchange rate","CHL","Chile","2021","2021",0.5,,
+"PATCCCBR","C08-Calcium channel blockers","TCPPERMT","/capita, US$ exchange rate","CHL","Chile","2022","2022",0.4,,
+"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2010","2010",0.8,,
+"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2011","2011",1,"B","Break"
+"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2012","2012",1,,
+"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2013","2013",0.9,,
+"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2014","2014",1,,
+"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2015","2015",1,,
+"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2016","2016",1,,
+"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2017","2017",1.2,,
+"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2018","2018",0.9,,
+"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2019","2019",0.9,,
+"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2020","2020",1.1,,
+"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2021","2021",0.9,,
+"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2022","2022",0.9,,
+"PATCCCBR","C08-Calcium channel blockers","ATCPTTMT","% of total sales","CHL","Chile","2010","2010",0.6,,
+"PATCCCBR","C08-Calcium channel blockers","ATCPTTMT","% of total sales","CHL","Chile","2011","2011",0.5,"B","Break"
+"PATCCCBR","C08-Calcium channel blockers","ATCPTTMT","% of total sales","CHL","Chile","2012","2012",0.5,,
+"PATCCCBR","C08-Calcium channel blockers","ATCPTTMT","% of total sales","CHL","Chile","2013","2013",0.4,,
+"PATCCCBR","C08-Calcium channel blockers","ATCPTTMT","% of total sales","CHL","Chile","2014","2014",0.4,,
+"PATCCCBR","C08-Calcium channel blockers","ATCPTTMT","% of total sales","CHL","Chile","2015","2015",0.4,,
+"PATCCCBR","C08-Calcium channel blockers","ATCPTTMT","% of total sales","CHL","Chile","2016","2016",0.3,,
+"PATCCCBR","C08-Calcium channel blockers","ATCPTTMT","% of total sales","CHL","Chile","2017","2017",0.4,,
+"PATCCCBR","C08-Calcium channel blockers","ATCPTTMT","% of total sales","CHL","Chile","2018","2018",0.3,,
+"PATCCCBR","C08-Calcium channel blockers","ATCPTTMT","% of total sales","CHL","Chile","2019","2019",0.3,,
+"PATCCCBR","C08-Calcium channel blockers","ATCPTTMT","% of total sales","CHL","Chile","2020","2020",0.3,,
+"PATCCCBR","C08-Calcium channel blockers","ATCPTTMT","% of total sales","CHL","Chile","2021","2021",0.3,,
+"PATCCCBR","C08-Calcium channel blockers","ATCPTTMT","% of total sales","CHL","Chile","2022","2022",0.3,,
+"PATCCCBR","C08-Calcium channel blockers","MLLNCUMT","Million of national currency units","EST","Estonia","2010","2010",4.9,,
+"PATCCCBR","C08-Calcium channel blockers","MLLNCUMT","Million of national currency units","EST","Estonia","2011","2011",3.7,,
+"PATCCCBR","C08-Calcium channel blockers","MLLNCUMT","Million of national currency units","EST","Estonia","2012","2012",3.5,,
+"PATCCCBR","C08-Calcium channel blockers","MLLNCUMT","Million of national currency units","EST","Estonia","2013","2013",2.9,,
+"PATCCCBR","C08-Calcium channel blockers","MLLNCUMT","Million of national currency units","EST","Estonia","2014","2014",2.6,,
+"PATCCCBR","C08-Calcium channel blockers","MLLNCUMT","Million of national currency units","EST","Estonia","2015","2015",2.3,,
+"PATCCCBR","C08-Calcium channel blockers","MLLNCUMT","Million of national currency units","EST","Estonia","2016","2016",2.1,,
+"PATCCCBR","C08-Calcium channel blockers","MLLNCUMT","Million of national currency units","EST","Estonia","2017","2017",1.9,,
+"PATCCCBR","C08-Calcium channel blockers","MLLNCUMT","Million of national currency units","EST","Estonia","2018","2018",1.8,,
+"PATCCCBR","C08-Calcium channel blockers","MLLNCUMT","Million of national currency units","EST","Estonia","2019","2019",1.7,,
+"PATCCCBR","C08-Calcium channel blockers","MLLNCUMT","Million of national currency units","EST","Estonia","2020","2020",1.7,,
+"PATCCCBR","C08-Calcium channel blockers","MLLNCUMT","Million of national currency units","EST","Estonia","2021","2021",1.6,,
+"PATCCCBR","C08-Calcium channel blockers","MLLNCUMT","Million of national currency units","EST","Estonia","2022","2022",1.5,,
+"PATCCCBR","C08-Calcium channel blockers","MTMOTCMT","Million US$ at exchange rate","EST","Estonia","2010","2010",6.6,,
+"PATCCCBR","C08-Calcium channel blockers","MTMOTCMT","Million US$ at exchange rate","EST","Estonia","2011","2011",5.2,,
+"PATCCCBR","C08-Calcium channel blockers","MTMOTCMT","Million US$ at exchange rate","EST","Estonia","2012","2012",4.5,,
+"PATCCCBR","C08-Calcium channel blockers","MTMOTCMT","Million US$ at exchange rate","EST","Estonia","2013","2013",3.9,,
+"PATCCCBR","C08-Calcium channel blockers","MTMOTCMT","Million US$ at exchange rate","EST","Estonia","2014","2014",3.4,,
+"PATCCCBR","C08-Calcium channel blockers","MTMOTCMT","Million US$ at exchange rate","EST","Estonia","2015","2015",2.6,,
+"PATCCCBR","C08-Calcium channel blockers","MTMOTCMT","Million US$ at exchange rate","EST","Estonia","2016","2016",2.3,,
+"PATCCCBR","C08-Calcium channel blockers","MTMOTCMT","Million US$ at exchange rate","EST","Estonia","2017","2017",2.1,,
+"PATCCCBR","C08-Calcium channel blockers","MTMOTCMT","Million US$ at exchange rate","EST","Estonia","2018","2018",2.1,,
+"PATCCCBR","C08-Calcium channel blockers","MTMOTCMT","Million US$ at exchange rate","EST","Estonia","2019","2019",1.9,,
+"PATCCCBR","C08-Calcium channel blockers","MTMOTCMT","Million US$ at exchange rate","EST","Estonia","2020","2020",1.9,,
+"PATCCCBR","C08-Calcium channel blockers","MTMOTCMT","Million US$ at exchange rate","EST","Estonia","2021","2021",1.9,,
+"PATCCCBR","C08-Calcium channel blockers","MTMOTCMT","Million US$ at exchange rate","EST","Estonia","2022","2022",1.6,,
+"PATCCCBR","C08-Calcium channel blockers","MTMOPPMT","Million US$, purchasing power parity","EST","Estonia","2010","2010",9.7,,
+"PATCCCBR","C08-Calcium channel blockers","MTMOPPMT","Million US$, purchasing power parity","EST","Estonia","2011","2011",7.2,,
+"PATCCCBR","C08-Calcium channel blockers","MTMOPPMT","Million US$, purchasing power parity","EST","Estonia","2012","2012",6.7,,
+"PATCCCBR","C08-Calcium channel blockers","MTMOPPMT","Million US$, purchasing power parity","EST","Estonia","2013","2013",5.6,,
+"PATCCCBR","C08-Calcium channel blockers","MTMOPPMT","Million US$, purchasing power parity","EST","Estonia","2014","2014",4.9,,
+"PATCCCBR","C08-Calcium channel blockers","MTMOPPMT","Million US$, purchasing power parity","EST","Estonia","2015","2015",4.4,,
+"PATCCCBR","C08-Calcium channel blockers","MTMOPPMT","Million US$, purchasing power parity","EST","Estonia","2016","2016",4,,
+"PATCCCBR","C08-Calcium channel blockers","MTMOPPMT","Million US$, purchasing power parity","EST","Estonia","2017","2017",3.5,,
+"PATCCCBR","C08-Calcium channel blockers","MTMOPPMT","Million US$, purchasing power parity","EST","Estonia","2018","2018",3.3,,
+"PATCCCBR","C08-Calcium channel blockers","MTMOPPMT","Million US$, purchasing power parity","EST","Estonia","2019","2019",3.2,,
+"PATCCCBR","C08-Calcium channel blockers","MTMOPPMT","Million US$, purchasing power parity","EST","Estonia","2020","2020",3.2,,
+"PATCCCBR","C08-Calcium channel blockers","MTMOPPMT","Million US$, purchasing power parity","EST","Estonia","2021","2021",2.9,,
+"PATCCCBR","C08-Calcium channel blockers","MTMOPPMT","Million US$, purchasing power parity","EST","Estonia","2022","2022",2.6,,
+"PATCCCBR","C08-Calcium channel blockers","TCPPERMT","/capita, US$ exchange rate","EST","Estonia","2010","2010",4.9,,
+"PATCCCBR","C08-Calcium channel blockers","TCPPERMT","/capita, US$ exchange rate","EST","Estonia","2011","2011",3.9,,
+"PATCCCBR","C08-Calcium channel blockers","TCPPERMT","/capita, US$ exchange rate","EST","Estonia","2012","2012",3.4,,
+"PATCCCBR","C08-Calcium channel blockers","TCPPERMT","/capita, US$ exchange rate","EST","Estonia","2013","2013",3,,
+"PATCCCBR","C08-Calcium channel blockers","TCPPERMT","/capita, US$ exchange rate","EST","Estonia","2014","2014",2.6,,
+"PATCCCBR","C08-Calcium channel blockers","TCPPERMT","/capita, US$ exchange rate","EST","Estonia","2015","2015",2,,
+"PATCCCBR","C08-Calcium channel blockers","TCPPERMT","/capita, US$ exchange rate","EST","Estonia","2016","2016",1.8,,
+"PATCCCBR","C08-Calcium channel blockers","TCPPERMT","/capita, US$ exchange rate","EST","Estonia","2017","2017",1.6,,
+"PATCCCBR","C08-Calcium channel blockers","TCPPERMT","/capita, US$ exchange rate","EST","Estonia","2018","2018",1.6,,
+"PATCCCBR","C08-Calcium channel blockers","TCPPERMT","/capita, US$ exchange rate","EST","Estonia","2019","2019",1.4,,
+"PATCCCBR","C08-Calcium channel blockers","TCPPERMT","/capita, US$ exchange rate","EST","Estonia","2020","2020",1.5,,
+"PATCCCBR","C08-Calcium channel blockers","TCPPERMT","/capita, US$ exchange rate","EST","Estonia","2021","2021",1.4,,
+"PATCCCBR","C08-Calcium channel blockers","TCPPERMT","/capita, US$ exchange rate","EST","Estonia","2022","2022",1.2,,
+"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2010","2010",7.3,,
+"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2011","2011",5.4,,
+"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2012","2012",5.1,,
+"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2013","2013",4.3,,
+"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2014","2014",3.7,,
+"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2015","2015",3.3,,
+"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2016","2016",3,,
+"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2017","2017",2.7,,
+"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2018","2018",2.5,,
+"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2019","2019",2.4,,
+"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2020","2020",2.4,,
+"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2021","2021",2.2,,
+"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2022","2022",2,,
+"PATCCCBR","C08-Calcium channel blockers","ATCPTTMT","% of total sales","EST","Estonia","2010","2010",2.6,,
+"PATCCCBR","C08-Calcium channel blockers","ATCPTTMT","% of total sales","EST","Estonia","2011","2011",1.8,,
+"PATCCCBR","C08-Calcium channel blockers","ATCPTTMT","% of total sales","EST","Estonia","2012","2012",1.6,,
+"PATCCCBR","C08-Calcium channel blockers","ATCPTTMT","% of total sales","EST","Estonia","2013","2013",1.3,,
+"PATCCCBR","C08-Calcium channel blockers","ATCPTTMT","% of total sales","EST","Estonia","2014","2014",1,,
+"PATCCCBR","C08-Calcium channel blockers","ATCPTTMT","% of total sales","EST","Estonia","2015","2015",0.9,,
+"PATCCCBR","C08-Calcium channel blockers","ATCPTTMT","% of total sales","EST","Estonia","2016","2016",0.7,,
+"PATCCCBR","C08-Calcium channel blockers","ATCPTTMT","% of total sales","EST","Estonia","2017","2017",0.6,,
+"PATCCCBR","C08-Calcium channel blockers","ATCPTTMT","% of total sales","EST","Estonia","2018","2018",0.6,,
+"PATCCCBR","C08-Calcium channel blockers","ATCPTTMT","% of total sales","EST","Estonia","2019","2019",0.5,,
+"PATCCCBR","C08-Calcium channel blockers","ATCPTTMT","% of total sales","EST","Estonia","2020","2020",0.5,,
+"PATCCCBR","C08-Calcium channel blockers","ATCPTTMT","% of total sales","EST","Estonia","2021","2021",0.4,,
+"PATCCCBR","C08-Calcium channel blockers","ATCPTTMT","% of total sales","EST","Estonia","2022","2022",0.3,,
+"PATCCCBR","C08-Calcium channel blockers","MLLNCUMT","Million of national currency units","SVN","Slovenia","2010","2010",10,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","MLLNCUMT","Million of national currency units","SVN","Slovenia","2011","2011",8.2,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","MLLNCUMT","Million of national currency units","SVN","Slovenia","2012","2012",6.7,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","MLLNCUMT","Million of national currency units","SVN","Slovenia","2013","2013",6.6,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","MLLNCUMT","Million of national currency units","SVN","Slovenia","2014","2014",6.4,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","MLLNCUMT","Million of national currency units","SVN","Slovenia","2015","2015",6.2,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","MLLNCUMT","Million of national currency units","SVN","Slovenia","2016","2016",6,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","MLLNCUMT","Million of national currency units","SVN","Slovenia","2017","2017",5.8,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","MLLNCUMT","Million of national currency units","SVN","Slovenia","2018","2018",5.6,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","MLLNCUMT","Million of national currency units","SVN","Slovenia","2019","2019",5.5,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","MLLNCUMT","Million of national currency units","SVN","Slovenia","2020","2020",5.7,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","MLLNCUMT","Million of national currency units","SVN","Slovenia","2021","2021",5.5,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","MLLNCUMT","Million of national currency units","SVN","Slovenia","2022","2022",5.3,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","MTMOTCMT","Million US$ at exchange rate","SVN","Slovenia","2010","2010",13.3,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","MTMOTCMT","Million US$ at exchange rate","SVN","Slovenia","2011","2011",11.4,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","MTMOTCMT","Million US$ at exchange rate","SVN","Slovenia","2012","2012",8.6,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","MTMOTCMT","Million US$ at exchange rate","SVN","Slovenia","2013","2013",8.8,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","MTMOTCMT","Million US$ at exchange rate","SVN","Slovenia","2014","2014",8.5,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","MTMOTCMT","Million US$ at exchange rate","SVN","Slovenia","2015","2015",6.8,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","MTMOTCMT","Million US$ at exchange rate","SVN","Slovenia","2016","2016",6.6,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","MTMOTCMT","Million US$ at exchange rate","SVN","Slovenia","2017","2017",6.6,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","MTMOTCMT","Million US$ at exchange rate","SVN","Slovenia","2018","2018",6.7,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","MTMOTCMT","Million US$ at exchange rate","SVN","Slovenia","2019","2019",6.2,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","MTMOTCMT","Million US$ at exchange rate","SVN","Slovenia","2020","2020",6.5,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","MTMOTCMT","Million US$ at exchange rate","SVN","Slovenia","2021","2021",6.5,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","MTMOTCMT","Million US$ at exchange rate","SVN","Slovenia","2022","2022",5.6,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","MTMOPPMT","Million US$, purchasing power parity","SVN","Slovenia","2010","2010",15.8,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","MTMOPPMT","Million US$, purchasing power parity","SVN","Slovenia","2011","2011",13.1,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","MTMOPPMT","Million US$, purchasing power parity","SVN","Slovenia","2012","2012",11,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","MTMOPPMT","Million US$, purchasing power parity","SVN","Slovenia","2013","2013",11.2,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","MTMOPPMT","Million US$, purchasing power parity","SVN","Slovenia","2014","2014",10.8,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","MTMOPPMT","Million US$, purchasing power parity","SVN","Slovenia","2015","2015",10.3,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","MTMOPPMT","Million US$, purchasing power parity","SVN","Slovenia","2016","2016",10.3,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","MTMOPPMT","Million US$, purchasing power parity","SVN","Slovenia","2017","2017",10.2,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","MTMOPPMT","Million US$, purchasing power parity","SVN","Slovenia","2018","2018",9.9,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","MTMOPPMT","Million US$, purchasing power parity","SVN","Slovenia","2019","2019",10,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","MTMOPPMT","Million US$, purchasing power parity","SVN","Slovenia","2020","2020",10.3,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","MTMOPPMT","Million US$, purchasing power parity","SVN","Slovenia","2021","2021",9.7,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","MTMOPPMT","Million US$, purchasing power parity","SVN","Slovenia","2022","2022",9.7,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","TCPPERMT","/capita, US$ exchange rate","SVN","Slovenia","2010","2010",6.5,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","TCPPERMT","/capita, US$ exchange rate","SVN","Slovenia","2011","2011",5.5,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","TCPPERMT","/capita, US$ exchange rate","SVN","Slovenia","2012","2012",4.2,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","TCPPERMT","/capita, US$ exchange rate","SVN","Slovenia","2013","2013",4.3,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","TCPPERMT","/capita, US$ exchange rate","SVN","Slovenia","2014","2014",4.1,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","TCPPERMT","/capita, US$ exchange rate","SVN","Slovenia","2015","2015",3.3,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","TCPPERMT","/capita, US$ exchange rate","SVN","Slovenia","2016","2016",3.2,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","TCPPERMT","/capita, US$ exchange rate","SVN","Slovenia","2017","2017",3.2,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","TCPPERMT","/capita, US$ exchange rate","SVN","Slovenia","2018","2018",3.2,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","TCPPERMT","/capita, US$ exchange rate","SVN","Slovenia","2019","2019",3,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","TCPPERMT","/capita, US$ exchange rate","SVN","Slovenia","2020","2020",3.1,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","TCPPERMT","/capita, US$ exchange rate","SVN","Slovenia","2021","2021",3.1,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","TCPPERMT","/capita, US$ exchange rate","SVN","Slovenia","2022","2022",2.7,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2010","2010",7.7,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2011","2011",6.4,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2012","2012",5.3,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2013","2013",5.5,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2014","2014",5.2,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2015","2015",5,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2016","2016",5,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2017","2017",4.9,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2018","2018",4.8,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2019","2019",4.8,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2020","2020",4.9,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2021","2021",4.6,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2022","2022",4.6,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","ATCPTTMT","% of total sales","SVN","Slovenia","2010","2010",2.1,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","ATCPTTMT","% of total sales","SVN","Slovenia","2011","2011",1.7,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","ATCPTTMT","% of total sales","SVN","Slovenia","2012","2012",1.5,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","ATCPTTMT","% of total sales","SVN","Slovenia","2013","2013",1.5,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","ATCPTTMT","% of total sales","SVN","Slovenia","2014","2014",1.5,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","ATCPTTMT","% of total sales","SVN","Slovenia","2015","2015",1.4,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","ATCPTTMT","% of total sales","SVN","Slovenia","2016","2016",1.3,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","ATCPTTMT","% of total sales","SVN","Slovenia","2017","2017",1.2,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","ATCPTTMT","% of total sales","SVN","Slovenia","2018","2018",1.1,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","ATCPTTMT","% of total sales","SVN","Slovenia","2019","2019",1,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","ATCPTTMT","% of total sales","SVN","Slovenia","2020","2020",1,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","ATCPTTMT","% of total sales","SVN","Slovenia","2021","2021",0.9,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","ATCPTTMT","% of total sales","SVN","Slovenia","2022","2022",0.8,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MLLNCUMT","Million of national currency units","AUS","Australia","2010","2010",592,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MLLNCUMT","Million of national currency units","AUS","Australia","2011","2011",609,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MLLNCUMT","Million of national currency units","AUS","Australia","2012","2012",562,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MLLNCUMT","Million of national currency units","AUS","Australia","2013","2013",740,"B; D","Break; Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MLLNCUMT","Million of national currency units","AUS","Australia","2014","2014",706,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MLLNCUMT","Million of national currency units","AUS","Australia","2015","2015",679,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MLLNCUMT","Million of national currency units","AUS","Australia","2016","2016",636,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MLLNCUMT","Million of national currency units","AUS","Australia","2017","2017",598,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MLLNCUMT","Million of national currency units","AUS","Australia","2018","2018",624,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MLLNCUMT","Million of national currency units","AUS","Australia","2019","2019",654,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MLLNCUMT","Million of national currency units","AUS","Australia","2020","2020",705,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MLLNCUMT","Million of national currency units","AUS","Australia","2021","2021",757,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOTCMT","Million US$ at exchange rate","AUS","Australia","2010","2010",543,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOTCMT","Million US$ at exchange rate","AUS","Australia","2011","2011",628.2,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOTCMT","Million US$ at exchange rate","AUS","Australia","2012","2012",581.9,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOTCMT","Million US$ at exchange rate","AUS","Australia","2013","2013",714.4,"B; D","Break; Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOTCMT","Million US$ at exchange rate","AUS","Australia","2014","2014",636.4,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOTCMT","Million US$ at exchange rate","AUS","Australia","2015","2015",510.1,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOTCMT","Million US$ at exchange rate","AUS","Australia","2016","2016",472.8,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOTCMT","Million US$ at exchange rate","AUS","Australia","2017","2017",458.3,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOTCMT","Million US$ at exchange rate","AUS","Australia","2018","2018",466.2,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOTCMT","Million US$ at exchange rate","AUS","Australia","2019","2019",454.6,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOTCMT","Million US$ at exchange rate","AUS","Australia","2020","2020",485.2,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOTCMT","Million US$ at exchange rate","AUS","Australia","2021","2021",568.6,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOPPMT","Million US$, purchasing power parity","AUS","Australia","2010","2010",393.7,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOPPMT","Million US$, purchasing power parity","AUS","Australia","2011","2011",403,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOPPMT","Million US$, purchasing power parity","AUS","Australia","2012","2012",364.9,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOPPMT","Million US$, purchasing power parity","AUS","Australia","2013","2013",511.4,"B; D","Break; Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOPPMT","Million US$, purchasing power parity","AUS","Australia","2014","2014",486.1,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOPPMT","Million US$, purchasing power parity","AUS","Australia","2015","2015",460.7,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOPPMT","Million US$, purchasing power parity","AUS","Australia","2016","2016",438.6,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOPPMT","Million US$, purchasing power parity","AUS","Australia","2017","2017",404.7,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOPPMT","Million US$, purchasing power parity","AUS","Australia","2018","2018",424.4,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOPPMT","Million US$, purchasing power parity","AUS","Australia","2019","2019",441.9,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOPPMT","Million US$, purchasing power parity","AUS","Australia","2020","2020",484.9,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOPPMT","Million US$, purchasing power parity","AUS","Australia","2021","2021",522.9,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","TCPPERMT","/capita, US$ exchange rate","AUS","Australia","2010","2010",24.6,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","TCPPERMT","/capita, US$ exchange rate","AUS","Australia","2011","2011",28.1,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","TCPPERMT","/capita, US$ exchange rate","AUS","Australia","2012","2012",25.6,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","TCPPERMT","/capita, US$ exchange rate","AUS","Australia","2013","2013",30.9,"B; D","Break; Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","TCPPERMT","/capita, US$ exchange rate","AUS","Australia","2014","2014",27.1,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","TCPPERMT","/capita, US$ exchange rate","AUS","Australia","2015","2015",21.4,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","TCPPERMT","/capita, US$ exchange rate","AUS","Australia","2016","2016",19.5,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","TCPPERMT","/capita, US$ exchange rate","AUS","Australia","2017","2017",18.6,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","TCPPERMT","/capita, US$ exchange rate","AUS","Australia","2018","2018",18.7,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","TCPPERMT","/capita, US$ exchange rate","AUS","Australia","2019","2019",17.9,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","TCPPERMT","/capita, US$ exchange rate","AUS","Australia","2020","2020",18.9,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","TCPPERMT","/capita, US$ exchange rate","AUS","Australia","2021","2021",22.1,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2010","2010",17.9,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2011","2011",18,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2012","2012",16.1,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2013","2013",22.1,"B; D","Break; Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2014","2014",20.7,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2015","2015",19.3,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2016","2016",18.1,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2017","2017",16.5,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2018","2018",17,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2019","2019",17.4,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2020","2020",18.9,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2021","2021",20.4,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","ATCPTTMT","% of total sales","AUS","Australia","2010","2010",6,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","ATCPTTMT","% of total sales","AUS","Australia","2011","2011",5.9,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","ATCPTTMT","% of total sales","AUS","Australia","2012","2012",5.4,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","ATCPTTMT","% of total sales","AUS","Australia","2013","2013",6.3,"B; D","Break; Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","ATCPTTMT","% of total sales","AUS","Australia","2014","2014",5.9,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","ATCPTTMT","% of total sales","AUS","Australia","2015","2015",5.5,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","ATCPTTMT","% of total sales","AUS","Australia","2016","2016",4.2,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","ATCPTTMT","% of total sales","AUS","Australia","2017","2017",4,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","ATCPTTMT","% of total sales","AUS","Australia","2018","2018",4.2,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","ATCPTTMT","% of total sales","AUS","Australia","2019","2019",4.2,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","ATCPTTMT","% of total sales","AUS","Australia","2020","2020",4.2,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","ATCPTTMT","% of total sales","AUS","Australia","2021","2021",4.3,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MLLNCUMT","Million of national currency units","AUT","Austria","2010","2010",195.4,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MLLNCUMT","Million of national currency units","AUT","Austria","2011","2011",197,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MLLNCUMT","Million of national currency units","AUT","Austria","2012","2012",194.6,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MLLNCUMT","Million of national currency units","AUT","Austria","2013","2013",167.1,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MLLNCUMT","Million of national currency units","AUT","Austria","2014","2014",160.7,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MLLNCUMT","Million of national currency units","AUT","Austria","2015","2015",157.5,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MLLNCUMT","Million of national currency units","AUT","Austria","2016","2016",159.2,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MLLNCUMT","Million of national currency units","AUT","Austria","2017","2017",160.5,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MLLNCUMT","Million of national currency units","AUT","Austria","2018","2018",155.1,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MLLNCUMT","Million of national currency units","AUT","Austria","2019","2019",142.3,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MLLNCUMT","Million of national currency units","AUT","Austria","2020","2020",138.3,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MLLNCUMT","Million of national currency units","AUT","Austria","2021","2021",127.7,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOTCMT","Million US$ at exchange rate","AUT","Austria","2010","2010",259.1,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOTCMT","Million US$ at exchange rate","AUT","Austria","2011","2011",274.2,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOTCMT","Million US$ at exchange rate","AUT","Austria","2012","2012",250,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOTCMT","Million US$ at exchange rate","AUT","Austria","2013","2013",221.9,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOTCMT","Million US$ at exchange rate","AUT","Austria","2014","2014",213.4,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOTCMT","Million US$ at exchange rate","AUT","Austria","2015","2015",174.8,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOTCMT","Million US$ at exchange rate","AUT","Austria","2016","2016",176.2,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOTCMT","Million US$ at exchange rate","AUT","Austria","2017","2017",181.3,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOTCMT","Million US$ at exchange rate","AUT","Austria","2018","2018",183.2,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOTCMT","Million US$ at exchange rate","AUT","Austria","2019","2019",159.3,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOTCMT","Million US$ at exchange rate","AUT","Austria","2020","2020",157.9,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOTCMT","Million US$ at exchange rate","AUT","Austria","2021","2021",151,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOPPMT","Million US$, purchasing power parity","AUT","Austria","2010","2010",232,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOPPMT","Million US$, purchasing power parity","AUT","Austria","2011","2011",237,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOPPMT","Million US$, purchasing power parity","AUT","Austria","2012","2012",239.2,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOPPMT","Million US$, purchasing power parity","AUT","Austria","2013","2013",209.6,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOPPMT","Million US$, purchasing power parity","AUT","Austria","2014","2014",201.1,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOPPMT","Million US$, purchasing power parity","AUT","Austria","2015","2015",197.2,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOPPMT","Million US$, purchasing power parity","AUT","Austria","2016","2016",204.9,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOPPMT","Million US$, purchasing power parity","AUT","Austria","2017","2017",207,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOPPMT","Million US$, purchasing power parity","AUT","Austria","2018","2018",202.7,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOPPMT","Million US$, purchasing power parity","AUT","Austria","2019","2019",189.9,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOPPMT","Million US$, purchasing power parity","AUT","Austria","2020","2020",185.2,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOPPMT","Million US$, purchasing power parity","AUT","Austria","2021","2021",168.9,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","TCPPERMT","/capita, US$ exchange rate","AUT","Austria","2010","2010",31,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","TCPPERMT","/capita, US$ exchange rate","AUT","Austria","2011","2011",32.7,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","TCPPERMT","/capita, US$ exchange rate","AUT","Austria","2012","2012",29.7,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","TCPPERMT","/capita, US$ exchange rate","AUT","Austria","2013","2013",26.2,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","TCPPERMT","/capita, US$ exchange rate","AUT","Austria","2014","2014",25,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","TCPPERMT","/capita, US$ exchange rate","AUT","Austria","2015","2015",20.2,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","TCPPERMT","/capita, US$ exchange rate","AUT","Austria","2016","2016",20.2,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","TCPPERMT","/capita, US$ exchange rate","AUT","Austria","2017","2017",20.6,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","TCPPERMT","/capita, US$ exchange rate","AUT","Austria","2018","2018",20.7,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","TCPPERMT","/capita, US$ exchange rate","AUT","Austria","2019","2019",17.9,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","TCPPERMT","/capita, US$ exchange rate","AUT","Austria","2020","2020",17.7,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","TCPPERMT","/capita, US$ exchange rate","AUT","Austria","2021","2021",16.9,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2010","2010",27.7,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2011","2011",28.2,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2012","2012",28.4,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2013","2013",24.7,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2014","2014",23.5,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2015","2015",22.8,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2016","2016",23.5,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2017","2017",23.5,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2018","2018",22.9,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2019","2019",21.4,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2020","2020",20.8,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2021","2021",18.9,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","ATCPTTMT","% of total sales","AUT","Austria","2010","2010",7.8,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","ATCPTTMT","% of total sales","AUT","Austria","2011","2011",7.7,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","ATCPTTMT","% of total sales","AUT","Austria","2012","2012",7.4,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","ATCPTTMT","% of total sales","AUT","Austria","2013","2013",6.3,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","ATCPTTMT","% of total sales","AUT","Austria","2014","2014",5.8,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","ATCPTTMT","% of total sales","AUT","Austria","2015","2015",5.4,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","ATCPTTMT","% of total sales","AUT","Austria","2016","2016",5.3,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","ATCPTTMT","% of total sales","AUT","Austria","2017","2017",5.1,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","ATCPTTMT","% of total sales","AUT","Austria","2018","2018",4.8,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","ATCPTTMT","% of total sales","AUT","Austria","2019","2019",4.3,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","ATCPTTMT","% of total sales","AUT","Austria","2020","2020",4,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","ATCPTTMT","% of total sales","AUT","Austria","2021","2021",3.4,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MLLNCUMT","Million of national currency units","BEL","Belgium","2010","2010",234.8,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MLLNCUMT","Million of national currency units","BEL","Belgium","2011","2011",233,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MLLNCUMT","Million of national currency units","BEL","Belgium","2012","2012",226.4,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MLLNCUMT","Million of national currency units","BEL","Belgium","2013","2013",218.2,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MLLNCUMT","Million of national currency units","BEL","Belgium","2014","2014",199.3,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MLLNCUMT","Million of national currency units","BEL","Belgium","2015","2015",196.5,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MLLNCUMT","Million of national currency units","BEL","Belgium","2016","2016",190.4,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MLLNCUMT","Million of national currency units","BEL","Belgium","2017","2017",175.5,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MLLNCUMT","Million of national currency units","BEL","Belgium","2018","2018",169.9,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MLLNCUMT","Million of national currency units","BEL","Belgium","2019","2019",188.8,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MLLNCUMT","Million of national currency units","BEL","Belgium","2020","2020",189.3,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MLLNCUMT","Million of national currency units","BEL","Belgium","2021","2021",190,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MLLNCUMT","Million of national currency units","BEL","Belgium","2022","2022",190.7,"E","Estimated value"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOTCMT","Million US$ at exchange rate","BEL","Belgium","2010","2010",311.3,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOTCMT","Million US$ at exchange rate","BEL","Belgium","2011","2011",324.3,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOTCMT","Million US$ at exchange rate","BEL","Belgium","2012","2012",290.9,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOTCMT","Million US$ at exchange rate","BEL","Belgium","2013","2013",289.7,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOTCMT","Million US$ at exchange rate","BEL","Belgium","2014","2014",264.8,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOTCMT","Million US$ at exchange rate","BEL","Belgium","2015","2015",218,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOTCMT","Million US$ at exchange rate","BEL","Belgium","2016","2016",210.7,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOTCMT","Million US$ at exchange rate","BEL","Belgium","2017","2017",198.3,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOTCMT","Million US$ at exchange rate","BEL","Belgium","2018","2018",200.6,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOTCMT","Million US$ at exchange rate","BEL","Belgium","2019","2019",211.4,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOTCMT","Million US$ at exchange rate","BEL","Belgium","2020","2020",216.2,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOTCMT","Million US$ at exchange rate","BEL","Belgium","2021","2021",224.7,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOTCMT","Million US$ at exchange rate","BEL","Belgium","2022","2022",200.8,"E","Estimated value"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOPPMT","Million US$, purchasing power parity","BEL","Belgium","2010","2010",280.7,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOPPMT","Million US$, purchasing power parity","BEL","Belgium","2011","2011",280,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOPPMT","Million US$, purchasing power parity","BEL","Belgium","2012","2012",275.4,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOPPMT","Million US$, purchasing power parity","BEL","Belgium","2013","2013",270.6,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOPPMT","Million US$, purchasing power parity","BEL","Belgium","2014","2014",249.1,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOPPMT","Million US$, purchasing power parity","BEL","Belgium","2015","2015",245.6,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOPPMT","Million US$, purchasing power parity","BEL","Belgium","2016","2016",243.7,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOPPMT","Million US$, purchasing power parity","BEL","Belgium","2017","2017",226.3,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOPPMT","Million US$, purchasing power parity","BEL","Belgium","2018","2018",221.6,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOPPMT","Million US$, purchasing power parity","BEL","Belgium","2019","2019",252.9,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOPPMT","Million US$, purchasing power parity","BEL","Belgium","2020","2020",259.2,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOPPMT","Million US$, purchasing power parity","BEL","Belgium","2021","2021",257.9,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOPPMT","Million US$, purchasing power parity","BEL","Belgium","2022","2022",267.1,"E","Estimated value"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","TCPPERMT","/capita, US$ exchange rate","BEL","Belgium","2010","2010",28.6,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","TCPPERMT","/capita, US$ exchange rate","BEL","Belgium","2011","2011",29.4,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","TCPPERMT","/capita, US$ exchange rate","BEL","Belgium","2012","2012",26.2,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","TCPPERMT","/capita, US$ exchange rate","BEL","Belgium","2013","2013",26,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","TCPPERMT","/capita, US$ exchange rate","BEL","Belgium","2014","2014",23.6,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","TCPPERMT","/capita, US$ exchange rate","BEL","Belgium","2015","2015",19.3,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","TCPPERMT","/capita, US$ exchange rate","BEL","Belgium","2016","2016",18.6,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","TCPPERMT","/capita, US$ exchange rate","BEL","Belgium","2017","2017",17.4,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","TCPPERMT","/capita, US$ exchange rate","BEL","Belgium","2018","2018",17.6,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","TCPPERMT","/capita, US$ exchange rate","BEL","Belgium","2019","2019",18.4,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","TCPPERMT","/capita, US$ exchange rate","BEL","Belgium","2020","2020",18.7,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","TCPPERMT","/capita, US$ exchange rate","BEL","Belgium","2021","2021",19.4,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","TCPPERMT","/capita, US$ exchange rate","BEL","Belgium","2022","2022",17.3,"E","Estimated value"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2010","2010",25.8,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2011","2011",25.4,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2012","2012",24.8,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2013","2013",24.2,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2014","2014",22.2,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2015","2015",21.8,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2016","2016",21.5,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2017","2017",19.9,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2018","2018",19.4,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2019","2019",22,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2020","2020",22.5,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2021","2021",22.3,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2022","2022",23,"E","Estimated value"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","ATCPTTMT","% of total sales","BEL","Belgium","2010","2010",4,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","ATCPTTMT","% of total sales","BEL","Belgium","2011","2011",3.9,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","ATCPTTMT","% of total sales","BEL","Belgium","2012","2012",3.8,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","ATCPTTMT","% of total sales","BEL","Belgium","2013","2013",3.7,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","ATCPTTMT","% of total sales","BEL","Belgium","2014","2014",3.4,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","ATCPTTMT","% of total sales","BEL","Belgium","2015","2015",3.2,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","ATCPTTMT","% of total sales","BEL","Belgium","2016","2016",3,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","ATCPTTMT","% of total sales","BEL","Belgium","2017","2017",2.7,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","ATCPTTMT","% of total sales","BEL","Belgium","2018","2018",2.5,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","ATCPTTMT","% of total sales","BEL","Belgium","2019","2019",2.6,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","ATCPTTMT","% of total sales","BEL","Belgium","2020","2020",2.5,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","ATCPTTMT","% of total sales","BEL","Belgium","2021","2021",2.4,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","ATCPTTMT","% of total sales","BEL","Belgium","2022","2022",2.1,"E","Estimated value"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MLLNCUMT","Million of national currency units","CAN","Canada","2012","2012",1362.7,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MLLNCUMT","Million of national currency units","CAN","Canada","2013","2013",1207.6,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MLLNCUMT","Million of national currency units","CAN","Canada","2014","2014",1208.7,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MLLNCUMT","Million of national currency units","CAN","Canada","2015","2015",1229,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MLLNCUMT","Million of national currency units","CAN","Canada","2016","2016",1272.1,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MLLNCUMT","Million of national currency units","CAN","Canada","2017","2017",1310,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MLLNCUMT","Million of national currency units","CAN","Canada","2018","2018",1051.8,"E; B; D","Estimated value; Break; Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MLLNCUMT","Million of national currency units","CAN","Canada","2019","2019",946.4,"E; D","Estimated value; Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MLLNCUMT","Million of national currency units","CAN","Canada","2020","2020",994,"E; D","Estimated value; Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MLLNCUMT","Million of national currency units","CAN","Canada","2021","2021",971.5,"E; D","Estimated value; Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MLLNCUMT","Million of national currency units","CAN","Canada","2022","2022",1013.8,"E; D","Estimated value; Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOTCMT","Million US$ at exchange rate","CAN","Canada","2012","2012",1363.6,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOTCMT","Million US$ at exchange rate","CAN","Canada","2013","2013",1172.3,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOTCMT","Million US$ at exchange rate","CAN","Canada","2014","2014",1094.1,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOTCMT","Million US$ at exchange rate","CAN","Canada","2015","2015",961.1,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOTCMT","Million US$ at exchange rate","CAN","Canada","2016","2016",959.6,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOTCMT","Million US$ at exchange rate","CAN","Canada","2017","2017",1009.3,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOTCMT","Million US$ at exchange rate","CAN","Canada","2018","2018",811.7,"E; B; D","Estimated value; Break; Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOTCMT","Million US$ at exchange rate","CAN","Canada","2019","2019",713.3,"E; D","Estimated value; Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOTCMT","Million US$ at exchange rate","CAN","Canada","2020","2020",741.2,"E; D","Estimated value; Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOTCMT","Million US$ at exchange rate","CAN","Canada","2021","2021",774.8,"E; D","Estimated value; Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOTCMT","Million US$ at exchange rate","CAN","Canada","2022","2022",778.9,"E; D","Estimated value; Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOPPMT","Million US$, purchasing power parity","CAN","Canada","2012","2012",1094.9,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOPPMT","Million US$, purchasing power parity","CAN","Canada","2013","2013",986.6,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOPPMT","Million US$, purchasing power parity","CAN","Canada","2014","2014",982.4,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOPPMT","Million US$, purchasing power parity","CAN","Canada","2015","2015",984.7,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOPPMT","Million US$, purchasing power parity","CAN","Canada","2016","2016",1053.9,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOPPMT","Million US$, purchasing power parity","CAN","Canada","2017","2017",1080.6,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOPPMT","Million US$, purchasing power parity","CAN","Canada","2018","2018",871.8,"E; B; D","Estimated value; Break; Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOPPMT","Million US$, purchasing power parity","CAN","Canada","2019","2019",766.5,"E; D","Estimated value; Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOPPMT","Million US$, purchasing power parity","CAN","Canada","2020","2020",807.5,"E; D","Estimated value; Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOPPMT","Million US$, purchasing power parity","CAN","Canada","2021","2021",784.6,"E; D","Estimated value; Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOPPMT","Million US$, purchasing power parity","CAN","Canada","2022","2022",808.5,"E; D","Estimated value; Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","TCPPERMT","/capita, US$ exchange rate","CAN","Canada","2012","2012",39.3,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","TCPPERMT","/capita, US$ exchange rate","CAN","Canada","2013","2013",33.4,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","TCPPERMT","/capita, US$ exchange rate","CAN","Canada","2014","2014",30.9,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","TCPPERMT","/capita, US$ exchange rate","CAN","Canada","2015","2015",26.9,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","TCPPERMT","/capita, US$ exchange rate","CAN","Canada","2016","2016",26.6,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","TCPPERMT","/capita, US$ exchange rate","CAN","Canada","2017","2017",27.6,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","TCPPERMT","/capita, US$ exchange rate","CAN","Canada","2018","2018",21.9,"E; B; D","Estimated value; Break; Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","TCPPERMT","/capita, US$ exchange rate","CAN","Canada","2019","2019",19,"E; D","Estimated value; Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","TCPPERMT","/capita, US$ exchange rate","CAN","Canada","2020","2020",19.5,"E; D","Estimated value; Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","TCPPERMT","/capita, US$ exchange rate","CAN","Canada","2021","2021",20.3,"E; D","Estimated value; Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","TCPPERMT","/capita, US$ exchange rate","CAN","Canada","2022","2022",20,"E; D","Estimated value; Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2012","2012",31.5,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2013","2013",28.1,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2014","2014",27.7,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2015","2015",27.6,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2016","2016",29.2,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2017","2017",29.6,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2018","2018",23.5,"E; B; D","Estimated value; Break; Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2019","2019",20.4,"E; D","Estimated value; Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2020","2020",21.2,"E; D","Estimated value; Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2021","2021",20.5,"E; D","Estimated value; Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2022","2022",20.8,"E; D","Estimated value; Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","ATCPTTMT","% of total sales","CAN","Canada","2012","2012",5.6,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","ATCPTTMT","% of total sales","CAN","Canada","2013","2013",4.9,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","ATCPTTMT","% of total sales","CAN","Canada","2014","2014",4.7,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","ATCPTTMT","% of total sales","CAN","Canada","2015","2015",4.5,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","ATCPTTMT","% of total sales","CAN","Canada","2016","2016",4.5,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","ATCPTTMT","% of total sales","CAN","Canada","2017","2017",4.4,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","ATCPTTMT","% of total sales","CAN","Canada","2018","2018",3.4,"E; B; D","Estimated value; Break; Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","ATCPTTMT","% of total sales","CAN","Canada","2019","2019",3,"E; D","Estimated value; Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","ATCPTTMT","% of total sales","CAN","Canada","2020","2020",2.9,"E; D","Estimated value; Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","ATCPTTMT","% of total sales","CAN","Canada","2021","2021",2.6,"E; D","Estimated value; Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","ATCPTTMT","% of total sales","CAN","Canada","2022","2022",2.5,"E; D","Estimated value; Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MLLNCUMT","Million of national currency units","CZE","Czech Republic","2010","2010",3919.6,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MLLNCUMT","Million of national currency units","CZE","Czech Republic","2011","2011",3853.8,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MLLNCUMT","Million of national currency units","CZE","Czech Republic","2012","2012",3699.1,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MLLNCUMT","Million of national currency units","CZE","Czech Republic","2013","2013",3409.1,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MLLNCUMT","Million of national currency units","CZE","Czech Republic","2014","2014",3058.7,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MLLNCUMT","Million of national currency units","CZE","Czech Republic","2015","2015",2834,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MLLNCUMT","Million of national currency units","CZE","Czech Republic","2016","2016",2861.3,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MLLNCUMT","Million of national currency units","CZE","Czech Republic","2017","2017",2895.6,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MLLNCUMT","Million of national currency units","CZE","Czech Republic","2018","2018",2896.8,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MLLNCUMT","Million of national currency units","CZE","Czech Republic","2019","2019",3060.9,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MLLNCUMT","Million of national currency units","CZE","Czech Republic","2020","2020",3164.7,"B","Break"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MLLNCUMT","Million of national currency units","CZE","Czech Republic","2021","2021",3292.2,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOTCMT","Million US$ at exchange rate","CZE","Czech Republic","2010","2010",205.2,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOTCMT","Million US$ at exchange rate","CZE","Czech Republic","2011","2011",217.8,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOTCMT","Million US$ at exchange rate","CZE","Czech Republic","2012","2012",188.9,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOTCMT","Million US$ at exchange rate","CZE","Czech Republic","2013","2013",174.2,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOTCMT","Million US$ at exchange rate","CZE","Czech Republic","2014","2014",147.4,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOTCMT","Million US$ at exchange rate","CZE","Czech Republic","2015","2015",115.2,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOTCMT","Million US$ at exchange rate","CZE","Czech Republic","2016","2016",117.1,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOTCMT","Million US$ at exchange rate","CZE","Czech Republic","2017","2017",123.9,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOTCMT","Million US$ at exchange rate","CZE","Czech Republic","2018","2018",133.3,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOTCMT","Million US$ at exchange rate","CZE","Czech Republic","2019","2019",133.5,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOTCMT","Million US$ at exchange rate","CZE","Czech Republic","2020","2020",136.3,"B","Break"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOTCMT","Million US$ at exchange rate","CZE","Czech Republic","2021","2021",151.9,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOPPMT","Million US$, purchasing power parity","CZE","Czech Republic","2010","2010",286.7,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOPPMT","Million US$, purchasing power parity","CZE","Czech Republic","2011","2011",288.8,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOPPMT","Million US$, purchasing power parity","CZE","Czech Republic","2012","2012",278.2,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOPPMT","Million US$, purchasing power parity","CZE","Czech Republic","2013","2013",266.6,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOPPMT","Million US$, purchasing power parity","CZE","Czech Republic","2014","2014",240.8,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOPPMT","Million US$, purchasing power parity","CZE","Czech Republic","2015","2015",219,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOPPMT","Million US$, purchasing power parity","CZE","Czech Republic","2016","2016",227.5,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOPPMT","Million US$, purchasing power parity","CZE","Czech Republic","2017","2017",233,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOPPMT","Million US$, purchasing power parity","CZE","Czech Republic","2018","2018",234.2,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOPPMT","Million US$, purchasing power parity","CZE","Czech Republic","2019","2019",249.4,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOPPMT","Million US$, purchasing power parity","CZE","Czech Republic","2020","2020",254,"B","Break"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOPPMT","Million US$, purchasing power parity","CZE","Czech Republic","2021","2021",258.4,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","TCPPERMT","/capita, US$ exchange rate","CZE","Czech Republic","2010","2010",19.6,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","TCPPERMT","/capita, US$ exchange rate","CZE","Czech Republic","2011","2011",20.7,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","TCPPERMT","/capita, US$ exchange rate","CZE","Czech Republic","2012","2012",18,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","TCPPERMT","/capita, US$ exchange rate","CZE","Czech Republic","2013","2013",16.6,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","TCPPERMT","/capita, US$ exchange rate","CZE","Czech Republic","2014","2014",14,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","TCPPERMT","/capita, US$ exchange rate","CZE","Czech Republic","2015","2015",10.9,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","TCPPERMT","/capita, US$ exchange rate","CZE","Czech Republic","2016","2016",11.1,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","TCPPERMT","/capita, US$ exchange rate","CZE","Czech Republic","2017","2017",11.7,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","TCPPERMT","/capita, US$ exchange rate","CZE","Czech Republic","2018","2018",12.5,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","TCPPERMT","/capita, US$ exchange rate","CZE","Czech Republic","2019","2019",12.5,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","TCPPERMT","/capita, US$ exchange rate","CZE","Czech Republic","2020","2020",12.7,"B","Break"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","TCPPERMT","/capita, US$ exchange rate","CZE","Czech Republic","2021","2021",14.5,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czech Republic","2010","2010",27.4,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czech Republic","2011","2011",27.5,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czech Republic","2012","2012",26.5,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czech Republic","2013","2013",25.4,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czech Republic","2014","2014",22.9,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czech Republic","2015","2015",20.8,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czech Republic","2016","2016",21.5,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czech Republic","2017","2017",22,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czech Republic","2018","2018",22,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czech Republic","2019","2019",23.4,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czech Republic","2020","2020",23.7,"B","Break"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czech Republic","2021","2021",24.6,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","ATCPTTMT","% of total sales","CZE","Czech Republic","2010","2010",4.8,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","ATCPTTMT","% of total sales","CZE","Czech Republic","2011","2011",4.8,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","ATCPTTMT","% of total sales","CZE","Czech Republic","2012","2012",4.4,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","ATCPTTMT","% of total sales","CZE","Czech Republic","2013","2013",4.3,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","ATCPTTMT","% of total sales","CZE","Czech Republic","2014","2014",3.8,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","ATCPTTMT","% of total sales","CZE","Czech Republic","2015","2015",3.4,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","ATCPTTMT","% of total sales","CZE","Czech Republic","2016","2016",3.3,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","ATCPTTMT","% of total sales","CZE","Czech Republic","2017","2017",3.1,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","ATCPTTMT","% of total sales","CZE","Czech Republic","2018","2018",3,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","ATCPTTMT","% of total sales","CZE","Czech Republic","2019","2019",3,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","ATCPTTMT","% of total sales","CZE","Czech Republic","2020","2020",3.6,"B","Break"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","ATCPTTMT","% of total sales","CZE","Czech Republic","2021","2021",3.5,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MLLNCUMT","Million of national currency units","FIN","Finland","2010","2010",77.8,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MLLNCUMT","Million of national currency units","FIN","Finland","2011","2011",71.4,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MLLNCUMT","Million of national currency units","FIN","Finland","2012","2012",63,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MLLNCUMT","Million of national currency units","FIN","Finland","2013","2013",57.1,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MLLNCUMT","Million of national currency units","FIN","Finland","2014","2014",54.5,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MLLNCUMT","Million of national currency units","FIN","Finland","2015","2015",55,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MLLNCUMT","Million of national currency units","FIN","Finland","2016","2016",54.2,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MLLNCUMT","Million of national currency units","FIN","Finland","2017","2017",50.5,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MLLNCUMT","Million of national currency units","FIN","Finland","2018","2018",46.5,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MLLNCUMT","Million of national currency units","FIN","Finland","2019","2019",43.2,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MLLNCUMT","Million of national currency units","FIN","Finland","2020","2020",38.5,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MLLNCUMT","Million of national currency units","FIN","Finland","2021","2021",34.5,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOTCMT","Million US$ at exchange rate","FIN","Finland","2010","2010",103.1,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOTCMT","Million US$ at exchange rate","FIN","Finland","2011","2011",99.4,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOTCMT","Million US$ at exchange rate","FIN","Finland","2012","2012",80.9,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOTCMT","Million US$ at exchange rate","FIN","Finland","2013","2013",75.8,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOTCMT","Million US$ at exchange rate","FIN","Finland","2014","2014",72.4,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOTCMT","Million US$ at exchange rate","FIN","Finland","2015","2015",61,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOTCMT","Million US$ at exchange rate","FIN","Finland","2016","2016",60,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOTCMT","Million US$ at exchange rate","FIN","Finland","2017","2017",57,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOTCMT","Million US$ at exchange rate","FIN","Finland","2018","2018",54.9,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOTCMT","Million US$ at exchange rate","FIN","Finland","2019","2019",48.4,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOTCMT","Million US$ at exchange rate","FIN","Finland","2020","2020",44,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOTCMT","Million US$ at exchange rate","FIN","Finland","2021","2021",40.8,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOPPMT","Million US$, purchasing power parity","FIN","Finland","2010","2010",86.4,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOPPMT","Million US$, purchasing power parity","FIN","Finland","2011","2011",79.5,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOPPMT","Million US$, purchasing power parity","FIN","Finland","2012","2012",69.3,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOPPMT","Million US$, purchasing power parity","FIN","Finland","2013","2013",63.1,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOPPMT","Million US$, purchasing power parity","FIN","Finland","2014","2014",60.1,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOPPMT","Million US$, purchasing power parity","FIN","Finland","2015","2015",60.6,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOPPMT","Million US$, purchasing power parity","FIN","Finland","2016","2016",61.5,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOPPMT","Million US$, purchasing power parity","FIN","Finland","2017","2017",58.5,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOPPMT","Million US$, purchasing power parity","FIN","Finland","2018","2018",54.5,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOPPMT","Million US$, purchasing power parity","FIN","Finland","2019","2019",51.5,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOPPMT","Million US$, purchasing power parity","FIN","Finland","2020","2020",46.8,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOPPMT","Million US$, purchasing power parity","FIN","Finland","2021","2021",41.7,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","TCPPERMT","/capita, US$ exchange rate","FIN","Finland","2010","2010",19.2,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","TCPPERMT","/capita, US$ exchange rate","FIN","Finland","2011","2011",18.4,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","TCPPERMT","/capita, US$ exchange rate","FIN","Finland","2012","2012",15,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","TCPPERMT","/capita, US$ exchange rate","FIN","Finland","2013","2013",13.9,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","TCPPERMT","/capita, US$ exchange rate","FIN","Finland","2014","2014",13.3,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","TCPPERMT","/capita, US$ exchange rate","FIN","Finland","2015","2015",11.1,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","TCPPERMT","/capita, US$ exchange rate","FIN","Finland","2016","2016",10.9,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","TCPPERMT","/capita, US$ exchange rate","FIN","Finland","2017","2017",10.4,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","TCPPERMT","/capita, US$ exchange rate","FIN","Finland","2018","2018",10,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","TCPPERMT","/capita, US$ exchange rate","FIN","Finland","2019","2019",8.8,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","TCPPERMT","/capita, US$ exchange rate","FIN","Finland","2020","2020",8,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","TCPPERMT","/capita, US$ exchange rate","FIN","Finland","2021","2021",7.4,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2010","2010",16.1,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2011","2011",14.8,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2012","2012",12.8,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2013","2013",11.6,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2014","2014",11,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2015","2015",11.1,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2016","2016",11.2,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2017","2017",10.6,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2018","2018",9.9,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2019","2019",9.3,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2020","2020",8.5,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2021","2021",7.5,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","ATCPTTMT","% of total sales","FIN","Finland","2010","2010",4.1,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","ATCPTTMT","% of total sales","FIN","Finland","2011","2011",3.7,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","ATCPTTMT","% of total sales","FIN","Finland","2012","2012",3.2,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","ATCPTTMT","% of total sales","FIN","Finland","2013","2013",2.8,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","ATCPTTMT","% of total sales","FIN","Finland","2014","2014",2.6,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","ATCPTTMT","% of total sales","FIN","Finland","2015","2015",2.5,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","ATCPTTMT","% of total sales","FIN","Finland","2016","2016",2.4,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","ATCPTTMT","% of total sales","FIN","Finland","2017","2017",2.2,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","ATCPTTMT","% of total sales","FIN","Finland","2018","2018",1.9,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","ATCPTTMT","% of total sales","FIN","Finland","2019","2019",1.6,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","ATCPTTMT","% of total sales","FIN","Finland","2020","2020",1.4,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","ATCPTTMT","% of total sales","FIN","Finland","2021","2021",1.2,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MLLNCUMT","Million of national currency units","DEU","Germany","2010","2010",2144.2,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MLLNCUMT","Million of national currency units","DEU","Germany","2011","2011",2149.7,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MLLNCUMT","Million of national currency units","DEU","Germany","2012","2012",1919.1,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MLLNCUMT","Million of national currency units","DEU","Germany","2013","2013",1860.4,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MLLNCUMT","Million of national currency units","DEU","Germany","2014","2014",1739.9,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MLLNCUMT","Million of national currency units","DEU","Germany","2015","2015",1590,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MLLNCUMT","Million of national currency units","DEU","Germany","2016","2016",1604.2,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MLLNCUMT","Million of national currency units","DEU","Germany","2017","2017",1609.5,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MLLNCUMT","Million of national currency units","DEU","Germany","2018","2018",1680,"B; D","Break; Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MLLNCUMT","Million of national currency units","DEU","Germany","2019","2019",1770.3,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MLLNCUMT","Million of national currency units","DEU","Germany","2020","2020",1838,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MLLNCUMT","Million of national currency units","DEU","Germany","2021","2021",1921.7,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOTCMT","Million US$ at exchange rate","DEU","Germany","2010","2010",2842.6,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOTCMT","Million US$ at exchange rate","DEU","Germany","2011","2011",2992.3,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOTCMT","Million US$ at exchange rate","DEU","Germany","2012","2012",2465.6,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOTCMT","Million US$ at exchange rate","DEU","Germany","2013","2013",2470.8,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOTCMT","Million US$ at exchange rate","DEU","Germany","2014","2014",2311.5,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOTCMT","Million US$ at exchange rate","DEU","Germany","2015","2015",1764.1,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOTCMT","Million US$ at exchange rate","DEU","Germany","2016","2016",1775.7,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOTCMT","Million US$ at exchange rate","DEU","Germany","2017","2017",1818.2,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOTCMT","Million US$ at exchange rate","DEU","Germany","2018","2018",1984,"B; D","Break; Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOTCMT","Million US$ at exchange rate","DEU","Germany","2019","2019",1981.8,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOTCMT","Million US$ at exchange rate","DEU","Germany","2020","2020",2099.4,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOTCMT","Million US$ at exchange rate","DEU","Germany","2021","2021",2272.9,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOPPMT","Million US$, purchasing power parity","DEU","Germany","2010","2010",2663.3,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOPPMT","Million US$, purchasing power parity","DEU","Germany","2011","2011",2725.5,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOPPMT","Million US$, purchasing power parity","DEU","Germany","2012","2012",2437.7,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOPPMT","Million US$, purchasing power parity","DEU","Germany","2013","2013",2401.2,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOPPMT","Million US$, purchasing power parity","DEU","Germany","2014","2014",2262.7,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOPPMT","Million US$, purchasing power parity","DEU","Germany","2015","2015",2043.4,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOPPMT","Million US$, purchasing power parity","DEU","Germany","2016","2016",2131.5,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOPPMT","Million US$, purchasing power parity","DEU","Germany","2017","2017",2161,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOPPMT","Million US$, purchasing power parity","DEU","Germany","2018","2018",2284.3,"B; D","Break; Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOPPMT","Million US$, purchasing power parity","DEU","Germany","2019","2019",2430.9,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOPPMT","Million US$, purchasing power parity","DEU","Germany","2020","2020",2535.2,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOPPMT","Million US$, purchasing power parity","DEU","Germany","2021","2021",2610,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","TCPPERMT","/capita, US$ exchange rate","DEU","Germany","2010","2010",34.8,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","TCPPERMT","/capita, US$ exchange rate","DEU","Germany","2011","2011",37.3,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","TCPPERMT","/capita, US$ exchange rate","DEU","Germany","2012","2012",30.7,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","TCPPERMT","/capita, US$ exchange rate","DEU","Germany","2013","2013",30.6,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","TCPPERMT","/capita, US$ exchange rate","DEU","Germany","2014","2014",28.5,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","TCPPERMT","/capita, US$ exchange rate","DEU","Germany","2015","2015",21.6,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","TCPPERMT","/capita, US$ exchange rate","DEU","Germany","2016","2016",21.6,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","TCPPERMT","/capita, US$ exchange rate","DEU","Germany","2017","2017",22,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","TCPPERMT","/capita, US$ exchange rate","DEU","Germany","2018","2018",23.9,"B; D","Break; Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","TCPPERMT","/capita, US$ exchange rate","DEU","Germany","2019","2019",23.9,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","TCPPERMT","/capita, US$ exchange rate","DEU","Germany","2020","2020",25.2,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","TCPPERMT","/capita, US$ exchange rate","DEU","Germany","2021","2021",27.3,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2010","2010",32.6,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2011","2011",34,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2012","2012",30.3,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2013","2013",29.8,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2014","2014",27.9,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2015","2015",25,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2016","2016",25.9,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2017","2017",26.1,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2018","2018",27.6,"B; D","Break; Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2019","2019",29.3,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2020","2020",30.5,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2021","2021",31.4,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","ATCPTTMT","% of total sales","DEU","Germany","2010","2010",7.2,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","ATCPTTMT","% of total sales","DEU","Germany","2011","2011",7.2,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","ATCPTTMT","% of total sales","DEU","Germany","2012","2012",6.3,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","ATCPTTMT","% of total sales","DEU","Germany","2013","2013",5.9,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","ATCPTTMT","% of total sales","DEU","Germany","2014","2014",5.2,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","ATCPTTMT","% of total sales","DEU","Germany","2015","2015",4.5,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","ATCPTTMT","% of total sales","DEU","Germany","2016","2016",4.4,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","ATCPTTMT","% of total sales","DEU","Germany","2017","2017",4.3,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","ATCPTTMT","% of total sales","DEU","Germany","2018","2018",3.8,"B; D","Break; Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","ATCPTTMT","% of total sales","DEU","Germany","2019","2019",3.8,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","ATCPTTMT","% of total sales","DEU","Germany","2020","2020",3.7,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","ATCPTTMT","% of total sales","DEU","Germany","2021","2021",3.6,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MLLNCUMT","Million of national currency units","GRC","Greece","2010","2010",539.5,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MLLNCUMT","Million of national currency units","GRC","Greece","2011","2011",523.1,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MLLNCUMT","Million of national currency units","GRC","Greece","2012","2012",473.3,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MLLNCUMT","Million of national currency units","GRC","Greece","2013","2013",400.1,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MLLNCUMT","Million of national currency units","GRC","Greece","2014","2014",364.8,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MLLNCUMT","Million of national currency units","GRC","Greece","2015","2015",331.1,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MLLNCUMT","Million of national currency units","GRC","Greece","2016","2016",362.6,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MLLNCUMT","Million of national currency units","GRC","Greece","2017","2017",334.4,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MLLNCUMT","Million of national currency units","GRC","Greece","2018","2018",304.2,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MLLNCUMT","Million of national currency units","GRC","Greece","2019","2019",299.4,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MLLNCUMT","Million of national currency units","GRC","Greece","2020","2020",273.4,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MLLNCUMT","Million of national currency units","GRC","Greece","2021","2021",258.6,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MLLNCUMT","Million of national currency units","GRC","Greece","2022","2022",201.3,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOTCMT","Million US$ at exchange rate","GRC","Greece","2010","2010",715.2,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOTCMT","Million US$ at exchange rate","GRC","Greece","2011","2011",728.2,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOTCMT","Million US$ at exchange rate","GRC","Greece","2012","2012",608,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOTCMT","Million US$ at exchange rate","GRC","Greece","2013","2013",531.3,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOTCMT","Million US$ at exchange rate","GRC","Greece","2014","2014",484.6,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOTCMT","Million US$ at exchange rate","GRC","Greece","2015","2015",367.4,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOTCMT","Million US$ at exchange rate","GRC","Greece","2016","2016",401.4,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOTCMT","Million US$ at exchange rate","GRC","Greece","2017","2017",377.7,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOTCMT","Million US$ at exchange rate","GRC","Greece","2018","2018",359.2,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOTCMT","Million US$ at exchange rate","GRC","Greece","2019","2019",335.2,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOTCMT","Million US$ at exchange rate","GRC","Greece","2020","2020",312.2,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOTCMT","Million US$ at exchange rate","GRC","Greece","2021","2021",305.8,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOTCMT","Million US$ at exchange rate","GRC","Greece","2022","2022",212,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOPPMT","Million US$, purchasing power parity","GRC","Greece","2010","2010",747.1,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOPPMT","Million US$, purchasing power parity","GRC","Greece","2011","2011",733.5,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOPPMT","Million US$, purchasing power parity","GRC","Greece","2012","2012",691.2,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOPPMT","Million US$, purchasing power parity","GRC","Greece","2013","2013",633.7,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOPPMT","Million US$, purchasing power parity","GRC","Greece","2014","2014",596.9,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOPPMT","Million US$, purchasing power parity","GRC","Greece","2015","2015",543.6,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOPPMT","Million US$, purchasing power parity","GRC","Greece","2016","2016",616.1,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOPPMT","Million US$, purchasing power parity","GRC","Greece","2017","2017",581.5,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOPPMT","Million US$, purchasing power parity","GRC","Greece","2018","2018",538.5,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOPPMT","Million US$, purchasing power parity","GRC","Greece","2019","2019",545.5,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOPPMT","Million US$, purchasing power parity","GRC","Greece","2020","2020",502.5,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOPPMT","Million US$, purchasing power parity","GRC","Greece","2021","2021",474,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOPPMT","Million US$, purchasing power parity","GRC","Greece","2022","2022",380.9,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","TCPPERMT","/capita, US$ exchange rate","GRC","Greece","2010","2010",64.3,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","TCPPERMT","/capita, US$ exchange rate","GRC","Greece","2011","2011",65.6,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","TCPPERMT","/capita, US$ exchange rate","GRC","Greece","2012","2012",55.1,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","TCPPERMT","/capita, US$ exchange rate","GRC","Greece","2013","2013",48.5,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","TCPPERMT","/capita, US$ exchange rate","GRC","Greece","2014","2014",44.5,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","TCPPERMT","/capita, US$ exchange rate","GRC","Greece","2015","2015",34,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","TCPPERMT","/capita, US$ exchange rate","GRC","Greece","2016","2016",37.2,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","TCPPERMT","/capita, US$ exchange rate","GRC","Greece","2017","2017",35.1,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","TCPPERMT","/capita, US$ exchange rate","GRC","Greece","2018","2018",33.5,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","TCPPERMT","/capita, US$ exchange rate","GRC","Greece","2019","2019",31.3,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","TCPPERMT","/capita, US$ exchange rate","GRC","Greece","2020","2020",29.2,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","TCPPERMT","/capita, US$ exchange rate","GRC","Greece","2021","2021",28.9,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","TCPPERMT","/capita, US$ exchange rate","GRC","Greece","2022","2022",20.3,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2010","2010",67.2,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2011","2011",66.1,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2012","2012",62.6,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2013","2013",57.8,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2014","2014",54.8,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2015","2015",50.2,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2016","2016",57.2,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2017","2017",54.1,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2018","2018",50.2,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2019","2019",50.9,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2020","2020",47,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2021","2021",44.8,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2022","2022",36.4,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MLLNCUMT","Million of national currency units","HUN","Hungary","2010","2010",48076.5,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MLLNCUMT","Million of national currency units","HUN","Hungary","2011","2011",45712.3,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MLLNCUMT","Million of national currency units","HUN","Hungary","2012","2012",37976.3,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MLLNCUMT","Million of national currency units","HUN","Hungary","2013","2013",35227.6,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MLLNCUMT","Million of national currency units","HUN","Hungary","2014","2014",34341.3,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MLLNCUMT","Million of national currency units","HUN","Hungary","2015","2015",35167.2,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MLLNCUMT","Million of national currency units","HUN","Hungary","2016","2016",36400.5,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MLLNCUMT","Million of national currency units","HUN","Hungary","2017","2017",37305.6,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MLLNCUMT","Million of national currency units","HUN","Hungary","2018","2018",38914.3,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MLLNCUMT","Million of national currency units","HUN","Hungary","2019","2019",40873.8,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MLLNCUMT","Million of national currency units","HUN","Hungary","2020","2020",43416.7,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MLLNCUMT","Million of national currency units","HUN","Hungary","2021","2021",43066.4,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MLLNCUMT","Million of national currency units","HUN","Hungary","2022","2022",44307.5,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOTCMT","Million US$ at exchange rate","HUN","Hungary","2010","2010",231.2,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOTCMT","Million US$ at exchange rate","HUN","Hungary","2011","2011",227.4,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOTCMT","Million US$ at exchange rate","HUN","Hungary","2012","2012",168.7,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOTCMT","Million US$ at exchange rate","HUN","Hungary","2013","2013",157.5,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOTCMT","Million US$ at exchange rate","HUN","Hungary","2014","2014",147.6,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOTCMT","Million US$ at exchange rate","HUN","Hungary","2015","2015",125.9,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOTCMT","Million US$ at exchange rate","HUN","Hungary","2016","2016",129.3,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOTCMT","Million US$ at exchange rate","HUN","Hungary","2017","2017",135.9,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOTCMT","Million US$ at exchange rate","HUN","Hungary","2018","2018",144,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOTCMT","Million US$ at exchange rate","HUN","Hungary","2019","2019",140.6,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOTCMT","Million US$ at exchange rate","HUN","Hungary","2020","2020",141,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOTCMT","Million US$ at exchange rate","HUN","Hungary","2021","2021",142.1,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOTCMT","Million US$ at exchange rate","HUN","Hungary","2022","2022",118.9,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOPPMT","Million US$, purchasing power parity","HUN","Hungary","2010","2010",380.3,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOPPMT","Million US$, purchasing power parity","HUN","Hungary","2011","2011",367.8,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOPPMT","Million US$, purchasing power parity","HUN","Hungary","2012","2012",302.3,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOPPMT","Million US$, purchasing power parity","HUN","Hungary","2013","2013",281.9,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOPPMT","Million US$, purchasing power parity","HUN","Hungary","2014","2014",265.4,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOPPMT","Million US$, purchasing power parity","HUN","Hungary","2015","2015",265.3,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOPPMT","Million US$, purchasing power parity","HUN","Hungary","2016","2016",275.7,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOPPMT","Million US$, purchasing power parity","HUN","Hungary","2017","2017",274.2,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOPPMT","Million US$, purchasing power parity","HUN","Hungary","2018","2018",279.8,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOPPMT","Million US$, purchasing power parity","HUN","Hungary","2019","2019",290.2,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOPPMT","Million US$, purchasing power parity","HUN","Hungary","2020","2020",298.7,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOPPMT","Million US$, purchasing power parity","HUN","Hungary","2021","2021",278.3,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOPPMT","Million US$, purchasing power parity","HUN","Hungary","2022","2022",274.8,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","TCPPERMT","/capita, US$ exchange rate","HUN","Hungary","2010","2010",23.1,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","TCPPERMT","/capita, US$ exchange rate","HUN","Hungary","2011","2011",22.8,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","TCPPERMT","/capita, US$ exchange rate","HUN","Hungary","2012","2012",17,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","TCPPERMT","/capita, US$ exchange rate","HUN","Hungary","2013","2013",15.9,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","TCPPERMT","/capita, US$ exchange rate","HUN","Hungary","2014","2014",15,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","TCPPERMT","/capita, US$ exchange rate","HUN","Hungary","2015","2015",12.8,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","TCPPERMT","/capita, US$ exchange rate","HUN","Hungary","2016","2016",13.2,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","TCPPERMT","/capita, US$ exchange rate","HUN","Hungary","2017","2017",13.9,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","TCPPERMT","/capita, US$ exchange rate","HUN","Hungary","2018","2018",14.7,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","TCPPERMT","/capita, US$ exchange rate","HUN","Hungary","2019","2019",14.4,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","TCPPERMT","/capita, US$ exchange rate","HUN","Hungary","2020","2020",14.5,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","TCPPERMT","/capita, US$ exchange rate","HUN","Hungary","2021","2021",14.6,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","TCPPERMT","/capita, US$ exchange rate","HUN","Hungary","2022","2022",12.3,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2010","2010",38,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2011","2011",36.9,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2012","2012",30.5,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2013","2013",28.5,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2014","2014",26.9,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2015","2015",27,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2016","2016",28.1,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2017","2017",28,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2018","2018",28.6,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2019","2019",29.7,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2020","2020",30.6,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2021","2021",28.7,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2022","2022",28.4,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","ATCPTTMT","% of total sales","HUN","Hungary","2010","2010",9.7,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","ATCPTTMT","% of total sales","HUN","Hungary","2011","2011",8.9,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","ATCPTTMT","% of total sales","HUN","Hungary","2012","2012",8.5,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","ATCPTTMT","% of total sales","HUN","Hungary","2013","2013",8.2,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","ATCPTTMT","% of total sales","HUN","Hungary","2014","2014",7.8,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","ATCPTTMT","% of total sales","HUN","Hungary","2015","2015",7.5,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","ATCPTTMT","% of total sales","HUN","Hungary","2016","2016",7.3,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","ATCPTTMT","% of total sales","HUN","Hungary","2017","2017",7.6,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","ATCPTTMT","% of total sales","HUN","Hungary","2018","2018",7.8,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","ATCPTTMT","% of total sales","HUN","Hungary","2019","2019",7.7,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","ATCPTTMT","% of total sales","HUN","Hungary","2020","2020",7.8,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","ATCPTTMT","% of total sales","HUN","Hungary","2021","2021",7.6,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","ATCPTTMT","% of total sales","HUN","Hungary","2022","2022",7.4,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MLLNCUMT","Million of national currency units","ISL","Iceland","2010","2010",543.8,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MLLNCUMT","Million of national currency units","ISL","Iceland","2011","2011",520.4,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MLLNCUMT","Million of national currency units","ISL","Iceland","2012","2012",435.6,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MLLNCUMT","Million of national currency units","ISL","Iceland","2013","2013",417.9,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MLLNCUMT","Million of national currency units","ISL","Iceland","2014","2014",439.8,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MLLNCUMT","Million of national currency units","ISL","Iceland","2015","2015",438,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MLLNCUMT","Million of national currency units","ISL","Iceland","2016","2016",448,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MLLNCUMT","Million of national currency units","ISL","Iceland","2017","2017",454.9,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MLLNCUMT","Million of national currency units","ISL","Iceland","2018","2018",522.5,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MLLNCUMT","Million of national currency units","ISL","Iceland","2019","2019",597.1,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MLLNCUMT","Million of national currency units","ISL","Iceland","2020","2020",663.5,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MLLNCUMT","Million of national currency units","ISL","Iceland","2021","2021",711.9,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOTCMT","Million US$ at exchange rate","ISL","Iceland","2010","2010",4.4,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOTCMT","Million US$ at exchange rate","ISL","Iceland","2011","2011",4.5,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOTCMT","Million US$ at exchange rate","ISL","Iceland","2012","2012",3.5,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOTCMT","Million US$ at exchange rate","ISL","Iceland","2013","2013",3.4,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOTCMT","Million US$ at exchange rate","ISL","Iceland","2014","2014",3.8,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOTCMT","Million US$ at exchange rate","ISL","Iceland","2015","2015",3.3,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOTCMT","Million US$ at exchange rate","ISL","Iceland","2016","2016",3.7,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOTCMT","Million US$ at exchange rate","ISL","Iceland","2017","2017",4.3,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOTCMT","Million US$ at exchange rate","ISL","Iceland","2018","2018",4.8,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOTCMT","Million US$ at exchange rate","ISL","Iceland","2019","2019",4.9,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOTCMT","Million US$ at exchange rate","ISL","Iceland","2020","2020",4.9,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOTCMT","Million US$ at exchange rate","ISL","Iceland","2021","2021",5.6,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOPPMT","Million US$, purchasing power parity","ISL","Iceland","2010","2010",4.1,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOPPMT","Million US$, purchasing power parity","ISL","Iceland","2011","2011",3.9,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOPPMT","Million US$, purchasing power parity","ISL","Iceland","2012","2012",3.2,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOPPMT","Million US$, purchasing power parity","ISL","Iceland","2013","2013",3,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOPPMT","Million US$, purchasing power parity","ISL","Iceland","2014","2014",3.2,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOPPMT","Million US$, purchasing power parity","ISL","Iceland","2015","2015",3.1,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOPPMT","Million US$, purchasing power parity","ISL","Iceland","2016","2016",3.2,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOPPMT","Million US$, purchasing power parity","ISL","Iceland","2017","2017",3.3,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOPPMT","Million US$, purchasing power parity","ISL","Iceland","2018","2018",3.7,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOPPMT","Million US$, purchasing power parity","ISL","Iceland","2019","2019",4.2,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOPPMT","Million US$, purchasing power parity","ISL","Iceland","2020","2020",4.5,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOPPMT","Million US$, purchasing power parity","ISL","Iceland","2021","2021",4.8,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","TCPPERMT","/capita, US$ exchange rate","ISL","Iceland","2010","2010",14,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","TCPPERMT","/capita, US$ exchange rate","ISL","Iceland","2011","2011",14.1,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","TCPPERMT","/capita, US$ exchange rate","ISL","Iceland","2012","2012",10.9,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","TCPPERMT","/capita, US$ exchange rate","ISL","Iceland","2013","2013",10.6,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","TCPPERMT","/capita, US$ exchange rate","ISL","Iceland","2014","2014",11.5,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","TCPPERMT","/capita, US$ exchange rate","ISL","Iceland","2015","2015",10,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","TCPPERMT","/capita, US$ exchange rate","ISL","Iceland","2016","2016",11.1,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","TCPPERMT","/capita, US$ exchange rate","ISL","Iceland","2017","2017",12.4,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","TCPPERMT","/capita, US$ exchange rate","ISL","Iceland","2018","2018",13.7,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","TCPPERMT","/capita, US$ exchange rate","ISL","Iceland","2019","2019",13.5,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","TCPPERMT","/capita, US$ exchange rate","ISL","Iceland","2020","2020",13.4,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","TCPPERMT","/capita, US$ exchange rate","ISL","Iceland","2021","2021",15,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2010","2010",12.9,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2011","2011",12.1,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2012","2012",9.9,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2013","2013",9.4,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2014","2014",9.7,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2015","2015",9.3,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2016","2016",9.5,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2017","2017",9.6,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2018","2018",10.5,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2019","2019",11.8,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2020","2020",12.3,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2021","2021",12.8,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","ATCPTTMT","% of total sales","ISL","Iceland","2010","2010",2.2,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","ATCPTTMT","% of total sales","ISL","Iceland","2011","2011",2,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","ATCPTTMT","% of total sales","ISL","Iceland","2012","2012",1.8,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","ATCPTTMT","% of total sales","ISL","Iceland","2013","2013",1.6,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","ATCPTTMT","% of total sales","ISL","Iceland","2014","2014",1.9,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","ATCPTTMT","% of total sales","ISL","Iceland","2015","2015",1.8,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","ATCPTTMT","% of total sales","ISL","Iceland","2016","2016",1.8,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","ATCPTTMT","% of total sales","ISL","Iceland","2017","2017",1.7,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","ATCPTTMT","% of total sales","ISL","Iceland","2018","2018",1.7,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","ATCPTTMT","% of total sales","ISL","Iceland","2019","2019",1.8,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","ATCPTTMT","% of total sales","ISL","Iceland","2020","2020",1.7,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","ATCPTTMT","% of total sales","ISL","Iceland","2021","2021",1.6,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MLLNCUMT","Million of national currency units","IRL","Ireland","2010","2010",95.8,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MLLNCUMT","Million of national currency units","IRL","Ireland","2011","2011",85.1,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MLLNCUMT","Million of national currency units","IRL","Ireland","2012","2012",85.7,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MLLNCUMT","Million of national currency units","IRL","Ireland","2013","2013",76.8,"B; D","Break; Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MLLNCUMT","Million of national currency units","IRL","Ireland","2014","2014",67.2,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MLLNCUMT","Million of national currency units","IRL","Ireland","2015","2015",59.5,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MLLNCUMT","Million of national currency units","IRL","Ireland","2016","2016",59.2,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MLLNCUMT","Million of national currency units","IRL","Ireland","2017","2017",53.1,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MLLNCUMT","Million of national currency units","IRL","Ireland","2018","2018",54.2,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MLLNCUMT","Million of national currency units","IRL","Ireland","2019","2019",55,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MLLNCUMT","Million of national currency units","IRL","Ireland","2020","2020",57.4,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MLLNCUMT","Million of national currency units","IRL","Ireland","2021","2021",60,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOTCMT","Million US$ at exchange rate","IRL","Ireland","2010","2010",127,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOTCMT","Million US$ at exchange rate","IRL","Ireland","2011","2011",118.5,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOTCMT","Million US$ at exchange rate","IRL","Ireland","2012","2012",110.1,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOTCMT","Million US$ at exchange rate","IRL","Ireland","2013","2013",102,"B; D","Break; Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOTCMT","Million US$ at exchange rate","IRL","Ireland","2014","2014",89.2,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOTCMT","Million US$ at exchange rate","IRL","Ireland","2015","2015",66,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOTCMT","Million US$ at exchange rate","IRL","Ireland","2016","2016",65.5,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOTCMT","Million US$ at exchange rate","IRL","Ireland","2017","2017",60,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOTCMT","Million US$ at exchange rate","IRL","Ireland","2018","2018",64.1,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOTCMT","Million US$ at exchange rate","IRL","Ireland","2019","2019",61.6,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOTCMT","Million US$ at exchange rate","IRL","Ireland","2020","2020",65.5,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOTCMT","Million US$ at exchange rate","IRL","Ireland","2021","2021",70.9,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOPPMT","Million US$, purchasing power parity","IRL","Ireland","2010","2010",112.8,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOPPMT","Million US$, purchasing power parity","IRL","Ireland","2011","2011",102.4,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOPPMT","Million US$, purchasing power parity","IRL","Ireland","2012","2012",104.1,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOPPMT","Million US$, purchasing power parity","IRL","Ireland","2013","2013",94.7,"B; D","Break; Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOPPMT","Million US$, purchasing power parity","IRL","Ireland","2014","2014",82,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOPPMT","Million US$, purchasing power parity","IRL","Ireland","2015","2015",73.4,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOPPMT","Million US$, purchasing power parity","IRL","Ireland","2016","2016",74.5,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOPPMT","Million US$, purchasing power parity","IRL","Ireland","2017","2017",66.9,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOPPMT","Million US$, purchasing power parity","IRL","Ireland","2018","2018",68.5,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOPPMT","Million US$, purchasing power parity","IRL","Ireland","2019","2019",68.3,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOPPMT","Million US$, purchasing power parity","IRL","Ireland","2020","2020",72.1,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOPPMT","Million US$, purchasing power parity","IRL","Ireland","2021","2021",75.5,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","TCPPERMT","/capita, US$ exchange rate","IRL","Ireland","2010","2010",27.9,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","TCPPERMT","/capita, US$ exchange rate","IRL","Ireland","2011","2011",25.9,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","TCPPERMT","/capita, US$ exchange rate","IRL","Ireland","2012","2012",23.9,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","TCPPERMT","/capita, US$ exchange rate","IRL","Ireland","2013","2013",22.1,"B; D","Break; Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","TCPPERMT","/capita, US$ exchange rate","IRL","Ireland","2014","2014",19.2,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","TCPPERMT","/capita, US$ exchange rate","IRL","Ireland","2015","2015",14,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","TCPPERMT","/capita, US$ exchange rate","IRL","Ireland","2016","2016",13.8,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","TCPPERMT","/capita, US$ exchange rate","IRL","Ireland","2017","2017",12.5,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","TCPPERMT","/capita, US$ exchange rate","IRL","Ireland","2018","2018",13.2,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","TCPPERMT","/capita, US$ exchange rate","IRL","Ireland","2019","2019",12.5,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","TCPPERMT","/capita, US$ exchange rate","IRL","Ireland","2020","2020",13.1,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","TCPPERMT","/capita, US$ exchange rate","IRL","Ireland","2021","2021",14.1,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2010","2010",24.7,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2011","2011",22.4,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2012","2012",22.6,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2013","2013",20.5,"B; D","Break; Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2014","2014",17.6,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2015","2015",15.6,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2016","2016",15.7,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2017","2017",13.9,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2018","2018",14.1,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2019","2019",13.8,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2020","2020",14.5,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2021","2021",15,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","ATCPTTMT","% of total sales","IRL","Ireland","2010","2010",4.7,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","ATCPTTMT","% of total sales","IRL","Ireland","2011","2011",4.4,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","ATCPTTMT","% of total sales","IRL","Ireland","2012","2012",4.2,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","ATCPTTMT","% of total sales","IRL","Ireland","2013","2013",3.9,"B; D","Break; Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","ATCPTTMT","% of total sales","IRL","Ireland","2014","2014",3.5,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","ATCPTTMT","% of total sales","IRL","Ireland","2015","2015",3,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","ATCPTTMT","% of total sales","IRL","Ireland","2016","2016",2.9,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","ATCPTTMT","% of total sales","IRL","Ireland","2017","2017",2.5,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","ATCPTTMT","% of total sales","IRL","Ireland","2018","2018",2.4,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","ATCPTTMT","% of total sales","IRL","Ireland","2019","2019",2.3,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","ATCPTTMT","% of total sales","IRL","Ireland","2020","2020",2.3,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","ATCPTTMT","% of total sales","IRL","Ireland","2021","2021",2.3,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MLLNCUMT","Million of national currency units","ITA","Italy","2011","2011",1932.3,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MLLNCUMT","Million of national currency units","ITA","Italy","2012","2012",1645.8,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MLLNCUMT","Million of national currency units","ITA","Italy","2013","2013",1551.9,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MLLNCUMT","Million of national currency units","ITA","Italy","2014","2014",1398.2,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MLLNCUMT","Million of national currency units","ITA","Italy","2015","2015",1378.2,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MLLNCUMT","Million of national currency units","ITA","Italy","2016","2016",1342.6,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MLLNCUMT","Million of national currency units","ITA","Italy","2017","2017",1212.7,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MLLNCUMT","Million of national currency units","ITA","Italy","2018","2018",1186.1,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MLLNCUMT","Million of national currency units","ITA","Italy","2019","2019",1177.9,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MLLNCUMT","Million of national currency units","ITA","Italy","2020","2020",1198.8,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MLLNCUMT","Million of national currency units","ITA","Italy","2021","2021",1202.1,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MLLNCUMT","Million of national currency units","ITA","Italy","2022","2022",1211.6,"E","Estimated value"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOTCMT","Million US$ at exchange rate","ITA","Italy","2011","2011",2689.7,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOTCMT","Million US$ at exchange rate","ITA","Italy","2012","2012",2114.6,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOTCMT","Million US$ at exchange rate","ITA","Italy","2013","2013",2061.2,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOTCMT","Million US$ at exchange rate","ITA","Italy","2014","2014",1857.5,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOTCMT","Million US$ at exchange rate","ITA","Italy","2015","2015",1529.2,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOTCMT","Million US$ at exchange rate","ITA","Italy","2016","2016",1486.1,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOTCMT","Million US$ at exchange rate","ITA","Italy","2017","2017",1370,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOTCMT","Million US$ at exchange rate","ITA","Italy","2018","2018",1400.7,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOTCMT","Million US$ at exchange rate","ITA","Italy","2019","2019",1318.7,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOTCMT","Million US$ at exchange rate","ITA","Italy","2020","2020",1369.3,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOTCMT","Million US$ at exchange rate","ITA","Italy","2021","2021",1421.7,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOTCMT","Million US$ at exchange rate","ITA","Italy","2022","2022",1275.8,"E","Estimated value"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOPPMT","Million US$, purchasing power parity","ITA","Italy","2011","2011",2546.9,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOPPMT","Million US$, purchasing power parity","ITA","Italy","2012","2012",2201.1,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOPPMT","Million US$, purchasing power parity","ITA","Italy","2013","2013",2104.9,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOPPMT","Million US$, purchasing power parity","ITA","Italy","2014","2014",1890.3,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOPPMT","Million US$, purchasing power parity","ITA","Italy","2015","2015",1865.8,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOPPMT","Million US$, purchasing power parity","ITA","Italy","2016","2016",1916.4,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOPPMT","Million US$, purchasing power parity","ITA","Italy","2017","2017",1757.8,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOPPMT","Million US$, purchasing power parity","ITA","Italy","2018","2018",1741.2,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOPPMT","Million US$, purchasing power parity","ITA","Italy","2019","2019",1793.5,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOPPMT","Million US$, purchasing power parity","ITA","Italy","2020","2020",1850.8,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOPPMT","Million US$, purchasing power parity","ITA","Italy","2021","2021",1856.3,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOPPMT","Million US$, purchasing power parity","ITA","Italy","2022","2022",1962.3,"E","Estimated value"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","TCPPERMT","/capita, US$ exchange rate","ITA","Italy","2011","2011",45.3,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","TCPPERMT","/capita, US$ exchange rate","ITA","Italy","2012","2012",35.5,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","TCPPERMT","/capita, US$ exchange rate","ITA","Italy","2013","2013",34.2,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","TCPPERMT","/capita, US$ exchange rate","ITA","Italy","2014","2014",30.6,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","TCPPERMT","/capita, US$ exchange rate","ITA","Italy","2015","2015",25.2,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","TCPPERMT","/capita, US$ exchange rate","ITA","Italy","2016","2016",24.5,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","TCPPERMT","/capita, US$ exchange rate","ITA","Italy","2017","2017",22.6,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","TCPPERMT","/capita, US$ exchange rate","ITA","Italy","2018","2018",23.2,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","TCPPERMT","/capita, US$ exchange rate","ITA","Italy","2019","2019",22.1,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","TCPPERMT","/capita, US$ exchange rate","ITA","Italy","2020","2020",23,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","TCPPERMT","/capita, US$ exchange rate","ITA","Italy","2021","2021",24,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","TCPPERMT","/capita, US$ exchange rate","ITA","Italy","2022","2022",21.6,"E","Estimated value"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2011","2011",42.9,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2012","2012",37,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2013","2013",34.9,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2014","2014",31.1,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2015","2015",30.7,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2016","2016",31.6,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2017","2017",29,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2018","2018",28.8,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2019","2019",30,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2020","2020",31.1,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2021","2021",31.4,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2022","2022",33.2,"E","Estimated value"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","ATCPTTMT","% of total sales","ITA","Italy","2011","2011",9.9,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","ATCPTTMT","% of total sales","ITA","Italy","2012","2012",8.6,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","ATCPTTMT","% of total sales","ITA","Italy","2013","2013",8,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","ATCPTTMT","% of total sales","ITA","Italy","2014","2014",7,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","ATCPTTMT","% of total sales","ITA","Italy","2015","2015",6.1,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","ATCPTTMT","% of total sales","ITA","Italy","2016","2016",5.9,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","ATCPTTMT","% of total sales","ITA","Italy","2017","2017",5.4,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","ATCPTTMT","% of total sales","ITA","Italy","2018","2018",5.3,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","ATCPTTMT","% of total sales","ITA","Italy","2019","2019",5.2,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","ATCPTTMT","% of total sales","ITA","Italy","2020","2020",5.2,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","ATCPTTMT","% of total sales","ITA","Italy","2021","2021",5,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","ATCPTTMT","% of total sales","ITA","Italy","2022","2022",4.9,"E","Estimated value"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MLLNCUMT","Million of national currency units","KOR","Korea","2010","2010",961836,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MLLNCUMT","Million of national currency units","KOR","Korea","2011","2011",1069530.1,"B","Break"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MLLNCUMT","Million of national currency units","KOR","Korea","2012","2012",1064218.4,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MLLNCUMT","Million of national currency units","KOR","Korea","2013","2013",1080388,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MLLNCUMT","Million of national currency units","KOR","Korea","2014","2014",1087636.8,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MLLNCUMT","Million of national currency units","KOR","Korea","2015","2015",1101576.5,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MLLNCUMT","Million of national currency units","KOR","Korea","2016","2016",1155427.7,"B","Break"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MLLNCUMT","Million of national currency units","KOR","Korea","2017","2017",1216111.5,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MLLNCUMT","Million of national currency units","KOR","Korea","2018","2018",1305044.9,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MLLNCUMT","Million of national currency units","KOR","Korea","2019","2019",1358778.3,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MLLNCUMT","Million of national currency units","KOR","Korea","2020","2020",1501478.5,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MLLNCUMT","Million of national currency units","KOR","Korea","2021","2021",1601805.7,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOTCMT","Million US$ at exchange rate","KOR","Korea","2010","2010",831.7,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOTCMT","Million US$ at exchange rate","KOR","Korea","2011","2011",965.1,"B","Break"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOTCMT","Million US$ at exchange rate","KOR","Korea","2012","2012",944.5,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOTCMT","Million US$ at exchange rate","KOR","Korea","2013","2013",986.7,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOTCMT","Million US$ at exchange rate","KOR","Korea","2014","2014",1033.1,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOTCMT","Million US$ at exchange rate","KOR","Korea","2015","2015",974,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOTCMT","Million US$ at exchange rate","KOR","Korea","2016","2016",995.4,"B","Break"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOTCMT","Million US$ at exchange rate","KOR","Korea","2017","2017",1075.3,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOTCMT","Million US$ at exchange rate","KOR","Korea","2018","2018",1186.2,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOTCMT","Million US$ at exchange rate","KOR","Korea","2019","2019",1166,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOTCMT","Million US$ at exchange rate","KOR","Korea","2020","2020",1272.2,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOTCMT","Million US$ at exchange rate","KOR","Korea","2021","2021",1400.2,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOPPMT","Million US$, purchasing power parity","KOR","Korea","2010","2010",1143.7,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOPPMT","Million US$, purchasing power parity","KOR","Korea","2011","2011",1251.5,"B","Break"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOPPMT","Million US$, purchasing power parity","KOR","Korea","2012","2012",1244.9,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOPPMT","Million US$, purchasing power parity","KOR","Korea","2013","2013",1243.1,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOPPMT","Million US$, purchasing power parity","KOR","Korea","2014","2014",1247.5,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOPPMT","Million US$, purchasing power parity","KOR","Korea","2015","2015",1284.7,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOPPMT","Million US$, purchasing power parity","KOR","Korea","2016","2016",1345.4,"B","Break"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOPPMT","Million US$, purchasing power parity","KOR","Korea","2017","2017",1393.6,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOPPMT","Million US$, purchasing power parity","KOR","Korea","2018","2018",1526.6,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOPPMT","Million US$, purchasing power parity","KOR","Korea","2019","2019",1586.6,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOPPMT","Million US$, purchasing power parity","KOR","Korea","2020","2020",1792.4,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOPPMT","Million US$, purchasing power parity","KOR","Korea","2021","2021",1875.4,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","TCPPERMT","/capita, US$ exchange rate","KOR","Korea","2010","2010",16.8,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","TCPPERMT","/capita, US$ exchange rate","KOR","Korea","2011","2011",19.3,"B","Break"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","TCPPERMT","/capita, US$ exchange rate","KOR","Korea","2012","2012",18.8,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","TCPPERMT","/capita, US$ exchange rate","KOR","Korea","2013","2013",19.6,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","TCPPERMT","/capita, US$ exchange rate","KOR","Korea","2014","2014",20.4,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","TCPPERMT","/capita, US$ exchange rate","KOR","Korea","2015","2015",19.1,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","TCPPERMT","/capita, US$ exchange rate","KOR","Korea","2016","2016",19.4,"B","Break"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","TCPPERMT","/capita, US$ exchange rate","KOR","Korea","2017","2017",20.9,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","TCPPERMT","/capita, US$ exchange rate","KOR","Korea","2018","2018",23,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","TCPPERMT","/capita, US$ exchange rate","KOR","Korea","2019","2019",22.5,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","TCPPERMT","/capita, US$ exchange rate","KOR","Korea","2020","2020",24.5,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","TCPPERMT","/capita, US$ exchange rate","KOR","Korea","2021","2021",27.1,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2010","2010",23.1,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2011","2011",25.1,"B","Break"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2012","2012",24.8,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2013","2013",24.7,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2014","2014",24.6,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2015","2015",25.2,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2016","2016",26.3,"B","Break"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2017","2017",27.1,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2018","2018",29.6,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2019","2019",30.6,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2020","2020",34.6,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2021","2021",36.2,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","ATCPTTMT","% of total sales","KOR","Korea","2010","2010",4.7,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","ATCPTTMT","% of total sales","KOR","Korea","2011","2011",4.8,"B","Break"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","ATCPTTMT","% of total sales","KOR","Korea","2012","2012",4.9,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","ATCPTTMT","% of total sales","KOR","Korea","2013","2013",4.8,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","ATCPTTMT","% of total sales","KOR","Korea","2014","2014",4.6,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","ATCPTTMT","% of total sales","KOR","Korea","2015","2015",4.5,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","ATCPTTMT","% of total sales","KOR","Korea","2016","2016",4.6,"B","Break"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","ATCPTTMT","% of total sales","KOR","Korea","2017","2017",4.5,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","ATCPTTMT","% of total sales","KOR","Korea","2018","2018",4.5,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","ATCPTTMT","% of total sales","KOR","Korea","2019","2019",4.4,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","ATCPTTMT","% of total sales","KOR","Korea","2020","2020",4.6,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","ATCPTTMT","% of total sales","KOR","Korea","2021","2021",4.6,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MLLNCUMT","Million of national currency units","LUX","Luxembourg","2010","2010",14.9,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MLLNCUMT","Million of national currency units","LUX","Luxembourg","2011","2011",14.6,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MLLNCUMT","Million of national currency units","LUX","Luxembourg","2012","2012",14.4,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MLLNCUMT","Million of national currency units","LUX","Luxembourg","2013","2013",13.3,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MLLNCUMT","Million of national currency units","LUX","Luxembourg","2014","2014",11.4,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MLLNCUMT","Million of national currency units","LUX","Luxembourg","2015","2015",11,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MLLNCUMT","Million of national currency units","LUX","Luxembourg","2016","2016",10.7,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MLLNCUMT","Million of national currency units","LUX","Luxembourg","2017","2017",9.8,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MLLNCUMT","Million of national currency units","LUX","Luxembourg","2018","2018",9.2,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MLLNCUMT","Million of national currency units","LUX","Luxembourg","2019","2019",10,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MLLNCUMT","Million of national currency units","LUX","Luxembourg","2020","2020",10.2,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MLLNCUMT","Million of national currency units","LUX","Luxembourg","2021","2021",10,"B; D; P","Break; Difference in methodology; Provisional value"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MLLNCUMT","Million of national currency units","LUX","Luxembourg","2022","2022",10,"D; P","Difference in methodology; Provisional value"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOTCMT","Million US$ at exchange rate","LUX","Luxembourg","2010","2010",19.8,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOTCMT","Million US$ at exchange rate","LUX","Luxembourg","2011","2011",20.3,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOTCMT","Million US$ at exchange rate","LUX","Luxembourg","2012","2012",18.6,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOTCMT","Million US$ at exchange rate","LUX","Luxembourg","2013","2013",17.6,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOTCMT","Million US$ at exchange rate","LUX","Luxembourg","2014","2014",15.1,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOTCMT","Million US$ at exchange rate","LUX","Luxembourg","2015","2015",12.2,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOTCMT","Million US$ at exchange rate","LUX","Luxembourg","2016","2016",11.8,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOTCMT","Million US$ at exchange rate","LUX","Luxembourg","2017","2017",11,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOTCMT","Million US$ at exchange rate","LUX","Luxembourg","2018","2018",10.9,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOTCMT","Million US$ at exchange rate","LUX","Luxembourg","2019","2019",11.1,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOTCMT","Million US$ at exchange rate","LUX","Luxembourg","2020","2020",11.6,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOTCMT","Million US$ at exchange rate","LUX","Luxembourg","2021","2021",11.9,"B; D; P","Break; Difference in methodology; Provisional value"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOTCMT","Million US$ at exchange rate","LUX","Luxembourg","2022","2022",10.6,"D; P","Difference in methodology; Provisional value"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOPPMT","Million US$, purchasing power parity","LUX","Luxembourg","2010","2010",16.1,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOPPMT","Million US$, purchasing power parity","LUX","Luxembourg","2011","2011",16.1,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOPPMT","Million US$, purchasing power parity","LUX","Luxembourg","2012","2012",15.9,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOPPMT","Million US$, purchasing power parity","LUX","Luxembourg","2013","2013",14.8,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOPPMT","Million US$, purchasing power parity","LUX","Luxembourg","2014","2014",12.9,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOPPMT","Million US$, purchasing power parity","LUX","Luxembourg","2015","2015",12.5,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOPPMT","Million US$, purchasing power parity","LUX","Luxembourg","2016","2016",12.5,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOPPMT","Million US$, purchasing power parity","LUX","Luxembourg","2017","2017",11.5,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOPPMT","Million US$, purchasing power parity","LUX","Luxembourg","2018","2018",10.9,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOPPMT","Million US$, purchasing power parity","LUX","Luxembourg","2019","2019",11.8,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOPPMT","Million US$, purchasing power parity","LUX","Luxembourg","2020","2020",11.9,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOPPMT","Million US$, purchasing power parity","LUX","Luxembourg","2021","2021",11.7,"B; D; P","Break; Difference in methodology; Provisional value"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOPPMT","Million US$, purchasing power parity","LUX","Luxembourg","2022","2022",12.1,"D; P","Difference in methodology; Provisional value"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","TCPPERMT","/capita, US$ exchange rate","LUX","Luxembourg","2010","2010",41.8,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","TCPPERMT","/capita, US$ exchange rate","LUX","Luxembourg","2011","2011",42.2,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","TCPPERMT","/capita, US$ exchange rate","LUX","Luxembourg","2012","2012",37.7,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","TCPPERMT","/capita, US$ exchange rate","LUX","Luxembourg","2013","2013",35.1,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","TCPPERMT","/capita, US$ exchange rate","LUX","Luxembourg","2014","2014",29.6,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","TCPPERMT","/capita, US$ exchange rate","LUX","Luxembourg","2015","2015",23.6,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","TCPPERMT","/capita, US$ exchange rate","LUX","Luxembourg","2016","2016",22.4,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","TCPPERMT","/capita, US$ exchange rate","LUX","Luxembourg","2017","2017",20.6,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","TCPPERMT","/capita, US$ exchange rate","LUX","Luxembourg","2018","2018",20,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","TCPPERMT","/capita, US$ exchange rate","LUX","Luxembourg","2019","2019",20,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","TCPPERMT","/capita, US$ exchange rate","LUX","Luxembourg","2020","2020",20.5,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","TCPPERMT","/capita, US$ exchange rate","LUX","Luxembourg","2021","2021",20.6,"B; D; P","Break; Difference in methodology; Provisional value"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","TCPPERMT","/capita, US$ exchange rate","LUX","Luxembourg","2022","2022",18,"D; P","Difference in methodology; Provisional value"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2010","2010",34,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2011","2011",33.5,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2012","2012",32.3,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2013","2013",29.5,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2014","2014",25.2,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2015","2015",24.1,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2016","2016",23.7,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2017","2017",21.5,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2018","2018",19.9,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2019","2019",21.2,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2020","2020",21,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2021","2021",20.3,"B; D; P","Break; Difference in methodology; Provisional value"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2022","2022",20.6,"D; P","Difference in methodology; Provisional value"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","ATCPTTMT","% of total sales","LUX","Luxembourg","2010","2010",7.9,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","ATCPTTMT","% of total sales","LUX","Luxembourg","2011","2011",7.7,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","ATCPTTMT","% of total sales","LUX","Luxembourg","2012","2012",7.4,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","ATCPTTMT","% of total sales","LUX","Luxembourg","2013","2013",6.8,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","ATCPTTMT","% of total sales","LUX","Luxembourg","2014","2014",6,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","ATCPTTMT","% of total sales","LUX","Luxembourg","2015","2015",5.7,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","ATCPTTMT","% of total sales","LUX","Luxembourg","2016","2016",5.5,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","ATCPTTMT","% of total sales","LUX","Luxembourg","2017","2017",5,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","ATCPTTMT","% of total sales","LUX","Luxembourg","2018","2018",4.6,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","ATCPTTMT","% of total sales","LUX","Luxembourg","2019","2019",4.9,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","ATCPTTMT","% of total sales","LUX","Luxembourg","2020","2020",4.9,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","ATCPTTMT","% of total sales","LUX","Luxembourg","2021","2021",4.2,"B; D; P","Break; Difference in methodology; Provisional value"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","ATCPTTMT","% of total sales","LUX","Luxembourg","2022","2022",3.9,"D; P","Difference in methodology; Provisional value"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MLLNCUMT","Million of national currency units","NLD","Netherlands","2010","2010",265.5,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MLLNCUMT","Million of national currency units","NLD","Netherlands","2011","2011",256.1,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MLLNCUMT","Million of national currency units","NLD","Netherlands","2012","2012",206.8,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MLLNCUMT","Million of national currency units","NLD","Netherlands","2013","2013",167.6,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MLLNCUMT","Million of national currency units","NLD","Netherlands","2014","2014",141.1,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOTCMT","Million US$ at exchange rate","NLD","Netherlands","2010","2010",352,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOTCMT","Million US$ at exchange rate","NLD","Netherlands","2011","2011",356.5,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOTCMT","Million US$ at exchange rate","NLD","Netherlands","2012","2012",265.6,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOTCMT","Million US$ at exchange rate","NLD","Netherlands","2013","2013",222.7,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOTCMT","Million US$ at exchange rate","NLD","Netherlands","2014","2014",187.5,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOPPMT","Million US$, purchasing power parity","NLD","Netherlands","2010","2010",310.9,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOPPMT","Million US$, purchasing power parity","NLD","Netherlands","2011","2011",306.4,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOPPMT","Million US$, purchasing power parity","NLD","Netherlands","2012","2012",250.8,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOPPMT","Million US$, purchasing power parity","NLD","Netherlands","2013","2013",210,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOPPMT","Million US$, purchasing power parity","NLD","Netherlands","2014","2014",174.5,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","TCPPERMT","/capita, US$ exchange rate","NLD","Netherlands","2010","2010",21.2,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","TCPPERMT","/capita, US$ exchange rate","NLD","Netherlands","2011","2011",21.4,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","TCPPERMT","/capita, US$ exchange rate","NLD","Netherlands","2012","2012",15.9,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","TCPPERMT","/capita, US$ exchange rate","NLD","Netherlands","2013","2013",13.2,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","TCPPERMT","/capita, US$ exchange rate","NLD","Netherlands","2014","2014",11.1,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","NLD","Netherlands","2010","2010",18.7,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","NLD","Netherlands","2011","2011",18.4,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","NLD","Netherlands","2012","2012",15,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","NLD","Netherlands","2013","2013",12.5,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","NLD","Netherlands","2014","2014",10.3,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","ATCPTTMT","% of total sales","NLD","Netherlands","2010","2010",5.1,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","ATCPTTMT","% of total sales","NLD","Netherlands","2011","2011",4.9,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","ATCPTTMT","% of total sales","NLD","Netherlands","2012","2012",4.5,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","ATCPTTMT","% of total sales","NLD","Netherlands","2013","2013",3.9,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","ATCPTTMT","% of total sales","NLD","Netherlands","2014","2014",3.3,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MLLNCUMT","Million of national currency units","NZL","New Zealand","2010","2010",34.5,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MLLNCUMT","Million of national currency units","NZL","New Zealand","2011","2011",34.6,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MLLNCUMT","Million of national currency units","NZL","New Zealand","2012","2012",31.7,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MLLNCUMT","Million of national currency units","NZL","New Zealand","2013","2013",17.8,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MLLNCUMT","Million of national currency units","NZL","New Zealand","2014","2014",14.7,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MLLNCUMT","Million of national currency units","NZL","New Zealand","2015","2015",13.4,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MLLNCUMT","Million of national currency units","NZL","New Zealand","2016","2016",12.3,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MLLNCUMT","Million of national currency units","NZL","New Zealand","2017","2017",11.8,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MLLNCUMT","Million of national currency units","NZL","New Zealand","2018","2018",12.3,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MLLNCUMT","Million of national currency units","NZL","New Zealand","2019","2019",11.9,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MLLNCUMT","Million of national currency units","NZL","New Zealand","2020","2020",15.5,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MLLNCUMT","Million of national currency units","NZL","New Zealand","2021","2021",22.1,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MLLNCUMT","Million of national currency units","NZL","New Zealand","2022","2022",31.7,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOTCMT","Million US$ at exchange rate","NZL","New Zealand","2010","2010",24.8,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOTCMT","Million US$ at exchange rate","NZL","New Zealand","2011","2011",27.3,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOTCMT","Million US$ at exchange rate","NZL","New Zealand","2012","2012",25.7,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOTCMT","Million US$ at exchange rate","NZL","New Zealand","2013","2013",14.6,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOTCMT","Million US$ at exchange rate","NZL","New Zealand","2014","2014",12.2,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOTCMT","Million US$ at exchange rate","NZL","New Zealand","2015","2015",9.4,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOTCMT","Million US$ at exchange rate","NZL","New Zealand","2016","2016",8.6,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOTCMT","Million US$ at exchange rate","NZL","New Zealand","2017","2017",8.4,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOTCMT","Million US$ at exchange rate","NZL","New Zealand","2018","2018",8.5,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOTCMT","Million US$ at exchange rate","NZL","New Zealand","2019","2019",7.8,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOTCMT","Million US$ at exchange rate","NZL","New Zealand","2020","2020",10.1,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOTCMT","Million US$ at exchange rate","NZL","New Zealand","2021","2021",15.6,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOTCMT","Million US$ at exchange rate","NZL","New Zealand","2022","2022",20.1,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOPPMT","Million US$, purchasing power parity","NZL","New Zealand","2010","2010",23,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOPPMT","Million US$, purchasing power parity","NZL","New Zealand","2011","2011",23.3,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOPPMT","Million US$, purchasing power parity","NZL","New Zealand","2012","2012",21.2,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOPPMT","Million US$, purchasing power parity","NZL","New Zealand","2013","2013",12.3,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOPPMT","Million US$, purchasing power parity","NZL","New Zealand","2014","2014",10.2,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOPPMT","Million US$, purchasing power parity","NZL","New Zealand","2015","2015",9.1,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOPPMT","Million US$, purchasing power parity","NZL","New Zealand","2016","2016",8.5,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOPPMT","Million US$, purchasing power parity","NZL","New Zealand","2017","2017",8.2,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOPPMT","Million US$, purchasing power parity","NZL","New Zealand","2018","2018",8.4,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOPPMT","Million US$, purchasing power parity","NZL","New Zealand","2019","2019",8.4,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOPPMT","Million US$, purchasing power parity","NZL","New Zealand","2020","2020",11,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOPPMT","Million US$, purchasing power parity","NZL","New Zealand","2021","2021",15.1,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOPPMT","Million US$, purchasing power parity","NZL","New Zealand","2022","2022",22,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","TCPPERMT","/capita, US$ exchange rate","NZL","New Zealand","2010","2010",5.7,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","TCPPERMT","/capita, US$ exchange rate","NZL","New Zealand","2011","2011",6.2,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","TCPPERMT","/capita, US$ exchange rate","NZL","New Zealand","2012","2012",5.8,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","TCPPERMT","/capita, US$ exchange rate","NZL","New Zealand","2013","2013",3.3,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","TCPPERMT","/capita, US$ exchange rate","NZL","New Zealand","2014","2014",2.7,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","TCPPERMT","/capita, US$ exchange rate","NZL","New Zealand","2015","2015",2,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","TCPPERMT","/capita, US$ exchange rate","NZL","New Zealand","2016","2016",1.8,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","TCPPERMT","/capita, US$ exchange rate","NZL","New Zealand","2017","2017",1.7,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","TCPPERMT","/capita, US$ exchange rate","NZL","New Zealand","2018","2018",1.7,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","TCPPERMT","/capita, US$ exchange rate","NZL","New Zealand","2019","2019",1.6,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","TCPPERMT","/capita, US$ exchange rate","NZL","New Zealand","2020","2020",2,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","TCPPERMT","/capita, US$ exchange rate","NZL","New Zealand","2021","2021",3.1,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","TCPPERMT","/capita, US$ exchange rate","NZL","New Zealand","2022","2022",3.9,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2010","2010",5.3,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2011","2011",5.3,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2012","2012",4.8,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2013","2013",2.8,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2014","2014",2.3,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2015","2015",2,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2016","2016",1.8,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2017","2017",1.7,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2018","2018",1.7,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2019","2019",1.7,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2020","2020",2.2,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2021","2021",3,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2022","2022",4.3,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","ATCPTTMT","% of total sales","NZL","New Zealand","2010","2010",4.6,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","ATCPTTMT","% of total sales","NZL","New Zealand","2011","2011",4.2,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","ATCPTTMT","% of total sales","NZL","New Zealand","2012","2012",3.4,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","ATCPTTMT","% of total sales","NZL","New Zealand","2013","2013",1.9,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","ATCPTTMT","% of total sales","NZL","New Zealand","2014","2014",1.5,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","ATCPTTMT","% of total sales","NZL","New Zealand","2015","2015",1.4,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","ATCPTTMT","% of total sales","NZL","New Zealand","2016","2016",1.1,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","ATCPTTMT","% of total sales","NZL","New Zealand","2017","2017",0.9,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","ATCPTTMT","% of total sales","NZL","New Zealand","2018","2018",0.9,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","ATCPTTMT","% of total sales","NZL","New Zealand","2019","2019",0.8,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","ATCPTTMT","% of total sales","NZL","New Zealand","2020","2020",0.9,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","ATCPTTMT","% of total sales","NZL","New Zealand","2021","2021",1.2,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","ATCPTTMT","% of total sales","NZL","New Zealand","2022","2022",1.7,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MLLNCUMT","Million of national currency units","NOR","Norway","2010","2010",808,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MLLNCUMT","Million of national currency units","NOR","Norway","2011","2011",782,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MLLNCUMT","Million of national currency units","NOR","Norway","2012","2012",647,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MLLNCUMT","Million of national currency units","NOR","Norway","2013","2013",471,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MLLNCUMT","Million of national currency units","NOR","Norway","2014","2014",443,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MLLNCUMT","Million of national currency units","NOR","Norway","2015","2015",420,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MLLNCUMT","Million of national currency units","NOR","Norway","2016","2016",440,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MLLNCUMT","Million of national currency units","NOR","Norway","2017","2017",451,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MLLNCUMT","Million of national currency units","NOR","Norway","2018","2018",472,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MLLNCUMT","Million of national currency units","NOR","Norway","2019","2019",520,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MLLNCUMT","Million of national currency units","NOR","Norway","2020","2020",546,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MLLNCUMT","Million of national currency units","NOR","Norway","2021","2021",570,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MLLNCUMT","Million of national currency units","NOR","Norway","2022","2022",566,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOTCMT","Million US$ at exchange rate","NOR","Norway","2010","2010",133.7,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOTCMT","Million US$ at exchange rate","NOR","Norway","2011","2011",139.5,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOTCMT","Million US$ at exchange rate","NOR","Norway","2012","2012",111.2,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOTCMT","Million US$ at exchange rate","NOR","Norway","2013","2013",80.2,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOTCMT","Million US$ at exchange rate","NOR","Norway","2014","2014",70.3,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOTCMT","Million US$ at exchange rate","NOR","Norway","2015","2015",52.1,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOTCMT","Million US$ at exchange rate","NOR","Norway","2016","2016",52.4,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOTCMT","Million US$ at exchange rate","NOR","Norway","2017","2017",54.5,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOTCMT","Million US$ at exchange rate","NOR","Norway","2018","2018",58,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOTCMT","Million US$ at exchange rate","NOR","Norway","2019","2019",59.1,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOTCMT","Million US$ at exchange rate","NOR","Norway","2020","2020",58,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOTCMT","Million US$ at exchange rate","NOR","Norway","2021","2021",66.4,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOTCMT","Million US$ at exchange rate","NOR","Norway","2022","2022",58.9,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOPPMT","Million US$, purchasing power parity","NOR","Norway","2010","2010",88.3,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOPPMT","Million US$, purchasing power parity","NOR","Norway","2011","2011",86.1,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOPPMT","Million US$, purchasing power parity","NOR","Norway","2012","2012",71.6,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOPPMT","Million US$, purchasing power parity","NOR","Norway","2013","2013",52.2,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOPPMT","Million US$, purchasing power parity","NOR","Norway","2014","2014",47.7,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOPPMT","Million US$, purchasing power parity","NOR","Norway","2015","2015",42.3,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOPPMT","Million US$, purchasing power parity","NOR","Norway","2016","2016",43.8,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOPPMT","Million US$, purchasing power parity","NOR","Norway","2017","2017",46.3,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOPPMT","Million US$, purchasing power parity","NOR","Norway","2018","2018",49.2,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOPPMT","Million US$, purchasing power parity","NOR","Norway","2019","2019",54.1,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOPPMT","Million US$, purchasing power parity","NOR","Norway","2020","2020",55.3,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOPPMT","Million US$, purchasing power parity","NOR","Norway","2021","2021",59.9,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOPPMT","Million US$, purchasing power parity","NOR","Norway","2022","2022",52.7,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","TCPPERMT","/capita, US$ exchange rate","NOR","Norway","2010","2010",27.3,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","TCPPERMT","/capita, US$ exchange rate","NOR","Norway","2011","2011",28.2,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","TCPPERMT","/capita, US$ exchange rate","NOR","Norway","2012","2012",22.2,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","TCPPERMT","/capita, US$ exchange rate","NOR","Norway","2013","2013",15.8,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","TCPPERMT","/capita, US$ exchange rate","NOR","Norway","2014","2014",13.7,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","TCPPERMT","/capita, US$ exchange rate","NOR","Norway","2015","2015",10,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","TCPPERMT","/capita, US$ exchange rate","NOR","Norway","2016","2016",10,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","TCPPERMT","/capita, US$ exchange rate","NOR","Norway","2017","2017",10.3,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","TCPPERMT","/capita, US$ exchange rate","NOR","Norway","2018","2018",10.9,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","TCPPERMT","/capita, US$ exchange rate","NOR","Norway","2019","2019",11,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","TCPPERMT","/capita, US$ exchange rate","NOR","Norway","2020","2020",10.8,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","TCPPERMT","/capita, US$ exchange rate","NOR","Norway","2021","2021",12.3,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","TCPPERMT","/capita, US$ exchange rate","NOR","Norway","2022","2022",10.9,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2010","2010",18.1,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2011","2011",17.4,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2012","2012",14.3,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2013","2013",10.3,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2014","2014",9.3,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2015","2015",8.1,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2016","2016",8.4,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2017","2017",8.8,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2018","2018",9.3,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2019","2019",10.1,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2020","2020",10.3,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2021","2021",11.1,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2022","2022",9.7,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","ATCPTTMT","% of total sales","NOR","Norway","2010","2010",4.5,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","ATCPTTMT","% of total sales","NOR","Norway","2011","2011",4.3,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","ATCPTTMT","% of total sales","NOR","Norway","2012","2012",3.4,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","ATCPTTMT","% of total sales","NOR","Norway","2013","2013",2.4,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","ATCPTTMT","% of total sales","NOR","Norway","2014","2014",2.1,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","ATCPTTMT","% of total sales","NOR","Norway","2015","2015",1.8,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","ATCPTTMT","% of total sales","NOR","Norway","2016","2016",1.8,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","ATCPTTMT","% of total sales","NOR","Norway","2017","2017",1.7,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","ATCPTTMT","% of total sales","NOR","Norway","2018","2018",1.7,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","ATCPTTMT","% of total sales","NOR","Norway","2019","2019",1.8,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","ATCPTTMT","% of total sales","NOR","Norway","2020","2020",1.8,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","ATCPTTMT","% of total sales","NOR","Norway","2021","2021",1.7,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","ATCPTTMT","% of total sales","NOR","Norway","2022","2022",1.6,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MLLNCUMT","Million of national currency units","PRT","Portugal","2010","2010",397.7,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MLLNCUMT","Million of national currency units","PRT","Portugal","2011","2011",374.4,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MLLNCUMT","Million of national currency units","PRT","Portugal","2012","2012",320.2,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MLLNCUMT","Million of national currency units","PRT","Portugal","2013","2013",268.4,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MLLNCUMT","Million of national currency units","PRT","Portugal","2014","2014",250,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MLLNCUMT","Million of national currency units","PRT","Portugal","2015","2015",233.2,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MLLNCUMT","Million of national currency units","PRT","Portugal","2016","2016",217,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MLLNCUMT","Million of national currency units","PRT","Portugal","2017","2017",202.7,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MLLNCUMT","Million of national currency units","PRT","Portugal","2018","2018",196.3,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MLLNCUMT","Million of national currency units","PRT","Portugal","2019","2019",204.2,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MLLNCUMT","Million of national currency units","PRT","Portugal","2020","2020",214.3,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MLLNCUMT","Million of national currency units","PRT","Portugal","2021","2021",223.8,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MLLNCUMT","Million of national currency units","PRT","Portugal","2022","2022",237.8,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOTCMT","Million US$ at exchange rate","PRT","Portugal","2010","2010",527.3,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOTCMT","Million US$ at exchange rate","PRT","Portugal","2011","2011",521.2,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOTCMT","Million US$ at exchange rate","PRT","Portugal","2012","2012",411.4,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOTCMT","Million US$ at exchange rate","PRT","Portugal","2013","2013",356.4,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOTCMT","Million US$ at exchange rate","PRT","Portugal","2014","2014",332.1,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOTCMT","Million US$ at exchange rate","PRT","Portugal","2015","2015",258.7,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOTCMT","Million US$ at exchange rate","PRT","Portugal","2016","2016",240.2,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOTCMT","Million US$ at exchange rate","PRT","Portugal","2017","2017",228.9,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOTCMT","Million US$ at exchange rate","PRT","Portugal","2018","2018",231.9,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOTCMT","Million US$ at exchange rate","PRT","Portugal","2019","2019",228.5,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOTCMT","Million US$ at exchange rate","PRT","Portugal","2020","2020",244.8,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOTCMT","Million US$ at exchange rate","PRT","Portugal","2021","2021",264.7,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOTCMT","Million US$ at exchange rate","PRT","Portugal","2022","2022",250.4,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOPPMT","Million US$, purchasing power parity","PRT","Portugal","2010","2010",638.2,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOPPMT","Million US$, purchasing power parity","PRT","Portugal","2011","2011",600.9,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOPPMT","Million US$, purchasing power parity","PRT","Portugal","2012","2012",529,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOPPMT","Million US$, purchasing power parity","PRT","Portugal","2013","2013",459.8,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOPPMT","Million US$, purchasing power parity","PRT","Portugal","2014","2014",431.9,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOPPMT","Million US$, purchasing power parity","PRT","Portugal","2015","2015",398.6,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOPPMT","Million US$, purchasing power parity","PRT","Portugal","2016","2016",379.7,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOPPMT","Million US$, purchasing power parity","PRT","Portugal","2017","2017",352,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOPPMT","Million US$, purchasing power parity","PRT","Portugal","2018","2018",343.7,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOPPMT","Million US$, purchasing power parity","PRT","Portugal","2019","2019",365.4,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOPPMT","Million US$, purchasing power parity","PRT","Portugal","2020","2020",384.7,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOPPMT","Million US$, purchasing power parity","PRT","Portugal","2021","2021",394.2,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOPPMT","Million US$, purchasing power parity","PRT","Portugal","2022","2022",432.4,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","TCPPERMT","/capita, US$ exchange rate","PRT","Portugal","2010","2010",49.9,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","TCPPERMT","/capita, US$ exchange rate","PRT","Portugal","2011","2011",49.4,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","TCPPERMT","/capita, US$ exchange rate","PRT","Portugal","2012","2012",39.1,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","TCPPERMT","/capita, US$ exchange rate","PRT","Portugal","2013","2013",34.1,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","TCPPERMT","/capita, US$ exchange rate","PRT","Portugal","2014","2014",31.9,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","TCPPERMT","/capita, US$ exchange rate","PRT","Portugal","2015","2015",25,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","TCPPERMT","/capita, US$ exchange rate","PRT","Portugal","2016","2016",23.3,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","TCPPERMT","/capita, US$ exchange rate","PRT","Portugal","2017","2017",22.2,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","TCPPERMT","/capita, US$ exchange rate","PRT","Portugal","2018","2018",22.5,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","TCPPERMT","/capita, US$ exchange rate","PRT","Portugal","2019","2019",22.2,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","TCPPERMT","/capita, US$ exchange rate","PRT","Portugal","2020","2020",23.8,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","TCPPERMT","/capita, US$ exchange rate","PRT","Portugal","2021","2021",25.5,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","TCPPERMT","/capita, US$ exchange rate","PRT","Portugal","2022","2022",24.2,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2010","2010",60.4,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2011","2011",56.9,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2012","2012",50.3,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2013","2013",44,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2014","2014",41.5,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2015","2015",38.5,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2016","2016",36.8,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2017","2017",34.2,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2018","2018",33.4,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2019","2019",35.5,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2020","2020",37.4,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2021","2021",38,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2022","2022",41.8,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","ATCPTTMT","% of total sales","PRT","Portugal","2010","2010",12.3,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","ATCPTTMT","% of total sales","PRT","Portugal","2011","2011",12.7,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","ATCPTTMT","% of total sales","PRT","Portugal","2012","2012",12.3,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","ATCPTTMT","% of total sales","PRT","Portugal","2013","2013",11.1,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","ATCPTTMT","% of total sales","PRT","Portugal","2014","2014",10.4,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","ATCPTTMT","% of total sales","PRT","Portugal","2015","2015",9.4,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","ATCPTTMT","% of total sales","PRT","Portugal","2016","2016",8.6,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","ATCPTTMT","% of total sales","PRT","Portugal","2017","2017",7.9,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","ATCPTTMT","% of total sales","PRT","Portugal","2018","2018",7.5,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","ATCPTTMT","% of total sales","PRT","Portugal","2019","2019",7.3,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","ATCPTTMT","% of total sales","PRT","Portugal","2020","2020",7.6,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","ATCPTTMT","% of total sales","PRT","Portugal","2021","2021",7.7,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","ATCPTTMT","% of total sales","PRT","Portugal","2022","2022",7.5,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MLLNCUMT","Million of national currency units","SVK","Slovak Republic","2010","2010",58.9,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MLLNCUMT","Million of national currency units","SVK","Slovak Republic","2011","2011",60.9,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MLLNCUMT","Million of national currency units","SVK","Slovak Republic","2012","2012",54.3,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MLLNCUMT","Million of national currency units","SVK","Slovak Republic","2013","2013",49.5,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MLLNCUMT","Million of national currency units","SVK","Slovak Republic","2014","2014",46.4,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MLLNCUMT","Million of national currency units","SVK","Slovak Republic","2015","2015",43.9,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MLLNCUMT","Million of national currency units","SVK","Slovak Republic","2016","2016",58.4,"B","Break"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MLLNCUMT","Million of national currency units","SVK","Slovak Republic","2017","2017",58.7,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MLLNCUMT","Million of national currency units","SVK","Slovak Republic","2018","2018",60.4,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MLLNCUMT","Million of national currency units","SVK","Slovak Republic","2019","2019",63.8,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MLLNCUMT","Million of national currency units","SVK","Slovak Republic","2020","2020",67.7,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MLLNCUMT","Million of national currency units","SVK","Slovak Republic","2021","2021",68.2,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOTCMT","Million US$ at exchange rate","SVK","Slovak Republic","2010","2010",78,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOTCMT","Million US$ at exchange rate","SVK","Slovak Republic","2011","2011",84.8,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOTCMT","Million US$ at exchange rate","SVK","Slovak Republic","2012","2012",69.7,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOTCMT","Million US$ at exchange rate","SVK","Slovak Republic","2013","2013",65.8,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOTCMT","Million US$ at exchange rate","SVK","Slovak Republic","2014","2014",61.6,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOTCMT","Million US$ at exchange rate","SVK","Slovak Republic","2015","2015",48.7,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOTCMT","Million US$ at exchange rate","SVK","Slovak Republic","2016","2016",64.6,"B","Break"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOTCMT","Million US$ at exchange rate","SVK","Slovak Republic","2017","2017",66.3,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOTCMT","Million US$ at exchange rate","SVK","Slovak Republic","2018","2018",71.3,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOTCMT","Million US$ at exchange rate","SVK","Slovak Republic","2019","2019",71.4,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOTCMT","Million US$ at exchange rate","SVK","Slovak Republic","2020","2020",77.3,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOTCMT","Million US$ at exchange rate","SVK","Slovak Republic","2021","2021",80.7,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOPPMT","Million US$, purchasing power parity","SVK","Slovak Republic","2010","2010",117.2,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOPPMT","Million US$, purchasing power parity","SVK","Slovak Republic","2011","2011",120.3,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOPPMT","Million US$, purchasing power parity","SVK","Slovak Republic","2012","2012",107.5,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOPPMT","Million US$, purchasing power parity","SVK","Slovak Republic","2013","2013",100.8,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOPPMT","Million US$, purchasing power parity","SVK","Slovak Republic","2014","2014",95.5,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOPPMT","Million US$, purchasing power parity","SVK","Slovak Republic","2015","2015",89.2,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOPPMT","Million US$, purchasing power parity","SVK","Slovak Republic","2016","2016",116,"B","Break"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOPPMT","Million US$, purchasing power parity","SVK","Slovak Republic","2017","2017",113.6,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOPPMT","Million US$, purchasing power parity","SVK","Slovak Republic","2018","2018",114.8,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOPPMT","Million US$, purchasing power parity","SVK","Slovak Republic","2019","2019",123.3,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOPPMT","Million US$, purchasing power parity","SVK","Slovak Republic","2020","2020",130.2,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOPPMT","Million US$, purchasing power parity","SVK","Slovak Republic","2021","2021",127.9,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","TCPPERMT","/capita, US$ exchange rate","SVK","Slovak Republic","2010","2010",14.5,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","TCPPERMT","/capita, US$ exchange rate","SVK","Slovak Republic","2011","2011",15.7,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","TCPPERMT","/capita, US$ exchange rate","SVK","Slovak Republic","2012","2012",12.9,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","TCPPERMT","/capita, US$ exchange rate","SVK","Slovak Republic","2013","2013",12.1,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","TCPPERMT","/capita, US$ exchange rate","SVK","Slovak Republic","2014","2014",11.4,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","TCPPERMT","/capita, US$ exchange rate","SVK","Slovak Republic","2015","2015",9,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","TCPPERMT","/capita, US$ exchange rate","SVK","Slovak Republic","2016","2016",11.9,"B","Break"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","TCPPERMT","/capita, US$ exchange rate","SVK","Slovak Republic","2017","2017",12.2,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","TCPPERMT","/capita, US$ exchange rate","SVK","Slovak Republic","2018","2018",13.1,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","TCPPERMT","/capita, US$ exchange rate","SVK","Slovak Republic","2019","2019",13.1,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","TCPPERMT","/capita, US$ exchange rate","SVK","Slovak Republic","2020","2020",14.2,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","TCPPERMT","/capita, US$ exchange rate","SVK","Slovak Republic","2021","2021",14.8,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2010","2010",21.7,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2011","2011",22.3,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2012","2012",19.9,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2013","2013",18.6,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2014","2014",17.6,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2015","2015",16.5,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2016","2016",21.4,"B","Break"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2017","2017",20.9,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2018","2018",21.1,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2019","2019",22.6,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2020","2020",23.9,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2021","2021",23.5,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","ATCPTTMT","% of total sales","SVK","Slovak Republic","2010","2010",5.3,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","ATCPTTMT","% of total sales","SVK","Slovak Republic","2011","2011",5.4,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","ATCPTTMT","% of total sales","SVK","Slovak Republic","2012","2012",4.9,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","ATCPTTMT","% of total sales","SVK","Slovak Republic","2013","2013",4,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","ATCPTTMT","% of total sales","SVK","Slovak Republic","2014","2014",3.5,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","ATCPTTMT","% of total sales","SVK","Slovak Republic","2015","2015",3.2,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","ATCPTTMT","% of total sales","SVK","Slovak Republic","2016","2016",3.7,"B","Break"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","ATCPTTMT","% of total sales","SVK","Slovak Republic","2017","2017",3.8,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","ATCPTTMT","% of total sales","SVK","Slovak Republic","2018","2018",3.7,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","ATCPTTMT","% of total sales","SVK","Slovak Republic","2019","2019",3.7,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","ATCPTTMT","% of total sales","SVK","Slovak Republic","2020","2020",4.1,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","ATCPTTMT","% of total sales","SVK","Slovak Republic","2021","2021",3.8,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MLLNCUMT","Million of national currency units","ESP","Spain","2010","2010",1246.3,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MLLNCUMT","Million of national currency units","ESP","Spain","2011","2011",1137.3,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MLLNCUMT","Million of national currency units","ESP","Spain","2012","2012",963,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MLLNCUMT","Million of national currency units","ESP","Spain","2013","2013",923,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MLLNCUMT","Million of national currency units","ESP","Spain","2014","2014",894.6,"B; D","Break; Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MLLNCUMT","Million of national currency units","ESP","Spain","2015","2015",870.1,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MLLNCUMT","Million of national currency units","ESP","Spain","2016","2016",884,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MLLNCUMT","Million of national currency units","ESP","Spain","2017","2017",837.8,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MLLNCUMT","Million of national currency units","ESP","Spain","2018","2018",836.7,"B","Break"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MLLNCUMT","Million of national currency units","ESP","Spain","2019","2019",852.7,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MLLNCUMT","Million of national currency units","ESP","Spain","2020","2020",878.3,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MLLNCUMT","Million of national currency units","ESP","Spain","2021","2021",905.9,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MLLNCUMT","Million of national currency units","ESP","Spain","2022","2022",935.1,"P","Provisional value"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOTCMT","Million US$ at exchange rate","ESP","Spain","2010","2010",1652.2,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOTCMT","Million US$ at exchange rate","ESP","Spain","2011","2011",1583.1,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOTCMT","Million US$ at exchange rate","ESP","Spain","2012","2012",1237.2,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOTCMT","Million US$ at exchange rate","ESP","Spain","2013","2013",1225.8,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOTCMT","Million US$ at exchange rate","ESP","Spain","2014","2014",1188.4,"B; D","Break; Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOTCMT","Million US$ at exchange rate","ESP","Spain","2015","2015",965.3,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOTCMT","Million US$ at exchange rate","ESP","Spain","2016","2016",978.5,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOTCMT","Million US$ at exchange rate","ESP","Spain","2017","2017",946.4,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOTCMT","Million US$ at exchange rate","ESP","Spain","2018","2018",988.1,"B","Break"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOTCMT","Million US$ at exchange rate","ESP","Spain","2019","2019",954.6,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOTCMT","Million US$ at exchange rate","ESP","Spain","2020","2020",1003.1,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOTCMT","Million US$ at exchange rate","ESP","Spain","2021","2021",1071.5,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOTCMT","Million US$ at exchange rate","ESP","Spain","2022","2022",984.7,"P","Provisional value"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOPPMT","Million US$, purchasing power parity","ESP","Spain","2010","2010",1714.3,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOPPMT","Million US$, purchasing power parity","ESP","Spain","2011","2011",1592.6,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOPPMT","Million US$, purchasing power parity","ESP","Spain","2012","2012",1385.6,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOPPMT","Million US$, purchasing power parity","ESP","Spain","2013","2013",1367.8,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOPPMT","Million US$, purchasing power parity","ESP","Spain","2014","2014",1350.6,"B; D","Break; Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOPPMT","Million US$, purchasing power parity","ESP","Spain","2015","2015",1308.9,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOPPMT","Million US$, purchasing power parity","ESP","Spain","2016","2016",1375.6,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOPPMT","Million US$, purchasing power parity","ESP","Spain","2017","2017",1328,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOPPMT","Million US$, purchasing power parity","ESP","Spain","2018","2018",1324.3,"B","Break"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOPPMT","Million US$, purchasing power parity","ESP","Spain","2019","2019",1391.1,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOPPMT","Million US$, purchasing power parity","ESP","Spain","2020","2020",1413.5,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOPPMT","Million US$, purchasing power parity","ESP","Spain","2021","2021",1447.3,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOPPMT","Million US$, purchasing power parity","ESP","Spain","2022","2022",1568.4,"P","Provisional value"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","TCPPERMT","/capita, US$ exchange rate","ESP","Spain","2010","2010",35.5,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","TCPPERMT","/capita, US$ exchange rate","ESP","Spain","2011","2011",33.9,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","TCPPERMT","/capita, US$ exchange rate","ESP","Spain","2012","2012",26.5,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","TCPPERMT","/capita, US$ exchange rate","ESP","Spain","2013","2013",26.3,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","TCPPERMT","/capita, US$ exchange rate","ESP","Spain","2014","2014",25.6,"B; D","Break; Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","TCPPERMT","/capita, US$ exchange rate","ESP","Spain","2015","2015",20.8,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","TCPPERMT","/capita, US$ exchange rate","ESP","Spain","2016","2016",21.1,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","TCPPERMT","/capita, US$ exchange rate","ESP","Spain","2017","2017",20.3,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","TCPPERMT","/capita, US$ exchange rate","ESP","Spain","2018","2018",21.1,"B","Break"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","TCPPERMT","/capita, US$ exchange rate","ESP","Spain","2019","2019",20.3,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","TCPPERMT","/capita, US$ exchange rate","ESP","Spain","2020","2020",21.2,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","TCPPERMT","/capita, US$ exchange rate","ESP","Spain","2021","2021",22.6,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","TCPPERMT","/capita, US$ exchange rate","ESP","Spain","2022","2022",20.8,"P","Provisional value"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2010","2010",36.8,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2011","2011",34.1,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2012","2012",29.6,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2013","2013",29.3,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2014","2014",29.1,"B; D","Break; Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2015","2015",28.2,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2016","2016",29.6,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2017","2017",28.5,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2018","2018",28.3,"B","Break"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2019","2019",29.5,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2020","2020",29.8,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2021","2021",30.5,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2022","2022",33.1,"P","Provisional value"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","ATCPTTMT","% of total sales","ESP","Spain","2010","2010",9.4,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","ATCPTTMT","% of total sales","ESP","Spain","2011","2011",9.2,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","ATCPTTMT","% of total sales","ESP","Spain","2012","2012",8.7,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","ATCPTTMT","% of total sales","ESP","Spain","2013","2013",8.7,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","ATCPTTMT","% of total sales","ESP","Spain","2014","2014",7.9,"B; D","Break; Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","ATCPTTMT","% of total sales","ESP","Spain","2015","2015",7.6,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","ATCPTTMT","% of total sales","ESP","Spain","2016","2016",7.5,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","ATCPTTMT","% of total sales","ESP","Spain","2017","2017",6.9,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","ATCPTTMT","% of total sales","ESP","Spain","2018","2018",4.4,"B","Break"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","ATCPTTMT","% of total sales","ESP","Spain","2019","2019",4.3,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","ATCPTTMT","% of total sales","ESP","Spain","2020","2020",4.2,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","ATCPTTMT","% of total sales","ESP","Spain","2021","2021",4.1,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","ATCPTTMT","% of total sales","ESP","Spain","2022","2022",4.1,"P","Provisional value"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MLLNCUMT","Million of national currency units","SWE","Sweden","2010","2010",998.7,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MLLNCUMT","Million of national currency units","SWE","Sweden","2011","2011",885.6,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MLLNCUMT","Million of national currency units","SWE","Sweden","2012","2012",627.9,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MLLNCUMT","Million of national currency units","SWE","Sweden","2013","2013",457.3,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MLLNCUMT","Million of national currency units","SWE","Sweden","2014","2014",413.6,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MLLNCUMT","Million of national currency units","SWE","Sweden","2015","2015",422,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MLLNCUMT","Million of national currency units","SWE","Sweden","2016","2016",414,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MLLNCUMT","Million of national currency units","SWE","Sweden","2017","2017",440.6,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MLLNCUMT","Million of national currency units","SWE","Sweden","2018","2018",561.7,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MLLNCUMT","Million of national currency units","SWE","Sweden","2019","2019",707.5,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MLLNCUMT","Million of national currency units","SWE","Sweden","2020","2020",756.5,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MLLNCUMT","Million of national currency units","SWE","Sweden","2021","2021",716.1,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MLLNCUMT","Million of national currency units","SWE","Sweden","2022","2022",800.5,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOTCMT","Million US$ at exchange rate","SWE","Sweden","2010","2010",138.6,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOTCMT","Million US$ at exchange rate","SWE","Sweden","2011","2011",136.4,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOTCMT","Million US$ at exchange rate","SWE","Sweden","2012","2012",92.7,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOTCMT","Million US$ at exchange rate","SWE","Sweden","2013","2013",70.2,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOTCMT","Million US$ at exchange rate","SWE","Sweden","2014","2014",60.3,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOTCMT","Million US$ at exchange rate","SWE","Sweden","2015","2015",50,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOTCMT","Million US$ at exchange rate","SWE","Sweden","2016","2016",48.4,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOTCMT","Million US$ at exchange rate","SWE","Sweden","2017","2017",51.5,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOTCMT","Million US$ at exchange rate","SWE","Sweden","2018","2018",64.6,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOTCMT","Million US$ at exchange rate","SWE","Sweden","2019","2019",74.8,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOTCMT","Million US$ at exchange rate","SWE","Sweden","2020","2020",82.1,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOTCMT","Million US$ at exchange rate","SWE","Sweden","2021","2021",83.5,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOTCMT","Million US$ at exchange rate","SWE","Sweden","2022","2022",79.1,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOPPMT","Million US$, purchasing power parity","SWE","Sweden","2010","2010",110.7,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOPPMT","Million US$, purchasing power parity","SWE","Sweden","2011","2011",100.1,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOPPMT","Million US$, purchasing power parity","SWE","Sweden","2012","2012",72.5,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOPPMT","Million US$, purchasing power parity","SWE","Sweden","2013","2013",53.2,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOPPMT","Million US$, purchasing power parity","SWE","Sweden","2014","2014",47.4,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOPPMT","Million US$, purchasing power parity","SWE","Sweden","2015","2015",47.7,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOPPMT","Million US$, purchasing power parity","SWE","Sweden","2016","2016",46.9,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOPPMT","Million US$, purchasing power parity","SWE","Sweden","2017","2017",49.8,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOPPMT","Million US$, purchasing power parity","SWE","Sweden","2018","2018",63.4,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOPPMT","Million US$, purchasing power parity","SWE","Sweden","2019","2019",81.2,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOPPMT","Million US$, purchasing power parity","SWE","Sweden","2020","2020",87.3,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOPPMT","Million US$, purchasing power parity","SWE","Sweden","2021","2021",82.1,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOPPMT","Million US$, purchasing power parity","SWE","Sweden","2022","2022",92.4,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","TCPPERMT","/capita, US$ exchange rate","SWE","Sweden","2010","2010",14.8,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","TCPPERMT","/capita, US$ exchange rate","SWE","Sweden","2011","2011",14.4,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","TCPPERMT","/capita, US$ exchange rate","SWE","Sweden","2012","2012",9.7,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","TCPPERMT","/capita, US$ exchange rate","SWE","Sweden","2013","2013",7.3,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","TCPPERMT","/capita, US$ exchange rate","SWE","Sweden","2014","2014",6.2,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","TCPPERMT","/capita, US$ exchange rate","SWE","Sweden","2015","2015",5.1,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","TCPPERMT","/capita, US$ exchange rate","SWE","Sweden","2016","2016",4.9,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","TCPPERMT","/capita, US$ exchange rate","SWE","Sweden","2017","2017",5.1,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","TCPPERMT","/capita, US$ exchange rate","SWE","Sweden","2018","2018",6.4,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","TCPPERMT","/capita, US$ exchange rate","SWE","Sweden","2019","2019",7.3,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","TCPPERMT","/capita, US$ exchange rate","SWE","Sweden","2020","2020",7.9,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","TCPPERMT","/capita, US$ exchange rate","SWE","Sweden","2021","2021",8,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","TCPPERMT","/capita, US$ exchange rate","SWE","Sweden","2022","2022",7.6,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2010","2010",11.8,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2011","2011",10.6,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2012","2012",7.6,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2013","2013",5.5,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2014","2014",4.9,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2015","2015",4.9,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2016","2016",4.7,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2017","2017",4.9,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2018","2018",6.2,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2019","2019",7.9,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2020","2020",8.4,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2021","2021",7.9,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2022","2022",8.8,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","ATCPTTMT","% of total sales","SWE","Sweden","2010","2010",2.8,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","ATCPTTMT","% of total sales","SWE","Sweden","2011","2011",2.4,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","ATCPTTMT","% of total sales","SWE","Sweden","2012","2012",1.7,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","ATCPTTMT","% of total sales","SWE","Sweden","2013","2013",1.3,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","ATCPTTMT","% of total sales","SWE","Sweden","2014","2014",1.1,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","ATCPTTMT","% of total sales","SWE","Sweden","2015","2015",1,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","ATCPTTMT","% of total sales","SWE","Sweden","2016","2016",1,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","ATCPTTMT","% of total sales","SWE","Sweden","2017","2017",1,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","ATCPTTMT","% of total sales","SWE","Sweden","2018","2018",1.2,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","ATCPTTMT","% of total sales","SWE","Sweden","2019","2019",1.4,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","ATCPTTMT","% of total sales","SWE","Sweden","2020","2020",1.4,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","ATCPTTMT","% of total sales","SWE","Sweden","2021","2021",1.3,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","ATCPTTMT","% of total sales","SWE","Sweden","2022","2022",1.4,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MLLNCUMT","Million of national currency units","TUR","Türkiye","2010","2010",827.4,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MLLNCUMT","Million of national currency units","TUR","Türkiye","2011","2011",707.2,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MLLNCUMT","Million of national currency units","TUR","Türkiye","2012","2012",597.5,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MLLNCUMT","Million of national currency units","TUR","Türkiye","2013","2013",586.1,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MLLNCUMT","Million of national currency units","TUR","Türkiye","2014","2014",564.9,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MLLNCUMT","Million of national currency units","TUR","Türkiye","2015","2015",590.4,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MLLNCUMT","Million of national currency units","TUR","Türkiye","2016","2016",648.2,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MLLNCUMT","Million of national currency units","TUR","Türkiye","2017","2017",760.5,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MLLNCUMT","Million of national currency units","TUR","Türkiye","2018","2018",900.9,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MLLNCUMT","Million of national currency units","TUR","Türkiye","2019","2019",1189.4,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MLLNCUMT","Million of national currency units","TUR","Türkiye","2020","2020",1480.9,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MLLNCUMT","Million of national currency units","TUR","Türkiye","2021","2021",1722.1,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOTCMT","Million US$ at exchange rate","TUR","Türkiye","2010","2010",550.5,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOTCMT","Million US$ at exchange rate","TUR","Türkiye","2011","2011",422.2,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOTCMT","Million US$ at exchange rate","TUR","Türkiye","2012","2012",332.7,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOTCMT","Million US$ at exchange rate","TUR","Türkiye","2013","2013",307.9,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOTCMT","Million US$ at exchange rate","TUR","Türkiye","2014","2014",258.1,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOTCMT","Million US$ at exchange rate","TUR","Türkiye","2015","2015",217.1,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOTCMT","Million US$ at exchange rate","TUR","Türkiye","2016","2016",214.6,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOTCMT","Million US$ at exchange rate","TUR","Türkiye","2017","2017",208.5,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOTCMT","Million US$ at exchange rate","TUR","Türkiye","2018","2018",186.6,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOTCMT","Million US$ at exchange rate","TUR","Türkiye","2019","2019",209.6,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOTCMT","Million US$ at exchange rate","TUR","Türkiye","2020","2020",211.3,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOTCMT","Million US$ at exchange rate","TUR","Türkiye","2021","2021",194.6,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOPPMT","Million US$, purchasing power parity","TUR","Türkiye","2010","2010",899,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOPPMT","Million US$, purchasing power parity","TUR","Türkiye","2011","2011",732,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOPPMT","Million US$, purchasing power parity","TUR","Türkiye","2012","2012",585.9,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOPPMT","Million US$, purchasing power parity","TUR","Türkiye","2013","2013",547.6,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOPPMT","Million US$, purchasing power parity","TUR","Türkiye","2014","2014",511.5,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOPPMT","Million US$, purchasing power parity","TUR","Türkiye","2015","2015",507.9,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOPPMT","Million US$, purchasing power parity","TUR","Türkiye","2016","2016",522.3,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOPPMT","Million US$, purchasing power parity","TUR","Türkiye","2017","2017",549.5,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOPPMT","Million US$, purchasing power parity","TUR","Türkiye","2018","2018",551.8,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOPPMT","Million US$, purchasing power parity","TUR","Türkiye","2019","2019",638.1,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOPPMT","Million US$, purchasing power parity","TUR","Türkiye","2020","2020",684.3,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOPPMT","Million US$, purchasing power parity","TUR","Türkiye","2021","2021",613.3,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","TCPPERMT","/capita, US$ exchange rate","TUR","Türkiye","2010","2010",7.5,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","TCPPERMT","/capita, US$ exchange rate","TUR","Türkiye","2011","2011",5.7,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","TCPPERMT","/capita, US$ exchange rate","TUR","Türkiye","2012","2012",4.4,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","TCPPERMT","/capita, US$ exchange rate","TUR","Türkiye","2013","2013",4,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","TCPPERMT","/capita, US$ exchange rate","TUR","Türkiye","2014","2014",3.3,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","TCPPERMT","/capita, US$ exchange rate","TUR","Türkiye","2015","2015",2.8,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","TCPPERMT","/capita, US$ exchange rate","TUR","Türkiye","2016","2016",2.7,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","TCPPERMT","/capita, US$ exchange rate","TUR","Türkiye","2017","2017",2.6,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","TCPPERMT","/capita, US$ exchange rate","TUR","Türkiye","2018","2018",2.3,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","TCPPERMT","/capita, US$ exchange rate","TUR","Türkiye","2019","2019",2.5,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","TCPPERMT","/capita, US$ exchange rate","TUR","Türkiye","2020","2020",2.5,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","TCPPERMT","/capita, US$ exchange rate","TUR","Türkiye","2021","2021",2.3,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2010","2010",12.3,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2011","2011",9.9,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2012","2012",7.8,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2013","2013",7.2,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2014","2014",6.6,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2015","2015",6.5,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2016","2016",6.6,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2017","2017",6.8,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2018","2018",6.8,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2019","2019",7.7,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2020","2020",8.2,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2021","2021",7.3,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","ATCPTTMT","% of total sales","TUR","Türkiye","2010","2010",5.3,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","ATCPTTMT","% of total sales","TUR","Türkiye","2011","2011",5,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","ATCPTTMT","% of total sales","TUR","Türkiye","2012","2012",4.4,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","ATCPTTMT","% of total sales","TUR","Türkiye","2013","2013",4.1,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","ATCPTTMT","% of total sales","TUR","Türkiye","2014","2014",3.6,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","ATCPTTMT","% of total sales","TUR","Türkiye","2015","2015",3.2,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","ATCPTTMT","% of total sales","TUR","Türkiye","2016","2016",3,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","ATCPTTMT","% of total sales","TUR","Türkiye","2017","2017",3,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","ATCPTTMT","% of total sales","TUR","Türkiye","2018","2018",2.8,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","ATCPTTMT","% of total sales","TUR","Türkiye","2019","2019",2.8,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","ATCPTTMT","% of total sales","TUR","Türkiye","2020","2020",3,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","ATCPTTMT","% of total sales","TUR","Türkiye","2021","2021",2.7,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MLLNCUMT","Million of national currency units","CHL","Chile","2010","2010",28108.5,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MLLNCUMT","Million of national currency units","CHL","Chile","2011","2011",32614.1,"B","Break"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MLLNCUMT","Million of national currency units","CHL","Chile","2012","2012",35202.9,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MLLNCUMT","Million of national currency units","CHL","Chile","2013","2013",36639.5,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MLLNCUMT","Million of national currency units","CHL","Chile","2014","2014",44854.1,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MLLNCUMT","Million of national currency units","CHL","Chile","2015","2015",49040.7,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MLLNCUMT","Million of national currency units","CHL","Chile","2016","2016",54643.5,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MLLNCUMT","Million of national currency units","CHL","Chile","2017","2017",55530.1,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MLLNCUMT","Million of national currency units","CHL","Chile","2018","2018",56121.4,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MLLNCUMT","Million of national currency units","CHL","Chile","2019","2019",64723.2,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MLLNCUMT","Million of national currency units","CHL","Chile","2020","2020",83853.6,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MLLNCUMT","Million of national currency units","CHL","Chile","2021","2021",71737.4,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MLLNCUMT","Million of national currency units","CHL","Chile","2022","2022",90072.2,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOTCMT","Million US$ at exchange rate","CHL","Chile","2010","2010",55.1,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOTCMT","Million US$ at exchange rate","CHL","Chile","2011","2011",67.4,"B","Break"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOTCMT","Million US$ at exchange rate","CHL","Chile","2012","2012",72.4,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOTCMT","Million US$ at exchange rate","CHL","Chile","2013","2013",74,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOTCMT","Million US$ at exchange rate","CHL","Chile","2014","2014",78.6,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOTCMT","Million US$ at exchange rate","CHL","Chile","2015","2015",75,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOTCMT","Million US$ at exchange rate","CHL","Chile","2016","2016",80.7,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOTCMT","Million US$ at exchange rate","CHL","Chile","2017","2017",85.6,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOTCMT","Million US$ at exchange rate","CHL","Chile","2018","2018",87.5,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOTCMT","Million US$ at exchange rate","CHL","Chile","2019","2019",92.1,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOTCMT","Million US$ at exchange rate","CHL","Chile","2020","2020",105.8,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOTCMT","Million US$ at exchange rate","CHL","Chile","2021","2021",94.5,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOTCMT","Million US$ at exchange rate","CHL","Chile","2022","2022",103.1,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOPPMT","Million US$, purchasing power parity","CHL","Chile","2010","2010",78.1,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOPPMT","Million US$, purchasing power parity","CHL","Chile","2011","2011",93.7,"B","Break"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOPPMT","Million US$, purchasing power parity","CHL","Chile","2012","2012",101.4,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOPPMT","Million US$, purchasing power parity","CHL","Chile","2013","2013",104.8,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOPPMT","Million US$, purchasing power parity","CHL","Chile","2014","2014",122.1,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOPPMT","Million US$, purchasing power parity","CHL","Chile","2015","2015",125.4,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOPPMT","Million US$, purchasing power parity","CHL","Chile","2016","2016",137.6,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOPPMT","Million US$, purchasing power parity","CHL","Chile","2017","2017",139.6,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOPPMT","Million US$, purchasing power parity","CHL","Chile","2018","2018",141.6,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOPPMT","Million US$, purchasing power parity","CHL","Chile","2019","2019",161.2,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOPPMT","Million US$, purchasing power parity","CHL","Chile","2020","2020",200.4,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOPPMT","Million US$, purchasing power parity","CHL","Chile","2021","2021",164.9,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOPPMT","Million US$, purchasing power parity","CHL","Chile","2022","2022",205.9,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","TCPPERMT","/capita, US$ exchange rate","CHL","Chile","2010","2010",3.2,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","TCPPERMT","/capita, US$ exchange rate","CHL","Chile","2011","2011",3.9,"B","Break"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","TCPPERMT","/capita, US$ exchange rate","CHL","Chile","2012","2012",4.1,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","TCPPERMT","/capita, US$ exchange rate","CHL","Chile","2013","2013",4.2,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","TCPPERMT","/capita, US$ exchange rate","CHL","Chile","2014","2014",4.4,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","TCPPERMT","/capita, US$ exchange rate","CHL","Chile","2015","2015",4.2,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","TCPPERMT","/capita, US$ exchange rate","CHL","Chile","2016","2016",4.4,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","TCPPERMT","/capita, US$ exchange rate","CHL","Chile","2017","2017",4.6,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","TCPPERMT","/capita, US$ exchange rate","CHL","Chile","2018","2018",4.7,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","TCPPERMT","/capita, US$ exchange rate","CHL","Chile","2019","2019",4.8,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","TCPPERMT","/capita, US$ exchange rate","CHL","Chile","2020","2020",5.4,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","TCPPERMT","/capita, US$ exchange rate","CHL","Chile","2021","2021",4.8,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","TCPPERMT","/capita, US$ exchange rate","CHL","Chile","2022","2022",5.2,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2010","2010",4.6,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2011","2011",5.4,"B","Break"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2012","2012",5.8,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2013","2013",5.9,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2014","2014",6.9,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2015","2015",7,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2016","2016",7.6,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2017","2017",7.6,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2018","2018",7.6,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2019","2019",8.4,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2020","2020",10.3,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2021","2021",8.4,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2022","2022",10.4,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","ATCPTTMT","% of total sales","CHL","Chile","2010","2010",3.4,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","ATCPTTMT","% of total sales","CHL","Chile","2011","2011",2.8,"B","Break"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","ATCPTTMT","% of total sales","CHL","Chile","2012","2012",2.8,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","ATCPTTMT","% of total sales","CHL","Chile","2013","2013",2.5,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","ATCPTTMT","% of total sales","CHL","Chile","2014","2014",2.9,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","ATCPTTMT","% of total sales","CHL","Chile","2015","2015",2.7,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","ATCPTTMT","% of total sales","CHL","Chile","2016","2016",2.7,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","ATCPTTMT","% of total sales","CHL","Chile","2017","2017",2.7,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","ATCPTTMT","% of total sales","CHL","Chile","2018","2018",2.4,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","ATCPTTMT","% of total sales","CHL","Chile","2019","2019",2.6,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","ATCPTTMT","% of total sales","CHL","Chile","2020","2020",3.1,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","ATCPTTMT","% of total sales","CHL","Chile","2021","2021",2.5,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","ATCPTTMT","% of total sales","CHL","Chile","2022","2022",3.2,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MLLNCUMT","Million of national currency units","EST","Estonia","2010","2010",11.7,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MLLNCUMT","Million of national currency units","EST","Estonia","2011","2011",11.1,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MLLNCUMT","Million of national currency units","EST","Estonia","2012","2012",11.9,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MLLNCUMT","Million of national currency units","EST","Estonia","2013","2013",12.4,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MLLNCUMT","Million of national currency units","EST","Estonia","2014","2014",12.9,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MLLNCUMT","Million of national currency units","EST","Estonia","2015","2015",12.3,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MLLNCUMT","Million of national currency units","EST","Estonia","2016","2016",12.3,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MLLNCUMT","Million of national currency units","EST","Estonia","2017","2017",11.7,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MLLNCUMT","Million of national currency units","EST","Estonia","2018","2018",12.2,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MLLNCUMT","Million of national currency units","EST","Estonia","2019","2019",12.8,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MLLNCUMT","Million of national currency units","EST","Estonia","2020","2020",13.9,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MLLNCUMT","Million of national currency units","EST","Estonia","2021","2021",14,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MLLNCUMT","Million of national currency units","EST","Estonia","2022","2022",14.6,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOTCMT","Million US$ at exchange rate","EST","Estonia","2010","2010",15.5,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOTCMT","Million US$ at exchange rate","EST","Estonia","2011","2011",15.5,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOTCMT","Million US$ at exchange rate","EST","Estonia","2012","2012",15.2,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOTCMT","Million US$ at exchange rate","EST","Estonia","2013","2013",16.5,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOTCMT","Million US$ at exchange rate","EST","Estonia","2014","2014",17.1,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOTCMT","Million US$ at exchange rate","EST","Estonia","2015","2015",13.7,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOTCMT","Million US$ at exchange rate","EST","Estonia","2016","2016",13.6,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOTCMT","Million US$ at exchange rate","EST","Estonia","2017","2017",13.3,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOTCMT","Million US$ at exchange rate","EST","Estonia","2018","2018",14.4,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOTCMT","Million US$ at exchange rate","EST","Estonia","2019","2019",14.3,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOTCMT","Million US$ at exchange rate","EST","Estonia","2020","2020",15.9,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOTCMT","Million US$ at exchange rate","EST","Estonia","2021","2021",16.5,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOTCMT","Million US$ at exchange rate","EST","Estonia","2022","2022",15.4,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOPPMT","Million US$, purchasing power parity","EST","Estonia","2010","2010",22.8,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOPPMT","Million US$, purchasing power parity","EST","Estonia","2011","2011",21.7,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOPPMT","Million US$, purchasing power parity","EST","Estonia","2012","2012",22.8,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOPPMT","Million US$, purchasing power parity","EST","Estonia","2013","2013",23.8,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOPPMT","Million US$, purchasing power parity","EST","Estonia","2014","2014",24.4,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOPPMT","Million US$, purchasing power parity","EST","Estonia","2015","2015",23,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOPPMT","Million US$, purchasing power parity","EST","Estonia","2016","2016",23.2,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOPPMT","Million US$, purchasing power parity","EST","Estonia","2017","2017",21.9,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOPPMT","Million US$, purchasing power parity","EST","Estonia","2018","2018",22.6,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOPPMT","Million US$, purchasing power parity","EST","Estonia","2019","2019",23.9,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOPPMT","Million US$, purchasing power parity","EST","Estonia","2020","2020",26.5,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOPPMT","Million US$, purchasing power parity","EST","Estonia","2021","2021",25.7,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOPPMT","Million US$, purchasing power parity","EST","Estonia","2022","2022",25.6,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","TCPPERMT","/capita, US$ exchange rate","EST","Estonia","2010","2010",11.6,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","TCPPERMT","/capita, US$ exchange rate","EST","Estonia","2011","2011",11.7,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","TCPPERMT","/capita, US$ exchange rate","EST","Estonia","2012","2012",11.5,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","TCPPERMT","/capita, US$ exchange rate","EST","Estonia","2013","2013",12.5,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","TCPPERMT","/capita, US$ exchange rate","EST","Estonia","2014","2014",13,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","TCPPERMT","/capita, US$ exchange rate","EST","Estonia","2015","2015",10.4,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","TCPPERMT","/capita, US$ exchange rate","EST","Estonia","2016","2016",10.3,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","TCPPERMT","/capita, US$ exchange rate","EST","Estonia","2017","2017",10.1,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","TCPPERMT","/capita, US$ exchange rate","EST","Estonia","2018","2018",10.9,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","TCPPERMT","/capita, US$ exchange rate","EST","Estonia","2019","2019",10.8,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","TCPPERMT","/capita, US$ exchange rate","EST","Estonia","2020","2020",11.9,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","TCPPERMT","/capita, US$ exchange rate","EST","Estonia","2021","2021",12.4,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","TCPPERMT","/capita, US$ exchange rate","EST","Estonia","2022","2022",11.5,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2010","2010",17.1,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2011","2011",16.4,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2012","2012",17.2,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2013","2013",18.1,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2014","2014",18.6,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2015","2015",17.5,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2016","2016",17.7,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2017","2017",16.7,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2018","2018",17.1,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2019","2019",18,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2020","2020",19.9,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2021","2021",19.3,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2022","2022",19.2,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","ATCPTTMT","% of total sales","EST","Estonia","2010","2010",6,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","ATCPTTMT","% of total sales","EST","Estonia","2011","2011",5.4,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","ATCPTTMT","% of total sales","EST","Estonia","2012","2012",5.4,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","ATCPTTMT","% of total sales","EST","Estonia","2013","2013",5.4,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","ATCPTTMT","% of total sales","EST","Estonia","2014","2014",5.2,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","ATCPTTMT","% of total sales","EST","Estonia","2015","2015",4.7,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","ATCPTTMT","% of total sales","EST","Estonia","2016","2016",4.2,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","ATCPTTMT","% of total sales","EST","Estonia","2017","2017",3.9,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","ATCPTTMT","% of total sales","EST","Estonia","2018","2018",3.7,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","ATCPTTMT","% of total sales","EST","Estonia","2019","2019",3.7,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","ATCPTTMT","% of total sales","EST","Estonia","2020","2020",3.9,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","ATCPTTMT","% of total sales","EST","Estonia","2021","2021",3.4,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","ATCPTTMT","% of total sales","EST","Estonia","2022","2022",3.4,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MLLNCUMT","Million of national currency units","SVN","Slovenia","2010","2010",54.9,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MLLNCUMT","Million of national currency units","SVN","Slovenia","2011","2011",51.6,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MLLNCUMT","Million of national currency units","SVN","Slovenia","2012","2012",47,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MLLNCUMT","Million of national currency units","SVN","Slovenia","2013","2013",42.5,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MLLNCUMT","Million of national currency units","SVN","Slovenia","2014","2014",33.8,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MLLNCUMT","Million of national currency units","SVN","Slovenia","2015","2015",30,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MLLNCUMT","Million of national currency units","SVN","Slovenia","2016","2016",28.2,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MLLNCUMT","Million of national currency units","SVN","Slovenia","2017","2017",28.4,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MLLNCUMT","Million of national currency units","SVN","Slovenia","2018","2018",28.8,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MLLNCUMT","Million of national currency units","SVN","Slovenia","2019","2019",30,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MLLNCUMT","Million of national currency units","SVN","Slovenia","2020","2020",31.5,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MLLNCUMT","Million of national currency units","SVN","Slovenia","2021","2021",32.7,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MLLNCUMT","Million of national currency units","SVN","Slovenia","2022","2022",35.3,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOTCMT","Million US$ at exchange rate","SVN","Slovenia","2010","2010",72.8,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOTCMT","Million US$ at exchange rate","SVN","Slovenia","2011","2011",71.8,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOTCMT","Million US$ at exchange rate","SVN","Slovenia","2012","2012",60.3,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOTCMT","Million US$ at exchange rate","SVN","Slovenia","2013","2013",56.5,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOTCMT","Million US$ at exchange rate","SVN","Slovenia","2014","2014",44.9,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOTCMT","Million US$ at exchange rate","SVN","Slovenia","2015","2015",33.3,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOTCMT","Million US$ at exchange rate","SVN","Slovenia","2016","2016",31.2,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOTCMT","Million US$ at exchange rate","SVN","Slovenia","2017","2017",32.1,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOTCMT","Million US$ at exchange rate","SVN","Slovenia","2018","2018",34,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOTCMT","Million US$ at exchange rate","SVN","Slovenia","2019","2019",33.6,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOTCMT","Million US$ at exchange rate","SVN","Slovenia","2020","2020",35.9,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOTCMT","Million US$ at exchange rate","SVN","Slovenia","2021","2021",38.7,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOTCMT","Million US$ at exchange rate","SVN","Slovenia","2022","2022",37.2,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOPPMT","Million US$, purchasing power parity","SVN","Slovenia","2010","2010",86.1,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOPPMT","Million US$, purchasing power parity","SVN","Slovenia","2011","2011",82.6,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOPPMT","Million US$, purchasing power parity","SVN","Slovenia","2012","2012",77.4,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOPPMT","Million US$, purchasing power parity","SVN","Slovenia","2013","2013",72,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOPPMT","Million US$, purchasing power parity","SVN","Slovenia","2014","2014",57.1,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOPPMT","Million US$, purchasing power parity","SVN","Slovenia","2015","2015",50.4,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOPPMT","Million US$, purchasing power parity","SVN","Slovenia","2016","2016",48.8,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOPPMT","Million US$, purchasing power parity","SVN","Slovenia","2017","2017",49.8,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOPPMT","Million US$, purchasing power parity","SVN","Slovenia","2018","2018",50.7,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOPPMT","Million US$, purchasing power parity","SVN","Slovenia","2019","2019",54.4,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOPPMT","Million US$, purchasing power parity","SVN","Slovenia","2020","2020",57.5,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOPPMT","Million US$, purchasing power parity","SVN","Slovenia","2021","2021",58.1,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOPPMT","Million US$, purchasing power parity","SVN","Slovenia","2022","2022",64,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","TCPPERMT","/capita, US$ exchange rate","SVN","Slovenia","2010","2010",35.5,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","TCPPERMT","/capita, US$ exchange rate","SVN","Slovenia","2011","2011",35,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","TCPPERMT","/capita, US$ exchange rate","SVN","Slovenia","2012","2012",29.3,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","TCPPERMT","/capita, US$ exchange rate","SVN","Slovenia","2013","2013",27.4,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","TCPPERMT","/capita, US$ exchange rate","SVN","Slovenia","2014","2014",21.8,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","TCPPERMT","/capita, US$ exchange rate","SVN","Slovenia","2015","2015",16.1,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","TCPPERMT","/capita, US$ exchange rate","SVN","Slovenia","2016","2016",15.1,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","TCPPERMT","/capita, US$ exchange rate","SVN","Slovenia","2017","2017",15.5,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","TCPPERMT","/capita, US$ exchange rate","SVN","Slovenia","2018","2018",16.4,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","TCPPERMT","/capita, US$ exchange rate","SVN","Slovenia","2019","2019",16.1,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","TCPPERMT","/capita, US$ exchange rate","SVN","Slovenia","2020","2020",17.1,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","TCPPERMT","/capita, US$ exchange rate","SVN","Slovenia","2021","2021",18.4,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","TCPPERMT","/capita, US$ exchange rate","SVN","Slovenia","2022","2022",17.6,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2010","2010",42,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2011","2011",40.2,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2012","2012",37.6,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2013","2013",35,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2014","2014",27.7,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2015","2015",24.4,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2016","2016",23.6,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2017","2017",24.1,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2018","2018",24.4,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2019","2019",26,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2020","2020",27.4,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2021","2021",27.6,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2022","2022",30.4,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","ATCPTTMT","% of total sales","SVN","Slovenia","2010","2010",11.6,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","ATCPTTMT","% of total sales","SVN","Slovenia","2011","2011",11,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","ATCPTTMT","% of total sales","SVN","Slovenia","2012","2012",10.3,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","ATCPTTMT","% of total sales","SVN","Slovenia","2013","2013",9.4,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","ATCPTTMT","% of total sales","SVN","Slovenia","2014","2014",7.8,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","ATCPTTMT","% of total sales","SVN","Slovenia","2015","2015",6.7,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","ATCPTTMT","% of total sales","SVN","Slovenia","2016","2016",6,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","ATCPTTMT","% of total sales","SVN","Slovenia","2017","2017",5.9,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","ATCPTTMT","% of total sales","SVN","Slovenia","2018","2018",5.6,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","ATCPTTMT","% of total sales","SVN","Slovenia","2019","2019",5.5,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","ATCPTTMT","% of total sales","SVN","Slovenia","2020","2020",5.5,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","ATCPTTMT","% of total sales","SVN","Slovenia","2021","2021",5.3,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","ATCPTTMT","% of total sales","SVN","Slovenia","2022","2022",5.2,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","MLLNCUMT","Million of national currency units","AUS","Australia","2010","2010",1680,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","MLLNCUMT","Million of national currency units","AUS","Australia","2011","2011",1756,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","MLLNCUMT","Million of national currency units","AUS","Australia","2012","2012",1538,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","MLLNCUMT","Million of national currency units","AUS","Australia","2013","2013",1288,"B; D","Break; Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","MLLNCUMT","Million of national currency units","AUS","Australia","2014","2014",1028,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","MLLNCUMT","Million of national currency units","AUS","Australia","2015","2015",820,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","MLLNCUMT","Million of national currency units","AUS","Australia","2016","2016",709,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","MLLNCUMT","Million of national currency units","AUS","Australia","2017","2017",674,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","MLLNCUMT","Million of national currency units","AUS","Australia","2018","2018",657,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","MLLNCUMT","Million of national currency units","AUS","Australia","2019","2019",639,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","MLLNCUMT","Million of national currency units","AUS","Australia","2020","2020",642,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","MLLNCUMT","Million of national currency units","AUS","Australia","2021","2021",646,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","MTMOTCMT","Million US$ at exchange rate","AUS","Australia","2010","2010",1541.1,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","MTMOTCMT","Million US$ at exchange rate","AUS","Australia","2011","2011",1811.3,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","MTMOTCMT","Million US$ at exchange rate","AUS","Australia","2012","2012",1592.5,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","MTMOTCMT","Million US$ at exchange rate","AUS","Australia","2013","2013",1243.4,"B; D","Break; Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","MTMOTCMT","Million US$ at exchange rate","AUS","Australia","2014","2014",926.7,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","MTMOTCMT","Million US$ at exchange rate","AUS","Australia","2015","2015",616,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","MTMOTCMT","Million US$ at exchange rate","AUS","Australia","2016","2016",527.1,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","MTMOTCMT","Million US$ at exchange rate","AUS","Australia","2017","2017",516.6,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","MTMOTCMT","Million US$ at exchange rate","AUS","Australia","2018","2018",490.9,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","MTMOTCMT","Million US$ at exchange rate","AUS","Australia","2019","2019",444.2,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","MTMOTCMT","Million US$ at exchange rate","AUS","Australia","2020","2020",441.8,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","MTMOTCMT","Million US$ at exchange rate","AUS","Australia","2021","2021",485.3,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","MTMOPPMT","Million US$, purchasing power parity","AUS","Australia","2010","2010",1117.3,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","MTMOPPMT","Million US$, purchasing power parity","AUS","Australia","2011","2011",1162.1,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","MTMOPPMT","Million US$, purchasing power parity","AUS","Australia","2012","2012",998.6,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","MTMOPPMT","Million US$, purchasing power parity","AUS","Australia","2013","2013",890,"B; D","Break; Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","MTMOPPMT","Million US$, purchasing power parity","AUS","Australia","2014","2014",707.8,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","MTMOPPMT","Million US$, purchasing power parity","AUS","Australia","2015","2015",556.4,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","MTMOPPMT","Million US$, purchasing power parity","AUS","Australia","2016","2016",488.9,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","MTMOPPMT","Million US$, purchasing power parity","AUS","Australia","2017","2017",456.2,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","MTMOPPMT","Million US$, purchasing power parity","AUS","Australia","2018","2018",446.8,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","MTMOPPMT","Million US$, purchasing power parity","AUS","Australia","2019","2019",431.8,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","MTMOPPMT","Million US$, purchasing power parity","AUS","Australia","2020","2020",441.6,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","MTMOPPMT","Million US$, purchasing power parity","AUS","Australia","2021","2021",446.3,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","TCPPERMT","/capita, US$ exchange rate","AUS","Australia","2010","2010",69.9,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","TCPPERMT","/capita, US$ exchange rate","AUS","Australia","2011","2011",81.1,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","TCPPERMT","/capita, US$ exchange rate","AUS","Australia","2012","2012",70,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","TCPPERMT","/capita, US$ exchange rate","AUS","Australia","2013","2013",53.8,"B; D","Break; Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","TCPPERMT","/capita, US$ exchange rate","AUS","Australia","2014","2014",39.5,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","TCPPERMT","/capita, US$ exchange rate","AUS","Australia","2015","2015",25.9,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","TCPPERMT","/capita, US$ exchange rate","AUS","Australia","2016","2016",21.8,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","TCPPERMT","/capita, US$ exchange rate","AUS","Australia","2017","2017",21,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","TCPPERMT","/capita, US$ exchange rate","AUS","Australia","2018","2018",19.7,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","TCPPERMT","/capita, US$ exchange rate","AUS","Australia","2019","2019",17.5,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","TCPPERMT","/capita, US$ exchange rate","AUS","Australia","2020","2020",17.2,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","TCPPERMT","/capita, US$ exchange rate","AUS","Australia","2021","2021",18.9,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2010","2010",50.7,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2011","2011",52,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2012","2012",43.9,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2013","2013",38.5,"B; D","Break; Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2014","2014",30.1,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2015","2015",23.4,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2016","2016",20.2,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2017","2017",18.5,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2018","2018",17.9,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2019","2019",17,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2020","2020",17.2,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2021","2021",17.4,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","ATCPTTMT","% of total sales","AUS","Australia","2010","2010",17.2,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","ATCPTTMT","% of total sales","AUS","Australia","2011","2011",17.1,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","ATCPTTMT","% of total sales","AUS","Australia","2012","2012",14.9,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","ATCPTTMT","% of total sales","AUS","Australia","2013","2013",10.9,"B; D","Break; Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","ATCPTTMT","% of total sales","AUS","Australia","2014","2014",8.6,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","ATCPTTMT","% of total sales","AUS","Australia","2015","2015",6.7,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","ATCPTTMT","% of total sales","AUS","Australia","2016","2016",4.6,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","ATCPTTMT","% of total sales","AUS","Australia","2017","2017",4.6,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","ATCPTTMT","% of total sales","AUS","Australia","2018","2018",4.4,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","ATCPTTMT","% of total sales","AUS","Australia","2019","2019",4.1,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","ATCPTTMT","% of total sales","AUS","Australia","2020","2020",3.9,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","ATCPTTMT","% of total sales","AUS","Australia","2021","2021",3.7,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","MLLNCUMT","Million of national currency units","AUT","Austria","2010","2010",96.4,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","MLLNCUMT","Million of national currency units","AUT","Austria","2011","2011",102.6,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","MLLNCUMT","Million of national currency units","AUT","Austria","2012","2012",102.1,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","MLLNCUMT","Million of national currency units","AUT","Austria","2013","2013",90,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","MLLNCUMT","Million of national currency units","AUT","Austria","2014","2014",91.8,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","MLLNCUMT","Million of national currency units","AUT","Austria","2015","2015",94.9,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","MLLNCUMT","Million of national currency units","AUT","Austria","2016","2016",102.2,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","MLLNCUMT","Million of national currency units","AUT","Austria","2017","2017",110.6,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","MLLNCUMT","Million of national currency units","AUT","Austria","2018","2018",108.8,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","MLLNCUMT","Million of national currency units","AUT","Austria","2019","2019",101.2,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","MLLNCUMT","Million of national currency units","AUT","Austria","2020","2020",97.6,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","MLLNCUMT","Million of national currency units","AUT","Austria","2021","2021",102.1,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","MTMOTCMT","Million US$ at exchange rate","AUT","Austria","2010","2010",127.8,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","MTMOTCMT","Million US$ at exchange rate","AUT","Austria","2011","2011",142.8,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","MTMOTCMT","Million US$ at exchange rate","AUT","Austria","2012","2012",131.1,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","MTMOTCMT","Million US$ at exchange rate","AUT","Austria","2013","2013",119.6,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","MTMOTCMT","Million US$ at exchange rate","AUT","Austria","2014","2014",122,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","MTMOTCMT","Million US$ at exchange rate","AUT","Austria","2015","2015",105.3,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","MTMOTCMT","Million US$ at exchange rate","AUT","Austria","2016","2016",113.1,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","MTMOTCMT","Million US$ at exchange rate","AUT","Austria","2017","2017",125,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","MTMOTCMT","Million US$ at exchange rate","AUT","Austria","2018","2018",128.5,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","MTMOTCMT","Million US$ at exchange rate","AUT","Austria","2019","2019",113.2,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","MTMOTCMT","Million US$ at exchange rate","AUT","Austria","2020","2020",111.5,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","MTMOTCMT","Million US$ at exchange rate","AUT","Austria","2021","2021",120.7,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","MTMOPPMT","Million US$, purchasing power parity","AUT","Austria","2010","2010",114.5,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","MTMOPPMT","Million US$, purchasing power parity","AUT","Austria","2011","2011",123.4,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","MTMOPPMT","Million US$, purchasing power parity","AUT","Austria","2012","2012",125.4,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","MTMOPPMT","Million US$, purchasing power parity","AUT","Austria","2013","2013",113,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","MTMOPPMT","Million US$, purchasing power parity","AUT","Austria","2014","2014",115,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","MTMOPPMT","Million US$, purchasing power parity","AUT","Austria","2015","2015",118.8,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","MTMOPPMT","Million US$, purchasing power parity","AUT","Austria","2016","2016",131.5,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","MTMOPPMT","Million US$, purchasing power parity","AUT","Austria","2017","2017",142.8,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","MTMOPPMT","Million US$, purchasing power parity","AUT","Austria","2018","2018",142.2,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","MTMOPPMT","Million US$, purchasing power parity","AUT","Austria","2019","2019",135,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","MTMOPPMT","Million US$, purchasing power parity","AUT","Austria","2020","2020",130.8,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","MTMOPPMT","Million US$, purchasing power parity","AUT","Austria","2021","2021",135,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","TCPPERMT","/capita, US$ exchange rate","AUT","Austria","2010","2010",15.3,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","TCPPERMT","/capita, US$ exchange rate","AUT","Austria","2011","2011",17,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","TCPPERMT","/capita, US$ exchange rate","AUT","Austria","2012","2012",15.6,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","TCPPERMT","/capita, US$ exchange rate","AUT","Austria","2013","2013",14.1,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","TCPPERMT","/capita, US$ exchange rate","AUT","Austria","2014","2014",14.3,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","TCPPERMT","/capita, US$ exchange rate","AUT","Austria","2015","2015",12.2,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","TCPPERMT","/capita, US$ exchange rate","AUT","Austria","2016","2016",12.9,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","TCPPERMT","/capita, US$ exchange rate","AUT","Austria","2017","2017",14.2,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","TCPPERMT","/capita, US$ exchange rate","AUT","Austria","2018","2018",14.5,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","TCPPERMT","/capita, US$ exchange rate","AUT","Austria","2019","2019",12.8,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","TCPPERMT","/capita, US$ exchange rate","AUT","Austria","2020","2020",12.5,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","TCPPERMT","/capita, US$ exchange rate","AUT","Austria","2021","2021",13.5,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2010","2010",13.7,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2011","2011",14.7,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2012","2012",14.9,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2013","2013",13.3,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2014","2014",13.5,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2015","2015",13.8,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2016","2016",15.1,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2017","2017",16.2,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2018","2018",16.1,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2019","2019",15.2,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2020","2020",14.7,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2021","2021",15.1,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","ATCPTTMT","% of total sales","AUT","Austria","2010","2010",3.9,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","ATCPTTMT","% of total sales","AUT","Austria","2011","2011",4,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","ATCPTTMT","% of total sales","AUT","Austria","2012","2012",3.9,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","ATCPTTMT","% of total sales","AUT","Austria","2013","2013",3.4,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","ATCPTTMT","% of total sales","AUT","Austria","2014","2014",3.3,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","ATCPTTMT","% of total sales","AUT","Austria","2015","2015",3.2,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","ATCPTTMT","% of total sales","AUT","Austria","2016","2016",3.4,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","ATCPTTMT","% of total sales","AUT","Austria","2017","2017",3.5,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","ATCPTTMT","% of total sales","AUT","Austria","2018","2018",3.4,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","ATCPTTMT","% of total sales","AUT","Austria","2019","2019",3.1,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","ATCPTTMT","% of total sales","AUT","Austria","2020","2020",2.8,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","ATCPTTMT","% of total sales","AUT","Austria","2021","2021",2.7,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","MLLNCUMT","Million of national currency units","BEL","Belgium","2010","2010",313.8,,
+"PATCCHLS","C10-Lipid modifying agents","MLLNCUMT","Million of national currency units","BEL","Belgium","2011","2011",328,,
+"PATCCHLS","C10-Lipid modifying agents","MLLNCUMT","Million of national currency units","BEL","Belgium","2012","2012",295.7,,
+"PATCCHLS","C10-Lipid modifying agents","MLLNCUMT","Million of national currency units","BEL","Belgium","2013","2013",253.9,,
+"PATCCHLS","C10-Lipid modifying agents","MLLNCUMT","Million of national currency units","BEL","Belgium","2014","2014",226.3,,
+"PATCCHLS","C10-Lipid modifying agents","MLLNCUMT","Million of national currency units","BEL","Belgium","2015","2015",219.7,,
+"PATCCHLS","C10-Lipid modifying agents","MLLNCUMT","Million of national currency units","BEL","Belgium","2016","2016",218.1,,
+"PATCCHLS","C10-Lipid modifying agents","MLLNCUMT","Million of national currency units","BEL","Belgium","2017","2017",212.7,,
+"PATCCHLS","C10-Lipid modifying agents","MLLNCUMT","Million of national currency units","BEL","Belgium","2018","2018",167.3,,
+"PATCCHLS","C10-Lipid modifying agents","MLLNCUMT","Million of national currency units","BEL","Belgium","2019","2019",156.7,,
+"PATCCHLS","C10-Lipid modifying agents","MLLNCUMT","Million of national currency units","BEL","Belgium","2020","2020",152.7,,
+"PATCCHLS","C10-Lipid modifying agents","MLLNCUMT","Million of national currency units","BEL","Belgium","2021","2021",154.7,,
+"PATCCHLS","C10-Lipid modifying agents","MLLNCUMT","Million of national currency units","BEL","Belgium","2022","2022",176.6,"E","Estimated value"
+"PATCCHLS","C10-Lipid modifying agents","MTMOTCMT","Million US$ at exchange rate","BEL","Belgium","2010","2010",416.1,,
+"PATCCHLS","C10-Lipid modifying agents","MTMOTCMT","Million US$ at exchange rate","BEL","Belgium","2011","2011",456.5,,
+"PATCCHLS","C10-Lipid modifying agents","MTMOTCMT","Million US$ at exchange rate","BEL","Belgium","2012","2012",379.9,,
+"PATCCHLS","C10-Lipid modifying agents","MTMOTCMT","Million US$ at exchange rate","BEL","Belgium","2013","2013",337.2,,
+"PATCCHLS","C10-Lipid modifying agents","MTMOTCMT","Million US$ at exchange rate","BEL","Belgium","2014","2014",300.6,,
+"PATCCHLS","C10-Lipid modifying agents","MTMOTCMT","Million US$ at exchange rate","BEL","Belgium","2015","2015",243.8,,
+"PATCCHLS","C10-Lipid modifying agents","MTMOTCMT","Million US$ at exchange rate","BEL","Belgium","2016","2016",241.4,,
+"PATCCHLS","C10-Lipid modifying agents","MTMOTCMT","Million US$ at exchange rate","BEL","Belgium","2017","2017",240.3,,
+"PATCCHLS","C10-Lipid modifying agents","MTMOTCMT","Million US$ at exchange rate","BEL","Belgium","2018","2018",197.5,,
+"PATCCHLS","C10-Lipid modifying agents","MTMOTCMT","Million US$ at exchange rate","BEL","Belgium","2019","2019",175.4,,
+"PATCCHLS","C10-Lipid modifying agents","MTMOTCMT","Million US$ at exchange rate","BEL","Belgium","2020","2020",174.4,,
+"PATCCHLS","C10-Lipid modifying agents","MTMOTCMT","Million US$ at exchange rate","BEL","Belgium","2021","2021",183,,
+"PATCCHLS","C10-Lipid modifying agents","MTMOTCMT","Million US$ at exchange rate","BEL","Belgium","2022","2022",186,"E","Estimated value"
+"PATCCHLS","C10-Lipid modifying agents","MTMOPPMT","Million US$, purchasing power parity","BEL","Belgium","2010","2010",375.1,,
+"PATCCHLS","C10-Lipid modifying agents","MTMOPPMT","Million US$, purchasing power parity","BEL","Belgium","2011","2011",394.3,,
+"PATCCHLS","C10-Lipid modifying agents","MTMOPPMT","Million US$, purchasing power parity","BEL","Belgium","2012","2012",359.7,,
+"PATCCHLS","C10-Lipid modifying agents","MTMOPPMT","Million US$, purchasing power parity","BEL","Belgium","2013","2013",314.9,,
+"PATCCHLS","C10-Lipid modifying agents","MTMOPPMT","Million US$, purchasing power parity","BEL","Belgium","2014","2014",282.8,,
+"PATCCHLS","C10-Lipid modifying agents","MTMOPPMT","Million US$, purchasing power parity","BEL","Belgium","2015","2015",274.7,,
+"PATCCHLS","C10-Lipid modifying agents","MTMOPPMT","Million US$, purchasing power parity","BEL","Belgium","2016","2016",279.3,,
+"PATCCHLS","C10-Lipid modifying agents","MTMOPPMT","Million US$, purchasing power parity","BEL","Belgium","2017","2017",274.2,,
+"PATCCHLS","C10-Lipid modifying agents","MTMOPPMT","Million US$, purchasing power parity","BEL","Belgium","2018","2018",218.3,,
+"PATCCHLS","C10-Lipid modifying agents","MTMOPPMT","Million US$, purchasing power parity","BEL","Belgium","2019","2019",209.9,,
+"PATCCHLS","C10-Lipid modifying agents","MTMOPPMT","Million US$, purchasing power parity","BEL","Belgium","2020","2020",209.1,,
+"PATCCHLS","C10-Lipid modifying agents","MTMOPPMT","Million US$, purchasing power parity","BEL","Belgium","2021","2021",210.1,,
+"PATCCHLS","C10-Lipid modifying agents","MTMOPPMT","Million US$, purchasing power parity","BEL","Belgium","2022","2022",247.4,"E","Estimated value"
+"PATCCHLS","C10-Lipid modifying agents","TCPPERMT","/capita, US$ exchange rate","BEL","Belgium","2010","2010",38.2,,
+"PATCCHLS","C10-Lipid modifying agents","TCPPERMT","/capita, US$ exchange rate","BEL","Belgium","2011","2011",41.4,,
+"PATCCHLS","C10-Lipid modifying agents","TCPPERMT","/capita, US$ exchange rate","BEL","Belgium","2012","2012",34.2,,
+"PATCCHLS","C10-Lipid modifying agents","TCPPERMT","/capita, US$ exchange rate","BEL","Belgium","2013","2013",30.2,,
+"PATCCHLS","C10-Lipid modifying agents","TCPPERMT","/capita, US$ exchange rate","BEL","Belgium","2014","2014",26.8,,
+"PATCCHLS","C10-Lipid modifying agents","TCPPERMT","/capita, US$ exchange rate","BEL","Belgium","2015","2015",21.6,,
+"PATCCHLS","C10-Lipid modifying agents","TCPPERMT","/capita, US$ exchange rate","BEL","Belgium","2016","2016",21.3,,
+"PATCCHLS","C10-Lipid modifying agents","TCPPERMT","/capita, US$ exchange rate","BEL","Belgium","2017","2017",21.1,,
+"PATCCHLS","C10-Lipid modifying agents","TCPPERMT","/capita, US$ exchange rate","BEL","Belgium","2018","2018",17.3,,
+"PATCCHLS","C10-Lipid modifying agents","TCPPERMT","/capita, US$ exchange rate","BEL","Belgium","2019","2019",15.3,,
+"PATCCHLS","C10-Lipid modifying agents","TCPPERMT","/capita, US$ exchange rate","BEL","Belgium","2020","2020",15.1,,
+"PATCCHLS","C10-Lipid modifying agents","TCPPERMT","/capita, US$ exchange rate","BEL","Belgium","2021","2021",15.8,,
+"PATCCHLS","C10-Lipid modifying agents","TCPPERMT","/capita, US$ exchange rate","BEL","Belgium","2022","2022",16,"E","Estimated value"
+"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2010","2010",34.4,,
+"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2011","2011",35.7,,
+"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2012","2012",32.4,,
+"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2013","2013",28.2,,
+"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2014","2014",25.2,,
+"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2015","2015",24.4,,
+"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2016","2016",24.6,,
+"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2017","2017",24.1,,
+"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2018","2018",19.1,,
+"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2019","2019",18.3,,
+"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2020","2020",18.1,,
+"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2021","2021",18.1,,
+"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2022","2022",21.3,"E","Estimated value"
+"PATCCHLS","C10-Lipid modifying agents","ATCPTTMT","% of total sales","BEL","Belgium","2010","2010",5.3,,
+"PATCCHLS","C10-Lipid modifying agents","ATCPTTMT","% of total sales","BEL","Belgium","2011","2011",5.5,,
+"PATCCHLS","C10-Lipid modifying agents","ATCPTTMT","% of total sales","BEL","Belgium","2012","2012",5,,
+"PATCCHLS","C10-Lipid modifying agents","ATCPTTMT","% of total sales","BEL","Belgium","2013","2013",4.3,,
+"PATCCHLS","C10-Lipid modifying agents","ATCPTTMT","% of total sales","BEL","Belgium","2014","2014",3.8,,
+"PATCCHLS","C10-Lipid modifying agents","ATCPTTMT","% of total sales","BEL","Belgium","2015","2015",3.5,,
+"PATCCHLS","C10-Lipid modifying agents","ATCPTTMT","% of total sales","BEL","Belgium","2016","2016",3.5,,
+"PATCCHLS","C10-Lipid modifying agents","ATCPTTMT","% of total sales","BEL","Belgium","2017","2017",3.3,,
+"PATCCHLS","C10-Lipid modifying agents","ATCPTTMT","% of total sales","BEL","Belgium","2018","2018",2.5,,
+"PATCCHLS","C10-Lipid modifying agents","ATCPTTMT","% of total sales","BEL","Belgium","2019","2019",2.1,,
+"PATCCHLS","C10-Lipid modifying agents","ATCPTTMT","% of total sales","BEL","Belgium","2020","2020",2,,
+"PATCCHLS","C10-Lipid modifying agents","ATCPTTMT","% of total sales","BEL","Belgium","2021","2021",1.9,,
+"PATCCHLS","C10-Lipid modifying agents","ATCPTTMT","% of total sales","BEL","Belgium","2022","2022",2,"E","Estimated value"
+"PATCCHLS","C10-Lipid modifying agents","MLLNCUMT","Million of national currency units","CAN","Canada","2012","2012",1823.4,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","MLLNCUMT","Million of national currency units","CAN","Canada","2013","2013",1484.4,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","MLLNCUMT","Million of national currency units","CAN","Canada","2014","2014",1370.1,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","MLLNCUMT","Million of national currency units","CAN","Canada","2015","2015",1237.3,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","MLLNCUMT","Million of national currency units","CAN","Canada","2016","2016",1239.2,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","MLLNCUMT","Million of national currency units","CAN","Canada","2017","2017",1229.5,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","MLLNCUMT","Million of national currency units","CAN","Canada","2018","2018",978.8,"E; B; D","Estimated value; Break; Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","MLLNCUMT","Million of national currency units","CAN","Canada","2019","2019",912.4,"E; D","Estimated value; Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","MLLNCUMT","Million of national currency units","CAN","Canada","2020","2020",958.7,"E; D","Estimated value; Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","MLLNCUMT","Million of national currency units","CAN","Canada","2021","2021",1014.6,"E; D","Estimated value; Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","MLLNCUMT","Million of national currency units","CAN","Canada","2022","2022",1085.5,"E; D","Estimated value; Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","MTMOTCMT","Million US$ at exchange rate","CAN","Canada","2012","2012",1824.6,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","MTMOTCMT","Million US$ at exchange rate","CAN","Canada","2013","2013",1441,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","MTMOTCMT","Million US$ at exchange rate","CAN","Canada","2014","2014",1240.2,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","MTMOTCMT","Million US$ at exchange rate","CAN","Canada","2015","2015",967.6,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","MTMOTCMT","Million US$ at exchange rate","CAN","Canada","2016","2016",934.8,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","MTMOTCMT","Million US$ at exchange rate","CAN","Canada","2017","2017",947.3,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","MTMOTCMT","Million US$ at exchange rate","CAN","Canada","2018","2018",755.4,"E; B; D","Estimated value; Break; Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","MTMOTCMT","Million US$ at exchange rate","CAN","Canada","2019","2019",687.6,"E; D","Estimated value; Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","MTMOTCMT","Million US$ at exchange rate","CAN","Canada","2020","2020",714.8,"E; D","Estimated value; Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","MTMOTCMT","Million US$ at exchange rate","CAN","Canada","2021","2021",809.1,"E; D","Estimated value; Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","MTMOTCMT","Million US$ at exchange rate","CAN","Canada","2022","2022",834,"E; D","Estimated value; Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","MTMOPPMT","Million US$, purchasing power parity","CAN","Canada","2012","2012",1465,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","MTMOPPMT","Million US$, purchasing power parity","CAN","Canada","2013","2013",1212.7,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","MTMOPPMT","Million US$, purchasing power parity","CAN","Canada","2014","2014",1113.6,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","MTMOPPMT","Million US$, purchasing power parity","CAN","Canada","2015","2015",991.4,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","MTMOPPMT","Million US$, purchasing power parity","CAN","Canada","2016","2016",1026.6,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","MTMOPPMT","Million US$, purchasing power parity","CAN","Canada","2017","2017",1014.2,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","MTMOPPMT","Million US$, purchasing power parity","CAN","Canada","2018","2018",811.3,"E; B; D","Estimated value; Break; Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","MTMOPPMT","Million US$, purchasing power parity","CAN","Canada","2019","2019",738.9,"E; D","Estimated value; Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","MTMOPPMT","Million US$, purchasing power parity","CAN","Canada","2020","2020",778.8,"E; D","Estimated value; Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","MTMOPPMT","Million US$, purchasing power parity","CAN","Canada","2021","2021",819.4,"E; D","Estimated value; Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","MTMOPPMT","Million US$, purchasing power parity","CAN","Canada","2022","2022",865.8,"E; D","Estimated value; Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","TCPPERMT","/capita, US$ exchange rate","CAN","Canada","2012","2012",52.6,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","TCPPERMT","/capita, US$ exchange rate","CAN","Canada","2013","2013",41.1,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","TCPPERMT","/capita, US$ exchange rate","CAN","Canada","2014","2014",35,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","TCPPERMT","/capita, US$ exchange rate","CAN","Canada","2015","2015",27.1,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","TCPPERMT","/capita, US$ exchange rate","CAN","Canada","2016","2016",25.9,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","TCPPERMT","/capita, US$ exchange rate","CAN","Canada","2017","2017",25.9,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","TCPPERMT","/capita, US$ exchange rate","CAN","Canada","2018","2018",20.4,"E; B; D","Estimated value; Break; Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","TCPPERMT","/capita, US$ exchange rate","CAN","Canada","2019","2019",18.3,"E; D","Estimated value; Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","TCPPERMT","/capita, US$ exchange rate","CAN","Canada","2020","2020",18.8,"E; D","Estimated value; Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","TCPPERMT","/capita, US$ exchange rate","CAN","Canada","2021","2021",21.2,"E; D","Estimated value; Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","TCPPERMT","/capita, US$ exchange rate","CAN","Canada","2022","2022",21.5,"E; D","Estimated value; Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2012","2012",42.2,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2013","2013",34.6,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2014","2014",31.4,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2015","2015",27.8,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2016","2016",28.4,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2017","2017",27.8,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2018","2018",21.9,"E; B; D","Estimated value; Break; Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2019","2019",19.7,"E; D","Estimated value; Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2020","2020",20.5,"E; D","Estimated value; Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2021","2021",21.4,"E; D","Estimated value; Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2022","2022",22.3,"E; D","Estimated value; Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","ATCPTTMT","% of total sales","CAN","Canada","2012","2012",7.5,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","ATCPTTMT","% of total sales","CAN","Canada","2013","2013",6,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","ATCPTTMT","% of total sales","CAN","Canada","2014","2014",5.4,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","ATCPTTMT","% of total sales","CAN","Canada","2015","2015",4.6,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","ATCPTTMT","% of total sales","CAN","Canada","2016","2016",4.4,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","ATCPTTMT","% of total sales","CAN","Canada","2017","2017",4.1,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","ATCPTTMT","% of total sales","CAN","Canada","2018","2018",3.2,"E; B; D","Estimated value; Break; Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","ATCPTTMT","% of total sales","CAN","Canada","2019","2019",2.9,"E; D","Estimated value; Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","ATCPTTMT","% of total sales","CAN","Canada","2020","2020",2.8,"E; D","Estimated value; Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","ATCPTTMT","% of total sales","CAN","Canada","2021","2021",2.8,"E; D","Estimated value; Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","ATCPTTMT","% of total sales","CAN","Canada","2022","2022",2.7,"E; D","Estimated value; Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","MLLNCUMT","Million of national currency units","CZE","Czech Republic","2010","2010",2875.5,,
+"PATCCHLS","C10-Lipid modifying agents","MLLNCUMT","Million of national currency units","CZE","Czech Republic","2011","2011",2950.4,,
+"PATCCHLS","C10-Lipid modifying agents","MLLNCUMT","Million of national currency units","CZE","Czech Republic","2012","2012",3248.7,,
+"PATCCHLS","C10-Lipid modifying agents","MLLNCUMT","Million of national currency units","CZE","Czech Republic","2013","2013",2840.5,,
+"PATCCHLS","C10-Lipid modifying agents","MLLNCUMT","Million of national currency units","CZE","Czech Republic","2014","2014",2107.8,,
+"PATCCHLS","C10-Lipid modifying agents","MLLNCUMT","Million of national currency units","CZE","Czech Republic","2015","2015",2029.8,,
+"PATCCHLS","C10-Lipid modifying agents","MLLNCUMT","Million of national currency units","CZE","Czech Republic","2016","2016",2070.4,,
+"PATCCHLS","C10-Lipid modifying agents","MLLNCUMT","Million of national currency units","CZE","Czech Republic","2017","2017",2015.6,,
+"PATCCHLS","C10-Lipid modifying agents","MLLNCUMT","Million of national currency units","CZE","Czech Republic","2018","2018",1993.4,,
+"PATCCHLS","C10-Lipid modifying agents","MLLNCUMT","Million of national currency units","CZE","Czech Republic","2019","2019",1986.6,,
+"PATCCHLS","C10-Lipid modifying agents","MLLNCUMT","Million of national currency units","CZE","Czech Republic","2020","2020",1561.3,"B","Break"
+"PATCCHLS","C10-Lipid modifying agents","MLLNCUMT","Million of national currency units","CZE","Czech Republic","2021","2021",1516.3,,
+"PATCCHLS","C10-Lipid modifying agents","MTMOTCMT","Million US$ at exchange rate","CZE","Czech Republic","2010","2010",150.6,,
+"PATCCHLS","C10-Lipid modifying agents","MTMOTCMT","Million US$ at exchange rate","CZE","Czech Republic","2011","2011",166.7,,
+"PATCCHLS","C10-Lipid modifying agents","MTMOTCMT","Million US$ at exchange rate","CZE","Czech Republic","2012","2012",165.9,,
+"PATCCHLS","C10-Lipid modifying agents","MTMOTCMT","Million US$ at exchange rate","CZE","Czech Republic","2013","2013",145.1,,
+"PATCCHLS","C10-Lipid modifying agents","MTMOTCMT","Million US$ at exchange rate","CZE","Czech Republic","2014","2014",101.5,,
+"PATCCHLS","C10-Lipid modifying agents","MTMOTCMT","Million US$ at exchange rate","CZE","Czech Republic","2015","2015",82.5,,
+"PATCCHLS","C10-Lipid modifying agents","MTMOTCMT","Million US$ at exchange rate","CZE","Czech Republic","2016","2016",84.7,,
+"PATCCHLS","C10-Lipid modifying agents","MTMOTCMT","Million US$ at exchange rate","CZE","Czech Republic","2017","2017",86.2,,
+"PATCCHLS","C10-Lipid modifying agents","MTMOTCMT","Million US$ at exchange rate","CZE","Czech Republic","2018","2018",91.7,,
+"PATCCHLS","C10-Lipid modifying agents","MTMOTCMT","Million US$ at exchange rate","CZE","Czech Republic","2019","2019",86.6,,
+"PATCCHLS","C10-Lipid modifying agents","MTMOTCMT","Million US$ at exchange rate","CZE","Czech Republic","2020","2020",67.3,"B","Break"
+"PATCCHLS","C10-Lipid modifying agents","MTMOTCMT","Million US$ at exchange rate","CZE","Czech Republic","2021","2021",69.9,,
+"PATCCHLS","C10-Lipid modifying agents","MTMOPPMT","Million US$, purchasing power parity","CZE","Czech Republic","2010","2010",210.3,,
+"PATCCHLS","C10-Lipid modifying agents","MTMOPPMT","Million US$, purchasing power parity","CZE","Czech Republic","2011","2011",221.1,,
+"PATCCHLS","C10-Lipid modifying agents","MTMOPPMT","Million US$, purchasing power parity","CZE","Czech Republic","2012","2012",244.3,,
+"PATCCHLS","C10-Lipid modifying agents","MTMOPPMT","Million US$, purchasing power parity","CZE","Czech Republic","2013","2013",222.2,,
+"PATCCHLS","C10-Lipid modifying agents","MTMOPPMT","Million US$, purchasing power parity","CZE","Czech Republic","2014","2014",165.9,,
+"PATCCHLS","C10-Lipid modifying agents","MTMOPPMT","Million US$, purchasing power parity","CZE","Czech Republic","2015","2015",156.9,,
+"PATCCHLS","C10-Lipid modifying agents","MTMOPPMT","Million US$, purchasing power parity","CZE","Czech Republic","2016","2016",164.6,,
+"PATCCHLS","C10-Lipid modifying agents","MTMOPPMT","Million US$, purchasing power parity","CZE","Czech Republic","2017","2017",162.2,,
+"PATCCHLS","C10-Lipid modifying agents","MTMOPPMT","Million US$, purchasing power parity","CZE","Czech Republic","2018","2018",161.1,,
+"PATCCHLS","C10-Lipid modifying agents","MTMOPPMT","Million US$, purchasing power parity","CZE","Czech Republic","2019","2019",161.8,,
+"PATCCHLS","C10-Lipid modifying agents","MTMOPPMT","Million US$, purchasing power parity","CZE","Czech Republic","2020","2020",125.3,"B","Break"
+"PATCCHLS","C10-Lipid modifying agents","MTMOPPMT","Million US$, purchasing power parity","CZE","Czech Republic","2021","2021",119,,
+"PATCCHLS","C10-Lipid modifying agents","TCPPERMT","/capita, US$ exchange rate","CZE","Czech Republic","2010","2010",14.4,,
+"PATCCHLS","C10-Lipid modifying agents","TCPPERMT","/capita, US$ exchange rate","CZE","Czech Republic","2011","2011",15.9,,
+"PATCCHLS","C10-Lipid modifying agents","TCPPERMT","/capita, US$ exchange rate","CZE","Czech Republic","2012","2012",15.8,,
+"PATCCHLS","C10-Lipid modifying agents","TCPPERMT","/capita, US$ exchange rate","CZE","Czech Republic","2013","2013",13.8,,
+"PATCCHLS","C10-Lipid modifying agents","TCPPERMT","/capita, US$ exchange rate","CZE","Czech Republic","2014","2014",9.6,,
+"PATCCHLS","C10-Lipid modifying agents","TCPPERMT","/capita, US$ exchange rate","CZE","Czech Republic","2015","2015",7.8,,
+"PATCCHLS","C10-Lipid modifying agents","TCPPERMT","/capita, US$ exchange rate","CZE","Czech Republic","2016","2016",8,,
+"PATCCHLS","C10-Lipid modifying agents","TCPPERMT","/capita, US$ exchange rate","CZE","Czech Republic","2017","2017",8.1,,
+"PATCCHLS","C10-Lipid modifying agents","TCPPERMT","/capita, US$ exchange rate","CZE","Czech Republic","2018","2018",8.6,,
+"PATCCHLS","C10-Lipid modifying agents","TCPPERMT","/capita, US$ exchange rate","CZE","Czech Republic","2019","2019",8.1,,
+"PATCCHLS","C10-Lipid modifying agents","TCPPERMT","/capita, US$ exchange rate","CZE","Czech Republic","2020","2020",6.3,"B","Break"
+"PATCCHLS","C10-Lipid modifying agents","TCPPERMT","/capita, US$ exchange rate","CZE","Czech Republic","2021","2021",6.7,,
+"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czech Republic","2010","2010",20.1,,
+"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czech Republic","2011","2011",21.1,,
+"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czech Republic","2012","2012",23.2,,
+"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czech Republic","2013","2013",21.1,,
+"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czech Republic","2014","2014",15.8,,
+"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czech Republic","2015","2015",14.9,,
+"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czech Republic","2016","2016",15.6,,
+"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czech Republic","2017","2017",15.3,,
+"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czech Republic","2018","2018",15.2,,
+"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czech Republic","2019","2019",15.2,,
+"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czech Republic","2020","2020",11.7,"B","Break"
+"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czech Republic","2021","2021",11.3,,
+"PATCCHLS","C10-Lipid modifying agents","ATCPTTMT","% of total sales","CZE","Czech Republic","2010","2010",3.5,,
+"PATCCHLS","C10-Lipid modifying agents","ATCPTTMT","% of total sales","CZE","Czech Republic","2011","2011",3.6,,
+"PATCCHLS","C10-Lipid modifying agents","ATCPTTMT","% of total sales","CZE","Czech Republic","2012","2012",3.9,,
+"PATCCHLS","C10-Lipid modifying agents","ATCPTTMT","% of total sales","CZE","Czech Republic","2013","2013",3.6,,
+"PATCCHLS","C10-Lipid modifying agents","ATCPTTMT","% of total sales","CZE","Czech Republic","2014","2014",2.6,,
+"PATCCHLS","C10-Lipid modifying agents","ATCPTTMT","% of total sales","CZE","Czech Republic","2015","2015",2.4,,
+"PATCCHLS","C10-Lipid modifying agents","ATCPTTMT","% of total sales","CZE","Czech Republic","2016","2016",2.4,,
+"PATCCHLS","C10-Lipid modifying agents","ATCPTTMT","% of total sales","CZE","Czech Republic","2017","2017",2.2,,
+"PATCCHLS","C10-Lipid modifying agents","ATCPTTMT","% of total sales","CZE","Czech Republic","2018","2018",2,,
+"PATCCHLS","C10-Lipid modifying agents","ATCPTTMT","% of total sales","CZE","Czech Republic","2019","2019",1.9,,
+"PATCCHLS","C10-Lipid modifying agents","ATCPTTMT","% of total sales","CZE","Czech Republic","2020","2020",1.8,"B","Break"
+"PATCCHLS","C10-Lipid modifying agents","ATCPTTMT","% of total sales","CZE","Czech Republic","2021","2021",1.6,,
+"PATCCHLS","C10-Lipid modifying agents","MLLNCUMT","Million of national currency units","FIN","Finland","2010","2010",34.8,,
+"PATCCHLS","C10-Lipid modifying agents","MLLNCUMT","Million of national currency units","FIN","Finland","2011","2011",29.7,,
+"PATCCHLS","C10-Lipid modifying agents","MLLNCUMT","Million of national currency units","FIN","Finland","2012","2012",35.2,,
+"PATCCHLS","C10-Lipid modifying agents","MLLNCUMT","Million of national currency units","FIN","Finland","2013","2013",41.9,,
+"PATCCHLS","C10-Lipid modifying agents","MLLNCUMT","Million of national currency units","FIN","Finland","2014","2014",49.1,,
+"PATCCHLS","C10-Lipid modifying agents","MLLNCUMT","Million of national currency units","FIN","Finland","2015","2015",58.7,,
+"PATCCHLS","C10-Lipid modifying agents","MLLNCUMT","Million of national currency units","FIN","Finland","2016","2016",66.8,,
+"PATCCHLS","C10-Lipid modifying agents","MLLNCUMT","Million of national currency units","FIN","Finland","2017","2017",65.1,,
+"PATCCHLS","C10-Lipid modifying agents","MLLNCUMT","Million of national currency units","FIN","Finland","2018","2018",45.2,,
+"PATCCHLS","C10-Lipid modifying agents","MLLNCUMT","Million of national currency units","FIN","Finland","2019","2019",31.3,,
+"PATCCHLS","C10-Lipid modifying agents","MLLNCUMT","Million of national currency units","FIN","Finland","2020","2020",23.7,,
+"PATCCHLS","C10-Lipid modifying agents","MLLNCUMT","Million of national currency units","FIN","Finland","2021","2021",22.2,,
+"PATCCHLS","C10-Lipid modifying agents","MTMOTCMT","Million US$ at exchange rate","FIN","Finland","2010","2010",46.1,,
+"PATCCHLS","C10-Lipid modifying agents","MTMOTCMT","Million US$ at exchange rate","FIN","Finland","2011","2011",41.3,,
+"PATCCHLS","C10-Lipid modifying agents","MTMOTCMT","Million US$ at exchange rate","FIN","Finland","2012","2012",45.2,,
+"PATCCHLS","C10-Lipid modifying agents","MTMOTCMT","Million US$ at exchange rate","FIN","Finland","2013","2013",55.6,,
+"PATCCHLS","C10-Lipid modifying agents","MTMOTCMT","Million US$ at exchange rate","FIN","Finland","2014","2014",65.2,,
+"PATCCHLS","C10-Lipid modifying agents","MTMOTCMT","Million US$ at exchange rate","FIN","Finland","2015","2015",65.1,,
+"PATCCHLS","C10-Lipid modifying agents","MTMOTCMT","Million US$ at exchange rate","FIN","Finland","2016","2016",73.9,,
+"PATCCHLS","C10-Lipid modifying agents","MTMOTCMT","Million US$ at exchange rate","FIN","Finland","2017","2017",73.5,,
+"PATCCHLS","C10-Lipid modifying agents","MTMOTCMT","Million US$ at exchange rate","FIN","Finland","2018","2018",53.4,,
+"PATCCHLS","C10-Lipid modifying agents","MTMOTCMT","Million US$ at exchange rate","FIN","Finland","2019","2019",35,,
+"PATCCHLS","C10-Lipid modifying agents","MTMOTCMT","Million US$ at exchange rate","FIN","Finland","2020","2020",27.1,,
+"PATCCHLS","C10-Lipid modifying agents","MTMOTCMT","Million US$ at exchange rate","FIN","Finland","2021","2021",26.3,,
+"PATCCHLS","C10-Lipid modifying agents","MTMOPPMT","Million US$, purchasing power parity","FIN","Finland","2010","2010",38.6,,
+"PATCCHLS","C10-Lipid modifying agents","MTMOPPMT","Million US$, purchasing power parity","FIN","Finland","2011","2011",33.1,,
+"PATCCHLS","C10-Lipid modifying agents","MTMOPPMT","Million US$, purchasing power parity","FIN","Finland","2012","2012",38.7,,
+"PATCCHLS","C10-Lipid modifying agents","MTMOPPMT","Million US$, purchasing power parity","FIN","Finland","2013","2013",46.3,,
+"PATCCHLS","C10-Lipid modifying agents","MTMOPPMT","Million US$, purchasing power parity","FIN","Finland","2014","2014",54.1,,
+"PATCCHLS","C10-Lipid modifying agents","MTMOPPMT","Million US$, purchasing power parity","FIN","Finland","2015","2015",64.7,,
+"PATCCHLS","C10-Lipid modifying agents","MTMOPPMT","Million US$, purchasing power parity","FIN","Finland","2016","2016",75.8,,
+"PATCCHLS","C10-Lipid modifying agents","MTMOPPMT","Million US$, purchasing power parity","FIN","Finland","2017","2017",75.4,,
+"PATCCHLS","C10-Lipid modifying agents","MTMOPPMT","Million US$, purchasing power parity","FIN","Finland","2018","2018",52.9,,
+"PATCCHLS","C10-Lipid modifying agents","MTMOPPMT","Million US$, purchasing power parity","FIN","Finland","2019","2019",37.3,,
+"PATCCHLS","C10-Lipid modifying agents","MTMOPPMT","Million US$, purchasing power parity","FIN","Finland","2020","2020",28.8,,
+"PATCCHLS","C10-Lipid modifying agents","MTMOPPMT","Million US$, purchasing power parity","FIN","Finland","2021","2021",26.9,,
+"PATCCHLS","C10-Lipid modifying agents","TCPPERMT","/capita, US$ exchange rate","FIN","Finland","2010","2010",8.6,,
+"PATCCHLS","C10-Lipid modifying agents","TCPPERMT","/capita, US$ exchange rate","FIN","Finland","2011","2011",7.7,,
+"PATCCHLS","C10-Lipid modifying agents","TCPPERMT","/capita, US$ exchange rate","FIN","Finland","2012","2012",8.4,,
+"PATCCHLS","C10-Lipid modifying agents","TCPPERMT","/capita, US$ exchange rate","FIN","Finland","2013","2013",10.2,,
+"PATCCHLS","C10-Lipid modifying agents","TCPPERMT","/capita, US$ exchange rate","FIN","Finland","2014","2014",11.9,,
+"PATCCHLS","C10-Lipid modifying agents","TCPPERMT","/capita, US$ exchange rate","FIN","Finland","2015","2015",11.9,,
+"PATCCHLS","C10-Lipid modifying agents","TCPPERMT","/capita, US$ exchange rate","FIN","Finland","2016","2016",13.5,,
+"PATCCHLS","C10-Lipid modifying agents","TCPPERMT","/capita, US$ exchange rate","FIN","Finland","2017","2017",13.4,,
+"PATCCHLS","C10-Lipid modifying agents","TCPPERMT","/capita, US$ exchange rate","FIN","Finland","2018","2018",9.7,,
+"PATCCHLS","C10-Lipid modifying agents","TCPPERMT","/capita, US$ exchange rate","FIN","Finland","2019","2019",6.3,,
+"PATCCHLS","C10-Lipid modifying agents","TCPPERMT","/capita, US$ exchange rate","FIN","Finland","2020","2020",4.9,,
+"PATCCHLS","C10-Lipid modifying agents","TCPPERMT","/capita, US$ exchange rate","FIN","Finland","2021","2021",4.7,,
+"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2010","2010",7.2,,
+"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2011","2011",6.1,,
+"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2012","2012",7.2,,
+"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2013","2013",8.5,,
+"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2014","2014",9.9,,
+"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2015","2015",11.8,,
+"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2016","2016",13.8,,
+"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2017","2017",13.7,,
+"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2018","2018",9.6,,
+"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2019","2019",6.8,,
+"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2020","2020",5.2,,
+"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2021","2021",4.8,,
+"PATCCHLS","C10-Lipid modifying agents","ATCPTTMT","% of total sales","FIN","Finland","2010","2010",1.9,,
+"PATCCHLS","C10-Lipid modifying agents","ATCPTTMT","% of total sales","FIN","Finland","2011","2011",1.5,,
+"PATCCHLS","C10-Lipid modifying agents","ATCPTTMT","% of total sales","FIN","Finland","2012","2012",1.8,,
+"PATCCHLS","C10-Lipid modifying agents","ATCPTTMT","% of total sales","FIN","Finland","2013","2013",2.1,,
+"PATCCHLS","C10-Lipid modifying agents","ATCPTTMT","% of total sales","FIN","Finland","2014","2014",2.3,,
+"PATCCHLS","C10-Lipid modifying agents","ATCPTTMT","% of total sales","FIN","Finland","2015","2015",2.7,,
+"PATCCHLS","C10-Lipid modifying agents","ATCPTTMT","% of total sales","FIN","Finland","2016","2016",2.9,,
+"PATCCHLS","C10-Lipid modifying agents","ATCPTTMT","% of total sales","FIN","Finland","2017","2017",2.8,,
+"PATCCHLS","C10-Lipid modifying agents","ATCPTTMT","% of total sales","FIN","Finland","2018","2018",1.8,,
+"PATCCHLS","C10-Lipid modifying agents","ATCPTTMT","% of total sales","FIN","Finland","2019","2019",1.2,,
+"PATCCHLS","C10-Lipid modifying agents","ATCPTTMT","% of total sales","FIN","Finland","2020","2020",0.9,,
+"PATCCHLS","C10-Lipid modifying agents","ATCPTTMT","% of total sales","FIN","Finland","2021","2021",0.8,,
+"PATCCHLS","C10-Lipid modifying agents","MLLNCUMT","Million of national currency units","DEU","Germany","2010","2010",708.7,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","MLLNCUMT","Million of national currency units","DEU","Germany","2011","2011",672.6,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","MLLNCUMT","Million of national currency units","DEU","Germany","2012","2012",641.9,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","MLLNCUMT","Million of national currency units","DEU","Germany","2013","2013",594,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","MLLNCUMT","Million of national currency units","DEU","Germany","2014","2014",587,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","MLLNCUMT","Million of national currency units","DEU","Germany","2015","2015",596.9,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","MLLNCUMT","Million of national currency units","DEU","Germany","2016","2016",665.6,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","MLLNCUMT","Million of national currency units","DEU","Germany","2017","2017",733.6,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","MLLNCUMT","Million of national currency units","DEU","Germany","2018","2018",792.7,"B; D","Break; Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","MLLNCUMT","Million of national currency units","DEU","Germany","2019","2019",779.8,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","MLLNCUMT","Million of national currency units","DEU","Germany","2020","2020",775.2,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","MLLNCUMT","Million of national currency units","DEU","Germany","2021","2021",800,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","MTMOTCMT","Million US$ at exchange rate","DEU","Germany","2010","2010",939.5,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","MTMOTCMT","Million US$ at exchange rate","DEU","Germany","2011","2011",936.2,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","MTMOTCMT","Million US$ at exchange rate","DEU","Germany","2012","2012",824.7,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","MTMOTCMT","Million US$ at exchange rate","DEU","Germany","2013","2013",788.9,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","MTMOTCMT","Million US$ at exchange rate","DEU","Germany","2014","2014",779.8,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","MTMOTCMT","Million US$ at exchange rate","DEU","Germany","2015","2015",662.3,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","MTMOTCMT","Million US$ at exchange rate","DEU","Germany","2016","2016",736.8,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","MTMOTCMT","Million US$ at exchange rate","DEU","Germany","2017","2017",828.7,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","MTMOTCMT","Million US$ at exchange rate","DEU","Germany","2018","2018",936.1,"B; D","Break; Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","MTMOTCMT","Million US$ at exchange rate","DEU","Germany","2019","2019",873,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","MTMOTCMT","Million US$ at exchange rate","DEU","Germany","2020","2020",885.4,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","MTMOTCMT","Million US$ at exchange rate","DEU","Germany","2021","2021",946.2,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","MTMOPPMT","Million US$, purchasing power parity","DEU","Germany","2010","2010",880.3,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","MTMOPPMT","Million US$, purchasing power parity","DEU","Germany","2011","2011",852.8,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","MTMOPPMT","Million US$, purchasing power parity","DEU","Germany","2012","2012",815.4,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","MTMOPPMT","Million US$, purchasing power parity","DEU","Germany","2013","2013",766.7,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","MTMOPPMT","Million US$, purchasing power parity","DEU","Germany","2014","2014",763.4,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","MTMOPPMT","Million US$, purchasing power parity","DEU","Germany","2015","2015",767.1,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","MTMOPPMT","Million US$, purchasing power parity","DEU","Germany","2016","2016",884.4,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","MTMOPPMT","Million US$, purchasing power parity","DEU","Germany","2017","2017",985,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","MTMOPPMT","Million US$, purchasing power parity","DEU","Germany","2018","2018",1077.8,"B; D","Break; Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","MTMOPPMT","Million US$, purchasing power parity","DEU","Germany","2019","2019",1070.8,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","MTMOPPMT","Million US$, purchasing power parity","DEU","Germany","2020","2020",1069.2,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","MTMOPPMT","Million US$, purchasing power parity","DEU","Germany","2021","2021",1086.5,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","TCPPERMT","/capita, US$ exchange rate","DEU","Germany","2010","2010",11.5,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","TCPPERMT","/capita, US$ exchange rate","DEU","Germany","2011","2011",11.7,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","TCPPERMT","/capita, US$ exchange rate","DEU","Germany","2012","2012",10.3,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","TCPPERMT","/capita, US$ exchange rate","DEU","Germany","2013","2013",9.8,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","TCPPERMT","/capita, US$ exchange rate","DEU","Germany","2014","2014",9.6,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","TCPPERMT","/capita, US$ exchange rate","DEU","Germany","2015","2015",8.1,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","TCPPERMT","/capita, US$ exchange rate","DEU","Germany","2016","2016",8.9,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","TCPPERMT","/capita, US$ exchange rate","DEU","Germany","2017","2017",10,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","TCPPERMT","/capita, US$ exchange rate","DEU","Germany","2018","2018",11.3,"B; D","Break; Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","TCPPERMT","/capita, US$ exchange rate","DEU","Germany","2019","2019",10.5,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","TCPPERMT","/capita, US$ exchange rate","DEU","Germany","2020","2020",10.6,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","TCPPERMT","/capita, US$ exchange rate","DEU","Germany","2021","2021",11.4,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2010","2010",10.8,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2011","2011",10.6,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2012","2012",10.1,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2013","2013",9.5,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2014","2014",9.4,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2015","2015",9.4,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2016","2016",10.7,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2017","2017",11.9,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2018","2018",13,"B; D","Break; Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2019","2019",12.9,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2020","2020",12.9,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2021","2021",13.1,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","ATCPTTMT","% of total sales","DEU","Germany","2010","2010",2.4,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","ATCPTTMT","% of total sales","DEU","Germany","2011","2011",2.3,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","ATCPTTMT","% of total sales","DEU","Germany","2012","2012",2.1,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","ATCPTTMT","% of total sales","DEU","Germany","2013","2013",1.9,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","ATCPTTMT","% of total sales","DEU","Germany","2014","2014",1.7,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","ATCPTTMT","% of total sales","DEU","Germany","2015","2015",1.7,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","ATCPTTMT","% of total sales","DEU","Germany","2016","2016",1.8,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","ATCPTTMT","% of total sales","DEU","Germany","2017","2017",2,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","ATCPTTMT","% of total sales","DEU","Germany","2018","2018",1.8,"B; D","Break; Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","ATCPTTMT","% of total sales","DEU","Germany","2019","2019",1.7,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","ATCPTTMT","% of total sales","DEU","Germany","2020","2020",1.6,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","ATCPTTMT","% of total sales","DEU","Germany","2021","2021",1.5,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","MLLNCUMT","Million of national currency units","GRC","Greece","2010","2010",543.3,,
+"PATCCHLS","C10-Lipid modifying agents","MLLNCUMT","Million of national currency units","GRC","Greece","2011","2011",480.3,,
+"PATCCHLS","C10-Lipid modifying agents","MLLNCUMT","Million of national currency units","GRC","Greece","2012","2012",434.9,,
+"PATCCHLS","C10-Lipid modifying agents","MLLNCUMT","Million of national currency units","GRC","Greece","2013","2013",362,,
+"PATCCHLS","C10-Lipid modifying agents","MLLNCUMT","Million of national currency units","GRC","Greece","2014","2014",348.5,,
+"PATCCHLS","C10-Lipid modifying agents","MLLNCUMT","Million of national currency units","GRC","Greece","2015","2015",304.5,,
+"PATCCHLS","C10-Lipid modifying agents","MLLNCUMT","Million of national currency units","GRC","Greece","2016","2016",344.7,,
+"PATCCHLS","C10-Lipid modifying agents","MLLNCUMT","Million of national currency units","GRC","Greece","2017","2017",311.9,,
+"PATCCHLS","C10-Lipid modifying agents","MLLNCUMT","Million of national currency units","GRC","Greece","2018","2018",328.9,,
+"PATCCHLS","C10-Lipid modifying agents","MLLNCUMT","Million of national currency units","GRC","Greece","2019","2019",331.5,,
+"PATCCHLS","C10-Lipid modifying agents","MLLNCUMT","Million of national currency units","GRC","Greece","2020","2020",306.7,,
+"PATCCHLS","C10-Lipid modifying agents","MLLNCUMT","Million of national currency units","GRC","Greece","2021","2021",330.6,,
+"PATCCHLS","C10-Lipid modifying agents","MLLNCUMT","Million of national currency units","GRC","Greece","2022","2022",264.3,,
+"PATCCHLS","C10-Lipid modifying agents","MTMOTCMT","Million US$ at exchange rate","GRC","Greece","2010","2010",720.2,,
+"PATCCHLS","C10-Lipid modifying agents","MTMOTCMT","Million US$ at exchange rate","GRC","Greece","2011","2011",668.5,,
+"PATCCHLS","C10-Lipid modifying agents","MTMOTCMT","Million US$ at exchange rate","GRC","Greece","2012","2012",558.8,,
+"PATCCHLS","C10-Lipid modifying agents","MTMOTCMT","Million US$ at exchange rate","GRC","Greece","2013","2013",480.8,,
+"PATCCHLS","C10-Lipid modifying agents","MTMOTCMT","Million US$ at exchange rate","GRC","Greece","2014","2014",463,,
+"PATCCHLS","C10-Lipid modifying agents","MTMOTCMT","Million US$ at exchange rate","GRC","Greece","2015","2015",337.8,,
+"PATCCHLS","C10-Lipid modifying agents","MTMOTCMT","Million US$ at exchange rate","GRC","Greece","2016","2016",381.6,,
+"PATCCHLS","C10-Lipid modifying agents","MTMOTCMT","Million US$ at exchange rate","GRC","Greece","2017","2017",352.4,,
+"PATCCHLS","C10-Lipid modifying agents","MTMOTCMT","Million US$ at exchange rate","GRC","Greece","2018","2018",388.4,,
+"PATCCHLS","C10-Lipid modifying agents","MTMOTCMT","Million US$ at exchange rate","GRC","Greece","2019","2019",371.1,,
+"PATCCHLS","C10-Lipid modifying agents","MTMOTCMT","Million US$ at exchange rate","GRC","Greece","2020","2020",350.3,,
+"PATCCHLS","C10-Lipid modifying agents","MTMOTCMT","Million US$ at exchange rate","GRC","Greece","2021","2021",391,,
+"PATCCHLS","C10-Lipid modifying agents","MTMOTCMT","Million US$ at exchange rate","GRC","Greece","2022","2022",278.4,,
+"PATCCHLS","C10-Lipid modifying agents","MTMOPPMT","Million US$, purchasing power parity","GRC","Greece","2010","2010",752.5,,
+"PATCCHLS","C10-Lipid modifying agents","MTMOPPMT","Million US$, purchasing power parity","GRC","Greece","2011","2011",673.5,,
+"PATCCHLS","C10-Lipid modifying agents","MTMOPPMT","Million US$, purchasing power parity","GRC","Greece","2012","2012",635.2,,
+"PATCCHLS","C10-Lipid modifying agents","MTMOPPMT","Million US$, purchasing power parity","GRC","Greece","2013","2013",573.4,,
+"PATCCHLS","C10-Lipid modifying agents","MTMOPPMT","Million US$, purchasing power parity","GRC","Greece","2014","2014",570.3,,
+"PATCCHLS","C10-Lipid modifying agents","MTMOPPMT","Million US$, purchasing power parity","GRC","Greece","2015","2015",499.9,,
+"PATCCHLS","C10-Lipid modifying agents","MTMOPPMT","Million US$, purchasing power parity","GRC","Greece","2016","2016",585.7,,
+"PATCCHLS","C10-Lipid modifying agents","MTMOPPMT","Million US$, purchasing power parity","GRC","Greece","2017","2017",542.4,,
+"PATCCHLS","C10-Lipid modifying agents","MTMOPPMT","Million US$, purchasing power parity","GRC","Greece","2018","2018",582.3,,
+"PATCCHLS","C10-Lipid modifying agents","MTMOPPMT","Million US$, purchasing power parity","GRC","Greece","2019","2019",603.9,,
+"PATCCHLS","C10-Lipid modifying agents","MTMOPPMT","Million US$, purchasing power parity","GRC","Greece","2020","2020",563.7,,
+"PATCCHLS","C10-Lipid modifying agents","MTMOPPMT","Million US$, purchasing power parity","GRC","Greece","2021","2021",605.9,,
+"PATCCHLS","C10-Lipid modifying agents","MTMOPPMT","Million US$, purchasing power parity","GRC","Greece","2022","2022",500.2,,
+"PATCCHLS","C10-Lipid modifying agents","TCPPERMT","/capita, US$ exchange rate","GRC","Greece","2010","2010",64.8,,
+"PATCCHLS","C10-Lipid modifying agents","TCPPERMT","/capita, US$ exchange rate","GRC","Greece","2011","2011",60.2,,
+"PATCCHLS","C10-Lipid modifying agents","TCPPERMT","/capita, US$ exchange rate","GRC","Greece","2012","2012",50.6,,
+"PATCCHLS","C10-Lipid modifying agents","TCPPERMT","/capita, US$ exchange rate","GRC","Greece","2013","2013",43.8,,
+"PATCCHLS","C10-Lipid modifying agents","TCPPERMT","/capita, US$ exchange rate","GRC","Greece","2014","2014",42.5,,
+"PATCCHLS","C10-Lipid modifying agents","TCPPERMT","/capita, US$ exchange rate","GRC","Greece","2015","2015",31.2,,
+"PATCCHLS","C10-Lipid modifying agents","TCPPERMT","/capita, US$ exchange rate","GRC","Greece","2016","2016",35.4,,
+"PATCCHLS","C10-Lipid modifying agents","TCPPERMT","/capita, US$ exchange rate","GRC","Greece","2017","2017",32.8,,
+"PATCCHLS","C10-Lipid modifying agents","TCPPERMT","/capita, US$ exchange rate","GRC","Greece","2018","2018",36.2,,
+"PATCCHLS","C10-Lipid modifying agents","TCPPERMT","/capita, US$ exchange rate","GRC","Greece","2019","2019",34.6,,
+"PATCCHLS","C10-Lipid modifying agents","TCPPERMT","/capita, US$ exchange rate","GRC","Greece","2020","2020",32.7,,
+"PATCCHLS","C10-Lipid modifying agents","TCPPERMT","/capita, US$ exchange rate","GRC","Greece","2021","2021",37,,
+"PATCCHLS","C10-Lipid modifying agents","TCPPERMT","/capita, US$ exchange rate","GRC","Greece","2022","2022",26.6,,
+"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2010","2010",67.7,,
+"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2011","2011",60.6,,
+"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2012","2012",57.5,,
+"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2013","2013",52.3,,
+"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2014","2014",52.4,,
+"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2015","2015",46.2,,
+"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2016","2016",54.4,,
+"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2017","2017",50.4,,
+"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2018","2018",54.3,,
+"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2019","2019",56.3,,
+"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2020","2020",52.7,,
+"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2021","2021",57.3,,
+"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2022","2022",47.8,,
+"PATCCHLS","C10-Lipid modifying agents","MLLNCUMT","Million of national currency units","HUN","Hungary","2010","2010",37190,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","MLLNCUMT","Million of national currency units","HUN","Hungary","2011","2011",37000.6,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","MLLNCUMT","Million of national currency units","HUN","Hungary","2012","2012",27959.9,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","MLLNCUMT","Million of national currency units","HUN","Hungary","2013","2013",22838.1,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","MLLNCUMT","Million of national currency units","HUN","Hungary","2014","2014",19830.2,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","MLLNCUMT","Million of national currency units","HUN","Hungary","2015","2015",18929.3,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","MLLNCUMT","Million of national currency units","HUN","Hungary","2016","2016",19032,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","MLLNCUMT","Million of national currency units","HUN","Hungary","2017","2017",19139.1,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","MLLNCUMT","Million of national currency units","HUN","Hungary","2018","2018",18500.9,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","MLLNCUMT","Million of national currency units","HUN","Hungary","2019","2019",17695.5,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","MLLNCUMT","Million of national currency units","HUN","Hungary","2020","2020",18469.8,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","MLLNCUMT","Million of national currency units","HUN","Hungary","2021","2021",18235.5,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","MLLNCUMT","Million of national currency units","HUN","Hungary","2022","2022",20344.7,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","MTMOTCMT","Million US$ at exchange rate","HUN","Hungary","2010","2010",178.8,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","MTMOTCMT","Million US$ at exchange rate","HUN","Hungary","2011","2011",184,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","MTMOTCMT","Million US$ at exchange rate","HUN","Hungary","2012","2012",124.2,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","MTMOTCMT","Million US$ at exchange rate","HUN","Hungary","2013","2013",102.1,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","MTMOTCMT","Million US$ at exchange rate","HUN","Hungary","2014","2014",85.3,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","MTMOTCMT","Million US$ at exchange rate","HUN","Hungary","2015","2015",67.8,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","MTMOTCMT","Million US$ at exchange rate","HUN","Hungary","2016","2016",67.6,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","MTMOTCMT","Million US$ at exchange rate","HUN","Hungary","2017","2017",69.7,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","MTMOTCMT","Million US$ at exchange rate","HUN","Hungary","2018","2018",68.5,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","MTMOTCMT","Million US$ at exchange rate","HUN","Hungary","2019","2019",60.9,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","MTMOTCMT","Million US$ at exchange rate","HUN","Hungary","2020","2020",60,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","MTMOTCMT","Million US$ at exchange rate","HUN","Hungary","2021","2021",60.2,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","MTMOTCMT","Million US$ at exchange rate","HUN","Hungary","2022","2022",54.6,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","MTMOPPMT","Million US$, purchasing power parity","HUN","Hungary","2010","2010",294.2,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","MTMOPPMT","Million US$, purchasing power parity","HUN","Hungary","2011","2011",297.7,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","MTMOPPMT","Million US$, purchasing power parity","HUN","Hungary","2012","2012",222.6,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","MTMOPPMT","Million US$, purchasing power parity","HUN","Hungary","2013","2013",182.7,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","MTMOPPMT","Million US$, purchasing power parity","HUN","Hungary","2014","2014",153.2,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","MTMOPPMT","Million US$, purchasing power parity","HUN","Hungary","2015","2015",142.8,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","MTMOPPMT","Million US$, purchasing power parity","HUN","Hungary","2016","2016",144.1,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","MTMOPPMT","Million US$, purchasing power parity","HUN","Hungary","2017","2017",140.7,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","MTMOPPMT","Million US$, purchasing power parity","HUN","Hungary","2018","2018",133,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","MTMOPPMT","Million US$, purchasing power parity","HUN","Hungary","2019","2019",125.7,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","MTMOPPMT","Million US$, purchasing power parity","HUN","Hungary","2020","2020",127.1,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","MTMOPPMT","Million US$, purchasing power parity","HUN","Hungary","2021","2021",117.8,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","MTMOPPMT","Million US$, purchasing power parity","HUN","Hungary","2022","2022",126.2,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","TCPPERMT","/capita, US$ exchange rate","HUN","Hungary","2010","2010",17.9,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","TCPPERMT","/capita, US$ exchange rate","HUN","Hungary","2011","2011",18.5,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","TCPPERMT","/capita, US$ exchange rate","HUN","Hungary","2012","2012",12.5,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","TCPPERMT","/capita, US$ exchange rate","HUN","Hungary","2013","2013",10.3,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","TCPPERMT","/capita, US$ exchange rate","HUN","Hungary","2014","2014",8.6,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","TCPPERMT","/capita, US$ exchange rate","HUN","Hungary","2015","2015",6.9,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","TCPPERMT","/capita, US$ exchange rate","HUN","Hungary","2016","2016",6.9,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","TCPPERMT","/capita, US$ exchange rate","HUN","Hungary","2017","2017",7.1,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","TCPPERMT","/capita, US$ exchange rate","HUN","Hungary","2018","2018",7,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","TCPPERMT","/capita, US$ exchange rate","HUN","Hungary","2019","2019",6.2,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","TCPPERMT","/capita, US$ exchange rate","HUN","Hungary","2020","2020",6.2,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","TCPPERMT","/capita, US$ exchange rate","HUN","Hungary","2021","2021",6.2,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","TCPPERMT","/capita, US$ exchange rate","HUN","Hungary","2022","2022",5.6,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2010","2010",29.4,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2011","2011",29.9,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2012","2012",22.4,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2013","2013",18.5,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2014","2014",15.5,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2015","2015",14.5,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2016","2016",14.7,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2017","2017",14.4,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2018","2018",13.6,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2019","2019",12.9,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2020","2020",13,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2021","2021",12.1,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2022","2022",13,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","ATCPTTMT","% of total sales","HUN","Hungary","2010","2010",7.5,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","ATCPTTMT","% of total sales","HUN","Hungary","2011","2011",7.2,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","ATCPTTMT","% of total sales","HUN","Hungary","2012","2012",6.3,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","ATCPTTMT","% of total sales","HUN","Hungary","2013","2013",5.3,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","ATCPTTMT","% of total sales","HUN","Hungary","2014","2014",4.5,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","ATCPTTMT","% of total sales","HUN","Hungary","2015","2015",4.1,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","ATCPTTMT","% of total sales","HUN","Hungary","2016","2016",3.8,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","ATCPTTMT","% of total sales","HUN","Hungary","2017","2017",3.9,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","ATCPTTMT","% of total sales","HUN","Hungary","2018","2018",3.7,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","ATCPTTMT","% of total sales","HUN","Hungary","2019","2019",3.4,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","ATCPTTMT","% of total sales","HUN","Hungary","2020","2020",3.3,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","ATCPTTMT","% of total sales","HUN","Hungary","2021","2021",3.2,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","ATCPTTMT","% of total sales","HUN","Hungary","2022","2022",3.4,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","MLLNCUMT","Million of national currency units","ISL","Iceland","2010","2010",335.4,,
+"PATCCHLS","C10-Lipid modifying agents","MLLNCUMT","Million of national currency units","ISL","Iceland","2011","2011",366,,
+"PATCCHLS","C10-Lipid modifying agents","MLLNCUMT","Million of national currency units","ISL","Iceland","2012","2012",367.8,,
+"PATCCHLS","C10-Lipid modifying agents","MLLNCUMT","Million of national currency units","ISL","Iceland","2013","2013",308.7,,
+"PATCCHLS","C10-Lipid modifying agents","MLLNCUMT","Million of national currency units","ISL","Iceland","2014","2014",333.6,,
+"PATCCHLS","C10-Lipid modifying agents","MLLNCUMT","Million of national currency units","ISL","Iceland","2015","2015",308.6,,
+"PATCCHLS","C10-Lipid modifying agents","MLLNCUMT","Million of national currency units","ISL","Iceland","2016","2016",326.4,,
+"PATCCHLS","C10-Lipid modifying agents","MLLNCUMT","Million of national currency units","ISL","Iceland","2017","2017",344.3,,
+"PATCCHLS","C10-Lipid modifying agents","MLLNCUMT","Million of national currency units","ISL","Iceland","2018","2018",380,,
+"PATCCHLS","C10-Lipid modifying agents","MLLNCUMT","Million of national currency units","ISL","Iceland","2019","2019",420.5,,
+"PATCCHLS","C10-Lipid modifying agents","MLLNCUMT","Million of national currency units","ISL","Iceland","2020","2020",473.5,,
+"PATCCHLS","C10-Lipid modifying agents","MLLNCUMT","Million of national currency units","ISL","Iceland","2021","2021",518.4,,
+"PATCCHLS","C10-Lipid modifying agents","MTMOTCMT","Million US$ at exchange rate","ISL","Iceland","2010","2010",2.7,,
+"PATCCHLS","C10-Lipid modifying agents","MTMOTCMT","Million US$ at exchange rate","ISL","Iceland","2011","2011",3.2,,
+"PATCCHLS","C10-Lipid modifying agents","MTMOTCMT","Million US$ at exchange rate","ISL","Iceland","2012","2012",2.9,,
+"PATCCHLS","C10-Lipid modifying agents","MTMOTCMT","Million US$ at exchange rate","ISL","Iceland","2013","2013",2.5,,
+"PATCCHLS","C10-Lipid modifying agents","MTMOTCMT","Million US$ at exchange rate","ISL","Iceland","2014","2014",2.9,,
+"PATCCHLS","C10-Lipid modifying agents","MTMOTCMT","Million US$ at exchange rate","ISL","Iceland","2015","2015",2.3,,
+"PATCCHLS","C10-Lipid modifying agents","MTMOTCMT","Million US$ at exchange rate","ISL","Iceland","2016","2016",2.7,,
+"PATCCHLS","C10-Lipid modifying agents","MTMOTCMT","Million US$ at exchange rate","ISL","Iceland","2017","2017",3.2,,
+"PATCCHLS","C10-Lipid modifying agents","MTMOTCMT","Million US$ at exchange rate","ISL","Iceland","2018","2018",3.5,,
+"PATCCHLS","C10-Lipid modifying agents","MTMOTCMT","Million US$ at exchange rate","ISL","Iceland","2019","2019",3.4,,
+"PATCCHLS","C10-Lipid modifying agents","MTMOTCMT","Million US$ at exchange rate","ISL","Iceland","2020","2020",3.5,,
+"PATCCHLS","C10-Lipid modifying agents","MTMOTCMT","Million US$ at exchange rate","ISL","Iceland","2021","2021",4.1,,
+"PATCCHLS","C10-Lipid modifying agents","MTMOPPMT","Million US$, purchasing power parity","ISL","Iceland","2010","2010",2.5,,
+"PATCCHLS","C10-Lipid modifying agents","MTMOPPMT","Million US$, purchasing power parity","ISL","Iceland","2011","2011",2.7,,
+"PATCCHLS","C10-Lipid modifying agents","MTMOPPMT","Million US$, purchasing power parity","ISL","Iceland","2012","2012",2.7,,
+"PATCCHLS","C10-Lipid modifying agents","MTMOPPMT","Million US$, purchasing power parity","ISL","Iceland","2013","2013",2.3,,
+"PATCCHLS","C10-Lipid modifying agents","MTMOPPMT","Million US$, purchasing power parity","ISL","Iceland","2014","2014",2.4,,
+"PATCCHLS","C10-Lipid modifying agents","MTMOPPMT","Million US$, purchasing power parity","ISL","Iceland","2015","2015",2.2,,
+"PATCCHLS","C10-Lipid modifying agents","MTMOPPMT","Million US$, purchasing power parity","ISL","Iceland","2016","2016",2.3,,
+"PATCCHLS","C10-Lipid modifying agents","MTMOPPMT","Million US$, purchasing power parity","ISL","Iceland","2017","2017",2.5,,
+"PATCCHLS","C10-Lipid modifying agents","MTMOPPMT","Million US$, purchasing power parity","ISL","Iceland","2018","2018",2.7,,
+"PATCCHLS","C10-Lipid modifying agents","MTMOPPMT","Million US$, purchasing power parity","ISL","Iceland","2019","2019",3,,
+"PATCCHLS","C10-Lipid modifying agents","MTMOPPMT","Million US$, purchasing power parity","ISL","Iceland","2020","2020",3.2,,
+"PATCCHLS","C10-Lipid modifying agents","MTMOPPMT","Million US$, purchasing power parity","ISL","Iceland","2021","2021",3.5,,
+"PATCCHLS","C10-Lipid modifying agents","TCPPERMT","/capita, US$ exchange rate","ISL","Iceland","2010","2010",8.6,,
+"PATCCHLS","C10-Lipid modifying agents","TCPPERMT","/capita, US$ exchange rate","ISL","Iceland","2011","2011",9.9,,
+"PATCCHLS","C10-Lipid modifying agents","TCPPERMT","/capita, US$ exchange rate","ISL","Iceland","2012","2012",9.2,,
+"PATCCHLS","C10-Lipid modifying agents","TCPPERMT","/capita, US$ exchange rate","ISL","Iceland","2013","2013",7.8,,
+"PATCCHLS","C10-Lipid modifying agents","TCPPERMT","/capita, US$ exchange rate","ISL","Iceland","2014","2014",8.7,,
+"PATCCHLS","C10-Lipid modifying agents","TCPPERMT","/capita, US$ exchange rate","ISL","Iceland","2015","2015",7.1,,
+"PATCCHLS","C10-Lipid modifying agents","TCPPERMT","/capita, US$ exchange rate","ISL","Iceland","2016","2016",8.1,,
+"PATCCHLS","C10-Lipid modifying agents","TCPPERMT","/capita, US$ exchange rate","ISL","Iceland","2017","2017",9.4,,
+"PATCCHLS","C10-Lipid modifying agents","TCPPERMT","/capita, US$ exchange rate","ISL","Iceland","2018","2018",9.9,,
+"PATCCHLS","C10-Lipid modifying agents","TCPPERMT","/capita, US$ exchange rate","ISL","Iceland","2019","2019",9.5,,
+"PATCCHLS","C10-Lipid modifying agents","TCPPERMT","/capita, US$ exchange rate","ISL","Iceland","2020","2020",9.5,,
+"PATCCHLS","C10-Lipid modifying agents","TCPPERMT","/capita, US$ exchange rate","ISL","Iceland","2021","2021",11,,
+"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2010","2010",7.9,,
+"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2011","2011",8.5,,
+"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2012","2012",8.4,,
+"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2013","2013",7,,
+"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2014","2014",7.4,,
+"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2015","2015",6.6,,
+"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2016","2016",6.9,,
+"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2017","2017",7.3,,
+"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2018","2018",7.6,,
+"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2019","2019",8.3,,
+"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2020","2020",8.8,,
+"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2021","2021",9.3,,
+"PATCCHLS","C10-Lipid modifying agents","ATCPTTMT","% of total sales","ISL","Iceland","2010","2010",1.3,,
+"PATCCHLS","C10-Lipid modifying agents","ATCPTTMT","% of total sales","ISL","Iceland","2011","2011",1.4,,
+"PATCCHLS","C10-Lipid modifying agents","ATCPTTMT","% of total sales","ISL","Iceland","2012","2012",1.5,,
+"PATCCHLS","C10-Lipid modifying agents","ATCPTTMT","% of total sales","ISL","Iceland","2013","2013",1.2,,
+"PATCCHLS","C10-Lipid modifying agents","ATCPTTMT","% of total sales","ISL","Iceland","2014","2014",1.4,,
+"PATCCHLS","C10-Lipid modifying agents","ATCPTTMT","% of total sales","ISL","Iceland","2015","2015",1.3,,
+"PATCCHLS","C10-Lipid modifying agents","ATCPTTMT","% of total sales","ISL","Iceland","2016","2016",1.3,,
+"PATCCHLS","C10-Lipid modifying agents","ATCPTTMT","% of total sales","ISL","Iceland","2017","2017",1.3,,
+"PATCCHLS","C10-Lipid modifying agents","ATCPTTMT","% of total sales","ISL","Iceland","2018","2018",1.3,,
+"PATCCHLS","C10-Lipid modifying agents","ATCPTTMT","% of total sales","ISL","Iceland","2019","2019",1.3,,
+"PATCCHLS","C10-Lipid modifying agents","ATCPTTMT","% of total sales","ISL","Iceland","2020","2020",1.2,,
+"PATCCHLS","C10-Lipid modifying agents","ATCPTTMT","% of total sales","ISL","Iceland","2021","2021",1.1,,
+"PATCCHLS","C10-Lipid modifying agents","MLLNCUMT","Million of national currency units","IRL","Ireland","2010","2010",193.6,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","MLLNCUMT","Million of national currency units","IRL","Ireland","2011","2011",150.8,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","MLLNCUMT","Million of national currency units","IRL","Ireland","2012","2012",145.8,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","MLLNCUMT","Million of national currency units","IRL","Ireland","2013","2013",112.4,"B; D","Break; Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","MLLNCUMT","Million of national currency units","IRL","Ireland","2014","2014",69.4,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","MLLNCUMT","Million of national currency units","IRL","Ireland","2015","2015",65.5,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","MLLNCUMT","Million of national currency units","IRL","Ireland","2016","2016",65.4,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","MLLNCUMT","Million of national currency units","IRL","Ireland","2017","2017",66.2,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","MLLNCUMT","Million of national currency units","IRL","Ireland","2018","2018",64.4,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","MLLNCUMT","Million of national currency units","IRL","Ireland","2019","2019",58.6,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","MLLNCUMT","Million of national currency units","IRL","Ireland","2020","2020",58.4,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","MLLNCUMT","Million of national currency units","IRL","Ireland","2021","2021",61.6,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","MTMOTCMT","Million US$ at exchange rate","IRL","Ireland","2010","2010",256.6,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","MTMOTCMT","Million US$ at exchange rate","IRL","Ireland","2011","2011",209.8,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","MTMOTCMT","Million US$ at exchange rate","IRL","Ireland","2012","2012",187.3,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","MTMOTCMT","Million US$ at exchange rate","IRL","Ireland","2013","2013",149.2,"B; D","Break; Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","MTMOTCMT","Million US$ at exchange rate","IRL","Ireland","2014","2014",92.2,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","MTMOTCMT","Million US$ at exchange rate","IRL","Ireland","2015","2015",72.7,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","MTMOTCMT","Million US$ at exchange rate","IRL","Ireland","2016","2016",72.4,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","MTMOTCMT","Million US$ at exchange rate","IRL","Ireland","2017","2017",74.8,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","MTMOTCMT","Million US$ at exchange rate","IRL","Ireland","2018","2018",76,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","MTMOTCMT","Million US$ at exchange rate","IRL","Ireland","2019","2019",65.7,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","MTMOTCMT","Million US$ at exchange rate","IRL","Ireland","2020","2020",66.7,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","MTMOTCMT","Million US$ at exchange rate","IRL","Ireland","2021","2021",72.9,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","MTMOPPMT","Million US$, purchasing power parity","IRL","Ireland","2010","2010",227.8,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","MTMOPPMT","Million US$, purchasing power parity","IRL","Ireland","2011","2011",181.3,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","MTMOPPMT","Million US$, purchasing power parity","IRL","Ireland","2012","2012",177.2,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","MTMOPPMT","Million US$, purchasing power parity","IRL","Ireland","2013","2013",138.5,"B; D","Break; Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","MTMOPPMT","Million US$, purchasing power parity","IRL","Ireland","2014","2014",84.7,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","MTMOPPMT","Million US$, purchasing power parity","IRL","Ireland","2015","2015",80.9,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","MTMOPPMT","Million US$, purchasing power parity","IRL","Ireland","2016","2016",82.3,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","MTMOPPMT","Million US$, purchasing power parity","IRL","Ireland","2017","2017",83.3,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","MTMOPPMT","Million US$, purchasing power parity","IRL","Ireland","2018","2018",81.2,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","MTMOPPMT","Million US$, purchasing power parity","IRL","Ireland","2019","2019",72.8,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","MTMOPPMT","Million US$, purchasing power parity","IRL","Ireland","2020","2020",73.4,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","MTMOPPMT","Million US$, purchasing power parity","IRL","Ireland","2021","2021",77.5,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","TCPPERMT","/capita, US$ exchange rate","IRL","Ireland","2010","2010",56.3,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","TCPPERMT","/capita, US$ exchange rate","IRL","Ireland","2011","2011",45.8,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","TCPPERMT","/capita, US$ exchange rate","IRL","Ireland","2012","2012",40.7,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","TCPPERMT","/capita, US$ exchange rate","IRL","Ireland","2013","2013",32.3,"B; D","Break; Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","TCPPERMT","/capita, US$ exchange rate","IRL","Ireland","2014","2014",19.8,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","TCPPERMT","/capita, US$ exchange rate","IRL","Ireland","2015","2015",15.5,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","TCPPERMT","/capita, US$ exchange rate","IRL","Ireland","2016","2016",15.2,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","TCPPERMT","/capita, US$ exchange rate","IRL","Ireland","2017","2017",15.6,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","TCPPERMT","/capita, US$ exchange rate","IRL","Ireland","2018","2018",15.6,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","TCPPERMT","/capita, US$ exchange rate","IRL","Ireland","2019","2019",13.3,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","TCPPERMT","/capita, US$ exchange rate","IRL","Ireland","2020","2020",13.4,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","TCPPERMT","/capita, US$ exchange rate","IRL","Ireland","2021","2021",14.5,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2010","2010",50,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2011","2011",39.6,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2012","2012",38.5,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2013","2013",30,"B; D","Break; Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2014","2014",18.2,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2015","2015",17.2,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2016","2016",17.3,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2017","2017",17.3,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2018","2018",16.7,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2019","2019",14.8,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2020","2020",14.7,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2021","2021",15.4,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","ATCPTTMT","% of total sales","IRL","Ireland","2010","2010",9.4,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","ATCPTTMT","% of total sales","IRL","Ireland","2011","2011",7.7,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","ATCPTTMT","% of total sales","IRL","Ireland","2012","2012",7.1,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","ATCPTTMT","% of total sales","IRL","Ireland","2013","2013",5.7,"B; D","Break; Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","ATCPTTMT","% of total sales","IRL","Ireland","2014","2014",3.6,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","ATCPTTMT","% of total sales","IRL","Ireland","2015","2015",3.3,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","ATCPTTMT","% of total sales","IRL","Ireland","2016","2016",3.1,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","ATCPTTMT","% of total sales","IRL","Ireland","2017","2017",3.1,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","ATCPTTMT","% of total sales","IRL","Ireland","2018","2018",2.8,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","ATCPTTMT","% of total sales","IRL","Ireland","2019","2019",2.4,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","ATCPTTMT","% of total sales","IRL","Ireland","2020","2020",2.4,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","ATCPTTMT","% of total sales","IRL","Ireland","2021","2021",2.4,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","MLLNCUMT","Million of national currency units","ITA","Italy","2011","2011",1377.2,,
+"PATCCHLS","C10-Lipid modifying agents","MLLNCUMT","Million of national currency units","ITA","Italy","2012","2012",1145,,
+"PATCCHLS","C10-Lipid modifying agents","MLLNCUMT","Million of national currency units","ITA","Italy","2013","2013",1033.1,,
+"PATCCHLS","C10-Lipid modifying agents","MLLNCUMT","Million of national currency units","ITA","Italy","2014","2014",1008.2,,
+"PATCCHLS","C10-Lipid modifying agents","MLLNCUMT","Million of national currency units","ITA","Italy","2015","2015",1012.2,,
+"PATCCHLS","C10-Lipid modifying agents","MLLNCUMT","Million of national currency units","ITA","Italy","2016","2016",1039.4,,
+"PATCCHLS","C10-Lipid modifying agents","MLLNCUMT","Million of national currency units","ITA","Italy","2017","2017",1092.2,,
+"PATCCHLS","C10-Lipid modifying agents","MLLNCUMT","Million of national currency units","ITA","Italy","2018","2018",875.1,,
+"PATCCHLS","C10-Lipid modifying agents","MLLNCUMT","Million of national currency units","ITA","Italy","2019","2019",830.6,,
+"PATCCHLS","C10-Lipid modifying agents","MLLNCUMT","Million of national currency units","ITA","Italy","2020","2020",890.9,,
+"PATCCHLS","C10-Lipid modifying agents","MLLNCUMT","Million of national currency units","ITA","Italy","2021","2021",955.8,,
+"PATCCHLS","C10-Lipid modifying agents","MLLNCUMT","Million of national currency units","ITA","Italy","2022","2022",1037.3,"E","Estimated value"
+"PATCCHLS","C10-Lipid modifying agents","MTMOTCMT","Million US$ at exchange rate","ITA","Italy","2011","2011",1917,,
+"PATCCHLS","C10-Lipid modifying agents","MTMOTCMT","Million US$ at exchange rate","ITA","Italy","2012","2012",1471.1,,
+"PATCCHLS","C10-Lipid modifying agents","MTMOTCMT","Million US$ at exchange rate","ITA","Italy","2013","2013",1372.1,,
+"PATCCHLS","C10-Lipid modifying agents","MTMOTCMT","Million US$ at exchange rate","ITA","Italy","2014","2014",1339.4,,
+"PATCCHLS","C10-Lipid modifying agents","MTMOTCMT","Million US$ at exchange rate","ITA","Italy","2015","2015",1123.1,,
+"PATCCHLS","C10-Lipid modifying agents","MTMOTCMT","Million US$ at exchange rate","ITA","Italy","2016","2016",1150.5,,
+"PATCCHLS","C10-Lipid modifying agents","MTMOTCMT","Million US$ at exchange rate","ITA","Italy","2017","2017",1233.8,,
+"PATCCHLS","C10-Lipid modifying agents","MTMOTCMT","Million US$ at exchange rate","ITA","Italy","2018","2018",1033.4,,
+"PATCCHLS","C10-Lipid modifying agents","MTMOTCMT","Million US$ at exchange rate","ITA","Italy","2019","2019",929.8,,
+"PATCCHLS","C10-Lipid modifying agents","MTMOTCMT","Million US$ at exchange rate","ITA","Italy","2020","2020",1017.6,,
+"PATCCHLS","C10-Lipid modifying agents","MTMOTCMT","Million US$ at exchange rate","ITA","Italy","2021","2021",1130.4,,
+"PATCCHLS","C10-Lipid modifying agents","MTMOTCMT","Million US$ at exchange rate","ITA","Italy","2022","2022",1092.4,"E","Estimated value"
+"PATCCHLS","C10-Lipid modifying agents","MTMOPPMT","Million US$, purchasing power parity","ITA","Italy","2011","2011",1815.3,,
+"PATCCHLS","C10-Lipid modifying agents","MTMOPPMT","Million US$, purchasing power parity","ITA","Italy","2012","2012",1531.3,,
+"PATCCHLS","C10-Lipid modifying agents","MTMOPPMT","Million US$, purchasing power parity","ITA","Italy","2013","2013",1401.2,,
+"PATCCHLS","C10-Lipid modifying agents","MTMOPPMT","Million US$, purchasing power parity","ITA","Italy","2014","2014",1363.1,,
+"PATCCHLS","C10-Lipid modifying agents","MTMOPPMT","Million US$, purchasing power parity","ITA","Italy","2015","2015",1370.3,,
+"PATCCHLS","C10-Lipid modifying agents","MTMOPPMT","Million US$, purchasing power parity","ITA","Italy","2016","2016",1483.7,,
+"PATCCHLS","C10-Lipid modifying agents","MTMOPPMT","Million US$, purchasing power parity","ITA","Italy","2017","2017",1583.1,,
+"PATCCHLS","C10-Lipid modifying agents","MTMOPPMT","Million US$, purchasing power parity","ITA","Italy","2018","2018",1284.6,,
+"PATCCHLS","C10-Lipid modifying agents","MTMOPPMT","Million US$, purchasing power parity","ITA","Italy","2019","2019",1264.6,,
+"PATCCHLS","C10-Lipid modifying agents","MTMOPPMT","Million US$, purchasing power parity","ITA","Italy","2020","2020",1375.5,,
+"PATCCHLS","C10-Lipid modifying agents","MTMOPPMT","Million US$, purchasing power parity","ITA","Italy","2021","2021",1476,,
+"PATCCHLS","C10-Lipid modifying agents","MTMOPPMT","Million US$, purchasing power parity","ITA","Italy","2022","2022",1680.1,"E","Estimated value"
+"PATCCHLS","C10-Lipid modifying agents","TCPPERMT","/capita, US$ exchange rate","ITA","Italy","2011","2011",32.3,,
+"PATCCHLS","C10-Lipid modifying agents","TCPPERMT","/capita, US$ exchange rate","ITA","Italy","2012","2012",24.7,,
+"PATCCHLS","C10-Lipid modifying agents","TCPPERMT","/capita, US$ exchange rate","ITA","Italy","2013","2013",22.8,,
+"PATCCHLS","C10-Lipid modifying agents","TCPPERMT","/capita, US$ exchange rate","ITA","Italy","2014","2014",22,,
+"PATCCHLS","C10-Lipid modifying agents","TCPPERMT","/capita, US$ exchange rate","ITA","Italy","2015","2015",18.5,,
+"PATCCHLS","C10-Lipid modifying agents","TCPPERMT","/capita, US$ exchange rate","ITA","Italy","2016","2016",19,,
+"PATCCHLS","C10-Lipid modifying agents","TCPPERMT","/capita, US$ exchange rate","ITA","Italy","2017","2017",20.4,,
+"PATCCHLS","C10-Lipid modifying agents","TCPPERMT","/capita, US$ exchange rate","ITA","Italy","2018","2018",17.1,,
+"PATCCHLS","C10-Lipid modifying agents","TCPPERMT","/capita, US$ exchange rate","ITA","Italy","2019","2019",15.6,,
+"PATCCHLS","C10-Lipid modifying agents","TCPPERMT","/capita, US$ exchange rate","ITA","Italy","2020","2020",17.1,,
+"PATCCHLS","C10-Lipid modifying agents","TCPPERMT","/capita, US$ exchange rate","ITA","Italy","2021","2021",19.1,,
+"PATCCHLS","C10-Lipid modifying agents","TCPPERMT","/capita, US$ exchange rate","ITA","Italy","2022","2022",18.5,"E","Estimated value"
+"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2011","2011",30.6,,
+"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2012","2012",25.7,,
+"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2013","2013",23.3,,
+"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2014","2014",22.4,,
+"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2015","2015",22.6,,
+"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2016","2016",24.5,,
+"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2017","2017",26.2,,
+"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2018","2018",21.3,,
+"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2019","2019",21.2,,
+"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2020","2020",23.1,,
+"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2021","2021",25,,
+"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2022","2022",28.5,"E","Estimated value"
+"PATCCHLS","C10-Lipid modifying agents","ATCPTTMT","% of total sales","ITA","Italy","2011","2011",7.1,,
+"PATCCHLS","C10-Lipid modifying agents","ATCPTTMT","% of total sales","ITA","Italy","2012","2012",6,,
+"PATCCHLS","C10-Lipid modifying agents","ATCPTTMT","% of total sales","ITA","Italy","2013","2013",5.3,,
+"PATCCHLS","C10-Lipid modifying agents","ATCPTTMT","% of total sales","ITA","Italy","2014","2014",5.1,,
+"PATCCHLS","C10-Lipid modifying agents","ATCPTTMT","% of total sales","ITA","Italy","2015","2015",4.5,,
+"PATCCHLS","C10-Lipid modifying agents","ATCPTTMT","% of total sales","ITA","Italy","2016","2016",4.6,,
+"PATCCHLS","C10-Lipid modifying agents","ATCPTTMT","% of total sales","ITA","Italy","2017","2017",4.8,,
+"PATCCHLS","C10-Lipid modifying agents","ATCPTTMT","% of total sales","ITA","Italy","2018","2018",3.9,,
+"PATCCHLS","C10-Lipid modifying agents","ATCPTTMT","% of total sales","ITA","Italy","2019","2019",3.6,,
+"PATCCHLS","C10-Lipid modifying agents","ATCPTTMT","% of total sales","ITA","Italy","2020","2020",3.8,,
+"PATCCHLS","C10-Lipid modifying agents","ATCPTTMT","% of total sales","ITA","Italy","2021","2021",4,,
+"PATCCHLS","C10-Lipid modifying agents","ATCPTTMT","% of total sales","ITA","Italy","2022","2022",4.2,"E","Estimated value"
+"PATCCHLS","C10-Lipid modifying agents","MLLNCUMT","Million of national currency units","KOR","Korea","2010","2010",675149,,
+"PATCCHLS","C10-Lipid modifying agents","MLLNCUMT","Million of national currency units","KOR","Korea","2011","2011",782416.7,"B","Break"
+"PATCCHLS","C10-Lipid modifying agents","MLLNCUMT","Million of national currency units","KOR","Korea","2012","2012",810160.3,,
+"PATCCHLS","C10-Lipid modifying agents","MLLNCUMT","Million of national currency units","KOR","Korea","2013","2013",892862.6,,
+"PATCCHLS","C10-Lipid modifying agents","MLLNCUMT","Million of national currency units","KOR","Korea","2014","2014",970126.7,,
+"PATCCHLS","C10-Lipid modifying agents","MLLNCUMT","Million of national currency units","KOR","Korea","2015","2015",1051102.3,,
+"PATCCHLS","C10-Lipid modifying agents","MLLNCUMT","Million of national currency units","KOR","Korea","2016","2016",1183828.3,"B","Break"
+"PATCCHLS","C10-Lipid modifying agents","MLLNCUMT","Million of national currency units","KOR","Korea","2017","2017",1343510.9,,
+"PATCCHLS","C10-Lipid modifying agents","MLLNCUMT","Million of national currency units","KOR","Korea","2018","2018",1501571.8,,
+"PATCCHLS","C10-Lipid modifying agents","MLLNCUMT","Million of national currency units","KOR","Korea","2019","2019",1659196.4,,
+"PATCCHLS","C10-Lipid modifying agents","MLLNCUMT","Million of national currency units","KOR","Korea","2020","2020",1932203,,
+"PATCCHLS","C10-Lipid modifying agents","MLLNCUMT","Million of national currency units","KOR","Korea","2021","2021",2227864,,
+"PATCCHLS","C10-Lipid modifying agents","MTMOTCMT","Million US$ at exchange rate","KOR","Korea","2010","2010",583.8,,
+"PATCCHLS","C10-Lipid modifying agents","MTMOTCMT","Million US$ at exchange rate","KOR","Korea","2011","2011",706,"B","Break"
+"PATCCHLS","C10-Lipid modifying agents","MTMOTCMT","Million US$ at exchange rate","KOR","Korea","2012","2012",719,,
+"PATCCHLS","C10-Lipid modifying agents","MTMOTCMT","Million US$ at exchange rate","KOR","Korea","2013","2013",815.4,,
+"PATCCHLS","C10-Lipid modifying agents","MTMOTCMT","Million US$ at exchange rate","KOR","Korea","2014","2014",921.4,,
+"PATCCHLS","C10-Lipid modifying agents","MTMOTCMT","Million US$ at exchange rate","KOR","Korea","2015","2015",929.4,,
+"PATCCHLS","C10-Lipid modifying agents","MTMOTCMT","Million US$ at exchange rate","KOR","Korea","2016","2016",1019.9,"B","Break"
+"PATCCHLS","C10-Lipid modifying agents","MTMOTCMT","Million US$ at exchange rate","KOR","Korea","2017","2017",1187.9,,
+"PATCCHLS","C10-Lipid modifying agents","MTMOTCMT","Million US$ at exchange rate","KOR","Korea","2018","2018",1364.9,,
+"PATCCHLS","C10-Lipid modifying agents","MTMOTCMT","Million US$ at exchange rate","KOR","Korea","2019","2019",1423.8,,
+"PATCCHLS","C10-Lipid modifying agents","MTMOTCMT","Million US$ at exchange rate","KOR","Korea","2020","2020",1637.1,,
+"PATCCHLS","C10-Lipid modifying agents","MTMOTCMT","Million US$ at exchange rate","KOR","Korea","2021","2021",1947.5,,
+"PATCCHLS","C10-Lipid modifying agents","MTMOPPMT","Million US$, purchasing power parity","KOR","Korea","2010","2010",802.8,,
+"PATCCHLS","C10-Lipid modifying agents","MTMOPPMT","Million US$, purchasing power parity","KOR","Korea","2011","2011",915.6,"B","Break"
+"PATCCHLS","C10-Lipid modifying agents","MTMOPPMT","Million US$, purchasing power parity","KOR","Korea","2012","2012",947.7,,
+"PATCCHLS","C10-Lipid modifying agents","MTMOPPMT","Million US$, purchasing power parity","KOR","Korea","2013","2013",1027.4,,
+"PATCCHLS","C10-Lipid modifying agents","MTMOPPMT","Million US$, purchasing power parity","KOR","Korea","2014","2014",1112.7,,
+"PATCCHLS","C10-Lipid modifying agents","MTMOPPMT","Million US$, purchasing power parity","KOR","Korea","2015","2015",1225.8,,
+"PATCCHLS","C10-Lipid modifying agents","MTMOPPMT","Million US$, purchasing power parity","KOR","Korea","2016","2016",1378.5,"B","Break"
+"PATCCHLS","C10-Lipid modifying agents","MTMOPPMT","Million US$, purchasing power parity","KOR","Korea","2017","2017",1539.6,,
+"PATCCHLS","C10-Lipid modifying agents","MTMOPPMT","Million US$, purchasing power parity","KOR","Korea","2018","2018",1756.5,,
+"PATCCHLS","C10-Lipid modifying agents","MTMOPPMT","Million US$, purchasing power parity","KOR","Korea","2019","2019",1937.3,,
+"PATCCHLS","C10-Lipid modifying agents","MTMOPPMT","Million US$, purchasing power parity","KOR","Korea","2020","2020",2306.6,,
+"PATCCHLS","C10-Lipid modifying agents","MTMOPPMT","Million US$, purchasing power parity","KOR","Korea","2021","2021",2608.4,,
+"PATCCHLS","C10-Lipid modifying agents","TCPPERMT","/capita, US$ exchange rate","KOR","Korea","2010","2010",11.8,,
+"PATCCHLS","C10-Lipid modifying agents","TCPPERMT","/capita, US$ exchange rate","KOR","Korea","2011","2011",14.1,"B","Break"
+"PATCCHLS","C10-Lipid modifying agents","TCPPERMT","/capita, US$ exchange rate","KOR","Korea","2012","2012",14.3,,
+"PATCCHLS","C10-Lipid modifying agents","TCPPERMT","/capita, US$ exchange rate","KOR","Korea","2013","2013",16.2,,
+"PATCCHLS","C10-Lipid modifying agents","TCPPERMT","/capita, US$ exchange rate","KOR","Korea","2014","2014",18.2,,
+"PATCCHLS","C10-Lipid modifying agents","TCPPERMT","/capita, US$ exchange rate","KOR","Korea","2015","2015",18.2,,
+"PATCCHLS","C10-Lipid modifying agents","TCPPERMT","/capita, US$ exchange rate","KOR","Korea","2016","2016",19.9,"B","Break"
+"PATCCHLS","C10-Lipid modifying agents","TCPPERMT","/capita, US$ exchange rate","KOR","Korea","2017","2017",23.1,,
+"PATCCHLS","C10-Lipid modifying agents","TCPPERMT","/capita, US$ exchange rate","KOR","Korea","2018","2018",26.5,,
+"PATCCHLS","C10-Lipid modifying agents","TCPPERMT","/capita, US$ exchange rate","KOR","Korea","2019","2019",27.5,,
+"PATCCHLS","C10-Lipid modifying agents","TCPPERMT","/capita, US$ exchange rate","KOR","Korea","2020","2020",31.6,,
+"PATCCHLS","C10-Lipid modifying agents","TCPPERMT","/capita, US$ exchange rate","KOR","Korea","2021","2021",37.6,,
+"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2010","2010",16.2,,
+"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2011","2011",18.3,"B","Break"
+"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2012","2012",18.9,,
+"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2013","2013",20.4,,
+"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2014","2014",21.9,,
+"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2015","2015",24,,
+"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2016","2016",26.9,"B","Break"
+"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2017","2017",30,,
+"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2018","2018",34.1,,
+"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2019","2019",37.4,,
+"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2020","2020",44.5,,
+"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2021","2021",50.4,,
+"PATCCHLS","C10-Lipid modifying agents","ATCPTTMT","% of total sales","KOR","Korea","2010","2010",3.3,,
+"PATCCHLS","C10-Lipid modifying agents","ATCPTTMT","% of total sales","KOR","Korea","2011","2011",3.5,"B","Break"
+"PATCCHLS","C10-Lipid modifying agents","ATCPTTMT","% of total sales","KOR","Korea","2012","2012",3.7,,
+"PATCCHLS","C10-Lipid modifying agents","ATCPTTMT","% of total sales","KOR","Korea","2013","2013",4,,
+"PATCCHLS","C10-Lipid modifying agents","ATCPTTMT","% of total sales","KOR","Korea","2014","2014",4.1,,
+"PATCCHLS","C10-Lipid modifying agents","ATCPTTMT","% of total sales","KOR","Korea","2015","2015",4.3,,
+"PATCCHLS","C10-Lipid modifying agents","ATCPTTMT","% of total sales","KOR","Korea","2016","2016",4.7,"B","Break"
+"PATCCHLS","C10-Lipid modifying agents","ATCPTTMT","% of total sales","KOR","Korea","2017","2017",5,,
+"PATCCHLS","C10-Lipid modifying agents","ATCPTTMT","% of total sales","KOR","Korea","2018","2018",5.2,,
+"PATCCHLS","C10-Lipid modifying agents","ATCPTTMT","% of total sales","KOR","Korea","2019","2019",5.3,,
+"PATCCHLS","C10-Lipid modifying agents","ATCPTTMT","% of total sales","KOR","Korea","2020","2020",5.9,,
+"PATCCHLS","C10-Lipid modifying agents","ATCPTTMT","% of total sales","KOR","Korea","2021","2021",6.4,,
+"PATCCHLS","C10-Lipid modifying agents","MLLNCUMT","Million of national currency units","LUX","Luxembourg","2010","2010",15.8,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","MLLNCUMT","Million of national currency units","LUX","Luxembourg","2011","2011",17.4,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","MLLNCUMT","Million of national currency units","LUX","Luxembourg","2012","2012",17.5,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","MLLNCUMT","Million of national currency units","LUX","Luxembourg","2013","2013",15.6,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","MLLNCUMT","Million of national currency units","LUX","Luxembourg","2014","2014",13.1,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","MLLNCUMT","Million of national currency units","LUX","Luxembourg","2015","2015",12.7,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","MLLNCUMT","Million of national currency units","LUX","Luxembourg","2016","2016",12.6,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","MLLNCUMT","Million of national currency units","LUX","Luxembourg","2017","2017",11.6,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","MLLNCUMT","Million of national currency units","LUX","Luxembourg","2018","2018",9,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","MLLNCUMT","Million of national currency units","LUX","Luxembourg","2019","2019",8,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","MLLNCUMT","Million of national currency units","LUX","Luxembourg","2020","2020",8.1,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","MLLNCUMT","Million of national currency units","LUX","Luxembourg","2021","2021",9,"B; D; P","Break; Difference in methodology; Provisional value"
+"PATCCHLS","C10-Lipid modifying agents","MLLNCUMT","Million of national currency units","LUX","Luxembourg","2022","2022",10,"D; P","Difference in methodology; Provisional value"
+"PATCCHLS","C10-Lipid modifying agents","MTMOTCMT","Million US$ at exchange rate","LUX","Luxembourg","2010","2010",21,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","MTMOTCMT","Million US$ at exchange rate","LUX","Luxembourg","2011","2011",24.3,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","MTMOTCMT","Million US$ at exchange rate","LUX","Luxembourg","2012","2012",22.4,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","MTMOTCMT","Million US$ at exchange rate","LUX","Luxembourg","2013","2013",20.7,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","MTMOTCMT","Million US$ at exchange rate","LUX","Luxembourg","2014","2014",17.4,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","MTMOTCMT","Million US$ at exchange rate","LUX","Luxembourg","2015","2015",14.1,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","MTMOTCMT","Million US$ at exchange rate","LUX","Luxembourg","2016","2016",13.9,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","MTMOTCMT","Million US$ at exchange rate","LUX","Luxembourg","2017","2017",13.1,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","MTMOTCMT","Million US$ at exchange rate","LUX","Luxembourg","2018","2018",10.6,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","MTMOTCMT","Million US$ at exchange rate","LUX","Luxembourg","2019","2019",9,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","MTMOTCMT","Million US$ at exchange rate","LUX","Luxembourg","2020","2020",9.3,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","MTMOTCMT","Million US$ at exchange rate","LUX","Luxembourg","2021","2021",10.7,"B; D; P","Break; Difference in methodology; Provisional value"
+"PATCCHLS","C10-Lipid modifying agents","MTMOTCMT","Million US$ at exchange rate","LUX","Luxembourg","2022","2022",10.5,"D; P","Difference in methodology; Provisional value"
+"PATCCHLS","C10-Lipid modifying agents","MTMOPPMT","Million US$, purchasing power parity","LUX","Luxembourg","2010","2010",17.1,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","MTMOPPMT","Million US$, purchasing power parity","LUX","Luxembourg","2011","2011",19.3,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","MTMOPPMT","Million US$, purchasing power parity","LUX","Luxembourg","2012","2012",19.3,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","MTMOPPMT","Million US$, purchasing power parity","LUX","Luxembourg","2013","2013",17.4,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","MTMOPPMT","Million US$, purchasing power parity","LUX","Luxembourg","2014","2014",14.8,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","MTMOPPMT","Million US$, purchasing power parity","LUX","Luxembourg","2015","2015",14.4,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","MTMOPPMT","Million US$, purchasing power parity","LUX","Luxembourg","2016","2016",14.8,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","MTMOPPMT","Million US$, purchasing power parity","LUX","Luxembourg","2017","2017",13.7,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","MTMOPPMT","Million US$, purchasing power parity","LUX","Luxembourg","2018","2018",10.6,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","MTMOPPMT","Million US$, purchasing power parity","LUX","Luxembourg","2019","2019",9.5,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","MTMOPPMT","Million US$, purchasing power parity","LUX","Luxembourg","2020","2020",9.5,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","MTMOPPMT","Million US$, purchasing power parity","LUX","Luxembourg","2021","2021",10.5,"B; D; P","Break; Difference in methodology; Provisional value"
+"PATCCHLS","C10-Lipid modifying agents","MTMOPPMT","Million US$, purchasing power parity","LUX","Luxembourg","2022","2022",12,"D; P","Difference in methodology; Provisional value"
+"PATCCHLS","C10-Lipid modifying agents","TCPPERMT","/capita, US$ exchange rate","LUX","Luxembourg","2010","2010",44.4,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","TCPPERMT","/capita, US$ exchange rate","LUX","Luxembourg","2011","2011",50.3,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","TCPPERMT","/capita, US$ exchange rate","LUX","Luxembourg","2012","2012",45.5,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","TCPPERMT","/capita, US$ exchange rate","LUX","Luxembourg","2013","2013",41.3,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","TCPPERMT","/capita, US$ exchange rate","LUX","Luxembourg","2014","2014",34.1,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","TCPPERMT","/capita, US$ exchange rate","LUX","Luxembourg","2015","2015",27.1,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","TCPPERMT","/capita, US$ exchange rate","LUX","Luxembourg","2016","2016",26.5,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","TCPPERMT","/capita, US$ exchange rate","LUX","Luxembourg","2017","2017",24.5,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","TCPPERMT","/capita, US$ exchange rate","LUX","Luxembourg","2018","2018",19.5,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","TCPPERMT","/capita, US$ exchange rate","LUX","Luxembourg","2019","2019",16.1,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","TCPPERMT","/capita, US$ exchange rate","LUX","Luxembourg","2020","2020",16.4,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","TCPPERMT","/capita, US$ exchange rate","LUX","Luxembourg","2021","2021",18.6,"B; D; P","Break; Difference in methodology; Provisional value"
+"PATCCHLS","C10-Lipid modifying agents","TCPPERMT","/capita, US$ exchange rate","LUX","Luxembourg","2022","2022",17.9,"D; P","Difference in methodology; Provisional value"
+"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2010","2010",36.1,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2011","2011",40,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2012","2012",39.1,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2013","2013",34.7,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2014","2014",29.1,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2015","2015",27.7,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2016","2016",28.1,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2017","2017",25.5,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2018","2018",19.4,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2019","2019",17.1,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2020","2020",16.7,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2021","2021",18.3,"B; D; P","Break; Difference in methodology; Provisional value"
+"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2022","2022",20.5,"D; P","Difference in methodology; Provisional value"
+"PATCCHLS","C10-Lipid modifying agents","ATCPTTMT","% of total sales","LUX","Luxembourg","2010","2010",8.4,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","ATCPTTMT","% of total sales","LUX","Luxembourg","2011","2011",9.2,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","ATCPTTMT","% of total sales","LUX","Luxembourg","2012","2012",8.9,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","ATCPTTMT","% of total sales","LUX","Luxembourg","2013","2013",8,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","ATCPTTMT","% of total sales","LUX","Luxembourg","2014","2014",6.9,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","ATCPTTMT","% of total sales","LUX","Luxembourg","2015","2015",6.6,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","ATCPTTMT","% of total sales","LUX","Luxembourg","2016","2016",6.5,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","ATCPTTMT","% of total sales","LUX","Luxembourg","2017","2017",6,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","ATCPTTMT","% of total sales","LUX","Luxembourg","2018","2018",4.5,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","ATCPTTMT","% of total sales","LUX","Luxembourg","2019","2019",3.9,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","ATCPTTMT","% of total sales","LUX","Luxembourg","2020","2020",3.9,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","ATCPTTMT","% of total sales","LUX","Luxembourg","2021","2021",3.8,"B; D; P","Break; Difference in methodology; Provisional value"
+"PATCCHLS","C10-Lipid modifying agents","ATCPTTMT","% of total sales","LUX","Luxembourg","2022","2022",3.9,"D; P","Difference in methodology; Provisional value"
+"PATCCHLS","C10-Lipid modifying agents","MLLNCUMT","Million of national currency units","NLD","Netherlands","2010","2010",298.9,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","MLLNCUMT","Million of national currency units","NLD","Netherlands","2011","2011",309.8,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","MLLNCUMT","Million of national currency units","NLD","Netherlands","2012","2012",242.3,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","MLLNCUMT","Million of national currency units","NLD","Netherlands","2013","2013",213.2,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","MLLNCUMT","Million of national currency units","NLD","Netherlands","2014","2014",213.7,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","MTMOTCMT","Million US$ at exchange rate","NLD","Netherlands","2010","2010",396.2,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","MTMOTCMT","Million US$ at exchange rate","NLD","Netherlands","2011","2011",431.2,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","MTMOTCMT","Million US$ at exchange rate","NLD","Netherlands","2012","2012",311.4,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","MTMOTCMT","Million US$ at exchange rate","NLD","Netherlands","2013","2013",283.2,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","MTMOTCMT","Million US$ at exchange rate","NLD","Netherlands","2014","2014",283.9,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","MTMOPPMT","Million US$, purchasing power parity","NLD","Netherlands","2010","2010",349.9,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","MTMOPPMT","Million US$, purchasing power parity","NLD","Netherlands","2011","2011",370.5,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","MTMOPPMT","Million US$, purchasing power parity","NLD","Netherlands","2012","2012",294,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","MTMOPPMT","Million US$, purchasing power parity","NLD","Netherlands","2013","2013",267.1,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","MTMOPPMT","Million US$, purchasing power parity","NLD","Netherlands","2014","2014",264.2,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","TCPPERMT","/capita, US$ exchange rate","NLD","Netherlands","2010","2010",23.8,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","TCPPERMT","/capita, US$ exchange rate","NLD","Netherlands","2011","2011",25.8,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","TCPPERMT","/capita, US$ exchange rate","NLD","Netherlands","2012","2012",18.6,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","TCPPERMT","/capita, US$ exchange rate","NLD","Netherlands","2013","2013",16.9,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","TCPPERMT","/capita, US$ exchange rate","NLD","Netherlands","2014","2014",16.8,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","NLD","Netherlands","2010","2010",21.1,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","NLD","Netherlands","2011","2011",22.2,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","NLD","Netherlands","2012","2012",17.5,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","NLD","Netherlands","2013","2013",15.9,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","NLD","Netherlands","2014","2014",15.7,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","ATCPTTMT","% of total sales","NLD","Netherlands","2010","2010",5.7,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","ATCPTTMT","% of total sales","NLD","Netherlands","2011","2011",5.9,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","ATCPTTMT","% of total sales","NLD","Netherlands","2012","2012",5.3,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","ATCPTTMT","% of total sales","NLD","Netherlands","2013","2013",5,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","ATCPTTMT","% of total sales","NLD","Netherlands","2014","2014",4.9,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","MLLNCUMT","Million of national currency units","NZL","New Zealand","2010","2010",37.9,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","MLLNCUMT","Million of national currency units","NZL","New Zealand","2011","2011",53.5,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","MLLNCUMT","Million of national currency units","NZL","New Zealand","2012","2012",76.5,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","MLLNCUMT","Million of national currency units","NZL","New Zealand","2013","2013",30.1,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","MLLNCUMT","Million of national currency units","NZL","New Zealand","2014","2014",17.5,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","MLLNCUMT","Million of national currency units","NZL","New Zealand","2015","2015",17.4,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","MLLNCUMT","Million of national currency units","NZL","New Zealand","2016","2016",11.7,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","MLLNCUMT","Million of national currency units","NZL","New Zealand","2017","2017",9.1,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","MLLNCUMT","Million of national currency units","NZL","New Zealand","2018","2018",7.8,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","MLLNCUMT","Million of national currency units","NZL","New Zealand","2019","2019",7,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","MLLNCUMT","Million of national currency units","NZL","New Zealand","2020","2020",7,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","MLLNCUMT","Million of national currency units","NZL","New Zealand","2021","2021",8.3,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","MLLNCUMT","Million of national currency units","NZL","New Zealand","2022","2022",8.9,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","MTMOTCMT","Million US$ at exchange rate","NZL","New Zealand","2010","2010",27.3,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","MTMOTCMT","Million US$ at exchange rate","NZL","New Zealand","2011","2011",42.3,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","MTMOTCMT","Million US$ at exchange rate","NZL","New Zealand","2012","2012",62,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","MTMOTCMT","Million US$ at exchange rate","NZL","New Zealand","2013","2013",24.7,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","MTMOTCMT","Million US$ at exchange rate","NZL","New Zealand","2014","2014",14.5,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","MTMOTCMT","Million US$ at exchange rate","NZL","New Zealand","2015","2015",12.2,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","MTMOTCMT","Million US$ at exchange rate","NZL","New Zealand","2016","2016",8.1,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","MTMOTCMT","Million US$ at exchange rate","NZL","New Zealand","2017","2017",6.5,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","MTMOTCMT","Million US$ at exchange rate","NZL","New Zealand","2018","2018",5.4,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","MTMOTCMT","Million US$ at exchange rate","NZL","New Zealand","2019","2019",4.6,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","MTMOTCMT","Million US$ at exchange rate","NZL","New Zealand","2020","2020",4.5,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","MTMOTCMT","Million US$ at exchange rate","NZL","New Zealand","2021","2021",5.8,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","MTMOTCMT","Million US$ at exchange rate","NZL","New Zealand","2022","2022",5.6,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","MTMOPPMT","Million US$, purchasing power parity","NZL","New Zealand","2010","2010",25.3,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","MTMOPPMT","Million US$, purchasing power parity","NZL","New Zealand","2011","2011",36,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","MTMOPPMT","Million US$, purchasing power parity","NZL","New Zealand","2012","2012",51.2,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","MTMOPPMT","Million US$, purchasing power parity","NZL","New Zealand","2013","2013",20.8,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","MTMOPPMT","Million US$, purchasing power parity","NZL","New Zealand","2014","2014",12.1,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","MTMOPPMT","Million US$, purchasing power parity","NZL","New Zealand","2015","2015",11.8,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","MTMOPPMT","Million US$, purchasing power parity","NZL","New Zealand","2016","2016",8.1,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","MTMOPPMT","Million US$, purchasing power parity","NZL","New Zealand","2017","2017",6.4,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","MTMOPPMT","Million US$, purchasing power parity","NZL","New Zealand","2018","2018",5.3,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","MTMOPPMT","Million US$, purchasing power parity","NZL","New Zealand","2019","2019",5,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","MTMOPPMT","Million US$, purchasing power parity","NZL","New Zealand","2020","2020",5,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","MTMOPPMT","Million US$, purchasing power parity","NZL","New Zealand","2021","2021",5.7,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","MTMOPPMT","Million US$, purchasing power parity","NZL","New Zealand","2022","2022",6.1,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","TCPPERMT","/capita, US$ exchange rate","NZL","New Zealand","2010","2010",6.3,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","TCPPERMT","/capita, US$ exchange rate","NZL","New Zealand","2011","2011",9.6,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","TCPPERMT","/capita, US$ exchange rate","NZL","New Zealand","2012","2012",14.1,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","TCPPERMT","/capita, US$ exchange rate","NZL","New Zealand","2013","2013",5.6,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","TCPPERMT","/capita, US$ exchange rate","NZL","New Zealand","2014","2014",3.2,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","TCPPERMT","/capita, US$ exchange rate","NZL","New Zealand","2015","2015",2.6,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","TCPPERMT","/capita, US$ exchange rate","NZL","New Zealand","2016","2016",1.7,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","TCPPERMT","/capita, US$ exchange rate","NZL","New Zealand","2017","2017",1.3,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","TCPPERMT","/capita, US$ exchange rate","NZL","New Zealand","2018","2018",1.1,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","TCPPERMT","/capita, US$ exchange rate","NZL","New Zealand","2019","2019",0.9,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","TCPPERMT","/capita, US$ exchange rate","NZL","New Zealand","2020","2020",0.9,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","TCPPERMT","/capita, US$ exchange rate","NZL","New Zealand","2021","2021",1.1,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","TCPPERMT","/capita, US$ exchange rate","NZL","New Zealand","2022","2022",1.1,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2010","2010",5.8,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2011","2011",8.2,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2012","2012",11.6,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2013","2013",4.7,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2014","2014",2.7,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2015","2015",2.6,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2016","2016",1.7,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2017","2017",1.3,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2018","2018",1.1,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2019","2019",1,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2020","2020",1,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2021","2021",1.1,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2022","2022",1.2,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","ATCPTTMT","% of total sales","NZL","New Zealand","2010","2010",5.1,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","ATCPTTMT","% of total sales","NZL","New Zealand","2011","2011",6.6,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","ATCPTTMT","% of total sales","NZL","New Zealand","2012","2012",8.3,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","ATCPTTMT","% of total sales","NZL","New Zealand","2013","2013",3.3,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","ATCPTTMT","% of total sales","NZL","New Zealand","2014","2014",1.8,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","ATCPTTMT","% of total sales","NZL","New Zealand","2015","2015",1.8,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","ATCPTTMT","% of total sales","NZL","New Zealand","2016","2016",1.1,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","ATCPTTMT","% of total sales","NZL","New Zealand","2017","2017",0.7,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","ATCPTTMT","% of total sales","NZL","New Zealand","2018","2018",0.6,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","ATCPTTMT","% of total sales","NZL","New Zealand","2019","2019",0.5,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","ATCPTTMT","% of total sales","NZL","New Zealand","2020","2020",0.4,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","ATCPTTMT","% of total sales","NZL","New Zealand","2021","2021",0.5,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","ATCPTTMT","% of total sales","NZL","New Zealand","2022","2022",0.5,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","MLLNCUMT","Million of national currency units","NOR","Norway","2010","2010",440,,
+"PATCCHLS","C10-Lipid modifying agents","MLLNCUMT","Million of national currency units","NOR","Norway","2011","2011",405,,
+"PATCCHLS","C10-Lipid modifying agents","MLLNCUMT","Million of national currency units","NOR","Norway","2012","2012",375,,
+"PATCCHLS","C10-Lipid modifying agents","MLLNCUMT","Million of national currency units","NOR","Norway","2013","2013",391,,
+"PATCCHLS","C10-Lipid modifying agents","MLLNCUMT","Million of national currency units","NOR","Norway","2014","2014",377,,
+"PATCCHLS","C10-Lipid modifying agents","MLLNCUMT","Million of national currency units","NOR","Norway","2015","2015",406,,
+"PATCCHLS","C10-Lipid modifying agents","MLLNCUMT","Million of national currency units","NOR","Norway","2016","2016",473,,
+"PATCCHLS","C10-Lipid modifying agents","MLLNCUMT","Million of national currency units","NOR","Norway","2017","2017",504,,
+"PATCCHLS","C10-Lipid modifying agents","MLLNCUMT","Million of national currency units","NOR","Norway","2018","2018",509,,
+"PATCCHLS","C10-Lipid modifying agents","MLLNCUMT","Million of national currency units","NOR","Norway","2019","2019",493,,
+"PATCCHLS","C10-Lipid modifying agents","MLLNCUMT","Million of national currency units","NOR","Norway","2020","2020",473,,
+"PATCCHLS","C10-Lipid modifying agents","MLLNCUMT","Million of national currency units","NOR","Norway","2021","2021",502,,
+"PATCCHLS","C10-Lipid modifying agents","MLLNCUMT","Million of national currency units","NOR","Norway","2022","2022",554,,
+"PATCCHLS","C10-Lipid modifying agents","MTMOTCMT","Million US$ at exchange rate","NOR","Norway","2010","2010",72.8,,
+"PATCCHLS","C10-Lipid modifying agents","MTMOTCMT","Million US$ at exchange rate","NOR","Norway","2011","2011",72.3,,
+"PATCCHLS","C10-Lipid modifying agents","MTMOTCMT","Million US$ at exchange rate","NOR","Norway","2012","2012",64.5,,
+"PATCCHLS","C10-Lipid modifying agents","MTMOTCMT","Million US$ at exchange rate","NOR","Norway","2013","2013",66.6,,
+"PATCCHLS","C10-Lipid modifying agents","MTMOTCMT","Million US$ at exchange rate","NOR","Norway","2014","2014",59.8,,
+"PATCCHLS","C10-Lipid modifying agents","MTMOTCMT","Million US$ at exchange rate","NOR","Norway","2015","2015",50.3,,
+"PATCCHLS","C10-Lipid modifying agents","MTMOTCMT","Million US$ at exchange rate","NOR","Norway","2016","2016",56.3,,
+"PATCCHLS","C10-Lipid modifying agents","MTMOTCMT","Million US$ at exchange rate","NOR","Norway","2017","2017",60.9,,
+"PATCCHLS","C10-Lipid modifying agents","MTMOTCMT","Million US$ at exchange rate","NOR","Norway","2018","2018",62.6,,
+"PATCCHLS","C10-Lipid modifying agents","MTMOTCMT","Million US$ at exchange rate","NOR","Norway","2019","2019",56,,
+"PATCCHLS","C10-Lipid modifying agents","MTMOTCMT","Million US$ at exchange rate","NOR","Norway","2020","2020",50.2,,
+"PATCCHLS","C10-Lipid modifying agents","MTMOTCMT","Million US$ at exchange rate","NOR","Norway","2021","2021",58.4,,
+"PATCCHLS","C10-Lipid modifying agents","MTMOTCMT","Million US$ at exchange rate","NOR","Norway","2022","2022",57.6,,
+"PATCCHLS","C10-Lipid modifying agents","MTMOPPMT","Million US$, purchasing power parity","NOR","Norway","2010","2010",48.1,,
+"PATCCHLS","C10-Lipid modifying agents","MTMOPPMT","Million US$, purchasing power parity","NOR","Norway","2011","2011",44.6,,
+"PATCCHLS","C10-Lipid modifying agents","MTMOPPMT","Million US$, purchasing power parity","NOR","Norway","2012","2012",41.5,,
+"PATCCHLS","C10-Lipid modifying agents","MTMOPPMT","Million US$, purchasing power parity","NOR","Norway","2013","2013",43.3,,
+"PATCCHLS","C10-Lipid modifying agents","MTMOPPMT","Million US$, purchasing power parity","NOR","Norway","2014","2014",40.6,,
+"PATCCHLS","C10-Lipid modifying agents","MTMOPPMT","Million US$, purchasing power parity","NOR","Norway","2015","2015",40.9,,
+"PATCCHLS","C10-Lipid modifying agents","MTMOPPMT","Million US$, purchasing power parity","NOR","Norway","2016","2016",47.1,,
+"PATCCHLS","C10-Lipid modifying agents","MTMOPPMT","Million US$, purchasing power parity","NOR","Norway","2017","2017",51.7,,
+"PATCCHLS","C10-Lipid modifying agents","MTMOPPMT","Million US$, purchasing power parity","NOR","Norway","2018","2018",53.1,,
+"PATCCHLS","C10-Lipid modifying agents","MTMOPPMT","Million US$, purchasing power parity","NOR","Norway","2019","2019",51.2,,
+"PATCCHLS","C10-Lipid modifying agents","MTMOPPMT","Million US$, purchasing power parity","NOR","Norway","2020","2020",47.9,,
+"PATCCHLS","C10-Lipid modifying agents","MTMOPPMT","Million US$, purchasing power parity","NOR","Norway","2021","2021",52.8,,
+"PATCCHLS","C10-Lipid modifying agents","MTMOPPMT","Million US$, purchasing power parity","NOR","Norway","2022","2022",51.6,,
+"PATCCHLS","C10-Lipid modifying agents","TCPPERMT","/capita, US$ exchange rate","NOR","Norway","2010","2010",14.9,,
+"PATCCHLS","C10-Lipid modifying agents","TCPPERMT","/capita, US$ exchange rate","NOR","Norway","2011","2011",14.6,,
+"PATCCHLS","C10-Lipid modifying agents","TCPPERMT","/capita, US$ exchange rate","NOR","Norway","2012","2012",12.8,,
+"PATCCHLS","C10-Lipid modifying agents","TCPPERMT","/capita, US$ exchange rate","NOR","Norway","2013","2013",13.1,,
+"PATCCHLS","C10-Lipid modifying agents","TCPPERMT","/capita, US$ exchange rate","NOR","Norway","2014","2014",11.6,,
+"PATCCHLS","C10-Lipid modifying agents","TCPPERMT","/capita, US$ exchange rate","NOR","Norway","2015","2015",9.7,,
+"PATCCHLS","C10-Lipid modifying agents","TCPPERMT","/capita, US$ exchange rate","NOR","Norway","2016","2016",10.8,,
+"PATCCHLS","C10-Lipid modifying agents","TCPPERMT","/capita, US$ exchange rate","NOR","Norway","2017","2017",11.5,,
+"PATCCHLS","C10-Lipid modifying agents","TCPPERMT","/capita, US$ exchange rate","NOR","Norway","2018","2018",11.8,,
+"PATCCHLS","C10-Lipid modifying agents","TCPPERMT","/capita, US$ exchange rate","NOR","Norway","2019","2019",10.5,,
+"PATCCHLS","C10-Lipid modifying agents","TCPPERMT","/capita, US$ exchange rate","NOR","Norway","2020","2020",9.3,,
+"PATCCHLS","C10-Lipid modifying agents","TCPPERMT","/capita, US$ exchange rate","NOR","Norway","2021","2021",10.8,,
+"PATCCHLS","C10-Lipid modifying agents","TCPPERMT","/capita, US$ exchange rate","NOR","Norway","2022","2022",10.6,,
+"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2010","2010",9.8,,
+"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2011","2011",9,,
+"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2012","2012",8.3,,
+"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2013","2013",8.5,,
+"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2014","2014",7.9,,
+"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2015","2015",7.9,,
+"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2016","2016",9,,
+"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2017","2017",9.8,,
+"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2018","2018",10,,
+"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2019","2019",9.6,,
+"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2020","2020",8.9,,
+"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2021","2021",9.8,,
+"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2022","2022",9.5,,
+"PATCCHLS","C10-Lipid modifying agents","ATCPTTMT","% of total sales","NOR","Norway","2010","2010",2.5,,
+"PATCCHLS","C10-Lipid modifying agents","ATCPTTMT","% of total sales","NOR","Norway","2011","2011",2.2,,
+"PATCCHLS","C10-Lipid modifying agents","ATCPTTMT","% of total sales","NOR","Norway","2012","2012",2,,
+"PATCCHLS","C10-Lipid modifying agents","ATCPTTMT","% of total sales","NOR","Norway","2013","2013",2,,
+"PATCCHLS","C10-Lipid modifying agents","ATCPTTMT","% of total sales","NOR","Norway","2014","2014",1.8,,
+"PATCCHLS","C10-Lipid modifying agents","ATCPTTMT","% of total sales","NOR","Norway","2015","2015",1.8,,
+"PATCCHLS","C10-Lipid modifying agents","ATCPTTMT","% of total sales","NOR","Norway","2016","2016",1.9,,
+"PATCCHLS","C10-Lipid modifying agents","ATCPTTMT","% of total sales","NOR","Norway","2017","2017",1.9,,
+"PATCCHLS","C10-Lipid modifying agents","ATCPTTMT","% of total sales","NOR","Norway","2018","2018",1.9,,
+"PATCCHLS","C10-Lipid modifying agents","ATCPTTMT","% of total sales","NOR","Norway","2019","2019",1.7,,
+"PATCCHLS","C10-Lipid modifying agents","ATCPTTMT","% of total sales","NOR","Norway","2020","2020",1.6,,
+"PATCCHLS","C10-Lipid modifying agents","ATCPTTMT","% of total sales","NOR","Norway","2021","2021",1.5,,
+"PATCCHLS","C10-Lipid modifying agents","ATCPTTMT","% of total sales","NOR","Norway","2022","2022",1.5,,
+"PATCCHLS","C10-Lipid modifying agents","MLLNCUMT","Million of national currency units","PRT","Portugal","2010","2010",256.5,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","MLLNCUMT","Million of national currency units","PRT","Portugal","2011","2011",202.3,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","MLLNCUMT","Million of national currency units","PRT","Portugal","2012","2012",163.9,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","MLLNCUMT","Million of national currency units","PRT","Portugal","2013","2013",153.4,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","MLLNCUMT","Million of national currency units","PRT","Portugal","2014","2014",157.8,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","MLLNCUMT","Million of national currency units","PRT","Portugal","2015","2015",161,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","MLLNCUMT","Million of national currency units","PRT","Portugal","2016","2016",166.3,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","MLLNCUMT","Million of national currency units","PRT","Portugal","2017","2017",160.3,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","MLLNCUMT","Million of national currency units","PRT","Portugal","2018","2018",143.8,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","MLLNCUMT","Million of national currency units","PRT","Portugal","2019","2019",149.4,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","MLLNCUMT","Million of national currency units","PRT","Portugal","2020","2020",160.2,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","MLLNCUMT","Million of national currency units","PRT","Portugal","2021","2021",170.3,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","MLLNCUMT","Million of national currency units","PRT","Portugal","2022","2022",188.2,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","MTMOTCMT","Million US$ at exchange rate","PRT","Portugal","2010","2010",340.1,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","MTMOTCMT","Million US$ at exchange rate","PRT","Portugal","2011","2011",281.6,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","MTMOTCMT","Million US$ at exchange rate","PRT","Portugal","2012","2012",210.6,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","MTMOTCMT","Million US$ at exchange rate","PRT","Portugal","2013","2013",203.7,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","MTMOTCMT","Million US$ at exchange rate","PRT","Portugal","2014","2014",209.7,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","MTMOTCMT","Million US$ at exchange rate","PRT","Portugal","2015","2015",178.7,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","MTMOTCMT","Million US$ at exchange rate","PRT","Portugal","2016","2016",184,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","MTMOTCMT","Million US$ at exchange rate","PRT","Portugal","2017","2017",181,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","MTMOTCMT","Million US$ at exchange rate","PRT","Portugal","2018","2018",169.8,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","MTMOTCMT","Million US$ at exchange rate","PRT","Portugal","2019","2019",167.2,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","MTMOTCMT","Million US$ at exchange rate","PRT","Portugal","2020","2020",182.9,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","MTMOTCMT","Million US$ at exchange rate","PRT","Portugal","2021","2021",201.5,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","MTMOTCMT","Million US$ at exchange rate","PRT","Portugal","2022","2022",198.2,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","MTMOPPMT","Million US$, purchasing power parity","PRT","Portugal","2010","2010",411.6,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","MTMOPPMT","Million US$, purchasing power parity","PRT","Portugal","2011","2011",324.7,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","MTMOPPMT","Million US$, purchasing power parity","PRT","Portugal","2012","2012",270.7,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","MTMOPPMT","Million US$, purchasing power parity","PRT","Portugal","2013","2013",262.8,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","MTMOPPMT","Million US$, purchasing power parity","PRT","Portugal","2014","2014",272.7,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","MTMOPPMT","Million US$, purchasing power parity","PRT","Portugal","2015","2015",275.3,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","MTMOPPMT","Million US$, purchasing power parity","PRT","Portugal","2016","2016",291,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","MTMOPPMT","Million US$, purchasing power parity","PRT","Portugal","2017","2017",278.4,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","MTMOPPMT","Million US$, purchasing power parity","PRT","Portugal","2018","2018",251.8,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","MTMOPPMT","Million US$, purchasing power parity","PRT","Portugal","2019","2019",267.3,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","MTMOPPMT","Million US$, purchasing power parity","PRT","Portugal","2020","2020",287.5,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","MTMOPPMT","Million US$, purchasing power parity","PRT","Portugal","2021","2021",300.1,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","MTMOPPMT","Million US$, purchasing power parity","PRT","Portugal","2022","2022",342.2,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","TCPPERMT","/capita, US$ exchange rate","PRT","Portugal","2010","2010",32.2,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","TCPPERMT","/capita, US$ exchange rate","PRT","Portugal","2011","2011",26.7,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","TCPPERMT","/capita, US$ exchange rate","PRT","Portugal","2012","2012",20,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","TCPPERMT","/capita, US$ exchange rate","PRT","Portugal","2013","2013",19.5,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","TCPPERMT","/capita, US$ exchange rate","PRT","Portugal","2014","2014",20.2,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","TCPPERMT","/capita, US$ exchange rate","PRT","Portugal","2015","2015",17.3,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","TCPPERMT","/capita, US$ exchange rate","PRT","Portugal","2016","2016",17.8,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","TCPPERMT","/capita, US$ exchange rate","PRT","Portugal","2017","2017",17.6,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","TCPPERMT","/capita, US$ exchange rate","PRT","Portugal","2018","2018",16.5,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","TCPPERMT","/capita, US$ exchange rate","PRT","Portugal","2019","2019",16.3,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","TCPPERMT","/capita, US$ exchange rate","PRT","Portugal","2020","2020",17.8,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","TCPPERMT","/capita, US$ exchange rate","PRT","Portugal","2021","2021",19.4,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","TCPPERMT","/capita, US$ exchange rate","PRT","Portugal","2022","2022",19.1,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2010","2010",38.9,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2011","2011",30.8,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2012","2012",25.7,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2013","2013",25.1,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2014","2014",26.2,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2015","2015",26.6,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2016","2016",28.2,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2017","2017",27,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2018","2018",24.5,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2019","2019",26,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2020","2020",27.9,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2021","2021",29,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2022","2022",33.1,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","ATCPTTMT","% of total sales","PRT","Portugal","2010","2010",7.9,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","ATCPTTMT","% of total sales","PRT","Portugal","2011","2011",6.9,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","ATCPTTMT","% of total sales","PRT","Portugal","2012","2012",6.3,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","ATCPTTMT","% of total sales","PRT","Portugal","2013","2013",6.4,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","ATCPTTMT","% of total sales","PRT","Portugal","2014","2014",6.6,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","ATCPTTMT","% of total sales","PRT","Portugal","2015","2015",6.5,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","ATCPTTMT","% of total sales","PRT","Portugal","2016","2016",6.6,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","ATCPTTMT","% of total sales","PRT","Portugal","2017","2017",6.3,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","ATCPTTMT","% of total sales","PRT","Portugal","2018","2018",5.5,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","ATCPTTMT","% of total sales","PRT","Portugal","2019","2019",5.4,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","ATCPTTMT","% of total sales","PRT","Portugal","2020","2020",5.7,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","ATCPTTMT","% of total sales","PRT","Portugal","2021","2021",5.8,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","ATCPTTMT","% of total sales","PRT","Portugal","2022","2022",5.9,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","MLLNCUMT","Million of national currency units","SVK","Slovak Republic","2010","2010",32.8,,
+"PATCCHLS","C10-Lipid modifying agents","MLLNCUMT","Million of national currency units","SVK","Slovak Republic","2011","2011",32.5,,
+"PATCCHLS","C10-Lipid modifying agents","MLLNCUMT","Million of national currency units","SVK","Slovak Republic","2012","2012",26.1,,
+"PATCCHLS","C10-Lipid modifying agents","MLLNCUMT","Million of national currency units","SVK","Slovak Republic","2013","2013",22,,
+"PATCCHLS","C10-Lipid modifying agents","MLLNCUMT","Million of national currency units","SVK","Slovak Republic","2014","2014",21.8,,
+"PATCCHLS","C10-Lipid modifying agents","MLLNCUMT","Million of national currency units","SVK","Slovak Republic","2015","2015",23.2,,
+"PATCCHLS","C10-Lipid modifying agents","MLLNCUMT","Million of national currency units","SVK","Slovak Republic","2016","2016",25.8,"B","Break"
+"PATCCHLS","C10-Lipid modifying agents","MLLNCUMT","Million of national currency units","SVK","Slovak Republic","2017","2017",27,,
+"PATCCHLS","C10-Lipid modifying agents","MLLNCUMT","Million of national currency units","SVK","Slovak Republic","2018","2018",27.2,,
+"PATCCHLS","C10-Lipid modifying agents","MLLNCUMT","Million of national currency units","SVK","Slovak Republic","2019","2019",27.4,,
+"PATCCHLS","C10-Lipid modifying agents","MLLNCUMT","Million of national currency units","SVK","Slovak Republic","2020","2020",29.8,,
+"PATCCHLS","C10-Lipid modifying agents","MLLNCUMT","Million of national currency units","SVK","Slovak Republic","2021","2021",32.1,,
+"PATCCHLS","C10-Lipid modifying agents","MTMOTCMT","Million US$ at exchange rate","SVK","Slovak Republic","2010","2010",43.5,,
+"PATCCHLS","C10-Lipid modifying agents","MTMOTCMT","Million US$ at exchange rate","SVK","Slovak Republic","2011","2011",45.3,,
+"PATCCHLS","C10-Lipid modifying agents","MTMOTCMT","Million US$ at exchange rate","SVK","Slovak Republic","2012","2012",33.5,,
+"PATCCHLS","C10-Lipid modifying agents","MTMOTCMT","Million US$ at exchange rate","SVK","Slovak Republic","2013","2013",29.2,,
+"PATCCHLS","C10-Lipid modifying agents","MTMOTCMT","Million US$ at exchange rate","SVK","Slovak Republic","2014","2014",28.9,,
+"PATCCHLS","C10-Lipid modifying agents","MTMOTCMT","Million US$ at exchange rate","SVK","Slovak Republic","2015","2015",25.7,,
+"PATCCHLS","C10-Lipid modifying agents","MTMOTCMT","Million US$ at exchange rate","SVK","Slovak Republic","2016","2016",28.6,"B","Break"
+"PATCCHLS","C10-Lipid modifying agents","MTMOTCMT","Million US$ at exchange rate","SVK","Slovak Republic","2017","2017",30.5,,
+"PATCCHLS","C10-Lipid modifying agents","MTMOTCMT","Million US$ at exchange rate","SVK","Slovak Republic","2018","2018",32.2,,
+"PATCCHLS","C10-Lipid modifying agents","MTMOTCMT","Million US$ at exchange rate","SVK","Slovak Republic","2019","2019",30.7,,
+"PATCCHLS","C10-Lipid modifying agents","MTMOTCMT","Million US$ at exchange rate","SVK","Slovak Republic","2020","2020",34,,
+"PATCCHLS","C10-Lipid modifying agents","MTMOTCMT","Million US$ at exchange rate","SVK","Slovak Republic","2021","2021",38,,
+"PATCCHLS","C10-Lipid modifying agents","MTMOPPMT","Million US$, purchasing power parity","SVK","Slovak Republic","2010","2010",65.4,,
+"PATCCHLS","C10-Lipid modifying agents","MTMOPPMT","Million US$, purchasing power parity","SVK","Slovak Republic","2011","2011",64.2,,
+"PATCCHLS","C10-Lipid modifying agents","MTMOPPMT","Million US$, purchasing power parity","SVK","Slovak Republic","2012","2012",51.7,,
+"PATCCHLS","C10-Lipid modifying agents","MTMOPPMT","Million US$, purchasing power parity","SVK","Slovak Republic","2013","2013",44.7,,
+"PATCCHLS","C10-Lipid modifying agents","MTMOPPMT","Million US$, purchasing power parity","SVK","Slovak Republic","2014","2014",44.8,,
+"PATCCHLS","C10-Lipid modifying agents","MTMOPPMT","Million US$, purchasing power parity","SVK","Slovak Republic","2015","2015",47.2,,
+"PATCCHLS","C10-Lipid modifying agents","MTMOPPMT","Million US$, purchasing power parity","SVK","Slovak Republic","2016","2016",51.3,"B","Break"
+"PATCCHLS","C10-Lipid modifying agents","MTMOPPMT","Million US$, purchasing power parity","SVK","Slovak Republic","2017","2017",52.3,,
+"PATCCHLS","C10-Lipid modifying agents","MTMOPPMT","Million US$, purchasing power parity","SVK","Slovak Republic","2018","2018",51.8,,
+"PATCCHLS","C10-Lipid modifying agents","MTMOPPMT","Million US$, purchasing power parity","SVK","Slovak Republic","2019","2019",53,,
+"PATCCHLS","C10-Lipid modifying agents","MTMOPPMT","Million US$, purchasing power parity","SVK","Slovak Republic","2020","2020",57.3,,
+"PATCCHLS","C10-Lipid modifying agents","MTMOPPMT","Million US$, purchasing power parity","SVK","Slovak Republic","2021","2021",60.3,,
+"PATCCHLS","C10-Lipid modifying agents","TCPPERMT","/capita, US$ exchange rate","SVK","Slovak Republic","2010","2010",8.1,,
+"PATCCHLS","C10-Lipid modifying agents","TCPPERMT","/capita, US$ exchange rate","SVK","Slovak Republic","2011","2011",8.4,,
+"PATCCHLS","C10-Lipid modifying agents","TCPPERMT","/capita, US$ exchange rate","SVK","Slovak Republic","2012","2012",6.2,,
+"PATCCHLS","C10-Lipid modifying agents","TCPPERMT","/capita, US$ exchange rate","SVK","Slovak Republic","2013","2013",5.4,,
+"PATCCHLS","C10-Lipid modifying agents","TCPPERMT","/capita, US$ exchange rate","SVK","Slovak Republic","2014","2014",5.3,,
+"PATCCHLS","C10-Lipid modifying agents","TCPPERMT","/capita, US$ exchange rate","SVK","Slovak Republic","2015","2015",4.7,,
+"PATCCHLS","C10-Lipid modifying agents","TCPPERMT","/capita, US$ exchange rate","SVK","Slovak Republic","2016","2016",5.3,"B","Break"
+"PATCCHLS","C10-Lipid modifying agents","TCPPERMT","/capita, US$ exchange rate","SVK","Slovak Republic","2017","2017",5.6,,
+"PATCCHLS","C10-Lipid modifying agents","TCPPERMT","/capita, US$ exchange rate","SVK","Slovak Republic","2018","2018",5.9,,
+"PATCCHLS","C10-Lipid modifying agents","TCPPERMT","/capita, US$ exchange rate","SVK","Slovak Republic","2019","2019",5.6,,
+"PATCCHLS","C10-Lipid modifying agents","TCPPERMT","/capita, US$ exchange rate","SVK","Slovak Republic","2020","2020",6.2,,
+"PATCCHLS","C10-Lipid modifying agents","TCPPERMT","/capita, US$ exchange rate","SVK","Slovak Republic","2021","2021",7,,
+"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2010","2010",12.1,,
+"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2011","2011",11.9,,
+"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2012","2012",9.6,,
+"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2013","2013",8.3,,
+"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2014","2014",8.3,,
+"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2015","2015",8.7,,
+"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2016","2016",9.5,"B","Break"
+"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2017","2017",9.6,,
+"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2018","2018",9.5,,
+"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2019","2019",9.7,,
+"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2020","2020",10.5,,
+"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2021","2021",11.1,,
+"PATCCHLS","C10-Lipid modifying agents","ATCPTTMT","% of total sales","SVK","Slovak Republic","2010","2010",2.9,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","ATCPTTMT","% of total sales","SVK","Slovak Republic","2011","2011",2.9,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","ATCPTTMT","% of total sales","SVK","Slovak Republic","2012","2012",2.4,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","ATCPTTMT","% of total sales","SVK","Slovak Republic","2013","2013",1.8,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","ATCPTTMT","% of total sales","SVK","Slovak Republic","2014","2014",1.7,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","ATCPTTMT","% of total sales","SVK","Slovak Republic","2015","2015",1.7,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","ATCPTTMT","% of total sales","SVK","Slovak Republic","2016","2016",1.6,"B","Break"
+"PATCCHLS","C10-Lipid modifying agents","ATCPTTMT","% of total sales","SVK","Slovak Republic","2017","2017",1.7,,
+"PATCCHLS","C10-Lipid modifying agents","ATCPTTMT","% of total sales","SVK","Slovak Republic","2018","2018",1.7,,
+"PATCCHLS","C10-Lipid modifying agents","ATCPTTMT","% of total sales","SVK","Slovak Republic","2019","2019",1.6,,
+"PATCCHLS","C10-Lipid modifying agents","ATCPTTMT","% of total sales","SVK","Slovak Republic","2020","2020",1.8,,
+"PATCCHLS","C10-Lipid modifying agents","ATCPTTMT","% of total sales","SVK","Slovak Republic","2021","2021",1.8,,
+"PATCCHLS","C10-Lipid modifying agents","MLLNCUMT","Million of national currency units","ESP","Spain","2010","2010",1024,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","MLLNCUMT","Million of national currency units","ESP","Spain","2011","2011",751.1,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","MLLNCUMT","Million of national currency units","ESP","Spain","2012","2012",662,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","MLLNCUMT","Million of national currency units","ESP","Spain","2013","2013",650.6,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","MLLNCUMT","Million of national currency units","ESP","Spain","2014","2014",715.3,"B; D","Break; Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","MLLNCUMT","Million of national currency units","ESP","Spain","2015","2015",765.3,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","MLLNCUMT","Million of national currency units","ESP","Spain","2016","2016",827.3,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","MLLNCUMT","Million of national currency units","ESP","Spain","2017","2017",858.1,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","MLLNCUMT","Million of national currency units","ESP","Spain","2018","2018",861,"B","Break"
+"PATCCHLS","C10-Lipid modifying agents","MLLNCUMT","Million of national currency units","ESP","Spain","2019","2019",886.7,,
+"PATCCHLS","C10-Lipid modifying agents","MLLNCUMT","Million of national currency units","ESP","Spain","2020","2020",931.5,,
+"PATCCHLS","C10-Lipid modifying agents","MLLNCUMT","Million of national currency units","ESP","Spain","2021","2021",928.1,,
+"PATCCHLS","C10-Lipid modifying agents","MLLNCUMT","Million of national currency units","ESP","Spain","2022","2022",999.7,"P","Provisional value"
+"PATCCHLS","C10-Lipid modifying agents","MTMOTCMT","Million US$ at exchange rate","ESP","Spain","2010","2010",1357.6,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","MTMOTCMT","Million US$ at exchange rate","ESP","Spain","2011","2011",1045.5,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","MTMOTCMT","Million US$ at exchange rate","ESP","Spain","2012","2012",850.6,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","MTMOTCMT","Million US$ at exchange rate","ESP","Spain","2013","2013",864,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","MTMOTCMT","Million US$ at exchange rate","ESP","Spain","2014","2014",950.3,"B; D","Break; Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","MTMOTCMT","Million US$ at exchange rate","ESP","Spain","2015","2015",849.1,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","MTMOTCMT","Million US$ at exchange rate","ESP","Spain","2016","2016",915.8,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","MTMOTCMT","Million US$ at exchange rate","ESP","Spain","2017","2017",969.4,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","MTMOTCMT","Million US$ at exchange rate","ESP","Spain","2018","2018",1016.8,"B","Break"
+"PATCCHLS","C10-Lipid modifying agents","MTMOTCMT","Million US$ at exchange rate","ESP","Spain","2019","2019",992.7,,
+"PATCCHLS","C10-Lipid modifying agents","MTMOTCMT","Million US$ at exchange rate","ESP","Spain","2020","2020",1064,,
+"PATCCHLS","C10-Lipid modifying agents","MTMOTCMT","Million US$ at exchange rate","ESP","Spain","2021","2021",1097.7,,
+"PATCCHLS","C10-Lipid modifying agents","MTMOTCMT","Million US$ at exchange rate","ESP","Spain","2022","2022",1052.8,"P","Provisional value"
+"PATCCHLS","C10-Lipid modifying agents","MTMOPPMT","Million US$, purchasing power parity","ESP","Spain","2010","2010",1408.7,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","MTMOPPMT","Million US$, purchasing power parity","ESP","Spain","2011","2011",1051.7,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","MTMOPPMT","Million US$, purchasing power parity","ESP","Spain","2012","2012",952.6,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","MTMOPPMT","Million US$, purchasing power parity","ESP","Spain","2013","2013",964.1,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","MTMOPPMT","Million US$, purchasing power parity","ESP","Spain","2014","2014",1080,"B; D","Break; Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","MTMOPPMT","Million US$, purchasing power parity","ESP","Spain","2015","2015",1151.3,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","MTMOPPMT","Million US$, purchasing power parity","ESP","Spain","2016","2016",1287.4,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","MTMOPPMT","Million US$, purchasing power parity","ESP","Spain","2017","2017",1360.3,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","MTMOPPMT","Million US$, purchasing power parity","ESP","Spain","2018","2018",1362.8,"B","Break"
+"PATCCHLS","C10-Lipid modifying agents","MTMOPPMT","Million US$, purchasing power parity","ESP","Spain","2019","2019",1446.6,,
+"PATCCHLS","C10-Lipid modifying agents","MTMOPPMT","Million US$, purchasing power parity","ESP","Spain","2020","2020",1499.3,,
+"PATCCHLS","C10-Lipid modifying agents","MTMOPPMT","Million US$, purchasing power parity","ESP","Spain","2021","2021",1482.7,,
+"PATCCHLS","C10-Lipid modifying agents","MTMOPPMT","Million US$, purchasing power parity","ESP","Spain","2022","2022",1676.8,"P","Provisional value"
+"PATCCHLS","C10-Lipid modifying agents","TCPPERMT","/capita, US$ exchange rate","ESP","Spain","2010","2010",29.1,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","TCPPERMT","/capita, US$ exchange rate","ESP","Spain","2011","2011",22.4,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","TCPPERMT","/capita, US$ exchange rate","ESP","Spain","2012","2012",18.2,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","TCPPERMT","/capita, US$ exchange rate","ESP","Spain","2013","2013",18.5,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","TCPPERMT","/capita, US$ exchange rate","ESP","Spain","2014","2014",20.4,"B; D","Break; Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","TCPPERMT","/capita, US$ exchange rate","ESP","Spain","2015","2015",18.3,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","TCPPERMT","/capita, US$ exchange rate","ESP","Spain","2016","2016",19.7,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","TCPPERMT","/capita, US$ exchange rate","ESP","Spain","2017","2017",20.8,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","TCPPERMT","/capita, US$ exchange rate","ESP","Spain","2018","2018",21.7,"B","Break"
+"PATCCHLS","C10-Lipid modifying agents","TCPPERMT","/capita, US$ exchange rate","ESP","Spain","2019","2019",21.1,,
+"PATCCHLS","C10-Lipid modifying agents","TCPPERMT","/capita, US$ exchange rate","ESP","Spain","2020","2020",22.5,,
+"PATCCHLS","C10-Lipid modifying agents","TCPPERMT","/capita, US$ exchange rate","ESP","Spain","2021","2021",23.2,,
+"PATCCHLS","C10-Lipid modifying agents","TCPPERMT","/capita, US$ exchange rate","ESP","Spain","2022","2022",22.2,"P","Provisional value"
+"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2010","2010",30.2,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2011","2011",22.5,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2012","2012",20.4,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2013","2013",20.7,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2014","2014",23.2,"B; D","Break; Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2015","2015",24.8,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2016","2016",27.7,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2017","2017",29.2,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2018","2018",29.1,"B","Break"
+"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2019","2019",30.7,,
+"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2020","2020",31.7,,
+"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2021","2021",31.3,,
+"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2022","2022",35.4,"P","Provisional value"
+"PATCCHLS","C10-Lipid modifying agents","ATCPTTMT","% of total sales","ESP","Spain","2010","2010",7.7,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","ATCPTTMT","% of total sales","ESP","Spain","2011","2011",6.1,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","ATCPTTMT","% of total sales","ESP","Spain","2012","2012",6,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","ATCPTTMT","% of total sales","ESP","Spain","2013","2013",6.1,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","ATCPTTMT","% of total sales","ESP","Spain","2014","2014",6.3,"B; D","Break; Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","ATCPTTMT","% of total sales","ESP","Spain","2015","2015",6.7,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","ATCPTTMT","% of total sales","ESP","Spain","2016","2016",7,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","ATCPTTMT","% of total sales","ESP","Spain","2017","2017",7.1,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","ATCPTTMT","% of total sales","ESP","Spain","2018","2018",4.5,"B","Break"
+"PATCCHLS","C10-Lipid modifying agents","ATCPTTMT","% of total sales","ESP","Spain","2019","2019",4.4,,
+"PATCCHLS","C10-Lipid modifying agents","ATCPTTMT","% of total sales","ESP","Spain","2020","2020",4.5,,
+"PATCCHLS","C10-Lipid modifying agents","ATCPTTMT","% of total sales","ESP","Spain","2021","2021",4.2,,
+"PATCCHLS","C10-Lipid modifying agents","ATCPTTMT","% of total sales","ESP","Spain","2022","2022",4.4,"P","Provisional value"
+"PATCCHLS","C10-Lipid modifying agents","MLLNCUMT","Million of national currency units","SWE","Sweden","2010","2010",722.6,,
+"PATCCHLS","C10-Lipid modifying agents","MLLNCUMT","Million of national currency units","SWE","Sweden","2011","2011",767.3,,
+"PATCCHLS","C10-Lipid modifying agents","MLLNCUMT","Million of national currency units","SWE","Sweden","2012","2012",558.3,,
+"PATCCHLS","C10-Lipid modifying agents","MLLNCUMT","Million of national currency units","SWE","Sweden","2013","2013",440.8,,
+"PATCCHLS","C10-Lipid modifying agents","MLLNCUMT","Million of national currency units","SWE","Sweden","2014","2014",480.8,,
+"PATCCHLS","C10-Lipid modifying agents","MLLNCUMT","Million of national currency units","SWE","Sweden","2015","2015",482.1,,
+"PATCCHLS","C10-Lipid modifying agents","MLLNCUMT","Million of national currency units","SWE","Sweden","2016","2016",522.1,,
+"PATCCHLS","C10-Lipid modifying agents","MLLNCUMT","Million of national currency units","SWE","Sweden","2017","2017",587.3,,
+"PATCCHLS","C10-Lipid modifying agents","MLLNCUMT","Million of national currency units","SWE","Sweden","2018","2018",451.5,,
+"PATCCHLS","C10-Lipid modifying agents","MLLNCUMT","Million of national currency units","SWE","Sweden","2019","2019",468.9,,
+"PATCCHLS","C10-Lipid modifying agents","MLLNCUMT","Million of national currency units","SWE","Sweden","2020","2020",525.3,,
+"PATCCHLS","C10-Lipid modifying agents","MLLNCUMT","Million of national currency units","SWE","Sweden","2021","2021",585.5,,
+"PATCCHLS","C10-Lipid modifying agents","MLLNCUMT","Million of national currency units","SWE","Sweden","2022","2022",730.3,,
+"PATCCHLS","C10-Lipid modifying agents","MTMOTCMT","Million US$ at exchange rate","SWE","Sweden","2010","2010",100.3,,
+"PATCCHLS","C10-Lipid modifying agents","MTMOTCMT","Million US$ at exchange rate","SWE","Sweden","2011","2011",118.2,,
+"PATCCHLS","C10-Lipid modifying agents","MTMOTCMT","Million US$ at exchange rate","SWE","Sweden","2012","2012",82.4,,
+"PATCCHLS","C10-Lipid modifying agents","MTMOTCMT","Million US$ at exchange rate","SWE","Sweden","2013","2013",67.7,,
+"PATCCHLS","C10-Lipid modifying agents","MTMOTCMT","Million US$ at exchange rate","SWE","Sweden","2014","2014",70.1,,
+"PATCCHLS","C10-Lipid modifying agents","MTMOTCMT","Million US$ at exchange rate","SWE","Sweden","2015","2015",57.2,,
+"PATCCHLS","C10-Lipid modifying agents","MTMOTCMT","Million US$ at exchange rate","SWE","Sweden","2016","2016",61,,
+"PATCCHLS","C10-Lipid modifying agents","MTMOTCMT","Million US$ at exchange rate","SWE","Sweden","2017","2017",68.7,,
+"PATCCHLS","C10-Lipid modifying agents","MTMOTCMT","Million US$ at exchange rate","SWE","Sweden","2018","2018",51.9,,
+"PATCCHLS","C10-Lipid modifying agents","MTMOTCMT","Million US$ at exchange rate","SWE","Sweden","2019","2019",49.6,,
+"PATCCHLS","C10-Lipid modifying agents","MTMOTCMT","Million US$ at exchange rate","SWE","Sweden","2020","2020",57,,
+"PATCCHLS","C10-Lipid modifying agents","MTMOTCMT","Million US$ at exchange rate","SWE","Sweden","2021","2021",68.3,,
+"PATCCHLS","C10-Lipid modifying agents","MTMOTCMT","Million US$ at exchange rate","SWE","Sweden","2022","2022",72.2,,
+"PATCCHLS","C10-Lipid modifying agents","MTMOPPMT","Million US$, purchasing power parity","SWE","Sweden","2010","2010",80.1,,
+"PATCCHLS","C10-Lipid modifying agents","MTMOPPMT","Million US$, purchasing power parity","SWE","Sweden","2011","2011",86.8,,
+"PATCCHLS","C10-Lipid modifying agents","MTMOPPMT","Million US$, purchasing power parity","SWE","Sweden","2012","2012",64.5,,
+"PATCCHLS","C10-Lipid modifying agents","MTMOPPMT","Million US$, purchasing power parity","SWE","Sweden","2013","2013",51.3,,
+"PATCCHLS","C10-Lipid modifying agents","MTMOPPMT","Million US$, purchasing power parity","SWE","Sweden","2014","2014",55.1,,
+"PATCCHLS","C10-Lipid modifying agents","MTMOPPMT","Million US$, purchasing power parity","SWE","Sweden","2015","2015",54.5,,
+"PATCCHLS","C10-Lipid modifying agents","MTMOPPMT","Million US$, purchasing power parity","SWE","Sweden","2016","2016",59.2,,
+"PATCCHLS","C10-Lipid modifying agents","MTMOPPMT","Million US$, purchasing power parity","SWE","Sweden","2017","2017",66.3,,
+"PATCCHLS","C10-Lipid modifying agents","MTMOPPMT","Million US$, purchasing power parity","SWE","Sweden","2018","2018",50.9,,
+"PATCCHLS","C10-Lipid modifying agents","MTMOPPMT","Million US$, purchasing power parity","SWE","Sweden","2019","2019",53.8,,
+"PATCCHLS","C10-Lipid modifying agents","MTMOPPMT","Million US$, purchasing power parity","SWE","Sweden","2020","2020",60.6,,
+"PATCCHLS","C10-Lipid modifying agents","MTMOPPMT","Million US$, purchasing power parity","SWE","Sweden","2021","2021",67.1,,
+"PATCCHLS","C10-Lipid modifying agents","MTMOPPMT","Million US$, purchasing power parity","SWE","Sweden","2022","2022",84.3,,
+"PATCCHLS","C10-Lipid modifying agents","TCPPERMT","/capita, US$ exchange rate","SWE","Sweden","2010","2010",10.7,,
+"PATCCHLS","C10-Lipid modifying agents","TCPPERMT","/capita, US$ exchange rate","SWE","Sweden","2011","2011",12.5,,
+"PATCCHLS","C10-Lipid modifying agents","TCPPERMT","/capita, US$ exchange rate","SWE","Sweden","2012","2012",8.7,,
+"PATCCHLS","C10-Lipid modifying agents","TCPPERMT","/capita, US$ exchange rate","SWE","Sweden","2013","2013",7,,
+"PATCCHLS","C10-Lipid modifying agents","TCPPERMT","/capita, US$ exchange rate","SWE","Sweden","2014","2014",7.2,,
+"PATCCHLS","C10-Lipid modifying agents","TCPPERMT","/capita, US$ exchange rate","SWE","Sweden","2015","2015",5.8,,
+"PATCCHLS","C10-Lipid modifying agents","TCPPERMT","/capita, US$ exchange rate","SWE","Sweden","2016","2016",6.1,,
+"PATCCHLS","C10-Lipid modifying agents","TCPPERMT","/capita, US$ exchange rate","SWE","Sweden","2017","2017",6.8,,
+"PATCCHLS","C10-Lipid modifying agents","TCPPERMT","/capita, US$ exchange rate","SWE","Sweden","2018","2018",5.1,,
+"PATCCHLS","C10-Lipid modifying agents","TCPPERMT","/capita, US$ exchange rate","SWE","Sweden","2019","2019",4.8,,
+"PATCCHLS","C10-Lipid modifying agents","TCPPERMT","/capita, US$ exchange rate","SWE","Sweden","2020","2020",5.5,,
+"PATCCHLS","C10-Lipid modifying agents","TCPPERMT","/capita, US$ exchange rate","SWE","Sweden","2021","2021",6.6,,
+"PATCCHLS","C10-Lipid modifying agents","TCPPERMT","/capita, US$ exchange rate","SWE","Sweden","2022","2022",6.9,,
+"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2010","2010",8.5,,
+"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2011","2011",9.2,,
+"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2012","2012",6.8,,
+"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2013","2013",5.3,,
+"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2014","2014",5.7,,
+"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2015","2015",5.6,,
+"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2016","2016",6,,
+"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2017","2017",6.6,,
+"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2018","2018",5,,
+"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2019","2019",5.2,,
+"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2020","2020",5.9,,
+"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2021","2021",6.4,,
+"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2022","2022",8.1,,
+"PATCCHLS","C10-Lipid modifying agents","ATCPTTMT","% of total sales","SWE","Sweden","2010","2010",2,,
+"PATCCHLS","C10-Lipid modifying agents","ATCPTTMT","% of total sales","SWE","Sweden","2011","2011",2.1,,
+"PATCCHLS","C10-Lipid modifying agents","ATCPTTMT","% of total sales","SWE","Sweden","2012","2012",1.5,,
+"PATCCHLS","C10-Lipid modifying agents","ATCPTTMT","% of total sales","SWE","Sweden","2013","2013",1.2,,
+"PATCCHLS","C10-Lipid modifying agents","ATCPTTMT","% of total sales","SWE","Sweden","2014","2014",1.3,,
+"PATCCHLS","C10-Lipid modifying agents","ATCPTTMT","% of total sales","SWE","Sweden","2015","2015",1.2,,
+"PATCCHLS","C10-Lipid modifying agents","ATCPTTMT","% of total sales","SWE","Sweden","2016","2016",1.2,,
+"PATCCHLS","C10-Lipid modifying agents","ATCPTTMT","% of total sales","SWE","Sweden","2017","2017",1.3,,
+"PATCCHLS","C10-Lipid modifying agents","ATCPTTMT","% of total sales","SWE","Sweden","2018","2018",0.9,,
+"PATCCHLS","C10-Lipid modifying agents","ATCPTTMT","% of total sales","SWE","Sweden","2019","2019",0.9,,
+"PATCCHLS","C10-Lipid modifying agents","ATCPTTMT","% of total sales","SWE","Sweden","2020","2020",1,,
+"PATCCHLS","C10-Lipid modifying agents","ATCPTTMT","% of total sales","SWE","Sweden","2021","2021",1.1,,
+"PATCCHLS","C10-Lipid modifying agents","ATCPTTMT","% of total sales","SWE","Sweden","2022","2022",1.3,,
+"PATCCHLS","C10-Lipid modifying agents","MLLNCUMT","Million of national currency units","TUR","Türkiye","2010","2010",449.3,,
+"PATCCHLS","C10-Lipid modifying agents","MLLNCUMT","Million of national currency units","TUR","Türkiye","2011","2011",329,,
+"PATCCHLS","C10-Lipid modifying agents","MLLNCUMT","Million of national currency units","TUR","Türkiye","2012","2012",207.8,,
+"PATCCHLS","C10-Lipid modifying agents","MLLNCUMT","Million of national currency units","TUR","Türkiye","2013","2013",140,,
+"PATCCHLS","C10-Lipid modifying agents","MLLNCUMT","Million of national currency units","TUR","Türkiye","2014","2014",138.5,,
+"PATCCHLS","C10-Lipid modifying agents","MLLNCUMT","Million of national currency units","TUR","Türkiye","2015","2015",152.1,,
+"PATCCHLS","C10-Lipid modifying agents","MLLNCUMT","Million of national currency units","TUR","Türkiye","2016","2016",180.7,,
+"PATCCHLS","C10-Lipid modifying agents","MLLNCUMT","Million of national currency units","TUR","Türkiye","2017","2017",235.5,,
+"PATCCHLS","C10-Lipid modifying agents","MLLNCUMT","Million of national currency units","TUR","Türkiye","2018","2018",302,,
+"PATCCHLS","C10-Lipid modifying agents","MLLNCUMT","Million of national currency units","TUR","Türkiye","2019","2019",377.7,,
+"PATCCHLS","C10-Lipid modifying agents","MLLNCUMT","Million of national currency units","TUR","Türkiye","2020","2020",527.2,,
+"PATCCHLS","C10-Lipid modifying agents","MLLNCUMT","Million of national currency units","TUR","Türkiye","2021","2021",679.1,,
+"PATCCHLS","C10-Lipid modifying agents","MTMOTCMT","Million US$ at exchange rate","TUR","Türkiye","2010","2010",298.9,,
+"PATCCHLS","C10-Lipid modifying agents","MTMOTCMT","Million US$ at exchange rate","TUR","Türkiye","2011","2011",196.4,,
+"PATCCHLS","C10-Lipid modifying agents","MTMOTCMT","Million US$ at exchange rate","TUR","Türkiye","2012","2012",115.7,,
+"PATCCHLS","C10-Lipid modifying agents","MTMOTCMT","Million US$ at exchange rate","TUR","Türkiye","2013","2013",73.5,,
+"PATCCHLS","C10-Lipid modifying agents","MTMOTCMT","Million US$ at exchange rate","TUR","Türkiye","2014","2014",63.3,,
+"PATCCHLS","C10-Lipid modifying agents","MTMOTCMT","Million US$ at exchange rate","TUR","Türkiye","2015","2015",55.9,,
+"PATCCHLS","C10-Lipid modifying agents","MTMOTCMT","Million US$ at exchange rate","TUR","Türkiye","2016","2016",59.8,,
+"PATCCHLS","C10-Lipid modifying agents","MTMOTCMT","Million US$ at exchange rate","TUR","Türkiye","2017","2017",64.5,,
+"PATCCHLS","C10-Lipid modifying agents","MTMOTCMT","Million US$ at exchange rate","TUR","Türkiye","2018","2018",62.5,,
+"PATCCHLS","C10-Lipid modifying agents","MTMOTCMT","Million US$ at exchange rate","TUR","Türkiye","2019","2019",66.6,,
+"PATCCHLS","C10-Lipid modifying agents","MTMOTCMT","Million US$ at exchange rate","TUR","Türkiye","2020","2020",75.2,,
+"PATCCHLS","C10-Lipid modifying agents","MTMOTCMT","Million US$ at exchange rate","TUR","Türkiye","2021","2021",76.7,,
+"PATCCHLS","C10-Lipid modifying agents","MTMOPPMT","Million US$, purchasing power parity","TUR","Türkiye","2010","2010",488.1,,
+"PATCCHLS","C10-Lipid modifying agents","MTMOPPMT","Million US$, purchasing power parity","TUR","Türkiye","2011","2011",340.6,,
+"PATCCHLS","C10-Lipid modifying agents","MTMOPPMT","Million US$, purchasing power parity","TUR","Türkiye","2012","2012",203.7,,
+"PATCCHLS","C10-Lipid modifying agents","MTMOPPMT","Million US$, purchasing power parity","TUR","Türkiye","2013","2013",130.8,,
+"PATCCHLS","C10-Lipid modifying agents","MTMOPPMT","Million US$, purchasing power parity","TUR","Türkiye","2014","2014",125.4,,
+"PATCCHLS","C10-Lipid modifying agents","MTMOPPMT","Million US$, purchasing power parity","TUR","Türkiye","2015","2015",130.8,,
+"PATCCHLS","C10-Lipid modifying agents","MTMOPPMT","Million US$, purchasing power parity","TUR","Türkiye","2016","2016",145.6,,
+"PATCCHLS","C10-Lipid modifying agents","MTMOPPMT","Million US$, purchasing power parity","TUR","Türkiye","2017","2017",170.1,,
+"PATCCHLS","C10-Lipid modifying agents","MTMOPPMT","Million US$, purchasing power parity","TUR","Türkiye","2018","2018",185,,
+"PATCCHLS","C10-Lipid modifying agents","MTMOPPMT","Million US$, purchasing power parity","TUR","Türkiye","2019","2019",202.7,,
+"PATCCHLS","C10-Lipid modifying agents","MTMOPPMT","Million US$, purchasing power parity","TUR","Türkiye","2020","2020",243.6,,
+"PATCCHLS","C10-Lipid modifying agents","MTMOPPMT","Million US$, purchasing power parity","TUR","Türkiye","2021","2021",241.8,,
+"PATCCHLS","C10-Lipid modifying agents","TCPPERMT","/capita, US$ exchange rate","TUR","Türkiye","2010","2010",4.1,,
+"PATCCHLS","C10-Lipid modifying agents","TCPPERMT","/capita, US$ exchange rate","TUR","Türkiye","2011","2011",2.6,,
+"PATCCHLS","C10-Lipid modifying agents","TCPPERMT","/capita, US$ exchange rate","TUR","Türkiye","2012","2012",1.5,,
+"PATCCHLS","C10-Lipid modifying agents","TCPPERMT","/capita, US$ exchange rate","TUR","Türkiye","2013","2013",1,,
+"PATCCHLS","C10-Lipid modifying agents","TCPPERMT","/capita, US$ exchange rate","TUR","Türkiye","2014","2014",0.8,,
+"PATCCHLS","C10-Lipid modifying agents","TCPPERMT","/capita, US$ exchange rate","TUR","Türkiye","2015","2015",0.7,,
+"PATCCHLS","C10-Lipid modifying agents","TCPPERMT","/capita, US$ exchange rate","TUR","Türkiye","2016","2016",0.8,,
+"PATCCHLS","C10-Lipid modifying agents","TCPPERMT","/capita, US$ exchange rate","TUR","Türkiye","2017","2017",0.8,,
+"PATCCHLS","C10-Lipid modifying agents","TCPPERMT","/capita, US$ exchange rate","TUR","Türkiye","2018","2018",0.8,,
+"PATCCHLS","C10-Lipid modifying agents","TCPPERMT","/capita, US$ exchange rate","TUR","Türkiye","2019","2019",0.8,,
+"PATCCHLS","C10-Lipid modifying agents","TCPPERMT","/capita, US$ exchange rate","TUR","Türkiye","2020","2020",0.9,,
+"PATCCHLS","C10-Lipid modifying agents","TCPPERMT","/capita, US$ exchange rate","TUR","Türkiye","2021","2021",0.9,,
+"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2010","2010",6.7,,
+"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2011","2011",4.6,,
+"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2012","2012",2.7,,
+"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2013","2013",1.7,,
+"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2014","2014",1.6,,
+"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2015","2015",1.7,,
+"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2016","2016",1.8,,
+"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2017","2017",2.1,,
+"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2018","2018",2.3,,
+"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2019","2019",2.5,,
+"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2020","2020",2.9,,
+"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2021","2021",2.9,,
+"PATCCHLS","C10-Lipid modifying agents","ATCPTTMT","% of total sales","TUR","Türkiye","2010","2010",2.9,,
+"PATCCHLS","C10-Lipid modifying agents","ATCPTTMT","% of total sales","TUR","Türkiye","2011","2011",2.3,,
+"PATCCHLS","C10-Lipid modifying agents","ATCPTTMT","% of total sales","TUR","Türkiye","2012","2012",1.5,,
+"PATCCHLS","C10-Lipid modifying agents","ATCPTTMT","% of total sales","TUR","Türkiye","2013","2013",1,,
+"PATCCHLS","C10-Lipid modifying agents","ATCPTTMT","% of total sales","TUR","Türkiye","2014","2014",0.9,,
+"PATCCHLS","C10-Lipid modifying agents","ATCPTTMT","% of total sales","TUR","Türkiye","2015","2015",0.8,,
+"PATCCHLS","C10-Lipid modifying agents","ATCPTTMT","% of total sales","TUR","Türkiye","2016","2016",0.8,,
+"PATCCHLS","C10-Lipid modifying agents","ATCPTTMT","% of total sales","TUR","Türkiye","2017","2017",0.9,,
+"PATCCHLS","C10-Lipid modifying agents","ATCPTTMT","% of total sales","TUR","Türkiye","2018","2018",0.9,,
+"PATCCHLS","C10-Lipid modifying agents","ATCPTTMT","% of total sales","TUR","Türkiye","2019","2019",0.9,,
+"PATCCHLS","C10-Lipid modifying agents","ATCPTTMT","% of total sales","TUR","Türkiye","2020","2020",1.1,,
+"PATCCHLS","C10-Lipid modifying agents","ATCPTTMT","% of total sales","TUR","Türkiye","2021","2021",1,,
+"PATCCHLS","C10-Lipid modifying agents","MLLNCUMT","Million of national currency units","CHL","Chile","2010","2010",19420.8,,
+"PATCCHLS","C10-Lipid modifying agents","MLLNCUMT","Million of national currency units","CHL","Chile","2011","2011",25005.3,"B","Break"
+"PATCCHLS","C10-Lipid modifying agents","MLLNCUMT","Million of national currency units","CHL","Chile","2012","2012",27634.2,,
+"PATCCHLS","C10-Lipid modifying agents","MLLNCUMT","Million of national currency units","CHL","Chile","2013","2013",30013.4,,
+"PATCCHLS","C10-Lipid modifying agents","MLLNCUMT","Million of national currency units","CHL","Chile","2014","2014",33677,,
+"PATCCHLS","C10-Lipid modifying agents","MLLNCUMT","Million of national currency units","CHL","Chile","2015","2015",39621.5,,
+"PATCCHLS","C10-Lipid modifying agents","MLLNCUMT","Million of national currency units","CHL","Chile","2016","2016",42911.6,,
+"PATCCHLS","C10-Lipid modifying agents","MLLNCUMT","Million of national currency units","CHL","Chile","2017","2017",35776.7,,
+"PATCCHLS","C10-Lipid modifying agents","MLLNCUMT","Million of national currency units","CHL","Chile","2018","2018",41618.8,,
+"PATCCHLS","C10-Lipid modifying agents","MLLNCUMT","Million of national currency units","CHL","Chile","2019","2019",40294.5,,
+"PATCCHLS","C10-Lipid modifying agents","MLLNCUMT","Million of national currency units","CHL","Chile","2020","2020",42777.7,,
+"PATCCHLS","C10-Lipid modifying agents","MLLNCUMT","Million of national currency units","CHL","Chile","2021","2021",41213.9,,
+"PATCCHLS","C10-Lipid modifying agents","MLLNCUMT","Million of national currency units","CHL","Chile","2022","2022",52646.2,,
+"PATCCHLS","C10-Lipid modifying agents","MTMOTCMT","Million US$ at exchange rate","CHL","Chile","2010","2010",38.1,,
+"PATCCHLS","C10-Lipid modifying agents","MTMOTCMT","Million US$ at exchange rate","CHL","Chile","2011","2011",51.7,"B","Break"
+"PATCCHLS","C10-Lipid modifying agents","MTMOTCMT","Million US$ at exchange rate","CHL","Chile","2012","2012",56.8,,
+"PATCCHLS","C10-Lipid modifying agents","MTMOTCMT","Million US$ at exchange rate","CHL","Chile","2013","2013",60.6,,
+"PATCCHLS","C10-Lipid modifying agents","MTMOTCMT","Million US$ at exchange rate","CHL","Chile","2014","2014",59,,
+"PATCCHLS","C10-Lipid modifying agents","MTMOTCMT","Million US$ at exchange rate","CHL","Chile","2015","2015",60.6,,
+"PATCCHLS","C10-Lipid modifying agents","MTMOTCMT","Million US$ at exchange rate","CHL","Chile","2016","2016",63.4,,
+"PATCCHLS","C10-Lipid modifying agents","MTMOTCMT","Million US$ at exchange rate","CHL","Chile","2017","2017",55.1,,
+"PATCCHLS","C10-Lipid modifying agents","MTMOTCMT","Million US$ at exchange rate","CHL","Chile","2018","2018",64.9,,
+"PATCCHLS","C10-Lipid modifying agents","MTMOTCMT","Million US$ at exchange rate","CHL","Chile","2019","2019",57.3,,
+"PATCCHLS","C10-Lipid modifying agents","MTMOTCMT","Million US$ at exchange rate","CHL","Chile","2020","2020",54,,
+"PATCCHLS","C10-Lipid modifying agents","MTMOTCMT","Million US$ at exchange rate","CHL","Chile","2021","2021",54.3,,
+"PATCCHLS","C10-Lipid modifying agents","MTMOTCMT","Million US$ at exchange rate","CHL","Chile","2022","2022",60.3,,
+"PATCCHLS","C10-Lipid modifying agents","MTMOPPMT","Million US$, purchasing power parity","CHL","Chile","2010","2010",54,,
+"PATCCHLS","C10-Lipid modifying agents","MTMOPPMT","Million US$, purchasing power parity","CHL","Chile","2011","2011",71.9,"B","Break"
+"PATCCHLS","C10-Lipid modifying agents","MTMOPPMT","Million US$, purchasing power parity","CHL","Chile","2012","2012",79.6,,
+"PATCCHLS","C10-Lipid modifying agents","MTMOPPMT","Million US$, purchasing power parity","CHL","Chile","2013","2013",85.8,,
+"PATCCHLS","C10-Lipid modifying agents","MTMOPPMT","Million US$, purchasing power parity","CHL","Chile","2014","2014",91.7,,
+"PATCCHLS","C10-Lipid modifying agents","MTMOPPMT","Million US$, purchasing power parity","CHL","Chile","2015","2015",101.3,,
+"PATCCHLS","C10-Lipid modifying agents","MTMOPPMT","Million US$, purchasing power parity","CHL","Chile","2016","2016",108,,
+"PATCCHLS","C10-Lipid modifying agents","MTMOPPMT","Million US$, purchasing power parity","CHL","Chile","2017","2017",90,,
+"PATCCHLS","C10-Lipid modifying agents","MTMOPPMT","Million US$, purchasing power parity","CHL","Chile","2018","2018",105,,
+"PATCCHLS","C10-Lipid modifying agents","MTMOPPMT","Million US$, purchasing power parity","CHL","Chile","2019","2019",100.3,,
+"PATCCHLS","C10-Lipid modifying agents","MTMOPPMT","Million US$, purchasing power parity","CHL","Chile","2020","2020",102.2,,
+"PATCCHLS","C10-Lipid modifying agents","MTMOPPMT","Million US$, purchasing power parity","CHL","Chile","2021","2021",94.7,,
+"PATCCHLS","C10-Lipid modifying agents","MTMOPPMT","Million US$, purchasing power parity","CHL","Chile","2022","2022",120.3,,
+"PATCCHLS","C10-Lipid modifying agents","TCPPERMT","/capita, US$ exchange rate","CHL","Chile","2010","2010",2.2,,
+"PATCCHLS","C10-Lipid modifying agents","TCPPERMT","/capita, US$ exchange rate","CHL","Chile","2011","2011",3,"B","Break"
+"PATCCHLS","C10-Lipid modifying agents","TCPPERMT","/capita, US$ exchange rate","CHL","Chile","2012","2012",3.3,,
+"PATCCHLS","C10-Lipid modifying agents","TCPPERMT","/capita, US$ exchange rate","CHL","Chile","2013","2013",3.4,,
+"PATCCHLS","C10-Lipid modifying agents","TCPPERMT","/capita, US$ exchange rate","CHL","Chile","2014","2014",3.3,,
+"PATCCHLS","C10-Lipid modifying agents","TCPPERMT","/capita, US$ exchange rate","CHL","Chile","2015","2015",3.4,,
+"PATCCHLS","C10-Lipid modifying agents","TCPPERMT","/capita, US$ exchange rate","CHL","Chile","2016","2016",3.5,,
+"PATCCHLS","C10-Lipid modifying agents","TCPPERMT","/capita, US$ exchange rate","CHL","Chile","2017","2017",3,,
+"PATCCHLS","C10-Lipid modifying agents","TCPPERMT","/capita, US$ exchange rate","CHL","Chile","2018","2018",3.5,,
+"PATCCHLS","C10-Lipid modifying agents","TCPPERMT","/capita, US$ exchange rate","CHL","Chile","2019","2019",3,,
+"PATCCHLS","C10-Lipid modifying agents","TCPPERMT","/capita, US$ exchange rate","CHL","Chile","2020","2020",2.8,,
+"PATCCHLS","C10-Lipid modifying agents","TCPPERMT","/capita, US$ exchange rate","CHL","Chile","2021","2021",2.8,,
+"PATCCHLS","C10-Lipid modifying agents","TCPPERMT","/capita, US$ exchange rate","CHL","Chile","2022","2022",3,,
+"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2010","2010",3.2,,
+"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2011","2011",4.2,"B","Break"
+"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2012","2012",4.6,,
+"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2013","2013",4.9,,
+"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2014","2014",5.2,,
+"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2015","2015",5.6,,
+"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2016","2016",5.9,,
+"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2017","2017",4.9,,
+"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2018","2018",5.6,,
+"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2019","2019",5.3,,
+"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2020","2020",5.3,,
+"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2021","2021",4.8,,
+"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2022","2022",6.1,,
+"PATCCHLS","C10-Lipid modifying agents","ATCPTTMT","% of total sales","CHL","Chile","2010","2010",2.4,,
+"PATCCHLS","C10-Lipid modifying agents","ATCPTTMT","% of total sales","CHL","Chile","2011","2011",2.1,"B","Break"
+"PATCCHLS","C10-Lipid modifying agents","ATCPTTMT","% of total sales","CHL","Chile","2012","2012",2.2,,
+"PATCCHLS","C10-Lipid modifying agents","ATCPTTMT","% of total sales","CHL","Chile","2013","2013",2.1,,
+"PATCCHLS","C10-Lipid modifying agents","ATCPTTMT","% of total sales","CHL","Chile","2014","2014",2.2,,
+"PATCCHLS","C10-Lipid modifying agents","ATCPTTMT","% of total sales","CHL","Chile","2015","2015",2.2,,
+"PATCCHLS","C10-Lipid modifying agents","ATCPTTMT","% of total sales","CHL","Chile","2016","2016",2.1,,
+"PATCCHLS","C10-Lipid modifying agents","ATCPTTMT","% of total sales","CHL","Chile","2017","2017",1.7,,
+"PATCCHLS","C10-Lipid modifying agents","ATCPTTMT","% of total sales","CHL","Chile","2018","2018",1.8,,
+"PATCCHLS","C10-Lipid modifying agents","ATCPTTMT","% of total sales","CHL","Chile","2019","2019",1.6,,
+"PATCCHLS","C10-Lipid modifying agents","ATCPTTMT","% of total sales","CHL","Chile","2020","2020",1.6,,
+"PATCCHLS","C10-Lipid modifying agents","ATCPTTMT","% of total sales","CHL","Chile","2021","2021",1.5,,
+"PATCCHLS","C10-Lipid modifying agents","ATCPTTMT","% of total sales","CHL","Chile","2022","2022",1.9,,
+"PATCCHLS","C10-Lipid modifying agents","MLLNCUMT","Million of national currency units","EST","Estonia","2010","2010",5.3,,
+"PATCCHLS","C10-Lipid modifying agents","MLLNCUMT","Million of national currency units","EST","Estonia","2011","2011",3.9,,
+"PATCCHLS","C10-Lipid modifying agents","MLLNCUMT","Million of national currency units","EST","Estonia","2012","2012",4,,
+"PATCCHLS","C10-Lipid modifying agents","MLLNCUMT","Million of national currency units","EST","Estonia","2013","2013",3.4,,
+"PATCCHLS","C10-Lipid modifying agents","MLLNCUMT","Million of national currency units","EST","Estonia","2014","2014",3.2,,
+"PATCCHLS","C10-Lipid modifying agents","MLLNCUMT","Million of national currency units","EST","Estonia","2015","2015",3.2,,
+"PATCCHLS","C10-Lipid modifying agents","MLLNCUMT","Million of national currency units","EST","Estonia","2016","2016",3.1,,
+"PATCCHLS","C10-Lipid modifying agents","MLLNCUMT","Million of national currency units","EST","Estonia","2017","2017",3.1,,
+"PATCCHLS","C10-Lipid modifying agents","MLLNCUMT","Million of national currency units","EST","Estonia","2018","2018",3.3,,
+"PATCCHLS","C10-Lipid modifying agents","MLLNCUMT","Million of national currency units","EST","Estonia","2019","2019",3.7,,
+"PATCCHLS","C10-Lipid modifying agents","MLLNCUMT","Million of national currency units","EST","Estonia","2020","2020",4.3,,
+"PATCCHLS","C10-Lipid modifying agents","MLLNCUMT","Million of national currency units","EST","Estonia","2021","2021",4.6,,
+"PATCCHLS","C10-Lipid modifying agents","MLLNCUMT","Million of national currency units","EST","Estonia","2022","2022",5.1,,
+"PATCCHLS","C10-Lipid modifying agents","MTMOTCMT","Million US$ at exchange rate","EST","Estonia","2010","2010",7.1,,
+"PATCCHLS","C10-Lipid modifying agents","MTMOTCMT","Million US$ at exchange rate","EST","Estonia","2011","2011",5.5,,
+"PATCCHLS","C10-Lipid modifying agents","MTMOTCMT","Million US$ at exchange rate","EST","Estonia","2012","2012",5.1,,
+"PATCCHLS","C10-Lipid modifying agents","MTMOTCMT","Million US$ at exchange rate","EST","Estonia","2013","2013",4.6,,
+"PATCCHLS","C10-Lipid modifying agents","MTMOTCMT","Million US$ at exchange rate","EST","Estonia","2014","2014",4.3,,
+"PATCCHLS","C10-Lipid modifying agents","MTMOTCMT","Million US$ at exchange rate","EST","Estonia","2015","2015",3.6,,
+"PATCCHLS","C10-Lipid modifying agents","MTMOTCMT","Million US$ at exchange rate","EST","Estonia","2016","2016",3.4,,
+"PATCCHLS","C10-Lipid modifying agents","MTMOTCMT","Million US$ at exchange rate","EST","Estonia","2017","2017",3.5,,
+"PATCCHLS","C10-Lipid modifying agents","MTMOTCMT","Million US$ at exchange rate","EST","Estonia","2018","2018",3.9,,
+"PATCCHLS","C10-Lipid modifying agents","MTMOTCMT","Million US$ at exchange rate","EST","Estonia","2019","2019",4.1,,
+"PATCCHLS","C10-Lipid modifying agents","MTMOTCMT","Million US$ at exchange rate","EST","Estonia","2020","2020",4.9,,
+"PATCCHLS","C10-Lipid modifying agents","MTMOTCMT","Million US$ at exchange rate","EST","Estonia","2021","2021",5.4,,
+"PATCCHLS","C10-Lipid modifying agents","MTMOTCMT","Million US$ at exchange rate","EST","Estonia","2022","2022",5.4,,
+"PATCCHLS","C10-Lipid modifying agents","MTMOPPMT","Million US$, purchasing power parity","EST","Estonia","2010","2010",10.4,,
+"PATCCHLS","C10-Lipid modifying agents","MTMOPPMT","Million US$, purchasing power parity","EST","Estonia","2011","2011",7.7,,
+"PATCCHLS","C10-Lipid modifying agents","MTMOPPMT","Million US$, purchasing power parity","EST","Estonia","2012","2012",7.6,,
+"PATCCHLS","C10-Lipid modifying agents","MTMOPPMT","Million US$, purchasing power parity","EST","Estonia","2013","2013",6.6,,
+"PATCCHLS","C10-Lipid modifying agents","MTMOPPMT","Million US$, purchasing power parity","EST","Estonia","2014","2014",6.1,,
+"PATCCHLS","C10-Lipid modifying agents","MTMOPPMT","Million US$, purchasing power parity","EST","Estonia","2015","2015",6,,
+"PATCCHLS","C10-Lipid modifying agents","MTMOPPMT","Million US$, purchasing power parity","EST","Estonia","2016","2016",5.8,,
+"PATCCHLS","C10-Lipid modifying agents","MTMOPPMT","Million US$, purchasing power parity","EST","Estonia","2017","2017",5.9,,
+"PATCCHLS","C10-Lipid modifying agents","MTMOPPMT","Million US$, purchasing power parity","EST","Estonia","2018","2018",6.2,,
+"PATCCHLS","C10-Lipid modifying agents","MTMOPPMT","Million US$, purchasing power parity","EST","Estonia","2019","2019",6.8,,
+"PATCCHLS","C10-Lipid modifying agents","MTMOPPMT","Million US$, purchasing power parity","EST","Estonia","2020","2020",8.1,,
+"PATCCHLS","C10-Lipid modifying agents","MTMOPPMT","Million US$, purchasing power parity","EST","Estonia","2021","2021",8.4,,
+"PATCCHLS","C10-Lipid modifying agents","MTMOPPMT","Million US$, purchasing power parity","EST","Estonia","2022","2022",9,,
+"PATCCHLS","C10-Lipid modifying agents","TCPPERMT","/capita, US$ exchange rate","EST","Estonia","2010","2010",5.3,,
+"PATCCHLS","C10-Lipid modifying agents","TCPPERMT","/capita, US$ exchange rate","EST","Estonia","2011","2011",4.1,,
+"PATCCHLS","C10-Lipid modifying agents","TCPPERMT","/capita, US$ exchange rate","EST","Estonia","2012","2012",3.8,,
+"PATCCHLS","C10-Lipid modifying agents","TCPPERMT","/capita, US$ exchange rate","EST","Estonia","2013","2013",3.5,,
+"PATCCHLS","C10-Lipid modifying agents","TCPPERMT","/capita, US$ exchange rate","EST","Estonia","2014","2014",3.3,,
+"PATCCHLS","C10-Lipid modifying agents","TCPPERMT","/capita, US$ exchange rate","EST","Estonia","2015","2015",2.7,,
+"PATCCHLS","C10-Lipid modifying agents","TCPPERMT","/capita, US$ exchange rate","EST","Estonia","2016","2016",2.6,,
+"PATCCHLS","C10-Lipid modifying agents","TCPPERMT","/capita, US$ exchange rate","EST","Estonia","2017","2017",2.7,,
+"PATCCHLS","C10-Lipid modifying agents","TCPPERMT","/capita, US$ exchange rate","EST","Estonia","2018","2018",3,,
+"PATCCHLS","C10-Lipid modifying agents","TCPPERMT","/capita, US$ exchange rate","EST","Estonia","2019","2019",3.1,,
+"PATCCHLS","C10-Lipid modifying agents","TCPPERMT","/capita, US$ exchange rate","EST","Estonia","2020","2020",3.7,,
+"PATCCHLS","C10-Lipid modifying agents","TCPPERMT","/capita, US$ exchange rate","EST","Estonia","2021","2021",4,,
+"PATCCHLS","C10-Lipid modifying agents","TCPPERMT","/capita, US$ exchange rate","EST","Estonia","2022","2022",4,,
+"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2010","2010",7.8,,
+"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2011","2011",5.8,,
+"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2012","2012",5.7,,
+"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2013","2013",5,,
+"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2014","2014",4.7,,
+"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2015","2015",4.6,,
+"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2016","2016",4.4,,
+"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2017","2017",4.5,,
+"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2018","2018",4.7,,
+"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2019","2019",5.1,,
+"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2020","2020",6.1,,
+"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2021","2021",6.3,,
+"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2022","2022",6.7,,
+"PATCCHLS","C10-Lipid modifying agents","ATCPTTMT","% of total sales","EST","Estonia","2010","2010",2.7,,
+"PATCCHLS","C10-Lipid modifying agents","ATCPTTMT","% of total sales","EST","Estonia","2011","2011",1.9,,
+"PATCCHLS","C10-Lipid modifying agents","ATCPTTMT","% of total sales","EST","Estonia","2012","2012",1.8,,
+"PATCCHLS","C10-Lipid modifying agents","ATCPTTMT","% of total sales","EST","Estonia","2013","2013",1.5,,
+"PATCCHLS","C10-Lipid modifying agents","ATCPTTMT","% of total sales","EST","Estonia","2014","2014",1.3,,
+"PATCCHLS","C10-Lipid modifying agents","ATCPTTMT","% of total sales","EST","Estonia","2015","2015",1.2,,
+"PATCCHLS","C10-Lipid modifying agents","ATCPTTMT","% of total sales","EST","Estonia","2016","2016",1.1,,
+"PATCCHLS","C10-Lipid modifying agents","ATCPTTMT","% of total sales","EST","Estonia","2017","2017",1,,
+"PATCCHLS","C10-Lipid modifying agents","ATCPTTMT","% of total sales","EST","Estonia","2018","2018",1,,
+"PATCCHLS","C10-Lipid modifying agents","ATCPTTMT","% of total sales","EST","Estonia","2019","2019",1.1,,
+"PATCCHLS","C10-Lipid modifying agents","ATCPTTMT","% of total sales","EST","Estonia","2020","2020",1.2,,
+"PATCCHLS","C10-Lipid modifying agents","ATCPTTMT","% of total sales","EST","Estonia","2021","2021",1.1,,
+"PATCCHLS","C10-Lipid modifying agents","ATCPTTMT","% of total sales","EST","Estonia","2022","2022",1.2,,
+"PATCCHLS","C10-Lipid modifying agents","MLLNCUMT","Million of national currency units","SVN","Slovenia","2010","2010",31,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","MLLNCUMT","Million of national currency units","SVN","Slovenia","2011","2011",27.8,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","MLLNCUMT","Million of national currency units","SVN","Slovenia","2012","2012",25.3,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","MLLNCUMT","Million of national currency units","SVN","Slovenia","2013","2013",24.7,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","MLLNCUMT","Million of national currency units","SVN","Slovenia","2014","2014",14.4,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","MLLNCUMT","Million of national currency units","SVN","Slovenia","2015","2015",14,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","MLLNCUMT","Million of national currency units","SVN","Slovenia","2016","2016",14.1,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","MLLNCUMT","Million of national currency units","SVN","Slovenia","2017","2017",14.3,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","MLLNCUMT","Million of national currency units","SVN","Slovenia","2018","2018",14.7,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","MLLNCUMT","Million of national currency units","SVN","Slovenia","2019","2019",15.7,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","MLLNCUMT","Million of national currency units","SVN","Slovenia","2020","2020",17.4,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","MLLNCUMT","Million of national currency units","SVN","Slovenia","2021","2021",18.5,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","MLLNCUMT","Million of national currency units","SVN","Slovenia","2022","2022",20.2,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","MTMOTCMT","Million US$ at exchange rate","SVN","Slovenia","2010","2010",41.1,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","MTMOTCMT","Million US$ at exchange rate","SVN","Slovenia","2011","2011",38.7,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","MTMOTCMT","Million US$ at exchange rate","SVN","Slovenia","2012","2012",32.6,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","MTMOTCMT","Million US$ at exchange rate","SVN","Slovenia","2013","2013",32.8,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","MTMOTCMT","Million US$ at exchange rate","SVN","Slovenia","2014","2014",19.1,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","MTMOTCMT","Million US$ at exchange rate","SVN","Slovenia","2015","2015",15.5,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","MTMOTCMT","Million US$ at exchange rate","SVN","Slovenia","2016","2016",15.6,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","MTMOTCMT","Million US$ at exchange rate","SVN","Slovenia","2017","2017",16.1,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","MTMOTCMT","Million US$ at exchange rate","SVN","Slovenia","2018","2018",17.3,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","MTMOTCMT","Million US$ at exchange rate","SVN","Slovenia","2019","2019",17.6,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","MTMOTCMT","Million US$ at exchange rate","SVN","Slovenia","2020","2020",19.9,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","MTMOTCMT","Million US$ at exchange rate","SVN","Slovenia","2021","2021",21.8,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","MTMOTCMT","Million US$ at exchange rate","SVN","Slovenia","2022","2022",21.2,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","MTMOPPMT","Million US$, purchasing power parity","SVN","Slovenia","2010","2010",48.6,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","MTMOPPMT","Million US$, purchasing power parity","SVN","Slovenia","2011","2011",44.5,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","MTMOPPMT","Million US$, purchasing power parity","SVN","Slovenia","2012","2012",41.8,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","MTMOPPMT","Million US$, purchasing power parity","SVN","Slovenia","2013","2013",41.8,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","MTMOPPMT","Million US$, purchasing power parity","SVN","Slovenia","2014","2014",24.3,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","MTMOPPMT","Million US$, purchasing power parity","SVN","Slovenia","2015","2015",23.5,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","MTMOPPMT","Million US$, purchasing power parity","SVN","Slovenia","2016","2016",24.4,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","MTMOPPMT","Million US$, purchasing power parity","SVN","Slovenia","2017","2017",25.1,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","MTMOPPMT","Million US$, purchasing power parity","SVN","Slovenia","2018","2018",25.8,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","MTMOPPMT","Million US$, purchasing power parity","SVN","Slovenia","2019","2019",28.4,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","MTMOPPMT","Million US$, purchasing power parity","SVN","Slovenia","2020","2020",31.8,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","MTMOPPMT","Million US$, purchasing power parity","SVN","Slovenia","2021","2021",32.8,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","MTMOPPMT","Million US$, purchasing power parity","SVN","Slovenia","2022","2022",36.6,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","TCPPERMT","/capita, US$ exchange rate","SVN","Slovenia","2010","2010",20.1,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","TCPPERMT","/capita, US$ exchange rate","SVN","Slovenia","2011","2011",18.8,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","TCPPERMT","/capita, US$ exchange rate","SVN","Slovenia","2012","2012",15.8,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","TCPPERMT","/capita, US$ exchange rate","SVN","Slovenia","2013","2013",15.9,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","TCPPERMT","/capita, US$ exchange rate","SVN","Slovenia","2014","2014",9.3,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","TCPPERMT","/capita, US$ exchange rate","SVN","Slovenia","2015","2015",7.5,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","TCPPERMT","/capita, US$ exchange rate","SVN","Slovenia","2016","2016",7.5,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","TCPPERMT","/capita, US$ exchange rate","SVN","Slovenia","2017","2017",7.8,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","TCPPERMT","/capita, US$ exchange rate","SVN","Slovenia","2018","2018",8.4,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","TCPPERMT","/capita, US$ exchange rate","SVN","Slovenia","2019","2019",8.4,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","TCPPERMT","/capita, US$ exchange rate","SVN","Slovenia","2020","2020",9.5,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","TCPPERMT","/capita, US$ exchange rate","SVN","Slovenia","2021","2021",10.4,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","TCPPERMT","/capita, US$ exchange rate","SVN","Slovenia","2022","2022",10.1,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2010","2010",23.7,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2011","2011",21.7,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2012","2012",20.3,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2013","2013",20.3,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2014","2014",11.8,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2015","2015",11.4,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2016","2016",11.8,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2017","2017",12.1,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2018","2018",12.5,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2019","2019",13.6,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2020","2020",15.1,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2021","2021",15.5,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2022","2022",17.4,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","ATCPTTMT","% of total sales","SVN","Slovenia","2010","2010",6.5,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","ATCPTTMT","% of total sales","SVN","Slovenia","2011","2011",5.9,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","ATCPTTMT","% of total sales","SVN","Slovenia","2012","2012",5.6,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","ATCPTTMT","% of total sales","SVN","Slovenia","2013","2013",5.5,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","ATCPTTMT","% of total sales","SVN","Slovenia","2014","2014",3.3,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","ATCPTTMT","% of total sales","SVN","Slovenia","2015","2015",3.1,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","ATCPTTMT","% of total sales","SVN","Slovenia","2016","2016",3,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","ATCPTTMT","% of total sales","SVN","Slovenia","2017","2017",3,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","ATCPTTMT","% of total sales","SVN","Slovenia","2018","2018",2.8,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","ATCPTTMT","% of total sales","SVN","Slovenia","2019","2019",2.9,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","ATCPTTMT","% of total sales","SVN","Slovenia","2020","2020",3.1,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","ATCPTTMT","% of total sales","SVN","Slovenia","2021","2021",3,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","ATCPTTMT","% of total sales","SVN","Slovenia","2022","2022",3,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","MLLNCUMT","Million of national currency units","AUS","Australia","2010","2010",138,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","MLLNCUMT","Million of national currency units","AUS","Australia","2011","2011",143,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","MLLNCUMT","Million of national currency units","AUS","Australia","2012","2012",155,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","MLLNCUMT","Million of national currency units","AUS","Australia","2013","2013",225,"B; D","Break; Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","MLLNCUMT","Million of national currency units","AUS","Australia","2014","2014",240,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","MLLNCUMT","Million of national currency units","AUS","Australia","2015","2015",298,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","MLLNCUMT","Million of national currency units","AUS","Australia","2016","2016",359,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","MLLNCUMT","Million of national currency units","AUS","Australia","2017","2017",362,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","MLLNCUMT","Million of national currency units","AUS","Australia","2018","2018",367,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","MLLNCUMT","Million of national currency units","AUS","Australia","2019","2019",383,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","MLLNCUMT","Million of national currency units","AUS","Australia","2020","2020",404,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","MLLNCUMT","Million of national currency units","AUS","Australia","2021","2021",438,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","MTMOTCMT","Million US$ at exchange rate","AUS","Australia","2010","2010",126.6,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","MTMOTCMT","Million US$ at exchange rate","AUS","Australia","2011","2011",147.5,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","MTMOTCMT","Million US$ at exchange rate","AUS","Australia","2012","2012",160.5,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","MTMOTCMT","Million US$ at exchange rate","AUS","Australia","2013","2013",217.2,"B; D","Break; Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","MTMOTCMT","Million US$ at exchange rate","AUS","Australia","2014","2014",216.3,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","MTMOTCMT","Million US$ at exchange rate","AUS","Australia","2015","2015",223.9,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","MTMOTCMT","Million US$ at exchange rate","AUS","Australia","2016","2016",266.9,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","MTMOTCMT","Million US$ at exchange rate","AUS","Australia","2017","2017",277.4,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","MTMOTCMT","Million US$ at exchange rate","AUS","Australia","2018","2018",274.2,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","MTMOTCMT","Million US$ at exchange rate","AUS","Australia","2019","2019",266.2,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","MTMOTCMT","Million US$ at exchange rate","AUS","Australia","2020","2020",278,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","MTMOTCMT","Million US$ at exchange rate","AUS","Australia","2021","2021",329,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","MTMOPPMT","Million US$, purchasing power parity","AUS","Australia","2010","2010",91.8,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","MTMOPPMT","Million US$, purchasing power parity","AUS","Australia","2011","2011",94.6,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","MTMOPPMT","Million US$, purchasing power parity","AUS","Australia","2012","2012",100.6,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","MTMOPPMT","Million US$, purchasing power parity","AUS","Australia","2013","2013",155.5,"B; D","Break; Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","MTMOPPMT","Million US$, purchasing power parity","AUS","Australia","2014","2014",165.2,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","MTMOPPMT","Million US$, purchasing power parity","AUS","Australia","2015","2015",202.2,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","MTMOPPMT","Million US$, purchasing power parity","AUS","Australia","2016","2016",247.6,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","MTMOPPMT","Million US$, purchasing power parity","AUS","Australia","2017","2017",245,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","MTMOPPMT","Million US$, purchasing power parity","AUS","Australia","2018","2018",249.6,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","MTMOPPMT","Million US$, purchasing power parity","AUS","Australia","2019","2019",258.8,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","MTMOPPMT","Million US$, purchasing power parity","AUS","Australia","2020","2020",277.9,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","MTMOPPMT","Million US$, purchasing power parity","AUS","Australia","2021","2021",302.6,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","TCPPERMT","/capita, US$ exchange rate","AUS","Australia","2010","2010",5.7,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","TCPPERMT","/capita, US$ exchange rate","AUS","Australia","2011","2011",6.6,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","TCPPERMT","/capita, US$ exchange rate","AUS","Australia","2012","2012",7.1,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","TCPPERMT","/capita, US$ exchange rate","AUS","Australia","2013","2013",9.4,"B; D","Break; Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","TCPPERMT","/capita, US$ exchange rate","AUS","Australia","2014","2014",9.2,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","TCPPERMT","/capita, US$ exchange rate","AUS","Australia","2015","2015",9.4,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","TCPPERMT","/capita, US$ exchange rate","AUS","Australia","2016","2016",11,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","TCPPERMT","/capita, US$ exchange rate","AUS","Australia","2017","2017",11.3,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","TCPPERMT","/capita, US$ exchange rate","AUS","Australia","2018","2018",11,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","TCPPERMT","/capita, US$ exchange rate","AUS","Australia","2019","2019",10.5,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","TCPPERMT","/capita, US$ exchange rate","AUS","Australia","2020","2020",10.8,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","TCPPERMT","/capita, US$ exchange rate","AUS","Australia","2021","2021",12.8,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2010","2010",4.2,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2011","2011",4.2,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2012","2012",4.4,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2013","2013",6.7,"B; D","Break; Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2014","2014",7,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2015","2015",8.5,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2016","2016",10.2,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2017","2017",10,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2018","2018",10,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2019","2019",10.2,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2020","2020",10.8,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2021","2021",11.8,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","ATCPTTMT","% of total sales","AUS","Australia","2010","2010",1.4,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","ATCPTTMT","% of total sales","AUS","Australia","2011","2011",1.4,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","ATCPTTMT","% of total sales","AUS","Australia","2012","2012",1.5,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","ATCPTTMT","% of total sales","AUS","Australia","2013","2013",1.9,"B; D","Break; Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","ATCPTTMT","% of total sales","AUS","Australia","2014","2014",2,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","ATCPTTMT","% of total sales","AUS","Australia","2015","2015",2.4,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","ATCPTTMT","% of total sales","AUS","Australia","2016","2016",2.3,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","ATCPTTMT","% of total sales","AUS","Australia","2017","2017",2.5,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","ATCPTTMT","% of total sales","AUS","Australia","2018","2018",2.5,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","ATCPTTMT","% of total sales","AUS","Australia","2019","2019",2.5,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","ATCPTTMT","% of total sales","AUS","Australia","2020","2020",2.4,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","ATCPTTMT","% of total sales","AUS","Australia","2021","2021",2.5,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","MLLNCUMT","Million of national currency units","AUT","Austria","2010","2010",43.7,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","MLLNCUMT","Million of national currency units","AUT","Austria","2011","2011",43.9,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","MLLNCUMT","Million of national currency units","AUT","Austria","2012","2012",45.4,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","MLLNCUMT","Million of national currency units","AUT","Austria","2013","2013",45.4,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","MLLNCUMT","Million of national currency units","AUT","Austria","2014","2014",45.3,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","MLLNCUMT","Million of national currency units","AUT","Austria","2015","2015",45.5,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","MLLNCUMT","Million of national currency units","AUT","Austria","2016","2016",46.6,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","MLLNCUMT","Million of national currency units","AUT","Austria","2017","2017",46.1,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","MLLNCUMT","Million of national currency units","AUT","Austria","2018","2018",43.1,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","MLLNCUMT","Million of national currency units","AUT","Austria","2019","2019",44.4,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","MLLNCUMT","Million of national currency units","AUT","Austria","2020","2020",40.7,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","MLLNCUMT","Million of national currency units","AUT","Austria","2021","2021",40.4,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","MTMOTCMT","Million US$ at exchange rate","AUT","Austria","2010","2010",57.9,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","MTMOTCMT","Million US$ at exchange rate","AUT","Austria","2011","2011",61.1,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","MTMOTCMT","Million US$ at exchange rate","AUT","Austria","2012","2012",58.3,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","MTMOTCMT","Million US$ at exchange rate","AUT","Austria","2013","2013",60.2,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","MTMOTCMT","Million US$ at exchange rate","AUT","Austria","2014","2014",60.2,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","MTMOTCMT","Million US$ at exchange rate","AUT","Austria","2015","2015",50.5,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","MTMOTCMT","Million US$ at exchange rate","AUT","Austria","2016","2016",51.6,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","MTMOTCMT","Million US$ at exchange rate","AUT","Austria","2017","2017",52.1,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","MTMOTCMT","Million US$ at exchange rate","AUT","Austria","2018","2018",50.9,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","MTMOTCMT","Million US$ at exchange rate","AUT","Austria","2019","2019",49.7,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","MTMOTCMT","Million US$ at exchange rate","AUT","Austria","2020","2020",46.5,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","MTMOTCMT","Million US$ at exchange rate","AUT","Austria","2021","2021",47.8,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","MTMOPPMT","Million US$, purchasing power parity","AUT","Austria","2010","2010",51.8,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","MTMOPPMT","Million US$, purchasing power parity","AUT","Austria","2011","2011",52.8,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","MTMOPPMT","Million US$, purchasing power parity","AUT","Austria","2012","2012",55.8,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","MTMOPPMT","Million US$, purchasing power parity","AUT","Austria","2013","2013",56.9,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","MTMOPPMT","Million US$, purchasing power parity","AUT","Austria","2014","2014",56.7,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","MTMOPPMT","Million US$, purchasing power parity","AUT","Austria","2015","2015",57,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","MTMOPPMT","Million US$, purchasing power parity","AUT","Austria","2016","2016",60,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","MTMOPPMT","Million US$, purchasing power parity","AUT","Austria","2017","2017",59.5,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","MTMOPPMT","Million US$, purchasing power parity","AUT","Austria","2018","2018",56.3,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","MTMOPPMT","Million US$, purchasing power parity","AUT","Austria","2019","2019",59.3,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","MTMOPPMT","Million US$, purchasing power parity","AUT","Austria","2020","2020",54.5,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","MTMOPPMT","Million US$, purchasing power parity","AUT","Austria","2021","2021",53.5,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","TCPPERMT","/capita, US$ exchange rate","AUT","Austria","2010","2010",6.9,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","TCPPERMT","/capita, US$ exchange rate","AUT","Austria","2011","2011",7.3,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","TCPPERMT","/capita, US$ exchange rate","AUT","Austria","2012","2012",6.9,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","TCPPERMT","/capita, US$ exchange rate","AUT","Austria","2013","2013",7.1,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","TCPPERMT","/capita, US$ exchange rate","AUT","Austria","2014","2014",7,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","TCPPERMT","/capita, US$ exchange rate","AUT","Austria","2015","2015",5.8,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","TCPPERMT","/capita, US$ exchange rate","AUT","Austria","2016","2016",5.9,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","TCPPERMT","/capita, US$ exchange rate","AUT","Austria","2017","2017",5.9,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","TCPPERMT","/capita, US$ exchange rate","AUT","Austria","2018","2018",5.8,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","TCPPERMT","/capita, US$ exchange rate","AUT","Austria","2019","2019",5.6,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","TCPPERMT","/capita, US$ exchange rate","AUT","Austria","2020","2020",5.2,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","TCPPERMT","/capita, US$ exchange rate","AUT","Austria","2021","2021",5.3,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2010","2010",6.2,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2011","2011",6.3,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2012","2012",6.6,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2013","2013",6.7,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2014","2014",6.6,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2015","2015",6.6,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2016","2016",6.9,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2017","2017",6.8,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2018","2018",6.4,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2019","2019",6.7,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2020","2020",6.1,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2021","2021",6,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","ATCPTTMT","% of total sales","AUT","Austria","2010","2010",1.8,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","ATCPTTMT","% of total sales","AUT","Austria","2011","2011",1.7,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","ATCPTTMT","% of total sales","AUT","Austria","2012","2012",1.7,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","ATCPTTMT","% of total sales","AUT","Austria","2013","2013",1.7,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","ATCPTTMT","% of total sales","AUT","Austria","2014","2014",1.6,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","ATCPTTMT","% of total sales","AUT","Austria","2015","2015",1.6,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","ATCPTTMT","% of total sales","AUT","Austria","2016","2016",1.5,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","ATCPTTMT","% of total sales","AUT","Austria","2017","2017",1.5,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","ATCPTTMT","% of total sales","AUT","Austria","2018","2018",1.3,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","ATCPTTMT","% of total sales","AUT","Austria","2019","2019",1.3,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","ATCPTTMT","% of total sales","AUT","Austria","2020","2020",1.2,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","ATCPTTMT","% of total sales","AUT","Austria","2021","2021",1.1,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","MLLNCUMT","Million of national currency units","BEL","Belgium","2010","2010",239.7,,
+"PATCGENU","G-Genito urinary system and sex hormones","MLLNCUMT","Million of national currency units","BEL","Belgium","2011","2011",241.5,,
+"PATCGENU","G-Genito urinary system and sex hormones","MLLNCUMT","Million of national currency units","BEL","Belgium","2012","2012",236.6,,
+"PATCGENU","G-Genito urinary system and sex hormones","MLLNCUMT","Million of national currency units","BEL","Belgium","2013","2013",232,,
+"PATCGENU","G-Genito urinary system and sex hormones","MLLNCUMT","Million of national currency units","BEL","Belgium","2014","2014",226.7,,
+"PATCGENU","G-Genito urinary system and sex hormones","MLLNCUMT","Million of national currency units","BEL","Belgium","2015","2015",224.7,,
+"PATCGENU","G-Genito urinary system and sex hormones","MLLNCUMT","Million of national currency units","BEL","Belgium","2016","2016",225.5,,
+"PATCGENU","G-Genito urinary system and sex hormones","MLLNCUMT","Million of national currency units","BEL","Belgium","2017","2017",223.5,,
+"PATCGENU","G-Genito urinary system and sex hormones","MLLNCUMT","Million of national currency units","BEL","Belgium","2018","2018",217.8,,
+"PATCGENU","G-Genito urinary system and sex hormones","MLLNCUMT","Million of national currency units","BEL","Belgium","2019","2019",226.3,,
+"PATCGENU","G-Genito urinary system and sex hormones","MLLNCUMT","Million of national currency units","BEL","Belgium","2020","2020",216,,
+"PATCGENU","G-Genito urinary system and sex hormones","MLLNCUMT","Million of national currency units","BEL","Belgium","2021","2021",219.7,,
+"PATCGENU","G-Genito urinary system and sex hormones","MLLNCUMT","Million of national currency units","BEL","Belgium","2022","2022",224.2,"E","Estimated value"
+"PATCGENU","G-Genito urinary system and sex hormones","MTMOTCMT","Million US$ at exchange rate","BEL","Belgium","2010","2010",317.7,,
+"PATCGENU","G-Genito urinary system and sex hormones","MTMOTCMT","Million US$ at exchange rate","BEL","Belgium","2011","2011",336.1,,
+"PATCGENU","G-Genito urinary system and sex hormones","MTMOTCMT","Million US$ at exchange rate","BEL","Belgium","2012","2012",303.9,,
+"PATCGENU","G-Genito urinary system and sex hormones","MTMOTCMT","Million US$ at exchange rate","BEL","Belgium","2013","2013",308.1,,
+"PATCGENU","G-Genito urinary system and sex hormones","MTMOTCMT","Million US$ at exchange rate","BEL","Belgium","2014","2014",301.1,,
+"PATCGENU","G-Genito urinary system and sex hormones","MTMOTCMT","Million US$ at exchange rate","BEL","Belgium","2015","2015",249.3,,
+"PATCGENU","G-Genito urinary system and sex hormones","MTMOTCMT","Million US$ at exchange rate","BEL","Belgium","2016","2016",249.6,,
+"PATCGENU","G-Genito urinary system and sex hormones","MTMOTCMT","Million US$ at exchange rate","BEL","Belgium","2017","2017",252.5,,
+"PATCGENU","G-Genito urinary system and sex hormones","MTMOTCMT","Million US$ at exchange rate","BEL","Belgium","2018","2018",257.3,,
+"PATCGENU","G-Genito urinary system and sex hormones","MTMOTCMT","Million US$ at exchange rate","BEL","Belgium","2019","2019",253.4,,
+"PATCGENU","G-Genito urinary system and sex hormones","MTMOTCMT","Million US$ at exchange rate","BEL","Belgium","2020","2020",246.7,,
+"PATCGENU","G-Genito urinary system and sex hormones","MTMOTCMT","Million US$ at exchange rate","BEL","Belgium","2021","2021",259.8,,
+"PATCGENU","G-Genito urinary system and sex hormones","MTMOTCMT","Million US$ at exchange rate","BEL","Belgium","2022","2022",236.1,"E","Estimated value"
+"PATCGENU","G-Genito urinary system and sex hormones","MTMOPPMT","Million US$, purchasing power parity","BEL","Belgium","2010","2010",286.5,,
+"PATCGENU","G-Genito urinary system and sex hormones","MTMOPPMT","Million US$, purchasing power parity","BEL","Belgium","2011","2011",290.3,,
+"PATCGENU","G-Genito urinary system and sex hormones","MTMOPPMT","Million US$, purchasing power parity","BEL","Belgium","2012","2012",287.7,,
+"PATCGENU","G-Genito urinary system and sex hormones","MTMOPPMT","Million US$, purchasing power parity","BEL","Belgium","2013","2013",287.7,,
+"PATCGENU","G-Genito urinary system and sex hormones","MTMOPPMT","Million US$, purchasing power parity","BEL","Belgium","2014","2014",283.2,,
+"PATCGENU","G-Genito urinary system and sex hormones","MTMOPPMT","Million US$, purchasing power parity","BEL","Belgium","2015","2015",280.9,,
+"PATCGENU","G-Genito urinary system and sex hormones","MTMOPPMT","Million US$, purchasing power parity","BEL","Belgium","2016","2016",288.7,,
+"PATCGENU","G-Genito urinary system and sex hormones","MTMOPPMT","Million US$, purchasing power parity","BEL","Belgium","2017","2017",288.2,,
+"PATCGENU","G-Genito urinary system and sex hormones","MTMOPPMT","Million US$, purchasing power parity","BEL","Belgium","2018","2018",284.2,,
+"PATCGENU","G-Genito urinary system and sex hormones","MTMOPPMT","Million US$, purchasing power parity","BEL","Belgium","2019","2019",303.2,,
+"PATCGENU","G-Genito urinary system and sex hormones","MTMOPPMT","Million US$, purchasing power parity","BEL","Belgium","2020","2020",295.8,,
+"PATCGENU","G-Genito urinary system and sex hormones","MTMOPPMT","Million US$, purchasing power parity","BEL","Belgium","2021","2021",298.2,,
+"PATCGENU","G-Genito urinary system and sex hormones","MTMOPPMT","Million US$, purchasing power parity","BEL","Belgium","2022","2022",314,"E","Estimated value"
+"PATCGENU","G-Genito urinary system and sex hormones","TCPPERMT","/capita, US$ exchange rate","BEL","Belgium","2010","2010",29.2,,
+"PATCGENU","G-Genito urinary system and sex hormones","TCPPERMT","/capita, US$ exchange rate","BEL","Belgium","2011","2011",30.5,,
+"PATCGENU","G-Genito urinary system and sex hormones","TCPPERMT","/capita, US$ exchange rate","BEL","Belgium","2012","2012",27.4,,
+"PATCGENU","G-Genito urinary system and sex hormones","TCPPERMT","/capita, US$ exchange rate","BEL","Belgium","2013","2013",27.6,,
+"PATCGENU","G-Genito urinary system and sex hormones","TCPPERMT","/capita, US$ exchange rate","BEL","Belgium","2014","2014",26.9,,
+"PATCGENU","G-Genito urinary system and sex hormones","TCPPERMT","/capita, US$ exchange rate","BEL","Belgium","2015","2015",22.1,,
+"PATCGENU","G-Genito urinary system and sex hormones","TCPPERMT","/capita, US$ exchange rate","BEL","Belgium","2016","2016",22,,
+"PATCGENU","G-Genito urinary system and sex hormones","TCPPERMT","/capita, US$ exchange rate","BEL","Belgium","2017","2017",22.2,,
+"PATCGENU","G-Genito urinary system and sex hormones","TCPPERMT","/capita, US$ exchange rate","BEL","Belgium","2018","2018",22.5,,
+"PATCGENU","G-Genito urinary system and sex hormones","TCPPERMT","/capita, US$ exchange rate","BEL","Belgium","2019","2019",22.1,,
+"PATCGENU","G-Genito urinary system and sex hormones","TCPPERMT","/capita, US$ exchange rate","BEL","Belgium","2020","2020",21.4,,
+"PATCGENU","G-Genito urinary system and sex hormones","TCPPERMT","/capita, US$ exchange rate","BEL","Belgium","2021","2021",22.4,,
+"PATCGENU","G-Genito urinary system and sex hormones","TCPPERMT","/capita, US$ exchange rate","BEL","Belgium","2022","2022",20.3,"E","Estimated value"
+"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2010","2010",26.3,,
+"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2011","2011",26.3,,
+"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2012","2012",25.9,,
+"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2013","2013",25.8,,
+"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2014","2014",25.3,,
+"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2015","2015",24.9,,
+"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2016","2016",25.5,,
+"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2017","2017",25.3,,
+"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2018","2018",24.9,,
+"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2019","2019",26.4,,
+"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2020","2020",25.6,,
+"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2021","2021",25.7,,
+"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2022","2022",27,"E","Estimated value"
+"PATCGENU","G-Genito urinary system and sex hormones","ATCPTTMT","% of total sales","BEL","Belgium","2010","2010",4.1,,
+"PATCGENU","G-Genito urinary system and sex hormones","ATCPTTMT","% of total sales","BEL","Belgium","2011","2011",4,,
+"PATCGENU","G-Genito urinary system and sex hormones","ATCPTTMT","% of total sales","BEL","Belgium","2012","2012",4,,
+"PATCGENU","G-Genito urinary system and sex hormones","ATCPTTMT","% of total sales","BEL","Belgium","2013","2013",3.9,,
+"PATCGENU","G-Genito urinary system and sex hormones","ATCPTTMT","% of total sales","BEL","Belgium","2014","2014",3.8,,
+"PATCGENU","G-Genito urinary system and sex hormones","ATCPTTMT","% of total sales","BEL","Belgium","2015","2015",3.6,,
+"PATCGENU","G-Genito urinary system and sex hormones","ATCPTTMT","% of total sales","BEL","Belgium","2016","2016",3.6,,
+"PATCGENU","G-Genito urinary system and sex hormones","ATCPTTMT","% of total sales","BEL","Belgium","2017","2017",3.4,,
+"PATCGENU","G-Genito urinary system and sex hormones","ATCPTTMT","% of total sales","BEL","Belgium","2018","2018",3.3,,
+"PATCGENU","G-Genito urinary system and sex hormones","ATCPTTMT","% of total sales","BEL","Belgium","2019","2019",3.1,,
+"PATCGENU","G-Genito urinary system and sex hormones","ATCPTTMT","% of total sales","BEL","Belgium","2020","2020",2.8,,
+"PATCGENU","G-Genito urinary system and sex hormones","ATCPTTMT","% of total sales","BEL","Belgium","2021","2021",2.7,,
+"PATCGENU","G-Genito urinary system and sex hormones","ATCPTTMT","% of total sales","BEL","Belgium","2022","2022",2.5,"E","Estimated value"
+"PATCGENU","G-Genito urinary system and sex hormones","MLLNCUMT","Million of national currency units","CAN","Canada","2012","2012",1430.6,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","MLLNCUMT","Million of national currency units","CAN","Canada","2013","2013",1473.9,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","MLLNCUMT","Million of national currency units","CAN","Canada","2014","2014",1512.5,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","MLLNCUMT","Million of national currency units","CAN","Canada","2015","2015",1511.3,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","MLLNCUMT","Million of national currency units","CAN","Canada","2016","2016",1485,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","MLLNCUMT","Million of national currency units","CAN","Canada","2017","2017",1517.6,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","MLLNCUMT","Million of national currency units","CAN","Canada","2018","2018",1563.2,"E; B; D","Estimated value; Break; Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","MLLNCUMT","Million of national currency units","CAN","Canada","2019","2019",1543,"E; D","Estimated value; Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","MLLNCUMT","Million of national currency units","CAN","Canada","2020","2020",1532.3,"E; D","Estimated value; Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","MLLNCUMT","Million of national currency units","CAN","Canada","2021","2021",1550.1,"E; D","Estimated value; Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","MLLNCUMT","Million of national currency units","CAN","Canada","2022","2022",1566.4,"E; D","Estimated value; Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","MTMOTCMT","Million US$ at exchange rate","CAN","Canada","2012","2012",1431.5,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","MTMOTCMT","Million US$ at exchange rate","CAN","Canada","2013","2013",1430.8,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","MTMOTCMT","Million US$ at exchange rate","CAN","Canada","2014","2014",1369.1,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","MTMOTCMT","Million US$ at exchange rate","CAN","Canada","2015","2015",1181.8,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","MTMOTCMT","Million US$ at exchange rate","CAN","Canada","2016","2016",1120.2,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","MTMOTCMT","Million US$ at exchange rate","CAN","Canada","2017","2017",1169.2,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","MTMOTCMT","Million US$ at exchange rate","CAN","Canada","2018","2018",1206.4,"E; B; D","Estimated value; Break; Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","MTMOTCMT","Million US$ at exchange rate","CAN","Canada","2019","2019",1163,"E; D","Estimated value; Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","MTMOTCMT","Million US$ at exchange rate","CAN","Canada","2020","2020",1142.5,"E; D","Estimated value; Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","MTMOTCMT","Million US$ at exchange rate","CAN","Canada","2021","2021",1236.2,"E; D","Estimated value; Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","MTMOTCMT","Million US$ at exchange rate","CAN","Canada","2022","2022",1203.5,"E; D","Estimated value; Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","MTMOPPMT","Million US$, purchasing power parity","CAN","Canada","2012","2012",1149.4,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","MTMOPPMT","Million US$, purchasing power parity","CAN","Canada","2013","2013",1204.2,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","MTMOPPMT","Million US$, purchasing power parity","CAN","Canada","2014","2014",1229.3,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","MTMOPPMT","Million US$, purchasing power parity","CAN","Canada","2015","2015",1210.9,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","MTMOPPMT","Million US$, purchasing power parity","CAN","Canada","2016","2016",1230.3,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","MTMOPPMT","Million US$, purchasing power parity","CAN","Canada","2017","2017",1251.8,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","MTMOPPMT","Million US$, purchasing power parity","CAN","Canada","2018","2018",1295.7,"E; B; D","Estimated value; Break; Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","MTMOPPMT","Million US$, purchasing power parity","CAN","Canada","2019","2019",1249.7,"E; D","Estimated value; Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","MTMOPPMT","Million US$, purchasing power parity","CAN","Canada","2020","2020",1244.7,"E; D","Estimated value; Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","MTMOPPMT","Million US$, purchasing power parity","CAN","Canada","2021","2021",1251.9,"E; D","Estimated value; Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","MTMOPPMT","Million US$, purchasing power parity","CAN","Canada","2022","2022",1249.3,"E; D","Estimated value; Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","TCPPERMT","/capita, US$ exchange rate","CAN","Canada","2012","2012",41.2,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","TCPPERMT","/capita, US$ exchange rate","CAN","Canada","2013","2013",40.8,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","TCPPERMT","/capita, US$ exchange rate","CAN","Canada","2014","2014",38.6,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","TCPPERMT","/capita, US$ exchange rate","CAN","Canada","2015","2015",33.1,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","TCPPERMT","/capita, US$ exchange rate","CAN","Canada","2016","2016",31,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","TCPPERMT","/capita, US$ exchange rate","CAN","Canada","2017","2017",32,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","TCPPERMT","/capita, US$ exchange rate","CAN","Canada","2018","2018",32.5,"E; B; D","Estimated value; Break; Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","TCPPERMT","/capita, US$ exchange rate","CAN","Canada","2019","2019",30.9,"E; D","Estimated value; Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","TCPPERMT","/capita, US$ exchange rate","CAN","Canada","2020","2020",30,"E; D","Estimated value; Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","TCPPERMT","/capita, US$ exchange rate","CAN","Canada","2021","2021",32.3,"E; D","Estimated value; Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","TCPPERMT","/capita, US$ exchange rate","CAN","Canada","2022","2022",31,"E; D","Estimated value; Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2012","2012",33.1,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2013","2013",34.3,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2014","2014",34.7,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2015","2015",33.9,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2016","2016",34.1,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2017","2017",34.3,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2018","2018",35,"E; B; D","Estimated value; Break; Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2019","2019",33.2,"E; D","Estimated value; Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2020","2020",32.7,"E; D","Estimated value; Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2021","2021",32.7,"E; D","Estimated value; Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2022","2022",32.1,"E; D","Estimated value; Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","ATCPTTMT","% of total sales","CAN","Canada","2012","2012",5.9,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","ATCPTTMT","% of total sales","CAN","Canada","2013","2013",6,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","ATCPTTMT","% of total sales","CAN","Canada","2014","2014",5.9,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","ATCPTTMT","% of total sales","CAN","Canada","2015","2015",5.6,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","ATCPTTMT","% of total sales","CAN","Canada","2016","2016",5.2,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","ATCPTTMT","% of total sales","CAN","Canada","2017","2017",5.1,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","ATCPTTMT","% of total sales","CAN","Canada","2018","2018",5.1,"E; B; D","Estimated value; Break; Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","ATCPTTMT","% of total sales","CAN","Canada","2019","2019",4.8,"E; D","Estimated value; Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","ATCPTTMT","% of total sales","CAN","Canada","2020","2020",4.5,"E; D","Estimated value; Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","ATCPTTMT","% of total sales","CAN","Canada","2021","2021",4.2,"E; D","Estimated value; Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","ATCPTTMT","% of total sales","CAN","Canada","2022","2022",3.9,"E; D","Estimated value; Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","MLLNCUMT","Million of national currency units","CZE","Czech Republic","2010","2010",4979.4,,
+"PATCGENU","G-Genito urinary system and sex hormones","MLLNCUMT","Million of national currency units","CZE","Czech Republic","2011","2011",4855,,
+"PATCGENU","G-Genito urinary system and sex hormones","MLLNCUMT","Million of national currency units","CZE","Czech Republic","2012","2012",5036,,
+"PATCGENU","G-Genito urinary system and sex hormones","MLLNCUMT","Million of national currency units","CZE","Czech Republic","2013","2013",4559.4,,
+"PATCGENU","G-Genito urinary system and sex hormones","MLLNCUMT","Million of national currency units","CZE","Czech Republic","2014","2014",4503.2,,
+"PATCGENU","G-Genito urinary system and sex hormones","MLLNCUMT","Million of national currency units","CZE","Czech Republic","2015","2015",4399.8,,
+"PATCGENU","G-Genito urinary system and sex hormones","MLLNCUMT","Million of national currency units","CZE","Czech Republic","2016","2016",4373.1,,
+"PATCGENU","G-Genito urinary system and sex hormones","MLLNCUMT","Million of national currency units","CZE","Czech Republic","2017","2017",4303.3,,
+"PATCGENU","G-Genito urinary system and sex hormones","MLLNCUMT","Million of national currency units","CZE","Czech Republic","2018","2018",4442.9,,
+"PATCGENU","G-Genito urinary system and sex hormones","MLLNCUMT","Million of national currency units","CZE","Czech Republic","2019","2019",4467.9,,
+"PATCGENU","G-Genito urinary system and sex hormones","MLLNCUMT","Million of national currency units","CZE","Czech Republic","2020","2020",2158.7,"B","Break"
+"PATCGENU","G-Genito urinary system and sex hormones","MLLNCUMT","Million of national currency units","CZE","Czech Republic","2021","2021",2049,,
+"PATCGENU","G-Genito urinary system and sex hormones","MTMOTCMT","Million US$ at exchange rate","CZE","Czech Republic","2010","2010",260.7,,
+"PATCGENU","G-Genito urinary system and sex hormones","MTMOTCMT","Million US$ at exchange rate","CZE","Czech Republic","2011","2011",274.4,,
+"PATCGENU","G-Genito urinary system and sex hormones","MTMOTCMT","Million US$ at exchange rate","CZE","Czech Republic","2012","2012",257.2,,
+"PATCGENU","G-Genito urinary system and sex hormones","MTMOTCMT","Million US$ at exchange rate","CZE","Czech Republic","2013","2013",233,,
+"PATCGENU","G-Genito urinary system and sex hormones","MTMOTCMT","Million US$ at exchange rate","CZE","Czech Republic","2014","2014",216.9,,
+"PATCGENU","G-Genito urinary system and sex hormones","MTMOTCMT","Million US$ at exchange rate","CZE","Czech Republic","2015","2015",178.9,,
+"PATCGENU","G-Genito urinary system and sex hormones","MTMOTCMT","Million US$ at exchange rate","CZE","Czech Republic","2016","2016",178.9,,
+"PATCGENU","G-Genito urinary system and sex hormones","MTMOTCMT","Million US$ at exchange rate","CZE","Czech Republic","2017","2017",184.1,,
+"PATCGENU","G-Genito urinary system and sex hormones","MTMOTCMT","Million US$ at exchange rate","CZE","Czech Republic","2018","2018",204.5,,
+"PATCGENU","G-Genito urinary system and sex hormones","MTMOTCMT","Million US$ at exchange rate","CZE","Czech Republic","2019","2019",194.8,,
+"PATCGENU","G-Genito urinary system and sex hormones","MTMOTCMT","Million US$ at exchange rate","CZE","Czech Republic","2020","2020",93,"B","Break"
+"PATCGENU","G-Genito urinary system and sex hormones","MTMOTCMT","Million US$ at exchange rate","CZE","Czech Republic","2021","2021",94.5,,
+"PATCGENU","G-Genito urinary system and sex hormones","MTMOPPMT","Million US$, purchasing power parity","CZE","Czech Republic","2010","2010",364.2,,
+"PATCGENU","G-Genito urinary system and sex hormones","MTMOPPMT","Million US$, purchasing power parity","CZE","Czech Republic","2011","2011",363.8,,
+"PATCGENU","G-Genito urinary system and sex hormones","MTMOPPMT","Million US$, purchasing power parity","CZE","Czech Republic","2012","2012",378.7,,
+"PATCGENU","G-Genito urinary system and sex hormones","MTMOPPMT","Million US$, purchasing power parity","CZE","Czech Republic","2013","2013",356.6,,
+"PATCGENU","G-Genito urinary system and sex hormones","MTMOPPMT","Million US$, purchasing power parity","CZE","Czech Republic","2014","2014",354.5,,
+"PATCGENU","G-Genito urinary system and sex hormones","MTMOPPMT","Million US$, purchasing power parity","CZE","Czech Republic","2015","2015",340.1,,
+"PATCGENU","G-Genito urinary system and sex hormones","MTMOPPMT","Million US$, purchasing power parity","CZE","Czech Republic","2016","2016",347.7,,
+"PATCGENU","G-Genito urinary system and sex hormones","MTMOPPMT","Million US$, purchasing power parity","CZE","Czech Republic","2017","2017",346.3,,
+"PATCGENU","G-Genito urinary system and sex hormones","MTMOPPMT","Million US$, purchasing power parity","CZE","Czech Republic","2018","2018",359.1,,
+"PATCGENU","G-Genito urinary system and sex hormones","MTMOPPMT","Million US$, purchasing power parity","CZE","Czech Republic","2019","2019",364,,
+"PATCGENU","G-Genito urinary system and sex hormones","MTMOPPMT","Million US$, purchasing power parity","CZE","Czech Republic","2020","2020",173.2,"B","Break"
+"PATCGENU","G-Genito urinary system and sex hormones","MTMOPPMT","Million US$, purchasing power parity","CZE","Czech Republic","2021","2021",160.8,,
+"PATCGENU","G-Genito urinary system and sex hormones","TCPPERMT","/capita, US$ exchange rate","CZE","Czech Republic","2010","2010",24.9,,
+"PATCGENU","G-Genito urinary system and sex hormones","TCPPERMT","/capita, US$ exchange rate","CZE","Czech Republic","2011","2011",26.1,,
+"PATCGENU","G-Genito urinary system and sex hormones","TCPPERMT","/capita, US$ exchange rate","CZE","Czech Republic","2012","2012",24.5,,
+"PATCGENU","G-Genito urinary system and sex hormones","TCPPERMT","/capita, US$ exchange rate","CZE","Czech Republic","2013","2013",22.2,,
+"PATCGENU","G-Genito urinary system and sex hormones","TCPPERMT","/capita, US$ exchange rate","CZE","Czech Republic","2014","2014",20.6,,
+"PATCGENU","G-Genito urinary system and sex hormones","TCPPERMT","/capita, US$ exchange rate","CZE","Czech Republic","2015","2015",17,,
+"PATCGENU","G-Genito urinary system and sex hormones","TCPPERMT","/capita, US$ exchange rate","CZE","Czech Republic","2016","2016",16.9,,
+"PATCGENU","G-Genito urinary system and sex hormones","TCPPERMT","/capita, US$ exchange rate","CZE","Czech Republic","2017","2017",17.4,,
+"PATCGENU","G-Genito urinary system and sex hormones","TCPPERMT","/capita, US$ exchange rate","CZE","Czech Republic","2018","2018",19.2,,
+"PATCGENU","G-Genito urinary system and sex hormones","TCPPERMT","/capita, US$ exchange rate","CZE","Czech Republic","2019","2019",18.3,,
+"PATCGENU","G-Genito urinary system and sex hormones","TCPPERMT","/capita, US$ exchange rate","CZE","Czech Republic","2020","2020",8.7,"B","Break"
+"PATCGENU","G-Genito urinary system and sex hormones","TCPPERMT","/capita, US$ exchange rate","CZE","Czech Republic","2021","2021",9,,
+"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czech Republic","2010","2010",34.8,,
+"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czech Republic","2011","2011",34.7,,
+"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czech Republic","2012","2012",36,,
+"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czech Republic","2013","2013",33.9,,
+"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czech Republic","2014","2014",33.7,,
+"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czech Republic","2015","2015",32.2,,
+"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czech Republic","2016","2016",32.9,,
+"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czech Republic","2017","2017",32.7,,
+"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czech Republic","2018","2018",33.8,,
+"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czech Republic","2019","2019",34.1,,
+"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czech Republic","2020","2020",16.2,"B","Break"
+"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czech Republic","2021","2021",15.3,,
+"PATCGENU","G-Genito urinary system and sex hormones","ATCPTTMT","% of total sales","CZE","Czech Republic","2010","2010",6.1,,
+"PATCGENU","G-Genito urinary system and sex hormones","ATCPTTMT","% of total sales","CZE","Czech Republic","2011","2011",6,,
+"PATCGENU","G-Genito urinary system and sex hormones","ATCPTTMT","% of total sales","CZE","Czech Republic","2012","2012",6,,
+"PATCGENU","G-Genito urinary system and sex hormones","ATCPTTMT","% of total sales","CZE","Czech Republic","2013","2013",5.7,,
+"PATCGENU","G-Genito urinary system and sex hormones","ATCPTTMT","% of total sales","CZE","Czech Republic","2014","2014",5.6,,
+"PATCGENU","G-Genito urinary system and sex hormones","ATCPTTMT","% of total sales","CZE","Czech Republic","2015","2015",5.2,,
+"PATCGENU","G-Genito urinary system and sex hormones","ATCPTTMT","% of total sales","CZE","Czech Republic","2016","2016",5,,
+"PATCGENU","G-Genito urinary system and sex hormones","ATCPTTMT","% of total sales","CZE","Czech Republic","2017","2017",4.7,,
+"PATCGENU","G-Genito urinary system and sex hormones","ATCPTTMT","% of total sales","CZE","Czech Republic","2018","2018",4.5,,
+"PATCGENU","G-Genito urinary system and sex hormones","ATCPTTMT","% of total sales","CZE","Czech Republic","2019","2019",4.3,,
+"PATCGENU","G-Genito urinary system and sex hormones","ATCPTTMT","% of total sales","CZE","Czech Republic","2020","2020",2.5,"B","Break"
+"PATCGENU","G-Genito urinary system and sex hormones","ATCPTTMT","% of total sales","CZE","Czech Republic","2021","2021",2.2,,
+"PATCGENU","G-Genito urinary system and sex hormones","MLLNCUMT","Million of national currency units","DNK","Denmark","2010","2010",1041.8,,
+"PATCGENU","G-Genito urinary system and sex hormones","MLLNCUMT","Million of national currency units","DNK","Denmark","2011","2011",946.1,,
+"PATCGENU","G-Genito urinary system and sex hormones","MLLNCUMT","Million of national currency units","DNK","Denmark","2012","2012",978,,
+"PATCGENU","G-Genito urinary system and sex hormones","MLLNCUMT","Million of national currency units","DNK","Denmark","2013","2013",870.4,,
+"PATCGENU","G-Genito urinary system and sex hormones","MLLNCUMT","Million of national currency units","DNK","Denmark","2014","2014",813.1,,
+"PATCGENU","G-Genito urinary system and sex hormones","MLLNCUMT","Million of national currency units","DNK","Denmark","2015","2015",834.9,,
+"PATCGENU","G-Genito urinary system and sex hormones","MLLNCUMT","Million of national currency units","DNK","Denmark","2016","2016",831.7,,
+"PATCGENU","G-Genito urinary system and sex hormones","MLLNCUMT","Million of national currency units","DNK","Denmark","2017","2017",830.2,,
+"PATCGENU","G-Genito urinary system and sex hormones","MLLNCUMT","Million of national currency units","DNK","Denmark","2018","2018",798.7,,
+"PATCGENU","G-Genito urinary system and sex hormones","MLLNCUMT","Million of national currency units","DNK","Denmark","2019","2019",808.9,,
+"PATCGENU","G-Genito urinary system and sex hormones","MLLNCUMT","Million of national currency units","DNK","Denmark","2020","2020",784.8,,
+"PATCGENU","G-Genito urinary system and sex hormones","MLLNCUMT","Million of national currency units","DNK","Denmark","2021","2021",790,,
+"PATCGENU","G-Genito urinary system and sex hormones","MTMOTCMT","Million US$ at exchange rate","DNK","Denmark","2010","2010",185.2,,
+"PATCGENU","G-Genito urinary system and sex hormones","MTMOTCMT","Million US$ at exchange rate","DNK","Denmark","2011","2011",176.2,,
+"PATCGENU","G-Genito urinary system and sex hormones","MTMOTCMT","Million US$ at exchange rate","DNK","Denmark","2012","2012",168.8,,
+"PATCGENU","G-Genito urinary system and sex hormones","MTMOTCMT","Million US$ at exchange rate","DNK","Denmark","2013","2013",155,,
+"PATCGENU","G-Genito urinary system and sex hormones","MTMOTCMT","Million US$ at exchange rate","DNK","Denmark","2014","2014",144.9,,
+"PATCGENU","G-Genito urinary system and sex hormones","MTMOTCMT","Million US$ at exchange rate","DNK","Denmark","2015","2015",124.1,,
+"PATCGENU","G-Genito urinary system and sex hormones","MTMOTCMT","Million US$ at exchange rate","DNK","Denmark","2016","2016",123.5,,
+"PATCGENU","G-Genito urinary system and sex hormones","MTMOTCMT","Million US$ at exchange rate","DNK","Denmark","2017","2017",125.7,,
+"PATCGENU","G-Genito urinary system and sex hormones","MTMOTCMT","Million US$ at exchange rate","DNK","Denmark","2018","2018",126.5,,
+"PATCGENU","G-Genito urinary system and sex hormones","MTMOTCMT","Million US$ at exchange rate","DNK","Denmark","2019","2019",121.3,,
+"PATCGENU","G-Genito urinary system and sex hormones","MTMOTCMT","Million US$ at exchange rate","DNK","Denmark","2020","2020",120,,
+"PATCGENU","G-Genito urinary system and sex hormones","MTMOTCMT","Million US$ at exchange rate","DNK","Denmark","2021","2021",125.7,,
+"PATCGENU","G-Genito urinary system and sex hormones","MTMOPPMT","Million US$, purchasing power parity","DNK","Denmark","2010","2010",137.2,,
+"PATCGENU","G-Genito urinary system and sex hormones","MTMOPPMT","Million US$, purchasing power parity","DNK","Denmark","2011","2011",126.7,,
+"PATCGENU","G-Genito urinary system and sex hormones","MTMOPPMT","Million US$, purchasing power parity","DNK","Denmark","2012","2012",129.3,,
+"PATCGENU","G-Genito urinary system and sex hormones","MTMOPPMT","Million US$, purchasing power parity","DNK","Denmark","2013","2013",118.3,,
+"PATCGENU","G-Genito urinary system and sex hormones","MTMOPPMT","Million US$, purchasing power parity","DNK","Denmark","2014","2014",110.9,,
+"PATCGENU","G-Genito urinary system and sex hormones","MTMOPPMT","Million US$, purchasing power parity","DNK","Denmark","2015","2015",114.3,,
+"PATCGENU","G-Genito urinary system and sex hormones","MTMOPPMT","Million US$, purchasing power parity","DNK","Denmark","2016","2016",117.5,,
+"PATCGENU","G-Genito urinary system and sex hormones","MTMOPPMT","Million US$, purchasing power parity","DNK","Denmark","2017","2017",120.8,,
+"PATCGENU","G-Genito urinary system and sex hormones","MTMOPPMT","Million US$, purchasing power parity","DNK","Denmark","2018","2018",118,,
+"PATCGENU","G-Genito urinary system and sex hormones","MTMOPPMT","Million US$, purchasing power parity","DNK","Denmark","2019","2019",121.9,,
+"PATCGENU","G-Genito urinary system and sex hormones","MTMOPPMT","Million US$, purchasing power parity","DNK","Denmark","2020","2020",119.8,,
+"PATCGENU","G-Genito urinary system and sex hormones","MTMOPPMT","Million US$, purchasing power parity","DNK","Denmark","2021","2021",119.9,,
+"PATCGENU","G-Genito urinary system and sex hormones","TCPPERMT","/capita, US$ exchange rate","DNK","Denmark","2010","2010",33.4,,
+"PATCGENU","G-Genito urinary system and sex hormones","TCPPERMT","/capita, US$ exchange rate","DNK","Denmark","2011","2011",31.6,,
+"PATCGENU","G-Genito urinary system and sex hormones","TCPPERMT","/capita, US$ exchange rate","DNK","Denmark","2012","2012",30.2,,
+"PATCGENU","G-Genito urinary system and sex hormones","TCPPERMT","/capita, US$ exchange rate","DNK","Denmark","2013","2013",27.6,,
+"PATCGENU","G-Genito urinary system and sex hormones","TCPPERMT","/capita, US$ exchange rate","DNK","Denmark","2014","2014",25.7,,
+"PATCGENU","G-Genito urinary system and sex hormones","TCPPERMT","/capita, US$ exchange rate","DNK","Denmark","2015","2015",21.8,,
+"PATCGENU","G-Genito urinary system and sex hormones","TCPPERMT","/capita, US$ exchange rate","DNK","Denmark","2016","2016",21.6,,
+"PATCGENU","G-Genito urinary system and sex hormones","TCPPERMT","/capita, US$ exchange rate","DNK","Denmark","2017","2017",21.8,,
+"PATCGENU","G-Genito urinary system and sex hormones","TCPPERMT","/capita, US$ exchange rate","DNK","Denmark","2018","2018",21.8,,
+"PATCGENU","G-Genito urinary system and sex hormones","TCPPERMT","/capita, US$ exchange rate","DNK","Denmark","2019","2019",20.9,,
+"PATCGENU","G-Genito urinary system and sex hormones","TCPPERMT","/capita, US$ exchange rate","DNK","Denmark","2020","2020",20.6,,
+"PATCGENU","G-Genito urinary system and sex hormones","TCPPERMT","/capita, US$ exchange rate","DNK","Denmark","2021","2021",21.5,,
+"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","DNK","Denmark","2010","2010",24.7,,
+"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","DNK","Denmark","2011","2011",22.7,,
+"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","DNK","Denmark","2012","2012",23.1,,
+"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","DNK","Denmark","2013","2013",21.1,,
+"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","DNK","Denmark","2014","2014",19.7,,
+"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","DNK","Denmark","2015","2015",20.1,,
+"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","DNK","Denmark","2016","2016",20.5,,
+"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","DNK","Denmark","2017","2017",21,,
+"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","DNK","Denmark","2018","2018",20.4,,
+"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","DNK","Denmark","2019","2019",21,,
+"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","DNK","Denmark","2020","2020",20.5,,
+"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","DNK","Denmark","2021","2021",20.5,,
+"PATCGENU","G-Genito urinary system and sex hormones","ATCPTTMT","% of total sales","DNK","Denmark","2010","2010",4.9,,
+"PATCGENU","G-Genito urinary system and sex hormones","ATCPTTMT","% of total sales","DNK","Denmark","2011","2011",4.6,,
+"PATCGENU","G-Genito urinary system and sex hormones","ATCPTTMT","% of total sales","DNK","Denmark","2012","2012",4.8,,
+"PATCGENU","G-Genito urinary system and sex hormones","ATCPTTMT","% of total sales","DNK","Denmark","2013","2013",4.3,,
+"PATCGENU","G-Genito urinary system and sex hormones","ATCPTTMT","% of total sales","DNK","Denmark","2014","2014",3.8,,
+"PATCGENU","G-Genito urinary system and sex hormones","ATCPTTMT","% of total sales","DNK","Denmark","2015","2015",3.8,,
+"PATCGENU","G-Genito urinary system and sex hormones","ATCPTTMT","% of total sales","DNK","Denmark","2016","2016",3.8,,
+"PATCGENU","G-Genito urinary system and sex hormones","ATCPTTMT","% of total sales","DNK","Denmark","2017","2017",3.6,,
+"PATCGENU","G-Genito urinary system and sex hormones","ATCPTTMT","% of total sales","DNK","Denmark","2018","2018",3.4,,
+"PATCGENU","G-Genito urinary system and sex hormones","ATCPTTMT","% of total sales","DNK","Denmark","2019","2019",3.3,,
+"PATCGENU","G-Genito urinary system and sex hormones","ATCPTTMT","% of total sales","DNK","Denmark","2020","2020",3.1,,
+"PATCGENU","G-Genito urinary system and sex hormones","ATCPTTMT","% of total sales","DNK","Denmark","2021","2021",3.1,,
+"PATCGENU","G-Genito urinary system and sex hormones","MLLNCUMT","Million of national currency units","FIN","Finland","2010","2010",108.1,,
+"PATCGENU","G-Genito urinary system and sex hormones","MLLNCUMT","Million of national currency units","FIN","Finland","2011","2011",105,,
+"PATCGENU","G-Genito urinary system and sex hormones","MLLNCUMT","Million of national currency units","FIN","Finland","2012","2012",105.1,,
+"PATCGENU","G-Genito urinary system and sex hormones","MLLNCUMT","Million of national currency units","FIN","Finland","2013","2013",108.9,,
+"PATCGENU","G-Genito urinary system and sex hormones","MLLNCUMT","Million of national currency units","FIN","Finland","2014","2014",111.4,,
+"PATCGENU","G-Genito urinary system and sex hormones","MLLNCUMT","Million of national currency units","FIN","Finland","2015","2015",112,,
+"PATCGENU","G-Genito urinary system and sex hormones","MLLNCUMT","Million of national currency units","FIN","Finland","2016","2016",114.7,,
+"PATCGENU","G-Genito urinary system and sex hormones","MLLNCUMT","Million of national currency units","FIN","Finland","2017","2017",112.6,,
+"PATCGENU","G-Genito urinary system and sex hormones","MLLNCUMT","Million of national currency units","FIN","Finland","2018","2018",110.6,,
+"PATCGENU","G-Genito urinary system and sex hormones","MLLNCUMT","Million of national currency units","FIN","Finland","2019","2019",112.7,,
+"PATCGENU","G-Genito urinary system and sex hormones","MLLNCUMT","Million of national currency units","FIN","Finland","2020","2020",104.3,,
+"PATCGENU","G-Genito urinary system and sex hormones","MLLNCUMT","Million of national currency units","FIN","Finland","2021","2021",92,,
+"PATCGENU","G-Genito urinary system and sex hormones","MTMOTCMT","Million US$ at exchange rate","FIN","Finland","2010","2010",143.3,,
+"PATCGENU","G-Genito urinary system and sex hormones","MTMOTCMT","Million US$ at exchange rate","FIN","Finland","2011","2011",146.2,,
+"PATCGENU","G-Genito urinary system and sex hormones","MTMOTCMT","Million US$ at exchange rate","FIN","Finland","2012","2012",135,,
+"PATCGENU","G-Genito urinary system and sex hormones","MTMOTCMT","Million US$ at exchange rate","FIN","Finland","2013","2013",144.6,,
+"PATCGENU","G-Genito urinary system and sex hormones","MTMOTCMT","Million US$ at exchange rate","FIN","Finland","2014","2014",148,,
+"PATCGENU","G-Genito urinary system and sex hormones","MTMOTCMT","Million US$ at exchange rate","FIN","Finland","2015","2015",124.3,,
+"PATCGENU","G-Genito urinary system and sex hormones","MTMOTCMT","Million US$ at exchange rate","FIN","Finland","2016","2016",127,,
+"PATCGENU","G-Genito urinary system and sex hormones","MTMOTCMT","Million US$ at exchange rate","FIN","Finland","2017","2017",127.2,,
+"PATCGENU","G-Genito urinary system and sex hormones","MTMOTCMT","Million US$ at exchange rate","FIN","Finland","2018","2018",130.6,,
+"PATCGENU","G-Genito urinary system and sex hormones","MTMOTCMT","Million US$ at exchange rate","FIN","Finland","2019","2019",126.2,,
+"PATCGENU","G-Genito urinary system and sex hormones","MTMOTCMT","Million US$ at exchange rate","FIN","Finland","2020","2020",119.1,,
+"PATCGENU","G-Genito urinary system and sex hormones","MTMOTCMT","Million US$ at exchange rate","FIN","Finland","2021","2021",108.8,,
+"PATCGENU","G-Genito urinary system and sex hormones","MTMOPPMT","Million US$, purchasing power parity","FIN","Finland","2010","2010",120,,
+"PATCGENU","G-Genito urinary system and sex hormones","MTMOPPMT","Million US$, purchasing power parity","FIN","Finland","2011","2011",116.9,,
+"PATCGENU","G-Genito urinary system and sex hormones","MTMOPPMT","Million US$, purchasing power parity","FIN","Finland","2012","2012",115.7,,
+"PATCGENU","G-Genito urinary system and sex hormones","MTMOPPMT","Million US$, purchasing power parity","FIN","Finland","2013","2013",120.3,,
+"PATCGENU","G-Genito urinary system and sex hormones","MTMOPPMT","Million US$, purchasing power parity","FIN","Finland","2014","2014",122.8,,
+"PATCGENU","G-Genito urinary system and sex hormones","MTMOPPMT","Million US$, purchasing power parity","FIN","Finland","2015","2015",123.4,,
+"PATCGENU","G-Genito urinary system and sex hormones","MTMOPPMT","Million US$, purchasing power parity","FIN","Finland","2016","2016",130.2,,
+"PATCGENU","G-Genito urinary system and sex hormones","MTMOPPMT","Million US$, purchasing power parity","FIN","Finland","2017","2017",130.4,,
+"PATCGENU","G-Genito urinary system and sex hormones","MTMOPPMT","Million US$, purchasing power parity","FIN","Finland","2018","2018",129.5,,
+"PATCGENU","G-Genito urinary system and sex hormones","MTMOPPMT","Million US$, purchasing power parity","FIN","Finland","2019","2019",134.4,,
+"PATCGENU","G-Genito urinary system and sex hormones","MTMOPPMT","Million US$, purchasing power parity","FIN","Finland","2020","2020",126.7,,
+"PATCGENU","G-Genito urinary system and sex hormones","MTMOPPMT","Million US$, purchasing power parity","FIN","Finland","2021","2021",111.3,,
+"PATCGENU","G-Genito urinary system and sex hormones","TCPPERMT","/capita, US$ exchange rate","FIN","Finland","2010","2010",26.7,,
+"PATCGENU","G-Genito urinary system and sex hormones","TCPPERMT","/capita, US$ exchange rate","FIN","Finland","2011","2011",27.1,,
+"PATCGENU","G-Genito urinary system and sex hormones","TCPPERMT","/capita, US$ exchange rate","FIN","Finland","2012","2012",24.9,,
+"PATCGENU","G-Genito urinary system and sex hormones","TCPPERMT","/capita, US$ exchange rate","FIN","Finland","2013","2013",26.6,,
+"PATCGENU","G-Genito urinary system and sex hormones","TCPPERMT","/capita, US$ exchange rate","FIN","Finland","2014","2014",27.1,,
+"PATCGENU","G-Genito urinary system and sex hormones","TCPPERMT","/capita, US$ exchange rate","FIN","Finland","2015","2015",22.7,,
+"PATCGENU","G-Genito urinary system and sex hormones","TCPPERMT","/capita, US$ exchange rate","FIN","Finland","2016","2016",23.1,,
+"PATCGENU","G-Genito urinary system and sex hormones","TCPPERMT","/capita, US$ exchange rate","FIN","Finland","2017","2017",23.1,,
+"PATCGENU","G-Genito urinary system and sex hormones","TCPPERMT","/capita, US$ exchange rate","FIN","Finland","2018","2018",23.7,,
+"PATCGENU","G-Genito urinary system and sex hormones","TCPPERMT","/capita, US$ exchange rate","FIN","Finland","2019","2019",22.8,,
+"PATCGENU","G-Genito urinary system and sex hormones","TCPPERMT","/capita, US$ exchange rate","FIN","Finland","2020","2020",21.5,,
+"PATCGENU","G-Genito urinary system and sex hormones","TCPPERMT","/capita, US$ exchange rate","FIN","Finland","2021","2021",19.6,,
+"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2010","2010",22.4,,
+"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2011","2011",21.7,,
+"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2012","2012",21.4,,
+"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2013","2013",22.1,,
+"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2014","2014",22.5,,
+"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2015","2015",22.5,,
+"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2016","2016",23.7,,
+"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2017","2017",23.7,,
+"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2018","2018",23.5,,
+"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2019","2019",24.3,,
+"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2020","2020",22.9,,
+"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2021","2021",20.1,,
+"PATCGENU","G-Genito urinary system and sex hormones","ATCPTTMT","% of total sales","FIN","Finland","2010","2010",5.7,,
+"PATCGENU","G-Genito urinary system and sex hormones","ATCPTTMT","% of total sales","FIN","Finland","2011","2011",5.4,,
+"PATCGENU","G-Genito urinary system and sex hormones","ATCPTTMT","% of total sales","FIN","Finland","2012","2012",5.3,,
+"PATCGENU","G-Genito urinary system and sex hormones","ATCPTTMT","% of total sales","FIN","Finland","2013","2013",5.4,,
+"PATCGENU","G-Genito urinary system and sex hormones","ATCPTTMT","% of total sales","FIN","Finland","2014","2014",5.3,,
+"PATCGENU","G-Genito urinary system and sex hormones","ATCPTTMT","% of total sales","FIN","Finland","2015","2015",5.1,,
+"PATCGENU","G-Genito urinary system and sex hormones","ATCPTTMT","% of total sales","FIN","Finland","2016","2016",5,,
+"PATCGENU","G-Genito urinary system and sex hormones","ATCPTTMT","% of total sales","FIN","Finland","2017","2017",4.9,,
+"PATCGENU","G-Genito urinary system and sex hormones","ATCPTTMT","% of total sales","FIN","Finland","2018","2018",4.4,,
+"PATCGENU","G-Genito urinary system and sex hormones","ATCPTTMT","% of total sales","FIN","Finland","2019","2019",4.2,,
+"PATCGENU","G-Genito urinary system and sex hormones","ATCPTTMT","% of total sales","FIN","Finland","2020","2020",3.9,,
+"PATCGENU","G-Genito urinary system and sex hormones","ATCPTTMT","% of total sales","FIN","Finland","2021","2021",3.2,,
+"PATCGENU","G-Genito urinary system and sex hormones","MLLNCUMT","Million of national currency units","FRA","France","2011","2011",1033.6,,
+"PATCGENU","G-Genito urinary system and sex hormones","MTMOTCMT","Million US$ at exchange rate","FRA","France","2011","2011",1438.7,,
+"PATCGENU","G-Genito urinary system and sex hormones","MTMOPPMT","Million US$, purchasing power parity","FRA","France","2011","2011",1228.5,,
+"PATCGENU","G-Genito urinary system and sex hormones","TCPPERMT","/capita, US$ exchange rate","FRA","France","2011","2011",22.1,,
+"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","FRA","France","2011","2011",18.9,,
+"PATCGENU","G-Genito urinary system and sex hormones","ATCPTTMT","% of total sales","FRA","France","2011","2011",3.7,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","MLLNCUMT","Million of national currency units","DEU","Germany","2010","2010",812.2,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","MLLNCUMT","Million of national currency units","DEU","Germany","2011","2011",788.7,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","MLLNCUMT","Million of national currency units","DEU","Germany","2012","2012",779.7,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","MLLNCUMT","Million of national currency units","DEU","Germany","2013","2013",780.3,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","MLLNCUMT","Million of national currency units","DEU","Germany","2014","2014",815.7,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","MLLNCUMT","Million of national currency units","DEU","Germany","2015","2015",829.9,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","MLLNCUMT","Million of national currency units","DEU","Germany","2016","2016",784.4,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","MLLNCUMT","Million of national currency units","DEU","Germany","2017","2017",751,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","MLLNCUMT","Million of national currency units","DEU","Germany","2018","2018",781.8,"B; D","Break; Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","MLLNCUMT","Million of national currency units","DEU","Germany","2019","2019",815.2,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","MLLNCUMT","Million of national currency units","DEU","Germany","2020","2020",797.7,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","MLLNCUMT","Million of national currency units","DEU","Germany","2021","2021",805.6,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","MTMOTCMT","Million US$ at exchange rate","DEU","Germany","2010","2010",1076.7,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","MTMOTCMT","Million US$ at exchange rate","DEU","Germany","2011","2011",1097.8,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","MTMOTCMT","Million US$ at exchange rate","DEU","Germany","2012","2012",1001.7,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","MTMOTCMT","Million US$ at exchange rate","DEU","Germany","2013","2013",1036.3,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","MTMOTCMT","Million US$ at exchange rate","DEU","Germany","2014","2014",1083.7,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","MTMOTCMT","Million US$ at exchange rate","DEU","Germany","2015","2015",920.8,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","MTMOTCMT","Million US$ at exchange rate","DEU","Germany","2016","2016",868.3,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","MTMOTCMT","Million US$ at exchange rate","DEU","Germany","2017","2017",848.4,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","MTMOTCMT","Million US$ at exchange rate","DEU","Germany","2018","2018",923.3,"B; D","Break; Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","MTMOTCMT","Million US$ at exchange rate","DEU","Germany","2019","2019",912.6,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","MTMOTCMT","Million US$ at exchange rate","DEU","Germany","2020","2020",911.1,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","MTMOTCMT","Million US$ at exchange rate","DEU","Germany","2021","2021",952.8,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","MTMOPPMT","Million US$, purchasing power parity","DEU","Germany","2010","2010",1008.8,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","MTMOPPMT","Million US$, purchasing power parity","DEU","Germany","2011","2011",1000,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","MTMOPPMT","Million US$, purchasing power parity","DEU","Germany","2012","2012",990.4,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","MTMOPPMT","Million US$, purchasing power parity","DEU","Germany","2013","2013",1007.1,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","MTMOPPMT","Million US$, purchasing power parity","DEU","Germany","2014","2014",1060.8,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","MTMOPPMT","Million US$, purchasing power parity","DEU","Germany","2015","2015",1066.5,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","MTMOPPMT","Million US$, purchasing power parity","DEU","Germany","2016","2016",1042.2,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","MTMOPPMT","Million US$, purchasing power parity","DEU","Germany","2017","2017",1008.3,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","MTMOPPMT","Million US$, purchasing power parity","DEU","Germany","2018","2018",1063,"B; D","Break; Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","MTMOPPMT","Million US$, purchasing power parity","DEU","Germany","2019","2019",1119.4,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","MTMOPPMT","Million US$, purchasing power parity","DEU","Germany","2020","2020",1100.3,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","MTMOPPMT","Million US$, purchasing power parity","DEU","Germany","2021","2021",1094.2,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","TCPPERMT","/capita, US$ exchange rate","DEU","Germany","2010","2010",13.2,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","TCPPERMT","/capita, US$ exchange rate","DEU","Germany","2011","2011",13.7,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","TCPPERMT","/capita, US$ exchange rate","DEU","Germany","2012","2012",12.5,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","TCPPERMT","/capita, US$ exchange rate","DEU","Germany","2013","2013",12.9,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","TCPPERMT","/capita, US$ exchange rate","DEU","Germany","2014","2014",13.4,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","TCPPERMT","/capita, US$ exchange rate","DEU","Germany","2015","2015",11.3,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","TCPPERMT","/capita, US$ exchange rate","DEU","Germany","2016","2016",10.5,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","TCPPERMT","/capita, US$ exchange rate","DEU","Germany","2017","2017",10.3,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","TCPPERMT","/capita, US$ exchange rate","DEU","Germany","2018","2018",11.1,"B; D","Break; Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","TCPPERMT","/capita, US$ exchange rate","DEU","Germany","2019","2019",11,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","TCPPERMT","/capita, US$ exchange rate","DEU","Germany","2020","2020",11,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","TCPPERMT","/capita, US$ exchange rate","DEU","Germany","2021","2021",11.5,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2010","2010",12.3,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2011","2011",12.5,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2012","2012",12.3,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2013","2013",12.5,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2014","2014",13.1,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2015","2015",13.1,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2016","2016",12.7,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2017","2017",12.2,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2018","2018",12.8,"B; D","Break; Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2019","2019",13.5,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2020","2020",13.2,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2021","2021",13.2,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","ATCPTTMT","% of total sales","DEU","Germany","2010","2010",2.7,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","ATCPTTMT","% of total sales","DEU","Germany","2011","2011",2.7,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","ATCPTTMT","% of total sales","DEU","Germany","2012","2012",2.6,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","ATCPTTMT","% of total sales","DEU","Germany","2013","2013",2.5,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","ATCPTTMT","% of total sales","DEU","Germany","2014","2014",2.4,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","ATCPTTMT","% of total sales","DEU","Germany","2015","2015",2.3,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","ATCPTTMT","% of total sales","DEU","Germany","2016","2016",2.2,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","ATCPTTMT","% of total sales","DEU","Germany","2017","2017",2,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","ATCPTTMT","% of total sales","DEU","Germany","2018","2018",1.8,"B; D","Break; Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","ATCPTTMT","% of total sales","DEU","Germany","2019","2019",1.7,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","ATCPTTMT","% of total sales","DEU","Germany","2020","2020",1.6,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","ATCPTTMT","% of total sales","DEU","Germany","2021","2021",1.5,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","MLLNCUMT","Million of national currency units","GRC","Greece","2010","2010",211.3,,
+"PATCGENU","G-Genito urinary system and sex hormones","MLLNCUMT","Million of national currency units","GRC","Greece","2011","2011",191.1,,
+"PATCGENU","G-Genito urinary system and sex hormones","MLLNCUMT","Million of national currency units","GRC","Greece","2012","2012",161.3,,
+"PATCGENU","G-Genito urinary system and sex hormones","MLLNCUMT","Million of national currency units","GRC","Greece","2013","2013",149,,
+"PATCGENU","G-Genito urinary system and sex hormones","MLLNCUMT","Million of national currency units","GRC","Greece","2014","2014",152.6,,
+"PATCGENU","G-Genito urinary system and sex hormones","MLLNCUMT","Million of national currency units","GRC","Greece","2015","2015",125.6,,
+"PATCGENU","G-Genito urinary system and sex hormones","MLLNCUMT","Million of national currency units","GRC","Greece","2016","2016",155.4,,
+"PATCGENU","G-Genito urinary system and sex hormones","MLLNCUMT","Million of national currency units","GRC","Greece","2017","2017",166.8,,
+"PATCGENU","G-Genito urinary system and sex hormones","MLLNCUMT","Million of national currency units","GRC","Greece","2018","2018",167.3,,
+"PATCGENU","G-Genito urinary system and sex hormones","MLLNCUMT","Million of national currency units","GRC","Greece","2019","2019",175.3,,
+"PATCGENU","G-Genito urinary system and sex hormones","MLLNCUMT","Million of national currency units","GRC","Greece","2020","2020",159.3,,
+"PATCGENU","G-Genito urinary system and sex hormones","MLLNCUMT","Million of national currency units","GRC","Greece","2021","2021",164.8,,
+"PATCGENU","G-Genito urinary system and sex hormones","MLLNCUMT","Million of national currency units","GRC","Greece","2022","2022",133.7,,
+"PATCGENU","G-Genito urinary system and sex hormones","MTMOTCMT","Million US$ at exchange rate","GRC","Greece","2010","2010",280.1,,
+"PATCGENU","G-Genito urinary system and sex hormones","MTMOTCMT","Million US$ at exchange rate","GRC","Greece","2011","2011",266,,
+"PATCGENU","G-Genito urinary system and sex hormones","MTMOTCMT","Million US$ at exchange rate","GRC","Greece","2012","2012",207.3,,
+"PATCGENU","G-Genito urinary system and sex hormones","MTMOTCMT","Million US$ at exchange rate","GRC","Greece","2013","2013",197.9,,
+"PATCGENU","G-Genito urinary system and sex hormones","MTMOTCMT","Million US$ at exchange rate","GRC","Greece","2014","2014",202.7,,
+"PATCGENU","G-Genito urinary system and sex hormones","MTMOTCMT","Million US$ at exchange rate","GRC","Greece","2015","2015",139.4,,
+"PATCGENU","G-Genito urinary system and sex hormones","MTMOTCMT","Million US$ at exchange rate","GRC","Greece","2016","2016",172.1,,
+"PATCGENU","G-Genito urinary system and sex hormones","MTMOTCMT","Million US$ at exchange rate","GRC","Greece","2017","2017",188.4,,
+"PATCGENU","G-Genito urinary system and sex hormones","MTMOTCMT","Million US$ at exchange rate","GRC","Greece","2018","2018",197.6,,
+"PATCGENU","G-Genito urinary system and sex hormones","MTMOTCMT","Million US$ at exchange rate","GRC","Greece","2019","2019",196.2,,
+"PATCGENU","G-Genito urinary system and sex hormones","MTMOTCMT","Million US$ at exchange rate","GRC","Greece","2020","2020",181.9,,
+"PATCGENU","G-Genito urinary system and sex hormones","MTMOTCMT","Million US$ at exchange rate","GRC","Greece","2021","2021",194.9,,
+"PATCGENU","G-Genito urinary system and sex hormones","MTMOTCMT","Million US$ at exchange rate","GRC","Greece","2022","2022",140.8,,
+"PATCGENU","G-Genito urinary system and sex hormones","MTMOPPMT","Million US$, purchasing power parity","GRC","Greece","2010","2010",292.6,,
+"PATCGENU","G-Genito urinary system and sex hormones","MTMOPPMT","Million US$, purchasing power parity","GRC","Greece","2011","2011",268,,
+"PATCGENU","G-Genito urinary system and sex hormones","MTMOPPMT","Million US$, purchasing power parity","GRC","Greece","2012","2012",235.6,,
+"PATCGENU","G-Genito urinary system and sex hormones","MTMOPPMT","Million US$, purchasing power parity","GRC","Greece","2013","2013",236,,
+"PATCGENU","G-Genito urinary system and sex hormones","MTMOPPMT","Million US$, purchasing power parity","GRC","Greece","2014","2014",249.7,,
+"PATCGENU","G-Genito urinary system and sex hormones","MTMOPPMT","Million US$, purchasing power parity","GRC","Greece","2015","2015",206.2,,
+"PATCGENU","G-Genito urinary system and sex hormones","MTMOPPMT","Million US$, purchasing power parity","GRC","Greece","2016","2016",264.1,,
+"PATCGENU","G-Genito urinary system and sex hormones","MTMOPPMT","Million US$, purchasing power parity","GRC","Greece","2017","2017",290,,
+"PATCGENU","G-Genito urinary system and sex hormones","MTMOPPMT","Million US$, purchasing power parity","GRC","Greece","2018","2018",296.2,,
+"PATCGENU","G-Genito urinary system and sex hormones","MTMOPPMT","Million US$, purchasing power parity","GRC","Greece","2019","2019",319.3,,
+"PATCGENU","G-Genito urinary system and sex hormones","MTMOPPMT","Million US$, purchasing power parity","GRC","Greece","2020","2020",292.7,,
+"PATCGENU","G-Genito urinary system and sex hormones","MTMOPPMT","Million US$, purchasing power parity","GRC","Greece","2021","2021",302.1,,
+"PATCGENU","G-Genito urinary system and sex hormones","MTMOPPMT","Million US$, purchasing power parity","GRC","Greece","2022","2022",252.9,,
+"PATCGENU","G-Genito urinary system and sex hormones","TCPPERMT","/capita, US$ exchange rate","GRC","Greece","2010","2010",25.2,,
+"PATCGENU","G-Genito urinary system and sex hormones","TCPPERMT","/capita, US$ exchange rate","GRC","Greece","2011","2011",24,,
+"PATCGENU","G-Genito urinary system and sex hormones","TCPPERMT","/capita, US$ exchange rate","GRC","Greece","2012","2012",18.8,,
+"PATCGENU","G-Genito urinary system and sex hormones","TCPPERMT","/capita, US$ exchange rate","GRC","Greece","2013","2013",18,,
+"PATCGENU","G-Genito urinary system and sex hormones","TCPPERMT","/capita, US$ exchange rate","GRC","Greece","2014","2014",18.6,,
+"PATCGENU","G-Genito urinary system and sex hormones","TCPPERMT","/capita, US$ exchange rate","GRC","Greece","2015","2015",12.9,,
+"PATCGENU","G-Genito urinary system and sex hormones","TCPPERMT","/capita, US$ exchange rate","GRC","Greece","2016","2016",16,,
+"PATCGENU","G-Genito urinary system and sex hormones","TCPPERMT","/capita, US$ exchange rate","GRC","Greece","2017","2017",17.5,,
+"PATCGENU","G-Genito urinary system and sex hormones","TCPPERMT","/capita, US$ exchange rate","GRC","Greece","2018","2018",18.4,,
+"PATCGENU","G-Genito urinary system and sex hormones","TCPPERMT","/capita, US$ exchange rate","GRC","Greece","2019","2019",18.3,,
+"PATCGENU","G-Genito urinary system and sex hormones","TCPPERMT","/capita, US$ exchange rate","GRC","Greece","2020","2020",17,,
+"PATCGENU","G-Genito urinary system and sex hormones","TCPPERMT","/capita, US$ exchange rate","GRC","Greece","2021","2021",18.4,,
+"PATCGENU","G-Genito urinary system and sex hormones","TCPPERMT","/capita, US$ exchange rate","GRC","Greece","2022","2022",13.5,,
+"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2010","2010",26.3,,
+"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2011","2011",24.1,,
+"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2012","2012",21.3,,
+"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2013","2013",21.5,,
+"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2014","2014",22.9,,
+"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2015","2015",19.1,,
+"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2016","2016",24.5,,
+"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2017","2017",27,,
+"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2018","2018",27.6,,
+"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2019","2019",29.8,,
+"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2020","2020",27.4,,
+"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2021","2021",28.6,,
+"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2022","2022",24.2,,
+"PATCGENU","G-Genito urinary system and sex hormones","MLLNCUMT","Million of national currency units","HUN","Hungary","2010","2010",7875,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","MLLNCUMT","Million of national currency units","HUN","Hungary","2011","2011",8316,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","MLLNCUMT","Million of national currency units","HUN","Hungary","2012","2012",8098.7,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","MLLNCUMT","Million of national currency units","HUN","Hungary","2013","2013",9141.6,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","MLLNCUMT","Million of national currency units","HUN","Hungary","2014","2014",9549.9,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","MLLNCUMT","Million of national currency units","HUN","Hungary","2015","2015",10463.8,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","MLLNCUMT","Million of national currency units","HUN","Hungary","2016","2016",11251.9,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","MLLNCUMT","Million of national currency units","HUN","Hungary","2017","2017",11937,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","MLLNCUMT","Million of national currency units","HUN","Hungary","2018","2018",12197.1,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","MLLNCUMT","Million of national currency units","HUN","Hungary","2019","2019",12269,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","MLLNCUMT","Million of national currency units","HUN","Hungary","2020","2020",12167.6,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","MLLNCUMT","Million of national currency units","HUN","Hungary","2021","2021",12856.2,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","MLLNCUMT","Million of national currency units","HUN","Hungary","2022","2022",13703.8,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","MTMOTCMT","Million US$ at exchange rate","HUN","Hungary","2010","2010",37.9,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","MTMOTCMT","Million US$ at exchange rate","HUN","Hungary","2011","2011",41.4,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","MTMOTCMT","Million US$ at exchange rate","HUN","Hungary","2012","2012",36,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","MTMOTCMT","Million US$ at exchange rate","HUN","Hungary","2013","2013",40.9,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","MTMOTCMT","Million US$ at exchange rate","HUN","Hungary","2014","2014",41.1,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","MTMOTCMT","Million US$ at exchange rate","HUN","Hungary","2015","2015",37.5,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","MTMOTCMT","Million US$ at exchange rate","HUN","Hungary","2016","2016",40,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","MTMOTCMT","Million US$ at exchange rate","HUN","Hungary","2017","2017",43.5,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","MTMOTCMT","Million US$ at exchange rate","HUN","Hungary","2018","2018",45.1,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","MTMOTCMT","Million US$ at exchange rate","HUN","Hungary","2019","2019",42.2,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","MTMOTCMT","Million US$ at exchange rate","HUN","Hungary","2020","2020",39.5,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","MTMOTCMT","Million US$ at exchange rate","HUN","Hungary","2021","2021",42.4,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","MTMOTCMT","Million US$ at exchange rate","HUN","Hungary","2022","2022",36.8,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","MTMOPPMT","Million US$, purchasing power parity","HUN","Hungary","2010","2010",62.3,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","MTMOPPMT","Million US$, purchasing power parity","HUN","Hungary","2011","2011",66.9,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","MTMOPPMT","Million US$, purchasing power parity","HUN","Hungary","2012","2012",64.5,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","MTMOPPMT","Million US$, purchasing power parity","HUN","Hungary","2013","2013",73.1,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","MTMOPPMT","Million US$, purchasing power parity","HUN","Hungary","2014","2014",73.8,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","MTMOPPMT","Million US$, purchasing power parity","HUN","Hungary","2015","2015",78.9,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","MTMOPPMT","Million US$, purchasing power parity","HUN","Hungary","2016","2016",85.2,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","MTMOPPMT","Million US$, purchasing power parity","HUN","Hungary","2017","2017",87.7,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","MTMOPPMT","Million US$, purchasing power parity","HUN","Hungary","2018","2018",87.7,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","MTMOPPMT","Million US$, purchasing power parity","HUN","Hungary","2019","2019",87.1,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","MTMOPPMT","Million US$, purchasing power parity","HUN","Hungary","2020","2020",83.7,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","MTMOPPMT","Million US$, purchasing power parity","HUN","Hungary","2021","2021",83.1,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","MTMOPPMT","Million US$, purchasing power parity","HUN","Hungary","2022","2022",85,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","TCPPERMT","/capita, US$ exchange rate","HUN","Hungary","2010","2010",3.8,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","TCPPERMT","/capita, US$ exchange rate","HUN","Hungary","2011","2011",4.1,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","TCPPERMT","/capita, US$ exchange rate","HUN","Hungary","2012","2012",3.6,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","TCPPERMT","/capita, US$ exchange rate","HUN","Hungary","2013","2013",4.1,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","TCPPERMT","/capita, US$ exchange rate","HUN","Hungary","2014","2014",4.2,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","TCPPERMT","/capita, US$ exchange rate","HUN","Hungary","2015","2015",3.8,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","TCPPERMT","/capita, US$ exchange rate","HUN","Hungary","2016","2016",4.1,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","TCPPERMT","/capita, US$ exchange rate","HUN","Hungary","2017","2017",4.4,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","TCPPERMT","/capita, US$ exchange rate","HUN","Hungary","2018","2018",4.6,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","TCPPERMT","/capita, US$ exchange rate","HUN","Hungary","2019","2019",4.3,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","TCPPERMT","/capita, US$ exchange rate","HUN","Hungary","2020","2020",4.1,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","TCPPERMT","/capita, US$ exchange rate","HUN","Hungary","2021","2021",4.4,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","TCPPERMT","/capita, US$ exchange rate","HUN","Hungary","2022","2022",3.8,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2010","2010",6.2,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2011","2011",6.7,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2012","2012",6.5,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2013","2013",7.4,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2014","2014",7.5,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2015","2015",8,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2016","2016",8.7,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2017","2017",9,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2018","2018",9,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2019","2019",8.9,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2020","2020",8.6,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2021","2021",8.6,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2022","2022",8.8,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","ATCPTTMT","% of total sales","HUN","Hungary","2010","2010",1.6,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","ATCPTTMT","% of total sales","HUN","Hungary","2011","2011",1.6,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","ATCPTTMT","% of total sales","HUN","Hungary","2012","2012",1.8,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","ATCPTTMT","% of total sales","HUN","Hungary","2013","2013",2.1,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","ATCPTTMT","% of total sales","HUN","Hungary","2014","2014",2.2,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","ATCPTTMT","% of total sales","HUN","Hungary","2015","2015",2.2,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","ATCPTTMT","% of total sales","HUN","Hungary","2016","2016",2.3,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","ATCPTTMT","% of total sales","HUN","Hungary","2017","2017",2.4,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","ATCPTTMT","% of total sales","HUN","Hungary","2018","2018",2.4,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","ATCPTTMT","% of total sales","HUN","Hungary","2019","2019",2.3,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","ATCPTTMT","% of total sales","HUN","Hungary","2020","2020",2.2,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","ATCPTTMT","% of total sales","HUN","Hungary","2021","2021",2.3,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","ATCPTTMT","% of total sales","HUN","Hungary","2022","2022",2.3,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","MLLNCUMT","Million of national currency units","ISL","Iceland","2010","2010",1497.1,,
+"PATCGENU","G-Genito urinary system and sex hormones","MLLNCUMT","Million of national currency units","ISL","Iceland","2011","2011",1436.1,,
+"PATCGENU","G-Genito urinary system and sex hormones","MLLNCUMT","Million of national currency units","ISL","Iceland","2012","2012",1476.1,,
+"PATCGENU","G-Genito urinary system and sex hormones","MLLNCUMT","Million of national currency units","ISL","Iceland","2013","2013",1498.7,,
+"PATCGENU","G-Genito urinary system and sex hormones","MLLNCUMT","Million of national currency units","ISL","Iceland","2014","2014",1343.4,,
+"PATCGENU","G-Genito urinary system and sex hormones","MLLNCUMT","Million of national currency units","ISL","Iceland","2015","2015",1315.4,,
+"PATCGENU","G-Genito urinary system and sex hormones","MLLNCUMT","Million of national currency units","ISL","Iceland","2016","2016",1335,,
+"PATCGENU","G-Genito urinary system and sex hormones","MLLNCUMT","Million of national currency units","ISL","Iceland","2017","2017",1308.1,,
+"PATCGENU","G-Genito urinary system and sex hormones","MLLNCUMT","Million of national currency units","ISL","Iceland","2018","2018",1441.3,,
+"PATCGENU","G-Genito urinary system and sex hormones","MLLNCUMT","Million of national currency units","ISL","Iceland","2019","2019",1549.8,,
+"PATCGENU","G-Genito urinary system and sex hormones","MLLNCUMT","Million of national currency units","ISL","Iceland","2020","2020",1691.8,,
+"PATCGENU","G-Genito urinary system and sex hormones","MLLNCUMT","Million of national currency units","ISL","Iceland","2021","2021",1807,,
+"PATCGENU","G-Genito urinary system and sex hormones","MTMOTCMT","Million US$ at exchange rate","ISL","Iceland","2010","2010",12.2,,
+"PATCGENU","G-Genito urinary system and sex hormones","MTMOTCMT","Million US$ at exchange rate","ISL","Iceland","2011","2011",12.4,,
+"PATCGENU","G-Genito urinary system and sex hormones","MTMOTCMT","Million US$ at exchange rate","ISL","Iceland","2012","2012",11.8,,
+"PATCGENU","G-Genito urinary system and sex hormones","MTMOTCMT","Million US$ at exchange rate","ISL","Iceland","2013","2013",12.3,,
+"PATCGENU","G-Genito urinary system and sex hormones","MTMOTCMT","Million US$ at exchange rate","ISL","Iceland","2014","2014",11.5,,
+"PATCGENU","G-Genito urinary system and sex hormones","MTMOTCMT","Million US$ at exchange rate","ISL","Iceland","2015","2015",10,,
+"PATCGENU","G-Genito urinary system and sex hormones","MTMOTCMT","Million US$ at exchange rate","ISL","Iceland","2016","2016",11.1,,
+"PATCGENU","G-Genito urinary system and sex hormones","MTMOTCMT","Million US$ at exchange rate","ISL","Iceland","2017","2017",12.2,,
+"PATCGENU","G-Genito urinary system and sex hormones","MTMOTCMT","Million US$ at exchange rate","ISL","Iceland","2018","2018",13.3,,
+"PATCGENU","G-Genito urinary system and sex hormones","MTMOTCMT","Million US$ at exchange rate","ISL","Iceland","2019","2019",12.6,,
+"PATCGENU","G-Genito urinary system and sex hormones","MTMOTCMT","Million US$ at exchange rate","ISL","Iceland","2020","2020",12.5,,
+"PATCGENU","G-Genito urinary system and sex hormones","MTMOTCMT","Million US$ at exchange rate","ISL","Iceland","2021","2021",14.2,,
+"PATCGENU","G-Genito urinary system and sex hormones","MTMOPPMT","Million US$, purchasing power parity","ISL","Iceland","2010","2010",11.3,,
+"PATCGENU","G-Genito urinary system and sex hormones","MTMOPPMT","Million US$, purchasing power parity","ISL","Iceland","2011","2011",10.6,,
+"PATCGENU","G-Genito urinary system and sex hormones","MTMOPPMT","Million US$, purchasing power parity","ISL","Iceland","2012","2012",10.8,,
+"PATCGENU","G-Genito urinary system and sex hormones","MTMOPPMT","Million US$, purchasing power parity","ISL","Iceland","2013","2013",10.9,,
+"PATCGENU","G-Genito urinary system and sex hormones","MTMOPPMT","Million US$, purchasing power parity","ISL","Iceland","2014","2014",9.7,,
+"PATCGENU","G-Genito urinary system and sex hormones","MTMOPPMT","Million US$, purchasing power parity","ISL","Iceland","2015","2015",9.3,,
+"PATCGENU","G-Genito urinary system and sex hormones","MTMOPPMT","Million US$, purchasing power parity","ISL","Iceland","2016","2016",9.5,,
+"PATCGENU","G-Genito urinary system and sex hormones","MTMOPPMT","Million US$, purchasing power parity","ISL","Iceland","2017","2017",9.5,,
+"PATCGENU","G-Genito urinary system and sex hormones","MTMOPPMT","Million US$, purchasing power parity","ISL","Iceland","2018","2018",10.2,,
+"PATCGENU","G-Genito urinary system and sex hormones","MTMOPPMT","Million US$, purchasing power parity","ISL","Iceland","2019","2019",11,,
+"PATCGENU","G-Genito urinary system and sex hormones","MTMOPPMT","Million US$, purchasing power parity","ISL","Iceland","2020","2020",11.5,,
+"PATCGENU","G-Genito urinary system and sex hormones","MTMOPPMT","Million US$, purchasing power parity","ISL","Iceland","2021","2021",12.1,,
+"PATCGENU","G-Genito urinary system and sex hormones","TCPPERMT","/capita, US$ exchange rate","ISL","Iceland","2010","2010",38.5,,
+"PATCGENU","G-Genito urinary system and sex hormones","TCPPERMT","/capita, US$ exchange rate","ISL","Iceland","2011","2011",38.8,,
+"PATCGENU","G-Genito urinary system and sex hormones","TCPPERMT","/capita, US$ exchange rate","ISL","Iceland","2012","2012",36.8,,
+"PATCGENU","G-Genito urinary system and sex hormones","TCPPERMT","/capita, US$ exchange rate","ISL","Iceland","2013","2013",37.9,,
+"PATCGENU","G-Genito urinary system and sex hormones","TCPPERMT","/capita, US$ exchange rate","ISL","Iceland","2014","2014",35.1,,
+"PATCGENU","G-Genito urinary system and sex hormones","TCPPERMT","/capita, US$ exchange rate","ISL","Iceland","2015","2015",30.1,,
+"PATCGENU","G-Genito urinary system and sex hormones","TCPPERMT","/capita, US$ exchange rate","ISL","Iceland","2016","2016",32.9,,
+"PATCGENU","G-Genito urinary system and sex hormones","TCPPERMT","/capita, US$ exchange rate","ISL","Iceland","2017","2017",35.7,,
+"PATCGENU","G-Genito urinary system and sex hormones","TCPPERMT","/capita, US$ exchange rate","ISL","Iceland","2018","2018",37.7,,
+"PATCGENU","G-Genito urinary system and sex hormones","TCPPERMT","/capita, US$ exchange rate","ISL","Iceland","2019","2019",35.1,,
+"PATCGENU","G-Genito urinary system and sex hormones","TCPPERMT","/capita, US$ exchange rate","ISL","Iceland","2020","2020",34.1,,
+"PATCGENU","G-Genito urinary system and sex hormones","TCPPERMT","/capita, US$ exchange rate","ISL","Iceland","2021","2021",38.2,,
+"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2010","2010",35.4,,
+"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2011","2011",33.3,,
+"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2012","2012",33.6,,
+"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2013","2013",33.8,,
+"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2014","2014",29.6,,
+"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2015","2015",28,,
+"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2016","2016",28.4,,
+"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2017","2017",27.5,,
+"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2018","2018",29,,
+"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2019","2019",30.5,,
+"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2020","2020",31.5,,
+"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2021","2021",32.4,,
+"PATCGENU","G-Genito urinary system and sex hormones","ATCPTTMT","% of total sales","ISL","Iceland","2010","2010",6,,
+"PATCGENU","G-Genito urinary system and sex hormones","ATCPTTMT","% of total sales","ISL","Iceland","2011","2011",5.5,,
+"PATCGENU","G-Genito urinary system and sex hormones","ATCPTTMT","% of total sales","ISL","Iceland","2012","2012",6.1,,
+"PATCGENU","G-Genito urinary system and sex hormones","ATCPTTMT","% of total sales","ISL","Iceland","2013","2013",5.8,,
+"PATCGENU","G-Genito urinary system and sex hormones","ATCPTTMT","% of total sales","ISL","Iceland","2014","2014",5.7,,
+"PATCGENU","G-Genito urinary system and sex hormones","ATCPTTMT","% of total sales","ISL","Iceland","2015","2015",5.4,,
+"PATCGENU","G-Genito urinary system and sex hormones","ATCPTTMT","% of total sales","ISL","Iceland","2016","2016",5.3,,
+"PATCGENU","G-Genito urinary system and sex hormones","ATCPTTMT","% of total sales","ISL","Iceland","2017","2017",4.9,,
+"PATCGENU","G-Genito urinary system and sex hormones","ATCPTTMT","% of total sales","ISL","Iceland","2018","2018",4.8,,
+"PATCGENU","G-Genito urinary system and sex hormones","ATCPTTMT","% of total sales","ISL","Iceland","2019","2019",4.6,,
+"PATCGENU","G-Genito urinary system and sex hormones","ATCPTTMT","% of total sales","ISL","Iceland","2020","2020",4.2,,
+"PATCGENU","G-Genito urinary system and sex hormones","ATCPTTMT","% of total sales","ISL","Iceland","2021","2021",4,,
+"PATCGENU","G-Genito urinary system and sex hormones","MLLNCUMT","Million of national currency units","IRL","Ireland","2010","2010",84.2,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","MLLNCUMT","Million of national currency units","IRL","Ireland","2011","2011",82.9,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","MLLNCUMT","Million of national currency units","IRL","Ireland","2012","2012",85.8,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","MLLNCUMT","Million of national currency units","IRL","Ireland","2013","2013",79.7,"B; D","Break; Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","MLLNCUMT","Million of national currency units","IRL","Ireland","2014","2014",74.2,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","MLLNCUMT","Million of national currency units","IRL","Ireland","2015","2015",74.3,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","MLLNCUMT","Million of national currency units","IRL","Ireland","2016","2016",76.6,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","MLLNCUMT","Million of national currency units","IRL","Ireland","2017","2017",71.2,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","MLLNCUMT","Million of national currency units","IRL","Ireland","2018","2018",73.2,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","MLLNCUMT","Million of national currency units","IRL","Ireland","2019","2019",77.9,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","MLLNCUMT","Million of national currency units","IRL","Ireland","2020","2020",79.6,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","MLLNCUMT","Million of national currency units","IRL","Ireland","2021","2021",93.6,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","MTMOTCMT","Million US$ at exchange rate","IRL","Ireland","2010","2010",111.6,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","MTMOTCMT","Million US$ at exchange rate","IRL","Ireland","2011","2011",115.4,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","MTMOTCMT","Million US$ at exchange rate","IRL","Ireland","2012","2012",110.2,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","MTMOTCMT","Million US$ at exchange rate","IRL","Ireland","2013","2013",105.8,"B; D","Break; Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","MTMOTCMT","Million US$ at exchange rate","IRL","Ireland","2014","2014",98.6,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","MTMOTCMT","Million US$ at exchange rate","IRL","Ireland","2015","2015",82.4,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","MTMOTCMT","Million US$ at exchange rate","IRL","Ireland","2016","2016",84.8,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","MTMOTCMT","Million US$ at exchange rate","IRL","Ireland","2017","2017",80.4,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","MTMOTCMT","Million US$ at exchange rate","IRL","Ireland","2018","2018",86.4,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","MTMOTCMT","Million US$ at exchange rate","IRL","Ireland","2019","2019",87.2,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","MTMOTCMT","Million US$ at exchange rate","IRL","Ireland","2020","2020",90.9,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","MTMOTCMT","Million US$ at exchange rate","IRL","Ireland","2021","2021",110.7,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","MTMOPPMT","Million US$, purchasing power parity","IRL","Ireland","2010","2010",99.1,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","MTMOPPMT","Million US$, purchasing power parity","IRL","Ireland","2011","2011",99.7,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","MTMOPPMT","Million US$, purchasing power parity","IRL","Ireland","2012","2012",104.2,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","MTMOPPMT","Million US$, purchasing power parity","IRL","Ireland","2013","2013",98.2,"B; D","Break; Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","MTMOPPMT","Million US$, purchasing power parity","IRL","Ireland","2014","2014",90.6,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","MTMOPPMT","Million US$, purchasing power parity","IRL","Ireland","2015","2015",91.7,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","MTMOPPMT","Million US$, purchasing power parity","IRL","Ireland","2016","2016",96.5,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","MTMOPPMT","Million US$, purchasing power parity","IRL","Ireland","2017","2017",89.6,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","MTMOPPMT","Million US$, purchasing power parity","IRL","Ireland","2018","2018",92.4,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","MTMOPPMT","Million US$, purchasing power parity","IRL","Ireland","2019","2019",96.6,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","MTMOPPMT","Million US$, purchasing power parity","IRL","Ireland","2020","2020",100,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","MTMOPPMT","Million US$, purchasing power parity","IRL","Ireland","2021","2021",117.8,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","TCPPERMT","/capita, US$ exchange rate","IRL","Ireland","2010","2010",24.5,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","TCPPERMT","/capita, US$ exchange rate","IRL","Ireland","2011","2011",25.2,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","TCPPERMT","/capita, US$ exchange rate","IRL","Ireland","2012","2012",24,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","TCPPERMT","/capita, US$ exchange rate","IRL","Ireland","2013","2013",22.9,"B; D","Break; Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","TCPPERMT","/capita, US$ exchange rate","IRL","Ireland","2014","2014",21.2,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","TCPPERMT","/capita, US$ exchange rate","IRL","Ireland","2015","2015",17.5,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","TCPPERMT","/capita, US$ exchange rate","IRL","Ireland","2016","2016",17.8,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","TCPPERMT","/capita, US$ exchange rate","IRL","Ireland","2017","2017",16.7,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","TCPPERMT","/capita, US$ exchange rate","IRL","Ireland","2018","2018",17.8,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","TCPPERMT","/capita, US$ exchange rate","IRL","Ireland","2019","2019",17.7,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","TCPPERMT","/capita, US$ exchange rate","IRL","Ireland","2020","2020",18.2,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","TCPPERMT","/capita, US$ exchange rate","IRL","Ireland","2021","2021",22,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2010","2010",21.7,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2011","2011",21.8,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2012","2012",22.7,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2013","2013",21.2,"B; D","Break; Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2014","2014",19.4,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2015","2015",19.5,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2016","2016",20.3,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2017","2017",18.6,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2018","2018",19,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2019","2019",19.6,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2020","2020",20.1,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2021","2021",23.4,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","ATCPTTMT","% of total sales","IRL","Ireland","2010","2010",4.1,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","ATCPTTMT","% of total sales","IRL","Ireland","2011","2011",4.2,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","ATCPTTMT","% of total sales","IRL","Ireland","2012","2012",4.2,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","ATCPTTMT","% of total sales","IRL","Ireland","2013","2013",4.1,"B; D","Break; Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","ATCPTTMT","% of total sales","IRL","Ireland","2014","2014",3.9,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","ATCPTTMT","% of total sales","IRL","Ireland","2015","2015",3.7,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","ATCPTTMT","% of total sales","IRL","Ireland","2016","2016",3.7,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","ATCPTTMT","% of total sales","IRL","Ireland","2017","2017",3.3,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","ATCPTTMT","% of total sales","IRL","Ireland","2018","2018",3.2,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","ATCPTTMT","% of total sales","IRL","Ireland","2019","2019",3.2,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","ATCPTTMT","% of total sales","IRL","Ireland","2020","2020",3.2,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","ATCPTTMT","% of total sales","IRL","Ireland","2021","2021",3.6,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","MLLNCUMT","Million of national currency units","ITA","Italy","2011","2011",503.5,,
+"PATCGENU","G-Genito urinary system and sex hormones","MLLNCUMT","Million of national currency units","ITA","Italy","2012","2012",500.5,,
+"PATCGENU","G-Genito urinary system and sex hormones","MLLNCUMT","Million of national currency units","ITA","Italy","2013","2013",516.5,,
+"PATCGENU","G-Genito urinary system and sex hormones","MLLNCUMT","Million of national currency units","ITA","Italy","2014","2014",532.6,,
+"PATCGENU","G-Genito urinary system and sex hormones","MLLNCUMT","Million of national currency units","ITA","Italy","2015","2015",548,,
+"PATCGENU","G-Genito urinary system and sex hormones","MLLNCUMT","Million of national currency units","ITA","Italy","2016","2016",560.9,,
+"PATCGENU","G-Genito urinary system and sex hormones","MLLNCUMT","Million of national currency units","ITA","Italy","2017","2017",514.6,,
+"PATCGENU","G-Genito urinary system and sex hormones","MLLNCUMT","Million of national currency units","ITA","Italy","2018","2018",437.5,,
+"PATCGENU","G-Genito urinary system and sex hormones","MLLNCUMT","Million of national currency units","ITA","Italy","2019","2019",441.8,,
+"PATCGENU","G-Genito urinary system and sex hormones","MLLNCUMT","Million of national currency units","ITA","Italy","2020","2020",396.3,,
+"PATCGENU","G-Genito urinary system and sex hormones","MLLNCUMT","Million of national currency units","ITA","Italy","2021","2021",409.4,,
+"PATCGENU","G-Genito urinary system and sex hormones","MLLNCUMT","Million of national currency units","ITA","Italy","2022","2022",405,"E","Estimated value"
+"PATCGENU","G-Genito urinary system and sex hormones","MTMOTCMT","Million US$ at exchange rate","ITA","Italy","2011","2011",700.8,,
+"PATCGENU","G-Genito urinary system and sex hormones","MTMOTCMT","Million US$ at exchange rate","ITA","Italy","2012","2012",643.1,,
+"PATCGENU","G-Genito urinary system and sex hormones","MTMOTCMT","Million US$ at exchange rate","ITA","Italy","2013","2013",686,,
+"PATCGENU","G-Genito urinary system and sex hormones","MTMOTCMT","Million US$ at exchange rate","ITA","Italy","2014","2014",707.6,,
+"PATCGENU","G-Genito urinary system and sex hormones","MTMOTCMT","Million US$ at exchange rate","ITA","Italy","2015","2015",608.1,,
+"PATCGENU","G-Genito urinary system and sex hormones","MTMOTCMT","Million US$ at exchange rate","ITA","Italy","2016","2016",620.9,,
+"PATCGENU","G-Genito urinary system and sex hormones","MTMOTCMT","Million US$ at exchange rate","ITA","Italy","2017","2017",581.4,,
+"PATCGENU","G-Genito urinary system and sex hormones","MTMOTCMT","Million US$ at exchange rate","ITA","Italy","2018","2018",516.7,,
+"PATCGENU","G-Genito urinary system and sex hormones","MTMOTCMT","Million US$ at exchange rate","ITA","Italy","2019","2019",494.6,,
+"PATCGENU","G-Genito urinary system and sex hormones","MTMOTCMT","Million US$ at exchange rate","ITA","Italy","2020","2020",452.7,,
+"PATCGENU","G-Genito urinary system and sex hormones","MTMOTCMT","Million US$ at exchange rate","ITA","Italy","2021","2021",484.2,,
+"PATCGENU","G-Genito urinary system and sex hormones","MTMOTCMT","Million US$ at exchange rate","ITA","Italy","2022","2022",426.5,"E","Estimated value"
+"PATCGENU","G-Genito urinary system and sex hormones","MTMOPPMT","Million US$, purchasing power parity","ITA","Italy","2011","2011",663.6,,
+"PATCGENU","G-Genito urinary system and sex hormones","MTMOPPMT","Million US$, purchasing power parity","ITA","Italy","2012","2012",669.4,,
+"PATCGENU","G-Genito urinary system and sex hormones","MTMOPPMT","Million US$, purchasing power parity","ITA","Italy","2013","2013",700.6,,
+"PATCGENU","G-Genito urinary system and sex hormones","MTMOPPMT","Million US$, purchasing power parity","ITA","Italy","2014","2014",720.1,,
+"PATCGENU","G-Genito urinary system and sex hormones","MTMOPPMT","Million US$, purchasing power parity","ITA","Italy","2015","2015",741.9,,
+"PATCGENU","G-Genito urinary system and sex hormones","MTMOPPMT","Million US$, purchasing power parity","ITA","Italy","2016","2016",800.7,,
+"PATCGENU","G-Genito urinary system and sex hormones","MTMOPPMT","Million US$, purchasing power parity","ITA","Italy","2017","2017",746,,
+"PATCGENU","G-Genito urinary system and sex hormones","MTMOPPMT","Million US$, purchasing power parity","ITA","Italy","2018","2018",642.2,,
+"PATCGENU","G-Genito urinary system and sex hormones","MTMOPPMT","Million US$, purchasing power parity","ITA","Italy","2019","2019",672.7,,
+"PATCGENU","G-Genito urinary system and sex hormones","MTMOPPMT","Million US$, purchasing power parity","ITA","Italy","2020","2020",611.9,,
+"PATCGENU","G-Genito urinary system and sex hormones","MTMOPPMT","Million US$, purchasing power parity","ITA","Italy","2021","2021",632.3,,
+"PATCGENU","G-Genito urinary system and sex hormones","MTMOPPMT","Million US$, purchasing power parity","ITA","Italy","2022","2022",655.9,"E","Estimated value"
+"PATCGENU","G-Genito urinary system and sex hormones","TCPPERMT","/capita, US$ exchange rate","ITA","Italy","2011","2011",11.8,,
+"PATCGENU","G-Genito urinary system and sex hormones","TCPPERMT","/capita, US$ exchange rate","ITA","Italy","2012","2012",10.8,,
+"PATCGENU","G-Genito urinary system and sex hormones","TCPPERMT","/capita, US$ exchange rate","ITA","Italy","2013","2013",11.4,,
+"PATCGENU","G-Genito urinary system and sex hormones","TCPPERMT","/capita, US$ exchange rate","ITA","Italy","2014","2014",11.6,,
+"PATCGENU","G-Genito urinary system and sex hormones","TCPPERMT","/capita, US$ exchange rate","ITA","Italy","2015","2015",10,,
+"PATCGENU","G-Genito urinary system and sex hormones","TCPPERMT","/capita, US$ exchange rate","ITA","Italy","2016","2016",10.2,,
+"PATCGENU","G-Genito urinary system and sex hormones","TCPPERMT","/capita, US$ exchange rate","ITA","Italy","2017","2017",9.6,,
+"PATCGENU","G-Genito urinary system and sex hormones","TCPPERMT","/capita, US$ exchange rate","ITA","Italy","2018","2018",8.6,,
+"PATCGENU","G-Genito urinary system and sex hormones","TCPPERMT","/capita, US$ exchange rate","ITA","Italy","2019","2019",8.3,,
+"PATCGENU","G-Genito urinary system and sex hormones","TCPPERMT","/capita, US$ exchange rate","ITA","Italy","2020","2020",7.6,,
+"PATCGENU","G-Genito urinary system and sex hormones","TCPPERMT","/capita, US$ exchange rate","ITA","Italy","2021","2021",8.2,,
+"PATCGENU","G-Genito urinary system and sex hormones","TCPPERMT","/capita, US$ exchange rate","ITA","Italy","2022","2022",7.2,"E","Estimated value"
+"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2011","2011",11.2,,
+"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2012","2012",11.2,,
+"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2013","2013",11.6,,
+"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2014","2014",11.8,,
+"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2015","2015",12.2,,
+"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2016","2016",13.2,,
+"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2017","2017",12.3,,
+"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2018","2018",10.6,,
+"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2019","2019",11.3,,
+"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2020","2020",10.3,,
+"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2021","2021",10.7,,
+"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2022","2022",11.1,"E","Estimated value"
+"PATCGENU","G-Genito urinary system and sex hormones","ATCPTTMT","% of total sales","ITA","Italy","2011","2011",2.6,,
+"PATCGENU","G-Genito urinary system and sex hormones","ATCPTTMT","% of total sales","ITA","Italy","2012","2012",2.6,,
+"PATCGENU","G-Genito urinary system and sex hormones","ATCPTTMT","% of total sales","ITA","Italy","2013","2013",2.7,,
+"PATCGENU","G-Genito urinary system and sex hormones","ATCPTTMT","% of total sales","ITA","Italy","2014","2014",2.7,,
+"PATCGENU","G-Genito urinary system and sex hormones","ATCPTTMT","% of total sales","ITA","Italy","2015","2015",2.4,,
+"PATCGENU","G-Genito urinary system and sex hormones","ATCPTTMT","% of total sales","ITA","Italy","2016","2016",2.5,,
+"PATCGENU","G-Genito urinary system and sex hormones","ATCPTTMT","% of total sales","ITA","Italy","2017","2017",2.3,,
+"PATCGENU","G-Genito urinary system and sex hormones","ATCPTTMT","% of total sales","ITA","Italy","2018","2018",2,,
+"PATCGENU","G-Genito urinary system and sex hormones","ATCPTTMT","% of total sales","ITA","Italy","2019","2019",1.9,,
+"PATCGENU","G-Genito urinary system and sex hormones","ATCPTTMT","% of total sales","ITA","Italy","2020","2020",1.7,,
+"PATCGENU","G-Genito urinary system and sex hormones","ATCPTTMT","% of total sales","ITA","Italy","2021","2021",1.7,,
+"PATCGENU","G-Genito urinary system and sex hormones","ATCPTTMT","% of total sales","ITA","Italy","2022","2022",1.6,"E","Estimated value"
+"PATCGENU","G-Genito urinary system and sex hormones","MLLNCUMT","Million of national currency units","JPN","Japan","2010","2010",158560,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","MLLNCUMT","Million of national currency units","JPN","Japan","2011","2011",156118,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","MLLNCUMT","Million of national currency units","JPN","Japan","2012","2012",176807,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","MLLNCUMT","Million of national currency units","JPN","Japan","2013","2013",168011,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","MLLNCUMT","Million of national currency units","JPN","Japan","2014","2014",152239,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","MLLNCUMT","Million of national currency units","JPN","Japan","2015","2015",147680,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","MLLNCUMT","Million of national currency units","JPN","Japan","2016","2016",134491,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","MLLNCUMT","Million of national currency units","JPN","Japan","2017","2017",162419,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","MLLNCUMT","Million of national currency units","JPN","Japan","2018","2018",157943,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","MLLNCUMT","Million of national currency units","JPN","Japan","2019","2019",167072,"B; D","Break; Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","MLLNCUMT","Million of national currency units","JPN","Japan","2020","2020",178904,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","MLLNCUMT","Million of national currency units","JPN","Japan","2021","2021",158339,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","MTMOTCMT","Million US$ at exchange rate","JPN","Japan","2010","2010",1806.3,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","MTMOTCMT","Million US$ at exchange rate","JPN","Japan","2011","2011",1956.2,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","MTMOTCMT","Million US$ at exchange rate","JPN","Japan","2012","2012",2215.9,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","MTMOTCMT","Million US$ at exchange rate","JPN","Japan","2013","2013",1721.5,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","MTMOTCMT","Million US$ at exchange rate","JPN","Japan","2014","2014",1437,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","MTMOTCMT","Million US$ at exchange rate","JPN","Japan","2015","2015",1220.1,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","MTMOTCMT","Million US$ at exchange rate","JPN","Japan","2016","2016",1236.2,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","MTMOTCMT","Million US$ at exchange rate","JPN","Japan","2017","2017",1448,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","MTMOTCMT","Million US$ at exchange rate","JPN","Japan","2018","2018",1430.3,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","MTMOTCMT","Million US$ at exchange rate","JPN","Japan","2019","2019",1532.6,"B; D","Break; Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","MTMOTCMT","Million US$ at exchange rate","JPN","Japan","2020","2020",1675.5,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","MTMOTCMT","Million US$ at exchange rate","JPN","Japan","2021","2021",1442.7,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","MTMOPPMT","Million US$, purchasing power parity","JPN","Japan","2010","2010",1419.4,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","MTMOPPMT","Million US$, purchasing power parity","JPN","Japan","2011","2011",1452.9,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","MTMOPPMT","Million US$, purchasing power parity","JPN","Japan","2012","2012",1695.6,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","MTMOPPMT","Million US$, purchasing power parity","JPN","Japan","2013","2013",1658.5,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","MTMOPPMT","Million US$, purchasing power parity","JPN","Japan","2014","2014",1477.3,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","MTMOPPMT","Million US$, purchasing power parity","JPN","Japan","2015","2015",1427.3,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","MTMOPPMT","Million US$, purchasing power parity","JPN","Japan","2016","2016",1274.6,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","MTMOPPMT","Million US$, purchasing power parity","JPN","Japan","2017","2017",1545.3,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","MTMOPPMT","Million US$, purchasing power parity","JPN","Japan","2018","2018",1516.4,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","MTMOPPMT","Million US$, purchasing power parity","JPN","Japan","2019","2019",1603,"B; D","Break; Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","MTMOPPMT","Million US$, purchasing power parity","JPN","Japan","2020","2020",1746.6,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","MTMOPPMT","Million US$, purchasing power parity","JPN","Japan","2021","2021",1551.6,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","TCPPERMT","/capita, US$ exchange rate","JPN","Japan","2010","2010",14.1,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","TCPPERMT","/capita, US$ exchange rate","JPN","Japan","2011","2011",15.3,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","TCPPERMT","/capita, US$ exchange rate","JPN","Japan","2012","2012",17.4,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","TCPPERMT","/capita, US$ exchange rate","JPN","Japan","2013","2013",13.5,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","TCPPERMT","/capita, US$ exchange rate","JPN","Japan","2014","2014",11.3,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","TCPPERMT","/capita, US$ exchange rate","JPN","Japan","2015","2015",9.6,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","TCPPERMT","/capita, US$ exchange rate","JPN","Japan","2016","2016",9.7,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","TCPPERMT","/capita, US$ exchange rate","JPN","Japan","2017","2017",11.4,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","TCPPERMT","/capita, US$ exchange rate","JPN","Japan","2018","2018",11.3,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","TCPPERMT","/capita, US$ exchange rate","JPN","Japan","2019","2019",12.1,"B; D","Break; Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","TCPPERMT","/capita, US$ exchange rate","JPN","Japan","2020","2020",13.3,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","TCPPERMT","/capita, US$ exchange rate","JPN","Japan","2021","2021",11.5,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","JPN","Japan","2010","2010",11.1,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","JPN","Japan","2011","2011",11.4,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","JPN","Japan","2012","2012",13.3,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","JPN","Japan","2013","2013",13,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","JPN","Japan","2014","2014",11.6,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","JPN","Japan","2015","2015",11.2,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","JPN","Japan","2016","2016",10,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","JPN","Japan","2017","2017",12.2,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","JPN","Japan","2018","2018",12,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","JPN","Japan","2019","2019",12.7,"B; D","Break; Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","JPN","Japan","2020","2020",13.8,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","JPN","Japan","2021","2021",12.4,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","ATCPTTMT","% of total sales","JPN","Japan","2010","2010",2.3,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","ATCPTTMT","% of total sales","JPN","Japan","2011","2011",2.2,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","ATCPTTMT","% of total sales","JPN","Japan","2012","2012",2.5,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","ATCPTTMT","% of total sales","JPN","Japan","2013","2013",2.4,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","ATCPTTMT","% of total sales","JPN","Japan","2014","2014",2.3,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","ATCPTTMT","% of total sales","JPN","Japan","2015","2015",2.2,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","ATCPTTMT","% of total sales","JPN","Japan","2016","2016",2,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","ATCPTTMT","% of total sales","JPN","Japan","2017","2017",2.4,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","ATCPTTMT","% of total sales","JPN","Japan","2018","2018",2.3,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","ATCPTTMT","% of total sales","JPN","Japan","2019","2019",1.8,"B; D","Break; Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","ATCPTTMT","% of total sales","JPN","Japan","2020","2020",1.9,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","ATCPTTMT","% of total sales","JPN","Japan","2021","2021",1.7,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","MLLNCUMT","Million of national currency units","KOR","Korea","2010","2010",540467,,
+"PATCGENU","G-Genito urinary system and sex hormones","MLLNCUMT","Million of national currency units","KOR","Korea","2011","2011",643575.9,"B","Break"
+"PATCGENU","G-Genito urinary system and sex hormones","MLLNCUMT","Million of national currency units","KOR","Korea","2012","2012",636824.2,,
+"PATCGENU","G-Genito urinary system and sex hormones","MLLNCUMT","Million of national currency units","KOR","Korea","2013","2013",646627.5,,
+"PATCGENU","G-Genito urinary system and sex hormones","MLLNCUMT","Million of national currency units","KOR","Korea","2014","2014",706494.9,,
+"PATCGENU","G-Genito urinary system and sex hormones","MLLNCUMT","Million of national currency units","KOR","Korea","2015","2015",742741.7,,
+"PATCGENU","G-Genito urinary system and sex hormones","MLLNCUMT","Million of national currency units","KOR","Korea","2016","2016",731218.5,"B","Break"
+"PATCGENU","G-Genito urinary system and sex hormones","MLLNCUMT","Million of national currency units","KOR","Korea","2017","2017",789700.2,,
+"PATCGENU","G-Genito urinary system and sex hormones","MLLNCUMT","Million of national currency units","KOR","Korea","2018","2018",842916.3,,
+"PATCGENU","G-Genito urinary system and sex hormones","MLLNCUMT","Million of national currency units","KOR","Korea","2019","2019",904006.4,,
+"PATCGENU","G-Genito urinary system and sex hormones","MLLNCUMT","Million of national currency units","KOR","Korea","2020","2020",976925.8,,
+"PATCGENU","G-Genito urinary system and sex hormones","MLLNCUMT","Million of national currency units","KOR","Korea","2021","2021",1048571.3,,
+"PATCGENU","G-Genito urinary system and sex hormones","MTMOTCMT","Million US$ at exchange rate","KOR","Korea","2010","2010",467.3,,
+"PATCGENU","G-Genito urinary system and sex hormones","MTMOTCMT","Million US$ at exchange rate","KOR","Korea","2011","2011",580.7,"B","Break"
+"PATCGENU","G-Genito urinary system and sex hormones","MTMOTCMT","Million US$ at exchange rate","KOR","Korea","2012","2012",565.2,,
+"PATCGENU","G-Genito urinary system and sex hormones","MTMOTCMT","Million US$ at exchange rate","KOR","Korea","2013","2013",590.5,,
+"PATCGENU","G-Genito urinary system and sex hormones","MTMOTCMT","Million US$ at exchange rate","KOR","Korea","2014","2014",671,,
+"PATCGENU","G-Genito urinary system and sex hormones","MTMOTCMT","Million US$ at exchange rate","KOR","Korea","2015","2015",656.7,,
+"PATCGENU","G-Genito urinary system and sex hormones","MTMOTCMT","Million US$ at exchange rate","KOR","Korea","2016","2016",629.9,"B","Break"
+"PATCGENU","G-Genito urinary system and sex hormones","MTMOTCMT","Million US$ at exchange rate","KOR","Korea","2017","2017",698.2,,
+"PATCGENU","G-Genito urinary system and sex hormones","MTMOTCMT","Million US$ at exchange rate","KOR","Korea","2018","2018",766.2,,
+"PATCGENU","G-Genito urinary system and sex hormones","MTMOTCMT","Million US$ at exchange rate","KOR","Korea","2019","2019",775.7,,
+"PATCGENU","G-Genito urinary system and sex hormones","MTMOTCMT","Million US$ at exchange rate","KOR","Korea","2020","2020",827.7,,
+"PATCGENU","G-Genito urinary system and sex hormones","MTMOTCMT","Million US$ at exchange rate","KOR","Korea","2021","2021",916.6,,
+"PATCGENU","G-Genito urinary system and sex hormones","MTMOPPMT","Million US$, purchasing power parity","KOR","Korea","2010","2010",642.7,,
+"PATCGENU","G-Genito urinary system and sex hormones","MTMOPPMT","Million US$, purchasing power parity","KOR","Korea","2011","2011",753.1,"B","Break"
+"PATCGENU","G-Genito urinary system and sex hormones","MTMOPPMT","Million US$, purchasing power parity","KOR","Korea","2012","2012",744.9,,
+"PATCGENU","G-Genito urinary system and sex hormones","MTMOPPMT","Million US$, purchasing power parity","KOR","Korea","2013","2013",744,,
+"PATCGENU","G-Genito urinary system and sex hormones","MTMOPPMT","Million US$, purchasing power parity","KOR","Korea","2014","2014",810.3,,
+"PATCGENU","G-Genito urinary system and sex hormones","MTMOPPMT","Million US$, purchasing power parity","KOR","Korea","2015","2015",866.2,,
+"PATCGENU","G-Genito urinary system and sex hormones","MTMOPPMT","Million US$, purchasing power parity","KOR","Korea","2016","2016",851.4,"B","Break"
+"PATCGENU","G-Genito urinary system and sex hormones","MTMOPPMT","Million US$, purchasing power parity","KOR","Korea","2017","2017",905,,
+"PATCGENU","G-Genito urinary system and sex hormones","MTMOPPMT","Million US$, purchasing power parity","KOR","Korea","2018","2018",986,,
+"PATCGENU","G-Genito urinary system and sex hormones","MTMOPPMT","Million US$, purchasing power parity","KOR","Korea","2019","2019",1055.6,,
+"PATCGENU","G-Genito urinary system and sex hormones","MTMOPPMT","Million US$, purchasing power parity","KOR","Korea","2020","2020",1166.2,,
+"PATCGENU","G-Genito urinary system and sex hormones","MTMOPPMT","Million US$, purchasing power parity","KOR","Korea","2021","2021",1227.7,,
+"PATCGENU","G-Genito urinary system and sex hormones","TCPPERMT","/capita, US$ exchange rate","KOR","Korea","2010","2010",9.4,,
+"PATCGENU","G-Genito urinary system and sex hormones","TCPPERMT","/capita, US$ exchange rate","KOR","Korea","2011","2011",11.6,"B","Break"
+"PATCGENU","G-Genito urinary system and sex hormones","TCPPERMT","/capita, US$ exchange rate","KOR","Korea","2012","2012",11.3,,
+"PATCGENU","G-Genito urinary system and sex hormones","TCPPERMT","/capita, US$ exchange rate","KOR","Korea","2013","2013",11.7,,
+"PATCGENU","G-Genito urinary system and sex hormones","TCPPERMT","/capita, US$ exchange rate","KOR","Korea","2014","2014",13.2,,
+"PATCGENU","G-Genito urinary system and sex hormones","TCPPERMT","/capita, US$ exchange rate","KOR","Korea","2015","2015",12.9,,
+"PATCGENU","G-Genito urinary system and sex hormones","TCPPERMT","/capita, US$ exchange rate","KOR","Korea","2016","2016",12.3,"B","Break"
+"PATCGENU","G-Genito urinary system and sex hormones","TCPPERMT","/capita, US$ exchange rate","KOR","Korea","2017","2017",13.6,,
+"PATCGENU","G-Genito urinary system and sex hormones","TCPPERMT","/capita, US$ exchange rate","KOR","Korea","2018","2018",14.9,,
+"PATCGENU","G-Genito urinary system and sex hormones","TCPPERMT","/capita, US$ exchange rate","KOR","Korea","2019","2019",15,,
+"PATCGENU","G-Genito urinary system and sex hormones","TCPPERMT","/capita, US$ exchange rate","KOR","Korea","2020","2020",16,,
+"PATCGENU","G-Genito urinary system and sex hormones","TCPPERMT","/capita, US$ exchange rate","KOR","Korea","2021","2021",17.7,,
+"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2010","2010",13,,
+"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2011","2011",15.1,"B","Break"
+"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2012","2012",14.8,,
+"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2013","2013",14.8,,
+"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2014","2014",16,,
+"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2015","2015",17,,
+"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2016","2016",16.6,"B","Break"
+"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2017","2017",17.6,,
+"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2018","2018",19.1,,
+"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2019","2019",20.4,,
+"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2020","2020",22.5,,
+"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2021","2021",23.7,,
+"PATCGENU","G-Genito urinary system and sex hormones","ATCPTTMT","% of total sales","KOR","Korea","2010","2010",2.7,,
+"PATCGENU","G-Genito urinary system and sex hormones","ATCPTTMT","% of total sales","KOR","Korea","2011","2011",2.9,"B","Break"
+"PATCGENU","G-Genito urinary system and sex hormones","ATCPTTMT","% of total sales","KOR","Korea","2012","2012",2.9,,
+"PATCGENU","G-Genito urinary system and sex hormones","ATCPTTMT","% of total sales","KOR","Korea","2013","2013",2.9,,
+"PATCGENU","G-Genito urinary system and sex hormones","ATCPTTMT","% of total sales","KOR","Korea","2014","2014",3,,
+"PATCGENU","G-Genito urinary system and sex hormones","ATCPTTMT","% of total sales","KOR","Korea","2015","2015",3,,
+"PATCGENU","G-Genito urinary system and sex hormones","ATCPTTMT","% of total sales","KOR","Korea","2016","2016",2.9,"B","Break"
+"PATCGENU","G-Genito urinary system and sex hormones","ATCPTTMT","% of total sales","KOR","Korea","2017","2017",2.9,,
+"PATCGENU","G-Genito urinary system and sex hormones","ATCPTTMT","% of total sales","KOR","Korea","2018","2018",2.9,,
+"PATCGENU","G-Genito urinary system and sex hormones","ATCPTTMT","% of total sales","KOR","Korea","2019","2019",2.9,,
+"PATCGENU","G-Genito urinary system and sex hormones","ATCPTTMT","% of total sales","KOR","Korea","2020","2020",3,,
+"PATCGENU","G-Genito urinary system and sex hormones","ATCPTTMT","% of total sales","KOR","Korea","2021","2021",3,,
+"PATCGENU","G-Genito urinary system and sex hormones","MLLNCUMT","Million of national currency units","LUX","Luxembourg","2010","2010",6.8,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","MLLNCUMT","Million of national currency units","LUX","Luxembourg","2011","2011",6.8,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","MLLNCUMT","Million of national currency units","LUX","Luxembourg","2012","2012",8.1,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","MLLNCUMT","Million of national currency units","LUX","Luxembourg","2013","2013",8,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","MLLNCUMT","Million of national currency units","LUX","Luxembourg","2014","2014",8.2,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","MLLNCUMT","Million of national currency units","LUX","Luxembourg","2015","2015",8.3,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","MLLNCUMT","Million of national currency units","LUX","Luxembourg","2016","2016",8.7,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","MLLNCUMT","Million of national currency units","LUX","Luxembourg","2017","2017",8.9,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","MLLNCUMT","Million of national currency units","LUX","Luxembourg","2018","2018",9.4,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","MLLNCUMT","Million of national currency units","LUX","Luxembourg","2019","2019",10.1,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","MLLNCUMT","Million of national currency units","LUX","Luxembourg","2020","2020",9.6,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","MLLNCUMT","Million of national currency units","LUX","Luxembourg","2021","2021",10,"B; D; P","Break; Difference in methodology; Provisional value"
+"PATCGENU","G-Genito urinary system and sex hormones","MLLNCUMT","Million of national currency units","LUX","Luxembourg","2022","2022",9.4,"D; P","Difference in methodology; Provisional value"
+"PATCGENU","G-Genito urinary system and sex hormones","MTMOTCMT","Million US$ at exchange rate","LUX","Luxembourg","2010","2010",9,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","MTMOTCMT","Million US$ at exchange rate","LUX","Luxembourg","2011","2011",9.5,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","MTMOTCMT","Million US$ at exchange rate","LUX","Luxembourg","2012","2012",10.3,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","MTMOTCMT","Million US$ at exchange rate","LUX","Luxembourg","2013","2013",10.7,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","MTMOTCMT","Million US$ at exchange rate","LUX","Luxembourg","2014","2014",10.9,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","MTMOTCMT","Million US$ at exchange rate","LUX","Luxembourg","2015","2015",9.2,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","MTMOTCMT","Million US$ at exchange rate","LUX","Luxembourg","2016","2016",9.6,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","MTMOTCMT","Million US$ at exchange rate","LUX","Luxembourg","2017","2017",10,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","MTMOTCMT","Million US$ at exchange rate","LUX","Luxembourg","2018","2018",11.1,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","MTMOTCMT","Million US$ at exchange rate","LUX","Luxembourg","2019","2019",11.3,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","MTMOTCMT","Million US$ at exchange rate","LUX","Luxembourg","2020","2020",10.9,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","MTMOTCMT","Million US$ at exchange rate","LUX","Luxembourg","2021","2021",11.8,"B; D; P","Break; Difference in methodology; Provisional value"
+"PATCGENU","G-Genito urinary system and sex hormones","MTMOTCMT","Million US$ at exchange rate","LUX","Luxembourg","2022","2022",9.9,"D; P","Difference in methodology; Provisional value"
+"PATCGENU","G-Genito urinary system and sex hormones","MTMOPPMT","Million US$, purchasing power parity","LUX","Luxembourg","2010","2010",7.3,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","MTMOPPMT","Million US$, purchasing power parity","LUX","Luxembourg","2011","2011",7.5,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","MTMOPPMT","Million US$, purchasing power parity","LUX","Luxembourg","2012","2012",8.9,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","MTMOPPMT","Million US$, purchasing power parity","LUX","Luxembourg","2013","2013",9,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","MTMOPPMT","Million US$, purchasing power parity","LUX","Luxembourg","2014","2014",9.3,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","MTMOPPMT","Million US$, purchasing power parity","LUX","Luxembourg","2015","2015",9.4,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","MTMOPPMT","Million US$, purchasing power parity","LUX","Luxembourg","2016","2016",10.2,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","MTMOPPMT","Million US$, purchasing power parity","LUX","Luxembourg","2017","2017",10.4,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","MTMOPPMT","Million US$, purchasing power parity","LUX","Luxembourg","2018","2018",11.1,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","MTMOPPMT","Million US$, purchasing power parity","LUX","Luxembourg","2019","2019",12,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","MTMOPPMT","Million US$, purchasing power parity","LUX","Luxembourg","2020","2020",11.2,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","MTMOPPMT","Million US$, purchasing power parity","LUX","Luxembourg","2021","2021",11.6,"B; D; P","Break; Difference in methodology; Provisional value"
+"PATCGENU","G-Genito urinary system and sex hormones","MTMOPPMT","Million US$, purchasing power parity","LUX","Luxembourg","2022","2022",11.3,"D; P","Difference in methodology; Provisional value"
+"PATCGENU","G-Genito urinary system and sex hormones","TCPPERMT","/capita, US$ exchange rate","LUX","Luxembourg","2010","2010",19.1,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","TCPPERMT","/capita, US$ exchange rate","LUX","Luxembourg","2011","2011",19.7,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","TCPPERMT","/capita, US$ exchange rate","LUX","Luxembourg","2012","2012",21,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","TCPPERMT","/capita, US$ exchange rate","LUX","Luxembourg","2013","2013",21.2,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","TCPPERMT","/capita, US$ exchange rate","LUX","Luxembourg","2014","2014",21.4,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","TCPPERMT","/capita, US$ exchange rate","LUX","Luxembourg","2015","2015",17.8,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","TCPPERMT","/capita, US$ exchange rate","LUX","Luxembourg","2016","2016",18.2,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","TCPPERMT","/capita, US$ exchange rate","LUX","Luxembourg","2017","2017",18.7,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","TCPPERMT","/capita, US$ exchange rate","LUX","Luxembourg","2018","2018",20.4,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","TCPPERMT","/capita, US$ exchange rate","LUX","Luxembourg","2019","2019",20.2,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","TCPPERMT","/capita, US$ exchange rate","LUX","Luxembourg","2020","2020",19.3,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","TCPPERMT","/capita, US$ exchange rate","LUX","Luxembourg","2021","2021",20.6,"B; D; P","Break; Difference in methodology; Provisional value"
+"PATCGENU","G-Genito urinary system and sex hormones","TCPPERMT","/capita, US$ exchange rate","LUX","Luxembourg","2022","2022",16.8,"D; P","Difference in methodology; Provisional value"
+"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2010","2010",15.5,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2011","2011",15.6,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2012","2012",18,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2013","2013",17.9,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2014","2014",18.2,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2015","2015",18.2,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2016","2016",19.3,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2017","2017",19.5,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2018","2018",20.4,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2019","2019",21.5,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2020","2020",19.7,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2021","2021",20.2,"B; D; P","Break; Difference in methodology; Provisional value"
+"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2022","2022",19.2,"D; P","Difference in methodology; Provisional value"
+"PATCGENU","G-Genito urinary system and sex hormones","ATCPTTMT","% of total sales","LUX","Luxembourg","2010","2010",3.6,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","ATCPTTMT","% of total sales","LUX","Luxembourg","2011","2011",3.6,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","ATCPTTMT","% of total sales","LUX","Luxembourg","2012","2012",4.1,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","ATCPTTMT","% of total sales","LUX","Luxembourg","2013","2013",4.1,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","ATCPTTMT","% of total sales","LUX","Luxembourg","2014","2014",4.3,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","ATCPTTMT","% of total sales","LUX","Luxembourg","2015","2015",4.3,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","ATCPTTMT","% of total sales","LUX","Luxembourg","2016","2016",4.4,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","ATCPTTMT","% of total sales","LUX","Luxembourg","2017","2017",4.6,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","ATCPTTMT","% of total sales","LUX","Luxembourg","2018","2018",4.8,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","ATCPTTMT","% of total sales","LUX","Luxembourg","2019","2019",4.9,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","ATCPTTMT","% of total sales","LUX","Luxembourg","2020","2020",4.6,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","ATCPTTMT","% of total sales","LUX","Luxembourg","2021","2021",4.2,"B; D; P","Break; Difference in methodology; Provisional value"
+"PATCGENU","G-Genito urinary system and sex hormones","ATCPTTMT","% of total sales","LUX","Luxembourg","2022","2022",3.6,"D; P","Difference in methodology; Provisional value"
+"PATCGENU","G-Genito urinary system and sex hormones","MLLNCUMT","Million of national currency units","NLD","Netherlands","2010","2010",206,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","MLLNCUMT","Million of national currency units","NLD","Netherlands","2011","2011",149.8,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","MLLNCUMT","Million of national currency units","NLD","Netherlands","2012","2012",147.7,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","MLLNCUMT","Million of national currency units","NLD","Netherlands","2013","2013",136.8,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","MLLNCUMT","Million of national currency units","NLD","Netherlands","2014","2014",105,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","MTMOTCMT","Million US$ at exchange rate","NLD","Netherlands","2010","2010",273.1,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","MTMOTCMT","Million US$ at exchange rate","NLD","Netherlands","2011","2011",208.5,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","MTMOTCMT","Million US$ at exchange rate","NLD","Netherlands","2012","2012",189.8,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","MTMOTCMT","Million US$ at exchange rate","NLD","Netherlands","2013","2013",181.7,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","MTMOTCMT","Million US$ at exchange rate","NLD","Netherlands","2014","2014",139.5,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","MTMOPPMT","Million US$, purchasing power parity","NLD","Netherlands","2010","2010",241.2,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","MTMOPPMT","Million US$, purchasing power parity","NLD","Netherlands","2011","2011",179.2,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","MTMOPPMT","Million US$, purchasing power parity","NLD","Netherlands","2012","2012",179.2,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","MTMOPPMT","Million US$, purchasing power parity","NLD","Netherlands","2013","2013",171.4,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","MTMOPPMT","Million US$, purchasing power parity","NLD","Netherlands","2014","2014",129.8,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","TCPPERMT","/capita, US$ exchange rate","NLD","Netherlands","2010","2010",16.4,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","TCPPERMT","/capita, US$ exchange rate","NLD","Netherlands","2011","2011",12.5,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","TCPPERMT","/capita, US$ exchange rate","NLD","Netherlands","2012","2012",11.3,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","TCPPERMT","/capita, US$ exchange rate","NLD","Netherlands","2013","2013",10.8,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","TCPPERMT","/capita, US$ exchange rate","NLD","Netherlands","2014","2014",8.3,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","NLD","Netherlands","2010","2010",14.5,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","NLD","Netherlands","2011","2011",10.7,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","NLD","Netherlands","2012","2012",10.7,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","NLD","Netherlands","2013","2013",10.2,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","NLD","Netherlands","2014","2014",7.7,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","ATCPTTMT","% of total sales","NLD","Netherlands","2010","2010",4,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","ATCPTTMT","% of total sales","NLD","Netherlands","2011","2011",2.9,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","ATCPTTMT","% of total sales","NLD","Netherlands","2012","2012",3.2,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","ATCPTTMT","% of total sales","NLD","Netherlands","2013","2013",3.2,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","ATCPTTMT","% of total sales","NLD","Netherlands","2014","2014",2.4,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","MLLNCUMT","Million of national currency units","NZL","New Zealand","2010","2010",18,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","MLLNCUMT","Million of national currency units","NZL","New Zealand","2011","2011",21.3,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","MLLNCUMT","Million of national currency units","NZL","New Zealand","2012","2012",22.8,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","MLLNCUMT","Million of national currency units","NZL","New Zealand","2013","2013",21,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","MLLNCUMT","Million of national currency units","NZL","New Zealand","2014","2014",21.1,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","MLLNCUMT","Million of national currency units","NZL","New Zealand","2015","2015",22.4,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","MLLNCUMT","Million of national currency units","NZL","New Zealand","2016","2016",21.6,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","MLLNCUMT","Million of national currency units","NZL","New Zealand","2017","2017",20.2,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","MLLNCUMT","Million of national currency units","NZL","New Zealand","2018","2018",19.1,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","MLLNCUMT","Million of national currency units","NZL","New Zealand","2019","2019",17.1,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","MLLNCUMT","Million of national currency units","NZL","New Zealand","2020","2020",21.6,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","MLLNCUMT","Million of national currency units","NZL","New Zealand","2021","2021",26.5,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","MLLNCUMT","Million of national currency units","NZL","New Zealand","2022","2022",27.4,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","MTMOTCMT","Million US$ at exchange rate","NZL","New Zealand","2010","2010",13,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","MTMOTCMT","Million US$ at exchange rate","NZL","New Zealand","2011","2011",16.8,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","MTMOTCMT","Million US$ at exchange rate","NZL","New Zealand","2012","2012",18.5,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","MTMOTCMT","Million US$ at exchange rate","NZL","New Zealand","2013","2013",17.2,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","MTMOTCMT","Million US$ at exchange rate","NZL","New Zealand","2014","2014",17.5,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","MTMOTCMT","Million US$ at exchange rate","NZL","New Zealand","2015","2015",15.6,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","MTMOTCMT","Million US$ at exchange rate","NZL","New Zealand","2016","2016",15,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","MTMOTCMT","Million US$ at exchange rate","NZL","New Zealand","2017","2017",14.3,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","MTMOTCMT","Million US$ at exchange rate","NZL","New Zealand","2018","2018",13.2,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","MTMOTCMT","Million US$ at exchange rate","NZL","New Zealand","2019","2019",11.3,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","MTMOTCMT","Million US$ at exchange rate","NZL","New Zealand","2020","2020",14,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","MTMOTCMT","Million US$ at exchange rate","NZL","New Zealand","2021","2021",18.8,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","MTMOTCMT","Million US$ at exchange rate","NZL","New Zealand","2022","2022",17.3,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","MTMOPPMT","Million US$, purchasing power parity","NZL","New Zealand","2010","2010",12,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","MTMOPPMT","Million US$, purchasing power parity","NZL","New Zealand","2011","2011",14.3,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","MTMOPPMT","Million US$, purchasing power parity","NZL","New Zealand","2012","2012",15.2,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","MTMOPPMT","Million US$, purchasing power parity","NZL","New Zealand","2013","2013",14.5,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","MTMOPPMT","Million US$, purchasing power parity","NZL","New Zealand","2014","2014",14.6,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","MTMOPPMT","Million US$, purchasing power parity","NZL","New Zealand","2015","2015",15.2,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","MTMOPPMT","Million US$, purchasing power parity","NZL","New Zealand","2016","2016",15,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","MTMOPPMT","Million US$, purchasing power parity","NZL","New Zealand","2017","2017",14.1,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","MTMOPPMT","Million US$, purchasing power parity","NZL","New Zealand","2018","2018",13,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","MTMOPPMT","Million US$, purchasing power parity","NZL","New Zealand","2019","2019",12.1,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","MTMOPPMT","Million US$, purchasing power parity","NZL","New Zealand","2020","2020",15.3,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","MTMOPPMT","Million US$, purchasing power parity","NZL","New Zealand","2021","2021",18.2,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","MTMOPPMT","Million US$, purchasing power parity","NZL","New Zealand","2022","2022",19,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","TCPPERMT","/capita, US$ exchange rate","NZL","New Zealand","2010","2010",3,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","TCPPERMT","/capita, US$ exchange rate","NZL","New Zealand","2011","2011",3.8,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","TCPPERMT","/capita, US$ exchange rate","NZL","New Zealand","2012","2012",4.2,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","TCPPERMT","/capita, US$ exchange rate","NZL","New Zealand","2013","2013",3.9,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","TCPPERMT","/capita, US$ exchange rate","NZL","New Zealand","2014","2014",3.9,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","TCPPERMT","/capita, US$ exchange rate","NZL","New Zealand","2015","2015",3.4,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","TCPPERMT","/capita, US$ exchange rate","NZL","New Zealand","2016","2016",3.2,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","TCPPERMT","/capita, US$ exchange rate","NZL","New Zealand","2017","2017",3,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","TCPPERMT","/capita, US$ exchange rate","NZL","New Zealand","2018","2018",2.7,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","TCPPERMT","/capita, US$ exchange rate","NZL","New Zealand","2019","2019",2.3,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","TCPPERMT","/capita, US$ exchange rate","NZL","New Zealand","2020","2020",2.7,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","TCPPERMT","/capita, US$ exchange rate","NZL","New Zealand","2021","2021",3.7,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","TCPPERMT","/capita, US$ exchange rate","NZL","New Zealand","2022","2022",3.4,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2010","2010",2.8,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2011","2011",3.3,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2012","2012",3.5,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2013","2013",3.3,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2014","2014",3.2,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2015","2015",3.3,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2016","2016",3.2,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2017","2017",2.9,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2018","2018",2.7,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2019","2019",2.4,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2020","2020",3,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2021","2021",3.6,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2022","2022",3.7,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","ATCPTTMT","% of total sales","NZL","New Zealand","2010","2010",2.4,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","ATCPTTMT","% of total sales","NZL","New Zealand","2011","2011",2.6,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","ATCPTTMT","% of total sales","NZL","New Zealand","2012","2012",2.5,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","ATCPTTMT","% of total sales","NZL","New Zealand","2013","2013",2.3,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","ATCPTTMT","% of total sales","NZL","New Zealand","2014","2014",2.2,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","ATCPTTMT","% of total sales","NZL","New Zealand","2015","2015",2.3,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","ATCPTTMT","% of total sales","NZL","New Zealand","2016","2016",2,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","ATCPTTMT","% of total sales","NZL","New Zealand","2017","2017",1.6,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","ATCPTTMT","% of total sales","NZL","New Zealand","2018","2018",1.4,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","ATCPTTMT","% of total sales","NZL","New Zealand","2019","2019",1.1,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","ATCPTTMT","% of total sales","NZL","New Zealand","2020","2020",1.3,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","ATCPTTMT","% of total sales","NZL","New Zealand","2021","2021",1.5,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","ATCPTTMT","% of total sales","NZL","New Zealand","2022","2022",1.4,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","MLLNCUMT","Million of national currency units","NOR","Norway","2010","2010",914,,
+"PATCGENU","G-Genito urinary system and sex hormones","MLLNCUMT","Million of national currency units","NOR","Norway","2011","2011",925,,
+"PATCGENU","G-Genito urinary system and sex hormones","MLLNCUMT","Million of national currency units","NOR","Norway","2012","2012",948,,
+"PATCGENU","G-Genito urinary system and sex hormones","MLLNCUMT","Million of national currency units","NOR","Norway","2013","2013",983,,
+"PATCGENU","G-Genito urinary system and sex hormones","MLLNCUMT","Million of national currency units","NOR","Norway","2014","2014",1015,,
+"PATCGENU","G-Genito urinary system and sex hormones","MLLNCUMT","Million of national currency units","NOR","Norway","2015","2015",1082,,
+"PATCGENU","G-Genito urinary system and sex hormones","MLLNCUMT","Million of national currency units","NOR","Norway","2016","2016",1162,,
+"PATCGENU","G-Genito urinary system and sex hormones","MLLNCUMT","Million of national currency units","NOR","Norway","2017","2017",1228,,
+"PATCGENU","G-Genito urinary system and sex hormones","MLLNCUMT","Million of national currency units","NOR","Norway","2018","2018",1182,,
+"PATCGENU","G-Genito urinary system and sex hormones","MLLNCUMT","Million of national currency units","NOR","Norway","2019","2019",1204,,
+"PATCGENU","G-Genito urinary system and sex hormones","MLLNCUMT","Million of national currency units","NOR","Norway","2020","2020",1301,,
+"PATCGENU","G-Genito urinary system and sex hormones","MLLNCUMT","Million of national currency units","NOR","Norway","2021","2021",1317,,
+"PATCGENU","G-Genito urinary system and sex hormones","MLLNCUMT","Million of national currency units","NOR","Norway","2022","2022",1298,,
+"PATCGENU","G-Genito urinary system and sex hormones","MTMOTCMT","Million US$ at exchange rate","NOR","Norway","2010","2010",151.2,,
+"PATCGENU","G-Genito urinary system and sex hormones","MTMOTCMT","Million US$ at exchange rate","NOR","Norway","2011","2011",165,,
+"PATCGENU","G-Genito urinary system and sex hormones","MTMOTCMT","Million US$ at exchange rate","NOR","Norway","2012","2012",163,,
+"PATCGENU","G-Genito urinary system and sex hormones","MTMOTCMT","Million US$ at exchange rate","NOR","Norway","2013","2013",167.3,,
+"PATCGENU","G-Genito urinary system and sex hormones","MTMOTCMT","Million US$ at exchange rate","NOR","Norway","2014","2014",161.1,,
+"PATCGENU","G-Genito urinary system and sex hormones","MTMOTCMT","Million US$ at exchange rate","NOR","Norway","2015","2015",134.2,,
+"PATCGENU","G-Genito urinary system and sex hormones","MTMOTCMT","Million US$ at exchange rate","NOR","Norway","2016","2016",138.3,,
+"PATCGENU","G-Genito urinary system and sex hormones","MTMOTCMT","Million US$ at exchange rate","NOR","Norway","2017","2017",148.5,,
+"PATCGENU","G-Genito urinary system and sex hormones","MTMOTCMT","Million US$ at exchange rate","NOR","Norway","2018","2018",145.3,,
+"PATCGENU","G-Genito urinary system and sex hormones","MTMOTCMT","Million US$ at exchange rate","NOR","Norway","2019","2019",136.8,,
+"PATCGENU","G-Genito urinary system and sex hormones","MTMOTCMT","Million US$ at exchange rate","NOR","Norway","2020","2020",138.2,,
+"PATCGENU","G-Genito urinary system and sex hormones","MTMOTCMT","Million US$ at exchange rate","NOR","Norway","2021","2021",153.3,,
+"PATCGENU","G-Genito urinary system and sex hormones","MTMOTCMT","Million US$ at exchange rate","NOR","Norway","2022","2022",135,,
+"PATCGENU","G-Genito urinary system and sex hormones","MTMOPPMT","Million US$, purchasing power parity","NOR","Norway","2010","2010",99.9,,
+"PATCGENU","G-Genito urinary system and sex hormones","MTMOPPMT","Million US$, purchasing power parity","NOR","Norway","2011","2011",101.8,,
+"PATCGENU","G-Genito urinary system and sex hormones","MTMOPPMT","Million US$, purchasing power parity","NOR","Norway","2012","2012",104.9,,
+"PATCGENU","G-Genito urinary system and sex hormones","MTMOPPMT","Million US$, purchasing power parity","NOR","Norway","2013","2013",108.9,,
+"PATCGENU","G-Genito urinary system and sex hormones","MTMOPPMT","Million US$, purchasing power parity","NOR","Norway","2014","2014",109.4,,
+"PATCGENU","G-Genito urinary system and sex hormones","MTMOPPMT","Million US$, purchasing power parity","NOR","Norway","2015","2015",108.9,,
+"PATCGENU","G-Genito urinary system and sex hormones","MTMOPPMT","Million US$, purchasing power parity","NOR","Norway","2016","2016",115.7,,
+"PATCGENU","G-Genito urinary system and sex hormones","MTMOPPMT","Million US$, purchasing power parity","NOR","Norway","2017","2017",126,,
+"PATCGENU","G-Genito urinary system and sex hormones","MTMOPPMT","Million US$, purchasing power parity","NOR","Norway","2018","2018",123.3,,
+"PATCGENU","G-Genito urinary system and sex hormones","MTMOPPMT","Million US$, purchasing power parity","NOR","Norway","2019","2019",125.2,,
+"PATCGENU","G-Genito urinary system and sex hormones","MTMOPPMT","Million US$, purchasing power parity","NOR","Norway","2020","2020",131.7,,
+"PATCGENU","G-Genito urinary system and sex hormones","MTMOPPMT","Million US$, purchasing power parity","NOR","Norway","2021","2021",138.5,,
+"PATCGENU","G-Genito urinary system and sex hormones","MTMOPPMT","Million US$, purchasing power parity","NOR","Norway","2022","2022",120.9,,
+"PATCGENU","G-Genito urinary system and sex hormones","TCPPERMT","/capita, US$ exchange rate","NOR","Norway","2010","2010",30.9,,
+"PATCGENU","G-Genito urinary system and sex hormones","TCPPERMT","/capita, US$ exchange rate","NOR","Norway","2011","2011",33.3,,
+"PATCGENU","G-Genito urinary system and sex hormones","TCPPERMT","/capita, US$ exchange rate","NOR","Norway","2012","2012",32.5,,
+"PATCGENU","G-Genito urinary system and sex hormones","TCPPERMT","/capita, US$ exchange rate","NOR","Norway","2013","2013",32.9,,
+"PATCGENU","G-Genito urinary system and sex hormones","TCPPERMT","/capita, US$ exchange rate","NOR","Norway","2014","2014",31.4,,
+"PATCGENU","G-Genito urinary system and sex hormones","TCPPERMT","/capita, US$ exchange rate","NOR","Norway","2015","2015",25.9,,
+"PATCGENU","G-Genito urinary system and sex hormones","TCPPERMT","/capita, US$ exchange rate","NOR","Norway","2016","2016",26.4,,
+"PATCGENU","G-Genito urinary system and sex hormones","TCPPERMT","/capita, US$ exchange rate","NOR","Norway","2017","2017",28.1,,
+"PATCGENU","G-Genito urinary system and sex hormones","TCPPERMT","/capita, US$ exchange rate","NOR","Norway","2018","2018",27.4,,
+"PATCGENU","G-Genito urinary system and sex hormones","TCPPERMT","/capita, US$ exchange rate","NOR","Norway","2019","2019",25.6,,
+"PATCGENU","G-Genito urinary system and sex hormones","TCPPERMT","/capita, US$ exchange rate","NOR","Norway","2020","2020",25.7,,
+"PATCGENU","G-Genito urinary system and sex hormones","TCPPERMT","/capita, US$ exchange rate","NOR","Norway","2021","2021",28.3,,
+"PATCGENU","G-Genito urinary system and sex hormones","TCPPERMT","/capita, US$ exchange rate","NOR","Norway","2022","2022",24.9,,
+"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2010","2010",20.4,,
+"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2011","2011",20.6,,
+"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2012","2012",20.9,,
+"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2013","2013",21.4,,
+"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2014","2014",21.3,,
+"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2015","2015",21,,
+"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2016","2016",22.1,,
+"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2017","2017",23.9,,
+"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2018","2018",23.2,,
+"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2019","2019",23.4,,
+"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2020","2020",24.5,,
+"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2021","2021",25.6,,
+"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2022","2022",22.3,,
+"PATCGENU","G-Genito urinary system and sex hormones","ATCPTTMT","% of total sales","NOR","Norway","2010","2010",5.1,,
+"PATCGENU","G-Genito urinary system and sex hormones","ATCPTTMT","% of total sales","NOR","Norway","2011","2011",5.1,,
+"PATCGENU","G-Genito urinary system and sex hormones","ATCPTTMT","% of total sales","NOR","Norway","2012","2012",5,,
+"PATCGENU","G-Genito urinary system and sex hormones","ATCPTTMT","% of total sales","NOR","Norway","2013","2013",5.1,,
+"PATCGENU","G-Genito urinary system and sex hormones","ATCPTTMT","% of total sales","NOR","Norway","2014","2014",4.8,,
+"PATCGENU","G-Genito urinary system and sex hormones","ATCPTTMT","% of total sales","NOR","Norway","2015","2015",4.8,,
+"PATCGENU","G-Genito urinary system and sex hormones","ATCPTTMT","% of total sales","NOR","Norway","2016","2016",4.7,,
+"PATCGENU","G-Genito urinary system and sex hormones","ATCPTTMT","% of total sales","NOR","Norway","2017","2017",4.6,,
+"PATCGENU","G-Genito urinary system and sex hormones","ATCPTTMT","% of total sales","NOR","Norway","2018","2018",4.3,,
+"PATCGENU","G-Genito urinary system and sex hormones","ATCPTTMT","% of total sales","NOR","Norway","2019","2019",4.2,,
+"PATCGENU","G-Genito urinary system and sex hormones","ATCPTTMT","% of total sales","NOR","Norway","2020","2020",4.4,,
+"PATCGENU","G-Genito urinary system and sex hormones","ATCPTTMT","% of total sales","NOR","Norway","2021","2021",3.9,,
+"PATCGENU","G-Genito urinary system and sex hormones","ATCPTTMT","% of total sales","NOR","Norway","2022","2022",3.6,,
+"PATCGENU","G-Genito urinary system and sex hormones","MLLNCUMT","Million of national currency units","PRT","Portugal","2010","2010",180.2,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","MLLNCUMT","Million of national currency units","PRT","Portugal","2011","2011",172.4,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","MLLNCUMT","Million of national currency units","PRT","Portugal","2012","2012",159.2,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","MLLNCUMT","Million of national currency units","PRT","Portugal","2013","2013",149.3,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","MLLNCUMT","Million of national currency units","PRT","Portugal","2014","2014",151.1,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","MLLNCUMT","Million of national currency units","PRT","Portugal","2015","2015",151.5,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","MLLNCUMT","Million of national currency units","PRT","Portugal","2016","2016",157.5,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","MLLNCUMT","Million of national currency units","PRT","Portugal","2017","2017",159,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","MLLNCUMT","Million of national currency units","PRT","Portugal","2018","2018",156.8,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","MLLNCUMT","Million of national currency units","PRT","Portugal","2019","2019",163.3,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","MLLNCUMT","Million of national currency units","PRT","Portugal","2020","2020",154.7,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","MLLNCUMT","Million of national currency units","PRT","Portugal","2021","2021",158.2,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","MLLNCUMT","Million of national currency units","PRT","Portugal","2022","2022",164.3,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","MTMOTCMT","Million US$ at exchange rate","PRT","Portugal","2010","2010",238.8,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","MTMOTCMT","Million US$ at exchange rate","PRT","Portugal","2011","2011",239.9,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","MTMOTCMT","Million US$ at exchange rate","PRT","Portugal","2012","2012",204.5,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","MTMOTCMT","Million US$ at exchange rate","PRT","Portugal","2013","2013",198.3,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","MTMOTCMT","Million US$ at exchange rate","PRT","Portugal","2014","2014",200.8,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","MTMOTCMT","Million US$ at exchange rate","PRT","Portugal","2015","2015",168.1,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","MTMOTCMT","Million US$ at exchange rate","PRT","Portugal","2016","2016",174.3,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","MTMOTCMT","Million US$ at exchange rate","PRT","Portugal","2017","2017",179.6,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","MTMOTCMT","Million US$ at exchange rate","PRT","Portugal","2018","2018",185.1,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","MTMOTCMT","Million US$ at exchange rate","PRT","Portugal","2019","2019",182.8,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","MTMOTCMT","Million US$ at exchange rate","PRT","Portugal","2020","2020",176.7,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","MTMOTCMT","Million US$ at exchange rate","PRT","Portugal","2021","2021",187.2,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","MTMOTCMT","Million US$ at exchange rate","PRT","Portugal","2022","2022",173,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","MTMOPPMT","Million US$, purchasing power parity","PRT","Portugal","2010","2010",289.1,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","MTMOPPMT","Million US$, purchasing power parity","PRT","Portugal","2011","2011",276.6,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","MTMOPPMT","Million US$, purchasing power parity","PRT","Portugal","2012","2012",262.9,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","MTMOPPMT","Million US$, purchasing power parity","PRT","Portugal","2013","2013",255.8,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","MTMOPPMT","Million US$, purchasing power parity","PRT","Portugal","2014","2014",261.1,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","MTMOPPMT","Million US$, purchasing power parity","PRT","Portugal","2015","2015",259,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","MTMOPPMT","Million US$, purchasing power parity","PRT","Portugal","2016","2016",275.6,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","MTMOPPMT","Million US$, purchasing power parity","PRT","Portugal","2017","2017",276.2,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","MTMOPPMT","Million US$, purchasing power parity","PRT","Portugal","2018","2018",274.5,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","MTMOPPMT","Million US$, purchasing power parity","PRT","Portugal","2019","2019",292.2,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","MTMOPPMT","Million US$, purchasing power parity","PRT","Portugal","2020","2020",277.7,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","MTMOPPMT","Million US$, purchasing power parity","PRT","Portugal","2021","2021",278.8,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","MTMOPPMT","Million US$, purchasing power parity","PRT","Portugal","2022","2022",298.7,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","TCPPERMT","/capita, US$ exchange rate","PRT","Portugal","2010","2010",22.6,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","TCPPERMT","/capita, US$ exchange rate","PRT","Portugal","2011","2011",22.7,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","TCPPERMT","/capita, US$ exchange rate","PRT","Portugal","2012","2012",19.4,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","TCPPERMT","/capita, US$ exchange rate","PRT","Portugal","2013","2013",19,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","TCPPERMT","/capita, US$ exchange rate","PRT","Portugal","2014","2014",19.3,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","TCPPERMT","/capita, US$ exchange rate","PRT","Portugal","2015","2015",16.2,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","TCPPERMT","/capita, US$ exchange rate","PRT","Portugal","2016","2016",16.9,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","TCPPERMT","/capita, US$ exchange rate","PRT","Portugal","2017","2017",17.4,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","TCPPERMT","/capita, US$ exchange rate","PRT","Portugal","2018","2018",18,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","TCPPERMT","/capita, US$ exchange rate","PRT","Portugal","2019","2019",17.8,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","TCPPERMT","/capita, US$ exchange rate","PRT","Portugal","2020","2020",17.2,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","TCPPERMT","/capita, US$ exchange rate","PRT","Portugal","2021","2021",18.1,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","TCPPERMT","/capita, US$ exchange rate","PRT","Portugal","2022","2022",16.7,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2010","2010",27.3,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2011","2011",26.2,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2012","2012",25,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2013","2013",24.5,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2014","2014",25.1,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2015","2015",25,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2016","2016",26.7,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2017","2017",26.8,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2018","2018",26.7,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2019","2019",28.4,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2020","2020",27,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2021","2021",26.9,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2022","2022",28.9,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","ATCPTTMT","% of total sales","PRT","Portugal","2010","2010",5.6,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","ATCPTTMT","% of total sales","PRT","Portugal","2011","2011",5.9,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","ATCPTTMT","% of total sales","PRT","Portugal","2012","2012",6.1,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","ATCPTTMT","% of total sales","PRT","Portugal","2013","2013",6.2,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","ATCPTTMT","% of total sales","PRT","Portugal","2014","2014",6.3,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","ATCPTTMT","% of total sales","PRT","Portugal","2015","2015",6.1,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","ATCPTTMT","% of total sales","PRT","Portugal","2016","2016",6.2,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","ATCPTTMT","% of total sales","PRT","Portugal","2017","2017",6.2,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","ATCPTTMT","% of total sales","PRT","Portugal","2018","2018",6,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","ATCPTTMT","% of total sales","PRT","Portugal","2019","2019",5.9,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","ATCPTTMT","% of total sales","PRT","Portugal","2020","2020",5.5,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","ATCPTTMT","% of total sales","PRT","Portugal","2021","2021",5.4,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","ATCPTTMT","% of total sales","PRT","Portugal","2022","2022",5.2,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","MLLNCUMT","Million of national currency units","SVK","Slovak Republic","2010","2010",44.5,,
+"PATCGENU","G-Genito urinary system and sex hormones","MLLNCUMT","Million of national currency units","SVK","Slovak Republic","2011","2011",45.6,,
+"PATCGENU","G-Genito urinary system and sex hormones","MLLNCUMT","Million of national currency units","SVK","Slovak Republic","2012","2012",43.4,,
+"PATCGENU","G-Genito urinary system and sex hormones","MLLNCUMT","Million of national currency units","SVK","Slovak Republic","2013","2013",48.8,,
+"PATCGENU","G-Genito urinary system and sex hormones","MLLNCUMT","Million of national currency units","SVK","Slovak Republic","2014","2014",50.8,,
+"PATCGENU","G-Genito urinary system and sex hormones","MLLNCUMT","Million of national currency units","SVK","Slovak Republic","2015","2015",51.2,,
+"PATCGENU","G-Genito urinary system and sex hormones","MLLNCUMT","Million of national currency units","SVK","Slovak Republic","2016","2016",51.3,"B","Break"
+"PATCGENU","G-Genito urinary system and sex hormones","MLLNCUMT","Million of national currency units","SVK","Slovak Republic","2017","2017",49.5,,
+"PATCGENU","G-Genito urinary system and sex hormones","MLLNCUMT","Million of national currency units","SVK","Slovak Republic","2018","2018",47.8,,
+"PATCGENU","G-Genito urinary system and sex hormones","MLLNCUMT","Million of national currency units","SVK","Slovak Republic","2019","2019",46.7,,
+"PATCGENU","G-Genito urinary system and sex hormones","MLLNCUMT","Million of national currency units","SVK","Slovak Republic","2020","2020",44.1,,
+"PATCGENU","G-Genito urinary system and sex hormones","MLLNCUMT","Million of national currency units","SVK","Slovak Republic","2021","2021",47.2,,
+"PATCGENU","G-Genito urinary system and sex hormones","MTMOTCMT","Million US$ at exchange rate","SVK","Slovak Republic","2010","2010",59,,
+"PATCGENU","G-Genito urinary system and sex hormones","MTMOTCMT","Million US$ at exchange rate","SVK","Slovak Republic","2011","2011",63.4,,
+"PATCGENU","G-Genito urinary system and sex hormones","MTMOTCMT","Million US$ at exchange rate","SVK","Slovak Republic","2012","2012",55.8,,
+"PATCGENU","G-Genito urinary system and sex hormones","MTMOTCMT","Million US$ at exchange rate","SVK","Slovak Republic","2013","2013",64.8,,
+"PATCGENU","G-Genito urinary system and sex hormones","MTMOTCMT","Million US$ at exchange rate","SVK","Slovak Republic","2014","2014",67.5,,
+"PATCGENU","G-Genito urinary system and sex hormones","MTMOTCMT","Million US$ at exchange rate","SVK","Slovak Republic","2015","2015",56.8,,
+"PATCGENU","G-Genito urinary system and sex hormones","MTMOTCMT","Million US$ at exchange rate","SVK","Slovak Republic","2016","2016",56.8,"B","Break"
+"PATCGENU","G-Genito urinary system and sex hormones","MTMOTCMT","Million US$ at exchange rate","SVK","Slovak Republic","2017","2017",55.9,,
+"PATCGENU","G-Genito urinary system and sex hormones","MTMOTCMT","Million US$ at exchange rate","SVK","Slovak Republic","2018","2018",56.4,,
+"PATCGENU","G-Genito urinary system and sex hormones","MTMOTCMT","Million US$ at exchange rate","SVK","Slovak Republic","2019","2019",52.3,,
+"PATCGENU","G-Genito urinary system and sex hormones","MTMOTCMT","Million US$ at exchange rate","SVK","Slovak Republic","2020","2020",50.4,,
+"PATCGENU","G-Genito urinary system and sex hormones","MTMOTCMT","Million US$ at exchange rate","SVK","Slovak Republic","2021","2021",55.8,,
+"PATCGENU","G-Genito urinary system and sex hormones","MTMOPPMT","Million US$, purchasing power parity","SVK","Slovak Republic","2010","2010",88.6,,
+"PATCGENU","G-Genito urinary system and sex hormones","MTMOPPMT","Million US$, purchasing power parity","SVK","Slovak Republic","2011","2011",90,,
+"PATCGENU","G-Genito urinary system and sex hormones","MTMOPPMT","Million US$, purchasing power parity","SVK","Slovak Republic","2012","2012",86.1,,
+"PATCGENU","G-Genito urinary system and sex hormones","MTMOPPMT","Million US$, purchasing power parity","SVK","Slovak Republic","2013","2013",99.4,,
+"PATCGENU","G-Genito urinary system and sex hormones","MTMOPPMT","Million US$, purchasing power parity","SVK","Slovak Republic","2014","2014",104.6,,
+"PATCGENU","G-Genito urinary system and sex hormones","MTMOPPMT","Million US$, purchasing power parity","SVK","Slovak Republic","2015","2015",104.2,,
+"PATCGENU","G-Genito urinary system and sex hormones","MTMOPPMT","Million US$, purchasing power parity","SVK","Slovak Republic","2016","2016",101.9,"B","Break"
+"PATCGENU","G-Genito urinary system and sex hormones","MTMOPPMT","Million US$, purchasing power parity","SVK","Slovak Republic","2017","2017",95.8,,
+"PATCGENU","G-Genito urinary system and sex hormones","MTMOPPMT","Million US$, purchasing power parity","SVK","Slovak Republic","2018","2018",90.8,,
+"PATCGENU","G-Genito urinary system and sex hormones","MTMOPPMT","Million US$, purchasing power parity","SVK","Slovak Republic","2019","2019",90.2,,
+"PATCGENU","G-Genito urinary system and sex hormones","MTMOPPMT","Million US$, purchasing power parity","SVK","Slovak Republic","2020","2020",84.9,,
+"PATCGENU","G-Genito urinary system and sex hormones","MTMOPPMT","Million US$, purchasing power parity","SVK","Slovak Republic","2021","2021",88.4,,
+"PATCGENU","G-Genito urinary system and sex hormones","TCPPERMT","/capita, US$ exchange rate","SVK","Slovak Republic","2010","2010",10.9,,
+"PATCGENU","G-Genito urinary system and sex hormones","TCPPERMT","/capita, US$ exchange rate","SVK","Slovak Republic","2011","2011",11.7,,
+"PATCGENU","G-Genito urinary system and sex hormones","TCPPERMT","/capita, US$ exchange rate","SVK","Slovak Republic","2012","2012",10.3,,
+"PATCGENU","G-Genito urinary system and sex hormones","TCPPERMT","/capita, US$ exchange rate","SVK","Slovak Republic","2013","2013",12,,
+"PATCGENU","G-Genito urinary system and sex hormones","TCPPERMT","/capita, US$ exchange rate","SVK","Slovak Republic","2014","2014",12.5,,
+"PATCGENU","G-Genito urinary system and sex hormones","TCPPERMT","/capita, US$ exchange rate","SVK","Slovak Republic","2015","2015",10.5,,
+"PATCGENU","G-Genito urinary system and sex hormones","TCPPERMT","/capita, US$ exchange rate","SVK","Slovak Republic","2016","2016",10.5,"B","Break"
+"PATCGENU","G-Genito urinary system and sex hormones","TCPPERMT","/capita, US$ exchange rate","SVK","Slovak Republic","2017","2017",10.3,,
+"PATCGENU","G-Genito urinary system and sex hormones","TCPPERMT","/capita, US$ exchange rate","SVK","Slovak Republic","2018","2018",10.4,,
+"PATCGENU","G-Genito urinary system and sex hormones","TCPPERMT","/capita, US$ exchange rate","SVK","Slovak Republic","2019","2019",9.6,,
+"PATCGENU","G-Genito urinary system and sex hormones","TCPPERMT","/capita, US$ exchange rate","SVK","Slovak Republic","2020","2020",9.2,,
+"PATCGENU","G-Genito urinary system and sex hormones","TCPPERMT","/capita, US$ exchange rate","SVK","Slovak Republic","2021","2021",10.2,,
+"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2010","2010",16.4,,
+"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2011","2011",16.7,,
+"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2012","2012",15.9,,
+"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2013","2013",18.4,,
+"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2014","2014",19.3,,
+"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2015","2015",19.2,,
+"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2016","2016",18.8,"B","Break"
+"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2017","2017",17.6,,
+"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2018","2018",16.7,,
+"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2019","2019",16.5,,
+"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2020","2020",15.5,,
+"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2021","2021",16.2,,
+"PATCGENU","G-Genito urinary system and sex hormones","ATCPTTMT","% of total sales","SVK","Slovak Republic","2010","2010",4,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","ATCPTTMT","% of total sales","SVK","Slovak Republic","2011","2011",4,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","ATCPTTMT","% of total sales","SVK","Slovak Republic","2012","2012",3.9,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","ATCPTTMT","% of total sales","SVK","Slovak Republic","2013","2013",4,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","ATCPTTMT","% of total sales","SVK","Slovak Republic","2014","2014",3.9,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","ATCPTTMT","% of total sales","SVK","Slovak Republic","2015","2015",3.7,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","ATCPTTMT","% of total sales","SVK","Slovak Republic","2016","2016",3.3,"B","Break"
+"PATCGENU","G-Genito urinary system and sex hormones","ATCPTTMT","% of total sales","SVK","Slovak Republic","2017","2017",3.2,,
+"PATCGENU","G-Genito urinary system and sex hormones","ATCPTTMT","% of total sales","SVK","Slovak Republic","2018","2018",2.9,,
+"PATCGENU","G-Genito urinary system and sex hormones","ATCPTTMT","% of total sales","SVK","Slovak Republic","2019","2019",2.7,,
+"PATCGENU","G-Genito urinary system and sex hormones","ATCPTTMT","% of total sales","SVK","Slovak Republic","2020","2020",2.7,,
+"PATCGENU","G-Genito urinary system and sex hormones","ATCPTTMT","% of total sales","SVK","Slovak Republic","2021","2021",2.6,,
+"PATCGENU","G-Genito urinary system and sex hormones","MLLNCUMT","Million of national currency units","ESP","Spain","2010","2010",512.2,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","MLLNCUMT","Million of national currency units","ESP","Spain","2011","2011",502.5,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","MLLNCUMT","Million of national currency units","ESP","Spain","2012","2012",478.2,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","MLLNCUMT","Million of national currency units","ESP","Spain","2013","2013",487,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","MLLNCUMT","Million of national currency units","ESP","Spain","2014","2014",515.1,"B; D","Break; Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","MLLNCUMT","Million of national currency units","ESP","Spain","2015","2015",534.8,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","MLLNCUMT","Million of national currency units","ESP","Spain","2016","2016",571.4,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","MLLNCUMT","Million of national currency units","ESP","Spain","2017","2017",600.1,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","MLLNCUMT","Million of national currency units","ESP","Spain","2018","2018",627.8,"B","Break"
+"PATCGENU","G-Genito urinary system and sex hormones","MLLNCUMT","Million of national currency units","ESP","Spain","2019","2019",593.3,,
+"PATCGENU","G-Genito urinary system and sex hormones","MLLNCUMT","Million of national currency units","ESP","Spain","2020","2020",555.8,,
+"PATCGENU","G-Genito urinary system and sex hormones","MLLNCUMT","Million of national currency units","ESP","Spain","2021","2021",595.5,,
+"PATCGENU","G-Genito urinary system and sex hormones","MLLNCUMT","Million of national currency units","ESP","Spain","2022","2022",630,"P","Provisional value"
+"PATCGENU","G-Genito urinary system and sex hormones","MTMOTCMT","Million US$ at exchange rate","ESP","Spain","2010","2010",679,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","MTMOTCMT","Million US$ at exchange rate","ESP","Spain","2011","2011",699.4,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","MTMOTCMT","Million US$ at exchange rate","ESP","Spain","2012","2012",614.3,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","MTMOTCMT","Million US$ at exchange rate","ESP","Spain","2013","2013",646.7,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","MTMOTCMT","Million US$ at exchange rate","ESP","Spain","2014","2014",684.3,"B; D","Break; Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","MTMOTCMT","Million US$ at exchange rate","ESP","Spain","2015","2015",593.4,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","MTMOTCMT","Million US$ at exchange rate","ESP","Spain","2016","2016",632.5,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","MTMOTCMT","Million US$ at exchange rate","ESP","Spain","2017","2017",677.9,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","MTMOTCMT","Million US$ at exchange rate","ESP","Spain","2018","2018",741.4,"B","Break"
+"PATCGENU","G-Genito urinary system and sex hormones","MTMOTCMT","Million US$ at exchange rate","ESP","Spain","2019","2019",664.2,,
+"PATCGENU","G-Genito urinary system and sex hormones","MTMOTCMT","Million US$ at exchange rate","ESP","Spain","2020","2020",634.8,,
+"PATCGENU","G-Genito urinary system and sex hormones","MTMOTCMT","Million US$ at exchange rate","ESP","Spain","2021","2021",704.3,,
+"PATCGENU","G-Genito urinary system and sex hormones","MTMOTCMT","Million US$ at exchange rate","ESP","Spain","2022","2022",663.5,"P","Provisional value"
+"PATCGENU","G-Genito urinary system and sex hormones","MTMOPPMT","Million US$, purchasing power parity","ESP","Spain","2010","2010",704.5,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","MTMOPPMT","Million US$, purchasing power parity","ESP","Spain","2011","2011",703.6,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","MTMOPPMT","Million US$, purchasing power parity","ESP","Spain","2012","2012",688,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","MTMOPPMT","Million US$, purchasing power parity","ESP","Spain","2013","2013",721.6,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","MTMOPPMT","Million US$, purchasing power parity","ESP","Spain","2014","2014",777.6,"B; D","Break; Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","MTMOPPMT","Million US$, purchasing power parity","ESP","Spain","2015","2015",804.6,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","MTMOPPMT","Million US$, purchasing power parity","ESP","Spain","2016","2016",889.2,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","MTMOPPMT","Million US$, purchasing power parity","ESP","Spain","2017","2017",951.3,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","MTMOPPMT","Million US$, purchasing power parity","ESP","Spain","2018","2018",993.7,"B","Break"
+"PATCGENU","G-Genito urinary system and sex hormones","MTMOPPMT","Million US$, purchasing power parity","ESP","Spain","2019","2019",968,,
+"PATCGENU","G-Genito urinary system and sex hormones","MTMOPPMT","Million US$, purchasing power parity","ESP","Spain","2020","2020",894.5,,
+"PATCGENU","G-Genito urinary system and sex hormones","MTMOPPMT","Million US$, purchasing power parity","ESP","Spain","2021","2021",951.3,,
+"PATCGENU","G-Genito urinary system and sex hormones","MTMOPPMT","Million US$, purchasing power parity","ESP","Spain","2022","2022",1056.7,"P","Provisional value"
+"PATCGENU","G-Genito urinary system and sex hormones","TCPPERMT","/capita, US$ exchange rate","ESP","Spain","2010","2010",14.6,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","TCPPERMT","/capita, US$ exchange rate","ESP","Spain","2011","2011",15,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","TCPPERMT","/capita, US$ exchange rate","ESP","Spain","2012","2012",13.1,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","TCPPERMT","/capita, US$ exchange rate","ESP","Spain","2013","2013",13.9,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","TCPPERMT","/capita, US$ exchange rate","ESP","Spain","2014","2014",14.7,"B; D","Break; Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","TCPPERMT","/capita, US$ exchange rate","ESP","Spain","2015","2015",12.8,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","TCPPERMT","/capita, US$ exchange rate","ESP","Spain","2016","2016",13.6,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","TCPPERMT","/capita, US$ exchange rate","ESP","Spain","2017","2017",14.5,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","TCPPERMT","/capita, US$ exchange rate","ESP","Spain","2018","2018",15.8,"B","Break"
+"PATCGENU","G-Genito urinary system and sex hormones","TCPPERMT","/capita, US$ exchange rate","ESP","Spain","2019","2019",14.1,,
+"PATCGENU","G-Genito urinary system and sex hormones","TCPPERMT","/capita, US$ exchange rate","ESP","Spain","2020","2020",13.4,,
+"PATCGENU","G-Genito urinary system and sex hormones","TCPPERMT","/capita, US$ exchange rate","ESP","Spain","2021","2021",14.9,,
+"PATCGENU","G-Genito urinary system and sex hormones","TCPPERMT","/capita, US$ exchange rate","ESP","Spain","2022","2022",14,"P","Provisional value"
+"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2010","2010",15.1,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2011","2011",15.1,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2012","2012",14.7,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2013","2013",15.5,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2014","2014",16.7,"B; D","Break; Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2015","2015",17.3,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2016","2016",19.1,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2017","2017",20.4,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2018","2018",21.2,"B","Break"
+"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2019","2019",20.5,,
+"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2020","2020",18.9,,
+"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2021","2021",20.1,,
+"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2022","2022",22.3,"P","Provisional value"
+"PATCGENU","G-Genito urinary system and sex hormones","ATCPTTMT","% of total sales","ESP","Spain","2010","2010",3.9,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","ATCPTTMT","% of total sales","ESP","Spain","2011","2011",4.1,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","ATCPTTMT","% of total sales","ESP","Spain","2012","2012",4.3,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","ATCPTTMT","% of total sales","ESP","Spain","2013","2013",4.6,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","ATCPTTMT","% of total sales","ESP","Spain","2014","2014",4.6,"B; D","Break; Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","ATCPTTMT","% of total sales","ESP","Spain","2015","2015",4.7,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","ATCPTTMT","% of total sales","ESP","Spain","2016","2016",4.8,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","ATCPTTMT","% of total sales","ESP","Spain","2017","2017",5,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","ATCPTTMT","% of total sales","ESP","Spain","2018","2018",3.3,"B","Break"
+"PATCGENU","G-Genito urinary system and sex hormones","ATCPTTMT","% of total sales","ESP","Spain","2019","2019",3,,
+"PATCGENU","G-Genito urinary system and sex hormones","ATCPTTMT","% of total sales","ESP","Spain","2020","2020",2.7,,
+"PATCGENU","G-Genito urinary system and sex hormones","ATCPTTMT","% of total sales","ESP","Spain","2021","2021",2.7,,
+"PATCGENU","G-Genito urinary system and sex hormones","ATCPTTMT","% of total sales","ESP","Spain","2022","2022",2.7,"P","Provisional value"
+"PATCGENU","G-Genito urinary system and sex hormones","MLLNCUMT","Million of national currency units","SWE","Sweden","2010","2010",1715.4,,
+"PATCGENU","G-Genito urinary system and sex hormones","MLLNCUMT","Million of national currency units","SWE","Sweden","2011","2011",1722.7,,
+"PATCGENU","G-Genito urinary system and sex hormones","MLLNCUMT","Million of national currency units","SWE","Sweden","2012","2012",1757.1,,
+"PATCGENU","G-Genito urinary system and sex hormones","MLLNCUMT","Million of national currency units","SWE","Sweden","2013","2013",1729,,
+"PATCGENU","G-Genito urinary system and sex hormones","MLLNCUMT","Million of national currency units","SWE","Sweden","2014","2014",1684.8,,
+"PATCGENU","G-Genito urinary system and sex hormones","MLLNCUMT","Million of national currency units","SWE","Sweden","2015","2015",1676.9,,
+"PATCGENU","G-Genito urinary system and sex hormones","MLLNCUMT","Million of national currency units","SWE","Sweden","2016","2016",1693.7,,
+"PATCGENU","G-Genito urinary system and sex hormones","MLLNCUMT","Million of national currency units","SWE","Sweden","2017","2017",1719.5,,
+"PATCGENU","G-Genito urinary system and sex hormones","MLLNCUMT","Million of national currency units","SWE","Sweden","2018","2018",1739.5,,
+"PATCGENU","G-Genito urinary system and sex hormones","MLLNCUMT","Million of national currency units","SWE","Sweden","2019","2019",1772.1,,
+"PATCGENU","G-Genito urinary system and sex hormones","MLLNCUMT","Million of national currency units","SWE","Sweden","2020","2020",1738.7,,
+"PATCGENU","G-Genito urinary system and sex hormones","MLLNCUMT","Million of national currency units","SWE","Sweden","2021","2021",1761.1,,
+"PATCGENU","G-Genito urinary system and sex hormones","MLLNCUMT","Million of national currency units","SWE","Sweden","2022","2022",1854.2,,
+"PATCGENU","G-Genito urinary system and sex hormones","MTMOTCMT","Million US$ at exchange rate","SWE","Sweden","2010","2010",238,,
+"PATCGENU","G-Genito urinary system and sex hormones","MTMOTCMT","Million US$ at exchange rate","SWE","Sweden","2011","2011",265.3,,
+"PATCGENU","G-Genito urinary system and sex hormones","MTMOTCMT","Million US$ at exchange rate","SWE","Sweden","2012","2012",259.3,,
+"PATCGENU","G-Genito urinary system and sex hormones","MTMOTCMT","Million US$ at exchange rate","SWE","Sweden","2013","2013",265.4,,
+"PATCGENU","G-Genito urinary system and sex hormones","MTMOTCMT","Million US$ at exchange rate","SWE","Sweden","2014","2014",245.6,,
+"PATCGENU","G-Genito urinary system and sex hormones","MTMOTCMT","Million US$ at exchange rate","SWE","Sweden","2015","2015",198.8,,
+"PATCGENU","G-Genito urinary system and sex hormones","MTMOTCMT","Million US$ at exchange rate","SWE","Sweden","2016","2016",197.8,,
+"PATCGENU","G-Genito urinary system and sex hormones","MTMOTCMT","Million US$ at exchange rate","SWE","Sweden","2017","2017",201.1,,
+"PATCGENU","G-Genito urinary system and sex hormones","MTMOTCMT","Million US$ at exchange rate","SWE","Sweden","2018","2018",200.1,,
+"PATCGENU","G-Genito urinary system and sex hormones","MTMOTCMT","Million US$ at exchange rate","SWE","Sweden","2019","2019",187.4,,
+"PATCGENU","G-Genito urinary system and sex hormones","MTMOTCMT","Million US$ at exchange rate","SWE","Sweden","2020","2020",188.8,,
+"PATCGENU","G-Genito urinary system and sex hormones","MTMOTCMT","Million US$ at exchange rate","SWE","Sweden","2021","2021",205.3,,
+"PATCGENU","G-Genito urinary system and sex hormones","MTMOTCMT","Million US$ at exchange rate","SWE","Sweden","2022","2022",183.3,,
+"PATCGENU","G-Genito urinary system and sex hormones","MTMOPPMT","Million US$, purchasing power parity","SWE","Sweden","2010","2010",190.1,,
+"PATCGENU","G-Genito urinary system and sex hormones","MTMOPPMT","Million US$, purchasing power parity","SWE","Sweden","2011","2011",194.8,,
+"PATCGENU","G-Genito urinary system and sex hormones","MTMOPPMT","Million US$, purchasing power parity","SWE","Sweden","2012","2012",203,,
+"PATCGENU","G-Genito urinary system and sex hormones","MTMOPPMT","Million US$, purchasing power parity","SWE","Sweden","2013","2013",201.1,,
+"PATCGENU","G-Genito urinary system and sex hormones","MTMOPPMT","Million US$, purchasing power parity","SWE","Sweden","2014","2014",193,,
+"PATCGENU","G-Genito urinary system and sex hormones","MTMOPPMT","Million US$, purchasing power parity","SWE","Sweden","2015","2015",189.4,,
+"PATCGENU","G-Genito urinary system and sex hormones","MTMOPPMT","Million US$, purchasing power parity","SWE","Sweden","2016","2016",192,,
+"PATCGENU","G-Genito urinary system and sex hormones","MTMOPPMT","Million US$, purchasing power parity","SWE","Sweden","2017","2017",194.2,,
+"PATCGENU","G-Genito urinary system and sex hormones","MTMOPPMT","Million US$, purchasing power parity","SWE","Sweden","2018","2018",196.2,,
+"PATCGENU","G-Genito urinary system and sex hormones","MTMOPPMT","Million US$, purchasing power parity","SWE","Sweden","2019","2019",203.5,,
+"PATCGENU","G-Genito urinary system and sex hormones","MTMOPPMT","Million US$, purchasing power parity","SWE","Sweden","2020","2020",200.6,,
+"PATCGENU","G-Genito urinary system and sex hormones","MTMOPPMT","Million US$, purchasing power parity","SWE","Sweden","2021","2021",201.9,,
+"PATCGENU","G-Genito urinary system and sex hormones","MTMOPPMT","Million US$, purchasing power parity","SWE","Sweden","2022","2022",214,,
+"PATCGENU","G-Genito urinary system and sex hormones","TCPPERMT","/capita, US$ exchange rate","SWE","Sweden","2010","2010",25.4,,
+"PATCGENU","G-Genito urinary system and sex hormones","TCPPERMT","/capita, US$ exchange rate","SWE","Sweden","2011","2011",28.1,,
+"PATCGENU","G-Genito urinary system and sex hormones","TCPPERMT","/capita, US$ exchange rate","SWE","Sweden","2012","2012",27.2,,
+"PATCGENU","G-Genito urinary system and sex hormones","TCPPERMT","/capita, US$ exchange rate","SWE","Sweden","2013","2013",27.6,,
+"PATCGENU","G-Genito urinary system and sex hormones","TCPPERMT","/capita, US$ exchange rate","SWE","Sweden","2014","2014",25.3,,
+"PATCGENU","G-Genito urinary system and sex hormones","TCPPERMT","/capita, US$ exchange rate","SWE","Sweden","2015","2015",20.3,,
+"PATCGENU","G-Genito urinary system and sex hormones","TCPPERMT","/capita, US$ exchange rate","SWE","Sweden","2016","2016",19.9,,
+"PATCGENU","G-Genito urinary system and sex hormones","TCPPERMT","/capita, US$ exchange rate","SWE","Sweden","2017","2017",20,,
+"PATCGENU","G-Genito urinary system and sex hormones","TCPPERMT","/capita, US$ exchange rate","SWE","Sweden","2018","2018",19.7,,
+"PATCGENU","G-Genito urinary system and sex hormones","TCPPERMT","/capita, US$ exchange rate","SWE","Sweden","2019","2019",18.2,,
+"PATCGENU","G-Genito urinary system and sex hormones","TCPPERMT","/capita, US$ exchange rate","SWE","Sweden","2020","2020",18.2,,
+"PATCGENU","G-Genito urinary system and sex hormones","TCPPERMT","/capita, US$ exchange rate","SWE","Sweden","2021","2021",19.7,,
+"PATCGENU","G-Genito urinary system and sex hormones","TCPPERMT","/capita, US$ exchange rate","SWE","Sweden","2022","2022",17.5,,
+"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2010","2010",20.3,,
+"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2011","2011",20.6,,
+"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2012","2012",21.3,,
+"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2013","2013",20.9,,
+"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2014","2014",19.9,,
+"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2015","2015",19.3,,
+"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2016","2016",19.3,,
+"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2017","2017",19.3,,
+"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2018","2018",19.3,,
+"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2019","2019",19.8,,
+"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2020","2020",19.4,,
+"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2021","2021",19.4,,
+"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2022","2022",20.5,,
+"PATCGENU","G-Genito urinary system and sex hormones","ATCPTTMT","% of total sales","SWE","Sweden","2010","2010",4.8,,
+"PATCGENU","G-Genito urinary system and sex hormones","ATCPTTMT","% of total sales","SWE","Sweden","2011","2011",4.7,,
+"PATCGENU","G-Genito urinary system and sex hormones","ATCPTTMT","% of total sales","SWE","Sweden","2012","2012",4.9,,
+"PATCGENU","G-Genito urinary system and sex hormones","ATCPTTMT","% of total sales","SWE","Sweden","2013","2013",4.8,,
+"PATCGENU","G-Genito urinary system and sex hormones","ATCPTTMT","% of total sales","SWE","Sweden","2014","2014",4.5,,
+"PATCGENU","G-Genito urinary system and sex hormones","ATCPTTMT","% of total sales","SWE","Sweden","2015","2015",4.1,,
+"PATCGENU","G-Genito urinary system and sex hormones","ATCPTTMT","% of total sales","SWE","Sweden","2016","2016",4,,
+"PATCGENU","G-Genito urinary system and sex hormones","ATCPTTMT","% of total sales","SWE","Sweden","2017","2017",3.9,,
+"PATCGENU","G-Genito urinary system and sex hormones","ATCPTTMT","% of total sales","SWE","Sweden","2018","2018",3.6,,
+"PATCGENU","G-Genito urinary system and sex hormones","ATCPTTMT","% of total sales","SWE","Sweden","2019","2019",3.5,,
+"PATCGENU","G-Genito urinary system and sex hormones","ATCPTTMT","% of total sales","SWE","Sweden","2020","2020",3.3,,
+"PATCGENU","G-Genito urinary system and sex hormones","ATCPTTMT","% of total sales","SWE","Sweden","2021","2021",3.3,,
+"PATCGENU","G-Genito urinary system and sex hormones","ATCPTTMT","% of total sales","SWE","Sweden","2022","2022",3.2,,
+"PATCGENU","G-Genito urinary system and sex hormones","MLLNCUMT","Million of national currency units","CHE","Switzerland","2010","2010",344.2,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","MLLNCUMT","Million of national currency units","CHE","Switzerland","2011","2011",349,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","MLLNCUMT","Million of national currency units","CHE","Switzerland","2012","2012",353,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","MLLNCUMT","Million of national currency units","CHE","Switzerland","2013","2013",353,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","MLLNCUMT","Million of national currency units","CHE","Switzerland","2014","2014",346,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","MLLNCUMT","Million of national currency units","CHE","Switzerland","2015","2015",348,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","MLLNCUMT","Million of national currency units","CHE","Switzerland","2016","2016",351,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","MLLNCUMT","Million of national currency units","CHE","Switzerland","2017","2017",347,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","MLLNCUMT","Million of national currency units","CHE","Switzerland","2018","2018",341,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","MLLNCUMT","Million of national currency units","CHE","Switzerland","2019","2019",336,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","MLLNCUMT","Million of national currency units","CHE","Switzerland","2020","2020",331,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","MLLNCUMT","Million of national currency units","CHE","Switzerland","2021","2021",331,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","MLLNCUMT","Million of national currency units","CHE","Switzerland","2022","2022",331,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","MTMOTCMT","Million US$ at exchange rate","CHE","Switzerland","2010","2010",330,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","MTMOTCMT","Million US$ at exchange rate","CHE","Switzerland","2011","2011",393,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","MTMOTCMT","Million US$ at exchange rate","CHE","Switzerland","2012","2012",376.5,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","MTMOTCMT","Million US$ at exchange rate","CHE","Switzerland","2013","2013",380.8,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","MTMOTCMT","Million US$ at exchange rate","CHE","Switzerland","2014","2014",377.7,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","MTMOTCMT","Million US$ at exchange rate","CHE","Switzerland","2015","2015",361.6,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","MTMOTCMT","Million US$ at exchange rate","CHE","Switzerland","2016","2016",356.2,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","MTMOTCMT","Million US$ at exchange rate","CHE","Switzerland","2017","2017",352.4,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","MTMOTCMT","Million US$ at exchange rate","CHE","Switzerland","2018","2018",348.7,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","MTMOTCMT","Million US$ at exchange rate","CHE","Switzerland","2019","2019",338.1,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","MTMOTCMT","Million US$ at exchange rate","CHE","Switzerland","2020","2020",352.5,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","MTMOTCMT","Million US$ at exchange rate","CHE","Switzerland","2021","2021",362.2,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","MTMOTCMT","Million US$ at exchange rate","CHE","Switzerland","2022","2022",346.7,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","MTMOPPMT","Million US$, purchasing power parity","CHE","Switzerland","2010","2010",234.8,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","MTMOPPMT","Million US$, purchasing power parity","CHE","Switzerland","2011","2011",249.7,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","MTMOPPMT","Million US$, purchasing power parity","CHE","Switzerland","2012","2012",260.7,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","MTMOPPMT","Million US$, purchasing power parity","CHE","Switzerland","2013","2013",269,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","MTMOPPMT","Million US$, purchasing power parity","CHE","Switzerland","2014","2014",269.9,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","MTMOPPMT","Million US$, purchasing power parity","CHE","Switzerland","2015","2015",281.6,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","MTMOPPMT","Million US$, purchasing power parity","CHE","Switzerland","2016","2016",292,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","MTMOPPMT","Million US$, purchasing power parity","CHE","Switzerland","2017","2017",292.2,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","MTMOPPMT","Million US$, purchasing power parity","CHE","Switzerland","2018","2018",289.3,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","MTMOPPMT","Million US$, purchasing power parity","CHE","Switzerland","2019","2019",292.1,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","MTMOPPMT","Million US$, purchasing power parity","CHE","Switzerland","2020","2020",291.5,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","MTMOPPMT","Million US$, purchasing power parity","CHE","Switzerland","2021","2021",299.2,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","MTMOPPMT","Million US$, purchasing power parity","CHE","Switzerland","2022","2022",310.5,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","TCPPERMT","/capita, US$ exchange rate","CHE","Switzerland","2010","2010",42.2,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","TCPPERMT","/capita, US$ exchange rate","CHE","Switzerland","2011","2011",49.7,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","TCPPERMT","/capita, US$ exchange rate","CHE","Switzerland","2012","2012",47.1,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","TCPPERMT","/capita, US$ exchange rate","CHE","Switzerland","2013","2013",47.1,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","TCPPERMT","/capita, US$ exchange rate","CHE","Switzerland","2014","2014",46.1,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","TCPPERMT","/capita, US$ exchange rate","CHE","Switzerland","2015","2015",43.7,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","TCPPERMT","/capita, US$ exchange rate","CHE","Switzerland","2016","2016",42.5,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","TCPPERMT","/capita, US$ exchange rate","CHE","Switzerland","2017","2017",41.7,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","TCPPERMT","/capita, US$ exchange rate","CHE","Switzerland","2018","2018",41,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","TCPPERMT","/capita, US$ exchange rate","CHE","Switzerland","2019","2019",39.4,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","TCPPERMT","/capita, US$ exchange rate","CHE","Switzerland","2020","2020",40.8,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","TCPPERMT","/capita, US$ exchange rate","CHE","Switzerland","2021","2021",41.6,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","TCPPERMT","/capita, US$ exchange rate","CHE","Switzerland","2022","2022",39.7,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","CHE","Switzerland","2010","2010",30,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","CHE","Switzerland","2011","2011",31.6,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","CHE","Switzerland","2012","2012",32.6,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","CHE","Switzerland","2013","2013",33.2,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","CHE","Switzerland","2014","2014",33,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","CHE","Switzerland","2015","2015",34,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","CHE","Switzerland","2016","2016",34.9,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","CHE","Switzerland","2017","2017",34.6,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","CHE","Switzerland","2018","2018",34,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","CHE","Switzerland","2019","2019",34.1,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","CHE","Switzerland","2020","2020",33.7,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","CHE","Switzerland","2021","2021",34.4,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","CHE","Switzerland","2022","2022",35.5,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","ATCPTTMT","% of total sales","CHE","Switzerland","2010","2010",6,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","ATCPTTMT","% of total sales","CHE","Switzerland","2011","2011",6,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","ATCPTTMT","% of total sales","CHE","Switzerland","2012","2012",5.9,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","ATCPTTMT","% of total sales","CHE","Switzerland","2013","2013",6,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","ATCPTTMT","% of total sales","CHE","Switzerland","2014","2014",5.8,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","ATCPTTMT","% of total sales","CHE","Switzerland","2015","2015",5.6,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","ATCPTTMT","% of total sales","CHE","Switzerland","2016","2016",5.5,"B; D","Break; Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","ATCPTTMT","% of total sales","CHE","Switzerland","2017","2017",5.3,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","ATCPTTMT","% of total sales","CHE","Switzerland","2018","2018",5.2,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","ATCPTTMT","% of total sales","CHE","Switzerland","2019","2019",5,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","ATCPTTMT","% of total sales","CHE","Switzerland","2020","2020",4.8,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","ATCPTTMT","% of total sales","CHE","Switzerland","2021","2021",4.7,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","ATCPTTMT","% of total sales","CHE","Switzerland","2022","2022",4.4,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","MLLNCUMT","Million of national currency units","TUR","Türkiye","2010","2010",719.2,,
+"PATCGENU","G-Genito urinary system and sex hormones","MLLNCUMT","Million of national currency units","TUR","Türkiye","2011","2011",618.4,,
+"PATCGENU","G-Genito urinary system and sex hormones","MLLNCUMT","Million of national currency units","TUR","Türkiye","2012","2012",645.8,,
+"PATCGENU","G-Genito urinary system and sex hormones","MLLNCUMT","Million of national currency units","TUR","Türkiye","2013","2013",665.1,,
+"PATCGENU","G-Genito urinary system and sex hormones","MLLNCUMT","Million of national currency units","TUR","Türkiye","2014","2014",731.8,,
+"PATCGENU","G-Genito urinary system and sex hormones","MLLNCUMT","Million of national currency units","TUR","Türkiye","2015","2015",840.7,,
+"PATCGENU","G-Genito urinary system and sex hormones","MLLNCUMT","Million of national currency units","TUR","Türkiye","2016","2016",983.3,,
+"PATCGENU","G-Genito urinary system and sex hormones","MLLNCUMT","Million of national currency units","TUR","Türkiye","2017","2017",1193.9,,
+"PATCGENU","G-Genito urinary system and sex hormones","MLLNCUMT","Million of national currency units","TUR","Türkiye","2018","2018",1485.5,,
+"PATCGENU","G-Genito urinary system and sex hormones","MLLNCUMT","Million of national currency units","TUR","Türkiye","2019","2019",1898,,
+"PATCGENU","G-Genito urinary system and sex hormones","MLLNCUMT","Million of national currency units","TUR","Türkiye","2020","2020",2006.2,,
+"PATCGENU","G-Genito urinary system and sex hormones","MLLNCUMT","Million of national currency units","TUR","Türkiye","2021","2021",2871.3,,
+"PATCGENU","G-Genito urinary system and sex hormones","MTMOTCMT","Million US$ at exchange rate","TUR","Türkiye","2010","2010",478.6,,
+"PATCGENU","G-Genito urinary system and sex hormones","MTMOTCMT","Million US$ at exchange rate","TUR","Türkiye","2011","2011",369.2,,
+"PATCGENU","G-Genito urinary system and sex hormones","MTMOTCMT","Million US$ at exchange rate","TUR","Türkiye","2012","2012",359.6,,
+"PATCGENU","G-Genito urinary system and sex hormones","MTMOTCMT","Million US$ at exchange rate","TUR","Türkiye","2013","2013",349.3,,
+"PATCGENU","G-Genito urinary system and sex hormones","MTMOTCMT","Million US$ at exchange rate","TUR","Türkiye","2014","2014",334.4,,
+"PATCGENU","G-Genito urinary system and sex hormones","MTMOTCMT","Million US$ at exchange rate","TUR","Türkiye","2015","2015",309.1,,
+"PATCGENU","G-Genito urinary system and sex hormones","MTMOTCMT","Million US$ at exchange rate","TUR","Türkiye","2016","2016",325.6,,
+"PATCGENU","G-Genito urinary system and sex hormones","MTMOTCMT","Million US$ at exchange rate","TUR","Türkiye","2017","2017",327.3,,
+"PATCGENU","G-Genito urinary system and sex hormones","MTMOTCMT","Million US$ at exchange rate","TUR","Türkiye","2018","2018",307.7,,
+"PATCGENU","G-Genito urinary system and sex hormones","MTMOTCMT","Million US$ at exchange rate","TUR","Türkiye","2019","2019",334.5,,
+"PATCGENU","G-Genito urinary system and sex hormones","MTMOTCMT","Million US$ at exchange rate","TUR","Türkiye","2020","2020",286.2,,
+"PATCGENU","G-Genito urinary system and sex hormones","MTMOTCMT","Million US$ at exchange rate","TUR","Türkiye","2021","2021",324.4,,
+"PATCGENU","G-Genito urinary system and sex hormones","MTMOPPMT","Million US$, purchasing power parity","TUR","Türkiye","2010","2010",781.5,,
+"PATCGENU","G-Genito urinary system and sex hormones","MTMOPPMT","Million US$, purchasing power parity","TUR","Türkiye","2011","2011",640,,
+"PATCGENU","G-Genito urinary system and sex hormones","MTMOPPMT","Million US$, purchasing power parity","TUR","Türkiye","2012","2012",633.2,,
+"PATCGENU","G-Genito urinary system and sex hormones","MTMOPPMT","Million US$, purchasing power parity","TUR","Türkiye","2013","2013",621.4,,
+"PATCGENU","G-Genito urinary system and sex hormones","MTMOPPMT","Million US$, purchasing power parity","TUR","Türkiye","2014","2014",662.5,,
+"PATCGENU","G-Genito urinary system and sex hormones","MTMOPPMT","Million US$, purchasing power parity","TUR","Türkiye","2015","2015",723.2,,
+"PATCGENU","G-Genito urinary system and sex hormones","MTMOPPMT","Million US$, purchasing power parity","TUR","Türkiye","2016","2016",792.3,,
+"PATCGENU","G-Genito urinary system and sex hormones","MTMOPPMT","Million US$, purchasing power parity","TUR","Türkiye","2017","2017",862.7,,
+"PATCGENU","G-Genito urinary system and sex hormones","MTMOPPMT","Million US$, purchasing power parity","TUR","Türkiye","2018","2018",909.9,,
+"PATCGENU","G-Genito urinary system and sex hormones","MTMOPPMT","Million US$, purchasing power parity","TUR","Türkiye","2019","2019",1018.2,,
+"PATCGENU","G-Genito urinary system and sex hormones","MTMOPPMT","Million US$, purchasing power parity","TUR","Türkiye","2020","2020",927,,
+"PATCGENU","G-Genito urinary system and sex hormones","MTMOPPMT","Million US$, purchasing power parity","TUR","Türkiye","2021","2021",1022.6,,
+"PATCGENU","G-Genito urinary system and sex hormones","TCPPERMT","/capita, US$ exchange rate","TUR","Türkiye","2010","2010",6.5,,
+"PATCGENU","G-Genito urinary system and sex hormones","TCPPERMT","/capita, US$ exchange rate","TUR","Türkiye","2011","2011",5,,
+"PATCGENU","G-Genito urinary system and sex hormones","TCPPERMT","/capita, US$ exchange rate","TUR","Türkiye","2012","2012",4.8,,
+"PATCGENU","G-Genito urinary system and sex hormones","TCPPERMT","/capita, US$ exchange rate","TUR","Türkiye","2013","2013",4.6,,
+"PATCGENU","G-Genito urinary system and sex hormones","TCPPERMT","/capita, US$ exchange rate","TUR","Türkiye","2014","2014",4.3,,
+"PATCGENU","G-Genito urinary system and sex hormones","TCPPERMT","/capita, US$ exchange rate","TUR","Türkiye","2015","2015",4,,
+"PATCGENU","G-Genito urinary system and sex hormones","TCPPERMT","/capita, US$ exchange rate","TUR","Türkiye","2016","2016",4.1,,
+"PATCGENU","G-Genito urinary system and sex hormones","TCPPERMT","/capita, US$ exchange rate","TUR","Türkiye","2017","2017",4.1,,
+"PATCGENU","G-Genito urinary system and sex hormones","TCPPERMT","/capita, US$ exchange rate","TUR","Türkiye","2018","2018",3.8,,
+"PATCGENU","G-Genito urinary system and sex hormones","TCPPERMT","/capita, US$ exchange rate","TUR","Türkiye","2019","2019",4.1,,
+"PATCGENU","G-Genito urinary system and sex hormones","TCPPERMT","/capita, US$ exchange rate","TUR","Türkiye","2020","2020",3.4,,
+"PATCGENU","G-Genito urinary system and sex hormones","TCPPERMT","/capita, US$ exchange rate","TUR","Türkiye","2021","2021",3.9,,
+"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2010","2010",10.7,,
+"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2011","2011",8.6,,
+"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2012","2012",8.4,,
+"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2013","2013",8.2,,
+"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2014","2014",8.6,,
+"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2015","2015",9.2,,
+"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2016","2016",10,,
+"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2017","2017",10.7,,
+"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2018","2018",11.2,,
+"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2019","2019",12.3,,
+"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2020","2020",11.1,,
+"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2021","2021",12.2,,
+"PATCGENU","G-Genito urinary system and sex hormones","ATCPTTMT","% of total sales","TUR","Türkiye","2010","2010",4.6,,
+"PATCGENU","G-Genito urinary system and sex hormones","ATCPTTMT","% of total sales","TUR","Türkiye","2011","2011",4.4,,
+"PATCGENU","G-Genito urinary system and sex hormones","ATCPTTMT","% of total sales","TUR","Türkiye","2012","2012",4.8,,
+"PATCGENU","G-Genito urinary system and sex hormones","ATCPTTMT","% of total sales","TUR","Türkiye","2013","2013",4.6,,
+"PATCGENU","G-Genito urinary system and sex hormones","ATCPTTMT","% of total sales","TUR","Türkiye","2014","2014",4.7,,
+"PATCGENU","G-Genito urinary system and sex hormones","ATCPTTMT","% of total sales","TUR","Türkiye","2015","2015",4.6,,
+"PATCGENU","G-Genito urinary system and sex hormones","ATCPTTMT","% of total sales","TUR","Türkiye","2016","2016",4.5,,
+"PATCGENU","G-Genito urinary system and sex hormones","ATCPTTMT","% of total sales","TUR","Türkiye","2017","2017",4.7,,
+"PATCGENU","G-Genito urinary system and sex hormones","ATCPTTMT","% of total sales","TUR","Türkiye","2018","2018",4.6,,
+"PATCGENU","G-Genito urinary system and sex hormones","ATCPTTMT","% of total sales","TUR","Türkiye","2019","2019",4.5,,
+"PATCGENU","G-Genito urinary system and sex hormones","ATCPTTMT","% of total sales","TUR","Türkiye","2020","2020",4,,
+"PATCGENU","G-Genito urinary system and sex hormones","ATCPTTMT","% of total sales","TUR","Türkiye","2021","2021",4.4,,
+"PATCGENU","G-Genito urinary system and sex hormones","MLLNCUMT","Million of national currency units","GBR","United Kingdom","2012","2012",684.3,"B","Break"
+"PATCGENU","G-Genito urinary system and sex hormones","MLLNCUMT","Million of national currency units","GBR","United Kingdom","2013","2013",680.1,,
+"PATCGENU","G-Genito urinary system and sex hormones","MLLNCUMT","Million of national currency units","GBR","United Kingdom","2014","2014",680.7,,
+"PATCGENU","G-Genito urinary system and sex hormones","MLLNCUMT","Million of national currency units","GBR","United Kingdom","2015","2015",707.9,,
+"PATCGENU","G-Genito urinary system and sex hormones","MLLNCUMT","Million of national currency units","GBR","United Kingdom","2016","2016",711.1,,
+"PATCGENU","G-Genito urinary system and sex hormones","MLLNCUMT","Million of national currency units","GBR","United Kingdom","2017","2017",757.8,,
+"PATCGENU","G-Genito urinary system and sex hormones","MLLNCUMT","Million of national currency units","GBR","United Kingdom","2018","2018",724.1,,
+"PATCGENU","G-Genito urinary system and sex hormones","MTMOTCMT","Million US$ at exchange rate","GBR","United Kingdom","2012","2012",1081,"B","Break"
+"PATCGENU","G-Genito urinary system and sex hormones","MTMOTCMT","Million US$ at exchange rate","GBR","United Kingdom","2013","2013",1063.2,,
+"PATCGENU","G-Genito urinary system and sex hormones","MTMOTCMT","Million US$ at exchange rate","GBR","United Kingdom","2014","2014",1120.1,,
+"PATCGENU","G-Genito urinary system and sex hormones","MTMOTCMT","Million US$ at exchange rate","GBR","United Kingdom","2015","2015",1081.5,,
+"PATCGENU","G-Genito urinary system and sex hormones","MTMOTCMT","Million US$ at exchange rate","GBR","United Kingdom","2016","2016",960.1,,
+"PATCGENU","G-Genito urinary system and sex hormones","MTMOTCMT","Million US$ at exchange rate","GBR","United Kingdom","2017","2017",975.3,,
+"PATCGENU","G-Genito urinary system and sex hormones","MTMOTCMT","Million US$ at exchange rate","GBR","United Kingdom","2018","2018",966.1,,
+"PATCGENU","G-Genito urinary system and sex hormones","MTMOPPMT","Million US$, purchasing power parity","GBR","United Kingdom","2012","2012",975.3,"B","Break"
+"PATCGENU","G-Genito urinary system and sex hormones","MTMOPPMT","Million US$, purchasing power parity","GBR","United Kingdom","2013","2013",978.2,,
+"PATCGENU","G-Genito urinary system and sex hormones","MTMOPPMT","Million US$, purchasing power parity","GBR","United Kingdom","2014","2014",974.6,,
+"PATCGENU","G-Genito urinary system and sex hormones","MTMOPPMT","Million US$, purchasing power parity","GBR","United Kingdom","2015","2015",1022.2,,
+"PATCGENU","G-Genito urinary system and sex hormones","MTMOPPMT","Million US$, purchasing power parity","GBR","United Kingdom","2016","2016",1032.7,,
+"PATCGENU","G-Genito urinary system and sex hormones","MTMOPPMT","Million US$, purchasing power parity","GBR","United Kingdom","2017","2017",1106.9,,
+"PATCGENU","G-Genito urinary system and sex hormones","MTMOPPMT","Million US$, purchasing power parity","GBR","United Kingdom","2018","2018",1052.9,,
+"PATCGENU","G-Genito urinary system and sex hormones","TCPPERMT","/capita, US$ exchange rate","GBR","United Kingdom","2012","2012",17,"B","Break"
+"PATCGENU","G-Genito urinary system and sex hormones","TCPPERMT","/capita, US$ exchange rate","GBR","United Kingdom","2013","2013",16.6,,
+"PATCGENU","G-Genito urinary system and sex hormones","TCPPERMT","/capita, US$ exchange rate","GBR","United Kingdom","2014","2014",17.3,,
+"PATCGENU","G-Genito urinary system and sex hormones","TCPPERMT","/capita, US$ exchange rate","GBR","United Kingdom","2015","2015",16.6,,
+"PATCGENU","G-Genito urinary system and sex hormones","TCPPERMT","/capita, US$ exchange rate","GBR","United Kingdom","2016","2016",14.6,,
+"PATCGENU","G-Genito urinary system and sex hormones","TCPPERMT","/capita, US$ exchange rate","GBR","United Kingdom","2017","2017",14.8,,
+"PATCGENU","G-Genito urinary system and sex hormones","TCPPERMT","/capita, US$ exchange rate","GBR","United Kingdom","2018","2018",14.5,,
+"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","GBR","United Kingdom","2012","2012",15.3,"B","Break"
+"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","GBR","United Kingdom","2013","2013",15.3,,
+"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","GBR","United Kingdom","2014","2014",15.1,,
+"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","GBR","United Kingdom","2015","2015",15.7,,
+"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","GBR","United Kingdom","2016","2016",15.7,,
+"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","GBR","United Kingdom","2017","2017",16.8,,
+"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","GBR","United Kingdom","2018","2018",15.8,,
+"PATCGENU","G-Genito urinary system and sex hormones","ATCPTTMT","% of total sales","GBR","United Kingdom","2012","2012",5,"B","Break"
+"PATCGENU","G-Genito urinary system and sex hormones","ATCPTTMT","% of total sales","GBR","United Kingdom","2013","2013",4.7,,
+"PATCGENU","G-Genito urinary system and sex hormones","ATCPTTMT","% of total sales","GBR","United Kingdom","2014","2014",4.3,,
+"PATCGENU","G-Genito urinary system and sex hormones","ATCPTTMT","% of total sales","GBR","United Kingdom","2015","2015",4,,
+"PATCGENU","G-Genito urinary system and sex hormones","ATCPTTMT","% of total sales","GBR","United Kingdom","2016","2016",3.8,,
+"PATCGENU","G-Genito urinary system and sex hormones","ATCPTTMT","% of total sales","GBR","United Kingdom","2017","2017",3.9,,
+"PATCGENU","G-Genito urinary system and sex hormones","ATCPTTMT","% of total sales","GBR","United Kingdom","2018","2018",3.5,,
+"PATCGENU","G-Genito urinary system and sex hormones","MLLNCUMT","Million of national currency units","CHL","Chile","2010","2010",81496.5,,
+"PATCGENU","G-Genito urinary system and sex hormones","MLLNCUMT","Million of national currency units","CHL","Chile","2011","2011",111351.6,"B","Break"
+"PATCGENU","G-Genito urinary system and sex hormones","MLLNCUMT","Million of national currency units","CHL","Chile","2012","2012",122348.3,,
+"PATCGENU","G-Genito urinary system and sex hormones","MLLNCUMT","Million of national currency units","CHL","Chile","2013","2013",134181.4,,
+"PATCGENU","G-Genito urinary system and sex hormones","MLLNCUMT","Million of national currency units","CHL","Chile","2014","2014",145380,,
+"PATCGENU","G-Genito urinary system and sex hormones","MLLNCUMT","Million of national currency units","CHL","Chile","2015","2015",165236.3,,
+"PATCGENU","G-Genito urinary system and sex hormones","MLLNCUMT","Million of national currency units","CHL","Chile","2016","2016",191680.8,,
+"PATCGENU","G-Genito urinary system and sex hormones","MLLNCUMT","Million of national currency units","CHL","Chile","2017","2017",178137.8,,
+"PATCGENU","G-Genito urinary system and sex hormones","MLLNCUMT","Million of national currency units","CHL","Chile","2018","2018",188269,,
+"PATCGENU","G-Genito urinary system and sex hormones","MLLNCUMT","Million of national currency units","CHL","Chile","2019","2019",193008.7,,
+"PATCGENU","G-Genito urinary system and sex hormones","MLLNCUMT","Million of national currency units","CHL","Chile","2020","2020",208701.4,,
+"PATCGENU","G-Genito urinary system and sex hormones","MLLNCUMT","Million of national currency units","CHL","Chile","2021","2021",241722.5,,
+"PATCGENU","G-Genito urinary system and sex hormones","MLLNCUMT","Million of national currency units","CHL","Chile","2022","2022",222620.9,,
+"PATCGENU","G-Genito urinary system and sex hormones","MTMOTCMT","Million US$ at exchange rate","CHL","Chile","2010","2010",159.7,,
+"PATCGENU","G-Genito urinary system and sex hormones","MTMOTCMT","Million US$ at exchange rate","CHL","Chile","2011","2011",230.2,"B","Break"
+"PATCGENU","G-Genito urinary system and sex hormones","MTMOTCMT","Million US$ at exchange rate","CHL","Chile","2012","2012",251.5,,
+"PATCGENU","G-Genito urinary system and sex hormones","MTMOTCMT","Million US$ at exchange rate","CHL","Chile","2013","2013",270.9,,
+"PATCGENU","G-Genito urinary system and sex hormones","MTMOTCMT","Million US$ at exchange rate","CHL","Chile","2014","2014",254.9,,
+"PATCGENU","G-Genito urinary system and sex hormones","MTMOTCMT","Million US$ at exchange rate","CHL","Chile","2015","2015",252.6,,
+"PATCGENU","G-Genito urinary system and sex hormones","MTMOTCMT","Million US$ at exchange rate","CHL","Chile","2016","2016",283.2,,
+"PATCGENU","G-Genito urinary system and sex hormones","MTMOTCMT","Million US$ at exchange rate","CHL","Chile","2017","2017",274.6,,
+"PATCGENU","G-Genito urinary system and sex hormones","MTMOTCMT","Million US$ at exchange rate","CHL","Chile","2018","2018",293.6,,
+"PATCGENU","G-Genito urinary system and sex hormones","MTMOTCMT","Million US$ at exchange rate","CHL","Chile","2019","2019",274.6,,
+"PATCGENU","G-Genito urinary system and sex hormones","MTMOTCMT","Million US$ at exchange rate","CHL","Chile","2020","2020",263.3,,
+"PATCGENU","G-Genito urinary system and sex hormones","MTMOTCMT","Million US$ at exchange rate","CHL","Chile","2021","2021",318.5,,
+"PATCGENU","G-Genito urinary system and sex hormones","MTMOTCMT","Million US$ at exchange rate","CHL","Chile","2022","2022",254.9,,
+"PATCGENU","G-Genito urinary system and sex hormones","MTMOPPMT","Million US$, purchasing power parity","CHL","Chile","2010","2010",226.5,,
+"PATCGENU","G-Genito urinary system and sex hormones","MTMOPPMT","Million US$, purchasing power parity","CHL","Chile","2011","2011",320,"B","Break"
+"PATCGENU","G-Genito urinary system and sex hormones","MTMOPPMT","Million US$, purchasing power parity","CHL","Chile","2012","2012",352.4,,
+"PATCGENU","G-Genito urinary system and sex hormones","MTMOPPMT","Million US$, purchasing power parity","CHL","Chile","2013","2013",383.7,,
+"PATCGENU","G-Genito urinary system and sex hormones","MTMOPPMT","Million US$, purchasing power parity","CHL","Chile","2014","2014",395.9,,
+"PATCGENU","G-Genito urinary system and sex hormones","MTMOPPMT","Million US$, purchasing power parity","CHL","Chile","2015","2015",422.4,,
+"PATCGENU","G-Genito urinary system and sex hormones","MTMOPPMT","Million US$, purchasing power parity","CHL","Chile","2016","2016",482.5,,
+"PATCGENU","G-Genito urinary system and sex hormones","MTMOPPMT","Million US$, purchasing power parity","CHL","Chile","2017","2017",447.9,,
+"PATCGENU","G-Genito urinary system and sex hormones","MTMOPPMT","Million US$, purchasing power parity","CHL","Chile","2018","2018",475.2,,
+"PATCGENU","G-Genito urinary system and sex hormones","MTMOPPMT","Million US$, purchasing power parity","CHL","Chile","2019","2019",480.6,,
+"PATCGENU","G-Genito urinary system and sex hormones","MTMOPPMT","Million US$, purchasing power parity","CHL","Chile","2020","2020",498.8,,
+"PATCGENU","G-Genito urinary system and sex hormones","MTMOPPMT","Million US$, purchasing power parity","CHL","Chile","2021","2021",555.5,,
+"PATCGENU","G-Genito urinary system and sex hormones","MTMOPPMT","Million US$, purchasing power parity","CHL","Chile","2022","2022",508.8,,
+"PATCGENU","G-Genito urinary system and sex hormones","TCPPERMT","/capita, US$ exchange rate","CHL","Chile","2010","2010",9.4,,
+"PATCGENU","G-Genito urinary system and sex hormones","TCPPERMT","/capita, US$ exchange rate","CHL","Chile","2011","2011",13.3,"B","Break"
+"PATCGENU","G-Genito urinary system and sex hormones","TCPPERMT","/capita, US$ exchange rate","CHL","Chile","2012","2012",14.4,,
+"PATCGENU","G-Genito urinary system and sex hormones","TCPPERMT","/capita, US$ exchange rate","CHL","Chile","2013","2013",15.4,,
+"PATCGENU","G-Genito urinary system and sex hormones","TCPPERMT","/capita, US$ exchange rate","CHL","Chile","2014","2014",14.3,,
+"PATCGENU","G-Genito urinary system and sex hormones","TCPPERMT","/capita, US$ exchange rate","CHL","Chile","2015","2015",14.1,,
+"PATCGENU","G-Genito urinary system and sex hormones","TCPPERMT","/capita, US$ exchange rate","CHL","Chile","2016","2016",15.6,,
+"PATCGENU","G-Genito urinary system and sex hormones","TCPPERMT","/capita, US$ exchange rate","CHL","Chile","2017","2017",14.9,,
+"PATCGENU","G-Genito urinary system and sex hormones","TCPPERMT","/capita, US$ exchange rate","CHL","Chile","2018","2018",15.7,,
+"PATCGENU","G-Genito urinary system and sex hormones","TCPPERMT","/capita, US$ exchange rate","CHL","Chile","2019","2019",14.4,,
+"PATCGENU","G-Genito urinary system and sex hormones","TCPPERMT","/capita, US$ exchange rate","CHL","Chile","2020","2020",13.5,,
+"PATCGENU","G-Genito urinary system and sex hormones","TCPPERMT","/capita, US$ exchange rate","CHL","Chile","2021","2021",16.2,,
+"PATCGENU","G-Genito urinary system and sex hormones","TCPPERMT","/capita, US$ exchange rate","CHL","Chile","2022","2022",12.9,,
+"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2010","2010",13.3,,
+"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2011","2011",18.5,"B","Break"
+"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2012","2012",20.2,,
+"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2013","2013",21.8,,
+"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2014","2014",22.3,,
+"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2015","2015",23.5,,
+"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2016","2016",26.6,,
+"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2017","2017",24.3,,
+"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2018","2018",25.3,,
+"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2019","2019",25.2,,
+"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2020","2020",25.6,,
+"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2021","2021",28.2,,
+"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2022","2022",25.7,,
+"PATCGENU","G-Genito urinary system and sex hormones","ATCPTTMT","% of total sales","CHL","Chile","2010","2010",9.9,,
+"PATCGENU","G-Genito urinary system and sex hormones","ATCPTTMT","% of total sales","CHL","Chile","2011","2011",9.4,"B","Break"
+"PATCGENU","G-Genito urinary system and sex hormones","ATCPTTMT","% of total sales","CHL","Chile","2012","2012",9.8,,
+"PATCGENU","G-Genito urinary system and sex hormones","ATCPTTMT","% of total sales","CHL","Chile","2013","2013",9.3,,
+"PATCGENU","G-Genito urinary system and sex hormones","ATCPTTMT","% of total sales","CHL","Chile","2014","2014",9.4,,
+"PATCGENU","G-Genito urinary system and sex hormones","ATCPTTMT","% of total sales","CHL","Chile","2015","2015",9.1,,
+"PATCGENU","G-Genito urinary system and sex hormones","ATCPTTMT","% of total sales","CHL","Chile","2016","2016",9.5,,
+"PATCGENU","G-Genito urinary system and sex hormones","ATCPTTMT","% of total sales","CHL","Chile","2017","2017",8.6,,
+"PATCGENU","G-Genito urinary system and sex hormones","ATCPTTMT","% of total sales","CHL","Chile","2018","2018",8.2,,
+"PATCGENU","G-Genito urinary system and sex hormones","ATCPTTMT","% of total sales","CHL","Chile","2019","2019",7.7,,
+"PATCGENU","G-Genito urinary system and sex hormones","ATCPTTMT","% of total sales","CHL","Chile","2020","2020",7.8,,
+"PATCGENU","G-Genito urinary system and sex hormones","ATCPTTMT","% of total sales","CHL","Chile","2021","2021",8.6,,
+"PATCGENU","G-Genito urinary system and sex hormones","ATCPTTMT","% of total sales","CHL","Chile","2022","2022",7.9,,
+"PATCGENU","G-Genito urinary system and sex hormones","MLLNCUMT","Million of national currency units","EST","Estonia","2010","2010",10.6,,
+"PATCGENU","G-Genito urinary system and sex hormones","MLLNCUMT","Million of national currency units","EST","Estonia","2011","2011",10.8,,
+"PATCGENU","G-Genito urinary system and sex hormones","MLLNCUMT","Million of national currency units","EST","Estonia","2012","2012",11.2,,
+"PATCGENU","G-Genito urinary system and sex hormones","MLLNCUMT","Million of national currency units","EST","Estonia","2013","2013",11.4,,
+"PATCGENU","G-Genito urinary system and sex hormones","MLLNCUMT","Million of national currency units","EST","Estonia","2014","2014",11.5,,
+"PATCGENU","G-Genito urinary system and sex hormones","MLLNCUMT","Million of national currency units","EST","Estonia","2015","2015",11.6,,
+"PATCGENU","G-Genito urinary system and sex hormones","MLLNCUMT","Million of national currency units","EST","Estonia","2016","2016",11.6,,
+"PATCGENU","G-Genito urinary system and sex hormones","MLLNCUMT","Million of national currency units","EST","Estonia","2017","2017",11.5,,
+"PATCGENU","G-Genito urinary system and sex hormones","MLLNCUMT","Million of national currency units","EST","Estonia","2018","2018",11.8,,
+"PATCGENU","G-Genito urinary system and sex hormones","MLLNCUMT","Million of national currency units","EST","Estonia","2019","2019",12.3,,
+"PATCGENU","G-Genito urinary system and sex hormones","MLLNCUMT","Million of national currency units","EST","Estonia","2020","2020",11.9,,
+"PATCGENU","G-Genito urinary system and sex hormones","MLLNCUMT","Million of national currency units","EST","Estonia","2021","2021",12.1,,
+"PATCGENU","G-Genito urinary system and sex hormones","MLLNCUMT","Million of national currency units","EST","Estonia","2022","2022",12.9,,
+"PATCGENU","G-Genito urinary system and sex hormones","MTMOTCMT","Million US$ at exchange rate","EST","Estonia","2010","2010",14.1,,
+"PATCGENU","G-Genito urinary system and sex hormones","MTMOTCMT","Million US$ at exchange rate","EST","Estonia","2011","2011",15,,
+"PATCGENU","G-Genito urinary system and sex hormones","MTMOTCMT","Million US$ at exchange rate","EST","Estonia","2012","2012",14.4,,
+"PATCGENU","G-Genito urinary system and sex hormones","MTMOTCMT","Million US$ at exchange rate","EST","Estonia","2013","2013",15.2,,
+"PATCGENU","G-Genito urinary system and sex hormones","MTMOTCMT","Million US$ at exchange rate","EST","Estonia","2014","2014",15.3,,
+"PATCGENU","G-Genito urinary system and sex hormones","MTMOTCMT","Million US$ at exchange rate","EST","Estonia","2015","2015",12.9,,
+"PATCGENU","G-Genito urinary system and sex hormones","MTMOTCMT","Million US$ at exchange rate","EST","Estonia","2016","2016",12.8,,
+"PATCGENU","G-Genito urinary system and sex hormones","MTMOTCMT","Million US$ at exchange rate","EST","Estonia","2017","2017",13,,
+"PATCGENU","G-Genito urinary system and sex hormones","MTMOTCMT","Million US$ at exchange rate","EST","Estonia","2018","2018",13.9,,
+"PATCGENU","G-Genito urinary system and sex hormones","MTMOTCMT","Million US$ at exchange rate","EST","Estonia","2019","2019",13.8,,
+"PATCGENU","G-Genito urinary system and sex hormones","MTMOTCMT","Million US$ at exchange rate","EST","Estonia","2020","2020",13.6,,
+"PATCGENU","G-Genito urinary system and sex hormones","MTMOTCMT","Million US$ at exchange rate","EST","Estonia","2021","2021",14.3,,
+"PATCGENU","G-Genito urinary system and sex hormones","MTMOTCMT","Million US$ at exchange rate","EST","Estonia","2022","2022",13.6,,
+"PATCGENU","G-Genito urinary system and sex hormones","MTMOPPMT","Million US$, purchasing power parity","EST","Estonia","2010","2010",20.7,,
+"PATCGENU","G-Genito urinary system and sex hormones","MTMOPPMT","Million US$, purchasing power parity","EST","Estonia","2011","2011",21.1,,
+"PATCGENU","G-Genito urinary system and sex hormones","MTMOPPMT","Million US$, purchasing power parity","EST","Estonia","2012","2012",21.5,,
+"PATCGENU","G-Genito urinary system and sex hormones","MTMOPPMT","Million US$, purchasing power parity","EST","Estonia","2013","2013",21.9,,
+"PATCGENU","G-Genito urinary system and sex hormones","MTMOPPMT","Million US$, purchasing power parity","EST","Estonia","2014","2014",21.8,,
+"PATCGENU","G-Genito urinary system and sex hormones","MTMOPPMT","Million US$, purchasing power parity","EST","Estonia","2015","2015",21.6,,
+"PATCGENU","G-Genito urinary system and sex hormones","MTMOPPMT","Million US$, purchasing power parity","EST","Estonia","2016","2016",22,,
+"PATCGENU","G-Genito urinary system and sex hormones","MTMOPPMT","Million US$, purchasing power parity","EST","Estonia","2017","2017",21.6,,
+"PATCGENU","G-Genito urinary system and sex hormones","MTMOPPMT","Million US$, purchasing power parity","EST","Estonia","2018","2018",21.9,,
+"PATCGENU","G-Genito urinary system and sex hormones","MTMOPPMT","Million US$, purchasing power parity","EST","Estonia","2019","2019",23,,
+"PATCGENU","G-Genito urinary system and sex hormones","MTMOPPMT","Million US$, purchasing power parity","EST","Estonia","2020","2020",22.7,,
+"PATCGENU","G-Genito urinary system and sex hormones","MTMOPPMT","Million US$, purchasing power parity","EST","Estonia","2021","2021",22.2,,
+"PATCGENU","G-Genito urinary system and sex hormones","MTMOPPMT","Million US$, purchasing power parity","EST","Estonia","2022","2022",22.7,,
+"PATCGENU","G-Genito urinary system and sex hormones","TCPPERMT","/capita, US$ exchange rate","EST","Estonia","2010","2010",10.6,,
+"PATCGENU","G-Genito urinary system and sex hormones","TCPPERMT","/capita, US$ exchange rate","EST","Estonia","2011","2011",11.3,,
+"PATCGENU","G-Genito urinary system and sex hormones","TCPPERMT","/capita, US$ exchange rate","EST","Estonia","2012","2012",10.9,,
+"PATCGENU","G-Genito urinary system and sex hormones","TCPPERMT","/capita, US$ exchange rate","EST","Estonia","2013","2013",11.5,,
+"PATCGENU","G-Genito urinary system and sex hormones","TCPPERMT","/capita, US$ exchange rate","EST","Estonia","2014","2014",11.6,,
+"PATCGENU","G-Genito urinary system and sex hormones","TCPPERMT","/capita, US$ exchange rate","EST","Estonia","2015","2015",9.8,,
+"PATCGENU","G-Genito urinary system and sex hormones","TCPPERMT","/capita, US$ exchange rate","EST","Estonia","2016","2016",9.8,,
+"PATCGENU","G-Genito urinary system and sex hormones","TCPPERMT","/capita, US$ exchange rate","EST","Estonia","2017","2017",9.9,,
+"PATCGENU","G-Genito urinary system and sex hormones","TCPPERMT","/capita, US$ exchange rate","EST","Estonia","2018","2018",10.5,,
+"PATCGENU","G-Genito urinary system and sex hormones","TCPPERMT","/capita, US$ exchange rate","EST","Estonia","2019","2019",10.4,,
+"PATCGENU","G-Genito urinary system and sex hormones","TCPPERMT","/capita, US$ exchange rate","EST","Estonia","2020","2020",10.2,,
+"PATCGENU","G-Genito urinary system and sex hormones","TCPPERMT","/capita, US$ exchange rate","EST","Estonia","2021","2021",10.7,,
+"PATCGENU","G-Genito urinary system and sex hormones","TCPPERMT","/capita, US$ exchange rate","EST","Estonia","2022","2022",10.2,,
+"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2010","2010",15.6,,
+"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2011","2011",15.9,,
+"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2012","2012",16.2,,
+"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2013","2013",16.6,,
+"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2014","2014",16.6,,
+"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2015","2015",16.4,,
+"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2016","2016",16.7,,
+"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2017","2017",16.4,,
+"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2018","2018",16.5,,
+"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2019","2019",17.3,,
+"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2020","2020",17.1,,
+"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2021","2021",16.7,,
+"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2022","2022",17,,
+"PATCGENU","G-Genito urinary system and sex hormones","ATCPTTMT","% of total sales","EST","Estonia","2010","2010",5.5,,
+"PATCGENU","G-Genito urinary system and sex hormones","ATCPTTMT","% of total sales","EST","Estonia","2011","2011",5.3,,
+"PATCGENU","G-Genito urinary system and sex hormones","ATCPTTMT","% of total sales","EST","Estonia","2012","2012",5,,
+"PATCGENU","G-Genito urinary system and sex hormones","ATCPTTMT","% of total sales","EST","Estonia","2013","2013",5,,
+"PATCGENU","G-Genito urinary system and sex hormones","ATCPTTMT","% of total sales","EST","Estonia","2014","2014",4.6,,
+"PATCGENU","G-Genito urinary system and sex hormones","ATCPTTMT","% of total sales","EST","Estonia","2015","2015",4.4,,
+"PATCGENU","G-Genito urinary system and sex hormones","ATCPTTMT","% of total sales","EST","Estonia","2016","2016",4,,
+"PATCGENU","G-Genito urinary system and sex hormones","ATCPTTMT","% of total sales","EST","Estonia","2017","2017",3.8,,
+"PATCGENU","G-Genito urinary system and sex hormones","ATCPTTMT","% of total sales","EST","Estonia","2018","2018",3.6,,
+"PATCGENU","G-Genito urinary system and sex hormones","ATCPTTMT","% of total sales","EST","Estonia","2019","2019",3.6,,
+"PATCGENU","G-Genito urinary system and sex hormones","ATCPTTMT","% of total sales","EST","Estonia","2020","2020",3.3,,
+"PATCGENU","G-Genito urinary system and sex hormones","ATCPTTMT","% of total sales","EST","Estonia","2021","2021",3,,
+"PATCGENU","G-Genito urinary system and sex hormones","ATCPTTMT","% of total sales","EST","Estonia","2022","2022",3,,
+"PATCGENU","G-Genito urinary system and sex hormones","MLLNCUMT","Million of national currency units","SVN","Slovenia","2010","2010",26.3,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","MLLNCUMT","Million of national currency units","SVN","Slovenia","2011","2011",26.3,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","MLLNCUMT","Million of national currency units","SVN","Slovenia","2012","2012",24.7,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","MLLNCUMT","Million of national currency units","SVN","Slovenia","2013","2013",23.5,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","MLLNCUMT","Million of national currency units","SVN","Slovenia","2014","2014",23.8,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","MLLNCUMT","Million of national currency units","SVN","Slovenia","2015","2015",22.6,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","MLLNCUMT","Million of national currency units","SVN","Slovenia","2016","2016",23.5,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","MLLNCUMT","Million of national currency units","SVN","Slovenia","2017","2017",23.8,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","MLLNCUMT","Million of national currency units","SVN","Slovenia","2018","2018",22.6,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","MLLNCUMT","Million of national currency units","SVN","Slovenia","2019","2019",22.9,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","MLLNCUMT","Million of national currency units","SVN","Slovenia","2020","2020",21.4,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","MLLNCUMT","Million of national currency units","SVN","Slovenia","2021","2021",19.3,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","MLLNCUMT","Million of national currency units","SVN","Slovenia","2022","2022",19.7,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","MTMOTCMT","Million US$ at exchange rate","SVN","Slovenia","2010","2010",34.9,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","MTMOTCMT","Million US$ at exchange rate","SVN","Slovenia","2011","2011",36.7,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","MTMOTCMT","Million US$ at exchange rate","SVN","Slovenia","2012","2012",31.7,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","MTMOTCMT","Million US$ at exchange rate","SVN","Slovenia","2013","2013",31.1,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","MTMOTCMT","Million US$ at exchange rate","SVN","Slovenia","2014","2014",31.6,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","MTMOTCMT","Million US$ at exchange rate","SVN","Slovenia","2015","2015",25.1,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","MTMOTCMT","Million US$ at exchange rate","SVN","Slovenia","2016","2016",26,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","MTMOTCMT","Million US$ at exchange rate","SVN","Slovenia","2017","2017",26.9,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","MTMOTCMT","Million US$ at exchange rate","SVN","Slovenia","2018","2018",26.7,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","MTMOTCMT","Million US$ at exchange rate","SVN","Slovenia","2019","2019",25.6,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","MTMOTCMT","Million US$ at exchange rate","SVN","Slovenia","2020","2020",24.4,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","MTMOTCMT","Million US$ at exchange rate","SVN","Slovenia","2021","2021",22.8,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","MTMOTCMT","Million US$ at exchange rate","SVN","Slovenia","2022","2022",20.7,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","MTMOPPMT","Million US$, purchasing power parity","SVN","Slovenia","2010","2010",41.2,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","MTMOPPMT","Million US$, purchasing power parity","SVN","Slovenia","2011","2011",42.2,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","MTMOPPMT","Million US$, purchasing power parity","SVN","Slovenia","2012","2012",40.7,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","MTMOPPMT","Million US$, purchasing power parity","SVN","Slovenia","2013","2013",39.7,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","MTMOPPMT","Million US$, purchasing power parity","SVN","Slovenia","2014","2014",40.2,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","MTMOPPMT","Million US$, purchasing power parity","SVN","Slovenia","2015","2015",38,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","MTMOPPMT","Million US$, purchasing power parity","SVN","Slovenia","2016","2016",40.7,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","MTMOPPMT","Million US$, purchasing power parity","SVN","Slovenia","2017","2017",41.7,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","MTMOPPMT","Million US$, purchasing power parity","SVN","Slovenia","2018","2018",39.8,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","MTMOPPMT","Million US$, purchasing power parity","SVN","Slovenia","2019","2019",41.4,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","MTMOPPMT","Million US$, purchasing power parity","SVN","Slovenia","2020","2020",39.1,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","MTMOPPMT","Million US$, purchasing power parity","SVN","Slovenia","2021","2021",34.2,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","MTMOPPMT","Million US$, purchasing power parity","SVN","Slovenia","2022","2022",35.7,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","TCPPERMT","/capita, US$ exchange rate","SVN","Slovenia","2010","2010",17,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","TCPPERMT","/capita, US$ exchange rate","SVN","Slovenia","2011","2011",17.9,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","TCPPERMT","/capita, US$ exchange rate","SVN","Slovenia","2012","2012",15.4,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","TCPPERMT","/capita, US$ exchange rate","SVN","Slovenia","2013","2013",15.1,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","TCPPERMT","/capita, US$ exchange rate","SVN","Slovenia","2014","2014",15.3,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","TCPPERMT","/capita, US$ exchange rate","SVN","Slovenia","2015","2015",12.2,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","TCPPERMT","/capita, US$ exchange rate","SVN","Slovenia","2016","2016",12.6,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","TCPPERMT","/capita, US$ exchange rate","SVN","Slovenia","2017","2017",13,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","TCPPERMT","/capita, US$ exchange rate","SVN","Slovenia","2018","2018",12.9,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","TCPPERMT","/capita, US$ exchange rate","SVN","Slovenia","2019","2019",12.3,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","TCPPERMT","/capita, US$ exchange rate","SVN","Slovenia","2020","2020",11.6,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","TCPPERMT","/capita, US$ exchange rate","SVN","Slovenia","2021","2021",10.8,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","TCPPERMT","/capita, US$ exchange rate","SVN","Slovenia","2022","2022",9.8,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2010","2010",20.1,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2011","2011",20.6,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2012","2012",19.8,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2013","2013",19.3,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2014","2014",19.5,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2015","2015",18.4,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2016","2016",19.7,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2017","2017",20.2,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2018","2018",19.2,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2019","2019",19.8,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2020","2020",18.6,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2021","2021",16.2,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2022","2022",16.9,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","ATCPTTMT","% of total sales","SVN","Slovenia","2010","2010",5.5,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","ATCPTTMT","% of total sales","SVN","Slovenia","2011","2011",5.6,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","ATCPTTMT","% of total sales","SVN","Slovenia","2012","2012",5.4,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","ATCPTTMT","% of total sales","SVN","Slovenia","2013","2013",5.2,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","ATCPTTMT","% of total sales","SVN","Slovenia","2014","2014",5.5,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","ATCPTTMT","% of total sales","SVN","Slovenia","2015","2015",5.1,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","ATCPTTMT","% of total sales","SVN","Slovenia","2016","2016",5,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","ATCPTTMT","% of total sales","SVN","Slovenia","2017","2017",4.9,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","ATCPTTMT","% of total sales","SVN","Slovenia","2018","2018",4.4,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","ATCPTTMT","% of total sales","SVN","Slovenia","2019","2019",4.2,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","ATCPTTMT","% of total sales","SVN","Slovenia","2020","2020",3.8,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","ATCPTTMT","% of total sales","SVN","Slovenia","2021","2021",3.1,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","ATCPTTMT","% of total sales","SVN","Slovenia","2022","2022",2.9,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MLLNCUMT","Million of national currency units","AUS","Australia","2010","2010",100,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MLLNCUMT","Million of national currency units","AUS","Australia","2011","2011",100,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MLLNCUMT","Million of national currency units","AUS","Australia","2012","2012",103,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MLLNCUMT","Million of national currency units","AUS","Australia","2013","2013",160,"B; D","Break; Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MLLNCUMT","Million of national currency units","AUS","Australia","2014","2014",167,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MLLNCUMT","Million of national currency units","AUS","Australia","2015","2015",220,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MLLNCUMT","Million of national currency units","AUS","Australia","2016","2016",278,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MLLNCUMT","Million of national currency units","AUS","Australia","2017","2017",271,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MLLNCUMT","Million of national currency units","AUS","Australia","2018","2018",272,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MLLNCUMT","Million of national currency units","AUS","Australia","2019","2019",282,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MLLNCUMT","Million of national currency units","AUS","Australia","2020","2020",295,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MLLNCUMT","Million of national currency units","AUS","Australia","2021","2021",321,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOTCMT","Million US$ at exchange rate","AUS","Australia","2010","2010",91.7,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOTCMT","Million US$ at exchange rate","AUS","Australia","2011","2011",103.1,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOTCMT","Million US$ at exchange rate","AUS","Australia","2012","2012",106.6,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOTCMT","Million US$ at exchange rate","AUS","Australia","2013","2013",154.5,"B; D","Break; Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOTCMT","Million US$ at exchange rate","AUS","Australia","2014","2014",150.5,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOTCMT","Million US$ at exchange rate","AUS","Australia","2015","2015",165.3,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOTCMT","Million US$ at exchange rate","AUS","Australia","2016","2016",206.7,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOTCMT","Million US$ at exchange rate","AUS","Australia","2017","2017",207.7,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOTCMT","Million US$ at exchange rate","AUS","Australia","2018","2018",203.2,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOTCMT","Million US$ at exchange rate","AUS","Australia","2019","2019",196,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOTCMT","Million US$ at exchange rate","AUS","Australia","2020","2020",203,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOTCMT","Million US$ at exchange rate","AUS","Australia","2021","2021",241.1,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOPPMT","Million US$, purchasing power parity","AUS","Australia","2010","2010",66.5,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOPPMT","Million US$, purchasing power parity","AUS","Australia","2011","2011",66.2,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOPPMT","Million US$, purchasing power parity","AUS","Australia","2012","2012",66.9,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOPPMT","Million US$, purchasing power parity","AUS","Australia","2013","2013",110.6,"B; D","Break; Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOPPMT","Million US$, purchasing power parity","AUS","Australia","2014","2014",115,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOPPMT","Million US$, purchasing power parity","AUS","Australia","2015","2015",149.3,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOPPMT","Million US$, purchasing power parity","AUS","Australia","2016","2016",191.7,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOPPMT","Million US$, purchasing power parity","AUS","Australia","2017","2017",183.4,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOPPMT","Million US$, purchasing power parity","AUS","Australia","2018","2018",185,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOPPMT","Million US$, purchasing power parity","AUS","Australia","2019","2019",190.6,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOPPMT","Million US$, purchasing power parity","AUS","Australia","2020","2020",202.9,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOPPMT","Million US$, purchasing power parity","AUS","Australia","2021","2021",221.7,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","TCPPERMT","/capita, US$ exchange rate","AUS","Australia","2010","2010",4.2,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","TCPPERMT","/capita, US$ exchange rate","AUS","Australia","2011","2011",4.6,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","TCPPERMT","/capita, US$ exchange rate","AUS","Australia","2012","2012",4.7,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","TCPPERMT","/capita, US$ exchange rate","AUS","Australia","2013","2013",6.7,"B; D","Break; Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","TCPPERMT","/capita, US$ exchange rate","AUS","Australia","2014","2014",6.4,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","TCPPERMT","/capita, US$ exchange rate","AUS","Australia","2015","2015",6.9,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","TCPPERMT","/capita, US$ exchange rate","AUS","Australia","2016","2016",8.5,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","TCPPERMT","/capita, US$ exchange rate","AUS","Australia","2017","2017",8.4,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","TCPPERMT","/capita, US$ exchange rate","AUS","Australia","2018","2018",8.1,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","TCPPERMT","/capita, US$ exchange rate","AUS","Australia","2019","2019",7.7,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","TCPPERMT","/capita, US$ exchange rate","AUS","Australia","2020","2020",7.9,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","TCPPERMT","/capita, US$ exchange rate","AUS","Australia","2021","2021",9.4,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2010","2010",3,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2011","2011",3,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2012","2012",2.9,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2013","2013",4.8,"B; D","Break; Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2014","2014",4.9,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2015","2015",6.3,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2016","2016",7.9,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2017","2017",7.5,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2018","2018",7.4,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2019","2019",7.5,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2020","2020",7.9,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2021","2021",8.6,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","ATCPTTMT","% of total sales","AUS","Australia","2010","2010",1,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","ATCPTTMT","% of total sales","AUS","Australia","2011","2011",1,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","ATCPTTMT","% of total sales","AUS","Australia","2012","2012",1,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","ATCPTTMT","% of total sales","AUS","Australia","2013","2013",1.4,"B; D","Break; Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","ATCPTTMT","% of total sales","AUS","Australia","2014","2014",1.4,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","ATCPTTMT","% of total sales","AUS","Australia","2015","2015",1.8,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","ATCPTTMT","% of total sales","AUS","Australia","2016","2016",1.8,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","ATCPTTMT","% of total sales","AUS","Australia","2017","2017",1.8,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","ATCPTTMT","% of total sales","AUS","Australia","2018","2018",1.8,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","ATCPTTMT","% of total sales","AUS","Australia","2019","2019",1.8,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","ATCPTTMT","% of total sales","AUS","Australia","2020","2020",1.8,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","ATCPTTMT","% of total sales","AUS","Australia","2021","2021",1.8,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MLLNCUMT","Million of national currency units","AUT","Austria","2010","2010",14.5,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MLLNCUMT","Million of national currency units","AUT","Austria","2011","2011",13.9,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MLLNCUMT","Million of national currency units","AUT","Austria","2012","2012",13.7,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MLLNCUMT","Million of national currency units","AUT","Austria","2013","2013",14,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MLLNCUMT","Million of national currency units","AUT","Austria","2014","2014",13.1,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MLLNCUMT","Million of national currency units","AUT","Austria","2015","2015",13,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MLLNCUMT","Million of national currency units","AUT","Austria","2016","2016",13.4,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MLLNCUMT","Million of national currency units","AUT","Austria","2017","2017",13.4,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MLLNCUMT","Million of national currency units","AUT","Austria","2018","2018",12.1,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MLLNCUMT","Million of national currency units","AUT","Austria","2019","2019",12.1,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MLLNCUMT","Million of national currency units","AUT","Austria","2020","2020",11.7,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MLLNCUMT","Million of national currency units","AUT","Austria","2021","2021",11.9,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOTCMT","Million US$ at exchange rate","AUT","Austria","2010","2010",19.3,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOTCMT","Million US$ at exchange rate","AUT","Austria","2011","2011",19.3,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOTCMT","Million US$ at exchange rate","AUT","Austria","2012","2012",17.6,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOTCMT","Million US$ at exchange rate","AUT","Austria","2013","2013",18.6,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOTCMT","Million US$ at exchange rate","AUT","Austria","2014","2014",17.4,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOTCMT","Million US$ at exchange rate","AUT","Austria","2015","2015",14.4,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOTCMT","Million US$ at exchange rate","AUT","Austria","2016","2016",14.9,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOTCMT","Million US$ at exchange rate","AUT","Austria","2017","2017",15.2,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOTCMT","Million US$ at exchange rate","AUT","Austria","2018","2018",14.3,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOTCMT","Million US$ at exchange rate","AUT","Austria","2019","2019",13.6,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOTCMT","Million US$ at exchange rate","AUT","Austria","2020","2020",13.4,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOTCMT","Million US$ at exchange rate","AUT","Austria","2021","2021",14.1,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOPPMT","Million US$, purchasing power parity","AUT","Austria","2010","2010",17.3,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOPPMT","Million US$, purchasing power parity","AUT","Austria","2011","2011",16.7,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOPPMT","Million US$, purchasing power parity","AUT","Austria","2012","2012",16.8,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOPPMT","Million US$, purchasing power parity","AUT","Austria","2013","2013",17.5,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOPPMT","Million US$, purchasing power parity","AUT","Austria","2014","2014",16.4,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOPPMT","Million US$, purchasing power parity","AUT","Austria","2015","2015",16.3,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOPPMT","Million US$, purchasing power parity","AUT","Austria","2016","2016",17.3,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOPPMT","Million US$, purchasing power parity","AUT","Austria","2017","2017",17.3,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOPPMT","Million US$, purchasing power parity","AUT","Austria","2018","2018",15.8,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOPPMT","Million US$, purchasing power parity","AUT","Austria","2019","2019",16.2,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOPPMT","Million US$, purchasing power parity","AUT","Austria","2020","2020",15.7,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOPPMT","Million US$, purchasing power parity","AUT","Austria","2021","2021",15.7,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","TCPPERMT","/capita, US$ exchange rate","AUT","Austria","2010","2010",2.3,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","TCPPERMT","/capita, US$ exchange rate","AUT","Austria","2011","2011",2.3,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","TCPPERMT","/capita, US$ exchange rate","AUT","Austria","2012","2012",2.1,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","TCPPERMT","/capita, US$ exchange rate","AUT","Austria","2013","2013",2.2,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","TCPPERMT","/capita, US$ exchange rate","AUT","Austria","2014","2014",2,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","TCPPERMT","/capita, US$ exchange rate","AUT","Austria","2015","2015",1.7,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","TCPPERMT","/capita, US$ exchange rate","AUT","Austria","2016","2016",1.7,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","TCPPERMT","/capita, US$ exchange rate","AUT","Austria","2017","2017",1.7,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","TCPPERMT","/capita, US$ exchange rate","AUT","Austria","2018","2018",1.6,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","TCPPERMT","/capita, US$ exchange rate","AUT","Austria","2019","2019",1.5,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","TCPPERMT","/capita, US$ exchange rate","AUT","Austria","2020","2020",1.5,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","TCPPERMT","/capita, US$ exchange rate","AUT","Austria","2021","2021",1.6,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2010","2010",2.1,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2011","2011",2,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2012","2012",2,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2013","2013",2.1,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2014","2014",1.9,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2015","2015",1.9,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2016","2016",2,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2017","2017",2,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2018","2018",1.8,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2019","2019",1.8,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2020","2020",1.8,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2021","2021",1.8,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","ATCPTTMT","% of total sales","AUT","Austria","2010","2010",0.6,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","ATCPTTMT","% of total sales","AUT","Austria","2011","2011",0.5,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","ATCPTTMT","% of total sales","AUT","Austria","2012","2012",0.5,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","ATCPTTMT","% of total sales","AUT","Austria","2013","2013",0.5,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","ATCPTTMT","% of total sales","AUT","Austria","2014","2014",0.5,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","ATCPTTMT","% of total sales","AUT","Austria","2015","2015",0.4,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","ATCPTTMT","% of total sales","AUT","Austria","2016","2016",0.4,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","ATCPTTMT","% of total sales","AUT","Austria","2017","2017",0.4,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","ATCPTTMT","% of total sales","AUT","Austria","2018","2018",0.4,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","ATCPTTMT","% of total sales","AUT","Austria","2019","2019",0.4,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","ATCPTTMT","% of total sales","AUT","Austria","2020","2020",0.3,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","ATCPTTMT","% of total sales","AUT","Austria","2021","2021",0.3,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MLLNCUMT","Million of national currency units","BEL","Belgium","2010","2010",135.6,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MLLNCUMT","Million of national currency units","BEL","Belgium","2011","2011",132.5,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MLLNCUMT","Million of national currency units","BEL","Belgium","2012","2012",124.1,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MLLNCUMT","Million of national currency units","BEL","Belgium","2013","2013",118,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MLLNCUMT","Million of national currency units","BEL","Belgium","2014","2014",113.7,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MLLNCUMT","Million of national currency units","BEL","Belgium","2015","2015",111,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MLLNCUMT","Million of national currency units","BEL","Belgium","2016","2016",109.3,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MLLNCUMT","Million of national currency units","BEL","Belgium","2017","2017",108,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MLLNCUMT","Million of national currency units","BEL","Belgium","2018","2018",106.5,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MLLNCUMT","Million of national currency units","BEL","Belgium","2019","2019",109.8,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MLLNCUMT","Million of national currency units","BEL","Belgium","2020","2020",105.5,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MLLNCUMT","Million of national currency units","BEL","Belgium","2021","2021",106.4,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MLLNCUMT","Million of national currency units","BEL","Belgium","2022","2022",108.9,"E","Estimated value"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOTCMT","Million US$ at exchange rate","BEL","Belgium","2010","2010",179.8,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOTCMT","Million US$ at exchange rate","BEL","Belgium","2011","2011",184.5,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOTCMT","Million US$ at exchange rate","BEL","Belgium","2012","2012",159.5,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOTCMT","Million US$ at exchange rate","BEL","Belgium","2013","2013",156.7,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOTCMT","Million US$ at exchange rate","BEL","Belgium","2014","2014",151,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOTCMT","Million US$ at exchange rate","BEL","Belgium","2015","2015",123.2,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOTCMT","Million US$ at exchange rate","BEL","Belgium","2016","2016",121,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOTCMT","Million US$ at exchange rate","BEL","Belgium","2017","2017",122,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOTCMT","Million US$ at exchange rate","BEL","Belgium","2018","2018",125.8,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOTCMT","Million US$ at exchange rate","BEL","Belgium","2019","2019",122.9,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOTCMT","Million US$ at exchange rate","BEL","Belgium","2020","2020",120.5,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOTCMT","Million US$ at exchange rate","BEL","Belgium","2021","2021",125.9,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOTCMT","Million US$ at exchange rate","BEL","Belgium","2022","2022",114.7,"E","Estimated value"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOPPMT","Million US$, purchasing power parity","BEL","Belgium","2010","2010",162.1,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOPPMT","Million US$, purchasing power parity","BEL","Belgium","2011","2011",159.3,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOPPMT","Million US$, purchasing power parity","BEL","Belgium","2012","2012",151,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOPPMT","Million US$, purchasing power parity","BEL","Belgium","2013","2013",146.4,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOPPMT","Million US$, purchasing power parity","BEL","Belgium","2014","2014",142,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOPPMT","Million US$, purchasing power parity","BEL","Belgium","2015","2015",138.8,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOPPMT","Million US$, purchasing power parity","BEL","Belgium","2016","2016",140,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOPPMT","Million US$, purchasing power parity","BEL","Belgium","2017","2017",139.2,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOPPMT","Million US$, purchasing power parity","BEL","Belgium","2018","2018",139,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOPPMT","Million US$, purchasing power parity","BEL","Belgium","2019","2019",147.1,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOPPMT","Million US$, purchasing power parity","BEL","Belgium","2020","2020",144.4,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOPPMT","Million US$, purchasing power parity","BEL","Belgium","2021","2021",144.5,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOPPMT","Million US$, purchasing power parity","BEL","Belgium","2022","2022",152.6,"E","Estimated value"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","TCPPERMT","/capita, US$ exchange rate","BEL","Belgium","2010","2010",16.5,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","TCPPERMT","/capita, US$ exchange rate","BEL","Belgium","2011","2011",16.7,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","TCPPERMT","/capita, US$ exchange rate","BEL","Belgium","2012","2012",14.4,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","TCPPERMT","/capita, US$ exchange rate","BEL","Belgium","2013","2013",14,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","TCPPERMT","/capita, US$ exchange rate","BEL","Belgium","2014","2014",13.5,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","TCPPERMT","/capita, US$ exchange rate","BEL","Belgium","2015","2015",10.9,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","TCPPERMT","/capita, US$ exchange rate","BEL","Belgium","2016","2016",10.7,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","TCPPERMT","/capita, US$ exchange rate","BEL","Belgium","2017","2017",10.7,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","TCPPERMT","/capita, US$ exchange rate","BEL","Belgium","2018","2018",11,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","TCPPERMT","/capita, US$ exchange rate","BEL","Belgium","2019","2019",10.7,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","TCPPERMT","/capita, US$ exchange rate","BEL","Belgium","2020","2020",10.4,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","TCPPERMT","/capita, US$ exchange rate","BEL","Belgium","2021","2021",10.9,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","TCPPERMT","/capita, US$ exchange rate","BEL","Belgium","2022","2022",9.9,"E","Estimated value"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2010","2010",14.9,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2011","2011",14.4,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2012","2012",13.6,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2013","2013",13.1,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2014","2014",12.7,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2015","2015",12.3,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2016","2016",12.4,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2017","2017",12.2,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2018","2018",12.2,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2019","2019",12.8,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2020","2020",12.5,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2021","2021",12.5,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2022","2022",13.1,"E","Estimated value"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","ATCPTTMT","% of total sales","BEL","Belgium","2010","2010",2.3,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","ATCPTTMT","% of total sales","BEL","Belgium","2011","2011",2.2,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","ATCPTTMT","% of total sales","BEL","Belgium","2012","2012",2.1,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","ATCPTTMT","% of total sales","BEL","Belgium","2013","2013",2,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","ATCPTTMT","% of total sales","BEL","Belgium","2014","2014",1.9,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","ATCPTTMT","% of total sales","BEL","Belgium","2015","2015",1.8,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","ATCPTTMT","% of total sales","BEL","Belgium","2016","2016",1.8,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","ATCPTTMT","% of total sales","BEL","Belgium","2017","2017",1.7,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","ATCPTTMT","% of total sales","BEL","Belgium","2018","2018",1.6,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","ATCPTTMT","% of total sales","BEL","Belgium","2019","2019",1.5,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","ATCPTTMT","% of total sales","BEL","Belgium","2020","2020",1.4,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","ATCPTTMT","% of total sales","BEL","Belgium","2021","2021",1.3,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","ATCPTTMT","% of total sales","BEL","Belgium","2022","2022",1.2,"E","Estimated value"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MLLNCUMT","Million of national currency units","CAN","Canada","2012","2012",751.1,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MLLNCUMT","Million of national currency units","CAN","Canada","2013","2013",784.7,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MLLNCUMT","Million of national currency units","CAN","Canada","2014","2014",798.1,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MLLNCUMT","Million of national currency units","CAN","Canada","2015","2015",809.3,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MLLNCUMT","Million of national currency units","CAN","Canada","2016","2016",804.9,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MLLNCUMT","Million of national currency units","CAN","Canada","2017","2017",813.5,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MLLNCUMT","Million of national currency units","CAN","Canada","2018","2018",827.7,"E; B; D","Estimated value; Break; Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MLLNCUMT","Million of national currency units","CAN","Canada","2019","2019",813.7,"E; D","Estimated value; Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MLLNCUMT","Million of national currency units","CAN","Canada","2020","2020",787,"E; D","Estimated value; Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MLLNCUMT","Million of national currency units","CAN","Canada","2021","2021",767.7,"E; D","Estimated value; Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MLLNCUMT","Million of national currency units","CAN","Canada","2022","2022",761.9,"E; D","Estimated value; Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOTCMT","Million US$ at exchange rate","CAN","Canada","2012","2012",751.6,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOTCMT","Million US$ at exchange rate","CAN","Canada","2013","2013",761.7,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOTCMT","Million US$ at exchange rate","CAN","Canada","2014","2014",722.4,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOTCMT","Million US$ at exchange rate","CAN","Canada","2015","2015",632.9,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOTCMT","Million US$ at exchange rate","CAN","Canada","2016","2016",607.2,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOTCMT","Million US$ at exchange rate","CAN","Canada","2017","2017",626.8,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOTCMT","Million US$ at exchange rate","CAN","Canada","2018","2018",638.7,"E; B; D","Estimated value; Break; Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOTCMT","Million US$ at exchange rate","CAN","Canada","2019","2019",613.3,"E; D","Estimated value; Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOTCMT","Million US$ at exchange rate","CAN","Canada","2020","2020",586.8,"E; D","Estimated value; Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOTCMT","Million US$ at exchange rate","CAN","Canada","2021","2021",612.3,"E; D","Estimated value; Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOTCMT","Million US$ at exchange rate","CAN","Canada","2022","2022",585.4,"E; D","Estimated value; Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOPPMT","Million US$, purchasing power parity","CAN","Canada","2012","2012",603.5,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOPPMT","Million US$, purchasing power parity","CAN","Canada","2013","2013",641.1,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOPPMT","Million US$, purchasing power parity","CAN","Canada","2014","2014",648.7,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOPPMT","Million US$, purchasing power parity","CAN","Canada","2015","2015",648.5,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOPPMT","Million US$, purchasing power parity","CAN","Canada","2016","2016",666.8,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOPPMT","Million US$, purchasing power parity","CAN","Canada","2017","2017",671,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOPPMT","Million US$, purchasing power parity","CAN","Canada","2018","2018",686,"E; B; D","Estimated value; Break; Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOPPMT","Million US$, purchasing power parity","CAN","Canada","2019","2019",659.1,"E; D","Estimated value; Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOPPMT","Million US$, purchasing power parity","CAN","Canada","2020","2020",639.3,"E; D","Estimated value; Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOPPMT","Million US$, purchasing power parity","CAN","Canada","2021","2021",620,"E; D","Estimated value; Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOPPMT","Million US$, purchasing power parity","CAN","Canada","2022","2022",607.7,"E; D","Estimated value; Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","TCPPERMT","/capita, US$ exchange rate","CAN","Canada","2012","2012",21.7,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","TCPPERMT","/capita, US$ exchange rate","CAN","Canada","2013","2013",21.7,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","TCPPERMT","/capita, US$ exchange rate","CAN","Canada","2014","2014",20.4,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","TCPPERMT","/capita, US$ exchange rate","CAN","Canada","2015","2015",17.7,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","TCPPERMT","/capita, US$ exchange rate","CAN","Canada","2016","2016",16.8,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","TCPPERMT","/capita, US$ exchange rate","CAN","Canada","2017","2017",17.2,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","TCPPERMT","/capita, US$ exchange rate","CAN","Canada","2018","2018",17.2,"E; B; D","Estimated value; Break; Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","TCPPERMT","/capita, US$ exchange rate","CAN","Canada","2019","2019",16.3,"E; D","Estimated value; Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","TCPPERMT","/capita, US$ exchange rate","CAN","Canada","2020","2020",15.4,"E; D","Estimated value; Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","TCPPERMT","/capita, US$ exchange rate","CAN","Canada","2021","2021",16,"E; D","Estimated value; Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","TCPPERMT","/capita, US$ exchange rate","CAN","Canada","2022","2022",15.1,"E; D","Estimated value; Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2012","2012",17.4,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2013","2013",18.3,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2014","2014",18.3,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2015","2015",18.2,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2016","2016",18.5,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2017","2017",18.4,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2018","2018",18.5,"E; B; D","Estimated value; Break; Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2019","2019",17.5,"E; D","Estimated value; Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2020","2020",16.8,"E; D","Estimated value; Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2021","2021",16.2,"E; D","Estimated value; Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2022","2022",15.6,"E; D","Estimated value; Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","ATCPTTMT","% of total sales","CAN","Canada","2012","2012",3.1,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","ATCPTTMT","% of total sales","CAN","Canada","2013","2013",3.2,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","ATCPTTMT","% of total sales","CAN","Canada","2014","2014",3.1,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","ATCPTTMT","% of total sales","CAN","Canada","2015","2015",3,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","ATCPTTMT","% of total sales","CAN","Canada","2016","2016",2.8,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","ATCPTTMT","% of total sales","CAN","Canada","2017","2017",2.7,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","ATCPTTMT","% of total sales","CAN","Canada","2018","2018",2.7,"E; B; D","Estimated value; Break; Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","ATCPTTMT","% of total sales","CAN","Canada","2019","2019",2.6,"E; D","Estimated value; Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","ATCPTTMT","% of total sales","CAN","Canada","2020","2020",2.3,"E; D","Estimated value; Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","ATCPTTMT","% of total sales","CAN","Canada","2021","2021",2.1,"E; D","Estimated value; Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","ATCPTTMT","% of total sales","CAN","Canada","2022","2022",1.9,"E; D","Estimated value; Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MLLNCUMT","Million of national currency units","CZE","Czech Republic","2010","2010",2853.4,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MLLNCUMT","Million of national currency units","CZE","Czech Republic","2011","2011",2666.5,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MLLNCUMT","Million of national currency units","CZE","Czech Republic","2012","2012",2720.8,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MLLNCUMT","Million of national currency units","CZE","Czech Republic","2013","2013",2500.2,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MLLNCUMT","Million of national currency units","CZE","Czech Republic","2014","2014",2387.5,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MLLNCUMT","Million of national currency units","CZE","Czech Republic","2015","2015",2238.8,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MLLNCUMT","Million of national currency units","CZE","Czech Republic","2016","2016",2154.4,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MLLNCUMT","Million of national currency units","CZE","Czech Republic","2017","2017",2125.4,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MLLNCUMT","Million of national currency units","CZE","Czech Republic","2018","2018",2118.1,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MLLNCUMT","Million of national currency units","CZE","Czech Republic","2019","2019",2124.3,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MLLNCUMT","Million of national currency units","CZE","Czech Republic","2020","2020",795,"B","Break"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MLLNCUMT","Million of national currency units","CZE","Czech Republic","2021","2021",800.6,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOTCMT","Million US$ at exchange rate","CZE","Czech Republic","2010","2010",149.4,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOTCMT","Million US$ at exchange rate","CZE","Czech Republic","2011","2011",150.7,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOTCMT","Million US$ at exchange rate","CZE","Czech Republic","2012","2012",139,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOTCMT","Million US$ at exchange rate","CZE","Czech Republic","2013","2013",127.8,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOTCMT","Million US$ at exchange rate","CZE","Czech Republic","2014","2014",115,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOTCMT","Million US$ at exchange rate","CZE","Czech Republic","2015","2015",91,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOTCMT","Million US$ at exchange rate","CZE","Czech Republic","2016","2016",88.2,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOTCMT","Million US$ at exchange rate","CZE","Czech Republic","2017","2017",90.9,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOTCMT","Million US$ at exchange rate","CZE","Czech Republic","2018","2018",97.5,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOTCMT","Million US$ at exchange rate","CZE","Czech Republic","2019","2019",92.6,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOTCMT","Million US$ at exchange rate","CZE","Czech Republic","2020","2020",34.3,"B","Break"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOTCMT","Million US$ at exchange rate","CZE","Czech Republic","2021","2021",36.9,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOPPMT","Million US$, purchasing power parity","CZE","Czech Republic","2010","2010",208.7,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOPPMT","Million US$, purchasing power parity","CZE","Czech Republic","2011","2011",199.8,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOPPMT","Million US$, purchasing power parity","CZE","Czech Republic","2012","2012",204.6,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOPPMT","Million US$, purchasing power parity","CZE","Czech Republic","2013","2013",195.6,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOPPMT","Million US$, purchasing power parity","CZE","Czech Republic","2014","2014",187.9,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOPPMT","Million US$, purchasing power parity","CZE","Czech Republic","2015","2015",173,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOPPMT","Million US$, purchasing power parity","CZE","Czech Republic","2016","2016",171.3,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOPPMT","Million US$, purchasing power parity","CZE","Czech Republic","2017","2017",171.1,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOPPMT","Million US$, purchasing power parity","CZE","Czech Republic","2018","2018",171.2,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOPPMT","Million US$, purchasing power parity","CZE","Czech Republic","2019","2019",173.1,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOPPMT","Million US$, purchasing power parity","CZE","Czech Republic","2020","2020",63.8,"B","Break"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOPPMT","Million US$, purchasing power parity","CZE","Czech Republic","2021","2021",62.8,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","TCPPERMT","/capita, US$ exchange rate","CZE","Czech Republic","2010","2010",14.3,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","TCPPERMT","/capita, US$ exchange rate","CZE","Czech Republic","2011","2011",14.4,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","TCPPERMT","/capita, US$ exchange rate","CZE","Czech Republic","2012","2012",13.2,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","TCPPERMT","/capita, US$ exchange rate","CZE","Czech Republic","2013","2013",12.2,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","TCPPERMT","/capita, US$ exchange rate","CZE","Czech Republic","2014","2014",10.9,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","TCPPERMT","/capita, US$ exchange rate","CZE","Czech Republic","2015","2015",8.6,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","TCPPERMT","/capita, US$ exchange rate","CZE","Czech Republic","2016","2016",8.3,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","TCPPERMT","/capita, US$ exchange rate","CZE","Czech Republic","2017","2017",8.6,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","TCPPERMT","/capita, US$ exchange rate","CZE","Czech Republic","2018","2018",9.2,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","TCPPERMT","/capita, US$ exchange rate","CZE","Czech Republic","2019","2019",8.7,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","TCPPERMT","/capita, US$ exchange rate","CZE","Czech Republic","2020","2020",3.2,"B","Break"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","TCPPERMT","/capita, US$ exchange rate","CZE","Czech Republic","2021","2021",3.5,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czech Republic","2010","2010",19.9,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czech Republic","2011","2011",19,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czech Republic","2012","2012",19.5,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czech Republic","2013","2013",18.6,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czech Republic","2014","2014",17.9,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czech Republic","2015","2015",16.4,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czech Republic","2016","2016",16.2,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czech Republic","2017","2017",16.1,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czech Republic","2018","2018",16.1,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czech Republic","2019","2019",16.2,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czech Republic","2020","2020",6,"B","Break"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czech Republic","2021","2021",6,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","ATCPTTMT","% of total sales","CZE","Czech Republic","2010","2010",3.5,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","ATCPTTMT","% of total sales","CZE","Czech Republic","2011","2011",3.3,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","ATCPTTMT","% of total sales","CZE","Czech Republic","2012","2012",3.2,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","ATCPTTMT","% of total sales","CZE","Czech Republic","2013","2013",3.1,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","ATCPTTMT","% of total sales","CZE","Czech Republic","2014","2014",2.9,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","ATCPTTMT","% of total sales","CZE","Czech Republic","2015","2015",2.7,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","ATCPTTMT","% of total sales","CZE","Czech Republic","2016","2016",2.5,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","ATCPTTMT","% of total sales","CZE","Czech Republic","2017","2017",2.3,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","ATCPTTMT","% of total sales","CZE","Czech Republic","2018","2018",2.2,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","ATCPTTMT","% of total sales","CZE","Czech Republic","2019","2019",2.1,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","ATCPTTMT","% of total sales","CZE","Czech Republic","2020","2020",0.9,"B","Break"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","ATCPTTMT","% of total sales","CZE","Czech Republic","2021","2021",0.9,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MLLNCUMT","Million of national currency units","FIN","Finland","2010","2010",54.7,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MLLNCUMT","Million of national currency units","FIN","Finland","2011","2011",55.7,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MLLNCUMT","Million of national currency units","FIN","Finland","2012","2012",55.6,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MLLNCUMT","Million of national currency units","FIN","Finland","2013","2013",56.9,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MLLNCUMT","Million of national currency units","FIN","Finland","2014","2014",57.7,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MLLNCUMT","Million of national currency units","FIN","Finland","2015","2015",58.4,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MLLNCUMT","Million of national currency units","FIN","Finland","2016","2016",57.7,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MLLNCUMT","Million of national currency units","FIN","Finland","2017","2017",57.7,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MLLNCUMT","Million of national currency units","FIN","Finland","2018","2018",57.8,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MLLNCUMT","Million of national currency units","FIN","Finland","2019","2019",59.6,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MLLNCUMT","Million of national currency units","FIN","Finland","2020","2020",56.7,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MLLNCUMT","Million of national currency units","FIN","Finland","2021","2021",50.3,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOTCMT","Million US$ at exchange rate","FIN","Finland","2010","2010",72.5,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOTCMT","Million US$ at exchange rate","FIN","Finland","2011","2011",77.5,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOTCMT","Million US$ at exchange rate","FIN","Finland","2012","2012",71.4,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOTCMT","Million US$ at exchange rate","FIN","Finland","2013","2013",75.6,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOTCMT","Million US$ at exchange rate","FIN","Finland","2014","2014",76.7,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOTCMT","Million US$ at exchange rate","FIN","Finland","2015","2015",64.8,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOTCMT","Million US$ at exchange rate","FIN","Finland","2016","2016",63.9,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOTCMT","Million US$ at exchange rate","FIN","Finland","2017","2017",65.2,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOTCMT","Million US$ at exchange rate","FIN","Finland","2018","2018",68.3,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOTCMT","Million US$ at exchange rate","FIN","Finland","2019","2019",66.7,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOTCMT","Million US$ at exchange rate","FIN","Finland","2020","2020",64.8,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOTCMT","Million US$ at exchange rate","FIN","Finland","2021","2021",59.5,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOPPMT","Million US$, purchasing power parity","FIN","Finland","2010","2010",60.7,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOPPMT","Million US$, purchasing power parity","FIN","Finland","2011","2011",62,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOPPMT","Million US$, purchasing power parity","FIN","Finland","2012","2012",61.2,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOPPMT","Million US$, purchasing power parity","FIN","Finland","2013","2013",62.8,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOPPMT","Million US$, purchasing power parity","FIN","Finland","2014","2014",63.6,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOPPMT","Million US$, purchasing power parity","FIN","Finland","2015","2015",64.3,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOPPMT","Million US$, purchasing power parity","FIN","Finland","2016","2016",65.5,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOPPMT","Million US$, purchasing power parity","FIN","Finland","2017","2017",66.8,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOPPMT","Million US$, purchasing power parity","FIN","Finland","2018","2018",67.7,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOPPMT","Million US$, purchasing power parity","FIN","Finland","2019","2019",71.1,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOPPMT","Million US$, purchasing power parity","FIN","Finland","2020","2020",68.9,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOPPMT","Million US$, purchasing power parity","FIN","Finland","2021","2021",60.8,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","TCPPERMT","/capita, US$ exchange rate","FIN","Finland","2010","2010",13.5,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","TCPPERMT","/capita, US$ exchange rate","FIN","Finland","2011","2011",14.4,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","TCPPERMT","/capita, US$ exchange rate","FIN","Finland","2012","2012",13.2,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","TCPPERMT","/capita, US$ exchange rate","FIN","Finland","2013","2013",13.9,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","TCPPERMT","/capita, US$ exchange rate","FIN","Finland","2014","2014",14,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","TCPPERMT","/capita, US$ exchange rate","FIN","Finland","2015","2015",11.8,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","TCPPERMT","/capita, US$ exchange rate","FIN","Finland","2016","2016",11.6,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","TCPPERMT","/capita, US$ exchange rate","FIN","Finland","2017","2017",11.8,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","TCPPERMT","/capita, US$ exchange rate","FIN","Finland","2018","2018",12.4,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","TCPPERMT","/capita, US$ exchange rate","FIN","Finland","2019","2019",12.1,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","TCPPERMT","/capita, US$ exchange rate","FIN","Finland","2020","2020",11.7,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","TCPPERMT","/capita, US$ exchange rate","FIN","Finland","2021","2021",10.7,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2010","2010",11.3,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2011","2011",11.5,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2012","2012",11.3,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2013","2013",11.6,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2014","2014",11.6,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2015","2015",11.7,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2016","2016",11.9,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2017","2017",12.1,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2018","2018",12.3,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2019","2019",12.9,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2020","2020",12.5,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2021","2021",11,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","ATCPTTMT","% of total sales","FIN","Finland","2010","2010",2.9,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","ATCPTTMT","% of total sales","FIN","Finland","2011","2011",2.9,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","ATCPTTMT","% of total sales","FIN","Finland","2012","2012",2.8,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","ATCPTTMT","% of total sales","FIN","Finland","2013","2013",2.8,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","ATCPTTMT","% of total sales","FIN","Finland","2014","2014",2.8,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","ATCPTTMT","% of total sales","FIN","Finland","2015","2015",2.7,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","ATCPTTMT","% of total sales","FIN","Finland","2016","2016",2.5,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","ATCPTTMT","% of total sales","FIN","Finland","2017","2017",2.5,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","ATCPTTMT","% of total sales","FIN","Finland","2018","2018",2.3,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","ATCPTTMT","% of total sales","FIN","Finland","2019","2019",2.2,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","ATCPTTMT","% of total sales","FIN","Finland","2020","2020",2.1,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","ATCPTTMT","% of total sales","FIN","Finland","2021","2021",1.8,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MLLNCUMT","Million of national currency units","DEU","Germany","2010","2010",419.8,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MLLNCUMT","Million of national currency units","DEU","Germany","2011","2011",395.4,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MLLNCUMT","Million of national currency units","DEU","Germany","2012","2012",383.5,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MLLNCUMT","Million of national currency units","DEU","Germany","2013","2013",377.9,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MLLNCUMT","Million of national currency units","DEU","Germany","2014","2014",395.1,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MLLNCUMT","Million of national currency units","DEU","Germany","2015","2015",407.4,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MLLNCUMT","Million of national currency units","DEU","Germany","2016","2016",401.2,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MLLNCUMT","Million of national currency units","DEU","Germany","2017","2017",388.3,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MLLNCUMT","Million of national currency units","DEU","Germany","2018","2018",375.5,"B; D","Break; Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MLLNCUMT","Million of national currency units","DEU","Germany","2019","2019",400,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MLLNCUMT","Million of national currency units","DEU","Germany","2020","2020",396.2,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MLLNCUMT","Million of national currency units","DEU","Germany","2021","2021",399.2,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOTCMT","Million US$ at exchange rate","DEU","Germany","2010","2010",556.5,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOTCMT","Million US$ at exchange rate","DEU","Germany","2011","2011",550.4,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOTCMT","Million US$ at exchange rate","DEU","Germany","2012","2012",492.7,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOTCMT","Million US$ at exchange rate","DEU","Germany","2013","2013",501.9,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOTCMT","Million US$ at exchange rate","DEU","Germany","2014","2014",524.9,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOTCMT","Million US$ at exchange rate","DEU","Germany","2015","2015",452,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOTCMT","Million US$ at exchange rate","DEU","Germany","2016","2016",444.1,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOTCMT","Million US$ at exchange rate","DEU","Germany","2017","2017",438.7,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOTCMT","Million US$ at exchange rate","DEU","Germany","2018","2018",443.4,"B; D","Break; Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOTCMT","Million US$ at exchange rate","DEU","Germany","2019","2019",447.8,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOTCMT","Million US$ at exchange rate","DEU","Germany","2020","2020",452.5,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOTCMT","Million US$ at exchange rate","DEU","Germany","2021","2021",472.2,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOPPMT","Million US$, purchasing power parity","DEU","Germany","2010","2010",521.4,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOPPMT","Million US$, purchasing power parity","DEU","Germany","2011","2011",501.3,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOPPMT","Million US$, purchasing power parity","DEU","Germany","2012","2012",487.1,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOPPMT","Million US$, purchasing power parity","DEU","Germany","2013","2013",487.7,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOPPMT","Million US$, purchasing power parity","DEU","Germany","2014","2014",513.8,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOPPMT","Million US$, purchasing power parity","DEU","Germany","2015","2015",523.6,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOPPMT","Million US$, purchasing power parity","DEU","Germany","2016","2016",533.1,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOPPMT","Million US$, purchasing power parity","DEU","Germany","2017","2017",521.4,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOPPMT","Million US$, purchasing power parity","DEU","Germany","2018","2018",510.6,"B; D","Break; Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOPPMT","Million US$, purchasing power parity","DEU","Germany","2019","2019",549.3,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOPPMT","Million US$, purchasing power parity","DEU","Germany","2020","2020",546.5,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOPPMT","Million US$, purchasing power parity","DEU","Germany","2021","2021",542.2,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","TCPPERMT","/capita, US$ exchange rate","DEU","Germany","2010","2010",6.8,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","TCPPERMT","/capita, US$ exchange rate","DEU","Germany","2011","2011",6.9,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","TCPPERMT","/capita, US$ exchange rate","DEU","Germany","2012","2012",6.1,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","TCPPERMT","/capita, US$ exchange rate","DEU","Germany","2013","2013",6.2,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","TCPPERMT","/capita, US$ exchange rate","DEU","Germany","2014","2014",6.5,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","TCPPERMT","/capita, US$ exchange rate","DEU","Germany","2015","2015",5.5,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","TCPPERMT","/capita, US$ exchange rate","DEU","Germany","2016","2016",5.4,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","TCPPERMT","/capita, US$ exchange rate","DEU","Germany","2017","2017",5.3,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","TCPPERMT","/capita, US$ exchange rate","DEU","Germany","2018","2018",5.3,"B; D","Break; Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","TCPPERMT","/capita, US$ exchange rate","DEU","Germany","2019","2019",5.4,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","TCPPERMT","/capita, US$ exchange rate","DEU","Germany","2020","2020",5.4,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","TCPPERMT","/capita, US$ exchange rate","DEU","Germany","2021","2021",5.7,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2010","2010",6.4,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2011","2011",6.2,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2012","2012",6.1,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2013","2013",6,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2014","2014",6.3,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2015","2015",6.4,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2016","2016",6.5,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2017","2017",6.3,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2018","2018",6.2,"B; D","Break; Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2019","2019",6.6,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2020","2020",6.6,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2021","2021",6.5,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","ATCPTTMT","% of total sales","DEU","Germany","2010","2010",1.4,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","ATCPTTMT","% of total sales","DEU","Germany","2011","2011",1.3,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","ATCPTTMT","% of total sales","DEU","Germany","2012","2012",1.3,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","ATCPTTMT","% of total sales","DEU","Germany","2013","2013",1.2,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","ATCPTTMT","% of total sales","DEU","Germany","2014","2014",1.2,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","ATCPTTMT","% of total sales","DEU","Germany","2015","2015",1.2,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","ATCPTTMT","% of total sales","DEU","Germany","2016","2016",1.1,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","ATCPTTMT","% of total sales","DEU","Germany","2017","2017",1,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","ATCPTTMT","% of total sales","DEU","Germany","2018","2018",0.8,"B; D","Break; Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","ATCPTTMT","% of total sales","DEU","Germany","2019","2019",0.9,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","ATCPTTMT","% of total sales","DEU","Germany","2020","2020",0.8,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","ATCPTTMT","% of total sales","DEU","Germany","2021","2021",0.7,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MLLNCUMT","Million of national currency units","GRC","Greece","2010","2010",67.5,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MLLNCUMT","Million of national currency units","GRC","Greece","2011","2011",65.3,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MLLNCUMT","Million of national currency units","GRC","Greece","2012","2012",50.2,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MLLNCUMT","Million of national currency units","GRC","Greece","2013","2013",38.6,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MLLNCUMT","Million of national currency units","GRC","Greece","2014","2014",40.6,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MLLNCUMT","Million of national currency units","GRC","Greece","2015","2015",33.8,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MLLNCUMT","Million of national currency units","GRC","Greece","2016","2016",37.3,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MLLNCUMT","Million of national currency units","GRC","Greece","2017","2017",38,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MLLNCUMT","Million of national currency units","GRC","Greece","2018","2018",41.4,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MLLNCUMT","Million of national currency units","GRC","Greece","2019","2019",41.2,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MLLNCUMT","Million of national currency units","GRC","Greece","2020","2020",42.6,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MLLNCUMT","Million of national currency units","GRC","Greece","2021","2021",45.6,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MLLNCUMT","Million of national currency units","GRC","Greece","2022","2022",38,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOTCMT","Million US$ at exchange rate","GRC","Greece","2010","2010",89.4,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOTCMT","Million US$ at exchange rate","GRC","Greece","2011","2011",90.9,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOTCMT","Million US$ at exchange rate","GRC","Greece","2012","2012",64.5,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOTCMT","Million US$ at exchange rate","GRC","Greece","2013","2013",51.3,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOTCMT","Million US$ at exchange rate","GRC","Greece","2014","2014",53.9,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOTCMT","Million US$ at exchange rate","GRC","Greece","2015","2015",37.5,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOTCMT","Million US$ at exchange rate","GRC","Greece","2016","2016",41.3,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOTCMT","Million US$ at exchange rate","GRC","Greece","2017","2017",42.9,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOTCMT","Million US$ at exchange rate","GRC","Greece","2018","2018",48.9,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOTCMT","Million US$ at exchange rate","GRC","Greece","2019","2019",46.1,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOTCMT","Million US$ at exchange rate","GRC","Greece","2020","2020",48.6,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOTCMT","Million US$ at exchange rate","GRC","Greece","2021","2021",53.9,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOTCMT","Million US$ at exchange rate","GRC","Greece","2022","2022",40,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOPPMT","Million US$, purchasing power parity","GRC","Greece","2010","2010",93.4,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOPPMT","Million US$, purchasing power parity","GRC","Greece","2011","2011",91.6,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOPPMT","Million US$, purchasing power parity","GRC","Greece","2012","2012",73.3,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOPPMT","Million US$, purchasing power parity","GRC","Greece","2013","2013",61.2,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOPPMT","Million US$, purchasing power parity","GRC","Greece","2014","2014",66.4,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOPPMT","Million US$, purchasing power parity","GRC","Greece","2015","2015",55.5,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOPPMT","Million US$, purchasing power parity","GRC","Greece","2016","2016",63.3,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOPPMT","Million US$, purchasing power parity","GRC","Greece","2017","2017",66.1,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOPPMT","Million US$, purchasing power parity","GRC","Greece","2018","2018",73.3,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOPPMT","Million US$, purchasing power parity","GRC","Greece","2019","2019",75,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOPPMT","Million US$, purchasing power parity","GRC","Greece","2020","2020",78.3,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOPPMT","Million US$, purchasing power parity","GRC","Greece","2021","2021",83.6,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOPPMT","Million US$, purchasing power parity","GRC","Greece","2022","2022",71.9,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","TCPPERMT","/capita, US$ exchange rate","GRC","Greece","2010","2010",8,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","TCPPERMT","/capita, US$ exchange rate","GRC","Greece","2011","2011",8.2,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","TCPPERMT","/capita, US$ exchange rate","GRC","Greece","2012","2012",5.8,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","TCPPERMT","/capita, US$ exchange rate","GRC","Greece","2013","2013",4.7,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","TCPPERMT","/capita, US$ exchange rate","GRC","Greece","2014","2014",4.9,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","TCPPERMT","/capita, US$ exchange rate","GRC","Greece","2015","2015",3.5,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","TCPPERMT","/capita, US$ exchange rate","GRC","Greece","2016","2016",3.8,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","TCPPERMT","/capita, US$ exchange rate","GRC","Greece","2017","2017",4,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","TCPPERMT","/capita, US$ exchange rate","GRC","Greece","2018","2018",4.6,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","TCPPERMT","/capita, US$ exchange rate","GRC","Greece","2019","2019",4.3,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","TCPPERMT","/capita, US$ exchange rate","GRC","Greece","2020","2020",4.5,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","TCPPERMT","/capita, US$ exchange rate","GRC","Greece","2021","2021",5.1,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","TCPPERMT","/capita, US$ exchange rate","GRC","Greece","2022","2022",3.8,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2010","2010",8.4,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2011","2011",8.2,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2012","2012",6.6,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2013","2013",5.6,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2014","2014",6.1,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2015","2015",5.1,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2016","2016",5.9,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2017","2017",6.1,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2018","2018",6.8,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2019","2019",7,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2020","2020",7.3,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2021","2021",7.9,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2022","2022",6.9,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MLLNCUMT","Million of national currency units","HUN","Hungary","2010","2010",3352.5,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MLLNCUMT","Million of national currency units","HUN","Hungary","2011","2011",3483,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MLLNCUMT","Million of national currency units","HUN","Hungary","2012","2012",3423.8,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MLLNCUMT","Million of national currency units","HUN","Hungary","2013","2013",4108.8,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MLLNCUMT","Million of national currency units","HUN","Hungary","2014","2014",4324.3,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MLLNCUMT","Million of national currency units","HUN","Hungary","2015","2015",4957.9,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MLLNCUMT","Million of national currency units","HUN","Hungary","2016","2016",5426.8,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MLLNCUMT","Million of national currency units","HUN","Hungary","2017","2017",5743.2,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MLLNCUMT","Million of national currency units","HUN","Hungary","2018","2018",5644.6,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MLLNCUMT","Million of national currency units","HUN","Hungary","2019","2019",5361.7,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MLLNCUMT","Million of national currency units","HUN","Hungary","2020","2020",5013.9,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MLLNCUMT","Million of national currency units","HUN","Hungary","2021","2021",6016.5,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MLLNCUMT","Million of national currency units","HUN","Hungary","2022","2022",6388,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOTCMT","Million US$ at exchange rate","HUN","Hungary","2010","2010",16.1,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOTCMT","Million US$ at exchange rate","HUN","Hungary","2011","2011",17.3,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOTCMT","Million US$ at exchange rate","HUN","Hungary","2012","2012",15.2,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOTCMT","Million US$ at exchange rate","HUN","Hungary","2013","2013",18.4,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOTCMT","Million US$ at exchange rate","HUN","Hungary","2014","2014",18.6,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOTCMT","Million US$ at exchange rate","HUN","Hungary","2015","2015",17.7,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOTCMT","Million US$ at exchange rate","HUN","Hungary","2016","2016",19.3,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOTCMT","Million US$ at exchange rate","HUN","Hungary","2017","2017",20.9,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOTCMT","Million US$ at exchange rate","HUN","Hungary","2018","2018",20.9,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOTCMT","Million US$ at exchange rate","HUN","Hungary","2019","2019",18.4,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOTCMT","Million US$ at exchange rate","HUN","Hungary","2020","2020",16.3,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOTCMT","Million US$ at exchange rate","HUN","Hungary","2021","2021",19.8,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOTCMT","Million US$ at exchange rate","HUN","Hungary","2022","2022",17.1,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOPPMT","Million US$, purchasing power parity","HUN","Hungary","2010","2010",26.5,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOPPMT","Million US$, purchasing power parity","HUN","Hungary","2011","2011",28,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOPPMT","Million US$, purchasing power parity","HUN","Hungary","2012","2012",27.3,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOPPMT","Million US$, purchasing power parity","HUN","Hungary","2013","2013",32.9,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOPPMT","Million US$, purchasing power parity","HUN","Hungary","2014","2014",33.4,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOPPMT","Million US$, purchasing power parity","HUN","Hungary","2015","2015",37.4,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOPPMT","Million US$, purchasing power parity","HUN","Hungary","2016","2016",41.1,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOPPMT","Million US$, purchasing power parity","HUN","Hungary","2017","2017",42.2,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOPPMT","Million US$, purchasing power parity","HUN","Hungary","2018","2018",40.6,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOPPMT","Million US$, purchasing power parity","HUN","Hungary","2019","2019",38.1,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOPPMT","Million US$, purchasing power parity","HUN","Hungary","2020","2020",34.5,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOPPMT","Million US$, purchasing power parity","HUN","Hungary","2021","2021",38.9,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOPPMT","Million US$, purchasing power parity","HUN","Hungary","2022","2022",39.6,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","TCPPERMT","/capita, US$ exchange rate","HUN","Hungary","2010","2010",1.6,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","TCPPERMT","/capita, US$ exchange rate","HUN","Hungary","2011","2011",1.7,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","TCPPERMT","/capita, US$ exchange rate","HUN","Hungary","2012","2012",1.5,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","TCPPERMT","/capita, US$ exchange rate","HUN","Hungary","2013","2013",1.9,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","TCPPERMT","/capita, US$ exchange rate","HUN","Hungary","2014","2014",1.9,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","TCPPERMT","/capita, US$ exchange rate","HUN","Hungary","2015","2015",1.8,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","TCPPERMT","/capita, US$ exchange rate","HUN","Hungary","2016","2016",2,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","TCPPERMT","/capita, US$ exchange rate","HUN","Hungary","2017","2017",2.1,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","TCPPERMT","/capita, US$ exchange rate","HUN","Hungary","2018","2018",2.1,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","TCPPERMT","/capita, US$ exchange rate","HUN","Hungary","2019","2019",1.9,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","TCPPERMT","/capita, US$ exchange rate","HUN","Hungary","2020","2020",1.7,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","TCPPERMT","/capita, US$ exchange rate","HUN","Hungary","2021","2021",2,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","TCPPERMT","/capita, US$ exchange rate","HUN","Hungary","2022","2022",1.8,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2010","2010",2.7,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2011","2011",2.8,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2012","2012",2.7,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2013","2013",3.3,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2014","2014",3.4,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2015","2015",3.8,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2016","2016",4.2,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2017","2017",4.3,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2018","2018",4.2,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2019","2019",3.9,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2020","2020",3.5,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2021","2021",4,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2022","2022",4.1,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","ATCPTTMT","% of total sales","HUN","Hungary","2010","2010",0.7,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","ATCPTTMT","% of total sales","HUN","Hungary","2011","2011",0.7,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","ATCPTTMT","% of total sales","HUN","Hungary","2012","2012",0.8,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","ATCPTTMT","% of total sales","HUN","Hungary","2013","2013",1,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","ATCPTTMT","% of total sales","HUN","Hungary","2014","2014",1,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","ATCPTTMT","% of total sales","HUN","Hungary","2015","2015",1.1,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","ATCPTTMT","% of total sales","HUN","Hungary","2016","2016",1.1,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","ATCPTTMT","% of total sales","HUN","Hungary","2017","2017",1.2,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","ATCPTTMT","% of total sales","HUN","Hungary","2018","2018",1.1,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","ATCPTTMT","% of total sales","HUN","Hungary","2019","2019",1,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","ATCPTTMT","% of total sales","HUN","Hungary","2020","2020",0.9,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","ATCPTTMT","% of total sales","HUN","Hungary","2021","2021",1.1,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","ATCPTTMT","% of total sales","HUN","Hungary","2022","2022",1.1,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MLLNCUMT","Million of national currency units","ISL","Iceland","2010","2010",846.9,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MLLNCUMT","Million of national currency units","ISL","Iceland","2011","2011",845,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MLLNCUMT","Million of national currency units","ISL","Iceland","2012","2012",865.6,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MLLNCUMT","Million of national currency units","ISL","Iceland","2013","2013",853.4,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MLLNCUMT","Million of national currency units","ISL","Iceland","2014","2014",754.3,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MLLNCUMT","Million of national currency units","ISL","Iceland","2015","2015",723.6,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MLLNCUMT","Million of national currency units","ISL","Iceland","2016","2016",729.9,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MLLNCUMT","Million of national currency units","ISL","Iceland","2017","2017",705.6,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MLLNCUMT","Million of national currency units","ISL","Iceland","2018","2018",770.3,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MLLNCUMT","Million of national currency units","ISL","Iceland","2019","2019",832.9,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MLLNCUMT","Million of national currency units","ISL","Iceland","2020","2020",902.6,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MLLNCUMT","Million of national currency units","ISL","Iceland","2021","2021",968.3,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOTCMT","Million US$ at exchange rate","ISL","Iceland","2010","2010",6.9,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOTCMT","Million US$ at exchange rate","ISL","Iceland","2011","2011",7.3,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOTCMT","Million US$ at exchange rate","ISL","Iceland","2012","2012",6.9,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOTCMT","Million US$ at exchange rate","ISL","Iceland","2013","2013",7,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOTCMT","Million US$ at exchange rate","ISL","Iceland","2014","2014",6.5,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOTCMT","Million US$ at exchange rate","ISL","Iceland","2015","2015",5.5,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOTCMT","Million US$ at exchange rate","ISL","Iceland","2016","2016",6,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOTCMT","Million US$ at exchange rate","ISL","Iceland","2017","2017",6.6,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOTCMT","Million US$ at exchange rate","ISL","Iceland","2018","2018",7.1,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOTCMT","Million US$ at exchange rate","ISL","Iceland","2019","2019",6.8,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOTCMT","Million US$ at exchange rate","ISL","Iceland","2020","2020",6.7,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOTCMT","Million US$ at exchange rate","ISL","Iceland","2021","2021",7.6,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOPPMT","Million US$, purchasing power parity","ISL","Iceland","2010","2010",6.4,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOPPMT","Million US$, purchasing power parity","ISL","Iceland","2011","2011",6.3,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOPPMT","Million US$, purchasing power parity","ISL","Iceland","2012","2012",6.3,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOPPMT","Million US$, purchasing power parity","ISL","Iceland","2013","2013",6.2,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOPPMT","Million US$, purchasing power parity","ISL","Iceland","2014","2014",5.4,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOPPMT","Million US$, purchasing power parity","ISL","Iceland","2015","2015",5.1,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOPPMT","Million US$, purchasing power parity","ISL","Iceland","2016","2016",5.2,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOPPMT","Million US$, purchasing power parity","ISL","Iceland","2017","2017",5.1,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOPPMT","Million US$, purchasing power parity","ISL","Iceland","2018","2018",5.5,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOPPMT","Million US$, purchasing power parity","ISL","Iceland","2019","2019",5.9,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOPPMT","Million US$, purchasing power parity","ISL","Iceland","2020","2020",6.2,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOPPMT","Million US$, purchasing power parity","ISL","Iceland","2021","2021",6.5,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","TCPPERMT","/capita, US$ exchange rate","ISL","Iceland","2010","2010",21.8,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","TCPPERMT","/capita, US$ exchange rate","ISL","Iceland","2011","2011",22.8,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","TCPPERMT","/capita, US$ exchange rate","ISL","Iceland","2012","2012",21.6,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","TCPPERMT","/capita, US$ exchange rate","ISL","Iceland","2013","2013",21.6,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","TCPPERMT","/capita, US$ exchange rate","ISL","Iceland","2014","2014",19.7,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","TCPPERMT","/capita, US$ exchange rate","ISL","Iceland","2015","2015",16.6,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","TCPPERMT","/capita, US$ exchange rate","ISL","Iceland","2016","2016",18,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","TCPPERMT","/capita, US$ exchange rate","ISL","Iceland","2017","2017",19.2,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","TCPPERMT","/capita, US$ exchange rate","ISL","Iceland","2018","2018",20.2,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","TCPPERMT","/capita, US$ exchange rate","ISL","Iceland","2019","2019",18.8,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","TCPPERMT","/capita, US$ exchange rate","ISL","Iceland","2020","2020",18.2,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","TCPPERMT","/capita, US$ exchange rate","ISL","Iceland","2021","2021",20.5,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2010","2010",20,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2011","2011",19.6,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2012","2012",19.7,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2013","2013",19.2,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2014","2014",16.6,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2015","2015",15.4,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2016","2016",15.5,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2017","2017",14.9,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2018","2018",15.5,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2019","2019",16.4,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2020","2020",16.8,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2021","2021",17.4,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","ATCPTTMT","% of total sales","ISL","Iceland","2010","2010",3.4,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","ATCPTTMT","% of total sales","ISL","Iceland","2011","2011",3.2,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","ATCPTTMT","% of total sales","ISL","Iceland","2012","2012",3.6,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","ATCPTTMT","% of total sales","ISL","Iceland","2013","2013",3.3,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","ATCPTTMT","% of total sales","ISL","Iceland","2014","2014",3.2,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","ATCPTTMT","% of total sales","ISL","Iceland","2015","2015",3,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","ATCPTTMT","% of total sales","ISL","Iceland","2016","2016",2.9,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","ATCPTTMT","% of total sales","ISL","Iceland","2017","2017",2.7,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","ATCPTTMT","% of total sales","ISL","Iceland","2018","2018",2.6,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","ATCPTTMT","% of total sales","ISL","Iceland","2019","2019",2.5,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","ATCPTTMT","% of total sales","ISL","Iceland","2020","2020",2.3,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","ATCPTTMT","% of total sales","ISL","Iceland","2021","2021",2.1,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MLLNCUMT","Million of national currency units","IRL","Ireland","2010","2010",35.1,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MLLNCUMT","Million of national currency units","IRL","Ireland","2011","2011",34.2,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MLLNCUMT","Million of national currency units","IRL","Ireland","2012","2012",34.7,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MLLNCUMT","Million of national currency units","IRL","Ireland","2013","2013",33.9,"B; D","Break; Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MLLNCUMT","Million of national currency units","IRL","Ireland","2014","2014",32.8,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MLLNCUMT","Million of national currency units","IRL","Ireland","2015","2015",34.3,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MLLNCUMT","Million of national currency units","IRL","Ireland","2016","2016",35.3,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MLLNCUMT","Million of national currency units","IRL","Ireland","2017","2017",32.8,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MLLNCUMT","Million of national currency units","IRL","Ireland","2018","2018",33.7,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MLLNCUMT","Million of national currency units","IRL","Ireland","2019","2019",36.4,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MLLNCUMT","Million of national currency units","IRL","Ireland","2020","2020",38.2,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MLLNCUMT","Million of national currency units","IRL","Ireland","2021","2021",51,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOTCMT","Million US$ at exchange rate","IRL","Ireland","2010","2010",46.5,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOTCMT","Million US$ at exchange rate","IRL","Ireland","2011","2011",47.6,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOTCMT","Million US$ at exchange rate","IRL","Ireland","2012","2012",44.6,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOTCMT","Million US$ at exchange rate","IRL","Ireland","2013","2013",45,"B; D","Break; Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOTCMT","Million US$ at exchange rate","IRL","Ireland","2014","2014",43.5,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOTCMT","Million US$ at exchange rate","IRL","Ireland","2015","2015",38.1,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOTCMT","Million US$ at exchange rate","IRL","Ireland","2016","2016",39,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOTCMT","Million US$ at exchange rate","IRL","Ireland","2017","2017",37,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOTCMT","Million US$ at exchange rate","IRL","Ireland","2018","2018",39.8,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOTCMT","Million US$ at exchange rate","IRL","Ireland","2019","2019",40.8,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOTCMT","Million US$ at exchange rate","IRL","Ireland","2020","2020",43.6,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOTCMT","Million US$ at exchange rate","IRL","Ireland","2021","2021",60.4,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOPPMT","Million US$, purchasing power parity","IRL","Ireland","2010","2010",41.3,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOPPMT","Million US$, purchasing power parity","IRL","Ireland","2011","2011",41.1,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOPPMT","Million US$, purchasing power parity","IRL","Ireland","2012","2012",42.2,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOPPMT","Million US$, purchasing power parity","IRL","Ireland","2013","2013",41.8,"B; D","Break; Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOPPMT","Million US$, purchasing power parity","IRL","Ireland","2014","2014",40,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOPPMT","Million US$, purchasing power parity","IRL","Ireland","2015","2015",42.4,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOPPMT","Million US$, purchasing power parity","IRL","Ireland","2016","2016",44.4,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOPPMT","Million US$, purchasing power parity","IRL","Ireland","2017","2017",41.3,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOPPMT","Million US$, purchasing power parity","IRL","Ireland","2018","2018",42.5,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOPPMT","Million US$, purchasing power parity","IRL","Ireland","2019","2019",45.2,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOPPMT","Million US$, purchasing power parity","IRL","Ireland","2020","2020",48,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOPPMT","Million US$, purchasing power parity","IRL","Ireland","2021","2021",64.2,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","TCPPERMT","/capita, US$ exchange rate","IRL","Ireland","2010","2010",10.2,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","TCPPERMT","/capita, US$ exchange rate","IRL","Ireland","2011","2011",10.4,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","TCPPERMT","/capita, US$ exchange rate","IRL","Ireland","2012","2012",9.7,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","TCPPERMT","/capita, US$ exchange rate","IRL","Ireland","2013","2013",9.7,"B; D","Break; Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","TCPPERMT","/capita, US$ exchange rate","IRL","Ireland","2014","2014",9.3,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","TCPPERMT","/capita, US$ exchange rate","IRL","Ireland","2015","2015",8.1,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","TCPPERMT","/capita, US$ exchange rate","IRL","Ireland","2016","2016",8.2,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","TCPPERMT","/capita, US$ exchange rate","IRL","Ireland","2017","2017",7.7,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","TCPPERMT","/capita, US$ exchange rate","IRL","Ireland","2018","2018",8.2,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","TCPPERMT","/capita, US$ exchange rate","IRL","Ireland","2019","2019",8.3,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","TCPPERMT","/capita, US$ exchange rate","IRL","Ireland","2020","2020",8.7,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","TCPPERMT","/capita, US$ exchange rate","IRL","Ireland","2021","2021",12,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2010","2010",9,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2011","2011",9,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2012","2012",9.2,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2013","2013",9,"B; D","Break; Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2014","2014",8.6,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2015","2015",9,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2016","2016",9.3,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2017","2017",8.6,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2018","2018",8.7,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2019","2019",9.2,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2020","2020",9.6,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2021","2021",12.8,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","ATCPTTMT","% of total sales","IRL","Ireland","2010","2010",1.7,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","ATCPTTMT","% of total sales","IRL","Ireland","2011","2011",1.7,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","ATCPTTMT","% of total sales","IRL","Ireland","2012","2012",1.7,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","ATCPTTMT","% of total sales","IRL","Ireland","2013","2013",1.7,"B; D","Break; Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","ATCPTTMT","% of total sales","IRL","Ireland","2014","2014",1.7,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","ATCPTTMT","% of total sales","IRL","Ireland","2015","2015",1.7,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","ATCPTTMT","% of total sales","IRL","Ireland","2016","2016",1.7,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","ATCPTTMT","% of total sales","IRL","Ireland","2017","2017",1.5,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","ATCPTTMT","% of total sales","IRL","Ireland","2018","2018",1.5,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","ATCPTTMT","% of total sales","IRL","Ireland","2019","2019",1.5,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","ATCPTTMT","% of total sales","IRL","Ireland","2020","2020",1.6,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","ATCPTTMT","% of total sales","IRL","Ireland","2021","2021",1.9,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MLLNCUMT","Million of national currency units","ITA","Italy","2011","2011",176.4,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MLLNCUMT","Million of national currency units","ITA","Italy","2012","2012",169.7,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MLLNCUMT","Million of national currency units","ITA","Italy","2013","2013",163.8,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MLLNCUMT","Million of national currency units","ITA","Italy","2014","2014",154.7,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MLLNCUMT","Million of national currency units","ITA","Italy","2015","2015",149.5,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MLLNCUMT","Million of national currency units","ITA","Italy","2016","2016",136.1,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MLLNCUMT","Million of national currency units","ITA","Italy","2017","2017",123.7,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MLLNCUMT","Million of national currency units","ITA","Italy","2018","2018",112.1,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MLLNCUMT","Million of national currency units","ITA","Italy","2019","2019",113.1,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MLLNCUMT","Million of national currency units","ITA","Italy","2020","2020",91.8,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MLLNCUMT","Million of national currency units","ITA","Italy","2021","2021",108,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MLLNCUMT","Million of national currency units","ITA","Italy","2022","2022",105,"E","Estimated value"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOTCMT","Million US$ at exchange rate","ITA","Italy","2011","2011",245.5,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOTCMT","Million US$ at exchange rate","ITA","Italy","2012","2012",218,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOTCMT","Million US$ at exchange rate","ITA","Italy","2013","2013",217.5,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOTCMT","Million US$ at exchange rate","ITA","Italy","2014","2014",205.5,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOTCMT","Million US$ at exchange rate","ITA","Italy","2015","2015",165.9,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOTCMT","Million US$ at exchange rate","ITA","Italy","2016","2016",150.6,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOTCMT","Million US$ at exchange rate","ITA","Italy","2017","2017",139.8,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOTCMT","Million US$ at exchange rate","ITA","Italy","2018","2018",132.4,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOTCMT","Million US$ at exchange rate","ITA","Italy","2019","2019",126.7,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOTCMT","Million US$ at exchange rate","ITA","Italy","2020","2020",104.9,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOTCMT","Million US$ at exchange rate","ITA","Italy","2021","2021",127.8,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOTCMT","Million US$ at exchange rate","ITA","Italy","2022","2022",110.6,"E","Estimated value"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOPPMT","Million US$, purchasing power parity","ITA","Italy","2011","2011",232.5,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOPPMT","Million US$, purchasing power parity","ITA","Italy","2012","2012",227,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOPPMT","Million US$, purchasing power parity","ITA","Italy","2013","2013",222.1,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOPPMT","Million US$, purchasing power parity","ITA","Italy","2014","2014",209.1,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOPPMT","Million US$, purchasing power parity","ITA","Italy","2015","2015",202.4,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOPPMT","Million US$, purchasing power parity","ITA","Italy","2016","2016",194.3,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOPPMT","Million US$, purchasing power parity","ITA","Italy","2017","2017",179.3,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOPPMT","Million US$, purchasing power parity","ITA","Italy","2018","2018",164.5,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOPPMT","Million US$, purchasing power parity","ITA","Italy","2019","2019",172.3,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOPPMT","Million US$, purchasing power parity","ITA","Italy","2020","2020",141.8,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOPPMT","Million US$, purchasing power parity","ITA","Italy","2021","2021",166.8,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOPPMT","Million US$, purchasing power parity","ITA","Italy","2022","2022",170.1,"E","Estimated value"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","TCPPERMT","/capita, US$ exchange rate","ITA","Italy","2011","2011",4.1,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","TCPPERMT","/capita, US$ exchange rate","ITA","Italy","2012","2012",3.7,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","TCPPERMT","/capita, US$ exchange rate","ITA","Italy","2013","2013",3.6,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","TCPPERMT","/capita, US$ exchange rate","ITA","Italy","2014","2014",3.4,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","TCPPERMT","/capita, US$ exchange rate","ITA","Italy","2015","2015",2.7,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","TCPPERMT","/capita, US$ exchange rate","ITA","Italy","2016","2016",2.5,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","TCPPERMT","/capita, US$ exchange rate","ITA","Italy","2017","2017",2.3,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","TCPPERMT","/capita, US$ exchange rate","ITA","Italy","2018","2018",2.2,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","TCPPERMT","/capita, US$ exchange rate","ITA","Italy","2019","2019",2.1,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","TCPPERMT","/capita, US$ exchange rate","ITA","Italy","2020","2020",1.8,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","TCPPERMT","/capita, US$ exchange rate","ITA","Italy","2021","2021",2.2,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","TCPPERMT","/capita, US$ exchange rate","ITA","Italy","2022","2022",1.9,"E","Estimated value"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2011","2011",3.9,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2012","2012",3.8,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2013","2013",3.7,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2014","2014",3.4,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2015","2015",3.3,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2016","2016",3.2,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2017","2017",3,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2018","2018",2.7,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2019","2019",2.9,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2020","2020",2.4,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2021","2021",2.8,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2022","2022",2.9,"E","Estimated value"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","ATCPTTMT","% of total sales","ITA","Italy","2011","2011",0.9,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","ATCPTTMT","% of total sales","ITA","Italy","2012","2012",0.9,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","ATCPTTMT","% of total sales","ITA","Italy","2013","2013",0.8,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","ATCPTTMT","% of total sales","ITA","Italy","2014","2014",0.8,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","ATCPTTMT","% of total sales","ITA","Italy","2015","2015",0.7,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","ATCPTTMT","% of total sales","ITA","Italy","2016","2016",0.6,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","ATCPTTMT","% of total sales","ITA","Italy","2017","2017",0.5,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","ATCPTTMT","% of total sales","ITA","Italy","2018","2018",0.5,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","ATCPTTMT","% of total sales","ITA","Italy","2019","2019",0.5,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","ATCPTTMT","% of total sales","ITA","Italy","2020","2020",0.4,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","ATCPTTMT","% of total sales","ITA","Italy","2021","2021",0.5,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","ATCPTTMT","% of total sales","ITA","Italy","2022","2022",0.4,"E","Estimated value"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MLLNCUMT","Million of national currency units","KOR","Korea","2010","2010",151191,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MLLNCUMT","Million of national currency units","KOR","Korea","2011","2011",152836.8,"B","Break"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MLLNCUMT","Million of national currency units","KOR","Korea","2012","2012",156433.3,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MLLNCUMT","Million of national currency units","KOR","Korea","2013","2013",176123.1,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MLLNCUMT","Million of national currency units","KOR","Korea","2014","2014",195737.3,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MLLNCUMT","Million of national currency units","KOR","Korea","2015","2015",194402,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MLLNCUMT","Million of national currency units","KOR","Korea","2016","2016",189297.4,"B","Break"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MLLNCUMT","Million of national currency units","KOR","Korea","2017","2017",199206.6,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MLLNCUMT","Million of national currency units","KOR","Korea","2018","2018",213761.7,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MLLNCUMT","Million of national currency units","KOR","Korea","2019","2019",231920.6,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MLLNCUMT","Million of national currency units","KOR","Korea","2020","2020",245225.1,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MLLNCUMT","Million of national currency units","KOR","Korea","2021","2021",272487.4,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOTCMT","Million US$ at exchange rate","KOR","Korea","2010","2010",130.7,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOTCMT","Million US$ at exchange rate","KOR","Korea","2011","2011",137.9,"B","Break"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOTCMT","Million US$ at exchange rate","KOR","Korea","2012","2012",138.8,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOTCMT","Million US$ at exchange rate","KOR","Korea","2013","2013",160.8,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOTCMT","Million US$ at exchange rate","KOR","Korea","2014","2014",185.9,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOTCMT","Million US$ at exchange rate","KOR","Korea","2015","2015",171.9,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOTCMT","Million US$ at exchange rate","KOR","Korea","2016","2016",163.1,"B","Break"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOTCMT","Million US$ at exchange rate","KOR","Korea","2017","2017",176.1,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOTCMT","Million US$ at exchange rate","KOR","Korea","2018","2018",194.3,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOTCMT","Million US$ at exchange rate","KOR","Korea","2019","2019",199,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOTCMT","Million US$ at exchange rate","KOR","Korea","2020","2020",207.8,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOTCMT","Million US$ at exchange rate","KOR","Korea","2021","2021",238.2,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOPPMT","Million US$, purchasing power parity","KOR","Korea","2010","2010",179.8,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOPPMT","Million US$, purchasing power parity","KOR","Korea","2011","2011",178.8,"B","Break"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOPPMT","Million US$, purchasing power parity","KOR","Korea","2012","2012",183,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOPPMT","Million US$, purchasing power parity","KOR","Korea","2013","2013",202.7,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOPPMT","Million US$, purchasing power parity","KOR","Korea","2014","2014",224.5,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOPPMT","Million US$, purchasing power parity","KOR","Korea","2015","2015",226.7,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOPPMT","Million US$, purchasing power parity","KOR","Korea","2016","2016",220.4,"B","Break"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOPPMT","Million US$, purchasing power parity","KOR","Korea","2017","2017",228.3,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOPPMT","Million US$, purchasing power parity","KOR","Korea","2018","2018",250.1,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOPPMT","Million US$, purchasing power parity","KOR","Korea","2019","2019",270.8,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOPPMT","Million US$, purchasing power parity","KOR","Korea","2020","2020",292.7,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOPPMT","Million US$, purchasing power parity","KOR","Korea","2021","2021",319,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","TCPPERMT","/capita, US$ exchange rate","KOR","Korea","2010","2010",2.6,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","TCPPERMT","/capita, US$ exchange rate","KOR","Korea","2011","2011",2.8,"B","Break"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","TCPPERMT","/capita, US$ exchange rate","KOR","Korea","2012","2012",2.8,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","TCPPERMT","/capita, US$ exchange rate","KOR","Korea","2013","2013",3.2,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","TCPPERMT","/capita, US$ exchange rate","KOR","Korea","2014","2014",3.7,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","TCPPERMT","/capita, US$ exchange rate","KOR","Korea","2015","2015",3.4,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","TCPPERMT","/capita, US$ exchange rate","KOR","Korea","2016","2016",3.2,"B","Break"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","TCPPERMT","/capita, US$ exchange rate","KOR","Korea","2017","2017",3.4,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","TCPPERMT","/capita, US$ exchange rate","KOR","Korea","2018","2018",3.8,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","TCPPERMT","/capita, US$ exchange rate","KOR","Korea","2019","2019",3.8,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","TCPPERMT","/capita, US$ exchange rate","KOR","Korea","2020","2020",4,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","TCPPERMT","/capita, US$ exchange rate","KOR","Korea","2021","2021",4.6,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2010","2010",3.6,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2011","2011",3.6,"B","Break"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2012","2012",3.6,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2013","2013",4,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2014","2014",4.4,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2015","2015",4.4,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2016","2016",4.3,"B","Break"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2017","2017",4.4,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2018","2018",4.8,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2019","2019",5.2,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2020","2020",5.6,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2021","2021",6.2,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","ATCPTTMT","% of total sales","KOR","Korea","2010","2010",0.7,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","ATCPTTMT","% of total sales","KOR","Korea","2011","2011",0.7,"B","Break"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","ATCPTTMT","% of total sales","KOR","Korea","2012","2012",0.7,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","ATCPTTMT","% of total sales","KOR","Korea","2013","2013",0.8,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","ATCPTTMT","% of total sales","KOR","Korea","2014","2014",0.8,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","ATCPTTMT","% of total sales","KOR","Korea","2015","2015",0.8,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","ATCPTTMT","% of total sales","KOR","Korea","2016","2016",0.7,"B","Break"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","ATCPTTMT","% of total sales","KOR","Korea","2017","2017",0.7,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","ATCPTTMT","% of total sales","KOR","Korea","2018","2018",0.7,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","ATCPTTMT","% of total sales","KOR","Korea","2019","2019",0.7,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","ATCPTTMT","% of total sales","KOR","Korea","2020","2020",0.8,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","ATCPTTMT","% of total sales","KOR","Korea","2021","2021",0.8,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MLLNCUMT","Million of national currency units","LUX","Luxembourg","2010","2010",2.4,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MLLNCUMT","Million of national currency units","LUX","Luxembourg","2011","2011",2.5,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MLLNCUMT","Million of national currency units","LUX","Luxembourg","2012","2012",3.5,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MLLNCUMT","Million of national currency units","LUX","Luxembourg","2013","2013",3.3,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MLLNCUMT","Million of national currency units","LUX","Luxembourg","2014","2014",3.4,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MLLNCUMT","Million of national currency units","LUX","Luxembourg","2015","2015",3.4,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MLLNCUMT","Million of national currency units","LUX","Luxembourg","2016","2016",3.5,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MLLNCUMT","Million of national currency units","LUX","Luxembourg","2017","2017",3.6,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MLLNCUMT","Million of national currency units","LUX","Luxembourg","2018","2018",3.9,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MLLNCUMT","Million of national currency units","LUX","Luxembourg","2019","2019",4.3,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MLLNCUMT","Million of national currency units","LUX","Luxembourg","2020","2020",4,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MLLNCUMT","Million of national currency units","LUX","Luxembourg","2021","2021",4.4,"B; D; P","Break; Difference in methodology; Provisional value"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MLLNCUMT","Million of national currency units","LUX","Luxembourg","2022","2022",4.1,"D; P","Difference in methodology; Provisional value"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOTCMT","Million US$ at exchange rate","LUX","Luxembourg","2010","2010",3.2,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOTCMT","Million US$ at exchange rate","LUX","Luxembourg","2011","2011",3.4,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOTCMT","Million US$ at exchange rate","LUX","Luxembourg","2012","2012",4.5,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOTCMT","Million US$ at exchange rate","LUX","Luxembourg","2013","2013",4.4,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOTCMT","Million US$ at exchange rate","LUX","Luxembourg","2014","2014",4.5,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOTCMT","Million US$ at exchange rate","LUX","Luxembourg","2015","2015",3.8,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOTCMT","Million US$ at exchange rate","LUX","Luxembourg","2016","2016",3.9,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOTCMT","Million US$ at exchange rate","LUX","Luxembourg","2017","2017",4.1,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOTCMT","Million US$ at exchange rate","LUX","Luxembourg","2018","2018",4.6,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOTCMT","Million US$ at exchange rate","LUX","Luxembourg","2019","2019",4.8,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOTCMT","Million US$ at exchange rate","LUX","Luxembourg","2020","2020",4.6,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOTCMT","Million US$ at exchange rate","LUX","Luxembourg","2021","2021",5.2,"B; D; P","Break; Difference in methodology; Provisional value"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOTCMT","Million US$ at exchange rate","LUX","Luxembourg","2022","2022",4.3,"D; P","Difference in methodology; Provisional value"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOPPMT","Million US$, purchasing power parity","LUX","Luxembourg","2010","2010",2.6,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOPPMT","Million US$, purchasing power parity","LUX","Luxembourg","2011","2011",2.7,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOPPMT","Million US$, purchasing power parity","LUX","Luxembourg","2012","2012",3.9,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOPPMT","Million US$, purchasing power parity","LUX","Luxembourg","2013","2013",3.7,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOPPMT","Million US$, purchasing power parity","LUX","Luxembourg","2014","2014",3.9,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOPPMT","Million US$, purchasing power parity","LUX","Luxembourg","2015","2015",3.9,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOPPMT","Million US$, purchasing power parity","LUX","Luxembourg","2016","2016",4.1,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOPPMT","Million US$, purchasing power parity","LUX","Luxembourg","2017","2017",4.3,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOPPMT","Million US$, purchasing power parity","LUX","Luxembourg","2018","2018",4.6,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOPPMT","Million US$, purchasing power parity","LUX","Luxembourg","2019","2019",5.1,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOPPMT","Million US$, purchasing power parity","LUX","Luxembourg","2020","2020",4.7,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOPPMT","Million US$, purchasing power parity","LUX","Luxembourg","2021","2021",5.1,"B; D; P","Break; Difference in methodology; Provisional value"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOPPMT","Million US$, purchasing power parity","LUX","Luxembourg","2022","2022",5,"D; P","Difference in methodology; Provisional value"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","TCPPERMT","/capita, US$ exchange rate","LUX","Luxembourg","2010","2010",6.8,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","TCPPERMT","/capita, US$ exchange rate","LUX","Luxembourg","2011","2011",7.1,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","TCPPERMT","/capita, US$ exchange rate","LUX","Luxembourg","2012","2012",9.2,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","TCPPERMT","/capita, US$ exchange rate","LUX","Luxembourg","2013","2013",8.8,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","TCPPERMT","/capita, US$ exchange rate","LUX","Luxembourg","2014","2014",8.9,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","TCPPERMT","/capita, US$ exchange rate","LUX","Luxembourg","2015","2015",7.3,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","TCPPERMT","/capita, US$ exchange rate","LUX","Luxembourg","2016","2016",7.4,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","TCPPERMT","/capita, US$ exchange rate","LUX","Luxembourg","2017","2017",7.7,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","TCPPERMT","/capita, US$ exchange rate","LUX","Luxembourg","2018","2018",8.4,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","TCPPERMT","/capita, US$ exchange rate","LUX","Luxembourg","2019","2019",8.6,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","TCPPERMT","/capita, US$ exchange rate","LUX","Luxembourg","2020","2020",8.1,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","TCPPERMT","/capita, US$ exchange rate","LUX","Luxembourg","2021","2021",9.1,"B; D; P","Break; Difference in methodology; Provisional value"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","TCPPERMT","/capita, US$ exchange rate","LUX","Luxembourg","2022","2022",7.4,"D; P","Difference in methodology; Provisional value"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2010","2010",5.5,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2011","2011",5.7,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2012","2012",7.9,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2013","2013",7.4,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2014","2014",7.6,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2015","2015",7.5,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2016","2016",7.8,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2017","2017",8,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2018","2018",8.4,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2019","2019",9.1,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2020","2020",8.2,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2021","2021",8.9,"B; D; P","Break; Difference in methodology; Provisional value"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2022","2022",8.5,"D; P","Difference in methodology; Provisional value"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","ATCPTTMT","% of total sales","LUX","Luxembourg","2010","2010",1.3,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","ATCPTTMT","% of total sales","LUX","Luxembourg","2011","2011",1.3,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","ATCPTTMT","% of total sales","LUX","Luxembourg","2012","2012",1.8,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","ATCPTTMT","% of total sales","LUX","Luxembourg","2013","2013",1.7,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","ATCPTTMT","% of total sales","LUX","Luxembourg","2014","2014",1.8,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","ATCPTTMT","% of total sales","LUX","Luxembourg","2015","2015",1.8,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","ATCPTTMT","% of total sales","LUX","Luxembourg","2016","2016",1.8,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","ATCPTTMT","% of total sales","LUX","Luxembourg","2017","2017",1.9,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","ATCPTTMT","% of total sales","LUX","Luxembourg","2018","2018",2,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","ATCPTTMT","% of total sales","LUX","Luxembourg","2019","2019",2.1,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","ATCPTTMT","% of total sales","LUX","Luxembourg","2020","2020",1.9,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","ATCPTTMT","% of total sales","LUX","Luxembourg","2021","2021",1.8,"B; D; P","Break; Difference in methodology; Provisional value"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","ATCPTTMT","% of total sales","LUX","Luxembourg","2022","2022",1.6,"D; P","Difference in methodology; Provisional value"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MLLNCUMT","Million of national currency units","NLD","Netherlands","2010","2010",122.7,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MLLNCUMT","Million of national currency units","NLD","Netherlands","2011","2011",72.2,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MLLNCUMT","Million of national currency units","NLD","Netherlands","2012","2012",68.2,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MLLNCUMT","Million of national currency units","NLD","Netherlands","2013","2013",59.9,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MLLNCUMT","Million of national currency units","NLD","Netherlands","2014","2014",28.1,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOTCMT","Million US$ at exchange rate","NLD","Netherlands","2010","2010",162.7,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOTCMT","Million US$ at exchange rate","NLD","Netherlands","2011","2011",100.4,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOTCMT","Million US$ at exchange rate","NLD","Netherlands","2012","2012",87.6,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOTCMT","Million US$ at exchange rate","NLD","Netherlands","2013","2013",79.6,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOTCMT","Million US$ at exchange rate","NLD","Netherlands","2014","2014",37.3,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOPPMT","Million US$, purchasing power parity","NLD","Netherlands","2010","2010",143.7,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOPPMT","Million US$, purchasing power parity","NLD","Netherlands","2011","2011",86.3,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOPPMT","Million US$, purchasing power parity","NLD","Netherlands","2012","2012",82.7,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOPPMT","Million US$, purchasing power parity","NLD","Netherlands","2013","2013",75.1,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOPPMT","Million US$, purchasing power parity","NLD","Netherlands","2014","2014",34.7,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","TCPPERMT","/capita, US$ exchange rate","NLD","Netherlands","2010","2010",9.8,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","TCPPERMT","/capita, US$ exchange rate","NLD","Netherlands","2011","2011",6,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","TCPPERMT","/capita, US$ exchange rate","NLD","Netherlands","2012","2012",5.2,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","TCPPERMT","/capita, US$ exchange rate","NLD","Netherlands","2013","2013",4.7,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","TCPPERMT","/capita, US$ exchange rate","NLD","Netherlands","2014","2014",2.2,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","NLD","Netherlands","2010","2010",8.6,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","NLD","Netherlands","2011","2011",5.2,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","NLD","Netherlands","2012","2012",4.9,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","NLD","Netherlands","2013","2013",4.5,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","NLD","Netherlands","2014","2014",2.1,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","ATCPTTMT","% of total sales","NLD","Netherlands","2010","2010",2.4,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","ATCPTTMT","% of total sales","NLD","Netherlands","2011","2011",1.4,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","ATCPTTMT","% of total sales","NLD","Netherlands","2012","2012",1.5,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","ATCPTTMT","% of total sales","NLD","Netherlands","2013","2013",1.4,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","ATCPTTMT","% of total sales","NLD","Netherlands","2014","2014",0.6,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MLLNCUMT","Million of national currency units","NZL","New Zealand","2010","2010",12.1,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MLLNCUMT","Million of national currency units","NZL","New Zealand","2011","2011",13.2,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MLLNCUMT","Million of national currency units","NZL","New Zealand","2012","2012",13.6,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MLLNCUMT","Million of national currency units","NZL","New Zealand","2013","2013",11.4,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MLLNCUMT","Million of national currency units","NZL","New Zealand","2014","2014",11.1,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MLLNCUMT","Million of national currency units","NZL","New Zealand","2015","2015",12.9,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MLLNCUMT","Million of national currency units","NZL","New Zealand","2016","2016",12.6,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MLLNCUMT","Million of national currency units","NZL","New Zealand","2017","2017",11.4,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MLLNCUMT","Million of national currency units","NZL","New Zealand","2018","2018",10.9,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MLLNCUMT","Million of national currency units","NZL","New Zealand","2019","2019",12.2,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MLLNCUMT","Million of national currency units","NZL","New Zealand","2020","2020",12.3,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MLLNCUMT","Million of national currency units","NZL","New Zealand","2021","2021",13.7,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MLLNCUMT","Million of national currency units","NZL","New Zealand","2022","2022",15.8,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOTCMT","Million US$ at exchange rate","NZL","New Zealand","2010","2010",8.7,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOTCMT","Million US$ at exchange rate","NZL","New Zealand","2011","2011",10.5,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOTCMT","Million US$ at exchange rate","NZL","New Zealand","2012","2012",11,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOTCMT","Million US$ at exchange rate","NZL","New Zealand","2013","2013",9.4,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOTCMT","Million US$ at exchange rate","NZL","New Zealand","2014","2014",9.2,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOTCMT","Million US$ at exchange rate","NZL","New Zealand","2015","2015",9,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOTCMT","Million US$ at exchange rate","NZL","New Zealand","2016","2016",8.8,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOTCMT","Million US$ at exchange rate","NZL","New Zealand","2017","2017",8.1,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOTCMT","Million US$ at exchange rate","NZL","New Zealand","2018","2018",7.5,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOTCMT","Million US$ at exchange rate","NZL","New Zealand","2019","2019",8.1,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOTCMT","Million US$ at exchange rate","NZL","New Zealand","2020","2020",8,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOTCMT","Million US$ at exchange rate","NZL","New Zealand","2021","2021",9.7,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOTCMT","Million US$ at exchange rate","NZL","New Zealand","2022","2022",10,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOPPMT","Million US$, purchasing power parity","NZL","New Zealand","2010","2010",8.1,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOPPMT","Million US$, purchasing power parity","NZL","New Zealand","2011","2011",8.9,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOPPMT","Million US$, purchasing power parity","NZL","New Zealand","2012","2012",9.1,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOPPMT","Million US$, purchasing power parity","NZL","New Zealand","2013","2013",7.9,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOPPMT","Million US$, purchasing power parity","NZL","New Zealand","2014","2014",7.7,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOPPMT","Million US$, purchasing power parity","NZL","New Zealand","2015","2015",8.7,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOPPMT","Million US$, purchasing power parity","NZL","New Zealand","2016","2016",8.8,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOPPMT","Million US$, purchasing power parity","NZL","New Zealand","2017","2017",7.9,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOPPMT","Million US$, purchasing power parity","NZL","New Zealand","2018","2018",7.4,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOPPMT","Million US$, purchasing power parity","NZL","New Zealand","2019","2019",8.6,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOPPMT","Million US$, purchasing power parity","NZL","New Zealand","2020","2020",8.7,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOPPMT","Million US$, purchasing power parity","NZL","New Zealand","2021","2021",9.4,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOPPMT","Million US$, purchasing power parity","NZL","New Zealand","2022","2022",10.9,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","TCPPERMT","/capita, US$ exchange rate","NZL","New Zealand","2010","2010",2,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","TCPPERMT","/capita, US$ exchange rate","NZL","New Zealand","2011","2011",2.4,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","TCPPERMT","/capita, US$ exchange rate","NZL","New Zealand","2012","2012",2.5,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","TCPPERMT","/capita, US$ exchange rate","NZL","New Zealand","2013","2013",2.1,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","TCPPERMT","/capita, US$ exchange rate","NZL","New Zealand","2014","2014",2,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","TCPPERMT","/capita, US$ exchange rate","NZL","New Zealand","2015","2015",1.9,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","TCPPERMT","/capita, US$ exchange rate","NZL","New Zealand","2016","2016",1.9,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","TCPPERMT","/capita, US$ exchange rate","NZL","New Zealand","2017","2017",1.7,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","TCPPERMT","/capita, US$ exchange rate","NZL","New Zealand","2018","2018",1.5,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","TCPPERMT","/capita, US$ exchange rate","NZL","New Zealand","2019","2019",1.6,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","TCPPERMT","/capita, US$ exchange rate","NZL","New Zealand","2020","2020",1.6,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","TCPPERMT","/capita, US$ exchange rate","NZL","New Zealand","2021","2021",1.9,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","TCPPERMT","/capita, US$ exchange rate","NZL","New Zealand","2022","2022",2,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2010","2010",1.9,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2011","2011",2,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2012","2012",2.1,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2013","2013",1.8,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2014","2014",1.7,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2015","2015",1.9,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2016","2016",1.9,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2017","2017",1.6,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2018","2018",1.5,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2019","2019",1.7,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2020","2020",1.7,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2021","2021",1.8,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2022","2022",2.1,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","ATCPTTMT","% of total sales","NZL","New Zealand","2010","2010",1.6,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","ATCPTTMT","% of total sales","NZL","New Zealand","2011","2011",1.6,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","ATCPTTMT","% of total sales","NZL","New Zealand","2012","2012",1.5,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","ATCPTTMT","% of total sales","NZL","New Zealand","2013","2013",1.2,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","ATCPTTMT","% of total sales","NZL","New Zealand","2014","2014",1.2,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","ATCPTTMT","% of total sales","NZL","New Zealand","2015","2015",1.3,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","ATCPTTMT","% of total sales","NZL","New Zealand","2016","2016",1.2,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","ATCPTTMT","% of total sales","NZL","New Zealand","2017","2017",0.9,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","ATCPTTMT","% of total sales","NZL","New Zealand","2018","2018",0.8,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","ATCPTTMT","% of total sales","NZL","New Zealand","2019","2019",0.8,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","ATCPTTMT","% of total sales","NZL","New Zealand","2020","2020",0.7,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","ATCPTTMT","% of total sales","NZL","New Zealand","2021","2021",0.8,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","ATCPTTMT","% of total sales","NZL","New Zealand","2022","2022",0.8,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MLLNCUMT","Million of national currency units","NOR","Norway","2010","2010",433,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MLLNCUMT","Million of national currency units","NOR","Norway","2011","2011",436,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MLLNCUMT","Million of national currency units","NOR","Norway","2012","2012",441,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MLLNCUMT","Million of national currency units","NOR","Norway","2013","2013",454,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MLLNCUMT","Million of national currency units","NOR","Norway","2014","2014",471,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MLLNCUMT","Million of national currency units","NOR","Norway","2015","2015",512,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MLLNCUMT","Million of national currency units","NOR","Norway","2016","2016",545,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MLLNCUMT","Million of national currency units","NOR","Norway","2017","2017",562,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MLLNCUMT","Million of national currency units","NOR","Norway","2018","2018",559,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MLLNCUMT","Million of national currency units","NOR","Norway","2019","2019",580,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MLLNCUMT","Million of national currency units","NOR","Norway","2020","2020",596,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MLLNCUMT","Million of national currency units","NOR","Norway","2021","2021",598,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MLLNCUMT","Million of national currency units","NOR","Norway","2022","2022",576,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOTCMT","Million US$ at exchange rate","NOR","Norway","2010","2010",71.6,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOTCMT","Million US$ at exchange rate","NOR","Norway","2011","2011",77.8,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOTCMT","Million US$ at exchange rate","NOR","Norway","2012","2012",75.8,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOTCMT","Million US$ at exchange rate","NOR","Norway","2013","2013",77.3,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOTCMT","Million US$ at exchange rate","NOR","Norway","2014","2014",74.7,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOTCMT","Million US$ at exchange rate","NOR","Norway","2015","2015",63.5,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOTCMT","Million US$ at exchange rate","NOR","Norway","2016","2016",64.9,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOTCMT","Million US$ at exchange rate","NOR","Norway","2017","2017",67.9,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOTCMT","Million US$ at exchange rate","NOR","Norway","2018","2018",68.7,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOTCMT","Million US$ at exchange rate","NOR","Norway","2019","2019",65.9,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOTCMT","Million US$ at exchange rate","NOR","Norway","2020","2020",63.3,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOTCMT","Million US$ at exchange rate","NOR","Norway","2021","2021",69.6,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOTCMT","Million US$ at exchange rate","NOR","Norway","2022","2022",59.9,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOPPMT","Million US$, purchasing power parity","NOR","Norway","2010","2010",47.3,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOPPMT","Million US$, purchasing power parity","NOR","Norway","2011","2011",48,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOPPMT","Million US$, purchasing power parity","NOR","Norway","2012","2012",48.8,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOPPMT","Million US$, purchasing power parity","NOR","Norway","2013","2013",50.3,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOPPMT","Million US$, purchasing power parity","NOR","Norway","2014","2014",50.8,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOPPMT","Million US$, purchasing power parity","NOR","Norway","2015","2015",51.5,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOPPMT","Million US$, purchasing power parity","NOR","Norway","2016","2016",54.3,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOPPMT","Million US$, purchasing power parity","NOR","Norway","2017","2017",57.6,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOPPMT","Million US$, purchasing power parity","NOR","Norway","2018","2018",58.3,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOPPMT","Million US$, purchasing power parity","NOR","Norway","2019","2019",60.3,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOPPMT","Million US$, purchasing power parity","NOR","Norway","2020","2020",60.3,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOPPMT","Million US$, purchasing power parity","NOR","Norway","2021","2021",62.9,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOPPMT","Million US$, purchasing power parity","NOR","Norway","2022","2022",53.6,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","TCPPERMT","/capita, US$ exchange rate","NOR","Norway","2010","2010",14.7,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","TCPPERMT","/capita, US$ exchange rate","NOR","Norway","2011","2011",15.7,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","TCPPERMT","/capita, US$ exchange rate","NOR","Norway","2012","2012",15.1,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","TCPPERMT","/capita, US$ exchange rate","NOR","Norway","2013","2013",15.2,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","TCPPERMT","/capita, US$ exchange rate","NOR","Norway","2014","2014",14.5,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","TCPPERMT","/capita, US$ exchange rate","NOR","Norway","2015","2015",12.2,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","TCPPERMT","/capita, US$ exchange rate","NOR","Norway","2016","2016",12.4,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","TCPPERMT","/capita, US$ exchange rate","NOR","Norway","2017","2017",12.9,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","TCPPERMT","/capita, US$ exchange rate","NOR","Norway","2018","2018",12.9,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","TCPPERMT","/capita, US$ exchange rate","NOR","Norway","2019","2019",12.3,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","TCPPERMT","/capita, US$ exchange rate","NOR","Norway","2020","2020",11.8,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","TCPPERMT","/capita, US$ exchange rate","NOR","Norway","2021","2021",12.9,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","TCPPERMT","/capita, US$ exchange rate","NOR","Norway","2022","2022",11,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2010","2010",9.7,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2011","2011",9.7,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2012","2012",9.7,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2013","2013",9.9,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2014","2014",9.9,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2015","2015",9.9,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2016","2016",10.4,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2017","2017",10.9,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2018","2018",11,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2019","2019",11.3,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2020","2020",11.2,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2021","2021",11.6,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2022","2022",9.9,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","ATCPTTMT","% of total sales","NOR","Norway","2010","2010",2.4,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","ATCPTTMT","% of total sales","NOR","Norway","2011","2011",2.4,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","ATCPTTMT","% of total sales","NOR","Norway","2012","2012",2.3,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","ATCPTTMT","% of total sales","NOR","Norway","2013","2013",2.4,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","ATCPTTMT","% of total sales","NOR","Norway","2014","2014",2.2,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","ATCPTTMT","% of total sales","NOR","Norway","2015","2015",2.2,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","ATCPTTMT","% of total sales","NOR","Norway","2016","2016",2.2,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","ATCPTTMT","% of total sales","NOR","Norway","2017","2017",2.1,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","ATCPTTMT","% of total sales","NOR","Norway","2018","2018",2,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","ATCPTTMT","% of total sales","NOR","Norway","2019","2019",2,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","ATCPTTMT","% of total sales","NOR","Norway","2020","2020",2,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","ATCPTTMT","% of total sales","NOR","Norway","2021","2021",1.8,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","ATCPTTMT","% of total sales","NOR","Norway","2022","2022",1.6,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MLLNCUMT","Million of national currency units","PRT","Portugal","2010","2010",81.5,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MLLNCUMT","Million of national currency units","PRT","Portugal","2011","2011",78.3,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MLLNCUMT","Million of national currency units","PRT","Portugal","2012","2012",74.7,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MLLNCUMT","Million of national currency units","PRT","Portugal","2013","2013",66.9,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MLLNCUMT","Million of national currency units","PRT","Portugal","2014","2014",63.3,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MLLNCUMT","Million of national currency units","PRT","Portugal","2015","2015",60.9,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MLLNCUMT","Million of national currency units","PRT","Portugal","2016","2016",61,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MLLNCUMT","Million of national currency units","PRT","Portugal","2017","2017",61.6,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MLLNCUMT","Million of national currency units","PRT","Portugal","2018","2018",60.8,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MLLNCUMT","Million of national currency units","PRT","Portugal","2019","2019",61.1,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MLLNCUMT","Million of national currency units","PRT","Portugal","2020","2020",58.6,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MLLNCUMT","Million of national currency units","PRT","Portugal","2021","2021",61.3,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MLLNCUMT","Million of national currency units","PRT","Portugal","2022","2022",62.7,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOTCMT","Million US$ at exchange rate","PRT","Portugal","2010","2010",108,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOTCMT","Million US$ at exchange rate","PRT","Portugal","2011","2011",108.9,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOTCMT","Million US$ at exchange rate","PRT","Portugal","2012","2012",95.9,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOTCMT","Million US$ at exchange rate","PRT","Portugal","2013","2013",88.9,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOTCMT","Million US$ at exchange rate","PRT","Portugal","2014","2014",84.1,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOTCMT","Million US$ at exchange rate","PRT","Portugal","2015","2015",67.6,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOTCMT","Million US$ at exchange rate","PRT","Portugal","2016","2016",67.5,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOTCMT","Million US$ at exchange rate","PRT","Portugal","2017","2017",69.6,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOTCMT","Million US$ at exchange rate","PRT","Portugal","2018","2018",71.8,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOTCMT","Million US$ at exchange rate","PRT","Portugal","2019","2019",68.4,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOTCMT","Million US$ at exchange rate","PRT","Portugal","2020","2020",66.9,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOTCMT","Million US$ at exchange rate","PRT","Portugal","2021","2021",72.5,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOTCMT","Million US$ at exchange rate","PRT","Portugal","2022","2022",66,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOPPMT","Million US$, purchasing power parity","PRT","Portugal","2010","2010",130.7,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOPPMT","Million US$, purchasing power parity","PRT","Portugal","2011","2011",125.6,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOPPMT","Million US$, purchasing power parity","PRT","Portugal","2012","2012",123.3,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOPPMT","Million US$, purchasing power parity","PRT","Portugal","2013","2013",114.6,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOPPMT","Million US$, purchasing power parity","PRT","Portugal","2014","2014",109.3,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOPPMT","Million US$, purchasing power parity","PRT","Portugal","2015","2015",104.1,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOPPMT","Million US$, purchasing power parity","PRT","Portugal","2016","2016",106.8,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOPPMT","Million US$, purchasing power parity","PRT","Portugal","2017","2017",107,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOPPMT","Million US$, purchasing power parity","PRT","Portugal","2018","2018",106.5,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOPPMT","Million US$, purchasing power parity","PRT","Portugal","2019","2019",109.4,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOPPMT","Million US$, purchasing power parity","PRT","Portugal","2020","2020",105.2,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOPPMT","Million US$, purchasing power parity","PRT","Portugal","2021","2021",108,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOPPMT","Million US$, purchasing power parity","PRT","Portugal","2022","2022",114,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","TCPPERMT","/capita, US$ exchange rate","PRT","Portugal","2010","2010",10.2,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","TCPPERMT","/capita, US$ exchange rate","PRT","Portugal","2011","2011",10.3,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","TCPPERMT","/capita, US$ exchange rate","PRT","Portugal","2012","2012",9.1,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","TCPPERMT","/capita, US$ exchange rate","PRT","Portugal","2013","2013",8.5,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","TCPPERMT","/capita, US$ exchange rate","PRT","Portugal","2014","2014",8.1,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","TCPPERMT","/capita, US$ exchange rate","PRT","Portugal","2015","2015",6.5,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","TCPPERMT","/capita, US$ exchange rate","PRT","Portugal","2016","2016",6.5,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","TCPPERMT","/capita, US$ exchange rate","PRT","Portugal","2017","2017",6.8,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","TCPPERMT","/capita, US$ exchange rate","PRT","Portugal","2018","2018",7,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","TCPPERMT","/capita, US$ exchange rate","PRT","Portugal","2019","2019",6.6,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","TCPPERMT","/capita, US$ exchange rate","PRT","Portugal","2020","2020",6.5,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","TCPPERMT","/capita, US$ exchange rate","PRT","Portugal","2021","2021",7,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","TCPPERMT","/capita, US$ exchange rate","PRT","Portugal","2022","2022",6.4,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2010","2010",12.4,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2011","2011",11.9,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2012","2012",11.7,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2013","2013",11,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2014","2014",10.5,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2015","2015",10.1,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2016","2016",10.3,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2017","2017",10.4,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2018","2018",10.4,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2019","2019",10.6,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2020","2020",10.2,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2021","2021",10.4,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2022","2022",11,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","ATCPTTMT","% of total sales","PRT","Portugal","2010","2010",2.5,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","ATCPTTMT","% of total sales","PRT","Portugal","2011","2011",2.7,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","ATCPTTMT","% of total sales","PRT","Portugal","2012","2012",2.9,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","ATCPTTMT","% of total sales","PRT","Portugal","2013","2013",2.8,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","ATCPTTMT","% of total sales","PRT","Portugal","2014","2014",2.6,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","ATCPTTMT","% of total sales","PRT","Portugal","2015","2015",2.4,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","ATCPTTMT","% of total sales","PRT","Portugal","2016","2016",2.4,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","ATCPTTMT","% of total sales","PRT","Portugal","2017","2017",2.4,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","ATCPTTMT","% of total sales","PRT","Portugal","2018","2018",2.3,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","ATCPTTMT","% of total sales","PRT","Portugal","2019","2019",2.2,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","ATCPTTMT","% of total sales","PRT","Portugal","2020","2020",2.1,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","ATCPTTMT","% of total sales","PRT","Portugal","2021","2021",2.1,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","ATCPTTMT","% of total sales","PRT","Portugal","2022","2022",2,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MLLNCUMT","Million of national currency units","SVK","Slovak Republic","2010","2010",21,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MLLNCUMT","Million of national currency units","SVK","Slovak Republic","2011","2011",20.8,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MLLNCUMT","Million of national currency units","SVK","Slovak Republic","2012","2012",19.1,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MLLNCUMT","Million of national currency units","SVK","Slovak Republic","2013","2013",19.6,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MLLNCUMT","Million of national currency units","SVK","Slovak Republic","2014","2014",17.9,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MLLNCUMT","Million of national currency units","SVK","Slovak Republic","2015","2015",17.4,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MLLNCUMT","Million of national currency units","SVK","Slovak Republic","2016","2016",19,"B","Break"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MLLNCUMT","Million of national currency units","SVK","Slovak Republic","2017","2017",18.7,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MLLNCUMT","Million of national currency units","SVK","Slovak Republic","2018","2018",18.3,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MLLNCUMT","Million of national currency units","SVK","Slovak Republic","2019","2019",17.8,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MLLNCUMT","Million of national currency units","SVK","Slovak Republic","2020","2020",16,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MLLNCUMT","Million of national currency units","SVK","Slovak Republic","2021","2021",18.1,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOTCMT","Million US$ at exchange rate","SVK","Slovak Republic","2010","2010",27.9,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOTCMT","Million US$ at exchange rate","SVK","Slovak Republic","2011","2011",28.9,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOTCMT","Million US$ at exchange rate","SVK","Slovak Republic","2012","2012",24.6,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOTCMT","Million US$ at exchange rate","SVK","Slovak Republic","2013","2013",26.1,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOTCMT","Million US$ at exchange rate","SVK","Slovak Republic","2014","2014",23.8,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOTCMT","Million US$ at exchange rate","SVK","Slovak Republic","2015","2015",19.3,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOTCMT","Million US$ at exchange rate","SVK","Slovak Republic","2016","2016",21,"B","Break"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOTCMT","Million US$ at exchange rate","SVK","Slovak Republic","2017","2017",21.2,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOTCMT","Million US$ at exchange rate","SVK","Slovak Republic","2018","2018",21.6,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOTCMT","Million US$ at exchange rate","SVK","Slovak Republic","2019","2019",19.9,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOTCMT","Million US$ at exchange rate","SVK","Slovak Republic","2020","2020",18.3,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOTCMT","Million US$ at exchange rate","SVK","Slovak Republic","2021","2021",21.4,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOPPMT","Million US$, purchasing power parity","SVK","Slovak Republic","2010","2010",41.9,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOPPMT","Million US$, purchasing power parity","SVK","Slovak Republic","2011","2011",41,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOPPMT","Million US$, purchasing power parity","SVK","Slovak Republic","2012","2012",37.9,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOPPMT","Million US$, purchasing power parity","SVK","Slovak Republic","2013","2013",40,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOPPMT","Million US$, purchasing power parity","SVK","Slovak Republic","2014","2014",36.8,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOPPMT","Million US$, purchasing power parity","SVK","Slovak Republic","2015","2015",35.3,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOPPMT","Million US$, purchasing power parity","SVK","Slovak Republic","2016","2016",37.7,"B","Break"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOPPMT","Million US$, purchasing power parity","SVK","Slovak Republic","2017","2017",36.3,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOPPMT","Million US$, purchasing power parity","SVK","Slovak Republic","2018","2018",34.8,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOPPMT","Million US$, purchasing power parity","SVK","Slovak Republic","2019","2019",34.4,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOPPMT","Million US$, purchasing power parity","SVK","Slovak Republic","2020","2020",30.8,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOPPMT","Million US$, purchasing power parity","SVK","Slovak Republic","2021","2021",33.9,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","TCPPERMT","/capita, US$ exchange rate","SVK","Slovak Republic","2010","2010",5.2,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","TCPPERMT","/capita, US$ exchange rate","SVK","Slovak Republic","2011","2011",5.4,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","TCPPERMT","/capita, US$ exchange rate","SVK","Slovak Republic","2012","2012",4.5,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","TCPPERMT","/capita, US$ exchange rate","SVK","Slovak Republic","2013","2013",4.8,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","TCPPERMT","/capita, US$ exchange rate","SVK","Slovak Republic","2014","2014",4.4,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","TCPPERMT","/capita, US$ exchange rate","SVK","Slovak Republic","2015","2015",3.6,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","TCPPERMT","/capita, US$ exchange rate","SVK","Slovak Republic","2016","2016",3.9,"B","Break"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","TCPPERMT","/capita, US$ exchange rate","SVK","Slovak Republic","2017","2017",3.9,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","TCPPERMT","/capita, US$ exchange rate","SVK","Slovak Republic","2018","2018",4,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","TCPPERMT","/capita, US$ exchange rate","SVK","Slovak Republic","2019","2019",3.7,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","TCPPERMT","/capita, US$ exchange rate","SVK","Slovak Republic","2020","2020",3.3,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","TCPPERMT","/capita, US$ exchange rate","SVK","Slovak Republic","2021","2021",3.9,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2010","2010",7.8,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2011","2011",7.6,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2012","2012",7,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2013","2013",7.4,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2014","2014",6.8,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2015","2015",6.5,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2016","2016",6.9,"B","Break"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2017","2017",6.7,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2018","2018",6.4,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2019","2019",6.3,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2020","2020",5.6,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2021","2021",6.2,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","ATCPTTMT","% of total sales","SVK","Slovak Republic","2010","2010",1.9,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","ATCPTTMT","% of total sales","SVK","Slovak Republic","2011","2011",1.8,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","ATCPTTMT","% of total sales","SVK","Slovak Republic","2012","2012",1.7,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","ATCPTTMT","% of total sales","SVK","Slovak Republic","2013","2013",1.6,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","ATCPTTMT","% of total sales","SVK","Slovak Republic","2014","2014",1.4,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","ATCPTTMT","% of total sales","SVK","Slovak Republic","2015","2015",1.3,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","ATCPTTMT","% of total sales","SVK","Slovak Republic","2016","2016",1.2,"B","Break"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","ATCPTTMT","% of total sales","SVK","Slovak Republic","2017","2017",1.2,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","ATCPTTMT","% of total sales","SVK","Slovak Republic","2018","2018",1.1,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","ATCPTTMT","% of total sales","SVK","Slovak Republic","2019","2019",1,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","ATCPTTMT","% of total sales","SVK","Slovak Republic","2020","2020",1,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","ATCPTTMT","% of total sales","SVK","Slovak Republic","2021","2021",1,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MLLNCUMT","Million of national currency units","ESP","Spain","2010","2010",124.8,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MLLNCUMT","Million of national currency units","ESP","Spain","2011","2011",114.8,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MLLNCUMT","Million of national currency units","ESP","Spain","2012","2012",125.1,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MLLNCUMT","Million of national currency units","ESP","Spain","2013","2013",121.7,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MLLNCUMT","Million of national currency units","ESP","Spain","2014","2014",103.4,"B; D","Break; Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MLLNCUMT","Million of national currency units","ESP","Spain","2015","2015",96.6,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MLLNCUMT","Million of national currency units","ESP","Spain","2016","2016",99.3,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MLLNCUMT","Million of national currency units","ESP","Spain","2017","2017",107.7,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MLLNCUMT","Million of national currency units","ESP","Spain","2018","2018",105.6,"B","Break"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MLLNCUMT","Million of national currency units","ESP","Spain","2019","2019",108.5,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MLLNCUMT","Million of national currency units","ESP","Spain","2020","2020",95,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MLLNCUMT","Million of national currency units","ESP","Spain","2021","2021",106.1,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MLLNCUMT","Million of national currency units","ESP","Spain","2022","2022",113.9,"P","Provisional value"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOTCMT","Million US$ at exchange rate","ESP","Spain","2010","2010",165.5,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOTCMT","Million US$ at exchange rate","ESP","Spain","2011","2011",159.7,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOTCMT","Million US$ at exchange rate","ESP","Spain","2012","2012",160.7,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOTCMT","Million US$ at exchange rate","ESP","Spain","2013","2013",161.7,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOTCMT","Million US$ at exchange rate","ESP","Spain","2014","2014",137.4,"B; D","Break; Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOTCMT","Million US$ at exchange rate","ESP","Spain","2015","2015",107.1,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOTCMT","Million US$ at exchange rate","ESP","Spain","2016","2016",110,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOTCMT","Million US$ at exchange rate","ESP","Spain","2017","2017",121.7,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOTCMT","Million US$ at exchange rate","ESP","Spain","2018","2018",124.7,"B","Break"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOTCMT","Million US$ at exchange rate","ESP","Spain","2019","2019",121.5,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOTCMT","Million US$ at exchange rate","ESP","Spain","2020","2020",108.5,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOTCMT","Million US$ at exchange rate","ESP","Spain","2021","2021",125.5,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOTCMT","Million US$ at exchange rate","ESP","Spain","2022","2022",120,"P","Provisional value"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOPPMT","Million US$, purchasing power parity","ESP","Spain","2010","2010",171.7,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOPPMT","Million US$, purchasing power parity","ESP","Spain","2011","2011",160.7,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOPPMT","Million US$, purchasing power parity","ESP","Spain","2012","2012",179.9,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOPPMT","Million US$, purchasing power parity","ESP","Spain","2013","2013",180.4,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOPPMT","Million US$, purchasing power parity","ESP","Spain","2014","2014",156.1,"B; D","Break; Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOPPMT","Million US$, purchasing power parity","ESP","Spain","2015","2015",145.3,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOPPMT","Million US$, purchasing power parity","ESP","Spain","2016","2016",154.6,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOPPMT","Million US$, purchasing power parity","ESP","Spain","2017","2017",170.7,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOPPMT","Million US$, purchasing power parity","ESP","Spain","2018","2018",167.1,"B","Break"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOPPMT","Million US$, purchasing power parity","ESP","Spain","2019","2019",177,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOPPMT","Million US$, purchasing power parity","ESP","Spain","2020","2020",152.8,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOPPMT","Million US$, purchasing power parity","ESP","Spain","2021","2021",169.5,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOPPMT","Million US$, purchasing power parity","ESP","Spain","2022","2022",191.1,"P","Provisional value"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","TCPPERMT","/capita, US$ exchange rate","ESP","Spain","2010","2010",3.6,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","TCPPERMT","/capita, US$ exchange rate","ESP","Spain","2011","2011",3.4,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","TCPPERMT","/capita, US$ exchange rate","ESP","Spain","2012","2012",3.4,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","TCPPERMT","/capita, US$ exchange rate","ESP","Spain","2013","2013",3.5,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","TCPPERMT","/capita, US$ exchange rate","ESP","Spain","2014","2014",3,"B; D","Break; Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","TCPPERMT","/capita, US$ exchange rate","ESP","Spain","2015","2015",2.3,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","TCPPERMT","/capita, US$ exchange rate","ESP","Spain","2016","2016",2.4,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","TCPPERMT","/capita, US$ exchange rate","ESP","Spain","2017","2017",2.6,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","TCPPERMT","/capita, US$ exchange rate","ESP","Spain","2018","2018",2.7,"B","Break"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","TCPPERMT","/capita, US$ exchange rate","ESP","Spain","2019","2019",2.6,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","TCPPERMT","/capita, US$ exchange rate","ESP","Spain","2020","2020",2.3,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","TCPPERMT","/capita, US$ exchange rate","ESP","Spain","2021","2021",2.6,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","TCPPERMT","/capita, US$ exchange rate","ESP","Spain","2022","2022",2.5,"P","Provisional value"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2010","2010",3.7,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2011","2011",3.4,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2012","2012",3.8,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2013","2013",3.9,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2014","2014",3.4,"B; D","Break; Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2015","2015",3.1,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2016","2016",3.3,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2017","2017",3.7,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2018","2018",3.6,"B","Break"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2019","2019",3.8,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2020","2020",3.2,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2021","2021",3.6,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2022","2022",4,"P","Provisional value"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","ATCPTTMT","% of total sales","ESP","Spain","2010","2010",0.9,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","ATCPTTMT","% of total sales","ESP","Spain","2011","2011",0.9,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","ATCPTTMT","% of total sales","ESP","Spain","2012","2012",1.1,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","ATCPTTMT","% of total sales","ESP","Spain","2013","2013",1.1,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","ATCPTTMT","% of total sales","ESP","Spain","2014","2014",0.9,"B; D","Break; Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","ATCPTTMT","% of total sales","ESP","Spain","2015","2015",0.8,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","ATCPTTMT","% of total sales","ESP","Spain","2016","2016",0.8,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","ATCPTTMT","% of total sales","ESP","Spain","2017","2017",0.9,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","ATCPTTMT","% of total sales","ESP","Spain","2018","2018",0.6,"B","Break"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","ATCPTTMT","% of total sales","ESP","Spain","2019","2019",0.5,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","ATCPTTMT","% of total sales","ESP","Spain","2020","2020",0.5,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","ATCPTTMT","% of total sales","ESP","Spain","2021","2021",0.5,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","ATCPTTMT","% of total sales","ESP","Spain","2022","2022",0.5,"P","Provisional value"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MLLNCUMT","Million of national currency units","SWE","Sweden","2010","2010",895.5,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MLLNCUMT","Million of national currency units","SWE","Sweden","2011","2011",898.8,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MLLNCUMT","Million of national currency units","SWE","Sweden","2012","2012",922.9,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MLLNCUMT","Million of national currency units","SWE","Sweden","2013","2013",928.4,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MLLNCUMT","Million of national currency units","SWE","Sweden","2014","2014",923.3,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MLLNCUMT","Million of national currency units","SWE","Sweden","2015","2015",925.1,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MLLNCUMT","Million of national currency units","SWE","Sweden","2016","2016",924.5,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MLLNCUMT","Million of national currency units","SWE","Sweden","2017","2017",927,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MLLNCUMT","Million of national currency units","SWE","Sweden","2018","2018",920.9,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MLLNCUMT","Million of national currency units","SWE","Sweden","2019","2019",951.8,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MLLNCUMT","Million of national currency units","SWE","Sweden","2020","2020",931,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MLLNCUMT","Million of national currency units","SWE","Sweden","2021","2021",958.6,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MLLNCUMT","Million of national currency units","SWE","Sweden","2022","2022",1010.5,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOTCMT","Million US$ at exchange rate","SWE","Sweden","2010","2010",124.2,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOTCMT","Million US$ at exchange rate","SWE","Sweden","2011","2011",138.4,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOTCMT","Million US$ at exchange rate","SWE","Sweden","2012","2012",136.2,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOTCMT","Million US$ at exchange rate","SWE","Sweden","2013","2013",142.5,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOTCMT","Million US$ at exchange rate","SWE","Sweden","2014","2014",134.6,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOTCMT","Million US$ at exchange rate","SWE","Sweden","2015","2015",109.7,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOTCMT","Million US$ at exchange rate","SWE","Sweden","2016","2016",108,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOTCMT","Million US$ at exchange rate","SWE","Sweden","2017","2017",108.4,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOTCMT","Million US$ at exchange rate","SWE","Sweden","2018","2018",105.9,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOTCMT","Million US$ at exchange rate","SWE","Sweden","2019","2019",100.6,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOTCMT","Million US$ at exchange rate","SWE","Sweden","2020","2020",101.1,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOTCMT","Million US$ at exchange rate","SWE","Sweden","2021","2021",111.8,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOTCMT","Million US$ at exchange rate","SWE","Sweden","2022","2022",99.9,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOPPMT","Million US$, purchasing power parity","SWE","Sweden","2010","2010",99.2,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOPPMT","Million US$, purchasing power parity","SWE","Sweden","2011","2011",101.6,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOPPMT","Million US$, purchasing power parity","SWE","Sweden","2012","2012",106.6,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOPPMT","Million US$, purchasing power parity","SWE","Sweden","2013","2013",108,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOPPMT","Million US$, purchasing power parity","SWE","Sweden","2014","2014",105.8,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOPPMT","Million US$, purchasing power parity","SWE","Sweden","2015","2015",104.5,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOPPMT","Million US$, purchasing power parity","SWE","Sweden","2016","2016",104.8,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOPPMT","Million US$, purchasing power parity","SWE","Sweden","2017","2017",104.7,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOPPMT","Million US$, purchasing power parity","SWE","Sweden","2018","2018",103.9,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOPPMT","Million US$, purchasing power parity","SWE","Sweden","2019","2019",109.3,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOPPMT","Million US$, purchasing power parity","SWE","Sweden","2020","2020",107.4,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOPPMT","Million US$, purchasing power parity","SWE","Sweden","2021","2021",109.9,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOPPMT","Million US$, purchasing power parity","SWE","Sweden","2022","2022",116.6,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","TCPPERMT","/capita, US$ exchange rate","SWE","Sweden","2010","2010",13.2,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","TCPPERMT","/capita, US$ exchange rate","SWE","Sweden","2011","2011",14.6,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","TCPPERMT","/capita, US$ exchange rate","SWE","Sweden","2012","2012",14.3,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","TCPPERMT","/capita, US$ exchange rate","SWE","Sweden","2013","2013",14.8,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","TCPPERMT","/capita, US$ exchange rate","SWE","Sweden","2014","2014",13.9,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","TCPPERMT","/capita, US$ exchange rate","SWE","Sweden","2015","2015",11.2,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","TCPPERMT","/capita, US$ exchange rate","SWE","Sweden","2016","2016",10.9,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","TCPPERMT","/capita, US$ exchange rate","SWE","Sweden","2017","2017",10.8,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","TCPPERMT","/capita, US$ exchange rate","SWE","Sweden","2018","2018",10.4,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","TCPPERMT","/capita, US$ exchange rate","SWE","Sweden","2019","2019",9.8,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","TCPPERMT","/capita, US$ exchange rate","SWE","Sweden","2020","2020",9.8,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","TCPPERMT","/capita, US$ exchange rate","SWE","Sweden","2021","2021",10.7,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","TCPPERMT","/capita, US$ exchange rate","SWE","Sweden","2022","2022",9.6,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2010","2010",10.6,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2011","2011",10.8,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2012","2012",11.2,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2013","2013",11.2,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2014","2014",10.9,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2015","2015",10.7,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2016","2016",10.6,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2017","2017",10.4,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2018","2018",10.2,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2019","2019",10.6,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2020","2020",10.4,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2021","2021",10.6,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2022","2022",11.2,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","ATCPTTMT","% of total sales","SWE","Sweden","2010","2010",2.5,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","ATCPTTMT","% of total sales","SWE","Sweden","2011","2011",2.4,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","ATCPTTMT","% of total sales","SWE","Sweden","2012","2012",2.6,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","ATCPTTMT","% of total sales","SWE","Sweden","2013","2013",2.6,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","ATCPTTMT","% of total sales","SWE","Sweden","2014","2014",2.4,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","ATCPTTMT","% of total sales","SWE","Sweden","2015","2015",2.3,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","ATCPTTMT","% of total sales","SWE","Sweden","2016","2016",2.2,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","ATCPTTMT","% of total sales","SWE","Sweden","2017","2017",2.1,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","ATCPTTMT","% of total sales","SWE","Sweden","2018","2018",1.9,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","ATCPTTMT","% of total sales","SWE","Sweden","2019","2019",1.9,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","ATCPTTMT","% of total sales","SWE","Sweden","2020","2020",1.8,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","ATCPTTMT","% of total sales","SWE","Sweden","2021","2021",1.8,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","ATCPTTMT","% of total sales","SWE","Sweden","2022","2022",1.7,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MLLNCUMT","Million of national currency units","TUR","Türkiye","2010","2010",188.6,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MLLNCUMT","Million of national currency units","TUR","Türkiye","2011","2011",187,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MLLNCUMT","Million of national currency units","TUR","Türkiye","2012","2012",197.6,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MLLNCUMT","Million of national currency units","TUR","Türkiye","2013","2013",230.7,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MLLNCUMT","Million of national currency units","TUR","Türkiye","2014","2014",263.3,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MLLNCUMT","Million of national currency units","TUR","Türkiye","2015","2015",305.1,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MLLNCUMT","Million of national currency units","TUR","Türkiye","2016","2016",335.4,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MLLNCUMT","Million of national currency units","TUR","Türkiye","2017","2017",406.5,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MLLNCUMT","Million of national currency units","TUR","Türkiye","2018","2018",494.3,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MLLNCUMT","Million of national currency units","TUR","Türkiye","2019","2019",656.5,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MLLNCUMT","Million of national currency units","TUR","Türkiye","2020","2020",721.2,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MLLNCUMT","Million of national currency units","TUR","Türkiye","2021","2021",1104.6,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOTCMT","Million US$ at exchange rate","TUR","Türkiye","2010","2010",125.5,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOTCMT","Million US$ at exchange rate","TUR","Türkiye","2011","2011",111.6,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOTCMT","Million US$ at exchange rate","TUR","Türkiye","2012","2012",110,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOTCMT","Million US$ at exchange rate","TUR","Türkiye","2013","2013",121.2,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOTCMT","Million US$ at exchange rate","TUR","Türkiye","2014","2014",120.3,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOTCMT","Million US$ at exchange rate","TUR","Türkiye","2015","2015",112.2,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOTCMT","Million US$ at exchange rate","TUR","Türkiye","2016","2016",111,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOTCMT","Million US$ at exchange rate","TUR","Türkiye","2017","2017",111.4,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOTCMT","Million US$ at exchange rate","TUR","Türkiye","2018","2018",102.4,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOTCMT","Million US$ at exchange rate","TUR","Türkiye","2019","2019",115.7,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOTCMT","Million US$ at exchange rate","TUR","Türkiye","2020","2020",102.9,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOTCMT","Million US$ at exchange rate","TUR","Türkiye","2021","2021",124.8,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOPPMT","Million US$, purchasing power parity","TUR","Türkiye","2010","2010",204.9,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOPPMT","Million US$, purchasing power parity","TUR","Türkiye","2011","2011",193.5,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOPPMT","Million US$, purchasing power parity","TUR","Türkiye","2012","2012",193.8,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOPPMT","Million US$, purchasing power parity","TUR","Türkiye","2013","2013",215.6,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOPPMT","Million US$, purchasing power parity","TUR","Türkiye","2014","2014",238.4,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOPPMT","Million US$, purchasing power parity","TUR","Türkiye","2015","2015",262.5,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOPPMT","Million US$, purchasing power parity","TUR","Türkiye","2016","2016",270.2,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOPPMT","Million US$, purchasing power parity","TUR","Türkiye","2017","2017",293.7,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOPPMT","Million US$, purchasing power parity","TUR","Türkiye","2018","2018",302.8,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOPPMT","Million US$, purchasing power parity","TUR","Türkiye","2019","2019",352.2,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOPPMT","Million US$, purchasing power parity","TUR","Türkiye","2020","2020",333.3,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOPPMT","Million US$, purchasing power parity","TUR","Türkiye","2021","2021",393.4,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","TCPPERMT","/capita, US$ exchange rate","TUR","Türkiye","2010","2010",1.7,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","TCPPERMT","/capita, US$ exchange rate","TUR","Türkiye","2011","2011",1.5,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","TCPPERMT","/capita, US$ exchange rate","TUR","Türkiye","2012","2012",1.5,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","TCPPERMT","/capita, US$ exchange rate","TUR","Türkiye","2013","2013",1.6,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","TCPPERMT","/capita, US$ exchange rate","TUR","Türkiye","2014","2014",1.6,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","TCPPERMT","/capita, US$ exchange rate","TUR","Türkiye","2015","2015",1.4,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","TCPPERMT","/capita, US$ exchange rate","TUR","Türkiye","2016","2016",1.4,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","TCPPERMT","/capita, US$ exchange rate","TUR","Türkiye","2017","2017",1.4,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","TCPPERMT","/capita, US$ exchange rate","TUR","Türkiye","2018","2018",1.3,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","TCPPERMT","/capita, US$ exchange rate","TUR","Türkiye","2019","2019",1.4,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","TCPPERMT","/capita, US$ exchange rate","TUR","Türkiye","2020","2020",1.2,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","TCPPERMT","/capita, US$ exchange rate","TUR","Türkiye","2021","2021",1.5,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2010","2010",2.8,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2011","2011",2.6,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2012","2012",2.6,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2013","2013",2.8,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2014","2014",3.1,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2015","2015",3.4,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2016","2016",3.4,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2017","2017",3.7,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2018","2018",3.7,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2019","2019",4.3,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2020","2020",4,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2021","2021",4.7,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","ATCPTTMT","% of total sales","TUR","Türkiye","2010","2010",1.2,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","ATCPTTMT","% of total sales","TUR","Türkiye","2011","2011",1.3,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","ATCPTTMT","% of total sales","TUR","Türkiye","2012","2012",1.5,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","ATCPTTMT","% of total sales","TUR","Türkiye","2013","2013",1.6,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","ATCPTTMT","% of total sales","TUR","Türkiye","2014","2014",1.7,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","ATCPTTMT","% of total sales","TUR","Türkiye","2015","2015",1.7,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","ATCPTTMT","% of total sales","TUR","Türkiye","2016","2016",1.5,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","ATCPTTMT","% of total sales","TUR","Türkiye","2017","2017",1.6,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","ATCPTTMT","% of total sales","TUR","Türkiye","2018","2018",1.5,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","ATCPTTMT","% of total sales","TUR","Türkiye","2019","2019",1.6,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","ATCPTTMT","% of total sales","TUR","Türkiye","2020","2020",1.4,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","ATCPTTMT","% of total sales","TUR","Türkiye","2021","2021",1.7,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MLLNCUMT","Million of national currency units","CHL","Chile","2010","2010",64724.6,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MLLNCUMT","Million of national currency units","CHL","Chile","2011","2011",80168.5,"B","Break"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MLLNCUMT","Million of national currency units","CHL","Chile","2012","2012",87798.2,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MLLNCUMT","Million of national currency units","CHL","Chile","2013","2013",95808.5,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MLLNCUMT","Million of national currency units","CHL","Chile","2014","2014",102222,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MLLNCUMT","Million of national currency units","CHL","Chile","2015","2015",117332.5,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MLLNCUMT","Million of national currency units","CHL","Chile","2016","2016",139368.4,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MLLNCUMT","Million of national currency units","CHL","Chile","2017","2017",124650.7,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MLLNCUMT","Million of national currency units","CHL","Chile","2018","2018",130609.5,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MLLNCUMT","Million of national currency units","CHL","Chile","2019","2019",139258.8,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MLLNCUMT","Million of national currency units","CHL","Chile","2020","2020",154941.7,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MLLNCUMT","Million of national currency units","CHL","Chile","2021","2021",189704.2,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MLLNCUMT","Million of national currency units","CHL","Chile","2022","2022",162563.3,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOTCMT","Million US$ at exchange rate","CHL","Chile","2010","2010",126.8,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOTCMT","Million US$ at exchange rate","CHL","Chile","2011","2011",165.8,"B","Break"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOTCMT","Million US$ at exchange rate","CHL","Chile","2012","2012",180.5,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOTCMT","Million US$ at exchange rate","CHL","Chile","2013","2013",193.4,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOTCMT","Million US$ at exchange rate","CHL","Chile","2014","2014",179.2,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOTCMT","Million US$ at exchange rate","CHL","Chile","2015","2015",179.4,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOTCMT","Million US$ at exchange rate","CHL","Chile","2016","2016",205.9,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOTCMT","Million US$ at exchange rate","CHL","Chile","2017","2017",192.1,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOTCMT","Million US$ at exchange rate","CHL","Chile","2018","2018",203.7,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOTCMT","Million US$ at exchange rate","CHL","Chile","2019","2019",198.1,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOTCMT","Million US$ at exchange rate","CHL","Chile","2020","2020",195.5,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOTCMT","Million US$ at exchange rate","CHL","Chile","2021","2021",250,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOTCMT","Million US$ at exchange rate","CHL","Chile","2022","2022",186.1,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOPPMT","Million US$, purchasing power parity","CHL","Chile","2010","2010",179.9,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOPPMT","Million US$, purchasing power parity","CHL","Chile","2011","2011",230.4,"B","Break"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOPPMT","Million US$, purchasing power parity","CHL","Chile","2012","2012",252.9,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOPPMT","Million US$, purchasing power parity","CHL","Chile","2013","2013",274,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOPPMT","Million US$, purchasing power parity","CHL","Chile","2014","2014",278.4,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOPPMT","Million US$, purchasing power parity","CHL","Chile","2015","2015",299.9,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOPPMT","Million US$, purchasing power parity","CHL","Chile","2016","2016",350.8,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOPPMT","Million US$, purchasing power parity","CHL","Chile","2017","2017",313.4,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOPPMT","Million US$, purchasing power parity","CHL","Chile","2018","2018",329.6,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOPPMT","Million US$, purchasing power parity","CHL","Chile","2019","2019",346.7,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOPPMT","Million US$, purchasing power parity","CHL","Chile","2020","2020",370.3,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOPPMT","Million US$, purchasing power parity","CHL","Chile","2021","2021",435.9,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOPPMT","Million US$, purchasing power parity","CHL","Chile","2022","2022",371.5,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","TCPPERMT","/capita, US$ exchange rate","CHL","Chile","2010","2010",7.4,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","TCPPERMT","/capita, US$ exchange rate","CHL","Chile","2011","2011",9.6,"B","Break"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","TCPPERMT","/capita, US$ exchange rate","CHL","Chile","2012","2012",10.3,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","TCPPERMT","/capita, US$ exchange rate","CHL","Chile","2013","2013",11,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","TCPPERMT","/capita, US$ exchange rate","CHL","Chile","2014","2014",10.1,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","TCPPERMT","/capita, US$ exchange rate","CHL","Chile","2015","2015",10,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","TCPPERMT","/capita, US$ exchange rate","CHL","Chile","2016","2016",11.3,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","TCPPERMT","/capita, US$ exchange rate","CHL","Chile","2017","2017",10.4,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","TCPPERMT","/capita, US$ exchange rate","CHL","Chile","2018","2018",10.9,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","TCPPERMT","/capita, US$ exchange rate","CHL","Chile","2019","2019",10.4,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","TCPPERMT","/capita, US$ exchange rate","CHL","Chile","2020","2020",10,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","TCPPERMT","/capita, US$ exchange rate","CHL","Chile","2021","2021",12.7,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","TCPPERMT","/capita, US$ exchange rate","CHL","Chile","2022","2022",9.4,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2010","2010",10.5,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2011","2011",13.4,"B","Break"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2012","2012",14.5,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2013","2013",15.6,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2014","2014",15.6,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2015","2015",16.7,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2016","2016",19.3,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2017","2017",17,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2018","2018",17.6,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2019","2019",18.1,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2020","2020",19,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2021","2021",22.2,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2022","2022",18.7,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","ATCPTTMT","% of total sales","CHL","Chile","2010","2010",7.8,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","ATCPTTMT","% of total sales","CHL","Chile","2011","2011",6.8,"B","Break"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","ATCPTTMT","% of total sales","CHL","Chile","2012","2012",7,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","ATCPTTMT","% of total sales","CHL","Chile","2013","2013",6.6,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","ATCPTTMT","% of total sales","CHL","Chile","2014","2014",6.6,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","ATCPTTMT","% of total sales","CHL","Chile","2015","2015",6.4,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","ATCPTTMT","% of total sales","CHL","Chile","2016","2016",6.9,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","ATCPTTMT","% of total sales","CHL","Chile","2017","2017",6,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","ATCPTTMT","% of total sales","CHL","Chile","2018","2018",5.7,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","ATCPTTMT","% of total sales","CHL","Chile","2019","2019",5.5,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","ATCPTTMT","% of total sales","CHL","Chile","2020","2020",5.8,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","ATCPTTMT","% of total sales","CHL","Chile","2021","2021",6.7,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","ATCPTTMT","% of total sales","CHL","Chile","2022","2022",5.8,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MLLNCUMT","Million of national currency units","EST","Estonia","2010","2010",6.5,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MLLNCUMT","Million of national currency units","EST","Estonia","2011","2011",6.5,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MLLNCUMT","Million of national currency units","EST","Estonia","2012","2012",6.6,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MLLNCUMT","Million of national currency units","EST","Estonia","2013","2013",6.4,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MLLNCUMT","Million of national currency units","EST","Estonia","2014","2014",6.2,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MLLNCUMT","Million of national currency units","EST","Estonia","2015","2015",6,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MLLNCUMT","Million of national currency units","EST","Estonia","2016","2016",5.8,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MLLNCUMT","Million of national currency units","EST","Estonia","2017","2017",5.4,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MLLNCUMT","Million of national currency units","EST","Estonia","2018","2018",5.3,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MLLNCUMT","Million of national currency units","EST","Estonia","2019","2019",5.5,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MLLNCUMT","Million of national currency units","EST","Estonia","2020","2020",5.1,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MLLNCUMT","Million of national currency units","EST","Estonia","2021","2021",5.3,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MLLNCUMT","Million of national currency units","EST","Estonia","2022","2022",5.8,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOTCMT","Million US$ at exchange rate","EST","Estonia","2010","2010",8.6,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOTCMT","Million US$ at exchange rate","EST","Estonia","2011","2011",9.1,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOTCMT","Million US$ at exchange rate","EST","Estonia","2012","2012",8.5,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOTCMT","Million US$ at exchange rate","EST","Estonia","2013","2013",8.5,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOTCMT","Million US$ at exchange rate","EST","Estonia","2014","2014",8.2,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOTCMT","Million US$ at exchange rate","EST","Estonia","2015","2015",6.6,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOTCMT","Million US$ at exchange rate","EST","Estonia","2016","2016",6.4,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOTCMT","Million US$ at exchange rate","EST","Estonia","2017","2017",6.1,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOTCMT","Million US$ at exchange rate","EST","Estonia","2018","2018",6.2,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOTCMT","Million US$ at exchange rate","EST","Estonia","2019","2019",6.2,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOTCMT","Million US$ at exchange rate","EST","Estonia","2020","2020",5.8,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOTCMT","Million US$ at exchange rate","EST","Estonia","2021","2021",6.3,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOTCMT","Million US$ at exchange rate","EST","Estonia","2022","2022",6.1,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOPPMT","Million US$, purchasing power parity","EST","Estonia","2010","2010",12.7,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOPPMT","Million US$, purchasing power parity","EST","Estonia","2011","2011",12.8,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOPPMT","Million US$, purchasing power parity","EST","Estonia","2012","2012",12.7,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOPPMT","Million US$, purchasing power parity","EST","Estonia","2013","2013",12.2,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOPPMT","Million US$, purchasing power parity","EST","Estonia","2014","2014",11.7,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOPPMT","Million US$, purchasing power parity","EST","Estonia","2015","2015",11.1,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOPPMT","Million US$, purchasing power parity","EST","Estonia","2016","2016",11,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOPPMT","Million US$, purchasing power parity","EST","Estonia","2017","2017",10.1,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOPPMT","Million US$, purchasing power parity","EST","Estonia","2018","2018",9.8,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOPPMT","Million US$, purchasing power parity","EST","Estonia","2019","2019",10.3,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOPPMT","Million US$, purchasing power parity","EST","Estonia","2020","2020",9.7,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOPPMT","Million US$, purchasing power parity","EST","Estonia","2021","2021",9.7,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOPPMT","Million US$, purchasing power parity","EST","Estonia","2022","2022",10.2,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","TCPPERMT","/capita, US$ exchange rate","EST","Estonia","2010","2010",6.5,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","TCPPERMT","/capita, US$ exchange rate","EST","Estonia","2011","2011",6.9,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","TCPPERMT","/capita, US$ exchange rate","EST","Estonia","2012","2012",6.4,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","TCPPERMT","/capita, US$ exchange rate","EST","Estonia","2013","2013",6.4,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","TCPPERMT","/capita, US$ exchange rate","EST","Estonia","2014","2014",6.2,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","TCPPERMT","/capita, US$ exchange rate","EST","Estonia","2015","2015",5.1,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","TCPPERMT","/capita, US$ exchange rate","EST","Estonia","2016","2016",4.9,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","TCPPERMT","/capita, US$ exchange rate","EST","Estonia","2017","2017",4.6,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","TCPPERMT","/capita, US$ exchange rate","EST","Estonia","2018","2018",4.7,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","TCPPERMT","/capita, US$ exchange rate","EST","Estonia","2019","2019",4.7,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","TCPPERMT","/capita, US$ exchange rate","EST","Estonia","2020","2020",4.4,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","TCPPERMT","/capita, US$ exchange rate","EST","Estonia","2021","2021",4.7,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","TCPPERMT","/capita, US$ exchange rate","EST","Estonia","2022","2022",4.6,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2010","2010",9.5,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2011","2011",9.6,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2012","2012",9.6,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2013","2013",9.3,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2014","2014",8.9,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2015","2015",8.5,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2016","2016",8.3,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2017","2017",7.6,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2018","2018",7.4,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2019","2019",7.8,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2020","2020",7.3,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2021","2021",7.3,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2022","2022",7.7,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","ATCPTTMT","% of total sales","EST","Estonia","2010","2010",3.4,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","ATCPTTMT","% of total sales","EST","Estonia","2011","2011",3.2,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","ATCPTTMT","% of total sales","EST","Estonia","2012","2012",3,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","ATCPTTMT","% of total sales","EST","Estonia","2013","2013",2.8,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","ATCPTTMT","% of total sales","EST","Estonia","2014","2014",2.5,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","ATCPTTMT","% of total sales","EST","Estonia","2015","2015",2.3,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","ATCPTTMT","% of total sales","EST","Estonia","2016","2016",2,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","ATCPTTMT","% of total sales","EST","Estonia","2017","2017",1.8,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","ATCPTTMT","% of total sales","EST","Estonia","2018","2018",1.6,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","ATCPTTMT","% of total sales","EST","Estonia","2019","2019",1.6,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","ATCPTTMT","% of total sales","EST","Estonia","2020","2020",1.4,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","ATCPTTMT","% of total sales","EST","Estonia","2021","2021",1.3,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","ATCPTTMT","% of total sales","EST","Estonia","2022","2022",1.3,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MLLNCUMT","Million of national currency units","SVN","Slovenia","2010","2010",10.1,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MLLNCUMT","Million of national currency units","SVN","Slovenia","2011","2011",9.8,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MLLNCUMT","Million of national currency units","SVN","Slovenia","2012","2012",9.1,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MLLNCUMT","Million of national currency units","SVN","Slovenia","2013","2013",8.2,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MLLNCUMT","Million of national currency units","SVN","Slovenia","2014","2014",8.1,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MLLNCUMT","Million of national currency units","SVN","Slovenia","2015","2015",7.7,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MLLNCUMT","Million of national currency units","SVN","Slovenia","2016","2016",7.5,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MLLNCUMT","Million of national currency units","SVN","Slovenia","2017","2017",7.5,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MLLNCUMT","Million of national currency units","SVN","Slovenia","2018","2018",7.1,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MLLNCUMT","Million of national currency units","SVN","Slovenia","2019","2019",7.3,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MLLNCUMT","Million of national currency units","SVN","Slovenia","2020","2020",6.4,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MLLNCUMT","Million of national currency units","SVN","Slovenia","2021","2021",6.1,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MLLNCUMT","Million of national currency units","SVN","Slovenia","2022","2022",5.9,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOTCMT","Million US$ at exchange rate","SVN","Slovenia","2010","2010",13.4,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOTCMT","Million US$ at exchange rate","SVN","Slovenia","2011","2011",13.7,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOTCMT","Million US$ at exchange rate","SVN","Slovenia","2012","2012",11.6,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOTCMT","Million US$ at exchange rate","SVN","Slovenia","2013","2013",10.9,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOTCMT","Million US$ at exchange rate","SVN","Slovenia","2014","2014",10.8,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOTCMT","Million US$ at exchange rate","SVN","Slovenia","2015","2015",8.5,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOTCMT","Million US$ at exchange rate","SVN","Slovenia","2016","2016",8.3,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOTCMT","Million US$ at exchange rate","SVN","Slovenia","2017","2017",8.4,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOTCMT","Million US$ at exchange rate","SVN","Slovenia","2018","2018",8.3,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOTCMT","Million US$ at exchange rate","SVN","Slovenia","2019","2019",8.2,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOTCMT","Million US$ at exchange rate","SVN","Slovenia","2020","2020",7.3,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOTCMT","Million US$ at exchange rate","SVN","Slovenia","2021","2021",7.2,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOTCMT","Million US$ at exchange rate","SVN","Slovenia","2022","2022",6.3,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOPPMT","Million US$, purchasing power parity","SVN","Slovenia","2010","2010",15.9,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOPPMT","Million US$, purchasing power parity","SVN","Slovenia","2011","2011",15.7,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOPPMT","Million US$, purchasing power parity","SVN","Slovenia","2012","2012",14.9,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOPPMT","Million US$, purchasing power parity","SVN","Slovenia","2013","2013",14,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOPPMT","Million US$, purchasing power parity","SVN","Slovenia","2014","2014",13.7,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOPPMT","Million US$, purchasing power parity","SVN","Slovenia","2015","2015",12.9,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOPPMT","Million US$, purchasing power parity","SVN","Slovenia","2016","2016",13,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOPPMT","Million US$, purchasing power parity","SVN","Slovenia","2017","2017",13.1,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOPPMT","Million US$, purchasing power parity","SVN","Slovenia","2018","2018",12.4,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOPPMT","Million US$, purchasing power parity","SVN","Slovenia","2019","2019",13.2,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOPPMT","Million US$, purchasing power parity","SVN","Slovenia","2020","2020",11.7,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOPPMT","Million US$, purchasing power parity","SVN","Slovenia","2021","2021",10.9,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOPPMT","Million US$, purchasing power parity","SVN","Slovenia","2022","2022",10.8,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","TCPPERMT","/capita, US$ exchange rate","SVN","Slovenia","2010","2010",6.6,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","TCPPERMT","/capita, US$ exchange rate","SVN","Slovenia","2011","2011",6.7,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","TCPPERMT","/capita, US$ exchange rate","SVN","Slovenia","2012","2012",5.7,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","TCPPERMT","/capita, US$ exchange rate","SVN","Slovenia","2013","2013",5.3,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","TCPPERMT","/capita, US$ exchange rate","SVN","Slovenia","2014","2014",5.2,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","TCPPERMT","/capita, US$ exchange rate","SVN","Slovenia","2015","2015",4.1,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","TCPPERMT","/capita, US$ exchange rate","SVN","Slovenia","2016","2016",4,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","TCPPERMT","/capita, US$ exchange rate","SVN","Slovenia","2017","2017",4.1,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","TCPPERMT","/capita, US$ exchange rate","SVN","Slovenia","2018","2018",4,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","TCPPERMT","/capita, US$ exchange rate","SVN","Slovenia","2019","2019",3.9,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","TCPPERMT","/capita, US$ exchange rate","SVN","Slovenia","2020","2020",3.5,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","TCPPERMT","/capita, US$ exchange rate","SVN","Slovenia","2021","2021",3.4,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","TCPPERMT","/capita, US$ exchange rate","SVN","Slovenia","2022","2022",3,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2010","2010",7.8,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2011","2011",7.7,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2012","2012",7.3,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2013","2013",6.8,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2014","2014",6.7,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2015","2015",6.3,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2016","2016",6.3,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2017","2017",6.3,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2018","2018",6,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2019","2019",6.3,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2020","2020",5.6,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2021","2021",5.2,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2022","2022",5.1,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","ATCPTTMT","% of total sales","SVN","Slovenia","2010","2010",2.1,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","ATCPTTMT","% of total sales","SVN","Slovenia","2011","2011",2.1,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","ATCPTTMT","% of total sales","SVN","Slovenia","2012","2012",2,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","ATCPTTMT","% of total sales","SVN","Slovenia","2013","2013",1.8,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","ATCPTTMT","% of total sales","SVN","Slovenia","2014","2014",1.9,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","ATCPTTMT","% of total sales","SVN","Slovenia","2015","2015",1.7,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","ATCPTTMT","% of total sales","SVN","Slovenia","2016","2016",1.6,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","ATCPTTMT","% of total sales","SVN","Slovenia","2017","2017",1.5,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","ATCPTTMT","% of total sales","SVN","Slovenia","2018","2018",1.4,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","ATCPTTMT","% of total sales","SVN","Slovenia","2019","2019",1.3,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","ATCPTTMT","% of total sales","SVN","Slovenia","2020","2020",1.1,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","ATCPTTMT","% of total sales","SVN","Slovenia","2021","2021",1,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","ATCPTTMT","% of total sales","SVN","Slovenia","2022","2022",0.9,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MLLNCUMT","Million of national currency units","AUS","Australia","2010","2010",79,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MLLNCUMT","Million of national currency units","AUS","Australia","2011","2011",86,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MLLNCUMT","Million of national currency units","AUS","Australia","2012","2012",98,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MLLNCUMT","Million of national currency units","AUS","Australia","2013","2013",156,"B; D","Break; Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MLLNCUMT","Million of national currency units","AUS","Australia","2014","2014",168,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MLLNCUMT","Million of national currency units","AUS","Australia","2015","2015",191,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MLLNCUMT","Million of national currency units","AUS","Australia","2016","2016",224,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MLLNCUMT","Million of national currency units","AUS","Australia","2017","2017",237,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MLLNCUMT","Million of national currency units","AUS","Australia","2018","2018",246,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MLLNCUMT","Million of national currency units","AUS","Australia","2019","2019",258,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MLLNCUMT","Million of national currency units","AUS","Australia","2020","2020",264,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MLLNCUMT","Million of national currency units","AUS","Australia","2021","2021",272,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOTCMT","Million US$ at exchange rate","AUS","Australia","2010","2010",72.5,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOTCMT","Million US$ at exchange rate","AUS","Australia","2011","2011",88.7,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOTCMT","Million US$ at exchange rate","AUS","Australia","2012","2012",101.5,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOTCMT","Million US$ at exchange rate","AUS","Australia","2013","2013",150.6,"B; D","Break; Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOTCMT","Million US$ at exchange rate","AUS","Australia","2014","2014",151.4,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOTCMT","Million US$ at exchange rate","AUS","Australia","2015","2015",143.5,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOTCMT","Million US$ at exchange rate","AUS","Australia","2016","2016",166.5,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOTCMT","Million US$ at exchange rate","AUS","Australia","2017","2017",181.6,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOTCMT","Million US$ at exchange rate","AUS","Australia","2018","2018",183.8,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOTCMT","Million US$ at exchange rate","AUS","Australia","2019","2019",179.4,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOTCMT","Million US$ at exchange rate","AUS","Australia","2020","2020",181.7,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOTCMT","Million US$ at exchange rate","AUS","Australia","2021","2021",204.3,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOPPMT","Million US$, purchasing power parity","AUS","Australia","2010","2010",52.5,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOPPMT","Million US$, purchasing power parity","AUS","Australia","2011","2011",56.9,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOPPMT","Million US$, purchasing power parity","AUS","Australia","2012","2012",63.6,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOPPMT","Million US$, purchasing power parity","AUS","Australia","2013","2013",107.8,"B; D","Break; Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOPPMT","Million US$, purchasing power parity","AUS","Australia","2014","2014",115.7,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOPPMT","Million US$, purchasing power parity","AUS","Australia","2015","2015",129.6,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOPPMT","Million US$, purchasing power parity","AUS","Australia","2016","2016",154.5,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOPPMT","Million US$, purchasing power parity","AUS","Australia","2017","2017",160.4,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOPPMT","Million US$, purchasing power parity","AUS","Australia","2018","2018",167.3,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOPPMT","Million US$, purchasing power parity","AUS","Australia","2019","2019",174.3,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOPPMT","Million US$, purchasing power parity","AUS","Australia","2020","2020",181.6,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOPPMT","Million US$, purchasing power parity","AUS","Australia","2021","2021",187.9,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","TCPPERMT","/capita, US$ exchange rate","AUS","Australia","2010","2010",3.3,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","TCPPERMT","/capita, US$ exchange rate","AUS","Australia","2011","2011",4,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","TCPPERMT","/capita, US$ exchange rate","AUS","Australia","2012","2012",4.5,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","TCPPERMT","/capita, US$ exchange rate","AUS","Australia","2013","2013",6.5,"B; D","Break; Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","TCPPERMT","/capita, US$ exchange rate","AUS","Australia","2014","2014",6.5,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","TCPPERMT","/capita, US$ exchange rate","AUS","Australia","2015","2015",6,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","TCPPERMT","/capita, US$ exchange rate","AUS","Australia","2016","2016",6.9,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","TCPPERMT","/capita, US$ exchange rate","AUS","Australia","2017","2017",7.4,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","TCPPERMT","/capita, US$ exchange rate","AUS","Australia","2018","2018",7.4,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","TCPPERMT","/capita, US$ exchange rate","AUS","Australia","2019","2019",7.1,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","TCPPERMT","/capita, US$ exchange rate","AUS","Australia","2020","2020",7.1,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","TCPPERMT","/capita, US$ exchange rate","AUS","Australia","2021","2021",8,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2010","2010",2.4,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2011","2011",2.5,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2012","2012",2.8,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2013","2013",4.7,"B; D","Break; Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2014","2014",4.9,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2015","2015",5.4,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2016","2016",6.4,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2017","2017",6.5,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2018","2018",6.7,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2019","2019",6.9,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2020","2020",7.1,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2021","2021",7.3,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","ATCPTTMT","% of total sales","AUS","Australia","2010","2010",0.8,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","ATCPTTMT","% of total sales","AUS","Australia","2011","2011",0.8,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","ATCPTTMT","% of total sales","AUS","Australia","2012","2012",0.9,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","ATCPTTMT","% of total sales","AUS","Australia","2013","2013",1.3,"B; D","Break; Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","ATCPTTMT","% of total sales","AUS","Australia","2014","2014",1.4,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","ATCPTTMT","% of total sales","AUS","Australia","2015","2015",1.6,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","ATCPTTMT","% of total sales","AUS","Australia","2016","2016",1.5,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","ATCPTTMT","% of total sales","AUS","Australia","2017","2017",1.6,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","ATCPTTMT","% of total sales","AUS","Australia","2018","2018",1.7,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","ATCPTTMT","% of total sales","AUS","Australia","2019","2019",1.7,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","ATCPTTMT","% of total sales","AUS","Australia","2020","2020",1.6,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","ATCPTTMT","% of total sales","AUS","Australia","2021","2021",1.5,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MLLNCUMT","Million of national currency units","AUT","Austria","2010","2010",47.6,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MLLNCUMT","Million of national currency units","AUT","Austria","2011","2011",47.9,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MLLNCUMT","Million of national currency units","AUT","Austria","2012","2012",48.1,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MLLNCUMT","Million of national currency units","AUT","Austria","2013","2013",50.2,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MLLNCUMT","Million of national currency units","AUT","Austria","2014","2014",51.1,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MLLNCUMT","Million of national currency units","AUT","Austria","2015","2015",52.6,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MLLNCUMT","Million of national currency units","AUT","Austria","2016","2016",55,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MLLNCUMT","Million of national currency units","AUT","Austria","2017","2017",56.5,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MLLNCUMT","Million of national currency units","AUT","Austria","2018","2018",58.8,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MLLNCUMT","Million of national currency units","AUT","Austria","2019","2019",61.3,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MLLNCUMT","Million of national currency units","AUT","Austria","2020","2020",64.6,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MLLNCUMT","Million of national currency units","AUT","Austria","2021","2021",60.9,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOTCMT","Million US$ at exchange rate","AUT","Austria","2010","2010",63,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOTCMT","Million US$ at exchange rate","AUT","Austria","2011","2011",66.7,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOTCMT","Million US$ at exchange rate","AUT","Austria","2012","2012",61.8,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOTCMT","Million US$ at exchange rate","AUT","Austria","2013","2013",66.6,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOTCMT","Million US$ at exchange rate","AUT","Austria","2014","2014",67.9,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOTCMT","Million US$ at exchange rate","AUT","Austria","2015","2015",58.3,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOTCMT","Million US$ at exchange rate","AUT","Austria","2016","2016",60.9,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOTCMT","Million US$ at exchange rate","AUT","Austria","2017","2017",63.9,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOTCMT","Million US$ at exchange rate","AUT","Austria","2018","2018",69.4,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOTCMT","Million US$ at exchange rate","AUT","Austria","2019","2019",68.7,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOTCMT","Million US$ at exchange rate","AUT","Austria","2020","2020",73.7,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOTCMT","Million US$ at exchange rate","AUT","Austria","2021","2021",72.1,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOPPMT","Million US$, purchasing power parity","AUT","Austria","2010","2010",56.5,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOPPMT","Million US$, purchasing power parity","AUT","Austria","2011","2011",57.7,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOPPMT","Million US$, purchasing power parity","AUT","Austria","2012","2012",59.1,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOPPMT","Million US$, purchasing power parity","AUT","Austria","2013","2013",63,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOPPMT","Million US$, purchasing power parity","AUT","Austria","2014","2014",64,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOPPMT","Million US$, purchasing power parity","AUT","Austria","2015","2015",65.8,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOPPMT","Million US$, purchasing power parity","AUT","Austria","2016","2016",70.8,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOPPMT","Million US$, purchasing power parity","AUT","Austria","2017","2017",73,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOPPMT","Million US$, purchasing power parity","AUT","Austria","2018","2018",76.8,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOPPMT","Million US$, purchasing power parity","AUT","Austria","2019","2019",81.9,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOPPMT","Million US$, purchasing power parity","AUT","Austria","2020","2020",86.5,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOPPMT","Million US$, purchasing power parity","AUT","Austria","2021","2021",80.6,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","TCPPERMT","/capita, US$ exchange rate","AUT","Austria","2010","2010",7.5,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","TCPPERMT","/capita, US$ exchange rate","AUT","Austria","2011","2011",8,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","TCPPERMT","/capita, US$ exchange rate","AUT","Austria","2012","2012",7.3,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","TCPPERMT","/capita, US$ exchange rate","AUT","Austria","2013","2013",7.9,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","TCPPERMT","/capita, US$ exchange rate","AUT","Austria","2014","2014",7.9,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","TCPPERMT","/capita, US$ exchange rate","AUT","Austria","2015","2015",6.8,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","TCPPERMT","/capita, US$ exchange rate","AUT","Austria","2016","2016",7,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","TCPPERMT","/capita, US$ exchange rate","AUT","Austria","2017","2017",7.3,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","TCPPERMT","/capita, US$ exchange rate","AUT","Austria","2018","2018",7.9,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","TCPPERMT","/capita, US$ exchange rate","AUT","Austria","2019","2019",7.7,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","TCPPERMT","/capita, US$ exchange rate","AUT","Austria","2020","2020",8.3,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","TCPPERMT","/capita, US$ exchange rate","AUT","Austria","2021","2021",8,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2010","2010",6.8,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2011","2011",6.9,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2012","2012",7,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2013","2013",7.4,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2014","2014",7.5,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2015","2015",7.6,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2016","2016",8.1,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2017","2017",8.3,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2018","2018",8.7,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2019","2019",9.2,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2020","2020",9.7,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2021","2021",9,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","ATCPTTMT","% of total sales","AUT","Austria","2010","2010",1.9,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","ATCPTTMT","% of total sales","AUT","Austria","2011","2011",1.9,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","ATCPTTMT","% of total sales","AUT","Austria","2012","2012",1.8,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","ATCPTTMT","% of total sales","AUT","Austria","2013","2013",1.9,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","ATCPTTMT","% of total sales","AUT","Austria","2014","2014",1.8,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","ATCPTTMT","% of total sales","AUT","Austria","2015","2015",1.8,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","ATCPTTMT","% of total sales","AUT","Austria","2016","2016",1.8,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","ATCPTTMT","% of total sales","AUT","Austria","2017","2017",1.8,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","ATCPTTMT","% of total sales","AUT","Austria","2018","2018",1.8,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","ATCPTTMT","% of total sales","AUT","Austria","2019","2019",1.9,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","ATCPTTMT","% of total sales","AUT","Austria","2020","2020",1.9,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","ATCPTTMT","% of total sales","AUT","Austria","2021","2021",1.6,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MLLNCUMT","Million of national currency units","BEL","Belgium","2010","2010",122.5,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MLLNCUMT","Million of national currency units","BEL","Belgium","2011","2011",125.4,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MLLNCUMT","Million of national currency units","BEL","Belgium","2012","2012",124.4,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MLLNCUMT","Million of national currency units","BEL","Belgium","2013","2013",124.8,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MLLNCUMT","Million of national currency units","BEL","Belgium","2014","2014",123.1,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MLLNCUMT","Million of national currency units","BEL","Belgium","2015","2015",126.9,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MLLNCUMT","Million of national currency units","BEL","Belgium","2016","2016",126.2,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MLLNCUMT","Million of national currency units","BEL","Belgium","2017","2017",128.1,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MLLNCUMT","Million of national currency units","BEL","Belgium","2018","2018",125.9,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MLLNCUMT","Million of national currency units","BEL","Belgium","2019","2019",132.5,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MLLNCUMT","Million of national currency units","BEL","Belgium","2020","2020",127.5,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MLLNCUMT","Million of national currency units","BEL","Belgium","2021","2021",127.8,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MLLNCUMT","Million of national currency units","BEL","Belgium","2022","2022",132.8,"E","Estimated value"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOTCMT","Million US$ at exchange rate","BEL","Belgium","2010","2010",162.4,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOTCMT","Million US$ at exchange rate","BEL","Belgium","2011","2011",174.6,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOTCMT","Million US$ at exchange rate","BEL","Belgium","2012","2012",159.8,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOTCMT","Million US$ at exchange rate","BEL","Belgium","2013","2013",165.8,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOTCMT","Million US$ at exchange rate","BEL","Belgium","2014","2014",163.6,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOTCMT","Million US$ at exchange rate","BEL","Belgium","2015","2015",140.8,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOTCMT","Million US$ at exchange rate","BEL","Belgium","2016","2016",139.7,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOTCMT","Million US$ at exchange rate","BEL","Belgium","2017","2017",144.7,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOTCMT","Million US$ at exchange rate","BEL","Belgium","2018","2018",148.6,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOTCMT","Million US$ at exchange rate","BEL","Belgium","2019","2019",148.3,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOTCMT","Million US$ at exchange rate","BEL","Belgium","2020","2020",145.7,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOTCMT","Million US$ at exchange rate","BEL","Belgium","2021","2021",151.1,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOTCMT","Million US$ at exchange rate","BEL","Belgium","2022","2022",139.9,"E","Estimated value"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOPPMT","Million US$, purchasing power parity","BEL","Belgium","2010","2010",146.4,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOPPMT","Million US$, purchasing power parity","BEL","Belgium","2011","2011",150.8,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOPPMT","Million US$, purchasing power parity","BEL","Belgium","2012","2012",151.3,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOPPMT","Million US$, purchasing power parity","BEL","Belgium","2013","2013",154.8,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOPPMT","Million US$, purchasing power parity","BEL","Belgium","2014","2014",153.8,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOPPMT","Million US$, purchasing power parity","BEL","Belgium","2015","2015",158.6,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOPPMT","Million US$, purchasing power parity","BEL","Belgium","2016","2016",161.6,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOPPMT","Million US$, purchasing power parity","BEL","Belgium","2017","2017",165.2,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOPPMT","Million US$, purchasing power parity","BEL","Belgium","2018","2018",164.2,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOPPMT","Million US$, purchasing power parity","BEL","Belgium","2019","2019",177.5,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOPPMT","Million US$, purchasing power parity","BEL","Belgium","2020","2020",174.6,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOPPMT","Million US$, purchasing power parity","BEL","Belgium","2021","2021",173.4,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOPPMT","Million US$, purchasing power parity","BEL","Belgium","2022","2022",186,"E","Estimated value"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","TCPPERMT","/capita, US$ exchange rate","BEL","Belgium","2010","2010",14.9,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","TCPPERMT","/capita, US$ exchange rate","BEL","Belgium","2011","2011",15.8,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","TCPPERMT","/capita, US$ exchange rate","BEL","Belgium","2012","2012",14.4,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","TCPPERMT","/capita, US$ exchange rate","BEL","Belgium","2013","2013",14.9,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","TCPPERMT","/capita, US$ exchange rate","BEL","Belgium","2014","2014",14.6,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","TCPPERMT","/capita, US$ exchange rate","BEL","Belgium","2015","2015",12.5,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","TCPPERMT","/capita, US$ exchange rate","BEL","Belgium","2016","2016",12.3,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","TCPPERMT","/capita, US$ exchange rate","BEL","Belgium","2017","2017",12.7,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","TCPPERMT","/capita, US$ exchange rate","BEL","Belgium","2018","2018",13,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","TCPPERMT","/capita, US$ exchange rate","BEL","Belgium","2019","2019",12.9,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","TCPPERMT","/capita, US$ exchange rate","BEL","Belgium","2020","2020",12.6,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","TCPPERMT","/capita, US$ exchange rate","BEL","Belgium","2021","2021",13,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","TCPPERMT","/capita, US$ exchange rate","BEL","Belgium","2022","2022",12,"E","Estimated value"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2010","2010",13.4,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2011","2011",13.7,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2012","2012",13.6,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2013","2013",13.9,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2014","2014",13.7,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2015","2015",14.1,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2016","2016",14.3,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2017","2017",14.5,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2018","2018",14.4,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2019","2019",15.4,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2020","2020",15.1,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2021","2021",15,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2022","2022",16,"E","Estimated value"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","ATCPTTMT","% of total sales","BEL","Belgium","2010","2010",2.1,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","ATCPTTMT","% of total sales","BEL","Belgium","2011","2011",2.1,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","ATCPTTMT","% of total sales","BEL","Belgium","2012","2012",2.1,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","ATCPTTMT","% of total sales","BEL","Belgium","2013","2013",2.1,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","ATCPTTMT","% of total sales","BEL","Belgium","2014","2014",2.1,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","ATCPTTMT","% of total sales","BEL","Belgium","2015","2015",2,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","ATCPTTMT","% of total sales","BEL","Belgium","2016","2016",2,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","ATCPTTMT","% of total sales","BEL","Belgium","2017","2017",2,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","ATCPTTMT","% of total sales","BEL","Belgium","2018","2018",1.9,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","ATCPTTMT","% of total sales","BEL","Belgium","2019","2019",1.8,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","ATCPTTMT","% of total sales","BEL","Belgium","2020","2020",1.7,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","ATCPTTMT","% of total sales","BEL","Belgium","2021","2021",1.6,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","ATCPTTMT","% of total sales","BEL","Belgium","2022","2022",1.5,"E","Estimated value"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MLLNCUMT","Million of national currency units","CAN","Canada","2012","2012",413.8,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MLLNCUMT","Million of national currency units","CAN","Canada","2013","2013",435.1,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MLLNCUMT","Million of national currency units","CAN","Canada","2014","2014",453.9,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MLLNCUMT","Million of national currency units","CAN","Canada","2015","2015",474,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MLLNCUMT","Million of national currency units","CAN","Canada","2016","2016",498.4,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MLLNCUMT","Million of national currency units","CAN","Canada","2017","2017",521.3,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MLLNCUMT","Million of national currency units","CAN","Canada","2018","2018",560.7,"E; B; D","Estimated value; Break; Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MLLNCUMT","Million of national currency units","CAN","Canada","2019","2019",598.3,"E; D","Estimated value; Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MLLNCUMT","Million of national currency units","CAN","Canada","2020","2020",625.1,"E; D","Estimated value; Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MLLNCUMT","Million of national currency units","CAN","Canada","2021","2021",652.4,"E; D","Estimated value; Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MLLNCUMT","Million of national currency units","CAN","Canada","2022","2022",680.7,"E; D","Estimated value; Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOTCMT","Million US$ at exchange rate","CAN","Canada","2012","2012",414.1,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOTCMT","Million US$ at exchange rate","CAN","Canada","2013","2013",422.4,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOTCMT","Million US$ at exchange rate","CAN","Canada","2014","2014",410.9,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOTCMT","Million US$ at exchange rate","CAN","Canada","2015","2015",370.7,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOTCMT","Million US$ at exchange rate","CAN","Canada","2016","2016",376,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOTCMT","Million US$ at exchange rate","CAN","Canada","2017","2017",401.6,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOTCMT","Million US$ at exchange rate","CAN","Canada","2018","2018",432.7,"E; B; D","Estimated value; Break; Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOTCMT","Million US$ at exchange rate","CAN","Canada","2019","2019",450.9,"E; D","Estimated value; Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOTCMT","Million US$ at exchange rate","CAN","Canada","2020","2020",466.1,"E; D","Estimated value; Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOTCMT","Million US$ at exchange rate","CAN","Canada","2021","2021",520.3,"E; D","Estimated value; Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOTCMT","Million US$ at exchange rate","CAN","Canada","2022","2022",523,"E; D","Estimated value; Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOPPMT","Million US$, purchasing power parity","CAN","Canada","2012","2012",332.5,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOPPMT","Million US$, purchasing power parity","CAN","Canada","2013","2013",355.5,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOPPMT","Million US$, purchasing power parity","CAN","Canada","2014","2014",368.9,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOPPMT","Million US$, purchasing power parity","CAN","Canada","2015","2015",379.8,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOPPMT","Million US$, purchasing power parity","CAN","Canada","2016","2016",412.9,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOPPMT","Million US$, purchasing power parity","CAN","Canada","2017","2017",430,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOPPMT","Million US$, purchasing power parity","CAN","Canada","2018","2018",464.7,"E; B; D","Estimated value; Break; Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOPPMT","Million US$, purchasing power parity","CAN","Canada","2019","2019",484.6,"E; D","Estimated value; Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOPPMT","Million US$, purchasing power parity","CAN","Canada","2020","2020",507.7,"E; D","Estimated value; Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOPPMT","Million US$, purchasing power parity","CAN","Canada","2021","2021",526.9,"E; D","Estimated value; Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOPPMT","Million US$, purchasing power parity","CAN","Canada","2022","2022",542.9,"E; D","Estimated value; Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","TCPPERMT","/capita, US$ exchange rate","CAN","Canada","2012","2012",11.9,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","TCPPERMT","/capita, US$ exchange rate","CAN","Canada","2013","2013",12,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","TCPPERMT","/capita, US$ exchange rate","CAN","Canada","2014","2014",11.6,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","TCPPERMT","/capita, US$ exchange rate","CAN","Canada","2015","2015",10.4,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","TCPPERMT","/capita, US$ exchange rate","CAN","Canada","2016","2016",10.4,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","TCPPERMT","/capita, US$ exchange rate","CAN","Canada","2017","2017",11,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","TCPPERMT","/capita, US$ exchange rate","CAN","Canada","2018","2018",11.7,"E; B; D","Estimated value; Break; Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","TCPPERMT","/capita, US$ exchange rate","CAN","Canada","2019","2019",12,"E; D","Estimated value; Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","TCPPERMT","/capita, US$ exchange rate","CAN","Canada","2020","2020",12.3,"E; D","Estimated value; Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","TCPPERMT","/capita, US$ exchange rate","CAN","Canada","2021","2021",13.6,"E; D","Estimated value; Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","TCPPERMT","/capita, US$ exchange rate","CAN","Canada","2022","2022",13.5,"E; D","Estimated value; Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2012","2012",9.6,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2013","2013",10.1,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2014","2014",10.4,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2015","2015",10.6,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2016","2016",11.4,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2017","2017",11.8,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2018","2018",12.5,"E; B; D","Estimated value; Break; Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2019","2019",12.9,"E; D","Estimated value; Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2020","2020",13.3,"E; D","Estimated value; Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2021","2021",13.8,"E; D","Estimated value; Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2022","2022",14,"E; D","Estimated value; Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","ATCPTTMT","% of total sales","CAN","Canada","2012","2012",1.7,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","ATCPTTMT","% of total sales","CAN","Canada","2013","2013",1.8,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","ATCPTTMT","% of total sales","CAN","Canada","2014","2014",1.8,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","ATCPTTMT","% of total sales","CAN","Canada","2015","2015",1.7,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","ATCPTTMT","% of total sales","CAN","Canada","2016","2016",1.8,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","ATCPTTMT","% of total sales","CAN","Canada","2017","2017",1.8,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","ATCPTTMT","% of total sales","CAN","Canada","2018","2018",1.8,"E; B; D","Estimated value; Break; Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","ATCPTTMT","% of total sales","CAN","Canada","2019","2019",1.9,"E; D","Estimated value; Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","ATCPTTMT","% of total sales","CAN","Canada","2020","2020",1.8,"E; D","Estimated value; Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","ATCPTTMT","% of total sales","CAN","Canada","2021","2021",1.8,"E; D","Estimated value; Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","ATCPTTMT","% of total sales","CAN","Canada","2022","2022",1.7,"E; D","Estimated value; Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MLLNCUMT","Million of national currency units","CZE","Czech Republic","2010","2010",1641.7,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MLLNCUMT","Million of national currency units","CZE","Czech Republic","2011","2011",1575.6,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MLLNCUMT","Million of national currency units","CZE","Czech Republic","2012","2012",1709.3,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MLLNCUMT","Million of national currency units","CZE","Czech Republic","2013","2013",1668.3,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MLLNCUMT","Million of national currency units","CZE","Czech Republic","2014","2014",1742.5,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MLLNCUMT","Million of national currency units","CZE","Czech Republic","2015","2015",1764.1,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MLLNCUMT","Million of national currency units","CZE","Czech Republic","2016","2016",1814.6,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MLLNCUMT","Million of national currency units","CZE","Czech Republic","2017","2017",1969.7,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MLLNCUMT","Million of national currency units","CZE","Czech Republic","2018","2018",2011,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MLLNCUMT","Million of national currency units","CZE","Czech Republic","2019","2019",2032.3,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MLLNCUMT","Million of national currency units","CZE","Czech Republic","2020","2020",1982.8,"B","Break"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MLLNCUMT","Million of national currency units","CZE","Czech Republic","2021","2021",2011.8,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOTCMT","Million US$ at exchange rate","CZE","Czech Republic","2010","2010",86,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOTCMT","Million US$ at exchange rate","CZE","Czech Republic","2011","2011",89,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOTCMT","Million US$ at exchange rate","CZE","Czech Republic","2012","2012",87.3,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOTCMT","Million US$ at exchange rate","CZE","Czech Republic","2013","2013",85.2,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOTCMT","Million US$ at exchange rate","CZE","Czech Republic","2014","2014",83.9,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOTCMT","Million US$ at exchange rate","CZE","Czech Republic","2015","2015",71.7,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOTCMT","Million US$ at exchange rate","CZE","Czech Republic","2016","2016",74.2,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOTCMT","Million US$ at exchange rate","CZE","Czech Republic","2017","2017",84.3,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOTCMT","Million US$ at exchange rate","CZE","Czech Republic","2018","2018",92.5,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOTCMT","Million US$ at exchange rate","CZE","Czech Republic","2019","2019",88.6,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOTCMT","Million US$ at exchange rate","CZE","Czech Republic","2020","2020",85.4,"B","Break"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOTCMT","Million US$ at exchange rate","CZE","Czech Republic","2021","2021",92.8,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOPPMT","Million US$, purchasing power parity","CZE","Czech Republic","2010","2010",120.1,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOPPMT","Million US$, purchasing power parity","CZE","Czech Republic","2011","2011",118.1,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOPPMT","Million US$, purchasing power parity","CZE","Czech Republic","2012","2012",128.5,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOPPMT","Million US$, purchasing power parity","CZE","Czech Republic","2013","2013",130.5,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOPPMT","Million US$, purchasing power parity","CZE","Czech Republic","2014","2014",137.2,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOPPMT","Million US$, purchasing power parity","CZE","Czech Republic","2015","2015",136.4,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOPPMT","Million US$, purchasing power parity","CZE","Czech Republic","2016","2016",144.3,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOPPMT","Million US$, purchasing power parity","CZE","Czech Republic","2017","2017",158.5,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOPPMT","Million US$, purchasing power parity","CZE","Czech Republic","2018","2018",162.5,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOPPMT","Million US$, purchasing power parity","CZE","Czech Republic","2019","2019",165.6,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOPPMT","Million US$, purchasing power parity","CZE","Czech Republic","2020","2020",159.1,"B","Break"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOPPMT","Million US$, purchasing power parity","CZE","Czech Republic","2021","2021",157.9,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","TCPPERMT","/capita, US$ exchange rate","CZE","Czech Republic","2010","2010",8.2,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","TCPPERMT","/capita, US$ exchange rate","CZE","Czech Republic","2011","2011",8.5,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","TCPPERMT","/capita, US$ exchange rate","CZE","Czech Republic","2012","2012",8.3,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","TCPPERMT","/capita, US$ exchange rate","CZE","Czech Republic","2013","2013",8.1,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","TCPPERMT","/capita, US$ exchange rate","CZE","Czech Republic","2014","2014",8,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","TCPPERMT","/capita, US$ exchange rate","CZE","Czech Republic","2015","2015",6.8,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","TCPPERMT","/capita, US$ exchange rate","CZE","Czech Republic","2016","2016",7,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","TCPPERMT","/capita, US$ exchange rate","CZE","Czech Republic","2017","2017",8,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","TCPPERMT","/capita, US$ exchange rate","CZE","Czech Republic","2018","2018",8.7,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","TCPPERMT","/capita, US$ exchange rate","CZE","Czech Republic","2019","2019",8.3,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","TCPPERMT","/capita, US$ exchange rate","CZE","Czech Republic","2020","2020",8,"B","Break"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","TCPPERMT","/capita, US$ exchange rate","CZE","Czech Republic","2021","2021",8.8,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czech Republic","2010","2010",11.5,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czech Republic","2011","2011",11.2,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czech Republic","2012","2012",12.2,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czech Republic","2013","2013",12.4,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czech Republic","2014","2014",13,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czech Republic","2015","2015",12.9,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czech Republic","2016","2016",13.7,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czech Republic","2017","2017",15,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czech Republic","2018","2018",15.3,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czech Republic","2019","2019",15.5,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czech Republic","2020","2020",14.9,"B","Break"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czech Republic","2021","2021",15,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","ATCPTTMT","% of total sales","CZE","Czech Republic","2010","2010",2,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","ATCPTTMT","% of total sales","CZE","Czech Republic","2011","2011",1.9,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","ATCPTTMT","% of total sales","CZE","Czech Republic","2012","2012",2,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","ATCPTTMT","% of total sales","CZE","Czech Republic","2013","2013",2.1,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","ATCPTTMT","% of total sales","CZE","Czech Republic","2014","2014",2.1,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","ATCPTTMT","% of total sales","CZE","Czech Republic","2015","2015",2.1,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","ATCPTTMT","% of total sales","CZE","Czech Republic","2016","2016",2.1,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","ATCPTTMT","% of total sales","CZE","Czech Republic","2017","2017",2.1,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","ATCPTTMT","% of total sales","CZE","Czech Republic","2018","2018",2.1,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","ATCPTTMT","% of total sales","CZE","Czech Republic","2019","2019",2,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","ATCPTTMT","% of total sales","CZE","Czech Republic","2020","2020",2.3,"B","Break"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","ATCPTTMT","% of total sales","CZE","Czech Republic","2021","2021",2.2,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MLLNCUMT","Million of national currency units","DNK","Denmark","2010","2010",497.6,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MLLNCUMT","Million of national currency units","DNK","Denmark","2011","2011",497.6,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MLLNCUMT","Million of national currency units","DNK","Denmark","2012","2012",482.7,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MLLNCUMT","Million of national currency units","DNK","Denmark","2013","2013",437,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MLLNCUMT","Million of national currency units","DNK","Denmark","2014","2014",465.8,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MLLNCUMT","Million of national currency units","DNK","Denmark","2015","2015",459.2,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MLLNCUMT","Million of national currency units","DNK","Denmark","2016","2016",466.9,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MLLNCUMT","Million of national currency units","DNK","Denmark","2017","2017",477.8,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MLLNCUMT","Million of national currency units","DNK","Denmark","2018","2018",500.2,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MLLNCUMT","Million of national currency units","DNK","Denmark","2019","2019",504.9,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MLLNCUMT","Million of national currency units","DNK","Denmark","2020","2020",485.5,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MLLNCUMT","Million of national currency units","DNK","Denmark","2021","2021",468,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOTCMT","Million US$ at exchange rate","DNK","Denmark","2010","2010",88.5,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOTCMT","Million US$ at exchange rate","DNK","Denmark","2011","2011",92.7,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOTCMT","Million US$ at exchange rate","DNK","Denmark","2012","2012",83.3,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOTCMT","Million US$ at exchange rate","DNK","Denmark","2013","2013",77.8,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOTCMT","Million US$ at exchange rate","DNK","Denmark","2014","2014",83,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOTCMT","Million US$ at exchange rate","DNK","Denmark","2015","2015",68.2,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOTCMT","Million US$ at exchange rate","DNK","Denmark","2016","2016",69.4,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOTCMT","Million US$ at exchange rate","DNK","Denmark","2017","2017",72.4,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOTCMT","Million US$ at exchange rate","DNK","Denmark","2018","2018",79.2,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOTCMT","Million US$ at exchange rate","DNK","Denmark","2019","2019",75.7,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOTCMT","Million US$ at exchange rate","DNK","Denmark","2020","2020",74.2,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOTCMT","Million US$ at exchange rate","DNK","Denmark","2021","2021",74.4,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOPPMT","Million US$, purchasing power parity","DNK","Denmark","2010","2010",65.6,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOPPMT","Million US$, purchasing power parity","DNK","Denmark","2011","2011",66.6,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOPPMT","Million US$, purchasing power parity","DNK","Denmark","2012","2012",63.8,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOPPMT","Million US$, purchasing power parity","DNK","Denmark","2013","2013",59.4,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOPPMT","Million US$, purchasing power parity","DNK","Denmark","2014","2014",63.6,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOPPMT","Million US$, purchasing power parity","DNK","Denmark","2015","2015",62.9,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOPPMT","Million US$, purchasing power parity","DNK","Denmark","2016","2016",66,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOPPMT","Million US$, purchasing power parity","DNK","Denmark","2017","2017",69.5,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOPPMT","Million US$, purchasing power parity","DNK","Denmark","2018","2018",73.9,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOPPMT","Million US$, purchasing power parity","DNK","Denmark","2019","2019",76.1,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOPPMT","Million US$, purchasing power parity","DNK","Denmark","2020","2020",74.1,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOPPMT","Million US$, purchasing power parity","DNK","Denmark","2021","2021",71,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","TCPPERMT","/capita, US$ exchange rate","DNK","Denmark","2010","2010",15.9,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","TCPPERMT","/capita, US$ exchange rate","DNK","Denmark","2011","2011",16.6,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","TCPPERMT","/capita, US$ exchange rate","DNK","Denmark","2012","2012",14.9,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","TCPPERMT","/capita, US$ exchange rate","DNK","Denmark","2013","2013",13.9,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","TCPPERMT","/capita, US$ exchange rate","DNK","Denmark","2014","2014",14.7,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","TCPPERMT","/capita, US$ exchange rate","DNK","Denmark","2015","2015",12,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","TCPPERMT","/capita, US$ exchange rate","DNK","Denmark","2016","2016",12.1,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","TCPPERMT","/capita, US$ exchange rate","DNK","Denmark","2017","2017",12.6,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","TCPPERMT","/capita, US$ exchange rate","DNK","Denmark","2018","2018",13.7,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","TCPPERMT","/capita, US$ exchange rate","DNK","Denmark","2019","2019",13,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","TCPPERMT","/capita, US$ exchange rate","DNK","Denmark","2020","2020",12.7,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","TCPPERMT","/capita, US$ exchange rate","DNK","Denmark","2021","2021",12.7,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","DNK","Denmark","2010","2010",11.8,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","DNK","Denmark","2011","2011",12,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","DNK","Denmark","2012","2012",11.4,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","DNK","Denmark","2013","2013",10.6,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","DNK","Denmark","2014","2014",11.3,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","DNK","Denmark","2015","2015",11.1,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","DNK","Denmark","2016","2016",11.5,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","DNK","Denmark","2017","2017",12.1,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","DNK","Denmark","2018","2018",12.8,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","DNK","Denmark","2019","2019",13.1,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","DNK","Denmark","2020","2020",12.7,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","DNK","Denmark","2021","2021",12.1,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","ATCPTTMT","% of total sales","DNK","Denmark","2010","2010",2.4,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","ATCPTTMT","% of total sales","DNK","Denmark","2011","2011",2.4,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","ATCPTTMT","% of total sales","DNK","Denmark","2012","2012",2.4,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","ATCPTTMT","% of total sales","DNK","Denmark","2013","2013",2.1,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","ATCPTTMT","% of total sales","DNK","Denmark","2014","2014",2.2,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","ATCPTTMT","% of total sales","DNK","Denmark","2015","2015",2.1,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","ATCPTTMT","% of total sales","DNK","Denmark","2016","2016",2.1,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","ATCPTTMT","% of total sales","DNK","Denmark","2017","2017",2.1,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","ATCPTTMT","% of total sales","DNK","Denmark","2018","2018",2.1,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","ATCPTTMT","% of total sales","DNK","Denmark","2019","2019",2.1,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","ATCPTTMT","% of total sales","DNK","Denmark","2020","2020",1.9,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","ATCPTTMT","% of total sales","DNK","Denmark","2021","2021",1.8,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MLLNCUMT","Million of national currency units","FIN","Finland","2010","2010",38.7,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MLLNCUMT","Million of national currency units","FIN","Finland","2011","2011",41.5,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MLLNCUMT","Million of national currency units","FIN","Finland","2012","2012",42.7,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MLLNCUMT","Million of national currency units","FIN","Finland","2013","2013",39.1,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MLLNCUMT","Million of national currency units","FIN","Finland","2014","2014",41,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MLLNCUMT","Million of national currency units","FIN","Finland","2015","2015",42.2,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MLLNCUMT","Million of national currency units","FIN","Finland","2016","2016",45.3,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MLLNCUMT","Million of national currency units","FIN","Finland","2017","2017",44.2,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MLLNCUMT","Million of national currency units","FIN","Finland","2018","2018",47,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MLLNCUMT","Million of national currency units","FIN","Finland","2019","2019",48.4,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MLLNCUMT","Million of national currency units","FIN","Finland","2020","2020",49.7,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MLLNCUMT","Million of national currency units","FIN","Finland","2021","2021",46.1,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOTCMT","Million US$ at exchange rate","FIN","Finland","2010","2010",51.3,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOTCMT","Million US$ at exchange rate","FIN","Finland","2011","2011",57.8,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOTCMT","Million US$ at exchange rate","FIN","Finland","2012","2012",54.9,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOTCMT","Million US$ at exchange rate","FIN","Finland","2013","2013",51.9,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOTCMT","Million US$ at exchange rate","FIN","Finland","2014","2014",54.5,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOTCMT","Million US$ at exchange rate","FIN","Finland","2015","2015",46.8,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOTCMT","Million US$ at exchange rate","FIN","Finland","2016","2016",50.1,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOTCMT","Million US$ at exchange rate","FIN","Finland","2017","2017",49.9,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOTCMT","Million US$ at exchange rate","FIN","Finland","2018","2018",55.5,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOTCMT","Million US$ at exchange rate","FIN","Finland","2019","2019",54.2,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOTCMT","Million US$ at exchange rate","FIN","Finland","2020","2020",56.8,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOTCMT","Million US$ at exchange rate","FIN","Finland","2021","2021",54.5,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOPPMT","Million US$, purchasing power parity","FIN","Finland","2010","2010",43,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOPPMT","Million US$, purchasing power parity","FIN","Finland","2011","2011",46.2,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOPPMT","Million US$, purchasing power parity","FIN","Finland","2012","2012",47,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOPPMT","Million US$, purchasing power parity","FIN","Finland","2013","2013",43.2,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOPPMT","Million US$, purchasing power parity","FIN","Finland","2014","2014",45.2,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOPPMT","Million US$, purchasing power parity","FIN","Finland","2015","2015",46.5,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOPPMT","Million US$, purchasing power parity","FIN","Finland","2016","2016",51.4,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOPPMT","Million US$, purchasing power parity","FIN","Finland","2017","2017",51.2,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOPPMT","Million US$, purchasing power parity","FIN","Finland","2018","2018",55.1,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOPPMT","Million US$, purchasing power parity","FIN","Finland","2019","2019",57.7,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOPPMT","Million US$, purchasing power parity","FIN","Finland","2020","2020",60.4,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOPPMT","Million US$, purchasing power parity","FIN","Finland","2021","2021",55.8,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","TCPPERMT","/capita, US$ exchange rate","FIN","Finland","2010","2010",9.6,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","TCPPERMT","/capita, US$ exchange rate","FIN","Finland","2011","2011",10.7,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","TCPPERMT","/capita, US$ exchange rate","FIN","Finland","2012","2012",10.1,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","TCPPERMT","/capita, US$ exchange rate","FIN","Finland","2013","2013",9.5,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","TCPPERMT","/capita, US$ exchange rate","FIN","Finland","2014","2014",10,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","TCPPERMT","/capita, US$ exchange rate","FIN","Finland","2015","2015",8.5,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","TCPPERMT","/capita, US$ exchange rate","FIN","Finland","2016","2016",9.1,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","TCPPERMT","/capita, US$ exchange rate","FIN","Finland","2017","2017",9.1,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","TCPPERMT","/capita, US$ exchange rate","FIN","Finland","2018","2018",10.1,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","TCPPERMT","/capita, US$ exchange rate","FIN","Finland","2019","2019",9.8,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","TCPPERMT","/capita, US$ exchange rate","FIN","Finland","2020","2020",10.3,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","TCPPERMT","/capita, US$ exchange rate","FIN","Finland","2021","2021",9.8,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2010","2010",8,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2011","2011",8.6,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2012","2012",8.7,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2013","2013",7.9,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2014","2014",8.3,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2015","2015",8.5,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2016","2016",9.4,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2017","2017",9.3,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2018","2018",10,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2019","2019",10.5,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2020","2020",10.9,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2021","2021",10.1,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","ATCPTTMT","% of total sales","FIN","Finland","2010","2010",2.1,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","ATCPTTMT","% of total sales","FIN","Finland","2011","2011",2.2,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","ATCPTTMT","% of total sales","FIN","Finland","2012","2012",2.2,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","ATCPTTMT","% of total sales","FIN","Finland","2013","2013",1.9,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","ATCPTTMT","% of total sales","FIN","Finland","2014","2014",2,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","ATCPTTMT","% of total sales","FIN","Finland","2015","2015",1.9,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","ATCPTTMT","% of total sales","FIN","Finland","2016","2016",2,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","ATCPTTMT","% of total sales","FIN","Finland","2017","2017",1.9,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","ATCPTTMT","% of total sales","FIN","Finland","2018","2018",1.9,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","ATCPTTMT","% of total sales","FIN","Finland","2019","2019",1.8,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","ATCPTTMT","% of total sales","FIN","Finland","2020","2020",1.8,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","ATCPTTMT","% of total sales","FIN","Finland","2021","2021",1.6,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MLLNCUMT","Million of national currency units","FRA","France","2011","2011",502.9,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOTCMT","Million US$ at exchange rate","FRA","France","2011","2011",700,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOPPMT","Million US$, purchasing power parity","FRA","France","2011","2011",597.7,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","TCPPERMT","/capita, US$ exchange rate","FRA","France","2011","2011",10.7,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","FRA","France","2011","2011",9.2,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","ATCPTTMT","% of total sales","FRA","France","2011","2011",1.8,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MLLNCUMT","Million of national currency units","DEU","Germany","2010","2010",987.2,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MLLNCUMT","Million of national currency units","DEU","Germany","2011","2011",994,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MLLNCUMT","Million of national currency units","DEU","Germany","2012","2012",1019.3,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MLLNCUMT","Million of national currency units","DEU","Germany","2013","2013",1046.4,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MLLNCUMT","Million of national currency units","DEU","Germany","2014","2014",1085.5,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MLLNCUMT","Million of national currency units","DEU","Germany","2015","2015",1111.7,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MLLNCUMT","Million of national currency units","DEU","Germany","2016","2016",1115.3,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MLLNCUMT","Million of national currency units","DEU","Germany","2017","2017",1132,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MLLNCUMT","Million of national currency units","DEU","Germany","2018","2018",1181.9,"B; D","Break; Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MLLNCUMT","Million of national currency units","DEU","Germany","2019","2019",1244.8,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MLLNCUMT","Million of national currency units","DEU","Germany","2020","2020",1257.3,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MLLNCUMT","Million of national currency units","DEU","Germany","2021","2021",1265.2,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOTCMT","Million US$ at exchange rate","DEU","Germany","2010","2010",1308.7,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOTCMT","Million US$ at exchange rate","DEU","Germany","2011","2011",1383.6,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOTCMT","Million US$ at exchange rate","DEU","Germany","2012","2012",1309.6,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOTCMT","Million US$ at exchange rate","DEU","Germany","2013","2013",1389.7,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOTCMT","Million US$ at exchange rate","DEU","Germany","2014","2014",1442.1,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOTCMT","Million US$ at exchange rate","DEU","Germany","2015","2015",1233.4,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOTCMT","Million US$ at exchange rate","DEU","Germany","2016","2016",1234.5,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOTCMT","Million US$ at exchange rate","DEU","Germany","2017","2017",1278.8,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOTCMT","Million US$ at exchange rate","DEU","Germany","2018","2018",1395.8,"B; D","Break; Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOTCMT","Million US$ at exchange rate","DEU","Germany","2019","2019",1393.5,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOTCMT","Million US$ at exchange rate","DEU","Germany","2020","2020",1436.1,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOTCMT","Million US$ at exchange rate","DEU","Germany","2021","2021",1496.4,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOPPMT","Million US$, purchasing power parity","DEU","Germany","2010","2010",1226.2,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOPPMT","Million US$, purchasing power parity","DEU","Germany","2011","2011",1260.2,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOPPMT","Million US$, purchasing power parity","DEU","Germany","2012","2012",1294.8,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOPPMT","Million US$, purchasing power parity","DEU","Germany","2013","2013",1350.6,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOPPMT","Million US$, purchasing power parity","DEU","Germany","2014","2014",1411.7,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOPPMT","Million US$, purchasing power parity","DEU","Germany","2015","2015",1428.7,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOPPMT","Million US$, purchasing power parity","DEU","Germany","2016","2016",1481.9,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOPPMT","Million US$, purchasing power parity","DEU","Germany","2017","2017",1519.9,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOPPMT","Million US$, purchasing power parity","DEU","Germany","2018","2018",1607,"B; D","Break; Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOPPMT","Million US$, purchasing power parity","DEU","Germany","2019","2019",1709.3,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOPPMT","Million US$, purchasing power parity","DEU","Germany","2020","2020",1734.2,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOPPMT","Million US$, purchasing power parity","DEU","Germany","2021","2021",1718.4,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","TCPPERMT","/capita, US$ exchange rate","DEU","Germany","2010","2010",16,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","TCPPERMT","/capita, US$ exchange rate","DEU","Germany","2011","2011",17.2,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","TCPPERMT","/capita, US$ exchange rate","DEU","Germany","2012","2012",16.3,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","TCPPERMT","/capita, US$ exchange rate","DEU","Germany","2013","2013",17.2,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","TCPPERMT","/capita, US$ exchange rate","DEU","Germany","2014","2014",17.8,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","TCPPERMT","/capita, US$ exchange rate","DEU","Germany","2015","2015",15.1,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","TCPPERMT","/capita, US$ exchange rate","DEU","Germany","2016","2016",15,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","TCPPERMT","/capita, US$ exchange rate","DEU","Germany","2017","2017",15.5,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","TCPPERMT","/capita, US$ exchange rate","DEU","Germany","2018","2018",16.8,"B; D","Break; Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","TCPPERMT","/capita, US$ exchange rate","DEU","Germany","2019","2019",16.8,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","TCPPERMT","/capita, US$ exchange rate","DEU","Germany","2020","2020",17.3,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","TCPPERMT","/capita, US$ exchange rate","DEU","Germany","2021","2021",18,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2010","2010",15,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2011","2011",15.7,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2012","2012",16.1,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2013","2013",16.7,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2014","2014",17.4,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2015","2015",17.5,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2016","2016",18,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2017","2017",18.4,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2018","2018",19.4,"B; D","Break; Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2019","2019",20.6,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2020","2020",20.9,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2021","2021",20.7,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","ATCPTTMT","% of total sales","DEU","Germany","2010","2010",3.3,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","ATCPTTMT","% of total sales","DEU","Germany","2011","2011",3.3,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","ATCPTTMT","% of total sales","DEU","Germany","2012","2012",3.3,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","ATCPTTMT","% of total sales","DEU","Germany","2013","2013",3.3,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","ATCPTTMT","% of total sales","DEU","Germany","2014","2014",3.2,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","ATCPTTMT","% of total sales","DEU","Germany","2015","2015",3.1,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","ATCPTTMT","% of total sales","DEU","Germany","2016","2016",3.1,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","ATCPTTMT","% of total sales","DEU","Germany","2017","2017",3,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","ATCPTTMT","% of total sales","DEU","Germany","2018","2018",2.7,"B; D","Break; Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","ATCPTTMT","% of total sales","DEU","Germany","2019","2019",2.7,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","ATCPTTMT","% of total sales","DEU","Germany","2020","2020",2.6,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","ATCPTTMT","% of total sales","DEU","Germany","2021","2021",2.4,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MLLNCUMT","Million of national currency units","GRC","Greece","2010","2010",169.2,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MLLNCUMT","Million of national currency units","GRC","Greece","2011","2011",157.2,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MLLNCUMT","Million of national currency units","GRC","Greece","2012","2012",136.4,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MLLNCUMT","Million of national currency units","GRC","Greece","2013","2013",114.7,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MLLNCUMT","Million of national currency units","GRC","Greece","2014","2014",115.7,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MLLNCUMT","Million of national currency units","GRC","Greece","2015","2015",99.5,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MLLNCUMT","Million of national currency units","GRC","Greece","2016","2016",122.7,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MLLNCUMT","Million of national currency units","GRC","Greece","2017","2017",129.2,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MLLNCUMT","Million of national currency units","GRC","Greece","2018","2018",132.9,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MLLNCUMT","Million of national currency units","GRC","Greece","2019","2019",142.5,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MLLNCUMT","Million of national currency units","GRC","Greece","2020","2020",150.3,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MLLNCUMT","Million of national currency units","GRC","Greece","2021","2021",159.1,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MLLNCUMT","Million of national currency units","GRC","Greece","2022","2022",123.6,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOTCMT","Million US$ at exchange rate","GRC","Greece","2010","2010",224.2,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOTCMT","Million US$ at exchange rate","GRC","Greece","2011","2011",218.8,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOTCMT","Million US$ at exchange rate","GRC","Greece","2012","2012",175.2,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOTCMT","Million US$ at exchange rate","GRC","Greece","2013","2013",152.3,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOTCMT","Million US$ at exchange rate","GRC","Greece","2014","2014",153.7,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOTCMT","Million US$ at exchange rate","GRC","Greece","2015","2015",110.3,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOTCMT","Million US$ at exchange rate","GRC","Greece","2016","2016",135.8,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOTCMT","Million US$ at exchange rate","GRC","Greece","2017","2017",146,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOTCMT","Million US$ at exchange rate","GRC","Greece","2018","2018",157,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOTCMT","Million US$ at exchange rate","GRC","Greece","2019","2019",159.5,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOTCMT","Million US$ at exchange rate","GRC","Greece","2020","2020",171.6,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOTCMT","Million US$ at exchange rate","GRC","Greece","2021","2021",188.2,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOTCMT","Million US$ at exchange rate","GRC","Greece","2022","2022",130.1,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOPPMT","Million US$, purchasing power parity","GRC","Greece","2010","2010",234.3,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOPPMT","Million US$, purchasing power parity","GRC","Greece","2011","2011",220.4,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOPPMT","Million US$, purchasing power parity","GRC","Greece","2012","2012",199.2,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOPPMT","Million US$, purchasing power parity","GRC","Greece","2013","2013",181.7,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOPPMT","Million US$, purchasing power parity","GRC","Greece","2014","2014",189.3,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOPPMT","Million US$, purchasing power parity","GRC","Greece","2015","2015",163.3,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOPPMT","Million US$, purchasing power parity","GRC","Greece","2016","2016",208.4,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOPPMT","Million US$, purchasing power parity","GRC","Greece","2017","2017",224.7,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOPPMT","Million US$, purchasing power parity","GRC","Greece","2018","2018",235.3,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOPPMT","Million US$, purchasing power parity","GRC","Greece","2019","2019",259.6,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOPPMT","Million US$, purchasing power parity","GRC","Greece","2020","2020",276.2,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOPPMT","Million US$, purchasing power parity","GRC","Greece","2021","2021",291.6,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOPPMT","Million US$, purchasing power parity","GRC","Greece","2022","2022",233.8,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","TCPPERMT","/capita, US$ exchange rate","GRC","Greece","2010","2010",20.2,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","TCPPERMT","/capita, US$ exchange rate","GRC","Greece","2011","2011",19.7,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","TCPPERMT","/capita, US$ exchange rate","GRC","Greece","2012","2012",15.9,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","TCPPERMT","/capita, US$ exchange rate","GRC","Greece","2013","2013",13.9,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","TCPPERMT","/capita, US$ exchange rate","GRC","Greece","2014","2014",14.1,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","TCPPERMT","/capita, US$ exchange rate","GRC","Greece","2015","2015",10.2,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","TCPPERMT","/capita, US$ exchange rate","GRC","Greece","2016","2016",12.6,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","TCPPERMT","/capita, US$ exchange rate","GRC","Greece","2017","2017",13.6,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","TCPPERMT","/capita, US$ exchange rate","GRC","Greece","2018","2018",14.6,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","TCPPERMT","/capita, US$ exchange rate","GRC","Greece","2019","2019",14.9,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","TCPPERMT","/capita, US$ exchange rate","GRC","Greece","2020","2020",16,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","TCPPERMT","/capita, US$ exchange rate","GRC","Greece","2021","2021",17.8,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","TCPPERMT","/capita, US$ exchange rate","GRC","Greece","2022","2022",12.4,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2010","2010",21.1,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2011","2011",19.8,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2012","2012",18,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2013","2013",16.6,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2014","2014",17.4,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2015","2015",15.1,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2016","2016",19.3,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2017","2017",20.9,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2018","2018",21.9,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2019","2019",24.2,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2020","2020",25.8,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2021","2021",27.6,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2022","2022",22.4,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MLLNCUMT","Million of national currency units","HUN","Hungary","2010","2010",6945,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MLLNCUMT","Million of national currency units","HUN","Hungary","2011","2011",7875.2,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MLLNCUMT","Million of national currency units","HUN","Hungary","2012","2012",8192.9,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MLLNCUMT","Million of national currency units","HUN","Hungary","2013","2013",8307.2,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MLLNCUMT","Million of national currency units","HUN","Hungary","2014","2014",9057.8,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MLLNCUMT","Million of national currency units","HUN","Hungary","2015","2015",9969.4,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MLLNCUMT","Million of national currency units","HUN","Hungary","2016","2016",10611,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MLLNCUMT","Million of national currency units","HUN","Hungary","2017","2017",10907.7,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MLLNCUMT","Million of national currency units","HUN","Hungary","2018","2018",11179.3,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MLLNCUMT","Million of national currency units","HUN","Hungary","2019","2019",11577.3,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MLLNCUMT","Million of national currency units","HUN","Hungary","2020","2020",11553.8,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MLLNCUMT","Million of national currency units","HUN","Hungary","2021","2021",11391.1,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MLLNCUMT","Million of national currency units","HUN","Hungary","2022","2022",11177.4,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOTCMT","Million US$ at exchange rate","HUN","Hungary","2010","2010",33.4,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOTCMT","Million US$ at exchange rate","HUN","Hungary","2011","2011",39.2,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOTCMT","Million US$ at exchange rate","HUN","Hungary","2012","2012",36.4,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOTCMT","Million US$ at exchange rate","HUN","Hungary","2013","2013",37.1,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOTCMT","Million US$ at exchange rate","HUN","Hungary","2014","2014",38.9,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOTCMT","Million US$ at exchange rate","HUN","Hungary","2015","2015",35.7,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOTCMT","Million US$ at exchange rate","HUN","Hungary","2016","2016",37.7,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOTCMT","Million US$ at exchange rate","HUN","Hungary","2017","2017",39.7,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOTCMT","Million US$ at exchange rate","HUN","Hungary","2018","2018",41.4,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOTCMT","Million US$ at exchange rate","HUN","Hungary","2019","2019",39.8,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOTCMT","Million US$ at exchange rate","HUN","Hungary","2020","2020",37.5,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOTCMT","Million US$ at exchange rate","HUN","Hungary","2021","2021",37.6,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOTCMT","Million US$ at exchange rate","HUN","Hungary","2022","2022",30,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOPPMT","Million US$, purchasing power parity","HUN","Hungary","2010","2010",54.9,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOPPMT","Million US$, purchasing power parity","HUN","Hungary","2011","2011",63.4,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOPPMT","Million US$, purchasing power parity","HUN","Hungary","2012","2012",65.2,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOPPMT","Million US$, purchasing power parity","HUN","Hungary","2013","2013",66.5,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOPPMT","Million US$, purchasing power parity","HUN","Hungary","2014","2014",70,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOPPMT","Million US$, purchasing power parity","HUN","Hungary","2015","2015",75.2,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOPPMT","Million US$, purchasing power parity","HUN","Hungary","2016","2016",80.4,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOPPMT","Million US$, purchasing power parity","HUN","Hungary","2017","2017",80.2,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOPPMT","Million US$, purchasing power parity","HUN","Hungary","2018","2018",80.4,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOPPMT","Million US$, purchasing power parity","HUN","Hungary","2019","2019",82.2,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOPPMT","Million US$, purchasing power parity","HUN","Hungary","2020","2020",79.5,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOPPMT","Million US$, purchasing power parity","HUN","Hungary","2021","2021",73.6,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOPPMT","Million US$, purchasing power parity","HUN","Hungary","2022","2022",69.3,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","TCPPERMT","/capita, US$ exchange rate","HUN","Hungary","2010","2010",3.3,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","TCPPERMT","/capita, US$ exchange rate","HUN","Hungary","2011","2011",3.9,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","TCPPERMT","/capita, US$ exchange rate","HUN","Hungary","2012","2012",3.7,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","TCPPERMT","/capita, US$ exchange rate","HUN","Hungary","2013","2013",3.8,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","TCPPERMT","/capita, US$ exchange rate","HUN","Hungary","2014","2014",3.9,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","TCPPERMT","/capita, US$ exchange rate","HUN","Hungary","2015","2015",3.6,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","TCPPERMT","/capita, US$ exchange rate","HUN","Hungary","2016","2016",3.8,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","TCPPERMT","/capita, US$ exchange rate","HUN","Hungary","2017","2017",4.1,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","TCPPERMT","/capita, US$ exchange rate","HUN","Hungary","2018","2018",4.2,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","TCPPERMT","/capita, US$ exchange rate","HUN","Hungary","2019","2019",4.1,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","TCPPERMT","/capita, US$ exchange rate","HUN","Hungary","2020","2020",3.8,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","TCPPERMT","/capita, US$ exchange rate","HUN","Hungary","2021","2021",3.9,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","TCPPERMT","/capita, US$ exchange rate","HUN","Hungary","2022","2022",3.1,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2010","2010",5.5,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2011","2011",6.4,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2012","2012",6.6,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2013","2013",6.7,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2014","2014",7.1,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2015","2015",7.6,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2016","2016",8.2,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2017","2017",8.2,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2018","2018",8.2,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2019","2019",8.4,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2020","2020",8.2,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2021","2021",7.6,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2022","2022",7.2,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","ATCPTTMT","% of total sales","HUN","Hungary","2010","2010",1.4,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","ATCPTTMT","% of total sales","HUN","Hungary","2011","2011",1.5,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","ATCPTTMT","% of total sales","HUN","Hungary","2012","2012",1.8,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","ATCPTTMT","% of total sales","HUN","Hungary","2013","2013",1.9,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","ATCPTTMT","% of total sales","HUN","Hungary","2014","2014",2,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","ATCPTTMT","% of total sales","HUN","Hungary","2015","2015",2.1,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","ATCPTTMT","% of total sales","HUN","Hungary","2016","2016",2.1,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","ATCPTTMT","% of total sales","HUN","Hungary","2017","2017",2.2,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","ATCPTTMT","% of total sales","HUN","Hungary","2018","2018",2.2,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","ATCPTTMT","% of total sales","HUN","Hungary","2019","2019",2.2,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","ATCPTTMT","% of total sales","HUN","Hungary","2020","2020",2.1,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","ATCPTTMT","% of total sales","HUN","Hungary","2021","2021",2,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","ATCPTTMT","% of total sales","HUN","Hungary","2022","2022",1.9,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MLLNCUMT","Million of national currency units","ISL","Iceland","2010","2010",585.4,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MLLNCUMT","Million of national currency units","ISL","Iceland","2011","2011",623.4,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MLLNCUMT","Million of national currency units","ISL","Iceland","2012","2012",617.7,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MLLNCUMT","Million of national currency units","ISL","Iceland","2013","2013",665,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MLLNCUMT","Million of national currency units","ISL","Iceland","2014","2014",656.6,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MLLNCUMT","Million of national currency units","ISL","Iceland","2015","2015",636,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MLLNCUMT","Million of national currency units","ISL","Iceland","2016","2016",670.4,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MLLNCUMT","Million of national currency units","ISL","Iceland","2017","2017",690.2,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MLLNCUMT","Million of national currency units","ISL","Iceland","2018","2018",761.1,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MLLNCUMT","Million of national currency units","ISL","Iceland","2019","2019",864.6,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MLLNCUMT","Million of national currency units","ISL","Iceland","2020","2020",931.3,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MLLNCUMT","Million of national currency units","ISL","Iceland","2021","2021",998.8,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOTCMT","Million US$ at exchange rate","ISL","Iceland","2010","2010",4.8,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOTCMT","Million US$ at exchange rate","ISL","Iceland","2011","2011",5.4,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOTCMT","Million US$ at exchange rate","ISL","Iceland","2012","2012",4.9,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOTCMT","Million US$ at exchange rate","ISL","Iceland","2013","2013",5.4,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOTCMT","Million US$ at exchange rate","ISL","Iceland","2014","2014",5.6,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOTCMT","Million US$ at exchange rate","ISL","Iceland","2015","2015",4.8,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOTCMT","Million US$ at exchange rate","ISL","Iceland","2016","2016",5.5,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOTCMT","Million US$ at exchange rate","ISL","Iceland","2017","2017",6.5,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOTCMT","Million US$ at exchange rate","ISL","Iceland","2018","2018",7,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOTCMT","Million US$ at exchange rate","ISL","Iceland","2019","2019",7.1,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOTCMT","Million US$ at exchange rate","ISL","Iceland","2020","2020",6.9,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOTCMT","Million US$ at exchange rate","ISL","Iceland","2021","2021",7.9,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOPPMT","Million US$, purchasing power parity","ISL","Iceland","2010","2010",4.4,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOPPMT","Million US$, purchasing power parity","ISL","Iceland","2011","2011",4.6,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOPPMT","Million US$, purchasing power parity","ISL","Iceland","2012","2012",4.5,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOPPMT","Million US$, purchasing power parity","ISL","Iceland","2013","2013",4.9,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOPPMT","Million US$, purchasing power parity","ISL","Iceland","2014","2014",4.7,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOPPMT","Million US$, purchasing power parity","ISL","Iceland","2015","2015",4.5,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOPPMT","Million US$, purchasing power parity","ISL","Iceland","2016","2016",4.8,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOPPMT","Million US$, purchasing power parity","ISL","Iceland","2017","2017",5,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOPPMT","Million US$, purchasing power parity","ISL","Iceland","2018","2018",5.4,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOPPMT","Million US$, purchasing power parity","ISL","Iceland","2019","2019",6.1,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOPPMT","Million US$, purchasing power parity","ISL","Iceland","2020","2020",6.3,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOPPMT","Million US$, purchasing power parity","ISL","Iceland","2021","2021",6.7,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","TCPPERMT","/capita, US$ exchange rate","ISL","Iceland","2010","2010",15.1,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","TCPPERMT","/capita, US$ exchange rate","ISL","Iceland","2011","2011",16.9,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","TCPPERMT","/capita, US$ exchange rate","ISL","Iceland","2012","2012",15.4,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","TCPPERMT","/capita, US$ exchange rate","ISL","Iceland","2013","2013",16.8,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","TCPPERMT","/capita, US$ exchange rate","ISL","Iceland","2014","2014",17.2,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","TCPPERMT","/capita, US$ exchange rate","ISL","Iceland","2015","2015",14.6,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","TCPPERMT","/capita, US$ exchange rate","ISL","Iceland","2016","2016",16.5,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","TCPPERMT","/capita, US$ exchange rate","ISL","Iceland","2017","2017",18.8,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","TCPPERMT","/capita, US$ exchange rate","ISL","Iceland","2018","2018",19.9,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","TCPPERMT","/capita, US$ exchange rate","ISL","Iceland","2019","2019",19.6,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","TCPPERMT","/capita, US$ exchange rate","ISL","Iceland","2020","2020",18.8,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","TCPPERMT","/capita, US$ exchange rate","ISL","Iceland","2021","2021",21.1,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2010","2010",13.9,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2011","2011",14.5,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2012","2012",14.1,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2013","2013",15,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2014","2014",14.5,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2015","2015",13.5,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2016","2016",14.3,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2017","2017",14.5,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2018","2018",15.3,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2019","2019",17,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2020","2020",17.3,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2021","2021",17.9,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","ATCPTTMT","% of total sales","ISL","Iceland","2010","2010",2.3,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","ATCPTTMT","% of total sales","ISL","Iceland","2011","2011",2.4,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","ATCPTTMT","% of total sales","ISL","Iceland","2012","2012",2.5,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","ATCPTTMT","% of total sales","ISL","Iceland","2013","2013",2.6,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","ATCPTTMT","% of total sales","ISL","Iceland","2014","2014",2.8,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","ATCPTTMT","% of total sales","ISL","Iceland","2015","2015",2.6,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","ATCPTTMT","% of total sales","ISL","Iceland","2016","2016",2.6,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","ATCPTTMT","% of total sales","ISL","Iceland","2017","2017",2.6,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","ATCPTTMT","% of total sales","ISL","Iceland","2018","2018",2.5,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","ATCPTTMT","% of total sales","ISL","Iceland","2019","2019",2.6,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","ATCPTTMT","% of total sales","ISL","Iceland","2020","2020",2.3,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","ATCPTTMT","% of total sales","ISL","Iceland","2021","2021",2.2,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MLLNCUMT","Million of national currency units","IRL","Ireland","2010","2010",44.3,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MLLNCUMT","Million of national currency units","IRL","Ireland","2011","2011",45.8,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MLLNCUMT","Million of national currency units","IRL","Ireland","2012","2012",48.6,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MLLNCUMT","Million of national currency units","IRL","Ireland","2013","2013",50.1,"B; D","Break; Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MLLNCUMT","Million of national currency units","IRL","Ireland","2014","2014",51.5,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MLLNCUMT","Million of national currency units","IRL","Ireland","2015","2015",53.4,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MLLNCUMT","Million of national currency units","IRL","Ireland","2016","2016",55.7,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MLLNCUMT","Million of national currency units","IRL","Ireland","2017","2017",55.5,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MLLNCUMT","Million of national currency units","IRL","Ireland","2018","2018",56.8,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MLLNCUMT","Million of national currency units","IRL","Ireland","2019","2019",60,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MLLNCUMT","Million of national currency units","IRL","Ireland","2020","2020",60,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MLLNCUMT","Million of national currency units","IRL","Ireland","2021","2021",59.6,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOTCMT","Million US$ at exchange rate","IRL","Ireland","2010","2010",58.7,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOTCMT","Million US$ at exchange rate","IRL","Ireland","2011","2011",63.8,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOTCMT","Million US$ at exchange rate","IRL","Ireland","2012","2012",62.4,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOTCMT","Million US$ at exchange rate","IRL","Ireland","2013","2013",66.6,"B; D","Break; Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOTCMT","Million US$ at exchange rate","IRL","Ireland","2014","2014",68.4,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOTCMT","Million US$ at exchange rate","IRL","Ireland","2015","2015",59.2,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOTCMT","Million US$ at exchange rate","IRL","Ireland","2016","2016",61.7,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOTCMT","Million US$ at exchange rate","IRL","Ireland","2017","2017",62.7,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOTCMT","Million US$ at exchange rate","IRL","Ireland","2018","2018",67.1,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOTCMT","Million US$ at exchange rate","IRL","Ireland","2019","2019",67.2,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOTCMT","Million US$ at exchange rate","IRL","Ireland","2020","2020",68.5,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOTCMT","Million US$ at exchange rate","IRL","Ireland","2021","2021",70.5,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOPPMT","Million US$, purchasing power parity","IRL","Ireland","2010","2010",52.1,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOPPMT","Million US$, purchasing power parity","IRL","Ireland","2011","2011",55.1,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOPPMT","Million US$, purchasing power parity","IRL","Ireland","2012","2012",59,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOPPMT","Million US$, purchasing power parity","IRL","Ireland","2013","2013",61.8,"B; D","Break; Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOPPMT","Million US$, purchasing power parity","IRL","Ireland","2014","2014",62.9,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOPPMT","Million US$, purchasing power parity","IRL","Ireland","2015","2015",65.9,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOPPMT","Million US$, purchasing power parity","IRL","Ireland","2016","2016",70.2,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOPPMT","Million US$, purchasing power parity","IRL","Ireland","2017","2017",69.9,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOPPMT","Million US$, purchasing power parity","IRL","Ireland","2018","2018",71.7,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOPPMT","Million US$, purchasing power parity","IRL","Ireland","2019","2019",74.5,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOPPMT","Million US$, purchasing power parity","IRL","Ireland","2020","2020",75.3,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOPPMT","Million US$, purchasing power parity","IRL","Ireland","2021","2021",75,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","TCPPERMT","/capita, US$ exchange rate","IRL","Ireland","2010","2010",12.9,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","TCPPERMT","/capita, US$ exchange rate","IRL","Ireland","2011","2011",13.9,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","TCPPERMT","/capita, US$ exchange rate","IRL","Ireland","2012","2012",13.6,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","TCPPERMT","/capita, US$ exchange rate","IRL","Ireland","2013","2013",14.4,"B; D","Break; Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","TCPPERMT","/capita, US$ exchange rate","IRL","Ireland","2014","2014",14.7,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","TCPPERMT","/capita, US$ exchange rate","IRL","Ireland","2015","2015",12.6,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","TCPPERMT","/capita, US$ exchange rate","IRL","Ireland","2016","2016",13,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","TCPPERMT","/capita, US$ exchange rate","IRL","Ireland","2017","2017",13,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","TCPPERMT","/capita, US$ exchange rate","IRL","Ireland","2018","2018",13.8,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","TCPPERMT","/capita, US$ exchange rate","IRL","Ireland","2019","2019",13.6,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","TCPPERMT","/capita, US$ exchange rate","IRL","Ireland","2020","2020",13.7,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","TCPPERMT","/capita, US$ exchange rate","IRL","Ireland","2021","2021",14,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2010","2010",11.4,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2011","2011",12,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2012","2012",12.8,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2013","2013",13.4,"B; D","Break; Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2014","2014",13.5,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2015","2015",14,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2016","2016",14.8,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2017","2017",14.5,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2018","2018",14.7,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2019","2019",15.1,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2020","2020",15.1,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2021","2021",14.9,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","ATCPTTMT","% of total sales","IRL","Ireland","2010","2010",2.2,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","ATCPTTMT","% of total sales","IRL","Ireland","2011","2011",2.3,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","ATCPTTMT","% of total sales","IRL","Ireland","2012","2012",2.4,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","ATCPTTMT","% of total sales","IRL","Ireland","2013","2013",2.6,"B; D","Break; Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","ATCPTTMT","% of total sales","IRL","Ireland","2014","2014",2.7,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","ATCPTTMT","% of total sales","IRL","Ireland","2015","2015",2.7,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","ATCPTTMT","% of total sales","IRL","Ireland","2016","2016",2.7,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","ATCPTTMT","% of total sales","IRL","Ireland","2017","2017",2.6,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","ATCPTTMT","% of total sales","IRL","Ireland","2018","2018",2.5,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","ATCPTTMT","% of total sales","IRL","Ireland","2019","2019",2.5,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","ATCPTTMT","% of total sales","IRL","Ireland","2020","2020",2.4,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","ATCPTTMT","% of total sales","IRL","Ireland","2021","2021",2.3,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MLLNCUMT","Million of national currency units","ITA","Italy","2011","2011",462.9,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MLLNCUMT","Million of national currency units","ITA","Italy","2012","2012",478.2,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MLLNCUMT","Million of national currency units","ITA","Italy","2013","2013",484.7,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MLLNCUMT","Million of national currency units","ITA","Italy","2014","2014",488.9,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MLLNCUMT","Million of national currency units","ITA","Italy","2015","2015",481.1,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MLLNCUMT","Million of national currency units","ITA","Italy","2016","2016",489.7,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MLLNCUMT","Million of national currency units","ITA","Italy","2017","2017",509.2,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MLLNCUMT","Million of national currency units","ITA","Italy","2018","2018",520.4,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MLLNCUMT","Million of national currency units","ITA","Italy","2019","2019",534.4,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MLLNCUMT","Million of national currency units","ITA","Italy","2020","2020",520.1,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MLLNCUMT","Million of national currency units","ITA","Italy","2021","2021",481.6,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MLLNCUMT","Million of national currency units","ITA","Italy","2022","2022",490.8,"E","Estimated value"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOTCMT","Million US$ at exchange rate","ITA","Italy","2011","2011",644.4,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOTCMT","Million US$ at exchange rate","ITA","Italy","2012","2012",614.3,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOTCMT","Million US$ at exchange rate","ITA","Italy","2013","2013",643.7,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOTCMT","Million US$ at exchange rate","ITA","Italy","2014","2014",649.5,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOTCMT","Million US$ at exchange rate","ITA","Italy","2015","2015",533.8,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOTCMT","Million US$ at exchange rate","ITA","Italy","2016","2016",542.1,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOTCMT","Million US$ at exchange rate","ITA","Italy","2017","2017",575.2,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOTCMT","Million US$ at exchange rate","ITA","Italy","2018","2018",614.6,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOTCMT","Million US$ at exchange rate","ITA","Italy","2019","2019",598.2,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOTCMT","Million US$ at exchange rate","ITA","Italy","2020","2020",594,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOTCMT","Million US$ at exchange rate","ITA","Italy","2021","2021",569.6,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOTCMT","Million US$ at exchange rate","ITA","Italy","2022","2022",516.8,"E","Estimated value"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOPPMT","Million US$, purchasing power parity","ITA","Italy","2011","2011",610.2,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOPPMT","Million US$, purchasing power parity","ITA","Italy","2012","2012",639.5,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOPPMT","Million US$, purchasing power parity","ITA","Italy","2013","2013",657.4,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOPPMT","Million US$, purchasing power parity","ITA","Italy","2014","2014",661,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOPPMT","Million US$, purchasing power parity","ITA","Italy","2015","2015",651.3,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOPPMT","Million US$, purchasing power parity","ITA","Italy","2016","2016",699,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOPPMT","Million US$, purchasing power parity","ITA","Italy","2017","2017",738,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOPPMT","Million US$, purchasing power parity","ITA","Italy","2018","2018",763.9,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOPPMT","Million US$, purchasing power parity","ITA","Italy","2019","2019",813.6,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOPPMT","Million US$, purchasing power parity","ITA","Italy","2020","2020",802.9,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOPPMT","Million US$, purchasing power parity","ITA","Italy","2021","2021",743.8,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOPPMT","Million US$, purchasing power parity","ITA","Italy","2022","2022",794.9,"E","Estimated value"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","TCPPERMT","/capita, US$ exchange rate","ITA","Italy","2011","2011",10.9,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","TCPPERMT","/capita, US$ exchange rate","ITA","Italy","2012","2012",10.3,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","TCPPERMT","/capita, US$ exchange rate","ITA","Italy","2013","2013",10.7,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","TCPPERMT","/capita, US$ exchange rate","ITA","Italy","2014","2014",10.7,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","TCPPERMT","/capita, US$ exchange rate","ITA","Italy","2015","2015",8.8,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","TCPPERMT","/capita, US$ exchange rate","ITA","Italy","2016","2016",8.9,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","TCPPERMT","/capita, US$ exchange rate","ITA","Italy","2017","2017",9.5,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","TCPPERMT","/capita, US$ exchange rate","ITA","Italy","2018","2018",10.2,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","TCPPERMT","/capita, US$ exchange rate","ITA","Italy","2019","2019",10,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","TCPPERMT","/capita, US$ exchange rate","ITA","Italy","2020","2020",10,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","TCPPERMT","/capita, US$ exchange rate","ITA","Italy","2021","2021",9.6,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","TCPPERMT","/capita, US$ exchange rate","ITA","Italy","2022","2022",8.8,"E","Estimated value"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2011","2011",10.3,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2012","2012",10.7,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2013","2013",10.9,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2014","2014",10.9,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2015","2015",10.7,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2016","2016",11.5,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2017","2017",12.2,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2018","2018",12.6,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2019","2019",13.6,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2020","2020",13.5,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2021","2021",12.6,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2022","2022",13.5,"E","Estimated value"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","ATCPTTMT","% of total sales","ITA","Italy","2011","2011",2.4,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","ATCPTTMT","% of total sales","ITA","Italy","2012","2012",2.5,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","ATCPTTMT","% of total sales","ITA","Italy","2013","2013",2.5,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","ATCPTTMT","% of total sales","ITA","Italy","2014","2014",2.5,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","ATCPTTMT","% of total sales","ITA","Italy","2015","2015",2.1,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","ATCPTTMT","% of total sales","ITA","Italy","2016","2016",2.1,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","ATCPTTMT","% of total sales","ITA","Italy","2017","2017",2.3,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","ATCPTTMT","% of total sales","ITA","Italy","2018","2018",2.3,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","ATCPTTMT","% of total sales","ITA","Italy","2019","2019",2.3,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","ATCPTTMT","% of total sales","ITA","Italy","2020","2020",2.2,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","ATCPTTMT","% of total sales","ITA","Italy","2021","2021",2,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","ATCPTTMT","% of total sales","ITA","Italy","2022","2022",2,"E","Estimated value"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MLLNCUMT","Million of national currency units","JPN","Japan","2010","2010",114985,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MLLNCUMT","Million of national currency units","JPN","Japan","2011","2011",139935,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MLLNCUMT","Million of national currency units","JPN","Japan","2012","2012",152914,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MLLNCUMT","Million of national currency units","JPN","Japan","2013","2013",166912,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MLLNCUMT","Million of national currency units","JPN","Japan","2014","2014",158691,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MLLNCUMT","Million of national currency units","JPN","Japan","2015","2015",182902,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MLLNCUMT","Million of national currency units","JPN","Japan","2016","2016",159150,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MLLNCUMT","Million of national currency units","JPN","Japan","2017","2017",175173,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MLLNCUMT","Million of national currency units","JPN","Japan","2018","2018",155562,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MLLNCUMT","Million of national currency units","JPN","Japan","2019","2019",259390,"B; D","Break; Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MLLNCUMT","Million of national currency units","JPN","Japan","2020","2020",253995,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MLLNCUMT","Million of national currency units","JPN","Japan","2021","2021",275742,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOTCMT","Million US$ at exchange rate","JPN","Japan","2010","2010",1309.9,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOTCMT","Million US$ at exchange rate","JPN","Japan","2011","2011",1753.4,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOTCMT","Million US$ at exchange rate","JPN","Japan","2012","2012",1916.4,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOTCMT","Million US$ at exchange rate","JPN","Japan","2013","2013",1710.2,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOTCMT","Million US$ at exchange rate","JPN","Japan","2014","2014",1497.9,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOTCMT","Million US$ at exchange rate","JPN","Japan","2015","2015",1511,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOTCMT","Million US$ at exchange rate","JPN","Japan","2016","2016",1462.9,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOTCMT","Million US$ at exchange rate","JPN","Japan","2017","2017",1561.7,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOTCMT","Million US$ at exchange rate","JPN","Japan","2018","2018",1408.8,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOTCMT","Million US$ at exchange rate","JPN","Japan","2019","2019",2379.5,"B; D","Break; Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOTCMT","Million US$ at exchange rate","JPN","Japan","2020","2020",2378.8,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOTCMT","Million US$ at exchange rate","JPN","Japan","2021","2021",2512.4,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOPPMT","Million US$, purchasing power parity","JPN","Japan","2010","2010",1029.3,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOPPMT","Million US$, purchasing power parity","JPN","Japan","2011","2011",1302.3,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOPPMT","Million US$, purchasing power parity","JPN","Japan","2012","2012",1466.5,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOPPMT","Million US$, purchasing power parity","JPN","Japan","2013","2013",1647.7,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOPPMT","Million US$, purchasing power parity","JPN","Japan","2014","2014",1539.9,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOPPMT","Million US$, purchasing power parity","JPN","Japan","2015","2015",1767.7,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOPPMT","Million US$, purchasing power parity","JPN","Japan","2016","2016",1508.3,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOPPMT","Million US$, purchasing power parity","JPN","Japan","2017","2017",1666.7,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOPPMT","Million US$, purchasing power parity","JPN","Japan","2018","2018",1493.5,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOPPMT","Million US$, purchasing power parity","JPN","Japan","2019","2019",2488.7,"B; D","Break; Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOPPMT","Million US$, purchasing power parity","JPN","Japan","2020","2020",2479.7,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOPPMT","Million US$, purchasing power parity","JPN","Japan","2021","2021",2702,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","TCPPERMT","/capita, US$ exchange rate","JPN","Japan","2010","2010",10.2,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","TCPPERMT","/capita, US$ exchange rate","JPN","Japan","2011","2011",13.7,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","TCPPERMT","/capita, US$ exchange rate","JPN","Japan","2012","2012",15,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","TCPPERMT","/capita, US$ exchange rate","JPN","Japan","2013","2013",13.4,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","TCPPERMT","/capita, US$ exchange rate","JPN","Japan","2014","2014",11.8,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","TCPPERMT","/capita, US$ exchange rate","JPN","Japan","2015","2015",11.9,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","TCPPERMT","/capita, US$ exchange rate","JPN","Japan","2016","2016",11.5,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","TCPPERMT","/capita, US$ exchange rate","JPN","Japan","2017","2017",12.3,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","TCPPERMT","/capita, US$ exchange rate","JPN","Japan","2018","2018",11.1,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","TCPPERMT","/capita, US$ exchange rate","JPN","Japan","2019","2019",18.9,"B; D","Break; Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","TCPPERMT","/capita, US$ exchange rate","JPN","Japan","2020","2020",18.9,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","TCPPERMT","/capita, US$ exchange rate","JPN","Japan","2021","2021",20,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","JPN","Japan","2010","2010",8,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","JPN","Japan","2011","2011",10.2,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","JPN","Japan","2012","2012",11.5,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","JPN","Japan","2013","2013",12.9,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","JPN","Japan","2014","2014",12.1,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","JPN","Japan","2015","2015",13.9,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","JPN","Japan","2016","2016",11.9,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","JPN","Japan","2017","2017",13.2,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","JPN","Japan","2018","2018",11.8,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","JPN","Japan","2019","2019",19.7,"B; D","Break; Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","JPN","Japan","2020","2020",19.7,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","JPN","Japan","2021","2021",21.5,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","ATCPTTMT","% of total sales","JPN","Japan","2010","2010",1.7,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","ATCPTTMT","% of total sales","JPN","Japan","2011","2011",2,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","ATCPTTMT","% of total sales","JPN","Japan","2012","2012",2.2,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","ATCPTTMT","% of total sales","JPN","Japan","2013","2013",2.4,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","ATCPTTMT","% of total sales","JPN","Japan","2014","2014",2.4,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","ATCPTTMT","% of total sales","JPN","Japan","2015","2015",2.7,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","ATCPTTMT","% of total sales","JPN","Japan","2016","2016",2.4,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","ATCPTTMT","% of total sales","JPN","Japan","2017","2017",2.6,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","ATCPTTMT","% of total sales","JPN","Japan","2018","2018",2.3,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","ATCPTTMT","% of total sales","JPN","Japan","2019","2019",2.7,"B; D","Break; Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","ATCPTTMT","% of total sales","JPN","Japan","2020","2020",2.7,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","ATCPTTMT","% of total sales","JPN","Japan","2021","2021",3,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MLLNCUMT","Million of national currency units","KOR","Korea","2010","2010",137957,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MLLNCUMT","Million of national currency units","KOR","Korea","2011","2011",232848.8,"B","Break"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MLLNCUMT","Million of national currency units","KOR","Korea","2012","2012",245185.4,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MLLNCUMT","Million of national currency units","KOR","Korea","2013","2013",251932.2,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MLLNCUMT","Million of national currency units","KOR","Korea","2014","2014",254331.1,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MLLNCUMT","Million of national currency units","KOR","Korea","2015","2015",259131.8,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MLLNCUMT","Million of national currency units","KOR","Korea","2016","2016",198179,"B","Break"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MLLNCUMT","Million of national currency units","KOR","Korea","2017","2017",196953.9,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MLLNCUMT","Million of national currency units","KOR","Korea","2018","2018",233107,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MLLNCUMT","Million of national currency units","KOR","Korea","2019","2019",275688.6,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MLLNCUMT","Million of national currency units","KOR","Korea","2020","2020",278416.1,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MLLNCUMT","Million of national currency units","KOR","Korea","2021","2021",336313.4,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOTCMT","Million US$ at exchange rate","KOR","Korea","2010","2010",119.3,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOTCMT","Million US$ at exchange rate","KOR","Korea","2011","2011",210.1,"B","Break"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOTCMT","Million US$ at exchange rate","KOR","Korea","2012","2012",217.6,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOTCMT","Million US$ at exchange rate","KOR","Korea","2013","2013",230.1,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOTCMT","Million US$ at exchange rate","KOR","Korea","2014","2014",241.6,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOTCMT","Million US$ at exchange rate","KOR","Korea","2015","2015",229.1,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOTCMT","Million US$ at exchange rate","KOR","Korea","2016","2016",170.7,"B","Break"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOTCMT","Million US$ at exchange rate","KOR","Korea","2017","2017",174.1,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOTCMT","Million US$ at exchange rate","KOR","Korea","2018","2018",211.9,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOTCMT","Million US$ at exchange rate","KOR","Korea","2019","2019",236.6,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOTCMT","Million US$ at exchange rate","KOR","Korea","2020","2020",235.9,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOTCMT","Million US$ at exchange rate","KOR","Korea","2021","2021",294,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOPPMT","Million US$, purchasing power parity","KOR","Korea","2010","2010",164,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOPPMT","Million US$, purchasing power parity","KOR","Korea","2011","2011",272.5,"B","Break"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOPPMT","Million US$, purchasing power parity","KOR","Korea","2012","2012",286.8,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOPPMT","Million US$, purchasing power parity","KOR","Korea","2013","2013",289.9,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOPPMT","Million US$, purchasing power parity","KOR","Korea","2014","2014",291.7,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOPPMT","Million US$, purchasing power parity","KOR","Korea","2015","2015",302.2,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOPPMT","Million US$, purchasing power parity","KOR","Korea","2016","2016",230.8,"B","Break"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOPPMT","Million US$, purchasing power parity","KOR","Korea","2017","2017",225.7,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOPPMT","Million US$, purchasing power parity","KOR","Korea","2018","2018",272.7,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOPPMT","Million US$, purchasing power parity","KOR","Korea","2019","2019",321.9,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOPPMT","Million US$, purchasing power parity","KOR","Korea","2020","2020",332.4,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOPPMT","Million US$, purchasing power parity","KOR","Korea","2021","2021",393.8,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","TCPPERMT","/capita, US$ exchange rate","KOR","Korea","2010","2010",2.4,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","TCPPERMT","/capita, US$ exchange rate","KOR","Korea","2011","2011",4.2,"B","Break"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","TCPPERMT","/capita, US$ exchange rate","KOR","Korea","2012","2012",4.3,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","TCPPERMT","/capita, US$ exchange rate","KOR","Korea","2013","2013",4.6,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","TCPPERMT","/capita, US$ exchange rate","KOR","Korea","2014","2014",4.8,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","TCPPERMT","/capita, US$ exchange rate","KOR","Korea","2015","2015",4.5,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","TCPPERMT","/capita, US$ exchange rate","KOR","Korea","2016","2016",3.3,"B","Break"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","TCPPERMT","/capita, US$ exchange rate","KOR","Korea","2017","2017",3.4,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","TCPPERMT","/capita, US$ exchange rate","KOR","Korea","2018","2018",4.1,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","TCPPERMT","/capita, US$ exchange rate","KOR","Korea","2019","2019",4.6,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","TCPPERMT","/capita, US$ exchange rate","KOR","Korea","2020","2020",4.6,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","TCPPERMT","/capita, US$ exchange rate","KOR","Korea","2021","2021",5.7,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2010","2010",3.3,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2011","2011",5.5,"B","Break"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2012","2012",5.7,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2013","2013",5.7,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2014","2014",5.7,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2015","2015",5.9,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2016","2016",4.5,"B","Break"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2017","2017",4.4,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2018","2018",5.3,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2019","2019",6.2,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2020","2020",6.4,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2021","2021",7.6,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","ATCPTTMT","% of total sales","KOR","Korea","2010","2010",0.7,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","ATCPTTMT","% of total sales","KOR","Korea","2011","2011",1.1,"B","Break"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","ATCPTTMT","% of total sales","KOR","Korea","2012","2012",1.1,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","ATCPTTMT","% of total sales","KOR","Korea","2013","2013",1.1,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","ATCPTTMT","% of total sales","KOR","Korea","2014","2014",1.1,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","ATCPTTMT","% of total sales","KOR","Korea","2015","2015",1.1,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","ATCPTTMT","% of total sales","KOR","Korea","2016","2016",0.8,"B","Break"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","ATCPTTMT","% of total sales","KOR","Korea","2017","2017",0.7,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","ATCPTTMT","% of total sales","KOR","Korea","2018","2018",0.8,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","ATCPTTMT","% of total sales","KOR","Korea","2019","2019",0.9,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","ATCPTTMT","% of total sales","KOR","Korea","2020","2020",0.9,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","ATCPTTMT","% of total sales","KOR","Korea","2021","2021",1,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MLLNCUMT","Million of national currency units","LUX","Luxembourg","2010","2010",4.1,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MLLNCUMT","Million of national currency units","LUX","Luxembourg","2011","2011",4.3,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MLLNCUMT","Million of national currency units","LUX","Luxembourg","2012","2012",4.9,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MLLNCUMT","Million of national currency units","LUX","Luxembourg","2013","2013",5.2,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MLLNCUMT","Million of national currency units","LUX","Luxembourg","2014","2014",5.3,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MLLNCUMT","Million of national currency units","LUX","Luxembourg","2015","2015",5.1,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MLLNCUMT","Million of national currency units","LUX","Luxembourg","2016","2016",5.3,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MLLNCUMT","Million of national currency units","LUX","Luxembourg","2017","2017",5.3,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MLLNCUMT","Million of national currency units","LUX","Luxembourg","2018","2018",5.5,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MLLNCUMT","Million of national currency units","LUX","Luxembourg","2019","2019",5.6,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MLLNCUMT","Million of national currency units","LUX","Luxembourg","2020","2020",5.6,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MLLNCUMT","Million of national currency units","LUX","Luxembourg","2021","2021",5.7,"B; D; P","Break; Difference in methodology; Provisional value"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MLLNCUMT","Million of national currency units","LUX","Luxembourg","2022","2022",5.6,"D; P","Difference in methodology; Provisional value"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOTCMT","Million US$ at exchange rate","LUX","Luxembourg","2010","2010",5.4,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOTCMT","Million US$ at exchange rate","LUX","Luxembourg","2011","2011",6,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOTCMT","Million US$ at exchange rate","LUX","Luxembourg","2012","2012",6.2,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOTCMT","Million US$ at exchange rate","LUX","Luxembourg","2013","2013",6.8,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOTCMT","Million US$ at exchange rate","LUX","Luxembourg","2014","2014",7.1,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOTCMT","Million US$ at exchange rate","LUX","Luxembourg","2015","2015",5.7,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOTCMT","Million US$ at exchange rate","LUX","Luxembourg","2016","2016",5.8,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOTCMT","Million US$ at exchange rate","LUX","Luxembourg","2017","2017",6,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOTCMT","Million US$ at exchange rate","LUX","Luxembourg","2018","2018",6.5,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOTCMT","Million US$ at exchange rate","LUX","Luxembourg","2019","2019",6.2,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOTCMT","Million US$ at exchange rate","LUX","Luxembourg","2020","2020",6.4,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOTCMT","Million US$ at exchange rate","LUX","Luxembourg","2021","2021",6.8,"B; D; P","Break; Difference in methodology; Provisional value"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOTCMT","Million US$ at exchange rate","LUX","Luxembourg","2022","2022",5.8,"D; P","Difference in methodology; Provisional value"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOPPMT","Million US$, purchasing power parity","LUX","Luxembourg","2010","2010",4.4,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOPPMT","Million US$, purchasing power parity","LUX","Luxembourg","2011","2011",4.8,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOPPMT","Million US$, purchasing power parity","LUX","Luxembourg","2012","2012",5.3,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOPPMT","Million US$, purchasing power parity","LUX","Luxembourg","2013","2013",5.8,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOPPMT","Million US$, purchasing power parity","LUX","Luxembourg","2014","2014",6,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOPPMT","Million US$, purchasing power parity","LUX","Luxembourg","2015","2015",5.8,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOPPMT","Million US$, purchasing power parity","LUX","Luxembourg","2016","2016",6.2,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOPPMT","Million US$, purchasing power parity","LUX","Luxembourg","2017","2017",6.3,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOPPMT","Million US$, purchasing power parity","LUX","Luxembourg","2018","2018",6.5,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOPPMT","Million US$, purchasing power parity","LUX","Luxembourg","2019","2019",6.6,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOPPMT","Million US$, purchasing power parity","LUX","Luxembourg","2020","2020",6.5,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOPPMT","Million US$, purchasing power parity","LUX","Luxembourg","2021","2021",6.7,"B; D; P","Break; Difference in methodology; Provisional value"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOPPMT","Million US$, purchasing power parity","LUX","Luxembourg","2022","2022",6.7,"D; P","Difference in methodology; Provisional value"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","TCPPERMT","/capita, US$ exchange rate","LUX","Luxembourg","2010","2010",11.5,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","TCPPERMT","/capita, US$ exchange rate","LUX","Luxembourg","2011","2011",12.4,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","TCPPERMT","/capita, US$ exchange rate","LUX","Luxembourg","2012","2012",12.7,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","TCPPERMT","/capita, US$ exchange rate","LUX","Luxembourg","2013","2013",13.6,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","TCPPERMT","/capita, US$ exchange rate","LUX","Luxembourg","2014","2014",13.8,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","TCPPERMT","/capita, US$ exchange rate","LUX","Luxembourg","2015","2015",11,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","TCPPERMT","/capita, US$ exchange rate","LUX","Luxembourg","2016","2016",11.1,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","TCPPERMT","/capita, US$ exchange rate","LUX","Luxembourg","2017","2017",11.3,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","TCPPERMT","/capita, US$ exchange rate","LUX","Luxembourg","2018","2018",11.9,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","TCPPERMT","/capita, US$ exchange rate","LUX","Luxembourg","2019","2019",11.2,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","TCPPERMT","/capita, US$ exchange rate","LUX","Luxembourg","2020","2020",11.3,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","TCPPERMT","/capita, US$ exchange rate","LUX","Luxembourg","2021","2021",11.8,"B; D; P","Break; Difference in methodology; Provisional value"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","TCPPERMT","/capita, US$ exchange rate","LUX","Luxembourg","2022","2022",10,"D; P","Difference in methodology; Provisional value"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2010","2010",9.4,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2011","2011",9.9,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2012","2012",10.9,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2013","2013",11.5,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2014","2014",11.8,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2015","2015",11.2,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2016","2016",11.7,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2017","2017",11.7,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2018","2018",11.8,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2019","2019",11.9,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2020","2020",11.5,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2021","2021",11.6,"B; D; P","Break; Difference in methodology; Provisional value"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2022","2022",11.4,"D; P","Difference in methodology; Provisional value"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","ATCPTTMT","% of total sales","LUX","Luxembourg","2010","2010",2.2,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","ATCPTTMT","% of total sales","LUX","Luxembourg","2011","2011",2.3,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","ATCPTTMT","% of total sales","LUX","Luxembourg","2012","2012",2.5,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","ATCPTTMT","% of total sales","LUX","Luxembourg","2013","2013",2.6,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","ATCPTTMT","% of total sales","LUX","Luxembourg","2014","2014",2.8,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","ATCPTTMT","% of total sales","LUX","Luxembourg","2015","2015",2.7,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","ATCPTTMT","% of total sales","LUX","Luxembourg","2016","2016",2.7,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","ATCPTTMT","% of total sales","LUX","Luxembourg","2017","2017",2.8,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","ATCPTTMT","% of total sales","LUX","Luxembourg","2018","2018",2.8,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","ATCPTTMT","% of total sales","LUX","Luxembourg","2019","2019",2.7,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","ATCPTTMT","% of total sales","LUX","Luxembourg","2020","2020",2.7,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","ATCPTTMT","% of total sales","LUX","Luxembourg","2021","2021",2.4,"B; D; P","Break; Difference in methodology; Provisional value"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","ATCPTTMT","% of total sales","LUX","Luxembourg","2022","2022",2.2,"D; P","Difference in methodology; Provisional value"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MLLNCUMT","Million of national currency units","NLD","Netherlands","2010","2010",169.1,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MLLNCUMT","Million of national currency units","NLD","Netherlands","2011","2011",174.4,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MLLNCUMT","Million of national currency units","NLD","Netherlands","2012","2012",174.2,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MLLNCUMT","Million of national currency units","NLD","Netherlands","2013","2013",127.9,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MLLNCUMT","Million of national currency units","NLD","Netherlands","2014","2014",129.9,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOTCMT","Million US$ at exchange rate","NLD","Netherlands","2010","2010",224.1,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOTCMT","Million US$ at exchange rate","NLD","Netherlands","2011","2011",242.8,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOTCMT","Million US$ at exchange rate","NLD","Netherlands","2012","2012",223.8,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOTCMT","Million US$ at exchange rate","NLD","Netherlands","2013","2013",169.8,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOTCMT","Million US$ at exchange rate","NLD","Netherlands","2014","2014",172.6,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOPPMT","Million US$, purchasing power parity","NLD","Netherlands","2010","2010",197.9,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOPPMT","Million US$, purchasing power parity","NLD","Netherlands","2011","2011",208.6,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOPPMT","Million US$, purchasing power parity","NLD","Netherlands","2012","2012",211.3,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOPPMT","Million US$, purchasing power parity","NLD","Netherlands","2013","2013",160.2,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOPPMT","Million US$, purchasing power parity","NLD","Netherlands","2014","2014",160.6,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","TCPPERMT","/capita, US$ exchange rate","NLD","Netherlands","2010","2010",13.5,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","TCPPERMT","/capita, US$ exchange rate","NLD","Netherlands","2011","2011",14.5,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","TCPPERMT","/capita, US$ exchange rate","NLD","Netherlands","2012","2012",13.4,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","TCPPERMT","/capita, US$ exchange rate","NLD","Netherlands","2013","2013",10.1,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","TCPPERMT","/capita, US$ exchange rate","NLD","Netherlands","2014","2014",10.2,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","NLD","Netherlands","2010","2010",11.9,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","NLD","Netherlands","2011","2011",12.5,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","NLD","Netherlands","2012","2012",12.6,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","NLD","Netherlands","2013","2013",9.5,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","NLD","Netherlands","2014","2014",9.5,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","ATCPTTMT","% of total sales","NLD","Netherlands","2010","2010",3.2,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","ATCPTTMT","% of total sales","NLD","Netherlands","2011","2011",3.3,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","ATCPTTMT","% of total sales","NLD","Netherlands","2012","2012",3.8,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","ATCPTTMT","% of total sales","NLD","Netherlands","2013","2013",3,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","ATCPTTMT","% of total sales","NLD","Netherlands","2014","2014",3,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MLLNCUMT","Million of national currency units","NZL","New Zealand","2010","2010",18.7,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MLLNCUMT","Million of national currency units","NZL","New Zealand","2011","2011",18.7,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MLLNCUMT","Million of national currency units","NZL","New Zealand","2012","2012",21.2,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MLLNCUMT","Million of national currency units","NZL","New Zealand","2013","2013",22.7,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MLLNCUMT","Million of national currency units","NZL","New Zealand","2014","2014",24.5,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MLLNCUMT","Million of national currency units","NZL","New Zealand","2015","2015",28.5,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MLLNCUMT","Million of national currency units","NZL","New Zealand","2016","2016",28.2,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MLLNCUMT","Million of national currency units","NZL","New Zealand","2017","2017",25,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MLLNCUMT","Million of national currency units","NZL","New Zealand","2018","2018",24.6,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MLLNCUMT","Million of national currency units","NZL","New Zealand","2019","2019",25.3,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MLLNCUMT","Million of national currency units","NZL","New Zealand","2020","2020",26.7,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MLLNCUMT","Million of national currency units","NZL","New Zealand","2021","2021",29.4,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MLLNCUMT","Million of national currency units","NZL","New Zealand","2022","2022",25.2,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOTCMT","Million US$ at exchange rate","NZL","New Zealand","2010","2010",13.4,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOTCMT","Million US$ at exchange rate","NZL","New Zealand","2011","2011",14.7,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOTCMT","Million US$ at exchange rate","NZL","New Zealand","2012","2012",17.2,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOTCMT","Million US$ at exchange rate","NZL","New Zealand","2013","2013",18.6,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOTCMT","Million US$ at exchange rate","NZL","New Zealand","2014","2014",20.3,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOTCMT","Million US$ at exchange rate","NZL","New Zealand","2015","2015",19.9,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOTCMT","Million US$ at exchange rate","NZL","New Zealand","2016","2016",19.6,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOTCMT","Million US$ at exchange rate","NZL","New Zealand","2017","2017",17.8,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOTCMT","Million US$ at exchange rate","NZL","New Zealand","2018","2018",17,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOTCMT","Million US$ at exchange rate","NZL","New Zealand","2019","2019",16.6,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOTCMT","Million US$ at exchange rate","NZL","New Zealand","2020","2020",17.3,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOTCMT","Million US$ at exchange rate","NZL","New Zealand","2021","2021",20.8,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOTCMT","Million US$ at exchange rate","NZL","New Zealand","2022","2022",16,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOPPMT","Million US$, purchasing power parity","NZL","New Zealand","2010","2010",12.5,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOPPMT","Million US$, purchasing power parity","NZL","New Zealand","2011","2011",12.6,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOPPMT","Million US$, purchasing power parity","NZL","New Zealand","2012","2012",14.2,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOPPMT","Million US$, purchasing power parity","NZL","New Zealand","2013","2013",15.7,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOPPMT","Million US$, purchasing power parity","NZL","New Zealand","2014","2014",17,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOPPMT","Million US$, purchasing power parity","NZL","New Zealand","2015","2015",19.3,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOPPMT","Million US$, purchasing power parity","NZL","New Zealand","2016","2016",19.6,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOPPMT","Million US$, purchasing power parity","NZL","New Zealand","2017","2017",17.5,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOPPMT","Million US$, purchasing power parity","NZL","New Zealand","2018","2018",16.7,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOPPMT","Million US$, purchasing power parity","NZL","New Zealand","2019","2019",17.8,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOPPMT","Million US$, purchasing power parity","NZL","New Zealand","2020","2020",18.9,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOPPMT","Million US$, purchasing power parity","NZL","New Zealand","2021","2021",20.1,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOPPMT","Million US$, purchasing power parity","NZL","New Zealand","2022","2022",17.5,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","TCPPERMT","/capita, US$ exchange rate","NZL","New Zealand","2010","2010",3.1,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","TCPPERMT","/capita, US$ exchange rate","NZL","New Zealand","2011","2011",3.4,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","TCPPERMT","/capita, US$ exchange rate","NZL","New Zealand","2012","2012",3.9,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","TCPPERMT","/capita, US$ exchange rate","NZL","New Zealand","2013","2013",4.2,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","TCPPERMT","/capita, US$ exchange rate","NZL","New Zealand","2014","2014",4.5,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","TCPPERMT","/capita, US$ exchange rate","NZL","New Zealand","2015","2015",4.3,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","TCPPERMT","/capita, US$ exchange rate","NZL","New Zealand","2016","2016",4.2,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","TCPPERMT","/capita, US$ exchange rate","NZL","New Zealand","2017","2017",3.7,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","TCPPERMT","/capita, US$ exchange rate","NZL","New Zealand","2018","2018",3.5,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","TCPPERMT","/capita, US$ exchange rate","NZL","New Zealand","2019","2019",3.3,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","TCPPERMT","/capita, US$ exchange rate","NZL","New Zealand","2020","2020",3.4,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","TCPPERMT","/capita, US$ exchange rate","NZL","New Zealand","2021","2021",4.1,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","TCPPERMT","/capita, US$ exchange rate","NZL","New Zealand","2022","2022",3.1,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2010","2010",2.9,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2011","2011",2.9,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2012","2012",3.2,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2013","2013",3.5,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2014","2014",3.8,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2015","2015",4.2,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2016","2016",4.1,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2017","2017",3.6,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2018","2018",3.4,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2019","2019",3.6,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2020","2020",3.7,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2021","2021",3.9,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2022","2022",3.4,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","ATCPTTMT","% of total sales","NZL","New Zealand","2010","2010",2.5,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","ATCPTTMT","% of total sales","NZL","New Zealand","2011","2011",2.3,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","ATCPTTMT","% of total sales","NZL","New Zealand","2012","2012",2.3,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","ATCPTTMT","% of total sales","NZL","New Zealand","2013","2013",2.5,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","ATCPTTMT","% of total sales","NZL","New Zealand","2014","2014",2.5,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","ATCPTTMT","% of total sales","NZL","New Zealand","2015","2015",2.9,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","ATCPTTMT","% of total sales","NZL","New Zealand","2016","2016",2.6,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","ATCPTTMT","% of total sales","NZL","New Zealand","2017","2017",2,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","ATCPTTMT","% of total sales","NZL","New Zealand","2018","2018",1.9,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","ATCPTTMT","% of total sales","NZL","New Zealand","2019","2019",1.7,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","ATCPTTMT","% of total sales","NZL","New Zealand","2020","2020",1.6,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","ATCPTTMT","% of total sales","NZL","New Zealand","2021","2021",1.7,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","ATCPTTMT","% of total sales","NZL","New Zealand","2022","2022",1.3,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MLLNCUMT","Million of national currency units","NOR","Norway","2010","2010",440,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MLLNCUMT","Million of national currency units","NOR","Norway","2011","2011",445,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MLLNCUMT","Million of national currency units","NOR","Norway","2012","2012",468,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MLLNCUMT","Million of national currency units","NOR","Norway","2013","2013",485,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MLLNCUMT","Million of national currency units","NOR","Norway","2014","2014",516,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MLLNCUMT","Million of national currency units","NOR","Norway","2015","2015",549,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MLLNCUMT","Million of national currency units","NOR","Norway","2016","2016",570,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MLLNCUMT","Million of national currency units","NOR","Norway","2017","2017",543,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MLLNCUMT","Million of national currency units","NOR","Norway","2018","2018",571,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MLLNCUMT","Million of national currency units","NOR","Norway","2019","2019",624,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MLLNCUMT","Million of national currency units","NOR","Norway","2020","2020",610,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MLLNCUMT","Million of national currency units","NOR","Norway","2021","2021",609,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MLLNCUMT","Million of national currency units","NOR","Norway","2022","2022",582,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOTCMT","Million US$ at exchange rate","NOR","Norway","2010","2010",72.8,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOTCMT","Million US$ at exchange rate","NOR","Norway","2011","2011",79.4,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOTCMT","Million US$ at exchange rate","NOR","Norway","2012","2012",80.4,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOTCMT","Million US$ at exchange rate","NOR","Norway","2013","2013",82.6,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOTCMT","Million US$ at exchange rate","NOR","Norway","2014","2014",81.9,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOTCMT","Million US$ at exchange rate","NOR","Norway","2015","2015",68.1,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOTCMT","Million US$ at exchange rate","NOR","Norway","2016","2016",67.9,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOTCMT","Million US$ at exchange rate","NOR","Norway","2017","2017",65.6,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOTCMT","Million US$ at exchange rate","NOR","Norway","2018","2018",70.2,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOTCMT","Million US$ at exchange rate","NOR","Norway","2019","2019",70.9,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOTCMT","Million US$ at exchange rate","NOR","Norway","2020","2020",64.8,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOTCMT","Million US$ at exchange rate","NOR","Norway","2021","2021",70.9,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOTCMT","Million US$ at exchange rate","NOR","Norway","2022","2022",60.5,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOPPMT","Million US$, purchasing power parity","NOR","Norway","2010","2010",48.1,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOPPMT","Million US$, purchasing power parity","NOR","Norway","2011","2011",49,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOPPMT","Million US$, purchasing power parity","NOR","Norway","2012","2012",51.8,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOPPMT","Million US$, purchasing power parity","NOR","Norway","2013","2013",53.7,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOPPMT","Million US$, purchasing power parity","NOR","Norway","2014","2014",55.6,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOPPMT","Million US$, purchasing power parity","NOR","Norway","2015","2015",55.3,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOPPMT","Million US$, purchasing power parity","NOR","Norway","2016","2016",56.8,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOPPMT","Million US$, purchasing power parity","NOR","Norway","2017","2017",55.7,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOPPMT","Million US$, purchasing power parity","NOR","Norway","2018","2018",59.6,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOPPMT","Million US$, purchasing power parity","NOR","Norway","2019","2019",64.9,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOPPMT","Million US$, purchasing power parity","NOR","Norway","2020","2020",61.7,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOPPMT","Million US$, purchasing power parity","NOR","Norway","2021","2021",64,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOPPMT","Million US$, purchasing power parity","NOR","Norway","2022","2022",54.2,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","TCPPERMT","/capita, US$ exchange rate","NOR","Norway","2010","2010",14.9,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","TCPPERMT","/capita, US$ exchange rate","NOR","Norway","2011","2011",16,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","TCPPERMT","/capita, US$ exchange rate","NOR","Norway","2012","2012",16,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","TCPPERMT","/capita, US$ exchange rate","NOR","Norway","2013","2013",16.3,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","TCPPERMT","/capita, US$ exchange rate","NOR","Norway","2014","2014",15.9,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","TCPPERMT","/capita, US$ exchange rate","NOR","Norway","2015","2015",13.1,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","TCPPERMT","/capita, US$ exchange rate","NOR","Norway","2016","2016",13,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","TCPPERMT","/capita, US$ exchange rate","NOR","Norway","2017","2017",12.4,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","TCPPERMT","/capita, US$ exchange rate","NOR","Norway","2018","2018",13.2,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","TCPPERMT","/capita, US$ exchange rate","NOR","Norway","2019","2019",13.3,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","TCPPERMT","/capita, US$ exchange rate","NOR","Norway","2020","2020",12,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","TCPPERMT","/capita, US$ exchange rate","NOR","Norway","2021","2021",13.1,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","TCPPERMT","/capita, US$ exchange rate","NOR","Norway","2022","2022",11.2,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2010","2010",9.8,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2011","2011",9.9,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2012","2012",10.3,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2013","2013",10.6,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2014","2014",10.8,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2015","2015",10.7,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2016","2016",10.8,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2017","2017",10.6,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2018","2018",11.2,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2019","2019",12.1,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2020","2020",11.5,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2021","2021",11.8,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2022","2022",10,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","ATCPTTMT","% of total sales","NOR","Norway","2010","2010",2.5,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","ATCPTTMT","% of total sales","NOR","Norway","2011","2011",2.4,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","ATCPTTMT","% of total sales","NOR","Norway","2012","2012",2.5,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","ATCPTTMT","% of total sales","NOR","Norway","2013","2013",2.5,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","ATCPTTMT","% of total sales","NOR","Norway","2014","2014",2.4,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","ATCPTTMT","% of total sales","NOR","Norway","2015","2015",2.4,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","ATCPTTMT","% of total sales","NOR","Norway","2016","2016",2.3,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","ATCPTTMT","% of total sales","NOR","Norway","2017","2017",2,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","ATCPTTMT","% of total sales","NOR","Norway","2018","2018",2.1,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","ATCPTTMT","% of total sales","NOR","Norway","2019","2019",2.2,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","ATCPTTMT","% of total sales","NOR","Norway","2020","2020",2.1,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","ATCPTTMT","% of total sales","NOR","Norway","2021","2021",1.8,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","ATCPTTMT","% of total sales","NOR","Norway","2022","2022",1.6,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MLLNCUMT","Million of national currency units","PRT","Portugal","2010","2010",24,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MLLNCUMT","Million of national currency units","PRT","Portugal","2011","2011",22.7,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MLLNCUMT","Million of national currency units","PRT","Portugal","2012","2012",20.6,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MLLNCUMT","Million of national currency units","PRT","Portugal","2013","2013",20,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MLLNCUMT","Million of national currency units","PRT","Portugal","2014","2014",21.5,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MLLNCUMT","Million of national currency units","PRT","Portugal","2015","2015",23.4,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MLLNCUMT","Million of national currency units","PRT","Portugal","2016","2016",24.5,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MLLNCUMT","Million of national currency units","PRT","Portugal","2017","2017",25.7,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MLLNCUMT","Million of national currency units","PRT","Portugal","2018","2018",26.9,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MLLNCUMT","Million of national currency units","PRT","Portugal","2019","2019",27.6,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MLLNCUMT","Million of national currency units","PRT","Portugal","2020","2020",25.8,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MLLNCUMT","Million of national currency units","PRT","Portugal","2021","2021",27.3,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MLLNCUMT","Million of national currency units","PRT","Portugal","2022","2022",29.9,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOTCMT","Million US$ at exchange rate","PRT","Portugal","2010","2010",31.8,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOTCMT","Million US$ at exchange rate","PRT","Portugal","2011","2011",31.7,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOTCMT","Million US$ at exchange rate","PRT","Portugal","2012","2012",26.5,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOTCMT","Million US$ at exchange rate","PRT","Portugal","2013","2013",26.6,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOTCMT","Million US$ at exchange rate","PRT","Portugal","2014","2014",28.6,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOTCMT","Million US$ at exchange rate","PRT","Portugal","2015","2015",25.9,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOTCMT","Million US$ at exchange rate","PRT","Portugal","2016","2016",27.1,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOTCMT","Million US$ at exchange rate","PRT","Portugal","2017","2017",29,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOTCMT","Million US$ at exchange rate","PRT","Portugal","2018","2018",31.8,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOTCMT","Million US$ at exchange rate","PRT","Portugal","2019","2019",30.9,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOTCMT","Million US$ at exchange rate","PRT","Portugal","2020","2020",29.5,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOTCMT","Million US$ at exchange rate","PRT","Portugal","2021","2021",32.3,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOTCMT","Million US$ at exchange rate","PRT","Portugal","2022","2022",31.5,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOPPMT","Million US$, purchasing power parity","PRT","Portugal","2010","2010",38.5,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOPPMT","Million US$, purchasing power parity","PRT","Portugal","2011","2011",36.5,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOPPMT","Million US$, purchasing power parity","PRT","Portugal","2012","2012",34.1,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOPPMT","Million US$, purchasing power parity","PRT","Portugal","2013","2013",34.3,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOPPMT","Million US$, purchasing power parity","PRT","Portugal","2014","2014",37.1,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOPPMT","Million US$, purchasing power parity","PRT","Portugal","2015","2015",39.9,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOPPMT","Million US$, purchasing power parity","PRT","Portugal","2016","2016",42.8,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOPPMT","Million US$, purchasing power parity","PRT","Portugal","2017","2017",44.6,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOPPMT","Million US$, purchasing power parity","PRT","Portugal","2018","2018",47.1,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOPPMT","Million US$, purchasing power parity","PRT","Portugal","2019","2019",49.3,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOPPMT","Million US$, purchasing power parity","PRT","Portugal","2020","2020",46.4,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOPPMT","Million US$, purchasing power parity","PRT","Portugal","2021","2021",48.1,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOPPMT","Million US$, purchasing power parity","PRT","Portugal","2022","2022",54.4,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","TCPPERMT","/capita, US$ exchange rate","PRT","Portugal","2010","2010",3,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","TCPPERMT","/capita, US$ exchange rate","PRT","Portugal","2011","2011",3,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","TCPPERMT","/capita, US$ exchange rate","PRT","Portugal","2012","2012",2.5,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","TCPPERMT","/capita, US$ exchange rate","PRT","Portugal","2013","2013",2.5,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","TCPPERMT","/capita, US$ exchange rate","PRT","Portugal","2014","2014",2.7,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","TCPPERMT","/capita, US$ exchange rate","PRT","Portugal","2015","2015",2.5,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","TCPPERMT","/capita, US$ exchange rate","PRT","Portugal","2016","2016",2.6,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","TCPPERMT","/capita, US$ exchange rate","PRT","Portugal","2017","2017",2.8,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","TCPPERMT","/capita, US$ exchange rate","PRT","Portugal","2018","2018",3.1,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","TCPPERMT","/capita, US$ exchange rate","PRT","Portugal","2019","2019",3,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","TCPPERMT","/capita, US$ exchange rate","PRT","Portugal","2020","2020",2.9,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","TCPPERMT","/capita, US$ exchange rate","PRT","Portugal","2021","2021",3.1,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","TCPPERMT","/capita, US$ exchange rate","PRT","Portugal","2022","2022",3,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2010","2010",3.6,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2011","2011",3.5,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2012","2012",3.2,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2013","2013",3.3,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2014","2014",3.6,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2015","2015",3.9,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2016","2016",4.1,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2017","2017",4.3,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2018","2018",4.6,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2019","2019",4.8,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2020","2020",4.5,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2021","2021",4.6,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2022","2022",5.3,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","ATCPTTMT","% of total sales","PRT","Portugal","2010","2010",0.7,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","ATCPTTMT","% of total sales","PRT","Portugal","2011","2011",0.8,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","ATCPTTMT","% of total sales","PRT","Portugal","2012","2012",0.8,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","ATCPTTMT","% of total sales","PRT","Portugal","2013","2013",0.8,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","ATCPTTMT","% of total sales","PRT","Portugal","2014","2014",0.9,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","ATCPTTMT","% of total sales","PRT","Portugal","2015","2015",0.9,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","ATCPTTMT","% of total sales","PRT","Portugal","2016","2016",1,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","ATCPTTMT","% of total sales","PRT","Portugal","2017","2017",1,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","ATCPTTMT","% of total sales","PRT","Portugal","2018","2018",1,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","ATCPTTMT","% of total sales","PRT","Portugal","2019","2019",1,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","ATCPTTMT","% of total sales","PRT","Portugal","2020","2020",0.9,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","ATCPTTMT","% of total sales","PRT","Portugal","2021","2021",0.9,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","ATCPTTMT","% of total sales","PRT","Portugal","2022","2022",0.9,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MLLNCUMT","Million of national currency units","SVK","Slovak Republic","2010","2010",20.5,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MLLNCUMT","Million of national currency units","SVK","Slovak Republic","2011","2011",17.8,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MLLNCUMT","Million of national currency units","SVK","Slovak Republic","2012","2012",19.3,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MLLNCUMT","Million of national currency units","SVK","Slovak Republic","2013","2013",22.1,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MLLNCUMT","Million of national currency units","SVK","Slovak Republic","2014","2014",25.3,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MLLNCUMT","Million of national currency units","SVK","Slovak Republic","2015","2015",24.6,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MLLNCUMT","Million of national currency units","SVK","Slovak Republic","2016","2016",27.2,"B","Break"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MLLNCUMT","Million of national currency units","SVK","Slovak Republic","2017","2017",26.9,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MLLNCUMT","Million of national currency units","SVK","Slovak Republic","2018","2018",27.6,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MLLNCUMT","Million of national currency units","SVK","Slovak Republic","2019","2019",28.4,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MLLNCUMT","Million of national currency units","SVK","Slovak Republic","2020","2020",26.7,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MLLNCUMT","Million of national currency units","SVK","Slovak Republic","2021","2021",28.5,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOTCMT","Million US$ at exchange rate","SVK","Slovak Republic","2010","2010",27.2,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOTCMT","Million US$ at exchange rate","SVK","Slovak Republic","2011","2011",24.8,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOTCMT","Million US$ at exchange rate","SVK","Slovak Republic","2012","2012",24.8,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOTCMT","Million US$ at exchange rate","SVK","Slovak Republic","2013","2013",29.4,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOTCMT","Million US$ at exchange rate","SVK","Slovak Republic","2014","2014",33.6,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOTCMT","Million US$ at exchange rate","SVK","Slovak Republic","2015","2015",27.3,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOTCMT","Million US$ at exchange rate","SVK","Slovak Republic","2016","2016",30.1,"B","Break"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOTCMT","Million US$ at exchange rate","SVK","Slovak Republic","2017","2017",30.4,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOTCMT","Million US$ at exchange rate","SVK","Slovak Republic","2018","2018",32.6,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOTCMT","Million US$ at exchange rate","SVK","Slovak Republic","2019","2019",31.8,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOTCMT","Million US$ at exchange rate","SVK","Slovak Republic","2020","2020",30.5,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOTCMT","Million US$ at exchange rate","SVK","Slovak Republic","2021","2021",33.6,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOPPMT","Million US$, purchasing power parity","SVK","Slovak Republic","2010","2010",40.9,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOPPMT","Million US$, purchasing power parity","SVK","Slovak Republic","2011","2011",35.2,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOPPMT","Million US$, purchasing power parity","SVK","Slovak Republic","2012","2012",38.2,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOPPMT","Million US$, purchasing power parity","SVK","Slovak Republic","2013","2013",45.1,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOPPMT","Million US$, purchasing power parity","SVK","Slovak Republic","2014","2014",52.2,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOPPMT","Million US$, purchasing power parity","SVK","Slovak Republic","2015","2015",50,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOPPMT","Million US$, purchasing power parity","SVK","Slovak Republic","2016","2016",54,"B","Break"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOPPMT","Million US$, purchasing power parity","SVK","Slovak Republic","2017","2017",52.1,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOPPMT","Million US$, purchasing power parity","SVK","Slovak Republic","2018","2018",52.4,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOPPMT","Million US$, purchasing power parity","SVK","Slovak Republic","2019","2019",54.9,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOPPMT","Million US$, purchasing power parity","SVK","Slovak Republic","2020","2020",51.3,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOPPMT","Million US$, purchasing power parity","SVK","Slovak Republic","2021","2021",53.3,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","TCPPERMT","/capita, US$ exchange rate","SVK","Slovak Republic","2010","2010",5,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","TCPPERMT","/capita, US$ exchange rate","SVK","Slovak Republic","2011","2011",4.6,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","TCPPERMT","/capita, US$ exchange rate","SVK","Slovak Republic","2012","2012",4.6,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","TCPPERMT","/capita, US$ exchange rate","SVK","Slovak Republic","2013","2013",5.4,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","TCPPERMT","/capita, US$ exchange rate","SVK","Slovak Republic","2014","2014",6.2,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","TCPPERMT","/capita, US$ exchange rate","SVK","Slovak Republic","2015","2015",5,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","TCPPERMT","/capita, US$ exchange rate","SVK","Slovak Republic","2016","2016",5.5,"B","Break"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","TCPPERMT","/capita, US$ exchange rate","SVK","Slovak Republic","2017","2017",5.6,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","TCPPERMT","/capita, US$ exchange rate","SVK","Slovak Republic","2018","2018",6,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","TCPPERMT","/capita, US$ exchange rate","SVK","Slovak Republic","2019","2019",5.8,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","TCPPERMT","/capita, US$ exchange rate","SVK","Slovak Republic","2020","2020",5.6,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","TCPPERMT","/capita, US$ exchange rate","SVK","Slovak Republic","2021","2021",6.2,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2010","2010",7.6,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2011","2011",6.5,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2012","2012",7.1,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2013","2013",8.3,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2014","2014",9.6,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2015","2015",9.2,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2016","2016",10,"B","Break"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2017","2017",9.6,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2018","2018",9.6,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2019","2019",10.1,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2020","2020",9.4,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2021","2021",9.8,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","ATCPTTMT","% of total sales","SVK","Slovak Republic","2010","2010",1.8,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","ATCPTTMT","% of total sales","SVK","Slovak Republic","2011","2011",1.6,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","ATCPTTMT","% of total sales","SVK","Slovak Republic","2012","2012",1.7,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","ATCPTTMT","% of total sales","SVK","Slovak Republic","2013","2013",1.8,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","ATCPTTMT","% of total sales","SVK","Slovak Republic","2014","2014",1.9,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","ATCPTTMT","% of total sales","SVK","Slovak Republic","2015","2015",1.8,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","ATCPTTMT","% of total sales","SVK","Slovak Republic","2016","2016",1.7,"B","Break"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","ATCPTTMT","% of total sales","SVK","Slovak Republic","2017","2017",1.7,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","ATCPTTMT","% of total sales","SVK","Slovak Republic","2018","2018",1.7,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","ATCPTTMT","% of total sales","SVK","Slovak Republic","2019","2019",1.6,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","ATCPTTMT","% of total sales","SVK","Slovak Republic","2020","2020",1.6,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","ATCPTTMT","% of total sales","SVK","Slovak Republic","2021","2021",1.6,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MLLNCUMT","Million of national currency units","ESP","Spain","2010","2010",256.8,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MLLNCUMT","Million of national currency units","ESP","Spain","2011","2011",258.9,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MLLNCUMT","Million of national currency units","ESP","Spain","2012","2012",235.7,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MLLNCUMT","Million of national currency units","ESP","Spain","2013","2013",206.1,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MLLNCUMT","Million of national currency units","ESP","Spain","2014","2014",224.5,"B; D","Break; Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MLLNCUMT","Million of national currency units","ESP","Spain","2015","2015",228.5,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MLLNCUMT","Million of national currency units","ESP","Spain","2016","2016",236.6,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MLLNCUMT","Million of national currency units","ESP","Spain","2017","2017",247.3,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MLLNCUMT","Million of national currency units","ESP","Spain","2018","2018",391.2,"B","Break"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MLLNCUMT","Million of national currency units","ESP","Spain","2019","2019",407.5,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MLLNCUMT","Million of national currency units","ESP","Spain","2020","2020",386.2,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MLLNCUMT","Million of national currency units","ESP","Spain","2021","2021",408.1,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MLLNCUMT","Million of national currency units","ESP","Spain","2022","2022",428.2,"P","Provisional value"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOTCMT","Million US$ at exchange rate","ESP","Spain","2010","2010",340.5,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOTCMT","Million US$ at exchange rate","ESP","Spain","2011","2011",360.3,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOTCMT","Million US$ at exchange rate","ESP","Spain","2012","2012",302.8,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOTCMT","Million US$ at exchange rate","ESP","Spain","2013","2013",273.8,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOTCMT","Million US$ at exchange rate","ESP","Spain","2014","2014",298.2,"B; D","Break; Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOTCMT","Million US$ at exchange rate","ESP","Spain","2015","2015",253.5,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOTCMT","Million US$ at exchange rate","ESP","Spain","2016","2016",261.9,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOTCMT","Million US$ at exchange rate","ESP","Spain","2017","2017",279.4,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOTCMT","Million US$ at exchange rate","ESP","Spain","2018","2018",462,"B","Break"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOTCMT","Million US$ at exchange rate","ESP","Spain","2019","2019",456.2,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOTCMT","Million US$ at exchange rate","ESP","Spain","2020","2020",441.1,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOTCMT","Million US$ at exchange rate","ESP","Spain","2021","2021",482.7,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOTCMT","Million US$ at exchange rate","ESP","Spain","2022","2022",450.9,"P","Provisional value"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOPPMT","Million US$, purchasing power parity","ESP","Spain","2010","2010",353.3,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOPPMT","Million US$, purchasing power parity","ESP","Spain","2011","2011",362.5,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOPPMT","Million US$, purchasing power parity","ESP","Spain","2012","2012",339.1,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOPPMT","Million US$, purchasing power parity","ESP","Spain","2013","2013",305.5,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOPPMT","Million US$, purchasing power parity","ESP","Spain","2014","2014",338.9,"B; D","Break; Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOPPMT","Million US$, purchasing power parity","ESP","Spain","2015","2015",343.8,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOPPMT","Million US$, purchasing power parity","ESP","Spain","2016","2016",368.2,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOPPMT","Million US$, purchasing power parity","ESP","Spain","2017","2017",392.1,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOPPMT","Million US$, purchasing power parity","ESP","Spain","2018","2018",619.2,"B","Break"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOPPMT","Million US$, purchasing power parity","ESP","Spain","2019","2019",664.9,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOPPMT","Million US$, purchasing power parity","ESP","Spain","2020","2020",621.6,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOPPMT","Million US$, purchasing power parity","ESP","Spain","2021","2021",652,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOPPMT","Million US$, purchasing power parity","ESP","Spain","2022","2022",718.2,"P","Provisional value"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","TCPPERMT","/capita, US$ exchange rate","ESP","Spain","2010","2010",7.3,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","TCPPERMT","/capita, US$ exchange rate","ESP","Spain","2011","2011",7.7,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","TCPPERMT","/capita, US$ exchange rate","ESP","Spain","2012","2012",6.5,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","TCPPERMT","/capita, US$ exchange rate","ESP","Spain","2013","2013",5.9,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","TCPPERMT","/capita, US$ exchange rate","ESP","Spain","2014","2014",6.4,"B; D","Break; Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","TCPPERMT","/capita, US$ exchange rate","ESP","Spain","2015","2015",5.5,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","TCPPERMT","/capita, US$ exchange rate","ESP","Spain","2016","2016",5.6,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","TCPPERMT","/capita, US$ exchange rate","ESP","Spain","2017","2017",6,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","TCPPERMT","/capita, US$ exchange rate","ESP","Spain","2018","2018",9.9,"B","Break"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","TCPPERMT","/capita, US$ exchange rate","ESP","Spain","2019","2019",9.7,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","TCPPERMT","/capita, US$ exchange rate","ESP","Spain","2020","2020",9.3,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","TCPPERMT","/capita, US$ exchange rate","ESP","Spain","2021","2021",10.2,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","TCPPERMT","/capita, US$ exchange rate","ESP","Spain","2022","2022",9.5,"P","Provisional value"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2010","2010",7.6,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2011","2011",7.8,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2012","2012",7.3,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2013","2013",6.6,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2014","2014",7.3,"B; D","Break; Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2015","2015",7.4,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2016","2016",7.9,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2017","2017",8.4,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2018","2018",13.2,"B","Break"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2019","2019",14.1,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2020","2020",13.1,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2021","2021",13.8,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2022","2022",15.1,"P","Provisional value"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","ATCPTTMT","% of total sales","ESP","Spain","2010","2010",1.9,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","ATCPTTMT","% of total sales","ESP","Spain","2011","2011",2.1,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","ATCPTTMT","% of total sales","ESP","Spain","2012","2012",2.1,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","ATCPTTMT","% of total sales","ESP","Spain","2013","2013",1.9,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","ATCPTTMT","% of total sales","ESP","Spain","2014","2014",2,"B; D","Break; Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","ATCPTTMT","% of total sales","ESP","Spain","2015","2015",2,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","ATCPTTMT","% of total sales","ESP","Spain","2016","2016",2,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","ATCPTTMT","% of total sales","ESP","Spain","2017","2017",2.1,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","ATCPTTMT","% of total sales","ESP","Spain","2018","2018",2.1,"B","Break"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","ATCPTTMT","% of total sales","ESP","Spain","2019","2019",2,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","ATCPTTMT","% of total sales","ESP","Spain","2020","2020",1.9,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","ATCPTTMT","% of total sales","ESP","Spain","2021","2021",1.9,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","ATCPTTMT","% of total sales","ESP","Spain","2022","2022",1.9,"P","Provisional value"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MLLNCUMT","Million of national currency units","SWE","Sweden","2010","2010",919.4,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MLLNCUMT","Million of national currency units","SWE","Sweden","2011","2011",934.9,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MLLNCUMT","Million of national currency units","SWE","Sweden","2012","2012",965.5,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MLLNCUMT","Million of national currency units","SWE","Sweden","2013","2013",973.5,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MLLNCUMT","Million of national currency units","SWE","Sweden","2014","2014",967.4,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MLLNCUMT","Million of national currency units","SWE","Sweden","2015","2015",983.4,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MLLNCUMT","Million of national currency units","SWE","Sweden","2016","2016",1026.8,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MLLNCUMT","Million of national currency units","SWE","Sweden","2017","2017",1054.6,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MLLNCUMT","Million of national currency units","SWE","Sweden","2018","2018",1090.3,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MLLNCUMT","Million of national currency units","SWE","Sweden","2019","2019",1116.3,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MLLNCUMT","Million of national currency units","SWE","Sweden","2020","2020",1102.7,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MLLNCUMT","Million of national currency units","SWE","Sweden","2021","2021",1088.1,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MLLNCUMT","Million of national currency units","SWE","Sweden","2022","2022",1109.1,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOTCMT","Million US$ at exchange rate","SWE","Sweden","2010","2010",127.6,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOTCMT","Million US$ at exchange rate","SWE","Sweden","2011","2011",144,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOTCMT","Million US$ at exchange rate","SWE","Sweden","2012","2012",142.5,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOTCMT","Million US$ at exchange rate","SWE","Sweden","2013","2013",149.4,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOTCMT","Million US$ at exchange rate","SWE","Sweden","2014","2014",141,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOTCMT","Million US$ at exchange rate","SWE","Sweden","2015","2015",116.6,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOTCMT","Million US$ at exchange rate","SWE","Sweden","2016","2016",119.9,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOTCMT","Million US$ at exchange rate","SWE","Sweden","2017","2017",123.4,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOTCMT","Million US$ at exchange rate","SWE","Sweden","2018","2018",125.4,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOTCMT","Million US$ at exchange rate","SWE","Sweden","2019","2019",118,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOTCMT","Million US$ at exchange rate","SWE","Sweden","2020","2020",119.7,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOTCMT","Million US$ at exchange rate","SWE","Sweden","2021","2021",126.9,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOTCMT","Million US$ at exchange rate","SWE","Sweden","2022","2022",109.7,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOPPMT","Million US$, purchasing power parity","SWE","Sweden","2010","2010",101.9,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOPPMT","Million US$, purchasing power parity","SWE","Sweden","2011","2011",105.7,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOPPMT","Million US$, purchasing power parity","SWE","Sweden","2012","2012",111.6,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOPPMT","Million US$, purchasing power parity","SWE","Sweden","2013","2013",113.2,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOPPMT","Million US$, purchasing power parity","SWE","Sweden","2014","2014",110.9,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOPPMT","Million US$, purchasing power parity","SWE","Sweden","2015","2015",111.1,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOPPMT","Million US$, purchasing power parity","SWE","Sweden","2016","2016",116.4,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOPPMT","Million US$, purchasing power parity","SWE","Sweden","2017","2017",119.1,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOPPMT","Million US$, purchasing power parity","SWE","Sweden","2018","2018",123,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOPPMT","Million US$, purchasing power parity","SWE","Sweden","2019","2019",128.2,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOPPMT","Million US$, purchasing power parity","SWE","Sweden","2020","2020",127.2,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOPPMT","Million US$, purchasing power parity","SWE","Sweden","2021","2021",124.8,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOPPMT","Million US$, purchasing power parity","SWE","Sweden","2022","2022",128,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","TCPPERMT","/capita, US$ exchange rate","SWE","Sweden","2010","2010",13.6,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","TCPPERMT","/capita, US$ exchange rate","SWE","Sweden","2011","2011",15.2,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","TCPPERMT","/capita, US$ exchange rate","SWE","Sweden","2012","2012",15,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","TCPPERMT","/capita, US$ exchange rate","SWE","Sweden","2013","2013",15.6,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","TCPPERMT","/capita, US$ exchange rate","SWE","Sweden","2014","2014",14.5,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","TCPPERMT","/capita, US$ exchange rate","SWE","Sweden","2015","2015",11.9,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","TCPPERMT","/capita, US$ exchange rate","SWE","Sweden","2016","2016",12.1,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","TCPPERMT","/capita, US$ exchange rate","SWE","Sweden","2017","2017",12.3,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","TCPPERMT","/capita, US$ exchange rate","SWE","Sweden","2018","2018",12.3,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","TCPPERMT","/capita, US$ exchange rate","SWE","Sweden","2019","2019",11.5,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","TCPPERMT","/capita, US$ exchange rate","SWE","Sweden","2020","2020",11.6,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","TCPPERMT","/capita, US$ exchange rate","SWE","Sweden","2021","2021",12.2,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","TCPPERMT","/capita, US$ exchange rate","SWE","Sweden","2022","2022",10.5,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2010","2010",10.9,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2011","2011",11.2,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2012","2012",11.7,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2013","2013",11.8,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2014","2014",11.4,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2015","2015",11.3,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2016","2016",11.7,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2017","2017",11.8,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2018","2018",12.1,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2019","2019",12.5,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2020","2020",12.3,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2021","2021",12,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2022","2022",12.2,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","ATCPTTMT","% of total sales","SWE","Sweden","2010","2010",2.5,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","ATCPTTMT","% of total sales","SWE","Sweden","2011","2011",2.5,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","ATCPTTMT","% of total sales","SWE","Sweden","2012","2012",2.7,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","ATCPTTMT","% of total sales","SWE","Sweden","2013","2013",2.7,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","ATCPTTMT","% of total sales","SWE","Sweden","2014","2014",2.6,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","ATCPTTMT","% of total sales","SWE","Sweden","2015","2015",2.4,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","ATCPTTMT","% of total sales","SWE","Sweden","2016","2016",2.4,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","ATCPTTMT","% of total sales","SWE","Sweden","2017","2017",2.4,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","ATCPTTMT","% of total sales","SWE","Sweden","2018","2018",2.3,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","ATCPTTMT","% of total sales","SWE","Sweden","2019","2019",2.2,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","ATCPTTMT","% of total sales","SWE","Sweden","2020","2020",2.1,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","ATCPTTMT","% of total sales","SWE","Sweden","2021","2021",2,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","ATCPTTMT","% of total sales","SWE","Sweden","2022","2022",1.9,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MLLNCUMT","Million of national currency units","CHE","Switzerland","2010","2010",71.4,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MLLNCUMT","Million of national currency units","CHE","Switzerland","2011","2011",73,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MLLNCUMT","Million of national currency units","CHE","Switzerland","2012","2012",83,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MLLNCUMT","Million of national currency units","CHE","Switzerland","2013","2013",84,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MLLNCUMT","Million of national currency units","CHE","Switzerland","2014","2014",85,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MLLNCUMT","Million of national currency units","CHE","Switzerland","2015","2015",87,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MLLNCUMT","Million of national currency units","CHE","Switzerland","2016","2016",91,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MLLNCUMT","Million of national currency units","CHE","Switzerland","2017","2017",93,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MLLNCUMT","Million of national currency units","CHE","Switzerland","2018","2018",86,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MLLNCUMT","Million of national currency units","CHE","Switzerland","2019","2019",86,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MLLNCUMT","Million of national currency units","CHE","Switzerland","2020","2020",89,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MLLNCUMT","Million of national currency units","CHE","Switzerland","2021","2021",85,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MLLNCUMT","Million of national currency units","CHE","Switzerland","2022","2022",89,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOTCMT","Million US$ at exchange rate","CHE","Switzerland","2010","2010",68.5,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOTCMT","Million US$ at exchange rate","CHE","Switzerland","2011","2011",82.2,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOTCMT","Million US$ at exchange rate","CHE","Switzerland","2012","2012",88.5,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOTCMT","Million US$ at exchange rate","CHE","Switzerland","2013","2013",90.6,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOTCMT","Million US$ at exchange rate","CHE","Switzerland","2014","2014",92.8,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOTCMT","Million US$ at exchange rate","CHE","Switzerland","2015","2015",90.4,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOTCMT","Million US$ at exchange rate","CHE","Switzerland","2016","2016",92.3,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOTCMT","Million US$ at exchange rate","CHE","Switzerland","2017","2017",94.4,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOTCMT","Million US$ at exchange rate","CHE","Switzerland","2018","2018",87.9,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOTCMT","Million US$ at exchange rate","CHE","Switzerland","2019","2019",86.5,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOTCMT","Million US$ at exchange rate","CHE","Switzerland","2020","2020",94.8,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOTCMT","Million US$ at exchange rate","CHE","Switzerland","2021","2021",93,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOTCMT","Million US$ at exchange rate","CHE","Switzerland","2022","2022",93.2,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOPPMT","Million US$, purchasing power parity","CHE","Switzerland","2010","2010",48.7,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOPPMT","Million US$, purchasing power parity","CHE","Switzerland","2011","2011",52.2,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOPPMT","Million US$, purchasing power parity","CHE","Switzerland","2012","2012",61.3,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOPPMT","Million US$, purchasing power parity","CHE","Switzerland","2013","2013",64,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOPPMT","Million US$, purchasing power parity","CHE","Switzerland","2014","2014",66.3,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOPPMT","Million US$, purchasing power parity","CHE","Switzerland","2015","2015",70.4,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOPPMT","Million US$, purchasing power parity","CHE","Switzerland","2016","2016",75.7,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOPPMT","Million US$, purchasing power parity","CHE","Switzerland","2017","2017",78.3,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOPPMT","Million US$, purchasing power parity","CHE","Switzerland","2018","2018",73,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOPPMT","Million US$, purchasing power parity","CHE","Switzerland","2019","2019",74.8,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOPPMT","Million US$, purchasing power parity","CHE","Switzerland","2020","2020",78.4,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOPPMT","Million US$, purchasing power parity","CHE","Switzerland","2021","2021",76.8,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOPPMT","Million US$, purchasing power parity","CHE","Switzerland","2022","2022",83.5,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","TCPPERMT","/capita, US$ exchange rate","CHE","Switzerland","2010","2010",8.8,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","TCPPERMT","/capita, US$ exchange rate","CHE","Switzerland","2011","2011",10.4,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","TCPPERMT","/capita, US$ exchange rate","CHE","Switzerland","2012","2012",11.1,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","TCPPERMT","/capita, US$ exchange rate","CHE","Switzerland","2013","2013",11.2,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","TCPPERMT","/capita, US$ exchange rate","CHE","Switzerland","2014","2014",11.3,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","TCPPERMT","/capita, US$ exchange rate","CHE","Switzerland","2015","2015",10.9,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","TCPPERMT","/capita, US$ exchange rate","CHE","Switzerland","2016","2016",11,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","TCPPERMT","/capita, US$ exchange rate","CHE","Switzerland","2017","2017",11.2,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","TCPPERMT","/capita, US$ exchange rate","CHE","Switzerland","2018","2018",10.3,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","TCPPERMT","/capita, US$ exchange rate","CHE","Switzerland","2019","2019",10.1,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","TCPPERMT","/capita, US$ exchange rate","CHE","Switzerland","2020","2020",11,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","TCPPERMT","/capita, US$ exchange rate","CHE","Switzerland","2021","2021",10.7,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","TCPPERMT","/capita, US$ exchange rate","CHE","Switzerland","2022","2022",10.7,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","CHE","Switzerland","2010","2010",6.2,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","CHE","Switzerland","2011","2011",6.6,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","CHE","Switzerland","2012","2012",7.7,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","CHE","Switzerland","2013","2013",7.9,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","CHE","Switzerland","2014","2014",8.1,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","CHE","Switzerland","2015","2015",8.5,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","CHE","Switzerland","2016","2016",9,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","CHE","Switzerland","2017","2017",9.3,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","CHE","Switzerland","2018","2018",8.6,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","CHE","Switzerland","2019","2019",8.7,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","CHE","Switzerland","2020","2020",9.1,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","CHE","Switzerland","2021","2021",8.8,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","CHE","Switzerland","2022","2022",9.6,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","ATCPTTMT","% of total sales","CHE","Switzerland","2010","2010",1.2,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","ATCPTTMT","% of total sales","CHE","Switzerland","2011","2011",1.3,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","ATCPTTMT","% of total sales","CHE","Switzerland","2012","2012",1.4,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","ATCPTTMT","% of total sales","CHE","Switzerland","2013","2013",1.4,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","ATCPTTMT","% of total sales","CHE","Switzerland","2014","2014",1.4,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","ATCPTTMT","% of total sales","CHE","Switzerland","2015","2015",1.4,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","ATCPTTMT","% of total sales","CHE","Switzerland","2016","2016",1.4,"B; D","Break; Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","ATCPTTMT","% of total sales","CHE","Switzerland","2017","2017",1.4,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","ATCPTTMT","% of total sales","CHE","Switzerland","2018","2018",1.3,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","ATCPTTMT","% of total sales","CHE","Switzerland","2019","2019",1.3,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","ATCPTTMT","% of total sales","CHE","Switzerland","2020","2020",1.3,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","ATCPTTMT","% of total sales","CHE","Switzerland","2021","2021",1.2,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","ATCPTTMT","% of total sales","CHE","Switzerland","2022","2022",1.2,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MLLNCUMT","Million of national currency units","TUR","Türkiye","2010","2010",237.4,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MLLNCUMT","Million of national currency units","TUR","Türkiye","2011","2011",246.1,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MLLNCUMT","Million of national currency units","TUR","Türkiye","2012","2012",240.2,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MLLNCUMT","Million of national currency units","TUR","Türkiye","2013","2013",258,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MLLNCUMT","Million of national currency units","TUR","Türkiye","2014","2014",297.2,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MLLNCUMT","Million of national currency units","TUR","Türkiye","2015","2015",352.6,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MLLNCUMT","Million of national currency units","TUR","Türkiye","2016","2016",411.4,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MLLNCUMT","Million of national currency units","TUR","Türkiye","2017","2017",476.7,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MLLNCUMT","Million of national currency units","TUR","Türkiye","2018","2018",614.4,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MLLNCUMT","Million of national currency units","TUR","Türkiye","2019","2019",753.3,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MLLNCUMT","Million of national currency units","TUR","Türkiye","2020","2020",861.1,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MLLNCUMT","Million of national currency units","TUR","Türkiye","2021","2021",1151.4,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOTCMT","Million US$ at exchange rate","TUR","Türkiye","2010","2010",157.9,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOTCMT","Million US$ at exchange rate","TUR","Türkiye","2011","2011",147,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOTCMT","Million US$ at exchange rate","TUR","Türkiye","2012","2012",133.7,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOTCMT","Million US$ at exchange rate","TUR","Türkiye","2013","2013",135.5,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOTCMT","Million US$ at exchange rate","TUR","Türkiye","2014","2014",135.8,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOTCMT","Million US$ at exchange rate","TUR","Türkiye","2015","2015",129.6,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOTCMT","Million US$ at exchange rate","TUR","Türkiye","2016","2016",136.2,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOTCMT","Million US$ at exchange rate","TUR","Türkiye","2017","2017",130.7,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOTCMT","Million US$ at exchange rate","TUR","Türkiye","2018","2018",127.2,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOTCMT","Million US$ at exchange rate","TUR","Türkiye","2019","2019",132.8,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOTCMT","Million US$ at exchange rate","TUR","Türkiye","2020","2020",122.9,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOTCMT","Million US$ at exchange rate","TUR","Türkiye","2021","2021",130.1,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOPPMT","Million US$, purchasing power parity","TUR","Türkiye","2010","2010",257.9,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOPPMT","Million US$, purchasing power parity","TUR","Türkiye","2011","2011",254.8,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOPPMT","Million US$, purchasing power parity","TUR","Türkiye","2012","2012",235.5,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOPPMT","Million US$, purchasing power parity","TUR","Türkiye","2013","2013",241.1,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOPPMT","Million US$, purchasing power parity","TUR","Türkiye","2014","2014",269.1,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOPPMT","Million US$, purchasing power parity","TUR","Türkiye","2015","2015",303.3,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOPPMT","Million US$, purchasing power parity","TUR","Türkiye","2016","2016",331.5,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOPPMT","Million US$, purchasing power parity","TUR","Türkiye","2017","2017",344.4,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOPPMT","Million US$, purchasing power parity","TUR","Türkiye","2018","2018",376.3,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOPPMT","Million US$, purchasing power parity","TUR","Türkiye","2019","2019",404.1,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOPPMT","Million US$, purchasing power parity","TUR","Türkiye","2020","2020",397.9,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOPPMT","Million US$, purchasing power parity","TUR","Türkiye","2021","2021",410.1,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","TCPPERMT","/capita, US$ exchange rate","TUR","Türkiye","2010","2010",2.2,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","TCPPERMT","/capita, US$ exchange rate","TUR","Türkiye","2011","2011",2,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","TCPPERMT","/capita, US$ exchange rate","TUR","Türkiye","2012","2012",1.8,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","TCPPERMT","/capita, US$ exchange rate","TUR","Türkiye","2013","2013",1.8,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","TCPPERMT","/capita, US$ exchange rate","TUR","Türkiye","2014","2014",1.8,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","TCPPERMT","/capita, US$ exchange rate","TUR","Türkiye","2015","2015",1.7,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","TCPPERMT","/capita, US$ exchange rate","TUR","Türkiye","2016","2016",1.7,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","TCPPERMT","/capita, US$ exchange rate","TUR","Türkiye","2017","2017",1.6,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","TCPPERMT","/capita, US$ exchange rate","TUR","Türkiye","2018","2018",1.6,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","TCPPERMT","/capita, US$ exchange rate","TUR","Türkiye","2019","2019",1.6,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","TCPPERMT","/capita, US$ exchange rate","TUR","Türkiye","2020","2020",1.5,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","TCPPERMT","/capita, US$ exchange rate","TUR","Türkiye","2021","2021",1.5,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2010","2010",3.5,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2011","2011",3.4,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2012","2012",3.1,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2013","2013",3.2,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2014","2014",3.5,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2015","2015",3.9,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2016","2016",4.2,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2017","2017",4.3,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2018","2018",4.6,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2019","2019",4.9,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2020","2020",4.8,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2021","2021",4.9,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","ATCPTTMT","% of total sales","TUR","Türkiye","2010","2010",1.5,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","ATCPTTMT","% of total sales","TUR","Türkiye","2011","2011",1.7,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","ATCPTTMT","% of total sales","TUR","Türkiye","2012","2012",1.8,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","ATCPTTMT","% of total sales","TUR","Türkiye","2013","2013",1.8,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","ATCPTTMT","% of total sales","TUR","Türkiye","2014","2014",1.9,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","ATCPTTMT","% of total sales","TUR","Türkiye","2015","2015",1.9,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","ATCPTTMT","% of total sales","TUR","Türkiye","2016","2016",1.9,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","ATCPTTMT","% of total sales","TUR","Türkiye","2017","2017",1.9,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","ATCPTTMT","% of total sales","TUR","Türkiye","2018","2018",1.9,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","ATCPTTMT","% of total sales","TUR","Türkiye","2019","2019",1.8,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","ATCPTTMT","% of total sales","TUR","Türkiye","2020","2020",1.7,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","ATCPTTMT","% of total sales","TUR","Türkiye","2021","2021",1.8,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MLLNCUMT","Million of national currency units","GBR","United Kingdom","2012","2012",338.3,"B","Break"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MLLNCUMT","Million of national currency units","GBR","United Kingdom","2013","2013",391.9,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MLLNCUMT","Million of national currency units","GBR","United Kingdom","2014","2014",478.3,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MLLNCUMT","Million of national currency units","GBR","United Kingdom","2015","2015",589.6,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MLLNCUMT","Million of national currency units","GBR","United Kingdom","2016","2016",607.3,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MLLNCUMT","Million of national currency units","GBR","United Kingdom","2017","2017",532.8,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MLLNCUMT","Million of national currency units","GBR","United Kingdom","2018","2018",442.9,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOTCMT","Million US$ at exchange rate","GBR","United Kingdom","2012","2012",534.4,"B","Break"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOTCMT","Million US$ at exchange rate","GBR","United Kingdom","2013","2013",612.7,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOTCMT","Million US$ at exchange rate","GBR","United Kingdom","2014","2014",787,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOTCMT","Million US$ at exchange rate","GBR","United Kingdom","2015","2015",900.8,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOTCMT","Million US$ at exchange rate","GBR","United Kingdom","2016","2016",820,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOTCMT","Million US$ at exchange rate","GBR","United Kingdom","2017","2017",685.7,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOTCMT","Million US$ at exchange rate","GBR","United Kingdom","2018","2018",590.9,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOPPMT","Million US$, purchasing power parity","GBR","United Kingdom","2012","2012",482.2,"B","Break"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOPPMT","Million US$, purchasing power parity","GBR","United Kingdom","2013","2013",563.7,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOPPMT","Million US$, purchasing power parity","GBR","United Kingdom","2014","2014",684.8,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOPPMT","Million US$, purchasing power parity","GBR","United Kingdom","2015","2015",851.3,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOPPMT","Million US$, purchasing power parity","GBR","United Kingdom","2016","2016",881.9,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOPPMT","Million US$, purchasing power parity","GBR","United Kingdom","2017","2017",778.3,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOPPMT","Million US$, purchasing power parity","GBR","United Kingdom","2018","2018",644,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","TCPPERMT","/capita, US$ exchange rate","GBR","United Kingdom","2012","2012",8.4,"B","Break"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","TCPPERMT","/capita, US$ exchange rate","GBR","United Kingdom","2013","2013",9.6,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","TCPPERMT","/capita, US$ exchange rate","GBR","United Kingdom","2014","2014",12.2,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","TCPPERMT","/capita, US$ exchange rate","GBR","United Kingdom","2015","2015",13.8,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","TCPPERMT","/capita, US$ exchange rate","GBR","United Kingdom","2016","2016",12.5,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","TCPPERMT","/capita, US$ exchange rate","GBR","United Kingdom","2017","2017",10.4,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","TCPPERMT","/capita, US$ exchange rate","GBR","United Kingdom","2018","2018",8.9,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","GBR","United Kingdom","2012","2012",7.6,"B","Break"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","GBR","United Kingdom","2013","2013",8.8,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","GBR","United Kingdom","2014","2014",10.6,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","GBR","United Kingdom","2015","2015",13.1,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","GBR","United Kingdom","2016","2016",13.4,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","GBR","United Kingdom","2017","2017",11.8,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","GBR","United Kingdom","2018","2018",9.7,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","ATCPTTMT","% of total sales","GBR","United Kingdom","2012","2012",2.5,"B","Break"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","ATCPTTMT","% of total sales","GBR","United Kingdom","2013","2013",2.7,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","ATCPTTMT","% of total sales","GBR","United Kingdom","2014","2014",3,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","ATCPTTMT","% of total sales","GBR","United Kingdom","2015","2015",3.3,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","ATCPTTMT","% of total sales","GBR","United Kingdom","2016","2016",3.3,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","ATCPTTMT","% of total sales","GBR","United Kingdom","2017","2017",2.7,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","ATCPTTMT","% of total sales","GBR","United Kingdom","2018","2018",2.2,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MLLNCUMT","Million of national currency units","CHL","Chile","2010","2010",12798,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MLLNCUMT","Million of national currency units","CHL","Chile","2011","2011",18495.4,"B","Break"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MLLNCUMT","Million of national currency units","CHL","Chile","2012","2012",27115.2,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MLLNCUMT","Million of national currency units","CHL","Chile","2013","2013",23741.8,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MLLNCUMT","Million of national currency units","CHL","Chile","2014","2014",38190.1,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MLLNCUMT","Million of national currency units","CHL","Chile","2015","2015",43736.2,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MLLNCUMT","Million of national currency units","CHL","Chile","2016","2016",50996.5,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MLLNCUMT","Million of national currency units","CHL","Chile","2017","2017",55462.8,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MLLNCUMT","Million of national currency units","CHL","Chile","2018","2018",62490.5,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MLLNCUMT","Million of national currency units","CHL","Chile","2019","2019",49123.2,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MLLNCUMT","Million of national currency units","CHL","Chile","2020","2020",58708.9,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MLLNCUMT","Million of national currency units","CHL","Chile","2021","2021",74745.2,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MLLNCUMT","Million of national currency units","CHL","Chile","2022","2022",76368.4,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOTCMT","Million US$ at exchange rate","CHL","Chile","2010","2010",25.1,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOTCMT","Million US$ at exchange rate","CHL","Chile","2011","2011",38.2,"B","Break"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOTCMT","Million US$ at exchange rate","CHL","Chile","2012","2012",55.7,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOTCMT","Million US$ at exchange rate","CHL","Chile","2013","2013",47.9,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOTCMT","Million US$ at exchange rate","CHL","Chile","2014","2014",67,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOTCMT","Million US$ at exchange rate","CHL","Chile","2015","2015",66.9,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOTCMT","Million US$ at exchange rate","CHL","Chile","2016","2016",75.3,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOTCMT","Million US$ at exchange rate","CHL","Chile","2017","2017",85.5,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOTCMT","Million US$ at exchange rate","CHL","Chile","2018","2018",97.4,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOTCMT","Million US$ at exchange rate","CHL","Chile","2019","2019",69.9,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOTCMT","Million US$ at exchange rate","CHL","Chile","2020","2020",74.1,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOTCMT","Million US$ at exchange rate","CHL","Chile","2021","2021",98.5,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOTCMT","Million US$ at exchange rate","CHL","Chile","2022","2022",87.4,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOPPMT","Million US$, purchasing power parity","CHL","Chile","2010","2010",35.6,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOPPMT","Million US$, purchasing power parity","CHL","Chile","2011","2011",53.1,"B","Break"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOPPMT","Million US$, purchasing power parity","CHL","Chile","2012","2012",78.1,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOPPMT","Million US$, purchasing power parity","CHL","Chile","2013","2013",67.9,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOPPMT","Million US$, purchasing power parity","CHL","Chile","2014","2014",104,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOPPMT","Million US$, purchasing power parity","CHL","Chile","2015","2015",111.8,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOPPMT","Million US$, purchasing power parity","CHL","Chile","2016","2016",128.4,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOPPMT","Million US$, purchasing power parity","CHL","Chile","2017","2017",139.5,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOPPMT","Million US$, purchasing power parity","CHL","Chile","2018","2018",157.7,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOPPMT","Million US$, purchasing power parity","CHL","Chile","2019","2019",122.3,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOPPMT","Million US$, purchasing power parity","CHL","Chile","2020","2020",140.3,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOPPMT","Million US$, purchasing power parity","CHL","Chile","2021","2021",171.8,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOPPMT","Million US$, purchasing power parity","CHL","Chile","2022","2022",174.5,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","TCPPERMT","/capita, US$ exchange rate","CHL","Chile","2010","2010",1.5,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","TCPPERMT","/capita, US$ exchange rate","CHL","Chile","2011","2011",2.2,"B","Break"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","TCPPERMT","/capita, US$ exchange rate","CHL","Chile","2012","2012",3.2,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","TCPPERMT","/capita, US$ exchange rate","CHL","Chile","2013","2013",2.7,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","TCPPERMT","/capita, US$ exchange rate","CHL","Chile","2014","2014",3.8,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","TCPPERMT","/capita, US$ exchange rate","CHL","Chile","2015","2015",3.7,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","TCPPERMT","/capita, US$ exchange rate","CHL","Chile","2016","2016",4.1,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","TCPPERMT","/capita, US$ exchange rate","CHL","Chile","2017","2017",4.6,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","TCPPERMT","/capita, US$ exchange rate","CHL","Chile","2018","2018",5.2,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","TCPPERMT","/capita, US$ exchange rate","CHL","Chile","2019","2019",3.7,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","TCPPERMT","/capita, US$ exchange rate","CHL","Chile","2020","2020",3.8,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","TCPPERMT","/capita, US$ exchange rate","CHL","Chile","2021","2021",5,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","TCPPERMT","/capita, US$ exchange rate","CHL","Chile","2022","2022",4.4,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2010","2010",2.1,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2011","2011",3.1,"B","Break"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2012","2012",4.5,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2013","2013",3.9,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2014","2014",5.8,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2015","2015",6.2,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2016","2016",7.1,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2017","2017",7.6,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2018","2018",8.4,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2019","2019",6.4,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2020","2020",7.2,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2021","2021",8.7,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2022","2022",8.8,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","ATCPTTMT","% of total sales","CHL","Chile","2010","2010",1.5,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","ATCPTTMT","% of total sales","CHL","Chile","2011","2011",1.6,"B","Break"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","ATCPTTMT","% of total sales","CHL","Chile","2012","2012",2.2,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","ATCPTTMT","% of total sales","CHL","Chile","2013","2013",1.6,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","ATCPTTMT","% of total sales","CHL","Chile","2014","2014",2.5,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","ATCPTTMT","% of total sales","CHL","Chile","2015","2015",2.4,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","ATCPTTMT","% of total sales","CHL","Chile","2016","2016",2.5,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","ATCPTTMT","% of total sales","CHL","Chile","2017","2017",2.7,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","ATCPTTMT","% of total sales","CHL","Chile","2018","2018",2.7,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","ATCPTTMT","% of total sales","CHL","Chile","2019","2019",1.9,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","ATCPTTMT","% of total sales","CHL","Chile","2020","2020",2.2,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","ATCPTTMT","% of total sales","CHL","Chile","2021","2021",2.7,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","ATCPTTMT","% of total sales","CHL","Chile","2022","2022",2.7,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MLLNCUMT","Million of national currency units","EST","Estonia","2010","2010",2.5,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MLLNCUMT","Million of national currency units","EST","Estonia","2011","2011",2.8,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MLLNCUMT","Million of national currency units","EST","Estonia","2012","2012",3,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MLLNCUMT","Million of national currency units","EST","Estonia","2013","2013",3.3,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MLLNCUMT","Million of national currency units","EST","Estonia","2014","2014",3.6,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MLLNCUMT","Million of national currency units","EST","Estonia","2015","2015",3.5,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MLLNCUMT","Million of national currency units","EST","Estonia","2016","2016",3.9,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MLLNCUMT","Million of national currency units","EST","Estonia","2017","2017",4.3,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MLLNCUMT","Million of national currency units","EST","Estonia","2018","2018",4.6,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MLLNCUMT","Million of national currency units","EST","Estonia","2019","2019",4.8,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MLLNCUMT","Million of national currency units","EST","Estonia","2020","2020",5,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MLLNCUMT","Million of national currency units","EST","Estonia","2021","2021",5.3,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MLLNCUMT","Million of national currency units","EST","Estonia","2022","2022",5.6,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOTCMT","Million US$ at exchange rate","EST","Estonia","2010","2010",3.3,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOTCMT","Million US$ at exchange rate","EST","Estonia","2011","2011",3.9,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOTCMT","Million US$ at exchange rate","EST","Estonia","2012","2012",3.9,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOTCMT","Million US$ at exchange rate","EST","Estonia","2013","2013",4.4,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOTCMT","Million US$ at exchange rate","EST","Estonia","2014","2014",4.7,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOTCMT","Million US$ at exchange rate","EST","Estonia","2015","2015",3.9,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOTCMT","Million US$ at exchange rate","EST","Estonia","2016","2016",4.3,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOTCMT","Million US$ at exchange rate","EST","Estonia","2017","2017",4.9,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOTCMT","Million US$ at exchange rate","EST","Estonia","2018","2018",5.4,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOTCMT","Million US$ at exchange rate","EST","Estonia","2019","2019",5.3,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOTCMT","Million US$ at exchange rate","EST","Estonia","2020","2020",5.7,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOTCMT","Million US$ at exchange rate","EST","Estonia","2021","2021",6.3,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOTCMT","Million US$ at exchange rate","EST","Estonia","2022","2022",5.9,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOPPMT","Million US$, purchasing power parity","EST","Estonia","2010","2010",4.9,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOPPMT","Million US$, purchasing power parity","EST","Estonia","2011","2011",5.5,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOPPMT","Million US$, purchasing power parity","EST","Estonia","2012","2012",5.8,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOPPMT","Million US$, purchasing power parity","EST","Estonia","2013","2013",6.3,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOPPMT","Million US$, purchasing power parity","EST","Estonia","2014","2014",6.8,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOPPMT","Million US$, purchasing power parity","EST","Estonia","2015","2015",6.6,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOPPMT","Million US$, purchasing power parity","EST","Estonia","2016","2016",7.4,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOPPMT","Million US$, purchasing power parity","EST","Estonia","2017","2017",8.1,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOPPMT","Million US$, purchasing power parity","EST","Estonia","2018","2018",8.5,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOPPMT","Million US$, purchasing power parity","EST","Estonia","2019","2019",8.9,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOPPMT","Million US$, purchasing power parity","EST","Estonia","2020","2020",9.5,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOPPMT","Million US$, purchasing power parity","EST","Estonia","2021","2021",9.8,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOPPMT","Million US$, purchasing power parity","EST","Estonia","2022","2022",9.8,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","TCPPERMT","/capita, US$ exchange rate","EST","Estonia","2010","2010",2.5,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","TCPPERMT","/capita, US$ exchange rate","EST","Estonia","2011","2011",2.9,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","TCPPERMT","/capita, US$ exchange rate","EST","Estonia","2012","2012",2.9,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","TCPPERMT","/capita, US$ exchange rate","EST","Estonia","2013","2013",3.3,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","TCPPERMT","/capita, US$ exchange rate","EST","Estonia","2014","2014",3.6,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","TCPPERMT","/capita, US$ exchange rate","EST","Estonia","2015","2015",3,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","TCPPERMT","/capita, US$ exchange rate","EST","Estonia","2016","2016",3.3,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","TCPPERMT","/capita, US$ exchange rate","EST","Estonia","2017","2017",3.7,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","TCPPERMT","/capita, US$ exchange rate","EST","Estonia","2018","2018",4.1,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","TCPPERMT","/capita, US$ exchange rate","EST","Estonia","2019","2019",4,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","TCPPERMT","/capita, US$ exchange rate","EST","Estonia","2020","2020",4.3,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","TCPPERMT","/capita, US$ exchange rate","EST","Estonia","2021","2021",4.7,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","TCPPERMT","/capita, US$ exchange rate","EST","Estonia","2022","2022",4.4,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2010","2010",3.7,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2011","2011",4.1,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2012","2012",4.4,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2013","2013",4.8,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2014","2014",5.2,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2015","2015",5,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2016","2016",5.6,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2017","2017",6.1,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2018","2018",6.4,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2019","2019",6.7,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2020","2020",7.1,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2021","2021",7.4,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2022","2022",7.3,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","ATCPTTMT","% of total sales","EST","Estonia","2010","2010",1.3,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","ATCPTTMT","% of total sales","EST","Estonia","2011","2011",1.4,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","ATCPTTMT","% of total sales","EST","Estonia","2012","2012",1.4,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","ATCPTTMT","% of total sales","EST","Estonia","2013","2013",1.4,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","ATCPTTMT","% of total sales","EST","Estonia","2014","2014",1.4,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","ATCPTTMT","% of total sales","EST","Estonia","2015","2015",1.3,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","ATCPTTMT","% of total sales","EST","Estonia","2016","2016",1.3,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","ATCPTTMT","% of total sales","EST","Estonia","2017","2017",1.4,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","ATCPTTMT","% of total sales","EST","Estonia","2018","2018",1.4,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","ATCPTTMT","% of total sales","EST","Estonia","2019","2019",1.4,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","ATCPTTMT","% of total sales","EST","Estonia","2020","2020",1.4,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","ATCPTTMT","% of total sales","EST","Estonia","2021","2021",1.3,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","ATCPTTMT","% of total sales","EST","Estonia","2022","2022",1.3,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MLLNCUMT","Million of national currency units","SVN","Slovenia","2010","2010",9,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MLLNCUMT","Million of national currency units","SVN","Slovenia","2011","2011",9.2,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MLLNCUMT","Million of national currency units","SVN","Slovenia","2012","2012",8.9,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MLLNCUMT","Million of national currency units","SVN","Slovenia","2013","2013",8.8,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MLLNCUMT","Million of national currency units","SVN","Slovenia","2014","2014",9.3,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MLLNCUMT","Million of national currency units","SVN","Slovenia","2015","2015",9.9,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MLLNCUMT","Million of national currency units","SVN","Slovenia","2016","2016",10.8,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MLLNCUMT","Million of national currency units","SVN","Slovenia","2017","2017",10.8,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MLLNCUMT","Million of national currency units","SVN","Slovenia","2018","2018",11.5,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MLLNCUMT","Million of national currency units","SVN","Slovenia","2019","2019",11.6,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MLLNCUMT","Million of national currency units","SVN","Slovenia","2020","2020",11,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MLLNCUMT","Million of national currency units","SVN","Slovenia","2021","2021",10.8,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MLLNCUMT","Million of national currency units","SVN","Slovenia","2022","2022",11.5,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOTCMT","Million US$ at exchange rate","SVN","Slovenia","2010","2010",11.9,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOTCMT","Million US$ at exchange rate","SVN","Slovenia","2011","2011",12.8,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOTCMT","Million US$ at exchange rate","SVN","Slovenia","2012","2012",11.5,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOTCMT","Million US$ at exchange rate","SVN","Slovenia","2013","2013",11.7,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOTCMT","Million US$ at exchange rate","SVN","Slovenia","2014","2014",12.3,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOTCMT","Million US$ at exchange rate","SVN","Slovenia","2015","2015",11,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOTCMT","Million US$ at exchange rate","SVN","Slovenia","2016","2016",11.9,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOTCMT","Million US$ at exchange rate","SVN","Slovenia","2017","2017",12.2,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOTCMT","Million US$ at exchange rate","SVN","Slovenia","2018","2018",13.5,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOTCMT","Million US$ at exchange rate","SVN","Slovenia","2019","2019",13,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOTCMT","Million US$ at exchange rate","SVN","Slovenia","2020","2020",12.5,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOTCMT","Million US$ at exchange rate","SVN","Slovenia","2021","2021",12.8,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOTCMT","Million US$ at exchange rate","SVN","Slovenia","2022","2022",12.1,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOPPMT","Million US$, purchasing power parity","SVN","Slovenia","2010","2010",14.1,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOPPMT","Million US$, purchasing power parity","SVN","Slovenia","2011","2011",14.7,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOPPMT","Million US$, purchasing power parity","SVN","Slovenia","2012","2012",14.7,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOPPMT","Million US$, purchasing power parity","SVN","Slovenia","2013","2013",15,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOPPMT","Million US$, purchasing power parity","SVN","Slovenia","2014","2014",15.7,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOPPMT","Million US$, purchasing power parity","SVN","Slovenia","2015","2015",16.7,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOPPMT","Million US$, purchasing power parity","SVN","Slovenia","2016","2016",18.7,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOPPMT","Million US$, purchasing power parity","SVN","Slovenia","2017","2017",19,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOPPMT","Million US$, purchasing power parity","SVN","Slovenia","2018","2018",20.2,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOPPMT","Million US$, purchasing power parity","SVN","Slovenia","2019","2019",21,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOPPMT","Million US$, purchasing power parity","SVN","Slovenia","2020","2020",20,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOPPMT","Million US$, purchasing power parity","SVN","Slovenia","2021","2021",19.2,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOPPMT","Million US$, purchasing power parity","SVN","Slovenia","2022","2022",20.9,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","TCPPERMT","/capita, US$ exchange rate","SVN","Slovenia","2010","2010",5.8,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","TCPPERMT","/capita, US$ exchange rate","SVN","Slovenia","2011","2011",6.2,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","TCPPERMT","/capita, US$ exchange rate","SVN","Slovenia","2012","2012",5.6,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","TCPPERMT","/capita, US$ exchange rate","SVN","Slovenia","2013","2013",5.7,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","TCPPERMT","/capita, US$ exchange rate","SVN","Slovenia","2014","2014",6,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","TCPPERMT","/capita, US$ exchange rate","SVN","Slovenia","2015","2015",5.3,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","TCPPERMT","/capita, US$ exchange rate","SVN","Slovenia","2016","2016",5.8,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","TCPPERMT","/capita, US$ exchange rate","SVN","Slovenia","2017","2017",5.9,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","TCPPERMT","/capita, US$ exchange rate","SVN","Slovenia","2018","2018",6.5,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","TCPPERMT","/capita, US$ exchange rate","SVN","Slovenia","2019","2019",6.2,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","TCPPERMT","/capita, US$ exchange rate","SVN","Slovenia","2020","2020",6,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","TCPPERMT","/capita, US$ exchange rate","SVN","Slovenia","2021","2021",6.1,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","TCPPERMT","/capita, US$ exchange rate","SVN","Slovenia","2022","2022",5.8,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2010","2010",6.9,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2011","2011",7.2,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2012","2012",7.2,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2013","2013",7.3,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2014","2014",7.6,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2015","2015",8.1,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2016","2016",9,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2017","2017",9.2,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2018","2018",9.7,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2019","2019",10.1,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2020","2020",9.5,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2021","2021",9.1,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2022","2022",9.9,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","ATCPTTMT","% of total sales","SVN","Slovenia","2010","2010",1.9,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","ATCPTTMT","% of total sales","SVN","Slovenia","2011","2011",2,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","ATCPTTMT","% of total sales","SVN","Slovenia","2012","2012",2,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","ATCPTTMT","% of total sales","SVN","Slovenia","2013","2013",2,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","ATCPTTMT","% of total sales","SVN","Slovenia","2014","2014",2.1,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","ATCPTTMT","% of total sales","SVN","Slovenia","2015","2015",2.2,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","ATCPTTMT","% of total sales","SVN","Slovenia","2016","2016",2.3,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","ATCPTTMT","% of total sales","SVN","Slovenia","2017","2017",2.2,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","ATCPTTMT","% of total sales","SVN","Slovenia","2018","2018",2.2,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","ATCPTTMT","% of total sales","SVN","Slovenia","2019","2019",2.1,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","ATCPTTMT","% of total sales","SVN","Slovenia","2020","2020",1.9,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","ATCPTTMT","% of total sales","SVN","Slovenia","2021","2021",1.8,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","ATCPTTMT","% of total sales","SVN","Slovenia","2022","2022",1.7,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","MLLNCUMT","Million of national currency units","AUS","Australia","2010","2010",354,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","MLLNCUMT","Million of national currency units","AUS","Australia","2011","2011",386,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","MLLNCUMT","Million of national currency units","AUS","Australia","2012","2012",446,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","MLLNCUMT","Million of national currency units","AUS","Australia","2013","2013",790,"B; D","Break; Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","MLLNCUMT","Million of national currency units","AUS","Australia","2014","2014",801,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","MLLNCUMT","Million of national currency units","AUS","Australia","2015","2015",822,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","MLLNCUMT","Million of national currency units","AUS","Australia","2016","2016",3422,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","MLLNCUMT","Million of national currency units","AUS","Australia","2017","2017",2540,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","MLLNCUMT","Million of national currency units","AUS","Australia","2018","2018",1794,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","MLLNCUMT","Million of national currency units","AUS","Australia","2019","2019",1378,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","MLLNCUMT","Million of national currency units","AUS","Australia","2020","2020",1133,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","MLLNCUMT","Million of national currency units","AUS","Australia","2021","2021",1030,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","MTMOTCMT","Million US$ at exchange rate","AUS","Australia","2010","2010",324.7,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","MTMOTCMT","Million US$ at exchange rate","AUS","Australia","2011","2011",398.2,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","MTMOTCMT","Million US$ at exchange rate","AUS","Australia","2012","2012",461.8,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","MTMOTCMT","Million US$ at exchange rate","AUS","Australia","2013","2013",762.7,"B; D","Break; Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","MTMOTCMT","Million US$ at exchange rate","AUS","Australia","2014","2014",722,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","MTMOTCMT","Million US$ at exchange rate","AUS","Australia","2015","2015",617.5,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","MTMOTCMT","Million US$ at exchange rate","AUS","Australia","2016","2016",2543.8,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","MTMOTCMT","Million US$ at exchange rate","AUS","Australia","2017","2017",1946.7,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","MTMOTCMT","Million US$ at exchange rate","AUS","Australia","2018","2018",1340.4,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","MTMOTCMT","Million US$ at exchange rate","AUS","Australia","2019","2019",957.9,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","MTMOTCMT","Million US$ at exchange rate","AUS","Australia","2020","2020",779.7,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","MTMOTCMT","Million US$ at exchange rate","AUS","Australia","2021","2021",773.7,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","MTMOPPMT","Million US$, purchasing power parity","AUS","Australia","2010","2010",235.4,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","MTMOPPMT","Million US$, purchasing power parity","AUS","Australia","2011","2011",255.5,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","MTMOPPMT","Million US$, purchasing power parity","AUS","Australia","2012","2012",289.6,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","MTMOPPMT","Million US$, purchasing power parity","AUS","Australia","2013","2013",545.9,"B; D","Break; Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","MTMOPPMT","Million US$, purchasing power parity","AUS","Australia","2014","2014",551.5,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","MTMOPPMT","Million US$, purchasing power parity","AUS","Australia","2015","2015",557.8,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","MTMOPPMT","Million US$, purchasing power parity","AUS","Australia","2016","2016",2359.7,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","MTMOPPMT","Million US$, purchasing power parity","AUS","Australia","2017","2017",1719.1,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","MTMOPPMT","Million US$, purchasing power parity","AUS","Australia","2018","2018",1220.1,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","MTMOPPMT","Million US$, purchasing power parity","AUS","Australia","2019","2019",931.2,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","MTMOPPMT","Million US$, purchasing power parity","AUS","Australia","2020","2020",779.3,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","MTMOPPMT","Million US$, purchasing power parity","AUS","Australia","2021","2021",711.5,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","TCPPERMT","/capita, US$ exchange rate","AUS","Australia","2010","2010",14.7,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","TCPPERMT","/capita, US$ exchange rate","AUS","Australia","2011","2011",17.8,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","TCPPERMT","/capita, US$ exchange rate","AUS","Australia","2012","2012",20.3,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","TCPPERMT","/capita, US$ exchange rate","AUS","Australia","2013","2013",33,"B; D","Break; Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","TCPPERMT","/capita, US$ exchange rate","AUS","Australia","2014","2014",30.8,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","TCPPERMT","/capita, US$ exchange rate","AUS","Australia","2015","2015",25.9,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","TCPPERMT","/capita, US$ exchange rate","AUS","Australia","2016","2016",105.2,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","TCPPERMT","/capita, US$ exchange rate","AUS","Australia","2017","2017",79.2,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","TCPPERMT","/capita, US$ exchange rate","AUS","Australia","2018","2018",53.7,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","TCPPERMT","/capita, US$ exchange rate","AUS","Australia","2019","2019",37.8,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","TCPPERMT","/capita, US$ exchange rate","AUS","Australia","2020","2020",30.4,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","TCPPERMT","/capita, US$ exchange rate","AUS","Australia","2021","2021",30.1,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2010","2010",10.7,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2011","2011",11.4,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2012","2012",12.7,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2013","2013",23.6,"B; D","Break; Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2014","2014",23.5,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2015","2015",23.4,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2016","2016",97.5,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2017","2017",69.9,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2018","2018",48.9,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2019","2019",36.7,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2020","2020",30.4,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2021","2021",27.7,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","ATCPTTMT","% of total sales","AUS","Australia","2010","2010",3.6,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","ATCPTTMT","% of total sales","AUS","Australia","2011","2011",3.8,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","ATCPTTMT","% of total sales","AUS","Australia","2012","2012",4.3,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","ATCPTTMT","% of total sales","AUS","Australia","2013","2013",6.7,"B; D","Break; Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","ATCPTTMT","% of total sales","AUS","Australia","2014","2014",6.7,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","ATCPTTMT","% of total sales","AUS","Australia","2015","2015",6.7,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","ATCPTTMT","% of total sales","AUS","Australia","2016","2016",22.4,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","ATCPTTMT","% of total sales","AUS","Australia","2017","2017",17.2,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","ATCPTTMT","% of total sales","AUS","Australia","2018","2018",12,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","ATCPTTMT","% of total sales","AUS","Australia","2019","2019",8.9,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","ATCPTTMT","% of total sales","AUS","Australia","2020","2020",6.8,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","ATCPTTMT","% of total sales","AUS","Australia","2021","2021",5.9,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","MLLNCUMT","Million of national currency units","AUT","Austria","2010","2010",162.8,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","MLLNCUMT","Million of national currency units","AUT","Austria","2011","2011",166.5,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","MLLNCUMT","Million of national currency units","AUT","Austria","2012","2012",177.7,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","MLLNCUMT","Million of national currency units","AUT","Austria","2013","2013",182.9,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","MLLNCUMT","Million of national currency units","AUT","Austria","2014","2014",241.5,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","MLLNCUMT","Million of national currency units","AUT","Austria","2015","2015",294.6,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","MLLNCUMT","Million of national currency units","AUT","Austria","2016","2016",260.6,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","MLLNCUMT","Million of national currency units","AUT","Austria","2017","2017",265.9,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","MLLNCUMT","Million of national currency units","AUT","Austria","2018","2018",247.5,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","MLLNCUMT","Million of national currency units","AUT","Austria","2019","2019",213.3,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","MLLNCUMT","Million of national currency units","AUT","Austria","2020","2020",188,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","MLLNCUMT","Million of national currency units","AUT","Austria","2021","2021",182.1,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","MTMOTCMT","Million US$ at exchange rate","AUT","Austria","2010","2010",215.8,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","MTMOTCMT","Million US$ at exchange rate","AUT","Austria","2011","2011",231.8,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","MTMOTCMT","Million US$ at exchange rate","AUT","Austria","2012","2012",228.4,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","MTMOTCMT","Million US$ at exchange rate","AUT","Austria","2013","2013",242.9,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","MTMOTCMT","Million US$ at exchange rate","AUT","Austria","2014","2014",320.8,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","MTMOTCMT","Million US$ at exchange rate","AUT","Austria","2015","2015",326.8,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","MTMOTCMT","Million US$ at exchange rate","AUT","Austria","2016","2016",288.4,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","MTMOTCMT","Million US$ at exchange rate","AUT","Austria","2017","2017",300.3,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","MTMOTCMT","Million US$ at exchange rate","AUT","Austria","2018","2018",292.3,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","MTMOTCMT","Million US$ at exchange rate","AUT","Austria","2019","2019",238.8,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","MTMOTCMT","Million US$ at exchange rate","AUT","Austria","2020","2020",214.7,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","MTMOTCMT","Million US$ at exchange rate","AUT","Austria","2021","2021",215.3,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","MTMOPPMT","Million US$, purchasing power parity","AUT","Austria","2010","2010",193.3,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","MTMOPPMT","Million US$, purchasing power parity","AUT","Austria","2011","2011",200.3,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","MTMOPPMT","Million US$, purchasing power parity","AUT","Austria","2012","2012",218.4,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","MTMOPPMT","Million US$, purchasing power parity","AUT","Austria","2013","2013",229.4,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","MTMOPPMT","Million US$, purchasing power parity","AUT","Austria","2014","2014",302.3,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","MTMOPPMT","Million US$, purchasing power parity","AUT","Austria","2015","2015",368.8,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","MTMOPPMT","Million US$, purchasing power parity","AUT","Austria","2016","2016",335.4,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","MTMOPPMT","Million US$, purchasing power parity","AUT","Austria","2017","2017",343.1,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","MTMOPPMT","Million US$, purchasing power parity","AUT","Austria","2018","2018",323.3,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","MTMOPPMT","Million US$, purchasing power parity","AUT","Austria","2019","2019",284.7,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","MTMOPPMT","Million US$, purchasing power parity","AUT","Austria","2020","2020",251.9,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","MTMOPPMT","Million US$, purchasing power parity","AUT","Austria","2021","2021",240.7,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","TCPPERMT","/capita, US$ exchange rate","AUT","Austria","2010","2010",25.8,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","TCPPERMT","/capita, US$ exchange rate","AUT","Austria","2011","2011",27.6,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","TCPPERMT","/capita, US$ exchange rate","AUT","Austria","2012","2012",27.1,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","TCPPERMT","/capita, US$ exchange rate","AUT","Austria","2013","2013",28.6,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","TCPPERMT","/capita, US$ exchange rate","AUT","Austria","2014","2014",37.5,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","TCPPERMT","/capita, US$ exchange rate","AUT","Austria","2015","2015",37.8,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","TCPPERMT","/capita, US$ exchange rate","AUT","Austria","2016","2016",33,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","TCPPERMT","/capita, US$ exchange rate","AUT","Austria","2017","2017",34.1,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","TCPPERMT","/capita, US$ exchange rate","AUT","Austria","2018","2018",33.1,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","TCPPERMT","/capita, US$ exchange rate","AUT","Austria","2019","2019",26.9,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","TCPPERMT","/capita, US$ exchange rate","AUT","Austria","2020","2020",24.1,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","TCPPERMT","/capita, US$ exchange rate","AUT","Austria","2021","2021",24,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2010","2010",23.1,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2011","2011",23.9,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2012","2012",25.9,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2013","2013",27.1,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2014","2014",35.4,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2015","2015",42.7,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2016","2016",38.4,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2017","2017",39,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2018","2018",36.6,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2019","2019",32.1,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2020","2020",28.3,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2021","2021",26.9,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","ATCPTTMT","% of total sales","AUT","Austria","2010","2010",6.5,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","ATCPTTMT","% of total sales","AUT","Austria","2011","2011",6.5,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","ATCPTTMT","% of total sales","AUT","Austria","2012","2012",6.8,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","ATCPTTMT","% of total sales","AUT","Austria","2013","2013",6.9,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","ATCPTTMT","% of total sales","AUT","Austria","2014","2014",8.7,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","ATCPTTMT","% of total sales","AUT","Austria","2015","2015",10.1,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","ATCPTTMT","% of total sales","AUT","Austria","2016","2016",8.7,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","ATCPTTMT","% of total sales","AUT","Austria","2017","2017",8.5,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","ATCPTTMT","% of total sales","AUT","Austria","2018","2018",7.7,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","ATCPTTMT","% of total sales","AUT","Austria","2019","2019",6.4,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","ATCPTTMT","% of total sales","AUT","Austria","2020","2020",5.4,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","ATCPTTMT","% of total sales","AUT","Austria","2021","2021",4.9,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","MLLNCUMT","Million of national currency units","BEL","Belgium","2010","2010",571.5,,
+"PATCINFC","J-Antiinfectives for systemic use","MLLNCUMT","Million of national currency units","BEL","Belgium","2011","2011",586.1,,
+"PATCINFC","J-Antiinfectives for systemic use","MLLNCUMT","Million of national currency units","BEL","Belgium","2012","2012",583.7,,
+"PATCINFC","J-Antiinfectives for systemic use","MLLNCUMT","Million of national currency units","BEL","Belgium","2013","2013",581.3,,
+"PATCINFC","J-Antiinfectives for systemic use","MLLNCUMT","Million of national currency units","BEL","Belgium","2014","2014",576.4,,
+"PATCINFC","J-Antiinfectives for systemic use","MLLNCUMT","Million of national currency units","BEL","Belgium","2015","2015",680.8,,
+"PATCINFC","J-Antiinfectives for systemic use","MLLNCUMT","Million of national currency units","BEL","Belgium","2016","2016",634.8,,
+"PATCINFC","J-Antiinfectives for systemic use","MLLNCUMT","Million of national currency units","BEL","Belgium","2017","2017",674.1,,
+"PATCINFC","J-Antiinfectives for systemic use","MLLNCUMT","Million of national currency units","BEL","Belgium","2018","2018",638.7,,
+"PATCINFC","J-Antiinfectives for systemic use","MLLNCUMT","Million of national currency units","BEL","Belgium","2019","2019",701.2,,
+"PATCINFC","J-Antiinfectives for systemic use","MLLNCUMT","Million of national currency units","BEL","Belgium","2020","2020",638.3,,
+"PATCINFC","J-Antiinfectives for systemic use","MLLNCUMT","Million of national currency units","BEL","Belgium","2021","2021",632.1,,
+"PATCINFC","J-Antiinfectives for systemic use","MLLNCUMT","Million of national currency units","BEL","Belgium","2022","2022",678,"E","Estimated value"
+"PATCINFC","J-Antiinfectives for systemic use","MTMOTCMT","Million US$ at exchange rate","BEL","Belgium","2010","2010",757.6,,
+"PATCINFC","J-Antiinfectives for systemic use","MTMOTCMT","Million US$ at exchange rate","BEL","Belgium","2011","2011",815.8,,
+"PATCINFC","J-Antiinfectives for systemic use","MTMOTCMT","Million US$ at exchange rate","BEL","Belgium","2012","2012",750,,
+"PATCINFC","J-Antiinfectives for systemic use","MTMOTCMT","Million US$ at exchange rate","BEL","Belgium","2013","2013",772,,
+"PATCINFC","J-Antiinfectives for systemic use","MTMOTCMT","Million US$ at exchange rate","BEL","Belgium","2014","2014",765.8,,
+"PATCINFC","J-Antiinfectives for systemic use","MTMOTCMT","Million US$ at exchange rate","BEL","Belgium","2015","2015",755.4,,
+"PATCINFC","J-Antiinfectives for systemic use","MTMOTCMT","Million US$ at exchange rate","BEL","Belgium","2016","2016",702.6,,
+"PATCINFC","J-Antiinfectives for systemic use","MTMOTCMT","Million US$ at exchange rate","BEL","Belgium","2017","2017",761.5,,
+"PATCINFC","J-Antiinfectives for systemic use","MTMOTCMT","Million US$ at exchange rate","BEL","Belgium","2018","2018",754.3,,
+"PATCINFC","J-Antiinfectives for systemic use","MTMOTCMT","Million US$ at exchange rate","BEL","Belgium","2019","2019",785,,
+"PATCINFC","J-Antiinfectives for systemic use","MTMOTCMT","Million US$ at exchange rate","BEL","Belgium","2020","2020",729.1,,
+"PATCINFC","J-Antiinfectives for systemic use","MTMOTCMT","Million US$ at exchange rate","BEL","Belgium","2021","2021",747.6,,
+"PATCINFC","J-Antiinfectives for systemic use","MTMOTCMT","Million US$ at exchange rate","BEL","Belgium","2022","2022",714,"E","Estimated value"
+"PATCINFC","J-Antiinfectives for systemic use","MTMOPPMT","Million US$, purchasing power parity","BEL","Belgium","2010","2010",683.1,,
+"PATCINFC","J-Antiinfectives for systemic use","MTMOPPMT","Million US$, purchasing power parity","BEL","Belgium","2011","2011",704.5,,
+"PATCINFC","J-Antiinfectives for systemic use","MTMOPPMT","Million US$, purchasing power parity","BEL","Belgium","2012","2012",710,,
+"PATCINFC","J-Antiinfectives for systemic use","MTMOPPMT","Million US$, purchasing power parity","BEL","Belgium","2013","2013",721,,
+"PATCINFC","J-Antiinfectives for systemic use","MTMOPPMT","Million US$, purchasing power parity","BEL","Belgium","2014","2014",720.3,,
+"PATCINFC","J-Antiinfectives for systemic use","MTMOPPMT","Million US$, purchasing power parity","BEL","Belgium","2015","2015",851,,
+"PATCINFC","J-Antiinfectives for systemic use","MTMOPPMT","Million US$, purchasing power parity","BEL","Belgium","2016","2016",812.7,,
+"PATCINFC","J-Antiinfectives for systemic use","MTMOPPMT","Million US$, purchasing power parity","BEL","Belgium","2017","2017",869.1,,
+"PATCINFC","J-Antiinfectives for systemic use","MTMOPPMT","Million US$, purchasing power parity","BEL","Belgium","2018","2018",833.4,,
+"PATCINFC","J-Antiinfectives for systemic use","MTMOPPMT","Million US$, purchasing power parity","BEL","Belgium","2019","2019",939.3,,
+"PATCINFC","J-Antiinfectives for systemic use","MTMOPPMT","Million US$, purchasing power parity","BEL","Belgium","2020","2020",874.1,,
+"PATCINFC","J-Antiinfectives for systemic use","MTMOPPMT","Million US$, purchasing power parity","BEL","Belgium","2021","2021",858,,
+"PATCINFC","J-Antiinfectives for systemic use","MTMOPPMT","Million US$, purchasing power parity","BEL","Belgium","2022","2022",949.7,"E","Estimated value"
+"PATCINFC","J-Antiinfectives for systemic use","TCPPERMT","/capita, US$ exchange rate","BEL","Belgium","2010","2010",69.5,,
+"PATCINFC","J-Antiinfectives for systemic use","TCPPERMT","/capita, US$ exchange rate","BEL","Belgium","2011","2011",73.9,,
+"PATCINFC","J-Antiinfectives for systemic use","TCPPERMT","/capita, US$ exchange rate","BEL","Belgium","2012","2012",67.5,,
+"PATCINFC","J-Antiinfectives for systemic use","TCPPERMT","/capita, US$ exchange rate","BEL","Belgium","2013","2013",69.2,,
+"PATCINFC","J-Antiinfectives for systemic use","TCPPERMT","/capita, US$ exchange rate","BEL","Belgium","2014","2014",68.3,,
+"PATCINFC","J-Antiinfectives for systemic use","TCPPERMT","/capita, US$ exchange rate","BEL","Belgium","2015","2015",67,,
+"PATCINFC","J-Antiinfectives for systemic use","TCPPERMT","/capita, US$ exchange rate","BEL","Belgium","2016","2016",62,,
+"PATCINFC","J-Antiinfectives for systemic use","TCPPERMT","/capita, US$ exchange rate","BEL","Belgium","2017","2017",66.9,,
+"PATCINFC","J-Antiinfectives for systemic use","TCPPERMT","/capita, US$ exchange rate","BEL","Belgium","2018","2018",66,,
+"PATCINFC","J-Antiinfectives for systemic use","TCPPERMT","/capita, US$ exchange rate","BEL","Belgium","2019","2019",68.3,,
+"PATCINFC","J-Antiinfectives for systemic use","TCPPERMT","/capita, US$ exchange rate","BEL","Belgium","2020","2020",63.2,,
+"PATCINFC","J-Antiinfectives for systemic use","TCPPERMT","/capita, US$ exchange rate","BEL","Belgium","2021","2021",64.5,,
+"PATCINFC","J-Antiinfectives for systemic use","TCPPERMT","/capita, US$ exchange rate","BEL","Belgium","2022","2022",61.5,"E","Estimated value"
+"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2010","2010",62.7,,
+"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2011","2011",63.8,,
+"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2012","2012",63.9,,
+"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2013","2013",64.6,,
+"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2014","2014",64.3,,
+"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2015","2015",75.5,,
+"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2016","2016",71.7,,
+"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2017","2017",76.4,,
+"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2018","2018",72.9,,
+"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2019","2019",81.8,,
+"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2020","2020",75.8,,
+"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2021","2021",74.1,,
+"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2022","2022",81.7,"E","Estimated value"
+"PATCINFC","J-Antiinfectives for systemic use","ATCPTTMT","% of total sales","BEL","Belgium","2010","2010",9.7,,
+"PATCINFC","J-Antiinfectives for systemic use","ATCPTTMT","% of total sales","BEL","Belgium","2011","2011",9.8,,
+"PATCINFC","J-Antiinfectives for systemic use","ATCPTTMT","% of total sales","BEL","Belgium","2012","2012",9.8,,
+"PATCINFC","J-Antiinfectives for systemic use","ATCPTTMT","% of total sales","BEL","Belgium","2013","2013",9.8,,
+"PATCINFC","J-Antiinfectives for systemic use","ATCPTTMT","% of total sales","BEL","Belgium","2014","2014",9.7,,
+"PATCINFC","J-Antiinfectives for systemic use","ATCPTTMT","% of total sales","BEL","Belgium","2015","2015",11,,
+"PATCINFC","J-Antiinfectives for systemic use","ATCPTTMT","% of total sales","BEL","Belgium","2016","2016",10.2,,
+"PATCINFC","J-Antiinfectives for systemic use","ATCPTTMT","% of total sales","BEL","Belgium","2017","2017",10.3,,
+"PATCINFC","J-Antiinfectives for systemic use","ATCPTTMT","% of total sales","BEL","Belgium","2018","2018",9.6,,
+"PATCINFC","J-Antiinfectives for systemic use","ATCPTTMT","% of total sales","BEL","Belgium","2019","2019",9.5,,
+"PATCINFC","J-Antiinfectives for systemic use","ATCPTTMT","% of total sales","BEL","Belgium","2020","2020",8.3,,
+"PATCINFC","J-Antiinfectives for systemic use","ATCPTTMT","% of total sales","BEL","Belgium","2021","2021",7.9,,
+"PATCINFC","J-Antiinfectives for systemic use","ATCPTTMT","% of total sales","BEL","Belgium","2022","2022",7.5,"E","Estimated value"
+"PATCINFC","J-Antiinfectives for systemic use","MLLNCUMT","Million of national currency units","CAN","Canada","2012","2012",1441.8,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","MLLNCUMT","Million of national currency units","CAN","Canada","2013","2013",1482.2,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","MLLNCUMT","Million of national currency units","CAN","Canada","2014","2014",1678.1,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","MLLNCUMT","Million of national currency units","CAN","Canada","2015","2015",2447.2,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","MLLNCUMT","Million of national currency units","CAN","Canada","2016","2016",2295.1,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","MLLNCUMT","Million of national currency units","CAN","Canada","2017","2017",2328,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","MLLNCUMT","Million of national currency units","CAN","Canada","2018","2018",2435.5,"E; B; D","Estimated value; Break; Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","MLLNCUMT","Million of national currency units","CAN","Canada","2019","2019",2275.2,"E; D","Estimated value; Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","MLLNCUMT","Million of national currency units","CAN","Canada","2020","2020",1981,"E; D","Estimated value; Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","MLLNCUMT","Million of national currency units","CAN","Canada","2021","2021",1952.7,"E; D","Estimated value; Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","MLLNCUMT","Million of national currency units","CAN","Canada","2022","2022",2066.1,"E; D","Estimated value; Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","MTMOTCMT","Million US$ at exchange rate","CAN","Canada","2012","2012",1442.7,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","MTMOTCMT","Million US$ at exchange rate","CAN","Canada","2013","2013",1438.8,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","MTMOTCMT","Million US$ at exchange rate","CAN","Canada","2014","2014",1519,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","MTMOTCMT","Million US$ at exchange rate","CAN","Canada","2015","2015",1913.7,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","MTMOTCMT","Million US$ at exchange rate","CAN","Canada","2016","2016",1731.3,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","MTMOTCMT","Million US$ at exchange rate","CAN","Canada","2017","2017",1793.6,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","MTMOTCMT","Million US$ at exchange rate","CAN","Canada","2018","2018",1879.5,"E; B; D","Estimated value; Break; Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","MTMOTCMT","Million US$ at exchange rate","CAN","Canada","2019","2019",1714.8,"E; D","Estimated value; Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","MTMOTCMT","Million US$ at exchange rate","CAN","Canada","2020","2020",1477.1,"E; D","Estimated value; Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","MTMOTCMT","Million US$ at exchange rate","CAN","Canada","2021","2021",1557.3,"E; D","Estimated value; Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","MTMOTCMT","Million US$ at exchange rate","CAN","Canada","2022","2022",1587.4,"E; D","Estimated value; Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","MTMOPPMT","Million US$, purchasing power parity","CAN","Canada","2012","2012",1158.4,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","MTMOPPMT","Million US$, purchasing power parity","CAN","Canada","2013","2013",1210.9,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","MTMOPPMT","Million US$, purchasing power parity","CAN","Canada","2014","2014",1363.9,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","MTMOPPMT","Million US$, purchasing power parity","CAN","Canada","2015","2015",1960.8,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","MTMOPPMT","Million US$, purchasing power parity","CAN","Canada","2016","2016",1901.4,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","MTMOPPMT","Million US$, purchasing power parity","CAN","Canada","2017","2017",1920.3,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","MTMOPPMT","Million US$, purchasing power parity","CAN","Canada","2018","2018",2018.6,"E; B; D","Estimated value; Break; Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","MTMOPPMT","Million US$, purchasing power parity","CAN","Canada","2019","2019",1842.7,"E; D","Estimated value; Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","MTMOPPMT","Million US$, purchasing power parity","CAN","Canada","2020","2020",1609.2,"E; D","Estimated value; Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","MTMOPPMT","Million US$, purchasing power parity","CAN","Canada","2021","2021",1577.1,"E; D","Estimated value; Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","MTMOPPMT","Million US$, purchasing power parity","CAN","Canada","2022","2022",1647.9,"E; D","Estimated value; Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","TCPPERMT","/capita, US$ exchange rate","CAN","Canada","2012","2012",41.6,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","TCPPERMT","/capita, US$ exchange rate","CAN","Canada","2013","2013",41,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","TCPPERMT","/capita, US$ exchange rate","CAN","Canada","2014","2014",42.9,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","TCPPERMT","/capita, US$ exchange rate","CAN","Canada","2015","2015",53.6,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","TCPPERMT","/capita, US$ exchange rate","CAN","Canada","2016","2016",47.9,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","TCPPERMT","/capita, US$ exchange rate","CAN","Canada","2017","2017",49.1,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","TCPPERMT","/capita, US$ exchange rate","CAN","Canada","2018","2018",50.7,"E; B; D","Estimated value; Break; Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","TCPPERMT","/capita, US$ exchange rate","CAN","Canada","2019","2019",45.6,"E; D","Estimated value; Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","TCPPERMT","/capita, US$ exchange rate","CAN","Canada","2020","2020",38.8,"E; D","Estimated value; Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","TCPPERMT","/capita, US$ exchange rate","CAN","Canada","2021","2021",40.7,"E; D","Estimated value; Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","TCPPERMT","/capita, US$ exchange rate","CAN","Canada","2022","2022",40.8,"E; D","Estimated value; Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2012","2012",33.4,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2013","2013",34.5,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2014","2014",38.5,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2015","2015",54.9,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2016","2016",52.7,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2017","2017",52.5,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2018","2018",54.5,"E; B; D","Estimated value; Break; Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2019","2019",49,"E; D","Estimated value; Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2020","2020",42.3,"E; D","Estimated value; Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2021","2021",41.2,"E; D","Estimated value; Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2022","2022",42.4,"E; D","Estimated value; Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","ATCPTTMT","% of total sales","CAN","Canada","2012","2012",5.9,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","ATCPTTMT","% of total sales","CAN","Canada","2013","2013",6,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","ATCPTTMT","% of total sales","CAN","Canada","2014","2014",6.6,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","ATCPTTMT","% of total sales","CAN","Canada","2015","2015",9,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","ATCPTTMT","% of total sales","CAN","Canada","2016","2016",8.1,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","ATCPTTMT","% of total sales","CAN","Canada","2017","2017",7.8,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","ATCPTTMT","% of total sales","CAN","Canada","2018","2018",8,"E; B; D","Estimated value; Break; Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","ATCPTTMT","% of total sales","CAN","Canada","2019","2019",7.1,"E; D","Estimated value; Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","ATCPTTMT","% of total sales","CAN","Canada","2020","2020",5.8,"E; D","Estimated value; Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","ATCPTTMT","% of total sales","CAN","Canada","2021","2021",5.3,"E; D","Estimated value; Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","ATCPTTMT","% of total sales","CAN","Canada","2022","2022",5.2,"E; D","Estimated value; Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","MLLNCUMT","Million of national currency units","CZE","Czech Republic","2010","2010",7138.5,,
+"PATCINFC","J-Antiinfectives for systemic use","MLLNCUMT","Million of national currency units","CZE","Czech Republic","2011","2011",7669,,
+"PATCINFC","J-Antiinfectives for systemic use","MLLNCUMT","Million of national currency units","CZE","Czech Republic","2012","2012",7424.5,,
+"PATCINFC","J-Antiinfectives for systemic use","MLLNCUMT","Million of national currency units","CZE","Czech Republic","2013","2013",6568.6,,
+"PATCINFC","J-Antiinfectives for systemic use","MLLNCUMT","Million of national currency units","CZE","Czech Republic","2014","2014",6451.7,,
+"PATCINFC","J-Antiinfectives for systemic use","MLLNCUMT","Million of national currency units","CZE","Czech Republic","2015","2015",6692.9,,
+"PATCINFC","J-Antiinfectives for systemic use","MLLNCUMT","Million of national currency units","CZE","Czech Republic","2016","2016",7213.7,,
+"PATCINFC","J-Antiinfectives for systemic use","MLLNCUMT","Million of national currency units","CZE","Czech Republic","2017","2017",7622.5,,
+"PATCINFC","J-Antiinfectives for systemic use","MLLNCUMT","Million of national currency units","CZE","Czech Republic","2018","2018",8324.4,,
+"PATCINFC","J-Antiinfectives for systemic use","MLLNCUMT","Million of national currency units","CZE","Czech Republic","2019","2019",9284.7,,
+"PATCINFC","J-Antiinfectives for systemic use","MLLNCUMT","Million of national currency units","CZE","Czech Republic","2020","2020",7833.4,"B","Break"
+"PATCINFC","J-Antiinfectives for systemic use","MLLNCUMT","Million of national currency units","CZE","Czech Republic","2021","2021",8201.3,,
+"PATCINFC","J-Antiinfectives for systemic use","MTMOTCMT","Million US$ at exchange rate","CZE","Czech Republic","2010","2010",373.8,,
+"PATCINFC","J-Antiinfectives for systemic use","MTMOTCMT","Million US$ at exchange rate","CZE","Czech Republic","2011","2011",433.4,,
+"PATCINFC","J-Antiinfectives for systemic use","MTMOTCMT","Million US$ at exchange rate","CZE","Czech Republic","2012","2012",379.2,,
+"PATCINFC","J-Antiinfectives for systemic use","MTMOTCMT","Million US$ at exchange rate","CZE","Czech Republic","2013","2013",335.6,,
+"PATCINFC","J-Antiinfectives for systemic use","MTMOTCMT","Million US$ at exchange rate","CZE","Czech Republic","2014","2014",310.8,,
+"PATCINFC","J-Antiinfectives for systemic use","MTMOTCMT","Million US$ at exchange rate","CZE","Czech Republic","2015","2015",272.1,,
+"PATCINFC","J-Antiinfectives for systemic use","MTMOTCMT","Million US$ at exchange rate","CZE","Czech Republic","2016","2016",295.2,,
+"PATCINFC","J-Antiinfectives for systemic use","MTMOTCMT","Million US$ at exchange rate","CZE","Czech Republic","2017","2017",326.1,,
+"PATCINFC","J-Antiinfectives for systemic use","MTMOTCMT","Million US$ at exchange rate","CZE","Czech Republic","2018","2018",383.1,,
+"PATCINFC","J-Antiinfectives for systemic use","MTMOTCMT","Million US$ at exchange rate","CZE","Czech Republic","2019","2019",404.9,,
+"PATCINFC","J-Antiinfectives for systemic use","MTMOTCMT","Million US$ at exchange rate","CZE","Czech Republic","2020","2020",337.5,"B","Break"
+"PATCINFC","J-Antiinfectives for systemic use","MTMOTCMT","Million US$ at exchange rate","CZE","Czech Republic","2021","2021",378.3,,
+"PATCINFC","J-Antiinfectives for systemic use","MTMOPPMT","Million US$, purchasing power parity","CZE","Czech Republic","2010","2010",522.1,,
+"PATCINFC","J-Antiinfectives for systemic use","MTMOPPMT","Million US$, purchasing power parity","CZE","Czech Republic","2011","2011",574.7,,
+"PATCINFC","J-Antiinfectives for systemic use","MTMOPPMT","Million US$, purchasing power parity","CZE","Czech Republic","2012","2012",558.3,,
+"PATCINFC","J-Antiinfectives for systemic use","MTMOPPMT","Million US$, purchasing power parity","CZE","Czech Republic","2013","2013",513.8,,
+"PATCINFC","J-Antiinfectives for systemic use","MTMOPPMT","Million US$, purchasing power parity","CZE","Czech Republic","2014","2014",507.9,,
+"PATCINFC","J-Antiinfectives for systemic use","MTMOPPMT","Million US$, purchasing power parity","CZE","Czech Republic","2015","2015",517.3,,
+"PATCINFC","J-Antiinfectives for systemic use","MTMOPPMT","Million US$, purchasing power parity","CZE","Czech Republic","2016","2016",573.6,,
+"PATCINFC","J-Antiinfectives for systemic use","MTMOPPMT","Million US$, purchasing power parity","CZE","Czech Republic","2017","2017",613.5,,
+"PATCINFC","J-Antiinfectives for systemic use","MTMOPPMT","Million US$, purchasing power parity","CZE","Czech Republic","2018","2018",672.9,,
+"PATCINFC","J-Antiinfectives for systemic use","MTMOPPMT","Million US$, purchasing power parity","CZE","Czech Republic","2019","2019",756.4,,
+"PATCINFC","J-Antiinfectives for systemic use","MTMOPPMT","Million US$, purchasing power parity","CZE","Czech Republic","2020","2020",628.6,"B","Break"
+"PATCINFC","J-Antiinfectives for systemic use","MTMOPPMT","Million US$, purchasing power parity","CZE","Czech Republic","2021","2021",643.6,,
+"PATCINFC","J-Antiinfectives for systemic use","TCPPERMT","/capita, US$ exchange rate","CZE","Czech Republic","2010","2010",35.7,,
+"PATCINFC","J-Antiinfectives for systemic use","TCPPERMT","/capita, US$ exchange rate","CZE","Czech Republic","2011","2011",41.3,,
+"PATCINFC","J-Antiinfectives for systemic use","TCPPERMT","/capita, US$ exchange rate","CZE","Czech Republic","2012","2012",36.1,,
+"PATCINFC","J-Antiinfectives for systemic use","TCPPERMT","/capita, US$ exchange rate","CZE","Czech Republic","2013","2013",31.9,,
+"PATCINFC","J-Antiinfectives for systemic use","TCPPERMT","/capita, US$ exchange rate","CZE","Czech Republic","2014","2014",29.5,,
+"PATCINFC","J-Antiinfectives for systemic use","TCPPERMT","/capita, US$ exchange rate","CZE","Czech Republic","2015","2015",25.8,,
+"PATCINFC","J-Antiinfectives for systemic use","TCPPERMT","/capita, US$ exchange rate","CZE","Czech Republic","2016","2016",27.9,,
+"PATCINFC","J-Antiinfectives for systemic use","TCPPERMT","/capita, US$ exchange rate","CZE","Czech Republic","2017","2017",30.8,,
+"PATCINFC","J-Antiinfectives for systemic use","TCPPERMT","/capita, US$ exchange rate","CZE","Czech Republic","2018","2018",36,,
+"PATCINFC","J-Antiinfectives for systemic use","TCPPERMT","/capita, US$ exchange rate","CZE","Czech Republic","2019","2019",37.9,,
+"PATCINFC","J-Antiinfectives for systemic use","TCPPERMT","/capita, US$ exchange rate","CZE","Czech Republic","2020","2020",31.5,"B","Break"
+"PATCINFC","J-Antiinfectives for systemic use","TCPPERMT","/capita, US$ exchange rate","CZE","Czech Republic","2021","2021",36,,
+"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czech Republic","2010","2010",49.8,,
+"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czech Republic","2011","2011",54.7,,
+"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czech Republic","2012","2012",53.1,,
+"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czech Republic","2013","2013",48.9,,
+"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czech Republic","2014","2014",48.3,,
+"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czech Republic","2015","2015",49.1,,
+"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czech Republic","2016","2016",54.3,,
+"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czech Republic","2017","2017",57.9,,
+"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czech Republic","2018","2018",63.3,,
+"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czech Republic","2019","2019",70.9,,
+"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czech Republic","2020","2020",58.8,"B","Break"
+"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czech Republic","2021","2021",61.3,,
+"PATCINFC","J-Antiinfectives for systemic use","ATCPTTMT","% of total sales","CZE","Czech Republic","2010","2010",8.8,,
+"PATCINFC","J-Antiinfectives for systemic use","ATCPTTMT","% of total sales","CZE","Czech Republic","2011","2011",9.5,,
+"PATCINFC","J-Antiinfectives for systemic use","ATCPTTMT","% of total sales","CZE","Czech Republic","2012","2012",8.9,,
+"PATCINFC","J-Antiinfectives for systemic use","ATCPTTMT","% of total sales","CZE","Czech Republic","2013","2013",8.2,,
+"PATCINFC","J-Antiinfectives for systemic use","ATCPTTMT","% of total sales","CZE","Czech Republic","2014","2014",8,,
+"PATCINFC","J-Antiinfectives for systemic use","ATCPTTMT","% of total sales","CZE","Czech Republic","2015","2015",7.9,,
+"PATCINFC","J-Antiinfectives for systemic use","ATCPTTMT","% of total sales","CZE","Czech Republic","2016","2016",8.3,,
+"PATCINFC","J-Antiinfectives for systemic use","ATCPTTMT","% of total sales","CZE","Czech Republic","2017","2017",8.3,,
+"PATCINFC","J-Antiinfectives for systemic use","ATCPTTMT","% of total sales","CZE","Czech Republic","2018","2018",8.5,,
+"PATCINFC","J-Antiinfectives for systemic use","ATCPTTMT","% of total sales","CZE","Czech Republic","2019","2019",9,,
+"PATCINFC","J-Antiinfectives for systemic use","ATCPTTMT","% of total sales","CZE","Czech Republic","2020","2020",8.9,"B","Break"
+"PATCINFC","J-Antiinfectives for systemic use","ATCPTTMT","% of total sales","CZE","Czech Republic","2021","2021",8.8,,
+"PATCINFC","J-Antiinfectives for systemic use","MLLNCUMT","Million of national currency units","DNK","Denmark","2010","2010",2056.7,,
+"PATCINFC","J-Antiinfectives for systemic use","MLLNCUMT","Million of national currency units","DNK","Denmark","2011","2011",2036.3,,
+"PATCINFC","J-Antiinfectives for systemic use","MLLNCUMT","Million of national currency units","DNK","Denmark","2012","2012",2015.8,,
+"PATCINFC","J-Antiinfectives for systemic use","MLLNCUMT","Million of national currency units","DNK","Denmark","2013","2013",2066.2,,
+"PATCINFC","J-Antiinfectives for systemic use","MLLNCUMT","Million of national currency units","DNK","Denmark","2014","2014",2107.4,,
+"PATCINFC","J-Antiinfectives for systemic use","MLLNCUMT","Million of national currency units","DNK","Denmark","2015","2015",2220.3,,
+"PATCINFC","J-Antiinfectives for systemic use","MLLNCUMT","Million of national currency units","DNK","Denmark","2016","2016",2066,,
+"PATCINFC","J-Antiinfectives for systemic use","MLLNCUMT","Million of national currency units","DNK","Denmark","2017","2017",1983.3,,
+"PATCINFC","J-Antiinfectives for systemic use","MLLNCUMT","Million of national currency units","DNK","Denmark","2018","2018",1929.7,,
+"PATCINFC","J-Antiinfectives for systemic use","MLLNCUMT","Million of national currency units","DNK","Denmark","2019","2019",2032.6,,
+"PATCINFC","J-Antiinfectives for systemic use","MLLNCUMT","Million of national currency units","DNK","Denmark","2020","2020",2186.5,,
+"PATCINFC","J-Antiinfectives for systemic use","MLLNCUMT","Million of national currency units","DNK","Denmark","2021","2021",2006,,
+"PATCINFC","J-Antiinfectives for systemic use","MTMOTCMT","Million US$ at exchange rate","DNK","Denmark","2010","2010",365.7,,
+"PATCINFC","J-Antiinfectives for systemic use","MTMOTCMT","Million US$ at exchange rate","DNK","Denmark","2011","2011",379.3,,
+"PATCINFC","J-Antiinfectives for systemic use","MTMOTCMT","Million US$ at exchange rate","DNK","Denmark","2012","2012",348,,
+"PATCINFC","J-Antiinfectives for systemic use","MTMOTCMT","Million US$ at exchange rate","DNK","Denmark","2013","2013",367.9,,
+"PATCINFC","J-Antiinfectives for systemic use","MTMOTCMT","Million US$ at exchange rate","DNK","Denmark","2014","2014",375.5,,
+"PATCINFC","J-Antiinfectives for systemic use","MTMOTCMT","Million US$ at exchange rate","DNK","Denmark","2015","2015",330,,
+"PATCINFC","J-Antiinfectives for systemic use","MTMOTCMT","Million US$ at exchange rate","DNK","Denmark","2016","2016",306.9,,
+"PATCINFC","J-Antiinfectives for systemic use","MTMOTCMT","Million US$ at exchange rate","DNK","Denmark","2017","2017",300.4,,
+"PATCINFC","J-Antiinfectives for systemic use","MTMOTCMT","Million US$ at exchange rate","DNK","Denmark","2018","2018",305.6,,
+"PATCINFC","J-Antiinfectives for systemic use","MTMOTCMT","Million US$ at exchange rate","DNK","Denmark","2019","2019",304.8,,
+"PATCINFC","J-Antiinfectives for systemic use","MTMOTCMT","Million US$ at exchange rate","DNK","Denmark","2020","2020",334.2,,
+"PATCINFC","J-Antiinfectives for systemic use","MTMOTCMT","Million US$ at exchange rate","DNK","Denmark","2021","2021",319.1,,
+"PATCINFC","J-Antiinfectives for systemic use","MTMOPPMT","Million US$, purchasing power parity","DNK","Denmark","2010","2010",270.9,,
+"PATCINFC","J-Antiinfectives for systemic use","MTMOPPMT","Million US$, purchasing power parity","DNK","Denmark","2011","2011",272.7,,
+"PATCINFC","J-Antiinfectives for systemic use","MTMOPPMT","Million US$, purchasing power parity","DNK","Denmark","2012","2012",266.5,,
+"PATCINFC","J-Antiinfectives for systemic use","MTMOPPMT","Million US$, purchasing power parity","DNK","Denmark","2013","2013",280.9,,
+"PATCINFC","J-Antiinfectives for systemic use","MTMOPPMT","Million US$, purchasing power parity","DNK","Denmark","2014","2014",287.6,,
+"PATCINFC","J-Antiinfectives for systemic use","MTMOPPMT","Million US$, purchasing power parity","DNK","Denmark","2015","2015",303.9,,
+"PATCINFC","J-Antiinfectives for systemic use","MTMOPPMT","Million US$, purchasing power parity","DNK","Denmark","2016","2016",291.8,,
+"PATCINFC","J-Antiinfectives for systemic use","MTMOPPMT","Million US$, purchasing power parity","DNK","Denmark","2017","2017",288.6,,
+"PATCINFC","J-Antiinfectives for systemic use","MTMOPPMT","Million US$, purchasing power parity","DNK","Denmark","2018","2018",285.2,,
+"PATCINFC","J-Antiinfectives for systemic use","MTMOPPMT","Million US$, purchasing power parity","DNK","Denmark","2019","2019",306.4,,
+"PATCINFC","J-Antiinfectives for systemic use","MTMOPPMT","Million US$, purchasing power parity","DNK","Denmark","2020","2020",333.8,,
+"PATCINFC","J-Antiinfectives for systemic use","MTMOPPMT","Million US$, purchasing power parity","DNK","Denmark","2021","2021",304.4,,
+"PATCINFC","J-Antiinfectives for systemic use","TCPPERMT","/capita, US$ exchange rate","DNK","Denmark","2010","2010",65.9,,
+"PATCINFC","J-Antiinfectives for systemic use","TCPPERMT","/capita, US$ exchange rate","DNK","Denmark","2011","2011",68.1,,
+"PATCINFC","J-Antiinfectives for systemic use","TCPPERMT","/capita, US$ exchange rate","DNK","Denmark","2012","2012",62.2,,
+"PATCINFC","J-Antiinfectives for systemic use","TCPPERMT","/capita, US$ exchange rate","DNK","Denmark","2013","2013",65.5,,
+"PATCINFC","J-Antiinfectives for systemic use","TCPPERMT","/capita, US$ exchange rate","DNK","Denmark","2014","2014",66.5,,
+"PATCINFC","J-Antiinfectives for systemic use","TCPPERMT","/capita, US$ exchange rate","DNK","Denmark","2015","2015",58.1,,
+"PATCINFC","J-Antiinfectives for systemic use","TCPPERMT","/capita, US$ exchange rate","DNK","Denmark","2016","2016",53.6,,
+"PATCINFC","J-Antiinfectives for systemic use","TCPPERMT","/capita, US$ exchange rate","DNK","Denmark","2017","2017",52.1,,
+"PATCINFC","J-Antiinfectives for systemic use","TCPPERMT","/capita, US$ exchange rate","DNK","Denmark","2018","2018",52.7,,
+"PATCINFC","J-Antiinfectives for systemic use","TCPPERMT","/capita, US$ exchange rate","DNK","Denmark","2019","2019",52.4,,
+"PATCINFC","J-Antiinfectives for systemic use","TCPPERMT","/capita, US$ exchange rate","DNK","Denmark","2020","2020",57.3,,
+"PATCINFC","J-Antiinfectives for systemic use","TCPPERMT","/capita, US$ exchange rate","DNK","Denmark","2021","2021",54.5,,
+"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","DNK","Denmark","2010","2010",48.8,,
+"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","DNK","Denmark","2011","2011",49,,
+"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","DNK","Denmark","2012","2012",47.7,,
+"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","DNK","Denmark","2013","2013",50,,
+"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","DNK","Denmark","2014","2014",51,,
+"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","DNK","Denmark","2015","2015",53.5,,
+"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","DNK","Denmark","2016","2016",50.9,,
+"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","DNK","Denmark","2017","2017",50.1,,
+"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","DNK","Denmark","2018","2018",49.2,,
+"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","DNK","Denmark","2019","2019",52.7,,
+"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","DNK","Denmark","2020","2020",57.2,,
+"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","DNK","Denmark","2021","2021",52,,
+"PATCINFC","J-Antiinfectives for systemic use","ATCPTTMT","% of total sales","DNK","Denmark","2010","2010",9.7,,
+"PATCINFC","J-Antiinfectives for systemic use","ATCPTTMT","% of total sales","DNK","Denmark","2011","2011",9.9,,
+"PATCINFC","J-Antiinfectives for systemic use","ATCPTTMT","% of total sales","DNK","Denmark","2012","2012",9.9,,
+"PATCINFC","J-Antiinfectives for systemic use","ATCPTTMT","% of total sales","DNK","Denmark","2013","2013",10.1,,
+"PATCINFC","J-Antiinfectives for systemic use","ATCPTTMT","% of total sales","DNK","Denmark","2014","2014",9.8,,
+"PATCINFC","J-Antiinfectives for systemic use","ATCPTTMT","% of total sales","DNK","Denmark","2015","2015",10.1,,
+"PATCINFC","J-Antiinfectives for systemic use","ATCPTTMT","% of total sales","DNK","Denmark","2016","2016",9.3,,
+"PATCINFC","J-Antiinfectives for systemic use","ATCPTTMT","% of total sales","DNK","Denmark","2017","2017",8.6,,
+"PATCINFC","J-Antiinfectives for systemic use","ATCPTTMT","% of total sales","DNK","Denmark","2018","2018",8.1,,
+"PATCINFC","J-Antiinfectives for systemic use","ATCPTTMT","% of total sales","DNK","Denmark","2019","2019",8.3,,
+"PATCINFC","J-Antiinfectives for systemic use","ATCPTTMT","% of total sales","DNK","Denmark","2020","2020",8.7,,
+"PATCINFC","J-Antiinfectives for systemic use","ATCPTTMT","% of total sales","DNK","Denmark","2021","2021",7.9,,
+"PATCINFC","J-Antiinfectives for systemic use","MLLNCUMT","Million of national currency units","FIN","Finland","2010","2010",148.9,,
+"PATCINFC","J-Antiinfectives for systemic use","MLLNCUMT","Million of national currency units","FIN","Finland","2011","2011",152.9,,
+"PATCINFC","J-Antiinfectives for systemic use","MLLNCUMT","Million of national currency units","FIN","Finland","2012","2012",140.8,,
+"PATCINFC","J-Antiinfectives for systemic use","MLLNCUMT","Million of national currency units","FIN","Finland","2013","2013",144.1,,
+"PATCINFC","J-Antiinfectives for systemic use","MLLNCUMT","Million of national currency units","FIN","Finland","2014","2014",145.7,,
+"PATCINFC","J-Antiinfectives for systemic use","MLLNCUMT","Million of national currency units","FIN","Finland","2015","2015",182.1,,
+"PATCINFC","J-Antiinfectives for systemic use","MLLNCUMT","Million of national currency units","FIN","Finland","2016","2016",184.1,,
+"PATCINFC","J-Antiinfectives for systemic use","MLLNCUMT","Million of national currency units","FIN","Finland","2017","2017",196.9,,
+"PATCINFC","J-Antiinfectives for systemic use","MLLNCUMT","Million of national currency units","FIN","Finland","2018","2018",246.9,,
+"PATCINFC","J-Antiinfectives for systemic use","MLLNCUMT","Million of national currency units","FIN","Finland","2019","2019",268,,
+"PATCINFC","J-Antiinfectives for systemic use","MLLNCUMT","Million of national currency units","FIN","Finland","2020","2020",256.8,,
+"PATCINFC","J-Antiinfectives for systemic use","MLLNCUMT","Million of national currency units","FIN","Finland","2021","2021",245.2,,
+"PATCINFC","J-Antiinfectives for systemic use","MTMOTCMT","Million US$ at exchange rate","FIN","Finland","2010","2010",197.4,,
+"PATCINFC","J-Antiinfectives for systemic use","MTMOTCMT","Million US$ at exchange rate","FIN","Finland","2011","2011",212.8,,
+"PATCINFC","J-Antiinfectives for systemic use","MTMOTCMT","Million US$ at exchange rate","FIN","Finland","2012","2012",180.9,,
+"PATCINFC","J-Antiinfectives for systemic use","MTMOTCMT","Million US$ at exchange rate","FIN","Finland","2013","2013",191.4,,
+"PATCINFC","J-Antiinfectives for systemic use","MTMOTCMT","Million US$ at exchange rate","FIN","Finland","2014","2014",193.6,,
+"PATCINFC","J-Antiinfectives for systemic use","MTMOTCMT","Million US$ at exchange rate","FIN","Finland","2015","2015",202,,
+"PATCINFC","J-Antiinfectives for systemic use","MTMOTCMT","Million US$ at exchange rate","FIN","Finland","2016","2016",203.8,,
+"PATCINFC","J-Antiinfectives for systemic use","MTMOTCMT","Million US$ at exchange rate","FIN","Finland","2017","2017",222.4,,
+"PATCINFC","J-Antiinfectives for systemic use","MTMOTCMT","Million US$ at exchange rate","FIN","Finland","2018","2018",291.6,,
+"PATCINFC","J-Antiinfectives for systemic use","MTMOTCMT","Million US$ at exchange rate","FIN","Finland","2019","2019",300,,
+"PATCINFC","J-Antiinfectives for systemic use","MTMOTCMT","Million US$ at exchange rate","FIN","Finland","2020","2020",293.3,,
+"PATCINFC","J-Antiinfectives for systemic use","MTMOTCMT","Million US$ at exchange rate","FIN","Finland","2021","2021",290,,
+"PATCINFC","J-Antiinfectives for systemic use","MTMOPPMT","Million US$, purchasing power parity","FIN","Finland","2010","2010",165.3,,
+"PATCINFC","J-Antiinfectives for systemic use","MTMOPPMT","Million US$, purchasing power parity","FIN","Finland","2011","2011",170.3,,
+"PATCINFC","J-Antiinfectives for systemic use","MTMOPPMT","Million US$, purchasing power parity","FIN","Finland","2012","2012",155,,
+"PATCINFC","J-Antiinfectives for systemic use","MTMOPPMT","Million US$, purchasing power parity","FIN","Finland","2013","2013",159.2,,
+"PATCINFC","J-Antiinfectives for systemic use","MTMOPPMT","Million US$, purchasing power parity","FIN","Finland","2014","2014",160.6,,
+"PATCINFC","J-Antiinfectives for systemic use","MTMOPPMT","Million US$, purchasing power parity","FIN","Finland","2015","2015",200.6,,
+"PATCINFC","J-Antiinfectives for systemic use","MTMOPPMT","Million US$, purchasing power parity","FIN","Finland","2016","2016",209,,
+"PATCINFC","J-Antiinfectives for systemic use","MTMOPPMT","Million US$, purchasing power parity","FIN","Finland","2017","2017",228,,
+"PATCINFC","J-Antiinfectives for systemic use","MTMOPPMT","Million US$, purchasing power parity","FIN","Finland","2018","2018",289.2,,
+"PATCINFC","J-Antiinfectives for systemic use","MTMOPPMT","Million US$, purchasing power parity","FIN","Finland","2019","2019",319.6,,
+"PATCINFC","J-Antiinfectives for systemic use","MTMOPPMT","Million US$, purchasing power parity","FIN","Finland","2020","2020",312,,
+"PATCINFC","J-Antiinfectives for systemic use","MTMOPPMT","Million US$, purchasing power parity","FIN","Finland","2021","2021",296.6,,
+"PATCINFC","J-Antiinfectives for systemic use","TCPPERMT","/capita, US$ exchange rate","FIN","Finland","2010","2010",36.8,,
+"PATCINFC","J-Antiinfectives for systemic use","TCPPERMT","/capita, US$ exchange rate","FIN","Finland","2011","2011",39.5,,
+"PATCINFC","J-Antiinfectives for systemic use","TCPPERMT","/capita, US$ exchange rate","FIN","Finland","2012","2012",33.4,,
+"PATCINFC","J-Antiinfectives for systemic use","TCPPERMT","/capita, US$ exchange rate","FIN","Finland","2013","2013",35.2,,
+"PATCINFC","J-Antiinfectives for systemic use","TCPPERMT","/capita, US$ exchange rate","FIN","Finland","2014","2014",35.4,,
+"PATCINFC","J-Antiinfectives for systemic use","TCPPERMT","/capita, US$ exchange rate","FIN","Finland","2015","2015",36.9,,
+"PATCINFC","J-Antiinfectives for systemic use","TCPPERMT","/capita, US$ exchange rate","FIN","Finland","2016","2016",37.1,,
+"PATCINFC","J-Antiinfectives for systemic use","TCPPERMT","/capita, US$ exchange rate","FIN","Finland","2017","2017",40.4,,
+"PATCINFC","J-Antiinfectives for systemic use","TCPPERMT","/capita, US$ exchange rate","FIN","Finland","2018","2018",52.9,,
+"PATCINFC","J-Antiinfectives for systemic use","TCPPERMT","/capita, US$ exchange rate","FIN","Finland","2019","2019",54.3,,
+"PATCINFC","J-Antiinfectives for systemic use","TCPPERMT","/capita, US$ exchange rate","FIN","Finland","2020","2020",53,,
+"PATCINFC","J-Antiinfectives for systemic use","TCPPERMT","/capita, US$ exchange rate","FIN","Finland","2021","2021",52.3,,
+"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2010","2010",30.8,,
+"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2011","2011",31.6,,
+"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2012","2012",28.6,,
+"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2013","2013",29.3,,
+"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2014","2014",29.4,,
+"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2015","2015",36.6,,
+"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2016","2016",38,,
+"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2017","2017",41.4,,
+"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2018","2018",52.4,,
+"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2019","2019",57.9,,
+"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2020","2020",56.4,,
+"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2021","2021",53.5,,
+"PATCINFC","J-Antiinfectives for systemic use","ATCPTTMT","% of total sales","FIN","Finland","2010","2010",7.9,,
+"PATCINFC","J-Antiinfectives for systemic use","ATCPTTMT","% of total sales","FIN","Finland","2011","2011",7.9,,
+"PATCINFC","J-Antiinfectives for systemic use","ATCPTTMT","% of total sales","FIN","Finland","2012","2012",7.2,,
+"PATCINFC","J-Antiinfectives for systemic use","ATCPTTMT","% of total sales","FIN","Finland","2013","2013",7.2,,
+"PATCINFC","J-Antiinfectives for systemic use","ATCPTTMT","% of total sales","FIN","Finland","2014","2014",7,,
+"PATCINFC","J-Antiinfectives for systemic use","ATCPTTMT","% of total sales","FIN","Finland","2015","2015",8.3,,
+"PATCINFC","J-Antiinfectives for systemic use","ATCPTTMT","% of total sales","FIN","Finland","2016","2016",8,,
+"PATCINFC","J-Antiinfectives for systemic use","ATCPTTMT","% of total sales","FIN","Finland","2017","2017",8.5,,
+"PATCINFC","J-Antiinfectives for systemic use","ATCPTTMT","% of total sales","FIN","Finland","2018","2018",9.9,,
+"PATCINFC","J-Antiinfectives for systemic use","ATCPTTMT","% of total sales","FIN","Finland","2019","2019",10.1,,
+"PATCINFC","J-Antiinfectives for systemic use","ATCPTTMT","% of total sales","FIN","Finland","2020","2020",9.5,,
+"PATCINFC","J-Antiinfectives for systemic use","ATCPTTMT","% of total sales","FIN","Finland","2021","2021",8.6,,
+"PATCINFC","J-Antiinfectives for systemic use","MLLNCUMT","Million of national currency units","FRA","France","2011","2011",3056.5,,
+"PATCINFC","J-Antiinfectives for systemic use","MTMOTCMT","Million US$ at exchange rate","FRA","France","2011","2011",4254.5,,
+"PATCINFC","J-Antiinfectives for systemic use","MTMOPPMT","Million US$, purchasing power parity","FRA","France","2011","2011",3632.8,,
+"PATCINFC","J-Antiinfectives for systemic use","TCPPERMT","/capita, US$ exchange rate","FRA","France","2011","2011",65.3,,
+"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","FRA","France","2011","2011",55.8,,
+"PATCINFC","J-Antiinfectives for systemic use","ATCPTTMT","% of total sales","FRA","France","2011","2011",11.1,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","MLLNCUMT","Million of national currency units","DEU","Germany","2010","2010",2029,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","MLLNCUMT","Million of national currency units","DEU","Germany","2011","2011",2098.9,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","MLLNCUMT","Million of national currency units","DEU","Germany","2012","2012",2411.2,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","MLLNCUMT","Million of national currency units","DEU","Germany","2013","2013",2395.3,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","MLLNCUMT","Million of national currency units","DEU","Germany","2014","2014",2966.1,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","MLLNCUMT","Million of national currency units","DEU","Germany","2015","2015",3743.8,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","MLLNCUMT","Million of national currency units","DEU","Germany","2016","2016",3238.3,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","MLLNCUMT","Million of national currency units","DEU","Germany","2017","2017",2922.7,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","MLLNCUMT","Million of national currency units","DEU","Germany","2018","2018",2898.8,"B; D","Break; Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","MLLNCUMT","Million of national currency units","DEU","Germany","2019","2019",2717.6,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","MLLNCUMT","Million of national currency units","DEU","Germany","2020","2020",2544.2,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","MLLNCUMT","Million of national currency units","DEU","Germany","2021","2021",2623,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","MTMOTCMT","Million US$ at exchange rate","DEU","Germany","2010","2010",2689.9,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","MTMOTCMT","Million US$ at exchange rate","DEU","Germany","2011","2011",2921.6,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","MTMOTCMT","Million US$ at exchange rate","DEU","Germany","2012","2012",3097.9,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","MTMOTCMT","Million US$ at exchange rate","DEU","Germany","2013","2013",3181.2,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","MTMOTCMT","Million US$ at exchange rate","DEU","Germany","2014","2014",3940.5,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","MTMOTCMT","Million US$ at exchange rate","DEU","Germany","2015","2015",4153.8,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","MTMOTCMT","Million US$ at exchange rate","DEU","Germany","2016","2016",3584.5,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","MTMOTCMT","Million US$ at exchange rate","DEU","Germany","2017","2017",3301.7,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","MTMOTCMT","Million US$ at exchange rate","DEU","Germany","2018","2018",3423.3,"B; D","Break; Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","MTMOTCMT","Million US$ at exchange rate","DEU","Germany","2019","2019",3042.3,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","MTMOTCMT","Million US$ at exchange rate","DEU","Germany","2020","2020",2906,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","MTMOTCMT","Million US$ at exchange rate","DEU","Germany","2021","2021",3102.3,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","MTMOPPMT","Million US$, purchasing power parity","DEU","Germany","2010","2010",2520.2,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","MTMOPPMT","Million US$, purchasing power parity","DEU","Germany","2011","2011",2661.1,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","MTMOPPMT","Million US$, purchasing power parity","DEU","Germany","2012","2012",3062.8,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","MTMOPPMT","Million US$, purchasing power parity","DEU","Germany","2013","2013",3091.6,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","MTMOPPMT","Million US$, purchasing power parity","DEU","Germany","2014","2014",3857.4,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","MTMOPPMT","Million US$, purchasing power parity","DEU","Germany","2015","2015",4811.3,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","MTMOPPMT","Million US$, purchasing power parity","DEU","Germany","2016","2016",4302.8,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","MTMOPPMT","Million US$, purchasing power parity","DEU","Germany","2017","2017",3924.2,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","MTMOPPMT","Million US$, purchasing power parity","DEU","Germany","2018","2018",3941.5,"B; D","Break; Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","MTMOPPMT","Million US$, purchasing power parity","DEU","Germany","2019","2019",3731.7,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","MTMOPPMT","Million US$, purchasing power parity","DEU","Germany","2020","2020",3509.2,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","MTMOPPMT","Million US$, purchasing power parity","DEU","Germany","2021","2021",3562.5,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","TCPPERMT","/capita, US$ exchange rate","DEU","Germany","2010","2010",32.9,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","TCPPERMT","/capita, US$ exchange rate","DEU","Germany","2011","2011",36.4,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","TCPPERMT","/capita, US$ exchange rate","DEU","Germany","2012","2012",38.5,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","TCPPERMT","/capita, US$ exchange rate","DEU","Germany","2013","2013",39.4,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","TCPPERMT","/capita, US$ exchange rate","DEU","Germany","2014","2014",48.7,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","TCPPERMT","/capita, US$ exchange rate","DEU","Germany","2015","2015",50.9,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","TCPPERMT","/capita, US$ exchange rate","DEU","Germany","2016","2016",43.5,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","TCPPERMT","/capita, US$ exchange rate","DEU","Germany","2017","2017",39.9,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","TCPPERMT","/capita, US$ exchange rate","DEU","Germany","2018","2018",41.3,"B; D","Break; Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","TCPPERMT","/capita, US$ exchange rate","DEU","Germany","2019","2019",36.6,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","TCPPERMT","/capita, US$ exchange rate","DEU","Germany","2020","2020",34.9,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","TCPPERMT","/capita, US$ exchange rate","DEU","Germany","2021","2021",37.3,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2010","2010",30.8,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2011","2011",33.1,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2012","2012",38.1,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2013","2013",38.3,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2014","2014",47.6,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2015","2015",58.9,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2016","2016",52.3,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2017","2017",47.5,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2018","2018",47.5,"B; D","Break; Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2019","2019",44.9,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2020","2020",42.2,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2021","2021",42.8,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","ATCPTTMT","% of total sales","DEU","Germany","2010","2010",6.8,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","ATCPTTMT","% of total sales","DEU","Germany","2011","2011",7.1,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","ATCPTTMT","% of total sales","DEU","Germany","2012","2012",7.9,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","ATCPTTMT","% of total sales","DEU","Germany","2013","2013",7.6,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","ATCPTTMT","% of total sales","DEU","Germany","2014","2014",8.8,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","ATCPTTMT","% of total sales","DEU","Germany","2015","2015",10.6,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","ATCPTTMT","% of total sales","DEU","Germany","2016","2016",9,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","ATCPTTMT","% of total sales","DEU","Germany","2017","2017",7.9,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","ATCPTTMT","% of total sales","DEU","Germany","2018","2018",6.6,"B; D","Break; Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","ATCPTTMT","% of total sales","DEU","Germany","2019","2019",5.8,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","ATCPTTMT","% of total sales","DEU","Germany","2020","2020",5.2,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","ATCPTTMT","% of total sales","DEU","Germany","2021","2021",4.9,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","MLLNCUMT","Million of national currency units","GRC","Greece","2010","2010",748.6,,
+"PATCINFC","J-Antiinfectives for systemic use","MLLNCUMT","Million of national currency units","GRC","Greece","2011","2011",693.5,,
+"PATCINFC","J-Antiinfectives for systemic use","MLLNCUMT","Million of national currency units","GRC","Greece","2012","2012",600.5,,
+"PATCINFC","J-Antiinfectives for systemic use","MLLNCUMT","Million of national currency units","GRC","Greece","2013","2013",518.5,,
+"PATCINFC","J-Antiinfectives for systemic use","MLLNCUMT","Million of national currency units","GRC","Greece","2014","2014",548.2,,
+"PATCINFC","J-Antiinfectives for systemic use","MLLNCUMT","Million of national currency units","GRC","Greece","2015","2015",538.2,,
+"PATCINFC","J-Antiinfectives for systemic use","MLLNCUMT","Million of national currency units","GRC","Greece","2016","2016",633.7,,
+"PATCINFC","J-Antiinfectives for systemic use","MLLNCUMT","Million of national currency units","GRC","Greece","2017","2017",653.1,,
+"PATCINFC","J-Antiinfectives for systemic use","MLLNCUMT","Million of national currency units","GRC","Greece","2018","2018",685.6,,
+"PATCINFC","J-Antiinfectives for systemic use","MLLNCUMT","Million of national currency units","GRC","Greece","2019","2019",700.3,,
+"PATCINFC","J-Antiinfectives for systemic use","MLLNCUMT","Million of national currency units","GRC","Greece","2020","2020",702,,
+"PATCINFC","J-Antiinfectives for systemic use","MLLNCUMT","Million of national currency units","GRC","Greece","2021","2021",666.5,,
+"PATCINFC","J-Antiinfectives for systemic use","MLLNCUMT","Million of national currency units","GRC","Greece","2022","2022",735.8,,
+"PATCINFC","J-Antiinfectives for systemic use","MTMOTCMT","Million US$ at exchange rate","GRC","Greece","2010","2010",992.4,,
+"PATCINFC","J-Antiinfectives for systemic use","MTMOTCMT","Million US$ at exchange rate","GRC","Greece","2011","2011",965.3,,
+"PATCINFC","J-Antiinfectives for systemic use","MTMOTCMT","Million US$ at exchange rate","GRC","Greece","2012","2012",771.6,,
+"PATCINFC","J-Antiinfectives for systemic use","MTMOTCMT","Million US$ at exchange rate","GRC","Greece","2013","2013",688.6,,
+"PATCINFC","J-Antiinfectives for systemic use","MTMOTCMT","Million US$ at exchange rate","GRC","Greece","2014","2014",728.3,,
+"PATCINFC","J-Antiinfectives for systemic use","MTMOTCMT","Million US$ at exchange rate","GRC","Greece","2015","2015",597.2,,
+"PATCINFC","J-Antiinfectives for systemic use","MTMOTCMT","Million US$ at exchange rate","GRC","Greece","2016","2016",701.4,,
+"PATCINFC","J-Antiinfectives for systemic use","MTMOTCMT","Million US$ at exchange rate","GRC","Greece","2017","2017",737.8,,
+"PATCINFC","J-Antiinfectives for systemic use","MTMOTCMT","Million US$ at exchange rate","GRC","Greece","2018","2018",809.7,,
+"PATCINFC","J-Antiinfectives for systemic use","MTMOTCMT","Million US$ at exchange rate","GRC","Greece","2019","2019",784,,
+"PATCINFC","J-Antiinfectives for systemic use","MTMOTCMT","Million US$ at exchange rate","GRC","Greece","2020","2020",801.8,,
+"PATCINFC","J-Antiinfectives for systemic use","MTMOTCMT","Million US$ at exchange rate","GRC","Greece","2021","2021",788.3,,
+"PATCINFC","J-Antiinfectives for systemic use","MTMOTCMT","Million US$ at exchange rate","GRC","Greece","2022","2022",774.8,,
+"PATCINFC","J-Antiinfectives for systemic use","MTMOPPMT","Million US$, purchasing power parity","GRC","Greece","2010","2010",1036.8,,
+"PATCINFC","J-Antiinfectives for systemic use","MTMOPPMT","Million US$, purchasing power parity","GRC","Greece","2011","2011",972.4,,
+"PATCINFC","J-Antiinfectives for systemic use","MTMOPPMT","Million US$, purchasing power parity","GRC","Greece","2012","2012",877.1,,
+"PATCINFC","J-Antiinfectives for systemic use","MTMOPPMT","Million US$, purchasing power parity","GRC","Greece","2013","2013",821.3,,
+"PATCINFC","J-Antiinfectives for systemic use","MTMOPPMT","Million US$, purchasing power parity","GRC","Greece","2014","2014",897,,
+"PATCINFC","J-Antiinfectives for systemic use","MTMOPPMT","Million US$, purchasing power parity","GRC","Greece","2015","2015",883.7,,
+"PATCINFC","J-Antiinfectives for systemic use","MTMOPPMT","Million US$, purchasing power parity","GRC","Greece","2016","2016",1076.6,,
+"PATCINFC","J-Antiinfectives for systemic use","MTMOPPMT","Million US$, purchasing power parity","GRC","Greece","2017","2017",1135.8,,
+"PATCINFC","J-Antiinfectives for systemic use","MTMOPPMT","Million US$, purchasing power parity","GRC","Greece","2018","2018",1213.8,,
+"PATCINFC","J-Antiinfectives for systemic use","MTMOPPMT","Million US$, purchasing power parity","GRC","Greece","2019","2019",1275.9,,
+"PATCINFC","J-Antiinfectives for systemic use","MTMOPPMT","Million US$, purchasing power parity","GRC","Greece","2020","2020",1290.3,,
+"PATCINFC","J-Antiinfectives for systemic use","MTMOPPMT","Million US$, purchasing power parity","GRC","Greece","2021","2021",1221.8,,
+"PATCINFC","J-Antiinfectives for systemic use","MTMOPPMT","Million US$, purchasing power parity","GRC","Greece","2022","2022",1392.3,,
+"PATCINFC","J-Antiinfectives for systemic use","TCPPERMT","/capita, US$ exchange rate","GRC","Greece","2010","2010",89.2,,
+"PATCINFC","J-Antiinfectives for systemic use","TCPPERMT","/capita, US$ exchange rate","GRC","Greece","2011","2011",86.9,,
+"PATCINFC","J-Antiinfectives for systemic use","TCPPERMT","/capita, US$ exchange rate","GRC","Greece","2012","2012",69.9,,
+"PATCINFC","J-Antiinfectives for systemic use","TCPPERMT","/capita, US$ exchange rate","GRC","Greece","2013","2013",62.8,,
+"PATCINFC","J-Antiinfectives for systemic use","TCPPERMT","/capita, US$ exchange rate","GRC","Greece","2014","2014",66.9,,
+"PATCINFC","J-Antiinfectives for systemic use","TCPPERMT","/capita, US$ exchange rate","GRC","Greece","2015","2015",55.2,,
+"PATCINFC","J-Antiinfectives for systemic use","TCPPERMT","/capita, US$ exchange rate","GRC","Greece","2016","2016",65.1,,
+"PATCINFC","J-Antiinfectives for systemic use","TCPPERMT","/capita, US$ exchange rate","GRC","Greece","2017","2017",68.6,,
+"PATCINFC","J-Antiinfectives for systemic use","TCPPERMT","/capita, US$ exchange rate","GRC","Greece","2018","2018",75.4,,
+"PATCINFC","J-Antiinfectives for systemic use","TCPPERMT","/capita, US$ exchange rate","GRC","Greece","2019","2019",73.1,,
+"PATCINFC","J-Antiinfectives for systemic use","TCPPERMT","/capita, US$ exchange rate","GRC","Greece","2020","2020",74.9,,
+"PATCINFC","J-Antiinfectives for systemic use","TCPPERMT","/capita, US$ exchange rate","GRC","Greece","2021","2021",74.6,,
+"PATCINFC","J-Antiinfectives for systemic use","TCPPERMT","/capita, US$ exchange rate","GRC","Greece","2022","2022",74.1,,
+"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2010","2010",93.2,,
+"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2011","2011",87.6,,
+"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2012","2012",79.4,,
+"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2013","2013",74.9,,
+"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2014","2014",82.4,,
+"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2015","2015",81.7,,
+"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2016","2016",99.9,,
+"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2017","2017",105.6,,
+"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2018","2018",113.1,,
+"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2019","2019",119,,
+"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2020","2020",120.6,,
+"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2021","2021",115.6,,
+"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2022","2022",133.1,,
+"PATCINFC","J-Antiinfectives for systemic use","MLLNCUMT","Million of national currency units","HUN","Hungary","2010","2010",22127.8,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","MLLNCUMT","Million of national currency units","HUN","Hungary","2011","2011",22409.7,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","MLLNCUMT","Million of national currency units","HUN","Hungary","2012","2012",21233.6,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","MLLNCUMT","Million of national currency units","HUN","Hungary","2013","2013",24081.3,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","MLLNCUMT","Million of national currency units","HUN","Hungary","2014","2014",26838.3,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","MLLNCUMT","Million of national currency units","HUN","Hungary","2015","2015",31313.2,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","MLLNCUMT","Million of national currency units","HUN","Hungary","2016","2016",39211.2,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","MLLNCUMT","Million of national currency units","HUN","Hungary","2017","2017",29379.9,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","MLLNCUMT","Million of national currency units","HUN","Hungary","2018","2018",22607.9,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","MLLNCUMT","Million of national currency units","HUN","Hungary","2019","2019",22177.8,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","MLLNCUMT","Million of national currency units","HUN","Hungary","2020","2020",19574.4,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","MLLNCUMT","Million of national currency units","HUN","Hungary","2021","2021",20729.3,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","MLLNCUMT","Million of national currency units","HUN","Hungary","2022","2022",23726.9,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","MTMOTCMT","Million US$ at exchange rate","HUN","Hungary","2010","2010",106.4,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","MTMOTCMT","Million US$ at exchange rate","HUN","Hungary","2011","2011",111.5,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","MTMOTCMT","Million US$ at exchange rate","HUN","Hungary","2012","2012",94.3,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","MTMOTCMT","Million US$ at exchange rate","HUN","Hungary","2013","2013",107.7,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","MTMOTCMT","Million US$ at exchange rate","HUN","Hungary","2014","2014",115.4,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","MTMOTCMT","Million US$ at exchange rate","HUN","Hungary","2015","2015",112.1,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","MTMOTCMT","Million US$ at exchange rate","HUN","Hungary","2016","2016",139.3,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","MTMOTCMT","Million US$ at exchange rate","HUN","Hungary","2017","2017",107.1,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","MTMOTCMT","Million US$ at exchange rate","HUN","Hungary","2018","2018",83.7,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","MTMOTCMT","Million US$ at exchange rate","HUN","Hungary","2019","2019",76.3,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","MTMOTCMT","Million US$ at exchange rate","HUN","Hungary","2020","2020",63.6,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","MTMOTCMT","Million US$ at exchange rate","HUN","Hungary","2021","2021",68.4,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","MTMOTCMT","Million US$ at exchange rate","HUN","Hungary","2022","2022",63.7,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","MTMOPPMT","Million US$, purchasing power parity","HUN","Hungary","2010","2010",175,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","MTMOPPMT","Million US$, purchasing power parity","HUN","Hungary","2011","2011",180.3,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","MTMOPPMT","Million US$, purchasing power parity","HUN","Hungary","2012","2012",169,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","MTMOPPMT","Million US$, purchasing power parity","HUN","Hungary","2013","2013",192.7,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","MTMOPPMT","Million US$, purchasing power parity","HUN","Hungary","2014","2014",207.4,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","MTMOPPMT","Million US$, purchasing power parity","HUN","Hungary","2015","2015",236.2,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","MTMOPPMT","Million US$, purchasing power parity","HUN","Hungary","2016","2016",297,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","MTMOPPMT","Million US$, purchasing power parity","HUN","Hungary","2017","2017",216,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","MTMOPPMT","Million US$, purchasing power parity","HUN","Hungary","2018","2018",162.5,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","MTMOPPMT","Million US$, purchasing power parity","HUN","Hungary","2019","2019",157.5,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","MTMOPPMT","Million US$, purchasing power parity","HUN","Hungary","2020","2020",134.7,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","MTMOPPMT","Million US$, purchasing power parity","HUN","Hungary","2021","2021",134,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","MTMOPPMT","Million US$, purchasing power parity","HUN","Hungary","2022","2022",147.2,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","TCPPERMT","/capita, US$ exchange rate","HUN","Hungary","2010","2010",10.6,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","TCPPERMT","/capita, US$ exchange rate","HUN","Hungary","2011","2011",11.2,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","TCPPERMT","/capita, US$ exchange rate","HUN","Hungary","2012","2012",9.5,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","TCPPERMT","/capita, US$ exchange rate","HUN","Hungary","2013","2013",10.9,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","TCPPERMT","/capita, US$ exchange rate","HUN","Hungary","2014","2014",11.7,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","TCPPERMT","/capita, US$ exchange rate","HUN","Hungary","2015","2015",11.4,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","TCPPERMT","/capita, US$ exchange rate","HUN","Hungary","2016","2016",14.2,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","TCPPERMT","/capita, US$ exchange rate","HUN","Hungary","2017","2017",10.9,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","TCPPERMT","/capita, US$ exchange rate","HUN","Hungary","2018","2018",8.6,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","TCPPERMT","/capita, US$ exchange rate","HUN","Hungary","2019","2019",7.8,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","TCPPERMT","/capita, US$ exchange rate","HUN","Hungary","2020","2020",6.5,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","TCPPERMT","/capita, US$ exchange rate","HUN","Hungary","2021","2021",7,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","TCPPERMT","/capita, US$ exchange rate","HUN","Hungary","2022","2022",6.6,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2010","2010",17.5,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2011","2011",18.1,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2012","2012",17,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2013","2013",19.5,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2014","2014",21,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2015","2015",24,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2016","2016",30.3,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2017","2017",22.1,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2018","2018",16.6,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2019","2019",16.1,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2020","2020",13.8,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2021","2021",13.8,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2022","2022",15.2,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","ATCPTTMT","% of total sales","HUN","Hungary","2010","2010",4.4,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","ATCPTTMT","% of total sales","HUN","Hungary","2011","2011",4.3,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","ATCPTTMT","% of total sales","HUN","Hungary","2012","2012",4.8,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","ATCPTTMT","% of total sales","HUN","Hungary","2013","2013",5.6,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","ATCPTTMT","% of total sales","HUN","Hungary","2014","2014",6.1,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","ATCPTTMT","% of total sales","HUN","Hungary","2015","2015",6.7,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","ATCPTTMT","% of total sales","HUN","Hungary","2016","2016",7.9,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","ATCPTTMT","% of total sales","HUN","Hungary","2017","2017",6,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","ATCPTTMT","% of total sales","HUN","Hungary","2018","2018",4.5,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","ATCPTTMT","% of total sales","HUN","Hungary","2019","2019",4.2,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","ATCPTTMT","% of total sales","HUN","Hungary","2020","2020",3.5,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","ATCPTTMT","% of total sales","HUN","Hungary","2021","2021",3.6,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","ATCPTTMT","% of total sales","HUN","Hungary","2022","2022",4,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","MLLNCUMT","Million of national currency units","ISL","Iceland","2010","2010",2185.2,,
+"PATCINFC","J-Antiinfectives for systemic use","MLLNCUMT","Million of national currency units","ISL","Iceland","2011","2011",2615.7,,
+"PATCINFC","J-Antiinfectives for systemic use","MLLNCUMT","Million of national currency units","ISL","Iceland","2012","2012",2794.5,,
+"PATCINFC","J-Antiinfectives for systemic use","MLLNCUMT","Million of national currency units","ISL","Iceland","2013","2013",2618.6,,
+"PATCINFC","J-Antiinfectives for systemic use","MLLNCUMT","Million of national currency units","ISL","Iceland","2014","2014",2663.1,,
+"PATCINFC","J-Antiinfectives for systemic use","MLLNCUMT","Million of national currency units","ISL","Iceland","2015","2015",2857.9,,
+"PATCINFC","J-Antiinfectives for systemic use","MLLNCUMT","Million of national currency units","ISL","Iceland","2016","2016",3055.4,,
+"PATCINFC","J-Antiinfectives for systemic use","MLLNCUMT","Million of national currency units","ISL","Iceland","2017","2017",3067.9,,
+"PATCINFC","J-Antiinfectives for systemic use","MLLNCUMT","Million of national currency units","ISL","Iceland","2018","2018",3463.7,,
+"PATCINFC","J-Antiinfectives for systemic use","MLLNCUMT","Million of national currency units","ISL","Iceland","2019","2019",4032.8,,
+"PATCINFC","J-Antiinfectives for systemic use","MLLNCUMT","Million of national currency units","ISL","Iceland","2020","2020",4515.4,,
+"PATCINFC","J-Antiinfectives for systemic use","MLLNCUMT","Million of national currency units","ISL","Iceland","2021","2021",5216.7,,
+"PATCINFC","J-Antiinfectives for systemic use","MTMOTCMT","Million US$ at exchange rate","ISL","Iceland","2010","2010",17.9,,
+"PATCINFC","J-Antiinfectives for systemic use","MTMOTCMT","Million US$ at exchange rate","ISL","Iceland","2011","2011",22.6,,
+"PATCINFC","J-Antiinfectives for systemic use","MTMOTCMT","Million US$ at exchange rate","ISL","Iceland","2012","2012",22.3,,
+"PATCINFC","J-Antiinfectives for systemic use","MTMOTCMT","Million US$ at exchange rate","ISL","Iceland","2013","2013",21.4,,
+"PATCINFC","J-Antiinfectives for systemic use","MTMOTCMT","Million US$ at exchange rate","ISL","Iceland","2014","2014",22.8,,
+"PATCINFC","J-Antiinfectives for systemic use","MTMOTCMT","Million US$ at exchange rate","ISL","Iceland","2015","2015",21.7,,
+"PATCINFC","J-Antiinfectives for systemic use","MTMOTCMT","Million US$ at exchange rate","ISL","Iceland","2016","2016",25.3,,
+"PATCINFC","J-Antiinfectives for systemic use","MTMOTCMT","Million US$ at exchange rate","ISL","Iceland","2017","2017",28.7,,
+"PATCINFC","J-Antiinfectives for systemic use","MTMOTCMT","Million US$ at exchange rate","ISL","Iceland","2018","2018",32,,
+"PATCINFC","J-Antiinfectives for systemic use","MTMOTCMT","Million US$ at exchange rate","ISL","Iceland","2019","2019",32.9,,
+"PATCINFC","J-Antiinfectives for systemic use","MTMOTCMT","Million US$ at exchange rate","ISL","Iceland","2020","2020",33.3,,
+"PATCINFC","J-Antiinfectives for systemic use","MTMOTCMT","Million US$ at exchange rate","ISL","Iceland","2021","2021",41.1,,
+"PATCINFC","J-Antiinfectives for systemic use","MTMOPPMT","Million US$, purchasing power parity","ISL","Iceland","2010","2010",16.4,,
+"PATCINFC","J-Antiinfectives for systemic use","MTMOPPMT","Million US$, purchasing power parity","ISL","Iceland","2011","2011",19.4,,
+"PATCINFC","J-Antiinfectives for systemic use","MTMOPPMT","Million US$, purchasing power parity","ISL","Iceland","2012","2012",20.4,,
+"PATCINFC","J-Antiinfectives for systemic use","MTMOPPMT","Million US$, purchasing power parity","ISL","Iceland","2013","2013",19.1,,
+"PATCINFC","J-Antiinfectives for systemic use","MTMOPPMT","Million US$, purchasing power parity","ISL","Iceland","2014","2014",19.2,,
+"PATCINFC","J-Antiinfectives for systemic use","MTMOPPMT","Million US$, purchasing power parity","ISL","Iceland","2015","2015",20.1,,
+"PATCINFC","J-Antiinfectives for systemic use","MTMOPPMT","Million US$, purchasing power parity","ISL","Iceland","2016","2016",21.8,,
+"PATCINFC","J-Antiinfectives for systemic use","MTMOPPMT","Million US$, purchasing power parity","ISL","Iceland","2017","2017",22.2,,
+"PATCINFC","J-Antiinfectives for systemic use","MTMOPPMT","Million US$, purchasing power parity","ISL","Iceland","2018","2018",24.6,,
+"PATCINFC","J-Antiinfectives for systemic use","MTMOPPMT","Million US$, purchasing power parity","ISL","Iceland","2019","2019",28.7,,
+"PATCINFC","J-Antiinfectives for systemic use","MTMOPPMT","Million US$, purchasing power parity","ISL","Iceland","2020","2020",30.8,,
+"PATCINFC","J-Antiinfectives for systemic use","MTMOPPMT","Million US$, purchasing power parity","ISL","Iceland","2021","2021",34.9,,
+"PATCINFC","J-Antiinfectives for systemic use","TCPPERMT","/capita, US$ exchange rate","ISL","Iceland","2010","2010",56.2,,
+"PATCINFC","J-Antiinfectives for systemic use","TCPPERMT","/capita, US$ exchange rate","ISL","Iceland","2011","2011",70.7,,
+"PATCINFC","J-Antiinfectives for systemic use","TCPPERMT","/capita, US$ exchange rate","ISL","Iceland","2012","2012",69.7,,
+"PATCINFC","J-Antiinfectives for systemic use","TCPPERMT","/capita, US$ exchange rate","ISL","Iceland","2013","2013",66.2,,
+"PATCINFC","J-Antiinfectives for systemic use","TCPPERMT","/capita, US$ exchange rate","ISL","Iceland","2014","2014",69.7,,
+"PATCINFC","J-Antiinfectives for systemic use","TCPPERMT","/capita, US$ exchange rate","ISL","Iceland","2015","2015",65.5,,
+"PATCINFC","J-Antiinfectives for systemic use","TCPPERMT","/capita, US$ exchange rate","ISL","Iceland","2016","2016",75.4,,
+"PATCINFC","J-Antiinfectives for systemic use","TCPPERMT","/capita, US$ exchange rate","ISL","Iceland","2017","2017",83.6,,
+"PATCINFC","J-Antiinfectives for systemic use","TCPPERMT","/capita, US$ exchange rate","ISL","Iceland","2018","2018",90.7,,
+"PATCINFC","J-Antiinfectives for systemic use","TCPPERMT","/capita, US$ exchange rate","ISL","Iceland","2019","2019",91.2,,
+"PATCINFC","J-Antiinfectives for systemic use","TCPPERMT","/capita, US$ exchange rate","ISL","Iceland","2020","2020",91,,
+"PATCINFC","J-Antiinfectives for systemic use","TCPPERMT","/capita, US$ exchange rate","ISL","Iceland","2021","2021",110.3,,
+"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2010","2010",51.7,,
+"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2011","2011",60.7,,
+"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2012","2012",63.6,,
+"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2013","2013",59,,
+"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2014","2014",58.7,,
+"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2015","2015",60.8,,
+"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2016","2016",65,,
+"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2017","2017",64.6,,
+"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2018","2018",69.7,,
+"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2019","2019",79.5,,
+"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2020","2020",84,,
+"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2021","2021",93.6,,
+"PATCINFC","J-Antiinfectives for systemic use","ATCPTTMT","% of total sales","ISL","Iceland","2010","2010",8.7,,
+"PATCINFC","J-Antiinfectives for systemic use","ATCPTTMT","% of total sales","ISL","Iceland","2011","2011",10,,
+"PATCINFC","J-Antiinfectives for systemic use","ATCPTTMT","% of total sales","ISL","Iceland","2012","2012",11.5,,
+"PATCINFC","J-Antiinfectives for systemic use","ATCPTTMT","% of total sales","ISL","Iceland","2013","2013",10.1,,
+"PATCINFC","J-Antiinfectives for systemic use","ATCPTTMT","% of total sales","ISL","Iceland","2014","2014",11.2,,
+"PATCINFC","J-Antiinfectives for systemic use","ATCPTTMT","% of total sales","ISL","Iceland","2015","2015",11.7,,
+"PATCINFC","J-Antiinfectives for systemic use","ATCPTTMT","% of total sales","ISL","Iceland","2016","2016",12,,
+"PATCINFC","J-Antiinfectives for systemic use","ATCPTTMT","% of total sales","ISL","Iceland","2017","2017",11.6,,
+"PATCINFC","J-Antiinfectives for systemic use","ATCPTTMT","% of total sales","ISL","Iceland","2018","2018",11.5,,
+"PATCINFC","J-Antiinfectives for systemic use","ATCPTTMT","% of total sales","ISL","Iceland","2019","2019",12,,
+"PATCINFC","J-Antiinfectives for systemic use","ATCPTTMT","% of total sales","ISL","Iceland","2020","2020",11.3,,
+"PATCINFC","J-Antiinfectives for systemic use","ATCPTTMT","% of total sales","ISL","Iceland","2021","2021",11.6,,
+"PATCINFC","J-Antiinfectives for systemic use","MLLNCUMT","Million of national currency units","IRL","Ireland","2010","2010",66.1,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","MLLNCUMT","Million of national currency units","IRL","Ireland","2011","2011",60.3,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","MLLNCUMT","Million of national currency units","IRL","Ireland","2012","2012",69.6,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","MLLNCUMT","Million of national currency units","IRL","Ireland","2013","2013",64.3,"B; D","Break; Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","MLLNCUMT","Million of national currency units","IRL","Ireland","2014","2014",68.5,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","MLLNCUMT","Million of national currency units","IRL","Ireland","2015","2015",89.6,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","MLLNCUMT","Million of national currency units","IRL","Ireland","2016","2016",102.8,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","MLLNCUMT","Million of national currency units","IRL","Ireland","2017","2017",113.6,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","MLLNCUMT","Million of national currency units","IRL","Ireland","2018","2018",122.6,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","MLLNCUMT","Million of national currency units","IRL","Ireland","2019","2019",102.6,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","MLLNCUMT","Million of national currency units","IRL","Ireland","2020","2020",75.4,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","MLLNCUMT","Million of national currency units","IRL","Ireland","2021","2021",77.7,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","MTMOTCMT","Million US$ at exchange rate","IRL","Ireland","2010","2010",87.7,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","MTMOTCMT","Million US$ at exchange rate","IRL","Ireland","2011","2011",83.9,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","MTMOTCMT","Million US$ at exchange rate","IRL","Ireland","2012","2012",89.5,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","MTMOTCMT","Million US$ at exchange rate","IRL","Ireland","2013","2013",85.4,"B; D","Break; Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","MTMOTCMT","Million US$ at exchange rate","IRL","Ireland","2014","2014",91,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","MTMOTCMT","Million US$ at exchange rate","IRL","Ireland","2015","2015",99.5,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","MTMOTCMT","Million US$ at exchange rate","IRL","Ireland","2016","2016",113.8,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","MTMOTCMT","Million US$ at exchange rate","IRL","Ireland","2017","2017",128.3,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","MTMOTCMT","Million US$ at exchange rate","IRL","Ireland","2018","2018",144.7,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","MTMOTCMT","Million US$ at exchange rate","IRL","Ireland","2019","2019",114.9,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","MTMOTCMT","Million US$ at exchange rate","IRL","Ireland","2020","2020",86.1,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","MTMOTCMT","Million US$ at exchange rate","IRL","Ireland","2021","2021",91.8,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","MTMOPPMT","Million US$, purchasing power parity","IRL","Ireland","2010","2010",77.8,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","MTMOPPMT","Million US$, purchasing power parity","IRL","Ireland","2011","2011",72.5,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","MTMOPPMT","Million US$, purchasing power parity","IRL","Ireland","2012","2012",84.6,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","MTMOPPMT","Million US$, purchasing power parity","IRL","Ireland","2013","2013",79.3,"B; D","Break; Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","MTMOPPMT","Million US$, purchasing power parity","IRL","Ireland","2014","2014",83.6,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","MTMOPPMT","Million US$, purchasing power parity","IRL","Ireland","2015","2015",110.7,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","MTMOPPMT","Million US$, purchasing power parity","IRL","Ireland","2016","2016",129.4,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","MTMOPPMT","Million US$, purchasing power parity","IRL","Ireland","2017","2017",143,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","MTMOPPMT","Million US$, purchasing power parity","IRL","Ireland","2018","2018",154.7,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","MTMOPPMT","Million US$, purchasing power parity","IRL","Ireland","2019","2019",127.3,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","MTMOPPMT","Million US$, purchasing power parity","IRL","Ireland","2020","2020",94.7,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","MTMOPPMT","Million US$, purchasing power parity","IRL","Ireland","2021","2021",97.7,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","TCPPERMT","/capita, US$ exchange rate","IRL","Ireland","2010","2010",19.2,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","TCPPERMT","/capita, US$ exchange rate","IRL","Ireland","2011","2011",18.3,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","TCPPERMT","/capita, US$ exchange rate","IRL","Ireland","2012","2012",19.5,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","TCPPERMT","/capita, US$ exchange rate","IRL","Ireland","2013","2013",18.5,"B; D","Break; Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","TCPPERMT","/capita, US$ exchange rate","IRL","Ireland","2014","2014",19.5,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","TCPPERMT","/capita, US$ exchange rate","IRL","Ireland","2015","2015",21.2,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","TCPPERMT","/capita, US$ exchange rate","IRL","Ireland","2016","2016",23.9,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","TCPPERMT","/capita, US$ exchange rate","IRL","Ireland","2017","2017",26.7,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","TCPPERMT","/capita, US$ exchange rate","IRL","Ireland","2018","2018",29.7,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","TCPPERMT","/capita, US$ exchange rate","IRL","Ireland","2019","2019",23.3,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","TCPPERMT","/capita, US$ exchange rate","IRL","Ireland","2020","2020",17.3,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","TCPPERMT","/capita, US$ exchange rate","IRL","Ireland","2021","2021",18.2,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2010","2010",17.1,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2011","2011",15.8,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2012","2012",18.4,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2013","2013",17.2,"B; D","Break; Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2014","2014",18,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2015","2015",23.5,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2016","2016",27.2,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2017","2017",29.7,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2018","2018",31.8,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2019","2019",25.8,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2020","2020",19,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2021","2021",19.4,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","ATCPTTMT","% of total sales","IRL","Ireland","2010","2010",3.2,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","ATCPTTMT","% of total sales","IRL","Ireland","2011","2011",3.1,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","ATCPTTMT","% of total sales","IRL","Ireland","2012","2012",3.4,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","ATCPTTMT","% of total sales","IRL","Ireland","2013","2013",3.3,"B; D","Break; Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","ATCPTTMT","% of total sales","IRL","Ireland","2014","2014",3.6,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","ATCPTTMT","% of total sales","IRL","Ireland","2015","2015",4.5,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","ATCPTTMT","% of total sales","IRL","Ireland","2016","2016",5,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","ATCPTTMT","% of total sales","IRL","Ireland","2017","2017",5.3,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","ATCPTTMT","% of total sales","IRL","Ireland","2018","2018",5.4,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","ATCPTTMT","% of total sales","IRL","Ireland","2019","2019",4.3,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","ATCPTTMT","% of total sales","IRL","Ireland","2020","2020",3.1,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","ATCPTTMT","% of total sales","IRL","Ireland","2021","2021",3,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","MLLNCUMT","Million of national currency units","ITA","Italy","2011","2011",2396.4,,
+"PATCINFC","J-Antiinfectives for systemic use","MLLNCUMT","Million of national currency units","ITA","Italy","2012","2012",2356.5,,
+"PATCINFC","J-Antiinfectives for systemic use","MLLNCUMT","Million of national currency units","ITA","Italy","2013","2013",2435.2,,
+"PATCINFC","J-Antiinfectives for systemic use","MLLNCUMT","Million of national currency units","ITA","Italy","2014","2014",2447.5,,
+"PATCINFC","J-Antiinfectives for systemic use","MLLNCUMT","Million of national currency units","ITA","Italy","2015","2015",4373.6,,
+"PATCINFC","J-Antiinfectives for systemic use","MLLNCUMT","Million of national currency units","ITA","Italy","2016","2016",4413.6,,
+"PATCINFC","J-Antiinfectives for systemic use","MLLNCUMT","Million of national currency units","ITA","Italy","2017","2017",3501.5,,
+"PATCINFC","J-Antiinfectives for systemic use","MLLNCUMT","Million of national currency units","ITA","Italy","2018","2018",2918,,
+"PATCINFC","J-Antiinfectives for systemic use","MLLNCUMT","Million of national currency units","ITA","Italy","2019","2019",2728.3,,
+"PATCINFC","J-Antiinfectives for systemic use","MLLNCUMT","Million of national currency units","ITA","Italy","2020","2020",2478.5,,
+"PATCINFC","J-Antiinfectives for systemic use","MLLNCUMT","Million of national currency units","ITA","Italy","2021","2021",2504,,
+"PATCINFC","J-Antiinfectives for systemic use","MLLNCUMT","Million of national currency units","ITA","Italy","2022","2022",2603.1,"E","Estimated value"
+"PATCINFC","J-Antiinfectives for systemic use","MTMOTCMT","Million US$ at exchange rate","ITA","Italy","2011","2011",3335.7,,
+"PATCINFC","J-Antiinfectives for systemic use","MTMOTCMT","Million US$ at exchange rate","ITA","Italy","2012","2012",3027.7,,
+"PATCINFC","J-Antiinfectives for systemic use","MTMOTCMT","Million US$ at exchange rate","ITA","Italy","2013","2013",3234.2,,
+"PATCINFC","J-Antiinfectives for systemic use","MTMOTCMT","Million US$ at exchange rate","ITA","Italy","2014","2014",3251.5,,
+"PATCINFC","J-Antiinfectives for systemic use","MTMOTCMT","Million US$ at exchange rate","ITA","Italy","2015","2015",4852.6,,
+"PATCINFC","J-Antiinfectives for systemic use","MTMOTCMT","Million US$ at exchange rate","ITA","Italy","2016","2016",4885.4,,
+"PATCINFC","J-Antiinfectives for systemic use","MTMOTCMT","Million US$ at exchange rate","ITA","Italy","2017","2017",3955.6,,
+"PATCINFC","J-Antiinfectives for systemic use","MTMOTCMT","Million US$ at exchange rate","ITA","Italy","2018","2018",3446.1,,
+"PATCINFC","J-Antiinfectives for systemic use","MTMOTCMT","Million US$ at exchange rate","ITA","Italy","2019","2019",3054.2,,
+"PATCINFC","J-Antiinfectives for systemic use","MTMOTCMT","Million US$ at exchange rate","ITA","Italy","2020","2020",2831,,
+"PATCINFC","J-Antiinfectives for systemic use","MTMOTCMT","Million US$ at exchange rate","ITA","Italy","2021","2021",2961.5,,
+"PATCINFC","J-Antiinfectives for systemic use","MTMOTCMT","Million US$ at exchange rate","ITA","Italy","2022","2022",2741.2,"E","Estimated value"
+"PATCINFC","J-Antiinfectives for systemic use","MTMOPPMT","Million US$, purchasing power parity","ITA","Italy","2011","2011",3158.6,,
+"PATCINFC","J-Antiinfectives for systemic use","MTMOPPMT","Million US$, purchasing power parity","ITA","Italy","2012","2012",3151.6,,
+"PATCINFC","J-Antiinfectives for systemic use","MTMOPPMT","Million US$, purchasing power parity","ITA","Italy","2013","2013",3302.9,,
+"PATCINFC","J-Antiinfectives for systemic use","MTMOPPMT","Million US$, purchasing power parity","ITA","Italy","2014","2014",3309,,
+"PATCINFC","J-Antiinfectives for systemic use","MTMOPPMT","Million US$, purchasing power parity","ITA","Italy","2015","2015",5920.7,,
+"PATCINFC","J-Antiinfectives for systemic use","MTMOPPMT","Million US$, purchasing power parity","ITA","Italy","2016","2016",6300.2,,
+"PATCINFC","J-Antiinfectives for systemic use","MTMOPPMT","Million US$, purchasing power parity","ITA","Italy","2017","2017",5075.4,,
+"PATCINFC","J-Antiinfectives for systemic use","MTMOPPMT","Million US$, purchasing power parity","ITA","Italy","2018","2018",4283.6,,
+"PATCINFC","J-Antiinfectives for systemic use","MTMOPPMT","Million US$, purchasing power parity","ITA","Italy","2019","2019",4154.1,,
+"PATCINFC","J-Antiinfectives for systemic use","MTMOPPMT","Million US$, purchasing power parity","ITA","Italy","2020","2020",3826.6,,
+"PATCINFC","J-Antiinfectives for systemic use","MTMOPPMT","Million US$, purchasing power parity","ITA","Italy","2021","2021",3866.9,,
+"PATCINFC","J-Antiinfectives for systemic use","MTMOPPMT","Million US$, purchasing power parity","ITA","Italy","2022","2022",4216.1,"E","Estimated value"
+"PATCINFC","J-Antiinfectives for systemic use","TCPPERMT","/capita, US$ exchange rate","ITA","Italy","2011","2011",56.2,,
+"PATCINFC","J-Antiinfectives for systemic use","TCPPERMT","/capita, US$ exchange rate","ITA","Italy","2012","2012",50.9,,
+"PATCINFC","J-Antiinfectives for systemic use","TCPPERMT","/capita, US$ exchange rate","ITA","Italy","2013","2013",53.7,,
+"PATCINFC","J-Antiinfectives for systemic use","TCPPERMT","/capita, US$ exchange rate","ITA","Italy","2014","2014",53.5,,
+"PATCINFC","J-Antiinfectives for systemic use","TCPPERMT","/capita, US$ exchange rate","ITA","Italy","2015","2015",79.9,,
+"PATCINFC","J-Antiinfectives for systemic use","TCPPERMT","/capita, US$ exchange rate","ITA","Italy","2016","2016",80.6,,
+"PATCINFC","J-Antiinfectives for systemic use","TCPPERMT","/capita, US$ exchange rate","ITA","Italy","2017","2017",65.3,,
+"PATCINFC","J-Antiinfectives for systemic use","TCPPERMT","/capita, US$ exchange rate","ITA","Italy","2018","2018",57,,
+"PATCINFC","J-Antiinfectives for systemic use","TCPPERMT","/capita, US$ exchange rate","ITA","Italy","2019","2019",51.1,,
+"PATCINFC","J-Antiinfectives for systemic use","TCPPERMT","/capita, US$ exchange rate","ITA","Italy","2020","2020",47.6,,
+"PATCINFC","J-Antiinfectives for systemic use","TCPPERMT","/capita, US$ exchange rate","ITA","Italy","2021","2021",50.1,,
+"PATCINFC","J-Antiinfectives for systemic use","TCPPERMT","/capita, US$ exchange rate","ITA","Italy","2022","2022",46.4,"E","Estimated value"
+"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2011","2011",53.2,,
+"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2012","2012",52.9,,
+"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2013","2013",54.8,,
+"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2014","2014",54.4,,
+"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2015","2015",97.5,,
+"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2016","2016",103.9,,
+"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2017","2017",83.8,,
+"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2018","2018",70.9,,
+"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2019","2019",69.5,,
+"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2020","2020",64.4,,
+"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2021","2021",65.4,,
+"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2022","2022",71.4,"E","Estimated value"
+"PATCINFC","J-Antiinfectives for systemic use","ATCPTTMT","% of total sales","ITA","Italy","2011","2011",12.3,,
+"PATCINFC","J-Antiinfectives for systemic use","ATCPTTMT","% of total sales","ITA","Italy","2012","2012",12.4,,
+"PATCINFC","J-Antiinfectives for systemic use","ATCPTTMT","% of total sales","ITA","Italy","2013","2013",12.5,,
+"PATCINFC","J-Antiinfectives for systemic use","ATCPTTMT","% of total sales","ITA","Italy","2014","2014",12.3,,
+"PATCINFC","J-Antiinfectives for systemic use","ATCPTTMT","% of total sales","ITA","Italy","2015","2015",19.3,,
+"PATCINFC","J-Antiinfectives for systemic use","ATCPTTMT","% of total sales","ITA","Italy","2016","2016",19.4,,
+"PATCINFC","J-Antiinfectives for systemic use","ATCPTTMT","% of total sales","ITA","Italy","2017","2017",15.5,,
+"PATCINFC","J-Antiinfectives for systemic use","ATCPTTMT","% of total sales","ITA","Italy","2018","2018",13,,
+"PATCINFC","J-Antiinfectives for systemic use","ATCPTTMT","% of total sales","ITA","Italy","2019","2019",11.9,,
+"PATCINFC","J-Antiinfectives for systemic use","ATCPTTMT","% of total sales","ITA","Italy","2020","2020",10.7,,
+"PATCINFC","J-Antiinfectives for systemic use","ATCPTTMT","% of total sales","ITA","Italy","2021","2021",10.5,,
+"PATCINFC","J-Antiinfectives for systemic use","ATCPTTMT","% of total sales","ITA","Italy","2022","2022",10.5,"E","Estimated value"
+"PATCINFC","J-Antiinfectives for systemic use","MLLNCUMT","Million of national currency units","JPN","Japan","2010","2010",240226,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","MLLNCUMT","Million of national currency units","JPN","Japan","2011","2011",265932,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","MLLNCUMT","Million of national currency units","JPN","Japan","2012","2012",251567,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","MLLNCUMT","Million of national currency units","JPN","Japan","2013","2013",234817,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","MLLNCUMT","Million of national currency units","JPN","Japan","2014","2014",236305,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","MLLNCUMT","Million of national currency units","JPN","Japan","2015","2015",219483,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","MLLNCUMT","Million of national currency units","JPN","Japan","2016","2016",209885,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","MLLNCUMT","Million of national currency units","JPN","Japan","2017","2017",169135,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","MLLNCUMT","Million of national currency units","JPN","Japan","2018","2018",125509,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","MLLNCUMT","Million of national currency units","JPN","Japan","2019","2019",155485,"B; D","Break; Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","MLLNCUMT","Million of national currency units","JPN","Japan","2020","2020",157486,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","MLLNCUMT","Million of national currency units","JPN","Japan","2021","2021",115171,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","MTMOTCMT","Million US$ at exchange rate","JPN","Japan","2010","2010",2736.7,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","MTMOTCMT","Million US$ at exchange rate","JPN","Japan","2011","2011",3332.2,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","MTMOTCMT","Million US$ at exchange rate","JPN","Japan","2012","2012",3152.8,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","MTMOTCMT","Million US$ at exchange rate","JPN","Japan","2013","2013",2406,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","MTMOTCMT","Million US$ at exchange rate","JPN","Japan","2014","2014",2230.5,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","MTMOTCMT","Million US$ at exchange rate","JPN","Japan","2015","2015",1813.2,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","MTMOTCMT","Million US$ at exchange rate","JPN","Japan","2016","2016",1929.2,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","MTMOTCMT","Million US$ at exchange rate","JPN","Japan","2017","2017",1507.9,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","MTMOTCMT","Million US$ at exchange rate","JPN","Japan","2018","2018",1136.6,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","MTMOTCMT","Million US$ at exchange rate","JPN","Japan","2019","2019",1426.3,"B; D","Break; Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","MTMOTCMT","Million US$ at exchange rate","JPN","Japan","2020","2020",1474.9,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","MTMOTCMT","Million US$ at exchange rate","JPN","Japan","2021","2021",1049.4,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","MTMOPPMT","Million US$, purchasing power parity","JPN","Japan","2010","2010",2150.5,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","MTMOPPMT","Million US$, purchasing power parity","JPN","Japan","2011","2011",2474.8,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","MTMOPPMT","Million US$, purchasing power parity","JPN","Japan","2012","2012",2412.6,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","MTMOPPMT","Million US$, purchasing power parity","JPN","Japan","2013","2013",2318,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","MTMOPPMT","Million US$, purchasing power parity","JPN","Japan","2014","2014",2293.1,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","MTMOPPMT","Million US$, purchasing power parity","JPN","Japan","2015","2015",2121.2,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","MTMOPPMT","Million US$, purchasing power parity","JPN","Japan","2016","2016",1989.1,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","MTMOPPMT","Million US$, purchasing power parity","JPN","Japan","2017","2017",1609.2,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","MTMOPPMT","Million US$, purchasing power parity","JPN","Japan","2018","2018",1205,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","MTMOPPMT","Million US$, purchasing power parity","JPN","Japan","2019","2019",1491.8,"B; D","Break; Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","MTMOPPMT","Million US$, purchasing power parity","JPN","Japan","2020","2020",1537.5,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","MTMOPPMT","Million US$, purchasing power parity","JPN","Japan","2021","2021",1128.6,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","TCPPERMT","/capita, US$ exchange rate","JPN","Japan","2010","2010",21.4,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","TCPPERMT","/capita, US$ exchange rate","JPN","Japan","2011","2011",26.1,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","TCPPERMT","/capita, US$ exchange rate","JPN","Japan","2012","2012",24.7,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","TCPPERMT","/capita, US$ exchange rate","JPN","Japan","2013","2013",18.9,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","TCPPERMT","/capita, US$ exchange rate","JPN","Japan","2014","2014",17.5,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","TCPPERMT","/capita, US$ exchange rate","JPN","Japan","2015","2015",14.3,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","TCPPERMT","/capita, US$ exchange rate","JPN","Japan","2016","2016",15.2,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","TCPPERMT","/capita, US$ exchange rate","JPN","Japan","2017","2017",11.9,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","TCPPERMT","/capita, US$ exchange rate","JPN","Japan","2018","2018",9,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","TCPPERMT","/capita, US$ exchange rate","JPN","Japan","2019","2019",11.3,"B; D","Break; Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","TCPPERMT","/capita, US$ exchange rate","JPN","Japan","2020","2020",11.7,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","TCPPERMT","/capita, US$ exchange rate","JPN","Japan","2021","2021",8.4,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","JPN","Japan","2010","2010",16.8,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","JPN","Japan","2011","2011",19.4,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","JPN","Japan","2012","2012",18.9,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","JPN","Japan","2013","2013",18.2,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","JPN","Japan","2014","2014",18,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","JPN","Japan","2015","2015",16.7,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","JPN","Japan","2016","2016",15.7,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","JPN","Japan","2017","2017",12.7,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","JPN","Japan","2018","2018",9.5,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","JPN","Japan","2019","2019",11.8,"B; D","Break; Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","JPN","Japan","2020","2020",12.2,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","JPN","Japan","2021","2021",9,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","ATCPTTMT","% of total sales","JPN","Japan","2010","2010",3.5,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","ATCPTTMT","% of total sales","JPN","Japan","2011","2011",3.8,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","ATCPTTMT","% of total sales","JPN","Japan","2012","2012",3.6,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","ATCPTTMT","% of total sales","JPN","Japan","2013","2013",3.4,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","ATCPTTMT","% of total sales","JPN","Japan","2014","2014",3.6,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","ATCPTTMT","% of total sales","JPN","Japan","2015","2015",3.3,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","ATCPTTMT","% of total sales","JPN","Japan","2016","2016",3.2,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","ATCPTTMT","% of total sales","JPN","Japan","2017","2017",2.5,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","ATCPTTMT","% of total sales","JPN","Japan","2018","2018",1.8,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","ATCPTTMT","% of total sales","JPN","Japan","2019","2019",1.6,"B; D","Break; Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","ATCPTTMT","% of total sales","JPN","Japan","2020","2020",1.7,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","ATCPTTMT","% of total sales","JPN","Japan","2021","2021",1.3,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","MLLNCUMT","Million of national currency units","KOR","Korea","2010","2010",2549474,,
+"PATCINFC","J-Antiinfectives for systemic use","MLLNCUMT","Million of national currency units","KOR","Korea","2011","2011",2880536.3,"B","Break"
+"PATCINFC","J-Antiinfectives for systemic use","MLLNCUMT","Million of national currency units","KOR","Korea","2012","2012",2716710.7,,
+"PATCINFC","J-Antiinfectives for systemic use","MLLNCUMT","Million of national currency units","KOR","Korea","2013","2013",2795930.8,,
+"PATCINFC","J-Antiinfectives for systemic use","MLLNCUMT","Million of national currency units","KOR","Korea","2014","2014",2840189.7,,
+"PATCINFC","J-Antiinfectives for systemic use","MLLNCUMT","Million of national currency units","KOR","Korea","2015","2015",2908070.1,,
+"PATCINFC","J-Antiinfectives for systemic use","MLLNCUMT","Million of national currency units","KOR","Korea","2016","2016",3044109.3,"B","Break"
+"PATCINFC","J-Antiinfectives for systemic use","MLLNCUMT","Million of national currency units","KOR","Korea","2017","2017",3072355.8,,
+"PATCINFC","J-Antiinfectives for systemic use","MLLNCUMT","Million of national currency units","KOR","Korea","2018","2018",3031844.1,,
+"PATCINFC","J-Antiinfectives for systemic use","MLLNCUMT","Million of national currency units","KOR","Korea","2019","2019",3112659.4,,
+"PATCINFC","J-Antiinfectives for systemic use","MLLNCUMT","Million of national currency units","KOR","Korea","2020","2020",3021018.1,,
+"PATCINFC","J-Antiinfectives for systemic use","MLLNCUMT","Million of national currency units","KOR","Korea","2021","2021",2889419.2,,
+"PATCINFC","J-Antiinfectives for systemic use","MTMOTCMT","Million US$ at exchange rate","KOR","Korea","2010","2010",2204.6,,
+"PATCINFC","J-Antiinfectives for systemic use","MTMOTCMT","Million US$ at exchange rate","KOR","Korea","2011","2011",2599.2,"B","Break"
+"PATCINFC","J-Antiinfectives for systemic use","MTMOTCMT","Million US$ at exchange rate","KOR","Korea","2012","2012",2411,,
+"PATCINFC","J-Antiinfectives for systemic use","MTMOTCMT","Million US$ at exchange rate","KOR","Korea","2013","2013",2553.4,,
+"PATCINFC","J-Antiinfectives for systemic use","MTMOTCMT","Million US$ at exchange rate","KOR","Korea","2014","2014",2697.6,,
+"PATCINFC","J-Antiinfectives for systemic use","MTMOTCMT","Million US$ at exchange rate","KOR","Korea","2015","2015",2571.3,,
+"PATCINFC","J-Antiinfectives for systemic use","MTMOTCMT","Million US$ at exchange rate","KOR","Korea","2016","2016",2622.5,"B","Break"
+"PATCINFC","J-Antiinfectives for systemic use","MTMOTCMT","Million US$ at exchange rate","KOR","Korea","2017","2017",2716.5,,
+"PATCINFC","J-Antiinfectives for systemic use","MTMOTCMT","Million US$ at exchange rate","KOR","Korea","2018","2018",2755.8,,
+"PATCINFC","J-Antiinfectives for systemic use","MTMOTCMT","Million US$ at exchange rate","KOR","Korea","2019","2019",2671,,
+"PATCINFC","J-Antiinfectives for systemic use","MTMOTCMT","Million US$ at exchange rate","KOR","Korea","2020","2020",2559.6,,
+"PATCINFC","J-Antiinfectives for systemic use","MTMOTCMT","Million US$ at exchange rate","KOR","Korea","2021","2021",2525.8,,
+"PATCINFC","J-Antiinfectives for systemic use","MTMOPPMT","Million US$, purchasing power parity","KOR","Korea","2010","2010",3031.5,,
+"PATCINFC","J-Antiinfectives for systemic use","MTMOPPMT","Million US$, purchasing power parity","KOR","Korea","2011","2011",3370.7,"B","Break"
+"PATCINFC","J-Antiinfectives for systemic use","MTMOPPMT","Million US$, purchasing power parity","KOR","Korea","2012","2012",3177.9,,
+"PATCINFC","J-Antiinfectives for systemic use","MTMOPPMT","Million US$, purchasing power parity","KOR","Korea","2013","2013",3217.1,,
+"PATCINFC","J-Antiinfectives for systemic use","MTMOPPMT","Million US$, purchasing power parity","KOR","Korea","2014","2014",3257.6,,
+"PATCINFC","J-Antiinfectives for systemic use","MTMOPPMT","Million US$, purchasing power parity","KOR","Korea","2015","2015",3391.4,,
+"PATCINFC","J-Antiinfectives for systemic use","MTMOPPMT","Million US$, purchasing power parity","KOR","Korea","2016","2016",3544.6,"B","Break"
+"PATCINFC","J-Antiinfectives for systemic use","MTMOPPMT","Million US$, purchasing power parity","KOR","Korea","2017","2017",3520.8,,
+"PATCINFC","J-Antiinfectives for systemic use","MTMOPPMT","Million US$, purchasing power parity","KOR","Korea","2018","2018",3546.5,,
+"PATCINFC","J-Antiinfectives for systemic use","MTMOPPMT","Million US$, purchasing power parity","KOR","Korea","2019","2019",3634.5,,
+"PATCINFC","J-Antiinfectives for systemic use","MTMOPPMT","Million US$, purchasing power parity","KOR","Korea","2020","2020",3606.4,,
+"PATCINFC","J-Antiinfectives for systemic use","MTMOPPMT","Million US$, purchasing power parity","KOR","Korea","2021","2021",3383,,
+"PATCINFC","J-Antiinfectives for systemic use","TCPPERMT","/capita, US$ exchange rate","KOR","Korea","2010","2010",44.5,,
+"PATCINFC","J-Antiinfectives for systemic use","TCPPERMT","/capita, US$ exchange rate","KOR","Korea","2011","2011",52.1,"B","Break"
+"PATCINFC","J-Antiinfectives for systemic use","TCPPERMT","/capita, US$ exchange rate","KOR","Korea","2012","2012",48,,
+"PATCINFC","J-Antiinfectives for systemic use","TCPPERMT","/capita, US$ exchange rate","KOR","Korea","2013","2013",50.6,,
+"PATCINFC","J-Antiinfectives for systemic use","TCPPERMT","/capita, US$ exchange rate","KOR","Korea","2014","2014",53.2,,
+"PATCINFC","J-Antiinfectives for systemic use","TCPPERMT","/capita, US$ exchange rate","KOR","Korea","2015","2015",50.4,,
+"PATCINFC","J-Antiinfectives for systemic use","TCPPERMT","/capita, US$ exchange rate","KOR","Korea","2016","2016",51.2,"B","Break"
+"PATCINFC","J-Antiinfectives for systemic use","TCPPERMT","/capita, US$ exchange rate","KOR","Korea","2017","2017",52.9,,
+"PATCINFC","J-Antiinfectives for systemic use","TCPPERMT","/capita, US$ exchange rate","KOR","Korea","2018","2018",53.4,,
+"PATCINFC","J-Antiinfectives for systemic use","TCPPERMT","/capita, US$ exchange rate","KOR","Korea","2019","2019",51.6,,
+"PATCINFC","J-Antiinfectives for systemic use","TCPPERMT","/capita, US$ exchange rate","KOR","Korea","2020","2020",49.4,,
+"PATCINFC","J-Antiinfectives for systemic use","TCPPERMT","/capita, US$ exchange rate","KOR","Korea","2021","2021",48.8,,
+"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2010","2010",61.2,,
+"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2011","2011",67.5,"B","Break"
+"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2012","2012",63.3,,
+"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2013","2013",63.8,,
+"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2014","2014",64.2,,
+"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2015","2015",66.5,,
+"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2016","2016",69.2,"B","Break"
+"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2017","2017",68.5,,
+"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2018","2018",68.8,,
+"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2019","2019",70.2,,
+"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2020","2020",69.6,,
+"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2021","2021",65.4,,
+"PATCINFC","J-Antiinfectives for systemic use","ATCPTTMT","% of total sales","KOR","Korea","2010","2010",12.5,,
+"PATCINFC","J-Antiinfectives for systemic use","ATCPTTMT","% of total sales","KOR","Korea","2011","2011",13.1,"B","Break"
+"PATCINFC","J-Antiinfectives for systemic use","ATCPTTMT","% of total sales","KOR","Korea","2012","2012",12.5,,
+"PATCINFC","J-Antiinfectives for systemic use","ATCPTTMT","% of total sales","KOR","Korea","2013","2013",12.4,,
+"PATCINFC","J-Antiinfectives for systemic use","ATCPTTMT","% of total sales","KOR","Korea","2014","2014",12,,
+"PATCINFC","J-Antiinfectives for systemic use","ATCPTTMT","% of total sales","KOR","Korea","2015","2015",11.8,,
+"PATCINFC","J-Antiinfectives for systemic use","ATCPTTMT","% of total sales","KOR","Korea","2016","2016",12,"B","Break"
+"PATCINFC","J-Antiinfectives for systemic use","ATCPTTMT","% of total sales","KOR","Korea","2017","2017",11.4,,
+"PATCINFC","J-Antiinfectives for systemic use","ATCPTTMT","% of total sales","KOR","Korea","2018","2018",10.5,,
+"PATCINFC","J-Antiinfectives for systemic use","ATCPTTMT","% of total sales","KOR","Korea","2019","2019",10,,
+"PATCINFC","J-Antiinfectives for systemic use","ATCPTTMT","% of total sales","KOR","Korea","2020","2020",9.3,,
+"PATCINFC","J-Antiinfectives for systemic use","ATCPTTMT","% of total sales","KOR","Korea","2021","2021",8.3,,
+"PATCINFC","J-Antiinfectives for systemic use","MLLNCUMT","Million of national currency units","LUX","Luxembourg","2010","2010",10.7,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","MLLNCUMT","Million of national currency units","LUX","Luxembourg","2011","2011",10.6,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","MLLNCUMT","Million of national currency units","LUX","Luxembourg","2012","2012",11.1,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","MLLNCUMT","Million of national currency units","LUX","Luxembourg","2013","2013",10.4,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","MLLNCUMT","Million of national currency units","LUX","Luxembourg","2014","2014",9.4,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","MLLNCUMT","Million of national currency units","LUX","Luxembourg","2015","2015",9.4,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","MLLNCUMT","Million of national currency units","LUX","Luxembourg","2016","2016",9,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","MLLNCUMT","Million of national currency units","LUX","Luxembourg","2017","2017",8.9,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","MLLNCUMT","Million of national currency units","LUX","Luxembourg","2018","2018",9.9,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","MLLNCUMT","Million of national currency units","LUX","Luxembourg","2019","2019",9.5,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","MLLNCUMT","Million of national currency units","LUX","Luxembourg","2020","2020",9.5,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","MLLNCUMT","Million of national currency units","LUX","Luxembourg","2021","2021",14.8,"B; D; P","Break; Difference in methodology; Provisional value"
+"PATCINFC","J-Antiinfectives for systemic use","MLLNCUMT","Million of national currency units","LUX","Luxembourg","2022","2022",16.7,"D; P","Difference in methodology; Provisional value"
+"PATCINFC","J-Antiinfectives for systemic use","MTMOTCMT","Million US$ at exchange rate","LUX","Luxembourg","2010","2010",14.1,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","MTMOTCMT","Million US$ at exchange rate","LUX","Luxembourg","2011","2011",14.8,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","MTMOTCMT","Million US$ at exchange rate","LUX","Luxembourg","2012","2012",14.2,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","MTMOTCMT","Million US$ at exchange rate","LUX","Luxembourg","2013","2013",13.9,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","MTMOTCMT","Million US$ at exchange rate","LUX","Luxembourg","2014","2014",12.5,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","MTMOTCMT","Million US$ at exchange rate","LUX","Luxembourg","2015","2015",10.4,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","MTMOTCMT","Million US$ at exchange rate","LUX","Luxembourg","2016","2016",10,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","MTMOTCMT","Million US$ at exchange rate","LUX","Luxembourg","2017","2017",10,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","MTMOTCMT","Million US$ at exchange rate","LUX","Luxembourg","2018","2018",11.7,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","MTMOTCMT","Million US$ at exchange rate","LUX","Luxembourg","2019","2019",10.7,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","MTMOTCMT","Million US$ at exchange rate","LUX","Luxembourg","2020","2020",10.8,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","MTMOTCMT","Million US$ at exchange rate","LUX","Luxembourg","2021","2021",17.5,"B; D; P","Break; Difference in methodology; Provisional value"
+"PATCINFC","J-Antiinfectives for systemic use","MTMOTCMT","Million US$ at exchange rate","LUX","Luxembourg","2022","2022",17.6,"D; P","Difference in methodology; Provisional value"
+"PATCINFC","J-Antiinfectives for systemic use","MTMOPPMT","Million US$, purchasing power parity","LUX","Luxembourg","2010","2010",11.5,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","MTMOPPMT","Million US$, purchasing power parity","LUX","Luxembourg","2011","2011",11.7,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","MTMOPPMT","Million US$, purchasing power parity","LUX","Luxembourg","2012","2012",12.2,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","MTMOPPMT","Million US$, purchasing power parity","LUX","Luxembourg","2013","2013",11.7,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","MTMOPPMT","Million US$, purchasing power parity","LUX","Luxembourg","2014","2014",10.7,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","MTMOPPMT","Million US$, purchasing power parity","LUX","Luxembourg","2015","2015",10.6,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","MTMOPPMT","Million US$, purchasing power parity","LUX","Luxembourg","2016","2016",10.6,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","MTMOPPMT","Million US$, purchasing power parity","LUX","Luxembourg","2017","2017",10.4,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","MTMOPPMT","Million US$, purchasing power parity","LUX","Luxembourg","2018","2018",11.7,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","MTMOPPMT","Million US$, purchasing power parity","LUX","Luxembourg","2019","2019",11.3,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","MTMOPPMT","Million US$, purchasing power parity","LUX","Luxembourg","2020","2020",11.1,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","MTMOPPMT","Million US$, purchasing power parity","LUX","Luxembourg","2021","2021",17.3,"B; D; P","Break; Difference in methodology; Provisional value"
+"PATCINFC","J-Antiinfectives for systemic use","MTMOPPMT","Million US$, purchasing power parity","LUX","Luxembourg","2022","2022",20.1,"D; P","Difference in methodology; Provisional value"
+"PATCINFC","J-Antiinfectives for systemic use","TCPPERMT","/capita, US$ exchange rate","LUX","Luxembourg","2010","2010",29.8,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","TCPPERMT","/capita, US$ exchange rate","LUX","Luxembourg","2011","2011",30.6,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","TCPPERMT","/capita, US$ exchange rate","LUX","Luxembourg","2012","2012",28.8,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","TCPPERMT","/capita, US$ exchange rate","LUX","Luxembourg","2013","2013",27.6,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","TCPPERMT","/capita, US$ exchange rate","LUX","Luxembourg","2014","2014",24.6,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","TCPPERMT","/capita, US$ exchange rate","LUX","Luxembourg","2015","2015",20,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","TCPPERMT","/capita, US$ exchange rate","LUX","Luxembourg","2016","2016",19,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","TCPPERMT","/capita, US$ exchange rate","LUX","Luxembourg","2017","2017",18.7,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","TCPPERMT","/capita, US$ exchange rate","LUX","Luxembourg","2018","2018",21.4,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","TCPPERMT","/capita, US$ exchange rate","LUX","Luxembourg","2019","2019",19.2,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","TCPPERMT","/capita, US$ exchange rate","LUX","Luxembourg","2020","2020",19.1,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","TCPPERMT","/capita, US$ exchange rate","LUX","Luxembourg","2021","2021",30.5,"B; D; P","Break; Difference in methodology; Provisional value"
+"PATCINFC","J-Antiinfectives for systemic use","TCPPERMT","/capita, US$ exchange rate","LUX","Luxembourg","2022","2022",30,"D; P","Difference in methodology; Provisional value"
+"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2010","2010",24.3,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2011","2011",24.3,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2012","2012",24.8,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2013","2013",23.2,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2014","2014",20.9,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2015","2015",20.5,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2016","2016",20.1,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2017","2017",19.5,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2018","2018",21.3,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2019","2019",20.3,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2020","2020",19.5,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2021","2021",30,"B; D; P","Break; Difference in methodology; Provisional value"
+"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2022","2022",34.2,"D; P","Difference in methodology; Provisional value"
+"PATCINFC","J-Antiinfectives for systemic use","ATCPTTMT","% of total sales","LUX","Luxembourg","2010","2010",5.6,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","ATCPTTMT","% of total sales","LUX","Luxembourg","2011","2011",5.6,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","ATCPTTMT","% of total sales","LUX","Luxembourg","2012","2012",5.6,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","ATCPTTMT","% of total sales","LUX","Luxembourg","2013","2013",5.4,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","ATCPTTMT","% of total sales","LUX","Luxembourg","2014","2014",4.9,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","ATCPTTMT","% of total sales","LUX","Luxembourg","2015","2015",4.9,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","ATCPTTMT","% of total sales","LUX","Luxembourg","2016","2016",4.6,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","ATCPTTMT","% of total sales","LUX","Luxembourg","2017","2017",4.6,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","ATCPTTMT","% of total sales","LUX","Luxembourg","2018","2018",5,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","ATCPTTMT","% of total sales","LUX","Luxembourg","2019","2019",4.7,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","ATCPTTMT","% of total sales","LUX","Luxembourg","2020","2020",4.5,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","ATCPTTMT","% of total sales","LUX","Luxembourg","2021","2021",6.2,"B; D; P","Break; Difference in methodology; Provisional value"
+"PATCINFC","J-Antiinfectives for systemic use","ATCPTTMT","% of total sales","LUX","Luxembourg","2022","2022",6.5,"D; P","Difference in methodology; Provisional value"
+"PATCINFC","J-Antiinfectives for systemic use","MLLNCUMT","Million of national currency units","MEX","Mexico","2010","2010",7478,,
+"PATCINFC","J-Antiinfectives for systemic use","MLLNCUMT","Million of national currency units","MEX","Mexico","2011","2011",7936,,
+"PATCINFC","J-Antiinfectives for systemic use","MLLNCUMT","Million of national currency units","MEX","Mexico","2012","2012",12173,,
+"PATCINFC","J-Antiinfectives for systemic use","MLLNCUMT","Million of national currency units","MEX","Mexico","2013","2013",18213,,
+"PATCINFC","J-Antiinfectives for systemic use","MLLNCUMT","Million of national currency units","MEX","Mexico","2014","2014",17720,,
+"PATCINFC","J-Antiinfectives for systemic use","MLLNCUMT","Million of national currency units","MEX","Mexico","2015","2015",19023,,
+"PATCINFC","J-Antiinfectives for systemic use","MLLNCUMT","Million of national currency units","MEX","Mexico","2016","2016",20942,,
+"PATCINFC","J-Antiinfectives for systemic use","MLLNCUMT","Million of national currency units","MEX","Mexico","2017","2017",22564,,
+"PATCINFC","J-Antiinfectives for systemic use","MLLNCUMT","Million of national currency units","MEX","Mexico","2018","2018",23071,,
+"PATCINFC","J-Antiinfectives for systemic use","MLLNCUMT","Million of national currency units","MEX","Mexico","2019","2019",22621,,
+"PATCINFC","J-Antiinfectives for systemic use","MLLNCUMT","Million of national currency units","MEX","Mexico","2020","2020",24725.7,,
+"PATCINFC","J-Antiinfectives for systemic use","MLLNCUMT","Million of national currency units","MEX","Mexico","2021","2021",22990.8,,
+"PATCINFC","J-Antiinfectives for systemic use","MLLNCUMT","Million of national currency units","MEX","Mexico","2022","2022",23059.8,"E","Estimated value"
+"PATCINFC","J-Antiinfectives for systemic use","MTMOTCMT","Million US$ at exchange rate","MEX","Mexico","2010","2010",591.8,,
+"PATCINFC","J-Antiinfectives for systemic use","MTMOTCMT","Million US$ at exchange rate","MEX","Mexico","2011","2011",638.8,,
+"PATCINFC","J-Antiinfectives for systemic use","MTMOTCMT","Million US$ at exchange rate","MEX","Mexico","2012","2012",924.3,,
+"PATCINFC","J-Antiinfectives for systemic use","MTMOTCMT","Million US$ at exchange rate","MEX","Mexico","2013","2013",1426,,
+"PATCINFC","J-Antiinfectives for systemic use","MTMOTCMT","Million US$ at exchange rate","MEX","Mexico","2014","2014",1333.1,,
+"PATCINFC","J-Antiinfectives for systemic use","MTMOTCMT","Million US$ at exchange rate","MEX","Mexico","2015","2015",1200.3,,
+"PATCINFC","J-Antiinfectives for systemic use","MTMOTCMT","Million US$ at exchange rate","MEX","Mexico","2016","2016",1122,,
+"PATCINFC","J-Antiinfectives for systemic use","MTMOTCMT","Million US$ at exchange rate","MEX","Mexico","2017","2017",1192.2,,
+"PATCINFC","J-Antiinfectives for systemic use","MTMOTCMT","Million US$ at exchange rate","MEX","Mexico","2018","2018",1198.8,,
+"PATCINFC","J-Antiinfectives for systemic use","MTMOTCMT","Million US$ at exchange rate","MEX","Mexico","2019","2019",1174.3,,
+"PATCINFC","J-Antiinfectives for systemic use","MTMOTCMT","Million US$ at exchange rate","MEX","Mexico","2020","2020",1150.8,,
+"PATCINFC","J-Antiinfectives for systemic use","MTMOTCMT","Million US$ at exchange rate","MEX","Mexico","2021","2021",1134.1,,
+"PATCINFC","J-Antiinfectives for systemic use","MTMOTCMT","Million US$ at exchange rate","MEX","Mexico","2022","2022",1145.7,"E","Estimated value"
+"PATCINFC","J-Antiinfectives for systemic use","MTMOPPMT","Million US$, purchasing power parity","MEX","Mexico","2010","2010",973.7,,
+"PATCINFC","J-Antiinfectives for systemic use","MTMOPPMT","Million US$, purchasing power parity","MEX","Mexico","2011","2011",1034.3,,
+"PATCINFC","J-Antiinfectives for systemic use","MTMOPPMT","Million US$, purchasing power parity","MEX","Mexico","2012","2012",1549,,
+"PATCINFC","J-Antiinfectives for systemic use","MTMOPPMT","Million US$, purchasing power parity","MEX","Mexico","2013","2013",2310,,
+"PATCINFC","J-Antiinfectives for systemic use","MTMOPPMT","Million US$, purchasing power parity","MEX","Mexico","2014","2014",2202.5,,
+"PATCINFC","J-Antiinfectives for systemic use","MTMOPPMT","Million US$, purchasing power parity","MEX","Mexico","2015","2015",2284.3,,
+"PATCINFC","J-Antiinfectives for systemic use","MTMOPPMT","Million US$, purchasing power parity","MEX","Mexico","2016","2016",2479.5,,
+"PATCINFC","J-Antiinfectives for systemic use","MTMOPPMT","Million US$, purchasing power parity","MEX","Mexico","2017","2017",2531.4,,
+"PATCINFC","J-Antiinfectives for systemic use","MTMOPPMT","Million US$, purchasing power parity","MEX","Mexico","2018","2018",2487.1,,
+"PATCINFC","J-Antiinfectives for systemic use","MTMOPPMT","Million US$, purchasing power parity","MEX","Mexico","2019","2019",2340.9,,
+"PATCINFC","J-Antiinfectives for systemic use","MTMOPPMT","Million US$, purchasing power parity","MEX","Mexico","2020","2020",2462.8,,
+"PATCINFC","J-Antiinfectives for systemic use","MTMOPPMT","Million US$, purchasing power parity","MEX","Mexico","2021","2021",2210.3,,
+"PATCINFC","J-Antiinfectives for systemic use","MTMOPPMT","Million US$, purchasing power parity","MEX","Mexico","2022","2022",2180.4,"E","Estimated value"
+"PATCINFC","J-Antiinfectives for systemic use","TCPPERMT","/capita, US$ exchange rate","MEX","Mexico","2010","2010",5.2,,
+"PATCINFC","J-Antiinfectives for systemic use","TCPPERMT","/capita, US$ exchange rate","MEX","Mexico","2011","2011",5.5,,
+"PATCINFC","J-Antiinfectives for systemic use","TCPPERMT","/capita, US$ exchange rate","MEX","Mexico","2012","2012",7.9,,
+"PATCINFC","J-Antiinfectives for systemic use","TCPPERMT","/capita, US$ exchange rate","MEX","Mexico","2013","2013",12,,
+"PATCINFC","J-Antiinfectives for systemic use","TCPPERMT","/capita, US$ exchange rate","MEX","Mexico","2014","2014",11.1,,
+"PATCINFC","J-Antiinfectives for systemic use","TCPPERMT","/capita, US$ exchange rate","MEX","Mexico","2015","2015",9.9,,
+"PATCINFC","J-Antiinfectives for systemic use","TCPPERMT","/capita, US$ exchange rate","MEX","Mexico","2016","2016",9.1,,
+"PATCINFC","J-Antiinfectives for systemic use","TCPPERMT","/capita, US$ exchange rate","MEX","Mexico","2017","2017",9.6,,
+"PATCINFC","J-Antiinfectives for systemic use","TCPPERMT","/capita, US$ exchange rate","MEX","Mexico","2018","2018",9.6,,
+"PATCINFC","J-Antiinfectives for systemic use","TCPPERMT","/capita, US$ exchange rate","MEX","Mexico","2019","2019",9.3,,
+"PATCINFC","J-Antiinfectives for systemic use","TCPPERMT","/capita, US$ exchange rate","MEX","Mexico","2020","2020",9,,
+"PATCINFC","J-Antiinfectives for systemic use","TCPPERMT","/capita, US$ exchange rate","MEX","Mexico","2021","2021",8.8,,
+"PATCINFC","J-Antiinfectives for systemic use","TCPPERMT","/capita, US$ exchange rate","MEX","Mexico","2022","2022",8.8,"E","Estimated value"
+"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","MEX","Mexico","2010","2010",8.6,,
+"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","MEX","Mexico","2011","2011",9,,
+"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","MEX","Mexico","2012","2012",13.2,,
+"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","MEX","Mexico","2013","2013",19.5,,
+"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","MEX","Mexico","2014","2014",18.4,,
+"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","MEX","Mexico","2015","2015",18.8,,
+"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","MEX","Mexico","2016","2016",20.2,,
+"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","MEX","Mexico","2017","2017",20.4,,
+"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","MEX","Mexico","2018","2018",19.8,,
+"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","MEX","Mexico","2019","2019",18.5,,
+"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","MEX","Mexico","2020","2020",19.3,,
+"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","MEX","Mexico","2021","2021",17.1,,
+"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","MEX","Mexico","2022","2022",16.8,"E","Estimated value"
+"PATCINFC","J-Antiinfectives for systemic use","ATCPTTMT","% of total sales","MEX","Mexico","2013","2013",12.8,,
+"PATCINFC","J-Antiinfectives for systemic use","ATCPTTMT","% of total sales","MEX","Mexico","2018","2018",10.1,,
+"PATCINFC","J-Antiinfectives for systemic use","MLLNCUMT","Million of national currency units","NLD","Netherlands","2010","2010",350.8,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","MLLNCUMT","Million of national currency units","NLD","Netherlands","2011","2011",358.2,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","MLLNCUMT","Million of national currency units","NLD","Netherlands","2012","2012",375.5,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","MLLNCUMT","Million of national currency units","NLD","Netherlands","2013","2013",393.7,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","MLLNCUMT","Million of national currency units","NLD","Netherlands","2014","2014",387.7,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","MTMOTCMT","Million US$ at exchange rate","NLD","Netherlands","2010","2010",465.1,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","MTMOTCMT","Million US$ at exchange rate","NLD","Netherlands","2011","2011",498.6,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","MTMOTCMT","Million US$ at exchange rate","NLD","Netherlands","2012","2012",482.5,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","MTMOTCMT","Million US$ at exchange rate","NLD","Netherlands","2013","2013",522.8,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","MTMOTCMT","Million US$ at exchange rate","NLD","Netherlands","2014","2014",515,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","MTMOPPMT","Million US$, purchasing power parity","NLD","Netherlands","2010","2010",410.8,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","MTMOPPMT","Million US$, purchasing power parity","NLD","Netherlands","2011","2011",428.5,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","MTMOPPMT","Million US$, purchasing power parity","NLD","Netherlands","2012","2012",455.5,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","MTMOPPMT","Million US$, purchasing power parity","NLD","Netherlands","2013","2013",493.2,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","MTMOPPMT","Million US$, purchasing power parity","NLD","Netherlands","2014","2014",479.3,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","TCPPERMT","/capita, US$ exchange rate","NLD","Netherlands","2010","2010",28,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","TCPPERMT","/capita, US$ exchange rate","NLD","Netherlands","2011","2011",29.9,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","TCPPERMT","/capita, US$ exchange rate","NLD","Netherlands","2012","2012",28.8,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","TCPPERMT","/capita, US$ exchange rate","NLD","Netherlands","2013","2013",31.1,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","TCPPERMT","/capita, US$ exchange rate","NLD","Netherlands","2014","2014",30.5,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","NLD","Netherlands","2010","2010",24.7,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","NLD","Netherlands","2011","2011",25.7,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","NLD","Netherlands","2012","2012",27.2,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","NLD","Netherlands","2013","2013",29.3,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","NLD","Netherlands","2014","2014",28.4,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","ATCPTTMT","% of total sales","NLD","Netherlands","2010","2010",6.7,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","ATCPTTMT","% of total sales","NLD","Netherlands","2011","2011",6.9,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","ATCPTTMT","% of total sales","NLD","Netherlands","2012","2012",8.1,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","ATCPTTMT","% of total sales","NLD","Netherlands","2013","2013",9.2,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","ATCPTTMT","% of total sales","NLD","Netherlands","2014","2014",9,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","MLLNCUMT","Million of national currency units","NZL","New Zealand","2010","2010",43.2,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","MLLNCUMT","Million of national currency units","NZL","New Zealand","2011","2011",50,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","MLLNCUMT","Million of national currency units","NZL","New Zealand","2012","2012",53.1,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","MLLNCUMT","Million of national currency units","NZL","New Zealand","2013","2013",98.1,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","MLLNCUMT","Million of national currency units","NZL","New Zealand","2014","2014",101.7,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","MLLNCUMT","Million of national currency units","NZL","New Zealand","2015","2015",109.9,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","MLLNCUMT","Million of national currency units","NZL","New Zealand","2016","2016",114.9,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","MLLNCUMT","Million of national currency units","NZL","New Zealand","2017","2017",170.3,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","MLLNCUMT","Million of national currency units","NZL","New Zealand","2018","2018",133.3,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","MLLNCUMT","Million of national currency units","NZL","New Zealand","2019","2019",173.8,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","MLLNCUMT","Million of national currency units","NZL","New Zealand","2020","2020",151.7,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","MLLNCUMT","Million of national currency units","NZL","New Zealand","2021","2021",109.5,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","MLLNCUMT","Million of national currency units","NZL","New Zealand","2022","2022",91.8,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","MTMOTCMT","Million US$ at exchange rate","NZL","New Zealand","2010","2010",31.1,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","MTMOTCMT","Million US$ at exchange rate","NZL","New Zealand","2011","2011",39.5,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","MTMOTCMT","Million US$ at exchange rate","NZL","New Zealand","2012","2012",43.1,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","MTMOTCMT","Million US$ at exchange rate","NZL","New Zealand","2013","2013",80.5,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","MTMOTCMT","Million US$ at exchange rate","NZL","New Zealand","2014","2014",84.4,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","MTMOTCMT","Million US$ at exchange rate","NZL","New Zealand","2015","2015",76.7,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","MTMOTCMT","Million US$ at exchange rate","NZL","New Zealand","2016","2016",80,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","MTMOTCMT","Million US$ at exchange rate","NZL","New Zealand","2017","2017",121,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","MTMOTCMT","Million US$ at exchange rate","NZL","New Zealand","2018","2018",92.3,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","MTMOTCMT","Million US$ at exchange rate","NZL","New Zealand","2019","2019",114.5,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","MTMOTCMT","Million US$ at exchange rate","NZL","New Zealand","2020","2020",98.4,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","MTMOTCMT","Million US$ at exchange rate","NZL","New Zealand","2021","2021",77.5,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","MTMOTCMT","Million US$ at exchange rate","NZL","New Zealand","2022","2022",58.2,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","MTMOPPMT","Million US$, purchasing power parity","NZL","New Zealand","2010","2010",28.8,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","MTMOPPMT","Million US$, purchasing power parity","NZL","New Zealand","2011","2011",33.6,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","MTMOPPMT","Million US$, purchasing power parity","NZL","New Zealand","2012","2012",35.5,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","MTMOPPMT","Million US$, purchasing power parity","NZL","New Zealand","2013","2013",67.9,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","MTMOPPMT","Million US$, purchasing power parity","NZL","New Zealand","2014","2014",70.6,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","MTMOPPMT","Million US$, purchasing power parity","NZL","New Zealand","2015","2015",74.4,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","MTMOPPMT","Million US$, purchasing power parity","NZL","New Zealand","2016","2016",79.8,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","MTMOPPMT","Million US$, purchasing power parity","NZL","New Zealand","2017","2017",119,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","MTMOPPMT","Million US$, purchasing power parity","NZL","New Zealand","2018","2018",90.7,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","MTMOPPMT","Million US$, purchasing power parity","NZL","New Zealand","2019","2019",122.7,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","MTMOPPMT","Million US$, purchasing power parity","NZL","New Zealand","2020","2020",107.3,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","MTMOPPMT","Million US$, purchasing power parity","NZL","New Zealand","2021","2021",75.1,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","MTMOPPMT","Million US$, purchasing power parity","NZL","New Zealand","2022","2022",63.6,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","TCPPERMT","/capita, US$ exchange rate","NZL","New Zealand","2010","2010",7.1,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","TCPPERMT","/capita, US$ exchange rate","NZL","New Zealand","2011","2011",9,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","TCPPERMT","/capita, US$ exchange rate","NZL","New Zealand","2012","2012",9.8,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","TCPPERMT","/capita, US$ exchange rate","NZL","New Zealand","2013","2013",18.1,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","TCPPERMT","/capita, US$ exchange rate","NZL","New Zealand","2014","2014",18.7,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","TCPPERMT","/capita, US$ exchange rate","NZL","New Zealand","2015","2015",16.6,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","TCPPERMT","/capita, US$ exchange rate","NZL","New Zealand","2016","2016",17,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","TCPPERMT","/capita, US$ exchange rate","NZL","New Zealand","2017","2017",25.1,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","TCPPERMT","/capita, US$ exchange rate","NZL","New Zealand","2018","2018",18.8,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","TCPPERMT","/capita, US$ exchange rate","NZL","New Zealand","2019","2019",23,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","TCPPERMT","/capita, US$ exchange rate","NZL","New Zealand","2020","2020",19.3,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","TCPPERMT","/capita, US$ exchange rate","NZL","New Zealand","2021","2021",15.2,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","TCPPERMT","/capita, US$ exchange rate","NZL","New Zealand","2022","2022",11.4,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2010","2010",6.6,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2011","2011",7.7,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2012","2012",8.1,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2013","2013",15.3,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2014","2014",15.6,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2015","2015",16.1,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2016","2016",16.9,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2017","2017",24.7,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2018","2018",18.5,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2019","2019",24.6,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2020","2020",21.1,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2021","2021",14.7,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2022","2022",12.4,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","ATCPTTMT","% of total sales","NZL","New Zealand","2010","2010",5.8,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","ATCPTTMT","% of total sales","NZL","New Zealand","2011","2011",6.1,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","ATCPTTMT","% of total sales","NZL","New Zealand","2012","2012",5.8,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","ATCPTTMT","% of total sales","NZL","New Zealand","2013","2013",10.6,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","ATCPTTMT","% of total sales","NZL","New Zealand","2014","2014",10.6,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","ATCPTTMT","% of total sales","NZL","New Zealand","2015","2015",11.1,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","ATCPTTMT","% of total sales","NZL","New Zealand","2016","2016",10.7,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","ATCPTTMT","% of total sales","NZL","New Zealand","2017","2017",13.5,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","ATCPTTMT","% of total sales","NZL","New Zealand","2018","2018",10.1,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","ATCPTTMT","% of total sales","NZL","New Zealand","2019","2019",11.6,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","ATCPTTMT","% of total sales","NZL","New Zealand","2020","2020",9.2,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","ATCPTTMT","% of total sales","NZL","New Zealand","2021","2021",6.2,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","ATCPTTMT","% of total sales","NZL","New Zealand","2022","2022",4.8,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","MLLNCUMT","Million of national currency units","NOR","Norway","2010","2010",1256,,
+"PATCINFC","J-Antiinfectives for systemic use","MLLNCUMT","Million of national currency units","NOR","Norway","2011","2011",1426,,
+"PATCINFC","J-Antiinfectives for systemic use","MLLNCUMT","Million of national currency units","NOR","Norway","2012","2012",1534,,
+"PATCINFC","J-Antiinfectives for systemic use","MLLNCUMT","Million of national currency units","NOR","Norway","2013","2013",1514,,
+"PATCINFC","J-Antiinfectives for systemic use","MLLNCUMT","Million of national currency units","NOR","Norway","2014","2014",1830,,
+"PATCINFC","J-Antiinfectives for systemic use","MLLNCUMT","Million of national currency units","NOR","Norway","2015","2015",2214,,
+"PATCINFC","J-Antiinfectives for systemic use","MLLNCUMT","Million of national currency units","NOR","Norway","2016","2016",2279,,
+"PATCINFC","J-Antiinfectives for systemic use","MLLNCUMT","Million of national currency units","NOR","Norway","2017","2017",2352,,
+"PATCINFC","J-Antiinfectives for systemic use","MLLNCUMT","Million of national currency units","NOR","Norway","2018","2018",2198,,
+"PATCINFC","J-Antiinfectives for systemic use","MLLNCUMT","Million of national currency units","NOR","Norway","2019","2019",2135,,
+"PATCINFC","J-Antiinfectives for systemic use","MLLNCUMT","Million of national currency units","NOR","Norway","2020","2020",1710,,
+"PATCINFC","J-Antiinfectives for systemic use","MLLNCUMT","Million of national currency units","NOR","Norway","2021","2021",3055,,
+"PATCINFC","J-Antiinfectives for systemic use","MLLNCUMT","Million of national currency units","NOR","Norway","2022","2022",3511,,
+"PATCINFC","J-Antiinfectives for systemic use","MTMOTCMT","Million US$ at exchange rate","NOR","Norway","2010","2010",207.8,,
+"PATCINFC","J-Antiinfectives for systemic use","MTMOTCMT","Million US$ at exchange rate","NOR","Norway","2011","2011",254.4,,
+"PATCINFC","J-Antiinfectives for systemic use","MTMOTCMT","Million US$ at exchange rate","NOR","Norway","2012","2012",263.7,,
+"PATCINFC","J-Antiinfectives for systemic use","MTMOTCMT","Million US$ at exchange rate","NOR","Norway","2013","2013",257.7,,
+"PATCINFC","J-Antiinfectives for systemic use","MTMOTCMT","Million US$ at exchange rate","NOR","Norway","2014","2014",290.4,,
+"PATCINFC","J-Antiinfectives for systemic use","MTMOTCMT","Million US$ at exchange rate","NOR","Norway","2015","2015",274.5,,
+"PATCINFC","J-Antiinfectives for systemic use","MTMOTCMT","Million US$ at exchange rate","NOR","Norway","2016","2016",271.3,,
+"PATCINFC","J-Antiinfectives for systemic use","MTMOTCMT","Million US$ at exchange rate","NOR","Norway","2017","2017",284.3,,
+"PATCINFC","J-Antiinfectives for systemic use","MTMOTCMT","Million US$ at exchange rate","NOR","Norway","2018","2018",270.3,,
+"PATCINFC","J-Antiinfectives for systemic use","MTMOTCMT","Million US$ at exchange rate","NOR","Norway","2019","2019",242.6,,
+"PATCINFC","J-Antiinfectives for systemic use","MTMOTCMT","Million US$ at exchange rate","NOR","Norway","2020","2020",181.6,,
+"PATCINFC","J-Antiinfectives for systemic use","MTMOTCMT","Million US$ at exchange rate","NOR","Norway","2021","2021",355.6,,
+"PATCINFC","J-Antiinfectives for systemic use","MTMOTCMT","Million US$ at exchange rate","NOR","Norway","2022","2022",365.2,,
+"PATCINFC","J-Antiinfectives for systemic use","MTMOPPMT","Million US$, purchasing power parity","NOR","Norway","2010","2010",137.2,,
+"PATCINFC","J-Antiinfectives for systemic use","MTMOPPMT","Million US$, purchasing power parity","NOR","Norway","2011","2011",157,,
+"PATCINFC","J-Antiinfectives for systemic use","MTMOPPMT","Million US$, purchasing power parity","NOR","Norway","2012","2012",169.7,,
+"PATCINFC","J-Antiinfectives for systemic use","MTMOPPMT","Million US$, purchasing power parity","NOR","Norway","2013","2013",167.7,,
+"PATCINFC","J-Antiinfectives for systemic use","MTMOPPMT","Million US$, purchasing power parity","NOR","Norway","2014","2014",197.2,,
+"PATCINFC","J-Antiinfectives for systemic use","MTMOPPMT","Million US$, purchasing power parity","NOR","Norway","2015","2015",222.9,,
+"PATCINFC","J-Antiinfectives for systemic use","MTMOPPMT","Million US$, purchasing power parity","NOR","Norway","2016","2016",226.9,,
+"PATCINFC","J-Antiinfectives for systemic use","MTMOPPMT","Million US$, purchasing power parity","NOR","Norway","2017","2017",241.2,,
+"PATCINFC","J-Antiinfectives for systemic use","MTMOPPMT","Million US$, purchasing power parity","NOR","Norway","2018","2018",229.3,,
+"PATCINFC","J-Antiinfectives for systemic use","MTMOPPMT","Million US$, purchasing power parity","NOR","Norway","2019","2019",221.9,,
+"PATCINFC","J-Antiinfectives for systemic use","MTMOPPMT","Million US$, purchasing power parity","NOR","Norway","2020","2020",173.1,,
+"PATCINFC","J-Antiinfectives for systemic use","MTMOPPMT","Million US$, purchasing power parity","NOR","Norway","2021","2021",321.2,,
+"PATCINFC","J-Antiinfectives for systemic use","MTMOPPMT","Million US$, purchasing power parity","NOR","Norway","2022","2022",326.9,,
+"PATCINFC","J-Antiinfectives for systemic use","TCPPERMT","/capita, US$ exchange rate","NOR","Norway","2010","2010",42.5,,
+"PATCINFC","J-Antiinfectives for systemic use","TCPPERMT","/capita, US$ exchange rate","NOR","Norway","2011","2011",51.4,,
+"PATCINFC","J-Antiinfectives for systemic use","TCPPERMT","/capita, US$ exchange rate","NOR","Norway","2012","2012",52.5,,
+"PATCINFC","J-Antiinfectives for systemic use","TCPPERMT","/capita, US$ exchange rate","NOR","Norway","2013","2013",50.7,,
+"PATCINFC","J-Antiinfectives for systemic use","TCPPERMT","/capita, US$ exchange rate","NOR","Norway","2014","2014",56.5,,
+"PATCINFC","J-Antiinfectives for systemic use","TCPPERMT","/capita, US$ exchange rate","NOR","Norway","2015","2015",52.9,,
+"PATCINFC","J-Antiinfectives for systemic use","TCPPERMT","/capita, US$ exchange rate","NOR","Norway","2016","2016",51.8,,
+"PATCINFC","J-Antiinfectives for systemic use","TCPPERMT","/capita, US$ exchange rate","NOR","Norway","2017","2017",53.9,,
+"PATCINFC","J-Antiinfectives for systemic use","TCPPERMT","/capita, US$ exchange rate","NOR","Norway","2018","2018",50.9,,
+"PATCINFC","J-Antiinfectives for systemic use","TCPPERMT","/capita, US$ exchange rate","NOR","Norway","2019","2019",45.4,,
+"PATCINFC","J-Antiinfectives for systemic use","TCPPERMT","/capita, US$ exchange rate","NOR","Norway","2020","2020",33.8,,
+"PATCINFC","J-Antiinfectives for systemic use","TCPPERMT","/capita, US$ exchange rate","NOR","Norway","2021","2021",65.8,,
+"PATCINFC","J-Antiinfectives for systemic use","TCPPERMT","/capita, US$ exchange rate","NOR","Norway","2022","2022",67.3,,
+"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2010","2010",28.1,,
+"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2011","2011",31.7,,
+"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2012","2012",33.8,,
+"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2013","2013",33,,
+"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2014","2014",38.4,,
+"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2015","2015",43,,
+"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2016","2016",43.4,,
+"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2017","2017",45.7,,
+"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2018","2018",43.2,,
+"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2019","2019",41.5,,
+"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2020","2020",32.2,,
+"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2021","2021",59.4,,
+"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2022","2022",60.3,,
+"PATCINFC","J-Antiinfectives for systemic use","ATCPTTMT","% of total sales","NOR","Norway","2010","2010",7,,
+"PATCINFC","J-Antiinfectives for systemic use","ATCPTTMT","% of total sales","NOR","Norway","2011","2011",7.8,,
+"PATCINFC","J-Antiinfectives for systemic use","ATCPTTMT","% of total sales","NOR","Norway","2012","2012",8.2,,
+"PATCINFC","J-Antiinfectives for systemic use","ATCPTTMT","% of total sales","NOR","Norway","2013","2013",7.8,,
+"PATCINFC","J-Antiinfectives for systemic use","ATCPTTMT","% of total sales","NOR","Norway","2014","2014",8.7,,
+"PATCINFC","J-Antiinfectives for systemic use","ATCPTTMT","% of total sales","NOR","Norway","2015","2015",9.7,,
+"PATCINFC","J-Antiinfectives for systemic use","ATCPTTMT","% of total sales","NOR","Norway","2016","2016",9.2,,
+"PATCINFC","J-Antiinfectives for systemic use","ATCPTTMT","% of total sales","NOR","Norway","2017","2017",8.8,,
+"PATCINFC","J-Antiinfectives for systemic use","ATCPTTMT","% of total sales","NOR","Norway","2018","2018",8,,
+"PATCINFC","J-Antiinfectives for systemic use","ATCPTTMT","% of total sales","NOR","Norway","2019","2019",7.5,,
+"PATCINFC","J-Antiinfectives for systemic use","ATCPTTMT","% of total sales","NOR","Norway","2020","2020",5.8,,
+"PATCINFC","J-Antiinfectives for systemic use","ATCPTTMT","% of total sales","NOR","Norway","2021","2021",9.1,,
+"PATCINFC","J-Antiinfectives for systemic use","ATCPTTMT","% of total sales","NOR","Norway","2022","2022",9.8,,
+"PATCINFC","J-Antiinfectives for systemic use","MLLNCUMT","Million of national currency units","PRT","Portugal","2010","2010",182.1,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","MLLNCUMT","Million of national currency units","PRT","Portugal","2011","2011",163.6,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","MLLNCUMT","Million of national currency units","PRT","Portugal","2012","2012",130,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","MLLNCUMT","Million of national currency units","PRT","Portugal","2013","2013",116.1,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","MLLNCUMT","Million of national currency units","PRT","Portugal","2014","2014",119,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","MLLNCUMT","Million of national currency units","PRT","Portugal","2015","2015",133.5,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","MLLNCUMT","Million of national currency units","PRT","Portugal","2016","2016",118.1,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","MLLNCUMT","Million of national currency units","PRT","Portugal","2017","2017",116.6,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","MLLNCUMT","Million of national currency units","PRT","Portugal","2018","2018",121.4,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","MLLNCUMT","Million of national currency units","PRT","Portugal","2019","2019",129.7,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","MLLNCUMT","Million of national currency units","PRT","Portugal","2020","2020",121.3,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","MLLNCUMT","Million of national currency units","PRT","Portugal","2021","2021",103.5,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","MLLNCUMT","Million of national currency units","PRT","Portugal","2022","2022",118.8,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","MTMOTCMT","Million US$ at exchange rate","PRT","Portugal","2010","2010",241.5,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","MTMOTCMT","Million US$ at exchange rate","PRT","Portugal","2011","2011",227.7,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","MTMOTCMT","Million US$ at exchange rate","PRT","Portugal","2012","2012",167,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","MTMOTCMT","Million US$ at exchange rate","PRT","Portugal","2013","2013",154.2,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","MTMOTCMT","Million US$ at exchange rate","PRT","Portugal","2014","2014",158.1,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","MTMOTCMT","Million US$ at exchange rate","PRT","Portugal","2015","2015",148.1,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","MTMOTCMT","Million US$ at exchange rate","PRT","Portugal","2016","2016",130.7,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","MTMOTCMT","Million US$ at exchange rate","PRT","Portugal","2017","2017",131.8,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","MTMOTCMT","Million US$ at exchange rate","PRT","Portugal","2018","2018",143.3,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","MTMOTCMT","Million US$ at exchange rate","PRT","Portugal","2019","2019",145.2,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","MTMOTCMT","Million US$ at exchange rate","PRT","Portugal","2020","2020",138.6,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","MTMOTCMT","Million US$ at exchange rate","PRT","Portugal","2021","2021",122.4,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","MTMOTCMT","Million US$ at exchange rate","PRT","Portugal","2022","2022",125.1,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","MTMOPPMT","Million US$, purchasing power parity","PRT","Portugal","2010","2010",292.3,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","MTMOPPMT","Million US$, purchasing power parity","PRT","Portugal","2011","2011",262.5,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","MTMOPPMT","Million US$, purchasing power parity","PRT","Portugal","2012","2012",214.7,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","MTMOPPMT","Million US$, purchasing power parity","PRT","Portugal","2013","2013",198.9,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","MTMOPPMT","Million US$, purchasing power parity","PRT","Portugal","2014","2014",205.6,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","MTMOPPMT","Million US$, purchasing power parity","PRT","Portugal","2015","2015",228.3,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","MTMOPPMT","Million US$, purchasing power parity","PRT","Portugal","2016","2016",206.6,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","MTMOPPMT","Million US$, purchasing power parity","PRT","Portugal","2017","2017",202.6,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","MTMOPPMT","Million US$, purchasing power parity","PRT","Portugal","2018","2018",212.4,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","MTMOPPMT","Million US$, purchasing power parity","PRT","Portugal","2019","2019",232.1,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","MTMOPPMT","Million US$, purchasing power parity","PRT","Portugal","2020","2020",217.8,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","MTMOPPMT","Million US$, purchasing power parity","PRT","Portugal","2021","2021",182.3,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","MTMOPPMT","Million US$, purchasing power parity","PRT","Portugal","2022","2022",215.9,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","TCPPERMT","/capita, US$ exchange rate","PRT","Portugal","2010","2010",22.8,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","TCPPERMT","/capita, US$ exchange rate","PRT","Portugal","2011","2011",21.6,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","TCPPERMT","/capita, US$ exchange rate","PRT","Portugal","2012","2012",15.9,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","TCPPERMT","/capita, US$ exchange rate","PRT","Portugal","2013","2013",14.7,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","TCPPERMT","/capita, US$ exchange rate","PRT","Portugal","2014","2014",15.2,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","TCPPERMT","/capita, US$ exchange rate","PRT","Portugal","2015","2015",14.3,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","TCPPERMT","/capita, US$ exchange rate","PRT","Portugal","2016","2016",12.7,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","TCPPERMT","/capita, US$ exchange rate","PRT","Portugal","2017","2017",12.8,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","TCPPERMT","/capita, US$ exchange rate","PRT","Portugal","2018","2018",13.9,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","TCPPERMT","/capita, US$ exchange rate","PRT","Portugal","2019","2019",14.1,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","TCPPERMT","/capita, US$ exchange rate","PRT","Portugal","2020","2020",13.5,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","TCPPERMT","/capita, US$ exchange rate","PRT","Portugal","2021","2021",11.8,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","TCPPERMT","/capita, US$ exchange rate","PRT","Portugal","2022","2022",12.1,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2010","2010",27.6,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2011","2011",24.9,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2012","2012",20.4,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2013","2013",19,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2014","2014",19.8,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2015","2015",22,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2016","2016",20,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2017","2017",19.7,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2018","2018",20.7,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2019","2019",22.6,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2020","2020",21.2,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2021","2021",17.6,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2022","2022",20.9,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","ATCPTTMT","% of total sales","PRT","Portugal","2010","2010",5.6,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","ATCPTTMT","% of total sales","PRT","Portugal","2011","2011",5.6,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","ATCPTTMT","% of total sales","PRT","Portugal","2012","2012",5,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","ATCPTTMT","% of total sales","PRT","Portugal","2013","2013",4.8,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","ATCPTTMT","% of total sales","PRT","Portugal","2014","2014",5,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","ATCPTTMT","% of total sales","PRT","Portugal","2015","2015",5.4,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","ATCPTTMT","% of total sales","PRT","Portugal","2016","2016",4.7,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","ATCPTTMT","% of total sales","PRT","Portugal","2017","2017",4.6,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","ATCPTTMT","% of total sales","PRT","Portugal","2018","2018",4.6,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","ATCPTTMT","% of total sales","PRT","Portugal","2019","2019",4.6,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","ATCPTTMT","% of total sales","PRT","Portugal","2020","2020",4.3,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","ATCPTTMT","% of total sales","PRT","Portugal","2021","2021",3.5,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","ATCPTTMT","% of total sales","PRT","Portugal","2022","2022",3.7,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","MLLNCUMT","Million of national currency units","SVK","Slovak Republic","2010","2010",106.1,,
+"PATCINFC","J-Antiinfectives for systemic use","MLLNCUMT","Million of national currency units","SVK","Slovak Republic","2011","2011",115.4,,
+"PATCINFC","J-Antiinfectives for systemic use","MLLNCUMT","Million of national currency units","SVK","Slovak Republic","2012","2012",120.6,,
+"PATCINFC","J-Antiinfectives for systemic use","MLLNCUMT","Million of national currency units","SVK","Slovak Republic","2013","2013",111.9,,
+"PATCINFC","J-Antiinfectives for systemic use","MLLNCUMT","Million of national currency units","SVK","Slovak Republic","2014","2014",122,,
+"PATCINFC","J-Antiinfectives for systemic use","MLLNCUMT","Million of national currency units","SVK","Slovak Republic","2015","2015",134.2,,
+"PATCINFC","J-Antiinfectives for systemic use","MLLNCUMT","Million of national currency units","SVK","Slovak Republic","2016","2016",114.8,"B","Break"
+"PATCINFC","J-Antiinfectives for systemic use","MLLNCUMT","Million of national currency units","SVK","Slovak Republic","2017","2017",112.3,,
+"PATCINFC","J-Antiinfectives for systemic use","MLLNCUMT","Million of national currency units","SVK","Slovak Republic","2018","2018",116.9,,
+"PATCINFC","J-Antiinfectives for systemic use","MLLNCUMT","Million of national currency units","SVK","Slovak Republic","2019","2019",118.9,,
+"PATCINFC","J-Antiinfectives for systemic use","MLLNCUMT","Million of national currency units","SVK","Slovak Republic","2020","2020",110.9,,
+"PATCINFC","J-Antiinfectives for systemic use","MLLNCUMT","Million of national currency units","SVK","Slovak Republic","2021","2021",135.6,,
+"PATCINFC","J-Antiinfectives for systemic use","MTMOTCMT","Million US$ at exchange rate","SVK","Slovak Republic","2010","2010",140.6,,
+"PATCINFC","J-Antiinfectives for systemic use","MTMOTCMT","Million US$ at exchange rate","SVK","Slovak Republic","2011","2011",160.7,,
+"PATCINFC","J-Antiinfectives for systemic use","MTMOTCMT","Million US$ at exchange rate","SVK","Slovak Republic","2012","2012",155,,
+"PATCINFC","J-Antiinfectives for systemic use","MTMOTCMT","Million US$ at exchange rate","SVK","Slovak Republic","2013","2013",148.6,,
+"PATCINFC","J-Antiinfectives for systemic use","MTMOTCMT","Million US$ at exchange rate","SVK","Slovak Republic","2014","2014",162.1,,
+"PATCINFC","J-Antiinfectives for systemic use","MTMOTCMT","Million US$ at exchange rate","SVK","Slovak Republic","2015","2015",148.9,,
+"PATCINFC","J-Antiinfectives for systemic use","MTMOTCMT","Million US$ at exchange rate","SVK","Slovak Republic","2016","2016",127.1,"B","Break"
+"PATCINFC","J-Antiinfectives for systemic use","MTMOTCMT","Million US$ at exchange rate","SVK","Slovak Republic","2017","2017",126.8,,
+"PATCINFC","J-Antiinfectives for systemic use","MTMOTCMT","Million US$ at exchange rate","SVK","Slovak Republic","2018","2018",138.1,,
+"PATCINFC","J-Antiinfectives for systemic use","MTMOTCMT","Million US$ at exchange rate","SVK","Slovak Republic","2019","2019",133.1,,
+"PATCINFC","J-Antiinfectives for systemic use","MTMOTCMT","Million US$ at exchange rate","SVK","Slovak Republic","2020","2020",126.6,,
+"PATCINFC","J-Antiinfectives for systemic use","MTMOTCMT","Million US$ at exchange rate","SVK","Slovak Republic","2021","2021",160.4,,
+"PATCINFC","J-Antiinfectives for systemic use","MTMOPPMT","Million US$, purchasing power parity","SVK","Slovak Republic","2010","2010",211.3,,
+"PATCINFC","J-Antiinfectives for systemic use","MTMOPPMT","Million US$, purchasing power parity","SVK","Slovak Republic","2011","2011",228,,
+"PATCINFC","J-Antiinfectives for systemic use","MTMOPPMT","Million US$, purchasing power parity","SVK","Slovak Republic","2012","2012",239.1,,
+"PATCINFC","J-Antiinfectives for systemic use","MTMOPPMT","Million US$, purchasing power parity","SVK","Slovak Republic","2013","2013",227.7,,
+"PATCINFC","J-Antiinfectives for systemic use","MTMOPPMT","Million US$, purchasing power parity","SVK","Slovak Republic","2014","2014",251.4,,
+"PATCINFC","J-Antiinfectives for systemic use","MTMOPPMT","Million US$, purchasing power parity","SVK","Slovak Republic","2015","2015",273,,
+"PATCINFC","J-Antiinfectives for systemic use","MTMOPPMT","Million US$, purchasing power parity","SVK","Slovak Republic","2016","2016",228.2,"B","Break"
+"PATCINFC","J-Antiinfectives for systemic use","MTMOPPMT","Million US$, purchasing power parity","SVK","Slovak Republic","2017","2017",217.4,,
+"PATCINFC","J-Antiinfectives for systemic use","MTMOPPMT","Million US$, purchasing power parity","SVK","Slovak Republic","2018","2018",222.2,,
+"PATCINFC","J-Antiinfectives for systemic use","MTMOPPMT","Million US$, purchasing power parity","SVK","Slovak Republic","2019","2019",229.8,,
+"PATCINFC","J-Antiinfectives for systemic use","MTMOPPMT","Million US$, purchasing power parity","SVK","Slovak Republic","2020","2020",213.2,,
+"PATCINFC","J-Antiinfectives for systemic use","MTMOPPMT","Million US$, purchasing power parity","SVK","Slovak Republic","2021","2021",254.2,,
+"PATCINFC","J-Antiinfectives for systemic use","TCPPERMT","/capita, US$ exchange rate","SVK","Slovak Republic","2010","2010",26.1,,
+"PATCINFC","J-Antiinfectives for systemic use","TCPPERMT","/capita, US$ exchange rate","SVK","Slovak Republic","2011","2011",29.8,,
+"PATCINFC","J-Antiinfectives for systemic use","TCPPERMT","/capita, US$ exchange rate","SVK","Slovak Republic","2012","2012",28.7,,
+"PATCINFC","J-Antiinfectives for systemic use","TCPPERMT","/capita, US$ exchange rate","SVK","Slovak Republic","2013","2013",27.4,,
+"PATCINFC","J-Antiinfectives for systemic use","TCPPERMT","/capita, US$ exchange rate","SVK","Slovak Republic","2014","2014",29.9,,
+"PATCINFC","J-Antiinfectives for systemic use","TCPPERMT","/capita, US$ exchange rate","SVK","Slovak Republic","2015","2015",27.4,,
+"PATCINFC","J-Antiinfectives for systemic use","TCPPERMT","/capita, US$ exchange rate","SVK","Slovak Republic","2016","2016",23.4,"B","Break"
+"PATCINFC","J-Antiinfectives for systemic use","TCPPERMT","/capita, US$ exchange rate","SVK","Slovak Republic","2017","2017",23.3,,
+"PATCINFC","J-Antiinfectives for systemic use","TCPPERMT","/capita, US$ exchange rate","SVK","Slovak Republic","2018","2018",25.3,,
+"PATCINFC","J-Antiinfectives for systemic use","TCPPERMT","/capita, US$ exchange rate","SVK","Slovak Republic","2019","2019",24.4,,
+"PATCINFC","J-Antiinfectives for systemic use","TCPPERMT","/capita, US$ exchange rate","SVK","Slovak Republic","2020","2020",23.2,,
+"PATCINFC","J-Antiinfectives for systemic use","TCPPERMT","/capita, US$ exchange rate","SVK","Slovak Republic","2021","2021",29.4,,
+"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2010","2010",39.2,,
+"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2011","2011",42.2,,
+"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2012","2012",44.2,,
+"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2013","2013",42.1,,
+"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2014","2014",46.4,,
+"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2015","2015",50.3,,
+"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2016","2016",42,"B","Break"
+"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2017","2017",40,,
+"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2018","2018",40.8,,
+"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2019","2019",42.1,,
+"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2020","2020",39.1,,
+"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2021","2021",46.7,,
+"PATCINFC","J-Antiinfectives for systemic use","ATCPTTMT","% of total sales","SVK","Slovak Republic","2010","2010",9.5,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","ATCPTTMT","% of total sales","SVK","Slovak Republic","2011","2011",10.2,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","ATCPTTMT","% of total sales","SVK","Slovak Republic","2012","2012",10.9,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","ATCPTTMT","% of total sales","SVK","Slovak Republic","2013","2013",9.1,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","ATCPTTMT","% of total sales","SVK","Slovak Republic","2014","2014",9.3,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","ATCPTTMT","% of total sales","SVK","Slovak Republic","2015","2015",9.7,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","ATCPTTMT","% of total sales","SVK","Slovak Republic","2016","2016",7.3,"B","Break"
+"PATCINFC","J-Antiinfectives for systemic use","ATCPTTMT","% of total sales","SVK","Slovak Republic","2017","2017",7.2,,
+"PATCINFC","J-Antiinfectives for systemic use","ATCPTTMT","% of total sales","SVK","Slovak Republic","2018","2018",7.2,,
+"PATCINFC","J-Antiinfectives for systemic use","ATCPTTMT","% of total sales","SVK","Slovak Republic","2019","2019",6.9,,
+"PATCINFC","J-Antiinfectives for systemic use","ATCPTTMT","% of total sales","SVK","Slovak Republic","2020","2020",6.7,,
+"PATCINFC","J-Antiinfectives for systemic use","ATCPTTMT","% of total sales","SVK","Slovak Republic","2021","2021",7.6,,
+"PATCINFC","J-Antiinfectives for systemic use","MLLNCUMT","Million of national currency units","ESP","Spain","2010","2010",365.9,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","MLLNCUMT","Million of national currency units","ESP","Spain","2011","2011",311.5,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","MLLNCUMT","Million of national currency units","ESP","Spain","2012","2012",274.8,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","MLLNCUMT","Million of national currency units","ESP","Spain","2013","2013",274.4,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","MLLNCUMT","Million of national currency units","ESP","Spain","2014","2014",302.2,"B; D","Break; Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","MLLNCUMT","Million of national currency units","ESP","Spain","2015","2015",302.5,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","MLLNCUMT","Million of national currency units","ESP","Spain","2016","2016",297.9,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","MLLNCUMT","Million of national currency units","ESP","Spain","2017","2017",293.2,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","MLLNCUMT","Million of national currency units","ESP","Spain","2018","2018",1868.6,"B","Break"
+"PATCINFC","J-Antiinfectives for systemic use","MLLNCUMT","Million of national currency units","ESP","Spain","2019","2019",1850.8,,
+"PATCINFC","J-Antiinfectives for systemic use","MLLNCUMT","Million of national currency units","ESP","Spain","2020","2020",1794.1,,
+"PATCINFC","J-Antiinfectives for systemic use","MLLNCUMT","Million of national currency units","ESP","Spain","2021","2021",1794.7,,
+"PATCINFC","J-Antiinfectives for systemic use","MLLNCUMT","Million of national currency units","ESP","Spain","2022","2022",1780.6,"P","Provisional value"
+"PATCINFC","J-Antiinfectives for systemic use","MTMOTCMT","Million US$ at exchange rate","ESP","Spain","2010","2010",485,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","MTMOTCMT","Million US$ at exchange rate","ESP","Spain","2011","2011",433.6,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","MTMOTCMT","Million US$ at exchange rate","ESP","Spain","2012","2012",353.1,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","MTMOTCMT","Million US$ at exchange rate","ESP","Spain","2013","2013",364.5,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","MTMOTCMT","Million US$ at exchange rate","ESP","Spain","2014","2014",401.5,"B; D","Break; Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","MTMOTCMT","Million US$ at exchange rate","ESP","Spain","2015","2015",335.6,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","MTMOTCMT","Million US$ at exchange rate","ESP","Spain","2016","2016",329.7,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","MTMOTCMT","Million US$ at exchange rate","ESP","Spain","2017","2017",331.2,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","MTMOTCMT","Million US$ at exchange rate","ESP","Spain","2018","2018",2206.7,"B","Break"
+"PATCINFC","J-Antiinfectives for systemic use","MTMOTCMT","Million US$ at exchange rate","ESP","Spain","2019","2019",2072,,
+"PATCINFC","J-Antiinfectives for systemic use","MTMOTCMT","Million US$ at exchange rate","ESP","Spain","2020","2020",2049.3,,
+"PATCINFC","J-Antiinfectives for systemic use","MTMOTCMT","Million US$ at exchange rate","ESP","Spain","2021","2021",2122.6,,
+"PATCINFC","J-Antiinfectives for systemic use","MTMOTCMT","Million US$ at exchange rate","ESP","Spain","2022","2022",1875,"P","Provisional value"
+"PATCINFC","J-Antiinfectives for systemic use","MTMOPPMT","Million US$, purchasing power parity","ESP","Spain","2010","2010",503.3,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","MTMOPPMT","Million US$, purchasing power parity","ESP","Spain","2011","2011",436.2,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","MTMOPPMT","Million US$, purchasing power parity","ESP","Spain","2012","2012",395.5,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","MTMOPPMT","Million US$, purchasing power parity","ESP","Spain","2013","2013",406.7,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","MTMOPPMT","Million US$, purchasing power parity","ESP","Spain","2014","2014",456.2,"B; D","Break; Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","MTMOPPMT","Million US$, purchasing power parity","ESP","Spain","2015","2015",455,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","MTMOPPMT","Million US$, purchasing power parity","ESP","Spain","2016","2016",463.5,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","MTMOPPMT","Million US$, purchasing power parity","ESP","Spain","2017","2017",464.8,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","MTMOPPMT","Million US$, purchasing power parity","ESP","Spain","2018","2018",2957.6,"B","Break"
+"PATCINFC","J-Antiinfectives for systemic use","MTMOPPMT","Million US$, purchasing power parity","ESP","Spain","2019","2019",3019.4,,
+"PATCINFC","J-Antiinfectives for systemic use","MTMOPPMT","Million US$, purchasing power parity","ESP","Spain","2020","2020",2887.5,,
+"PATCINFC","J-Antiinfectives for systemic use","MTMOPPMT","Million US$, purchasing power parity","ESP","Spain","2021","2021",2867.1,,
+"PATCINFC","J-Antiinfectives for systemic use","MTMOPPMT","Million US$, purchasing power parity","ESP","Spain","2022","2022",2986.5,"P","Provisional value"
+"PATCINFC","J-Antiinfectives for systemic use","TCPPERMT","/capita, US$ exchange rate","ESP","Spain","2010","2010",10.4,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","TCPPERMT","/capita, US$ exchange rate","ESP","Spain","2011","2011",9.3,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","TCPPERMT","/capita, US$ exchange rate","ESP","Spain","2012","2012",7.5,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","TCPPERMT","/capita, US$ exchange rate","ESP","Spain","2013","2013",7.8,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","TCPPERMT","/capita, US$ exchange rate","ESP","Spain","2014","2014",8.6,"B; D","Break; Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","TCPPERMT","/capita, US$ exchange rate","ESP","Spain","2015","2015",7.2,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","TCPPERMT","/capita, US$ exchange rate","ESP","Spain","2016","2016",7.1,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","TCPPERMT","/capita, US$ exchange rate","ESP","Spain","2017","2017",7.1,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","TCPPERMT","/capita, US$ exchange rate","ESP","Spain","2018","2018",47.2,"B","Break"
+"PATCINFC","J-Antiinfectives for systemic use","TCPPERMT","/capita, US$ exchange rate","ESP","Spain","2019","2019",44,,
+"PATCINFC","J-Antiinfectives for systemic use","TCPPERMT","/capita, US$ exchange rate","ESP","Spain","2020","2020",43.3,,
+"PATCINFC","J-Antiinfectives for systemic use","TCPPERMT","/capita, US$ exchange rate","ESP","Spain","2021","2021",44.8,,
+"PATCINFC","J-Antiinfectives for systemic use","TCPPERMT","/capita, US$ exchange rate","ESP","Spain","2022","2022",39.5,"P","Provisional value"
+"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2010","2010",10.8,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2011","2011",9.3,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2012","2012",8.5,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2013","2013",8.7,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2014","2014",9.8,"B; D","Break; Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2015","2015",9.8,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2016","2016",10,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2017","2017",10,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2018","2018",63.2,"B","Break"
+"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2019","2019",64.1,,
+"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2020","2020",61,,
+"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2021","2021",60.5,,
+"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2022","2022",63,"P","Provisional value"
+"PATCINFC","J-Antiinfectives for systemic use","ATCPTTMT","% of total sales","ESP","Spain","2010","2010",2.8,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","ATCPTTMT","% of total sales","ESP","Spain","2011","2011",2.5,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","ATCPTTMT","% of total sales","ESP","Spain","2012","2012",2.5,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","ATCPTTMT","% of total sales","ESP","Spain","2013","2013",2.6,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","ATCPTTMT","% of total sales","ESP","Spain","2014","2014",2.7,"B; D","Break; Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","ATCPTTMT","% of total sales","ESP","Spain","2015","2015",2.7,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","ATCPTTMT","% of total sales","ESP","Spain","2016","2016",2.5,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","ATCPTTMT","% of total sales","ESP","Spain","2017","2017",2.4,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","ATCPTTMT","% of total sales","ESP","Spain","2018","2018",9.8,"B","Break"
+"PATCINFC","J-Antiinfectives for systemic use","ATCPTTMT","% of total sales","ESP","Spain","2019","2019",9.3,,
+"PATCINFC","J-Antiinfectives for systemic use","ATCPTTMT","% of total sales","ESP","Spain","2020","2020",8.6,,
+"PATCINFC","J-Antiinfectives for systemic use","ATCPTTMT","% of total sales","ESP","Spain","2021","2021",8.1,,
+"PATCINFC","J-Antiinfectives for systemic use","ATCPTTMT","% of total sales","ESP","Spain","2022","2022",7.8,"P","Provisional value"
+"PATCINFC","J-Antiinfectives for systemic use","MLLNCUMT","Million of national currency units","SWE","Sweden","2010","2010",2649.2,,
+"PATCINFC","J-Antiinfectives for systemic use","MLLNCUMT","Million of national currency units","SWE","Sweden","2011","2011",2551,,
+"PATCINFC","J-Antiinfectives for systemic use","MLLNCUMT","Million of national currency units","SWE","Sweden","2012","2012",2540.3,,
+"PATCINFC","J-Antiinfectives for systemic use","MLLNCUMT","Million of national currency units","SWE","Sweden","2013","2013",2367.4,,
+"PATCINFC","J-Antiinfectives for systemic use","MLLNCUMT","Million of national currency units","SWE","Sweden","2014","2014",3029.8,,
+"PATCINFC","J-Antiinfectives for systemic use","MLLNCUMT","Million of national currency units","SWE","Sweden","2015","2015",3983.5,,
+"PATCINFC","J-Antiinfectives for systemic use","MLLNCUMT","Million of national currency units","SWE","Sweden","2016","2016",3888.6,,
+"PATCINFC","J-Antiinfectives for systemic use","MLLNCUMT","Million of national currency units","SWE","Sweden","2017","2017",3285.5,,
+"PATCINFC","J-Antiinfectives for systemic use","MLLNCUMT","Million of national currency units","SWE","Sweden","2018","2018",4538.7,,
+"PATCINFC","J-Antiinfectives for systemic use","MLLNCUMT","Million of national currency units","SWE","Sweden","2019","2019",3807.6,,
+"PATCINFC","J-Antiinfectives for systemic use","MLLNCUMT","Million of national currency units","SWE","Sweden","2020","2020",3307.9,,
+"PATCINFC","J-Antiinfectives for systemic use","MLLNCUMT","Million of national currency units","SWE","Sweden","2021","2021",3341.1,,
+"PATCINFC","J-Antiinfectives for systemic use","MLLNCUMT","Million of national currency units","SWE","Sweden","2022","2022",3543.7,,
+"PATCINFC","J-Antiinfectives for systemic use","MTMOTCMT","Million US$ at exchange rate","SWE","Sweden","2010","2010",367.6,,
+"PATCINFC","J-Antiinfectives for systemic use","MTMOTCMT","Million US$ at exchange rate","SWE","Sweden","2011","2011",392.9,,
+"PATCINFC","J-Antiinfectives for systemic use","MTMOTCMT","Million US$ at exchange rate","SWE","Sweden","2012","2012",374.9,,
+"PATCINFC","J-Antiinfectives for systemic use","MTMOTCMT","Million US$ at exchange rate","SWE","Sweden","2013","2013",363.4,,
+"PATCINFC","J-Antiinfectives for systemic use","MTMOTCMT","Million US$ at exchange rate","SWE","Sweden","2014","2014",441.6,,
+"PATCINFC","J-Antiinfectives for systemic use","MTMOTCMT","Million US$ at exchange rate","SWE","Sweden","2015","2015",472.3,,
+"PATCINFC","J-Antiinfectives for systemic use","MTMOTCMT","Million US$ at exchange rate","SWE","Sweden","2016","2016",454.2,,
+"PATCINFC","J-Antiinfectives for systemic use","MTMOTCMT","Million US$ at exchange rate","SWE","Sweden","2017","2017",384.3,,
+"PATCINFC","J-Antiinfectives for systemic use","MTMOTCMT","Million US$ at exchange rate","SWE","Sweden","2018","2018",522.1,,
+"PATCINFC","J-Antiinfectives for systemic use","MTMOTCMT","Million US$ at exchange rate","SWE","Sweden","2019","2019",402.6,,
+"PATCINFC","J-Antiinfectives for systemic use","MTMOTCMT","Million US$ at exchange rate","SWE","Sweden","2020","2020",359.1,,
+"PATCINFC","J-Antiinfectives for systemic use","MTMOTCMT","Million US$ at exchange rate","SWE","Sweden","2021","2021",389.6,,
+"PATCINFC","J-Antiinfectives for systemic use","MTMOTCMT","Million US$ at exchange rate","SWE","Sweden","2022","2022",350.4,,
+"PATCINFC","J-Antiinfectives for systemic use","MTMOPPMT","Million US$, purchasing power parity","SWE","Sweden","2010","2010",293.5,,
+"PATCINFC","J-Antiinfectives for systemic use","MTMOPPMT","Million US$, purchasing power parity","SWE","Sweden","2011","2011",288.4,,
+"PATCINFC","J-Antiinfectives for systemic use","MTMOPPMT","Million US$, purchasing power parity","SWE","Sweden","2012","2012",293.5,,
+"PATCINFC","J-Antiinfectives for systemic use","MTMOPPMT","Million US$, purchasing power parity","SWE","Sweden","2013","2013",275.3,,
+"PATCINFC","J-Antiinfectives for systemic use","MTMOPPMT","Million US$, purchasing power parity","SWE","Sweden","2014","2014",347.2,,
+"PATCINFC","J-Antiinfectives for systemic use","MTMOPPMT","Million US$, purchasing power parity","SWE","Sweden","2015","2015",449.9,,
+"PATCINFC","J-Antiinfectives for systemic use","MTMOPPMT","Million US$, purchasing power parity","SWE","Sweden","2016","2016",440.8,,
+"PATCINFC","J-Antiinfectives for systemic use","MTMOPPMT","Million US$, purchasing power parity","SWE","Sweden","2017","2017",371.1,,
+"PATCINFC","J-Antiinfectives for systemic use","MTMOPPMT","Million US$, purchasing power parity","SWE","Sweden","2018","2018",511.9,,
+"PATCINFC","J-Antiinfectives for systemic use","MTMOPPMT","Million US$, purchasing power parity","SWE","Sweden","2019","2019",437.2,,
+"PATCINFC","J-Antiinfectives for systemic use","MTMOPPMT","Million US$, purchasing power parity","SWE","Sweden","2020","2020",381.6,,
+"PATCINFC","J-Antiinfectives for systemic use","MTMOPPMT","Million US$, purchasing power parity","SWE","Sweden","2021","2021",383.1,,
+"PATCINFC","J-Antiinfectives for systemic use","MTMOPPMT","Million US$, purchasing power parity","SWE","Sweden","2022","2022",408.9,,
+"PATCINFC","J-Antiinfectives for systemic use","TCPPERMT","/capita, US$ exchange rate","SWE","Sweden","2010","2010",39.2,,
+"PATCINFC","J-Antiinfectives for systemic use","TCPPERMT","/capita, US$ exchange rate","SWE","Sweden","2011","2011",41.6,,
+"PATCINFC","J-Antiinfectives for systemic use","TCPPERMT","/capita, US$ exchange rate","SWE","Sweden","2012","2012",39.4,,
+"PATCINFC","J-Antiinfectives for systemic use","TCPPERMT","/capita, US$ exchange rate","SWE","Sweden","2013","2013",37.9,,
+"PATCINFC","J-Antiinfectives for systemic use","TCPPERMT","/capita, US$ exchange rate","SWE","Sweden","2014","2014",45.5,,
+"PATCINFC","J-Antiinfectives for systemic use","TCPPERMT","/capita, US$ exchange rate","SWE","Sweden","2015","2015",48.2,,
+"PATCINFC","J-Antiinfectives for systemic use","TCPPERMT","/capita, US$ exchange rate","SWE","Sweden","2016","2016",45.8,,
+"PATCINFC","J-Antiinfectives for systemic use","TCPPERMT","/capita, US$ exchange rate","SWE","Sweden","2017","2017",38.2,,
+"PATCINFC","J-Antiinfectives for systemic use","TCPPERMT","/capita, US$ exchange rate","SWE","Sweden","2018","2018",51.3,,
+"PATCINFC","J-Antiinfectives for systemic use","TCPPERMT","/capita, US$ exchange rate","SWE","Sweden","2019","2019",39.2,,
+"PATCINFC","J-Antiinfectives for systemic use","TCPPERMT","/capita, US$ exchange rate","SWE","Sweden","2020","2020",34.7,,
+"PATCINFC","J-Antiinfectives for systemic use","TCPPERMT","/capita, US$ exchange rate","SWE","Sweden","2021","2021",37.4,,
+"PATCINFC","J-Antiinfectives for systemic use","TCPPERMT","/capita, US$ exchange rate","SWE","Sweden","2022","2022",33.5,,
+"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2010","2010",31.3,,
+"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2011","2011",30.5,,
+"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2012","2012",30.8,,
+"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2013","2013",28.7,,
+"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2014","2014",35.8,,
+"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2015","2015",45.9,,
+"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2016","2016",44.4,,
+"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2017","2017",36.9,,
+"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2018","2018",50.3,,
+"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2019","2019",42.5,,
+"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2020","2020",36.9,,
+"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2021","2021",36.8,,
+"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2022","2022",39.1,,
+"PATCINFC","J-Antiinfectives for systemic use","ATCPTTMT","% of total sales","SWE","Sweden","2010","2010",7.3,,
+"PATCINFC","J-Antiinfectives for systemic use","ATCPTTMT","% of total sales","SWE","Sweden","2011","2011",6.9,,
+"PATCINFC","J-Antiinfectives for systemic use","ATCPTTMT","% of total sales","SWE","Sweden","2012","2012",7,,
+"PATCINFC","J-Antiinfectives for systemic use","ATCPTTMT","% of total sales","SWE","Sweden","2013","2013",6.5,,
+"PATCINFC","J-Antiinfectives for systemic use","ATCPTTMT","% of total sales","SWE","Sweden","2014","2014",8,,
+"PATCINFC","J-Antiinfectives for systemic use","ATCPTTMT","% of total sales","SWE","Sweden","2015","2015",9.8,,
+"PATCINFC","J-Antiinfectives for systemic use","ATCPTTMT","% of total sales","SWE","Sweden","2016","2016",9.2,,
+"PATCINFC","J-Antiinfectives for systemic use","ATCPTTMT","% of total sales","SWE","Sweden","2017","2017",7.5,,
+"PATCINFC","J-Antiinfectives for systemic use","ATCPTTMT","% of total sales","SWE","Sweden","2018","2018",9.5,,
+"PATCINFC","J-Antiinfectives for systemic use","ATCPTTMT","% of total sales","SWE","Sweden","2019","2019",7.5,,
+"PATCINFC","J-Antiinfectives for systemic use","ATCPTTMT","% of total sales","SWE","Sweden","2020","2020",6.3,,
+"PATCINFC","J-Antiinfectives for systemic use","ATCPTTMT","% of total sales","SWE","Sweden","2021","2021",6.2,,
+"PATCINFC","J-Antiinfectives for systemic use","ATCPTTMT","% of total sales","SWE","Sweden","2022","2022",6.1,,
+"PATCINFC","J-Antiinfectives for systemic use","MLLNCUMT","Million of national currency units","CHE","Switzerland","2010","2010",437.3,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","MLLNCUMT","Million of national currency units","CHE","Switzerland","2011","2011",445,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","MLLNCUMT","Million of national currency units","CHE","Switzerland","2012","2012",463,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","MLLNCUMT","Million of national currency units","CHE","Switzerland","2013","2013",449,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","MLLNCUMT","Million of national currency units","CHE","Switzerland","2014","2014",459,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","MLLNCUMT","Million of national currency units","CHE","Switzerland","2015","2015",569,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","MLLNCUMT","Million of national currency units","CHE","Switzerland","2016","2016",546,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","MLLNCUMT","Million of national currency units","CHE","Switzerland","2017","2017",554,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","MLLNCUMT","Million of national currency units","CHE","Switzerland","2018","2018",553,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","MLLNCUMT","Million of national currency units","CHE","Switzerland","2019","2019",551,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","MLLNCUMT","Million of national currency units","CHE","Switzerland","2020","2020",490,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","MLLNCUMT","Million of national currency units","CHE","Switzerland","2021","2021",476,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","MLLNCUMT","Million of national currency units","CHE","Switzerland","2022","2022",523,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","MTMOTCMT","Million US$ at exchange rate","CHE","Switzerland","2010","2010",419.3,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","MTMOTCMT","Million US$ at exchange rate","CHE","Switzerland","2011","2011",501.1,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","MTMOTCMT","Million US$ at exchange rate","CHE","Switzerland","2012","2012",493.8,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","MTMOTCMT","Million US$ at exchange rate","CHE","Switzerland","2013","2013",484.4,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","MTMOTCMT","Million US$ at exchange rate","CHE","Switzerland","2014","2014",501,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","MTMOTCMT","Million US$ at exchange rate","CHE","Switzerland","2015","2015",591.2,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","MTMOTCMT","Million US$ at exchange rate","CHE","Switzerland","2016","2016",554.1,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","MTMOTCMT","Million US$ at exchange rate","CHE","Switzerland","2017","2017",562.6,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","MTMOTCMT","Million US$ at exchange rate","CHE","Switzerland","2018","2018",565.5,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","MTMOTCMT","Million US$ at exchange rate","CHE","Switzerland","2019","2019",554.5,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","MTMOTCMT","Million US$ at exchange rate","CHE","Switzerland","2020","2020",521.9,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","MTMOTCMT","Million US$ at exchange rate","CHE","Switzerland","2021","2021",520.9,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","MTMOTCMT","Million US$ at exchange rate","CHE","Switzerland","2022","2022",547.7,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","MTMOPPMT","Million US$, purchasing power parity","CHE","Switzerland","2010","2010",298.3,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","MTMOPPMT","Million US$, purchasing power parity","CHE","Switzerland","2011","2011",318.4,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","MTMOPPMT","Million US$, purchasing power parity","CHE","Switzerland","2012","2012",341.9,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","MTMOPPMT","Million US$, purchasing power parity","CHE","Switzerland","2013","2013",342.1,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","MTMOPPMT","Million US$, purchasing power parity","CHE","Switzerland","2014","2014",358.1,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","MTMOPPMT","Million US$, purchasing power parity","CHE","Switzerland","2015","2015",460.4,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","MTMOPPMT","Million US$, purchasing power parity","CHE","Switzerland","2016","2016",454.3,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","MTMOPPMT","Million US$, purchasing power parity","CHE","Switzerland","2017","2017",466.4,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","MTMOPPMT","Million US$, purchasing power parity","CHE","Switzerland","2018","2018",469.1,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","MTMOPPMT","Million US$, purchasing power parity","CHE","Switzerland","2019","2019",479,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","MTMOPPMT","Million US$, purchasing power parity","CHE","Switzerland","2020","2020",431.5,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","MTMOPPMT","Million US$, purchasing power parity","CHE","Switzerland","2021","2021",430.2,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","MTMOPPMT","Million US$, purchasing power parity","CHE","Switzerland","2022","2022",490.6,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","TCPPERMT","/capita, US$ exchange rate","CHE","Switzerland","2010","2010",53.6,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","TCPPERMT","/capita, US$ exchange rate","CHE","Switzerland","2011","2011",63.3,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","TCPPERMT","/capita, US$ exchange rate","CHE","Switzerland","2012","2012",61.7,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","TCPPERMT","/capita, US$ exchange rate","CHE","Switzerland","2013","2013",59.9,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","TCPPERMT","/capita, US$ exchange rate","CHE","Switzerland","2014","2014",61.2,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","TCPPERMT","/capita, US$ exchange rate","CHE","Switzerland","2015","2015",71.4,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","TCPPERMT","/capita, US$ exchange rate","CHE","Switzerland","2016","2016",66.2,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","TCPPERMT","/capita, US$ exchange rate","CHE","Switzerland","2017","2017",66.6,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","TCPPERMT","/capita, US$ exchange rate","CHE","Switzerland","2018","2018",66.4,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","TCPPERMT","/capita, US$ exchange rate","CHE","Switzerland","2019","2019",64.7,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","TCPPERMT","/capita, US$ exchange rate","CHE","Switzerland","2020","2020",60.4,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","TCPPERMT","/capita, US$ exchange rate","CHE","Switzerland","2021","2021",59.8,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","TCPPERMT","/capita, US$ exchange rate","CHE","Switzerland","2022","2022",62.7,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","CHE","Switzerland","2010","2010",38.1,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","CHE","Switzerland","2011","2011",40.2,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","CHE","Switzerland","2012","2012",42.8,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","CHE","Switzerland","2013","2013",42.3,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","CHE","Switzerland","2014","2014",43.7,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","CHE","Switzerland","2015","2015",55.6,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","CHE","Switzerland","2016","2016",54.3,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","CHE","Switzerland","2017","2017",55.2,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","CHE","Switzerland","2018","2018",55.1,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","CHE","Switzerland","2019","2019",55.9,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","CHE","Switzerland","2020","2020",49.9,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","CHE","Switzerland","2021","2021",49.4,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","CHE","Switzerland","2022","2022",56.1,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","ATCPTTMT","% of total sales","CHE","Switzerland","2010","2010",7.6,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","ATCPTTMT","% of total sales","CHE","Switzerland","2011","2011",7.7,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","ATCPTTMT","% of total sales","CHE","Switzerland","2012","2012",7.8,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","ATCPTTMT","% of total sales","CHE","Switzerland","2013","2013",7.6,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","ATCPTTMT","% of total sales","CHE","Switzerland","2014","2014",7.7,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","ATCPTTMT","% of total sales","CHE","Switzerland","2015","2015",9.2,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","ATCPTTMT","% of total sales","CHE","Switzerland","2016","2016",8.6,"B; D","Break; Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","ATCPTTMT","% of total sales","CHE","Switzerland","2017","2017",8.5,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","ATCPTTMT","% of total sales","CHE","Switzerland","2018","2018",8.4,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","ATCPTTMT","% of total sales","CHE","Switzerland","2019","2019",8.2,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","ATCPTTMT","% of total sales","CHE","Switzerland","2020","2020",7.2,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","ATCPTTMT","% of total sales","CHE","Switzerland","2021","2021",6.7,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","ATCPTTMT","% of total sales","CHE","Switzerland","2022","2022",6.9,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","MLLNCUMT","Million of national currency units","TUR","Türkiye","2010","2010",2580.6,,
+"PATCINFC","J-Antiinfectives for systemic use","MLLNCUMT","Million of national currency units","TUR","Türkiye","2011","2011",1976.4,,
+"PATCINFC","J-Antiinfectives for systemic use","MLLNCUMT","Million of national currency units","TUR","Türkiye","2012","2012",1910.4,,
+"PATCINFC","J-Antiinfectives for systemic use","MLLNCUMT","Million of national currency units","TUR","Türkiye","2013","2013",1992.2,,
+"PATCINFC","J-Antiinfectives for systemic use","MLLNCUMT","Million of national currency units","TUR","Türkiye","2014","2014",2049.4,,
+"PATCINFC","J-Antiinfectives for systemic use","MLLNCUMT","Million of national currency units","TUR","Türkiye","2015","2015",2341.6,,
+"PATCINFC","J-Antiinfectives for systemic use","MLLNCUMT","Million of national currency units","TUR","Türkiye","2016","2016",2699.2,,
+"PATCINFC","J-Antiinfectives for systemic use","MLLNCUMT","Million of national currency units","TUR","Türkiye","2017","2017",3002.3,,
+"PATCINFC","J-Antiinfectives for systemic use","MLLNCUMT","Million of national currency units","TUR","Türkiye","2018","2018",3895.8,,
+"PATCINFC","J-Antiinfectives for systemic use","MLLNCUMT","Million of national currency units","TUR","Türkiye","2019","2019",5252,,
+"PATCINFC","J-Antiinfectives for systemic use","MLLNCUMT","Million of national currency units","TUR","Türkiye","2020","2020",5511.5,,
+"PATCINFC","J-Antiinfectives for systemic use","MLLNCUMT","Million of national currency units","TUR","Türkiye","2021","2021",6853.7,,
+"PATCINFC","J-Antiinfectives for systemic use","MTMOTCMT","Million US$ at exchange rate","TUR","Türkiye","2010","2010",1717.1,,
+"PATCINFC","J-Antiinfectives for systemic use","MTMOTCMT","Million US$ at exchange rate","TUR","Türkiye","2011","2011",1180,,
+"PATCINFC","J-Antiinfectives for systemic use","MTMOTCMT","Million US$ at exchange rate","TUR","Türkiye","2012","2012",1063.7,,
+"PATCINFC","J-Antiinfectives for systemic use","MTMOTCMT","Million US$ at exchange rate","TUR","Türkiye","2013","2013",1046.4,,
+"PATCINFC","J-Antiinfectives for systemic use","MTMOTCMT","Million US$ at exchange rate","TUR","Türkiye","2014","2014",936.4,,
+"PATCINFC","J-Antiinfectives for systemic use","MTMOTCMT","Million US$ at exchange rate","TUR","Türkiye","2015","2015",860.9,,
+"PATCINFC","J-Antiinfectives for systemic use","MTMOTCMT","Million US$ at exchange rate","TUR","Türkiye","2016","2016",893.7,,
+"PATCINFC","J-Antiinfectives for systemic use","MTMOTCMT","Million US$ at exchange rate","TUR","Türkiye","2017","2017",823,,
+"PATCINFC","J-Antiinfectives for systemic use","MTMOTCMT","Million US$ at exchange rate","TUR","Türkiye","2018","2018",806.9,,
+"PATCINFC","J-Antiinfectives for systemic use","MTMOTCMT","Million US$ at exchange rate","TUR","Türkiye","2019","2019",925.6,,
+"PATCINFC","J-Antiinfectives for systemic use","MTMOTCMT","Million US$ at exchange rate","TUR","Türkiye","2020","2020",786.4,,
+"PATCINFC","J-Antiinfectives for systemic use","MTMOTCMT","Million US$ at exchange rate","TUR","Türkiye","2021","2021",774.4,,
+"PATCINFC","J-Antiinfectives for systemic use","MTMOPPMT","Million US$, purchasing power parity","TUR","Türkiye","2010","2010",2803.9,,
+"PATCINFC","J-Antiinfectives for systemic use","MTMOPPMT","Million US$, purchasing power parity","TUR","Türkiye","2011","2011",2045.6,,
+"PATCINFC","J-Antiinfectives for systemic use","MTMOPPMT","Million US$, purchasing power parity","TUR","Türkiye","2012","2012",1873.2,,
+"PATCINFC","J-Antiinfectives for systemic use","MTMOPPMT","Million US$, purchasing power parity","TUR","Türkiye","2013","2013",1861.3,,
+"PATCINFC","J-Antiinfectives for systemic use","MTMOPPMT","Million US$, purchasing power parity","TUR","Türkiye","2014","2014",1855.5,,
+"PATCINFC","J-Antiinfectives for systemic use","MTMOPPMT","Million US$, purchasing power parity","TUR","Türkiye","2015","2015",2014.4,,
+"PATCINFC","J-Antiinfectives for systemic use","MTMOPPMT","Million US$, purchasing power parity","TUR","Türkiye","2016","2016",2174.9,,
+"PATCINFC","J-Antiinfectives for systemic use","MTMOPPMT","Million US$, purchasing power parity","TUR","Türkiye","2017","2017",2169.3,,
+"PATCINFC","J-Antiinfectives for systemic use","MTMOPPMT","Million US$, purchasing power parity","TUR","Türkiye","2018","2018",2386.2,,
+"PATCINFC","J-Antiinfectives for systemic use","MTMOPPMT","Million US$, purchasing power parity","TUR","Türkiye","2019","2019",2817.6,,
+"PATCINFC","J-Antiinfectives for systemic use","MTMOPPMT","Million US$, purchasing power parity","TUR","Türkiye","2020","2020",2546.7,,
+"PATCINFC","J-Antiinfectives for systemic use","MTMOPPMT","Million US$, purchasing power parity","TUR","Türkiye","2021","2021",2440.9,,
+"PATCINFC","J-Antiinfectives for systemic use","TCPPERMT","/capita, US$ exchange rate","TUR","Türkiye","2010","2010",23.5,,
+"PATCINFC","J-Antiinfectives for systemic use","TCPPERMT","/capita, US$ exchange rate","TUR","Türkiye","2011","2011",15.9,,
+"PATCINFC","J-Antiinfectives for systemic use","TCPPERMT","/capita, US$ exchange rate","TUR","Türkiye","2012","2012",14.1,,
+"PATCINFC","J-Antiinfectives for systemic use","TCPPERMT","/capita, US$ exchange rate","TUR","Türkiye","2013","2013",13.7,,
+"PATCINFC","J-Antiinfectives for systemic use","TCPPERMT","/capita, US$ exchange rate","TUR","Türkiye","2014","2014",12.1,,
+"PATCINFC","J-Antiinfectives for systemic use","TCPPERMT","/capita, US$ exchange rate","TUR","Türkiye","2015","2015",11,,
+"PATCINFC","J-Antiinfectives for systemic use","TCPPERMT","/capita, US$ exchange rate","TUR","Türkiye","2016","2016",11.3,,
+"PATCINFC","J-Antiinfectives for systemic use","TCPPERMT","/capita, US$ exchange rate","TUR","Türkiye","2017","2017",10.2,,
+"PATCINFC","J-Antiinfectives for systemic use","TCPPERMT","/capita, US$ exchange rate","TUR","Türkiye","2018","2018",9.9,,
+"PATCINFC","J-Antiinfectives for systemic use","TCPPERMT","/capita, US$ exchange rate","TUR","Türkiye","2019","2019",11.2,,
+"PATCINFC","J-Antiinfectives for systemic use","TCPPERMT","/capita, US$ exchange rate","TUR","Türkiye","2020","2020",9.4,,
+"PATCINFC","J-Antiinfectives for systemic use","TCPPERMT","/capita, US$ exchange rate","TUR","Türkiye","2021","2021",9.2,,
+"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2010","2010",38.3,,
+"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2011","2011",27.6,,
+"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2012","2012",24.9,,
+"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2013","2013",24.4,,
+"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2014","2014",24,,
+"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2015","2015",25.8,,
+"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2016","2016",27.4,,
+"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2017","2017",27,,
+"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2018","2018",29.3,,
+"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2019","2019",34.1,,
+"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2020","2020",30.5,,
+"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2021","2021",29,,
+"PATCINFC","J-Antiinfectives for systemic use","ATCPTTMT","% of total sales","TUR","Türkiye","2010","2010",16.6,,
+"PATCINFC","J-Antiinfectives for systemic use","ATCPTTMT","% of total sales","TUR","Türkiye","2011","2011",14,,
+"PATCINFC","J-Antiinfectives for systemic use","ATCPTTMT","% of total sales","TUR","Türkiye","2012","2012",14.1,,
+"PATCINFC","J-Antiinfectives for systemic use","ATCPTTMT","% of total sales","TUR","Türkiye","2013","2013",13.9,,
+"PATCINFC","J-Antiinfectives for systemic use","ATCPTTMT","% of total sales","TUR","Türkiye","2014","2014",13.1,,
+"PATCINFC","J-Antiinfectives for systemic use","ATCPTTMT","% of total sales","TUR","Türkiye","2015","2015",12.8,,
+"PATCINFC","J-Antiinfectives for systemic use","ATCPTTMT","% of total sales","TUR","Türkiye","2016","2016",12.3,,
+"PATCINFC","J-Antiinfectives for systemic use","ATCPTTMT","% of total sales","TUR","Türkiye","2017","2017",11.8,,
+"PATCINFC","J-Antiinfectives for systemic use","ATCPTTMT","% of total sales","TUR","Türkiye","2018","2018",12.2,,
+"PATCINFC","J-Antiinfectives for systemic use","ATCPTTMT","% of total sales","TUR","Türkiye","2019","2019",12.5,,
+"PATCINFC","J-Antiinfectives for systemic use","ATCPTTMT","% of total sales","TUR","Türkiye","2020","2020",11,,
+"PATCINFC","J-Antiinfectives for systemic use","ATCPTTMT","% of total sales","TUR","Türkiye","2021","2021",10.6,,
+"PATCINFC","J-Antiinfectives for systemic use","MLLNCUMT","Million of national currency units","GBR","United Kingdom","2012","2012",1606,"B","Break"
+"PATCINFC","J-Antiinfectives for systemic use","MLLNCUMT","Million of national currency units","GBR","United Kingdom","2013","2013",1729.4,,
+"PATCINFC","J-Antiinfectives for systemic use","MLLNCUMT","Million of national currency units","GBR","United Kingdom","2014","2014",1844.2,,
+"PATCINFC","J-Antiinfectives for systemic use","MLLNCUMT","Million of national currency units","GBR","United Kingdom","2015","2015",2079.5,,
+"PATCINFC","J-Antiinfectives for systemic use","MLLNCUMT","Million of national currency units","GBR","United Kingdom","2016","2016",2346.9,,
+"PATCINFC","J-Antiinfectives for systemic use","MLLNCUMT","Million of national currency units","GBR","United Kingdom","2017","2017",2615.7,,
+"PATCINFC","J-Antiinfectives for systemic use","MLLNCUMT","Million of national currency units","GBR","United Kingdom","2018","2018",2657.7,,
+"PATCINFC","J-Antiinfectives for systemic use","MTMOTCMT","Million US$ at exchange rate","GBR","United Kingdom","2012","2012",2536.9,"B","Break"
+"PATCINFC","J-Antiinfectives for systemic use","MTMOTCMT","Million US$ at exchange rate","GBR","United Kingdom","2013","2013",2703.6,,
+"PATCINFC","J-Antiinfectives for systemic use","MTMOTCMT","Million US$ at exchange rate","GBR","United Kingdom","2014","2014",3034.6,,
+"PATCINFC","J-Antiinfectives for systemic use","MTMOTCMT","Million US$ at exchange rate","GBR","United Kingdom","2015","2015",3177,,
+"PATCINFC","J-Antiinfectives for systemic use","MTMOTCMT","Million US$ at exchange rate","GBR","United Kingdom","2016","2016",3168.8,,
+"PATCINFC","J-Antiinfectives for systemic use","MTMOTCMT","Million US$ at exchange rate","GBR","United Kingdom","2017","2017",3366.5,,
+"PATCINFC","J-Antiinfectives for systemic use","MTMOTCMT","Million US$ at exchange rate","GBR","United Kingdom","2018","2018",3545.8,,
+"PATCINFC","J-Antiinfectives for systemic use","MTMOPPMT","Million US$, purchasing power parity","GBR","United Kingdom","2012","2012",2288.9,"B","Break"
+"PATCINFC","J-Antiinfectives for systemic use","MTMOPPMT","Million US$, purchasing power parity","GBR","United Kingdom","2013","2013",2487.5,,
+"PATCINFC","J-Antiinfectives for systemic use","MTMOPPMT","Million US$, purchasing power parity","GBR","United Kingdom","2014","2014",2640.4,,
+"PATCINFC","J-Antiinfectives for systemic use","MTMOPPMT","Million US$, purchasing power parity","GBR","United Kingdom","2015","2015",3002.7,,
+"PATCINFC","J-Antiinfectives for systemic use","MTMOPPMT","Million US$, purchasing power parity","GBR","United Kingdom","2016","2016",3408.2,,
+"PATCINFC","J-Antiinfectives for systemic use","MTMOPPMT","Million US$, purchasing power parity","GBR","United Kingdom","2017","2017",3820.8,,
+"PATCINFC","J-Antiinfectives for systemic use","MTMOPPMT","Million US$, purchasing power parity","GBR","United Kingdom","2018","2018",3864.5,,
+"PATCINFC","J-Antiinfectives for systemic use","TCPPERMT","/capita, US$ exchange rate","GBR","United Kingdom","2012","2012",39.8,"B","Break"
+"PATCINFC","J-Antiinfectives for systemic use","TCPPERMT","/capita, US$ exchange rate","GBR","United Kingdom","2013","2013",42.2,,
+"PATCINFC","J-Antiinfectives for systemic use","TCPPERMT","/capita, US$ exchange rate","GBR","United Kingdom","2014","2014",47,,
+"PATCINFC","J-Antiinfectives for systemic use","TCPPERMT","/capita, US$ exchange rate","GBR","United Kingdom","2015","2015",48.8,,
+"PATCINFC","J-Antiinfectives for systemic use","TCPPERMT","/capita, US$ exchange rate","GBR","United Kingdom","2016","2016",48.3,,
+"PATCINFC","J-Antiinfectives for systemic use","TCPPERMT","/capita, US$ exchange rate","GBR","United Kingdom","2017","2017",51,,
+"PATCINFC","J-Antiinfectives for systemic use","TCPPERMT","/capita, US$ exchange rate","GBR","United Kingdom","2018","2018",53.4,,
+"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","GBR","United Kingdom","2012","2012",35.9,"B","Break"
+"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","GBR","United Kingdom","2013","2013",38.8,,
+"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","GBR","United Kingdom","2014","2014",40.9,,
+"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","GBR","United Kingdom","2015","2015",46.1,,
+"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","GBR","United Kingdom","2016","2016",51.9,,
+"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","GBR","United Kingdom","2017","2017",57.9,,
+"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","GBR","United Kingdom","2018","2018",58.2,,
+"PATCINFC","J-Antiinfectives for systemic use","ATCPTTMT","% of total sales","GBR","United Kingdom","2012","2012",11.7,"B","Break"
+"PATCINFC","J-Antiinfectives for systemic use","ATCPTTMT","% of total sales","GBR","United Kingdom","2013","2013",11.8,,
+"PATCINFC","J-Antiinfectives for systemic use","ATCPTTMT","% of total sales","GBR","United Kingdom","2014","2014",11.5,,
+"PATCINFC","J-Antiinfectives for systemic use","ATCPTTMT","% of total sales","GBR","United Kingdom","2015","2015",11.8,,
+"PATCINFC","J-Antiinfectives for systemic use","ATCPTTMT","% of total sales","GBR","United Kingdom","2016","2016",12.6,,
+"PATCINFC","J-Antiinfectives for systemic use","ATCPTTMT","% of total sales","GBR","United Kingdom","2017","2017",13.4,,
+"PATCINFC","J-Antiinfectives for systemic use","ATCPTTMT","% of total sales","GBR","United Kingdom","2018","2018",13,,
+"PATCINFC","J-Antiinfectives for systemic use","MLLNCUMT","Million of national currency units","CHL","Chile","2010","2010",58760.8,,
+"PATCINFC","J-Antiinfectives for systemic use","MLLNCUMT","Million of national currency units","CHL","Chile","2011","2011",177900.9,"B","Break"
+"PATCINFC","J-Antiinfectives for systemic use","MLLNCUMT","Million of national currency units","CHL","Chile","2012","2012",132266.7,,
+"PATCINFC","J-Antiinfectives for systemic use","MLLNCUMT","Million of national currency units","CHL","Chile","2013","2013",209955.4,,
+"PATCINFC","J-Antiinfectives for systemic use","MLLNCUMT","Million of national currency units","CHL","Chile","2014","2014",180250.2,,
+"PATCINFC","J-Antiinfectives for systemic use","MLLNCUMT","Million of national currency units","CHL","Chile","2015","2015",241797.7,,
+"PATCINFC","J-Antiinfectives for systemic use","MLLNCUMT","Million of national currency units","CHL","Chile","2016","2016",281371,,
+"PATCINFC","J-Antiinfectives for systemic use","MLLNCUMT","Million of national currency units","CHL","Chile","2017","2017",255295,,
+"PATCINFC","J-Antiinfectives for systemic use","MLLNCUMT","Million of national currency units","CHL","Chile","2018","2018",351495.1,,
+"PATCINFC","J-Antiinfectives for systemic use","MLLNCUMT","Million of national currency units","CHL","Chile","2019","2019",359508.7,,
+"PATCINFC","J-Antiinfectives for systemic use","MLLNCUMT","Million of national currency units","CHL","Chile","2020","2020",433351.4,,
+"PATCINFC","J-Antiinfectives for systemic use","MLLNCUMT","Million of national currency units","CHL","Chile","2021","2021",310910.4,,
+"PATCINFC","J-Antiinfectives for systemic use","MLLNCUMT","Million of national currency units","CHL","Chile","2022","2022",391011.8,,
+"PATCINFC","J-Antiinfectives for systemic use","MTMOTCMT","Million US$ at exchange rate","CHL","Chile","2010","2010",115.2,,
+"PATCINFC","J-Antiinfectives for systemic use","MTMOTCMT","Million US$ at exchange rate","CHL","Chile","2011","2011",367.8,"B","Break"
+"PATCINFC","J-Antiinfectives for systemic use","MTMOTCMT","Million US$ at exchange rate","CHL","Chile","2012","2012",271.9,,
+"PATCINFC","J-Antiinfectives for systemic use","MTMOTCMT","Million US$ at exchange rate","CHL","Chile","2013","2013",423.9,,
+"PATCINFC","J-Antiinfectives for systemic use","MTMOTCMT","Million US$ at exchange rate","CHL","Chile","2014","2014",316,,
+"PATCINFC","J-Antiinfectives for systemic use","MTMOTCMT","Million US$ at exchange rate","CHL","Chile","2015","2015",369.7,,
+"PATCINFC","J-Antiinfectives for systemic use","MTMOTCMT","Million US$ at exchange rate","CHL","Chile","2016","2016",415.6,,
+"PATCINFC","J-Antiinfectives for systemic use","MTMOTCMT","Million US$ at exchange rate","CHL","Chile","2017","2017",393.5,,
+"PATCINFC","J-Antiinfectives for systemic use","MTMOTCMT","Million US$ at exchange rate","CHL","Chile","2018","2018",548.1,,
+"PATCINFC","J-Antiinfectives for systemic use","MTMOTCMT","Million US$ at exchange rate","CHL","Chile","2019","2019",511.5,,
+"PATCINFC","J-Antiinfectives for systemic use","MTMOTCMT","Million US$ at exchange rate","CHL","Chile","2020","2020",546.7,,
+"PATCINFC","J-Antiinfectives for systemic use","MTMOTCMT","Million US$ at exchange rate","CHL","Chile","2021","2021",409.7,,
+"PATCINFC","J-Antiinfectives for systemic use","MTMOTCMT","Million US$ at exchange rate","CHL","Chile","2022","2022",447.7,,
+"PATCINFC","J-Antiinfectives for systemic use","MTMOPPMT","Million US$, purchasing power parity","CHL","Chile","2010","2010",163.3,,
+"PATCINFC","J-Antiinfectives for systemic use","MTMOPPMT","Million US$, purchasing power parity","CHL","Chile","2011","2011",511.2,"B","Break"
+"PATCINFC","J-Antiinfectives for systemic use","MTMOPPMT","Million US$, purchasing power parity","CHL","Chile","2012","2012",380.9,,
+"PATCINFC","J-Antiinfectives for systemic use","MTMOPPMT","Million US$, purchasing power parity","CHL","Chile","2013","2013",600.4,,
+"PATCINFC","J-Antiinfectives for systemic use","MTMOPPMT","Million US$, purchasing power parity","CHL","Chile","2014","2014",490.9,,
+"PATCINFC","J-Antiinfectives for systemic use","MTMOPPMT","Million US$, purchasing power parity","CHL","Chile","2015","2015",618.1,,
+"PATCINFC","J-Antiinfectives for systemic use","MTMOPPMT","Million US$, purchasing power parity","CHL","Chile","2016","2016",708.3,,
+"PATCINFC","J-Antiinfectives for systemic use","MTMOPPMT","Million US$, purchasing power parity","CHL","Chile","2017","2017",641.9,,
+"PATCINFC","J-Antiinfectives for systemic use","MTMOPPMT","Million US$, purchasing power parity","CHL","Chile","2018","2018",887.1,,
+"PATCINFC","J-Antiinfectives for systemic use","MTMOPPMT","Million US$, purchasing power parity","CHL","Chile","2019","2019",895.2,,
+"PATCINFC","J-Antiinfectives for systemic use","MTMOPPMT","Million US$, purchasing power parity","CHL","Chile","2020","2020",1035.6,,
+"PATCINFC","J-Antiinfectives for systemic use","MTMOPPMT","Million US$, purchasing power parity","CHL","Chile","2021","2021",714.5,,
+"PATCINFC","J-Antiinfectives for systemic use","MTMOPPMT","Million US$, purchasing power parity","CHL","Chile","2022","2022",893.6,,
+"PATCINFC","J-Antiinfectives for systemic use","TCPPERMT","/capita, US$ exchange rate","CHL","Chile","2010","2010",6.7,,
+"PATCINFC","J-Antiinfectives for systemic use","TCPPERMT","/capita, US$ exchange rate","CHL","Chile","2011","2011",21.3,"B","Break"
+"PATCINFC","J-Antiinfectives for systemic use","TCPPERMT","/capita, US$ exchange rate","CHL","Chile","2012","2012",15.6,,
+"PATCINFC","J-Antiinfectives for systemic use","TCPPERMT","/capita, US$ exchange rate","CHL","Chile","2013","2013",24.1,,
+"PATCINFC","J-Antiinfectives for systemic use","TCPPERMT","/capita, US$ exchange rate","CHL","Chile","2014","2014",17.8,,
+"PATCINFC","J-Antiinfectives for systemic use","TCPPERMT","/capita, US$ exchange rate","CHL","Chile","2015","2015",20.6,,
+"PATCINFC","J-Antiinfectives for systemic use","TCPPERMT","/capita, US$ exchange rate","CHL","Chile","2016","2016",22.9,,
+"PATCINFC","J-Antiinfectives for systemic use","TCPPERMT","/capita, US$ exchange rate","CHL","Chile","2017","2017",21.4,,
+"PATCINFC","J-Antiinfectives for systemic use","TCPPERMT","/capita, US$ exchange rate","CHL","Chile","2018","2018",29.2,,
+"PATCINFC","J-Antiinfectives for systemic use","TCPPERMT","/capita, US$ exchange rate","CHL","Chile","2019","2019",26.8,,
+"PATCINFC","J-Antiinfectives for systemic use","TCPPERMT","/capita, US$ exchange rate","CHL","Chile","2020","2020",28.1,,
+"PATCINFC","J-Antiinfectives for systemic use","TCPPERMT","/capita, US$ exchange rate","CHL","Chile","2021","2021",20.8,,
+"PATCINFC","J-Antiinfectives for systemic use","TCPPERMT","/capita, US$ exchange rate","CHL","Chile","2022","2022",22.6,,
+"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2010","2010",9.6,,
+"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2011","2011",29.6,"B","Break"
+"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2012","2012",21.8,,
+"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2013","2013",34.1,,
+"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2014","2014",27.6,,
+"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2015","2015",34.4,,
+"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2016","2016",39,,
+"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2017","2017",34.9,,
+"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2018","2018",47.3,,
+"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2019","2019",46.8,,
+"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2020","2020",53.2,,
+"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2021","2021",36.3,,
+"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2022","2022",45.1,,
+"PATCINFC","J-Antiinfectives for systemic use","ATCPTTMT","% of total sales","CHL","Chile","2010","2010",7.1,,
+"PATCINFC","J-Antiinfectives for systemic use","ATCPTTMT","% of total sales","CHL","Chile","2011","2011",15.1,"B","Break"
+"PATCINFC","J-Antiinfectives for systemic use","ATCPTTMT","% of total sales","CHL","Chile","2012","2012",10.6,,
+"PATCINFC","J-Antiinfectives for systemic use","ATCPTTMT","% of total sales","CHL","Chile","2013","2013",14.5,,
+"PATCINFC","J-Antiinfectives for systemic use","ATCPTTMT","% of total sales","CHL","Chile","2014","2014",11.7,,
+"PATCINFC","J-Antiinfectives for systemic use","ATCPTTMT","% of total sales","CHL","Chile","2015","2015",13.3,,
+"PATCINFC","J-Antiinfectives for systemic use","ATCPTTMT","% of total sales","CHL","Chile","2016","2016",13.9,,
+"PATCINFC","J-Antiinfectives for systemic use","ATCPTTMT","% of total sales","CHL","Chile","2017","2017",12.3,,
+"PATCINFC","J-Antiinfectives for systemic use","ATCPTTMT","% of total sales","CHL","Chile","2018","2018",15.3,,
+"PATCINFC","J-Antiinfectives for systemic use","ATCPTTMT","% of total sales","CHL","Chile","2019","2019",14.3,,
+"PATCINFC","J-Antiinfectives for systemic use","ATCPTTMT","% of total sales","CHL","Chile","2020","2020",16.1,,
+"PATCINFC","J-Antiinfectives for systemic use","ATCPTTMT","% of total sales","CHL","Chile","2021","2021",11.1,,
+"PATCINFC","J-Antiinfectives for systemic use","ATCPTTMT","% of total sales","CHL","Chile","2022","2022",13.9,,
+"PATCINFC","J-Antiinfectives for systemic use","MLLNCUMT","Million of national currency units","EST","Estonia","2010","2010",19.8,,
+"PATCINFC","J-Antiinfectives for systemic use","MLLNCUMT","Million of national currency units","EST","Estonia","2011","2011",22.4,,
+"PATCINFC","J-Antiinfectives for systemic use","MLLNCUMT","Million of national currency units","EST","Estonia","2012","2012",24.5,,
+"PATCINFC","J-Antiinfectives for systemic use","MLLNCUMT","Million of national currency units","EST","Estonia","2013","2013",23.9,,
+"PATCINFC","J-Antiinfectives for systemic use","MLLNCUMT","Million of national currency units","EST","Estonia","2014","2014",28,,
+"PATCINFC","J-Antiinfectives for systemic use","MLLNCUMT","Million of national currency units","EST","Estonia","2015","2015",31.8,,
+"PATCINFC","J-Antiinfectives for systemic use","MLLNCUMT","Million of national currency units","EST","Estonia","2016","2016",44.3,,
+"PATCINFC","J-Antiinfectives for systemic use","MLLNCUMT","Million of national currency units","EST","Estonia","2017","2017",43.8,,
+"PATCINFC","J-Antiinfectives for systemic use","MLLNCUMT","Million of national currency units","EST","Estonia","2018","2018",46.9,,
+"PATCINFC","J-Antiinfectives for systemic use","MLLNCUMT","Million of national currency units","EST","Estonia","2019","2019",48.4,,
+"PATCINFC","J-Antiinfectives for systemic use","MLLNCUMT","Million of national currency units","EST","Estonia","2020","2020",44,,
+"PATCINFC","J-Antiinfectives for systemic use","MLLNCUMT","Million of national currency units","EST","Estonia","2021","2021",75.7,,
+"PATCINFC","J-Antiinfectives for systemic use","MLLNCUMT","Million of national currency units","EST","Estonia","2022","2022",60.4,,
+"PATCINFC","J-Antiinfectives for systemic use","MTMOTCMT","Million US$ at exchange rate","EST","Estonia","2010","2010",26.3,,
+"PATCINFC","J-Antiinfectives for systemic use","MTMOTCMT","Million US$ at exchange rate","EST","Estonia","2011","2011",31.1,,
+"PATCINFC","J-Antiinfectives for systemic use","MTMOTCMT","Million US$ at exchange rate","EST","Estonia","2012","2012",31.5,,
+"PATCINFC","J-Antiinfectives for systemic use","MTMOTCMT","Million US$ at exchange rate","EST","Estonia","2013","2013",31.8,,
+"PATCINFC","J-Antiinfectives for systemic use","MTMOTCMT","Million US$ at exchange rate","EST","Estonia","2014","2014",37.2,,
+"PATCINFC","J-Antiinfectives for systemic use","MTMOTCMT","Million US$ at exchange rate","EST","Estonia","2015","2015",35.3,,
+"PATCINFC","J-Antiinfectives for systemic use","MTMOTCMT","Million US$ at exchange rate","EST","Estonia","2016","2016",49.1,,
+"PATCINFC","J-Antiinfectives for systemic use","MTMOTCMT","Million US$ at exchange rate","EST","Estonia","2017","2017",49.4,,
+"PATCINFC","J-Antiinfectives for systemic use","MTMOTCMT","Million US$ at exchange rate","EST","Estonia","2018","2018",55.4,,
+"PATCINFC","J-Antiinfectives for systemic use","MTMOTCMT","Million US$ at exchange rate","EST","Estonia","2019","2019",54.2,,
+"PATCINFC","J-Antiinfectives for systemic use","MTMOTCMT","Million US$ at exchange rate","EST","Estonia","2020","2020",50.3,,
+"PATCINFC","J-Antiinfectives for systemic use","MTMOTCMT","Million US$ at exchange rate","EST","Estonia","2021","2021",89.6,,
+"PATCINFC","J-Antiinfectives for systemic use","MTMOTCMT","Million US$ at exchange rate","EST","Estonia","2022","2022",63.6,,
+"PATCINFC","J-Antiinfectives for systemic use","MTMOPPMT","Million US$, purchasing power parity","EST","Estonia","2010","2010",38.7,,
+"PATCINFC","J-Antiinfectives for systemic use","MTMOPPMT","Million US$, purchasing power parity","EST","Estonia","2011","2011",43.7,,
+"PATCINFC","J-Antiinfectives for systemic use","MTMOPPMT","Million US$, purchasing power parity","EST","Estonia","2012","2012",47.1,,
+"PATCINFC","J-Antiinfectives for systemic use","MTMOPPMT","Million US$, purchasing power parity","EST","Estonia","2013","2013",45.8,,
+"PATCINFC","J-Antiinfectives for systemic use","MTMOPPMT","Million US$, purchasing power parity","EST","Estonia","2014","2014",53.2,,
+"PATCINFC","J-Antiinfectives for systemic use","MTMOPPMT","Million US$, purchasing power parity","EST","Estonia","2015","2015",59.2,,
+"PATCINFC","J-Antiinfectives for systemic use","MTMOPPMT","Million US$, purchasing power parity","EST","Estonia","2016","2016",84,,
+"PATCINFC","J-Antiinfectives for systemic use","MTMOPPMT","Million US$, purchasing power parity","EST","Estonia","2017","2017",81.8,,
+"PATCINFC","J-Antiinfectives for systemic use","MTMOPPMT","Million US$, purchasing power parity","EST","Estonia","2018","2018",87.1,,
+"PATCINFC","J-Antiinfectives for systemic use","MTMOPPMT","Million US$, purchasing power parity","EST","Estonia","2019","2019",90.2,,
+"PATCINFC","J-Antiinfectives for systemic use","MTMOPPMT","Million US$, purchasing power parity","EST","Estonia","2020","2020",84.1,,
+"PATCINFC","J-Antiinfectives for systemic use","MTMOPPMT","Million US$, purchasing power parity","EST","Estonia","2021","2021",139.4,,
+"PATCINFC","J-Antiinfectives for systemic use","MTMOPPMT","Million US$, purchasing power parity","EST","Estonia","2022","2022",106.1,,
+"PATCINFC","J-Antiinfectives for systemic use","TCPPERMT","/capita, US$ exchange rate","EST","Estonia","2010","2010",19.7,,
+"PATCINFC","J-Antiinfectives for systemic use","TCPPERMT","/capita, US$ exchange rate","EST","Estonia","2011","2011",23.4,,
+"PATCINFC","J-Antiinfectives for systemic use","TCPPERMT","/capita, US$ exchange rate","EST","Estonia","2012","2012",23.8,,
+"PATCINFC","J-Antiinfectives for systemic use","TCPPERMT","/capita, US$ exchange rate","EST","Estonia","2013","2013",24.1,,
+"PATCINFC","J-Antiinfectives for systemic use","TCPPERMT","/capita, US$ exchange rate","EST","Estonia","2014","2014",28.3,,
+"PATCINFC","J-Antiinfectives for systemic use","TCPPERMT","/capita, US$ exchange rate","EST","Estonia","2015","2015",26.8,,
+"PATCINFC","J-Antiinfectives for systemic use","TCPPERMT","/capita, US$ exchange rate","EST","Estonia","2016","2016",37.3,,
+"PATCINFC","J-Antiinfectives for systemic use","TCPPERMT","/capita, US$ exchange rate","EST","Estonia","2017","2017",37.5,,
+"PATCINFC","J-Antiinfectives for systemic use","TCPPERMT","/capita, US$ exchange rate","EST","Estonia","2018","2018",41.9,,
+"PATCINFC","J-Antiinfectives for systemic use","TCPPERMT","/capita, US$ exchange rate","EST","Estonia","2019","2019",40.8,,
+"PATCINFC","J-Antiinfectives for systemic use","TCPPERMT","/capita, US$ exchange rate","EST","Estonia","2020","2020",37.8,,
+"PATCINFC","J-Antiinfectives for systemic use","TCPPERMT","/capita, US$ exchange rate","EST","Estonia","2021","2021",67.3,,
+"PATCINFC","J-Antiinfectives for systemic use","TCPPERMT","/capita, US$ exchange rate","EST","Estonia","2022","2022",47.8,,
+"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2010","2010",29.1,,
+"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2011","2011",32.9,,
+"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2012","2012",35.6,,
+"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2013","2013",34.7,,
+"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2014","2014",40.5,,
+"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2015","2015",45,,
+"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2016","2016",63.8,,
+"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2017","2017",62.1,,
+"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2018","2018",65.9,,
+"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2019","2019",68,,
+"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2020","2020",63.3,,
+"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2021","2021",104.7,,
+"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2022","2022",79.7,,
+"PATCINFC","J-Antiinfectives for systemic use","ATCPTTMT","% of total sales","EST","Estonia","2010","2010",10.2,,
+"PATCINFC","J-Antiinfectives for systemic use","ATCPTTMT","% of total sales","EST","Estonia","2011","2011",10.9,,
+"PATCINFC","J-Antiinfectives for systemic use","ATCPTTMT","% of total sales","EST","Estonia","2012","2012",11.1,,
+"PATCINFC","J-Antiinfectives for systemic use","ATCPTTMT","% of total sales","EST","Estonia","2013","2013",10.4,,
+"PATCINFC","J-Antiinfectives for systemic use","ATCPTTMT","% of total sales","EST","Estonia","2014","2014",11.2,,
+"PATCINFC","J-Antiinfectives for systemic use","ATCPTTMT","% of total sales","EST","Estonia","2015","2015",12,,
+"PATCINFC","J-Antiinfectives for systemic use","ATCPTTMT","% of total sales","EST","Estonia","2016","2016",15.3,,
+"PATCINFC","J-Antiinfectives for systemic use","ATCPTTMT","% of total sales","EST","Estonia","2017","2017",14.5,,
+"PATCINFC","J-Antiinfectives for systemic use","ATCPTTMT","% of total sales","EST","Estonia","2018","2018",14.4,,
+"PATCINFC","J-Antiinfectives for systemic use","ATCPTTMT","% of total sales","EST","Estonia","2019","2019",14.1,,
+"PATCINFC","J-Antiinfectives for systemic use","ATCPTTMT","% of total sales","EST","Estonia","2020","2020",12.3,,
+"PATCINFC","J-Antiinfectives for systemic use","ATCPTTMT","% of total sales","EST","Estonia","2021","2021",18.5,,
+"PATCINFC","J-Antiinfectives for systemic use","ATCPTTMT","% of total sales","EST","Estonia","2022","2022",14,,
+"PATCINFC","J-Antiinfectives for systemic use","MLLNCUMT","Million of national currency units","SVN","Slovenia","2010","2010",19,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","MLLNCUMT","Million of national currency units","SVN","Slovenia","2011","2011",19.6,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","MLLNCUMT","Million of national currency units","SVN","Slovenia","2012","2012",19.9,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","MLLNCUMT","Million of national currency units","SVN","Slovenia","2013","2013",21.2,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","MLLNCUMT","Million of national currency units","SVN","Slovenia","2014","2014",19.9,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","MLLNCUMT","Million of national currency units","SVN","Slovenia","2015","2015",26.6,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","MLLNCUMT","Million of national currency units","SVN","Slovenia","2016","2016",29.5,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","MLLNCUMT","Million of national currency units","SVN","Slovenia","2017","2017",27.2,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","MLLNCUMT","Million of national currency units","SVN","Slovenia","2018","2018",29.5,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","MLLNCUMT","Million of national currency units","SVN","Slovenia","2019","2019",27.7,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","MLLNCUMT","Million of national currency units","SVN","Slovenia","2020","2020",22.3,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","MLLNCUMT","Million of national currency units","SVN","Slovenia","2021","2021",22.1,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","MLLNCUMT","Million of national currency units","SVN","Slovenia","2022","2022",25.8,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","MTMOTCMT","Million US$ at exchange rate","SVN","Slovenia","2010","2010",25.2,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","MTMOTCMT","Million US$ at exchange rate","SVN","Slovenia","2011","2011",27.3,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","MTMOTCMT","Million US$ at exchange rate","SVN","Slovenia","2012","2012",25.5,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","MTMOTCMT","Million US$ at exchange rate","SVN","Slovenia","2013","2013",28.2,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","MTMOTCMT","Million US$ at exchange rate","SVN","Slovenia","2014","2014",26.4,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","MTMOTCMT","Million US$ at exchange rate","SVN","Slovenia","2015","2015",29.5,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","MTMOTCMT","Million US$ at exchange rate","SVN","Slovenia","2016","2016",32.7,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","MTMOTCMT","Million US$ at exchange rate","SVN","Slovenia","2017","2017",30.8,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","MTMOTCMT","Million US$ at exchange rate","SVN","Slovenia","2018","2018",34.8,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","MTMOTCMT","Million US$ at exchange rate","SVN","Slovenia","2019","2019",31,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","MTMOTCMT","Million US$ at exchange rate","SVN","Slovenia","2020","2020",25.5,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","MTMOTCMT","Million US$ at exchange rate","SVN","Slovenia","2021","2021",26.1,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","MTMOTCMT","Million US$ at exchange rate","SVN","Slovenia","2022","2022",27.2,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","MTMOPPMT","Million US$, purchasing power parity","SVN","Slovenia","2010","2010",29.8,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","MTMOPPMT","Million US$, purchasing power parity","SVN","Slovenia","2011","2011",31.5,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","MTMOPPMT","Million US$, purchasing power parity","SVN","Slovenia","2012","2012",32.7,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","MTMOPPMT","Million US$, purchasing power parity","SVN","Slovenia","2013","2013",36,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","MTMOPPMT","Million US$, purchasing power parity","SVN","Slovenia","2014","2014",33.6,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","MTMOPPMT","Million US$, purchasing power parity","SVN","Slovenia","2015","2015",44.7,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","MTMOPPMT","Million US$, purchasing power parity","SVN","Slovenia","2016","2016",51.1,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","MTMOPPMT","Million US$, purchasing power parity","SVN","Slovenia","2017","2017",47.8,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","MTMOPPMT","Million US$, purchasing power parity","SVN","Slovenia","2018","2018",51.9,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","MTMOPPMT","Million US$, purchasing power parity","SVN","Slovenia","2019","2019",50.1,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","MTMOPPMT","Million US$, purchasing power parity","SVN","Slovenia","2020","2020",40.8,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","MTMOPPMT","Million US$, purchasing power parity","SVN","Slovenia","2021","2021",39.2,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","MTMOPPMT","Million US$, purchasing power parity","SVN","Slovenia","2022","2022",46.8,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","TCPPERMT","/capita, US$ exchange rate","SVN","Slovenia","2010","2010",12.3,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","TCPPERMT","/capita, US$ exchange rate","SVN","Slovenia","2011","2011",13.3,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","TCPPERMT","/capita, US$ exchange rate","SVN","Slovenia","2012","2012",12.4,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","TCPPERMT","/capita, US$ exchange rate","SVN","Slovenia","2013","2013",13.7,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","TCPPERMT","/capita, US$ exchange rate","SVN","Slovenia","2014","2014",12.8,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","TCPPERMT","/capita, US$ exchange rate","SVN","Slovenia","2015","2015",14.3,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","TCPPERMT","/capita, US$ exchange rate","SVN","Slovenia","2016","2016",15.8,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","TCPPERMT","/capita, US$ exchange rate","SVN","Slovenia","2017","2017",14.9,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","TCPPERMT","/capita, US$ exchange rate","SVN","Slovenia","2018","2018",16.8,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","TCPPERMT","/capita, US$ exchange rate","SVN","Slovenia","2019","2019",14.8,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","TCPPERMT","/capita, US$ exchange rate","SVN","Slovenia","2020","2020",12.1,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","TCPPERMT","/capita, US$ exchange rate","SVN","Slovenia","2021","2021",12.4,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","TCPPERMT","/capita, US$ exchange rate","SVN","Slovenia","2022","2022",12.9,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2010","2010",14.6,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2011","2011",15.3,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2012","2012",15.9,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2013","2013",17.5,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2014","2014",16.3,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2015","2015",21.6,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2016","2016",24.8,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2017","2017",23.1,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2018","2018",25,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2019","2019",24,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2020","2020",19.4,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2021","2021",18.6,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2022","2022",22.2,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","ATCPTTMT","% of total sales","SVN","Slovenia","2010","2010",4,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","ATCPTTMT","% of total sales","SVN","Slovenia","2011","2011",4.2,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","ATCPTTMT","% of total sales","SVN","Slovenia","2012","2012",4.4,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","ATCPTTMT","% of total sales","SVN","Slovenia","2013","2013",4.7,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","ATCPTTMT","% of total sales","SVN","Slovenia","2014","2014",4.6,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","ATCPTTMT","% of total sales","SVN","Slovenia","2015","2015",6,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","ATCPTTMT","% of total sales","SVN","Slovenia","2016","2016",6.3,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","ATCPTTMT","% of total sales","SVN","Slovenia","2017","2017",5.6,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","ATCPTTMT","% of total sales","SVN","Slovenia","2018","2018",5.7,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","ATCPTTMT","% of total sales","SVN","Slovenia","2019","2019",5.1,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","ATCPTTMT","% of total sales","SVN","Slovenia","2020","2020",3.9,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","ATCPTTMT","% of total sales","SVN","Slovenia","2021","2021",3.6,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","ATCPTTMT","% of total sales","SVN","Slovenia","2022","2022",3.8,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","MLLNCUMT","Million of national currency units","AUS","Australia","2010","2010",194,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","MLLNCUMT","Million of national currency units","AUS","Australia","2011","2011",198,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","MLLNCUMT","Million of national currency units","AUS","Australia","2012","2012",184,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","MLLNCUMT","Million of national currency units","AUS","Australia","2013","2013",320,"B; D","Break; Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","MLLNCUMT","Million of national currency units","AUS","Australia","2014","2014",320,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","MLLNCUMT","Million of national currency units","AUS","Australia","2015","2015",363,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","MLLNCUMT","Million of national currency units","AUS","Australia","2016","2016",392,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","MLLNCUMT","Million of national currency units","AUS","Australia","2017","2017",395,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","MLLNCUMT","Million of national currency units","AUS","Australia","2018","2018",389,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","MLLNCUMT","Million of national currency units","AUS","Australia","2019","2019",400,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","MLLNCUMT","Million of national currency units","AUS","Australia","2020","2020",311,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","MLLNCUMT","Million of national currency units","AUS","Australia","2021","2021",323,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","MTMOTCMT","Million US$ at exchange rate","AUS","Australia","2010","2010",178,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","MTMOTCMT","Million US$ at exchange rate","AUS","Australia","2011","2011",204.2,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","MTMOTCMT","Million US$ at exchange rate","AUS","Australia","2012","2012",190.5,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","MTMOTCMT","Million US$ at exchange rate","AUS","Australia","2013","2013",308.9,"B; D","Break; Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","MTMOTCMT","Million US$ at exchange rate","AUS","Australia","2014","2014",288.5,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","MTMOTCMT","Million US$ at exchange rate","AUS","Australia","2015","2015",272.7,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","MTMOTCMT","Million US$ at exchange rate","AUS","Australia","2016","2016",291.4,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","MTMOTCMT","Million US$ at exchange rate","AUS","Australia","2017","2017",302.7,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","MTMOTCMT","Million US$ at exchange rate","AUS","Australia","2018","2018",290.6,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","MTMOTCMT","Million US$ at exchange rate","AUS","Australia","2019","2019",278.1,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","MTMOTCMT","Million US$ at exchange rate","AUS","Australia","2020","2020",214,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","MTMOTCMT","Million US$ at exchange rate","AUS","Australia","2021","2021",242.6,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","MTMOPPMT","Million US$, purchasing power parity","AUS","Australia","2010","2010",129,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","MTMOPPMT","Million US$, purchasing power parity","AUS","Australia","2011","2011",131,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","MTMOPPMT","Million US$, purchasing power parity","AUS","Australia","2012","2012",119.5,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","MTMOPPMT","Million US$, purchasing power parity","AUS","Australia","2013","2013",221.1,"B; D","Break; Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","MTMOPPMT","Million US$, purchasing power parity","AUS","Australia","2014","2014",220.3,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","MTMOPPMT","Million US$, purchasing power parity","AUS","Australia","2015","2015",246.3,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","MTMOPPMT","Million US$, purchasing power parity","AUS","Australia","2016","2016",270.3,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","MTMOPPMT","Million US$, purchasing power parity","AUS","Australia","2017","2017",267.3,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","MTMOPPMT","Million US$, purchasing power parity","AUS","Australia","2018","2018",264.6,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","MTMOPPMT","Million US$, purchasing power parity","AUS","Australia","2019","2019",270.3,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","MTMOPPMT","Million US$, purchasing power parity","AUS","Australia","2020","2020",213.9,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","MTMOPPMT","Million US$, purchasing power parity","AUS","Australia","2021","2021",223.1,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","TCPPERMT","/capita, US$ exchange rate","AUS","Australia","2010","2010",8.1,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","TCPPERMT","/capita, US$ exchange rate","AUS","Australia","2011","2011",9.1,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","TCPPERMT","/capita, US$ exchange rate","AUS","Australia","2012","2012",8.4,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","TCPPERMT","/capita, US$ exchange rate","AUS","Australia","2013","2013",13.4,"B; D","Break; Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","TCPPERMT","/capita, US$ exchange rate","AUS","Australia","2014","2014",12.3,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","TCPPERMT","/capita, US$ exchange rate","AUS","Australia","2015","2015",11.5,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","TCPPERMT","/capita, US$ exchange rate","AUS","Australia","2016","2016",12,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","TCPPERMT","/capita, US$ exchange rate","AUS","Australia","2017","2017",12.3,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","TCPPERMT","/capita, US$ exchange rate","AUS","Australia","2018","2018",11.6,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","TCPPERMT","/capita, US$ exchange rate","AUS","Australia","2019","2019",11,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","TCPPERMT","/capita, US$ exchange rate","AUS","Australia","2020","2020",8.3,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","TCPPERMT","/capita, US$ exchange rate","AUS","Australia","2021","2021",9.4,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2010","2010",5.9,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2011","2011",5.9,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2012","2012",5.3,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2013","2013",9.6,"B; D","Break; Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2014","2014",9.4,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2015","2015",10.3,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2016","2016",11.2,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2017","2017",10.9,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2018","2018",10.6,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2019","2019",10.7,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2020","2020",8.3,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2021","2021",8.7,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","ATCPTTMT","% of total sales","AUS","Australia","2010","2010",2,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","ATCPTTMT","% of total sales","AUS","Australia","2011","2011",1.9,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","ATCPTTMT","% of total sales","AUS","Australia","2012","2012",1.8,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","ATCPTTMT","% of total sales","AUS","Australia","2013","2013",2.7,"B; D","Break; Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","ATCPTTMT","% of total sales","AUS","Australia","2014","2014",2.7,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","ATCPTTMT","% of total sales","AUS","Australia","2015","2015",3,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","ATCPTTMT","% of total sales","AUS","Australia","2016","2016",2.6,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","ATCPTTMT","% of total sales","AUS","Australia","2017","2017",2.7,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","ATCPTTMT","% of total sales","AUS","Australia","2018","2018",2.6,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","ATCPTTMT","% of total sales","AUS","Australia","2019","2019",2.6,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","ATCPTTMT","% of total sales","AUS","Australia","2020","2020",1.9,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","ATCPTTMT","% of total sales","AUS","Australia","2021","2021",1.8,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","MLLNCUMT","Million of national currency units","AUT","Austria","2010","2010",74.3,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","MLLNCUMT","Million of national currency units","AUT","Austria","2011","2011",71.8,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","MLLNCUMT","Million of national currency units","AUT","Austria","2012","2012",68.2,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","MLLNCUMT","Million of national currency units","AUT","Austria","2013","2013",69.7,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","MLLNCUMT","Million of national currency units","AUT","Austria","2014","2014",66.1,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","MLLNCUMT","Million of national currency units","AUT","Austria","2015","2015",65.2,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","MLLNCUMT","Million of national currency units","AUT","Austria","2016","2016",62.6,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","MLLNCUMT","Million of national currency units","AUT","Austria","2017","2017",59.8,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","MLLNCUMT","Million of national currency units","AUT","Austria","2018","2018",58.1,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","MLLNCUMT","Million of national currency units","AUT","Austria","2019","2019",54.3,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","MLLNCUMT","Million of national currency units","AUT","Austria","2020","2020",43.5,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","MLLNCUMT","Million of national currency units","AUT","Austria","2021","2021",41.8,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","MTMOTCMT","Million US$ at exchange rate","AUT","Austria","2010","2010",98.5,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","MTMOTCMT","Million US$ at exchange rate","AUT","Austria","2011","2011",100,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","MTMOTCMT","Million US$ at exchange rate","AUT","Austria","2012","2012",87.6,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","MTMOTCMT","Million US$ at exchange rate","AUT","Austria","2013","2013",92.6,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","MTMOTCMT","Million US$ at exchange rate","AUT","Austria","2014","2014",87.8,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","MTMOTCMT","Million US$ at exchange rate","AUT","Austria","2015","2015",72.3,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","MTMOTCMT","Million US$ at exchange rate","AUT","Austria","2016","2016",69.3,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","MTMOTCMT","Million US$ at exchange rate","AUT","Austria","2017","2017",67.6,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","MTMOTCMT","Million US$ at exchange rate","AUT","Austria","2018","2018",68.6,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","MTMOTCMT","Million US$ at exchange rate","AUT","Austria","2019","2019",60.8,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","MTMOTCMT","Million US$ at exchange rate","AUT","Austria","2020","2020",49.6,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","MTMOTCMT","Million US$ at exchange rate","AUT","Austria","2021","2021",49.4,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","MTMOPPMT","Million US$, purchasing power parity","AUT","Austria","2010","2010",88.2,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","MTMOPPMT","Million US$, purchasing power parity","AUT","Austria","2011","2011",86.4,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","MTMOPPMT","Million US$, purchasing power parity","AUT","Austria","2012","2012",83.8,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","MTMOPPMT","Million US$, purchasing power parity","AUT","Austria","2013","2013",87.5,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","MTMOPPMT","Million US$, purchasing power parity","AUT","Austria","2014","2014",82.7,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","MTMOPPMT","Million US$, purchasing power parity","AUT","Austria","2015","2015",81.6,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","MTMOPPMT","Million US$, purchasing power parity","AUT","Austria","2016","2016",80.6,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","MTMOPPMT","Million US$, purchasing power parity","AUT","Austria","2017","2017",77.2,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","MTMOPPMT","Million US$, purchasing power parity","AUT","Austria","2018","2018",75.9,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","MTMOPPMT","Million US$, purchasing power parity","AUT","Austria","2019","2019",72.5,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","MTMOPPMT","Million US$, purchasing power parity","AUT","Austria","2020","2020",58.2,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","MTMOPPMT","Million US$, purchasing power parity","AUT","Austria","2021","2021",55.2,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","TCPPERMT","/capita, US$ exchange rate","AUT","Austria","2010","2010",11.8,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","TCPPERMT","/capita, US$ exchange rate","AUT","Austria","2011","2011",11.9,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","TCPPERMT","/capita, US$ exchange rate","AUT","Austria","2012","2012",10.4,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","TCPPERMT","/capita, US$ exchange rate","AUT","Austria","2013","2013",10.9,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","TCPPERMT","/capita, US$ exchange rate","AUT","Austria","2014","2014",10.3,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","TCPPERMT","/capita, US$ exchange rate","AUT","Austria","2015","2015",8.4,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","TCPPERMT","/capita, US$ exchange rate","AUT","Austria","2016","2016",7.9,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","TCPPERMT","/capita, US$ exchange rate","AUT","Austria","2017","2017",7.7,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","TCPPERMT","/capita, US$ exchange rate","AUT","Austria","2018","2018",7.8,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","TCPPERMT","/capita, US$ exchange rate","AUT","Austria","2019","2019",6.8,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","TCPPERMT","/capita, US$ exchange rate","AUT","Austria","2020","2020",5.6,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","TCPPERMT","/capita, US$ exchange rate","AUT","Austria","2021","2021",5.5,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2010","2010",10.6,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2011","2011",10.3,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2012","2012",9.9,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2013","2013",10.3,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2014","2014",9.7,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2015","2015",9.4,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2016","2016",9.2,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2017","2017",8.8,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2018","2018",8.6,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2019","2019",8.2,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2020","2020",6.5,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2021","2021",6.2,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","ATCPTTMT","% of total sales","AUT","Austria","2010","2010",3,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","ATCPTTMT","% of total sales","AUT","Austria","2011","2011",2.8,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","ATCPTTMT","% of total sales","AUT","Austria","2012","2012",2.6,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","ATCPTTMT","% of total sales","AUT","Austria","2013","2013",2.6,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","ATCPTTMT","% of total sales","AUT","Austria","2014","2014",2.4,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","ATCPTTMT","% of total sales","AUT","Austria","2015","2015",2.2,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","ATCPTTMT","% of total sales","AUT","Austria","2016","2016",2.1,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","ATCPTTMT","% of total sales","AUT","Austria","2017","2017",1.9,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","ATCPTTMT","% of total sales","AUT","Austria","2018","2018",1.8,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","ATCPTTMT","% of total sales","AUT","Austria","2019","2019",1.6,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","ATCPTTMT","% of total sales","AUT","Austria","2020","2020",1.3,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","ATCPTTMT","% of total sales","AUT","Austria","2021","2021",1.1,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","MLLNCUMT","Million of national currency units","BEL","Belgium","2010","2010",251.4,,
+"PATCBIOT","J01-Antibacterials for systemic use","MLLNCUMT","Million of national currency units","BEL","Belgium","2011","2011",244.6,,
+"PATCBIOT","J01-Antibacterials for systemic use","MLLNCUMT","Million of national currency units","BEL","Belgium","2012","2012",225.8,,
+"PATCBIOT","J01-Antibacterials for systemic use","MLLNCUMT","Million of national currency units","BEL","Belgium","2013","2013",218.9,,
+"PATCBIOT","J01-Antibacterials for systemic use","MLLNCUMT","Million of national currency units","BEL","Belgium","2014","2014",213.6,,
+"PATCBIOT","J01-Antibacterials for systemic use","MLLNCUMT","Million of national currency units","BEL","Belgium","2015","2015",215.7,,
+"PATCBIOT","J01-Antibacterials for systemic use","MLLNCUMT","Million of national currency units","BEL","Belgium","2016","2016",197.1,,
+"PATCBIOT","J01-Antibacterials for systemic use","MLLNCUMT","Million of national currency units","BEL","Belgium","2017","2017",189.6,,
+"PATCBIOT","J01-Antibacterials for systemic use","MLLNCUMT","Million of national currency units","BEL","Belgium","2018","2018",186.6,,
+"PATCBIOT","J01-Antibacterials for systemic use","MLLNCUMT","Million of national currency units","BEL","Belgium","2019","2019",193.2,,
+"PATCBIOT","J01-Antibacterials for systemic use","MLLNCUMT","Million of national currency units","BEL","Belgium","2020","2020",168.9,,
+"PATCBIOT","J01-Antibacterials for systemic use","MLLNCUMT","Million of national currency units","BEL","Belgium","2021","2021",177.4,,
+"PATCBIOT","J01-Antibacterials for systemic use","MLLNCUMT","Million of national currency units","BEL","Belgium","2022","2022",203,"E","Estimated value"
+"PATCBIOT","J01-Antibacterials for systemic use","MTMOTCMT","Million US$ at exchange rate","BEL","Belgium","2010","2010",333.3,,
+"PATCBIOT","J01-Antibacterials for systemic use","MTMOTCMT","Million US$ at exchange rate","BEL","Belgium","2011","2011",340.5,,
+"PATCBIOT","J01-Antibacterials for systemic use","MTMOTCMT","Million US$ at exchange rate","BEL","Belgium","2012","2012",290.2,,
+"PATCBIOT","J01-Antibacterials for systemic use","MTMOTCMT","Million US$ at exchange rate","BEL","Belgium","2013","2013",290.7,,
+"PATCBIOT","J01-Antibacterials for systemic use","MTMOTCMT","Million US$ at exchange rate","BEL","Belgium","2014","2014",283.7,,
+"PATCBIOT","J01-Antibacterials for systemic use","MTMOTCMT","Million US$ at exchange rate","BEL","Belgium","2015","2015",239.3,,
+"PATCBIOT","J01-Antibacterials for systemic use","MTMOTCMT","Million US$ at exchange rate","BEL","Belgium","2016","2016",218.2,,
+"PATCBIOT","J01-Antibacterials for systemic use","MTMOTCMT","Million US$ at exchange rate","BEL","Belgium","2017","2017",214.2,,
+"PATCBIOT","J01-Antibacterials for systemic use","MTMOTCMT","Million US$ at exchange rate","BEL","Belgium","2018","2018",220.4,,
+"PATCBIOT","J01-Antibacterials for systemic use","MTMOTCMT","Million US$ at exchange rate","BEL","Belgium","2019","2019",216.3,,
+"PATCBIOT","J01-Antibacterials for systemic use","MTMOTCMT","Million US$ at exchange rate","BEL","Belgium","2020","2020",192.9,,
+"PATCBIOT","J01-Antibacterials for systemic use","MTMOTCMT","Million US$ at exchange rate","BEL","Belgium","2021","2021",209.8,,
+"PATCBIOT","J01-Antibacterials for systemic use","MTMOTCMT","Million US$ at exchange rate","BEL","Belgium","2022","2022",213.8,"E","Estimated value"
+"PATCBIOT","J01-Antibacterials for systemic use","MTMOPPMT","Million US$, purchasing power parity","BEL","Belgium","2010","2010",300.5,,
+"PATCBIOT","J01-Antibacterials for systemic use","MTMOPPMT","Million US$, purchasing power parity","BEL","Belgium","2011","2011",294.1,,
+"PATCBIOT","J01-Antibacterials for systemic use","MTMOPPMT","Million US$, purchasing power parity","BEL","Belgium","2012","2012",274.7,,
+"PATCBIOT","J01-Antibacterials for systemic use","MTMOPPMT","Million US$, purchasing power parity","BEL","Belgium","2013","2013",271.5,,
+"PATCBIOT","J01-Antibacterials for systemic use","MTMOPPMT","Million US$, purchasing power parity","BEL","Belgium","2014","2014",266.9,,
+"PATCBIOT","J01-Antibacterials for systemic use","MTMOPPMT","Million US$, purchasing power parity","BEL","Belgium","2015","2015",269.6,,
+"PATCBIOT","J01-Antibacterials for systemic use","MTMOPPMT","Million US$, purchasing power parity","BEL","Belgium","2016","2016",252.4,,
+"PATCBIOT","J01-Antibacterials for systemic use","MTMOPPMT","Million US$, purchasing power parity","BEL","Belgium","2017","2017",244.4,,
+"PATCBIOT","J01-Antibacterials for systemic use","MTMOPPMT","Million US$, purchasing power parity","BEL","Belgium","2018","2018",243.5,,
+"PATCBIOT","J01-Antibacterials for systemic use","MTMOPPMT","Million US$, purchasing power parity","BEL","Belgium","2019","2019",258.7,,
+"PATCBIOT","J01-Antibacterials for systemic use","MTMOPPMT","Million US$, purchasing power parity","BEL","Belgium","2020","2020",231.3,,
+"PATCBIOT","J01-Antibacterials for systemic use","MTMOPPMT","Million US$, purchasing power parity","BEL","Belgium","2021","2021",240.7,,
+"PATCBIOT","J01-Antibacterials for systemic use","MTMOPPMT","Million US$, purchasing power parity","BEL","Belgium","2022","2022",284.3,"E","Estimated value"
+"PATCBIOT","J01-Antibacterials for systemic use","TCPPERMT","/capita, US$ exchange rate","BEL","Belgium","2010","2010",30.6,,
+"PATCBIOT","J01-Antibacterials for systemic use","TCPPERMT","/capita, US$ exchange rate","BEL","Belgium","2011","2011",30.8,,
+"PATCBIOT","J01-Antibacterials for systemic use","TCPPERMT","/capita, US$ exchange rate","BEL","Belgium","2012","2012",26.1,,
+"PATCBIOT","J01-Antibacterials for systemic use","TCPPERMT","/capita, US$ exchange rate","BEL","Belgium","2013","2013",26.1,,
+"PATCBIOT","J01-Antibacterials for systemic use","TCPPERMT","/capita, US$ exchange rate","BEL","Belgium","2014","2014",25.3,,
+"PATCBIOT","J01-Antibacterials for systemic use","TCPPERMT","/capita, US$ exchange rate","BEL","Belgium","2015","2015",21.2,,
+"PATCBIOT","J01-Antibacterials for systemic use","TCPPERMT","/capita, US$ exchange rate","BEL","Belgium","2016","2016",19.3,,
+"PATCBIOT","J01-Antibacterials for systemic use","TCPPERMT","/capita, US$ exchange rate","BEL","Belgium","2017","2017",18.8,,
+"PATCBIOT","J01-Antibacterials for systemic use","TCPPERMT","/capita, US$ exchange rate","BEL","Belgium","2018","2018",19.3,,
+"PATCBIOT","J01-Antibacterials for systemic use","TCPPERMT","/capita, US$ exchange rate","BEL","Belgium","2019","2019",18.8,,
+"PATCBIOT","J01-Antibacterials for systemic use","TCPPERMT","/capita, US$ exchange rate","BEL","Belgium","2020","2020",16.7,,
+"PATCBIOT","J01-Antibacterials for systemic use","TCPPERMT","/capita, US$ exchange rate","BEL","Belgium","2021","2021",18.1,,
+"PATCBIOT","J01-Antibacterials for systemic use","TCPPERMT","/capita, US$ exchange rate","BEL","Belgium","2022","2022",18.4,"E","Estimated value"
+"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2010","2010",27.6,,
+"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2011","2011",26.6,,
+"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2012","2012",24.7,,
+"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2013","2013",24.3,,
+"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2014","2014",23.8,,
+"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2015","2015",23.9,,
+"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2016","2016",22.3,,
+"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2017","2017",21.5,,
+"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2018","2018",21.3,,
+"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2019","2019",22.5,,
+"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2020","2020",20,,
+"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2021","2021",20.8,,
+"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2022","2022",24.5,"E","Estimated value"
+"PATCBIOT","J01-Antibacterials for systemic use","ATCPTTMT","% of total sales","BEL","Belgium","2010","2010",4.3,,
+"PATCBIOT","J01-Antibacterials for systemic use","ATCPTTMT","% of total sales","BEL","Belgium","2011","2011",4.1,,
+"PATCBIOT","J01-Antibacterials for systemic use","ATCPTTMT","% of total sales","BEL","Belgium","2012","2012",3.8,,
+"PATCBIOT","J01-Antibacterials for systemic use","ATCPTTMT","% of total sales","BEL","Belgium","2013","2013",3.7,,
+"PATCBIOT","J01-Antibacterials for systemic use","ATCPTTMT","% of total sales","BEL","Belgium","2014","2014",3.6,,
+"PATCBIOT","J01-Antibacterials for systemic use","ATCPTTMT","% of total sales","BEL","Belgium","2015","2015",3.5,,
+"PATCBIOT","J01-Antibacterials for systemic use","ATCPTTMT","% of total sales","BEL","Belgium","2016","2016",3.2,,
+"PATCBIOT","J01-Antibacterials for systemic use","ATCPTTMT","% of total sales","BEL","Belgium","2017","2017",2.9,,
+"PATCBIOT","J01-Antibacterials for systemic use","ATCPTTMT","% of total sales","BEL","Belgium","2018","2018",2.8,,
+"PATCBIOT","J01-Antibacterials for systemic use","ATCPTTMT","% of total sales","BEL","Belgium","2019","2019",2.6,,
+"PATCBIOT","J01-Antibacterials for systemic use","ATCPTTMT","% of total sales","BEL","Belgium","2020","2020",2.2,,
+"PATCBIOT","J01-Antibacterials for systemic use","ATCPTTMT","% of total sales","BEL","Belgium","2021","2021",2.2,,
+"PATCBIOT","J01-Antibacterials for systemic use","ATCPTTMT","% of total sales","BEL","Belgium","2022","2022",2.3,"E","Estimated value"
+"PATCBIOT","J01-Antibacterials for systemic use","MLLNCUMT","Million of national currency units","CAN","Canada","2012","2012",694.2,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","MLLNCUMT","Million of national currency units","CAN","Canada","2013","2013",678.7,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","MLLNCUMT","Million of national currency units","CAN","Canada","2014","2014",683.2,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","MLLNCUMT","Million of national currency units","CAN","Canada","2015","2015",678.2,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","MLLNCUMT","Million of national currency units","CAN","Canada","2016","2016",687.1,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","MLLNCUMT","Million of national currency units","CAN","Canada","2017","2017",694.6,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","MLLNCUMT","Million of national currency units","CAN","Canada","2018","2018",646.3,"E; B; D","Estimated value; Break; Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","MLLNCUMT","Million of national currency units","CAN","Canada","2019","2019",564.5,"E; D","Estimated value; Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","MLLNCUMT","Million of national currency units","CAN","Canada","2020","2020",460.8,"E; D","Estimated value; Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","MLLNCUMT","Million of national currency units","CAN","Canada","2021","2021",445.2,"E; D","Estimated value; Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","MLLNCUMT","Million of national currency units","CAN","Canada","2022","2022",494.8,"E; D","Estimated value; Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","MTMOTCMT","Million US$ at exchange rate","CAN","Canada","2012","2012",694.6,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","MTMOTCMT","Million US$ at exchange rate","CAN","Canada","2013","2013",658.8,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","MTMOTCMT","Million US$ at exchange rate","CAN","Canada","2014","2014",618.4,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","MTMOTCMT","Million US$ at exchange rate","CAN","Canada","2015","2015",530.4,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","MTMOTCMT","Million US$ at exchange rate","CAN","Canada","2016","2016",518.3,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","MTMOTCMT","Million US$ at exchange rate","CAN","Canada","2017","2017",535.2,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","MTMOTCMT","Million US$ at exchange rate","CAN","Canada","2018","2018",498.8,"E; B; D","Estimated value; Break; Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","MTMOTCMT","Million US$ at exchange rate","CAN","Canada","2019","2019",425.5,"E; D","Estimated value; Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","MTMOTCMT","Million US$ at exchange rate","CAN","Canada","2020","2020",343.6,"E; D","Estimated value; Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","MTMOTCMT","Million US$ at exchange rate","CAN","Canada","2021","2021",355.1,"E; D","Estimated value; Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","MTMOTCMT","Million US$ at exchange rate","CAN","Canada","2022","2022",380.2,"E; D","Estimated value; Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","MTMOPPMT","Million US$, purchasing power parity","CAN","Canada","2012","2012",557.8,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","MTMOPPMT","Million US$, purchasing power parity","CAN","Canada","2013","2013",554.5,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","MTMOPPMT","Million US$, purchasing power parity","CAN","Canada","2014","2014",555.3,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","MTMOPPMT","Million US$, purchasing power parity","CAN","Canada","2015","2015",543.4,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","MTMOPPMT","Million US$, purchasing power parity","CAN","Canada","2016","2016",569.2,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","MTMOPPMT","Million US$, purchasing power parity","CAN","Canada","2017","2017",573,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","MTMOPPMT","Million US$, purchasing power parity","CAN","Canada","2018","2018",535.7,"E; B; D","Estimated value; Break; Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","MTMOPPMT","Million US$, purchasing power parity","CAN","Canada","2019","2019",457.2,"E; D","Estimated value; Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","MTMOPPMT","Million US$, purchasing power parity","CAN","Canada","2020","2020",374.3,"E; D","Estimated value; Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","MTMOPPMT","Million US$, purchasing power parity","CAN","Canada","2021","2021",359.6,"E; D","Estimated value; Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","MTMOPPMT","Million US$, purchasing power parity","CAN","Canada","2022","2022",394.6,"E; D","Estimated value; Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","TCPPERMT","/capita, US$ exchange rate","CAN","Canada","2012","2012",20,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","TCPPERMT","/capita, US$ exchange rate","CAN","Canada","2013","2013",18.8,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","TCPPERMT","/capita, US$ exchange rate","CAN","Canada","2014","2014",17.5,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","TCPPERMT","/capita, US$ exchange rate","CAN","Canada","2015","2015",14.9,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","TCPPERMT","/capita, US$ exchange rate","CAN","Canada","2016","2016",14.4,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","TCPPERMT","/capita, US$ exchange rate","CAN","Canada","2017","2017",14.6,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","TCPPERMT","/capita, US$ exchange rate","CAN","Canada","2018","2018",13.5,"E; B; D","Estimated value; Break; Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","TCPPERMT","/capita, US$ exchange rate","CAN","Canada","2019","2019",11.3,"E; D","Estimated value; Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","TCPPERMT","/capita, US$ exchange rate","CAN","Canada","2020","2020",9,"E; D","Estimated value; Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","TCPPERMT","/capita, US$ exchange rate","CAN","Canada","2021","2021",9.3,"E; D","Estimated value; Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","TCPPERMT","/capita, US$ exchange rate","CAN","Canada","2022","2022",9.8,"E; D","Estimated value; Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2012","2012",16.1,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2013","2013",15.8,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2014","2014",15.7,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2015","2015",15.2,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2016","2016",15.8,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2017","2017",15.7,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2018","2018",14.5,"E; B; D","Estimated value; Break; Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2019","2019",12.2,"E; D","Estimated value; Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2020","2020",9.8,"E; D","Estimated value; Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2021","2021",9.4,"E; D","Estimated value; Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2022","2022",10.1,"E; D","Estimated value; Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","ATCPTTMT","% of total sales","CAN","Canada","2012","2012",2.9,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","ATCPTTMT","% of total sales","CAN","Canada","2013","2013",2.8,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","ATCPTTMT","% of total sales","CAN","Canada","2014","2014",2.7,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","ATCPTTMT","% of total sales","CAN","Canada","2015","2015",2.5,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","ATCPTTMT","% of total sales","CAN","Canada","2016","2016",2.4,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","ATCPTTMT","% of total sales","CAN","Canada","2017","2017",2.3,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","ATCPTTMT","% of total sales","CAN","Canada","2018","2018",2.1,"E; B; D","Estimated value; Break; Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","ATCPTTMT","% of total sales","CAN","Canada","2019","2019",1.8,"E; D","Estimated value; Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","ATCPTTMT","% of total sales","CAN","Canada","2020","2020",1.3,"E; D","Estimated value; Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","ATCPTTMT","% of total sales","CAN","Canada","2021","2021",1.2,"E; D","Estimated value; Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","ATCPTTMT","% of total sales","CAN","Canada","2022","2022",1.2,"E; D","Estimated value; Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","MLLNCUMT","Million of national currency units","CZE","Czech Republic","2010","2010",2686.9,,
+"PATCBIOT","J01-Antibacterials for systemic use","MLLNCUMT","Million of national currency units","CZE","Czech Republic","2011","2011",2528.8,,
+"PATCBIOT","J01-Antibacterials for systemic use","MLLNCUMT","Million of national currency units","CZE","Czech Republic","2012","2012",2592,,
+"PATCBIOT","J01-Antibacterials for systemic use","MLLNCUMT","Million of national currency units","CZE","Czech Republic","2013","2013",2544.9,,
+"PATCBIOT","J01-Antibacterials for systemic use","MLLNCUMT","Million of national currency units","CZE","Czech Republic","2014","2014",2245.4,,
+"PATCBIOT","J01-Antibacterials for systemic use","MLLNCUMT","Million of national currency units","CZE","Czech Republic","2015","2015",2167.6,,
+"PATCBIOT","J01-Antibacterials for systemic use","MLLNCUMT","Million of national currency units","CZE","Czech Republic","2016","2016",2101,,
+"PATCBIOT","J01-Antibacterials for systemic use","MLLNCUMT","Million of national currency units","CZE","Czech Republic","2017","2017",2230.1,,
+"PATCBIOT","J01-Antibacterials for systemic use","MLLNCUMT","Million of national currency units","CZE","Czech Republic","2018","2018",2392.8,,
+"PATCBIOT","J01-Antibacterials for systemic use","MLLNCUMT","Million of national currency units","CZE","Czech Republic","2019","2019",2440.6,,
+"PATCBIOT","J01-Antibacterials for systemic use","MLLNCUMT","Million of national currency units","CZE","Czech Republic","2020","2020",2014.9,"B","Break"
+"PATCBIOT","J01-Antibacterials for systemic use","MLLNCUMT","Million of national currency units","CZE","Czech Republic","2021","2021",2113.8,,
+"PATCBIOT","J01-Antibacterials for systemic use","MTMOTCMT","Million US$ at exchange rate","CZE","Czech Republic","2010","2010",140.7,,
+"PATCBIOT","J01-Antibacterials for systemic use","MTMOTCMT","Million US$ at exchange rate","CZE","Czech Republic","2011","2011",142.9,,
+"PATCBIOT","J01-Antibacterials for systemic use","MTMOTCMT","Million US$ at exchange rate","CZE","Czech Republic","2012","2012",132.4,,
+"PATCBIOT","J01-Antibacterials for systemic use","MTMOTCMT","Million US$ at exchange rate","CZE","Czech Republic","2013","2013",130,,
+"PATCBIOT","J01-Antibacterials for systemic use","MTMOTCMT","Million US$ at exchange rate","CZE","Czech Republic","2014","2014",108.2,,
+"PATCBIOT","J01-Antibacterials for systemic use","MTMOTCMT","Million US$ at exchange rate","CZE","Czech Republic","2015","2015",88.1,,
+"PATCBIOT","J01-Antibacterials for systemic use","MTMOTCMT","Million US$ at exchange rate","CZE","Czech Republic","2016","2016",86,,
+"PATCBIOT","J01-Antibacterials for systemic use","MTMOTCMT","Million US$ at exchange rate","CZE","Czech Republic","2017","2017",95.4,,
+"PATCBIOT","J01-Antibacterials for systemic use","MTMOTCMT","Million US$ at exchange rate","CZE","Czech Republic","2018","2018",110.1,,
+"PATCBIOT","J01-Antibacterials for systemic use","MTMOTCMT","Million US$ at exchange rate","CZE","Czech Republic","2019","2019",106.4,,
+"PATCBIOT","J01-Antibacterials for systemic use","MTMOTCMT","Million US$ at exchange rate","CZE","Czech Republic","2020","2020",86.8,"B","Break"
+"PATCBIOT","J01-Antibacterials for systemic use","MTMOTCMT","Million US$ at exchange rate","CZE","Czech Republic","2021","2021",97.5,,
+"PATCBIOT","J01-Antibacterials for systemic use","MTMOPPMT","Million US$, purchasing power parity","CZE","Czech Republic","2010","2010",196.5,,
+"PATCBIOT","J01-Antibacterials for systemic use","MTMOPPMT","Million US$, purchasing power parity","CZE","Czech Republic","2011","2011",189.5,,
+"PATCBIOT","J01-Antibacterials for systemic use","MTMOPPMT","Million US$, purchasing power parity","CZE","Czech Republic","2012","2012",194.9,,
+"PATCBIOT","J01-Antibacterials for systemic use","MTMOPPMT","Million US$, purchasing power parity","CZE","Czech Republic","2013","2013",199.1,,
+"PATCBIOT","J01-Antibacterials for systemic use","MTMOPPMT","Million US$, purchasing power parity","CZE","Czech Republic","2014","2014",176.8,,
+"PATCBIOT","J01-Antibacterials for systemic use","MTMOPPMT","Million US$, purchasing power parity","CZE","Czech Republic","2015","2015",167.5,,
+"PATCBIOT","J01-Antibacterials for systemic use","MTMOPPMT","Million US$, purchasing power parity","CZE","Czech Republic","2016","2016",167.1,,
+"PATCBIOT","J01-Antibacterials for systemic use","MTMOPPMT","Million US$, purchasing power parity","CZE","Czech Republic","2017","2017",179.5,,
+"PATCBIOT","J01-Antibacterials for systemic use","MTMOPPMT","Million US$, purchasing power parity","CZE","Czech Republic","2018","2018",193.4,,
+"PATCBIOT","J01-Antibacterials for systemic use","MTMOPPMT","Million US$, purchasing power parity","CZE","Czech Republic","2019","2019",198.8,,
+"PATCBIOT","J01-Antibacterials for systemic use","MTMOPPMT","Million US$, purchasing power parity","CZE","Czech Republic","2020","2020",161.7,"B","Break"
+"PATCBIOT","J01-Antibacterials for systemic use","MTMOPPMT","Million US$, purchasing power parity","CZE","Czech Republic","2021","2021",165.9,,
+"PATCBIOT","J01-Antibacterials for systemic use","TCPPERMT","/capita, US$ exchange rate","CZE","Czech Republic","2010","2010",13.4,,
+"PATCBIOT","J01-Antibacterials for systemic use","TCPPERMT","/capita, US$ exchange rate","CZE","Czech Republic","2011","2011",13.6,,
+"PATCBIOT","J01-Antibacterials for systemic use","TCPPERMT","/capita, US$ exchange rate","CZE","Czech Republic","2012","2012",12.6,,
+"PATCBIOT","J01-Antibacterials for systemic use","TCPPERMT","/capita, US$ exchange rate","CZE","Czech Republic","2013","2013",12.4,,
+"PATCBIOT","J01-Antibacterials for systemic use","TCPPERMT","/capita, US$ exchange rate","CZE","Czech Republic","2014","2014",10.3,,
+"PATCBIOT","J01-Antibacterials for systemic use","TCPPERMT","/capita, US$ exchange rate","CZE","Czech Republic","2015","2015",8.4,,
+"PATCBIOT","J01-Antibacterials for systemic use","TCPPERMT","/capita, US$ exchange rate","CZE","Czech Republic","2016","2016",8.1,,
+"PATCBIOT","J01-Antibacterials for systemic use","TCPPERMT","/capita, US$ exchange rate","CZE","Czech Republic","2017","2017",9,,
+"PATCBIOT","J01-Antibacterials for systemic use","TCPPERMT","/capita, US$ exchange rate","CZE","Czech Republic","2018","2018",10.4,,
+"PATCBIOT","J01-Antibacterials for systemic use","TCPPERMT","/capita, US$ exchange rate","CZE","Czech Republic","2019","2019",10,,
+"PATCBIOT","J01-Antibacterials for systemic use","TCPPERMT","/capita, US$ exchange rate","CZE","Czech Republic","2020","2020",8.1,"B","Break"
+"PATCBIOT","J01-Antibacterials for systemic use","TCPPERMT","/capita, US$ exchange rate","CZE","Czech Republic","2021","2021",9.3,,
+"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czech Republic","2010","2010",18.8,,
+"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czech Republic","2011","2011",18.1,,
+"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czech Republic","2012","2012",18.5,,
+"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czech Republic","2013","2013",18.9,,
+"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czech Republic","2014","2014",16.8,,
+"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czech Republic","2015","2015",15.9,,
+"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czech Republic","2016","2016",15.8,,
+"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czech Republic","2017","2017",16.9,,
+"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czech Republic","2018","2018",18.2,,
+"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czech Republic","2019","2019",18.6,,
+"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czech Republic","2020","2020",15.1,"B","Break"
+"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czech Republic","2021","2021",15.8,,
+"PATCBIOT","J01-Antibacterials for systemic use","ATCPTTMT","% of total sales","CZE","Czech Republic","2010","2010",3.3,,
+"PATCBIOT","J01-Antibacterials for systemic use","ATCPTTMT","% of total sales","CZE","Czech Republic","2011","2011",3.1,,
+"PATCBIOT","J01-Antibacterials for systemic use","ATCPTTMT","% of total sales","CZE","Czech Republic","2012","2012",3.1,,
+"PATCBIOT","J01-Antibacterials for systemic use","ATCPTTMT","% of total sales","CZE","Czech Republic","2013","2013",3.2,,
+"PATCBIOT","J01-Antibacterials for systemic use","ATCPTTMT","% of total sales","CZE","Czech Republic","2014","2014",2.8,,
+"PATCBIOT","J01-Antibacterials for systemic use","ATCPTTMT","% of total sales","CZE","Czech Republic","2015","2015",2.6,,
+"PATCBIOT","J01-Antibacterials for systemic use","ATCPTTMT","% of total sales","CZE","Czech Republic","2016","2016",2.4,,
+"PATCBIOT","J01-Antibacterials for systemic use","ATCPTTMT","% of total sales","CZE","Czech Republic","2017","2017",2.4,,
+"PATCBIOT","J01-Antibacterials for systemic use","ATCPTTMT","% of total sales","CZE","Czech Republic","2018","2018",2.4,,
+"PATCBIOT","J01-Antibacterials for systemic use","ATCPTTMT","% of total sales","CZE","Czech Republic","2019","2019",2.4,,
+"PATCBIOT","J01-Antibacterials for systemic use","ATCPTTMT","% of total sales","CZE","Czech Republic","2020","2020",2.3,"B","Break"
+"PATCBIOT","J01-Antibacterials for systemic use","ATCPTTMT","% of total sales","CZE","Czech Republic","2021","2021",2.3,,
+"PATCBIOT","J01-Antibacterials for systemic use","MLLNCUMT","Million of national currency units","FIN","Finland","2010","2010",67.1,,
+"PATCBIOT","J01-Antibacterials for systemic use","MLLNCUMT","Million of national currency units","FIN","Finland","2011","2011",65.6,,
+"PATCBIOT","J01-Antibacterials for systemic use","MLLNCUMT","Million of national currency units","FIN","Finland","2012","2012",55,,
+"PATCBIOT","J01-Antibacterials for systemic use","MLLNCUMT","Million of national currency units","FIN","Finland","2013","2013",53.8,,
+"PATCBIOT","J01-Antibacterials for systemic use","MLLNCUMT","Million of national currency units","FIN","Finland","2014","2014",50.3,,
+"PATCBIOT","J01-Antibacterials for systemic use","MLLNCUMT","Million of national currency units","FIN","Finland","2015","2015",51.8,,
+"PATCBIOT","J01-Antibacterials for systemic use","MLLNCUMT","Million of national currency units","FIN","Finland","2016","2016",55.2,,
+"PATCBIOT","J01-Antibacterials for systemic use","MLLNCUMT","Million of national currency units","FIN","Finland","2017","2017",52.6,,
+"PATCBIOT","J01-Antibacterials for systemic use","MLLNCUMT","Million of national currency units","FIN","Finland","2018","2018",49.6,,
+"PATCBIOT","J01-Antibacterials for systemic use","MLLNCUMT","Million of national currency units","FIN","Finland","2019","2019",44.7,,
+"PATCBIOT","J01-Antibacterials for systemic use","MLLNCUMT","Million of national currency units","FIN","Finland","2020","2020",41.6,,
+"PATCBIOT","J01-Antibacterials for systemic use","MLLNCUMT","Million of national currency units","FIN","Finland","2021","2021",39,,
+"PATCBIOT","J01-Antibacterials for systemic use","MTMOTCMT","Million US$ at exchange rate","FIN","Finland","2010","2010",89,,
+"PATCBIOT","J01-Antibacterials for systemic use","MTMOTCMT","Million US$ at exchange rate","FIN","Finland","2011","2011",91.3,,
+"PATCBIOT","J01-Antibacterials for systemic use","MTMOTCMT","Million US$ at exchange rate","FIN","Finland","2012","2012",70.7,,
+"PATCBIOT","J01-Antibacterials for systemic use","MTMOTCMT","Million US$ at exchange rate","FIN","Finland","2013","2013",71.5,,
+"PATCBIOT","J01-Antibacterials for systemic use","MTMOTCMT","Million US$ at exchange rate","FIN","Finland","2014","2014",66.8,,
+"PATCBIOT","J01-Antibacterials for systemic use","MTMOTCMT","Million US$ at exchange rate","FIN","Finland","2015","2015",57.5,,
+"PATCBIOT","J01-Antibacterials for systemic use","MTMOTCMT","Million US$ at exchange rate","FIN","Finland","2016","2016",61.1,,
+"PATCBIOT","J01-Antibacterials for systemic use","MTMOTCMT","Million US$ at exchange rate","FIN","Finland","2017","2017",59.4,,
+"PATCBIOT","J01-Antibacterials for systemic use","MTMOTCMT","Million US$ at exchange rate","FIN","Finland","2018","2018",58.6,,
+"PATCBIOT","J01-Antibacterials for systemic use","MTMOTCMT","Million US$ at exchange rate","FIN","Finland","2019","2019",50,,
+"PATCBIOT","J01-Antibacterials for systemic use","MTMOTCMT","Million US$ at exchange rate","FIN","Finland","2020","2020",47.5,,
+"PATCBIOT","J01-Antibacterials for systemic use","MTMOTCMT","Million US$ at exchange rate","FIN","Finland","2021","2021",46.1,,
+"PATCBIOT","J01-Antibacterials for systemic use","MTMOPPMT","Million US$, purchasing power parity","FIN","Finland","2010","2010",74.5,,
+"PATCBIOT","J01-Antibacterials for systemic use","MTMOPPMT","Million US$, purchasing power parity","FIN","Finland","2011","2011",73,,
+"PATCBIOT","J01-Antibacterials for systemic use","MTMOPPMT","Million US$, purchasing power parity","FIN","Finland","2012","2012",60.5,,
+"PATCBIOT","J01-Antibacterials for systemic use","MTMOPPMT","Million US$, purchasing power parity","FIN","Finland","2013","2013",59.4,,
+"PATCBIOT","J01-Antibacterials for systemic use","MTMOPPMT","Million US$, purchasing power parity","FIN","Finland","2014","2014",55.4,,
+"PATCBIOT","J01-Antibacterials for systemic use","MTMOPPMT","Million US$, purchasing power parity","FIN","Finland","2015","2015",57.1,,
+"PATCBIOT","J01-Antibacterials for systemic use","MTMOPPMT","Million US$, purchasing power parity","FIN","Finland","2016","2016",62.7,,
+"PATCBIOT","J01-Antibacterials for systemic use","MTMOPPMT","Million US$, purchasing power parity","FIN","Finland","2017","2017",60.9,,
+"PATCBIOT","J01-Antibacterials for systemic use","MTMOPPMT","Million US$, purchasing power parity","FIN","Finland","2018","2018",58.1,,
+"PATCBIOT","J01-Antibacterials for systemic use","MTMOPPMT","Million US$, purchasing power parity","FIN","Finland","2019","2019",53.3,,
+"PATCBIOT","J01-Antibacterials for systemic use","MTMOPPMT","Million US$, purchasing power parity","FIN","Finland","2020","2020",50.5,,
+"PATCBIOT","J01-Antibacterials for systemic use","MTMOPPMT","Million US$, purchasing power parity","FIN","Finland","2021","2021",47.2,,
+"PATCBIOT","J01-Antibacterials for systemic use","TCPPERMT","/capita, US$ exchange rate","FIN","Finland","2010","2010",16.6,,
+"PATCBIOT","J01-Antibacterials for systemic use","TCPPERMT","/capita, US$ exchange rate","FIN","Finland","2011","2011",16.9,,
+"PATCBIOT","J01-Antibacterials for systemic use","TCPPERMT","/capita, US$ exchange rate","FIN","Finland","2012","2012",13.1,,
+"PATCBIOT","J01-Antibacterials for systemic use","TCPPERMT","/capita, US$ exchange rate","FIN","Finland","2013","2013",13.1,,
+"PATCBIOT","J01-Antibacterials for systemic use","TCPPERMT","/capita, US$ exchange rate","FIN","Finland","2014","2014",12.2,,
+"PATCBIOT","J01-Antibacterials for systemic use","TCPPERMT","/capita, US$ exchange rate","FIN","Finland","2015","2015",10.5,,
+"PATCBIOT","J01-Antibacterials for systemic use","TCPPERMT","/capita, US$ exchange rate","FIN","Finland","2016","2016",11.1,,
+"PATCBIOT","J01-Antibacterials for systemic use","TCPPERMT","/capita, US$ exchange rate","FIN","Finland","2017","2017",10.8,,
+"PATCBIOT","J01-Antibacterials for systemic use","TCPPERMT","/capita, US$ exchange rate","FIN","Finland","2018","2018",10.6,,
+"PATCBIOT","J01-Antibacterials for systemic use","TCPPERMT","/capita, US$ exchange rate","FIN","Finland","2019","2019",9.1,,
+"PATCBIOT","J01-Antibacterials for systemic use","TCPPERMT","/capita, US$ exchange rate","FIN","Finland","2020","2020",8.6,,
+"PATCBIOT","J01-Antibacterials for systemic use","TCPPERMT","/capita, US$ exchange rate","FIN","Finland","2021","2021",8.3,,
+"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2010","2010",13.9,,
+"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2011","2011",13.6,,
+"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2012","2012",11.2,,
+"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2013","2013",10.9,,
+"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2014","2014",10.2,,
+"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2015","2015",10.4,,
+"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2016","2016",11.4,,
+"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2017","2017",11.1,,
+"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2018","2018",10.5,,
+"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2019","2019",9.7,,
+"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2020","2020",9.1,,
+"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2021","2021",8.5,,
+"PATCBIOT","J01-Antibacterials for systemic use","ATCPTTMT","% of total sales","FIN","Finland","2010","2010",3.6,,
+"PATCBIOT","J01-Antibacterials for systemic use","ATCPTTMT","% of total sales","FIN","Finland","2011","2011",3.4,,
+"PATCBIOT","J01-Antibacterials for systemic use","ATCPTTMT","% of total sales","FIN","Finland","2012","2012",2.8,,
+"PATCBIOT","J01-Antibacterials for systemic use","ATCPTTMT","% of total sales","FIN","Finland","2013","2013",2.7,,
+"PATCBIOT","J01-Antibacterials for systemic use","ATCPTTMT","% of total sales","FIN","Finland","2014","2014",2.4,,
+"PATCBIOT","J01-Antibacterials for systemic use","ATCPTTMT","% of total sales","FIN","Finland","2015","2015",2.4,,
+"PATCBIOT","J01-Antibacterials for systemic use","ATCPTTMT","% of total sales","FIN","Finland","2016","2016",2.4,,
+"PATCBIOT","J01-Antibacterials for systemic use","ATCPTTMT","% of total sales","FIN","Finland","2017","2017",2.3,,
+"PATCBIOT","J01-Antibacterials for systemic use","ATCPTTMT","% of total sales","FIN","Finland","2018","2018",2,,
+"PATCBIOT","J01-Antibacterials for systemic use","ATCPTTMT","% of total sales","FIN","Finland","2019","2019",1.7,,
+"PATCBIOT","J01-Antibacterials for systemic use","ATCPTTMT","% of total sales","FIN","Finland","2020","2020",1.5,,
+"PATCBIOT","J01-Antibacterials for systemic use","ATCPTTMT","% of total sales","FIN","Finland","2021","2021",1.4,,
+"PATCBIOT","J01-Antibacterials for systemic use","MLLNCUMT","Million of national currency units","DEU","Germany","2010","2010",740.2,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","MLLNCUMT","Million of national currency units","DEU","Germany","2011","2011",712.3,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","MLLNCUMT","Million of national currency units","DEU","Germany","2012","2012",772.9,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","MLLNCUMT","Million of national currency units","DEU","Germany","2013","2013",828.2,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","MLLNCUMT","Million of national currency units","DEU","Germany","2014","2014",782.7,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","MLLNCUMT","Million of national currency units","DEU","Germany","2015","2015",769.7,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","MLLNCUMT","Million of national currency units","DEU","Germany","2016","2016",754.6,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","MLLNCUMT","Million of national currency units","DEU","Germany","2017","2017",732.8,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","MLLNCUMT","Million of national currency units","DEU","Germany","2018","2018",746,"B; D","Break; Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","MLLNCUMT","Million of national currency units","DEU","Germany","2019","2019",713.1,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","MLLNCUMT","Million of national currency units","DEU","Germany","2020","2020",576.8,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","MLLNCUMT","Million of national currency units","DEU","Germany","2021","2021",541,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","MTMOTCMT","Million US$ at exchange rate","DEU","Germany","2010","2010",981.3,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","MTMOTCMT","Million US$ at exchange rate","DEU","Germany","2011","2011",991.5,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","MTMOTCMT","Million US$ at exchange rate","DEU","Germany","2012","2012",993,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","MTMOTCMT","Million US$ at exchange rate","DEU","Germany","2013","2013",1099.9,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","MTMOTCMT","Million US$ at exchange rate","DEU","Germany","2014","2014",1039.8,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","MTMOTCMT","Million US$ at exchange rate","DEU","Germany","2015","2015",854,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","MTMOTCMT","Million US$ at exchange rate","DEU","Germany","2016","2016",835.3,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","MTMOTCMT","Million US$ at exchange rate","DEU","Germany","2017","2017",827.8,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","MTMOTCMT","Million US$ at exchange rate","DEU","Germany","2018","2018",881,"B; D","Break; Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","MTMOTCMT","Million US$ at exchange rate","DEU","Germany","2019","2019",798.3,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","MTMOTCMT","Million US$ at exchange rate","DEU","Germany","2020","2020",658.8,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","MTMOTCMT","Million US$ at exchange rate","DEU","Germany","2021","2021",639.9,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","MTMOPPMT","Million US$, purchasing power parity","DEU","Germany","2010","2010",919.4,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","MTMOPPMT","Million US$, purchasing power parity","DEU","Germany","2011","2011",903.1,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","MTMOPPMT","Million US$, purchasing power parity","DEU","Germany","2012","2012",981.8,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","MTMOPPMT","Million US$, purchasing power parity","DEU","Germany","2013","2013",1068.9,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","MTMOPPMT","Million US$, purchasing power parity","DEU","Germany","2014","2014",1017.9,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","MTMOPPMT","Million US$, purchasing power parity","DEU","Germany","2015","2015",989.2,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","MTMOPPMT","Million US$, purchasing power parity","DEU","Germany","2016","2016",1002.6,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","MTMOPPMT","Million US$, purchasing power parity","DEU","Germany","2017","2017",983.9,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","MTMOPPMT","Million US$, purchasing power parity","DEU","Germany","2018","2018",1014.3,"B; D","Break; Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","MTMOPPMT","Million US$, purchasing power parity","DEU","Germany","2019","2019",979.2,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","MTMOPPMT","Million US$, purchasing power parity","DEU","Germany","2020","2020",795.6,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","MTMOPPMT","Million US$, purchasing power parity","DEU","Germany","2021","2021",734.8,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","TCPPERMT","/capita, US$ exchange rate","DEU","Germany","2010","2010",12,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","TCPPERMT","/capita, US$ exchange rate","DEU","Germany","2011","2011",12.4,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","TCPPERMT","/capita, US$ exchange rate","DEU","Germany","2012","2012",12.3,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","TCPPERMT","/capita, US$ exchange rate","DEU","Germany","2013","2013",13.6,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","TCPPERMT","/capita, US$ exchange rate","DEU","Germany","2014","2014",12.8,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","TCPPERMT","/capita, US$ exchange rate","DEU","Germany","2015","2015",10.5,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","TCPPERMT","/capita, US$ exchange rate","DEU","Germany","2016","2016",10.1,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","TCPPERMT","/capita, US$ exchange rate","DEU","Germany","2017","2017",10,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","TCPPERMT","/capita, US$ exchange rate","DEU","Germany","2018","2018",10.6,"B; D","Break; Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","TCPPERMT","/capita, US$ exchange rate","DEU","Germany","2019","2019",9.6,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","TCPPERMT","/capita, US$ exchange rate","DEU","Germany","2020","2020",7.9,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","TCPPERMT","/capita, US$ exchange rate","DEU","Germany","2021","2021",7.7,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2010","2010",11.2,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2011","2011",11.2,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2012","2012",12.2,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2013","2013",13.3,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2014","2014",12.6,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2015","2015",12.1,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2016","2016",12.2,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2017","2017",11.9,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2018","2018",12.2,"B; D","Break; Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2019","2019",11.8,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2020","2020",9.6,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2021","2021",8.8,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","ATCPTTMT","% of total sales","DEU","Germany","2010","2010",2.5,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","ATCPTTMT","% of total sales","DEU","Germany","2011","2011",2.4,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","ATCPTTMT","% of total sales","DEU","Germany","2012","2012",2.5,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","ATCPTTMT","% of total sales","DEU","Germany","2013","2013",2.6,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","ATCPTTMT","% of total sales","DEU","Germany","2014","2014",2.3,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","ATCPTTMT","% of total sales","DEU","Germany","2015","2015",2.2,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","ATCPTTMT","% of total sales","DEU","Germany","2016","2016",2.1,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","ATCPTTMT","% of total sales","DEU","Germany","2017","2017",2,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","ATCPTTMT","% of total sales","DEU","Germany","2018","2018",1.7,"B; D","Break; Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","ATCPTTMT","% of total sales","DEU","Germany","2019","2019",1.5,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","ATCPTTMT","% of total sales","DEU","Germany","2020","2020",1.2,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","ATCPTTMT","% of total sales","DEU","Germany","2021","2021",1,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","MLLNCUMT","Million of national currency units","GRC","Greece","2010","2010",366.1,,
+"PATCBIOT","J01-Antibacterials for systemic use","MLLNCUMT","Million of national currency units","GRC","Greece","2011","2011",340.7,,
+"PATCBIOT","J01-Antibacterials for systemic use","MLLNCUMT","Million of national currency units","GRC","Greece","2012","2012",294.1,,
+"PATCBIOT","J01-Antibacterials for systemic use","MLLNCUMT","Million of national currency units","GRC","Greece","2013","2013",227.4,,
+"PATCBIOT","J01-Antibacterials for systemic use","MLLNCUMT","Million of national currency units","GRC","Greece","2014","2014",235.9,,
+"PATCBIOT","J01-Antibacterials for systemic use","MLLNCUMT","Million of national currency units","GRC","Greece","2015","2015",228.5,,
+"PATCBIOT","J01-Antibacterials for systemic use","MLLNCUMT","Million of national currency units","GRC","Greece","2016","2016",231.5,,
+"PATCBIOT","J01-Antibacterials for systemic use","MLLNCUMT","Million of national currency units","GRC","Greece","2017","2017",226.2,,
+"PATCBIOT","J01-Antibacterials for systemic use","MLLNCUMT","Million of national currency units","GRC","Greece","2018","2018",224.7,,
+"PATCBIOT","J01-Antibacterials for systemic use","MLLNCUMT","Million of national currency units","GRC","Greece","2019","2019",227.3,,
+"PATCBIOT","J01-Antibacterials for systemic use","MLLNCUMT","Million of national currency units","GRC","Greece","2020","2020",211.5,,
+"PATCBIOT","J01-Antibacterials for systemic use","MLLNCUMT","Million of national currency units","GRC","Greece","2021","2021",223.9,,
+"PATCBIOT","J01-Antibacterials for systemic use","MLLNCUMT","Million of national currency units","GRC","Greece","2022","2022",209.3,,
+"PATCBIOT","J01-Antibacterials for systemic use","MTMOTCMT","Million US$ at exchange rate","GRC","Greece","2010","2010",485.4,,
+"PATCBIOT","J01-Antibacterials for systemic use","MTMOTCMT","Million US$ at exchange rate","GRC","Greece","2011","2011",474.2,,
+"PATCBIOT","J01-Antibacterials for systemic use","MTMOTCMT","Million US$ at exchange rate","GRC","Greece","2012","2012",377.9,,
+"PATCBIOT","J01-Antibacterials for systemic use","MTMOTCMT","Million US$ at exchange rate","GRC","Greece","2013","2013",301.9,,
+"PATCBIOT","J01-Antibacterials for systemic use","MTMOTCMT","Million US$ at exchange rate","GRC","Greece","2014","2014",313.3,,
+"PATCBIOT","J01-Antibacterials for systemic use","MTMOTCMT","Million US$ at exchange rate","GRC","Greece","2015","2015",253.5,,
+"PATCBIOT","J01-Antibacterials for systemic use","MTMOTCMT","Million US$ at exchange rate","GRC","Greece","2016","2016",256.3,,
+"PATCBIOT","J01-Antibacterials for systemic use","MTMOTCMT","Million US$ at exchange rate","GRC","Greece","2017","2017",255.5,,
+"PATCBIOT","J01-Antibacterials for systemic use","MTMOTCMT","Million US$ at exchange rate","GRC","Greece","2018","2018",265.3,,
+"PATCBIOT","J01-Antibacterials for systemic use","MTMOTCMT","Million US$ at exchange rate","GRC","Greece","2019","2019",254.4,,
+"PATCBIOT","J01-Antibacterials for systemic use","MTMOTCMT","Million US$ at exchange rate","GRC","Greece","2020","2020",241.6,,
+"PATCBIOT","J01-Antibacterials for systemic use","MTMOTCMT","Million US$ at exchange rate","GRC","Greece","2021","2021",264.8,,
+"PATCBIOT","J01-Antibacterials for systemic use","MTMOTCMT","Million US$ at exchange rate","GRC","Greece","2022","2022",220.4,,
+"PATCBIOT","J01-Antibacterials for systemic use","MTMOPPMT","Million US$, purchasing power parity","GRC","Greece","2010","2010",507.1,,
+"PATCBIOT","J01-Antibacterials for systemic use","MTMOPPMT","Million US$, purchasing power parity","GRC","Greece","2011","2011",477.7,,
+"PATCBIOT","J01-Antibacterials for systemic use","MTMOPPMT","Million US$, purchasing power parity","GRC","Greece","2012","2012",429.6,,
+"PATCBIOT","J01-Antibacterials for systemic use","MTMOPPMT","Million US$, purchasing power parity","GRC","Greece","2013","2013",360.1,,
+"PATCBIOT","J01-Antibacterials for systemic use","MTMOPPMT","Million US$, purchasing power parity","GRC","Greece","2014","2014",385.9,,
+"PATCBIOT","J01-Antibacterials for systemic use","MTMOPPMT","Million US$, purchasing power parity","GRC","Greece","2015","2015",375.1,,
+"PATCBIOT","J01-Antibacterials for systemic use","MTMOPPMT","Million US$, purchasing power parity","GRC","Greece","2016","2016",393.4,,
+"PATCBIOT","J01-Antibacterials for systemic use","MTMOPPMT","Million US$, purchasing power parity","GRC","Greece","2017","2017",393.3,,
+"PATCBIOT","J01-Antibacterials for systemic use","MTMOPPMT","Million US$, purchasing power parity","GRC","Greece","2018","2018",397.8,,
+"PATCBIOT","J01-Antibacterials for systemic use","MTMOPPMT","Million US$, purchasing power parity","GRC","Greece","2019","2019",414,,
+"PATCBIOT","J01-Antibacterials for systemic use","MTMOPPMT","Million US$, purchasing power parity","GRC","Greece","2020","2020",388.7,,
+"PATCBIOT","J01-Antibacterials for systemic use","MTMOPPMT","Million US$, purchasing power parity","GRC","Greece","2021","2021",410.3,,
+"PATCBIOT","J01-Antibacterials for systemic use","MTMOPPMT","Million US$, purchasing power parity","GRC","Greece","2022","2022",396,,
+"PATCBIOT","J01-Antibacterials for systemic use","TCPPERMT","/capita, US$ exchange rate","GRC","Greece","2010","2010",43.6,,
+"PATCBIOT","J01-Antibacterials for systemic use","TCPPERMT","/capita, US$ exchange rate","GRC","Greece","2011","2011",42.7,,
+"PATCBIOT","J01-Antibacterials for systemic use","TCPPERMT","/capita, US$ exchange rate","GRC","Greece","2012","2012",34.2,,
+"PATCBIOT","J01-Antibacterials for systemic use","TCPPERMT","/capita, US$ exchange rate","GRC","Greece","2013","2013",27.5,,
+"PATCBIOT","J01-Antibacterials for systemic use","TCPPERMT","/capita, US$ exchange rate","GRC","Greece","2014","2014",28.8,,
+"PATCBIOT","J01-Antibacterials for systemic use","TCPPERMT","/capita, US$ exchange rate","GRC","Greece","2015","2015",23.4,,
+"PATCBIOT","J01-Antibacterials for systemic use","TCPPERMT","/capita, US$ exchange rate","GRC","Greece","2016","2016",23.8,,
+"PATCBIOT","J01-Antibacterials for systemic use","TCPPERMT","/capita, US$ exchange rate","GRC","Greece","2017","2017",23.8,,
+"PATCBIOT","J01-Antibacterials for systemic use","TCPPERMT","/capita, US$ exchange rate","GRC","Greece","2018","2018",24.7,,
+"PATCBIOT","J01-Antibacterials for systemic use","TCPPERMT","/capita, US$ exchange rate","GRC","Greece","2019","2019",23.7,,
+"PATCBIOT","J01-Antibacterials for systemic use","TCPPERMT","/capita, US$ exchange rate","GRC","Greece","2020","2020",22.6,,
+"PATCBIOT","J01-Antibacterials for systemic use","TCPPERMT","/capita, US$ exchange rate","GRC","Greece","2021","2021",25.1,,
+"PATCBIOT","J01-Antibacterials for systemic use","TCPPERMT","/capita, US$ exchange rate","GRC","Greece","2022","2022",21.1,,
+"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2010","2010",45.6,,
+"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2011","2011",43,,
+"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2012","2012",38.9,,
+"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2013","2013",32.8,,
+"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2014","2014",35.4,,
+"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2015","2015",34.7,,
+"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2016","2016",36.5,,
+"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2017","2017",36.6,,
+"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2018","2018",37.1,,
+"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2019","2019",38.6,,
+"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2020","2020",36.3,,
+"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2021","2021",38.8,,
+"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2022","2022",37.9,,
+"PATCBIOT","J01-Antibacterials for systemic use","MLLNCUMT","Million of national currency units","HUN","Hungary","2010","2010",14338.6,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","MLLNCUMT","Million of national currency units","HUN","Hungary","2011","2011",14278.5,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","MLLNCUMT","Million of national currency units","HUN","Hungary","2012","2012",12925.5,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","MLLNCUMT","Million of national currency units","HUN","Hungary","2013","2013",12938.1,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","MLLNCUMT","Million of national currency units","HUN","Hungary","2014","2014",13239.1,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","MLLNCUMT","Million of national currency units","HUN","Hungary","2015","2015",13565.6,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","MLLNCUMT","Million of national currency units","HUN","Hungary","2016","2016",12865.7,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","MLLNCUMT","Million of national currency units","HUN","Hungary","2017","2017",12714.9,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","MLLNCUMT","Million of national currency units","HUN","Hungary","2018","2018",12637.2,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","MLLNCUMT","Million of national currency units","HUN","Hungary","2019","2019",11775.4,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","MLLNCUMT","Million of national currency units","HUN","Hungary","2020","2020",9059.5,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","MLLNCUMT","Million of national currency units","HUN","Hungary","2021","2021",9655,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","MLLNCUMT","Million of national currency units","HUN","Hungary","2022","2022",12042.5,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","MTMOTCMT","Million US$ at exchange rate","HUN","Hungary","2010","2010",69,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","MTMOTCMT","Million US$ at exchange rate","HUN","Hungary","2011","2011",71,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","MTMOTCMT","Million US$ at exchange rate","HUN","Hungary","2012","2012",57.4,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","MTMOTCMT","Million US$ at exchange rate","HUN","Hungary","2013","2013",57.8,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","MTMOTCMT","Million US$ at exchange rate","HUN","Hungary","2014","2014",56.9,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","MTMOTCMT","Million US$ at exchange rate","HUN","Hungary","2015","2015",48.6,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","MTMOTCMT","Million US$ at exchange rate","HUN","Hungary","2016","2016",45.7,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","MTMOTCMT","Million US$ at exchange rate","HUN","Hungary","2017","2017",46.3,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","MTMOTCMT","Million US$ at exchange rate","HUN","Hungary","2018","2018",46.8,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","MTMOTCMT","Million US$ at exchange rate","HUN","Hungary","2019","2019",40.5,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","MTMOTCMT","Million US$ at exchange rate","HUN","Hungary","2020","2020",29.4,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","MTMOTCMT","Million US$ at exchange rate","HUN","Hungary","2021","2021",31.8,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","MTMOTCMT","Million US$ at exchange rate","HUN","Hungary","2022","2022",32.3,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","MTMOPPMT","Million US$, purchasing power parity","HUN","Hungary","2010","2010",113.4,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","MTMOPPMT","Million US$, purchasing power parity","HUN","Hungary","2011","2011",114.9,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","MTMOPPMT","Million US$, purchasing power parity","HUN","Hungary","2012","2012",102.9,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","MTMOPPMT","Million US$, purchasing power parity","HUN","Hungary","2013","2013",103.5,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","MTMOPPMT","Million US$, purchasing power parity","HUN","Hungary","2014","2014",102.3,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","MTMOPPMT","Million US$, purchasing power parity","HUN","Hungary","2015","2015",102.3,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","MTMOPPMT","Million US$, purchasing power parity","HUN","Hungary","2016","2016",97.4,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","MTMOPPMT","Million US$, purchasing power parity","HUN","Hungary","2017","2017",93.5,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","MTMOPPMT","Million US$, purchasing power parity","HUN","Hungary","2018","2018",90.9,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","MTMOPPMT","Million US$, purchasing power parity","HUN","Hungary","2019","2019",83.6,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","MTMOPPMT","Million US$, purchasing power parity","HUN","Hungary","2020","2020",62.3,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","MTMOPPMT","Million US$, purchasing power parity","HUN","Hungary","2021","2021",62.4,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","MTMOPPMT","Million US$, purchasing power parity","HUN","Hungary","2022","2022",74.7,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","TCPPERMT","/capita, US$ exchange rate","HUN","Hungary","2010","2010",6.9,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","TCPPERMT","/capita, US$ exchange rate","HUN","Hungary","2011","2011",7.1,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","TCPPERMT","/capita, US$ exchange rate","HUN","Hungary","2012","2012",5.8,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","TCPPERMT","/capita, US$ exchange rate","HUN","Hungary","2013","2013",5.8,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","TCPPERMT","/capita, US$ exchange rate","HUN","Hungary","2014","2014",5.8,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","TCPPERMT","/capita, US$ exchange rate","HUN","Hungary","2015","2015",4.9,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","TCPPERMT","/capita, US$ exchange rate","HUN","Hungary","2016","2016",4.7,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","TCPPERMT","/capita, US$ exchange rate","HUN","Hungary","2017","2017",4.7,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","TCPPERMT","/capita, US$ exchange rate","HUN","Hungary","2018","2018",4.8,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","TCPPERMT","/capita, US$ exchange rate","HUN","Hungary","2019","2019",4.1,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","TCPPERMT","/capita, US$ exchange rate","HUN","Hungary","2020","2020",3,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","TCPPERMT","/capita, US$ exchange rate","HUN","Hungary","2021","2021",3.3,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","TCPPERMT","/capita, US$ exchange rate","HUN","Hungary","2022","2022",3.3,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2010","2010",11.3,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2011","2011",11.5,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2012","2012",10.4,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2013","2013",10.5,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2014","2014",10.4,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2015","2015",10.4,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2016","2016",9.9,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2017","2017",9.5,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2018","2018",9.3,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2019","2019",8.6,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2020","2020",6.4,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2021","2021",6.4,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2022","2022",7.7,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","ATCPTTMT","% of total sales","HUN","Hungary","2010","2010",2.9,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","ATCPTTMT","% of total sales","HUN","Hungary","2011","2011",2.8,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","ATCPTTMT","% of total sales","HUN","Hungary","2012","2012",2.9,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","ATCPTTMT","% of total sales","HUN","Hungary","2013","2013",3,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","ATCPTTMT","% of total sales","HUN","Hungary","2014","2014",3,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","ATCPTTMT","% of total sales","HUN","Hungary","2015","2015",2.9,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","ATCPTTMT","% of total sales","HUN","Hungary","2016","2016",2.6,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","ATCPTTMT","% of total sales","HUN","Hungary","2017","2017",2.6,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","ATCPTTMT","% of total sales","HUN","Hungary","2018","2018",2.5,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","ATCPTTMT","% of total sales","HUN","Hungary","2019","2019",2.2,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","ATCPTTMT","% of total sales","HUN","Hungary","2020","2020",1.6,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","ATCPTTMT","% of total sales","HUN","Hungary","2021","2021",1.7,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","ATCPTTMT","% of total sales","HUN","Hungary","2022","2022",2,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","MLLNCUMT","Million of national currency units","ISL","Iceland","2010","2010",942.2,,
+"PATCBIOT","J01-Antibacterials for systemic use","MLLNCUMT","Million of national currency units","ISL","Iceland","2011","2011",966.8,,
+"PATCBIOT","J01-Antibacterials for systemic use","MLLNCUMT","Million of national currency units","ISL","Iceland","2012","2012",1031.1,,
+"PATCBIOT","J01-Antibacterials for systemic use","MLLNCUMT","Million of national currency units","ISL","Iceland","2013","2013",1047.8,,
+"PATCBIOT","J01-Antibacterials for systemic use","MLLNCUMT","Million of national currency units","ISL","Iceland","2014","2014",997.1,,
+"PATCBIOT","J01-Antibacterials for systemic use","MLLNCUMT","Million of national currency units","ISL","Iceland","2015","2015",1040.8,,
+"PATCBIOT","J01-Antibacterials for systemic use","MLLNCUMT","Million of national currency units","ISL","Iceland","2016","2016",1062.7,,
+"PATCBIOT","J01-Antibacterials for systemic use","MLLNCUMT","Million of national currency units","ISL","Iceland","2017","2017",1066.3,,
+"PATCBIOT","J01-Antibacterials for systemic use","MLLNCUMT","Million of national currency units","ISL","Iceland","2018","2018",1161.3,,
+"PATCBIOT","J01-Antibacterials for systemic use","MLLNCUMT","Million of national currency units","ISL","Iceland","2019","2019",1102.6,,
+"PATCBIOT","J01-Antibacterials for systemic use","MLLNCUMT","Million of national currency units","ISL","Iceland","2020","2020",1063.7,,
+"PATCBIOT","J01-Antibacterials for systemic use","MLLNCUMT","Million of national currency units","ISL","Iceland","2021","2021",1195.3,,
+"PATCBIOT","J01-Antibacterials for systemic use","MTMOTCMT","Million US$ at exchange rate","ISL","Iceland","2010","2010",7.7,,
+"PATCBIOT","J01-Antibacterials for systemic use","MTMOTCMT","Million US$ at exchange rate","ISL","Iceland","2011","2011",8.3,,
+"PATCBIOT","J01-Antibacterials for systemic use","MTMOTCMT","Million US$ at exchange rate","ISL","Iceland","2012","2012",8.2,,
+"PATCBIOT","J01-Antibacterials for systemic use","MTMOTCMT","Million US$ at exchange rate","ISL","Iceland","2013","2013",8.6,,
+"PATCBIOT","J01-Antibacterials for systemic use","MTMOTCMT","Million US$ at exchange rate","ISL","Iceland","2014","2014",8.5,,
+"PATCBIOT","J01-Antibacterials for systemic use","MTMOTCMT","Million US$ at exchange rate","ISL","Iceland","2015","2015",7.9,,
+"PATCBIOT","J01-Antibacterials for systemic use","MTMOTCMT","Million US$ at exchange rate","ISL","Iceland","2016","2016",8.8,,
+"PATCBIOT","J01-Antibacterials for systemic use","MTMOTCMT","Million US$ at exchange rate","ISL","Iceland","2017","2017",10,,
+"PATCBIOT","J01-Antibacterials for systemic use","MTMOTCMT","Million US$ at exchange rate","ISL","Iceland","2018","2018",10.7,,
+"PATCBIOT","J01-Antibacterials for systemic use","MTMOTCMT","Million US$ at exchange rate","ISL","Iceland","2019","2019",9,,
+"PATCBIOT","J01-Antibacterials for systemic use","MTMOTCMT","Million US$ at exchange rate","ISL","Iceland","2020","2020",7.9,,
+"PATCBIOT","J01-Antibacterials for systemic use","MTMOTCMT","Million US$ at exchange rate","ISL","Iceland","2021","2021",9.4,,
+"PATCBIOT","J01-Antibacterials for systemic use","MTMOPPMT","Million US$, purchasing power parity","ISL","Iceland","2010","2010",7.1,,
+"PATCBIOT","J01-Antibacterials for systemic use","MTMOPPMT","Million US$, purchasing power parity","ISL","Iceland","2011","2011",7.2,,
+"PATCBIOT","J01-Antibacterials for systemic use","MTMOPPMT","Million US$, purchasing power parity","ISL","Iceland","2012","2012",7.5,,
+"PATCBIOT","J01-Antibacterials for systemic use","MTMOPPMT","Million US$, purchasing power parity","ISL","Iceland","2013","2013",7.6,,
+"PATCBIOT","J01-Antibacterials for systemic use","MTMOPPMT","Million US$, purchasing power parity","ISL","Iceland","2014","2014",7.2,,
+"PATCBIOT","J01-Antibacterials for systemic use","MTMOPPMT","Million US$, purchasing power parity","ISL","Iceland","2015","2015",7.3,,
+"PATCBIOT","J01-Antibacterials for systemic use","MTMOPPMT","Million US$, purchasing power parity","ISL","Iceland","2016","2016",7.6,,
+"PATCBIOT","J01-Antibacterials for systemic use","MTMOPPMT","Million US$, purchasing power parity","ISL","Iceland","2017","2017",7.7,,
+"PATCBIOT","J01-Antibacterials for systemic use","MTMOPPMT","Million US$, purchasing power parity","ISL","Iceland","2018","2018",8.2,,
+"PATCBIOT","J01-Antibacterials for systemic use","MTMOPPMT","Million US$, purchasing power parity","ISL","Iceland","2019","2019",7.8,,
+"PATCBIOT","J01-Antibacterials for systemic use","MTMOPPMT","Million US$, purchasing power parity","ISL","Iceland","2020","2020",7.3,,
+"PATCBIOT","J01-Antibacterials for systemic use","MTMOPPMT","Million US$, purchasing power parity","ISL","Iceland","2021","2021",8,,
+"PATCBIOT","J01-Antibacterials for systemic use","TCPPERMT","/capita, US$ exchange rate","ISL","Iceland","2010","2010",24.2,,
+"PATCBIOT","J01-Antibacterials for systemic use","TCPPERMT","/capita, US$ exchange rate","ISL","Iceland","2011","2011",26.1,,
+"PATCBIOT","J01-Antibacterials for systemic use","TCPPERMT","/capita, US$ exchange rate","ISL","Iceland","2012","2012",25.7,,
+"PATCBIOT","J01-Antibacterials for systemic use","TCPPERMT","/capita, US$ exchange rate","ISL","Iceland","2013","2013",26.5,,
+"PATCBIOT","J01-Antibacterials for systemic use","TCPPERMT","/capita, US$ exchange rate","ISL","Iceland","2014","2014",26.1,,
+"PATCBIOT","J01-Antibacterials for systemic use","TCPPERMT","/capita, US$ exchange rate","ISL","Iceland","2015","2015",23.8,,
+"PATCBIOT","J01-Antibacterials for systemic use","TCPPERMT","/capita, US$ exchange rate","ISL","Iceland","2016","2016",26.2,,
+"PATCBIOT","J01-Antibacterials for systemic use","TCPPERMT","/capita, US$ exchange rate","ISL","Iceland","2017","2017",29.1,,
+"PATCBIOT","J01-Antibacterials for systemic use","TCPPERMT","/capita, US$ exchange rate","ISL","Iceland","2018","2018",30.4,,
+"PATCBIOT","J01-Antibacterials for systemic use","TCPPERMT","/capita, US$ exchange rate","ISL","Iceland","2019","2019",24.9,,
+"PATCBIOT","J01-Antibacterials for systemic use","TCPPERMT","/capita, US$ exchange rate","ISL","Iceland","2020","2020",21.4,,
+"PATCBIOT","J01-Antibacterials for systemic use","TCPPERMT","/capita, US$ exchange rate","ISL","Iceland","2021","2021",25.3,,
+"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2010","2010",22.3,,
+"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2011","2011",22.4,,
+"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2012","2012",23.5,,
+"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2013","2013",23.6,,
+"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2014","2014",22,,
+"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2015","2015",22.2,,
+"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2016","2016",22.6,,
+"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2017","2017",22.5,,
+"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2018","2018",23.4,,
+"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2019","2019",21.7,,
+"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2020","2020",19.8,,
+"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2021","2021",21.4,,
+"PATCBIOT","J01-Antibacterials for systemic use","ATCPTTMT","% of total sales","ISL","Iceland","2010","2010",3.8,,
+"PATCBIOT","J01-Antibacterials for systemic use","ATCPTTMT","% of total sales","ISL","Iceland","2011","2011",3.7,,
+"PATCBIOT","J01-Antibacterials for systemic use","ATCPTTMT","% of total sales","ISL","Iceland","2012","2012",4.2,,
+"PATCBIOT","J01-Antibacterials for systemic use","ATCPTTMT","% of total sales","ISL","Iceland","2013","2013",4,,
+"PATCBIOT","J01-Antibacterials for systemic use","ATCPTTMT","% of total sales","ISL","Iceland","2014","2014",4.2,,
+"PATCBIOT","J01-Antibacterials for systemic use","ATCPTTMT","% of total sales","ISL","Iceland","2015","2015",4.3,,
+"PATCBIOT","J01-Antibacterials for systemic use","ATCPTTMT","% of total sales","ISL","Iceland","2016","2016",4.2,,
+"PATCBIOT","J01-Antibacterials for systemic use","ATCPTTMT","% of total sales","ISL","Iceland","2017","2017",4,,
+"PATCBIOT","J01-Antibacterials for systemic use","ATCPTTMT","% of total sales","ISL","Iceland","2018","2018",3.8,,
+"PATCBIOT","J01-Antibacterials for systemic use","ATCPTTMT","% of total sales","ISL","Iceland","2019","2019",3.3,,
+"PATCBIOT","J01-Antibacterials for systemic use","ATCPTTMT","% of total sales","ISL","Iceland","2020","2020",2.7,,
+"PATCBIOT","J01-Antibacterials for systemic use","ATCPTTMT","% of total sales","ISL","Iceland","2021","2021",2.6,,
+"PATCBIOT","J01-Antibacterials for systemic use","MLLNCUMT","Million of national currency units","IRL","Ireland","2010","2010",48.2,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","MLLNCUMT","Million of national currency units","IRL","Ireland","2011","2011",44.3,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","MLLNCUMT","Million of national currency units","IRL","Ireland","2012","2012",54.2,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","MLLNCUMT","Million of national currency units","IRL","Ireland","2013","2013",48.1,"B; D","Break; Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","MLLNCUMT","Million of national currency units","IRL","Ireland","2014","2014",48,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","MLLNCUMT","Million of national currency units","IRL","Ireland","2015","2015",47.7,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","MLLNCUMT","Million of national currency units","IRL","Ireland","2016","2016",44.9,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","MLLNCUMT","Million of national currency units","IRL","Ireland","2017","2017",42.9,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","MLLNCUMT","Million of national currency units","IRL","Ireland","2018","2018",41.5,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","MLLNCUMT","Million of national currency units","IRL","Ireland","2019","2019",39.3,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","MLLNCUMT","Million of national currency units","IRL","Ireland","2020","2020",33.8,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","MLLNCUMT","Million of national currency units","IRL","Ireland","2021","2021",38.7,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","MTMOTCMT","Million US$ at exchange rate","IRL","Ireland","2010","2010",64,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","MTMOTCMT","Million US$ at exchange rate","IRL","Ireland","2011","2011",61.6,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","MTMOTCMT","Million US$ at exchange rate","IRL","Ireland","2012","2012",69.6,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","MTMOTCMT","Million US$ at exchange rate","IRL","Ireland","2013","2013",63.8,"B; D","Break; Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","MTMOTCMT","Million US$ at exchange rate","IRL","Ireland","2014","2014",63.8,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","MTMOTCMT","Million US$ at exchange rate","IRL","Ireland","2015","2015",53,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","MTMOTCMT","Million US$ at exchange rate","IRL","Ireland","2016","2016",49.7,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","MTMOTCMT","Million US$ at exchange rate","IRL","Ireland","2017","2017",48.5,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","MTMOTCMT","Million US$ at exchange rate","IRL","Ireland","2018","2018",49,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","MTMOTCMT","Million US$ at exchange rate","IRL","Ireland","2019","2019",44,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","MTMOTCMT","Million US$ at exchange rate","IRL","Ireland","2020","2020",38.6,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","MTMOTCMT","Million US$ at exchange rate","IRL","Ireland","2021","2021",45.8,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","MTMOPPMT","Million US$, purchasing power parity","IRL","Ireland","2010","2010",56.8,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","MTMOPPMT","Million US$, purchasing power parity","IRL","Ireland","2011","2011",53.2,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","MTMOPPMT","Million US$, purchasing power parity","IRL","Ireland","2012","2012",65.8,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","MTMOPPMT","Million US$, purchasing power parity","IRL","Ireland","2013","2013",59.2,"B; D","Break; Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","MTMOPPMT","Million US$, purchasing power parity","IRL","Ireland","2014","2014",58.6,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","MTMOPPMT","Million US$, purchasing power parity","IRL","Ireland","2015","2015",58.9,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","MTMOPPMT","Million US$, purchasing power parity","IRL","Ireland","2016","2016",56.5,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","MTMOPPMT","Million US$, purchasing power parity","IRL","Ireland","2017","2017",54,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","MTMOPPMT","Million US$, purchasing power parity","IRL","Ireland","2018","2018",52.4,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","MTMOPPMT","Million US$, purchasing power parity","IRL","Ireland","2019","2019",48.8,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","MTMOPPMT","Million US$, purchasing power parity","IRL","Ireland","2020","2020",42.5,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","MTMOPPMT","Million US$, purchasing power parity","IRL","Ireland","2021","2021",48.7,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","TCPPERMT","/capita, US$ exchange rate","IRL","Ireland","2010","2010",14,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","TCPPERMT","/capita, US$ exchange rate","IRL","Ireland","2011","2011",13.5,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","TCPPERMT","/capita, US$ exchange rate","IRL","Ireland","2012","2012",15.1,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","TCPPERMT","/capita, US$ exchange rate","IRL","Ireland","2013","2013",13.8,"B; D","Break; Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","TCPPERMT","/capita, US$ exchange rate","IRL","Ireland","2014","2014",13.7,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","TCPPERMT","/capita, US$ exchange rate","IRL","Ireland","2015","2015",11.3,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","TCPPERMT","/capita, US$ exchange rate","IRL","Ireland","2016","2016",10.4,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","TCPPERMT","/capita, US$ exchange rate","IRL","Ireland","2017","2017",10.1,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","TCPPERMT","/capita, US$ exchange rate","IRL","Ireland","2018","2018",10.1,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","TCPPERMT","/capita, US$ exchange rate","IRL","Ireland","2019","2019",8.9,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","TCPPERMT","/capita, US$ exchange rate","IRL","Ireland","2020","2020",7.8,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","TCPPERMT","/capita, US$ exchange rate","IRL","Ireland","2021","2021",9.1,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2010","2010",12.5,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2011","2011",11.6,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2012","2012",14.3,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2013","2013",12.8,"B; D","Break; Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2014","2014",12.6,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2015","2015",12.5,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2016","2016",11.9,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2017","2017",11.2,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2018","2018",10.8,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2019","2019",9.9,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2020","2020",8.5,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2021","2021",9.7,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","ATCPTTMT","% of total sales","IRL","Ireland","2010","2010",2.4,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","ATCPTTMT","% of total sales","IRL","Ireland","2011","2011",2.3,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","ATCPTTMT","% of total sales","IRL","Ireland","2012","2012",2.6,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","ATCPTTMT","% of total sales","IRL","Ireland","2013","2013",2.5,"B; D","Break; Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","ATCPTTMT","% of total sales","IRL","Ireland","2014","2014",2.5,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","ATCPTTMT","% of total sales","IRL","Ireland","2015","2015",2.4,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","ATCPTTMT","% of total sales","IRL","Ireland","2016","2016",2.2,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","ATCPTTMT","% of total sales","IRL","Ireland","2017","2017",2,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","ATCPTTMT","% of total sales","IRL","Ireland","2018","2018",1.8,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","ATCPTTMT","% of total sales","IRL","Ireland","2019","2019",1.6,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","ATCPTTMT","% of total sales","IRL","Ireland","2020","2020",1.4,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","ATCPTTMT","% of total sales","IRL","Ireland","2021","2021",1.5,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","MLLNCUMT","Million of national currency units","ITA","Italy","2011","2011",1124.5,,
+"PATCBIOT","J01-Antibacterials for systemic use","MLLNCUMT","Million of national currency units","ITA","Italy","2012","2012",998.1,,
+"PATCBIOT","J01-Antibacterials for systemic use","MLLNCUMT","Million of national currency units","ITA","Italy","2013","2013",979.4,,
+"PATCBIOT","J01-Antibacterials for systemic use","MLLNCUMT","Million of national currency units","ITA","Italy","2014","2014",974.3,,
+"PATCBIOT","J01-Antibacterials for systemic use","MLLNCUMT","Million of national currency units","ITA","Italy","2015","2015",956.2,,
+"PATCBIOT","J01-Antibacterials for systemic use","MLLNCUMT","Million of national currency units","ITA","Italy","2016","2016",884.2,,
+"PATCBIOT","J01-Antibacterials for systemic use","MLLNCUMT","Million of national currency units","ITA","Italy","2017","2017",871,,
+"PATCBIOT","J01-Antibacterials for systemic use","MLLNCUMT","Million of national currency units","ITA","Italy","2018","2018",864.4,,
+"PATCBIOT","J01-Antibacterials for systemic use","MLLNCUMT","Million of national currency units","ITA","Italy","2019","2019",839.2,,
+"PATCBIOT","J01-Antibacterials for systemic use","MLLNCUMT","Million of national currency units","ITA","Italy","2020","2020",689.4,,
+"PATCBIOT","J01-Antibacterials for systemic use","MLLNCUMT","Million of national currency units","ITA","Italy","2021","2021",653.8,,
+"PATCBIOT","J01-Antibacterials for systemic use","MLLNCUMT","Million of national currency units","ITA","Italy","2022","2022",740.5,"E","Estimated value"
+"PATCBIOT","J01-Antibacterials for systemic use","MTMOTCMT","Million US$ at exchange rate","ITA","Italy","2011","2011",1565.3,,
+"PATCBIOT","J01-Antibacterials for systemic use","MTMOTCMT","Million US$ at exchange rate","ITA","Italy","2012","2012",1282.4,,
+"PATCBIOT","J01-Antibacterials for systemic use","MTMOTCMT","Million US$ at exchange rate","ITA","Italy","2013","2013",1300.7,,
+"PATCBIOT","J01-Antibacterials for systemic use","MTMOTCMT","Million US$ at exchange rate","ITA","Italy","2014","2014",1294.3,,
+"PATCBIOT","J01-Antibacterials for systemic use","MTMOTCMT","Million US$ at exchange rate","ITA","Italy","2015","2015",1060.9,,
+"PATCBIOT","J01-Antibacterials for systemic use","MTMOTCMT","Million US$ at exchange rate","ITA","Italy","2016","2016",978.7,,
+"PATCBIOT","J01-Antibacterials for systemic use","MTMOTCMT","Million US$ at exchange rate","ITA","Italy","2017","2017",983.9,,
+"PATCBIOT","J01-Antibacterials for systemic use","MTMOTCMT","Million US$ at exchange rate","ITA","Italy","2018","2018",1020.8,,
+"PATCBIOT","J01-Antibacterials for systemic use","MTMOTCMT","Million US$ at exchange rate","ITA","Italy","2019","2019",939.4,,
+"PATCBIOT","J01-Antibacterials for systemic use","MTMOTCMT","Million US$ at exchange rate","ITA","Italy","2020","2020",787.5,,
+"PATCBIOT","J01-Antibacterials for systemic use","MTMOTCMT","Million US$ at exchange rate","ITA","Italy","2021","2021",773.3,,
+"PATCBIOT","J01-Antibacterials for systemic use","MTMOTCMT","Million US$ at exchange rate","ITA","Italy","2022","2022",779.7,"E","Estimated value"
+"PATCBIOT","J01-Antibacterials for systemic use","MTMOPPMT","Million US$, purchasing power parity","ITA","Italy","2011","2011",1482.2,,
+"PATCBIOT","J01-Antibacterials for systemic use","MTMOPPMT","Million US$, purchasing power parity","ITA","Italy","2012","2012",1334.9,,
+"PATCBIOT","J01-Antibacterials for systemic use","MTMOPPMT","Million US$, purchasing power parity","ITA","Italy","2013","2013",1328.3,,
+"PATCBIOT","J01-Antibacterials for systemic use","MTMOPPMT","Million US$, purchasing power parity","ITA","Italy","2014","2014",1317.2,,
+"PATCBIOT","J01-Antibacterials for systemic use","MTMOPPMT","Million US$, purchasing power parity","ITA","Italy","2015","2015",1294.4,,
+"PATCBIOT","J01-Antibacterials for systemic use","MTMOPPMT","Million US$, purchasing power parity","ITA","Italy","2016","2016",1262.1,,
+"PATCBIOT","J01-Antibacterials for systemic use","MTMOPPMT","Million US$, purchasing power parity","ITA","Italy","2017","2017",1262.5,,
+"PATCBIOT","J01-Antibacterials for systemic use","MTMOPPMT","Million US$, purchasing power parity","ITA","Italy","2018","2018",1268.9,,
+"PATCBIOT","J01-Antibacterials for systemic use","MTMOPPMT","Million US$, purchasing power parity","ITA","Italy","2019","2019",1277.7,,
+"PATCBIOT","J01-Antibacterials for systemic use","MTMOPPMT","Million US$, purchasing power parity","ITA","Italy","2020","2020",1064.4,,
+"PATCBIOT","J01-Antibacterials for systemic use","MTMOPPMT","Million US$, purchasing power parity","ITA","Italy","2021","2021",1009.7,,
+"PATCBIOT","J01-Antibacterials for systemic use","MTMOPPMT","Million US$, purchasing power parity","ITA","Italy","2022","2022",1199.3,"E","Estimated value"
+"PATCBIOT","J01-Antibacterials for systemic use","TCPPERMT","/capita, US$ exchange rate","ITA","Italy","2011","2011",26.4,,
+"PATCBIOT","J01-Antibacterials for systemic use","TCPPERMT","/capita, US$ exchange rate","ITA","Italy","2012","2012",21.5,,
+"PATCBIOT","J01-Antibacterials for systemic use","TCPPERMT","/capita, US$ exchange rate","ITA","Italy","2013","2013",21.6,,
+"PATCBIOT","J01-Antibacterials for systemic use","TCPPERMT","/capita, US$ exchange rate","ITA","Italy","2014","2014",21.3,,
+"PATCBIOT","J01-Antibacterials for systemic use","TCPPERMT","/capita, US$ exchange rate","ITA","Italy","2015","2015",17.5,,
+"PATCBIOT","J01-Antibacterials for systemic use","TCPPERMT","/capita, US$ exchange rate","ITA","Italy","2016","2016",16.1,,
+"PATCBIOT","J01-Antibacterials for systemic use","TCPPERMT","/capita, US$ exchange rate","ITA","Italy","2017","2017",16.3,,
+"PATCBIOT","J01-Antibacterials for systemic use","TCPPERMT","/capita, US$ exchange rate","ITA","Italy","2018","2018",16.9,,
+"PATCBIOT","J01-Antibacterials for systemic use","TCPPERMT","/capita, US$ exchange rate","ITA","Italy","2019","2019",15.7,,
+"PATCBIOT","J01-Antibacterials for systemic use","TCPPERMT","/capita, US$ exchange rate","ITA","Italy","2020","2020",13.2,,
+"PATCBIOT","J01-Antibacterials for systemic use","TCPPERMT","/capita, US$ exchange rate","ITA","Italy","2021","2021",13.1,,
+"PATCBIOT","J01-Antibacterials for systemic use","TCPPERMT","/capita, US$ exchange rate","ITA","Italy","2022","2022",13.2,"E","Estimated value"
+"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2011","2011",25,,
+"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2012","2012",22.4,,
+"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2013","2013",22.1,,
+"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2014","2014",21.7,,
+"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2015","2015",21.3,,
+"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2016","2016",20.8,,
+"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2017","2017",20.9,,
+"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2018","2018",21,,
+"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2019","2019",21.4,,
+"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2020","2020",17.9,,
+"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2021","2021",17.1,,
+"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2022","2022",20.3,"E","Estimated value"
+"PATCBIOT","J01-Antibacterials for systemic use","ATCPTTMT","% of total sales","ITA","Italy","2011","2011",5.8,,
+"PATCBIOT","J01-Antibacterials for systemic use","ATCPTTMT","% of total sales","ITA","Italy","2012","2012",5.2,,
+"PATCBIOT","J01-Antibacterials for systemic use","ATCPTTMT","% of total sales","ITA","Italy","2013","2013",5,,
+"PATCBIOT","J01-Antibacterials for systemic use","ATCPTTMT","% of total sales","ITA","Italy","2014","2014",4.9,,
+"PATCBIOT","J01-Antibacterials for systemic use","ATCPTTMT","% of total sales","ITA","Italy","2015","2015",4.2,,
+"PATCBIOT","J01-Antibacterials for systemic use","ATCPTTMT","% of total sales","ITA","Italy","2016","2016",3.9,,
+"PATCBIOT","J01-Antibacterials for systemic use","ATCPTTMT","% of total sales","ITA","Italy","2017","2017",3.9,,
+"PATCBIOT","J01-Antibacterials for systemic use","ATCPTTMT","% of total sales","ITA","Italy","2018","2018",3.9,,
+"PATCBIOT","J01-Antibacterials for systemic use","ATCPTTMT","% of total sales","ITA","Italy","2019","2019",3.7,,
+"PATCBIOT","J01-Antibacterials for systemic use","ATCPTTMT","% of total sales","ITA","Italy","2020","2020",3,,
+"PATCBIOT","J01-Antibacterials for systemic use","ATCPTTMT","% of total sales","ITA","Italy","2021","2021",2.7,,
+"PATCBIOT","J01-Antibacterials for systemic use","ATCPTTMT","% of total sales","ITA","Italy","2022","2022",3,"E","Estimated value"
+"PATCBIOT","J01-Antibacterials for systemic use","MLLNCUMT","Million of national currency units","KOR","Korea","2010","2010",1524345,,
+"PATCBIOT","J01-Antibacterials for systemic use","MLLNCUMT","Million of national currency units","KOR","Korea","2011","2011",1553418.7,"B","Break"
+"PATCBIOT","J01-Antibacterials for systemic use","MLLNCUMT","Million of national currency units","KOR","Korea","2012","2012",1384956.9,,
+"PATCBIOT","J01-Antibacterials for systemic use","MLLNCUMT","Million of national currency units","KOR","Korea","2013","2013",1321304.3,,
+"PATCBIOT","J01-Antibacterials for systemic use","MLLNCUMT","Million of national currency units","KOR","Korea","2014","2014",1328207.1,,
+"PATCBIOT","J01-Antibacterials for systemic use","MLLNCUMT","Million of national currency units","KOR","Korea","2015","2015",1345422.7,,
+"PATCBIOT","J01-Antibacterials for systemic use","MLLNCUMT","Million of national currency units","KOR","Korea","2016","2016",1264533.9,"B","Break"
+"PATCBIOT","J01-Antibacterials for systemic use","MLLNCUMT","Million of national currency units","KOR","Korea","2017","2017",1268716.8,,
+"PATCBIOT","J01-Antibacterials for systemic use","MLLNCUMT","Million of national currency units","KOR","Korea","2018","2018",1313986.4,,
+"PATCBIOT","J01-Antibacterials for systemic use","MLLNCUMT","Million of national currency units","KOR","Korea","2019","2019",1306743.5,,
+"PATCBIOT","J01-Antibacterials for systemic use","MLLNCUMT","Million of national currency units","KOR","Korea","2020","2020",1093254.9,,
+"PATCBIOT","J01-Antibacterials for systemic use","MLLNCUMT","Million of national currency units","KOR","Korea","2021","2021",1064966.1,,
+"PATCBIOT","J01-Antibacterials for systemic use","MTMOTCMT","Million US$ at exchange rate","KOR","Korea","2010","2010",1318.1,,
+"PATCBIOT","J01-Antibacterials for systemic use","MTMOTCMT","Million US$ at exchange rate","KOR","Korea","2011","2011",1401.7,"B","Break"
+"PATCBIOT","J01-Antibacterials for systemic use","MTMOTCMT","Million US$ at exchange rate","KOR","Korea","2012","2012",1229.1,,
+"PATCBIOT","J01-Antibacterials for systemic use","MTMOTCMT","Million US$ at exchange rate","KOR","Korea","2013","2013",1206.7,,
+"PATCBIOT","J01-Antibacterials for systemic use","MTMOTCMT","Million US$ at exchange rate","KOR","Korea","2014","2014",1261.5,,
+"PATCBIOT","J01-Antibacterials for systemic use","MTMOTCMT","Million US$ at exchange rate","KOR","Korea","2015","2015",1189.6,,
+"PATCBIOT","J01-Antibacterials for systemic use","MTMOTCMT","Million US$ at exchange rate","KOR","Korea","2016","2016",1089.4,"B","Break"
+"PATCBIOT","J01-Antibacterials for systemic use","MTMOTCMT","Million US$ at exchange rate","KOR","Korea","2017","2017",1121.8,,
+"PATCBIOT","J01-Antibacterials for systemic use","MTMOTCMT","Million US$ at exchange rate","KOR","Korea","2018","2018",1194.4,,
+"PATCBIOT","J01-Antibacterials for systemic use","MTMOTCMT","Million US$ at exchange rate","KOR","Korea","2019","2019",1121.3,,
+"PATCBIOT","J01-Antibacterials for systemic use","MTMOTCMT","Million US$ at exchange rate","KOR","Korea","2020","2020",926.3,,
+"PATCBIOT","J01-Antibacterials for systemic use","MTMOTCMT","Million US$ at exchange rate","KOR","Korea","2021","2021",931,,
+"PATCBIOT","J01-Antibacterials for systemic use","MTMOPPMT","Million US$, purchasing power parity","KOR","Korea","2010","2010",1812.6,,
+"PATCBIOT","J01-Antibacterials for systemic use","MTMOPPMT","Million US$, purchasing power parity","KOR","Korea","2011","2011",1817.7,"B","Break"
+"PATCBIOT","J01-Antibacterials for systemic use","MTMOPPMT","Million US$, purchasing power parity","KOR","Korea","2012","2012",1620,,
+"PATCBIOT","J01-Antibacterials for systemic use","MTMOPPMT","Million US$, purchasing power parity","KOR","Korea","2013","2013",1520.3,,
+"PATCBIOT","J01-Antibacterials for systemic use","MTMOPPMT","Million US$, purchasing power parity","KOR","Korea","2014","2014",1523.4,,
+"PATCBIOT","J01-Antibacterials for systemic use","MTMOPPMT","Million US$, purchasing power parity","KOR","Korea","2015","2015",1569,,
+"PATCBIOT","J01-Antibacterials for systemic use","MTMOPPMT","Million US$, purchasing power parity","KOR","Korea","2016","2016",1472.4,"B","Break"
+"PATCBIOT","J01-Antibacterials for systemic use","MTMOPPMT","Million US$, purchasing power parity","KOR","Korea","2017","2017",1453.9,,
+"PATCBIOT","J01-Antibacterials for systemic use","MTMOPPMT","Million US$, purchasing power parity","KOR","Korea","2018","2018",1537.1,,
+"PATCBIOT","J01-Antibacterials for systemic use","MTMOPPMT","Million US$, purchasing power parity","KOR","Korea","2019","2019",1525.8,,
+"PATCBIOT","J01-Antibacterials for systemic use","MTMOPPMT","Million US$, purchasing power parity","KOR","Korea","2020","2020",1305.1,,
+"PATCBIOT","J01-Antibacterials for systemic use","MTMOPPMT","Million US$, purchasing power parity","KOR","Korea","2021","2021",1246.9,,
+"PATCBIOT","J01-Antibacterials for systemic use","TCPPERMT","/capita, US$ exchange rate","KOR","Korea","2010","2010",26.6,,
+"PATCBIOT","J01-Antibacterials for systemic use","TCPPERMT","/capita, US$ exchange rate","KOR","Korea","2011","2011",28.1,"B","Break"
+"PATCBIOT","J01-Antibacterials for systemic use","TCPPERMT","/capita, US$ exchange rate","KOR","Korea","2012","2012",24.5,,
+"PATCBIOT","J01-Antibacterials for systemic use","TCPPERMT","/capita, US$ exchange rate","KOR","Korea","2013","2013",23.9,,
+"PATCBIOT","J01-Antibacterials for systemic use","TCPPERMT","/capita, US$ exchange rate","KOR","Korea","2014","2014",24.9,,
+"PATCBIOT","J01-Antibacterials for systemic use","TCPPERMT","/capita, US$ exchange rate","KOR","Korea","2015","2015",23.3,,
+"PATCBIOT","J01-Antibacterials for systemic use","TCPPERMT","/capita, US$ exchange rate","KOR","Korea","2016","2016",21.3,"B","Break"
+"PATCBIOT","J01-Antibacterials for systemic use","TCPPERMT","/capita, US$ exchange rate","KOR","Korea","2017","2017",21.8,,
+"PATCBIOT","J01-Antibacterials for systemic use","TCPPERMT","/capita, US$ exchange rate","KOR","Korea","2018","2018",23.2,,
+"PATCBIOT","J01-Antibacterials for systemic use","TCPPERMT","/capita, US$ exchange rate","KOR","Korea","2019","2019",21.7,,
+"PATCBIOT","J01-Antibacterials for systemic use","TCPPERMT","/capita, US$ exchange rate","KOR","Korea","2020","2020",17.9,,
+"PATCBIOT","J01-Antibacterials for systemic use","TCPPERMT","/capita, US$ exchange rate","KOR","Korea","2021","2021",18,,
+"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2010","2010",36.6,,
+"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2011","2011",36.4,"B","Break"
+"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2012","2012",32.3,,
+"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2013","2013",30.1,,
+"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2014","2014",30,,
+"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2015","2015",30.8,,
+"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2016","2016",28.7,"B","Break"
+"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2017","2017",28.3,,
+"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2018","2018",29.8,,
+"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2019","2019",29.5,,
+"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2020","2020",25.2,,
+"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2021","2021",24.1,,
+"PATCBIOT","J01-Antibacterials for systemic use","ATCPTTMT","% of total sales","KOR","Korea","2010","2010",7.5,,
+"PATCBIOT","J01-Antibacterials for systemic use","ATCPTTMT","% of total sales","KOR","Korea","2011","2011",7,"B","Break"
+"PATCBIOT","J01-Antibacterials for systemic use","ATCPTTMT","% of total sales","KOR","Korea","2012","2012",6.4,,
+"PATCBIOT","J01-Antibacterials for systemic use","ATCPTTMT","% of total sales","KOR","Korea","2013","2013",5.9,,
+"PATCBIOT","J01-Antibacterials for systemic use","ATCPTTMT","% of total sales","KOR","Korea","2014","2014",5.6,,
+"PATCBIOT","J01-Antibacterials for systemic use","ATCPTTMT","% of total sales","KOR","Korea","2015","2015",5.5,,
+"PATCBIOT","J01-Antibacterials for systemic use","ATCPTTMT","% of total sales","KOR","Korea","2016","2016",5,"B","Break"
+"PATCBIOT","J01-Antibacterials for systemic use","ATCPTTMT","% of total sales","KOR","Korea","2017","2017",4.7,,
+"PATCBIOT","J01-Antibacterials for systemic use","ATCPTTMT","% of total sales","KOR","Korea","2018","2018",4.5,,
+"PATCBIOT","J01-Antibacterials for systemic use","ATCPTTMT","% of total sales","KOR","Korea","2019","2019",4.2,,
+"PATCBIOT","J01-Antibacterials for systemic use","ATCPTTMT","% of total sales","KOR","Korea","2020","2020",3.4,,
+"PATCBIOT","J01-Antibacterials for systemic use","ATCPTTMT","% of total sales","KOR","Korea","2021","2021",3.1,,
+"PATCBIOT","J01-Antibacterials for systemic use","MLLNCUMT","Million of national currency units","LUX","Luxembourg","2010","2010",7.1,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","MLLNCUMT","Million of national currency units","LUX","Luxembourg","2011","2011",6.8,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","MLLNCUMT","Million of national currency units","LUX","Luxembourg","2012","2012",6.5,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","MLLNCUMT","Million of national currency units","LUX","Luxembourg","2013","2013",6.3,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","MLLNCUMT","Million of national currency units","LUX","Luxembourg","2014","2014",6,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","MLLNCUMT","Million of national currency units","LUX","Luxembourg","2015","2015",5.8,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","MLLNCUMT","Million of national currency units","LUX","Luxembourg","2016","2016",5.8,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","MLLNCUMT","Million of national currency units","LUX","Luxembourg","2017","2017",5.5,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","MLLNCUMT","Million of national currency units","LUX","Luxembourg","2018","2018",5.5,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","MLLNCUMT","Million of national currency units","LUX","Luxembourg","2019","2019",5.4,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","MLLNCUMT","Million of national currency units","LUX","Luxembourg","2020","2020",4.3,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","MLLNCUMT","Million of national currency units","LUX","Luxembourg","2021","2021",4.2,"B; D; P","Break; Difference in methodology; Provisional value"
+"PATCBIOT","J01-Antibacterials for systemic use","MLLNCUMT","Million of national currency units","LUX","Luxembourg","2022","2022",4.5,"D; P","Difference in methodology; Provisional value"
+"PATCBIOT","J01-Antibacterials for systemic use","MTMOTCMT","Million US$ at exchange rate","LUX","Luxembourg","2010","2010",9.4,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","MTMOTCMT","Million US$ at exchange rate","LUX","Luxembourg","2011","2011",9.5,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","MTMOTCMT","Million US$ at exchange rate","LUX","Luxembourg","2012","2012",8.3,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","MTMOTCMT","Million US$ at exchange rate","LUX","Luxembourg","2013","2013",8.4,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","MTMOTCMT","Million US$ at exchange rate","LUX","Luxembourg","2014","2014",7.9,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","MTMOTCMT","Million US$ at exchange rate","LUX","Luxembourg","2015","2015",6.4,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","MTMOTCMT","Million US$ at exchange rate","LUX","Luxembourg","2016","2016",6.4,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","MTMOTCMT","Million US$ at exchange rate","LUX","Luxembourg","2017","2017",6.2,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","MTMOTCMT","Million US$ at exchange rate","LUX","Luxembourg","2018","2018",6.5,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","MTMOTCMT","Million US$ at exchange rate","LUX","Luxembourg","2019","2019",6,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","MTMOTCMT","Million US$ at exchange rate","LUX","Luxembourg","2020","2020",4.9,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","MTMOTCMT","Million US$ at exchange rate","LUX","Luxembourg","2021","2021",5,"B; D; P","Break; Difference in methodology; Provisional value"
+"PATCBIOT","J01-Antibacterials for systemic use","MTMOTCMT","Million US$ at exchange rate","LUX","Luxembourg","2022","2022",4.7,"D; P","Difference in methodology; Provisional value"
+"PATCBIOT","J01-Antibacterials for systemic use","MTMOPPMT","Million US$, purchasing power parity","LUX","Luxembourg","2010","2010",7.7,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","MTMOPPMT","Million US$, purchasing power parity","LUX","Luxembourg","2011","2011",7.5,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","MTMOPPMT","Million US$, purchasing power parity","LUX","Luxembourg","2012","2012",7.1,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","MTMOPPMT","Million US$, purchasing power parity","LUX","Luxembourg","2013","2013",7,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","MTMOPPMT","Million US$, purchasing power parity","LUX","Luxembourg","2014","2014",6.7,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","MTMOPPMT","Million US$, purchasing power parity","LUX","Luxembourg","2015","2015",6.6,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","MTMOPPMT","Million US$, purchasing power parity","LUX","Luxembourg","2016","2016",6.7,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","MTMOPPMT","Million US$, purchasing power parity","LUX","Luxembourg","2017","2017",6.4,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","MTMOPPMT","Million US$, purchasing power parity","LUX","Luxembourg","2018","2018",6.5,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","MTMOPPMT","Million US$, purchasing power parity","LUX","Luxembourg","2019","2019",6.4,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","MTMOPPMT","Million US$, purchasing power parity","LUX","Luxembourg","2020","2020",5,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","MTMOPPMT","Million US$, purchasing power parity","LUX","Luxembourg","2021","2021",4.9,"B; D; P","Break; Difference in methodology; Provisional value"
+"PATCBIOT","J01-Antibacterials for systemic use","MTMOPPMT","Million US$, purchasing power parity","LUX","Luxembourg","2022","2022",5.4,"D; P","Difference in methodology; Provisional value"
+"PATCBIOT","J01-Antibacterials for systemic use","TCPPERMT","/capita, US$ exchange rate","LUX","Luxembourg","2010","2010",19.9,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","TCPPERMT","/capita, US$ exchange rate","LUX","Luxembourg","2011","2011",19.7,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","TCPPERMT","/capita, US$ exchange rate","LUX","Luxembourg","2012","2012",16.9,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","TCPPERMT","/capita, US$ exchange rate","LUX","Luxembourg","2013","2013",16.6,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","TCPPERMT","/capita, US$ exchange rate","LUX","Luxembourg","2014","2014",15.5,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","TCPPERMT","/capita, US$ exchange rate","LUX","Luxembourg","2015","2015",12.4,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","TCPPERMT","/capita, US$ exchange rate","LUX","Luxembourg","2016","2016",12.1,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","TCPPERMT","/capita, US$ exchange rate","LUX","Luxembourg","2017","2017",11.5,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","TCPPERMT","/capita, US$ exchange rate","LUX","Luxembourg","2018","2018",12,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","TCPPERMT","/capita, US$ exchange rate","LUX","Luxembourg","2019","2019",10.8,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","TCPPERMT","/capita, US$ exchange rate","LUX","Luxembourg","2020","2020",8.6,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","TCPPERMT","/capita, US$ exchange rate","LUX","Luxembourg","2021","2021",8.6,"B; D; P","Break; Difference in methodology; Provisional value"
+"PATCBIOT","J01-Antibacterials for systemic use","TCPPERMT","/capita, US$ exchange rate","LUX","Luxembourg","2022","2022",8.1,"D; P","Difference in methodology; Provisional value"
+"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2010","2010",16.2,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2011","2011",15.6,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2012","2012",14.5,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2013","2013",14,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2014","2014",13.2,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2015","2015",12.7,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2016","2016",12.8,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2017","2017",12,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2018","2018",12,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2019","2019",11.4,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2020","2020",8.8,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2021","2021",8.5,"B; D; P","Break; Difference in methodology; Provisional value"
+"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2022","2022",9.2,"D; P","Difference in methodology; Provisional value"
+"PATCBIOT","J01-Antibacterials for systemic use","ATCPTTMT","% of total sales","LUX","Luxembourg","2010","2010",3.7,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","ATCPTTMT","% of total sales","LUX","Luxembourg","2011","2011",3.6,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","ATCPTTMT","% of total sales","LUX","Luxembourg","2012","2012",3.3,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","ATCPTTMT","% of total sales","LUX","Luxembourg","2013","2013",3.2,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","ATCPTTMT","% of total sales","LUX","Luxembourg","2014","2014",3.1,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","ATCPTTMT","% of total sales","LUX","Luxembourg","2015","2015",3,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","ATCPTTMT","% of total sales","LUX","Luxembourg","2016","2016",3,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","ATCPTTMT","% of total sales","LUX","Luxembourg","2017","2017",2.8,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","ATCPTTMT","% of total sales","LUX","Luxembourg","2018","2018",2.8,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","ATCPTTMT","% of total sales","LUX","Luxembourg","2019","2019",2.6,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","ATCPTTMT","% of total sales","LUX","Luxembourg","2020","2020",2,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","ATCPTTMT","% of total sales","LUX","Luxembourg","2021","2021",1.8,"B; D; P","Break; Difference in methodology; Provisional value"
+"PATCBIOT","J01-Antibacterials for systemic use","ATCPTTMT","% of total sales","LUX","Luxembourg","2022","2022",1.8,"D; P","Difference in methodology; Provisional value"
+"PATCBIOT","J01-Antibacterials for systemic use","MLLNCUMT","Million of national currency units","NLD","Netherlands","2010","2010",131.9,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","MLLNCUMT","Million of national currency units","NLD","Netherlands","2011","2011",126.9,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","MLLNCUMT","Million of national currency units","NLD","Netherlands","2012","2012",120.6,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","MLLNCUMT","Million of national currency units","NLD","Netherlands","2013","2013",120.2,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","MLLNCUMT","Million of national currency units","NLD","Netherlands","2014","2014",102.9,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","MTMOTCMT","Million US$ at exchange rate","NLD","Netherlands","2010","2010",174.8,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","MTMOTCMT","Million US$ at exchange rate","NLD","Netherlands","2011","2011",176.7,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","MTMOTCMT","Million US$ at exchange rate","NLD","Netherlands","2012","2012",155,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","MTMOTCMT","Million US$ at exchange rate","NLD","Netherlands","2013","2013",159.6,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","MTMOTCMT","Million US$ at exchange rate","NLD","Netherlands","2014","2014",136.7,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","MTMOPPMT","Million US$, purchasing power parity","NLD","Netherlands","2010","2010",154.4,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","MTMOPPMT","Million US$, purchasing power parity","NLD","Netherlands","2011","2011",151.8,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","MTMOPPMT","Million US$, purchasing power parity","NLD","Netherlands","2012","2012",146.3,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","MTMOPPMT","Million US$, purchasing power parity","NLD","Netherlands","2013","2013",150.6,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","MTMOPPMT","Million US$, purchasing power parity","NLD","Netherlands","2014","2014",127.2,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","TCPPERMT","/capita, US$ exchange rate","NLD","Netherlands","2010","2010",10.5,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","TCPPERMT","/capita, US$ exchange rate","NLD","Netherlands","2011","2011",10.6,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","TCPPERMT","/capita, US$ exchange rate","NLD","Netherlands","2012","2012",9.3,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","TCPPERMT","/capita, US$ exchange rate","NLD","Netherlands","2013","2013",9.5,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","TCPPERMT","/capita, US$ exchange rate","NLD","Netherlands","2014","2014",8.1,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","NLD","Netherlands","2010","2010",9.3,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","NLD","Netherlands","2011","2011",9.1,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","NLD","Netherlands","2012","2012",8.7,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","NLD","Netherlands","2013","2013",9,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","NLD","Netherlands","2014","2014",7.5,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","ATCPTTMT","% of total sales","NLD","Netherlands","2010","2010",2.5,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","ATCPTTMT","% of total sales","NLD","Netherlands","2011","2011",2.4,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","ATCPTTMT","% of total sales","NLD","Netherlands","2012","2012",2.6,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","ATCPTTMT","% of total sales","NLD","Netherlands","2013","2013",2.8,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","ATCPTTMT","% of total sales","NLD","Netherlands","2014","2014",2.4,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","MLLNCUMT","Million of national currency units","NZL","New Zealand","2010","2010",16.7,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","MLLNCUMT","Million of national currency units","NZL","New Zealand","2011","2011",18.9,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","MLLNCUMT","Million of national currency units","NZL","New Zealand","2012","2012",18.8,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","MLLNCUMT","Million of national currency units","NZL","New Zealand","2013","2013",15.9,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","MLLNCUMT","Million of national currency units","NZL","New Zealand","2014","2014",15,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","MLLNCUMT","Million of national currency units","NZL","New Zealand","2015","2015",17,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","MLLNCUMT","Million of national currency units","NZL","New Zealand","2016","2016",18.5,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","MLLNCUMT","Million of national currency units","NZL","New Zealand","2017","2017",15.3,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","MLLNCUMT","Million of national currency units","NZL","New Zealand","2018","2018",13.5,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","MLLNCUMT","Million of national currency units","NZL","New Zealand","2019","2019",14.5,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","MLLNCUMT","Million of national currency units","NZL","New Zealand","2020","2020",15.3,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","MLLNCUMT","Million of national currency units","NZL","New Zealand","2021","2021",16.7,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","MLLNCUMT","Million of national currency units","NZL","New Zealand","2022","2022",16.5,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","MTMOTCMT","Million US$ at exchange rate","NZL","New Zealand","2010","2010",12,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","MTMOTCMT","Million US$ at exchange rate","NZL","New Zealand","2011","2011",14.9,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","MTMOTCMT","Million US$ at exchange rate","NZL","New Zealand","2012","2012",15.3,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","MTMOTCMT","Million US$ at exchange rate","NZL","New Zealand","2013","2013",13,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","MTMOTCMT","Million US$ at exchange rate","NZL","New Zealand","2014","2014",12.4,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","MTMOTCMT","Million US$ at exchange rate","NZL","New Zealand","2015","2015",11.9,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","MTMOTCMT","Million US$ at exchange rate","NZL","New Zealand","2016","2016",12.9,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","MTMOTCMT","Million US$ at exchange rate","NZL","New Zealand","2017","2017",10.9,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","MTMOTCMT","Million US$ at exchange rate","NZL","New Zealand","2018","2018",9.4,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","MTMOTCMT","Million US$ at exchange rate","NZL","New Zealand","2019","2019",9.5,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","MTMOTCMT","Million US$ at exchange rate","NZL","New Zealand","2020","2020",9.9,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","MTMOTCMT","Million US$ at exchange rate","NZL","New Zealand","2021","2021",11.8,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","MTMOTCMT","Million US$ at exchange rate","NZL","New Zealand","2022","2022",10.4,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","MTMOPPMT","Million US$, purchasing power parity","NZL","New Zealand","2010","2010",11.1,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","MTMOPPMT","Million US$, purchasing power parity","NZL","New Zealand","2011","2011",12.7,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","MTMOPPMT","Million US$, purchasing power parity","NZL","New Zealand","2012","2012",12.6,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","MTMOPPMT","Million US$, purchasing power parity","NZL","New Zealand","2013","2013",11,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","MTMOPPMT","Million US$, purchasing power parity","NZL","New Zealand","2014","2014",10.4,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","MTMOPPMT","Million US$, purchasing power parity","NZL","New Zealand","2015","2015",11.5,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","MTMOPPMT","Million US$, purchasing power parity","NZL","New Zealand","2016","2016",12.8,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","MTMOPPMT","Million US$, purchasing power parity","NZL","New Zealand","2017","2017",10.7,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","MTMOPPMT","Million US$, purchasing power parity","NZL","New Zealand","2018","2018",9.2,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","MTMOPPMT","Million US$, purchasing power parity","NZL","New Zealand","2019","2019",10.2,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","MTMOPPMT","Million US$, purchasing power parity","NZL","New Zealand","2020","2020",10.8,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","MTMOPPMT","Million US$, purchasing power parity","NZL","New Zealand","2021","2021",11.4,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","MTMOPPMT","Million US$, purchasing power parity","NZL","New Zealand","2022","2022",11.4,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","TCPPERMT","/capita, US$ exchange rate","NZL","New Zealand","2010","2010",2.8,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","TCPPERMT","/capita, US$ exchange rate","NZL","New Zealand","2011","2011",3.4,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","TCPPERMT","/capita, US$ exchange rate","NZL","New Zealand","2012","2012",3.5,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","TCPPERMT","/capita, US$ exchange rate","NZL","New Zealand","2013","2013",2.9,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","TCPPERMT","/capita, US$ exchange rate","NZL","New Zealand","2014","2014",2.8,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","TCPPERMT","/capita, US$ exchange rate","NZL","New Zealand","2015","2015",2.6,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","TCPPERMT","/capita, US$ exchange rate","NZL","New Zealand","2016","2016",2.7,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","TCPPERMT","/capita, US$ exchange rate","NZL","New Zealand","2017","2017",2.3,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","TCPPERMT","/capita, US$ exchange rate","NZL","New Zealand","2018","2018",1.9,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","TCPPERMT","/capita, US$ exchange rate","NZL","New Zealand","2019","2019",1.9,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","TCPPERMT","/capita, US$ exchange rate","NZL","New Zealand","2020","2020",2,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","TCPPERMT","/capita, US$ exchange rate","NZL","New Zealand","2021","2021",2.3,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","TCPPERMT","/capita, US$ exchange rate","NZL","New Zealand","2022","2022",2,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2010","2010",2.6,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2011","2011",2.9,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2012","2012",2.9,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2013","2013",2.5,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2014","2014",2.3,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2015","2015",2.5,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2016","2016",2.7,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2017","2017",2.2,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2018","2018",1.9,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2019","2019",2.1,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2020","2020",2.1,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2021","2021",2.2,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2022","2022",2.2,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","ATCPTTMT","% of total sales","NZL","New Zealand","2010","2010",2.2,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","ATCPTTMT","% of total sales","NZL","New Zealand","2011","2011",2.3,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","ATCPTTMT","% of total sales","NZL","New Zealand","2012","2012",2,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","ATCPTTMT","% of total sales","NZL","New Zealand","2013","2013",1.7,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","ATCPTTMT","% of total sales","NZL","New Zealand","2014","2014",1.6,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","ATCPTTMT","% of total sales","NZL","New Zealand","2015","2015",1.7,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","ATCPTTMT","% of total sales","NZL","New Zealand","2016","2016",1.7,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","ATCPTTMT","% of total sales","NZL","New Zealand","2017","2017",1.2,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","ATCPTTMT","% of total sales","NZL","New Zealand","2018","2018",1,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","ATCPTTMT","% of total sales","NZL","New Zealand","2019","2019",1,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","ATCPTTMT","% of total sales","NZL","New Zealand","2020","2020",0.9,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","ATCPTTMT","% of total sales","NZL","New Zealand","2021","2021",0.9,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","ATCPTTMT","% of total sales","NZL","New Zealand","2022","2022",0.9,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","MLLNCUMT","Million of national currency units","NOR","Norway","2010","2010",454,,
+"PATCBIOT","J01-Antibacterials for systemic use","MLLNCUMT","Million of national currency units","NOR","Norway","2011","2011",448,,
+"PATCBIOT","J01-Antibacterials for systemic use","MLLNCUMT","Million of national currency units","NOR","Norway","2012","2012",458,,
+"PATCBIOT","J01-Antibacterials for systemic use","MLLNCUMT","Million of national currency units","NOR","Norway","2013","2013",423,,
+"PATCBIOT","J01-Antibacterials for systemic use","MLLNCUMT","Million of national currency units","NOR","Norway","2014","2014",454,,
+"PATCBIOT","J01-Antibacterials for systemic use","MLLNCUMT","Million of national currency units","NOR","Norway","2015","2015",460,,
+"PATCBIOT","J01-Antibacterials for systemic use","MLLNCUMT","Million of national currency units","NOR","Norway","2016","2016",469,,
+"PATCBIOT","J01-Antibacterials for systemic use","MLLNCUMT","Million of national currency units","NOR","Norway","2017","2017",434,,
+"PATCBIOT","J01-Antibacterials for systemic use","MLLNCUMT","Million of national currency units","NOR","Norway","2018","2018",414,,
+"PATCBIOT","J01-Antibacterials for systemic use","MLLNCUMT","Million of national currency units","NOR","Norway","2019","2019",409,,
+"PATCBIOT","J01-Antibacterials for systemic use","MLLNCUMT","Million of national currency units","NOR","Norway","2020","2020",413,,
+"PATCBIOT","J01-Antibacterials for systemic use","MLLNCUMT","Million of national currency units","NOR","Norway","2021","2021",403,,
+"PATCBIOT","J01-Antibacterials for systemic use","MLLNCUMT","Million of national currency units","NOR","Norway","2022","2022",495,,
+"PATCBIOT","J01-Antibacterials for systemic use","MTMOTCMT","Million US$ at exchange rate","NOR","Norway","2010","2010",75.1,,
+"PATCBIOT","J01-Antibacterials for systemic use","MTMOTCMT","Million US$ at exchange rate","NOR","Norway","2011","2011",79.9,,
+"PATCBIOT","J01-Antibacterials for systemic use","MTMOTCMT","Million US$ at exchange rate","NOR","Norway","2012","2012",78.7,,
+"PATCBIOT","J01-Antibacterials for systemic use","MTMOTCMT","Million US$ at exchange rate","NOR","Norway","2013","2013",72,,
+"PATCBIOT","J01-Antibacterials for systemic use","MTMOTCMT","Million US$ at exchange rate","NOR","Norway","2014","2014",72,,
+"PATCBIOT","J01-Antibacterials for systemic use","MTMOTCMT","Million US$ at exchange rate","NOR","Norway","2015","2015",57,,
+"PATCBIOT","J01-Antibacterials for systemic use","MTMOTCMT","Million US$ at exchange rate","NOR","Norway","2016","2016",55.8,,
+"PATCBIOT","J01-Antibacterials for systemic use","MTMOTCMT","Million US$ at exchange rate","NOR","Norway","2017","2017",52.5,,
+"PATCBIOT","J01-Antibacterials for systemic use","MTMOTCMT","Million US$ at exchange rate","NOR","Norway","2018","2018",50.9,,
+"PATCBIOT","J01-Antibacterials for systemic use","MTMOTCMT","Million US$ at exchange rate","NOR","Norway","2019","2019",46.5,,
+"PATCBIOT","J01-Antibacterials for systemic use","MTMOTCMT","Million US$ at exchange rate","NOR","Norway","2020","2020",43.9,,
+"PATCBIOT","J01-Antibacterials for systemic use","MTMOTCMT","Million US$ at exchange rate","NOR","Norway","2021","2021",46.9,,
+"PATCBIOT","J01-Antibacterials for systemic use","MTMOTCMT","Million US$ at exchange rate","NOR","Norway","2022","2022",51.5,,
+"PATCBIOT","J01-Antibacterials for systemic use","MTMOPPMT","Million US$, purchasing power parity","NOR","Norway","2010","2010",49.6,,
+"PATCBIOT","J01-Antibacterials for systemic use","MTMOPPMT","Million US$, purchasing power parity","NOR","Norway","2011","2011",49.3,,
+"PATCBIOT","J01-Antibacterials for systemic use","MTMOPPMT","Million US$, purchasing power parity","NOR","Norway","2012","2012",50.7,,
+"PATCBIOT","J01-Antibacterials for systemic use","MTMOPPMT","Million US$, purchasing power parity","NOR","Norway","2013","2013",46.8,,
+"PATCBIOT","J01-Antibacterials for systemic use","MTMOPPMT","Million US$, purchasing power parity","NOR","Norway","2014","2014",48.9,,
+"PATCBIOT","J01-Antibacterials for systemic use","MTMOPPMT","Million US$, purchasing power parity","NOR","Norway","2015","2015",46.3,,
+"PATCBIOT","J01-Antibacterials for systemic use","MTMOPPMT","Million US$, purchasing power parity","NOR","Norway","2016","2016",46.7,,
+"PATCBIOT","J01-Antibacterials for systemic use","MTMOPPMT","Million US$, purchasing power parity","NOR","Norway","2017","2017",44.5,,
+"PATCBIOT","J01-Antibacterials for systemic use","MTMOPPMT","Million US$, purchasing power parity","NOR","Norway","2018","2018",43.2,,
+"PATCBIOT","J01-Antibacterials for systemic use","MTMOPPMT","Million US$, purchasing power parity","NOR","Norway","2019","2019",42.5,,
+"PATCBIOT","J01-Antibacterials for systemic use","MTMOPPMT","Million US$, purchasing power parity","NOR","Norway","2020","2020",41.8,,
+"PATCBIOT","J01-Antibacterials for systemic use","MTMOPPMT","Million US$, purchasing power parity","NOR","Norway","2021","2021",42.4,,
+"PATCBIOT","J01-Antibacterials for systemic use","MTMOPPMT","Million US$, purchasing power parity","NOR","Norway","2022","2022",46.1,,
+"PATCBIOT","J01-Antibacterials for systemic use","TCPPERMT","/capita, US$ exchange rate","NOR","Norway","2010","2010",15.4,,
+"PATCBIOT","J01-Antibacterials for systemic use","TCPPERMT","/capita, US$ exchange rate","NOR","Norway","2011","2011",16.1,,
+"PATCBIOT","J01-Antibacterials for systemic use","TCPPERMT","/capita, US$ exchange rate","NOR","Norway","2012","2012",15.7,,
+"PATCBIOT","J01-Antibacterials for systemic use","TCPPERMT","/capita, US$ exchange rate","NOR","Norway","2013","2013",14.2,,
+"PATCBIOT","J01-Antibacterials for systemic use","TCPPERMT","/capita, US$ exchange rate","NOR","Norway","2014","2014",14,,
+"PATCBIOT","J01-Antibacterials for systemic use","TCPPERMT","/capita, US$ exchange rate","NOR","Norway","2015","2015",11,,
+"PATCBIOT","J01-Antibacterials for systemic use","TCPPERMT","/capita, US$ exchange rate","NOR","Norway","2016","2016",10.7,,
+"PATCBIOT","J01-Antibacterials for systemic use","TCPPERMT","/capita, US$ exchange rate","NOR","Norway","2017","2017",9.9,,
+"PATCBIOT","J01-Antibacterials for systemic use","TCPPERMT","/capita, US$ exchange rate","NOR","Norway","2018","2018",9.6,,
+"PATCBIOT","J01-Antibacterials for systemic use","TCPPERMT","/capita, US$ exchange rate","NOR","Norway","2019","2019",8.7,,
+"PATCBIOT","J01-Antibacterials for systemic use","TCPPERMT","/capita, US$ exchange rate","NOR","Norway","2020","2020",8.2,,
+"PATCBIOT","J01-Antibacterials for systemic use","TCPPERMT","/capita, US$ exchange rate","NOR","Norway","2021","2021",8.7,,
+"PATCBIOT","J01-Antibacterials for systemic use","TCPPERMT","/capita, US$ exchange rate","NOR","Norway","2022","2022",9.5,,
+"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2010","2010",10.1,,
+"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2011","2011",10,,
+"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2012","2012",10.1,,
+"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2013","2013",9.2,,
+"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2014","2014",9.5,,
+"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2015","2015",8.9,,
+"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2016","2016",8.9,,
+"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2017","2017",8.4,,
+"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2018","2018",8.1,,
+"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2019","2019",8,,
+"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2020","2020",7.8,,
+"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2021","2021",7.8,,
+"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2022","2022",8.5,,
+"PATCBIOT","J01-Antibacterials for systemic use","ATCPTTMT","% of total sales","NOR","Norway","2010","2010",2.5,,
+"PATCBIOT","J01-Antibacterials for systemic use","ATCPTTMT","% of total sales","NOR","Norway","2011","2011",2.5,,
+"PATCBIOT","J01-Antibacterials for systemic use","ATCPTTMT","% of total sales","NOR","Norway","2012","2012",2.4,,
+"PATCBIOT","J01-Antibacterials for systemic use","ATCPTTMT","% of total sales","NOR","Norway","2013","2013",2.2,,
+"PATCBIOT","J01-Antibacterials for systemic use","ATCPTTMT","% of total sales","NOR","Norway","2014","2014",2.2,,
+"PATCBIOT","J01-Antibacterials for systemic use","ATCPTTMT","% of total sales","NOR","Norway","2015","2015",2,,
+"PATCBIOT","J01-Antibacterials for systemic use","ATCPTTMT","% of total sales","NOR","Norway","2016","2016",1.9,,
+"PATCBIOT","J01-Antibacterials for systemic use","ATCPTTMT","% of total sales","NOR","Norway","2017","2017",1.6,,
+"PATCBIOT","J01-Antibacterials for systemic use","ATCPTTMT","% of total sales","NOR","Norway","2018","2018",1.5,,
+"PATCBIOT","J01-Antibacterials for systemic use","ATCPTTMT","% of total sales","NOR","Norway","2019","2019",1.4,,
+"PATCBIOT","J01-Antibacterials for systemic use","ATCPTTMT","% of total sales","NOR","Norway","2020","2020",1.4,,
+"PATCBIOT","J01-Antibacterials for systemic use","ATCPTTMT","% of total sales","NOR","Norway","2021","2021",1.2,,
+"PATCBIOT","J01-Antibacterials for systemic use","ATCPTTMT","% of total sales","NOR","Norway","2022","2022",1.4,,
+"PATCBIOT","J01-Antibacterials for systemic use","MLLNCUMT","Million of national currency units","PRT","Portugal","2010","2010",102.5,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","MLLNCUMT","Million of national currency units","PRT","Portugal","2011","2011",91.4,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","MLLNCUMT","Million of national currency units","PRT","Portugal","2012","2012",75.9,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","MLLNCUMT","Million of national currency units","PRT","Portugal","2013","2013",68.6,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","MLLNCUMT","Million of national currency units","PRT","Portugal","2014","2014",64.8,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","MLLNCUMT","Million of national currency units","PRT","Portugal","2015","2015",66.8,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","MLLNCUMT","Million of national currency units","PRT","Portugal","2016","2016",63.4,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","MLLNCUMT","Million of national currency units","PRT","Portugal","2017","2017",59.9,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","MLLNCUMT","Million of national currency units","PRT","Portugal","2018","2018",61.7,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","MLLNCUMT","Million of national currency units","PRT","Portugal","2019","2019",60.4,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","MLLNCUMT","Million of national currency units","PRT","Portugal","2020","2020",45.7,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","MLLNCUMT","Million of national currency units","PRT","Portugal","2021","2021",45.4,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","MLLNCUMT","Million of national currency units","PRT","Portugal","2022","2022",57.9,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","MTMOTCMT","Million US$ at exchange rate","PRT","Portugal","2010","2010",135.8,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","MTMOTCMT","Million US$ at exchange rate","PRT","Portugal","2011","2011",127.2,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","MTMOTCMT","Million US$ at exchange rate","PRT","Portugal","2012","2012",97.5,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","MTMOTCMT","Million US$ at exchange rate","PRT","Portugal","2013","2013",91.1,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","MTMOTCMT","Million US$ at exchange rate","PRT","Portugal","2014","2014",86.1,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","MTMOTCMT","Million US$ at exchange rate","PRT","Portugal","2015","2015",74.1,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","MTMOTCMT","Million US$ at exchange rate","PRT","Portugal","2016","2016",70.2,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","MTMOTCMT","Million US$ at exchange rate","PRT","Portugal","2017","2017",67.7,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","MTMOTCMT","Million US$ at exchange rate","PRT","Portugal","2018","2018",72.8,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","MTMOTCMT","Million US$ at exchange rate","PRT","Portugal","2019","2019",67.6,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","MTMOTCMT","Million US$ at exchange rate","PRT","Portugal","2020","2020",52.2,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","MTMOTCMT","Million US$ at exchange rate","PRT","Portugal","2021","2021",53.7,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","MTMOTCMT","Million US$ at exchange rate","PRT","Portugal","2022","2022",61,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","MTMOPPMT","Million US$, purchasing power parity","PRT","Portugal","2010","2010",164.4,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","MTMOPPMT","Million US$, purchasing power parity","PRT","Portugal","2011","2011",146.6,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","MTMOPPMT","Million US$, purchasing power parity","PRT","Portugal","2012","2012",125.3,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","MTMOPPMT","Million US$, purchasing power parity","PRT","Portugal","2013","2013",117.5,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","MTMOPPMT","Million US$, purchasing power parity","PRT","Portugal","2014","2014",112,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","MTMOPPMT","Million US$, purchasing power parity","PRT","Portugal","2015","2015",114.1,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","MTMOPPMT","Million US$, purchasing power parity","PRT","Portugal","2016","2016",110.9,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","MTMOPPMT","Million US$, purchasing power parity","PRT","Portugal","2017","2017",104.1,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","MTMOPPMT","Million US$, purchasing power parity","PRT","Portugal","2018","2018",108,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","MTMOPPMT","Million US$, purchasing power parity","PRT","Portugal","2019","2019",108.1,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","MTMOPPMT","Million US$, purchasing power parity","PRT","Portugal","2020","2020",82,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","MTMOPPMT","Million US$, purchasing power parity","PRT","Portugal","2021","2021",80,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","MTMOPPMT","Million US$, purchasing power parity","PRT","Portugal","2022","2022",105.3,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","TCPPERMT","/capita, US$ exchange rate","PRT","Portugal","2010","2010",12.8,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","TCPPERMT","/capita, US$ exchange rate","PRT","Portugal","2011","2011",12,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","TCPPERMT","/capita, US$ exchange rate","PRT","Portugal","2012","2012",9.3,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","TCPPERMT","/capita, US$ exchange rate","PRT","Portugal","2013","2013",8.7,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","TCPPERMT","/capita, US$ exchange rate","PRT","Portugal","2014","2014",8.3,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","TCPPERMT","/capita, US$ exchange rate","PRT","Portugal","2015","2015",7.2,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","TCPPERMT","/capita, US$ exchange rate","PRT","Portugal","2016","2016",6.8,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","TCPPERMT","/capita, US$ exchange rate","PRT","Portugal","2017","2017",6.6,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","TCPPERMT","/capita, US$ exchange rate","PRT","Portugal","2018","2018",7.1,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","TCPPERMT","/capita, US$ exchange rate","PRT","Portugal","2019","2019",6.6,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","TCPPERMT","/capita, US$ exchange rate","PRT","Portugal","2020","2020",5.1,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","TCPPERMT","/capita, US$ exchange rate","PRT","Portugal","2021","2021",5.2,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","TCPPERMT","/capita, US$ exchange rate","PRT","Portugal","2022","2022",5.9,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2010","2010",15.6,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2011","2011",13.9,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2012","2012",11.9,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2013","2013",11.2,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2014","2014",10.8,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2015","2015",11,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2016","2016",10.7,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2017","2017",10.1,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2018","2018",10.5,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2019","2019",10.5,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2020","2020",8,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2021","2021",7.7,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2022","2022",10.2,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","ATCPTTMT","% of total sales","PRT","Portugal","2010","2010",3.2,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","ATCPTTMT","% of total sales","PRT","Portugal","2011","2011",3.1,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","ATCPTTMT","% of total sales","PRT","Portugal","2012","2012",2.9,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","ATCPTTMT","% of total sales","PRT","Portugal","2013","2013",2.8,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","ATCPTTMT","% of total sales","PRT","Portugal","2014","2014",2.7,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","ATCPTTMT","% of total sales","PRT","Portugal","2015","2015",2.7,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","ATCPTTMT","% of total sales","PRT","Portugal","2016","2016",2.5,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","ATCPTTMT","% of total sales","PRT","Portugal","2017","2017",2.3,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","ATCPTTMT","% of total sales","PRT","Portugal","2018","2018",2.3,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","ATCPTTMT","% of total sales","PRT","Portugal","2019","2019",2.2,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","ATCPTTMT","% of total sales","PRT","Portugal","2020","2020",1.6,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","ATCPTTMT","% of total sales","PRT","Portugal","2021","2021",1.6,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","ATCPTTMT","% of total sales","PRT","Portugal","2022","2022",1.8,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","MLLNCUMT","Million of national currency units","SVK","Slovak Republic","2010","2010",52.7,,
+"PATCBIOT","J01-Antibacterials for systemic use","MLLNCUMT","Million of national currency units","SVK","Slovak Republic","2011","2011",64.2,,
+"PATCBIOT","J01-Antibacterials for systemic use","MLLNCUMT","Million of national currency units","SVK","Slovak Republic","2012","2012",74.5,,
+"PATCBIOT","J01-Antibacterials for systemic use","MLLNCUMT","Million of national currency units","SVK","Slovak Republic","2013","2013",55.6,,
+"PATCBIOT","J01-Antibacterials for systemic use","MLLNCUMT","Million of national currency units","SVK","Slovak Republic","2014","2014",60.9,,
+"PATCBIOT","J01-Antibacterials for systemic use","MLLNCUMT","Million of national currency units","SVK","Slovak Republic","2015","2015",65.3,,
+"PATCBIOT","J01-Antibacterials for systemic use","MLLNCUMT","Million of national currency units","SVK","Slovak Republic","2016","2016",42.3,"B","Break"
+"PATCBIOT","J01-Antibacterials for systemic use","MLLNCUMT","Million of national currency units","SVK","Slovak Republic","2017","2017",41,,
+"PATCBIOT","J01-Antibacterials for systemic use","MLLNCUMT","Million of national currency units","SVK","Slovak Republic","2018","2018",41.8,,
+"PATCBIOT","J01-Antibacterials for systemic use","MLLNCUMT","Million of national currency units","SVK","Slovak Republic","2019","2019",40.4,,
+"PATCBIOT","J01-Antibacterials for systemic use","MLLNCUMT","Million of national currency units","SVK","Slovak Republic","2020","2020",32.6,,
+"PATCBIOT","J01-Antibacterials for systemic use","MLLNCUMT","Million of national currency units","SVK","Slovak Republic","2021","2021",38.3,,
+"PATCBIOT","J01-Antibacterials for systemic use","MTMOTCMT","Million US$ at exchange rate","SVK","Slovak Republic","2010","2010",69.8,,
+"PATCBIOT","J01-Antibacterials for systemic use","MTMOTCMT","Million US$ at exchange rate","SVK","Slovak Republic","2011","2011",89.3,,
+"PATCBIOT","J01-Antibacterials for systemic use","MTMOTCMT","Million US$ at exchange rate","SVK","Slovak Republic","2012","2012",95.7,,
+"PATCBIOT","J01-Antibacterials for systemic use","MTMOTCMT","Million US$ at exchange rate","SVK","Slovak Republic","2013","2013",73.8,,
+"PATCBIOT","J01-Antibacterials for systemic use","MTMOTCMT","Million US$ at exchange rate","SVK","Slovak Republic","2014","2014",80.9,,
+"PATCBIOT","J01-Antibacterials for systemic use","MTMOTCMT","Million US$ at exchange rate","SVK","Slovak Republic","2015","2015",72.5,,
+"PATCBIOT","J01-Antibacterials for systemic use","MTMOTCMT","Million US$ at exchange rate","SVK","Slovak Republic","2016","2016",46.8,"B","Break"
+"PATCBIOT","J01-Antibacterials for systemic use","MTMOTCMT","Million US$ at exchange rate","SVK","Slovak Republic","2017","2017",46.3,,
+"PATCBIOT","J01-Antibacterials for systemic use","MTMOTCMT","Million US$ at exchange rate","SVK","Slovak Republic","2018","2018",49.3,,
+"PATCBIOT","J01-Antibacterials for systemic use","MTMOTCMT","Million US$ at exchange rate","SVK","Slovak Republic","2019","2019",45.2,,
+"PATCBIOT","J01-Antibacterials for systemic use","MTMOTCMT","Million US$ at exchange rate","SVK","Slovak Republic","2020","2020",37.3,,
+"PATCBIOT","J01-Antibacterials for systemic use","MTMOTCMT","Million US$ at exchange rate","SVK","Slovak Republic","2021","2021",45.4,,
+"PATCBIOT","J01-Antibacterials for systemic use","MTMOPPMT","Million US$, purchasing power parity","SVK","Slovak Republic","2010","2010",104.9,,
+"PATCBIOT","J01-Antibacterials for systemic use","MTMOPPMT","Million US$, purchasing power parity","SVK","Slovak Republic","2011","2011",126.7,,
+"PATCBIOT","J01-Antibacterials for systemic use","MTMOPPMT","Million US$, purchasing power parity","SVK","Slovak Republic","2012","2012",147.7,,
+"PATCBIOT","J01-Antibacterials for systemic use","MTMOPPMT","Million US$, purchasing power parity","SVK","Slovak Republic","2013","2013",113.1,,
+"PATCBIOT","J01-Antibacterials for systemic use","MTMOPPMT","Million US$, purchasing power parity","SVK","Slovak Republic","2014","2014",125.4,,
+"PATCBIOT","J01-Antibacterials for systemic use","MTMOPPMT","Million US$, purchasing power parity","SVK","Slovak Republic","2015","2015",132.9,,
+"PATCBIOT","J01-Antibacterials for systemic use","MTMOPPMT","Million US$, purchasing power parity","SVK","Slovak Republic","2016","2016",84.1,"B","Break"
+"PATCBIOT","J01-Antibacterials for systemic use","MTMOPPMT","Million US$, purchasing power parity","SVK","Slovak Republic","2017","2017",79.4,,
+"PATCBIOT","J01-Antibacterials for systemic use","MTMOPPMT","Million US$, purchasing power parity","SVK","Slovak Republic","2018","2018",79.4,,
+"PATCBIOT","J01-Antibacterials for systemic use","MTMOPPMT","Million US$, purchasing power parity","SVK","Slovak Republic","2019","2019",78.1,,
+"PATCBIOT","J01-Antibacterials for systemic use","MTMOPPMT","Million US$, purchasing power parity","SVK","Slovak Republic","2020","2020",62.7,,
+"PATCBIOT","J01-Antibacterials for systemic use","MTMOPPMT","Million US$, purchasing power parity","SVK","Slovak Republic","2021","2021",71.9,,
+"PATCBIOT","J01-Antibacterials for systemic use","TCPPERMT","/capita, US$ exchange rate","SVK","Slovak Republic","2010","2010",13,,
+"PATCBIOT","J01-Antibacterials for systemic use","TCPPERMT","/capita, US$ exchange rate","SVK","Slovak Republic","2011","2011",16.5,,
+"PATCBIOT","J01-Antibacterials for systemic use","TCPPERMT","/capita, US$ exchange rate","SVK","Slovak Republic","2012","2012",17.7,,
+"PATCBIOT","J01-Antibacterials for systemic use","TCPPERMT","/capita, US$ exchange rate","SVK","Slovak Republic","2013","2013",13.6,,
+"PATCBIOT","J01-Antibacterials for systemic use","TCPPERMT","/capita, US$ exchange rate","SVK","Slovak Republic","2014","2014",14.9,,
+"PATCBIOT","J01-Antibacterials for systemic use","TCPPERMT","/capita, US$ exchange rate","SVK","Slovak Republic","2015","2015",13.4,,
+"PATCBIOT","J01-Antibacterials for systemic use","TCPPERMT","/capita, US$ exchange rate","SVK","Slovak Republic","2016","2016",8.6,"B","Break"
+"PATCBIOT","J01-Antibacterials for systemic use","TCPPERMT","/capita, US$ exchange rate","SVK","Slovak Republic","2017","2017",8.5,,
+"PATCBIOT","J01-Antibacterials for systemic use","TCPPERMT","/capita, US$ exchange rate","SVK","Slovak Republic","2018","2018",9.1,,
+"PATCBIOT","J01-Antibacterials for systemic use","TCPPERMT","/capita, US$ exchange rate","SVK","Slovak Republic","2019","2019",8.3,,
+"PATCBIOT","J01-Antibacterials for systemic use","TCPPERMT","/capita, US$ exchange rate","SVK","Slovak Republic","2020","2020",6.8,,
+"PATCBIOT","J01-Antibacterials for systemic use","TCPPERMT","/capita, US$ exchange rate","SVK","Slovak Republic","2021","2021",8.3,,
+"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2010","2010",19.5,,
+"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2011","2011",23.5,,
+"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2012","2012",27.3,,
+"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2013","2013",20.9,,
+"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2014","2014",23.1,,
+"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2015","2015",24.5,,
+"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2016","2016",15.5,"B","Break"
+"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2017","2017",14.6,,
+"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2018","2018",14.6,,
+"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2019","2019",14.3,,
+"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2020","2020",11.5,,
+"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2021","2021",13.2,,
+"PATCBIOT","J01-Antibacterials for systemic use","ATCPTTMT","% of total sales","SVK","Slovak Republic","2010","2010",4.7,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","ATCPTTMT","% of total sales","SVK","Slovak Republic","2011","2011",5.7,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","ATCPTTMT","% of total sales","SVK","Slovak Republic","2012","2012",6.7,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","ATCPTTMT","% of total sales","SVK","Slovak Republic","2013","2013",4.5,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","ATCPTTMT","% of total sales","SVK","Slovak Republic","2014","2014",4.6,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","ATCPTTMT","% of total sales","SVK","Slovak Republic","2015","2015",4.7,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","ATCPTTMT","% of total sales","SVK","Slovak Republic","2016","2016",2.7,"B","Break"
+"PATCBIOT","J01-Antibacterials for systemic use","ATCPTTMT","% of total sales","SVK","Slovak Republic","2017","2017",2.6,,
+"PATCBIOT","J01-Antibacterials for systemic use","ATCPTTMT","% of total sales","SVK","Slovak Republic","2018","2018",2.6,,
+"PATCBIOT","J01-Antibacterials for systemic use","ATCPTTMT","% of total sales","SVK","Slovak Republic","2019","2019",2.3,,
+"PATCBIOT","J01-Antibacterials for systemic use","ATCPTTMT","% of total sales","SVK","Slovak Republic","2020","2020",2,,
+"PATCBIOT","J01-Antibacterials for systemic use","ATCPTTMT","% of total sales","SVK","Slovak Republic","2021","2021",2.1,,
+"PATCBIOT","J01-Antibacterials for systemic use","MLLNCUMT","Million of national currency units","ESP","Spain","2010","2010",305.1,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","MLLNCUMT","Million of national currency units","ESP","Spain","2011","2011",260.9,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","MLLNCUMT","Million of national currency units","ESP","Spain","2012","2012",227.4,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","MLLNCUMT","Million of national currency units","ESP","Spain","2013","2013",227.8,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","MLLNCUMT","Million of national currency units","ESP","Spain","2014","2014",250.8,"B; D","Break; Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","MLLNCUMT","Million of national currency units","ESP","Spain","2015","2015",249.7,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","MLLNCUMT","Million of national currency units","ESP","Spain","2016","2016",243,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","MLLNCUMT","Million of national currency units","ESP","Spain","2017","2017",237.4,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","MLLNCUMT","Million of national currency units","ESP","Spain","2018","2018",480,"B","Break"
+"PATCBIOT","J01-Antibacterials for systemic use","MLLNCUMT","Million of national currency units","ESP","Spain","2019","2019",488.4,,
+"PATCBIOT","J01-Antibacterials for systemic use","MLLNCUMT","Million of national currency units","ESP","Spain","2020","2020",449.2,,
+"PATCBIOT","J01-Antibacterials for systemic use","MLLNCUMT","Million of national currency units","ESP","Spain","2021","2021",466.3,,
+"PATCBIOT","J01-Antibacterials for systemic use","MLLNCUMT","Million of national currency units","ESP","Spain","2022","2022",486.7,"P","Provisional value"
+"PATCBIOT","J01-Antibacterials for systemic use","MTMOTCMT","Million US$ at exchange rate","ESP","Spain","2010","2010",404.5,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","MTMOTCMT","Million US$ at exchange rate","ESP","Spain","2011","2011",363.1,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","MTMOTCMT","Million US$ at exchange rate","ESP","Spain","2012","2012",292.1,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","MTMOTCMT","Million US$ at exchange rate","ESP","Spain","2013","2013",302.5,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","MTMOTCMT","Million US$ at exchange rate","ESP","Spain","2014","2014",333.1,"B; D","Break; Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","MTMOTCMT","Million US$ at exchange rate","ESP","Spain","2015","2015",277.1,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","MTMOTCMT","Million US$ at exchange rate","ESP","Spain","2016","2016",268.9,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","MTMOTCMT","Million US$ at exchange rate","ESP","Spain","2017","2017",268.2,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","MTMOTCMT","Million US$ at exchange rate","ESP","Spain","2018","2018",566.9,"B","Break"
+"PATCBIOT","J01-Antibacterials for systemic use","MTMOTCMT","Million US$ at exchange rate","ESP","Spain","2019","2019",546.7,,
+"PATCBIOT","J01-Antibacterials for systemic use","MTMOTCMT","Million US$ at exchange rate","ESP","Spain","2020","2020",513.1,,
+"PATCBIOT","J01-Antibacterials for systemic use","MTMOTCMT","Million US$ at exchange rate","ESP","Spain","2021","2021",551.6,,
+"PATCBIOT","J01-Antibacterials for systemic use","MTMOTCMT","Million US$ at exchange rate","ESP","Spain","2022","2022",512.5,"P","Provisional value"
+"PATCBIOT","J01-Antibacterials for systemic use","MTMOPPMT","Million US$, purchasing power parity","ESP","Spain","2010","2010",419.7,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","MTMOPPMT","Million US$, purchasing power parity","ESP","Spain","2011","2011",365.3,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","MTMOPPMT","Million US$, purchasing power parity","ESP","Spain","2012","2012",327.1,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","MTMOPPMT","Million US$, purchasing power parity","ESP","Spain","2013","2013",337.5,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","MTMOPPMT","Million US$, purchasing power parity","ESP","Spain","2014","2014",378.6,"B; D","Break; Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","MTMOPPMT","Million US$, purchasing power parity","ESP","Spain","2015","2015",375.7,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","MTMOPPMT","Million US$, purchasing power parity","ESP","Spain","2016","2016",378.1,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","MTMOPPMT","Million US$, purchasing power parity","ESP","Spain","2017","2017",376.3,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","MTMOPPMT","Million US$, purchasing power parity","ESP","Spain","2018","2018",759.7,"B","Break"
+"PATCBIOT","J01-Antibacterials for systemic use","MTMOPPMT","Million US$, purchasing power parity","ESP","Spain","2019","2019",796.7,,
+"PATCBIOT","J01-Antibacterials for systemic use","MTMOPPMT","Million US$, purchasing power parity","ESP","Spain","2020","2020",723,,
+"PATCBIOT","J01-Antibacterials for systemic use","MTMOPPMT","Million US$, purchasing power parity","ESP","Spain","2021","2021",745,,
+"PATCBIOT","J01-Antibacterials for systemic use","MTMOPPMT","Million US$, purchasing power parity","ESP","Spain","2022","2022",816.3,"P","Provisional value"
+"PATCBIOT","J01-Antibacterials for systemic use","TCPPERMT","/capita, US$ exchange rate","ESP","Spain","2010","2010",8.7,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","TCPPERMT","/capita, US$ exchange rate","ESP","Spain","2011","2011",7.8,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","TCPPERMT","/capita, US$ exchange rate","ESP","Spain","2012","2012",6.2,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","TCPPERMT","/capita, US$ exchange rate","ESP","Spain","2013","2013",6.5,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","TCPPERMT","/capita, US$ exchange rate","ESP","Spain","2014","2014",7.2,"B; D","Break; Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","TCPPERMT","/capita, US$ exchange rate","ESP","Spain","2015","2015",6,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","TCPPERMT","/capita, US$ exchange rate","ESP","Spain","2016","2016",5.8,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","TCPPERMT","/capita, US$ exchange rate","ESP","Spain","2017","2017",5.8,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","TCPPERMT","/capita, US$ exchange rate","ESP","Spain","2018","2018",12.1,"B","Break"
+"PATCBIOT","J01-Antibacterials for systemic use","TCPPERMT","/capita, US$ exchange rate","ESP","Spain","2019","2019",11.6,,
+"PATCBIOT","J01-Antibacterials for systemic use","TCPPERMT","/capita, US$ exchange rate","ESP","Spain","2020","2020",10.8,,
+"PATCBIOT","J01-Antibacterials for systemic use","TCPPERMT","/capita, US$ exchange rate","ESP","Spain","2021","2021",11.6,,
+"PATCBIOT","J01-Antibacterials for systemic use","TCPPERMT","/capita, US$ exchange rate","ESP","Spain","2022","2022",10.8,"P","Provisional value"
+"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2010","2010",9,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2011","2011",7.8,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2012","2012",7,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2013","2013",7.2,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2014","2014",8.1,"B; D","Break; Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2015","2015",8.1,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2016","2016",8.1,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2017","2017",8.1,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2018","2018",16.2,"B","Break"
+"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2019","2019",16.9,,
+"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2020","2020",15.3,,
+"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2021","2021",15.7,,
+"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2022","2022",17.2,"P","Provisional value"
+"PATCBIOT","J01-Antibacterials for systemic use","ATCPTTMT","% of total sales","ESP","Spain","2010","2010",2.3,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","ATCPTTMT","% of total sales","ESP","Spain","2011","2011",2.1,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","ATCPTTMT","% of total sales","ESP","Spain","2012","2012",2.1,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","ATCPTTMT","% of total sales","ESP","Spain","2013","2013",2.1,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","ATCPTTMT","% of total sales","ESP","Spain","2014","2014",2.2,"B; D","Break; Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","ATCPTTMT","% of total sales","ESP","Spain","2015","2015",2.2,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","ATCPTTMT","% of total sales","ESP","Spain","2016","2016",2.1,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","ATCPTTMT","% of total sales","ESP","Spain","2017","2017",2,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","ATCPTTMT","% of total sales","ESP","Spain","2018","2018",2.5,"B","Break"
+"PATCBIOT","J01-Antibacterials for systemic use","ATCPTTMT","% of total sales","ESP","Spain","2019","2019",2.4,,
+"PATCBIOT","J01-Antibacterials for systemic use","ATCPTTMT","% of total sales","ESP","Spain","2020","2020",2.2,,
+"PATCBIOT","J01-Antibacterials for systemic use","ATCPTTMT","% of total sales","ESP","Spain","2021","2021",2.1,,
+"PATCBIOT","J01-Antibacterials for systemic use","ATCPTTMT","% of total sales","ESP","Spain","2022","2022",2.1,"P","Provisional value"
+"PATCBIOT","J01-Antibacterials for systemic use","MLLNCUMT","Million of national currency units","SWE","Sweden","2010","2010",1003,,
+"PATCBIOT","J01-Antibacterials for systemic use","MLLNCUMT","Million of national currency units","SWE","Sweden","2011","2011",934.3,,
+"PATCBIOT","J01-Antibacterials for systemic use","MLLNCUMT","Million of national currency units","SWE","Sweden","2012","2012",850.4,,
+"PATCBIOT","J01-Antibacterials for systemic use","MLLNCUMT","Million of national currency units","SWE","Sweden","2013","2013",720.8,,
+"PATCBIOT","J01-Antibacterials for systemic use","MLLNCUMT","Million of national currency units","SWE","Sweden","2014","2014",710.3,,
+"PATCBIOT","J01-Antibacterials for systemic use","MLLNCUMT","Million of national currency units","SWE","Sweden","2015","2015",749.5,,
+"PATCBIOT","J01-Antibacterials for systemic use","MLLNCUMT","Million of national currency units","SWE","Sweden","2016","2016",724.5,,
+"PATCBIOT","J01-Antibacterials for systemic use","MLLNCUMT","Million of national currency units","SWE","Sweden","2017","2017",694.2,,
+"PATCBIOT","J01-Antibacterials for systemic use","MLLNCUMT","Million of national currency units","SWE","Sweden","2018","2018",692.6,,
+"PATCBIOT","J01-Antibacterials for systemic use","MLLNCUMT","Million of national currency units","SWE","Sweden","2019","2019",738.5,,
+"PATCBIOT","J01-Antibacterials for systemic use","MLLNCUMT","Million of national currency units","SWE","Sweden","2020","2020",713.3,,
+"PATCBIOT","J01-Antibacterials for systemic use","MLLNCUMT","Million of national currency units","SWE","Sweden","2021","2021",686.7,,
+"PATCBIOT","J01-Antibacterials for systemic use","MLLNCUMT","Million of national currency units","SWE","Sweden","2022","2022",728.5,,
+"PATCBIOT","J01-Antibacterials for systemic use","MTMOTCMT","Million US$ at exchange rate","SWE","Sweden","2010","2010",139.2,,
+"PATCBIOT","J01-Antibacterials for systemic use","MTMOTCMT","Million US$ at exchange rate","SWE","Sweden","2011","2011",143.9,,
+"PATCBIOT","J01-Antibacterials for systemic use","MTMOTCMT","Million US$ at exchange rate","SWE","Sweden","2012","2012",125.5,,
+"PATCBIOT","J01-Antibacterials for systemic use","MTMOTCMT","Million US$ at exchange rate","SWE","Sweden","2013","2013",110.7,,
+"PATCBIOT","J01-Antibacterials for systemic use","MTMOTCMT","Million US$ at exchange rate","SWE","Sweden","2014","2014",103.5,,
+"PATCBIOT","J01-Antibacterials for systemic use","MTMOTCMT","Million US$ at exchange rate","SWE","Sweden","2015","2015",88.9,,
+"PATCBIOT","J01-Antibacterials for systemic use","MTMOTCMT","Million US$ at exchange rate","SWE","Sweden","2016","2016",84.6,,
+"PATCBIOT","J01-Antibacterials for systemic use","MTMOTCMT","Million US$ at exchange rate","SWE","Sweden","2017","2017",81.2,,
+"PATCBIOT","J01-Antibacterials for systemic use","MTMOTCMT","Million US$ at exchange rate","SWE","Sweden","2018","2018",79.7,,
+"PATCBIOT","J01-Antibacterials for systemic use","MTMOTCMT","Million US$ at exchange rate","SWE","Sweden","2019","2019",78.1,,
+"PATCBIOT","J01-Antibacterials for systemic use","MTMOTCMT","Million US$ at exchange rate","SWE","Sweden","2020","2020",77.4,,
+"PATCBIOT","J01-Antibacterials for systemic use","MTMOTCMT","Million US$ at exchange rate","SWE","Sweden","2021","2021",80.1,,
+"PATCBIOT","J01-Antibacterials for systemic use","MTMOTCMT","Million US$ at exchange rate","SWE","Sweden","2022","2022",72,,
+"PATCBIOT","J01-Antibacterials for systemic use","MTMOPPMT","Million US$, purchasing power parity","SWE","Sweden","2010","2010",111.1,,
+"PATCBIOT","J01-Antibacterials for systemic use","MTMOPPMT","Million US$, purchasing power parity","SWE","Sweden","2011","2011",105.6,,
+"PATCBIOT","J01-Antibacterials for systemic use","MTMOPPMT","Million US$, purchasing power parity","SWE","Sweden","2012","2012",98.3,,
+"PATCBIOT","J01-Antibacterials for systemic use","MTMOPPMT","Million US$, purchasing power parity","SWE","Sweden","2013","2013",83.8,,
+"PATCBIOT","J01-Antibacterials for systemic use","MTMOPPMT","Million US$, purchasing power parity","SWE","Sweden","2014","2014",81.4,,
+"PATCBIOT","J01-Antibacterials for systemic use","MTMOPPMT","Million US$, purchasing power parity","SWE","Sweden","2015","2015",84.6,,
+"PATCBIOT","J01-Antibacterials for systemic use","MTMOPPMT","Million US$, purchasing power parity","SWE","Sweden","2016","2016",82.1,,
+"PATCBIOT","J01-Antibacterials for systemic use","MTMOPPMT","Million US$, purchasing power parity","SWE","Sweden","2017","2017",78.4,,
+"PATCBIOT","J01-Antibacterials for systemic use","MTMOPPMT","Million US$, purchasing power parity","SWE","Sweden","2018","2018",78.1,,
+"PATCBIOT","J01-Antibacterials for systemic use","MTMOPPMT","Million US$, purchasing power parity","SWE","Sweden","2019","2019",84.8,,
+"PATCBIOT","J01-Antibacterials for systemic use","MTMOPPMT","Million US$, purchasing power parity","SWE","Sweden","2020","2020",82.3,,
+"PATCBIOT","J01-Antibacterials for systemic use","MTMOPPMT","Million US$, purchasing power parity","SWE","Sweden","2021","2021",78.7,,
+"PATCBIOT","J01-Antibacterials for systemic use","MTMOPPMT","Million US$, purchasing power parity","SWE","Sweden","2022","2022",84.1,,
+"PATCBIOT","J01-Antibacterials for systemic use","TCPPERMT","/capita, US$ exchange rate","SWE","Sweden","2010","2010",14.8,,
+"PATCBIOT","J01-Antibacterials for systemic use","TCPPERMT","/capita, US$ exchange rate","SWE","Sweden","2011","2011",15.2,,
+"PATCBIOT","J01-Antibacterials for systemic use","TCPPERMT","/capita, US$ exchange rate","SWE","Sweden","2012","2012",13.2,,
+"PATCBIOT","J01-Antibacterials for systemic use","TCPPERMT","/capita, US$ exchange rate","SWE","Sweden","2013","2013",11.5,,
+"PATCBIOT","J01-Antibacterials for systemic use","TCPPERMT","/capita, US$ exchange rate","SWE","Sweden","2014","2014",10.7,,
+"PATCBIOT","J01-Antibacterials for systemic use","TCPPERMT","/capita, US$ exchange rate","SWE","Sweden","2015","2015",9.1,,
+"PATCBIOT","J01-Antibacterials for systemic use","TCPPERMT","/capita, US$ exchange rate","SWE","Sweden","2016","2016",8.5,,
+"PATCBIOT","J01-Antibacterials for systemic use","TCPPERMT","/capita, US$ exchange rate","SWE","Sweden","2017","2017",8.1,,
+"PATCBIOT","J01-Antibacterials for systemic use","TCPPERMT","/capita, US$ exchange rate","SWE","Sweden","2018","2018",7.8,,
+"PATCBIOT","J01-Antibacterials for systemic use","TCPPERMT","/capita, US$ exchange rate","SWE","Sweden","2019","2019",7.6,,
+"PATCBIOT","J01-Antibacterials for systemic use","TCPPERMT","/capita, US$ exchange rate","SWE","Sweden","2020","2020",7.5,,
+"PATCBIOT","J01-Antibacterials for systemic use","TCPPERMT","/capita, US$ exchange rate","SWE","Sweden","2021","2021",7.7,,
+"PATCBIOT","J01-Antibacterials for systemic use","TCPPERMT","/capita, US$ exchange rate","SWE","Sweden","2022","2022",6.9,,
+"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2010","2010",11.9,,
+"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2011","2011",11.2,,
+"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2012","2012",10.3,,
+"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2013","2013",8.7,,
+"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2014","2014",8.4,,
+"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2015","2015",8.6,,
+"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2016","2016",8.3,,
+"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2017","2017",7.8,,
+"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2018","2018",7.7,,
+"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2019","2019",8.2,,
+"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2020","2020",7.9,,
+"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2021","2021",7.6,,
+"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2022","2022",8,,
+"PATCBIOT","J01-Antibacterials for systemic use","ATCPTTMT","% of total sales","SWE","Sweden","2010","2010",2.8,,
+"PATCBIOT","J01-Antibacterials for systemic use","ATCPTTMT","% of total sales","SWE","Sweden","2011","2011",2.5,,
+"PATCBIOT","J01-Antibacterials for systemic use","ATCPTTMT","% of total sales","SWE","Sweden","2012","2012",2.4,,
+"PATCBIOT","J01-Antibacterials for systemic use","ATCPTTMT","% of total sales","SWE","Sweden","2013","2013",2,,
+"PATCBIOT","J01-Antibacterials for systemic use","ATCPTTMT","% of total sales","SWE","Sweden","2014","2014",1.9,,
+"PATCBIOT","J01-Antibacterials for systemic use","ATCPTTMT","% of total sales","SWE","Sweden","2015","2015",1.8,,
+"PATCBIOT","J01-Antibacterials for systemic use","ATCPTTMT","% of total sales","SWE","Sweden","2016","2016",1.7,,
+"PATCBIOT","J01-Antibacterials for systemic use","ATCPTTMT","% of total sales","SWE","Sweden","2017","2017",1.6,,
+"PATCBIOT","J01-Antibacterials for systemic use","ATCPTTMT","% of total sales","SWE","Sweden","2018","2018",1.4,,
+"PATCBIOT","J01-Antibacterials for systemic use","ATCPTTMT","% of total sales","SWE","Sweden","2019","2019",1.5,,
+"PATCBIOT","J01-Antibacterials for systemic use","ATCPTTMT","% of total sales","SWE","Sweden","2020","2020",1.4,,
+"PATCBIOT","J01-Antibacterials for systemic use","ATCPTTMT","% of total sales","SWE","Sweden","2021","2021",1.3,,
+"PATCBIOT","J01-Antibacterials for systemic use","ATCPTTMT","% of total sales","SWE","Sweden","2022","2022",1.3,,
+"PATCBIOT","J01-Antibacterials for systemic use","MLLNCUMT","Million of national currency units","TUR","Türkiye","2010","2010",1925.3,,
+"PATCBIOT","J01-Antibacterials for systemic use","MLLNCUMT","Million of national currency units","TUR","Türkiye","2011","2011",1340.9,,
+"PATCBIOT","J01-Antibacterials for systemic use","MLLNCUMT","Million of national currency units","TUR","Türkiye","2012","2012",1246.7,,
+"PATCBIOT","J01-Antibacterials for systemic use","MLLNCUMT","Million of national currency units","TUR","Türkiye","2013","2013",1182.8,,
+"PATCBIOT","J01-Antibacterials for systemic use","MLLNCUMT","Million of national currency units","TUR","Türkiye","2014","2014",1141.7,,
+"PATCBIOT","J01-Antibacterials for systemic use","MLLNCUMT","Million of national currency units","TUR","Türkiye","2015","2015",1289.4,,
+"PATCBIOT","J01-Antibacterials for systemic use","MLLNCUMT","Million of national currency units","TUR","Türkiye","2016","2016",1450.8,,
+"PATCBIOT","J01-Antibacterials for systemic use","MLLNCUMT","Million of national currency units","TUR","Türkiye","2017","2017",1448.7,,
+"PATCBIOT","J01-Antibacterials for systemic use","MLLNCUMT","Million of national currency units","TUR","Türkiye","2018","2018",1701.3,,
+"PATCBIOT","J01-Antibacterials for systemic use","MLLNCUMT","Million of national currency units","TUR","Türkiye","2019","2019",2350.3,,
+"PATCBIOT","J01-Antibacterials for systemic use","MLLNCUMT","Million of national currency units","TUR","Türkiye","2020","2020",1985.5,,
+"PATCBIOT","J01-Antibacterials for systemic use","MLLNCUMT","Million of national currency units","TUR","Türkiye","2021","2021",2387.3,,
+"PATCBIOT","J01-Antibacterials for systemic use","MTMOTCMT","Million US$ at exchange rate","TUR","Türkiye","2010","2010",1281.1,,
+"PATCBIOT","J01-Antibacterials for systemic use","MTMOTCMT","Million US$ at exchange rate","TUR","Türkiye","2011","2011",800.6,,
+"PATCBIOT","J01-Antibacterials for systemic use","MTMOTCMT","Million US$ at exchange rate","TUR","Türkiye","2012","2012",694.2,,
+"PATCBIOT","J01-Antibacterials for systemic use","MTMOTCMT","Million US$ at exchange rate","TUR","Türkiye","2013","2013",621.3,,
+"PATCBIOT","J01-Antibacterials for systemic use","MTMOTCMT","Million US$ at exchange rate","TUR","Türkiye","2014","2014",521.7,,
+"PATCBIOT","J01-Antibacterials for systemic use","MTMOTCMT","Million US$ at exchange rate","TUR","Türkiye","2015","2015",474,,
+"PATCBIOT","J01-Antibacterials for systemic use","MTMOTCMT","Million US$ at exchange rate","TUR","Türkiye","2016","2016",480.4,,
+"PATCBIOT","J01-Antibacterials for systemic use","MTMOTCMT","Million US$ at exchange rate","TUR","Türkiye","2017","2017",397.1,,
+"PATCBIOT","J01-Antibacterials for systemic use","MTMOTCMT","Million US$ at exchange rate","TUR","Türkiye","2018","2018",352.4,,
+"PATCBIOT","J01-Antibacterials for systemic use","MTMOTCMT","Million US$ at exchange rate","TUR","Türkiye","2019","2019",414.2,,
+"PATCBIOT","J01-Antibacterials for systemic use","MTMOTCMT","Million US$ at exchange rate","TUR","Türkiye","2020","2020",283.3,,
+"PATCBIOT","J01-Antibacterials for systemic use","MTMOTCMT","Million US$ at exchange rate","TUR","Türkiye","2021","2021",269.7,,
+"PATCBIOT","J01-Antibacterials for systemic use","MTMOPPMT","Million US$, purchasing power parity","TUR","Türkiye","2010","2010",2091.9,,
+"PATCBIOT","J01-Antibacterials for systemic use","MTMOPPMT","Million US$, purchasing power parity","TUR","Türkiye","2011","2011",1387.9,,
+"PATCBIOT","J01-Antibacterials for systemic use","MTMOPPMT","Million US$, purchasing power parity","TUR","Türkiye","2012","2012",1222.4,,
+"PATCBIOT","J01-Antibacterials for systemic use","MTMOPPMT","Million US$, purchasing power parity","TUR","Türkiye","2013","2013",1105.1,,
+"PATCBIOT","J01-Antibacterials for systemic use","MTMOPPMT","Million US$, purchasing power parity","TUR","Türkiye","2014","2014",1033.7,,
+"PATCBIOT","J01-Antibacterials for systemic use","MTMOPPMT","Million US$, purchasing power parity","TUR","Türkiye","2015","2015",1109.2,,
+"PATCBIOT","J01-Antibacterials for systemic use","MTMOPPMT","Million US$, purchasing power parity","TUR","Türkiye","2016","2016",1169,,
+"PATCBIOT","J01-Antibacterials for systemic use","MTMOPPMT","Million US$, purchasing power parity","TUR","Türkiye","2017","2017",1046.8,,
+"PATCBIOT","J01-Antibacterials for systemic use","MTMOPPMT","Million US$, purchasing power parity","TUR","Türkiye","2018","2018",1042.1,,
+"PATCBIOT","J01-Antibacterials for systemic use","MTMOPPMT","Million US$, purchasing power parity","TUR","Türkiye","2019","2019",1260.9,,
+"PATCBIOT","J01-Antibacterials for systemic use","MTMOPPMT","Million US$, purchasing power parity","TUR","Türkiye","2020","2020",917.4,,
+"PATCBIOT","J01-Antibacterials for systemic use","MTMOPPMT","Million US$, purchasing power parity","TUR","Türkiye","2021","2021",850.2,,
+"PATCBIOT","J01-Antibacterials for systemic use","TCPPERMT","/capita, US$ exchange rate","TUR","Türkiye","2010","2010",17.5,,
+"PATCBIOT","J01-Antibacterials for systemic use","TCPPERMT","/capita, US$ exchange rate","TUR","Türkiye","2011","2011",10.8,,
+"PATCBIOT","J01-Antibacterials for systemic use","TCPPERMT","/capita, US$ exchange rate","TUR","Türkiye","2012","2012",9.2,,
+"PATCBIOT","J01-Antibacterials for systemic use","TCPPERMT","/capita, US$ exchange rate","TUR","Türkiye","2013","2013",8.2,,
+"PATCBIOT","J01-Antibacterials for systemic use","TCPPERMT","/capita, US$ exchange rate","TUR","Türkiye","2014","2014",6.8,,
+"PATCBIOT","J01-Antibacterials for systemic use","TCPPERMT","/capita, US$ exchange rate","TUR","Türkiye","2015","2015",6.1,,
+"PATCBIOT","J01-Antibacterials for systemic use","TCPPERMT","/capita, US$ exchange rate","TUR","Türkiye","2016","2016",6.1,,
+"PATCBIOT","J01-Antibacterials for systemic use","TCPPERMT","/capita, US$ exchange rate","TUR","Türkiye","2017","2017",4.9,,
+"PATCBIOT","J01-Antibacterials for systemic use","TCPPERMT","/capita, US$ exchange rate","TUR","Türkiye","2018","2018",4.3,,
+"PATCBIOT","J01-Antibacterials for systemic use","TCPPERMT","/capita, US$ exchange rate","TUR","Türkiye","2019","2019",5,,
+"PATCBIOT","J01-Antibacterials for systemic use","TCPPERMT","/capita, US$ exchange rate","TUR","Türkiye","2020","2020",3.4,,
+"PATCBIOT","J01-Antibacterials for systemic use","TCPPERMT","/capita, US$ exchange rate","TUR","Türkiye","2021","2021",3.2,,
+"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2010","2010",28.6,,
+"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2011","2011",18.7,,
+"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2012","2012",16.3,,
+"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2013","2013",14.5,,
+"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2014","2014",13.4,,
+"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2015","2015",14.2,,
+"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2016","2016",14.7,,
+"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2017","2017",13,,
+"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2018","2018",12.8,,
+"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2019","2019",15.3,,
+"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2020","2020",11,,
+"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2021","2021",10.1,,
+"PATCBIOT","J01-Antibacterials for systemic use","ATCPTTMT","% of total sales","TUR","Türkiye","2010","2010",12.4,,
+"PATCBIOT","J01-Antibacterials for systemic use","ATCPTTMT","% of total sales","TUR","Türkiye","2011","2011",9.5,,
+"PATCBIOT","J01-Antibacterials for systemic use","ATCPTTMT","% of total sales","TUR","Türkiye","2012","2012",9.2,,
+"PATCBIOT","J01-Antibacterials for systemic use","ATCPTTMT","% of total sales","TUR","Türkiye","2013","2013",8.3,,
+"PATCBIOT","J01-Antibacterials for systemic use","ATCPTTMT","% of total sales","TUR","Türkiye","2014","2014",7.3,,
+"PATCBIOT","J01-Antibacterials for systemic use","ATCPTTMT","% of total sales","TUR","Türkiye","2015","2015",7,,
+"PATCBIOT","J01-Antibacterials for systemic use","ATCPTTMT","% of total sales","TUR","Türkiye","2016","2016",6.6,,
+"PATCBIOT","J01-Antibacterials for systemic use","ATCPTTMT","% of total sales","TUR","Türkiye","2017","2017",5.7,,
+"PATCBIOT","J01-Antibacterials for systemic use","ATCPTTMT","% of total sales","TUR","Türkiye","2018","2018",5.3,,
+"PATCBIOT","J01-Antibacterials for systemic use","ATCPTTMT","% of total sales","TUR","Türkiye","2019","2019",5.6,,
+"PATCBIOT","J01-Antibacterials for systemic use","ATCPTTMT","% of total sales","TUR","Türkiye","2020","2020",4,,
+"PATCBIOT","J01-Antibacterials for systemic use","ATCPTTMT","% of total sales","TUR","Türkiye","2021","2021",3.7,,
+"PATCBIOT","J01-Antibacterials for systemic use","MLLNCUMT","Million of national currency units","CHL","Chile","2010","2010",38463.8,,
+"PATCBIOT","J01-Antibacterials for systemic use","MLLNCUMT","Million of national currency units","CHL","Chile","2011","2011",60319.9,"B","Break"
+"PATCBIOT","J01-Antibacterials for systemic use","MLLNCUMT","Million of national currency units","CHL","Chile","2012","2012",67944,,
+"PATCBIOT","J01-Antibacterials for systemic use","MLLNCUMT","Million of national currency units","CHL","Chile","2013","2013",70741,,
+"PATCBIOT","J01-Antibacterials for systemic use","MLLNCUMT","Million of national currency units","CHL","Chile","2014","2014",72295.7,,
+"PATCBIOT","J01-Antibacterials for systemic use","MLLNCUMT","Million of national currency units","CHL","Chile","2015","2015",79384.9,,
+"PATCBIOT","J01-Antibacterials for systemic use","MLLNCUMT","Million of national currency units","CHL","Chile","2016","2016",83434.7,,
+"PATCBIOT","J01-Antibacterials for systemic use","MLLNCUMT","Million of national currency units","CHL","Chile","2017","2017",79791.6,,
+"PATCBIOT","J01-Antibacterials for systemic use","MLLNCUMT","Million of national currency units","CHL","Chile","2018","2018",77671.1,,
+"PATCBIOT","J01-Antibacterials for systemic use","MLLNCUMT","Million of national currency units","CHL","Chile","2019","2019",79619.6,,
+"PATCBIOT","J01-Antibacterials for systemic use","MLLNCUMT","Million of national currency units","CHL","Chile","2020","2020",71250.7,,
+"PATCBIOT","J01-Antibacterials for systemic use","MLLNCUMT","Million of national currency units","CHL","Chile","2021","2021",77557.6,,
+"PATCBIOT","J01-Antibacterials for systemic use","MLLNCUMT","Million of national currency units","CHL","Chile","2022","2022",100217.8,,
+"PATCBIOT","J01-Antibacterials for systemic use","MTMOTCMT","Million US$ at exchange rate","CHL","Chile","2010","2010",75.4,,
+"PATCBIOT","J01-Antibacterials for systemic use","MTMOTCMT","Million US$ at exchange rate","CHL","Chile","2011","2011",124.7,"B","Break"
+"PATCBIOT","J01-Antibacterials for systemic use","MTMOTCMT","Million US$ at exchange rate","CHL","Chile","2012","2012",139.7,,
+"PATCBIOT","J01-Antibacterials for systemic use","MTMOTCMT","Million US$ at exchange rate","CHL","Chile","2013","2013",142.8,,
+"PATCBIOT","J01-Antibacterials for systemic use","MTMOTCMT","Million US$ at exchange rate","CHL","Chile","2014","2014",126.8,,
+"PATCBIOT","J01-Antibacterials for systemic use","MTMOTCMT","Million US$ at exchange rate","CHL","Chile","2015","2015",121.4,,
+"PATCBIOT","J01-Antibacterials for systemic use","MTMOTCMT","Million US$ at exchange rate","CHL","Chile","2016","2016",123.2,,
+"PATCBIOT","J01-Antibacterials for systemic use","MTMOTCMT","Million US$ at exchange rate","CHL","Chile","2017","2017",123,,
+"PATCBIOT","J01-Antibacterials for systemic use","MTMOTCMT","Million US$ at exchange rate","CHL","Chile","2018","2018",121.1,,
+"PATCBIOT","J01-Antibacterials for systemic use","MTMOTCMT","Million US$ at exchange rate","CHL","Chile","2019","2019",113.3,,
+"PATCBIOT","J01-Antibacterials for systemic use","MTMOTCMT","Million US$ at exchange rate","CHL","Chile","2020","2020",89.9,,
+"PATCBIOT","J01-Antibacterials for systemic use","MTMOTCMT","Million US$ at exchange rate","CHL","Chile","2021","2021",102.2,,
+"PATCBIOT","J01-Antibacterials for systemic use","MTMOTCMT","Million US$ at exchange rate","CHL","Chile","2022","2022",114.8,,
+"PATCBIOT","J01-Antibacterials for systemic use","MTMOPPMT","Million US$, purchasing power parity","CHL","Chile","2010","2010",106.9,,
+"PATCBIOT","J01-Antibacterials for systemic use","MTMOPPMT","Million US$, purchasing power parity","CHL","Chile","2011","2011",173.3,"B","Break"
+"PATCBIOT","J01-Antibacterials for systemic use","MTMOPPMT","Million US$, purchasing power parity","CHL","Chile","2012","2012",195.7,,
+"PATCBIOT","J01-Antibacterials for systemic use","MTMOPPMT","Million US$, purchasing power parity","CHL","Chile","2013","2013",202.3,,
+"PATCBIOT","J01-Antibacterials for systemic use","MTMOPPMT","Million US$, purchasing power parity","CHL","Chile","2014","2014",196.9,,
+"PATCBIOT","J01-Antibacterials for systemic use","MTMOPPMT","Million US$, purchasing power parity","CHL","Chile","2015","2015",202.9,,
+"PATCBIOT","J01-Antibacterials for systemic use","MTMOPPMT","Million US$, purchasing power parity","CHL","Chile","2016","2016",210,,
+"PATCBIOT","J01-Antibacterials for systemic use","MTMOPPMT","Million US$, purchasing power parity","CHL","Chile","2017","2017",200.6,,
+"PATCBIOT","J01-Antibacterials for systemic use","MTMOPPMT","Million US$, purchasing power parity","CHL","Chile","2018","2018",196,,
+"PATCBIOT","J01-Antibacterials for systemic use","MTMOPPMT","Million US$, purchasing power parity","CHL","Chile","2019","2019",198.2,,
+"PATCBIOT","J01-Antibacterials for systemic use","MTMOPPMT","Million US$, purchasing power parity","CHL","Chile","2020","2020",170.3,,
+"PATCBIOT","J01-Antibacterials for systemic use","MTMOPPMT","Million US$, purchasing power parity","CHL","Chile","2021","2021",178.2,,
+"PATCBIOT","J01-Antibacterials for systemic use","MTMOPPMT","Million US$, purchasing power parity","CHL","Chile","2022","2022",229,,
+"PATCBIOT","J01-Antibacterials for systemic use","TCPPERMT","/capita, US$ exchange rate","CHL","Chile","2010","2010",4.4,,
+"PATCBIOT","J01-Antibacterials for systemic use","TCPPERMT","/capita, US$ exchange rate","CHL","Chile","2011","2011",7.2,"B","Break"
+"PATCBIOT","J01-Antibacterials for systemic use","TCPPERMT","/capita, US$ exchange rate","CHL","Chile","2012","2012",8,,
+"PATCBIOT","J01-Antibacterials for systemic use","TCPPERMT","/capita, US$ exchange rate","CHL","Chile","2013","2013",8.1,,
+"PATCBIOT","J01-Antibacterials for systemic use","TCPPERMT","/capita, US$ exchange rate","CHL","Chile","2014","2014",7.1,,
+"PATCBIOT","J01-Antibacterials for systemic use","TCPPERMT","/capita, US$ exchange rate","CHL","Chile","2015","2015",6.8,,
+"PATCBIOT","J01-Antibacterials for systemic use","TCPPERMT","/capita, US$ exchange rate","CHL","Chile","2016","2016",6.8,,
+"PATCBIOT","J01-Antibacterials for systemic use","TCPPERMT","/capita, US$ exchange rate","CHL","Chile","2017","2017",6.7,,
+"PATCBIOT","J01-Antibacterials for systemic use","TCPPERMT","/capita, US$ exchange rate","CHL","Chile","2018","2018",6.5,,
+"PATCBIOT","J01-Antibacterials for systemic use","TCPPERMT","/capita, US$ exchange rate","CHL","Chile","2019","2019",5.9,,
+"PATCBIOT","J01-Antibacterials for systemic use","TCPPERMT","/capita, US$ exchange rate","CHL","Chile","2020","2020",4.6,,
+"PATCBIOT","J01-Antibacterials for systemic use","TCPPERMT","/capita, US$ exchange rate","CHL","Chile","2021","2021",5.2,,
+"PATCBIOT","J01-Antibacterials for systemic use","TCPPERMT","/capita, US$ exchange rate","CHL","Chile","2022","2022",5.8,,
+"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2010","2010",6.3,,
+"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2011","2011",10,"B","Break"
+"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2012","2012",11.2,,
+"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2013","2013",11.5,,
+"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2014","2014",11.1,,
+"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2015","2015",11.3,,
+"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2016","2016",11.6,,
+"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2017","2017",10.9,,
+"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2018","2018",10.5,,
+"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2019","2019",10.4,,
+"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2020","2020",8.8,,
+"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2021","2021",9.1,,
+"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2022","2022",11.6,,
+"PATCBIOT","J01-Antibacterials for systemic use","ATCPTTMT","% of total sales","CHL","Chile","2010","2010",4.7,,
+"PATCBIOT","J01-Antibacterials for systemic use","ATCPTTMT","% of total sales","CHL","Chile","2011","2011",5.1,"B","Break"
+"PATCBIOT","J01-Antibacterials for systemic use","ATCPTTMT","% of total sales","CHL","Chile","2012","2012",5.4,,
+"PATCBIOT","J01-Antibacterials for systemic use","ATCPTTMT","% of total sales","CHL","Chile","2013","2013",4.9,,
+"PATCBIOT","J01-Antibacterials for systemic use","ATCPTTMT","% of total sales","CHL","Chile","2014","2014",4.7,,
+"PATCBIOT","J01-Antibacterials for systemic use","ATCPTTMT","% of total sales","CHL","Chile","2015","2015",4.4,,
+"PATCBIOT","J01-Antibacterials for systemic use","ATCPTTMT","% of total sales","CHL","Chile","2016","2016",4.1,,
+"PATCBIOT","J01-Antibacterials for systemic use","ATCPTTMT","% of total sales","CHL","Chile","2017","2017",3.9,,
+"PATCBIOT","J01-Antibacterials for systemic use","ATCPTTMT","% of total sales","CHL","Chile","2018","2018",3.4,,
+"PATCBIOT","J01-Antibacterials for systemic use","ATCPTTMT","% of total sales","CHL","Chile","2019","2019",3.2,,
+"PATCBIOT","J01-Antibacterials for systemic use","ATCPTTMT","% of total sales","CHL","Chile","2020","2020",2.6,,
+"PATCBIOT","J01-Antibacterials for systemic use","ATCPTTMT","% of total sales","CHL","Chile","2021","2021",2.8,,
+"PATCBIOT","J01-Antibacterials for systemic use","ATCPTTMT","% of total sales","CHL","Chile","2022","2022",3.6,,
+"PATCBIOT","J01-Antibacterials for systemic use","MLLNCUMT","Million of national currency units","EST","Estonia","2010","2010",7.9,,
+"PATCBIOT","J01-Antibacterials for systemic use","MLLNCUMT","Million of national currency units","EST","Estonia","2011","2011",8.1,,
+"PATCBIOT","J01-Antibacterials for systemic use","MLLNCUMT","Million of national currency units","EST","Estonia","2012","2012",7.9,,
+"PATCBIOT","J01-Antibacterials for systemic use","MLLNCUMT","Million of national currency units","EST","Estonia","2013","2013",7.3,,
+"PATCBIOT","J01-Antibacterials for systemic use","MLLNCUMT","Million of national currency units","EST","Estonia","2014","2014",7,,
+"PATCBIOT","J01-Antibacterials for systemic use","MLLNCUMT","Million of national currency units","EST","Estonia","2015","2015",6.9,,
+"PATCBIOT","J01-Antibacterials for systemic use","MLLNCUMT","Million of national currency units","EST","Estonia","2016","2016",6.9,,
+"PATCBIOT","J01-Antibacterials for systemic use","MLLNCUMT","Million of national currency units","EST","Estonia","2017","2017",6.6,,
+"PATCBIOT","J01-Antibacterials for systemic use","MLLNCUMT","Million of national currency units","EST","Estonia","2018","2018",6.7,,
+"PATCBIOT","J01-Antibacterials for systemic use","MLLNCUMT","Million of national currency units","EST","Estonia","2019","2019",6.6,,
+"PATCBIOT","J01-Antibacterials for systemic use","MLLNCUMT","Million of national currency units","EST","Estonia","2020","2020",6.4,,
+"PATCBIOT","J01-Antibacterials for systemic use","MLLNCUMT","Million of national currency units","EST","Estonia","2021","2021",6.4,,
+"PATCBIOT","J01-Antibacterials for systemic use","MLLNCUMT","Million of national currency units","EST","Estonia","2022","2022",7.2,,
+"PATCBIOT","J01-Antibacterials for systemic use","MTMOTCMT","Million US$ at exchange rate","EST","Estonia","2010","2010",10.4,,
+"PATCBIOT","J01-Antibacterials for systemic use","MTMOTCMT","Million US$ at exchange rate","EST","Estonia","2011","2011",11.2,,
+"PATCBIOT","J01-Antibacterials for systemic use","MTMOTCMT","Million US$ at exchange rate","EST","Estonia","2012","2012",10.2,,
+"PATCBIOT","J01-Antibacterials for systemic use","MTMOTCMT","Million US$ at exchange rate","EST","Estonia","2013","2013",9.7,,
+"PATCBIOT","J01-Antibacterials for systemic use","MTMOTCMT","Million US$ at exchange rate","EST","Estonia","2014","2014",9.4,,
+"PATCBIOT","J01-Antibacterials for systemic use","MTMOTCMT","Million US$ at exchange rate","EST","Estonia","2015","2015",7.7,,
+"PATCBIOT","J01-Antibacterials for systemic use","MTMOTCMT","Million US$ at exchange rate","EST","Estonia","2016","2016",7.6,,
+"PATCBIOT","J01-Antibacterials for systemic use","MTMOTCMT","Million US$ at exchange rate","EST","Estonia","2017","2017",7.5,,
+"PATCBIOT","J01-Antibacterials for systemic use","MTMOTCMT","Million US$ at exchange rate","EST","Estonia","2018","2018",7.9,,
+"PATCBIOT","J01-Antibacterials for systemic use","MTMOTCMT","Million US$ at exchange rate","EST","Estonia","2019","2019",7.4,,
+"PATCBIOT","J01-Antibacterials for systemic use","MTMOTCMT","Million US$ at exchange rate","EST","Estonia","2020","2020",7.3,,
+"PATCBIOT","J01-Antibacterials for systemic use","MTMOTCMT","Million US$ at exchange rate","EST","Estonia","2021","2021",7.5,,
+"PATCBIOT","J01-Antibacterials for systemic use","MTMOTCMT","Million US$ at exchange rate","EST","Estonia","2022","2022",7.6,,
+"PATCBIOT","J01-Antibacterials for systemic use","MTMOPPMT","Million US$, purchasing power parity","EST","Estonia","2010","2010",15.3,,
+"PATCBIOT","J01-Antibacterials for systemic use","MTMOPPMT","Million US$, purchasing power parity","EST","Estonia","2011","2011",15.8,,
+"PATCBIOT","J01-Antibacterials for systemic use","MTMOPPMT","Million US$, purchasing power parity","EST","Estonia","2012","2012",15.2,,
+"PATCBIOT","J01-Antibacterials for systemic use","MTMOPPMT","Million US$, purchasing power parity","EST","Estonia","2013","2013",14,,
+"PATCBIOT","J01-Antibacterials for systemic use","MTMOPPMT","Million US$, purchasing power parity","EST","Estonia","2014","2014",13.4,,
+"PATCBIOT","J01-Antibacterials for systemic use","MTMOPPMT","Million US$, purchasing power parity","EST","Estonia","2015","2015",12.9,,
+"PATCBIOT","J01-Antibacterials for systemic use","MTMOPPMT","Million US$, purchasing power parity","EST","Estonia","2016","2016",13,,
+"PATCBIOT","J01-Antibacterials for systemic use","MTMOPPMT","Million US$, purchasing power parity","EST","Estonia","2017","2017",12.4,,
+"PATCBIOT","J01-Antibacterials for systemic use","MTMOPPMT","Million US$, purchasing power parity","EST","Estonia","2018","2018",12.5,,
+"PATCBIOT","J01-Antibacterials for systemic use","MTMOPPMT","Million US$, purchasing power parity","EST","Estonia","2019","2019",12.3,,
+"PATCBIOT","J01-Antibacterials for systemic use","MTMOPPMT","Million US$, purchasing power parity","EST","Estonia","2020","2020",12.2,,
+"PATCBIOT","J01-Antibacterials for systemic use","MTMOPPMT","Million US$, purchasing power parity","EST","Estonia","2021","2021",11.7,,
+"PATCBIOT","J01-Antibacterials for systemic use","MTMOPPMT","Million US$, purchasing power parity","EST","Estonia","2022","2022",12.7,,
+"PATCBIOT","J01-Antibacterials for systemic use","TCPPERMT","/capita, US$ exchange rate","EST","Estonia","2010","2010",7.8,,
+"PATCBIOT","J01-Antibacterials for systemic use","TCPPERMT","/capita, US$ exchange rate","EST","Estonia","2011","2011",8.5,,
+"PATCBIOT","J01-Antibacterials for systemic use","TCPPERMT","/capita, US$ exchange rate","EST","Estonia","2012","2012",7.7,,
+"PATCBIOT","J01-Antibacterials for systemic use","TCPPERMT","/capita, US$ exchange rate","EST","Estonia","2013","2013",7.4,,
+"PATCBIOT","J01-Antibacterials for systemic use","TCPPERMT","/capita, US$ exchange rate","EST","Estonia","2014","2014",7.1,,
+"PATCBIOT","J01-Antibacterials for systemic use","TCPPERMT","/capita, US$ exchange rate","EST","Estonia","2015","2015",5.9,,
+"PATCBIOT","J01-Antibacterials for systemic use","TCPPERMT","/capita, US$ exchange rate","EST","Estonia","2016","2016",5.8,,
+"PATCBIOT","J01-Antibacterials for systemic use","TCPPERMT","/capita, US$ exchange rate","EST","Estonia","2017","2017",5.7,,
+"PATCBIOT","J01-Antibacterials for systemic use","TCPPERMT","/capita, US$ exchange rate","EST","Estonia","2018","2018",6,,
+"PATCBIOT","J01-Antibacterials for systemic use","TCPPERMT","/capita, US$ exchange rate","EST","Estonia","2019","2019",5.5,,
+"PATCBIOT","J01-Antibacterials for systemic use","TCPPERMT","/capita, US$ exchange rate","EST","Estonia","2020","2020",5.5,,
+"PATCBIOT","J01-Antibacterials for systemic use","TCPPERMT","/capita, US$ exchange rate","EST","Estonia","2021","2021",5.7,,
+"PATCBIOT","J01-Antibacterials for systemic use","TCPPERMT","/capita, US$ exchange rate","EST","Estonia","2022","2022",5.7,,
+"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2010","2010",11.5,,
+"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2011","2011",11.9,,
+"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2012","2012",11.5,,
+"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2013","2013",10.6,,
+"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2014","2014",10.2,,
+"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2015","2015",9.8,,
+"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2016","2016",9.9,,
+"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2017","2017",9.4,,
+"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2018","2018",9.4,,
+"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2019","2019",9.2,,
+"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2020","2020",9.2,,
+"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2021","2021",8.8,,
+"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2022","2022",9.5,,
+"PATCBIOT","J01-Antibacterials for systemic use","ATCPTTMT","% of total sales","EST","Estonia","2010","2010",4,,
+"PATCBIOT","J01-Antibacterials for systemic use","ATCPTTMT","% of total sales","EST","Estonia","2011","2011",3.9,,
+"PATCBIOT","J01-Antibacterials for systemic use","ATCPTTMT","% of total sales","EST","Estonia","2012","2012",3.6,,
+"PATCBIOT","J01-Antibacterials for systemic use","ATCPTTMT","% of total sales","EST","Estonia","2013","2013",3.2,,
+"PATCBIOT","J01-Antibacterials for systemic use","ATCPTTMT","% of total sales","EST","Estonia","2014","2014",2.8,,
+"PATCBIOT","J01-Antibacterials for systemic use","ATCPTTMT","% of total sales","EST","Estonia","2015","2015",2.6,,
+"PATCBIOT","J01-Antibacterials for systemic use","ATCPTTMT","% of total sales","EST","Estonia","2016","2016",2.4,,
+"PATCBIOT","J01-Antibacterials for systemic use","ATCPTTMT","% of total sales","EST","Estonia","2017","2017",2.2,,
+"PATCBIOT","J01-Antibacterials for systemic use","ATCPTTMT","% of total sales","EST","Estonia","2018","2018",2.1,,
+"PATCBIOT","J01-Antibacterials for systemic use","ATCPTTMT","% of total sales","EST","Estonia","2019","2019",1.9,,
+"PATCBIOT","J01-Antibacterials for systemic use","ATCPTTMT","% of total sales","EST","Estonia","2020","2020",1.8,,
+"PATCBIOT","J01-Antibacterials for systemic use","ATCPTTMT","% of total sales","EST","Estonia","2021","2021",1.6,,
+"PATCBIOT","J01-Antibacterials for systemic use","ATCPTTMT","% of total sales","EST","Estonia","2022","2022",1.7,,
+"PATCBIOT","J01-Antibacterials for systemic use","MLLNCUMT","Million of national currency units","SVN","Slovenia","2010","2010",11.8,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","MLLNCUMT","Million of national currency units","SVN","Slovenia","2011","2011",11.7,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","MLLNCUMT","Million of national currency units","SVN","Slovenia","2012","2012",11.4,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","MLLNCUMT","Million of national currency units","SVN","Slovenia","2013","2013",11.6,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","MLLNCUMT","Million of national currency units","SVN","Slovenia","2014","2014",11.2,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","MLLNCUMT","Million of national currency units","SVN","Slovenia","2015","2015",11.4,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","MLLNCUMT","Million of national currency units","SVN","Slovenia","2016","2016",11.2,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","MLLNCUMT","Million of national currency units","SVN","Slovenia","2017","2017",11.3,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","MLLNCUMT","Million of national currency units","SVN","Slovenia","2018","2018",11.3,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","MLLNCUMT","Million of national currency units","SVN","Slovenia","2019","2019",11.9,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","MLLNCUMT","Million of national currency units","SVN","Slovenia","2020","2020",9.5,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","MLLNCUMT","Million of national currency units","SVN","Slovenia","2021","2021",9.6,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","MLLNCUMT","Million of national currency units","SVN","Slovenia","2022","2022",12.3,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","MTMOTCMT","Million US$ at exchange rate","SVN","Slovenia","2010","2010",15.6,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","MTMOTCMT","Million US$ at exchange rate","SVN","Slovenia","2011","2011",16.4,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","MTMOTCMT","Million US$ at exchange rate","SVN","Slovenia","2012","2012",14.7,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","MTMOTCMT","Million US$ at exchange rate","SVN","Slovenia","2013","2013",15.4,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","MTMOTCMT","Million US$ at exchange rate","SVN","Slovenia","2014","2014",14.8,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","MTMOTCMT","Million US$ at exchange rate","SVN","Slovenia","2015","2015",12.6,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","MTMOTCMT","Million US$ at exchange rate","SVN","Slovenia","2016","2016",12.4,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","MTMOTCMT","Million US$ at exchange rate","SVN","Slovenia","2017","2017",12.7,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","MTMOTCMT","Million US$ at exchange rate","SVN","Slovenia","2018","2018",13.4,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","MTMOTCMT","Million US$ at exchange rate","SVN","Slovenia","2019","2019",13.3,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","MTMOTCMT","Million US$ at exchange rate","SVN","Slovenia","2020","2020",10.8,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","MTMOTCMT","Million US$ at exchange rate","SVN","Slovenia","2021","2021",11.4,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","MTMOTCMT","Million US$ at exchange rate","SVN","Slovenia","2022","2022",12.9,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","MTMOPPMT","Million US$, purchasing power parity","SVN","Slovenia","2010","2010",18.5,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","MTMOPPMT","Million US$, purchasing power parity","SVN","Slovenia","2011","2011",18.8,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","MTMOPPMT","Million US$, purchasing power parity","SVN","Slovenia","2012","2012",18.8,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","MTMOPPMT","Million US$, purchasing power parity","SVN","Slovenia","2013","2013",19.6,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","MTMOPPMT","Million US$, purchasing power parity","SVN","Slovenia","2014","2014",18.9,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","MTMOPPMT","Million US$, purchasing power parity","SVN","Slovenia","2015","2015",19.2,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","MTMOPPMT","Million US$, purchasing power parity","SVN","Slovenia","2016","2016",19.5,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","MTMOPPMT","Million US$, purchasing power parity","SVN","Slovenia","2017","2017",19.8,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","MTMOPPMT","Million US$, purchasing power parity","SVN","Slovenia","2018","2018",19.9,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","MTMOPPMT","Million US$, purchasing power parity","SVN","Slovenia","2019","2019",21.5,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","MTMOPPMT","Million US$, purchasing power parity","SVN","Slovenia","2020","2020",17.3,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","MTMOPPMT","Million US$, purchasing power parity","SVN","Slovenia","2021","2021",17.1,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","MTMOPPMT","Million US$, purchasing power parity","SVN","Slovenia","2022","2022",22.2,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","TCPPERMT","/capita, US$ exchange rate","SVN","Slovenia","2010","2010",7.6,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","TCPPERMT","/capita, US$ exchange rate","SVN","Slovenia","2011","2011",8,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","TCPPERMT","/capita, US$ exchange rate","SVN","Slovenia","2012","2012",7.1,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","TCPPERMT","/capita, US$ exchange rate","SVN","Slovenia","2013","2013",7.5,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","TCPPERMT","/capita, US$ exchange rate","SVN","Slovenia","2014","2014",7.2,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","TCPPERMT","/capita, US$ exchange rate","SVN","Slovenia","2015","2015",6.1,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","TCPPERMT","/capita, US$ exchange rate","SVN","Slovenia","2016","2016",6,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","TCPPERMT","/capita, US$ exchange rate","SVN","Slovenia","2017","2017",6.2,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","TCPPERMT","/capita, US$ exchange rate","SVN","Slovenia","2018","2018",6.4,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","TCPPERMT","/capita, US$ exchange rate","SVN","Slovenia","2019","2019",6.4,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","TCPPERMT","/capita, US$ exchange rate","SVN","Slovenia","2020","2020",5.2,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","TCPPERMT","/capita, US$ exchange rate","SVN","Slovenia","2021","2021",5.4,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","TCPPERMT","/capita, US$ exchange rate","SVN","Slovenia","2022","2022",6.1,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2010","2010",9,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2011","2011",9.2,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2012","2012",9.2,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2013","2013",9.5,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2014","2014",9.2,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2015","2015",9.3,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2016","2016",9.4,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2017","2017",9.6,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2018","2018",9.6,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2019","2019",10.3,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2020","2020",8.2,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2021","2021",8.1,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2022","2022",10.5,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","ATCPTTMT","% of total sales","SVN","Slovenia","2010","2010",2.5,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","ATCPTTMT","% of total sales","SVN","Slovenia","2011","2011",2.5,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","ATCPTTMT","% of total sales","SVN","Slovenia","2012","2012",2.5,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","ATCPTTMT","% of total sales","SVN","Slovenia","2013","2013",2.6,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","ATCPTTMT","% of total sales","SVN","Slovenia","2014","2014",2.6,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","ATCPTTMT","% of total sales","SVN","Slovenia","2015","2015",2.6,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","ATCPTTMT","% of total sales","SVN","Slovenia","2016","2016",2.4,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","ATCPTTMT","% of total sales","SVN","Slovenia","2017","2017",2.3,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","ATCPTTMT","% of total sales","SVN","Slovenia","2018","2018",2.2,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","ATCPTTMT","% of total sales","SVN","Slovenia","2019","2019",2.2,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","ATCPTTMT","% of total sales","SVN","Slovenia","2020","2020",1.7,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","ATCPTTMT","% of total sales","SVN","Slovenia","2021","2021",1.6,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","ATCPTTMT","% of total sales","SVN","Slovenia","2022","2022",1.8,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","MLLNCUMT","Million of national currency units","AUS","Australia","2010","2010",324,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","MLLNCUMT","Million of national currency units","AUS","Australia","2011","2011",309,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","MLLNCUMT","Million of national currency units","AUS","Australia","2012","2012",312,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","MLLNCUMT","Million of national currency units","AUS","Australia","2013","2013",378,"B; D","Break; Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","MLLNCUMT","Million of national currency units","AUS","Australia","2014","2014",383,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","MLLNCUMT","Million of national currency units","AUS","Australia","2015","2015",401,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","MLLNCUMT","Million of national currency units","AUS","Australia","2016","2016",426,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","MLLNCUMT","Million of national currency units","AUS","Australia","2017","2017",429,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","MLLNCUMT","Million of national currency units","AUS","Australia","2018","2018",500,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","MLLNCUMT","Million of national currency units","AUS","Australia","2019","2019",535,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","MLLNCUMT","Million of national currency units","AUS","Australia","2020","2020",570,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","MLLNCUMT","Million of national currency units","AUS","Australia","2021","2021",584,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","MTMOTCMT","Million US$ at exchange rate","AUS","Australia","2010","2010",297.2,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","MTMOTCMT","Million US$ at exchange rate","AUS","Australia","2011","2011",318.7,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","MTMOTCMT","Million US$ at exchange rate","AUS","Australia","2012","2012",323,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","MTMOTCMT","Million US$ at exchange rate","AUS","Australia","2013","2013",364.9,"B; D","Break; Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","MTMOTCMT","Million US$ at exchange rate","AUS","Australia","2014","2014",345.2,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","MTMOTCMT","Million US$ at exchange rate","AUS","Australia","2015","2015",301.3,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","MTMOTCMT","Million US$ at exchange rate","AUS","Australia","2016","2016",316.7,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","MTMOTCMT","Million US$ at exchange rate","AUS","Australia","2017","2017",328.8,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","MTMOTCMT","Million US$ at exchange rate","AUS","Australia","2018","2018",373.6,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","MTMOTCMT","Million US$ at exchange rate","AUS","Australia","2019","2019",371.9,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","MTMOTCMT","Million US$ at exchange rate","AUS","Australia","2020","2020",392.3,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","MTMOTCMT","Million US$ at exchange rate","AUS","Australia","2021","2021",438.7,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","MTMOPPMT","Million US$, purchasing power parity","AUS","Australia","2010","2010",215.5,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","MTMOPPMT","Million US$, purchasing power parity","AUS","Australia","2011","2011",204.5,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","MTMOPPMT","Million US$, purchasing power parity","AUS","Australia","2012","2012",202.6,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","MTMOPPMT","Million US$, purchasing power parity","AUS","Australia","2013","2013",261.2,"B; D","Break; Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","MTMOPPMT","Million US$, purchasing power parity","AUS","Australia","2014","2014",263.7,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","MTMOPPMT","Million US$, purchasing power parity","AUS","Australia","2015","2015",272.1,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","MTMOPPMT","Million US$, purchasing power parity","AUS","Australia","2016","2016",293.8,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","MTMOPPMT","Million US$, purchasing power parity","AUS","Australia","2017","2017",290.3,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","MTMOPPMT","Million US$, purchasing power parity","AUS","Australia","2018","2018",340,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","MTMOPPMT","Million US$, purchasing power parity","AUS","Australia","2019","2019",361.5,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","MTMOPPMT","Million US$, purchasing power parity","AUS","Australia","2020","2020",392,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","MTMOPPMT","Million US$, purchasing power parity","AUS","Australia","2021","2021",403.4,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","TCPPERMT","/capita, US$ exchange rate","AUS","Australia","2010","2010",13.5,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","TCPPERMT","/capita, US$ exchange rate","AUS","Australia","2011","2011",14.3,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","TCPPERMT","/capita, US$ exchange rate","AUS","Australia","2012","2012",14.2,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","TCPPERMT","/capita, US$ exchange rate","AUS","Australia","2013","2013",15.8,"B; D","Break; Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","TCPPERMT","/capita, US$ exchange rate","AUS","Australia","2014","2014",14.7,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","TCPPERMT","/capita, US$ exchange rate","AUS","Australia","2015","2015",12.6,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","TCPPERMT","/capita, US$ exchange rate","AUS","Australia","2016","2016",13.1,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","TCPPERMT","/capita, US$ exchange rate","AUS","Australia","2017","2017",13.4,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","TCPPERMT","/capita, US$ exchange rate","AUS","Australia","2018","2018",15,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","TCPPERMT","/capita, US$ exchange rate","AUS","Australia","2019","2019",14.7,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","TCPPERMT","/capita, US$ exchange rate","AUS","Australia","2020","2020",15.3,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","TCPPERMT","/capita, US$ exchange rate","AUS","Australia","2021","2021",17.1,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2010","2010",9.8,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2011","2011",9.2,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2012","2012",8.9,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2013","2013",11.3,"B; D","Break; Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2014","2014",11.2,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2015","2015",11.4,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2016","2016",12.1,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2017","2017",11.8,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2018","2018",13.6,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2019","2019",14.3,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2020","2020",15.3,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2021","2021",15.7,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","ATCPTTMT","% of total sales","AUS","Australia","2010","2010",3.3,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","ATCPTTMT","% of total sales","AUS","Australia","2011","2011",3,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","ATCPTTMT","% of total sales","AUS","Australia","2012","2012",3,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","ATCPTTMT","% of total sales","AUS","Australia","2013","2013",3.2,"B; D","Break; Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","ATCPTTMT","% of total sales","AUS","Australia","2014","2014",3.2,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","ATCPTTMT","% of total sales","AUS","Australia","2015","2015",3.3,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","ATCPTTMT","% of total sales","AUS","Australia","2016","2016",2.8,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","ATCPTTMT","% of total sales","AUS","Australia","2017","2017",2.9,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","ATCPTTMT","% of total sales","AUS","Australia","2018","2018",3.4,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","ATCPTTMT","% of total sales","AUS","Australia","2019","2019",3.4,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","ATCPTTMT","% of total sales","AUS","Australia","2020","2020",3.4,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","ATCPTTMT","% of total sales","AUS","Australia","2021","2021",3.3,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","MLLNCUMT","Million of national currency units","AUT","Austria","2010","2010",109.6,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","MLLNCUMT","Million of national currency units","AUT","Austria","2011","2011",109.5,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","MLLNCUMT","Million of national currency units","AUT","Austria","2012","2012",107.7,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","MLLNCUMT","Million of national currency units","AUT","Austria","2013","2013",101.2,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","MLLNCUMT","Million of national currency units","AUT","Austria","2014","2014",100.5,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","MLLNCUMT","Million of national currency units","AUT","Austria","2015","2015",100.2,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","MLLNCUMT","Million of national currency units","AUT","Austria","2016","2016",102.8,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","MLLNCUMT","Million of national currency units","AUT","Austria","2017","2017",105.5,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","MLLNCUMT","Million of national currency units","AUT","Austria","2018","2018",105.1,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","MLLNCUMT","Million of national currency units","AUT","Austria","2019","2019",107.7,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","MLLNCUMT","Million of national currency units","AUT","Austria","2020","2020",106.2,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","MLLNCUMT","Million of national currency units","AUT","Austria","2021","2021",116.6,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","MTMOTCMT","Million US$ at exchange rate","AUT","Austria","2010","2010",145.2,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","MTMOTCMT","Million US$ at exchange rate","AUT","Austria","2011","2011",152.4,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","MTMOTCMT","Million US$ at exchange rate","AUT","Austria","2012","2012",138.4,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","MTMOTCMT","Million US$ at exchange rate","AUT","Austria","2013","2013",134.4,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","MTMOTCMT","Million US$ at exchange rate","AUT","Austria","2014","2014",133.6,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","MTMOTCMT","Million US$ at exchange rate","AUT","Austria","2015","2015",111.1,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","MTMOTCMT","Million US$ at exchange rate","AUT","Austria","2016","2016",113.7,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","MTMOTCMT","Million US$ at exchange rate","AUT","Austria","2017","2017",119.2,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","MTMOTCMT","Million US$ at exchange rate","AUT","Austria","2018","2018",124.1,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","MTMOTCMT","Million US$ at exchange rate","AUT","Austria","2019","2019",120.6,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","MTMOTCMT","Million US$ at exchange rate","AUT","Austria","2020","2020",121.3,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","MTMOTCMT","Million US$ at exchange rate","AUT","Austria","2021","2021",137.9,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","MTMOPPMT","Million US$, purchasing power parity","AUT","Austria","2010","2010",130.1,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","MTMOPPMT","Million US$, purchasing power parity","AUT","Austria","2011","2011",131.7,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","MTMOPPMT","Million US$, purchasing power parity","AUT","Austria","2012","2012",132.4,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","MTMOPPMT","Million US$, purchasing power parity","AUT","Austria","2013","2013",127,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","MTMOPPMT","Million US$, purchasing power parity","AUT","Austria","2014","2014",125.9,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","MTMOPPMT","Million US$, purchasing power parity","AUT","Austria","2015","2015",125.4,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","MTMOPPMT","Million US$, purchasing power parity","AUT","Austria","2016","2016",132.3,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","MTMOPPMT","Million US$, purchasing power parity","AUT","Austria","2017","2017",136.1,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","MTMOPPMT","Million US$, purchasing power parity","AUT","Austria","2018","2018",137.3,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","MTMOPPMT","Million US$, purchasing power parity","AUT","Austria","2019","2019",143.8,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","MTMOPPMT","Million US$, purchasing power parity","AUT","Austria","2020","2020",142.3,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","MTMOPPMT","Million US$, purchasing power parity","AUT","Austria","2021","2021",154.2,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","TCPPERMT","/capita, US$ exchange rate","AUT","Austria","2010","2010",17.4,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","TCPPERMT","/capita, US$ exchange rate","AUT","Austria","2011","2011",18.2,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","TCPPERMT","/capita, US$ exchange rate","AUT","Austria","2012","2012",16.4,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","TCPPERMT","/capita, US$ exchange rate","AUT","Austria","2013","2013",15.9,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","TCPPERMT","/capita, US$ exchange rate","AUT","Austria","2014","2014",15.6,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","TCPPERMT","/capita, US$ exchange rate","AUT","Austria","2015","2015",12.9,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","TCPPERMT","/capita, US$ exchange rate","AUT","Austria","2016","2016",13,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","TCPPERMT","/capita, US$ exchange rate","AUT","Austria","2017","2017",13.5,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","TCPPERMT","/capita, US$ exchange rate","AUT","Austria","2018","2018",14,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","TCPPERMT","/capita, US$ exchange rate","AUT","Austria","2019","2019",13.6,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","TCPPERMT","/capita, US$ exchange rate","AUT","Austria","2020","2020",13.6,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","TCPPERMT","/capita, US$ exchange rate","AUT","Austria","2021","2021",15.4,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2010","2010",15.6,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2011","2011",15.7,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2012","2012",15.7,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2013","2013",15,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2014","2014",14.7,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2015","2015",14.5,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2016","2016",15.1,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2017","2017",15.5,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2018","2018",15.5,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2019","2019",16.2,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2020","2020",16,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2021","2021",17.2,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","ATCPTTMT","% of total sales","AUT","Austria","2010","2010",4.4,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","ATCPTTMT","% of total sales","AUT","Austria","2011","2011",4.3,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","ATCPTTMT","% of total sales","AUT","Austria","2012","2012",4.1,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","ATCPTTMT","% of total sales","AUT","Austria","2013","2013",3.8,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","ATCPTTMT","% of total sales","AUT","Austria","2014","2014",3.6,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","ATCPTTMT","% of total sales","AUT","Austria","2015","2015",3.4,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","ATCPTTMT","% of total sales","AUT","Austria","2016","2016",3.4,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","ATCPTTMT","% of total sales","AUT","Austria","2017","2017",3.4,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","ATCPTTMT","% of total sales","AUT","Austria","2018","2018",3.3,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","ATCPTTMT","% of total sales","AUT","Austria","2019","2019",3.3,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","ATCPTTMT","% of total sales","AUT","Austria","2020","2020",3.1,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","ATCPTTMT","% of total sales","AUT","Austria","2021","2021",3.1,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","MLLNCUMT","Million of national currency units","BEL","Belgium","2010","2010",250.3,,
+"PATCSKEL","M-Musculo-skeletal system","MLLNCUMT","Million of national currency units","BEL","Belgium","2011","2011",250.8,,
+"PATCSKEL","M-Musculo-skeletal system","MLLNCUMT","Million of national currency units","BEL","Belgium","2012","2012",249.7,,
+"PATCSKEL","M-Musculo-skeletal system","MLLNCUMT","Million of national currency units","BEL","Belgium","2013","2013",251.9,,
+"PATCSKEL","M-Musculo-skeletal system","MLLNCUMT","Million of national currency units","BEL","Belgium","2014","2014",254.9,,
+"PATCSKEL","M-Musculo-skeletal system","MLLNCUMT","Million of national currency units","BEL","Belgium","2015","2015",256.3,,
+"PATCSKEL","M-Musculo-skeletal system","MLLNCUMT","Million of national currency units","BEL","Belgium","2016","2016",254.3,,
+"PATCSKEL","M-Musculo-skeletal system","MLLNCUMT","Million of national currency units","BEL","Belgium","2017","2017",247.7,,
+"PATCSKEL","M-Musculo-skeletal system","MLLNCUMT","Million of national currency units","BEL","Belgium","2018","2018",236.7,,
+"PATCSKEL","M-Musculo-skeletal system","MLLNCUMT","Million of national currency units","BEL","Belgium","2019","2019",253.5,,
+"PATCSKEL","M-Musculo-skeletal system","MLLNCUMT","Million of national currency units","BEL","Belgium","2020","2020",231.5,,
+"PATCSKEL","M-Musculo-skeletal system","MLLNCUMT","Million of national currency units","BEL","Belgium","2021","2021",218.5,,
+"PATCSKEL","M-Musculo-skeletal system","MLLNCUMT","Million of national currency units","BEL","Belgium","2022","2022",242.6,"E","Estimated value"
+"PATCSKEL","M-Musculo-skeletal system","MTMOTCMT","Million US$ at exchange rate","BEL","Belgium","2010","2010",331.9,,
+"PATCSKEL","M-Musculo-skeletal system","MTMOTCMT","Million US$ at exchange rate","BEL","Belgium","2011","2011",349.2,,
+"PATCSKEL","M-Musculo-skeletal system","MTMOTCMT","Million US$ at exchange rate","BEL","Belgium","2012","2012",320.8,,
+"PATCSKEL","M-Musculo-skeletal system","MTMOTCMT","Million US$ at exchange rate","BEL","Belgium","2013","2013",334.6,,
+"PATCSKEL","M-Musculo-skeletal system","MTMOTCMT","Million US$ at exchange rate","BEL","Belgium","2014","2014",338.6,,
+"PATCSKEL","M-Musculo-skeletal system","MTMOTCMT","Million US$ at exchange rate","BEL","Belgium","2015","2015",284.4,,
+"PATCSKEL","M-Musculo-skeletal system","MTMOTCMT","Million US$ at exchange rate","BEL","Belgium","2016","2016",281.5,,
+"PATCSKEL","M-Musculo-skeletal system","MTMOTCMT","Million US$ at exchange rate","BEL","Belgium","2017","2017",279.8,,
+"PATCSKEL","M-Musculo-skeletal system","MTMOTCMT","Million US$ at exchange rate","BEL","Belgium","2018","2018",279.6,,
+"PATCSKEL","M-Musculo-skeletal system","MTMOTCMT","Million US$ at exchange rate","BEL","Belgium","2019","2019",283.8,,
+"PATCSKEL","M-Musculo-skeletal system","MTMOTCMT","Million US$ at exchange rate","BEL","Belgium","2020","2020",264.4,,
+"PATCSKEL","M-Musculo-skeletal system","MTMOTCMT","Million US$ at exchange rate","BEL","Belgium","2021","2021",258.4,,
+"PATCSKEL","M-Musculo-skeletal system","MTMOTCMT","Million US$ at exchange rate","BEL","Belgium","2022","2022",255.4,"E","Estimated value"
+"PATCSKEL","M-Musculo-skeletal system","MTMOPPMT","Million US$, purchasing power parity","BEL","Belgium","2010","2010",299.2,,
+"PATCSKEL","M-Musculo-skeletal system","MTMOPPMT","Million US$, purchasing power parity","BEL","Belgium","2011","2011",301.5,,
+"PATCSKEL","M-Musculo-skeletal system","MTMOPPMT","Million US$, purchasing power parity","BEL","Belgium","2012","2012",303.7,,
+"PATCSKEL","M-Musculo-skeletal system","MTMOPPMT","Million US$, purchasing power parity","BEL","Belgium","2013","2013",312.5,,
+"PATCSKEL","M-Musculo-skeletal system","MTMOPPMT","Million US$, purchasing power parity","BEL","Belgium","2014","2014",318.5,,
+"PATCSKEL","M-Musculo-skeletal system","MTMOPPMT","Million US$, purchasing power parity","BEL","Belgium","2015","2015",320.4,,
+"PATCSKEL","M-Musculo-skeletal system","MTMOPPMT","Million US$, purchasing power parity","BEL","Belgium","2016","2016",325.6,,
+"PATCSKEL","M-Musculo-skeletal system","MTMOPPMT","Million US$, purchasing power parity","BEL","Belgium","2017","2017",319.3,,
+"PATCSKEL","M-Musculo-skeletal system","MTMOPPMT","Million US$, purchasing power parity","BEL","Belgium","2018","2018",308.9,,
+"PATCSKEL","M-Musculo-skeletal system","MTMOPPMT","Million US$, purchasing power parity","BEL","Belgium","2019","2019",339.6,,
+"PATCSKEL","M-Musculo-skeletal system","MTMOPPMT","Million US$, purchasing power parity","BEL","Belgium","2020","2020",316.9,,
+"PATCSKEL","M-Musculo-skeletal system","MTMOPPMT","Million US$, purchasing power parity","BEL","Belgium","2021","2021",296.6,,
+"PATCSKEL","M-Musculo-skeletal system","MTMOPPMT","Million US$, purchasing power parity","BEL","Belgium","2022","2022",339.7,"E","Estimated value"
+"PATCSKEL","M-Musculo-skeletal system","TCPPERMT","/capita, US$ exchange rate","BEL","Belgium","2010","2010",30.5,,
+"PATCSKEL","M-Musculo-skeletal system","TCPPERMT","/capita, US$ exchange rate","BEL","Belgium","2011","2011",31.6,,
+"PATCSKEL","M-Musculo-skeletal system","TCPPERMT","/capita, US$ exchange rate","BEL","Belgium","2012","2012",28.9,,
+"PATCSKEL","M-Musculo-skeletal system","TCPPERMT","/capita, US$ exchange rate","BEL","Belgium","2013","2013",30,,
+"PATCSKEL","M-Musculo-skeletal system","TCPPERMT","/capita, US$ exchange rate","BEL","Belgium","2014","2014",30.2,,
+"PATCSKEL","M-Musculo-skeletal system","TCPPERMT","/capita, US$ exchange rate","BEL","Belgium","2015","2015",25.2,,
+"PATCSKEL","M-Musculo-skeletal system","TCPPERMT","/capita, US$ exchange rate","BEL","Belgium","2016","2016",24.8,,
+"PATCSKEL","M-Musculo-skeletal system","TCPPERMT","/capita, US$ exchange rate","BEL","Belgium","2017","2017",24.6,,
+"PATCSKEL","M-Musculo-skeletal system","TCPPERMT","/capita, US$ exchange rate","BEL","Belgium","2018","2018",24.5,,
+"PATCSKEL","M-Musculo-skeletal system","TCPPERMT","/capita, US$ exchange rate","BEL","Belgium","2019","2019",24.7,,
+"PATCSKEL","M-Musculo-skeletal system","TCPPERMT","/capita, US$ exchange rate","BEL","Belgium","2020","2020",22.9,,
+"PATCSKEL","M-Musculo-skeletal system","TCPPERMT","/capita, US$ exchange rate","BEL","Belgium","2021","2021",22.3,,
+"PATCSKEL","M-Musculo-skeletal system","TCPPERMT","/capita, US$ exchange rate","BEL","Belgium","2022","2022",22,"E","Estimated value"
+"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2010","2010",27.5,,
+"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2011","2011",27.3,,
+"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2012","2012",27.3,,
+"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2013","2013",28,,
+"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2014","2014",28.4,,
+"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2015","2015",28.4,,
+"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2016","2016",28.7,,
+"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2017","2017",28.1,,
+"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2018","2018",27,,
+"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2019","2019",29.6,,
+"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2020","2020",27.5,,
+"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2021","2021",25.6,,
+"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2022","2022",29.2,"E","Estimated value"
+"PATCSKEL","M-Musculo-skeletal system","ATCPTTMT","% of total sales","BEL","Belgium","2010","2010",4.3,,
+"PATCSKEL","M-Musculo-skeletal system","ATCPTTMT","% of total sales","BEL","Belgium","2011","2011",4.2,,
+"PATCSKEL","M-Musculo-skeletal system","ATCPTTMT","% of total sales","BEL","Belgium","2012","2012",4.2,,
+"PATCSKEL","M-Musculo-skeletal system","ATCPTTMT","% of total sales","BEL","Belgium","2013","2013",4.2,,
+"PATCSKEL","M-Musculo-skeletal system","ATCPTTMT","% of total sales","BEL","Belgium","2014","2014",4.3,,
+"PATCSKEL","M-Musculo-skeletal system","ATCPTTMT","% of total sales","BEL","Belgium","2015","2015",4.1,,
+"PATCSKEL","M-Musculo-skeletal system","ATCPTTMT","% of total sales","BEL","Belgium","2016","2016",4.1,,
+"PATCSKEL","M-Musculo-skeletal system","ATCPTTMT","% of total sales","BEL","Belgium","2017","2017",3.8,,
+"PATCSKEL","M-Musculo-skeletal system","ATCPTTMT","% of total sales","BEL","Belgium","2018","2018",3.5,,
+"PATCSKEL","M-Musculo-skeletal system","ATCPTTMT","% of total sales","BEL","Belgium","2019","2019",3.4,,
+"PATCSKEL","M-Musculo-skeletal system","ATCPTTMT","% of total sales","BEL","Belgium","2020","2020",3,,
+"PATCSKEL","M-Musculo-skeletal system","ATCPTTMT","% of total sales","BEL","Belgium","2021","2021",2.7,,
+"PATCSKEL","M-Musculo-skeletal system","ATCPTTMT","% of total sales","BEL","Belgium","2022","2022",2.7,"E","Estimated value"
+"PATCSKEL","M-Musculo-skeletal system","MLLNCUMT","Million of national currency units","CAN","Canada","2012","2012",980.8,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","MLLNCUMT","Million of national currency units","CAN","Canada","2013","2013",989.4,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","MLLNCUMT","Million of national currency units","CAN","Canada","2014","2014",988,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","MLLNCUMT","Million of national currency units","CAN","Canada","2015","2015",907,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","MLLNCUMT","Million of national currency units","CAN","Canada","2016","2016",910.8,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","MLLNCUMT","Million of national currency units","CAN","Canada","2017","2017",929.4,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","MLLNCUMT","Million of national currency units","CAN","Canada","2018","2018",978,"E; B; D","Estimated value; Break; Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","MLLNCUMT","Million of national currency units","CAN","Canada","2019","2019",1061.5,"E; D","Estimated value; Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","MLLNCUMT","Million of national currency units","CAN","Canada","2020","2020",1060.8,"E; D","Estimated value; Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","MLLNCUMT","Million of national currency units","CAN","Canada","2021","2021",1182.8,"E; D","Estimated value; Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","MLLNCUMT","Million of national currency units","CAN","Canada","2022","2022",1176.3,"E; D","Estimated value; Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","MTMOTCMT","Million US$ at exchange rate","CAN","Canada","2012","2012",981.4,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","MTMOTCMT","Million US$ at exchange rate","CAN","Canada","2013","2013",960.5,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","MTMOTCMT","Million US$ at exchange rate","CAN","Canada","2014","2014",894.3,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","MTMOTCMT","Million US$ at exchange rate","CAN","Canada","2015","2015",709.3,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","MTMOTCMT","Million US$ at exchange rate","CAN","Canada","2016","2016",687.1,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","MTMOTCMT","Million US$ at exchange rate","CAN","Canada","2017","2017",716.1,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","MTMOTCMT","Million US$ at exchange rate","CAN","Canada","2018","2018",754.8,"E; B; D","Estimated value; Break; Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","MTMOTCMT","Million US$ at exchange rate","CAN","Canada","2019","2019",800,"E; D","Estimated value; Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","MTMOTCMT","Million US$ at exchange rate","CAN","Canada","2020","2020",791,"E; D","Estimated value; Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","MTMOTCMT","Million US$ at exchange rate","CAN","Canada","2021","2021",943.3,"E; D","Estimated value; Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","MTMOTCMT","Million US$ at exchange rate","CAN","Canada","2022","2022",903.8,"E; D","Estimated value; Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","MTMOPPMT","Million US$, purchasing power parity","CAN","Canada","2012","2012",788,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","MTMOPPMT","Million US$, purchasing power parity","CAN","Canada","2013","2013",808.3,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","MTMOPPMT","Million US$, purchasing power parity","CAN","Canada","2014","2014",803,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","MTMOPPMT","Million US$, purchasing power parity","CAN","Canada","2015","2015",726.7,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","MTMOPPMT","Million US$, purchasing power parity","CAN","Canada","2016","2016",754.6,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","MTMOPPMT","Million US$, purchasing power parity","CAN","Canada","2017","2017",766.6,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","MTMOPPMT","Million US$, purchasing power parity","CAN","Canada","2018","2018",810.6,"E; B; D","Estimated value; Break; Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","MTMOPPMT","Million US$, purchasing power parity","CAN","Canada","2019","2019",859.7,"E; D","Estimated value; Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","MTMOPPMT","Million US$, purchasing power parity","CAN","Canada","2020","2020",861.7,"E; D","Estimated value; Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","MTMOPPMT","Million US$, purchasing power parity","CAN","Canada","2021","2021",955.3,"E; D","Estimated value; Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","MTMOPPMT","Million US$, purchasing power parity","CAN","Canada","2022","2022",938.2,"E; D","Estimated value; Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","TCPPERMT","/capita, US$ exchange rate","CAN","Canada","2012","2012",28.3,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","TCPPERMT","/capita, US$ exchange rate","CAN","Canada","2013","2013",27.4,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","TCPPERMT","/capita, US$ exchange rate","CAN","Canada","2014","2014",25.2,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","TCPPERMT","/capita, US$ exchange rate","CAN","Canada","2015","2015",19.9,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","TCPPERMT","/capita, US$ exchange rate","CAN","Canada","2016","2016",19,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","TCPPERMT","/capita, US$ exchange rate","CAN","Canada","2017","2017",19.6,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","TCPPERMT","/capita, US$ exchange rate","CAN","Canada","2018","2018",20.4,"E; B; D","Estimated value; Break; Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","TCPPERMT","/capita, US$ exchange rate","CAN","Canada","2019","2019",21.3,"E; D","Estimated value; Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","TCPPERMT","/capita, US$ exchange rate","CAN","Canada","2020","2020",20.8,"E; D","Estimated value; Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","TCPPERMT","/capita, US$ exchange rate","CAN","Canada","2021","2021",24.7,"E; D","Estimated value; Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","TCPPERMT","/capita, US$ exchange rate","CAN","Canada","2022","2022",23.2,"E; D","Estimated value; Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2012","2012",22.7,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2013","2013",23,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2014","2014",22.7,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2015","2015",20.4,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2016","2016",20.9,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2017","2017",21,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2018","2018",21.9,"E; B; D","Estimated value; Break; Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2019","2019",22.9,"E; D","Estimated value; Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2020","2020",22.7,"E; D","Estimated value; Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2021","2021",25,"E; D","Estimated value; Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2022","2022",24.1,"E; D","Estimated value; Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","ATCPTTMT","% of total sales","CAN","Canada","2012","2012",4,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","ATCPTTMT","% of total sales","CAN","Canada","2013","2013",4,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","ATCPTTMT","% of total sales","CAN","Canada","2014","2014",3.9,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","ATCPTTMT","% of total sales","CAN","Canada","2015","2015",3.3,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","ATCPTTMT","% of total sales","CAN","Canada","2016","2016",3.2,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","ATCPTTMT","% of total sales","CAN","Canada","2017","2017",3.1,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","ATCPTTMT","% of total sales","CAN","Canada","2018","2018",3.2,"E; B; D","Estimated value; Break; Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","ATCPTTMT","% of total sales","CAN","Canada","2019","2019",3.3,"E; D","Estimated value; Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","ATCPTTMT","% of total sales","CAN","Canada","2020","2020",3.1,"E; D","Estimated value; Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","ATCPTTMT","% of total sales","CAN","Canada","2021","2021",3.2,"E; D","Estimated value; Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","ATCPTTMT","% of total sales","CAN","Canada","2022","2022",2.9,"E; D","Estimated value; Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","MLLNCUMT","Million of national currency units","CZE","Czech Republic","2010","2010",4066.7,,
+"PATCSKEL","M-Musculo-skeletal system","MLLNCUMT","Million of national currency units","CZE","Czech Republic","2011","2011",3994.3,,
+"PATCSKEL","M-Musculo-skeletal system","MLLNCUMT","Million of national currency units","CZE","Czech Republic","2012","2012",4113.7,,
+"PATCSKEL","M-Musculo-skeletal system","MLLNCUMT","Million of national currency units","CZE","Czech Republic","2013","2013",4023.6,,
+"PATCSKEL","M-Musculo-skeletal system","MLLNCUMT","Million of national currency units","CZE","Czech Republic","2014","2014",4051.8,,
+"PATCSKEL","M-Musculo-skeletal system","MLLNCUMT","Million of national currency units","CZE","Czech Republic","2015","2015",3999.4,,
+"PATCSKEL","M-Musculo-skeletal system","MLLNCUMT","Million of national currency units","CZE","Czech Republic","2016","2016",4145.5,,
+"PATCSKEL","M-Musculo-skeletal system","MLLNCUMT","Million of national currency units","CZE","Czech Republic","2017","2017",4340.3,,
+"PATCSKEL","M-Musculo-skeletal system","MLLNCUMT","Million of national currency units","CZE","Czech Republic","2018","2018",5176.4,,
+"PATCSKEL","M-Musculo-skeletal system","MLLNCUMT","Million of national currency units","CZE","Czech Republic","2019","2019",5269.6,,
+"PATCSKEL","M-Musculo-skeletal system","MLLNCUMT","Million of national currency units","CZE","Czech Republic","2020","2020",2204.5,"B","Break"
+"PATCSKEL","M-Musculo-skeletal system","MLLNCUMT","Million of national currency units","CZE","Czech Republic","2021","2021",2384.9,,
+"PATCSKEL","M-Musculo-skeletal system","MTMOTCMT","Million US$ at exchange rate","CZE","Czech Republic","2010","2010",212.9,,
+"PATCSKEL","M-Musculo-skeletal system","MTMOTCMT","Million US$ at exchange rate","CZE","Czech Republic","2011","2011",225.7,,
+"PATCSKEL","M-Musculo-skeletal system","MTMOTCMT","Million US$ at exchange rate","CZE","Czech Republic","2012","2012",210.1,,
+"PATCSKEL","M-Musculo-skeletal system","MTMOTCMT","Million US$ at exchange rate","CZE","Czech Republic","2013","2013",205.6,,
+"PATCSKEL","M-Musculo-skeletal system","MTMOTCMT","Million US$ at exchange rate","CZE","Czech Republic","2014","2014",195.2,,
+"PATCSKEL","M-Musculo-skeletal system","MTMOTCMT","Million US$ at exchange rate","CZE","Czech Republic","2015","2015",162.6,,
+"PATCSKEL","M-Musculo-skeletal system","MTMOTCMT","Million US$ at exchange rate","CZE","Czech Republic","2016","2016",169.6,,
+"PATCSKEL","M-Musculo-skeletal system","MTMOTCMT","Million US$ at exchange rate","CZE","Czech Republic","2017","2017",185.7,,
+"PATCSKEL","M-Musculo-skeletal system","MTMOTCMT","Million US$ at exchange rate","CZE","Czech Republic","2018","2018",238.2,,
+"PATCSKEL","M-Musculo-skeletal system","MTMOTCMT","Million US$ at exchange rate","CZE","Czech Republic","2019","2019",229.8,,
+"PATCSKEL","M-Musculo-skeletal system","MTMOTCMT","Million US$ at exchange rate","CZE","Czech Republic","2020","2020",95,"B","Break"
+"PATCSKEL","M-Musculo-skeletal system","MTMOTCMT","Million US$ at exchange rate","CZE","Czech Republic","2021","2021",110,,
+"PATCSKEL","M-Musculo-skeletal system","MTMOPPMT","Million US$, purchasing power parity","CZE","Czech Republic","2010","2010",297.4,,
+"PATCSKEL","M-Musculo-skeletal system","MTMOPPMT","Million US$, purchasing power parity","CZE","Czech Republic","2011","2011",299.3,,
+"PATCSKEL","M-Musculo-skeletal system","MTMOPPMT","Million US$, purchasing power parity","CZE","Czech Republic","2012","2012",309.4,,
+"PATCSKEL","M-Musculo-skeletal system","MTMOPPMT","Million US$, purchasing power parity","CZE","Czech Republic","2013","2013",314.7,,
+"PATCSKEL","M-Musculo-skeletal system","MTMOPPMT","Million US$, purchasing power parity","CZE","Czech Republic","2014","2014",319,,
+"PATCSKEL","M-Musculo-skeletal system","MTMOPPMT","Million US$, purchasing power parity","CZE","Czech Republic","2015","2015",309.1,,
+"PATCSKEL","M-Musculo-skeletal system","MTMOPPMT","Million US$, purchasing power parity","CZE","Czech Republic","2016","2016",329.6,,
+"PATCSKEL","M-Musculo-skeletal system","MTMOPPMT","Million US$, purchasing power parity","CZE","Czech Republic","2017","2017",349.3,,
+"PATCSKEL","M-Musculo-skeletal system","MTMOPPMT","Million US$, purchasing power parity","CZE","Czech Republic","2018","2018",418.4,,
+"PATCSKEL","M-Musculo-skeletal system","MTMOPPMT","Million US$, purchasing power parity","CZE","Czech Republic","2019","2019",429.3,,
+"PATCSKEL","M-Musculo-skeletal system","MTMOPPMT","Million US$, purchasing power parity","CZE","Czech Republic","2020","2020",176.9,"B","Break"
+"PATCSKEL","M-Musculo-skeletal system","MTMOPPMT","Million US$, purchasing power parity","CZE","Czech Republic","2021","2021",187.2,,
+"PATCSKEL","M-Musculo-skeletal system","TCPPERMT","/capita, US$ exchange rate","CZE","Czech Republic","2010","2010",20.3,,
+"PATCSKEL","M-Musculo-skeletal system","TCPPERMT","/capita, US$ exchange rate","CZE","Czech Republic","2011","2011",21.5,,
+"PATCSKEL","M-Musculo-skeletal system","TCPPERMT","/capita, US$ exchange rate","CZE","Czech Republic","2012","2012",20,,
+"PATCSKEL","M-Musculo-skeletal system","TCPPERMT","/capita, US$ exchange rate","CZE","Czech Republic","2013","2013",19.6,,
+"PATCSKEL","M-Musculo-skeletal system","TCPPERMT","/capita, US$ exchange rate","CZE","Czech Republic","2014","2014",18.5,,
+"PATCSKEL","M-Musculo-skeletal system","TCPPERMT","/capita, US$ exchange rate","CZE","Czech Republic","2015","2015",15.4,,
+"PATCSKEL","M-Musculo-skeletal system","TCPPERMT","/capita, US$ exchange rate","CZE","Czech Republic","2016","2016",16.1,,
+"PATCSKEL","M-Musculo-skeletal system","TCPPERMT","/capita, US$ exchange rate","CZE","Czech Republic","2017","2017",17.5,,
+"PATCSKEL","M-Musculo-skeletal system","TCPPERMT","/capita, US$ exchange rate","CZE","Czech Republic","2018","2018",22.4,,
+"PATCSKEL","M-Musculo-skeletal system","TCPPERMT","/capita, US$ exchange rate","CZE","Czech Republic","2019","2019",21.5,,
+"PATCSKEL","M-Musculo-skeletal system","TCPPERMT","/capita, US$ exchange rate","CZE","Czech Republic","2020","2020",8.9,"B","Break"
+"PATCSKEL","M-Musculo-skeletal system","TCPPERMT","/capita, US$ exchange rate","CZE","Czech Republic","2021","2021",10.5,,
+"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czech Republic","2010","2010",28.4,,
+"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czech Republic","2011","2011",28.5,,
+"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czech Republic","2012","2012",29.4,,
+"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czech Republic","2013","2013",29.9,,
+"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czech Republic","2014","2014",30.3,,
+"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czech Republic","2015","2015",29.3,,
+"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czech Republic","2016","2016",31.2,,
+"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czech Republic","2017","2017",33,,
+"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czech Republic","2018","2018",39.4,,
+"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czech Republic","2019","2019",40.2,,
+"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czech Republic","2020","2020",16.5,"B","Break"
+"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czech Republic","2021","2021",17.8,,
+"PATCSKEL","M-Musculo-skeletal system","ATCPTTMT","% of total sales","CZE","Czech Republic","2010","2010",5,,
+"PATCSKEL","M-Musculo-skeletal system","ATCPTTMT","% of total sales","CZE","Czech Republic","2011","2011",4.9,,
+"PATCSKEL","M-Musculo-skeletal system","ATCPTTMT","% of total sales","CZE","Czech Republic","2012","2012",4.9,,
+"PATCSKEL","M-Musculo-skeletal system","ATCPTTMT","% of total sales","CZE","Czech Republic","2013","2013",5,,
+"PATCSKEL","M-Musculo-skeletal system","ATCPTTMT","% of total sales","CZE","Czech Republic","2014","2014",5,,
+"PATCSKEL","M-Musculo-skeletal system","ATCPTTMT","% of total sales","CZE","Czech Republic","2015","2015",4.7,,
+"PATCSKEL","M-Musculo-skeletal system","ATCPTTMT","% of total sales","CZE","Czech Republic","2016","2016",4.8,,
+"PATCSKEL","M-Musculo-skeletal system","ATCPTTMT","% of total sales","CZE","Czech Republic","2017","2017",4.7,,
+"PATCSKEL","M-Musculo-skeletal system","ATCPTTMT","% of total sales","CZE","Czech Republic","2018","2018",5.3,,
+"PATCSKEL","M-Musculo-skeletal system","ATCPTTMT","% of total sales","CZE","Czech Republic","2019","2019",5.1,,
+"PATCSKEL","M-Musculo-skeletal system","ATCPTTMT","% of total sales","CZE","Czech Republic","2020","2020",2.5,"B","Break"
+"PATCSKEL","M-Musculo-skeletal system","ATCPTTMT","% of total sales","CZE","Czech Republic","2021","2021",2.6,,
+"PATCSKEL","M-Musculo-skeletal system","MLLNCUMT","Million of national currency units","DNK","Denmark","2010","2010",618.3,,
+"PATCSKEL","M-Musculo-skeletal system","MLLNCUMT","Million of national currency units","DNK","Denmark","2011","2011",646,,
+"PATCSKEL","M-Musculo-skeletal system","MLLNCUMT","Million of national currency units","DNK","Denmark","2012","2012",543.8,,
+"PATCSKEL","M-Musculo-skeletal system","MLLNCUMT","Million of national currency units","DNK","Denmark","2013","2013",551.8,,
+"PATCSKEL","M-Musculo-skeletal system","MLLNCUMT","Million of national currency units","DNK","Denmark","2014","2014",534.2,,
+"PATCSKEL","M-Musculo-skeletal system","MLLNCUMT","Million of national currency units","DNK","Denmark","2015","2015",578.9,,
+"PATCSKEL","M-Musculo-skeletal system","MLLNCUMT","Million of national currency units","DNK","Denmark","2016","2016",593.4,,
+"PATCSKEL","M-Musculo-skeletal system","MLLNCUMT","Million of national currency units","DNK","Denmark","2017","2017",598.1,,
+"PATCSKEL","M-Musculo-skeletal system","MLLNCUMT","Million of national currency units","DNK","Denmark","2018","2018",630.3,,
+"PATCSKEL","M-Musculo-skeletal system","MLLNCUMT","Million of national currency units","DNK","Denmark","2019","2019",713.4,,
+"PATCSKEL","M-Musculo-skeletal system","MLLNCUMT","Million of national currency units","DNK","Denmark","2020","2020",667.5,,
+"PATCSKEL","M-Musculo-skeletal system","MLLNCUMT","Million of national currency units","DNK","Denmark","2021","2021",610,,
+"PATCSKEL","M-Musculo-skeletal system","MTMOTCMT","Million US$ at exchange rate","DNK","Denmark","2010","2010",109.9,,
+"PATCSKEL","M-Musculo-skeletal system","MTMOTCMT","Million US$ at exchange rate","DNK","Denmark","2011","2011",120.3,,
+"PATCSKEL","M-Musculo-skeletal system","MTMOTCMT","Million US$ at exchange rate","DNK","Denmark","2012","2012",93.9,,
+"PATCSKEL","M-Musculo-skeletal system","MTMOTCMT","Million US$ at exchange rate","DNK","Denmark","2013","2013",98.2,,
+"PATCSKEL","M-Musculo-skeletal system","MTMOTCMT","Million US$ at exchange rate","DNK","Denmark","2014","2014",95.2,,
+"PATCSKEL","M-Musculo-skeletal system","MTMOTCMT","Million US$ at exchange rate","DNK","Denmark","2015","2015",86,,
+"PATCSKEL","M-Musculo-skeletal system","MTMOTCMT","Million US$ at exchange rate","DNK","Denmark","2016","2016",88.1,,
+"PATCSKEL","M-Musculo-skeletal system","MTMOTCMT","Million US$ at exchange rate","DNK","Denmark","2017","2017",90.6,,
+"PATCSKEL","M-Musculo-skeletal system","MTMOTCMT","Million US$ at exchange rate","DNK","Denmark","2018","2018",99.8,,
+"PATCSKEL","M-Musculo-skeletal system","MTMOTCMT","Million US$ at exchange rate","DNK","Denmark","2019","2019",107,,
+"PATCSKEL","M-Musculo-skeletal system","MTMOTCMT","Million US$ at exchange rate","DNK","Denmark","2020","2020",102,,
+"PATCSKEL","M-Musculo-skeletal system","MTMOTCMT","Million US$ at exchange rate","DNK","Denmark","2021","2021",97,,
+"PATCSKEL","M-Musculo-skeletal system","MTMOPPMT","Million US$, purchasing power parity","DNK","Denmark","2010","2010",81.5,,
+"PATCSKEL","M-Musculo-skeletal system","MTMOPPMT","Million US$, purchasing power parity","DNK","Denmark","2011","2011",86.5,,
+"PATCSKEL","M-Musculo-skeletal system","MTMOPPMT","Million US$, purchasing power parity","DNK","Denmark","2012","2012",71.9,,
+"PATCSKEL","M-Musculo-skeletal system","MTMOPPMT","Million US$, purchasing power parity","DNK","Denmark","2013","2013",75,,
+"PATCSKEL","M-Musculo-skeletal system","MTMOPPMT","Million US$, purchasing power parity","DNK","Denmark","2014","2014",72.9,,
+"PATCSKEL","M-Musculo-skeletal system","MTMOPPMT","Million US$, purchasing power parity","DNK","Denmark","2015","2015",79.2,,
+"PATCSKEL","M-Musculo-skeletal system","MTMOPPMT","Million US$, purchasing power parity","DNK","Denmark","2016","2016",83.8,,
+"PATCSKEL","M-Musculo-skeletal system","MTMOPPMT","Million US$, purchasing power parity","DNK","Denmark","2017","2017",87,,
+"PATCSKEL","M-Musculo-skeletal system","MTMOPPMT","Million US$, purchasing power parity","DNK","Denmark","2018","2018",93.2,,
+"PATCSKEL","M-Musculo-skeletal system","MTMOPPMT","Million US$, purchasing power parity","DNK","Denmark","2019","2019",107.5,,
+"PATCSKEL","M-Musculo-skeletal system","MTMOPPMT","Million US$, purchasing power parity","DNK","Denmark","2020","2020",101.9,,
+"PATCSKEL","M-Musculo-skeletal system","MTMOPPMT","Million US$, purchasing power parity","DNK","Denmark","2021","2021",92.6,,
+"PATCSKEL","M-Musculo-skeletal system","TCPPERMT","/capita, US$ exchange rate","DNK","Denmark","2010","2010",19.8,,
+"PATCSKEL","M-Musculo-skeletal system","TCPPERMT","/capita, US$ exchange rate","DNK","Denmark","2011","2011",21.6,,
+"PATCSKEL","M-Musculo-skeletal system","TCPPERMT","/capita, US$ exchange rate","DNK","Denmark","2012","2012",16.8,,
+"PATCSKEL","M-Musculo-skeletal system","TCPPERMT","/capita, US$ exchange rate","DNK","Denmark","2013","2013",17.5,,
+"PATCSKEL","M-Musculo-skeletal system","TCPPERMT","/capita, US$ exchange rate","DNK","Denmark","2014","2014",16.9,,
+"PATCSKEL","M-Musculo-skeletal system","TCPPERMT","/capita, US$ exchange rate","DNK","Denmark","2015","2015",15.1,,
+"PATCSKEL","M-Musculo-skeletal system","TCPPERMT","/capita, US$ exchange rate","DNK","Denmark","2016","2016",15.4,,
+"PATCSKEL","M-Musculo-skeletal system","TCPPERMT","/capita, US$ exchange rate","DNK","Denmark","2017","2017",15.7,,
+"PATCSKEL","M-Musculo-skeletal system","TCPPERMT","/capita, US$ exchange rate","DNK","Denmark","2018","2018",17.2,,
+"PATCSKEL","M-Musculo-skeletal system","TCPPERMT","/capita, US$ exchange rate","DNK","Denmark","2019","2019",18.4,,
+"PATCSKEL","M-Musculo-skeletal system","TCPPERMT","/capita, US$ exchange rate","DNK","Denmark","2020","2020",17.5,,
+"PATCSKEL","M-Musculo-skeletal system","TCPPERMT","/capita, US$ exchange rate","DNK","Denmark","2021","2021",16.6,,
+"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","DNK","Denmark","2010","2010",14.7,,
+"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","DNK","Denmark","2011","2011",15.5,,
+"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","DNK","Denmark","2012","2012",12.9,,
+"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","DNK","Denmark","2013","2013",13.4,,
+"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","DNK","Denmark","2014","2014",12.9,,
+"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","DNK","Denmark","2015","2015",13.9,,
+"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","DNK","Denmark","2016","2016",14.6,,
+"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","DNK","Denmark","2017","2017",15.1,,
+"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","DNK","Denmark","2018","2018",16.1,,
+"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","DNK","Denmark","2019","2019",18.5,,
+"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","DNK","Denmark","2020","2020",17.5,,
+"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","DNK","Denmark","2021","2021",15.8,,
+"PATCSKEL","M-Musculo-skeletal system","ATCPTTMT","% of total sales","DNK","Denmark","2010","2010",2.9,,
+"PATCSKEL","M-Musculo-skeletal system","ATCPTTMT","% of total sales","DNK","Denmark","2011","2011",3.1,,
+"PATCSKEL","M-Musculo-skeletal system","ATCPTTMT","% of total sales","DNK","Denmark","2012","2012",2.7,,
+"PATCSKEL","M-Musculo-skeletal system","ATCPTTMT","% of total sales","DNK","Denmark","2013","2013",2.7,,
+"PATCSKEL","M-Musculo-skeletal system","ATCPTTMT","% of total sales","DNK","Denmark","2014","2014",2.5,,
+"PATCSKEL","M-Musculo-skeletal system","ATCPTTMT","% of total sales","DNK","Denmark","2015","2015",2.6,,
+"PATCSKEL","M-Musculo-skeletal system","ATCPTTMT","% of total sales","DNK","Denmark","2016","2016",2.7,,
+"PATCSKEL","M-Musculo-skeletal system","ATCPTTMT","% of total sales","DNK","Denmark","2017","2017",2.6,,
+"PATCSKEL","M-Musculo-skeletal system","ATCPTTMT","% of total sales","DNK","Denmark","2018","2018",2.6,,
+"PATCSKEL","M-Musculo-skeletal system","ATCPTTMT","% of total sales","DNK","Denmark","2019","2019",2.9,,
+"PATCSKEL","M-Musculo-skeletal system","ATCPTTMT","% of total sales","DNK","Denmark","2020","2020",2.6,,
+"PATCSKEL","M-Musculo-skeletal system","ATCPTTMT","% of total sales","DNK","Denmark","2021","2021",2.4,,
+"PATCSKEL","M-Musculo-skeletal system","MLLNCUMT","Million of national currency units","FIN","Finland","2010","2010",91,,
+"PATCSKEL","M-Musculo-skeletal system","MLLNCUMT","Million of national currency units","FIN","Finland","2011","2011",91,,
+"PATCSKEL","M-Musculo-skeletal system","MLLNCUMT","Million of national currency units","FIN","Finland","2012","2012",96.1,,
+"PATCSKEL","M-Musculo-skeletal system","MLLNCUMT","Million of national currency units","FIN","Finland","2013","2013",96.7,,
+"PATCSKEL","M-Musculo-skeletal system","MLLNCUMT","Million of national currency units","FIN","Finland","2014","2014",98.9,,
+"PATCSKEL","M-Musculo-skeletal system","MLLNCUMT","Million of national currency units","FIN","Finland","2015","2015",98.2,,
+"PATCSKEL","M-Musculo-skeletal system","MLLNCUMT","Million of national currency units","FIN","Finland","2016","2016",97.8,,
+"PATCSKEL","M-Musculo-skeletal system","MLLNCUMT","Million of national currency units","FIN","Finland","2017","2017",96.1,,
+"PATCSKEL","M-Musculo-skeletal system","MLLNCUMT","Million of national currency units","FIN","Finland","2018","2018",101.9,,
+"PATCSKEL","M-Musculo-skeletal system","MLLNCUMT","Million of national currency units","FIN","Finland","2019","2019",102.4,,
+"PATCSKEL","M-Musculo-skeletal system","MLLNCUMT","Million of national currency units","FIN","Finland","2020","2020",97.8,,
+"PATCSKEL","M-Musculo-skeletal system","MLLNCUMT","Million of national currency units","FIN","Finland","2021","2021",99.6,,
+"PATCSKEL","M-Musculo-skeletal system","MTMOTCMT","Million US$ at exchange rate","FIN","Finland","2010","2010",120.6,,
+"PATCSKEL","M-Musculo-skeletal system","MTMOTCMT","Million US$ at exchange rate","FIN","Finland","2011","2011",126.7,,
+"PATCSKEL","M-Musculo-skeletal system","MTMOTCMT","Million US$ at exchange rate","FIN","Finland","2012","2012",123.5,,
+"PATCSKEL","M-Musculo-skeletal system","MTMOTCMT","Million US$ at exchange rate","FIN","Finland","2013","2013",128.4,,
+"PATCSKEL","M-Musculo-skeletal system","MTMOTCMT","Million US$ at exchange rate","FIN","Finland","2014","2014",131.4,,
+"PATCSKEL","M-Musculo-skeletal system","MTMOTCMT","Million US$ at exchange rate","FIN","Finland","2015","2015",109,,
+"PATCSKEL","M-Musculo-skeletal system","MTMOTCMT","Million US$ at exchange rate","FIN","Finland","2016","2016",108.3,,
+"PATCSKEL","M-Musculo-skeletal system","MTMOTCMT","Million US$ at exchange rate","FIN","Finland","2017","2017",108.6,,
+"PATCSKEL","M-Musculo-skeletal system","MTMOTCMT","Million US$ at exchange rate","FIN","Finland","2018","2018",120.3,,
+"PATCSKEL","M-Musculo-skeletal system","MTMOTCMT","Million US$ at exchange rate","FIN","Finland","2019","2019",114.6,,
+"PATCSKEL","M-Musculo-skeletal system","MTMOTCMT","Million US$ at exchange rate","FIN","Finland","2020","2020",111.7,,
+"PATCSKEL","M-Musculo-skeletal system","MTMOTCMT","Million US$ at exchange rate","FIN","Finland","2021","2021",117.8,,
+"PATCSKEL","M-Musculo-skeletal system","MTMOPPMT","Million US$, purchasing power parity","FIN","Finland","2010","2010",101.1,,
+"PATCSKEL","M-Musculo-skeletal system","MTMOPPMT","Million US$, purchasing power parity","FIN","Finland","2011","2011",101.3,,
+"PATCSKEL","M-Musculo-skeletal system","MTMOPPMT","Million US$, purchasing power parity","FIN","Finland","2012","2012",105.8,,
+"PATCSKEL","M-Musculo-skeletal system","MTMOPPMT","Million US$, purchasing power parity","FIN","Finland","2013","2013",106.8,,
+"PATCSKEL","M-Musculo-skeletal system","MTMOPPMT","Million US$, purchasing power parity","FIN","Finland","2014","2014",109,,
+"PATCSKEL","M-Musculo-skeletal system","MTMOPPMT","Million US$, purchasing power parity","FIN","Finland","2015","2015",108.2,,
+"PATCSKEL","M-Musculo-skeletal system","MTMOPPMT","Million US$, purchasing power parity","FIN","Finland","2016","2016",111,,
+"PATCSKEL","M-Musculo-skeletal system","MTMOPPMT","Million US$, purchasing power parity","FIN","Finland","2017","2017",111.3,,
+"PATCSKEL","M-Musculo-skeletal system","MTMOPPMT","Million US$, purchasing power parity","FIN","Finland","2018","2018",119.4,,
+"PATCSKEL","M-Musculo-skeletal system","MTMOPPMT","Million US$, purchasing power parity","FIN","Finland","2019","2019",122.1,,
+"PATCSKEL","M-Musculo-skeletal system","MTMOPPMT","Million US$, purchasing power parity","FIN","Finland","2020","2020",118.8,,
+"PATCSKEL","M-Musculo-skeletal system","MTMOPPMT","Million US$, purchasing power parity","FIN","Finland","2021","2021",120.5,,
+"PATCSKEL","M-Musculo-skeletal system","TCPPERMT","/capita, US$ exchange rate","FIN","Finland","2010","2010",22.5,,
+"PATCSKEL","M-Musculo-skeletal system","TCPPERMT","/capita, US$ exchange rate","FIN","Finland","2011","2011",23.5,,
+"PATCSKEL","M-Musculo-skeletal system","TCPPERMT","/capita, US$ exchange rate","FIN","Finland","2012","2012",22.8,,
+"PATCSKEL","M-Musculo-skeletal system","TCPPERMT","/capita, US$ exchange rate","FIN","Finland","2013","2013",23.6,,
+"PATCSKEL","M-Musculo-skeletal system","TCPPERMT","/capita, US$ exchange rate","FIN","Finland","2014","2014",24.1,,
+"PATCSKEL","M-Musculo-skeletal system","TCPPERMT","/capita, US$ exchange rate","FIN","Finland","2015","2015",19.9,,
+"PATCSKEL","M-Musculo-skeletal system","TCPPERMT","/capita, US$ exchange rate","FIN","Finland","2016","2016",19.7,,
+"PATCSKEL","M-Musculo-skeletal system","TCPPERMT","/capita, US$ exchange rate","FIN","Finland","2017","2017",19.7,,
+"PATCSKEL","M-Musculo-skeletal system","TCPPERMT","/capita, US$ exchange rate","FIN","Finland","2018","2018",21.8,,
+"PATCSKEL","M-Musculo-skeletal system","TCPPERMT","/capita, US$ exchange rate","FIN","Finland","2019","2019",20.8,,
+"PATCSKEL","M-Musculo-skeletal system","TCPPERMT","/capita, US$ exchange rate","FIN","Finland","2020","2020",20.2,,
+"PATCSKEL","M-Musculo-skeletal system","TCPPERMT","/capita, US$ exchange rate","FIN","Finland","2021","2021",21.3,,
+"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2010","2010",18.8,,
+"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2011","2011",18.8,,
+"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2012","2012",19.5,,
+"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2013","2013",19.6,,
+"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2014","2014",20,,
+"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2015","2015",19.7,,
+"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2016","2016",20.2,,
+"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2017","2017",20.2,,
+"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2018","2018",21.6,,
+"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2019","2019",22.1,,
+"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2020","2020",21.5,,
+"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2021","2021",21.7,,
+"PATCSKEL","M-Musculo-skeletal system","ATCPTTMT","% of total sales","FIN","Finland","2010","2010",4.8,,
+"PATCSKEL","M-Musculo-skeletal system","ATCPTTMT","% of total sales","FIN","Finland","2011","2011",4.7,,
+"PATCSKEL","M-Musculo-skeletal system","ATCPTTMT","% of total sales","FIN","Finland","2012","2012",4.9,,
+"PATCSKEL","M-Musculo-skeletal system","ATCPTTMT","% of total sales","FIN","Finland","2013","2013",4.8,,
+"PATCSKEL","M-Musculo-skeletal system","ATCPTTMT","% of total sales","FIN","Finland","2014","2014",4.7,,
+"PATCSKEL","M-Musculo-skeletal system","ATCPTTMT","% of total sales","FIN","Finland","2015","2015",4.5,,
+"PATCSKEL","M-Musculo-skeletal system","ATCPTTMT","% of total sales","FIN","Finland","2016","2016",4.3,,
+"PATCSKEL","M-Musculo-skeletal system","ATCPTTMT","% of total sales","FIN","Finland","2017","2017",4.2,,
+"PATCSKEL","M-Musculo-skeletal system","ATCPTTMT","% of total sales","FIN","Finland","2018","2018",4.1,,
+"PATCSKEL","M-Musculo-skeletal system","ATCPTTMT","% of total sales","FIN","Finland","2019","2019",3.9,,
+"PATCSKEL","M-Musculo-skeletal system","ATCPTTMT","% of total sales","FIN","Finland","2020","2020",3.6,,
+"PATCSKEL","M-Musculo-skeletal system","ATCPTTMT","% of total sales","FIN","Finland","2021","2021",3.5,,
+"PATCSKEL","M-Musculo-skeletal system","MLLNCUMT","Million of national currency units","FRA","France","2011","2011",934.8,,
+"PATCSKEL","M-Musculo-skeletal system","MTMOTCMT","Million US$ at exchange rate","FRA","France","2011","2011",1301.2,,
+"PATCSKEL","M-Musculo-skeletal system","MTMOPPMT","Million US$, purchasing power parity","FRA","France","2011","2011",1111.1,,
+"PATCSKEL","M-Musculo-skeletal system","TCPPERMT","/capita, US$ exchange rate","FRA","France","2011","2011",20,,
+"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","FRA","France","2011","2011",17.1,,
+"PATCSKEL","M-Musculo-skeletal system","ATCPTTMT","% of total sales","FRA","France","2011","2011",3.4,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","MLLNCUMT","Million of national currency units","DEU","Germany","2010","2010",1336.2,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","MLLNCUMT","Million of national currency units","DEU","Germany","2011","2011",1285.2,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","MLLNCUMT","Million of national currency units","DEU","Germany","2012","2012",1338.2,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","MLLNCUMT","Million of national currency units","DEU","Germany","2013","2013",1361.5,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","MLLNCUMT","Million of national currency units","DEU","Germany","2014","2014",1386,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","MLLNCUMT","Million of national currency units","DEU","Germany","2015","2015",1397.1,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","MLLNCUMT","Million of national currency units","DEU","Germany","2016","2016",1405.1,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","MLLNCUMT","Million of national currency units","DEU","Germany","2017","2017",1390.3,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","MLLNCUMT","Million of national currency units","DEU","Germany","2018","2018",1295.1,"B; D","Break; Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","MLLNCUMT","Million of national currency units","DEU","Germany","2019","2019",1296.3,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","MLLNCUMT","Million of national currency units","DEU","Germany","2020","2020",1242.7,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","MLLNCUMT","Million of national currency units","DEU","Germany","2021","2021",1413.2,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","MTMOTCMT","Million US$ at exchange rate","DEU","Germany","2010","2010",1771.4,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","MTMOTCMT","Million US$ at exchange rate","DEU","Germany","2011","2011",1788.9,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","MTMOTCMT","Million US$ at exchange rate","DEU","Germany","2012","2012",1719.3,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","MTMOTCMT","Million US$ at exchange rate","DEU","Germany","2013","2013",1808.2,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","MTMOTCMT","Million US$ at exchange rate","DEU","Germany","2014","2014",1841.3,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","MTMOTCMT","Million US$ at exchange rate","DEU","Germany","2015","2015",1550.1,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","MTMOTCMT","Million US$ at exchange rate","DEU","Germany","2016","2016",1555.3,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","MTMOTCMT","Million US$ at exchange rate","DEU","Germany","2017","2017",1570.6,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","MTMOTCMT","Million US$ at exchange rate","DEU","Germany","2018","2018",1529.5,"B; D","Break; Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","MTMOTCMT","Million US$ at exchange rate","DEU","Germany","2019","2019",1451.2,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","MTMOTCMT","Million US$ at exchange rate","DEU","Germany","2020","2020",1419.4,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","MTMOTCMT","Million US$ at exchange rate","DEU","Germany","2021","2021",1671.4,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","MTMOPPMT","Million US$, purchasing power parity","DEU","Germany","2010","2010",1659.7,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","MTMOPPMT","Million US$, purchasing power parity","DEU","Germany","2011","2011",1629.4,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","MTMOPPMT","Million US$, purchasing power parity","DEU","Germany","2012","2012",1699.8,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","MTMOPPMT","Million US$, purchasing power parity","DEU","Germany","2013","2013",1757.3,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","MTMOPPMT","Million US$, purchasing power parity","DEU","Germany","2014","2014",1802.5,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","MTMOPPMT","Million US$, purchasing power parity","DEU","Germany","2015","2015",1795.5,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","MTMOPPMT","Million US$, purchasing power parity","DEU","Germany","2016","2016",1867,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","MTMOPPMT","Million US$, purchasing power parity","DEU","Germany","2017","2017",1866.7,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","MTMOPPMT","Million US$, purchasing power parity","DEU","Germany","2018","2018",1761,"B; D","Break; Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","MTMOPPMT","Million US$, purchasing power parity","DEU","Germany","2019","2019",1780,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","MTMOPPMT","Million US$, purchasing power parity","DEU","Germany","2020","2020",1714.1,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","MTMOPPMT","Million US$, purchasing power parity","DEU","Germany","2021","2021",1919.4,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","TCPPERMT","/capita, US$ exchange rate","DEU","Germany","2010","2010",21.7,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","TCPPERMT","/capita, US$ exchange rate","DEU","Germany","2011","2011",22.3,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","TCPPERMT","/capita, US$ exchange rate","DEU","Germany","2012","2012",21.4,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","TCPPERMT","/capita, US$ exchange rate","DEU","Germany","2013","2013",22.4,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","TCPPERMT","/capita, US$ exchange rate","DEU","Germany","2014","2014",22.7,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","TCPPERMT","/capita, US$ exchange rate","DEU","Germany","2015","2015",19,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","TCPPERMT","/capita, US$ exchange rate","DEU","Germany","2016","2016",18.9,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","TCPPERMT","/capita, US$ exchange rate","DEU","Germany","2017","2017",19,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","TCPPERMT","/capita, US$ exchange rate","DEU","Germany","2018","2018",18.4,"B; D","Break; Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","TCPPERMT","/capita, US$ exchange rate","DEU","Germany","2019","2019",17.5,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","TCPPERMT","/capita, US$ exchange rate","DEU","Germany","2020","2020",17.1,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","TCPPERMT","/capita, US$ exchange rate","DEU","Germany","2021","2021",20.1,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2010","2010",20.3,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2011","2011",20.3,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2012","2012",21.1,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2013","2013",21.8,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2014","2014",22.3,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2015","2015",22,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2016","2016",22.7,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2017","2017",22.6,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2018","2018",21.2,"B; D","Break; Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2019","2019",21.4,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2020","2020",20.6,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2021","2021",23.1,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","ATCPTTMT","% of total sales","DEU","Germany","2010","2010",4.5,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","ATCPTTMT","% of total sales","DEU","Germany","2011","2011",4.3,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","ATCPTTMT","% of total sales","DEU","Germany","2012","2012",4.4,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","ATCPTTMT","% of total sales","DEU","Germany","2013","2013",4.3,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","ATCPTTMT","% of total sales","DEU","Germany","2014","2014",4.1,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","ATCPTTMT","% of total sales","DEU","Germany","2015","2015",4,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","ATCPTTMT","% of total sales","DEU","Germany","2016","2016",3.9,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","ATCPTTMT","% of total sales","DEU","Germany","2017","2017",3.7,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","ATCPTTMT","% of total sales","DEU","Germany","2018","2018",2.9,"B; D","Break; Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","ATCPTTMT","% of total sales","DEU","Germany","2019","2019",2.8,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","ATCPTTMT","% of total sales","DEU","Germany","2020","2020",2.5,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","ATCPTTMT","% of total sales","DEU","Germany","2021","2021",2.7,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","MLLNCUMT","Million of national currency units","GRC","Greece","2010","2010",317.4,,
+"PATCSKEL","M-Musculo-skeletal system","MLLNCUMT","Million of national currency units","GRC","Greece","2011","2011",275.8,,
+"PATCSKEL","M-Musculo-skeletal system","MLLNCUMT","Million of national currency units","GRC","Greece","2012","2012",245,,
+"PATCSKEL","M-Musculo-skeletal system","MLLNCUMT","Million of national currency units","GRC","Greece","2013","2013",221,,
+"PATCSKEL","M-Musculo-skeletal system","MLLNCUMT","Million of national currency units","GRC","Greece","2014","2014",211.4,,
+"PATCSKEL","M-Musculo-skeletal system","MLLNCUMT","Million of national currency units","GRC","Greece","2015","2015",187.1,,
+"PATCSKEL","M-Musculo-skeletal system","MLLNCUMT","Million of national currency units","GRC","Greece","2016","2016",215.5,,
+"PATCSKEL","M-Musculo-skeletal system","MLLNCUMT","Million of national currency units","GRC","Greece","2017","2017",212.1,,
+"PATCSKEL","M-Musculo-skeletal system","MLLNCUMT","Million of national currency units","GRC","Greece","2018","2018",236.8,,
+"PATCSKEL","M-Musculo-skeletal system","MLLNCUMT","Million of national currency units","GRC","Greece","2019","2019",233.9,,
+"PATCSKEL","M-Musculo-skeletal system","MLLNCUMT","Million of national currency units","GRC","Greece","2020","2020",237.9,,
+"PATCSKEL","M-Musculo-skeletal system","MLLNCUMT","Million of national currency units","GRC","Greece","2021","2021",243.6,,
+"PATCSKEL","M-Musculo-skeletal system","MLLNCUMT","Million of national currency units","GRC","Greece","2022","2022",228.7,,
+"PATCSKEL","M-Musculo-skeletal system","MTMOTCMT","Million US$ at exchange rate","GRC","Greece","2010","2010",420.8,,
+"PATCSKEL","M-Musculo-skeletal system","MTMOTCMT","Million US$ at exchange rate","GRC","Greece","2011","2011",383.9,,
+"PATCSKEL","M-Musculo-skeletal system","MTMOTCMT","Million US$ at exchange rate","GRC","Greece","2012","2012",314.8,,
+"PATCSKEL","M-Musculo-skeletal system","MTMOTCMT","Million US$ at exchange rate","GRC","Greece","2013","2013",293.6,,
+"PATCSKEL","M-Musculo-skeletal system","MTMOTCMT","Million US$ at exchange rate","GRC","Greece","2014","2014",280.8,,
+"PATCSKEL","M-Musculo-skeletal system","MTMOTCMT","Million US$ at exchange rate","GRC","Greece","2015","2015",207.5,,
+"PATCSKEL","M-Musculo-skeletal system","MTMOTCMT","Million US$ at exchange rate","GRC","Greece","2016","2016",238.5,,
+"PATCSKEL","M-Musculo-skeletal system","MTMOTCMT","Million US$ at exchange rate","GRC","Greece","2017","2017",239.6,,
+"PATCSKEL","M-Musculo-skeletal system","MTMOTCMT","Million US$ at exchange rate","GRC","Greece","2018","2018",279.7,,
+"PATCSKEL","M-Musculo-skeletal system","MTMOTCMT","Million US$ at exchange rate","GRC","Greece","2019","2019",261.9,,
+"PATCSKEL","M-Musculo-skeletal system","MTMOTCMT","Million US$ at exchange rate","GRC","Greece","2020","2020",271.7,,
+"PATCSKEL","M-Musculo-skeletal system","MTMOTCMT","Million US$ at exchange rate","GRC","Greece","2021","2021",288.1,,
+"PATCSKEL","M-Musculo-skeletal system","MTMOTCMT","Million US$ at exchange rate","GRC","Greece","2022","2022",240.9,,
+"PATCSKEL","M-Musculo-skeletal system","MTMOPPMT","Million US$, purchasing power parity","GRC","Greece","2010","2010",439.6,,
+"PATCSKEL","M-Musculo-skeletal system","MTMOPPMT","Million US$, purchasing power parity","GRC","Greece","2011","2011",386.7,,
+"PATCSKEL","M-Musculo-skeletal system","MTMOPPMT","Million US$, purchasing power parity","GRC","Greece","2012","2012",357.8,,
+"PATCSKEL","M-Musculo-skeletal system","MTMOPPMT","Million US$, purchasing power parity","GRC","Greece","2013","2013",350.1,,
+"PATCSKEL","M-Musculo-skeletal system","MTMOPPMT","Million US$, purchasing power parity","GRC","Greece","2014","2014",345.8,,
+"PATCSKEL","M-Musculo-skeletal system","MTMOPPMT","Million US$, purchasing power parity","GRC","Greece","2015","2015",307.1,,
+"PATCSKEL","M-Musculo-skeletal system","MTMOPPMT","Million US$, purchasing power parity","GRC","Greece","2016","2016",366.1,,
+"PATCSKEL","M-Musculo-skeletal system","MTMOPPMT","Million US$, purchasing power parity","GRC","Greece","2017","2017",368.9,,
+"PATCSKEL","M-Musculo-skeletal system","MTMOPPMT","Million US$, purchasing power parity","GRC","Greece","2018","2018",419.3,,
+"PATCSKEL","M-Musculo-skeletal system","MTMOPPMT","Million US$, purchasing power parity","GRC","Greece","2019","2019",426.2,,
+"PATCSKEL","M-Musculo-skeletal system","MTMOPPMT","Million US$, purchasing power parity","GRC","Greece","2020","2020",437.3,,
+"PATCSKEL","M-Musculo-skeletal system","MTMOPPMT","Million US$, purchasing power parity","GRC","Greece","2021","2021",446.5,,
+"PATCSKEL","M-Musculo-skeletal system","MTMOPPMT","Million US$, purchasing power parity","GRC","Greece","2022","2022",432.8,,
+"PATCSKEL","M-Musculo-skeletal system","TCPPERMT","/capita, US$ exchange rate","GRC","Greece","2010","2010",37.8,,
+"PATCSKEL","M-Musculo-skeletal system","TCPPERMT","/capita, US$ exchange rate","GRC","Greece","2011","2011",34.6,,
+"PATCSKEL","M-Musculo-skeletal system","TCPPERMT","/capita, US$ exchange rate","GRC","Greece","2012","2012",28.5,,
+"PATCSKEL","M-Musculo-skeletal system","TCPPERMT","/capita, US$ exchange rate","GRC","Greece","2013","2013",26.8,,
+"PATCSKEL","M-Musculo-skeletal system","TCPPERMT","/capita, US$ exchange rate","GRC","Greece","2014","2014",25.8,,
+"PATCSKEL","M-Musculo-skeletal system","TCPPERMT","/capita, US$ exchange rate","GRC","Greece","2015","2015",19.2,,
+"PATCSKEL","M-Musculo-skeletal system","TCPPERMT","/capita, US$ exchange rate","GRC","Greece","2016","2016",22.1,,
+"PATCSKEL","M-Musculo-skeletal system","TCPPERMT","/capita, US$ exchange rate","GRC","Greece","2017","2017",22.3,,
+"PATCSKEL","M-Musculo-skeletal system","TCPPERMT","/capita, US$ exchange rate","GRC","Greece","2018","2018",26.1,,
+"PATCSKEL","M-Musculo-skeletal system","TCPPERMT","/capita, US$ exchange rate","GRC","Greece","2019","2019",24.4,,
+"PATCSKEL","M-Musculo-skeletal system","TCPPERMT","/capita, US$ exchange rate","GRC","Greece","2020","2020",25.4,,
+"PATCSKEL","M-Musculo-skeletal system","TCPPERMT","/capita, US$ exchange rate","GRC","Greece","2021","2021",27.3,,
+"PATCSKEL","M-Musculo-skeletal system","TCPPERMT","/capita, US$ exchange rate","GRC","Greece","2022","2022",23,,
+"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2010","2010",39.5,,
+"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2011","2011",34.8,,
+"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2012","2012",32.4,,
+"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2013","2013",31.9,,
+"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2014","2014",31.7,,
+"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2015","2015",28.4,,
+"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2016","2016",34,,
+"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2017","2017",34.3,,
+"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2018","2018",39.1,,
+"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2019","2019",39.8,,
+"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2020","2020",40.9,,
+"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2021","2021",42.2,,
+"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2022","2022",41.4,,
+"PATCSKEL","M-Musculo-skeletal system","MLLNCUMT","Million of national currency units","HUN","Hungary","2010","2010",22271.6,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","MLLNCUMT","Million of national currency units","HUN","Hungary","2011","2011",21144.6,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","MLLNCUMT","Million of national currency units","HUN","Hungary","2012","2012",19341.8,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","MLLNCUMT","Million of national currency units","HUN","Hungary","2013","2013",18632.7,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","MLLNCUMT","Million of national currency units","HUN","Hungary","2014","2014",17751.8,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","MLLNCUMT","Million of national currency units","HUN","Hungary","2015","2015",17492.2,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","MLLNCUMT","Million of national currency units","HUN","Hungary","2016","2016",17665.2,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","MLLNCUMT","Million of national currency units","HUN","Hungary","2017","2017",17723.5,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","MLLNCUMT","Million of national currency units","HUN","Hungary","2018","2018",17843.3,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","MLLNCUMT","Million of national currency units","HUN","Hungary","2019","2019",18397.1,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","MLLNCUMT","Million of national currency units","HUN","Hungary","2020","2020",17674.2,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","MLLNCUMT","Million of national currency units","HUN","Hungary","2021","2021",17380.1,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","MLLNCUMT","Million of national currency units","HUN","Hungary","2022","2022",18106.2,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","MTMOTCMT","Million US$ at exchange rate","HUN","Hungary","2010","2010",107.1,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","MTMOTCMT","Million US$ at exchange rate","HUN","Hungary","2011","2011",105.2,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","MTMOTCMT","Million US$ at exchange rate","HUN","Hungary","2012","2012",85.9,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","MTMOTCMT","Million US$ at exchange rate","HUN","Hungary","2013","2013",83.3,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","MTMOTCMT","Million US$ at exchange rate","HUN","Hungary","2014","2014",76.3,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","MTMOTCMT","Million US$ at exchange rate","HUN","Hungary","2015","2015",62.6,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","MTMOTCMT","Million US$ at exchange rate","HUN","Hungary","2016","2016",62.7,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","MTMOTCMT","Million US$ at exchange rate","HUN","Hungary","2017","2017",64.6,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","MTMOTCMT","Million US$ at exchange rate","HUN","Hungary","2018","2018",66,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","MTMOTCMT","Million US$ at exchange rate","HUN","Hungary","2019","2019",63.3,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","MTMOTCMT","Million US$ at exchange rate","HUN","Hungary","2020","2020",57.4,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","MTMOTCMT","Million US$ at exchange rate","HUN","Hungary","2021","2021",57.3,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","MTMOTCMT","Million US$ at exchange rate","HUN","Hungary","2022","2022",48.6,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","MTMOPPMT","Million US$, purchasing power parity","HUN","Hungary","2010","2010",176.2,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","MTMOPPMT","Million US$, purchasing power parity","HUN","Hungary","2011","2011",170.1,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","MTMOPPMT","Million US$, purchasing power parity","HUN","Hungary","2012","2012",154,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","MTMOPPMT","Million US$, purchasing power parity","HUN","Hungary","2013","2013",149.1,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","MTMOPPMT","Million US$, purchasing power parity","HUN","Hungary","2014","2014",137.2,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","MTMOPPMT","Million US$, purchasing power parity","HUN","Hungary","2015","2015",132,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","MTMOPPMT","Million US$, purchasing power parity","HUN","Hungary","2016","2016",133.8,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","MTMOPPMT","Million US$, purchasing power parity","HUN","Hungary","2017","2017",130.3,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","MTMOPPMT","Million US$, purchasing power parity","HUN","Hungary","2018","2018",128.3,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","MTMOPPMT","Million US$, purchasing power parity","HUN","Hungary","2019","2019",130.6,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","MTMOPPMT","Million US$, purchasing power parity","HUN","Hungary","2020","2020",121.6,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","MTMOPPMT","Million US$, purchasing power parity","HUN","Hungary","2021","2021",112.3,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","MTMOPPMT","Million US$, purchasing power parity","HUN","Hungary","2022","2022",112.3,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","TCPPERMT","/capita, US$ exchange rate","HUN","Hungary","2010","2010",10.7,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","TCPPERMT","/capita, US$ exchange rate","HUN","Hungary","2011","2011",10.5,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","TCPPERMT","/capita, US$ exchange rate","HUN","Hungary","2012","2012",8.7,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","TCPPERMT","/capita, US$ exchange rate","HUN","Hungary","2013","2013",8.4,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","TCPPERMT","/capita, US$ exchange rate","HUN","Hungary","2014","2014",7.7,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","TCPPERMT","/capita, US$ exchange rate","HUN","Hungary","2015","2015",6.4,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","TCPPERMT","/capita, US$ exchange rate","HUN","Hungary","2016","2016",6.4,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","TCPPERMT","/capita, US$ exchange rate","HUN","Hungary","2017","2017",6.6,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","TCPPERMT","/capita, US$ exchange rate","HUN","Hungary","2018","2018",6.8,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","TCPPERMT","/capita, US$ exchange rate","HUN","Hungary","2019","2019",6.5,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","TCPPERMT","/capita, US$ exchange rate","HUN","Hungary","2020","2020",5.9,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","TCPPERMT","/capita, US$ exchange rate","HUN","Hungary","2021","2021",5.9,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","TCPPERMT","/capita, US$ exchange rate","HUN","Hungary","2022","2022",5,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2010","2010",17.6,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2011","2011",17.1,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2012","2012",15.5,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2013","2013",15.1,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2014","2014",13.9,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2015","2015",13.4,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2016","2016",13.6,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2017","2017",13.3,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2018","2018",13.1,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2019","2019",13.4,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2020","2020",12.5,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2021","2021",11.6,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2022","2022",11.6,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","ATCPTTMT","% of total sales","HUN","Hungary","2010","2010",4.5,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","ATCPTTMT","% of total sales","HUN","Hungary","2011","2011",4.1,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","ATCPTTMT","% of total sales","HUN","Hungary","2012","2012",4.4,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","ATCPTTMT","% of total sales","HUN","Hungary","2013","2013",4.3,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","ATCPTTMT","% of total sales","HUN","Hungary","2014","2014",4,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","ATCPTTMT","% of total sales","HUN","Hungary","2015","2015",3.8,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","ATCPTTMT","% of total sales","HUN","Hungary","2016","2016",3.5,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","ATCPTTMT","% of total sales","HUN","Hungary","2017","2017",3.6,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","ATCPTTMT","% of total sales","HUN","Hungary","2018","2018",3.6,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","ATCPTTMT","% of total sales","HUN","Hungary","2019","2019",3.5,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","ATCPTTMT","% of total sales","HUN","Hungary","2020","2020",3.2,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","ATCPTTMT","% of total sales","HUN","Hungary","2021","2021",3.1,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","ATCPTTMT","% of total sales","HUN","Hungary","2022","2022",3,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","MLLNCUMT","Million of national currency units","ISL","Iceland","2010","2010",1220.1,,
+"PATCSKEL","M-Musculo-skeletal system","MLLNCUMT","Million of national currency units","ISL","Iceland","2011","2011",760.9,,
+"PATCSKEL","M-Musculo-skeletal system","MLLNCUMT","Million of national currency units","ISL","Iceland","2012","2012",765,,
+"PATCSKEL","M-Musculo-skeletal system","MLLNCUMT","Million of national currency units","ISL","Iceland","2013","2013",945.5,,
+"PATCSKEL","M-Musculo-skeletal system","MLLNCUMT","Million of national currency units","ISL","Iceland","2014","2014",699.9,,
+"PATCSKEL","M-Musculo-skeletal system","MLLNCUMT","Million of national currency units","ISL","Iceland","2015","2015",645.8,,
+"PATCSKEL","M-Musculo-skeletal system","MLLNCUMT","Million of national currency units","ISL","Iceland","2016","2016",697.1,,
+"PATCSKEL","M-Musculo-skeletal system","MLLNCUMT","Million of national currency units","ISL","Iceland","2017","2017",698.3,,
+"PATCSKEL","M-Musculo-skeletal system","MLLNCUMT","Million of national currency units","ISL","Iceland","2018","2018",761.6,,
+"PATCSKEL","M-Musculo-skeletal system","MLLNCUMT","Million of national currency units","ISL","Iceland","2019","2019",936.4,,
+"PATCSKEL","M-Musculo-skeletal system","MLLNCUMT","Million of national currency units","ISL","Iceland","2020","2020",1184.6,,
+"PATCSKEL","M-Musculo-skeletal system","MLLNCUMT","Million of national currency units","ISL","Iceland","2021","2021",1260.6,,
+"PATCSKEL","M-Musculo-skeletal system","MTMOTCMT","Million US$ at exchange rate","ISL","Iceland","2010","2010",10,,
+"PATCSKEL","M-Musculo-skeletal system","MTMOTCMT","Million US$ at exchange rate","ISL","Iceland","2011","2011",6.6,,
+"PATCSKEL","M-Musculo-skeletal system","MTMOTCMT","Million US$ at exchange rate","ISL","Iceland","2012","2012",6.1,,
+"PATCSKEL","M-Musculo-skeletal system","MTMOTCMT","Million US$ at exchange rate","ISL","Iceland","2013","2013",7.7,,
+"PATCSKEL","M-Musculo-skeletal system","MTMOTCMT","Million US$ at exchange rate","ISL","Iceland","2014","2014",6,,
+"PATCSKEL","M-Musculo-skeletal system","MTMOTCMT","Million US$ at exchange rate","ISL","Iceland","2015","2015",4.9,,
+"PATCSKEL","M-Musculo-skeletal system","MTMOTCMT","Million US$ at exchange rate","ISL","Iceland","2016","2016",5.8,,
+"PATCSKEL","M-Musculo-skeletal system","MTMOTCMT","Million US$ at exchange rate","ISL","Iceland","2017","2017",6.5,,
+"PATCSKEL","M-Musculo-skeletal system","MTMOTCMT","Million US$ at exchange rate","ISL","Iceland","2018","2018",7,,
+"PATCSKEL","M-Musculo-skeletal system","MTMOTCMT","Million US$ at exchange rate","ISL","Iceland","2019","2019",7.6,,
+"PATCSKEL","M-Musculo-skeletal system","MTMOTCMT","Million US$ at exchange rate","ISL","Iceland","2020","2020",8.7,,
+"PATCSKEL","M-Musculo-skeletal system","MTMOTCMT","Million US$ at exchange rate","ISL","Iceland","2021","2021",9.9,,
+"PATCSKEL","M-Musculo-skeletal system","MTMOPPMT","Million US$, purchasing power parity","ISL","Iceland","2010","2010",9.2,,
+"PATCSKEL","M-Musculo-skeletal system","MTMOPPMT","Million US$, purchasing power parity","ISL","Iceland","2011","2011",5.6,,
+"PATCSKEL","M-Musculo-skeletal system","MTMOPPMT","Million US$, purchasing power parity","ISL","Iceland","2012","2012",5.6,,
+"PATCSKEL","M-Musculo-skeletal system","MTMOPPMT","Million US$, purchasing power parity","ISL","Iceland","2013","2013",6.9,,
+"PATCSKEL","M-Musculo-skeletal system","MTMOPPMT","Million US$, purchasing power parity","ISL","Iceland","2014","2014",5.1,,
+"PATCSKEL","M-Musculo-skeletal system","MTMOPPMT","Million US$, purchasing power parity","ISL","Iceland","2015","2015",4.5,,
+"PATCSKEL","M-Musculo-skeletal system","MTMOPPMT","Million US$, purchasing power parity","ISL","Iceland","2016","2016",5,,
+"PATCSKEL","M-Musculo-skeletal system","MTMOPPMT","Million US$, purchasing power parity","ISL","Iceland","2017","2017",5.1,,
+"PATCSKEL","M-Musculo-skeletal system","MTMOPPMT","Million US$, purchasing power parity","ISL","Iceland","2018","2018",5.4,,
+"PATCSKEL","M-Musculo-skeletal system","MTMOPPMT","Million US$, purchasing power parity","ISL","Iceland","2019","2019",6.7,,
+"PATCSKEL","M-Musculo-skeletal system","MTMOPPMT","Million US$, purchasing power parity","ISL","Iceland","2020","2020",8.1,,
+"PATCSKEL","M-Musculo-skeletal system","MTMOPPMT","Million US$, purchasing power parity","ISL","Iceland","2021","2021",8.4,,
+"PATCSKEL","M-Musculo-skeletal system","TCPPERMT","/capita, US$ exchange rate","ISL","Iceland","2010","2010",31.4,,
+"PATCSKEL","M-Musculo-skeletal system","TCPPERMT","/capita, US$ exchange rate","ISL","Iceland","2011","2011",20.6,,
+"PATCSKEL","M-Musculo-skeletal system","TCPPERMT","/capita, US$ exchange rate","ISL","Iceland","2012","2012",19.1,,
+"PATCSKEL","M-Musculo-skeletal system","TCPPERMT","/capita, US$ exchange rate","ISL","Iceland","2013","2013",23.9,,
+"PATCSKEL","M-Musculo-skeletal system","TCPPERMT","/capita, US$ exchange rate","ISL","Iceland","2014","2014",18.3,,
+"PATCSKEL","M-Musculo-skeletal system","TCPPERMT","/capita, US$ exchange rate","ISL","Iceland","2015","2015",14.8,,
+"PATCSKEL","M-Musculo-skeletal system","TCPPERMT","/capita, US$ exchange rate","ISL","Iceland","2016","2016",17.2,,
+"PATCSKEL","M-Musculo-skeletal system","TCPPERMT","/capita, US$ exchange rate","ISL","Iceland","2017","2017",19,,
+"PATCSKEL","M-Musculo-skeletal system","TCPPERMT","/capita, US$ exchange rate","ISL","Iceland","2018","2018",19.9,,
+"PATCSKEL","M-Musculo-skeletal system","TCPPERMT","/capita, US$ exchange rate","ISL","Iceland","2019","2019",21.2,,
+"PATCSKEL","M-Musculo-skeletal system","TCPPERMT","/capita, US$ exchange rate","ISL","Iceland","2020","2020",23.9,,
+"PATCSKEL","M-Musculo-skeletal system","TCPPERMT","/capita, US$ exchange rate","ISL","Iceland","2021","2021",26.6,,
+"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2010","2010",28.9,,
+"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2011","2011",17.6,,
+"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2012","2012",17.4,,
+"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2013","2013",21.3,,
+"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2014","2014",15.4,,
+"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2015","2015",13.7,,
+"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2016","2016",14.8,,
+"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2017","2017",14.7,,
+"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2018","2018",15.3,,
+"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2019","2019",18.5,,
+"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2020","2020",22,,
+"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2021","2021",22.6,,
+"PATCSKEL","M-Musculo-skeletal system","ATCPTTMT","% of total sales","ISL","Iceland","2010","2010",4.9,,
+"PATCSKEL","M-Musculo-skeletal system","ATCPTTMT","% of total sales","ISL","Iceland","2011","2011",2.9,,
+"PATCSKEL","M-Musculo-skeletal system","ATCPTTMT","% of total sales","ISL","Iceland","2012","2012",3.2,,
+"PATCSKEL","M-Musculo-skeletal system","ATCPTTMT","% of total sales","ISL","Iceland","2013","2013",3.6,,
+"PATCSKEL","M-Musculo-skeletal system","ATCPTTMT","% of total sales","ISL","Iceland","2014","2014",3,,
+"PATCSKEL","M-Musculo-skeletal system","ATCPTTMT","% of total sales","ISL","Iceland","2015","2015",2.6,,
+"PATCSKEL","M-Musculo-skeletal system","ATCPTTMT","% of total sales","ISL","Iceland","2016","2016",2.7,,
+"PATCSKEL","M-Musculo-skeletal system","ATCPTTMT","% of total sales","ISL","Iceland","2017","2017",2.6,,
+"PATCSKEL","M-Musculo-skeletal system","ATCPTTMT","% of total sales","ISL","Iceland","2018","2018",2.5,,
+"PATCSKEL","M-Musculo-skeletal system","ATCPTTMT","% of total sales","ISL","Iceland","2019","2019",2.8,,
+"PATCSKEL","M-Musculo-skeletal system","ATCPTTMT","% of total sales","ISL","Iceland","2020","2020",3,,
+"PATCSKEL","M-Musculo-skeletal system","ATCPTTMT","% of total sales","ISL","Iceland","2021","2021",2.8,,
+"PATCSKEL","M-Musculo-skeletal system","MLLNCUMT","Million of national currency units","IRL","Ireland","2010","2010",88.1,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","MLLNCUMT","Million of national currency units","IRL","Ireland","2011","2011",74.9,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","MLLNCUMT","Million of national currency units","IRL","Ireland","2012","2012",74.9,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","MLLNCUMT","Million of national currency units","IRL","Ireland","2013","2013",67.1,"B; D","Break; Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","MLLNCUMT","Million of national currency units","IRL","Ireland","2014","2014",66,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","MLLNCUMT","Million of national currency units","IRL","Ireland","2015","2015",66.2,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","MLLNCUMT","Million of national currency units","IRL","Ireland","2016","2016",67.5,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","MLLNCUMT","Million of national currency units","IRL","Ireland","2017","2017",67.5,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","MLLNCUMT","Million of national currency units","IRL","Ireland","2018","2018",68.4,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","MLLNCUMT","Million of national currency units","IRL","Ireland","2019","2019",70.7,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","MLLNCUMT","Million of national currency units","IRL","Ireland","2020","2020",71.6,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","MLLNCUMT","Million of national currency units","IRL","Ireland","2021","2021",75.6,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","MTMOTCMT","Million US$ at exchange rate","IRL","Ireland","2010","2010",116.8,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","MTMOTCMT","Million US$ at exchange rate","IRL","Ireland","2011","2011",104.3,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","MTMOTCMT","Million US$ at exchange rate","IRL","Ireland","2012","2012",96.2,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","MTMOTCMT","Million US$ at exchange rate","IRL","Ireland","2013","2013",89.1,"B; D","Break; Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","MTMOTCMT","Million US$ at exchange rate","IRL","Ireland","2014","2014",87.6,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","MTMOTCMT","Million US$ at exchange rate","IRL","Ireland","2015","2015",73.5,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","MTMOTCMT","Million US$ at exchange rate","IRL","Ireland","2016","2016",74.7,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","MTMOTCMT","Million US$ at exchange rate","IRL","Ireland","2017","2017",76.2,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","MTMOTCMT","Million US$ at exchange rate","IRL","Ireland","2018","2018",80.7,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","MTMOTCMT","Million US$ at exchange rate","IRL","Ireland","2019","2019",79.1,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","MTMOTCMT","Million US$ at exchange rate","IRL","Ireland","2020","2020",81.8,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","MTMOTCMT","Million US$ at exchange rate","IRL","Ireland","2021","2021",89.4,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","MTMOPPMT","Million US$, purchasing power parity","IRL","Ireland","2010","2010",103.7,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","MTMOPPMT","Million US$, purchasing power parity","IRL","Ireland","2011","2011",90.1,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","MTMOPPMT","Million US$, purchasing power parity","IRL","Ireland","2012","2012",90.9,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","MTMOPPMT","Million US$, purchasing power parity","IRL","Ireland","2013","2013",82.7,"B; D","Break; Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","MTMOPPMT","Million US$, purchasing power parity","IRL","Ireland","2014","2014",80.5,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","MTMOPPMT","Million US$, purchasing power parity","IRL","Ireland","2015","2015",81.8,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","MTMOPPMT","Million US$, purchasing power parity","IRL","Ireland","2016","2016",84.9,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","MTMOPPMT","Million US$, purchasing power parity","IRL","Ireland","2017","2017",85,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","MTMOPPMT","Million US$, purchasing power parity","IRL","Ireland","2018","2018",86.3,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","MTMOPPMT","Million US$, purchasing power parity","IRL","Ireland","2019","2019",87.7,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","MTMOPPMT","Million US$, purchasing power parity","IRL","Ireland","2020","2020",89.9,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","MTMOPPMT","Million US$, purchasing power parity","IRL","Ireland","2021","2021",95.1,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","TCPPERMT","/capita, US$ exchange rate","IRL","Ireland","2010","2010",25.6,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","TCPPERMT","/capita, US$ exchange rate","IRL","Ireland","2011","2011",22.8,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","TCPPERMT","/capita, US$ exchange rate","IRL","Ireland","2012","2012",20.9,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","TCPPERMT","/capita, US$ exchange rate","IRL","Ireland","2013","2013",19.3,"B; D","Break; Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","TCPPERMT","/capita, US$ exchange rate","IRL","Ireland","2014","2014",18.8,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","TCPPERMT","/capita, US$ exchange rate","IRL","Ireland","2015","2015",15.6,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","TCPPERMT","/capita, US$ exchange rate","IRL","Ireland","2016","2016",15.7,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","TCPPERMT","/capita, US$ exchange rate","IRL","Ireland","2017","2017",15.9,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","TCPPERMT","/capita, US$ exchange rate","IRL","Ireland","2018","2018",16.6,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","TCPPERMT","/capita, US$ exchange rate","IRL","Ireland","2019","2019",16,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","TCPPERMT","/capita, US$ exchange rate","IRL","Ireland","2020","2020",16.4,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","TCPPERMT","/capita, US$ exchange rate","IRL","Ireland","2021","2021",17.8,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2010","2010",22.7,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2011","2011",19.7,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2012","2012",19.8,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2013","2013",17.9,"B; D","Break; Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2014","2014",17.3,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2015","2015",17.4,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2016","2016",17.9,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2017","2017",17.7,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2018","2018",17.7,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2019","2019",17.8,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2020","2020",18,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2021","2021",18.9,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","ATCPTTMT","% of total sales","IRL","Ireland","2010","2010",4.3,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","ATCPTTMT","% of total sales","IRL","Ireland","2011","2011",3.8,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","ATCPTTMT","% of total sales","IRL","Ireland","2012","2012",3.7,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","ATCPTTMT","% of total sales","IRL","Ireland","2013","2013",3.4,"B; D","Break; Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","ATCPTTMT","% of total sales","IRL","Ireland","2014","2014",3.4,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","ATCPTTMT","% of total sales","IRL","Ireland","2015","2015",3.3,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","ATCPTTMT","% of total sales","IRL","Ireland","2016","2016",3.2,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","ATCPTTMT","% of total sales","IRL","Ireland","2017","2017",3.2,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","ATCPTTMT","% of total sales","IRL","Ireland","2018","2018",3,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","ATCPTTMT","% of total sales","IRL","Ireland","2019","2019",2.9,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","ATCPTTMT","% of total sales","IRL","Ireland","2020","2020",2.9,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","ATCPTTMT","% of total sales","IRL","Ireland","2021","2021",2.9,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","MLLNCUMT","Million of national currency units","ITA","Italy","2011","2011",640.1,,
+"PATCSKEL","M-Musculo-skeletal system","MLLNCUMT","Million of national currency units","ITA","Italy","2012","2012",589.4,,
+"PATCSKEL","M-Musculo-skeletal system","MLLNCUMT","Million of national currency units","ITA","Italy","2013","2013",551.2,,
+"PATCSKEL","M-Musculo-skeletal system","MLLNCUMT","Million of national currency units","ITA","Italy","2014","2014",505.9,,
+"PATCSKEL","M-Musculo-skeletal system","MLLNCUMT","Million of national currency units","ITA","Italy","2015","2015",485.2,,
+"PATCSKEL","M-Musculo-skeletal system","MLLNCUMT","Million of national currency units","ITA","Italy","2016","2016",467.9,,
+"PATCSKEL","M-Musculo-skeletal system","MLLNCUMT","Million of national currency units","ITA","Italy","2017","2017",462,,
+"PATCSKEL","M-Musculo-skeletal system","MLLNCUMT","Million of national currency units","ITA","Italy","2018","2018",534.1,,
+"PATCSKEL","M-Musculo-skeletal system","MLLNCUMT","Million of national currency units","ITA","Italy","2019","2019",538.6,,
+"PATCSKEL","M-Musculo-skeletal system","MLLNCUMT","Million of national currency units","ITA","Italy","2020","2020",521.2,,
+"PATCSKEL","M-Musculo-skeletal system","MLLNCUMT","Million of national currency units","ITA","Italy","2021","2021",533.9,,
+"PATCSKEL","M-Musculo-skeletal system","MLLNCUMT","Million of national currency units","ITA","Italy","2022","2022",579.1,"E","Estimated value"
+"PATCSKEL","M-Musculo-skeletal system","MTMOTCMT","Million US$ at exchange rate","ITA","Italy","2011","2011",891,,
+"PATCSKEL","M-Musculo-skeletal system","MTMOTCMT","Million US$ at exchange rate","ITA","Italy","2012","2012",757.3,,
+"PATCSKEL","M-Musculo-skeletal system","MTMOTCMT","Million US$ at exchange rate","ITA","Italy","2013","2013",732,,
+"PATCSKEL","M-Musculo-skeletal system","MTMOTCMT","Million US$ at exchange rate","ITA","Italy","2014","2014",672.1,,
+"PATCSKEL","M-Musculo-skeletal system","MTMOTCMT","Million US$ at exchange rate","ITA","Italy","2015","2015",538.4,,
+"PATCSKEL","M-Musculo-skeletal system","MTMOTCMT","Million US$ at exchange rate","ITA","Italy","2016","2016",517.9,,
+"PATCSKEL","M-Musculo-skeletal system","MTMOTCMT","Million US$ at exchange rate","ITA","Italy","2017","2017",521.9,,
+"PATCSKEL","M-Musculo-skeletal system","MTMOTCMT","Million US$ at exchange rate","ITA","Italy","2018","2018",630.7,,
+"PATCSKEL","M-Musculo-skeletal system","MTMOTCMT","Million US$ at exchange rate","ITA","Italy","2019","2019",603,,
+"PATCSKEL","M-Musculo-skeletal system","MTMOTCMT","Million US$ at exchange rate","ITA","Italy","2020","2020",595.3,,
+"PATCSKEL","M-Musculo-skeletal system","MTMOTCMT","Million US$ at exchange rate","ITA","Italy","2021","2021",631.5,,
+"PATCSKEL","M-Musculo-skeletal system","MTMOTCMT","Million US$ at exchange rate","ITA","Italy","2022","2022",609.8,"E","Estimated value"
+"PATCSKEL","M-Musculo-skeletal system","MTMOPPMT","Million US$, purchasing power parity","ITA","Italy","2011","2011",843.7,,
+"PATCSKEL","M-Musculo-skeletal system","MTMOPPMT","Million US$, purchasing power parity","ITA","Italy","2012","2012",788.3,,
+"PATCSKEL","M-Musculo-skeletal system","MTMOPPMT","Million US$, purchasing power parity","ITA","Italy","2013","2013",747.6,,
+"PATCSKEL","M-Musculo-skeletal system","MTMOPPMT","Million US$, purchasing power parity","ITA","Italy","2014","2014",683.9,,
+"PATCSKEL","M-Musculo-skeletal system","MTMOPPMT","Million US$, purchasing power parity","ITA","Italy","2015","2015",656.9,,
+"PATCSKEL","M-Musculo-skeletal system","MTMOPPMT","Million US$, purchasing power parity","ITA","Italy","2016","2016",667.9,,
+"PATCSKEL","M-Musculo-skeletal system","MTMOPPMT","Million US$, purchasing power parity","ITA","Italy","2017","2017",669.7,,
+"PATCSKEL","M-Musculo-skeletal system","MTMOPPMT","Million US$, purchasing power parity","ITA","Italy","2018","2018",784,,
+"PATCSKEL","M-Musculo-skeletal system","MTMOPPMT","Million US$, purchasing power parity","ITA","Italy","2019","2019",820.1,,
+"PATCSKEL","M-Musculo-skeletal system","MTMOPPMT","Million US$, purchasing power parity","ITA","Italy","2020","2020",804.7,,
+"PATCSKEL","M-Musculo-skeletal system","MTMOPPMT","Million US$, purchasing power parity","ITA","Italy","2021","2021",824.5,,
+"PATCSKEL","M-Musculo-skeletal system","MTMOPPMT","Million US$, purchasing power parity","ITA","Italy","2022","2022",937.9,"E","Estimated value"
+"PATCSKEL","M-Musculo-skeletal system","TCPPERMT","/capita, US$ exchange rate","ITA","Italy","2011","2011",15,,
+"PATCSKEL","M-Musculo-skeletal system","TCPPERMT","/capita, US$ exchange rate","ITA","Italy","2012","2012",12.7,,
+"PATCSKEL","M-Musculo-skeletal system","TCPPERMT","/capita, US$ exchange rate","ITA","Italy","2013","2013",12.2,,
+"PATCSKEL","M-Musculo-skeletal system","TCPPERMT","/capita, US$ exchange rate","ITA","Italy","2014","2014",11.1,,
+"PATCSKEL","M-Musculo-skeletal system","TCPPERMT","/capita, US$ exchange rate","ITA","Italy","2015","2015",8.9,,
+"PATCSKEL","M-Musculo-skeletal system","TCPPERMT","/capita, US$ exchange rate","ITA","Italy","2016","2016",8.5,,
+"PATCSKEL","M-Musculo-skeletal system","TCPPERMT","/capita, US$ exchange rate","ITA","Italy","2017","2017",8.6,,
+"PATCSKEL","M-Musculo-skeletal system","TCPPERMT","/capita, US$ exchange rate","ITA","Italy","2018","2018",10.4,,
+"PATCSKEL","M-Musculo-skeletal system","TCPPERMT","/capita, US$ exchange rate","ITA","Italy","2019","2019",10.1,,
+"PATCSKEL","M-Musculo-skeletal system","TCPPERMT","/capita, US$ exchange rate","ITA","Italy","2020","2020",10,,
+"PATCSKEL","M-Musculo-skeletal system","TCPPERMT","/capita, US$ exchange rate","ITA","Italy","2021","2021",10.7,,
+"PATCSKEL","M-Musculo-skeletal system","TCPPERMT","/capita, US$ exchange rate","ITA","Italy","2022","2022",10.3,"E","Estimated value"
+"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2011","2011",14.2,,
+"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2012","2012",13.2,,
+"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2013","2013",12.4,,
+"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2014","2014",11.3,,
+"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2015","2015",10.8,,
+"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2016","2016",11,,
+"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2017","2017",11.1,,
+"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2018","2018",13,,
+"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2019","2019",13.7,,
+"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2020","2020",13.5,,
+"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2021","2021",13.9,,
+"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2022","2022",15.9,"E","Estimated value"
+"PATCSKEL","M-Musculo-skeletal system","ATCPTTMT","% of total sales","ITA","Italy","2011","2011",3.3,,
+"PATCSKEL","M-Musculo-skeletal system","ATCPTTMT","% of total sales","ITA","Italy","2012","2012",3.1,,
+"PATCSKEL","M-Musculo-skeletal system","ATCPTTMT","% of total sales","ITA","Italy","2013","2013",2.8,,
+"PATCSKEL","M-Musculo-skeletal system","ATCPTTMT","% of total sales","ITA","Italy","2014","2014",2.5,,
+"PATCSKEL","M-Musculo-skeletal system","ATCPTTMT","% of total sales","ITA","Italy","2015","2015",2.1,,
+"PATCSKEL","M-Musculo-skeletal system","ATCPTTMT","% of total sales","ITA","Italy","2016","2016",2.1,,
+"PATCSKEL","M-Musculo-skeletal system","ATCPTTMT","% of total sales","ITA","Italy","2017","2017",2,,
+"PATCSKEL","M-Musculo-skeletal system","ATCPTTMT","% of total sales","ITA","Italy","2018","2018",2.4,,
+"PATCSKEL","M-Musculo-skeletal system","ATCPTTMT","% of total sales","ITA","Italy","2019","2019",2.4,,
+"PATCSKEL","M-Musculo-skeletal system","ATCPTTMT","% of total sales","ITA","Italy","2020","2020",2.3,,
+"PATCSKEL","M-Musculo-skeletal system","ATCPTTMT","% of total sales","ITA","Italy","2021","2021",2.2,,
+"PATCSKEL","M-Musculo-skeletal system","ATCPTTMT","% of total sales","ITA","Italy","2022","2022",2.3,"E","Estimated value"
+"PATCSKEL","M-Musculo-skeletal system","MLLNCUMT","Million of national currency units","KOR","Korea","2010","2010",1236172,,
+"PATCSKEL","M-Musculo-skeletal system","MLLNCUMT","Million of national currency units","KOR","Korea","2011","2011",1380748.4,"B","Break"
+"PATCSKEL","M-Musculo-skeletal system","MLLNCUMT","Million of national currency units","KOR","Korea","2012","2012",1278113.1,,
+"PATCSKEL","M-Musculo-skeletal system","MLLNCUMT","Million of national currency units","KOR","Korea","2013","2013",1291743.5,,
+"PATCSKEL","M-Musculo-skeletal system","MLLNCUMT","Million of national currency units","KOR","Korea","2014","2014",1352796.4,,
+"PATCSKEL","M-Musculo-skeletal system","MLLNCUMT","Million of national currency units","KOR","Korea","2015","2015",1360086.7,,
+"PATCSKEL","M-Musculo-skeletal system","MLLNCUMT","Million of national currency units","KOR","Korea","2016","2016",1350832.8,"B","Break"
+"PATCSKEL","M-Musculo-skeletal system","MLLNCUMT","Million of national currency units","KOR","Korea","2017","2017",1415318.7,,
+"PATCSKEL","M-Musculo-skeletal system","MLLNCUMT","Million of national currency units","KOR","Korea","2018","2018",1521399.6,,
+"PATCSKEL","M-Musculo-skeletal system","MLLNCUMT","Million of national currency units","KOR","Korea","2019","2019",1642015.8,,
+"PATCSKEL","M-Musculo-skeletal system","MLLNCUMT","Million of national currency units","KOR","Korea","2020","2020",1708187.4,,
+"PATCSKEL","M-Musculo-skeletal system","MLLNCUMT","Million of national currency units","KOR","Korea","2021","2021",1819792.3,,
+"PATCSKEL","M-Musculo-skeletal system","MTMOTCMT","Million US$ at exchange rate","KOR","Korea","2010","2010",1068.9,,
+"PATCSKEL","M-Musculo-skeletal system","MTMOTCMT","Million US$ at exchange rate","KOR","Korea","2011","2011",1245.9,"B","Break"
+"PATCSKEL","M-Musculo-skeletal system","MTMOTCMT","Million US$ at exchange rate","KOR","Korea","2012","2012",1134.3,,
+"PATCSKEL","M-Musculo-skeletal system","MTMOTCMT","Million US$ at exchange rate","KOR","Korea","2013","2013",1179.7,,
+"PATCSKEL","M-Musculo-skeletal system","MTMOTCMT","Million US$ at exchange rate","KOR","Korea","2014","2014",1284.9,,
+"PATCSKEL","M-Musculo-skeletal system","MTMOTCMT","Million US$ at exchange rate","KOR","Korea","2015","2015",1202.6,,
+"PATCSKEL","M-Musculo-skeletal system","MTMOTCMT","Million US$ at exchange rate","KOR","Korea","2016","2016",1163.7,"B","Break"
+"PATCSKEL","M-Musculo-skeletal system","MTMOTCMT","Million US$ at exchange rate","KOR","Korea","2017","2017",1251.4,,
+"PATCSKEL","M-Musculo-skeletal system","MTMOTCMT","Million US$ at exchange rate","KOR","Korea","2018","2018",1382.9,,
+"PATCSKEL","M-Musculo-skeletal system","MTMOTCMT","Million US$ at exchange rate","KOR","Korea","2019","2019",1409,,
+"PATCSKEL","M-Musculo-skeletal system","MTMOTCMT","Million US$ at exchange rate","KOR","Korea","2020","2020",1447.3,,
+"PATCSKEL","M-Musculo-skeletal system","MTMOTCMT","Million US$ at exchange rate","KOR","Korea","2021","2021",1590.8,,
+"PATCSKEL","M-Musculo-skeletal system","MTMOPPMT","Million US$, purchasing power parity","KOR","Korea","2010","2010",1469.9,,
+"PATCSKEL","M-Musculo-skeletal system","MTMOPPMT","Million US$, purchasing power parity","KOR","Korea","2011","2011",1615.7,"B","Break"
+"PATCSKEL","M-Musculo-skeletal system","MTMOPPMT","Million US$, purchasing power parity","KOR","Korea","2012","2012",1495.1,,
+"PATCSKEL","M-Musculo-skeletal system","MTMOPPMT","Million US$, purchasing power parity","KOR","Korea","2013","2013",1486.3,,
+"PATCSKEL","M-Musculo-skeletal system","MTMOPPMT","Million US$, purchasing power parity","KOR","Korea","2014","2014",1551.6,,
+"PATCSKEL","M-Musculo-skeletal system","MTMOPPMT","Million US$, purchasing power parity","KOR","Korea","2015","2015",1586.1,,
+"PATCSKEL","M-Musculo-skeletal system","MTMOPPMT","Million US$, purchasing power parity","KOR","Korea","2016","2016",1572.9,"B","Break"
+"PATCSKEL","M-Musculo-skeletal system","MTMOPPMT","Million US$, purchasing power parity","KOR","Korea","2017","2017",1621.9,,
+"PATCSKEL","M-Musculo-skeletal system","MTMOPPMT","Million US$, purchasing power parity","KOR","Korea","2018","2018",1779.7,,
+"PATCSKEL","M-Musculo-skeletal system","MTMOPPMT","Million US$, purchasing power parity","KOR","Korea","2019","2019",1917.3,,
+"PATCSKEL","M-Musculo-skeletal system","MTMOPPMT","Million US$, purchasing power parity","KOR","Korea","2020","2020",2039.2,,
+"PATCSKEL","M-Musculo-skeletal system","MTMOPPMT","Million US$, purchasing power parity","KOR","Korea","2021","2021",2130.7,,
+"PATCSKEL","M-Musculo-skeletal system","TCPPERMT","/capita, US$ exchange rate","KOR","Korea","2010","2010",21.6,,
+"PATCSKEL","M-Musculo-skeletal system","TCPPERMT","/capita, US$ exchange rate","KOR","Korea","2011","2011",24.9,"B","Break"
+"PATCSKEL","M-Musculo-skeletal system","TCPPERMT","/capita, US$ exchange rate","KOR","Korea","2012","2012",22.6,,
+"PATCSKEL","M-Musculo-skeletal system","TCPPERMT","/capita, US$ exchange rate","KOR","Korea","2013","2013",23.4,,
+"PATCSKEL","M-Musculo-skeletal system","TCPPERMT","/capita, US$ exchange rate","KOR","Korea","2014","2014",25.3,,
+"PATCSKEL","M-Musculo-skeletal system","TCPPERMT","/capita, US$ exchange rate","KOR","Korea","2015","2015",23.6,,
+"PATCSKEL","M-Musculo-skeletal system","TCPPERMT","/capita, US$ exchange rate","KOR","Korea","2016","2016",22.7,"B","Break"
+"PATCSKEL","M-Musculo-skeletal system","TCPPERMT","/capita, US$ exchange rate","KOR","Korea","2017","2017",24.4,,
+"PATCSKEL","M-Musculo-skeletal system","TCPPERMT","/capita, US$ exchange rate","KOR","Korea","2018","2018",26.8,,
+"PATCSKEL","M-Musculo-skeletal system","TCPPERMT","/capita, US$ exchange rate","KOR","Korea","2019","2019",27.2,,
+"PATCSKEL","M-Musculo-skeletal system","TCPPERMT","/capita, US$ exchange rate","KOR","Korea","2020","2020",27.9,,
+"PATCSKEL","M-Musculo-skeletal system","TCPPERMT","/capita, US$ exchange rate","KOR","Korea","2021","2021",30.7,,
+"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2010","2010",29.7,,
+"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2011","2011",32.4,"B","Break"
+"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2012","2012",29.8,,
+"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2013","2013",29.5,,
+"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2014","2014",30.6,,
+"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2015","2015",31.1,,
+"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2016","2016",30.7,"B","Break"
+"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2017","2017",31.6,,
+"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2018","2018",34.5,,
+"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2019","2019",37,,
+"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2020","2020",39.3,,
+"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2021","2021",41.2,,
+"PATCSKEL","M-Musculo-skeletal system","ATCPTTMT","% of total sales","KOR","Korea","2010","2010",6.1,,
+"PATCSKEL","M-Musculo-skeletal system","ATCPTTMT","% of total sales","KOR","Korea","2011","2011",6.3,"B","Break"
+"PATCSKEL","M-Musculo-skeletal system","ATCPTTMT","% of total sales","KOR","Korea","2012","2012",5.9,,
+"PATCSKEL","M-Musculo-skeletal system","ATCPTTMT","% of total sales","KOR","Korea","2013","2013",5.7,,
+"PATCSKEL","M-Musculo-skeletal system","ATCPTTMT","% of total sales","KOR","Korea","2014","2014",5.7,,
+"PATCSKEL","M-Musculo-skeletal system","ATCPTTMT","% of total sales","KOR","Korea","2015","2015",5.5,,
+"PATCSKEL","M-Musculo-skeletal system","ATCPTTMT","% of total sales","KOR","Korea","2016","2016",5.3,"B","Break"
+"PATCSKEL","M-Musculo-skeletal system","ATCPTTMT","% of total sales","KOR","Korea","2017","2017",5.3,,
+"PATCSKEL","M-Musculo-skeletal system","ATCPTTMT","% of total sales","KOR","Korea","2018","2018",5.3,,
+"PATCSKEL","M-Musculo-skeletal system","ATCPTTMT","% of total sales","KOR","Korea","2019","2019",5.3,,
+"PATCSKEL","M-Musculo-skeletal system","ATCPTTMT","% of total sales","KOR","Korea","2020","2020",5.3,,
+"PATCSKEL","M-Musculo-skeletal system","ATCPTTMT","% of total sales","KOR","Korea","2021","2021",5.2,,
+"PATCSKEL","M-Musculo-skeletal system","MLLNCUMT","Million of national currency units","LUX","Luxembourg","2010","2010",9.7,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","MLLNCUMT","Million of national currency units","LUX","Luxembourg","2011","2011",9.2,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","MLLNCUMT","Million of national currency units","LUX","Luxembourg","2012","2012",9.8,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","MLLNCUMT","Million of national currency units","LUX","Luxembourg","2013","2013",10.5,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","MLLNCUMT","Million of national currency units","LUX","Luxembourg","2014","2014",10.7,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","MLLNCUMT","Million of national currency units","LUX","Luxembourg","2015","2015",10.8,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","MLLNCUMT","Million of national currency units","LUX","Luxembourg","2016","2016",11.2,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","MLLNCUMT","Million of national currency units","LUX","Luxembourg","2017","2017",10.7,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","MLLNCUMT","Million of national currency units","LUX","Luxembourg","2018","2018",10.5,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","MLLNCUMT","Million of national currency units","LUX","Luxembourg","2019","2019",9.9,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","MLLNCUMT","Million of national currency units","LUX","Luxembourg","2020","2020",8.6,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","MLLNCUMT","Million of national currency units","LUX","Luxembourg","2021","2021",9.2,"B; D; P","Break; Difference in methodology; Provisional value"
+"PATCSKEL","M-Musculo-skeletal system","MLLNCUMT","Million of national currency units","LUX","Luxembourg","2022","2022",9.1,"D; P","Difference in methodology; Provisional value"
+"PATCSKEL","M-Musculo-skeletal system","MTMOTCMT","Million US$ at exchange rate","LUX","Luxembourg","2010","2010",12.8,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","MTMOTCMT","Million US$ at exchange rate","LUX","Luxembourg","2011","2011",12.8,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","MTMOTCMT","Million US$ at exchange rate","LUX","Luxembourg","2012","2012",12.6,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","MTMOTCMT","Million US$ at exchange rate","LUX","Luxembourg","2013","2013",13.9,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","MTMOTCMT","Million US$ at exchange rate","LUX","Luxembourg","2014","2014",14.2,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","MTMOTCMT","Million US$ at exchange rate","LUX","Luxembourg","2015","2015",11.9,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","MTMOTCMT","Million US$ at exchange rate","LUX","Luxembourg","2016","2016",12.4,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","MTMOTCMT","Million US$ at exchange rate","LUX","Luxembourg","2017","2017",12.1,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","MTMOTCMT","Million US$ at exchange rate","LUX","Luxembourg","2018","2018",12.4,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","MTMOTCMT","Million US$ at exchange rate","LUX","Luxembourg","2019","2019",11.1,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","MTMOTCMT","Million US$ at exchange rate","LUX","Luxembourg","2020","2020",9.8,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","MTMOTCMT","Million US$ at exchange rate","LUX","Luxembourg","2021","2021",10.9,"B; D; P","Break; Difference in methodology; Provisional value"
+"PATCSKEL","M-Musculo-skeletal system","MTMOTCMT","Million US$ at exchange rate","LUX","Luxembourg","2022","2022",9.6,"D; P","Difference in methodology; Provisional value"
+"PATCSKEL","M-Musculo-skeletal system","MTMOPPMT","Million US$, purchasing power parity","LUX","Luxembourg","2010","2010",10.4,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","MTMOPPMT","Million US$, purchasing power parity","LUX","Luxembourg","2011","2011",10.2,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","MTMOPPMT","Million US$, purchasing power parity","LUX","Luxembourg","2012","2012",10.8,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","MTMOPPMT","Million US$, purchasing power parity","LUX","Luxembourg","2013","2013",11.7,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","MTMOPPMT","Million US$, purchasing power parity","LUX","Luxembourg","2014","2014",12.1,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","MTMOPPMT","Million US$, purchasing power parity","LUX","Luxembourg","2015","2015",12.2,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","MTMOPPMT","Million US$, purchasing power parity","LUX","Luxembourg","2016","2016",13.1,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","MTMOPPMT","Million US$, purchasing power parity","LUX","Luxembourg","2017","2017",12.6,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","MTMOPPMT","Million US$, purchasing power parity","LUX","Luxembourg","2018","2018",12.3,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","MTMOPPMT","Million US$, purchasing power parity","LUX","Luxembourg","2019","2019",11.8,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","MTMOPPMT","Million US$, purchasing power parity","LUX","Luxembourg","2020","2020",10.1,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","MTMOPPMT","Million US$, purchasing power parity","LUX","Luxembourg","2021","2021",10.7,"B; D; P","Break; Difference in methodology; Provisional value"
+"PATCSKEL","M-Musculo-skeletal system","MTMOPPMT","Million US$, purchasing power parity","LUX","Luxembourg","2022","2022",11,"D; P","Difference in methodology; Provisional value"
+"PATCSKEL","M-Musculo-skeletal system","TCPPERMT","/capita, US$ exchange rate","LUX","Luxembourg","2010","2010",27,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","TCPPERMT","/capita, US$ exchange rate","LUX","Luxembourg","2011","2011",26.7,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","TCPPERMT","/capita, US$ exchange rate","LUX","Luxembourg","2012","2012",25.6,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","TCPPERMT","/capita, US$ exchange rate","LUX","Luxembourg","2013","2013",27.8,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","TCPPERMT","/capita, US$ exchange rate","LUX","Luxembourg","2014","2014",27.9,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","TCPPERMT","/capita, US$ exchange rate","LUX","Luxembourg","2015","2015",23,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","TCPPERMT","/capita, US$ exchange rate","LUX","Luxembourg","2016","2016",23.5,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","TCPPERMT","/capita, US$ exchange rate","LUX","Luxembourg","2017","2017",22.5,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","TCPPERMT","/capita, US$ exchange rate","LUX","Luxembourg","2018","2018",22.6,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","TCPPERMT","/capita, US$ exchange rate","LUX","Luxembourg","2019","2019",20,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","TCPPERMT","/capita, US$ exchange rate","LUX","Luxembourg","2020","2020",17.3,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","TCPPERMT","/capita, US$ exchange rate","LUX","Luxembourg","2021","2021",18.9,"B; D; P","Break; Difference in methodology; Provisional value"
+"PATCSKEL","M-Musculo-skeletal system","TCPPERMT","/capita, US$ exchange rate","LUX","Luxembourg","2022","2022",16.4,"D; P","Difference in methodology; Provisional value"
+"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2010","2010",22,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2011","2011",21.2,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2012","2012",21.9,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2013","2013",23.4,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2014","2014",23.7,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2015","2015",23.5,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2016","2016",25,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2017","2017",23.5,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2018","2018",22.6,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2019","2019",21.2,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2020","2020",17.7,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2021","2021",18.6,"B; D; P","Break; Difference in methodology; Provisional value"
+"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2022","2022",18.7,"D; P","Difference in methodology; Provisional value"
+"PATCSKEL","M-Musculo-skeletal system","ATCPTTMT","% of total sales","LUX","Luxembourg","2010","2010",5.1,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","ATCPTTMT","% of total sales","LUX","Luxembourg","2011","2011",4.8,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","ATCPTTMT","% of total sales","LUX","Luxembourg","2012","2012",5,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","ATCPTTMT","% of total sales","LUX","Luxembourg","2013","2013",5.4,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","ATCPTTMT","% of total sales","LUX","Luxembourg","2014","2014",5.6,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","ATCPTTMT","% of total sales","LUX","Luxembourg","2015","2015",5.6,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","ATCPTTMT","% of total sales","LUX","Luxembourg","2016","2016",5.7,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","ATCPTTMT","% of total sales","LUX","Luxembourg","2017","2017",5.5,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","ATCPTTMT","% of total sales","LUX","Luxembourg","2018","2018",5.3,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","ATCPTTMT","% of total sales","LUX","Luxembourg","2019","2019",4.9,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","ATCPTTMT","% of total sales","LUX","Luxembourg","2020","2020",4.1,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","ATCPTTMT","% of total sales","LUX","Luxembourg","2021","2021",3.8,"B; D; P","Break; Difference in methodology; Provisional value"
+"PATCSKEL","M-Musculo-skeletal system","ATCPTTMT","% of total sales","LUX","Luxembourg","2022","2022",3.5,"D; P","Difference in methodology; Provisional value"
+"PATCSKEL","M-Musculo-skeletal system","MLLNCUMT","Million of national currency units","MEX","Mexico","2010","2010",5495,,
+"PATCSKEL","M-Musculo-skeletal system","MLLNCUMT","Million of national currency units","MEX","Mexico","2011","2011",4208,,
+"PATCSKEL","M-Musculo-skeletal system","MLLNCUMT","Million of national currency units","MEX","Mexico","2012","2012",4445,,
+"PATCSKEL","M-Musculo-skeletal system","MLLNCUMT","Million of national currency units","MEX","Mexico","2013","2013",3553,,
+"PATCSKEL","M-Musculo-skeletal system","MLLNCUMT","Million of national currency units","MEX","Mexico","2014","2014",3091,,
+"PATCSKEL","M-Musculo-skeletal system","MLLNCUMT","Million of national currency units","MEX","Mexico","2015","2015",3283,,
+"PATCSKEL","M-Musculo-skeletal system","MLLNCUMT","Million of national currency units","MEX","Mexico","2016","2016",2604,,
+"PATCSKEL","M-Musculo-skeletal system","MLLNCUMT","Million of national currency units","MEX","Mexico","2017","2017",2708,,
+"PATCSKEL","M-Musculo-skeletal system","MLLNCUMT","Million of national currency units","MEX","Mexico","2018","2018",2023,,
+"PATCSKEL","M-Musculo-skeletal system","MLLNCUMT","Million of national currency units","MEX","Mexico","2019","2019",2559.3,,
+"PATCSKEL","M-Musculo-skeletal system","MLLNCUMT","Million of national currency units","MEX","Mexico","2020","2020",2274.8,,
+"PATCSKEL","M-Musculo-skeletal system","MLLNCUMT","Million of national currency units","MEX","Mexico","2021","2021",2395.3,,
+"PATCSKEL","M-Musculo-skeletal system","MLLNCUMT","Million of national currency units","MEX","Mexico","2022","2022",2280.5,"E","Estimated value"
+"PATCSKEL","M-Musculo-skeletal system","MTMOTCMT","Million US$ at exchange rate","MEX","Mexico","2010","2010",434.9,,
+"PATCSKEL","M-Musculo-skeletal system","MTMOTCMT","Million US$ at exchange rate","MEX","Mexico","2011","2011",338.7,,
+"PATCSKEL","M-Musculo-skeletal system","MTMOTCMT","Million US$ at exchange rate","MEX","Mexico","2012","2012",337.5,,
+"PATCSKEL","M-Musculo-skeletal system","MTMOTCMT","Million US$ at exchange rate","MEX","Mexico","2013","2013",278.2,,
+"PATCSKEL","M-Musculo-skeletal system","MTMOTCMT","Million US$ at exchange rate","MEX","Mexico","2014","2014",232.5,,
+"PATCSKEL","M-Musculo-skeletal system","MTMOTCMT","Million US$ at exchange rate","MEX","Mexico","2015","2015",207.2,,
+"PATCSKEL","M-Musculo-skeletal system","MTMOTCMT","Million US$ at exchange rate","MEX","Mexico","2016","2016",139.5,,
+"PATCSKEL","M-Musculo-skeletal system","MTMOTCMT","Million US$ at exchange rate","MEX","Mexico","2017","2017",143.1,,
+"PATCSKEL","M-Musculo-skeletal system","MTMOTCMT","Million US$ at exchange rate","MEX","Mexico","2018","2018",105.1,,
+"PATCSKEL","M-Musculo-skeletal system","MTMOTCMT","Million US$ at exchange rate","MEX","Mexico","2019","2019",132.9,,
+"PATCSKEL","M-Musculo-skeletal system","MTMOTCMT","Million US$ at exchange rate","MEX","Mexico","2020","2020",105.9,,
+"PATCSKEL","M-Musculo-skeletal system","MTMOTCMT","Million US$ at exchange rate","MEX","Mexico","2021","2021",118.2,,
+"PATCSKEL","M-Musculo-skeletal system","MTMOTCMT","Million US$ at exchange rate","MEX","Mexico","2022","2022",113.3,"E","Estimated value"
+"PATCSKEL","M-Musculo-skeletal system","MTMOPPMT","Million US$, purchasing power parity","MEX","Mexico","2010","2010",715.5,,
+"PATCSKEL","M-Musculo-skeletal system","MTMOPPMT","Million US$, purchasing power parity","MEX","Mexico","2011","2011",548.4,,
+"PATCSKEL","M-Musculo-skeletal system","MTMOPPMT","Million US$, purchasing power parity","MEX","Mexico","2012","2012",565.6,,
+"PATCSKEL","M-Musculo-skeletal system","MTMOPPMT","Million US$, purchasing power parity","MEX","Mexico","2013","2013",450.6,,
+"PATCSKEL","M-Musculo-skeletal system","MTMOPPMT","Million US$, purchasing power parity","MEX","Mexico","2014","2014",384.2,,
+"PATCSKEL","M-Musculo-skeletal system","MTMOPPMT","Million US$, purchasing power parity","MEX","Mexico","2015","2015",394.2,,
+"PATCSKEL","M-Musculo-skeletal system","MTMOPPMT","Million US$, purchasing power parity","MEX","Mexico","2016","2016",308.3,,
+"PATCSKEL","M-Musculo-skeletal system","MTMOPPMT","Million US$, purchasing power parity","MEX","Mexico","2017","2017",303.8,,
+"PATCSKEL","M-Musculo-skeletal system","MTMOPPMT","Million US$, purchasing power parity","MEX","Mexico","2018","2018",218.1,,
+"PATCSKEL","M-Musculo-skeletal system","MTMOPPMT","Million US$, purchasing power parity","MEX","Mexico","2019","2019",264.9,,
+"PATCSKEL","M-Musculo-skeletal system","MTMOPPMT","Million US$, purchasing power parity","MEX","Mexico","2020","2020",226.6,,
+"PATCSKEL","M-Musculo-skeletal system","MTMOPPMT","Million US$, purchasing power parity","MEX","Mexico","2021","2021",230.3,,
+"PATCSKEL","M-Musculo-skeletal system","MTMOPPMT","Million US$, purchasing power parity","MEX","Mexico","2022","2022",215.6,"E","Estimated value"
+"PATCSKEL","M-Musculo-skeletal system","TCPPERMT","/capita, US$ exchange rate","MEX","Mexico","2010","2010",3.8,,
+"PATCSKEL","M-Musculo-skeletal system","TCPPERMT","/capita, US$ exchange rate","MEX","Mexico","2011","2011",2.9,,
+"PATCSKEL","M-Musculo-skeletal system","TCPPERMT","/capita, US$ exchange rate","MEX","Mexico","2012","2012",2.9,,
+"PATCSKEL","M-Musculo-skeletal system","TCPPERMT","/capita, US$ exchange rate","MEX","Mexico","2013","2013",2.3,,
+"PATCSKEL","M-Musculo-skeletal system","TCPPERMT","/capita, US$ exchange rate","MEX","Mexico","2014","2014",1.9,,
+"PATCSKEL","M-Musculo-skeletal system","TCPPERMT","/capita, US$ exchange rate","MEX","Mexico","2015","2015",1.7,,
+"PATCSKEL","M-Musculo-skeletal system","TCPPERMT","/capita, US$ exchange rate","MEX","Mexico","2016","2016",1.1,,
+"PATCSKEL","M-Musculo-skeletal system","TCPPERMT","/capita, US$ exchange rate","MEX","Mexico","2017","2017",1.2,,
+"PATCSKEL","M-Musculo-skeletal system","TCPPERMT","/capita, US$ exchange rate","MEX","Mexico","2018","2018",0.8,,
+"PATCSKEL","M-Musculo-skeletal system","TCPPERMT","/capita, US$ exchange rate","MEX","Mexico","2019","2019",1,,
+"PATCSKEL","M-Musculo-skeletal system","TCPPERMT","/capita, US$ exchange rate","MEX","Mexico","2020","2020",0.8,,
+"PATCSKEL","M-Musculo-skeletal system","TCPPERMT","/capita, US$ exchange rate","MEX","Mexico","2021","2021",0.9,,
+"PATCSKEL","M-Musculo-skeletal system","TCPPERMT","/capita, US$ exchange rate","MEX","Mexico","2022","2022",0.9,"E","Estimated value"
+"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","MEX","Mexico","2010","2010",6.3,,
+"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","MEX","Mexico","2011","2011",4.8,,
+"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","MEX","Mexico","2012","2012",4.8,,
+"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","MEX","Mexico","2013","2013",3.8,,
+"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","MEX","Mexico","2014","2014",3.2,,
+"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","MEX","Mexico","2015","2015",3.2,,
+"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","MEX","Mexico","2016","2016",2.5,,
+"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","MEX","Mexico","2017","2017",2.4,,
+"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","MEX","Mexico","2018","2018",1.7,,
+"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","MEX","Mexico","2019","2019",2.1,,
+"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","MEX","Mexico","2020","2020",1.8,,
+"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","MEX","Mexico","2021","2021",1.8,,
+"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","MEX","Mexico","2022","2022",1.7,"E","Estimated value"
+"PATCSKEL","M-Musculo-skeletal system","ATCPTTMT","% of total sales","MEX","Mexico","2013","2013",2.5,,
+"PATCSKEL","M-Musculo-skeletal system","ATCPTTMT","% of total sales","MEX","Mexico","2018","2018",0.9,,
+"PATCSKEL","M-Musculo-skeletal system","MLLNCUMT","Million of national currency units","NLD","Netherlands","2010","2010",160.1,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","MLLNCUMT","Million of national currency units","NLD","Netherlands","2011","2011",148.4,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","MLLNCUMT","Million of national currency units","NLD","Netherlands","2012","2012",136.5,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","MLLNCUMT","Million of national currency units","NLD","Netherlands","2013","2013",133.3,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","MLLNCUMT","Million of national currency units","NLD","Netherlands","2014","2014",121.1,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","MTMOTCMT","Million US$ at exchange rate","NLD","Netherlands","2010","2010",212.2,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","MTMOTCMT","Million US$ at exchange rate","NLD","Netherlands","2011","2011",206.6,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","MTMOTCMT","Million US$ at exchange rate","NLD","Netherlands","2012","2012",175.4,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","MTMOTCMT","Million US$ at exchange rate","NLD","Netherlands","2013","2013",177.1,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","MTMOTCMT","Million US$ at exchange rate","NLD","Netherlands","2014","2014",160.9,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","MTMOPPMT","Million US$, purchasing power parity","NLD","Netherlands","2010","2010",187.4,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","MTMOPPMT","Million US$, purchasing power parity","NLD","Netherlands","2011","2011",177.5,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","MTMOPPMT","Million US$, purchasing power parity","NLD","Netherlands","2012","2012",165.6,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","MTMOPPMT","Million US$, purchasing power parity","NLD","Netherlands","2013","2013",167.1,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","MTMOPPMT","Million US$, purchasing power parity","NLD","Netherlands","2014","2014",149.7,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","TCPPERMT","/capita, US$ exchange rate","NLD","Netherlands","2010","2010",12.8,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","TCPPERMT","/capita, US$ exchange rate","NLD","Netherlands","2011","2011",12.4,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","TCPPERMT","/capita, US$ exchange rate","NLD","Netherlands","2012","2012",10.5,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","TCPPERMT","/capita, US$ exchange rate","NLD","Netherlands","2013","2013",10.5,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","TCPPERMT","/capita, US$ exchange rate","NLD","Netherlands","2014","2014",9.5,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","NLD","Netherlands","2010","2010",11.3,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","NLD","Netherlands","2011","2011",10.6,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","NLD","Netherlands","2012","2012",9.9,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","NLD","Netherlands","2013","2013",9.9,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","NLD","Netherlands","2014","2014",8.9,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","ATCPTTMT","% of total sales","NLD","Netherlands","2010","2010",3.1,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","ATCPTTMT","% of total sales","NLD","Netherlands","2011","2011",2.8,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","ATCPTTMT","% of total sales","NLD","Netherlands","2012","2012",3,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","ATCPTTMT","% of total sales","NLD","Netherlands","2013","2013",3.1,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","ATCPTTMT","% of total sales","NLD","Netherlands","2014","2014",2.8,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","MLLNCUMT","Million of national currency units","NZL","New Zealand","2010","2010",25.8,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","MLLNCUMT","Million of national currency units","NZL","New Zealand","2011","2011",26.2,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","MLLNCUMT","Million of national currency units","NZL","New Zealand","2012","2012",23.3,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","MLLNCUMT","Million of national currency units","NZL","New Zealand","2013","2013",24.3,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","MLLNCUMT","Million of national currency units","NZL","New Zealand","2014","2014",24.8,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","MLLNCUMT","Million of national currency units","NZL","New Zealand","2015","2015",21.9,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","MLLNCUMT","Million of national currency units","NZL","New Zealand","2016","2016",21.7,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","MLLNCUMT","Million of national currency units","NZL","New Zealand","2017","2017",21.7,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","MLLNCUMT","Million of national currency units","NZL","New Zealand","2018","2018",23.6,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","MLLNCUMT","Million of national currency units","NZL","New Zealand","2019","2019",24,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","MLLNCUMT","Million of national currency units","NZL","New Zealand","2020","2020",12.8,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","MLLNCUMT","Million of national currency units","NZL","New Zealand","2021","2021",14.8,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","MLLNCUMT","Million of national currency units","NZL","New Zealand","2022","2022",18.9,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","MTMOTCMT","Million US$ at exchange rate","NZL","New Zealand","2010","2010",18.6,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","MTMOTCMT","Million US$ at exchange rate","NZL","New Zealand","2011","2011",20.7,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","MTMOTCMT","Million US$ at exchange rate","NZL","New Zealand","2012","2012",18.9,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","MTMOTCMT","Million US$ at exchange rate","NZL","New Zealand","2013","2013",19.9,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","MTMOTCMT","Million US$ at exchange rate","NZL","New Zealand","2014","2014",20.6,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","MTMOTCMT","Million US$ at exchange rate","NZL","New Zealand","2015","2015",15.3,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","MTMOTCMT","Million US$ at exchange rate","NZL","New Zealand","2016","2016",15.1,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","MTMOTCMT","Million US$ at exchange rate","NZL","New Zealand","2017","2017",15.4,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","MTMOTCMT","Million US$ at exchange rate","NZL","New Zealand","2018","2018",16.3,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","MTMOTCMT","Million US$ at exchange rate","NZL","New Zealand","2019","2019",15.8,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","MTMOTCMT","Million US$ at exchange rate","NZL","New Zealand","2020","2020",8.3,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","MTMOTCMT","Million US$ at exchange rate","NZL","New Zealand","2021","2021",10.4,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","MTMOTCMT","Million US$ at exchange rate","NZL","New Zealand","2022","2022",12,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","MTMOPPMT","Million US$, purchasing power parity","NZL","New Zealand","2010","2010",17.2,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","MTMOPPMT","Million US$, purchasing power parity","NZL","New Zealand","2011","2011",17.6,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","MTMOPPMT","Million US$, purchasing power parity","NZL","New Zealand","2012","2012",15.6,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","MTMOPPMT","Million US$, purchasing power parity","NZL","New Zealand","2013","2013",16.8,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","MTMOPPMT","Million US$, purchasing power parity","NZL","New Zealand","2014","2014",17.2,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","MTMOPPMT","Million US$, purchasing power parity","NZL","New Zealand","2015","2015",14.8,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","MTMOPPMT","Million US$, purchasing power parity","NZL","New Zealand","2016","2016",15.1,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","MTMOPPMT","Million US$, purchasing power parity","NZL","New Zealand","2017","2017",15.2,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","MTMOPPMT","Million US$, purchasing power parity","NZL","New Zealand","2018","2018",16,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","MTMOPPMT","Million US$, purchasing power parity","NZL","New Zealand","2019","2019",16.9,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","MTMOPPMT","Million US$, purchasing power parity","NZL","New Zealand","2020","2020",9,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","MTMOPPMT","Million US$, purchasing power parity","NZL","New Zealand","2021","2021",10.1,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","MTMOPPMT","Million US$, purchasing power parity","NZL","New Zealand","2022","2022",13.1,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","TCPPERMT","/capita, US$ exchange rate","NZL","New Zealand","2010","2010",4.3,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","TCPPERMT","/capita, US$ exchange rate","NZL","New Zealand","2011","2011",4.7,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","TCPPERMT","/capita, US$ exchange rate","NZL","New Zealand","2012","2012",4.3,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","TCPPERMT","/capita, US$ exchange rate","NZL","New Zealand","2013","2013",4.5,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","TCPPERMT","/capita, US$ exchange rate","NZL","New Zealand","2014","2014",4.6,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","TCPPERMT","/capita, US$ exchange rate","NZL","New Zealand","2015","2015",3.3,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","TCPPERMT","/capita, US$ exchange rate","NZL","New Zealand","2016","2016",3.2,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","TCPPERMT","/capita, US$ exchange rate","NZL","New Zealand","2017","2017",3.2,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","TCPPERMT","/capita, US$ exchange rate","NZL","New Zealand","2018","2018",3.3,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","TCPPERMT","/capita, US$ exchange rate","NZL","New Zealand","2019","2019",3.2,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","TCPPERMT","/capita, US$ exchange rate","NZL","New Zealand","2020","2020",1.6,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","TCPPERMT","/capita, US$ exchange rate","NZL","New Zealand","2021","2021",2,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","TCPPERMT","/capita, US$ exchange rate","NZL","New Zealand","2022","2022",2.3,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2010","2010",4,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2011","2011",4,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2012","2012",3.5,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2013","2013",3.8,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2014","2014",3.8,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2015","2015",3.2,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2016","2016",3.2,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2017","2017",3.1,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2018","2018",3.3,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2019","2019",3.4,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2020","2020",1.8,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2021","2021",2,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2022","2022",2.6,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","ATCPTTMT","% of total sales","NZL","New Zealand","2010","2010",3.4,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","ATCPTTMT","% of total sales","NZL","New Zealand","2011","2011",3.2,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","ATCPTTMT","% of total sales","NZL","New Zealand","2012","2012",2.5,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","ATCPTTMT","% of total sales","NZL","New Zealand","2013","2013",2.6,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","ATCPTTMT","% of total sales","NZL","New Zealand","2014","2014",2.6,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","ATCPTTMT","% of total sales","NZL","New Zealand","2015","2015",2.2,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","ATCPTTMT","% of total sales","NZL","New Zealand","2016","2016",2,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","ATCPTTMT","% of total sales","NZL","New Zealand","2017","2017",1.7,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","ATCPTTMT","% of total sales","NZL","New Zealand","2018","2018",1.8,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","ATCPTTMT","% of total sales","NZL","New Zealand","2019","2019",1.6,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","ATCPTTMT","% of total sales","NZL","New Zealand","2020","2020",0.8,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","ATCPTTMT","% of total sales","NZL","New Zealand","2021","2021",0.8,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","ATCPTTMT","% of total sales","NZL","New Zealand","2022","2022",1,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","MLLNCUMT","Million of national currency units","NOR","Norway","2010","2010",609,,
+"PATCSKEL","M-Musculo-skeletal system","MLLNCUMT","Million of national currency units","NOR","Norway","2011","2011",630,,
+"PATCSKEL","M-Musculo-skeletal system","MLLNCUMT","Million of national currency units","NOR","Norway","2012","2012",661,,
+"PATCSKEL","M-Musculo-skeletal system","MLLNCUMT","Million of national currency units","NOR","Norway","2013","2013",714,,
+"PATCSKEL","M-Musculo-skeletal system","MLLNCUMT","Million of national currency units","NOR","Norway","2014","2014",754,,
+"PATCSKEL","M-Musculo-skeletal system","MLLNCUMT","Million of national currency units","NOR","Norway","2015","2015",833,,
+"PATCSKEL","M-Musculo-skeletal system","MLLNCUMT","Million of national currency units","NOR","Norway","2016","2016",922,,
+"PATCSKEL","M-Musculo-skeletal system","MLLNCUMT","Million of national currency units","NOR","Norway","2017","2017",998,,
+"PATCSKEL","M-Musculo-skeletal system","MLLNCUMT","Million of national currency units","NOR","Norway","2018","2018",1137,,
+"PATCSKEL","M-Musculo-skeletal system","MLLNCUMT","Million of national currency units","NOR","Norway","2019","2019",1165,,
+"PATCSKEL","M-Musculo-skeletal system","MLLNCUMT","Million of national currency units","NOR","Norway","2020","2020",1152,,
+"PATCSKEL","M-Musculo-skeletal system","MLLNCUMT","Million of national currency units","NOR","Norway","2021","2021",1336,,
+"PATCSKEL","M-Musculo-skeletal system","MLLNCUMT","Million of national currency units","NOR","Norway","2022","2022",1417,,
+"PATCSKEL","M-Musculo-skeletal system","MTMOTCMT","Million US$ at exchange rate","NOR","Norway","2010","2010",100.8,,
+"PATCSKEL","M-Musculo-skeletal system","MTMOTCMT","Million US$ at exchange rate","NOR","Norway","2011","2011",112.4,,
+"PATCSKEL","M-Musculo-skeletal system","MTMOTCMT","Million US$ at exchange rate","NOR","Norway","2012","2012",113.6,,
+"PATCSKEL","M-Musculo-skeletal system","MTMOTCMT","Million US$ at exchange rate","NOR","Norway","2013","2013",121.5,,
+"PATCSKEL","M-Musculo-skeletal system","MTMOTCMT","Million US$ at exchange rate","NOR","Norway","2014","2014",119.7,,
+"PATCSKEL","M-Musculo-skeletal system","MTMOTCMT","Million US$ at exchange rate","NOR","Norway","2015","2015",103.3,,
+"PATCSKEL","M-Musculo-skeletal system","MTMOTCMT","Million US$ at exchange rate","NOR","Norway","2016","2016",109.8,,
+"PATCSKEL","M-Musculo-skeletal system","MTMOTCMT","Million US$ at exchange rate","NOR","Norway","2017","2017",120.7,,
+"PATCSKEL","M-Musculo-skeletal system","MTMOTCMT","Million US$ at exchange rate","NOR","Norway","2018","2018",139.8,,
+"PATCSKEL","M-Musculo-skeletal system","MTMOTCMT","Million US$ at exchange rate","NOR","Norway","2019","2019",132.4,,
+"PATCSKEL","M-Musculo-skeletal system","MTMOTCMT","Million US$ at exchange rate","NOR","Norway","2020","2020",122.3,,
+"PATCSKEL","M-Musculo-skeletal system","MTMOTCMT","Million US$ at exchange rate","NOR","Norway","2021","2021",155.5,,
+"PATCSKEL","M-Musculo-skeletal system","MTMOTCMT","Million US$ at exchange rate","NOR","Norway","2022","2022",147.4,,
+"PATCSKEL","M-Musculo-skeletal system","MTMOPPMT","Million US$, purchasing power parity","NOR","Norway","2010","2010",66.5,,
+"PATCSKEL","M-Musculo-skeletal system","MTMOPPMT","Million US$, purchasing power parity","NOR","Norway","2011","2011",69.4,,
+"PATCSKEL","M-Musculo-skeletal system","MTMOPPMT","Million US$, purchasing power parity","NOR","Norway","2012","2012",73.1,,
+"PATCSKEL","M-Musculo-skeletal system","MTMOPPMT","Million US$, purchasing power parity","NOR","Norway","2013","2013",79.1,,
+"PATCSKEL","M-Musculo-skeletal system","MTMOPPMT","Million US$, purchasing power parity","NOR","Norway","2014","2014",81.3,,
+"PATCSKEL","M-Musculo-skeletal system","MTMOPPMT","Million US$, purchasing power parity","NOR","Norway","2015","2015",83.9,,
+"PATCSKEL","M-Musculo-skeletal system","MTMOPPMT","Million US$, purchasing power parity","NOR","Norway","2016","2016",91.8,,
+"PATCSKEL","M-Musculo-skeletal system","MTMOPPMT","Million US$, purchasing power parity","NOR","Norway","2017","2017",102.4,,
+"PATCSKEL","M-Musculo-skeletal system","MTMOPPMT","Million US$, purchasing power parity","NOR","Norway","2018","2018",118.6,,
+"PATCSKEL","M-Musculo-skeletal system","MTMOPPMT","Million US$, purchasing power parity","NOR","Norway","2019","2019",121.1,,
+"PATCSKEL","M-Musculo-skeletal system","MTMOPPMT","Million US$, purchasing power parity","NOR","Norway","2020","2020",116.6,,
+"PATCSKEL","M-Musculo-skeletal system","MTMOPPMT","Million US$, purchasing power parity","NOR","Norway","2021","2021",140.5,,
+"PATCSKEL","M-Musculo-skeletal system","MTMOPPMT","Million US$, purchasing power parity","NOR","Norway","2022","2022",131.9,,
+"PATCSKEL","M-Musculo-skeletal system","TCPPERMT","/capita, US$ exchange rate","NOR","Norway","2010","2010",20.6,,
+"PATCSKEL","M-Musculo-skeletal system","TCPPERMT","/capita, US$ exchange rate","NOR","Norway","2011","2011",22.7,,
+"PATCSKEL","M-Musculo-skeletal system","TCPPERMT","/capita, US$ exchange rate","NOR","Norway","2012","2012",22.6,,
+"PATCSKEL","M-Musculo-skeletal system","TCPPERMT","/capita, US$ exchange rate","NOR","Norway","2013","2013",23.9,,
+"PATCSKEL","M-Musculo-skeletal system","TCPPERMT","/capita, US$ exchange rate","NOR","Norway","2014","2014",23.3,,
+"PATCSKEL","M-Musculo-skeletal system","TCPPERMT","/capita, US$ exchange rate","NOR","Norway","2015","2015",19.9,,
+"PATCSKEL","M-Musculo-skeletal system","TCPPERMT","/capita, US$ exchange rate","NOR","Norway","2016","2016",21,,
+"PATCSKEL","M-Musculo-skeletal system","TCPPERMT","/capita, US$ exchange rate","NOR","Norway","2017","2017",22.9,,
+"PATCSKEL","M-Musculo-skeletal system","TCPPERMT","/capita, US$ exchange rate","NOR","Norway","2018","2018",26.3,,
+"PATCSKEL","M-Musculo-skeletal system","TCPPERMT","/capita, US$ exchange rate","NOR","Norway","2019","2019",24.8,,
+"PATCSKEL","M-Musculo-skeletal system","TCPPERMT","/capita, US$ exchange rate","NOR","Norway","2020","2020",22.7,,
+"PATCSKEL","M-Musculo-skeletal system","TCPPERMT","/capita, US$ exchange rate","NOR","Norway","2021","2021",28.8,,
+"PATCSKEL","M-Musculo-skeletal system","TCPPERMT","/capita, US$ exchange rate","NOR","Norway","2022","2022",27.2,,
+"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2010","2010",13.6,,
+"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2011","2011",14,,
+"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2012","2012",14.6,,
+"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2013","2013",15.6,,
+"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2014","2014",15.8,,
+"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2015","2015",16.2,,
+"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2016","2016",17.5,,
+"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2017","2017",19.4,,
+"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2018","2018",22.3,,
+"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2019","2019",22.6,,
+"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2020","2020",21.7,,
+"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2021","2021",26,,
+"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2022","2022",24.3,,
+"PATCSKEL","M-Musculo-skeletal system","ATCPTTMT","% of total sales","NOR","Norway","2010","2010",3.4,,
+"PATCSKEL","M-Musculo-skeletal system","ATCPTTMT","% of total sales","NOR","Norway","2011","2011",3.5,,
+"PATCSKEL","M-Musculo-skeletal system","ATCPTTMT","% of total sales","NOR","Norway","2012","2012",3.5,,
+"PATCSKEL","M-Musculo-skeletal system","ATCPTTMT","% of total sales","NOR","Norway","2013","2013",3.7,,
+"PATCSKEL","M-Musculo-skeletal system","ATCPTTMT","% of total sales","NOR","Norway","2014","2014",3.6,,
+"PATCSKEL","M-Musculo-skeletal system","ATCPTTMT","% of total sales","NOR","Norway","2015","2015",3.7,,
+"PATCSKEL","M-Musculo-skeletal system","ATCPTTMT","% of total sales","NOR","Norway","2016","2016",3.7,,
+"PATCSKEL","M-Musculo-skeletal system","ATCPTTMT","% of total sales","NOR","Norway","2017","2017",3.7,,
+"PATCSKEL","M-Musculo-skeletal system","ATCPTTMT","% of total sales","NOR","Norway","2018","2018",4.1,,
+"PATCSKEL","M-Musculo-skeletal system","ATCPTTMT","% of total sales","NOR","Norway","2019","2019",4.1,,
+"PATCSKEL","M-Musculo-skeletal system","ATCPTTMT","% of total sales","NOR","Norway","2020","2020",3.9,,
+"PATCSKEL","M-Musculo-skeletal system","ATCPTTMT","% of total sales","NOR","Norway","2021","2021",4,,
+"PATCSKEL","M-Musculo-skeletal system","ATCPTTMT","% of total sales","NOR","Norway","2022","2022",3.9,,
+"PATCSKEL","M-Musculo-skeletal system","MLLNCUMT","Million of national currency units","PRT","Portugal","2010","2010",252.5,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","MLLNCUMT","Million of national currency units","PRT","Portugal","2011","2011",226.7,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","MLLNCUMT","Million of national currency units","PRT","Portugal","2012","2012",204.3,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","MLLNCUMT","Million of national currency units","PRT","Portugal","2013","2013",184.9,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","MLLNCUMT","Million of national currency units","PRT","Portugal","2014","2014",172.5,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","MLLNCUMT","Million of national currency units","PRT","Portugal","2015","2015",169.1,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","MLLNCUMT","Million of national currency units","PRT","Portugal","2016","2016",167,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","MLLNCUMT","Million of national currency units","PRT","Portugal","2017","2017",161.1,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","MLLNCUMT","Million of national currency units","PRT","Portugal","2018","2018",161,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","MLLNCUMT","Million of national currency units","PRT","Portugal","2019","2019",165.2,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","MLLNCUMT","Million of national currency units","PRT","Portugal","2020","2020",151.9,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","MLLNCUMT","Million of national currency units","PRT","Portugal","2021","2021",160.6,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","MLLNCUMT","Million of national currency units","PRT","Portugal","2022","2022",176.6,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","MTMOTCMT","Million US$ at exchange rate","PRT","Portugal","2010","2010",334.8,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","MTMOTCMT","Million US$ at exchange rate","PRT","Portugal","2011","2011",315.5,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","MTMOTCMT","Million US$ at exchange rate","PRT","Portugal","2012","2012",262.5,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","MTMOTCMT","Million US$ at exchange rate","PRT","Portugal","2013","2013",245.5,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","MTMOTCMT","Million US$ at exchange rate","PRT","Portugal","2014","2014",229.1,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","MTMOTCMT","Million US$ at exchange rate","PRT","Portugal","2015","2015",187.6,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","MTMOTCMT","Million US$ at exchange rate","PRT","Portugal","2016","2016",184.8,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","MTMOTCMT","Million US$ at exchange rate","PRT","Portugal","2017","2017",182,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","MTMOTCMT","Million US$ at exchange rate","PRT","Portugal","2018","2018",190.1,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","MTMOTCMT","Million US$ at exchange rate","PRT","Portugal","2019","2019",185,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","MTMOTCMT","Million US$ at exchange rate","PRT","Portugal","2020","2020",173.4,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","MTMOTCMT","Million US$ at exchange rate","PRT","Portugal","2021","2021",190,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","MTMOTCMT","Million US$ at exchange rate","PRT","Portugal","2022","2022",185.9,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","MTMOPPMT","Million US$, purchasing power parity","PRT","Portugal","2010","2010",405.2,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","MTMOPPMT","Million US$, purchasing power parity","PRT","Portugal","2011","2011",363.8,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","MTMOPPMT","Million US$, purchasing power parity","PRT","Portugal","2012","2012",337.5,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","MTMOPPMT","Million US$, purchasing power parity","PRT","Portugal","2013","2013",316.7,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","MTMOPPMT","Million US$, purchasing power parity","PRT","Portugal","2014","2014",298,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","MTMOPPMT","Million US$, purchasing power parity","PRT","Portugal","2015","2015",289.1,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","MTMOPPMT","Million US$, purchasing power parity","PRT","Portugal","2016","2016",292.2,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","MTMOPPMT","Million US$, purchasing power parity","PRT","Portugal","2017","2017",279.8,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","MTMOPPMT","Million US$, purchasing power parity","PRT","Portugal","2018","2018",281.9,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","MTMOPPMT","Million US$, purchasing power parity","PRT","Portugal","2019","2019",295.7,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","MTMOPPMT","Million US$, purchasing power parity","PRT","Portugal","2020","2020",272.6,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","MTMOPPMT","Million US$, purchasing power parity","PRT","Portugal","2021","2021",282.9,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","MTMOPPMT","Million US$, purchasing power parity","PRT","Portugal","2022","2022",321.1,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","TCPPERMT","/capita, US$ exchange rate","PRT","Portugal","2010","2010",31.7,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","TCPPERMT","/capita, US$ exchange rate","PRT","Portugal","2011","2011",29.9,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","TCPPERMT","/capita, US$ exchange rate","PRT","Portugal","2012","2012",25,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","TCPPERMT","/capita, US$ exchange rate","PRT","Portugal","2013","2013",23.5,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","TCPPERMT","/capita, US$ exchange rate","PRT","Portugal","2014","2014",22,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","TCPPERMT","/capita, US$ exchange rate","PRT","Portugal","2015","2015",18.1,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","TCPPERMT","/capita, US$ exchange rate","PRT","Portugal","2016","2016",17.9,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","TCPPERMT","/capita, US$ exchange rate","PRT","Portugal","2017","2017",17.7,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","TCPPERMT","/capita, US$ exchange rate","PRT","Portugal","2018","2018",18.5,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","TCPPERMT","/capita, US$ exchange rate","PRT","Portugal","2019","2019",18,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","TCPPERMT","/capita, US$ exchange rate","PRT","Portugal","2020","2020",16.8,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","TCPPERMT","/capita, US$ exchange rate","PRT","Portugal","2021","2021",18.3,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","TCPPERMT","/capita, US$ exchange rate","PRT","Portugal","2022","2022",18,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2010","2010",38.3,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2011","2011",34.5,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2012","2012",32.1,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2013","2013",30.3,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2014","2014",28.6,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2015","2015",27.9,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2016","2016",28.3,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2017","2017",27.2,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2018","2018",27.4,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2019","2019",28.7,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2020","2020",26.5,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2021","2021",27.3,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2022","2022",31,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","ATCPTTMT","% of total sales","PRT","Portugal","2010","2010",7.8,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","ATCPTTMT","% of total sales","PRT","Portugal","2011","2011",7.7,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","ATCPTTMT","% of total sales","PRT","Portugal","2012","2012",7.8,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","ATCPTTMT","% of total sales","PRT","Portugal","2013","2013",7.7,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","ATCPTTMT","% of total sales","PRT","Portugal","2014","2014",7.2,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","ATCPTTMT","% of total sales","PRT","Portugal","2015","2015",6.8,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","ATCPTTMT","% of total sales","PRT","Portugal","2016","2016",6.6,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","ATCPTTMT","% of total sales","PRT","Portugal","2017","2017",6.3,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","ATCPTTMT","% of total sales","PRT","Portugal","2018","2018",6.1,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","ATCPTTMT","% of total sales","PRT","Portugal","2019","2019",5.9,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","ATCPTTMT","% of total sales","PRT","Portugal","2020","2020",5.4,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","ATCPTTMT","% of total sales","PRT","Portugal","2021","2021",5.5,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","ATCPTTMT","% of total sales","PRT","Portugal","2022","2022",5.5,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","MLLNCUMT","Million of national currency units","SVK","Slovak Republic","2010","2010",62.9,,
+"PATCSKEL","M-Musculo-skeletal system","MLLNCUMT","Million of national currency units","SVK","Slovak Republic","2011","2011",63.1,,
+"PATCSKEL","M-Musculo-skeletal system","MLLNCUMT","Million of national currency units","SVK","Slovak Republic","2012","2012",59.9,,
+"PATCSKEL","M-Musculo-skeletal system","MLLNCUMT","Million of national currency units","SVK","Slovak Republic","2013","2013",65.8,,
+"PATCSKEL","M-Musculo-skeletal system","MLLNCUMT","Million of national currency units","SVK","Slovak Republic","2014","2014",69.1,,
+"PATCSKEL","M-Musculo-skeletal system","MLLNCUMT","Million of national currency units","SVK","Slovak Republic","2015","2015",67,,
+"PATCSKEL","M-Musculo-skeletal system","MLLNCUMT","Million of national currency units","SVK","Slovak Republic","2016","2016",76.7,"B","Break"
+"PATCSKEL","M-Musculo-skeletal system","MLLNCUMT","Million of national currency units","SVK","Slovak Republic","2017","2017",79.8,,
+"PATCSKEL","M-Musculo-skeletal system","MLLNCUMT","Million of national currency units","SVK","Slovak Republic","2018","2018",84.3,,
+"PATCSKEL","M-Musculo-skeletal system","MLLNCUMT","Million of national currency units","SVK","Slovak Republic","2019","2019",98.2,,
+"PATCSKEL","M-Musculo-skeletal system","MLLNCUMT","Million of national currency units","SVK","Slovak Republic","2020","2020",94.6,,
+"PATCSKEL","M-Musculo-skeletal system","MLLNCUMT","Million of national currency units","SVK","Slovak Republic","2021","2021",107.6,,
+"PATCSKEL","M-Musculo-skeletal system","MTMOTCMT","Million US$ at exchange rate","SVK","Slovak Republic","2010","2010",83.4,,
+"PATCSKEL","M-Musculo-skeletal system","MTMOTCMT","Million US$ at exchange rate","SVK","Slovak Republic","2011","2011",87.8,,
+"PATCSKEL","M-Musculo-skeletal system","MTMOTCMT","Million US$ at exchange rate","SVK","Slovak Republic","2012","2012",77,,
+"PATCSKEL","M-Musculo-skeletal system","MTMOTCMT","Million US$ at exchange rate","SVK","Slovak Republic","2013","2013",87.4,,
+"PATCSKEL","M-Musculo-skeletal system","MTMOTCMT","Million US$ at exchange rate","SVK","Slovak Republic","2014","2014",91.8,,
+"PATCSKEL","M-Musculo-skeletal system","MTMOTCMT","Million US$ at exchange rate","SVK","Slovak Republic","2015","2015",74.4,,
+"PATCSKEL","M-Musculo-skeletal system","MTMOTCMT","Million US$ at exchange rate","SVK","Slovak Republic","2016","2016",84.9,"B","Break"
+"PATCSKEL","M-Musculo-skeletal system","MTMOTCMT","Million US$ at exchange rate","SVK","Slovak Republic","2017","2017",90.2,,
+"PATCSKEL","M-Musculo-skeletal system","MTMOTCMT","Million US$ at exchange rate","SVK","Slovak Republic","2018","2018",99.6,,
+"PATCSKEL","M-Musculo-skeletal system","MTMOTCMT","Million US$ at exchange rate","SVK","Slovak Republic","2019","2019",109.9,,
+"PATCSKEL","M-Musculo-skeletal system","MTMOTCMT","Million US$ at exchange rate","SVK","Slovak Republic","2020","2020",108.1,,
+"PATCSKEL","M-Musculo-skeletal system","MTMOTCMT","Million US$ at exchange rate","SVK","Slovak Republic","2021","2021",127.2,,
+"PATCSKEL","M-Musculo-skeletal system","MTMOPPMT","Million US$, purchasing power parity","SVK","Slovak Republic","2010","2010",125.3,,
+"PATCSKEL","M-Musculo-skeletal system","MTMOPPMT","Million US$, purchasing power parity","SVK","Slovak Republic","2011","2011",124.6,,
+"PATCSKEL","M-Musculo-skeletal system","MTMOPPMT","Million US$, purchasing power parity","SVK","Slovak Republic","2012","2012",118.8,,
+"PATCSKEL","M-Musculo-skeletal system","MTMOPPMT","Million US$, purchasing power parity","SVK","Slovak Republic","2013","2013",133.9,,
+"PATCSKEL","M-Musculo-skeletal system","MTMOPPMT","Million US$, purchasing power parity","SVK","Slovak Republic","2014","2014",142.3,,
+"PATCSKEL","M-Musculo-skeletal system","MTMOPPMT","Million US$, purchasing power parity","SVK","Slovak Republic","2015","2015",136.3,,
+"PATCSKEL","M-Musculo-skeletal system","MTMOPPMT","Million US$, purchasing power parity","SVK","Slovak Republic","2016","2016",152.4,"B","Break"
+"PATCSKEL","M-Musculo-skeletal system","MTMOPPMT","Million US$, purchasing power parity","SVK","Slovak Republic","2017","2017",154.6,,
+"PATCSKEL","M-Musculo-skeletal system","MTMOPPMT","Million US$, purchasing power parity","SVK","Slovak Republic","2018","2018",160.3,,
+"PATCSKEL","M-Musculo-skeletal system","MTMOPPMT","Million US$, purchasing power parity","SVK","Slovak Republic","2019","2019",189.7,,
+"PATCSKEL","M-Musculo-skeletal system","MTMOPPMT","Million US$, purchasing power parity","SVK","Slovak Republic","2020","2020",182,,
+"PATCSKEL","M-Musculo-skeletal system","MTMOPPMT","Million US$, purchasing power parity","SVK","Slovak Republic","2021","2021",201.7,,
+"PATCSKEL","M-Musculo-skeletal system","TCPPERMT","/capita, US$ exchange rate","SVK","Slovak Republic","2010","2010",15.5,,
+"PATCSKEL","M-Musculo-skeletal system","TCPPERMT","/capita, US$ exchange rate","SVK","Slovak Republic","2011","2011",16.3,,
+"PATCSKEL","M-Musculo-skeletal system","TCPPERMT","/capita, US$ exchange rate","SVK","Slovak Republic","2012","2012",14.2,,
+"PATCSKEL","M-Musculo-skeletal system","TCPPERMT","/capita, US$ exchange rate","SVK","Slovak Republic","2013","2013",16.1,,
+"PATCSKEL","M-Musculo-skeletal system","TCPPERMT","/capita, US$ exchange rate","SVK","Slovak Republic","2014","2014",16.9,,
+"PATCSKEL","M-Musculo-skeletal system","TCPPERMT","/capita, US$ exchange rate","SVK","Slovak Republic","2015","2015",13.7,,
+"PATCSKEL","M-Musculo-skeletal system","TCPPERMT","/capita, US$ exchange rate","SVK","Slovak Republic","2016","2016",15.6,"B","Break"
+"PATCSKEL","M-Musculo-skeletal system","TCPPERMT","/capita, US$ exchange rate","SVK","Slovak Republic","2017","2017",16.6,,
+"PATCSKEL","M-Musculo-skeletal system","TCPPERMT","/capita, US$ exchange rate","SVK","Slovak Republic","2018","2018",18.3,,
+"PATCSKEL","M-Musculo-skeletal system","TCPPERMT","/capita, US$ exchange rate","SVK","Slovak Republic","2019","2019",20.2,,
+"PATCSKEL","M-Musculo-skeletal system","TCPPERMT","/capita, US$ exchange rate","SVK","Slovak Republic","2020","2020",19.8,,
+"PATCSKEL","M-Musculo-skeletal system","TCPPERMT","/capita, US$ exchange rate","SVK","Slovak Republic","2021","2021",23.4,,
+"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2010","2010",23.2,,
+"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2011","2011",23.1,,
+"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2012","2012",22,,
+"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2013","2013",24.7,,
+"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2014","2014",26.3,,
+"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2015","2015",25.1,,
+"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2016","2016",28.1,"B","Break"
+"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2017","2017",28.4,,
+"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2018","2018",29.4,,
+"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2019","2019",34.8,,
+"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2020","2020",33.3,,
+"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2021","2021",37,,
+"PATCSKEL","M-Musculo-skeletal system","ATCPTTMT","% of total sales","SVK","Slovak Republic","2010","2010",5.6,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","ATCPTTMT","% of total sales","SVK","Slovak Republic","2011","2011",5.6,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","ATCPTTMT","% of total sales","SVK","Slovak Republic","2012","2012",5.4,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","ATCPTTMT","% of total sales","SVK","Slovak Republic","2013","2013",5.4,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","ATCPTTMT","% of total sales","SVK","Slovak Republic","2014","2014",5.2,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","ATCPTTMT","% of total sales","SVK","Slovak Republic","2015","2015",4.8,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","ATCPTTMT","% of total sales","SVK","Slovak Republic","2016","2016",4.9,"B","Break"
+"PATCSKEL","M-Musculo-skeletal system","ATCPTTMT","% of total sales","SVK","Slovak Republic","2017","2017",5.1,,
+"PATCSKEL","M-Musculo-skeletal system","ATCPTTMT","% of total sales","SVK","Slovak Republic","2018","2018",5.2,,
+"PATCSKEL","M-Musculo-skeletal system","ATCPTTMT","% of total sales","SVK","Slovak Republic","2019","2019",5.7,,
+"PATCSKEL","M-Musculo-skeletal system","ATCPTTMT","% of total sales","SVK","Slovak Republic","2020","2020",5.7,,
+"PATCSKEL","M-Musculo-skeletal system","ATCPTTMT","% of total sales","SVK","Slovak Republic","2021","2021",6,,
+"PATCSKEL","M-Musculo-skeletal system","MLLNCUMT","Million of national currency units","ESP","Spain","2010","2010",845.6,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","MLLNCUMT","Million of national currency units","ESP","Spain","2011","2011",759.1,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","MLLNCUMT","Million of national currency units","ESP","Spain","2012","2012",635.4,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","MLLNCUMT","Million of national currency units","ESP","Spain","2013","2013",548.2,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","MLLNCUMT","Million of national currency units","ESP","Spain","2014","2014",509.4,"B; D","Break; Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","MLLNCUMT","Million of national currency units","ESP","Spain","2015","2015",461.5,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","MLLNCUMT","Million of national currency units","ESP","Spain","2016","2016",465.4,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","MLLNCUMT","Million of national currency units","ESP","Spain","2017","2017",448.2,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","MLLNCUMT","Million of national currency units","ESP","Spain","2018","2018",512.4,"B","Break"
+"PATCSKEL","M-Musculo-skeletal system","MLLNCUMT","Million of national currency units","ESP","Spain","2019","2019",531.9,,
+"PATCSKEL","M-Musculo-skeletal system","MLLNCUMT","Million of national currency units","ESP","Spain","2020","2020",511.6,,
+"PATCSKEL","M-Musculo-skeletal system","MLLNCUMT","Million of national currency units","ESP","Spain","2021","2021",560.4,,
+"PATCSKEL","M-Musculo-skeletal system","MLLNCUMT","Million of national currency units","ESP","Spain","2022","2022",611,"P","Provisional value"
+"PATCSKEL","M-Musculo-skeletal system","MTMOTCMT","Million US$ at exchange rate","ESP","Spain","2010","2010",1121,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","MTMOTCMT","Million US$ at exchange rate","ESP","Spain","2011","2011",1056.6,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","MTMOTCMT","Million US$ at exchange rate","ESP","Spain","2012","2012",816.3,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","MTMOTCMT","Million US$ at exchange rate","ESP","Spain","2013","2013",728.1,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","MTMOTCMT","Million US$ at exchange rate","ESP","Spain","2014","2014",676.7,"B; D","Break; Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","MTMOTCMT","Million US$ at exchange rate","ESP","Spain","2015","2015",512.1,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","MTMOTCMT","Million US$ at exchange rate","ESP","Spain","2016","2016",515.2,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","MTMOTCMT","Million US$ at exchange rate","ESP","Spain","2017","2017",506.3,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","MTMOTCMT","Million US$ at exchange rate","ESP","Spain","2018","2018",605.1,"B","Break"
+"PATCSKEL","M-Musculo-skeletal system","MTMOTCMT","Million US$ at exchange rate","ESP","Spain","2019","2019",595.4,,
+"PATCSKEL","M-Musculo-skeletal system","MTMOTCMT","Million US$ at exchange rate","ESP","Spain","2020","2020",584.4,,
+"PATCSKEL","M-Musculo-skeletal system","MTMOTCMT","Million US$ at exchange rate","ESP","Spain","2021","2021",662.8,,
+"PATCSKEL","M-Musculo-skeletal system","MTMOTCMT","Million US$ at exchange rate","ESP","Spain","2022","2022",643.4,"P","Provisional value"
+"PATCSKEL","M-Musculo-skeletal system","MTMOPPMT","Million US$, purchasing power parity","ESP","Spain","2010","2010",1163.2,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","MTMOPPMT","Million US$, purchasing power parity","ESP","Spain","2011","2011",1063,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","MTMOPPMT","Million US$, purchasing power parity","ESP","Spain","2012","2012",914.2,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","MTMOPPMT","Million US$, purchasing power parity","ESP","Spain","2013","2013",812.4,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","MTMOPPMT","Million US$, purchasing power parity","ESP","Spain","2014","2014",769.1,"B; D","Break; Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","MTMOPPMT","Million US$, purchasing power parity","ESP","Spain","2015","2015",694.3,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","MTMOPPMT","Million US$, purchasing power parity","ESP","Spain","2016","2016",724.2,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","MTMOPPMT","Million US$, purchasing power parity","ESP","Spain","2017","2017",710.4,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","MTMOPPMT","Million US$, purchasing power parity","ESP","Spain","2018","2018",811,"B","Break"
+"PATCSKEL","M-Musculo-skeletal system","MTMOPPMT","Million US$, purchasing power parity","ESP","Spain","2019","2019",867.7,,
+"PATCSKEL","M-Musculo-skeletal system","MTMOPPMT","Million US$, purchasing power parity","ESP","Spain","2020","2020",823.4,,
+"PATCSKEL","M-Musculo-skeletal system","MTMOPPMT","Million US$, purchasing power parity","ESP","Spain","2021","2021",895.3,,
+"PATCSKEL","M-Musculo-skeletal system","MTMOPPMT","Million US$, purchasing power parity","ESP","Spain","2022","2022",1024.7,"P","Provisional value"
+"PATCSKEL","M-Musculo-skeletal system","TCPPERMT","/capita, US$ exchange rate","ESP","Spain","2010","2010",24.1,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","TCPPERMT","/capita, US$ exchange rate","ESP","Spain","2011","2011",22.6,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","TCPPERMT","/capita, US$ exchange rate","ESP","Spain","2012","2012",17.5,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","TCPPERMT","/capita, US$ exchange rate","ESP","Spain","2013","2013",15.6,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","TCPPERMT","/capita, US$ exchange rate","ESP","Spain","2014","2014",14.6,"B; D","Break; Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","TCPPERMT","/capita, US$ exchange rate","ESP","Spain","2015","2015",11,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","TCPPERMT","/capita, US$ exchange rate","ESP","Spain","2016","2016",11.1,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","TCPPERMT","/capita, US$ exchange rate","ESP","Spain","2017","2017",10.9,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","TCPPERMT","/capita, US$ exchange rate","ESP","Spain","2018","2018",12.9,"B","Break"
+"PATCSKEL","M-Musculo-skeletal system","TCPPERMT","/capita, US$ exchange rate","ESP","Spain","2019","2019",12.6,,
+"PATCSKEL","M-Musculo-skeletal system","TCPPERMT","/capita, US$ exchange rate","ESP","Spain","2020","2020",12.3,,
+"PATCSKEL","M-Musculo-skeletal system","TCPPERMT","/capita, US$ exchange rate","ESP","Spain","2021","2021",14,,
+"PATCSKEL","M-Musculo-skeletal system","TCPPERMT","/capita, US$ exchange rate","ESP","Spain","2022","2022",13.6,"P","Provisional value"
+"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2010","2010",25,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2011","2011",22.7,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2012","2012",19.5,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2013","2013",17.4,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2014","2014",16.5,"B; D","Break; Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2015","2015",14.9,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2016","2016",15.6,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2017","2017",15.2,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2018","2018",17.3,"B","Break"
+"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2019","2019",18.4,,
+"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2020","2020",17.4,,
+"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2021","2021",18.9,,
+"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2022","2022",21.6,"P","Provisional value"
+"PATCSKEL","M-Musculo-skeletal system","ATCPTTMT","% of total sales","ESP","Spain","2010","2010",6.4,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","ATCPTTMT","% of total sales","ESP","Spain","2011","2011",6.1,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","ATCPTTMT","% of total sales","ESP","Spain","2012","2012",5.7,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","ATCPTTMT","% of total sales","ESP","Spain","2013","2013",5.1,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","ATCPTTMT","% of total sales","ESP","Spain","2014","2014",4.5,"B; D","Break; Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","ATCPTTMT","% of total sales","ESP","Spain","2015","2015",4,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","ATCPTTMT","% of total sales","ESP","Spain","2016","2016",3.9,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","ATCPTTMT","% of total sales","ESP","Spain","2017","2017",3.7,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","ATCPTTMT","% of total sales","ESP","Spain","2018","2018",2.7,"B","Break"
+"PATCSKEL","M-Musculo-skeletal system","ATCPTTMT","% of total sales","ESP","Spain","2019","2019",2.7,,
+"PATCSKEL","M-Musculo-skeletal system","ATCPTTMT","% of total sales","ESP","Spain","2020","2020",2.5,,
+"PATCSKEL","M-Musculo-skeletal system","ATCPTTMT","% of total sales","ESP","Spain","2021","2021",2.5,,
+"PATCSKEL","M-Musculo-skeletal system","ATCPTTMT","% of total sales","ESP","Spain","2022","2022",2.7,"P","Provisional value"
+"PATCSKEL","M-Musculo-skeletal system","MLLNCUMT","Million of national currency units","SWE","Sweden","2010","2010",1241.2,,
+"PATCSKEL","M-Musculo-skeletal system","MLLNCUMT","Million of national currency units","SWE","Sweden","2011","2011",1181.9,,
+"PATCSKEL","M-Musculo-skeletal system","MLLNCUMT","Million of national currency units","SWE","Sweden","2012","2012",1188.3,,
+"PATCSKEL","M-Musculo-skeletal system","MLLNCUMT","Million of national currency units","SWE","Sweden","2013","2013",1249.9,,
+"PATCSKEL","M-Musculo-skeletal system","MLLNCUMT","Million of national currency units","SWE","Sweden","2014","2014",1287.3,,
+"PATCSKEL","M-Musculo-skeletal system","MLLNCUMT","Million of national currency units","SWE","Sweden","2015","2015",1375.3,,
+"PATCSKEL","M-Musculo-skeletal system","MLLNCUMT","Million of national currency units","SWE","Sweden","2016","2016",1502.6,,
+"PATCSKEL","M-Musculo-skeletal system","MLLNCUMT","Million of national currency units","SWE","Sweden","2017","2017",1595.2,,
+"PATCSKEL","M-Musculo-skeletal system","MLLNCUMT","Million of national currency units","SWE","Sweden","2018","2018",1751.8,,
+"PATCSKEL","M-Musculo-skeletal system","MLLNCUMT","Million of national currency units","SWE","Sweden","2019","2019",1913.9,,
+"PATCSKEL","M-Musculo-skeletal system","MLLNCUMT","Million of national currency units","SWE","Sweden","2020","2020",1861.6,,
+"PATCSKEL","M-Musculo-skeletal system","MLLNCUMT","Million of national currency units","SWE","Sweden","2021","2021",1920.8,,
+"PATCSKEL","M-Musculo-skeletal system","MLLNCUMT","Million of national currency units","SWE","Sweden","2022","2022",1984.6,,
+"PATCSKEL","M-Musculo-skeletal system","MTMOTCMT","Million US$ at exchange rate","SWE","Sweden","2010","2010",172.2,,
+"PATCSKEL","M-Musculo-skeletal system","MTMOTCMT","Million US$ at exchange rate","SWE","Sweden","2011","2011",182,,
+"PATCSKEL","M-Musculo-skeletal system","MTMOTCMT","Million US$ at exchange rate","SWE","Sweden","2012","2012",175.4,,
+"PATCSKEL","M-Musculo-skeletal system","MTMOTCMT","Million US$ at exchange rate","SWE","Sweden","2013","2013",191.9,,
+"PATCSKEL","M-Musculo-skeletal system","MTMOTCMT","Million US$ at exchange rate","SWE","Sweden","2014","2014",187.6,,
+"PATCSKEL","M-Musculo-skeletal system","MTMOTCMT","Million US$ at exchange rate","SWE","Sweden","2015","2015",163,,
+"PATCSKEL","M-Musculo-skeletal system","MTMOTCMT","Million US$ at exchange rate","SWE","Sweden","2016","2016",175.5,,
+"PATCSKEL","M-Musculo-skeletal system","MTMOTCMT","Million US$ at exchange rate","SWE","Sweden","2017","2017",186.6,,
+"PATCSKEL","M-Musculo-skeletal system","MTMOTCMT","Million US$ at exchange rate","SWE","Sweden","2018","2018",201.5,,
+"PATCSKEL","M-Musculo-skeletal system","MTMOTCMT","Million US$ at exchange rate","SWE","Sweden","2019","2019",202.3,,
+"PATCSKEL","M-Musculo-skeletal system","MTMOTCMT","Million US$ at exchange rate","SWE","Sweden","2020","2020",202.1,,
+"PATCSKEL","M-Musculo-skeletal system","MTMOTCMT","Million US$ at exchange rate","SWE","Sweden","2021","2021",224,,
+"PATCSKEL","M-Musculo-skeletal system","MTMOTCMT","Million US$ at exchange rate","SWE","Sweden","2022","2022",196.2,,
+"PATCSKEL","M-Musculo-skeletal system","MTMOPPMT","Million US$, purchasing power parity","SWE","Sweden","2010","2010",137.5,,
+"PATCSKEL","M-Musculo-skeletal system","MTMOPPMT","Million US$, purchasing power parity","SWE","Sweden","2011","2011",133.6,,
+"PATCSKEL","M-Musculo-skeletal system","MTMOPPMT","Million US$, purchasing power parity","SWE","Sweden","2012","2012",137.3,,
+"PATCSKEL","M-Musculo-skeletal system","MTMOPPMT","Million US$, purchasing power parity","SWE","Sweden","2013","2013",145.4,,
+"PATCSKEL","M-Musculo-skeletal system","MTMOPPMT","Million US$, purchasing power parity","SWE","Sweden","2014","2014",147.5,,
+"PATCSKEL","M-Musculo-skeletal system","MTMOPPMT","Million US$, purchasing power parity","SWE","Sweden","2015","2015",155.3,,
+"PATCSKEL","M-Musculo-skeletal system","MTMOPPMT","Million US$, purchasing power parity","SWE","Sweden","2016","2016",170.3,,
+"PATCSKEL","M-Musculo-skeletal system","MTMOPPMT","Million US$, purchasing power parity","SWE","Sweden","2017","2017",180.2,,
+"PATCSKEL","M-Musculo-skeletal system","MTMOPPMT","Million US$, purchasing power parity","SWE","Sweden","2018","2018",197.6,,
+"PATCSKEL","M-Musculo-skeletal system","MTMOPPMT","Million US$, purchasing power parity","SWE","Sweden","2019","2019",219.7,,
+"PATCSKEL","M-Musculo-skeletal system","MTMOPPMT","Million US$, purchasing power parity","SWE","Sweden","2020","2020",214.8,,
+"PATCSKEL","M-Musculo-skeletal system","MTMOPPMT","Million US$, purchasing power parity","SWE","Sweden","2021","2021",220.2,,
+"PATCSKEL","M-Musculo-skeletal system","MTMOPPMT","Million US$, purchasing power parity","SWE","Sweden","2022","2022",229,,
+"PATCSKEL","M-Musculo-skeletal system","TCPPERMT","/capita, US$ exchange rate","SWE","Sweden","2010","2010",18.4,,
+"PATCSKEL","M-Musculo-skeletal system","TCPPERMT","/capita, US$ exchange rate","SWE","Sweden","2011","2011",19.3,,
+"PATCSKEL","M-Musculo-skeletal system","TCPPERMT","/capita, US$ exchange rate","SWE","Sweden","2012","2012",18.4,,
+"PATCSKEL","M-Musculo-skeletal system","TCPPERMT","/capita, US$ exchange rate","SWE","Sweden","2013","2013",20,,
+"PATCSKEL","M-Musculo-skeletal system","TCPPERMT","/capita, US$ exchange rate","SWE","Sweden","2014","2014",19.4,,
+"PATCSKEL","M-Musculo-skeletal system","TCPPERMT","/capita, US$ exchange rate","SWE","Sweden","2015","2015",16.6,,
+"PATCSKEL","M-Musculo-skeletal system","TCPPERMT","/capita, US$ exchange rate","SWE","Sweden","2016","2016",17.7,,
+"PATCSKEL","M-Musculo-skeletal system","TCPPERMT","/capita, US$ exchange rate","SWE","Sweden","2017","2017",18.6,,
+"PATCSKEL","M-Musculo-skeletal system","TCPPERMT","/capita, US$ exchange rate","SWE","Sweden","2018","2018",19.8,,
+"PATCSKEL","M-Musculo-skeletal system","TCPPERMT","/capita, US$ exchange rate","SWE","Sweden","2019","2019",19.7,,
+"PATCSKEL","M-Musculo-skeletal system","TCPPERMT","/capita, US$ exchange rate","SWE","Sweden","2020","2020",19.5,,
+"PATCSKEL","M-Musculo-skeletal system","TCPPERMT","/capita, US$ exchange rate","SWE","Sweden","2021","2021",21.5,,
+"PATCSKEL","M-Musculo-skeletal system","TCPPERMT","/capita, US$ exchange rate","SWE","Sweden","2022","2022",18.8,,
+"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2010","2010",14.7,,
+"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2011","2011",14.1,,
+"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2012","2012",14.4,,
+"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2013","2013",15.1,,
+"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2014","2014",15.2,,
+"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2015","2015",15.9,,
+"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2016","2016",17.2,,
+"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2017","2017",17.9,,
+"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2018","2018",19.4,,
+"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2019","2019",21.4,,
+"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2020","2020",20.7,,
+"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2021","2021",21.1,,
+"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2022","2022",21.9,,
+"PATCSKEL","M-Musculo-skeletal system","ATCPTTMT","% of total sales","SWE","Sweden","2010","2010",3.4,,
+"PATCSKEL","M-Musculo-skeletal system","ATCPTTMT","% of total sales","SWE","Sweden","2011","2011",3.2,,
+"PATCSKEL","M-Musculo-skeletal system","ATCPTTMT","% of total sales","SWE","Sweden","2012","2012",3.3,,
+"PATCSKEL","M-Musculo-skeletal system","ATCPTTMT","% of total sales","SWE","Sweden","2013","2013",3.4,,
+"PATCSKEL","M-Musculo-skeletal system","ATCPTTMT","% of total sales","SWE","Sweden","2014","2014",3.4,,
+"PATCSKEL","M-Musculo-skeletal system","ATCPTTMT","% of total sales","SWE","Sweden","2015","2015",3.4,,
+"PATCSKEL","M-Musculo-skeletal system","ATCPTTMT","% of total sales","SWE","Sweden","2016","2016",3.5,,
+"PATCSKEL","M-Musculo-skeletal system","ATCPTTMT","% of total sales","SWE","Sweden","2017","2017",3.7,,
+"PATCSKEL","M-Musculo-skeletal system","ATCPTTMT","% of total sales","SWE","Sweden","2018","2018",3.7,,
+"PATCSKEL","M-Musculo-skeletal system","ATCPTTMT","% of total sales","SWE","Sweden","2019","2019",3.8,,
+"PATCSKEL","M-Musculo-skeletal system","ATCPTTMT","% of total sales","SWE","Sweden","2020","2020",3.6,,
+"PATCSKEL","M-Musculo-skeletal system","ATCPTTMT","% of total sales","SWE","Sweden","2021","2021",3.6,,
+"PATCSKEL","M-Musculo-skeletal system","ATCPTTMT","% of total sales","SWE","Sweden","2022","2022",3.4,,
+"PATCSKEL","M-Musculo-skeletal system","MLLNCUMT","Million of national currency units","CHE","Switzerland","2010","2010",346.2,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","MLLNCUMT","Million of national currency units","CHE","Switzerland","2011","2011",345,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","MLLNCUMT","Million of national currency units","CHE","Switzerland","2012","2012",356,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","MLLNCUMT","Million of national currency units","CHE","Switzerland","2013","2013",355,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","MLLNCUMT","Million of national currency units","CHE","Switzerland","2014","2014",383,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","MLLNCUMT","Million of national currency units","CHE","Switzerland","2015","2015",398,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","MLLNCUMT","Million of national currency units","CHE","Switzerland","2016","2016",416,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","MLLNCUMT","Million of national currency units","CHE","Switzerland","2017","2017",427,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","MLLNCUMT","Million of national currency units","CHE","Switzerland","2018","2018",418,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","MLLNCUMT","Million of national currency units","CHE","Switzerland","2019","2019",430,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","MLLNCUMT","Million of national currency units","CHE","Switzerland","2020","2020",408,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","MLLNCUMT","Million of national currency units","CHE","Switzerland","2021","2021",421,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","MLLNCUMT","Million of national currency units","CHE","Switzerland","2022","2022",412,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","MTMOTCMT","Million US$ at exchange rate","CHE","Switzerland","2010","2010",331.9,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","MTMOTCMT","Million US$ at exchange rate","CHE","Switzerland","2011","2011",388.5,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","MTMOTCMT","Million US$ at exchange rate","CHE","Switzerland","2012","2012",379.7,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","MTMOTCMT","Million US$ at exchange rate","CHE","Switzerland","2013","2013",383,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","MTMOTCMT","Million US$ at exchange rate","CHE","Switzerland","2014","2014",418.1,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","MTMOTCMT","Million US$ at exchange rate","CHE","Switzerland","2015","2015",413.6,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","MTMOTCMT","Million US$ at exchange rate","CHE","Switzerland","2016","2016",422.2,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","MTMOTCMT","Million US$ at exchange rate","CHE","Switzerland","2017","2017",433.6,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","MTMOTCMT","Million US$ at exchange rate","CHE","Switzerland","2018","2018",427.5,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","MTMOTCMT","Million US$ at exchange rate","CHE","Switzerland","2019","2019",432.7,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","MTMOTCMT","Million US$ at exchange rate","CHE","Switzerland","2020","2020",434.5,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","MTMOTCMT","Million US$ at exchange rate","CHE","Switzerland","2021","2021",460.7,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","MTMOTCMT","Million US$ at exchange rate","CHE","Switzerland","2022","2022",431.5,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","MTMOPPMT","Million US$, purchasing power parity","CHE","Switzerland","2010","2010",236.1,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","MTMOPPMT","Million US$, purchasing power parity","CHE","Switzerland","2011","2011",246.9,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","MTMOPPMT","Million US$, purchasing power parity","CHE","Switzerland","2012","2012",262.9,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","MTMOPPMT","Million US$, purchasing power parity","CHE","Switzerland","2013","2013",270.5,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","MTMOPPMT","Million US$, purchasing power parity","CHE","Switzerland","2014","2014",298.8,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","MTMOPPMT","Million US$, purchasing power parity","CHE","Switzerland","2015","2015",322.1,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","MTMOPPMT","Million US$, purchasing power parity","CHE","Switzerland","2016","2016",346.1,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","MTMOPPMT","Million US$, purchasing power parity","CHE","Switzerland","2017","2017",359.5,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","MTMOPPMT","Million US$, purchasing power parity","CHE","Switzerland","2018","2018",354.6,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","MTMOPPMT","Million US$, purchasing power parity","CHE","Switzerland","2019","2019",373.8,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","MTMOPPMT","Million US$, purchasing power parity","CHE","Switzerland","2020","2020",359.3,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","MTMOPPMT","Million US$, purchasing power parity","CHE","Switzerland","2021","2021",380.5,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","MTMOPPMT","Million US$, purchasing power parity","CHE","Switzerland","2022","2022",386.5,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","TCPPERMT","/capita, US$ exchange rate","CHE","Switzerland","2010","2010",42.4,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","TCPPERMT","/capita, US$ exchange rate","CHE","Switzerland","2011","2011",49.1,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","TCPPERMT","/capita, US$ exchange rate","CHE","Switzerland","2012","2012",47.5,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","TCPPERMT","/capita, US$ exchange rate","CHE","Switzerland","2013","2013",47.3,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","TCPPERMT","/capita, US$ exchange rate","CHE","Switzerland","2014","2014",51.1,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","TCPPERMT","/capita, US$ exchange rate","CHE","Switzerland","2015","2015",49.9,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","TCPPERMT","/capita, US$ exchange rate","CHE","Switzerland","2016","2016",50.4,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","TCPPERMT","/capita, US$ exchange rate","CHE","Switzerland","2017","2017",51.3,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","TCPPERMT","/capita, US$ exchange rate","CHE","Switzerland","2018","2018",50.2,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","TCPPERMT","/capita, US$ exchange rate","CHE","Switzerland","2019","2019",50.5,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","TCPPERMT","/capita, US$ exchange rate","CHE","Switzerland","2020","2020",50.3,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","TCPPERMT","/capita, US$ exchange rate","CHE","Switzerland","2021","2021",52.9,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","TCPPERMT","/capita, US$ exchange rate","CHE","Switzerland","2022","2022",49.4,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","CHE","Switzerland","2010","2010",30.2,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","CHE","Switzerland","2011","2011",31.2,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","CHE","Switzerland","2012","2012",32.9,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","CHE","Switzerland","2013","2013",33.4,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","CHE","Switzerland","2014","2014",36.5,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","CHE","Switzerland","2015","2015",38.9,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","CHE","Switzerland","2016","2016",41.3,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","CHE","Switzerland","2017","2017",42.5,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","CHE","Switzerland","2018","2018",41.6,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","CHE","Switzerland","2019","2019",43.6,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","CHE","Switzerland","2020","2020",41.6,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","CHE","Switzerland","2021","2021",43.7,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","CHE","Switzerland","2022","2022",44.2,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","ATCPTTMT","% of total sales","CHE","Switzerland","2010","2010",6,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","ATCPTTMT","% of total sales","CHE","Switzerland","2011","2011",6,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","ATCPTTMT","% of total sales","CHE","Switzerland","2012","2012",6,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","ATCPTTMT","% of total sales","CHE","Switzerland","2013","2013",6,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","ATCPTTMT","% of total sales","CHE","Switzerland","2014","2014",6.5,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","ATCPTTMT","% of total sales","CHE","Switzerland","2015","2015",6.4,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","ATCPTTMT","% of total sales","CHE","Switzerland","2016","2016",6.5,"B; D","Break; Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","ATCPTTMT","% of total sales","CHE","Switzerland","2017","2017",6.5,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","ATCPTTMT","% of total sales","CHE","Switzerland","2018","2018",6.3,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","ATCPTTMT","% of total sales","CHE","Switzerland","2019","2019",6.4,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","ATCPTTMT","% of total sales","CHE","Switzerland","2020","2020",6,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","ATCPTTMT","% of total sales","CHE","Switzerland","2021","2021",5.9,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","ATCPTTMT","% of total sales","CHE","Switzerland","2022","2022",5.4,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","MLLNCUMT","Million of national currency units","TUR","Türkiye","2010","2010",1085.1,,
+"PATCSKEL","M-Musculo-skeletal system","MLLNCUMT","Million of national currency units","TUR","Türkiye","2011","2011",954.2,,
+"PATCSKEL","M-Musculo-skeletal system","MLLNCUMT","Million of national currency units","TUR","Türkiye","2012","2012",911,,
+"PATCSKEL","M-Musculo-skeletal system","MLLNCUMT","Million of national currency units","TUR","Türkiye","2013","2013",913.1,,
+"PATCSKEL","M-Musculo-skeletal system","MLLNCUMT","Million of national currency units","TUR","Türkiye","2014","2014",955.7,,
+"PATCSKEL","M-Musculo-skeletal system","MLLNCUMT","Million of national currency units","TUR","Türkiye","2015","2015",1082.8,,
+"PATCSKEL","M-Musculo-skeletal system","MLLNCUMT","Million of national currency units","TUR","Türkiye","2016","2016",1295.4,,
+"PATCSKEL","M-Musculo-skeletal system","MLLNCUMT","Million of national currency units","TUR","Türkiye","2017","2017",1578.9,,
+"PATCSKEL","M-Musculo-skeletal system","MLLNCUMT","Million of national currency units","TUR","Türkiye","2018","2018",1915.1,,
+"PATCSKEL","M-Musculo-skeletal system","MLLNCUMT","Million of national currency units","TUR","Türkiye","2019","2019",2441.3,,
+"PATCSKEL","M-Musculo-skeletal system","MLLNCUMT","Million of national currency units","TUR","Türkiye","2020","2020",2509.3,,
+"PATCSKEL","M-Musculo-skeletal system","MLLNCUMT","Million of national currency units","TUR","Türkiye","2021","2021",3327.6,,
+"PATCSKEL","M-Musculo-skeletal system","MTMOTCMT","Million US$ at exchange rate","TUR","Türkiye","2010","2010",722.1,,
+"PATCSKEL","M-Musculo-skeletal system","MTMOTCMT","Million US$ at exchange rate","TUR","Türkiye","2011","2011",569.7,,
+"PATCSKEL","M-Musculo-skeletal system","MTMOTCMT","Million US$ at exchange rate","TUR","Türkiye","2012","2012",507.2,,
+"PATCSKEL","M-Musculo-skeletal system","MTMOTCMT","Million US$ at exchange rate","TUR","Türkiye","2013","2013",479.6,,
+"PATCSKEL","M-Musculo-skeletal system","MTMOTCMT","Million US$ at exchange rate","TUR","Türkiye","2014","2014",436.7,,
+"PATCSKEL","M-Musculo-skeletal system","MTMOTCMT","Million US$ at exchange rate","TUR","Türkiye","2015","2015",398.1,,
+"PATCSKEL","M-Musculo-skeletal system","MTMOTCMT","Million US$ at exchange rate","TUR","Türkiye","2016","2016",428.9,,
+"PATCSKEL","M-Musculo-skeletal system","MTMOTCMT","Million US$ at exchange rate","TUR","Türkiye","2017","2017",432.8,,
+"PATCSKEL","M-Musculo-skeletal system","MTMOTCMT","Million US$ at exchange rate","TUR","Türkiye","2018","2018",396.6,,
+"PATCSKEL","M-Musculo-skeletal system","MTMOTCMT","Million US$ at exchange rate","TUR","Türkiye","2019","2019",430.3,,
+"PATCSKEL","M-Musculo-skeletal system","MTMOTCMT","Million US$ at exchange rate","TUR","Türkiye","2020","2020",358,,
+"PATCSKEL","M-Musculo-skeletal system","MTMOTCMT","Million US$ at exchange rate","TUR","Türkiye","2021","2021",376,,
+"PATCSKEL","M-Musculo-skeletal system","MTMOPPMT","Million US$, purchasing power parity","TUR","Türkiye","2010","2010",1179.1,,
+"PATCSKEL","M-Musculo-skeletal system","MTMOPPMT","Million US$, purchasing power parity","TUR","Türkiye","2011","2011",987.6,,
+"PATCSKEL","M-Musculo-skeletal system","MTMOPPMT","Million US$, purchasing power parity","TUR","Türkiye","2012","2012",893.2,,
+"PATCSKEL","M-Musculo-skeletal system","MTMOPPMT","Million US$, purchasing power parity","TUR","Türkiye","2013","2013",853.1,,
+"PATCSKEL","M-Musculo-skeletal system","MTMOPPMT","Million US$, purchasing power parity","TUR","Türkiye","2014","2014",865.3,,
+"PATCSKEL","M-Musculo-skeletal system","MTMOPPMT","Million US$, purchasing power parity","TUR","Türkiye","2015","2015",931.5,,
+"PATCSKEL","M-Musculo-skeletal system","MTMOPPMT","Million US$, purchasing power parity","TUR","Türkiye","2016","2016",1043.8,,
+"PATCSKEL","M-Musculo-skeletal system","MTMOPPMT","Million US$, purchasing power parity","TUR","Türkiye","2017","2017",1140.9,,
+"PATCSKEL","M-Musculo-skeletal system","MTMOPPMT","Million US$, purchasing power parity","TUR","Türkiye","2018","2018",1173,,
+"PATCSKEL","M-Musculo-skeletal system","MTMOPPMT","Million US$, purchasing power parity","TUR","Türkiye","2019","2019",1309.7,,
+"PATCSKEL","M-Musculo-skeletal system","MTMOPPMT","Million US$, purchasing power parity","TUR","Türkiye","2020","2020",1159.5,,
+"PATCSKEL","M-Musculo-skeletal system","MTMOPPMT","Million US$, purchasing power parity","TUR","Türkiye","2021","2021",1185.1,,
+"PATCSKEL","M-Musculo-skeletal system","TCPPERMT","/capita, US$ exchange rate","TUR","Türkiye","2010","2010",9.9,,
+"PATCSKEL","M-Musculo-skeletal system","TCPPERMT","/capita, US$ exchange rate","TUR","Türkiye","2011","2011",7.7,,
+"PATCSKEL","M-Musculo-skeletal system","TCPPERMT","/capita, US$ exchange rate","TUR","Türkiye","2012","2012",6.7,,
+"PATCSKEL","M-Musculo-skeletal system","TCPPERMT","/capita, US$ exchange rate","TUR","Türkiye","2013","2013",6.3,,
+"PATCSKEL","M-Musculo-skeletal system","TCPPERMT","/capita, US$ exchange rate","TUR","Türkiye","2014","2014",5.7,,
+"PATCSKEL","M-Musculo-skeletal system","TCPPERMT","/capita, US$ exchange rate","TUR","Türkiye","2015","2015",5.1,,
+"PATCSKEL","M-Musculo-skeletal system","TCPPERMT","/capita, US$ exchange rate","TUR","Türkiye","2016","2016",5.4,,
+"PATCSKEL","M-Musculo-skeletal system","TCPPERMT","/capita, US$ exchange rate","TUR","Türkiye","2017","2017",5.4,,
+"PATCSKEL","M-Musculo-skeletal system","TCPPERMT","/capita, US$ exchange rate","TUR","Türkiye","2018","2018",4.9,,
+"PATCSKEL","M-Musculo-skeletal system","TCPPERMT","/capita, US$ exchange rate","TUR","Türkiye","2019","2019",5.2,,
+"PATCSKEL","M-Musculo-skeletal system","TCPPERMT","/capita, US$ exchange rate","TUR","Türkiye","2020","2020",4.3,,
+"PATCSKEL","M-Musculo-skeletal system","TCPPERMT","/capita, US$ exchange rate","TUR","Türkiye","2021","2021",4.5,,
+"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2010","2010",16.1,,
+"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2011","2011",13.3,,
+"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2012","2012",11.9,,
+"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2013","2013",11.2,,
+"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2014","2014",11.2,,
+"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2015","2015",11.9,,
+"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2016","2016",13.2,,
+"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2017","2017",14.2,,
+"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2018","2018",14.4,,
+"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2019","2019",15.9,,
+"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2020","2020",13.9,,
+"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2021","2021",14.1,,
+"PATCSKEL","M-Musculo-skeletal system","ATCPTTMT","% of total sales","TUR","Türkiye","2010","2010",7,,
+"PATCSKEL","M-Musculo-skeletal system","ATCPTTMT","% of total sales","TUR","Türkiye","2011","2011",6.7,,
+"PATCSKEL","M-Musculo-skeletal system","ATCPTTMT","% of total sales","TUR","Türkiye","2012","2012",6.7,,
+"PATCSKEL","M-Musculo-skeletal system","ATCPTTMT","% of total sales","TUR","Türkiye","2013","2013",6.4,,
+"PATCSKEL","M-Musculo-skeletal system","ATCPTTMT","% of total sales","TUR","Türkiye","2014","2014",6.1,,
+"PATCSKEL","M-Musculo-skeletal system","ATCPTTMT","% of total sales","TUR","Türkiye","2015","2015",5.9,,
+"PATCSKEL","M-Musculo-skeletal system","ATCPTTMT","% of total sales","TUR","Türkiye","2016","2016",5.9,,
+"PATCSKEL","M-Musculo-skeletal system","ATCPTTMT","% of total sales","TUR","Türkiye","2017","2017",6.2,,
+"PATCSKEL","M-Musculo-skeletal system","ATCPTTMT","% of total sales","TUR","Türkiye","2018","2018",6,,
+"PATCSKEL","M-Musculo-skeletal system","ATCPTTMT","% of total sales","TUR","Türkiye","2019","2019",5.8,,
+"PATCSKEL","M-Musculo-skeletal system","ATCPTTMT","% of total sales","TUR","Türkiye","2020","2020",5,,
+"PATCSKEL","M-Musculo-skeletal system","ATCPTTMT","% of total sales","TUR","Türkiye","2021","2021",5.1,,
+"PATCSKEL","M-Musculo-skeletal system","MLLNCUMT","Million of national currency units","GBR","United Kingdom","2012","2012",359.8,"B","Break"
+"PATCSKEL","M-Musculo-skeletal system","MLLNCUMT","Million of national currency units","GBR","United Kingdom","2013","2013",374.4,,
+"PATCSKEL","M-Musculo-skeletal system","MLLNCUMT","Million of national currency units","GBR","United Kingdom","2014","2014",402.1,,
+"PATCSKEL","M-Musculo-skeletal system","MLLNCUMT","Million of national currency units","GBR","United Kingdom","2015","2015",440.4,,
+"PATCSKEL","M-Musculo-skeletal system","MLLNCUMT","Million of national currency units","GBR","United Kingdom","2016","2016",457.8,,
+"PATCSKEL","M-Musculo-skeletal system","MLLNCUMT","Million of national currency units","GBR","United Kingdom","2017","2017",492.7,,
+"PATCSKEL","M-Musculo-skeletal system","MLLNCUMT","Million of national currency units","GBR","United Kingdom","2018","2018",532.3,,
+"PATCSKEL","M-Musculo-skeletal system","MTMOTCMT","Million US$ at exchange rate","GBR","United Kingdom","2012","2012",568.4,"B","Break"
+"PATCSKEL","M-Musculo-skeletal system","MTMOTCMT","Million US$ at exchange rate","GBR","United Kingdom","2013","2013",585.3,,
+"PATCSKEL","M-Musculo-skeletal system","MTMOTCMT","Million US$ at exchange rate","GBR","United Kingdom","2014","2014",661.6,,
+"PATCSKEL","M-Musculo-skeletal system","MTMOTCMT","Million US$ at exchange rate","GBR","United Kingdom","2015","2015",672.8,,
+"PATCSKEL","M-Musculo-skeletal system","MTMOTCMT","Million US$ at exchange rate","GBR","United Kingdom","2016","2016",618.1,,
+"PATCSKEL","M-Musculo-skeletal system","MTMOTCMT","Million US$ at exchange rate","GBR","United Kingdom","2017","2017",634.1,,
+"PATCSKEL","M-Musculo-skeletal system","MTMOTCMT","Million US$ at exchange rate","GBR","United Kingdom","2018","2018",710.2,,
+"PATCSKEL","M-Musculo-skeletal system","MTMOPPMT","Million US$, purchasing power parity","GBR","United Kingdom","2012","2012",512.8,"B","Break"
+"PATCSKEL","M-Musculo-skeletal system","MTMOPPMT","Million US$, purchasing power parity","GBR","United Kingdom","2013","2013",538.5,,
+"PATCSKEL","M-Musculo-skeletal system","MTMOPPMT","Million US$, purchasing power parity","GBR","United Kingdom","2014","2014",575.7,,
+"PATCSKEL","M-Musculo-skeletal system","MTMOPPMT","Million US$, purchasing power parity","GBR","United Kingdom","2015","2015",635.9,,
+"PATCSKEL","M-Musculo-skeletal system","MTMOPPMT","Million US$, purchasing power parity","GBR","United Kingdom","2016","2016",664.8,,
+"PATCSKEL","M-Musculo-skeletal system","MTMOPPMT","Million US$, purchasing power parity","GBR","United Kingdom","2017","2017",719.7,,
+"PATCSKEL","M-Musculo-skeletal system","MTMOPPMT","Million US$, purchasing power parity","GBR","United Kingdom","2018","2018",774,,
+"PATCSKEL","M-Musculo-skeletal system","TCPPERMT","/capita, US$ exchange rate","GBR","United Kingdom","2012","2012",8.9,"B","Break"
+"PATCSKEL","M-Musculo-skeletal system","TCPPERMT","/capita, US$ exchange rate","GBR","United Kingdom","2013","2013",9.1,,
+"PATCSKEL","M-Musculo-skeletal system","TCPPERMT","/capita, US$ exchange rate","GBR","United Kingdom","2014","2014",10.2,,
+"PATCSKEL","M-Musculo-skeletal system","TCPPERMT","/capita, US$ exchange rate","GBR","United Kingdom","2015","2015",10.3,,
+"PATCSKEL","M-Musculo-skeletal system","TCPPERMT","/capita, US$ exchange rate","GBR","United Kingdom","2016","2016",9.4,,
+"PATCSKEL","M-Musculo-skeletal system","TCPPERMT","/capita, US$ exchange rate","GBR","United Kingdom","2017","2017",9.6,,
+"PATCSKEL","M-Musculo-skeletal system","TCPPERMT","/capita, US$ exchange rate","GBR","United Kingdom","2018","2018",10.7,,
+"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","GBR","United Kingdom","2012","2012",8,"B","Break"
+"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","GBR","United Kingdom","2013","2013",8.4,,
+"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","GBR","United Kingdom","2014","2014",8.9,,
+"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","GBR","United Kingdom","2015","2015",9.8,,
+"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","GBR","United Kingdom","2016","2016",10.1,,
+"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","GBR","United Kingdom","2017","2017",10.9,,
+"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","GBR","United Kingdom","2018","2018",11.7,,
+"PATCSKEL","M-Musculo-skeletal system","ATCPTTMT","% of total sales","GBR","United Kingdom","2012","2012",2.6,"B","Break"
+"PATCSKEL","M-Musculo-skeletal system","ATCPTTMT","% of total sales","GBR","United Kingdom","2013","2013",2.6,,
+"PATCSKEL","M-Musculo-skeletal system","ATCPTTMT","% of total sales","GBR","United Kingdom","2014","2014",2.5,,
+"PATCSKEL","M-Musculo-skeletal system","ATCPTTMT","% of total sales","GBR","United Kingdom","2015","2015",2.5,,
+"PATCSKEL","M-Musculo-skeletal system","ATCPTTMT","% of total sales","GBR","United Kingdom","2016","2016",2.5,,
+"PATCSKEL","M-Musculo-skeletal system","ATCPTTMT","% of total sales","GBR","United Kingdom","2017","2017",2.5,,
+"PATCSKEL","M-Musculo-skeletal system","ATCPTTMT","% of total sales","GBR","United Kingdom","2018","2018",2.6,,
+"PATCSKEL","M-Musculo-skeletal system","MLLNCUMT","Million of national currency units","CHL","Chile","2010","2010",68438.5,,
+"PATCSKEL","M-Musculo-skeletal system","MLLNCUMT","Million of national currency units","CHL","Chile","2011","2011",61502,"B","Break"
+"PATCSKEL","M-Musculo-skeletal system","MLLNCUMT","Million of national currency units","CHL","Chile","2012","2012",86133.7,,
+"PATCSKEL","M-Musculo-skeletal system","MLLNCUMT","Million of national currency units","CHL","Chile","2013","2013",87138.2,,
+"PATCSKEL","M-Musculo-skeletal system","MLLNCUMT","Million of national currency units","CHL","Chile","2014","2014",107902.8,,
+"PATCSKEL","M-Musculo-skeletal system","MLLNCUMT","Million of national currency units","CHL","Chile","2015","2015",123321.4,,
+"PATCSKEL","M-Musculo-skeletal system","MLLNCUMT","Million of national currency units","CHL","Chile","2016","2016",120374.3,,
+"PATCSKEL","M-Musculo-skeletal system","MLLNCUMT","Million of national currency units","CHL","Chile","2017","2017",116144,,
+"PATCSKEL","M-Musculo-skeletal system","MLLNCUMT","Million of national currency units","CHL","Chile","2018","2018",121434.3,,
+"PATCSKEL","M-Musculo-skeletal system","MLLNCUMT","Million of national currency units","CHL","Chile","2019","2019",98242.4,,
+"PATCSKEL","M-Musculo-skeletal system","MLLNCUMT","Million of national currency units","CHL","Chile","2020","2020",105910.8,,
+"PATCSKEL","M-Musculo-skeletal system","MLLNCUMT","Million of national currency units","CHL","Chile","2021","2021",151550.4,,
+"PATCSKEL","M-Musculo-skeletal system","MLLNCUMT","Million of national currency units","CHL","Chile","2022","2022",129489.1,,
+"PATCSKEL","M-Musculo-skeletal system","MTMOTCMT","Million US$ at exchange rate","CHL","Chile","2010","2010",134.1,,
+"PATCSKEL","M-Musculo-skeletal system","MTMOTCMT","Million US$ at exchange rate","CHL","Chile","2011","2011",127.2,"B","Break"
+"PATCSKEL","M-Musculo-skeletal system","MTMOTCMT","Million US$ at exchange rate","CHL","Chile","2012","2012",177.1,,
+"PATCSKEL","M-Musculo-skeletal system","MTMOTCMT","Million US$ at exchange rate","CHL","Chile","2013","2013",175.9,,
+"PATCSKEL","M-Musculo-skeletal system","MTMOTCMT","Million US$ at exchange rate","CHL","Chile","2014","2014",189.2,,
+"PATCSKEL","M-Musculo-skeletal system","MTMOTCMT","Million US$ at exchange rate","CHL","Chile","2015","2015",188.5,,
+"PATCSKEL","M-Musculo-skeletal system","MTMOTCMT","Million US$ at exchange rate","CHL","Chile","2016","2016",177.8,,
+"PATCSKEL","M-Musculo-skeletal system","MTMOTCMT","Million US$ at exchange rate","CHL","Chile","2017","2017",179,,
+"PATCSKEL","M-Musculo-skeletal system","MTMOTCMT","Million US$ at exchange rate","CHL","Chile","2018","2018",189.4,,
+"PATCSKEL","M-Musculo-skeletal system","MTMOTCMT","Million US$ at exchange rate","CHL","Chile","2019","2019",139.8,,
+"PATCSKEL","M-Musculo-skeletal system","MTMOTCMT","Million US$ at exchange rate","CHL","Chile","2020","2020",133.6,,
+"PATCSKEL","M-Musculo-skeletal system","MTMOTCMT","Million US$ at exchange rate","CHL","Chile","2021","2021",199.7,,
+"PATCSKEL","M-Musculo-skeletal system","MTMOTCMT","Million US$ at exchange rate","CHL","Chile","2022","2022",148.3,,
+"PATCSKEL","M-Musculo-skeletal system","MTMOPPMT","Million US$, purchasing power parity","CHL","Chile","2010","2010",190.2,,
+"PATCSKEL","M-Musculo-skeletal system","MTMOPPMT","Million US$, purchasing power parity","CHL","Chile","2011","2011",176.7,"B","Break"
+"PATCSKEL","M-Musculo-skeletal system","MTMOPPMT","Million US$, purchasing power parity","CHL","Chile","2012","2012",248.1,,
+"PATCSKEL","M-Musculo-skeletal system","MTMOPPMT","Million US$, purchasing power parity","CHL","Chile","2013","2013",249.2,,
+"PATCSKEL","M-Musculo-skeletal system","MTMOPPMT","Million US$, purchasing power parity","CHL","Chile","2014","2014",293.8,,
+"PATCSKEL","M-Musculo-skeletal system","MTMOPPMT","Million US$, purchasing power parity","CHL","Chile","2015","2015",315.3,,
+"PATCSKEL","M-Musculo-skeletal system","MTMOPPMT","Million US$, purchasing power parity","CHL","Chile","2016","2016",303,,
+"PATCSKEL","M-Musculo-skeletal system","MTMOPPMT","Million US$, purchasing power parity","CHL","Chile","2017","2017",292,,
+"PATCSKEL","M-Musculo-skeletal system","MTMOPPMT","Million US$, purchasing power parity","CHL","Chile","2018","2018",306.5,,
+"PATCSKEL","M-Musculo-skeletal system","MTMOPPMT","Million US$, purchasing power parity","CHL","Chile","2019","2019",244.6,,
+"PATCSKEL","M-Musculo-skeletal system","MTMOPPMT","Million US$, purchasing power parity","CHL","Chile","2020","2020",253.1,,
+"PATCSKEL","M-Musculo-skeletal system","MTMOPPMT","Million US$, purchasing power parity","CHL","Chile","2021","2021",348.3,,
+"PATCSKEL","M-Musculo-skeletal system","MTMOPPMT","Million US$, purchasing power parity","CHL","Chile","2022","2022",295.9,,
+"PATCSKEL","M-Musculo-skeletal system","TCPPERMT","/capita, US$ exchange rate","CHL","Chile","2010","2010",7.9,,
+"PATCSKEL","M-Musculo-skeletal system","TCPPERMT","/capita, US$ exchange rate","CHL","Chile","2011","2011",7.4,"B","Break"
+"PATCSKEL","M-Musculo-skeletal system","TCPPERMT","/capita, US$ exchange rate","CHL","Chile","2012","2012",10.2,,
+"PATCSKEL","M-Musculo-skeletal system","TCPPERMT","/capita, US$ exchange rate","CHL","Chile","2013","2013",10,,
+"PATCSKEL","M-Musculo-skeletal system","TCPPERMT","/capita, US$ exchange rate","CHL","Chile","2014","2014",10.6,,
+"PATCSKEL","M-Musculo-skeletal system","TCPPERMT","/capita, US$ exchange rate","CHL","Chile","2015","2015",10.5,,
+"PATCSKEL","M-Musculo-skeletal system","TCPPERMT","/capita, US$ exchange rate","CHL","Chile","2016","2016",9.8,,
+"PATCSKEL","M-Musculo-skeletal system","TCPPERMT","/capita, US$ exchange rate","CHL","Chile","2017","2017",9.7,,
+"PATCSKEL","M-Musculo-skeletal system","TCPPERMT","/capita, US$ exchange rate","CHL","Chile","2018","2018",10.1,,
+"PATCSKEL","M-Musculo-skeletal system","TCPPERMT","/capita, US$ exchange rate","CHL","Chile","2019","2019",7.3,,
+"PATCSKEL","M-Musculo-skeletal system","TCPPERMT","/capita, US$ exchange rate","CHL","Chile","2020","2020",6.9,,
+"PATCSKEL","M-Musculo-skeletal system","TCPPERMT","/capita, US$ exchange rate","CHL","Chile","2021","2021",10.1,,
+"PATCSKEL","M-Musculo-skeletal system","TCPPERMT","/capita, US$ exchange rate","CHL","Chile","2022","2022",7.5,,
+"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2010","2010",11.1,,
+"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2011","2011",10.2,"B","Break"
+"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2012","2012",14.2,,
+"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2013","2013",14.1,,
+"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2014","2014",16.5,,
+"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2015","2015",17.5,,
+"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2016","2016",16.7,,
+"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2017","2017",15.9,,
+"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2018","2018",16.3,,
+"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2019","2019",12.8,,
+"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2020","2020",13,,
+"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2021","2021",17.7,,
+"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2022","2022",14.9,,
+"PATCSKEL","M-Musculo-skeletal system","ATCPTTMT","% of total sales","CHL","Chile","2010","2010",8.3,,
+"PATCSKEL","M-Musculo-skeletal system","ATCPTTMT","% of total sales","CHL","Chile","2011","2011",5.2,"B","Break"
+"PATCSKEL","M-Musculo-skeletal system","ATCPTTMT","% of total sales","CHL","Chile","2012","2012",6.9,,
+"PATCSKEL","M-Musculo-skeletal system","ATCPTTMT","% of total sales","CHL","Chile","2013","2013",6,,
+"PATCSKEL","M-Musculo-skeletal system","ATCPTTMT","% of total sales","CHL","Chile","2014","2014",7,,
+"PATCSKEL","M-Musculo-skeletal system","ATCPTTMT","% of total sales","CHL","Chile","2015","2015",6.8,,
+"PATCSKEL","M-Musculo-skeletal system","ATCPTTMT","% of total sales","CHL","Chile","2016","2016",5.9,,
+"PATCSKEL","M-Musculo-skeletal system","ATCPTTMT","% of total sales","CHL","Chile","2017","2017",5.6,,
+"PATCSKEL","M-Musculo-skeletal system","ATCPTTMT","% of total sales","CHL","Chile","2018","2018",5.3,,
+"PATCSKEL","M-Musculo-skeletal system","ATCPTTMT","% of total sales","CHL","Chile","2019","2019",3.9,,
+"PATCSKEL","M-Musculo-skeletal system","ATCPTTMT","% of total sales","CHL","Chile","2020","2020",3.9,,
+"PATCSKEL","M-Musculo-skeletal system","ATCPTTMT","% of total sales","CHL","Chile","2021","2021",5.4,,
+"PATCSKEL","M-Musculo-skeletal system","ATCPTTMT","% of total sales","CHL","Chile","2022","2022",4.6,,
+"PATCSKEL","M-Musculo-skeletal system","MLLNCUMT","Million of national currency units","EST","Estonia","2010","2010",10.8,,
+"PATCSKEL","M-Musculo-skeletal system","MLLNCUMT","Million of national currency units","EST","Estonia","2011","2011",11.1,,
+"PATCSKEL","M-Musculo-skeletal system","MLLNCUMT","Million of national currency units","EST","Estonia","2012","2012",12.2,,
+"PATCSKEL","M-Musculo-skeletal system","MLLNCUMT","Million of national currency units","EST","Estonia","2013","2013",13.2,,
+"PATCSKEL","M-Musculo-skeletal system","MLLNCUMT","Million of national currency units","EST","Estonia","2014","2014",14.3,,
+"PATCSKEL","M-Musculo-skeletal system","MLLNCUMT","Million of national currency units","EST","Estonia","2015","2015",15.6,,
+"PATCSKEL","M-Musculo-skeletal system","MLLNCUMT","Million of national currency units","EST","Estonia","2016","2016",16.4,,
+"PATCSKEL","M-Musculo-skeletal system","MLLNCUMT","Million of national currency units","EST","Estonia","2017","2017",16.8,,
+"PATCSKEL","M-Musculo-skeletal system","MLLNCUMT","Million of national currency units","EST","Estonia","2018","2018",17.2,,
+"PATCSKEL","M-Musculo-skeletal system","MLLNCUMT","Million of national currency units","EST","Estonia","2019","2019",18.1,,
+"PATCSKEL","M-Musculo-skeletal system","MLLNCUMT","Million of national currency units","EST","Estonia","2020","2020",18.2,,
+"PATCSKEL","M-Musculo-skeletal system","MLLNCUMT","Million of national currency units","EST","Estonia","2021","2021",19.3,,
+"PATCSKEL","M-Musculo-skeletal system","MLLNCUMT","Million of national currency units","EST","Estonia","2022","2022",24.9,,
+"PATCSKEL","M-Musculo-skeletal system","MTMOTCMT","Million US$ at exchange rate","EST","Estonia","2010","2010",14.3,,
+"PATCSKEL","M-Musculo-skeletal system","MTMOTCMT","Million US$ at exchange rate","EST","Estonia","2011","2011",15.4,,
+"PATCSKEL","M-Musculo-skeletal system","MTMOTCMT","Million US$ at exchange rate","EST","Estonia","2012","2012",15.7,,
+"PATCSKEL","M-Musculo-skeletal system","MTMOTCMT","Million US$ at exchange rate","EST","Estonia","2013","2013",17.5,,
+"PATCSKEL","M-Musculo-skeletal system","MTMOTCMT","Million US$ at exchange rate","EST","Estonia","2014","2014",19.1,,
+"PATCSKEL","M-Musculo-skeletal system","MTMOTCMT","Million US$ at exchange rate","EST","Estonia","2015","2015",17.3,,
+"PATCSKEL","M-Musculo-skeletal system","MTMOTCMT","Million US$ at exchange rate","EST","Estonia","2016","2016",18.1,,
+"PATCSKEL","M-Musculo-skeletal system","MTMOTCMT","Million US$ at exchange rate","EST","Estonia","2017","2017",19,,
+"PATCSKEL","M-Musculo-skeletal system","MTMOTCMT","Million US$ at exchange rate","EST","Estonia","2018","2018",20.3,,
+"PATCSKEL","M-Musculo-skeletal system","MTMOTCMT","Million US$ at exchange rate","EST","Estonia","2019","2019",20.3,,
+"PATCSKEL","M-Musculo-skeletal system","MTMOTCMT","Million US$ at exchange rate","EST","Estonia","2020","2020",20.8,,
+"PATCSKEL","M-Musculo-skeletal system","MTMOTCMT","Million US$ at exchange rate","EST","Estonia","2021","2021",22.8,,
+"PATCSKEL","M-Musculo-skeletal system","MTMOTCMT","Million US$ at exchange rate","EST","Estonia","2022","2022",26.2,,
+"PATCSKEL","M-Musculo-skeletal system","MTMOPPMT","Million US$, purchasing power parity","EST","Estonia","2010","2010",21.1,,
+"PATCSKEL","M-Musculo-skeletal system","MTMOPPMT","Million US$, purchasing power parity","EST","Estonia","2011","2011",21.6,,
+"PATCSKEL","M-Musculo-skeletal system","MTMOPPMT","Million US$, purchasing power parity","EST","Estonia","2012","2012",23.4,,
+"PATCSKEL","M-Musculo-skeletal system","MTMOPPMT","Million US$, purchasing power parity","EST","Estonia","2013","2013",25.3,,
+"PATCSKEL","M-Musculo-skeletal system","MTMOPPMT","Million US$, purchasing power parity","EST","Estonia","2014","2014",27.2,,
+"PATCSKEL","M-Musculo-skeletal system","MTMOPPMT","Million US$, purchasing power parity","EST","Estonia","2015","2015",29.1,,
+"PATCSKEL","M-Musculo-skeletal system","MTMOPPMT","Million US$, purchasing power parity","EST","Estonia","2016","2016",31,,
+"PATCSKEL","M-Musculo-skeletal system","MTMOPPMT","Million US$, purchasing power parity","EST","Estonia","2017","2017",31.5,,
+"PATCSKEL","M-Musculo-skeletal system","MTMOPPMT","Million US$, purchasing power parity","EST","Estonia","2018","2018",31.9,,
+"PATCSKEL","M-Musculo-skeletal system","MTMOPPMT","Million US$, purchasing power parity","EST","Estonia","2019","2019",33.8,,
+"PATCSKEL","M-Musculo-skeletal system","MTMOPPMT","Million US$, purchasing power parity","EST","Estonia","2020","2020",34.8,,
+"PATCSKEL","M-Musculo-skeletal system","MTMOPPMT","Million US$, purchasing power parity","EST","Estonia","2021","2021",35.5,,
+"PATCSKEL","M-Musculo-skeletal system","MTMOPPMT","Million US$, purchasing power parity","EST","Estonia","2022","2022",43.7,,
+"PATCSKEL","M-Musculo-skeletal system","TCPPERMT","/capita, US$ exchange rate","EST","Estonia","2010","2010",10.7,,
+"PATCSKEL","M-Musculo-skeletal system","TCPPERMT","/capita, US$ exchange rate","EST","Estonia","2011","2011",11.6,,
+"PATCSKEL","M-Musculo-skeletal system","TCPPERMT","/capita, US$ exchange rate","EST","Estonia","2012","2012",11.9,,
+"PATCSKEL","M-Musculo-skeletal system","TCPPERMT","/capita, US$ exchange rate","EST","Estonia","2013","2013",13.3,,
+"PATCSKEL","M-Musculo-skeletal system","TCPPERMT","/capita, US$ exchange rate","EST","Estonia","2014","2014",14.5,,
+"PATCSKEL","M-Musculo-skeletal system","TCPPERMT","/capita, US$ exchange rate","EST","Estonia","2015","2015",13.2,,
+"PATCSKEL","M-Musculo-skeletal system","TCPPERMT","/capita, US$ exchange rate","EST","Estonia","2016","2016",13.8,,
+"PATCSKEL","M-Musculo-skeletal system","TCPPERMT","/capita, US$ exchange rate","EST","Estonia","2017","2017",14.4,,
+"PATCSKEL","M-Musculo-skeletal system","TCPPERMT","/capita, US$ exchange rate","EST","Estonia","2018","2018",15.4,,
+"PATCSKEL","M-Musculo-skeletal system","TCPPERMT","/capita, US$ exchange rate","EST","Estonia","2019","2019",15.3,,
+"PATCSKEL","M-Musculo-skeletal system","TCPPERMT","/capita, US$ exchange rate","EST","Estonia","2020","2020",15.7,,
+"PATCSKEL","M-Musculo-skeletal system","TCPPERMT","/capita, US$ exchange rate","EST","Estonia","2021","2021",17.1,,
+"PATCSKEL","M-Musculo-skeletal system","TCPPERMT","/capita, US$ exchange rate","EST","Estonia","2022","2022",19.7,,
+"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2010","2010",15.8,,
+"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2011","2011",16.3,,
+"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2012","2012",17.7,,
+"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2013","2013",19.2,,
+"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2014","2014",20.7,,
+"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2015","2015",22.1,,
+"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2016","2016",23.6,,
+"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2017","2017",23.9,,
+"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2018","2018",24.1,,
+"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2019","2019",25.5,,
+"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2020","2020",26.2,,
+"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2021","2021",26.7,,
+"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2022","2022",32.8,,
+"PATCSKEL","M-Musculo-skeletal system","ATCPTTMT","% of total sales","EST","Estonia","2010","2010",5.6,,
+"PATCSKEL","M-Musculo-skeletal system","ATCPTTMT","% of total sales","EST","Estonia","2011","2011",5.4,,
+"PATCSKEL","M-Musculo-skeletal system","ATCPTTMT","% of total sales","EST","Estonia","2012","2012",5.5,,
+"PATCSKEL","M-Musculo-skeletal system","ATCPTTMT","% of total sales","EST","Estonia","2013","2013",5.7,,
+"PATCSKEL","M-Musculo-skeletal system","ATCPTTMT","% of total sales","EST","Estonia","2014","2014",5.8,,
+"PATCSKEL","M-Musculo-skeletal system","ATCPTTMT","% of total sales","EST","Estonia","2015","2015",5.9,,
+"PATCSKEL","M-Musculo-skeletal system","ATCPTTMT","% of total sales","EST","Estonia","2016","2016",5.6,,
+"PATCSKEL","M-Musculo-skeletal system","ATCPTTMT","% of total sales","EST","Estonia","2017","2017",5.6,,
+"PATCSKEL","M-Musculo-skeletal system","ATCPTTMT","% of total sales","EST","Estonia","2018","2018",5.3,,
+"PATCSKEL","M-Musculo-skeletal system","ATCPTTMT","% of total sales","EST","Estonia","2019","2019",5.3,,
+"PATCSKEL","M-Musculo-skeletal system","ATCPTTMT","% of total sales","EST","Estonia","2020","2020",5.1,,
+"PATCSKEL","M-Musculo-skeletal system","ATCPTTMT","% of total sales","EST","Estonia","2021","2021",4.7,,
+"PATCSKEL","M-Musculo-skeletal system","ATCPTTMT","% of total sales","EST","Estonia","2022","2022",5.8,,
+"PATCSKEL","M-Musculo-skeletal system","MLLNCUMT","Million of national currency units","SVN","Slovenia","2010","2010",21,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","MLLNCUMT","Million of national currency units","SVN","Slovenia","2011","2011",19.3,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","MLLNCUMT","Million of national currency units","SVN","Slovenia","2012","2012",18.6,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","MLLNCUMT","Million of national currency units","SVN","Slovenia","2013","2013",17.4,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","MLLNCUMT","Million of national currency units","SVN","Slovenia","2014","2014",15.7,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","MLLNCUMT","Million of national currency units","SVN","Slovenia","2015","2015",15.7,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","MLLNCUMT","Million of national currency units","SVN","Slovenia","2016","2016",15.6,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","MLLNCUMT","Million of national currency units","SVN","Slovenia","2017","2017",16.4,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","MLLNCUMT","Million of national currency units","SVN","Slovenia","2018","2018",17.7,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","MLLNCUMT","Million of national currency units","SVN","Slovenia","2019","2019",18.9,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","MLLNCUMT","Million of national currency units","SVN","Slovenia","2020","2020",19,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","MLLNCUMT","Million of national currency units","SVN","Slovenia","2021","2021",19.8,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","MLLNCUMT","Million of national currency units","SVN","Slovenia","2022","2022",29.1,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","MTMOTCMT","Million US$ at exchange rate","SVN","Slovenia","2010","2010",27.8,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","MTMOTCMT","Million US$ at exchange rate","SVN","Slovenia","2011","2011",26.9,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","MTMOTCMT","Million US$ at exchange rate","SVN","Slovenia","2012","2012",23.9,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","MTMOTCMT","Million US$ at exchange rate","SVN","Slovenia","2013","2013",23.1,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","MTMOTCMT","Million US$ at exchange rate","SVN","Slovenia","2014","2014",20.9,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","MTMOTCMT","Million US$ at exchange rate","SVN","Slovenia","2015","2015",17.4,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","MTMOTCMT","Million US$ at exchange rate","SVN","Slovenia","2016","2016",17.3,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","MTMOTCMT","Million US$ at exchange rate","SVN","Slovenia","2017","2017",18.5,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","MTMOTCMT","Million US$ at exchange rate","SVN","Slovenia","2018","2018",20.9,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","MTMOTCMT","Million US$ at exchange rate","SVN","Slovenia","2019","2019",21.2,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","MTMOTCMT","Million US$ at exchange rate","SVN","Slovenia","2020","2020",21.7,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","MTMOTCMT","Million US$ at exchange rate","SVN","Slovenia","2021","2021",23.4,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","MTMOTCMT","Million US$ at exchange rate","SVN","Slovenia","2022","2022",30.7,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","MTMOPPMT","Million US$, purchasing power parity","SVN","Slovenia","2010","2010",32.9,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","MTMOPPMT","Million US$, purchasing power parity","SVN","Slovenia","2011","2011",31,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","MTMOPPMT","Million US$, purchasing power parity","SVN","Slovenia","2012","2012",30.6,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","MTMOPPMT","Million US$, purchasing power parity","SVN","Slovenia","2013","2013",29.4,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","MTMOPPMT","Million US$, purchasing power parity","SVN","Slovenia","2014","2014",26.6,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","MTMOPPMT","Million US$, purchasing power parity","SVN","Slovenia","2015","2015",26.3,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","MTMOPPMT","Million US$, purchasing power parity","SVN","Slovenia","2016","2016",27,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","MTMOPPMT","Million US$, purchasing power parity","SVN","Slovenia","2017","2017",28.7,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","MTMOPPMT","Million US$, purchasing power parity","SVN","Slovenia","2018","2018",31.2,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","MTMOPPMT","Million US$, purchasing power parity","SVN","Slovenia","2019","2019",34.2,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","MTMOPPMT","Million US$, purchasing power parity","SVN","Slovenia","2020","2020",34.7,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","MTMOPPMT","Million US$, purchasing power parity","SVN","Slovenia","2021","2021",35.1,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","MTMOPPMT","Million US$, purchasing power parity","SVN","Slovenia","2022","2022",52.8,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","TCPPERMT","/capita, US$ exchange rate","SVN","Slovenia","2010","2010",13.6,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","TCPPERMT","/capita, US$ exchange rate","SVN","Slovenia","2011","2011",13.1,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","TCPPERMT","/capita, US$ exchange rate","SVN","Slovenia","2012","2012",11.6,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","TCPPERMT","/capita, US$ exchange rate","SVN","Slovenia","2013","2013",11.2,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","TCPPERMT","/capita, US$ exchange rate","SVN","Slovenia","2014","2014",10.1,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","TCPPERMT","/capita, US$ exchange rate","SVN","Slovenia","2015","2015",8.4,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","TCPPERMT","/capita, US$ exchange rate","SVN","Slovenia","2016","2016",8.4,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","TCPPERMT","/capita, US$ exchange rate","SVN","Slovenia","2017","2017",9,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","TCPPERMT","/capita, US$ exchange rate","SVN","Slovenia","2018","2018",10.1,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","TCPPERMT","/capita, US$ exchange rate","SVN","Slovenia","2019","2019",10.1,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","TCPPERMT","/capita, US$ exchange rate","SVN","Slovenia","2020","2020",10.3,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","TCPPERMT","/capita, US$ exchange rate","SVN","Slovenia","2021","2021",11.1,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","TCPPERMT","/capita, US$ exchange rate","SVN","Slovenia","2022","2022",14.6,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2010","2010",16.1,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2011","2011",15.1,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2012","2012",14.9,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2013","2013",14.3,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2014","2014",12.9,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2015","2015",12.8,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2016","2016",13.1,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2017","2017",13.9,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2018","2018",15,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2019","2019",16.4,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2020","2020",16.5,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2021","2021",16.7,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2022","2022",25.1,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","ATCPTTMT","% of total sales","SVN","Slovenia","2010","2010",4.4,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","ATCPTTMT","% of total sales","SVN","Slovenia","2011","2011",4.1,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","ATCPTTMT","% of total sales","SVN","Slovenia","2012","2012",4.1,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","ATCPTTMT","% of total sales","SVN","Slovenia","2013","2013",3.9,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","ATCPTTMT","% of total sales","SVN","Slovenia","2014","2014",3.6,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","ATCPTTMT","% of total sales","SVN","Slovenia","2015","2015",3.5,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","ATCPTTMT","% of total sales","SVN","Slovenia","2016","2016",3.3,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","ATCPTTMT","% of total sales","SVN","Slovenia","2017","2017",3.4,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","ATCPTTMT","% of total sales","SVN","Slovenia","2018","2018",3.4,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","ATCPTTMT","% of total sales","SVN","Slovenia","2019","2019",3.5,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","ATCPTTMT","% of total sales","SVN","Slovenia","2020","2020",3.3,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","ATCPTTMT","% of total sales","SVN","Slovenia","2021","2021",3.2,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","ATCPTTMT","% of total sales","SVN","Slovenia","2022","2022",4.3,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MLLNCUMT","Million of national currency units","AUS","Australia","2010","2010",102,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MLLNCUMT","Million of national currency units","AUS","Australia","2011","2011",93,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MLLNCUMT","Million of national currency units","AUS","Australia","2012","2012",85,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MLLNCUMT","Million of national currency units","AUS","Australia","2013","2013",128,"B; D","Break; Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MLLNCUMT","Million of national currency units","AUS","Australia","2014","2014",122,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MLLNCUMT","Million of national currency units","AUS","Australia","2015","2015",119,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MLLNCUMT","Million of national currency units","AUS","Australia","2016","2016",115,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MLLNCUMT","Million of national currency units","AUS","Australia","2017","2017",104,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MLLNCUMT","Million of national currency units","AUS","Australia","2018","2018",104,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MLLNCUMT","Million of national currency units","AUS","Australia","2019","2019",102,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MLLNCUMT","Million of national currency units","AUS","Australia","2020","2020",103,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MLLNCUMT","Million of national currency units","AUS","Australia","2021","2021",103,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOTCMT","Million US$ at exchange rate","AUS","Australia","2010","2010",93.6,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOTCMT","Million US$ at exchange rate","AUS","Australia","2011","2011",95.9,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOTCMT","Million US$ at exchange rate","AUS","Australia","2012","2012",88,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOTCMT","Million US$ at exchange rate","AUS","Australia","2013","2013",123.6,"B; D","Break; Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOTCMT","Million US$ at exchange rate","AUS","Australia","2014","2014",110,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOTCMT","Million US$ at exchange rate","AUS","Australia","2015","2015",89.4,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOTCMT","Million US$ at exchange rate","AUS","Australia","2016","2016",85.5,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOTCMT","Million US$ at exchange rate","AUS","Australia","2017","2017",79.7,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOTCMT","Million US$ at exchange rate","AUS","Australia","2018","2018",77.7,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOTCMT","Million US$ at exchange rate","AUS","Australia","2019","2019",70.9,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOTCMT","Million US$ at exchange rate","AUS","Australia","2020","2020",70.9,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOTCMT","Million US$ at exchange rate","AUS","Australia","2021","2021",77.4,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOPPMT","Million US$, purchasing power parity","AUS","Australia","2010","2010",67.8,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOPPMT","Million US$, purchasing power parity","AUS","Australia","2011","2011",61.5,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOPPMT","Million US$, purchasing power parity","AUS","Australia","2012","2012",55.2,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOPPMT","Million US$, purchasing power parity","AUS","Australia","2013","2013",88.5,"B; D","Break; Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOPPMT","Million US$, purchasing power parity","AUS","Australia","2014","2014",84,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOPPMT","Million US$, purchasing power parity","AUS","Australia","2015","2015",80.7,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOPPMT","Million US$, purchasing power parity","AUS","Australia","2016","2016",79.3,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOPPMT","Million US$, purchasing power parity","AUS","Australia","2017","2017",70.4,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOPPMT","Million US$, purchasing power parity","AUS","Australia","2018","2018",70.7,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOPPMT","Million US$, purchasing power parity","AUS","Australia","2019","2019",68.9,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOPPMT","Million US$, purchasing power parity","AUS","Australia","2020","2020",70.8,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOPPMT","Million US$, purchasing power parity","AUS","Australia","2021","2021",71.2,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","TCPPERMT","/capita, US$ exchange rate","AUS","Australia","2010","2010",4.2,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","TCPPERMT","/capita, US$ exchange rate","AUS","Australia","2011","2011",4.3,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","TCPPERMT","/capita, US$ exchange rate","AUS","Australia","2012","2012",3.9,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","TCPPERMT","/capita, US$ exchange rate","AUS","Australia","2013","2013",5.3,"B; D","Break; Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","TCPPERMT","/capita, US$ exchange rate","AUS","Australia","2014","2014",4.7,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","TCPPERMT","/capita, US$ exchange rate","AUS","Australia","2015","2015",3.8,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","TCPPERMT","/capita, US$ exchange rate","AUS","Australia","2016","2016",3.5,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","TCPPERMT","/capita, US$ exchange rate","AUS","Australia","2017","2017",3.2,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","TCPPERMT","/capita, US$ exchange rate","AUS","Australia","2018","2018",3.1,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","TCPPERMT","/capita, US$ exchange rate","AUS","Australia","2019","2019",2.8,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","TCPPERMT","/capita, US$ exchange rate","AUS","Australia","2020","2020",2.8,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","TCPPERMT","/capita, US$ exchange rate","AUS","Australia","2021","2021",3,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2010","2010",3.1,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2011","2011",2.8,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2012","2012",2.4,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2013","2013",3.8,"B; D","Break; Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2014","2014",3.6,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2015","2015",3.4,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2016","2016",3.3,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2017","2017",2.9,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2018","2018",2.8,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2019","2019",2.7,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2020","2020",2.8,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2021","2021",2.8,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","ATCPTTMT","% of total sales","AUS","Australia","2010","2010",1,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","ATCPTTMT","% of total sales","AUS","Australia","2011","2011",0.9,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","ATCPTTMT","% of total sales","AUS","Australia","2012","2012",0.8,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","ATCPTTMT","% of total sales","AUS","Australia","2013","2013",1.1,"B; D","Break; Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","ATCPTTMT","% of total sales","AUS","Australia","2014","2014",1,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","ATCPTTMT","% of total sales","AUS","Australia","2015","2015",1,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","ATCPTTMT","% of total sales","AUS","Australia","2016","2016",0.8,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","ATCPTTMT","% of total sales","AUS","Australia","2017","2017",0.7,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","ATCPTTMT","% of total sales","AUS","Australia","2018","2018",0.7,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","ATCPTTMT","% of total sales","AUS","Australia","2019","2019",0.7,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","ATCPTTMT","% of total sales","AUS","Australia","2020","2020",0.6,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","ATCPTTMT","% of total sales","AUS","Australia","2021","2021",0.6,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MLLNCUMT","Million of national currency units","AUT","Austria","2010","2010",42.1,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MLLNCUMT","Million of national currency units","AUT","Austria","2011","2011",42.6,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MLLNCUMT","Million of national currency units","AUT","Austria","2012","2012",43.4,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MLLNCUMT","Million of national currency units","AUT","Austria","2013","2013",43.4,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MLLNCUMT","Million of national currency units","AUT","Austria","2014","2014",42.6,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MLLNCUMT","Million of national currency units","AUT","Austria","2015","2015",41.8,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MLLNCUMT","Million of national currency units","AUT","Austria","2016","2016",41.6,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MLLNCUMT","Million of national currency units","AUT","Austria","2017","2017",40.5,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MLLNCUMT","Million of national currency units","AUT","Austria","2018","2018",37.7,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MLLNCUMT","Million of national currency units","AUT","Austria","2019","2019",37.1,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MLLNCUMT","Million of national currency units","AUT","Austria","2020","2020",35.2,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MLLNCUMT","Million of national currency units","AUT","Austria","2021","2021",35.8,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOTCMT","Million US$ at exchange rate","AUT","Austria","2010","2010",55.8,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOTCMT","Million US$ at exchange rate","AUT","Austria","2011","2011",59.2,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOTCMT","Million US$ at exchange rate","AUT","Austria","2012","2012",55.7,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOTCMT","Million US$ at exchange rate","AUT","Austria","2013","2013",57.6,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOTCMT","Million US$ at exchange rate","AUT","Austria","2014","2014",56.5,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOTCMT","Million US$ at exchange rate","AUT","Austria","2015","2015",46.4,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOTCMT","Million US$ at exchange rate","AUT","Austria","2016","2016",46,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOTCMT","Million US$ at exchange rate","AUT","Austria","2017","2017",45.7,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOTCMT","Million US$ at exchange rate","AUT","Austria","2018","2018",44.5,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOTCMT","Million US$ at exchange rate","AUT","Austria","2019","2019",41.6,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOTCMT","Million US$ at exchange rate","AUT","Austria","2020","2020",40.2,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOTCMT","Million US$ at exchange rate","AUT","Austria","2021","2021",42.3,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOPPMT","Million US$, purchasing power parity","AUT","Austria","2010","2010",50,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOPPMT","Million US$, purchasing power parity","AUT","Austria","2011","2011",51.2,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOPPMT","Million US$, purchasing power parity","AUT","Austria","2012","2012",53.3,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOPPMT","Million US$, purchasing power parity","AUT","Austria","2013","2013",54.5,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOPPMT","Million US$, purchasing power parity","AUT","Austria","2014","2014",53.3,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOPPMT","Million US$, purchasing power parity","AUT","Austria","2015","2015",52.4,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOPPMT","Million US$, purchasing power parity","AUT","Austria","2016","2016",53.5,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOPPMT","Million US$, purchasing power parity","AUT","Austria","2017","2017",52.2,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOPPMT","Million US$, purchasing power parity","AUT","Austria","2018","2018",49.2,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOPPMT","Million US$, purchasing power parity","AUT","Austria","2019","2019",49.6,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOPPMT","Million US$, purchasing power parity","AUT","Austria","2020","2020",47.1,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOPPMT","Million US$, purchasing power parity","AUT","Austria","2021","2021",47.3,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","TCPPERMT","/capita, US$ exchange rate","AUT","Austria","2010","2010",6.7,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","TCPPERMT","/capita, US$ exchange rate","AUT","Austria","2011","2011",7.1,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","TCPPERMT","/capita, US$ exchange rate","AUT","Austria","2012","2012",6.6,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","TCPPERMT","/capita, US$ exchange rate","AUT","Austria","2013","2013",6.8,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","TCPPERMT","/capita, US$ exchange rate","AUT","Austria","2014","2014",6.6,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","TCPPERMT","/capita, US$ exchange rate","AUT","Austria","2015","2015",5.4,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","TCPPERMT","/capita, US$ exchange rate","AUT","Austria","2016","2016",5.3,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","TCPPERMT","/capita, US$ exchange rate","AUT","Austria","2017","2017",5.2,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","TCPPERMT","/capita, US$ exchange rate","AUT","Austria","2018","2018",5,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","TCPPERMT","/capita, US$ exchange rate","AUT","Austria","2019","2019",4.7,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","TCPPERMT","/capita, US$ exchange rate","AUT","Austria","2020","2020",4.5,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","TCPPERMT","/capita, US$ exchange rate","AUT","Austria","2021","2021",4.7,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2010","2010",6,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2011","2011",6.1,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2012","2012",6.3,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2013","2013",6.4,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2014","2014",6.2,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2015","2015",6.1,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2016","2016",6.1,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2017","2017",5.9,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2018","2018",5.6,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2019","2019",5.6,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2020","2020",5.3,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2021","2021",5.3,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","ATCPTTMT","% of total sales","AUT","Austria","2010","2010",1.7,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","ATCPTTMT","% of total sales","AUT","Austria","2011","2011",1.7,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","ATCPTTMT","% of total sales","AUT","Austria","2012","2012",1.7,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","ATCPTTMT","% of total sales","AUT","Austria","2013","2013",1.6,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","ATCPTTMT","% of total sales","AUT","Austria","2014","2014",1.5,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","ATCPTTMT","% of total sales","AUT","Austria","2015","2015",1.4,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","ATCPTTMT","% of total sales","AUT","Austria","2016","2016",1.4,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","ATCPTTMT","% of total sales","AUT","Austria","2017","2017",1.3,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","ATCPTTMT","% of total sales","AUT","Austria","2018","2018",1.2,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","ATCPTTMT","% of total sales","AUT","Austria","2019","2019",1.1,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","ATCPTTMT","% of total sales","AUT","Austria","2020","2020",1,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","ATCPTTMT","% of total sales","AUT","Austria","2021","2021",1,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MLLNCUMT","Million of national currency units","BEL","Belgium","2010","2010",112,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MLLNCUMT","Million of national currency units","BEL","Belgium","2011","2011",117.5,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MLLNCUMT","Million of national currency units","BEL","Belgium","2012","2012",117.2,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MLLNCUMT","Million of national currency units","BEL","Belgium","2013","2013",114.4,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MLLNCUMT","Million of national currency units","BEL","Belgium","2014","2014",110.8,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MLLNCUMT","Million of national currency units","BEL","Belgium","2015","2015",109.7,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MLLNCUMT","Million of national currency units","BEL","Belgium","2016","2016",109,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MLLNCUMT","Million of national currency units","BEL","Belgium","2017","2017",104.5,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MLLNCUMT","Million of national currency units","BEL","Belgium","2018","2018",96,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MLLNCUMT","Million of national currency units","BEL","Belgium","2019","2019",96.2,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MLLNCUMT","Million of national currency units","BEL","Belgium","2020","2020",79.3,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MLLNCUMT","Million of national currency units","BEL","Belgium","2021","2021",81.1,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MLLNCUMT","Million of national currency units","BEL","Belgium","2022","2022",94.3,"E","Estimated value"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOTCMT","Million US$ at exchange rate","BEL","Belgium","2010","2010",148.5,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOTCMT","Million US$ at exchange rate","BEL","Belgium","2011","2011",163.6,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOTCMT","Million US$ at exchange rate","BEL","Belgium","2012","2012",150.6,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOTCMT","Million US$ at exchange rate","BEL","Belgium","2013","2013",151.9,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOTCMT","Million US$ at exchange rate","BEL","Belgium","2014","2014",147.2,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOTCMT","Million US$ at exchange rate","BEL","Belgium","2015","2015",121.7,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOTCMT","Million US$ at exchange rate","BEL","Belgium","2016","2016",120.7,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOTCMT","Million US$ at exchange rate","BEL","Belgium","2017","2017",118.1,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOTCMT","Million US$ at exchange rate","BEL","Belgium","2018","2018",113.4,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOTCMT","Million US$ at exchange rate","BEL","Belgium","2019","2019",107.7,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOTCMT","Million US$ at exchange rate","BEL","Belgium","2020","2020",90.5,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOTCMT","Million US$ at exchange rate","BEL","Belgium","2021","2021",95.9,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOTCMT","Million US$ at exchange rate","BEL","Belgium","2022","2022",99.3,"E","Estimated value"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOPPMT","Million US$, purchasing power parity","BEL","Belgium","2010","2010",133.9,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOPPMT","Million US$, purchasing power parity","BEL","Belgium","2011","2011",141.3,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOPPMT","Million US$, purchasing power parity","BEL","Belgium","2012","2012",142.5,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOPPMT","Million US$, purchasing power parity","BEL","Belgium","2013","2013",141.9,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOPPMT","Million US$, purchasing power parity","BEL","Belgium","2014","2014",138.5,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOPPMT","Million US$, purchasing power parity","BEL","Belgium","2015","2015",137.2,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOPPMT","Million US$, purchasing power parity","BEL","Belgium","2016","2016",139.6,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOPPMT","Million US$, purchasing power parity","BEL","Belgium","2017","2017",134.8,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOPPMT","Million US$, purchasing power parity","BEL","Belgium","2018","2018",125.2,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOPPMT","Million US$, purchasing power parity","BEL","Belgium","2019","2019",128.8,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOPPMT","Million US$, purchasing power parity","BEL","Belgium","2020","2020",108.5,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOPPMT","Million US$, purchasing power parity","BEL","Belgium","2021","2021",110.1,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOPPMT","Million US$, purchasing power parity","BEL","Belgium","2022","2022",132,"E","Estimated value"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","TCPPERMT","/capita, US$ exchange rate","BEL","Belgium","2010","2010",13.6,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","TCPPERMT","/capita, US$ exchange rate","BEL","Belgium","2011","2011",14.8,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","TCPPERMT","/capita, US$ exchange rate","BEL","Belgium","2012","2012",13.6,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","TCPPERMT","/capita, US$ exchange rate","BEL","Belgium","2013","2013",13.6,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","TCPPERMT","/capita, US$ exchange rate","BEL","Belgium","2014","2014",13.1,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","TCPPERMT","/capita, US$ exchange rate","BEL","Belgium","2015","2015",10.8,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","TCPPERMT","/capita, US$ exchange rate","BEL","Belgium","2016","2016",10.6,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","TCPPERMT","/capita, US$ exchange rate","BEL","Belgium","2017","2017",10.4,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","TCPPERMT","/capita, US$ exchange rate","BEL","Belgium","2018","2018",9.9,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","TCPPERMT","/capita, US$ exchange rate","BEL","Belgium","2019","2019",9.4,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","TCPPERMT","/capita, US$ exchange rate","BEL","Belgium","2020","2020",7.8,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","TCPPERMT","/capita, US$ exchange rate","BEL","Belgium","2021","2021",8.3,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","TCPPERMT","/capita, US$ exchange rate","BEL","Belgium","2022","2022",8.5,"E","Estimated value"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2010","2010",12.3,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2011","2011",12.8,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2012","2012",12.8,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2013","2013",12.7,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2014","2014",12.4,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2015","2015",12.2,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2016","2016",12.3,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2017","2017",11.8,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2018","2018",11,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2019","2019",11.2,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2020","2020",9.4,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2021","2021",9.5,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2022","2022",11.4,"E","Estimated value"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","ATCPTTMT","% of total sales","BEL","Belgium","2010","2010",1.9,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","ATCPTTMT","% of total sales","BEL","Belgium","2011","2011",2,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","ATCPTTMT","% of total sales","BEL","Belgium","2012","2012",2,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","ATCPTTMT","% of total sales","BEL","Belgium","2013","2013",1.9,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","ATCPTTMT","% of total sales","BEL","Belgium","2014","2014",1.9,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","ATCPTTMT","% of total sales","BEL","Belgium","2015","2015",1.8,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","ATCPTTMT","% of total sales","BEL","Belgium","2016","2016",1.7,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","ATCPTTMT","% of total sales","BEL","Belgium","2017","2017",1.6,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","ATCPTTMT","% of total sales","BEL","Belgium","2018","2018",1.4,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","ATCPTTMT","% of total sales","BEL","Belgium","2019","2019",1.3,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","ATCPTTMT","% of total sales","BEL","Belgium","2020","2020",1,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","ATCPTTMT","% of total sales","BEL","Belgium","2021","2021",1,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","ATCPTTMT","% of total sales","BEL","Belgium","2022","2022",1,"E","Estimated value"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MLLNCUMT","Million of national currency units","CAN","Canada","2012","2012",454.1,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MLLNCUMT","Million of national currency units","CAN","Canada","2013","2013",455.1,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MLLNCUMT","Million of national currency units","CAN","Canada","2014","2014",450.2,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MLLNCUMT","Million of national currency units","CAN","Canada","2015","2015",338,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MLLNCUMT","Million of national currency units","CAN","Canada","2016","2016",321.9,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MLLNCUMT","Million of national currency units","CAN","Canada","2017","2017",308.6,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MLLNCUMT","Million of national currency units","CAN","Canada","2018","2018",331.8,"E; B; D","Estimated value; Break; Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MLLNCUMT","Million of national currency units","CAN","Canada","2019","2019",361.6,"E; D","Estimated value; Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MLLNCUMT","Million of national currency units","CAN","Canada","2020","2020",292.3,"E; D","Estimated value; Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MLLNCUMT","Million of national currency units","CAN","Canada","2021","2021",336.6,"E; D","Estimated value; Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MLLNCUMT","Million of national currency units","CAN","Canada","2022","2022",305.7,"E; D","Estimated value; Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOTCMT","Million US$ at exchange rate","CAN","Canada","2012","2012",454.4,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOTCMT","Million US$ at exchange rate","CAN","Canada","2013","2013",441.8,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOTCMT","Million US$ at exchange rate","CAN","Canada","2014","2014",407.5,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOTCMT","Million US$ at exchange rate","CAN","Canada","2015","2015",264.3,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOTCMT","Million US$ at exchange rate","CAN","Canada","2016","2016",242.8,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOTCMT","Million US$ at exchange rate","CAN","Canada","2017","2017",237.8,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOTCMT","Million US$ at exchange rate","CAN","Canada","2018","2018",256,"E; B; D","Estimated value; Break; Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOTCMT","Million US$ at exchange rate","CAN","Canada","2019","2019",272.5,"E; D","Estimated value; Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOTCMT","Million US$ at exchange rate","CAN","Canada","2020","2020",217.9,"E; D","Estimated value; Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOTCMT","Million US$ at exchange rate","CAN","Canada","2021","2021",268.4,"E; D","Estimated value; Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOTCMT","Million US$ at exchange rate","CAN","Canada","2022","2022",234.9,"E; D","Estimated value; Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOPPMT","Million US$, purchasing power parity","CAN","Canada","2012","2012",364.9,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOPPMT","Million US$, purchasing power parity","CAN","Canada","2013","2013",371.8,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOPPMT","Million US$, purchasing power parity","CAN","Canada","2014","2014",365.9,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOPPMT","Million US$, purchasing power parity","CAN","Canada","2015","2015",270.8,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOPPMT","Million US$, purchasing power parity","CAN","Canada","2016","2016",266.7,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOPPMT","Million US$, purchasing power parity","CAN","Canada","2017","2017",254.6,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOPPMT","Million US$, purchasing power parity","CAN","Canada","2018","2018",275,"E; B; D","Estimated value; Break; Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOPPMT","Million US$, purchasing power parity","CAN","Canada","2019","2019",292.8,"E; D","Estimated value; Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOPPMT","Million US$, purchasing power parity","CAN","Canada","2020","2020",237.4,"E; D","Estimated value; Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOPPMT","Million US$, purchasing power parity","CAN","Canada","2021","2021",271.8,"E; D","Estimated value; Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOPPMT","Million US$, purchasing power parity","CAN","Canada","2022","2022",243.8,"E; D","Estimated value; Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","TCPPERMT","/capita, US$ exchange rate","CAN","Canada","2012","2012",13.1,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","TCPPERMT","/capita, US$ exchange rate","CAN","Canada","2013","2013",12.6,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","TCPPERMT","/capita, US$ exchange rate","CAN","Canada","2014","2014",11.5,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","TCPPERMT","/capita, US$ exchange rate","CAN","Canada","2015","2015",7.4,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","TCPPERMT","/capita, US$ exchange rate","CAN","Canada","2016","2016",6.7,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","TCPPERMT","/capita, US$ exchange rate","CAN","Canada","2017","2017",6.5,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","TCPPERMT","/capita, US$ exchange rate","CAN","Canada","2018","2018",6.9,"E; B; D","Estimated value; Break; Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","TCPPERMT","/capita, US$ exchange rate","CAN","Canada","2019","2019",7.2,"E; D","Estimated value; Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","TCPPERMT","/capita, US$ exchange rate","CAN","Canada","2020","2020",5.7,"E; D","Estimated value; Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","TCPPERMT","/capita, US$ exchange rate","CAN","Canada","2021","2021",7,"E; D","Estimated value; Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","TCPPERMT","/capita, US$ exchange rate","CAN","Canada","2022","2022",6,"E; D","Estimated value; Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2012","2012",10.5,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2013","2013",10.6,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2014","2014",10.3,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2015","2015",7.6,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2016","2016",7.4,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2017","2017",7,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2018","2018",7.4,"E; B; D","Estimated value; Break; Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2019","2019",7.8,"E; D","Estimated value; Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2020","2020",6.2,"E; D","Estimated value; Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2021","2021",7.1,"E; D","Estimated value; Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2022","2022",6.3,"E; D","Estimated value; Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","ATCPTTMT","% of total sales","CAN","Canada","2012","2012",1.9,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","ATCPTTMT","% of total sales","CAN","Canada","2013","2013",1.9,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","ATCPTTMT","% of total sales","CAN","Canada","2014","2014",1.8,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","ATCPTTMT","% of total sales","CAN","Canada","2015","2015",1.2,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","ATCPTTMT","% of total sales","CAN","Canada","2016","2016",1.1,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","ATCPTTMT","% of total sales","CAN","Canada","2017","2017",1,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","ATCPTTMT","% of total sales","CAN","Canada","2018","2018",1.1,"E; B; D","Estimated value; Break; Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","ATCPTTMT","% of total sales","CAN","Canada","2019","2019",1.1,"E; D","Estimated value; Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","ATCPTTMT","% of total sales","CAN","Canada","2020","2020",0.9,"E; D","Estimated value; Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","ATCPTTMT","% of total sales","CAN","Canada","2021","2021",0.9,"E; D","Estimated value; Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","ATCPTTMT","% of total sales","CAN","Canada","2022","2022",0.8,"E; D","Estimated value; Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MLLNCUMT","Million of national currency units","CZE","Czech Republic","2010","2010",1746.4,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MLLNCUMT","Million of national currency units","CZE","Czech Republic","2011","2011",1757.9,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MLLNCUMT","Million of national currency units","CZE","Czech Republic","2012","2012",1849,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MLLNCUMT","Million of national currency units","CZE","Czech Republic","2013","2013",1848.5,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MLLNCUMT","Million of national currency units","CZE","Czech Republic","2014","2014",1840.7,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MLLNCUMT","Million of national currency units","CZE","Czech Republic","2015","2015",1783.9,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MLLNCUMT","Million of national currency units","CZE","Czech Republic","2016","2016",1788.2,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MLLNCUMT","Million of national currency units","CZE","Czech Republic","2017","2017",1841.9,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MLLNCUMT","Million of national currency units","CZE","Czech Republic","2018","2018",1941.7,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MLLNCUMT","Million of national currency units","CZE","Czech Republic","2019","2019",1973.7,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MLLNCUMT","Million of national currency units","CZE","Czech Republic","2020","2020",884.9,"B","Break"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MLLNCUMT","Million of national currency units","CZE","Czech Republic","2021","2021",898.9,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOTCMT","Million US$ at exchange rate","CZE","Czech Republic","2010","2010",91.4,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOTCMT","Million US$ at exchange rate","CZE","Czech Republic","2011","2011",99.3,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOTCMT","Million US$ at exchange rate","CZE","Czech Republic","2012","2012",94.4,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOTCMT","Million US$ at exchange rate","CZE","Czech Republic","2013","2013",94.5,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOTCMT","Million US$ at exchange rate","CZE","Czech Republic","2014","2014",88.7,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOTCMT","Million US$ at exchange rate","CZE","Czech Republic","2015","2015",72.5,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOTCMT","Million US$ at exchange rate","CZE","Czech Republic","2016","2016",73.2,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOTCMT","Million US$ at exchange rate","CZE","Czech Republic","2017","2017",78.8,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOTCMT","Million US$ at exchange rate","CZE","Czech Republic","2018","2018",89.4,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOTCMT","Million US$ at exchange rate","CZE","Czech Republic","2019","2019",86.1,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOTCMT","Million US$ at exchange rate","CZE","Czech Republic","2020","2020",38.1,"B","Break"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOTCMT","Million US$ at exchange rate","CZE","Czech Republic","2021","2021",41.5,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOPPMT","Million US$, purchasing power parity","CZE","Czech Republic","2010","2010",127.7,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOPPMT","Million US$, purchasing power parity","CZE","Czech Republic","2011","2011",131.7,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOPPMT","Million US$, purchasing power parity","CZE","Czech Republic","2012","2012",139,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOPPMT","Million US$, purchasing power parity","CZE","Czech Republic","2013","2013",144.6,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOPPMT","Million US$, purchasing power parity","CZE","Czech Republic","2014","2014",144.9,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOPPMT","Million US$, purchasing power parity","CZE","Czech Republic","2015","2015",137.9,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOPPMT","Million US$, purchasing power parity","CZE","Czech Republic","2016","2016",142.2,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOPPMT","Million US$, purchasing power parity","CZE","Czech Republic","2017","2017",148.2,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOPPMT","Million US$, purchasing power parity","CZE","Czech Republic","2018","2018",157,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOPPMT","Million US$, purchasing power parity","CZE","Czech Republic","2019","2019",160.8,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOPPMT","Million US$, purchasing power parity","CZE","Czech Republic","2020","2020",71,"B","Break"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOPPMT","Million US$, purchasing power parity","CZE","Czech Republic","2021","2021",70.5,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","TCPPERMT","/capita, US$ exchange rate","CZE","Czech Republic","2010","2010",8.7,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","TCPPERMT","/capita, US$ exchange rate","CZE","Czech Republic","2011","2011",9.5,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","TCPPERMT","/capita, US$ exchange rate","CZE","Czech Republic","2012","2012",9,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","TCPPERMT","/capita, US$ exchange rate","CZE","Czech Republic","2013","2013",9,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","TCPPERMT","/capita, US$ exchange rate","CZE","Czech Republic","2014","2014",8.4,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","TCPPERMT","/capita, US$ exchange rate","CZE","Czech Republic","2015","2015",6.9,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","TCPPERMT","/capita, US$ exchange rate","CZE","Czech Republic","2016","2016",6.9,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","TCPPERMT","/capita, US$ exchange rate","CZE","Czech Republic","2017","2017",7.4,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","TCPPERMT","/capita, US$ exchange rate","CZE","Czech Republic","2018","2018",8.4,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","TCPPERMT","/capita, US$ exchange rate","CZE","Czech Republic","2019","2019",8.1,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","TCPPERMT","/capita, US$ exchange rate","CZE","Czech Republic","2020","2020",3.6,"B","Break"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","TCPPERMT","/capita, US$ exchange rate","CZE","Czech Republic","2021","2021",3.9,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czech Republic","2010","2010",12.2,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czech Republic","2011","2011",12.5,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czech Republic","2012","2012",13.2,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czech Republic","2013","2013",13.8,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czech Republic","2014","2014",13.8,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czech Republic","2015","2015",13.1,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czech Republic","2016","2016",13.5,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czech Republic","2017","2017",14,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czech Republic","2018","2018",14.8,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czech Republic","2019","2019",15.1,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czech Republic","2020","2020",6.6,"B","Break"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czech Republic","2021","2021",6.7,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","ATCPTTMT","% of total sales","CZE","Czech Republic","2010","2010",2.1,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","ATCPTTMT","% of total sales","CZE","Czech Republic","2011","2011",2.2,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","ATCPTTMT","% of total sales","CZE","Czech Republic","2012","2012",2.2,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","ATCPTTMT","% of total sales","CZE","Czech Republic","2013","2013",2.3,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","ATCPTTMT","% of total sales","CZE","Czech Republic","2014","2014",2.3,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","ATCPTTMT","% of total sales","CZE","Czech Republic","2015","2015",2.1,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","ATCPTTMT","% of total sales","CZE","Czech Republic","2016","2016",2,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","ATCPTTMT","% of total sales","CZE","Czech Republic","2017","2017",2,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","ATCPTTMT","% of total sales","CZE","Czech Republic","2018","2018",2,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","ATCPTTMT","% of total sales","CZE","Czech Republic","2019","2019",1.9,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","ATCPTTMT","% of total sales","CZE","Czech Republic","2020","2020",1,"B","Break"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","ATCPTTMT","% of total sales","CZE","Czech Republic","2021","2021",1,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MLLNCUMT","Million of national currency units","FIN","Finland","2010","2010",51.4,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MLLNCUMT","Million of national currency units","FIN","Finland","2011","2011",53.2,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MLLNCUMT","Million of national currency units","FIN","Finland","2012","2012",55.6,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MLLNCUMT","Million of national currency units","FIN","Finland","2013","2013",53.9,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MLLNCUMT","Million of national currency units","FIN","Finland","2014","2014",54,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MLLNCUMT","Million of national currency units","FIN","Finland","2015","2015",52.6,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MLLNCUMT","Million of national currency units","FIN","Finland","2016","2016",52.3,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MLLNCUMT","Million of national currency units","FIN","Finland","2017","2017",49.2,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MLLNCUMT","Million of national currency units","FIN","Finland","2018","2018",45.5,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MLLNCUMT","Million of national currency units","FIN","Finland","2019","2019",45.9,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MLLNCUMT","Million of national currency units","FIN","Finland","2020","2020",42.8,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MLLNCUMT","Million of national currency units","FIN","Finland","2021","2021",42.1,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOTCMT","Million US$ at exchange rate","FIN","Finland","2010","2010",68.1,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOTCMT","Million US$ at exchange rate","FIN","Finland","2011","2011",74.1,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOTCMT","Million US$ at exchange rate","FIN","Finland","2012","2012",71.4,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOTCMT","Million US$ at exchange rate","FIN","Finland","2013","2013",71.6,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOTCMT","Million US$ at exchange rate","FIN","Finland","2014","2014",71.7,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOTCMT","Million US$ at exchange rate","FIN","Finland","2015","2015",58.4,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOTCMT","Million US$ at exchange rate","FIN","Finland","2016","2016",57.9,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOTCMT","Million US$ at exchange rate","FIN","Finland","2017","2017",55.6,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOTCMT","Million US$ at exchange rate","FIN","Finland","2018","2018",53.7,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOTCMT","Million US$ at exchange rate","FIN","Finland","2019","2019",51.4,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOTCMT","Million US$ at exchange rate","FIN","Finland","2020","2020",48.9,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOTCMT","Million US$ at exchange rate","FIN","Finland","2021","2021",49.8,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOPPMT","Million US$, purchasing power parity","FIN","Finland","2010","2010",57.1,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOPPMT","Million US$, purchasing power parity","FIN","Finland","2011","2011",59.2,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOPPMT","Million US$, purchasing power parity","FIN","Finland","2012","2012",61.2,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOPPMT","Million US$, purchasing power parity","FIN","Finland","2013","2013",59.5,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOPPMT","Million US$, purchasing power parity","FIN","Finland","2014","2014",59.5,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOPPMT","Million US$, purchasing power parity","FIN","Finland","2015","2015",57.9,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOPPMT","Million US$, purchasing power parity","FIN","Finland","2016","2016",59.4,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOPPMT","Million US$, purchasing power parity","FIN","Finland","2017","2017",57,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOPPMT","Million US$, purchasing power parity","FIN","Finland","2018","2018",53.3,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOPPMT","Million US$, purchasing power parity","FIN","Finland","2019","2019",54.7,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOPPMT","Million US$, purchasing power parity","FIN","Finland","2020","2020",52,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOPPMT","Million US$, purchasing power parity","FIN","Finland","2021","2021",50.9,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","TCPPERMT","/capita, US$ exchange rate","FIN","Finland","2010","2010",12.7,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","TCPPERMT","/capita, US$ exchange rate","FIN","Finland","2011","2011",13.7,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","TCPPERMT","/capita, US$ exchange rate","FIN","Finland","2012","2012",13.2,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","TCPPERMT","/capita, US$ exchange rate","FIN","Finland","2013","2013",13.2,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","TCPPERMT","/capita, US$ exchange rate","FIN","Finland","2014","2014",13.1,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","TCPPERMT","/capita, US$ exchange rate","FIN","Finland","2015","2015",10.7,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","TCPPERMT","/capita, US$ exchange rate","FIN","Finland","2016","2016",10.5,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","TCPPERMT","/capita, US$ exchange rate","FIN","Finland","2017","2017",10.1,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","TCPPERMT","/capita, US$ exchange rate","FIN","Finland","2018","2018",9.7,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","TCPPERMT","/capita, US$ exchange rate","FIN","Finland","2019","2019",9.3,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","TCPPERMT","/capita, US$ exchange rate","FIN","Finland","2020","2020",8.8,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","TCPPERMT","/capita, US$ exchange rate","FIN","Finland","2021","2021",9,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2010","2010",10.6,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2011","2011",11,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2012","2012",11.3,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2013","2013",10.9,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2014","2014",10.9,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2015","2015",10.6,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2016","2016",10.8,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2017","2017",10.3,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2018","2018",9.7,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2019","2019",9.9,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2020","2020",9.4,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2021","2021",9.2,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","ATCPTTMT","% of total sales","FIN","Finland","2010","2010",2.7,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","ATCPTTMT","% of total sales","FIN","Finland","2011","2011",2.8,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","ATCPTTMT","% of total sales","FIN","Finland","2012","2012",2.8,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","ATCPTTMT","% of total sales","FIN","Finland","2013","2013",2.7,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","ATCPTTMT","% of total sales","FIN","Finland","2014","2014",2.6,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","ATCPTTMT","% of total sales","FIN","Finland","2015","2015",2.4,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","ATCPTTMT","% of total sales","FIN","Finland","2016","2016",2.3,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","ATCPTTMT","% of total sales","FIN","Finland","2017","2017",2.1,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","ATCPTTMT","% of total sales","FIN","Finland","2018","2018",1.8,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","ATCPTTMT","% of total sales","FIN","Finland","2019","2019",1.7,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","ATCPTTMT","% of total sales","FIN","Finland","2020","2020",1.6,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","ATCPTTMT","% of total sales","FIN","Finland","2021","2021",1.5,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MLLNCUMT","Million of national currency units","DEU","Germany","2010","2010",555.1,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MLLNCUMT","Million of national currency units","DEU","Germany","2011","2011",555,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MLLNCUMT","Million of national currency units","DEU","Germany","2012","2012",591.4,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MLLNCUMT","Million of national currency units","DEU","Germany","2013","2013",617.8,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MLLNCUMT","Million of national currency units","DEU","Germany","2014","2014",620.4,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MLLNCUMT","Million of national currency units","DEU","Germany","2015","2015",606.3,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MLLNCUMT","Million of national currency units","DEU","Germany","2016","2016",588.8,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MLLNCUMT","Million of national currency units","DEU","Germany","2017","2017",556.5,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MLLNCUMT","Million of national currency units","DEU","Germany","2018","2018",531.4,"B; D","Break; Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MLLNCUMT","Million of national currency units","DEU","Germany","2019","2019",517.6,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MLLNCUMT","Million of national currency units","DEU","Germany","2020","2020",482.1,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MLLNCUMT","Million of national currency units","DEU","Germany","2021","2021",496.1,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOTCMT","Million US$ at exchange rate","DEU","Germany","2010","2010",735.9,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOTCMT","Million US$ at exchange rate","DEU","Germany","2011","2011",772.5,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOTCMT","Million US$ at exchange rate","DEU","Germany","2012","2012",759.8,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOTCMT","Million US$ at exchange rate","DEU","Germany","2013","2013",820.5,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOTCMT","Million US$ at exchange rate","DEU","Germany","2014","2014",824.2,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOTCMT","Million US$ at exchange rate","DEU","Germany","2015","2015",672.7,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOTCMT","Million US$ at exchange rate","DEU","Germany","2016","2016",651.7,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOTCMT","Million US$ at exchange rate","DEU","Germany","2017","2017",628.7,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOTCMT","Million US$ at exchange rate","DEU","Germany","2018","2018",627.6,"B; D","Break; Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOTCMT","Million US$ at exchange rate","DEU","Germany","2019","2019",579.4,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOTCMT","Million US$ at exchange rate","DEU","Germany","2020","2020",550.7,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOTCMT","Million US$ at exchange rate","DEU","Germany","2021","2021",586.8,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOPPMT","Million US$, purchasing power parity","DEU","Germany","2010","2010",689.5,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOPPMT","Million US$, purchasing power parity","DEU","Germany","2011","2011",703.7,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOPPMT","Million US$, purchasing power parity","DEU","Germany","2012","2012",751.2,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOPPMT","Million US$, purchasing power parity","DEU","Germany","2013","2013",797.4,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOPPMT","Million US$, purchasing power parity","DEU","Germany","2014","2014",806.8,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOPPMT","Million US$, purchasing power parity","DEU","Germany","2015","2015",779.2,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOPPMT","Million US$, purchasing power parity","DEU","Germany","2016","2016",782.3,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOPPMT","Million US$, purchasing power parity","DEU","Germany","2017","2017",747.2,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOPPMT","Million US$, purchasing power parity","DEU","Germany","2018","2018",722.6,"B; D","Break; Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOPPMT","Million US$, purchasing power parity","DEU","Germany","2019","2019",710.7,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOPPMT","Million US$, purchasing power parity","DEU","Germany","2020","2020",665,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOPPMT","Million US$, purchasing power parity","DEU","Germany","2021","2021",673.8,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","TCPPERMT","/capita, US$ exchange rate","DEU","Germany","2010","2010",9,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","TCPPERMT","/capita, US$ exchange rate","DEU","Germany","2011","2011",9.6,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","TCPPERMT","/capita, US$ exchange rate","DEU","Germany","2012","2012",9.4,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","TCPPERMT","/capita, US$ exchange rate","DEU","Germany","2013","2013",10.2,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","TCPPERMT","/capita, US$ exchange rate","DEU","Germany","2014","2014",10.2,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","TCPPERMT","/capita, US$ exchange rate","DEU","Germany","2015","2015",8.2,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","TCPPERMT","/capita, US$ exchange rate","DEU","Germany","2016","2016",7.9,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","TCPPERMT","/capita, US$ exchange rate","DEU","Germany","2017","2017",7.6,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","TCPPERMT","/capita, US$ exchange rate","DEU","Germany","2018","2018",7.6,"B; D","Break; Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","TCPPERMT","/capita, US$ exchange rate","DEU","Germany","2019","2019",7,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","TCPPERMT","/capita, US$ exchange rate","DEU","Germany","2020","2020",6.6,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","TCPPERMT","/capita, US$ exchange rate","DEU","Germany","2021","2021",7.1,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2010","2010",8.4,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2011","2011",8.8,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2012","2012",9.3,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2013","2013",9.9,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2014","2014",10,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2015","2015",9.5,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2016","2016",9.5,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2017","2017",9,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2018","2018",8.7,"B; D","Break; Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2019","2019",8.6,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2020","2020",8,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2021","2021",8.1,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","ATCPTTMT","% of total sales","DEU","Germany","2010","2010",1.9,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","ATCPTTMT","% of total sales","DEU","Germany","2011","2011",1.9,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","ATCPTTMT","% of total sales","DEU","Germany","2012","2012",1.9,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","ATCPTTMT","% of total sales","DEU","Germany","2013","2013",2,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","ATCPTTMT","% of total sales","DEU","Germany","2014","2014",1.8,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","ATCPTTMT","% of total sales","DEU","Germany","2015","2015",1.7,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","ATCPTTMT","% of total sales","DEU","Germany","2016","2016",1.6,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","ATCPTTMT","% of total sales","DEU","Germany","2017","2017",1.5,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","ATCPTTMT","% of total sales","DEU","Germany","2018","2018",1.2,"B; D","Break; Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","ATCPTTMT","% of total sales","DEU","Germany","2019","2019",1.1,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","ATCPTTMT","% of total sales","DEU","Germany","2020","2020",1,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","ATCPTTMT","% of total sales","DEU","Germany","2021","2021",0.9,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MLLNCUMT","Million of national currency units","GRC","Greece","2010","2010",101.4,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MLLNCUMT","Million of national currency units","GRC","Greece","2011","2011",83.3,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MLLNCUMT","Million of national currency units","GRC","Greece","2012","2012",74.2,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MLLNCUMT","Million of national currency units","GRC","Greece","2013","2013",67.6,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MLLNCUMT","Million of national currency units","GRC","Greece","2014","2014",66,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MLLNCUMT","Million of national currency units","GRC","Greece","2015","2015",62.4,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MLLNCUMT","Million of national currency units","GRC","Greece","2016","2016",66.5,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MLLNCUMT","Million of national currency units","GRC","Greece","2017","2017",64.2,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MLLNCUMT","Million of national currency units","GRC","Greece","2018","2018",65.5,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MLLNCUMT","Million of national currency units","GRC","Greece","2019","2019",63.9,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MLLNCUMT","Million of national currency units","GRC","Greece","2020","2020",55.9,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MLLNCUMT","Million of national currency units","GRC","Greece","2021","2021",57,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MLLNCUMT","Million of national currency units","GRC","Greece","2022","2022",55.1,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOTCMT","Million US$ at exchange rate","GRC","Greece","2010","2010",134.5,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOTCMT","Million US$ at exchange rate","GRC","Greece","2011","2011",115.9,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOTCMT","Million US$ at exchange rate","GRC","Greece","2012","2012",95.3,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOTCMT","Million US$ at exchange rate","GRC","Greece","2013","2013",89.8,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOTCMT","Million US$ at exchange rate","GRC","Greece","2014","2014",87.7,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOTCMT","Million US$ at exchange rate","GRC","Greece","2015","2015",69.3,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOTCMT","Million US$ at exchange rate","GRC","Greece","2016","2016",73.6,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOTCMT","Million US$ at exchange rate","GRC","Greece","2017","2017",72.5,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOTCMT","Million US$ at exchange rate","GRC","Greece","2018","2018",77.4,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOTCMT","Million US$ at exchange rate","GRC","Greece","2019","2019",71.5,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOTCMT","Million US$ at exchange rate","GRC","Greece","2020","2020",63.9,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOTCMT","Million US$ at exchange rate","GRC","Greece","2021","2021",67.4,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOTCMT","Million US$ at exchange rate","GRC","Greece","2022","2022",58.1,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOPPMT","Million US$, purchasing power parity","GRC","Greece","2010","2010",140.5,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOPPMT","Million US$, purchasing power parity","GRC","Greece","2011","2011",116.8,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOPPMT","Million US$, purchasing power parity","GRC","Greece","2012","2012",108.4,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOPPMT","Million US$, purchasing power parity","GRC","Greece","2013","2013",107.1,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOPPMT","Million US$, purchasing power parity","GRC","Greece","2014","2014",108.1,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOPPMT","Million US$, purchasing power parity","GRC","Greece","2015","2015",102.5,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOPPMT","Million US$, purchasing power parity","GRC","Greece","2016","2016",112.9,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOPPMT","Million US$, purchasing power parity","GRC","Greece","2017","2017",111.6,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOPPMT","Million US$, purchasing power parity","GRC","Greece","2018","2018",116,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOPPMT","Million US$, purchasing power parity","GRC","Greece","2019","2019",116.4,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOPPMT","Million US$, purchasing power parity","GRC","Greece","2020","2020",102.8,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOPPMT","Million US$, purchasing power parity","GRC","Greece","2021","2021",104.5,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOPPMT","Million US$, purchasing power parity","GRC","Greece","2022","2022",104.3,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","TCPPERMT","/capita, US$ exchange rate","GRC","Greece","2010","2010",12.1,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","TCPPERMT","/capita, US$ exchange rate","GRC","Greece","2011","2011",10.4,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","TCPPERMT","/capita, US$ exchange rate","GRC","Greece","2012","2012",8.6,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","TCPPERMT","/capita, US$ exchange rate","GRC","Greece","2013","2013",8.2,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","TCPPERMT","/capita, US$ exchange rate","GRC","Greece","2014","2014",8.1,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","TCPPERMT","/capita, US$ exchange rate","GRC","Greece","2015","2015",6.4,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","TCPPERMT","/capita, US$ exchange rate","GRC","Greece","2016","2016",6.8,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","TCPPERMT","/capita, US$ exchange rate","GRC","Greece","2017","2017",6.7,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","TCPPERMT","/capita, US$ exchange rate","GRC","Greece","2018","2018",7.2,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","TCPPERMT","/capita, US$ exchange rate","GRC","Greece","2019","2019",6.7,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","TCPPERMT","/capita, US$ exchange rate","GRC","Greece","2020","2020",6,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","TCPPERMT","/capita, US$ exchange rate","GRC","Greece","2021","2021",6.4,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","TCPPERMT","/capita, US$ exchange rate","GRC","Greece","2022","2022",5.6,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2010","2010",12.6,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2011","2011",10.5,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2012","2012",9.8,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2013","2013",9.8,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2014","2014",9.9,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2015","2015",9.5,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2016","2016",10.5,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2017","2017",10.4,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2018","2018",10.8,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2019","2019",10.9,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2020","2020",9.6,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2021","2021",9.9,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2022","2022",10,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MLLNCUMT","Million of national currency units","HUN","Hungary","2010","2010",6442.7,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MLLNCUMT","Million of national currency units","HUN","Hungary","2011","2011",5672.5,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MLLNCUMT","Million of national currency units","HUN","Hungary","2012","2012",5181.6,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MLLNCUMT","Million of national currency units","HUN","Hungary","2013","2013",5250,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MLLNCUMT","Million of national currency units","HUN","Hungary","2014","2014",5568.3,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MLLNCUMT","Million of national currency units","HUN","Hungary","2015","2015",5542.3,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MLLNCUMT","Million of national currency units","HUN","Hungary","2016","2016",5595.1,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MLLNCUMT","Million of national currency units","HUN","Hungary","2017","2017",5629.9,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MLLNCUMT","Million of national currency units","HUN","Hungary","2018","2018",5578.6,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MLLNCUMT","Million of national currency units","HUN","Hungary","2019","2019",5610.8,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MLLNCUMT","Million of national currency units","HUN","Hungary","2020","2020",5439.6,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MLLNCUMT","Million of national currency units","HUN","Hungary","2021","2021",5220.6,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MLLNCUMT","Million of national currency units","HUN","Hungary","2022","2022",4952.5,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOTCMT","Million US$ at exchange rate","HUN","Hungary","2010","2010",31,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOTCMT","Million US$ at exchange rate","HUN","Hungary","2011","2011",28.2,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOTCMT","Million US$ at exchange rate","HUN","Hungary","2012","2012",23,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOTCMT","Million US$ at exchange rate","HUN","Hungary","2013","2013",23.5,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOTCMT","Million US$ at exchange rate","HUN","Hungary","2014","2014",23.9,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOTCMT","Million US$ at exchange rate","HUN","Hungary","2015","2015",19.8,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOTCMT","Million US$ at exchange rate","HUN","Hungary","2016","2016",19.9,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOTCMT","Million US$ at exchange rate","HUN","Hungary","2017","2017",20.5,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOTCMT","Million US$ at exchange rate","HUN","Hungary","2018","2018",20.6,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOTCMT","Million US$ at exchange rate","HUN","Hungary","2019","2019",19.3,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOTCMT","Million US$ at exchange rate","HUN","Hungary","2020","2020",17.7,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOTCMT","Million US$ at exchange rate","HUN","Hungary","2021","2021",17.2,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOTCMT","Million US$ at exchange rate","HUN","Hungary","2022","2022",13.3,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOPPMT","Million US$, purchasing power parity","HUN","Hungary","2010","2010",51,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOPPMT","Million US$, purchasing power parity","HUN","Hungary","2011","2011",45.6,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOPPMT","Million US$, purchasing power parity","HUN","Hungary","2012","2012",41.2,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOPPMT","Million US$, purchasing power parity","HUN","Hungary","2013","2013",42,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOPPMT","Million US$, purchasing power parity","HUN","Hungary","2014","2014",43,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOPPMT","Million US$, purchasing power parity","HUN","Hungary","2015","2015",41.8,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOPPMT","Million US$, purchasing power parity","HUN","Hungary","2016","2016",42.4,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOPPMT","Million US$, purchasing power parity","HUN","Hungary","2017","2017",41.4,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOPPMT","Million US$, purchasing power parity","HUN","Hungary","2018","2018",40.1,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOPPMT","Million US$, purchasing power parity","HUN","Hungary","2019","2019",39.8,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOPPMT","Million US$, purchasing power parity","HUN","Hungary","2020","2020",37.4,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOPPMT","Million US$, purchasing power parity","HUN","Hungary","2021","2021",33.7,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOPPMT","Million US$, purchasing power parity","HUN","Hungary","2022","2022",30.7,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","TCPPERMT","/capita, US$ exchange rate","HUN","Hungary","2010","2010",3.1,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","TCPPERMT","/capita, US$ exchange rate","HUN","Hungary","2011","2011",2.8,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","TCPPERMT","/capita, US$ exchange rate","HUN","Hungary","2012","2012",2.3,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","TCPPERMT","/capita, US$ exchange rate","HUN","Hungary","2013","2013",2.4,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","TCPPERMT","/capita, US$ exchange rate","HUN","Hungary","2014","2014",2.4,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","TCPPERMT","/capita, US$ exchange rate","HUN","Hungary","2015","2015",2,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","TCPPERMT","/capita, US$ exchange rate","HUN","Hungary","2016","2016",2,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","TCPPERMT","/capita, US$ exchange rate","HUN","Hungary","2017","2017",2.1,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","TCPPERMT","/capita, US$ exchange rate","HUN","Hungary","2018","2018",2.1,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","TCPPERMT","/capita, US$ exchange rate","HUN","Hungary","2019","2019",2,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","TCPPERMT","/capita, US$ exchange rate","HUN","Hungary","2020","2020",1.8,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","TCPPERMT","/capita, US$ exchange rate","HUN","Hungary","2021","2021",1.8,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","TCPPERMT","/capita, US$ exchange rate","HUN","Hungary","2022","2022",1.4,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2010","2010",5.1,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2011","2011",4.6,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2012","2012",4.2,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2013","2013",4.2,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2014","2014",4.4,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2015","2015",4.2,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2016","2016",4.3,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2017","2017",4.2,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2018","2018",4.1,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2019","2019",4.1,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2020","2020",3.8,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2021","2021",3.5,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2022","2022",3.2,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","ATCPTTMT","% of total sales","HUN","Hungary","2010","2010",1.3,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","ATCPTTMT","% of total sales","HUN","Hungary","2011","2011",1.1,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","ATCPTTMT","% of total sales","HUN","Hungary","2012","2012",1.2,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","ATCPTTMT","% of total sales","HUN","Hungary","2013","2013",1.2,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","ATCPTTMT","% of total sales","HUN","Hungary","2014","2014",1.3,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","ATCPTTMT","% of total sales","HUN","Hungary","2015","2015",1.2,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","ATCPTTMT","% of total sales","HUN","Hungary","2016","2016",1.1,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","ATCPTTMT","% of total sales","HUN","Hungary","2017","2017",1.1,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","ATCPTTMT","% of total sales","HUN","Hungary","2018","2018",1.1,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","ATCPTTMT","% of total sales","HUN","Hungary","2019","2019",1.1,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","ATCPTTMT","% of total sales","HUN","Hungary","2020","2020",1,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","ATCPTTMT","% of total sales","HUN","Hungary","2021","2021",0.9,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","ATCPTTMT","% of total sales","HUN","Hungary","2022","2022",0.8,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MLLNCUMT","Million of national currency units","ISL","Iceland","2010","2010",903.3,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MLLNCUMT","Million of national currency units","ISL","Iceland","2011","2011",485.5,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MLLNCUMT","Million of national currency units","ISL","Iceland","2012","2012",482.3,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MLLNCUMT","Million of national currency units","ISL","Iceland","2013","2013",638.8,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MLLNCUMT","Million of national currency units","ISL","Iceland","2014","2014",446,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MLLNCUMT","Million of national currency units","ISL","Iceland","2015","2015",430.1,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MLLNCUMT","Million of national currency units","ISL","Iceland","2016","2016",431.9,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MLLNCUMT","Million of national currency units","ISL","Iceland","2017","2017",431.6,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MLLNCUMT","Million of national currency units","ISL","Iceland","2018","2018",404.5,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MLLNCUMT","Million of national currency units","ISL","Iceland","2019","2019",426.1,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MLLNCUMT","Million of national currency units","ISL","Iceland","2020","2020",504.5,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MLLNCUMT","Million of national currency units","ISL","Iceland","2021","2021",550.9,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOTCMT","Million US$ at exchange rate","ISL","Iceland","2010","2010",7.4,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOTCMT","Million US$ at exchange rate","ISL","Iceland","2011","2011",4.2,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOTCMT","Million US$ at exchange rate","ISL","Iceland","2012","2012",3.9,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOTCMT","Million US$ at exchange rate","ISL","Iceland","2013","2013",5.2,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOTCMT","Million US$ at exchange rate","ISL","Iceland","2014","2014",3.8,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOTCMT","Million US$ at exchange rate","ISL","Iceland","2015","2015",3.3,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOTCMT","Million US$ at exchange rate","ISL","Iceland","2016","2016",3.6,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOTCMT","Million US$ at exchange rate","ISL","Iceland","2017","2017",4,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOTCMT","Million US$ at exchange rate","ISL","Iceland","2018","2018",3.7,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOTCMT","Million US$ at exchange rate","ISL","Iceland","2019","2019",3.5,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOTCMT","Million US$ at exchange rate","ISL","Iceland","2020","2020",3.7,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOTCMT","Million US$ at exchange rate","ISL","Iceland","2021","2021",4.3,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOPPMT","Million US$, purchasing power parity","ISL","Iceland","2010","2010",6.8,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOPPMT","Million US$, purchasing power parity","ISL","Iceland","2011","2011",3.6,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOPPMT","Million US$, purchasing power parity","ISL","Iceland","2012","2012",3.5,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOPPMT","Million US$, purchasing power parity","ISL","Iceland","2013","2013",4.7,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOPPMT","Million US$, purchasing power parity","ISL","Iceland","2014","2014",3.2,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOPPMT","Million US$, purchasing power parity","ISL","Iceland","2015","2015",3,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOPPMT","Million US$, purchasing power parity","ISL","Iceland","2016","2016",3.1,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOPPMT","Million US$, purchasing power parity","ISL","Iceland","2017","2017",3.1,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOPPMT","Million US$, purchasing power parity","ISL","Iceland","2018","2018",2.9,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOPPMT","Million US$, purchasing power parity","ISL","Iceland","2019","2019",3,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOPPMT","Million US$, purchasing power parity","ISL","Iceland","2020","2020",3.4,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOPPMT","Million US$, purchasing power parity","ISL","Iceland","2021","2021",3.7,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","TCPPERMT","/capita, US$ exchange rate","ISL","Iceland","2010","2010",23.2,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","TCPPERMT","/capita, US$ exchange rate","ISL","Iceland","2011","2011",13.1,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","TCPPERMT","/capita, US$ exchange rate","ISL","Iceland","2012","2012",12,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","TCPPERMT","/capita, US$ exchange rate","ISL","Iceland","2013","2013",16.1,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","TCPPERMT","/capita, US$ exchange rate","ISL","Iceland","2014","2014",11.7,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","TCPPERMT","/capita, US$ exchange rate","ISL","Iceland","2015","2015",9.9,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","TCPPERMT","/capita, US$ exchange rate","ISL","Iceland","2016","2016",10.7,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","TCPPERMT","/capita, US$ exchange rate","ISL","Iceland","2017","2017",11.8,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","TCPPERMT","/capita, US$ exchange rate","ISL","Iceland","2018","2018",10.6,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","TCPPERMT","/capita, US$ exchange rate","ISL","Iceland","2019","2019",9.6,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","TCPPERMT","/capita, US$ exchange rate","ISL","Iceland","2020","2020",10.2,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","TCPPERMT","/capita, US$ exchange rate","ISL","Iceland","2021","2021",11.6,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2010","2010",21.4,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2011","2011",11.3,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2012","2012",11,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2013","2013",14.4,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2014","2014",9.8,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2015","2015",9.2,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2016","2016",9.2,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2017","2017",9.1,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2018","2018",8.1,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2019","2019",8.4,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2020","2020",9.4,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2021","2021",9.9,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","ATCPTTMT","% of total sales","ISL","Iceland","2010","2010",3.6,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","ATCPTTMT","% of total sales","ISL","Iceland","2011","2011",1.9,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","ATCPTTMT","% of total sales","ISL","Iceland","2012","2012",2,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","ATCPTTMT","% of total sales","ISL","Iceland","2013","2013",2.5,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","ATCPTTMT","% of total sales","ISL","Iceland","2014","2014",1.9,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","ATCPTTMT","% of total sales","ISL","Iceland","2015","2015",1.8,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","ATCPTTMT","% of total sales","ISL","Iceland","2016","2016",1.7,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","ATCPTTMT","% of total sales","ISL","Iceland","2017","2017",1.6,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","ATCPTTMT","% of total sales","ISL","Iceland","2018","2018",1.3,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","ATCPTTMT","% of total sales","ISL","Iceland","2019","2019",1.3,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","ATCPTTMT","% of total sales","ISL","Iceland","2020","2020",1.3,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","ATCPTTMT","% of total sales","ISL","Iceland","2021","2021",1.2,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MLLNCUMT","Million of national currency units","IRL","Ireland","2010","2010",34.3,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MLLNCUMT","Million of national currency units","IRL","Ireland","2011","2011",29.9,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MLLNCUMT","Million of national currency units","IRL","Ireland","2012","2012",27.8,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MLLNCUMT","Million of national currency units","IRL","Ireland","2013","2013",21.3,"B; D","Break; Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MLLNCUMT","Million of national currency units","IRL","Ireland","2014","2014",19.9,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MLLNCUMT","Million of national currency units","IRL","Ireland","2015","2015",19.7,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MLLNCUMT","Million of national currency units","IRL","Ireland","2016","2016",19.2,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MLLNCUMT","Million of national currency units","IRL","Ireland","2017","2017",17.8,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MLLNCUMT","Million of national currency units","IRL","Ireland","2018","2018",15.6,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MLLNCUMT","Million of national currency units","IRL","Ireland","2019","2019",15,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MLLNCUMT","Million of national currency units","IRL","Ireland","2020","2020",14.9,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MLLNCUMT","Million of national currency units","IRL","Ireland","2021","2021",15.3,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOTCMT","Million US$ at exchange rate","IRL","Ireland","2010","2010",45.4,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOTCMT","Million US$ at exchange rate","IRL","Ireland","2011","2011",41.6,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOTCMT","Million US$ at exchange rate","IRL","Ireland","2012","2012",35.7,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOTCMT","Million US$ at exchange rate","IRL","Ireland","2013","2013",28.3,"B; D","Break; Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOTCMT","Million US$ at exchange rate","IRL","Ireland","2014","2014",26.4,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOTCMT","Million US$ at exchange rate","IRL","Ireland","2015","2015",21.9,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOTCMT","Million US$ at exchange rate","IRL","Ireland","2016","2016",21.2,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOTCMT","Million US$ at exchange rate","IRL","Ireland","2017","2017",20.1,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOTCMT","Million US$ at exchange rate","IRL","Ireland","2018","2018",18.4,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOTCMT","Million US$ at exchange rate","IRL","Ireland","2019","2019",16.8,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOTCMT","Million US$ at exchange rate","IRL","Ireland","2020","2020",17,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOTCMT","Million US$ at exchange rate","IRL","Ireland","2021","2021",18,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOPPMT","Million US$, purchasing power parity","IRL","Ireland","2010","2010",40.4,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOPPMT","Million US$, purchasing power parity","IRL","Ireland","2011","2011",36,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOPPMT","Million US$, purchasing power parity","IRL","Ireland","2012","2012",33.8,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOPPMT","Million US$, purchasing power parity","IRL","Ireland","2013","2013",26.3,"B; D","Break; Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOPPMT","Million US$, purchasing power parity","IRL","Ireland","2014","2014",24.3,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOPPMT","Million US$, purchasing power parity","IRL","Ireland","2015","2015",24.4,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOPPMT","Million US$, purchasing power parity","IRL","Ireland","2016","2016",24.1,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOPPMT","Million US$, purchasing power parity","IRL","Ireland","2017","2017",22.4,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOPPMT","Million US$, purchasing power parity","IRL","Ireland","2018","2018",19.6,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOPPMT","Million US$, purchasing power parity","IRL","Ireland","2019","2019",18.6,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOPPMT","Million US$, purchasing power parity","IRL","Ireland","2020","2020",18.7,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOPPMT","Million US$, purchasing power parity","IRL","Ireland","2021","2021",19.2,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","TCPPERMT","/capita, US$ exchange rate","IRL","Ireland","2010","2010",10,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","TCPPERMT","/capita, US$ exchange rate","IRL","Ireland","2011","2011",9.1,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","TCPPERMT","/capita, US$ exchange rate","IRL","Ireland","2012","2012",7.8,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","TCPPERMT","/capita, US$ exchange rate","IRL","Ireland","2013","2013",6.1,"B; D","Break; Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","TCPPERMT","/capita, US$ exchange rate","IRL","Ireland","2014","2014",5.7,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","TCPPERMT","/capita, US$ exchange rate","IRL","Ireland","2015","2015",4.7,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","TCPPERMT","/capita, US$ exchange rate","IRL","Ireland","2016","2016",4.5,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","TCPPERMT","/capita, US$ exchange rate","IRL","Ireland","2017","2017",4.2,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","TCPPERMT","/capita, US$ exchange rate","IRL","Ireland","2018","2018",3.8,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","TCPPERMT","/capita, US$ exchange rate","IRL","Ireland","2019","2019",3.4,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","TCPPERMT","/capita, US$ exchange rate","IRL","Ireland","2020","2020",3.4,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","TCPPERMT","/capita, US$ exchange rate","IRL","Ireland","2021","2021",3.6,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2010","2010",8.8,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2011","2011",7.9,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2012","2012",7.3,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2013","2013",5.7,"B; D","Break; Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2014","2014",5.2,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2015","2015",5.2,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2016","2016",5.1,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2017","2017",4.7,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2018","2018",4,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2019","2019",3.8,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2020","2020",3.8,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2021","2021",3.8,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","ATCPTTMT","% of total sales","IRL","Ireland","2010","2010",1.7,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","ATCPTTMT","% of total sales","IRL","Ireland","2011","2011",1.5,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","ATCPTTMT","% of total sales","IRL","Ireland","2012","2012",1.4,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","ATCPTTMT","% of total sales","IRL","Ireland","2013","2013",1.1,"B; D","Break; Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","ATCPTTMT","% of total sales","IRL","Ireland","2014","2014",1,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","ATCPTTMT","% of total sales","IRL","Ireland","2015","2015",1,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","ATCPTTMT","% of total sales","IRL","Ireland","2016","2016",0.9,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","ATCPTTMT","% of total sales","IRL","Ireland","2017","2017",0.8,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","ATCPTTMT","% of total sales","IRL","Ireland","2018","2018",0.7,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","ATCPTTMT","% of total sales","IRL","Ireland","2019","2019",0.6,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","ATCPTTMT","% of total sales","IRL","Ireland","2020","2020",0.6,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","ATCPTTMT","% of total sales","IRL","Ireland","2021","2021",0.6,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MLLNCUMT","Million of national currency units","ITA","Italy","2011","2011",250,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MLLNCUMT","Million of national currency units","ITA","Italy","2012","2012",234.5,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MLLNCUMT","Million of national currency units","ITA","Italy","2013","2013",235.2,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MLLNCUMT","Million of national currency units","ITA","Italy","2014","2014",232.6,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MLLNCUMT","Million of national currency units","ITA","Italy","2015","2015",209.1,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MLLNCUMT","Million of national currency units","ITA","Italy","2016","2016",195.1,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MLLNCUMT","Million of national currency units","ITA","Italy","2017","2017",174.7,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MLLNCUMT","Million of national currency units","ITA","Italy","2018","2018",152.5,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MLLNCUMT","Million of national currency units","ITA","Italy","2019","2019",149.9,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MLLNCUMT","Million of national currency units","ITA","Italy","2020","2020",139.4,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MLLNCUMT","Million of national currency units","ITA","Italy","2021","2021",146.7,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MLLNCUMT","Million of national currency units","ITA","Italy","2022","2022",155.9,"E","Estimated value"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOTCMT","Million US$ at exchange rate","ITA","Italy","2011","2011",347.9,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOTCMT","Million US$ at exchange rate","ITA","Italy","2012","2012",301.3,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOTCMT","Million US$ at exchange rate","ITA","Italy","2013","2013",312.4,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOTCMT","Million US$ at exchange rate","ITA","Italy","2014","2014",309,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOTCMT","Million US$ at exchange rate","ITA","Italy","2015","2015",232,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOTCMT","Million US$ at exchange rate","ITA","Italy","2016","2016",216,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOTCMT","Million US$ at exchange rate","ITA","Italy","2017","2017",197.3,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOTCMT","Million US$ at exchange rate","ITA","Italy","2018","2018",180.1,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOTCMT","Million US$ at exchange rate","ITA","Italy","2019","2019",167.8,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOTCMT","Million US$ at exchange rate","ITA","Italy","2020","2020",159.2,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOTCMT","Million US$ at exchange rate","ITA","Italy","2021","2021",173.5,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOTCMT","Million US$ at exchange rate","ITA","Italy","2022","2022",164.1,"E","Estimated value"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOPPMT","Million US$, purchasing power parity","ITA","Italy","2011","2011",329.5,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOPPMT","Million US$, purchasing power parity","ITA","Italy","2012","2012",313.6,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOPPMT","Million US$, purchasing power parity","ITA","Italy","2013","2013",319,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOPPMT","Million US$, purchasing power parity","ITA","Italy","2014","2014",314.5,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOPPMT","Million US$, purchasing power parity","ITA","Italy","2015","2015",283.1,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOPPMT","Million US$, purchasing power parity","ITA","Italy","2016","2016",278.5,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOPPMT","Million US$, purchasing power parity","ITA","Italy","2017","2017",253.2,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOPPMT","Million US$, purchasing power parity","ITA","Italy","2018","2018",223.9,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOPPMT","Million US$, purchasing power parity","ITA","Italy","2019","2019",228.3,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOPPMT","Million US$, purchasing power parity","ITA","Italy","2020","2020",215.3,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOPPMT","Million US$, purchasing power parity","ITA","Italy","2021","2021",226.5,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOPPMT","Million US$, purchasing power parity","ITA","Italy","2022","2022",252.4,"E","Estimated value"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","TCPPERMT","/capita, US$ exchange rate","ITA","Italy","2011","2011",5.9,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","TCPPERMT","/capita, US$ exchange rate","ITA","Italy","2012","2012",5.1,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","TCPPERMT","/capita, US$ exchange rate","ITA","Italy","2013","2013",5.2,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","TCPPERMT","/capita, US$ exchange rate","ITA","Italy","2014","2014",5.1,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","TCPPERMT","/capita, US$ exchange rate","ITA","Italy","2015","2015",3.8,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","TCPPERMT","/capita, US$ exchange rate","ITA","Italy","2016","2016",3.6,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","TCPPERMT","/capita, US$ exchange rate","ITA","Italy","2017","2017",3.3,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","TCPPERMT","/capita, US$ exchange rate","ITA","Italy","2018","2018",3,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","TCPPERMT","/capita, US$ exchange rate","ITA","Italy","2019","2019",2.8,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","TCPPERMT","/capita, US$ exchange rate","ITA","Italy","2020","2020",2.7,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","TCPPERMT","/capita, US$ exchange rate","ITA","Italy","2021","2021",2.9,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","TCPPERMT","/capita, US$ exchange rate","ITA","Italy","2022","2022",2.8,"E","Estimated value"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2011","2011",5.5,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2012","2012",5.3,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2013","2013",5.3,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2014","2014",5.2,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2015","2015",4.7,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2016","2016",4.6,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2017","2017",4.2,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2018","2018",3.7,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2019","2019",3.8,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2020","2020",3.6,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2021","2021",3.8,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2022","2022",4.3,"E","Estimated value"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","ATCPTTMT","% of total sales","ITA","Italy","2011","2011",1.3,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","ATCPTTMT","% of total sales","ITA","Italy","2012","2012",1.2,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","ATCPTTMT","% of total sales","ITA","Italy","2013","2013",1.2,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","ATCPTTMT","% of total sales","ITA","Italy","2014","2014",1.2,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","ATCPTTMT","% of total sales","ITA","Italy","2015","2015",0.9,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","ATCPTTMT","% of total sales","ITA","Italy","2016","2016",0.9,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","ATCPTTMT","% of total sales","ITA","Italy","2017","2017",0.8,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","ATCPTTMT","% of total sales","ITA","Italy","2018","2018",0.7,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","ATCPTTMT","% of total sales","ITA","Italy","2019","2019",0.7,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","ATCPTTMT","% of total sales","ITA","Italy","2020","2020",0.6,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","ATCPTTMT","% of total sales","ITA","Italy","2021","2021",0.6,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","ATCPTTMT","% of total sales","ITA","Italy","2022","2022",0.6,"E","Estimated value"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MLLNCUMT","Million of national currency units","KOR","Korea","2010","2010",621791,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MLLNCUMT","Million of national currency units","KOR","Korea","2011","2011",637074,"B","Break"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MLLNCUMT","Million of national currency units","KOR","Korea","2012","2012",576586.2,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MLLNCUMT","Million of national currency units","KOR","Korea","2013","2013",574582.4,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MLLNCUMT","Million of national currency units","KOR","Korea","2014","2014",610839.9,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MLLNCUMT","Million of national currency units","KOR","Korea","2015","2015",633297.3,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MLLNCUMT","Million of national currency units","KOR","Korea","2016","2016",598544.4,"B","Break"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MLLNCUMT","Million of national currency units","KOR","Korea","2017","2017",619492.2,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MLLNCUMT","Million of national currency units","KOR","Korea","2018","2018",668448,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MLLNCUMT","Million of national currency units","KOR","Korea","2019","2019",705416.7,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MLLNCUMT","Million of national currency units","KOR","Korea","2020","2020",713909.5,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MLLNCUMT","Million of national currency units","KOR","Korea","2021","2021",747821.4,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOTCMT","Million US$ at exchange rate","KOR","Korea","2010","2010",537.7,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOTCMT","Million US$ at exchange rate","KOR","Korea","2011","2011",574.9,"B","Break"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOTCMT","Million US$ at exchange rate","KOR","Korea","2012","2012",511.7,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOTCMT","Million US$ at exchange rate","KOR","Korea","2013","2013",524.7,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOTCMT","Million US$ at exchange rate","KOR","Korea","2014","2014",580.2,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOTCMT","Million US$ at exchange rate","KOR","Korea","2015","2015",560,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOTCMT","Million US$ at exchange rate","KOR","Korea","2016","2016",515.6,"B","Break"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOTCMT","Million US$ at exchange rate","KOR","Korea","2017","2017",547.7,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOTCMT","Million US$ at exchange rate","KOR","Korea","2018","2018",607.6,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOTCMT","Million US$ at exchange rate","KOR","Korea","2019","2019",605.3,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOTCMT","Million US$ at exchange rate","KOR","Korea","2020","2020",604.9,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOTCMT","Million US$ at exchange rate","KOR","Korea","2021","2021",653.7,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOPPMT","Million US$, purchasing power parity","KOR","Korea","2010","2010",739.4,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOPPMT","Million US$, purchasing power parity","KOR","Korea","2011","2011",745.5,"B","Break"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOPPMT","Million US$, purchasing power parity","KOR","Korea","2012","2012",674.5,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOPPMT","Million US$, purchasing power parity","KOR","Korea","2013","2013",661.1,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOPPMT","Million US$, purchasing power parity","KOR","Korea","2014","2014",700.6,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOPPMT","Million US$, purchasing power parity","KOR","Korea","2015","2015",738.6,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOPPMT","Million US$, purchasing power parity","KOR","Korea","2016","2016",696.9,"B","Break"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOPPMT","Million US$, purchasing power parity","KOR","Korea","2017","2017",709.9,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOPPMT","Million US$, purchasing power parity","KOR","Korea","2018","2018",781.9,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOPPMT","Million US$, purchasing power parity","KOR","Korea","2019","2019",823.7,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOPPMT","Million US$, purchasing power parity","KOR","Korea","2020","2020",852.3,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOPPMT","Million US$, purchasing power parity","KOR","Korea","2021","2021",875.6,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","TCPPERMT","/capita, US$ exchange rate","KOR","Korea","2010","2010",10.9,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","TCPPERMT","/capita, US$ exchange rate","KOR","Korea","2011","2011",11.5,"B","Break"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","TCPPERMT","/capita, US$ exchange rate","KOR","Korea","2012","2012",10.2,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","TCPPERMT","/capita, US$ exchange rate","KOR","Korea","2013","2013",10.4,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","TCPPERMT","/capita, US$ exchange rate","KOR","Korea","2014","2014",11.4,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","TCPPERMT","/capita, US$ exchange rate","KOR","Korea","2015","2015",11,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","TCPPERMT","/capita, US$ exchange rate","KOR","Korea","2016","2016",10.1,"B","Break"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","TCPPERMT","/capita, US$ exchange rate","KOR","Korea","2017","2017",10.7,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","TCPPERMT","/capita, US$ exchange rate","KOR","Korea","2018","2018",11.8,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","TCPPERMT","/capita, US$ exchange rate","KOR","Korea","2019","2019",11.7,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","TCPPERMT","/capita, US$ exchange rate","KOR","Korea","2020","2020",11.7,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","TCPPERMT","/capita, US$ exchange rate","KOR","Korea","2021","2021",12.6,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2010","2010",14.9,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2011","2011",14.9,"B","Break"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2012","2012",13.4,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2013","2013",13.1,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2014","2014",13.8,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2015","2015",14.5,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2016","2016",13.6,"B","Break"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2017","2017",13.8,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2018","2018",15.2,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2019","2019",15.9,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2020","2020",16.4,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2021","2021",16.9,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","ATCPTTMT","% of total sales","KOR","Korea","2010","2010",3.1,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","ATCPTTMT","% of total sales","KOR","Korea","2011","2011",2.9,"B","Break"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","ATCPTTMT","% of total sales","KOR","Korea","2012","2012",2.7,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","ATCPTTMT","% of total sales","KOR","Korea","2013","2013",2.5,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","ATCPTTMT","% of total sales","KOR","Korea","2014","2014",2.6,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","ATCPTTMT","% of total sales","KOR","Korea","2015","2015",2.6,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","ATCPTTMT","% of total sales","KOR","Korea","2016","2016",2.4,"B","Break"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","ATCPTTMT","% of total sales","KOR","Korea","2017","2017",2.3,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","ATCPTTMT","% of total sales","KOR","Korea","2018","2018",2.3,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","ATCPTTMT","% of total sales","KOR","Korea","2019","2019",2.3,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","ATCPTTMT","% of total sales","KOR","Korea","2020","2020",2.2,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","ATCPTTMT","% of total sales","KOR","Korea","2021","2021",2.2,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MLLNCUMT","Million of national currency units","LUX","Luxembourg","2010","2010",5.5,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MLLNCUMT","Million of national currency units","LUX","Luxembourg","2011","2011",5.5,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MLLNCUMT","Million of national currency units","LUX","Luxembourg","2012","2012",6,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MLLNCUMT","Million of national currency units","LUX","Luxembourg","2013","2013",6.2,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MLLNCUMT","Million of national currency units","LUX","Luxembourg","2014","2014",6.1,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MLLNCUMT","Million of national currency units","LUX","Luxembourg","2015","2015",5.9,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MLLNCUMT","Million of national currency units","LUX","Luxembourg","2016","2016",5.9,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MLLNCUMT","Million of national currency units","LUX","Luxembourg","2017","2017",5.5,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MLLNCUMT","Million of national currency units","LUX","Luxembourg","2018","2018",5.2,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MLLNCUMT","Million of national currency units","LUX","Luxembourg","2019","2019",4.9,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MLLNCUMT","Million of national currency units","LUX","Luxembourg","2020","2020",4,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MLLNCUMT","Million of national currency units","LUX","Luxembourg","2021","2021",4,"B; D; P","Break; Difference in methodology; Provisional value"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MLLNCUMT","Million of national currency units","LUX","Luxembourg","2022","2022",4.1,"D; P","Difference in methodology; Provisional value"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOTCMT","Million US$ at exchange rate","LUX","Luxembourg","2010","2010",7.3,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOTCMT","Million US$ at exchange rate","LUX","Luxembourg","2011","2011",7.7,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOTCMT","Million US$ at exchange rate","LUX","Luxembourg","2012","2012",7.7,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOTCMT","Million US$ at exchange rate","LUX","Luxembourg","2013","2013",8.2,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOTCMT","Million US$ at exchange rate","LUX","Luxembourg","2014","2014",8.1,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOTCMT","Million US$ at exchange rate","LUX","Luxembourg","2015","2015",6.5,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOTCMT","Million US$ at exchange rate","LUX","Luxembourg","2016","2016",6.6,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOTCMT","Million US$ at exchange rate","LUX","Luxembourg","2017","2017",6.2,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOTCMT","Million US$ at exchange rate","LUX","Luxembourg","2018","2018",6.1,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOTCMT","Million US$ at exchange rate","LUX","Luxembourg","2019","2019",5.4,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOTCMT","Million US$ at exchange rate","LUX","Luxembourg","2020","2020",4.5,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOTCMT","Million US$ at exchange rate","LUX","Luxembourg","2021","2021",4.7,"B; D; P","Break; Difference in methodology; Provisional value"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOTCMT","Million US$ at exchange rate","LUX","Luxembourg","2022","2022",4.3,"D; P","Difference in methodology; Provisional value"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOPPMT","Million US$, purchasing power parity","LUX","Luxembourg","2010","2010",6,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOPPMT","Million US$, purchasing power parity","LUX","Luxembourg","2011","2011",6.1,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOPPMT","Million US$, purchasing power parity","LUX","Luxembourg","2012","2012",6.6,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOPPMT","Million US$, purchasing power parity","LUX","Luxembourg","2013","2013",6.9,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOPPMT","Million US$, purchasing power parity","LUX","Luxembourg","2014","2014",6.9,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOPPMT","Million US$, purchasing power parity","LUX","Luxembourg","2015","2015",6.7,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOPPMT","Million US$, purchasing power parity","LUX","Luxembourg","2016","2016",7,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOPPMT","Million US$, purchasing power parity","LUX","Luxembourg","2017","2017",6.4,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOPPMT","Million US$, purchasing power parity","LUX","Luxembourg","2018","2018",6.1,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOPPMT","Million US$, purchasing power parity","LUX","Luxembourg","2019","2019",5.8,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOPPMT","Million US$, purchasing power parity","LUX","Luxembourg","2020","2020",4.6,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOPPMT","Million US$, purchasing power parity","LUX","Luxembourg","2021","2021",4.7,"B; D; P","Break; Difference in methodology; Provisional value"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOPPMT","Million US$, purchasing power parity","LUX","Luxembourg","2022","2022",4.9,"D; P","Difference in methodology; Provisional value"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","TCPPERMT","/capita, US$ exchange rate","LUX","Luxembourg","2010","2010",15.5,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","TCPPERMT","/capita, US$ exchange rate","LUX","Luxembourg","2011","2011",15.9,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","TCPPERMT","/capita, US$ exchange rate","LUX","Luxembourg","2012","2012",15.7,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","TCPPERMT","/capita, US$ exchange rate","LUX","Luxembourg","2013","2013",16.3,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","TCPPERMT","/capita, US$ exchange rate","LUX","Luxembourg","2014","2014",15.9,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","TCPPERMT","/capita, US$ exchange rate","LUX","Luxembourg","2015","2015",12.6,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","TCPPERMT","/capita, US$ exchange rate","LUX","Luxembourg","2016","2016",12.5,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","TCPPERMT","/capita, US$ exchange rate","LUX","Luxembourg","2017","2017",11.5,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","TCPPERMT","/capita, US$ exchange rate","LUX","Luxembourg","2018","2018",11.2,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","TCPPERMT","/capita, US$ exchange rate","LUX","Luxembourg","2019","2019",9.8,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","TCPPERMT","/capita, US$ exchange rate","LUX","Luxembourg","2020","2020",8,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","TCPPERMT","/capita, US$ exchange rate","LUX","Luxembourg","2021","2021",8.2,"B; D; P","Break; Difference in methodology; Provisional value"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","TCPPERMT","/capita, US$ exchange rate","LUX","Luxembourg","2022","2022",7.3,"D; P","Difference in methodology; Provisional value"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2010","2010",12.6,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2011","2011",12.6,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2012","2012",13.4,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2013","2013",13.7,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2014","2014",13.6,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2015","2015",12.9,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2016","2016",13.2,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2017","2017",12,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2018","2018",11.2,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2019","2019",10.4,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2020","2020",8.2,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2021","2021",8.1,"B; D; P","Break; Difference in methodology; Provisional value"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2022","2022",8.4,"D; P","Difference in methodology; Provisional value"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","ATCPTTMT","% of total sales","LUX","Luxembourg","2010","2010",2.9,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","ATCPTTMT","% of total sales","LUX","Luxembourg","2011","2011",2.9,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","ATCPTTMT","% of total sales","LUX","Luxembourg","2012","2012",3.1,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","ATCPTTMT","% of total sales","LUX","Luxembourg","2013","2013",3.2,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","ATCPTTMT","% of total sales","LUX","Luxembourg","2014","2014",3.2,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","ATCPTTMT","% of total sales","LUX","Luxembourg","2015","2015",3.1,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","ATCPTTMT","% of total sales","LUX","Luxembourg","2016","2016",3,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","ATCPTTMT","% of total sales","LUX","Luxembourg","2017","2017",2.8,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","ATCPTTMT","% of total sales","LUX","Luxembourg","2018","2018",2.6,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","ATCPTTMT","% of total sales","LUX","Luxembourg","2019","2019",2.4,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","ATCPTTMT","% of total sales","LUX","Luxembourg","2020","2020",1.9,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","ATCPTTMT","% of total sales","LUX","Luxembourg","2021","2021",1.7,"B; D; P","Break; Difference in methodology; Provisional value"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","ATCPTTMT","% of total sales","LUX","Luxembourg","2022","2022",1.6,"D; P","Difference in methodology; Provisional value"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MLLNCUMT","Million of national currency units","NLD","Netherlands","2010","2010",94.3,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MLLNCUMT","Million of national currency units","NLD","Netherlands","2011","2011",91.7,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MLLNCUMT","Million of national currency units","NLD","Netherlands","2012","2012",83.9,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MLLNCUMT","Million of national currency units","NLD","Netherlands","2013","2013",80.9,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MLLNCUMT","Million of national currency units","NLD","Netherlands","2014","2014",69,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOTCMT","Million US$ at exchange rate","NLD","Netherlands","2010","2010",125,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOTCMT","Million US$ at exchange rate","NLD","Netherlands","2011","2011",127.6,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOTCMT","Million US$ at exchange rate","NLD","Netherlands","2012","2012",107.8,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOTCMT","Million US$ at exchange rate","NLD","Netherlands","2013","2013",107.5,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOTCMT","Million US$ at exchange rate","NLD","Netherlands","2014","2014",91.6,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOPPMT","Million US$, purchasing power parity","NLD","Netherlands","2010","2010",110.4,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOPPMT","Million US$, purchasing power parity","NLD","Netherlands","2011","2011",109.6,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOPPMT","Million US$, purchasing power parity","NLD","Netherlands","2012","2012",101.8,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOPPMT","Million US$, purchasing power parity","NLD","Netherlands","2013","2013",101.4,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOPPMT","Million US$, purchasing power parity","NLD","Netherlands","2014","2014",85.3,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","TCPPERMT","/capita, US$ exchange rate","NLD","Netherlands","2010","2010",7.5,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","TCPPERMT","/capita, US$ exchange rate","NLD","Netherlands","2011","2011",7.6,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","TCPPERMT","/capita, US$ exchange rate","NLD","Netherlands","2012","2012",6.4,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","TCPPERMT","/capita, US$ exchange rate","NLD","Netherlands","2013","2013",6.4,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","TCPPERMT","/capita, US$ exchange rate","NLD","Netherlands","2014","2014",5.4,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","NLD","Netherlands","2010","2010",6.6,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","NLD","Netherlands","2011","2011",6.6,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","NLD","Netherlands","2012","2012",6.1,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","NLD","Netherlands","2013","2013",6,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","NLD","Netherlands","2014","2014",5.1,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","ATCPTTMT","% of total sales","NLD","Netherlands","2010","2010",1.8,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","ATCPTTMT","% of total sales","NLD","Netherlands","2011","2011",1.8,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","ATCPTTMT","% of total sales","NLD","Netherlands","2012","2012",1.8,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","ATCPTTMT","% of total sales","NLD","Netherlands","2013","2013",1.9,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","ATCPTTMT","% of total sales","NLD","Netherlands","2014","2014",1.6,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MLLNCUMT","Million of national currency units","NZL","New Zealand","2010","2010",6.5,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MLLNCUMT","Million of national currency units","NZL","New Zealand","2011","2011",6.5,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MLLNCUMT","Million of national currency units","NZL","New Zealand","2012","2012",7.2,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MLLNCUMT","Million of national currency units","NZL","New Zealand","2013","2013",7.3,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MLLNCUMT","Million of national currency units","NZL","New Zealand","2014","2014",7.5,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MLLNCUMT","Million of national currency units","NZL","New Zealand","2015","2015",7.7,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MLLNCUMT","Million of national currency units","NZL","New Zealand","2016","2016",7.9,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MLLNCUMT","Million of national currency units","NZL","New Zealand","2017","2017",7,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MLLNCUMT","Million of national currency units","NZL","New Zealand","2018","2018",6.7,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MLLNCUMT","Million of national currency units","NZL","New Zealand","2019","2019",7.2,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MLLNCUMT","Million of national currency units","NZL","New Zealand","2020","2020",6.7,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MLLNCUMT","Million of national currency units","NZL","New Zealand","2021","2021",6.4,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MLLNCUMT","Million of national currency units","NZL","New Zealand","2022","2022",10.4,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOTCMT","Million US$ at exchange rate","NZL","New Zealand","2010","2010",4.7,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOTCMT","Million US$ at exchange rate","NZL","New Zealand","2011","2011",5.2,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOTCMT","Million US$ at exchange rate","NZL","New Zealand","2012","2012",5.8,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOTCMT","Million US$ at exchange rate","NZL","New Zealand","2013","2013",6,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOTCMT","Million US$ at exchange rate","NZL","New Zealand","2014","2014",6.2,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOTCMT","Million US$ at exchange rate","NZL","New Zealand","2015","2015",5.4,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOTCMT","Million US$ at exchange rate","NZL","New Zealand","2016","2016",5.5,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOTCMT","Million US$ at exchange rate","NZL","New Zealand","2017","2017",5,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOTCMT","Million US$ at exchange rate","NZL","New Zealand","2018","2018",4.6,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOTCMT","Million US$ at exchange rate","NZL","New Zealand","2019","2019",4.8,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOTCMT","Million US$ at exchange rate","NZL","New Zealand","2020","2020",4.3,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOTCMT","Million US$ at exchange rate","NZL","New Zealand","2021","2021",4.5,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOTCMT","Million US$ at exchange rate","NZL","New Zealand","2022","2022",6.6,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOPPMT","Million US$, purchasing power parity","NZL","New Zealand","2010","2010",4.4,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOPPMT","Million US$, purchasing power parity","NZL","New Zealand","2011","2011",4.4,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOPPMT","Million US$, purchasing power parity","NZL","New Zealand","2012","2012",4.8,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOPPMT","Million US$, purchasing power parity","NZL","New Zealand","2013","2013",5.1,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOPPMT","Million US$, purchasing power parity","NZL","New Zealand","2014","2014",5.2,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOPPMT","Million US$, purchasing power parity","NZL","New Zealand","2015","2015",5.2,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOPPMT","Million US$, purchasing power parity","NZL","New Zealand","2016","2016",5.5,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOPPMT","Million US$, purchasing power parity","NZL","New Zealand","2017","2017",4.9,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOPPMT","Million US$, purchasing power parity","NZL","New Zealand","2018","2018",4.5,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOPPMT","Million US$, purchasing power parity","NZL","New Zealand","2019","2019",5.1,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOPPMT","Million US$, purchasing power parity","NZL","New Zealand","2020","2020",4.7,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOPPMT","Million US$, purchasing power parity","NZL","New Zealand","2021","2021",4.4,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOPPMT","Million US$, purchasing power parity","NZL","New Zealand","2022","2022",7.2,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","TCPPERMT","/capita, US$ exchange rate","NZL","New Zealand","2010","2010",1.1,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","TCPPERMT","/capita, US$ exchange rate","NZL","New Zealand","2011","2011",1.2,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","TCPPERMT","/capita, US$ exchange rate","NZL","New Zealand","2012","2012",1.3,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","TCPPERMT","/capita, US$ exchange rate","NZL","New Zealand","2013","2013",1.4,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","TCPPERMT","/capita, US$ exchange rate","NZL","New Zealand","2014","2014",1.4,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","TCPPERMT","/capita, US$ exchange rate","NZL","New Zealand","2015","2015",1.2,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","TCPPERMT","/capita, US$ exchange rate","NZL","New Zealand","2016","2016",1.2,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","TCPPERMT","/capita, US$ exchange rate","NZL","New Zealand","2017","2017",1,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","TCPPERMT","/capita, US$ exchange rate","NZL","New Zealand","2018","2018",0.9,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","TCPPERMT","/capita, US$ exchange rate","NZL","New Zealand","2019","2019",1,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","TCPPERMT","/capita, US$ exchange rate","NZL","New Zealand","2020","2020",0.8,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","TCPPERMT","/capita, US$ exchange rate","NZL","New Zealand","2021","2021",0.9,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","TCPPERMT","/capita, US$ exchange rate","NZL","New Zealand","2022","2022",1.3,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2010","2010",1,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2011","2011",1,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2012","2012",1.1,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2013","2013",1.1,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2014","2014",1.1,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2015","2015",1.1,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2016","2016",1.2,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2017","2017",1,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2018","2018",0.9,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2019","2019",1,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2020","2020",0.9,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2021","2021",0.9,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2022","2022",1.4,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","ATCPTTMT","% of total sales","NZL","New Zealand","2010","2010",0.9,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","ATCPTTMT","% of total sales","NZL","New Zealand","2011","2011",0.8,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","ATCPTTMT","% of total sales","NZL","New Zealand","2012","2012",0.8,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","ATCPTTMT","% of total sales","NZL","New Zealand","2013","2013",0.8,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","ATCPTTMT","% of total sales","NZL","New Zealand","2014","2014",0.8,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","ATCPTTMT","% of total sales","NZL","New Zealand","2015","2015",0.8,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","ATCPTTMT","% of total sales","NZL","New Zealand","2016","2016",0.7,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","ATCPTTMT","% of total sales","NZL","New Zealand","2017","2017",0.6,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","ATCPTTMT","% of total sales","NZL","New Zealand","2018","2018",0.5,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","ATCPTTMT","% of total sales","NZL","New Zealand","2019","2019",0.5,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","ATCPTTMT","% of total sales","NZL","New Zealand","2020","2020",0.4,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","ATCPTTMT","% of total sales","NZL","New Zealand","2021","2021",0.4,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","ATCPTTMT","% of total sales","NZL","New Zealand","2022","2022",0.5,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MLLNCUMT","Million of national currency units","NOR","Norway","2010","2010",425,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MLLNCUMT","Million of national currency units","NOR","Norway","2011","2011",437,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MLLNCUMT","Million of national currency units","NOR","Norway","2012","2012",446,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MLLNCUMT","Million of national currency units","NOR","Norway","2013","2013",464,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MLLNCUMT","Million of national currency units","NOR","Norway","2014","2014",474,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MLLNCUMT","Million of national currency units","NOR","Norway","2015","2015",515,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MLLNCUMT","Million of national currency units","NOR","Norway","2016","2016",537,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MLLNCUMT","Million of national currency units","NOR","Norway","2017","2017",550,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MLLNCUMT","Million of national currency units","NOR","Norway","2018","2018",514,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MLLNCUMT","Million of national currency units","NOR","Norway","2019","2019",528,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MLLNCUMT","Million of national currency units","NOR","Norway","2020","2020",540,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MLLNCUMT","Million of national currency units","NOR","Norway","2021","2021",594,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MLLNCUMT","Million of national currency units","NOR","Norway","2022","2022",620,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOTCMT","Million US$ at exchange rate","NOR","Norway","2010","2010",70.3,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOTCMT","Million US$ at exchange rate","NOR","Norway","2011","2011",78,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOTCMT","Million US$ at exchange rate","NOR","Norway","2012","2012",76.7,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOTCMT","Million US$ at exchange rate","NOR","Norway","2013","2013",79,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOTCMT","Million US$ at exchange rate","NOR","Norway","2014","2014",75.2,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOTCMT","Million US$ at exchange rate","NOR","Norway","2015","2015",63.9,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOTCMT","Million US$ at exchange rate","NOR","Norway","2016","2016",63.9,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOTCMT","Million US$ at exchange rate","NOR","Norway","2017","2017",66.5,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOTCMT","Million US$ at exchange rate","NOR","Norway","2018","2018",63.2,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOTCMT","Million US$ at exchange rate","NOR","Norway","2019","2019",60,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOTCMT","Million US$ at exchange rate","NOR","Norway","2020","2020",57.4,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOTCMT","Million US$ at exchange rate","NOR","Norway","2021","2021",69.2,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOTCMT","Million US$ at exchange rate","NOR","Norway","2022","2022",64.5,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOPPMT","Million US$, purchasing power parity","NOR","Norway","2010","2010",46.4,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOPPMT","Million US$, purchasing power parity","NOR","Norway","2011","2011",48.1,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOPPMT","Million US$, purchasing power parity","NOR","Norway","2012","2012",49.4,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOPPMT","Million US$, purchasing power parity","NOR","Norway","2013","2013",51.4,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOPPMT","Million US$, purchasing power parity","NOR","Norway","2014","2014",51.1,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOPPMT","Million US$, purchasing power parity","NOR","Norway","2015","2015",51.8,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOPPMT","Million US$, purchasing power parity","NOR","Norway","2016","2016",53.5,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOPPMT","Million US$, purchasing power parity","NOR","Norway","2017","2017",56.4,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOPPMT","Million US$, purchasing power parity","NOR","Norway","2018","2018",53.6,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOPPMT","Million US$, purchasing power parity","NOR","Norway","2019","2019",54.9,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOPPMT","Million US$, purchasing power parity","NOR","Norway","2020","2020",54.7,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOPPMT","Million US$, purchasing power parity","NOR","Norway","2021","2021",62.4,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOPPMT","Million US$, purchasing power parity","NOR","Norway","2022","2022",57.7,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","TCPPERMT","/capita, US$ exchange rate","NOR","Norway","2010","2010",14.4,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","TCPPERMT","/capita, US$ exchange rate","NOR","Norway","2011","2011",15.7,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","TCPPERMT","/capita, US$ exchange rate","NOR","Norway","2012","2012",15.3,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","TCPPERMT","/capita, US$ exchange rate","NOR","Norway","2013","2013",15.5,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","TCPPERMT","/capita, US$ exchange rate","NOR","Norway","2014","2014",14.6,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","TCPPERMT","/capita, US$ exchange rate","NOR","Norway","2015","2015",12.3,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","TCPPERMT","/capita, US$ exchange rate","NOR","Norway","2016","2016",12.2,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","TCPPERMT","/capita, US$ exchange rate","NOR","Norway","2017","2017",12.6,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","TCPPERMT","/capita, US$ exchange rate","NOR","Norway","2018","2018",11.9,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","TCPPERMT","/capita, US$ exchange rate","NOR","Norway","2019","2019",11.2,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","TCPPERMT","/capita, US$ exchange rate","NOR","Norway","2020","2020",10.7,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","TCPPERMT","/capita, US$ exchange rate","NOR","Norway","2021","2021",12.8,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","TCPPERMT","/capita, US$ exchange rate","NOR","Norway","2022","2022",11.9,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2010","2010",9.5,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2011","2011",9.7,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2012","2012",9.8,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2013","2013",10.1,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2014","2014",9.9,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2015","2015",10,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2016","2016",10.2,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2017","2017",10.7,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2018","2018",10.1,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2019","2019",10.3,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2020","2020",10.2,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2021","2021",11.5,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2022","2022",10.6,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","ATCPTTMT","% of total sales","NOR","Norway","2010","2010",2.4,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","ATCPTTMT","% of total sales","NOR","Norway","2011","2011",2.4,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","ATCPTTMT","% of total sales","NOR","Norway","2012","2012",2.4,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","ATCPTTMT","% of total sales","NOR","Norway","2013","2013",2.4,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","ATCPTTMT","% of total sales","NOR","Norway","2014","2014",2.2,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","ATCPTTMT","% of total sales","NOR","Norway","2015","2015",2.3,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","ATCPTTMT","% of total sales","NOR","Norway","2016","2016",2.2,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","ATCPTTMT","% of total sales","NOR","Norway","2017","2017",2.1,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","ATCPTTMT","% of total sales","NOR","Norway","2018","2018",1.9,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","ATCPTTMT","% of total sales","NOR","Norway","2019","2019",1.9,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","ATCPTTMT","% of total sales","NOR","Norway","2020","2020",1.8,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","ATCPTTMT","% of total sales","NOR","Norway","2021","2021",1.8,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","ATCPTTMT","% of total sales","NOR","Norway","2022","2022",1.7,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MLLNCUMT","Million of national currency units","PRT","Portugal","2010","2010",127.9,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MLLNCUMT","Million of national currency units","PRT","Portugal","2011","2011",112.3,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MLLNCUMT","Million of national currency units","PRT","Portugal","2012","2012",105,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MLLNCUMT","Million of national currency units","PRT","Portugal","2013","2013",99.8,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MLLNCUMT","Million of national currency units","PRT","Portugal","2014","2014",98.3,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MLLNCUMT","Million of national currency units","PRT","Portugal","2015","2015",97.4,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MLLNCUMT","Million of national currency units","PRT","Portugal","2016","2016",96.9,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MLLNCUMT","Million of national currency units","PRT","Portugal","2017","2017",93,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MLLNCUMT","Million of national currency units","PRT","Portugal","2018","2018",92,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MLLNCUMT","Million of national currency units","PRT","Portugal","2019","2019",92.1,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MLLNCUMT","Million of national currency units","PRT","Portugal","2020","2020",80.9,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MLLNCUMT","Million of national currency units","PRT","Portugal","2021","2021",81.8,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MLLNCUMT","Million of national currency units","PRT","Portugal","2022","2022",94.4,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOTCMT","Million US$ at exchange rate","PRT","Portugal","2010","2010",169.5,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOTCMT","Million US$ at exchange rate","PRT","Portugal","2011","2011",156.3,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOTCMT","Million US$ at exchange rate","PRT","Portugal","2012","2012",135,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOTCMT","Million US$ at exchange rate","PRT","Portugal","2013","2013",132.6,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOTCMT","Million US$ at exchange rate","PRT","Portugal","2014","2014",130.6,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOTCMT","Million US$ at exchange rate","PRT","Portugal","2015","2015",108.1,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOTCMT","Million US$ at exchange rate","PRT","Portugal","2016","2016",107.2,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOTCMT","Million US$ at exchange rate","PRT","Portugal","2017","2017",105.1,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOTCMT","Million US$ at exchange rate","PRT","Portugal","2018","2018",108.7,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOTCMT","Million US$ at exchange rate","PRT","Portugal","2019","2019",103.1,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOTCMT","Million US$ at exchange rate","PRT","Portugal","2020","2020",92.4,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOTCMT","Million US$ at exchange rate","PRT","Portugal","2021","2021",96.8,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOTCMT","Million US$ at exchange rate","PRT","Portugal","2022","2022",99.4,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOPPMT","Million US$, purchasing power parity","PRT","Portugal","2010","2010",205.2,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOPPMT","Million US$, purchasing power parity","PRT","Portugal","2011","2011",180.2,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOPPMT","Million US$, purchasing power parity","PRT","Portugal","2012","2012",173.5,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOPPMT","Million US$, purchasing power parity","PRT","Portugal","2013","2013",171,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOPPMT","Million US$, purchasing power parity","PRT","Portugal","2014","2014",169.9,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOPPMT","Million US$, purchasing power parity","PRT","Portugal","2015","2015",166.5,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOPPMT","Million US$, purchasing power parity","PRT","Portugal","2016","2016",169.5,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOPPMT","Million US$, purchasing power parity","PRT","Portugal","2017","2017",161.6,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOPPMT","Million US$, purchasing power parity","PRT","Portugal","2018","2018",161.1,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOPPMT","Million US$, purchasing power parity","PRT","Portugal","2019","2019",164.8,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOPPMT","Million US$, purchasing power parity","PRT","Portugal","2020","2020",145.1,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOPPMT","Million US$, purchasing power parity","PRT","Portugal","2021","2021",144.2,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOPPMT","Million US$, purchasing power parity","PRT","Portugal","2022","2022",171.7,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","TCPPERMT","/capita, US$ exchange rate","PRT","Portugal","2010","2010",16,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","TCPPERMT","/capita, US$ exchange rate","PRT","Portugal","2011","2011",14.8,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","TCPPERMT","/capita, US$ exchange rate","PRT","Portugal","2012","2012",12.8,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","TCPPERMT","/capita, US$ exchange rate","PRT","Portugal","2013","2013",12.7,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","TCPPERMT","/capita, US$ exchange rate","PRT","Portugal","2014","2014",12.6,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","TCPPERMT","/capita, US$ exchange rate","PRT","Portugal","2015","2015",10.4,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","TCPPERMT","/capita, US$ exchange rate","PRT","Portugal","2016","2016",10.4,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","TCPPERMT","/capita, US$ exchange rate","PRT","Portugal","2017","2017",10.2,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","TCPPERMT","/capita, US$ exchange rate","PRT","Portugal","2018","2018",10.6,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","TCPPERMT","/capita, US$ exchange rate","PRT","Portugal","2019","2019",10,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","TCPPERMT","/capita, US$ exchange rate","PRT","Portugal","2020","2020",9,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","TCPPERMT","/capita, US$ exchange rate","PRT","Portugal","2021","2021",9.3,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","TCPPERMT","/capita, US$ exchange rate","PRT","Portugal","2022","2022",9.6,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2010","2010",19.4,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2011","2011",17.1,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2012","2012",16.5,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2013","2013",16.4,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2014","2014",16.3,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2015","2015",16.1,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2016","2016",16.4,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2017","2017",15.7,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2018","2018",15.7,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2019","2019",16,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2020","2020",14.1,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2021","2021",13.9,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2022","2022",16.6,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","ATCPTTMT","% of total sales","PRT","Portugal","2010","2010",3.9,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","ATCPTTMT","% of total sales","PRT","Portugal","2011","2011",3.8,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","ATCPTTMT","% of total sales","PRT","Portugal","2012","2012",4,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","ATCPTTMT","% of total sales","PRT","Portugal","2013","2013",4.1,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","ATCPTTMT","% of total sales","PRT","Portugal","2014","2014",4.1,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","ATCPTTMT","% of total sales","PRT","Portugal","2015","2015",3.9,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","ATCPTTMT","% of total sales","PRT","Portugal","2016","2016",3.8,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","ATCPTTMT","% of total sales","PRT","Portugal","2017","2017",3.6,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","ATCPTTMT","% of total sales","PRT","Portugal","2018","2018",3.5,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","ATCPTTMT","% of total sales","PRT","Portugal","2019","2019",3.3,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","ATCPTTMT","% of total sales","PRT","Portugal","2020","2020",2.9,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","ATCPTTMT","% of total sales","PRT","Portugal","2021","2021",2.8,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","ATCPTTMT","% of total sales","PRT","Portugal","2022","2022",3,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MLLNCUMT","Million of national currency units","SVK","Slovak Republic","2010","2010",28.6,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MLLNCUMT","Million of national currency units","SVK","Slovak Republic","2011","2011",28.1,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MLLNCUMT","Million of national currency units","SVK","Slovak Republic","2012","2012",25.8,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MLLNCUMT","Million of national currency units","SVK","Slovak Republic","2013","2013",29.2,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MLLNCUMT","Million of national currency units","SVK","Slovak Republic","2014","2014",30.2,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MLLNCUMT","Million of national currency units","SVK","Slovak Republic","2015","2015",28.9,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MLLNCUMT","Million of national currency units","SVK","Slovak Republic","2016","2016",34.1,"B","Break"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MLLNCUMT","Million of national currency units","SVK","Slovak Republic","2017","2017",28.6,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MLLNCUMT","Million of national currency units","SVK","Slovak Republic","2018","2018",35.2,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MLLNCUMT","Million of national currency units","SVK","Slovak Republic","2019","2019",36.5,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MLLNCUMT","Million of national currency units","SVK","Slovak Republic","2020","2020",36,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MLLNCUMT","Million of national currency units","SVK","Slovak Republic","2021","2021",41.6,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOTCMT","Million US$ at exchange rate","SVK","Slovak Republic","2010","2010",37.9,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOTCMT","Million US$ at exchange rate","SVK","Slovak Republic","2011","2011",39.1,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOTCMT","Million US$ at exchange rate","SVK","Slovak Republic","2012","2012",33.2,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOTCMT","Million US$ at exchange rate","SVK","Slovak Republic","2013","2013",38.7,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOTCMT","Million US$ at exchange rate","SVK","Slovak Republic","2014","2014",40.1,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOTCMT","Million US$ at exchange rate","SVK","Slovak Republic","2015","2015",32.1,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOTCMT","Million US$ at exchange rate","SVK","Slovak Republic","2016","2016",37.7,"B","Break"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOTCMT","Million US$ at exchange rate","SVK","Slovak Republic","2017","2017",32.3,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOTCMT","Million US$ at exchange rate","SVK","Slovak Republic","2018","2018",41.5,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOTCMT","Million US$ at exchange rate","SVK","Slovak Republic","2019","2019",40.8,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOTCMT","Million US$ at exchange rate","SVK","Slovak Republic","2020","2020",41.1,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOTCMT","Million US$ at exchange rate","SVK","Slovak Republic","2021","2021",49.2,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOPPMT","Million US$, purchasing power parity","SVK","Slovak Republic","2010","2010",56.9,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOPPMT","Million US$, purchasing power parity","SVK","Slovak Republic","2011","2011",55.4,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOPPMT","Million US$, purchasing power parity","SVK","Slovak Republic","2012","2012",51.2,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOPPMT","Million US$, purchasing power parity","SVK","Slovak Republic","2013","2013",59.4,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOPPMT","Million US$, purchasing power parity","SVK","Slovak Republic","2014","2014",62.2,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOPPMT","Million US$, purchasing power parity","SVK","Slovak Republic","2015","2015",58.8,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOPPMT","Million US$, purchasing power parity","SVK","Slovak Republic","2016","2016",67.7,"B","Break"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOPPMT","Million US$, purchasing power parity","SVK","Slovak Republic","2017","2017",55.3,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOPPMT","Million US$, purchasing power parity","SVK","Slovak Republic","2018","2018",66.9,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOPPMT","Million US$, purchasing power parity","SVK","Slovak Republic","2019","2019",70.5,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOPPMT","Million US$, purchasing power parity","SVK","Slovak Republic","2020","2020",69.3,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOPPMT","Million US$, purchasing power parity","SVK","Slovak Republic","2021","2021",78,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","TCPPERMT","/capita, US$ exchange rate","SVK","Slovak Republic","2010","2010",7,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","TCPPERMT","/capita, US$ exchange rate","SVK","Slovak Republic","2011","2011",7.2,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","TCPPERMT","/capita, US$ exchange rate","SVK","Slovak Republic","2012","2012",6.1,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","TCPPERMT","/capita, US$ exchange rate","SVK","Slovak Republic","2013","2013",7.2,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","TCPPERMT","/capita, US$ exchange rate","SVK","Slovak Republic","2014","2014",7.4,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","TCPPERMT","/capita, US$ exchange rate","SVK","Slovak Republic","2015","2015",5.9,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","TCPPERMT","/capita, US$ exchange rate","SVK","Slovak Republic","2016","2016",6.9,"B","Break"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","TCPPERMT","/capita, US$ exchange rate","SVK","Slovak Republic","2017","2017",5.9,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","TCPPERMT","/capita, US$ exchange rate","SVK","Slovak Republic","2018","2018",7.6,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","TCPPERMT","/capita, US$ exchange rate","SVK","Slovak Republic","2019","2019",7.5,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","TCPPERMT","/capita, US$ exchange rate","SVK","Slovak Republic","2020","2020",7.5,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","TCPPERMT","/capita, US$ exchange rate","SVK","Slovak Republic","2021","2021",9,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2010","2010",10.6,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2011","2011",10.3,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2012","2012",9.5,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2013","2013",11,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2014","2014",11.5,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2015","2015",10.8,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2016","2016",12.5,"B","Break"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2017","2017",10.2,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2018","2018",12.3,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2019","2019",12.9,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2020","2020",12.7,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2021","2021",14.3,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","ATCPTTMT","% of total sales","SVK","Slovak Republic","2010","2010",2.6,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","ATCPTTMT","% of total sales","SVK","Slovak Republic","2011","2011",2.5,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","ATCPTTMT","% of total sales","SVK","Slovak Republic","2012","2012",2.3,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","ATCPTTMT","% of total sales","SVK","Slovak Republic","2013","2013",2.4,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","ATCPTTMT","% of total sales","SVK","Slovak Republic","2014","2014",2.3,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","ATCPTTMT","% of total sales","SVK","Slovak Republic","2015","2015",2.1,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","ATCPTTMT","% of total sales","SVK","Slovak Republic","2016","2016",2.2,"B","Break"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","ATCPTTMT","% of total sales","SVK","Slovak Republic","2017","2017",1.8,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","ATCPTTMT","% of total sales","SVK","Slovak Republic","2018","2018",2.2,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","ATCPTTMT","% of total sales","SVK","Slovak Republic","2019","2019",2.1,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","ATCPTTMT","% of total sales","SVK","Slovak Republic","2020","2020",2.2,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","ATCPTTMT","% of total sales","SVK","Slovak Republic","2021","2021",2.3,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MLLNCUMT","Million of national currency units","ESP","Spain","2010","2010",403,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MLLNCUMT","Million of national currency units","ESP","Spain","2011","2011",385,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MLLNCUMT","Million of national currency units","ESP","Spain","2012","2012",352.4,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MLLNCUMT","Million of national currency units","ESP","Spain","2013","2013",332.7,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MLLNCUMT","Million of national currency units","ESP","Spain","2014","2014",309.3,"B; D","Break; Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MLLNCUMT","Million of national currency units","ESP","Spain","2015","2015",272.2,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MLLNCUMT","Million of national currency units","ESP","Spain","2016","2016",269.9,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MLLNCUMT","Million of national currency units","ESP","Spain","2017","2017",246.7,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MLLNCUMT","Million of national currency units","ESP","Spain","2018","2018",225.9,"B","Break"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MLLNCUMT","Million of national currency units","ESP","Spain","2019","2019",222.2,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MLLNCUMT","Million of national currency units","ESP","Spain","2020","2020",209.8,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MLLNCUMT","Million of national currency units","ESP","Spain","2021","2021",232.9,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MLLNCUMT","Million of national currency units","ESP","Spain","2022","2022",257.3,"P","Provisional value"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOTCMT","Million US$ at exchange rate","ESP","Spain","2010","2010",534.3,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOTCMT","Million US$ at exchange rate","ESP","Spain","2011","2011",535.8,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOTCMT","Million US$ at exchange rate","ESP","Spain","2012","2012",452.8,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOTCMT","Million US$ at exchange rate","ESP","Spain","2013","2013",441.9,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOTCMT","Million US$ at exchange rate","ESP","Spain","2014","2014",410.9,"B; D","Break; Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOTCMT","Million US$ at exchange rate","ESP","Spain","2015","2015",302,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOTCMT","Million US$ at exchange rate","ESP","Spain","2016","2016",298.7,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOTCMT","Million US$ at exchange rate","ESP","Spain","2017","2017",278.7,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOTCMT","Million US$ at exchange rate","ESP","Spain","2018","2018",266.8,"B","Break"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOTCMT","Million US$ at exchange rate","ESP","Spain","2019","2019",248.8,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOTCMT","Million US$ at exchange rate","ESP","Spain","2020","2020",239.6,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOTCMT","Million US$ at exchange rate","ESP","Spain","2021","2021",275.4,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOTCMT","Million US$ at exchange rate","ESP","Spain","2022","2022",271,"P","Provisional value"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOPPMT","Million US$, purchasing power parity","ESP","Spain","2010","2010",554.4,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOPPMT","Million US$, purchasing power parity","ESP","Spain","2011","2011",539,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOPPMT","Million US$, purchasing power parity","ESP","Spain","2012","2012",507.1,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOPPMT","Million US$, purchasing power parity","ESP","Spain","2013","2013",493,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOPPMT","Million US$, purchasing power parity","ESP","Spain","2014","2014",467,"B; D","Break; Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOPPMT","Million US$, purchasing power parity","ESP","Spain","2015","2015",409.4,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOPPMT","Million US$, purchasing power parity","ESP","Spain","2016","2016",420,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOPPMT","Million US$, purchasing power parity","ESP","Spain","2017","2017",391.1,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOPPMT","Million US$, purchasing power parity","ESP","Spain","2018","2018",357.6,"B","Break"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOPPMT","Million US$, purchasing power parity","ESP","Spain","2019","2019",362.5,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOPPMT","Million US$, purchasing power parity","ESP","Spain","2020","2020",337.6,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOPPMT","Million US$, purchasing power parity","ESP","Spain","2021","2021",372,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOPPMT","Million US$, purchasing power parity","ESP","Spain","2022","2022",431.6,"P","Provisional value"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","TCPPERMT","/capita, US$ exchange rate","ESP","Spain","2010","2010",11.5,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","TCPPERMT","/capita, US$ exchange rate","ESP","Spain","2011","2011",11.5,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","TCPPERMT","/capita, US$ exchange rate","ESP","Spain","2012","2012",9.7,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","TCPPERMT","/capita, US$ exchange rate","ESP","Spain","2013","2013",9.5,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","TCPPERMT","/capita, US$ exchange rate","ESP","Spain","2014","2014",8.8,"B; D","Break; Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","TCPPERMT","/capita, US$ exchange rate","ESP","Spain","2015","2015",6.5,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","TCPPERMT","/capita, US$ exchange rate","ESP","Spain","2016","2016",6.4,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","TCPPERMT","/capita, US$ exchange rate","ESP","Spain","2017","2017",6,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","TCPPERMT","/capita, US$ exchange rate","ESP","Spain","2018","2018",5.7,"B","Break"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","TCPPERMT","/capita, US$ exchange rate","ESP","Spain","2019","2019",5.3,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","TCPPERMT","/capita, US$ exchange rate","ESP","Spain","2020","2020",5.1,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","TCPPERMT","/capita, US$ exchange rate","ESP","Spain","2021","2021",5.8,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","TCPPERMT","/capita, US$ exchange rate","ESP","Spain","2022","2022",5.7,"P","Provisional value"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2010","2010",11.9,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2011","2011",11.5,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2012","2012",10.8,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2013","2013",10.6,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2014","2014",10,"B; D","Break; Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2015","2015",8.8,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2016","2016",9,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2017","2017",8.4,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2018","2018",7.6,"B","Break"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2019","2019",7.7,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2020","2020",7.1,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2021","2021",7.8,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2022","2022",9.1,"P","Provisional value"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","ATCPTTMT","% of total sales","ESP","Spain","2010","2010",3,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","ATCPTTMT","% of total sales","ESP","Spain","2011","2011",3.1,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","ATCPTTMT","% of total sales","ESP","Spain","2012","2012",3.2,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","ATCPTTMT","% of total sales","ESP","Spain","2013","2013",3.1,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","ATCPTTMT","% of total sales","ESP","Spain","2014","2014",2.7,"B; D","Break; Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","ATCPTTMT","% of total sales","ESP","Spain","2015","2015",2.4,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","ATCPTTMT","% of total sales","ESP","Spain","2016","2016",2.3,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","ATCPTTMT","% of total sales","ESP","Spain","2017","2017",2,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","ATCPTTMT","% of total sales","ESP","Spain","2018","2018",1.2,"B","Break"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","ATCPTTMT","% of total sales","ESP","Spain","2019","2019",1.1,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","ATCPTTMT","% of total sales","ESP","Spain","2020","2020",1,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","ATCPTTMT","% of total sales","ESP","Spain","2021","2021",1.1,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","ATCPTTMT","% of total sales","ESP","Spain","2022","2022",1.1,"P","Provisional value"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MLLNCUMT","Million of national currency units","SWE","Sweden","2010","2010",739.8,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MLLNCUMT","Million of national currency units","SWE","Sweden","2011","2011",710,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MLLNCUMT","Million of national currency units","SWE","Sweden","2012","2012",722.2,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MLLNCUMT","Million of national currency units","SWE","Sweden","2013","2013",715.4,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MLLNCUMT","Million of national currency units","SWE","Sweden","2014","2014",718.9,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MLLNCUMT","Million of national currency units","SWE","Sweden","2015","2015",752.3,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MLLNCUMT","Million of national currency units","SWE","Sweden","2016","2016",800.6,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MLLNCUMT","Million of national currency units","SWE","Sweden","2017","2017",761.3,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MLLNCUMT","Million of national currency units","SWE","Sweden","2018","2018",746.7,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MLLNCUMT","Million of national currency units","SWE","Sweden","2019","2019",756.2,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MLLNCUMT","Million of national currency units","SWE","Sweden","2020","2020",658.7,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MLLNCUMT","Million of national currency units","SWE","Sweden","2021","2021",639.8,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MLLNCUMT","Million of national currency units","SWE","Sweden","2022","2022",722.6,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOTCMT","Million US$ at exchange rate","SWE","Sweden","2010","2010",102.6,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOTCMT","Million US$ at exchange rate","SWE","Sweden","2011","2011",109.3,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOTCMT","Million US$ at exchange rate","SWE","Sweden","2012","2012",106.6,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOTCMT","Million US$ at exchange rate","SWE","Sweden","2013","2013",109.8,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOTCMT","Million US$ at exchange rate","SWE","Sweden","2014","2014",104.8,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOTCMT","Million US$ at exchange rate","SWE","Sweden","2015","2015",89.2,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOTCMT","Million US$ at exchange rate","SWE","Sweden","2016","2016",93.5,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOTCMT","Million US$ at exchange rate","SWE","Sweden","2017","2017",89,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOTCMT","Million US$ at exchange rate","SWE","Sweden","2018","2018",85.9,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOTCMT","Million US$ at exchange rate","SWE","Sweden","2019","2019",80,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOTCMT","Million US$ at exchange rate","SWE","Sweden","2020","2020",71.5,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOTCMT","Million US$ at exchange rate","SWE","Sweden","2021","2021",74.6,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOTCMT","Million US$ at exchange rate","SWE","Sweden","2022","2022",71.4,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOPPMT","Million US$, purchasing power parity","SWE","Sweden","2010","2010",82,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOPPMT","Million US$, purchasing power parity","SWE","Sweden","2011","2011",80.3,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOPPMT","Million US$, purchasing power parity","SWE","Sweden","2012","2012",83.4,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOPPMT","Million US$, purchasing power parity","SWE","Sweden","2013","2013",83.2,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOPPMT","Million US$, purchasing power parity","SWE","Sweden","2014","2014",82.4,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOPPMT","Million US$, purchasing power parity","SWE","Sweden","2015","2015",85,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOPPMT","Million US$, purchasing power parity","SWE","Sweden","2016","2016",90.7,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOPPMT","Million US$, purchasing power parity","SWE","Sweden","2017","2017",86,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOPPMT","Million US$, purchasing power parity","SWE","Sweden","2018","2018",84.2,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOPPMT","Million US$, purchasing power parity","SWE","Sweden","2019","2019",86.8,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOPPMT","Million US$, purchasing power parity","SWE","Sweden","2020","2020",76,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOPPMT","Million US$, purchasing power parity","SWE","Sweden","2021","2021",73.4,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOPPMT","Million US$, purchasing power parity","SWE","Sweden","2022","2022",83.4,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","TCPPERMT","/capita, US$ exchange rate","SWE","Sweden","2010","2010",10.9,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","TCPPERMT","/capita, US$ exchange rate","SWE","Sweden","2011","2011",11.6,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","TCPPERMT","/capita, US$ exchange rate","SWE","Sweden","2012","2012",11.2,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","TCPPERMT","/capita, US$ exchange rate","SWE","Sweden","2013","2013",11.4,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","TCPPERMT","/capita, US$ exchange rate","SWE","Sweden","2014","2014",10.8,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","TCPPERMT","/capita, US$ exchange rate","SWE","Sweden","2015","2015",9.1,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","TCPPERMT","/capita, US$ exchange rate","SWE","Sweden","2016","2016",9.4,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","TCPPERMT","/capita, US$ exchange rate","SWE","Sweden","2017","2017",8.9,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","TCPPERMT","/capita, US$ exchange rate","SWE","Sweden","2018","2018",8.4,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","TCPPERMT","/capita, US$ exchange rate","SWE","Sweden","2019","2019",7.8,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","TCPPERMT","/capita, US$ exchange rate","SWE","Sweden","2020","2020",6.9,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","TCPPERMT","/capita, US$ exchange rate","SWE","Sweden","2021","2021",7.2,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","TCPPERMT","/capita, US$ exchange rate","SWE","Sweden","2022","2022",6.8,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2010","2010",8.7,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2011","2011",8.5,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2012","2012",8.8,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2013","2013",8.7,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2014","2014",8.5,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2015","2015",8.7,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2016","2016",9.1,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2017","2017",8.6,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2018","2018",8.3,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2019","2019",8.4,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2020","2020",7.3,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2021","2021",7,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2022","2022",8,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","ATCPTTMT","% of total sales","SWE","Sweden","2010","2010",2.1,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","ATCPTTMT","% of total sales","SWE","Sweden","2011","2011",1.9,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","ATCPTTMT","% of total sales","SWE","Sweden","2012","2012",2,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","ATCPTTMT","% of total sales","SWE","Sweden","2013","2013",2,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","ATCPTTMT","% of total sales","SWE","Sweden","2014","2014",1.9,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","ATCPTTMT","% of total sales","SWE","Sweden","2015","2015",1.9,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","ATCPTTMT","% of total sales","SWE","Sweden","2016","2016",1.9,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","ATCPTTMT","% of total sales","SWE","Sweden","2017","2017",1.7,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","ATCPTTMT","% of total sales","SWE","Sweden","2018","2018",1.6,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","ATCPTTMT","% of total sales","SWE","Sweden","2019","2019",1.5,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","ATCPTTMT","% of total sales","SWE","Sweden","2020","2020",1.3,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","ATCPTTMT","% of total sales","SWE","Sweden","2021","2021",1.2,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","ATCPTTMT","% of total sales","SWE","Sweden","2022","2022",1.3,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MLLNCUMT","Million of national currency units","TUR","Türkiye","2010","2010",492.4,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MLLNCUMT","Million of national currency units","TUR","Türkiye","2011","2011",413.6,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MLLNCUMT","Million of national currency units","TUR","Türkiye","2012","2012",403.8,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MLLNCUMT","Million of national currency units","TUR","Türkiye","2013","2013",377,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MLLNCUMT","Million of national currency units","TUR","Türkiye","2014","2014",402.9,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MLLNCUMT","Million of national currency units","TUR","Türkiye","2015","2015",458.7,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MLLNCUMT","Million of national currency units","TUR","Türkiye","2016","2016",557.4,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MLLNCUMT","Million of national currency units","TUR","Türkiye","2017","2017",668.2,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MLLNCUMT","Million of national currency units","TUR","Türkiye","2018","2018",766.2,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MLLNCUMT","Million of national currency units","TUR","Türkiye","2019","2019",1119.3,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MLLNCUMT","Million of national currency units","TUR","Türkiye","2020","2020",1180.7,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MLLNCUMT","Million of national currency units","TUR","Türkiye","2021","2021",1320.3,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOTCMT","Million US$ at exchange rate","TUR","Türkiye","2010","2010",327.7,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOTCMT","Million US$ at exchange rate","TUR","Türkiye","2011","2011",246.9,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOTCMT","Million US$ at exchange rate","TUR","Türkiye","2012","2012",224.8,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOTCMT","Million US$ at exchange rate","TUR","Türkiye","2013","2013",198,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOTCMT","Million US$ at exchange rate","TUR","Türkiye","2014","2014",184.1,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOTCMT","Million US$ at exchange rate","TUR","Türkiye","2015","2015",168.6,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOTCMT","Million US$ at exchange rate","TUR","Türkiye","2016","2016",184.6,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOTCMT","Million US$ at exchange rate","TUR","Türkiye","2017","2017",183.2,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOTCMT","Million US$ at exchange rate","TUR","Türkiye","2018","2018",158.7,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOTCMT","Million US$ at exchange rate","TUR","Türkiye","2019","2019",197.3,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOTCMT","Million US$ at exchange rate","TUR","Türkiye","2020","2020",168.5,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOTCMT","Million US$ at exchange rate","TUR","Türkiye","2021","2021",149.2,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOPPMT","Million US$, purchasing power parity","TUR","Türkiye","2010","2010",535,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOPPMT","Million US$, purchasing power parity","TUR","Türkiye","2011","2011",428,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOPPMT","Million US$, purchasing power parity","TUR","Türkiye","2012","2012",395.9,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOPPMT","Million US$, purchasing power parity","TUR","Türkiye","2013","2013",352.2,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOPPMT","Million US$, purchasing power parity","TUR","Türkiye","2014","2014",364.8,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOPPMT","Million US$, purchasing power parity","TUR","Türkiye","2015","2015",394.6,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOPPMT","Million US$, purchasing power parity","TUR","Türkiye","2016","2016",449.1,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOPPMT","Million US$, purchasing power parity","TUR","Türkiye","2017","2017",482.8,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOPPMT","Million US$, purchasing power parity","TUR","Türkiye","2018","2018",469.3,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOPPMT","Million US$, purchasing power parity","TUR","Türkiye","2019","2019",600.5,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOPPMT","Million US$, purchasing power parity","TUR","Türkiye","2020","2020",545.5,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOPPMT","Million US$, purchasing power parity","TUR","Türkiye","2021","2021",470.2,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","TCPPERMT","/capita, US$ exchange rate","TUR","Türkiye","2010","2010",4.5,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","TCPPERMT","/capita, US$ exchange rate","TUR","Türkiye","2011","2011",3.3,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","TCPPERMT","/capita, US$ exchange rate","TUR","Türkiye","2012","2012",3,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","TCPPERMT","/capita, US$ exchange rate","TUR","Türkiye","2013","2013",2.6,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","TCPPERMT","/capita, US$ exchange rate","TUR","Türkiye","2014","2014",2.4,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","TCPPERMT","/capita, US$ exchange rate","TUR","Türkiye","2015","2015",2.2,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","TCPPERMT","/capita, US$ exchange rate","TUR","Türkiye","2016","2016",2.3,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","TCPPERMT","/capita, US$ exchange rate","TUR","Türkiye","2017","2017",2.3,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","TCPPERMT","/capita, US$ exchange rate","TUR","Türkiye","2018","2018",1.9,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","TCPPERMT","/capita, US$ exchange rate","TUR","Türkiye","2019","2019",2.4,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","TCPPERMT","/capita, US$ exchange rate","TUR","Türkiye","2020","2020",2,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","TCPPERMT","/capita, US$ exchange rate","TUR","Türkiye","2021","2021",1.8,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2010","2010",7.3,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2011","2011",5.8,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2012","2012",5.3,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2013","2013",4.6,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2014","2014",4.7,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2015","2015",5,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2016","2016",5.7,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2017","2017",6,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2018","2018",5.8,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2019","2019",7.3,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2020","2020",6.5,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2021","2021",5.6,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","ATCPTTMT","% of total sales","TUR","Türkiye","2010","2010",3.2,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","ATCPTTMT","% of total sales","TUR","Türkiye","2011","2011",2.9,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","ATCPTTMT","% of total sales","TUR","Türkiye","2012","2012",3,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","ATCPTTMT","% of total sales","TUR","Türkiye","2013","2013",2.6,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","ATCPTTMT","% of total sales","TUR","Türkiye","2014","2014",2.6,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","ATCPTTMT","% of total sales","TUR","Türkiye","2015","2015",2.5,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","ATCPTTMT","% of total sales","TUR","Türkiye","2016","2016",2.5,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","ATCPTTMT","% of total sales","TUR","Türkiye","2017","2017",2.6,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","ATCPTTMT","% of total sales","TUR","Türkiye","2018","2018",2.4,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","ATCPTTMT","% of total sales","TUR","Türkiye","2019","2019",2.7,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","ATCPTTMT","% of total sales","TUR","Türkiye","2020","2020",2.4,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","ATCPTTMT","% of total sales","TUR","Türkiye","2021","2021",2,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MLLNCUMT","Million of national currency units","CHL","Chile","2010","2010",35363.2,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MLLNCUMT","Million of national currency units","CHL","Chile","2011","2011",47430.8,"B","Break"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MLLNCUMT","Million of national currency units","CHL","Chile","2012","2012",50640.7,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MLLNCUMT","Million of national currency units","CHL","Chile","2013","2013",54075.4,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MLLNCUMT","Million of national currency units","CHL","Chile","2014","2014",57880.5,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MLLNCUMT","Million of national currency units","CHL","Chile","2015","2015",65023.8,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MLLNCUMT","Million of national currency units","CHL","Chile","2016","2016",61219.5,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MLLNCUMT","Million of national currency units","CHL","Chile","2017","2017",57012.2,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MLLNCUMT","Million of national currency units","CHL","Chile","2018","2018",56688.5,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MLLNCUMT","Million of national currency units","CHL","Chile","2019","2019",40188.1,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MLLNCUMT","Million of national currency units","CHL","Chile","2020","2020",65698.8,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MLLNCUMT","Million of national currency units","CHL","Chile","2021","2021",88252.4,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MLLNCUMT","Million of national currency units","CHL","Chile","2022","2022",97525.3,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOTCMT","Million US$ at exchange rate","CHL","Chile","2010","2010",69.3,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOTCMT","Million US$ at exchange rate","CHL","Chile","2011","2011",98.1,"B","Break"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOTCMT","Million US$ at exchange rate","CHL","Chile","2012","2012",104.1,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOTCMT","Million US$ at exchange rate","CHL","Chile","2013","2013",109.2,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOTCMT","Million US$ at exchange rate","CHL","Chile","2014","2014",101.5,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOTCMT","Million US$ at exchange rate","CHL","Chile","2015","2015",99.4,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOTCMT","Million US$ at exchange rate","CHL","Chile","2016","2016",90.4,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOTCMT","Million US$ at exchange rate","CHL","Chile","2017","2017",87.9,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOTCMT","Million US$ at exchange rate","CHL","Chile","2018","2018",88.4,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOTCMT","Million US$ at exchange rate","CHL","Chile","2019","2019",57.2,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOTCMT","Million US$ at exchange rate","CHL","Chile","2020","2020",82.9,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOTCMT","Million US$ at exchange rate","CHL","Chile","2021","2021",116.3,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOTCMT","Million US$ at exchange rate","CHL","Chile","2022","2022",111.7,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOPPMT","Million US$, purchasing power parity","CHL","Chile","2010","2010",98.3,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOPPMT","Million US$, purchasing power parity","CHL","Chile","2011","2011",136.3,"B","Break"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOPPMT","Million US$, purchasing power parity","CHL","Chile","2012","2012",145.8,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOPPMT","Million US$, purchasing power parity","CHL","Chile","2013","2013",154.6,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOPPMT","Million US$, purchasing power parity","CHL","Chile","2014","2014",157.6,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOPPMT","Million US$, purchasing power parity","CHL","Chile","2015","2015",166.2,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOPPMT","Million US$, purchasing power parity","CHL","Chile","2016","2016",154.1,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOPPMT","Million US$, purchasing power parity","CHL","Chile","2017","2017",143.4,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOPPMT","Million US$, purchasing power parity","CHL","Chile","2018","2018",143.1,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOPPMT","Million US$, purchasing power parity","CHL","Chile","2019","2019",100.1,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOPPMT","Million US$, purchasing power parity","CHL","Chile","2020","2020",157,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOPPMT","Million US$, purchasing power parity","CHL","Chile","2021","2021",202.8,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOPPMT","Million US$, purchasing power parity","CHL","Chile","2022","2022",222.9,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","TCPPERMT","/capita, US$ exchange rate","CHL","Chile","2010","2010",4.1,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","TCPPERMT","/capita, US$ exchange rate","CHL","Chile","2011","2011",5.7,"B","Break"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","TCPPERMT","/capita, US$ exchange rate","CHL","Chile","2012","2012",6,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","TCPPERMT","/capita, US$ exchange rate","CHL","Chile","2013","2013",6.2,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","TCPPERMT","/capita, US$ exchange rate","CHL","Chile","2014","2014",5.7,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","TCPPERMT","/capita, US$ exchange rate","CHL","Chile","2015","2015",5.5,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","TCPPERMT","/capita, US$ exchange rate","CHL","Chile","2016","2016",5,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","TCPPERMT","/capita, US$ exchange rate","CHL","Chile","2017","2017",4.8,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","TCPPERMT","/capita, US$ exchange rate","CHL","Chile","2018","2018",4.7,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","TCPPERMT","/capita, US$ exchange rate","CHL","Chile","2019","2019",3,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","TCPPERMT","/capita, US$ exchange rate","CHL","Chile","2020","2020",4.3,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","TCPPERMT","/capita, US$ exchange rate","CHL","Chile","2021","2021",5.9,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","TCPPERMT","/capita, US$ exchange rate","CHL","Chile","2022","2022",5.6,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2010","2010",5.8,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2011","2011",7.9,"B","Break"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2012","2012",8.4,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2013","2013",8.8,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2014","2014",8.9,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2015","2015",9.2,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2016","2016",8.5,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2017","2017",7.8,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2018","2018",7.6,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2019","2019",5.2,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2020","2020",8.1,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2021","2021",10.3,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2022","2022",11.2,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","ATCPTTMT","% of total sales","CHL","Chile","2010","2010",4.3,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","ATCPTTMT","% of total sales","CHL","Chile","2011","2011",4,"B","Break"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","ATCPTTMT","% of total sales","CHL","Chile","2012","2012",4.1,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","ATCPTTMT","% of total sales","CHL","Chile","2013","2013",3.7,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","ATCPTTMT","% of total sales","CHL","Chile","2014","2014",3.7,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","ATCPTTMT","% of total sales","CHL","Chile","2015","2015",3.6,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","ATCPTTMT","% of total sales","CHL","Chile","2016","2016",3,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","ATCPTTMT","% of total sales","CHL","Chile","2017","2017",2.8,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","ATCPTTMT","% of total sales","CHL","Chile","2018","2018",2.5,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","ATCPTTMT","% of total sales","CHL","Chile","2019","2019",1.6,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","ATCPTTMT","% of total sales","CHL","Chile","2020","2020",2.4,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","ATCPTTMT","% of total sales","CHL","Chile","2021","2021",3.1,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","ATCPTTMT","% of total sales","CHL","Chile","2022","2022",3.5,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MLLNCUMT","Million of national currency units","EST","Estonia","2010","2010",6.1,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MLLNCUMT","Million of national currency units","EST","Estonia","2011","2011",6.3,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MLLNCUMT","Million of national currency units","EST","Estonia","2012","2012",7.1,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MLLNCUMT","Million of national currency units","EST","Estonia","2013","2013",7.9,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MLLNCUMT","Million of national currency units","EST","Estonia","2014","2014",8.7,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MLLNCUMT","Million of national currency units","EST","Estonia","2015","2015",9.2,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MLLNCUMT","Million of national currency units","EST","Estonia","2016","2016",9.5,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MLLNCUMT","Million of national currency units","EST","Estonia","2017","2017",9.5,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MLLNCUMT","Million of national currency units","EST","Estonia","2018","2018",9.4,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MLLNCUMT","Million of national currency units","EST","Estonia","2019","2019",9.7,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MLLNCUMT","Million of national currency units","EST","Estonia","2020","2020",9.9,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MLLNCUMT","Million of national currency units","EST","Estonia","2021","2021",9.9,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MLLNCUMT","Million of national currency units","EST","Estonia","2022","2022",11.2,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOTCMT","Million US$ at exchange rate","EST","Estonia","2010","2010",8.1,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOTCMT","Million US$ at exchange rate","EST","Estonia","2011","2011",8.7,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOTCMT","Million US$ at exchange rate","EST","Estonia","2012","2012",9.1,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOTCMT","Million US$ at exchange rate","EST","Estonia","2013","2013",10.6,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOTCMT","Million US$ at exchange rate","EST","Estonia","2014","2014",11.5,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOTCMT","Million US$ at exchange rate","EST","Estonia","2015","2015",10.2,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOTCMT","Million US$ at exchange rate","EST","Estonia","2016","2016",10.5,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOTCMT","Million US$ at exchange rate","EST","Estonia","2017","2017",10.7,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOTCMT","Million US$ at exchange rate","EST","Estonia","2018","2018",11.2,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOTCMT","Million US$ at exchange rate","EST","Estonia","2019","2019",10.9,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOTCMT","Million US$ at exchange rate","EST","Estonia","2020","2020",11.3,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOTCMT","Million US$ at exchange rate","EST","Estonia","2021","2021",11.7,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOTCMT","Million US$ at exchange rate","EST","Estonia","2022","2022",11.7,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOPPMT","Million US$, purchasing power parity","EST","Estonia","2010","2010",11.9,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOPPMT","Million US$, purchasing power parity","EST","Estonia","2011","2011",12.3,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOPPMT","Million US$, purchasing power parity","EST","Estonia","2012","2012",13.6,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOPPMT","Million US$, purchasing power parity","EST","Estonia","2013","2013",15.2,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOPPMT","Million US$, purchasing power parity","EST","Estonia","2014","2014",16.5,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOPPMT","Million US$, purchasing power parity","EST","Estonia","2015","2015",17.2,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOPPMT","Million US$, purchasing power parity","EST","Estonia","2016","2016",18,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOPPMT","Million US$, purchasing power parity","EST","Estonia","2017","2017",17.8,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOPPMT","Million US$, purchasing power parity","EST","Estonia","2018","2018",17.5,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOPPMT","Million US$, purchasing power parity","EST","Estonia","2019","2019",18.1,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOPPMT","Million US$, purchasing power parity","EST","Estonia","2020","2020",18.8,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOPPMT","Million US$, purchasing power parity","EST","Estonia","2021","2021",18.2,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOPPMT","Million US$, purchasing power parity","EST","Estonia","2022","2022",19.6,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","TCPPERMT","/capita, US$ exchange rate","EST","Estonia","2010","2010",6.1,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","TCPPERMT","/capita, US$ exchange rate","EST","Estonia","2011","2011",6.6,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","TCPPERMT","/capita, US$ exchange rate","EST","Estonia","2012","2012",6.9,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","TCPPERMT","/capita, US$ exchange rate","EST","Estonia","2013","2013",8,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","TCPPERMT","/capita, US$ exchange rate","EST","Estonia","2014","2014",8.8,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","TCPPERMT","/capita, US$ exchange rate","EST","Estonia","2015","2015",7.8,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","TCPPERMT","/capita, US$ exchange rate","EST","Estonia","2016","2016",8,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","TCPPERMT","/capita, US$ exchange rate","EST","Estonia","2017","2017",8.1,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","TCPPERMT","/capita, US$ exchange rate","EST","Estonia","2018","2018",8.4,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","TCPPERMT","/capita, US$ exchange rate","EST","Estonia","2019","2019",8.2,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","TCPPERMT","/capita, US$ exchange rate","EST","Estonia","2020","2020",8.5,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","TCPPERMT","/capita, US$ exchange rate","EST","Estonia","2021","2021",8.8,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","TCPPERMT","/capita, US$ exchange rate","EST","Estonia","2022","2022",8.8,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2010","2010",9,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2011","2011",9.3,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2012","2012",10.3,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2013","2013",11.5,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2014","2014",12.5,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2015","2015",13.1,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2016","2016",13.7,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2017","2017",13.5,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2018","2018",13.3,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2019","2019",13.7,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2020","2020",14.2,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2021","2021",13.7,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2022","2022",14.7,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","ATCPTTMT","% of total sales","EST","Estonia","2010","2010",3.2,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","ATCPTTMT","% of total sales","EST","Estonia","2011","2011",3.1,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","ATCPTTMT","% of total sales","EST","Estonia","2012","2012",3.2,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","ATCPTTMT","% of total sales","EST","Estonia","2013","2013",3.4,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","ATCPTTMT","% of total sales","EST","Estonia","2014","2014",3.5,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","ATCPTTMT","% of total sales","EST","Estonia","2015","2015",3.5,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","ATCPTTMT","% of total sales","EST","Estonia","2016","2016",3.3,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","ATCPTTMT","% of total sales","EST","Estonia","2017","2017",3.2,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","ATCPTTMT","% of total sales","EST","Estonia","2018","2018",2.9,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","ATCPTTMT","% of total sales","EST","Estonia","2019","2019",2.8,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","ATCPTTMT","% of total sales","EST","Estonia","2020","2020",2.8,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","ATCPTTMT","% of total sales","EST","Estonia","2021","2021",2.4,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","ATCPTTMT","% of total sales","EST","Estonia","2022","2022",2.6,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MLLNCUMT","Million of national currency units","SVN","Slovenia","2010","2010",9.2,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MLLNCUMT","Million of national currency units","SVN","Slovenia","2011","2011",8.3,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MLLNCUMT","Million of national currency units","SVN","Slovenia","2012","2012",7.8,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MLLNCUMT","Million of national currency units","SVN","Slovenia","2013","2013",8.2,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MLLNCUMT","Million of national currency units","SVN","Slovenia","2014","2014",8.5,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MLLNCUMT","Million of national currency units","SVN","Slovenia","2015","2015",8.9,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MLLNCUMT","Million of national currency units","SVN","Slovenia","2016","2016",8.6,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MLLNCUMT","Million of national currency units","SVN","Slovenia","2017","2017",8.4,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MLLNCUMT","Million of national currency units","SVN","Slovenia","2018","2018",8.2,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MLLNCUMT","Million of national currency units","SVN","Slovenia","2019","2019",8.3,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MLLNCUMT","Million of national currency units","SVN","Slovenia","2020","2020",7.8,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MLLNCUMT","Million of national currency units","SVN","Slovenia","2021","2021",7.9,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MLLNCUMT","Million of national currency units","SVN","Slovenia","2022","2022",8.7,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOTCMT","Million US$ at exchange rate","SVN","Slovenia","2010","2010",12.2,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOTCMT","Million US$ at exchange rate","SVN","Slovenia","2011","2011",11.6,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOTCMT","Million US$ at exchange rate","SVN","Slovenia","2012","2012",10.1,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOTCMT","Million US$ at exchange rate","SVN","Slovenia","2013","2013",10.9,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOTCMT","Million US$ at exchange rate","SVN","Slovenia","2014","2014",11.4,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOTCMT","Million US$ at exchange rate","SVN","Slovenia","2015","2015",9.9,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOTCMT","Million US$ at exchange rate","SVN","Slovenia","2016","2016",9.5,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOTCMT","Million US$ at exchange rate","SVN","Slovenia","2017","2017",9.5,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOTCMT","Million US$ at exchange rate","SVN","Slovenia","2018","2018",9.6,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOTCMT","Million US$ at exchange rate","SVN","Slovenia","2019","2019",9.3,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOTCMT","Million US$ at exchange rate","SVN","Slovenia","2020","2020",8.9,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOTCMT","Million US$ at exchange rate","SVN","Slovenia","2021","2021",9.4,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOTCMT","Million US$ at exchange rate","SVN","Slovenia","2022","2022",9.2,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOPPMT","Million US$, purchasing power parity","SVN","Slovenia","2010","2010",14.5,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOPPMT","Million US$, purchasing power parity","SVN","Slovenia","2011","2011",13.3,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOPPMT","Million US$, purchasing power parity","SVN","Slovenia","2012","2012",12.9,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOPPMT","Million US$, purchasing power parity","SVN","Slovenia","2013","2013",13.9,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOPPMT","Million US$, purchasing power parity","SVN","Slovenia","2014","2014",14.5,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOPPMT","Million US$, purchasing power parity","SVN","Slovenia","2015","2015",15,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOPPMT","Million US$, purchasing power parity","SVN","Slovenia","2016","2016",14.9,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOPPMT","Million US$, purchasing power parity","SVN","Slovenia","2017","2017",14.7,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOPPMT","Million US$, purchasing power parity","SVN","Slovenia","2018","2018",14.4,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOPPMT","Million US$, purchasing power parity","SVN","Slovenia","2019","2019",15,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOPPMT","Million US$, purchasing power parity","SVN","Slovenia","2020","2020",14.2,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOPPMT","Million US$, purchasing power parity","SVN","Slovenia","2021","2021",14.1,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOPPMT","Million US$, purchasing power parity","SVN","Slovenia","2022","2022",15.8,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","TCPPERMT","/capita, US$ exchange rate","SVN","Slovenia","2010","2010",6,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","TCPPERMT","/capita, US$ exchange rate","SVN","Slovenia","2011","2011",5.6,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","TCPPERMT","/capita, US$ exchange rate","SVN","Slovenia","2012","2012",4.9,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","TCPPERMT","/capita, US$ exchange rate","SVN","Slovenia","2013","2013",5.3,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","TCPPERMT","/capita, US$ exchange rate","SVN","Slovenia","2014","2014",5.5,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","TCPPERMT","/capita, US$ exchange rate","SVN","Slovenia","2015","2015",4.8,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","TCPPERMT","/capita, US$ exchange rate","SVN","Slovenia","2016","2016",4.6,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","TCPPERMT","/capita, US$ exchange rate","SVN","Slovenia","2017","2017",4.6,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","TCPPERMT","/capita, US$ exchange rate","SVN","Slovenia","2018","2018",4.6,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","TCPPERMT","/capita, US$ exchange rate","SVN","Slovenia","2019","2019",4.5,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","TCPPERMT","/capita, US$ exchange rate","SVN","Slovenia","2020","2020",4.2,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","TCPPERMT","/capita, US$ exchange rate","SVN","Slovenia","2021","2021",4.5,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","TCPPERMT","/capita, US$ exchange rate","SVN","Slovenia","2022","2022",4.4,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2010","2010",7.1,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2011","2011",6.5,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2012","2012",6.3,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2013","2013",6.8,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2014","2014",7,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2015","2015",7.3,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2016","2016",7.2,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2017","2017",7.1,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2018","2018",6.9,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2019","2019",7.2,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2020","2020",6.8,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2021","2021",6.7,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2022","2022",7.5,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","ATCPTTMT","% of total sales","SVN","Slovenia","2010","2010",1.9,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","ATCPTTMT","% of total sales","SVN","Slovenia","2011","2011",1.8,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","ATCPTTMT","% of total sales","SVN","Slovenia","2012","2012",1.7,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","ATCPTTMT","% of total sales","SVN","Slovenia","2013","2013",1.8,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","ATCPTTMT","% of total sales","SVN","Slovenia","2014","2014",2,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","ATCPTTMT","% of total sales","SVN","Slovenia","2015","2015",2,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","ATCPTTMT","% of total sales","SVN","Slovenia","2016","2016",1.8,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","ATCPTTMT","% of total sales","SVN","Slovenia","2017","2017",1.7,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","ATCPTTMT","% of total sales","SVN","Slovenia","2018","2018",1.6,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","ATCPTTMT","% of total sales","SVN","Slovenia","2019","2019",1.5,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","ATCPTTMT","% of total sales","SVN","Slovenia","2020","2020",1.4,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","ATCPTTMT","% of total sales","SVN","Slovenia","2021","2021",1.3,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","ATCPTTMT","% of total sales","SVN","Slovenia","2022","2022",1.3,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","MLLNCUMT","Million of national currency units","AUS","Australia","2010","2010",1707,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","MLLNCUMT","Million of national currency units","AUS","Australia","2011","2011",1790,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","MLLNCUMT","Million of national currency units","AUS","Australia","2012","2012",1768,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","MLLNCUMT","Million of national currency units","AUS","Australia","2013","2013",1998,"B; D","Break; Difference in methodology"
+"PATCCNSY","N-Nervous system","MLLNCUMT","Million of national currency units","AUS","Australia","2014","2014",1924,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","MLLNCUMT","Million of national currency units","AUS","Australia","2015","2015",1926,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","MLLNCUMT","Million of national currency units","AUS","Australia","2016","2016",1899,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","MLLNCUMT","Million of national currency units","AUS","Australia","2017","2017",1920,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","MLLNCUMT","Million of national currency units","AUS","Australia","2018","2018",1944,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","MLLNCUMT","Million of national currency units","AUS","Australia","2019","2019",1940,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","MLLNCUMT","Million of national currency units","AUS","Australia","2020","2020",2007,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","MLLNCUMT","Million of national currency units","AUS","Australia","2021","2021",2072,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","MTMOTCMT","Million US$ at exchange rate","AUS","Australia","2010","2010",1565.8,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","MTMOTCMT","Million US$ at exchange rate","AUS","Australia","2011","2011",1846.4,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","MTMOTCMT","Million US$ at exchange rate","AUS","Australia","2012","2012",1830.6,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","MTMOTCMT","Million US$ at exchange rate","AUS","Australia","2013","2013",1928.9,"B; D","Break; Difference in methodology"
+"PATCCNSY","N-Nervous system","MTMOTCMT","Million US$ at exchange rate","AUS","Australia","2014","2014",1734.3,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","MTMOTCMT","Million US$ at exchange rate","AUS","Australia","2015","2015",1446.9,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","MTMOTCMT","Million US$ at exchange rate","AUS","Australia","2016","2016",1411.7,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","MTMOTCMT","Million US$ at exchange rate","AUS","Australia","2017","2017",1471.5,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","MTMOTCMT","Million US$ at exchange rate","AUS","Australia","2018","2018",1452.5,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","MTMOTCMT","Million US$ at exchange rate","AUS","Australia","2019","2019",1348.6,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","MTMOTCMT","Million US$ at exchange rate","AUS","Australia","2020","2020",1381.2,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","MTMOTCMT","Million US$ at exchange rate","AUS","Australia","2021","2021",1556.5,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","MTMOPPMT","Million US$, purchasing power parity","AUS","Australia","2010","2010",1135.3,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","MTMOPPMT","Million US$, purchasing power parity","AUS","Australia","2011","2011",1184.6,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","MTMOPPMT","Million US$, purchasing power parity","AUS","Australia","2012","2012",1148,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","MTMOPPMT","Million US$, purchasing power parity","AUS","Australia","2013","2013",1380.7,"B; D","Break; Difference in methodology"
+"PATCCNSY","N-Nervous system","MTMOPPMT","Million US$, purchasing power parity","AUS","Australia","2014","2014",1324.6,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","MTMOPPMT","Million US$, purchasing power parity","AUS","Australia","2015","2015",1306.9,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","MTMOPPMT","Million US$, purchasing power parity","AUS","Australia","2016","2016",1309.5,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","MTMOPPMT","Million US$, purchasing power parity","AUS","Australia","2017","2017",1299.4,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","MTMOPPMT","Million US$, purchasing power parity","AUS","Australia","2018","2018",1322.1,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","MTMOPPMT","Million US$, purchasing power parity","AUS","Australia","2019","2019",1310.9,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","MTMOPPMT","Million US$, purchasing power parity","AUS","Australia","2020","2020",1380.4,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","MTMOPPMT","Million US$, purchasing power parity","AUS","Australia","2021","2021",1431.4,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","TCPPERMT","/capita, US$ exchange rate","AUS","Australia","2010","2010",71.1,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","TCPPERMT","/capita, US$ exchange rate","AUS","Australia","2011","2011",82.6,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","TCPPERMT","/capita, US$ exchange rate","AUS","Australia","2012","2012",80.5,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","TCPPERMT","/capita, US$ exchange rate","AUS","Australia","2013","2013",83.4,"B; D","Break; Difference in methodology"
+"PATCCNSY","N-Nervous system","TCPPERMT","/capita, US$ exchange rate","AUS","Australia","2014","2014",73.9,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","TCPPERMT","/capita, US$ exchange rate","AUS","Australia","2015","2015",60.8,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","TCPPERMT","/capita, US$ exchange rate","AUS","Australia","2016","2016",58.4,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","TCPPERMT","/capita, US$ exchange rate","AUS","Australia","2017","2017",59.8,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","TCPPERMT","/capita, US$ exchange rate","AUS","Australia","2018","2018",58.2,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","TCPPERMT","/capita, US$ exchange rate","AUS","Australia","2019","2019",53.2,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","TCPPERMT","/capita, US$ exchange rate","AUS","Australia","2020","2020",53.8,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","TCPPERMT","/capita, US$ exchange rate","AUS","Australia","2021","2021",60.6,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2010","2010",51.5,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2011","2011",53,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2012","2012",50.5,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2013","2013",59.7,"B; D","Break; Difference in methodology"
+"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2014","2014",56.4,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2015","2015",54.9,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2016","2016",54.1,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2017","2017",52.8,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2018","2018",53,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2019","2019",51.7,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2020","2020",53.8,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2021","2021",55.7,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","ATCPTTMT","% of total sales","AUS","Australia","2010","2010",17.4,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","ATCPTTMT","% of total sales","AUS","Australia","2011","2011",17.4,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","ATCPTTMT","% of total sales","AUS","Australia","2012","2012",17.1,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","ATCPTTMT","% of total sales","AUS","Australia","2013","2013",16.9,"B; D","Break; Difference in methodology"
+"PATCCNSY","N-Nervous system","ATCPTTMT","% of total sales","AUS","Australia","2014","2014",16.2,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","ATCPTTMT","% of total sales","AUS","Australia","2015","2015",15.7,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","ATCPTTMT","% of total sales","AUS","Australia","2016","2016",12.4,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","ATCPTTMT","% of total sales","AUS","Australia","2017","2017",13,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","ATCPTTMT","% of total sales","AUS","Australia","2018","2018",13,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","ATCPTTMT","% of total sales","AUS","Australia","2019","2019",12.5,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","ATCPTTMT","% of total sales","AUS","Australia","2020","2020",12.1,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","ATCPTTMT","% of total sales","AUS","Australia","2021","2021",11.8,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","MLLNCUMT","Million of national currency units","AUT","Austria","2010","2010",467.4,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","MLLNCUMT","Million of national currency units","AUT","Austria","2011","2011",490.1,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","MLLNCUMT","Million of national currency units","AUT","Austria","2012","2012",487.1,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","MLLNCUMT","Million of national currency units","AUT","Austria","2013","2013",473.8,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","MLLNCUMT","Million of national currency units","AUT","Austria","2014","2014",477.6,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","MLLNCUMT","Million of national currency units","AUT","Austria","2015","2015",465.1,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","MLLNCUMT","Million of national currency units","AUT","Austria","2016","2016",443.7,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","MLLNCUMT","Million of national currency units","AUT","Austria","2017","2017",439.7,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","MLLNCUMT","Million of national currency units","AUT","Austria","2018","2018",439.3,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","MLLNCUMT","Million of national currency units","AUT","Austria","2019","2019",433.9,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","MLLNCUMT","Million of national currency units","AUT","Austria","2020","2020",456.3,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","MLLNCUMT","Million of national currency units","AUT","Austria","2021","2021",501.7,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","MTMOTCMT","Million US$ at exchange rate","AUT","Austria","2010","2010",619.6,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","MTMOTCMT","Million US$ at exchange rate","AUT","Austria","2011","2011",682.3,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","MTMOTCMT","Million US$ at exchange rate","AUT","Austria","2012","2012",625.9,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","MTMOTCMT","Million US$ at exchange rate","AUT","Austria","2013","2013",629.3,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","MTMOTCMT","Million US$ at exchange rate","AUT","Austria","2014","2014",634.5,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","MTMOTCMT","Million US$ at exchange rate","AUT","Austria","2015","2015",516,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","MTMOTCMT","Million US$ at exchange rate","AUT","Austria","2016","2016",491.2,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","MTMOTCMT","Million US$ at exchange rate","AUT","Austria","2017","2017",496.7,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","MTMOTCMT","Million US$ at exchange rate","AUT","Austria","2018","2018",518.8,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","MTMOTCMT","Million US$ at exchange rate","AUT","Austria","2019","2019",485.7,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","MTMOTCMT","Million US$ at exchange rate","AUT","Austria","2020","2020",521.2,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","MTMOTCMT","Million US$ at exchange rate","AUT","Austria","2021","2021",593.4,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","MTMOPPMT","Million US$, purchasing power parity","AUT","Austria","2010","2010",554.9,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","MTMOPPMT","Million US$, purchasing power parity","AUT","Austria","2011","2011",589.6,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","MTMOPPMT","Million US$, purchasing power parity","AUT","Austria","2012","2012",598.7,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","MTMOPPMT","Million US$, purchasing power parity","AUT","Austria","2013","2013",594.4,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","MTMOPPMT","Million US$, purchasing power parity","AUT","Austria","2014","2014",597.9,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","MTMOPPMT","Million US$, purchasing power parity","AUT","Austria","2015","2015",582.2,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","MTMOPPMT","Million US$, purchasing power parity","AUT","Austria","2016","2016",571.1,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","MTMOPPMT","Million US$, purchasing power parity","AUT","Austria","2017","2017",567.4,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","MTMOPPMT","Million US$, purchasing power parity","AUT","Austria","2018","2018",573.9,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","MTMOPPMT","Million US$, purchasing power parity","AUT","Austria","2019","2019",579.2,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","MTMOPPMT","Million US$, purchasing power parity","AUT","Austria","2020","2020",611.4,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","MTMOPPMT","Million US$, purchasing power parity","AUT","Austria","2021","2021",663.4,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","TCPPERMT","/capita, US$ exchange rate","AUT","Austria","2010","2010",74.1,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","TCPPERMT","/capita, US$ exchange rate","AUT","Austria","2011","2011",81.3,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","TCPPERMT","/capita, US$ exchange rate","AUT","Austria","2012","2012",74.2,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","TCPPERMT","/capita, US$ exchange rate","AUT","Austria","2013","2013",74.2,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","TCPPERMT","/capita, US$ exchange rate","AUT","Austria","2014","2014",74.2,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","TCPPERMT","/capita, US$ exchange rate","AUT","Austria","2015","2015",59.7,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","TCPPERMT","/capita, US$ exchange rate","AUT","Austria","2016","2016",56.2,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","TCPPERMT","/capita, US$ exchange rate","AUT","Austria","2017","2017",56.5,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","TCPPERMT","/capita, US$ exchange rate","AUT","Austria","2018","2018",58.7,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","TCPPERMT","/capita, US$ exchange rate","AUT","Austria","2019","2019",54.7,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","TCPPERMT","/capita, US$ exchange rate","AUT","Austria","2020","2020",58.4,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","TCPPERMT","/capita, US$ exchange rate","AUT","Austria","2021","2021",66.3,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2010","2010",66.3,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2011","2011",70.3,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2012","2012",71,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2013","2013",70.1,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2014","2014",70,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2015","2015",67.4,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2016","2016",65.4,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2017","2017",64.5,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2018","2018",64.9,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2019","2019",65.2,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2020","2020",68.6,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2021","2021",74.1,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","ATCPTTMT","% of total sales","AUT","Austria","2010","2010",18.7,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","ATCPTTMT","% of total sales","AUT","Austria","2011","2011",19.2,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","ATCPTTMT","% of total sales","AUT","Austria","2012","2012",18.6,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","ATCPTTMT","% of total sales","AUT","Austria","2013","2013",18,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","ATCPTTMT","% of total sales","AUT","Austria","2014","2014",17.1,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","ATCPTTMT","% of total sales","AUT","Austria","2015","2015",15.9,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","ATCPTTMT","% of total sales","AUT","Austria","2016","2016",14.8,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","ATCPTTMT","% of total sales","AUT","Austria","2017","2017",14.1,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","ATCPTTMT","% of total sales","AUT","Austria","2018","2018",13.7,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","ATCPTTMT","% of total sales","AUT","Austria","2019","2019",13.1,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","ATCPTTMT","% of total sales","AUT","Austria","2020","2020",13.1,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","ATCPTTMT","% of total sales","AUT","Austria","2021","2021",13.5,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","MLLNCUMT","Million of national currency units","BEL","Belgium","2010","2010",1019.6,,
+"PATCCNSY","N-Nervous system","MLLNCUMT","Million of national currency units","BEL","Belgium","2011","2011",1050.7,,
+"PATCCNSY","N-Nervous system","MLLNCUMT","Million of national currency units","BEL","Belgium","2012","2012",1005.5,,
+"PATCCNSY","N-Nervous system","MLLNCUMT","Million of national currency units","BEL","Belgium","2013","2013",978.6,,
+"PATCCNSY","N-Nervous system","MLLNCUMT","Million of national currency units","BEL","Belgium","2014","2014",958.5,,
+"PATCCNSY","N-Nervous system","MLLNCUMT","Million of national currency units","BEL","Belgium","2015","2015",940.8,,
+"PATCCNSY","N-Nervous system","MLLNCUMT","Million of national currency units","BEL","Belgium","2016","2016",910.9,,
+"PATCCNSY","N-Nervous system","MLLNCUMT","Million of national currency units","BEL","Belgium","2017","2017",901,,
+"PATCCNSY","N-Nervous system","MLLNCUMT","Million of national currency units","BEL","Belgium","2018","2018",861.3,,
+"PATCCNSY","N-Nervous system","MLLNCUMT","Million of national currency units","BEL","Belgium","2019","2019",865.7,,
+"PATCCNSY","N-Nervous system","MLLNCUMT","Million of national currency units","BEL","Belgium","2020","2020",862.2,,
+"PATCCNSY","N-Nervous system","MLLNCUMT","Million of national currency units","BEL","Belgium","2021","2021",884.9,,
+"PATCCNSY","N-Nervous system","MLLNCUMT","Million of national currency units","BEL","Belgium","2022","2022",999.7,"E","Estimated value"
+"PATCCNSY","N-Nervous system","MTMOTCMT","Million US$ at exchange rate","BEL","Belgium","2010","2010",1351.7,,
+"PATCCNSY","N-Nervous system","MTMOTCMT","Million US$ at exchange rate","BEL","Belgium","2011","2011",1462.5,,
+"PATCCNSY","N-Nervous system","MTMOTCMT","Million US$ at exchange rate","BEL","Belgium","2012","2012",1291.9,,
+"PATCCNSY","N-Nervous system","MTMOTCMT","Million US$ at exchange rate","BEL","Belgium","2013","2013",1299.7,,
+"PATCCNSY","N-Nervous system","MTMOTCMT","Million US$ at exchange rate","BEL","Belgium","2014","2014",1273.4,,
+"PATCCNSY","N-Nervous system","MTMOTCMT","Million US$ at exchange rate","BEL","Belgium","2015","2015",1043.8,,
+"PATCCNSY","N-Nervous system","MTMOTCMT","Million US$ at exchange rate","BEL","Belgium","2016","2016",1008.3,,
+"PATCCNSY","N-Nervous system","MTMOTCMT","Million US$ at exchange rate","BEL","Belgium","2017","2017",1017.8,,
+"PATCCNSY","N-Nervous system","MTMOTCMT","Million US$ at exchange rate","BEL","Belgium","2018","2018",1017.1,,
+"PATCCNSY","N-Nervous system","MTMOTCMT","Million US$ at exchange rate","BEL","Belgium","2019","2019",969.1,,
+"PATCCNSY","N-Nervous system","MTMOTCMT","Million US$ at exchange rate","BEL","Belgium","2020","2020",984.8,,
+"PATCCNSY","N-Nervous system","MTMOTCMT","Million US$ at exchange rate","BEL","Belgium","2021","2021",1046.6,,
+"PATCCNSY","N-Nervous system","MTMOTCMT","Million US$ at exchange rate","BEL","Belgium","2022","2022",1052.7,"E","Estimated value"
+"PATCCNSY","N-Nervous system","MTMOPPMT","Million US$, purchasing power parity","BEL","Belgium","2010","2010",1218.7,,
+"PATCCNSY","N-Nervous system","MTMOPPMT","Million US$, purchasing power parity","BEL","Belgium","2011","2011",1263,,
+"PATCCNSY","N-Nervous system","MTMOPPMT","Million US$, purchasing power parity","BEL","Belgium","2012","2012",1223.1,,
+"PATCCNSY","N-Nervous system","MTMOPPMT","Million US$, purchasing power parity","BEL","Belgium","2013","2013",1213.9,,
+"PATCCNSY","N-Nervous system","MTMOPPMT","Million US$, purchasing power parity","BEL","Belgium","2014","2014",1197.8,,
+"PATCCNSY","N-Nervous system","MTMOPPMT","Million US$, purchasing power parity","BEL","Belgium","2015","2015",1176,,
+"PATCCNSY","N-Nervous system","MTMOPPMT","Million US$, purchasing power parity","BEL","Belgium","2016","2016",1166.3,,
+"PATCCNSY","N-Nervous system","MTMOPPMT","Million US$, purchasing power parity","BEL","Belgium","2017","2017",1161.6,,
+"PATCCNSY","N-Nervous system","MTMOPPMT","Million US$, purchasing power parity","BEL","Belgium","2018","2018",1123.8,,
+"PATCCNSY","N-Nervous system","MTMOPPMT","Million US$, purchasing power parity","BEL","Belgium","2019","2019",1159.5,,
+"PATCCNSY","N-Nervous system","MTMOPPMT","Million US$, purchasing power parity","BEL","Belgium","2020","2020",1180.7,,
+"PATCCNSY","N-Nervous system","MTMOPPMT","Million US$, purchasing power parity","BEL","Belgium","2021","2021",1201.2,,
+"PATCCNSY","N-Nervous system","MTMOPPMT","Million US$, purchasing power parity","BEL","Belgium","2022","2022",1400.2,"E","Estimated value"
+"PATCCNSY","N-Nervous system","TCPPERMT","/capita, US$ exchange rate","BEL","Belgium","2010","2010",124.1,,
+"PATCCNSY","N-Nervous system","TCPPERMT","/capita, US$ exchange rate","BEL","Belgium","2011","2011",132.5,,
+"PATCCNSY","N-Nervous system","TCPPERMT","/capita, US$ exchange rate","BEL","Belgium","2012","2012",116.3,,
+"PATCCNSY","N-Nervous system","TCPPERMT","/capita, US$ exchange rate","BEL","Belgium","2013","2013",116.5,,
+"PATCCNSY","N-Nervous system","TCPPERMT","/capita, US$ exchange rate","BEL","Belgium","2014","2014",113.6,,
+"PATCCNSY","N-Nervous system","TCPPERMT","/capita, US$ exchange rate","BEL","Belgium","2015","2015",92.6,,
+"PATCCNSY","N-Nervous system","TCPPERMT","/capita, US$ exchange rate","BEL","Belgium","2016","2016",89,,
+"PATCCNSY","N-Nervous system","TCPPERMT","/capita, US$ exchange rate","BEL","Belgium","2017","2017",89.5,,
+"PATCCNSY","N-Nervous system","TCPPERMT","/capita, US$ exchange rate","BEL","Belgium","2018","2018",89,,
+"PATCCNSY","N-Nervous system","TCPPERMT","/capita, US$ exchange rate","BEL","Belgium","2019","2019",84.4,,
+"PATCCNSY","N-Nervous system","TCPPERMT","/capita, US$ exchange rate","BEL","Belgium","2020","2020",85.4,,
+"PATCCNSY","N-Nervous system","TCPPERMT","/capita, US$ exchange rate","BEL","Belgium","2021","2021",90.3,,
+"PATCCNSY","N-Nervous system","TCPPERMT","/capita, US$ exchange rate","BEL","Belgium","2022","2022",90.6,"E","Estimated value"
+"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2010","2010",111.9,,
+"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2011","2011",114.4,,
+"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2012","2012",110.1,,
+"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2013","2013",108.8,,
+"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2014","2014",106.9,,
+"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2015","2015",104.3,,
+"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2016","2016",102.9,,
+"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2017","2017",102.1,,
+"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2018","2018",98.3,,
+"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2019","2019",100.9,,
+"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2020","2020",102.3,,
+"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2021","2021",103.7,,
+"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2022","2022",120.5,"E","Estimated value"
+"PATCCNSY","N-Nervous system","ATCPTTMT","% of total sales","BEL","Belgium","2010","2010",17.3,,
+"PATCCNSY","N-Nervous system","ATCPTTMT","% of total sales","BEL","Belgium","2011","2011",17.5,,
+"PATCCNSY","N-Nervous system","ATCPTTMT","% of total sales","BEL","Belgium","2012","2012",16.9,,
+"PATCCNSY","N-Nervous system","ATCPTTMT","% of total sales","BEL","Belgium","2013","2013",16.5,,
+"PATCCNSY","N-Nervous system","ATCPTTMT","% of total sales","BEL","Belgium","2014","2014",16.1,,
+"PATCCNSY","N-Nervous system","ATCPTTMT","% of total sales","BEL","Belgium","2015","2015",15.2,,
+"PATCCNSY","N-Nervous system","ATCPTTMT","% of total sales","BEL","Belgium","2016","2016",14.6,,
+"PATCCNSY","N-Nervous system","ATCPTTMT","% of total sales","BEL","Belgium","2017","2017",13.8,,
+"PATCCNSY","N-Nervous system","ATCPTTMT","% of total sales","BEL","Belgium","2018","2018",12.9,,
+"PATCCNSY","N-Nervous system","ATCPTTMT","% of total sales","BEL","Belgium","2019","2019",11.8,,
+"PATCCNSY","N-Nervous system","ATCPTTMT","% of total sales","BEL","Belgium","2020","2020",11.3,,
+"PATCCNSY","N-Nervous system","ATCPTTMT","% of total sales","BEL","Belgium","2021","2021",11,,
+"PATCCNSY","N-Nervous system","ATCPTTMT","% of total sales","BEL","Belgium","2022","2022",11.1,"E","Estimated value"
+"PATCCNSY","N-Nervous system","MLLNCUMT","Million of national currency units","CAN","Canada","2012","2012",5200.6,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","MLLNCUMT","Million of national currency units","CAN","Canada","2013","2013",5224.8,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","MLLNCUMT","Million of national currency units","CAN","Canada","2014","2014",5321.8,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","MLLNCUMT","Million of national currency units","CAN","Canada","2015","2015",5435.7,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","MLLNCUMT","Million of national currency units","CAN","Canada","2016","2016",5608.5,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","MLLNCUMT","Million of national currency units","CAN","Canada","2017","2017",5705.3,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","MLLNCUMT","Million of national currency units","CAN","Canada","2018","2018",5547.2,"E; B; D","Estimated value; Break; Difference in methodology"
+"PATCCNSY","N-Nervous system","MLLNCUMT","Million of national currency units","CAN","Canada","2019","2019",5554.1,"E; D","Estimated value; Difference in methodology"
+"PATCCNSY","N-Nervous system","MLLNCUMT","Million of national currency units","CAN","Canada","2020","2020",6017.4,"E; D","Estimated value; Difference in methodology"
+"PATCCNSY","N-Nervous system","MLLNCUMT","Million of national currency units","CAN","Canada","2021","2021",6528.7,"E; D","Estimated value; Difference in methodology"
+"PATCCNSY","N-Nervous system","MLLNCUMT","Million of national currency units","CAN","Canada","2022","2022",7071.4,"E; D","Estimated value; Difference in methodology"
+"PATCCNSY","N-Nervous system","MTMOTCMT","Million US$ at exchange rate","CAN","Canada","2012","2012",5203.9,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","MTMOTCMT","Million US$ at exchange rate","CAN","Canada","2013","2013",5071.9,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","MTMOTCMT","Million US$ at exchange rate","CAN","Canada","2014","2014",4817.2,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","MTMOTCMT","Million US$ at exchange rate","CAN","Canada","2015","2015",4250.7,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","MTMOTCMT","Million US$ at exchange rate","CAN","Canada","2016","2016",4230.9,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","MTMOTCMT","Million US$ at exchange rate","CAN","Canada","2017","2017",4395.7,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","MTMOTCMT","Million US$ at exchange rate","CAN","Canada","2018","2018",4280.8,"E; B; D","Estimated value; Break; Difference in methodology"
+"PATCCNSY","N-Nervous system","MTMOTCMT","Million US$ at exchange rate","CAN","Canada","2019","2019",4186.1,"E; D","Estimated value; Difference in methodology"
+"PATCCNSY","N-Nervous system","MTMOTCMT","Million US$ at exchange rate","CAN","Canada","2020","2020",4486.7,"E; D","Estimated value; Difference in methodology"
+"PATCCNSY","N-Nervous system","MTMOTCMT","Million US$ at exchange rate","CAN","Canada","2021","2021",5206.8,"E; D","Estimated value; Difference in methodology"
+"PATCCNSY","N-Nervous system","MTMOTCMT","Million US$ at exchange rate","CAN","Canada","2022","2022",5433,"E; D","Estimated value; Difference in methodology"
+"PATCCNSY","N-Nervous system","MTMOPPMT","Million US$, purchasing power parity","CAN","Canada","2012","2012",4178.5,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","MTMOPPMT","Million US$, purchasing power parity","CAN","Canada","2013","2013",4268.6,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","MTMOPPMT","Million US$, purchasing power parity","CAN","Canada","2014","2014",4325.4,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","MTMOPPMT","Million US$, purchasing power parity","CAN","Canada","2015","2015",4355.4,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","MTMOPPMT","Million US$, purchasing power parity","CAN","Canada","2016","2016",4646.5,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","MTMOPPMT","Million US$, purchasing power parity","CAN","Canada","2017","2017",4706.2,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","MTMOPPMT","Million US$, purchasing power parity","CAN","Canada","2018","2018",4597.6,"E; B; D","Estimated value; Break; Difference in methodology"
+"PATCCNSY","N-Nervous system","MTMOPPMT","Million US$, purchasing power parity","CAN","Canada","2019","2019",4498.3,"E; D","Estimated value; Difference in methodology"
+"PATCCNSY","N-Nervous system","MTMOPPMT","Million US$, purchasing power parity","CAN","Canada","2020","2020",4888,"E; D","Estimated value; Difference in methodology"
+"PATCCNSY","N-Nervous system","MTMOPPMT","Million US$, purchasing power parity","CAN","Canada","2021","2021",5272.9,"E; D","Estimated value; Difference in methodology"
+"PATCCNSY","N-Nervous system","MTMOPPMT","Million US$, purchasing power parity","CAN","Canada","2022","2022",5639.8,"E; D","Estimated value; Difference in methodology"
+"PATCCNSY","N-Nervous system","TCPPERMT","/capita, US$ exchange rate","CAN","Canada","2012","2012",149.9,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","TCPPERMT","/capita, US$ exchange rate","CAN","Canada","2013","2013",144.6,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","TCPPERMT","/capita, US$ exchange rate","CAN","Canada","2014","2014",135.9,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","TCPPERMT","/capita, US$ exchange rate","CAN","Canada","2015","2015",119.1,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","TCPPERMT","/capita, US$ exchange rate","CAN","Canada","2016","2016",117.2,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","TCPPERMT","/capita, US$ exchange rate","CAN","Canada","2017","2017",120.3,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","TCPPERMT","/capita, US$ exchange rate","CAN","Canada","2018","2018",115.5,"E; B; D","Estimated value; Break; Difference in methodology"
+"PATCCNSY","N-Nervous system","TCPPERMT","/capita, US$ exchange rate","CAN","Canada","2019","2019",111.3,"E; D","Estimated value; Difference in methodology"
+"PATCCNSY","N-Nervous system","TCPPERMT","/capita, US$ exchange rate","CAN","Canada","2020","2020",118,"E; D","Estimated value; Difference in methodology"
+"PATCCNSY","N-Nervous system","TCPPERMT","/capita, US$ exchange rate","CAN","Canada","2021","2021",136.1,"E; D","Estimated value; Difference in methodology"
+"PATCCNSY","N-Nervous system","TCPPERMT","/capita, US$ exchange rate","CAN","Canada","2022","2022",139.7,"E; D","Estimated value; Difference in methodology"
+"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2012","2012",120.4,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2013","2013",121.7,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2014","2014",122.1,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2015","2015",122,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2016","2016",128.7,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2017","2017",128.8,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2018","2018",124,"E; B; D","Estimated value; Break; Difference in methodology"
+"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2019","2019",119.6,"E; D","Estimated value; Difference in methodology"
+"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2020","2020",128.5,"E; D","Estimated value; Difference in methodology"
+"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2021","2021",137.9,"E; D","Estimated value; Difference in methodology"
+"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2022","2022",145,"E; D","Estimated value; Difference in methodology"
+"PATCCNSY","N-Nervous system","ATCPTTMT","% of total sales","CAN","Canada","2012","2012",21.4,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","ATCPTTMT","% of total sales","CAN","Canada","2013","2013",21.3,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","ATCPTTMT","% of total sales","CAN","Canada","2014","2014",20.9,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","ATCPTTMT","% of total sales","CAN","Canada","2015","2015",20,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","ATCPTTMT","% of total sales","CAN","Canada","2016","2016",19.8,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","ATCPTTMT","% of total sales","CAN","Canada","2017","2017",19.2,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","ATCPTTMT","% of total sales","CAN","Canada","2018","2018",18.1,"E; B; D","Estimated value; Break; Difference in methodology"
+"PATCCNSY","N-Nervous system","ATCPTTMT","% of total sales","CAN","Canada","2019","2019",17.4,"E; D","Estimated value; Difference in methodology"
+"PATCCNSY","N-Nervous system","ATCPTTMT","% of total sales","CAN","Canada","2020","2020",17.6,"E; D","Estimated value; Difference in methodology"
+"PATCCNSY","N-Nervous system","ATCPTTMT","% of total sales","CAN","Canada","2021","2021",17.7,"E; D","Estimated value; Difference in methodology"
+"PATCCNSY","N-Nervous system","ATCPTTMT","% of total sales","CAN","Canada","2022","2022",17.7,"E; D","Estimated value; Difference in methodology"
+"PATCCNSY","N-Nervous system","MLLNCUMT","Million of national currency units","CZE","Czech Republic","2010","2010",9951.4,,
+"PATCCNSY","N-Nervous system","MLLNCUMT","Million of national currency units","CZE","Czech Republic","2011","2011",9889.6,,
+"PATCCNSY","N-Nervous system","MLLNCUMT","Million of national currency units","CZE","Czech Republic","2012","2012",10162,,
+"PATCCNSY","N-Nervous system","MLLNCUMT","Million of national currency units","CZE","Czech Republic","2013","2013",9599,,
+"PATCCNSY","N-Nervous system","MLLNCUMT","Million of national currency units","CZE","Czech Republic","2014","2014",9618.2,,
+"PATCCNSY","N-Nervous system","MLLNCUMT","Million of national currency units","CZE","Czech Republic","2015","2015",9677,,
+"PATCCNSY","N-Nervous system","MLLNCUMT","Million of national currency units","CZE","Czech Republic","2016","2016",9666,,
+"PATCCNSY","N-Nervous system","MLLNCUMT","Million of national currency units","CZE","Czech Republic","2017","2017",10331.5,,
+"PATCCNSY","N-Nervous system","MLLNCUMT","Million of national currency units","CZE","Czech Republic","2018","2018",10668.2,,
+"PATCCNSY","N-Nervous system","MLLNCUMT","Million of national currency units","CZE","Czech Republic","2019","2019",10951.8,,
+"PATCCNSY","N-Nervous system","MLLNCUMT","Million of national currency units","CZE","Czech Republic","2020","2020",8569.9,"B","Break"
+"PATCCNSY","N-Nervous system","MLLNCUMT","Million of national currency units","CZE","Czech Republic","2021","2021",9038.9,,
+"PATCCNSY","N-Nervous system","MTMOTCMT","Million US$ at exchange rate","CZE","Czech Republic","2010","2010",521.1,,
+"PATCCNSY","N-Nervous system","MTMOTCMT","Million US$ at exchange rate","CZE","Czech Republic","2011","2011",558.9,,
+"PATCCNSY","N-Nervous system","MTMOTCMT","Million US$ at exchange rate","CZE","Czech Republic","2012","2012",519.1,,
+"PATCCNSY","N-Nervous system","MTMOTCMT","Million US$ at exchange rate","CZE","Czech Republic","2013","2013",490.5,,
+"PATCCNSY","N-Nervous system","MTMOTCMT","Million US$ at exchange rate","CZE","Czech Republic","2014","2014",463.4,,
+"PATCCNSY","N-Nervous system","MTMOTCMT","Million US$ at exchange rate","CZE","Czech Republic","2015","2015",393.4,,
+"PATCCNSY","N-Nervous system","MTMOTCMT","Million US$ at exchange rate","CZE","Czech Republic","2016","2016",395.5,,
+"PATCCNSY","N-Nervous system","MTMOTCMT","Million US$ at exchange rate","CZE","Czech Republic","2017","2017",442,,
+"PATCCNSY","N-Nervous system","MTMOTCMT","Million US$ at exchange rate","CZE","Czech Republic","2018","2018",490.9,,
+"PATCCNSY","N-Nervous system","MTMOTCMT","Million US$ at exchange rate","CZE","Czech Republic","2019","2019",477.6,,
+"PATCCNSY","N-Nervous system","MTMOTCMT","Million US$ at exchange rate","CZE","Czech Republic","2020","2020",369.2,"B","Break"
+"PATCCNSY","N-Nervous system","MTMOTCMT","Million US$ at exchange rate","CZE","Czech Republic","2021","2021",417,,
+"PATCCNSY","N-Nervous system","MTMOPPMT","Million US$, purchasing power parity","CZE","Czech Republic","2010","2010",727.8,,
+"PATCCNSY","N-Nervous system","MTMOPPMT","Million US$, purchasing power parity","CZE","Czech Republic","2011","2011",741.1,,
+"PATCCNSY","N-Nervous system","MTMOPPMT","Million US$, purchasing power parity","CZE","Czech Republic","2012","2012",764.2,,
+"PATCCNSY","N-Nervous system","MTMOPPMT","Million US$, purchasing power parity","CZE","Czech Republic","2013","2013",750.8,,
+"PATCCNSY","N-Nervous system","MTMOPPMT","Million US$, purchasing power parity","CZE","Czech Republic","2014","2014",757.1,,
+"PATCCNSY","N-Nervous system","MTMOPPMT","Million US$, purchasing power parity","CZE","Czech Republic","2015","2015",747.9,,
+"PATCCNSY","N-Nervous system","MTMOPPMT","Million US$, purchasing power parity","CZE","Czech Republic","2016","2016",768.6,,
+"PATCCNSY","N-Nervous system","MTMOPPMT","Million US$, purchasing power parity","CZE","Czech Republic","2017","2017",831.5,,
+"PATCCNSY","N-Nervous system","MTMOPPMT","Million US$, purchasing power parity","CZE","Czech Republic","2018","2018",862.3,,
+"PATCCNSY","N-Nervous system","MTMOPPMT","Million US$, purchasing power parity","CZE","Czech Republic","2019","2019",892.2,,
+"PATCCNSY","N-Nervous system","MTMOPPMT","Million US$, purchasing power parity","CZE","Czech Republic","2020","2020",687.7,"B","Break"
+"PATCCNSY","N-Nervous system","MTMOPPMT","Million US$, purchasing power parity","CZE","Czech Republic","2021","2021",709.3,,
+"PATCCNSY","N-Nervous system","TCPPERMT","/capita, US$ exchange rate","CZE","Czech Republic","2010","2010",49.7,,
+"PATCCNSY","N-Nervous system","TCPPERMT","/capita, US$ exchange rate","CZE","Czech Republic","2011","2011",53.2,,
+"PATCCNSY","N-Nervous system","TCPPERMT","/capita, US$ exchange rate","CZE","Czech Republic","2012","2012",49.4,,
+"PATCCNSY","N-Nervous system","TCPPERMT","/capita, US$ exchange rate","CZE","Czech Republic","2013","2013",46.6,,
+"PATCCNSY","N-Nervous system","TCPPERMT","/capita, US$ exchange rate","CZE","Czech Republic","2014","2014",44,,
+"PATCCNSY","N-Nervous system","TCPPERMT","/capita, US$ exchange rate","CZE","Czech Republic","2015","2015",37.3,,
+"PATCCNSY","N-Nervous system","TCPPERMT","/capita, US$ exchange rate","CZE","Czech Republic","2016","2016",37.4,,
+"PATCCNSY","N-Nervous system","TCPPERMT","/capita, US$ exchange rate","CZE","Czech Republic","2017","2017",41.7,,
+"PATCCNSY","N-Nervous system","TCPPERMT","/capita, US$ exchange rate","CZE","Czech Republic","2018","2018",46.2,,
+"PATCCNSY","N-Nervous system","TCPPERMT","/capita, US$ exchange rate","CZE","Czech Republic","2019","2019",44.8,,
+"PATCCNSY","N-Nervous system","TCPPERMT","/capita, US$ exchange rate","CZE","Czech Republic","2020","2020",34.5,"B","Break"
+"PATCCNSY","N-Nervous system","TCPPERMT","/capita, US$ exchange rate","CZE","Czech Republic","2021","2021",39.7,,
+"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czech Republic","2010","2010",69.5,,
+"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czech Republic","2011","2011",70.6,,
+"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czech Republic","2012","2012",72.7,,
+"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czech Republic","2013","2013",71.4,,
+"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czech Republic","2014","2014",71.9,,
+"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czech Republic","2015","2015",70.9,,
+"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czech Republic","2016","2016",72.7,,
+"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czech Republic","2017","2017",78.5,,
+"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czech Republic","2018","2018",81.1,,
+"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czech Republic","2019","2019",83.6,,
+"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czech Republic","2020","2020",64.3,"B","Break"
+"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czech Republic","2021","2021",67.5,,
+"PATCCNSY","N-Nervous system","ATCPTTMT","% of total sales","CZE","Czech Republic","2010","2010",12.2,,
+"PATCCNSY","N-Nervous system","ATCPTTMT","% of total sales","CZE","Czech Republic","2011","2011",12.2,,
+"PATCCNSY","N-Nervous system","ATCPTTMT","% of total sales","CZE","Czech Republic","2012","2012",12.1,,
+"PATCCNSY","N-Nervous system","ATCPTTMT","% of total sales","CZE","Czech Republic","2013","2013",12,,
+"PATCCNSY","N-Nervous system","ATCPTTMT","% of total sales","CZE","Czech Republic","2014","2014",11.9,,
+"PATCCNSY","N-Nervous system","ATCPTTMT","% of total sales","CZE","Czech Republic","2015","2015",11.5,,
+"PATCCNSY","N-Nervous system","ATCPTTMT","% of total sales","CZE","Czech Republic","2016","2016",11.1,,
+"PATCCNSY","N-Nervous system","ATCPTTMT","% of total sales","CZE","Czech Republic","2017","2017",11.2,,
+"PATCCNSY","N-Nervous system","ATCPTTMT","% of total sales","CZE","Czech Republic","2018","2018",10.9,,
+"PATCCNSY","N-Nervous system","ATCPTTMT","% of total sales","CZE","Czech Republic","2019","2019",10.6,,
+"PATCCNSY","N-Nervous system","ATCPTTMT","% of total sales","CZE","Czech Republic","2020","2020",9.8,"B","Break"
+"PATCCNSY","N-Nervous system","ATCPTTMT","% of total sales","CZE","Czech Republic","2021","2021",9.7,,
+"PATCCNSY","N-Nervous system","MLLNCUMT","Million of national currency units","DNK","Denmark","2010","2010",4646,,
+"PATCCNSY","N-Nervous system","MLLNCUMT","Million of national currency units","DNK","Denmark","2011","2011",4583.4,,
+"PATCCNSY","N-Nervous system","MLLNCUMT","Million of national currency units","DNK","Denmark","2012","2012",4090.7,,
+"PATCCNSY","N-Nervous system","MLLNCUMT","Million of national currency units","DNK","Denmark","2013","2013",3689.7,,
+"PATCCNSY","N-Nervous system","MLLNCUMT","Million of national currency units","DNK","Denmark","2014","2014",3658.3,,
+"PATCCNSY","N-Nervous system","MLLNCUMT","Million of national currency units","DNK","Denmark","2015","2015",3596.9,,
+"PATCCNSY","N-Nervous system","MLLNCUMT","Million of national currency units","DNK","Denmark","2016","2016",3484.1,,
+"PATCCNSY","N-Nervous system","MLLNCUMT","Million of national currency units","DNK","Denmark","2017","2017",3316.9,,
+"PATCCNSY","N-Nervous system","MLLNCUMT","Million of national currency units","DNK","Denmark","2018","2018",3354.7,,
+"PATCCNSY","N-Nervous system","MLLNCUMT","Million of national currency units","DNK","Denmark","2019","2019",3397.1,,
+"PATCCNSY","N-Nervous system","MLLNCUMT","Million of national currency units","DNK","Denmark","2020","2020",3478.9,,
+"PATCCNSY","N-Nervous system","MLLNCUMT","Million of national currency units","DNK","Denmark","2021","2021",3456.4,,
+"PATCCNSY","N-Nervous system","MTMOTCMT","Million US$ at exchange rate","DNK","Denmark","2010","2010",826.1,,
+"PATCCNSY","N-Nervous system","MTMOTCMT","Million US$ at exchange rate","DNK","Denmark","2011","2011",853.7,,
+"PATCCNSY","N-Nervous system","MTMOTCMT","Million US$ at exchange rate","DNK","Denmark","2012","2012",706.2,,
+"PATCCNSY","N-Nervous system","MTMOTCMT","Million US$ at exchange rate","DNK","Denmark","2013","2013",657,,
+"PATCCNSY","N-Nervous system","MTMOTCMT","Million US$ at exchange rate","DNK","Denmark","2014","2014",651.8,,
+"PATCCNSY","N-Nervous system","MTMOTCMT","Million US$ at exchange rate","DNK","Denmark","2015","2015",534.6,,
+"PATCCNSY","N-Nervous system","MTMOTCMT","Million US$ at exchange rate","DNK","Denmark","2016","2016",517.6,,
+"PATCCNSY","N-Nervous system","MTMOTCMT","Million US$ at exchange rate","DNK","Denmark","2017","2017",502.3,,
+"PATCCNSY","N-Nervous system","MTMOTCMT","Million US$ at exchange rate","DNK","Denmark","2018","2018",531.3,,
+"PATCCNSY","N-Nervous system","MTMOTCMT","Million US$ at exchange rate","DNK","Denmark","2019","2019",509.3,,
+"PATCCNSY","N-Nervous system","MTMOTCMT","Million US$ at exchange rate","DNK","Denmark","2020","2020",531.8,,
+"PATCCNSY","N-Nervous system","MTMOTCMT","Million US$ at exchange rate","DNK","Denmark","2021","2021",549.8,,
+"PATCCNSY","N-Nervous system","MTMOPPMT","Million US$, purchasing power parity","DNK","Denmark","2010","2010",612,,
+"PATCCNSY","N-Nervous system","MTMOPPMT","Million US$, purchasing power parity","DNK","Denmark","2011","2011",613.9,,
+"PATCCNSY","N-Nervous system","MTMOPPMT","Million US$, purchasing power parity","DNK","Denmark","2012","2012",540.8,,
+"PATCCNSY","N-Nervous system","MTMOPPMT","Million US$, purchasing power parity","DNK","Denmark","2013","2013",501.7,,
+"PATCCNSY","N-Nervous system","MTMOPPMT","Million US$, purchasing power parity","DNK","Denmark","2014","2014",499.2,,
+"PATCCNSY","N-Nervous system","MTMOPPMT","Million US$, purchasing power parity","DNK","Denmark","2015","2015",492.4,,
+"PATCCNSY","N-Nervous system","MTMOPPMT","Million US$, purchasing power parity","DNK","Denmark","2016","2016",492.1,,
+"PATCCNSY","N-Nervous system","MTMOPPMT","Million US$, purchasing power parity","DNK","Denmark","2017","2017",482.7,,
+"PATCCNSY","N-Nervous system","MTMOPPMT","Million US$, purchasing power parity","DNK","Denmark","2018","2018",495.8,,
+"PATCCNSY","N-Nervous system","MTMOPPMT","Million US$, purchasing power parity","DNK","Denmark","2019","2019",512.1,,
+"PATCCNSY","N-Nervous system","MTMOPPMT","Million US$, purchasing power parity","DNK","Denmark","2020","2020",531,,
+"PATCCNSY","N-Nervous system","MTMOPPMT","Million US$, purchasing power parity","DNK","Denmark","2021","2021",524.5,,
+"PATCCNSY","N-Nervous system","TCPPERMT","/capita, US$ exchange rate","DNK","Denmark","2010","2010",148.9,,
+"PATCCNSY","N-Nervous system","TCPPERMT","/capita, US$ exchange rate","DNK","Denmark","2011","2011",153.3,,
+"PATCCNSY","N-Nervous system","TCPPERMT","/capita, US$ exchange rate","DNK","Denmark","2012","2012",126.3,,
+"PATCCNSY","N-Nervous system","TCPPERMT","/capita, US$ exchange rate","DNK","Denmark","2013","2013",117,,
+"PATCCNSY","N-Nervous system","TCPPERMT","/capita, US$ exchange rate","DNK","Denmark","2014","2014",115.5,,
+"PATCCNSY","N-Nervous system","TCPPERMT","/capita, US$ exchange rate","DNK","Denmark","2015","2015",94.1,,
+"PATCCNSY","N-Nervous system","TCPPERMT","/capita, US$ exchange rate","DNK","Denmark","2016","2016",90.4,,
+"PATCCNSY","N-Nervous system","TCPPERMT","/capita, US$ exchange rate","DNK","Denmark","2017","2017",87.1,,
+"PATCCNSY","N-Nervous system","TCPPERMT","/capita, US$ exchange rate","DNK","Denmark","2018","2018",91.7,,
+"PATCCNSY","N-Nervous system","TCPPERMT","/capita, US$ exchange rate","DNK","Denmark","2019","2019",87.6,,
+"PATCCNSY","N-Nervous system","TCPPERMT","/capita, US$ exchange rate","DNK","Denmark","2020","2020",91.2,,
+"PATCCNSY","N-Nervous system","TCPPERMT","/capita, US$ exchange rate","DNK","Denmark","2021","2021",93.9,,
+"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","DNK","Denmark","2010","2010",110.3,,
+"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","DNK","Denmark","2011","2011",110.2,,
+"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","DNK","Denmark","2012","2012",96.7,,
+"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","DNK","Denmark","2013","2013",89.3,,
+"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","DNK","Denmark","2014","2014",88.5,,
+"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","DNK","Denmark","2015","2015",86.6,,
+"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","DNK","Denmark","2016","2016",85.9,,
+"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","DNK","Denmark","2017","2017",83.7,,
+"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","DNK","Denmark","2018","2018",85.6,,
+"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","DNK","Denmark","2019","2019",88.1,,
+"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","DNK","Denmark","2020","2020",91.1,,
+"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","DNK","Denmark","2021","2021",89.6,,
+"PATCCNSY","N-Nervous system","ATCPTTMT","% of total sales","DNK","Denmark","2010","2010",21.9,,
+"PATCCNSY","N-Nervous system","ATCPTTMT","% of total sales","DNK","Denmark","2011","2011",22.3,,
+"PATCCNSY","N-Nervous system","ATCPTTMT","% of total sales","DNK","Denmark","2012","2012",20,,
+"PATCCNSY","N-Nervous system","ATCPTTMT","% of total sales","DNK","Denmark","2013","2013",18.1,,
+"PATCCNSY","N-Nervous system","ATCPTTMT","% of total sales","DNK","Denmark","2014","2014",17.1,,
+"PATCCNSY","N-Nervous system","ATCPTTMT","% of total sales","DNK","Denmark","2015","2015",16.4,,
+"PATCCNSY","N-Nervous system","ATCPTTMT","% of total sales","DNK","Denmark","2016","2016",15.8,,
+"PATCCNSY","N-Nervous system","ATCPTTMT","% of total sales","DNK","Denmark","2017","2017",14.5,,
+"PATCCNSY","N-Nervous system","ATCPTTMT","% of total sales","DNK","Denmark","2018","2018",14.1,,
+"PATCCNSY","N-Nervous system","ATCPTTMT","% of total sales","DNK","Denmark","2019","2019",13.8,,
+"PATCCNSY","N-Nervous system","ATCPTTMT","% of total sales","DNK","Denmark","2020","2020",13.8,,
+"PATCCNSY","N-Nervous system","ATCPTTMT","% of total sales","DNK","Denmark","2021","2021",13.5,,
+"PATCCNSY","N-Nervous system","MLLNCUMT","Million of national currency units","FIN","Finland","2010","2010",344,,
+"PATCCNSY","N-Nervous system","MLLNCUMT","Million of national currency units","FIN","Finland","2011","2011",353.8,,
+"PATCCNSY","N-Nervous system","MLLNCUMT","Million of national currency units","FIN","Finland","2012","2012",350.6,,
+"PATCCNSY","N-Nervous system","MLLNCUMT","Million of national currency units","FIN","Finland","2013","2013",341.2,,
+"PATCCNSY","N-Nervous system","MLLNCUMT","Million of national currency units","FIN","Finland","2014","2014",335.5,,
+"PATCCNSY","N-Nervous system","MLLNCUMT","Million of national currency units","FIN","Finland","2015","2015",319.8,,
+"PATCCNSY","N-Nervous system","MLLNCUMT","Million of national currency units","FIN","Finland","2016","2016",307,,
+"PATCCNSY","N-Nervous system","MLLNCUMT","Million of national currency units","FIN","Finland","2017","2017",297.2,,
+"PATCCNSY","N-Nervous system","MLLNCUMT","Million of national currency units","FIN","Finland","2018","2018",294.2,,
+"PATCCNSY","N-Nervous system","MLLNCUMT","Million of national currency units","FIN","Finland","2019","2019",306.4,,
+"PATCCNSY","N-Nervous system","MLLNCUMT","Million of national currency units","FIN","Finland","2020","2020",320.4,,
+"PATCCNSY","N-Nervous system","MLLNCUMT","Million of national currency units","FIN","Finland","2021","2021",395.9,,
+"PATCCNSY","N-Nervous system","MTMOTCMT","Million US$ at exchange rate","FIN","Finland","2010","2010",456,,
+"PATCCNSY","N-Nervous system","MTMOTCMT","Million US$ at exchange rate","FIN","Finland","2011","2011",492.5,,
+"PATCCNSY","N-Nervous system","MTMOTCMT","Million US$ at exchange rate","FIN","Finland","2012","2012",450.4,,
+"PATCCNSY","N-Nervous system","MTMOTCMT","Million US$ at exchange rate","FIN","Finland","2013","2013",453.2,,
+"PATCCNSY","N-Nervous system","MTMOTCMT","Million US$ at exchange rate","FIN","Finland","2014","2014",445.7,,
+"PATCCNSY","N-Nervous system","MTMOTCMT","Million US$ at exchange rate","FIN","Finland","2015","2015",354.8,,
+"PATCCNSY","N-Nervous system","MTMOTCMT","Million US$ at exchange rate","FIN","Finland","2016","2016",339.8,,
+"PATCCNSY","N-Nervous system","MTMOTCMT","Million US$ at exchange rate","FIN","Finland","2017","2017",335.7,,
+"PATCCNSY","N-Nervous system","MTMOTCMT","Million US$ at exchange rate","FIN","Finland","2018","2018",347.4,,
+"PATCCNSY","N-Nervous system","MTMOTCMT","Million US$ at exchange rate","FIN","Finland","2019","2019",343,,
+"PATCCNSY","N-Nervous system","MTMOTCMT","Million US$ at exchange rate","FIN","Finland","2020","2020",366,,
+"PATCCNSY","N-Nervous system","MTMOTCMT","Million US$ at exchange rate","FIN","Finland","2021","2021",468.2,,
+"PATCCNSY","N-Nervous system","MTMOPPMT","Million US$, purchasing power parity","FIN","Finland","2010","2010",382,,
+"PATCCNSY","N-Nervous system","MTMOPPMT","Million US$, purchasing power parity","FIN","Finland","2011","2011",394,,
+"PATCCNSY","N-Nervous system","MTMOPPMT","Million US$, purchasing power parity","FIN","Finland","2012","2012",385.9,,
+"PATCCNSY","N-Nervous system","MTMOPPMT","Million US$, purchasing power parity","FIN","Finland","2013","2013",376.9,,
+"PATCCNSY","N-Nervous system","MTMOPPMT","Million US$, purchasing power parity","FIN","Finland","2014","2014",369.8,,
+"PATCCNSY","N-Nervous system","MTMOPPMT","Million US$, purchasing power parity","FIN","Finland","2015","2015",352.3,,
+"PATCCNSY","N-Nervous system","MTMOPPMT","Million US$, purchasing power parity","FIN","Finland","2016","2016",348.5,,
+"PATCCNSY","N-Nervous system","MTMOPPMT","Million US$, purchasing power parity","FIN","Finland","2017","2017",344.1,,
+"PATCCNSY","N-Nervous system","MTMOPPMT","Million US$, purchasing power parity","FIN","Finland","2018","2018",344.6,,
+"PATCCNSY","N-Nervous system","MTMOPPMT","Million US$, purchasing power parity","FIN","Finland","2019","2019",365.4,,
+"PATCCNSY","N-Nervous system","MTMOPPMT","Million US$, purchasing power parity","FIN","Finland","2020","2020",389.3,,
+"PATCCNSY","N-Nervous system","MTMOPPMT","Million US$, purchasing power parity","FIN","Finland","2021","2021",478.9,,
+"PATCCNSY","N-Nervous system","TCPPERMT","/capita, US$ exchange rate","FIN","Finland","2010","2010",85,,
+"PATCCNSY","N-Nervous system","TCPPERMT","/capita, US$ exchange rate","FIN","Finland","2011","2011",91.4,,
+"PATCCNSY","N-Nervous system","TCPPERMT","/capita, US$ exchange rate","FIN","Finland","2012","2012",83.2,,
+"PATCCNSY","N-Nervous system","TCPPERMT","/capita, US$ exchange rate","FIN","Finland","2013","2013",83.3,,
+"PATCCNSY","N-Nervous system","TCPPERMT","/capita, US$ exchange rate","FIN","Finland","2014","2014",81.6,,
+"PATCCNSY","N-Nervous system","TCPPERMT","/capita, US$ exchange rate","FIN","Finland","2015","2015",64.8,,
+"PATCCNSY","N-Nervous system","TCPPERMT","/capita, US$ exchange rate","FIN","Finland","2016","2016",61.8,,
+"PATCCNSY","N-Nervous system","TCPPERMT","/capita, US$ exchange rate","FIN","Finland","2017","2017",61,,
+"PATCCNSY","N-Nervous system","TCPPERMT","/capita, US$ exchange rate","FIN","Finland","2018","2018",63,,
+"PATCCNSY","N-Nervous system","TCPPERMT","/capita, US$ exchange rate","FIN","Finland","2019","2019",62.1,,
+"PATCCNSY","N-Nervous system","TCPPERMT","/capita, US$ exchange rate","FIN","Finland","2020","2020",66.2,,
+"PATCCNSY","N-Nervous system","TCPPERMT","/capita, US$ exchange rate","FIN","Finland","2021","2021",84.5,,
+"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2010","2010",71.2,,
+"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2011","2011",73.1,,
+"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2012","2012",71.3,,
+"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2013","2013",69.3,,
+"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2014","2014",67.7,,
+"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2015","2015",64.3,,
+"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2016","2016",63.4,,
+"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2017","2017",62.5,,
+"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2018","2018",62.5,,
+"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2019","2019",66.2,,
+"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2020","2020",70.4,,
+"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2021","2021",86.4,,
+"PATCCNSY","N-Nervous system","ATCPTTMT","% of total sales","FIN","Finland","2010","2010",18.3,,
+"PATCCNSY","N-Nervous system","ATCPTTMT","% of total sales","FIN","Finland","2011","2011",18.4,,
+"PATCCNSY","N-Nervous system","ATCPTTMT","% of total sales","FIN","Finland","2012","2012",17.8,,
+"PATCCNSY","N-Nervous system","ATCPTTMT","% of total sales","FIN","Finland","2013","2013",17,,
+"PATCCNSY","N-Nervous system","ATCPTTMT","% of total sales","FIN","Finland","2014","2014",16,,
+"PATCCNSY","N-Nervous system","ATCPTTMT","% of total sales","FIN","Finland","2015","2015",14.5,,
+"PATCCNSY","N-Nervous system","ATCPTTMT","% of total sales","FIN","Finland","2016","2016",13.4,,
+"PATCCNSY","N-Nervous system","ATCPTTMT","% of total sales","FIN","Finland","2017","2017",12.8,,
+"PATCCNSY","N-Nervous system","ATCPTTMT","% of total sales","FIN","Finland","2018","2018",11.8,,
+"PATCCNSY","N-Nervous system","ATCPTTMT","% of total sales","FIN","Finland","2019","2019",11.5,,
+"PATCCNSY","N-Nervous system","ATCPTTMT","% of total sales","FIN","Finland","2020","2020",11.9,,
+"PATCCNSY","N-Nervous system","ATCPTTMT","% of total sales","FIN","Finland","2021","2021",13.9,,
+"PATCCNSY","N-Nervous system","MLLNCUMT","Million of national currency units","FRA","France","2011","2011",3898.9,,
+"PATCCNSY","N-Nervous system","MTMOTCMT","Million US$ at exchange rate","FRA","France","2011","2011",5427.1,,
+"PATCCNSY","N-Nervous system","MTMOPPMT","Million US$, purchasing power parity","FRA","France","2011","2011",4634,,
+"PATCCNSY","N-Nervous system","TCPPERMT","/capita, US$ exchange rate","FRA","France","2011","2011",83.3,,
+"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","FRA","France","2011","2011",71.2,,
+"PATCCNSY","N-Nervous system","ATCPTTMT","% of total sales","FRA","France","2011","2011",14.1,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","MLLNCUMT","Million of national currency units","DEU","Germany","2010","2010",5688.1,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","MLLNCUMT","Million of national currency units","DEU","Germany","2011","2011",5679.2,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","MLLNCUMT","Million of national currency units","DEU","Germany","2012","2012",5439.9,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","MLLNCUMT","Million of national currency units","DEU","Germany","2013","2013",5380.2,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","MLLNCUMT","Million of national currency units","DEU","Germany","2014","2014",5672.9,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","MLLNCUMT","Million of national currency units","DEU","Germany","2015","2015",5401.9,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","MLLNCUMT","Million of national currency units","DEU","Germany","2016","2016",5260.4,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","MLLNCUMT","Million of national currency units","DEU","Germany","2017","2017",5004.2,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","MLLNCUMT","Million of national currency units","DEU","Germany","2018","2018",5091.8,"B; D","Break; Difference in methodology"
+"PATCCNSY","N-Nervous system","MLLNCUMT","Million of national currency units","DEU","Germany","2019","2019",5267.2,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","MLLNCUMT","Million of national currency units","DEU","Germany","2020","2020",5384.5,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","MLLNCUMT","Million of national currency units","DEU","Germany","2021","2021",5731.7,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","MTMOTCMT","Million US$ at exchange rate","DEU","Germany","2010","2010",7540.8,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","MTMOTCMT","Million US$ at exchange rate","DEU","Germany","2011","2011",7905.2,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","MTMOTCMT","Million US$ at exchange rate","DEU","Germany","2012","2012",6989.1,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","MTMOTCMT","Million US$ at exchange rate","DEU","Germany","2013","2013",7145.5,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","MTMOTCMT","Million US$ at exchange rate","DEU","Germany","2014","2014",7536.5,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","MTMOTCMT","Million US$ at exchange rate","DEU","Germany","2015","2015",5993.5,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","MTMOTCMT","Million US$ at exchange rate","DEU","Germany","2016","2016",5822.8,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","MTMOTCMT","Million US$ at exchange rate","DEU","Germany","2017","2017",5653.1,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","MTMOTCMT","Million US$ at exchange rate","DEU","Germany","2018","2018",6013.2,"B; D","Break; Difference in methodology"
+"PATCCNSY","N-Nervous system","MTMOTCMT","Million US$ at exchange rate","DEU","Germany","2019","2019",5896.5,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","MTMOTCMT","Million US$ at exchange rate","DEU","Germany","2020","2020",6150.2,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","MTMOTCMT","Million US$ at exchange rate","DEU","Germany","2021","2021",6779.1,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","MTMOPPMT","Million US$, purchasing power parity","DEU","Germany","2010","2010",7065.3,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","MTMOPPMT","Million US$, purchasing power parity","DEU","Germany","2011","2011",7200.4,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","MTMOPPMT","Million US$, purchasing power parity","DEU","Germany","2012","2012",6910,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","MTMOPPMT","Million US$, purchasing power parity","DEU","Germany","2013","2013",6944.1,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","MTMOPPMT","Million US$, purchasing power parity","DEU","Germany","2014","2014",7377.6,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","MTMOPPMT","Million US$, purchasing power parity","DEU","Germany","2015","2015",6942.2,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","MTMOPPMT","Million US$, purchasing power parity","DEU","Germany","2016","2016",6989.6,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","MTMOPPMT","Million US$, purchasing power parity","DEU","Germany","2017","2017",6719,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","MTMOPPMT","Million US$, purchasing power parity","DEU","Germany","2018","2018",6923.4,"B; D","Break; Difference in methodology"
+"PATCCNSY","N-Nervous system","MTMOPPMT","Million US$, purchasing power parity","DEU","Germany","2019","2019",7232.7,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","MTMOPPMT","Million US$, purchasing power parity","DEU","Germany","2020","2020",7426.9,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","MTMOPPMT","Million US$, purchasing power parity","DEU","Germany","2021","2021",7784.7,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","TCPPERMT","/capita, US$ exchange rate","DEU","Germany","2010","2010",92.2,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","TCPPERMT","/capita, US$ exchange rate","DEU","Germany","2011","2011",98.5,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","TCPPERMT","/capita, US$ exchange rate","DEU","Germany","2012","2012",86.9,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","TCPPERMT","/capita, US$ exchange rate","DEU","Germany","2013","2013",88.6,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","TCPPERMT","/capita, US$ exchange rate","DEU","Germany","2014","2014",93.1,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","TCPPERMT","/capita, US$ exchange rate","DEU","Germany","2015","2015",73.4,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","TCPPERMT","/capita, US$ exchange rate","DEU","Germany","2016","2016",70.7,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","TCPPERMT","/capita, US$ exchange rate","DEU","Germany","2017","2017",68.4,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","TCPPERMT","/capita, US$ exchange rate","DEU","Germany","2018","2018",72.5,"B; D","Break; Difference in methodology"
+"PATCCNSY","N-Nervous system","TCPPERMT","/capita, US$ exchange rate","DEU","Germany","2019","2019",71,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","TCPPERMT","/capita, US$ exchange rate","DEU","Germany","2020","2020",74,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","TCPPERMT","/capita, US$ exchange rate","DEU","Germany","2021","2021",81.5,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2010","2010",86.4,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2011","2011",89.7,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2012","2012",85.9,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2013","2013",86.1,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2014","2014",91.1,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2015","2015",85,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2016","2016",84.9,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2017","2017",81.3,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2018","2018",83.5,"B; D","Break; Difference in methodology"
+"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2019","2019",87,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2020","2020",89.3,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2021","2021",93.6,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","ATCPTTMT","% of total sales","DEU","Germany","2010","2010",19.1,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","ATCPTTMT","% of total sales","DEU","Germany","2011","2011",19.1,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","ATCPTTMT","% of total sales","DEU","Germany","2012","2012",17.9,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","ATCPTTMT","% of total sales","DEU","Germany","2013","2013",17.1,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","ATCPTTMT","% of total sales","DEU","Germany","2014","2014",16.9,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","ATCPTTMT","% of total sales","DEU","Germany","2015","2015",15.3,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","ATCPTTMT","% of total sales","DEU","Germany","2016","2016",14.6,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","ATCPTTMT","% of total sales","DEU","Germany","2017","2017",13.5,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","ATCPTTMT","% of total sales","DEU","Germany","2018","2018",11.5,"B; D","Break; Difference in methodology"
+"PATCCNSY","N-Nervous system","ATCPTTMT","% of total sales","DEU","Germany","2019","2019",11.2,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","ATCPTTMT","% of total sales","DEU","Germany","2020","2020",11,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","ATCPTTMT","% of total sales","DEU","Germany","2021","2021",10.8,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","MLLNCUMT","Million of national currency units","GRC","Greece","2010","2010",1043.9,,
+"PATCCNSY","N-Nervous system","MLLNCUMT","Million of national currency units","GRC","Greece","2011","2011",914.1,,
+"PATCCNSY","N-Nervous system","MLLNCUMT","Million of national currency units","GRC","Greece","2012","2012",790,,
+"PATCCNSY","N-Nervous system","MLLNCUMT","Million of national currency units","GRC","Greece","2013","2013",706.8,,
+"PATCCNSY","N-Nervous system","MLLNCUMT","Million of national currency units","GRC","Greece","2014","2014",665.2,,
+"PATCCNSY","N-Nervous system","MLLNCUMT","Million of national currency units","GRC","Greece","2015","2015",564.5,,
+"PATCCNSY","N-Nervous system","MLLNCUMT","Million of national currency units","GRC","Greece","2016","2016",680.3,,
+"PATCCNSY","N-Nervous system","MLLNCUMT","Million of national currency units","GRC","Greece","2017","2017",647,,
+"PATCCNSY","N-Nervous system","MLLNCUMT","Million of national currency units","GRC","Greece","2018","2018",671.2,,
+"PATCCNSY","N-Nervous system","MLLNCUMT","Million of national currency units","GRC","Greece","2019","2019",692.3,,
+"PATCCNSY","N-Nervous system","MLLNCUMT","Million of national currency units","GRC","Greece","2020","2020",663.7,,
+"PATCCNSY","N-Nervous system","MLLNCUMT","Million of national currency units","GRC","Greece","2021","2021",670.4,,
+"PATCCNSY","N-Nervous system","MLLNCUMT","Million of national currency units","GRC","Greece","2022","2022",546.8,,
+"PATCCNSY","N-Nervous system","MTMOTCMT","Million US$ at exchange rate","GRC","Greece","2010","2010",1383.9,,
+"PATCCNSY","N-Nervous system","MTMOTCMT","Million US$ at exchange rate","GRC","Greece","2011","2011",1272.3,,
+"PATCCNSY","N-Nervous system","MTMOTCMT","Million US$ at exchange rate","GRC","Greece","2012","2012",1015,,
+"PATCCNSY","N-Nervous system","MTMOTCMT","Million US$ at exchange rate","GRC","Greece","2013","2013",938.7,,
+"PATCCNSY","N-Nervous system","MTMOTCMT","Million US$ at exchange rate","GRC","Greece","2014","2014",883.7,,
+"PATCCNSY","N-Nervous system","MTMOTCMT","Million US$ at exchange rate","GRC","Greece","2015","2015",626.3,,
+"PATCCNSY","N-Nervous system","MTMOTCMT","Million US$ at exchange rate","GRC","Greece","2016","2016",753,,
+"PATCCNSY","N-Nervous system","MTMOTCMT","Million US$ at exchange rate","GRC","Greece","2017","2017",730.9,,
+"PATCCNSY","N-Nervous system","MTMOTCMT","Million US$ at exchange rate","GRC","Greece","2018","2018",792.6,,
+"PATCCNSY","N-Nervous system","MTMOTCMT","Million US$ at exchange rate","GRC","Greece","2019","2019",775,,
+"PATCCNSY","N-Nervous system","MTMOTCMT","Million US$ at exchange rate","GRC","Greece","2020","2020",758.1,,
+"PATCCNSY","N-Nervous system","MTMOTCMT","Million US$ at exchange rate","GRC","Greece","2021","2021",792.9,,
+"PATCCNSY","N-Nervous system","MTMOTCMT","Million US$ at exchange rate","GRC","Greece","2022","2022",575.8,,
+"PATCCNSY","N-Nervous system","MTMOPPMT","Million US$, purchasing power parity","GRC","Greece","2010","2010",1445.8,,
+"PATCCNSY","N-Nervous system","MTMOPPMT","Million US$, purchasing power parity","GRC","Greece","2011","2011",1281.7,,
+"PATCCNSY","N-Nervous system","MTMOPPMT","Million US$, purchasing power parity","GRC","Greece","2012","2012",1153.9,,
+"PATCCNSY","N-Nervous system","MTMOPPMT","Million US$, purchasing power parity","GRC","Greece","2013","2013",1119.6,,
+"PATCCNSY","N-Nervous system","MTMOPPMT","Million US$, purchasing power parity","GRC","Greece","2014","2014",1088.5,,
+"PATCCNSY","N-Nervous system","MTMOPPMT","Million US$, purchasing power parity","GRC","Greece","2015","2015",926.8,,
+"PATCCNSY","N-Nervous system","MTMOPPMT","Million US$, purchasing power parity","GRC","Greece","2016","2016",1155.8,,
+"PATCCNSY","N-Nervous system","MTMOPPMT","Million US$, purchasing power parity","GRC","Greece","2017","2017",1125.1,,
+"PATCCNSY","N-Nervous system","MTMOPPMT","Million US$, purchasing power parity","GRC","Greece","2018","2018",1188.2,,
+"PATCCNSY","N-Nervous system","MTMOPPMT","Million US$, purchasing power parity","GRC","Greece","2019","2019",1261.3,,
+"PATCCNSY","N-Nervous system","MTMOPPMT","Million US$, purchasing power parity","GRC","Greece","2020","2020",1219.9,,
+"PATCCNSY","N-Nervous system","MTMOPPMT","Million US$, purchasing power parity","GRC","Greece","2021","2021",1228.8,,
+"PATCCNSY","N-Nervous system","MTMOPPMT","Million US$, purchasing power parity","GRC","Greece","2022","2022",1034.6,,
+"PATCCNSY","N-Nervous system","TCPPERMT","/capita, US$ exchange rate","GRC","Greece","2010","2010",124.4,,
+"PATCCNSY","N-Nervous system","TCPPERMT","/capita, US$ exchange rate","GRC","Greece","2011","2011",114.6,,
+"PATCCNSY","N-Nervous system","TCPPERMT","/capita, US$ exchange rate","GRC","Greece","2012","2012",91.9,,
+"PATCCNSY","N-Nervous system","TCPPERMT","/capita, US$ exchange rate","GRC","Greece","2013","2013",85.6,,
+"PATCCNSY","N-Nervous system","TCPPERMT","/capita, US$ exchange rate","GRC","Greece","2014","2014",81.1,,
+"PATCCNSY","N-Nervous system","TCPPERMT","/capita, US$ exchange rate","GRC","Greece","2015","2015",57.9,,
+"PATCCNSY","N-Nervous system","TCPPERMT","/capita, US$ exchange rate","GRC","Greece","2016","2016",69.9,,
+"PATCCNSY","N-Nervous system","TCPPERMT","/capita, US$ exchange rate","GRC","Greece","2017","2017",68,,
+"PATCCNSY","N-Nervous system","TCPPERMT","/capita, US$ exchange rate","GRC","Greece","2018","2018",73.9,,
+"PATCCNSY","N-Nervous system","TCPPERMT","/capita, US$ exchange rate","GRC","Greece","2019","2019",72.3,,
+"PATCCNSY","N-Nervous system","TCPPERMT","/capita, US$ exchange rate","GRC","Greece","2020","2020",70.9,,
+"PATCCNSY","N-Nervous system","TCPPERMT","/capita, US$ exchange rate","GRC","Greece","2021","2021",75,,
+"PATCCNSY","N-Nervous system","TCPPERMT","/capita, US$ exchange rate","GRC","Greece","2022","2022",55,,
+"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2010","2010",130,,
+"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2011","2011",115.4,,
+"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2012","2012",104.5,,
+"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2013","2013",102.1,,
+"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2014","2014",99.9,,
+"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2015","2015",85.7,,
+"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2016","2016",107.3,,
+"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2017","2017",104.6,,
+"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2018","2018",110.7,,
+"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2019","2019",117.6,,
+"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2020","2020",114,,
+"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2021","2021",116.3,,
+"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2022","2022",98.9,,
+"PATCCNSY","N-Nervous system","MLLNCUMT","Million of national currency units","HUN","Hungary","2010","2010",62105.9,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","MLLNCUMT","Million of national currency units","HUN","Hungary","2011","2011",64409,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","MLLNCUMT","Million of national currency units","HUN","Hungary","2012","2012",58615.1,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","MLLNCUMT","Million of national currency units","HUN","Hungary","2013","2013",58867.3,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","MLLNCUMT","Million of national currency units","HUN","Hungary","2014","2014",59797.2,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","MLLNCUMT","Million of national currency units","HUN","Hungary","2015","2015",60933.7,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","MLLNCUMT","Million of national currency units","HUN","Hungary","2016","2016",59756.4,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","MLLNCUMT","Million of national currency units","HUN","Hungary","2017","2017",59790.5,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","MLLNCUMT","Million of national currency units","HUN","Hungary","2018","2018",60008.8,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","MLLNCUMT","Million of national currency units","HUN","Hungary","2019","2019",60953,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","MLLNCUMT","Million of national currency units","HUN","Hungary","2020","2020",60723.8,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","MLLNCUMT","Million of national currency units","HUN","Hungary","2021","2021",59597.1,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","MLLNCUMT","Million of national currency units","HUN","Hungary","2022","2022",53713.3,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","MTMOTCMT","Million US$ at exchange rate","HUN","Hungary","2010","2010",298.7,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","MTMOTCMT","Million US$ at exchange rate","HUN","Hungary","2011","2011",320.4,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","MTMOTCMT","Million US$ at exchange rate","HUN","Hungary","2012","2012",260.4,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","MTMOTCMT","Million US$ at exchange rate","HUN","Hungary","2013","2013",263.2,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","MTMOTCMT","Million US$ at exchange rate","HUN","Hungary","2014","2014",257.1,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","MTMOTCMT","Million US$ at exchange rate","HUN","Hungary","2015","2015",218.1,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","MTMOTCMT","Million US$ at exchange rate","HUN","Hungary","2016","2016",212.3,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","MTMOTCMT","Million US$ at exchange rate","HUN","Hungary","2017","2017",217.9,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","MTMOTCMT","Million US$ at exchange rate","HUN","Hungary","2018","2018",222.1,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","MTMOTCMT","Million US$ at exchange rate","HUN","Hungary","2019","2019",209.7,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","MTMOTCMT","Million US$ at exchange rate","HUN","Hungary","2020","2020",197.2,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","MTMOTCMT","Million US$ at exchange rate","HUN","Hungary","2021","2021",196.6,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","MTMOTCMT","Million US$ at exchange rate","HUN","Hungary","2022","2022",144.2,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","MTMOPPMT","Million US$, purchasing power parity","HUN","Hungary","2010","2010",491.3,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","MTMOPPMT","Million US$, purchasing power parity","HUN","Hungary","2011","2011",518.3,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","MTMOPPMT","Million US$, purchasing power parity","HUN","Hungary","2012","2012",466.6,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","MTMOPPMT","Million US$, purchasing power parity","HUN","Hungary","2013","2013",471,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","MTMOPPMT","Million US$, purchasing power parity","HUN","Hungary","2014","2014",462.1,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","MTMOPPMT","Million US$, purchasing power parity","HUN","Hungary","2015","2015",459.7,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","MTMOPPMT","Million US$, purchasing power parity","HUN","Hungary","2016","2016",452.6,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","MTMOPPMT","Million US$, purchasing power parity","HUN","Hungary","2017","2017",439.5,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","MTMOPPMT","Million US$, purchasing power parity","HUN","Hungary","2018","2018",431.4,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","MTMOPPMT","Million US$, purchasing power parity","HUN","Hungary","2019","2019",432.8,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","MTMOPPMT","Million US$, purchasing power parity","HUN","Hungary","2020","2020",417.8,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","MTMOPPMT","Million US$, purchasing power parity","HUN","Hungary","2021","2021",385.1,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","MTMOPPMT","Million US$, purchasing power parity","HUN","Hungary","2022","2022",333.1,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","TCPPERMT","/capita, US$ exchange rate","HUN","Hungary","2010","2010",29.9,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","TCPPERMT","/capita, US$ exchange rate","HUN","Hungary","2011","2011",32.1,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","TCPPERMT","/capita, US$ exchange rate","HUN","Hungary","2012","2012",26.2,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","TCPPERMT","/capita, US$ exchange rate","HUN","Hungary","2013","2013",26.6,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","TCPPERMT","/capita, US$ exchange rate","HUN","Hungary","2014","2014",26.1,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","TCPPERMT","/capita, US$ exchange rate","HUN","Hungary","2015","2015",22.2,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","TCPPERMT","/capita, US$ exchange rate","HUN","Hungary","2016","2016",21.6,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","TCPPERMT","/capita, US$ exchange rate","HUN","Hungary","2017","2017",22.3,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","TCPPERMT","/capita, US$ exchange rate","HUN","Hungary","2018","2018",22.7,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","TCPPERMT","/capita, US$ exchange rate","HUN","Hungary","2019","2019",21.5,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","TCPPERMT","/capita, US$ exchange rate","HUN","Hungary","2020","2020",20.2,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","TCPPERMT","/capita, US$ exchange rate","HUN","Hungary","2021","2021",20.2,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","TCPPERMT","/capita, US$ exchange rate","HUN","Hungary","2022","2022",14.9,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2010","2010",49.1,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2011","2011",52,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2012","2012",47,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2013","2013",47.6,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2014","2014",46.8,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2015","2015",46.7,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2016","2016",46.1,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2017","2017",44.9,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2018","2018",44.1,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2019","2019",44.3,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2020","2020",42.8,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2021","2021",39.7,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2022","2022",34.4,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","ATCPTTMT","% of total sales","HUN","Hungary","2010","2010",12.5,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","ATCPTTMT","% of total sales","HUN","Hungary","2011","2011",12.5,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","ATCPTTMT","% of total sales","HUN","Hungary","2012","2012",13.2,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","ATCPTTMT","% of total sales","HUN","Hungary","2013","2013",13.7,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","ATCPTTMT","% of total sales","HUN","Hungary","2014","2014",13.5,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","ATCPTTMT","% of total sales","HUN","Hungary","2015","2015",13.1,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","ATCPTTMT","% of total sales","HUN","Hungary","2016","2016",12,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","ATCPTTMT","% of total sales","HUN","Hungary","2017","2017",12.1,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","ATCPTTMT","% of total sales","HUN","Hungary","2018","2018",12,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","ATCPTTMT","% of total sales","HUN","Hungary","2019","2019",11.6,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","ATCPTTMT","% of total sales","HUN","Hungary","2020","2020",10.9,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","ATCPTTMT","% of total sales","HUN","Hungary","2021","2021",10.5,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","ATCPTTMT","% of total sales","HUN","Hungary","2022","2022",9,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","MLLNCUMT","Million of national currency units","ISL","Iceland","2010","2010",6783.8,,
+"PATCCNSY","N-Nervous system","MLLNCUMT","Million of national currency units","ISL","Iceland","2011","2011",5703.4,,
+"PATCCNSY","N-Nervous system","MLLNCUMT","Million of national currency units","ISL","Iceland","2012","2012",5666.6,,
+"PATCCNSY","N-Nervous system","MLLNCUMT","Million of national currency units","ISL","Iceland","2013","2013",6429.3,,
+"PATCCNSY","N-Nervous system","MLLNCUMT","Million of national currency units","ISL","Iceland","2014","2014",5314.4,,
+"PATCCNSY","N-Nervous system","MLLNCUMT","Million of national currency units","ISL","Iceland","2015","2015",5341.2,,
+"PATCCNSY","N-Nervous system","MLLNCUMT","Million of national currency units","ISL","Iceland","2016","2016",5561.3,,
+"PATCCNSY","N-Nervous system","MLLNCUMT","Million of national currency units","ISL","Iceland","2017","2017",5265,,
+"PATCCNSY","N-Nervous system","MLLNCUMT","Million of national currency units","ISL","Iceland","2018","2018",5364.9,,
+"PATCCNSY","N-Nervous system","MLLNCUMT","Million of national currency units","ISL","Iceland","2019","2019",5953.4,,
+"PATCCNSY","N-Nervous system","MLLNCUMT","Million of national currency units","ISL","Iceland","2020","2020",7013.7,,
+"PATCCNSY","N-Nervous system","MLLNCUMT","Million of national currency units","ISL","Iceland","2021","2021",7969.3,,
+"PATCCNSY","N-Nervous system","MTMOTCMT","Million US$ at exchange rate","ISL","Iceland","2010","2010",55.5,,
+"PATCCNSY","N-Nervous system","MTMOTCMT","Million US$ at exchange rate","ISL","Iceland","2011","2011",49.2,,
+"PATCCNSY","N-Nervous system","MTMOTCMT","Million US$ at exchange rate","ISL","Iceland","2012","2012",45.3,,
+"PATCCNSY","N-Nervous system","MTMOTCMT","Million US$ at exchange rate","ISL","Iceland","2013","2013",52.6,,
+"PATCCNSY","N-Nervous system","MTMOTCMT","Million US$ at exchange rate","ISL","Iceland","2014","2014",45.5,,
+"PATCCNSY","N-Nervous system","MTMOTCMT","Million US$ at exchange rate","ISL","Iceland","2015","2015",40.5,,
+"PATCCNSY","N-Nervous system","MTMOTCMT","Million US$ at exchange rate","ISL","Iceland","2016","2016",46,,
+"PATCCNSY","N-Nervous system","MTMOTCMT","Million US$ at exchange rate","ISL","Iceland","2017","2017",49.3,,
+"PATCCNSY","N-Nervous system","MTMOTCMT","Million US$ at exchange rate","ISL","Iceland","2018","2018",49.5,,
+"PATCCNSY","N-Nervous system","MTMOTCMT","Million US$ at exchange rate","ISL","Iceland","2019","2019",48.6,,
+"PATCCNSY","N-Nervous system","MTMOTCMT","Million US$ at exchange rate","ISL","Iceland","2020","2020",51.8,,
+"PATCCNSY","N-Nervous system","MTMOTCMT","Million US$ at exchange rate","ISL","Iceland","2021","2021",62.8,,
+"PATCCNSY","N-Nervous system","MTMOPPMT","Million US$, purchasing power parity","ISL","Iceland","2010","2010",51,,
+"PATCCNSY","N-Nervous system","MTMOPPMT","Million US$, purchasing power parity","ISL","Iceland","2011","2011",42.2,,
+"PATCCNSY","N-Nervous system","MTMOPPMT","Million US$, purchasing power parity","ISL","Iceland","2012","2012",41.4,,
+"PATCCNSY","N-Nervous system","MTMOPPMT","Million US$, purchasing power parity","ISL","Iceland","2013","2013",46.9,,
+"PATCCNSY","N-Nervous system","MTMOPPMT","Million US$, purchasing power parity","ISL","Iceland","2014","2014",38.4,,
+"PATCCNSY","N-Nervous system","MTMOPPMT","Million US$, purchasing power parity","ISL","Iceland","2015","2015",37.6,,
+"PATCCNSY","N-Nervous system","MTMOPPMT","Million US$, purchasing power parity","ISL","Iceland","2016","2016",39.7,,
+"PATCCNSY","N-Nervous system","MTMOPPMT","Million US$, purchasing power parity","ISL","Iceland","2017","2017",38.1,,
+"PATCCNSY","N-Nervous system","MTMOPPMT","Million US$, purchasing power parity","ISL","Iceland","2018","2018",38.1,,
+"PATCCNSY","N-Nervous system","MTMOPPMT","Million US$, purchasing power parity","ISL","Iceland","2019","2019",42.3,,
+"PATCCNSY","N-Nervous system","MTMOPPMT","Million US$, purchasing power parity","ISL","Iceland","2020","2020",47.8,,
+"PATCCNSY","N-Nervous system","MTMOPPMT","Million US$, purchasing power parity","ISL","Iceland","2021","2021",53.2,,
+"PATCCNSY","N-Nervous system","TCPPERMT","/capita, US$ exchange rate","ISL","Iceland","2010","2010",174.5,,
+"PATCCNSY","N-Nervous system","TCPPERMT","/capita, US$ exchange rate","ISL","Iceland","2011","2011",154.2,,
+"PATCCNSY","N-Nervous system","TCPPERMT","/capita, US$ exchange rate","ISL","Iceland","2012","2012",141.3,,
+"PATCCNSY","N-Nervous system","TCPPERMT","/capita, US$ exchange rate","ISL","Iceland","2013","2013",162.5,,
+"PATCCNSY","N-Nervous system","TCPPERMT","/capita, US$ exchange rate","ISL","Iceland","2014","2014",139,,
+"PATCCNSY","N-Nervous system","TCPPERMT","/capita, US$ exchange rate","ISL","Iceland","2015","2015",122.4,,
+"PATCCNSY","N-Nervous system","TCPPERMT","/capita, US$ exchange rate","ISL","Iceland","2016","2016",137.2,,
+"PATCCNSY","N-Nervous system","TCPPERMT","/capita, US$ exchange rate","ISL","Iceland","2017","2017",143.5,,
+"PATCCNSY","N-Nervous system","TCPPERMT","/capita, US$ exchange rate","ISL","Iceland","2018","2018",140.4,,
+"PATCCNSY","N-Nervous system","TCPPERMT","/capita, US$ exchange rate","ISL","Iceland","2019","2019",134.7,,
+"PATCCNSY","N-Nervous system","TCPPERMT","/capita, US$ exchange rate","ISL","Iceland","2020","2020",141.3,,
+"PATCCNSY","N-Nervous system","TCPPERMT","/capita, US$ exchange rate","ISL","Iceland","2021","2021",168.5,,
+"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2010","2010",160.5,,
+"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2011","2011",132.3,,
+"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2012","2012",129,,
+"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2013","2013",144.9,,
+"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2014","2014",117.2,,
+"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2015","2015",113.7,,
+"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2016","2016",118.4,,
+"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2017","2017",110.9,,
+"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2018","2018",107.9,,
+"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2019","2019",117.4,,
+"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2020","2020",130.5,,
+"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2021","2021",142.9,,
+"PATCCNSY","N-Nervous system","ATCPTTMT","% of total sales","ISL","Iceland","2010","2010",27.1,,
+"PATCCNSY","N-Nervous system","ATCPTTMT","% of total sales","ISL","Iceland","2011","2011",21.9,,
+"PATCCNSY","N-Nervous system","ATCPTTMT","% of total sales","ISL","Iceland","2012","2012",23.3,,
+"PATCCNSY","N-Nervous system","ATCPTTMT","% of total sales","ISL","Iceland","2013","2013",24.7,,
+"PATCCNSY","N-Nervous system","ATCPTTMT","% of total sales","ISL","Iceland","2014","2014",22.4,,
+"PATCCNSY","N-Nervous system","ATCPTTMT","% of total sales","ISL","Iceland","2015","2015",21.9,,
+"PATCCNSY","N-Nervous system","ATCPTTMT","% of total sales","ISL","Iceland","2016","2016",21.9,,
+"PATCCNSY","N-Nervous system","ATCPTTMT","% of total sales","ISL","Iceland","2017","2017",19.9,,
+"PATCCNSY","N-Nervous system","ATCPTTMT","% of total sales","ISL","Iceland","2018","2018",17.8,,
+"PATCCNSY","N-Nervous system","ATCPTTMT","% of total sales","ISL","Iceland","2019","2019",17.7,,
+"PATCCNSY","N-Nervous system","ATCPTTMT","% of total sales","ISL","Iceland","2020","2020",17.6,,
+"PATCCNSY","N-Nervous system","ATCPTTMT","% of total sales","ISL","Iceland","2021","2021",17.7,,
+"PATCCNSY","N-Nervous system","MLLNCUMT","Million of national currency units","IRL","Ireland","2010","2010",345.2,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","MLLNCUMT","Million of national currency units","IRL","Ireland","2011","2011",358.3,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","MLLNCUMT","Million of national currency units","IRL","Ireland","2012","2012",387.9,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","MLLNCUMT","Million of national currency units","IRL","Ireland","2013","2013",357.7,"B; D","Break; Difference in methodology"
+"PATCCNSY","N-Nervous system","MLLNCUMT","Million of national currency units","IRL","Ireland","2014","2014",352.3,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","MLLNCUMT","Million of national currency units","IRL","Ireland","2015","2015",349.3,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","MLLNCUMT","Million of national currency units","IRL","Ireland","2016","2016",338.8,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","MLLNCUMT","Million of national currency units","IRL","Ireland","2017","2017",311.2,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","MLLNCUMT","Million of national currency units","IRL","Ireland","2018","2018",288.1,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","MLLNCUMT","Million of national currency units","IRL","Ireland","2019","2019",280,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","MLLNCUMT","Million of national currency units","IRL","Ireland","2020","2020",278,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","MLLNCUMT","Million of national currency units","IRL","Ireland","2021","2021",279.8,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","MTMOTCMT","Million US$ at exchange rate","IRL","Ireland","2010","2010",457.6,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","MTMOTCMT","Million US$ at exchange rate","IRL","Ireland","2011","2011",498.7,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","MTMOTCMT","Million US$ at exchange rate","IRL","Ireland","2012","2012",498.4,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","MTMOTCMT","Million US$ at exchange rate","IRL","Ireland","2013","2013",475.1,"B; D","Break; Difference in methodology"
+"PATCCNSY","N-Nervous system","MTMOTCMT","Million US$ at exchange rate","IRL","Ireland","2014","2014",468.1,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","MTMOTCMT","Million US$ at exchange rate","IRL","Ireland","2015","2015",387.5,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","MTMOTCMT","Million US$ at exchange rate","IRL","Ireland","2016","2016",375,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","MTMOTCMT","Million US$ at exchange rate","IRL","Ireland","2017","2017",351.6,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","MTMOTCMT","Million US$ at exchange rate","IRL","Ireland","2018","2018",340.3,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","MTMOTCMT","Million US$ at exchange rate","IRL","Ireland","2019","2019",313.4,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","MTMOTCMT","Million US$ at exchange rate","IRL","Ireland","2020","2020",317.5,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","MTMOTCMT","Million US$ at exchange rate","IRL","Ireland","2021","2021",330.9,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","MTMOPPMT","Million US$, purchasing power parity","IRL","Ireland","2010","2010",406.3,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","MTMOPPMT","Million US$, purchasing power parity","IRL","Ireland","2011","2011",430.9,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","MTMOPPMT","Million US$, purchasing power parity","IRL","Ireland","2012","2012",471.3,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","MTMOPPMT","Million US$, purchasing power parity","IRL","Ireland","2013","2013",441,"B; D","Break; Difference in methodology"
+"PATCCNSY","N-Nervous system","MTMOPPMT","Million US$, purchasing power parity","IRL","Ireland","2014","2014",430.2,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","MTMOPPMT","Million US$, purchasing power parity","IRL","Ireland","2015","2015",431.4,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","MTMOPPMT","Million US$, purchasing power parity","IRL","Ireland","2016","2016",426.5,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","MTMOPPMT","Million US$, purchasing power parity","IRL","Ireland","2017","2017",391.8,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","MTMOPPMT","Million US$, purchasing power parity","IRL","Ireland","2018","2018",363.7,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","MTMOPPMT","Million US$, purchasing power parity","IRL","Ireland","2019","2019",347.4,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","MTMOPPMT","Million US$, purchasing power parity","IRL","Ireland","2020","2020",349.2,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","MTMOPPMT","Million US$, purchasing power parity","IRL","Ireland","2021","2021",352.1,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","TCPPERMT","/capita, US$ exchange rate","IRL","Ireland","2010","2010",100.4,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","TCPPERMT","/capita, US$ exchange rate","IRL","Ireland","2011","2011",108.9,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","TCPPERMT","/capita, US$ exchange rate","IRL","Ireland","2012","2012",108.4,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","TCPPERMT","/capita, US$ exchange rate","IRL","Ireland","2013","2013",102.8,"B; D","Break; Difference in methodology"
+"PATCCNSY","N-Nervous system","TCPPERMT","/capita, US$ exchange rate","IRL","Ireland","2014","2014",100.5,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","TCPPERMT","/capita, US$ exchange rate","IRL","Ireland","2015","2015",82.4,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","TCPPERMT","/capita, US$ exchange rate","IRL","Ireland","2016","2016",78.9,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","TCPPERMT","/capita, US$ exchange rate","IRL","Ireland","2017","2017",73.1,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","TCPPERMT","/capita, US$ exchange rate","IRL","Ireland","2018","2018",69.9,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","TCPPERMT","/capita, US$ exchange rate","IRL","Ireland","2019","2019",63.5,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","TCPPERMT","/capita, US$ exchange rate","IRL","Ireland","2020","2020",63.7,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","TCPPERMT","/capita, US$ exchange rate","IRL","Ireland","2021","2021",65.8,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2010","2010",89.1,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2011","2011",94.1,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2012","2012",102.5,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2013","2013",95.4,"B; D","Break; Difference in methodology"
+"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2014","2014",92.4,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2015","2015",91.7,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2016","2016",89.7,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2017","2017",81.5,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2018","2018",74.7,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2019","2019",70.4,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2020","2020",70,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2021","2021",70,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","ATCPTTMT","% of total sales","IRL","Ireland","2010","2010",16.8,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","ATCPTTMT","% of total sales","IRL","Ireland","2011","2011",18.3,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","ATCPTTMT","% of total sales","IRL","Ireland","2012","2012",19,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","ATCPTTMT","% of total sales","IRL","Ireland","2013","2013",18.3,"B; D","Break; Difference in methodology"
+"PATCCNSY","N-Nervous system","ATCPTTMT","% of total sales","IRL","Ireland","2014","2014",18.4,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","ATCPTTMT","% of total sales","IRL","Ireland","2015","2015",17.6,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","ATCPTTMT","% of total sales","IRL","Ireland","2016","2016",16.3,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","ATCPTTMT","% of total sales","IRL","Ireland","2017","2017",14.7,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","ATCPTTMT","% of total sales","IRL","Ireland","2018","2018",12.7,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","ATCPTTMT","% of total sales","IRL","Ireland","2019","2019",11.6,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","ATCPTTMT","% of total sales","IRL","Ireland","2020","2020",11.3,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","ATCPTTMT","% of total sales","IRL","Ireland","2021","2021",10.7,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","MLLNCUMT","Million of national currency units","ITA","Italy","2011","2011",1995.7,,
+"PATCCNSY","N-Nervous system","MLLNCUMT","Million of national currency units","ITA","Italy","2012","2012",1936.9,,
+"PATCCNSY","N-Nervous system","MLLNCUMT","Million of national currency units","ITA","Italy","2013","2013",1897.9,,
+"PATCCNSY","N-Nervous system","MLLNCUMT","Million of national currency units","ITA","Italy","2014","2014",1881.8,,
+"PATCCNSY","N-Nervous system","MLLNCUMT","Million of national currency units","ITA","Italy","2015","2015",1902,,
+"PATCCNSY","N-Nervous system","MLLNCUMT","Million of national currency units","ITA","Italy","2016","2016",1807.4,,
+"PATCCNSY","N-Nervous system","MLLNCUMT","Million of national currency units","ITA","Italy","2017","2017",1787.6,,
+"PATCCNSY","N-Nervous system","MLLNCUMT","Million of national currency units","ITA","Italy","2018","2018",1793.8,,
+"PATCCNSY","N-Nervous system","MLLNCUMT","Million of national currency units","ITA","Italy","2019","2019",1852.7,,
+"PATCCNSY","N-Nervous system","MLLNCUMT","Million of national currency units","ITA","Italy","2020","2020",1888,,
+"PATCCNSY","N-Nervous system","MLLNCUMT","Million of national currency units","ITA","Italy","2021","2021",1918.5,,
+"PATCCNSY","N-Nervous system","MLLNCUMT","Million of national currency units","ITA","Italy","2022","2022",1990.7,"E","Estimated value"
+"PATCCNSY","N-Nervous system","MTMOTCMT","Million US$ at exchange rate","ITA","Italy","2011","2011",2778,,
+"PATCCNSY","N-Nervous system","MTMOTCMT","Million US$ at exchange rate","ITA","Italy","2012","2012",2488.5,,
+"PATCCNSY","N-Nervous system","MTMOTCMT","Million US$ at exchange rate","ITA","Italy","2013","2013",2520.6,,
+"PATCCNSY","N-Nervous system","MTMOTCMT","Million US$ at exchange rate","ITA","Italy","2014","2014",2499.9,,
+"PATCCNSY","N-Nervous system","MTMOTCMT","Million US$ at exchange rate","ITA","Italy","2015","2015",2110.3,,
+"PATCCNSY","N-Nervous system","MTMOTCMT","Million US$ at exchange rate","ITA","Italy","2016","2016",2000.6,,
+"PATCCNSY","N-Nervous system","MTMOTCMT","Million US$ at exchange rate","ITA","Italy","2017","2017",2019.4,,
+"PATCCNSY","N-Nervous system","MTMOTCMT","Million US$ at exchange rate","ITA","Italy","2018","2018",2118.4,,
+"PATCCNSY","N-Nervous system","MTMOTCMT","Million US$ at exchange rate","ITA","Italy","2019","2019",2074.1,,
+"PATCCNSY","N-Nervous system","MTMOTCMT","Million US$ at exchange rate","ITA","Italy","2020","2020",2156.4,,
+"PATCCNSY","N-Nervous system","MTMOTCMT","Million US$ at exchange rate","ITA","Italy","2021","2021",2269.1,,
+"PATCCNSY","N-Nervous system","MTMOTCMT","Million US$ at exchange rate","ITA","Italy","2022","2022",2096.3,"E","Estimated value"
+"PATCCNSY","N-Nervous system","MTMOPPMT","Million US$, purchasing power parity","ITA","Italy","2011","2011",2630.5,,
+"PATCCNSY","N-Nervous system","MTMOPPMT","Million US$, purchasing power parity","ITA","Italy","2012","2012",2590.3,,
+"PATCCNSY","N-Nervous system","MTMOPPMT","Million US$, purchasing power parity","ITA","Italy","2013","2013",2574.1,,
+"PATCCNSY","N-Nervous system","MTMOPPMT","Million US$, purchasing power parity","ITA","Italy","2014","2014",2544.1,,
+"PATCCNSY","N-Nervous system","MTMOPPMT","Million US$, purchasing power parity","ITA","Italy","2015","2015",2574.8,,
+"PATCCNSY","N-Nervous system","MTMOPPMT","Million US$, purchasing power parity","ITA","Italy","2016","2016",2579.9,,
+"PATCCNSY","N-Nervous system","MTMOPPMT","Million US$, purchasing power parity","ITA","Italy","2017","2017",2591.1,,
+"PATCCNSY","N-Nervous system","MTMOPPMT","Million US$, purchasing power parity","ITA","Italy","2018","2018",2633.3,,
+"PATCCNSY","N-Nervous system","MTMOPPMT","Million US$, purchasing power parity","ITA","Italy","2019","2019",2820.9,,
+"PATCCNSY","N-Nervous system","MTMOPPMT","Million US$, purchasing power parity","ITA","Italy","2020","2020",2914.8,,
+"PATCCNSY","N-Nervous system","MTMOPPMT","Million US$, purchasing power parity","ITA","Italy","2021","2021",2962.8,,
+"PATCCNSY","N-Nervous system","MTMOPPMT","Million US$, purchasing power parity","ITA","Italy","2022","2022",3224.2,"E","Estimated value"
+"PATCCNSY","N-Nervous system","TCPPERMT","/capita, US$ exchange rate","ITA","Italy","2011","2011",46.8,,
+"PATCCNSY","N-Nervous system","TCPPERMT","/capita, US$ exchange rate","ITA","Italy","2012","2012",41.8,,
+"PATCCNSY","N-Nervous system","TCPPERMT","/capita, US$ exchange rate","ITA","Italy","2013","2013",41.8,,
+"PATCCNSY","N-Nervous system","TCPPERMT","/capita, US$ exchange rate","ITA","Italy","2014","2014",41.1,,
+"PATCCNSY","N-Nervous system","TCPPERMT","/capita, US$ exchange rate","ITA","Italy","2015","2015",34.7,,
+"PATCCNSY","N-Nervous system","TCPPERMT","/capita, US$ exchange rate","ITA","Italy","2016","2016",33,,
+"PATCCNSY","N-Nervous system","TCPPERMT","/capita, US$ exchange rate","ITA","Italy","2017","2017",33.4,,
+"PATCCNSY","N-Nervous system","TCPPERMT","/capita, US$ exchange rate","ITA","Italy","2018","2018",35.1,,
+"PATCCNSY","N-Nervous system","TCPPERMT","/capita, US$ exchange rate","ITA","Italy","2019","2019",34.7,,
+"PATCCNSY","N-Nervous system","TCPPERMT","/capita, US$ exchange rate","ITA","Italy","2020","2020",36.3,,
+"PATCCNSY","N-Nervous system","TCPPERMT","/capita, US$ exchange rate","ITA","Italy","2021","2021",38.4,,
+"PATCCNSY","N-Nervous system","TCPPERMT","/capita, US$ exchange rate","ITA","Italy","2022","2022",35.5,"E","Estimated value"
+"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2011","2011",44.3,,
+"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2012","2012",43.5,,
+"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2013","2013",42.7,,
+"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2014","2014",41.9,,
+"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2015","2015",42.4,,
+"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2016","2016",42.6,,
+"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2017","2017",42.8,,
+"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2018","2018",43.6,,
+"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2019","2019",47.2,,
+"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2020","2020",49,,
+"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2021","2021",50.1,,
+"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2022","2022",54.6,"E","Estimated value"
+"PATCCNSY","N-Nervous system","ATCPTTMT","% of total sales","ITA","Italy","2011","2011",10.2,,
+"PATCCNSY","N-Nervous system","ATCPTTMT","% of total sales","ITA","Italy","2012","2012",10.2,,
+"PATCCNSY","N-Nervous system","ATCPTTMT","% of total sales","ITA","Italy","2013","2013",9.8,,
+"PATCCNSY","N-Nervous system","ATCPTTMT","% of total sales","ITA","Italy","2014","2014",9.5,,
+"PATCCNSY","N-Nervous system","ATCPTTMT","% of total sales","ITA","Italy","2015","2015",8.4,,
+"PATCCNSY","N-Nervous system","ATCPTTMT","% of total sales","ITA","Italy","2016","2016",7.9,,
+"PATCCNSY","N-Nervous system","ATCPTTMT","% of total sales","ITA","Italy","2017","2017",7.9,,
+"PATCCNSY","N-Nervous system","ATCPTTMT","% of total sales","ITA","Italy","2018","2018",8,,
+"PATCCNSY","N-Nervous system","ATCPTTMT","% of total sales","ITA","Italy","2019","2019",8.1,,
+"PATCCNSY","N-Nervous system","ATCPTTMT","% of total sales","ITA","Italy","2020","2020",8.2,,
+"PATCCNSY","N-Nervous system","ATCPTTMT","% of total sales","ITA","Italy","2021","2021",8,,
+"PATCCNSY","N-Nervous system","ATCPTTMT","% of total sales","ITA","Italy","2022","2022",8,"E","Estimated value"
+"PATCCNSY","N-Nervous system","MLLNCUMT","Million of national currency units","JPN","Japan","2010","2010",812255,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","MLLNCUMT","Million of national currency units","JPN","Japan","2011","2011",890011,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","MLLNCUMT","Million of national currency units","JPN","Japan","2012","2012",884343,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","MLLNCUMT","Million of national currency units","JPN","Japan","2013","2013",830706,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","MLLNCUMT","Million of national currency units","JPN","Japan","2014","2014",821393,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","MLLNCUMT","Million of national currency units","JPN","Japan","2015","2015",814267,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","MLLNCUMT","Million of national currency units","JPN","Japan","2016","2016",830000,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","MLLNCUMT","Million of national currency units","JPN","Japan","2017","2017",779318,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","MLLNCUMT","Million of national currency units","JPN","Japan","2018","2018",806949,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","MLLNCUMT","Million of national currency units","JPN","Japan","2019","2019",1151962,"B; D","Break; Difference in methodology"
+"PATCCNSY","N-Nervous system","MLLNCUMT","Million of national currency units","JPN","Japan","2020","2020",1086297,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","MLLNCUMT","Million of national currency units","JPN","Japan","2021","2021",971269,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","MTMOTCMT","Million US$ at exchange rate","JPN","Japan","2010","2010",9253.3,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","MTMOTCMT","Million US$ at exchange rate","JPN","Japan","2011","2011",11152,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","MTMOTCMT","Million US$ at exchange rate","JPN","Japan","2012","2012",11083.3,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","MTMOTCMT","Million US$ at exchange rate","JPN","Japan","2013","2013",8511.7,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","MTMOTCMT","Million US$ at exchange rate","JPN","Japan","2014","2014",7753,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","MTMOTCMT","Million US$ at exchange rate","JPN","Japan","2015","2015",6727,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","MTMOTCMT","Million US$ at exchange rate","JPN","Japan","2016","2016",7629.2,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","MTMOTCMT","Million US$ at exchange rate","JPN","Japan","2017","2017",6947.9,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","MTMOTCMT","Million US$ at exchange rate","JPN","Japan","2018","2018",7307.8,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","MTMOTCMT","Million US$ at exchange rate","JPN","Japan","2019","2019",10567.5,"B; D","Break; Difference in methodology"
+"PATCCNSY","N-Nervous system","MTMOTCMT","Million US$ at exchange rate","JPN","Japan","2020","2020",10173.7,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","MTMOTCMT","Million US$ at exchange rate","JPN","Japan","2021","2021",8849.5,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","MTMOPPMT","Million US$, purchasing power parity","JPN","Japan","2010","2010",7271.1,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","MTMOPPMT","Million US$, purchasing power parity","JPN","Japan","2011","2011",8282.7,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","MTMOPPMT","Million US$, purchasing power parity","JPN","Japan","2012","2012",8481,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","MTMOPPMT","Million US$, purchasing power parity","JPN","Japan","2013","2013",8200.2,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","MTMOPPMT","Million US$, purchasing power parity","JPN","Japan","2014","2014",7970.7,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","MTMOPPMT","Million US$, purchasing power parity","JPN","Japan","2015","2015",7869.6,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","MTMOPPMT","Million US$, purchasing power parity","JPN","Japan","2016","2016",7865.8,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","MTMOPPMT","Million US$, purchasing power parity","JPN","Japan","2017","2017",7414.9,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","MTMOPPMT","Million US$, purchasing power parity","JPN","Japan","2018","2018",7747.3,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","MTMOPPMT","Million US$, purchasing power parity","JPN","Japan","2019","2019",11052.5,"B; D","Break; Difference in methodology"
+"PATCCNSY","N-Nervous system","MTMOPPMT","Million US$, purchasing power parity","JPN","Japan","2020","2020",10605.5,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","MTMOPPMT","Million US$, purchasing power parity","JPN","Japan","2021","2021",9517.6,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","TCPPERMT","/capita, US$ exchange rate","JPN","Japan","2010","2010",72.3,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","TCPPERMT","/capita, US$ exchange rate","JPN","Japan","2011","2011",87.2,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","TCPPERMT","/capita, US$ exchange rate","JPN","Japan","2012","2012",86.9,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","TCPPERMT","/capita, US$ exchange rate","JPN","Japan","2013","2013",66.8,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","TCPPERMT","/capita, US$ exchange rate","JPN","Japan","2014","2014",60.9,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","TCPPERMT","/capita, US$ exchange rate","JPN","Japan","2015","2015",52.9,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","TCPPERMT","/capita, US$ exchange rate","JPN","Japan","2016","2016",60.1,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","TCPPERMT","/capita, US$ exchange rate","JPN","Japan","2017","2017",54.8,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","TCPPERMT","/capita, US$ exchange rate","JPN","Japan","2018","2018",57.8,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","TCPPERMT","/capita, US$ exchange rate","JPN","Japan","2019","2019",83.8,"B; D","Break; Difference in methodology"
+"PATCCNSY","N-Nervous system","TCPPERMT","/capita, US$ exchange rate","JPN","Japan","2020","2020",80.7,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","TCPPERMT","/capita, US$ exchange rate","JPN","Japan","2021","2021",70.5,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","JPN","Japan","2010","2010",56.8,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","JPN","Japan","2011","2011",64.8,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","JPN","Japan","2012","2012",66.5,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","JPN","Japan","2013","2013",64.4,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","JPN","Japan","2014","2014",62.6,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","JPN","Japan","2015","2015",61.9,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","JPN","Japan","2016","2016",62,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","JPN","Japan","2017","2017",58.5,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","JPN","Japan","2018","2018",61.3,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","JPN","Japan","2019","2019",87.6,"B; D","Break; Difference in methodology"
+"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","JPN","Japan","2020","2020",84.1,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","JPN","Japan","2021","2021",75.8,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","ATCPTTMT","% of total sales","JPN","Japan","2010","2010",12,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","ATCPTTMT","% of total sales","JPN","Japan","2011","2011",12.7,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","ATCPTTMT","% of total sales","JPN","Japan","2012","2012",12.7,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","ATCPTTMT","% of total sales","JPN","Japan","2013","2013",12,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","ATCPTTMT","% of total sales","JPN","Japan","2014","2014",12.5,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","ATCPTTMT","% of total sales","JPN","Japan","2015","2015",12.1,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","ATCPTTMT","% of total sales","JPN","Japan","2016","2016",12.5,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","ATCPTTMT","% of total sales","JPN","Japan","2017","2017",11.6,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","ATCPTTMT","% of total sales","JPN","Japan","2018","2018",11.7,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","ATCPTTMT","% of total sales","JPN","Japan","2019","2019",12.1,"B; D","Break; Difference in methodology"
+"PATCCNSY","N-Nervous system","ATCPTTMT","% of total sales","JPN","Japan","2020","2020",11.7,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","ATCPTTMT","% of total sales","JPN","Japan","2021","2021",10.6,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","MLLNCUMT","Million of national currency units","KOR","Korea","2010","2010",1551504,,
+"PATCCNSY","N-Nervous system","MLLNCUMT","Million of national currency units","KOR","Korea","2011","2011",1818155.8,"B","Break"
+"PATCCNSY","N-Nervous system","MLLNCUMT","Million of national currency units","KOR","Korea","2012","2012",1787843.7,,
+"PATCCNSY","N-Nervous system","MLLNCUMT","Million of national currency units","KOR","Korea","2013","2013",1891529.7,,
+"PATCCNSY","N-Nervous system","MLLNCUMT","Million of national currency units","KOR","Korea","2014","2014",2006379.4,,
+"PATCCNSY","N-Nervous system","MLLNCUMT","Million of national currency units","KOR","Korea","2015","2015",2123722.8,,
+"PATCCNSY","N-Nervous system","MLLNCUMT","Million of national currency units","KOR","Korea","2016","2016",2089238.2,"B","Break"
+"PATCCNSY","N-Nervous system","MLLNCUMT","Million of national currency units","KOR","Korea","2017","2017",2269880.5,,
+"PATCCNSY","N-Nervous system","MLLNCUMT","Million of national currency units","KOR","Korea","2018","2018",2464267.3,,
+"PATCCNSY","N-Nervous system","MLLNCUMT","Million of national currency units","KOR","Korea","2019","2019",2711705.5,,
+"PATCCNSY","N-Nervous system","MLLNCUMT","Million of national currency units","KOR","Korea","2020","2020",3009813.8,,
+"PATCCNSY","N-Nervous system","MLLNCUMT","Million of national currency units","KOR","Korea","2021","2021",3272920.3,,
+"PATCCNSY","N-Nervous system","MTMOTCMT","Million US$ at exchange rate","KOR","Korea","2010","2010",1341.6,,
+"PATCCNSY","N-Nervous system","MTMOTCMT","Million US$ at exchange rate","KOR","Korea","2011","2011",1640.6,"B","Break"
+"PATCCNSY","N-Nervous system","MTMOTCMT","Million US$ at exchange rate","KOR","Korea","2012","2012",1586.6,,
+"PATCCNSY","N-Nervous system","MTMOTCMT","Million US$ at exchange rate","KOR","Korea","2013","2013",1727.5,,
+"PATCCNSY","N-Nervous system","MTMOTCMT","Million US$ at exchange rate","KOR","Korea","2014","2014",1905.7,,
+"PATCCNSY","N-Nervous system","MTMOTCMT","Million US$ at exchange rate","KOR","Korea","2015","2015",1877.8,,
+"PATCCNSY","N-Nervous system","MTMOTCMT","Million US$ at exchange rate","KOR","Korea","2016","2016",1799.9,"B","Break"
+"PATCCNSY","N-Nervous system","MTMOTCMT","Million US$ at exchange rate","KOR","Korea","2017","2017",2007,,
+"PATCCNSY","N-Nervous system","MTMOTCMT","Million US$ at exchange rate","KOR","Korea","2018","2018",2239.9,,
+"PATCCNSY","N-Nervous system","MTMOTCMT","Million US$ at exchange rate","KOR","Korea","2019","2019",2326.9,,
+"PATCCNSY","N-Nervous system","MTMOTCMT","Million US$ at exchange rate","KOR","Korea","2020","2020",2550.1,,
+"PATCCNSY","N-Nervous system","MTMOTCMT","Million US$ at exchange rate","KOR","Korea","2021","2021",2861.1,,
+"PATCCNSY","N-Nervous system","MTMOPPMT","Million US$, purchasing power parity","KOR","Korea","2010","2010",1844.9,,
+"PATCCNSY","N-Nervous system","MTMOPPMT","Million US$, purchasing power parity","KOR","Korea","2011","2011",2127.5,"B","Break"
+"PATCCNSY","N-Nervous system","MTMOPPMT","Million US$, purchasing power parity","KOR","Korea","2012","2012",2091.3,,
+"PATCCNSY","N-Nervous system","MTMOPPMT","Million US$, purchasing power parity","KOR","Korea","2013","2013",2176.5,,
+"PATCCNSY","N-Nervous system","MTMOPPMT","Million US$, purchasing power parity","KOR","Korea","2014","2014",2301.2,,
+"PATCCNSY","N-Nervous system","MTMOPPMT","Million US$, purchasing power parity","KOR","Korea","2015","2015",2476.7,,
+"PATCCNSY","N-Nervous system","MTMOPPMT","Million US$, purchasing power parity","KOR","Korea","2016","2016",2432.7,"B","Break"
+"PATCCNSY","N-Nervous system","MTMOPPMT","Million US$, purchasing power parity","KOR","Korea","2017","2017",2601.2,,
+"PATCCNSY","N-Nervous system","MTMOPPMT","Million US$, purchasing power parity","KOR","Korea","2018","2018",2882.6,,
+"PATCCNSY","N-Nervous system","MTMOPPMT","Million US$, purchasing power parity","KOR","Korea","2019","2019",3166.3,,
+"PATCCNSY","N-Nervous system","MTMOPPMT","Million US$, purchasing power parity","KOR","Korea","2020","2020",3593.1,,
+"PATCCNSY","N-Nervous system","MTMOPPMT","Million US$, purchasing power parity","KOR","Korea","2021","2021",3832,,
+"PATCCNSY","N-Nervous system","TCPPERMT","/capita, US$ exchange rate","KOR","Korea","2010","2010",27.1,,
+"PATCCNSY","N-Nervous system","TCPPERMT","/capita, US$ exchange rate","KOR","Korea","2011","2011",32.9,"B","Break"
+"PATCCNSY","N-Nervous system","TCPPERMT","/capita, US$ exchange rate","KOR","Korea","2012","2012",31.6,,
+"PATCCNSY","N-Nervous system","TCPPERMT","/capita, US$ exchange rate","KOR","Korea","2013","2013",34.3,,
+"PATCCNSY","N-Nervous system","TCPPERMT","/capita, US$ exchange rate","KOR","Korea","2014","2014",37.6,,
+"PATCCNSY","N-Nervous system","TCPPERMT","/capita, US$ exchange rate","KOR","Korea","2015","2015",36.8,,
+"PATCCNSY","N-Nervous system","TCPPERMT","/capita, US$ exchange rate","KOR","Korea","2016","2016",35.1,"B","Break"
+"PATCCNSY","N-Nervous system","TCPPERMT","/capita, US$ exchange rate","KOR","Korea","2017","2017",39.1,,
+"PATCCNSY","N-Nervous system","TCPPERMT","/capita, US$ exchange rate","KOR","Korea","2018","2018",43.4,,
+"PATCCNSY","N-Nervous system","TCPPERMT","/capita, US$ exchange rate","KOR","Korea","2019","2019",45,,
+"PATCCNSY","N-Nervous system","TCPPERMT","/capita, US$ exchange rate","KOR","Korea","2020","2020",49.2,,
+"PATCCNSY","N-Nervous system","TCPPERMT","/capita, US$ exchange rate","KOR","Korea","2021","2021",55.3,,
+"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2010","2010",37.2,,
+"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2011","2011",42.6,"B","Break"
+"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2012","2012",41.7,,
+"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2013","2013",43.2,,
+"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2014","2014",45.3,,
+"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2015","2015",48.5,,
+"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2016","2016",47.5,"B","Break"
+"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2017","2017",50.6,,
+"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2018","2018",55.9,,
+"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2019","2019",61.2,,
+"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2020","2020",69.3,,
+"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2021","2021",74.1,,
+"PATCCNSY","N-Nervous system","ATCPTTMT","% of total sales","KOR","Korea","2010","2010",7.6,,
+"PATCCNSY","N-Nervous system","ATCPTTMT","% of total sales","KOR","Korea","2011","2011",8.2,"B","Break"
+"PATCCNSY","N-Nervous system","ATCPTTMT","% of total sales","KOR","Korea","2012","2012",8.2,,
+"PATCCNSY","N-Nervous system","ATCPTTMT","% of total sales","KOR","Korea","2013","2013",8.4,,
+"PATCCNSY","N-Nervous system","ATCPTTMT","% of total sales","KOR","Korea","2014","2014",8.5,,
+"PATCCNSY","N-Nervous system","ATCPTTMT","% of total sales","KOR","Korea","2015","2015",8.6,,
+"PATCCNSY","N-Nervous system","ATCPTTMT","% of total sales","KOR","Korea","2016","2016",8.2,"B","Break"
+"PATCCNSY","N-Nervous system","ATCPTTMT","% of total sales","KOR","Korea","2017","2017",8.4,,
+"PATCCNSY","N-Nervous system","ATCPTTMT","% of total sales","KOR","Korea","2018","2018",8.5,,
+"PATCCNSY","N-Nervous system","ATCPTTMT","% of total sales","KOR","Korea","2019","2019",8.7,,
+"PATCCNSY","N-Nervous system","ATCPTTMT","% of total sales","KOR","Korea","2020","2020",9.3,,
+"PATCCNSY","N-Nervous system","ATCPTTMT","% of total sales","KOR","Korea","2021","2021",9.4,,
+"PATCCNSY","N-Nervous system","MLLNCUMT","Million of national currency units","LUX","Luxembourg","2010","2010",32.7,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","MLLNCUMT","Million of national currency units","LUX","Luxembourg","2011","2011",33.5,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","MLLNCUMT","Million of national currency units","LUX","Luxembourg","2012","2012",32.9,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","MLLNCUMT","Million of national currency units","LUX","Luxembourg","2013","2013",31.7,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","MLLNCUMT","Million of national currency units","LUX","Luxembourg","2014","2014",31.8,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","MLLNCUMT","Million of national currency units","LUX","Luxembourg","2015","2015",33.2,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","MLLNCUMT","Million of national currency units","LUX","Luxembourg","2016","2016",31.8,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","MLLNCUMT","Million of national currency units","LUX","Luxembourg","2017","2017",31.5,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","MLLNCUMT","Million of national currency units","LUX","Luxembourg","2018","2018",31.9,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","MLLNCUMT","Million of national currency units","LUX","Luxembourg","2019","2019",32.9,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","MLLNCUMT","Million of national currency units","LUX","Luxembourg","2020","2020",33.8,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","MLLNCUMT","Million of national currency units","LUX","Luxembourg","2021","2021",35.7,"B; D; P","Break; Difference in methodology; Provisional value"
+"PATCCNSY","N-Nervous system","MLLNCUMT","Million of national currency units","LUX","Luxembourg","2022","2022",36.1,"D; P","Difference in methodology; Provisional value"
+"PATCCNSY","N-Nervous system","MTMOTCMT","Million US$ at exchange rate","LUX","Luxembourg","2010","2010",43.4,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","MTMOTCMT","Million US$ at exchange rate","LUX","Luxembourg","2011","2011",46.6,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","MTMOTCMT","Million US$ at exchange rate","LUX","Luxembourg","2012","2012",42.2,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","MTMOTCMT","Million US$ at exchange rate","LUX","Luxembourg","2013","2013",42,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","MTMOTCMT","Million US$ at exchange rate","LUX","Luxembourg","2014","2014",42.3,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","MTMOTCMT","Million US$ at exchange rate","LUX","Luxembourg","2015","2015",36.8,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","MTMOTCMT","Million US$ at exchange rate","LUX","Luxembourg","2016","2016",35.2,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","MTMOTCMT","Million US$ at exchange rate","LUX","Luxembourg","2017","2017",35.6,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","MTMOTCMT","Million US$ at exchange rate","LUX","Luxembourg","2018","2018",37.6,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","MTMOTCMT","Million US$ at exchange rate","LUX","Luxembourg","2019","2019",36.9,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","MTMOTCMT","Million US$ at exchange rate","LUX","Luxembourg","2020","2020",38.6,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","MTMOTCMT","Million US$ at exchange rate","LUX","Luxembourg","2021","2021",42.3,"B; D; P","Break; Difference in methodology; Provisional value"
+"PATCCNSY","N-Nervous system","MTMOTCMT","Million US$ at exchange rate","LUX","Luxembourg","2022","2022",38.1,"D; P","Difference in methodology; Provisional value"
+"PATCCNSY","N-Nervous system","MTMOPPMT","Million US$, purchasing power parity","LUX","Luxembourg","2010","2010",35.3,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","MTMOPPMT","Million US$, purchasing power parity","LUX","Luxembourg","2011","2011",37,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","MTMOPPMT","Million US$, purchasing power parity","LUX","Luxembourg","2012","2012",36.2,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","MTMOPPMT","Million US$, purchasing power parity","LUX","Luxembourg","2013","2013",35.4,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","MTMOPPMT","Million US$, purchasing power parity","LUX","Luxembourg","2014","2014",36,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","MTMOPPMT","Million US$, purchasing power parity","LUX","Luxembourg","2015","2015",37.7,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","MTMOPPMT","Million US$, purchasing power parity","LUX","Luxembourg","2016","2016",37.3,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","MTMOPPMT","Million US$, purchasing power parity","LUX","Luxembourg","2017","2017",37.2,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","MTMOPPMT","Million US$, purchasing power parity","LUX","Luxembourg","2018","2018",37.5,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","MTMOPPMT","Million US$, purchasing power parity","LUX","Luxembourg","2019","2019",39.1,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","MTMOPPMT","Million US$, purchasing power parity","LUX","Luxembourg","2020","2020",39.5,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","MTMOPPMT","Million US$, purchasing power parity","LUX","Luxembourg","2021","2021",41.6,"B; D; P","Break; Difference in methodology; Provisional value"
+"PATCCNSY","N-Nervous system","MTMOPPMT","Million US$, purchasing power parity","LUX","Luxembourg","2022","2022",43.5,"D; P","Difference in methodology; Provisional value"
+"PATCCNSY","N-Nervous system","TCPPERMT","/capita, US$ exchange rate","LUX","Luxembourg","2010","2010",91.7,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","TCPPERMT","/capita, US$ exchange rate","LUX","Luxembourg","2011","2011",96.8,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","TCPPERMT","/capita, US$ exchange rate","LUX","Luxembourg","2012","2012",85.7,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","TCPPERMT","/capita, US$ exchange rate","LUX","Luxembourg","2013","2013",83.7,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","TCPPERMT","/capita, US$ exchange rate","LUX","Luxembourg","2014","2014",82.8,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","TCPPERMT","/capita, US$ exchange rate","LUX","Luxembourg","2015","2015",71.1,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","TCPPERMT","/capita, US$ exchange rate","LUX","Luxembourg","2016","2016",66.8,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","TCPPERMT","/capita, US$ exchange rate","LUX","Luxembourg","2017","2017",66.4,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","TCPPERMT","/capita, US$ exchange rate","LUX","Luxembourg","2018","2018",69,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","TCPPERMT","/capita, US$ exchange rate","LUX","Luxembourg","2019","2019",66.2,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","TCPPERMT","/capita, US$ exchange rate","LUX","Luxembourg","2020","2020",68.1,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","TCPPERMT","/capita, US$ exchange rate","LUX","Luxembourg","2021","2021",73.5,"B; D; P","Break; Difference in methodology; Provisional value"
+"PATCCNSY","N-Nervous system","TCPPERMT","/capita, US$ exchange rate","LUX","Luxembourg","2022","2022",64.9,"D; P","Difference in methodology; Provisional value"
+"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2010","2010",74.7,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2011","2011",76.8,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2012","2012",73.6,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2013","2013",70.4,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2014","2014",70.5,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2015","2015",72.7,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2016","2016",70.9,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2017","2017",69.3,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2018","2018",68.8,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2019","2019",70.3,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2020","2020",69.6,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2021","2021",72.3,"B; D; P","Break; Difference in methodology; Provisional value"
+"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2022","2022",74.1,"D; P","Difference in methodology; Provisional value"
+"PATCCNSY","N-Nervous system","ATCPTTMT","% of total sales","LUX","Luxembourg","2010","2010",17.3,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","ATCPTTMT","% of total sales","LUX","Luxembourg","2011","2011",17.6,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","ATCPTTMT","% of total sales","LUX","Luxembourg","2012","2012",16.8,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","ATCPTTMT","% of total sales","LUX","Luxembourg","2013","2013",16.2,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","ATCPTTMT","% of total sales","LUX","Luxembourg","2014","2014",16.6,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","ATCPTTMT","% of total sales","LUX","Luxembourg","2015","2015",17.2,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","ATCPTTMT","% of total sales","LUX","Luxembourg","2016","2016",16.3,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","ATCPTTMT","% of total sales","LUX","Luxembourg","2017","2017",16.2,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","ATCPTTMT","% of total sales","LUX","Luxembourg","2018","2018",16,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","ATCPTTMT","% of total sales","LUX","Luxembourg","2019","2019",16.1,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","ATCPTTMT","% of total sales","LUX","Luxembourg","2020","2020",16.2,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","ATCPTTMT","% of total sales","LUX","Luxembourg","2021","2021",14.9,"B; D; P","Break; Difference in methodology; Provisional value"
+"PATCCNSY","N-Nervous system","ATCPTTMT","% of total sales","LUX","Luxembourg","2022","2022",14,"D; P","Difference in methodology; Provisional value"
+"PATCCNSY","N-Nervous system","MLLNCUMT","Million of national currency units","MEX","Mexico","2010","2010",14077,,
+"PATCCNSY","N-Nervous system","MLLNCUMT","Million of national currency units","MEX","Mexico","2011","2011",12584,,
+"PATCCNSY","N-Nervous system","MLLNCUMT","Million of national currency units","MEX","Mexico","2012","2012",12804,,
+"PATCCNSY","N-Nervous system","MLLNCUMT","Million of national currency units","MEX","Mexico","2013","2013",13836,,
+"PATCCNSY","N-Nervous system","MLLNCUMT","Million of national currency units","MEX","Mexico","2014","2014",14128,,
+"PATCCNSY","N-Nervous system","MLLNCUMT","Million of national currency units","MEX","Mexico","2015","2015",14984,,
+"PATCCNSY","N-Nervous system","MLLNCUMT","Million of national currency units","MEX","Mexico","2016","2016",15668,,
+"PATCCNSY","N-Nervous system","MLLNCUMT","Million of national currency units","MEX","Mexico","2017","2017",16565,,
+"PATCCNSY","N-Nervous system","MLLNCUMT","Million of national currency units","MEX","Mexico","2018","2018",15443,,
+"PATCCNSY","N-Nervous system","MLLNCUMT","Million of national currency units","MEX","Mexico","2019","2019",17275.3,,
+"PATCCNSY","N-Nervous system","MLLNCUMT","Million of national currency units","MEX","Mexico","2020","2020",18357.5,,
+"PATCCNSY","N-Nervous system","MLLNCUMT","Million of national currency units","MEX","Mexico","2021","2021",18875.3,,
+"PATCCNSY","N-Nervous system","MLLNCUMT","Million of national currency units","MEX","Mexico","2022","2022",20539.3,"E","Estimated value"
+"PATCCNSY","N-Nervous system","MTMOTCMT","Million US$ at exchange rate","MEX","Mexico","2010","2010",1114,,
+"PATCCNSY","N-Nervous system","MTMOTCMT","Million US$ at exchange rate","MEX","Mexico","2011","2011",1012.9,,
+"PATCCNSY","N-Nervous system","MTMOTCMT","Million US$ at exchange rate","MEX","Mexico","2012","2012",972.2,,
+"PATCCNSY","N-Nervous system","MTMOTCMT","Million US$ at exchange rate","MEX","Mexico","2013","2013",1083.3,,
+"PATCCNSY","N-Nervous system","MTMOTCMT","Million US$ at exchange rate","MEX","Mexico","2014","2014",1062.9,,
+"PATCCNSY","N-Nervous system","MTMOTCMT","Million US$ at exchange rate","MEX","Mexico","2015","2015",945.5,,
+"PATCCNSY","N-Nervous system","MTMOTCMT","Million US$ at exchange rate","MEX","Mexico","2016","2016",839.5,,
+"PATCCNSY","N-Nervous system","MTMOTCMT","Million US$ at exchange rate","MEX","Mexico","2017","2017",875.2,,
+"PATCCNSY","N-Nervous system","MTMOTCMT","Million US$ at exchange rate","MEX","Mexico","2018","2018",802.5,,
+"PATCCNSY","N-Nervous system","MTMOTCMT","Million US$ at exchange rate","MEX","Mexico","2019","2019",896.8,,
+"PATCCNSY","N-Nervous system","MTMOTCMT","Million US$ at exchange rate","MEX","Mexico","2020","2020",854.4,,
+"PATCCNSY","N-Nervous system","MTMOTCMT","Million US$ at exchange rate","MEX","Mexico","2021","2021",931.1,,
+"PATCCNSY","N-Nervous system","MTMOTCMT","Million US$ at exchange rate","MEX","Mexico","2022","2022",1020.5,"E","Estimated value"
+"PATCCNSY","N-Nervous system","MTMOPPMT","Million US$, purchasing power parity","MEX","Mexico","2010","2010",1833,,
+"PATCCNSY","N-Nervous system","MTMOPPMT","Million US$, purchasing power parity","MEX","Mexico","2011","2011",1640,,
+"PATCCNSY","N-Nervous system","MTMOPPMT","Million US$, purchasing power parity","MEX","Mexico","2012","2012",1629.3,,
+"PATCCNSY","N-Nervous system","MTMOPPMT","Million US$, purchasing power parity","MEX","Mexico","2013","2013",1754.9,,
+"PATCCNSY","N-Nervous system","MTMOPPMT","Million US$, purchasing power parity","MEX","Mexico","2014","2014",1756.1,,
+"PATCCNSY","N-Nervous system","MTMOPPMT","Million US$, purchasing power parity","MEX","Mexico","2015","2015",1799.3,,
+"PATCCNSY","N-Nervous system","MTMOPPMT","Million US$, purchasing power parity","MEX","Mexico","2016","2016",1855.1,,
+"PATCCNSY","N-Nervous system","MTMOPPMT","Million US$, purchasing power parity","MEX","Mexico","2017","2017",1858.4,,
+"PATCCNSY","N-Nervous system","MTMOPPMT","Million US$, purchasing power parity","MEX","Mexico","2018","2018",1664.8,,
+"PATCCNSY","N-Nervous system","MTMOPPMT","Million US$, purchasing power parity","MEX","Mexico","2019","2019",1787.7,,
+"PATCCNSY","N-Nervous system","MTMOPPMT","Million US$, purchasing power parity","MEX","Mexico","2020","2020",1828.5,,
+"PATCCNSY","N-Nervous system","MTMOPPMT","Million US$, purchasing power parity","MEX","Mexico","2021","2021",1814.6,,
+"PATCCNSY","N-Nervous system","MTMOPPMT","Million US$, purchasing power parity","MEX","Mexico","2022","2022",1942,"E","Estimated value"
+"PATCCNSY","N-Nervous system","TCPPERMT","/capita, US$ exchange rate","MEX","Mexico","2010","2010",9.8,,
+"PATCCNSY","N-Nervous system","TCPPERMT","/capita, US$ exchange rate","MEX","Mexico","2011","2011",8.8,,
+"PATCCNSY","N-Nervous system","TCPPERMT","/capita, US$ exchange rate","MEX","Mexico","2012","2012",8.3,,
+"PATCCNSY","N-Nervous system","TCPPERMT","/capita, US$ exchange rate","MEX","Mexico","2013","2013",9.1,,
+"PATCCNSY","N-Nervous system","TCPPERMT","/capita, US$ exchange rate","MEX","Mexico","2014","2014",8.9,,
+"PATCCNSY","N-Nervous system","TCPPERMT","/capita, US$ exchange rate","MEX","Mexico","2015","2015",7.8,,
+"PATCCNSY","N-Nervous system","TCPPERMT","/capita, US$ exchange rate","MEX","Mexico","2016","2016",6.8,,
+"PATCCNSY","N-Nervous system","TCPPERMT","/capita, US$ exchange rate","MEX","Mexico","2017","2017",7.1,,
+"PATCCNSY","N-Nervous system","TCPPERMT","/capita, US$ exchange rate","MEX","Mexico","2018","2018",6.4,,
+"PATCCNSY","N-Nervous system","TCPPERMT","/capita, US$ exchange rate","MEX","Mexico","2019","2019",7.1,,
+"PATCCNSY","N-Nervous system","TCPPERMT","/capita, US$ exchange rate","MEX","Mexico","2020","2020",6.7,,
+"PATCCNSY","N-Nervous system","TCPPERMT","/capita, US$ exchange rate","MEX","Mexico","2021","2021",7.2,,
+"PATCCNSY","N-Nervous system","TCPPERMT","/capita, US$ exchange rate","MEX","Mexico","2022","2022",7.8,"E","Estimated value"
+"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","MEX","Mexico","2010","2010",16.1,,
+"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","MEX","Mexico","2011","2011",14.2,,
+"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","MEX","Mexico","2012","2012",13.9,,
+"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","MEX","Mexico","2013","2013",14.8,,
+"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","MEX","Mexico","2014","2014",14.6,,
+"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","MEX","Mexico","2015","2015",14.8,,
+"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","MEX","Mexico","2016","2016",15.1,,
+"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","MEX","Mexico","2017","2017",15,,
+"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","MEX","Mexico","2018","2018",13.3,,
+"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","MEX","Mexico","2019","2019",14.1,,
+"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","MEX","Mexico","2020","2020",14.3,,
+"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","MEX","Mexico","2021","2021",14.1,,
+"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","MEX","Mexico","2022","2022",14.9,"E","Estimated value"
+"PATCCNSY","N-Nervous system","ATCPTTMT","% of total sales","MEX","Mexico","2013","2013",9.8,,
+"PATCCNSY","N-Nervous system","ATCPTTMT","% of total sales","MEX","Mexico","2018","2018",6.8,,
+"PATCCNSY","N-Nervous system","MLLNCUMT","Million of national currency units","NLD","Netherlands","2010","2010",598.6,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","MLLNCUMT","Million of national currency units","NLD","Netherlands","2011","2011",630.2,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","MLLNCUMT","Million of national currency units","NLD","Netherlands","2012","2012",592.9,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","MLLNCUMT","Million of national currency units","NLD","Netherlands","2013","2013",568.2,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","MLLNCUMT","Million of national currency units","NLD","Netherlands","2014","2014",571.7,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","MTMOTCMT","Million US$ at exchange rate","NLD","Netherlands","2010","2010",793.6,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","MTMOTCMT","Million US$ at exchange rate","NLD","Netherlands","2011","2011",877.2,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","MTMOTCMT","Million US$ at exchange rate","NLD","Netherlands","2012","2012",761.8,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","MTMOTCMT","Million US$ at exchange rate","NLD","Netherlands","2013","2013",754.7,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","MTMOTCMT","Million US$ at exchange rate","NLD","Netherlands","2014","2014",759.6,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","MTMOPPMT","Million US$, purchasing power parity","NLD","Netherlands","2010","2010",700.9,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","MTMOPPMT","Million US$, purchasing power parity","NLD","Netherlands","2011","2011",753.8,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","MTMOPPMT","Million US$, purchasing power parity","NLD","Netherlands","2012","2012",719.2,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","MTMOPPMT","Million US$, purchasing power parity","NLD","Netherlands","2013","2013",711.9,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","MTMOPPMT","Million US$, purchasing power parity","NLD","Netherlands","2014","2014",706.9,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","TCPPERMT","/capita, US$ exchange rate","NLD","Netherlands","2010","2010",47.8,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","TCPPERMT","/capita, US$ exchange rate","NLD","Netherlands","2011","2011",52.6,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","TCPPERMT","/capita, US$ exchange rate","NLD","Netherlands","2012","2012",45.5,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","TCPPERMT","/capita, US$ exchange rate","NLD","Netherlands","2013","2013",44.9,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","TCPPERMT","/capita, US$ exchange rate","NLD","Netherlands","2014","2014",45,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","NLD","Netherlands","2010","2010",42.2,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","NLD","Netherlands","2011","2011",45.2,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","NLD","Netherlands","2012","2012",42.9,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","NLD","Netherlands","2013","2013",42.4,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","NLD","Netherlands","2014","2014",41.9,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","ATCPTTMT","% of total sales","NLD","Netherlands","2010","2010",11.5,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","ATCPTTMT","% of total sales","NLD","Netherlands","2011","2011",12.1,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","ATCPTTMT","% of total sales","NLD","Netherlands","2012","2012",12.9,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","ATCPTTMT","% of total sales","NLD","Netherlands","2013","2013",13.2,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","ATCPTTMT","% of total sales","NLD","Netherlands","2014","2014",13.2,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","MLLNCUMT","Million of national currency units","NZL","New Zealand","2010","2010",164.5,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","MLLNCUMT","Million of national currency units","NZL","New Zealand","2011","2011",182.6,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","MLLNCUMT","Million of national currency units","NZL","New Zealand","2012","2012",156.7,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","MLLNCUMT","Million of national currency units","NZL","New Zealand","2013","2013",147.4,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","MLLNCUMT","Million of national currency units","NZL","New Zealand","2014","2014",136,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","MLLNCUMT","Million of national currency units","NZL","New Zealand","2015","2015",167.5,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","MLLNCUMT","Million of national currency units","NZL","New Zealand","2016","2016",171.8,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","MLLNCUMT","Million of national currency units","NZL","New Zealand","2017","2017",167.6,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","MLLNCUMT","Million of national currency units","NZL","New Zealand","2018","2018",174,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","MLLNCUMT","Million of national currency units","NZL","New Zealand","2019","2019",173.3,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","MLLNCUMT","Million of national currency units","NZL","New Zealand","2020","2020",169.6,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","MLLNCUMT","Million of national currency units","NZL","New Zealand","2021","2021",189.4,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","MLLNCUMT","Million of national currency units","NZL","New Zealand","2022","2022",197.9,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","MTMOTCMT","Million US$ at exchange rate","NZL","New Zealand","2010","2010",118.5,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","MTMOTCMT","Million US$ at exchange rate","NZL","New Zealand","2011","2011",144.2,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","MTMOTCMT","Million US$ at exchange rate","NZL","New Zealand","2012","2012",126.9,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","MTMOTCMT","Million US$ at exchange rate","NZL","New Zealand","2013","2013",120.9,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","MTMOTCMT","Million US$ at exchange rate","NZL","New Zealand","2014","2014",112.9,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","MTMOTCMT","Million US$ at exchange rate","NZL","New Zealand","2015","2015",116.8,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","MTMOTCMT","Million US$ at exchange rate","NZL","New Zealand","2016","2016",119.6,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","MTMOTCMT","Million US$ at exchange rate","NZL","New Zealand","2017","2017",119.1,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","MTMOTCMT","Million US$ at exchange rate","NZL","New Zealand","2018","2018",120.4,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","MTMOTCMT","Million US$ at exchange rate","NZL","New Zealand","2019","2019",114.2,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","MTMOTCMT","Million US$ at exchange rate","NZL","New Zealand","2020","2020",110,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","MTMOTCMT","Million US$ at exchange rate","NZL","New Zealand","2021","2021",134,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","MTMOTCMT","Million US$ at exchange rate","NZL","New Zealand","2022","2022",125.5,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","MTMOPPMT","Million US$, purchasing power parity","NZL","New Zealand","2010","2010",109.9,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","MTMOPPMT","Million US$, purchasing power parity","NZL","New Zealand","2011","2011",122.9,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","MTMOPPMT","Million US$, purchasing power parity","NZL","New Zealand","2012","2012",104.8,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","MTMOPPMT","Million US$, purchasing power parity","NZL","New Zealand","2013","2013",101.9,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","MTMOPPMT","Million US$, purchasing power parity","NZL","New Zealand","2014","2014",94.4,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","MTMOPPMT","Million US$, purchasing power parity","NZL","New Zealand","2015","2015",113.4,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","MTMOPPMT","Million US$, purchasing power parity","NZL","New Zealand","2016","2016",119.2,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","MTMOPPMT","Million US$, purchasing power parity","NZL","New Zealand","2017","2017",117.1,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","MTMOPPMT","Million US$, purchasing power parity","NZL","New Zealand","2018","2018",118.4,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","MTMOPPMT","Million US$, purchasing power parity","NZL","New Zealand","2019","2019",122.3,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","MTMOPPMT","Million US$, purchasing power parity","NZL","New Zealand","2020","2020",119.9,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","MTMOPPMT","Million US$, purchasing power parity","NZL","New Zealand","2021","2021",129.8,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","MTMOPPMT","Million US$, purchasing power parity","NZL","New Zealand","2022","2022",137.2,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","TCPPERMT","/capita, US$ exchange rate","NZL","New Zealand","2010","2010",27.2,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","TCPPERMT","/capita, US$ exchange rate","NZL","New Zealand","2011","2011",32.9,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","TCPPERMT","/capita, US$ exchange rate","NZL","New Zealand","2012","2012",28.8,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","TCPPERMT","/capita, US$ exchange rate","NZL","New Zealand","2013","2013",27.2,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","TCPPERMT","/capita, US$ exchange rate","NZL","New Zealand","2014","2014",25,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","TCPPERMT","/capita, US$ exchange rate","NZL","New Zealand","2015","2015",25.3,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","TCPPERMT","/capita, US$ exchange rate","NZL","New Zealand","2016","2016",25.4,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","TCPPERMT","/capita, US$ exchange rate","NZL","New Zealand","2017","2017",24.7,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","TCPPERMT","/capita, US$ exchange rate","NZL","New Zealand","2018","2018",24.6,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","TCPPERMT","/capita, US$ exchange rate","NZL","New Zealand","2019","2019",22.9,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","TCPPERMT","/capita, US$ exchange rate","NZL","New Zealand","2020","2020",21.6,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","TCPPERMT","/capita, US$ exchange rate","NZL","New Zealand","2021","2021",26.2,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","TCPPERMT","/capita, US$ exchange rate","NZL","New Zealand","2022","2022",24.5,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2010","2010",25.3,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2011","2011",28,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2012","2012",23.8,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2013","2013",22.9,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2014","2014",20.9,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2015","2015",24.6,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2016","2016",25.3,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2017","2017",24.3,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2018","2018",24.2,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2019","2019",24.6,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2020","2020",23.6,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2021","2021",25.4,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2022","2022",26.8,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","ATCPTTMT","% of total sales","NZL","New Zealand","2010","2010",22,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","ATCPTTMT","% of total sales","NZL","New Zealand","2011","2011",22.3,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","ATCPTTMT","% of total sales","NZL","New Zealand","2012","2012",17,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","ATCPTTMT","% of total sales","NZL","New Zealand","2013","2013",16,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","ATCPTTMT","% of total sales","NZL","New Zealand","2014","2014",14.2,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","ATCPTTMT","% of total sales","NZL","New Zealand","2015","2015",17,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","ATCPTTMT","% of total sales","NZL","New Zealand","2016","2016",16,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","ATCPTTMT","% of total sales","NZL","New Zealand","2017","2017",13.3,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","ATCPTTMT","% of total sales","NZL","New Zealand","2018","2018",13.2,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","ATCPTTMT","% of total sales","NZL","New Zealand","2019","2019",11.6,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","ATCPTTMT","% of total sales","NZL","New Zealand","2020","2020",10.3,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","ATCPTTMT","% of total sales","NZL","New Zealand","2021","2021",10.7,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","ATCPTTMT","% of total sales","NZL","New Zealand","2022","2022",10.4,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","MLLNCUMT","Million of national currency units","NOR","Norway","2010","2010",3463,,
+"PATCCNSY","N-Nervous system","MLLNCUMT","Million of national currency units","NOR","Norway","2011","2011",3458,,
+"PATCCNSY","N-Nervous system","MLLNCUMT","Million of national currency units","NOR","Norway","2012","2012",3599,,
+"PATCCNSY","N-Nervous system","MLLNCUMT","Million of national currency units","NOR","Norway","2013","2013",3570,,
+"PATCCNSY","N-Nervous system","MLLNCUMT","Million of national currency units","NOR","Norway","2014","2014",3753,,
+"PATCCNSY","N-Nervous system","MLLNCUMT","Million of national currency units","NOR","Norway","2015","2015",3929,,
+"PATCCNSY","N-Nervous system","MLLNCUMT","Million of national currency units","NOR","Norway","2016","2016",4133,,
+"PATCCNSY","N-Nervous system","MLLNCUMT","Million of national currency units","NOR","Norway","2017","2017",4277,,
+"PATCCNSY","N-Nervous system","MLLNCUMT","Million of national currency units","NOR","Norway","2018","2018",4313,,
+"PATCCNSY","N-Nervous system","MLLNCUMT","Million of national currency units","NOR","Norway","2019","2019",4521,,
+"PATCCNSY","N-Nervous system","MLLNCUMT","Million of national currency units","NOR","Norway","2020","2020",5159,,
+"PATCCNSY","N-Nervous system","MLLNCUMT","Million of national currency units","NOR","Norway","2021","2021",5550,,
+"PATCCNSY","N-Nervous system","MLLNCUMT","Million of national currency units","NOR","Norway","2022","2022",5871,,
+"PATCCNSY","N-Nervous system","MTMOTCMT","Million US$ at exchange rate","NOR","Norway","2010","2010",572.9,,
+"PATCCNSY","N-Nervous system","MTMOTCMT","Million US$ at exchange rate","NOR","Norway","2011","2011",617,,
+"PATCCNSY","N-Nervous system","MTMOTCMT","Million US$ at exchange rate","NOR","Norway","2012","2012",618.7,,
+"PATCCNSY","N-Nervous system","MTMOTCMT","Million US$ at exchange rate","NOR","Norway","2013","2013",607.7,,
+"PATCCNSY","N-Nervous system","MTMOTCMT","Million US$ at exchange rate","NOR","Norway","2014","2014",595.6,,
+"PATCCNSY","N-Nervous system","MTMOTCMT","Million US$ at exchange rate","NOR","Norway","2015","2015",487.2,,
+"PATCCNSY","N-Nervous system","MTMOTCMT","Million US$ at exchange rate","NOR","Norway","2016","2016",492,,
+"PATCCNSY","N-Nervous system","MTMOTCMT","Million US$ at exchange rate","NOR","Norway","2017","2017",517.1,,
+"PATCCNSY","N-Nervous system","MTMOTCMT","Million US$ at exchange rate","NOR","Norway","2018","2018",530.3,,
+"PATCCNSY","N-Nervous system","MTMOTCMT","Million US$ at exchange rate","NOR","Norway","2019","2019",513.8,,
+"PATCCNSY","N-Nervous system","MTMOTCMT","Million US$ at exchange rate","NOR","Norway","2020","2020",547.9,,
+"PATCCNSY","N-Nervous system","MTMOTCMT","Million US$ at exchange rate","NOR","Norway","2021","2021",646.1,,
+"PATCCNSY","N-Nervous system","MTMOTCMT","Million US$ at exchange rate","NOR","Norway","2022","2022",610.7,,
+"PATCCNSY","N-Nervous system","MTMOPPMT","Million US$, purchasing power parity","NOR","Norway","2010","2010",378.4,,
+"PATCCNSY","N-Nervous system","MTMOPPMT","Million US$, purchasing power parity","NOR","Norway","2011","2011",380.7,,
+"PATCCNSY","N-Nervous system","MTMOPPMT","Million US$, purchasing power parity","NOR","Norway","2012","2012",398.2,,
+"PATCCNSY","N-Nervous system","MTMOPPMT","Million US$, purchasing power parity","NOR","Norway","2013","2013",395.4,,
+"PATCCNSY","N-Nervous system","MTMOPPMT","Million US$, purchasing power parity","NOR","Norway","2014","2014",404.5,,
+"PATCCNSY","N-Nervous system","MTMOPPMT","Million US$, purchasing power parity","NOR","Norway","2015","2015",395.6,,
+"PATCCNSY","N-Nervous system","MTMOPPMT","Million US$, purchasing power parity","NOR","Norway","2016","2016",411.6,,
+"PATCCNSY","N-Nervous system","MTMOPPMT","Million US$, purchasing power parity","NOR","Norway","2017","2017",438.7,,
+"PATCCNSY","N-Nervous system","MTMOPPMT","Million US$, purchasing power parity","NOR","Norway","2018","2018",450,,
+"PATCCNSY","N-Nervous system","MTMOPPMT","Million US$, purchasing power parity","NOR","Norway","2019","2019",470,,
+"PATCCNSY","N-Nervous system","MTMOPPMT","Million US$, purchasing power parity","NOR","Norway","2020","2020",522.2,,
+"PATCCNSY","N-Nervous system","MTMOPPMT","Million US$, purchasing power parity","NOR","Norway","2021","2021",583.5,,
+"PATCCNSY","N-Nervous system","MTMOPPMT","Million US$, purchasing power parity","NOR","Norway","2022","2022",546.7,,
+"PATCCNSY","N-Nervous system","TCPPERMT","/capita, US$ exchange rate","NOR","Norway","2010","2010",117.2,,
+"PATCCNSY","N-Nervous system","TCPPERMT","/capita, US$ exchange rate","NOR","Norway","2011","2011",124.6,,
+"PATCCNSY","N-Nervous system","TCPPERMT","/capita, US$ exchange rate","NOR","Norway","2012","2012",123.3,,
+"PATCCNSY","N-Nervous system","TCPPERMT","/capita, US$ exchange rate","NOR","Norway","2013","2013",119.6,,
+"PATCCNSY","N-Nervous system","TCPPERMT","/capita, US$ exchange rate","NOR","Norway","2014","2014",115.9,,
+"PATCCNSY","N-Nervous system","TCPPERMT","/capita, US$ exchange rate","NOR","Norway","2015","2015",93.9,,
+"PATCCNSY","N-Nervous system","TCPPERMT","/capita, US$ exchange rate","NOR","Norway","2016","2016",94,,
+"PATCCNSY","N-Nervous system","TCPPERMT","/capita, US$ exchange rate","NOR","Norway","2017","2017",98,,
+"PATCCNSY","N-Nervous system","TCPPERMT","/capita, US$ exchange rate","NOR","Norway","2018","2018",99.8,,
+"PATCCNSY","N-Nervous system","TCPPERMT","/capita, US$ exchange rate","NOR","Norway","2019","2019",96.1,,
+"PATCCNSY","N-Nervous system","TCPPERMT","/capita, US$ exchange rate","NOR","Norway","2020","2020",101.9,,
+"PATCCNSY","N-Nervous system","TCPPERMT","/capita, US$ exchange rate","NOR","Norway","2021","2021",119.5,,
+"PATCCNSY","N-Nervous system","TCPPERMT","/capita, US$ exchange rate","NOR","Norway","2022","2022",112.6,,
+"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2010","2010",77.4,,
+"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2011","2011",76.9,,
+"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2012","2012",79.4,,
+"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2013","2013",77.8,,
+"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2014","2014",78.7,,
+"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2015","2015",76.2,,
+"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2016","2016",78.6,,
+"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2017","2017",83.1,,
+"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2018","2018",84.7,,
+"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2019","2019",87.9,,
+"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2020","2020",97.1,,
+"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2021","2021",107.9,,
+"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2022","2022",100.8,,
+"PATCCNSY","N-Nervous system","ATCPTTMT","% of total sales","NOR","Norway","2010","2010",19.4,,
+"PATCCNSY","N-Nervous system","ATCPTTMT","% of total sales","NOR","Norway","2011","2011",19,,
+"PATCCNSY","N-Nervous system","ATCPTTMT","% of total sales","NOR","Norway","2012","2012",19.1,,
+"PATCCNSY","N-Nervous system","ATCPTTMT","% of total sales","NOR","Norway","2013","2013",18.5,,
+"PATCCNSY","N-Nervous system","ATCPTTMT","% of total sales","NOR","Norway","2014","2014",17.8,,
+"PATCCNSY","N-Nervous system","ATCPTTMT","% of total sales","NOR","Norway","2015","2015",17.3,,
+"PATCCNSY","N-Nervous system","ATCPTTMT","% of total sales","NOR","Norway","2016","2016",16.7,,
+"PATCCNSY","N-Nervous system","ATCPTTMT","% of total sales","NOR","Norway","2017","2017",16,,
+"PATCCNSY","N-Nervous system","ATCPTTMT","% of total sales","NOR","Norway","2018","2018",15.7,,
+"PATCCNSY","N-Nervous system","ATCPTTMT","% of total sales","NOR","Norway","2019","2019",15.9,,
+"PATCCNSY","N-Nervous system","ATCPTTMT","% of total sales","NOR","Norway","2020","2020",17.4,,
+"PATCCNSY","N-Nervous system","ATCPTTMT","% of total sales","NOR","Norway","2021","2021",16.5,,
+"PATCCNSY","N-Nervous system","ATCPTTMT","% of total sales","NOR","Norway","2022","2022",16.3,,
+"PATCCNSY","N-Nervous system","MLLNCUMT","Million of national currency units","PRT","Portugal","2010","2010",700.4,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","MLLNCUMT","Million of national currency units","PRT","Portugal","2011","2011",645.2,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","MLLNCUMT","Million of national currency units","PRT","Portugal","2012","2012",571.7,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","MLLNCUMT","Million of national currency units","PRT","Portugal","2013","2013",512.2,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","MLLNCUMT","Million of national currency units","PRT","Portugal","2014","2014",511.1,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","MLLNCUMT","Million of national currency units","PRT","Portugal","2015","2015",509.2,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","MLLNCUMT","Million of national currency units","PRT","Portugal","2016","2016",506.8,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","MLLNCUMT","Million of national currency units","PRT","Portugal","2017","2017",517.2,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","MLLNCUMT","Million of national currency units","PRT","Portugal","2018","2018",527.2,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","MLLNCUMT","Million of national currency units","PRT","Portugal","2019","2019",552.8,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","MLLNCUMT","Million of national currency units","PRT","Portugal","2020","2020",562.7,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","MLLNCUMT","Million of national currency units","PRT","Portugal","2021","2021",576.1,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","MLLNCUMT","Million of national currency units","PRT","Portugal","2022","2022",601.6,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","MTMOTCMT","Million US$ at exchange rate","PRT","Portugal","2010","2010",928.6,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","MTMOTCMT","Million US$ at exchange rate","PRT","Portugal","2011","2011",898.1,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","MTMOTCMT","Million US$ at exchange rate","PRT","Portugal","2012","2012",734.5,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","MTMOTCMT","Million US$ at exchange rate","PRT","Portugal","2013","2013",680.3,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","MTMOTCMT","Million US$ at exchange rate","PRT","Portugal","2014","2014",678.9,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","MTMOTCMT","Million US$ at exchange rate","PRT","Portugal","2015","2015",565,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","MTMOTCMT","Million US$ at exchange rate","PRT","Portugal","2016","2016",561,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","MTMOTCMT","Million US$ at exchange rate","PRT","Portugal","2017","2017",584.3,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","MTMOTCMT","Million US$ at exchange rate","PRT","Portugal","2018","2018",622.6,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","MTMOTCMT","Million US$ at exchange rate","PRT","Portugal","2019","2019",618.8,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","MTMOTCMT","Million US$ at exchange rate","PRT","Portugal","2020","2020",642.8,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","MTMOTCMT","Million US$ at exchange rate","PRT","Portugal","2021","2021",681.3,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","MTMOTCMT","Million US$ at exchange rate","PRT","Portugal","2022","2022",633.5,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","MTMOPPMT","Million US$, purchasing power parity","PRT","Portugal","2010","2010",1124,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","MTMOPPMT","Million US$, purchasing power parity","PRT","Portugal","2011","2011",1035.5,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","MTMOPPMT","Million US$, purchasing power parity","PRT","Portugal","2012","2012",944.4,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","MTMOPPMT","Million US$, purchasing power parity","PRT","Portugal","2013","2013",877.7,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","MTMOPPMT","Million US$, purchasing power parity","PRT","Portugal","2014","2014",882.9,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","MTMOPPMT","Million US$, purchasing power parity","PRT","Portugal","2015","2015",870.6,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","MTMOPPMT","Million US$, purchasing power parity","PRT","Portugal","2016","2016",887,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","MTMOPPMT","Million US$, purchasing power parity","PRT","Portugal","2017","2017",898.4,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","MTMOPPMT","Million US$, purchasing power parity","PRT","Portugal","2018","2018",922.9,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","MTMOPPMT","Million US$, purchasing power parity","PRT","Portugal","2019","2019",989.3,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","MTMOPPMT","Million US$, purchasing power parity","PRT","Portugal","2020","2020",1010.1,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","MTMOPPMT","Million US$, purchasing power parity","PRT","Portugal","2021","2021",1014.8,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","MTMOPPMT","Million US$, purchasing power parity","PRT","Portugal","2022","2022",1093.9,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","TCPPERMT","/capita, US$ exchange rate","PRT","Portugal","2010","2010",87.8,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","TCPPERMT","/capita, US$ exchange rate","PRT","Portugal","2011","2011",85.1,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","TCPPERMT","/capita, US$ exchange rate","PRT","Portugal","2012","2012",69.9,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","TCPPERMT","/capita, US$ exchange rate","PRT","Portugal","2013","2013",65.1,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","TCPPERMT","/capita, US$ exchange rate","PRT","Portugal","2014","2014",65.3,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","TCPPERMT","/capita, US$ exchange rate","PRT","Portugal","2015","2015",54.5,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","TCPPERMT","/capita, US$ exchange rate","PRT","Portugal","2016","2016",54.3,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","TCPPERMT","/capita, US$ exchange rate","PRT","Portugal","2017","2017",56.7,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","TCPPERMT","/capita, US$ exchange rate","PRT","Portugal","2018","2018",60.5,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","TCPPERMT","/capita, US$ exchange rate","PRT","Portugal","2019","2019",60.2,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","TCPPERMT","/capita, US$ exchange rate","PRT","Portugal","2020","2020",62.4,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","TCPPERMT","/capita, US$ exchange rate","PRT","Portugal","2021","2021",65.8,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","TCPPERMT","/capita, US$ exchange rate","PRT","Portugal","2022","2022",61.2,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2010","2010",106.3,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2011","2011",98.1,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2012","2012",89.8,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2013","2013",83.9,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2014","2014",84.9,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2015","2015",84,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2016","2016",85.9,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2017","2017",87.2,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2018","2018",89.7,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2019","2019",96.2,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2020","2020",98.1,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2021","2021",97.9,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2022","2022",105.7,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","ATCPTTMT","% of total sales","PRT","Portugal","2010","2010",21.6,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","ATCPTTMT","% of total sales","PRT","Portugal","2011","2011",21.9,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","ATCPTTMT","% of total sales","PRT","Portugal","2012","2012",21.9,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","ATCPTTMT","% of total sales","PRT","Portugal","2013","2013",21.3,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","ATCPTTMT","% of total sales","PRT","Portugal","2014","2014",21.3,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","ATCPTTMT","% of total sales","PRT","Portugal","2015","2015",20.4,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","ATCPTTMT","% of total sales","PRT","Portugal","2016","2016",20,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","ATCPTTMT","% of total sales","PRT","Portugal","2017","2017",20.2,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","ATCPTTMT","% of total sales","PRT","Portugal","2018","2018",20.1,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","ATCPTTMT","% of total sales","PRT","Portugal","2019","2019",19.8,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","ATCPTTMT","% of total sales","PRT","Portugal","2020","2020",20,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","ATCPTTMT","% of total sales","PRT","Portugal","2021","2021",19.7,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","ATCPTTMT","% of total sales","PRT","Portugal","2022","2022",18.9,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","MLLNCUMT","Million of national currency units","SVK","Slovak Republic","2010","2010",134.3,,
+"PATCCNSY","N-Nervous system","MLLNCUMT","Million of national currency units","SVK","Slovak Republic","2011","2011",135.1,,
+"PATCCNSY","N-Nervous system","MLLNCUMT","Million of national currency units","SVK","Slovak Republic","2012","2012",124.9,,
+"PATCCNSY","N-Nervous system","MLLNCUMT","Million of national currency units","SVK","Slovak Republic","2013","2013",136.2,,
+"PATCCNSY","N-Nervous system","MLLNCUMT","Million of national currency units","SVK","Slovak Republic","2014","2014",139.3,,
+"PATCCNSY","N-Nervous system","MLLNCUMT","Million of national currency units","SVK","Slovak Republic","2015","2015",140,,
+"PATCCNSY","N-Nervous system","MLLNCUMT","Million of national currency units","SVK","Slovak Republic","2016","2016",156.6,"B","Break"
+"PATCCNSY","N-Nervous system","MLLNCUMT","Million of national currency units","SVK","Slovak Republic","2017","2017",147.2,,
+"PATCCNSY","N-Nervous system","MLLNCUMT","Million of national currency units","SVK","Slovak Republic","2018","2018",145.9,,
+"PATCCNSY","N-Nervous system","MLLNCUMT","Million of national currency units","SVK","Slovak Republic","2019","2019",147.2,,
+"PATCCNSY","N-Nervous system","MLLNCUMT","Million of national currency units","SVK","Slovak Republic","2020","2020",148.2,,
+"PATCCNSY","N-Nervous system","MLLNCUMT","Million of national currency units","SVK","Slovak Republic","2021","2021",157.8,,
+"PATCCNSY","N-Nervous system","MTMOTCMT","Million US$ at exchange rate","SVK","Slovak Republic","2010","2010",178,,
+"PATCCNSY","N-Nervous system","MTMOTCMT","Million US$ at exchange rate","SVK","Slovak Republic","2011","2011",188,,
+"PATCCNSY","N-Nervous system","MTMOTCMT","Million US$ at exchange rate","SVK","Slovak Republic","2012","2012",160.5,,
+"PATCCNSY","N-Nervous system","MTMOTCMT","Million US$ at exchange rate","SVK","Slovak Republic","2013","2013",180.9,,
+"PATCCNSY","N-Nervous system","MTMOTCMT","Million US$ at exchange rate","SVK","Slovak Republic","2014","2014",185.1,,
+"PATCCNSY","N-Nervous system","MTMOTCMT","Million US$ at exchange rate","SVK","Slovak Republic","2015","2015",155.3,,
+"PATCCNSY","N-Nervous system","MTMOTCMT","Million US$ at exchange rate","SVK","Slovak Republic","2016","2016",173.4,"B","Break"
+"PATCCNSY","N-Nervous system","MTMOTCMT","Million US$ at exchange rate","SVK","Slovak Republic","2017","2017",166.3,,
+"PATCCNSY","N-Nervous system","MTMOTCMT","Million US$ at exchange rate","SVK","Slovak Republic","2018","2018",172.3,,
+"PATCCNSY","N-Nervous system","MTMOTCMT","Million US$ at exchange rate","SVK","Slovak Republic","2019","2019",164.8,,
+"PATCCNSY","N-Nervous system","MTMOTCMT","Million US$ at exchange rate","SVK","Slovak Republic","2020","2020",169.2,,
+"PATCCNSY","N-Nervous system","MTMOTCMT","Million US$ at exchange rate","SVK","Slovak Republic","2021","2021",186.6,,
+"PATCCNSY","N-Nervous system","MTMOPPMT","Million US$, purchasing power parity","SVK","Slovak Republic","2010","2010",267.4,,
+"PATCCNSY","N-Nervous system","MTMOPPMT","Million US$, purchasing power parity","SVK","Slovak Republic","2011","2011",266.7,,
+"PATCCNSY","N-Nervous system","MTMOPPMT","Million US$, purchasing power parity","SVK","Slovak Republic","2012","2012",247.6,,
+"PATCCNSY","N-Nervous system","MTMOPPMT","Million US$, purchasing power parity","SVK","Slovak Republic","2013","2013",277.4,,
+"PATCCNSY","N-Nervous system","MTMOPPMT","Million US$, purchasing power parity","SVK","Slovak Republic","2014","2014",287,,
+"PATCCNSY","N-Nervous system","MTMOPPMT","Million US$, purchasing power parity","SVK","Slovak Republic","2015","2015",284.7,,
+"PATCCNSY","N-Nervous system","MTMOPPMT","Million US$, purchasing power parity","SVK","Slovak Republic","2016","2016",311.3,"B","Break"
+"PATCCNSY","N-Nervous system","MTMOPPMT","Million US$, purchasing power parity","SVK","Slovak Republic","2017","2017",285.1,,
+"PATCCNSY","N-Nervous system","MTMOPPMT","Million US$, purchasing power parity","SVK","Slovak Republic","2018","2018",277.3,,
+"PATCCNSY","N-Nervous system","MTMOPPMT","Million US$, purchasing power parity","SVK","Slovak Republic","2019","2019",284.5,,
+"PATCCNSY","N-Nervous system","MTMOPPMT","Million US$, purchasing power parity","SVK","Slovak Republic","2020","2020",285,,
+"PATCCNSY","N-Nervous system","MTMOPPMT","Million US$, purchasing power parity","SVK","Slovak Republic","2021","2021",295.8,,
+"PATCCNSY","N-Nervous system","TCPPERMT","/capita, US$ exchange rate","SVK","Slovak Republic","2010","2010",33,,
+"PATCCNSY","N-Nervous system","TCPPERMT","/capita, US$ exchange rate","SVK","Slovak Republic","2011","2011",34.8,,
+"PATCCNSY","N-Nervous system","TCPPERMT","/capita, US$ exchange rate","SVK","Slovak Republic","2012","2012",29.7,,
+"PATCCNSY","N-Nervous system","TCPPERMT","/capita, US$ exchange rate","SVK","Slovak Republic","2013","2013",33.4,,
+"PATCCNSY","N-Nervous system","TCPPERMT","/capita, US$ exchange rate","SVK","Slovak Republic","2014","2014",34.2,,
+"PATCCNSY","N-Nervous system","TCPPERMT","/capita, US$ exchange rate","SVK","Slovak Republic","2015","2015",28.6,,
+"PATCCNSY","N-Nervous system","TCPPERMT","/capita, US$ exchange rate","SVK","Slovak Republic","2016","2016",31.9,"B","Break"
+"PATCCNSY","N-Nervous system","TCPPERMT","/capita, US$ exchange rate","SVK","Slovak Republic","2017","2017",30.6,,
+"PATCCNSY","N-Nervous system","TCPPERMT","/capita, US$ exchange rate","SVK","Slovak Republic","2018","2018",31.6,,
+"PATCCNSY","N-Nervous system","TCPPERMT","/capita, US$ exchange rate","SVK","Slovak Republic","2019","2019",30.2,,
+"PATCCNSY","N-Nervous system","TCPPERMT","/capita, US$ exchange rate","SVK","Slovak Republic","2020","2020",31,,
+"PATCCNSY","N-Nervous system","TCPPERMT","/capita, US$ exchange rate","SVK","Slovak Republic","2021","2021",34.3,,
+"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2010","2010",49.6,,
+"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2011","2011",49.4,,
+"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2012","2012",45.8,,
+"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2013","2013",51.2,,
+"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2014","2014",53,,
+"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2015","2015",52.5,,
+"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2016","2016",57.3,"B","Break"
+"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2017","2017",52.4,,
+"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2018","2018",50.9,,
+"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2019","2019",52.2,,
+"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2020","2020",52.2,,
+"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2021","2021",54.3,,
+"PATCCNSY","N-Nervous system","ATCPTTMT","% of total sales","SVK","Slovak Republic","2010","2010",12,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","ATCPTTMT","% of total sales","SVK","Slovak Republic","2011","2011",12,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","ATCPTTMT","% of total sales","SVK","Slovak Republic","2012","2012",11.3,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","ATCPTTMT","% of total sales","SVK","Slovak Republic","2013","2013",11.1,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","ATCPTTMT","% of total sales","SVK","Slovak Republic","2014","2014",10.6,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","ATCPTTMT","% of total sales","SVK","Slovak Republic","2015","2015",10.1,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","ATCPTTMT","% of total sales","SVK","Slovak Republic","2016","2016",10,"B","Break"
+"PATCCNSY","N-Nervous system","ATCPTTMT","% of total sales","SVK","Slovak Republic","2017","2017",9.4,,
+"PATCCNSY","N-Nervous system","ATCPTTMT","% of total sales","SVK","Slovak Republic","2018","2018",9,,
+"PATCCNSY","N-Nervous system","ATCPTTMT","% of total sales","SVK","Slovak Republic","2019","2019",8.5,,
+"PATCCNSY","N-Nervous system","ATCPTTMT","% of total sales","SVK","Slovak Republic","2020","2020",8.9,,
+"PATCCNSY","N-Nervous system","ATCPTTMT","% of total sales","SVK","Slovak Republic","2021","2021",8.8,,
+"PATCCNSY","N-Nervous system","MLLNCUMT","Million of national currency units","ESP","Spain","2010","2010",3140.7,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","MLLNCUMT","Million of national currency units","ESP","Spain","2011","2011",3080.3,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","MLLNCUMT","Million of national currency units","ESP","Spain","2012","2012",2838.9,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","MLLNCUMT","Million of national currency units","ESP","Spain","2013","2013",2862.9,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","MLLNCUMT","Million of national currency units","ESP","Spain","2014","2014",3043.9,"B; D","Break; Difference in methodology"
+"PATCCNSY","N-Nervous system","MLLNCUMT","Million of national currency units","ESP","Spain","2015","2015",2946.2,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","MLLNCUMT","Million of national currency units","ESP","Spain","2016","2016",3022.3,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","MLLNCUMT","Million of national currency units","ESP","Spain","2017","2017",3070.2,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","MLLNCUMT","Million of national currency units","ESP","Spain","2018","2018",3413.3,"B","Break"
+"PATCCNSY","N-Nervous system","MLLNCUMT","Million of national currency units","ESP","Spain","2019","2019",3390,,
+"PATCCNSY","N-Nervous system","MLLNCUMT","Million of national currency units","ESP","Spain","2020","2020",3561.2,,
+"PATCCNSY","N-Nervous system","MLLNCUMT","Million of national currency units","ESP","Spain","2021","2021",3674.3,,
+"PATCCNSY","N-Nervous system","MLLNCUMT","Million of national currency units","ESP","Spain","2022","2022",3713.2,"P","Provisional value"
+"PATCCNSY","N-Nervous system","MTMOTCMT","Million US$ at exchange rate","ESP","Spain","2010","2010",4163.7,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","MTMOTCMT","Million US$ at exchange rate","ESP","Spain","2011","2011",4287.7,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","MTMOTCMT","Million US$ at exchange rate","ESP","Spain","2012","2012",3647.4,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","MTMOTCMT","Million US$ at exchange rate","ESP","Spain","2013","2013",3802.2,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","MTMOTCMT","Million US$ at exchange rate","ESP","Spain","2014","2014",4043.9,"B; D","Break; Difference in methodology"
+"PATCCNSY","N-Nervous system","MTMOTCMT","Million US$ at exchange rate","ESP","Spain","2015","2015",3268.8,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","MTMOTCMT","Million US$ at exchange rate","ESP","Spain","2016","2016",3345.4,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","MTMOTCMT","Million US$ at exchange rate","ESP","Spain","2017","2017",3468.4,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","MTMOTCMT","Million US$ at exchange rate","ESP","Spain","2018","2018",4031,"B","Break"
+"PATCCNSY","N-Nervous system","MTMOTCMT","Million US$ at exchange rate","ESP","Spain","2019","2019",3795.1,,
+"PATCCNSY","N-Nervous system","MTMOTCMT","Million US$ at exchange rate","ESP","Spain","2020","2020",4067.6,,
+"PATCCNSY","N-Nervous system","MTMOTCMT","Million US$ at exchange rate","ESP","Spain","2021","2021",4345.7,,
+"PATCCNSY","N-Nervous system","MTMOTCMT","Million US$ at exchange rate","ESP","Spain","2022","2022",3910.2,"P","Provisional value"
+"PATCCNSY","N-Nervous system","MTMOPPMT","Million US$, purchasing power parity","ESP","Spain","2010","2010",4320.3,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","MTMOPPMT","Million US$, purchasing power parity","ESP","Spain","2011","2011",4313.4,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","MTMOPPMT","Million US$, purchasing power parity","ESP","Spain","2012","2012",4084.9,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","MTMOPPMT","Million US$, purchasing power parity","ESP","Spain","2013","2013",4242.6,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","MTMOPPMT","Million US$, purchasing power parity","ESP","Spain","2014","2014",4595.6,"B; D","Break; Difference in methodology"
+"PATCCNSY","N-Nervous system","MTMOPPMT","Million US$, purchasing power parity","ESP","Spain","2015","2015",4432.1,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","MTMOPPMT","Million US$, purchasing power parity","ESP","Spain","2016","2016",4702.9,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","MTMOPPMT","Million US$, purchasing power parity","ESP","Spain","2017","2017",4866.9,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","MTMOPPMT","Million US$, purchasing power parity","ESP","Spain","2018","2018",5402.6,"B","Break"
+"PATCCNSY","N-Nervous system","MTMOPPMT","Million US$, purchasing power parity","ESP","Spain","2019","2019",5530.5,,
+"PATCCNSY","N-Nervous system","MTMOPPMT","Million US$, purchasing power parity","ESP","Spain","2020","2020",5731.6,,
+"PATCCNSY","N-Nervous system","MTMOPPMT","Million US$, purchasing power parity","ESP","Spain","2021","2021",5869.9,,
+"PATCCNSY","N-Nervous system","MTMOPPMT","Million US$, purchasing power parity","ESP","Spain","2022","2022",6228,"P","Provisional value"
+"PATCCNSY","N-Nervous system","TCPPERMT","/capita, US$ exchange rate","ESP","Spain","2010","2010",89.4,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","TCPPERMT","/capita, US$ exchange rate","ESP","Spain","2011","2011",91.7,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","TCPPERMT","/capita, US$ exchange rate","ESP","Spain","2012","2012",78,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","TCPPERMT","/capita, US$ exchange rate","ESP","Spain","2013","2013",81.6,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","TCPPERMT","/capita, US$ exchange rate","ESP","Spain","2014","2014",87,"B; D","Break; Difference in methodology"
+"PATCCNSY","N-Nervous system","TCPPERMT","/capita, US$ exchange rate","ESP","Spain","2015","2015",70.4,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","TCPPERMT","/capita, US$ exchange rate","ESP","Spain","2016","2016",72,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","TCPPERMT","/capita, US$ exchange rate","ESP","Spain","2017","2017",74.4,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","TCPPERMT","/capita, US$ exchange rate","ESP","Spain","2018","2018",86.1,"B","Break"
+"PATCCNSY","N-Nervous system","TCPPERMT","/capita, US$ exchange rate","ESP","Spain","2019","2019",80.5,,
+"PATCCNSY","N-Nervous system","TCPPERMT","/capita, US$ exchange rate","ESP","Spain","2020","2020",85.9,,
+"PATCCNSY","N-Nervous system","TCPPERMT","/capita, US$ exchange rate","ESP","Spain","2021","2021",91.7,,
+"PATCCNSY","N-Nervous system","TCPPERMT","/capita, US$ exchange rate","ESP","Spain","2022","2022",82.4,"P","Provisional value"
+"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2010","2010",92.8,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2011","2011",92.3,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2012","2012",87.3,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2013","2013",91,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2014","2014",98.9,"B; D","Break; Difference in methodology"
+"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2015","2015",95.4,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2016","2016",101.2,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2017","2017",104.5,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2018","2018",115.4,"B","Break"
+"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2019","2019",117.3,,
+"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2020","2020",121,,
+"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2021","2021",123.8,,
+"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2022","2022",131.3,"P","Provisional value"
+"PATCCNSY","N-Nervous system","ATCPTTMT","% of total sales","ESP","Spain","2010","2010",23.7,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","ATCPTTMT","% of total sales","ESP","Spain","2011","2011",24.9,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","ATCPTTMT","% of total sales","ESP","Spain","2012","2012",25.6,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","ATCPTTMT","% of total sales","ESP","Spain","2013","2013",26.8,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","ATCPTTMT","% of total sales","ESP","Spain","2014","2014",26.9,"B; D","Break; Difference in methodology"
+"PATCCNSY","N-Nervous system","ATCPTTMT","% of total sales","ESP","Spain","2015","2015",25.8,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","ATCPTTMT","% of total sales","ESP","Spain","2016","2016",25.5,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","ATCPTTMT","% of total sales","ESP","Spain","2017","2017",25.4,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","ATCPTTMT","% of total sales","ESP","Spain","2018","2018",18,"B","Break"
+"PATCCNSY","N-Nervous system","ATCPTTMT","% of total sales","ESP","Spain","2019","2019",16.9,,
+"PATCCNSY","N-Nervous system","ATCPTTMT","% of total sales","ESP","Spain","2020","2020",17.1,,
+"PATCCNSY","N-Nervous system","ATCPTTMT","% of total sales","ESP","Spain","2021","2021",16.7,,
+"PATCCNSY","N-Nervous system","ATCPTTMT","% of total sales","ESP","Spain","2022","2022",16.2,"P","Provisional value"
+"PATCCNSY","N-Nervous system","MLLNCUMT","Million of national currency units","SWE","Sweden","2010","2010",7256.9,,
+"PATCCNSY","N-Nervous system","MLLNCUMT","Million of national currency units","SWE","Sweden","2011","2011",7595.8,,
+"PATCCNSY","N-Nervous system","MLLNCUMT","Million of national currency units","SWE","Sweden","2012","2012",7234.7,,
+"PATCCNSY","N-Nervous system","MLLNCUMT","Million of national currency units","SWE","Sweden","2013","2013",7295,,
+"PATCCNSY","N-Nervous system","MLLNCUMT","Million of national currency units","SWE","Sweden","2014","2014",7342.3,,
+"PATCCNSY","N-Nervous system","MLLNCUMT","Million of national currency units","SWE","Sweden","2015","2015",7485.8,,
+"PATCCNSY","N-Nervous system","MLLNCUMT","Million of national currency units","SWE","Sweden","2016","2016",7411.8,,
+"PATCCNSY","N-Nervous system","MLLNCUMT","Million of national currency units","SWE","Sweden","2017","2017",7573.2,,
+"PATCCNSY","N-Nervous system","MLLNCUMT","Million of national currency units","SWE","Sweden","2018","2018",7843.8,,
+"PATCCNSY","N-Nervous system","MLLNCUMT","Million of national currency units","SWE","Sweden","2019","2019",8349.4,,
+"PATCCNSY","N-Nervous system","MLLNCUMT","Million of national currency units","SWE","Sweden","2020","2020",8805.1,,
+"PATCCNSY","N-Nervous system","MLLNCUMT","Million of national currency units","SWE","Sweden","2021","2021",8532.4,,
+"PATCCNSY","N-Nervous system","MLLNCUMT","Million of national currency units","SWE","Sweden","2022","2022",9178.9,,
+"PATCCNSY","N-Nervous system","MTMOTCMT","Million US$ at exchange rate","SWE","Sweden","2010","2010",1006.9,,
+"PATCCNSY","N-Nervous system","MTMOTCMT","Million US$ at exchange rate","SWE","Sweden","2011","2011",1169.7,,
+"PATCCNSY","N-Nervous system","MTMOTCMT","Million US$ at exchange rate","SWE","Sweden","2012","2012",1067.8,,
+"PATCCNSY","N-Nervous system","MTMOTCMT","Million US$ at exchange rate","SWE","Sweden","2013","2013",1119.9,,
+"PATCCNSY","N-Nervous system","MTMOTCMT","Million US$ at exchange rate","SWE","Sweden","2014","2014",1070.2,,
+"PATCCNSY","N-Nervous system","MTMOTCMT","Million US$ at exchange rate","SWE","Sweden","2015","2015",887.5,,
+"PATCCNSY","N-Nervous system","MTMOTCMT","Million US$ at exchange rate","SWE","Sweden","2016","2016",865.7,,
+"PATCCNSY","N-Nervous system","MTMOTCMT","Million US$ at exchange rate","SWE","Sweden","2017","2017",885.9,,
+"PATCCNSY","N-Nervous system","MTMOTCMT","Million US$ at exchange rate","SWE","Sweden","2018","2018",902.4,,
+"PATCCNSY","N-Nervous system","MTMOTCMT","Million US$ at exchange rate","SWE","Sweden","2019","2019",882.8,,
+"PATCCNSY","N-Nervous system","MTMOTCMT","Million US$ at exchange rate","SWE","Sweden","2020","2020",956,,
+"PATCCNSY","N-Nervous system","MTMOTCMT","Million US$ at exchange rate","SWE","Sweden","2021","2021",994.9,,
+"PATCCNSY","N-Nervous system","MTMOTCMT","Million US$ at exchange rate","SWE","Sweden","2022","2022",907.5,,
+"PATCCNSY","N-Nervous system","MTMOPPMT","Million US$, purchasing power parity","SWE","Sweden","2010","2010",804.1,,
+"PATCCNSY","N-Nervous system","MTMOPPMT","Million US$, purchasing power parity","SWE","Sweden","2011","2011",858.9,,
+"PATCCNSY","N-Nervous system","MTMOPPMT","Million US$, purchasing power parity","SWE","Sweden","2012","2012",835.9,,
+"PATCCNSY","N-Nervous system","MTMOPPMT","Million US$, purchasing power parity","SWE","Sweden","2013","2013",848.5,,
+"PATCCNSY","N-Nervous system","MTMOPPMT","Million US$, purchasing power parity","SWE","Sweden","2014","2014",841.3,,
+"PATCCNSY","N-Nervous system","MTMOPPMT","Million US$, purchasing power parity","SWE","Sweden","2015","2015",845.4,,
+"PATCCNSY","N-Nervous system","MTMOPPMT","Million US$, purchasing power parity","SWE","Sweden","2016","2016",840.1,,
+"PATCCNSY","N-Nervous system","MTMOPPMT","Million US$, purchasing power parity","SWE","Sweden","2017","2017",855.5,,
+"PATCCNSY","N-Nervous system","MTMOPPMT","Million US$, purchasing power parity","SWE","Sweden","2018","2018",884.7,,
+"PATCCNSY","N-Nervous system","MTMOPPMT","Million US$, purchasing power parity","SWE","Sweden","2019","2019",958.6,,
+"PATCCNSY","N-Nervous system","MTMOPPMT","Million US$, purchasing power parity","SWE","Sweden","2020","2020",1015.8,,
+"PATCCNSY","N-Nervous system","MTMOPPMT","Million US$, purchasing power parity","SWE","Sweden","2021","2021",978.3,,
+"PATCCNSY","N-Nervous system","MTMOPPMT","Million US$, purchasing power parity","SWE","Sweden","2022","2022",1059.2,,
+"PATCCNSY","N-Nervous system","TCPPERMT","/capita, US$ exchange rate","SWE","Sweden","2010","2010",107.4,,
+"PATCCNSY","N-Nervous system","TCPPERMT","/capita, US$ exchange rate","SWE","Sweden","2011","2011",123.8,,
+"PATCCNSY","N-Nervous system","TCPPERMT","/capita, US$ exchange rate","SWE","Sweden","2012","2012",112.2,,
+"PATCCNSY","N-Nervous system","TCPPERMT","/capita, US$ exchange rate","SWE","Sweden","2013","2013",116.7,,
+"PATCCNSY","N-Nervous system","TCPPERMT","/capita, US$ exchange rate","SWE","Sweden","2014","2014",110.4,,
+"PATCCNSY","N-Nervous system","TCPPERMT","/capita, US$ exchange rate","SWE","Sweden","2015","2015",90.6,,
+"PATCCNSY","N-Nervous system","TCPPERMT","/capita, US$ exchange rate","SWE","Sweden","2016","2016",87.2,,
+"PATCCNSY","N-Nervous system","TCPPERMT","/capita, US$ exchange rate","SWE","Sweden","2017","2017",88.1,,
+"PATCCNSY","N-Nervous system","TCPPERMT","/capita, US$ exchange rate","SWE","Sweden","2018","2018",88.7,,
+"PATCCNSY","N-Nervous system","TCPPERMT","/capita, US$ exchange rate","SWE","Sweden","2019","2019",85.9,,
+"PATCCNSY","N-Nervous system","TCPPERMT","/capita, US$ exchange rate","SWE","Sweden","2020","2020",92.3,,
+"PATCCNSY","N-Nervous system","TCPPERMT","/capita, US$ exchange rate","SWE","Sweden","2021","2021",95.5,,
+"PATCCNSY","N-Nervous system","TCPPERMT","/capita, US$ exchange rate","SWE","Sweden","2022","2022",86.8,,
+"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2010","2010",85.7,,
+"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2011","2011",90.9,,
+"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2012","2012",87.8,,
+"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2013","2013",88.4,,
+"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2014","2014",86.8,,
+"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2015","2015",86.3,,
+"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2016","2016",84.7,,
+"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2017","2017",85.1,,
+"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2018","2018",86.9,,
+"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2019","2019",93.3,,
+"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2020","2020",98.1,,
+"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2021","2021",93.9,,
+"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2022","2022",101.3,,
+"PATCCNSY","N-Nervous system","ATCPTTMT","% of total sales","SWE","Sweden","2010","2010",20.1,,
+"PATCCNSY","N-Nervous system","ATCPTTMT","% of total sales","SWE","Sweden","2011","2011",20.7,,
+"PATCCNSY","N-Nervous system","ATCPTTMT","% of total sales","SWE","Sweden","2012","2012",20,,
+"PATCCNSY","N-Nervous system","ATCPTTMT","% of total sales","SWE","Sweden","2013","2013",20.1,,
+"PATCCNSY","N-Nervous system","ATCPTTMT","% of total sales","SWE","Sweden","2014","2014",19.4,,
+"PATCCNSY","N-Nervous system","ATCPTTMT","% of total sales","SWE","Sweden","2015","2015",18.5,,
+"PATCCNSY","N-Nervous system","ATCPTTMT","% of total sales","SWE","Sweden","2016","2016",17.5,,
+"PATCCNSY","N-Nervous system","ATCPTTMT","% of total sales","SWE","Sweden","2017","2017",17.3,,
+"PATCCNSY","N-Nervous system","ATCPTTMT","% of total sales","SWE","Sweden","2018","2018",16.4,,
+"PATCCNSY","N-Nervous system","ATCPTTMT","% of total sales","SWE","Sweden","2019","2019",16.5,,
+"PATCCNSY","N-Nervous system","ATCPTTMT","% of total sales","SWE","Sweden","2020","2020",16.8,,
+"PATCCNSY","N-Nervous system","ATCPTTMT","% of total sales","SWE","Sweden","2021","2021",15.8,,
+"PATCCNSY","N-Nervous system","ATCPTTMT","% of total sales","SWE","Sweden","2022","2022",15.9,,
+"PATCCNSY","N-Nervous system","MLLNCUMT","Million of national currency units","CHE","Switzerland","2010","2010",1042.3,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","MLLNCUMT","Million of national currency units","CHE","Switzerland","2011","2011",1063,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","MLLNCUMT","Million of national currency units","CHE","Switzerland","2012","2012",1060,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","MLLNCUMT","Million of national currency units","CHE","Switzerland","2013","2013",1045,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","MLLNCUMT","Million of national currency units","CHE","Switzerland","2014","2014",1028,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","MLLNCUMT","Million of national currency units","CHE","Switzerland","2015","2015",1036,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","MLLNCUMT","Million of national currency units","CHE","Switzerland","2016","2016",1221,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","MLLNCUMT","Million of national currency units","CHE","Switzerland","2017","2017",1214,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","MLLNCUMT","Million of national currency units","CHE","Switzerland","2018","2018",1224,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","MLLNCUMT","Million of national currency units","CHE","Switzerland","2019","2019",1174,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","MLLNCUMT","Million of national currency units","CHE","Switzerland","2020","2020",1194,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","MLLNCUMT","Million of national currency units","CHE","Switzerland","2021","2021",1217,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","MLLNCUMT","Million of national currency units","CHE","Switzerland","2022","2022",1250,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","MTMOTCMT","Million US$ at exchange rate","CHE","Switzerland","2010","2010",999.4,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","MTMOTCMT","Million US$ at exchange rate","CHE","Switzerland","2011","2011",1197,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","MTMOTCMT","Million US$ at exchange rate","CHE","Switzerland","2012","2012",1130.4,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","MTMOTCMT","Million US$ at exchange rate","CHE","Switzerland","2013","2013",1127.4,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","MTMOTCMT","Million US$ at exchange rate","CHE","Switzerland","2014","2014",1122.1,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","MTMOTCMT","Million US$ at exchange rate","CHE","Switzerland","2015","2015",1076.5,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","MTMOTCMT","Million US$ at exchange rate","CHE","Switzerland","2016","2016",1239.1,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","MTMOTCMT","Million US$ at exchange rate","CHE","Switzerland","2017","2017",1232.9,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","MTMOTCMT","Million US$ at exchange rate","CHE","Switzerland","2018","2018",1251.7,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","MTMOTCMT","Million US$ at exchange rate","CHE","Switzerland","2019","2019",1181.4,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","MTMOTCMT","Million US$ at exchange rate","CHE","Switzerland","2020","2020",1271.6,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","MTMOTCMT","Million US$ at exchange rate","CHE","Switzerland","2021","2021",1331.7,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","MTMOTCMT","Million US$ at exchange rate","CHE","Switzerland","2022","2022",1309.1,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","MTMOPPMT","Million US$, purchasing power parity","CHE","Switzerland","2010","2010",710.9,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","MTMOPPMT","Million US$, purchasing power parity","CHE","Switzerland","2011","2011",760.6,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","MTMOPPMT","Million US$, purchasing power parity","CHE","Switzerland","2012","2012",782.8,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","MTMOPPMT","Million US$, purchasing power parity","CHE","Switzerland","2013","2013",796.2,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","MTMOPPMT","Million US$, purchasing power parity","CHE","Switzerland","2014","2014",802,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","MTMOPPMT","Million US$, purchasing power parity","CHE","Switzerland","2015","2015",838.3,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","MTMOPPMT","Million US$, purchasing power parity","CHE","Switzerland","2016","2016",1015.8,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","MTMOPPMT","Million US$, purchasing power parity","CHE","Switzerland","2017","2017",1022.1,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","MTMOPPMT","Million US$, purchasing power parity","CHE","Switzerland","2018","2018",1038.3,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","MTMOPPMT","Million US$, purchasing power parity","CHE","Switzerland","2019","2019",1020.5,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","MTMOPPMT","Million US$, purchasing power parity","CHE","Switzerland","2020","2020",1051.4,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","MTMOPPMT","Million US$, purchasing power parity","CHE","Switzerland","2021","2021",1099.9,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","MTMOPPMT","Million US$, purchasing power parity","CHE","Switzerland","2022","2022",1172.7,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","TCPPERMT","/capita, US$ exchange rate","CHE","Switzerland","2010","2010",127.7,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","TCPPERMT","/capita, US$ exchange rate","CHE","Switzerland","2011","2011",151.3,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","TCPPERMT","/capita, US$ exchange rate","CHE","Switzerland","2012","2012",141.4,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","TCPPERMT","/capita, US$ exchange rate","CHE","Switzerland","2013","2013",139.4,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","TCPPERMT","/capita, US$ exchange rate","CHE","Switzerland","2014","2014",137,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","TCPPERMT","/capita, US$ exchange rate","CHE","Switzerland","2015","2015",130,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","TCPPERMT","/capita, US$ exchange rate","CHE","Switzerland","2016","2016",148,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","TCPPERMT","/capita, US$ exchange rate","CHE","Switzerland","2017","2017",145.9,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","TCPPERMT","/capita, US$ exchange rate","CHE","Switzerland","2018","2018",147,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","TCPPERMT","/capita, US$ exchange rate","CHE","Switzerland","2019","2019",137.8,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","TCPPERMT","/capita, US$ exchange rate","CHE","Switzerland","2020","2020",147.2,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","TCPPERMT","/capita, US$ exchange rate","CHE","Switzerland","2021","2021",153,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","TCPPERMT","/capita, US$ exchange rate","CHE","Switzerland","2022","2022",149.8,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","CHE","Switzerland","2010","2010",90.9,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","CHE","Switzerland","2011","2011",96.1,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","CHE","Switzerland","2012","2012",97.9,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","CHE","Switzerland","2013","2013",98.4,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","CHE","Switzerland","2014","2014",97.9,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","CHE","Switzerland","2015","2015",101.2,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","CHE","Switzerland","2016","2016",121.3,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","CHE","Switzerland","2017","2017",120.9,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","CHE","Switzerland","2018","2018",121.9,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","CHE","Switzerland","2019","2019",119,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","CHE","Switzerland","2020","2020",121.7,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","CHE","Switzerland","2021","2021",126.4,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","CHE","Switzerland","2022","2022",134.2,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","ATCPTTMT","% of total sales","CHE","Switzerland","2010","2010",18.1,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","ATCPTTMT","% of total sales","CHE","Switzerland","2011","2011",18.4,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","ATCPTTMT","% of total sales","CHE","Switzerland","2012","2012",17.9,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","ATCPTTMT","% of total sales","CHE","Switzerland","2013","2013",17.6,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","ATCPTTMT","% of total sales","CHE","Switzerland","2014","2014",17.3,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","ATCPTTMT","% of total sales","CHE","Switzerland","2015","2015",16.8,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","ATCPTTMT","% of total sales","CHE","Switzerland","2016","2016",19.1,"B; D","Break; Difference in methodology"
+"PATCCNSY","N-Nervous system","ATCPTTMT","% of total sales","CHE","Switzerland","2017","2017",18.6,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","ATCPTTMT","% of total sales","CHE","Switzerland","2018","2018",18.5,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","ATCPTTMT","% of total sales","CHE","Switzerland","2019","2019",17.5,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","ATCPTTMT","% of total sales","CHE","Switzerland","2020","2020",17.5,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","ATCPTTMT","% of total sales","CHE","Switzerland","2021","2021",17.1,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","ATCPTTMT","% of total sales","CHE","Switzerland","2022","2022",16.5,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","MLLNCUMT","Million of national currency units","TUR","Türkiye","2010","2010",1782.4,,
+"PATCCNSY","N-Nervous system","MLLNCUMT","Million of national currency units","TUR","Türkiye","2011","2011",1661.5,,
+"PATCCNSY","N-Nervous system","MLLNCUMT","Million of national currency units","TUR","Türkiye","2012","2012",1498.5,,
+"PATCCNSY","N-Nervous system","MLLNCUMT","Million of national currency units","TUR","Türkiye","2013","2013",1583,,
+"PATCCNSY","N-Nervous system","MLLNCUMT","Million of national currency units","TUR","Türkiye","2014","2014",1693.4,,
+"PATCCNSY","N-Nervous system","MLLNCUMT","Million of national currency units","TUR","Türkiye","2015","2015",1972,,
+"PATCCNSY","N-Nervous system","MLLNCUMT","Million of national currency units","TUR","Türkiye","2016","2016",2512.7,,
+"PATCCNSY","N-Nervous system","MLLNCUMT","Million of national currency units","TUR","Türkiye","2017","2017",3002.5,,
+"PATCCNSY","N-Nervous system","MLLNCUMT","Million of national currency units","TUR","Türkiye","2018","2018",3607.3,,
+"PATCCNSY","N-Nervous system","MLLNCUMT","Million of national currency units","TUR","Türkiye","2019","2019",4659.9,,
+"PATCCNSY","N-Nervous system","MLLNCUMT","Million of national currency units","TUR","Türkiye","2020","2020",5563.4,,
+"PATCCNSY","N-Nervous system","MLLNCUMT","Million of national currency units","TUR","Türkiye","2021","2021",7050.7,,
+"PATCCNSY","N-Nervous system","MTMOTCMT","Million US$ at exchange rate","TUR","Türkiye","2010","2010",1186,,
+"PATCCNSY","N-Nervous system","MTMOTCMT","Million US$ at exchange rate","TUR","Türkiye","2011","2011",992,,
+"PATCCNSY","N-Nervous system","MTMOTCMT","Million US$ at exchange rate","TUR","Türkiye","2012","2012",834.3,,
+"PATCCNSY","N-Nervous system","MTMOTCMT","Million US$ at exchange rate","TUR","Türkiye","2013","2013",831.5,,
+"PATCCNSY","N-Nervous system","MTMOTCMT","Million US$ at exchange rate","TUR","Türkiye","2014","2014",773.7,,
+"PATCCNSY","N-Nervous system","MTMOTCMT","Million US$ at exchange rate","TUR","Türkiye","2015","2015",725,,
+"PATCCNSY","N-Nervous system","MTMOTCMT","Million US$ at exchange rate","TUR","Türkiye","2016","2016",832,,
+"PATCCNSY","N-Nervous system","MTMOTCMT","Million US$ at exchange rate","TUR","Türkiye","2017","2017",823,,
+"PATCCNSY","N-Nervous system","MTMOTCMT","Million US$ at exchange rate","TUR","Türkiye","2018","2018",747.1,,
+"PATCCNSY","N-Nervous system","MTMOTCMT","Million US$ at exchange rate","TUR","Türkiye","2019","2019",821.3,,
+"PATCCNSY","N-Nervous system","MTMOTCMT","Million US$ at exchange rate","TUR","Türkiye","2020","2020",793.8,,
+"PATCCNSY","N-Nervous system","MTMOTCMT","Million US$ at exchange rate","TUR","Türkiye","2021","2021",796.7,,
+"PATCCNSY","N-Nervous system","MTMOPPMT","Million US$, purchasing power parity","TUR","Türkiye","2010","2010",1936.7,,
+"PATCCNSY","N-Nervous system","MTMOPPMT","Million US$, purchasing power parity","TUR","Türkiye","2011","2011",1719.6,,
+"PATCCNSY","N-Nervous system","MTMOPPMT","Million US$, purchasing power parity","TUR","Türkiye","2012","2012",1469.3,,
+"PATCCNSY","N-Nervous system","MTMOPPMT","Million US$, purchasing power parity","TUR","Türkiye","2013","2013",1479,,
+"PATCCNSY","N-Nervous system","MTMOPPMT","Million US$, purchasing power parity","TUR","Türkiye","2014","2014",1533.1,,
+"PATCCNSY","N-Nervous system","MTMOPPMT","Million US$, purchasing power parity","TUR","Türkiye","2015","2015",1696.5,,
+"PATCCNSY","N-Nervous system","MTMOPPMT","Million US$, purchasing power parity","TUR","Türkiye","2016","2016",2024.6,,
+"PATCCNSY","N-Nervous system","MTMOPPMT","Million US$, purchasing power parity","TUR","Türkiye","2017","2017",2169.4,,
+"PATCCNSY","N-Nervous system","MTMOPPMT","Million US$, purchasing power parity","TUR","Türkiye","2018","2018",2209.5,,
+"PATCCNSY","N-Nervous system","MTMOPPMT","Million US$, purchasing power parity","TUR","Türkiye","2019","2019",2499.9,,
+"PATCCNSY","N-Nervous system","MTMOPPMT","Million US$, purchasing power parity","TUR","Türkiye","2020","2020",2570.7,,
+"PATCCNSY","N-Nervous system","MTMOPPMT","Million US$, purchasing power parity","TUR","Türkiye","2021","2021",2511,,
+"PATCCNSY","N-Nervous system","TCPPERMT","/capita, US$ exchange rate","TUR","Türkiye","2010","2010",16.2,,
+"PATCCNSY","N-Nervous system","TCPPERMT","/capita, US$ exchange rate","TUR","Türkiye","2011","2011",13.4,,
+"PATCCNSY","N-Nervous system","TCPPERMT","/capita, US$ exchange rate","TUR","Türkiye","2012","2012",11.1,,
+"PATCCNSY","N-Nervous system","TCPPERMT","/capita, US$ exchange rate","TUR","Türkiye","2013","2013",10.9,,
+"PATCCNSY","N-Nervous system","TCPPERMT","/capita, US$ exchange rate","TUR","Türkiye","2014","2014",10,,
+"PATCCNSY","N-Nervous system","TCPPERMT","/capita, US$ exchange rate","TUR","Türkiye","2015","2015",9.3,,
+"PATCCNSY","N-Nervous system","TCPPERMT","/capita, US$ exchange rate","TUR","Türkiye","2016","2016",10.5,,
+"PATCCNSY","N-Nervous system","TCPPERMT","/capita, US$ exchange rate","TUR","Türkiye","2017","2017",10.2,,
+"PATCCNSY","N-Nervous system","TCPPERMT","/capita, US$ exchange rate","TUR","Türkiye","2018","2018",9.2,,
+"PATCCNSY","N-Nervous system","TCPPERMT","/capita, US$ exchange rate","TUR","Türkiye","2019","2019",9.9,,
+"PATCCNSY","N-Nervous system","TCPPERMT","/capita, US$ exchange rate","TUR","Türkiye","2020","2020",9.5,,
+"PATCCNSY","N-Nervous system","TCPPERMT","/capita, US$ exchange rate","TUR","Türkiye","2021","2021",9.5,,
+"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2010","2010",26.5,,
+"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2011","2011",23.2,,
+"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2012","2012",19.5,,
+"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2013","2013",19.4,,
+"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2014","2014",19.9,,
+"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2015","2015",21.7,,
+"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2016","2016",25.5,,
+"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2017","2017",27,,
+"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2018","2018",27.1,,
+"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2019","2019",30.3,,
+"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2020","2020",30.8,,
+"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2021","2021",29.8,,
+"PATCCNSY","N-Nervous system","ATCPTTMT","% of total sales","TUR","Türkiye","2010","2010",11.4,,
+"PATCCNSY","N-Nervous system","ATCPTTMT","% of total sales","TUR","Türkiye","2011","2011",11.7,,
+"PATCCNSY","N-Nervous system","ATCPTTMT","% of total sales","TUR","Türkiye","2012","2012",11.1,,
+"PATCCNSY","N-Nervous system","ATCPTTMT","% of total sales","TUR","Türkiye","2013","2013",11,,
+"PATCCNSY","N-Nervous system","ATCPTTMT","% of total sales","TUR","Türkiye","2014","2014",10.8,,
+"PATCCNSY","N-Nervous system","ATCPTTMT","% of total sales","TUR","Türkiye","2015","2015",10.8,,
+"PATCCNSY","N-Nervous system","ATCPTTMT","% of total sales","TUR","Türkiye","2016","2016",11.5,,
+"PATCCNSY","N-Nervous system","ATCPTTMT","% of total sales","TUR","Türkiye","2017","2017",11.8,,
+"PATCCNSY","N-Nervous system","ATCPTTMT","% of total sales","TUR","Türkiye","2018","2018",11.3,,
+"PATCCNSY","N-Nervous system","ATCPTTMT","% of total sales","TUR","Türkiye","2019","2019",11.1,,
+"PATCCNSY","N-Nervous system","ATCPTTMT","% of total sales","TUR","Türkiye","2020","2020",11.1,,
+"PATCCNSY","N-Nervous system","ATCPTTMT","% of total sales","TUR","Türkiye","2021","2021",10.9,,
+"PATCCNSY","N-Nervous system","MLLNCUMT","Million of national currency units","GBR","United Kingdom","2012","2012",2581.8,"B","Break"
+"PATCCNSY","N-Nervous system","MLLNCUMT","Million of national currency units","GBR","United Kingdom","2013","2013",2760.2,,
+"PATCCNSY","N-Nervous system","MLLNCUMT","Million of national currency units","GBR","United Kingdom","2014","2014",2955.9,,
+"PATCCNSY","N-Nervous system","MLLNCUMT","Million of national currency units","GBR","United Kingdom","2015","2015",3222.4,,
+"PATCCNSY","N-Nervous system","MLLNCUMT","Million of national currency units","GBR","United Kingdom","2016","2016",3253,,
+"PATCCNSY","N-Nervous system","MLLNCUMT","Million of national currency units","GBR","United Kingdom","2017","2017",3191.5,,
+"PATCCNSY","N-Nervous system","MLLNCUMT","Million of national currency units","GBR","United Kingdom","2018","2018",3170.2,,
+"PATCCNSY","N-Nervous system","MTMOTCMT","Million US$ at exchange rate","GBR","United Kingdom","2012","2012",4078.4,"B","Break"
+"PATCCNSY","N-Nervous system","MTMOTCMT","Million US$ at exchange rate","GBR","United Kingdom","2013","2013",4315.1,,
+"PATCCNSY","N-Nervous system","MTMOTCMT","Million US$ at exchange rate","GBR","United Kingdom","2014","2014",4863.8,,
+"PATCCNSY","N-Nervous system","MTMOTCMT","Million US$ at exchange rate","GBR","United Kingdom","2015","2015",4923.1,,
+"PATCCNSY","N-Nervous system","MTMOTCMT","Million US$ at exchange rate","GBR","United Kingdom","2016","2016",4392.2,,
+"PATCCNSY","N-Nervous system","MTMOTCMT","Million US$ at exchange rate","GBR","United Kingdom","2017","2017",4107.6,,
+"PATCCNSY","N-Nervous system","MTMOTCMT","Million US$ at exchange rate","GBR","United Kingdom","2018","2018",4229.6,,
+"PATCCNSY","N-Nervous system","MTMOPPMT","Million US$, purchasing power parity","GBR","United Kingdom","2012","2012",3679.7,"B","Break"
+"PATCCNSY","N-Nervous system","MTMOPPMT","Million US$, purchasing power parity","GBR","United Kingdom","2013","2013",3970.1,,
+"PATCCNSY","N-Nervous system","MTMOPPMT","Million US$, purchasing power parity","GBR","United Kingdom","2014","2014",4232.1,,
+"PATCCNSY","N-Nervous system","MTMOPPMT","Million US$, purchasing power parity","GBR","United Kingdom","2015","2015",4652.9,,
+"PATCCNSY","N-Nervous system","MTMOPPMT","Million US$, purchasing power parity","GBR","United Kingdom","2016","2016",4724.1,,
+"PATCCNSY","N-Nervous system","MTMOPPMT","Million US$, purchasing power parity","GBR","United Kingdom","2017","2017",4661.8,,
+"PATCCNSY","N-Nervous system","MTMOPPMT","Million US$, purchasing power parity","GBR","United Kingdom","2018","2018",4609.8,,
+"PATCCNSY","N-Nervous system","TCPPERMT","/capita, US$ exchange rate","GBR","United Kingdom","2012","2012",64,"B","Break"
+"PATCCNSY","N-Nervous system","TCPPERMT","/capita, US$ exchange rate","GBR","United Kingdom","2013","2013",67.3,,
+"PATCCNSY","N-Nervous system","TCPPERMT","/capita, US$ exchange rate","GBR","United Kingdom","2014","2014",75.3,,
+"PATCCNSY","N-Nervous system","TCPPERMT","/capita, US$ exchange rate","GBR","United Kingdom","2015","2015",75.6,,
+"PATCCNSY","N-Nervous system","TCPPERMT","/capita, US$ exchange rate","GBR","United Kingdom","2016","2016",66.9,,
+"PATCCNSY","N-Nervous system","TCPPERMT","/capita, US$ exchange rate","GBR","United Kingdom","2017","2017",62.2,,
+"PATCCNSY","N-Nervous system","TCPPERMT","/capita, US$ exchange rate","GBR","United Kingdom","2018","2018",63.7,,
+"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","GBR","United Kingdom","2012","2012",57.8,"B","Break"
+"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","GBR","United Kingdom","2013","2013",61.9,,
+"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","GBR","United Kingdom","2014","2014",65.5,,
+"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","GBR","United Kingdom","2015","2015",71.5,,
+"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","GBR","United Kingdom","2016","2016",72,,
+"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","GBR","United Kingdom","2017","2017",70.6,,
+"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","GBR","United Kingdom","2018","2018",69.4,,
+"PATCCNSY","N-Nervous system","ATCPTTMT","% of total sales","GBR","United Kingdom","2012","2012",18.7,"B","Break"
+"PATCCNSY","N-Nervous system","ATCPTTMT","% of total sales","GBR","United Kingdom","2013","2013",18.9,,
+"PATCCNSY","N-Nervous system","ATCPTTMT","% of total sales","GBR","United Kingdom","2014","2014",18.5,,
+"PATCCNSY","N-Nervous system","ATCPTTMT","% of total sales","GBR","United Kingdom","2015","2015",18.2,,
+"PATCCNSY","N-Nervous system","ATCPTTMT","% of total sales","GBR","United Kingdom","2016","2016",17.5,,
+"PATCCNSY","N-Nervous system","ATCPTTMT","% of total sales","GBR","United Kingdom","2017","2017",16.3,,
+"PATCCNSY","N-Nervous system","ATCPTTMT","% of total sales","GBR","United Kingdom","2018","2018",15.5,,
+"PATCCNSY","N-Nervous system","MLLNCUMT","Million of national currency units","CHL","Chile","2010","2010",154950.4,,
+"PATCCNSY","N-Nervous system","MLLNCUMT","Million of national currency units","CHL","Chile","2011","2011",187215,"B","Break"
+"PATCCNSY","N-Nervous system","MLLNCUMT","Million of national currency units","CHL","Chile","2012","2012",205981.7,,
+"PATCCNSY","N-Nervous system","MLLNCUMT","Million of national currency units","CHL","Chile","2013","2013",214727.7,,
+"PATCCNSY","N-Nervous system","MLLNCUMT","Million of national currency units","CHL","Chile","2014","2014",249601.3,,
+"PATCCNSY","N-Nervous system","MLLNCUMT","Million of national currency units","CHL","Chile","2015","2015",283661.8,,
+"PATCCNSY","N-Nervous system","MLLNCUMT","Million of national currency units","CHL","Chile","2016","2016",303392,,
+"PATCCNSY","N-Nervous system","MLLNCUMT","Million of national currency units","CHL","Chile","2017","2017",310804,,
+"PATCCNSY","N-Nervous system","MLLNCUMT","Million of national currency units","CHL","Chile","2018","2018",321757.3,,
+"PATCCNSY","N-Nervous system","MLLNCUMT","Million of national currency units","CHL","Chile","2019","2019",331298.1,,
+"PATCCNSY","N-Nervous system","MLLNCUMT","Million of national currency units","CHL","Chile","2020","2020",380815.7,,
+"PATCCNSY","N-Nervous system","MLLNCUMT","Million of national currency units","CHL","Chile","2021","2021",446706.8,,
+"PATCCNSY","N-Nervous system","MLLNCUMT","Million of national currency units","CHL","Chile","2022","2022",424777.8,,
+"PATCCNSY","N-Nervous system","MTMOTCMT","Million US$ at exchange rate","CHL","Chile","2010","2010",303.7,,
+"PATCCNSY","N-Nervous system","MTMOTCMT","Million US$ at exchange rate","CHL","Chile","2011","2011",387.1,"B","Break"
+"PATCCNSY","N-Nervous system","MTMOTCMT","Million US$ at exchange rate","CHL","Chile","2012","2012",423.4,,
+"PATCCNSY","N-Nervous system","MTMOTCMT","Million US$ at exchange rate","CHL","Chile","2013","2013",433.6,,
+"PATCCNSY","N-Nervous system","MTMOTCMT","Million US$ at exchange rate","CHL","Chile","2014","2014",437.6,,
+"PATCCNSY","N-Nervous system","MTMOTCMT","Million US$ at exchange rate","CHL","Chile","2015","2015",433.7,,
+"PATCCNSY","N-Nervous system","MTMOTCMT","Million US$ at exchange rate","CHL","Chile","2016","2016",448.2,,
+"PATCCNSY","N-Nervous system","MTMOTCMT","Million US$ at exchange rate","CHL","Chile","2017","2017",479,,
+"PATCCNSY","N-Nervous system","MTMOTCMT","Million US$ at exchange rate","CHL","Chile","2018","2018",501.7,,
+"PATCCNSY","N-Nervous system","MTMOTCMT","Million US$ at exchange rate","CHL","Chile","2019","2019",471.3,,
+"PATCCNSY","N-Nervous system","MTMOTCMT","Million US$ at exchange rate","CHL","Chile","2020","2020",480.4,,
+"PATCCNSY","N-Nervous system","MTMOTCMT","Million US$ at exchange rate","CHL","Chile","2021","2021",588.6,,
+"PATCCNSY","N-Nervous system","MTMOTCMT","Million US$ at exchange rate","CHL","Chile","2022","2022",486.4,,
+"PATCCNSY","N-Nervous system","MTMOPPMT","Million US$, purchasing power parity","CHL","Chile","2010","2010",430.6,,
+"PATCCNSY","N-Nervous system","MTMOPPMT","Million US$, purchasing power parity","CHL","Chile","2011","2011",537.9,"B","Break"
+"PATCCNSY","N-Nervous system","MTMOPPMT","Million US$, purchasing power parity","CHL","Chile","2012","2012",593.2,,
+"PATCCNSY","N-Nervous system","MTMOPPMT","Million US$, purchasing power parity","CHL","Chile","2013","2013",614.1,,
+"PATCCNSY","N-Nervous system","MTMOPPMT","Million US$, purchasing power parity","CHL","Chile","2014","2014",679.7,,
+"PATCCNSY","N-Nervous system","MTMOPPMT","Million US$, purchasing power parity","CHL","Chile","2015","2015",725.1,,
+"PATCCNSY","N-Nervous system","MTMOPPMT","Million US$, purchasing power parity","CHL","Chile","2016","2016",763.7,,
+"PATCCNSY","N-Nervous system","MTMOPPMT","Million US$, purchasing power parity","CHL","Chile","2017","2017",781.5,,
+"PATCCNSY","N-Nervous system","MTMOPPMT","Million US$, purchasing power parity","CHL","Chile","2018","2018",812,,
+"PATCCNSY","N-Nervous system","MTMOPPMT","Million US$, purchasing power parity","CHL","Chile","2019","2019",824.9,,
+"PATCCNSY","N-Nervous system","MTMOPPMT","Million US$, purchasing power parity","CHL","Chile","2020","2020",910.1,,
+"PATCCNSY","N-Nervous system","MTMOPPMT","Million US$, purchasing power parity","CHL","Chile","2021","2021",1026.5,,
+"PATCCNSY","N-Nervous system","MTMOPPMT","Million US$, purchasing power parity","CHL","Chile","2022","2022",970.8,,
+"PATCCNSY","N-Nervous system","TCPPERMT","/capita, US$ exchange rate","CHL","Chile","2010","2010",17.8,,
+"PATCCNSY","N-Nervous system","TCPPERMT","/capita, US$ exchange rate","CHL","Chile","2011","2011",22.4,"B","Break"
+"PATCCNSY","N-Nervous system","TCPPERMT","/capita, US$ exchange rate","CHL","Chile","2012","2012",24.3,,
+"PATCCNSY","N-Nervous system","TCPPERMT","/capita, US$ exchange rate","CHL","Chile","2013","2013",24.6,,
+"PATCCNSY","N-Nervous system","TCPPERMT","/capita, US$ exchange rate","CHL","Chile","2014","2014",24.6,,
+"PATCCNSY","N-Nervous system","TCPPERMT","/capita, US$ exchange rate","CHL","Chile","2015","2015",24.1,,
+"PATCCNSY","N-Nervous system","TCPPERMT","/capita, US$ exchange rate","CHL","Chile","2016","2016",24.7,,
+"PATCCNSY","N-Nervous system","TCPPERMT","/capita, US$ exchange rate","CHL","Chile","2017","2017",26,,
+"PATCCNSY","N-Nervous system","TCPPERMT","/capita, US$ exchange rate","CHL","Chile","2018","2018",26.8,,
+"PATCCNSY","N-Nervous system","TCPPERMT","/capita, US$ exchange rate","CHL","Chile","2019","2019",24.7,,
+"PATCCNSY","N-Nervous system","TCPPERMT","/capita, US$ exchange rate","CHL","Chile","2020","2020",24.7,,
+"PATCCNSY","N-Nervous system","TCPPERMT","/capita, US$ exchange rate","CHL","Chile","2021","2021",29.9,,
+"PATCCNSY","N-Nervous system","TCPPERMT","/capita, US$ exchange rate","CHL","Chile","2022","2022",24.5,,
+"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2010","2010",25.2,,
+"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2011","2011",31.2,"B","Break"
+"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2012","2012",34,,
+"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2013","2013",34.9,,
+"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2014","2014",38.2,,
+"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2015","2015",40.3,,
+"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2016","2016",42,,
+"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2017","2017",42.4,,
+"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2018","2018",43.3,,
+"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2019","2019",43.2,,
+"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2020","2020",46.8,,
+"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2021","2021",52.2,,
+"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2022","2022",49,,
+"PATCCNSY","N-Nervous system","ATCPTTMT","% of total sales","CHL","Chile","2010","2010",18.8,,
+"PATCCNSY","N-Nervous system","ATCPTTMT","% of total sales","CHL","Chile","2011","2011",15.9,"B","Break"
+"PATCCNSY","N-Nervous system","ATCPTTMT","% of total sales","CHL","Chile","2012","2012",16.5,,
+"PATCCNSY","N-Nervous system","ATCPTTMT","% of total sales","CHL","Chile","2013","2013",14.8,,
+"PATCCNSY","N-Nervous system","ATCPTTMT","% of total sales","CHL","Chile","2014","2014",16.1,,
+"PATCCNSY","N-Nervous system","ATCPTTMT","% of total sales","CHL","Chile","2015","2015",15.6,,
+"PATCCNSY","N-Nervous system","ATCPTTMT","% of total sales","CHL","Chile","2016","2016",15,,
+"PATCCNSY","N-Nervous system","ATCPTTMT","% of total sales","CHL","Chile","2017","2017",15,,
+"PATCCNSY","N-Nervous system","ATCPTTMT","% of total sales","CHL","Chile","2018","2018",14,,
+"PATCCNSY","N-Nervous system","ATCPTTMT","% of total sales","CHL","Chile","2019","2019",13.1,,
+"PATCCNSY","N-Nervous system","ATCPTTMT","% of total sales","CHL","Chile","2020","2020",14.2,,
+"PATCCNSY","N-Nervous system","ATCPTTMT","% of total sales","CHL","Chile","2021","2021",15.9,,
+"PATCCNSY","N-Nervous system","ATCPTTMT","% of total sales","CHL","Chile","2022","2022",15.1,,
+"PATCCNSY","N-Nervous system","MLLNCUMT","Million of national currency units","EST","Estonia","2010","2010",21.5,,
+"PATCCNSY","N-Nervous system","MLLNCUMT","Million of national currency units","EST","Estonia","2011","2011",22.1,,
+"PATCCNSY","N-Nervous system","MLLNCUMT","Million of national currency units","EST","Estonia","2012","2012",22.9,,
+"PATCCNSY","N-Nervous system","MLLNCUMT","Million of national currency units","EST","Estonia","2013","2013",23.2,,
+"PATCCNSY","N-Nervous system","MLLNCUMT","Million of national currency units","EST","Estonia","2014","2014",23.9,,
+"PATCCNSY","N-Nervous system","MLLNCUMT","Million of national currency units","EST","Estonia","2015","2015",25,,
+"PATCCNSY","N-Nervous system","MLLNCUMT","Million of national currency units","EST","Estonia","2016","2016",25.3,,
+"PATCCNSY","N-Nervous system","MLLNCUMT","Million of national currency units","EST","Estonia","2017","2017",26.2,,
+"PATCCNSY","N-Nervous system","MLLNCUMT","Million of national currency units","EST","Estonia","2018","2018",28.2,,
+"PATCCNSY","N-Nervous system","MLLNCUMT","Million of national currency units","EST","Estonia","2019","2019",30.2,,
+"PATCCNSY","N-Nervous system","MLLNCUMT","Million of national currency units","EST","Estonia","2020","2020",32.2,,
+"PATCCNSY","N-Nervous system","MLLNCUMT","Million of national currency units","EST","Estonia","2021","2021",34.5,,
+"PATCCNSY","N-Nervous system","MLLNCUMT","Million of national currency units","EST","Estonia","2022","2022",38.8,,
+"PATCCNSY","N-Nervous system","MTMOTCMT","Million US$ at exchange rate","EST","Estonia","2010","2010",28.5,,
+"PATCCNSY","N-Nervous system","MTMOTCMT","Million US$ at exchange rate","EST","Estonia","2011","2011",30.8,,
+"PATCCNSY","N-Nervous system","MTMOTCMT","Million US$ at exchange rate","EST","Estonia","2012","2012",29.4,,
+"PATCCNSY","N-Nervous system","MTMOTCMT","Million US$ at exchange rate","EST","Estonia","2013","2013",30.8,,
+"PATCCNSY","N-Nervous system","MTMOTCMT","Million US$ at exchange rate","EST","Estonia","2014","2014",31.7,,
+"PATCCNSY","N-Nervous system","MTMOTCMT","Million US$ at exchange rate","EST","Estonia","2015","2015",27.7,,
+"PATCCNSY","N-Nervous system","MTMOTCMT","Million US$ at exchange rate","EST","Estonia","2016","2016",28,,
+"PATCCNSY","N-Nervous system","MTMOTCMT","Million US$ at exchange rate","EST","Estonia","2017","2017",29.6,,
+"PATCCNSY","N-Nervous system","MTMOTCMT","Million US$ at exchange rate","EST","Estonia","2018","2018",33.3,,
+"PATCCNSY","N-Nervous system","MTMOTCMT","Million US$ at exchange rate","EST","Estonia","2019","2019",33.8,,
+"PATCCNSY","N-Nervous system","MTMOTCMT","Million US$ at exchange rate","EST","Estonia","2020","2020",36.8,,
+"PATCCNSY","N-Nervous system","MTMOTCMT","Million US$ at exchange rate","EST","Estonia","2021","2021",40.8,,
+"PATCCNSY","N-Nervous system","MTMOTCMT","Million US$ at exchange rate","EST","Estonia","2022","2022",40.9,,
+"PATCCNSY","N-Nervous system","MTMOPPMT","Million US$, purchasing power parity","EST","Estonia","2010","2010",42,,
+"PATCCNSY","N-Nervous system","MTMOPPMT","Million US$, purchasing power parity","EST","Estonia","2011","2011",43.3,,
+"PATCCNSY","N-Nervous system","MTMOPPMT","Million US$, purchasing power parity","EST","Estonia","2012","2012",43.9,,
+"PATCCNSY","N-Nervous system","MTMOPPMT","Million US$, purchasing power parity","EST","Estonia","2013","2013",44.3,,
+"PATCCNSY","N-Nervous system","MTMOPPMT","Million US$, purchasing power parity","EST","Estonia","2014","2014",45.3,,
+"PATCCNSY","N-Nervous system","MTMOPPMT","Million US$, purchasing power parity","EST","Estonia","2015","2015",46.4,,
+"PATCCNSY","N-Nervous system","MTMOPPMT","Million US$, purchasing power parity","EST","Estonia","2016","2016",47.9,,
+"PATCCNSY","N-Nervous system","MTMOPPMT","Million US$, purchasing power parity","EST","Estonia","2017","2017",49,,
+"PATCCNSY","N-Nervous system","MTMOPPMT","Million US$, purchasing power parity","EST","Estonia","2018","2018",52.3,,
+"PATCCNSY","N-Nervous system","MTMOPPMT","Million US$, purchasing power parity","EST","Estonia","2019","2019",56.3,,
+"PATCCNSY","N-Nervous system","MTMOPPMT","Million US$, purchasing power parity","EST","Estonia","2020","2020",61.5,,
+"PATCCNSY","N-Nervous system","MTMOPPMT","Million US$, purchasing power parity","EST","Estonia","2021","2021",63.4,,
+"PATCCNSY","N-Nervous system","MTMOPPMT","Million US$, purchasing power parity","EST","Estonia","2022","2022",68.1,,
+"PATCCNSY","N-Nervous system","TCPPERMT","/capita, US$ exchange rate","EST","Estonia","2010","2010",21.4,,
+"PATCCNSY","N-Nervous system","TCPPERMT","/capita, US$ exchange rate","EST","Estonia","2011","2011",23.2,,
+"PATCCNSY","N-Nervous system","TCPPERMT","/capita, US$ exchange rate","EST","Estonia","2012","2012",22.2,,
+"PATCCNSY","N-Nervous system","TCPPERMT","/capita, US$ exchange rate","EST","Estonia","2013","2013",23.3,,
+"PATCCNSY","N-Nervous system","TCPPERMT","/capita, US$ exchange rate","EST","Estonia","2014","2014",24.1,,
+"PATCCNSY","N-Nervous system","TCPPERMT","/capita, US$ exchange rate","EST","Estonia","2015","2015",21.1,,
+"PATCCNSY","N-Nervous system","TCPPERMT","/capita, US$ exchange rate","EST","Estonia","2016","2016",21.3,,
+"PATCCNSY","N-Nervous system","TCPPERMT","/capita, US$ exchange rate","EST","Estonia","2017","2017",22.5,,
+"PATCCNSY","N-Nervous system","TCPPERMT","/capita, US$ exchange rate","EST","Estonia","2018","2018",25.2,,
+"PATCCNSY","N-Nervous system","TCPPERMT","/capita, US$ exchange rate","EST","Estonia","2019","2019",25.5,,
+"PATCCNSY","N-Nervous system","TCPPERMT","/capita, US$ exchange rate","EST","Estonia","2020","2020",27.7,,
+"PATCCNSY","N-Nervous system","TCPPERMT","/capita, US$ exchange rate","EST","Estonia","2021","2021",30.6,,
+"PATCCNSY","N-Nervous system","TCPPERMT","/capita, US$ exchange rate","EST","Estonia","2022","2022",30.7,,
+"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2010","2010",31.5,,
+"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2011","2011",32.6,,
+"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2012","2012",33.2,,
+"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2013","2013",33.6,,
+"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2014","2014",34.5,,
+"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2015","2015",35.3,,
+"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2016","2016",36.4,,
+"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2017","2017",37.2,,
+"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2018","2018",39.5,,
+"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2019","2019",42.5,,
+"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2020","2020",46.2,,
+"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2021","2021",47.7,,
+"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2022","2022",51.2,,
+"PATCCNSY","N-Nervous system","ATCPTTMT","% of total sales","EST","Estonia","2010","2010",11.1,,
+"PATCCNSY","N-Nervous system","ATCPTTMT","% of total sales","EST","Estonia","2011","2011",10.8,,
+"PATCCNSY","N-Nervous system","ATCPTTMT","% of total sales","EST","Estonia","2012","2012",10.3,,
+"PATCCNSY","N-Nervous system","ATCPTTMT","% of total sales","EST","Estonia","2013","2013",10,,
+"PATCCNSY","N-Nervous system","ATCPTTMT","% of total sales","EST","Estonia","2014","2014",9.6,,
+"PATCCNSY","N-Nervous system","ATCPTTMT","% of total sales","EST","Estonia","2015","2015",9.4,,
+"PATCCNSY","N-Nervous system","ATCPTTMT","% of total sales","EST","Estonia","2016","2016",8.7,,
+"PATCCNSY","N-Nervous system","ATCPTTMT","% of total sales","EST","Estonia","2017","2017",8.7,,
+"PATCCNSY","N-Nervous system","ATCPTTMT","% of total sales","EST","Estonia","2018","2018",8.7,,
+"PATCCNSY","N-Nervous system","ATCPTTMT","% of total sales","EST","Estonia","2019","2019",8.8,,
+"PATCCNSY","N-Nervous system","ATCPTTMT","% of total sales","EST","Estonia","2020","2020",9,,
+"PATCCNSY","N-Nervous system","ATCPTTMT","% of total sales","EST","Estonia","2021","2021",8.4,,
+"PATCCNSY","N-Nervous system","ATCPTTMT","% of total sales","EST","Estonia","2022","2022",9,,
+"PATCCNSY","N-Nervous system","MLLNCUMT","Million of national currency units","SVN","Slovenia","2010","2010",80.4,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","MLLNCUMT","Million of national currency units","SVN","Slovenia","2011","2011",79.9,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","MLLNCUMT","Million of national currency units","SVN","Slovenia","2012","2012",74.1,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","MLLNCUMT","Million of national currency units","SVN","Slovenia","2013","2013",71.9,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","MLLNCUMT","Million of national currency units","SVN","Slovenia","2014","2014",69.6,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","MLLNCUMT","Million of national currency units","SVN","Slovenia","2015","2015",65.9,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","MLLNCUMT","Million of national currency units","SVN","Slovenia","2016","2016",65.1,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","MLLNCUMT","Million of national currency units","SVN","Slovenia","2017","2017",63.2,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","MLLNCUMT","Million of national currency units","SVN","Slovenia","2018","2018",64.8,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","MLLNCUMT","Million of national currency units","SVN","Slovenia","2019","2019",65.5,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","MLLNCUMT","Million of national currency units","SVN","Slovenia","2020","2020",67.5,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","MLLNCUMT","Million of national currency units","SVN","Slovenia","2021","2021",70.8,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","MLLNCUMT","Million of national currency units","SVN","Slovenia","2022","2022",75.3,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","MTMOTCMT","Million US$ at exchange rate","SVN","Slovenia","2010","2010",106.5,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","MTMOTCMT","Million US$ at exchange rate","SVN","Slovenia","2011","2011",111.2,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","MTMOTCMT","Million US$ at exchange rate","SVN","Slovenia","2012","2012",95.2,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","MTMOTCMT","Million US$ at exchange rate","SVN","Slovenia","2013","2013",95.5,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","MTMOTCMT","Million US$ at exchange rate","SVN","Slovenia","2014","2014",92.5,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","MTMOTCMT","Million US$ at exchange rate","SVN","Slovenia","2015","2015",73.2,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","MTMOTCMT","Million US$ at exchange rate","SVN","Slovenia","2016","2016",72.1,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","MTMOTCMT","Million US$ at exchange rate","SVN","Slovenia","2017","2017",71.4,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","MTMOTCMT","Million US$ at exchange rate","SVN","Slovenia","2018","2018",76.5,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","MTMOTCMT","Million US$ at exchange rate","SVN","Slovenia","2019","2019",73.3,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","MTMOTCMT","Million US$ at exchange rate","SVN","Slovenia","2020","2020",77.1,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","MTMOTCMT","Million US$ at exchange rate","SVN","Slovenia","2021","2021",83.7,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","MTMOTCMT","Million US$ at exchange rate","SVN","Slovenia","2022","2022",79.3,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","MTMOPPMT","Million US$, purchasing power parity","SVN","Slovenia","2010","2010",126,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","MTMOPPMT","Million US$, purchasing power parity","SVN","Slovenia","2011","2011",128.1,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","MTMOPPMT","Million US$, purchasing power parity","SVN","Slovenia","2012","2012",122.2,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","MTMOPPMT","Million US$, purchasing power parity","SVN","Slovenia","2013","2013",121.8,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","MTMOPPMT","Million US$, purchasing power parity","SVN","Slovenia","2014","2014",117.8,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","MTMOPPMT","Million US$, purchasing power parity","SVN","Slovenia","2015","2015",110.8,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","MTMOPPMT","Million US$, purchasing power parity","SVN","Slovenia","2016","2016",112.9,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","MTMOPPMT","Million US$, purchasing power parity","SVN","Slovenia","2017","2017",110.9,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","MTMOPPMT","Million US$, purchasing power parity","SVN","Slovenia","2018","2018",114.1,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","MTMOPPMT","Million US$, purchasing power parity","SVN","Slovenia","2019","2019",118.7,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","MTMOPPMT","Million US$, purchasing power parity","SVN","Slovenia","2020","2020",123.4,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","MTMOPPMT","Million US$, purchasing power parity","SVN","Slovenia","2021","2021",125.7,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","MTMOPPMT","Million US$, purchasing power parity","SVN","Slovenia","2022","2022",136.5,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","TCPPERMT","/capita, US$ exchange rate","SVN","Slovenia","2010","2010",52,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","TCPPERMT","/capita, US$ exchange rate","SVN","Slovenia","2011","2011",54.2,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","TCPPERMT","/capita, US$ exchange rate","SVN","Slovenia","2012","2012",46.3,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","TCPPERMT","/capita, US$ exchange rate","SVN","Slovenia","2013","2013",46.3,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","TCPPERMT","/capita, US$ exchange rate","SVN","Slovenia","2014","2014",44.9,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","TCPPERMT","/capita, US$ exchange rate","SVN","Slovenia","2015","2015",35.4,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","TCPPERMT","/capita, US$ exchange rate","SVN","Slovenia","2016","2016",34.9,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","TCPPERMT","/capita, US$ exchange rate","SVN","Slovenia","2017","2017",34.6,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","TCPPERMT","/capita, US$ exchange rate","SVN","Slovenia","2018","2018",36.9,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","TCPPERMT","/capita, US$ exchange rate","SVN","Slovenia","2019","2019",35.1,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","TCPPERMT","/capita, US$ exchange rate","SVN","Slovenia","2020","2020",36.7,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","TCPPERMT","/capita, US$ exchange rate","SVN","Slovenia","2021","2021",39.7,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","TCPPERMT","/capita, US$ exchange rate","SVN","Slovenia","2022","2022",37.6,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2010","2010",61.5,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2011","2011",62.4,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2012","2012",59.4,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2013","2013",59.1,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2014","2014",57.1,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2015","2015",53.7,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2016","2016",54.7,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2017","2017",53.7,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2018","2018",55,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2019","2019",56.8,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2020","2020",58.7,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2021","2021",59.6,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2022","2022",64.8,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","ATCPTTMT","% of total sales","SVN","Slovenia","2010","2010",16.9,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","ATCPTTMT","% of total sales","SVN","Slovenia","2011","2011",17,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","ATCPTTMT","% of total sales","SVN","Slovenia","2012","2012",16.3,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","ATCPTTMT","% of total sales","SVN","Slovenia","2013","2013",15.9,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","ATCPTTMT","% of total sales","SVN","Slovenia","2014","2014",16.1,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","ATCPTTMT","% of total sales","SVN","Slovenia","2015","2015",14.8,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","ATCPTTMT","% of total sales","SVN","Slovenia","2016","2016",14,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","ATCPTTMT","% of total sales","SVN","Slovenia","2017","2017",13.1,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","ATCPTTMT","% of total sales","SVN","Slovenia","2018","2018",12.5,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","ATCPTTMT","% of total sales","SVN","Slovenia","2019","2019",12.1,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","ATCPTTMT","% of total sales","SVN","Slovenia","2020","2020",11.9,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","ATCPTTMT","% of total sales","SVN","Slovenia","2021","2021",11.5,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","ATCPTTMT","% of total sales","SVN","Slovenia","2022","2022",11.1,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","MLLNCUMT","Million of national currency units","AUS","Australia","2010","2010",378,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","MLLNCUMT","Million of national currency units","AUS","Australia","2011","2011",408,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","MLLNCUMT","Million of national currency units","AUS","Australia","2012","2012",433,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","MLLNCUMT","Million of national currency units","AUS","Australia","2013","2013",503,"B; D","Break; Difference in methodology"
+"PATCANAL","N02-Analgesics","MLLNCUMT","Million of national currency units","AUS","Australia","2014","2014",516,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","MLLNCUMT","Million of national currency units","AUS","Australia","2015","2015",554,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","MLLNCUMT","Million of national currency units","AUS","Australia","2016","2016",497,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","MLLNCUMT","Million of national currency units","AUS","Australia","2017","2017",512,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","MLLNCUMT","Million of national currency units","AUS","Australia","2018","2018",516,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","MLLNCUMT","Million of national currency units","AUS","Australia","2019","2019",499,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","MLLNCUMT","Million of national currency units","AUS","Australia","2020","2020",498,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","MLLNCUMT","Million of national currency units","AUS","Australia","2021","2021",525,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","MTMOTCMT","Million US$ at exchange rate","AUS","Australia","2010","2010",346.7,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","MTMOTCMT","Million US$ at exchange rate","AUS","Australia","2011","2011",420.9,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","MTMOTCMT","Million US$ at exchange rate","AUS","Australia","2012","2012",448.3,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","MTMOTCMT","Million US$ at exchange rate","AUS","Australia","2013","2013",485.6,"B; D","Break; Difference in methodology"
+"PATCANAL","N02-Analgesics","MTMOTCMT","Million US$ at exchange rate","AUS","Australia","2014","2014",465.1,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","MTMOTCMT","Million US$ at exchange rate","AUS","Australia","2015","2015",416.2,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","MTMOTCMT","Million US$ at exchange rate","AUS","Australia","2016","2016",369.5,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","MTMOTCMT","Million US$ at exchange rate","AUS","Australia","2017","2017",392.4,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","MTMOTCMT","Million US$ at exchange rate","AUS","Australia","2018","2018",385.5,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","MTMOTCMT","Million US$ at exchange rate","AUS","Australia","2019","2019",346.9,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","MTMOTCMT","Million US$ at exchange rate","AUS","Australia","2020","2020",342.7,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","MTMOTCMT","Million US$ at exchange rate","AUS","Australia","2021","2021",394.4,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","MTMOPPMT","Million US$, purchasing power parity","AUS","Australia","2010","2010",251.4,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","MTMOPPMT","Million US$, purchasing power parity","AUS","Australia","2011","2011",270,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","MTMOPPMT","Million US$, purchasing power parity","AUS","Australia","2012","2012",281.1,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","MTMOPPMT","Million US$, purchasing power parity","AUS","Australia","2013","2013",347.6,"B; D","Break; Difference in methodology"
+"PATCANAL","N02-Analgesics","MTMOPPMT","Million US$, purchasing power parity","AUS","Australia","2014","2014",355.3,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","MTMOPPMT","Million US$, purchasing power parity","AUS","Australia","2015","2015",375.9,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","MTMOPPMT","Million US$, purchasing power parity","AUS","Australia","2016","2016",342.7,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","MTMOPPMT","Million US$, purchasing power parity","AUS","Australia","2017","2017",346.5,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","MTMOPPMT","Million US$, purchasing power parity","AUS","Australia","2018","2018",350.9,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","MTMOPPMT","Million US$, purchasing power parity","AUS","Australia","2019","2019",337.2,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","MTMOPPMT","Million US$, purchasing power parity","AUS","Australia","2020","2020",342.5,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","MTMOPPMT","Million US$, purchasing power parity","AUS","Australia","2021","2021",362.7,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","TCPPERMT","/capita, US$ exchange rate","AUS","Australia","2010","2010",15.7,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","TCPPERMT","/capita, US$ exchange rate","AUS","Australia","2011","2011",18.8,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","TCPPERMT","/capita, US$ exchange rate","AUS","Australia","2012","2012",19.7,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","TCPPERMT","/capita, US$ exchange rate","AUS","Australia","2013","2013",21,"B; D","Break; Difference in methodology"
+"PATCANAL","N02-Analgesics","TCPPERMT","/capita, US$ exchange rate","AUS","Australia","2014","2014",19.8,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","TCPPERMT","/capita, US$ exchange rate","AUS","Australia","2015","2015",17.5,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","TCPPERMT","/capita, US$ exchange rate","AUS","Australia","2016","2016",15.3,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","TCPPERMT","/capita, US$ exchange rate","AUS","Australia","2017","2017",16,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","TCPPERMT","/capita, US$ exchange rate","AUS","Australia","2018","2018",15.4,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","TCPPERMT","/capita, US$ exchange rate","AUS","Australia","2019","2019",13.7,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","TCPPERMT","/capita, US$ exchange rate","AUS","Australia","2020","2020",13.4,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","TCPPERMT","/capita, US$ exchange rate","AUS","Australia","2021","2021",15.4,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2010","2010",11.4,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2011","2011",12.1,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2012","2012",12.4,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2013","2013",15,"B; D","Break; Difference in methodology"
+"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2014","2014",15.1,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2015","2015",15.8,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2016","2016",14.2,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2017","2017",14.1,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2018","2018",14.1,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2019","2019",13.3,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2020","2020",13.4,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2021","2021",14.1,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","ATCPTTMT","% of total sales","AUS","Australia","2010","2010",3.9,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","ATCPTTMT","% of total sales","AUS","Australia","2011","2011",4,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","ATCPTTMT","% of total sales","AUS","Australia","2012","2012",4.2,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","ATCPTTMT","% of total sales","AUS","Australia","2013","2013",4.3,"B; D","Break; Difference in methodology"
+"PATCANAL","N02-Analgesics","ATCPTTMT","% of total sales","AUS","Australia","2014","2014",4.3,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","ATCPTTMT","% of total sales","AUS","Australia","2015","2015",4.5,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","ATCPTTMT","% of total sales","AUS","Australia","2016","2016",3.2,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","ATCPTTMT","% of total sales","AUS","Australia","2017","2017",3.5,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","ATCPTTMT","% of total sales","AUS","Australia","2018","2018",3.5,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","ATCPTTMT","% of total sales","AUS","Australia","2019","2019",3.2,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","ATCPTTMT","% of total sales","AUS","Australia","2020","2020",3,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","ATCPTTMT","% of total sales","AUS","Australia","2021","2021",3,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","MLLNCUMT","Million of national currency units","AUT","Austria","2010","2010",61.9,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","MLLNCUMT","Million of national currency units","AUT","Austria","2011","2011",59.5,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","MLLNCUMT","Million of national currency units","AUT","Austria","2012","2012",60.3,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","MLLNCUMT","Million of national currency units","AUT","Austria","2013","2013",58.8,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","MLLNCUMT","Million of national currency units","AUT","Austria","2014","2014",61.6,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","MLLNCUMT","Million of national currency units","AUT","Austria","2015","2015",63.3,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","MLLNCUMT","Million of national currency units","AUT","Austria","2016","2016",65.7,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","MLLNCUMT","Million of national currency units","AUT","Austria","2017","2017",67.6,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","MLLNCUMT","Million of national currency units","AUT","Austria","2018","2018",66.9,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","MLLNCUMT","Million of national currency units","AUT","Austria","2019","2019",68.1,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","MLLNCUMT","Million of national currency units","AUT","Austria","2020","2020",74.4,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","MLLNCUMT","Million of national currency units","AUT","Austria","2021","2021",81.9,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","MTMOTCMT","Million US$ at exchange rate","AUT","Austria","2010","2010",82,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","MTMOTCMT","Million US$ at exchange rate","AUT","Austria","2011","2011",82.8,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","MTMOTCMT","Million US$ at exchange rate","AUT","Austria","2012","2012",77.4,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","MTMOTCMT","Million US$ at exchange rate","AUT","Austria","2013","2013",78.1,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","MTMOTCMT","Million US$ at exchange rate","AUT","Austria","2014","2014",81.9,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","MTMOTCMT","Million US$ at exchange rate","AUT","Austria","2015","2015",70.2,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","MTMOTCMT","Million US$ at exchange rate","AUT","Austria","2016","2016",72.7,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","MTMOTCMT","Million US$ at exchange rate","AUT","Austria","2017","2017",76.4,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","MTMOTCMT","Million US$ at exchange rate","AUT","Austria","2018","2018",79,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","MTMOTCMT","Million US$ at exchange rate","AUT","Austria","2019","2019",76.2,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","MTMOTCMT","Million US$ at exchange rate","AUT","Austria","2020","2020",85,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","MTMOTCMT","Million US$ at exchange rate","AUT","Austria","2021","2021",96.9,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","MTMOPPMT","Million US$, purchasing power parity","AUT","Austria","2010","2010",73.4,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","MTMOPPMT","Million US$, purchasing power parity","AUT","Austria","2011","2011",71.5,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","MTMOPPMT","Million US$, purchasing power parity","AUT","Austria","2012","2012",74.1,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","MTMOPPMT","Million US$, purchasing power parity","AUT","Austria","2013","2013",73.8,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","MTMOPPMT","Million US$, purchasing power parity","AUT","Austria","2014","2014",77.1,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","MTMOPPMT","Million US$, purchasing power parity","AUT","Austria","2015","2015",79.2,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","MTMOPPMT","Million US$, purchasing power parity","AUT","Austria","2016","2016",84.5,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","MTMOPPMT","Million US$, purchasing power parity","AUT","Austria","2017","2017",87.2,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","MTMOPPMT","Million US$, purchasing power parity","AUT","Austria","2018","2018",87.4,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","MTMOPPMT","Million US$, purchasing power parity","AUT","Austria","2019","2019",90.9,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","MTMOPPMT","Million US$, purchasing power parity","AUT","Austria","2020","2020",99.7,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","MTMOPPMT","Million US$, purchasing power parity","AUT","Austria","2021","2021",108.3,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","TCPPERMT","/capita, US$ exchange rate","AUT","Austria","2010","2010",9.8,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","TCPPERMT","/capita, US$ exchange rate","AUT","Austria","2011","2011",9.9,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","TCPPERMT","/capita, US$ exchange rate","AUT","Austria","2012","2012",9.2,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","TCPPERMT","/capita, US$ exchange rate","AUT","Austria","2013","2013",9.2,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","TCPPERMT","/capita, US$ exchange rate","AUT","Austria","2014","2014",9.6,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","TCPPERMT","/capita, US$ exchange rate","AUT","Austria","2015","2015",8.1,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","TCPPERMT","/capita, US$ exchange rate","AUT","Austria","2016","2016",8.3,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","TCPPERMT","/capita, US$ exchange rate","AUT","Austria","2017","2017",8.7,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","TCPPERMT","/capita, US$ exchange rate","AUT","Austria","2018","2018",8.9,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","TCPPERMT","/capita, US$ exchange rate","AUT","Austria","2019","2019",8.6,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","TCPPERMT","/capita, US$ exchange rate","AUT","Austria","2020","2020",9.5,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","TCPPERMT","/capita, US$ exchange rate","AUT","Austria","2021","2021",10.8,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2010","2010",8.8,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2011","2011",8.5,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2012","2012",8.8,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2013","2013",8.7,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2014","2014",9,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2015","2015",9.2,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2016","2016",9.7,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2017","2017",9.9,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2018","2018",9.9,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2019","2019",10.2,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2020","2020",11.2,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2021","2021",12.1,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","ATCPTTMT","% of total sales","AUT","Austria","2010","2010",2.5,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","ATCPTTMT","% of total sales","AUT","Austria","2011","2011",2.3,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","ATCPTTMT","% of total sales","AUT","Austria","2012","2012",2.3,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","ATCPTTMT","% of total sales","AUT","Austria","2013","2013",2.2,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","ATCPTTMT","% of total sales","AUT","Austria","2014","2014",2.2,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","ATCPTTMT","% of total sales","AUT","Austria","2015","2015",2.2,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","ATCPTTMT","% of total sales","AUT","Austria","2016","2016",2.2,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","ATCPTTMT","% of total sales","AUT","Austria","2017","2017",2.2,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","ATCPTTMT","% of total sales","AUT","Austria","2018","2018",2.1,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","ATCPTTMT","% of total sales","AUT","Austria","2019","2019",2.1,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","ATCPTTMT","% of total sales","AUT","Austria","2020","2020",2.1,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","ATCPTTMT","% of total sales","AUT","Austria","2021","2021",2.2,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","MLLNCUMT","Million of national currency units","BEL","Belgium","2010","2010",245.6,,
+"PATCANAL","N02-Analgesics","MLLNCUMT","Million of national currency units","BEL","Belgium","2011","2011",255.3,,
+"PATCANAL","N02-Analgesics","MLLNCUMT","Million of national currency units","BEL","Belgium","2012","2012",250.3,,
+"PATCANAL","N02-Analgesics","MLLNCUMT","Million of national currency units","BEL","Belgium","2013","2013",245.5,,
+"PATCANAL","N02-Analgesics","MLLNCUMT","Million of national currency units","BEL","Belgium","2014","2014",236.3,,
+"PATCANAL","N02-Analgesics","MLLNCUMT","Million of national currency units","BEL","Belgium","2015","2015",239.9,,
+"PATCANAL","N02-Analgesics","MLLNCUMT","Million of national currency units","BEL","Belgium","2016","2016",246.8,,
+"PATCANAL","N02-Analgesics","MLLNCUMT","Million of national currency units","BEL","Belgium","2017","2017",246.6,,
+"PATCANAL","N02-Analgesics","MLLNCUMT","Million of national currency units","BEL","Belgium","2018","2018",240.7,,
+"PATCANAL","N02-Analgesics","MLLNCUMT","Million of national currency units","BEL","Belgium","2019","2019",239,,
+"PATCANAL","N02-Analgesics","MLLNCUMT","Million of national currency units","BEL","Belgium","2020","2020",238.6,,
+"PATCANAL","N02-Analgesics","MLLNCUMT","Million of national currency units","BEL","Belgium","2021","2021",253,,
+"PATCANAL","N02-Analgesics","MLLNCUMT","Million of national currency units","BEL","Belgium","2022","2022",286.3,"E","Estimated value"
+"PATCANAL","N02-Analgesics","MTMOTCMT","Million US$ at exchange rate","BEL","Belgium","2010","2010",325.6,,
+"PATCANAL","N02-Analgesics","MTMOTCMT","Million US$ at exchange rate","BEL","Belgium","2011","2011",355.3,,
+"PATCANAL","N02-Analgesics","MTMOTCMT","Million US$ at exchange rate","BEL","Belgium","2012","2012",321.5,,
+"PATCANAL","N02-Analgesics","MTMOTCMT","Million US$ at exchange rate","BEL","Belgium","2013","2013",326.1,,
+"PATCANAL","N02-Analgesics","MTMOTCMT","Million US$ at exchange rate","BEL","Belgium","2014","2014",314,,
+"PATCANAL","N02-Analgesics","MTMOTCMT","Million US$ at exchange rate","BEL","Belgium","2015","2015",266.2,,
+"PATCANAL","N02-Analgesics","MTMOTCMT","Million US$ at exchange rate","BEL","Belgium","2016","2016",273.2,,
+"PATCANAL","N02-Analgesics","MTMOTCMT","Million US$ at exchange rate","BEL","Belgium","2017","2017",278.6,,
+"PATCANAL","N02-Analgesics","MTMOTCMT","Million US$ at exchange rate","BEL","Belgium","2018","2018",284.2,,
+"PATCANAL","N02-Analgesics","MTMOTCMT","Million US$ at exchange rate","BEL","Belgium","2019","2019",267.6,,
+"PATCANAL","N02-Analgesics","MTMOTCMT","Million US$ at exchange rate","BEL","Belgium","2020","2020",272.5,,
+"PATCANAL","N02-Analgesics","MTMOTCMT","Million US$ at exchange rate","BEL","Belgium","2021","2021",299.2,,
+"PATCANAL","N02-Analgesics","MTMOTCMT","Million US$ at exchange rate","BEL","Belgium","2022","2022",301.5,"E","Estimated value"
+"PATCANAL","N02-Analgesics","MTMOPPMT","Million US$, purchasing power parity","BEL","Belgium","2010","2010",293.5,,
+"PATCANAL","N02-Analgesics","MTMOPPMT","Million US$, purchasing power parity","BEL","Belgium","2011","2011",306.9,,
+"PATCANAL","N02-Analgesics","MTMOPPMT","Million US$, purchasing power parity","BEL","Belgium","2012","2012",304.4,,
+"PATCANAL","N02-Analgesics","MTMOPPMT","Million US$, purchasing power parity","BEL","Belgium","2013","2013",304.5,,
+"PATCANAL","N02-Analgesics","MTMOPPMT","Million US$, purchasing power parity","BEL","Belgium","2014","2014",295.3,,
+"PATCANAL","N02-Analgesics","MTMOPPMT","Million US$, purchasing power parity","BEL","Belgium","2015","2015",299.9,,
+"PATCANAL","N02-Analgesics","MTMOPPMT","Million US$, purchasing power parity","BEL","Belgium","2016","2016",316,,
+"PATCANAL","N02-Analgesics","MTMOPPMT","Million US$, purchasing power parity","BEL","Belgium","2017","2017",318,,
+"PATCANAL","N02-Analgesics","MTMOPPMT","Million US$, purchasing power parity","BEL","Belgium","2018","2018",314,,
+"PATCANAL","N02-Analgesics","MTMOPPMT","Million US$, purchasing power parity","BEL","Belgium","2019","2019",320.2,,
+"PATCANAL","N02-Analgesics","MTMOPPMT","Million US$, purchasing power parity","BEL","Belgium","2020","2020",326.7,,
+"PATCANAL","N02-Analgesics","MTMOPPMT","Million US$, purchasing power parity","BEL","Belgium","2021","2021",343.4,,
+"PATCANAL","N02-Analgesics","MTMOPPMT","Million US$, purchasing power parity","BEL","Belgium","2022","2022",401,"E","Estimated value"
+"PATCANAL","N02-Analgesics","TCPPERMT","/capita, US$ exchange rate","BEL","Belgium","2010","2010",29.9,,
+"PATCANAL","N02-Analgesics","TCPPERMT","/capita, US$ exchange rate","BEL","Belgium","2011","2011",32.2,,
+"PATCANAL","N02-Analgesics","TCPPERMT","/capita, US$ exchange rate","BEL","Belgium","2012","2012",28.9,,
+"PATCANAL","N02-Analgesics","TCPPERMT","/capita, US$ exchange rate","BEL","Belgium","2013","2013",29.2,,
+"PATCANAL","N02-Analgesics","TCPPERMT","/capita, US$ exchange rate","BEL","Belgium","2014","2014",28,,
+"PATCANAL","N02-Analgesics","TCPPERMT","/capita, US$ exchange rate","BEL","Belgium","2015","2015",23.6,,
+"PATCANAL","N02-Analgesics","TCPPERMT","/capita, US$ exchange rate","BEL","Belgium","2016","2016",24.1,,
+"PATCANAL","N02-Analgesics","TCPPERMT","/capita, US$ exchange rate","BEL","Belgium","2017","2017",24.5,,
+"PATCANAL","N02-Analgesics","TCPPERMT","/capita, US$ exchange rate","BEL","Belgium","2018","2018",24.9,,
+"PATCANAL","N02-Analgesics","TCPPERMT","/capita, US$ exchange rate","BEL","Belgium","2019","2019",23.3,,
+"PATCANAL","N02-Analgesics","TCPPERMT","/capita, US$ exchange rate","BEL","Belgium","2020","2020",23.6,,
+"PATCANAL","N02-Analgesics","TCPPERMT","/capita, US$ exchange rate","BEL","Belgium","2021","2021",25.8,,
+"PATCANAL","N02-Analgesics","TCPPERMT","/capita, US$ exchange rate","BEL","Belgium","2022","2022",26,"E","Estimated value"
+"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2010","2010",26.9,,
+"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2011","2011",27.8,,
+"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2012","2012",27.4,,
+"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2013","2013",27.3,,
+"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2014","2014",26.3,,
+"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2015","2015",26.6,,
+"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2016","2016",27.9,,
+"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2017","2017",28,,
+"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2018","2018",27.5,,
+"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2019","2019",27.9,,
+"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2020","2020",28.3,,
+"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2021","2021",29.6,,
+"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2022","2022",34.5,"E","Estimated value"
+"PATCANAL","N02-Analgesics","ATCPTTMT","% of total sales","BEL","Belgium","2010","2010",4.2,,
+"PATCANAL","N02-Analgesics","ATCPTTMT","% of total sales","BEL","Belgium","2011","2011",4.3,,
+"PATCANAL","N02-Analgesics","ATCPTTMT","% of total sales","BEL","Belgium","2012","2012",4.2,,
+"PATCANAL","N02-Analgesics","ATCPTTMT","% of total sales","BEL","Belgium","2013","2013",4.1,,
+"PATCANAL","N02-Analgesics","ATCPTTMT","% of total sales","BEL","Belgium","2014","2014",4,,
+"PATCANAL","N02-Analgesics","ATCPTTMT","% of total sales","BEL","Belgium","2015","2015",3.9,,
+"PATCANAL","N02-Analgesics","ATCPTTMT","% of total sales","BEL","Belgium","2016","2016",4,,
+"PATCANAL","N02-Analgesics","ATCPTTMT","% of total sales","BEL","Belgium","2017","2017",3.8,,
+"PATCANAL","N02-Analgesics","ATCPTTMT","% of total sales","BEL","Belgium","2018","2018",3.6,,
+"PATCANAL","N02-Analgesics","ATCPTTMT","% of total sales","BEL","Belgium","2019","2019",3.2,,
+"PATCANAL","N02-Analgesics","ATCPTTMT","% of total sales","BEL","Belgium","2020","2020",3.1,,
+"PATCANAL","N02-Analgesics","ATCPTTMT","% of total sales","BEL","Belgium","2021","2021",3.1,,
+"PATCANAL","N02-Analgesics","ATCPTTMT","% of total sales","BEL","Belgium","2022","2022",3.2,"E","Estimated value"
+"PATCANAL","N02-Analgesics","MLLNCUMT","Million of national currency units","CAN","Canada","2012","2012",1115.5,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","MLLNCUMT","Million of national currency units","CAN","Canada","2013","2013",1093.6,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","MLLNCUMT","Million of national currency units","CAN","Canada","2014","2014",1107.9,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","MLLNCUMT","Million of national currency units","CAN","Canada","2015","2015",1117.2,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","MLLNCUMT","Million of national currency units","CAN","Canada","2016","2016",1117.2,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","MLLNCUMT","Million of national currency units","CAN","Canada","2017","2017",1077.1,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","MLLNCUMT","Million of national currency units","CAN","Canada","2018","2018",995.2,"E; B; D","Estimated value; Break; Difference in methodology"
+"PATCANAL","N02-Analgesics","MLLNCUMT","Million of national currency units","CAN","Canada","2019","2019",937.1,"E; D","Estimated value; Difference in methodology"
+"PATCANAL","N02-Analgesics","MLLNCUMT","Million of national currency units","CAN","Canada","2020","2020",1016,"E; D","Estimated value; Difference in methodology"
+"PATCANAL","N02-Analgesics","MLLNCUMT","Million of national currency units","CAN","Canada","2021","2021",1048.8,"E; D","Estimated value; Difference in methodology"
+"PATCANAL","N02-Analgesics","MLLNCUMT","Million of national currency units","CAN","Canada","2022","2022",1069.4,"E; D","Estimated value; Difference in methodology"
+"PATCANAL","N02-Analgesics","MTMOTCMT","Million US$ at exchange rate","CAN","Canada","2012","2012",1116.2,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","MTMOTCMT","Million US$ at exchange rate","CAN","Canada","2013","2013",1061.6,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","MTMOTCMT","Million US$ at exchange rate","CAN","Canada","2014","2014",1002.9,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","MTMOTCMT","Million US$ at exchange rate","CAN","Canada","2015","2015",873.6,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","MTMOTCMT","Million US$ at exchange rate","CAN","Canada","2016","2016",842.8,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","MTMOTCMT","Million US$ at exchange rate","CAN","Canada","2017","2017",829.9,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","MTMOTCMT","Million US$ at exchange rate","CAN","Canada","2018","2018",768,"E; B; D","Estimated value; Break; Difference in methodology"
+"PATCANAL","N02-Analgesics","MTMOTCMT","Million US$ at exchange rate","CAN","Canada","2019","2019",706.3,"E; D","Estimated value; Difference in methodology"
+"PATCANAL","N02-Analgesics","MTMOTCMT","Million US$ at exchange rate","CAN","Canada","2020","2020",757.6,"E; D","Estimated value; Difference in methodology"
+"PATCANAL","N02-Analgesics","MTMOTCMT","Million US$ at exchange rate","CAN","Canada","2021","2021",836.4,"E; D","Estimated value; Difference in methodology"
+"PATCANAL","N02-Analgesics","MTMOTCMT","Million US$ at exchange rate","CAN","Canada","2022","2022",821.6,"E; D","Estimated value; Difference in methodology"
+"PATCANAL","N02-Analgesics","MTMOPPMT","Million US$, purchasing power parity","CAN","Canada","2012","2012",896.3,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","MTMOPPMT","Million US$, purchasing power parity","CAN","Canada","2013","2013",893.5,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","MTMOPPMT","Million US$, purchasing power parity","CAN","Canada","2014","2014",900.5,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","MTMOPPMT","Million US$, purchasing power parity","CAN","Canada","2015","2015",895.2,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","MTMOPPMT","Million US$, purchasing power parity","CAN","Canada","2016","2016",925.6,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","MTMOPPMT","Million US$, purchasing power parity","CAN","Canada","2017","2017",888.5,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","MTMOPPMT","Million US$, purchasing power parity","CAN","Canada","2018","2018",824.8,"E; B; D","Estimated value; Break; Difference in methodology"
+"PATCANAL","N02-Analgesics","MTMOPPMT","Million US$, purchasing power parity","CAN","Canada","2019","2019",759,"E; D","Estimated value; Difference in methodology"
+"PATCANAL","N02-Analgesics","MTMOPPMT","Million US$, purchasing power parity","CAN","Canada","2020","2020",825.3,"E; D","Estimated value; Difference in methodology"
+"PATCANAL","N02-Analgesics","MTMOPPMT","Million US$, purchasing power parity","CAN","Canada","2021","2021",847.1,"E; D","Estimated value; Difference in methodology"
+"PATCANAL","N02-Analgesics","MTMOPPMT","Million US$, purchasing power parity","CAN","Canada","2022","2022",852.9,"E; D","Estimated value; Difference in methodology"
+"PATCANAL","N02-Analgesics","TCPPERMT","/capita, US$ exchange rate","CAN","Canada","2012","2012",32.2,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","TCPPERMT","/capita, US$ exchange rate","CAN","Canada","2013","2013",30.3,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","TCPPERMT","/capita, US$ exchange rate","CAN","Canada","2014","2014",28.3,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","TCPPERMT","/capita, US$ exchange rate","CAN","Canada","2015","2015",24.5,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","TCPPERMT","/capita, US$ exchange rate","CAN","Canada","2016","2016",23.3,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","TCPPERMT","/capita, US$ exchange rate","CAN","Canada","2017","2017",22.7,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","TCPPERMT","/capita, US$ exchange rate","CAN","Canada","2018","2018",20.7,"E; B; D","Estimated value; Break; Difference in methodology"
+"PATCANAL","N02-Analgesics","TCPPERMT","/capita, US$ exchange rate","CAN","Canada","2019","2019",18.8,"E; D","Estimated value; Difference in methodology"
+"PATCANAL","N02-Analgesics","TCPPERMT","/capita, US$ exchange rate","CAN","Canada","2020","2020",19.9,"E; D","Estimated value; Difference in methodology"
+"PATCANAL","N02-Analgesics","TCPPERMT","/capita, US$ exchange rate","CAN","Canada","2021","2021",21.9,"E; D","Estimated value; Difference in methodology"
+"PATCANAL","N02-Analgesics","TCPPERMT","/capita, US$ exchange rate","CAN","Canada","2022","2022",21.1,"E; D","Estimated value; Difference in methodology"
+"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2012","2012",25.8,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2013","2013",25.5,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2014","2014",25.4,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2015","2015",25.1,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2016","2016",25.6,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2017","2017",24.3,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2018","2018",22.3,"E; B; D","Estimated value; Break; Difference in methodology"
+"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2019","2019",20.2,"E; D","Estimated value; Difference in methodology"
+"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2020","2020",21.7,"E; D","Estimated value; Difference in methodology"
+"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2021","2021",22.1,"E; D","Estimated value; Difference in methodology"
+"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2022","2022",21.9,"E; D","Estimated value; Difference in methodology"
+"PATCANAL","N02-Analgesics","ATCPTTMT","% of total sales","CAN","Canada","2012","2012",4.6,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","ATCPTTMT","% of total sales","CAN","Canada","2013","2013",4.4,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","ATCPTTMT","% of total sales","CAN","Canada","2014","2014",4.3,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","ATCPTTMT","% of total sales","CAN","Canada","2015","2015",4.1,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","ATCPTTMT","% of total sales","CAN","Canada","2016","2016",3.9,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","ATCPTTMT","% of total sales","CAN","Canada","2017","2017",3.6,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","ATCPTTMT","% of total sales","CAN","Canada","2018","2018",3.3,"E; B; D","Estimated value; Break; Difference in methodology"
+"PATCANAL","N02-Analgesics","ATCPTTMT","% of total sales","CAN","Canada","2019","2019",2.9,"E; D","Estimated value; Difference in methodology"
+"PATCANAL","N02-Analgesics","ATCPTTMT","% of total sales","CAN","Canada","2020","2020",3,"E; D","Estimated value; Difference in methodology"
+"PATCANAL","N02-Analgesics","ATCPTTMT","% of total sales","CAN","Canada","2021","2021",2.8,"E; D","Estimated value; Difference in methodology"
+"PATCANAL","N02-Analgesics","ATCPTTMT","% of total sales","CAN","Canada","2022","2022",2.7,"E; D","Estimated value; Difference in methodology"
+"PATCANAL","N02-Analgesics","MLLNCUMT","Million of national currency units","CZE","Czech Republic","2010","2010",2309.6,,
+"PATCANAL","N02-Analgesics","MLLNCUMT","Million of national currency units","CZE","Czech Republic","2011","2011",2704.5,,
+"PATCANAL","N02-Analgesics","MLLNCUMT","Million of national currency units","CZE","Czech Republic","2012","2012",2841.5,,
+"PATCANAL","N02-Analgesics","MLLNCUMT","Million of national currency units","CZE","Czech Republic","2013","2013",2923.9,,
+"PATCANAL","N02-Analgesics","MLLNCUMT","Million of national currency units","CZE","Czech Republic","2014","2014",2967.4,,
+"PATCANAL","N02-Analgesics","MLLNCUMT","Million of national currency units","CZE","Czech Republic","2015","2015",3119.3,,
+"PATCANAL","N02-Analgesics","MLLNCUMT","Million of national currency units","CZE","Czech Republic","2016","2016",3154.2,,
+"PATCANAL","N02-Analgesics","MLLNCUMT","Million of national currency units","CZE","Czech Republic","2017","2017",3451.3,,
+"PATCANAL","N02-Analgesics","MLLNCUMT","Million of national currency units","CZE","Czech Republic","2018","2018",3532.5,,
+"PATCANAL","N02-Analgesics","MLLNCUMT","Million of national currency units","CZE","Czech Republic","2019","2019",3331.3,,
+"PATCANAL","N02-Analgesics","MLLNCUMT","Million of national currency units","CZE","Czech Republic","2020","2020",2331,"B","Break"
+"PATCANAL","N02-Analgesics","MLLNCUMT","Million of national currency units","CZE","Czech Republic","2021","2021",2423.5,,
+"PATCANAL","N02-Analgesics","MTMOTCMT","Million US$ at exchange rate","CZE","Czech Republic","2010","2010",120.9,,
+"PATCANAL","N02-Analgesics","MTMOTCMT","Million US$ at exchange rate","CZE","Czech Republic","2011","2011",152.8,,
+"PATCANAL","N02-Analgesics","MTMOTCMT","Million US$ at exchange rate","CZE","Czech Republic","2012","2012",145.1,,
+"PATCANAL","N02-Analgesics","MTMOTCMT","Million US$ at exchange rate","CZE","Czech Republic","2013","2013",149.4,,
+"PATCANAL","N02-Analgesics","MTMOTCMT","Million US$ at exchange rate","CZE","Czech Republic","2014","2014",143,,
+"PATCANAL","N02-Analgesics","MTMOTCMT","Million US$ at exchange rate","CZE","Czech Republic","2015","2015",126.8,,
+"PATCANAL","N02-Analgesics","MTMOTCMT","Million US$ at exchange rate","CZE","Czech Republic","2016","2016",129.1,,
+"PATCANAL","N02-Analgesics","MTMOTCMT","Million US$ at exchange rate","CZE","Czech Republic","2017","2017",147.6,,
+"PATCANAL","N02-Analgesics","MTMOTCMT","Million US$ at exchange rate","CZE","Czech Republic","2018","2018",162.6,,
+"PATCANAL","N02-Analgesics","MTMOTCMT","Million US$ at exchange rate","CZE","Czech Republic","2019","2019",145.3,,
+"PATCANAL","N02-Analgesics","MTMOTCMT","Million US$ at exchange rate","CZE","Czech Republic","2020","2020",100.4,"B","Break"
+"PATCANAL","N02-Analgesics","MTMOTCMT","Million US$ at exchange rate","CZE","Czech Republic","2021","2021",111.8,,
+"PATCANAL","N02-Analgesics","MTMOPPMT","Million US$, purchasing power parity","CZE","Czech Republic","2010","2010",168.9,,
+"PATCANAL","N02-Analgesics","MTMOPPMT","Million US$, purchasing power parity","CZE","Czech Republic","2011","2011",202.7,,
+"PATCANAL","N02-Analgesics","MTMOPPMT","Million US$, purchasing power parity","CZE","Czech Republic","2012","2012",213.7,,
+"PATCANAL","N02-Analgesics","MTMOPPMT","Million US$, purchasing power parity","CZE","Czech Republic","2013","2013",228.7,,
+"PATCANAL","N02-Analgesics","MTMOPPMT","Million US$, purchasing power parity","CZE","Czech Republic","2014","2014",233.6,,
+"PATCANAL","N02-Analgesics","MTMOPPMT","Million US$, purchasing power parity","CZE","Czech Republic","2015","2015",241.1,,
+"PATCANAL","N02-Analgesics","MTMOPPMT","Million US$, purchasing power parity","CZE","Czech Republic","2016","2016",250.8,,
+"PATCANAL","N02-Analgesics","MTMOPPMT","Million US$, purchasing power parity","CZE","Czech Republic","2017","2017",277.8,,
+"PATCANAL","N02-Analgesics","MTMOPPMT","Million US$, purchasing power parity","CZE","Czech Republic","2018","2018",285.5,,
+"PATCANAL","N02-Analgesics","MTMOPPMT","Million US$, purchasing power parity","CZE","Czech Republic","2019","2019",271.4,,
+"PATCANAL","N02-Analgesics","MTMOPPMT","Million US$, purchasing power parity","CZE","Czech Republic","2020","2020",187.1,"B","Break"
+"PATCANAL","N02-Analgesics","MTMOPPMT","Million US$, purchasing power parity","CZE","Czech Republic","2021","2021",190.2,,
+"PATCANAL","N02-Analgesics","TCPPERMT","/capita, US$ exchange rate","CZE","Czech Republic","2010","2010",11.5,,
+"PATCANAL","N02-Analgesics","TCPPERMT","/capita, US$ exchange rate","CZE","Czech Republic","2011","2011",14.6,,
+"PATCANAL","N02-Analgesics","TCPPERMT","/capita, US$ exchange rate","CZE","Czech Republic","2012","2012",13.8,,
+"PATCANAL","N02-Analgesics","TCPPERMT","/capita, US$ exchange rate","CZE","Czech Republic","2013","2013",14.2,,
+"PATCANAL","N02-Analgesics","TCPPERMT","/capita, US$ exchange rate","CZE","Czech Republic","2014","2014",13.6,,
+"PATCANAL","N02-Analgesics","TCPPERMT","/capita, US$ exchange rate","CZE","Czech Republic","2015","2015",12,,
+"PATCANAL","N02-Analgesics","TCPPERMT","/capita, US$ exchange rate","CZE","Czech Republic","2016","2016",12.2,,
+"PATCANAL","N02-Analgesics","TCPPERMT","/capita, US$ exchange rate","CZE","Czech Republic","2017","2017",13.9,,
+"PATCANAL","N02-Analgesics","TCPPERMT","/capita, US$ exchange rate","CZE","Czech Republic","2018","2018",15.3,,
+"PATCANAL","N02-Analgesics","TCPPERMT","/capita, US$ exchange rate","CZE","Czech Republic","2019","2019",13.6,,
+"PATCANAL","N02-Analgesics","TCPPERMT","/capita, US$ exchange rate","CZE","Czech Republic","2020","2020",9.4,"B","Break"
+"PATCANAL","N02-Analgesics","TCPPERMT","/capita, US$ exchange rate","CZE","Czech Republic","2021","2021",10.6,,
+"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czech Republic","2010","2010",16.1,,
+"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czech Republic","2011","2011",19.3,,
+"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czech Republic","2012","2012",20.3,,
+"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czech Republic","2013","2013",21.8,,
+"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czech Republic","2014","2014",22.2,,
+"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czech Republic","2015","2015",22.9,,
+"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czech Republic","2016","2016",23.7,,
+"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czech Republic","2017","2017",26.2,,
+"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czech Republic","2018","2018",26.9,,
+"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czech Republic","2019","2019",25.4,,
+"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czech Republic","2020","2020",17.5,"B","Break"
+"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czech Republic","2021","2021",18.1,,
+"PATCANAL","N02-Analgesics","ATCPTTMT","% of total sales","CZE","Czech Republic","2010","2010",2.8,,
+"PATCANAL","N02-Analgesics","ATCPTTMT","% of total sales","CZE","Czech Republic","2011","2011",3.3,,
+"PATCANAL","N02-Analgesics","ATCPTTMT","% of total sales","CZE","Czech Republic","2012","2012",3.4,,
+"PATCANAL","N02-Analgesics","ATCPTTMT","% of total sales","CZE","Czech Republic","2013","2013",3.7,,
+"PATCANAL","N02-Analgesics","ATCPTTMT","% of total sales","CZE","Czech Republic","2014","2014",3.7,,
+"PATCANAL","N02-Analgesics","ATCPTTMT","% of total sales","CZE","Czech Republic","2015","2015",3.7,,
+"PATCANAL","N02-Analgesics","ATCPTTMT","% of total sales","CZE","Czech Republic","2016","2016",3.6,,
+"PATCANAL","N02-Analgesics","ATCPTTMT","% of total sales","CZE","Czech Republic","2017","2017",3.8,,
+"PATCANAL","N02-Analgesics","ATCPTTMT","% of total sales","CZE","Czech Republic","2018","2018",3.6,,
+"PATCANAL","N02-Analgesics","ATCPTTMT","% of total sales","CZE","Czech Republic","2019","2019",3.2,,
+"PATCANAL","N02-Analgesics","ATCPTTMT","% of total sales","CZE","Czech Republic","2020","2020",2.7,"B","Break"
+"PATCANAL","N02-Analgesics","ATCPTTMT","% of total sales","CZE","Czech Republic","2021","2021",2.6,,
+"PATCANAL","N02-Analgesics","MLLNCUMT","Million of national currency units","FIN","Finland","2010","2010",66.1,,
+"PATCANAL","N02-Analgesics","MLLNCUMT","Million of national currency units","FIN","Finland","2011","2011",67.9,,
+"PATCANAL","N02-Analgesics","MLLNCUMT","Million of national currency units","FIN","Finland","2012","2012",70.8,,
+"PATCANAL","N02-Analgesics","MLLNCUMT","Million of national currency units","FIN","Finland","2013","2013",69.7,,
+"PATCANAL","N02-Analgesics","MLLNCUMT","Million of national currency units","FIN","Finland","2014","2014",70.4,,
+"PATCANAL","N02-Analgesics","MLLNCUMT","Million of national currency units","FIN","Finland","2015","2015",71.9,,
+"PATCANAL","N02-Analgesics","MLLNCUMT","Million of national currency units","FIN","Finland","2016","2016",72.2,,
+"PATCANAL","N02-Analgesics","MLLNCUMT","Million of national currency units","FIN","Finland","2017","2017",66.6,,
+"PATCANAL","N02-Analgesics","MLLNCUMT","Million of national currency units","FIN","Finland","2018","2018",63.9,,
+"PATCANAL","N02-Analgesics","MLLNCUMT","Million of national currency units","FIN","Finland","2019","2019",74.5,,
+"PATCANAL","N02-Analgesics","MLLNCUMT","Million of national currency units","FIN","Finland","2020","2020",82.2,,
+"PATCANAL","N02-Analgesics","MLLNCUMT","Million of national currency units","FIN","Finland","2021","2021",81.5,,
+"PATCANAL","N02-Analgesics","MTMOTCMT","Million US$ at exchange rate","FIN","Finland","2010","2010",87.6,,
+"PATCANAL","N02-Analgesics","MTMOTCMT","Million US$ at exchange rate","FIN","Finland","2011","2011",94.5,,
+"PATCANAL","N02-Analgesics","MTMOTCMT","Million US$ at exchange rate","FIN","Finland","2012","2012",91,,
+"PATCANAL","N02-Analgesics","MTMOTCMT","Million US$ at exchange rate","FIN","Finland","2013","2013",92.6,,
+"PATCANAL","N02-Analgesics","MTMOTCMT","Million US$ at exchange rate","FIN","Finland","2014","2014",93.5,,
+"PATCANAL","N02-Analgesics","MTMOTCMT","Million US$ at exchange rate","FIN","Finland","2015","2015",79.8,,
+"PATCANAL","N02-Analgesics","MTMOTCMT","Million US$ at exchange rate","FIN","Finland","2016","2016",79.9,,
+"PATCANAL","N02-Analgesics","MTMOTCMT","Million US$ at exchange rate","FIN","Finland","2017","2017",75.2,,
+"PATCANAL","N02-Analgesics","MTMOTCMT","Million US$ at exchange rate","FIN","Finland","2018","2018",75.5,,
+"PATCANAL","N02-Analgesics","MTMOTCMT","Million US$ at exchange rate","FIN","Finland","2019","2019",83.4,,
+"PATCANAL","N02-Analgesics","MTMOTCMT","Million US$ at exchange rate","FIN","Finland","2020","2020",93.9,,
+"PATCANAL","N02-Analgesics","MTMOTCMT","Million US$ at exchange rate","FIN","Finland","2021","2021",96.4,,
+"PATCANAL","N02-Analgesics","MTMOPPMT","Million US$, purchasing power parity","FIN","Finland","2010","2010",73.4,,
+"PATCANAL","N02-Analgesics","MTMOPPMT","Million US$, purchasing power parity","FIN","Finland","2011","2011",75.6,,
+"PATCANAL","N02-Analgesics","MTMOPPMT","Million US$, purchasing power parity","FIN","Finland","2012","2012",77.9,,
+"PATCANAL","N02-Analgesics","MTMOPPMT","Million US$, purchasing power parity","FIN","Finland","2013","2013",77,,
+"PATCANAL","N02-Analgesics","MTMOPPMT","Million US$, purchasing power parity","FIN","Finland","2014","2014",77.6,,
+"PATCANAL","N02-Analgesics","MTMOPPMT","Million US$, purchasing power parity","FIN","Finland","2015","2015",79.2,,
+"PATCANAL","N02-Analgesics","MTMOPPMT","Million US$, purchasing power parity","FIN","Finland","2016","2016",82,,
+"PATCANAL","N02-Analgesics","MTMOPPMT","Million US$, purchasing power parity","FIN","Finland","2017","2017",77.1,,
+"PATCANAL","N02-Analgesics","MTMOPPMT","Million US$, purchasing power parity","FIN","Finland","2018","2018",74.8,,
+"PATCANAL","N02-Analgesics","MTMOPPMT","Million US$, purchasing power parity","FIN","Finland","2019","2019",88.9,,
+"PATCANAL","N02-Analgesics","MTMOPPMT","Million US$, purchasing power parity","FIN","Finland","2020","2020",99.9,,
+"PATCANAL","N02-Analgesics","MTMOPPMT","Million US$, purchasing power parity","FIN","Finland","2021","2021",98.6,,
+"PATCANAL","N02-Analgesics","TCPPERMT","/capita, US$ exchange rate","FIN","Finland","2010","2010",16.3,,
+"PATCANAL","N02-Analgesics","TCPPERMT","/capita, US$ exchange rate","FIN","Finland","2011","2011",17.5,,
+"PATCANAL","N02-Analgesics","TCPPERMT","/capita, US$ exchange rate","FIN","Finland","2012","2012",16.8,,
+"PATCANAL","N02-Analgesics","TCPPERMT","/capita, US$ exchange rate","FIN","Finland","2013","2013",17,,
+"PATCANAL","N02-Analgesics","TCPPERMT","/capita, US$ exchange rate","FIN","Finland","2014","2014",17.1,,
+"PATCANAL","N02-Analgesics","TCPPERMT","/capita, US$ exchange rate","FIN","Finland","2015","2015",14.6,,
+"PATCANAL","N02-Analgesics","TCPPERMT","/capita, US$ exchange rate","FIN","Finland","2016","2016",14.5,,
+"PATCANAL","N02-Analgesics","TCPPERMT","/capita, US$ exchange rate","FIN","Finland","2017","2017",13.7,,
+"PATCANAL","N02-Analgesics","TCPPERMT","/capita, US$ exchange rate","FIN","Finland","2018","2018",13.7,,
+"PATCANAL","N02-Analgesics","TCPPERMT","/capita, US$ exchange rate","FIN","Finland","2019","2019",15.1,,
+"PATCANAL","N02-Analgesics","TCPPERMT","/capita, US$ exchange rate","FIN","Finland","2020","2020",17,,
+"PATCANAL","N02-Analgesics","TCPPERMT","/capita, US$ exchange rate","FIN","Finland","2021","2021",17.4,,
+"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2010","2010",13.7,,
+"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2011","2011",14,,
+"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2012","2012",14.4,,
+"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2013","2013",14.2,,
+"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2014","2014",14.2,,
+"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2015","2015",14.5,,
+"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2016","2016",14.9,,
+"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2017","2017",14,,
+"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2018","2018",13.6,,
+"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2019","2019",16.1,,
+"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2020","2020",18.1,,
+"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2021","2021",17.8,,
+"PATCANAL","N02-Analgesics","ATCPTTMT","% of total sales","FIN","Finland","2010","2010",3.5,,
+"PATCANAL","N02-Analgesics","ATCPTTMT","% of total sales","FIN","Finland","2011","2011",3.5,,
+"PATCANAL","N02-Analgesics","ATCPTTMT","% of total sales","FIN","Finland","2012","2012",3.6,,
+"PATCANAL","N02-Analgesics","ATCPTTMT","% of total sales","FIN","Finland","2013","2013",3.5,,
+"PATCANAL","N02-Analgesics","ATCPTTMT","% of total sales","FIN","Finland","2014","2014",3.4,,
+"PATCANAL","N02-Analgesics","ATCPTTMT","% of total sales","FIN","Finland","2015","2015",3.3,,
+"PATCANAL","N02-Analgesics","ATCPTTMT","% of total sales","FIN","Finland","2016","2016",3.2,,
+"PATCANAL","N02-Analgesics","ATCPTTMT","% of total sales","FIN","Finland","2017","2017",2.9,,
+"PATCANAL","N02-Analgesics","ATCPTTMT","% of total sales","FIN","Finland","2018","2018",2.6,,
+"PATCANAL","N02-Analgesics","ATCPTTMT","% of total sales","FIN","Finland","2019","2019",2.8,,
+"PATCANAL","N02-Analgesics","ATCPTTMT","% of total sales","FIN","Finland","2020","2020",3.1,,
+"PATCANAL","N02-Analgesics","ATCPTTMT","% of total sales","FIN","Finland","2021","2021",2.9,,
+"PATCANAL","N02-Analgesics","MLLNCUMT","Million of national currency units","DEU","Germany","2010","2010",1561.1,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","MLLNCUMT","Million of national currency units","DEU","Germany","2011","2011",1574.9,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","MLLNCUMT","Million of national currency units","DEU","Germany","2012","2012",1629.1,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","MLLNCUMT","Million of national currency units","DEU","Germany","2013","2013",1654.3,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","MLLNCUMT","Million of national currency units","DEU","Germany","2014","2014",1675.8,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","MLLNCUMT","Million of national currency units","DEU","Germany","2015","2015",1692,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","MLLNCUMT","Million of national currency units","DEU","Germany","2016","2016",1735.8,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","MLLNCUMT","Million of national currency units","DEU","Germany","2017","2017",1763.8,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","MLLNCUMT","Million of national currency units","DEU","Germany","2018","2018",1818.4,"B; D","Break; Difference in methodology"
+"PATCANAL","N02-Analgesics","MLLNCUMT","Million of national currency units","DEU","Germany","2019","2019",1883.1,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","MLLNCUMT","Million of national currency units","DEU","Germany","2020","2020",1873.6,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","MLLNCUMT","Million of national currency units","DEU","Germany","2021","2021",2252.3,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","MTMOTCMT","Million US$ at exchange rate","DEU","Germany","2010","2010",2069.6,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","MTMOTCMT","Million US$ at exchange rate","DEU","Germany","2011","2011",2192.2,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","MTMOTCMT","Million US$ at exchange rate","DEU","Germany","2012","2012",2093,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","MTMOTCMT","Million US$ at exchange rate","DEU","Germany","2013","2013",2197.1,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","MTMOTCMT","Million US$ at exchange rate","DEU","Germany","2014","2014",2226.3,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","MTMOTCMT","Million US$ at exchange rate","DEU","Germany","2015","2015",1877.3,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","MTMOTCMT","Million US$ at exchange rate","DEU","Germany","2016","2016",1921.4,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","MTMOTCMT","Million US$ at exchange rate","DEU","Germany","2017","2017",1992.5,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","MTMOTCMT","Million US$ at exchange rate","DEU","Germany","2018","2018",2147.4,"B; D","Break; Difference in methodology"
+"PATCANAL","N02-Analgesics","MTMOTCMT","Million US$ at exchange rate","DEU","Germany","2019","2019",2108.1,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","MTMOTCMT","Million US$ at exchange rate","DEU","Germany","2020","2020",2140,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","MTMOTCMT","Million US$ at exchange rate","DEU","Germany","2021","2021",2663.9,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","MTMOPPMT","Million US$, purchasing power parity","DEU","Germany","2010","2010",1939.1,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","MTMOPPMT","Million US$, purchasing power parity","DEU","Germany","2011","2011",1996.7,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","MTMOPPMT","Million US$, purchasing power parity","DEU","Germany","2012","2012",2069.4,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","MTMOPPMT","Million US$, purchasing power parity","DEU","Germany","2013","2013",2135.2,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","MTMOPPMT","Million US$, purchasing power parity","DEU","Germany","2014","2014",2179.4,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","MTMOPPMT","Million US$, purchasing power parity","DEU","Germany","2015","2015",2174.5,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","MTMOPPMT","Million US$, purchasing power parity","DEU","Germany","2016","2016",2306.4,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","MTMOPPMT","Million US$, purchasing power parity","DEU","Germany","2017","2017",2368.2,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","MTMOPPMT","Million US$, purchasing power parity","DEU","Germany","2018","2018",2472.5,"B; D","Break; Difference in methodology"
+"PATCANAL","N02-Analgesics","MTMOPPMT","Million US$, purchasing power parity","DEU","Germany","2019","2019",2585.8,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","MTMOPPMT","Million US$, purchasing power parity","DEU","Germany","2020","2020",2584.3,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","MTMOPPMT","Million US$, purchasing power parity","DEU","Germany","2021","2021",3059,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","TCPPERMT","/capita, US$ exchange rate","DEU","Germany","2010","2010",25.3,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","TCPPERMT","/capita, US$ exchange rate","DEU","Germany","2011","2011",27.3,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","TCPPERMT","/capita, US$ exchange rate","DEU","Germany","2012","2012",26,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","TCPPERMT","/capita, US$ exchange rate","DEU","Germany","2013","2013",27.2,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","TCPPERMT","/capita, US$ exchange rate","DEU","Germany","2014","2014",27.5,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","TCPPERMT","/capita, US$ exchange rate","DEU","Germany","2015","2015",23,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","TCPPERMT","/capita, US$ exchange rate","DEU","Germany","2016","2016",23.3,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","TCPPERMT","/capita, US$ exchange rate","DEU","Germany","2017","2017",24.1,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","TCPPERMT","/capita, US$ exchange rate","DEU","Germany","2018","2018",25.9,"B; D","Break; Difference in methodology"
+"PATCANAL","N02-Analgesics","TCPPERMT","/capita, US$ exchange rate","DEU","Germany","2019","2019",25.4,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","TCPPERMT","/capita, US$ exchange rate","DEU","Germany","2020","2020",25.7,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","TCPPERMT","/capita, US$ exchange rate","DEU","Germany","2021","2021",32,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2010","2010",23.7,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2011","2011",24.9,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2012","2012",25.7,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2013","2013",26.5,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2014","2014",26.9,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2015","2015",26.6,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2016","2016",28,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2017","2017",28.7,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2018","2018",29.8,"B; D","Break; Difference in methodology"
+"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2019","2019",31.1,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2020","2020",31.1,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2021","2021",36.8,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","ATCPTTMT","% of total sales","DEU","Germany","2010","2010",5.3,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","ATCPTTMT","% of total sales","DEU","Germany","2011","2011",5.3,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","ATCPTTMT","% of total sales","DEU","Germany","2012","2012",5.4,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","ATCPTTMT","% of total sales","DEU","Germany","2013","2013",5.2,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","ATCPTTMT","% of total sales","DEU","Germany","2014","2014",5,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","ATCPTTMT","% of total sales","DEU","Germany","2015","2015",4.8,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","ATCPTTMT","% of total sales","DEU","Germany","2016","2016",4.8,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","ATCPTTMT","% of total sales","DEU","Germany","2017","2017",4.7,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","ATCPTTMT","% of total sales","DEU","Germany","2018","2018",4.1,"B; D","Break; Difference in methodology"
+"PATCANAL","N02-Analgesics","ATCPTTMT","% of total sales","DEU","Germany","2019","2019",4,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","ATCPTTMT","% of total sales","DEU","Germany","2020","2020",3.8,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","ATCPTTMT","% of total sales","DEU","Germany","2021","2021",4.2,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","MLLNCUMT","Million of national currency units","GRC","Greece","2010","2010",76.5,,
+"PATCANAL","N02-Analgesics","MLLNCUMT","Million of national currency units","GRC","Greece","2011","2011",80.9,,
+"PATCANAL","N02-Analgesics","MLLNCUMT","Million of national currency units","GRC","Greece","2012","2012",84.3,,
+"PATCANAL","N02-Analgesics","MLLNCUMT","Million of national currency units","GRC","Greece","2013","2013",82.9,,
+"PATCANAL","N02-Analgesics","MLLNCUMT","Million of national currency units","GRC","Greece","2014","2014",89.8,,
+"PATCANAL","N02-Analgesics","MLLNCUMT","Million of national currency units","GRC","Greece","2015","2015",84.1,,
+"PATCANAL","N02-Analgesics","MLLNCUMT","Million of national currency units","GRC","Greece","2016","2016",143.3,,
+"PATCANAL","N02-Analgesics","MLLNCUMT","Million of national currency units","GRC","Greece","2017","2017",141.8,,
+"PATCANAL","N02-Analgesics","MLLNCUMT","Million of national currency units","GRC","Greece","2018","2018",147.9,,
+"PATCANAL","N02-Analgesics","MLLNCUMT","Million of national currency units","GRC","Greece","2019","2019",169.2,,
+"PATCANAL","N02-Analgesics","MLLNCUMT","Million of national currency units","GRC","Greece","2020","2020",127.4,,
+"PATCANAL","N02-Analgesics","MLLNCUMT","Million of national currency units","GRC","Greece","2021","2021",115.3,,
+"PATCANAL","N02-Analgesics","MLLNCUMT","Million of national currency units","GRC","Greece","2022","2022",115.3,,
+"PATCANAL","N02-Analgesics","MTMOTCMT","Million US$ at exchange rate","GRC","Greece","2010","2010",101.4,,
+"PATCANAL","N02-Analgesics","MTMOTCMT","Million US$ at exchange rate","GRC","Greece","2011","2011",112.7,,
+"PATCANAL","N02-Analgesics","MTMOTCMT","Million US$ at exchange rate","GRC","Greece","2012","2012",108.4,,
+"PATCANAL","N02-Analgesics","MTMOTCMT","Million US$ at exchange rate","GRC","Greece","2013","2013",110.1,,
+"PATCANAL","N02-Analgesics","MTMOTCMT","Million US$ at exchange rate","GRC","Greece","2014","2014",119.2,,
+"PATCANAL","N02-Analgesics","MTMOTCMT","Million US$ at exchange rate","GRC","Greece","2015","2015",93.4,,
+"PATCANAL","N02-Analgesics","MTMOTCMT","Million US$ at exchange rate","GRC","Greece","2016","2016",158.6,,
+"PATCANAL","N02-Analgesics","MTMOTCMT","Million US$ at exchange rate","GRC","Greece","2017","2017",160.2,,
+"PATCANAL","N02-Analgesics","MTMOTCMT","Million US$ at exchange rate","GRC","Greece","2018","2018",174.7,,
+"PATCANAL","N02-Analgesics","MTMOTCMT","Million US$ at exchange rate","GRC","Greece","2019","2019",189.5,,
+"PATCANAL","N02-Analgesics","MTMOTCMT","Million US$ at exchange rate","GRC","Greece","2020","2020",145.5,,
+"PATCANAL","N02-Analgesics","MTMOTCMT","Million US$ at exchange rate","GRC","Greece","2021","2021",136.4,,
+"PATCANAL","N02-Analgesics","MTMOTCMT","Million US$ at exchange rate","GRC","Greece","2022","2022",121.4,,
+"PATCANAL","N02-Analgesics","MTMOPPMT","Million US$, purchasing power parity","GRC","Greece","2010","2010",106,,
+"PATCANAL","N02-Analgesics","MTMOPPMT","Million US$, purchasing power parity","GRC","Greece","2011","2011",113.5,,
+"PATCANAL","N02-Analgesics","MTMOPPMT","Million US$, purchasing power parity","GRC","Greece","2012","2012",123.2,,
+"PATCANAL","N02-Analgesics","MTMOPPMT","Million US$, purchasing power parity","GRC","Greece","2013","2013",131.4,,
+"PATCANAL","N02-Analgesics","MTMOPPMT","Million US$, purchasing power parity","GRC","Greece","2014","2014",146.9,,
+"PATCANAL","N02-Analgesics","MTMOPPMT","Million US$, purchasing power parity","GRC","Greece","2015","2015",138.1,,
+"PATCANAL","N02-Analgesics","MTMOPPMT","Million US$, purchasing power parity","GRC","Greece","2016","2016",243.4,,
+"PATCANAL","N02-Analgesics","MTMOPPMT","Million US$, purchasing power parity","GRC","Greece","2017","2017",246.7,,
+"PATCANAL","N02-Analgesics","MTMOPPMT","Million US$, purchasing power parity","GRC","Greece","2018","2018",261.9,,
+"PATCANAL","N02-Analgesics","MTMOPPMT","Million US$, purchasing power parity","GRC","Greece","2019","2019",308.3,,
+"PATCANAL","N02-Analgesics","MTMOPPMT","Million US$, purchasing power parity","GRC","Greece","2020","2020",234.1,,
+"PATCANAL","N02-Analgesics","MTMOPPMT","Million US$, purchasing power parity","GRC","Greece","2021","2021",211.4,,
+"PATCANAL","N02-Analgesics","MTMOPPMT","Million US$, purchasing power parity","GRC","Greece","2022","2022",218.2,,
+"PATCANAL","N02-Analgesics","TCPPERMT","/capita, US$ exchange rate","GRC","Greece","2010","2010",9.1,,
+"PATCANAL","N02-Analgesics","TCPPERMT","/capita, US$ exchange rate","GRC","Greece","2011","2011",10.1,,
+"PATCANAL","N02-Analgesics","TCPPERMT","/capita, US$ exchange rate","GRC","Greece","2012","2012",9.8,,
+"PATCANAL","N02-Analgesics","TCPPERMT","/capita, US$ exchange rate","GRC","Greece","2013","2013",10,,
+"PATCANAL","N02-Analgesics","TCPPERMT","/capita, US$ exchange rate","GRC","Greece","2014","2014",10.9,,
+"PATCANAL","N02-Analgesics","TCPPERMT","/capita, US$ exchange rate","GRC","Greece","2015","2015",8.6,,
+"PATCANAL","N02-Analgesics","TCPPERMT","/capita, US$ exchange rate","GRC","Greece","2016","2016",14.7,,
+"PATCANAL","N02-Analgesics","TCPPERMT","/capita, US$ exchange rate","GRC","Greece","2017","2017",14.9,,
+"PATCANAL","N02-Analgesics","TCPPERMT","/capita, US$ exchange rate","GRC","Greece","2018","2018",16.3,,
+"PATCANAL","N02-Analgesics","TCPPERMT","/capita, US$ exchange rate","GRC","Greece","2019","2019",17.7,,
+"PATCANAL","N02-Analgesics","TCPPERMT","/capita, US$ exchange rate","GRC","Greece","2020","2020",13.6,,
+"PATCANAL","N02-Analgesics","TCPPERMT","/capita, US$ exchange rate","GRC","Greece","2021","2021",12.9,,
+"PATCANAL","N02-Analgesics","TCPPERMT","/capita, US$ exchange rate","GRC","Greece","2022","2022",11.6,,
+"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2010","2010",9.5,,
+"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2011","2011",10.2,,
+"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2012","2012",11.2,,
+"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2013","2013",12,,
+"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2014","2014",13.5,,
+"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2015","2015",12.8,,
+"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2016","2016",22.6,,
+"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2017","2017",22.9,,
+"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2018","2018",24.4,,
+"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2019","2019",28.8,,
+"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2020","2020",21.9,,
+"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2021","2021",20,,
+"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2022","2022",20.9,,
+"PATCANAL","N02-Analgesics","MLLNCUMT","Million of national currency units","HUN","Hungary","2010","2010",5356.6,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","MLLNCUMT","Million of national currency units","HUN","Hungary","2011","2011",5439.1,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","MLLNCUMT","Million of national currency units","HUN","Hungary","2012","2012",5276.2,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","MLLNCUMT","Million of national currency units","HUN","Hungary","2013","2013",5228.6,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","MLLNCUMT","Million of national currency units","HUN","Hungary","2014","2014",5304.8,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","MLLNCUMT","Million of national currency units","HUN","Hungary","2015","2015",5270.6,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","MLLNCUMT","Million of national currency units","HUN","Hungary","2016","2016",5247.3,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","MLLNCUMT","Million of national currency units","HUN","Hungary","2017","2017",5346.6,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","MLLNCUMT","Million of national currency units","HUN","Hungary","2018","2018",5501.3,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","MLLNCUMT","Million of national currency units","HUN","Hungary","2019","2019",5247.2,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","MLLNCUMT","Million of national currency units","HUN","Hungary","2020","2020",5043.1,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","MLLNCUMT","Million of national currency units","HUN","Hungary","2021","2021",4857.4,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","MLLNCUMT","Million of national currency units","HUN","Hungary","2022","2022",4869.2,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","MTMOTCMT","Million US$ at exchange rate","HUN","Hungary","2010","2010",25.8,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","MTMOTCMT","Million US$ at exchange rate","HUN","Hungary","2011","2011",27.1,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","MTMOTCMT","Million US$ at exchange rate","HUN","Hungary","2012","2012",23.4,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","MTMOTCMT","Million US$ at exchange rate","HUN","Hungary","2013","2013",23.4,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","MTMOTCMT","Million US$ at exchange rate","HUN","Hungary","2014","2014",22.8,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","MTMOTCMT","Million US$ at exchange rate","HUN","Hungary","2015","2015",18.9,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","MTMOTCMT","Million US$ at exchange rate","HUN","Hungary","2016","2016",18.6,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","MTMOTCMT","Million US$ at exchange rate","HUN","Hungary","2017","2017",19.5,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","MTMOTCMT","Million US$ at exchange rate","HUN","Hungary","2018","2018",20.4,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","MTMOTCMT","Million US$ at exchange rate","HUN","Hungary","2019","2019",18.1,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","MTMOTCMT","Million US$ at exchange rate","HUN","Hungary","2020","2020",16.4,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","MTMOTCMT","Million US$ at exchange rate","HUN","Hungary","2021","2021",16,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","MTMOTCMT","Million US$ at exchange rate","HUN","Hungary","2022","2022",13.1,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","MTMOPPMT","Million US$, purchasing power parity","HUN","Hungary","2010","2010",42.4,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","MTMOPPMT","Million US$, purchasing power parity","HUN","Hungary","2011","2011",43.8,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","MTMOPPMT","Million US$, purchasing power parity","HUN","Hungary","2012","2012",42,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","MTMOPPMT","Million US$, purchasing power parity","HUN","Hungary","2013","2013",41.8,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","MTMOPPMT","Million US$, purchasing power parity","HUN","Hungary","2014","2014",41,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","MTMOPPMT","Million US$, purchasing power parity","HUN","Hungary","2015","2015",39.8,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","MTMOPPMT","Million US$, purchasing power parity","HUN","Hungary","2016","2016",39.7,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","MTMOPPMT","Million US$, purchasing power parity","HUN","Hungary","2017","2017",39.3,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","MTMOPPMT","Million US$, purchasing power parity","HUN","Hungary","2018","2018",39.6,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","MTMOPPMT","Million US$, purchasing power parity","HUN","Hungary","2019","2019",37.3,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","MTMOPPMT","Million US$, purchasing power parity","HUN","Hungary","2020","2020",34.7,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","MTMOPPMT","Million US$, purchasing power parity","HUN","Hungary","2021","2021",31.4,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","MTMOPPMT","Million US$, purchasing power parity","HUN","Hungary","2022","2022",30.2,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","TCPPERMT","/capita, US$ exchange rate","HUN","Hungary","2010","2010",2.6,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","TCPPERMT","/capita, US$ exchange rate","HUN","Hungary","2011","2011",2.7,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","TCPPERMT","/capita, US$ exchange rate","HUN","Hungary","2012","2012",2.4,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","TCPPERMT","/capita, US$ exchange rate","HUN","Hungary","2013","2013",2.4,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","TCPPERMT","/capita, US$ exchange rate","HUN","Hungary","2014","2014",2.3,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","TCPPERMT","/capita, US$ exchange rate","HUN","Hungary","2015","2015",1.9,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","TCPPERMT","/capita, US$ exchange rate","HUN","Hungary","2016","2016",1.9,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","TCPPERMT","/capita, US$ exchange rate","HUN","Hungary","2017","2017",2,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","TCPPERMT","/capita, US$ exchange rate","HUN","Hungary","2018","2018",2.1,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","TCPPERMT","/capita, US$ exchange rate","HUN","Hungary","2019","2019",1.8,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","TCPPERMT","/capita, US$ exchange rate","HUN","Hungary","2020","2020",1.7,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","TCPPERMT","/capita, US$ exchange rate","HUN","Hungary","2021","2021",1.7,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","TCPPERMT","/capita, US$ exchange rate","HUN","Hungary","2022","2022",1.3,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2010","2010",4.2,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2011","2011",4.4,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2012","2012",4.2,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2013","2013",4.2,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2014","2014",4.2,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2015","2015",4,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2016","2016",4,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2017","2017",4,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2018","2018",4,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2019","2019",3.8,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2020","2020",3.6,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2021","2021",3.2,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2022","2022",3.1,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","ATCPTTMT","% of total sales","HUN","Hungary","2010","2010",1.1,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","ATCPTTMT","% of total sales","HUN","Hungary","2011","2011",1.1,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","ATCPTTMT","% of total sales","HUN","Hungary","2012","2012",1.2,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","ATCPTTMT","% of total sales","HUN","Hungary","2013","2013",1.2,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","ATCPTTMT","% of total sales","HUN","Hungary","2014","2014",1.2,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","ATCPTTMT","% of total sales","HUN","Hungary","2015","2015",1.1,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","ATCPTTMT","% of total sales","HUN","Hungary","2016","2016",1.1,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","ATCPTTMT","% of total sales","HUN","Hungary","2017","2017",1.1,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","ATCPTTMT","% of total sales","HUN","Hungary","2018","2018",1.1,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","ATCPTTMT","% of total sales","HUN","Hungary","2019","2019",1,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","ATCPTTMT","% of total sales","HUN","Hungary","2020","2020",0.9,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","ATCPTTMT","% of total sales","HUN","Hungary","2021","2021",0.9,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","ATCPTTMT","% of total sales","HUN","Hungary","2022","2022",0.8,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","MLLNCUMT","Million of national currency units","ISL","Iceland","2010","2010",1011.6,,
+"PATCANAL","N02-Analgesics","MLLNCUMT","Million of national currency units","ISL","Iceland","2011","2011",789.8,,
+"PATCANAL","N02-Analgesics","MLLNCUMT","Million of national currency units","ISL","Iceland","2012","2012",787.5,,
+"PATCANAL","N02-Analgesics","MLLNCUMT","Million of national currency units","ISL","Iceland","2013","2013",998.9,,
+"PATCANAL","N02-Analgesics","MLLNCUMT","Million of national currency units","ISL","Iceland","2014","2014",843.8,,
+"PATCANAL","N02-Analgesics","MLLNCUMT","Million of national currency units","ISL","Iceland","2015","2015",841.5,,
+"PATCANAL","N02-Analgesics","MLLNCUMT","Million of national currency units","ISL","Iceland","2016","2016",873.8,,
+"PATCANAL","N02-Analgesics","MLLNCUMT","Million of national currency units","ISL","Iceland","2017","2017",903,,
+"PATCANAL","N02-Analgesics","MLLNCUMT","Million of national currency units","ISL","Iceland","2018","2018",899.7,,
+"PATCANAL","N02-Analgesics","MLLNCUMT","Million of national currency units","ISL","Iceland","2019","2019",974.7,,
+"PATCANAL","N02-Analgesics","MLLNCUMT","Million of national currency units","ISL","Iceland","2020","2020",1100.5,,
+"PATCANAL","N02-Analgesics","MLLNCUMT","Million of national currency units","ISL","Iceland","2021","2021",1218.3,,
+"PATCANAL","N02-Analgesics","MTMOTCMT","Million US$ at exchange rate","ISL","Iceland","2010","2010",8.3,,
+"PATCANAL","N02-Analgesics","MTMOTCMT","Million US$ at exchange rate","ISL","Iceland","2011","2011",6.8,,
+"PATCANAL","N02-Analgesics","MTMOTCMT","Million US$ at exchange rate","ISL","Iceland","2012","2012",6.3,,
+"PATCANAL","N02-Analgesics","MTMOTCMT","Million US$ at exchange rate","ISL","Iceland","2013","2013",8.2,,
+"PATCANAL","N02-Analgesics","MTMOTCMT","Million US$ at exchange rate","ISL","Iceland","2014","2014",7.2,,
+"PATCANAL","N02-Analgesics","MTMOTCMT","Million US$ at exchange rate","ISL","Iceland","2015","2015",6.4,,
+"PATCANAL","N02-Analgesics","MTMOTCMT","Million US$ at exchange rate","ISL","Iceland","2016","2016",7.2,,
+"PATCANAL","N02-Analgesics","MTMOTCMT","Million US$ at exchange rate","ISL","Iceland","2017","2017",8.5,,
+"PATCANAL","N02-Analgesics","MTMOTCMT","Million US$ at exchange rate","ISL","Iceland","2018","2018",8.3,,
+"PATCANAL","N02-Analgesics","MTMOTCMT","Million US$ at exchange rate","ISL","Iceland","2019","2019",7.9,,
+"PATCANAL","N02-Analgesics","MTMOTCMT","Million US$ at exchange rate","ISL","Iceland","2020","2020",8.1,,
+"PATCANAL","N02-Analgesics","MTMOTCMT","Million US$ at exchange rate","ISL","Iceland","2021","2021",9.6,,
+"PATCANAL","N02-Analgesics","MTMOPPMT","Million US$, purchasing power parity","ISL","Iceland","2010","2010",7.6,,
+"PATCANAL","N02-Analgesics","MTMOPPMT","Million US$, purchasing power parity","ISL","Iceland","2011","2011",5.8,,
+"PATCANAL","N02-Analgesics","MTMOPPMT","Million US$, purchasing power parity","ISL","Iceland","2012","2012",5.7,,
+"PATCANAL","N02-Analgesics","MTMOPPMT","Million US$, purchasing power parity","ISL","Iceland","2013","2013",7.3,,
+"PATCANAL","N02-Analgesics","MTMOPPMT","Million US$, purchasing power parity","ISL","Iceland","2014","2014",6.1,,
+"PATCANAL","N02-Analgesics","MTMOPPMT","Million US$, purchasing power parity","ISL","Iceland","2015","2015",5.9,,
+"PATCANAL","N02-Analgesics","MTMOPPMT","Million US$, purchasing power parity","ISL","Iceland","2016","2016",6.2,,
+"PATCANAL","N02-Analgesics","MTMOPPMT","Million US$, purchasing power parity","ISL","Iceland","2017","2017",6.5,,
+"PATCANAL","N02-Analgesics","MTMOPPMT","Million US$, purchasing power parity","ISL","Iceland","2018","2018",6.4,,
+"PATCANAL","N02-Analgesics","MTMOPPMT","Million US$, purchasing power parity","ISL","Iceland","2019","2019",6.9,,
+"PATCANAL","N02-Analgesics","MTMOPPMT","Million US$, purchasing power parity","ISL","Iceland","2020","2020",7.5,,
+"PATCANAL","N02-Analgesics","MTMOPPMT","Million US$, purchasing power parity","ISL","Iceland","2021","2021",8.1,,
+"PATCANAL","N02-Analgesics","TCPPERMT","/capita, US$ exchange rate","ISL","Iceland","2010","2010",26,,
+"PATCANAL","N02-Analgesics","TCPPERMT","/capita, US$ exchange rate","ISL","Iceland","2011","2011",21.4,,
+"PATCANAL","N02-Analgesics","TCPPERMT","/capita, US$ exchange rate","ISL","Iceland","2012","2012",19.6,,
+"PATCANAL","N02-Analgesics","TCPPERMT","/capita, US$ exchange rate","ISL","Iceland","2013","2013",25.3,,
+"PATCANAL","N02-Analgesics","TCPPERMT","/capita, US$ exchange rate","ISL","Iceland","2014","2014",22.1,,
+"PATCANAL","N02-Analgesics","TCPPERMT","/capita, US$ exchange rate","ISL","Iceland","2015","2015",19.3,,
+"PATCANAL","N02-Analgesics","TCPPERMT","/capita, US$ exchange rate","ISL","Iceland","2016","2016",21.6,,
+"PATCANAL","N02-Analgesics","TCPPERMT","/capita, US$ exchange rate","ISL","Iceland","2017","2017",24.6,,
+"PATCANAL","N02-Analgesics","TCPPERMT","/capita, US$ exchange rate","ISL","Iceland","2018","2018",23.6,,
+"PATCANAL","N02-Analgesics","TCPPERMT","/capita, US$ exchange rate","ISL","Iceland","2019","2019",22,,
+"PATCANAL","N02-Analgesics","TCPPERMT","/capita, US$ exchange rate","ISL","Iceland","2020","2020",22.2,,
+"PATCANAL","N02-Analgesics","TCPPERMT","/capita, US$ exchange rate","ISL","Iceland","2021","2021",25.8,,
+"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2010","2010",23.9,,
+"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2011","2011",18.3,,
+"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2012","2012",17.9,,
+"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2013","2013",22.5,,
+"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2014","2014",18.6,,
+"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2015","2015",17.9,,
+"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2016","2016",18.6,,
+"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2017","2017",19,,
+"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2018","2018",18.1,,
+"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2019","2019",19.2,,
+"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2020","2020",20.5,,
+"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2021","2021",21.8,,
+"PATCANAL","N02-Analgesics","ATCPTTMT","% of total sales","ISL","Iceland","2010","2010",4,,
+"PATCANAL","N02-Analgesics","ATCPTTMT","% of total sales","ISL","Iceland","2011","2011",3,,
+"PATCANAL","N02-Analgesics","ATCPTTMT","% of total sales","ISL","Iceland","2012","2012",3.2,,
+"PATCANAL","N02-Analgesics","ATCPTTMT","% of total sales","ISL","Iceland","2013","2013",3.8,,
+"PATCANAL","N02-Analgesics","ATCPTTMT","% of total sales","ISL","Iceland","2014","2014",3.6,,
+"PATCANAL","N02-Analgesics","ATCPTTMT","% of total sales","ISL","Iceland","2015","2015",3.4,,
+"PATCANAL","N02-Analgesics","ATCPTTMT","% of total sales","ISL","Iceland","2016","2016",3.4,,
+"PATCANAL","N02-Analgesics","ATCPTTMT","% of total sales","ISL","Iceland","2017","2017",3.4,,
+"PATCANAL","N02-Analgesics","ATCPTTMT","% of total sales","ISL","Iceland","2018","2018",3,,
+"PATCANAL","N02-Analgesics","ATCPTTMT","% of total sales","ISL","Iceland","2019","2019",2.9,,
+"PATCANAL","N02-Analgesics","ATCPTTMT","% of total sales","ISL","Iceland","2020","2020",2.8,,
+"PATCANAL","N02-Analgesics","ATCPTTMT","% of total sales","ISL","Iceland","2021","2021",2.7,,
+"PATCANAL","N02-Analgesics","MLLNCUMT","Million of national currency units","IRL","Ireland","2010","2010",55.1,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","MLLNCUMT","Million of national currency units","IRL","Ireland","2011","2011",57.1,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","MLLNCUMT","Million of national currency units","IRL","Ireland","2012","2012",59.2,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","MLLNCUMT","Million of national currency units","IRL","Ireland","2013","2013",54.7,"B; D","Break; Difference in methodology"
+"PATCANAL","N02-Analgesics","MLLNCUMT","Million of national currency units","IRL","Ireland","2014","2014",54.9,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","MLLNCUMT","Million of national currency units","IRL","Ireland","2015","2015",57.5,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","MLLNCUMT","Million of national currency units","IRL","Ireland","2016","2016",58,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","MLLNCUMT","Million of national currency units","IRL","Ireland","2017","2017",54.8,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","MLLNCUMT","Million of national currency units","IRL","Ireland","2018","2018",54,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","MLLNCUMT","Million of national currency units","IRL","Ireland","2019","2019",53.5,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","MLLNCUMT","Million of national currency units","IRL","Ireland","2020","2020",55.3,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","MLLNCUMT","Million of national currency units","IRL","Ireland","2021","2021",56.2,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","MTMOTCMT","Million US$ at exchange rate","IRL","Ireland","2010","2010",73.1,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","MTMOTCMT","Million US$ at exchange rate","IRL","Ireland","2011","2011",79.4,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","MTMOTCMT","Million US$ at exchange rate","IRL","Ireland","2012","2012",76,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","MTMOTCMT","Million US$ at exchange rate","IRL","Ireland","2013","2013",72.7,"B; D","Break; Difference in methodology"
+"PATCANAL","N02-Analgesics","MTMOTCMT","Million US$ at exchange rate","IRL","Ireland","2014","2014",73,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","MTMOTCMT","Million US$ at exchange rate","IRL","Ireland","2015","2015",63.7,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","MTMOTCMT","Million US$ at exchange rate","IRL","Ireland","2016","2016",64.2,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","MTMOTCMT","Million US$ at exchange rate","IRL","Ireland","2017","2017",61.9,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","MTMOTCMT","Million US$ at exchange rate","IRL","Ireland","2018","2018",63.7,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","MTMOTCMT","Million US$ at exchange rate","IRL","Ireland","2019","2019",59.9,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","MTMOTCMT","Million US$ at exchange rate","IRL","Ireland","2020","2020",63.1,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","MTMOTCMT","Million US$ at exchange rate","IRL","Ireland","2021","2021",66.5,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","MTMOPPMT","Million US$, purchasing power parity","IRL","Ireland","2010","2010",64.9,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","MTMOPPMT","Million US$, purchasing power parity","IRL","Ireland","2011","2011",68.6,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","MTMOPPMT","Million US$, purchasing power parity","IRL","Ireland","2012","2012",71.9,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","MTMOPPMT","Million US$, purchasing power parity","IRL","Ireland","2013","2013",67.5,"B; D","Break; Difference in methodology"
+"PATCANAL","N02-Analgesics","MTMOPPMT","Million US$, purchasing power parity","IRL","Ireland","2014","2014",67.1,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","MTMOPPMT","Million US$, purchasing power parity","IRL","Ireland","2015","2015",71,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","MTMOPPMT","Million US$, purchasing power parity","IRL","Ireland","2016","2016",73,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","MTMOPPMT","Million US$, purchasing power parity","IRL","Ireland","2017","2017",69,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","MTMOPPMT","Million US$, purchasing power parity","IRL","Ireland","2018","2018",68.1,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","MTMOPPMT","Million US$, purchasing power parity","IRL","Ireland","2019","2019",66.4,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","MTMOPPMT","Million US$, purchasing power parity","IRL","Ireland","2020","2020",69.4,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","MTMOPPMT","Million US$, purchasing power parity","IRL","Ireland","2021","2021",70.7,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","TCPPERMT","/capita, US$ exchange rate","IRL","Ireland","2010","2010",16,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","TCPPERMT","/capita, US$ exchange rate","IRL","Ireland","2011","2011",17.3,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","TCPPERMT","/capita, US$ exchange rate","IRL","Ireland","2012","2012",16.5,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","TCPPERMT","/capita, US$ exchange rate","IRL","Ireland","2013","2013",15.7,"B; D","Break; Difference in methodology"
+"PATCANAL","N02-Analgesics","TCPPERMT","/capita, US$ exchange rate","IRL","Ireland","2014","2014",15.7,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","TCPPERMT","/capita, US$ exchange rate","IRL","Ireland","2015","2015",13.6,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","TCPPERMT","/capita, US$ exchange rate","IRL","Ireland","2016","2016",13.5,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","TCPPERMT","/capita, US$ exchange rate","IRL","Ireland","2017","2017",12.9,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","TCPPERMT","/capita, US$ exchange rate","IRL","Ireland","2018","2018",13.1,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","TCPPERMT","/capita, US$ exchange rate","IRL","Ireland","2019","2019",12.1,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","TCPPERMT","/capita, US$ exchange rate","IRL","Ireland","2020","2020",12.7,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","TCPPERMT","/capita, US$ exchange rate","IRL","Ireland","2021","2021",13.2,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2010","2010",14.2,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2011","2011",15,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2012","2012",15.6,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2013","2013",14.6,"B; D","Break; Difference in methodology"
+"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2014","2014",14.4,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2015","2015",15.1,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2016","2016",15.4,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2017","2017",14.4,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2018","2018",14,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2019","2019",13.5,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2020","2020",13.9,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2021","2021",14.1,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","ATCPTTMT","% of total sales","IRL","Ireland","2010","2010",2.7,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","ATCPTTMT","% of total sales","IRL","Ireland","2011","2011",2.9,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","ATCPTTMT","% of total sales","IRL","Ireland","2012","2012",2.9,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","ATCPTTMT","% of total sales","IRL","Ireland","2013","2013",2.8,"B; D","Break; Difference in methodology"
+"PATCANAL","N02-Analgesics","ATCPTTMT","% of total sales","IRL","Ireland","2014","2014",2.9,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","ATCPTTMT","% of total sales","IRL","Ireland","2015","2015",2.9,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","ATCPTTMT","% of total sales","IRL","Ireland","2016","2016",2.8,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","ATCPTTMT","% of total sales","IRL","Ireland","2017","2017",2.6,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","ATCPTTMT","% of total sales","IRL","Ireland","2018","2018",2.4,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","ATCPTTMT","% of total sales","IRL","Ireland","2019","2019",2.2,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","ATCPTTMT","% of total sales","IRL","Ireland","2020","2020",2.2,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","ATCPTTMT","% of total sales","IRL","Ireland","2021","2021",2.1,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","MLLNCUMT","Million of national currency units","ITA","Italy","2011","2011",285,,
+"PATCANAL","N02-Analgesics","MLLNCUMT","Million of national currency units","ITA","Italy","2012","2012",306.2,,
+"PATCANAL","N02-Analgesics","MLLNCUMT","Million of national currency units","ITA","Italy","2013","2013",326.5,,
+"PATCANAL","N02-Analgesics","MLLNCUMT","Million of national currency units","ITA","Italy","2014","2014",346.5,,
+"PATCANAL","N02-Analgesics","MLLNCUMT","Million of national currency units","ITA","Italy","2015","2015",337.1,,
+"PATCANAL","N02-Analgesics","MLLNCUMT","Million of national currency units","ITA","Italy","2016","2016",358.1,,
+"PATCANAL","N02-Analgesics","MLLNCUMT","Million of national currency units","ITA","Italy","2017","2017",372.7,,
+"PATCANAL","N02-Analgesics","MLLNCUMT","Million of national currency units","ITA","Italy","2018","2018",380.1,,
+"PATCANAL","N02-Analgesics","MLLNCUMT","Million of national currency units","ITA","Italy","2019","2019",386.3,,
+"PATCANAL","N02-Analgesics","MLLNCUMT","Million of national currency units","ITA","Italy","2020","2020",377.6,,
+"PATCANAL","N02-Analgesics","MLLNCUMT","Million of national currency units","ITA","Italy","2021","2021",390.2,,
+"PATCANAL","N02-Analgesics","MLLNCUMT","Million of national currency units","ITA","Italy","2022","2022",369.8,"E","Estimated value"
+"PATCANAL","N02-Analgesics","MTMOTCMT","Million US$ at exchange rate","ITA","Italy","2011","2011",396.7,,
+"PATCANAL","N02-Analgesics","MTMOTCMT","Million US$ at exchange rate","ITA","Italy","2012","2012",393.4,,
+"PATCANAL","N02-Analgesics","MTMOTCMT","Million US$ at exchange rate","ITA","Italy","2013","2013",433.6,,
+"PATCANAL","N02-Analgesics","MTMOTCMT","Million US$ at exchange rate","ITA","Italy","2014","2014",460.3,,
+"PATCANAL","N02-Analgesics","MTMOTCMT","Million US$ at exchange rate","ITA","Italy","2015","2015",374,,
+"PATCANAL","N02-Analgesics","MTMOTCMT","Million US$ at exchange rate","ITA","Italy","2016","2016",396.4,,
+"PATCANAL","N02-Analgesics","MTMOTCMT","Million US$ at exchange rate","ITA","Italy","2017","2017",421.1,,
+"PATCANAL","N02-Analgesics","MTMOTCMT","Million US$ at exchange rate","ITA","Italy","2018","2018",448.8,,
+"PATCANAL","N02-Analgesics","MTMOTCMT","Million US$ at exchange rate","ITA","Italy","2019","2019",432.4,,
+"PATCANAL","N02-Analgesics","MTMOTCMT","Million US$ at exchange rate","ITA","Italy","2020","2020",431.2,,
+"PATCANAL","N02-Analgesics","MTMOTCMT","Million US$ at exchange rate","ITA","Italy","2021","2021",461.5,,
+"PATCANAL","N02-Analgesics","MTMOTCMT","Million US$ at exchange rate","ITA","Italy","2022","2022",389.4,"E","Estimated value"
+"PATCANAL","N02-Analgesics","MTMOPPMT","Million US$, purchasing power parity","ITA","Italy","2011","2011",375.6,,
+"PATCANAL","N02-Analgesics","MTMOPPMT","Million US$, purchasing power parity","ITA","Italy","2012","2012",409.5,,
+"PATCANAL","N02-Analgesics","MTMOPPMT","Million US$, purchasing power parity","ITA","Italy","2013","2013",442.8,,
+"PATCANAL","N02-Analgesics","MTMOPPMT","Million US$, purchasing power parity","ITA","Italy","2014","2014",468.5,,
+"PATCANAL","N02-Analgesics","MTMOPPMT","Million US$, purchasing power parity","ITA","Italy","2015","2015",456.4,,
+"PATCANAL","N02-Analgesics","MTMOPPMT","Million US$, purchasing power parity","ITA","Italy","2016","2016",511.2,,
+"PATCANAL","N02-Analgesics","MTMOPPMT","Million US$, purchasing power parity","ITA","Italy","2017","2017",540.3,,
+"PATCANAL","N02-Analgesics","MTMOPPMT","Million US$, purchasing power parity","ITA","Italy","2018","2018",557.9,,
+"PATCANAL","N02-Analgesics","MTMOPPMT","Million US$, purchasing power parity","ITA","Italy","2019","2019",588.2,,
+"PATCANAL","N02-Analgesics","MTMOPPMT","Million US$, purchasing power parity","ITA","Italy","2020","2020",582.9,,
+"PATCANAL","N02-Analgesics","MTMOPPMT","Million US$, purchasing power parity","ITA","Italy","2021","2021",602.6,,
+"PATCANAL","N02-Analgesics","MTMOPPMT","Million US$, purchasing power parity","ITA","Italy","2022","2022",598.9,"E","Estimated value"
+"PATCANAL","N02-Analgesics","TCPPERMT","/capita, US$ exchange rate","ITA","Italy","2011","2011",6.7,,
+"PATCANAL","N02-Analgesics","TCPPERMT","/capita, US$ exchange rate","ITA","Italy","2012","2012",6.6,,
+"PATCANAL","N02-Analgesics","TCPPERMT","/capita, US$ exchange rate","ITA","Italy","2013","2013",7.2,,
+"PATCANAL","N02-Analgesics","TCPPERMT","/capita, US$ exchange rate","ITA","Italy","2014","2014",7.6,,
+"PATCANAL","N02-Analgesics","TCPPERMT","/capita, US$ exchange rate","ITA","Italy","2015","2015",6.2,,
+"PATCANAL","N02-Analgesics","TCPPERMT","/capita, US$ exchange rate","ITA","Italy","2016","2016",6.5,,
+"PATCANAL","N02-Analgesics","TCPPERMT","/capita, US$ exchange rate","ITA","Italy","2017","2017",7,,
+"PATCANAL","N02-Analgesics","TCPPERMT","/capita, US$ exchange rate","ITA","Italy","2018","2018",7.4,,
+"PATCANAL","N02-Analgesics","TCPPERMT","/capita, US$ exchange rate","ITA","Italy","2019","2019",7.2,,
+"PATCANAL","N02-Analgesics","TCPPERMT","/capita, US$ exchange rate","ITA","Italy","2020","2020",7.3,,
+"PATCANAL","N02-Analgesics","TCPPERMT","/capita, US$ exchange rate","ITA","Italy","2021","2021",7.8,,
+"PATCANAL","N02-Analgesics","TCPPERMT","/capita, US$ exchange rate","ITA","Italy","2022","2022",6.6,"E","Estimated value"
+"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2011","2011",6.3,,
+"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2012","2012",6.9,,
+"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2013","2013",7.4,,
+"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2014","2014",7.7,,
+"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2015","2015",7.5,,
+"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2016","2016",8.4,,
+"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2017","2017",8.9,,
+"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2018","2018",9.2,,
+"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2019","2019",9.8,,
+"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2020","2020",9.8,,
+"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2021","2021",10.2,,
+"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2022","2022",10.1,"E","Estimated value"
+"PATCANAL","N02-Analgesics","ATCPTTMT","% of total sales","ITA","Italy","2011","2011",1.5,,
+"PATCANAL","N02-Analgesics","ATCPTTMT","% of total sales","ITA","Italy","2012","2012",1.6,,
+"PATCANAL","N02-Analgesics","ATCPTTMT","% of total sales","ITA","Italy","2013","2013",1.7,,
+"PATCANAL","N02-Analgesics","ATCPTTMT","% of total sales","ITA","Italy","2014","2014",1.7,,
+"PATCANAL","N02-Analgesics","ATCPTTMT","% of total sales","ITA","Italy","2015","2015",1.5,,
+"PATCANAL","N02-Analgesics","ATCPTTMT","% of total sales","ITA","Italy","2016","2016",1.6,,
+"PATCANAL","N02-Analgesics","ATCPTTMT","% of total sales","ITA","Italy","2017","2017",1.6,,
+"PATCANAL","N02-Analgesics","ATCPTTMT","% of total sales","ITA","Italy","2018","2018",1.7,,
+"PATCANAL","N02-Analgesics","ATCPTTMT","% of total sales","ITA","Italy","2019","2019",1.7,,
+"PATCANAL","N02-Analgesics","ATCPTTMT","% of total sales","ITA","Italy","2020","2020",1.6,,
+"PATCANAL","N02-Analgesics","ATCPTTMT","% of total sales","ITA","Italy","2021","2021",1.6,,
+"PATCANAL","N02-Analgesics","ATCPTTMT","% of total sales","ITA","Italy","2022","2022",1.5,"E","Estimated value"
+"PATCANAL","N02-Analgesics","MLLNCUMT","Million of national currency units","KOR","Korea","2010","2010",313776,,
+"PATCANAL","N02-Analgesics","MLLNCUMT","Million of national currency units","KOR","Korea","2011","2011",323074.3,"B","Break"
+"PATCANAL","N02-Analgesics","MLLNCUMT","Million of national currency units","KOR","Korea","2012","2012",323368.2,,
+"PATCANAL","N02-Analgesics","MLLNCUMT","Million of national currency units","KOR","Korea","2013","2013",341579.5,,
+"PATCANAL","N02-Analgesics","MLLNCUMT","Million of national currency units","KOR","Korea","2014","2014",368535.7,,
+"PATCANAL","N02-Analgesics","MLLNCUMT","Million of national currency units","KOR","Korea","2015","2015",373609.1,,
+"PATCANAL","N02-Analgesics","MLLNCUMT","Million of national currency units","KOR","Korea","2016","2016",381135.2,"B","Break"
+"PATCANAL","N02-Analgesics","MLLNCUMT","Million of national currency units","KOR","Korea","2017","2017",395424.9,,
+"PATCANAL","N02-Analgesics","MLLNCUMT","Million of national currency units","KOR","Korea","2018","2018",419795.5,,
+"PATCANAL","N02-Analgesics","MLLNCUMT","Million of national currency units","KOR","Korea","2019","2019",460197.4,,
+"PATCANAL","N02-Analgesics","MLLNCUMT","Million of national currency units","KOR","Korea","2020","2020",487736.6,,
+"PATCANAL","N02-Analgesics","MLLNCUMT","Million of national currency units","KOR","Korea","2021","2021",548535.1,,
+"PATCANAL","N02-Analgesics","MTMOTCMT","Million US$ at exchange rate","KOR","Korea","2010","2010",271.3,,
+"PATCANAL","N02-Analgesics","MTMOTCMT","Million US$ at exchange rate","KOR","Korea","2011","2011",291.5,"B","Break"
+"PATCANAL","N02-Analgesics","MTMOTCMT","Million US$ at exchange rate","KOR","Korea","2012","2012",287,,
+"PATCANAL","N02-Analgesics","MTMOTCMT","Million US$ at exchange rate","KOR","Korea","2013","2013",311.9,,
+"PATCANAL","N02-Analgesics","MTMOTCMT","Million US$ at exchange rate","KOR","Korea","2014","2014",350,,
+"PATCANAL","N02-Analgesics","MTMOTCMT","Million US$ at exchange rate","KOR","Korea","2015","2015",330.3,,
+"PATCANAL","N02-Analgesics","MTMOTCMT","Million US$ at exchange rate","KOR","Korea","2016","2016",328.3,"B","Break"
+"PATCANAL","N02-Analgesics","MTMOTCMT","Million US$ at exchange rate","KOR","Korea","2017","2017",349.6,,
+"PATCANAL","N02-Analgesics","MTMOTCMT","Million US$ at exchange rate","KOR","Korea","2018","2018",381.6,,
+"PATCANAL","N02-Analgesics","MTMOTCMT","Million US$ at exchange rate","KOR","Korea","2019","2019",394.9,,
+"PATCANAL","N02-Analgesics","MTMOTCMT","Million US$ at exchange rate","KOR","Korea","2020","2020",413.2,,
+"PATCANAL","N02-Analgesics","MTMOTCMT","Million US$ at exchange rate","KOR","Korea","2021","2021",479.5,,
+"PATCANAL","N02-Analgesics","MTMOPPMT","Million US$, purchasing power parity","KOR","Korea","2010","2010",373.1,,
+"PATCANAL","N02-Analgesics","MTMOPPMT","Million US$, purchasing power parity","KOR","Korea","2011","2011",378,"B","Break"
+"PATCANAL","N02-Analgesics","MTMOPPMT","Million US$, purchasing power parity","KOR","Korea","2012","2012",378.3,,
+"PATCANAL","N02-Analgesics","MTMOPPMT","Million US$, purchasing power parity","KOR","Korea","2013","2013",393,,
+"PATCANAL","N02-Analgesics","MTMOPPMT","Million US$, purchasing power parity","KOR","Korea","2014","2014",422.7,,
+"PATCANAL","N02-Analgesics","MTMOPPMT","Million US$, purchasing power parity","KOR","Korea","2015","2015",435.7,,
+"PATCANAL","N02-Analgesics","MTMOPPMT","Million US$, purchasing power parity","KOR","Korea","2016","2016",443.8,"B","Break"
+"PATCANAL","N02-Analgesics","MTMOPPMT","Million US$, purchasing power parity","KOR","Korea","2017","2017",453.1,,
+"PATCANAL","N02-Analgesics","MTMOPPMT","Million US$, purchasing power parity","KOR","Korea","2018","2018",491.1,,
+"PATCANAL","N02-Analgesics","MTMOPPMT","Million US$, purchasing power parity","KOR","Korea","2019","2019",537.3,,
+"PATCANAL","N02-Analgesics","MTMOPPMT","Million US$, purchasing power parity","KOR","Korea","2020","2020",582.3,,
+"PATCANAL","N02-Analgesics","MTMOPPMT","Million US$, purchasing power parity","KOR","Korea","2021","2021",642.2,,
+"PATCANAL","N02-Analgesics","TCPPERMT","/capita, US$ exchange rate","KOR","Korea","2010","2010",5.5,,
+"PATCANAL","N02-Analgesics","TCPPERMT","/capita, US$ exchange rate","KOR","Korea","2011","2011",5.8,"B","Break"
+"PATCANAL","N02-Analgesics","TCPPERMT","/capita, US$ exchange rate","KOR","Korea","2012","2012",5.7,,
+"PATCANAL","N02-Analgesics","TCPPERMT","/capita, US$ exchange rate","KOR","Korea","2013","2013",6.2,,
+"PATCANAL","N02-Analgesics","TCPPERMT","/capita, US$ exchange rate","KOR","Korea","2014","2014",6.9,,
+"PATCANAL","N02-Analgesics","TCPPERMT","/capita, US$ exchange rate","KOR","Korea","2015","2015",6.5,,
+"PATCANAL","N02-Analgesics","TCPPERMT","/capita, US$ exchange rate","KOR","Korea","2016","2016",6.4,"B","Break"
+"PATCANAL","N02-Analgesics","TCPPERMT","/capita, US$ exchange rate","KOR","Korea","2017","2017",6.8,,
+"PATCANAL","N02-Analgesics","TCPPERMT","/capita, US$ exchange rate","KOR","Korea","2018","2018",7.4,,
+"PATCANAL","N02-Analgesics","TCPPERMT","/capita, US$ exchange rate","KOR","Korea","2019","2019",7.6,,
+"PATCANAL","N02-Analgesics","TCPPERMT","/capita, US$ exchange rate","KOR","Korea","2020","2020",8,,
+"PATCANAL","N02-Analgesics","TCPPERMT","/capita, US$ exchange rate","KOR","Korea","2021","2021",9.3,,
+"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2010","2010",7.5,,
+"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2011","2011",7.6,"B","Break"
+"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2012","2012",7.5,,
+"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2013","2013",7.8,,
+"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2014","2014",8.3,,
+"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2015","2015",8.5,,
+"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2016","2016",8.7,"B","Break"
+"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2017","2017",8.8,,
+"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2018","2018",9.5,,
+"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2019","2019",10.4,,
+"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2020","2020",11.2,,
+"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2021","2021",12.4,,
+"PATCANAL","N02-Analgesics","ATCPTTMT","% of total sales","KOR","Korea","2010","2010",1.5,,
+"PATCANAL","N02-Analgesics","ATCPTTMT","% of total sales","KOR","Korea","2011","2011",1.5,"B","Break"
+"PATCANAL","N02-Analgesics","ATCPTTMT","% of total sales","KOR","Korea","2012","2012",1.5,,
+"PATCANAL","N02-Analgesics","ATCPTTMT","% of total sales","KOR","Korea","2013","2013",1.5,,
+"PATCANAL","N02-Analgesics","ATCPTTMT","% of total sales","KOR","Korea","2014","2014",1.6,,
+"PATCANAL","N02-Analgesics","ATCPTTMT","% of total sales","KOR","Korea","2015","2015",1.5,,
+"PATCANAL","N02-Analgesics","ATCPTTMT","% of total sales","KOR","Korea","2016","2016",1.5,"B","Break"
+"PATCANAL","N02-Analgesics","ATCPTTMT","% of total sales","KOR","Korea","2017","2017",1.5,,
+"PATCANAL","N02-Analgesics","ATCPTTMT","% of total sales","KOR","Korea","2018","2018",1.5,,
+"PATCANAL","N02-Analgesics","ATCPTTMT","% of total sales","KOR","Korea","2019","2019",1.5,,
+"PATCANAL","N02-Analgesics","ATCPTTMT","% of total sales","KOR","Korea","2020","2020",1.5,,
+"PATCANAL","N02-Analgesics","ATCPTTMT","% of total sales","KOR","Korea","2021","2021",1.6,,
+"PATCANAL","N02-Analgesics","MLLNCUMT","Million of national currency units","LUX","Luxembourg","2010","2010",6.8,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","MLLNCUMT","Million of national currency units","LUX","Luxembourg","2011","2011",7.3,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","MLLNCUMT","Million of national currency units","LUX","Luxembourg","2012","2012",7.5,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","MLLNCUMT","Million of national currency units","LUX","Luxembourg","2013","2013",7.6,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","MLLNCUMT","Million of national currency units","LUX","Luxembourg","2014","2014",7.6,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","MLLNCUMT","Million of national currency units","LUX","Luxembourg","2015","2015",7.7,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","MLLNCUMT","Million of national currency units","LUX","Luxembourg","2016","2016",7.8,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","MLLNCUMT","Million of national currency units","LUX","Luxembourg","2017","2017",7.7,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","MLLNCUMT","Million of national currency units","LUX","Luxembourg","2018","2018",8.1,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","MLLNCUMT","Million of national currency units","LUX","Luxembourg","2019","2019",8.8,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","MLLNCUMT","Million of national currency units","LUX","Luxembourg","2020","2020",9.6,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","MLLNCUMT","Million of national currency units","LUX","Luxembourg","2021","2021",10.5,"B; D; P","Break; Difference in methodology; Provisional value"
+"PATCANAL","N02-Analgesics","MLLNCUMT","Million of national currency units","LUX","Luxembourg","2022","2022",10.7,"D; P","Difference in methodology; Provisional value"
+"PATCANAL","N02-Analgesics","MTMOTCMT","Million US$ at exchange rate","LUX","Luxembourg","2010","2010",9,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","MTMOTCMT","Million US$ at exchange rate","LUX","Luxembourg","2011","2011",10.1,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","MTMOTCMT","Million US$ at exchange rate","LUX","Luxembourg","2012","2012",9.6,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","MTMOTCMT","Million US$ at exchange rate","LUX","Luxembourg","2013","2013",10.1,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","MTMOTCMT","Million US$ at exchange rate","LUX","Luxembourg","2014","2014",10.1,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","MTMOTCMT","Million US$ at exchange rate","LUX","Luxembourg","2015","2015",8.6,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","MTMOTCMT","Million US$ at exchange rate","LUX","Luxembourg","2016","2016",8.6,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","MTMOTCMT","Million US$ at exchange rate","LUX","Luxembourg","2017","2017",8.7,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","MTMOTCMT","Million US$ at exchange rate","LUX","Luxembourg","2018","2018",9.5,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","MTMOTCMT","Million US$ at exchange rate","LUX","Luxembourg","2019","2019",9.9,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","MTMOTCMT","Million US$ at exchange rate","LUX","Luxembourg","2020","2020",11,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","MTMOTCMT","Million US$ at exchange rate","LUX","Luxembourg","2021","2021",12.5,"B; D; P","Break; Difference in methodology; Provisional value"
+"PATCANAL","N02-Analgesics","MTMOTCMT","Million US$ at exchange rate","LUX","Luxembourg","2022","2022",11.2,"D; P","Difference in methodology; Provisional value"
+"PATCANAL","N02-Analgesics","MTMOPPMT","Million US$, purchasing power parity","LUX","Luxembourg","2010","2010",7.4,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","MTMOPPMT","Million US$, purchasing power parity","LUX","Luxembourg","2011","2011",8,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","MTMOPPMT","Million US$, purchasing power parity","LUX","Luxembourg","2012","2012",8.2,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","MTMOPPMT","Million US$, purchasing power parity","LUX","Luxembourg","2013","2013",8.5,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","MTMOPPMT","Million US$, purchasing power parity","LUX","Luxembourg","2014","2014",8.6,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","MTMOPPMT","Million US$, purchasing power parity","LUX","Luxembourg","2015","2015",8.8,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","MTMOPPMT","Million US$, purchasing power parity","LUX","Luxembourg","2016","2016",9.1,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","MTMOPPMT","Million US$, purchasing power parity","LUX","Luxembourg","2017","2017",9.1,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","MTMOPPMT","Million US$, purchasing power parity","LUX","Luxembourg","2018","2018",9.5,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","MTMOPPMT","Million US$, purchasing power parity","LUX","Luxembourg","2019","2019",10.5,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","MTMOPPMT","Million US$, purchasing power parity","LUX","Luxembourg","2020","2020",11.2,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","MTMOPPMT","Million US$, purchasing power parity","LUX","Luxembourg","2021","2021",12.3,"B; D; P","Break; Difference in methodology; Provisional value"
+"PATCANAL","N02-Analgesics","MTMOPPMT","Million US$, purchasing power parity","LUX","Luxembourg","2022","2022",12.8,"D; P","Difference in methodology; Provisional value"
+"PATCANAL","N02-Analgesics","TCPPERMT","/capita, US$ exchange rate","LUX","Luxembourg","2010","2010",19.1,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","TCPPERMT","/capita, US$ exchange rate","LUX","Luxembourg","2011","2011",21,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","TCPPERMT","/capita, US$ exchange rate","LUX","Luxembourg","2012","2012",19.5,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","TCPPERMT","/capita, US$ exchange rate","LUX","Luxembourg","2013","2013",20.2,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","TCPPERMT","/capita, US$ exchange rate","LUX","Luxembourg","2014","2014",19.8,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","TCPPERMT","/capita, US$ exchange rate","LUX","Luxembourg","2015","2015",16.6,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","TCPPERMT","/capita, US$ exchange rate","LUX","Luxembourg","2016","2016",16.3,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","TCPPERMT","/capita, US$ exchange rate","LUX","Luxembourg","2017","2017",16.3,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","TCPPERMT","/capita, US$ exchange rate","LUX","Luxembourg","2018","2018",17.4,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","TCPPERMT","/capita, US$ exchange rate","LUX","Luxembourg","2019","2019",17.7,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","TCPPERMT","/capita, US$ exchange rate","LUX","Luxembourg","2020","2020",19.3,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","TCPPERMT","/capita, US$ exchange rate","LUX","Luxembourg","2021","2021",21.6,"B; D; P","Break; Difference in methodology; Provisional value"
+"PATCANAL","N02-Analgesics","TCPPERMT","/capita, US$ exchange rate","LUX","Luxembourg","2022","2022",19.1,"D; P","Difference in methodology; Provisional value"
+"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2010","2010",15.6,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2011","2011",16.7,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2012","2012",16.7,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2013","2013",17,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2014","2014",16.8,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2015","2015",16.9,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2016","2016",17.3,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2017","2017",17,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2018","2018",17.4,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2019","2019",18.8,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2020","2020",19.8,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2021","2021",21.3,"B; D; P","Break; Difference in methodology; Provisional value"
+"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2022","2022",21.9,"D; P","Difference in methodology; Provisional value"
+"PATCANAL","N02-Analgesics","ATCPTTMT","% of total sales","LUX","Luxembourg","2010","2010",3.6,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","ATCPTTMT","% of total sales","LUX","Luxembourg","2011","2011",3.8,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","ATCPTTMT","% of total sales","LUX","Luxembourg","2012","2012",3.8,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","ATCPTTMT","% of total sales","LUX","Luxembourg","2013","2013",3.9,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","ATCPTTMT","% of total sales","LUX","Luxembourg","2014","2014",4,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","ATCPTTMT","% of total sales","LUX","Luxembourg","2015","2015",4,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","ATCPTTMT","% of total sales","LUX","Luxembourg","2016","2016",4,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","ATCPTTMT","% of total sales","LUX","Luxembourg","2017","2017",4,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","ATCPTTMT","% of total sales","LUX","Luxembourg","2018","2018",4.1,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","ATCPTTMT","% of total sales","LUX","Luxembourg","2019","2019",4.3,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","ATCPTTMT","% of total sales","LUX","Luxembourg","2020","2020",4.6,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","ATCPTTMT","% of total sales","LUX","Luxembourg","2021","2021",4.4,"B; D; P","Break; Difference in methodology; Provisional value"
+"PATCANAL","N02-Analgesics","ATCPTTMT","% of total sales","LUX","Luxembourg","2022","2022",4.1,"D; P","Difference in methodology; Provisional value"
+"PATCANAL","N02-Analgesics","MLLNCUMT","Million of national currency units","NLD","Netherlands","2010","2010",146.5,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","MLLNCUMT","Million of national currency units","NLD","Netherlands","2011","2011",159.7,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","MLLNCUMT","Million of national currency units","NLD","Netherlands","2012","2012",162.5,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","MLLNCUMT","Million of national currency units","NLD","Netherlands","2013","2013",148.9,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","MLLNCUMT","Million of national currency units","NLD","Netherlands","2014","2014",143.6,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","MTMOTCMT","Million US$ at exchange rate","NLD","Netherlands","2010","2010",194.2,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","MTMOTCMT","Million US$ at exchange rate","NLD","Netherlands","2011","2011",222.3,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","MTMOTCMT","Million US$ at exchange rate","NLD","Netherlands","2012","2012",208.8,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","MTMOTCMT","Million US$ at exchange rate","NLD","Netherlands","2013","2013",197.7,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","MTMOTCMT","Million US$ at exchange rate","NLD","Netherlands","2014","2014",190.8,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","MTMOPPMT","Million US$, purchasing power parity","NLD","Netherlands","2010","2010",171.5,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","MTMOPPMT","Million US$, purchasing power parity","NLD","Netherlands","2011","2011",191.1,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","MTMOPPMT","Million US$, purchasing power parity","NLD","Netherlands","2012","2012",197.1,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","MTMOPPMT","Million US$, purchasing power parity","NLD","Netherlands","2013","2013",186.5,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","MTMOPPMT","Million US$, purchasing power parity","NLD","Netherlands","2014","2014",177.6,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","TCPPERMT","/capita, US$ exchange rate","NLD","Netherlands","2010","2010",11.7,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","TCPPERMT","/capita, US$ exchange rate","NLD","Netherlands","2011","2011",13.3,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","TCPPERMT","/capita, US$ exchange rate","NLD","Netherlands","2012","2012",12.5,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","TCPPERMT","/capita, US$ exchange rate","NLD","Netherlands","2013","2013",11.8,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","TCPPERMT","/capita, US$ exchange rate","NLD","Netherlands","2014","2014",11.3,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","NLD","Netherlands","2010","2010",10.3,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","NLD","Netherlands","2011","2011",11.4,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","NLD","Netherlands","2012","2012",11.8,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","NLD","Netherlands","2013","2013",11.1,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","NLD","Netherlands","2014","2014",10.5,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","ATCPTTMT","% of total sales","NLD","Netherlands","2010","2010",2.8,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","ATCPTTMT","% of total sales","NLD","Netherlands","2011","2011",3.1,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","ATCPTTMT","% of total sales","NLD","Netherlands","2012","2012",3.5,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","ATCPTTMT","% of total sales","NLD","Netherlands","2013","2013",3.5,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","ATCPTTMT","% of total sales","NLD","Netherlands","2014","2014",3.3,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","MLLNCUMT","Million of national currency units","NZL","New Zealand","2010","2010",29.7,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","MLLNCUMT","Million of national currency units","NZL","New Zealand","2011","2011",29.8,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","MLLNCUMT","Million of national currency units","NZL","New Zealand","2012","2012",28.7,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","MLLNCUMT","Million of national currency units","NZL","New Zealand","2013","2013",23.9,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","MLLNCUMT","Million of national currency units","NZL","New Zealand","2014","2014",21.2,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","MLLNCUMT","Million of national currency units","NZL","New Zealand","2015","2015",20.4,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","MLLNCUMT","Million of national currency units","NZL","New Zealand","2016","2016",19.6,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","MLLNCUMT","Million of national currency units","NZL","New Zealand","2017","2017",16.9,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","MLLNCUMT","Million of national currency units","NZL","New Zealand","2018","2018",18.1,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","MLLNCUMT","Million of national currency units","NZL","New Zealand","2019","2019",17.9,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","MLLNCUMT","Million of national currency units","NZL","New Zealand","2020","2020",16.5,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","MLLNCUMT","Million of national currency units","NZL","New Zealand","2021","2021",25.6,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","MLLNCUMT","Million of national currency units","NZL","New Zealand","2022","2022",25,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","MTMOTCMT","Million US$ at exchange rate","NZL","New Zealand","2010","2010",21.4,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","MTMOTCMT","Million US$ at exchange rate","NZL","New Zealand","2011","2011",23.6,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","MTMOTCMT","Million US$ at exchange rate","NZL","New Zealand","2012","2012",23.2,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","MTMOTCMT","Million US$ at exchange rate","NZL","New Zealand","2013","2013",19.6,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","MTMOTCMT","Million US$ at exchange rate","NZL","New Zealand","2014","2014",17.6,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","MTMOTCMT","Million US$ at exchange rate","NZL","New Zealand","2015","2015",14.2,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","MTMOTCMT","Million US$ at exchange rate","NZL","New Zealand","2016","2016",13.7,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","MTMOTCMT","Million US$ at exchange rate","NZL","New Zealand","2017","2017",12,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","MTMOTCMT","Million US$ at exchange rate","NZL","New Zealand","2018","2018",12.5,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","MTMOTCMT","Million US$ at exchange rate","NZL","New Zealand","2019","2019",11.8,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","MTMOTCMT","Million US$ at exchange rate","NZL","New Zealand","2020","2020",10.7,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","MTMOTCMT","Million US$ at exchange rate","NZL","New Zealand","2021","2021",18.1,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","MTMOTCMT","Million US$ at exchange rate","NZL","New Zealand","2022","2022",15.9,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","MTMOPPMT","Million US$, purchasing power parity","NZL","New Zealand","2010","2010",19.9,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","MTMOPPMT","Million US$, purchasing power parity","NZL","New Zealand","2011","2011",20.1,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","MTMOPPMT","Million US$, purchasing power parity","NZL","New Zealand","2012","2012",19.2,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","MTMOPPMT","Million US$, purchasing power parity","NZL","New Zealand","2013","2013",16.5,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","MTMOPPMT","Million US$, purchasing power parity","NZL","New Zealand","2014","2014",14.7,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","MTMOPPMT","Million US$, purchasing power parity","NZL","New Zealand","2015","2015",13.8,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","MTMOPPMT","Million US$, purchasing power parity","NZL","New Zealand","2016","2016",13.6,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","MTMOPPMT","Million US$, purchasing power parity","NZL","New Zealand","2017","2017",11.8,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","MTMOPPMT","Million US$, purchasing power parity","NZL","New Zealand","2018","2018",12.3,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","MTMOPPMT","Million US$, purchasing power parity","NZL","New Zealand","2019","2019",12.6,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","MTMOPPMT","Million US$, purchasing power parity","NZL","New Zealand","2020","2020",11.7,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","MTMOPPMT","Million US$, purchasing power parity","NZL","New Zealand","2021","2021",17.6,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","MTMOPPMT","Million US$, purchasing power parity","NZL","New Zealand","2022","2022",17.3,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","TCPPERMT","/capita, US$ exchange rate","NZL","New Zealand","2010","2010",4.9,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","TCPPERMT","/capita, US$ exchange rate","NZL","New Zealand","2011","2011",5.4,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","TCPPERMT","/capita, US$ exchange rate","NZL","New Zealand","2012","2012",5.3,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","TCPPERMT","/capita, US$ exchange rate","NZL","New Zealand","2013","2013",4.4,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","TCPPERMT","/capita, US$ exchange rate","NZL","New Zealand","2014","2014",3.9,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","TCPPERMT","/capita, US$ exchange rate","NZL","New Zealand","2015","2015",3.1,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","TCPPERMT","/capita, US$ exchange rate","NZL","New Zealand","2016","2016",2.9,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","TCPPERMT","/capita, US$ exchange rate","NZL","New Zealand","2017","2017",2.5,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","TCPPERMT","/capita, US$ exchange rate","NZL","New Zealand","2018","2018",2.6,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","TCPPERMT","/capita, US$ exchange rate","NZL","New Zealand","2019","2019",2.4,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","TCPPERMT","/capita, US$ exchange rate","NZL","New Zealand","2020","2020",2.1,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","TCPPERMT","/capita, US$ exchange rate","NZL","New Zealand","2021","2021",3.5,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","TCPPERMT","/capita, US$ exchange rate","NZL","New Zealand","2022","2022",3.1,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2010","2010",4.6,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2011","2011",4.6,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2012","2012",4.4,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2013","2013",3.7,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2014","2014",3.3,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2015","2015",3,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2016","2016",2.9,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2017","2017",2.5,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2018","2018",2.5,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2019","2019",2.5,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2020","2020",2.3,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2021","2021",3.4,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2022","2022",3.4,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","ATCPTTMT","% of total sales","NZL","New Zealand","2010","2010",4,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","ATCPTTMT","% of total sales","NZL","New Zealand","2011","2011",3.7,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","ATCPTTMT","% of total sales","NZL","New Zealand","2012","2012",3.1,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","ATCPTTMT","% of total sales","NZL","New Zealand","2013","2013",2.6,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","ATCPTTMT","% of total sales","NZL","New Zealand","2014","2014",2.2,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","ATCPTTMT","% of total sales","NZL","New Zealand","2015","2015",2.1,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","ATCPTTMT","% of total sales","NZL","New Zealand","2016","2016",1.8,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","ATCPTTMT","% of total sales","NZL","New Zealand","2017","2017",1.3,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","ATCPTTMT","% of total sales","NZL","New Zealand","2018","2018",1.4,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","ATCPTTMT","% of total sales","NZL","New Zealand","2019","2019",1.2,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","ATCPTTMT","% of total sales","NZL","New Zealand","2020","2020",1,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","ATCPTTMT","% of total sales","NZL","New Zealand","2021","2021",1.4,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","ATCPTTMT","% of total sales","NZL","New Zealand","2022","2022",1.3,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","MLLNCUMT","Million of national currency units","NOR","Norway","2010","2010",1194,,
+"PATCANAL","N02-Analgesics","MLLNCUMT","Million of national currency units","NOR","Norway","2011","2011",1219,,
+"PATCANAL","N02-Analgesics","MLLNCUMT","Million of national currency units","NOR","Norway","2012","2012",1256,,
+"PATCANAL","N02-Analgesics","MLLNCUMT","Million of national currency units","NOR","Norway","2013","2013",1255,,
+"PATCANAL","N02-Analgesics","MLLNCUMT","Million of national currency units","NOR","Norway","2014","2014",1317,,
+"PATCANAL","N02-Analgesics","MLLNCUMT","Million of national currency units","NOR","Norway","2015","2015",1391,,
+"PATCANAL","N02-Analgesics","MLLNCUMT","Million of national currency units","NOR","Norway","2016","2016",1465,,
+"PATCANAL","N02-Analgesics","MLLNCUMT","Million of national currency units","NOR","Norway","2017","2017",1482,,
+"PATCANAL","N02-Analgesics","MLLNCUMT","Million of national currency units","NOR","Norway","2018","2018",1459,,
+"PATCANAL","N02-Analgesics","MLLNCUMT","Million of national currency units","NOR","Norway","2019","2019",1520,,
+"PATCANAL","N02-Analgesics","MLLNCUMT","Million of national currency units","NOR","Norway","2020","2020",1818,,
+"PATCANAL","N02-Analgesics","MLLNCUMT","Million of national currency units","NOR","Norway","2021","2021",2006,,
+"PATCANAL","N02-Analgesics","MLLNCUMT","Million of national currency units","NOR","Norway","2022","2022",2213,,
+"PATCANAL","N02-Analgesics","MTMOTCMT","Million US$ at exchange rate","NOR","Norway","2010","2010",197.5,,
+"PATCANAL","N02-Analgesics","MTMOTCMT","Million US$ at exchange rate","NOR","Norway","2011","2011",217.5,,
+"PATCANAL","N02-Analgesics","MTMOTCMT","Million US$ at exchange rate","NOR","Norway","2012","2012",215.9,,
+"PATCANAL","N02-Analgesics","MTMOTCMT","Million US$ at exchange rate","NOR","Norway","2013","2013",213.6,,
+"PATCANAL","N02-Analgesics","MTMOTCMT","Million US$ at exchange rate","NOR","Norway","2014","2014",209,,
+"PATCANAL","N02-Analgesics","MTMOTCMT","Million US$ at exchange rate","NOR","Norway","2015","2015",172.5,,
+"PATCANAL","N02-Analgesics","MTMOTCMT","Million US$ at exchange rate","NOR","Norway","2016","2016",174.4,,
+"PATCANAL","N02-Analgesics","MTMOTCMT","Million US$ at exchange rate","NOR","Norway","2017","2017",179.2,,
+"PATCANAL","N02-Analgesics","MTMOTCMT","Million US$ at exchange rate","NOR","Norway","2018","2018",179.4,,
+"PATCANAL","N02-Analgesics","MTMOTCMT","Million US$ at exchange rate","NOR","Norway","2019","2019",172.7,,
+"PATCANAL","N02-Analgesics","MTMOTCMT","Million US$ at exchange rate","NOR","Norway","2020","2020",193.1,,
+"PATCANAL","N02-Analgesics","MTMOTCMT","Million US$ at exchange rate","NOR","Norway","2021","2021",233.5,,
+"PATCANAL","N02-Analgesics","MTMOTCMT","Million US$ at exchange rate","NOR","Norway","2022","2022",230.2,,
+"PATCANAL","N02-Analgesics","MTMOPPMT","Million US$, purchasing power parity","NOR","Norway","2010","2010",130.5,,
+"PATCANAL","N02-Analgesics","MTMOPPMT","Million US$, purchasing power parity","NOR","Norway","2011","2011",134.2,,
+"PATCANAL","N02-Analgesics","MTMOPPMT","Million US$, purchasing power parity","NOR","Norway","2012","2012",139,,
+"PATCANAL","N02-Analgesics","MTMOPPMT","Million US$, purchasing power parity","NOR","Norway","2013","2013",139,,
+"PATCANAL","N02-Analgesics","MTMOPPMT","Million US$, purchasing power parity","NOR","Norway","2014","2014",141.9,,
+"PATCANAL","N02-Analgesics","MTMOPPMT","Million US$, purchasing power parity","NOR","Norway","2015","2015",140,,
+"PATCANAL","N02-Analgesics","MTMOPPMT","Million US$, purchasing power parity","NOR","Norway","2016","2016",145.9,,
+"PATCANAL","N02-Analgesics","MTMOPPMT","Million US$, purchasing power parity","NOR","Norway","2017","2017",152,,
+"PATCANAL","N02-Analgesics","MTMOPPMT","Million US$, purchasing power parity","NOR","Norway","2018","2018",152.2,,
+"PATCANAL","N02-Analgesics","MTMOPPMT","Million US$, purchasing power parity","NOR","Norway","2019","2019",158,,
+"PATCANAL","N02-Analgesics","MTMOPPMT","Million US$, purchasing power parity","NOR","Norway","2020","2020",184,,
+"PATCANAL","N02-Analgesics","MTMOPPMT","Million US$, purchasing power parity","NOR","Norway","2021","2021",210.9,,
+"PATCANAL","N02-Analgesics","MTMOPPMT","Million US$, purchasing power parity","NOR","Norway","2022","2022",206.1,,
+"PATCANAL","N02-Analgesics","TCPPERMT","/capita, US$ exchange rate","NOR","Norway","2010","2010",40.4,,
+"PATCANAL","N02-Analgesics","TCPPERMT","/capita, US$ exchange rate","NOR","Norway","2011","2011",43.9,,
+"PATCANAL","N02-Analgesics","TCPPERMT","/capita, US$ exchange rate","NOR","Norway","2012","2012",43,,
+"PATCANAL","N02-Analgesics","TCPPERMT","/capita, US$ exchange rate","NOR","Norway","2013","2013",42.1,,
+"PATCANAL","N02-Analgesics","TCPPERMT","/capita, US$ exchange rate","NOR","Norway","2014","2014",40.7,,
+"PATCANAL","N02-Analgesics","TCPPERMT","/capita, US$ exchange rate","NOR","Norway","2015","2015",33.2,,
+"PATCANAL","N02-Analgesics","TCPPERMT","/capita, US$ exchange rate","NOR","Norway","2016","2016",33.3,,
+"PATCANAL","N02-Analgesics","TCPPERMT","/capita, US$ exchange rate","NOR","Norway","2017","2017",34,,
+"PATCANAL","N02-Analgesics","TCPPERMT","/capita, US$ exchange rate","NOR","Norway","2018","2018",33.8,,
+"PATCANAL","N02-Analgesics","TCPPERMT","/capita, US$ exchange rate","NOR","Norway","2019","2019",32.3,,
+"PATCANAL","N02-Analgesics","TCPPERMT","/capita, US$ exchange rate","NOR","Norway","2020","2020",35.9,,
+"PATCANAL","N02-Analgesics","TCPPERMT","/capita, US$ exchange rate","NOR","Norway","2021","2021",43.2,,
+"PATCANAL","N02-Analgesics","TCPPERMT","/capita, US$ exchange rate","NOR","Norway","2022","2022",42.4,,
+"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2010","2010",26.7,,
+"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2011","2011",27.1,,
+"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2012","2012",27.7,,
+"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2013","2013",27.4,,
+"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2014","2014",27.6,,
+"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2015","2015",27,,
+"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2016","2016",27.9,,
+"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2017","2017",28.8,,
+"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2018","2018",28.7,,
+"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2019","2019",29.5,,
+"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2020","2020",34.2,,
+"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2021","2021",39,,
+"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2022","2022",38,,
+"PATCANAL","N02-Analgesics","ATCPTTMT","% of total sales","NOR","Norway","2010","2010",6.7,,
+"PATCANAL","N02-Analgesics","ATCPTTMT","% of total sales","NOR","Norway","2011","2011",6.7,,
+"PATCANAL","N02-Analgesics","ATCPTTMT","% of total sales","NOR","Norway","2012","2012",6.7,,
+"PATCANAL","N02-Analgesics","ATCPTTMT","% of total sales","NOR","Norway","2013","2013",6.5,,
+"PATCANAL","N02-Analgesics","ATCPTTMT","% of total sales","NOR","Norway","2014","2014",6.2,,
+"PATCANAL","N02-Analgesics","ATCPTTMT","% of total sales","NOR","Norway","2015","2015",6.1,,
+"PATCANAL","N02-Analgesics","ATCPTTMT","% of total sales","NOR","Norway","2016","2016",5.9,,
+"PATCANAL","N02-Analgesics","ATCPTTMT","% of total sales","NOR","Norway","2017","2017",5.6,,
+"PATCANAL","N02-Analgesics","ATCPTTMT","% of total sales","NOR","Norway","2018","2018",5.3,,
+"PATCANAL","N02-Analgesics","ATCPTTMT","% of total sales","NOR","Norway","2019","2019",5.4,,
+"PATCANAL","N02-Analgesics","ATCPTTMT","% of total sales","NOR","Norway","2020","2020",6.1,,
+"PATCANAL","N02-Analgesics","ATCPTTMT","% of total sales","NOR","Norway","2021","2021",6,,
+"PATCANAL","N02-Analgesics","ATCPTTMT","% of total sales","NOR","Norway","2022","2022",6.1,,
+"PATCANAL","N02-Analgesics","MLLNCUMT","Million of national currency units","PRT","Portugal","2010","2010",110.3,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","MLLNCUMT","Million of national currency units","PRT","Portugal","2011","2011",108.1,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","MLLNCUMT","Million of national currency units","PRT","Portugal","2012","2012",111.8,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","MLLNCUMT","Million of national currency units","PRT","Portugal","2013","2013",108.8,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","MLLNCUMT","Million of national currency units","PRT","Portugal","2014","2014",121.6,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","MLLNCUMT","Million of national currency units","PRT","Portugal","2015","2015",122.3,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","MLLNCUMT","Million of national currency units","PRT","Portugal","2016","2016",119.1,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","MLLNCUMT","Million of national currency units","PRT","Portugal","2017","2017",125,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","MLLNCUMT","Million of national currency units","PRT","Portugal","2018","2018",128.3,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","MLLNCUMT","Million of national currency units","PRT","Portugal","2019","2019",138.3,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","MLLNCUMT","Million of national currency units","PRT","Portugal","2020","2020",140.8,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","MLLNCUMT","Million of national currency units","PRT","Portugal","2021","2021",144.2,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","MLLNCUMT","Million of national currency units","PRT","Portugal","2022","2022",164.2,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","MTMOTCMT","Million US$ at exchange rate","PRT","Portugal","2010","2010",146.2,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","MTMOTCMT","Million US$ at exchange rate","PRT","Portugal","2011","2011",150.5,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","MTMOTCMT","Million US$ at exchange rate","PRT","Portugal","2012","2012",143.7,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","MTMOTCMT","Million US$ at exchange rate","PRT","Portugal","2013","2013",144.5,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","MTMOTCMT","Million US$ at exchange rate","PRT","Portugal","2014","2014",161.5,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","MTMOTCMT","Million US$ at exchange rate","PRT","Portugal","2015","2015",135.7,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","MTMOTCMT","Million US$ at exchange rate","PRT","Portugal","2016","2016",131.9,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","MTMOTCMT","Million US$ at exchange rate","PRT","Portugal","2017","2017",141.2,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","MTMOTCMT","Million US$ at exchange rate","PRT","Portugal","2018","2018",151.5,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","MTMOTCMT","Million US$ at exchange rate","PRT","Portugal","2019","2019",154.8,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","MTMOTCMT","Million US$ at exchange rate","PRT","Portugal","2020","2020",160.8,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","MTMOTCMT","Million US$ at exchange rate","PRT","Portugal","2021","2021",170.5,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","MTMOTCMT","Million US$ at exchange rate","PRT","Portugal","2022","2022",172.9,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","MTMOPPMT","Million US$, purchasing power parity","PRT","Portugal","2010","2010",176.9,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","MTMOPPMT","Million US$, purchasing power parity","PRT","Portugal","2011","2011",173.5,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","MTMOPPMT","Million US$, purchasing power parity","PRT","Portugal","2012","2012",184.7,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","MTMOPPMT","Million US$, purchasing power parity","PRT","Portugal","2013","2013",186.5,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","MTMOPPMT","Million US$, purchasing power parity","PRT","Portugal","2014","2014",210,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","MTMOPPMT","Million US$, purchasing power parity","PRT","Portugal","2015","2015",209.1,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","MTMOPPMT","Million US$, purchasing power parity","PRT","Portugal","2016","2016",208.5,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","MTMOPPMT","Million US$, purchasing power parity","PRT","Portugal","2017","2017",217.1,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","MTMOPPMT","Million US$, purchasing power parity","PRT","Portugal","2018","2018",224.6,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","MTMOPPMT","Million US$, purchasing power parity","PRT","Portugal","2019","2019",247.4,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","MTMOPPMT","Million US$, purchasing power parity","PRT","Portugal","2020","2020",252.8,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","MTMOPPMT","Million US$, purchasing power parity","PRT","Portugal","2021","2021",254,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","MTMOPPMT","Million US$, purchasing power parity","PRT","Portugal","2022","2022",298.6,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","TCPPERMT","/capita, US$ exchange rate","PRT","Portugal","2010","2010",13.8,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","TCPPERMT","/capita, US$ exchange rate","PRT","Portugal","2011","2011",14.3,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","TCPPERMT","/capita, US$ exchange rate","PRT","Portugal","2012","2012",13.7,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","TCPPERMT","/capita, US$ exchange rate","PRT","Portugal","2013","2013",13.8,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","TCPPERMT","/capita, US$ exchange rate","PRT","Portugal","2014","2014",15.5,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","TCPPERMT","/capita, US$ exchange rate","PRT","Portugal","2015","2015",13.1,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","TCPPERMT","/capita, US$ exchange rate","PRT","Portugal","2016","2016",12.8,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","TCPPERMT","/capita, US$ exchange rate","PRT","Portugal","2017","2017",13.7,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","TCPPERMT","/capita, US$ exchange rate","PRT","Portugal","2018","2018",14.7,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","TCPPERMT","/capita, US$ exchange rate","PRT","Portugal","2019","2019",15,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","TCPPERMT","/capita, US$ exchange rate","PRT","Portugal","2020","2020",15.6,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","TCPPERMT","/capita, US$ exchange rate","PRT","Portugal","2021","2021",16.5,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","TCPPERMT","/capita, US$ exchange rate","PRT","Portugal","2022","2022",16.7,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2010","2010",16.7,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2011","2011",16.4,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2012","2012",17.6,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2013","2013",17.8,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2014","2014",20.2,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2015","2015",20.2,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2016","2016",20.2,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2017","2017",21.1,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2018","2018",21.8,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2019","2019",24.1,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2020","2020",24.5,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2021","2021",24.5,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2022","2022",28.8,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","ATCPTTMT","% of total sales","PRT","Portugal","2010","2010",3.4,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","ATCPTTMT","% of total sales","PRT","Portugal","2011","2011",3.7,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","ATCPTTMT","% of total sales","PRT","Portugal","2012","2012",4.3,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","ATCPTTMT","% of total sales","PRT","Portugal","2013","2013",4.5,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","ATCPTTMT","% of total sales","PRT","Portugal","2014","2014",5.1,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","ATCPTTMT","% of total sales","PRT","Portugal","2015","2015",4.9,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","ATCPTTMT","% of total sales","PRT","Portugal","2016","2016",4.7,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","ATCPTTMT","% of total sales","PRT","Portugal","2017","2017",4.9,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","ATCPTTMT","% of total sales","PRT","Portugal","2018","2018",4.9,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","ATCPTTMT","% of total sales","PRT","Portugal","2019","2019",5,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","ATCPTTMT","% of total sales","PRT","Portugal","2020","2020",5,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","ATCPTTMT","% of total sales","PRT","Portugal","2021","2021",4.9,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","ATCPTTMT","% of total sales","PRT","Portugal","2022","2022",5.2,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","MLLNCUMT","Million of national currency units","SVK","Slovak Republic","2010","2010",28.9,,
+"PATCANAL","N02-Analgesics","MLLNCUMT","Million of national currency units","SVK","Slovak Republic","2011","2011",31.5,,
+"PATCANAL","N02-Analgesics","MLLNCUMT","Million of national currency units","SVK","Slovak Republic","2012","2012",30.4,,
+"PATCANAL","N02-Analgesics","MLLNCUMT","Million of national currency units","SVK","Slovak Republic","2013","2013",33.7,,
+"PATCANAL","N02-Analgesics","MLLNCUMT","Million of national currency units","SVK","Slovak Republic","2014","2014",32,,
+"PATCANAL","N02-Analgesics","MLLNCUMT","Million of national currency units","SVK","Slovak Republic","2015","2015",32.3,,
+"PATCANAL","N02-Analgesics","MLLNCUMT","Million of national currency units","SVK","Slovak Republic","2016","2016",40.8,"B","Break"
+"PATCANAL","N02-Analgesics","MLLNCUMT","Million of national currency units","SVK","Slovak Republic","2017","2017",40.1,,
+"PATCANAL","N02-Analgesics","MLLNCUMT","Million of national currency units","SVK","Slovak Republic","2018","2018",41,,
+"PATCANAL","N02-Analgesics","MLLNCUMT","Million of national currency units","SVK","Slovak Republic","2019","2019",41.2,,
+"PATCANAL","N02-Analgesics","MLLNCUMT","Million of national currency units","SVK","Slovak Republic","2020","2020",42.3,,
+"PATCANAL","N02-Analgesics","MLLNCUMT","Million of national currency units","SVK","Slovak Republic","2021","2021",44.8,,
+"PATCANAL","N02-Analgesics","MTMOTCMT","Million US$ at exchange rate","SVK","Slovak Republic","2010","2010",38.3,,
+"PATCANAL","N02-Analgesics","MTMOTCMT","Million US$ at exchange rate","SVK","Slovak Republic","2011","2011",43.8,,
+"PATCANAL","N02-Analgesics","MTMOTCMT","Million US$ at exchange rate","SVK","Slovak Republic","2012","2012",39.1,,
+"PATCANAL","N02-Analgesics","MTMOTCMT","Million US$ at exchange rate","SVK","Slovak Republic","2013","2013",44.7,,
+"PATCANAL","N02-Analgesics","MTMOTCMT","Million US$ at exchange rate","SVK","Slovak Republic","2014","2014",42.5,,
+"PATCANAL","N02-Analgesics","MTMOTCMT","Million US$ at exchange rate","SVK","Slovak Republic","2015","2015",35.9,,
+"PATCANAL","N02-Analgesics","MTMOTCMT","Million US$ at exchange rate","SVK","Slovak Republic","2016","2016",45.1,"B","Break"
+"PATCANAL","N02-Analgesics","MTMOTCMT","Million US$ at exchange rate","SVK","Slovak Republic","2017","2017",45.3,,
+"PATCANAL","N02-Analgesics","MTMOTCMT","Million US$ at exchange rate","SVK","Slovak Republic","2018","2018",48.4,,
+"PATCANAL","N02-Analgesics","MTMOTCMT","Million US$ at exchange rate","SVK","Slovak Republic","2019","2019",46.1,,
+"PATCANAL","N02-Analgesics","MTMOTCMT","Million US$ at exchange rate","SVK","Slovak Republic","2020","2020",48.4,,
+"PATCANAL","N02-Analgesics","MTMOTCMT","Million US$ at exchange rate","SVK","Slovak Republic","2021","2021",53,,
+"PATCANAL","N02-Analgesics","MTMOPPMT","Million US$, purchasing power parity","SVK","Slovak Republic","2010","2010",57.5,,
+"PATCANAL","N02-Analgesics","MTMOPPMT","Million US$, purchasing power parity","SVK","Slovak Republic","2011","2011",62.1,,
+"PATCANAL","N02-Analgesics","MTMOPPMT","Million US$, purchasing power parity","SVK","Slovak Republic","2012","2012",60.3,,
+"PATCANAL","N02-Analgesics","MTMOPPMT","Million US$, purchasing power parity","SVK","Slovak Republic","2013","2013",68.6,,
+"PATCANAL","N02-Analgesics","MTMOPPMT","Million US$, purchasing power parity","SVK","Slovak Republic","2014","2014",65.8,,
+"PATCANAL","N02-Analgesics","MTMOPPMT","Million US$, purchasing power parity","SVK","Slovak Republic","2015","2015",65.7,,
+"PATCANAL","N02-Analgesics","MTMOPPMT","Million US$, purchasing power parity","SVK","Slovak Republic","2016","2016",81,"B","Break"
+"PATCANAL","N02-Analgesics","MTMOPPMT","Million US$, purchasing power parity","SVK","Slovak Republic","2017","2017",77.7,,
+"PATCANAL","N02-Analgesics","MTMOPPMT","Million US$, purchasing power parity","SVK","Slovak Republic","2018","2018",77.9,,
+"PATCANAL","N02-Analgesics","MTMOPPMT","Million US$, purchasing power parity","SVK","Slovak Republic","2019","2019",79.6,,
+"PATCANAL","N02-Analgesics","MTMOPPMT","Million US$, purchasing power parity","SVK","Slovak Republic","2020","2020",81.4,,
+"PATCANAL","N02-Analgesics","MTMOPPMT","Million US$, purchasing power parity","SVK","Slovak Republic","2021","2021",84,,
+"PATCANAL","N02-Analgesics","TCPPERMT","/capita, US$ exchange rate","SVK","Slovak Republic","2010","2010",7.1,,
+"PATCANAL","N02-Analgesics","TCPPERMT","/capita, US$ exchange rate","SVK","Slovak Republic","2011","2011",8.1,,
+"PATCANAL","N02-Analgesics","TCPPERMT","/capita, US$ exchange rate","SVK","Slovak Republic","2012","2012",7.2,,
+"PATCANAL","N02-Analgesics","TCPPERMT","/capita, US$ exchange rate","SVK","Slovak Republic","2013","2013",8.3,,
+"PATCANAL","N02-Analgesics","TCPPERMT","/capita, US$ exchange rate","SVK","Slovak Republic","2014","2014",7.8,,
+"PATCANAL","N02-Analgesics","TCPPERMT","/capita, US$ exchange rate","SVK","Slovak Republic","2015","2015",6.6,,
+"PATCANAL","N02-Analgesics","TCPPERMT","/capita, US$ exchange rate","SVK","Slovak Republic","2016","2016",8.3,"B","Break"
+"PATCANAL","N02-Analgesics","TCPPERMT","/capita, US$ exchange rate","SVK","Slovak Republic","2017","2017",8.3,,
+"PATCANAL","N02-Analgesics","TCPPERMT","/capita, US$ exchange rate","SVK","Slovak Republic","2018","2018",8.9,,
+"PATCANAL","N02-Analgesics","TCPPERMT","/capita, US$ exchange rate","SVK","Slovak Republic","2019","2019",8.5,,
+"PATCANAL","N02-Analgesics","TCPPERMT","/capita, US$ exchange rate","SVK","Slovak Republic","2020","2020",8.9,,
+"PATCANAL","N02-Analgesics","TCPPERMT","/capita, US$ exchange rate","SVK","Slovak Republic","2021","2021",9.7,,
+"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2010","2010",10.7,,
+"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2011","2011",11.5,,
+"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2012","2012",11.1,,
+"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2013","2013",12.7,,
+"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2014","2014",12.1,,
+"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2015","2015",12.1,,
+"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2016","2016",14.9,"B","Break"
+"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2017","2017",14.3,,
+"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2018","2018",14.3,,
+"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2019","2019",14.6,,
+"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2020","2020",14.9,,
+"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2021","2021",15.4,,
+"PATCANAL","N02-Analgesics","ATCPTTMT","% of total sales","SVK","Slovak Republic","2010","2010",2.6,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","ATCPTTMT","% of total sales","SVK","Slovak Republic","2011","2011",2.8,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","ATCPTTMT","% of total sales","SVK","Slovak Republic","2012","2012",2.8,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","ATCPTTMT","% of total sales","SVK","Slovak Republic","2013","2013",2.7,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","ATCPTTMT","% of total sales","SVK","Slovak Republic","2014","2014",2.4,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","ATCPTTMT","% of total sales","SVK","Slovak Republic","2015","2015",2.3,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","ATCPTTMT","% of total sales","SVK","Slovak Republic","2016","2016",2.6,"B","Break"
+"PATCANAL","N02-Analgesics","ATCPTTMT","% of total sales","SVK","Slovak Republic","2017","2017",2.6,,
+"PATCANAL","N02-Analgesics","ATCPTTMT","% of total sales","SVK","Slovak Republic","2018","2018",2.5,,
+"PATCANAL","N02-Analgesics","ATCPTTMT","% of total sales","SVK","Slovak Republic","2019","2019",2.4,,
+"PATCANAL","N02-Analgesics","ATCPTTMT","% of total sales","SVK","Slovak Republic","2020","2020",2.5,,
+"PATCANAL","N02-Analgesics","ATCPTTMT","% of total sales","SVK","Slovak Republic","2021","2021",2.5,,
+"PATCANAL","N02-Analgesics","MLLNCUMT","Million of national currency units","ESP","Spain","2010","2010",485,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","MLLNCUMT","Million of national currency units","ESP","Spain","2011","2011",482.3,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","MLLNCUMT","Million of national currency units","ESP","Spain","2012","2012",468.8,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","MLLNCUMT","Million of national currency units","ESP","Spain","2013","2013",489.2,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","MLLNCUMT","Million of national currency units","ESP","Spain","2014","2014",570.2,"B; D","Break; Difference in methodology"
+"PATCANAL","N02-Analgesics","MLLNCUMT","Million of national currency units","ESP","Spain","2015","2015",620,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","MLLNCUMT","Million of national currency units","ESP","Spain","2016","2016",687.3,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","MLLNCUMT","Million of national currency units","ESP","Spain","2017","2017",718.2,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","MLLNCUMT","Million of national currency units","ESP","Spain","2018","2018",749.6,,
+"PATCANAL","N02-Analgesics","MLLNCUMT","Million of national currency units","ESP","Spain","2019","2019",773.6,,
+"PATCANAL","N02-Analgesics","MLLNCUMT","Million of national currency units","ESP","Spain","2020","2020",796.5,,
+"PATCANAL","N02-Analgesics","MLLNCUMT","Million of national currency units","ESP","Spain","2021","2021",831.4,,
+"PATCANAL","N02-Analgesics","MLLNCUMT","Million of national currency units","ESP","Spain","2022","2022",857,"P","Provisional value"
+"PATCANAL","N02-Analgesics","MTMOTCMT","Million US$ at exchange rate","ESP","Spain","2010","2010",643,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","MTMOTCMT","Million US$ at exchange rate","ESP","Spain","2011","2011",671.3,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","MTMOTCMT","Million US$ at exchange rate","ESP","Spain","2012","2012",602.3,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","MTMOTCMT","Million US$ at exchange rate","ESP","Spain","2013","2013",649.7,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","MTMOTCMT","Million US$ at exchange rate","ESP","Spain","2014","2014",757.6,"B; D","Break; Difference in methodology"
+"PATCANAL","N02-Analgesics","MTMOTCMT","Million US$ at exchange rate","ESP","Spain","2015","2015",687.9,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","MTMOTCMT","Million US$ at exchange rate","ESP","Spain","2016","2016",760.7,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","MTMOTCMT","Million US$ at exchange rate","ESP","Spain","2017","2017",811.4,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","MTMOTCMT","Million US$ at exchange rate","ESP","Spain","2018","2018",885.2,,
+"PATCANAL","N02-Analgesics","MTMOTCMT","Million US$ at exchange rate","ESP","Spain","2019","2019",866,,
+"PATCANAL","N02-Analgesics","MTMOTCMT","Million US$ at exchange rate","ESP","Spain","2020","2020",909.8,,
+"PATCANAL","N02-Analgesics","MTMOTCMT","Million US$ at exchange rate","ESP","Spain","2021","2021",983.3,,
+"PATCANAL","N02-Analgesics","MTMOTCMT","Million US$ at exchange rate","ESP","Spain","2022","2022",902.5,"P","Provisional value"
+"PATCANAL","N02-Analgesics","MTMOPPMT","Million US$, purchasing power parity","ESP","Spain","2010","2010",667.2,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","MTMOPPMT","Million US$, purchasing power parity","ESP","Spain","2011","2011",675.4,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","MTMOPPMT","Million US$, purchasing power parity","ESP","Spain","2012","2012",674.6,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","MTMOPPMT","Million US$, purchasing power parity","ESP","Spain","2013","2013",725,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","MTMOPPMT","Million US$, purchasing power parity","ESP","Spain","2014","2014",860.9,"B; D","Break; Difference in methodology"
+"PATCANAL","N02-Analgesics","MTMOPPMT","Million US$, purchasing power parity","ESP","Spain","2015","2015",932.7,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","MTMOPPMT","Million US$, purchasing power parity","ESP","Spain","2016","2016",1069.4,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","MTMOPPMT","Million US$, purchasing power parity","ESP","Spain","2017","2017",1138.5,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","MTMOPPMT","Million US$, purchasing power parity","ESP","Spain","2018","2018",1186.4,,
+"PATCANAL","N02-Analgesics","MTMOPPMT","Million US$, purchasing power parity","ESP","Spain","2019","2019",1262.1,,
+"PATCANAL","N02-Analgesics","MTMOPPMT","Million US$, purchasing power parity","ESP","Spain","2020","2020",1281.9,,
+"PATCANAL","N02-Analgesics","MTMOPPMT","Million US$, purchasing power parity","ESP","Spain","2021","2021",1328.2,,
+"PATCANAL","N02-Analgesics","MTMOPPMT","Million US$, purchasing power parity","ESP","Spain","2022","2022",1437.4,"P","Provisional value"
+"PATCANAL","N02-Analgesics","TCPPERMT","/capita, US$ exchange rate","ESP","Spain","2010","2010",13.8,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","TCPPERMT","/capita, US$ exchange rate","ESP","Spain","2011","2011",14.4,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","TCPPERMT","/capita, US$ exchange rate","ESP","Spain","2012","2012",12.9,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","TCPPERMT","/capita, US$ exchange rate","ESP","Spain","2013","2013",13.9,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","TCPPERMT","/capita, US$ exchange rate","ESP","Spain","2014","2014",16.3,"B; D","Break; Difference in methodology"
+"PATCANAL","N02-Analgesics","TCPPERMT","/capita, US$ exchange rate","ESP","Spain","2015","2015",14.8,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","TCPPERMT","/capita, US$ exchange rate","ESP","Spain","2016","2016",16.4,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","TCPPERMT","/capita, US$ exchange rate","ESP","Spain","2017","2017",17.4,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","TCPPERMT","/capita, US$ exchange rate","ESP","Spain","2018","2018",18.9,,
+"PATCANAL","N02-Analgesics","TCPPERMT","/capita, US$ exchange rate","ESP","Spain","2019","2019",18.4,,
+"PATCANAL","N02-Analgesics","TCPPERMT","/capita, US$ exchange rate","ESP","Spain","2020","2020",19.2,,
+"PATCANAL","N02-Analgesics","TCPPERMT","/capita, US$ exchange rate","ESP","Spain","2021","2021",20.7,,
+"PATCANAL","N02-Analgesics","TCPPERMT","/capita, US$ exchange rate","ESP","Spain","2022","2022",19,"P","Provisional value"
+"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2010","2010",14.3,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2011","2011",14.4,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2012","2012",14.4,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2013","2013",15.6,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2014","2014",18.5,"B; D","Break; Difference in methodology"
+"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2015","2015",20.1,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2016","2016",23,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2017","2017",24.4,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2018","2018",25.4,,
+"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2019","2019",26.8,,
+"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2020","2020",27.1,,
+"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2021","2021",28,,
+"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2022","2022",30.3,"P","Provisional value"
+"PATCANAL","N02-Analgesics","ATCPTTMT","% of total sales","ESP","Spain","2010","2010",3.7,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","ATCPTTMT","% of total sales","ESP","Spain","2011","2011",3.9,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","ATCPTTMT","% of total sales","ESP","Spain","2012","2012",4.2,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","ATCPTTMT","% of total sales","ESP","Spain","2013","2013",4.6,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","ATCPTTMT","% of total sales","ESP","Spain","2014","2014",5,"B; D","Break; Difference in methodology"
+"PATCANAL","N02-Analgesics","ATCPTTMT","% of total sales","ESP","Spain","2015","2015",5.4,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","ATCPTTMT","% of total sales","ESP","Spain","2016","2016",5.8,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","ATCPTTMT","% of total sales","ESP","Spain","2017","2017",6,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","ATCPTTMT","% of total sales","ESP","Spain","2018","2018",3.9,"B","Break"
+"PATCANAL","N02-Analgesics","ATCPTTMT","% of total sales","ESP","Spain","2019","2019",3.9,,
+"PATCANAL","N02-Analgesics","ATCPTTMT","% of total sales","ESP","Spain","2020","2020",3.8,,
+"PATCANAL","N02-Analgesics","ATCPTTMT","% of total sales","ESP","Spain","2021","2021",3.8,,
+"PATCANAL","N02-Analgesics","ATCPTTMT","% of total sales","ESP","Spain","2022","2022",3.7,"P","Provisional value"
+"PATCANAL","N02-Analgesics","MLLNCUMT","Million of national currency units","SWE","Sweden","2010","2010",2021.1,,
+"PATCANAL","N02-Analgesics","MLLNCUMT","Million of national currency units","SWE","Sweden","2011","2011",2016.5,,
+"PATCANAL","N02-Analgesics","MLLNCUMT","Million of national currency units","SWE","Sweden","2012","2012",1936.1,,
+"PATCANAL","N02-Analgesics","MLLNCUMT","Million of national currency units","SWE","Sweden","2013","2013",1972,,
+"PATCANAL","N02-Analgesics","MLLNCUMT","Million of national currency units","SWE","Sweden","2014","2014",1985.9,,
+"PATCANAL","N02-Analgesics","MLLNCUMT","Million of national currency units","SWE","Sweden","2015","2015",2044.8,,
+"PATCANAL","N02-Analgesics","MLLNCUMT","Million of national currency units","SWE","Sweden","2016","2016",2020,,
+"PATCANAL","N02-Analgesics","MLLNCUMT","Million of national currency units","SWE","Sweden","2017","2017",1969.4,,
+"PATCANAL","N02-Analgesics","MLLNCUMT","Million of national currency units","SWE","Sweden","2018","2018",2291.2,,
+"PATCANAL","N02-Analgesics","MLLNCUMT","Million of national currency units","SWE","Sweden","2019","2019",2453.8,,
+"PATCANAL","N02-Analgesics","MLLNCUMT","Million of national currency units","SWE","Sweden","2020","2020",2538.5,,
+"PATCANAL","N02-Analgesics","MLLNCUMT","Million of national currency units","SWE","Sweden","2021","2021",2487,,
+"PATCANAL","N02-Analgesics","MLLNCUMT","Million of national currency units","SWE","Sweden","2022","2022",2726.5,,
+"PATCANAL","N02-Analgesics","MTMOTCMT","Million US$ at exchange rate","SWE","Sweden","2010","2010",280.4,,
+"PATCANAL","N02-Analgesics","MTMOTCMT","Million US$ at exchange rate","SWE","Sweden","2011","2011",310.5,,
+"PATCANAL","N02-Analgesics","MTMOTCMT","Million US$ at exchange rate","SWE","Sweden","2012","2012",285.8,,
+"PATCANAL","N02-Analgesics","MTMOTCMT","Million US$ at exchange rate","SWE","Sweden","2013","2013",302.7,,
+"PATCANAL","N02-Analgesics","MTMOTCMT","Million US$ at exchange rate","SWE","Sweden","2014","2014",289.5,,
+"PATCANAL","N02-Analgesics","MTMOTCMT","Million US$ at exchange rate","SWE","Sweden","2015","2015",242.4,,
+"PATCANAL","N02-Analgesics","MTMOTCMT","Million US$ at exchange rate","SWE","Sweden","2016","2016",235.9,,
+"PATCANAL","N02-Analgesics","MTMOTCMT","Million US$ at exchange rate","SWE","Sweden","2017","2017",230.4,,
+"PATCANAL","N02-Analgesics","MTMOTCMT","Million US$ at exchange rate","SWE","Sweden","2018","2018",263.6,,
+"PATCANAL","N02-Analgesics","MTMOTCMT","Million US$ at exchange rate","SWE","Sweden","2019","2019",259.4,,
+"PATCANAL","N02-Analgesics","MTMOTCMT","Million US$ at exchange rate","SWE","Sweden","2020","2020",275.6,,
+"PATCANAL","N02-Analgesics","MTMOTCMT","Million US$ at exchange rate","SWE","Sweden","2021","2021",290,,
+"PATCANAL","N02-Analgesics","MTMOTCMT","Million US$ at exchange rate","SWE","Sweden","2022","2022",269.6,,
+"PATCANAL","N02-Analgesics","MTMOPPMT","Million US$, purchasing power parity","SWE","Sweden","2010","2010",223.9,,
+"PATCANAL","N02-Analgesics","MTMOPPMT","Million US$, purchasing power parity","SWE","Sweden","2011","2011",228,,
+"PATCANAL","N02-Analgesics","MTMOPPMT","Million US$, purchasing power parity","SWE","Sweden","2012","2012",223.7,,
+"PATCANAL","N02-Analgesics","MTMOPPMT","Million US$, purchasing power parity","SWE","Sweden","2013","2013",229.4,,
+"PATCANAL","N02-Analgesics","MTMOPPMT","Million US$, purchasing power parity","SWE","Sweden","2014","2014",227.6,,
+"PATCANAL","N02-Analgesics","MTMOPPMT","Million US$, purchasing power parity","SWE","Sweden","2015","2015",230.9,,
+"PATCANAL","N02-Analgesics","MTMOPPMT","Million US$, purchasing power parity","SWE","Sweden","2016","2016",229,,
+"PATCANAL","N02-Analgesics","MTMOPPMT","Million US$, purchasing power parity","SWE","Sweden","2017","2017",222.5,,
+"PATCANAL","N02-Analgesics","MTMOPPMT","Million US$, purchasing power parity","SWE","Sweden","2018","2018",258.4,,
+"PATCANAL","N02-Analgesics","MTMOPPMT","Million US$, purchasing power parity","SWE","Sweden","2019","2019",281.7,,
+"PATCANAL","N02-Analgesics","MTMOPPMT","Million US$, purchasing power parity","SWE","Sweden","2020","2020",292.8,,
+"PATCANAL","N02-Analgesics","MTMOPPMT","Million US$, purchasing power parity","SWE","Sweden","2021","2021",285.2,,
+"PATCANAL","N02-Analgesics","MTMOPPMT","Million US$, purchasing power parity","SWE","Sweden","2022","2022",314.6,,
+"PATCANAL","N02-Analgesics","TCPPERMT","/capita, US$ exchange rate","SWE","Sweden","2010","2010",29.9,,
+"PATCANAL","N02-Analgesics","TCPPERMT","/capita, US$ exchange rate","SWE","Sweden","2011","2011",32.9,,
+"PATCANAL","N02-Analgesics","TCPPERMT","/capita, US$ exchange rate","SWE","Sweden","2012","2012",30,,
+"PATCANAL","N02-Analgesics","TCPPERMT","/capita, US$ exchange rate","SWE","Sweden","2013","2013",31.5,,
+"PATCANAL","N02-Analgesics","TCPPERMT","/capita, US$ exchange rate","SWE","Sweden","2014","2014",29.9,,
+"PATCANAL","N02-Analgesics","TCPPERMT","/capita, US$ exchange rate","SWE","Sweden","2015","2015",24.7,,
+"PATCANAL","N02-Analgesics","TCPPERMT","/capita, US$ exchange rate","SWE","Sweden","2016","2016",23.8,,
+"PATCANAL","N02-Analgesics","TCPPERMT","/capita, US$ exchange rate","SWE","Sweden","2017","2017",22.9,,
+"PATCANAL","N02-Analgesics","TCPPERMT","/capita, US$ exchange rate","SWE","Sweden","2018","2018",25.9,,
+"PATCANAL","N02-Analgesics","TCPPERMT","/capita, US$ exchange rate","SWE","Sweden","2019","2019",25.2,,
+"PATCANAL","N02-Analgesics","TCPPERMT","/capita, US$ exchange rate","SWE","Sweden","2020","2020",26.6,,
+"PATCANAL","N02-Analgesics","TCPPERMT","/capita, US$ exchange rate","SWE","Sweden","2021","2021",27.8,,
+"PATCANAL","N02-Analgesics","TCPPERMT","/capita, US$ exchange rate","SWE","Sweden","2022","2022",25.8,,
+"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2010","2010",23.9,,
+"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2011","2011",24.1,,
+"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2012","2012",23.5,,
+"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2013","2013",23.9,,
+"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2014","2014",23.5,,
+"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2015","2015",23.6,,
+"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2016","2016",23.1,,
+"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2017","2017",22.1,,
+"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2018","2018",25.4,,
+"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2019","2019",27.4,,
+"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2020","2020",28.3,,
+"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2021","2021",27.4,,
+"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2022","2022",30.1,,
+"PATCANAL","N02-Analgesics","ATCPTTMT","% of total sales","SWE","Sweden","2010","2010",5.6,,
+"PATCANAL","N02-Analgesics","ATCPTTMT","% of total sales","SWE","Sweden","2011","2011",5.5,,
+"PATCANAL","N02-Analgesics","ATCPTTMT","% of total sales","SWE","Sweden","2012","2012",5.4,,
+"PATCANAL","N02-Analgesics","ATCPTTMT","% of total sales","SWE","Sweden","2013","2013",5.4,,
+"PATCANAL","N02-Analgesics","ATCPTTMT","% of total sales","SWE","Sweden","2014","2014",5.3,,
+"PATCANAL","N02-Analgesics","ATCPTTMT","% of total sales","SWE","Sweden","2015","2015",5,,
+"PATCANAL","N02-Analgesics","ATCPTTMT","% of total sales","SWE","Sweden","2016","2016",4.8,,
+"PATCANAL","N02-Analgesics","ATCPTTMT","% of total sales","SWE","Sweden","2017","2017",4.5,,
+"PATCANAL","N02-Analgesics","ATCPTTMT","% of total sales","SWE","Sweden","2018","2018",4.8,,
+"PATCANAL","N02-Analgesics","ATCPTTMT","% of total sales","SWE","Sweden","2019","2019",4.9,,
+"PATCANAL","N02-Analgesics","ATCPTTMT","% of total sales","SWE","Sweden","2020","2020",4.8,,
+"PATCANAL","N02-Analgesics","ATCPTTMT","% of total sales","SWE","Sweden","2021","2021",4.6,,
+"PATCANAL","N02-Analgesics","ATCPTTMT","% of total sales","SWE","Sweden","2022","2022",4.7,,
+"PATCANAL","N02-Analgesics","MLLNCUMT","Million of national currency units","TUR","Türkiye","2010","2010",306.7,,
+"PATCANAL","N02-Analgesics","MLLNCUMT","Million of national currency units","TUR","Türkiye","2011","2011",291.9,,
+"PATCANAL","N02-Analgesics","MLLNCUMT","Million of national currency units","TUR","Türkiye","2012","2012",264.2,,
+"PATCANAL","N02-Analgesics","MLLNCUMT","Million of national currency units","TUR","Türkiye","2013","2013",295.7,,
+"PATCANAL","N02-Analgesics","MLLNCUMT","Million of national currency units","TUR","Türkiye","2014","2014",320.4,,
+"PATCANAL","N02-Analgesics","MLLNCUMT","Million of national currency units","TUR","Türkiye","2015","2015",352.7,,
+"PATCANAL","N02-Analgesics","MLLNCUMT","Million of national currency units","TUR","Türkiye","2016","2016",447.4,,
+"PATCANAL","N02-Analgesics","MLLNCUMT","Million of national currency units","TUR","Türkiye","2017","2017",582.3,,
+"PATCANAL","N02-Analgesics","MLLNCUMT","Million of national currency units","TUR","Türkiye","2018","2018",696.2,,
+"PATCANAL","N02-Analgesics","MLLNCUMT","Million of national currency units","TUR","Türkiye","2019","2019",936.1,,
+"PATCANAL","N02-Analgesics","MLLNCUMT","Million of national currency units","TUR","Türkiye","2020","2020",1051.6,,
+"PATCANAL","N02-Analgesics","MLLNCUMT","Million of national currency units","TUR","Türkiye","2021","2021",1401.1,,
+"PATCANAL","N02-Analgesics","MTMOTCMT","Million US$ at exchange rate","TUR","Türkiye","2010","2010",204.1,,
+"PATCANAL","N02-Analgesics","MTMOTCMT","Million US$ at exchange rate","TUR","Türkiye","2011","2011",174.3,,
+"PATCANAL","N02-Analgesics","MTMOTCMT","Million US$ at exchange rate","TUR","Türkiye","2012","2012",147.1,,
+"PATCANAL","N02-Analgesics","MTMOTCMT","Million US$ at exchange rate","TUR","Türkiye","2013","2013",155.3,,
+"PATCANAL","N02-Analgesics","MTMOTCMT","Million US$ at exchange rate","TUR","Türkiye","2014","2014",146.4,,
+"PATCANAL","N02-Analgesics","MTMOTCMT","Million US$ at exchange rate","TUR","Türkiye","2015","2015",129.7,,
+"PATCANAL","N02-Analgesics","MTMOTCMT","Million US$ at exchange rate","TUR","Türkiye","2016","2016",148.1,,
+"PATCANAL","N02-Analgesics","MTMOTCMT","Million US$ at exchange rate","TUR","Türkiye","2017","2017",159.6,,
+"PATCANAL","N02-Analgesics","MTMOTCMT","Million US$ at exchange rate","TUR","Türkiye","2018","2018",144.2,,
+"PATCANAL","N02-Analgesics","MTMOTCMT","Million US$ at exchange rate","TUR","Türkiye","2019","2019",165,,
+"PATCANAL","N02-Analgesics","MTMOTCMT","Million US$ at exchange rate","TUR","Türkiye","2020","2020",150,,
+"PATCANAL","N02-Analgesics","MTMOTCMT","Million US$ at exchange rate","TUR","Türkiye","2021","2021",158.3,,
+"PATCANAL","N02-Analgesics","MTMOPPMT","Million US$, purchasing power parity","TUR","Türkiye","2010","2010",333.3,,
+"PATCANAL","N02-Analgesics","MTMOPPMT","Million US$, purchasing power parity","TUR","Türkiye","2011","2011",302.1,,
+"PATCANAL","N02-Analgesics","MTMOPPMT","Million US$, purchasing power parity","TUR","Türkiye","2012","2012",259.1,,
+"PATCANAL","N02-Analgesics","MTMOPPMT","Million US$, purchasing power parity","TUR","Türkiye","2013","2013",276.3,,
+"PATCANAL","N02-Analgesics","MTMOPPMT","Million US$, purchasing power parity","TUR","Türkiye","2014","2014",290.1,,
+"PATCANAL","N02-Analgesics","MTMOPPMT","Million US$, purchasing power parity","TUR","Türkiye","2015","2015",303.4,,
+"PATCANAL","N02-Analgesics","MTMOPPMT","Million US$, purchasing power parity","TUR","Türkiye","2016","2016",360.5,,
+"PATCANAL","N02-Analgesics","MTMOPPMT","Million US$, purchasing power parity","TUR","Türkiye","2017","2017",420.7,,
+"PATCANAL","N02-Analgesics","MTMOPPMT","Million US$, purchasing power parity","TUR","Türkiye","2018","2018",426.4,,
+"PATCANAL","N02-Analgesics","MTMOPPMT","Million US$, purchasing power parity","TUR","Türkiye","2019","2019",502.2,,
+"PATCANAL","N02-Analgesics","MTMOPPMT","Million US$, purchasing power parity","TUR","Türkiye","2020","2020",485.9,,
+"PATCANAL","N02-Analgesics","MTMOPPMT","Million US$, purchasing power parity","TUR","Türkiye","2021","2021",499,,
+"PATCANAL","N02-Analgesics","TCPPERMT","/capita, US$ exchange rate","TUR","Türkiye","2010","2010",2.8,,
+"PATCANAL","N02-Analgesics","TCPPERMT","/capita, US$ exchange rate","TUR","Türkiye","2011","2011",2.3,,
+"PATCANAL","N02-Analgesics","TCPPERMT","/capita, US$ exchange rate","TUR","Türkiye","2012","2012",2,,
+"PATCANAL","N02-Analgesics","TCPPERMT","/capita, US$ exchange rate","TUR","Türkiye","2013","2013",2,,
+"PATCANAL","N02-Analgesics","TCPPERMT","/capita, US$ exchange rate","TUR","Türkiye","2014","2014",1.9,,
+"PATCANAL","N02-Analgesics","TCPPERMT","/capita, US$ exchange rate","TUR","Türkiye","2015","2015",1.7,,
+"PATCANAL","N02-Analgesics","TCPPERMT","/capita, US$ exchange rate","TUR","Türkiye","2016","2016",1.9,,
+"PATCANAL","N02-Analgesics","TCPPERMT","/capita, US$ exchange rate","TUR","Türkiye","2017","2017",2,,
+"PATCANAL","N02-Analgesics","TCPPERMT","/capita, US$ exchange rate","TUR","Türkiye","2018","2018",1.8,,
+"PATCANAL","N02-Analgesics","TCPPERMT","/capita, US$ exchange rate","TUR","Türkiye","2019","2019",2,,
+"PATCANAL","N02-Analgesics","TCPPERMT","/capita, US$ exchange rate","TUR","Türkiye","2020","2020",1.8,,
+"PATCANAL","N02-Analgesics","TCPPERMT","/capita, US$ exchange rate","TUR","Türkiye","2021","2021",1.9,,
+"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2010","2010",4.6,,
+"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2011","2011",4.1,,
+"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2012","2012",3.4,,
+"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2013","2013",3.6,,
+"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2014","2014",3.8,,
+"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2015","2015",3.9,,
+"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2016","2016",4.5,,
+"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2017","2017",5.2,,
+"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2018","2018",5.2,,
+"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2019","2019",6.1,,
+"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2020","2020",5.8,,
+"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2021","2021",5.9,,
+"PATCANAL","N02-Analgesics","ATCPTTMT","% of total sales","TUR","Türkiye","2010","2010",2,,
+"PATCANAL","N02-Analgesics","ATCPTTMT","% of total sales","TUR","Türkiye","2011","2011",2.1,,
+"PATCANAL","N02-Analgesics","ATCPTTMT","% of total sales","TUR","Türkiye","2012","2012",2,,
+"PATCANAL","N02-Analgesics","ATCPTTMT","% of total sales","TUR","Türkiye","2013","2013",2.1,,
+"PATCANAL","N02-Analgesics","ATCPTTMT","% of total sales","TUR","Türkiye","2014","2014",2,,
+"PATCANAL","N02-Analgesics","ATCPTTMT","% of total sales","TUR","Türkiye","2015","2015",1.9,,
+"PATCANAL","N02-Analgesics","ATCPTTMT","% of total sales","TUR","Türkiye","2016","2016",2,,
+"PATCANAL","N02-Analgesics","ATCPTTMT","% of total sales","TUR","Türkiye","2017","2017",2.3,,
+"PATCANAL","N02-Analgesics","ATCPTTMT","% of total sales","TUR","Türkiye","2018","2018",2.2,,
+"PATCANAL","N02-Analgesics","ATCPTTMT","% of total sales","TUR","Türkiye","2019","2019",2.2,,
+"PATCANAL","N02-Analgesics","ATCPTTMT","% of total sales","TUR","Türkiye","2020","2020",2.1,,
+"PATCANAL","N02-Analgesics","ATCPTTMT","% of total sales","TUR","Türkiye","2021","2021",2.2,,
+"PATCANAL","N02-Analgesics","MLLNCUMT","Million of national currency units","CHL","Chile","2010","2010",54002.2,,
+"PATCANAL","N02-Analgesics","MLLNCUMT","Million of national currency units","CHL","Chile","2011","2011",58995.7,"B","Break"
+"PATCANAL","N02-Analgesics","MLLNCUMT","Million of national currency units","CHL","Chile","2012","2012",64056.5,,
+"PATCANAL","N02-Analgesics","MLLNCUMT","Million of national currency units","CHL","Chile","2013","2013",63983.2,,
+"PATCANAL","N02-Analgesics","MLLNCUMT","Million of national currency units","CHL","Chile","2014","2014",66475.8,,
+"PATCANAL","N02-Analgesics","MLLNCUMT","Million of national currency units","CHL","Chile","2015","2015",75558.7,,
+"PATCANAL","N02-Analgesics","MLLNCUMT","Million of national currency units","CHL","Chile","2016","2016",85860.4,,
+"PATCANAL","N02-Analgesics","MLLNCUMT","Million of national currency units","CHL","Chile","2017","2017",79662.9,,
+"PATCANAL","N02-Analgesics","MLLNCUMT","Million of national currency units","CHL","Chile","2018","2018",84241.7,,
+"PATCANAL","N02-Analgesics","MLLNCUMT","Million of national currency units","CHL","Chile","2019","2019",73963.6,,
+"PATCANAL","N02-Analgesics","MLLNCUMT","Million of national currency units","CHL","Chile","2020","2020",75501.4,,
+"PATCANAL","N02-Analgesics","MLLNCUMT","Million of national currency units","CHL","Chile","2021","2021",89508.5,,
+"PATCANAL","N02-Analgesics","MLLNCUMT","Million of national currency units","CHL","Chile","2022","2022",84258.5,,
+"PATCANAL","N02-Analgesics","MTMOTCMT","Million US$ at exchange rate","CHL","Chile","2010","2010",105.8,,
+"PATCANAL","N02-Analgesics","MTMOTCMT","Million US$ at exchange rate","CHL","Chile","2011","2011",122,"B","Break"
+"PATCANAL","N02-Analgesics","MTMOTCMT","Million US$ at exchange rate","CHL","Chile","2012","2012",131.7,,
+"PATCANAL","N02-Analgesics","MTMOTCMT","Million US$ at exchange rate","CHL","Chile","2013","2013",129.2,,
+"PATCANAL","N02-Analgesics","MTMOTCMT","Million US$ at exchange rate","CHL","Chile","2014","2014",116.6,,
+"PATCANAL","N02-Analgesics","MTMOTCMT","Million US$ at exchange rate","CHL","Chile","2015","2015",115.5,,
+"PATCANAL","N02-Analgesics","MTMOTCMT","Million US$ at exchange rate","CHL","Chile","2016","2016",126.8,,
+"PATCANAL","N02-Analgesics","MTMOTCMT","Million US$ at exchange rate","CHL","Chile","2017","2017",122.8,,
+"PATCANAL","N02-Analgesics","MTMOTCMT","Million US$ at exchange rate","CHL","Chile","2018","2018",131.4,,
+"PATCANAL","N02-Analgesics","MTMOTCMT","Million US$ at exchange rate","CHL","Chile","2019","2019",105.2,,
+"PATCANAL","N02-Analgesics","MTMOTCMT","Million US$ at exchange rate","CHL","Chile","2020","2020",95.2,,
+"PATCANAL","N02-Analgesics","MTMOTCMT","Million US$ at exchange rate","CHL","Chile","2021","2021",117.9,,
+"PATCANAL","N02-Analgesics","MTMOTCMT","Million US$ at exchange rate","CHL","Chile","2022","2022",96.5,,
+"PATCANAL","N02-Analgesics","MTMOPPMT","Million US$, purchasing power parity","CHL","Chile","2010","2010",150.1,,
+"PATCANAL","N02-Analgesics","MTMOPPMT","Million US$, purchasing power parity","CHL","Chile","2011","2011",169.5,"B","Break"
+"PATCANAL","N02-Analgesics","MTMOPPMT","Million US$, purchasing power parity","CHL","Chile","2012","2012",184.5,,
+"PATCANAL","N02-Analgesics","MTMOPPMT","Million US$, purchasing power parity","CHL","Chile","2013","2013",183,,
+"PATCANAL","N02-Analgesics","MTMOPPMT","Million US$, purchasing power parity","CHL","Chile","2014","2014",181,,
+"PATCANAL","N02-Analgesics","MTMOPPMT","Million US$, purchasing power parity","CHL","Chile","2015","2015",193.2,,
+"PATCANAL","N02-Analgesics","MTMOPPMT","Million US$, purchasing power parity","CHL","Chile","2016","2016",216.1,,
+"PATCANAL","N02-Analgesics","MTMOPPMT","Million US$, purchasing power parity","CHL","Chile","2017","2017",200.3,,
+"PATCANAL","N02-Analgesics","MTMOPPMT","Million US$, purchasing power parity","CHL","Chile","2018","2018",212.6,,
+"PATCANAL","N02-Analgesics","MTMOPPMT","Million US$, purchasing power parity","CHL","Chile","2019","2019",184.2,,
+"PATCANAL","N02-Analgesics","MTMOPPMT","Million US$, purchasing power parity","CHL","Chile","2020","2020",180.4,,
+"PATCANAL","N02-Analgesics","MTMOPPMT","Million US$, purchasing power parity","CHL","Chile","2021","2021",205.7,,
+"PATCANAL","N02-Analgesics","MTMOPPMT","Million US$, purchasing power parity","CHL","Chile","2022","2022",192.6,,
+"PATCANAL","N02-Analgesics","TCPPERMT","/capita, US$ exchange rate","CHL","Chile","2010","2010",6.2,,
+"PATCANAL","N02-Analgesics","TCPPERMT","/capita, US$ exchange rate","CHL","Chile","2011","2011",7.1,"B","Break"
+"PATCANAL","N02-Analgesics","TCPPERMT","/capita, US$ exchange rate","CHL","Chile","2012","2012",7.5,,
+"PATCANAL","N02-Analgesics","TCPPERMT","/capita, US$ exchange rate","CHL","Chile","2013","2013",7.3,,
+"PATCANAL","N02-Analgesics","TCPPERMT","/capita, US$ exchange rate","CHL","Chile","2014","2014",6.6,,
+"PATCANAL","N02-Analgesics","TCPPERMT","/capita, US$ exchange rate","CHL","Chile","2015","2015",6.4,,
+"PATCANAL","N02-Analgesics","TCPPERMT","/capita, US$ exchange rate","CHL","Chile","2016","2016",7,,
+"PATCANAL","N02-Analgesics","TCPPERMT","/capita, US$ exchange rate","CHL","Chile","2017","2017",6.7,,
+"PATCANAL","N02-Analgesics","TCPPERMT","/capita, US$ exchange rate","CHL","Chile","2018","2018",7,,
+"PATCANAL","N02-Analgesics","TCPPERMT","/capita, US$ exchange rate","CHL","Chile","2019","2019",5.5,,
+"PATCANAL","N02-Analgesics","TCPPERMT","/capita, US$ exchange rate","CHL","Chile","2020","2020",4.9,,
+"PATCANAL","N02-Analgesics","TCPPERMT","/capita, US$ exchange rate","CHL","Chile","2021","2021",6,,
+"PATCANAL","N02-Analgesics","TCPPERMT","/capita, US$ exchange rate","CHL","Chile","2022","2022",4.9,,
+"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2010","2010",8.8,,
+"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2011","2011",9.8,"B","Break"
+"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2012","2012",10.6,,
+"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2013","2013",10.4,,
+"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2014","2014",10.2,,
+"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2015","2015",10.7,,
+"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2016","2016",11.9,,
+"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2017","2017",10.9,,
+"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2018","2018",11.3,,
+"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2019","2019",9.6,,
+"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2020","2020",9.3,,
+"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2021","2021",10.5,,
+"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2022","2022",9.7,,
+"PATCANAL","N02-Analgesics","ATCPTTMT","% of total sales","CHL","Chile","2010","2010",6.5,,
+"PATCANAL","N02-Analgesics","ATCPTTMT","% of total sales","CHL","Chile","2011","2011",5,"B","Break"
+"PATCANAL","N02-Analgesics","ATCPTTMT","% of total sales","CHL","Chile","2012","2012",5.1,,
+"PATCANAL","N02-Analgesics","ATCPTTMT","% of total sales","CHL","Chile","2013","2013",4.4,,
+"PATCANAL","N02-Analgesics","ATCPTTMT","% of total sales","CHL","Chile","2014","2014",4.3,,
+"PATCANAL","N02-Analgesics","ATCPTTMT","% of total sales","CHL","Chile","2015","2015",4.1,,
+"PATCANAL","N02-Analgesics","ATCPTTMT","% of total sales","CHL","Chile","2016","2016",4.2,,
+"PATCANAL","N02-Analgesics","ATCPTTMT","% of total sales","CHL","Chile","2017","2017",3.9,,
+"PATCANAL","N02-Analgesics","ATCPTTMT","% of total sales","CHL","Chile","2018","2018",3.7,,
+"PATCANAL","N02-Analgesics","ATCPTTMT","% of total sales","CHL","Chile","2019","2019",2.9,,
+"PATCANAL","N02-Analgesics","ATCPTTMT","% of total sales","CHL","Chile","2020","2020",2.8,,
+"PATCANAL","N02-Analgesics","ATCPTTMT","% of total sales","CHL","Chile","2021","2021",3.2,,
+"PATCANAL","N02-Analgesics","ATCPTTMT","% of total sales","CHL","Chile","2022","2022",3,,
+"PATCANAL","N02-Analgesics","MLLNCUMT","Million of national currency units","EST","Estonia","2010","2010",5.2,,
+"PATCANAL","N02-Analgesics","MLLNCUMT","Million of national currency units","EST","Estonia","2011","2011",5.4,,
+"PATCANAL","N02-Analgesics","MLLNCUMT","Million of national currency units","EST","Estonia","2012","2012",5.5,,
+"PATCANAL","N02-Analgesics","MLLNCUMT","Million of national currency units","EST","Estonia","2013","2013",5.9,,
+"PATCANAL","N02-Analgesics","MLLNCUMT","Million of national currency units","EST","Estonia","2014","2014",6.3,,
+"PATCANAL","N02-Analgesics","MLLNCUMT","Million of national currency units","EST","Estonia","2015","2015",6.8,,
+"PATCANAL","N02-Analgesics","MLLNCUMT","Million of national currency units","EST","Estonia","2016","2016",7.5,,
+"PATCANAL","N02-Analgesics","MLLNCUMT","Million of national currency units","EST","Estonia","2017","2017",7.9,,
+"PATCANAL","N02-Analgesics","MLLNCUMT","Million of national currency units","EST","Estonia","2018","2018",8.7,,
+"PATCANAL","N02-Analgesics","MLLNCUMT","Million of national currency units","EST","Estonia","2019","2019",9.4,,
+"PATCANAL","N02-Analgesics","MLLNCUMT","Million of national currency units","EST","Estonia","2020","2020",10.3,,
+"PATCANAL","N02-Analgesics","MLLNCUMT","Million of national currency units","EST","Estonia","2021","2021",10.8,,
+"PATCANAL","N02-Analgesics","MLLNCUMT","Million of national currency units","EST","Estonia","2022","2022",13.4,,
+"PATCANAL","N02-Analgesics","MTMOTCMT","Million US$ at exchange rate","EST","Estonia","2010","2010",6.9,,
+"PATCANAL","N02-Analgesics","MTMOTCMT","Million US$ at exchange rate","EST","Estonia","2011","2011",7.5,,
+"PATCANAL","N02-Analgesics","MTMOTCMT","Million US$ at exchange rate","EST","Estonia","2012","2012",7.1,,
+"PATCANAL","N02-Analgesics","MTMOTCMT","Million US$ at exchange rate","EST","Estonia","2013","2013",7.8,,
+"PATCANAL","N02-Analgesics","MTMOTCMT","Million US$ at exchange rate","EST","Estonia","2014","2014",8.4,,
+"PATCANAL","N02-Analgesics","MTMOTCMT","Million US$ at exchange rate","EST","Estonia","2015","2015",7.6,,
+"PATCANAL","N02-Analgesics","MTMOTCMT","Million US$ at exchange rate","EST","Estonia","2016","2016",8.3,,
+"PATCANAL","N02-Analgesics","MTMOTCMT","Million US$ at exchange rate","EST","Estonia","2017","2017",9,,
+"PATCANAL","N02-Analgesics","MTMOTCMT","Million US$ at exchange rate","EST","Estonia","2018","2018",10.2,,
+"PATCANAL","N02-Analgesics","MTMOTCMT","Million US$ at exchange rate","EST","Estonia","2019","2019",10.6,,
+"PATCANAL","N02-Analgesics","MTMOTCMT","Million US$ at exchange rate","EST","Estonia","2020","2020",11.7,,
+"PATCANAL","N02-Analgesics","MTMOTCMT","Million US$ at exchange rate","EST","Estonia","2021","2021",12.8,,
+"PATCANAL","N02-Analgesics","MTMOTCMT","Million US$ at exchange rate","EST","Estonia","2022","2022",14.1,,
+"PATCANAL","N02-Analgesics","MTMOPPMT","Million US$, purchasing power parity","EST","Estonia","2010","2010",10.2,,
+"PATCANAL","N02-Analgesics","MTMOPPMT","Million US$, purchasing power parity","EST","Estonia","2011","2011",10.5,,
+"PATCANAL","N02-Analgesics","MTMOPPMT","Million US$, purchasing power parity","EST","Estonia","2012","2012",10.6,,
+"PATCANAL","N02-Analgesics","MTMOPPMT","Million US$, purchasing power parity","EST","Estonia","2013","2013",11.3,,
+"PATCANAL","N02-Analgesics","MTMOPPMT","Million US$, purchasing power parity","EST","Estonia","2014","2014",12,,
+"PATCANAL","N02-Analgesics","MTMOPPMT","Million US$, purchasing power parity","EST","Estonia","2015","2015",12.7,,
+"PATCANAL","N02-Analgesics","MTMOPPMT","Million US$, purchasing power parity","EST","Estonia","2016","2016",14.1,,
+"PATCANAL","N02-Analgesics","MTMOPPMT","Million US$, purchasing power parity","EST","Estonia","2017","2017",14.9,,
+"PATCANAL","N02-Analgesics","MTMOPPMT","Million US$, purchasing power parity","EST","Estonia","2018","2018",16.1,,
+"PATCANAL","N02-Analgesics","MTMOPPMT","Million US$, purchasing power parity","EST","Estonia","2019","2019",17.6,,
+"PATCANAL","N02-Analgesics","MTMOPPMT","Million US$, purchasing power parity","EST","Estonia","2020","2020",19.6,,
+"PATCANAL","N02-Analgesics","MTMOPPMT","Million US$, purchasing power parity","EST","Estonia","2021","2021",19.9,,
+"PATCANAL","N02-Analgesics","MTMOPPMT","Million US$, purchasing power parity","EST","Estonia","2022","2022",23.5,,
+"PATCANAL","N02-Analgesics","TCPPERMT","/capita, US$ exchange rate","EST","Estonia","2010","2010",5.2,,
+"PATCANAL","N02-Analgesics","TCPPERMT","/capita, US$ exchange rate","EST","Estonia","2011","2011",5.6,,
+"PATCANAL","N02-Analgesics","TCPPERMT","/capita, US$ exchange rate","EST","Estonia","2012","2012",5.4,,
+"PATCANAL","N02-Analgesics","TCPPERMT","/capita, US$ exchange rate","EST","Estonia","2013","2013",6,,
+"PATCANAL","N02-Analgesics","TCPPERMT","/capita, US$ exchange rate","EST","Estonia","2014","2014",6.4,,
+"PATCANAL","N02-Analgesics","TCPPERMT","/capita, US$ exchange rate","EST","Estonia","2015","2015",5.8,,
+"PATCANAL","N02-Analgesics","TCPPERMT","/capita, US$ exchange rate","EST","Estonia","2016","2016",6.3,,
+"PATCANAL","N02-Analgesics","TCPPERMT","/capita, US$ exchange rate","EST","Estonia","2017","2017",6.8,,
+"PATCANAL","N02-Analgesics","TCPPERMT","/capita, US$ exchange rate","EST","Estonia","2018","2018",7.8,,
+"PATCANAL","N02-Analgesics","TCPPERMT","/capita, US$ exchange rate","EST","Estonia","2019","2019",8,,
+"PATCANAL","N02-Analgesics","TCPPERMT","/capita, US$ exchange rate","EST","Estonia","2020","2020",8.8,,
+"PATCANAL","N02-Analgesics","TCPPERMT","/capita, US$ exchange rate","EST","Estonia","2021","2021",9.6,,
+"PATCANAL","N02-Analgesics","TCPPERMT","/capita, US$ exchange rate","EST","Estonia","2022","2022",10.6,,
+"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2010","2010",7.6,,
+"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2011","2011",7.9,,
+"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2012","2012",8,,
+"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2013","2013",8.6,,
+"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2014","2014",9.1,,
+"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2015","2015",9.7,,
+"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2016","2016",10.7,,
+"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2017","2017",11.3,,
+"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2018","2018",12.2,,
+"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2019","2019",13.2,,
+"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2020","2020",14.7,,
+"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2021","2021",15,,
+"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2022","2022",17.7,,
+"PATCANAL","N02-Analgesics","ATCPTTMT","% of total sales","EST","Estonia","2010","2010",2.7,,
+"PATCANAL","N02-Analgesics","ATCPTTMT","% of total sales","EST","Estonia","2011","2011",2.6,,
+"PATCANAL","N02-Analgesics","ATCPTTMT","% of total sales","EST","Estonia","2012","2012",2.5,,
+"PATCANAL","N02-Analgesics","ATCPTTMT","% of total sales","EST","Estonia","2013","2013",2.6,,
+"PATCANAL","N02-Analgesics","ATCPTTMT","% of total sales","EST","Estonia","2014","2014",2.5,,
+"PATCANAL","N02-Analgesics","ATCPTTMT","% of total sales","EST","Estonia","2015","2015",2.6,,
+"PATCANAL","N02-Analgesics","ATCPTTMT","% of total sales","EST","Estonia","2016","2016",2.6,,
+"PATCANAL","N02-Analgesics","ATCPTTMT","% of total sales","EST","Estonia","2017","2017",2.6,,
+"PATCANAL","N02-Analgesics","ATCPTTMT","% of total sales","EST","Estonia","2018","2018",2.7,,
+"PATCANAL","N02-Analgesics","ATCPTTMT","% of total sales","EST","Estonia","2019","2019",2.7,,
+"PATCANAL","N02-Analgesics","ATCPTTMT","% of total sales","EST","Estonia","2020","2020",2.9,,
+"PATCANAL","N02-Analgesics","ATCPTTMT","% of total sales","EST","Estonia","2021","2021",2.6,,
+"PATCANAL","N02-Analgesics","ATCPTTMT","% of total sales","EST","Estonia","2022","2022",3.1,,
+"PATCANAL","N02-Analgesics","MLLNCUMT","Million of national currency units","SVN","Slovenia","2010","2010",17.2,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","MLLNCUMT","Million of national currency units","SVN","Slovenia","2011","2011",16.6,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","MLLNCUMT","Million of national currency units","SVN","Slovenia","2012","2012",16,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","MLLNCUMT","Million of national currency units","SVN","Slovenia","2013","2013",17.2,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","MLLNCUMT","Million of national currency units","SVN","Slovenia","2014","2014",17.8,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","MLLNCUMT","Million of national currency units","SVN","Slovenia","2015","2015",18.4,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","MLLNCUMT","Million of national currency units","SVN","Slovenia","2016","2016",18.6,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","MLLNCUMT","Million of national currency units","SVN","Slovenia","2017","2017",18.3,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","MLLNCUMT","Million of national currency units","SVN","Slovenia","2018","2018",18.3,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","MLLNCUMT","Million of national currency units","SVN","Slovenia","2019","2019",18.5,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","MLLNCUMT","Million of national currency units","SVN","Slovenia","2020","2020",20.6,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","MLLNCUMT","Million of national currency units","SVN","Slovenia","2021","2021",22.1,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","MLLNCUMT","Million of national currency units","SVN","Slovenia","2022","2022",24.9,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","MTMOTCMT","Million US$ at exchange rate","SVN","Slovenia","2010","2010",22.7,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","MTMOTCMT","Million US$ at exchange rate","SVN","Slovenia","2011","2011",23.1,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","MTMOTCMT","Million US$ at exchange rate","SVN","Slovenia","2012","2012",20.6,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","MTMOTCMT","Million US$ at exchange rate","SVN","Slovenia","2013","2013",22.9,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","MTMOTCMT","Million US$ at exchange rate","SVN","Slovenia","2014","2014",23.6,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","MTMOTCMT","Million US$ at exchange rate","SVN","Slovenia","2015","2015",20.4,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","MTMOTCMT","Million US$ at exchange rate","SVN","Slovenia","2016","2016",20.6,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","MTMOTCMT","Million US$ at exchange rate","SVN","Slovenia","2017","2017",20.7,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","MTMOTCMT","Million US$ at exchange rate","SVN","Slovenia","2018","2018",21.6,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","MTMOTCMT","Million US$ at exchange rate","SVN","Slovenia","2019","2019",20.8,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","MTMOTCMT","Million US$ at exchange rate","SVN","Slovenia","2020","2020",23.5,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","MTMOTCMT","Million US$ at exchange rate","SVN","Slovenia","2021","2021",26.1,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","MTMOTCMT","Million US$ at exchange rate","SVN","Slovenia","2022","2022",26.2,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","MTMOPPMT","Million US$, purchasing power parity","SVN","Slovenia","2010","2010",26.9,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","MTMOPPMT","Million US$, purchasing power parity","SVN","Slovenia","2011","2011",26.7,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","MTMOPPMT","Million US$, purchasing power parity","SVN","Slovenia","2012","2012",26.4,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","MTMOPPMT","Million US$, purchasing power parity","SVN","Slovenia","2013","2013",29.2,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","MTMOPPMT","Million US$, purchasing power parity","SVN","Slovenia","2014","2014",30.1,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","MTMOPPMT","Million US$, purchasing power parity","SVN","Slovenia","2015","2015",30.9,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","MTMOPPMT","Million US$, purchasing power parity","SVN","Slovenia","2016","2016",32.2,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","MTMOPPMT","Million US$, purchasing power parity","SVN","Slovenia","2017","2017",32.1,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","MTMOPPMT","Million US$, purchasing power parity","SVN","Slovenia","2018","2018",32.2,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","MTMOPPMT","Million US$, purchasing power parity","SVN","Slovenia","2019","2019",33.6,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","MTMOPPMT","Million US$, purchasing power parity","SVN","Slovenia","2020","2020",37.6,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","MTMOPPMT","Million US$, purchasing power parity","SVN","Slovenia","2021","2021",39.2,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","MTMOPPMT","Million US$, purchasing power parity","SVN","Slovenia","2022","2022",45.1,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","TCPPERMT","/capita, US$ exchange rate","SVN","Slovenia","2010","2010",11.1,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","TCPPERMT","/capita, US$ exchange rate","SVN","Slovenia","2011","2011",11.3,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","TCPPERMT","/capita, US$ exchange rate","SVN","Slovenia","2012","2012",10,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","TCPPERMT","/capita, US$ exchange rate","SVN","Slovenia","2013","2013",11.1,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","TCPPERMT","/capita, US$ exchange rate","SVN","Slovenia","2014","2014",11.5,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","TCPPERMT","/capita, US$ exchange rate","SVN","Slovenia","2015","2015",9.9,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","TCPPERMT","/capita, US$ exchange rate","SVN","Slovenia","2016","2016",10,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","TCPPERMT","/capita, US$ exchange rate","SVN","Slovenia","2017","2017",10,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","TCPPERMT","/capita, US$ exchange rate","SVN","Slovenia","2018","2018",10.4,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","TCPPERMT","/capita, US$ exchange rate","SVN","Slovenia","2019","2019",9.9,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","TCPPERMT","/capita, US$ exchange rate","SVN","Slovenia","2020","2020",11.2,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","TCPPERMT","/capita, US$ exchange rate","SVN","Slovenia","2021","2021",12.4,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","TCPPERMT","/capita, US$ exchange rate","SVN","Slovenia","2022","2022",12.4,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2010","2010",13.1,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2011","2011",13,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2012","2012",12.8,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2013","2013",14.2,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2014","2014",14.6,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2015","2015",15,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2016","2016",15.6,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2017","2017",15.5,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2018","2018",15.5,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2019","2019",16.1,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2020","2020",17.9,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2021","2021",18.6,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2022","2022",21.4,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","ATCPTTMT","% of total sales","SVN","Slovenia","2010","2010",3.6,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","ATCPTTMT","% of total sales","SVN","Slovenia","2011","2011",3.5,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","ATCPTTMT","% of total sales","SVN","Slovenia","2012","2012",3.5,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","ATCPTTMT","% of total sales","SVN","Slovenia","2013","2013",3.8,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","ATCPTTMT","% of total sales","SVN","Slovenia","2014","2014",4.1,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","ATCPTTMT","% of total sales","SVN","Slovenia","2015","2015",4.1,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","ATCPTTMT","% of total sales","SVN","Slovenia","2016","2016",4,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","ATCPTTMT","% of total sales","SVN","Slovenia","2017","2017",3.8,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","ATCPTTMT","% of total sales","SVN","Slovenia","2018","2018",3.5,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","ATCPTTMT","% of total sales","SVN","Slovenia","2019","2019",3.4,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","ATCPTTMT","% of total sales","SVN","Slovenia","2020","2020",3.6,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","ATCPTTMT","% of total sales","SVN","Slovenia","2021","2021",3.6,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","ATCPTTMT","% of total sales","SVN","Slovenia","2022","2022",3.7,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","MLLNCUMT","Million of national currency units","AUS","Australia","2010","2010",29,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","MLLNCUMT","Million of national currency units","AUS","Australia","2011","2011",28,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","MLLNCUMT","Million of national currency units","AUS","Australia","2012","2012",27,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","MLLNCUMT","Million of national currency units","AUS","Australia","2013","2013",34,"B; D","Break; Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","MLLNCUMT","Million of national currency units","AUS","Australia","2014","2014",33,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","MLLNCUMT","Million of national currency units","AUS","Australia","2015","2015",39,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","MLLNCUMT","Million of national currency units","AUS","Australia","2016","2016",45,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","MLLNCUMT","Million of national currency units","AUS","Australia","2017","2017",48,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","MLLNCUMT","Million of national currency units","AUS","Australia","2018","2018",50,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","MLLNCUMT","Million of national currency units","AUS","Australia","2019","2019",48,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","MLLNCUMT","Million of national currency units","AUS","Australia","2020","2020",48,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","MLLNCUMT","Million of national currency units","AUS","Australia","2021","2021",46,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","MTMOTCMT","Million US$ at exchange rate","AUS","Australia","2010","2010",26.6,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","MTMOTCMT","Million US$ at exchange rate","AUS","Australia","2011","2011",28.9,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","MTMOTCMT","Million US$ at exchange rate","AUS","Australia","2012","2012",28,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","MTMOTCMT","Million US$ at exchange rate","AUS","Australia","2013","2013",32.8,"B; D","Break; Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","MTMOTCMT","Million US$ at exchange rate","AUS","Australia","2014","2014",29.7,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","MTMOTCMT","Million US$ at exchange rate","AUS","Australia","2015","2015",29.3,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","MTMOTCMT","Million US$ at exchange rate","AUS","Australia","2016","2016",33.5,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","MTMOTCMT","Million US$ at exchange rate","AUS","Australia","2017","2017",36.8,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","MTMOTCMT","Million US$ at exchange rate","AUS","Australia","2018","2018",37.4,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","MTMOTCMT","Million US$ at exchange rate","AUS","Australia","2019","2019",33.4,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","MTMOTCMT","Million US$ at exchange rate","AUS","Australia","2020","2020",33,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","MTMOTCMT","Million US$ at exchange rate","AUS","Australia","2021","2021",34.6,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","MTMOPPMT","Million US$, purchasing power parity","AUS","Australia","2010","2010",19.3,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","MTMOPPMT","Million US$, purchasing power parity","AUS","Australia","2011","2011",18.5,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","MTMOPPMT","Million US$, purchasing power parity","AUS","Australia","2012","2012",17.5,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","MTMOPPMT","Million US$, purchasing power parity","AUS","Australia","2013","2013",23.5,"B; D","Break; Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","MTMOPPMT","Million US$, purchasing power parity","AUS","Australia","2014","2014",22.7,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","MTMOPPMT","Million US$, purchasing power parity","AUS","Australia","2015","2015",26.5,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","MTMOPPMT","Million US$, purchasing power parity","AUS","Australia","2016","2016",31,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","MTMOPPMT","Million US$, purchasing power parity","AUS","Australia","2017","2017",32.5,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","MTMOPPMT","Million US$, purchasing power parity","AUS","Australia","2018","2018",34,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","MTMOPPMT","Million US$, purchasing power parity","AUS","Australia","2019","2019",32.4,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","MTMOPPMT","Million US$, purchasing power parity","AUS","Australia","2020","2020",33,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","MTMOPPMT","Million US$, purchasing power parity","AUS","Australia","2021","2021",31.8,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","TCPPERMT","/capita, US$ exchange rate","AUS","Australia","2010","2010",1.2,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","TCPPERMT","/capita, US$ exchange rate","AUS","Australia","2011","2011",1.3,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","TCPPERMT","/capita, US$ exchange rate","AUS","Australia","2012","2012",1.2,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","TCPPERMT","/capita, US$ exchange rate","AUS","Australia","2013","2013",1.4,"B; D","Break; Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","TCPPERMT","/capita, US$ exchange rate","AUS","Australia","2014","2014",1.3,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","TCPPERMT","/capita, US$ exchange rate","AUS","Australia","2015","2015",1.2,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","TCPPERMT","/capita, US$ exchange rate","AUS","Australia","2016","2016",1.4,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","TCPPERMT","/capita, US$ exchange rate","AUS","Australia","2017","2017",1.5,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","TCPPERMT","/capita, US$ exchange rate","AUS","Australia","2018","2018",1.5,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","TCPPERMT","/capita, US$ exchange rate","AUS","Australia","2019","2019",1.3,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","TCPPERMT","/capita, US$ exchange rate","AUS","Australia","2020","2020",1.3,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","TCPPERMT","/capita, US$ exchange rate","AUS","Australia","2021","2021",1.3,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2010","2010",0.9,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2011","2011",0.8,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2012","2012",0.8,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2013","2013",1,"B; D","Break; Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2014","2014",1,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2015","2015",1.1,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2016","2016",1.3,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2017","2017",1.3,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2018","2018",1.4,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2019","2019",1.3,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2020","2020",1.3,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2021","2021",1.2,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","ATCPTTMT","% of total sales","AUS","Australia","2010","2010",0.3,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","ATCPTTMT","% of total sales","AUS","Australia","2011","2011",0.3,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","ATCPTTMT","% of total sales","AUS","Australia","2012","2012",0.3,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","ATCPTTMT","% of total sales","AUS","Australia","2013","2013",0.3,"B; D","Break; Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","ATCPTTMT","% of total sales","AUS","Australia","2014","2014",0.3,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","ATCPTTMT","% of total sales","AUS","Australia","2015","2015",0.3,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","ATCPTTMT","% of total sales","AUS","Australia","2016","2016",0.3,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","ATCPTTMT","% of total sales","AUS","Australia","2017","2017",0.3,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","ATCPTTMT","% of total sales","AUS","Australia","2018","2018",0.3,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","ATCPTTMT","% of total sales","AUS","Australia","2019","2019",0.3,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","ATCPTTMT","% of total sales","AUS","Australia","2020","2020",0.3,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","ATCPTTMT","% of total sales","AUS","Australia","2021","2021",0.3,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","MLLNCUMT","Million of national currency units","AUT","Austria","2010","2010",6.2,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","MLLNCUMT","Million of national currency units","AUT","Austria","2011","2011",6.5,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","MLLNCUMT","Million of national currency units","AUT","Austria","2012","2012",6.5,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","MLLNCUMT","Million of national currency units","AUT","Austria","2013","2013",6.8,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","MLLNCUMT","Million of national currency units","AUT","Austria","2014","2014",7.1,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","MLLNCUMT","Million of national currency units","AUT","Austria","2015","2015",6.8,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","MLLNCUMT","Million of national currency units","AUT","Austria","2016","2016",6.5,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","MLLNCUMT","Million of national currency units","AUT","Austria","2017","2017",6.5,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","MLLNCUMT","Million of national currency units","AUT","Austria","2018","2018",7,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","MLLNCUMT","Million of national currency units","AUT","Austria","2019","2019",6.7,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","MLLNCUMT","Million of national currency units","AUT","Austria","2020","2020",5.8,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","MLLNCUMT","Million of national currency units","AUT","Austria","2021","2021",5.6,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","MTMOTCMT","Million US$ at exchange rate","AUT","Austria","2010","2010",8.2,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","MTMOTCMT","Million US$ at exchange rate","AUT","Austria","2011","2011",9,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","MTMOTCMT","Million US$ at exchange rate","AUT","Austria","2012","2012",8.3,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","MTMOTCMT","Million US$ at exchange rate","AUT","Austria","2013","2013",9,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","MTMOTCMT","Million US$ at exchange rate","AUT","Austria","2014","2014",9.4,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","MTMOTCMT","Million US$ at exchange rate","AUT","Austria","2015","2015",7.6,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","MTMOTCMT","Million US$ at exchange rate","AUT","Austria","2016","2016",7.2,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","MTMOTCMT","Million US$ at exchange rate","AUT","Austria","2017","2017",7.3,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","MTMOTCMT","Million US$ at exchange rate","AUT","Austria","2018","2018",8.2,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","MTMOTCMT","Million US$ at exchange rate","AUT","Austria","2019","2019",7.4,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","MTMOTCMT","Million US$ at exchange rate","AUT","Austria","2020","2020",6.6,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","MTMOTCMT","Million US$ at exchange rate","AUT","Austria","2021","2021",6.6,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","MTMOPPMT","Million US$, purchasing power parity","AUT","Austria","2010","2010",7.3,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","MTMOPPMT","Million US$, purchasing power parity","AUT","Austria","2011","2011",7.8,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","MTMOPPMT","Million US$, purchasing power parity","AUT","Austria","2012","2012",8,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","MTMOPPMT","Million US$, purchasing power parity","AUT","Austria","2013","2013",8.5,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","MTMOPPMT","Million US$, purchasing power parity","AUT","Austria","2014","2014",8.8,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","MTMOPPMT","Million US$, purchasing power parity","AUT","Austria","2015","2015",8.5,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","MTMOPPMT","Million US$, purchasing power parity","AUT","Austria","2016","2016",8.4,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","MTMOPPMT","Million US$, purchasing power parity","AUT","Austria","2017","2017",8.4,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","MTMOPPMT","Million US$, purchasing power parity","AUT","Austria","2018","2018",9.1,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","MTMOPPMT","Million US$, purchasing power parity","AUT","Austria","2019","2019",8.9,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","MTMOPPMT","Million US$, purchasing power parity","AUT","Austria","2020","2020",7.7,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","MTMOPPMT","Million US$, purchasing power parity","AUT","Austria","2021","2021",7.4,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","TCPPERMT","/capita, US$ exchange rate","AUT","Austria","2010","2010",1,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","TCPPERMT","/capita, US$ exchange rate","AUT","Austria","2011","2011",1.1,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","TCPPERMT","/capita, US$ exchange rate","AUT","Austria","2012","2012",1,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","TCPPERMT","/capita, US$ exchange rate","AUT","Austria","2013","2013",1.1,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","TCPPERMT","/capita, US$ exchange rate","AUT","Austria","2014","2014",1.1,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","TCPPERMT","/capita, US$ exchange rate","AUT","Austria","2015","2015",0.9,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","TCPPERMT","/capita, US$ exchange rate","AUT","Austria","2016","2016",0.8,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","TCPPERMT","/capita, US$ exchange rate","AUT","Austria","2017","2017",0.8,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","TCPPERMT","/capita, US$ exchange rate","AUT","Austria","2018","2018",0.9,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","TCPPERMT","/capita, US$ exchange rate","AUT","Austria","2019","2019",0.8,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","TCPPERMT","/capita, US$ exchange rate","AUT","Austria","2020","2020",0.7,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","TCPPERMT","/capita, US$ exchange rate","AUT","Austria","2021","2021",0.7,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2010","2010",0.9,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2011","2011",0.9,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2012","2012",0.9,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2013","2013",1,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2014","2014",1,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2015","2015",1,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2016","2016",1,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2017","2017",1,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2018","2018",1,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2019","2019",1,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2020","2020",0.9,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2021","2021",0.8,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","ATCPTTMT","% of total sales","AUT","Austria","2010","2010",0.2,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","ATCPTTMT","% of total sales","AUT","Austria","2011","2011",0.3,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","ATCPTTMT","% of total sales","AUT","Austria","2012","2012",0.2,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","ATCPTTMT","% of total sales","AUT","Austria","2013","2013",0.3,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","ATCPTTMT","% of total sales","AUT","Austria","2014","2014",0.3,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","ATCPTTMT","% of total sales","AUT","Austria","2015","2015",0.2,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","ATCPTTMT","% of total sales","AUT","Austria","2016","2016",0.2,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","ATCPTTMT","% of total sales","AUT","Austria","2017","2017",0.2,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","ATCPTTMT","% of total sales","AUT","Austria","2018","2018",0.2,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","ATCPTTMT","% of total sales","AUT","Austria","2019","2019",0.2,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","ATCPTTMT","% of total sales","AUT","Austria","2020","2020",0.2,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","ATCPTTMT","% of total sales","AUT","Austria","2021","2021",0.2,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","MLLNCUMT","Million of national currency units","BEL","Belgium","2010","2010",64.4,,
+"PATCANXO","N05B-Anxiolytics","MLLNCUMT","Million of national currency units","BEL","Belgium","2011","2011",65,,
+"PATCANXO","N05B-Anxiolytics","MLLNCUMT","Million of national currency units","BEL","Belgium","2012","2012",63.8,,
+"PATCANXO","N05B-Anxiolytics","MLLNCUMT","Million of national currency units","BEL","Belgium","2013","2013",68.1,,
+"PATCANXO","N05B-Anxiolytics","MLLNCUMT","Million of national currency units","BEL","Belgium","2014","2014",70.3,,
+"PATCANXO","N05B-Anxiolytics","MLLNCUMT","Million of national currency units","BEL","Belgium","2015","2015",69.7,,
+"PATCANXO","N05B-Anxiolytics","MLLNCUMT","Million of national currency units","BEL","Belgium","2016","2016",72.5,,
+"PATCANXO","N05B-Anxiolytics","MLLNCUMT","Million of national currency units","BEL","Belgium","2017","2017",68.8,,
+"PATCANXO","N05B-Anxiolytics","MLLNCUMT","Million of national currency units","BEL","Belgium","2018","2018",66.7,,
+"PATCANXO","N05B-Anxiolytics","MLLNCUMT","Million of national currency units","BEL","Belgium","2019","2019",63.1,,
+"PATCANXO","N05B-Anxiolytics","MLLNCUMT","Million of national currency units","BEL","Belgium","2020","2020",63.4,,
+"PATCANXO","N05B-Anxiolytics","MLLNCUMT","Million of national currency units","BEL","Belgium","2021","2021",63.5,,
+"PATCANXO","N05B-Anxiolytics","MLLNCUMT","Million of national currency units","BEL","Belgium","2022","2022",63.4,"E","Estimated value"
+"PATCANXO","N05B-Anxiolytics","MTMOTCMT","Million US$ at exchange rate","BEL","Belgium","2010","2010",85.3,,
+"PATCANXO","N05B-Anxiolytics","MTMOTCMT","Million US$ at exchange rate","BEL","Belgium","2011","2011",90.5,,
+"PATCANXO","N05B-Anxiolytics","MTMOTCMT","Million US$ at exchange rate","BEL","Belgium","2012","2012",82,,
+"PATCANXO","N05B-Anxiolytics","MTMOTCMT","Million US$ at exchange rate","BEL","Belgium","2013","2013",90.4,,
+"PATCANXO","N05B-Anxiolytics","MTMOTCMT","Million US$ at exchange rate","BEL","Belgium","2014","2014",93.4,,
+"PATCANXO","N05B-Anxiolytics","MTMOTCMT","Million US$ at exchange rate","BEL","Belgium","2015","2015",77.3,,
+"PATCANXO","N05B-Anxiolytics","MTMOTCMT","Million US$ at exchange rate","BEL","Belgium","2016","2016",80.2,,
+"PATCANXO","N05B-Anxiolytics","MTMOTCMT","Million US$ at exchange rate","BEL","Belgium","2017","2017",77.7,,
+"PATCANXO","N05B-Anxiolytics","MTMOTCMT","Million US$ at exchange rate","BEL","Belgium","2018","2018",78.8,,
+"PATCANXO","N05B-Anxiolytics","MTMOTCMT","Million US$ at exchange rate","BEL","Belgium","2019","2019",70.7,,
+"PATCANXO","N05B-Anxiolytics","MTMOTCMT","Million US$ at exchange rate","BEL","Belgium","2020","2020",72.4,,
+"PATCANXO","N05B-Anxiolytics","MTMOTCMT","Million US$ at exchange rate","BEL","Belgium","2021","2021",75.1,,
+"PATCANXO","N05B-Anxiolytics","MTMOTCMT","Million US$ at exchange rate","BEL","Belgium","2022","2022",66.7,"E","Estimated value"
+"PATCANXO","N05B-Anxiolytics","MTMOPPMT","Million US$, purchasing power parity","BEL","Belgium","2010","2010",76.9,,
+"PATCANXO","N05B-Anxiolytics","MTMOPPMT","Million US$, purchasing power parity","BEL","Belgium","2011","2011",78.2,,
+"PATCANXO","N05B-Anxiolytics","MTMOPPMT","Million US$, purchasing power parity","BEL","Belgium","2012","2012",77.6,,
+"PATCANXO","N05B-Anxiolytics","MTMOPPMT","Million US$, purchasing power parity","BEL","Belgium","2013","2013",84.5,,
+"PATCANXO","N05B-Anxiolytics","MTMOPPMT","Million US$, purchasing power parity","BEL","Belgium","2014","2014",87.8,,
+"PATCANXO","N05B-Anxiolytics","MTMOPPMT","Million US$, purchasing power parity","BEL","Belgium","2015","2015",87.1,,
+"PATCANXO","N05B-Anxiolytics","MTMOPPMT","Million US$, purchasing power parity","BEL","Belgium","2016","2016",92.8,,
+"PATCANXO","N05B-Anxiolytics","MTMOPPMT","Million US$, purchasing power parity","BEL","Belgium","2017","2017",88.7,,
+"PATCANXO","N05B-Anxiolytics","MTMOPPMT","Million US$, purchasing power parity","BEL","Belgium","2018","2018",87,,
+"PATCANXO","N05B-Anxiolytics","MTMOPPMT","Million US$, purchasing power parity","BEL","Belgium","2019","2019",84.6,,
+"PATCANXO","N05B-Anxiolytics","MTMOPPMT","Million US$, purchasing power parity","BEL","Belgium","2020","2020",86.8,,
+"PATCANXO","N05B-Anxiolytics","MTMOPPMT","Million US$, purchasing power parity","BEL","Belgium","2021","2021",86.2,,
+"PATCANXO","N05B-Anxiolytics","MTMOPPMT","Million US$, purchasing power parity","BEL","Belgium","2022","2022",88.8,"E","Estimated value"
+"PATCANXO","N05B-Anxiolytics","TCPPERMT","/capita, US$ exchange rate","BEL","Belgium","2010","2010",7.8,,
+"PATCANXO","N05B-Anxiolytics","TCPPERMT","/capita, US$ exchange rate","BEL","Belgium","2011","2011",8.2,,
+"PATCANXO","N05B-Anxiolytics","TCPPERMT","/capita, US$ exchange rate","BEL","Belgium","2012","2012",7.4,,
+"PATCANXO","N05B-Anxiolytics","TCPPERMT","/capita, US$ exchange rate","BEL","Belgium","2013","2013",8.1,,
+"PATCANXO","N05B-Anxiolytics","TCPPERMT","/capita, US$ exchange rate","BEL","Belgium","2014","2014",8.3,,
+"PATCANXO","N05B-Anxiolytics","TCPPERMT","/capita, US$ exchange rate","BEL","Belgium","2015","2015",6.9,,
+"PATCANXO","N05B-Anxiolytics","TCPPERMT","/capita, US$ exchange rate","BEL","Belgium","2016","2016",7.1,,
+"PATCANXO","N05B-Anxiolytics","TCPPERMT","/capita, US$ exchange rate","BEL","Belgium","2017","2017",6.8,,
+"PATCANXO","N05B-Anxiolytics","TCPPERMT","/capita, US$ exchange rate","BEL","Belgium","2018","2018",6.9,,
+"PATCANXO","N05B-Anxiolytics","TCPPERMT","/capita, US$ exchange rate","BEL","Belgium","2019","2019",6.2,,
+"PATCANXO","N05B-Anxiolytics","TCPPERMT","/capita, US$ exchange rate","BEL","Belgium","2020","2020",6.3,,
+"PATCANXO","N05B-Anxiolytics","TCPPERMT","/capita, US$ exchange rate","BEL","Belgium","2021","2021",6.5,,
+"PATCANXO","N05B-Anxiolytics","TCPPERMT","/capita, US$ exchange rate","BEL","Belgium","2022","2022",5.7,"E","Estimated value"
+"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2010","2010",7.1,,
+"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2011","2011",7.1,,
+"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2012","2012",7,,
+"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2013","2013",7.6,,
+"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2014","2014",7.8,,
+"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2015","2015",7.7,,
+"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2016","2016",8.2,,
+"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2017","2017",7.8,,
+"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2018","2018",7.6,,
+"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2019","2019",7.4,,
+"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2020","2020",7.5,,
+"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2021","2021",7.4,,
+"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2022","2022",7.6,"E","Estimated value"
+"PATCANXO","N05B-Anxiolytics","ATCPTTMT","% of total sales","BEL","Belgium","2010","2010",1.1,,
+"PATCANXO","N05B-Anxiolytics","ATCPTTMT","% of total sales","BEL","Belgium","2011","2011",1.1,,
+"PATCANXO","N05B-Anxiolytics","ATCPTTMT","% of total sales","BEL","Belgium","2012","2012",1.1,,
+"PATCANXO","N05B-Anxiolytics","ATCPTTMT","% of total sales","BEL","Belgium","2013","2013",1.1,,
+"PATCANXO","N05B-Anxiolytics","ATCPTTMT","% of total sales","BEL","Belgium","2014","2014",1.2,,
+"PATCANXO","N05B-Anxiolytics","ATCPTTMT","% of total sales","BEL","Belgium","2015","2015",1.1,,
+"PATCANXO","N05B-Anxiolytics","ATCPTTMT","% of total sales","BEL","Belgium","2016","2016",1.2,,
+"PATCANXO","N05B-Anxiolytics","ATCPTTMT","% of total sales","BEL","Belgium","2017","2017",1.1,,
+"PATCANXO","N05B-Anxiolytics","ATCPTTMT","% of total sales","BEL","Belgium","2018","2018",1,,
+"PATCANXO","N05B-Anxiolytics","ATCPTTMT","% of total sales","BEL","Belgium","2019","2019",0.9,,
+"PATCANXO","N05B-Anxiolytics","ATCPTTMT","% of total sales","BEL","Belgium","2020","2020",0.8,,
+"PATCANXO","N05B-Anxiolytics","ATCPTTMT","% of total sales","BEL","Belgium","2021","2021",0.8,,
+"PATCANXO","N05B-Anxiolytics","ATCPTTMT","% of total sales","BEL","Belgium","2022","2022",0.7,"E","Estimated value"
+"PATCANXO","N05B-Anxiolytics","MLLNCUMT","Million of national currency units","CAN","Canada","2012","2012",164.8,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","MLLNCUMT","Million of national currency units","CAN","Canada","2013","2013",164.2,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","MLLNCUMT","Million of national currency units","CAN","Canada","2014","2014",163.8,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","MLLNCUMT","Million of national currency units","CAN","Canada","2015","2015",163.1,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","MLLNCUMT","Million of national currency units","CAN","Canada","2016","2016",163.4,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","MLLNCUMT","Million of national currency units","CAN","Canada","2017","2017",160.2,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","MLLNCUMT","Million of national currency units","CAN","Canada","2018","2018",155.2,"E; B; D","Estimated value; Break; Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","MLLNCUMT","Million of national currency units","CAN","Canada","2019","2019",151,"E; D","Estimated value; Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","MLLNCUMT","Million of national currency units","CAN","Canada","2020","2020",152.8,"E; D","Estimated value; Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","MLLNCUMT","Million of national currency units","CAN","Canada","2021","2021",146.9,"E; D","Estimated value; Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","MLLNCUMT","Million of national currency units","CAN","Canada","2022","2022",141.6,"E; D","Estimated value; Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","MTMOTCMT","Million US$ at exchange rate","CAN","Canada","2012","2012",164.9,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","MTMOTCMT","Million US$ at exchange rate","CAN","Canada","2013","2013",159.4,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","MTMOTCMT","Million US$ at exchange rate","CAN","Canada","2014","2014",148.3,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","MTMOTCMT","Million US$ at exchange rate","CAN","Canada","2015","2015",127.5,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","MTMOTCMT","Million US$ at exchange rate","CAN","Canada","2016","2016",123.3,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","MTMOTCMT","Million US$ at exchange rate","CAN","Canada","2017","2017",123.4,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","MTMOTCMT","Million US$ at exchange rate","CAN","Canada","2018","2018",119.8,"E; B; D","Estimated value; Break; Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","MTMOTCMT","Million US$ at exchange rate","CAN","Canada","2019","2019",113.8,"E; D","Estimated value; Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","MTMOTCMT","Million US$ at exchange rate","CAN","Canada","2020","2020",113.9,"E; D","Estimated value; Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","MTMOTCMT","Million US$ at exchange rate","CAN","Canada","2021","2021",117.1,"E; D","Estimated value; Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","MTMOTCMT","Million US$ at exchange rate","CAN","Canada","2022","2022",108.8,"E; D","Estimated value; Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","MTMOPPMT","Million US$, purchasing power parity","CAN","Canada","2012","2012",132.4,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","MTMOPPMT","Million US$, purchasing power parity","CAN","Canada","2013","2013",134.2,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","MTMOPPMT","Million US$, purchasing power parity","CAN","Canada","2014","2014",133.1,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","MTMOPPMT","Million US$, purchasing power parity","CAN","Canada","2015","2015",130.7,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","MTMOPPMT","Million US$, purchasing power parity","CAN","Canada","2016","2016",135.4,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","MTMOPPMT","Million US$, purchasing power parity","CAN","Canada","2017","2017",132.1,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","MTMOPPMT","Million US$, purchasing power parity","CAN","Canada","2018","2018",128.7,"E; B; D","Estimated value; Break; Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","MTMOPPMT","Million US$, purchasing power parity","CAN","Canada","2019","2019",122.3,"E; D","Estimated value; Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","MTMOPPMT","Million US$, purchasing power parity","CAN","Canada","2020","2020",124.1,"E; D","Estimated value; Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","MTMOPPMT","Million US$, purchasing power parity","CAN","Canada","2021","2021",118.6,"E; D","Estimated value; Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","MTMOPPMT","Million US$, purchasing power parity","CAN","Canada","2022","2022",112.9,"E; D","Estimated value; Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","TCPPERMT","/capita, US$ exchange rate","CAN","Canada","2012","2012",4.8,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","TCPPERMT","/capita, US$ exchange rate","CAN","Canada","2013","2013",4.5,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","TCPPERMT","/capita, US$ exchange rate","CAN","Canada","2014","2014",4.2,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","TCPPERMT","/capita, US$ exchange rate","CAN","Canada","2015","2015",3.6,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","TCPPERMT","/capita, US$ exchange rate","CAN","Canada","2016","2016",3.4,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","TCPPERMT","/capita, US$ exchange rate","CAN","Canada","2017","2017",3.4,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","TCPPERMT","/capita, US$ exchange rate","CAN","Canada","2018","2018",3.2,"E; B; D","Estimated value; Break; Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","TCPPERMT","/capita, US$ exchange rate","CAN","Canada","2019","2019",3,"E; D","Estimated value; Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","TCPPERMT","/capita, US$ exchange rate","CAN","Canada","2020","2020",3,"E; D","Estimated value; Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","TCPPERMT","/capita, US$ exchange rate","CAN","Canada","2021","2021",3.1,"E; D","Estimated value; Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","TCPPERMT","/capita, US$ exchange rate","CAN","Canada","2022","2022",2.8,"E; D","Estimated value; Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2012","2012",3.8,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2013","2013",3.8,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2014","2014",3.8,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2015","2015",3.7,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2016","2016",3.7,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2017","2017",3.6,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2018","2018",3.5,"E; B; D","Estimated value; Break; Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2019","2019",3.3,"E; D","Estimated value; Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2020","2020",3.3,"E; D","Estimated value; Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2021","2021",3.1,"E; D","Estimated value; Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2022","2022",2.9,"E; D","Estimated value; Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","ATCPTTMT","% of total sales","CAN","Canada","2012","2012",0.7,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","ATCPTTMT","% of total sales","CAN","Canada","2013","2013",0.7,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","ATCPTTMT","% of total sales","CAN","Canada","2014","2014",0.6,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","ATCPTTMT","% of total sales","CAN","Canada","2015","2015",0.6,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","ATCPTTMT","% of total sales","CAN","Canada","2016","2016",0.6,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","ATCPTTMT","% of total sales","CAN","Canada","2017","2017",0.5,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","ATCPTTMT","% of total sales","CAN","Canada","2018","2018",0.5,"E; B; D","Estimated value; Break; Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","ATCPTTMT","% of total sales","CAN","Canada","2019","2019",0.5,"E; D","Estimated value; Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","ATCPTTMT","% of total sales","CAN","Canada","2020","2020",0.4,"E; D","Estimated value; Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","ATCPTTMT","% of total sales","CAN","Canada","2021","2021",0.4,"E; D","Estimated value; Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","ATCPTTMT","% of total sales","CAN","Canada","2022","2022",0.4,"E; D","Estimated value; Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","MLLNCUMT","Million of national currency units","CZE","Czech Republic","2010","2010",344.7,,
+"PATCANXO","N05B-Anxiolytics","MLLNCUMT","Million of national currency units","CZE","Czech Republic","2011","2011",372.5,,
+"PATCANXO","N05B-Anxiolytics","MLLNCUMT","Million of national currency units","CZE","Czech Republic","2012","2012",421.9,,
+"PATCANXO","N05B-Anxiolytics","MLLNCUMT","Million of national currency units","CZE","Czech Republic","2013","2013",424.6,,
+"PATCANXO","N05B-Anxiolytics","MLLNCUMT","Million of national currency units","CZE","Czech Republic","2014","2014",414.2,,
+"PATCANXO","N05B-Anxiolytics","MLLNCUMT","Million of national currency units","CZE","Czech Republic","2015","2015",397.2,,
+"PATCANXO","N05B-Anxiolytics","MLLNCUMT","Million of national currency units","CZE","Czech Republic","2016","2016",396.7,,
+"PATCANXO","N05B-Anxiolytics","MLLNCUMT","Million of national currency units","CZE","Czech Republic","2017","2017",397,,
+"PATCANXO","N05B-Anxiolytics","MLLNCUMT","Million of national currency units","CZE","Czech Republic","2018","2018",381.4,,
+"PATCANXO","N05B-Anxiolytics","MLLNCUMT","Million of national currency units","CZE","Czech Republic","2019","2019",393.9,,
+"PATCANXO","N05B-Anxiolytics","MLLNCUMT","Million of national currency units","CZE","Czech Republic","2020","2020",255.9,"B","Break"
+"PATCANXO","N05B-Anxiolytics","MLLNCUMT","Million of national currency units","CZE","Czech Republic","2021","2021",264.6,,
+"PATCANXO","N05B-Anxiolytics","MTMOTCMT","Million US$ at exchange rate","CZE","Czech Republic","2010","2010",18,,
+"PATCANXO","N05B-Anxiolytics","MTMOTCMT","Million US$ at exchange rate","CZE","Czech Republic","2011","2011",21.1,,
+"PATCANXO","N05B-Anxiolytics","MTMOTCMT","Million US$ at exchange rate","CZE","Czech Republic","2012","2012",21.5,,
+"PATCANXO","N05B-Anxiolytics","MTMOTCMT","Million US$ at exchange rate","CZE","Czech Republic","2013","2013",21.7,,
+"PATCANXO","N05B-Anxiolytics","MTMOTCMT","Million US$ at exchange rate","CZE","Czech Republic","2014","2014",20,,
+"PATCANXO","N05B-Anxiolytics","MTMOTCMT","Million US$ at exchange rate","CZE","Czech Republic","2015","2015",16.1,,
+"PATCANXO","N05B-Anxiolytics","MTMOTCMT","Million US$ at exchange rate","CZE","Czech Republic","2016","2016",16.2,,
+"PATCANXO","N05B-Anxiolytics","MTMOTCMT","Million US$ at exchange rate","CZE","Czech Republic","2017","2017",17,,
+"PATCANXO","N05B-Anxiolytics","MTMOTCMT","Million US$ at exchange rate","CZE","Czech Republic","2018","2018",17.6,,
+"PATCANXO","N05B-Anxiolytics","MTMOTCMT","Million US$ at exchange rate","CZE","Czech Republic","2019","2019",17.2,,
+"PATCANXO","N05B-Anxiolytics","MTMOTCMT","Million US$ at exchange rate","CZE","Czech Republic","2020","2020",11,"B","Break"
+"PATCANXO","N05B-Anxiolytics","MTMOTCMT","Million US$ at exchange rate","CZE","Czech Republic","2021","2021",12.2,,
+"PATCANXO","N05B-Anxiolytics","MTMOPPMT","Million US$, purchasing power parity","CZE","Czech Republic","2010","2010",25.2,,
+"PATCANXO","N05B-Anxiolytics","MTMOPPMT","Million US$, purchasing power parity","CZE","Czech Republic","2011","2011",27.9,,
+"PATCANXO","N05B-Anxiolytics","MTMOPPMT","Million US$, purchasing power parity","CZE","Czech Republic","2012","2012",31.7,,
+"PATCANXO","N05B-Anxiolytics","MTMOPPMT","Million US$, purchasing power parity","CZE","Czech Republic","2013","2013",33.2,,
+"PATCANXO","N05B-Anxiolytics","MTMOPPMT","Million US$, purchasing power parity","CZE","Czech Republic","2014","2014",32.6,,
+"PATCANXO","N05B-Anxiolytics","MTMOPPMT","Million US$, purchasing power parity","CZE","Czech Republic","2015","2015",30.7,,
+"PATCANXO","N05B-Anxiolytics","MTMOPPMT","Million US$, purchasing power parity","CZE","Czech Republic","2016","2016",31.5,,
+"PATCANXO","N05B-Anxiolytics","MTMOPPMT","Million US$, purchasing power parity","CZE","Czech Republic","2017","2017",32,,
+"PATCANXO","N05B-Anxiolytics","MTMOPPMT","Million US$, purchasing power parity","CZE","Czech Republic","2018","2018",30.8,,
+"PATCANXO","N05B-Anxiolytics","MTMOPPMT","Million US$, purchasing power parity","CZE","Czech Republic","2019","2019",32.1,,
+"PATCANXO","N05B-Anxiolytics","MTMOPPMT","Million US$, purchasing power parity","CZE","Czech Republic","2020","2020",20.5,"B","Break"
+"PATCANXO","N05B-Anxiolytics","MTMOPPMT","Million US$, purchasing power parity","CZE","Czech Republic","2021","2021",20.8,,
+"PATCANXO","N05B-Anxiolytics","TCPPERMT","/capita, US$ exchange rate","CZE","Czech Republic","2010","2010",1.7,,
+"PATCANXO","N05B-Anxiolytics","TCPPERMT","/capita, US$ exchange rate","CZE","Czech Republic","2011","2011",2,,
+"PATCANXO","N05B-Anxiolytics","TCPPERMT","/capita, US$ exchange rate","CZE","Czech Republic","2012","2012",2.1,,
+"PATCANXO","N05B-Anxiolytics","TCPPERMT","/capita, US$ exchange rate","CZE","Czech Republic","2013","2013",2.1,,
+"PATCANXO","N05B-Anxiolytics","TCPPERMT","/capita, US$ exchange rate","CZE","Czech Republic","2014","2014",1.9,,
+"PATCANXO","N05B-Anxiolytics","TCPPERMT","/capita, US$ exchange rate","CZE","Czech Republic","2015","2015",1.5,,
+"PATCANXO","N05B-Anxiolytics","TCPPERMT","/capita, US$ exchange rate","CZE","Czech Republic","2016","2016",1.5,,
+"PATCANXO","N05B-Anxiolytics","TCPPERMT","/capita, US$ exchange rate","CZE","Czech Republic","2017","2017",1.6,,
+"PATCANXO","N05B-Anxiolytics","TCPPERMT","/capita, US$ exchange rate","CZE","Czech Republic","2018","2018",1.7,,
+"PATCANXO","N05B-Anxiolytics","TCPPERMT","/capita, US$ exchange rate","CZE","Czech Republic","2019","2019",1.6,,
+"PATCANXO","N05B-Anxiolytics","TCPPERMT","/capita, US$ exchange rate","CZE","Czech Republic","2020","2020",1,"B","Break"
+"PATCANXO","N05B-Anxiolytics","TCPPERMT","/capita, US$ exchange rate","CZE","Czech Republic","2021","2021",1.2,,
+"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czech Republic","2010","2010",2.4,,
+"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czech Republic","2011","2011",2.7,,
+"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czech Republic","2012","2012",3,,
+"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czech Republic","2013","2013",3.2,,
+"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czech Republic","2014","2014",3.1,,
+"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czech Republic","2015","2015",2.9,,
+"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czech Republic","2016","2016",3,,
+"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czech Republic","2017","2017",3,,
+"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czech Republic","2018","2018",2.9,,
+"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czech Republic","2019","2019",3,,
+"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czech Republic","2020","2020",1.9,"B","Break"
+"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czech Republic","2021","2021",2,,
+"PATCANXO","N05B-Anxiolytics","ATCPTTMT","% of total sales","CZE","Czech Republic","2010","2010",0.4,,
+"PATCANXO","N05B-Anxiolytics","ATCPTTMT","% of total sales","CZE","Czech Republic","2011","2011",0.5,,
+"PATCANXO","N05B-Anxiolytics","ATCPTTMT","% of total sales","CZE","Czech Republic","2012","2012",0.5,,
+"PATCANXO","N05B-Anxiolytics","ATCPTTMT","% of total sales","CZE","Czech Republic","2013","2013",0.5,,
+"PATCANXO","N05B-Anxiolytics","ATCPTTMT","% of total sales","CZE","Czech Republic","2014","2014",0.5,,
+"PATCANXO","N05B-Anxiolytics","ATCPTTMT","% of total sales","CZE","Czech Republic","2015","2015",0.5,,
+"PATCANXO","N05B-Anxiolytics","ATCPTTMT","% of total sales","CZE","Czech Republic","2016","2016",0.5,,
+"PATCANXO","N05B-Anxiolytics","ATCPTTMT","% of total sales","CZE","Czech Republic","2017","2017",0.4,,
+"PATCANXO","N05B-Anxiolytics","ATCPTTMT","% of total sales","CZE","Czech Republic","2018","2018",0.4,,
+"PATCANXO","N05B-Anxiolytics","ATCPTTMT","% of total sales","CZE","Czech Republic","2019","2019",0.4,,
+"PATCANXO","N05B-Anxiolytics","ATCPTTMT","% of total sales","CZE","Czech Republic","2020","2020",0.3,"B","Break"
+"PATCANXO","N05B-Anxiolytics","ATCPTTMT","% of total sales","CZE","Czech Republic","2021","2021",0.3,,
+"PATCANXO","N05B-Anxiolytics","MLLNCUMT","Million of national currency units","FIN","Finland","2010","2010",8.3,,
+"PATCANXO","N05B-Anxiolytics","MLLNCUMT","Million of national currency units","FIN","Finland","2011","2011",8.2,,
+"PATCANXO","N05B-Anxiolytics","MLLNCUMT","Million of national currency units","FIN","Finland","2012","2012",8.1,,
+"PATCANXO","N05B-Anxiolytics","MLLNCUMT","Million of national currency units","FIN","Finland","2013","2013",7.9,,
+"PATCANXO","N05B-Anxiolytics","MLLNCUMT","Million of national currency units","FIN","Finland","2014","2014",7.9,,
+"PATCANXO","N05B-Anxiolytics","MLLNCUMT","Million of national currency units","FIN","Finland","2015","2015",7.8,,
+"PATCANXO","N05B-Anxiolytics","MLLNCUMT","Million of national currency units","FIN","Finland","2016","2016",7.2,,
+"PATCANXO","N05B-Anxiolytics","MLLNCUMT","Million of national currency units","FIN","Finland","2017","2017",6.6,,
+"PATCANXO","N05B-Anxiolytics","MLLNCUMT","Million of national currency units","FIN","Finland","2018","2018",6.4,,
+"PATCANXO","N05B-Anxiolytics","MLLNCUMT","Million of national currency units","FIN","Finland","2019","2019",6,,
+"PATCANXO","N05B-Anxiolytics","MLLNCUMT","Million of national currency units","FIN","Finland","2020","2020",6.9,,
+"PATCANXO","N05B-Anxiolytics","MLLNCUMT","Million of national currency units","FIN","Finland","2021","2021",7.1,,
+"PATCANXO","N05B-Anxiolytics","MTMOTCMT","Million US$ at exchange rate","FIN","Finland","2010","2010",11,,
+"PATCANXO","N05B-Anxiolytics","MTMOTCMT","Million US$ at exchange rate","FIN","Finland","2011","2011",11.4,,
+"PATCANXO","N05B-Anxiolytics","MTMOTCMT","Million US$ at exchange rate","FIN","Finland","2012","2012",10.4,,
+"PATCANXO","N05B-Anxiolytics","MTMOTCMT","Million US$ at exchange rate","FIN","Finland","2013","2013",10.5,,
+"PATCANXO","N05B-Anxiolytics","MTMOTCMT","Million US$ at exchange rate","FIN","Finland","2014","2014",10.5,,
+"PATCANXO","N05B-Anxiolytics","MTMOTCMT","Million US$ at exchange rate","FIN","Finland","2015","2015",8.7,,
+"PATCANXO","N05B-Anxiolytics","MTMOTCMT","Million US$ at exchange rate","FIN","Finland","2016","2016",8,,
+"PATCANXO","N05B-Anxiolytics","MTMOTCMT","Million US$ at exchange rate","FIN","Finland","2017","2017",7.5,,
+"PATCANXO","N05B-Anxiolytics","MTMOTCMT","Million US$ at exchange rate","FIN","Finland","2018","2018",7.6,,
+"PATCANXO","N05B-Anxiolytics","MTMOTCMT","Million US$ at exchange rate","FIN","Finland","2019","2019",6.7,,
+"PATCANXO","N05B-Anxiolytics","MTMOTCMT","Million US$ at exchange rate","FIN","Finland","2020","2020",7.9,,
+"PATCANXO","N05B-Anxiolytics","MTMOTCMT","Million US$ at exchange rate","FIN","Finland","2021","2021",8.4,,
+"PATCANXO","N05B-Anxiolytics","MTMOPPMT","Million US$, purchasing power parity","FIN","Finland","2010","2010",9.2,,
+"PATCANXO","N05B-Anxiolytics","MTMOPPMT","Million US$, purchasing power parity","FIN","Finland","2011","2011",9.1,,
+"PATCANXO","N05B-Anxiolytics","MTMOPPMT","Million US$, purchasing power parity","FIN","Finland","2012","2012",8.9,,
+"PATCANXO","N05B-Anxiolytics","MTMOPPMT","Million US$, purchasing power parity","FIN","Finland","2013","2013",8.7,,
+"PATCANXO","N05B-Anxiolytics","MTMOPPMT","Million US$, purchasing power parity","FIN","Finland","2014","2014",8.7,,
+"PATCANXO","N05B-Anxiolytics","MTMOPPMT","Million US$, purchasing power parity","FIN","Finland","2015","2015",8.6,,
+"PATCANXO","N05B-Anxiolytics","MTMOPPMT","Million US$, purchasing power parity","FIN","Finland","2016","2016",8.2,,
+"PATCANXO","N05B-Anxiolytics","MTMOPPMT","Million US$, purchasing power parity","FIN","Finland","2017","2017",7.6,,
+"PATCANXO","N05B-Anxiolytics","MTMOPPMT","Million US$, purchasing power parity","FIN","Finland","2018","2018",7.5,,
+"PATCANXO","N05B-Anxiolytics","MTMOPPMT","Million US$, purchasing power parity","FIN","Finland","2019","2019",7.2,,
+"PATCANXO","N05B-Anxiolytics","MTMOPPMT","Million US$, purchasing power parity","FIN","Finland","2020","2020",8.4,,
+"PATCANXO","N05B-Anxiolytics","MTMOPPMT","Million US$, purchasing power parity","FIN","Finland","2021","2021",8.6,,
+"PATCANXO","N05B-Anxiolytics","TCPPERMT","/capita, US$ exchange rate","FIN","Finland","2010","2010",2.1,,
+"PATCANXO","N05B-Anxiolytics","TCPPERMT","/capita, US$ exchange rate","FIN","Finland","2011","2011",2.1,,
+"PATCANXO","N05B-Anxiolytics","TCPPERMT","/capita, US$ exchange rate","FIN","Finland","2012","2012",1.9,,
+"PATCANXO","N05B-Anxiolytics","TCPPERMT","/capita, US$ exchange rate","FIN","Finland","2013","2013",1.9,,
+"PATCANXO","N05B-Anxiolytics","TCPPERMT","/capita, US$ exchange rate","FIN","Finland","2014","2014",1.9,,
+"PATCANXO","N05B-Anxiolytics","TCPPERMT","/capita, US$ exchange rate","FIN","Finland","2015","2015",1.6,,
+"PATCANXO","N05B-Anxiolytics","TCPPERMT","/capita, US$ exchange rate","FIN","Finland","2016","2016",1.5,,
+"PATCANXO","N05B-Anxiolytics","TCPPERMT","/capita, US$ exchange rate","FIN","Finland","2017","2017",1.4,,
+"PATCANXO","N05B-Anxiolytics","TCPPERMT","/capita, US$ exchange rate","FIN","Finland","2018","2018",1.4,,
+"PATCANXO","N05B-Anxiolytics","TCPPERMT","/capita, US$ exchange rate","FIN","Finland","2019","2019",1.2,,
+"PATCANXO","N05B-Anxiolytics","TCPPERMT","/capita, US$ exchange rate","FIN","Finland","2020","2020",1.4,,
+"PATCANXO","N05B-Anxiolytics","TCPPERMT","/capita, US$ exchange rate","FIN","Finland","2021","2021",1.5,,
+"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2010","2010",1.7,,
+"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2011","2011",1.7,,
+"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2012","2012",1.6,,
+"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2013","2013",1.6,,
+"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2014","2014",1.6,,
+"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2015","2015",1.6,,
+"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2016","2016",1.5,,
+"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2017","2017",1.4,,
+"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2018","2018",1.4,,
+"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2019","2019",1.3,,
+"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2020","2020",1.5,,
+"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2021","2021",1.5,,
+"PATCANXO","N05B-Anxiolytics","ATCPTTMT","% of total sales","FIN","Finland","2010","2010",0.4,,
+"PATCANXO","N05B-Anxiolytics","ATCPTTMT","% of total sales","FIN","Finland","2011","2011",0.4,,
+"PATCANXO","N05B-Anxiolytics","ATCPTTMT","% of total sales","FIN","Finland","2012","2012",0.4,,
+"PATCANXO","N05B-Anxiolytics","ATCPTTMT","% of total sales","FIN","Finland","2013","2013",0.4,,
+"PATCANXO","N05B-Anxiolytics","ATCPTTMT","% of total sales","FIN","Finland","2014","2014",0.4,,
+"PATCANXO","N05B-Anxiolytics","ATCPTTMT","% of total sales","FIN","Finland","2015","2015",0.4,,
+"PATCANXO","N05B-Anxiolytics","ATCPTTMT","% of total sales","FIN","Finland","2016","2016",0.3,,
+"PATCANXO","N05B-Anxiolytics","ATCPTTMT","% of total sales","FIN","Finland","2017","2017",0.3,,
+"PATCANXO","N05B-Anxiolytics","ATCPTTMT","% of total sales","FIN","Finland","2018","2018",0.3,,
+"PATCANXO","N05B-Anxiolytics","ATCPTTMT","% of total sales","FIN","Finland","2019","2019",0.2,,
+"PATCANXO","N05B-Anxiolytics","ATCPTTMT","% of total sales","FIN","Finland","2020","2020",0.3,,
+"PATCANXO","N05B-Anxiolytics","ATCPTTMT","% of total sales","FIN","Finland","2021","2021",0.2,,
+"PATCANXO","N05B-Anxiolytics","MLLNCUMT","Million of national currency units","DEU","Germany","2010","2010",85,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","MLLNCUMT","Million of national currency units","DEU","Germany","2011","2011",80.1,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","MLLNCUMT","Million of national currency units","DEU","Germany","2012","2012",78.9,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","MLLNCUMT","Million of national currency units","DEU","Germany","2013","2013",77,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","MLLNCUMT","Million of national currency units","DEU","Germany","2014","2014",76.8,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","MLLNCUMT","Million of national currency units","DEU","Germany","2015","2015",73.3,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","MLLNCUMT","Million of national currency units","DEU","Germany","2016","2016",68.8,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","MLLNCUMT","Million of national currency units","DEU","Germany","2017","2017",65.6,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","MLLNCUMT","Million of national currency units","DEU","Germany","2018","2018",65.2,"B; D","Break; Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","MLLNCUMT","Million of national currency units","DEU","Germany","2019","2019",63.5,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","MLLNCUMT","Million of national currency units","DEU","Germany","2020","2020",62.2,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","MLLNCUMT","Million of national currency units","DEU","Germany","2021","2021",62.3,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","MTMOTCMT","Million US$ at exchange rate","DEU","Germany","2010","2010",112.7,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","MTMOTCMT","Million US$ at exchange rate","DEU","Germany","2011","2011",111.5,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","MTMOTCMT","Million US$ at exchange rate","DEU","Germany","2012","2012",101.4,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","MTMOTCMT","Million US$ at exchange rate","DEU","Germany","2013","2013",102.3,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","MTMOTCMT","Million US$ at exchange rate","DEU","Germany","2014","2014",102,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","MTMOTCMT","Million US$ at exchange rate","DEU","Germany","2015","2015",81.3,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","MTMOTCMT","Million US$ at exchange rate","DEU","Germany","2016","2016",76.2,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","MTMOTCMT","Million US$ at exchange rate","DEU","Germany","2017","2017",74.1,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","MTMOTCMT","Million US$ at exchange rate","DEU","Germany","2018","2018",77,"B; D","Break; Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","MTMOTCMT","Million US$ at exchange rate","DEU","Germany","2019","2019",71.1,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","MTMOTCMT","Million US$ at exchange rate","DEU","Germany","2020","2020",71,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","MTMOTCMT","Million US$ at exchange rate","DEU","Germany","2021","2021",73.7,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","MTMOPPMT","Million US$, purchasing power parity","DEU","Germany","2010","2010",105.6,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","MTMOPPMT","Million US$, purchasing power parity","DEU","Germany","2011","2011",101.6,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","MTMOPPMT","Million US$, purchasing power parity","DEU","Germany","2012","2012",100.2,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","MTMOPPMT","Million US$, purchasing power parity","DEU","Germany","2013","2013",99.4,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","MTMOPPMT","Million US$, purchasing power parity","DEU","Germany","2014","2014",99.9,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","MTMOPPMT","Million US$, purchasing power parity","DEU","Germany","2015","2015",94.2,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","MTMOPPMT","Million US$, purchasing power parity","DEU","Germany","2016","2016",91.4,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","MTMOPPMT","Million US$, purchasing power parity","DEU","Germany","2017","2017",88.1,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","MTMOPPMT","Million US$, purchasing power parity","DEU","Germany","2018","2018",88.7,"B; D","Break; Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","MTMOPPMT","Million US$, purchasing power parity","DEU","Germany","2019","2019",87.2,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","MTMOPPMT","Million US$, purchasing power parity","DEU","Germany","2020","2020",85.8,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","MTMOPPMT","Million US$, purchasing power parity","DEU","Germany","2021","2021",84.6,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","TCPPERMT","/capita, US$ exchange rate","DEU","Germany","2010","2010",1.4,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","TCPPERMT","/capita, US$ exchange rate","DEU","Germany","2011","2011",1.4,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","TCPPERMT","/capita, US$ exchange rate","DEU","Germany","2012","2012",1.3,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","TCPPERMT","/capita, US$ exchange rate","DEU","Germany","2013","2013",1.3,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","TCPPERMT","/capita, US$ exchange rate","DEU","Germany","2014","2014",1.3,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","TCPPERMT","/capita, US$ exchange rate","DEU","Germany","2015","2015",1,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","TCPPERMT","/capita, US$ exchange rate","DEU","Germany","2016","2016",0.9,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","TCPPERMT","/capita, US$ exchange rate","DEU","Germany","2017","2017",0.9,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","TCPPERMT","/capita, US$ exchange rate","DEU","Germany","2018","2018",0.9,"B; D","Break; Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","TCPPERMT","/capita, US$ exchange rate","DEU","Germany","2019","2019",0.9,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","TCPPERMT","/capita, US$ exchange rate","DEU","Germany","2020","2020",0.9,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","TCPPERMT","/capita, US$ exchange rate","DEU","Germany","2021","2021",0.9,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2010","2010",1.3,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2011","2011",1.3,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2012","2012",1.2,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2013","2013",1.2,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2014","2014",1.2,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2015","2015",1.2,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2016","2016",1.1,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2017","2017",1.1,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2018","2018",1.1,"B; D","Break; Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2019","2019",1,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2020","2020",1,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2021","2021",1,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","ATCPTTMT","% of total sales","DEU","Germany","2010","2010",0.3,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","ATCPTTMT","% of total sales","DEU","Germany","2011","2011",0.3,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","ATCPTTMT","% of total sales","DEU","Germany","2012","2012",0.3,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","ATCPTTMT","% of total sales","DEU","Germany","2013","2013",0.2,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","ATCPTTMT","% of total sales","DEU","Germany","2014","2014",0.2,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","ATCPTTMT","% of total sales","DEU","Germany","2015","2015",0.2,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","ATCPTTMT","% of total sales","DEU","Germany","2016","2016",0.2,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","ATCPTTMT","% of total sales","DEU","Germany","2017","2017",0.2,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","ATCPTTMT","% of total sales","DEU","Germany","2018","2018",0.1,"B; D","Break; Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","ATCPTTMT","% of total sales","DEU","Germany","2019","2019",0.1,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","ATCPTTMT","% of total sales","DEU","Germany","2020","2020",0.1,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","ATCPTTMT","% of total sales","DEU","Germany","2021","2021",0.1,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","MLLNCUMT","Million of national currency units","GRC","Greece","2010","2010",22.3,,
+"PATCANXO","N05B-Anxiolytics","MLLNCUMT","Million of national currency units","GRC","Greece","2011","2011",22.6,,
+"PATCANXO","N05B-Anxiolytics","MLLNCUMT","Million of national currency units","GRC","Greece","2012","2012",21.1,,
+"PATCANXO","N05B-Anxiolytics","MLLNCUMT","Million of national currency units","GRC","Greece","2013","2013",21.8,,
+"PATCANXO","N05B-Anxiolytics","MLLNCUMT","Million of national currency units","GRC","Greece","2014","2014",20.2,,
+"PATCANXO","N05B-Anxiolytics","MLLNCUMT","Million of national currency units","GRC","Greece","2015","2015",20.7,,
+"PATCANXO","N05B-Anxiolytics","MLLNCUMT","Million of national currency units","GRC","Greece","2016","2016",21.4,,
+"PATCANXO","N05B-Anxiolytics","MLLNCUMT","Million of national currency units","GRC","Greece","2017","2017",22.2,,
+"PATCANXO","N05B-Anxiolytics","MLLNCUMT","Million of national currency units","GRC","Greece","2018","2018",22.6,,
+"PATCANXO","N05B-Anxiolytics","MLLNCUMT","Million of national currency units","GRC","Greece","2019","2019",21.7,,
+"PATCANXO","N05B-Anxiolytics","MLLNCUMT","Million of national currency units","GRC","Greece","2020","2020",25.1,,
+"PATCANXO","N05B-Anxiolytics","MLLNCUMT","Million of national currency units","GRC","Greece","2021","2021",23.4,,
+"PATCANXO","N05B-Anxiolytics","MLLNCUMT","Million of national currency units","GRC","Greece","2022","2022",15.7,,
+"PATCANXO","N05B-Anxiolytics","MTMOTCMT","Million US$ at exchange rate","GRC","Greece","2010","2010",29.5,,
+"PATCANXO","N05B-Anxiolytics","MTMOTCMT","Million US$ at exchange rate","GRC","Greece","2011","2011",31.4,,
+"PATCANXO","N05B-Anxiolytics","MTMOTCMT","Million US$ at exchange rate","GRC","Greece","2012","2012",27.1,,
+"PATCANXO","N05B-Anxiolytics","MTMOTCMT","Million US$ at exchange rate","GRC","Greece","2013","2013",29,,
+"PATCANXO","N05B-Anxiolytics","MTMOTCMT","Million US$ at exchange rate","GRC","Greece","2014","2014",26.8,,
+"PATCANXO","N05B-Anxiolytics","MTMOTCMT","Million US$ at exchange rate","GRC","Greece","2015","2015",23,,
+"PATCANXO","N05B-Anxiolytics","MTMOTCMT","Million US$ at exchange rate","GRC","Greece","2016","2016",23.7,,
+"PATCANXO","N05B-Anxiolytics","MTMOTCMT","Million US$ at exchange rate","GRC","Greece","2017","2017",25.1,,
+"PATCANXO","N05B-Anxiolytics","MTMOTCMT","Million US$ at exchange rate","GRC","Greece","2018","2018",26.7,,
+"PATCANXO","N05B-Anxiolytics","MTMOTCMT","Million US$ at exchange rate","GRC","Greece","2019","2019",24.3,,
+"PATCANXO","N05B-Anxiolytics","MTMOTCMT","Million US$ at exchange rate","GRC","Greece","2020","2020",28.7,,
+"PATCANXO","N05B-Anxiolytics","MTMOTCMT","Million US$ at exchange rate","GRC","Greece","2021","2021",27.7,,
+"PATCANXO","N05B-Anxiolytics","MTMOTCMT","Million US$ at exchange rate","GRC","Greece","2022","2022",16.5,,
+"PATCANXO","N05B-Anxiolytics","MTMOPPMT","Million US$, purchasing power parity","GRC","Greece","2010","2010",30.8,,
+"PATCANXO","N05B-Anxiolytics","MTMOPPMT","Million US$, purchasing power parity","GRC","Greece","2011","2011",31.7,,
+"PATCANXO","N05B-Anxiolytics","MTMOPPMT","Million US$, purchasing power parity","GRC","Greece","2012","2012",30.8,,
+"PATCANXO","N05B-Anxiolytics","MTMOPPMT","Million US$, purchasing power parity","GRC","Greece","2013","2013",34.6,,
+"PATCANXO","N05B-Anxiolytics","MTMOPPMT","Million US$, purchasing power parity","GRC","Greece","2014","2014",33.1,,
+"PATCANXO","N05B-Anxiolytics","MTMOPPMT","Million US$, purchasing power parity","GRC","Greece","2015","2015",34,,
+"PATCANXO","N05B-Anxiolytics","MTMOPPMT","Million US$, purchasing power parity","GRC","Greece","2016","2016",36.4,,
+"PATCANXO","N05B-Anxiolytics","MTMOPPMT","Million US$, purchasing power parity","GRC","Greece","2017","2017",38.7,,
+"PATCANXO","N05B-Anxiolytics","MTMOPPMT","Million US$, purchasing power parity","GRC","Greece","2018","2018",40,,
+"PATCANXO","N05B-Anxiolytics","MTMOPPMT","Million US$, purchasing power parity","GRC","Greece","2019","2019",39.6,,
+"PATCANXO","N05B-Anxiolytics","MTMOPPMT","Million US$, purchasing power parity","GRC","Greece","2020","2020",46.2,,
+"PATCANXO","N05B-Anxiolytics","MTMOPPMT","Million US$, purchasing power parity","GRC","Greece","2021","2021",42.9,,
+"PATCANXO","N05B-Anxiolytics","MTMOPPMT","Million US$, purchasing power parity","GRC","Greece","2022","2022",29.7,,
+"PATCANXO","N05B-Anxiolytics","TCPPERMT","/capita, US$ exchange rate","GRC","Greece","2010","2010",2.7,,
+"PATCANXO","N05B-Anxiolytics","TCPPERMT","/capita, US$ exchange rate","GRC","Greece","2011","2011",2.8,,
+"PATCANXO","N05B-Anxiolytics","TCPPERMT","/capita, US$ exchange rate","GRC","Greece","2012","2012",2.5,,
+"PATCANXO","N05B-Anxiolytics","TCPPERMT","/capita, US$ exchange rate","GRC","Greece","2013","2013",2.6,,
+"PATCANXO","N05B-Anxiolytics","TCPPERMT","/capita, US$ exchange rate","GRC","Greece","2014","2014",2.5,,
+"PATCANXO","N05B-Anxiolytics","TCPPERMT","/capita, US$ exchange rate","GRC","Greece","2015","2015",2.1,,
+"PATCANXO","N05B-Anxiolytics","TCPPERMT","/capita, US$ exchange rate","GRC","Greece","2016","2016",2.2,,
+"PATCANXO","N05B-Anxiolytics","TCPPERMT","/capita, US$ exchange rate","GRC","Greece","2017","2017",2.3,,
+"PATCANXO","N05B-Anxiolytics","TCPPERMT","/capita, US$ exchange rate","GRC","Greece","2018","2018",2.5,,
+"PATCANXO","N05B-Anxiolytics","TCPPERMT","/capita, US$ exchange rate","GRC","Greece","2019","2019",2.3,,
+"PATCANXO","N05B-Anxiolytics","TCPPERMT","/capita, US$ exchange rate","GRC","Greece","2020","2020",2.7,,
+"PATCANXO","N05B-Anxiolytics","TCPPERMT","/capita, US$ exchange rate","GRC","Greece","2021","2021",2.6,,
+"PATCANXO","N05B-Anxiolytics","TCPPERMT","/capita, US$ exchange rate","GRC","Greece","2022","2022",1.6,,
+"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2010","2010",2.8,,
+"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2011","2011",2.9,,
+"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2012","2012",2.8,,
+"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2013","2013",3.2,,
+"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2014","2014",3,,
+"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2015","2015",3.1,,
+"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2016","2016",3.4,,
+"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2017","2017",3.6,,
+"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2018","2018",3.7,,
+"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2019","2019",3.7,,
+"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2020","2020",4.3,,
+"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2021","2021",4.1,,
+"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2022","2022",2.8,,
+"PATCANXO","N05B-Anxiolytics","MLLNCUMT","Million of national currency units","HUN","Hungary","2010","2010",2903.2,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","MLLNCUMT","Million of national currency units","HUN","Hungary","2011","2011",3057.1,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","MLLNCUMT","Million of national currency units","HUN","Hungary","2012","2012",2947,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","MLLNCUMT","Million of national currency units","HUN","Hungary","2013","2013",2974.6,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","MLLNCUMT","Million of national currency units","HUN","Hungary","2014","2014",2958.9,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","MLLNCUMT","Million of national currency units","HUN","Hungary","2015","2015",2888.3,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","MLLNCUMT","Million of national currency units","HUN","Hungary","2016","2016",2872.5,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","MLLNCUMT","Million of national currency units","HUN","Hungary","2017","2017",2831.3,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","MLLNCUMT","Million of national currency units","HUN","Hungary","2018","2018",2756.3,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","MLLNCUMT","Million of national currency units","HUN","Hungary","2019","2019",2709.2,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","MLLNCUMT","Million of national currency units","HUN","Hungary","2020","2020",2664.2,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","MLLNCUMT","Million of national currency units","HUN","Hungary","2021","2021",2500.5,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","MLLNCUMT","Million of national currency units","HUN","Hungary","2022","2022",2400.9,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","MTMOTCMT","Million US$ at exchange rate","HUN","Hungary","2010","2010",14,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","MTMOTCMT","Million US$ at exchange rate","HUN","Hungary","2011","2011",15.2,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","MTMOTCMT","Million US$ at exchange rate","HUN","Hungary","2012","2012",13.1,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","MTMOTCMT","Million US$ at exchange rate","HUN","Hungary","2013","2013",13.3,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","MTMOTCMT","Million US$ at exchange rate","HUN","Hungary","2014","2014",12.7,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","MTMOTCMT","Million US$ at exchange rate","HUN","Hungary","2015","2015",10.3,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","MTMOTCMT","Million US$ at exchange rate","HUN","Hungary","2016","2016",10.2,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","MTMOTCMT","Million US$ at exchange rate","HUN","Hungary","2017","2017",10.3,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","MTMOTCMT","Million US$ at exchange rate","HUN","Hungary","2018","2018",10.2,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","MTMOTCMT","Million US$ at exchange rate","HUN","Hungary","2019","2019",9.3,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","MTMOTCMT","Million US$ at exchange rate","HUN","Hungary","2020","2020",8.7,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","MTMOTCMT","Million US$ at exchange rate","HUN","Hungary","2021","2021",8.2,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","MTMOTCMT","Million US$ at exchange rate","HUN","Hungary","2022","2022",6.4,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","MTMOPPMT","Million US$, purchasing power parity","HUN","Hungary","2010","2010",23,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","MTMOPPMT","Million US$, purchasing power parity","HUN","Hungary","2011","2011",24.6,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","MTMOPPMT","Million US$, purchasing power parity","HUN","Hungary","2012","2012",23.5,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","MTMOPPMT","Million US$, purchasing power parity","HUN","Hungary","2013","2013",23.8,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","MTMOPPMT","Million US$, purchasing power parity","HUN","Hungary","2014","2014",22.9,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","MTMOPPMT","Million US$, purchasing power parity","HUN","Hungary","2015","2015",21.8,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","MTMOPPMT","Million US$, purchasing power parity","HUN","Hungary","2016","2016",21.8,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","MTMOPPMT","Million US$, purchasing power parity","HUN","Hungary","2017","2017",20.8,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","MTMOPPMT","Million US$, purchasing power parity","HUN","Hungary","2018","2018",19.8,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","MTMOPPMT","Million US$, purchasing power parity","HUN","Hungary","2019","2019",19.2,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","MTMOPPMT","Million US$, purchasing power parity","HUN","Hungary","2020","2020",18.3,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","MTMOPPMT","Million US$, purchasing power parity","HUN","Hungary","2021","2021",16.2,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","MTMOPPMT","Million US$, purchasing power parity","HUN","Hungary","2022","2022",14.9,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","TCPPERMT","/capita, US$ exchange rate","HUN","Hungary","2010","2010",1.4,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","TCPPERMT","/capita, US$ exchange rate","HUN","Hungary","2011","2011",1.5,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","TCPPERMT","/capita, US$ exchange rate","HUN","Hungary","2012","2012",1.3,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","TCPPERMT","/capita, US$ exchange rate","HUN","Hungary","2013","2013",1.3,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","TCPPERMT","/capita, US$ exchange rate","HUN","Hungary","2014","2014",1.3,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","TCPPERMT","/capita, US$ exchange rate","HUN","Hungary","2015","2015",1.1,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","TCPPERMT","/capita, US$ exchange rate","HUN","Hungary","2016","2016",1,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","TCPPERMT","/capita, US$ exchange rate","HUN","Hungary","2017","2017",1.1,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","TCPPERMT","/capita, US$ exchange rate","HUN","Hungary","2018","2018",1,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","TCPPERMT","/capita, US$ exchange rate","HUN","Hungary","2019","2019",1,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","TCPPERMT","/capita, US$ exchange rate","HUN","Hungary","2020","2020",0.9,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","TCPPERMT","/capita, US$ exchange rate","HUN","Hungary","2021","2021",0.8,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","TCPPERMT","/capita, US$ exchange rate","HUN","Hungary","2022","2022",0.7,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2010","2010",2.3,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2011","2011",2.5,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2012","2012",2.4,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2013","2013",2.4,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2014","2014",2.3,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2015","2015",2.2,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2016","2016",2.2,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2017","2017",2.1,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2018","2018",2,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2019","2019",2,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2020","2020",1.9,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2021","2021",1.7,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2022","2022",1.5,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","ATCPTTMT","% of total sales","HUN","Hungary","2010","2010",0.6,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","ATCPTTMT","% of total sales","HUN","Hungary","2011","2011",0.6,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","ATCPTTMT","% of total sales","HUN","Hungary","2012","2012",0.7,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","ATCPTTMT","% of total sales","HUN","Hungary","2013","2013",0.7,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","ATCPTTMT","% of total sales","HUN","Hungary","2014","2014",0.7,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","ATCPTTMT","% of total sales","HUN","Hungary","2015","2015",0.6,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","ATCPTTMT","% of total sales","HUN","Hungary","2016","2016",0.6,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","ATCPTTMT","% of total sales","HUN","Hungary","2017","2017",0.6,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","ATCPTTMT","% of total sales","HUN","Hungary","2018","2018",0.6,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","ATCPTTMT","% of total sales","HUN","Hungary","2019","2019",0.5,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","ATCPTTMT","% of total sales","HUN","Hungary","2020","2020",0.5,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","ATCPTTMT","% of total sales","HUN","Hungary","2021","2021",0.4,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","ATCPTTMT","% of total sales","HUN","Hungary","2022","2022",0.4,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","MLLNCUMT","Million of national currency units","ISL","Iceland","2010","2010",262.1,,
+"PATCANXO","N05B-Anxiolytics","MLLNCUMT","Million of national currency units","ISL","Iceland","2011","2011",214.7,,
+"PATCANXO","N05B-Anxiolytics","MLLNCUMT","Million of national currency units","ISL","Iceland","2012","2012",256.8,,
+"PATCANXO","N05B-Anxiolytics","MLLNCUMT","Million of national currency units","ISL","Iceland","2013","2013",270.4,,
+"PATCANXO","N05B-Anxiolytics","MLLNCUMT","Million of national currency units","ISL","Iceland","2014","2014",263.5,,
+"PATCANXO","N05B-Anxiolytics","MLLNCUMT","Million of national currency units","ISL","Iceland","2015","2015",268,,
+"PATCANXO","N05B-Anxiolytics","MLLNCUMT","Million of national currency units","ISL","Iceland","2016","2016",265.2,,
+"PATCANXO","N05B-Anxiolytics","MLLNCUMT","Million of national currency units","ISL","Iceland","2017","2017",276.7,,
+"PATCANXO","N05B-Anxiolytics","MLLNCUMT","Million of national currency units","ISL","Iceland","2018","2018",286,,
+"PATCANXO","N05B-Anxiolytics","MLLNCUMT","Million of national currency units","ISL","Iceland","2019","2019",282.1,,
+"PATCANXO","N05B-Anxiolytics","MLLNCUMT","Million of national currency units","ISL","Iceland","2020","2020",316.4,,
+"PATCANXO","N05B-Anxiolytics","MLLNCUMT","Million of national currency units","ISL","Iceland","2021","2021",345.4,,
+"PATCANXO","N05B-Anxiolytics","MTMOTCMT","Million US$ at exchange rate","ISL","Iceland","2010","2010",2.1,,
+"PATCANXO","N05B-Anxiolytics","MTMOTCMT","Million US$ at exchange rate","ISL","Iceland","2011","2011",1.9,,
+"PATCANXO","N05B-Anxiolytics","MTMOTCMT","Million US$ at exchange rate","ISL","Iceland","2012","2012",2.1,,
+"PATCANXO","N05B-Anxiolytics","MTMOTCMT","Million US$ at exchange rate","ISL","Iceland","2013","2013",2.2,,
+"PATCANXO","N05B-Anxiolytics","MTMOTCMT","Million US$ at exchange rate","ISL","Iceland","2014","2014",2.3,,
+"PATCANXO","N05B-Anxiolytics","MTMOTCMT","Million US$ at exchange rate","ISL","Iceland","2015","2015",2,,
+"PATCANXO","N05B-Anxiolytics","MTMOTCMT","Million US$ at exchange rate","ISL","Iceland","2016","2016",2.2,,
+"PATCANXO","N05B-Anxiolytics","MTMOTCMT","Million US$ at exchange rate","ISL","Iceland","2017","2017",2.6,,
+"PATCANXO","N05B-Anxiolytics","MTMOTCMT","Million US$ at exchange rate","ISL","Iceland","2018","2018",2.6,,
+"PATCANXO","N05B-Anxiolytics","MTMOTCMT","Million US$ at exchange rate","ISL","Iceland","2019","2019",2.3,,
+"PATCANXO","N05B-Anxiolytics","MTMOTCMT","Million US$ at exchange rate","ISL","Iceland","2020","2020",2.3,,
+"PATCANXO","N05B-Anxiolytics","MTMOTCMT","Million US$ at exchange rate","ISL","Iceland","2021","2021",2.7,,
+"PATCANXO","N05B-Anxiolytics","MTMOPPMT","Million US$, purchasing power parity","ISL","Iceland","2010","2010",2,,
+"PATCANXO","N05B-Anxiolytics","MTMOPPMT","Million US$, purchasing power parity","ISL","Iceland","2011","2011",1.6,,
+"PATCANXO","N05B-Anxiolytics","MTMOPPMT","Million US$, purchasing power parity","ISL","Iceland","2012","2012",1.9,,
+"PATCANXO","N05B-Anxiolytics","MTMOPPMT","Million US$, purchasing power parity","ISL","Iceland","2013","2013",2,,
+"PATCANXO","N05B-Anxiolytics","MTMOPPMT","Million US$, purchasing power parity","ISL","Iceland","2014","2014",1.9,,
+"PATCANXO","N05B-Anxiolytics","MTMOPPMT","Million US$, purchasing power parity","ISL","Iceland","2015","2015",1.9,,
+"PATCANXO","N05B-Anxiolytics","MTMOPPMT","Million US$, purchasing power parity","ISL","Iceland","2016","2016",1.9,,
+"PATCANXO","N05B-Anxiolytics","MTMOPPMT","Million US$, purchasing power parity","ISL","Iceland","2017","2017",2,,
+"PATCANXO","N05B-Anxiolytics","MTMOPPMT","Million US$, purchasing power parity","ISL","Iceland","2018","2018",2,,
+"PATCANXO","N05B-Anxiolytics","MTMOPPMT","Million US$, purchasing power parity","ISL","Iceland","2019","2019",2,,
+"PATCANXO","N05B-Anxiolytics","MTMOPPMT","Million US$, purchasing power parity","ISL","Iceland","2020","2020",2.2,,
+"PATCANXO","N05B-Anxiolytics","MTMOPPMT","Million US$, purchasing power parity","ISL","Iceland","2021","2021",2.3,,
+"PATCANXO","N05B-Anxiolytics","TCPPERMT","/capita, US$ exchange rate","ISL","Iceland","2010","2010",6.7,,
+"PATCANXO","N05B-Anxiolytics","TCPPERMT","/capita, US$ exchange rate","ISL","Iceland","2011","2011",5.8,,
+"PATCANXO","N05B-Anxiolytics","TCPPERMT","/capita, US$ exchange rate","ISL","Iceland","2012","2012",6.4,,
+"PATCANXO","N05B-Anxiolytics","TCPPERMT","/capita, US$ exchange rate","ISL","Iceland","2013","2013",6.8,,
+"PATCANXO","N05B-Anxiolytics","TCPPERMT","/capita, US$ exchange rate","ISL","Iceland","2014","2014",6.9,,
+"PATCANXO","N05B-Anxiolytics","TCPPERMT","/capita, US$ exchange rate","ISL","Iceland","2015","2015",6.1,,
+"PATCANXO","N05B-Anxiolytics","TCPPERMT","/capita, US$ exchange rate","ISL","Iceland","2016","2016",6.5,,
+"PATCANXO","N05B-Anxiolytics","TCPPERMT","/capita, US$ exchange rate","ISL","Iceland","2017","2017",7.5,,
+"PATCANXO","N05B-Anxiolytics","TCPPERMT","/capita, US$ exchange rate","ISL","Iceland","2018","2018",7.5,,
+"PATCANXO","N05B-Anxiolytics","TCPPERMT","/capita, US$ exchange rate","ISL","Iceland","2019","2019",6.4,,
+"PATCANXO","N05B-Anxiolytics","TCPPERMT","/capita, US$ exchange rate","ISL","Iceland","2020","2020",6.4,,
+"PATCANXO","N05B-Anxiolytics","TCPPERMT","/capita, US$ exchange rate","ISL","Iceland","2021","2021",7.3,,
+"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2010","2010",6.2,,
+"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2011","2011",5,,
+"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2012","2012",5.8,,
+"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2013","2013",6.1,,
+"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2014","2014",5.8,,
+"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2015","2015",5.7,,
+"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2016","2016",5.6,,
+"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2017","2017",5.8,,
+"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2018","2018",5.8,,
+"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2019","2019",5.6,,
+"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2020","2020",5.9,,
+"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2021","2021",6.2,,
+"PATCANXO","N05B-Anxiolytics","ATCPTTMT","% of total sales","ISL","Iceland","2010","2010",1,,
+"PATCANXO","N05B-Anxiolytics","ATCPTTMT","% of total sales","ISL","Iceland","2011","2011",0.8,,
+"PATCANXO","N05B-Anxiolytics","ATCPTTMT","% of total sales","ISL","Iceland","2012","2012",1.1,,
+"PATCANXO","N05B-Anxiolytics","ATCPTTMT","% of total sales","ISL","Iceland","2013","2013",1,,
+"PATCANXO","N05B-Anxiolytics","ATCPTTMT","% of total sales","ISL","Iceland","2014","2014",1.1,,
+"PATCANXO","N05B-Anxiolytics","ATCPTTMT","% of total sales","ISL","Iceland","2015","2015",1.1,,
+"PATCANXO","N05B-Anxiolytics","ATCPTTMT","% of total sales","ISL","Iceland","2016","2016",1,,
+"PATCANXO","N05B-Anxiolytics","ATCPTTMT","% of total sales","ISL","Iceland","2017","2017",1,,
+"PATCANXO","N05B-Anxiolytics","ATCPTTMT","% of total sales","ISL","Iceland","2018","2018",0.9,,
+"PATCANXO","N05B-Anxiolytics","ATCPTTMT","% of total sales","ISL","Iceland","2019","2019",0.8,,
+"PATCANXO","N05B-Anxiolytics","ATCPTTMT","% of total sales","ISL","Iceland","2020","2020",0.8,,
+"PATCANXO","N05B-Anxiolytics","ATCPTTMT","% of total sales","ISL","Iceland","2021","2021",0.8,,
+"PATCANXO","N05B-Anxiolytics","MLLNCUMT","Million of national currency units","IRL","Ireland","2010","2010",9.7,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","MLLNCUMT","Million of national currency units","IRL","Ireland","2011","2011",9.6,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","MLLNCUMT","Million of national currency units","IRL","Ireland","2012","2012",9.7,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","MLLNCUMT","Million of national currency units","IRL","Ireland","2013","2013",9.5,"B; D","Break; Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","MLLNCUMT","Million of national currency units","IRL","Ireland","2014","2014",9.3,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","MLLNCUMT","Million of national currency units","IRL","Ireland","2015","2015",9.4,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","MLLNCUMT","Million of national currency units","IRL","Ireland","2016","2016",9.3,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","MLLNCUMT","Million of national currency units","IRL","Ireland","2017","2017",9,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","MLLNCUMT","Million of national currency units","IRL","Ireland","2018","2018",8.7,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","MLLNCUMT","Million of national currency units","IRL","Ireland","2019","2019",8.6,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","MLLNCUMT","Million of national currency units","IRL","Ireland","2020","2020",8.5,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","MLLNCUMT","Million of national currency units","IRL","Ireland","2021","2021",8.6,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","MTMOTCMT","Million US$ at exchange rate","IRL","Ireland","2010","2010",12.9,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","MTMOTCMT","Million US$ at exchange rate","IRL","Ireland","2011","2011",13.4,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","MTMOTCMT","Million US$ at exchange rate","IRL","Ireland","2012","2012",12.5,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","MTMOTCMT","Million US$ at exchange rate","IRL","Ireland","2013","2013",12.6,"B; D","Break; Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","MTMOTCMT","Million US$ at exchange rate","IRL","Ireland","2014","2014",12.3,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","MTMOTCMT","Million US$ at exchange rate","IRL","Ireland","2015","2015",10.4,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","MTMOTCMT","Million US$ at exchange rate","IRL","Ireland","2016","2016",10.3,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","MTMOTCMT","Million US$ at exchange rate","IRL","Ireland","2017","2017",10.2,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","MTMOTCMT","Million US$ at exchange rate","IRL","Ireland","2018","2018",10.3,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","MTMOTCMT","Million US$ at exchange rate","IRL","Ireland","2019","2019",9.6,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","MTMOTCMT","Million US$ at exchange rate","IRL","Ireland","2020","2020",9.7,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","MTMOTCMT","Million US$ at exchange rate","IRL","Ireland","2021","2021",10.1,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","MTMOPPMT","Million US$, purchasing power parity","IRL","Ireland","2010","2010",11.5,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","MTMOPPMT","Million US$, purchasing power parity","IRL","Ireland","2011","2011",11.5,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","MTMOPPMT","Million US$, purchasing power parity","IRL","Ireland","2012","2012",11.8,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","MTMOPPMT","Million US$, purchasing power parity","IRL","Ireland","2013","2013",11.7,"B; D","Break; Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","MTMOPPMT","Million US$, purchasing power parity","IRL","Ireland","2014","2014",11.3,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","MTMOPPMT","Million US$, purchasing power parity","IRL","Ireland","2015","2015",11.6,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","MTMOPPMT","Million US$, purchasing power parity","IRL","Ireland","2016","2016",11.8,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","MTMOPPMT","Million US$, purchasing power parity","IRL","Ireland","2017","2017",11.3,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","MTMOPPMT","Million US$, purchasing power parity","IRL","Ireland","2018","2018",11,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","MTMOPPMT","Million US$, purchasing power parity","IRL","Ireland","2019","2019",10.7,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","MTMOPPMT","Million US$, purchasing power parity","IRL","Ireland","2020","2020",10.7,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","MTMOPPMT","Million US$, purchasing power parity","IRL","Ireland","2021","2021",10.8,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","TCPPERMT","/capita, US$ exchange rate","IRL","Ireland","2010","2010",2.8,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","TCPPERMT","/capita, US$ exchange rate","IRL","Ireland","2011","2011",2.9,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","TCPPERMT","/capita, US$ exchange rate","IRL","Ireland","2012","2012",2.7,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","TCPPERMT","/capita, US$ exchange rate","IRL","Ireland","2013","2013",2.7,"B; D","Break; Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","TCPPERMT","/capita, US$ exchange rate","IRL","Ireland","2014","2014",2.6,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","TCPPERMT","/capita, US$ exchange rate","IRL","Ireland","2015","2015",2.2,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","TCPPERMT","/capita, US$ exchange rate","IRL","Ireland","2016","2016",2.2,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","TCPPERMT","/capita, US$ exchange rate","IRL","Ireland","2017","2017",2.1,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","TCPPERMT","/capita, US$ exchange rate","IRL","Ireland","2018","2018",2.1,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","TCPPERMT","/capita, US$ exchange rate","IRL","Ireland","2019","2019",1.9,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","TCPPERMT","/capita, US$ exchange rate","IRL","Ireland","2020","2020",1.9,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","TCPPERMT","/capita, US$ exchange rate","IRL","Ireland","2021","2021",2,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2010","2010",2.5,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2011","2011",2.5,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2012","2012",2.6,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2013","2013",2.5,"B; D","Break; Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2014","2014",2.4,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2015","2015",2.5,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2016","2016",2.5,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2017","2017",2.4,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2018","2018",2.3,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2019","2019",2.2,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2020","2020",2.1,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2021","2021",2.1,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","ATCPTTMT","% of total sales","IRL","Ireland","2010","2010",0.5,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","ATCPTTMT","% of total sales","IRL","Ireland","2011","2011",0.5,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","ATCPTTMT","% of total sales","IRL","Ireland","2012","2012",0.5,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","ATCPTTMT","% of total sales","IRL","Ireland","2013","2013",0.5,"B; D","Break; Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","ATCPTTMT","% of total sales","IRL","Ireland","2014","2014",0.5,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","ATCPTTMT","% of total sales","IRL","Ireland","2015","2015",0.5,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","ATCPTTMT","% of total sales","IRL","Ireland","2016","2016",0.4,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","ATCPTTMT","% of total sales","IRL","Ireland","2017","2017",0.4,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","ATCPTTMT","% of total sales","IRL","Ireland","2018","2018",0.4,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","ATCPTTMT","% of total sales","IRL","Ireland","2019","2019",0.4,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","ATCPTTMT","% of total sales","IRL","Ireland","2020","2020",0.3,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","ATCPTTMT","% of total sales","IRL","Ireland","2021","2021",0.3,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","MLLNCUMT","Million of national currency units","ITA","Italy","2011","2011",3.7,,
+"PATCANXO","N05B-Anxiolytics","MLLNCUMT","Million of national currency units","ITA","Italy","2012","2012",3.9,,
+"PATCANXO","N05B-Anxiolytics","MLLNCUMT","Million of national currency units","ITA","Italy","2013","2013",4,,
+"PATCANXO","N05B-Anxiolytics","MLLNCUMT","Million of national currency units","ITA","Italy","2014","2014",3.5,,
+"PATCANXO","N05B-Anxiolytics","MLLNCUMT","Million of national currency units","ITA","Italy","2015","2015",3,,
+"PATCANXO","N05B-Anxiolytics","MLLNCUMT","Million of national currency units","ITA","Italy","2016","2016",3,,
+"PATCANXO","N05B-Anxiolytics","MLLNCUMT","Million of national currency units","ITA","Italy","2017","2017",3.3,,
+"PATCANXO","N05B-Anxiolytics","MLLNCUMT","Million of national currency units","ITA","Italy","2018","2018",3.2,,
+"PATCANXO","N05B-Anxiolytics","MLLNCUMT","Million of national currency units","ITA","Italy","2019","2019",3.5,,
+"PATCANXO","N05B-Anxiolytics","MLLNCUMT","Million of national currency units","ITA","Italy","2020","2020",3.8,,
+"PATCANXO","N05B-Anxiolytics","MLLNCUMT","Million of national currency units","ITA","Italy","2021","2021",4,,
+"PATCANXO","N05B-Anxiolytics","MLLNCUMT","Million of national currency units","ITA","Italy","2022","2022",4.5,"E","Estimated value"
+"PATCANXO","N05B-Anxiolytics","MTMOTCMT","Million US$ at exchange rate","ITA","Italy","2011","2011",5.1,,
+"PATCANXO","N05B-Anxiolytics","MTMOTCMT","Million US$ at exchange rate","ITA","Italy","2012","2012",5,,
+"PATCANXO","N05B-Anxiolytics","MTMOTCMT","Million US$ at exchange rate","ITA","Italy","2013","2013",5.3,,
+"PATCANXO","N05B-Anxiolytics","MTMOTCMT","Million US$ at exchange rate","ITA","Italy","2014","2014",4.7,,
+"PATCANXO","N05B-Anxiolytics","MTMOTCMT","Million US$ at exchange rate","ITA","Italy","2015","2015",3.4,,
+"PATCANXO","N05B-Anxiolytics","MTMOTCMT","Million US$ at exchange rate","ITA","Italy","2016","2016",3.4,,
+"PATCANXO","N05B-Anxiolytics","MTMOTCMT","Million US$ at exchange rate","ITA","Italy","2017","2017",3.7,,
+"PATCANXO","N05B-Anxiolytics","MTMOTCMT","Million US$ at exchange rate","ITA","Italy","2018","2018",3.8,,
+"PATCANXO","N05B-Anxiolytics","MTMOTCMT","Million US$ at exchange rate","ITA","Italy","2019","2019",3.9,,
+"PATCANXO","N05B-Anxiolytics","MTMOTCMT","Million US$ at exchange rate","ITA","Italy","2020","2020",4.3,,
+"PATCANXO","N05B-Anxiolytics","MTMOTCMT","Million US$ at exchange rate","ITA","Italy","2021","2021",4.7,,
+"PATCANXO","N05B-Anxiolytics","MTMOTCMT","Million US$ at exchange rate","ITA","Italy","2022","2022",4.8,"E","Estimated value"
+"PATCANXO","N05B-Anxiolytics","MTMOPPMT","Million US$, purchasing power parity","ITA","Italy","2011","2011",4.8,,
+"PATCANXO","N05B-Anxiolytics","MTMOPPMT","Million US$, purchasing power parity","ITA","Italy","2012","2012",5.2,,
+"PATCANXO","N05B-Anxiolytics","MTMOPPMT","Million US$, purchasing power parity","ITA","Italy","2013","2013",5.4,,
+"PATCANXO","N05B-Anxiolytics","MTMOPPMT","Million US$, purchasing power parity","ITA","Italy","2014","2014",4.7,,
+"PATCANXO","N05B-Anxiolytics","MTMOPPMT","Million US$, purchasing power parity","ITA","Italy","2015","2015",4.1,,
+"PATCANXO","N05B-Anxiolytics","MTMOPPMT","Million US$, purchasing power parity","ITA","Italy","2016","2016",4.3,,
+"PATCANXO","N05B-Anxiolytics","MTMOPPMT","Million US$, purchasing power parity","ITA","Italy","2017","2017",4.8,,
+"PATCANXO","N05B-Anxiolytics","MTMOPPMT","Million US$, purchasing power parity","ITA","Italy","2018","2018",4.8,,
+"PATCANXO","N05B-Anxiolytics","MTMOPPMT","Million US$, purchasing power parity","ITA","Italy","2019","2019",5.3,,
+"PATCANXO","N05B-Anxiolytics","MTMOPPMT","Million US$, purchasing power parity","ITA","Italy","2020","2020",5.8,,
+"PATCANXO","N05B-Anxiolytics","MTMOPPMT","Million US$, purchasing power parity","ITA","Italy","2021","2021",6.1,,
+"PATCANXO","N05B-Anxiolytics","MTMOPPMT","Million US$, purchasing power parity","ITA","Italy","2022","2022",7.4,"E","Estimated value"
+"PATCANXO","N05B-Anxiolytics","TCPPERMT","/capita, US$ exchange rate","ITA","Italy","2011","2011",0.1,,
+"PATCANXO","N05B-Anxiolytics","TCPPERMT","/capita, US$ exchange rate","ITA","Italy","2012","2012",0.1,,
+"PATCANXO","N05B-Anxiolytics","TCPPERMT","/capita, US$ exchange rate","ITA","Italy","2013","2013",0.1,,
+"PATCANXO","N05B-Anxiolytics","TCPPERMT","/capita, US$ exchange rate","ITA","Italy","2014","2014",0.1,,
+"PATCANXO","N05B-Anxiolytics","TCPPERMT","/capita, US$ exchange rate","ITA","Italy","2015","2015",0.1,,
+"PATCANXO","N05B-Anxiolytics","TCPPERMT","/capita, US$ exchange rate","ITA","Italy","2016","2016",0.1,,
+"PATCANXO","N05B-Anxiolytics","TCPPERMT","/capita, US$ exchange rate","ITA","Italy","2017","2017",0.1,,
+"PATCANXO","N05B-Anxiolytics","TCPPERMT","/capita, US$ exchange rate","ITA","Italy","2018","2018",0.1,,
+"PATCANXO","N05B-Anxiolytics","TCPPERMT","/capita, US$ exchange rate","ITA","Italy","2019","2019",0.1,,
+"PATCANXO","N05B-Anxiolytics","TCPPERMT","/capita, US$ exchange rate","ITA","Italy","2020","2020",0.1,,
+"PATCANXO","N05B-Anxiolytics","TCPPERMT","/capita, US$ exchange rate","ITA","Italy","2021","2021",0.1,,
+"PATCANXO","N05B-Anxiolytics","TCPPERMT","/capita, US$ exchange rate","ITA","Italy","2022","2022",0.1,"E","Estimated value"
+"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2011","2011",0.1,,
+"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2012","2012",0.1,,
+"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2013","2013",0.1,,
+"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2014","2014",0.1,,
+"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2015","2015",0.1,,
+"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2016","2016",0.1,,
+"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2017","2017",0.1,,
+"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2018","2018",0.1,,
+"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2019","2019",0.1,,
+"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2020","2020",0.1,,
+"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2021","2021",0.1,,
+"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2022","2022",0.1,"E","Estimated value"
+"PATCANXO","N05B-Anxiolytics","ATCPTTMT","% of total sales","ITA","Italy","2011","2011",0,,
+"PATCANXO","N05B-Anxiolytics","ATCPTTMT","% of total sales","ITA","Italy","2012","2012",0,,
+"PATCANXO","N05B-Anxiolytics","ATCPTTMT","% of total sales","ITA","Italy","2013","2013",0,,
+"PATCANXO","N05B-Anxiolytics","ATCPTTMT","% of total sales","ITA","Italy","2014","2014",0,,
+"PATCANXO","N05B-Anxiolytics","ATCPTTMT","% of total sales","ITA","Italy","2015","2015",0,,
+"PATCANXO","N05B-Anxiolytics","ATCPTTMT","% of total sales","ITA","Italy","2016","2016",0,,
+"PATCANXO","N05B-Anxiolytics","ATCPTTMT","% of total sales","ITA","Italy","2017","2017",0,,
+"PATCANXO","N05B-Anxiolytics","ATCPTTMT","% of total sales","ITA","Italy","2018","2018",0,,
+"PATCANXO","N05B-Anxiolytics","ATCPTTMT","% of total sales","ITA","Italy","2019","2019",0,,
+"PATCANXO","N05B-Anxiolytics","ATCPTTMT","% of total sales","ITA","Italy","2020","2020",0,,
+"PATCANXO","N05B-Anxiolytics","ATCPTTMT","% of total sales","ITA","Italy","2021","2021",0,,
+"PATCANXO","N05B-Anxiolytics","ATCPTTMT","% of total sales","ITA","Italy","2022","2022",0,"E","Estimated value"
+"PATCANXO","N05B-Anxiolytics","MLLNCUMT","Million of national currency units","KOR","Korea","2010","2010",70183,,
+"PATCANXO","N05B-Anxiolytics","MLLNCUMT","Million of national currency units","KOR","Korea","2011","2011",69662.7,"B","Break"
+"PATCANXO","N05B-Anxiolytics","MLLNCUMT","Million of national currency units","KOR","Korea","2012","2012",65916.3,,
+"PATCANXO","N05B-Anxiolytics","MLLNCUMT","Million of national currency units","KOR","Korea","2013","2013",63671.3,,
+"PATCANXO","N05B-Anxiolytics","MLLNCUMT","Million of national currency units","KOR","Korea","2014","2014",63182.8,,
+"PATCANXO","N05B-Anxiolytics","MLLNCUMT","Million of national currency units","KOR","Korea","2015","2015",63755.3,,
+"PATCANXO","N05B-Anxiolytics","MLLNCUMT","Million of national currency units","KOR","Korea","2016","2016",59216.6,"B","Break"
+"PATCANXO","N05B-Anxiolytics","MLLNCUMT","Million of national currency units","KOR","Korea","2017","2017",59332.7,,
+"PATCANXO","N05B-Anxiolytics","MLLNCUMT","Million of national currency units","KOR","Korea","2018","2018",60670.3,,
+"PATCANXO","N05B-Anxiolytics","MLLNCUMT","Million of national currency units","KOR","Korea","2019","2019",61587.3,,
+"PATCANXO","N05B-Anxiolytics","MLLNCUMT","Million of national currency units","KOR","Korea","2020","2020",65347.9,,
+"PATCANXO","N05B-Anxiolytics","MLLNCUMT","Million of national currency units","KOR","Korea","2021","2021",68390.5,,
+"PATCANXO","N05B-Anxiolytics","MTMOTCMT","Million US$ at exchange rate","KOR","Korea","2010","2010",60.7,,
+"PATCANXO","N05B-Anxiolytics","MTMOTCMT","Million US$ at exchange rate","KOR","Korea","2011","2011",62.9,"B","Break"
+"PATCANXO","N05B-Anxiolytics","MTMOTCMT","Million US$ at exchange rate","KOR","Korea","2012","2012",58.5,,
+"PATCANXO","N05B-Anxiolytics","MTMOTCMT","Million US$ at exchange rate","KOR","Korea","2013","2013",58.1,,
+"PATCANXO","N05B-Anxiolytics","MTMOTCMT","Million US$ at exchange rate","KOR","Korea","2014","2014",60,,
+"PATCANXO","N05B-Anxiolytics","MTMOTCMT","Million US$ at exchange rate","KOR","Korea","2015","2015",56.4,,
+"PATCANXO","N05B-Anxiolytics","MTMOTCMT","Million US$ at exchange rate","KOR","Korea","2016","2016",51,"B","Break"
+"PATCANXO","N05B-Anxiolytics","MTMOTCMT","Million US$ at exchange rate","KOR","Korea","2017","2017",52.5,,
+"PATCANXO","N05B-Anxiolytics","MTMOTCMT","Million US$ at exchange rate","KOR","Korea","2018","2018",55.1,,
+"PATCANXO","N05B-Anxiolytics","MTMOTCMT","Million US$ at exchange rate","KOR","Korea","2019","2019",52.8,,
+"PATCANXO","N05B-Anxiolytics","MTMOTCMT","Million US$ at exchange rate","KOR","Korea","2020","2020",55.4,,
+"PATCANXO","N05B-Anxiolytics","MTMOTCMT","Million US$ at exchange rate","KOR","Korea","2021","2021",59.8,,
+"PATCANXO","N05B-Anxiolytics","MTMOPPMT","Million US$, purchasing power parity","KOR","Korea","2010","2010",83.5,,
+"PATCANXO","N05B-Anxiolytics","MTMOPPMT","Million US$, purchasing power parity","KOR","Korea","2011","2011",81.5,"B","Break"
+"PATCANXO","N05B-Anxiolytics","MTMOPPMT","Million US$, purchasing power parity","KOR","Korea","2012","2012",77.1,,
+"PATCANXO","N05B-Anxiolytics","MTMOPPMT","Million US$, purchasing power parity","KOR","Korea","2013","2013",73.3,,
+"PATCANXO","N05B-Anxiolytics","MTMOPPMT","Million US$, purchasing power parity","KOR","Korea","2014","2014",72.5,,
+"PATCANXO","N05B-Anxiolytics","MTMOPPMT","Million US$, purchasing power parity","KOR","Korea","2015","2015",74.4,,
+"PATCANXO","N05B-Anxiolytics","MTMOPPMT","Million US$, purchasing power parity","KOR","Korea","2016","2016",69,"B","Break"
+"PATCANXO","N05B-Anxiolytics","MTMOPPMT","Million US$, purchasing power parity","KOR","Korea","2017","2017",68,,
+"PATCANXO","N05B-Anxiolytics","MTMOPPMT","Million US$, purchasing power parity","KOR","Korea","2018","2018",71,,
+"PATCANXO","N05B-Anxiolytics","MTMOPPMT","Million US$, purchasing power parity","KOR","Korea","2019","2019",71.9,,
+"PATCANXO","N05B-Anxiolytics","MTMOPPMT","Million US$, purchasing power parity","KOR","Korea","2020","2020",78,,
+"PATCANXO","N05B-Anxiolytics","MTMOPPMT","Million US$, purchasing power parity","KOR","Korea","2021","2021",80.1,,
+"PATCANXO","N05B-Anxiolytics","TCPPERMT","/capita, US$ exchange rate","KOR","Korea","2010","2010",1.2,,
+"PATCANXO","N05B-Anxiolytics","TCPPERMT","/capita, US$ exchange rate","KOR","Korea","2011","2011",1.3,"B","Break"
+"PATCANXO","N05B-Anxiolytics","TCPPERMT","/capita, US$ exchange rate","KOR","Korea","2012","2012",1.2,,
+"PATCANXO","N05B-Anxiolytics","TCPPERMT","/capita, US$ exchange rate","KOR","Korea","2013","2013",1.2,,
+"PATCANXO","N05B-Anxiolytics","TCPPERMT","/capita, US$ exchange rate","KOR","Korea","2014","2014",1.2,,
+"PATCANXO","N05B-Anxiolytics","TCPPERMT","/capita, US$ exchange rate","KOR","Korea","2015","2015",1.1,,
+"PATCANXO","N05B-Anxiolytics","TCPPERMT","/capita, US$ exchange rate","KOR","Korea","2016","2016",1,"B","Break"
+"PATCANXO","N05B-Anxiolytics","TCPPERMT","/capita, US$ exchange rate","KOR","Korea","2017","2017",1,,
+"PATCANXO","N05B-Anxiolytics","TCPPERMT","/capita, US$ exchange rate","KOR","Korea","2018","2018",1.1,,
+"PATCANXO","N05B-Anxiolytics","TCPPERMT","/capita, US$ exchange rate","KOR","Korea","2019","2019",1,,
+"PATCANXO","N05B-Anxiolytics","TCPPERMT","/capita, US$ exchange rate","KOR","Korea","2020","2020",1.1,,
+"PATCANXO","N05B-Anxiolytics","TCPPERMT","/capita, US$ exchange rate","KOR","Korea","2021","2021",1.2,,
+"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2010","2010",1.7,,
+"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2011","2011",1.6,"B","Break"
+"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2012","2012",1.5,,
+"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2013","2013",1.5,,
+"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2014","2014",1.4,,
+"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2015","2015",1.5,,
+"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2016","2016",1.3,"B","Break"
+"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2017","2017",1.3,,
+"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2018","2018",1.4,,
+"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2019","2019",1.4,,
+"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2020","2020",1.5,,
+"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2021","2021",1.5,,
+"PATCANXO","N05B-Anxiolytics","ATCPTTMT","% of total sales","KOR","Korea","2010","2010",0.3,,
+"PATCANXO","N05B-Anxiolytics","ATCPTTMT","% of total sales","KOR","Korea","2011","2011",0.3,"B","Break"
+"PATCANXO","N05B-Anxiolytics","ATCPTTMT","% of total sales","KOR","Korea","2012","2012",0.3,,
+"PATCANXO","N05B-Anxiolytics","ATCPTTMT","% of total sales","KOR","Korea","2013","2013",0.3,,
+"PATCANXO","N05B-Anxiolytics","ATCPTTMT","% of total sales","KOR","Korea","2014","2014",0.3,,
+"PATCANXO","N05B-Anxiolytics","ATCPTTMT","% of total sales","KOR","Korea","2015","2015",0.3,,
+"PATCANXO","N05B-Anxiolytics","ATCPTTMT","% of total sales","KOR","Korea","2016","2016",0.2,"B","Break"
+"PATCANXO","N05B-Anxiolytics","ATCPTTMT","% of total sales","KOR","Korea","2017","2017",0.2,,
+"PATCANXO","N05B-Anxiolytics","ATCPTTMT","% of total sales","KOR","Korea","2018","2018",0.2,,
+"PATCANXO","N05B-Anxiolytics","ATCPTTMT","% of total sales","KOR","Korea","2019","2019",0.2,,
+"PATCANXO","N05B-Anxiolytics","ATCPTTMT","% of total sales","KOR","Korea","2020","2020",0.2,,
+"PATCANXO","N05B-Anxiolytics","ATCPTTMT","% of total sales","KOR","Korea","2021","2021",0.2,,
+"PATCANXO","N05B-Anxiolytics","MLLNCUMT","Million of national currency units","LUX","Luxembourg","2010","2010",2.4,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","MLLNCUMT","Million of national currency units","LUX","Luxembourg","2011","2011",2.4,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","MLLNCUMT","Million of national currency units","LUX","Luxembourg","2012","2012",2.3,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","MLLNCUMT","Million of national currency units","LUX","Luxembourg","2013","2013",2.3,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","MLLNCUMT","Million of national currency units","LUX","Luxembourg","2014","2014",2.4,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","MLLNCUMT","Million of national currency units","LUX","Luxembourg","2015","2015",2.4,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","MLLNCUMT","Million of national currency units","LUX","Luxembourg","2016","2016",2.5,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","MLLNCUMT","Million of national currency units","LUX","Luxembourg","2017","2017",2.6,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","MLLNCUMT","Million of national currency units","LUX","Luxembourg","2018","2018",2.5,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","MLLNCUMT","Million of national currency units","LUX","Luxembourg","2019","2019",2.5,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","MLLNCUMT","Million of national currency units","LUX","Luxembourg","2020","2020",2.5,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","MLLNCUMT","Million of national currency units","LUX","Luxembourg","2021","2021",2.5,"B; D; P","Break; Difference in methodology; Provisional value"
+"PATCANXO","N05B-Anxiolytics","MLLNCUMT","Million of national currency units","LUX","Luxembourg","2022","2022",2.3,"D; P","Difference in methodology; Provisional value"
+"PATCANXO","N05B-Anxiolytics","MTMOTCMT","Million US$ at exchange rate","LUX","Luxembourg","2010","2010",3.2,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","MTMOTCMT","Million US$ at exchange rate","LUX","Luxembourg","2011","2011",3.3,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","MTMOTCMT","Million US$ at exchange rate","LUX","Luxembourg","2012","2012",3,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","MTMOTCMT","Million US$ at exchange rate","LUX","Luxembourg","2013","2013",3.1,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","MTMOTCMT","Million US$ at exchange rate","LUX","Luxembourg","2014","2014",3.2,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","MTMOTCMT","Million US$ at exchange rate","LUX","Luxembourg","2015","2015",2.7,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","MTMOTCMT","Million US$ at exchange rate","LUX","Luxembourg","2016","2016",2.8,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","MTMOTCMT","Million US$ at exchange rate","LUX","Luxembourg","2017","2017",2.9,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","MTMOTCMT","Million US$ at exchange rate","LUX","Luxembourg","2018","2018",3,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","MTMOTCMT","Million US$ at exchange rate","LUX","Luxembourg","2019","2019",2.8,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","MTMOTCMT","Million US$ at exchange rate","LUX","Luxembourg","2020","2020",2.9,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","MTMOTCMT","Million US$ at exchange rate","LUX","Luxembourg","2021","2021",2.9,"B; D; P","Break; Difference in methodology; Provisional value"
+"PATCANXO","N05B-Anxiolytics","MTMOTCMT","Million US$ at exchange rate","LUX","Luxembourg","2022","2022",2.4,"D; P","Difference in methodology; Provisional value"
+"PATCANXO","N05B-Anxiolytics","MTMOPPMT","Million US$, purchasing power parity","LUX","Luxembourg","2010","2010",2.6,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","MTMOPPMT","Million US$, purchasing power parity","LUX","Luxembourg","2011","2011",2.6,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","MTMOPPMT","Million US$, purchasing power parity","LUX","Luxembourg","2012","2012",2.6,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","MTMOPPMT","Million US$, purchasing power parity","LUX","Luxembourg","2013","2013",2.6,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","MTMOPPMT","Million US$, purchasing power parity","LUX","Luxembourg","2014","2014",2.7,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","MTMOPPMT","Million US$, purchasing power parity","LUX","Luxembourg","2015","2015",2.7,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","MTMOPPMT","Million US$, purchasing power parity","LUX","Luxembourg","2016","2016",2.9,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","MTMOPPMT","Million US$, purchasing power parity","LUX","Luxembourg","2017","2017",3,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","MTMOPPMT","Million US$, purchasing power parity","LUX","Luxembourg","2018","2018",3,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","MTMOPPMT","Million US$, purchasing power parity","LUX","Luxembourg","2019","2019",3,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","MTMOPPMT","Million US$, purchasing power parity","LUX","Luxembourg","2020","2020",2.9,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","MTMOPPMT","Million US$, purchasing power parity","LUX","Luxembourg","2021","2021",2.9,"B; D; P","Break; Difference in methodology; Provisional value"
+"PATCANXO","N05B-Anxiolytics","MTMOPPMT","Million US$, purchasing power parity","LUX","Luxembourg","2022","2022",2.8,"D; P","Difference in methodology; Provisional value"
+"PATCANXO","N05B-Anxiolytics","TCPPERMT","/capita, US$ exchange rate","LUX","Luxembourg","2010","2010",6.7,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","TCPPERMT","/capita, US$ exchange rate","LUX","Luxembourg","2011","2011",6.9,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","TCPPERMT","/capita, US$ exchange rate","LUX","Luxembourg","2012","2012",6.1,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","TCPPERMT","/capita, US$ exchange rate","LUX","Luxembourg","2013","2013",6.2,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","TCPPERMT","/capita, US$ exchange rate","LUX","Luxembourg","2014","2014",6.2,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","TCPPERMT","/capita, US$ exchange rate","LUX","Luxembourg","2015","2015",5.1,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","TCPPERMT","/capita, US$ exchange rate","LUX","Luxembourg","2016","2016",5.2,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","TCPPERMT","/capita, US$ exchange rate","LUX","Luxembourg","2017","2017",5.4,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","TCPPERMT","/capita, US$ exchange rate","LUX","Luxembourg","2018","2018",5.5,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","TCPPERMT","/capita, US$ exchange rate","LUX","Luxembourg","2019","2019",5,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","TCPPERMT","/capita, US$ exchange rate","LUX","Luxembourg","2020","2020",5.1,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","TCPPERMT","/capita, US$ exchange rate","LUX","Luxembourg","2021","2021",5,"B; D; P","Break; Difference in methodology; Provisional value"
+"PATCANXO","N05B-Anxiolytics","TCPPERMT","/capita, US$ exchange rate","LUX","Luxembourg","2022","2022",4.1,"D; P","Difference in methodology; Provisional value"
+"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2010","2010",5.5,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2011","2011",5.5,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2012","2012",5.2,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2013","2013",5.2,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2014","2014",5.3,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2015","2015",5.2,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2016","2016",5.5,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2017","2017",5.6,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2018","2018",5.4,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2019","2019",5.3,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2020","2020",5.2,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2021","2021",5,"B; D; P","Break; Difference in methodology; Provisional value"
+"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2022","2022",4.7,"D; P","Difference in methodology; Provisional value"
+"PATCANXO","N05B-Anxiolytics","ATCPTTMT","% of total sales","LUX","Luxembourg","2010","2010",1.3,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","ATCPTTMT","% of total sales","LUX","Luxembourg","2011","2011",1.3,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","ATCPTTMT","% of total sales","LUX","Luxembourg","2012","2012",1.2,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","ATCPTTMT","% of total sales","LUX","Luxembourg","2013","2013",1.2,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","ATCPTTMT","% of total sales","LUX","Luxembourg","2014","2014",1.2,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","ATCPTTMT","% of total sales","LUX","Luxembourg","2015","2015",1.2,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","ATCPTTMT","% of total sales","LUX","Luxembourg","2016","2016",1.3,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","ATCPTTMT","% of total sales","LUX","Luxembourg","2017","2017",1.3,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","ATCPTTMT","% of total sales","LUX","Luxembourg","2018","2018",1.3,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","ATCPTTMT","% of total sales","LUX","Luxembourg","2019","2019",1.2,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","ATCPTTMT","% of total sales","LUX","Luxembourg","2020","2020",1.2,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","ATCPTTMT","% of total sales","LUX","Luxembourg","2021","2021",1,"B; D; P","Break; Difference in methodology; Provisional value"
+"PATCANXO","N05B-Anxiolytics","ATCPTTMT","% of total sales","LUX","Luxembourg","2022","2022",0.9,"D; P","Difference in methodology; Provisional value"
+"PATCANXO","N05B-Anxiolytics","MLLNCUMT","Million of national currency units","NLD","Netherlands","2010","2010",21.3,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","MLLNCUMT","Million of national currency units","NLD","Netherlands","2011","2011",20.3,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","MLLNCUMT","Million of national currency units","NLD","Netherlands","2012","2012",19.6,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","MLLNCUMT","Million of national currency units","NLD","Netherlands","2013","2013",20.1,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","MLLNCUMT","Million of national currency units","NLD","Netherlands","2014","2014",20.4,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","MTMOTCMT","Million US$ at exchange rate","NLD","Netherlands","2010","2010",28.3,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","MTMOTCMT","Million US$ at exchange rate","NLD","Netherlands","2011","2011",28.3,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","MTMOTCMT","Million US$ at exchange rate","NLD","Netherlands","2012","2012",25.1,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","MTMOTCMT","Million US$ at exchange rate","NLD","Netherlands","2013","2013",26.7,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","MTMOTCMT","Million US$ at exchange rate","NLD","Netherlands","2014","2014",27.1,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","MTMOPPMT","Million US$, purchasing power parity","NLD","Netherlands","2010","2010",25,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","MTMOPPMT","Million US$, purchasing power parity","NLD","Netherlands","2011","2011",24.3,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","MTMOPPMT","Million US$, purchasing power parity","NLD","Netherlands","2012","2012",23.7,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","MTMOPPMT","Million US$, purchasing power parity","NLD","Netherlands","2013","2013",25.2,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","MTMOPPMT","Million US$, purchasing power parity","NLD","Netherlands","2014","2014",25.2,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","TCPPERMT","/capita, US$ exchange rate","NLD","Netherlands","2010","2010",1.7,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","TCPPERMT","/capita, US$ exchange rate","NLD","Netherlands","2011","2011",1.7,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","TCPPERMT","/capita, US$ exchange rate","NLD","Netherlands","2012","2012",1.5,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","TCPPERMT","/capita, US$ exchange rate","NLD","Netherlands","2013","2013",1.6,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","TCPPERMT","/capita, US$ exchange rate","NLD","Netherlands","2014","2014",1.6,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","NLD","Netherlands","2010","2010",1.5,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","NLD","Netherlands","2011","2011",1.5,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","NLD","Netherlands","2012","2012",1.4,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","NLD","Netherlands","2013","2013",1.5,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","NLD","Netherlands","2014","2014",1.5,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","ATCPTTMT","% of total sales","NLD","Netherlands","2010","2010",0.4,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","ATCPTTMT","% of total sales","NLD","Netherlands","2011","2011",0.4,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","ATCPTTMT","% of total sales","NLD","Netherlands","2012","2012",0.4,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","ATCPTTMT","% of total sales","NLD","Netherlands","2013","2013",0.5,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","ATCPTTMT","% of total sales","NLD","Netherlands","2014","2014",0.5,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","MLLNCUMT","Million of national currency units","NZL","New Zealand","2010","2010",0.9,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","MLLNCUMT","Million of national currency units","NZL","New Zealand","2011","2011",1.2,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","MLLNCUMT","Million of national currency units","NZL","New Zealand","2012","2012",1.3,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","MLLNCUMT","Million of national currency units","NZL","New Zealand","2013","2013",1.2,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","MLLNCUMT","Million of national currency units","NZL","New Zealand","2014","2014",1.3,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","MLLNCUMT","Million of national currency units","NZL","New Zealand","2015","2015",2.5,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","MLLNCUMT","Million of national currency units","NZL","New Zealand","2016","2016",2.7,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","MLLNCUMT","Million of national currency units","NZL","New Zealand","2017","2017",1.2,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","MLLNCUMT","Million of national currency units","NZL","New Zealand","2018","2018",1.4,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","MLLNCUMT","Million of national currency units","NZL","New Zealand","2019","2019",1.5,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","MLLNCUMT","Million of national currency units","NZL","New Zealand","2020","2020",1.3,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","MLLNCUMT","Million of national currency units","NZL","New Zealand","2021","2021",2,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","MLLNCUMT","Million of national currency units","NZL","New Zealand","2022","2022",2.1,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","MTMOTCMT","Million US$ at exchange rate","NZL","New Zealand","2010","2010",0.6,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","MTMOTCMT","Million US$ at exchange rate","NZL","New Zealand","2011","2011",0.9,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","MTMOTCMT","Million US$ at exchange rate","NZL","New Zealand","2012","2012",1,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","MTMOTCMT","Million US$ at exchange rate","NZL","New Zealand","2013","2013",1,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","MTMOTCMT","Million US$ at exchange rate","NZL","New Zealand","2014","2014",1.1,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","MTMOTCMT","Million US$ at exchange rate","NZL","New Zealand","2015","2015",1.8,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","MTMOTCMT","Million US$ at exchange rate","NZL","New Zealand","2016","2016",1.9,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","MTMOTCMT","Million US$ at exchange rate","NZL","New Zealand","2017","2017",0.9,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","MTMOTCMT","Million US$ at exchange rate","NZL","New Zealand","2018","2018",1,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","MTMOTCMT","Million US$ at exchange rate","NZL","New Zealand","2019","2019",1,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","MTMOTCMT","Million US$ at exchange rate","NZL","New Zealand","2020","2020",0.8,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","MTMOTCMT","Million US$ at exchange rate","NZL","New Zealand","2021","2021",1.4,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","MTMOTCMT","Million US$ at exchange rate","NZL","New Zealand","2022","2022",1.3,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","MTMOPPMT","Million US$, purchasing power parity","NZL","New Zealand","2010","2010",0.6,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","MTMOPPMT","Million US$, purchasing power parity","NZL","New Zealand","2011","2011",0.8,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","MTMOPPMT","Million US$, purchasing power parity","NZL","New Zealand","2012","2012",0.9,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","MTMOPPMT","Million US$, purchasing power parity","NZL","New Zealand","2013","2013",0.9,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","MTMOPPMT","Million US$, purchasing power parity","NZL","New Zealand","2014","2014",0.9,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","MTMOPPMT","Million US$, purchasing power parity","NZL","New Zealand","2015","2015",1.7,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","MTMOPPMT","Million US$, purchasing power parity","NZL","New Zealand","2016","2016",1.9,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","MTMOPPMT","Million US$, purchasing power parity","NZL","New Zealand","2017","2017",0.9,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","MTMOPPMT","Million US$, purchasing power parity","NZL","New Zealand","2018","2018",1,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","MTMOPPMT","Million US$, purchasing power parity","NZL","New Zealand","2019","2019",1.1,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","MTMOPPMT","Million US$, purchasing power parity","NZL","New Zealand","2020","2020",0.9,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","MTMOPPMT","Million US$, purchasing power parity","NZL","New Zealand","2021","2021",1.4,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","MTMOPPMT","Million US$, purchasing power parity","NZL","New Zealand","2022","2022",1.4,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","TCPPERMT","/capita, US$ exchange rate","NZL","New Zealand","2010","2010",0.1,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","TCPPERMT","/capita, US$ exchange rate","NZL","New Zealand","2011","2011",0.2,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","TCPPERMT","/capita, US$ exchange rate","NZL","New Zealand","2012","2012",0.2,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","TCPPERMT","/capita, US$ exchange rate","NZL","New Zealand","2013","2013",0.2,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","TCPPERMT","/capita, US$ exchange rate","NZL","New Zealand","2014","2014",0.2,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","TCPPERMT","/capita, US$ exchange rate","NZL","New Zealand","2015","2015",0.4,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","TCPPERMT","/capita, US$ exchange rate","NZL","New Zealand","2016","2016",0.4,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","TCPPERMT","/capita, US$ exchange rate","NZL","New Zealand","2017","2017",0.2,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","TCPPERMT","/capita, US$ exchange rate","NZL","New Zealand","2018","2018",0.2,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","TCPPERMT","/capita, US$ exchange rate","NZL","New Zealand","2019","2019",0.2,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","TCPPERMT","/capita, US$ exchange rate","NZL","New Zealand","2020","2020",0.2,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","TCPPERMT","/capita, US$ exchange rate","NZL","New Zealand","2021","2021",0.3,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","TCPPERMT","/capita, US$ exchange rate","NZL","New Zealand","2022","2022",0.3,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2010","2010",0.1,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2011","2011",0.2,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2012","2012",0.2,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2013","2013",0.2,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2014","2014",0.2,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2015","2015",0.4,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2016","2016",0.4,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2017","2017",0.2,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2018","2018",0.2,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2019","2019",0.2,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2020","2020",0.2,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2021","2021",0.3,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2022","2022",0.3,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","ATCPTTMT","% of total sales","NZL","New Zealand","2010","2010",0.1,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","ATCPTTMT","% of total sales","NZL","New Zealand","2011","2011",0.1,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","ATCPTTMT","% of total sales","NZL","New Zealand","2012","2012",0.1,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","ATCPTTMT","% of total sales","NZL","New Zealand","2013","2013",0.1,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","ATCPTTMT","% of total sales","NZL","New Zealand","2014","2014",0.1,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","ATCPTTMT","% of total sales","NZL","New Zealand","2015","2015",0.3,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","ATCPTTMT","% of total sales","NZL","New Zealand","2016","2016",0.3,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","ATCPTTMT","% of total sales","NZL","New Zealand","2017","2017",0.1,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","ATCPTTMT","% of total sales","NZL","New Zealand","2018","2018",0.1,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","ATCPTTMT","% of total sales","NZL","New Zealand","2019","2019",0.1,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","ATCPTTMT","% of total sales","NZL","New Zealand","2020","2020",0.1,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","ATCPTTMT","% of total sales","NZL","New Zealand","2021","2021",0.1,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","ATCPTTMT","% of total sales","NZL","New Zealand","2022","2022",0.1,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","MLLNCUMT","Million of national currency units","NOR","Norway","2010","2010",122,,
+"PATCANXO","N05B-Anxiolytics","MLLNCUMT","Million of national currency units","NOR","Norway","2011","2011",118,,
+"PATCANXO","N05B-Anxiolytics","MLLNCUMT","Million of national currency units","NOR","Norway","2012","2012",116,,
+"PATCANXO","N05B-Anxiolytics","MLLNCUMT","Million of national currency units","NOR","Norway","2013","2013",114,,
+"PATCANXO","N05B-Anxiolytics","MLLNCUMT","Million of national currency units","NOR","Norway","2014","2014",121,,
+"PATCANXO","N05B-Anxiolytics","MLLNCUMT","Million of national currency units","NOR","Norway","2015","2015",115,,
+"PATCANXO","N05B-Anxiolytics","MLLNCUMT","Million of national currency units","NOR","Norway","2016","2016",119,,
+"PATCANXO","N05B-Anxiolytics","MLLNCUMT","Million of national currency units","NOR","Norway","2017","2017",116,,
+"PATCANXO","N05B-Anxiolytics","MLLNCUMT","Million of national currency units","NOR","Norway","2018","2018",113,,
+"PATCANXO","N05B-Anxiolytics","MLLNCUMT","Million of national currency units","NOR","Norway","2019","2019",136,,
+"PATCANXO","N05B-Anxiolytics","MLLNCUMT","Million of national currency units","NOR","Norway","2020","2020",142,,
+"PATCANXO","N05B-Anxiolytics","MLLNCUMT","Million of national currency units","NOR","Norway","2021","2021",151,,
+"PATCANXO","N05B-Anxiolytics","MLLNCUMT","Million of national currency units","NOR","Norway","2022","2022",145,,
+"PATCANXO","N05B-Anxiolytics","MTMOTCMT","Million US$ at exchange rate","NOR","Norway","2010","2010",20.2,,
+"PATCANXO","N05B-Anxiolytics","MTMOTCMT","Million US$ at exchange rate","NOR","Norway","2011","2011",21.1,,
+"PATCANXO","N05B-Anxiolytics","MTMOTCMT","Million US$ at exchange rate","NOR","Norway","2012","2012",19.9,,
+"PATCANXO","N05B-Anxiolytics","MTMOTCMT","Million US$ at exchange rate","NOR","Norway","2013","2013",19.4,,
+"PATCANXO","N05B-Anxiolytics","MTMOTCMT","Million US$ at exchange rate","NOR","Norway","2014","2014",19.2,,
+"PATCANXO","N05B-Anxiolytics","MTMOTCMT","Million US$ at exchange rate","NOR","Norway","2015","2015",14.3,,
+"PATCANXO","N05B-Anxiolytics","MTMOTCMT","Million US$ at exchange rate","NOR","Norway","2016","2016",14.2,,
+"PATCANXO","N05B-Anxiolytics","MTMOTCMT","Million US$ at exchange rate","NOR","Norway","2017","2017",14,,
+"PATCANXO","N05B-Anxiolytics","MTMOTCMT","Million US$ at exchange rate","NOR","Norway","2018","2018",13.9,,
+"PATCANXO","N05B-Anxiolytics","MTMOTCMT","Million US$ at exchange rate","NOR","Norway","2019","2019",15.5,,
+"PATCANXO","N05B-Anxiolytics","MTMOTCMT","Million US$ at exchange rate","NOR","Norway","2020","2020",15.1,,
+"PATCANXO","N05B-Anxiolytics","MTMOTCMT","Million US$ at exchange rate","NOR","Norway","2021","2021",17.6,,
+"PATCANXO","N05B-Anxiolytics","MTMOTCMT","Million US$ at exchange rate","NOR","Norway","2022","2022",15.1,,
+"PATCANXO","N05B-Anxiolytics","MTMOPPMT","Million US$, purchasing power parity","NOR","Norway","2010","2010",13.3,,
+"PATCANXO","N05B-Anxiolytics","MTMOPPMT","Million US$, purchasing power parity","NOR","Norway","2011","2011",13,,
+"PATCANXO","N05B-Anxiolytics","MTMOPPMT","Million US$, purchasing power parity","NOR","Norway","2012","2012",12.8,,
+"PATCANXO","N05B-Anxiolytics","MTMOPPMT","Million US$, purchasing power parity","NOR","Norway","2013","2013",12.6,,
+"PATCANXO","N05B-Anxiolytics","MTMOPPMT","Million US$, purchasing power parity","NOR","Norway","2014","2014",13,,
+"PATCANXO","N05B-Anxiolytics","MTMOPPMT","Million US$, purchasing power parity","NOR","Norway","2015","2015",11.6,,
+"PATCANXO","N05B-Anxiolytics","MTMOPPMT","Million US$, purchasing power parity","NOR","Norway","2016","2016",11.9,,
+"PATCANXO","N05B-Anxiolytics","MTMOPPMT","Million US$, purchasing power parity","NOR","Norway","2017","2017",11.9,,
+"PATCANXO","N05B-Anxiolytics","MTMOPPMT","Million US$, purchasing power parity","NOR","Norway","2018","2018",11.8,,
+"PATCANXO","N05B-Anxiolytics","MTMOPPMT","Million US$, purchasing power parity","NOR","Norway","2019","2019",14.1,,
+"PATCANXO","N05B-Anxiolytics","MTMOPPMT","Million US$, purchasing power parity","NOR","Norway","2020","2020",14.4,,
+"PATCANXO","N05B-Anxiolytics","MTMOPPMT","Million US$, purchasing power parity","NOR","Norway","2021","2021",15.9,,
+"PATCANXO","N05B-Anxiolytics","MTMOPPMT","Million US$, purchasing power parity","NOR","Norway","2022","2022",13.5,,
+"PATCANXO","N05B-Anxiolytics","TCPPERMT","/capita, US$ exchange rate","NOR","Norway","2010","2010",4.1,,
+"PATCANXO","N05B-Anxiolytics","TCPPERMT","/capita, US$ exchange rate","NOR","Norway","2011","2011",4.3,,
+"PATCANXO","N05B-Anxiolytics","TCPPERMT","/capita, US$ exchange rate","NOR","Norway","2012","2012",4,,
+"PATCANXO","N05B-Anxiolytics","TCPPERMT","/capita, US$ exchange rate","NOR","Norway","2013","2013",3.8,,
+"PATCANXO","N05B-Anxiolytics","TCPPERMT","/capita, US$ exchange rate","NOR","Norway","2014","2014",3.7,,
+"PATCANXO","N05B-Anxiolytics","TCPPERMT","/capita, US$ exchange rate","NOR","Norway","2015","2015",2.7,,
+"PATCANXO","N05B-Anxiolytics","TCPPERMT","/capita, US$ exchange rate","NOR","Norway","2016","2016",2.7,,
+"PATCANXO","N05B-Anxiolytics","TCPPERMT","/capita, US$ exchange rate","NOR","Norway","2017","2017",2.7,,
+"PATCANXO","N05B-Anxiolytics","TCPPERMT","/capita, US$ exchange rate","NOR","Norway","2018","2018",2.6,,
+"PATCANXO","N05B-Anxiolytics","TCPPERMT","/capita, US$ exchange rate","NOR","Norway","2019","2019",2.9,,
+"PATCANXO","N05B-Anxiolytics","TCPPERMT","/capita, US$ exchange rate","NOR","Norway","2020","2020",2.8,,
+"PATCANXO","N05B-Anxiolytics","TCPPERMT","/capita, US$ exchange rate","NOR","Norway","2021","2021",3.3,,
+"PATCANXO","N05B-Anxiolytics","TCPPERMT","/capita, US$ exchange rate","NOR","Norway","2022","2022",2.8,,
+"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2010","2010",2.7,,
+"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2011","2011",2.6,,
+"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2012","2012",2.6,,
+"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2013","2013",2.5,,
+"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2014","2014",2.5,,
+"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2015","2015",2.2,,
+"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2016","2016",2.3,,
+"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2017","2017",2.3,,
+"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2018","2018",2.2,,
+"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2019","2019",2.6,,
+"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2020","2020",2.7,,
+"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2021","2021",2.9,,
+"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2022","2022",2.5,,
+"PATCANXO","N05B-Anxiolytics","ATCPTTMT","% of total sales","NOR","Norway","2010","2010",0.7,,
+"PATCANXO","N05B-Anxiolytics","ATCPTTMT","% of total sales","NOR","Norway","2011","2011",0.6,,
+"PATCANXO","N05B-Anxiolytics","ATCPTTMT","% of total sales","NOR","Norway","2012","2012",0.6,,
+"PATCANXO","N05B-Anxiolytics","ATCPTTMT","% of total sales","NOR","Norway","2013","2013",0.6,,
+"PATCANXO","N05B-Anxiolytics","ATCPTTMT","% of total sales","NOR","Norway","2014","2014",0.6,,
+"PATCANXO","N05B-Anxiolytics","ATCPTTMT","% of total sales","NOR","Norway","2015","2015",0.5,,
+"PATCANXO","N05B-Anxiolytics","ATCPTTMT","% of total sales","NOR","Norway","2016","2016",0.5,,
+"PATCANXO","N05B-Anxiolytics","ATCPTTMT","% of total sales","NOR","Norway","2017","2017",0.4,,
+"PATCANXO","N05B-Anxiolytics","ATCPTTMT","% of total sales","NOR","Norway","2018","2018",0.4,,
+"PATCANXO","N05B-Anxiolytics","ATCPTTMT","% of total sales","NOR","Norway","2019","2019",0.5,,
+"PATCANXO","N05B-Anxiolytics","ATCPTTMT","% of total sales","NOR","Norway","2020","2020",0.5,,
+"PATCANXO","N05B-Anxiolytics","ATCPTTMT","% of total sales","NOR","Norway","2021","2021",0.4,,
+"PATCANXO","N05B-Anxiolytics","ATCPTTMT","% of total sales","NOR","Norway","2022","2022",0.4,,
+"PATCANXO","N05B-Anxiolytics","MLLNCUMT","Million of national currency units","PRT","Portugal","2010","2010",61.2,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","MLLNCUMT","Million of national currency units","PRT","Portugal","2011","2011",57.6,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","MLLNCUMT","Million of national currency units","PRT","Portugal","2012","2012",56.1,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","MLLNCUMT","Million of national currency units","PRT","Portugal","2013","2013",54.1,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","MLLNCUMT","Million of national currency units","PRT","Portugal","2014","2014",54.8,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","MLLNCUMT","Million of national currency units","PRT","Portugal","2015","2015",54.4,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","MLLNCUMT","Million of national currency units","PRT","Portugal","2016","2016",52.6,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","MLLNCUMT","Million of national currency units","PRT","Portugal","2017","2017",51.4,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","MLLNCUMT","Million of national currency units","PRT","Portugal","2018","2018",50.5,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","MLLNCUMT","Million of national currency units","PRT","Portugal","2019","2019",49.3,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","MLLNCUMT","Million of national currency units","PRT","Portugal","2020","2020",49.2,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","MLLNCUMT","Million of national currency units","PRT","Portugal","2021","2021",49.3,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","MLLNCUMT","Million of national currency units","PRT","Portugal","2022","2022",48.5,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","MTMOTCMT","Million US$ at exchange rate","PRT","Portugal","2010","2010",81.2,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","MTMOTCMT","Million US$ at exchange rate","PRT","Portugal","2011","2011",80.1,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","MTMOTCMT","Million US$ at exchange rate","PRT","Portugal","2012","2012",72.1,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","MTMOTCMT","Million US$ at exchange rate","PRT","Portugal","2013","2013",71.8,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","MTMOTCMT","Million US$ at exchange rate","PRT","Portugal","2014","2014",72.8,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","MTMOTCMT","Million US$ at exchange rate","PRT","Portugal","2015","2015",60.3,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","MTMOTCMT","Million US$ at exchange rate","PRT","Portugal","2016","2016",58.2,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","MTMOTCMT","Million US$ at exchange rate","PRT","Portugal","2017","2017",58,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","MTMOTCMT","Million US$ at exchange rate","PRT","Portugal","2018","2018",59.7,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","MTMOTCMT","Million US$ at exchange rate","PRT","Portugal","2019","2019",55.2,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","MTMOTCMT","Million US$ at exchange rate","PRT","Portugal","2020","2020",56.2,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","MTMOTCMT","Million US$ at exchange rate","PRT","Portugal","2021","2021",58.4,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","MTMOTCMT","Million US$ at exchange rate","PRT","Portugal","2022","2022",51.1,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","MTMOPPMT","Million US$, purchasing power parity","PRT","Portugal","2010","2010",98.3,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","MTMOPPMT","Million US$, purchasing power parity","PRT","Portugal","2011","2011",92.4,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","MTMOPPMT","Million US$, purchasing power parity","PRT","Portugal","2012","2012",92.7,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","MTMOPPMT","Million US$, purchasing power parity","PRT","Portugal","2013","2013",92.6,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","MTMOPPMT","Million US$, purchasing power parity","PRT","Portugal","2014","2014",94.6,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","MTMOPPMT","Million US$, purchasing power parity","PRT","Portugal","2015","2015",92.9,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","MTMOPPMT","Million US$, purchasing power parity","PRT","Portugal","2016","2016",92,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","MTMOPPMT","Million US$, purchasing power parity","PRT","Portugal","2017","2017",89.2,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","MTMOPPMT","Million US$, purchasing power parity","PRT","Portugal","2018","2018",88.4,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","MTMOPPMT","Million US$, purchasing power parity","PRT","Portugal","2019","2019",88.2,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","MTMOPPMT","Million US$, purchasing power parity","PRT","Portugal","2020","2020",88.3,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","MTMOPPMT","Million US$, purchasing power parity","PRT","Portugal","2021","2021",86.9,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","MTMOPPMT","Million US$, purchasing power parity","PRT","Portugal","2022","2022",88.2,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","TCPPERMT","/capita, US$ exchange rate","PRT","Portugal","2010","2010",7.7,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","TCPPERMT","/capita, US$ exchange rate","PRT","Portugal","2011","2011",7.6,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","TCPPERMT","/capita, US$ exchange rate","PRT","Portugal","2012","2012",6.9,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","TCPPERMT","/capita, US$ exchange rate","PRT","Portugal","2013","2013",6.9,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","TCPPERMT","/capita, US$ exchange rate","PRT","Portugal","2014","2014",7,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","TCPPERMT","/capita, US$ exchange rate","PRT","Portugal","2015","2015",5.8,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","TCPPERMT","/capita, US$ exchange rate","PRT","Portugal","2016","2016",5.6,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","TCPPERMT","/capita, US$ exchange rate","PRT","Portugal","2017","2017",5.6,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","TCPPERMT","/capita, US$ exchange rate","PRT","Portugal","2018","2018",5.8,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","TCPPERMT","/capita, US$ exchange rate","PRT","Portugal","2019","2019",5.4,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","TCPPERMT","/capita, US$ exchange rate","PRT","Portugal","2020","2020",5.5,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","TCPPERMT","/capita, US$ exchange rate","PRT","Portugal","2021","2021",5.6,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","TCPPERMT","/capita, US$ exchange rate","PRT","Portugal","2022","2022",4.9,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2010","2010",9.3,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2011","2011",8.8,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2012","2012",8.8,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2013","2013",8.9,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2014","2014",9.1,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2015","2015",9,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2016","2016",8.9,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2017","2017",8.7,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2018","2018",8.6,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2019","2019",8.6,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2020","2020",8.6,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2021","2021",8.4,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2022","2022",8.5,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","ATCPTTMT","% of total sales","PRT","Portugal","2010","2010",1.9,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","ATCPTTMT","% of total sales","PRT","Portugal","2011","2011",2,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","ATCPTTMT","% of total sales","PRT","Portugal","2012","2012",2.1,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","ATCPTTMT","% of total sales","PRT","Portugal","2013","2013",2.2,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","ATCPTTMT","% of total sales","PRT","Portugal","2014","2014",2.3,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","ATCPTTMT","% of total sales","PRT","Portugal","2015","2015",2.2,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","ATCPTTMT","% of total sales","PRT","Portugal","2016","2016",2.1,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","ATCPTTMT","% of total sales","PRT","Portugal","2017","2017",2,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","ATCPTTMT","% of total sales","PRT","Portugal","2018","2018",1.9,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","ATCPTTMT","% of total sales","PRT","Portugal","2019","2019",1.8,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","ATCPTTMT","% of total sales","PRT","Portugal","2020","2020",1.8,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","ATCPTTMT","% of total sales","PRT","Portugal","2021","2021",1.7,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","ATCPTTMT","% of total sales","PRT","Portugal","2022","2022",1.5,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","MLLNCUMT","Million of national currency units","SVK","Slovak Republic","2010","2010",5,,
+"PATCANXO","N05B-Anxiolytics","MLLNCUMT","Million of national currency units","SVK","Slovak Republic","2011","2011",5.1,,
+"PATCANXO","N05B-Anxiolytics","MLLNCUMT","Million of national currency units","SVK","Slovak Republic","2012","2012",4.6,,
+"PATCANXO","N05B-Anxiolytics","MLLNCUMT","Million of national currency units","SVK","Slovak Republic","2013","2013",5.1,,
+"PATCANXO","N05B-Anxiolytics","MLLNCUMT","Million of national currency units","SVK","Slovak Republic","2014","2014",5.5,,
+"PATCANXO","N05B-Anxiolytics","MLLNCUMT","Million of national currency units","SVK","Slovak Republic","2015","2015",6.4,,
+"PATCANXO","N05B-Anxiolytics","MLLNCUMT","Million of national currency units","SVK","Slovak Republic","2016","2016",7.4,"B","Break"
+"PATCANXO","N05B-Anxiolytics","MLLNCUMT","Million of national currency units","SVK","Slovak Republic","2017","2017",6.8,,
+"PATCANXO","N05B-Anxiolytics","MLLNCUMT","Million of national currency units","SVK","Slovak Republic","2018","2018",7.4,,
+"PATCANXO","N05B-Anxiolytics","MLLNCUMT","Million of national currency units","SVK","Slovak Republic","2019","2019",8.6,,
+"PATCANXO","N05B-Anxiolytics","MLLNCUMT","Million of national currency units","SVK","Slovak Republic","2020","2020",9.3,,
+"PATCANXO","N05B-Anxiolytics","MLLNCUMT","Million of national currency units","SVK","Slovak Republic","2021","2021",10.2,,
+"PATCANXO","N05B-Anxiolytics","MTMOTCMT","Million US$ at exchange rate","SVK","Slovak Republic","2010","2010",6.7,,
+"PATCANXO","N05B-Anxiolytics","MTMOTCMT","Million US$ at exchange rate","SVK","Slovak Republic","2011","2011",7,,
+"PATCANXO","N05B-Anxiolytics","MTMOTCMT","Million US$ at exchange rate","SVK","Slovak Republic","2012","2012",5.9,,
+"PATCANXO","N05B-Anxiolytics","MTMOTCMT","Million US$ at exchange rate","SVK","Slovak Republic","2013","2013",6.8,,
+"PATCANXO","N05B-Anxiolytics","MTMOTCMT","Million US$ at exchange rate","SVK","Slovak Republic","2014","2014",7.3,,
+"PATCANXO","N05B-Anxiolytics","MTMOTCMT","Million US$ at exchange rate","SVK","Slovak Republic","2015","2015",7.1,,
+"PATCANXO","N05B-Anxiolytics","MTMOTCMT","Million US$ at exchange rate","SVK","Slovak Republic","2016","2016",8.2,"B","Break"
+"PATCANXO","N05B-Anxiolytics","MTMOTCMT","Million US$ at exchange rate","SVK","Slovak Republic","2017","2017",7.7,,
+"PATCANXO","N05B-Anxiolytics","MTMOTCMT","Million US$ at exchange rate","SVK","Slovak Republic","2018","2018",8.8,,
+"PATCANXO","N05B-Anxiolytics","MTMOTCMT","Million US$ at exchange rate","SVK","Slovak Republic","2019","2019",9.6,,
+"PATCANXO","N05B-Anxiolytics","MTMOTCMT","Million US$ at exchange rate","SVK","Slovak Republic","2020","2020",10.6,,
+"PATCANXO","N05B-Anxiolytics","MTMOTCMT","Million US$ at exchange rate","SVK","Slovak Republic","2021","2021",12.1,,
+"PATCANXO","N05B-Anxiolytics","MTMOPPMT","Million US$, purchasing power parity","SVK","Slovak Republic","2010","2010",10,,
+"PATCANXO","N05B-Anxiolytics","MTMOPPMT","Million US$, purchasing power parity","SVK","Slovak Republic","2011","2011",10,,
+"PATCANXO","N05B-Anxiolytics","MTMOPPMT","Million US$, purchasing power parity","SVK","Slovak Republic","2012","2012",9.2,,
+"PATCANXO","N05B-Anxiolytics","MTMOPPMT","Million US$, purchasing power parity","SVK","Slovak Republic","2013","2013",10.4,,
+"PATCANXO","N05B-Anxiolytics","MTMOPPMT","Million US$, purchasing power parity","SVK","Slovak Republic","2014","2014",11.4,,
+"PATCANXO","N05B-Anxiolytics","MTMOPPMT","Million US$, purchasing power parity","SVK","Slovak Republic","2015","2015",13,,
+"PATCANXO","N05B-Anxiolytics","MTMOPPMT","Million US$, purchasing power parity","SVK","Slovak Republic","2016","2016",14.7,"B","Break"
+"PATCANXO","N05B-Anxiolytics","MTMOPPMT","Million US$, purchasing power parity","SVK","Slovak Republic","2017","2017",13.1,,
+"PATCANXO","N05B-Anxiolytics","MTMOPPMT","Million US$, purchasing power parity","SVK","Slovak Republic","2018","2018",14.1,,
+"PATCANXO","N05B-Anxiolytics","MTMOPPMT","Million US$, purchasing power parity","SVK","Slovak Republic","2019","2019",16.6,,
+"PATCANXO","N05B-Anxiolytics","MTMOPPMT","Million US$, purchasing power parity","SVK","Slovak Republic","2020","2020",17.8,,
+"PATCANXO","N05B-Anxiolytics","MTMOPPMT","Million US$, purchasing power parity","SVK","Slovak Republic","2021","2021",19.2,,
+"PATCANXO","N05B-Anxiolytics","TCPPERMT","/capita, US$ exchange rate","SVK","Slovak Republic","2010","2010",1.2,,
+"PATCANXO","N05B-Anxiolytics","TCPPERMT","/capita, US$ exchange rate","SVK","Slovak Republic","2011","2011",1.3,,
+"PATCANXO","N05B-Anxiolytics","TCPPERMT","/capita, US$ exchange rate","SVK","Slovak Republic","2012","2012",1.1,,
+"PATCANXO","N05B-Anxiolytics","TCPPERMT","/capita, US$ exchange rate","SVK","Slovak Republic","2013","2013",1.3,,
+"PATCANXO","N05B-Anxiolytics","TCPPERMT","/capita, US$ exchange rate","SVK","Slovak Republic","2014","2014",1.4,,
+"PATCANXO","N05B-Anxiolytics","TCPPERMT","/capita, US$ exchange rate","SVK","Slovak Republic","2015","2015",1.3,,
+"PATCANXO","N05B-Anxiolytics","TCPPERMT","/capita, US$ exchange rate","SVK","Slovak Republic","2016","2016",1.5,"B","Break"
+"PATCANXO","N05B-Anxiolytics","TCPPERMT","/capita, US$ exchange rate","SVK","Slovak Republic","2017","2017",1.4,,
+"PATCANXO","N05B-Anxiolytics","TCPPERMT","/capita, US$ exchange rate","SVK","Slovak Republic","2018","2018",1.6,,
+"PATCANXO","N05B-Anxiolytics","TCPPERMT","/capita, US$ exchange rate","SVK","Slovak Republic","2019","2019",1.8,,
+"PATCANXO","N05B-Anxiolytics","TCPPERMT","/capita, US$ exchange rate","SVK","Slovak Republic","2020","2020",1.9,,
+"PATCANXO","N05B-Anxiolytics","TCPPERMT","/capita, US$ exchange rate","SVK","Slovak Republic","2021","2021",2.2,,
+"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2010","2010",1.9,,
+"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2011","2011",1.8,,
+"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2012","2012",1.7,,
+"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2013","2013",1.9,,
+"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2014","2014",2.1,,
+"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2015","2015",2.4,,
+"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2016","2016",2.7,"B","Break"
+"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2017","2017",2.4,,
+"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2018","2018",2.6,,
+"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2019","2019",3,,
+"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2020","2020",3.3,,
+"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2021","2021",3.5,,
+"PATCANXO","N05B-Anxiolytics","ATCPTTMT","% of total sales","SVK","Slovak Republic","2010","2010",0.5,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","ATCPTTMT","% of total sales","SVK","Slovak Republic","2011","2011",0.4,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","ATCPTTMT","% of total sales","SVK","Slovak Republic","2012","2012",0.4,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","ATCPTTMT","% of total sales","SVK","Slovak Republic","2013","2013",0.4,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","ATCPTTMT","% of total sales","SVK","Slovak Republic","2014","2014",0.4,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","ATCPTTMT","% of total sales","SVK","Slovak Republic","2015","2015",0.5,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","ATCPTTMT","% of total sales","SVK","Slovak Republic","2016","2016",0.5,"B","Break"
+"PATCANXO","N05B-Anxiolytics","ATCPTTMT","% of total sales","SVK","Slovak Republic","2017","2017",0.4,,
+"PATCANXO","N05B-Anxiolytics","ATCPTTMT","% of total sales","SVK","Slovak Republic","2018","2018",0.5,,
+"PATCANXO","N05B-Anxiolytics","ATCPTTMT","% of total sales","SVK","Slovak Republic","2019","2019",0.5,,
+"PATCANXO","N05B-Anxiolytics","ATCPTTMT","% of total sales","SVK","Slovak Republic","2020","2020",0.6,,
+"PATCANXO","N05B-Anxiolytics","ATCPTTMT","% of total sales","SVK","Slovak Republic","2021","2021",0.6,,
+"PATCANXO","N05B-Anxiolytics","MLLNCUMT","Million of national currency units","ESP","Spain","2010","2010",122,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","MLLNCUMT","Million of national currency units","ESP","Spain","2011","2011",113.4,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","MLLNCUMT","Million of national currency units","ESP","Spain","2012","2012",98.2,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","MLLNCUMT","Million of national currency units","ESP","Spain","2013","2013",98.3,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","MLLNCUMT","Million of national currency units","ESP","Spain","2014","2014",103.8,"B; D","Break; Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","MLLNCUMT","Million of national currency units","ESP","Spain","2015","2015",100.7,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","MLLNCUMT","Million of national currency units","ESP","Spain","2016","2016",100.9,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","MLLNCUMT","Million of national currency units","ESP","Spain","2017","2017",100.4,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","MLLNCUMT","Million of national currency units","ESP","Spain","2018","2018",101.4,,
+"PATCANXO","N05B-Anxiolytics","MLLNCUMT","Million of national currency units","ESP","Spain","2019","2019",101.2,,
+"PATCANXO","N05B-Anxiolytics","MLLNCUMT","Million of national currency units","ESP","Spain","2020","2020",105.5,,
+"PATCANXO","N05B-Anxiolytics","MLLNCUMT","Million of national currency units","ESP","Spain","2021","2021",109,,
+"PATCANXO","N05B-Anxiolytics","MLLNCUMT","Million of national currency units","ESP","Spain","2022","2022",108,"P","Provisional value"
+"PATCANXO","N05B-Anxiolytics","MTMOTCMT","Million US$ at exchange rate","ESP","Spain","2010","2010",161.8,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","MTMOTCMT","Million US$ at exchange rate","ESP","Spain","2011","2011",157.9,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","MTMOTCMT","Million US$ at exchange rate","ESP","Spain","2012","2012",126.2,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","MTMOTCMT","Million US$ at exchange rate","ESP","Spain","2013","2013",130.5,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","MTMOTCMT","Million US$ at exchange rate","ESP","Spain","2014","2014",137.9,"B; D","Break; Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","MTMOTCMT","Million US$ at exchange rate","ESP","Spain","2015","2015",111.7,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","MTMOTCMT","Million US$ at exchange rate","ESP","Spain","2016","2016",111.7,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","MTMOTCMT","Million US$ at exchange rate","ESP","Spain","2017","2017",113.4,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","MTMOTCMT","Million US$ at exchange rate","ESP","Spain","2018","2018",119.7,,
+"PATCANXO","N05B-Anxiolytics","MTMOTCMT","Million US$ at exchange rate","ESP","Spain","2019","2019",113.3,,
+"PATCANXO","N05B-Anxiolytics","MTMOTCMT","Million US$ at exchange rate","ESP","Spain","2020","2020",120.5,,
+"PATCANXO","N05B-Anxiolytics","MTMOTCMT","Million US$ at exchange rate","ESP","Spain","2021","2021",128.9,,
+"PATCANXO","N05B-Anxiolytics","MTMOTCMT","Million US$ at exchange rate","ESP","Spain","2022","2022",113.8,"P","Provisional value"
+"PATCANXO","N05B-Anxiolytics","MTMOPPMT","Million US$, purchasing power parity","ESP","Spain","2010","2010",167.9,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","MTMOPPMT","Million US$, purchasing power parity","ESP","Spain","2011","2011",158.8,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","MTMOPPMT","Million US$, purchasing power parity","ESP","Spain","2012","2012",141.3,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","MTMOPPMT","Million US$, purchasing power parity","ESP","Spain","2013","2013",145.6,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","MTMOPPMT","Million US$, purchasing power parity","ESP","Spain","2014","2014",156.8,"B; D","Break; Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","MTMOPPMT","Million US$, purchasing power parity","ESP","Spain","2015","2015",151.4,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","MTMOPPMT","Million US$, purchasing power parity","ESP","Spain","2016","2016",157,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","MTMOPPMT","Million US$, purchasing power parity","ESP","Spain","2017","2017",159.1,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","MTMOPPMT","Million US$, purchasing power parity","ESP","Spain","2018","2018",160.5,,
+"PATCANXO","N05B-Anxiolytics","MTMOPPMT","Million US$, purchasing power parity","ESP","Spain","2019","2019",165.1,,
+"PATCANXO","N05B-Anxiolytics","MTMOPPMT","Million US$, purchasing power parity","ESP","Spain","2020","2020",169.9,,
+"PATCANXO","N05B-Anxiolytics","MTMOPPMT","Million US$, purchasing power parity","ESP","Spain","2021","2021",174.1,,
+"PATCANXO","N05B-Anxiolytics","MTMOPPMT","Million US$, purchasing power parity","ESP","Spain","2022","2022",181.2,"P","Provisional value"
+"PATCANXO","N05B-Anxiolytics","TCPPERMT","/capita, US$ exchange rate","ESP","Spain","2010","2010",3.5,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","TCPPERMT","/capita, US$ exchange rate","ESP","Spain","2011","2011",3.4,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","TCPPERMT","/capita, US$ exchange rate","ESP","Spain","2012","2012",2.7,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","TCPPERMT","/capita, US$ exchange rate","ESP","Spain","2013","2013",2.8,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","TCPPERMT","/capita, US$ exchange rate","ESP","Spain","2014","2014",3,"B; D","Break; Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","TCPPERMT","/capita, US$ exchange rate","ESP","Spain","2015","2015",2.4,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","TCPPERMT","/capita, US$ exchange rate","ESP","Spain","2016","2016",2.4,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","TCPPERMT","/capita, US$ exchange rate","ESP","Spain","2017","2017",2.4,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","TCPPERMT","/capita, US$ exchange rate","ESP","Spain","2018","2018",2.6,,
+"PATCANXO","N05B-Anxiolytics","TCPPERMT","/capita, US$ exchange rate","ESP","Spain","2019","2019",2.4,,
+"PATCANXO","N05B-Anxiolytics","TCPPERMT","/capita, US$ exchange rate","ESP","Spain","2020","2020",2.5,,
+"PATCANXO","N05B-Anxiolytics","TCPPERMT","/capita, US$ exchange rate","ESP","Spain","2021","2021",2.7,,
+"PATCANXO","N05B-Anxiolytics","TCPPERMT","/capita, US$ exchange rate","ESP","Spain","2022","2022",2.4,"P","Provisional value"
+"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2010","2010",3.6,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2011","2011",3.4,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2012","2012",3,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2013","2013",3.1,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2014","2014",3.4,"B; D","Break; Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2015","2015",3.3,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2016","2016",3.4,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2017","2017",3.4,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2018","2018",3.4,,
+"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2019","2019",3.5,,
+"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2020","2020",3.6,,
+"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2021","2021",3.7,,
+"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2022","2022",3.8,"P","Provisional value"
+"PATCANXO","N05B-Anxiolytics","ATCPTTMT","% of total sales","ESP","Spain","2010","2010",0.9,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","ATCPTTMT","% of total sales","ESP","Spain","2011","2011",0.9,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","ATCPTTMT","% of total sales","ESP","Spain","2012","2012",0.9,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","ATCPTTMT","% of total sales","ESP","Spain","2013","2013",0.9,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","ATCPTTMT","% of total sales","ESP","Spain","2014","2014",0.9,"B; D","Break; Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","ATCPTTMT","% of total sales","ESP","Spain","2015","2015",0.9,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","ATCPTTMT","% of total sales","ESP","Spain","2016","2016",0.9,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","ATCPTTMT","% of total sales","ESP","Spain","2017","2017",0.8,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","ATCPTTMT","% of total sales","ESP","Spain","2018","2018",0.5,"B","Break"
+"PATCANXO","N05B-Anxiolytics","ATCPTTMT","% of total sales","ESP","Spain","2019","2019",0.5,,
+"PATCANXO","N05B-Anxiolytics","ATCPTTMT","% of total sales","ESP","Spain","2020","2020",0.5,,
+"PATCANXO","N05B-Anxiolytics","ATCPTTMT","% of total sales","ESP","Spain","2021","2021",0.5,,
+"PATCANXO","N05B-Anxiolytics","ATCPTTMT","% of total sales","ESP","Spain","2022","2022",0.5,"P","Provisional value"
+"PATCANXO","N05B-Anxiolytics","MLLNCUMT","Million of national currency units","SWE","Sweden","2010","2010",187.6,,
+"PATCANXO","N05B-Anxiolytics","MLLNCUMT","Million of national currency units","SWE","Sweden","2011","2011",190.1,,
+"PATCANXO","N05B-Anxiolytics","MLLNCUMT","Million of national currency units","SWE","Sweden","2012","2012",191.6,,
+"PATCANXO","N05B-Anxiolytics","MLLNCUMT","Million of national currency units","SWE","Sweden","2013","2013",200.7,,
+"PATCANXO","N05B-Anxiolytics","MLLNCUMT","Million of national currency units","SWE","Sweden","2014","2014",201.4,,
+"PATCANXO","N05B-Anxiolytics","MLLNCUMT","Million of national currency units","SWE","Sweden","2015","2015",199.8,,
+"PATCANXO","N05B-Anxiolytics","MLLNCUMT","Million of national currency units","SWE","Sweden","2016","2016",198.3,,
+"PATCANXO","N05B-Anxiolytics","MLLNCUMT","Million of national currency units","SWE","Sweden","2017","2017",197,,
+"PATCANXO","N05B-Anxiolytics","MLLNCUMT","Million of national currency units","SWE","Sweden","2018","2018",188.9,,
+"PATCANXO","N05B-Anxiolytics","MLLNCUMT","Million of national currency units","SWE","Sweden","2019","2019",185.5,,
+"PATCANXO","N05B-Anxiolytics","MLLNCUMT","Million of national currency units","SWE","Sweden","2020","2020",176.8,,
+"PATCANXO","N05B-Anxiolytics","MLLNCUMT","Million of national currency units","SWE","Sweden","2021","2021",167.3,,
+"PATCANXO","N05B-Anxiolytics","MLLNCUMT","Million of national currency units","SWE","Sweden","2022","2022",168,,
+"PATCANXO","N05B-Anxiolytics","MTMOTCMT","Million US$ at exchange rate","SWE","Sweden","2010","2010",26,,
+"PATCANXO","N05B-Anxiolytics","MTMOTCMT","Million US$ at exchange rate","SWE","Sweden","2011","2011",29.3,,
+"PATCANXO","N05B-Anxiolytics","MTMOTCMT","Million US$ at exchange rate","SWE","Sweden","2012","2012",28.3,,
+"PATCANXO","N05B-Anxiolytics","MTMOTCMT","Million US$ at exchange rate","SWE","Sweden","2013","2013",30.8,,
+"PATCANXO","N05B-Anxiolytics","MTMOTCMT","Million US$ at exchange rate","SWE","Sweden","2014","2014",29.4,,
+"PATCANXO","N05B-Anxiolytics","MTMOTCMT","Million US$ at exchange rate","SWE","Sweden","2015","2015",23.7,,
+"PATCANXO","N05B-Anxiolytics","MTMOTCMT","Million US$ at exchange rate","SWE","Sweden","2016","2016",23.2,,
+"PATCANXO","N05B-Anxiolytics","MTMOTCMT","Million US$ at exchange rate","SWE","Sweden","2017","2017",23,,
+"PATCANXO","N05B-Anxiolytics","MTMOTCMT","Million US$ at exchange rate","SWE","Sweden","2018","2018",21.7,,
+"PATCANXO","N05B-Anxiolytics","MTMOTCMT","Million US$ at exchange rate","SWE","Sweden","2019","2019",19.6,,
+"PATCANXO","N05B-Anxiolytics","MTMOTCMT","Million US$ at exchange rate","SWE","Sweden","2020","2020",19.2,,
+"PATCANXO","N05B-Anxiolytics","MTMOTCMT","Million US$ at exchange rate","SWE","Sweden","2021","2021",19.5,,
+"PATCANXO","N05B-Anxiolytics","MTMOTCMT","Million US$ at exchange rate","SWE","Sweden","2022","2022",16.6,,
+"PATCANXO","N05B-Anxiolytics","MTMOPPMT","Million US$, purchasing power parity","SWE","Sweden","2010","2010",20.8,,
+"PATCANXO","N05B-Anxiolytics","MTMOPPMT","Million US$, purchasing power parity","SWE","Sweden","2011","2011",21.5,,
+"PATCANXO","N05B-Anxiolytics","MTMOPPMT","Million US$, purchasing power parity","SWE","Sweden","2012","2012",22.1,,
+"PATCANXO","N05B-Anxiolytics","MTMOPPMT","Million US$, purchasing power parity","SWE","Sweden","2013","2013",23.3,,
+"PATCANXO","N05B-Anxiolytics","MTMOPPMT","Million US$, purchasing power parity","SWE","Sweden","2014","2014",23.1,,
+"PATCANXO","N05B-Anxiolytics","MTMOPPMT","Million US$, purchasing power parity","SWE","Sweden","2015","2015",22.6,,
+"PATCANXO","N05B-Anxiolytics","MTMOPPMT","Million US$, purchasing power parity","SWE","Sweden","2016","2016",22.5,,
+"PATCANXO","N05B-Anxiolytics","MTMOPPMT","Million US$, purchasing power parity","SWE","Sweden","2017","2017",22.3,,
+"PATCANXO","N05B-Anxiolytics","MTMOPPMT","Million US$, purchasing power parity","SWE","Sweden","2018","2018",21.3,,
+"PATCANXO","N05B-Anxiolytics","MTMOPPMT","Million US$, purchasing power parity","SWE","Sweden","2019","2019",21.3,,
+"PATCANXO","N05B-Anxiolytics","MTMOPPMT","Million US$, purchasing power parity","SWE","Sweden","2020","2020",20.4,,
+"PATCANXO","N05B-Anxiolytics","MTMOPPMT","Million US$, purchasing power parity","SWE","Sweden","2021","2021",19.2,,
+"PATCANXO","N05B-Anxiolytics","MTMOPPMT","Million US$, purchasing power parity","SWE","Sweden","2022","2022",19.4,,
+"PATCANXO","N05B-Anxiolytics","TCPPERMT","/capita, US$ exchange rate","SWE","Sweden","2010","2010",2.8,,
+"PATCANXO","N05B-Anxiolytics","TCPPERMT","/capita, US$ exchange rate","SWE","Sweden","2011","2011",3.1,,
+"PATCANXO","N05B-Anxiolytics","TCPPERMT","/capita, US$ exchange rate","SWE","Sweden","2012","2012",3,,
+"PATCANXO","N05B-Anxiolytics","TCPPERMT","/capita, US$ exchange rate","SWE","Sweden","2013","2013",3.2,,
+"PATCANXO","N05B-Anxiolytics","TCPPERMT","/capita, US$ exchange rate","SWE","Sweden","2014","2014",3,,
+"PATCANXO","N05B-Anxiolytics","TCPPERMT","/capita, US$ exchange rate","SWE","Sweden","2015","2015",2.4,,
+"PATCANXO","N05B-Anxiolytics","TCPPERMT","/capita, US$ exchange rate","SWE","Sweden","2016","2016",2.3,,
+"PATCANXO","N05B-Anxiolytics","TCPPERMT","/capita, US$ exchange rate","SWE","Sweden","2017","2017",2.3,,
+"PATCANXO","N05B-Anxiolytics","TCPPERMT","/capita, US$ exchange rate","SWE","Sweden","2018","2018",2.1,,
+"PATCANXO","N05B-Anxiolytics","TCPPERMT","/capita, US$ exchange rate","SWE","Sweden","2019","2019",1.9,,
+"PATCANXO","N05B-Anxiolytics","TCPPERMT","/capita, US$ exchange rate","SWE","Sweden","2020","2020",1.9,,
+"PATCANXO","N05B-Anxiolytics","TCPPERMT","/capita, US$ exchange rate","SWE","Sweden","2021","2021",1.9,,
+"PATCANXO","N05B-Anxiolytics","TCPPERMT","/capita, US$ exchange rate","SWE","Sweden","2022","2022",1.6,,
+"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2010","2010",2.2,,
+"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2011","2011",2.3,,
+"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2012","2012",2.3,,
+"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2013","2013",2.4,,
+"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2014","2014",2.4,,
+"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2015","2015",2.3,,
+"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2016","2016",2.3,,
+"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2017","2017",2.2,,
+"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2018","2018",2.1,,
+"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2019","2019",2.1,,
+"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2020","2020",2,,
+"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2021","2021",1.8,,
+"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2022","2022",1.9,,
+"PATCANXO","N05B-Anxiolytics","ATCPTTMT","% of total sales","SWE","Sweden","2010","2010",0.5,,
+"PATCANXO","N05B-Anxiolytics","ATCPTTMT","% of total sales","SWE","Sweden","2011","2011",0.5,,
+"PATCANXO","N05B-Anxiolytics","ATCPTTMT","% of total sales","SWE","Sweden","2012","2012",0.5,,
+"PATCANXO","N05B-Anxiolytics","ATCPTTMT","% of total sales","SWE","Sweden","2013","2013",0.6,,
+"PATCANXO","N05B-Anxiolytics","ATCPTTMT","% of total sales","SWE","Sweden","2014","2014",0.5,,
+"PATCANXO","N05B-Anxiolytics","ATCPTTMT","% of total sales","SWE","Sweden","2015","2015",0.5,,
+"PATCANXO","N05B-Anxiolytics","ATCPTTMT","% of total sales","SWE","Sweden","2016","2016",0.5,,
+"PATCANXO","N05B-Anxiolytics","ATCPTTMT","% of total sales","SWE","Sweden","2017","2017",0.5,,
+"PATCANXO","N05B-Anxiolytics","ATCPTTMT","% of total sales","SWE","Sweden","2018","2018",0.4,,
+"PATCANXO","N05B-Anxiolytics","ATCPTTMT","% of total sales","SWE","Sweden","2019","2019",0.4,,
+"PATCANXO","N05B-Anxiolytics","ATCPTTMT","% of total sales","SWE","Sweden","2020","2020",0.3,,
+"PATCANXO","N05B-Anxiolytics","ATCPTTMT","% of total sales","SWE","Sweden","2021","2021",0.3,,
+"PATCANXO","N05B-Anxiolytics","ATCPTTMT","% of total sales","SWE","Sweden","2022","2022",0.3,,
+"PATCANXO","N05B-Anxiolytics","MLLNCUMT","Million of national currency units","TUR","Türkiye","2010","2010",14.4,,
+"PATCANXO","N05B-Anxiolytics","MLLNCUMT","Million of national currency units","TUR","Türkiye","2011","2011",14.1,,
+"PATCANXO","N05B-Anxiolytics","MLLNCUMT","Million of national currency units","TUR","Türkiye","2012","2012",12.7,,
+"PATCANXO","N05B-Anxiolytics","MLLNCUMT","Million of national currency units","TUR","Türkiye","2013","2013",13.1,,
+"PATCANXO","N05B-Anxiolytics","MLLNCUMT","Million of national currency units","TUR","Türkiye","2014","2014",15.2,,
+"PATCANXO","N05B-Anxiolytics","MLLNCUMT","Million of national currency units","TUR","Türkiye","2015","2015",17.8,,
+"PATCANXO","N05B-Anxiolytics","MLLNCUMT","Million of national currency units","TUR","Türkiye","2016","2016",14.5,,
+"PATCANXO","N05B-Anxiolytics","MLLNCUMT","Million of national currency units","TUR","Türkiye","2017","2017",16,,
+"PATCANXO","N05B-Anxiolytics","MLLNCUMT","Million of national currency units","TUR","Türkiye","2018","2018",25.7,,
+"PATCANXO","N05B-Anxiolytics","MLLNCUMT","Million of national currency units","TUR","Türkiye","2019","2019",34,,
+"PATCANXO","N05B-Anxiolytics","MLLNCUMT","Million of national currency units","TUR","Türkiye","2020","2020",44.2,,
+"PATCANXO","N05B-Anxiolytics","MLLNCUMT","Million of national currency units","TUR","Türkiye","2021","2021",57.5,,
+"PATCANXO","N05B-Anxiolytics","MTMOTCMT","Million US$ at exchange rate","TUR","Türkiye","2010","2010",9.6,,
+"PATCANXO","N05B-Anxiolytics","MTMOTCMT","Million US$ at exchange rate","TUR","Türkiye","2011","2011",8.4,,
+"PATCANXO","N05B-Anxiolytics","MTMOTCMT","Million US$ at exchange rate","TUR","Türkiye","2012","2012",7,,
+"PATCANXO","N05B-Anxiolytics","MTMOTCMT","Million US$ at exchange rate","TUR","Türkiye","2013","2013",6.9,,
+"PATCANXO","N05B-Anxiolytics","MTMOTCMT","Million US$ at exchange rate","TUR","Türkiye","2014","2014",6.9,,
+"PATCANXO","N05B-Anxiolytics","MTMOTCMT","Million US$ at exchange rate","TUR","Türkiye","2015","2015",6.6,,
+"PATCANXO","N05B-Anxiolytics","MTMOTCMT","Million US$ at exchange rate","TUR","Türkiye","2016","2016",4.8,,
+"PATCANXO","N05B-Anxiolytics","MTMOTCMT","Million US$ at exchange rate","TUR","Türkiye","2017","2017",4.4,,
+"PATCANXO","N05B-Anxiolytics","MTMOTCMT","Million US$ at exchange rate","TUR","Türkiye","2018","2018",5.3,,
+"PATCANXO","N05B-Anxiolytics","MTMOTCMT","Million US$ at exchange rate","TUR","Türkiye","2019","2019",6,,
+"PATCANXO","N05B-Anxiolytics","MTMOTCMT","Million US$ at exchange rate","TUR","Türkiye","2020","2020",6.3,,
+"PATCANXO","N05B-Anxiolytics","MTMOTCMT","Million US$ at exchange rate","TUR","Türkiye","2021","2021",6.5,,
+"PATCANXO","N05B-Anxiolytics","MTMOPPMT","Million US$, purchasing power parity","TUR","Türkiye","2010","2010",15.6,,
+"PATCANXO","N05B-Anxiolytics","MTMOPPMT","Million US$, purchasing power parity","TUR","Türkiye","2011","2011",14.6,,
+"PATCANXO","N05B-Anxiolytics","MTMOPPMT","Million US$, purchasing power parity","TUR","Türkiye","2012","2012",12.4,,
+"PATCANXO","N05B-Anxiolytics","MTMOPPMT","Million US$, purchasing power parity","TUR","Türkiye","2013","2013",12.2,,
+"PATCANXO","N05B-Anxiolytics","MTMOPPMT","Million US$, purchasing power parity","TUR","Türkiye","2014","2014",13.8,,
+"PATCANXO","N05B-Anxiolytics","MTMOPPMT","Million US$, purchasing power parity","TUR","Türkiye","2015","2015",15.3,,
+"PATCANXO","N05B-Anxiolytics","MTMOPPMT","Million US$, purchasing power parity","TUR","Türkiye","2016","2016",11.7,,
+"PATCANXO","N05B-Anxiolytics","MTMOPPMT","Million US$, purchasing power parity","TUR","Türkiye","2017","2017",11.6,,
+"PATCANXO","N05B-Anxiolytics","MTMOPPMT","Million US$, purchasing power parity","TUR","Türkiye","2018","2018",15.8,,
+"PATCANXO","N05B-Anxiolytics","MTMOPPMT","Million US$, purchasing power parity","TUR","Türkiye","2019","2019",18.2,,
+"PATCANXO","N05B-Anxiolytics","MTMOPPMT","Million US$, purchasing power parity","TUR","Türkiye","2020","2020",20.4,,
+"PATCANXO","N05B-Anxiolytics","MTMOPPMT","Million US$, purchasing power parity","TUR","Türkiye","2021","2021",20.5,,
+"PATCANXO","N05B-Anxiolytics","TCPPERMT","/capita, US$ exchange rate","TUR","Türkiye","2010","2010",0.1,,
+"PATCANXO","N05B-Anxiolytics","TCPPERMT","/capita, US$ exchange rate","TUR","Türkiye","2011","2011",0.1,,
+"PATCANXO","N05B-Anxiolytics","TCPPERMT","/capita, US$ exchange rate","TUR","Türkiye","2012","2012",0.1,,
+"PATCANXO","N05B-Anxiolytics","TCPPERMT","/capita, US$ exchange rate","TUR","Türkiye","2013","2013",0.1,,
+"PATCANXO","N05B-Anxiolytics","TCPPERMT","/capita, US$ exchange rate","TUR","Türkiye","2014","2014",0.1,,
+"PATCANXO","N05B-Anxiolytics","TCPPERMT","/capita, US$ exchange rate","TUR","Türkiye","2015","2015",0.1,,
+"PATCANXO","N05B-Anxiolytics","TCPPERMT","/capita, US$ exchange rate","TUR","Türkiye","2016","2016",0.1,,
+"PATCANXO","N05B-Anxiolytics","TCPPERMT","/capita, US$ exchange rate","TUR","Türkiye","2017","2017",0.1,,
+"PATCANXO","N05B-Anxiolytics","TCPPERMT","/capita, US$ exchange rate","TUR","Türkiye","2018","2018",0.1,,
+"PATCANXO","N05B-Anxiolytics","TCPPERMT","/capita, US$ exchange rate","TUR","Türkiye","2019","2019",0.1,,
+"PATCANXO","N05B-Anxiolytics","TCPPERMT","/capita, US$ exchange rate","TUR","Türkiye","2020","2020",0.1,,
+"PATCANXO","N05B-Anxiolytics","TCPPERMT","/capita, US$ exchange rate","TUR","Türkiye","2021","2021",0.1,,
+"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2010","2010",0.2,,
+"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2011","2011",0.2,,
+"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2012","2012",0.2,,
+"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2013","2013",0.2,,
+"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2014","2014",0.2,,
+"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2015","2015",0.2,,
+"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2016","2016",0.1,,
+"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2017","2017",0.1,,
+"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2018","2018",0.2,,
+"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2019","2019",0.2,,
+"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2020","2020",0.2,,
+"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2021","2021",0.2,,
+"PATCANXO","N05B-Anxiolytics","ATCPTTMT","% of total sales","TUR","Türkiye","2010","2010",0.1,,
+"PATCANXO","N05B-Anxiolytics","ATCPTTMT","% of total sales","TUR","Türkiye","2011","2011",0.1,,
+"PATCANXO","N05B-Anxiolytics","ATCPTTMT","% of total sales","TUR","Türkiye","2012","2012",0.1,,
+"PATCANXO","N05B-Anxiolytics","ATCPTTMT","% of total sales","TUR","Türkiye","2013","2013",0.1,,
+"PATCANXO","N05B-Anxiolytics","ATCPTTMT","% of total sales","TUR","Türkiye","2014","2014",0.1,,
+"PATCANXO","N05B-Anxiolytics","ATCPTTMT","% of total sales","TUR","Türkiye","2015","2015",0.1,,
+"PATCANXO","N05B-Anxiolytics","ATCPTTMT","% of total sales","TUR","Türkiye","2016","2016",0.1,,
+"PATCANXO","N05B-Anxiolytics","ATCPTTMT","% of total sales","TUR","Türkiye","2017","2017",0.1,,
+"PATCANXO","N05B-Anxiolytics","ATCPTTMT","% of total sales","TUR","Türkiye","2018","2018",0.1,,
+"PATCANXO","N05B-Anxiolytics","ATCPTTMT","% of total sales","TUR","Türkiye","2019","2019",0.1,,
+"PATCANXO","N05B-Anxiolytics","ATCPTTMT","% of total sales","TUR","Türkiye","2020","2020",0.1,,
+"PATCANXO","N05B-Anxiolytics","ATCPTTMT","% of total sales","TUR","Türkiye","2021","2021",0.1,,
+"PATCANXO","N05B-Anxiolytics","MLLNCUMT","Million of national currency units","CHL","Chile","2010","2010",8596,,
+"PATCANXO","N05B-Anxiolytics","MLLNCUMT","Million of national currency units","CHL","Chile","2011","2011",9773,"B","Break"
+"PATCANXO","N05B-Anxiolytics","MLLNCUMT","Million of national currency units","CHL","Chile","2012","2012",10633.1,,
+"PATCANXO","N05B-Anxiolytics","MLLNCUMT","Million of national currency units","CHL","Chile","2013","2013",11038.7,,
+"PATCANXO","N05B-Anxiolytics","MLLNCUMT","Million of national currency units","CHL","Chile","2014","2014",11744.7,,
+"PATCANXO","N05B-Anxiolytics","MLLNCUMT","Million of national currency units","CHL","Chile","2015","2015",12721.9,,
+"PATCANXO","N05B-Anxiolytics","MLLNCUMT","Million of national currency units","CHL","Chile","2016","2016",13974.1,,
+"PATCANXO","N05B-Anxiolytics","MLLNCUMT","Million of national currency units","CHL","Chile","2017","2017",15592.8,,
+"PATCANXO","N05B-Anxiolytics","MLLNCUMT","Million of national currency units","CHL","Chile","2018","2018",16516.5,,
+"PATCANXO","N05B-Anxiolytics","MLLNCUMT","Million of national currency units","CHL","Chile","2019","2019",15342.7,,
+"PATCANXO","N05B-Anxiolytics","MLLNCUMT","Million of national currency units","CHL","Chile","2020","2020",15030.4,,
+"PATCANXO","N05B-Anxiolytics","MLLNCUMT","Million of national currency units","CHL","Chile","2021","2021",17699.2,,
+"PATCANXO","N05B-Anxiolytics","MLLNCUMT","Million of national currency units","CHL","Chile","2022","2022",17471.1,,
+"PATCANXO","N05B-Anxiolytics","MTMOTCMT","Million US$ at exchange rate","CHL","Chile","2010","2010",16.8,,
+"PATCANXO","N05B-Anxiolytics","MTMOTCMT","Million US$ at exchange rate","CHL","Chile","2011","2011",20.2,"B","Break"
+"PATCANXO","N05B-Anxiolytics","MTMOTCMT","Million US$ at exchange rate","CHL","Chile","2012","2012",21.9,,
+"PATCANXO","N05B-Anxiolytics","MTMOTCMT","Million US$ at exchange rate","CHL","Chile","2013","2013",22.3,,
+"PATCANXO","N05B-Anxiolytics","MTMOTCMT","Million US$ at exchange rate","CHL","Chile","2014","2014",20.6,,
+"PATCANXO","N05B-Anxiolytics","MTMOTCMT","Million US$ at exchange rate","CHL","Chile","2015","2015",19.4,,
+"PATCANXO","N05B-Anxiolytics","MTMOTCMT","Million US$ at exchange rate","CHL","Chile","2016","2016",20.6,,
+"PATCANXO","N05B-Anxiolytics","MTMOTCMT","Million US$ at exchange rate","CHL","Chile","2017","2017",24,,
+"PATCANXO","N05B-Anxiolytics","MTMOTCMT","Million US$ at exchange rate","CHL","Chile","2018","2018",25.8,,
+"PATCANXO","N05B-Anxiolytics","MTMOTCMT","Million US$ at exchange rate","CHL","Chile","2019","2019",21.8,,
+"PATCANXO","N05B-Anxiolytics","MTMOTCMT","Million US$ at exchange rate","CHL","Chile","2020","2020",19,,
+"PATCANXO","N05B-Anxiolytics","MTMOTCMT","Million US$ at exchange rate","CHL","Chile","2021","2021",23.3,,
+"PATCANXO","N05B-Anxiolytics","MTMOTCMT","Million US$ at exchange rate","CHL","Chile","2022","2022",20,,
+"PATCANXO","N05B-Anxiolytics","MTMOPPMT","Million US$, purchasing power parity","CHL","Chile","2010","2010",23.9,,
+"PATCANXO","N05B-Anxiolytics","MTMOPPMT","Million US$, purchasing power parity","CHL","Chile","2011","2011",28.1,"B","Break"
+"PATCANXO","N05B-Anxiolytics","MTMOPPMT","Million US$, purchasing power parity","CHL","Chile","2012","2012",30.6,,
+"PATCANXO","N05B-Anxiolytics","MTMOPPMT","Million US$, purchasing power parity","CHL","Chile","2013","2013",31.6,,
+"PATCANXO","N05B-Anxiolytics","MTMOPPMT","Million US$, purchasing power parity","CHL","Chile","2014","2014",32,,
+"PATCANXO","N05B-Anxiolytics","MTMOPPMT","Million US$, purchasing power parity","CHL","Chile","2015","2015",32.5,,
+"PATCANXO","N05B-Anxiolytics","MTMOPPMT","Million US$, purchasing power parity","CHL","Chile","2016","2016",35.2,,
+"PATCANXO","N05B-Anxiolytics","MTMOPPMT","Million US$, purchasing power parity","CHL","Chile","2017","2017",39.2,,
+"PATCANXO","N05B-Anxiolytics","MTMOPPMT","Million US$, purchasing power parity","CHL","Chile","2018","2018",41.7,,
+"PATCANXO","N05B-Anxiolytics","MTMOPPMT","Million US$, purchasing power parity","CHL","Chile","2019","2019",38.2,,
+"PATCANXO","N05B-Anxiolytics","MTMOPPMT","Million US$, purchasing power parity","CHL","Chile","2020","2020",35.9,,
+"PATCANXO","N05B-Anxiolytics","MTMOPPMT","Million US$, purchasing power parity","CHL","Chile","2021","2021",40.7,,
+"PATCANXO","N05B-Anxiolytics","MTMOPPMT","Million US$, purchasing power parity","CHL","Chile","2022","2022",39.9,,
+"PATCANXO","N05B-Anxiolytics","TCPPERMT","/capita, US$ exchange rate","CHL","Chile","2010","2010",1,,
+"PATCANXO","N05B-Anxiolytics","TCPPERMT","/capita, US$ exchange rate","CHL","Chile","2011","2011",1.2,"B","Break"
+"PATCANXO","N05B-Anxiolytics","TCPPERMT","/capita, US$ exchange rate","CHL","Chile","2012","2012",1.3,,
+"PATCANXO","N05B-Anxiolytics","TCPPERMT","/capita, US$ exchange rate","CHL","Chile","2013","2013",1.3,,
+"PATCANXO","N05B-Anxiolytics","TCPPERMT","/capita, US$ exchange rate","CHL","Chile","2014","2014",1.2,,
+"PATCANXO","N05B-Anxiolytics","TCPPERMT","/capita, US$ exchange rate","CHL","Chile","2015","2015",1.1,,
+"PATCANXO","N05B-Anxiolytics","TCPPERMT","/capita, US$ exchange rate","CHL","Chile","2016","2016",1.1,,
+"PATCANXO","N05B-Anxiolytics","TCPPERMT","/capita, US$ exchange rate","CHL","Chile","2017","2017",1.3,,
+"PATCANXO","N05B-Anxiolytics","TCPPERMT","/capita, US$ exchange rate","CHL","Chile","2018","2018",1.4,,
+"PATCANXO","N05B-Anxiolytics","TCPPERMT","/capita, US$ exchange rate","CHL","Chile","2019","2019",1.1,,
+"PATCANXO","N05B-Anxiolytics","TCPPERMT","/capita, US$ exchange rate","CHL","Chile","2020","2020",1,,
+"PATCANXO","N05B-Anxiolytics","TCPPERMT","/capita, US$ exchange rate","CHL","Chile","2021","2021",1.2,,
+"PATCANXO","N05B-Anxiolytics","TCPPERMT","/capita, US$ exchange rate","CHL","Chile","2022","2022",1,,
+"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2010","2010",1.4,,
+"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2011","2011",1.6,"B","Break"
+"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2012","2012",1.8,,
+"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2013","2013",1.8,,
+"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2014","2014",1.8,,
+"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2015","2015",1.8,,
+"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2016","2016",1.9,,
+"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2017","2017",2.1,,
+"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2018","2018",2.2,,
+"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2019","2019",2,,
+"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2020","2020",1.8,,
+"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2021","2021",2.1,,
+"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2022","2022",2,,
+"PATCANXO","N05B-Anxiolytics","ATCPTTMT","% of total sales","CHL","Chile","2010","2010",1,,
+"PATCANXO","N05B-Anxiolytics","ATCPTTMT","% of total sales","CHL","Chile","2011","2011",0.8,"B","Break"
+"PATCANXO","N05B-Anxiolytics","ATCPTTMT","% of total sales","CHL","Chile","2012","2012",0.9,,
+"PATCANXO","N05B-Anxiolytics","ATCPTTMT","% of total sales","CHL","Chile","2013","2013",0.8,,
+"PATCANXO","N05B-Anxiolytics","ATCPTTMT","% of total sales","CHL","Chile","2014","2014",0.8,,
+"PATCANXO","N05B-Anxiolytics","ATCPTTMT","% of total sales","CHL","Chile","2015","2015",0.7,,
+"PATCANXO","N05B-Anxiolytics","ATCPTTMT","% of total sales","CHL","Chile","2016","2016",0.7,,
+"PATCANXO","N05B-Anxiolytics","ATCPTTMT","% of total sales","CHL","Chile","2017","2017",0.8,,
+"PATCANXO","N05B-Anxiolytics","ATCPTTMT","% of total sales","CHL","Chile","2018","2018",0.7,,
+"PATCANXO","N05B-Anxiolytics","ATCPTTMT","% of total sales","CHL","Chile","2019","2019",0.6,,
+"PATCANXO","N05B-Anxiolytics","ATCPTTMT","% of total sales","CHL","Chile","2020","2020",0.6,,
+"PATCANXO","N05B-Anxiolytics","ATCPTTMT","% of total sales","CHL","Chile","2021","2021",0.6,,
+"PATCANXO","N05B-Anxiolytics","ATCPTTMT","% of total sales","CHL","Chile","2022","2022",0.6,,
+"PATCANXO","N05B-Anxiolytics","MLLNCUMT","Million of national currency units","EST","Estonia","2010","2010",1.1,,
+"PATCANXO","N05B-Anxiolytics","MLLNCUMT","Million of national currency units","EST","Estonia","2011","2011",1.2,,
+"PATCANXO","N05B-Anxiolytics","MLLNCUMT","Million of national currency units","EST","Estonia","2012","2012",1.3,,
+"PATCANXO","N05B-Anxiolytics","MLLNCUMT","Million of national currency units","EST","Estonia","2013","2013",1.3,,
+"PATCANXO","N05B-Anxiolytics","MLLNCUMT","Million of national currency units","EST","Estonia","2014","2014",1.4,,
+"PATCANXO","N05B-Anxiolytics","MLLNCUMT","Million of national currency units","EST","Estonia","2015","2015",1.4,,
+"PATCANXO","N05B-Anxiolytics","MLLNCUMT","Million of national currency units","EST","Estonia","2016","2016",1.4,,
+"PATCANXO","N05B-Anxiolytics","MLLNCUMT","Million of national currency units","EST","Estonia","2017","2017",1.4,,
+"PATCANXO","N05B-Anxiolytics","MLLNCUMT","Million of national currency units","EST","Estonia","2018","2018",1.3,,
+"PATCANXO","N05B-Anxiolytics","MLLNCUMT","Million of national currency units","EST","Estonia","2019","2019",1.4,,
+"PATCANXO","N05B-Anxiolytics","MLLNCUMT","Million of national currency units","EST","Estonia","2020","2020",1.4,,
+"PATCANXO","N05B-Anxiolytics","MLLNCUMT","Million of national currency units","EST","Estonia","2021","2021",1.5,,
+"PATCANXO","N05B-Anxiolytics","MLLNCUMT","Million of national currency units","EST","Estonia","2022","2022",1.6,,
+"PATCANXO","N05B-Anxiolytics","MTMOTCMT","Million US$ at exchange rate","EST","Estonia","2010","2010",1.5,,
+"PATCANXO","N05B-Anxiolytics","MTMOTCMT","Million US$ at exchange rate","EST","Estonia","2011","2011",1.6,,
+"PATCANXO","N05B-Anxiolytics","MTMOTCMT","Million US$ at exchange rate","EST","Estonia","2012","2012",1.6,,
+"PATCANXO","N05B-Anxiolytics","MTMOTCMT","Million US$ at exchange rate","EST","Estonia","2013","2013",1.8,,
+"PATCANXO","N05B-Anxiolytics","MTMOTCMT","Million US$ at exchange rate","EST","Estonia","2014","2014",1.9,,
+"PATCANXO","N05B-Anxiolytics","MTMOTCMT","Million US$ at exchange rate","EST","Estonia","2015","2015",1.6,,
+"PATCANXO","N05B-Anxiolytics","MTMOTCMT","Million US$ at exchange rate","EST","Estonia","2016","2016",1.5,,
+"PATCANXO","N05B-Anxiolytics","MTMOTCMT","Million US$ at exchange rate","EST","Estonia","2017","2017",1.6,,
+"PATCANXO","N05B-Anxiolytics","MTMOTCMT","Million US$ at exchange rate","EST","Estonia","2018","2018",1.6,,
+"PATCANXO","N05B-Anxiolytics","MTMOTCMT","Million US$ at exchange rate","EST","Estonia","2019","2019",1.6,,
+"PATCANXO","N05B-Anxiolytics","MTMOTCMT","Million US$ at exchange rate","EST","Estonia","2020","2020",1.6,,
+"PATCANXO","N05B-Anxiolytics","MTMOTCMT","Million US$ at exchange rate","EST","Estonia","2021","2021",1.8,,
+"PATCANXO","N05B-Anxiolytics","MTMOTCMT","Million US$ at exchange rate","EST","Estonia","2022","2022",1.7,,
+"PATCANXO","N05B-Anxiolytics","MTMOPPMT","Million US$, purchasing power parity","EST","Estonia","2010","2010",2.2,,
+"PATCANXO","N05B-Anxiolytics","MTMOPPMT","Million US$, purchasing power parity","EST","Estonia","2011","2011",2.3,,
+"PATCANXO","N05B-Anxiolytics","MTMOPPMT","Million US$, purchasing power parity","EST","Estonia","2012","2012",2.4,,
+"PATCANXO","N05B-Anxiolytics","MTMOPPMT","Million US$, purchasing power parity","EST","Estonia","2013","2013",2.5,,
+"PATCANXO","N05B-Anxiolytics","MTMOPPMT","Million US$, purchasing power parity","EST","Estonia","2014","2014",2.7,,
+"PATCANXO","N05B-Anxiolytics","MTMOPPMT","Million US$, purchasing power parity","EST","Estonia","2015","2015",2.6,,
+"PATCANXO","N05B-Anxiolytics","MTMOPPMT","Million US$, purchasing power parity","EST","Estonia","2016","2016",2.6,,
+"PATCANXO","N05B-Anxiolytics","MTMOPPMT","Million US$, purchasing power parity","EST","Estonia","2017","2017",2.6,,
+"PATCANXO","N05B-Anxiolytics","MTMOPPMT","Million US$, purchasing power parity","EST","Estonia","2018","2018",2.5,,
+"PATCANXO","N05B-Anxiolytics","MTMOPPMT","Million US$, purchasing power parity","EST","Estonia","2019","2019",2.6,,
+"PATCANXO","N05B-Anxiolytics","MTMOPPMT","Million US$, purchasing power parity","EST","Estonia","2020","2020",2.7,,
+"PATCANXO","N05B-Anxiolytics","MTMOPPMT","Million US$, purchasing power parity","EST","Estonia","2021","2021",2.8,,
+"PATCANXO","N05B-Anxiolytics","MTMOPPMT","Million US$, purchasing power parity","EST","Estonia","2022","2022",2.8,,
+"PATCANXO","N05B-Anxiolytics","TCPPERMT","/capita, US$ exchange rate","EST","Estonia","2010","2010",1.1,,
+"PATCANXO","N05B-Anxiolytics","TCPPERMT","/capita, US$ exchange rate","EST","Estonia","2011","2011",1.2,,
+"PATCANXO","N05B-Anxiolytics","TCPPERMT","/capita, US$ exchange rate","EST","Estonia","2012","2012",1.2,,
+"PATCANXO","N05B-Anxiolytics","TCPPERMT","/capita, US$ exchange rate","EST","Estonia","2013","2013",1.3,,
+"PATCANXO","N05B-Anxiolytics","TCPPERMT","/capita, US$ exchange rate","EST","Estonia","2014","2014",1.4,,
+"PATCANXO","N05B-Anxiolytics","TCPPERMT","/capita, US$ exchange rate","EST","Estonia","2015","2015",1.2,,
+"PATCANXO","N05B-Anxiolytics","TCPPERMT","/capita, US$ exchange rate","EST","Estonia","2016","2016",1.2,,
+"PATCANXO","N05B-Anxiolytics","TCPPERMT","/capita, US$ exchange rate","EST","Estonia","2017","2017",1.2,,
+"PATCANXO","N05B-Anxiolytics","TCPPERMT","/capita, US$ exchange rate","EST","Estonia","2018","2018",1.2,,
+"PATCANXO","N05B-Anxiolytics","TCPPERMT","/capita, US$ exchange rate","EST","Estonia","2019","2019",1.2,,
+"PATCANXO","N05B-Anxiolytics","TCPPERMT","/capita, US$ exchange rate","EST","Estonia","2020","2020",1.2,,
+"PATCANXO","N05B-Anxiolytics","TCPPERMT","/capita, US$ exchange rate","EST","Estonia","2021","2021",1.3,,
+"PATCANXO","N05B-Anxiolytics","TCPPERMT","/capita, US$ exchange rate","EST","Estonia","2022","2022",1.3,,
+"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2010","2010",1.7,,
+"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2011","2011",1.7,,
+"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2012","2012",1.8,,
+"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2013","2013",1.9,,
+"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2014","2014",2,,
+"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2015","2015",2,,
+"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2016","2016",2,,
+"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2017","2017",2,,
+"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2018","2018",1.9,,
+"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2019","2019",2,,
+"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2020","2020",2.1,,
+"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2021","2021",2.1,,
+"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2022","2022",2.1,,
+"PATCANXO","N05B-Anxiolytics","ATCPTTMT","% of total sales","EST","Estonia","2010","2010",0.6,,
+"PATCANXO","N05B-Anxiolytics","ATCPTTMT","% of total sales","EST","Estonia","2011","2011",0.6,,
+"PATCANXO","N05B-Anxiolytics","ATCPTTMT","% of total sales","EST","Estonia","2012","2012",0.6,,
+"PATCANXO","N05B-Anxiolytics","ATCPTTMT","% of total sales","EST","Estonia","2013","2013",0.6,,
+"PATCANXO","N05B-Anxiolytics","ATCPTTMT","% of total sales","EST","Estonia","2014","2014",0.6,,
+"PATCANXO","N05B-Anxiolytics","ATCPTTMT","% of total sales","EST","Estonia","2015","2015",0.5,,
+"PATCANXO","N05B-Anxiolytics","ATCPTTMT","% of total sales","EST","Estonia","2016","2016",0.5,,
+"PATCANXO","N05B-Anxiolytics","ATCPTTMT","% of total sales","EST","Estonia","2017","2017",0.5,,
+"PATCANXO","N05B-Anxiolytics","ATCPTTMT","% of total sales","EST","Estonia","2018","2018",0.4,,
+"PATCANXO","N05B-Anxiolytics","ATCPTTMT","% of total sales","EST","Estonia","2019","2019",0.4,,
+"PATCANXO","N05B-Anxiolytics","ATCPTTMT","% of total sales","EST","Estonia","2020","2020",0.4,,
+"PATCANXO","N05B-Anxiolytics","ATCPTTMT","% of total sales","EST","Estonia","2021","2021",0.4,,
+"PATCANXO","N05B-Anxiolytics","ATCPTTMT","% of total sales","EST","Estonia","2022","2022",0.4,,
+"PATCANXO","N05B-Anxiolytics","MLLNCUMT","Million of national currency units","SVN","Slovenia","2010","2010",3,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","MLLNCUMT","Million of national currency units","SVN","Slovenia","2011","2011",2.9,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","MLLNCUMT","Million of national currency units","SVN","Slovenia","2012","2012",2.9,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","MLLNCUMT","Million of national currency units","SVN","Slovenia","2013","2013",3,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","MLLNCUMT","Million of national currency units","SVN","Slovenia","2014","2014",2.8,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","MLLNCUMT","Million of national currency units","SVN","Slovenia","2015","2015",2.7,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","MLLNCUMT","Million of national currency units","SVN","Slovenia","2016","2016",2.7,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","MLLNCUMT","Million of national currency units","SVN","Slovenia","2017","2017",2.6,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","MLLNCUMT","Million of national currency units","SVN","Slovenia","2018","2018",2.7,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","MLLNCUMT","Million of national currency units","SVN","Slovenia","2019","2019",2.8,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","MLLNCUMT","Million of national currency units","SVN","Slovenia","2020","2020",3,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","MLLNCUMT","Million of national currency units","SVN","Slovenia","2021","2021",3,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","MLLNCUMT","Million of national currency units","SVN","Slovenia","2022","2022",2.9,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","MTMOTCMT","Million US$ at exchange rate","SVN","Slovenia","2010","2010",4,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","MTMOTCMT","Million US$ at exchange rate","SVN","Slovenia","2011","2011",4.1,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","MTMOTCMT","Million US$ at exchange rate","SVN","Slovenia","2012","2012",3.7,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","MTMOTCMT","Million US$ at exchange rate","SVN","Slovenia","2013","2013",3.9,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","MTMOTCMT","Million US$ at exchange rate","SVN","Slovenia","2014","2014",3.7,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","MTMOTCMT","Million US$ at exchange rate","SVN","Slovenia","2015","2015",3.1,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","MTMOTCMT","Million US$ at exchange rate","SVN","Slovenia","2016","2016",3,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","MTMOTCMT","Million US$ at exchange rate","SVN","Slovenia","2017","2017",3,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","MTMOTCMT","Million US$ at exchange rate","SVN","Slovenia","2018","2018",3.2,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","MTMOTCMT","Million US$ at exchange rate","SVN","Slovenia","2019","2019",3.2,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","MTMOTCMT","Million US$ at exchange rate","SVN","Slovenia","2020","2020",3.4,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","MTMOTCMT","Million US$ at exchange rate","SVN","Slovenia","2021","2021",3.5,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","MTMOTCMT","Million US$ at exchange rate","SVN","Slovenia","2022","2022",3,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","MTMOPPMT","Million US$, purchasing power parity","SVN","Slovenia","2010","2010",4.7,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","MTMOPPMT","Million US$, purchasing power parity","SVN","Slovenia","2011","2011",4.7,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","MTMOPPMT","Million US$, purchasing power parity","SVN","Slovenia","2012","2012",4.7,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","MTMOPPMT","Million US$, purchasing power parity","SVN","Slovenia","2013","2013",5,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","MTMOPPMT","Million US$, purchasing power parity","SVN","Slovenia","2014","2014",4.8,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","MTMOPPMT","Million US$, purchasing power parity","SVN","Slovenia","2015","2015",4.6,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","MTMOPPMT","Million US$, purchasing power parity","SVN","Slovenia","2016","2016",4.7,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","MTMOPPMT","Million US$, purchasing power parity","SVN","Slovenia","2017","2017",4.6,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","MTMOPPMT","Million US$, purchasing power parity","SVN","Slovenia","2018","2018",4.8,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","MTMOPPMT","Million US$, purchasing power parity","SVN","Slovenia","2019","2019",5.1,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","MTMOPPMT","Million US$, purchasing power parity","SVN","Slovenia","2020","2020",5.5,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","MTMOPPMT","Million US$, purchasing power parity","SVN","Slovenia","2021","2021",5.3,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","MTMOPPMT","Million US$, purchasing power parity","SVN","Slovenia","2022","2022",5.3,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","TCPPERMT","/capita, US$ exchange rate","SVN","Slovenia","2010","2010",1.9,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","TCPPERMT","/capita, US$ exchange rate","SVN","Slovenia","2011","2011",2,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","TCPPERMT","/capita, US$ exchange rate","SVN","Slovenia","2012","2012",1.8,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","TCPPERMT","/capita, US$ exchange rate","SVN","Slovenia","2013","2013",1.9,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","TCPPERMT","/capita, US$ exchange rate","SVN","Slovenia","2014","2014",1.8,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","TCPPERMT","/capita, US$ exchange rate","SVN","Slovenia","2015","2015",1.5,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","TCPPERMT","/capita, US$ exchange rate","SVN","Slovenia","2016","2016",1.4,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","TCPPERMT","/capita, US$ exchange rate","SVN","Slovenia","2017","2017",1.4,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","TCPPERMT","/capita, US$ exchange rate","SVN","Slovenia","2018","2018",1.6,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","TCPPERMT","/capita, US$ exchange rate","SVN","Slovenia","2019","2019",1.5,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","TCPPERMT","/capita, US$ exchange rate","SVN","Slovenia","2020","2020",1.6,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","TCPPERMT","/capita, US$ exchange rate","SVN","Slovenia","2021","2021",1.7,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","TCPPERMT","/capita, US$ exchange rate","SVN","Slovenia","2022","2022",1.4,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2010","2010",2.3,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2011","2011",2.3,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2012","2012",2.3,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2013","2013",2.4,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2014","2014",2.3,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2015","2015",2.2,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2016","2016",2.3,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2017","2017",2.2,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2018","2018",2.3,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2019","2019",2.5,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2020","2020",2.6,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2021","2021",2.5,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2022","2022",2.5,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","ATCPTTMT","% of total sales","SVN","Slovenia","2010","2010",0.6,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","ATCPTTMT","% of total sales","SVN","Slovenia","2011","2011",0.6,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","ATCPTTMT","% of total sales","SVN","Slovenia","2012","2012",0.6,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","ATCPTTMT","% of total sales","SVN","Slovenia","2013","2013",0.7,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","ATCPTTMT","% of total sales","SVN","Slovenia","2014","2014",0.7,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","ATCPTTMT","% of total sales","SVN","Slovenia","2015","2015",0.6,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","ATCPTTMT","% of total sales","SVN","Slovenia","2016","2016",0.6,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","ATCPTTMT","% of total sales","SVN","Slovenia","2017","2017",0.5,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","ATCPTTMT","% of total sales","SVN","Slovenia","2018","2018",0.5,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","ATCPTTMT","% of total sales","SVN","Slovenia","2019","2019",0.5,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","ATCPTTMT","% of total sales","SVN","Slovenia","2020","2020",0.5,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","ATCPTTMT","% of total sales","SVN","Slovenia","2021","2021",0.5,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","ATCPTTMT","% of total sales","SVN","Slovenia","2022","2022",0.4,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","MLLNCUMT","Million of national currency units","AUS","Australia","2010","2010",19,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","MLLNCUMT","Million of national currency units","AUS","Australia","2011","2011",18,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","MLLNCUMT","Million of national currency units","AUS","Australia","2012","2012",17,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","MLLNCUMT","Million of national currency units","AUS","Australia","2013","2013",21,"B; D","Break; Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","MLLNCUMT","Million of national currency units","AUS","Australia","2014","2014",21,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","MLLNCUMT","Million of national currency units","AUS","Australia","2015","2015",24,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","MLLNCUMT","Million of national currency units","AUS","Australia","2016","2016",28,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","MLLNCUMT","Million of national currency units","AUS","Australia","2017","2017",28,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","MLLNCUMT","Million of national currency units","AUS","Australia","2018","2018",28,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","MLLNCUMT","Million of national currency units","AUS","Australia","2019","2019",27,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","MLLNCUMT","Million of national currency units","AUS","Australia","2020","2020",26,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","MLLNCUMT","Million of national currency units","AUS","Australia","2021","2021",24,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","MTMOTCMT","Million US$ at exchange rate","AUS","Australia","2010","2010",17.4,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","MTMOTCMT","Million US$ at exchange rate","AUS","Australia","2011","2011",18.6,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","MTMOTCMT","Million US$ at exchange rate","AUS","Australia","2012","2012",17.6,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","MTMOTCMT","Million US$ at exchange rate","AUS","Australia","2013","2013",20.3,"B; D","Break; Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","MTMOTCMT","Million US$ at exchange rate","AUS","Australia","2014","2014",18.9,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","MTMOTCMT","Million US$ at exchange rate","AUS","Australia","2015","2015",18,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","MTMOTCMT","Million US$ at exchange rate","AUS","Australia","2016","2016",20.8,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","MTMOTCMT","Million US$ at exchange rate","AUS","Australia","2017","2017",21.5,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","MTMOTCMT","Million US$ at exchange rate","AUS","Australia","2018","2018",20.9,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","MTMOTCMT","Million US$ at exchange rate","AUS","Australia","2019","2019",18.8,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","MTMOTCMT","Million US$ at exchange rate","AUS","Australia","2020","2020",17.9,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","MTMOTCMT","Million US$ at exchange rate","AUS","Australia","2021","2021",18,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","MTMOPPMT","Million US$, purchasing power parity","AUS","Australia","2010","2010",12.6,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","MTMOPPMT","Million US$, purchasing power parity","AUS","Australia","2011","2011",11.9,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","MTMOPPMT","Million US$, purchasing power parity","AUS","Australia","2012","2012",11,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","MTMOPPMT","Million US$, purchasing power parity","AUS","Australia","2013","2013",14.5,"B; D","Break; Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","MTMOPPMT","Million US$, purchasing power parity","AUS","Australia","2014","2014",14.5,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","MTMOPPMT","Million US$, purchasing power parity","AUS","Australia","2015","2015",16.3,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","MTMOPPMT","Million US$, purchasing power parity","AUS","Australia","2016","2016",19.3,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","MTMOPPMT","Million US$, purchasing power parity","AUS","Australia","2017","2017",19,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","MTMOPPMT","Million US$, purchasing power parity","AUS","Australia","2018","2018",19,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","MTMOPPMT","Million US$, purchasing power parity","AUS","Australia","2019","2019",18.2,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","MTMOPPMT","Million US$, purchasing power parity","AUS","Australia","2020","2020",17.9,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","MTMOPPMT","Million US$, purchasing power parity","AUS","Australia","2021","2021",16.6,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","TCPPERMT","/capita, US$ exchange rate","AUS","Australia","2010","2010",0.8,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","TCPPERMT","/capita, US$ exchange rate","AUS","Australia","2011","2011",0.8,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","TCPPERMT","/capita, US$ exchange rate","AUS","Australia","2012","2012",0.8,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","TCPPERMT","/capita, US$ exchange rate","AUS","Australia","2013","2013",0.9,"B; D","Break; Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","TCPPERMT","/capita, US$ exchange rate","AUS","Australia","2014","2014",0.8,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","TCPPERMT","/capita, US$ exchange rate","AUS","Australia","2015","2015",0.8,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","TCPPERMT","/capita, US$ exchange rate","AUS","Australia","2016","2016",0.9,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","TCPPERMT","/capita, US$ exchange rate","AUS","Australia","2017","2017",0.9,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","TCPPERMT","/capita, US$ exchange rate","AUS","Australia","2018","2018",0.8,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","TCPPERMT","/capita, US$ exchange rate","AUS","Australia","2019","2019",0.7,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","TCPPERMT","/capita, US$ exchange rate","AUS","Australia","2020","2020",0.7,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","TCPPERMT","/capita, US$ exchange rate","AUS","Australia","2021","2021",0.7,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2010","2010",0.6,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2011","2011",0.5,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2012","2012",0.5,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2013","2013",0.6,"B; D","Break; Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2014","2014",0.6,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2015","2015",0.7,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2016","2016",0.8,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2017","2017",0.8,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2018","2018",0.8,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2019","2019",0.7,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2020","2020",0.7,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2021","2021",0.6,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","ATCPTTMT","% of total sales","AUS","Australia","2010","2010",0.2,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","ATCPTTMT","% of total sales","AUS","Australia","2011","2011",0.2,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","ATCPTTMT","% of total sales","AUS","Australia","2012","2012",0.2,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","ATCPTTMT","% of total sales","AUS","Australia","2013","2013",0.2,"B; D","Break; Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","ATCPTTMT","% of total sales","AUS","Australia","2014","2014",0.2,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","ATCPTTMT","% of total sales","AUS","Australia","2015","2015",0.2,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","ATCPTTMT","% of total sales","AUS","Australia","2016","2016",0.2,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","ATCPTTMT","% of total sales","AUS","Australia","2017","2017",0.2,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","ATCPTTMT","% of total sales","AUS","Australia","2018","2018",0.2,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","ATCPTTMT","% of total sales","AUS","Australia","2019","2019",0.2,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","ATCPTTMT","% of total sales","AUS","Australia","2020","2020",0.2,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","ATCPTTMT","% of total sales","AUS","Australia","2021","2021",0.1,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","MLLNCUMT","Million of national currency units","AUT","Austria","2010","2010",2.5,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","MLLNCUMT","Million of national currency units","AUT","Austria","2011","2011",2.6,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","MLLNCUMT","Million of national currency units","AUT","Austria","2012","2012",2.6,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","MLLNCUMT","Million of national currency units","AUT","Austria","2013","2013",2.6,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","MLLNCUMT","Million of national currency units","AUT","Austria","2014","2014",2.8,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","MLLNCUMT","Million of national currency units","AUT","Austria","2015","2015",2.6,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","MLLNCUMT","Million of national currency units","AUT","Austria","2016","2016",2.7,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","MLLNCUMT","Million of national currency units","AUT","Austria","2017","2017",2.9,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","MLLNCUMT","Million of national currency units","AUT","Austria","2018","2018",2.8,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","MLLNCUMT","Million of national currency units","AUT","Austria","2019","2019",2.9,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","MLLNCUMT","Million of national currency units","AUT","Austria","2020","2020",3,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","MLLNCUMT","Million of national currency units","AUT","Austria","2021","2021",2.9,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","MTMOTCMT","Million US$ at exchange rate","AUT","Austria","2010","2010",3.3,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","MTMOTCMT","Million US$ at exchange rate","AUT","Austria","2011","2011",3.7,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","MTMOTCMT","Million US$ at exchange rate","AUT","Austria","2012","2012",3.3,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","MTMOTCMT","Million US$ at exchange rate","AUT","Austria","2013","2013",3.4,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","MTMOTCMT","Million US$ at exchange rate","AUT","Austria","2014","2014",3.7,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","MTMOTCMT","Million US$ at exchange rate","AUT","Austria","2015","2015",2.9,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","MTMOTCMT","Million US$ at exchange rate","AUT","Austria","2016","2016",3,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","MTMOTCMT","Million US$ at exchange rate","AUT","Austria","2017","2017",3.3,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","MTMOTCMT","Million US$ at exchange rate","AUT","Austria","2018","2018",3.3,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","MTMOTCMT","Million US$ at exchange rate","AUT","Austria","2019","2019",3.3,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","MTMOTCMT","Million US$ at exchange rate","AUT","Austria","2020","2020",3.4,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","MTMOTCMT","Million US$ at exchange rate","AUT","Austria","2021","2021",3.4,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","MTMOPPMT","Million US$, purchasing power parity","AUT","Austria","2010","2010",3,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","MTMOPPMT","Million US$, purchasing power parity","AUT","Austria","2011","2011",3.2,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","MTMOPPMT","Million US$, purchasing power parity","AUT","Austria","2012","2012",3.2,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","MTMOPPMT","Million US$, purchasing power parity","AUT","Austria","2013","2013",3.2,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","MTMOPPMT","Million US$, purchasing power parity","AUT","Austria","2014","2014",3.5,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","MTMOPPMT","Million US$, purchasing power parity","AUT","Austria","2015","2015",3.2,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","MTMOPPMT","Million US$, purchasing power parity","AUT","Austria","2016","2016",3.5,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","MTMOPPMT","Million US$, purchasing power parity","AUT","Austria","2017","2017",3.8,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","MTMOPPMT","Million US$, purchasing power parity","AUT","Austria","2018","2018",3.7,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","MTMOPPMT","Million US$, purchasing power parity","AUT","Austria","2019","2019",3.9,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","MTMOPPMT","Million US$, purchasing power parity","AUT","Austria","2020","2020",4,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","MTMOPPMT","Million US$, purchasing power parity","AUT","Austria","2021","2021",3.9,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","TCPPERMT","/capita, US$ exchange rate","AUT","Austria","2010","2010",0.4,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","TCPPERMT","/capita, US$ exchange rate","AUT","Austria","2011","2011",0.4,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","TCPPERMT","/capita, US$ exchange rate","AUT","Austria","2012","2012",0.4,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","TCPPERMT","/capita, US$ exchange rate","AUT","Austria","2013","2013",0.4,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","TCPPERMT","/capita, US$ exchange rate","AUT","Austria","2014","2014",0.4,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","TCPPERMT","/capita, US$ exchange rate","AUT","Austria","2015","2015",0.3,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","TCPPERMT","/capita, US$ exchange rate","AUT","Austria","2016","2016",0.3,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","TCPPERMT","/capita, US$ exchange rate","AUT","Austria","2017","2017",0.4,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","TCPPERMT","/capita, US$ exchange rate","AUT","Austria","2018","2018",0.4,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","TCPPERMT","/capita, US$ exchange rate","AUT","Austria","2019","2019",0.4,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","TCPPERMT","/capita, US$ exchange rate","AUT","Austria","2020","2020",0.4,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","TCPPERMT","/capita, US$ exchange rate","AUT","Austria","2021","2021",0.4,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2010","2010",0.4,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2011","2011",0.4,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2012","2012",0.4,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2013","2013",0.4,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2014","2014",0.4,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2015","2015",0.4,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2016","2016",0.4,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2017","2017",0.4,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2018","2018",0.4,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2019","2019",0.4,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2020","2020",0.4,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2021","2021",0.4,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","ATCPTTMT","% of total sales","AUT","Austria","2010","2010",0.1,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","ATCPTTMT","% of total sales","AUT","Austria","2011","2011",0.1,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","ATCPTTMT","% of total sales","AUT","Austria","2012","2012",0.1,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","ATCPTTMT","% of total sales","AUT","Austria","2013","2013",0.1,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","ATCPTTMT","% of total sales","AUT","Austria","2014","2014",0.1,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","ATCPTTMT","% of total sales","AUT","Austria","2015","2015",0.1,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","ATCPTTMT","% of total sales","AUT","Austria","2016","2016",0.1,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","ATCPTTMT","% of total sales","AUT","Austria","2017","2017",0.1,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","ATCPTTMT","% of total sales","AUT","Austria","2018","2018",0.1,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","ATCPTTMT","% of total sales","AUT","Austria","2019","2019",0.1,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","ATCPTTMT","% of total sales","AUT","Austria","2020","2020",0.1,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","ATCPTTMT","% of total sales","AUT","Austria","2021","2021",0.1,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","MLLNCUMT","Million of national currency units","BEL","Belgium","2010","2010",67.6,,
+"PATCHYPN","N05C-Hypnotics and sedatives","MLLNCUMT","Million of national currency units","BEL","Belgium","2011","2011",71.2,,
+"PATCHYPN","N05C-Hypnotics and sedatives","MLLNCUMT","Million of national currency units","BEL","Belgium","2012","2012",70.2,,
+"PATCHYPN","N05C-Hypnotics and sedatives","MLLNCUMT","Million of national currency units","BEL","Belgium","2013","2013",75.4,,
+"PATCHYPN","N05C-Hypnotics and sedatives","MLLNCUMT","Million of national currency units","BEL","Belgium","2014","2014",75.3,,
+"PATCHYPN","N05C-Hypnotics and sedatives","MLLNCUMT","Million of national currency units","BEL","Belgium","2015","2015",78,,
+"PATCHYPN","N05C-Hypnotics and sedatives","MLLNCUMT","Million of national currency units","BEL","Belgium","2016","2016",77.6,,
+"PATCHYPN","N05C-Hypnotics and sedatives","MLLNCUMT","Million of national currency units","BEL","Belgium","2017","2017",77.2,,
+"PATCHYPN","N05C-Hypnotics and sedatives","MLLNCUMT","Million of national currency units","BEL","Belgium","2018","2018",74,,
+"PATCHYPN","N05C-Hypnotics and sedatives","MLLNCUMT","Million of national currency units","BEL","Belgium","2019","2019",66.7,,
+"PATCHYPN","N05C-Hypnotics and sedatives","MLLNCUMT","Million of national currency units","BEL","Belgium","2020","2020",72.6,,
+"PATCHYPN","N05C-Hypnotics and sedatives","MLLNCUMT","Million of national currency units","BEL","Belgium","2021","2021",74.6,,
+"PATCHYPN","N05C-Hypnotics and sedatives","MLLNCUMT","Million of national currency units","BEL","Belgium","2022","2022",73.6,"E","Estimated value"
+"PATCHYPN","N05C-Hypnotics and sedatives","MTMOTCMT","Million US$ at exchange rate","BEL","Belgium","2010","2010",89.7,,
+"PATCHYPN","N05C-Hypnotics and sedatives","MTMOTCMT","Million US$ at exchange rate","BEL","Belgium","2011","2011",99.1,,
+"PATCHYPN","N05C-Hypnotics and sedatives","MTMOTCMT","Million US$ at exchange rate","BEL","Belgium","2012","2012",90.2,,
+"PATCHYPN","N05C-Hypnotics and sedatives","MTMOTCMT","Million US$ at exchange rate","BEL","Belgium","2013","2013",100.2,,
+"PATCHYPN","N05C-Hypnotics and sedatives","MTMOTCMT","Million US$ at exchange rate","BEL","Belgium","2014","2014",100,,
+"PATCHYPN","N05C-Hypnotics and sedatives","MTMOTCMT","Million US$ at exchange rate","BEL","Belgium","2015","2015",86.6,,
+"PATCHYPN","N05C-Hypnotics and sedatives","MTMOTCMT","Million US$ at exchange rate","BEL","Belgium","2016","2016",85.9,,
+"PATCHYPN","N05C-Hypnotics and sedatives","MTMOTCMT","Million US$ at exchange rate","BEL","Belgium","2017","2017",87.2,,
+"PATCHYPN","N05C-Hypnotics and sedatives","MTMOTCMT","Million US$ at exchange rate","BEL","Belgium","2018","2018",87.4,,
+"PATCHYPN","N05C-Hypnotics and sedatives","MTMOTCMT","Million US$ at exchange rate","BEL","Belgium","2019","2019",74.6,,
+"PATCHYPN","N05C-Hypnotics and sedatives","MTMOTCMT","Million US$ at exchange rate","BEL","Belgium","2020","2020",82.9,,
+"PATCHYPN","N05C-Hypnotics and sedatives","MTMOTCMT","Million US$ at exchange rate","BEL","Belgium","2021","2021",88.2,,
+"PATCHYPN","N05C-Hypnotics and sedatives","MTMOTCMT","Million US$ at exchange rate","BEL","Belgium","2022","2022",77.5,"E","Estimated value"
+"PATCHYPN","N05C-Hypnotics and sedatives","MTMOPPMT","Million US$, purchasing power parity","BEL","Belgium","2010","2010",80.9,,
+"PATCHYPN","N05C-Hypnotics and sedatives","MTMOPPMT","Million US$, purchasing power parity","BEL","Belgium","2011","2011",85.5,,
+"PATCHYPN","N05C-Hypnotics and sedatives","MTMOPPMT","Million US$, purchasing power parity","BEL","Belgium","2012","2012",85.4,,
+"PATCHYPN","N05C-Hypnotics and sedatives","MTMOPPMT","Million US$, purchasing power parity","BEL","Belgium","2013","2013",93.6,,
+"PATCHYPN","N05C-Hypnotics and sedatives","MTMOPPMT","Million US$, purchasing power parity","BEL","Belgium","2014","2014",94,,
+"PATCHYPN","N05C-Hypnotics and sedatives","MTMOPPMT","Million US$, purchasing power parity","BEL","Belgium","2015","2015",97.6,,
+"PATCHYPN","N05C-Hypnotics and sedatives","MTMOPPMT","Million US$, purchasing power parity","BEL","Belgium","2016","2016",99.4,,
+"PATCHYPN","N05C-Hypnotics and sedatives","MTMOPPMT","Million US$, purchasing power parity","BEL","Belgium","2017","2017",99.5,,
+"PATCHYPN","N05C-Hypnotics and sedatives","MTMOPPMT","Million US$, purchasing power parity","BEL","Belgium","2018","2018",96.5,,
+"PATCHYPN","N05C-Hypnotics and sedatives","MTMOPPMT","Million US$, purchasing power parity","BEL","Belgium","2019","2019",89.3,,
+"PATCHYPN","N05C-Hypnotics and sedatives","MTMOPPMT","Million US$, purchasing power parity","BEL","Belgium","2020","2020",99.4,,
+"PATCHYPN","N05C-Hypnotics and sedatives","MTMOPPMT","Million US$, purchasing power parity","BEL","Belgium","2021","2021",101.2,,
+"PATCHYPN","N05C-Hypnotics and sedatives","MTMOPPMT","Million US$, purchasing power parity","BEL","Belgium","2022","2022",103.1,"E","Estimated value"
+"PATCHYPN","N05C-Hypnotics and sedatives","TCPPERMT","/capita, US$ exchange rate","BEL","Belgium","2010","2010",8.2,,
+"PATCHYPN","N05C-Hypnotics and sedatives","TCPPERMT","/capita, US$ exchange rate","BEL","Belgium","2011","2011",9,,
+"PATCHYPN","N05C-Hypnotics and sedatives","TCPPERMT","/capita, US$ exchange rate","BEL","Belgium","2012","2012",8.1,,
+"PATCHYPN","N05C-Hypnotics and sedatives","TCPPERMT","/capita, US$ exchange rate","BEL","Belgium","2013","2013",9,,
+"PATCHYPN","N05C-Hypnotics and sedatives","TCPPERMT","/capita, US$ exchange rate","BEL","Belgium","2014","2014",8.9,,
+"PATCHYPN","N05C-Hypnotics and sedatives","TCPPERMT","/capita, US$ exchange rate","BEL","Belgium","2015","2015",7.7,,
+"PATCHYPN","N05C-Hypnotics and sedatives","TCPPERMT","/capita, US$ exchange rate","BEL","Belgium","2016","2016",7.6,,
+"PATCHYPN","N05C-Hypnotics and sedatives","TCPPERMT","/capita, US$ exchange rate","BEL","Belgium","2017","2017",7.7,,
+"PATCHYPN","N05C-Hypnotics and sedatives","TCPPERMT","/capita, US$ exchange rate","BEL","Belgium","2018","2018",7.6,,
+"PATCHYPN","N05C-Hypnotics and sedatives","TCPPERMT","/capita, US$ exchange rate","BEL","Belgium","2019","2019",6.5,,
+"PATCHYPN","N05C-Hypnotics and sedatives","TCPPERMT","/capita, US$ exchange rate","BEL","Belgium","2020","2020",7.2,,
+"PATCHYPN","N05C-Hypnotics and sedatives","TCPPERMT","/capita, US$ exchange rate","BEL","Belgium","2021","2021",7.6,,
+"PATCHYPN","N05C-Hypnotics and sedatives","TCPPERMT","/capita, US$ exchange rate","BEL","Belgium","2022","2022",6.7,"E","Estimated value"
+"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2010","2010",7.4,,
+"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2011","2011",7.7,,
+"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2012","2012",7.7,,
+"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2013","2013",8.4,,
+"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2014","2014",8.4,,
+"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2015","2015",8.7,,
+"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2016","2016",8.8,,
+"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2017","2017",8.7,,
+"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2018","2018",8.4,,
+"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2019","2019",7.8,,
+"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2020","2020",8.6,,
+"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2021","2021",8.7,,
+"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2022","2022",8.9,"E","Estimated value"
+"PATCHYPN","N05C-Hypnotics and sedatives","ATCPTTMT","% of total sales","BEL","Belgium","2010","2010",1.2,,
+"PATCHYPN","N05C-Hypnotics and sedatives","ATCPTTMT","% of total sales","BEL","Belgium","2011","2011",1.2,,
+"PATCHYPN","N05C-Hypnotics and sedatives","ATCPTTMT","% of total sales","BEL","Belgium","2012","2012",1.2,,
+"PATCHYPN","N05C-Hypnotics and sedatives","ATCPTTMT","% of total sales","BEL","Belgium","2013","2013",1.3,,
+"PATCHYPN","N05C-Hypnotics and sedatives","ATCPTTMT","% of total sales","BEL","Belgium","2014","2014",1.3,,
+"PATCHYPN","N05C-Hypnotics and sedatives","ATCPTTMT","% of total sales","BEL","Belgium","2015","2015",1.3,,
+"PATCHYPN","N05C-Hypnotics and sedatives","ATCPTTMT","% of total sales","BEL","Belgium","2016","2016",1.2,,
+"PATCHYPN","N05C-Hypnotics and sedatives","ATCPTTMT","% of total sales","BEL","Belgium","2017","2017",1.2,,
+"PATCHYPN","N05C-Hypnotics and sedatives","ATCPTTMT","% of total sales","BEL","Belgium","2018","2018",1.1,,
+"PATCHYPN","N05C-Hypnotics and sedatives","ATCPTTMT","% of total sales","BEL","Belgium","2019","2019",0.9,,
+"PATCHYPN","N05C-Hypnotics and sedatives","ATCPTTMT","% of total sales","BEL","Belgium","2020","2020",0.9,,
+"PATCHYPN","N05C-Hypnotics and sedatives","ATCPTTMT","% of total sales","BEL","Belgium","2021","2021",0.9,,
+"PATCHYPN","N05C-Hypnotics and sedatives","ATCPTTMT","% of total sales","BEL","Belgium","2022","2022",0.8,"E","Estimated value"
+"PATCHYPN","N05C-Hypnotics and sedatives","MLLNCUMT","Million of national currency units","CAN","Canada","2012","2012",187,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","MLLNCUMT","Million of national currency units","CAN","Canada","2013","2013",193.2,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","MLLNCUMT","Million of national currency units","CAN","Canada","2014","2014",199.8,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","MLLNCUMT","Million of national currency units","CAN","Canada","2015","2015",204.2,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","MLLNCUMT","Million of national currency units","CAN","Canada","2016","2016",203.5,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","MLLNCUMT","Million of national currency units","CAN","Canada","2017","2017",202.8,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","MLLNCUMT","Million of national currency units","CAN","Canada","2018","2018",179.7,"E; B; D","Estimated value; Break; Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","MLLNCUMT","Million of national currency units","CAN","Canada","2019","2019",173.9,"E; D","Estimated value; Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","MLLNCUMT","Million of national currency units","CAN","Canada","2020","2020",179.5,"E; D","Estimated value; Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","MLLNCUMT","Million of national currency units","CAN","Canada","2021","2021",190.2,"E; D","Estimated value; Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","MLLNCUMT","Million of national currency units","CAN","Canada","2022","2022",202.4,"E; D","Estimated value; Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","MTMOTCMT","Million US$ at exchange rate","CAN","Canada","2012","2012",187.1,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","MTMOTCMT","Million US$ at exchange rate","CAN","Canada","2013","2013",187.5,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","MTMOTCMT","Million US$ at exchange rate","CAN","Canada","2014","2014",180.9,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","MTMOTCMT","Million US$ at exchange rate","CAN","Canada","2015","2015",159.7,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","MTMOTCMT","Million US$ at exchange rate","CAN","Canada","2016","2016",153.5,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","MTMOTCMT","Million US$ at exchange rate","CAN","Canada","2017","2017",156.2,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","MTMOTCMT","Million US$ at exchange rate","CAN","Canada","2018","2018",138.6,"E; B; D","Estimated value; Break; Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","MTMOTCMT","Million US$ at exchange rate","CAN","Canada","2019","2019",131.1,"E; D","Estimated value; Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","MTMOTCMT","Million US$ at exchange rate","CAN","Canada","2020","2020",133.8,"E; D","Estimated value; Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","MTMOTCMT","Million US$ at exchange rate","CAN","Canada","2021","2021",151.7,"E; D","Estimated value; Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","MTMOTCMT","Million US$ at exchange rate","CAN","Canada","2022","2022",155.5,"E; D","Estimated value; Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","MTMOPPMT","Million US$, purchasing power parity","CAN","Canada","2012","2012",150.2,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","MTMOPPMT","Million US$, purchasing power parity","CAN","Canada","2013","2013",157.8,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","MTMOPPMT","Million US$, purchasing power parity","CAN","Canada","2014","2014",162.4,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","MTMOPPMT","Million US$, purchasing power parity","CAN","Canada","2015","2015",163.6,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","MTMOPPMT","Million US$, purchasing power parity","CAN","Canada","2016","2016",168.6,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","MTMOPPMT","Million US$, purchasing power parity","CAN","Canada","2017","2017",167.3,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","MTMOPPMT","Million US$, purchasing power parity","CAN","Canada","2018","2018",148.9,"E; B; D","Estimated value; Break; Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","MTMOPPMT","Million US$, purchasing power parity","CAN","Canada","2019","2019",140.9,"E; D","Estimated value; Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","MTMOPPMT","Million US$, purchasing power parity","CAN","Canada","2020","2020",145.8,"E; D","Estimated value; Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","MTMOPPMT","Million US$, purchasing power parity","CAN","Canada","2021","2021",153.6,"E; D","Estimated value; Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","MTMOPPMT","Million US$, purchasing power parity","CAN","Canada","2022","2022",161.4,"E; D","Estimated value; Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","TCPPERMT","/capita, US$ exchange rate","CAN","Canada","2012","2012",5.4,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","TCPPERMT","/capita, US$ exchange rate","CAN","Canada","2013","2013",5.3,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","TCPPERMT","/capita, US$ exchange rate","CAN","Canada","2014","2014",5.1,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","TCPPERMT","/capita, US$ exchange rate","CAN","Canada","2015","2015",4.5,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","TCPPERMT","/capita, US$ exchange rate","CAN","Canada","2016","2016",4.3,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","TCPPERMT","/capita, US$ exchange rate","CAN","Canada","2017","2017",4.3,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","TCPPERMT","/capita, US$ exchange rate","CAN","Canada","2018","2018",3.7,"E; B; D","Estimated value; Break; Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","TCPPERMT","/capita, US$ exchange rate","CAN","Canada","2019","2019",3.5,"E; D","Estimated value; Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","TCPPERMT","/capita, US$ exchange rate","CAN","Canada","2020","2020",3.5,"E; D","Estimated value; Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","TCPPERMT","/capita, US$ exchange rate","CAN","Canada","2021","2021",4,"E; D","Estimated value; Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","TCPPERMT","/capita, US$ exchange rate","CAN","Canada","2022","2022",4,"E; D","Estimated value; Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2012","2012",4.3,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2013","2013",4.5,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2014","2014",4.6,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2015","2015",4.6,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2016","2016",4.7,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2017","2017",4.6,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2018","2018",4,"E; B; D","Estimated value; Break; Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2019","2019",3.7,"E; D","Estimated value; Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2020","2020",3.8,"E; D","Estimated value; Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2021","2021",4,"E; D","Estimated value; Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2022","2022",4.2,"E; D","Estimated value; Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","ATCPTTMT","% of total sales","CAN","Canada","2012","2012",0.8,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","ATCPTTMT","% of total sales","CAN","Canada","2013","2013",0.8,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","ATCPTTMT","% of total sales","CAN","Canada","2014","2014",0.8,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","ATCPTTMT","% of total sales","CAN","Canada","2015","2015",0.8,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","ATCPTTMT","% of total sales","CAN","Canada","2016","2016",0.7,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","ATCPTTMT","% of total sales","CAN","Canada","2017","2017",0.7,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","ATCPTTMT","% of total sales","CAN","Canada","2018","2018",0.6,"E; B; D","Estimated value; Break; Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","ATCPTTMT","% of total sales","CAN","Canada","2019","2019",0.5,"E; D","Estimated value; Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","ATCPTTMT","% of total sales","CAN","Canada","2020","2020",0.5,"E; D","Estimated value; Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","ATCPTTMT","% of total sales","CAN","Canada","2021","2021",0.5,"E; D","Estimated value; Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","ATCPTTMT","% of total sales","CAN","Canada","2022","2022",0.5,"E; D","Estimated value; Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","MLLNCUMT","Million of national currency units","CZE","Czech Republic","2010","2010",454.5,,
+"PATCHYPN","N05C-Hypnotics and sedatives","MLLNCUMT","Million of national currency units","CZE","Czech Republic","2011","2011",459.6,,
+"PATCHYPN","N05C-Hypnotics and sedatives","MLLNCUMT","Million of national currency units","CZE","Czech Republic","2012","2012",468.4,,
+"PATCHYPN","N05C-Hypnotics and sedatives","MLLNCUMT","Million of national currency units","CZE","Czech Republic","2013","2013",455.9,,
+"PATCHYPN","N05C-Hypnotics and sedatives","MLLNCUMT","Million of national currency units","CZE","Czech Republic","2014","2014",460.1,,
+"PATCHYPN","N05C-Hypnotics and sedatives","MLLNCUMT","Million of national currency units","CZE","Czech Republic","2015","2015",436.4,,
+"PATCHYPN","N05C-Hypnotics and sedatives","MLLNCUMT","Million of national currency units","CZE","Czech Republic","2016","2016",430.7,,
+"PATCHYPN","N05C-Hypnotics and sedatives","MLLNCUMT","Million of national currency units","CZE","Czech Republic","2017","2017",463.1,,
+"PATCHYPN","N05C-Hypnotics and sedatives","MLLNCUMT","Million of national currency units","CZE","Czech Republic","2018","2018",477.9,,
+"PATCHYPN","N05C-Hypnotics and sedatives","MLLNCUMT","Million of national currency units","CZE","Czech Republic","2019","2019",497.9,,
+"PATCHYPN","N05C-Hypnotics and sedatives","MLLNCUMT","Million of national currency units","CZE","Czech Republic","2020","2020",44.2,"B","Break"
+"PATCHYPN","N05C-Hypnotics and sedatives","MLLNCUMT","Million of national currency units","CZE","Czech Republic","2021","2021",58.8,,
+"PATCHYPN","N05C-Hypnotics and sedatives","MTMOTCMT","Million US$ at exchange rate","CZE","Czech Republic","2010","2010",23.8,,
+"PATCHYPN","N05C-Hypnotics and sedatives","MTMOTCMT","Million US$ at exchange rate","CZE","Czech Republic","2011","2011",26,,
+"PATCHYPN","N05C-Hypnotics and sedatives","MTMOTCMT","Million US$ at exchange rate","CZE","Czech Republic","2012","2012",23.9,,
+"PATCHYPN","N05C-Hypnotics and sedatives","MTMOTCMT","Million US$ at exchange rate","CZE","Czech Republic","2013","2013",23.3,,
+"PATCHYPN","N05C-Hypnotics and sedatives","MTMOTCMT","Million US$ at exchange rate","CZE","Czech Republic","2014","2014",22.2,,
+"PATCHYPN","N05C-Hypnotics and sedatives","MTMOTCMT","Million US$ at exchange rate","CZE","Czech Republic","2015","2015",17.7,,
+"PATCHYPN","N05C-Hypnotics and sedatives","MTMOTCMT","Million US$ at exchange rate","CZE","Czech Republic","2016","2016",17.6,,
+"PATCHYPN","N05C-Hypnotics and sedatives","MTMOTCMT","Million US$ at exchange rate","CZE","Czech Republic","2017","2017",19.8,,
+"PATCHYPN","N05C-Hypnotics and sedatives","MTMOTCMT","Million US$ at exchange rate","CZE","Czech Republic","2018","2018",22,,
+"PATCHYPN","N05C-Hypnotics and sedatives","MTMOTCMT","Million US$ at exchange rate","CZE","Czech Republic","2019","2019",21.7,,
+"PATCHYPN","N05C-Hypnotics and sedatives","MTMOTCMT","Million US$ at exchange rate","CZE","Czech Republic","2020","2020",1.9,"B","Break"
+"PATCHYPN","N05C-Hypnotics and sedatives","MTMOTCMT","Million US$ at exchange rate","CZE","Czech Republic","2021","2021",2.7,,
+"PATCHYPN","N05C-Hypnotics and sedatives","MTMOPPMT","Million US$, purchasing power parity","CZE","Czech Republic","2010","2010",33.2,,
+"PATCHYPN","N05C-Hypnotics and sedatives","MTMOPPMT","Million US$, purchasing power parity","CZE","Czech Republic","2011","2011",34.4,,
+"PATCHYPN","N05C-Hypnotics and sedatives","MTMOPPMT","Million US$, purchasing power parity","CZE","Czech Republic","2012","2012",35.2,,
+"PATCHYPN","N05C-Hypnotics and sedatives","MTMOPPMT","Million US$, purchasing power parity","CZE","Czech Republic","2013","2013",35.7,,
+"PATCHYPN","N05C-Hypnotics and sedatives","MTMOPPMT","Million US$, purchasing power parity","CZE","Czech Republic","2014","2014",36.2,,
+"PATCHYPN","N05C-Hypnotics and sedatives","MTMOPPMT","Million US$, purchasing power parity","CZE","Czech Republic","2015","2015",33.7,,
+"PATCHYPN","N05C-Hypnotics and sedatives","MTMOPPMT","Million US$, purchasing power parity","CZE","Czech Republic","2016","2016",34.2,,
+"PATCHYPN","N05C-Hypnotics and sedatives","MTMOPPMT","Million US$, purchasing power parity","CZE","Czech Republic","2017","2017",37.3,,
+"PATCHYPN","N05C-Hypnotics and sedatives","MTMOPPMT","Million US$, purchasing power parity","CZE","Czech Republic","2018","2018",38.6,,
+"PATCHYPN","N05C-Hypnotics and sedatives","MTMOPPMT","Million US$, purchasing power parity","CZE","Czech Republic","2019","2019",40.6,,
+"PATCHYPN","N05C-Hypnotics and sedatives","MTMOPPMT","Million US$, purchasing power parity","CZE","Czech Republic","2020","2020",3.5,"B","Break"
+"PATCHYPN","N05C-Hypnotics and sedatives","MTMOPPMT","Million US$, purchasing power parity","CZE","Czech Republic","2021","2021",4.6,,
+"PATCHYPN","N05C-Hypnotics and sedatives","TCPPERMT","/capita, US$ exchange rate","CZE","Czech Republic","2010","2010",2.3,,
+"PATCHYPN","N05C-Hypnotics and sedatives","TCPPERMT","/capita, US$ exchange rate","CZE","Czech Republic","2011","2011",2.5,,
+"PATCHYPN","N05C-Hypnotics and sedatives","TCPPERMT","/capita, US$ exchange rate","CZE","Czech Republic","2012","2012",2.3,,
+"PATCHYPN","N05C-Hypnotics and sedatives","TCPPERMT","/capita, US$ exchange rate","CZE","Czech Republic","2013","2013",2.2,,
+"PATCHYPN","N05C-Hypnotics and sedatives","TCPPERMT","/capita, US$ exchange rate","CZE","Czech Republic","2014","2014",2.1,,
+"PATCHYPN","N05C-Hypnotics and sedatives","TCPPERMT","/capita, US$ exchange rate","CZE","Czech Republic","2015","2015",1.7,,
+"PATCHYPN","N05C-Hypnotics and sedatives","TCPPERMT","/capita, US$ exchange rate","CZE","Czech Republic","2016","2016",1.7,,
+"PATCHYPN","N05C-Hypnotics and sedatives","TCPPERMT","/capita, US$ exchange rate","CZE","Czech Republic","2017","2017",1.9,,
+"PATCHYPN","N05C-Hypnotics and sedatives","TCPPERMT","/capita, US$ exchange rate","CZE","Czech Republic","2018","2018",2.1,,
+"PATCHYPN","N05C-Hypnotics and sedatives","TCPPERMT","/capita, US$ exchange rate","CZE","Czech Republic","2019","2019",2,,
+"PATCHYPN","N05C-Hypnotics and sedatives","TCPPERMT","/capita, US$ exchange rate","CZE","Czech Republic","2020","2020",0.2,"B","Break"
+"PATCHYPN","N05C-Hypnotics and sedatives","TCPPERMT","/capita, US$ exchange rate","CZE","Czech Republic","2021","2021",0.3,,
+"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czech Republic","2010","2010",3.2,,
+"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czech Republic","2011","2011",3.3,,
+"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czech Republic","2012","2012",3.4,,
+"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czech Republic","2013","2013",3.4,,
+"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czech Republic","2014","2014",3.4,,
+"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czech Republic","2015","2015",3.2,,
+"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czech Republic","2016","2016",3.2,,
+"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czech Republic","2017","2017",3.5,,
+"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czech Republic","2018","2018",3.6,,
+"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czech Republic","2019","2019",3.8,,
+"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czech Republic","2020","2020",0.3,"B","Break"
+"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czech Republic","2021","2021",0.4,,
+"PATCHYPN","N05C-Hypnotics and sedatives","ATCPTTMT","% of total sales","CZE","Czech Republic","2010","2010",0.6,,
+"PATCHYPN","N05C-Hypnotics and sedatives","ATCPTTMT","% of total sales","CZE","Czech Republic","2011","2011",0.6,,
+"PATCHYPN","N05C-Hypnotics and sedatives","ATCPTTMT","% of total sales","CZE","Czech Republic","2012","2012",0.6,,
+"PATCHYPN","N05C-Hypnotics and sedatives","ATCPTTMT","% of total sales","CZE","Czech Republic","2013","2013",0.6,,
+"PATCHYPN","N05C-Hypnotics and sedatives","ATCPTTMT","% of total sales","CZE","Czech Republic","2014","2014",0.6,,
+"PATCHYPN","N05C-Hypnotics and sedatives","ATCPTTMT","% of total sales","CZE","Czech Republic","2015","2015",0.5,,
+"PATCHYPN","N05C-Hypnotics and sedatives","ATCPTTMT","% of total sales","CZE","Czech Republic","2016","2016",0.5,,
+"PATCHYPN","N05C-Hypnotics and sedatives","ATCPTTMT","% of total sales","CZE","Czech Republic","2017","2017",0.5,,
+"PATCHYPN","N05C-Hypnotics and sedatives","ATCPTTMT","% of total sales","CZE","Czech Republic","2018","2018",0.5,,
+"PATCHYPN","N05C-Hypnotics and sedatives","ATCPTTMT","% of total sales","CZE","Czech Republic","2019","2019",0.5,,
+"PATCHYPN","N05C-Hypnotics and sedatives","ATCPTTMT","% of total sales","CZE","Czech Republic","2020","2020",0.1,"B","Break"
+"PATCHYPN","N05C-Hypnotics and sedatives","ATCPTTMT","% of total sales","CZE","Czech Republic","2021","2021",0.1,,
+"PATCHYPN","N05C-Hypnotics and sedatives","MLLNCUMT","Million of national currency units","FIN","Finland","2010","2010",9.8,,
+"PATCHYPN","N05C-Hypnotics and sedatives","MLLNCUMT","Million of national currency units","FIN","Finland","2011","2011",10.5,,
+"PATCHYPN","N05C-Hypnotics and sedatives","MLLNCUMT","Million of national currency units","FIN","Finland","2012","2012",12.2,,
+"PATCHYPN","N05C-Hypnotics and sedatives","MLLNCUMT","Million of national currency units","FIN","Finland","2013","2013",12.6,,
+"PATCHYPN","N05C-Hypnotics and sedatives","MLLNCUMT","Million of national currency units","FIN","Finland","2014","2014",12.8,,
+"PATCHYPN","N05C-Hypnotics and sedatives","MLLNCUMT","Million of national currency units","FIN","Finland","2015","2015",12.5,,
+"PATCHYPN","N05C-Hypnotics and sedatives","MLLNCUMT","Million of national currency units","FIN","Finland","2016","2016",12.1,,
+"PATCHYPN","N05C-Hypnotics and sedatives","MLLNCUMT","Million of national currency units","FIN","Finland","2017","2017",12.8,,
+"PATCHYPN","N05C-Hypnotics and sedatives","MLLNCUMT","Million of national currency units","FIN","Finland","2018","2018",13.6,,
+"PATCHYPN","N05C-Hypnotics and sedatives","MLLNCUMT","Million of national currency units","FIN","Finland","2019","2019",14,,
+"PATCHYPN","N05C-Hypnotics and sedatives","MLLNCUMT","Million of national currency units","FIN","Finland","2020","2020",14.4,,
+"PATCHYPN","N05C-Hypnotics and sedatives","MLLNCUMT","Million of national currency units","FIN","Finland","2021","2021",14.3,,
+"PATCHYPN","N05C-Hypnotics and sedatives","MTMOTCMT","Million US$ at exchange rate","FIN","Finland","2010","2010",13,,
+"PATCHYPN","N05C-Hypnotics and sedatives","MTMOTCMT","Million US$ at exchange rate","FIN","Finland","2011","2011",14.6,,
+"PATCHYPN","N05C-Hypnotics and sedatives","MTMOTCMT","Million US$ at exchange rate","FIN","Finland","2012","2012",15.7,,
+"PATCHYPN","N05C-Hypnotics and sedatives","MTMOTCMT","Million US$ at exchange rate","FIN","Finland","2013","2013",16.7,,
+"PATCHYPN","N05C-Hypnotics and sedatives","MTMOTCMT","Million US$ at exchange rate","FIN","Finland","2014","2014",17,,
+"PATCHYPN","N05C-Hypnotics and sedatives","MTMOTCMT","Million US$ at exchange rate","FIN","Finland","2015","2015",13.9,,
+"PATCHYPN","N05C-Hypnotics and sedatives","MTMOTCMT","Million US$ at exchange rate","FIN","Finland","2016","2016",13.4,,
+"PATCHYPN","N05C-Hypnotics and sedatives","MTMOTCMT","Million US$ at exchange rate","FIN","Finland","2017","2017",14.5,,
+"PATCHYPN","N05C-Hypnotics and sedatives","MTMOTCMT","Million US$ at exchange rate","FIN","Finland","2018","2018",16.1,,
+"PATCHYPN","N05C-Hypnotics and sedatives","MTMOTCMT","Million US$ at exchange rate","FIN","Finland","2019","2019",15.7,,
+"PATCHYPN","N05C-Hypnotics and sedatives","MTMOTCMT","Million US$ at exchange rate","FIN","Finland","2020","2020",16.4,,
+"PATCHYPN","N05C-Hypnotics and sedatives","MTMOTCMT","Million US$ at exchange rate","FIN","Finland","2021","2021",16.9,,
+"PATCHYPN","N05C-Hypnotics and sedatives","MTMOPPMT","Million US$, purchasing power parity","FIN","Finland","2010","2010",10.9,,
+"PATCHYPN","N05C-Hypnotics and sedatives","MTMOPPMT","Million US$, purchasing power parity","FIN","Finland","2011","2011",11.7,,
+"PATCHYPN","N05C-Hypnotics and sedatives","MTMOPPMT","Million US$, purchasing power parity","FIN","Finland","2012","2012",13.4,,
+"PATCHYPN","N05C-Hypnotics and sedatives","MTMOPPMT","Million US$, purchasing power parity","FIN","Finland","2013","2013",13.9,,
+"PATCHYPN","N05C-Hypnotics and sedatives","MTMOPPMT","Million US$, purchasing power parity","FIN","Finland","2014","2014",14.1,,
+"PATCHYPN","N05C-Hypnotics and sedatives","MTMOPPMT","Million US$, purchasing power parity","FIN","Finland","2015","2015",13.8,,
+"PATCHYPN","N05C-Hypnotics and sedatives","MTMOPPMT","Million US$, purchasing power parity","FIN","Finland","2016","2016",13.7,,
+"PATCHYPN","N05C-Hypnotics and sedatives","MTMOPPMT","Million US$, purchasing power parity","FIN","Finland","2017","2017",14.8,,
+"PATCHYPN","N05C-Hypnotics and sedatives","MTMOPPMT","Million US$, purchasing power parity","FIN","Finland","2018","2018",15.9,,
+"PATCHYPN","N05C-Hypnotics and sedatives","MTMOPPMT","Million US$, purchasing power parity","FIN","Finland","2019","2019",16.7,,
+"PATCHYPN","N05C-Hypnotics and sedatives","MTMOPPMT","Million US$, purchasing power parity","FIN","Finland","2020","2020",17.5,,
+"PATCHYPN","N05C-Hypnotics and sedatives","MTMOPPMT","Million US$, purchasing power parity","FIN","Finland","2021","2021",17.3,,
+"PATCHYPN","N05C-Hypnotics and sedatives","TCPPERMT","/capita, US$ exchange rate","FIN","Finland","2010","2010",2.4,,
+"PATCHYPN","N05C-Hypnotics and sedatives","TCPPERMT","/capita, US$ exchange rate","FIN","Finland","2011","2011",2.7,,
+"PATCHYPN","N05C-Hypnotics and sedatives","TCPPERMT","/capita, US$ exchange rate","FIN","Finland","2012","2012",2.9,,
+"PATCHYPN","N05C-Hypnotics and sedatives","TCPPERMT","/capita, US$ exchange rate","FIN","Finland","2013","2013",3.1,,
+"PATCHYPN","N05C-Hypnotics and sedatives","TCPPERMT","/capita, US$ exchange rate","FIN","Finland","2014","2014",3.1,,
+"PATCHYPN","N05C-Hypnotics and sedatives","TCPPERMT","/capita, US$ exchange rate","FIN","Finland","2015","2015",2.5,,
+"PATCHYPN","N05C-Hypnotics and sedatives","TCPPERMT","/capita, US$ exchange rate","FIN","Finland","2016","2016",2.4,,
+"PATCHYPN","N05C-Hypnotics and sedatives","TCPPERMT","/capita, US$ exchange rate","FIN","Finland","2017","2017",2.6,,
+"PATCHYPN","N05C-Hypnotics and sedatives","TCPPERMT","/capita, US$ exchange rate","FIN","Finland","2018","2018",2.9,,
+"PATCHYPN","N05C-Hypnotics and sedatives","TCPPERMT","/capita, US$ exchange rate","FIN","Finland","2019","2019",2.8,,
+"PATCHYPN","N05C-Hypnotics and sedatives","TCPPERMT","/capita, US$ exchange rate","FIN","Finland","2020","2020",3,,
+"PATCHYPN","N05C-Hypnotics and sedatives","TCPPERMT","/capita, US$ exchange rate","FIN","Finland","2021","2021",3.1,,
+"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2010","2010",2,,
+"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2011","2011",2.2,,
+"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2012","2012",2.5,,
+"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2013","2013",2.6,,
+"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2014","2014",2.6,,
+"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2015","2015",2.5,,
+"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2016","2016",2.5,,
+"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2017","2017",2.7,,
+"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2018","2018",2.9,,
+"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2019","2019",3,,
+"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2020","2020",3.2,,
+"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2021","2021",3.1,,
+"PATCHYPN","N05C-Hypnotics and sedatives","ATCPTTMT","% of total sales","FIN","Finland","2010","2010",0.5,,
+"PATCHYPN","N05C-Hypnotics and sedatives","ATCPTTMT","% of total sales","FIN","Finland","2011","2011",0.5,,
+"PATCHYPN","N05C-Hypnotics and sedatives","ATCPTTMT","% of total sales","FIN","Finland","2012","2012",0.6,,
+"PATCHYPN","N05C-Hypnotics and sedatives","ATCPTTMT","% of total sales","FIN","Finland","2013","2013",0.6,,
+"PATCHYPN","N05C-Hypnotics and sedatives","ATCPTTMT","% of total sales","FIN","Finland","2014","2014",0.6,,
+"PATCHYPN","N05C-Hypnotics and sedatives","ATCPTTMT","% of total sales","FIN","Finland","2015","2015",0.6,,
+"PATCHYPN","N05C-Hypnotics and sedatives","ATCPTTMT","% of total sales","FIN","Finland","2016","2016",0.5,,
+"PATCHYPN","N05C-Hypnotics and sedatives","ATCPTTMT","% of total sales","FIN","Finland","2017","2017",0.6,,
+"PATCHYPN","N05C-Hypnotics and sedatives","ATCPTTMT","% of total sales","FIN","Finland","2018","2018",0.5,,
+"PATCHYPN","N05C-Hypnotics and sedatives","ATCPTTMT","% of total sales","FIN","Finland","2019","2019",0.5,,
+"PATCHYPN","N05C-Hypnotics and sedatives","ATCPTTMT","% of total sales","FIN","Finland","2020","2020",0.5,,
+"PATCHYPN","N05C-Hypnotics and sedatives","ATCPTTMT","% of total sales","FIN","Finland","2021","2021",0.5,,
+"PATCHYPN","N05C-Hypnotics and sedatives","MLLNCUMT","Million of national currency units","DEU","Germany","2010","2010",110.3,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","MLLNCUMT","Million of national currency units","DEU","Germany","2011","2011",103.7,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","MLLNCUMT","Million of national currency units","DEU","Germany","2012","2012",99.3,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","MLLNCUMT","Million of national currency units","DEU","Germany","2013","2013",97.4,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","MLLNCUMT","Million of national currency units","DEU","Germany","2014","2014",97.6,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","MLLNCUMT","Million of national currency units","DEU","Germany","2015","2015",94.5,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","MLLNCUMT","Million of national currency units","DEU","Germany","2016","2016",90.5,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","MLLNCUMT","Million of national currency units","DEU","Germany","2017","2017",89.8,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","MLLNCUMT","Million of national currency units","DEU","Germany","2018","2018",81.3,"B; D","Break; Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","MLLNCUMT","Million of national currency units","DEU","Germany","2019","2019",84.9,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","MLLNCUMT","Million of national currency units","DEU","Germany","2020","2020",87.8,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","MLLNCUMT","Million of national currency units","DEU","Germany","2021","2021",94.4,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","MTMOTCMT","Million US$ at exchange rate","DEU","Germany","2010","2010",146.2,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","MTMOTCMT","Million US$ at exchange rate","DEU","Germany","2011","2011",144.3,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","MTMOTCMT","Million US$ at exchange rate","DEU","Germany","2012","2012",127.6,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","MTMOTCMT","Million US$ at exchange rate","DEU","Germany","2013","2013",129.4,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","MTMOTCMT","Million US$ at exchange rate","DEU","Germany","2014","2014",129.7,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","MTMOTCMT","Million US$ at exchange rate","DEU","Germany","2015","2015",104.8,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","MTMOTCMT","Million US$ at exchange rate","DEU","Germany","2016","2016",100.2,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","MTMOTCMT","Million US$ at exchange rate","DEU","Germany","2017","2017",101.4,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","MTMOTCMT","Million US$ at exchange rate","DEU","Germany","2018","2018",96,"B; D","Break; Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","MTMOTCMT","Million US$ at exchange rate","DEU","Germany","2019","2019",95,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","MTMOTCMT","Million US$ at exchange rate","DEU","Germany","2020","2020",100.3,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","MTMOTCMT","Million US$ at exchange rate","DEU","Germany","2021","2021",111.7,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","MTMOPPMT","Million US$, purchasing power parity","DEU","Germany","2010","2010",137,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","MTMOPPMT","Million US$, purchasing power parity","DEU","Germany","2011","2011",131.5,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","MTMOPPMT","Million US$, purchasing power parity","DEU","Germany","2012","2012",126.1,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","MTMOPPMT","Million US$, purchasing power parity","DEU","Germany","2013","2013",125.7,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","MTMOPPMT","Million US$, purchasing power parity","DEU","Germany","2014","2014",126.9,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","MTMOPPMT","Million US$, purchasing power parity","DEU","Germany","2015","2015",121.4,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","MTMOPPMT","Million US$, purchasing power parity","DEU","Germany","2016","2016",120.2,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","MTMOPPMT","Million US$, purchasing power parity","DEU","Germany","2017","2017",120.6,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","MTMOPPMT","Million US$, purchasing power parity","DEU","Germany","2018","2018",110.5,"B; D","Break; Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","MTMOPPMT","Million US$, purchasing power parity","DEU","Germany","2019","2019",116.6,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","MTMOPPMT","Million US$, purchasing power parity","DEU","Germany","2020","2020",121.1,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","MTMOPPMT","Million US$, purchasing power parity","DEU","Germany","2021","2021",128.2,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","TCPPERMT","/capita, US$ exchange rate","DEU","Germany","2010","2010",1.8,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","TCPPERMT","/capita, US$ exchange rate","DEU","Germany","2011","2011",1.8,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","TCPPERMT","/capita, US$ exchange rate","DEU","Germany","2012","2012",1.6,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","TCPPERMT","/capita, US$ exchange rate","DEU","Germany","2013","2013",1.6,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","TCPPERMT","/capita, US$ exchange rate","DEU","Germany","2014","2014",1.6,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","TCPPERMT","/capita, US$ exchange rate","DEU","Germany","2015","2015",1.3,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","TCPPERMT","/capita, US$ exchange rate","DEU","Germany","2016","2016",1.2,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","TCPPERMT","/capita, US$ exchange rate","DEU","Germany","2017","2017",1.2,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","TCPPERMT","/capita, US$ exchange rate","DEU","Germany","2018","2018",1.2,"B; D","Break; Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","TCPPERMT","/capita, US$ exchange rate","DEU","Germany","2019","2019",1.1,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","TCPPERMT","/capita, US$ exchange rate","DEU","Germany","2020","2020",1.2,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","TCPPERMT","/capita, US$ exchange rate","DEU","Germany","2021","2021",1.3,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2010","2010",1.7,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2011","2011",1.6,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2012","2012",1.6,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2013","2013",1.6,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2014","2014",1.6,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2015","2015",1.5,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2016","2016",1.5,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2017","2017",1.5,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2018","2018",1.3,"B; D","Break; Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2019","2019",1.4,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2020","2020",1.5,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2021","2021",1.5,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","ATCPTTMT","% of total sales","DEU","Germany","2010","2010",0.4,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","ATCPTTMT","% of total sales","DEU","Germany","2011","2011",0.3,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","ATCPTTMT","% of total sales","DEU","Germany","2012","2012",0.3,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","ATCPTTMT","% of total sales","DEU","Germany","2013","2013",0.3,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","ATCPTTMT","% of total sales","DEU","Germany","2014","2014",0.3,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","ATCPTTMT","% of total sales","DEU","Germany","2015","2015",0.3,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","ATCPTTMT","% of total sales","DEU","Germany","2016","2016",0.3,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","ATCPTTMT","% of total sales","DEU","Germany","2017","2017",0.2,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","ATCPTTMT","% of total sales","DEU","Germany","2018","2018",0.2,"B; D","Break; Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","ATCPTTMT","% of total sales","DEU","Germany","2019","2019",0.2,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","ATCPTTMT","% of total sales","DEU","Germany","2020","2020",0.2,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","ATCPTTMT","% of total sales","DEU","Germany","2021","2021",0.2,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","MLLNCUMT","Million of national currency units","GRC","Greece","2010","2010",10.7,,
+"PATCHYPN","N05C-Hypnotics and sedatives","MLLNCUMT","Million of national currency units","GRC","Greece","2011","2011",10.2,,
+"PATCHYPN","N05C-Hypnotics and sedatives","MLLNCUMT","Million of national currency units","GRC","Greece","2012","2012",8.9,,
+"PATCHYPN","N05C-Hypnotics and sedatives","MLLNCUMT","Million of national currency units","GRC","Greece","2013","2013",8.2,,
+"PATCHYPN","N05C-Hypnotics and sedatives","MLLNCUMT","Million of national currency units","GRC","Greece","2014","2014",8.9,,
+"PATCHYPN","N05C-Hypnotics and sedatives","MLLNCUMT","Million of national currency units","GRC","Greece","2015","2015",7.4,,
+"PATCHYPN","N05C-Hypnotics and sedatives","MLLNCUMT","Million of national currency units","GRC","Greece","2016","2016",8.2,,
+"PATCHYPN","N05C-Hypnotics and sedatives","MLLNCUMT","Million of national currency units","GRC","Greece","2017","2017",8.4,,
+"PATCHYPN","N05C-Hypnotics and sedatives","MLLNCUMT","Million of national currency units","GRC","Greece","2018","2018",8.9,,
+"PATCHYPN","N05C-Hypnotics and sedatives","MLLNCUMT","Million of national currency units","GRC","Greece","2019","2019",9.2,,
+"PATCHYPN","N05C-Hypnotics and sedatives","MLLNCUMT","Million of national currency units","GRC","Greece","2020","2020",10,,
+"PATCHYPN","N05C-Hypnotics and sedatives","MLLNCUMT","Million of national currency units","GRC","Greece","2021","2021",14.1,,
+"PATCHYPN","N05C-Hypnotics and sedatives","MLLNCUMT","Million of national currency units","GRC","Greece","2022","2022",10.5,,
+"PATCHYPN","N05C-Hypnotics and sedatives","MTMOTCMT","Million US$ at exchange rate","GRC","Greece","2010","2010",14.2,,
+"PATCHYPN","N05C-Hypnotics and sedatives","MTMOTCMT","Million US$ at exchange rate","GRC","Greece","2011","2011",14.2,,
+"PATCHYPN","N05C-Hypnotics and sedatives","MTMOTCMT","Million US$ at exchange rate","GRC","Greece","2012","2012",11.4,,
+"PATCHYPN","N05C-Hypnotics and sedatives","MTMOTCMT","Million US$ at exchange rate","GRC","Greece","2013","2013",10.9,,
+"PATCHYPN","N05C-Hypnotics and sedatives","MTMOTCMT","Million US$ at exchange rate","GRC","Greece","2014","2014",11.9,,
+"PATCHYPN","N05C-Hypnotics and sedatives","MTMOTCMT","Million US$ at exchange rate","GRC","Greece","2015","2015",8.3,,
+"PATCHYPN","N05C-Hypnotics and sedatives","MTMOTCMT","Million US$ at exchange rate","GRC","Greece","2016","2016",9.1,,
+"PATCHYPN","N05C-Hypnotics and sedatives","MTMOTCMT","Million US$ at exchange rate","GRC","Greece","2017","2017",9.5,,
+"PATCHYPN","N05C-Hypnotics and sedatives","MTMOTCMT","Million US$ at exchange rate","GRC","Greece","2018","2018",10.5,,
+"PATCHYPN","N05C-Hypnotics and sedatives","MTMOTCMT","Million US$ at exchange rate","GRC","Greece","2019","2019",10.3,,
+"PATCHYPN","N05C-Hypnotics and sedatives","MTMOTCMT","Million US$ at exchange rate","GRC","Greece","2020","2020",11.4,,
+"PATCHYPN","N05C-Hypnotics and sedatives","MTMOTCMT","Million US$ at exchange rate","GRC","Greece","2021","2021",16.7,,
+"PATCHYPN","N05C-Hypnotics and sedatives","MTMOTCMT","Million US$ at exchange rate","GRC","Greece","2022","2022",11.1,,
+"PATCHYPN","N05C-Hypnotics and sedatives","MTMOPPMT","Million US$, purchasing power parity","GRC","Greece","2010","2010",14.8,,
+"PATCHYPN","N05C-Hypnotics and sedatives","MTMOPPMT","Million US$, purchasing power parity","GRC","Greece","2011","2011",14.3,,
+"PATCHYPN","N05C-Hypnotics and sedatives","MTMOPPMT","Million US$, purchasing power parity","GRC","Greece","2012","2012",13,,
+"PATCHYPN","N05C-Hypnotics and sedatives","MTMOPPMT","Million US$, purchasing power parity","GRC","Greece","2013","2013",13,,
+"PATCHYPN","N05C-Hypnotics and sedatives","MTMOPPMT","Million US$, purchasing power parity","GRC","Greece","2014","2014",14.6,,
+"PATCHYPN","N05C-Hypnotics and sedatives","MTMOPPMT","Million US$, purchasing power parity","GRC","Greece","2015","2015",12.2,,
+"PATCHYPN","N05C-Hypnotics and sedatives","MTMOPPMT","Million US$, purchasing power parity","GRC","Greece","2016","2016",13.9,,
+"PATCHYPN","N05C-Hypnotics and sedatives","MTMOPPMT","Million US$, purchasing power parity","GRC","Greece","2017","2017",14.6,,
+"PATCHYPN","N05C-Hypnotics and sedatives","MTMOPPMT","Million US$, purchasing power parity","GRC","Greece","2018","2018",15.7,,
+"PATCHYPN","N05C-Hypnotics and sedatives","MTMOPPMT","Million US$, purchasing power parity","GRC","Greece","2019","2019",16.8,,
+"PATCHYPN","N05C-Hypnotics and sedatives","MTMOPPMT","Million US$, purchasing power parity","GRC","Greece","2020","2020",18.4,,
+"PATCHYPN","N05C-Hypnotics and sedatives","MTMOPPMT","Million US$, purchasing power parity","GRC","Greece","2021","2021",25.9,,
+"PATCHYPN","N05C-Hypnotics and sedatives","MTMOPPMT","Million US$, purchasing power parity","GRC","Greece","2022","2022",19.9,,
+"PATCHYPN","N05C-Hypnotics and sedatives","TCPPERMT","/capita, US$ exchange rate","GRC","Greece","2010","2010",1.3,,
+"PATCHYPN","N05C-Hypnotics and sedatives","TCPPERMT","/capita, US$ exchange rate","GRC","Greece","2011","2011",1.3,,
+"PATCHYPN","N05C-Hypnotics and sedatives","TCPPERMT","/capita, US$ exchange rate","GRC","Greece","2012","2012",1,,
+"PATCHYPN","N05C-Hypnotics and sedatives","TCPPERMT","/capita, US$ exchange rate","GRC","Greece","2013","2013",1,,
+"PATCHYPN","N05C-Hypnotics and sedatives","TCPPERMT","/capita, US$ exchange rate","GRC","Greece","2014","2014",1.1,,
+"PATCHYPN","N05C-Hypnotics and sedatives","TCPPERMT","/capita, US$ exchange rate","GRC","Greece","2015","2015",0.8,,
+"PATCHYPN","N05C-Hypnotics and sedatives","TCPPERMT","/capita, US$ exchange rate","GRC","Greece","2016","2016",0.8,,
+"PATCHYPN","N05C-Hypnotics and sedatives","TCPPERMT","/capita, US$ exchange rate","GRC","Greece","2017","2017",0.9,,
+"PATCHYPN","N05C-Hypnotics and sedatives","TCPPERMT","/capita, US$ exchange rate","GRC","Greece","2018","2018",1,,
+"PATCHYPN","N05C-Hypnotics and sedatives","TCPPERMT","/capita, US$ exchange rate","GRC","Greece","2019","2019",1,,
+"PATCHYPN","N05C-Hypnotics and sedatives","TCPPERMT","/capita, US$ exchange rate","GRC","Greece","2020","2020",1.1,,
+"PATCHYPN","N05C-Hypnotics and sedatives","TCPPERMT","/capita, US$ exchange rate","GRC","Greece","2021","2021",1.6,,
+"PATCHYPN","N05C-Hypnotics and sedatives","TCPPERMT","/capita, US$ exchange rate","GRC","Greece","2022","2022",1.1,,
+"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2010","2010",1.3,,
+"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2011","2011",1.3,,
+"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2012","2012",1.2,,
+"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2013","2013",1.2,,
+"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2014","2014",1.3,,
+"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2015","2015",1.1,,
+"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2016","2016",1.3,,
+"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2017","2017",1.4,,
+"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2018","2018",1.5,,
+"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2019","2019",1.6,,
+"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2020","2020",1.7,,
+"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2021","2021",2.5,,
+"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2022","2022",1.9,,
+"PATCHYPN","N05C-Hypnotics and sedatives","MLLNCUMT","Million of national currency units","HUN","Hungary","2010","2010",9.8,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","MLLNCUMT","Million of national currency units","HUN","Hungary","2011","2011",3.3,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","MLLNCUMT","Million of national currency units","HUN","Hungary","2012","2012",0.5,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","MLLNCUMT","Million of national currency units","HUN","Hungary","2013","2013",0.8,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","MLLNCUMT","Million of national currency units","HUN","Hungary","2014","2014",1.1,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","MLLNCUMT","Million of national currency units","HUN","Hungary","2015","2015",1.1,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","MLLNCUMT","Million of national currency units","HUN","Hungary","2016","2016",0.9,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","MLLNCUMT","Million of national currency units","HUN","Hungary","2017","2017",1,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","MLLNCUMT","Million of national currency units","HUN","Hungary","2018","2018",1.2,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","MLLNCUMT","Million of national currency units","HUN","Hungary","2019","2019",1.8,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","MLLNCUMT","Million of national currency units","HUN","Hungary","2020","2020",2.2,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","MLLNCUMT","Million of national currency units","HUN","Hungary","2021","2021",2.4,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","MLLNCUMT","Million of national currency units","HUN","Hungary","2022","2022",3.5,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","MTMOTCMT","Million US$ at exchange rate","HUN","Hungary","2010","2010",0,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","MTMOTCMT","Million US$ at exchange rate","HUN","Hungary","2011","2011",0,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","MTMOTCMT","Million US$ at exchange rate","HUN","Hungary","2012","2012",0,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","MTMOTCMT","Million US$ at exchange rate","HUN","Hungary","2013","2013",0,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","MTMOTCMT","Million US$ at exchange rate","HUN","Hungary","2014","2014",0,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","MTMOTCMT","Million US$ at exchange rate","HUN","Hungary","2015","2015",0,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","MTMOTCMT","Million US$ at exchange rate","HUN","Hungary","2016","2016",0,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","MTMOTCMT","Million US$ at exchange rate","HUN","Hungary","2017","2017",0,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","MTMOTCMT","Million US$ at exchange rate","HUN","Hungary","2018","2018",0,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","MTMOTCMT","Million US$ at exchange rate","HUN","Hungary","2019","2019",0,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","MTMOTCMT","Million US$ at exchange rate","HUN","Hungary","2020","2020",0,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","MTMOTCMT","Million US$ at exchange rate","HUN","Hungary","2021","2021",0,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","MTMOTCMT","Million US$ at exchange rate","HUN","Hungary","2022","2022",0,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","MTMOPPMT","Million US$, purchasing power parity","HUN","Hungary","2010","2010",0.1,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","MTMOPPMT","Million US$, purchasing power parity","HUN","Hungary","2011","2011",0,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","MTMOPPMT","Million US$, purchasing power parity","HUN","Hungary","2012","2012",0,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","MTMOPPMT","Million US$, purchasing power parity","HUN","Hungary","2013","2013",0,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","MTMOPPMT","Million US$, purchasing power parity","HUN","Hungary","2014","2014",0,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","MTMOPPMT","Million US$, purchasing power parity","HUN","Hungary","2015","2015",0,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","MTMOPPMT","Million US$, purchasing power parity","HUN","Hungary","2016","2016",0,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","MTMOPPMT","Million US$, purchasing power parity","HUN","Hungary","2017","2017",0,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","MTMOPPMT","Million US$, purchasing power parity","HUN","Hungary","2018","2018",0,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","MTMOPPMT","Million US$, purchasing power parity","HUN","Hungary","2019","2019",0,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","MTMOPPMT","Million US$, purchasing power parity","HUN","Hungary","2020","2020",0,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","MTMOPPMT","Million US$, purchasing power parity","HUN","Hungary","2021","2021",0,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","MTMOPPMT","Million US$, purchasing power parity","HUN","Hungary","2022","2022",0,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","TCPPERMT","/capita, US$ exchange rate","HUN","Hungary","2010","2010",0,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","TCPPERMT","/capita, US$ exchange rate","HUN","Hungary","2011","2011",0,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","TCPPERMT","/capita, US$ exchange rate","HUN","Hungary","2012","2012",0,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","TCPPERMT","/capita, US$ exchange rate","HUN","Hungary","2013","2013",0,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","TCPPERMT","/capita, US$ exchange rate","HUN","Hungary","2014","2014",0,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","TCPPERMT","/capita, US$ exchange rate","HUN","Hungary","2015","2015",0,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","TCPPERMT","/capita, US$ exchange rate","HUN","Hungary","2016","2016",0,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","TCPPERMT","/capita, US$ exchange rate","HUN","Hungary","2017","2017",0,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","TCPPERMT","/capita, US$ exchange rate","HUN","Hungary","2018","2018",0,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","TCPPERMT","/capita, US$ exchange rate","HUN","Hungary","2019","2019",0,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","TCPPERMT","/capita, US$ exchange rate","HUN","Hungary","2020","2020",0,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","TCPPERMT","/capita, US$ exchange rate","HUN","Hungary","2021","2021",0,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","TCPPERMT","/capita, US$ exchange rate","HUN","Hungary","2022","2022",0,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2010","2010",0,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2011","2011",0,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2012","2012",0,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2013","2013",0,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2014","2014",0,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2015","2015",0,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2016","2016",0,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2017","2017",0,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2018","2018",0,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2019","2019",0,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2020","2020",0,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2021","2021",0,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2022","2022",0,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","ATCPTTMT","% of total sales","HUN","Hungary","2010","2010",0,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","ATCPTTMT","% of total sales","HUN","Hungary","2011","2011",0,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","ATCPTTMT","% of total sales","HUN","Hungary","2012","2012",0,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","ATCPTTMT","% of total sales","HUN","Hungary","2013","2013",0,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","ATCPTTMT","% of total sales","HUN","Hungary","2014","2014",0,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","ATCPTTMT","% of total sales","HUN","Hungary","2015","2015",0,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","ATCPTTMT","% of total sales","HUN","Hungary","2016","2016",0,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","ATCPTTMT","% of total sales","HUN","Hungary","2017","2017",0,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","ATCPTTMT","% of total sales","HUN","Hungary","2018","2018",0,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","ATCPTTMT","% of total sales","HUN","Hungary","2019","2019",0,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","ATCPTTMT","% of total sales","HUN","Hungary","2020","2020",0,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","ATCPTTMT","% of total sales","HUN","Hungary","2021","2021",0,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","ATCPTTMT","% of total sales","HUN","Hungary","2022","2022",0,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","MLLNCUMT","Million of national currency units","ISL","Iceland","2010","2010",461.2,,
+"PATCHYPN","N05C-Hypnotics and sedatives","MLLNCUMT","Million of national currency units","ISL","Iceland","2011","2011",466.6,,
+"PATCHYPN","N05C-Hypnotics and sedatives","MLLNCUMT","Million of national currency units","ISL","Iceland","2012","2012",463.9,,
+"PATCHYPN","N05C-Hypnotics and sedatives","MLLNCUMT","Million of national currency units","ISL","Iceland","2013","2013",449.1,,
+"PATCHYPN","N05C-Hypnotics and sedatives","MLLNCUMT","Million of national currency units","ISL","Iceland","2014","2014",451.9,,
+"PATCHYPN","N05C-Hypnotics and sedatives","MLLNCUMT","Million of national currency units","ISL","Iceland","2015","2015",460.4,,
+"PATCHYPN","N05C-Hypnotics and sedatives","MLLNCUMT","Million of national currency units","ISL","Iceland","2016","2016",471.8,,
+"PATCHYPN","N05C-Hypnotics and sedatives","MLLNCUMT","Million of national currency units","ISL","Iceland","2017","2017",509.2,,
+"PATCHYPN","N05C-Hypnotics and sedatives","MLLNCUMT","Million of national currency units","ISL","Iceland","2018","2018",572.4,,
+"PATCHYPN","N05C-Hypnotics and sedatives","MLLNCUMT","Million of national currency units","ISL","Iceland","2019","2019",623,,
+"PATCHYPN","N05C-Hypnotics and sedatives","MLLNCUMT","Million of national currency units","ISL","Iceland","2020","2020",736.6,,
+"PATCHYPN","N05C-Hypnotics and sedatives","MLLNCUMT","Million of national currency units","ISL","Iceland","2021","2021",838.4,,
+"PATCHYPN","N05C-Hypnotics and sedatives","MTMOTCMT","Million US$ at exchange rate","ISL","Iceland","2010","2010",3.8,,
+"PATCHYPN","N05C-Hypnotics and sedatives","MTMOTCMT","Million US$ at exchange rate","ISL","Iceland","2011","2011",4,,
+"PATCHYPN","N05C-Hypnotics and sedatives","MTMOTCMT","Million US$ at exchange rate","ISL","Iceland","2012","2012",3.7,,
+"PATCHYPN","N05C-Hypnotics and sedatives","MTMOTCMT","Million US$ at exchange rate","ISL","Iceland","2013","2013",3.7,,
+"PATCHYPN","N05C-Hypnotics and sedatives","MTMOTCMT","Million US$ at exchange rate","ISL","Iceland","2014","2014",3.9,,
+"PATCHYPN","N05C-Hypnotics and sedatives","MTMOTCMT","Million US$ at exchange rate","ISL","Iceland","2015","2015",3.5,,
+"PATCHYPN","N05C-Hypnotics and sedatives","MTMOTCMT","Million US$ at exchange rate","ISL","Iceland","2016","2016",3.9,,
+"PATCHYPN","N05C-Hypnotics and sedatives","MTMOTCMT","Million US$ at exchange rate","ISL","Iceland","2017","2017",4.8,,
+"PATCHYPN","N05C-Hypnotics and sedatives","MTMOTCMT","Million US$ at exchange rate","ISL","Iceland","2018","2018",5.3,,
+"PATCHYPN","N05C-Hypnotics and sedatives","MTMOTCMT","Million US$ at exchange rate","ISL","Iceland","2019","2019",5.1,,
+"PATCHYPN","N05C-Hypnotics and sedatives","MTMOTCMT","Million US$ at exchange rate","ISL","Iceland","2020","2020",5.4,,
+"PATCHYPN","N05C-Hypnotics and sedatives","MTMOTCMT","Million US$ at exchange rate","ISL","Iceland","2021","2021",6.6,,
+"PATCHYPN","N05C-Hypnotics and sedatives","MTMOPPMT","Million US$, purchasing power parity","ISL","Iceland","2010","2010",3.5,,
+"PATCHYPN","N05C-Hypnotics and sedatives","MTMOPPMT","Million US$, purchasing power parity","ISL","Iceland","2011","2011",3.5,,
+"PATCHYPN","N05C-Hypnotics and sedatives","MTMOPPMT","Million US$, purchasing power parity","ISL","Iceland","2012","2012",3.4,,
+"PATCHYPN","N05C-Hypnotics and sedatives","MTMOPPMT","Million US$, purchasing power parity","ISL","Iceland","2013","2013",3.3,,
+"PATCHYPN","N05C-Hypnotics and sedatives","MTMOPPMT","Million US$, purchasing power parity","ISL","Iceland","2014","2014",3.3,,
+"PATCHYPN","N05C-Hypnotics and sedatives","MTMOPPMT","Million US$, purchasing power parity","ISL","Iceland","2015","2015",3.2,,
+"PATCHYPN","N05C-Hypnotics and sedatives","MTMOPPMT","Million US$, purchasing power parity","ISL","Iceland","2016","2016",3.4,,
+"PATCHYPN","N05C-Hypnotics and sedatives","MTMOPPMT","Million US$, purchasing power parity","ISL","Iceland","2017","2017",3.7,,
+"PATCHYPN","N05C-Hypnotics and sedatives","MTMOPPMT","Million US$, purchasing power parity","ISL","Iceland","2018","2018",4.1,,
+"PATCHYPN","N05C-Hypnotics and sedatives","MTMOPPMT","Million US$, purchasing power parity","ISL","Iceland","2019","2019",4.4,,
+"PATCHYPN","N05C-Hypnotics and sedatives","MTMOPPMT","Million US$, purchasing power parity","ISL","Iceland","2020","2020",5,,
+"PATCHYPN","N05C-Hypnotics and sedatives","MTMOPPMT","Million US$, purchasing power parity","ISL","Iceland","2021","2021",5.6,,
+"PATCHYPN","N05C-Hypnotics and sedatives","TCPPERMT","/capita, US$ exchange rate","ISL","Iceland","2010","2010",11.9,,
+"PATCHYPN","N05C-Hypnotics and sedatives","TCPPERMT","/capita, US$ exchange rate","ISL","Iceland","2011","2011",12.6,,
+"PATCHYPN","N05C-Hypnotics and sedatives","TCPPERMT","/capita, US$ exchange rate","ISL","Iceland","2012","2012",11.6,,
+"PATCHYPN","N05C-Hypnotics and sedatives","TCPPERMT","/capita, US$ exchange rate","ISL","Iceland","2013","2013",11.4,,
+"PATCHYPN","N05C-Hypnotics and sedatives","TCPPERMT","/capita, US$ exchange rate","ISL","Iceland","2014","2014",11.8,,
+"PATCHYPN","N05C-Hypnotics and sedatives","TCPPERMT","/capita, US$ exchange rate","ISL","Iceland","2015","2015",10.5,,
+"PATCHYPN","N05C-Hypnotics and sedatives","TCPPERMT","/capita, US$ exchange rate","ISL","Iceland","2016","2016",11.6,,
+"PATCHYPN","N05C-Hypnotics and sedatives","TCPPERMT","/capita, US$ exchange rate","ISL","Iceland","2017","2017",13.9,,
+"PATCHYPN","N05C-Hypnotics and sedatives","TCPPERMT","/capita, US$ exchange rate","ISL","Iceland","2018","2018",15,,
+"PATCHYPN","N05C-Hypnotics and sedatives","TCPPERMT","/capita, US$ exchange rate","ISL","Iceland","2019","2019",14.1,,
+"PATCHYPN","N05C-Hypnotics and sedatives","TCPPERMT","/capita, US$ exchange rate","ISL","Iceland","2020","2020",14.8,,
+"PATCHYPN","N05C-Hypnotics and sedatives","TCPPERMT","/capita, US$ exchange rate","ISL","Iceland","2021","2021",17.7,,
+"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2010","2010",10.9,,
+"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2011","2011",10.8,,
+"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2012","2012",10.6,,
+"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2013","2013",10.1,,
+"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2014","2014",10,,
+"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2015","2015",9.8,,
+"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2016","2016",10,,
+"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2017","2017",10.7,,
+"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2018","2018",11.5,,
+"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2019","2019",12.3,,
+"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2020","2020",13.7,,
+"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2021","2021",15,,
+"PATCHYPN","N05C-Hypnotics and sedatives","ATCPTTMT","% of total sales","ISL","Iceland","2010","2010",1.8,,
+"PATCHYPN","N05C-Hypnotics and sedatives","ATCPTTMT","% of total sales","ISL","Iceland","2011","2011",1.8,,
+"PATCHYPN","N05C-Hypnotics and sedatives","ATCPTTMT","% of total sales","ISL","Iceland","2012","2012",1.9,,
+"PATCHYPN","N05C-Hypnotics and sedatives","ATCPTTMT","% of total sales","ISL","Iceland","2013","2013",1.7,,
+"PATCHYPN","N05C-Hypnotics and sedatives","ATCPTTMT","% of total sales","ISL","Iceland","2014","2014",1.9,,
+"PATCHYPN","N05C-Hypnotics and sedatives","ATCPTTMT","% of total sales","ISL","Iceland","2015","2015",1.9,,
+"PATCHYPN","N05C-Hypnotics and sedatives","ATCPTTMT","% of total sales","ISL","Iceland","2016","2016",1.9,,
+"PATCHYPN","N05C-Hypnotics and sedatives","ATCPTTMT","% of total sales","ISL","Iceland","2017","2017",1.9,,
+"PATCHYPN","N05C-Hypnotics and sedatives","ATCPTTMT","% of total sales","ISL","Iceland","2018","2018",1.9,,
+"PATCHYPN","N05C-Hypnotics and sedatives","ATCPTTMT","% of total sales","ISL","Iceland","2019","2019",1.9,,
+"PATCHYPN","N05C-Hypnotics and sedatives","ATCPTTMT","% of total sales","ISL","Iceland","2020","2020",1.8,,
+"PATCHYPN","N05C-Hypnotics and sedatives","ATCPTTMT","% of total sales","ISL","Iceland","2021","2021",1.9,,
+"PATCHYPN","N05C-Hypnotics and sedatives","MLLNCUMT","Million of national currency units","IRL","Ireland","2010","2010",16.8,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","MLLNCUMT","Million of national currency units","IRL","Ireland","2011","2011",17,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","MLLNCUMT","Million of national currency units","IRL","Ireland","2012","2012",17.7,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","MLLNCUMT","Million of national currency units","IRL","Ireland","2013","2013",18.2,"B; D","Break; Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","MLLNCUMT","Million of national currency units","IRL","Ireland","2014","2014",18.8,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","MLLNCUMT","Million of national currency units","IRL","Ireland","2015","2015",18.3,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","MLLNCUMT","Million of national currency units","IRL","Ireland","2016","2016",18.8,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","MLLNCUMT","Million of national currency units","IRL","Ireland","2017","2017",18.3,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","MLLNCUMT","Million of national currency units","IRL","Ireland","2018","2018",18,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","MLLNCUMT","Million of national currency units","IRL","Ireland","2019","2019",17.8,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","MLLNCUMT","Million of national currency units","IRL","Ireland","2020","2020",18.3,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","MLLNCUMT","Million of national currency units","IRL","Ireland","2021","2021",17.5,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","MTMOTCMT","Million US$ at exchange rate","IRL","Ireland","2010","2010",22.2,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","MTMOTCMT","Million US$ at exchange rate","IRL","Ireland","2011","2011",23.6,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","MTMOTCMT","Million US$ at exchange rate","IRL","Ireland","2012","2012",22.7,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","MTMOTCMT","Million US$ at exchange rate","IRL","Ireland","2013","2013",24.2,"B; D","Break; Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","MTMOTCMT","Million US$ at exchange rate","IRL","Ireland","2014","2014",24.9,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","MTMOTCMT","Million US$ at exchange rate","IRL","Ireland","2015","2015",20.3,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","MTMOTCMT","Million US$ at exchange rate","IRL","Ireland","2016","2016",20.8,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","MTMOTCMT","Million US$ at exchange rate","IRL","Ireland","2017","2017",20.7,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","MTMOTCMT","Million US$ at exchange rate","IRL","Ireland","2018","2018",21.3,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","MTMOTCMT","Million US$ at exchange rate","IRL","Ireland","2019","2019",19.9,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","MTMOTCMT","Million US$ at exchange rate","IRL","Ireland","2020","2020",20.9,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","MTMOTCMT","Million US$ at exchange rate","IRL","Ireland","2021","2021",20.8,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","MTMOPPMT","Million US$, purchasing power parity","IRL","Ireland","2010","2010",19.7,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","MTMOPPMT","Million US$, purchasing power parity","IRL","Ireland","2011","2011",20.4,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","MTMOPPMT","Million US$, purchasing power parity","IRL","Ireland","2012","2012",21.5,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","MTMOPPMT","Million US$, purchasing power parity","IRL","Ireland","2013","2013",22.5,"B; D","Break; Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","MTMOPPMT","Million US$, purchasing power parity","IRL","Ireland","2014","2014",22.9,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","MTMOPPMT","Million US$, purchasing power parity","IRL","Ireland","2015","2015",22.6,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","MTMOPPMT","Million US$, purchasing power parity","IRL","Ireland","2016","2016",23.6,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","MTMOPPMT","Million US$, purchasing power parity","IRL","Ireland","2017","2017",23.1,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","MTMOPPMT","Million US$, purchasing power parity","IRL","Ireland","2018","2018",22.7,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","MTMOPPMT","Million US$, purchasing power parity","IRL","Ireland","2019","2019",22.1,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","MTMOPPMT","Million US$, purchasing power parity","IRL","Ireland","2020","2020",23,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","MTMOPPMT","Million US$, purchasing power parity","IRL","Ireland","2021","2021",22.1,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","TCPPERMT","/capita, US$ exchange rate","IRL","Ireland","2010","2010",4.9,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","TCPPERMT","/capita, US$ exchange rate","IRL","Ireland","2011","2011",5.2,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","TCPPERMT","/capita, US$ exchange rate","IRL","Ireland","2012","2012",4.9,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","TCPPERMT","/capita, US$ exchange rate","IRL","Ireland","2013","2013",5.2,"B; D","Break; Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","TCPPERMT","/capita, US$ exchange rate","IRL","Ireland","2014","2014",5.4,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","TCPPERMT","/capita, US$ exchange rate","IRL","Ireland","2015","2015",4.3,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","TCPPERMT","/capita, US$ exchange rate","IRL","Ireland","2016","2016",4.4,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","TCPPERMT","/capita, US$ exchange rate","IRL","Ireland","2017","2017",4.3,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","TCPPERMT","/capita, US$ exchange rate","IRL","Ireland","2018","2018",4.4,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","TCPPERMT","/capita, US$ exchange rate","IRL","Ireland","2019","2019",4,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","TCPPERMT","/capita, US$ exchange rate","IRL","Ireland","2020","2020",4.2,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","TCPPERMT","/capita, US$ exchange rate","IRL","Ireland","2021","2021",4.1,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2010","2010",4.3,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2011","2011",4.5,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2012","2012",4.7,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2013","2013",4.9,"B; D","Break; Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2014","2014",4.9,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2015","2015",4.8,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2016","2016",5,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2017","2017",4.8,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2018","2018",4.7,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2019","2019",4.5,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2020","2020",4.6,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2021","2021",4.4,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","ATCPTTMT","% of total sales","IRL","Ireland","2010","2010",0.8,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","ATCPTTMT","% of total sales","IRL","Ireland","2011","2011",0.9,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","ATCPTTMT","% of total sales","IRL","Ireland","2012","2012",0.9,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","ATCPTTMT","% of total sales","IRL","Ireland","2013","2013",0.9,"B; D","Break; Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","ATCPTTMT","% of total sales","IRL","Ireland","2014","2014",1,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","ATCPTTMT","% of total sales","IRL","Ireland","2015","2015",0.9,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","ATCPTTMT","% of total sales","IRL","Ireland","2016","2016",0.9,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","ATCPTTMT","% of total sales","IRL","Ireland","2017","2017",0.9,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","ATCPTTMT","% of total sales","IRL","Ireland","2018","2018",0.8,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","ATCPTTMT","% of total sales","IRL","Ireland","2019","2019",0.7,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","ATCPTTMT","% of total sales","IRL","Ireland","2020","2020",0.7,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","ATCPTTMT","% of total sales","IRL","Ireland","2021","2021",0.7,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","MLLNCUMT","Million of national currency units","ITA","Italy","2011","2011",3.1,,
+"PATCHYPN","N05C-Hypnotics and sedatives","MLLNCUMT","Million of national currency units","ITA","Italy","2012","2012",3.8,,
+"PATCHYPN","N05C-Hypnotics and sedatives","MLLNCUMT","Million of national currency units","ITA","Italy","2013","2013",3.1,,
+"PATCHYPN","N05C-Hypnotics and sedatives","MLLNCUMT","Million of national currency units","ITA","Italy","2014","2014",2.5,,
+"PATCHYPN","N05C-Hypnotics and sedatives","MLLNCUMT","Million of national currency units","ITA","Italy","2015","2015",4.1,,
+"PATCHYPN","N05C-Hypnotics and sedatives","MLLNCUMT","Million of national currency units","ITA","Italy","2016","2016",7.1,,
+"PATCHYPN","N05C-Hypnotics and sedatives","MLLNCUMT","Million of national currency units","ITA","Italy","2017","2017",10.1,,
+"PATCHYPN","N05C-Hypnotics and sedatives","MLLNCUMT","Million of national currency units","ITA","Italy","2018","2018",11.8,,
+"PATCHYPN","N05C-Hypnotics and sedatives","MLLNCUMT","Million of national currency units","ITA","Italy","2019","2019",12.9,,
+"PATCHYPN","N05C-Hypnotics and sedatives","MLLNCUMT","Million of national currency units","ITA","Italy","2020","2020",19.5,,
+"PATCHYPN","N05C-Hypnotics and sedatives","MLLNCUMT","Million of national currency units","ITA","Italy","2021","2021",13.9,,
+"PATCHYPN","N05C-Hypnotics and sedatives","MLLNCUMT","Million of national currency units","ITA","Italy","2022","2022",8.6,"E","Estimated value"
+"PATCHYPN","N05C-Hypnotics and sedatives","MTMOTCMT","Million US$ at exchange rate","ITA","Italy","2011","2011",4.3,,
+"PATCHYPN","N05C-Hypnotics and sedatives","MTMOTCMT","Million US$ at exchange rate","ITA","Italy","2012","2012",4.9,,
+"PATCHYPN","N05C-Hypnotics and sedatives","MTMOTCMT","Million US$ at exchange rate","ITA","Italy","2013","2013",4.1,,
+"PATCHYPN","N05C-Hypnotics and sedatives","MTMOTCMT","Million US$ at exchange rate","ITA","Italy","2014","2014",3.3,,
+"PATCHYPN","N05C-Hypnotics and sedatives","MTMOTCMT","Million US$ at exchange rate","ITA","Italy","2015","2015",4.5,,
+"PATCHYPN","N05C-Hypnotics and sedatives","MTMOTCMT","Million US$ at exchange rate","ITA","Italy","2016","2016",7.9,,
+"PATCHYPN","N05C-Hypnotics and sedatives","MTMOTCMT","Million US$ at exchange rate","ITA","Italy","2017","2017",11.4,,
+"PATCHYPN","N05C-Hypnotics and sedatives","MTMOTCMT","Million US$ at exchange rate","ITA","Italy","2018","2018",13.9,,
+"PATCHYPN","N05C-Hypnotics and sedatives","MTMOTCMT","Million US$ at exchange rate","ITA","Italy","2019","2019",14.5,,
+"PATCHYPN","N05C-Hypnotics and sedatives","MTMOTCMT","Million US$ at exchange rate","ITA","Italy","2020","2020",22.2,,
+"PATCHYPN","N05C-Hypnotics and sedatives","MTMOTCMT","Million US$ at exchange rate","ITA","Italy","2021","2021",16.4,,
+"PATCHYPN","N05C-Hypnotics and sedatives","MTMOTCMT","Million US$ at exchange rate","ITA","Italy","2022","2022",9,"E","Estimated value"
+"PATCHYPN","N05C-Hypnotics and sedatives","MTMOPPMT","Million US$, purchasing power parity","ITA","Italy","2011","2011",4.1,,
+"PATCHYPN","N05C-Hypnotics and sedatives","MTMOPPMT","Million US$, purchasing power parity","ITA","Italy","2012","2012",5.1,,
+"PATCHYPN","N05C-Hypnotics and sedatives","MTMOPPMT","Million US$, purchasing power parity","ITA","Italy","2013","2013",4.2,,
+"PATCHYPN","N05C-Hypnotics and sedatives","MTMOPPMT","Million US$, purchasing power parity","ITA","Italy","2014","2014",3.4,,
+"PATCHYPN","N05C-Hypnotics and sedatives","MTMOPPMT","Million US$, purchasing power parity","ITA","Italy","2015","2015",5.5,,
+"PATCHYPN","N05C-Hypnotics and sedatives","MTMOPPMT","Million US$, purchasing power parity","ITA","Italy","2016","2016",10.2,,
+"PATCHYPN","N05C-Hypnotics and sedatives","MTMOPPMT","Million US$, purchasing power parity","ITA","Italy","2017","2017",14.6,,
+"PATCHYPN","N05C-Hypnotics and sedatives","MTMOPPMT","Million US$, purchasing power parity","ITA","Italy","2018","2018",17.3,,
+"PATCHYPN","N05C-Hypnotics and sedatives","MTMOPPMT","Million US$, purchasing power parity","ITA","Italy","2019","2019",19.7,,
+"PATCHYPN","N05C-Hypnotics and sedatives","MTMOPPMT","Million US$, purchasing power parity","ITA","Italy","2020","2020",30,,
+"PATCHYPN","N05C-Hypnotics and sedatives","MTMOPPMT","Million US$, purchasing power parity","ITA","Italy","2021","2021",21.4,,
+"PATCHYPN","N05C-Hypnotics and sedatives","MTMOPPMT","Million US$, purchasing power parity","ITA","Italy","2022","2022",13.9,"E","Estimated value"
+"PATCHYPN","N05C-Hypnotics and sedatives","TCPPERMT","/capita, US$ exchange rate","ITA","Italy","2011","2011",0.1,,
+"PATCHYPN","N05C-Hypnotics and sedatives","TCPPERMT","/capita, US$ exchange rate","ITA","Italy","2012","2012",0.1,,
+"PATCHYPN","N05C-Hypnotics and sedatives","TCPPERMT","/capita, US$ exchange rate","ITA","Italy","2013","2013",0.1,,
+"PATCHYPN","N05C-Hypnotics and sedatives","TCPPERMT","/capita, US$ exchange rate","ITA","Italy","2014","2014",0.1,,
+"PATCHYPN","N05C-Hypnotics and sedatives","TCPPERMT","/capita, US$ exchange rate","ITA","Italy","2015","2015",0.1,,
+"PATCHYPN","N05C-Hypnotics and sedatives","TCPPERMT","/capita, US$ exchange rate","ITA","Italy","2016","2016",0.1,,
+"PATCHYPN","N05C-Hypnotics and sedatives","TCPPERMT","/capita, US$ exchange rate","ITA","Italy","2017","2017",0.2,,
+"PATCHYPN","N05C-Hypnotics and sedatives","TCPPERMT","/capita, US$ exchange rate","ITA","Italy","2018","2018",0.2,,
+"PATCHYPN","N05C-Hypnotics and sedatives","TCPPERMT","/capita, US$ exchange rate","ITA","Italy","2019","2019",0.2,,
+"PATCHYPN","N05C-Hypnotics and sedatives","TCPPERMT","/capita, US$ exchange rate","ITA","Italy","2020","2020",0.4,,
+"PATCHYPN","N05C-Hypnotics and sedatives","TCPPERMT","/capita, US$ exchange rate","ITA","Italy","2021","2021",0.3,,
+"PATCHYPN","N05C-Hypnotics and sedatives","TCPPERMT","/capita, US$ exchange rate","ITA","Italy","2022","2022",0.2,"E","Estimated value"
+"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2011","2011",0.1,,
+"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2012","2012",0.1,,
+"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2013","2013",0.1,,
+"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2014","2014",0.1,,
+"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2015","2015",0.1,,
+"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2016","2016",0.2,,
+"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2017","2017",0.2,,
+"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2018","2018",0.3,,
+"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2019","2019",0.3,,
+"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2020","2020",0.5,,
+"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2021","2021",0.4,,
+"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2022","2022",0.2,"E","Estimated value"
+"PATCHYPN","N05C-Hypnotics and sedatives","ATCPTTMT","% of total sales","ITA","Italy","2011","2011",0,,
+"PATCHYPN","N05C-Hypnotics and sedatives","ATCPTTMT","% of total sales","ITA","Italy","2012","2012",0,,
+"PATCHYPN","N05C-Hypnotics and sedatives","ATCPTTMT","% of total sales","ITA","Italy","2013","2013",0,,
+"PATCHYPN","N05C-Hypnotics and sedatives","ATCPTTMT","% of total sales","ITA","Italy","2014","2014",0,,
+"PATCHYPN","N05C-Hypnotics and sedatives","ATCPTTMT","% of total sales","ITA","Italy","2015","2015",0,,
+"PATCHYPN","N05C-Hypnotics and sedatives","ATCPTTMT","% of total sales","ITA","Italy","2016","2016",0,,
+"PATCHYPN","N05C-Hypnotics and sedatives","ATCPTTMT","% of total sales","ITA","Italy","2017","2017",0,,
+"PATCHYPN","N05C-Hypnotics and sedatives","ATCPTTMT","% of total sales","ITA","Italy","2018","2018",0.1,,
+"PATCHYPN","N05C-Hypnotics and sedatives","ATCPTTMT","% of total sales","ITA","Italy","2019","2019",0.1,,
+"PATCHYPN","N05C-Hypnotics and sedatives","ATCPTTMT","% of total sales","ITA","Italy","2020","2020",0.1,,
+"PATCHYPN","N05C-Hypnotics and sedatives","ATCPTTMT","% of total sales","ITA","Italy","2021","2021",0.1,,
+"PATCHYPN","N05C-Hypnotics and sedatives","ATCPTTMT","% of total sales","ITA","Italy","2022","2022",0,"E","Estimated value"
+"PATCHYPN","N05C-Hypnotics and sedatives","MLLNCUMT","Million of national currency units","KOR","Korea","2010","2010",37011,,
+"PATCHYPN","N05C-Hypnotics and sedatives","MLLNCUMT","Million of national currency units","KOR","Korea","2011","2011",40290.3,"B","Break"
+"PATCHYPN","N05C-Hypnotics and sedatives","MLLNCUMT","Million of national currency units","KOR","Korea","2012","2012",36827.7,,
+"PATCHYPN","N05C-Hypnotics and sedatives","MLLNCUMT","Million of national currency units","KOR","Korea","2013","2013",39454.2,,
+"PATCHYPN","N05C-Hypnotics and sedatives","MLLNCUMT","Million of national currency units","KOR","Korea","2014","2014",42828.8,,
+"PATCHYPN","N05C-Hypnotics and sedatives","MLLNCUMT","Million of national currency units","KOR","Korea","2015","2015",47029,,
+"PATCHYPN","N05C-Hypnotics and sedatives","MLLNCUMT","Million of national currency units","KOR","Korea","2016","2016",48946.6,"B","Break"
+"PATCHYPN","N05C-Hypnotics and sedatives","MLLNCUMT","Million of national currency units","KOR","Korea","2017","2017",50664.8,,
+"PATCHYPN","N05C-Hypnotics and sedatives","MLLNCUMT","Million of national currency units","KOR","Korea","2018","2018",49591.5,,
+"PATCHYPN","N05C-Hypnotics and sedatives","MLLNCUMT","Million of national currency units","KOR","Korea","2019","2019",60192.1,,
+"PATCHYPN","N05C-Hypnotics and sedatives","MLLNCUMT","Million of national currency units","KOR","Korea","2020","2020",68593.2,,
+"PATCHYPN","N05C-Hypnotics and sedatives","MLLNCUMT","Million of national currency units","KOR","Korea","2021","2021",77611,,
+"PATCHYPN","N05C-Hypnotics and sedatives","MTMOTCMT","Million US$ at exchange rate","KOR","Korea","2010","2010",32,,
+"PATCHYPN","N05C-Hypnotics and sedatives","MTMOTCMT","Million US$ at exchange rate","KOR","Korea","2011","2011",36.4,"B","Break"
+"PATCHYPN","N05C-Hypnotics and sedatives","MTMOTCMT","Million US$ at exchange rate","KOR","Korea","2012","2012",32.7,,
+"PATCHYPN","N05C-Hypnotics and sedatives","MTMOTCMT","Million US$ at exchange rate","KOR","Korea","2013","2013",36,,
+"PATCHYPN","N05C-Hypnotics and sedatives","MTMOTCMT","Million US$ at exchange rate","KOR","Korea","2014","2014",40.7,,
+"PATCHYPN","N05C-Hypnotics and sedatives","MTMOTCMT","Million US$ at exchange rate","KOR","Korea","2015","2015",41.6,,
+"PATCHYPN","N05C-Hypnotics and sedatives","MTMOTCMT","Million US$ at exchange rate","KOR","Korea","2016","2016",42.2,"B","Break"
+"PATCHYPN","N05C-Hypnotics and sedatives","MTMOTCMT","Million US$ at exchange rate","KOR","Korea","2017","2017",44.8,,
+"PATCHYPN","N05C-Hypnotics and sedatives","MTMOTCMT","Million US$ at exchange rate","KOR","Korea","2018","2018",45.1,,
+"PATCHYPN","N05C-Hypnotics and sedatives","MTMOTCMT","Million US$ at exchange rate","KOR","Korea","2019","2019",51.7,,
+"PATCHYPN","N05C-Hypnotics and sedatives","MTMOTCMT","Million US$ at exchange rate","KOR","Korea","2020","2020",58.1,,
+"PATCHYPN","N05C-Hypnotics and sedatives","MTMOTCMT","Million US$ at exchange rate","KOR","Korea","2021","2021",67.8,,
+"PATCHYPN","N05C-Hypnotics and sedatives","MTMOPPMT","Million US$, purchasing power parity","KOR","Korea","2010","2010",44,,
+"PATCHYPN","N05C-Hypnotics and sedatives","MTMOPPMT","Million US$, purchasing power parity","KOR","Korea","2011","2011",47.1,"B","Break"
+"PATCHYPN","N05C-Hypnotics and sedatives","MTMOPPMT","Million US$, purchasing power parity","KOR","Korea","2012","2012",43.1,,
+"PATCHYPN","N05C-Hypnotics and sedatives","MTMOPPMT","Million US$, purchasing power parity","KOR","Korea","2013","2013",45.4,,
+"PATCHYPN","N05C-Hypnotics and sedatives","MTMOPPMT","Million US$, purchasing power parity","KOR","Korea","2014","2014",49.1,,
+"PATCHYPN","N05C-Hypnotics and sedatives","MTMOPPMT","Million US$, purchasing power parity","KOR","Korea","2015","2015",54.8,,
+"PATCHYPN","N05C-Hypnotics and sedatives","MTMOPPMT","Million US$, purchasing power parity","KOR","Korea","2016","2016",57,"B","Break"
+"PATCHYPN","N05C-Hypnotics and sedatives","MTMOPPMT","Million US$, purchasing power parity","KOR","Korea","2017","2017",58.1,,
+"PATCHYPN","N05C-Hypnotics and sedatives","MTMOPPMT","Million US$, purchasing power parity","KOR","Korea","2018","2018",58,,
+"PATCHYPN","N05C-Hypnotics and sedatives","MTMOPPMT","Million US$, purchasing power parity","KOR","Korea","2019","2019",70.3,,
+"PATCHYPN","N05C-Hypnotics and sedatives","MTMOPPMT","Million US$, purchasing power parity","KOR","Korea","2020","2020",81.9,,
+"PATCHYPN","N05C-Hypnotics and sedatives","MTMOPPMT","Million US$, purchasing power parity","KOR","Korea","2021","2021",90.9,,
+"PATCHYPN","N05C-Hypnotics and sedatives","TCPPERMT","/capita, US$ exchange rate","KOR","Korea","2010","2010",0.6,,
+"PATCHYPN","N05C-Hypnotics and sedatives","TCPPERMT","/capita, US$ exchange rate","KOR","Korea","2011","2011",0.7,"B","Break"
+"PATCHYPN","N05C-Hypnotics and sedatives","TCPPERMT","/capita, US$ exchange rate","KOR","Korea","2012","2012",0.7,,
+"PATCHYPN","N05C-Hypnotics and sedatives","TCPPERMT","/capita, US$ exchange rate","KOR","Korea","2013","2013",0.7,,
+"PATCHYPN","N05C-Hypnotics and sedatives","TCPPERMT","/capita, US$ exchange rate","KOR","Korea","2014","2014",0.8,,
+"PATCHYPN","N05C-Hypnotics and sedatives","TCPPERMT","/capita, US$ exchange rate","KOR","Korea","2015","2015",0.8,,
+"PATCHYPN","N05C-Hypnotics and sedatives","TCPPERMT","/capita, US$ exchange rate","KOR","Korea","2016","2016",0.8,"B","Break"
+"PATCHYPN","N05C-Hypnotics and sedatives","TCPPERMT","/capita, US$ exchange rate","KOR","Korea","2017","2017",0.9,,
+"PATCHYPN","N05C-Hypnotics and sedatives","TCPPERMT","/capita, US$ exchange rate","KOR","Korea","2018","2018",0.9,,
+"PATCHYPN","N05C-Hypnotics and sedatives","TCPPERMT","/capita, US$ exchange rate","KOR","Korea","2019","2019",1,,
+"PATCHYPN","N05C-Hypnotics and sedatives","TCPPERMT","/capita, US$ exchange rate","KOR","Korea","2020","2020",1.1,,
+"PATCHYPN","N05C-Hypnotics and sedatives","TCPPERMT","/capita, US$ exchange rate","KOR","Korea","2021","2021",1.3,,
+"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2010","2010",0.9,,
+"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2011","2011",0.9,"B","Break"
+"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2012","2012",0.9,,
+"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2013","2013",0.9,,
+"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2014","2014",1,,
+"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2015","2015",1.1,,
+"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2016","2016",1.1,"B","Break"
+"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2017","2017",1.1,,
+"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2018","2018",1.1,,
+"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2019","2019",1.4,,
+"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2020","2020",1.6,,
+"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2021","2021",1.8,,
+"PATCHYPN","N05C-Hypnotics and sedatives","ATCPTTMT","% of total sales","KOR","Korea","2010","2010",0.2,,
+"PATCHYPN","N05C-Hypnotics and sedatives","ATCPTTMT","% of total sales","KOR","Korea","2011","2011",0.2,"B","Break"
+"PATCHYPN","N05C-Hypnotics and sedatives","ATCPTTMT","% of total sales","KOR","Korea","2012","2012",0.2,,
+"PATCHYPN","N05C-Hypnotics and sedatives","ATCPTTMT","% of total sales","KOR","Korea","2013","2013",0.2,,
+"PATCHYPN","N05C-Hypnotics and sedatives","ATCPTTMT","% of total sales","KOR","Korea","2014","2014",0.2,,
+"PATCHYPN","N05C-Hypnotics and sedatives","ATCPTTMT","% of total sales","KOR","Korea","2015","2015",0.2,,
+"PATCHYPN","N05C-Hypnotics and sedatives","ATCPTTMT","% of total sales","KOR","Korea","2016","2016",0.2,"B","Break"
+"PATCHYPN","N05C-Hypnotics and sedatives","ATCPTTMT","% of total sales","KOR","Korea","2017","2017",0.2,,
+"PATCHYPN","N05C-Hypnotics and sedatives","ATCPTTMT","% of total sales","KOR","Korea","2018","2018",0.2,,
+"PATCHYPN","N05C-Hypnotics and sedatives","ATCPTTMT","% of total sales","KOR","Korea","2019","2019",0.2,,
+"PATCHYPN","N05C-Hypnotics and sedatives","ATCPTTMT","% of total sales","KOR","Korea","2020","2020",0.2,,
+"PATCHYPN","N05C-Hypnotics and sedatives","ATCPTTMT","% of total sales","KOR","Korea","2021","2021",0.2,,
+"PATCHYPN","N05C-Hypnotics and sedatives","MLLNCUMT","Million of national currency units","LUX","Luxembourg","2010","2010",3,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","MLLNCUMT","Million of national currency units","LUX","Luxembourg","2011","2011",3,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","MLLNCUMT","Million of national currency units","LUX","Luxembourg","2012","2012",3,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","MLLNCUMT","Million of national currency units","LUX","Luxembourg","2013","2013",3,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","MLLNCUMT","Million of national currency units","LUX","Luxembourg","2014","2014",3.1,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","MLLNCUMT","Million of national currency units","LUX","Luxembourg","2015","2015",3.4,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","MLLNCUMT","Million of national currency units","LUX","Luxembourg","2016","2016",3.4,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","MLLNCUMT","Million of national currency units","LUX","Luxembourg","2017","2017",3.4,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","MLLNCUMT","Million of national currency units","LUX","Luxembourg","2018","2018",3.2,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","MLLNCUMT","Million of national currency units","LUX","Luxembourg","2019","2019",3.2,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","MLLNCUMT","Million of national currency units","LUX","Luxembourg","2020","2020",3.4,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","MLLNCUMT","Million of national currency units","LUX","Luxembourg","2021","2021",3.3,"B; D; P","Break; Difference in methodology; Provisional value"
+"PATCHYPN","N05C-Hypnotics and sedatives","MLLNCUMT","Million of national currency units","LUX","Luxembourg","2022","2022",3,"D; P","Difference in methodology; Provisional value"
+"PATCHYPN","N05C-Hypnotics and sedatives","MTMOTCMT","Million US$ at exchange rate","LUX","Luxembourg","2010","2010",4,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","MTMOTCMT","Million US$ at exchange rate","LUX","Luxembourg","2011","2011",4.2,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","MTMOTCMT","Million US$ at exchange rate","LUX","Luxembourg","2012","2012",3.9,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","MTMOTCMT","Million US$ at exchange rate","LUX","Luxembourg","2013","2013",4,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","MTMOTCMT","Million US$ at exchange rate","LUX","Luxembourg","2014","2014",4.2,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","MTMOTCMT","Million US$ at exchange rate","LUX","Luxembourg","2015","2015",3.8,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","MTMOTCMT","Million US$ at exchange rate","LUX","Luxembourg","2016","2016",3.8,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","MTMOTCMT","Million US$ at exchange rate","LUX","Luxembourg","2017","2017",3.9,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","MTMOTCMT","Million US$ at exchange rate","LUX","Luxembourg","2018","2018",3.8,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","MTMOTCMT","Million US$ at exchange rate","LUX","Luxembourg","2019","2019",3.6,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","MTMOTCMT","Million US$ at exchange rate","LUX","Luxembourg","2020","2020",3.8,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","MTMOTCMT","Million US$ at exchange rate","LUX","Luxembourg","2021","2021",3.9,"B; D; P","Break; Difference in methodology; Provisional value"
+"PATCHYPN","N05C-Hypnotics and sedatives","MTMOTCMT","Million US$ at exchange rate","LUX","Luxembourg","2022","2022",3.1,"D; P","Difference in methodology; Provisional value"
+"PATCHYPN","N05C-Hypnotics and sedatives","MTMOPPMT","Million US$, purchasing power parity","LUX","Luxembourg","2010","2010",3.2,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","MTMOPPMT","Million US$, purchasing power parity","LUX","Luxembourg","2011","2011",3.3,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","MTMOPPMT","Million US$, purchasing power parity","LUX","Luxembourg","2012","2012",3.3,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","MTMOPPMT","Million US$, purchasing power parity","LUX","Luxembourg","2013","2013",3.4,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","MTMOPPMT","Million US$, purchasing power parity","LUX","Luxembourg","2014","2014",3.6,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","MTMOPPMT","Million US$, purchasing power parity","LUX","Luxembourg","2015","2015",3.9,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","MTMOPPMT","Million US$, purchasing power parity","LUX","Luxembourg","2016","2016",4,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","MTMOPPMT","Million US$, purchasing power parity","LUX","Luxembourg","2017","2017",4,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","MTMOPPMT","Million US$, purchasing power parity","LUX","Luxembourg","2018","2018",3.8,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","MTMOPPMT","Million US$, purchasing power parity","LUX","Luxembourg","2019","2019",3.8,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","MTMOPPMT","Million US$, purchasing power parity","LUX","Luxembourg","2020","2020",3.9,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","MTMOPPMT","Million US$, purchasing power parity","LUX","Luxembourg","2021","2021",3.8,"B; D; P","Break; Difference in methodology; Provisional value"
+"PATCHYPN","N05C-Hypnotics and sedatives","MTMOPPMT","Million US$, purchasing power parity","LUX","Luxembourg","2022","2022",3.5,"D; P","Difference in methodology; Provisional value"
+"PATCHYPN","N05C-Hypnotics and sedatives","TCPPERMT","/capita, US$ exchange rate","LUX","Luxembourg","2010","2010",8.4,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","TCPPERMT","/capita, US$ exchange rate","LUX","Luxembourg","2011","2011",8.7,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","TCPPERMT","/capita, US$ exchange rate","LUX","Luxembourg","2012","2012",7.8,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","TCPPERMT","/capita, US$ exchange rate","LUX","Luxembourg","2013","2013",8,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","TCPPERMT","/capita, US$ exchange rate","LUX","Luxembourg","2014","2014",8.2,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","TCPPERMT","/capita, US$ exchange rate","LUX","Luxembourg","2015","2015",7.3,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","TCPPERMT","/capita, US$ exchange rate","LUX","Luxembourg","2016","2016",7.2,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","TCPPERMT","/capita, US$ exchange rate","LUX","Luxembourg","2017","2017",7.2,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","TCPPERMT","/capita, US$ exchange rate","LUX","Luxembourg","2018","2018",7,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","TCPPERMT","/capita, US$ exchange rate","LUX","Luxembourg","2019","2019",6.4,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","TCPPERMT","/capita, US$ exchange rate","LUX","Luxembourg","2020","2020",6.8,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","TCPPERMT","/capita, US$ exchange rate","LUX","Luxembourg","2021","2021",6.8,"B; D; P","Break; Difference in methodology; Provisional value"
+"PATCHYPN","N05C-Hypnotics and sedatives","TCPPERMT","/capita, US$ exchange rate","LUX","Luxembourg","2022","2022",5.3,"D; P","Difference in methodology; Provisional value"
+"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2010","2010",6.8,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2011","2011",6.9,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2012","2012",6.7,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2013","2013",6.7,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2014","2014",7,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2015","2015",7.5,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2016","2016",7.7,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2017","2017",7.5,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2018","2018",6.9,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2019","2019",6.8,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2020","2020",6.9,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2021","2021",6.7,"B; D; P","Break; Difference in methodology; Provisional value"
+"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2022","2022",6,"D; P","Difference in methodology; Provisional value"
+"PATCHYPN","N05C-Hypnotics and sedatives","ATCPTTMT","% of total sales","LUX","Luxembourg","2010","2010",1.6,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","ATCPTTMT","% of total sales","LUX","Luxembourg","2011","2011",1.6,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","ATCPTTMT","% of total sales","LUX","Luxembourg","2012","2012",1.5,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","ATCPTTMT","% of total sales","LUX","Luxembourg","2013","2013",1.6,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","ATCPTTMT","% of total sales","LUX","Luxembourg","2014","2014",1.6,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","ATCPTTMT","% of total sales","LUX","Luxembourg","2015","2015",1.8,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","ATCPTTMT","% of total sales","LUX","Luxembourg","2016","2016",1.8,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","ATCPTTMT","% of total sales","LUX","Luxembourg","2017","2017",1.8,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","ATCPTTMT","% of total sales","LUX","Luxembourg","2018","2018",1.6,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","ATCPTTMT","% of total sales","LUX","Luxembourg","2019","2019",1.6,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","ATCPTTMT","% of total sales","LUX","Luxembourg","2020","2020",1.6,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","ATCPTTMT","% of total sales","LUX","Luxembourg","2021","2021",1.4,"B; D; P","Break; Difference in methodology; Provisional value"
+"PATCHYPN","N05C-Hypnotics and sedatives","ATCPTTMT","% of total sales","LUX","Luxembourg","2022","2022",1.1,"D; P","Difference in methodology; Provisional value"
+"PATCHYPN","N05C-Hypnotics and sedatives","MLLNCUMT","Million of national currency units","NLD","Netherlands","2010","2010",11.7,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","MLLNCUMT","Million of national currency units","NLD","Netherlands","2011","2011",12.4,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","MLLNCUMT","Million of national currency units","NLD","Netherlands","2012","2012",12.4,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","MLLNCUMT","Million of national currency units","NLD","Netherlands","2013","2013",12.7,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","MLLNCUMT","Million of national currency units","NLD","Netherlands","2014","2014",13.9,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","MTMOTCMT","Million US$ at exchange rate","NLD","Netherlands","2010","2010",15.5,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","MTMOTCMT","Million US$ at exchange rate","NLD","Netherlands","2011","2011",17.3,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","MTMOTCMT","Million US$ at exchange rate","NLD","Netherlands","2012","2012",16,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","MTMOTCMT","Million US$ at exchange rate","NLD","Netherlands","2013","2013",16.9,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","MTMOTCMT","Million US$ at exchange rate","NLD","Netherlands","2014","2014",18.5,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","MTMOPPMT","Million US$, purchasing power parity","NLD","Netherlands","2010","2010",13.7,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","MTMOPPMT","Million US$, purchasing power parity","NLD","Netherlands","2011","2011",14.8,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","MTMOPPMT","Million US$, purchasing power parity","NLD","Netherlands","2012","2012",15.1,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","MTMOPPMT","Million US$, purchasing power parity","NLD","Netherlands","2013","2013",16,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","MTMOPPMT","Million US$, purchasing power parity","NLD","Netherlands","2014","2014",17.2,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","TCPPERMT","/capita, US$ exchange rate","NLD","Netherlands","2010","2010",0.9,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","TCPPERMT","/capita, US$ exchange rate","NLD","Netherlands","2011","2011",1,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","TCPPERMT","/capita, US$ exchange rate","NLD","Netherlands","2012","2012",1,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","TCPPERMT","/capita, US$ exchange rate","NLD","Netherlands","2013","2013",1,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","TCPPERMT","/capita, US$ exchange rate","NLD","Netherlands","2014","2014",1.1,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","NLD","Netherlands","2010","2010",0.8,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","NLD","Netherlands","2011","2011",0.9,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","NLD","Netherlands","2012","2012",0.9,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","NLD","Netherlands","2013","2013",0.9,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","NLD","Netherlands","2014","2014",1,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","ATCPTTMT","% of total sales","NLD","Netherlands","2010","2010",0.2,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","ATCPTTMT","% of total sales","NLD","Netherlands","2011","2011",0.2,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","ATCPTTMT","% of total sales","NLD","Netherlands","2012","2012",0.3,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","ATCPTTMT","% of total sales","NLD","Netherlands","2013","2013",0.3,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","ATCPTTMT","% of total sales","NLD","Netherlands","2014","2014",0.3,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","MLLNCUMT","Million of national currency units","NZL","New Zealand","2010","2010",1.5,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","MLLNCUMT","Million of national currency units","NZL","New Zealand","2011","2011",1.7,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","MLLNCUMT","Million of national currency units","NZL","New Zealand","2012","2012",1.4,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","MLLNCUMT","Million of national currency units","NZL","New Zealand","2013","2013",1.5,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","MLLNCUMT","Million of national currency units","NZL","New Zealand","2014","2014",1.6,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","MLLNCUMT","Million of national currency units","NZL","New Zealand","2015","2015",1.7,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","MLLNCUMT","Million of national currency units","NZL","New Zealand","2016","2016",1.8,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","MLLNCUMT","Million of national currency units","NZL","New Zealand","2017","2017",1.1,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","MLLNCUMT","Million of national currency units","NZL","New Zealand","2018","2018",2.8,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","MLLNCUMT","Million of national currency units","NZL","New Zealand","2019","2019",4.1,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","MLLNCUMT","Million of national currency units","NZL","New Zealand","2020","2020",5.2,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","MLLNCUMT","Million of national currency units","NZL","New Zealand","2021","2021",6.4,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","MLLNCUMT","Million of national currency units","NZL","New Zealand","2022","2022",6.1,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","MTMOTCMT","Million US$ at exchange rate","NZL","New Zealand","2010","2010",1,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","MTMOTCMT","Million US$ at exchange rate","NZL","New Zealand","2011","2011",1.3,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","MTMOTCMT","Million US$ at exchange rate","NZL","New Zealand","2012","2012",1.2,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","MTMOTCMT","Million US$ at exchange rate","NZL","New Zealand","2013","2013",1.3,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","MTMOTCMT","Million US$ at exchange rate","NZL","New Zealand","2014","2014",1.3,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","MTMOTCMT","Million US$ at exchange rate","NZL","New Zealand","2015","2015",1.2,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","MTMOTCMT","Million US$ at exchange rate","NZL","New Zealand","2016","2016",1.2,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","MTMOTCMT","Million US$ at exchange rate","NZL","New Zealand","2017","2017",0.8,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","MTMOTCMT","Million US$ at exchange rate","NZL","New Zealand","2018","2018",1.9,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","MTMOTCMT","Million US$ at exchange rate","NZL","New Zealand","2019","2019",2.7,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","MTMOTCMT","Million US$ at exchange rate","NZL","New Zealand","2020","2020",3.4,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","MTMOTCMT","Million US$ at exchange rate","NZL","New Zealand","2021","2021",4.5,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","MTMOTCMT","Million US$ at exchange rate","NZL","New Zealand","2022","2022",3.9,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","MTMOPPMT","Million US$, purchasing power parity","NZL","New Zealand","2010","2010",1,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","MTMOPPMT","Million US$, purchasing power parity","NZL","New Zealand","2011","2011",1.1,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","MTMOPPMT","Million US$, purchasing power parity","NZL","New Zealand","2012","2012",1,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","MTMOPPMT","Million US$, purchasing power parity","NZL","New Zealand","2013","2013",1.1,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","MTMOPPMT","Million US$, purchasing power parity","NZL","New Zealand","2014","2014",1.1,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","MTMOPPMT","Million US$, purchasing power parity","NZL","New Zealand","2015","2015",1.1,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","MTMOPPMT","Million US$, purchasing power parity","NZL","New Zealand","2016","2016",1.2,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","MTMOPPMT","Million US$, purchasing power parity","NZL","New Zealand","2017","2017",0.8,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","MTMOPPMT","Million US$, purchasing power parity","NZL","New Zealand","2018","2018",1.9,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","MTMOPPMT","Million US$, purchasing power parity","NZL","New Zealand","2019","2019",2.9,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","MTMOPPMT","Million US$, purchasing power parity","NZL","New Zealand","2020","2020",3.7,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","MTMOPPMT","Million US$, purchasing power parity","NZL","New Zealand","2021","2021",4.4,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","MTMOPPMT","Million US$, purchasing power parity","NZL","New Zealand","2022","2022",4.2,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","TCPPERMT","/capita, US$ exchange rate","NZL","New Zealand","2010","2010",0.2,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","TCPPERMT","/capita, US$ exchange rate","NZL","New Zealand","2011","2011",0.3,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","TCPPERMT","/capita, US$ exchange rate","NZL","New Zealand","2012","2012",0.3,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","TCPPERMT","/capita, US$ exchange rate","NZL","New Zealand","2013","2013",0.3,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","TCPPERMT","/capita, US$ exchange rate","NZL","New Zealand","2014","2014",0.3,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","TCPPERMT","/capita, US$ exchange rate","NZL","New Zealand","2015","2015",0.3,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","TCPPERMT","/capita, US$ exchange rate","NZL","New Zealand","2016","2016",0.3,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","TCPPERMT","/capita, US$ exchange rate","NZL","New Zealand","2017","2017",0.2,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","TCPPERMT","/capita, US$ exchange rate","NZL","New Zealand","2018","2018",0.4,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","TCPPERMT","/capita, US$ exchange rate","NZL","New Zealand","2019","2019",0.5,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","TCPPERMT","/capita, US$ exchange rate","NZL","New Zealand","2020","2020",0.7,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","TCPPERMT","/capita, US$ exchange rate","NZL","New Zealand","2021","2021",0.9,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","TCPPERMT","/capita, US$ exchange rate","NZL","New Zealand","2022","2022",0.8,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2010","2010",0.2,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2011","2011",0.3,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2012","2012",0.2,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2013","2013",0.2,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2014","2014",0.2,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2015","2015",0.2,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2016","2016",0.3,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2017","2017",0.2,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2018","2018",0.4,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2019","2019",0.6,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2020","2020",0.7,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2021","2021",0.9,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2022","2022",0.8,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","ATCPTTMT","% of total sales","NZL","New Zealand","2010","2010",0.2,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","ATCPTTMT","% of total sales","NZL","New Zealand","2011","2011",0.2,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","ATCPTTMT","% of total sales","NZL","New Zealand","2012","2012",0.2,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","ATCPTTMT","% of total sales","NZL","New Zealand","2013","2013",0.2,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","ATCPTTMT","% of total sales","NZL","New Zealand","2014","2014",0.2,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","ATCPTTMT","% of total sales","NZL","New Zealand","2015","2015",0.2,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","ATCPTTMT","% of total sales","NZL","New Zealand","2016","2016",0.2,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","ATCPTTMT","% of total sales","NZL","New Zealand","2017","2017",0.1,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","ATCPTTMT","% of total sales","NZL","New Zealand","2018","2018",0.2,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","ATCPTTMT","% of total sales","NZL","New Zealand","2019","2019",0.3,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","ATCPTTMT","% of total sales","NZL","New Zealand","2020","2020",0.3,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","ATCPTTMT","% of total sales","NZL","New Zealand","2021","2021",0.4,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","ATCPTTMT","% of total sales","NZL","New Zealand","2022","2022",0.3,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","MLLNCUMT","Million of national currency units","NOR","Norway","2010","2010",172,,
+"PATCHYPN","N05C-Hypnotics and sedatives","MLLNCUMT","Million of national currency units","NOR","Norway","2011","2011",172,,
+"PATCHYPN","N05C-Hypnotics and sedatives","MLLNCUMT","Million of national currency units","NOR","Norway","2012","2012",194,,
+"PATCHYPN","N05C-Hypnotics and sedatives","MLLNCUMT","Million of national currency units","NOR","Norway","2013","2013",191,,
+"PATCHYPN","N05C-Hypnotics and sedatives","MLLNCUMT","Million of national currency units","NOR","Norway","2014","2014",211,,
+"PATCHYPN","N05C-Hypnotics and sedatives","MLLNCUMT","Million of national currency units","NOR","Norway","2015","2015",222,,
+"PATCHYPN","N05C-Hypnotics and sedatives","MLLNCUMT","Million of national currency units","NOR","Norway","2016","2016",254,,
+"PATCHYPN","N05C-Hypnotics and sedatives","MLLNCUMT","Million of national currency units","NOR","Norway","2017","2017",257,,
+"PATCHYPN","N05C-Hypnotics and sedatives","MLLNCUMT","Million of national currency units","NOR","Norway","2018","2018",263,,
+"PATCHYPN","N05C-Hypnotics and sedatives","MLLNCUMT","Million of national currency units","NOR","Norway","2019","2019",275,,
+"PATCHYPN","N05C-Hypnotics and sedatives","MLLNCUMT","Million of national currency units","NOR","Norway","2020","2020",364,,
+"PATCHYPN","N05C-Hypnotics and sedatives","MLLNCUMT","Million of national currency units","NOR","Norway","2021","2021",385,,
+"PATCHYPN","N05C-Hypnotics and sedatives","MLLNCUMT","Million of national currency units","NOR","Norway","2022","2022",375,,
+"PATCHYPN","N05C-Hypnotics and sedatives","MTMOTCMT","Million US$ at exchange rate","NOR","Norway","2010","2010",28.5,,
+"PATCHYPN","N05C-Hypnotics and sedatives","MTMOTCMT","Million US$ at exchange rate","NOR","Norway","2011","2011",30.7,,
+"PATCHYPN","N05C-Hypnotics and sedatives","MTMOTCMT","Million US$ at exchange rate","NOR","Norway","2012","2012",33.3,,
+"PATCHYPN","N05C-Hypnotics and sedatives","MTMOTCMT","Million US$ at exchange rate","NOR","Norway","2013","2013",32.5,,
+"PATCHYPN","N05C-Hypnotics and sedatives","MTMOTCMT","Million US$ at exchange rate","NOR","Norway","2014","2014",33.5,,
+"PATCHYPN","N05C-Hypnotics and sedatives","MTMOTCMT","Million US$ at exchange rate","NOR","Norway","2015","2015",27.5,,
+"PATCHYPN","N05C-Hypnotics and sedatives","MTMOTCMT","Million US$ at exchange rate","NOR","Norway","2016","2016",30.2,,
+"PATCHYPN","N05C-Hypnotics and sedatives","MTMOTCMT","Million US$ at exchange rate","NOR","Norway","2017","2017",31.1,,
+"PATCHYPN","N05C-Hypnotics and sedatives","MTMOTCMT","Million US$ at exchange rate","NOR","Norway","2018","2018",32.3,,
+"PATCHYPN","N05C-Hypnotics and sedatives","MTMOTCMT","Million US$ at exchange rate","NOR","Norway","2019","2019",31.3,,
+"PATCHYPN","N05C-Hypnotics and sedatives","MTMOTCMT","Million US$ at exchange rate","NOR","Norway","2020","2020",38.7,,
+"PATCHYPN","N05C-Hypnotics and sedatives","MTMOTCMT","Million US$ at exchange rate","NOR","Norway","2021","2021",44.8,,
+"PATCHYPN","N05C-Hypnotics and sedatives","MTMOTCMT","Million US$ at exchange rate","NOR","Norway","2022","2022",39,,
+"PATCHYPN","N05C-Hypnotics and sedatives","MTMOPPMT","Million US$, purchasing power parity","NOR","Norway","2010","2010",18.8,,
+"PATCHYPN","N05C-Hypnotics and sedatives","MTMOPPMT","Million US$, purchasing power parity","NOR","Norway","2011","2011",18.9,,
+"PATCHYPN","N05C-Hypnotics and sedatives","MTMOPPMT","Million US$, purchasing power parity","NOR","Norway","2012","2012",21.5,,
+"PATCHYPN","N05C-Hypnotics and sedatives","MTMOPPMT","Million US$, purchasing power parity","NOR","Norway","2013","2013",21.2,,
+"PATCHYPN","N05C-Hypnotics and sedatives","MTMOPPMT","Million US$, purchasing power parity","NOR","Norway","2014","2014",22.7,,
+"PATCHYPN","N05C-Hypnotics and sedatives","MTMOPPMT","Million US$, purchasing power parity","NOR","Norway","2015","2015",22.4,,
+"PATCHYPN","N05C-Hypnotics and sedatives","MTMOPPMT","Million US$, purchasing power parity","NOR","Norway","2016","2016",25.3,,
+"PATCHYPN","N05C-Hypnotics and sedatives","MTMOPPMT","Million US$, purchasing power parity","NOR","Norway","2017","2017",26.4,,
+"PATCHYPN","N05C-Hypnotics and sedatives","MTMOPPMT","Million US$, purchasing power parity","NOR","Norway","2018","2018",27.4,,
+"PATCHYPN","N05C-Hypnotics and sedatives","MTMOPPMT","Million US$, purchasing power parity","NOR","Norway","2019","2019",28.6,,
+"PATCHYPN","N05C-Hypnotics and sedatives","MTMOPPMT","Million US$, purchasing power parity","NOR","Norway","2020","2020",36.8,,
+"PATCHYPN","N05C-Hypnotics and sedatives","MTMOPPMT","Million US$, purchasing power parity","NOR","Norway","2021","2021",40.5,,
+"PATCHYPN","N05C-Hypnotics and sedatives","MTMOPPMT","Million US$, purchasing power parity","NOR","Norway","2022","2022",34.9,,
+"PATCHYPN","N05C-Hypnotics and sedatives","TCPPERMT","/capita, US$ exchange rate","NOR","Norway","2010","2010",5.8,,
+"PATCHYPN","N05C-Hypnotics and sedatives","TCPPERMT","/capita, US$ exchange rate","NOR","Norway","2011","2011",6.2,,
+"PATCHYPN","N05C-Hypnotics and sedatives","TCPPERMT","/capita, US$ exchange rate","NOR","Norway","2012","2012",6.6,,
+"PATCHYPN","N05C-Hypnotics and sedatives","TCPPERMT","/capita, US$ exchange rate","NOR","Norway","2013","2013",6.4,,
+"PATCHYPN","N05C-Hypnotics and sedatives","TCPPERMT","/capita, US$ exchange rate","NOR","Norway","2014","2014",6.5,,
+"PATCHYPN","N05C-Hypnotics and sedatives","TCPPERMT","/capita, US$ exchange rate","NOR","Norway","2015","2015",5.3,,
+"PATCHYPN","N05C-Hypnotics and sedatives","TCPPERMT","/capita, US$ exchange rate","NOR","Norway","2016","2016",5.8,,
+"PATCHYPN","N05C-Hypnotics and sedatives","TCPPERMT","/capita, US$ exchange rate","NOR","Norway","2017","2017",5.9,,
+"PATCHYPN","N05C-Hypnotics and sedatives","TCPPERMT","/capita, US$ exchange rate","NOR","Norway","2018","2018",6.1,,
+"PATCHYPN","N05C-Hypnotics and sedatives","TCPPERMT","/capita, US$ exchange rate","NOR","Norway","2019","2019",5.8,,
+"PATCHYPN","N05C-Hypnotics and sedatives","TCPPERMT","/capita, US$ exchange rate","NOR","Norway","2020","2020",7.2,,
+"PATCHYPN","N05C-Hypnotics and sedatives","TCPPERMT","/capita, US$ exchange rate","NOR","Norway","2021","2021",8.3,,
+"PATCHYPN","N05C-Hypnotics and sedatives","TCPPERMT","/capita, US$ exchange rate","NOR","Norway","2022","2022",7.2,,
+"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2010","2010",3.8,,
+"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2011","2011",3.8,,
+"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2012","2012",4.3,,
+"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2013","2013",4.2,,
+"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2014","2014",4.4,,
+"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2015","2015",4.3,,
+"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2016","2016",4.8,,
+"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2017","2017",5,,
+"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2018","2018",5.2,,
+"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2019","2019",5.3,,
+"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2020","2020",6.8,,
+"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2021","2021",7.5,,
+"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2022","2022",6.4,,
+"PATCHYPN","N05C-Hypnotics and sedatives","ATCPTTMT","% of total sales","NOR","Norway","2010","2010",1,,
+"PATCHYPN","N05C-Hypnotics and sedatives","ATCPTTMT","% of total sales","NOR","Norway","2011","2011",0.9,,
+"PATCHYPN","N05C-Hypnotics and sedatives","ATCPTTMT","% of total sales","NOR","Norway","2012","2012",1,,
+"PATCHYPN","N05C-Hypnotics and sedatives","ATCPTTMT","% of total sales","NOR","Norway","2013","2013",1,,
+"PATCHYPN","N05C-Hypnotics and sedatives","ATCPTTMT","% of total sales","NOR","Norway","2014","2014",1,,
+"PATCHYPN","N05C-Hypnotics and sedatives","ATCPTTMT","% of total sales","NOR","Norway","2015","2015",1,,
+"PATCHYPN","N05C-Hypnotics and sedatives","ATCPTTMT","% of total sales","NOR","Norway","2016","2016",1,,
+"PATCHYPN","N05C-Hypnotics and sedatives","ATCPTTMT","% of total sales","NOR","Norway","2017","2017",1,,
+"PATCHYPN","N05C-Hypnotics and sedatives","ATCPTTMT","% of total sales","NOR","Norway","2018","2018",1,,
+"PATCHYPN","N05C-Hypnotics and sedatives","ATCPTTMT","% of total sales","NOR","Norway","2019","2019",1,,
+"PATCHYPN","N05C-Hypnotics and sedatives","ATCPTTMT","% of total sales","NOR","Norway","2020","2020",1.2,,
+"PATCHYPN","N05C-Hypnotics and sedatives","ATCPTTMT","% of total sales","NOR","Norway","2021","2021",1.1,,
+"PATCHYPN","N05C-Hypnotics and sedatives","ATCPTTMT","% of total sales","NOR","Norway","2022","2022",1,,
+"PATCHYPN","N05C-Hypnotics and sedatives","MLLNCUMT","Million of national currency units","PRT","Portugal","2010","2010",18.4,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","MLLNCUMT","Million of national currency units","PRT","Portugal","2011","2011",17.8,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","MLLNCUMT","Million of national currency units","PRT","Portugal","2012","2012",18.7,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","MLLNCUMT","Million of national currency units","PRT","Portugal","2013","2013",20.1,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","MLLNCUMT","Million of national currency units","PRT","Portugal","2014","2014",21.3,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","MLLNCUMT","Million of national currency units","PRT","Portugal","2015","2015",20.8,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","MLLNCUMT","Million of national currency units","PRT","Portugal","2016","2016",19.8,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","MLLNCUMT","Million of national currency units","PRT","Portugal","2017","2017",19,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","MLLNCUMT","Million of national currency units","PRT","Portugal","2018","2018",18.2,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","MLLNCUMT","Million of national currency units","PRT","Portugal","2019","2019",18,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","MLLNCUMT","Million of national currency units","PRT","Portugal","2020","2020",18,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","MLLNCUMT","Million of national currency units","PRT","Portugal","2021","2021",18.4,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","MLLNCUMT","Million of national currency units","PRT","Portugal","2022","2022",18.8,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","MTMOTCMT","Million US$ at exchange rate","PRT","Portugal","2010","2010",24.4,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","MTMOTCMT","Million US$ at exchange rate","PRT","Portugal","2011","2011",24.7,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","MTMOTCMT","Million US$ at exchange rate","PRT","Portugal","2012","2012",24,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","MTMOTCMT","Million US$ at exchange rate","PRT","Portugal","2013","2013",26.7,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","MTMOTCMT","Million US$ at exchange rate","PRT","Portugal","2014","2014",28.3,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","MTMOTCMT","Million US$ at exchange rate","PRT","Portugal","2015","2015",23.1,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","MTMOTCMT","Million US$ at exchange rate","PRT","Portugal","2016","2016",22,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","MTMOTCMT","Million US$ at exchange rate","PRT","Portugal","2017","2017",21.4,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","MTMOTCMT","Million US$ at exchange rate","PRT","Portugal","2018","2018",21.4,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","MTMOTCMT","Million US$ at exchange rate","PRT","Portugal","2019","2019",20.2,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","MTMOTCMT","Million US$ at exchange rate","PRT","Portugal","2020","2020",20.6,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","MTMOTCMT","Million US$ at exchange rate","PRT","Portugal","2021","2021",21.7,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","MTMOTCMT","Million US$ at exchange rate","PRT","Portugal","2022","2022",19.8,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","MTMOPPMT","Million US$, purchasing power parity","PRT","Portugal","2010","2010",29.6,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","MTMOPPMT","Million US$, purchasing power parity","PRT","Portugal","2011","2011",28.5,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","MTMOPPMT","Million US$, purchasing power parity","PRT","Portugal","2012","2012",30.9,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","MTMOPPMT","Million US$, purchasing power parity","PRT","Portugal","2013","2013",34.5,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","MTMOPPMT","Million US$, purchasing power parity","PRT","Portugal","2014","2014",36.7,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","MTMOPPMT","Million US$, purchasing power parity","PRT","Portugal","2015","2015",35.5,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","MTMOPPMT","Million US$, purchasing power parity","PRT","Portugal","2016","2016",34.7,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","MTMOPPMT","Million US$, purchasing power parity","PRT","Portugal","2017","2017",32.9,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","MTMOPPMT","Million US$, purchasing power parity","PRT","Portugal","2018","2018",31.8,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","MTMOPPMT","Million US$, purchasing power parity","PRT","Portugal","2019","2019",32.2,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","MTMOPPMT","Million US$, purchasing power parity","PRT","Portugal","2020","2020",32.3,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","MTMOPPMT","Million US$, purchasing power parity","PRT","Portugal","2021","2021",32.3,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","MTMOPPMT","Million US$, purchasing power parity","PRT","Portugal","2022","2022",34.3,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","TCPPERMT","/capita, US$ exchange rate","PRT","Portugal","2010","2010",2.3,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","TCPPERMT","/capita, US$ exchange rate","PRT","Portugal","2011","2011",2.3,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","TCPPERMT","/capita, US$ exchange rate","PRT","Portugal","2012","2012",2.3,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","TCPPERMT","/capita, US$ exchange rate","PRT","Portugal","2013","2013",2.6,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","TCPPERMT","/capita, US$ exchange rate","PRT","Portugal","2014","2014",2.7,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","TCPPERMT","/capita, US$ exchange rate","PRT","Portugal","2015","2015",2.2,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","TCPPERMT","/capita, US$ exchange rate","PRT","Portugal","2016","2016",2.1,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","TCPPERMT","/capita, US$ exchange rate","PRT","Portugal","2017","2017",2.1,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","TCPPERMT","/capita, US$ exchange rate","PRT","Portugal","2018","2018",2.1,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","TCPPERMT","/capita, US$ exchange rate","PRT","Portugal","2019","2019",2,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","TCPPERMT","/capita, US$ exchange rate","PRT","Portugal","2020","2020",2,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","TCPPERMT","/capita, US$ exchange rate","PRT","Portugal","2021","2021",2.1,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","TCPPERMT","/capita, US$ exchange rate","PRT","Portugal","2022","2022",1.9,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2010","2010",2.8,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2011","2011",2.7,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2012","2012",2.9,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2013","2013",3.3,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2014","2014",3.5,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2015","2015",3.4,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2016","2016",3.4,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2017","2017",3.2,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2018","2018",3.1,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2019","2019",3.1,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2020","2020",3.1,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2021","2021",3.1,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2022","2022",3.3,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","ATCPTTMT","% of total sales","PRT","Portugal","2010","2010",0.6,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","ATCPTTMT","% of total sales","PRT","Portugal","2011","2011",0.6,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","ATCPTTMT","% of total sales","PRT","Portugal","2012","2012",0.7,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","ATCPTTMT","% of total sales","PRT","Portugal","2013","2013",0.8,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","ATCPTTMT","% of total sales","PRT","Portugal","2014","2014",0.9,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","ATCPTTMT","% of total sales","PRT","Portugal","2015","2015",0.8,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","ATCPTTMT","% of total sales","PRT","Portugal","2016","2016",0.8,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","ATCPTTMT","% of total sales","PRT","Portugal","2017","2017",0.7,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","ATCPTTMT","% of total sales","PRT","Portugal","2018","2018",0.7,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","ATCPTTMT","% of total sales","PRT","Portugal","2019","2019",0.6,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","ATCPTTMT","% of total sales","PRT","Portugal","2020","2020",0.6,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","ATCPTTMT","% of total sales","PRT","Portugal","2021","2021",0.6,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","ATCPTTMT","% of total sales","PRT","Portugal","2022","2022",0.6,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","MLLNCUMT","Million of national currency units","SVK","Slovak Republic","2010","2010",4.1,,
+"PATCHYPN","N05C-Hypnotics and sedatives","MLLNCUMT","Million of national currency units","SVK","Slovak Republic","2011","2011",4.3,,
+"PATCHYPN","N05C-Hypnotics and sedatives","MLLNCUMT","Million of national currency units","SVK","Slovak Republic","2012","2012",3.6,,
+"PATCHYPN","N05C-Hypnotics and sedatives","MLLNCUMT","Million of national currency units","SVK","Slovak Republic","2013","2013",4.5,,
+"PATCHYPN","N05C-Hypnotics and sedatives","MLLNCUMT","Million of national currency units","SVK","Slovak Republic","2014","2014",4.7,,
+"PATCHYPN","N05C-Hypnotics and sedatives","MLLNCUMT","Million of national currency units","SVK","Slovak Republic","2015","2015",4.9,,
+"PATCHYPN","N05C-Hypnotics and sedatives","MLLNCUMT","Million of national currency units","SVK","Slovak Republic","2016","2016",6.3,"B","Break"
+"PATCHYPN","N05C-Hypnotics and sedatives","MLLNCUMT","Million of national currency units","SVK","Slovak Republic","2017","2017",4.5,,
+"PATCHYPN","N05C-Hypnotics and sedatives","MLLNCUMT","Million of national currency units","SVK","Slovak Republic","2018","2018",6.6,,
+"PATCHYPN","N05C-Hypnotics and sedatives","MLLNCUMT","Million of national currency units","SVK","Slovak Republic","2019","2019",6.6,,
+"PATCHYPN","N05C-Hypnotics and sedatives","MLLNCUMT","Million of national currency units","SVK","Slovak Republic","2020","2020",6.7,,
+"PATCHYPN","N05C-Hypnotics and sedatives","MLLNCUMT","Million of national currency units","SVK","Slovak Republic","2021","2021",7.7,,
+"PATCHYPN","N05C-Hypnotics and sedatives","MTMOTCMT","Million US$ at exchange rate","SVK","Slovak Republic","2010","2010",5.4,,
+"PATCHYPN","N05C-Hypnotics and sedatives","MTMOTCMT","Million US$ at exchange rate","SVK","Slovak Republic","2011","2011",6,,
+"PATCHYPN","N05C-Hypnotics and sedatives","MTMOTCMT","Million US$ at exchange rate","SVK","Slovak Republic","2012","2012",4.7,,
+"PATCHYPN","N05C-Hypnotics and sedatives","MTMOTCMT","Million US$ at exchange rate","SVK","Slovak Republic","2013","2013",5.9,,
+"PATCHYPN","N05C-Hypnotics and sedatives","MTMOTCMT","Million US$ at exchange rate","SVK","Slovak Republic","2014","2014",6.2,,
+"PATCHYPN","N05C-Hypnotics and sedatives","MTMOTCMT","Million US$ at exchange rate","SVK","Slovak Republic","2015","2015",5.4,,
+"PATCHYPN","N05C-Hypnotics and sedatives","MTMOTCMT","Million US$ at exchange rate","SVK","Slovak Republic","2016","2016",6.9,"B","Break"
+"PATCHYPN","N05C-Hypnotics and sedatives","MTMOTCMT","Million US$ at exchange rate","SVK","Slovak Republic","2017","2017",5.1,,
+"PATCHYPN","N05C-Hypnotics and sedatives","MTMOTCMT","Million US$ at exchange rate","SVK","Slovak Republic","2018","2018",7.8,,
+"PATCHYPN","N05C-Hypnotics and sedatives","MTMOTCMT","Million US$ at exchange rate","SVK","Slovak Republic","2019","2019",7.4,,
+"PATCHYPN","N05C-Hypnotics and sedatives","MTMOTCMT","Million US$ at exchange rate","SVK","Slovak Republic","2020","2020",7.6,,
+"PATCHYPN","N05C-Hypnotics and sedatives","MTMOTCMT","Million US$ at exchange rate","SVK","Slovak Republic","2021","2021",9.1,,
+"PATCHYPN","N05C-Hypnotics and sedatives","MTMOPPMT","Million US$, purchasing power parity","SVK","Slovak Republic","2010","2010",8.1,,
+"PATCHYPN","N05C-Hypnotics and sedatives","MTMOPPMT","Million US$, purchasing power parity","SVK","Slovak Republic","2011","2011",8.5,,
+"PATCHYPN","N05C-Hypnotics and sedatives","MTMOPPMT","Million US$, purchasing power parity","SVK","Slovak Republic","2012","2012",7.2,,
+"PATCHYPN","N05C-Hypnotics and sedatives","MTMOPPMT","Million US$, purchasing power parity","SVK","Slovak Republic","2013","2013",9.1,,
+"PATCHYPN","N05C-Hypnotics and sedatives","MTMOPPMT","Million US$, purchasing power parity","SVK","Slovak Republic","2014","2014",9.7,,
+"PATCHYPN","N05C-Hypnotics and sedatives","MTMOPPMT","Million US$, purchasing power parity","SVK","Slovak Republic","2015","2015",10,,
+"PATCHYPN","N05C-Hypnotics and sedatives","MTMOPPMT","Million US$, purchasing power parity","SVK","Slovak Republic","2016","2016",12.4,"B","Break"
+"PATCHYPN","N05C-Hypnotics and sedatives","MTMOPPMT","Million US$, purchasing power parity","SVK","Slovak Republic","2017","2017",8.8,,
+"PATCHYPN","N05C-Hypnotics and sedatives","MTMOPPMT","Million US$, purchasing power parity","SVK","Slovak Republic","2018","2018",12.6,,
+"PATCHYPN","N05C-Hypnotics and sedatives","MTMOPPMT","Million US$, purchasing power parity","SVK","Slovak Republic","2019","2019",12.7,,
+"PATCHYPN","N05C-Hypnotics and sedatives","MTMOPPMT","Million US$, purchasing power parity","SVK","Slovak Republic","2020","2020",12.9,,
+"PATCHYPN","N05C-Hypnotics and sedatives","MTMOPPMT","Million US$, purchasing power parity","SVK","Slovak Republic","2021","2021",14.4,,
+"PATCHYPN","N05C-Hypnotics and sedatives","TCPPERMT","/capita, US$ exchange rate","SVK","Slovak Republic","2010","2010",1,,
+"PATCHYPN","N05C-Hypnotics and sedatives","TCPPERMT","/capita, US$ exchange rate","SVK","Slovak Republic","2011","2011",1.1,,
+"PATCHYPN","N05C-Hypnotics and sedatives","TCPPERMT","/capita, US$ exchange rate","SVK","Slovak Republic","2012","2012",0.9,,
+"PATCHYPN","N05C-Hypnotics and sedatives","TCPPERMT","/capita, US$ exchange rate","SVK","Slovak Republic","2013","2013",1.1,,
+"PATCHYPN","N05C-Hypnotics and sedatives","TCPPERMT","/capita, US$ exchange rate","SVK","Slovak Republic","2014","2014",1.2,,
+"PATCHYPN","N05C-Hypnotics and sedatives","TCPPERMT","/capita, US$ exchange rate","SVK","Slovak Republic","2015","2015",1,,
+"PATCHYPN","N05C-Hypnotics and sedatives","TCPPERMT","/capita, US$ exchange rate","SVK","Slovak Republic","2016","2016",1.3,"B","Break"
+"PATCHYPN","N05C-Hypnotics and sedatives","TCPPERMT","/capita, US$ exchange rate","SVK","Slovak Republic","2017","2017",0.9,,
+"PATCHYPN","N05C-Hypnotics and sedatives","TCPPERMT","/capita, US$ exchange rate","SVK","Slovak Republic","2018","2018",1.4,,
+"PATCHYPN","N05C-Hypnotics and sedatives","TCPPERMT","/capita, US$ exchange rate","SVK","Slovak Republic","2019","2019",1.4,,
+"PATCHYPN","N05C-Hypnotics and sedatives","TCPPERMT","/capita, US$ exchange rate","SVK","Slovak Republic","2020","2020",1.4,,
+"PATCHYPN","N05C-Hypnotics and sedatives","TCPPERMT","/capita, US$ exchange rate","SVK","Slovak Republic","2021","2021",1.7,,
+"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2010","2010",1.5,,
+"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2011","2011",1.6,,
+"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2012","2012",1.3,,
+"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2013","2013",1.7,,
+"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2014","2014",1.8,,
+"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2015","2015",1.8,,
+"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2016","2016",2.3,"B","Break"
+"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2017","2017",1.6,,
+"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2018","2018",2.3,,
+"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2019","2019",2.3,,
+"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2020","2020",2.4,,
+"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2021","2021",2.6,,
+"PATCHYPN","N05C-Hypnotics and sedatives","ATCPTTMT","% of total sales","SVK","Slovak Republic","2010","2010",0.4,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","ATCPTTMT","% of total sales","SVK","Slovak Republic","2011","2011",0.4,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","ATCPTTMT","% of total sales","SVK","Slovak Republic","2012","2012",0.3,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","ATCPTTMT","% of total sales","SVK","Slovak Republic","2013","2013",0.4,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","ATCPTTMT","% of total sales","SVK","Slovak Republic","2014","2014",0.4,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","ATCPTTMT","% of total sales","SVK","Slovak Republic","2015","2015",0.4,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","ATCPTTMT","% of total sales","SVK","Slovak Republic","2016","2016",0.4,"B","Break"
+"PATCHYPN","N05C-Hypnotics and sedatives","ATCPTTMT","% of total sales","SVK","Slovak Republic","2017","2017",0.3,,
+"PATCHYPN","N05C-Hypnotics and sedatives","ATCPTTMT","% of total sales","SVK","Slovak Republic","2018","2018",0.4,,
+"PATCHYPN","N05C-Hypnotics and sedatives","ATCPTTMT","% of total sales","SVK","Slovak Republic","2019","2019",0.4,,
+"PATCHYPN","N05C-Hypnotics and sedatives","ATCPTTMT","% of total sales","SVK","Slovak Republic","2020","2020",0.4,,
+"PATCHYPN","N05C-Hypnotics and sedatives","ATCPTTMT","% of total sales","SVK","Slovak Republic","2021","2021",0.4,,
+"PATCHYPN","N05C-Hypnotics and sedatives","MLLNCUMT","Million of national currency units","ESP","Spain","2010","2010",42.1,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","MLLNCUMT","Million of national currency units","ESP","Spain","2011","2011",41.2,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","MLLNCUMT","Million of national currency units","ESP","Spain","2012","2012",40.1,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","MLLNCUMT","Million of national currency units","ESP","Spain","2013","2013",41.9,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","MLLNCUMT","Million of national currency units","ESP","Spain","2014","2014",44.7,"B; D","Break; Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","MLLNCUMT","Million of national currency units","ESP","Spain","2015","2015",45.6,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","MLLNCUMT","Million of national currency units","ESP","Spain","2016","2016",46.9,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","MLLNCUMT","Million of national currency units","ESP","Spain","2017","2017",47.6,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","MLLNCUMT","Million of national currency units","ESP","Spain","2018","2018",54.7,"B","Break"
+"PATCHYPN","N05C-Hypnotics and sedatives","MLLNCUMT","Million of national currency units","ESP","Spain","2019","2019",58.4,,
+"PATCHYPN","N05C-Hypnotics and sedatives","MLLNCUMT","Million of national currency units","ESP","Spain","2020","2020",69.9,,
+"PATCHYPN","N05C-Hypnotics and sedatives","MLLNCUMT","Million of national currency units","ESP","Spain","2021","2021",66.2,,
+"PATCHYPN","N05C-Hypnotics and sedatives","MLLNCUMT","Million of national currency units","ESP","Spain","2022","2022",59.8,"P","Provisional value"
+"PATCHYPN","N05C-Hypnotics and sedatives","MTMOTCMT","Million US$ at exchange rate","ESP","Spain","2010","2010",55.8,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","MTMOTCMT","Million US$ at exchange rate","ESP","Spain","2011","2011",57.3,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","MTMOTCMT","Million US$ at exchange rate","ESP","Spain","2012","2012",51.5,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","MTMOTCMT","Million US$ at exchange rate","ESP","Spain","2013","2013",55.7,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","MTMOTCMT","Million US$ at exchange rate","ESP","Spain","2014","2014",59.4,"B; D","Break; Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","MTMOTCMT","Million US$ at exchange rate","ESP","Spain","2015","2015",50.6,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","MTMOTCMT","Million US$ at exchange rate","ESP","Spain","2016","2016",51.9,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","MTMOTCMT","Million US$ at exchange rate","ESP","Spain","2017","2017",53.8,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","MTMOTCMT","Million US$ at exchange rate","ESP","Spain","2018","2018",64.6,"B","Break"
+"PATCHYPN","N05C-Hypnotics and sedatives","MTMOTCMT","Million US$ at exchange rate","ESP","Spain","2019","2019",65.4,,
+"PATCHYPN","N05C-Hypnotics and sedatives","MTMOTCMT","Million US$ at exchange rate","ESP","Spain","2020","2020",79.9,,
+"PATCHYPN","N05C-Hypnotics and sedatives","MTMOTCMT","Million US$ at exchange rate","ESP","Spain","2021","2021",78.3,,
+"PATCHYPN","N05C-Hypnotics and sedatives","MTMOTCMT","Million US$ at exchange rate","ESP","Spain","2022","2022",63,"P","Provisional value"
+"PATCHYPN","N05C-Hypnotics and sedatives","MTMOPPMT","Million US$, purchasing power parity","ESP","Spain","2010","2010",57.9,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","MTMOPPMT","Million US$, purchasing power parity","ESP","Spain","2011","2011",57.6,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","MTMOPPMT","Million US$, purchasing power parity","ESP","Spain","2012","2012",57.7,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","MTMOPPMT","Million US$, purchasing power parity","ESP","Spain","2013","2013",62.1,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","MTMOPPMT","Million US$, purchasing power parity","ESP","Spain","2014","2014",67.6,"B; D","Break; Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","MTMOPPMT","Million US$, purchasing power parity","ESP","Spain","2015","2015",68.6,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","MTMOPPMT","Million US$, purchasing power parity","ESP","Spain","2016","2016",73,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","MTMOPPMT","Million US$, purchasing power parity","ESP","Spain","2017","2017",75.5,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","MTMOPPMT","Million US$, purchasing power parity","ESP","Spain","2018","2018",86.6,"B","Break"
+"PATCHYPN","N05C-Hypnotics and sedatives","MTMOPPMT","Million US$, purchasing power parity","ESP","Spain","2019","2019",95.3,,
+"PATCHYPN","N05C-Hypnotics and sedatives","MTMOPPMT","Million US$, purchasing power parity","ESP","Spain","2020","2020",112.5,,
+"PATCHYPN","N05C-Hypnotics and sedatives","MTMOPPMT","Million US$, purchasing power parity","ESP","Spain","2021","2021",105.7,,
+"PATCHYPN","N05C-Hypnotics and sedatives","MTMOPPMT","Million US$, purchasing power parity","ESP","Spain","2022","2022",100.4,"P","Provisional value"
+"PATCHYPN","N05C-Hypnotics and sedatives","TCPPERMT","/capita, US$ exchange rate","ESP","Spain","2010","2010",1.2,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","TCPPERMT","/capita, US$ exchange rate","ESP","Spain","2011","2011",1.2,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","TCPPERMT","/capita, US$ exchange rate","ESP","Spain","2012","2012",1.1,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","TCPPERMT","/capita, US$ exchange rate","ESP","Spain","2013","2013",1.2,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","TCPPERMT","/capita, US$ exchange rate","ESP","Spain","2014","2014",1.3,"B; D","Break; Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","TCPPERMT","/capita, US$ exchange rate","ESP","Spain","2015","2015",1.1,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","TCPPERMT","/capita, US$ exchange rate","ESP","Spain","2016","2016",1.1,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","TCPPERMT","/capita, US$ exchange rate","ESP","Spain","2017","2017",1.2,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","TCPPERMT","/capita, US$ exchange rate","ESP","Spain","2018","2018",1.4,"B","Break"
+"PATCHYPN","N05C-Hypnotics and sedatives","TCPPERMT","/capita, US$ exchange rate","ESP","Spain","2019","2019",1.4,,
+"PATCHYPN","N05C-Hypnotics and sedatives","TCPPERMT","/capita, US$ exchange rate","ESP","Spain","2020","2020",1.7,,
+"PATCHYPN","N05C-Hypnotics and sedatives","TCPPERMT","/capita, US$ exchange rate","ESP","Spain","2021","2021",1.7,,
+"PATCHYPN","N05C-Hypnotics and sedatives","TCPPERMT","/capita, US$ exchange rate","ESP","Spain","2022","2022",1.3,"P","Provisional value"
+"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2010","2010",1.2,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2011","2011",1.2,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2012","2012",1.2,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2013","2013",1.3,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2014","2014",1.5,"B; D","Break; Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2015","2015",1.5,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2016","2016",1.6,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2017","2017",1.6,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2018","2018",1.9,"B","Break"
+"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2019","2019",2,,
+"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2020","2020",2.4,,
+"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2021","2021",2.2,,
+"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2022","2022",2.1,"P","Provisional value"
+"PATCHYPN","N05C-Hypnotics and sedatives","ATCPTTMT","% of total sales","ESP","Spain","2010","2010",0.3,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","ATCPTTMT","% of total sales","ESP","Spain","2011","2011",0.3,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","ATCPTTMT","% of total sales","ESP","Spain","2012","2012",0.4,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","ATCPTTMT","% of total sales","ESP","Spain","2013","2013",0.4,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","ATCPTTMT","% of total sales","ESP","Spain","2014","2014",0.4,"B; D","Break; Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","ATCPTTMT","% of total sales","ESP","Spain","2015","2015",0.4,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","ATCPTTMT","% of total sales","ESP","Spain","2016","2016",0.4,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","ATCPTTMT","% of total sales","ESP","Spain","2017","2017",0.4,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","ATCPTTMT","% of total sales","ESP","Spain","2018","2018",0.3,"B","Break"
+"PATCHYPN","N05C-Hypnotics and sedatives","ATCPTTMT","% of total sales","ESP","Spain","2019","2019",0.3,,
+"PATCHYPN","N05C-Hypnotics and sedatives","ATCPTTMT","% of total sales","ESP","Spain","2020","2020",0.3,,
+"PATCHYPN","N05C-Hypnotics and sedatives","ATCPTTMT","% of total sales","ESP","Spain","2021","2021",0.3,,
+"PATCHYPN","N05C-Hypnotics and sedatives","ATCPTTMT","% of total sales","ESP","Spain","2022","2022",0.3,"P","Provisional value"
+"PATCHYPN","N05C-Hypnotics and sedatives","MLLNCUMT","Million of national currency units","SWE","Sweden","2010","2010",271.6,,
+"PATCHYPN","N05C-Hypnotics and sedatives","MLLNCUMT","Million of national currency units","SWE","Sweden","2011","2011",280.4,,
+"PATCHYPN","N05C-Hypnotics and sedatives","MLLNCUMT","Million of national currency units","SWE","Sweden","2012","2012",298.3,,
+"PATCHYPN","N05C-Hypnotics and sedatives","MLLNCUMT","Million of national currency units","SWE","Sweden","2013","2013",314.9,,
+"PATCHYPN","N05C-Hypnotics and sedatives","MLLNCUMT","Million of national currency units","SWE","Sweden","2014","2014",342.5,,
+"PATCHYPN","N05C-Hypnotics and sedatives","MLLNCUMT","Million of national currency units","SWE","Sweden","2015","2015",364.1,,
+"PATCHYPN","N05C-Hypnotics and sedatives","MLLNCUMT","Million of national currency units","SWE","Sweden","2016","2016",433.4,,
+"PATCHYPN","N05C-Hypnotics and sedatives","MLLNCUMT","Million of national currency units","SWE","Sweden","2017","2017",523.8,,
+"PATCHYPN","N05C-Hypnotics and sedatives","MLLNCUMT","Million of national currency units","SWE","Sweden","2018","2018",607.9,,
+"PATCHYPN","N05C-Hypnotics and sedatives","MLLNCUMT","Million of national currency units","SWE","Sweden","2019","2019",690.6,,
+"PATCHYPN","N05C-Hypnotics and sedatives","MLLNCUMT","Million of national currency units","SWE","Sweden","2020","2020",816.9,,
+"PATCHYPN","N05C-Hypnotics and sedatives","MLLNCUMT","Million of national currency units","SWE","Sweden","2021","2021",604.2,,
+"PATCHYPN","N05C-Hypnotics and sedatives","MLLNCUMT","Million of national currency units","SWE","Sweden","2022","2022",663.1,,
+"PATCHYPN","N05C-Hypnotics and sedatives","MTMOTCMT","Million US$ at exchange rate","SWE","Sweden","2010","2010",37.7,,
+"PATCHYPN","N05C-Hypnotics and sedatives","MTMOTCMT","Million US$ at exchange rate","SWE","Sweden","2011","2011",43.2,,
+"PATCHYPN","N05C-Hypnotics and sedatives","MTMOTCMT","Million US$ at exchange rate","SWE","Sweden","2012","2012",44,,
+"PATCHYPN","N05C-Hypnotics and sedatives","MTMOTCMT","Million US$ at exchange rate","SWE","Sweden","2013","2013",48.3,,
+"PATCHYPN","N05C-Hypnotics and sedatives","MTMOTCMT","Million US$ at exchange rate","SWE","Sweden","2014","2014",49.9,,
+"PATCHYPN","N05C-Hypnotics and sedatives","MTMOTCMT","Million US$ at exchange rate","SWE","Sweden","2015","2015",43.2,,
+"PATCHYPN","N05C-Hypnotics and sedatives","MTMOTCMT","Million US$ at exchange rate","SWE","Sweden","2016","2016",50.6,,
+"PATCHYPN","N05C-Hypnotics and sedatives","MTMOTCMT","Million US$ at exchange rate","SWE","Sweden","2017","2017",61.3,,
+"PATCHYPN","N05C-Hypnotics and sedatives","MTMOTCMT","Million US$ at exchange rate","SWE","Sweden","2018","2018",69.9,,
+"PATCHYPN","N05C-Hypnotics and sedatives","MTMOTCMT","Million US$ at exchange rate","SWE","Sweden","2019","2019",73,,
+"PATCHYPN","N05C-Hypnotics and sedatives","MTMOTCMT","Million US$ at exchange rate","SWE","Sweden","2020","2020",88.7,,
+"PATCHYPN","N05C-Hypnotics and sedatives","MTMOTCMT","Million US$ at exchange rate","SWE","Sweden","2021","2021",70.5,,
+"PATCHYPN","N05C-Hypnotics and sedatives","MTMOTCMT","Million US$ at exchange rate","SWE","Sweden","2022","2022",65.6,,
+"PATCHYPN","N05C-Hypnotics and sedatives","MTMOPPMT","Million US$, purchasing power parity","SWE","Sweden","2010","2010",30.1,,
+"PATCHYPN","N05C-Hypnotics and sedatives","MTMOPPMT","Million US$, purchasing power parity","SWE","Sweden","2011","2011",31.7,,
+"PATCHYPN","N05C-Hypnotics and sedatives","MTMOPPMT","Million US$, purchasing power parity","SWE","Sweden","2012","2012",34.5,,
+"PATCHYPN","N05C-Hypnotics and sedatives","MTMOPPMT","Million US$, purchasing power parity","SWE","Sweden","2013","2013",36.6,,
+"PATCHYPN","N05C-Hypnotics and sedatives","MTMOPPMT","Million US$, purchasing power parity","SWE","Sweden","2014","2014",39.3,,
+"PATCHYPN","N05C-Hypnotics and sedatives","MTMOPPMT","Million US$, purchasing power parity","SWE","Sweden","2015","2015",41.1,,
+"PATCHYPN","N05C-Hypnotics and sedatives","MTMOPPMT","Million US$, purchasing power parity","SWE","Sweden","2016","2016",49.1,,
+"PATCHYPN","N05C-Hypnotics and sedatives","MTMOPPMT","Million US$, purchasing power parity","SWE","Sweden","2017","2017",59.2,,
+"PATCHYPN","N05C-Hypnotics and sedatives","MTMOPPMT","Million US$, purchasing power parity","SWE","Sweden","2018","2018",68.6,,
+"PATCHYPN","N05C-Hypnotics and sedatives","MTMOPPMT","Million US$, purchasing power parity","SWE","Sweden","2019","2019",79.3,,
+"PATCHYPN","N05C-Hypnotics and sedatives","MTMOPPMT","Million US$, purchasing power parity","SWE","Sweden","2020","2020",94.2,,
+"PATCHYPN","N05C-Hypnotics and sedatives","MTMOPPMT","Million US$, purchasing power parity","SWE","Sweden","2021","2021",69.3,,
+"PATCHYPN","N05C-Hypnotics and sedatives","MTMOPPMT","Million US$, purchasing power parity","SWE","Sweden","2022","2022",76.5,,
+"PATCHYPN","N05C-Hypnotics and sedatives","TCPPERMT","/capita, US$ exchange rate","SWE","Sweden","2010","2010",4,,
+"PATCHYPN","N05C-Hypnotics and sedatives","TCPPERMT","/capita, US$ exchange rate","SWE","Sweden","2011","2011",4.6,,
+"PATCHYPN","N05C-Hypnotics and sedatives","TCPPERMT","/capita, US$ exchange rate","SWE","Sweden","2012","2012",4.6,,
+"PATCHYPN","N05C-Hypnotics and sedatives","TCPPERMT","/capita, US$ exchange rate","SWE","Sweden","2013","2013",5,,
+"PATCHYPN","N05C-Hypnotics and sedatives","TCPPERMT","/capita, US$ exchange rate","SWE","Sweden","2014","2014",5.1,,
+"PATCHYPN","N05C-Hypnotics and sedatives","TCPPERMT","/capita, US$ exchange rate","SWE","Sweden","2015","2015",4.4,,
+"PATCHYPN","N05C-Hypnotics and sedatives","TCPPERMT","/capita, US$ exchange rate","SWE","Sweden","2016","2016",5.1,,
+"PATCHYPN","N05C-Hypnotics and sedatives","TCPPERMT","/capita, US$ exchange rate","SWE","Sweden","2017","2017",6.1,,
+"PATCHYPN","N05C-Hypnotics and sedatives","TCPPERMT","/capita, US$ exchange rate","SWE","Sweden","2018","2018",6.9,,
+"PATCHYPN","N05C-Hypnotics and sedatives","TCPPERMT","/capita, US$ exchange rate","SWE","Sweden","2019","2019",7.1,,
+"PATCHYPN","N05C-Hypnotics and sedatives","TCPPERMT","/capita, US$ exchange rate","SWE","Sweden","2020","2020",8.6,,
+"PATCHYPN","N05C-Hypnotics and sedatives","TCPPERMT","/capita, US$ exchange rate","SWE","Sweden","2021","2021",6.8,,
+"PATCHYPN","N05C-Hypnotics and sedatives","TCPPERMT","/capita, US$ exchange rate","SWE","Sweden","2022","2022",6.3,,
+"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2010","2010",3.2,,
+"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2011","2011",3.4,,
+"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2012","2012",3.6,,
+"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2013","2013",3.8,,
+"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2014","2014",4,,
+"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2015","2015",4.2,,
+"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2016","2016",5,,
+"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2017","2017",5.9,,
+"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2018","2018",6.7,,
+"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2019","2019",7.7,,
+"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2020","2020",9.1,,
+"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2021","2021",6.7,,
+"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2022","2022",7.3,,
+"PATCHYPN","N05C-Hypnotics and sedatives","ATCPTTMT","% of total sales","SWE","Sweden","2010","2010",0.8,,
+"PATCHYPN","N05C-Hypnotics and sedatives","ATCPTTMT","% of total sales","SWE","Sweden","2011","2011",0.8,,
+"PATCHYPN","N05C-Hypnotics and sedatives","ATCPTTMT","% of total sales","SWE","Sweden","2012","2012",0.8,,
+"PATCHYPN","N05C-Hypnotics and sedatives","ATCPTTMT","% of total sales","SWE","Sweden","2013","2013",0.9,,
+"PATCHYPN","N05C-Hypnotics and sedatives","ATCPTTMT","% of total sales","SWE","Sweden","2014","2014",0.9,,
+"PATCHYPN","N05C-Hypnotics and sedatives","ATCPTTMT","% of total sales","SWE","Sweden","2015","2015",0.9,,
+"PATCHYPN","N05C-Hypnotics and sedatives","ATCPTTMT","% of total sales","SWE","Sweden","2016","2016",1,,
+"PATCHYPN","N05C-Hypnotics and sedatives","ATCPTTMT","% of total sales","SWE","Sweden","2017","2017",1.2,,
+"PATCHYPN","N05C-Hypnotics and sedatives","ATCPTTMT","% of total sales","SWE","Sweden","2018","2018",1.3,,
+"PATCHYPN","N05C-Hypnotics and sedatives","ATCPTTMT","% of total sales","SWE","Sweden","2019","2019",1.4,,
+"PATCHYPN","N05C-Hypnotics and sedatives","ATCPTTMT","% of total sales","SWE","Sweden","2020","2020",1.6,,
+"PATCHYPN","N05C-Hypnotics and sedatives","ATCPTTMT","% of total sales","SWE","Sweden","2021","2021",1.1,,
+"PATCHYPN","N05C-Hypnotics and sedatives","ATCPTTMT","% of total sales","SWE","Sweden","2022","2022",1.1,,
+"PATCHYPN","N05C-Hypnotics and sedatives","MLLNCUMT","Million of national currency units","TUR","Türkiye","2010","2010",7.7,,
+"PATCHYPN","N05C-Hypnotics and sedatives","MLLNCUMT","Million of national currency units","TUR","Türkiye","2011","2011",8.5,,
+"PATCHYPN","N05C-Hypnotics and sedatives","MLLNCUMT","Million of national currency units","TUR","Türkiye","2012","2012",9.7,,
+"PATCHYPN","N05C-Hypnotics and sedatives","MLLNCUMT","Million of national currency units","TUR","Türkiye","2013","2013",10.4,,
+"PATCHYPN","N05C-Hypnotics and sedatives","MLLNCUMT","Million of national currency units","TUR","Türkiye","2014","2014",11.5,,
+"PATCHYPN","N05C-Hypnotics and sedatives","MLLNCUMT","Million of national currency units","TUR","Türkiye","2015","2015",12,,
+"PATCHYPN","N05C-Hypnotics and sedatives","MLLNCUMT","Million of national currency units","TUR","Türkiye","2016","2016",19.9,,
+"PATCHYPN","N05C-Hypnotics and sedatives","MLLNCUMT","Million of national currency units","TUR","Türkiye","2017","2017",21.2,,
+"PATCHYPN","N05C-Hypnotics and sedatives","MLLNCUMT","Million of national currency units","TUR","Türkiye","2018","2018",18.3,,
+"PATCHYPN","N05C-Hypnotics and sedatives","MLLNCUMT","Million of national currency units","TUR","Türkiye","2019","2019",20.9,,
+"PATCHYPN","N05C-Hypnotics and sedatives","MLLNCUMT","Million of national currency units","TUR","Türkiye","2020","2020",29.3,,
+"PATCHYPN","N05C-Hypnotics and sedatives","MLLNCUMT","Million of national currency units","TUR","Türkiye","2021","2021",51.6,,
+"PATCHYPN","N05C-Hypnotics and sedatives","MTMOTCMT","Million US$ at exchange rate","TUR","Türkiye","2010","2010",5.1,,
+"PATCHYPN","N05C-Hypnotics and sedatives","MTMOTCMT","Million US$ at exchange rate","TUR","Türkiye","2011","2011",5.1,,
+"PATCHYPN","N05C-Hypnotics and sedatives","MTMOTCMT","Million US$ at exchange rate","TUR","Türkiye","2012","2012",5.4,,
+"PATCHYPN","N05C-Hypnotics and sedatives","MTMOTCMT","Million US$ at exchange rate","TUR","Türkiye","2013","2013",5.5,,
+"PATCHYPN","N05C-Hypnotics and sedatives","MTMOTCMT","Million US$ at exchange rate","TUR","Türkiye","2014","2014",5.2,,
+"PATCHYPN","N05C-Hypnotics and sedatives","MTMOTCMT","Million US$ at exchange rate","TUR","Türkiye","2015","2015",4.4,,
+"PATCHYPN","N05C-Hypnotics and sedatives","MTMOTCMT","Million US$ at exchange rate","TUR","Türkiye","2016","2016",6.6,,
+"PATCHYPN","N05C-Hypnotics and sedatives","MTMOTCMT","Million US$ at exchange rate","TUR","Türkiye","2017","2017",5.8,,
+"PATCHYPN","N05C-Hypnotics and sedatives","MTMOTCMT","Million US$ at exchange rate","TUR","Türkiye","2018","2018",3.8,,
+"PATCHYPN","N05C-Hypnotics and sedatives","MTMOTCMT","Million US$ at exchange rate","TUR","Türkiye","2019","2019",3.7,,
+"PATCHYPN","N05C-Hypnotics and sedatives","MTMOTCMT","Million US$ at exchange rate","TUR","Türkiye","2020","2020",4.2,,
+"PATCHYPN","N05C-Hypnotics and sedatives","MTMOTCMT","Million US$ at exchange rate","TUR","Türkiye","2021","2021",5.8,,
+"PATCHYPN","N05C-Hypnotics and sedatives","MTMOPPMT","Million US$, purchasing power parity","TUR","Türkiye","2010","2010",8.3,,
+"PATCHYPN","N05C-Hypnotics and sedatives","MTMOPPMT","Million US$, purchasing power parity","TUR","Türkiye","2011","2011",8.8,,
+"PATCHYPN","N05C-Hypnotics and sedatives","MTMOPPMT","Million US$, purchasing power parity","TUR","Türkiye","2012","2012",9.5,,
+"PATCHYPN","N05C-Hypnotics and sedatives","MTMOPPMT","Million US$, purchasing power parity","TUR","Türkiye","2013","2013",9.7,,
+"PATCHYPN","N05C-Hypnotics and sedatives","MTMOPPMT","Million US$, purchasing power parity","TUR","Türkiye","2014","2014",10.4,,
+"PATCHYPN","N05C-Hypnotics and sedatives","MTMOPPMT","Million US$, purchasing power parity","TUR","Türkiye","2015","2015",10.3,,
+"PATCHYPN","N05C-Hypnotics and sedatives","MTMOPPMT","Million US$, purchasing power parity","TUR","Türkiye","2016","2016",16.1,,
+"PATCHYPN","N05C-Hypnotics and sedatives","MTMOPPMT","Million US$, purchasing power parity","TUR","Türkiye","2017","2017",15.3,,
+"PATCHYPN","N05C-Hypnotics and sedatives","MTMOPPMT","Million US$, purchasing power parity","TUR","Türkiye","2018","2018",11.2,,
+"PATCHYPN","N05C-Hypnotics and sedatives","MTMOPPMT","Million US$, purchasing power parity","TUR","Türkiye","2019","2019",11.2,,
+"PATCHYPN","N05C-Hypnotics and sedatives","MTMOPPMT","Million US$, purchasing power parity","TUR","Türkiye","2020","2020",13.5,,
+"PATCHYPN","N05C-Hypnotics and sedatives","MTMOPPMT","Million US$, purchasing power parity","TUR","Türkiye","2021","2021",18.4,,
+"PATCHYPN","N05C-Hypnotics and sedatives","TCPPERMT","/capita, US$ exchange rate","TUR","Türkiye","2010","2010",0.1,,
+"PATCHYPN","N05C-Hypnotics and sedatives","TCPPERMT","/capita, US$ exchange rate","TUR","Türkiye","2011","2011",0.1,,
+"PATCHYPN","N05C-Hypnotics and sedatives","TCPPERMT","/capita, US$ exchange rate","TUR","Türkiye","2012","2012",0.1,,
+"PATCHYPN","N05C-Hypnotics and sedatives","TCPPERMT","/capita, US$ exchange rate","TUR","Türkiye","2013","2013",0.1,,
+"PATCHYPN","N05C-Hypnotics and sedatives","TCPPERMT","/capita, US$ exchange rate","TUR","Türkiye","2014","2014",0.1,,
+"PATCHYPN","N05C-Hypnotics and sedatives","TCPPERMT","/capita, US$ exchange rate","TUR","Türkiye","2015","2015",0.1,,
+"PATCHYPN","N05C-Hypnotics and sedatives","TCPPERMT","/capita, US$ exchange rate","TUR","Türkiye","2016","2016",0.1,,
+"PATCHYPN","N05C-Hypnotics and sedatives","TCPPERMT","/capita, US$ exchange rate","TUR","Türkiye","2017","2017",0.1,,
+"PATCHYPN","N05C-Hypnotics and sedatives","TCPPERMT","/capita, US$ exchange rate","TUR","Türkiye","2018","2018",0,,
+"PATCHYPN","N05C-Hypnotics and sedatives","TCPPERMT","/capita, US$ exchange rate","TUR","Türkiye","2019","2019",0,,
+"PATCHYPN","N05C-Hypnotics and sedatives","TCPPERMT","/capita, US$ exchange rate","TUR","Türkiye","2020","2020",0.1,,
+"PATCHYPN","N05C-Hypnotics and sedatives","TCPPERMT","/capita, US$ exchange rate","TUR","Türkiye","2021","2021",0.1,,
+"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2010","2010",0.1,,
+"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2011","2011",0.1,,
+"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2012","2012",0.1,,
+"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2013","2013",0.1,,
+"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2014","2014",0.1,,
+"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2015","2015",0.1,,
+"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2016","2016",0.2,,
+"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2017","2017",0.2,,
+"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2018","2018",0.1,,
+"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2019","2019",0.1,,
+"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2020","2020",0.2,,
+"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2021","2021",0.2,,
+"PATCHYPN","N05C-Hypnotics and sedatives","ATCPTTMT","% of total sales","TUR","Türkiye","2010","2010",0,,
+"PATCHYPN","N05C-Hypnotics and sedatives","ATCPTTMT","% of total sales","TUR","Türkiye","2011","2011",0.1,,
+"PATCHYPN","N05C-Hypnotics and sedatives","ATCPTTMT","% of total sales","TUR","Türkiye","2012","2012",0.1,,
+"PATCHYPN","N05C-Hypnotics and sedatives","ATCPTTMT","% of total sales","TUR","Türkiye","2013","2013",0.1,,
+"PATCHYPN","N05C-Hypnotics and sedatives","ATCPTTMT","% of total sales","TUR","Türkiye","2014","2014",0.1,,
+"PATCHYPN","N05C-Hypnotics and sedatives","ATCPTTMT","% of total sales","TUR","Türkiye","2015","2015",0.1,,
+"PATCHYPN","N05C-Hypnotics and sedatives","ATCPTTMT","% of total sales","TUR","Türkiye","2016","2016",0.1,,
+"PATCHYPN","N05C-Hypnotics and sedatives","ATCPTTMT","% of total sales","TUR","Türkiye","2017","2017",0.1,,
+"PATCHYPN","N05C-Hypnotics and sedatives","ATCPTTMT","% of total sales","TUR","Türkiye","2018","2018",0.1,,
+"PATCHYPN","N05C-Hypnotics and sedatives","ATCPTTMT","% of total sales","TUR","Türkiye","2019","2019",0,,
+"PATCHYPN","N05C-Hypnotics and sedatives","ATCPTTMT","% of total sales","TUR","Türkiye","2020","2020",0.1,,
+"PATCHYPN","N05C-Hypnotics and sedatives","ATCPTTMT","% of total sales","TUR","Türkiye","2021","2021",0.1,,
+"PATCHYPN","N05C-Hypnotics and sedatives","MLLNCUMT","Million of national currency units","CHL","Chile","2010","2010",3361.7,,
+"PATCHYPN","N05C-Hypnotics and sedatives","MLLNCUMT","Million of national currency units","CHL","Chile","2011","2011",5170.6,"B","Break"
+"PATCHYPN","N05C-Hypnotics and sedatives","MLLNCUMT","Million of national currency units","CHL","Chile","2012","2012",5909.7,,
+"PATCHYPN","N05C-Hypnotics and sedatives","MLLNCUMT","Million of national currency units","CHL","Chile","2013","2013",7153.9,,
+"PATCHYPN","N05C-Hypnotics and sedatives","MLLNCUMT","Million of national currency units","CHL","Chile","2014","2014",8655.6,,
+"PATCHYPN","N05C-Hypnotics and sedatives","MLLNCUMT","Million of national currency units","CHL","Chile","2015","2015",9241.4,,
+"PATCHYPN","N05C-Hypnotics and sedatives","MLLNCUMT","Million of national currency units","CHL","Chile","2016","2016",10849.8,,
+"PATCHYPN","N05C-Hypnotics and sedatives","MLLNCUMT","Million of national currency units","CHL","Chile","2017","2017",12193.6,,
+"PATCHYPN","N05C-Hypnotics and sedatives","MLLNCUMT","Million of national currency units","CHL","Chile","2018","2018",14373.1,,
+"PATCHYPN","N05C-Hypnotics and sedatives","MLLNCUMT","Million of national currency units","CHL","Chile","2019","2019",20030,,
+"PATCHYPN","N05C-Hypnotics and sedatives","MLLNCUMT","Million of national currency units","CHL","Chile","2020","2020",33988.3,,
+"PATCHYPN","N05C-Hypnotics and sedatives","MLLNCUMT","Million of national currency units","CHL","Chile","2021","2021",37671.2,,
+"PATCHYPN","N05C-Hypnotics and sedatives","MLLNCUMT","Million of national currency units","CHL","Chile","2022","2022",29554.3,,
+"PATCHYPN","N05C-Hypnotics and sedatives","MTMOTCMT","Million US$ at exchange rate","CHL","Chile","2010","2010",6.6,,
+"PATCHYPN","N05C-Hypnotics and sedatives","MTMOTCMT","Million US$ at exchange rate","CHL","Chile","2011","2011",10.7,"B","Break"
+"PATCHYPN","N05C-Hypnotics and sedatives","MTMOTCMT","Million US$ at exchange rate","CHL","Chile","2012","2012",12.1,,
+"PATCHYPN","N05C-Hypnotics and sedatives","MTMOTCMT","Million US$ at exchange rate","CHL","Chile","2013","2013",14.4,,
+"PATCHYPN","N05C-Hypnotics and sedatives","MTMOTCMT","Million US$ at exchange rate","CHL","Chile","2014","2014",15.2,,
+"PATCHYPN","N05C-Hypnotics and sedatives","MTMOTCMT","Million US$ at exchange rate","CHL","Chile","2015","2015",14.1,,
+"PATCHYPN","N05C-Hypnotics and sedatives","MTMOTCMT","Million US$ at exchange rate","CHL","Chile","2016","2016",16,,
+"PATCHYPN","N05C-Hypnotics and sedatives","MTMOTCMT","Million US$ at exchange rate","CHL","Chile","2017","2017",18.8,,
+"PATCHYPN","N05C-Hypnotics and sedatives","MTMOTCMT","Million US$ at exchange rate","CHL","Chile","2018","2018",22.4,,
+"PATCHYPN","N05C-Hypnotics and sedatives","MTMOTCMT","Million US$ at exchange rate","CHL","Chile","2019","2019",28.5,,
+"PATCHYPN","N05C-Hypnotics and sedatives","MTMOTCMT","Million US$ at exchange rate","CHL","Chile","2020","2020",42.9,,
+"PATCHYPN","N05C-Hypnotics and sedatives","MTMOTCMT","Million US$ at exchange rate","CHL","Chile","2021","2021",49.6,,
+"PATCHYPN","N05C-Hypnotics and sedatives","MTMOTCMT","Million US$ at exchange rate","CHL","Chile","2022","2022",33.8,,
+"PATCHYPN","N05C-Hypnotics and sedatives","MTMOPPMT","Million US$, purchasing power parity","CHL","Chile","2010","2010",9.3,,
+"PATCHYPN","N05C-Hypnotics and sedatives","MTMOPPMT","Million US$, purchasing power parity","CHL","Chile","2011","2011",14.9,"B","Break"
+"PATCHYPN","N05C-Hypnotics and sedatives","MTMOPPMT","Million US$, purchasing power parity","CHL","Chile","2012","2012",17,,
+"PATCHYPN","N05C-Hypnotics and sedatives","MTMOPPMT","Million US$, purchasing power parity","CHL","Chile","2013","2013",20.5,,
+"PATCHYPN","N05C-Hypnotics and sedatives","MTMOPPMT","Million US$, purchasing power parity","CHL","Chile","2014","2014",23.6,,
+"PATCHYPN","N05C-Hypnotics and sedatives","MTMOPPMT","Million US$, purchasing power parity","CHL","Chile","2015","2015",23.6,,
+"PATCHYPN","N05C-Hypnotics and sedatives","MTMOPPMT","Million US$, purchasing power parity","CHL","Chile","2016","2016",27.3,,
+"PATCHYPN","N05C-Hypnotics and sedatives","MTMOPPMT","Million US$, purchasing power parity","CHL","Chile","2017","2017",30.7,,
+"PATCHYPN","N05C-Hypnotics and sedatives","MTMOPPMT","Million US$, purchasing power parity","CHL","Chile","2018","2018",36.3,,
+"PATCHYPN","N05C-Hypnotics and sedatives","MTMOPPMT","Million US$, purchasing power parity","CHL","Chile","2019","2019",49.9,,
+"PATCHYPN","N05C-Hypnotics and sedatives","MTMOPPMT","Million US$, purchasing power parity","CHL","Chile","2020","2020",81.2,,
+"PATCHYPN","N05C-Hypnotics and sedatives","MTMOPPMT","Million US$, purchasing power parity","CHL","Chile","2021","2021",86.6,,
+"PATCHYPN","N05C-Hypnotics and sedatives","MTMOPPMT","Million US$, purchasing power parity","CHL","Chile","2022","2022",67.5,,
+"PATCHYPN","N05C-Hypnotics and sedatives","TCPPERMT","/capita, US$ exchange rate","CHL","Chile","2010","2010",0.4,,
+"PATCHYPN","N05C-Hypnotics and sedatives","TCPPERMT","/capita, US$ exchange rate","CHL","Chile","2011","2011",0.6,"B","Break"
+"PATCHYPN","N05C-Hypnotics and sedatives","TCPPERMT","/capita, US$ exchange rate","CHL","Chile","2012","2012",0.7,,
+"PATCHYPN","N05C-Hypnotics and sedatives","TCPPERMT","/capita, US$ exchange rate","CHL","Chile","2013","2013",0.8,,
+"PATCHYPN","N05C-Hypnotics and sedatives","TCPPERMT","/capita, US$ exchange rate","CHL","Chile","2014","2014",0.9,,
+"PATCHYPN","N05C-Hypnotics and sedatives","TCPPERMT","/capita, US$ exchange rate","CHL","Chile","2015","2015",0.8,,
+"PATCHYPN","N05C-Hypnotics and sedatives","TCPPERMT","/capita, US$ exchange rate","CHL","Chile","2016","2016",0.9,,
+"PATCHYPN","N05C-Hypnotics and sedatives","TCPPERMT","/capita, US$ exchange rate","CHL","Chile","2017","2017",1,,
+"PATCHYPN","N05C-Hypnotics and sedatives","TCPPERMT","/capita, US$ exchange rate","CHL","Chile","2018","2018",1.2,,
+"PATCHYPN","N05C-Hypnotics and sedatives","TCPPERMT","/capita, US$ exchange rate","CHL","Chile","2019","2019",1.5,,
+"PATCHYPN","N05C-Hypnotics and sedatives","TCPPERMT","/capita, US$ exchange rate","CHL","Chile","2020","2020",2.2,,
+"PATCHYPN","N05C-Hypnotics and sedatives","TCPPERMT","/capita, US$ exchange rate","CHL","Chile","2021","2021",2.5,,
+"PATCHYPN","N05C-Hypnotics and sedatives","TCPPERMT","/capita, US$ exchange rate","CHL","Chile","2022","2022",1.7,,
+"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2010","2010",0.5,,
+"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2011","2011",0.9,"B","Break"
+"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2012","2012",1,,
+"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2013","2013",1.2,,
+"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2014","2014",1.3,,
+"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2015","2015",1.3,,
+"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2016","2016",1.5,,
+"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2017","2017",1.7,,
+"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2018","2018",1.9,,
+"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2019","2019",2.6,,
+"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2020","2020",4.2,,
+"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2021","2021",4.4,,
+"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2022","2022",3.4,,
+"PATCHYPN","N05C-Hypnotics and sedatives","ATCPTTMT","% of total sales","CHL","Chile","2010","2010",0.4,,
+"PATCHYPN","N05C-Hypnotics and sedatives","ATCPTTMT","% of total sales","CHL","Chile","2011","2011",0.4,"B","Break"
+"PATCHYPN","N05C-Hypnotics and sedatives","ATCPTTMT","% of total sales","CHL","Chile","2012","2012",0.5,,
+"PATCHYPN","N05C-Hypnotics and sedatives","ATCPTTMT","% of total sales","CHL","Chile","2013","2013",0.5,,
+"PATCHYPN","N05C-Hypnotics and sedatives","ATCPTTMT","% of total sales","CHL","Chile","2014","2014",0.6,,
+"PATCHYPN","N05C-Hypnotics and sedatives","ATCPTTMT","% of total sales","CHL","Chile","2015","2015",0.5,,
+"PATCHYPN","N05C-Hypnotics and sedatives","ATCPTTMT","% of total sales","CHL","Chile","2016","2016",0.5,,
+"PATCHYPN","N05C-Hypnotics and sedatives","ATCPTTMT","% of total sales","CHL","Chile","2017","2017",0.6,,
+"PATCHYPN","N05C-Hypnotics and sedatives","ATCPTTMT","% of total sales","CHL","Chile","2018","2018",0.6,,
+"PATCHYPN","N05C-Hypnotics and sedatives","ATCPTTMT","% of total sales","CHL","Chile","2019","2019",0.8,,
+"PATCHYPN","N05C-Hypnotics and sedatives","ATCPTTMT","% of total sales","CHL","Chile","2020","2020",1.3,,
+"PATCHYPN","N05C-Hypnotics and sedatives","ATCPTTMT","% of total sales","CHL","Chile","2021","2021",1.3,,
+"PATCHYPN","N05C-Hypnotics and sedatives","ATCPTTMT","% of total sales","CHL","Chile","2022","2022",1,,
+"PATCHYPN","N05C-Hypnotics and sedatives","MLLNCUMT","Million of national currency units","EST","Estonia","2010","2010",1.4,,
+"PATCHYPN","N05C-Hypnotics and sedatives","MLLNCUMT","Million of national currency units","EST","Estonia","2011","2011",1.4,,
+"PATCHYPN","N05C-Hypnotics and sedatives","MLLNCUMT","Million of national currency units","EST","Estonia","2012","2012",1.5,,
+"PATCHYPN","N05C-Hypnotics and sedatives","MLLNCUMT","Million of national currency units","EST","Estonia","2013","2013",1.5,,
+"PATCHYPN","N05C-Hypnotics and sedatives","MLLNCUMT","Million of national currency units","EST","Estonia","2014","2014",1.7,,
+"PATCHYPN","N05C-Hypnotics and sedatives","MLLNCUMT","Million of national currency units","EST","Estonia","2015","2015",1.8,,
+"PATCHYPN","N05C-Hypnotics and sedatives","MLLNCUMT","Million of national currency units","EST","Estonia","2016","2016",1.8,,
+"PATCHYPN","N05C-Hypnotics and sedatives","MLLNCUMT","Million of national currency units","EST","Estonia","2017","2017",2,,
+"PATCHYPN","N05C-Hypnotics and sedatives","MLLNCUMT","Million of national currency units","EST","Estonia","2018","2018",2.2,,
+"PATCHYPN","N05C-Hypnotics and sedatives","MLLNCUMT","Million of national currency units","EST","Estonia","2019","2019",2.3,,
+"PATCHYPN","N05C-Hypnotics and sedatives","MLLNCUMT","Million of national currency units","EST","Estonia","2020","2020",2.4,,
+"PATCHYPN","N05C-Hypnotics and sedatives","MLLNCUMT","Million of national currency units","EST","Estonia","2021","2021",2.8,,
+"PATCHYPN","N05C-Hypnotics and sedatives","MLLNCUMT","Million of national currency units","EST","Estonia","2022","2022",2.7,,
+"PATCHYPN","N05C-Hypnotics and sedatives","MTMOTCMT","Million US$ at exchange rate","EST","Estonia","2010","2010",1.8,,
+"PATCHYPN","N05C-Hypnotics and sedatives","MTMOTCMT","Million US$ at exchange rate","EST","Estonia","2011","2011",2,,
+"PATCHYPN","N05C-Hypnotics and sedatives","MTMOTCMT","Million US$ at exchange rate","EST","Estonia","2012","2012",2,,
+"PATCHYPN","N05C-Hypnotics and sedatives","MTMOTCMT","Million US$ at exchange rate","EST","Estonia","2013","2013",2.1,,
+"PATCHYPN","N05C-Hypnotics and sedatives","MTMOTCMT","Million US$ at exchange rate","EST","Estonia","2014","2014",2.2,,
+"PATCHYPN","N05C-Hypnotics and sedatives","MTMOTCMT","Million US$ at exchange rate","EST","Estonia","2015","2015",1.9,,
+"PATCHYPN","N05C-Hypnotics and sedatives","MTMOTCMT","Million US$ at exchange rate","EST","Estonia","2016","2016",2,,
+"PATCHYPN","N05C-Hypnotics and sedatives","MTMOTCMT","Million US$ at exchange rate","EST","Estonia","2017","2017",2.2,,
+"PATCHYPN","N05C-Hypnotics and sedatives","MTMOTCMT","Million US$ at exchange rate","EST","Estonia","2018","2018",2.6,,
+"PATCHYPN","N05C-Hypnotics and sedatives","MTMOTCMT","Million US$ at exchange rate","EST","Estonia","2019","2019",2.6,,
+"PATCHYPN","N05C-Hypnotics and sedatives","MTMOTCMT","Million US$ at exchange rate","EST","Estonia","2020","2020",2.8,,
+"PATCHYPN","N05C-Hypnotics and sedatives","MTMOTCMT","Million US$ at exchange rate","EST","Estonia","2021","2021",3.3,,
+"PATCHYPN","N05C-Hypnotics and sedatives","MTMOTCMT","Million US$ at exchange rate","EST","Estonia","2022","2022",2.8,,
+"PATCHYPN","N05C-Hypnotics and sedatives","MTMOPPMT","Million US$, purchasing power parity","EST","Estonia","2010","2010",2.7,,
+"PATCHYPN","N05C-Hypnotics and sedatives","MTMOPPMT","Million US$, purchasing power parity","EST","Estonia","2011","2011",2.8,,
+"PATCHYPN","N05C-Hypnotics and sedatives","MTMOPPMT","Million US$, purchasing power parity","EST","Estonia","2012","2012",2.9,,
+"PATCHYPN","N05C-Hypnotics and sedatives","MTMOPPMT","Million US$, purchasing power parity","EST","Estonia","2013","2013",3,,
+"PATCHYPN","N05C-Hypnotics and sedatives","MTMOPPMT","Million US$, purchasing power parity","EST","Estonia","2014","2014",3.2,,
+"PATCHYPN","N05C-Hypnotics and sedatives","MTMOPPMT","Million US$, purchasing power parity","EST","Estonia","2015","2015",3.3,,
+"PATCHYPN","N05C-Hypnotics and sedatives","MTMOPPMT","Million US$, purchasing power parity","EST","Estonia","2016","2016",3.4,,
+"PATCHYPN","N05C-Hypnotics and sedatives","MTMOPPMT","Million US$, purchasing power parity","EST","Estonia","2017","2017",3.7,,
+"PATCHYPN","N05C-Hypnotics and sedatives","MTMOPPMT","Million US$, purchasing power parity","EST","Estonia","2018","2018",4,,
+"PATCHYPN","N05C-Hypnotics and sedatives","MTMOPPMT","Million US$, purchasing power parity","EST","Estonia","2019","2019",4.2,,
+"PATCHYPN","N05C-Hypnotics and sedatives","MTMOPPMT","Million US$, purchasing power parity","EST","Estonia","2020","2020",4.6,,
+"PATCHYPN","N05C-Hypnotics and sedatives","MTMOPPMT","Million US$, purchasing power parity","EST","Estonia","2021","2021",5.2,,
+"PATCHYPN","N05C-Hypnotics and sedatives","MTMOPPMT","Million US$, purchasing power parity","EST","Estonia","2022","2022",4.7,,
+"PATCHYPN","N05C-Hypnotics and sedatives","TCPPERMT","/capita, US$ exchange rate","EST","Estonia","2010","2010",1.4,,
+"PATCHYPN","N05C-Hypnotics and sedatives","TCPPERMT","/capita, US$ exchange rate","EST","Estonia","2011","2011",1.5,,
+"PATCHYPN","N05C-Hypnotics and sedatives","TCPPERMT","/capita, US$ exchange rate","EST","Estonia","2012","2012",1.5,,
+"PATCHYPN","N05C-Hypnotics and sedatives","TCPPERMT","/capita, US$ exchange rate","EST","Estonia","2013","2013",1.6,,
+"PATCHYPN","N05C-Hypnotics and sedatives","TCPPERMT","/capita, US$ exchange rate","EST","Estonia","2014","2014",1.7,,
+"PATCHYPN","N05C-Hypnotics and sedatives","TCPPERMT","/capita, US$ exchange rate","EST","Estonia","2015","2015",1.5,,
+"PATCHYPN","N05C-Hypnotics and sedatives","TCPPERMT","/capita, US$ exchange rate","EST","Estonia","2016","2016",1.5,,
+"PATCHYPN","N05C-Hypnotics and sedatives","TCPPERMT","/capita, US$ exchange rate","EST","Estonia","2017","2017",1.7,,
+"PATCHYPN","N05C-Hypnotics and sedatives","TCPPERMT","/capita, US$ exchange rate","EST","Estonia","2018","2018",1.9,,
+"PATCHYPN","N05C-Hypnotics and sedatives","TCPPERMT","/capita, US$ exchange rate","EST","Estonia","2019","2019",1.9,,
+"PATCHYPN","N05C-Hypnotics and sedatives","TCPPERMT","/capita, US$ exchange rate","EST","Estonia","2020","2020",2.1,,
+"PATCHYPN","N05C-Hypnotics and sedatives","TCPPERMT","/capita, US$ exchange rate","EST","Estonia","2021","2021",2.5,,
+"PATCHYPN","N05C-Hypnotics and sedatives","TCPPERMT","/capita, US$ exchange rate","EST","Estonia","2022","2022",2.1,,
+"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2010","2010",2,,
+"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2011","2011",2.1,,
+"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2012","2012",2.2,,
+"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2013","2013",2.2,,
+"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2014","2014",2.4,,
+"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2015","2015",2.5,,
+"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2016","2016",2.6,,
+"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2017","2017",2.8,,
+"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2018","2018",3.1,,
+"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2019","2019",3.2,,
+"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2020","2020",3.5,,
+"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2021","2021",3.9,,
+"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2022","2022",3.5,,
+"PATCHYPN","N05C-Hypnotics and sedatives","ATCPTTMT","% of total sales","EST","Estonia","2010","2010",0.7,,
+"PATCHYPN","N05C-Hypnotics and sedatives","ATCPTTMT","% of total sales","EST","Estonia","2011","2011",0.7,,
+"PATCHYPN","N05C-Hypnotics and sedatives","ATCPTTMT","% of total sales","EST","Estonia","2012","2012",0.7,,
+"PATCHYPN","N05C-Hypnotics and sedatives","ATCPTTMT","% of total sales","EST","Estonia","2013","2013",0.7,,
+"PATCHYPN","N05C-Hypnotics and sedatives","ATCPTTMT","% of total sales","EST","Estonia","2014","2014",0.7,,
+"PATCHYPN","N05C-Hypnotics and sedatives","ATCPTTMT","% of total sales","EST","Estonia","2015","2015",0.7,,
+"PATCHYPN","N05C-Hypnotics and sedatives","ATCPTTMT","% of total sales","EST","Estonia","2016","2016",0.6,,
+"PATCHYPN","N05C-Hypnotics and sedatives","ATCPTTMT","% of total sales","EST","Estonia","2017","2017",0.7,,
+"PATCHYPN","N05C-Hypnotics and sedatives","ATCPTTMT","% of total sales","EST","Estonia","2018","2018",0.7,,
+"PATCHYPN","N05C-Hypnotics and sedatives","ATCPTTMT","% of total sales","EST","Estonia","2019","2019",0.7,,
+"PATCHYPN","N05C-Hypnotics and sedatives","ATCPTTMT","% of total sales","EST","Estonia","2020","2020",0.7,,
+"PATCHYPN","N05C-Hypnotics and sedatives","ATCPTTMT","% of total sales","EST","Estonia","2021","2021",0.7,,
+"PATCHYPN","N05C-Hypnotics and sedatives","ATCPTTMT","% of total sales","EST","Estonia","2022","2022",0.6,,
+"PATCHYPN","N05C-Hypnotics and sedatives","MLLNCUMT","Million of national currency units","SVN","Slovenia","2010","2010",2.9,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","MLLNCUMT","Million of national currency units","SVN","Slovenia","2011","2011",2.7,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","MLLNCUMT","Million of national currency units","SVN","Slovenia","2012","2012",2.6,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","MLLNCUMT","Million of national currency units","SVN","Slovenia","2013","2013",2.5,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","MLLNCUMT","Million of national currency units","SVN","Slovenia","2014","2014",2.4,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","MLLNCUMT","Million of national currency units","SVN","Slovenia","2015","2015",2.5,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","MLLNCUMT","Million of national currency units","SVN","Slovenia","2016","2016",2.4,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","MLLNCUMT","Million of national currency units","SVN","Slovenia","2017","2017",2.3,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","MLLNCUMT","Million of national currency units","SVN","Slovenia","2018","2018",2.4,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","MLLNCUMT","Million of national currency units","SVN","Slovenia","2019","2019",2.4,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","MLLNCUMT","Million of national currency units","SVN","Slovenia","2020","2020",2.4,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","MLLNCUMT","Million of national currency units","SVN","Slovenia","2021","2021",2.6,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","MLLNCUMT","Million of national currency units","SVN","Slovenia","2022","2022",2.5,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","MTMOTCMT","Million US$ at exchange rate","SVN","Slovenia","2010","2010",3.8,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","MTMOTCMT","Million US$ at exchange rate","SVN","Slovenia","2011","2011",3.8,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","MTMOTCMT","Million US$ at exchange rate","SVN","Slovenia","2012","2012",3.3,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","MTMOTCMT","Million US$ at exchange rate","SVN","Slovenia","2013","2013",3.3,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","MTMOTCMT","Million US$ at exchange rate","SVN","Slovenia","2014","2014",3.2,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","MTMOTCMT","Million US$ at exchange rate","SVN","Slovenia","2015","2015",2.7,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","MTMOTCMT","Million US$ at exchange rate","SVN","Slovenia","2016","2016",2.6,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","MTMOTCMT","Million US$ at exchange rate","SVN","Slovenia","2017","2017",2.6,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","MTMOTCMT","Million US$ at exchange rate","SVN","Slovenia","2018","2018",2.8,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","MTMOTCMT","Million US$ at exchange rate","SVN","Slovenia","2019","2019",2.6,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","MTMOTCMT","Million US$ at exchange rate","SVN","Slovenia","2020","2020",2.8,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","MTMOTCMT","Million US$ at exchange rate","SVN","Slovenia","2021","2021",3,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","MTMOTCMT","Million US$ at exchange rate","SVN","Slovenia","2022","2022",2.6,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","MTMOPPMT","Million US$, purchasing power parity","SVN","Slovenia","2010","2010",4.5,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","MTMOPPMT","Million US$, purchasing power parity","SVN","Slovenia","2011","2011",4.3,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","MTMOPPMT","Million US$, purchasing power parity","SVN","Slovenia","2012","2012",4.2,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","MTMOPPMT","Million US$, purchasing power parity","SVN","Slovenia","2013","2013",4.3,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","MTMOPPMT","Million US$, purchasing power parity","SVN","Slovenia","2014","2014",4.1,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","MTMOPPMT","Million US$, purchasing power parity","SVN","Slovenia","2015","2015",4.1,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","MTMOPPMT","Million US$, purchasing power parity","SVN","Slovenia","2016","2016",4.1,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","MTMOPPMT","Million US$, purchasing power parity","SVN","Slovenia","2017","2017",4.1,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","MTMOPPMT","Million US$, purchasing power parity","SVN","Slovenia","2018","2018",4.1,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","MTMOPPMT","Million US$, purchasing power parity","SVN","Slovenia","2019","2019",4.3,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","MTMOPPMT","Million US$, purchasing power parity","SVN","Slovenia","2020","2020",4.4,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","MTMOPPMT","Million US$, purchasing power parity","SVN","Slovenia","2021","2021",4.6,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","MTMOPPMT","Million US$, purchasing power parity","SVN","Slovenia","2022","2022",4.5,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","TCPPERMT","/capita, US$ exchange rate","SVN","Slovenia","2010","2010",1.9,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","TCPPERMT","/capita, US$ exchange rate","SVN","Slovenia","2011","2011",1.8,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","TCPPERMT","/capita, US$ exchange rate","SVN","Slovenia","2012","2012",1.6,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","TCPPERMT","/capita, US$ exchange rate","SVN","Slovenia","2013","2013",1.6,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","TCPPERMT","/capita, US$ exchange rate","SVN","Slovenia","2014","2014",1.6,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","TCPPERMT","/capita, US$ exchange rate","SVN","Slovenia","2015","2015",1.3,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","TCPPERMT","/capita, US$ exchange rate","SVN","Slovenia","2016","2016",1.3,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","TCPPERMT","/capita, US$ exchange rate","SVN","Slovenia","2017","2017",1.3,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","TCPPERMT","/capita, US$ exchange rate","SVN","Slovenia","2018","2018",1.3,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","TCPPERMT","/capita, US$ exchange rate","SVN","Slovenia","2019","2019",1.3,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","TCPPERMT","/capita, US$ exchange rate","SVN","Slovenia","2020","2020",1.3,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","TCPPERMT","/capita, US$ exchange rate","SVN","Slovenia","2021","2021",1.4,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","TCPPERMT","/capita, US$ exchange rate","SVN","Slovenia","2022","2022",1.2,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2010","2010",2.2,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2011","2011",2.1,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2012","2012",2.1,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2013","2013",2.1,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2014","2014",2,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2015","2015",2,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2016","2016",2,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2017","2017",2,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2018","2018",2,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2019","2019",2,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2020","2020",2.1,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2021","2021",2.2,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2022","2022",2.1,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","ATCPTTMT","% of total sales","SVN","Slovenia","2010","2010",0.6,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","ATCPTTMT","% of total sales","SVN","Slovenia","2011","2011",0.6,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","ATCPTTMT","% of total sales","SVN","Slovenia","2012","2012",0.6,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","ATCPTTMT","% of total sales","SVN","Slovenia","2013","2013",0.6,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","ATCPTTMT","% of total sales","SVN","Slovenia","2014","2014",0.6,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","ATCPTTMT","% of total sales","SVN","Slovenia","2015","2015",0.6,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","ATCPTTMT","% of total sales","SVN","Slovenia","2016","2016",0.5,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","ATCPTTMT","% of total sales","SVN","Slovenia","2017","2017",0.5,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","ATCPTTMT","% of total sales","SVN","Slovenia","2018","2018",0.5,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","ATCPTTMT","% of total sales","SVN","Slovenia","2019","2019",0.4,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","ATCPTTMT","% of total sales","SVN","Slovenia","2020","2020",0.4,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","ATCPTTMT","% of total sales","SVN","Slovenia","2021","2021",0.4,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","ATCPTTMT","% of total sales","SVN","Slovenia","2022","2022",0.4,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","MLLNCUMT","Million of national currency units","AUS","Australia","2010","2010",468,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","MLLNCUMT","Million of national currency units","AUS","Australia","2011","2011",488,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","MLLNCUMT","Million of national currency units","AUS","Australia","2012","2012",446,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","MLLNCUMT","Million of national currency units","AUS","Australia","2013","2013",524,"B; D","Break; Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","MLLNCUMT","Million of national currency units","AUS","Australia","2014","2014",464,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","MLLNCUMT","Million of national currency units","AUS","Australia","2015","2015",438,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","MLLNCUMT","Million of national currency units","AUS","Australia","2016","2016",441,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","MLLNCUMT","Million of national currency units","AUS","Australia","2017","2017",433,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","MLLNCUMT","Million of national currency units","AUS","Australia","2018","2018",445,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","MLLNCUMT","Million of national currency units","AUS","Australia","2019","2019",464,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","MLLNCUMT","Million of national currency units","AUS","Australia","2020","2020",506,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","MLLNCUMT","Million of national currency units","AUS","Australia","2021","2021",549,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","MTMOTCMT","Million US$ at exchange rate","AUS","Australia","2010","2010",429.3,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","MTMOTCMT","Million US$ at exchange rate","AUS","Australia","2011","2011",503.4,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","MTMOTCMT","Million US$ at exchange rate","AUS","Australia","2012","2012",461.8,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","MTMOTCMT","Million US$ at exchange rate","AUS","Australia","2013","2013",505.9,"B; D","Break; Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","MTMOTCMT","Million US$ at exchange rate","AUS","Australia","2014","2014",418.3,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","MTMOTCMT","Million US$ at exchange rate","AUS","Australia","2015","2015",329.1,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","MTMOTCMT","Million US$ at exchange rate","AUS","Australia","2016","2016",327.8,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","MTMOTCMT","Million US$ at exchange rate","AUS","Australia","2017","2017",331.9,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","MTMOTCMT","Million US$ at exchange rate","AUS","Australia","2018","2018",332.5,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","MTMOTCMT","Million US$ at exchange rate","AUS","Australia","2019","2019",322.6,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","MTMOTCMT","Million US$ at exchange rate","AUS","Australia","2020","2020",348.2,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","MTMOTCMT","Million US$ at exchange rate","AUS","Australia","2021","2021",412.4,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","MTMOPPMT","Million US$, purchasing power parity","AUS","Australia","2010","2010",311.2,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","MTMOPPMT","Million US$, purchasing power parity","AUS","Australia","2011","2011",323,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","MTMOPPMT","Million US$, purchasing power parity","AUS","Australia","2012","2012",289.6,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","MTMOPPMT","Million US$, purchasing power parity","AUS","Australia","2013","2013",362.1,"B; D","Break; Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","MTMOPPMT","Million US$, purchasing power parity","AUS","Australia","2014","2014",319.5,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","MTMOPPMT","Million US$, purchasing power parity","AUS","Australia","2015","2015",297.2,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","MTMOPPMT","Million US$, purchasing power parity","AUS","Australia","2016","2016",304.1,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","MTMOPPMT","Million US$, purchasing power parity","AUS","Australia","2017","2017",293.1,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","MTMOPPMT","Million US$, purchasing power parity","AUS","Australia","2018","2018",302.6,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","MTMOPPMT","Million US$, purchasing power parity","AUS","Australia","2019","2019",313.5,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","MTMOPPMT","Million US$, purchasing power parity","AUS","Australia","2020","2020",348,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","MTMOPPMT","Million US$, purchasing power parity","AUS","Australia","2021","2021",379.3,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","TCPPERMT","/capita, US$ exchange rate","AUS","Australia","2010","2010",19.5,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","TCPPERMT","/capita, US$ exchange rate","AUS","Australia","2011","2011",22.5,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","TCPPERMT","/capita, US$ exchange rate","AUS","Australia","2012","2012",20.3,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","TCPPERMT","/capita, US$ exchange rate","AUS","Australia","2013","2013",21.9,"B; D","Break; Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","TCPPERMT","/capita, US$ exchange rate","AUS","Australia","2014","2014",17.8,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","TCPPERMT","/capita, US$ exchange rate","AUS","Australia","2015","2015",13.8,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","TCPPERMT","/capita, US$ exchange rate","AUS","Australia","2016","2016",13.6,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","TCPPERMT","/capita, US$ exchange rate","AUS","Australia","2017","2017",13.5,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","TCPPERMT","/capita, US$ exchange rate","AUS","Australia","2018","2018",13.3,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","TCPPERMT","/capita, US$ exchange rate","AUS","Australia","2019","2019",12.7,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","TCPPERMT","/capita, US$ exchange rate","AUS","Australia","2020","2020",13.6,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","TCPPERMT","/capita, US$ exchange rate","AUS","Australia","2021","2021",16.1,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2010","2010",14.1,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2011","2011",14.5,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2012","2012",12.7,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2013","2013",15.7,"B; D","Break; Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2014","2014",13.6,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2015","2015",12.5,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2016","2016",12.6,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2017","2017",11.9,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2018","2018",12.1,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2019","2019",12.4,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2020","2020",13.6,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2021","2021",14.8,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","ATCPTTMT","% of total sales","AUS","Australia","2010","2010",4.8,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","ATCPTTMT","% of total sales","AUS","Australia","2011","2011",4.8,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","ATCPTTMT","% of total sales","AUS","Australia","2012","2012",4.3,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","ATCPTTMT","% of total sales","AUS","Australia","2013","2013",4.4,"B; D","Break; Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","ATCPTTMT","% of total sales","AUS","Australia","2014","2014",3.9,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","ATCPTTMT","% of total sales","AUS","Australia","2015","2015",3.6,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","ATCPTTMT","% of total sales","AUS","Australia","2016","2016",2.9,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","ATCPTTMT","% of total sales","AUS","Australia","2017","2017",2.9,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","ATCPTTMT","% of total sales","AUS","Australia","2018","2018",3,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","ATCPTTMT","% of total sales","AUS","Australia","2019","2019",3,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","ATCPTTMT","% of total sales","AUS","Australia","2020","2020",3,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","ATCPTTMT","% of total sales","AUS","Australia","2021","2021",3.1,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","MLLNCUMT","Million of national currency units","AUT","Austria","2010","2010",94,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","MLLNCUMT","Million of national currency units","AUT","Austria","2011","2011",99.3,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","MLLNCUMT","Million of national currency units","AUT","Austria","2012","2012",103.2,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","MLLNCUMT","Million of national currency units","AUT","Austria","2013","2013",107.2,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","MLLNCUMT","Million of national currency units","AUT","Austria","2014","2014",109.5,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","MLLNCUMT","Million of national currency units","AUT","Austria","2015","2015",95.3,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","MLLNCUMT","Million of national currency units","AUT","Austria","2016","2016",85.5,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","MLLNCUMT","Million of national currency units","AUT","Austria","2017","2017",80.1,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","MLLNCUMT","Million of national currency units","AUT","Austria","2018","2018",77.2,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","MLLNCUMT","Million of national currency units","AUT","Austria","2019","2019",77,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","MLLNCUMT","Million of national currency units","AUT","Austria","2020","2020",75.7,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","MLLNCUMT","Million of national currency units","AUT","Austria","2021","2021",74.7,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","MTMOTCMT","Million US$ at exchange rate","AUT","Austria","2010","2010",124.6,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","MTMOTCMT","Million US$ at exchange rate","AUT","Austria","2011","2011",138.3,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","MTMOTCMT","Million US$ at exchange rate","AUT","Austria","2012","2012",132.6,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","MTMOTCMT","Million US$ at exchange rate","AUT","Austria","2013","2013",142.4,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","MTMOTCMT","Million US$ at exchange rate","AUT","Austria","2014","2014",145.5,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","MTMOTCMT","Million US$ at exchange rate","AUT","Austria","2015","2015",105.7,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","MTMOTCMT","Million US$ at exchange rate","AUT","Austria","2016","2016",94.6,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","MTMOTCMT","Million US$ at exchange rate","AUT","Austria","2017","2017",90.4,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","MTMOTCMT","Million US$ at exchange rate","AUT","Austria","2018","2018",91.2,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","MTMOTCMT","Million US$ at exchange rate","AUT","Austria","2019","2019",86.3,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","MTMOTCMT","Million US$ at exchange rate","AUT","Austria","2020","2020",86.5,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","MTMOTCMT","Million US$ at exchange rate","AUT","Austria","2021","2021",88.3,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","MTMOPPMT","Million US$, purchasing power parity","AUT","Austria","2010","2010",111.6,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","MTMOPPMT","Million US$, purchasing power parity","AUT","Austria","2011","2011",119.5,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","MTMOPPMT","Million US$, purchasing power parity","AUT","Austria","2012","2012",126.8,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","MTMOPPMT","Million US$, purchasing power parity","AUT","Austria","2013","2013",134.5,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","MTMOPPMT","Million US$, purchasing power parity","AUT","Austria","2014","2014",137.1,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","MTMOPPMT","Million US$, purchasing power parity","AUT","Austria","2015","2015",119.3,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","MTMOPPMT","Million US$, purchasing power parity","AUT","Austria","2016","2016",110,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","MTMOPPMT","Million US$, purchasing power parity","AUT","Austria","2017","2017",103.3,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","MTMOPPMT","Million US$, purchasing power parity","AUT","Austria","2018","2018",100.9,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","MTMOPPMT","Million US$, purchasing power parity","AUT","Austria","2019","2019",102.8,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","MTMOPPMT","Million US$, purchasing power parity","AUT","Austria","2020","2020",101.4,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","MTMOPPMT","Million US$, purchasing power parity","AUT","Austria","2021","2021",98.7,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","TCPPERMT","/capita, US$ exchange rate","AUT","Austria","2010","2010",14.9,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","TCPPERMT","/capita, US$ exchange rate","AUT","Austria","2011","2011",16.5,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","TCPPERMT","/capita, US$ exchange rate","AUT","Austria","2012","2012",15.7,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","TCPPERMT","/capita, US$ exchange rate","AUT","Austria","2013","2013",16.8,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","TCPPERMT","/capita, US$ exchange rate","AUT","Austria","2014","2014",17,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","TCPPERMT","/capita, US$ exchange rate","AUT","Austria","2015","2015",12.2,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","TCPPERMT","/capita, US$ exchange rate","AUT","Austria","2016","2016",10.8,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","TCPPERMT","/capita, US$ exchange rate","AUT","Austria","2017","2017",10.3,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","TCPPERMT","/capita, US$ exchange rate","AUT","Austria","2018","2018",10.3,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","TCPPERMT","/capita, US$ exchange rate","AUT","Austria","2019","2019",9.7,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","TCPPERMT","/capita, US$ exchange rate","AUT","Austria","2020","2020",9.7,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","TCPPERMT","/capita, US$ exchange rate","AUT","Austria","2021","2021",9.9,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2010","2010",13.3,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2011","2011",14.2,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2012","2012",15,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2013","2013",15.9,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2014","2014",16,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2015","2015",13.8,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2016","2016",12.6,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2017","2017",11.7,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2018","2018",11.4,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2019","2019",11.6,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2020","2020",11.4,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2021","2021",11,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","ATCPTTMT","% of total sales","AUT","Austria","2010","2010",3.8,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","ATCPTTMT","% of total sales","AUT","Austria","2011","2011",3.9,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","ATCPTTMT","% of total sales","AUT","Austria","2012","2012",3.9,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","ATCPTTMT","% of total sales","AUT","Austria","2013","2013",4.1,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","ATCPTTMT","% of total sales","AUT","Austria","2014","2014",3.9,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","ATCPTTMT","% of total sales","AUT","Austria","2015","2015",3.3,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","ATCPTTMT","% of total sales","AUT","Austria","2016","2016",2.8,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","ATCPTTMT","% of total sales","AUT","Austria","2017","2017",2.6,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","ATCPTTMT","% of total sales","AUT","Austria","2018","2018",2.4,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","ATCPTTMT","% of total sales","AUT","Austria","2019","2019",2.3,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","ATCPTTMT","% of total sales","AUT","Austria","2020","2020",2.2,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","ATCPTTMT","% of total sales","AUT","Austria","2021","2021",2,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","MLLNCUMT","Million of national currency units","BEL","Belgium","2010","2010",186.8,,
+"PATCDEPR","N06A-Antidepressants","MLLNCUMT","Million of national currency units","BEL","Belgium","2011","2011",188.6,,
+"PATCDEPR","N06A-Antidepressants","MLLNCUMT","Million of national currency units","BEL","Belgium","2012","2012",185.6,,
+"PATCDEPR","N06A-Antidepressants","MLLNCUMT","Million of national currency units","BEL","Belgium","2013","2013",181.3,,
+"PATCDEPR","N06A-Antidepressants","MLLNCUMT","Million of national currency units","BEL","Belgium","2014","2014",179.1,,
+"PATCDEPR","N06A-Antidepressants","MLLNCUMT","Million of national currency units","BEL","Belgium","2015","2015",155.6,,
+"PATCDEPR","N06A-Antidepressants","MLLNCUMT","Million of national currency units","BEL","Belgium","2016","2016",130.1,,
+"PATCDEPR","N06A-Antidepressants","MLLNCUMT","Million of national currency units","BEL","Belgium","2017","2017",125.3,,
+"PATCDEPR","N06A-Antidepressants","MLLNCUMT","Million of national currency units","BEL","Belgium","2018","2018",119.8,,
+"PATCDEPR","N06A-Antidepressants","MLLNCUMT","Million of national currency units","BEL","Belgium","2019","2019",122.8,,
+"PATCDEPR","N06A-Antidepressants","MLLNCUMT","Million of national currency units","BEL","Belgium","2020","2020",115.7,,
+"PATCDEPR","N06A-Antidepressants","MLLNCUMT","Million of national currency units","BEL","Belgium","2021","2021",113.6,,
+"PATCDEPR","N06A-Antidepressants","MLLNCUMT","Million of national currency units","BEL","Belgium","2022","2022",122.1,"E","Estimated value"
+"PATCDEPR","N06A-Antidepressants","MTMOTCMT","Million US$ at exchange rate","BEL","Belgium","2010","2010",247.6,,
+"PATCDEPR","N06A-Antidepressants","MTMOTCMT","Million US$ at exchange rate","BEL","Belgium","2011","2011",262.5,,
+"PATCDEPR","N06A-Antidepressants","MTMOTCMT","Million US$ at exchange rate","BEL","Belgium","2012","2012",238.4,,
+"PATCDEPR","N06A-Antidepressants","MTMOTCMT","Million US$ at exchange rate","BEL","Belgium","2013","2013",240.8,,
+"PATCDEPR","N06A-Antidepressants","MTMOTCMT","Million US$ at exchange rate","BEL","Belgium","2014","2014",238,,
+"PATCDEPR","N06A-Antidepressants","MTMOTCMT","Million US$ at exchange rate","BEL","Belgium","2015","2015",172.7,,
+"PATCDEPR","N06A-Antidepressants","MTMOTCMT","Million US$ at exchange rate","BEL","Belgium","2016","2016",144,,
+"PATCDEPR","N06A-Antidepressants","MTMOTCMT","Million US$ at exchange rate","BEL","Belgium","2017","2017",141.6,,
+"PATCDEPR","N06A-Antidepressants","MTMOTCMT","Million US$ at exchange rate","BEL","Belgium","2018","2018",141.5,,
+"PATCDEPR","N06A-Antidepressants","MTMOTCMT","Million US$ at exchange rate","BEL","Belgium","2019","2019",137.5,,
+"PATCDEPR","N06A-Antidepressants","MTMOTCMT","Million US$ at exchange rate","BEL","Belgium","2020","2020",132.2,,
+"PATCDEPR","N06A-Antidepressants","MTMOTCMT","Million US$ at exchange rate","BEL","Belgium","2021","2021",134.3,,
+"PATCDEPR","N06A-Antidepressants","MTMOTCMT","Million US$ at exchange rate","BEL","Belgium","2022","2022",128.5,"E","Estimated value"
+"PATCDEPR","N06A-Antidepressants","MTMOPPMT","Million US$, purchasing power parity","BEL","Belgium","2010","2010",223.2,,
+"PATCDEPR","N06A-Antidepressants","MTMOPPMT","Million US$, purchasing power parity","BEL","Belgium","2011","2011",226.7,,
+"PATCDEPR","N06A-Antidepressants","MTMOPPMT","Million US$, purchasing power parity","BEL","Belgium","2012","2012",225.7,,
+"PATCDEPR","N06A-Antidepressants","MTMOPPMT","Million US$, purchasing power parity","BEL","Belgium","2013","2013",224.9,,
+"PATCDEPR","N06A-Antidepressants","MTMOPPMT","Million US$, purchasing power parity","BEL","Belgium","2014","2014",223.8,,
+"PATCDEPR","N06A-Antidepressants","MTMOPPMT","Million US$, purchasing power parity","BEL","Belgium","2015","2015",194.5,,
+"PATCDEPR","N06A-Antidepressants","MTMOPPMT","Million US$, purchasing power parity","BEL","Belgium","2016","2016",166.5,,
+"PATCDEPR","N06A-Antidepressants","MTMOPPMT","Million US$, purchasing power parity","BEL","Belgium","2017","2017",161.5,,
+"PATCDEPR","N06A-Antidepressants","MTMOPPMT","Million US$, purchasing power parity","BEL","Belgium","2018","2018",156.3,,
+"PATCDEPR","N06A-Antidepressants","MTMOPPMT","Million US$, purchasing power parity","BEL","Belgium","2019","2019",164.5,,
+"PATCDEPR","N06A-Antidepressants","MTMOPPMT","Million US$, purchasing power parity","BEL","Belgium","2020","2020",158.5,,
+"PATCDEPR","N06A-Antidepressants","MTMOPPMT","Million US$, purchasing power parity","BEL","Belgium","2021","2021",154.2,,
+"PATCDEPR","N06A-Antidepressants","MTMOPPMT","Million US$, purchasing power parity","BEL","Belgium","2022","2022",171,"E","Estimated value"
+"PATCDEPR","N06A-Antidepressants","TCPPERMT","/capita, US$ exchange rate","BEL","Belgium","2010","2010",22.7,,
+"PATCDEPR","N06A-Antidepressants","TCPPERMT","/capita, US$ exchange rate","BEL","Belgium","2011","2011",23.8,,
+"PATCDEPR","N06A-Antidepressants","TCPPERMT","/capita, US$ exchange rate","BEL","Belgium","2012","2012",21.5,,
+"PATCDEPR","N06A-Antidepressants","TCPPERMT","/capita, US$ exchange rate","BEL","Belgium","2013","2013",21.6,,
+"PATCDEPR","N06A-Antidepressants","TCPPERMT","/capita, US$ exchange rate","BEL","Belgium","2014","2014",21.2,,
+"PATCDEPR","N06A-Antidepressants","TCPPERMT","/capita, US$ exchange rate","BEL","Belgium","2015","2015",15.3,,
+"PATCDEPR","N06A-Antidepressants","TCPPERMT","/capita, US$ exchange rate","BEL","Belgium","2016","2016",12.7,,
+"PATCDEPR","N06A-Antidepressants","TCPPERMT","/capita, US$ exchange rate","BEL","Belgium","2017","2017",12.4,,
+"PATCDEPR","N06A-Antidepressants","TCPPERMT","/capita, US$ exchange rate","BEL","Belgium","2018","2018",12.4,,
+"PATCDEPR","N06A-Antidepressants","TCPPERMT","/capita, US$ exchange rate","BEL","Belgium","2019","2019",12,,
+"PATCDEPR","N06A-Antidepressants","TCPPERMT","/capita, US$ exchange rate","BEL","Belgium","2020","2020",11.5,,
+"PATCDEPR","N06A-Antidepressants","TCPPERMT","/capita, US$ exchange rate","BEL","Belgium","2021","2021",11.6,,
+"PATCDEPR","N06A-Antidepressants","TCPPERMT","/capita, US$ exchange rate","BEL","Belgium","2022","2022",11.1,"E","Estimated value"
+"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2010","2010",20.5,,
+"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2011","2011",20.5,,
+"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2012","2012",20.3,,
+"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2013","2013",20.2,,
+"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2014","2014",20,,
+"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2015","2015",17.3,,
+"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2016","2016",14.7,,
+"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2017","2017",14.2,,
+"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2018","2018",13.7,,
+"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2019","2019",14.3,,
+"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2020","2020",13.7,,
+"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2021","2021",13.3,,
+"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2022","2022",14.7,"E","Estimated value"
+"PATCDEPR","N06A-Antidepressants","ATCPTTMT","% of total sales","BEL","Belgium","2010","2010",3.2,,
+"PATCDEPR","N06A-Antidepressants","ATCPTTMT","% of total sales","BEL","Belgium","2011","2011",3.1,,
+"PATCDEPR","N06A-Antidepressants","ATCPTTMT","% of total sales","BEL","Belgium","2012","2012",3.1,,
+"PATCDEPR","N06A-Antidepressants","ATCPTTMT","% of total sales","BEL","Belgium","2013","2013",3,,
+"PATCDEPR","N06A-Antidepressants","ATCPTTMT","% of total sales","BEL","Belgium","2014","2014",3,,
+"PATCDEPR","N06A-Antidepressants","ATCPTTMT","% of total sales","BEL","Belgium","2015","2015",2.5,,
+"PATCDEPR","N06A-Antidepressants","ATCPTTMT","% of total sales","BEL","Belgium","2016","2016",2.1,,
+"PATCDEPR","N06A-Antidepressants","ATCPTTMT","% of total sales","BEL","Belgium","2017","2017",1.9,,
+"PATCDEPR","N06A-Antidepressants","ATCPTTMT","% of total sales","BEL","Belgium","2018","2018",1.8,,
+"PATCDEPR","N06A-Antidepressants","ATCPTTMT","% of total sales","BEL","Belgium","2019","2019",1.7,,
+"PATCDEPR","N06A-Antidepressants","ATCPTTMT","% of total sales","BEL","Belgium","2020","2020",1.5,,
+"PATCDEPR","N06A-Antidepressants","ATCPTTMT","% of total sales","BEL","Belgium","2021","2021",1.4,,
+"PATCDEPR","N06A-Antidepressants","ATCPTTMT","% of total sales","BEL","Belgium","2022","2022",1.4,"E","Estimated value"
+"PATCDEPR","N06A-Antidepressants","MLLNCUMT","Million of national currency units","CAN","Canada","2012","2012",1444.2,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","MLLNCUMT","Million of national currency units","CAN","Canada","2013","2013",1456.4,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","MLLNCUMT","Million of national currency units","CAN","Canada","2014","2014",1496.5,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","MLLNCUMT","Million of national currency units","CAN","Canada","2015","2015",1432.9,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","MLLNCUMT","Million of national currency units","CAN","Canada","2016","2016",1418,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","MLLNCUMT","Million of national currency units","CAN","Canada","2017","2017",1391.7,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","MLLNCUMT","Million of national currency units","CAN","Canada","2018","2018",1283.2,"E; B; D","Estimated value; Break; Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","MLLNCUMT","Million of national currency units","CAN","Canada","2019","2019",1316.6,"E; D","Estimated value; Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","MLLNCUMT","Million of national currency units","CAN","Canada","2020","2020",1385.1,"E; D","Estimated value; Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","MLLNCUMT","Million of national currency units","CAN","Canada","2021","2021",1488.4,"E; D","Estimated value; Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","MLLNCUMT","Million of national currency units","CAN","Canada","2022","2022",1609.1,"E; D","Estimated value; Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","MTMOTCMT","Million US$ at exchange rate","CAN","Canada","2012","2012",1445.1,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","MTMOTCMT","Million US$ at exchange rate","CAN","Canada","2013","2013",1413.8,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","MTMOTCMT","Million US$ at exchange rate","CAN","Canada","2014","2014",1354.6,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","MTMOTCMT","Million US$ at exchange rate","CAN","Canada","2015","2015",1120.5,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","MTMOTCMT","Million US$ at exchange rate","CAN","Canada","2016","2016",1069.7,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","MTMOTCMT","Million US$ at exchange rate","CAN","Canada","2017","2017",1072.2,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","MTMOTCMT","Million US$ at exchange rate","CAN","Canada","2018","2018",990.3,"E; B; D","Estimated value; Break; Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","MTMOTCMT","Million US$ at exchange rate","CAN","Canada","2019","2019",992.3,"E; D","Estimated value; Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","MTMOTCMT","Million US$ at exchange rate","CAN","Canada","2020","2020",1032.7,"E; D","Estimated value; Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","MTMOTCMT","Million US$ at exchange rate","CAN","Canada","2021","2021",1187,"E; D","Estimated value; Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","MTMOTCMT","Million US$ at exchange rate","CAN","Canada","2022","2022",1236.3,"E; D","Estimated value; Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","MTMOPPMT","Million US$, purchasing power parity","CAN","Canada","2012","2012",1160.4,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","MTMOPPMT","Million US$, purchasing power parity","CAN","Canada","2013","2013",1189.9,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","MTMOPPMT","Million US$, purchasing power parity","CAN","Canada","2014","2014",1216.3,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","MTMOPPMT","Million US$, purchasing power parity","CAN","Canada","2015","2015",1148.1,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","MTMOPPMT","Million US$, purchasing power parity","CAN","Canada","2016","2016",1174.8,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","MTMOPPMT","Million US$, purchasing power parity","CAN","Canada","2017","2017",1148,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","MTMOPPMT","Million US$, purchasing power parity","CAN","Canada","2018","2018",1063.6,"E; B; D","Estimated value; Break; Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","MTMOPPMT","Million US$, purchasing power parity","CAN","Canada","2019","2019",1066.3,"E; D","Estimated value; Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","MTMOPPMT","Million US$, purchasing power parity","CAN","Canada","2020","2020",1125.1,"E; D","Estimated value; Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","MTMOPPMT","Million US$, purchasing power parity","CAN","Canada","2021","2021",1202.1,"E; D","Estimated value; Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","MTMOPPMT","Million US$, purchasing power parity","CAN","Canada","2022","2022",1283.4,"E; D","Estimated value; Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","TCPPERMT","/capita, US$ exchange rate","CAN","Canada","2012","2012",41.6,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","TCPPERMT","/capita, US$ exchange rate","CAN","Canada","2013","2013",40.3,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","TCPPERMT","/capita, US$ exchange rate","CAN","Canada","2014","2014",38.2,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","TCPPERMT","/capita, US$ exchange rate","CAN","Canada","2015","2015",31.4,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","TCPPERMT","/capita, US$ exchange rate","CAN","Canada","2016","2016",29.6,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","TCPPERMT","/capita, US$ exchange rate","CAN","Canada","2017","2017",29.3,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","TCPPERMT","/capita, US$ exchange rate","CAN","Canada","2018","2018",26.7,"E; B; D","Estimated value; Break; Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","TCPPERMT","/capita, US$ exchange rate","CAN","Canada","2019","2019",26.4,"E; D","Estimated value; Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","TCPPERMT","/capita, US$ exchange rate","CAN","Canada","2020","2020",27.2,"E; D","Estimated value; Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","TCPPERMT","/capita, US$ exchange rate","CAN","Canada","2021","2021",31,"E; D","Estimated value; Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","TCPPERMT","/capita, US$ exchange rate","CAN","Canada","2022","2022",31.8,"E; D","Estimated value; Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2012","2012",33.4,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2013","2013",33.9,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2014","2014",34.3,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2015","2015",32.2,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2016","2016",32.5,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2017","2017",31.4,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2018","2018",28.7,"E; B; D","Estimated value; Break; Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2019","2019",28.4,"E; D","Estimated value; Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2020","2020",29.6,"E; D","Estimated value; Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2021","2021",31.4,"E; D","Estimated value; Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2022","2022",33,"E; D","Estimated value; Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","ATCPTTMT","% of total sales","CAN","Canada","2012","2012",5.9,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","ATCPTTMT","% of total sales","CAN","Canada","2013","2013",5.9,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","ATCPTTMT","% of total sales","CAN","Canada","2014","2014",5.9,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","ATCPTTMT","% of total sales","CAN","Canada","2015","2015",5.3,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","ATCPTTMT","% of total sales","CAN","Canada","2016","2016",5,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","ATCPTTMT","% of total sales","CAN","Canada","2017","2017",4.7,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","ATCPTTMT","% of total sales","CAN","Canada","2018","2018",4.2,"E; B; D","Estimated value; Break; Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","ATCPTTMT","% of total sales","CAN","Canada","2019","2019",4.1,"E; D","Estimated value; Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","ATCPTTMT","% of total sales","CAN","Canada","2020","2020",4,"E; D","Estimated value; Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","ATCPTTMT","% of total sales","CAN","Canada","2021","2021",4,"E; D","Estimated value; Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","ATCPTTMT","% of total sales","CAN","Canada","2022","2022",4,"E; D","Estimated value; Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","MLLNCUMT","Million of national currency units","CZE","Czech Republic","2010","2010",1740.5,,
+"PATCDEPR","N06A-Antidepressants","MLLNCUMT","Million of national currency units","CZE","Czech Republic","2011","2011",1649.4,,
+"PATCDEPR","N06A-Antidepressants","MLLNCUMT","Million of national currency units","CZE","Czech Republic","2012","2012",1714.2,,
+"PATCDEPR","N06A-Antidepressants","MLLNCUMT","Million of national currency units","CZE","Czech Republic","2013","2013",1496.6,,
+"PATCDEPR","N06A-Antidepressants","MLLNCUMT","Million of national currency units","CZE","Czech Republic","2014","2014",1423,,
+"PATCDEPR","N06A-Antidepressants","MLLNCUMT","Million of national currency units","CZE","Czech Republic","2015","2015",1238.7,,
+"PATCDEPR","N06A-Antidepressants","MLLNCUMT","Million of national currency units","CZE","Czech Republic","2016","2016",1163.3,,
+"PATCDEPR","N06A-Antidepressants","MLLNCUMT","Million of national currency units","CZE","Czech Republic","2017","2017",1307.2,,
+"PATCDEPR","N06A-Antidepressants","MLLNCUMT","Million of national currency units","CZE","Czech Republic","2018","2018",1447,,
+"PATCDEPR","N06A-Antidepressants","MLLNCUMT","Million of national currency units","CZE","Czech Republic","2019","2019",1543.3,,
+"PATCDEPR","N06A-Antidepressants","MLLNCUMT","Million of national currency units","CZE","Czech Republic","2020","2020",1536.4,"B","Break"
+"PATCDEPR","N06A-Antidepressants","MLLNCUMT","Million of national currency units","CZE","Czech Republic","2021","2021",1621.3,,
+"PATCDEPR","N06A-Antidepressants","MTMOTCMT","Million US$ at exchange rate","CZE","Czech Republic","2010","2010",91.1,,
+"PATCDEPR","N06A-Antidepressants","MTMOTCMT","Million US$ at exchange rate","CZE","Czech Republic","2011","2011",93.2,,
+"PATCDEPR","N06A-Antidepressants","MTMOTCMT","Million US$ at exchange rate","CZE","Czech Republic","2012","2012",87.6,,
+"PATCDEPR","N06A-Antidepressants","MTMOTCMT","Million US$ at exchange rate","CZE","Czech Republic","2013","2013",76.5,,
+"PATCDEPR","N06A-Antidepressants","MTMOTCMT","Million US$ at exchange rate","CZE","Czech Republic","2014","2014",68.6,,
+"PATCDEPR","N06A-Antidepressants","MTMOTCMT","Million US$ at exchange rate","CZE","Czech Republic","2015","2015",50.4,,
+"PATCDEPR","N06A-Antidepressants","MTMOTCMT","Million US$ at exchange rate","CZE","Czech Republic","2016","2016",47.6,,
+"PATCDEPR","N06A-Antidepressants","MTMOTCMT","Million US$ at exchange rate","CZE","Czech Republic","2017","2017",55.9,,
+"PATCDEPR","N06A-Antidepressants","MTMOTCMT","Million US$ at exchange rate","CZE","Czech Republic","2018","2018",66.6,,
+"PATCDEPR","N06A-Antidepressants","MTMOTCMT","Million US$ at exchange rate","CZE","Czech Republic","2019","2019",67.3,,
+"PATCDEPR","N06A-Antidepressants","MTMOTCMT","Million US$ at exchange rate","CZE","Czech Republic","2020","2020",66.2,"B","Break"
+"PATCDEPR","N06A-Antidepressants","MTMOTCMT","Million US$ at exchange rate","CZE","Czech Republic","2021","2021",74.8,,
+"PATCDEPR","N06A-Antidepressants","MTMOPPMT","Million US$, purchasing power parity","CZE","Czech Republic","2010","2010",127.3,,
+"PATCDEPR","N06A-Antidepressants","MTMOPPMT","Million US$, purchasing power parity","CZE","Czech Republic","2011","2011",123.6,,
+"PATCDEPR","N06A-Antidepressants","MTMOPPMT","Million US$, purchasing power parity","CZE","Czech Republic","2012","2012",128.9,,
+"PATCDEPR","N06A-Antidepressants","MTMOPPMT","Million US$, purchasing power parity","CZE","Czech Republic","2013","2013",117.1,,
+"PATCDEPR","N06A-Antidepressants","MTMOPPMT","Million US$, purchasing power parity","CZE","Czech Republic","2014","2014",112,,
+"PATCDEPR","N06A-Antidepressants","MTMOPPMT","Million US$, purchasing power parity","CZE","Czech Republic","2015","2015",95.7,,
+"PATCDEPR","N06A-Antidepressants","MTMOPPMT","Million US$, purchasing power parity","CZE","Czech Republic","2016","2016",92.5,,
+"PATCDEPR","N06A-Antidepressants","MTMOPPMT","Million US$, purchasing power parity","CZE","Czech Republic","2017","2017",105.2,,
+"PATCDEPR","N06A-Antidepressants","MTMOPPMT","Million US$, purchasing power parity","CZE","Czech Republic","2018","2018",117,,
+"PATCDEPR","N06A-Antidepressants","MTMOPPMT","Million US$, purchasing power parity","CZE","Czech Republic","2019","2019",125.7,,
+"PATCDEPR","N06A-Antidepressants","MTMOPPMT","Million US$, purchasing power parity","CZE","Czech Republic","2020","2020",123.3,"B","Break"
+"PATCDEPR","N06A-Antidepressants","MTMOPPMT","Million US$, purchasing power parity","CZE","Czech Republic","2021","2021",127.2,,
+"PATCDEPR","N06A-Antidepressants","TCPPERMT","/capita, US$ exchange rate","CZE","Czech Republic","2010","2010",8.7,,
+"PATCDEPR","N06A-Antidepressants","TCPPERMT","/capita, US$ exchange rate","CZE","Czech Republic","2011","2011",8.9,,
+"PATCDEPR","N06A-Antidepressants","TCPPERMT","/capita, US$ exchange rate","CZE","Czech Republic","2012","2012",8.3,,
+"PATCDEPR","N06A-Antidepressants","TCPPERMT","/capita, US$ exchange rate","CZE","Czech Republic","2013","2013",7.3,,
+"PATCDEPR","N06A-Antidepressants","TCPPERMT","/capita, US$ exchange rate","CZE","Czech Republic","2014","2014",6.5,,
+"PATCDEPR","N06A-Antidepressants","TCPPERMT","/capita, US$ exchange rate","CZE","Czech Republic","2015","2015",4.8,,
+"PATCDEPR","N06A-Antidepressants","TCPPERMT","/capita, US$ exchange rate","CZE","Czech Republic","2016","2016",4.5,,
+"PATCDEPR","N06A-Antidepressants","TCPPERMT","/capita, US$ exchange rate","CZE","Czech Republic","2017","2017",5.3,,
+"PATCDEPR","N06A-Antidepressants","TCPPERMT","/capita, US$ exchange rate","CZE","Czech Republic","2018","2018",6.3,,
+"PATCDEPR","N06A-Antidepressants","TCPPERMT","/capita, US$ exchange rate","CZE","Czech Republic","2019","2019",6.3,,
+"PATCDEPR","N06A-Antidepressants","TCPPERMT","/capita, US$ exchange rate","CZE","Czech Republic","2020","2020",6.2,"B","Break"
+"PATCDEPR","N06A-Antidepressants","TCPPERMT","/capita, US$ exchange rate","CZE","Czech Republic","2021","2021",7.1,,
+"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czech Republic","2010","2010",12.2,,
+"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czech Republic","2011","2011",11.8,,
+"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czech Republic","2012","2012",12.3,,
+"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czech Republic","2013","2013",11.1,,
+"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czech Republic","2014","2014",10.6,,
+"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czech Republic","2015","2015",9.1,,
+"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czech Republic","2016","2016",8.8,,
+"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czech Republic","2017","2017",9.9,,
+"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czech Republic","2018","2018",11,,
+"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czech Republic","2019","2019",11.8,,
+"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czech Republic","2020","2020",11.5,"B","Break"
+"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czech Republic","2021","2021",12.1,,
+"PATCDEPR","N06A-Antidepressants","ATCPTTMT","% of total sales","CZE","Czech Republic","2010","2010",2.1,,
+"PATCDEPR","N06A-Antidepressants","ATCPTTMT","% of total sales","CZE","Czech Republic","2011","2011",2,,
+"PATCDEPR","N06A-Antidepressants","ATCPTTMT","% of total sales","CZE","Czech Republic","2012","2012",2,,
+"PATCDEPR","N06A-Antidepressants","ATCPTTMT","% of total sales","CZE","Czech Republic","2013","2013",1.9,,
+"PATCDEPR","N06A-Antidepressants","ATCPTTMT","% of total sales","CZE","Czech Republic","2014","2014",1.8,,
+"PATCDEPR","N06A-Antidepressants","ATCPTTMT","% of total sales","CZE","Czech Republic","2015","2015",1.5,,
+"PATCDEPR","N06A-Antidepressants","ATCPTTMT","% of total sales","CZE","Czech Republic","2016","2016",1.3,,
+"PATCDEPR","N06A-Antidepressants","ATCPTTMT","% of total sales","CZE","Czech Republic","2017","2017",1.4,,
+"PATCDEPR","N06A-Antidepressants","ATCPTTMT","% of total sales","CZE","Czech Republic","2018","2018",1.5,,
+"PATCDEPR","N06A-Antidepressants","ATCPTTMT","% of total sales","CZE","Czech Republic","2019","2019",1.5,,
+"PATCDEPR","N06A-Antidepressants","ATCPTTMT","% of total sales","CZE","Czech Republic","2020","2020",1.8,"B","Break"
+"PATCDEPR","N06A-Antidepressants","ATCPTTMT","% of total sales","CZE","Czech Republic","2021","2021",1.7,,
+"PATCDEPR","N06A-Antidepressants","MLLNCUMT","Million of national currency units","FIN","Finland","2010","2010",31.7,,
+"PATCDEPR","N06A-Antidepressants","MLLNCUMT","Million of national currency units","FIN","Finland","2011","2011",29.4,,
+"PATCDEPR","N06A-Antidepressants","MLLNCUMT","Million of national currency units","FIN","Finland","2012","2012",29.5,,
+"PATCDEPR","N06A-Antidepressants","MLLNCUMT","Million of national currency units","FIN","Finland","2013","2013",30.8,,
+"PATCDEPR","N06A-Antidepressants","MLLNCUMT","Million of national currency units","FIN","Finland","2014","2014",32.9,,
+"PATCDEPR","N06A-Antidepressants","MLLNCUMT","Million of national currency units","FIN","Finland","2015","2015",32.1,,
+"PATCDEPR","N06A-Antidepressants","MLLNCUMT","Million of national currency units","FIN","Finland","2016","2016",30.8,,
+"PATCDEPR","N06A-Antidepressants","MLLNCUMT","Million of national currency units","FIN","Finland","2017","2017",30.3,,
+"PATCDEPR","N06A-Antidepressants","MLLNCUMT","Million of national currency units","FIN","Finland","2018","2018",31.4,,
+"PATCDEPR","N06A-Antidepressants","MLLNCUMT","Million of national currency units","FIN","Finland","2019","2019",33.5,,
+"PATCDEPR","N06A-Antidepressants","MLLNCUMT","Million of national currency units","FIN","Finland","2020","2020",36,,
+"PATCDEPR","N06A-Antidepressants","MLLNCUMT","Million of national currency units","FIN","Finland","2021","2021",38.2,,
+"PATCDEPR","N06A-Antidepressants","MTMOTCMT","Million US$ at exchange rate","FIN","Finland","2010","2010",42,,
+"PATCDEPR","N06A-Antidepressants","MTMOTCMT","Million US$ at exchange rate","FIN","Finland","2011","2011",40.9,,
+"PATCDEPR","N06A-Antidepressants","MTMOTCMT","Million US$ at exchange rate","FIN","Finland","2012","2012",37.9,,
+"PATCDEPR","N06A-Antidepressants","MTMOTCMT","Million US$ at exchange rate","FIN","Finland","2013","2013",40.9,,
+"PATCDEPR","N06A-Antidepressants","MTMOTCMT","Million US$ at exchange rate","FIN","Finland","2014","2014",43.7,,
+"PATCDEPR","N06A-Antidepressants","MTMOTCMT","Million US$ at exchange rate","FIN","Finland","2015","2015",35.6,,
+"PATCDEPR","N06A-Antidepressants","MTMOTCMT","Million US$ at exchange rate","FIN","Finland","2016","2016",34.1,,
+"PATCDEPR","N06A-Antidepressants","MTMOTCMT","Million US$ at exchange rate","FIN","Finland","2017","2017",34.2,,
+"PATCDEPR","N06A-Antidepressants","MTMOTCMT","Million US$ at exchange rate","FIN","Finland","2018","2018",37.1,,
+"PATCDEPR","N06A-Antidepressants","MTMOTCMT","Million US$ at exchange rate","FIN","Finland","2019","2019",37.5,,
+"PATCDEPR","N06A-Antidepressants","MTMOTCMT","Million US$ at exchange rate","FIN","Finland","2020","2020",41.1,,
+"PATCDEPR","N06A-Antidepressants","MTMOTCMT","Million US$ at exchange rate","FIN","Finland","2021","2021",45.2,,
+"PATCDEPR","N06A-Antidepressants","MTMOPPMT","Million US$, purchasing power parity","FIN","Finland","2010","2010",35.2,,
+"PATCDEPR","N06A-Antidepressants","MTMOPPMT","Million US$, purchasing power parity","FIN","Finland","2011","2011",32.7,,
+"PATCDEPR","N06A-Antidepressants","MTMOPPMT","Million US$, purchasing power parity","FIN","Finland","2012","2012",32.5,,
+"PATCDEPR","N06A-Antidepressants","MTMOPPMT","Million US$, purchasing power parity","FIN","Finland","2013","2013",34,,
+"PATCDEPR","N06A-Antidepressants","MTMOPPMT","Million US$, purchasing power parity","FIN","Finland","2014","2014",36.3,,
+"PATCDEPR","N06A-Antidepressants","MTMOPPMT","Million US$, purchasing power parity","FIN","Finland","2015","2015",35.4,,
+"PATCDEPR","N06A-Antidepressants","MTMOPPMT","Million US$, purchasing power parity","FIN","Finland","2016","2016",35,,
+"PATCDEPR","N06A-Antidepressants","MTMOPPMT","Million US$, purchasing power parity","FIN","Finland","2017","2017",35.1,,
+"PATCDEPR","N06A-Antidepressants","MTMOPPMT","Million US$, purchasing power parity","FIN","Finland","2018","2018",36.8,,
+"PATCDEPR","N06A-Antidepressants","MTMOPPMT","Million US$, purchasing power parity","FIN","Finland","2019","2019",40,,
+"PATCDEPR","N06A-Antidepressants","MTMOPPMT","Million US$, purchasing power parity","FIN","Finland","2020","2020",43.7,,
+"PATCDEPR","N06A-Antidepressants","MTMOPPMT","Million US$, purchasing power parity","FIN","Finland","2021","2021",46.2,,
+"PATCDEPR","N06A-Antidepressants","TCPPERMT","/capita, US$ exchange rate","FIN","Finland","2010","2010",7.8,,
+"PATCDEPR","N06A-Antidepressants","TCPPERMT","/capita, US$ exchange rate","FIN","Finland","2011","2011",7.6,,
+"PATCDEPR","N06A-Antidepressants","TCPPERMT","/capita, US$ exchange rate","FIN","Finland","2012","2012",7,,
+"PATCDEPR","N06A-Antidepressants","TCPPERMT","/capita, US$ exchange rate","FIN","Finland","2013","2013",7.5,,
+"PATCDEPR","N06A-Antidepressants","TCPPERMT","/capita, US$ exchange rate","FIN","Finland","2014","2014",8,,
+"PATCDEPR","N06A-Antidepressants","TCPPERMT","/capita, US$ exchange rate","FIN","Finland","2015","2015",6.5,,
+"PATCDEPR","N06A-Antidepressants","TCPPERMT","/capita, US$ exchange rate","FIN","Finland","2016","2016",6.2,,
+"PATCDEPR","N06A-Antidepressants","TCPPERMT","/capita, US$ exchange rate","FIN","Finland","2017","2017",6.2,,
+"PATCDEPR","N06A-Antidepressants","TCPPERMT","/capita, US$ exchange rate","FIN","Finland","2018","2018",6.7,,
+"PATCDEPR","N06A-Antidepressants","TCPPERMT","/capita, US$ exchange rate","FIN","Finland","2019","2019",6.8,,
+"PATCDEPR","N06A-Antidepressants","TCPPERMT","/capita, US$ exchange rate","FIN","Finland","2020","2020",7.4,,
+"PATCDEPR","N06A-Antidepressants","TCPPERMT","/capita, US$ exchange rate","FIN","Finland","2021","2021",8.2,,
+"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2010","2010",6.6,,
+"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2011","2011",6.1,,
+"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2012","2012",6,,
+"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2013","2013",6.3,,
+"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2014","2014",6.6,,
+"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2015","2015",6.5,,
+"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2016","2016",6.4,,
+"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2017","2017",6.4,,
+"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2018","2018",6.7,,
+"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2019","2019",7.2,,
+"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2020","2020",7.9,,
+"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2021","2021",8.3,,
+"PATCDEPR","N06A-Antidepressants","ATCPTTMT","% of total sales","FIN","Finland","2010","2010",1.7,,
+"PATCDEPR","N06A-Antidepressants","ATCPTTMT","% of total sales","FIN","Finland","2011","2011",1.5,,
+"PATCDEPR","N06A-Antidepressants","ATCPTTMT","% of total sales","FIN","Finland","2012","2012",1.5,,
+"PATCDEPR","N06A-Antidepressants","ATCPTTMT","% of total sales","FIN","Finland","2013","2013",1.5,,
+"PATCDEPR","N06A-Antidepressants","ATCPTTMT","% of total sales","FIN","Finland","2014","2014",1.6,,
+"PATCDEPR","N06A-Antidepressants","ATCPTTMT","% of total sales","FIN","Finland","2015","2015",1.5,,
+"PATCDEPR","N06A-Antidepressants","ATCPTTMT","% of total sales","FIN","Finland","2016","2016",1.3,,
+"PATCDEPR","N06A-Antidepressants","ATCPTTMT","% of total sales","FIN","Finland","2017","2017",1.3,,
+"PATCDEPR","N06A-Antidepressants","ATCPTTMT","% of total sales","FIN","Finland","2018","2018",1.3,,
+"PATCDEPR","N06A-Antidepressants","ATCPTTMT","% of total sales","FIN","Finland","2019","2019",1.3,,
+"PATCDEPR","N06A-Antidepressants","ATCPTTMT","% of total sales","FIN","Finland","2020","2020",1.3,,
+"PATCDEPR","N06A-Antidepressants","ATCPTTMT","% of total sales","FIN","Finland","2021","2021",1.3,,
+"PATCDEPR","N06A-Antidepressants","MLLNCUMT","Million of national currency units","DEU","Germany","2010","2010",798.5,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","MLLNCUMT","Million of national currency units","DEU","Germany","2011","2011",765.4,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","MLLNCUMT","Million of national currency units","DEU","Germany","2012","2012",746.5,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","MLLNCUMT","Million of national currency units","DEU","Germany","2013","2013",791.7,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","MLLNCUMT","Million of national currency units","DEU","Germany","2014","2014",832.6,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","MLLNCUMT","Million of national currency units","DEU","Germany","2015","2015",805.8,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","MLLNCUMT","Million of national currency units","DEU","Germany","2016","2016",759.1,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","MLLNCUMT","Million of national currency units","DEU","Germany","2017","2017",702.5,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","MLLNCUMT","Million of national currency units","DEU","Germany","2018","2018",716.7,"B; D","Break; Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","MLLNCUMT","Million of national currency units","DEU","Germany","2019","2019",737.1,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","MLLNCUMT","Million of national currency units","DEU","Germany","2020","2020",711,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","MLLNCUMT","Million of national currency units","DEU","Germany","2021","2021",714,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","MTMOTCMT","Million US$ at exchange rate","DEU","Germany","2010","2010",1058.6,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","MTMOTCMT","Million US$ at exchange rate","DEU","Germany","2011","2011",1065.4,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","MTMOTCMT","Million US$ at exchange rate","DEU","Germany","2012","2012",959.1,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","MTMOTCMT","Million US$ at exchange rate","DEU","Germany","2013","2013",1051.5,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","MTMOTCMT","Million US$ at exchange rate","DEU","Germany","2014","2014",1106.1,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","MTMOTCMT","Million US$ at exchange rate","DEU","Germany","2015","2015",894,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","MTMOTCMT","Million US$ at exchange rate","DEU","Germany","2016","2016",840.3,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","MTMOTCMT","Million US$ at exchange rate","DEU","Germany","2017","2017",793.6,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","MTMOTCMT","Million US$ at exchange rate","DEU","Germany","2018","2018",846.4,"B; D","Break; Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","MTMOTCMT","Million US$ at exchange rate","DEU","Germany","2019","2019",825.2,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","MTMOTCMT","Million US$ at exchange rate","DEU","Germany","2020","2020",812.1,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","MTMOTCMT","Million US$ at exchange rate","DEU","Germany","2021","2021",844.5,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","MTMOPPMT","Million US$, purchasing power parity","DEU","Germany","2010","2010",991.8,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","MTMOPPMT","Million US$, purchasing power parity","DEU","Germany","2011","2011",970.4,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","MTMOPPMT","Million US$, purchasing power parity","DEU","Germany","2012","2012",948.2,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","MTMOPPMT","Million US$, purchasing power parity","DEU","Germany","2013","2013",1021.8,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","MTMOPPMT","Million US$, purchasing power parity","DEU","Germany","2014","2014",1082.8,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","MTMOPPMT","Million US$, purchasing power parity","DEU","Germany","2015","2015",1035.6,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","MTMOPPMT","Million US$, purchasing power parity","DEU","Germany","2016","2016",1008.6,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","MTMOPPMT","Million US$, purchasing power parity","DEU","Germany","2017","2017",943.2,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","MTMOPPMT","Million US$, purchasing power parity","DEU","Germany","2018","2018",974.5,"B; D","Break; Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","MTMOPPMT","Million US$, purchasing power parity","DEU","Germany","2019","2019",1012.2,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","MTMOPPMT","Million US$, purchasing power parity","DEU","Germany","2020","2020",980.7,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","MTMOPPMT","Million US$, purchasing power parity","DEU","Germany","2021","2021",969.7,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","TCPPERMT","/capita, US$ exchange rate","DEU","Germany","2010","2010",12.9,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","TCPPERMT","/capita, US$ exchange rate","DEU","Germany","2011","2011",13.3,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","TCPPERMT","/capita, US$ exchange rate","DEU","Germany","2012","2012",11.9,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","TCPPERMT","/capita, US$ exchange rate","DEU","Germany","2013","2013",13,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","TCPPERMT","/capita, US$ exchange rate","DEU","Germany","2014","2014",13.7,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","TCPPERMT","/capita, US$ exchange rate","DEU","Germany","2015","2015",10.9,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","TCPPERMT","/capita, US$ exchange rate","DEU","Germany","2016","2016",10.2,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","TCPPERMT","/capita, US$ exchange rate","DEU","Germany","2017","2017",9.6,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","TCPPERMT","/capita, US$ exchange rate","DEU","Germany","2018","2018",10.2,"B; D","Break; Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","TCPPERMT","/capita, US$ exchange rate","DEU","Germany","2019","2019",9.9,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","TCPPERMT","/capita, US$ exchange rate","DEU","Germany","2020","2020",9.8,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","TCPPERMT","/capita, US$ exchange rate","DEU","Germany","2021","2021",10.2,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2010","2010",12.1,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2011","2011",12.1,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2012","2012",11.8,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2013","2013",12.7,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2014","2014",13.4,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2015","2015",12.7,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2016","2016",12.2,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2017","2017",11.4,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2018","2018",11.8,"B; D","Break; Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2019","2019",12.2,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2020","2020",11.8,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2021","2021",11.7,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","ATCPTTMT","% of total sales","DEU","Germany","2010","2010",2.7,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","ATCPTTMT","% of total sales","DEU","Germany","2011","2011",2.6,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","ATCPTTMT","% of total sales","DEU","Germany","2012","2012",2.5,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","ATCPTTMT","% of total sales","DEU","Germany","2013","2013",2.5,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","ATCPTTMT","% of total sales","DEU","Germany","2014","2014",2.5,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","ATCPTTMT","% of total sales","DEU","Germany","2015","2015",2.3,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","ATCPTTMT","% of total sales","DEU","Germany","2016","2016",2.1,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","ATCPTTMT","% of total sales","DEU","Germany","2017","2017",1.9,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","ATCPTTMT","% of total sales","DEU","Germany","2018","2018",1.6,"B; D","Break; Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","ATCPTTMT","% of total sales","DEU","Germany","2019","2019",1.6,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","ATCPTTMT","% of total sales","DEU","Germany","2020","2020",1.4,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","ATCPTTMT","% of total sales","DEU","Germany","2021","2021",1.3,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","MLLNCUMT","Million of national currency units","GRC","Greece","2010","2010",186.6,,
+"PATCDEPR","N06A-Antidepressants","MLLNCUMT","Million of national currency units","GRC","Greece","2011","2011",156.1,,
+"PATCDEPR","N06A-Antidepressants","MLLNCUMT","Million of national currency units","GRC","Greece","2012","2012",137,,
+"PATCDEPR","N06A-Antidepressants","MLLNCUMT","Million of national currency units","GRC","Greece","2013","2013",134.9,,
+"PATCDEPR","N06A-Antidepressants","MLLNCUMT","Million of national currency units","GRC","Greece","2014","2014",119.2,,
+"PATCDEPR","N06A-Antidepressants","MLLNCUMT","Million of national currency units","GRC","Greece","2015","2015",105.3,,
+"PATCDEPR","N06A-Antidepressants","MLLNCUMT","Million of national currency units","GRC","Greece","2016","2016",107.6,,
+"PATCDEPR","N06A-Antidepressants","MLLNCUMT","Million of national currency units","GRC","Greece","2017","2017",100,,
+"PATCDEPR","N06A-Antidepressants","MLLNCUMT","Million of national currency units","GRC","Greece","2018","2018",106.2,,
+"PATCDEPR","N06A-Antidepressants","MLLNCUMT","Million of national currency units","GRC","Greece","2019","2019",110.9,,
+"PATCDEPR","N06A-Antidepressants","MLLNCUMT","Million of national currency units","GRC","Greece","2020","2020",113.3,,
+"PATCDEPR","N06A-Antidepressants","MLLNCUMT","Million of national currency units","GRC","Greece","2021","2021",114,,
+"PATCDEPR","N06A-Antidepressants","MLLNCUMT","Million of national currency units","GRC","Greece","2022","2022",93.9,,
+"PATCDEPR","N06A-Antidepressants","MTMOTCMT","Million US$ at exchange rate","GRC","Greece","2010","2010",247.4,,
+"PATCDEPR","N06A-Antidepressants","MTMOTCMT","Million US$ at exchange rate","GRC","Greece","2011","2011",217.3,,
+"PATCDEPR","N06A-Antidepressants","MTMOTCMT","Million US$ at exchange rate","GRC","Greece","2012","2012",176,,
+"PATCDEPR","N06A-Antidepressants","MTMOTCMT","Million US$ at exchange rate","GRC","Greece","2013","2013",179.2,,
+"PATCDEPR","N06A-Antidepressants","MTMOTCMT","Million US$ at exchange rate","GRC","Greece","2014","2014",158.4,,
+"PATCDEPR","N06A-Antidepressants","MTMOTCMT","Million US$ at exchange rate","GRC","Greece","2015","2015",116.8,,
+"PATCDEPR","N06A-Antidepressants","MTMOTCMT","Million US$ at exchange rate","GRC","Greece","2016","2016",119.1,,
+"PATCDEPR","N06A-Antidepressants","MTMOTCMT","Million US$ at exchange rate","GRC","Greece","2017","2017",112.9,,
+"PATCDEPR","N06A-Antidepressants","MTMOTCMT","Million US$ at exchange rate","GRC","Greece","2018","2018",125.4,,
+"PATCDEPR","N06A-Antidepressants","MTMOTCMT","Million US$ at exchange rate","GRC","Greece","2019","2019",124.2,,
+"PATCDEPR","N06A-Antidepressants","MTMOTCMT","Million US$ at exchange rate","GRC","Greece","2020","2020",129.4,,
+"PATCDEPR","N06A-Antidepressants","MTMOTCMT","Million US$ at exchange rate","GRC","Greece","2021","2021",134.8,,
+"PATCDEPR","N06A-Antidepressants","MTMOTCMT","Million US$ at exchange rate","GRC","Greece","2022","2022",98.9,,
+"PATCDEPR","N06A-Antidepressants","MTMOPPMT","Million US$, purchasing power parity","GRC","Greece","2010","2010",258.4,,
+"PATCDEPR","N06A-Antidepressants","MTMOPPMT","Million US$, purchasing power parity","GRC","Greece","2011","2011",218.9,,
+"PATCDEPR","N06A-Antidepressants","MTMOPPMT","Million US$, purchasing power parity","GRC","Greece","2012","2012",200,,
+"PATCDEPR","N06A-Antidepressants","MTMOPPMT","Million US$, purchasing power parity","GRC","Greece","2013","2013",213.8,,
+"PATCDEPR","N06A-Antidepressants","MTMOPPMT","Million US$, purchasing power parity","GRC","Greece","2014","2014",195.1,,
+"PATCDEPR","N06A-Antidepressants","MTMOPPMT","Million US$, purchasing power parity","GRC","Greece","2015","2015",172.9,,
+"PATCDEPR","N06A-Antidepressants","MTMOPPMT","Million US$, purchasing power parity","GRC","Greece","2016","2016",182.8,,
+"PATCDEPR","N06A-Antidepressants","MTMOPPMT","Million US$, purchasing power parity","GRC","Greece","2017","2017",173.8,,
+"PATCDEPR","N06A-Antidepressants","MTMOPPMT","Million US$, purchasing power parity","GRC","Greece","2018","2018",188,,
+"PATCDEPR","N06A-Antidepressants","MTMOPPMT","Million US$, purchasing power parity","GRC","Greece","2019","2019",202.1,,
+"PATCDEPR","N06A-Antidepressants","MTMOPPMT","Million US$, purchasing power parity","GRC","Greece","2020","2020",208.2,,
+"PATCDEPR","N06A-Antidepressants","MTMOPPMT","Million US$, purchasing power parity","GRC","Greece","2021","2021",208.9,,
+"PATCDEPR","N06A-Antidepressants","MTMOPPMT","Million US$, purchasing power parity","GRC","Greece","2022","2022",177.6,,
+"PATCDEPR","N06A-Antidepressants","TCPPERMT","/capita, US$ exchange rate","GRC","Greece","2010","2010",22.2,,
+"PATCDEPR","N06A-Antidepressants","TCPPERMT","/capita, US$ exchange rate","GRC","Greece","2011","2011",19.6,,
+"PATCDEPR","N06A-Antidepressants","TCPPERMT","/capita, US$ exchange rate","GRC","Greece","2012","2012",15.9,,
+"PATCDEPR","N06A-Antidepressants","TCPPERMT","/capita, US$ exchange rate","GRC","Greece","2013","2013",16.3,,
+"PATCDEPR","N06A-Antidepressants","TCPPERMT","/capita, US$ exchange rate","GRC","Greece","2014","2014",14.5,,
+"PATCDEPR","N06A-Antidepressants","TCPPERMT","/capita, US$ exchange rate","GRC","Greece","2015","2015",10.8,,
+"PATCDEPR","N06A-Antidepressants","TCPPERMT","/capita, US$ exchange rate","GRC","Greece","2016","2016",11.1,,
+"PATCDEPR","N06A-Antidepressants","TCPPERMT","/capita, US$ exchange rate","GRC","Greece","2017","2017",10.5,,
+"PATCDEPR","N06A-Antidepressants","TCPPERMT","/capita, US$ exchange rate","GRC","Greece","2018","2018",11.7,,
+"PATCDEPR","N06A-Antidepressants","TCPPERMT","/capita, US$ exchange rate","GRC","Greece","2019","2019",11.6,,
+"PATCDEPR","N06A-Antidepressants","TCPPERMT","/capita, US$ exchange rate","GRC","Greece","2020","2020",12.1,,
+"PATCDEPR","N06A-Antidepressants","TCPPERMT","/capita, US$ exchange rate","GRC","Greece","2021","2021",12.8,,
+"PATCDEPR","N06A-Antidepressants","TCPPERMT","/capita, US$ exchange rate","GRC","Greece","2022","2022",9.5,,
+"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2010","2010",23.2,,
+"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2011","2011",19.7,,
+"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2012","2012",18.1,,
+"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2013","2013",19.5,,
+"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2014","2014",17.9,,
+"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2015","2015",16,,
+"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2016","2016",17,,
+"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2017","2017",16.2,,
+"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2018","2018",17.5,,
+"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2019","2019",18.9,,
+"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2020","2020",19.5,,
+"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2021","2021",19.8,,
+"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2022","2022",17,,
+"PATCDEPR","N06A-Antidepressants","MLLNCUMT","Million of national currency units","HUN","Hungary","2010","2010",11947.1,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","MLLNCUMT","Million of national currency units","HUN","Hungary","2011","2011",12569.5,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","MLLNCUMT","Million of national currency units","HUN","Hungary","2012","2012",11070.4,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","MLLNCUMT","Million of national currency units","HUN","Hungary","2013","2013",10723.6,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","MLLNCUMT","Million of national currency units","HUN","Hungary","2014","2014",10500.3,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","MLLNCUMT","Million of national currency units","HUN","Hungary","2015","2015",9404.9,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","MLLNCUMT","Million of national currency units","HUN","Hungary","2016","2016",8047.7,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","MLLNCUMT","Million of national currency units","HUN","Hungary","2017","2017",8013.6,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","MLLNCUMT","Million of national currency units","HUN","Hungary","2018","2018",8189.1,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","MLLNCUMT","Million of national currency units","HUN","Hungary","2019","2019",8103.7,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","MLLNCUMT","Million of national currency units","HUN","Hungary","2020","2020",7985.7,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","MLLNCUMT","Million of national currency units","HUN","Hungary","2021","2021",7905.7,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","MLLNCUMT","Million of national currency units","HUN","Hungary","2022","2022",8264,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","MTMOTCMT","Million US$ at exchange rate","HUN","Hungary","2010","2010",57.5,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","MTMOTCMT","Million US$ at exchange rate","HUN","Hungary","2011","2011",62.5,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","MTMOTCMT","Million US$ at exchange rate","HUN","Hungary","2012","2012",49.2,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","MTMOTCMT","Million US$ at exchange rate","HUN","Hungary","2013","2013",47.9,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","MTMOTCMT","Million US$ at exchange rate","HUN","Hungary","2014","2014",45.1,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","MTMOTCMT","Million US$ at exchange rate","HUN","Hungary","2015","2015",33.7,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","MTMOTCMT","Million US$ at exchange rate","HUN","Hungary","2016","2016",28.6,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","MTMOTCMT","Million US$ at exchange rate","HUN","Hungary","2017","2017",29.2,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","MTMOTCMT","Million US$ at exchange rate","HUN","Hungary","2018","2018",30.3,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","MTMOTCMT","Million US$ at exchange rate","HUN","Hungary","2019","2019",27.9,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","MTMOTCMT","Million US$ at exchange rate","HUN","Hungary","2020","2020",25.9,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","MTMOTCMT","Million US$ at exchange rate","HUN","Hungary","2021","2021",26.1,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","MTMOTCMT","Million US$ at exchange rate","HUN","Hungary","2022","2022",22.2,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","MTMOPPMT","Million US$, purchasing power parity","HUN","Hungary","2010","2010",94.5,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","MTMOPPMT","Million US$, purchasing power parity","HUN","Hungary","2011","2011",101.1,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","MTMOPPMT","Million US$, purchasing power parity","HUN","Hungary","2012","2012",88.1,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","MTMOPPMT","Million US$, purchasing power parity","HUN","Hungary","2013","2013",85.8,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","MTMOPPMT","Million US$, purchasing power parity","HUN","Hungary","2014","2014",81.1,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","MTMOPPMT","Million US$, purchasing power parity","HUN","Hungary","2015","2015",71,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","MTMOPPMT","Million US$, purchasing power parity","HUN","Hungary","2016","2016",61,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","MTMOPPMT","Million US$, purchasing power parity","HUN","Hungary","2017","2017",58.9,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","MTMOPPMT","Million US$, purchasing power parity","HUN","Hungary","2018","2018",58.9,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","MTMOPPMT","Million US$, purchasing power parity","HUN","Hungary","2019","2019",57.5,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","MTMOPPMT","Million US$, purchasing power parity","HUN","Hungary","2020","2020",54.9,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","MTMOPPMT","Million US$, purchasing power parity","HUN","Hungary","2021","2021",51.1,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","MTMOPPMT","Million US$, purchasing power parity","HUN","Hungary","2022","2022",51.3,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","TCPPERMT","/capita, US$ exchange rate","HUN","Hungary","2010","2010",5.7,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","TCPPERMT","/capita, US$ exchange rate","HUN","Hungary","2011","2011",6.3,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","TCPPERMT","/capita, US$ exchange rate","HUN","Hungary","2012","2012",5,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","TCPPERMT","/capita, US$ exchange rate","HUN","Hungary","2013","2013",4.8,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","TCPPERMT","/capita, US$ exchange rate","HUN","Hungary","2014","2014",4.6,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","TCPPERMT","/capita, US$ exchange rate","HUN","Hungary","2015","2015",3.4,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","TCPPERMT","/capita, US$ exchange rate","HUN","Hungary","2016","2016",2.9,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","TCPPERMT","/capita, US$ exchange rate","HUN","Hungary","2017","2017",3,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","TCPPERMT","/capita, US$ exchange rate","HUN","Hungary","2018","2018",3.1,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","TCPPERMT","/capita, US$ exchange rate","HUN","Hungary","2019","2019",2.9,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","TCPPERMT","/capita, US$ exchange rate","HUN","Hungary","2020","2020",2.7,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","TCPPERMT","/capita, US$ exchange rate","HUN","Hungary","2021","2021",2.7,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","TCPPERMT","/capita, US$ exchange rate","HUN","Hungary","2022","2022",2.3,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2010","2010",9.5,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2011","2011",10.1,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2012","2012",8.9,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2013","2013",8.7,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2014","2014",8.2,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2015","2015",7.2,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2016","2016",6.2,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2017","2017",6,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2018","2018",6,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2019","2019",5.9,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2020","2020",5.6,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2021","2021",5.3,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2022","2022",5.3,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","ATCPTTMT","% of total sales","HUN","Hungary","2010","2010",2.4,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","ATCPTTMT","% of total sales","HUN","Hungary","2011","2011",2.4,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","ATCPTTMT","% of total sales","HUN","Hungary","2012","2012",2.5,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","ATCPTTMT","% of total sales","HUN","Hungary","2013","2013",2.5,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","ATCPTTMT","% of total sales","HUN","Hungary","2014","2014",2.4,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","ATCPTTMT","% of total sales","HUN","Hungary","2015","2015",2,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","ATCPTTMT","% of total sales","HUN","Hungary","2016","2016",1.6,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","ATCPTTMT","% of total sales","HUN","Hungary","2017","2017",1.6,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","ATCPTTMT","% of total sales","HUN","Hungary","2018","2018",1.6,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","ATCPTTMT","% of total sales","HUN","Hungary","2019","2019",1.5,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","ATCPTTMT","% of total sales","HUN","Hungary","2020","2020",1.4,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","ATCPTTMT","% of total sales","HUN","Hungary","2021","2021",1.4,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","ATCPTTMT","% of total sales","HUN","Hungary","2022","2022",1.4,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","MLLNCUMT","Million of national currency units","ISL","Iceland","2010","2010",1101.8,,
+"PATCDEPR","N06A-Antidepressants","MLLNCUMT","Million of national currency units","ISL","Iceland","2011","2011",865.8,,
+"PATCDEPR","N06A-Antidepressants","MLLNCUMT","Million of national currency units","ISL","Iceland","2012","2012",842.3,,
+"PATCDEPR","N06A-Antidepressants","MLLNCUMT","Million of national currency units","ISL","Iceland","2013","2013",767.5,,
+"PATCDEPR","N06A-Antidepressants","MLLNCUMT","Million of national currency units","ISL","Iceland","2014","2014",730.7,,
+"PATCDEPR","N06A-Antidepressants","MLLNCUMT","Million of national currency units","ISL","Iceland","2015","2015",759.2,,
+"PATCDEPR","N06A-Antidepressants","MLLNCUMT","Million of national currency units","ISL","Iceland","2016","2016",744.1,,
+"PATCDEPR","N06A-Antidepressants","MLLNCUMT","Million of national currency units","ISL","Iceland","2017","2017",769.4,,
+"PATCDEPR","N06A-Antidepressants","MLLNCUMT","Million of national currency units","ISL","Iceland","2018","2018",854.9,,
+"PATCDEPR","N06A-Antidepressants","MLLNCUMT","Million of national currency units","ISL","Iceland","2019","2019",960.6,,
+"PATCDEPR","N06A-Antidepressants","MLLNCUMT","Million of national currency units","ISL","Iceland","2020","2020",1119.8,,
+"PATCDEPR","N06A-Antidepressants","MLLNCUMT","Million of national currency units","ISL","Iceland","2021","2021",1217.6,,
+"PATCDEPR","N06A-Antidepressants","MTMOTCMT","Million US$ at exchange rate","ISL","Iceland","2010","2010",9,,
+"PATCDEPR","N06A-Antidepressants","MTMOTCMT","Million US$ at exchange rate","ISL","Iceland","2011","2011",7.5,,
+"PATCDEPR","N06A-Antidepressants","MTMOTCMT","Million US$ at exchange rate","ISL","Iceland","2012","2012",6.7,,
+"PATCDEPR","N06A-Antidepressants","MTMOTCMT","Million US$ at exchange rate","ISL","Iceland","2013","2013",6.3,,
+"PATCDEPR","N06A-Antidepressants","MTMOTCMT","Million US$ at exchange rate","ISL","Iceland","2014","2014",6.3,,
+"PATCDEPR","N06A-Antidepressants","MTMOTCMT","Million US$ at exchange rate","ISL","Iceland","2015","2015",5.8,,
+"PATCDEPR","N06A-Antidepressants","MTMOTCMT","Million US$ at exchange rate","ISL","Iceland","2016","2016",6.2,,
+"PATCDEPR","N06A-Antidepressants","MTMOTCMT","Million US$ at exchange rate","ISL","Iceland","2017","2017",7.2,,
+"PATCDEPR","N06A-Antidepressants","MTMOTCMT","Million US$ at exchange rate","ISL","Iceland","2018","2018",7.9,,
+"PATCDEPR","N06A-Antidepressants","MTMOTCMT","Million US$ at exchange rate","ISL","Iceland","2019","2019",7.8,,
+"PATCDEPR","N06A-Antidepressants","MTMOTCMT","Million US$ at exchange rate","ISL","Iceland","2020","2020",8.3,,
+"PATCDEPR","N06A-Antidepressants","MTMOTCMT","Million US$ at exchange rate","ISL","Iceland","2021","2021",9.6,,
+"PATCDEPR","N06A-Antidepressants","MTMOPPMT","Million US$, purchasing power parity","ISL","Iceland","2010","2010",8.3,,
+"PATCDEPR","N06A-Antidepressants","MTMOPPMT","Million US$, purchasing power parity","ISL","Iceland","2011","2011",6.4,,
+"PATCDEPR","N06A-Antidepressants","MTMOPPMT","Million US$, purchasing power parity","ISL","Iceland","2012","2012",6.1,,
+"PATCDEPR","N06A-Antidepressants","MTMOPPMT","Million US$, purchasing power parity","ISL","Iceland","2013","2013",5.6,,
+"PATCDEPR","N06A-Antidepressants","MTMOPPMT","Million US$, purchasing power parity","ISL","Iceland","2014","2014",5.3,,
+"PATCDEPR","N06A-Antidepressants","MTMOPPMT","Million US$, purchasing power parity","ISL","Iceland","2015","2015",5.3,,
+"PATCDEPR","N06A-Antidepressants","MTMOPPMT","Million US$, purchasing power parity","ISL","Iceland","2016","2016",5.3,,
+"PATCDEPR","N06A-Antidepressants","MTMOPPMT","Million US$, purchasing power parity","ISL","Iceland","2017","2017",5.6,,
+"PATCDEPR","N06A-Antidepressants","MTMOPPMT","Million US$, purchasing power parity","ISL","Iceland","2018","2018",6.1,,
+"PATCDEPR","N06A-Antidepressants","MTMOPPMT","Million US$, purchasing power parity","ISL","Iceland","2019","2019",6.8,,
+"PATCDEPR","N06A-Antidepressants","MTMOPPMT","Million US$, purchasing power parity","ISL","Iceland","2020","2020",7.6,,
+"PATCDEPR","N06A-Antidepressants","MTMOPPMT","Million US$, purchasing power parity","ISL","Iceland","2021","2021",8.1,,
+"PATCDEPR","N06A-Antidepressants","TCPPERMT","/capita, US$ exchange rate","ISL","Iceland","2010","2010",28.3,,
+"PATCDEPR","N06A-Antidepressants","TCPPERMT","/capita, US$ exchange rate","ISL","Iceland","2011","2011",23.4,,
+"PATCDEPR","N06A-Antidepressants","TCPPERMT","/capita, US$ exchange rate","ISL","Iceland","2012","2012",21,,
+"PATCDEPR","N06A-Antidepressants","TCPPERMT","/capita, US$ exchange rate","ISL","Iceland","2013","2013",19.4,,
+"PATCDEPR","N06A-Antidepressants","TCPPERMT","/capita, US$ exchange rate","ISL","Iceland","2014","2014",19.1,,
+"PATCDEPR","N06A-Antidepressants","TCPPERMT","/capita, US$ exchange rate","ISL","Iceland","2015","2015",17.4,,
+"PATCDEPR","N06A-Antidepressants","TCPPERMT","/capita, US$ exchange rate","ISL","Iceland","2016","2016",18.4,,
+"PATCDEPR","N06A-Antidepressants","TCPPERMT","/capita, US$ exchange rate","ISL","Iceland","2017","2017",21,,
+"PATCDEPR","N06A-Antidepressants","TCPPERMT","/capita, US$ exchange rate","ISL","Iceland","2018","2018",22.4,,
+"PATCDEPR","N06A-Antidepressants","TCPPERMT","/capita, US$ exchange rate","ISL","Iceland","2019","2019",21.7,,
+"PATCDEPR","N06A-Antidepressants","TCPPERMT","/capita, US$ exchange rate","ISL","Iceland","2020","2020",22.6,,
+"PATCDEPR","N06A-Antidepressants","TCPPERMT","/capita, US$ exchange rate","ISL","Iceland","2021","2021",25.7,,
+"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2010","2010",26.1,,
+"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2011","2011",20.1,,
+"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2012","2012",19.2,,
+"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2013","2013",17.3,,
+"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2014","2014",16.1,,
+"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2015","2015",16.2,,
+"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2016","2016",15.8,,
+"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2017","2017",16.2,,
+"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2018","2018",17.2,,
+"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2019","2019",18.9,,
+"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2020","2020",20.8,,
+"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2021","2021",21.8,,
+"PATCDEPR","N06A-Antidepressants","ATCPTTMT","% of total sales","ISL","Iceland","2010","2010",4.4,,
+"PATCDEPR","N06A-Antidepressants","ATCPTTMT","% of total sales","ISL","Iceland","2011","2011",3.3,,
+"PATCDEPR","N06A-Antidepressants","ATCPTTMT","% of total sales","ISL","Iceland","2012","2012",3.5,,
+"PATCDEPR","N06A-Antidepressants","ATCPTTMT","% of total sales","ISL","Iceland","2013","2013",2.9,,
+"PATCDEPR","N06A-Antidepressants","ATCPTTMT","% of total sales","ISL","Iceland","2014","2014",3.1,,
+"PATCDEPR","N06A-Antidepressants","ATCPTTMT","% of total sales","ISL","Iceland","2015","2015",3.1,,
+"PATCDEPR","N06A-Antidepressants","ATCPTTMT","% of total sales","ISL","Iceland","2016","2016",2.9,,
+"PATCDEPR","N06A-Antidepressants","ATCPTTMT","% of total sales","ISL","Iceland","2017","2017",2.9,,
+"PATCDEPR","N06A-Antidepressants","ATCPTTMT","% of total sales","ISL","Iceland","2018","2018",2.8,,
+"PATCDEPR","N06A-Antidepressants","ATCPTTMT","% of total sales","ISL","Iceland","2019","2019",2.9,,
+"PATCDEPR","N06A-Antidepressants","ATCPTTMT","% of total sales","ISL","Iceland","2020","2020",2.8,,
+"PATCDEPR","N06A-Antidepressants","ATCPTTMT","% of total sales","ISL","Iceland","2021","2021",2.7,,
+"PATCDEPR","N06A-Antidepressants","MLLNCUMT","Million of national currency units","IRL","Ireland","2010","2010",67.2,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","MLLNCUMT","Million of national currency units","IRL","Ireland","2011","2011",67.1,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","MLLNCUMT","Million of national currency units","IRL","Ireland","2012","2012",72.8,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","MLLNCUMT","Million of national currency units","IRL","Ireland","2013","2013",72.7,"B; D","Break; Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","MLLNCUMT","Million of national currency units","IRL","Ireland","2014","2014",70.1,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","MLLNCUMT","Million of national currency units","IRL","Ireland","2015","2015",56.2,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","MLLNCUMT","Million of national currency units","IRL","Ireland","2016","2016",49.7,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","MLLNCUMT","Million of national currency units","IRL","Ireland","2017","2017",44.4,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","MLLNCUMT","Million of national currency units","IRL","Ireland","2018","2018",44.7,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","MLLNCUMT","Million of national currency units","IRL","Ireland","2019","2019",45.5,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","MLLNCUMT","Million of national currency units","IRL","Ireland","2020","2020",47.4,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","MLLNCUMT","Million of national currency units","IRL","Ireland","2021","2021",49.9,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","MTMOTCMT","Million US$ at exchange rate","IRL","Ireland","2010","2010",89.1,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","MTMOTCMT","Million US$ at exchange rate","IRL","Ireland","2011","2011",93.3,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","MTMOTCMT","Million US$ at exchange rate","IRL","Ireland","2012","2012",93.6,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","MTMOTCMT","Million US$ at exchange rate","IRL","Ireland","2013","2013",96.6,"B; D","Break; Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","MTMOTCMT","Million US$ at exchange rate","IRL","Ireland","2014","2014",93.1,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","MTMOTCMT","Million US$ at exchange rate","IRL","Ireland","2015","2015",62.3,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","MTMOTCMT","Million US$ at exchange rate","IRL","Ireland","2016","2016",55,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","MTMOTCMT","Million US$ at exchange rate","IRL","Ireland","2017","2017",50.1,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","MTMOTCMT","Million US$ at exchange rate","IRL","Ireland","2018","2018",52.8,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","MTMOTCMT","Million US$ at exchange rate","IRL","Ireland","2019","2019",50.9,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","MTMOTCMT","Million US$ at exchange rate","IRL","Ireland","2020","2020",54.1,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","MTMOTCMT","Million US$ at exchange rate","IRL","Ireland","2021","2021",59.1,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","MTMOPPMT","Million US$, purchasing power parity","IRL","Ireland","2010","2010",79.1,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","MTMOPPMT","Million US$, purchasing power parity","IRL","Ireland","2011","2011",80.6,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","MTMOPPMT","Million US$, purchasing power parity","IRL","Ireland","2012","2012",88.5,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","MTMOPPMT","Million US$, purchasing power parity","IRL","Ireland","2013","2013",89.7,"B; D","Break; Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","MTMOPPMT","Million US$, purchasing power parity","IRL","Ireland","2014","2014",85.6,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","MTMOPPMT","Million US$, purchasing power parity","IRL","Ireland","2015","2015",69.4,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","MTMOPPMT","Million US$, purchasing power parity","IRL","Ireland","2016","2016",62.5,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","MTMOPPMT","Million US$, purchasing power parity","IRL","Ireland","2017","2017",55.8,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","MTMOPPMT","Million US$, purchasing power parity","IRL","Ireland","2018","2018",56.4,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","MTMOPPMT","Million US$, purchasing power parity","IRL","Ireland","2019","2019",56.5,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","MTMOPPMT","Million US$, purchasing power parity","IRL","Ireland","2020","2020",59.5,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","MTMOPPMT","Million US$, purchasing power parity","IRL","Ireland","2021","2021",62.8,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","TCPPERMT","/capita, US$ exchange rate","IRL","Ireland","2010","2010",19.5,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","TCPPERMT","/capita, US$ exchange rate","IRL","Ireland","2011","2011",20.4,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","TCPPERMT","/capita, US$ exchange rate","IRL","Ireland","2012","2012",20.3,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","TCPPERMT","/capita, US$ exchange rate","IRL","Ireland","2013","2013",20.9,"B; D","Break; Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","TCPPERMT","/capita, US$ exchange rate","IRL","Ireland","2014","2014",20,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","TCPPERMT","/capita, US$ exchange rate","IRL","Ireland","2015","2015",13.3,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","TCPPERMT","/capita, US$ exchange rate","IRL","Ireland","2016","2016",11.6,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","TCPPERMT","/capita, US$ exchange rate","IRL","Ireland","2017","2017",10.4,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","TCPPERMT","/capita, US$ exchange rate","IRL","Ireland","2018","2018",10.8,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","TCPPERMT","/capita, US$ exchange rate","IRL","Ireland","2019","2019",10.3,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","TCPPERMT","/capita, US$ exchange rate","IRL","Ireland","2020","2020",10.9,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","TCPPERMT","/capita, US$ exchange rate","IRL","Ireland","2021","2021",11.7,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2010","2010",17.4,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2011","2011",17.6,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2012","2012",19.2,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2013","2013",19.4,"B; D","Break; Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2014","2014",18.4,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2015","2015",14.8,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2016","2016",13.2,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2017","2017",11.6,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2018","2018",11.6,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2019","2019",11.4,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2020","2020",11.9,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2021","2021",12.5,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","ATCPTTMT","% of total sales","IRL","Ireland","2010","2010",3.3,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","ATCPTTMT","% of total sales","IRL","Ireland","2011","2011",3.4,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","ATCPTTMT","% of total sales","IRL","Ireland","2012","2012",3.6,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","ATCPTTMT","% of total sales","IRL","Ireland","2013","2013",3.7,"B; D","Break; Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","ATCPTTMT","% of total sales","IRL","Ireland","2014","2014",3.7,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","ATCPTTMT","% of total sales","IRL","Ireland","2015","2015",2.8,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","ATCPTTMT","% of total sales","IRL","Ireland","2016","2016",2.4,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","ATCPTTMT","% of total sales","IRL","Ireland","2017","2017",2.1,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","ATCPTTMT","% of total sales","IRL","Ireland","2018","2018",2,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","ATCPTTMT","% of total sales","IRL","Ireland","2019","2019",1.9,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","ATCPTTMT","% of total sales","IRL","Ireland","2020","2020",1.9,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","ATCPTTMT","% of total sales","IRL","Ireland","2021","2021",1.9,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","MLLNCUMT","Million of national currency units","ITA","Italy","2011","2011",497.4,,
+"PATCDEPR","N06A-Antidepressants","MLLNCUMT","Million of national currency units","ITA","Italy","2012","2012",493,,
+"PATCDEPR","N06A-Antidepressants","MLLNCUMT","Million of national currency units","ITA","Italy","2013","2013",493.2,,
+"PATCDEPR","N06A-Antidepressants","MLLNCUMT","Million of national currency units","ITA","Italy","2014","2014",464.5,,
+"PATCDEPR","N06A-Antidepressants","MLLNCUMT","Million of national currency units","ITA","Italy","2015","2015",406.3,,
+"PATCDEPR","N06A-Antidepressants","MLLNCUMT","Million of national currency units","ITA","Italy","2016","2016",359.2,,
+"PATCDEPR","N06A-Antidepressants","MLLNCUMT","Million of national currency units","ITA","Italy","2017","2017",369,,
+"PATCDEPR","N06A-Antidepressants","MLLNCUMT","Million of national currency units","ITA","Italy","2018","2018",382.1,,
+"PATCDEPR","N06A-Antidepressants","MLLNCUMT","Million of national currency units","ITA","Italy","2019","2019",391.6,,
+"PATCDEPR","N06A-Antidepressants","MLLNCUMT","Million of national currency units","ITA","Italy","2020","2020",399.3,,
+"PATCDEPR","N06A-Antidepressants","MLLNCUMT","Million of national currency units","ITA","Italy","2021","2021",406.8,,
+"PATCDEPR","N06A-Antidepressants","MLLNCUMT","Million of national currency units","ITA","Italy","2022","2022",413.3,"E","Estimated value"
+"PATCDEPR","N06A-Antidepressants","MTMOTCMT","Million US$ at exchange rate","ITA","Italy","2011","2011",692.4,,
+"PATCDEPR","N06A-Antidepressants","MTMOTCMT","Million US$ at exchange rate","ITA","Italy","2012","2012",633.4,,
+"PATCDEPR","N06A-Antidepressants","MTMOTCMT","Million US$ at exchange rate","ITA","Italy","2013","2013",655,,
+"PATCDEPR","N06A-Antidepressants","MTMOTCMT","Million US$ at exchange rate","ITA","Italy","2014","2014",617.1,,
+"PATCDEPR","N06A-Antidepressants","MTMOTCMT","Million US$ at exchange rate","ITA","Italy","2015","2015",450.8,,
+"PATCDEPR","N06A-Antidepressants","MTMOTCMT","Million US$ at exchange rate","ITA","Italy","2016","2016",397.6,,
+"PATCDEPR","N06A-Antidepressants","MTMOTCMT","Million US$ at exchange rate","ITA","Italy","2017","2017",416.9,,
+"PATCDEPR","N06A-Antidepressants","MTMOTCMT","Million US$ at exchange rate","ITA","Italy","2018","2018",451.2,,
+"PATCDEPR","N06A-Antidepressants","MTMOTCMT","Million US$ at exchange rate","ITA","Italy","2019","2019",438.4,,
+"PATCDEPR","N06A-Antidepressants","MTMOTCMT","Million US$ at exchange rate","ITA","Italy","2020","2020",456.1,,
+"PATCDEPR","N06A-Antidepressants","MTMOTCMT","Million US$ at exchange rate","ITA","Italy","2021","2021",481.1,,
+"PATCDEPR","N06A-Antidepressants","MTMOTCMT","Million US$ at exchange rate","ITA","Italy","2022","2022",435.2,"E","Estimated value"
+"PATCDEPR","N06A-Antidepressants","MTMOPPMT","Million US$, purchasing power parity","ITA","Italy","2011","2011",655.6,,
+"PATCDEPR","N06A-Antidepressants","MTMOPPMT","Million US$, purchasing power parity","ITA","Italy","2012","2012",659.4,,
+"PATCDEPR","N06A-Antidepressants","MTMOPPMT","Million US$, purchasing power parity","ITA","Italy","2013","2013",668.9,,
+"PATCDEPR","N06A-Antidepressants","MTMOPPMT","Million US$, purchasing power parity","ITA","Italy","2014","2014",628,,
+"PATCDEPR","N06A-Antidepressants","MTMOPPMT","Million US$, purchasing power parity","ITA","Italy","2015","2015",550,,
+"PATCDEPR","N06A-Antidepressants","MTMOPPMT","Million US$, purchasing power parity","ITA","Italy","2016","2016",512.7,,
+"PATCDEPR","N06A-Antidepressants","MTMOPPMT","Million US$, purchasing power parity","ITA","Italy","2017","2017",534.9,,
+"PATCDEPR","N06A-Antidepressants","MTMOPPMT","Million US$, purchasing power parity","ITA","Italy","2018","2018",560.9,,
+"PATCDEPR","N06A-Antidepressants","MTMOPPMT","Million US$, purchasing power parity","ITA","Italy","2019","2019",596.2,,
+"PATCDEPR","N06A-Antidepressants","MTMOPPMT","Million US$, purchasing power parity","ITA","Italy","2020","2020",616.5,,
+"PATCDEPR","N06A-Antidepressants","MTMOPPMT","Million US$, purchasing power parity","ITA","Italy","2021","2021",628.2,,
+"PATCDEPR","N06A-Antidepressants","MTMOPPMT","Million US$, purchasing power parity","ITA","Italy","2022","2022",669.4,"E","Estimated value"
+"PATCDEPR","N06A-Antidepressants","TCPPERMT","/capita, US$ exchange rate","ITA","Italy","2011","2011",11.7,,
+"PATCDEPR","N06A-Antidepressants","TCPPERMT","/capita, US$ exchange rate","ITA","Italy","2012","2012",10.6,,
+"PATCDEPR","N06A-Antidepressants","TCPPERMT","/capita, US$ exchange rate","ITA","Italy","2013","2013",10.9,,
+"PATCDEPR","N06A-Antidepressants","TCPPERMT","/capita, US$ exchange rate","ITA","Italy","2014","2014",10.2,,
+"PATCDEPR","N06A-Antidepressants","TCPPERMT","/capita, US$ exchange rate","ITA","Italy","2015","2015",7.4,,
+"PATCDEPR","N06A-Antidepressants","TCPPERMT","/capita, US$ exchange rate","ITA","Italy","2016","2016",6.6,,
+"PATCDEPR","N06A-Antidepressants","TCPPERMT","/capita, US$ exchange rate","ITA","Italy","2017","2017",6.9,,
+"PATCDEPR","N06A-Antidepressants","TCPPERMT","/capita, US$ exchange rate","ITA","Italy","2018","2018",7.5,,
+"PATCDEPR","N06A-Antidepressants","TCPPERMT","/capita, US$ exchange rate","ITA","Italy","2019","2019",7.3,,
+"PATCDEPR","N06A-Antidepressants","TCPPERMT","/capita, US$ exchange rate","ITA","Italy","2020","2020",7.7,,
+"PATCDEPR","N06A-Antidepressants","TCPPERMT","/capita, US$ exchange rate","ITA","Italy","2021","2021",8.1,,
+"PATCDEPR","N06A-Antidepressants","TCPPERMT","/capita, US$ exchange rate","ITA","Italy","2022","2022",7.4,"E","Estimated value"
+"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2011","2011",11,,
+"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2012","2012",11.1,,
+"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2013","2013",11.1,,
+"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2014","2014",10.3,,
+"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2015","2015",9.1,,
+"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2016","2016",8.5,,
+"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2017","2017",8.8,,
+"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2018","2018",9.3,,
+"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2019","2019",10,,
+"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2020","2020",10.4,,
+"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2021","2021",10.6,,
+"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2022","2022",11.3,"E","Estimated value"
+"PATCDEPR","N06A-Antidepressants","ATCPTTMT","% of total sales","ITA","Italy","2011","2011",2.5,,
+"PATCDEPR","N06A-Antidepressants","ATCPTTMT","% of total sales","ITA","Italy","2012","2012",2.6,,
+"PATCDEPR","N06A-Antidepressants","ATCPTTMT","% of total sales","ITA","Italy","2013","2013",2.5,,
+"PATCDEPR","N06A-Antidepressants","ATCPTTMT","% of total sales","ITA","Italy","2014","2014",2.3,,
+"PATCDEPR","N06A-Antidepressants","ATCPTTMT","% of total sales","ITA","Italy","2015","2015",1.8,,
+"PATCDEPR","N06A-Antidepressants","ATCPTTMT","% of total sales","ITA","Italy","2016","2016",1.6,,
+"PATCDEPR","N06A-Antidepressants","ATCPTTMT","% of total sales","ITA","Italy","2017","2017",1.6,,
+"PATCDEPR","N06A-Antidepressants","ATCPTTMT","% of total sales","ITA","Italy","2018","2018",1.7,,
+"PATCDEPR","N06A-Antidepressants","ATCPTTMT","% of total sales","ITA","Italy","2019","2019",1.7,,
+"PATCDEPR","N06A-Antidepressants","ATCPTTMT","% of total sales","ITA","Italy","2020","2020",1.7,,
+"PATCDEPR","N06A-Antidepressants","ATCPTTMT","% of total sales","ITA","Italy","2021","2021",1.7,,
+"PATCDEPR","N06A-Antidepressants","ATCPTTMT","% of total sales","ITA","Italy","2022","2022",1.7,"E","Estimated value"
+"PATCDEPR","N06A-Antidepressants","MLLNCUMT","Million of national currency units","KOR","Korea","2010","2010",151818,,
+"PATCDEPR","N06A-Antidepressants","MLLNCUMT","Million of national currency units","KOR","Korea","2011","2011",175161.8,"B","Break"
+"PATCDEPR","N06A-Antidepressants","MLLNCUMT","Million of national currency units","KOR","Korea","2012","2012",165576.8,,
+"PATCDEPR","N06A-Antidepressants","MLLNCUMT","Million of national currency units","KOR","Korea","2013","2013",175592.8,,
+"PATCDEPR","N06A-Antidepressants","MLLNCUMT","Million of national currency units","KOR","Korea","2014","2014",188434.5,,
+"PATCDEPR","N06A-Antidepressants","MLLNCUMT","Million of national currency units","KOR","Korea","2015","2015",205375.1,,
+"PATCDEPR","N06A-Antidepressants","MLLNCUMT","Million of national currency units","KOR","Korea","2016","2016",177097.2,"B","Break"
+"PATCDEPR","N06A-Antidepressants","MLLNCUMT","Million of national currency units","KOR","Korea","2017","2017",194400.8,,
+"PATCDEPR","N06A-Antidepressants","MLLNCUMT","Million of national currency units","KOR","Korea","2018","2018",214513.3,,
+"PATCDEPR","N06A-Antidepressants","MLLNCUMT","Million of national currency units","KOR","Korea","2019","2019",240231.6,,
+"PATCDEPR","N06A-Antidepressants","MLLNCUMT","Million of national currency units","KOR","Korea","2020","2020",272925.5,,
+"PATCDEPR","N06A-Antidepressants","MLLNCUMT","Million of national currency units","KOR","Korea","2021","2021",315802.3,,
+"PATCDEPR","N06A-Antidepressants","MTMOTCMT","Million US$ at exchange rate","KOR","Korea","2010","2010",131.3,,
+"PATCDEPR","N06A-Antidepressants","MTMOTCMT","Million US$ at exchange rate","KOR","Korea","2011","2011",158.1,"B","Break"
+"PATCDEPR","N06A-Antidepressants","MTMOTCMT","Million US$ at exchange rate","KOR","Korea","2012","2012",146.9,,
+"PATCDEPR","N06A-Antidepressants","MTMOTCMT","Million US$ at exchange rate","KOR","Korea","2013","2013",160.4,,
+"PATCDEPR","N06A-Antidepressants","MTMOTCMT","Million US$ at exchange rate","KOR","Korea","2014","2014",179,,
+"PATCDEPR","N06A-Antidepressants","MTMOTCMT","Million US$ at exchange rate","KOR","Korea","2015","2015",181.6,,
+"PATCDEPR","N06A-Antidepressants","MTMOTCMT","Million US$ at exchange rate","KOR","Korea","2016","2016",152.6,"B","Break"
+"PATCDEPR","N06A-Antidepressants","MTMOTCMT","Million US$ at exchange rate","KOR","Korea","2017","2017",171.9,,
+"PATCDEPR","N06A-Antidepressants","MTMOTCMT","Million US$ at exchange rate","KOR","Korea","2018","2018",195,,
+"PATCDEPR","N06A-Antidepressants","MTMOTCMT","Million US$ at exchange rate","KOR","Korea","2019","2019",206.1,,
+"PATCDEPR","N06A-Antidepressants","MTMOTCMT","Million US$ at exchange rate","KOR","Korea","2020","2020",231.2,,
+"PATCDEPR","N06A-Antidepressants","MTMOTCMT","Million US$ at exchange rate","KOR","Korea","2021","2021",276.1,,
+"PATCDEPR","N06A-Antidepressants","MTMOPPMT","Million US$, purchasing power parity","KOR","Korea","2010","2010",180.5,,
+"PATCDEPR","N06A-Antidepressants","MTMOPPMT","Million US$, purchasing power parity","KOR","Korea","2011","2011",205,"B","Break"
+"PATCDEPR","N06A-Antidepressants","MTMOPPMT","Million US$, purchasing power parity","KOR","Korea","2012","2012",193.7,,
+"PATCDEPR","N06A-Antidepressants","MTMOPPMT","Million US$, purchasing power parity","KOR","Korea","2013","2013",202,,
+"PATCDEPR","N06A-Antidepressants","MTMOPPMT","Million US$, purchasing power parity","KOR","Korea","2014","2014",216.1,,
+"PATCDEPR","N06A-Antidepressants","MTMOPPMT","Million US$, purchasing power parity","KOR","Korea","2015","2015",239.5,,
+"PATCDEPR","N06A-Antidepressants","MTMOPPMT","Million US$, purchasing power parity","KOR","Korea","2016","2016",206.2,"B","Break"
+"PATCDEPR","N06A-Antidepressants","MTMOPPMT","Million US$, purchasing power parity","KOR","Korea","2017","2017",222.8,,
+"PATCDEPR","N06A-Antidepressants","MTMOPPMT","Million US$, purchasing power parity","KOR","Korea","2018","2018",250.9,,
+"PATCDEPR","N06A-Antidepressants","MTMOPPMT","Million US$, purchasing power parity","KOR","Korea","2019","2019",280.5,,
+"PATCDEPR","N06A-Antidepressants","MTMOPPMT","Million US$, purchasing power parity","KOR","Korea","2020","2020",325.8,,
+"PATCDEPR","N06A-Antidepressants","MTMOPPMT","Million US$, purchasing power parity","KOR","Korea","2021","2021",369.8,,
+"PATCDEPR","N06A-Antidepressants","TCPPERMT","/capita, US$ exchange rate","KOR","Korea","2010","2010",2.6,,
+"PATCDEPR","N06A-Antidepressants","TCPPERMT","/capita, US$ exchange rate","KOR","Korea","2011","2011",3.2,"B","Break"
+"PATCDEPR","N06A-Antidepressants","TCPPERMT","/capita, US$ exchange rate","KOR","Korea","2012","2012",2.9,,
+"PATCDEPR","N06A-Antidepressants","TCPPERMT","/capita, US$ exchange rate","KOR","Korea","2013","2013",3.2,,
+"PATCDEPR","N06A-Antidepressants","TCPPERMT","/capita, US$ exchange rate","KOR","Korea","2014","2014",3.5,,
+"PATCDEPR","N06A-Antidepressants","TCPPERMT","/capita, US$ exchange rate","KOR","Korea","2015","2015",3.6,,
+"PATCDEPR","N06A-Antidepressants","TCPPERMT","/capita, US$ exchange rate","KOR","Korea","2016","2016",3,"B","Break"
+"PATCDEPR","N06A-Antidepressants","TCPPERMT","/capita, US$ exchange rate","KOR","Korea","2017","2017",3.3,,
+"PATCDEPR","N06A-Antidepressants","TCPPERMT","/capita, US$ exchange rate","KOR","Korea","2018","2018",3.8,,
+"PATCDEPR","N06A-Antidepressants","TCPPERMT","/capita, US$ exchange rate","KOR","Korea","2019","2019",4,,
+"PATCDEPR","N06A-Antidepressants","TCPPERMT","/capita, US$ exchange rate","KOR","Korea","2020","2020",4.5,,
+"PATCDEPR","N06A-Antidepressants","TCPPERMT","/capita, US$ exchange rate","KOR","Korea","2021","2021",5.3,,
+"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2010","2010",3.6,,
+"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2011","2011",4.1,"B","Break"
+"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2012","2012",3.9,,
+"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2013","2013",4,,
+"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2014","2014",4.3,,
+"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2015","2015",4.7,,
+"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2016","2016",4,"B","Break"
+"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2017","2017",4.3,,
+"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2018","2018",4.9,,
+"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2019","2019",5.4,,
+"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2020","2020",6.3,,
+"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2021","2021",7.1,,
+"PATCDEPR","N06A-Antidepressants","ATCPTTMT","% of total sales","KOR","Korea","2010","2010",0.7,,
+"PATCDEPR","N06A-Antidepressants","ATCPTTMT","% of total sales","KOR","Korea","2011","2011",0.8,"B","Break"
+"PATCDEPR","N06A-Antidepressants","ATCPTTMT","% of total sales","KOR","Korea","2012","2012",0.8,,
+"PATCDEPR","N06A-Antidepressants","ATCPTTMT","% of total sales","KOR","Korea","2013","2013",0.8,,
+"PATCDEPR","N06A-Antidepressants","ATCPTTMT","% of total sales","KOR","Korea","2014","2014",0.8,,
+"PATCDEPR","N06A-Antidepressants","ATCPTTMT","% of total sales","KOR","Korea","2015","2015",0.8,,
+"PATCDEPR","N06A-Antidepressants","ATCPTTMT","% of total sales","KOR","Korea","2016","2016",0.7,"B","Break"
+"PATCDEPR","N06A-Antidepressants","ATCPTTMT","% of total sales","KOR","Korea","2017","2017",0.7,,
+"PATCDEPR","N06A-Antidepressants","ATCPTTMT","% of total sales","KOR","Korea","2018","2018",0.7,,
+"PATCDEPR","N06A-Antidepressants","ATCPTTMT","% of total sales","KOR","Korea","2019","2019",0.8,,
+"PATCDEPR","N06A-Antidepressants","ATCPTTMT","% of total sales","KOR","Korea","2020","2020",0.8,,
+"PATCDEPR","N06A-Antidepressants","ATCPTTMT","% of total sales","KOR","Korea","2021","2021",0.9,,
+"PATCDEPR","N06A-Antidepressants","MLLNCUMT","Million of national currency units","LUX","Luxembourg","2010","2010",7.1,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","MLLNCUMT","Million of national currency units","LUX","Luxembourg","2011","2011",6.8,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","MLLNCUMT","Million of national currency units","LUX","Luxembourg","2012","2012",6.7,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","MLLNCUMT","Million of national currency units","LUX","Luxembourg","2013","2013",6.5,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","MLLNCUMT","Million of national currency units","LUX","Luxembourg","2014","2014",6.3,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","MLLNCUMT","Million of national currency units","LUX","Luxembourg","2015","2015",5.7,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","MLLNCUMT","Million of national currency units","LUX","Luxembourg","2016","2016",5.4,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","MLLNCUMT","Million of national currency units","LUX","Luxembourg","2017","2017",5.1,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","MLLNCUMT","Million of national currency units","LUX","Luxembourg","2018","2018",5,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","MLLNCUMT","Million of national currency units","LUX","Luxembourg","2019","2019",5.1,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","MLLNCUMT","Million of national currency units","LUX","Luxembourg","2020","2020",5,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","MLLNCUMT","Million of national currency units","LUX","Luxembourg","2021","2021",4.7,"B; D; P","Break; Difference in methodology; Provisional value"
+"PATCDEPR","N06A-Antidepressants","MLLNCUMT","Million of national currency units","LUX","Luxembourg","2022","2022",4.3,"D; P","Difference in methodology; Provisional value"
+"PATCDEPR","N06A-Antidepressants","MTMOTCMT","Million US$ at exchange rate","LUX","Luxembourg","2010","2010",9.4,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","MTMOTCMT","Million US$ at exchange rate","LUX","Luxembourg","2011","2011",9.5,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","MTMOTCMT","Million US$ at exchange rate","LUX","Luxembourg","2012","2012",8.6,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","MTMOTCMT","Million US$ at exchange rate","LUX","Luxembourg","2013","2013",8.7,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","MTMOTCMT","Million US$ at exchange rate","LUX","Luxembourg","2014","2014",8.3,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","MTMOTCMT","Million US$ at exchange rate","LUX","Luxembourg","2015","2015",6.3,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","MTMOTCMT","Million US$ at exchange rate","LUX","Luxembourg","2016","2016",5.9,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","MTMOTCMT","Million US$ at exchange rate","LUX","Luxembourg","2017","2017",5.8,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","MTMOTCMT","Million US$ at exchange rate","LUX","Luxembourg","2018","2018",5.9,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","MTMOTCMT","Million US$ at exchange rate","LUX","Luxembourg","2019","2019",5.7,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","MTMOTCMT","Million US$ at exchange rate","LUX","Luxembourg","2020","2020",5.7,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","MTMOTCMT","Million US$ at exchange rate","LUX","Luxembourg","2021","2021",5.6,"B; D; P","Break; Difference in methodology; Provisional value"
+"PATCDEPR","N06A-Antidepressants","MTMOTCMT","Million US$ at exchange rate","LUX","Luxembourg","2022","2022",4.6,"D; P","Difference in methodology; Provisional value"
+"PATCDEPR","N06A-Antidepressants","MTMOPPMT","Million US$, purchasing power parity","LUX","Luxembourg","2010","2010",7.6,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","MTMOPPMT","Million US$, purchasing power parity","LUX","Luxembourg","2011","2011",7.5,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","MTMOPPMT","Million US$, purchasing power parity","LUX","Luxembourg","2012","2012",7.4,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","MTMOPPMT","Million US$, purchasing power parity","LUX","Luxembourg","2013","2013",7.3,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","MTMOPPMT","Million US$, purchasing power parity","LUX","Luxembourg","2014","2014",7.1,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","MTMOPPMT","Million US$, purchasing power parity","LUX","Luxembourg","2015","2015",6.5,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","MTMOPPMT","Million US$, purchasing power parity","LUX","Luxembourg","2016","2016",6.3,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","MTMOPPMT","Million US$, purchasing power parity","LUX","Luxembourg","2017","2017",6,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","MTMOPPMT","Million US$, purchasing power parity","LUX","Luxembourg","2018","2018",5.9,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","MTMOPPMT","Million US$, purchasing power parity","LUX","Luxembourg","2019","2019",6.1,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","MTMOPPMT","Million US$, purchasing power parity","LUX","Luxembourg","2020","2020",5.8,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","MTMOPPMT","Million US$, purchasing power parity","LUX","Luxembourg","2021","2021",5.5,"B; D; P","Break; Difference in methodology; Provisional value"
+"PATCDEPR","N06A-Antidepressants","MTMOPPMT","Million US$, purchasing power parity","LUX","Luxembourg","2022","2022",5.2,"D; P","Difference in methodology; Provisional value"
+"PATCDEPR","N06A-Antidepressants","TCPPERMT","/capita, US$ exchange rate","LUX","Luxembourg","2010","2010",19.8,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","TCPPERMT","/capita, US$ exchange rate","LUX","Luxembourg","2011","2011",19.6,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","TCPPERMT","/capita, US$ exchange rate","LUX","Luxembourg","2012","2012",17.6,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","TCPPERMT","/capita, US$ exchange rate","LUX","Luxembourg","2013","2013",17.3,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","TCPPERMT","/capita, US$ exchange rate","LUX","Luxembourg","2014","2014",16.3,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","TCPPERMT","/capita, US$ exchange rate","LUX","Luxembourg","2015","2015",12.2,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","TCPPERMT","/capita, US$ exchange rate","LUX","Luxembourg","2016","2016",11.2,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","TCPPERMT","/capita, US$ exchange rate","LUX","Luxembourg","2017","2017",10.8,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","TCPPERMT","/capita, US$ exchange rate","LUX","Luxembourg","2018","2018",10.9,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","TCPPERMT","/capita, US$ exchange rate","LUX","Luxembourg","2019","2019",10.3,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","TCPPERMT","/capita, US$ exchange rate","LUX","Luxembourg","2020","2020",10.1,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","TCPPERMT","/capita, US$ exchange rate","LUX","Luxembourg","2021","2021",9.7,"B; D; P","Break; Difference in methodology; Provisional value"
+"PATCDEPR","N06A-Antidepressants","TCPPERMT","/capita, US$ exchange rate","LUX","Luxembourg","2022","2022",7.8,"D; P","Difference in methodology; Provisional value"
+"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2010","2010",16.2,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2011","2011",15.6,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2012","2012",15.1,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2013","2013",14.5,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2014","2014",13.8,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2015","2015",12.5,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2016","2016",11.9,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2017","2017",11.3,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2018","2018",10.9,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2019","2019",10.9,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2020","2020",10.3,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2021","2021",9.6,"B; D; P","Break; Difference in methodology; Provisional value"
+"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2022","2022",8.9,"D; P","Difference in methodology; Provisional value"
+"PATCDEPR","N06A-Antidepressants","ATCPTTMT","% of total sales","LUX","Luxembourg","2010","2010",3.7,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","ATCPTTMT","% of total sales","LUX","Luxembourg","2011","2011",3.6,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","ATCPTTMT","% of total sales","LUX","Luxembourg","2012","2012",3.4,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","ATCPTTMT","% of total sales","LUX","Luxembourg","2013","2013",3.3,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","ATCPTTMT","% of total sales","LUX","Luxembourg","2014","2014",3.3,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","ATCPTTMT","% of total sales","LUX","Luxembourg","2015","2015",3,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","ATCPTTMT","% of total sales","LUX","Luxembourg","2016","2016",2.7,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","ATCPTTMT","% of total sales","LUX","Luxembourg","2017","2017",2.6,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","ATCPTTMT","% of total sales","LUX","Luxembourg","2018","2018",2.5,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","ATCPTTMT","% of total sales","LUX","Luxembourg","2019","2019",2.5,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","ATCPTTMT","% of total sales","LUX","Luxembourg","2020","2020",2.4,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","ATCPTTMT","% of total sales","LUX","Luxembourg","2021","2021",2,"B; D; P","Break; Difference in methodology; Provisional value"
+"PATCDEPR","N06A-Antidepressants","ATCPTTMT","% of total sales","LUX","Luxembourg","2022","2022",1.7,"D; P","Difference in methodology; Provisional value"
+"PATCDEPR","N06A-Antidepressants","MLLNCUMT","Million of national currency units","NLD","Netherlands","2010","2010",91.7,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","MLLNCUMT","Million of national currency units","NLD","Netherlands","2011","2011",95.7,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","MLLNCUMT","Million of national currency units","NLD","Netherlands","2012","2012",94.9,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","MLLNCUMT","Million of national currency units","NLD","Netherlands","2013","2013",98.3,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","MLLNCUMT","Million of national currency units","NLD","Netherlands","2014","2014",99.7,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","MTMOTCMT","Million US$ at exchange rate","NLD","Netherlands","2010","2010",121.6,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","MTMOTCMT","Million US$ at exchange rate","NLD","Netherlands","2011","2011",133.3,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","MTMOTCMT","Million US$ at exchange rate","NLD","Netherlands","2012","2012",121.9,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","MTMOTCMT","Million US$ at exchange rate","NLD","Netherlands","2013","2013",130.6,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","MTMOTCMT","Million US$ at exchange rate","NLD","Netherlands","2014","2014",132.4,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","MTMOPPMT","Million US$, purchasing power parity","NLD","Netherlands","2010","2010",107.4,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","MTMOPPMT","Million US$, purchasing power parity","NLD","Netherlands","2011","2011",114.5,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","MTMOPPMT","Million US$, purchasing power parity","NLD","Netherlands","2012","2012",115.1,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","MTMOPPMT","Million US$, purchasing power parity","NLD","Netherlands","2013","2013",123.2,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","MTMOPPMT","Million US$, purchasing power parity","NLD","Netherlands","2014","2014",123.3,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","TCPPERMT","/capita, US$ exchange rate","NLD","Netherlands","2010","2010",7.3,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","TCPPERMT","/capita, US$ exchange rate","NLD","Netherlands","2011","2011",8,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","TCPPERMT","/capita, US$ exchange rate","NLD","Netherlands","2012","2012",7.3,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","TCPPERMT","/capita, US$ exchange rate","NLD","Netherlands","2013","2013",7.8,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","TCPPERMT","/capita, US$ exchange rate","NLD","Netherlands","2014","2014",7.9,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","NLD","Netherlands","2010","2010",6.5,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","NLD","Netherlands","2011","2011",6.9,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","NLD","Netherlands","2012","2012",6.9,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","NLD","Netherlands","2013","2013",7.3,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","NLD","Netherlands","2014","2014",7.3,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","ATCPTTMT","% of total sales","NLD","Netherlands","2010","2010",1.8,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","ATCPTTMT","% of total sales","NLD","Netherlands","2011","2011",1.8,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","ATCPTTMT","% of total sales","NLD","Netherlands","2012","2012",2.1,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","ATCPTTMT","% of total sales","NLD","Netherlands","2013","2013",2.3,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","ATCPTTMT","% of total sales","NLD","Netherlands","2014","2014",2.3,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","MLLNCUMT","Million of national currency units","NZL","New Zealand","2010","2010",29.5,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","MLLNCUMT","Million of national currency units","NZL","New Zealand","2011","2011",32.2,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","MLLNCUMT","Million of national currency units","NZL","New Zealand","2012","2012",32.9,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","MLLNCUMT","Million of national currency units","NZL","New Zealand","2013","2013",29.2,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","MLLNCUMT","Million of national currency units","NZL","New Zealand","2014","2014",17.5,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","MLLNCUMT","Million of national currency units","NZL","New Zealand","2015","2015",15.6,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","MLLNCUMT","Million of national currency units","NZL","New Zealand","2016","2016",13.7,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","MLLNCUMT","Million of national currency units","NZL","New Zealand","2017","2017",13.5,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","MLLNCUMT","Million of national currency units","NZL","New Zealand","2018","2018",8.5,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","MLLNCUMT","Million of national currency units","NZL","New Zealand","2019","2019",9.3,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","MLLNCUMT","Million of national currency units","NZL","New Zealand","2020","2020",9.8,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","MLLNCUMT","Million of national currency units","NZL","New Zealand","2021","2021",10.7,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","MLLNCUMT","Million of national currency units","NZL","New Zealand","2022","2022",11.4,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","MTMOTCMT","Million US$ at exchange rate","NZL","New Zealand","2010","2010",21.2,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","MTMOTCMT","Million US$ at exchange rate","NZL","New Zealand","2011","2011",25.4,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","MTMOTCMT","Million US$ at exchange rate","NZL","New Zealand","2012","2012",26.6,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","MTMOTCMT","Million US$ at exchange rate","NZL","New Zealand","2013","2013",24,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","MTMOTCMT","Million US$ at exchange rate","NZL","New Zealand","2014","2014",14.5,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","MTMOTCMT","Million US$ at exchange rate","NZL","New Zealand","2015","2015",10.8,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","MTMOTCMT","Million US$ at exchange rate","NZL","New Zealand","2016","2016",9.5,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","MTMOTCMT","Million US$ at exchange rate","NZL","New Zealand","2017","2017",9.6,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","MTMOTCMT","Million US$ at exchange rate","NZL","New Zealand","2018","2018",5.9,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","MTMOTCMT","Million US$ at exchange rate","NZL","New Zealand","2019","2019",6.1,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","MTMOTCMT","Million US$ at exchange rate","NZL","New Zealand","2020","2020",6.3,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","MTMOTCMT","Million US$ at exchange rate","NZL","New Zealand","2021","2021",7.6,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","MTMOTCMT","Million US$ at exchange rate","NZL","New Zealand","2022","2022",7.2,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","MTMOPPMT","Million US$, purchasing power parity","NZL","New Zealand","2010","2010",19.7,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","MTMOPPMT","Million US$, purchasing power parity","NZL","New Zealand","2011","2011",21.7,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","MTMOPPMT","Million US$, purchasing power parity","NZL","New Zealand","2012","2012",22,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","MTMOPPMT","Million US$, purchasing power parity","NZL","New Zealand","2013","2013",20.2,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","MTMOPPMT","Million US$, purchasing power parity","NZL","New Zealand","2014","2014",12.1,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","MTMOPPMT","Million US$, purchasing power parity","NZL","New Zealand","2015","2015",10.5,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","MTMOPPMT","Million US$, purchasing power parity","NZL","New Zealand","2016","2016",9.5,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","MTMOPPMT","Million US$, purchasing power parity","NZL","New Zealand","2017","2017",9.4,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","MTMOPPMT","Million US$, purchasing power parity","NZL","New Zealand","2018","2018",5.8,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","MTMOPPMT","Million US$, purchasing power parity","NZL","New Zealand","2019","2019",6.6,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","MTMOPPMT","Million US$, purchasing power parity","NZL","New Zealand","2020","2020",6.9,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","MTMOPPMT","Million US$, purchasing power parity","NZL","New Zealand","2021","2021",7.3,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","MTMOPPMT","Million US$, purchasing power parity","NZL","New Zealand","2022","2022",7.9,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","TCPPERMT","/capita, US$ exchange rate","NZL","New Zealand","2010","2010",4.9,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","TCPPERMT","/capita, US$ exchange rate","NZL","New Zealand","2011","2011",5.8,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","TCPPERMT","/capita, US$ exchange rate","NZL","New Zealand","2012","2012",6,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","TCPPERMT","/capita, US$ exchange rate","NZL","New Zealand","2013","2013",5.4,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","TCPPERMT","/capita, US$ exchange rate","NZL","New Zealand","2014","2014",3.2,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","TCPPERMT","/capita, US$ exchange rate","NZL","New Zealand","2015","2015",2.4,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","TCPPERMT","/capita, US$ exchange rate","NZL","New Zealand","2016","2016",2,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","TCPPERMT","/capita, US$ exchange rate","NZL","New Zealand","2017","2017",2,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","TCPPERMT","/capita, US$ exchange rate","NZL","New Zealand","2018","2018",1.2,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","TCPPERMT","/capita, US$ exchange rate","NZL","New Zealand","2019","2019",1.2,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","TCPPERMT","/capita, US$ exchange rate","NZL","New Zealand","2020","2020",1.2,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","TCPPERMT","/capita, US$ exchange rate","NZL","New Zealand","2021","2021",1.5,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","TCPPERMT","/capita, US$ exchange rate","NZL","New Zealand","2022","2022",1.4,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2010","2010",4.5,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2011","2011",4.9,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2012","2012",5,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2013","2013",4.5,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2014","2014",2.7,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2015","2015",2.3,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2016","2016",2,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2017","2017",2,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2018","2018",1.2,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2019","2019",1.3,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2020","2020",1.4,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2021","2021",1.4,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2022","2022",1.5,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","ATCPTTMT","% of total sales","NZL","New Zealand","2010","2010",3.9,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","ATCPTTMT","% of total sales","NZL","New Zealand","2011","2011",3.9,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","ATCPTTMT","% of total sales","NZL","New Zealand","2012","2012",3.6,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","ATCPTTMT","% of total sales","NZL","New Zealand","2013","2013",3.2,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","ATCPTTMT","% of total sales","NZL","New Zealand","2014","2014",1.8,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","ATCPTTMT","% of total sales","NZL","New Zealand","2015","2015",1.6,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","ATCPTTMT","% of total sales","NZL","New Zealand","2016","2016",1.3,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","ATCPTTMT","% of total sales","NZL","New Zealand","2017","2017",1.1,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","ATCPTTMT","% of total sales","NZL","New Zealand","2018","2018",0.6,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","ATCPTTMT","% of total sales","NZL","New Zealand","2019","2019",0.6,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","ATCPTTMT","% of total sales","NZL","New Zealand","2020","2020",0.6,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","ATCPTTMT","% of total sales","NZL","New Zealand","2021","2021",0.6,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","ATCPTTMT","% of total sales","NZL","New Zealand","2022","2022",0.6,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","MLLNCUMT","Million of national currency units","NOR","Norway","2010","2010",324,,
+"PATCDEPR","N06A-Antidepressants","MLLNCUMT","Million of national currency units","NOR","Norway","2011","2011",266,,
+"PATCDEPR","N06A-Antidepressants","MLLNCUMT","Million of national currency units","NOR","Norway","2012","2012",266,,
+"PATCDEPR","N06A-Antidepressants","MLLNCUMT","Million of national currency units","NOR","Norway","2013","2013",261,,
+"PATCDEPR","N06A-Antidepressants","MLLNCUMT","Million of national currency units","NOR","Norway","2014","2014",263,,
+"PATCDEPR","N06A-Antidepressants","MLLNCUMT","Million of national currency units","NOR","Norway","2015","2015",264,,
+"PATCDEPR","N06A-Antidepressants","MLLNCUMT","Million of national currency units","NOR","Norway","2016","2016",267,,
+"PATCDEPR","N06A-Antidepressants","MLLNCUMT","Million of national currency units","NOR","Norway","2017","2017",277,,
+"PATCDEPR","N06A-Antidepressants","MLLNCUMT","Million of national currency units","NOR","Norway","2018","2018",280,,
+"PATCDEPR","N06A-Antidepressants","MLLNCUMT","Million of national currency units","NOR","Norway","2019","2019",291,,
+"PATCDEPR","N06A-Antidepressants","MLLNCUMT","Million of national currency units","NOR","Norway","2020","2020",311,,
+"PATCDEPR","N06A-Antidepressants","MLLNCUMT","Million of national currency units","NOR","Norway","2021","2021",307,,
+"PATCDEPR","N06A-Antidepressants","MLLNCUMT","Million of national currency units","NOR","Norway","2022","2022",316,,
+"PATCDEPR","N06A-Antidepressants","MTMOTCMT","Million US$ at exchange rate","NOR","Norway","2010","2010",53.6,,
+"PATCDEPR","N06A-Antidepressants","MTMOTCMT","Million US$ at exchange rate","NOR","Norway","2011","2011",47.5,,
+"PATCDEPR","N06A-Antidepressants","MTMOTCMT","Million US$ at exchange rate","NOR","Norway","2012","2012",45.7,,
+"PATCDEPR","N06A-Antidepressants","MTMOTCMT","Million US$ at exchange rate","NOR","Norway","2013","2013",44.4,,
+"PATCDEPR","N06A-Antidepressants","MTMOTCMT","Million US$ at exchange rate","NOR","Norway","2014","2014",41.7,,
+"PATCDEPR","N06A-Antidepressants","MTMOTCMT","Million US$ at exchange rate","NOR","Norway","2015","2015",32.7,,
+"PATCDEPR","N06A-Antidepressants","MTMOTCMT","Million US$ at exchange rate","NOR","Norway","2016","2016",31.8,,
+"PATCDEPR","N06A-Antidepressants","MTMOTCMT","Million US$ at exchange rate","NOR","Norway","2017","2017",33.5,,
+"PATCDEPR","N06A-Antidepressants","MTMOTCMT","Million US$ at exchange rate","NOR","Norway","2018","2018",34.4,,
+"PATCDEPR","N06A-Antidepressants","MTMOTCMT","Million US$ at exchange rate","NOR","Norway","2019","2019",33.1,,
+"PATCDEPR","N06A-Antidepressants","MTMOTCMT","Million US$ at exchange rate","NOR","Norway","2020","2020",33,,
+"PATCDEPR","N06A-Antidepressants","MTMOTCMT","Million US$ at exchange rate","NOR","Norway","2021","2021",35.7,,
+"PATCDEPR","N06A-Antidepressants","MTMOTCMT","Million US$ at exchange rate","NOR","Norway","2022","2022",32.9,,
+"PATCDEPR","N06A-Antidepressants","MTMOPPMT","Million US$, purchasing power parity","NOR","Norway","2010","2010",35.4,,
+"PATCDEPR","N06A-Antidepressants","MTMOPPMT","Million US$, purchasing power parity","NOR","Norway","2011","2011",29.3,,
+"PATCDEPR","N06A-Antidepressants","MTMOPPMT","Million US$, purchasing power parity","NOR","Norway","2012","2012",29.4,,
+"PATCDEPR","N06A-Antidepressants","MTMOPPMT","Million US$, purchasing power parity","NOR","Norway","2013","2013",28.9,,
+"PATCDEPR","N06A-Antidepressants","MTMOPPMT","Million US$, purchasing power parity","NOR","Norway","2014","2014",28.3,,
+"PATCDEPR","N06A-Antidepressants","MTMOPPMT","Million US$, purchasing power parity","NOR","Norway","2015","2015",26.6,,
+"PATCDEPR","N06A-Antidepressants","MTMOPPMT","Million US$, purchasing power parity","NOR","Norway","2016","2016",26.6,,
+"PATCDEPR","N06A-Antidepressants","MTMOPPMT","Million US$, purchasing power parity","NOR","Norway","2017","2017",28.4,,
+"PATCDEPR","N06A-Antidepressants","MTMOPPMT","Million US$, purchasing power parity","NOR","Norway","2018","2018",29.2,,
+"PATCDEPR","N06A-Antidepressants","MTMOPPMT","Million US$, purchasing power parity","NOR","Norway","2019","2019",30.2,,
+"PATCDEPR","N06A-Antidepressants","MTMOPPMT","Million US$, purchasing power parity","NOR","Norway","2020","2020",31.5,,
+"PATCDEPR","N06A-Antidepressants","MTMOPPMT","Million US$, purchasing power parity","NOR","Norway","2021","2021",32.3,,
+"PATCDEPR","N06A-Antidepressants","MTMOPPMT","Million US$, purchasing power parity","NOR","Norway","2022","2022",29.4,,
+"PATCDEPR","N06A-Antidepressants","TCPPERMT","/capita, US$ exchange rate","NOR","Norway","2010","2010",11,,
+"PATCDEPR","N06A-Antidepressants","TCPPERMT","/capita, US$ exchange rate","NOR","Norway","2011","2011",9.6,,
+"PATCDEPR","N06A-Antidepressants","TCPPERMT","/capita, US$ exchange rate","NOR","Norway","2012","2012",9.1,,
+"PATCDEPR","N06A-Antidepressants","TCPPERMT","/capita, US$ exchange rate","NOR","Norway","2013","2013",8.7,,
+"PATCDEPR","N06A-Antidepressants","TCPPERMT","/capita, US$ exchange rate","NOR","Norway","2014","2014",8.1,,
+"PATCDEPR","N06A-Antidepressants","TCPPERMT","/capita, US$ exchange rate","NOR","Norway","2015","2015",6.3,,
+"PATCDEPR","N06A-Antidepressants","TCPPERMT","/capita, US$ exchange rate","NOR","Norway","2016","2016",6.1,,
+"PATCDEPR","N06A-Antidepressants","TCPPERMT","/capita, US$ exchange rate","NOR","Norway","2017","2017",6.3,,
+"PATCDEPR","N06A-Antidepressants","TCPPERMT","/capita, US$ exchange rate","NOR","Norway","2018","2018",6.5,,
+"PATCDEPR","N06A-Antidepressants","TCPPERMT","/capita, US$ exchange rate","NOR","Norway","2019","2019",6.2,,
+"PATCDEPR","N06A-Antidepressants","TCPPERMT","/capita, US$ exchange rate","NOR","Norway","2020","2020",6.1,,
+"PATCDEPR","N06A-Antidepressants","TCPPERMT","/capita, US$ exchange rate","NOR","Norway","2021","2021",6.6,,
+"PATCDEPR","N06A-Antidepressants","TCPPERMT","/capita, US$ exchange rate","NOR","Norway","2022","2022",6.1,,
+"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2010","2010",7.2,,
+"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2011","2011",5.9,,
+"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2012","2012",5.9,,
+"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2013","2013",5.7,,
+"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2014","2014",5.5,,
+"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2015","2015",5.1,,
+"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2016","2016",5.1,,
+"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2017","2017",5.4,,
+"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2018","2018",5.5,,
+"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2019","2019",5.7,,
+"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2020","2020",5.9,,
+"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2021","2021",6,,
+"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2022","2022",5.4,,
+"PATCDEPR","N06A-Antidepressants","ATCPTTMT","% of total sales","NOR","Norway","2010","2010",1.8,,
+"PATCDEPR","N06A-Antidepressants","ATCPTTMT","% of total sales","NOR","Norway","2011","2011",1.5,,
+"PATCDEPR","N06A-Antidepressants","ATCPTTMT","% of total sales","NOR","Norway","2012","2012",1.4,,
+"PATCDEPR","N06A-Antidepressants","ATCPTTMT","% of total sales","NOR","Norway","2013","2013",1.4,,
+"PATCDEPR","N06A-Antidepressants","ATCPTTMT","% of total sales","NOR","Norway","2014","2014",1.2,,
+"PATCDEPR","N06A-Antidepressants","ATCPTTMT","% of total sales","NOR","Norway","2015","2015",1.2,,
+"PATCDEPR","N06A-Antidepressants","ATCPTTMT","% of total sales","NOR","Norway","2016","2016",1.1,,
+"PATCDEPR","N06A-Antidepressants","ATCPTTMT","% of total sales","NOR","Norway","2017","2017",1,,
+"PATCDEPR","N06A-Antidepressants","ATCPTTMT","% of total sales","NOR","Norway","2018","2018",1,,
+"PATCDEPR","N06A-Antidepressants","ATCPTTMT","% of total sales","NOR","Norway","2019","2019",1,,
+"PATCDEPR","N06A-Antidepressants","ATCPTTMT","% of total sales","NOR","Norway","2020","2020",1,,
+"PATCDEPR","N06A-Antidepressants","ATCPTTMT","% of total sales","NOR","Norway","2021","2021",0.9,,
+"PATCDEPR","N06A-Antidepressants","ATCPTTMT","% of total sales","NOR","Norway","2022","2022",0.9,,
+"PATCDEPR","N06A-Antidepressants","MLLNCUMT","Million of national currency units","PRT","Portugal","2010","2010",158.3,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","MLLNCUMT","Million of national currency units","PRT","Portugal","2011","2011",140.4,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","MLLNCUMT","Million of national currency units","PRT","Portugal","2012","2012",116.6,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","MLLNCUMT","Million of national currency units","PRT","Portugal","2013","2013",97.7,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","MLLNCUMT","Million of national currency units","PRT","Portugal","2014","2014",95.4,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","MLLNCUMT","Million of national currency units","PRT","Portugal","2015","2015",92.9,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","MLLNCUMT","Million of national currency units","PRT","Portugal","2016","2016",93.6,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","MLLNCUMT","Million of national currency units","PRT","Portugal","2017","2017",96,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","MLLNCUMT","Million of national currency units","PRT","Portugal","2018","2018",99.7,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","MLLNCUMT","Million of national currency units","PRT","Portugal","2019","2019",107.1,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","MLLNCUMT","Million of national currency units","PRT","Portugal","2020","2020",111.8,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","MLLNCUMT","Million of national currency units","PRT","Portugal","2021","2021",119.2,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","MLLNCUMT","Million of national currency units","PRT","Portugal","2022","2022",128.7,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","MTMOTCMT","Million US$ at exchange rate","PRT","Portugal","2010","2010",209.9,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","MTMOTCMT","Million US$ at exchange rate","PRT","Portugal","2011","2011",195.4,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","MTMOTCMT","Million US$ at exchange rate","PRT","Portugal","2012","2012",149.9,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","MTMOTCMT","Million US$ at exchange rate","PRT","Portugal","2013","2013",129.8,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","MTMOTCMT","Million US$ at exchange rate","PRT","Portugal","2014","2014",126.7,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","MTMOTCMT","Million US$ at exchange rate","PRT","Portugal","2015","2015",103.1,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","MTMOTCMT","Million US$ at exchange rate","PRT","Portugal","2016","2016",103.6,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","MTMOTCMT","Million US$ at exchange rate","PRT","Portugal","2017","2017",108.4,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","MTMOTCMT","Million US$ at exchange rate","PRT","Portugal","2018","2018",117.7,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","MTMOTCMT","Million US$ at exchange rate","PRT","Portugal","2019","2019",119.9,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","MTMOTCMT","Million US$ at exchange rate","PRT","Portugal","2020","2020",127.7,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","MTMOTCMT","Million US$ at exchange rate","PRT","Portugal","2021","2021",141,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","MTMOTCMT","Million US$ at exchange rate","PRT","Portugal","2022","2022",135.5,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","MTMOPPMT","Million US$, purchasing power parity","PRT","Portugal","2010","2010",254.1,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","MTMOPPMT","Million US$, purchasing power parity","PRT","Portugal","2011","2011",225.3,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","MTMOPPMT","Million US$, purchasing power parity","PRT","Portugal","2012","2012",192.7,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","MTMOPPMT","Million US$, purchasing power parity","PRT","Portugal","2013","2013",167.4,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","MTMOPPMT","Million US$, purchasing power parity","PRT","Portugal","2014","2014",164.8,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","MTMOPPMT","Million US$, purchasing power parity","PRT","Portugal","2015","2015",158.8,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","MTMOPPMT","Million US$, purchasing power parity","PRT","Portugal","2016","2016",163.7,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","MTMOPPMT","Million US$, purchasing power parity","PRT","Portugal","2017","2017",166.8,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","MTMOPPMT","Million US$, purchasing power parity","PRT","Portugal","2018","2018",174.5,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","MTMOPPMT","Million US$, purchasing power parity","PRT","Portugal","2019","2019",191.6,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","MTMOPPMT","Million US$, purchasing power parity","PRT","Portugal","2020","2020",200.8,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","MTMOPPMT","Million US$, purchasing power parity","PRT","Portugal","2021","2021",210,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","MTMOPPMT","Million US$, purchasing power parity","PRT","Portugal","2022","2022",233.9,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","TCPPERMT","/capita, US$ exchange rate","PRT","Portugal","2010","2010",19.9,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","TCPPERMT","/capita, US$ exchange rate","PRT","Portugal","2011","2011",18.5,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","TCPPERMT","/capita, US$ exchange rate","PRT","Portugal","2012","2012",14.3,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","TCPPERMT","/capita, US$ exchange rate","PRT","Portugal","2013","2013",12.4,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","TCPPERMT","/capita, US$ exchange rate","PRT","Portugal","2014","2014",12.2,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","TCPPERMT","/capita, US$ exchange rate","PRT","Portugal","2015","2015",10,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","TCPPERMT","/capita, US$ exchange rate","PRT","Portugal","2016","2016",10,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","TCPPERMT","/capita, US$ exchange rate","PRT","Portugal","2017","2017",10.5,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","TCPPERMT","/capita, US$ exchange rate","PRT","Portugal","2018","2018",11.4,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","TCPPERMT","/capita, US$ exchange rate","PRT","Portugal","2019","2019",11.7,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","TCPPERMT","/capita, US$ exchange rate","PRT","Portugal","2020","2020",12.4,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","TCPPERMT","/capita, US$ exchange rate","PRT","Portugal","2021","2021",13.6,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","TCPPERMT","/capita, US$ exchange rate","PRT","Portugal","2022","2022",13.1,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2010","2010",24,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2011","2011",21.3,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2012","2012",18.3,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2013","2013",16,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2014","2014",15.8,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2015","2015",15.3,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2016","2016",15.9,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2017","2017",16.2,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2018","2018",17,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2019","2019",18.6,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2020","2020",19.5,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2021","2021",20.3,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2022","2022",22.6,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","ATCPTTMT","% of total sales","PRT","Portugal","2010","2010",4.9,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","ATCPTTMT","% of total sales","PRT","Portugal","2011","2011",4.8,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","ATCPTTMT","% of total sales","PRT","Portugal","2012","2012",4.5,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","ATCPTTMT","% of total sales","PRT","Portugal","2013","2013",4.1,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","ATCPTTMT","% of total sales","PRT","Portugal","2014","2014",4,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","ATCPTTMT","% of total sales","PRT","Portugal","2015","2015",3.7,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","ATCPTTMT","% of total sales","PRT","Portugal","2016","2016",3.7,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","ATCPTTMT","% of total sales","PRT","Portugal","2017","2017",3.8,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","ATCPTTMT","% of total sales","PRT","Portugal","2018","2018",3.8,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","ATCPTTMT","% of total sales","PRT","Portugal","2019","2019",3.8,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","ATCPTTMT","% of total sales","PRT","Portugal","2020","2020",4,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","ATCPTTMT","% of total sales","PRT","Portugal","2021","2021",4.1,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","ATCPTTMT","% of total sales","PRT","Portugal","2022","2022",4,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","MLLNCUMT","Million of national currency units","SVK","Slovak Republic","2010","2010",16.3,,
+"PATCDEPR","N06A-Antidepressants","MLLNCUMT","Million of national currency units","SVK","Slovak Republic","2011","2011",15.1,,
+"PATCDEPR","N06A-Antidepressants","MLLNCUMT","Million of national currency units","SVK","Slovak Republic","2012","2012",12.7,,
+"PATCDEPR","N06A-Antidepressants","MLLNCUMT","Million of national currency units","SVK","Slovak Republic","2013","2013",12.3,,
+"PATCDEPR","N06A-Antidepressants","MLLNCUMT","Million of national currency units","SVK","Slovak Republic","2014","2014",14,,
+"PATCDEPR","N06A-Antidepressants","MLLNCUMT","Million of national currency units","SVK","Slovak Republic","2015","2015",14.9,,
+"PATCDEPR","N06A-Antidepressants","MLLNCUMT","Million of national currency units","SVK","Slovak Republic","2016","2016",16.7,"B","Break"
+"PATCDEPR","N06A-Antidepressants","MLLNCUMT","Million of national currency units","SVK","Slovak Republic","2017","2017",15.7,,
+"PATCDEPR","N06A-Antidepressants","MLLNCUMT","Million of national currency units","SVK","Slovak Republic","2018","2018",16.3,,
+"PATCDEPR","N06A-Antidepressants","MLLNCUMT","Million of national currency units","SVK","Slovak Republic","2019","2019",16.6,,
+"PATCDEPR","N06A-Antidepressants","MLLNCUMT","Million of national currency units","SVK","Slovak Republic","2020","2020",16.8,,
+"PATCDEPR","N06A-Antidepressants","MLLNCUMT","Million of national currency units","SVK","Slovak Republic","2021","2021",17.1,,
+"PATCDEPR","N06A-Antidepressants","MTMOTCMT","Million US$ at exchange rate","SVK","Slovak Republic","2010","2010",21.6,,
+"PATCDEPR","N06A-Antidepressants","MTMOTCMT","Million US$ at exchange rate","SVK","Slovak Republic","2011","2011",20.9,,
+"PATCDEPR","N06A-Antidepressants","MTMOTCMT","Million US$ at exchange rate","SVK","Slovak Republic","2012","2012",16.3,,
+"PATCDEPR","N06A-Antidepressants","MTMOTCMT","Million US$ at exchange rate","SVK","Slovak Republic","2013","2013",16.4,,
+"PATCDEPR","N06A-Antidepressants","MTMOTCMT","Million US$ at exchange rate","SVK","Slovak Republic","2014","2014",18.7,,
+"PATCDEPR","N06A-Antidepressants","MTMOTCMT","Million US$ at exchange rate","SVK","Slovak Republic","2015","2015",16.5,,
+"PATCDEPR","N06A-Antidepressants","MTMOTCMT","Million US$ at exchange rate","SVK","Slovak Republic","2016","2016",18.5,"B","Break"
+"PATCDEPR","N06A-Antidepressants","MTMOTCMT","Million US$ at exchange rate","SVK","Slovak Republic","2017","2017",17.7,,
+"PATCDEPR","N06A-Antidepressants","MTMOTCMT","Million US$ at exchange rate","SVK","Slovak Republic","2018","2018",19.3,,
+"PATCDEPR","N06A-Antidepressants","MTMOTCMT","Million US$ at exchange rate","SVK","Slovak Republic","2019","2019",18.6,,
+"PATCDEPR","N06A-Antidepressants","MTMOTCMT","Million US$ at exchange rate","SVK","Slovak Republic","2020","2020",19.2,,
+"PATCDEPR","N06A-Antidepressants","MTMOTCMT","Million US$ at exchange rate","SVK","Slovak Republic","2021","2021",20.2,,
+"PATCDEPR","N06A-Antidepressants","MTMOPPMT","Million US$, purchasing power parity","SVK","Slovak Republic","2010","2010",32.4,,
+"PATCDEPR","N06A-Antidepressants","MTMOPPMT","Million US$, purchasing power parity","SVK","Slovak Republic","2011","2011",29.7,,
+"PATCDEPR","N06A-Antidepressants","MTMOPPMT","Million US$, purchasing power parity","SVK","Slovak Republic","2012","2012",25.2,,
+"PATCDEPR","N06A-Antidepressants","MTMOPPMT","Million US$, purchasing power parity","SVK","Slovak Republic","2013","2013",25.1,,
+"PATCDEPR","N06A-Antidepressants","MTMOPPMT","Million US$, purchasing power parity","SVK","Slovak Republic","2014","2014",28.9,,
+"PATCDEPR","N06A-Antidepressants","MTMOPPMT","Million US$, purchasing power parity","SVK","Slovak Republic","2015","2015",30.3,,
+"PATCDEPR","N06A-Antidepressants","MTMOPPMT","Million US$, purchasing power parity","SVK","Slovak Republic","2016","2016",33.2,"B","Break"
+"PATCDEPR","N06A-Antidepressants","MTMOPPMT","Million US$, purchasing power parity","SVK","Slovak Republic","2017","2017",30.4,,
+"PATCDEPR","N06A-Antidepressants","MTMOPPMT","Million US$, purchasing power parity","SVK","Slovak Republic","2018","2018",31,,
+"PATCDEPR","N06A-Antidepressants","MTMOPPMT","Million US$, purchasing power parity","SVK","Slovak Republic","2019","2019",32.1,,
+"PATCDEPR","N06A-Antidepressants","MTMOPPMT","Million US$, purchasing power parity","SVK","Slovak Republic","2020","2020",32.3,,
+"PATCDEPR","N06A-Antidepressants","MTMOPPMT","Million US$, purchasing power parity","SVK","Slovak Republic","2021","2021",32.1,,
+"PATCDEPR","N06A-Antidepressants","TCPPERMT","/capita, US$ exchange rate","SVK","Slovak Republic","2010","2010",4,,
+"PATCDEPR","N06A-Antidepressants","TCPPERMT","/capita, US$ exchange rate","SVK","Slovak Republic","2011","2011",3.9,,
+"PATCDEPR","N06A-Antidepressants","TCPPERMT","/capita, US$ exchange rate","SVK","Slovak Republic","2012","2012",3,,
+"PATCDEPR","N06A-Antidepressants","TCPPERMT","/capita, US$ exchange rate","SVK","Slovak Republic","2013","2013",3,,
+"PATCDEPR","N06A-Antidepressants","TCPPERMT","/capita, US$ exchange rate","SVK","Slovak Republic","2014","2014",3.4,,
+"PATCDEPR","N06A-Antidepressants","TCPPERMT","/capita, US$ exchange rate","SVK","Slovak Republic","2015","2015",3,,
+"PATCDEPR","N06A-Antidepressants","TCPPERMT","/capita, US$ exchange rate","SVK","Slovak Republic","2016","2016",3.4,"B","Break"
+"PATCDEPR","N06A-Antidepressants","TCPPERMT","/capita, US$ exchange rate","SVK","Slovak Republic","2017","2017",3.3,,
+"PATCDEPR","N06A-Antidepressants","TCPPERMT","/capita, US$ exchange rate","SVK","Slovak Republic","2018","2018",3.5,,
+"PATCDEPR","N06A-Antidepressants","TCPPERMT","/capita, US$ exchange rate","SVK","Slovak Republic","2019","2019",3.4,,
+"PATCDEPR","N06A-Antidepressants","TCPPERMT","/capita, US$ exchange rate","SVK","Slovak Republic","2020","2020",3.5,,
+"PATCDEPR","N06A-Antidepressants","TCPPERMT","/capita, US$ exchange rate","SVK","Slovak Republic","2021","2021",3.7,,
+"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2010","2010",6,,
+"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2011","2011",5.5,,
+"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2012","2012",4.7,,
+"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2013","2013",4.6,,
+"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2014","2014",5.3,,
+"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2015","2015",5.6,,
+"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2016","2016",6.1,"B","Break"
+"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2017","2017",5.6,,
+"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2018","2018",5.7,,
+"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2019","2019",5.9,,
+"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2020","2020",5.9,,
+"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2021","2021",5.9,,
+"PATCDEPR","N06A-Antidepressants","ATCPTTMT","% of total sales","SVK","Slovak Republic","2010","2010",1.5,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","ATCPTTMT","% of total sales","SVK","Slovak Republic","2011","2011",1.3,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","ATCPTTMT","% of total sales","SVK","Slovak Republic","2012","2012",1.2,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","ATCPTTMT","% of total sales","SVK","Slovak Republic","2013","2013",1,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","ATCPTTMT","% of total sales","SVK","Slovak Republic","2014","2014",1.1,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","ATCPTTMT","% of total sales","SVK","Slovak Republic","2015","2015",1.1,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","ATCPTTMT","% of total sales","SVK","Slovak Republic","2016","2016",1.1,"B","Break"
+"PATCDEPR","N06A-Antidepressants","ATCPTTMT","% of total sales","SVK","Slovak Republic","2017","2017",1,,
+"PATCDEPR","N06A-Antidepressants","ATCPTTMT","% of total sales","SVK","Slovak Republic","2018","2018",1,,
+"PATCDEPR","N06A-Antidepressants","ATCPTTMT","% of total sales","SVK","Slovak Republic","2019","2019",1,,
+"PATCDEPR","N06A-Antidepressants","ATCPTTMT","% of total sales","SVK","Slovak Republic","2020","2020",1,,
+"PATCDEPR","N06A-Antidepressants","ATCPTTMT","% of total sales","SVK","Slovak Republic","2021","2021",1,,
+"PATCDEPR","N06A-Antidepressants","MLLNCUMT","Million of national currency units","ESP","Spain","2010","2010",687.2,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","MLLNCUMT","Million of national currency units","ESP","Spain","2011","2011",590.4,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","MLLNCUMT","Million of national currency units","ESP","Spain","2012","2012",488.7,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","MLLNCUMT","Million of national currency units","ESP","Spain","2013","2013",500.6,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","MLLNCUMT","Million of national currency units","ESP","Spain","2014","2014",535.3,"B; D","Break; Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","MLLNCUMT","Million of national currency units","ESP","Spain","2015","2015",484.6,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","MLLNCUMT","Million of national currency units","ESP","Spain","2016","2016",483.9,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","MLLNCUMT","Million of national currency units","ESP","Spain","2017","2017",500.8,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","MLLNCUMT","Million of national currency units","ESP","Spain","2018","2018",526.6,"B","Break"
+"PATCDEPR","N06A-Antidepressants","MLLNCUMT","Million of national currency units","ESP","Spain","2019","2019",538.1,,
+"PATCDEPR","N06A-Antidepressants","MLLNCUMT","Million of national currency units","ESP","Spain","2020","2020",568.2,,
+"PATCDEPR","N06A-Antidepressants","MLLNCUMT","Million of national currency units","ESP","Spain","2021","2021",610.3,,
+"PATCDEPR","N06A-Antidepressants","MLLNCUMT","Million of national currency units","ESP","Spain","2022","2022",655.9,"P","Provisional value"
+"PATCDEPR","N06A-Antidepressants","MTMOTCMT","Million US$ at exchange rate","ESP","Spain","2010","2010",911,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","MTMOTCMT","Million US$ at exchange rate","ESP","Spain","2011","2011",821.9,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","MTMOTCMT","Million US$ at exchange rate","ESP","Spain","2012","2012",627.9,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","MTMOTCMT","Million US$ at exchange rate","ESP","Spain","2013","2013",664.9,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","MTMOTCMT","Million US$ at exchange rate","ESP","Spain","2014","2014",711.2,"B; D","Break; Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","MTMOTCMT","Million US$ at exchange rate","ESP","Spain","2015","2015",537.7,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","MTMOTCMT","Million US$ at exchange rate","ESP","Spain","2016","2016",535.6,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","MTMOTCMT","Million US$ at exchange rate","ESP","Spain","2017","2017",565.7,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","MTMOTCMT","Million US$ at exchange rate","ESP","Spain","2018","2018",621.9,"B","Break"
+"PATCDEPR","N06A-Antidepressants","MTMOTCMT","Million US$ at exchange rate","ESP","Spain","2019","2019",602.4,,
+"PATCDEPR","N06A-Antidepressants","MTMOTCMT","Million US$ at exchange rate","ESP","Spain","2020","2020",649,,
+"PATCDEPR","N06A-Antidepressants","MTMOTCMT","Million US$ at exchange rate","ESP","Spain","2021","2021",721.9,,
+"PATCDEPR","N06A-Antidepressants","MTMOTCMT","Million US$ at exchange rate","ESP","Spain","2022","2022",690.7,"P","Provisional value"
+"PATCDEPR","N06A-Antidepressants","MTMOPPMT","Million US$, purchasing power parity","ESP","Spain","2010","2010",945.2,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","MTMOPPMT","Million US$, purchasing power parity","ESP","Spain","2011","2011",826.8,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","MTMOPPMT","Million US$, purchasing power parity","ESP","Spain","2012","2012",703.2,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","MTMOPPMT","Million US$, purchasing power parity","ESP","Spain","2013","2013",741.9,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","MTMOPPMT","Million US$, purchasing power parity","ESP","Spain","2014","2014",808.2,"B; D","Break; Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","MTMOPPMT","Million US$, purchasing power parity","ESP","Spain","2015","2015",729,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","MTMOPPMT","Million US$, purchasing power parity","ESP","Spain","2016","2016",753,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","MTMOPPMT","Million US$, purchasing power parity","ESP","Spain","2017","2017",793.8,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","MTMOPPMT","Million US$, purchasing power parity","ESP","Spain","2018","2018",833.5,"B","Break"
+"PATCDEPR","N06A-Antidepressants","MTMOPPMT","Million US$, purchasing power parity","ESP","Spain","2019","2019",877.8,,
+"PATCDEPR","N06A-Antidepressants","MTMOPPMT","Million US$, purchasing power parity","ESP","Spain","2020","2020",914.5,,
+"PATCDEPR","N06A-Antidepressants","MTMOPPMT","Million US$, purchasing power parity","ESP","Spain","2021","2021",975.1,,
+"PATCDEPR","N06A-Antidepressants","MTMOPPMT","Million US$, purchasing power parity","ESP","Spain","2022","2022",1100.1,"P","Provisional value"
+"PATCDEPR","N06A-Antidepressants","TCPPERMT","/capita, US$ exchange rate","ESP","Spain","2010","2010",19.6,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","TCPPERMT","/capita, US$ exchange rate","ESP","Spain","2011","2011",17.6,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","TCPPERMT","/capita, US$ exchange rate","ESP","Spain","2012","2012",13.4,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","TCPPERMT","/capita, US$ exchange rate","ESP","Spain","2013","2013",14.3,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","TCPPERMT","/capita, US$ exchange rate","ESP","Spain","2014","2014",15.3,"B; D","Break; Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","TCPPERMT","/capita, US$ exchange rate","ESP","Spain","2015","2015",11.6,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","TCPPERMT","/capita, US$ exchange rate","ESP","Spain","2016","2016",11.5,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","TCPPERMT","/capita, US$ exchange rate","ESP","Spain","2017","2017",12.1,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","TCPPERMT","/capita, US$ exchange rate","ESP","Spain","2018","2018",13.3,"B","Break"
+"PATCDEPR","N06A-Antidepressants","TCPPERMT","/capita, US$ exchange rate","ESP","Spain","2019","2019",12.8,,
+"PATCDEPR","N06A-Antidepressants","TCPPERMT","/capita, US$ exchange rate","ESP","Spain","2020","2020",13.7,,
+"PATCDEPR","N06A-Antidepressants","TCPPERMT","/capita, US$ exchange rate","ESP","Spain","2021","2021",15.2,,
+"PATCDEPR","N06A-Antidepressants","TCPPERMT","/capita, US$ exchange rate","ESP","Spain","2022","2022",14.6,"P","Provisional value"
+"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2010","2010",20.3,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2011","2011",17.7,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2012","2012",15,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2013","2013",15.9,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2014","2014",17.4,"B; D","Break; Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2015","2015",15.7,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2016","2016",16.2,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2017","2017",17,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2018","2018",17.8,"B","Break"
+"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2019","2019",18.6,,
+"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2020","2020",19.3,,
+"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2021","2021",20.6,,
+"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2022","2022",23.2,"P","Provisional value"
+"PATCDEPR","N06A-Antidepressants","ATCPTTMT","% of total sales","ESP","Spain","2010","2010",5.2,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","ATCPTTMT","% of total sales","ESP","Spain","2011","2011",4.8,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","ATCPTTMT","% of total sales","ESP","Spain","2012","2012",4.4,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","ATCPTTMT","% of total sales","ESP","Spain","2013","2013",4.7,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","ATCPTTMT","% of total sales","ESP","Spain","2014","2014",4.7,"B; D","Break; Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","ATCPTTMT","% of total sales","ESP","Spain","2015","2015",4.2,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","ATCPTTMT","% of total sales","ESP","Spain","2016","2016",4.1,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","ATCPTTMT","% of total sales","ESP","Spain","2017","2017",4.2,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","ATCPTTMT","% of total sales","ESP","Spain","2018","2018",2.8,"B","Break"
+"PATCDEPR","N06A-Antidepressants","ATCPTTMT","% of total sales","ESP","Spain","2019","2019",2.7,,
+"PATCDEPR","N06A-Antidepressants","ATCPTTMT","% of total sales","ESP","Spain","2020","2020",2.7,,
+"PATCDEPR","N06A-Antidepressants","ATCPTTMT","% of total sales","ESP","Spain","2021","2021",2.8,,
+"PATCDEPR","N06A-Antidepressants","ATCPTTMT","% of total sales","ESP","Spain","2022","2022",2.9,"P","Provisional value"
+"PATCDEPR","N06A-Antidepressants","MLLNCUMT","Million of national currency units","SWE","Sweden","2010","2010",625.7,,
+"PATCDEPR","N06A-Antidepressants","MLLNCUMT","Million of national currency units","SWE","Sweden","2011","2011",660.8,,
+"PATCDEPR","N06A-Antidepressants","MLLNCUMT","Million of national currency units","SWE","Sweden","2012","2012",678.8,,
+"PATCDEPR","N06A-Antidepressants","MLLNCUMT","Million of national currency units","SWE","Sweden","2013","2013",744.4,,
+"PATCDEPR","N06A-Antidepressants","MLLNCUMT","Million of national currency units","SWE","Sweden","2014","2014",721.3,,
+"PATCDEPR","N06A-Antidepressants","MLLNCUMT","Million of national currency units","SWE","Sweden","2015","2015",668.4,,
+"PATCDEPR","N06A-Antidepressants","MLLNCUMT","Million of national currency units","SWE","Sweden","2016","2016",590.1,,
+"PATCDEPR","N06A-Antidepressants","MLLNCUMT","Million of national currency units","SWE","Sweden","2017","2017",618.9,,
+"PATCDEPR","N06A-Antidepressants","MLLNCUMT","Million of national currency units","SWE","Sweden","2018","2018",724.2,,
+"PATCDEPR","N06A-Antidepressants","MLLNCUMT","Million of national currency units","SWE","Sweden","2019","2019",788.6,,
+"PATCDEPR","N06A-Antidepressants","MLLNCUMT","Million of national currency units","SWE","Sweden","2020","2020",842.8,,
+"PATCDEPR","N06A-Antidepressants","MLLNCUMT","Million of national currency units","SWE","Sweden","2021","2021",754.8,,
+"PATCDEPR","N06A-Antidepressants","MLLNCUMT","Million of national currency units","SWE","Sweden","2022","2022",753.4,,
+"PATCDEPR","N06A-Antidepressants","MTMOTCMT","Million US$ at exchange rate","SWE","Sweden","2010","2010",86.8,,
+"PATCDEPR","N06A-Antidepressants","MTMOTCMT","Million US$ at exchange rate","SWE","Sweden","2011","2011",101.8,,
+"PATCDEPR","N06A-Antidepressants","MTMOTCMT","Million US$ at exchange rate","SWE","Sweden","2012","2012",100.2,,
+"PATCDEPR","N06A-Antidepressants","MTMOTCMT","Million US$ at exchange rate","SWE","Sweden","2013","2013",114.3,,
+"PATCDEPR","N06A-Antidepressants","MTMOTCMT","Million US$ at exchange rate","SWE","Sweden","2014","2014",105.1,,
+"PATCDEPR","N06A-Antidepressants","MTMOTCMT","Million US$ at exchange rate","SWE","Sweden","2015","2015",79.2,,
+"PATCDEPR","N06A-Antidepressants","MTMOTCMT","Million US$ at exchange rate","SWE","Sweden","2016","2016",68.9,,
+"PATCDEPR","N06A-Antidepressants","MTMOTCMT","Million US$ at exchange rate","SWE","Sweden","2017","2017",72.4,,
+"PATCDEPR","N06A-Antidepressants","MTMOTCMT","Million US$ at exchange rate","SWE","Sweden","2018","2018",83.3,,
+"PATCDEPR","N06A-Antidepressants","MTMOTCMT","Million US$ at exchange rate","SWE","Sweden","2019","2019",83.4,,
+"PATCDEPR","N06A-Antidepressants","MTMOTCMT","Million US$ at exchange rate","SWE","Sweden","2020","2020",91.5,,
+"PATCDEPR","N06A-Antidepressants","MTMOTCMT","Million US$ at exchange rate","SWE","Sweden","2021","2021",88,,
+"PATCDEPR","N06A-Antidepressants","MTMOTCMT","Million US$ at exchange rate","SWE","Sweden","2022","2022",74.5,,
+"PATCDEPR","N06A-Antidepressants","MTMOPPMT","Million US$, purchasing power parity","SWE","Sweden","2010","2010",69.3,,
+"PATCDEPR","N06A-Antidepressants","MTMOPPMT","Million US$, purchasing power parity","SWE","Sweden","2011","2011",74.7,,
+"PATCDEPR","N06A-Antidepressants","MTMOPPMT","Million US$, purchasing power parity","SWE","Sweden","2012","2012",78.4,,
+"PATCDEPR","N06A-Antidepressants","MTMOPPMT","Million US$, purchasing power parity","SWE","Sweden","2013","2013",86.6,,
+"PATCDEPR","N06A-Antidepressants","MTMOPPMT","Million US$, purchasing power parity","SWE","Sweden","2014","2014",82.7,,
+"PATCDEPR","N06A-Antidepressants","MTMOPPMT","Million US$, purchasing power parity","SWE","Sweden","2015","2015",75.5,,
+"PATCDEPR","N06A-Antidepressants","MTMOPPMT","Million US$, purchasing power parity","SWE","Sweden","2016","2016",66.9,,
+"PATCDEPR","N06A-Antidepressants","MTMOPPMT","Million US$, purchasing power parity","SWE","Sweden","2017","2017",69.9,,
+"PATCDEPR","N06A-Antidepressants","MTMOPPMT","Million US$, purchasing power parity","SWE","Sweden","2018","2018",81.7,,
+"PATCDEPR","N06A-Antidepressants","MTMOPPMT","Million US$, purchasing power parity","SWE","Sweden","2019","2019",90.5,,
+"PATCDEPR","N06A-Antidepressants","MTMOPPMT","Million US$, purchasing power parity","SWE","Sweden","2020","2020",97.2,,
+"PATCDEPR","N06A-Antidepressants","MTMOPPMT","Million US$, purchasing power parity","SWE","Sweden","2021","2021",86.5,,
+"PATCDEPR","N06A-Antidepressants","MTMOPPMT","Million US$, purchasing power parity","SWE","Sweden","2022","2022",86.9,,
+"PATCDEPR","N06A-Antidepressants","TCPPERMT","/capita, US$ exchange rate","SWE","Sweden","2010","2010",9.3,,
+"PATCDEPR","N06A-Antidepressants","TCPPERMT","/capita, US$ exchange rate","SWE","Sweden","2011","2011",10.8,,
+"PATCDEPR","N06A-Antidepressants","TCPPERMT","/capita, US$ exchange rate","SWE","Sweden","2012","2012",10.5,,
+"PATCDEPR","N06A-Antidepressants","TCPPERMT","/capita, US$ exchange rate","SWE","Sweden","2013","2013",11.9,,
+"PATCDEPR","N06A-Antidepressants","TCPPERMT","/capita, US$ exchange rate","SWE","Sweden","2014","2014",10.8,,
+"PATCDEPR","N06A-Antidepressants","TCPPERMT","/capita, US$ exchange rate","SWE","Sweden","2015","2015",8.1,,
+"PATCDEPR","N06A-Antidepressants","TCPPERMT","/capita, US$ exchange rate","SWE","Sweden","2016","2016",6.9,,
+"PATCDEPR","N06A-Antidepressants","TCPPERMT","/capita, US$ exchange rate","SWE","Sweden","2017","2017",7.2,,
+"PATCDEPR","N06A-Antidepressants","TCPPERMT","/capita, US$ exchange rate","SWE","Sweden","2018","2018",8.2,,
+"PATCDEPR","N06A-Antidepressants","TCPPERMT","/capita, US$ exchange rate","SWE","Sweden","2019","2019",8.1,,
+"PATCDEPR","N06A-Antidepressants","TCPPERMT","/capita, US$ exchange rate","SWE","Sweden","2020","2020",8.8,,
+"PATCDEPR","N06A-Antidepressants","TCPPERMT","/capita, US$ exchange rate","SWE","Sweden","2021","2021",8.4,,
+"PATCDEPR","N06A-Antidepressants","TCPPERMT","/capita, US$ exchange rate","SWE","Sweden","2022","2022",7.1,,
+"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2010","2010",7.4,,
+"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2011","2011",7.9,,
+"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2012","2012",8.2,,
+"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2013","2013",9,,
+"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2014","2014",8.5,,
+"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2015","2015",7.7,,
+"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2016","2016",6.7,,
+"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2017","2017",7,,
+"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2018","2018",8,,
+"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2019","2019",8.8,,
+"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2020","2020",9.4,,
+"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2021","2021",8.3,,
+"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2022","2022",8.3,,
+"PATCDEPR","N06A-Antidepressants","ATCPTTMT","% of total sales","SWE","Sweden","2010","2010",1.7,,
+"PATCDEPR","N06A-Antidepressants","ATCPTTMT","% of total sales","SWE","Sweden","2011","2011",1.8,,
+"PATCDEPR","N06A-Antidepressants","ATCPTTMT","% of total sales","SWE","Sweden","2012","2012",1.9,,
+"PATCDEPR","N06A-Antidepressants","ATCPTTMT","% of total sales","SWE","Sweden","2013","2013",2,,
+"PATCDEPR","N06A-Antidepressants","ATCPTTMT","% of total sales","SWE","Sweden","2014","2014",1.9,,
+"PATCDEPR","N06A-Antidepressants","ATCPTTMT","% of total sales","SWE","Sweden","2015","2015",1.6,,
+"PATCDEPR","N06A-Antidepressants","ATCPTTMT","% of total sales","SWE","Sweden","2016","2016",1.4,,
+"PATCDEPR","N06A-Antidepressants","ATCPTTMT","% of total sales","SWE","Sweden","2017","2017",1.4,,
+"PATCDEPR","N06A-Antidepressants","ATCPTTMT","% of total sales","SWE","Sweden","2018","2018",1.5,,
+"PATCDEPR","N06A-Antidepressants","ATCPTTMT","% of total sales","SWE","Sweden","2019","2019",1.6,,
+"PATCDEPR","N06A-Antidepressants","ATCPTTMT","% of total sales","SWE","Sweden","2020","2020",1.6,,
+"PATCDEPR","N06A-Antidepressants","ATCPTTMT","% of total sales","SWE","Sweden","2021","2021",1.4,,
+"PATCDEPR","N06A-Antidepressants","ATCPTTMT","% of total sales","SWE","Sweden","2022","2022",1.3,,
+"PATCDEPR","N06A-Antidepressants","MLLNCUMT","Million of national currency units","TUR","Türkiye","2010","2010",372.9,,
+"PATCDEPR","N06A-Antidepressants","MLLNCUMT","Million of national currency units","TUR","Türkiye","2011","2011",338.8,,
+"PATCDEPR","N06A-Antidepressants","MLLNCUMT","Million of national currency units","TUR","Türkiye","2012","2012",269.7,,
+"PATCDEPR","N06A-Antidepressants","MLLNCUMT","Million of national currency units","TUR","Türkiye","2013","2013",263,,
+"PATCDEPR","N06A-Antidepressants","MLLNCUMT","Million of national currency units","TUR","Türkiye","2014","2014",278.5,,
+"PATCDEPR","N06A-Antidepressants","MLLNCUMT","Million of national currency units","TUR","Türkiye","2015","2015",317.7,,
+"PATCDEPR","N06A-Antidepressants","MLLNCUMT","Million of national currency units","TUR","Türkiye","2016","2016",367.9,,
+"PATCDEPR","N06A-Antidepressants","MLLNCUMT","Million of national currency units","TUR","Türkiye","2017","2017",446.5,,
+"PATCDEPR","N06A-Antidepressants","MLLNCUMT","Million of national currency units","TUR","Türkiye","2018","2018",527.7,,
+"PATCDEPR","N06A-Antidepressants","MLLNCUMT","Million of national currency units","TUR","Türkiye","2019","2019",664.1,,
+"PATCDEPR","N06A-Antidepressants","MLLNCUMT","Million of national currency units","TUR","Türkiye","2020","2020",974.8,,
+"PATCDEPR","N06A-Antidepressants","MLLNCUMT","Million of national currency units","TUR","Türkiye","2021","2021",1043.7,,
+"PATCDEPR","N06A-Antidepressants","MTMOTCMT","Million US$ at exchange rate","TUR","Türkiye","2010","2010",248.1,,
+"PATCDEPR","N06A-Antidepressants","MTMOTCMT","Million US$ at exchange rate","TUR","Türkiye","2011","2011",202.3,,
+"PATCDEPR","N06A-Antidepressants","MTMOTCMT","Million US$ at exchange rate","TUR","Türkiye","2012","2012",150.2,,
+"PATCDEPR","N06A-Antidepressants","MTMOTCMT","Million US$ at exchange rate","TUR","Türkiye","2013","2013",138.2,,
+"PATCDEPR","N06A-Antidepressants","MTMOTCMT","Million US$ at exchange rate","TUR","Türkiye","2014","2014",127.3,,
+"PATCDEPR","N06A-Antidepressants","MTMOTCMT","Million US$ at exchange rate","TUR","Türkiye","2015","2015",116.8,,
+"PATCDEPR","N06A-Antidepressants","MTMOTCMT","Million US$ at exchange rate","TUR","Türkiye","2016","2016",121.8,,
+"PATCDEPR","N06A-Antidepressants","MTMOTCMT","Million US$ at exchange rate","TUR","Türkiye","2017","2017",122.4,,
+"PATCDEPR","N06A-Antidepressants","MTMOTCMT","Million US$ at exchange rate","TUR","Türkiye","2018","2018",109.3,,
+"PATCDEPR","N06A-Antidepressants","MTMOTCMT","Million US$ at exchange rate","TUR","Türkiye","2019","2019",117.1,,
+"PATCDEPR","N06A-Antidepressants","MTMOTCMT","Million US$ at exchange rate","TUR","Türkiye","2020","2020",139.1,,
+"PATCDEPR","N06A-Antidepressants","MTMOTCMT","Million US$ at exchange rate","TUR","Türkiye","2021","2021",117.9,,
+"PATCDEPR","N06A-Antidepressants","MTMOPPMT","Million US$, purchasing power parity","TUR","Türkiye","2010","2010",405.1,,
+"PATCDEPR","N06A-Antidepressants","MTMOPPMT","Million US$, purchasing power parity","TUR","Türkiye","2011","2011",350.7,,
+"PATCDEPR","N06A-Antidepressants","MTMOPPMT","Million US$, purchasing power parity","TUR","Türkiye","2012","2012",264.5,,
+"PATCDEPR","N06A-Antidepressants","MTMOPPMT","Million US$, purchasing power parity","TUR","Türkiye","2013","2013",245.7,,
+"PATCDEPR","N06A-Antidepressants","MTMOPPMT","Million US$, purchasing power parity","TUR","Türkiye","2014","2014",252.1,,
+"PATCDEPR","N06A-Antidepressants","MTMOPPMT","Million US$, purchasing power parity","TUR","Türkiye","2015","2015",273.3,,
+"PATCDEPR","N06A-Antidepressants","MTMOPPMT","Million US$, purchasing power parity","TUR","Türkiye","2016","2016",296.5,,
+"PATCDEPR","N06A-Antidepressants","MTMOPPMT","Million US$, purchasing power parity","TUR","Türkiye","2017","2017",322.6,,
+"PATCDEPR","N06A-Antidepressants","MTMOPPMT","Million US$, purchasing power parity","TUR","Türkiye","2018","2018",323.2,,
+"PATCDEPR","N06A-Antidepressants","MTMOPPMT","Million US$, purchasing power parity","TUR","Türkiye","2019","2019",356.3,,
+"PATCDEPR","N06A-Antidepressants","MTMOPPMT","Million US$, purchasing power parity","TUR","Türkiye","2020","2020",450.4,,
+"PATCDEPR","N06A-Antidepressants","MTMOPPMT","Million US$, purchasing power parity","TUR","Türkiye","2021","2021",371.7,,
+"PATCDEPR","N06A-Antidepressants","TCPPERMT","/capita, US$ exchange rate","TUR","Türkiye","2010","2010",3.4,,
+"PATCDEPR","N06A-Antidepressants","TCPPERMT","/capita, US$ exchange rate","TUR","Türkiye","2011","2011",2.7,,
+"PATCDEPR","N06A-Antidepressants","TCPPERMT","/capita, US$ exchange rate","TUR","Türkiye","2012","2012",2,,
+"PATCDEPR","N06A-Antidepressants","TCPPERMT","/capita, US$ exchange rate","TUR","Türkiye","2013","2013",1.8,,
+"PATCDEPR","N06A-Antidepressants","TCPPERMT","/capita, US$ exchange rate","TUR","Türkiye","2014","2014",1.6,,
+"PATCDEPR","N06A-Antidepressants","TCPPERMT","/capita, US$ exchange rate","TUR","Türkiye","2015","2015",1.5,,
+"PATCDEPR","N06A-Antidepressants","TCPPERMT","/capita, US$ exchange rate","TUR","Türkiye","2016","2016",1.5,,
+"PATCDEPR","N06A-Antidepressants","TCPPERMT","/capita, US$ exchange rate","TUR","Türkiye","2017","2017",1.5,,
+"PATCDEPR","N06A-Antidepressants","TCPPERMT","/capita, US$ exchange rate","TUR","Türkiye","2018","2018",1.3,,
+"PATCDEPR","N06A-Antidepressants","TCPPERMT","/capita, US$ exchange rate","TUR","Türkiye","2019","2019",1.4,,
+"PATCDEPR","N06A-Antidepressants","TCPPERMT","/capita, US$ exchange rate","TUR","Türkiye","2020","2020",1.7,,
+"PATCDEPR","N06A-Antidepressants","TCPPERMT","/capita, US$ exchange rate","TUR","Türkiye","2021","2021",1.4,,
+"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2010","2010",5.5,,
+"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2011","2011",4.7,,
+"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2012","2012",3.5,,
+"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2013","2013",3.2,,
+"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2014","2014",3.3,,
+"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2015","2015",3.5,,
+"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2016","2016",3.7,,
+"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2017","2017",4,,
+"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2018","2018",4,,
+"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2019","2019",4.3,,
+"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2020","2020",5.4,,
+"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2021","2021",4.4,,
+"PATCDEPR","N06A-Antidepressants","ATCPTTMT","% of total sales","TUR","Türkiye","2010","2010",2.4,,
+"PATCDEPR","N06A-Antidepressants","ATCPTTMT","% of total sales","TUR","Türkiye","2011","2011",2.4,,
+"PATCDEPR","N06A-Antidepressants","ATCPTTMT","% of total sales","TUR","Türkiye","2012","2012",2,,
+"PATCDEPR","N06A-Antidepressants","ATCPTTMT","% of total sales","TUR","Türkiye","2013","2013",1.8,,
+"PATCDEPR","N06A-Antidepressants","ATCPTTMT","% of total sales","TUR","Türkiye","2014","2014",1.8,,
+"PATCDEPR","N06A-Antidepressants","ATCPTTMT","% of total sales","TUR","Türkiye","2015","2015",1.7,,
+"PATCDEPR","N06A-Antidepressants","ATCPTTMT","% of total sales","TUR","Türkiye","2016","2016",1.7,,
+"PATCDEPR","N06A-Antidepressants","ATCPTTMT","% of total sales","TUR","Türkiye","2017","2017",1.8,,
+"PATCDEPR","N06A-Antidepressants","ATCPTTMT","% of total sales","TUR","Türkiye","2018","2018",1.6,,
+"PATCDEPR","N06A-Antidepressants","ATCPTTMT","% of total sales","TUR","Türkiye","2019","2019",1.6,,
+"PATCDEPR","N06A-Antidepressants","ATCPTTMT","% of total sales","TUR","Türkiye","2020","2020",2,,
+"PATCDEPR","N06A-Antidepressants","ATCPTTMT","% of total sales","TUR","Türkiye","2021","2021",1.6,,
+"PATCDEPR","N06A-Antidepressants","MLLNCUMT","Million of national currency units","CHL","Chile","2010","2010",31955.1,,
+"PATCDEPR","N06A-Antidepressants","MLLNCUMT","Million of national currency units","CHL","Chile","2011","2011",25714.6,"B","Break"
+"PATCDEPR","N06A-Antidepressants","MLLNCUMT","Million of national currency units","CHL","Chile","2012","2012",28119.5,,
+"PATCDEPR","N06A-Antidepressants","MLLNCUMT","Million of national currency units","CHL","Chile","2013","2013",30007.6,,
+"PATCDEPR","N06A-Antidepressants","MLLNCUMT","Million of national currency units","CHL","Chile","2014","2014",48805.4,,
+"PATCDEPR","N06A-Antidepressants","MLLNCUMT","Million of national currency units","CHL","Chile","2015","2015",56272,,
+"PATCDEPR","N06A-Antidepressants","MLLNCUMT","Million of national currency units","CHL","Chile","2016","2016",60183.9,,
+"PATCDEPR","N06A-Antidepressants","MLLNCUMT","Million of national currency units","CHL","Chile","2017","2017",62830.3,,
+"PATCDEPR","N06A-Antidepressants","MLLNCUMT","Million of national currency units","CHL","Chile","2018","2018",64587.1,,
+"PATCDEPR","N06A-Antidepressants","MLLNCUMT","Million of national currency units","CHL","Chile","2019","2019",67892.2,,
+"PATCDEPR","N06A-Antidepressants","MLLNCUMT","Million of national currency units","CHL","Chile","2020","2020",79843.8,,
+"PATCDEPR","N06A-Antidepressants","MLLNCUMT","Million of national currency units","CHL","Chile","2021","2021",92278.8,,
+"PATCDEPR","N06A-Antidepressants","MLLNCUMT","Million of national currency units","CHL","Chile","2022","2022",104325.5,,
+"PATCDEPR","N06A-Antidepressants","MTMOTCMT","Million US$ at exchange rate","CHL","Chile","2010","2010",62.6,,
+"PATCDEPR","N06A-Antidepressants","MTMOTCMT","Million US$ at exchange rate","CHL","Chile","2011","2011",53.2,"B","Break"
+"PATCDEPR","N06A-Antidepressants","MTMOTCMT","Million US$ at exchange rate","CHL","Chile","2012","2012",57.8,,
+"PATCDEPR","N06A-Antidepressants","MTMOTCMT","Million US$ at exchange rate","CHL","Chile","2013","2013",60.6,,
+"PATCDEPR","N06A-Antidepressants","MTMOTCMT","Million US$ at exchange rate","CHL","Chile","2014","2014",85.6,,
+"PATCDEPR","N06A-Antidepressants","MTMOTCMT","Million US$ at exchange rate","CHL","Chile","2015","2015",86,,
+"PATCDEPR","N06A-Antidepressants","MTMOTCMT","Million US$ at exchange rate","CHL","Chile","2016","2016",88.9,,
+"PATCDEPR","N06A-Antidepressants","MTMOTCMT","Million US$ at exchange rate","CHL","Chile","2017","2017",96.8,,
+"PATCDEPR","N06A-Antidepressants","MTMOTCMT","Million US$ at exchange rate","CHL","Chile","2018","2018",100.7,,
+"PATCDEPR","N06A-Antidepressants","MTMOTCMT","Million US$ at exchange rate","CHL","Chile","2019","2019",96.6,,
+"PATCDEPR","N06A-Antidepressants","MTMOTCMT","Million US$ at exchange rate","CHL","Chile","2020","2020",100.7,,
+"PATCDEPR","N06A-Antidepressants","MTMOTCMT","Million US$ at exchange rate","CHL","Chile","2021","2021",121.6,,
+"PATCDEPR","N06A-Antidepressants","MTMOTCMT","Million US$ at exchange rate","CHL","Chile","2022","2022",119.5,,
+"PATCDEPR","N06A-Antidepressants","MTMOPPMT","Million US$, purchasing power parity","CHL","Chile","2010","2010",88.8,,
+"PATCDEPR","N06A-Antidepressants","MTMOPPMT","Million US$, purchasing power parity","CHL","Chile","2011","2011",73.9,"B","Break"
+"PATCDEPR","N06A-Antidepressants","MTMOPPMT","Million US$, purchasing power parity","CHL","Chile","2012","2012",81,,
+"PATCDEPR","N06A-Antidepressants","MTMOPPMT","Million US$, purchasing power parity","CHL","Chile","2013","2013",85.8,,
+"PATCDEPR","N06A-Antidepressants","MTMOPPMT","Million US$, purchasing power parity","CHL","Chile","2014","2014",132.9,,
+"PATCDEPR","N06A-Antidepressants","MTMOPPMT","Million US$, purchasing power parity","CHL","Chile","2015","2015",143.9,,
+"PATCDEPR","N06A-Antidepressants","MTMOPPMT","Million US$, purchasing power parity","CHL","Chile","2016","2016",151.5,,
+"PATCDEPR","N06A-Antidepressants","MTMOPPMT","Million US$, purchasing power parity","CHL","Chile","2017","2017",158,,
+"PATCDEPR","N06A-Antidepressants","MTMOPPMT","Million US$, purchasing power parity","CHL","Chile","2018","2018",163,,
+"PATCDEPR","N06A-Antidepressants","MTMOPPMT","Million US$, purchasing power parity","CHL","Chile","2019","2019",169,,
+"PATCDEPR","N06A-Antidepressants","MTMOPPMT","Million US$, purchasing power parity","CHL","Chile","2020","2020",190.8,,
+"PATCDEPR","N06A-Antidepressants","MTMOPPMT","Million US$, purchasing power parity","CHL","Chile","2021","2021",212.1,,
+"PATCDEPR","N06A-Antidepressants","MTMOPPMT","Million US$, purchasing power parity","CHL","Chile","2022","2022",238.4,,
+"PATCDEPR","N06A-Antidepressants","TCPPERMT","/capita, US$ exchange rate","CHL","Chile","2010","2010",3.7,,
+"PATCDEPR","N06A-Antidepressants","TCPPERMT","/capita, US$ exchange rate","CHL","Chile","2011","2011",3.1,"B","Break"
+"PATCDEPR","N06A-Antidepressants","TCPPERMT","/capita, US$ exchange rate","CHL","Chile","2012","2012",3.3,,
+"PATCDEPR","N06A-Antidepressants","TCPPERMT","/capita, US$ exchange rate","CHL","Chile","2013","2013",3.4,,
+"PATCDEPR","N06A-Antidepressants","TCPPERMT","/capita, US$ exchange rate","CHL","Chile","2014","2014",4.8,,
+"PATCDEPR","N06A-Antidepressants","TCPPERMT","/capita, US$ exchange rate","CHL","Chile","2015","2015",4.8,,
+"PATCDEPR","N06A-Antidepressants","TCPPERMT","/capita, US$ exchange rate","CHL","Chile","2016","2016",4.9,,
+"PATCDEPR","N06A-Antidepressants","TCPPERMT","/capita, US$ exchange rate","CHL","Chile","2017","2017",5.3,,
+"PATCDEPR","N06A-Antidepressants","TCPPERMT","/capita, US$ exchange rate","CHL","Chile","2018","2018",5.4,,
+"PATCDEPR","N06A-Antidepressants","TCPPERMT","/capita, US$ exchange rate","CHL","Chile","2019","2019",5.1,,
+"PATCDEPR","N06A-Antidepressants","TCPPERMT","/capita, US$ exchange rate","CHL","Chile","2020","2020",5.2,,
+"PATCDEPR","N06A-Antidepressants","TCPPERMT","/capita, US$ exchange rate","CHL","Chile","2021","2021",6.2,,
+"PATCDEPR","N06A-Antidepressants","TCPPERMT","/capita, US$ exchange rate","CHL","Chile","2022","2022",6,,
+"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2010","2010",5.2,,
+"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2011","2011",4.3,"B","Break"
+"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2012","2012",4.6,,
+"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2013","2013",4.9,,
+"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2014","2014",7.5,,
+"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2015","2015",8,,
+"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2016","2016",8.3,,
+"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2017","2017",8.6,,
+"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2018","2018",8.7,,
+"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2019","2019",8.8,,
+"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2020","2020",9.8,,
+"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2021","2021",10.8,,
+"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2022","2022",12,,
+"PATCDEPR","N06A-Antidepressants","ATCPTTMT","% of total sales","CHL","Chile","2010","2010",3.9,,
+"PATCDEPR","N06A-Antidepressants","ATCPTTMT","% of total sales","CHL","Chile","2011","2011",2.2,"B","Break"
+"PATCDEPR","N06A-Antidepressants","ATCPTTMT","% of total sales","CHL","Chile","2012","2012",2.3,,
+"PATCDEPR","N06A-Antidepressants","ATCPTTMT","% of total sales","CHL","Chile","2013","2013",2.1,,
+"PATCDEPR","N06A-Antidepressants","ATCPTTMT","% of total sales","CHL","Chile","2014","2014",3.2,,
+"PATCDEPR","N06A-Antidepressants","ATCPTTMT","% of total sales","CHL","Chile","2015","2015",3.1,,
+"PATCDEPR","N06A-Antidepressants","ATCPTTMT","% of total sales","CHL","Chile","2016","2016",3,,
+"PATCDEPR","N06A-Antidepressants","ATCPTTMT","% of total sales","CHL","Chile","2017","2017",3,,
+"PATCDEPR","N06A-Antidepressants","ATCPTTMT","% of total sales","CHL","Chile","2018","2018",2.8,,
+"PATCDEPR","N06A-Antidepressants","ATCPTTMT","% of total sales","CHL","Chile","2019","2019",2.7,,
+"PATCDEPR","N06A-Antidepressants","ATCPTTMT","% of total sales","CHL","Chile","2020","2020",3,,
+"PATCDEPR","N06A-Antidepressants","ATCPTTMT","% of total sales","CHL","Chile","2021","2021",3.3,,
+"PATCDEPR","N06A-Antidepressants","ATCPTTMT","% of total sales","CHL","Chile","2022","2022",3.7,,
+"PATCDEPR","N06A-Antidepressants","MLLNCUMT","Million of national currency units","EST","Estonia","2010","2010",3,,
+"PATCDEPR","N06A-Antidepressants","MLLNCUMT","Million of national currency units","EST","Estonia","2011","2011",2.9,,
+"PATCDEPR","N06A-Antidepressants","MLLNCUMT","Million of national currency units","EST","Estonia","2012","2012",2.9,,
+"PATCDEPR","N06A-Antidepressants","MLLNCUMT","Million of national currency units","EST","Estonia","2013","2013",2.9,,
+"PATCDEPR","N06A-Antidepressants","MLLNCUMT","Million of national currency units","EST","Estonia","2014","2014",3,,
+"PATCDEPR","N06A-Antidepressants","MLLNCUMT","Million of national currency units","EST","Estonia","2015","2015",3.2,,
+"PATCDEPR","N06A-Antidepressants","MLLNCUMT","Million of national currency units","EST","Estonia","2016","2016",3.3,,
+"PATCDEPR","N06A-Antidepressants","MLLNCUMT","Million of national currency units","EST","Estonia","2017","2017",3.2,,
+"PATCDEPR","N06A-Antidepressants","MLLNCUMT","Million of national currency units","EST","Estonia","2018","2018",3.6,,
+"PATCDEPR","N06A-Antidepressants","MLLNCUMT","Million of national currency units","EST","Estonia","2019","2019",3.9,,
+"PATCDEPR","N06A-Antidepressants","MLLNCUMT","Million of national currency units","EST","Estonia","2020","2020",4.2,,
+"PATCDEPR","N06A-Antidepressants","MLLNCUMT","Million of national currency units","EST","Estonia","2021","2021",4.6,,
+"PATCDEPR","N06A-Antidepressants","MLLNCUMT","Million of national currency units","EST","Estonia","2022","2022",5.1,,
+"PATCDEPR","N06A-Antidepressants","MTMOTCMT","Million US$ at exchange rate","EST","Estonia","2010","2010",4,,
+"PATCDEPR","N06A-Antidepressants","MTMOTCMT","Million US$ at exchange rate","EST","Estonia","2011","2011",4.1,,
+"PATCDEPR","N06A-Antidepressants","MTMOTCMT","Million US$ at exchange rate","EST","Estonia","2012","2012",3.8,,
+"PATCDEPR","N06A-Antidepressants","MTMOTCMT","Million US$ at exchange rate","EST","Estonia","2013","2013",3.9,,
+"PATCDEPR","N06A-Antidepressants","MTMOTCMT","Million US$ at exchange rate","EST","Estonia","2014","2014",4.1,,
+"PATCDEPR","N06A-Antidepressants","MTMOTCMT","Million US$ at exchange rate","EST","Estonia","2015","2015",3.6,,
+"PATCDEPR","N06A-Antidepressants","MTMOTCMT","Million US$ at exchange rate","EST","Estonia","2016","2016",3.6,,
+"PATCDEPR","N06A-Antidepressants","MTMOTCMT","Million US$ at exchange rate","EST","Estonia","2017","2017",3.6,,
+"PATCDEPR","N06A-Antidepressants","MTMOTCMT","Million US$ at exchange rate","EST","Estonia","2018","2018",4.3,,
+"PATCDEPR","N06A-Antidepressants","MTMOTCMT","Million US$ at exchange rate","EST","Estonia","2019","2019",4.4,,
+"PATCDEPR","N06A-Antidepressants","MTMOTCMT","Million US$ at exchange rate","EST","Estonia","2020","2020",4.8,,
+"PATCDEPR","N06A-Antidepressants","MTMOTCMT","Million US$ at exchange rate","EST","Estonia","2021","2021",5.5,,
+"PATCDEPR","N06A-Antidepressants","MTMOTCMT","Million US$ at exchange rate","EST","Estonia","2022","2022",5.4,,
+"PATCDEPR","N06A-Antidepressants","MTMOPPMT","Million US$, purchasing power parity","EST","Estonia","2010","2010",5.9,,
+"PATCDEPR","N06A-Antidepressants","MTMOPPMT","Million US$, purchasing power parity","EST","Estonia","2011","2011",5.8,,
+"PATCDEPR","N06A-Antidepressants","MTMOPPMT","Million US$, purchasing power parity","EST","Estonia","2012","2012",5.6,,
+"PATCDEPR","N06A-Antidepressants","MTMOPPMT","Million US$, purchasing power parity","EST","Estonia","2013","2013",5.6,,
+"PATCDEPR","N06A-Antidepressants","MTMOPPMT","Million US$, purchasing power parity","EST","Estonia","2014","2014",5.8,,
+"PATCDEPR","N06A-Antidepressants","MTMOPPMT","Million US$, purchasing power parity","EST","Estonia","2015","2015",6,,
+"PATCDEPR","N06A-Antidepressants","MTMOPPMT","Million US$, purchasing power parity","EST","Estonia","2016","2016",6.2,,
+"PATCDEPR","N06A-Antidepressants","MTMOPPMT","Million US$, purchasing power parity","EST","Estonia","2017","2017",6,,
+"PATCDEPR","N06A-Antidepressants","MTMOPPMT","Million US$, purchasing power parity","EST","Estonia","2018","2018",6.7,,
+"PATCDEPR","N06A-Antidepressants","MTMOPPMT","Million US$, purchasing power parity","EST","Estonia","2019","2019",7.3,,
+"PATCDEPR","N06A-Antidepressants","MTMOPPMT","Million US$, purchasing power parity","EST","Estonia","2020","2020",8,,
+"PATCDEPR","N06A-Antidepressants","MTMOPPMT","Million US$, purchasing power parity","EST","Estonia","2021","2021",8.5,,
+"PATCDEPR","N06A-Antidepressants","MTMOPPMT","Million US$, purchasing power parity","EST","Estonia","2022","2022",9,,
+"PATCDEPR","N06A-Antidepressants","TCPPERMT","/capita, US$ exchange rate","EST","Estonia","2010","2010",3,,
+"PATCDEPR","N06A-Antidepressants","TCPPERMT","/capita, US$ exchange rate","EST","Estonia","2011","2011",3.1,,
+"PATCDEPR","N06A-Antidepressants","TCPPERMT","/capita, US$ exchange rate","EST","Estonia","2012","2012",2.9,,
+"PATCDEPR","N06A-Antidepressants","TCPPERMT","/capita, US$ exchange rate","EST","Estonia","2013","2013",2.9,,
+"PATCDEPR","N06A-Antidepressants","TCPPERMT","/capita, US$ exchange rate","EST","Estonia","2014","2014",3.1,,
+"PATCDEPR","N06A-Antidepressants","TCPPERMT","/capita, US$ exchange rate","EST","Estonia","2015","2015",2.7,,
+"PATCDEPR","N06A-Antidepressants","TCPPERMT","/capita, US$ exchange rate","EST","Estonia","2016","2016",2.7,,
+"PATCDEPR","N06A-Antidepressants","TCPPERMT","/capita, US$ exchange rate","EST","Estonia","2017","2017",2.8,,
+"PATCDEPR","N06A-Antidepressants","TCPPERMT","/capita, US$ exchange rate","EST","Estonia","2018","2018",3.2,,
+"PATCDEPR","N06A-Antidepressants","TCPPERMT","/capita, US$ exchange rate","EST","Estonia","2019","2019",3.3,,
+"PATCDEPR","N06A-Antidepressants","TCPPERMT","/capita, US$ exchange rate","EST","Estonia","2020","2020",3.6,,
+"PATCDEPR","N06A-Antidepressants","TCPPERMT","/capita, US$ exchange rate","EST","Estonia","2021","2021",4.1,,
+"PATCDEPR","N06A-Antidepressants","TCPPERMT","/capita, US$ exchange rate","EST","Estonia","2022","2022",4.1,,
+"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2010","2010",4.4,,
+"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2011","2011",4.3,,
+"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2012","2012",4.3,,
+"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2013","2013",4.2,,
+"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2014","2014",4.4,,
+"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2015","2015",4.6,,
+"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2016","2016",4.7,,
+"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2017","2017",4.6,,
+"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2018","2018",5.1,,
+"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2019","2019",5.5,,
+"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2020","2020",6,,
+"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2021","2021",6.4,,
+"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2022","2022",6.8,,
+"PATCDEPR","N06A-Antidepressants","ATCPTTMT","% of total sales","EST","Estonia","2010","2010",1.6,,
+"PATCDEPR","N06A-Antidepressants","ATCPTTMT","% of total sales","EST","Estonia","2011","2011",1.4,,
+"PATCDEPR","N06A-Antidepressants","ATCPTTMT","% of total sales","EST","Estonia","2012","2012",1.3,,
+"PATCDEPR","N06A-Antidepressants","ATCPTTMT","% of total sales","EST","Estonia","2013","2013",1.3,,
+"PATCDEPR","N06A-Antidepressants","ATCPTTMT","% of total sales","EST","Estonia","2014","2014",1.2,,
+"PATCDEPR","N06A-Antidepressants","ATCPTTMT","% of total sales","EST","Estonia","2015","2015",1.2,,
+"PATCDEPR","N06A-Antidepressants","ATCPTTMT","% of total sales","EST","Estonia","2016","2016",1.1,,
+"PATCDEPR","N06A-Antidepressants","ATCPTTMT","% of total sales","EST","Estonia","2017","2017",1.1,,
+"PATCDEPR","N06A-Antidepressants","ATCPTTMT","% of total sales","EST","Estonia","2018","2018",1.1,,
+"PATCDEPR","N06A-Antidepressants","ATCPTTMT","% of total sales","EST","Estonia","2019","2019",1.1,,
+"PATCDEPR","N06A-Antidepressants","ATCPTTMT","% of total sales","EST","Estonia","2020","2020",1.2,,
+"PATCDEPR","N06A-Antidepressants","ATCPTTMT","% of total sales","EST","Estonia","2021","2021",1.1,,
+"PATCDEPR","N06A-Antidepressants","ATCPTTMT","% of total sales","EST","Estonia","2022","2022",1.2,,
+"PATCDEPR","N06A-Antidepressants","MLLNCUMT","Million of national currency units","SVN","Slovenia","2010","2010",15.6,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","MLLNCUMT","Million of national currency units","SVN","Slovenia","2011","2011",15.9,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","MLLNCUMT","Million of national currency units","SVN","Slovenia","2012","2012",14.6,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","MLLNCUMT","Million of national currency units","SVN","Slovenia","2013","2013",14.5,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","MLLNCUMT","Million of national currency units","SVN","Slovenia","2014","2014",13.5,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","MLLNCUMT","Million of national currency units","SVN","Slovenia","2015","2015",11.7,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","MLLNCUMT","Million of national currency units","SVN","Slovenia","2016","2016",11.2,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","MLLNCUMT","Million of national currency units","SVN","Slovenia","2017","2017",10.6,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","MLLNCUMT","Million of national currency units","SVN","Slovenia","2018","2018",11.1,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","MLLNCUMT","Million of national currency units","SVN","Slovenia","2019","2019",11.7,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","MLLNCUMT","Million of national currency units","SVN","Slovenia","2020","2020",11.6,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","MLLNCUMT","Million of national currency units","SVN","Slovenia","2021","2021",11.8,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","MLLNCUMT","Million of national currency units","SVN","Slovenia","2022","2022",12.1,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","MTMOTCMT","Million US$ at exchange rate","SVN","Slovenia","2010","2010",20.6,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","MTMOTCMT","Million US$ at exchange rate","SVN","Slovenia","2011","2011",22.1,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","MTMOTCMT","Million US$ at exchange rate","SVN","Slovenia","2012","2012",18.8,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","MTMOTCMT","Million US$ at exchange rate","SVN","Slovenia","2013","2013",19.3,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","MTMOTCMT","Million US$ at exchange rate","SVN","Slovenia","2014","2014",17.9,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","MTMOTCMT","Million US$ at exchange rate","SVN","Slovenia","2015","2015",13,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","MTMOTCMT","Million US$ at exchange rate","SVN","Slovenia","2016","2016",12.4,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","MTMOTCMT","Million US$ at exchange rate","SVN","Slovenia","2017","2017",11.9,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","MTMOTCMT","Million US$ at exchange rate","SVN","Slovenia","2018","2018",13.1,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","MTMOTCMT","Million US$ at exchange rate","SVN","Slovenia","2019","2019",13.1,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","MTMOTCMT","Million US$ at exchange rate","SVN","Slovenia","2020","2020",13.3,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","MTMOTCMT","Million US$ at exchange rate","SVN","Slovenia","2021","2021",14,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","MTMOTCMT","Million US$ at exchange rate","SVN","Slovenia","2022","2022",12.7,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","MTMOPPMT","Million US$, purchasing power parity","SVN","Slovenia","2010","2010",24.4,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","MTMOPPMT","Million US$, purchasing power parity","SVN","Slovenia","2011","2011",25.5,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","MTMOPPMT","Million US$, purchasing power parity","SVN","Slovenia","2012","2012",24.1,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","MTMOPPMT","Million US$, purchasing power parity","SVN","Slovenia","2013","2013",24.6,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","MTMOPPMT","Million US$, purchasing power parity","SVN","Slovenia","2014","2014",22.8,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","MTMOPPMT","Million US$, purchasing power parity","SVN","Slovenia","2015","2015",19.6,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","MTMOPPMT","Million US$, purchasing power parity","SVN","Slovenia","2016","2016",19.4,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","MTMOPPMT","Million US$, purchasing power parity","SVN","Slovenia","2017","2017",18.5,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","MTMOPPMT","Million US$, purchasing power parity","SVN","Slovenia","2018","2018",19.5,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","MTMOPPMT","Million US$, purchasing power parity","SVN","Slovenia","2019","2019",21.2,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","MTMOPPMT","Million US$, purchasing power parity","SVN","Slovenia","2020","2020",21.3,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","MTMOPPMT","Million US$, purchasing power parity","SVN","Slovenia","2021","2021",21,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","MTMOPPMT","Million US$, purchasing power parity","SVN","Slovenia","2022","2022",21.9,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","TCPPERMT","/capita, US$ exchange rate","SVN","Slovenia","2010","2010",10.1,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","TCPPERMT","/capita, US$ exchange rate","SVN","Slovenia","2011","2011",10.8,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","TCPPERMT","/capita, US$ exchange rate","SVN","Slovenia","2012","2012",9.1,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","TCPPERMT","/capita, US$ exchange rate","SVN","Slovenia","2013","2013",9.3,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","TCPPERMT","/capita, US$ exchange rate","SVN","Slovenia","2014","2014",8.7,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","TCPPERMT","/capita, US$ exchange rate","SVN","Slovenia","2015","2015",6.3,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","TCPPERMT","/capita, US$ exchange rate","SVN","Slovenia","2016","2016",6,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","TCPPERMT","/capita, US$ exchange rate","SVN","Slovenia","2017","2017",5.8,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","TCPPERMT","/capita, US$ exchange rate","SVN","Slovenia","2018","2018",6.3,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","TCPPERMT","/capita, US$ exchange rate","SVN","Slovenia","2019","2019",6.3,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","TCPPERMT","/capita, US$ exchange rate","SVN","Slovenia","2020","2020",6.3,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","TCPPERMT","/capita, US$ exchange rate","SVN","Slovenia","2021","2021",6.6,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","TCPPERMT","/capita, US$ exchange rate","SVN","Slovenia","2022","2022",6,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2010","2010",11.9,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2011","2011",12.4,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2012","2012",11.7,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2013","2013",11.9,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2014","2014",11.1,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2015","2015",9.5,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2016","2016",9.4,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2017","2017",9,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2018","2018",9.4,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2019","2019",10.2,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2020","2020",10.1,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2021","2021",10,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2022","2022",10.4,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","ATCPTTMT","% of total sales","SVN","Slovenia","2010","2010",3.3,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","ATCPTTMT","% of total sales","SVN","Slovenia","2011","2011",3.4,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","ATCPTTMT","% of total sales","SVN","Slovenia","2012","2012",3.2,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","ATCPTTMT","% of total sales","SVN","Slovenia","2013","2013",3.2,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","ATCPTTMT","% of total sales","SVN","Slovenia","2014","2014",3.1,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","ATCPTTMT","% of total sales","SVN","Slovenia","2015","2015",2.6,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","ATCPTTMT","% of total sales","SVN","Slovenia","2016","2016",2.4,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","ATCPTTMT","% of total sales","SVN","Slovenia","2017","2017",2.2,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","ATCPTTMT","% of total sales","SVN","Slovenia","2018","2018",2.1,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","ATCPTTMT","% of total sales","SVN","Slovenia","2019","2019",2.2,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","ATCPTTMT","% of total sales","SVN","Slovenia","2020","2020",2,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","ATCPTTMT","% of total sales","SVN","Slovenia","2021","2021",1.9,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","ATCPTTMT","% of total sales","SVN","Slovenia","2022","2022",1.8,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","MLLNCUMT","Million of national currency units","AUS","Australia","2010","2010",551,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","MLLNCUMT","Million of national currency units","AUS","Australia","2011","2011",572,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","MLLNCUMT","Million of national currency units","AUS","Australia","2012","2012",598,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","MLLNCUMT","Million of national currency units","AUS","Australia","2013","2013",638,"B; D","Break; Difference in methodology"
+"PATCRESS","R-Respiratory system","MLLNCUMT","Million of national currency units","AUS","Australia","2014","2014",659,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","MLLNCUMT","Million of national currency units","AUS","Australia","2015","2015",697,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","MLLNCUMT","Million of national currency units","AUS","Australia","2016","2016",710,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","MLLNCUMT","Million of national currency units","AUS","Australia","2017","2017",729,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","MLLNCUMT","Million of national currency units","AUS","Australia","2018","2018",728,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","MLLNCUMT","Million of national currency units","AUS","Australia","2019","2019",908,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","MLLNCUMT","Million of national currency units","AUS","Australia","2020","2020",1067,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","MLLNCUMT","Million of national currency units","AUS","Australia","2021","2021",1088,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","MTMOTCMT","Million US$ at exchange rate","AUS","Australia","2010","2010",505.4,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","MTMOTCMT","Million US$ at exchange rate","AUS","Australia","2011","2011",590,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","MTMOTCMT","Million US$ at exchange rate","AUS","Australia","2012","2012",619.2,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","MTMOTCMT","Million US$ at exchange rate","AUS","Australia","2013","2013",615.9,"B; D","Break; Difference in methodology"
+"PATCRESS","R-Respiratory system","MTMOTCMT","Million US$ at exchange rate","AUS","Australia","2014","2014",594,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","MTMOTCMT","Million US$ at exchange rate","AUS","Australia","2015","2015",523.6,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","MTMOTCMT","Million US$ at exchange rate","AUS","Australia","2016","2016",527.8,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","MTMOTCMT","Million US$ at exchange rate","AUS","Australia","2017","2017",558.7,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","MTMOTCMT","Million US$ at exchange rate","AUS","Australia","2018","2018",543.9,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","MTMOTCMT","Million US$ at exchange rate","AUS","Australia","2019","2019",631.2,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","MTMOTCMT","Million US$ at exchange rate","AUS","Australia","2020","2020",734.3,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","MTMOTCMT","Million US$ at exchange rate","AUS","Australia","2021","2021",817.3,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","MTMOPPMT","Million US$, purchasing power parity","AUS","Australia","2010","2010",366.4,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","MTMOPPMT","Million US$, purchasing power parity","AUS","Australia","2011","2011",378.5,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","MTMOPPMT","Million US$, purchasing power parity","AUS","Australia","2012","2012",388.3,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","MTMOPPMT","Million US$, purchasing power parity","AUS","Australia","2013","2013",440.9,"B; D","Break; Difference in methodology"
+"PATCRESS","R-Respiratory system","MTMOPPMT","Million US$, purchasing power parity","AUS","Australia","2014","2014",453.7,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","MTMOPPMT","Million US$, purchasing power parity","AUS","Australia","2015","2015",473,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","MTMOPPMT","Million US$, purchasing power parity","AUS","Australia","2016","2016",489.6,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","MTMOPPMT","Million US$, purchasing power parity","AUS","Australia","2017","2017",493.4,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","MTMOPPMT","Million US$, purchasing power parity","AUS","Australia","2018","2018",495.1,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","MTMOPPMT","Million US$, purchasing power parity","AUS","Australia","2019","2019",613.6,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","MTMOPPMT","Million US$, purchasing power parity","AUS","Australia","2020","2020",733.9,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","MTMOPPMT","Million US$, purchasing power parity","AUS","Australia","2021","2021",751.6,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","TCPPERMT","/capita, US$ exchange rate","AUS","Australia","2010","2010",22.9,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","TCPPERMT","/capita, US$ exchange rate","AUS","Australia","2011","2011",26.4,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","TCPPERMT","/capita, US$ exchange rate","AUS","Australia","2012","2012",27.2,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","TCPPERMT","/capita, US$ exchange rate","AUS","Australia","2013","2013",26.6,"B; D","Break; Difference in methodology"
+"PATCRESS","R-Respiratory system","TCPPERMT","/capita, US$ exchange rate","AUS","Australia","2014","2014",25.3,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","TCPPERMT","/capita, US$ exchange rate","AUS","Australia","2015","2015",22,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","TCPPERMT","/capita, US$ exchange rate","AUS","Australia","2016","2016",21.8,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","TCPPERMT","/capita, US$ exchange rate","AUS","Australia","2017","2017",22.7,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","TCPPERMT","/capita, US$ exchange rate","AUS","Australia","2018","2018",21.8,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","TCPPERMT","/capita, US$ exchange rate","AUS","Australia","2019","2019",24.9,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","TCPPERMT","/capita, US$ exchange rate","AUS","Australia","2020","2020",28.6,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","TCPPERMT","/capita, US$ exchange rate","AUS","Australia","2021","2021",31.8,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2010","2010",16.6,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2011","2011",16.9,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2012","2012",17.1,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2013","2013",19.1,"B; D","Break; Difference in methodology"
+"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2014","2014",19.3,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2015","2015",19.9,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2016","2016",20.2,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2017","2017",20.1,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2018","2018",19.8,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2019","2019",24.2,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2020","2020",28.6,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2021","2021",29.3,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","ATCPTTMT","% of total sales","AUS","Australia","2010","2010",5.6,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","ATCPTTMT","% of total sales","AUS","Australia","2011","2011",5.6,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","ATCPTTMT","% of total sales","AUS","Australia","2012","2012",5.8,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","ATCPTTMT","% of total sales","AUS","Australia","2013","2013",5.4,"B; D","Break; Difference in methodology"
+"PATCRESS","R-Respiratory system","ATCPTTMT","% of total sales","AUS","Australia","2014","2014",5.5,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","ATCPTTMT","% of total sales","AUS","Australia","2015","2015",5.7,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","ATCPTTMT","% of total sales","AUS","Australia","2016","2016",4.6,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","ATCPTTMT","% of total sales","AUS","Australia","2017","2017",4.9,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","ATCPTTMT","% of total sales","AUS","Australia","2018","2018",4.9,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","ATCPTTMT","% of total sales","AUS","Australia","2019","2019",5.8,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","ATCPTTMT","% of total sales","AUS","Australia","2020","2020",6.4,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","ATCPTTMT","% of total sales","AUS","Australia","2021","2021",6.2,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","MLLNCUMT","Million of national currency units","AUT","Austria","2010","2010",154.8,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","MLLNCUMT","Million of national currency units","AUT","Austria","2011","2011",159.6,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","MLLNCUMT","Million of national currency units","AUT","Austria","2012","2012",161.4,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","MLLNCUMT","Million of national currency units","AUT","Austria","2013","2013",164.6,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","MLLNCUMT","Million of national currency units","AUT","Austria","2014","2014",163.8,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","MLLNCUMT","Million of national currency units","AUT","Austria","2015","2015",168.4,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","MLLNCUMT","Million of national currency units","AUT","Austria","2016","2016",172.2,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","MLLNCUMT","Million of national currency units","AUT","Austria","2017","2017",177.4,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","MLLNCUMT","Million of national currency units","AUT","Austria","2018","2018",186.7,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","MLLNCUMT","Million of national currency units","AUT","Austria","2019","2019",202.6,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","MLLNCUMT","Million of national currency units","AUT","Austria","2020","2020",219.8,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","MLLNCUMT","Million of national currency units","AUT","Austria","2021","2021",251.1,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","MTMOTCMT","Million US$ at exchange rate","AUT","Austria","2010","2010",205.3,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","MTMOTCMT","Million US$ at exchange rate","AUT","Austria","2011","2011",222.2,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","MTMOTCMT","Million US$ at exchange rate","AUT","Austria","2012","2012",207.4,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","MTMOTCMT","Million US$ at exchange rate","AUT","Austria","2013","2013",218.6,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","MTMOTCMT","Million US$ at exchange rate","AUT","Austria","2014","2014",217.5,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","MTMOTCMT","Million US$ at exchange rate","AUT","Austria","2015","2015",186.9,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","MTMOTCMT","Million US$ at exchange rate","AUT","Austria","2016","2016",190.6,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","MTMOTCMT","Million US$ at exchange rate","AUT","Austria","2017","2017",200.4,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","MTMOTCMT","Million US$ at exchange rate","AUT","Austria","2018","2018",220.5,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","MTMOTCMT","Million US$ at exchange rate","AUT","Austria","2019","2019",226.8,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","MTMOTCMT","Million US$ at exchange rate","AUT","Austria","2020","2020",251,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","MTMOTCMT","Million US$ at exchange rate","AUT","Austria","2021","2021",296.9,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","MTMOPPMT","Million US$, purchasing power parity","AUT","Austria","2010","2010",183.8,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","MTMOPPMT","Million US$, purchasing power parity","AUT","Austria","2011","2011",192,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","MTMOPPMT","Million US$, purchasing power parity","AUT","Austria","2012","2012",198.4,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","MTMOPPMT","Million US$, purchasing power parity","AUT","Austria","2013","2013",206.5,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","MTMOPPMT","Million US$, purchasing power parity","AUT","Austria","2014","2014",205,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","MTMOPPMT","Million US$, purchasing power parity","AUT","Austria","2015","2015",210.9,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","MTMOPPMT","Million US$, purchasing power parity","AUT","Austria","2016","2016",221.6,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","MTMOPPMT","Million US$, purchasing power parity","AUT","Austria","2017","2017",228.9,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","MTMOPPMT","Million US$, purchasing power parity","AUT","Austria","2018","2018",244,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","MTMOPPMT","Million US$, purchasing power parity","AUT","Austria","2019","2019",270.5,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","MTMOPPMT","Million US$, purchasing power parity","AUT","Austria","2020","2020",294.5,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","MTMOPPMT","Million US$, purchasing power parity","AUT","Austria","2021","2021",331.9,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","TCPPERMT","/capita, US$ exchange rate","AUT","Austria","2010","2010",24.5,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","TCPPERMT","/capita, US$ exchange rate","AUT","Austria","2011","2011",26.5,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","TCPPERMT","/capita, US$ exchange rate","AUT","Austria","2012","2012",24.6,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","TCPPERMT","/capita, US$ exchange rate","AUT","Austria","2013","2013",25.8,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","TCPPERMT","/capita, US$ exchange rate","AUT","Austria","2014","2014",25.5,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","TCPPERMT","/capita, US$ exchange rate","AUT","Austria","2015","2015",21.6,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","TCPPERMT","/capita, US$ exchange rate","AUT","Austria","2016","2016",21.8,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","TCPPERMT","/capita, US$ exchange rate","AUT","Austria","2017","2017",22.8,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","TCPPERMT","/capita, US$ exchange rate","AUT","Austria","2018","2018",24.9,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","TCPPERMT","/capita, US$ exchange rate","AUT","Austria","2019","2019",25.5,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","TCPPERMT","/capita, US$ exchange rate","AUT","Austria","2020","2020",28.2,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","TCPPERMT","/capita, US$ exchange rate","AUT","Austria","2021","2021",33.2,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2010","2010",22,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2011","2011",22.9,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2012","2012",23.5,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2013","2013",24.4,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2014","2014",24,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2015","2015",24.4,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2016","2016",25.4,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2017","2017",26,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2018","2018",27.6,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2019","2019",30.5,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2020","2020",33,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2021","2021",37.1,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","ATCPTTMT","% of total sales","AUT","Austria","2010","2010",6.2,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","ATCPTTMT","% of total sales","AUT","Austria","2011","2011",6.3,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","ATCPTTMT","% of total sales","AUT","Austria","2012","2012",6.2,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","ATCPTTMT","% of total sales","AUT","Austria","2013","2013",6.2,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","ATCPTTMT","% of total sales","AUT","Austria","2014","2014",5.9,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","ATCPTTMT","% of total sales","AUT","Austria","2015","2015",5.8,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","ATCPTTMT","% of total sales","AUT","Austria","2016","2016",5.7,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","ATCPTTMT","% of total sales","AUT","Austria","2017","2017",5.7,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","ATCPTTMT","% of total sales","AUT","Austria","2018","2018",5.8,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","ATCPTTMT","% of total sales","AUT","Austria","2019","2019",6.1,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","ATCPTTMT","% of total sales","AUT","Austria","2020","2020",6.3,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","ATCPTTMT","% of total sales","AUT","Austria","2021","2021",6.8,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","MLLNCUMT","Million of national currency units","BEL","Belgium","2010","2010",512.7,,
+"PATCRESS","R-Respiratory system","MLLNCUMT","Million of national currency units","BEL","Belgium","2011","2011",522.2,,
+"PATCRESS","R-Respiratory system","MLLNCUMT","Million of national currency units","BEL","Belgium","2012","2012",517.1,,
+"PATCRESS","R-Respiratory system","MLLNCUMT","Million of national currency units","BEL","Belgium","2013","2013",530.9,,
+"PATCRESS","R-Respiratory system","MLLNCUMT","Million of national currency units","BEL","Belgium","2014","2014",505.5,,
+"PATCRESS","R-Respiratory system","MLLNCUMT","Million of national currency units","BEL","Belgium","2015","2015",525.9,,
+"PATCRESS","R-Respiratory system","MLLNCUMT","Million of national currency units","BEL","Belgium","2016","2016",510.7,,
+"PATCRESS","R-Respiratory system","MLLNCUMT","Million of national currency units","BEL","Belgium","2017","2017",509.8,,
+"PATCRESS","R-Respiratory system","MLLNCUMT","Million of national currency units","BEL","Belgium","2018","2018",520,,
+"PATCRESS","R-Respiratory system","MLLNCUMT","Million of national currency units","BEL","Belgium","2019","2019",539,,
+"PATCRESS","R-Respiratory system","MLLNCUMT","Million of national currency units","BEL","Belgium","2020","2020",497,,
+"PATCRESS","R-Respiratory system","MLLNCUMT","Million of national currency units","BEL","Belgium","2021","2021",511.1,,
+"PATCRESS","R-Respiratory system","MLLNCUMT","Million of national currency units","BEL","Belgium","2022","2022",716.2,"E","Estimated value"
+"PATCRESS","R-Respiratory system","MTMOTCMT","Million US$ at exchange rate","BEL","Belgium","2010","2010",679.7,,
+"PATCRESS","R-Respiratory system","MTMOTCMT","Million US$ at exchange rate","BEL","Belgium","2011","2011",726.9,,
+"PATCRESS","R-Respiratory system","MTMOTCMT","Million US$ at exchange rate","BEL","Belgium","2012","2012",664.4,,
+"PATCRESS","R-Respiratory system","MTMOTCMT","Million US$ at exchange rate","BEL","Belgium","2013","2013",705.1,,
+"PATCRESS","R-Respiratory system","MTMOTCMT","Million US$ at exchange rate","BEL","Belgium","2014","2014",671.6,,
+"PATCRESS","R-Respiratory system","MTMOTCMT","Million US$ at exchange rate","BEL","Belgium","2015","2015",583.5,,
+"PATCRESS","R-Respiratory system","MTMOTCMT","Million US$ at exchange rate","BEL","Belgium","2016","2016",565.2,,
+"PATCRESS","R-Respiratory system","MTMOTCMT","Million US$ at exchange rate","BEL","Belgium","2017","2017",575.9,,
+"PATCRESS","R-Respiratory system","MTMOTCMT","Million US$ at exchange rate","BEL","Belgium","2018","2018",614,,
+"PATCRESS","R-Respiratory system","MTMOTCMT","Million US$ at exchange rate","BEL","Belgium","2019","2019",603.4,,
+"PATCRESS","R-Respiratory system","MTMOTCMT","Million US$ at exchange rate","BEL","Belgium","2020","2020",567.6,,
+"PATCRESS","R-Respiratory system","MTMOTCMT","Million US$ at exchange rate","BEL","Belgium","2021","2021",604.5,,
+"PATCRESS","R-Respiratory system","MTMOTCMT","Million US$ at exchange rate","BEL","Belgium","2022","2022",754.2,"E","Estimated value"
+"PATCRESS","R-Respiratory system","MTMOPPMT","Million US$, purchasing power parity","BEL","Belgium","2010","2010",612.9,,
+"PATCRESS","R-Respiratory system","MTMOPPMT","Million US$, purchasing power parity","BEL","Belgium","2011","2011",627.7,,
+"PATCRESS","R-Respiratory system","MTMOPPMT","Million US$, purchasing power parity","BEL","Belgium","2012","2012",629,,
+"PATCRESS","R-Respiratory system","MTMOPPMT","Million US$, purchasing power parity","BEL","Belgium","2013","2013",658.5,,
+"PATCRESS","R-Respiratory system","MTMOPPMT","Million US$, purchasing power parity","BEL","Belgium","2014","2014",631.7,,
+"PATCRESS","R-Respiratory system","MTMOPPMT","Million US$, purchasing power parity","BEL","Belgium","2015","2015",657.4,,
+"PATCRESS","R-Respiratory system","MTMOPPMT","Million US$, purchasing power parity","BEL","Belgium","2016","2016",653.8,,
+"PATCRESS","R-Respiratory system","MTMOPPMT","Million US$, purchasing power parity","BEL","Belgium","2017","2017",657.2,,
+"PATCRESS","R-Respiratory system","MTMOPPMT","Million US$, purchasing power parity","BEL","Belgium","2018","2018",678.4,,
+"PATCRESS","R-Respiratory system","MTMOPPMT","Million US$, purchasing power parity","BEL","Belgium","2019","2019",721.9,,
+"PATCRESS","R-Respiratory system","MTMOPPMT","Million US$, purchasing power parity","BEL","Belgium","2020","2020",680.5,,
+"PATCRESS","R-Respiratory system","MTMOPPMT","Million US$, purchasing power parity","BEL","Belgium","2021","2021",693.7,,
+"PATCRESS","R-Respiratory system","MTMOPPMT","Million US$, purchasing power parity","BEL","Belgium","2022","2022",1003.2,"E","Estimated value"
+"PATCRESS","R-Respiratory system","TCPPERMT","/capita, US$ exchange rate","BEL","Belgium","2010","2010",62.4,,
+"PATCRESS","R-Respiratory system","TCPPERMT","/capita, US$ exchange rate","BEL","Belgium","2011","2011",65.8,,
+"PATCRESS","R-Respiratory system","TCPPERMT","/capita, US$ exchange rate","BEL","Belgium","2012","2012",59.8,,
+"PATCRESS","R-Respiratory system","TCPPERMT","/capita, US$ exchange rate","BEL","Belgium","2013","2013",63.2,,
+"PATCRESS","R-Respiratory system","TCPPERMT","/capita, US$ exchange rate","BEL","Belgium","2014","2014",59.9,,
+"PATCRESS","R-Respiratory system","TCPPERMT","/capita, US$ exchange rate","BEL","Belgium","2015","2015",51.8,,
+"PATCRESS","R-Respiratory system","TCPPERMT","/capita, US$ exchange rate","BEL","Belgium","2016","2016",49.9,,
+"PATCRESS","R-Respiratory system","TCPPERMT","/capita, US$ exchange rate","BEL","Belgium","2017","2017",50.6,,
+"PATCRESS","R-Respiratory system","TCPPERMT","/capita, US$ exchange rate","BEL","Belgium","2018","2018",53.7,,
+"PATCRESS","R-Respiratory system","TCPPERMT","/capita, US$ exchange rate","BEL","Belgium","2019","2019",52.5,,
+"PATCRESS","R-Respiratory system","TCPPERMT","/capita, US$ exchange rate","BEL","Belgium","2020","2020",49.2,,
+"PATCRESS","R-Respiratory system","TCPPERMT","/capita, US$ exchange rate","BEL","Belgium","2021","2021",52.2,,
+"PATCRESS","R-Respiratory system","TCPPERMT","/capita, US$ exchange rate","BEL","Belgium","2022","2022",64.9,"E","Estimated value"
+"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2010","2010",56.2,,
+"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2011","2011",56.9,,
+"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2012","2012",56.6,,
+"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2013","2013",59,,
+"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2014","2014",56.4,,
+"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2015","2015",58.3,,
+"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2016","2016",57.7,,
+"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2017","2017",57.8,,
+"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2018","2018",59.4,,
+"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2019","2019",62.8,,
+"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2020","2020",59,,
+"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2021","2021",59.9,,
+"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2022","2022",86.4,"E","Estimated value"
+"PATCRESS","R-Respiratory system","ATCPTTMT","% of total sales","BEL","Belgium","2010","2010",8.7,,
+"PATCRESS","R-Respiratory system","ATCPTTMT","% of total sales","BEL","Belgium","2011","2011",8.7,,
+"PATCRESS","R-Respiratory system","ATCPTTMT","% of total sales","BEL","Belgium","2012","2012",8.7,,
+"PATCRESS","R-Respiratory system","ATCPTTMT","% of total sales","BEL","Belgium","2013","2013",8.9,,
+"PATCRESS","R-Respiratory system","ATCPTTMT","% of total sales","BEL","Belgium","2014","2014",8.5,,
+"PATCRESS","R-Respiratory system","ATCPTTMT","% of total sales","BEL","Belgium","2015","2015",8.5,,
+"PATCRESS","R-Respiratory system","ATCPTTMT","% of total sales","BEL","Belgium","2016","2016",8.2,,
+"PATCRESS","R-Respiratory system","ATCPTTMT","% of total sales","BEL","Belgium","2017","2017",7.8,,
+"PATCRESS","R-Respiratory system","ATCPTTMT","% of total sales","BEL","Belgium","2018","2018",7.8,,
+"PATCRESS","R-Respiratory system","ATCPTTMT","% of total sales","BEL","Belgium","2019","2019",7.3,,
+"PATCRESS","R-Respiratory system","ATCPTTMT","% of total sales","BEL","Belgium","2020","2020",6.5,,
+"PATCRESS","R-Respiratory system","ATCPTTMT","% of total sales","BEL","Belgium","2021","2021",6.3,,
+"PATCRESS","R-Respiratory system","ATCPTTMT","% of total sales","BEL","Belgium","2022","2022",8,"E","Estimated value"
+"PATCRESS","R-Respiratory system","MLLNCUMT","Million of national currency units","CAN","Canada","2012","2012",1676.3,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","MLLNCUMT","Million of national currency units","CAN","Canada","2013","2013",1729.2,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","MLLNCUMT","Million of national currency units","CAN","Canada","2014","2014",1794.4,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","MLLNCUMT","Million of national currency units","CAN","Canada","2015","2015",1874.5,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","MLLNCUMT","Million of national currency units","CAN","Canada","2016","2016",1936,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","MLLNCUMT","Million of national currency units","CAN","Canada","2017","2017",1991.3,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","MLLNCUMT","Million of national currency units","CAN","Canada","2018","2018",2127.8,"E; B; D","Estimated value; Break; Difference in methodology"
+"PATCRESS","R-Respiratory system","MLLNCUMT","Million of national currency units","CAN","Canada","2019","2019",2246.9,"E; D","Estimated value; Difference in methodology"
+"PATCRESS","R-Respiratory system","MLLNCUMT","Million of national currency units","CAN","Canada","2020","2020",2423.6,"E; D","Estimated value; Difference in methodology"
+"PATCRESS","R-Respiratory system","MLLNCUMT","Million of national currency units","CAN","Canada","2021","2021",2380.1,"E; D","Estimated value; Difference in methodology"
+"PATCRESS","R-Respiratory system","MLLNCUMT","Million of national currency units","CAN","Canada","2022","2022",2624.3,"E; D","Estimated value; Difference in methodology"
+"PATCRESS","R-Respiratory system","MTMOTCMT","Million US$ at exchange rate","CAN","Canada","2012","2012",1677.4,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","MTMOTCMT","Million US$ at exchange rate","CAN","Canada","2013","2013",1678.6,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","MTMOTCMT","Million US$ at exchange rate","CAN","Canada","2014","2014",1624.3,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","MTMOTCMT","Million US$ at exchange rate","CAN","Canada","2015","2015",1465.8,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","MTMOTCMT","Million US$ at exchange rate","CAN","Canada","2016","2016",1460.5,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","MTMOTCMT","Million US$ at exchange rate","CAN","Canada","2017","2017",1534.2,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","MTMOTCMT","Million US$ at exchange rate","CAN","Canada","2018","2018",1642.1,"E; B; D","Estimated value; Break; Difference in methodology"
+"PATCRESS","R-Respiratory system","MTMOTCMT","Million US$ at exchange rate","CAN","Canada","2019","2019",1693.5,"E; D","Estimated value; Difference in methodology"
+"PATCRESS","R-Respiratory system","MTMOTCMT","Million US$ at exchange rate","CAN","Canada","2020","2020",1807.1,"E; D","Estimated value; Difference in methodology"
+"PATCRESS","R-Respiratory system","MTMOTCMT","Million US$ at exchange rate","CAN","Canada","2021","2021",1898.2,"E; D","Estimated value; Difference in methodology"
+"PATCRESS","R-Respiratory system","MTMOTCMT","Million US$ at exchange rate","CAN","Canada","2022","2022",2016.3,"E; D","Estimated value; Difference in methodology"
+"PATCRESS","R-Respiratory system","MTMOPPMT","Million US$, purchasing power parity","CAN","Canada","2012","2012",1346.9,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","MTMOPPMT","Million US$, purchasing power parity","CAN","Canada","2013","2013",1412.7,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","MTMOPPMT","Million US$, purchasing power parity","CAN","Canada","2014","2014",1458.4,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","MTMOPPMT","Million US$, purchasing power parity","CAN","Canada","2015","2015",1502,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","MTMOPPMT","Million US$, purchasing power parity","CAN","Canada","2016","2016",1603.9,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","MTMOPPMT","Million US$, purchasing power parity","CAN","Canada","2017","2017",1642.6,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","MTMOPPMT","Million US$, purchasing power parity","CAN","Canada","2018","2018",1763.6,"E; B; D","Estimated value; Break; Difference in methodology"
+"PATCRESS","R-Respiratory system","MTMOPPMT","Million US$, purchasing power parity","CAN","Canada","2019","2019",1819.7,"E; D","Estimated value; Difference in methodology"
+"PATCRESS","R-Respiratory system","MTMOPPMT","Million US$, purchasing power parity","CAN","Canada","2020","2020",1968.7,"E; D","Estimated value; Difference in methodology"
+"PATCRESS","R-Respiratory system","MTMOPPMT","Million US$, purchasing power parity","CAN","Canada","2021","2021",1922.3,"E; D","Estimated value; Difference in methodology"
+"PATCRESS","R-Respiratory system","MTMOPPMT","Million US$, purchasing power parity","CAN","Canada","2022","2022",2093,"E; D","Estimated value; Difference in methodology"
+"PATCRESS","R-Respiratory system","TCPPERMT","/capita, US$ exchange rate","CAN","Canada","2012","2012",48.3,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","TCPPERMT","/capita, US$ exchange rate","CAN","Canada","2013","2013",47.8,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","TCPPERMT","/capita, US$ exchange rate","CAN","Canada","2014","2014",45.8,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","TCPPERMT","/capita, US$ exchange rate","CAN","Canada","2015","2015",41.1,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","TCPPERMT","/capita, US$ exchange rate","CAN","Canada","2016","2016",40.4,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","TCPPERMT","/capita, US$ exchange rate","CAN","Canada","2017","2017",42,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","TCPPERMT","/capita, US$ exchange rate","CAN","Canada","2018","2018",44.3,"E; B; D","Estimated value; Break; Difference in methodology"
+"PATCRESS","R-Respiratory system","TCPPERMT","/capita, US$ exchange rate","CAN","Canada","2019","2019",45,"E; D","Estimated value; Difference in methodology"
+"PATCRESS","R-Respiratory system","TCPPERMT","/capita, US$ exchange rate","CAN","Canada","2020","2020",47.5,"E; D","Estimated value; Difference in methodology"
+"PATCRESS","R-Respiratory system","TCPPERMT","/capita, US$ exchange rate","CAN","Canada","2021","2021",49.6,"E; D","Estimated value; Difference in methodology"
+"PATCRESS","R-Respiratory system","TCPPERMT","/capita, US$ exchange rate","CAN","Canada","2022","2022",51.9,"E; D","Estimated value; Difference in methodology"
+"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2012","2012",38.8,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2013","2013",40.3,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2014","2014",41.2,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2015","2015",42.1,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2016","2016",44.4,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2017","2017",44.9,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2018","2018",47.6,"E; B; D","Estimated value; Break; Difference in methodology"
+"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2019","2019",48.4,"E; D","Estimated value; Difference in methodology"
+"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2020","2020",51.8,"E; D","Estimated value; Difference in methodology"
+"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2021","2021",50.3,"E; D","Estimated value; Difference in methodology"
+"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2022","2022",53.8,"E; D","Estimated value; Difference in methodology"
+"PATCRESS","R-Respiratory system","ATCPTTMT","% of total sales","CAN","Canada","2012","2012",6.9,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","ATCPTTMT","% of total sales","CAN","Canada","2013","2013",7,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","ATCPTTMT","% of total sales","CAN","Canada","2014","2014",7,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","ATCPTTMT","% of total sales","CAN","Canada","2015","2015",6.9,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","ATCPTTMT","% of total sales","CAN","Canada","2016","2016",6.8,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","ATCPTTMT","% of total sales","CAN","Canada","2017","2017",6.7,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","ATCPTTMT","% of total sales","CAN","Canada","2018","2018",7,"E; B; D","Estimated value; Break; Difference in methodology"
+"PATCRESS","R-Respiratory system","ATCPTTMT","% of total sales","CAN","Canada","2019","2019",7.1,"E; D","Estimated value; Difference in methodology"
+"PATCRESS","R-Respiratory system","ATCPTTMT","% of total sales","CAN","Canada","2020","2020",7.1,"E; D","Estimated value; Difference in methodology"
+"PATCRESS","R-Respiratory system","ATCPTTMT","% of total sales","CAN","Canada","2021","2021",6.5,"E; D","Estimated value; Difference in methodology"
+"PATCRESS","R-Respiratory system","ATCPTTMT","% of total sales","CAN","Canada","2022","2022",6.6,"E; D","Estimated value; Difference in methodology"
+"PATCRESS","R-Respiratory system","MLLNCUMT","Million of national currency units","CZE","Czech Republic","2010","2010",6506.8,,
+"PATCRESS","R-Respiratory system","MLLNCUMT","Million of national currency units","CZE","Czech Republic","2011","2011",6696.7,,
+"PATCRESS","R-Respiratory system","MLLNCUMT","Million of national currency units","CZE","Czech Republic","2012","2012",6786.3,,
+"PATCRESS","R-Respiratory system","MLLNCUMT","Million of national currency units","CZE","Czech Republic","2013","2013",6744.7,,
+"PATCRESS","R-Respiratory system","MLLNCUMT","Million of national currency units","CZE","Czech Republic","2014","2014",6900.6,,
+"PATCRESS","R-Respiratory system","MLLNCUMT","Million of national currency units","CZE","Czech Republic","2015","2015",7138.5,,
+"PATCRESS","R-Respiratory system","MLLNCUMT","Million of national currency units","CZE","Czech Republic","2016","2016",6983.6,,
+"PATCRESS","R-Respiratory system","MLLNCUMT","Million of national currency units","CZE","Czech Republic","2017","2017",7450.8,,
+"PATCRESS","R-Respiratory system","MLLNCUMT","Million of national currency units","CZE","Czech Republic","2018","2018",7632.1,,
+"PATCRESS","R-Respiratory system","MLLNCUMT","Million of national currency units","CZE","Czech Republic","2019","2019",7854.3,,
+"PATCRESS","R-Respiratory system","MLLNCUMT","Million of national currency units","CZE","Czech Republic","2020","2020",5139.3,"B","Break"
+"PATCRESS","R-Respiratory system","MLLNCUMT","Million of national currency units","CZE","Czech Republic","2021","2021",5237.6,,
+"PATCRESS","R-Respiratory system","MTMOTCMT","Million US$ at exchange rate","CZE","Czech Republic","2010","2010",340.7,,
+"PATCRESS","R-Respiratory system","MTMOTCMT","Million US$ at exchange rate","CZE","Czech Republic","2011","2011",378.4,,
+"PATCRESS","R-Respiratory system","MTMOTCMT","Million US$ at exchange rate","CZE","Czech Republic","2012","2012",346.6,,
+"PATCRESS","R-Respiratory system","MTMOTCMT","Million US$ at exchange rate","CZE","Czech Republic","2013","2013",344.6,,
+"PATCRESS","R-Respiratory system","MTMOTCMT","Million US$ at exchange rate","CZE","Czech Republic","2014","2014",332.4,,
+"PATCRESS","R-Respiratory system","MTMOTCMT","Million US$ at exchange rate","CZE","Czech Republic","2015","2015",290.2,,
+"PATCRESS","R-Respiratory system","MTMOTCMT","Million US$ at exchange rate","CZE","Czech Republic","2016","2016",285.7,,
+"PATCRESS","R-Respiratory system","MTMOTCMT","Million US$ at exchange rate","CZE","Czech Republic","2017","2017",318.7,,
+"PATCRESS","R-Respiratory system","MTMOTCMT","Million US$ at exchange rate","CZE","Czech Republic","2018","2018",351.2,,
+"PATCRESS","R-Respiratory system","MTMOTCMT","Million US$ at exchange rate","CZE","Czech Republic","2019","2019",342.5,,
+"PATCRESS","R-Respiratory system","MTMOTCMT","Million US$ at exchange rate","CZE","Czech Republic","2020","2020",221.4,"B","Break"
+"PATCRESS","R-Respiratory system","MTMOTCMT","Million US$ at exchange rate","CZE","Czech Republic","2021","2021",241.6,,
+"PATCRESS","R-Respiratory system","MTMOPPMT","Million US$, purchasing power parity","CZE","Czech Republic","2010","2010",475.9,,
+"PATCRESS","R-Respiratory system","MTMOPPMT","Million US$, purchasing power parity","CZE","Czech Republic","2011","2011",501.8,,
+"PATCRESS","R-Respiratory system","MTMOPPMT","Million US$, purchasing power parity","CZE","Czech Republic","2012","2012",510.3,,
+"PATCRESS","R-Respiratory system","MTMOPPMT","Million US$, purchasing power parity","CZE","Czech Republic","2013","2013",527.5,,
+"PATCRESS","R-Respiratory system","MTMOPPMT","Million US$, purchasing power parity","CZE","Czech Republic","2014","2014",543.2,,
+"PATCRESS","R-Respiratory system","MTMOPPMT","Million US$, purchasing power parity","CZE","Czech Republic","2015","2015",551.7,,
+"PATCRESS","R-Respiratory system","MTMOPPMT","Million US$, purchasing power parity","CZE","Czech Republic","2016","2016",555.3,,
+"PATCRESS","R-Respiratory system","MTMOPPMT","Million US$, purchasing power parity","CZE","Czech Republic","2017","2017",599.7,,
+"PATCRESS","R-Respiratory system","MTMOPPMT","Million US$, purchasing power parity","CZE","Czech Republic","2018","2018",616.9,,
+"PATCRESS","R-Respiratory system","MTMOPPMT","Million US$, purchasing power parity","CZE","Czech Republic","2019","2019",639.9,,
+"PATCRESS","R-Respiratory system","MTMOPPMT","Million US$, purchasing power parity","CZE","Czech Republic","2020","2020",412.4,"B","Break"
+"PATCRESS","R-Respiratory system","MTMOPPMT","Million US$, purchasing power parity","CZE","Czech Republic","2021","2021",411,,
+"PATCRESS","R-Respiratory system","TCPPERMT","/capita, US$ exchange rate","CZE","Czech Republic","2010","2010",32.5,,
+"PATCRESS","R-Respiratory system","TCPPERMT","/capita, US$ exchange rate","CZE","Czech Republic","2011","2011",36.1,,
+"PATCRESS","R-Respiratory system","TCPPERMT","/capita, US$ exchange rate","CZE","Czech Republic","2012","2012",33,,
+"PATCRESS","R-Respiratory system","TCPPERMT","/capita, US$ exchange rate","CZE","Czech Republic","2013","2013",32.8,,
+"PATCRESS","R-Respiratory system","TCPPERMT","/capita, US$ exchange rate","CZE","Czech Republic","2014","2014",31.6,,
+"PATCRESS","R-Respiratory system","TCPPERMT","/capita, US$ exchange rate","CZE","Czech Republic","2015","2015",27.5,,
+"PATCRESS","R-Respiratory system","TCPPERMT","/capita, US$ exchange rate","CZE","Czech Republic","2016","2016",27,,
+"PATCRESS","R-Respiratory system","TCPPERMT","/capita, US$ exchange rate","CZE","Czech Republic","2017","2017",30.1,,
+"PATCRESS","R-Respiratory system","TCPPERMT","/capita, US$ exchange rate","CZE","Czech Republic","2018","2018",33,,
+"PATCRESS","R-Respiratory system","TCPPERMT","/capita, US$ exchange rate","CZE","Czech Republic","2019","2019",32.1,,
+"PATCRESS","R-Respiratory system","TCPPERMT","/capita, US$ exchange rate","CZE","Czech Republic","2020","2020",20.7,"B","Break"
+"PATCRESS","R-Respiratory system","TCPPERMT","/capita, US$ exchange rate","CZE","Czech Republic","2021","2021",23,,
+"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czech Republic","2010","2010",45.4,,
+"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czech Republic","2011","2011",47.8,,
+"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czech Republic","2012","2012",48.6,,
+"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czech Republic","2013","2013",50.2,,
+"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czech Republic","2014","2014",51.6,,
+"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czech Republic","2015","2015",52.3,,
+"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czech Republic","2016","2016",52.6,,
+"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czech Republic","2017","2017",56.6,,
+"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czech Republic","2018","2018",58,,
+"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czech Republic","2019","2019",60,,
+"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czech Republic","2020","2020",38.6,"B","Break"
+"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czech Republic","2021","2021",39.1,,
+"PATCRESS","R-Respiratory system","ATCPTTMT","% of total sales","CZE","Czech Republic","2010","2010",8,,
+"PATCRESS","R-Respiratory system","ATCPTTMT","% of total sales","CZE","Czech Republic","2011","2011",8.3,,
+"PATCRESS","R-Respiratory system","ATCPTTMT","% of total sales","CZE","Czech Republic","2012","2012",8.1,,
+"PATCRESS","R-Respiratory system","ATCPTTMT","% of total sales","CZE","Czech Republic","2013","2013",8.5,,
+"PATCRESS","R-Respiratory system","ATCPTTMT","% of total sales","CZE","Czech Republic","2014","2014",8.5,,
+"PATCRESS","R-Respiratory system","ATCPTTMT","% of total sales","CZE","Czech Republic","2015","2015",8.5,,
+"PATCRESS","R-Respiratory system","ATCPTTMT","% of total sales","CZE","Czech Republic","2016","2016",8,,
+"PATCRESS","R-Respiratory system","ATCPTTMT","% of total sales","CZE","Czech Republic","2017","2017",8.1,,
+"PATCRESS","R-Respiratory system","ATCPTTMT","% of total sales","CZE","Czech Republic","2018","2018",7.8,,
+"PATCRESS","R-Respiratory system","ATCPTTMT","% of total sales","CZE","Czech Republic","2019","2019",7.6,,
+"PATCRESS","R-Respiratory system","ATCPTTMT","% of total sales","CZE","Czech Republic","2020","2020",5.9,"B","Break"
+"PATCRESS","R-Respiratory system","ATCPTTMT","% of total sales","CZE","Czech Republic","2021","2021",5.6,,
+"PATCRESS","R-Respiratory system","MLLNCUMT","Million of national currency units","DNK","Denmark","2010","2010",1917.9,,
+"PATCRESS","R-Respiratory system","MLLNCUMT","Million of national currency units","DNK","Denmark","2011","2011",1913.4,,
+"PATCRESS","R-Respiratory system","MLLNCUMT","Million of national currency units","DNK","Denmark","2012","2012",1977.5,,
+"PATCRESS","R-Respiratory system","MLLNCUMT","Million of national currency units","DNK","Denmark","2013","2013",1909.3,,
+"PATCRESS","R-Respiratory system","MLLNCUMT","Million of national currency units","DNK","Denmark","2014","2014",1944.7,,
+"PATCRESS","R-Respiratory system","MLLNCUMT","Million of national currency units","DNK","Denmark","2015","2015",1968.7,,
+"PATCRESS","R-Respiratory system","MLLNCUMT","Million of national currency units","DNK","Denmark","2016","2016",1954.6,,
+"PATCRESS","R-Respiratory system","MLLNCUMT","Million of national currency units","DNK","Denmark","2017","2017",1925.4,,
+"PATCRESS","R-Respiratory system","MLLNCUMT","Million of national currency units","DNK","Denmark","2018","2018",1989.8,,
+"PATCRESS","R-Respiratory system","MLLNCUMT","Million of national currency units","DNK","Denmark","2019","2019",2074.5,,
+"PATCRESS","R-Respiratory system","MLLNCUMT","Million of national currency units","DNK","Denmark","2020","2020",2121.8,,
+"PATCRESS","R-Respiratory system","MLLNCUMT","Million of national currency units","DNK","Denmark","2021","2021",2168.6,,
+"PATCRESS","R-Respiratory system","MTMOTCMT","Million US$ at exchange rate","DNK","Denmark","2010","2010",341,,
+"PATCRESS","R-Respiratory system","MTMOTCMT","Million US$ at exchange rate","DNK","Denmark","2011","2011",356.4,,
+"PATCRESS","R-Respiratory system","MTMOTCMT","Million US$ at exchange rate","DNK","Denmark","2012","2012",341.4,,
+"PATCRESS","R-Respiratory system","MTMOTCMT","Million US$ at exchange rate","DNK","Denmark","2013","2013",340,,
+"PATCRESS","R-Respiratory system","MTMOTCMT","Million US$ at exchange rate","DNK","Denmark","2014","2014",346.5,,
+"PATCRESS","R-Respiratory system","MTMOTCMT","Million US$ at exchange rate","DNK","Denmark","2015","2015",292.6,,
+"PATCRESS","R-Respiratory system","MTMOTCMT","Million US$ at exchange rate","DNK","Denmark","2016","2016",290.4,,
+"PATCRESS","R-Respiratory system","MTMOTCMT","Million US$ at exchange rate","DNK","Denmark","2017","2017",291.6,,
+"PATCRESS","R-Respiratory system","MTMOTCMT","Million US$ at exchange rate","DNK","Denmark","2018","2018",315.1,,
+"PATCRESS","R-Respiratory system","MTMOTCMT","Million US$ at exchange rate","DNK","Denmark","2019","2019",311,,
+"PATCRESS","R-Respiratory system","MTMOTCMT","Million US$ at exchange rate","DNK","Denmark","2020","2020",324.3,,
+"PATCRESS","R-Respiratory system","MTMOTCMT","Million US$ at exchange rate","DNK","Denmark","2021","2021",344.9,,
+"PATCRESS","R-Respiratory system","MTMOPPMT","Million US$, purchasing power parity","DNK","Denmark","2010","2010",252.7,,
+"PATCRESS","R-Respiratory system","MTMOPPMT","Million US$, purchasing power parity","DNK","Denmark","2011","2011",256.3,,
+"PATCRESS","R-Respiratory system","MTMOPPMT","Million US$, purchasing power parity","DNK","Denmark","2012","2012",261.4,,
+"PATCRESS","R-Respiratory system","MTMOPPMT","Million US$, purchasing power parity","DNK","Denmark","2013","2013",259.6,,
+"PATCRESS","R-Respiratory system","MTMOPPMT","Million US$, purchasing power parity","DNK","Denmark","2014","2014",265.4,,
+"PATCRESS","R-Respiratory system","MTMOPPMT","Million US$, purchasing power parity","DNK","Denmark","2015","2015",269.5,,
+"PATCRESS","R-Respiratory system","MTMOPPMT","Million US$, purchasing power parity","DNK","Denmark","2016","2016",276.1,,
+"PATCRESS","R-Respiratory system","MTMOPPMT","Million US$, purchasing power parity","DNK","Denmark","2017","2017",280.2,,
+"PATCRESS","R-Respiratory system","MTMOPPMT","Million US$, purchasing power parity","DNK","Denmark","2018","2018",294.1,,
+"PATCRESS","R-Respiratory system","MTMOPPMT","Million US$, purchasing power parity","DNK","Denmark","2019","2019",312.7,,
+"PATCRESS","R-Respiratory system","MTMOPPMT","Million US$, purchasing power parity","DNK","Denmark","2020","2020",323.9,,
+"PATCRESS","R-Respiratory system","MTMOPPMT","Million US$, purchasing power parity","DNK","Denmark","2021","2021",329.1,,
+"PATCRESS","R-Respiratory system","TCPPERMT","/capita, US$ exchange rate","DNK","Denmark","2010","2010",61.5,,
+"PATCRESS","R-Respiratory system","TCPPERMT","/capita, US$ exchange rate","DNK","Denmark","2011","2011",64,,
+"PATCRESS","R-Respiratory system","TCPPERMT","/capita, US$ exchange rate","DNK","Denmark","2012","2012",61.1,,
+"PATCRESS","R-Respiratory system","TCPPERMT","/capita, US$ exchange rate","DNK","Denmark","2013","2013",60.5,,
+"PATCRESS","R-Respiratory system","TCPPERMT","/capita, US$ exchange rate","DNK","Denmark","2014","2014",61.4,,
+"PATCRESS","R-Respiratory system","TCPPERMT","/capita, US$ exchange rate","DNK","Denmark","2015","2015",51.5,,
+"PATCRESS","R-Respiratory system","TCPPERMT","/capita, US$ exchange rate","DNK","Denmark","2016","2016",50.7,,
+"PATCRESS","R-Respiratory system","TCPPERMT","/capita, US$ exchange rate","DNK","Denmark","2017","2017",50.6,,
+"PATCRESS","R-Respiratory system","TCPPERMT","/capita, US$ exchange rate","DNK","Denmark","2018","2018",54.4,,
+"PATCRESS","R-Respiratory system","TCPPERMT","/capita, US$ exchange rate","DNK","Denmark","2019","2019",53.5,,
+"PATCRESS","R-Respiratory system","TCPPERMT","/capita, US$ exchange rate","DNK","Denmark","2020","2020",55.6,,
+"PATCRESS","R-Respiratory system","TCPPERMT","/capita, US$ exchange rate","DNK","Denmark","2021","2021",58.9,,
+"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","DNK","Denmark","2010","2010",45.5,,
+"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","DNK","Denmark","2011","2011",46,,
+"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","DNK","Denmark","2012","2012",46.8,,
+"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","DNK","Denmark","2013","2013",46.2,,
+"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","DNK","Denmark","2014","2014",47,,
+"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","DNK","Denmark","2015","2015",47.4,,
+"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","DNK","Denmark","2016","2016",48.2,,
+"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","DNK","Denmark","2017","2017",48.6,,
+"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","DNK","Denmark","2018","2018",50.8,,
+"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","DNK","Denmark","2019","2019",53.8,,
+"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","DNK","Denmark","2020","2020",55.5,,
+"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","DNK","Denmark","2021","2021",56.2,,
+"PATCRESS","R-Respiratory system","ATCPTTMT","% of total sales","DNK","Denmark","2010","2010",9.1,,
+"PATCRESS","R-Respiratory system","ATCPTTMT","% of total sales","DNK","Denmark","2011","2011",9.3,,
+"PATCRESS","R-Respiratory system","ATCPTTMT","% of total sales","DNK","Denmark","2012","2012",9.7,,
+"PATCRESS","R-Respiratory system","ATCPTTMT","% of total sales","DNK","Denmark","2013","2013",9.3,,
+"PATCRESS","R-Respiratory system","ATCPTTMT","% of total sales","DNK","Denmark","2014","2014",9.1,,
+"PATCRESS","R-Respiratory system","ATCPTTMT","% of total sales","DNK","Denmark","2015","2015",9,,
+"PATCRESS","R-Respiratory system","ATCPTTMT","% of total sales","DNK","Denmark","2016","2016",8.8,,
+"PATCRESS","R-Respiratory system","ATCPTTMT","% of total sales","DNK","Denmark","2017","2017",8.4,,
+"PATCRESS","R-Respiratory system","ATCPTTMT","% of total sales","DNK","Denmark","2018","2018",8.3,,
+"PATCRESS","R-Respiratory system","ATCPTTMT","% of total sales","DNK","Denmark","2019","2019",8.4,,
+"PATCRESS","R-Respiratory system","ATCPTTMT","% of total sales","DNK","Denmark","2020","2020",8.4,,
+"PATCRESS","R-Respiratory system","ATCPTTMT","% of total sales","DNK","Denmark","2021","2021",8.5,,
+"PATCRESS","R-Respiratory system","MLLNCUMT","Million of national currency units","FIN","Finland","2010","2010",147.6,,
+"PATCRESS","R-Respiratory system","MLLNCUMT","Million of national currency units","FIN","Finland","2011","2011",148.7,,
+"PATCRESS","R-Respiratory system","MLLNCUMT","Million of national currency units","FIN","Finland","2012","2012",154.4,,
+"PATCRESS","R-Respiratory system","MLLNCUMT","Million of national currency units","FIN","Finland","2013","2013",146.3,,
+"PATCRESS","R-Respiratory system","MLLNCUMT","Million of national currency units","FIN","Finland","2014","2014",148.8,,
+"PATCRESS","R-Respiratory system","MLLNCUMT","Million of national currency units","FIN","Finland","2015","2015",144.4,,
+"PATCRESS","R-Respiratory system","MLLNCUMT","Million of national currency units","FIN","Finland","2016","2016",150.2,,
+"PATCRESS","R-Respiratory system","MLLNCUMT","Million of national currency units","FIN","Finland","2017","2017",150.1,,
+"PATCRESS","R-Respiratory system","MLLNCUMT","Million of national currency units","FIN","Finland","2018","2018",154.2,,
+"PATCRESS","R-Respiratory system","MLLNCUMT","Million of national currency units","FIN","Finland","2019","2019",152.8,,
+"PATCRESS","R-Respiratory system","MLLNCUMT","Million of national currency units","FIN","Finland","2020","2020",148.7,,
+"PATCRESS","R-Respiratory system","MLLNCUMT","Million of national currency units","FIN","Finland","2021","2021",151,,
+"PATCRESS","R-Respiratory system","MTMOTCMT","Million US$ at exchange rate","FIN","Finland","2010","2010",195.7,,
+"PATCRESS","R-Respiratory system","MTMOTCMT","Million US$ at exchange rate","FIN","Finland","2011","2011",207,,
+"PATCRESS","R-Respiratory system","MTMOTCMT","Million US$ at exchange rate","FIN","Finland","2012","2012",198.4,,
+"PATCRESS","R-Respiratory system","MTMOTCMT","Million US$ at exchange rate","FIN","Finland","2013","2013",194.3,,
+"PATCRESS","R-Respiratory system","MTMOTCMT","Million US$ at exchange rate","FIN","Finland","2014","2014",197.7,,
+"PATCRESS","R-Respiratory system","MTMOTCMT","Million US$ at exchange rate","FIN","Finland","2015","2015",160.2,,
+"PATCRESS","R-Respiratory system","MTMOTCMT","Million US$ at exchange rate","FIN","Finland","2016","2016",166.3,,
+"PATCRESS","R-Respiratory system","MTMOTCMT","Million US$ at exchange rate","FIN","Finland","2017","2017",169.6,,
+"PATCRESS","R-Respiratory system","MTMOTCMT","Million US$ at exchange rate","FIN","Finland","2018","2018",182.1,,
+"PATCRESS","R-Respiratory system","MTMOTCMT","Million US$ at exchange rate","FIN","Finland","2019","2019",171.1,,
+"PATCRESS","R-Respiratory system","MTMOTCMT","Million US$ at exchange rate","FIN","Finland","2020","2020",169.8,,
+"PATCRESS","R-Respiratory system","MTMOTCMT","Million US$ at exchange rate","FIN","Finland","2021","2021",178.6,,
+"PATCRESS","R-Respiratory system","MTMOPPMT","Million US$, purchasing power parity","FIN","Finland","2010","2010",163.9,,
+"PATCRESS","R-Respiratory system","MTMOPPMT","Million US$, purchasing power parity","FIN","Finland","2011","2011",165.6,,
+"PATCRESS","R-Respiratory system","MTMOPPMT","Million US$, purchasing power parity","FIN","Finland","2012","2012",170,,
+"PATCRESS","R-Respiratory system","MTMOPPMT","Million US$, purchasing power parity","FIN","Finland","2013","2013",161.6,,
+"PATCRESS","R-Respiratory system","MTMOPPMT","Million US$, purchasing power parity","FIN","Finland","2014","2014",164,,
+"PATCRESS","R-Respiratory system","MTMOPPMT","Million US$, purchasing power parity","FIN","Finland","2015","2015",159.1,,
+"PATCRESS","R-Respiratory system","MTMOPPMT","Million US$, purchasing power parity","FIN","Finland","2016","2016",170.5,,
+"PATCRESS","R-Respiratory system","MTMOPPMT","Million US$, purchasing power parity","FIN","Finland","2017","2017",173.8,,
+"PATCRESS","R-Respiratory system","MTMOPPMT","Million US$, purchasing power parity","FIN","Finland","2018","2018",180.6,,
+"PATCRESS","R-Respiratory system","MTMOPPMT","Million US$, purchasing power parity","FIN","Finland","2019","2019",182.2,,
+"PATCRESS","R-Respiratory system","MTMOPPMT","Million US$, purchasing power parity","FIN","Finland","2020","2020",180.7,,
+"PATCRESS","R-Respiratory system","MTMOPPMT","Million US$, purchasing power parity","FIN","Finland","2021","2021",182.7,,
+"PATCRESS","R-Respiratory system","TCPPERMT","/capita, US$ exchange rate","FIN","Finland","2010","2010",36.5,,
+"PATCRESS","R-Respiratory system","TCPPERMT","/capita, US$ exchange rate","FIN","Finland","2011","2011",38.4,,
+"PATCRESS","R-Respiratory system","TCPPERMT","/capita, US$ exchange rate","FIN","Finland","2012","2012",36.6,,
+"PATCRESS","R-Respiratory system","TCPPERMT","/capita, US$ exchange rate","FIN","Finland","2013","2013",35.7,,
+"PATCRESS","R-Respiratory system","TCPPERMT","/capita, US$ exchange rate","FIN","Finland","2014","2014",36.2,,
+"PATCRESS","R-Respiratory system","TCPPERMT","/capita, US$ exchange rate","FIN","Finland","2015","2015",29.2,,
+"PATCRESS","R-Respiratory system","TCPPERMT","/capita, US$ exchange rate","FIN","Finland","2016","2016",30.3,,
+"PATCRESS","R-Respiratory system","TCPPERMT","/capita, US$ exchange rate","FIN","Finland","2017","2017",30.8,,
+"PATCRESS","R-Respiratory system","TCPPERMT","/capita, US$ exchange rate","FIN","Finland","2018","2018",33,,
+"PATCRESS","R-Respiratory system","TCPPERMT","/capita, US$ exchange rate","FIN","Finland","2019","2019",31,,
+"PATCRESS","R-Respiratory system","TCPPERMT","/capita, US$ exchange rate","FIN","Finland","2020","2020",30.7,,
+"PATCRESS","R-Respiratory system","TCPPERMT","/capita, US$ exchange rate","FIN","Finland","2021","2021",32.2,,
+"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2010","2010",30.6,,
+"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2011","2011",30.7,,
+"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2012","2012",31.4,,
+"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2013","2013",29.7,,
+"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2014","2014",30,,
+"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2015","2015",29,,
+"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2016","2016",31,,
+"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2017","2017",31.6,,
+"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2018","2018",32.7,,
+"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2019","2019",33,,
+"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2020","2020",32.7,,
+"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2021","2021",33,,
+"PATCRESS","R-Respiratory system","ATCPTTMT","% of total sales","FIN","Finland","2010","2010",7.9,,
+"PATCRESS","R-Respiratory system","ATCPTTMT","% of total sales","FIN","Finland","2011","2011",7.7,,
+"PATCRESS","R-Respiratory system","ATCPTTMT","% of total sales","FIN","Finland","2012","2012",7.9,,
+"PATCRESS","R-Respiratory system","ATCPTTMT","% of total sales","FIN","Finland","2013","2013",7.3,,
+"PATCRESS","R-Respiratory system","ATCPTTMT","% of total sales","FIN","Finland","2014","2014",7.1,,
+"PATCRESS","R-Respiratory system","ATCPTTMT","% of total sales","FIN","Finland","2015","2015",6.6,,
+"PATCRESS","R-Respiratory system","ATCPTTMT","% of total sales","FIN","Finland","2016","2016",6.6,,
+"PATCRESS","R-Respiratory system","ATCPTTMT","% of total sales","FIN","Finland","2017","2017",6.5,,
+"PATCRESS","R-Respiratory system","ATCPTTMT","% of total sales","FIN","Finland","2018","2018",6.2,,
+"PATCRESS","R-Respiratory system","ATCPTTMT","% of total sales","FIN","Finland","2019","2019",5.7,,
+"PATCRESS","R-Respiratory system","ATCPTTMT","% of total sales","FIN","Finland","2020","2020",5.5,,
+"PATCRESS","R-Respiratory system","ATCPTTMT","% of total sales","FIN","Finland","2021","2021",5.3,,
+"PATCRESS","R-Respiratory system","MLLNCUMT","Million of national currency units","FRA","France","2011","2011",2016,,
+"PATCRESS","R-Respiratory system","MTMOTCMT","Million US$ at exchange rate","FRA","France","2011","2011",2806.2,,
+"PATCRESS","R-Respiratory system","MTMOPPMT","Million US$, purchasing power parity","FRA","France","2011","2011",2396.1,,
+"PATCRESS","R-Respiratory system","TCPPERMT","/capita, US$ exchange rate","FRA","France","2011","2011",43.1,,
+"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","FRA","France","2011","2011",36.8,,
+"PATCRESS","R-Respiratory system","ATCPTTMT","% of total sales","FRA","France","2011","2011",7.3,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","MLLNCUMT","Million of national currency units","DEU","Germany","2010","2010",2051.5,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","MLLNCUMT","Million of national currency units","DEU","Germany","2011","2011",1987.3,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","MLLNCUMT","Million of national currency units","DEU","Germany","2012","2012",1927.9,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","MLLNCUMT","Million of national currency units","DEU","Germany","2013","2013",2036.5,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","MLLNCUMT","Million of national currency units","DEU","Germany","2014","2014",2047.5,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","MLLNCUMT","Million of national currency units","DEU","Germany","2015","2015",2054.6,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","MLLNCUMT","Million of national currency units","DEU","Germany","2016","2016",2134.3,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","MLLNCUMT","Million of national currency units","DEU","Germany","2017","2017",2146.1,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","MLLNCUMT","Million of national currency units","DEU","Germany","2018","2018",2313,"B; D","Break; Difference in methodology"
+"PATCRESS","R-Respiratory system","MLLNCUMT","Million of national currency units","DEU","Germany","2019","2019",2508,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","MLLNCUMT","Million of national currency units","DEU","Germany","2020","2020",2620.2,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","MLLNCUMT","Million of national currency units","DEU","Germany","2021","2021",2931.9,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","MTMOTCMT","Million US$ at exchange rate","DEU","Germany","2010","2010",2719.7,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","MTMOTCMT","Million US$ at exchange rate","DEU","Germany","2011","2011",2766.2,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","MTMOTCMT","Million US$ at exchange rate","DEU","Germany","2012","2012",2476.9,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","MTMOTCMT","Million US$ at exchange rate","DEU","Germany","2013","2013",2704.7,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","MTMOTCMT","Million US$ at exchange rate","DEU","Germany","2014","2014",2720.1,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","MTMOTCMT","Million US$ at exchange rate","DEU","Germany","2015","2015",2279.6,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","MTMOTCMT","Million US$ at exchange rate","DEU","Germany","2016","2016",2362.5,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","MTMOTCMT","Million US$ at exchange rate","DEU","Germany","2017","2017",2424.4,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","MTMOTCMT","Million US$ at exchange rate","DEU","Germany","2018","2018",2731.5,"B; D","Break; Difference in methodology"
+"PATCRESS","R-Respiratory system","MTMOTCMT","Million US$ at exchange rate","DEU","Germany","2019","2019",2807.6,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","MTMOTCMT","Million US$ at exchange rate","DEU","Germany","2020","2020",2992.8,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","MTMOTCMT","Million US$ at exchange rate","DEU","Germany","2021","2021",3467.7,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","MTMOPPMT","Million US$, purchasing power parity","DEU","Germany","2010","2010",2548.2,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","MTMOPPMT","Million US$, purchasing power parity","DEU","Germany","2011","2011",2519.6,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","MTMOPPMT","Million US$, purchasing power parity","DEU","Germany","2012","2012",2448.9,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","MTMOPPMT","Million US$, purchasing power parity","DEU","Germany","2013","2013",2628.5,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","MTMOPPMT","Million US$, purchasing power parity","DEU","Germany","2014","2014",2662.8,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","MTMOPPMT","Million US$, purchasing power parity","DEU","Germany","2015","2015",2640.5,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","MTMOPPMT","Million US$, purchasing power parity","DEU","Germany","2016","2016",2835.9,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","MTMOPPMT","Million US$, purchasing power parity","DEU","Germany","2017","2017",2881.5,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","MTMOPPMT","Million US$, purchasing power parity","DEU","Germany","2018","2018",3145,"B; D","Break; Difference in methodology"
+"PATCRESS","R-Respiratory system","MTMOPPMT","Million US$, purchasing power parity","DEU","Germany","2019","2019",3443.9,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","MTMOPPMT","Million US$, purchasing power parity","DEU","Germany","2020","2020",3614.1,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","MTMOPPMT","Million US$, purchasing power parity","DEU","Germany","2021","2021",3982.1,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","TCPPERMT","/capita, US$ exchange rate","DEU","Germany","2010","2010",33.3,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","TCPPERMT","/capita, US$ exchange rate","DEU","Germany","2011","2011",34.5,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","TCPPERMT","/capita, US$ exchange rate","DEU","Germany","2012","2012",30.8,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","TCPPERMT","/capita, US$ exchange rate","DEU","Germany","2013","2013",33.5,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","TCPPERMT","/capita, US$ exchange rate","DEU","Germany","2014","2014",33.6,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","TCPPERMT","/capita, US$ exchange rate","DEU","Germany","2015","2015",27.9,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","TCPPERMT","/capita, US$ exchange rate","DEU","Germany","2016","2016",28.7,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","TCPPERMT","/capita, US$ exchange rate","DEU","Germany","2017","2017",29.3,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","TCPPERMT","/capita, US$ exchange rate","DEU","Germany","2018","2018",32.9,"B; D","Break; Difference in methodology"
+"PATCRESS","R-Respiratory system","TCPPERMT","/capita, US$ exchange rate","DEU","Germany","2019","2019",33.8,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","TCPPERMT","/capita, US$ exchange rate","DEU","Germany","2020","2020",36,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","TCPPERMT","/capita, US$ exchange rate","DEU","Germany","2021","2021",41.7,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2010","2010",31.2,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2011","2011",31.4,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2012","2012",30.4,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2013","2013",32.6,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2014","2014",32.9,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2015","2015",32.3,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2016","2016",34.4,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2017","2017",34.9,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2018","2018",37.9,"B; D","Break; Difference in methodology"
+"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2019","2019",41.4,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2020","2020",43.5,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2021","2021",47.9,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","ATCPTTMT","% of total sales","DEU","Germany","2010","2010",6.9,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","ATCPTTMT","% of total sales","DEU","Germany","2011","2011",6.7,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","ATCPTTMT","% of total sales","DEU","Germany","2012","2012",6.3,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","ATCPTTMT","% of total sales","DEU","Germany","2013","2013",6.5,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","ATCPTTMT","% of total sales","DEU","Germany","2014","2014",6.1,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","ATCPTTMT","% of total sales","DEU","Germany","2015","2015",5.8,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","ATCPTTMT","% of total sales","DEU","Germany","2016","2016",5.9,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","ATCPTTMT","% of total sales","DEU","Germany","2017","2017",5.8,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","ATCPTTMT","% of total sales","DEU","Germany","2018","2018",5.2,"B; D","Break; Difference in methodology"
+"PATCRESS","R-Respiratory system","ATCPTTMT","% of total sales","DEU","Germany","2019","2019",5.4,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","ATCPTTMT","% of total sales","DEU","Germany","2020","2020",5.3,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","ATCPTTMT","% of total sales","DEU","Germany","2021","2021",5.5,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","MLLNCUMT","Million of national currency units","GRC","Greece","2010","2010",459.6,,
+"PATCRESS","R-Respiratory system","MLLNCUMT","Million of national currency units","GRC","Greece","2011","2011",451.6,,
+"PATCRESS","R-Respiratory system","MLLNCUMT","Million of national currency units","GRC","Greece","2012","2012",398.3,,
+"PATCRESS","R-Respiratory system","MLLNCUMT","Million of national currency units","GRC","Greece","2013","2013",359.2,,
+"PATCRESS","R-Respiratory system","MLLNCUMT","Million of national currency units","GRC","Greece","2014","2014",365.1,,
+"PATCRESS","R-Respiratory system","MLLNCUMT","Million of national currency units","GRC","Greece","2015","2015",331.4,,
+"PATCRESS","R-Respiratory system","MLLNCUMT","Million of national currency units","GRC","Greece","2016","2016",405.5,,
+"PATCRESS","R-Respiratory system","MLLNCUMT","Million of national currency units","GRC","Greece","2017","2017",410.4,,
+"PATCRESS","R-Respiratory system","MLLNCUMT","Million of national currency units","GRC","Greece","2018","2018",419.4,,
+"PATCRESS","R-Respiratory system","MLLNCUMT","Million of national currency units","GRC","Greece","2019","2019",430.4,,
+"PATCRESS","R-Respiratory system","MLLNCUMT","Million of national currency units","GRC","Greece","2020","2020",418,,
+"PATCRESS","R-Respiratory system","MLLNCUMT","Million of national currency units","GRC","Greece","2021","2021",405.1,,
+"PATCRESS","R-Respiratory system","MLLNCUMT","Million of national currency units","GRC","Greece","2022","2022",471.9,,
+"PATCRESS","R-Respiratory system","MTMOTCMT","Million US$ at exchange rate","GRC","Greece","2010","2010",609.3,,
+"PATCRESS","R-Respiratory system","MTMOTCMT","Million US$ at exchange rate","GRC","Greece","2011","2011",628.6,,
+"PATCRESS","R-Respiratory system","MTMOTCMT","Million US$ at exchange rate","GRC","Greece","2012","2012",511.7,,
+"PATCRESS","R-Respiratory system","MTMOTCMT","Million US$ at exchange rate","GRC","Greece","2013","2013",477,,
+"PATCRESS","R-Respiratory system","MTMOTCMT","Million US$ at exchange rate","GRC","Greece","2014","2014",485.1,,
+"PATCRESS","R-Respiratory system","MTMOTCMT","Million US$ at exchange rate","GRC","Greece","2015","2015",367.7,,
+"PATCRESS","R-Respiratory system","MTMOTCMT","Million US$ at exchange rate","GRC","Greece","2016","2016",448.8,,
+"PATCRESS","R-Respiratory system","MTMOTCMT","Million US$ at exchange rate","GRC","Greece","2017","2017",463.7,,
+"PATCRESS","R-Respiratory system","MTMOTCMT","Million US$ at exchange rate","GRC","Greece","2018","2018",495.2,,
+"PATCRESS","R-Respiratory system","MTMOTCMT","Million US$ at exchange rate","GRC","Greece","2019","2019",481.9,,
+"PATCRESS","R-Respiratory system","MTMOTCMT","Million US$ at exchange rate","GRC","Greece","2020","2020",477.4,,
+"PATCRESS","R-Respiratory system","MTMOTCMT","Million US$ at exchange rate","GRC","Greece","2021","2021",479.1,,
+"PATCRESS","R-Respiratory system","MTMOTCMT","Million US$ at exchange rate","GRC","Greece","2022","2022",496.9,,
+"PATCRESS","R-Respiratory system","MTMOPPMT","Million US$, purchasing power parity","GRC","Greece","2010","2010",636.5,,
+"PATCRESS","R-Respiratory system","MTMOPPMT","Million US$, purchasing power parity","GRC","Greece","2011","2011",633.2,,
+"PATCRESS","R-Respiratory system","MTMOPPMT","Million US$, purchasing power parity","GRC","Greece","2012","2012",581.7,,
+"PATCRESS","R-Respiratory system","MTMOPPMT","Million US$, purchasing power parity","GRC","Greece","2013","2013",568.9,,
+"PATCRESS","R-Respiratory system","MTMOPPMT","Million US$, purchasing power parity","GRC","Greece","2014","2014",597.5,,
+"PATCRESS","R-Respiratory system","MTMOPPMT","Million US$, purchasing power parity","GRC","Greece","2015","2015",544.2,,
+"PATCRESS","R-Respiratory system","MTMOPPMT","Million US$, purchasing power parity","GRC","Greece","2016","2016",688.9,,
+"PATCRESS","R-Respiratory system","MTMOPPMT","Million US$, purchasing power parity","GRC","Greece","2017","2017",713.8,,
+"PATCRESS","R-Respiratory system","MTMOPPMT","Million US$, purchasing power parity","GRC","Greece","2018","2018",742.4,,
+"PATCRESS","R-Respiratory system","MTMOPPMT","Million US$, purchasing power parity","GRC","Greece","2019","2019",784.2,,
+"PATCRESS","R-Respiratory system","MTMOPPMT","Million US$, purchasing power parity","GRC","Greece","2020","2020",768.3,,
+"PATCRESS","R-Respiratory system","MTMOPPMT","Million US$, purchasing power parity","GRC","Greece","2021","2021",742.5,,
+"PATCRESS","R-Respiratory system","MTMOPPMT","Million US$, purchasing power parity","GRC","Greece","2022","2022",892.9,,
+"PATCRESS","R-Respiratory system","TCPPERMT","/capita, US$ exchange rate","GRC","Greece","2010","2010",54.8,,
+"PATCRESS","R-Respiratory system","TCPPERMT","/capita, US$ exchange rate","GRC","Greece","2011","2011",56.6,,
+"PATCRESS","R-Respiratory system","TCPPERMT","/capita, US$ exchange rate","GRC","Greece","2012","2012",46.3,,
+"PATCRESS","R-Respiratory system","TCPPERMT","/capita, US$ exchange rate","GRC","Greece","2013","2013",43.5,,
+"PATCRESS","R-Respiratory system","TCPPERMT","/capita, US$ exchange rate","GRC","Greece","2014","2014",44.5,,
+"PATCRESS","R-Respiratory system","TCPPERMT","/capita, US$ exchange rate","GRC","Greece","2015","2015",34,,
+"PATCRESS","R-Respiratory system","TCPPERMT","/capita, US$ exchange rate","GRC","Greece","2016","2016",41.7,,
+"PATCRESS","R-Respiratory system","TCPPERMT","/capita, US$ exchange rate","GRC","Greece","2017","2017",43.1,,
+"PATCRESS","R-Respiratory system","TCPPERMT","/capita, US$ exchange rate","GRC","Greece","2018","2018",46.1,,
+"PATCRESS","R-Respiratory system","TCPPERMT","/capita, US$ exchange rate","GRC","Greece","2019","2019",44.9,,
+"PATCRESS","R-Respiratory system","TCPPERMT","/capita, US$ exchange rate","GRC","Greece","2020","2020",44.6,,
+"PATCRESS","R-Respiratory system","TCPPERMT","/capita, US$ exchange rate","GRC","Greece","2021","2021",45.3,,
+"PATCRESS","R-Respiratory system","TCPPERMT","/capita, US$ exchange rate","GRC","Greece","2022","2022",47.5,,
+"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2010","2010",57.2,,
+"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2011","2011",57,,
+"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2012","2012",52.7,,
+"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2013","2013",51.9,,
+"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2014","2014",54.9,,
+"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2015","2015",50.3,,
+"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2016","2016",63.9,,
+"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2017","2017",66.4,,
+"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2018","2018",69.2,,
+"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2019","2019",73.1,,
+"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2020","2020",71.8,,
+"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2021","2021",70.3,,
+"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2022","2022",85.4,,
+"PATCRESS","R-Respiratory system","MLLNCUMT","Million of national currency units","HUN","Hungary","2010","2010",34020,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","MLLNCUMT","Million of national currency units","HUN","Hungary","2011","2011",35728.1,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","MLLNCUMT","Million of national currency units","HUN","Hungary","2012","2012",33762.7,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","MLLNCUMT","Million of national currency units","HUN","Hungary","2013","2013",34278.8,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","MLLNCUMT","Million of national currency units","HUN","Hungary","2014","2014",34198.5,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","MLLNCUMT","Million of national currency units","HUN","Hungary","2015","2015",33515.8,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","MLLNCUMT","Million of national currency units","HUN","Hungary","2016","2016",34173.3,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","MLLNCUMT","Million of national currency units","HUN","Hungary","2017","2017",34496.8,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","MLLNCUMT","Million of national currency units","HUN","Hungary","2018","2018",35063.1,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","MLLNCUMT","Million of national currency units","HUN","Hungary","2019","2019",35957,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","MLLNCUMT","Million of national currency units","HUN","Hungary","2020","2020",37471.7,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","MLLNCUMT","Million of national currency units","HUN","Hungary","2021","2021",35884.5,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","MLLNCUMT","Million of national currency units","HUN","Hungary","2022","2022",36809.7,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","MTMOTCMT","Million US$ at exchange rate","HUN","Hungary","2010","2010",163.6,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","MTMOTCMT","Million US$ at exchange rate","HUN","Hungary","2011","2011",177.7,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","MTMOTCMT","Million US$ at exchange rate","HUN","Hungary","2012","2012",150,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","MTMOTCMT","Million US$ at exchange rate","HUN","Hungary","2013","2013",153.2,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","MTMOTCMT","Million US$ at exchange rate","HUN","Hungary","2014","2014",147,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","MTMOTCMT","Million US$ at exchange rate","HUN","Hungary","2015","2015",120,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","MTMOTCMT","Million US$ at exchange rate","HUN","Hungary","2016","2016",121.4,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","MTMOTCMT","Million US$ at exchange rate","HUN","Hungary","2017","2017",125.7,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","MTMOTCMT","Million US$ at exchange rate","HUN","Hungary","2018","2018",129.8,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","MTMOTCMT","Million US$ at exchange rate","HUN","Hungary","2019","2019",123.7,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","MTMOTCMT","Million US$ at exchange rate","HUN","Hungary","2020","2020",121.7,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","MTMOTCMT","Million US$ at exchange rate","HUN","Hungary","2021","2021",118.4,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","MTMOTCMT","Million US$ at exchange rate","HUN","Hungary","2022","2022",98.8,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","MTMOPPMT","Million US$, purchasing power parity","HUN","Hungary","2010","2010",269.1,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","MTMOPPMT","Million US$, purchasing power parity","HUN","Hungary","2011","2011",287.5,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","MTMOPPMT","Million US$, purchasing power parity","HUN","Hungary","2012","2012",268.8,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","MTMOPPMT","Million US$, purchasing power parity","HUN","Hungary","2013","2013",274.3,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","MTMOPPMT","Million US$, purchasing power parity","HUN","Hungary","2014","2014",264.3,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","MTMOPPMT","Million US$, purchasing power parity","HUN","Hungary","2015","2015",252.8,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","MTMOPPMT","Million US$, purchasing power parity","HUN","Hungary","2016","2016",258.8,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","MTMOPPMT","Million US$, purchasing power parity","HUN","Hungary","2017","2017",253.6,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","MTMOPPMT","Million US$, purchasing power parity","HUN","Hungary","2018","2018",252.1,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","MTMOPPMT","Million US$, purchasing power parity","HUN","Hungary","2019","2019",255.3,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","MTMOPPMT","Million US$, purchasing power parity","HUN","Hungary","2020","2020",257.8,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","MTMOPPMT","Million US$, purchasing power parity","HUN","Hungary","2021","2021",231.9,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","MTMOPPMT","Million US$, purchasing power parity","HUN","Hungary","2022","2022",228.3,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","TCPPERMT","/capita, US$ exchange rate","HUN","Hungary","2010","2010",16.4,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","TCPPERMT","/capita, US$ exchange rate","HUN","Hungary","2011","2011",17.8,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","TCPPERMT","/capita, US$ exchange rate","HUN","Hungary","2012","2012",15.1,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","TCPPERMT","/capita, US$ exchange rate","HUN","Hungary","2013","2013",15.5,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","TCPPERMT","/capita, US$ exchange rate","HUN","Hungary","2014","2014",14.9,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","TCPPERMT","/capita, US$ exchange rate","HUN","Hungary","2015","2015",12.2,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","TCPPERMT","/capita, US$ exchange rate","HUN","Hungary","2016","2016",12.4,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","TCPPERMT","/capita, US$ exchange rate","HUN","Hungary","2017","2017",12.8,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","TCPPERMT","/capita, US$ exchange rate","HUN","Hungary","2018","2018",13.3,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","TCPPERMT","/capita, US$ exchange rate","HUN","Hungary","2019","2019",12.7,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","TCPPERMT","/capita, US$ exchange rate","HUN","Hungary","2020","2020",12.5,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","TCPPERMT","/capita, US$ exchange rate","HUN","Hungary","2021","2021",12.2,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","TCPPERMT","/capita, US$ exchange rate","HUN","Hungary","2022","2022",10.2,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2010","2010",26.9,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2011","2011",28.8,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2012","2012",27.1,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2013","2013",27.7,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2014","2014",26.8,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2015","2015",25.7,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2016","2016",26.4,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2017","2017",25.9,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2018","2018",25.8,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2019","2019",26.1,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2020","2020",26.4,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2021","2021",23.9,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2022","2022",23.6,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","ATCPTTMT","% of total sales","HUN","Hungary","2010","2010",6.8,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","ATCPTTMT","% of total sales","HUN","Hungary","2011","2011",6.9,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","ATCPTTMT","% of total sales","HUN","Hungary","2012","2012",7.6,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","ATCPTTMT","% of total sales","HUN","Hungary","2013","2013",8,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","ATCPTTMT","% of total sales","HUN","Hungary","2014","2014",7.7,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","ATCPTTMT","% of total sales","HUN","Hungary","2015","2015",7.2,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","ATCPTTMT","% of total sales","HUN","Hungary","2016","2016",6.9,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","ATCPTTMT","% of total sales","HUN","Hungary","2017","2017",7,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","ATCPTTMT","% of total sales","HUN","Hungary","2018","2018",7,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","ATCPTTMT","% of total sales","HUN","Hungary","2019","2019",6.8,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","ATCPTTMT","% of total sales","HUN","Hungary","2020","2020",6.7,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","ATCPTTMT","% of total sales","HUN","Hungary","2021","2021",6.3,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","ATCPTTMT","% of total sales","HUN","Hungary","2022","2022",6.2,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","MLLNCUMT","Million of national currency units","ISL","Iceland","2010","2010",1762.5,,
+"PATCRESS","R-Respiratory system","MLLNCUMT","Million of national currency units","ISL","Iceland","2011","2011",1558.2,,
+"PATCRESS","R-Respiratory system","MLLNCUMT","Million of national currency units","ISL","Iceland","2012","2012",1582.6,,
+"PATCRESS","R-Respiratory system","MLLNCUMT","Million of national currency units","ISL","Iceland","2013","2013",1836.6,,
+"PATCRESS","R-Respiratory system","MLLNCUMT","Million of national currency units","ISL","Iceland","2014","2014",1516.1,,
+"PATCRESS","R-Respiratory system","MLLNCUMT","Million of national currency units","ISL","Iceland","2015","2015",1444.8,,
+"PATCRESS","R-Respiratory system","MLLNCUMT","Million of national currency units","ISL","Iceland","2016","2016",1508.4,,
+"PATCRESS","R-Respiratory system","MLLNCUMT","Million of national currency units","ISL","Iceland","2017","2017",1532.7,,
+"PATCRESS","R-Respiratory system","MLLNCUMT","Million of national currency units","ISL","Iceland","2018","2018",1706.8,,
+"PATCRESS","R-Respiratory system","MLLNCUMT","Million of national currency units","ISL","Iceland","2019","2019",1899.8,,
+"PATCRESS","R-Respiratory system","MLLNCUMT","Million of national currency units","ISL","Iceland","2020","2020",2155,,
+"PATCRESS","R-Respiratory system","MLLNCUMT","Million of national currency units","ISL","Iceland","2021","2021",2301.2,,
+"PATCRESS","R-Respiratory system","MTMOTCMT","Million US$ at exchange rate","ISL","Iceland","2010","2010",14.4,,
+"PATCRESS","R-Respiratory system","MTMOTCMT","Million US$ at exchange rate","ISL","Iceland","2011","2011",13.4,,
+"PATCRESS","R-Respiratory system","MTMOTCMT","Million US$ at exchange rate","ISL","Iceland","2012","2012",12.7,,
+"PATCRESS","R-Respiratory system","MTMOTCMT","Million US$ at exchange rate","ISL","Iceland","2013","2013",15,,
+"PATCRESS","R-Respiratory system","MTMOTCMT","Million US$ at exchange rate","ISL","Iceland","2014","2014",13,,
+"PATCRESS","R-Respiratory system","MTMOTCMT","Million US$ at exchange rate","ISL","Iceland","2015","2015",11,,
+"PATCRESS","R-Respiratory system","MTMOTCMT","Million US$ at exchange rate","ISL","Iceland","2016","2016",12.5,,
+"PATCRESS","R-Respiratory system","MTMOTCMT","Million US$ at exchange rate","ISL","Iceland","2017","2017",14.3,,
+"PATCRESS","R-Respiratory system","MTMOTCMT","Million US$ at exchange rate","ISL","Iceland","2018","2018",15.8,,
+"PATCRESS","R-Respiratory system","MTMOTCMT","Million US$ at exchange rate","ISL","Iceland","2019","2019",15.5,,
+"PATCRESS","R-Respiratory system","MTMOTCMT","Million US$ at exchange rate","ISL","Iceland","2020","2020",15.9,,
+"PATCRESS","R-Respiratory system","MTMOTCMT","Million US$ at exchange rate","ISL","Iceland","2021","2021",18.1,,
+"PATCRESS","R-Respiratory system","MTMOPPMT","Million US$, purchasing power parity","ISL","Iceland","2010","2010",13.3,,
+"PATCRESS","R-Respiratory system","MTMOPPMT","Million US$, purchasing power parity","ISL","Iceland","2011","2011",11.5,,
+"PATCRESS","R-Respiratory system","MTMOPPMT","Million US$, purchasing power parity","ISL","Iceland","2012","2012",11.6,,
+"PATCRESS","R-Respiratory system","MTMOPPMT","Million US$, purchasing power parity","ISL","Iceland","2013","2013",13.4,,
+"PATCRESS","R-Respiratory system","MTMOPPMT","Million US$, purchasing power parity","ISL","Iceland","2014","2014",10.9,,
+"PATCRESS","R-Respiratory system","MTMOPPMT","Million US$, purchasing power parity","ISL","Iceland","2015","2015",10.2,,
+"PATCRESS","R-Respiratory system","MTMOPPMT","Million US$, purchasing power parity","ISL","Iceland","2016","2016",10.8,,
+"PATCRESS","R-Respiratory system","MTMOPPMT","Million US$, purchasing power parity","ISL","Iceland","2017","2017",11.1,,
+"PATCRESS","R-Respiratory system","MTMOPPMT","Million US$, purchasing power parity","ISL","Iceland","2018","2018",12.1,,
+"PATCRESS","R-Respiratory system","MTMOPPMT","Million US$, purchasing power parity","ISL","Iceland","2019","2019",13.5,,
+"PATCRESS","R-Respiratory system","MTMOPPMT","Million US$, purchasing power parity","ISL","Iceland","2020","2020",14.7,,
+"PATCRESS","R-Respiratory system","MTMOPPMT","Million US$, purchasing power parity","ISL","Iceland","2021","2021",15.4,,
+"PATCRESS","R-Respiratory system","TCPPERMT","/capita, US$ exchange rate","ISL","Iceland","2010","2010",45.3,,
+"PATCRESS","R-Respiratory system","TCPPERMT","/capita, US$ exchange rate","ISL","Iceland","2011","2011",42.1,,
+"PATCRESS","R-Respiratory system","TCPPERMT","/capita, US$ exchange rate","ISL","Iceland","2012","2012",39.5,,
+"PATCRESS","R-Respiratory system","TCPPERMT","/capita, US$ exchange rate","ISL","Iceland","2013","2013",46.4,,
+"PATCRESS","R-Respiratory system","TCPPERMT","/capita, US$ exchange rate","ISL","Iceland","2014","2014",39.7,,
+"PATCRESS","R-Respiratory system","TCPPERMT","/capita, US$ exchange rate","ISL","Iceland","2015","2015",33.1,,
+"PATCRESS","R-Respiratory system","TCPPERMT","/capita, US$ exchange rate","ISL","Iceland","2016","2016",37.2,,
+"PATCRESS","R-Respiratory system","TCPPERMT","/capita, US$ exchange rate","ISL","Iceland","2017","2017",41.8,,
+"PATCRESS","R-Respiratory system","TCPPERMT","/capita, US$ exchange rate","ISL","Iceland","2018","2018",44.7,,
+"PATCRESS","R-Respiratory system","TCPPERMT","/capita, US$ exchange rate","ISL","Iceland","2019","2019",43,,
+"PATCRESS","R-Respiratory system","TCPPERMT","/capita, US$ exchange rate","ISL","Iceland","2020","2020",43.4,,
+"PATCRESS","R-Respiratory system","TCPPERMT","/capita, US$ exchange rate","ISL","Iceland","2021","2021",48.6,,
+"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2010","2010",41.7,,
+"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2011","2011",36.1,,
+"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2012","2012",36,,
+"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2013","2013",41.4,,
+"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2014","2014",33.4,,
+"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2015","2015",30.8,,
+"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2016","2016",32.1,,
+"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2017","2017",32.3,,
+"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2018","2018",34.3,,
+"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2019","2019",37.4,,
+"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2020","2020",40.1,,
+"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2021","2021",41.3,,
+"PATCRESS","R-Respiratory system","ATCPTTMT","% of total sales","ISL","Iceland","2010","2010",7,,
+"PATCRESS","R-Respiratory system","ATCPTTMT","% of total sales","ISL","Iceland","2011","2011",6,,
+"PATCRESS","R-Respiratory system","ATCPTTMT","% of total sales","ISL","Iceland","2012","2012",6.5,,
+"PATCRESS","R-Respiratory system","ATCPTTMT","% of total sales","ISL","Iceland","2013","2013",7.1,,
+"PATCRESS","R-Respiratory system","ATCPTTMT","% of total sales","ISL","Iceland","2014","2014",6.4,,
+"PATCRESS","R-Respiratory system","ATCPTTMT","% of total sales","ISL","Iceland","2015","2015",5.9,,
+"PATCRESS","R-Respiratory system","ATCPTTMT","% of total sales","ISL","Iceland","2016","2016",5.9,,
+"PATCRESS","R-Respiratory system","ATCPTTMT","% of total sales","ISL","Iceland","2017","2017",5.8,,
+"PATCRESS","R-Respiratory system","ATCPTTMT","% of total sales","ISL","Iceland","2018","2018",5.7,,
+"PATCRESS","R-Respiratory system","ATCPTTMT","% of total sales","ISL","Iceland","2019","2019",5.6,,
+"PATCRESS","R-Respiratory system","ATCPTTMT","% of total sales","ISL","Iceland","2020","2020",5.4,,
+"PATCRESS","R-Respiratory system","ATCPTTMT","% of total sales","ISL","Iceland","2021","2021",5.1,,
+"PATCRESS","R-Respiratory system","MLLNCUMT","Million of national currency units","IRL","Ireland","2010","2010",158.6,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","MLLNCUMT","Million of national currency units","IRL","Ireland","2011","2011",151,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","MLLNCUMT","Million of national currency units","IRL","Ireland","2012","2012",156,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","MLLNCUMT","Million of national currency units","IRL","Ireland","2013","2013",163.5,"B; D","Break; Difference in methodology"
+"PATCRESS","R-Respiratory system","MLLNCUMT","Million of national currency units","IRL","Ireland","2014","2014",165,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","MLLNCUMT","Million of national currency units","IRL","Ireland","2015","2015",169.5,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","MLLNCUMT","Million of national currency units","IRL","Ireland","2016","2016",167.8,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","MLLNCUMT","Million of national currency units","IRL","Ireland","2017","2017",181.8,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","MLLNCUMT","Million of national currency units","IRL","Ireland","2018","2018",225.3,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","MLLNCUMT","Million of national currency units","IRL","Ireland","2019","2019",243.4,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","MLLNCUMT","Million of national currency units","IRL","Ireland","2020","2020",216.8,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","MLLNCUMT","Million of national currency units","IRL","Ireland","2021","2021",213,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","MTMOTCMT","Million US$ at exchange rate","IRL","Ireland","2010","2010",210.2,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","MTMOTCMT","Million US$ at exchange rate","IRL","Ireland","2011","2011",210.2,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","MTMOTCMT","Million US$ at exchange rate","IRL","Ireland","2012","2012",200.4,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","MTMOTCMT","Million US$ at exchange rate","IRL","Ireland","2013","2013",217.1,"B; D","Break; Difference in methodology"
+"PATCRESS","R-Respiratory system","MTMOTCMT","Million US$ at exchange rate","IRL","Ireland","2014","2014",219.3,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","MTMOTCMT","Million US$ at exchange rate","IRL","Ireland","2015","2015",188.1,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","MTMOTCMT","Million US$ at exchange rate","IRL","Ireland","2016","2016",185.7,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","MTMOTCMT","Million US$ at exchange rate","IRL","Ireland","2017","2017",205.3,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","MTMOTCMT","Million US$ at exchange rate","IRL","Ireland","2018","2018",266.1,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","MTMOTCMT","Million US$ at exchange rate","IRL","Ireland","2019","2019",272.5,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","MTMOTCMT","Million US$ at exchange rate","IRL","Ireland","2020","2020",247.6,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","MTMOTCMT","Million US$ at exchange rate","IRL","Ireland","2021","2021",251.9,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","MTMOPPMT","Million US$, purchasing power parity","IRL","Ireland","2010","2010",186.6,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","MTMOPPMT","Million US$, purchasing power parity","IRL","Ireland","2011","2011",181.6,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","MTMOPPMT","Million US$, purchasing power parity","IRL","Ireland","2012","2012",189.5,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","MTMOPPMT","Million US$, purchasing power parity","IRL","Ireland","2013","2013",201.5,"B; D","Break; Difference in methodology"
+"PATCRESS","R-Respiratory system","MTMOPPMT","Million US$, purchasing power parity","IRL","Ireland","2014","2014",201.5,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","MTMOPPMT","Million US$, purchasing power parity","IRL","Ireland","2015","2015",209.4,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","MTMOPPMT","Million US$, purchasing power parity","IRL","Ireland","2016","2016",211.3,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","MTMOPPMT","Million US$, purchasing power parity","IRL","Ireland","2017","2017",228.8,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","MTMOPPMT","Million US$, purchasing power parity","IRL","Ireland","2018","2018",284.4,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","MTMOPPMT","Million US$, purchasing power parity","IRL","Ireland","2019","2019",302.1,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","MTMOPPMT","Million US$, purchasing power parity","IRL","Ireland","2020","2020",272.3,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","MTMOPPMT","Million US$, purchasing power parity","IRL","Ireland","2021","2021",268,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","TCPPERMT","/capita, US$ exchange rate","IRL","Ireland","2010","2010",46.1,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","TCPPERMT","/capita, US$ exchange rate","IRL","Ireland","2011","2011",45.9,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","TCPPERMT","/capita, US$ exchange rate","IRL","Ireland","2012","2012",43.6,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","TCPPERMT","/capita, US$ exchange rate","IRL","Ireland","2013","2013",47,"B; D","Break; Difference in methodology"
+"PATCRESS","R-Respiratory system","TCPPERMT","/capita, US$ exchange rate","IRL","Ireland","2014","2014",47.1,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","TCPPERMT","/capita, US$ exchange rate","IRL","Ireland","2015","2015",40,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","TCPPERMT","/capita, US$ exchange rate","IRL","Ireland","2016","2016",39.1,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","TCPPERMT","/capita, US$ exchange rate","IRL","Ireland","2017","2017",42.7,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","TCPPERMT","/capita, US$ exchange rate","IRL","Ireland","2018","2018",54.7,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","TCPPERMT","/capita, US$ exchange rate","IRL","Ireland","2019","2019",55.2,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","TCPPERMT","/capita, US$ exchange rate","IRL","Ireland","2020","2020",49.7,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","TCPPERMT","/capita, US$ exchange rate","IRL","Ireland","2021","2021",50.1,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2010","2010",40.9,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2011","2011",39.7,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2012","2012",41.2,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2013","2013",43.6,"B; D","Break; Difference in methodology"
+"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2014","2014",43.3,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2015","2015",44.5,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2016","2016",44.4,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2017","2017",47.6,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2018","2018",58.4,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2019","2019",61.2,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2020","2020",54.6,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2021","2021",53.2,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","ATCPTTMT","% of total sales","IRL","Ireland","2010","2010",7.7,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","ATCPTTMT","% of total sales","IRL","Ireland","2011","2011",7.7,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","ATCPTTMT","% of total sales","IRL","Ireland","2012","2012",7.6,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","ATCPTTMT","% of total sales","IRL","Ireland","2013","2013",8.3,"B; D","Break; Difference in methodology"
+"PATCRESS","R-Respiratory system","ATCPTTMT","% of total sales","IRL","Ireland","2014","2014",8.6,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","ATCPTTMT","% of total sales","IRL","Ireland","2015","2015",8.5,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","ATCPTTMT","% of total sales","IRL","Ireland","2016","2016",8.1,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","ATCPTTMT","% of total sales","IRL","Ireland","2017","2017",8.6,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","ATCPTTMT","% of total sales","IRL","Ireland","2018","2018",9.9,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","ATCPTTMT","% of total sales","IRL","Ireland","2019","2019",10.1,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","ATCPTTMT","% of total sales","IRL","Ireland","2020","2020",8.8,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","ATCPTTMT","% of total sales","IRL","Ireland","2021","2021",8.1,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","MLLNCUMT","Million of national currency units","ITA","Italy","2011","2011",1136.7,,
+"PATCRESS","R-Respiratory system","MLLNCUMT","Million of national currency units","ITA","Italy","2012","2012",1109.7,,
+"PATCRESS","R-Respiratory system","MLLNCUMT","Million of national currency units","ITA","Italy","2013","2013",1076.3,,
+"PATCRESS","R-Respiratory system","MLLNCUMT","Million of national currency units","ITA","Italy","2014","2014",1103.1,,
+"PATCRESS","R-Respiratory system","MLLNCUMT","Million of national currency units","ITA","Italy","2015","2015",1125.4,,
+"PATCRESS","R-Respiratory system","MLLNCUMT","Million of national currency units","ITA","Italy","2016","2016",1107.4,,
+"PATCRESS","R-Respiratory system","MLLNCUMT","Million of national currency units","ITA","Italy","2017","2017",1119.8,,
+"PATCRESS","R-Respiratory system","MLLNCUMT","Million of national currency units","ITA","Italy","2018","2018",1166.4,,
+"PATCRESS","R-Respiratory system","MLLNCUMT","Million of national currency units","ITA","Italy","2019","2019",1242.6,,
+"PATCRESS","R-Respiratory system","MLLNCUMT","Million of national currency units","ITA","Italy","2020","2020",1308.3,,
+"PATCRESS","R-Respiratory system","MLLNCUMT","Million of national currency units","ITA","Italy","2021","2021",1294.3,,
+"PATCRESS","R-Respiratory system","MLLNCUMT","Million of national currency units","ITA","Italy","2022","2022",1426.1,"E","Estimated value"
+"PATCRESS","R-Respiratory system","MTMOTCMT","Million US$ at exchange rate","ITA","Italy","2011","2011",1582.3,,
+"PATCRESS","R-Respiratory system","MTMOTCMT","Million US$ at exchange rate","ITA","Italy","2012","2012",1425.7,,
+"PATCRESS","R-Respiratory system","MTMOTCMT","Million US$ at exchange rate","ITA","Italy","2013","2013",1429.5,,
+"PATCRESS","R-Respiratory system","MTMOTCMT","Million US$ at exchange rate","ITA","Italy","2014","2014",1465.4,,
+"PATCRESS","R-Respiratory system","MTMOTCMT","Million US$ at exchange rate","ITA","Italy","2015","2015",1248.7,,
+"PATCRESS","R-Respiratory system","MTMOTCMT","Million US$ at exchange rate","ITA","Italy","2016","2016",1225.8,,
+"PATCRESS","R-Respiratory system","MTMOTCMT","Million US$ at exchange rate","ITA","Italy","2017","2017",1265,,
+"PATCRESS","R-Respiratory system","MTMOTCMT","Million US$ at exchange rate","ITA","Italy","2018","2018",1377.5,,
+"PATCRESS","R-Respiratory system","MTMOTCMT","Million US$ at exchange rate","ITA","Italy","2019","2019",1391,,
+"PATCRESS","R-Respiratory system","MTMOTCMT","Million US$ at exchange rate","ITA","Italy","2020","2020",1494.3,,
+"PATCRESS","R-Respiratory system","MTMOTCMT","Million US$ at exchange rate","ITA","Italy","2021","2021",1530.8,,
+"PATCRESS","R-Respiratory system","MTMOTCMT","Million US$ at exchange rate","ITA","Italy","2022","2022",1501.7,"E","Estimated value"
+"PATCRESS","R-Respiratory system","MTMOPPMT","Million US$, purchasing power parity","ITA","Italy","2011","2011",1498.3,,
+"PATCRESS","R-Respiratory system","MTMOPPMT","Million US$, purchasing power parity","ITA","Italy","2012","2012",1484.1,,
+"PATCRESS","R-Respiratory system","MTMOPPMT","Million US$, purchasing power parity","ITA","Italy","2013","2013",1459.8,,
+"PATCRESS","R-Respiratory system","MTMOPPMT","Million US$, purchasing power parity","ITA","Italy","2014","2014",1491.4,,
+"PATCRESS","R-Respiratory system","MTMOPPMT","Million US$, purchasing power parity","ITA","Italy","2015","2015",1523.6,,
+"PATCRESS","R-Respiratory system","MTMOPPMT","Million US$, purchasing power parity","ITA","Italy","2016","2016",1580.8,,
+"PATCRESS","R-Respiratory system","MTMOPPMT","Million US$, purchasing power parity","ITA","Italy","2017","2017",1623.1,,
+"PATCRESS","R-Respiratory system","MTMOPPMT","Million US$, purchasing power parity","ITA","Italy","2018","2018",1712.3,,
+"PATCRESS","R-Respiratory system","MTMOPPMT","Million US$, purchasing power parity","ITA","Italy","2019","2019",1891.9,,
+"PATCRESS","R-Respiratory system","MTMOPPMT","Million US$, purchasing power parity","ITA","Italy","2020","2020",2019.8,,
+"PATCRESS","R-Respiratory system","MTMOPPMT","Million US$, purchasing power parity","ITA","Italy","2021","2021",1998.8,,
+"PATCRESS","R-Respiratory system","MTMOPPMT","Million US$, purchasing power parity","ITA","Italy","2022","2022",2309.8,"E","Estimated value"
+"PATCRESS","R-Respiratory system","TCPPERMT","/capita, US$ exchange rate","ITA","Italy","2011","2011",26.6,,
+"PATCRESS","R-Respiratory system","TCPPERMT","/capita, US$ exchange rate","ITA","Italy","2012","2012",23.9,,
+"PATCRESS","R-Respiratory system","TCPPERMT","/capita, US$ exchange rate","ITA","Italy","2013","2013",23.7,,
+"PATCRESS","R-Respiratory system","TCPPERMT","/capita, US$ exchange rate","ITA","Italy","2014","2014",24.1,,
+"PATCRESS","R-Respiratory system","TCPPERMT","/capita, US$ exchange rate","ITA","Italy","2015","2015",20.6,,
+"PATCRESS","R-Respiratory system","TCPPERMT","/capita, US$ exchange rate","ITA","Italy","2016","2016",20.2,,
+"PATCRESS","R-Respiratory system","TCPPERMT","/capita, US$ exchange rate","ITA","Italy","2017","2017",20.9,,
+"PATCRESS","R-Respiratory system","TCPPERMT","/capita, US$ exchange rate","ITA","Italy","2018","2018",22.8,,
+"PATCRESS","R-Respiratory system","TCPPERMT","/capita, US$ exchange rate","ITA","Italy","2019","2019",23.3,,
+"PATCRESS","R-Respiratory system","TCPPERMT","/capita, US$ exchange rate","ITA","Italy","2020","2020",25.1,,
+"PATCRESS","R-Respiratory system","TCPPERMT","/capita, US$ exchange rate","ITA","Italy","2021","2021",25.9,,
+"PATCRESS","R-Respiratory system","TCPPERMT","/capita, US$ exchange rate","ITA","Italy","2022","2022",25.4,"E","Estimated value"
+"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2011","2011",25.2,,
+"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2012","2012",24.9,,
+"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2013","2013",24.2,,
+"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2014","2014",24.5,,
+"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2015","2015",25.1,,
+"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2016","2016",26.1,,
+"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2017","2017",26.8,,
+"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2018","2018",28.3,,
+"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2019","2019",31.7,,
+"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2020","2020",34,,
+"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2021","2021",33.8,,
+"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2022","2022",39.1,"E","Estimated value"
+"PATCRESS","R-Respiratory system","ATCPTTMT","% of total sales","ITA","Italy","2011","2011",5.8,,
+"PATCRESS","R-Respiratory system","ATCPTTMT","% of total sales","ITA","Italy","2012","2012",5.8,,
+"PATCRESS","R-Respiratory system","ATCPTTMT","% of total sales","ITA","Italy","2013","2013",5.5,,
+"PATCRESS","R-Respiratory system","ATCPTTMT","% of total sales","ITA","Italy","2014","2014",5.5,,
+"PATCRESS","R-Respiratory system","ATCPTTMT","% of total sales","ITA","Italy","2015","2015",5,,
+"PATCRESS","R-Respiratory system","ATCPTTMT","% of total sales","ITA","Italy","2016","2016",4.9,,
+"PATCRESS","R-Respiratory system","ATCPTTMT","% of total sales","ITA","Italy","2017","2017",5,,
+"PATCRESS","R-Respiratory system","ATCPTTMT","% of total sales","ITA","Italy","2018","2018",5.2,,
+"PATCRESS","R-Respiratory system","ATCPTTMT","% of total sales","ITA","Italy","2019","2019",5.4,,
+"PATCRESS","R-Respiratory system","ATCPTTMT","% of total sales","ITA","Italy","2020","2020",5.7,,
+"PATCRESS","R-Respiratory system","ATCPTTMT","% of total sales","ITA","Italy","2021","2021",5.4,,
+"PATCRESS","R-Respiratory system","ATCPTTMT","% of total sales","ITA","Italy","2022","2022",5.8,"E","Estimated value"
+"PATCRESS","R-Respiratory system","MLLNCUMT","Million of national currency units","JPN","Japan","2010","2010",123160,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","MLLNCUMT","Million of national currency units","JPN","Japan","2011","2011",123835,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","MLLNCUMT","Million of national currency units","JPN","Japan","2012","2012",127386,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","MLLNCUMT","Million of national currency units","JPN","Japan","2013","2013",118406,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","MLLNCUMT","Million of national currency units","JPN","Japan","2014","2014",98066,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","MLLNCUMT","Million of national currency units","JPN","Japan","2015","2015",119017,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","MLLNCUMT","Million of national currency units","JPN","Japan","2016","2016",119619,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","MLLNCUMT","Million of national currency units","JPN","Japan","2017","2017",135053,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","MLLNCUMT","Million of national currency units","JPN","Japan","2018","2018",112068,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","MLLNCUMT","Million of national currency units","JPN","Japan","2019","2019",138720,"B; D","Break; Difference in methodology"
+"PATCRESS","R-Respiratory system","MLLNCUMT","Million of national currency units","JPN","Japan","2020","2020",124575,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","MLLNCUMT","Million of national currency units","JPN","Japan","2021","2021",97931,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","MTMOTCMT","Million US$ at exchange rate","JPN","Japan","2010","2010",1403.1,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","MTMOTCMT","Million US$ at exchange rate","JPN","Japan","2011","2011",1551.7,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","MTMOTCMT","Million US$ at exchange rate","JPN","Japan","2012","2012",1596.5,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","MTMOTCMT","Million US$ at exchange rate","JPN","Japan","2013","2013",1213.2,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","MTMOTCMT","Million US$ at exchange rate","JPN","Japan","2014","2014",925.6,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","MTMOTCMT","Million US$ at exchange rate","JPN","Japan","2015","2015",983.3,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","MTMOTCMT","Million US$ at exchange rate","JPN","Japan","2016","2016",1099.5,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","MTMOTCMT","Million US$ at exchange rate","JPN","Japan","2017","2017",1204,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","MTMOTCMT","Million US$ at exchange rate","JPN","Japan","2018","2018",1014.9,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","MTMOTCMT","Million US$ at exchange rate","JPN","Japan","2019","2019",1272.5,"B; D","Break; Difference in methodology"
+"PATCRESS","R-Respiratory system","MTMOTCMT","Million US$ at exchange rate","JPN","Japan","2020","2020",1166.7,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","MTMOTCMT","Million US$ at exchange rate","JPN","Japan","2021","2021",892.3,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","MTMOPPMT","Million US$, purchasing power parity","JPN","Japan","2010","2010",1102.5,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","MTMOPPMT","Million US$, purchasing power parity","JPN","Japan","2011","2011",1152.4,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","MTMOPPMT","Million US$, purchasing power parity","JPN","Japan","2012","2012",1221.6,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","MTMOPPMT","Million US$, purchasing power parity","JPN","Japan","2013","2013",1168.8,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","MTMOPPMT","Million US$, purchasing power parity","JPN","Japan","2014","2014",951.6,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","MTMOPPMT","Million US$, purchasing power parity","JPN","Japan","2015","2015",1150.3,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","MTMOPPMT","Million US$, purchasing power parity","JPN","Japan","2016","2016",1133.6,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","MTMOPPMT","Million US$, purchasing power parity","JPN","Japan","2017","2017",1285,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","MTMOPPMT","Million US$, purchasing power parity","JPN","Japan","2018","2018",1075.9,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","MTMOPPMT","Million US$, purchasing power parity","JPN","Japan","2019","2019",1331,"B; D","Break; Difference in methodology"
+"PATCRESS","R-Respiratory system","MTMOPPMT","Million US$, purchasing power parity","JPN","Japan","2020","2020",1216.2,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","MTMOPPMT","Million US$, purchasing power parity","JPN","Japan","2021","2021",959.6,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","TCPPERMT","/capita, US$ exchange rate","JPN","Japan","2010","2010",11,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","TCPPERMT","/capita, US$ exchange rate","JPN","Japan","2011","2011",12.1,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","TCPPERMT","/capita, US$ exchange rate","JPN","Japan","2012","2012",12.5,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","TCPPERMT","/capita, US$ exchange rate","JPN","Japan","2013","2013",9.5,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","TCPPERMT","/capita, US$ exchange rate","JPN","Japan","2014","2014",7.3,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","TCPPERMT","/capita, US$ exchange rate","JPN","Japan","2015","2015",7.7,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","TCPPERMT","/capita, US$ exchange rate","JPN","Japan","2016","2016",8.7,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","TCPPERMT","/capita, US$ exchange rate","JPN","Japan","2017","2017",9.5,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","TCPPERMT","/capita, US$ exchange rate","JPN","Japan","2018","2018",8,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","TCPPERMT","/capita, US$ exchange rate","JPN","Japan","2019","2019",10.1,"B; D","Break; Difference in methodology"
+"PATCRESS","R-Respiratory system","TCPPERMT","/capita, US$ exchange rate","JPN","Japan","2020","2020",9.2,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","TCPPERMT","/capita, US$ exchange rate","JPN","Japan","2021","2021",7.1,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","JPN","Japan","2010","2010",8.6,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","JPN","Japan","2011","2011",9,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","JPN","Japan","2012","2012",9.6,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","JPN","Japan","2013","2013",9.2,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","JPN","Japan","2014","2014",7.5,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","JPN","Japan","2015","2015",9.1,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","JPN","Japan","2016","2016",8.9,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","JPN","Japan","2017","2017",10.1,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","JPN","Japan","2018","2018",8.5,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","JPN","Japan","2019","2019",10.5,"B; D","Break; Difference in methodology"
+"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","JPN","Japan","2020","2020",9.6,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","JPN","Japan","2021","2021",7.6,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","ATCPTTMT","% of total sales","JPN","Japan","2010","2010",1.8,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","ATCPTTMT","% of total sales","JPN","Japan","2011","2011",1.8,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","ATCPTTMT","% of total sales","JPN","Japan","2012","2012",1.8,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","ATCPTTMT","% of total sales","JPN","Japan","2013","2013",1.7,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","ATCPTTMT","% of total sales","JPN","Japan","2014","2014",1.5,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","ATCPTTMT","% of total sales","JPN","Japan","2015","2015",1.8,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","ATCPTTMT","% of total sales","JPN","Japan","2016","2016",1.8,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","ATCPTTMT","% of total sales","JPN","Japan","2017","2017",2,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","ATCPTTMT","% of total sales","JPN","Japan","2018","2018",1.6,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","ATCPTTMT","% of total sales","JPN","Japan","2019","2019",1.5,"B; D","Break; Difference in methodology"
+"PATCRESS","R-Respiratory system","ATCPTTMT","% of total sales","JPN","Japan","2020","2020",1.3,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","ATCPTTMT","% of total sales","JPN","Japan","2021","2021",1.1,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","MLLNCUMT","Million of national currency units","KOR","Korea","2010","2010",1005103,,
+"PATCRESS","R-Respiratory system","MLLNCUMT","Million of national currency units","KOR","Korea","2011","2011",989661.7,"B","Break"
+"PATCRESS","R-Respiratory system","MLLNCUMT","Million of national currency units","KOR","Korea","2012","2012",955295.2,,
+"PATCRESS","R-Respiratory system","MLLNCUMT","Million of national currency units","KOR","Korea","2013","2013",951300.4,,
+"PATCRESS","R-Respiratory system","MLLNCUMT","Million of national currency units","KOR","Korea","2014","2014",1026144.4,,
+"PATCRESS","R-Respiratory system","MLLNCUMT","Million of national currency units","KOR","Korea","2015","2015",1048376.9,,
+"PATCRESS","R-Respiratory system","MLLNCUMT","Million of national currency units","KOR","Korea","2016","2016",1097011.9,"B","Break"
+"PATCRESS","R-Respiratory system","MLLNCUMT","Million of national currency units","KOR","Korea","2017","2017",1125767.9,,
+"PATCRESS","R-Respiratory system","MLLNCUMT","Million of national currency units","KOR","Korea","2018","2018",1217876.9,,
+"PATCRESS","R-Respiratory system","MLLNCUMT","Million of national currency units","KOR","Korea","2019","2019",1244223.3,,
+"PATCRESS","R-Respiratory system","MLLNCUMT","Million of national currency units","KOR","Korea","2020","2020",1098631,,
+"PATCRESS","R-Respiratory system","MLLNCUMT","Million of national currency units","KOR","Korea","2021","2021",1036337.9,,
+"PATCRESS","R-Respiratory system","MTMOTCMT","Million US$ at exchange rate","KOR","Korea","2010","2010",869.1,,
+"PATCRESS","R-Respiratory system","MTMOTCMT","Million US$ at exchange rate","KOR","Korea","2011","2011",893,"B","Break"
+"PATCRESS","R-Respiratory system","MTMOTCMT","Million US$ at exchange rate","KOR","Korea","2012","2012",847.8,,
+"PATCRESS","R-Respiratory system","MTMOTCMT","Million US$ at exchange rate","KOR","Korea","2013","2013",868.8,,
+"PATCRESS","R-Respiratory system","MTMOTCMT","Million US$ at exchange rate","KOR","Korea","2014","2014",974.6,,
+"PATCRESS","R-Respiratory system","MTMOTCMT","Million US$ at exchange rate","KOR","Korea","2015","2015",927,,
+"PATCRESS","R-Respiratory system","MTMOTCMT","Million US$ at exchange rate","KOR","Korea","2016","2016",945.1,"B","Break"
+"PATCRESS","R-Respiratory system","MTMOTCMT","Million US$ at exchange rate","KOR","Korea","2017","2017",995.4,,
+"PATCRESS","R-Respiratory system","MTMOTCMT","Million US$ at exchange rate","KOR","Korea","2018","2018",1107,,
+"PATCRESS","R-Respiratory system","MTMOTCMT","Million US$ at exchange rate","KOR","Korea","2019","2019",1067.7,,
+"PATCRESS","R-Respiratory system","MTMOTCMT","Million US$ at exchange rate","KOR","Korea","2020","2020",930.8,,
+"PATCRESS","R-Respiratory system","MTMOTCMT","Million US$ at exchange rate","KOR","Korea","2021","2021",905.9,,
+"PATCRESS","R-Respiratory system","MTMOPPMT","Million US$, purchasing power parity","KOR","Korea","2010","2010",1195.1,,
+"PATCRESS","R-Respiratory system","MTMOPPMT","Million US$, purchasing power parity","KOR","Korea","2011","2011",1158.1,"B","Break"
+"PATCRESS","R-Respiratory system","MTMOPPMT","Million US$, purchasing power parity","KOR","Korea","2012","2012",1117.5,,
+"PATCRESS","R-Respiratory system","MTMOPPMT","Million US$, purchasing power parity","KOR","Korea","2013","2013",1094.6,,
+"PATCRESS","R-Respiratory system","MTMOPPMT","Million US$, purchasing power parity","KOR","Korea","2014","2014",1176.9,,
+"PATCRESS","R-Respiratory system","MTMOPPMT","Million US$, purchasing power parity","KOR","Korea","2015","2015",1222.6,,
+"PATCRESS","R-Respiratory system","MTMOPPMT","Million US$, purchasing power parity","KOR","Korea","2016","2016",1277.4,"B","Break"
+"PATCRESS","R-Respiratory system","MTMOPPMT","Million US$, purchasing power parity","KOR","Korea","2017","2017",1290.1,,
+"PATCRESS","R-Respiratory system","MTMOPPMT","Million US$, purchasing power parity","KOR","Korea","2018","2018",1424.6,,
+"PATCRESS","R-Respiratory system","MTMOPPMT","Million US$, purchasing power parity","KOR","Korea","2019","2019",1452.8,,
+"PATCRESS","R-Respiratory system","MTMOPPMT","Million US$, purchasing power parity","KOR","Korea","2020","2020",1311.5,,
+"PATCRESS","R-Respiratory system","MTMOPPMT","Million US$, purchasing power parity","KOR","Korea","2021","2021",1213.4,,
+"PATCRESS","R-Respiratory system","TCPPERMT","/capita, US$ exchange rate","KOR","Korea","2010","2010",17.5,,
+"PATCRESS","R-Respiratory system","TCPPERMT","/capita, US$ exchange rate","KOR","Korea","2011","2011",17.9,"B","Break"
+"PATCRESS","R-Respiratory system","TCPPERMT","/capita, US$ exchange rate","KOR","Korea","2012","2012",16.9,,
+"PATCRESS","R-Respiratory system","TCPPERMT","/capita, US$ exchange rate","KOR","Korea","2013","2013",17.2,,
+"PATCRESS","R-Respiratory system","TCPPERMT","/capita, US$ exchange rate","KOR","Korea","2014","2014",19.2,,
+"PATCRESS","R-Respiratory system","TCPPERMT","/capita, US$ exchange rate","KOR","Korea","2015","2015",18.2,,
+"PATCRESS","R-Respiratory system","TCPPERMT","/capita, US$ exchange rate","KOR","Korea","2016","2016",18.5,"B","Break"
+"PATCRESS","R-Respiratory system","TCPPERMT","/capita, US$ exchange rate","KOR","Korea","2017","2017",19.4,,
+"PATCRESS","R-Respiratory system","TCPPERMT","/capita, US$ exchange rate","KOR","Korea","2018","2018",21.5,,
+"PATCRESS","R-Respiratory system","TCPPERMT","/capita, US$ exchange rate","KOR","Korea","2019","2019",20.6,,
+"PATCRESS","R-Respiratory system","TCPPERMT","/capita, US$ exchange rate","KOR","Korea","2020","2020",18,,
+"PATCRESS","R-Respiratory system","TCPPERMT","/capita, US$ exchange rate","KOR","Korea","2021","2021",17.5,,
+"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2010","2010",24.1,,
+"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2011","2011",23.2,"B","Break"
+"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2012","2012",22.3,,
+"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2013","2013",21.7,,
+"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2014","2014",23.2,,
+"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2015","2015",24,,
+"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2016","2016",24.9,"B","Break"
+"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2017","2017",25.1,,
+"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2018","2018",27.6,,
+"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2019","2019",28.1,,
+"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2020","2020",25.3,,
+"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2021","2021",23.4,,
+"PATCRESS","R-Respiratory system","ATCPTTMT","% of total sales","KOR","Korea","2010","2010",4.9,,
+"PATCRESS","R-Respiratory system","ATCPTTMT","% of total sales","KOR","Korea","2011","2011",4.5,"B","Break"
+"PATCRESS","R-Respiratory system","ATCPTTMT","% of total sales","KOR","Korea","2012","2012",4.4,,
+"PATCRESS","R-Respiratory system","ATCPTTMT","% of total sales","KOR","Korea","2013","2013",4.2,,
+"PATCRESS","R-Respiratory system","ATCPTTMT","% of total sales","KOR","Korea","2014","2014",4.3,,
+"PATCRESS","R-Respiratory system","ATCPTTMT","% of total sales","KOR","Korea","2015","2015",4.3,,
+"PATCRESS","R-Respiratory system","ATCPTTMT","% of total sales","KOR","Korea","2016","2016",4.3,"B","Break"
+"PATCRESS","R-Respiratory system","ATCPTTMT","% of total sales","KOR","Korea","2017","2017",4.2,,
+"PATCRESS","R-Respiratory system","ATCPTTMT","% of total sales","KOR","Korea","2018","2018",4.2,,
+"PATCRESS","R-Respiratory system","ATCPTTMT","% of total sales","KOR","Korea","2019","2019",4,,
+"PATCRESS","R-Respiratory system","ATCPTTMT","% of total sales","KOR","Korea","2020","2020",3.4,,
+"PATCRESS","R-Respiratory system","ATCPTTMT","% of total sales","KOR","Korea","2021","2021",3,,
+"PATCRESS","R-Respiratory system","MLLNCUMT","Million of national currency units","LUX","Luxembourg","2010","2010",15.3,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","MLLNCUMT","Million of national currency units","LUX","Luxembourg","2011","2011",15,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","MLLNCUMT","Million of national currency units","LUX","Luxembourg","2012","2012",15.1,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","MLLNCUMT","Million of national currency units","LUX","Luxembourg","2013","2013",15.6,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","MLLNCUMT","Million of national currency units","LUX","Luxembourg","2014","2014",14.8,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","MLLNCUMT","Million of national currency units","LUX","Luxembourg","2015","2015",14.5,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","MLLNCUMT","Million of national currency units","LUX","Luxembourg","2016","2016",14.1,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","MLLNCUMT","Million of national currency units","LUX","Luxembourg","2017","2017",13.2,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","MLLNCUMT","Million of national currency units","LUX","Luxembourg","2018","2018",13.8,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","MLLNCUMT","Million of national currency units","LUX","Luxembourg","2019","2019",13.6,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","MLLNCUMT","Million of national currency units","LUX","Luxembourg","2020","2020",13.8,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","MLLNCUMT","Million of national currency units","LUX","Luxembourg","2021","2021",17.6,"B; D; P","Break; Difference in methodology; Provisional value"
+"PATCRESS","R-Respiratory system","MLLNCUMT","Million of national currency units","LUX","Luxembourg","2022","2022",19.3,"D; P","Difference in methodology; Provisional value"
+"PATCRESS","R-Respiratory system","MTMOTCMT","Million US$ at exchange rate","LUX","Luxembourg","2010","2010",20.3,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","MTMOTCMT","Million US$ at exchange rate","LUX","Luxembourg","2011","2011",20.8,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","MTMOTCMT","Million US$ at exchange rate","LUX","Luxembourg","2012","2012",19.4,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","MTMOTCMT","Million US$ at exchange rate","LUX","Luxembourg","2013","2013",20.8,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","MTMOTCMT","Million US$ at exchange rate","LUX","Luxembourg","2014","2014",19.6,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","MTMOTCMT","Million US$ at exchange rate","LUX","Luxembourg","2015","2015",16.1,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","MTMOTCMT","Million US$ at exchange rate","LUX","Luxembourg","2016","2016",15.6,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","MTMOTCMT","Million US$ at exchange rate","LUX","Luxembourg","2017","2017",14.9,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","MTMOTCMT","Million US$ at exchange rate","LUX","Luxembourg","2018","2018",16.2,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","MTMOTCMT","Million US$ at exchange rate","LUX","Luxembourg","2019","2019",15.3,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","MTMOTCMT","Million US$ at exchange rate","LUX","Luxembourg","2020","2020",15.7,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","MTMOTCMT","Million US$ at exchange rate","LUX","Luxembourg","2021","2021",20.8,"B; D; P","Break; Difference in methodology; Provisional value"
+"PATCRESS","R-Respiratory system","MTMOTCMT","Million US$ at exchange rate","LUX","Luxembourg","2022","2022",20.3,"D; P","Difference in methodology; Provisional value"
+"PATCRESS","R-Respiratory system","MTMOPPMT","Million US$, purchasing power parity","LUX","Luxembourg","2010","2010",16.5,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","MTMOPPMT","Million US$, purchasing power parity","LUX","Luxembourg","2011","2011",16.5,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","MTMOPPMT","Million US$, purchasing power parity","LUX","Luxembourg","2012","2012",16.7,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","MTMOPPMT","Million US$, purchasing power parity","LUX","Luxembourg","2013","2013",17.5,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","MTMOPPMT","Million US$, purchasing power parity","LUX","Luxembourg","2014","2014",16.7,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","MTMOPPMT","Million US$, purchasing power parity","LUX","Luxembourg","2015","2015",16.5,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","MTMOPPMT","Million US$, purchasing power parity","LUX","Luxembourg","2016","2016",16.5,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","MTMOPPMT","Million US$, purchasing power parity","LUX","Luxembourg","2017","2017",15.5,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","MTMOPPMT","Million US$, purchasing power parity","LUX","Luxembourg","2018","2018",16.2,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","MTMOPPMT","Million US$, purchasing power parity","LUX","Luxembourg","2019","2019",16.2,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","MTMOPPMT","Million US$, purchasing power parity","LUX","Luxembourg","2020","2020",16.1,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","MTMOPPMT","Million US$, purchasing power parity","LUX","Luxembourg","2021","2021",20.5,"B; D; P","Break; Difference in methodology; Provisional value"
+"PATCRESS","R-Respiratory system","MTMOPPMT","Million US$, purchasing power parity","LUX","Luxembourg","2022","2022",23.2,"D; P","Difference in methodology; Provisional value"
+"PATCRESS","R-Respiratory system","TCPPERMT","/capita, US$ exchange rate","LUX","Luxembourg","2010","2010",42.9,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","TCPPERMT","/capita, US$ exchange rate","LUX","Luxembourg","2011","2011",43.2,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","TCPPERMT","/capita, US$ exchange rate","LUX","Luxembourg","2012","2012",39.4,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","TCPPERMT","/capita, US$ exchange rate","LUX","Luxembourg","2013","2013",41.4,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","TCPPERMT","/capita, US$ exchange rate","LUX","Luxembourg","2014","2014",38.4,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","TCPPERMT","/capita, US$ exchange rate","LUX","Luxembourg","2015","2015",31.1,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","TCPPERMT","/capita, US$ exchange rate","LUX","Luxembourg","2016","2016",29.6,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","TCPPERMT","/capita, US$ exchange rate","LUX","Luxembourg","2017","2017",27.7,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","TCPPERMT","/capita, US$ exchange rate","LUX","Luxembourg","2018","2018",29.7,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","TCPPERMT","/capita, US$ exchange rate","LUX","Luxembourg","2019","2019",27.4,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","TCPPERMT","/capita, US$ exchange rate","LUX","Luxembourg","2020","2020",27.7,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","TCPPERMT","/capita, US$ exchange rate","LUX","Luxembourg","2021","2021",36.2,"B; D; P","Break; Difference in methodology; Provisional value"
+"PATCRESS","R-Respiratory system","TCPPERMT","/capita, US$ exchange rate","LUX","Luxembourg","2022","2022",34.6,"D; P","Difference in methodology; Provisional value"
+"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2010","2010",34.9,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2011","2011",34.3,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2012","2012",33.9,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2013","2013",34.8,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2014","2014",32.7,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2015","2015",31.8,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2016","2016",31.4,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2017","2017",28.9,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2018","2018",29.7,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2019","2019",29.1,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2020","2020",28.4,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2021","2021",35.6,"B; D; P","Break; Difference in methodology; Provisional value"
+"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2022","2022",39.5,"D; P","Difference in methodology; Provisional value"
+"PATCRESS","R-Respiratory system","ATCPTTMT","% of total sales","LUX","Luxembourg","2010","2010",8.1,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","ATCPTTMT","% of total sales","LUX","Luxembourg","2011","2011",7.9,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","ATCPTTMT","% of total sales","LUX","Luxembourg","2012","2012",7.7,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","ATCPTTMT","% of total sales","LUX","Luxembourg","2013","2013",8,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","ATCPTTMT","% of total sales","LUX","Luxembourg","2014","2014",7.7,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","ATCPTTMT","% of total sales","LUX","Luxembourg","2015","2015",7.5,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","ATCPTTMT","% of total sales","LUX","Luxembourg","2016","2016",7.2,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","ATCPTTMT","% of total sales","LUX","Luxembourg","2017","2017",6.8,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","ATCPTTMT","% of total sales","LUX","Luxembourg","2018","2018",6.9,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","ATCPTTMT","% of total sales","LUX","Luxembourg","2019","2019",6.7,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","ATCPTTMT","% of total sales","LUX","Luxembourg","2020","2020",6.6,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","ATCPTTMT","% of total sales","LUX","Luxembourg","2021","2021",7.3,"B; D; P","Break; Difference in methodology; Provisional value"
+"PATCRESS","R-Respiratory system","ATCPTTMT","% of total sales","LUX","Luxembourg","2022","2022",7.5,"D; P","Difference in methodology; Provisional value"
+"PATCRESS","R-Respiratory system","MLLNCUMT","Million of national currency units","MEX","Mexico","2010","2010",8936,,
+"PATCRESS","R-Respiratory system","MLLNCUMT","Million of national currency units","MEX","Mexico","2011","2011",7354,,
+"PATCRESS","R-Respiratory system","MLLNCUMT","Million of national currency units","MEX","Mexico","2012","2012",7999,,
+"PATCRESS","R-Respiratory system","MLLNCUMT","Million of national currency units","MEX","Mexico","2013","2013",7254,,
+"PATCRESS","R-Respiratory system","MLLNCUMT","Million of national currency units","MEX","Mexico","2014","2014",6950,,
+"PATCRESS","R-Respiratory system","MLLNCUMT","Million of national currency units","MEX","Mexico","2015","2015",5656,,
+"PATCRESS","R-Respiratory system","MLLNCUMT","Million of national currency units","MEX","Mexico","2016","2016",6149,,
+"PATCRESS","R-Respiratory system","MLLNCUMT","Million of national currency units","MEX","Mexico","2017","2017",5570,,
+"PATCRESS","R-Respiratory system","MLLNCUMT","Million of national currency units","MEX","Mexico","2018","2018",5722,,
+"PATCRESS","R-Respiratory system","MLLNCUMT","Million of national currency units","MEX","Mexico","2019","2019",5741.2,,
+"PATCRESS","R-Respiratory system","MLLNCUMT","Million of national currency units","MEX","Mexico","2020","2020",5030.9,,
+"PATCRESS","R-Respiratory system","MLLNCUMT","Million of national currency units","MEX","Mexico","2021","2021",3975.3,,
+"PATCRESS","R-Respiratory system","MLLNCUMT","Million of national currency units","MEX","Mexico","2022","2022",5965,"E","Estimated value"
+"PATCRESS","R-Respiratory system","MTMOTCMT","Million US$ at exchange rate","MEX","Mexico","2010","2010",707.2,,
+"PATCRESS","R-Respiratory system","MTMOTCMT","Million US$ at exchange rate","MEX","Mexico","2011","2011",592,,
+"PATCRESS","R-Respiratory system","MTMOTCMT","Million US$ at exchange rate","MEX","Mexico","2012","2012",607.4,,
+"PATCRESS","R-Respiratory system","MTMOTCMT","Million US$ at exchange rate","MEX","Mexico","2013","2013",568,,
+"PATCRESS","R-Respiratory system","MTMOTCMT","Million US$ at exchange rate","MEX","Mexico","2014","2014",522.9,,
+"PATCRESS","R-Respiratory system","MTMOTCMT","Million US$ at exchange rate","MEX","Mexico","2015","2015",356.9,,
+"PATCRESS","R-Respiratory system","MTMOTCMT","Million US$ at exchange rate","MEX","Mexico","2016","2016",329.5,,
+"PATCRESS","R-Respiratory system","MTMOTCMT","Million US$ at exchange rate","MEX","Mexico","2017","2017",294.3,,
+"PATCRESS","R-Respiratory system","MTMOTCMT","Million US$ at exchange rate","MEX","Mexico","2018","2018",297.3,,
+"PATCRESS","R-Respiratory system","MTMOTCMT","Million US$ at exchange rate","MEX","Mexico","2019","2019",298,,
+"PATCRESS","R-Respiratory system","MTMOTCMT","Million US$ at exchange rate","MEX","Mexico","2020","2020",234.2,,
+"PATCRESS","R-Respiratory system","MTMOTCMT","Million US$ at exchange rate","MEX","Mexico","2021","2021",196.1,,
+"PATCRESS","R-Respiratory system","MTMOTCMT","Million US$ at exchange rate","MEX","Mexico","2022","2022",296.4,"E","Estimated value"
+"PATCRESS","R-Respiratory system","MTMOPPMT","Million US$, purchasing power parity","MEX","Mexico","2010","2010",1163.6,,
+"PATCRESS","R-Respiratory system","MTMOPPMT","Million US$, purchasing power parity","MEX","Mexico","2011","2011",958.4,,
+"PATCRESS","R-Respiratory system","MTMOPPMT","Million US$, purchasing power parity","MEX","Mexico","2012","2012",1017.9,,
+"PATCRESS","R-Respiratory system","MTMOPPMT","Million US$, purchasing power parity","MEX","Mexico","2013","2013",920,,
+"PATCRESS","R-Respiratory system","MTMOPPMT","Million US$, purchasing power parity","MEX","Mexico","2014","2014",863.9,,
+"PATCRESS","R-Respiratory system","MTMOPPMT","Million US$, purchasing power parity","MEX","Mexico","2015","2015",679.2,,
+"PATCRESS","R-Respiratory system","MTMOPPMT","Million US$, purchasing power parity","MEX","Mexico","2016","2016",728,,
+"PATCRESS","R-Respiratory system","MTMOPPMT","Million US$, purchasing power parity","MEX","Mexico","2017","2017",624.9,,
+"PATCRESS","R-Respiratory system","MTMOPPMT","Million US$, purchasing power parity","MEX","Mexico","2018","2018",616.8,,
+"PATCRESS","R-Respiratory system","MTMOPPMT","Million US$, purchasing power parity","MEX","Mexico","2019","2019",594.1,,
+"PATCRESS","R-Respiratory system","MTMOPPMT","Million US$, purchasing power parity","MEX","Mexico","2020","2020",501.1,,
+"PATCRESS","R-Respiratory system","MTMOPPMT","Million US$, purchasing power parity","MEX","Mexico","2021","2021",382.2,,
+"PATCRESS","R-Respiratory system","MTMOPPMT","Million US$, purchasing power parity","MEX","Mexico","2022","2022",564,"E","Estimated value"
+"PATCRESS","R-Respiratory system","TCPPERMT","/capita, US$ exchange rate","MEX","Mexico","2010","2010",6.2,,
+"PATCRESS","R-Respiratory system","TCPPERMT","/capita, US$ exchange rate","MEX","Mexico","2011","2011",5.1,,
+"PATCRESS","R-Respiratory system","TCPPERMT","/capita, US$ exchange rate","MEX","Mexico","2012","2012",5.2,,
+"PATCRESS","R-Respiratory system","TCPPERMT","/capita, US$ exchange rate","MEX","Mexico","2013","2013",4.8,,
+"PATCRESS","R-Respiratory system","TCPPERMT","/capita, US$ exchange rate","MEX","Mexico","2014","2014",4.4,,
+"PATCRESS","R-Respiratory system","TCPPERMT","/capita, US$ exchange rate","MEX","Mexico","2015","2015",2.9,,
+"PATCRESS","R-Respiratory system","TCPPERMT","/capita, US$ exchange rate","MEX","Mexico","2016","2016",2.7,,
+"PATCRESS","R-Respiratory system","TCPPERMT","/capita, US$ exchange rate","MEX","Mexico","2017","2017",2.4,,
+"PATCRESS","R-Respiratory system","TCPPERMT","/capita, US$ exchange rate","MEX","Mexico","2018","2018",2.4,,
+"PATCRESS","R-Respiratory system","TCPPERMT","/capita, US$ exchange rate","MEX","Mexico","2019","2019",2.4,,
+"PATCRESS","R-Respiratory system","TCPPERMT","/capita, US$ exchange rate","MEX","Mexico","2020","2020",1.8,,
+"PATCRESS","R-Respiratory system","TCPPERMT","/capita, US$ exchange rate","MEX","Mexico","2021","2021",1.5,,
+"PATCRESS","R-Respiratory system","TCPPERMT","/capita, US$ exchange rate","MEX","Mexico","2022","2022",2.3,"E","Estimated value"
+"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","MEX","Mexico","2010","2010",10.2,,
+"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","MEX","Mexico","2011","2011",8.3,,
+"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","MEX","Mexico","2012","2012",8.7,,
+"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","MEX","Mexico","2013","2013",7.8,,
+"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","MEX","Mexico","2014","2014",7.2,,
+"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","MEX","Mexico","2015","2015",5.6,,
+"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","MEX","Mexico","2016","2016",5.9,,
+"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","MEX","Mexico","2017","2017",5,,
+"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","MEX","Mexico","2018","2018",4.9,,
+"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","MEX","Mexico","2019","2019",4.7,,
+"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","MEX","Mexico","2020","2020",3.9,,
+"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","MEX","Mexico","2021","2021",3,,
+"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","MEX","Mexico","2022","2022",4.3,"E","Estimated value"
+"PATCRESS","R-Respiratory system","ATCPTTMT","% of total sales","MEX","Mexico","2013","2013",5.1,,
+"PATCRESS","R-Respiratory system","ATCPTTMT","% of total sales","MEX","Mexico","2018","2018",2.5,,
+"PATCRESS","R-Respiratory system","MLLNCUMT","Million of national currency units","NLD","Netherlands","2010","2010",566.5,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","MLLNCUMT","Million of national currency units","NLD","Netherlands","2011","2011",586.7,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","MLLNCUMT","Million of national currency units","NLD","Netherlands","2012","2012",559.6,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","MLLNCUMT","Million of national currency units","NLD","Netherlands","2013","2013",540.6,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","MLLNCUMT","Million of national currency units","NLD","Netherlands","2014","2014",516.5,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","MTMOTCMT","Million US$ at exchange rate","NLD","Netherlands","2010","2010",751,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","MTMOTCMT","Million US$ at exchange rate","NLD","Netherlands","2011","2011",816.7,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","MTMOTCMT","Million US$ at exchange rate","NLD","Netherlands","2012","2012",719,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","MTMOTCMT","Million US$ at exchange rate","NLD","Netherlands","2013","2013",718,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","MTMOTCMT","Million US$ at exchange rate","NLD","Netherlands","2014","2014",686.1,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","MTMOPPMT","Million US$, purchasing power parity","NLD","Netherlands","2010","2010",663.2,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","MTMOPPMT","Million US$, purchasing power parity","NLD","Netherlands","2011","2011",701.8,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","MTMOPPMT","Million US$, purchasing power parity","NLD","Netherlands","2012","2012",678.8,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","MTMOPPMT","Million US$, purchasing power parity","NLD","Netherlands","2013","2013",677.3,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","MTMOPPMT","Million US$, purchasing power parity","NLD","Netherlands","2014","2014",638.6,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","TCPPERMT","/capita, US$ exchange rate","NLD","Netherlands","2010","2010",45.2,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","TCPPERMT","/capita, US$ exchange rate","NLD","Netherlands","2011","2011",48.9,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","TCPPERMT","/capita, US$ exchange rate","NLD","Netherlands","2012","2012",42.9,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","TCPPERMT","/capita, US$ exchange rate","NLD","Netherlands","2013","2013",42.7,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","TCPPERMT","/capita, US$ exchange rate","NLD","Netherlands","2014","2014",40.7,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","NLD","Netherlands","2010","2010",39.9,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","NLD","Netherlands","2011","2011",42,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","NLD","Netherlands","2012","2012",40.5,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","NLD","Netherlands","2013","2013",40.3,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","NLD","Netherlands","2014","2014",37.9,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","ATCPTTMT","% of total sales","NLD","Netherlands","2010","2010",10.9,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","ATCPTTMT","% of total sales","NLD","Netherlands","2011","2011",11.3,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","ATCPTTMT","% of total sales","NLD","Netherlands","2012","2012",12.1,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","ATCPTTMT","% of total sales","NLD","Netherlands","2013","2013",12.6,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","ATCPTTMT","% of total sales","NLD","Netherlands","2014","2014",11.9,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","MLLNCUMT","Million of national currency units","NZL","New Zealand","2010","2010",75.5,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","MLLNCUMT","Million of national currency units","NZL","New Zealand","2011","2011",83.2,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","MLLNCUMT","Million of national currency units","NZL","New Zealand","2012","2012",88.7,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","MLLNCUMT","Million of national currency units","NZL","New Zealand","2013","2013",90,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","MLLNCUMT","Million of national currency units","NZL","New Zealand","2014","2014",92.1,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","MLLNCUMT","Million of national currency units","NZL","New Zealand","2015","2015",100.6,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","MLLNCUMT","Million of national currency units","NZL","New Zealand","2016","2016",103.2,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","MLLNCUMT","Million of national currency units","NZL","New Zealand","2017","2017",97.6,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","MLLNCUMT","Million of national currency units","NZL","New Zealand","2018","2018",107.6,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","MLLNCUMT","Million of national currency units","NZL","New Zealand","2019","2019",111.6,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","MLLNCUMT","Million of national currency units","NZL","New Zealand","2020","2020",122.4,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","MLLNCUMT","Million of national currency units","NZL","New Zealand","2021","2021",133.7,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","MLLNCUMT","Million of national currency units","NZL","New Zealand","2022","2022",157.9,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","MTMOTCMT","Million US$ at exchange rate","NZL","New Zealand","2010","2010",54.4,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","MTMOTCMT","Million US$ at exchange rate","NZL","New Zealand","2011","2011",65.7,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","MTMOTCMT","Million US$ at exchange rate","NZL","New Zealand","2012","2012",71.9,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","MTMOTCMT","Million US$ at exchange rate","NZL","New Zealand","2013","2013",73.8,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","MTMOTCMT","Million US$ at exchange rate","NZL","New Zealand","2014","2014",76.4,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","MTMOTCMT","Million US$ at exchange rate","NZL","New Zealand","2015","2015",70.2,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","MTMOTCMT","Million US$ at exchange rate","NZL","New Zealand","2016","2016",71.9,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","MTMOTCMT","Million US$ at exchange rate","NZL","New Zealand","2017","2017",69.3,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","MTMOTCMT","Million US$ at exchange rate","NZL","New Zealand","2018","2018",74.5,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","MTMOTCMT","Million US$ at exchange rate","NZL","New Zealand","2019","2019",73.5,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","MTMOTCMT","Million US$ at exchange rate","NZL","New Zealand","2020","2020",79.4,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","MTMOTCMT","Million US$ at exchange rate","NZL","New Zealand","2021","2021",94.6,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","MTMOTCMT","Million US$ at exchange rate","NZL","New Zealand","2022","2022",100.1,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","MTMOPPMT","Million US$, purchasing power parity","NZL","New Zealand","2010","2010",50.4,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","MTMOPPMT","Million US$, purchasing power parity","NZL","New Zealand","2011","2011",56,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","MTMOPPMT","Million US$, purchasing power parity","NZL","New Zealand","2012","2012",59.3,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","MTMOPPMT","Million US$, purchasing power parity","NZL","New Zealand","2013","2013",62.3,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","MTMOPPMT","Million US$, purchasing power parity","NZL","New Zealand","2014","2014",63.9,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","MTMOPPMT","Million US$, purchasing power parity","NZL","New Zealand","2015","2015",68.1,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","MTMOPPMT","Million US$, purchasing power parity","NZL","New Zealand","2016","2016",71.6,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","MTMOPPMT","Million US$, purchasing power parity","NZL","New Zealand","2017","2017",68.2,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","MTMOPPMT","Million US$, purchasing power parity","NZL","New Zealand","2018","2018",73.2,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","MTMOPPMT","Million US$, purchasing power parity","NZL","New Zealand","2019","2019",78.8,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","MTMOPPMT","Million US$, purchasing power parity","NZL","New Zealand","2020","2020",86.6,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","MTMOPPMT","Million US$, purchasing power parity","NZL","New Zealand","2021","2021",91.6,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","MTMOPPMT","Million US$, purchasing power parity","NZL","New Zealand","2022","2022",109.5,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","TCPPERMT","/capita, US$ exchange rate","NZL","New Zealand","2010","2010",12.5,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","TCPPERMT","/capita, US$ exchange rate","NZL","New Zealand","2011","2011",15,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","TCPPERMT","/capita, US$ exchange rate","NZL","New Zealand","2012","2012",16.3,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","TCPPERMT","/capita, US$ exchange rate","NZL","New Zealand","2013","2013",16.6,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","TCPPERMT","/capita, US$ exchange rate","NZL","New Zealand","2014","2014",16.9,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","TCPPERMT","/capita, US$ exchange rate","NZL","New Zealand","2015","2015",15.2,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","TCPPERMT","/capita, US$ exchange rate","NZL","New Zealand","2016","2016",15.2,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","TCPPERMT","/capita, US$ exchange rate","NZL","New Zealand","2017","2017",14.4,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","TCPPERMT","/capita, US$ exchange rate","NZL","New Zealand","2018","2018",15.2,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","TCPPERMT","/capita, US$ exchange rate","NZL","New Zealand","2019","2019",14.8,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","TCPPERMT","/capita, US$ exchange rate","NZL","New Zealand","2020","2020",15.6,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","TCPPERMT","/capita, US$ exchange rate","NZL","New Zealand","2021","2021",18.5,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","TCPPERMT","/capita, US$ exchange rate","NZL","New Zealand","2022","2022",19.5,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2010","2010",11.6,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2011","2011",12.8,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2012","2012",13.5,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2013","2013",14,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2014","2014",14.2,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2015","2015",14.8,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2016","2016",15.2,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2017","2017",14.2,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2018","2018",14.9,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2019","2019",15.8,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2020","2020",17,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2021","2021",17.9,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2022","2022",21.4,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","ATCPTTMT","% of total sales","NZL","New Zealand","2010","2010",10.1,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","ATCPTTMT","% of total sales","NZL","New Zealand","2011","2011",10.2,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","ATCPTTMT","% of total sales","NZL","New Zealand","2012","2012",9.6,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","ATCPTTMT","% of total sales","NZL","New Zealand","2013","2013",9.8,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","ATCPTTMT","% of total sales","NZL","New Zealand","2014","2014",9.6,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","ATCPTTMT","% of total sales","NZL","New Zealand","2015","2015",10.2,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","ATCPTTMT","% of total sales","NZL","New Zealand","2016","2016",9.6,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","ATCPTTMT","% of total sales","NZL","New Zealand","2017","2017",7.7,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","ATCPTTMT","% of total sales","NZL","New Zealand","2018","2018",8.1,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","ATCPTTMT","% of total sales","NZL","New Zealand","2019","2019",7.5,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","ATCPTTMT","% of total sales","NZL","New Zealand","2020","2020",7.4,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","ATCPTTMT","% of total sales","NZL","New Zealand","2021","2021",7.5,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","ATCPTTMT","% of total sales","NZL","New Zealand","2022","2022",8.3,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","MLLNCUMT","Million of national currency units","NOR","Norway","2010","2010",1917,,
+"PATCRESS","R-Respiratory system","MLLNCUMT","Million of national currency units","NOR","Norway","2011","2011",1902,,
+"PATCRESS","R-Respiratory system","MLLNCUMT","Million of national currency units","NOR","Norway","2012","2012",1928,,
+"PATCRESS","R-Respiratory system","MLLNCUMT","Million of national currency units","NOR","Norway","2013","2013",1859,,
+"PATCRESS","R-Respiratory system","MLLNCUMT","Million of national currency units","NOR","Norway","2014","2014",2001,,
+"PATCRESS","R-Respiratory system","MLLNCUMT","Million of national currency units","NOR","Norway","2015","2015",2093,,
+"PATCRESS","R-Respiratory system","MLLNCUMT","Million of national currency units","NOR","Norway","2016","2016",2273,,
+"PATCRESS","R-Respiratory system","MLLNCUMT","Million of national currency units","NOR","Norway","2017","2017",2421,,
+"PATCRESS","R-Respiratory system","MLLNCUMT","Million of national currency units","NOR","Norway","2018","2018",2484,,
+"PATCRESS","R-Respiratory system","MLLNCUMT","Million of national currency units","NOR","Norway","2019","2019",2653,,
+"PATCRESS","R-Respiratory system","MLLNCUMT","Million of national currency units","NOR","Norway","2020","2020",2716,,
+"PATCRESS","R-Respiratory system","MLLNCUMT","Million of national currency units","NOR","Norway","2021","2021",2924,,
+"PATCRESS","R-Respiratory system","MLLNCUMT","Million of national currency units","NOR","Norway","2022","2022",3355,,
+"PATCRESS","R-Respiratory system","MTMOTCMT","Million US$ at exchange rate","NOR","Norway","2010","2010",317.2,,
+"PATCRESS","R-Respiratory system","MTMOTCMT","Million US$ at exchange rate","NOR","Norway","2011","2011",339.4,,
+"PATCRESS","R-Respiratory system","MTMOTCMT","Million US$ at exchange rate","NOR","Norway","2012","2012",331.4,,
+"PATCRESS","R-Respiratory system","MTMOTCMT","Million US$ at exchange rate","NOR","Norway","2013","2013",316.4,,
+"PATCRESS","R-Respiratory system","MTMOTCMT","Million US$ at exchange rate","NOR","Norway","2014","2014",317.5,,
+"PATCRESS","R-Respiratory system","MTMOTCMT","Million US$ at exchange rate","NOR","Norway","2015","2015",259.5,,
+"PATCRESS","R-Respiratory system","MTMOTCMT","Million US$ at exchange rate","NOR","Norway","2016","2016",270.6,,
+"PATCRESS","R-Respiratory system","MTMOTCMT","Million US$ at exchange rate","NOR","Norway","2017","2017",292.7,,
+"PATCRESS","R-Respiratory system","MTMOTCMT","Million US$ at exchange rate","NOR","Norway","2018","2018",305.4,,
+"PATCRESS","R-Respiratory system","MTMOTCMT","Million US$ at exchange rate","NOR","Norway","2019","2019",301.5,,
+"PATCRESS","R-Respiratory system","MTMOTCMT","Million US$ at exchange rate","NOR","Norway","2020","2020",288.5,,
+"PATCRESS","R-Respiratory system","MTMOTCMT","Million US$ at exchange rate","NOR","Norway","2021","2021",340.4,,
+"PATCRESS","R-Respiratory system","MTMOTCMT","Million US$ at exchange rate","NOR","Norway","2022","2022",349,,
+"PATCRESS","R-Respiratory system","MTMOPPMT","Million US$, purchasing power parity","NOR","Norway","2010","2010",209.5,,
+"PATCRESS","R-Respiratory system","MTMOPPMT","Million US$, purchasing power parity","NOR","Norway","2011","2011",209.4,,
+"PATCRESS","R-Respiratory system","MTMOPPMT","Million US$, purchasing power parity","NOR","Norway","2012","2012",213.3,,
+"PATCRESS","R-Respiratory system","MTMOPPMT","Million US$, purchasing power parity","NOR","Norway","2013","2013",205.9,,
+"PATCRESS","R-Respiratory system","MTMOPPMT","Million US$, purchasing power parity","NOR","Norway","2014","2014",215.7,,
+"PATCRESS","R-Respiratory system","MTMOPPMT","Million US$, purchasing power parity","NOR","Norway","2015","2015",210.7,,
+"PATCRESS","R-Respiratory system","MTMOPPMT","Million US$, purchasing power parity","NOR","Norway","2016","2016",226.4,,
+"PATCRESS","R-Respiratory system","MTMOPPMT","Million US$, purchasing power parity","NOR","Norway","2017","2017",248.3,,
+"PATCRESS","R-Respiratory system","MTMOPPMT","Million US$, purchasing power parity","NOR","Norway","2018","2018",259.2,,
+"PATCRESS","R-Respiratory system","MTMOPPMT","Million US$, purchasing power parity","NOR","Norway","2019","2019",275.8,,
+"PATCRESS","R-Respiratory system","MTMOPPMT","Million US$, purchasing power parity","NOR","Norway","2020","2020",274.9,,
+"PATCRESS","R-Respiratory system","MTMOPPMT","Million US$, purchasing power parity","NOR","Norway","2021","2021",307.4,,
+"PATCRESS","R-Respiratory system","MTMOPPMT","Million US$, purchasing power parity","NOR","Norway","2022","2022",312.4,,
+"PATCRESS","R-Respiratory system","TCPPERMT","/capita, US$ exchange rate","NOR","Norway","2010","2010",64.9,,
+"PATCRESS","R-Respiratory system","TCPPERMT","/capita, US$ exchange rate","NOR","Norway","2011","2011",68.5,,
+"PATCRESS","R-Respiratory system","TCPPERMT","/capita, US$ exchange rate","NOR","Norway","2012","2012",66,,
+"PATCRESS","R-Respiratory system","TCPPERMT","/capita, US$ exchange rate","NOR","Norway","2013","2013",62.3,,
+"PATCRESS","R-Respiratory system","TCPPERMT","/capita, US$ exchange rate","NOR","Norway","2014","2014",61.8,,
+"PATCRESS","R-Respiratory system","TCPPERMT","/capita, US$ exchange rate","NOR","Norway","2015","2015",50,,
+"PATCRESS","R-Respiratory system","TCPPERMT","/capita, US$ exchange rate","NOR","Norway","2016","2016",51.7,,
+"PATCRESS","R-Respiratory system","TCPPERMT","/capita, US$ exchange rate","NOR","Norway","2017","2017",55.5,,
+"PATCRESS","R-Respiratory system","TCPPERMT","/capita, US$ exchange rate","NOR","Norway","2018","2018",57.5,,
+"PATCRESS","R-Respiratory system","TCPPERMT","/capita, US$ exchange rate","NOR","Norway","2019","2019",56.4,,
+"PATCRESS","R-Respiratory system","TCPPERMT","/capita, US$ exchange rate","NOR","Norway","2020","2020",53.6,,
+"PATCRESS","R-Respiratory system","TCPPERMT","/capita, US$ exchange rate","NOR","Norway","2021","2021",62.9,,
+"PATCRESS","R-Respiratory system","TCPPERMT","/capita, US$ exchange rate","NOR","Norway","2022","2022",64.3,,
+"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2010","2010",42.8,,
+"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2011","2011",42.3,,
+"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2012","2012",42.5,,
+"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2013","2013",40.5,,
+"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2014","2014",42,,
+"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2015","2015",40.6,,
+"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2016","2016",43.2,,
+"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2017","2017",47.1,,
+"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2018","2018",48.8,,
+"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2019","2019",51.6,,
+"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2020","2020",51.1,,
+"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2021","2021",56.8,,
+"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2022","2022",57.6,,
+"PATCRESS","R-Respiratory system","ATCPTTMT","% of total sales","NOR","Norway","2010","2010",10.7,,
+"PATCRESS","R-Respiratory system","ATCPTTMT","% of total sales","NOR","Norway","2011","2011",10.5,,
+"PATCRESS","R-Respiratory system","ATCPTTMT","% of total sales","NOR","Norway","2012","2012",10.3,,
+"PATCRESS","R-Respiratory system","ATCPTTMT","% of total sales","NOR","Norway","2013","2013",9.6,,
+"PATCRESS","R-Respiratory system","ATCPTTMT","% of total sales","NOR","Norway","2014","2014",9.5,,
+"PATCRESS","R-Respiratory system","ATCPTTMT","% of total sales","NOR","Norway","2015","2015",9.2,,
+"PATCRESS","R-Respiratory system","ATCPTTMT","% of total sales","NOR","Norway","2016","2016",9.2,,
+"PATCRESS","R-Respiratory system","ATCPTTMT","% of total sales","NOR","Norway","2017","2017",9.1,,
+"PATCRESS","R-Respiratory system","ATCPTTMT","% of total sales","NOR","Norway","2018","2018",9,,
+"PATCRESS","R-Respiratory system","ATCPTTMT","% of total sales","NOR","Norway","2019","2019",9.3,,
+"PATCRESS","R-Respiratory system","ATCPTTMT","% of total sales","NOR","Norway","2020","2020",9.1,,
+"PATCRESS","R-Respiratory system","ATCPTTMT","% of total sales","NOR","Norway","2021","2021",8.7,,
+"PATCRESS","R-Respiratory system","ATCPTTMT","% of total sales","NOR","Norway","2022","2022",9.3,,
+"PATCRESS","R-Respiratory system","MLLNCUMT","Million of national currency units","PRT","Portugal","2010","2010",214.6,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","MLLNCUMT","Million of national currency units","PRT","Portugal","2011","2011",213.4,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","MLLNCUMT","Million of national currency units","PRT","Portugal","2012","2012",214.8,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","MLLNCUMT","Million of national currency units","PRT","Portugal","2013","2013",201.9,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","MLLNCUMT","Million of national currency units","PRT","Portugal","2014","2014",192.3,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","MLLNCUMT","Million of national currency units","PRT","Portugal","2015","2015",214.3,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","MLLNCUMT","Million of national currency units","PRT","Portugal","2016","2016",222.8,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","MLLNCUMT","Million of national currency units","PRT","Portugal","2017","2017",222.4,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","MLLNCUMT","Million of national currency units","PRT","Portugal","2018","2018",232.1,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","MLLNCUMT","Million of national currency units","PRT","Portugal","2019","2019",244.8,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","MLLNCUMT","Million of national currency units","PRT","Portugal","2020","2020",232.8,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","MLLNCUMT","Million of national currency units","PRT","Portugal","2021","2021",223.6,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","MLLNCUMT","Million of national currency units","PRT","Portugal","2022","2022",272.3,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","MTMOTCMT","Million US$ at exchange rate","PRT","Portugal","2010","2010",284.6,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","MTMOTCMT","Million US$ at exchange rate","PRT","Portugal","2011","2011",297,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","MTMOTCMT","Million US$ at exchange rate","PRT","Portugal","2012","2012",275.9,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","MTMOTCMT","Million US$ at exchange rate","PRT","Portugal","2013","2013",268.2,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","MTMOTCMT","Million US$ at exchange rate","PRT","Portugal","2014","2014",255.4,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","MTMOTCMT","Million US$ at exchange rate","PRT","Portugal","2015","2015",237.8,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","MTMOTCMT","Million US$ at exchange rate","PRT","Portugal","2016","2016",246.6,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","MTMOTCMT","Million US$ at exchange rate","PRT","Portugal","2017","2017",251.2,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","MTMOTCMT","Million US$ at exchange rate","PRT","Portugal","2018","2018",274.1,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","MTMOTCMT","Million US$ at exchange rate","PRT","Portugal","2019","2019",274.1,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","MTMOTCMT","Million US$ at exchange rate","PRT","Portugal","2020","2020",265.9,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","MTMOTCMT","Million US$ at exchange rate","PRT","Portugal","2021","2021",264.5,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","MTMOTCMT","Million US$ at exchange rate","PRT","Portugal","2022","2022",286.7,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","MTMOPPMT","Million US$, purchasing power parity","PRT","Portugal","2010","2010",344.5,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","MTMOPPMT","Million US$, purchasing power parity","PRT","Portugal","2011","2011",342.5,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","MTMOPPMT","Million US$, purchasing power parity","PRT","Portugal","2012","2012",354.8,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","MTMOPPMT","Million US$, purchasing power parity","PRT","Portugal","2013","2013",346,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","MTMOPPMT","Million US$, purchasing power parity","PRT","Portugal","2014","2014",332.1,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","MTMOPPMT","Million US$, purchasing power parity","PRT","Portugal","2015","2015",366.4,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","MTMOPPMT","Million US$, purchasing power parity","PRT","Portugal","2016","2016",389.8,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","MTMOPPMT","Million US$, purchasing power parity","PRT","Portugal","2017","2017",386.3,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","MTMOPPMT","Million US$, purchasing power parity","PRT","Portugal","2018","2018",406.3,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","MTMOPPMT","Million US$, purchasing power parity","PRT","Portugal","2019","2019",438.2,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","MTMOPPMT","Million US$, purchasing power parity","PRT","Portugal","2020","2020",417.9,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","MTMOPPMT","Million US$, purchasing power parity","PRT","Portugal","2021","2021",394,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","MTMOPPMT","Million US$, purchasing power parity","PRT","Portugal","2022","2022",495.1,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","TCPPERMT","/capita, US$ exchange rate","PRT","Portugal","2010","2010",26.9,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","TCPPERMT","/capita, US$ exchange rate","PRT","Portugal","2011","2011",28.1,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","TCPPERMT","/capita, US$ exchange rate","PRT","Portugal","2012","2012",26.2,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","TCPPERMT","/capita, US$ exchange rate","PRT","Portugal","2013","2013",25.6,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","TCPPERMT","/capita, US$ exchange rate","PRT","Portugal","2014","2014",24.6,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","TCPPERMT","/capita, US$ exchange rate","PRT","Portugal","2015","2015",23,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","TCPPERMT","/capita, US$ exchange rate","PRT","Portugal","2016","2016",23.9,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","TCPPERMT","/capita, US$ exchange rate","PRT","Portugal","2017","2017",24.4,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","TCPPERMT","/capita, US$ exchange rate","PRT","Portugal","2018","2018",26.7,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","TCPPERMT","/capita, US$ exchange rate","PRT","Portugal","2019","2019",26.6,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","TCPPERMT","/capita, US$ exchange rate","PRT","Portugal","2020","2020",25.8,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","TCPPERMT","/capita, US$ exchange rate","PRT","Portugal","2021","2021",25.5,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","TCPPERMT","/capita, US$ exchange rate","PRT","Portugal","2022","2022",27.7,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2010","2010",32.6,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2011","2011",32.4,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2012","2012",33.7,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2013","2013",33.1,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2014","2014",31.9,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2015","2015",35.4,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2016","2016",37.8,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2017","2017",37.5,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2018","2018",39.5,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2019","2019",42.6,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2020","2020",40.6,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2021","2021",38,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2022","2022",47.8,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","ATCPTTMT","% of total sales","PRT","Portugal","2010","2010",6.6,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","ATCPTTMT","% of total sales","PRT","Portugal","2011","2011",7.3,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","ATCPTTMT","% of total sales","PRT","Portugal","2012","2012",8.2,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","ATCPTTMT","% of total sales","PRT","Portugal","2013","2013",8.4,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","ATCPTTMT","% of total sales","PRT","Portugal","2014","2014",8,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","ATCPTTMT","% of total sales","PRT","Portugal","2015","2015",8.6,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","ATCPTTMT","% of total sales","PRT","Portugal","2016","2016",8.8,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","ATCPTTMT","% of total sales","PRT","Portugal","2017","2017",8.7,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","ATCPTTMT","% of total sales","PRT","Portugal","2018","2018",8.8,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","ATCPTTMT","% of total sales","PRT","Portugal","2019","2019",8.8,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","ATCPTTMT","% of total sales","PRT","Portugal","2020","2020",8.3,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","ATCPTTMT","% of total sales","PRT","Portugal","2021","2021",7.7,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","ATCPTTMT","% of total sales","PRT","Portugal","2022","2022",8.5,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","MLLNCUMT","Million of national currency units","SVK","Slovak Republic","2010","2010",83.3,,
+"PATCRESS","R-Respiratory system","MLLNCUMT","Million of national currency units","SVK","Slovak Republic","2011","2011",86.7,,
+"PATCRESS","R-Respiratory system","MLLNCUMT","Million of national currency units","SVK","Slovak Republic","2012","2012",76.2,,
+"PATCRESS","R-Respiratory system","MLLNCUMT","Million of national currency units","SVK","Slovak Republic","2013","2013",87.5,,
+"PATCRESS","R-Respiratory system","MLLNCUMT","Million of national currency units","SVK","Slovak Republic","2014","2014",91.4,,
+"PATCRESS","R-Respiratory system","MLLNCUMT","Million of national currency units","SVK","Slovak Republic","2015","2015",97.5,,
+"PATCRESS","R-Respiratory system","MLLNCUMT","Million of national currency units","SVK","Slovak Republic","2016","2016",119.3,"B","Break"
+"PATCRESS","R-Respiratory system","MLLNCUMT","Million of national currency units","SVK","Slovak Republic","2017","2017",120.2,,
+"PATCRESS","R-Respiratory system","MLLNCUMT","Million of national currency units","SVK","Slovak Republic","2018","2018",118.8,,
+"PATCRESS","R-Respiratory system","MLLNCUMT","Million of national currency units","SVK","Slovak Republic","2019","2019",122.3,,
+"PATCRESS","R-Respiratory system","MLLNCUMT","Million of national currency units","SVK","Slovak Republic","2020","2020",112.7,,
+"PATCRESS","R-Respiratory system","MLLNCUMT","Million of national currency units","SVK","Slovak Republic","2021","2021",133.8,,
+"PATCRESS","R-Respiratory system","MTMOTCMT","Million US$ at exchange rate","SVK","Slovak Republic","2010","2010",110.5,,
+"PATCRESS","R-Respiratory system","MTMOTCMT","Million US$ at exchange rate","SVK","Slovak Republic","2011","2011",120.7,,
+"PATCRESS","R-Respiratory system","MTMOTCMT","Million US$ at exchange rate","SVK","Slovak Republic","2012","2012",97.9,,
+"PATCRESS","R-Respiratory system","MTMOTCMT","Million US$ at exchange rate","SVK","Slovak Republic","2013","2013",116.2,,
+"PATCRESS","R-Respiratory system","MTMOTCMT","Million US$ at exchange rate","SVK","Slovak Republic","2014","2014",121.5,,
+"PATCRESS","R-Respiratory system","MTMOTCMT","Million US$ at exchange rate","SVK","Slovak Republic","2015","2015",108.2,,
+"PATCRESS","R-Respiratory system","MTMOTCMT","Million US$ at exchange rate","SVK","Slovak Republic","2016","2016",132,"B","Break"
+"PATCRESS","R-Respiratory system","MTMOTCMT","Million US$ at exchange rate","SVK","Slovak Republic","2017","2017",135.8,,
+"PATCRESS","R-Respiratory system","MTMOTCMT","Million US$ at exchange rate","SVK","Slovak Republic","2018","2018",140.3,,
+"PATCRESS","R-Respiratory system","MTMOTCMT","Million US$ at exchange rate","SVK","Slovak Republic","2019","2019",136.9,,
+"PATCRESS","R-Respiratory system","MTMOTCMT","Million US$ at exchange rate","SVK","Slovak Republic","2020","2020",128.7,,
+"PATCRESS","R-Respiratory system","MTMOTCMT","Million US$ at exchange rate","SVK","Slovak Republic","2021","2021",158.3,,
+"PATCRESS","R-Respiratory system","MTMOPPMT","Million US$, purchasing power parity","SVK","Slovak Republic","2010","2010",166,,
+"PATCRESS","R-Respiratory system","MTMOPPMT","Million US$, purchasing power parity","SVK","Slovak Republic","2011","2011",171.2,,
+"PATCRESS","R-Respiratory system","MTMOPPMT","Million US$, purchasing power parity","SVK","Slovak Republic","2012","2012",151,,
+"PATCRESS","R-Respiratory system","MTMOPPMT","Million US$, purchasing power parity","SVK","Slovak Republic","2013","2013",178.1,,
+"PATCRESS","R-Respiratory system","MTMOPPMT","Million US$, purchasing power parity","SVK","Slovak Republic","2014","2014",188.4,,
+"PATCRESS","R-Respiratory system","MTMOPPMT","Million US$, purchasing power parity","SVK","Slovak Republic","2015","2015",198.4,,
+"PATCRESS","R-Respiratory system","MTMOPPMT","Million US$, purchasing power parity","SVK","Slovak Republic","2016","2016",237,"B","Break"
+"PATCRESS","R-Respiratory system","MTMOPPMT","Million US$, purchasing power parity","SVK","Slovak Republic","2017","2017",232.8,,
+"PATCRESS","R-Respiratory system","MTMOPPMT","Million US$, purchasing power parity","SVK","Slovak Republic","2018","2018",225.9,,
+"PATCRESS","R-Respiratory system","MTMOPPMT","Million US$, purchasing power parity","SVK","Slovak Republic","2019","2019",236.3,,
+"PATCRESS","R-Respiratory system","MTMOPPMT","Million US$, purchasing power parity","SVK","Slovak Republic","2020","2020",216.7,,
+"PATCRESS","R-Respiratory system","MTMOPPMT","Million US$, purchasing power parity","SVK","Slovak Republic","2021","2021",250.9,,
+"PATCRESS","R-Respiratory system","TCPPERMT","/capita, US$ exchange rate","SVK","Slovak Republic","2010","2010",20.5,,
+"PATCRESS","R-Respiratory system","TCPPERMT","/capita, US$ exchange rate","SVK","Slovak Republic","2011","2011",22.4,,
+"PATCRESS","R-Respiratory system","TCPPERMT","/capita, US$ exchange rate","SVK","Slovak Republic","2012","2012",18.1,,
+"PATCRESS","R-Respiratory system","TCPPERMT","/capita, US$ exchange rate","SVK","Slovak Republic","2013","2013",21.5,,
+"PATCRESS","R-Respiratory system","TCPPERMT","/capita, US$ exchange rate","SVK","Slovak Republic","2014","2014",22.4,,
+"PATCRESS","R-Respiratory system","TCPPERMT","/capita, US$ exchange rate","SVK","Slovak Republic","2015","2015",20,,
+"PATCRESS","R-Respiratory system","TCPPERMT","/capita, US$ exchange rate","SVK","Slovak Republic","2016","2016",24.3,"B","Break"
+"PATCRESS","R-Respiratory system","TCPPERMT","/capita, US$ exchange rate","SVK","Slovak Republic","2017","2017",25,,
+"PATCRESS","R-Respiratory system","TCPPERMT","/capita, US$ exchange rate","SVK","Slovak Republic","2018","2018",25.8,,
+"PATCRESS","R-Respiratory system","TCPPERMT","/capita, US$ exchange rate","SVK","Slovak Republic","2019","2019",25.1,,
+"PATCRESS","R-Respiratory system","TCPPERMT","/capita, US$ exchange rate","SVK","Slovak Republic","2020","2020",23.6,,
+"PATCRESS","R-Respiratory system","TCPPERMT","/capita, US$ exchange rate","SVK","Slovak Republic","2021","2021",29.1,,
+"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2010","2010",30.8,,
+"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2011","2011",31.7,,
+"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2012","2012",27.9,,
+"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2013","2013",32.9,,
+"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2014","2014",34.8,,
+"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2015","2015",36.6,,
+"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2016","2016",43.6,"B","Break"
+"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2017","2017",42.8,,
+"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2018","2018",41.5,,
+"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2019","2019",43.3,,
+"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2020","2020",39.7,,
+"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2021","2021",46.1,,
+"PATCRESS","R-Respiratory system","ATCPTTMT","% of total sales","SVK","Slovak Republic","2010","2010",7.5,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","ATCPTTMT","% of total sales","SVK","Slovak Republic","2011","2011",7.7,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","ATCPTTMT","% of total sales","SVK","Slovak Republic","2012","2012",6.9,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","ATCPTTMT","% of total sales","SVK","Slovak Republic","2013","2013",7.1,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","ATCPTTMT","% of total sales","SVK","Slovak Republic","2014","2014",6.9,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","ATCPTTMT","% of total sales","SVK","Slovak Republic","2015","2015",7,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","ATCPTTMT","% of total sales","SVK","Slovak Republic","2016","2016",7.6,"B","Break"
+"PATCRESS","R-Respiratory system","ATCPTTMT","% of total sales","SVK","Slovak Republic","2017","2017",7.7,,
+"PATCRESS","R-Respiratory system","ATCPTTMT","% of total sales","SVK","Slovak Republic","2018","2018",7.3,,
+"PATCRESS","R-Respiratory system","ATCPTTMT","% of total sales","SVK","Slovak Republic","2019","2019",7.1,,
+"PATCRESS","R-Respiratory system","ATCPTTMT","% of total sales","SVK","Slovak Republic","2020","2020",6.8,,
+"PATCRESS","R-Respiratory system","ATCPTTMT","% of total sales","SVK","Slovak Republic","2021","2021",7.5,,
+"PATCRESS","R-Respiratory system","MLLNCUMT","Million of national currency units","ESP","Spain","2010","2010",1304.6,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","MLLNCUMT","Million of national currency units","ESP","Spain","2011","2011",1311.5,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","MLLNCUMT","Million of national currency units","ESP","Spain","2012","2012",1201.6,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","MLLNCUMT","Million of national currency units","ESP","Spain","2013","2013",1092.6,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","MLLNCUMT","Million of national currency units","ESP","Spain","2014","2014",1150.2,"B; D","Break; Difference in methodology"
+"PATCRESS","R-Respiratory system","MLLNCUMT","Million of national currency units","ESP","Spain","2015","2015",1182.8,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","MLLNCUMT","Million of national currency units","ESP","Spain","2016","2016",1161.6,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","MLLNCUMT","Million of national currency units","ESP","Spain","2017","2017",1134.8,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","MLLNCUMT","Million of national currency units","ESP","Spain","2018","2018",1340.1,"B","Break"
+"PATCRESS","R-Respiratory system","MLLNCUMT","Million of national currency units","ESP","Spain","2019","2019",1384.8,,
+"PATCRESS","R-Respiratory system","MLLNCUMT","Million of national currency units","ESP","Spain","2020","2020",1454.3,,
+"PATCRESS","R-Respiratory system","MLLNCUMT","Million of national currency units","ESP","Spain","2021","2021",1470.2,,
+"PATCRESS","R-Respiratory system","MLLNCUMT","Million of national currency units","ESP","Spain","2022","2022",1655.1,"P","Provisional value"
+"PATCRESS","R-Respiratory system","MTMOTCMT","Million US$ at exchange rate","ESP","Spain","2010","2010",1729.5,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","MTMOTCMT","Million US$ at exchange rate","ESP","Spain","2011","2011",1825.5,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","MTMOTCMT","Million US$ at exchange rate","ESP","Spain","2012","2012",1543.8,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","MTMOTCMT","Million US$ at exchange rate","ESP","Spain","2013","2013",1451.1,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","MTMOTCMT","Million US$ at exchange rate","ESP","Spain","2014","2014",1528,"B; D","Break; Difference in methodology"
+"PATCRESS","R-Respiratory system","MTMOTCMT","Million US$ at exchange rate","ESP","Spain","2015","2015",1312.3,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","MTMOTCMT","Million US$ at exchange rate","ESP","Spain","2016","2016",1285.8,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","MTMOTCMT","Million US$ at exchange rate","ESP","Spain","2017","2017",1281.9,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","MTMOTCMT","Million US$ at exchange rate","ESP","Spain","2018","2018",1582.6,"B","Break"
+"PATCRESS","R-Respiratory system","MTMOTCMT","Million US$ at exchange rate","ESP","Spain","2019","2019",1550.3,,
+"PATCRESS","R-Respiratory system","MTMOTCMT","Million US$ at exchange rate","ESP","Spain","2020","2020",1661.1,,
+"PATCRESS","R-Respiratory system","MTMOTCMT","Million US$ at exchange rate","ESP","Spain","2021","2021",1738.8,,
+"PATCRESS","R-Respiratory system","MTMOTCMT","Million US$ at exchange rate","ESP","Spain","2022","2022",1742.9,"P","Provisional value"
+"PATCRESS","R-Respiratory system","MTMOPPMT","Million US$, purchasing power parity","ESP","Spain","2010","2010",1794.5,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","MTMOPPMT","Million US$, purchasing power parity","ESP","Spain","2011","2011",1836.5,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","MTMOPPMT","Million US$, purchasing power parity","ESP","Spain","2012","2012",1729,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","MTMOPPMT","Million US$, purchasing power parity","ESP","Spain","2013","2013",1619.2,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","MTMOPPMT","Million US$, purchasing power parity","ESP","Spain","2014","2014",1736.5,"B; D","Break; Difference in methodology"
+"PATCRESS","R-Respiratory system","MTMOPPMT","Million US$, purchasing power parity","ESP","Spain","2015","2015",1779.3,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","MTMOPPMT","Million US$, purchasing power parity","ESP","Spain","2016","2016",1807.6,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","MTMOPPMT","Million US$, purchasing power parity","ESP","Spain","2017","2017",1798.8,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","MTMOPPMT","Million US$, purchasing power parity","ESP","Spain","2018","2018",2121,"B","Break"
+"PATCRESS","R-Respiratory system","MTMOPPMT","Million US$, purchasing power parity","ESP","Spain","2019","2019",2259.2,,
+"PATCRESS","R-Respiratory system","MTMOPPMT","Million US$, purchasing power parity","ESP","Spain","2020","2020",2340.5,,
+"PATCRESS","R-Respiratory system","MTMOPPMT","Million US$, purchasing power parity","ESP","Spain","2021","2021",2348.7,,
+"PATCRESS","R-Respiratory system","MTMOPPMT","Million US$, purchasing power parity","ESP","Spain","2022","2022",2776,"P","Provisional value"
+"PATCRESS","R-Respiratory system","TCPPERMT","/capita, US$ exchange rate","ESP","Spain","2010","2010",37.1,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","TCPPERMT","/capita, US$ exchange rate","ESP","Spain","2011","2011",39.1,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","TCPPERMT","/capita, US$ exchange rate","ESP","Spain","2012","2012",33,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","TCPPERMT","/capita, US$ exchange rate","ESP","Spain","2013","2013",31.1,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","TCPPERMT","/capita, US$ exchange rate","ESP","Spain","2014","2014",32.9,"B; D","Break; Difference in methodology"
+"PATCRESS","R-Respiratory system","TCPPERMT","/capita, US$ exchange rate","ESP","Spain","2015","2015",28.3,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","TCPPERMT","/capita, US$ exchange rate","ESP","Spain","2016","2016",27.7,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","TCPPERMT","/capita, US$ exchange rate","ESP","Spain","2017","2017",27.5,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","TCPPERMT","/capita, US$ exchange rate","ESP","Spain","2018","2018",33.8,"B","Break"
+"PATCRESS","R-Respiratory system","TCPPERMT","/capita, US$ exchange rate","ESP","Spain","2019","2019",32.9,,
+"PATCRESS","R-Respiratory system","TCPPERMT","/capita, US$ exchange rate","ESP","Spain","2020","2020",35.1,,
+"PATCRESS","R-Respiratory system","TCPPERMT","/capita, US$ exchange rate","ESP","Spain","2021","2021",36.7,,
+"PATCRESS","R-Respiratory system","TCPPERMT","/capita, US$ exchange rate","ESP","Spain","2022","2022",36.7,"P","Provisional value"
+"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2010","2010",38.5,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2011","2011",39.3,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2012","2012",37,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2013","2013",34.7,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2014","2014",37.4,"B; D","Break; Difference in methodology"
+"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2015","2015",38.3,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2016","2016",38.9,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2017","2017",38.6,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2018","2018",45.3,"B","Break"
+"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2019","2019",47.9,,
+"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2020","2020",49.4,,
+"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2021","2021",49.5,,
+"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2022","2022",58.5,"P","Provisional value"
+"PATCRESS","R-Respiratory system","ATCPTTMT","% of total sales","ESP","Spain","2010","2010",9.9,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","ATCPTTMT","% of total sales","ESP","Spain","2011","2011",10.6,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","ATCPTTMT","% of total sales","ESP","Spain","2012","2012",10.9,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","ATCPTTMT","% of total sales","ESP","Spain","2013","2013",10.2,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","ATCPTTMT","% of total sales","ESP","Spain","2014","2014",10.2,"B; D","Break; Difference in methodology"
+"PATCRESS","R-Respiratory system","ATCPTTMT","% of total sales","ESP","Spain","2015","2015",10.4,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","ATCPTTMT","% of total sales","ESP","Spain","2016","2016",9.8,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","ATCPTTMT","% of total sales","ESP","Spain","2017","2017",9.4,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","ATCPTTMT","% of total sales","ESP","Spain","2018","2018",7.1,"B","Break"
+"PATCRESS","R-Respiratory system","ATCPTTMT","% of total sales","ESP","Spain","2019","2019",6.9,,
+"PATCRESS","R-Respiratory system","ATCPTTMT","% of total sales","ESP","Spain","2020","2020",7,,
+"PATCRESS","R-Respiratory system","ATCPTTMT","% of total sales","ESP","Spain","2021","2021",6.7,,
+"PATCRESS","R-Respiratory system","ATCPTTMT","% of total sales","ESP","Spain","2022","2022",7.2,"P","Provisional value"
+"PATCRESS","R-Respiratory system","MLLNCUMT","Million of national currency units","SWE","Sweden","2010","2010",3323.9,,
+"PATCRESS","R-Respiratory system","MLLNCUMT","Million of national currency units","SWE","Sweden","2011","2011",3447.6,,
+"PATCRESS","R-Respiratory system","MLLNCUMT","Million of national currency units","SWE","Sweden","2012","2012",3572.8,,
+"PATCRESS","R-Respiratory system","MLLNCUMT","Million of national currency units","SWE","Sweden","2013","2013",3551.1,,
+"PATCRESS","R-Respiratory system","MLLNCUMT","Million of national currency units","SWE","Sweden","2014","2014",3534.1,,
+"PATCRESS","R-Respiratory system","MLLNCUMT","Million of national currency units","SWE","Sweden","2015","2015",3332.4,,
+"PATCRESS","R-Respiratory system","MLLNCUMT","Million of national currency units","SWE","Sweden","2016","2016",3456.4,,
+"PATCRESS","R-Respiratory system","MLLNCUMT","Million of national currency units","SWE","Sweden","2017","2017",3523.8,,
+"PATCRESS","R-Respiratory system","MLLNCUMT","Million of national currency units","SWE","Sweden","2018","2018",3803.4,,
+"PATCRESS","R-Respiratory system","MLLNCUMT","Million of national currency units","SWE","Sweden","2019","2019",4222.6,,
+"PATCRESS","R-Respiratory system","MLLNCUMT","Million of national currency units","SWE","Sweden","2020","2020",4310.2,,
+"PATCRESS","R-Respiratory system","MLLNCUMT","Million of national currency units","SWE","Sweden","2021","2021",4261,,
+"PATCRESS","R-Respiratory system","MLLNCUMT","Million of national currency units","SWE","Sweden","2022","2022",4814.5,,
+"PATCRESS","R-Respiratory system","MTMOTCMT","Million US$ at exchange rate","SWE","Sweden","2010","2010",461.2,,
+"PATCRESS","R-Respiratory system","MTMOTCMT","Million US$ at exchange rate","SWE","Sweden","2011","2011",530.9,,
+"PATCRESS","R-Respiratory system","MTMOTCMT","Million US$ at exchange rate","SWE","Sweden","2012","2012",527.3,,
+"PATCRESS","R-Respiratory system","MTMOTCMT","Million US$ at exchange rate","SWE","Sweden","2013","2013",545.2,,
+"PATCRESS","R-Respiratory system","MTMOTCMT","Million US$ at exchange rate","SWE","Sweden","2014","2014",515.1,,
+"PATCRESS","R-Respiratory system","MTMOTCMT","Million US$ at exchange rate","SWE","Sweden","2015","2015",395.1,,
+"PATCRESS","R-Respiratory system","MTMOTCMT","Million US$ at exchange rate","SWE","Sweden","2016","2016",403.7,,
+"PATCRESS","R-Respiratory system","MTMOTCMT","Million US$ at exchange rate","SWE","Sweden","2017","2017",412.2,,
+"PATCRESS","R-Respiratory system","MTMOTCMT","Million US$ at exchange rate","SWE","Sweden","2018","2018",437.6,,
+"PATCRESS","R-Respiratory system","MTMOTCMT","Million US$ at exchange rate","SWE","Sweden","2019","2019",446.4,,
+"PATCRESS","R-Respiratory system","MTMOTCMT","Million US$ at exchange rate","SWE","Sweden","2020","2020",468,,
+"PATCRESS","R-Respiratory system","MTMOTCMT","Million US$ at exchange rate","SWE","Sweden","2021","2021",496.8,,
+"PATCRESS","R-Respiratory system","MTMOTCMT","Million US$ at exchange rate","SWE","Sweden","2022","2022",476,,
+"PATCRESS","R-Respiratory system","MTMOPPMT","Million US$, purchasing power parity","SWE","Sweden","2010","2010",368.3,,
+"PATCRESS","R-Respiratory system","MTMOPPMT","Million US$, purchasing power parity","SWE","Sweden","2011","2011",389.8,,
+"PATCRESS","R-Respiratory system","MTMOPPMT","Million US$, purchasing power parity","SWE","Sweden","2012","2012",412.8,,
+"PATCRESS","R-Respiratory system","MTMOPPMT","Million US$, purchasing power parity","SWE","Sweden","2013","2013",413,,
+"PATCRESS","R-Respiratory system","MTMOPPMT","Million US$, purchasing power parity","SWE","Sweden","2014","2014",405,,
+"PATCRESS","R-Respiratory system","MTMOPPMT","Million US$, purchasing power parity","SWE","Sweden","2015","2015",376.4,,
+"PATCRESS","R-Respiratory system","MTMOPPMT","Million US$, purchasing power parity","SWE","Sweden","2016","2016",391.8,,
+"PATCRESS","R-Respiratory system","MTMOPPMT","Million US$, purchasing power parity","SWE","Sweden","2017","2017",398.1,,
+"PATCRESS","R-Respiratory system","MTMOPPMT","Million US$, purchasing power parity","SWE","Sweden","2018","2018",429,,
+"PATCRESS","R-Respiratory system","MTMOPPMT","Million US$, purchasing power parity","SWE","Sweden","2019","2019",484.8,,
+"PATCRESS","R-Respiratory system","MTMOPPMT","Million US$, purchasing power parity","SWE","Sweden","2020","2020",497.2,,
+"PATCRESS","R-Respiratory system","MTMOPPMT","Million US$, purchasing power parity","SWE","Sweden","2021","2021",488.6,,
+"PATCRESS","R-Respiratory system","MTMOPPMT","Million US$, purchasing power parity","SWE","Sweden","2022","2022",555.5,,
+"PATCRESS","R-Respiratory system","TCPPERMT","/capita, US$ exchange rate","SWE","Sweden","2010","2010",49.2,,
+"PATCRESS","R-Respiratory system","TCPPERMT","/capita, US$ exchange rate","SWE","Sweden","2011","2011",56.2,,
+"PATCRESS","R-Respiratory system","TCPPERMT","/capita, US$ exchange rate","SWE","Sweden","2012","2012",55.4,,
+"PATCRESS","R-Respiratory system","TCPPERMT","/capita, US$ exchange rate","SWE","Sweden","2013","2013",56.8,,
+"PATCRESS","R-Respiratory system","TCPPERMT","/capita, US$ exchange rate","SWE","Sweden","2014","2014",53.1,,
+"PATCRESS","R-Respiratory system","TCPPERMT","/capita, US$ exchange rate","SWE","Sweden","2015","2015",40.3,,
+"PATCRESS","R-Respiratory system","TCPPERMT","/capita, US$ exchange rate","SWE","Sweden","2016","2016",40.7,,
+"PATCRESS","R-Respiratory system","TCPPERMT","/capita, US$ exchange rate","SWE","Sweden","2017","2017",41,,
+"PATCRESS","R-Respiratory system","TCPPERMT","/capita, US$ exchange rate","SWE","Sweden","2018","2018",43,,
+"PATCRESS","R-Respiratory system","TCPPERMT","/capita, US$ exchange rate","SWE","Sweden","2019","2019",43.4,,
+"PATCRESS","R-Respiratory system","TCPPERMT","/capita, US$ exchange rate","SWE","Sweden","2020","2020",45.2,,
+"PATCRESS","R-Respiratory system","TCPPERMT","/capita, US$ exchange rate","SWE","Sweden","2021","2021",47.7,,
+"PATCRESS","R-Respiratory system","TCPPERMT","/capita, US$ exchange rate","SWE","Sweden","2022","2022",45.5,,
+"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2010","2010",39.3,,
+"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2011","2011",41.3,,
+"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2012","2012",43.4,,
+"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2013","2013",43,,
+"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2014","2014",41.8,,
+"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2015","2015",38.4,,
+"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2016","2016",39.5,,
+"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2017","2017",39.6,,
+"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2018","2018",42.2,,
+"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2019","2019",47.2,,
+"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2020","2020",48,,
+"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2021","2021",46.9,,
+"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2022","2022",53.2,,
+"PATCRESS","R-Respiratory system","ATCPTTMT","% of total sales","SWE","Sweden","2010","2010",9.2,,
+"PATCRESS","R-Respiratory system","ATCPTTMT","% of total sales","SWE","Sweden","2011","2011",9.4,,
+"PATCRESS","R-Respiratory system","ATCPTTMT","% of total sales","SWE","Sweden","2012","2012",9.9,,
+"PATCRESS","R-Respiratory system","ATCPTTMT","% of total sales","SWE","Sweden","2013","2013",9.8,,
+"PATCRESS","R-Respiratory system","ATCPTTMT","% of total sales","SWE","Sweden","2014","2014",9.3,,
+"PATCRESS","R-Respiratory system","ATCPTTMT","% of total sales","SWE","Sweden","2015","2015",8.2,,
+"PATCRESS","R-Respiratory system","ATCPTTMT","% of total sales","SWE","Sweden","2016","2016",8.2,,
+"PATCRESS","R-Respiratory system","ATCPTTMT","% of total sales","SWE","Sweden","2017","2017",8.1,,
+"PATCRESS","R-Respiratory system","ATCPTTMT","% of total sales","SWE","Sweden","2018","2018",8,,
+"PATCRESS","R-Respiratory system","ATCPTTMT","% of total sales","SWE","Sweden","2019","2019",8.4,,
+"PATCRESS","R-Respiratory system","ATCPTTMT","% of total sales","SWE","Sweden","2020","2020",8.2,,
+"PATCRESS","R-Respiratory system","ATCPTTMT","% of total sales","SWE","Sweden","2021","2021",7.9,,
+"PATCRESS","R-Respiratory system","ATCPTTMT","% of total sales","SWE","Sweden","2022","2022",8.3,,
+"PATCRESS","R-Respiratory system","MLLNCUMT","Million of national currency units","CHE","Switzerland","2010","2010",484.8,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","MLLNCUMT","Million of national currency units","CHE","Switzerland","2011","2011",487,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","MLLNCUMT","Million of national currency units","CHE","Switzerland","2012","2012",494,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","MLLNCUMT","Million of national currency units","CHE","Switzerland","2013","2013",513,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","MLLNCUMT","Million of national currency units","CHE","Switzerland","2014","2014",476,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","MLLNCUMT","Million of national currency units","CHE","Switzerland","2015","2015",503,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","MLLNCUMT","Million of national currency units","CHE","Switzerland","2016","2016",497,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","MLLNCUMT","Million of national currency units","CHE","Switzerland","2017","2017",507,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","MLLNCUMT","Million of national currency units","CHE","Switzerland","2018","2018",521,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","MLLNCUMT","Million of national currency units","CHE","Switzerland","2019","2019",527,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","MLLNCUMT","Million of national currency units","CHE","Switzerland","2020","2020",486,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","MLLNCUMT","Million of national currency units","CHE","Switzerland","2021","2021",457,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","MLLNCUMT","Million of national currency units","CHE","Switzerland","2022","2022",593,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","MTMOTCMT","Million US$ at exchange rate","CHE","Switzerland","2010","2010",464.8,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","MTMOTCMT","Million US$ at exchange rate","CHE","Switzerland","2011","2011",548.4,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","MTMOTCMT","Million US$ at exchange rate","CHE","Switzerland","2012","2012",526.8,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","MTMOTCMT","Million US$ at exchange rate","CHE","Switzerland","2013","2013",553.5,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","MTMOTCMT","Million US$ at exchange rate","CHE","Switzerland","2014","2014",519.6,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","MTMOTCMT","Million US$ at exchange rate","CHE","Switzerland","2015","2015",522.7,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","MTMOTCMT","Million US$ at exchange rate","CHE","Switzerland","2016","2016",504.4,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","MTMOTCMT","Million US$ at exchange rate","CHE","Switzerland","2017","2017",514.9,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","MTMOTCMT","Million US$ at exchange rate","CHE","Switzerland","2018","2018",532.8,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","MTMOTCMT","Million US$ at exchange rate","CHE","Switzerland","2019","2019",530.3,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","MTMOTCMT","Million US$ at exchange rate","CHE","Switzerland","2020","2020",517.6,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","MTMOTCMT","Million US$ at exchange rate","CHE","Switzerland","2021","2021",500.1,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","MTMOTCMT","Million US$ at exchange rate","CHE","Switzerland","2022","2022",621.1,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","MTMOPPMT","Million US$, purchasing power parity","CHE","Switzerland","2010","2010",330.6,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","MTMOPPMT","Million US$, purchasing power parity","CHE","Switzerland","2011","2011",348.5,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","MTMOPPMT","Million US$, purchasing power parity","CHE","Switzerland","2012","2012",364.8,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","MTMOPPMT","Million US$, purchasing power parity","CHE","Switzerland","2013","2013",390.9,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","MTMOPPMT","Million US$, purchasing power parity","CHE","Switzerland","2014","2014",371.4,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","MTMOPPMT","Million US$, purchasing power parity","CHE","Switzerland","2015","2015",407,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","MTMOPPMT","Million US$, purchasing power parity","CHE","Switzerland","2016","2016",413.5,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","MTMOPPMT","Million US$, purchasing power parity","CHE","Switzerland","2017","2017",426.9,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","MTMOPPMT","Million US$, purchasing power parity","CHE","Switzerland","2018","2018",442,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","MTMOPPMT","Million US$, purchasing power parity","CHE","Switzerland","2019","2019",458.1,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","MTMOPPMT","Million US$, purchasing power parity","CHE","Switzerland","2020","2020",427.9,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","MTMOPPMT","Million US$, purchasing power parity","CHE","Switzerland","2021","2021",413,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","MTMOPPMT","Million US$, purchasing power parity","CHE","Switzerland","2022","2022",556.3,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","TCPPERMT","/capita, US$ exchange rate","CHE","Switzerland","2010","2010",59.4,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","TCPPERMT","/capita, US$ exchange rate","CHE","Switzerland","2011","2011",69.3,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","TCPPERMT","/capita, US$ exchange rate","CHE","Switzerland","2012","2012",65.9,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","TCPPERMT","/capita, US$ exchange rate","CHE","Switzerland","2013","2013",68.4,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","TCPPERMT","/capita, US$ exchange rate","CHE","Switzerland","2014","2014",63.4,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","TCPPERMT","/capita, US$ exchange rate","CHE","Switzerland","2015","2015",63.1,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","TCPPERMT","/capita, US$ exchange rate","CHE","Switzerland","2016","2016",60.2,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","TCPPERMT","/capita, US$ exchange rate","CHE","Switzerland","2017","2017",60.9,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","TCPPERMT","/capita, US$ exchange rate","CHE","Switzerland","2018","2018",62.6,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","TCPPERMT","/capita, US$ exchange rate","CHE","Switzerland","2019","2019",61.8,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","TCPPERMT","/capita, US$ exchange rate","CHE","Switzerland","2020","2020",59.9,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","TCPPERMT","/capita, US$ exchange rate","CHE","Switzerland","2021","2021",57.5,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","TCPPERMT","/capita, US$ exchange rate","CHE","Switzerland","2022","2022",71.1,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","CHE","Switzerland","2010","2010",42.3,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","CHE","Switzerland","2011","2011",44,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","CHE","Switzerland","2012","2012",45.6,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","CHE","Switzerland","2013","2013",48.3,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","CHE","Switzerland","2014","2014",45.4,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","CHE","Switzerland","2015","2015",49.1,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","CHE","Switzerland","2016","2016",49.4,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","CHE","Switzerland","2017","2017",50.5,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","CHE","Switzerland","2018","2018",51.9,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","CHE","Switzerland","2019","2019",53.4,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","CHE","Switzerland","2020","2020",49.5,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","CHE","Switzerland","2021","2021",47.5,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","CHE","Switzerland","2022","2022",63.7,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","ATCPTTMT","% of total sales","CHE","Switzerland","2010","2010",8.4,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","ATCPTTMT","% of total sales","CHE","Switzerland","2011","2011",8.4,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","ATCPTTMT","% of total sales","CHE","Switzerland","2012","2012",8.3,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","ATCPTTMT","% of total sales","CHE","Switzerland","2013","2013",8.6,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","ATCPTTMT","% of total sales","CHE","Switzerland","2014","2014",8,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","ATCPTTMT","% of total sales","CHE","Switzerland","2015","2015",8.1,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","ATCPTTMT","% of total sales","CHE","Switzerland","2016","2016",7.8,"B; D","Break; Difference in methodology"
+"PATCRESS","R-Respiratory system","ATCPTTMT","% of total sales","CHE","Switzerland","2017","2017",7.8,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","ATCPTTMT","% of total sales","CHE","Switzerland","2018","2018",7.9,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","ATCPTTMT","% of total sales","CHE","Switzerland","2019","2019",7.9,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","ATCPTTMT","% of total sales","CHE","Switzerland","2020","2020",7.1,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","ATCPTTMT","% of total sales","CHE","Switzerland","2021","2021",6.4,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","ATCPTTMT","% of total sales","CHE","Switzerland","2022","2022",7.8,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","MLLNCUMT","Million of national currency units","TUR","Türkiye","2010","2010",1716.5,,
+"PATCRESS","R-Respiratory system","MLLNCUMT","Million of national currency units","TUR","Türkiye","2011","2011",1627.9,,
+"PATCRESS","R-Respiratory system","MLLNCUMT","Million of national currency units","TUR","Türkiye","2012","2012",1382.8,,
+"PATCRESS","R-Respiratory system","MLLNCUMT","Million of national currency units","TUR","Türkiye","2013","2013",1432,,
+"PATCRESS","R-Respiratory system","MLLNCUMT","Million of national currency units","TUR","Türkiye","2014","2014",1549.6,,
+"PATCRESS","R-Respiratory system","MLLNCUMT","Million of national currency units","TUR","Türkiye","2015","2015",1685.7,,
+"PATCRESS","R-Respiratory system","MLLNCUMT","Million of national currency units","TUR","Türkiye","2016","2016",2002.5,,
+"PATCRESS","R-Respiratory system","MLLNCUMT","Million of national currency units","TUR","Türkiye","2017","2017",2431.1,,
+"PATCRESS","R-Respiratory system","MLLNCUMT","Million of national currency units","TUR","Türkiye","2018","2018",3020,,
+"PATCRESS","R-Respiratory system","MLLNCUMT","Million of national currency units","TUR","Türkiye","2019","2019",3906.6,,
+"PATCRESS","R-Respiratory system","MLLNCUMT","Million of national currency units","TUR","Türkiye","2020","2020",4172,,
+"PATCRESS","R-Respiratory system","MLLNCUMT","Million of national currency units","TUR","Türkiye","2021","2021",5267.7,,
+"PATCRESS","R-Respiratory system","MTMOTCMT","Million US$ at exchange rate","TUR","Türkiye","2010","2010",1142.2,,
+"PATCRESS","R-Respiratory system","MTMOTCMT","Million US$ at exchange rate","TUR","Türkiye","2011","2011",971.9,,
+"PATCRESS","R-Respiratory system","MTMOTCMT","Million US$ at exchange rate","TUR","Türkiye","2012","2012",769.9,,
+"PATCRESS","R-Respiratory system","MTMOTCMT","Million US$ at exchange rate","TUR","Türkiye","2013","2013",752.2,,
+"PATCRESS","R-Respiratory system","MTMOTCMT","Million US$ at exchange rate","TUR","Türkiye","2014","2014",708,,
+"PATCRESS","R-Respiratory system","MTMOTCMT","Million US$ at exchange rate","TUR","Türkiye","2015","2015",619.7,,
+"PATCRESS","R-Respiratory system","MTMOTCMT","Million US$ at exchange rate","TUR","Türkiye","2016","2016",663,,
+"PATCRESS","R-Respiratory system","MTMOTCMT","Million US$ at exchange rate","TUR","Türkiye","2017","2017",666.4,,
+"PATCRESS","R-Respiratory system","MTMOTCMT","Million US$ at exchange rate","TUR","Türkiye","2018","2018",625.5,,
+"PATCRESS","R-Respiratory system","MTMOTCMT","Million US$ at exchange rate","TUR","Türkiye","2019","2019",688.5,,
+"PATCRESS","R-Respiratory system","MTMOTCMT","Million US$ at exchange rate","TUR","Türkiye","2020","2020",595.3,,
+"PATCRESS","R-Respiratory system","MTMOTCMT","Million US$ at exchange rate","TUR","Türkiye","2021","2021",595.2,,
+"PATCRESS","R-Respiratory system","MTMOPPMT","Million US$, purchasing power parity","TUR","Türkiye","2010","2010",1865,,
+"PATCRESS","R-Respiratory system","MTMOPPMT","Million US$, purchasing power parity","TUR","Türkiye","2011","2011",1684.9,,
+"PATCRESS","R-Respiratory system","MTMOPPMT","Million US$, purchasing power parity","TUR","Türkiye","2012","2012",1355.9,,
+"PATCRESS","R-Respiratory system","MTMOPPMT","Million US$, purchasing power parity","TUR","Türkiye","2013","2013",1337.9,,
+"PATCRESS","R-Respiratory system","MTMOPPMT","Million US$, purchasing power parity","TUR","Türkiye","2014","2014",1403,,
+"PATCRESS","R-Respiratory system","MTMOPPMT","Million US$, purchasing power parity","TUR","Türkiye","2015","2015",1450.1,,
+"PATCRESS","R-Respiratory system","MTMOPPMT","Million US$, purchasing power parity","TUR","Türkiye","2016","2016",1613.5,,
+"PATCRESS","R-Respiratory system","MTMOPPMT","Million US$, purchasing power parity","TUR","Türkiye","2017","2017",1756.6,,
+"PATCRESS","R-Respiratory system","MTMOPPMT","Million US$, purchasing power parity","TUR","Türkiye","2018","2018",1849.8,,
+"PATCRESS","R-Respiratory system","MTMOPPMT","Million US$, purchasing power parity","TUR","Türkiye","2019","2019",2095.8,,
+"PATCRESS","R-Respiratory system","MTMOPPMT","Million US$, purchasing power parity","TUR","Türkiye","2020","2020",1927.7,,
+"PATCRESS","R-Respiratory system","MTMOPPMT","Million US$, purchasing power parity","TUR","Türkiye","2021","2021",1876.1,,
+"PATCRESS","R-Respiratory system","TCPPERMT","/capita, US$ exchange rate","TUR","Türkiye","2010","2010",15.6,,
+"PATCRESS","R-Respiratory system","TCPPERMT","/capita, US$ exchange rate","TUR","Türkiye","2011","2011",13.1,,
+"PATCRESS","R-Respiratory system","TCPPERMT","/capita, US$ exchange rate","TUR","Türkiye","2012","2012",10.2,,
+"PATCRESS","R-Respiratory system","TCPPERMT","/capita, US$ exchange rate","TUR","Türkiye","2013","2013",9.9,,
+"PATCRESS","R-Respiratory system","TCPPERMT","/capita, US$ exchange rate","TUR","Türkiye","2014","2014",9.2,,
+"PATCRESS","R-Respiratory system","TCPPERMT","/capita, US$ exchange rate","TUR","Türkiye","2015","2015",7.9,,
+"PATCRESS","R-Respiratory system","TCPPERMT","/capita, US$ exchange rate","TUR","Türkiye","2016","2016",8.4,,
+"PATCRESS","R-Respiratory system","TCPPERMT","/capita, US$ exchange rate","TUR","Türkiye","2017","2017",8.3,,
+"PATCRESS","R-Respiratory system","TCPPERMT","/capita, US$ exchange rate","TUR","Türkiye","2018","2018",7.7,,
+"PATCRESS","R-Respiratory system","TCPPERMT","/capita, US$ exchange rate","TUR","Türkiye","2019","2019",8.3,,
+"PATCRESS","R-Respiratory system","TCPPERMT","/capita, US$ exchange rate","TUR","Türkiye","2020","2020",7.1,,
+"PATCRESS","R-Respiratory system","TCPPERMT","/capita, US$ exchange rate","TUR","Türkiye","2021","2021",7.1,,
+"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2010","2010",25.5,,
+"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2011","2011",22.7,,
+"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2012","2012",18,,
+"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2013","2013",17.6,,
+"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2014","2014",18.2,,
+"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2015","2015",18.5,,
+"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2016","2016",20.4,,
+"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2017","2017",21.9,,
+"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2018","2018",22.7,,
+"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2019","2019",25.4,,
+"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2020","2020",23.1,,
+"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2021","2021",22.3,,
+"PATCRESS","R-Respiratory system","ATCPTTMT","% of total sales","TUR","Türkiye","2010","2010",11,,
+"PATCRESS","R-Respiratory system","ATCPTTMT","% of total sales","TUR","Türkiye","2011","2011",11.5,,
+"PATCRESS","R-Respiratory system","ATCPTTMT","% of total sales","TUR","Türkiye","2012","2012",10.2,,
+"PATCRESS","R-Respiratory system","ATCPTTMT","% of total sales","TUR","Türkiye","2013","2013",10,,
+"PATCRESS","R-Respiratory system","ATCPTTMT","% of total sales","TUR","Türkiye","2014","2014",9.9,,
+"PATCRESS","R-Respiratory system","ATCPTTMT","% of total sales","TUR","Türkiye","2015","2015",9.2,,
+"PATCRESS","R-Respiratory system","ATCPTTMT","% of total sales","TUR","Türkiye","2016","2016",9.1,,
+"PATCRESS","R-Respiratory system","ATCPTTMT","% of total sales","TUR","Türkiye","2017","2017",9.6,,
+"PATCRESS","R-Respiratory system","ATCPTTMT","% of total sales","TUR","Türkiye","2018","2018",9.4,,
+"PATCRESS","R-Respiratory system","ATCPTTMT","% of total sales","TUR","Türkiye","2019","2019",9.3,,
+"PATCRESS","R-Respiratory system","ATCPTTMT","% of total sales","TUR","Türkiye","2020","2020",8.3,,
+"PATCRESS","R-Respiratory system","ATCPTTMT","% of total sales","TUR","Türkiye","2021","2021",8.1,,
+"PATCRESS","R-Respiratory system","MLLNCUMT","Million of national currency units","GBR","United Kingdom","2012","2012",1440.3,"B","Break"
+"PATCRESS","R-Respiratory system","MLLNCUMT","Million of national currency units","GBR","United Kingdom","2013","2013",1526.5,,
+"PATCRESS","R-Respiratory system","MLLNCUMT","Million of national currency units","GBR","United Kingdom","2014","2014",1581.1,,
+"PATCRESS","R-Respiratory system","MLLNCUMT","Million of national currency units","GBR","United Kingdom","2015","2015",1618.9,,
+"PATCRESS","R-Respiratory system","MLLNCUMT","Million of national currency units","GBR","United Kingdom","2016","2016",1653,,
+"PATCRESS","R-Respiratory system","MLLNCUMT","Million of national currency units","GBR","United Kingdom","2017","2017",1666.1,,
+"PATCRESS","R-Respiratory system","MLLNCUMT","Million of national currency units","GBR","United Kingdom","2018","2018",1630.1,,
+"PATCRESS","R-Respiratory system","MTMOTCMT","Million US$ at exchange rate","GBR","United Kingdom","2012","2012",2275.2,"B","Break"
+"PATCRESS","R-Respiratory system","MTMOTCMT","Million US$ at exchange rate","GBR","United Kingdom","2013","2013",2386.4,,
+"PATCRESS","R-Respiratory system","MTMOTCMT","Million US$ at exchange rate","GBR","United Kingdom","2014","2014",2601.6,,
+"PATCRESS","R-Respiratory system","MTMOTCMT","Million US$ at exchange rate","GBR","United Kingdom","2015","2015",2473.3,,
+"PATCRESS","R-Respiratory system","MTMOTCMT","Million US$ at exchange rate","GBR","United Kingdom","2016","2016",2231.9,,
+"PATCRESS","R-Respiratory system","MTMOTCMT","Million US$ at exchange rate","GBR","United Kingdom","2017","2017",2144.3,,
+"PATCRESS","R-Respiratory system","MTMOTCMT","Million US$ at exchange rate","GBR","United Kingdom","2018","2018",2174.8,,
+"PATCRESS","R-Respiratory system","MTMOPPMT","Million US$, purchasing power parity","GBR","United Kingdom","2012","2012",2052.8,"B","Break"
+"PATCRESS","R-Respiratory system","MTMOPPMT","Million US$, purchasing power parity","GBR","United Kingdom","2013","2013",2195.6,,
+"PATCRESS","R-Respiratory system","MTMOPPMT","Million US$, purchasing power parity","GBR","United Kingdom","2014","2014",2263.7,,
+"PATCRESS","R-Respiratory system","MTMOPPMT","Million US$, purchasing power parity","GBR","United Kingdom","2015","2015",2337.6,,
+"PATCRESS","R-Respiratory system","MTMOPPMT","Million US$, purchasing power parity","GBR","United Kingdom","2016","2016",2400.5,,
+"PATCRESS","R-Respiratory system","MTMOPPMT","Million US$, purchasing power parity","GBR","United Kingdom","2017","2017",2433.7,,
+"PATCRESS","R-Respiratory system","MTMOPPMT","Million US$, purchasing power parity","GBR","United Kingdom","2018","2018",2370.3,,
+"PATCRESS","R-Respiratory system","TCPPERMT","/capita, US$ exchange rate","GBR","United Kingdom","2012","2012",35.7,"B","Break"
+"PATCRESS","R-Respiratory system","TCPPERMT","/capita, US$ exchange rate","GBR","United Kingdom","2013","2013",37.2,,
+"PATCRESS","R-Respiratory system","TCPPERMT","/capita, US$ exchange rate","GBR","United Kingdom","2014","2014",40.3,,
+"PATCRESS","R-Respiratory system","TCPPERMT","/capita, US$ exchange rate","GBR","United Kingdom","2015","2015",38,,
+"PATCRESS","R-Respiratory system","TCPPERMT","/capita, US$ exchange rate","GBR","United Kingdom","2016","2016",34,,
+"PATCRESS","R-Respiratory system","TCPPERMT","/capita, US$ exchange rate","GBR","United Kingdom","2017","2017",32.5,,
+"PATCRESS","R-Respiratory system","TCPPERMT","/capita, US$ exchange rate","GBR","United Kingdom","2018","2018",32.7,,
+"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","GBR","United Kingdom","2012","2012",32.2,"B","Break"
+"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","GBR","United Kingdom","2013","2013",34.3,,
+"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","GBR","United Kingdom","2014","2014",35,,
+"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","GBR","United Kingdom","2015","2015",35.9,,
+"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","GBR","United Kingdom","2016","2016",36.6,,
+"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","GBR","United Kingdom","2017","2017",36.9,,
+"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","GBR","United Kingdom","2018","2018",35.7,,
+"PATCRESS","R-Respiratory system","ATCPTTMT","% of total sales","GBR","United Kingdom","2012","2012",10.5,"B","Break"
+"PATCRESS","R-Respiratory system","ATCPTTMT","% of total sales","GBR","United Kingdom","2013","2013",10.5,,
+"PATCRESS","R-Respiratory system","ATCPTTMT","% of total sales","GBR","United Kingdom","2014","2014",9.9,,
+"PATCRESS","R-Respiratory system","ATCPTTMT","% of total sales","GBR","United Kingdom","2015","2015",9.2,,
+"PATCRESS","R-Respiratory system","ATCPTTMT","% of total sales","GBR","United Kingdom","2016","2016",8.9,,
+"PATCRESS","R-Respiratory system","ATCPTTMT","% of total sales","GBR","United Kingdom","2017","2017",8.5,,
+"PATCRESS","R-Respiratory system","ATCPTTMT","% of total sales","GBR","United Kingdom","2018","2018",8,,
+"PATCRESS","R-Respiratory system","MLLNCUMT","Million of national currency units","CHL","Chile","2010","2010",108206.7,,
+"PATCRESS","R-Respiratory system","MLLNCUMT","Million of national currency units","CHL","Chile","2011","2011",124669.7,"B","Break"
+"PATCRESS","R-Respiratory system","MLLNCUMT","Million of national currency units","CHL","Chile","2012","2012",133945.9,,
+"PATCRESS","R-Respiratory system","MLLNCUMT","Million of national currency units","CHL","Chile","2013","2013",140586,,
+"PATCRESS","R-Respiratory system","MLLNCUMT","Million of national currency units","CHL","Chile","2014","2014",153706.6,,
+"PATCRESS","R-Respiratory system","MLLNCUMT","Million of national currency units","CHL","Chile","2015","2015",175733,,
+"PATCRESS","R-Respiratory system","MLLNCUMT","Million of national currency units","CHL","Chile","2016","2016",190353.2,,
+"PATCRESS","R-Respiratory system","MLLNCUMT","Million of national currency units","CHL","Chile","2017","2017",200656.9,,
+"PATCRESS","R-Respiratory system","MLLNCUMT","Million of national currency units","CHL","Chile","2018","2018",207557.3,,
+"PATCRESS","R-Respiratory system","MLLNCUMT","Million of national currency units","CHL","Chile","2019","2019",206047.5,,
+"PATCRESS","R-Respiratory system","MLLNCUMT","Million of national currency units","CHL","Chile","2020","2020",163545.5,,
+"PATCRESS","R-Respiratory system","MLLNCUMT","Million of national currency units","CHL","Chile","2021","2021",181298.3,,
+"PATCRESS","R-Respiratory system","MLLNCUMT","Million of national currency units","CHL","Chile","2022","2022",237300,,
+"PATCRESS","R-Respiratory system","MTMOTCMT","Million US$ at exchange rate","CHL","Chile","2010","2010",212.1,,
+"PATCRESS","R-Respiratory system","MTMOTCMT","Million US$ at exchange rate","CHL","Chile","2011","2011",257.8,"B","Break"
+"PATCRESS","R-Respiratory system","MTMOTCMT","Million US$ at exchange rate","CHL","Chile","2012","2012",275.3,,
+"PATCRESS","R-Respiratory system","MTMOTCMT","Million US$ at exchange rate","CHL","Chile","2013","2013",283.9,,
+"PATCRESS","R-Respiratory system","MTMOTCMT","Million US$ at exchange rate","CHL","Chile","2014","2014",269.5,,
+"PATCRESS","R-Respiratory system","MTMOTCMT","Million US$ at exchange rate","CHL","Chile","2015","2015",268.7,,
+"PATCRESS","R-Respiratory system","MTMOTCMT","Million US$ at exchange rate","CHL","Chile","2016","2016",281.2,,
+"PATCRESS","R-Respiratory system","MTMOTCMT","Million US$ at exchange rate","CHL","Chile","2017","2017",309.3,,
+"PATCRESS","R-Respiratory system","MTMOTCMT","Million US$ at exchange rate","CHL","Chile","2018","2018",323.7,,
+"PATCRESS","R-Respiratory system","MTMOTCMT","Million US$ at exchange rate","CHL","Chile","2019","2019",293.1,,
+"PATCRESS","R-Respiratory system","MTMOTCMT","Million US$ at exchange rate","CHL","Chile","2020","2020",206.3,,
+"PATCRESS","R-Respiratory system","MTMOTCMT","Million US$ at exchange rate","CHL","Chile","2021","2021",238.9,,
+"PATCRESS","R-Respiratory system","MTMOTCMT","Million US$ at exchange rate","CHL","Chile","2022","2022",271.7,,
+"PATCRESS","R-Respiratory system","MTMOPPMT","Million US$, purchasing power parity","CHL","Chile","2010","2010",300.7,,
+"PATCRESS","R-Respiratory system","MTMOPPMT","Million US$, purchasing power parity","CHL","Chile","2011","2011",358.2,"B","Break"
+"PATCRESS","R-Respiratory system","MTMOPPMT","Million US$, purchasing power parity","CHL","Chile","2012","2012",385.8,,
+"PATCRESS","R-Respiratory system","MTMOPPMT","Million US$, purchasing power parity","CHL","Chile","2013","2013",402,,
+"PATCRESS","R-Respiratory system","MTMOPPMT","Million US$, purchasing power parity","CHL","Chile","2014","2014",418.6,,
+"PATCRESS","R-Respiratory system","MTMOPPMT","Million US$, purchasing power parity","CHL","Chile","2015","2015",449.2,,
+"PATCRESS","R-Respiratory system","MTMOPPMT","Million US$, purchasing power parity","CHL","Chile","2016","2016",479.2,,
+"PATCRESS","R-Respiratory system","MTMOPPMT","Million US$, purchasing power parity","CHL","Chile","2017","2017",504.6,,
+"PATCRESS","R-Respiratory system","MTMOPPMT","Million US$, purchasing power parity","CHL","Chile","2018","2018",523.8,,
+"PATCRESS","R-Respiratory system","MTMOPPMT","Million US$, purchasing power parity","CHL","Chile","2019","2019",513,,
+"PATCRESS","R-Respiratory system","MTMOPPMT","Million US$, purchasing power parity","CHL","Chile","2020","2020",390.8,,
+"PATCRESS","R-Respiratory system","MTMOPPMT","Million US$, purchasing power parity","CHL","Chile","2021","2021",416.6,,
+"PATCRESS","R-Respiratory system","MTMOPPMT","Million US$, purchasing power parity","CHL","Chile","2022","2022",542.3,,
+"PATCRESS","R-Respiratory system","TCPPERMT","/capita, US$ exchange rate","CHL","Chile","2010","2010",12.4,,
+"PATCRESS","R-Respiratory system","TCPPERMT","/capita, US$ exchange rate","CHL","Chile","2011","2011",14.9,"B","Break"
+"PATCRESS","R-Respiratory system","TCPPERMT","/capita, US$ exchange rate","CHL","Chile","2012","2012",15.8,,
+"PATCRESS","R-Respiratory system","TCPPERMT","/capita, US$ exchange rate","CHL","Chile","2013","2013",16.1,,
+"PATCRESS","R-Respiratory system","TCPPERMT","/capita, US$ exchange rate","CHL","Chile","2014","2014",15.2,,
+"PATCRESS","R-Respiratory system","TCPPERMT","/capita, US$ exchange rate","CHL","Chile","2015","2015",14.9,,
+"PATCRESS","R-Respiratory system","TCPPERMT","/capita, US$ exchange rate","CHL","Chile","2016","2016",15.5,,
+"PATCRESS","R-Respiratory system","TCPPERMT","/capita, US$ exchange rate","CHL","Chile","2017","2017",16.8,,
+"PATCRESS","R-Respiratory system","TCPPERMT","/capita, US$ exchange rate","CHL","Chile","2018","2018",17.3,,
+"PATCRESS","R-Respiratory system","TCPPERMT","/capita, US$ exchange rate","CHL","Chile","2019","2019",15.3,,
+"PATCRESS","R-Respiratory system","TCPPERMT","/capita, US$ exchange rate","CHL","Chile","2020","2020",10.6,,
+"PATCRESS","R-Respiratory system","TCPPERMT","/capita, US$ exchange rate","CHL","Chile","2021","2021",12.1,,
+"PATCRESS","R-Respiratory system","TCPPERMT","/capita, US$ exchange rate","CHL","Chile","2022","2022",13.7,,
+"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2010","2010",17.6,,
+"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2011","2011",20.8,"B","Break"
+"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2012","2012",22.1,,
+"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2013","2013",22.8,,
+"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2014","2014",23.5,,
+"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2015","2015",25,,
+"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2016","2016",26.4,,
+"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2017","2017",27.4,,
+"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2018","2018",27.9,,
+"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2019","2019",26.9,,
+"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2020","2020",20.1,,
+"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2021","2021",21.2,,
+"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2022","2022",27.4,,
+"PATCRESS","R-Respiratory system","ATCPTTMT","% of total sales","CHL","Chile","2010","2010",13.1,,
+"PATCRESS","R-Respiratory system","ATCPTTMT","% of total sales","CHL","Chile","2011","2011",10.6,"B","Break"
+"PATCRESS","R-Respiratory system","ATCPTTMT","% of total sales","CHL","Chile","2012","2012",10.7,,
+"PATCRESS","R-Respiratory system","ATCPTTMT","% of total sales","CHL","Chile","2013","2013",9.7,,
+"PATCRESS","R-Respiratory system","ATCPTTMT","% of total sales","CHL","Chile","2014","2014",9.9,,
+"PATCRESS","R-Respiratory system","ATCPTTMT","% of total sales","CHL","Chile","2015","2015",9.6,,
+"PATCRESS","R-Respiratory system","ATCPTTMT","% of total sales","CHL","Chile","2016","2016",9.4,,
+"PATCRESS","R-Respiratory system","ATCPTTMT","% of total sales","CHL","Chile","2017","2017",9.7,,
+"PATCRESS","R-Respiratory system","ATCPTTMT","% of total sales","CHL","Chile","2018","2018",9,,
+"PATCRESS","R-Respiratory system","ATCPTTMT","% of total sales","CHL","Chile","2019","2019",8.2,,
+"PATCRESS","R-Respiratory system","ATCPTTMT","% of total sales","CHL","Chile","2020","2020",6.1,,
+"PATCRESS","R-Respiratory system","ATCPTTMT","% of total sales","CHL","Chile","2021","2021",6.4,,
+"PATCRESS","R-Respiratory system","ATCPTTMT","% of total sales","CHL","Chile","2022","2022",8.4,,
+"PATCRESS","R-Respiratory system","MLLNCUMT","Million of national currency units","EST","Estonia","2010","2010",14.5,,
+"PATCRESS","R-Respiratory system","MLLNCUMT","Million of national currency units","EST","Estonia","2011","2011",15.1,,
+"PATCRESS","R-Respiratory system","MLLNCUMT","Million of national currency units","EST","Estonia","2012","2012",16.7,,
+"PATCRESS","R-Respiratory system","MLLNCUMT","Million of national currency units","EST","Estonia","2013","2013",18.6,,
+"PATCRESS","R-Respiratory system","MLLNCUMT","Million of national currency units","EST","Estonia","2014","2014",19.7,,
+"PATCRESS","R-Respiratory system","MLLNCUMT","Million of national currency units","EST","Estonia","2015","2015",20.4,,
+"PATCRESS","R-Respiratory system","MLLNCUMT","Million of national currency units","EST","Estonia","2016","2016",21.3,,
+"PATCRESS","R-Respiratory system","MLLNCUMT","Million of national currency units","EST","Estonia","2017","2017",22.1,,
+"PATCRESS","R-Respiratory system","MLLNCUMT","Million of national currency units","EST","Estonia","2018","2018",24.1,,
+"PATCRESS","R-Respiratory system","MLLNCUMT","Million of national currency units","EST","Estonia","2019","2019",24.6,,
+"PATCRESS","R-Respiratory system","MLLNCUMT","Million of national currency units","EST","Estonia","2020","2020",24.2,,
+"PATCRESS","R-Respiratory system","MLLNCUMT","Million of national currency units","EST","Estonia","2021","2021",26.1,,
+"PATCRESS","R-Respiratory system","MLLNCUMT","Million of national currency units","EST","Estonia","2022","2022",32.5,,
+"PATCRESS","R-Respiratory system","MTMOTCMT","Million US$ at exchange rate","EST","Estonia","2010","2010",19.2,,
+"PATCRESS","R-Respiratory system","MTMOTCMT","Million US$ at exchange rate","EST","Estonia","2011","2011",21,,
+"PATCRESS","R-Respiratory system","MTMOTCMT","Million US$ at exchange rate","EST","Estonia","2012","2012",21.4,,
+"PATCRESS","R-Respiratory system","MTMOTCMT","Million US$ at exchange rate","EST","Estonia","2013","2013",24.8,,
+"PATCRESS","R-Respiratory system","MTMOTCMT","Million US$ at exchange rate","EST","Estonia","2014","2014",26.2,,
+"PATCRESS","R-Respiratory system","MTMOTCMT","Million US$ at exchange rate","EST","Estonia","2015","2015",22.6,,
+"PATCRESS","R-Respiratory system","MTMOTCMT","Million US$ at exchange rate","EST","Estonia","2016","2016",23.6,,
+"PATCRESS","R-Respiratory system","MTMOTCMT","Million US$ at exchange rate","EST","Estonia","2017","2017",25,,
+"PATCRESS","R-Respiratory system","MTMOTCMT","Million US$ at exchange rate","EST","Estonia","2018","2018",28.5,,
+"PATCRESS","R-Respiratory system","MTMOTCMT","Million US$ at exchange rate","EST","Estonia","2019","2019",27.6,,
+"PATCRESS","R-Respiratory system","MTMOTCMT","Million US$ at exchange rate","EST","Estonia","2020","2020",27.6,,
+"PATCRESS","R-Respiratory system","MTMOTCMT","Million US$ at exchange rate","EST","Estonia","2021","2021",30.9,,
+"PATCRESS","R-Respiratory system","MTMOTCMT","Million US$ at exchange rate","EST","Estonia","2022","2022",34.2,,
+"PATCRESS","R-Respiratory system","MTMOPPMT","Million US$, purchasing power parity","EST","Estonia","2010","2010",28.2,,
+"PATCRESS","R-Respiratory system","MTMOPPMT","Million US$, purchasing power parity","EST","Estonia","2011","2011",29.5,,
+"PATCRESS","R-Respiratory system","MTMOPPMT","Million US$, purchasing power parity","EST","Estonia","2012","2012",32,,
+"PATCRESS","R-Respiratory system","MTMOPPMT","Million US$, purchasing power parity","EST","Estonia","2013","2013",35.7,,
+"PATCRESS","R-Respiratory system","MTMOPPMT","Million US$, purchasing power parity","EST","Estonia","2014","2014",37.5,,
+"PATCRESS","R-Respiratory system","MTMOPPMT","Million US$, purchasing power parity","EST","Estonia","2015","2015",37.9,,
+"PATCRESS","R-Respiratory system","MTMOPPMT","Million US$, purchasing power parity","EST","Estonia","2016","2016",40.4,,
+"PATCRESS","R-Respiratory system","MTMOPPMT","Million US$, purchasing power parity","EST","Estonia","2017","2017",41.3,,
+"PATCRESS","R-Respiratory system","MTMOPPMT","Million US$, purchasing power parity","EST","Estonia","2018","2018",44.7,,
+"PATCRESS","R-Respiratory system","MTMOPPMT","Million US$, purchasing power parity","EST","Estonia","2019","2019",45.9,,
+"PATCRESS","R-Respiratory system","MTMOPPMT","Million US$, purchasing power parity","EST","Estonia","2020","2020",46.1,,
+"PATCRESS","R-Respiratory system","MTMOPPMT","Million US$, purchasing power parity","EST","Estonia","2021","2021",48,,
+"PATCRESS","R-Respiratory system","MTMOPPMT","Million US$, purchasing power parity","EST","Estonia","2022","2022",57,,
+"PATCRESS","R-Respiratory system","TCPPERMT","/capita, US$ exchange rate","EST","Estonia","2010","2010",14.4,,
+"PATCRESS","R-Respiratory system","TCPPERMT","/capita, US$ exchange rate","EST","Estonia","2011","2011",15.8,,
+"PATCRESS","R-Respiratory system","TCPPERMT","/capita, US$ exchange rate","EST","Estonia","2012","2012",16.2,,
+"PATCRESS","R-Respiratory system","TCPPERMT","/capita, US$ exchange rate","EST","Estonia","2013","2013",18.8,,
+"PATCRESS","R-Respiratory system","TCPPERMT","/capita, US$ exchange rate","EST","Estonia","2014","2014",20,,
+"PATCRESS","R-Respiratory system","TCPPERMT","/capita, US$ exchange rate","EST","Estonia","2015","2015",17.2,,
+"PATCRESS","R-Respiratory system","TCPPERMT","/capita, US$ exchange rate","EST","Estonia","2016","2016",17.9,,
+"PATCRESS","R-Respiratory system","TCPPERMT","/capita, US$ exchange rate","EST","Estonia","2017","2017",18.9,,
+"PATCRESS","R-Respiratory system","TCPPERMT","/capita, US$ exchange rate","EST","Estonia","2018","2018",21.5,,
+"PATCRESS","R-Respiratory system","TCPPERMT","/capita, US$ exchange rate","EST","Estonia","2019","2019",20.8,,
+"PATCRESS","R-Respiratory system","TCPPERMT","/capita, US$ exchange rate","EST","Estonia","2020","2020",20.8,,
+"PATCRESS","R-Respiratory system","TCPPERMT","/capita, US$ exchange rate","EST","Estonia","2021","2021",23.2,,
+"PATCRESS","R-Respiratory system","TCPPERMT","/capita, US$ exchange rate","EST","Estonia","2022","2022",25.7,,
+"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2010","2010",21.2,,
+"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2011","2011",22.2,,
+"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2012","2012",24.2,,
+"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2013","2013",27.1,,
+"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2014","2014",28.5,,
+"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2015","2015",28.8,,
+"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2016","2016",30.7,,
+"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2017","2017",31.4,,
+"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2018","2018",33.8,,
+"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2019","2019",34.6,,
+"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2020","2020",34.7,,
+"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2021","2021",36.1,,
+"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2022","2022",42.8,,
+"PATCRESS","R-Respiratory system","ATCPTTMT","% of total sales","EST","Estonia","2010","2010",7.5,,
+"PATCRESS","R-Respiratory system","ATCPTTMT","% of total sales","EST","Estonia","2011","2011",7.4,,
+"PATCRESS","R-Respiratory system","ATCPTTMT","% of total sales","EST","Estonia","2012","2012",7.5,,
+"PATCRESS","R-Respiratory system","ATCPTTMT","% of total sales","EST","Estonia","2013","2013",8.1,,
+"PATCRESS","R-Respiratory system","ATCPTTMT","% of total sales","EST","Estonia","2014","2014",7.9,,
+"PATCRESS","R-Respiratory system","ATCPTTMT","% of total sales","EST","Estonia","2015","2015",7.7,,
+"PATCRESS","R-Respiratory system","ATCPTTMT","% of total sales","EST","Estonia","2016","2016",7.4,,
+"PATCRESS","R-Respiratory system","ATCPTTMT","% of total sales","EST","Estonia","2017","2017",7.3,,
+"PATCRESS","R-Respiratory system","ATCPTTMT","% of total sales","EST","Estonia","2018","2018",7.4,,
+"PATCRESS","R-Respiratory system","ATCPTTMT","% of total sales","EST","Estonia","2019","2019",7.2,,
+"PATCRESS","R-Respiratory system","ATCPTTMT","% of total sales","EST","Estonia","2020","2020",6.7,,
+"PATCRESS","R-Respiratory system","ATCPTTMT","% of total sales","EST","Estonia","2021","2021",6.4,,
+"PATCRESS","R-Respiratory system","ATCPTTMT","% of total sales","EST","Estonia","2022","2022",7.5,,
+"PATCRESS","R-Respiratory system","MLLNCUMT","Million of national currency units","SVN","Slovenia","2010","2010",29.3,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","MLLNCUMT","Million of national currency units","SVN","Slovenia","2011","2011",29.2,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","MLLNCUMT","Million of national currency units","SVN","Slovenia","2012","2012",28.2,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","MLLNCUMT","Million of national currency units","SVN","Slovenia","2013","2013",27.2,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","MLLNCUMT","Million of national currency units","SVN","Slovenia","2014","2014",26.6,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","MLLNCUMT","Million of national currency units","SVN","Slovenia","2015","2015",26.4,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","MLLNCUMT","Million of national currency units","SVN","Slovenia","2016","2016",27.2,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","MLLNCUMT","Million of national currency units","SVN","Slovenia","2017","2017",25.6,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","MLLNCUMT","Million of national currency units","SVN","Slovenia","2018","2018",24.1,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","MLLNCUMT","Million of national currency units","SVN","Slovenia","2019","2019",25.6,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","MLLNCUMT","Million of national currency units","SVN","Slovenia","2020","2020",27.7,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","MLLNCUMT","Million of national currency units","SVN","Slovenia","2021","2021",36.2,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","MLLNCUMT","Million of national currency units","SVN","Slovenia","2022","2022",40.5,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","MTMOTCMT","Million US$ at exchange rate","SVN","Slovenia","2010","2010",38.8,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","MTMOTCMT","Million US$ at exchange rate","SVN","Slovenia","2011","2011",40.6,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","MTMOTCMT","Million US$ at exchange rate","SVN","Slovenia","2012","2012",36.2,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","MTMOTCMT","Million US$ at exchange rate","SVN","Slovenia","2013","2013",36.2,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","MTMOTCMT","Million US$ at exchange rate","SVN","Slovenia","2014","2014",35.4,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","MTMOTCMT","Million US$ at exchange rate","SVN","Slovenia","2015","2015",29.3,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","MTMOTCMT","Million US$ at exchange rate","SVN","Slovenia","2016","2016",30.1,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","MTMOTCMT","Million US$ at exchange rate","SVN","Slovenia","2017","2017",28.9,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","MTMOTCMT","Million US$ at exchange rate","SVN","Slovenia","2018","2018",28.4,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","MTMOTCMT","Million US$ at exchange rate","SVN","Slovenia","2019","2019",28.7,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","MTMOTCMT","Million US$ at exchange rate","SVN","Slovenia","2020","2020",31.6,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","MTMOTCMT","Million US$ at exchange rate","SVN","Slovenia","2021","2021",42.9,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","MTMOTCMT","Million US$ at exchange rate","SVN","Slovenia","2022","2022",42.6,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","MTMOPPMT","Million US$, purchasing power parity","SVN","Slovenia","2010","2010",45.9,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","MTMOPPMT","Million US$, purchasing power parity","SVN","Slovenia","2011","2011",46.8,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","MTMOPPMT","Million US$, purchasing power parity","SVN","Slovenia","2012","2012",46.5,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","MTMOPPMT","Million US$, purchasing power parity","SVN","Slovenia","2013","2013",46.1,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","MTMOPPMT","Million US$, purchasing power parity","SVN","Slovenia","2014","2014",45.1,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","MTMOPPMT","Million US$, purchasing power parity","SVN","Slovenia","2015","2015",44.4,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","MTMOPPMT","Million US$, purchasing power parity","SVN","Slovenia","2016","2016",47.1,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","MTMOPPMT","Million US$, purchasing power parity","SVN","Slovenia","2017","2017",44.8,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","MTMOPPMT","Million US$, purchasing power parity","SVN","Slovenia","2018","2018",42.4,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","MTMOPPMT","Million US$, purchasing power parity","SVN","Slovenia","2019","2019",46.4,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","MTMOPPMT","Million US$, purchasing power parity","SVN","Slovenia","2020","2020",50.6,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","MTMOPPMT","Million US$, purchasing power parity","SVN","Slovenia","2021","2021",64.4,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","MTMOPPMT","Million US$, purchasing power parity","SVN","Slovenia","2022","2022",73.3,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","TCPPERMT","/capita, US$ exchange rate","SVN","Slovenia","2010","2010",18.9,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","TCPPERMT","/capita, US$ exchange rate","SVN","Slovenia","2011","2011",19.8,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","TCPPERMT","/capita, US$ exchange rate","SVN","Slovenia","2012","2012",17.6,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","TCPPERMT","/capita, US$ exchange rate","SVN","Slovenia","2013","2013",17.6,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","TCPPERMT","/capita, US$ exchange rate","SVN","Slovenia","2014","2014",17.2,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","TCPPERMT","/capita, US$ exchange rate","SVN","Slovenia","2015","2015",14.2,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","TCPPERMT","/capita, US$ exchange rate","SVN","Slovenia","2016","2016",14.6,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","TCPPERMT","/capita, US$ exchange rate","SVN","Slovenia","2017","2017",14,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","TCPPERMT","/capita, US$ exchange rate","SVN","Slovenia","2018","2018",13.7,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","TCPPERMT","/capita, US$ exchange rate","SVN","Slovenia","2019","2019",13.7,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","TCPPERMT","/capita, US$ exchange rate","SVN","Slovenia","2020","2020",15,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","TCPPERMT","/capita, US$ exchange rate","SVN","Slovenia","2021","2021",20.3,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","TCPPERMT","/capita, US$ exchange rate","SVN","Slovenia","2022","2022",20.2,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2010","2010",22.4,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2011","2011",22.8,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2012","2012",22.6,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2013","2013",22.4,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2014","2014",21.9,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2015","2015",21.5,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2016","2016",22.8,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2017","2017",21.7,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2018","2018",20.5,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2019","2019",22.2,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2020","2020",24.1,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2021","2021",30.5,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2022","2022",34.8,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","ATCPTTMT","% of total sales","SVN","Slovenia","2010","2010",6.2,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","ATCPTTMT","% of total sales","SVN","Slovenia","2011","2011",6.2,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","ATCPTTMT","% of total sales","SVN","Slovenia","2012","2012",6.2,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","ATCPTTMT","% of total sales","SVN","Slovenia","2013","2013",6,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","ATCPTTMT","% of total sales","SVN","Slovenia","2014","2014",6.2,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","ATCPTTMT","% of total sales","SVN","Slovenia","2015","2015",5.9,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","ATCPTTMT","% of total sales","SVN","Slovenia","2016","2016",5.8,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","ATCPTTMT","% of total sales","SVN","Slovenia","2017","2017",5.3,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","ATCPTTMT","% of total sales","SVN","Slovenia","2018","2018",4.7,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","ATCPTTMT","% of total sales","SVN","Slovenia","2019","2019",4.7,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","ATCPTTMT","% of total sales","SVN","Slovenia","2020","2020",4.9,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","ATCPTTMT","% of total sales","SVN","Slovenia","2021","2021",5.9,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","ATCPTTMT","% of total sales","SVN","Slovenia","2022","2022",6,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MLLNCUMT","Million of national currency units","AUS","Australia","2010","2010",542,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MLLNCUMT","Million of national currency units","AUS","Australia","2011","2011",562,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MLLNCUMT","Million of national currency units","AUS","Australia","2012","2012",586,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MLLNCUMT","Million of national currency units","AUS","Australia","2013","2013",617,"B; D","Break; Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MLLNCUMT","Million of national currency units","AUS","Australia","2014","2014",634,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MLLNCUMT","Million of national currency units","AUS","Australia","2015","2015",618,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MLLNCUMT","Million of national currency units","AUS","Australia","2016","2016",629,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MLLNCUMT","Million of national currency units","AUS","Australia","2017","2017",650,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MLLNCUMT","Million of national currency units","AUS","Australia","2018","2018",633,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MLLNCUMT","Million of national currency units","AUS","Australia","2019","2019",668,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MLLNCUMT","Million of national currency units","AUS","Australia","2020","2020",743,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MLLNCUMT","Million of national currency units","AUS","Australia","2021","2021",746,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOTCMT","Million US$ at exchange rate","AUS","Australia","2010","2010",497.2,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOTCMT","Million US$ at exchange rate","AUS","Australia","2011","2011",579.7,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOTCMT","Million US$ at exchange rate","AUS","Australia","2012","2012",606.8,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOTCMT","Million US$ at exchange rate","AUS","Australia","2013","2013",595.7,"B; D","Break; Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOTCMT","Million US$ at exchange rate","AUS","Australia","2014","2014",571.5,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOTCMT","Million US$ at exchange rate","AUS","Australia","2015","2015",464.3,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOTCMT","Million US$ at exchange rate","AUS","Australia","2016","2016",467.6,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOTCMT","Million US$ at exchange rate","AUS","Australia","2017","2017",498.2,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOTCMT","Million US$ at exchange rate","AUS","Australia","2018","2018",472.9,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOTCMT","Million US$ at exchange rate","AUS","Australia","2019","2019",464.4,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOTCMT","Million US$ at exchange rate","AUS","Australia","2020","2020",511.3,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOTCMT","Million US$ at exchange rate","AUS","Australia","2021","2021",560.4,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOPPMT","Million US$, purchasing power parity","AUS","Australia","2010","2010",360.5,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOPPMT","Million US$, purchasing power parity","AUS","Australia","2011","2011",371.9,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOPPMT","Million US$, purchasing power parity","AUS","Australia","2012","2012",380.5,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOPPMT","Million US$, purchasing power parity","AUS","Australia","2013","2013",426.4,"B; D","Break; Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOPPMT","Million US$, purchasing power parity","AUS","Australia","2014","2014",436.5,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOPPMT","Million US$, purchasing power parity","AUS","Australia","2015","2015",419.4,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOPPMT","Million US$, purchasing power parity","AUS","Australia","2016","2016",433.7,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOPPMT","Million US$, purchasing power parity","AUS","Australia","2017","2017",439.9,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOPPMT","Million US$, purchasing power parity","AUS","Australia","2018","2018",430.5,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOPPMT","Million US$, purchasing power parity","AUS","Australia","2019","2019",451.4,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOPPMT","Million US$, purchasing power parity","AUS","Australia","2020","2020",511,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOPPMT","Million US$, purchasing power parity","AUS","Australia","2021","2021",515.3,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","TCPPERMT","/capita, US$ exchange rate","AUS","Australia","2010","2010",22.6,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","TCPPERMT","/capita, US$ exchange rate","AUS","Australia","2011","2011",25.9,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","TCPPERMT","/capita, US$ exchange rate","AUS","Australia","2012","2012",26.7,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","TCPPERMT","/capita, US$ exchange rate","AUS","Australia","2013","2013",25.8,"B; D","Break; Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","TCPPERMT","/capita, US$ exchange rate","AUS","Australia","2014","2014",24.3,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","TCPPERMT","/capita, US$ exchange rate","AUS","Australia","2015","2015",19.5,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","TCPPERMT","/capita, US$ exchange rate","AUS","Australia","2016","2016",19.3,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","TCPPERMT","/capita, US$ exchange rate","AUS","Australia","2017","2017",20.3,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","TCPPERMT","/capita, US$ exchange rate","AUS","Australia","2018","2018",18.9,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","TCPPERMT","/capita, US$ exchange rate","AUS","Australia","2019","2019",18.3,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","TCPPERMT","/capita, US$ exchange rate","AUS","Australia","2020","2020",19.9,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","TCPPERMT","/capita, US$ exchange rate","AUS","Australia","2021","2021",21.8,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2010","2010",16.4,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2011","2011",16.6,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2012","2012",16.7,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2013","2013",18.4,"B; D","Break; Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2014","2014",18.6,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2015","2015",17.6,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2016","2016",17.9,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2017","2017",17.9,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2018","2018",17.2,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2019","2019",17.8,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2020","2020",19.9,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2021","2021",20.1,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","ATCPTTMT","% of total sales","AUS","Australia","2010","2010",5.5,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","ATCPTTMT","% of total sales","AUS","Australia","2011","2011",5.5,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","ATCPTTMT","% of total sales","AUS","Australia","2012","2012",5.7,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","ATCPTTMT","% of total sales","AUS","Australia","2013","2013",5.2,"B; D","Break; Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","ATCPTTMT","% of total sales","AUS","Australia","2014","2014",5.3,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","ATCPTTMT","% of total sales","AUS","Australia","2015","2015",5,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","ATCPTTMT","% of total sales","AUS","Australia","2016","2016",4.1,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","ATCPTTMT","% of total sales","AUS","Australia","2017","2017",4.4,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","ATCPTTMT","% of total sales","AUS","Australia","2018","2018",4.2,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","ATCPTTMT","% of total sales","AUS","Australia","2019","2019",4.3,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","ATCPTTMT","% of total sales","AUS","Australia","2020","2020",4.5,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","ATCPTTMT","% of total sales","AUS","Australia","2021","2021",4.2,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MLLNCUMT","Million of national currency units","AUT","Austria","2010","2010",132.5,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MLLNCUMT","Million of national currency units","AUT","Austria","2011","2011",136.9,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MLLNCUMT","Million of national currency units","AUT","Austria","2012","2012",139.9,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MLLNCUMT","Million of national currency units","AUT","Austria","2013","2013",143.5,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MLLNCUMT","Million of national currency units","AUT","Austria","2014","2014",141.9,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MLLNCUMT","Million of national currency units","AUT","Austria","2015","2015",146.9,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MLLNCUMT","Million of national currency units","AUT","Austria","2016","2016",146.7,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MLLNCUMT","Million of national currency units","AUT","Austria","2017","2017",148.3,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MLLNCUMT","Million of national currency units","AUT","Austria","2018","2018",155.2,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MLLNCUMT","Million of national currency units","AUT","Austria","2019","2019",164.3,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MLLNCUMT","Million of national currency units","AUT","Austria","2020","2020",173.3,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MLLNCUMT","Million of national currency units","AUT","Austria","2021","2021",179,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOTCMT","Million US$ at exchange rate","AUT","Austria","2010","2010",175.7,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOTCMT","Million US$ at exchange rate","AUT","Austria","2011","2011",190.6,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOTCMT","Million US$ at exchange rate","AUT","Austria","2012","2012",179.7,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOTCMT","Million US$ at exchange rate","AUT","Austria","2013","2013",190.6,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOTCMT","Million US$ at exchange rate","AUT","Austria","2014","2014",188.5,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOTCMT","Million US$ at exchange rate","AUT","Austria","2015","2015",162.9,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOTCMT","Million US$ at exchange rate","AUT","Austria","2016","2016",162.3,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOTCMT","Million US$ at exchange rate","AUT","Austria","2017","2017",167.5,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOTCMT","Million US$ at exchange rate","AUT","Austria","2018","2018",183.3,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOTCMT","Million US$ at exchange rate","AUT","Austria","2019","2019",183.9,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOTCMT","Million US$ at exchange rate","AUT","Austria","2020","2020",198,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOTCMT","Million US$ at exchange rate","AUT","Austria","2021","2021",211.7,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOPPMT","Million US$, purchasing power parity","AUT","Austria","2010","2010",157.3,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOPPMT","Million US$, purchasing power parity","AUT","Austria","2011","2011",164.7,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOPPMT","Million US$, purchasing power parity","AUT","Austria","2012","2012",171.9,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOPPMT","Million US$, purchasing power parity","AUT","Austria","2013","2013",180.1,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOPPMT","Million US$, purchasing power parity","AUT","Austria","2014","2014",177.7,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOPPMT","Million US$, purchasing power parity","AUT","Austria","2015","2015",183.8,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOPPMT","Million US$, purchasing power parity","AUT","Austria","2016","2016",188.8,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOPPMT","Million US$, purchasing power parity","AUT","Austria","2017","2017",191.4,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOPPMT","Million US$, purchasing power parity","AUT","Austria","2018","2018",202.8,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOPPMT","Million US$, purchasing power parity","AUT","Austria","2019","2019",219.3,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOPPMT","Million US$, purchasing power parity","AUT","Austria","2020","2020",232.2,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOPPMT","Million US$, purchasing power parity","AUT","Austria","2021","2021",236.7,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","TCPPERMT","/capita, US$ exchange rate","AUT","Austria","2010","2010",21,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","TCPPERMT","/capita, US$ exchange rate","AUT","Austria","2011","2011",22.7,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","TCPPERMT","/capita, US$ exchange rate","AUT","Austria","2012","2012",21.3,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","TCPPERMT","/capita, US$ exchange rate","AUT","Austria","2013","2013",22.5,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","TCPPERMT","/capita, US$ exchange rate","AUT","Austria","2014","2014",22.1,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","TCPPERMT","/capita, US$ exchange rate","AUT","Austria","2015","2015",18.9,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","TCPPERMT","/capita, US$ exchange rate","AUT","Austria","2016","2016",18.6,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","TCPPERMT","/capita, US$ exchange rate","AUT","Austria","2017","2017",19,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","TCPPERMT","/capita, US$ exchange rate","AUT","Austria","2018","2018",20.7,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","TCPPERMT","/capita, US$ exchange rate","AUT","Austria","2019","2019",20.7,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","TCPPERMT","/capita, US$ exchange rate","AUT","Austria","2020","2020",22.2,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","TCPPERMT","/capita, US$ exchange rate","AUT","Austria","2021","2021",23.6,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2010","2010",18.8,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2011","2011",19.6,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2012","2012",20.4,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2013","2013",21.2,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2014","2014",20.8,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2015","2015",21.3,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2016","2016",21.6,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2017","2017",21.8,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2018","2018",22.9,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2019","2019",24.7,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2020","2020",26,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2021","2021",26.4,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","ATCPTTMT","% of total sales","AUT","Austria","2010","2010",5.3,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","ATCPTTMT","% of total sales","AUT","Austria","2011","2011",5.4,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","ATCPTTMT","% of total sales","AUT","Austria","2012","2012",5.4,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","ATCPTTMT","% of total sales","AUT","Austria","2013","2013",5.4,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","ATCPTTMT","% of total sales","AUT","Austria","2014","2014",5.1,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","ATCPTTMT","% of total sales","AUT","Austria","2015","2015",5,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","ATCPTTMT","% of total sales","AUT","Austria","2016","2016",4.9,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","ATCPTTMT","% of total sales","AUT","Austria","2017","2017",4.7,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","ATCPTTMT","% of total sales","AUT","Austria","2018","2018",4.8,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","ATCPTTMT","% of total sales","AUT","Austria","2019","2019",5,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","ATCPTTMT","% of total sales","AUT","Austria","2020","2020",5,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","ATCPTTMT","% of total sales","AUT","Austria","2021","2021",4.8,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MLLNCUMT","Million of national currency units","BEL","Belgium","2010","2010",250.5,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MLLNCUMT","Million of national currency units","BEL","Belgium","2011","2011",255.1,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MLLNCUMT","Million of national currency units","BEL","Belgium","2012","2012",253.7,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MLLNCUMT","Million of national currency units","BEL","Belgium","2013","2013",256.4,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MLLNCUMT","Million of national currency units","BEL","Belgium","2014","2014",250.7,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MLLNCUMT","Million of national currency units","BEL","Belgium","2015","2015",247.8,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MLLNCUMT","Million of national currency units","BEL","Belgium","2016","2016",243.6,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MLLNCUMT","Million of national currency units","BEL","Belgium","2017","2017",251.3,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MLLNCUMT","Million of national currency units","BEL","Belgium","2018","2018",261.9,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MLLNCUMT","Million of national currency units","BEL","Belgium","2019","2019",279.3,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MLLNCUMT","Million of national currency units","BEL","Belgium","2020","2020",275.2,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MLLNCUMT","Million of national currency units","BEL","Belgium","2021","2021",286.1,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MLLNCUMT","Million of national currency units","BEL","Belgium","2022","2022",309.3,"E","Estimated value"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOTCMT","Million US$ at exchange rate","BEL","Belgium","2010","2010",332.1,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOTCMT","Million US$ at exchange rate","BEL","Belgium","2011","2011",355.1,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOTCMT","Million US$ at exchange rate","BEL","Belgium","2012","2012",326,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOTCMT","Million US$ at exchange rate","BEL","Belgium","2013","2013",340.5,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOTCMT","Million US$ at exchange rate","BEL","Belgium","2014","2014",333.1,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOTCMT","Million US$ at exchange rate","BEL","Belgium","2015","2015",274.9,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOTCMT","Million US$ at exchange rate","BEL","Belgium","2016","2016",269.6,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOTCMT","Million US$ at exchange rate","BEL","Belgium","2017","2017",283.9,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOTCMT","Million US$ at exchange rate","BEL","Belgium","2018","2018",309.3,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOTCMT","Million US$ at exchange rate","BEL","Belgium","2019","2019",312.7,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOTCMT","Million US$ at exchange rate","BEL","Belgium","2020","2020",314.3,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOTCMT","Million US$ at exchange rate","BEL","Belgium","2021","2021",338.4,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOTCMT","Million US$ at exchange rate","BEL","Belgium","2022","2022",325.7,"E","Estimated value"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOPPMT","Million US$, purchasing power parity","BEL","Belgium","2010","2010",299.4,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOPPMT","Million US$, purchasing power parity","BEL","Belgium","2011","2011",306.7,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOPPMT","Million US$, purchasing power parity","BEL","Belgium","2012","2012",308.6,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOPPMT","Million US$, purchasing power parity","BEL","Belgium","2013","2013",318,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOPPMT","Million US$, purchasing power parity","BEL","Belgium","2014","2014",313.3,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOPPMT","Million US$, purchasing power parity","BEL","Belgium","2015","2015",309.7,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOPPMT","Million US$, purchasing power parity","BEL","Belgium","2016","2016",311.9,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOPPMT","Million US$, purchasing power parity","BEL","Belgium","2017","2017",324,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOPPMT","Million US$, purchasing power parity","BEL","Belgium","2018","2018",341.8,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOPPMT","Million US$, purchasing power parity","BEL","Belgium","2019","2019",374.1,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOPPMT","Million US$, purchasing power parity","BEL","Belgium","2020","2020",376.8,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOPPMT","Million US$, purchasing power parity","BEL","Belgium","2021","2021",388.4,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOPPMT","Million US$, purchasing power parity","BEL","Belgium","2022","2022",433.2,"E","Estimated value"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","TCPPERMT","/capita, US$ exchange rate","BEL","Belgium","2010","2010",30.5,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","TCPPERMT","/capita, US$ exchange rate","BEL","Belgium","2011","2011",32.2,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","TCPPERMT","/capita, US$ exchange rate","BEL","Belgium","2012","2012",29.4,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","TCPPERMT","/capita, US$ exchange rate","BEL","Belgium","2013","2013",30.5,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","TCPPERMT","/capita, US$ exchange rate","BEL","Belgium","2014","2014",29.7,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","TCPPERMT","/capita, US$ exchange rate","BEL","Belgium","2015","2015",24.4,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","TCPPERMT","/capita, US$ exchange rate","BEL","Belgium","2016","2016",23.8,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","TCPPERMT","/capita, US$ exchange rate","BEL","Belgium","2017","2017",25,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","TCPPERMT","/capita, US$ exchange rate","BEL","Belgium","2018","2018",27.1,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","TCPPERMT","/capita, US$ exchange rate","BEL","Belgium","2019","2019",27.2,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","TCPPERMT","/capita, US$ exchange rate","BEL","Belgium","2020","2020",27.2,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","TCPPERMT","/capita, US$ exchange rate","BEL","Belgium","2021","2021",29.2,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","TCPPERMT","/capita, US$ exchange rate","BEL","Belgium","2022","2022",28,"E","Estimated value"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2010","2010",27.5,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2011","2011",27.8,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2012","2012",27.8,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2013","2013",28.5,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2014","2014",28,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2015","2015",27.5,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2016","2016",27.5,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2017","2017",28.5,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2018","2018",29.9,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2019","2019",32.6,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2020","2020",32.7,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2021","2021",33.5,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2022","2022",37.3,"E","Estimated value"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","ATCPTTMT","% of total sales","BEL","Belgium","2010","2010",4.3,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","ATCPTTMT","% of total sales","BEL","Belgium","2011","2011",4.3,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","ATCPTTMT","% of total sales","BEL","Belgium","2012","2012",4.3,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","ATCPTTMT","% of total sales","BEL","Belgium","2013","2013",4.3,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","ATCPTTMT","% of total sales","BEL","Belgium","2014","2014",4.2,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","ATCPTTMT","% of total sales","BEL","Belgium","2015","2015",4,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","ATCPTTMT","% of total sales","BEL","Belgium","2016","2016",3.9,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","ATCPTTMT","% of total sales","BEL","Belgium","2017","2017",3.8,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","ATCPTTMT","% of total sales","BEL","Belgium","2018","2018",3.9,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","ATCPTTMT","% of total sales","BEL","Belgium","2019","2019",3.8,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","ATCPTTMT","% of total sales","BEL","Belgium","2020","2020",3.6,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","ATCPTTMT","% of total sales","BEL","Belgium","2021","2021",3.6,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","ATCPTTMT","% of total sales","BEL","Belgium","2022","2022",3.4,"E","Estimated value"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MLLNCUMT","Million of national currency units","CAN","Canada","2012","2012",1350.4,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MLLNCUMT","Million of national currency units","CAN","Canada","2013","2013",1399.8,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MLLNCUMT","Million of national currency units","CAN","Canada","2014","2014",1464,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MLLNCUMT","Million of national currency units","CAN","Canada","2015","2015",1498.6,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MLLNCUMT","Million of national currency units","CAN","Canada","2016","2016",1540,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MLLNCUMT","Million of national currency units","CAN","Canada","2017","2017",1593.4,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MLLNCUMT","Million of national currency units","CAN","Canada","2018","2018",1695,"E; B; D","Estimated value; Break; Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MLLNCUMT","Million of national currency units","CAN","Canada","2019","2019",1784.2,"E; D","Estimated value; Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MLLNCUMT","Million of national currency units","CAN","Canada","2020","2020",1926.8,"E; D","Estimated value; Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MLLNCUMT","Million of national currency units","CAN","Canada","2021","2021",1866.8,"E; D","Estimated value; Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MLLNCUMT","Million of national currency units","CAN","Canada","2022","2022",2060.8,"E; D","Estimated value; Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOTCMT","Million US$ at exchange rate","CAN","Canada","2012","2012",1351.3,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOTCMT","Million US$ at exchange rate","CAN","Canada","2013","2013",1358.8,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOTCMT","Million US$ at exchange rate","CAN","Canada","2014","2014",1325.2,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOTCMT","Million US$ at exchange rate","CAN","Canada","2015","2015",1171.9,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOTCMT","Million US$ at exchange rate","CAN","Canada","2016","2016",1161.7,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOTCMT","Million US$ at exchange rate","CAN","Canada","2017","2017",1227.6,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOTCMT","Million US$ at exchange rate","CAN","Canada","2018","2018",1308,"E; B; D","Estimated value; Break; Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOTCMT","Million US$ at exchange rate","CAN","Canada","2019","2019",1344.8,"E; D","Estimated value; Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOTCMT","Million US$ at exchange rate","CAN","Canada","2020","2020",1436.7,"E; D","Estimated value; Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOTCMT","Million US$ at exchange rate","CAN","Canada","2021","2021",1488.8,"E; D","Estimated value; Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOTCMT","Million US$ at exchange rate","CAN","Canada","2022","2022",1583.4,"E; D","Estimated value; Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOPPMT","Million US$, purchasing power parity","CAN","Canada","2012","2012",1085,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOPPMT","Million US$, purchasing power parity","CAN","Canada","2013","2013",1143.6,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOPPMT","Million US$, purchasing power parity","CAN","Canada","2014","2014",1189.9,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOPPMT","Million US$, purchasing power parity","CAN","Canada","2015","2015",1200.8,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOPPMT","Million US$, purchasing power parity","CAN","Canada","2016","2016",1275.8,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOPPMT","Million US$, purchasing power parity","CAN","Canada","2017","2017",1314.4,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOPPMT","Million US$, purchasing power parity","CAN","Canada","2018","2018",1404.8,"E; B; D","Estimated value; Break; Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOPPMT","Million US$, purchasing power parity","CAN","Canada","2019","2019",1445.1,"E; D","Estimated value; Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOPPMT","Million US$, purchasing power parity","CAN","Canada","2020","2020",1565.1,"E; D","Estimated value; Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOPPMT","Million US$, purchasing power parity","CAN","Canada","2021","2021",1507.7,"E; D","Estimated value; Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOPPMT","Million US$, purchasing power parity","CAN","Canada","2022","2022",1643.6,"E; D","Estimated value; Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","TCPPERMT","/capita, US$ exchange rate","CAN","Canada","2012","2012",38.9,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","TCPPERMT","/capita, US$ exchange rate","CAN","Canada","2013","2013",38.7,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","TCPPERMT","/capita, US$ exchange rate","CAN","Canada","2014","2014",37.4,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","TCPPERMT","/capita, US$ exchange rate","CAN","Canada","2015","2015",32.8,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","TCPPERMT","/capita, US$ exchange rate","CAN","Canada","2016","2016",32.2,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","TCPPERMT","/capita, US$ exchange rate","CAN","Canada","2017","2017",33.6,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","TCPPERMT","/capita, US$ exchange rate","CAN","Canada","2018","2018",35.3,"E; B; D","Estimated value; Break; Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","TCPPERMT","/capita, US$ exchange rate","CAN","Canada","2019","2019",35.8,"E; D","Estimated value; Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","TCPPERMT","/capita, US$ exchange rate","CAN","Canada","2020","2020",37.8,"E; D","Estimated value; Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","TCPPERMT","/capita, US$ exchange rate","CAN","Canada","2021","2021",38.9,"E; D","Estimated value; Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","TCPPERMT","/capita, US$ exchange rate","CAN","Canada","2022","2022",40.7,"E; D","Estimated value; Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2012","2012",31.3,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2013","2013",32.6,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2014","2014",33.6,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2015","2015",33.6,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2016","2016",35.3,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2017","2017",36,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2018","2018",37.9,"E; B; D","Estimated value; Break; Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2019","2019",38.4,"E; D","Estimated value; Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2020","2020",41.1,"E; D","Estimated value; Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2021","2021",39.4,"E; D","Estimated value; Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2022","2022",42.3,"E; D","Estimated value; Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","ATCPTTMT","% of total sales","CAN","Canada","2012","2012",5.6,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","ATCPTTMT","% of total sales","CAN","Canada","2013","2013",5.7,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","ATCPTTMT","% of total sales","CAN","Canada","2014","2014",5.7,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","ATCPTTMT","% of total sales","CAN","Canada","2015","2015",5.5,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","ATCPTTMT","% of total sales","CAN","Canada","2016","2016",5.4,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","ATCPTTMT","% of total sales","CAN","Canada","2017","2017",5.4,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","ATCPTTMT","% of total sales","CAN","Canada","2018","2018",5.5,"E; B; D","Estimated value; Break; Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","ATCPTTMT","% of total sales","CAN","Canada","2019","2019",5.6,"E; D","Estimated value; Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","ATCPTTMT","% of total sales","CAN","Canada","2020","2020",5.6,"E; D","Estimated value; Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","ATCPTTMT","% of total sales","CAN","Canada","2021","2021",5.1,"E; D","Estimated value; Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","ATCPTTMT","% of total sales","CAN","Canada","2022","2022",5.2,"E; D","Estimated value; Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MLLNCUMT","Million of national currency units","CZE","Czech Republic","2010","2010",3200.3,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MLLNCUMT","Million of national currency units","CZE","Czech Republic","2011","2011",3155.2,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MLLNCUMT","Million of national currency units","CZE","Czech Republic","2012","2012",3344.8,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MLLNCUMT","Million of national currency units","CZE","Czech Republic","2013","2013",3073.7,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MLLNCUMT","Million of national currency units","CZE","Czech Republic","2014","2014",3286.9,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MLLNCUMT","Million of national currency units","CZE","Czech Republic","2015","2015",3432,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MLLNCUMT","Million of national currency units","CZE","Czech Republic","2016","2016",3470.3,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MLLNCUMT","Million of national currency units","CZE","Czech Republic","2017","2017",3722.1,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MLLNCUMT","Million of national currency units","CZE","Czech Republic","2018","2018",3754.7,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MLLNCUMT","Million of national currency units","CZE","Czech Republic","2019","2019",3906.5,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MLLNCUMT","Million of national currency units","CZE","Czech Republic","2020","2020",3877.4,"B","Break"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MLLNCUMT","Million of national currency units","CZE","Czech Republic","2021","2021",3971.2,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOTCMT","Million US$ at exchange rate","CZE","Czech Republic","2010","2010",167.6,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOTCMT","Million US$ at exchange rate","CZE","Czech Republic","2011","2011",178.3,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOTCMT","Million US$ at exchange rate","CZE","Czech Republic","2012","2012",170.8,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOTCMT","Million US$ at exchange rate","CZE","Czech Republic","2013","2013",157.1,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOTCMT","Million US$ at exchange rate","CZE","Czech Republic","2014","2014",158.3,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOTCMT","Million US$ at exchange rate","CZE","Czech Republic","2015","2015",139.5,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOTCMT","Million US$ at exchange rate","CZE","Czech Republic","2016","2016",142,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOTCMT","Million US$ at exchange rate","CZE","Czech Republic","2017","2017",159.2,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOTCMT","Million US$ at exchange rate","CZE","Czech Republic","2018","2018",172.8,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOTCMT","Million US$ at exchange rate","CZE","Czech Republic","2019","2019",170.4,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOTCMT","Million US$ at exchange rate","CZE","Czech Republic","2020","2020",167.1,"B","Break"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOTCMT","Million US$ at exchange rate","CZE","Czech Republic","2021","2021",183.2,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOPPMT","Million US$, purchasing power parity","CZE","Czech Republic","2010","2010",234.1,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOPPMT","Million US$, purchasing power parity","CZE","Czech Republic","2011","2011",236.4,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOPPMT","Million US$, purchasing power parity","CZE","Czech Republic","2012","2012",251.5,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOPPMT","Million US$, purchasing power parity","CZE","Czech Republic","2013","2013",240.4,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOPPMT","Million US$, purchasing power parity","CZE","Czech Republic","2014","2014",258.7,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOPPMT","Million US$, purchasing power parity","CZE","Czech Republic","2015","2015",265.3,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOPPMT","Million US$, purchasing power parity","CZE","Czech Republic","2016","2016",275.9,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOPPMT","Million US$, purchasing power parity","CZE","Czech Republic","2017","2017",299.6,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOPPMT","Million US$, purchasing power parity","CZE","Czech Republic","2018","2018",303.5,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOPPMT","Million US$, purchasing power parity","CZE","Czech Republic","2019","2019",318.3,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOPPMT","Million US$, purchasing power parity","CZE","Czech Republic","2020","2020",311.2,"B","Break"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOPPMT","Million US$, purchasing power parity","CZE","Czech Republic","2021","2021",311.6,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","TCPPERMT","/capita, US$ exchange rate","CZE","Czech Republic","2010","2010",16,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","TCPPERMT","/capita, US$ exchange rate","CZE","Czech Republic","2011","2011",17,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","TCPPERMT","/capita, US$ exchange rate","CZE","Czech Republic","2012","2012",16.3,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","TCPPERMT","/capita, US$ exchange rate","CZE","Czech Republic","2013","2013",14.9,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","TCPPERMT","/capita, US$ exchange rate","CZE","Czech Republic","2014","2014",15,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","TCPPERMT","/capita, US$ exchange rate","CZE","Czech Republic","2015","2015",13.2,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","TCPPERMT","/capita, US$ exchange rate","CZE","Czech Republic","2016","2016",13.4,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","TCPPERMT","/capita, US$ exchange rate","CZE","Czech Republic","2017","2017",15,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","TCPPERMT","/capita, US$ exchange rate","CZE","Czech Republic","2018","2018",16.3,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","TCPPERMT","/capita, US$ exchange rate","CZE","Czech Republic","2019","2019",16,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","TCPPERMT","/capita, US$ exchange rate","CZE","Czech Republic","2020","2020",15.6,"B","Break"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","TCPPERMT","/capita, US$ exchange rate","CZE","Czech Republic","2021","2021",17.4,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czech Republic","2010","2010",22.3,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czech Republic","2011","2011",22.5,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czech Republic","2012","2012",23.9,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czech Republic","2013","2013",22.9,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czech Republic","2014","2014",24.6,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czech Republic","2015","2015",25.2,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czech Republic","2016","2016",26.1,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czech Republic","2017","2017",28.3,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czech Republic","2018","2018",28.6,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czech Republic","2019","2019",29.8,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czech Republic","2020","2020",29.1,"B","Break"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czech Republic","2021","2021",29.7,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","ATCPTTMT","% of total sales","CZE","Czech Republic","2010","2010",3.9,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","ATCPTTMT","% of total sales","CZE","Czech Republic","2011","2011",3.9,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","ATCPTTMT","% of total sales","CZE","Czech Republic","2012","2012",4,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","ATCPTTMT","% of total sales","CZE","Czech Republic","2013","2013",3.9,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","ATCPTTMT","% of total sales","CZE","Czech Republic","2014","2014",4.1,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","ATCPTTMT","% of total sales","CZE","Czech Republic","2015","2015",4.1,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","ATCPTTMT","% of total sales","CZE","Czech Republic","2016","2016",4,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","ATCPTTMT","% of total sales","CZE","Czech Republic","2017","2017",4,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","ATCPTTMT","% of total sales","CZE","Czech Republic","2018","2018",3.8,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","ATCPTTMT","% of total sales","CZE","Czech Republic","2019","2019",3.8,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","ATCPTTMT","% of total sales","CZE","Czech Republic","2020","2020",4.4,"B","Break"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","ATCPTTMT","% of total sales","CZE","Czech Republic","2021","2021",4.3,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MLLNCUMT","Million of national currency units","FIN","Finland","2010","2010",95.5,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MLLNCUMT","Million of national currency units","FIN","Finland","2011","2011",93.8,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MLLNCUMT","Million of national currency units","FIN","Finland","2012","2012",95.9,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MLLNCUMT","Million of national currency units","FIN","Finland","2013","2013",92.4,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MLLNCUMT","Million of national currency units","FIN","Finland","2014","2014",90.9,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MLLNCUMT","Million of national currency units","FIN","Finland","2015","2015",87.5,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MLLNCUMT","Million of national currency units","FIN","Finland","2016","2016",90.5,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MLLNCUMT","Million of national currency units","FIN","Finland","2017","2017",92.4,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MLLNCUMT","Million of national currency units","FIN","Finland","2018","2018",93.6,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MLLNCUMT","Million of national currency units","FIN","Finland","2019","2019",91,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MLLNCUMT","Million of national currency units","FIN","Finland","2020","2020",93.8,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MLLNCUMT","Million of national currency units","FIN","Finland","2021","2021",90.3,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOTCMT","Million US$ at exchange rate","FIN","Finland","2010","2010",126.6,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOTCMT","Million US$ at exchange rate","FIN","Finland","2011","2011",130.6,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOTCMT","Million US$ at exchange rate","FIN","Finland","2012","2012",123.2,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOTCMT","Million US$ at exchange rate","FIN","Finland","2013","2013",122.7,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOTCMT","Million US$ at exchange rate","FIN","Finland","2014","2014",120.8,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOTCMT","Million US$ at exchange rate","FIN","Finland","2015","2015",97.1,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOTCMT","Million US$ at exchange rate","FIN","Finland","2016","2016",100.2,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOTCMT","Million US$ at exchange rate","FIN","Finland","2017","2017",104.4,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOTCMT","Million US$ at exchange rate","FIN","Finland","2018","2018",110.5,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOTCMT","Million US$ at exchange rate","FIN","Finland","2019","2019",101.9,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOTCMT","Million US$ at exchange rate","FIN","Finland","2020","2020",107.1,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOTCMT","Million US$ at exchange rate","FIN","Finland","2021","2021",106.8,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOPPMT","Million US$, purchasing power parity","FIN","Finland","2010","2010",106,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOPPMT","Million US$, purchasing power parity","FIN","Finland","2011","2011",104.4,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOPPMT","Million US$, purchasing power parity","FIN","Finland","2012","2012",105.6,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOPPMT","Million US$, purchasing power parity","FIN","Finland","2013","2013",102.1,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOPPMT","Million US$, purchasing power parity","FIN","Finland","2014","2014",100.2,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOPPMT","Million US$, purchasing power parity","FIN","Finland","2015","2015",96.4,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOPPMT","Million US$, purchasing power parity","FIN","Finland","2016","2016",102.7,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOPPMT","Million US$, purchasing power parity","FIN","Finland","2017","2017",107,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOPPMT","Million US$, purchasing power parity","FIN","Finland","2018","2018",109.6,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOPPMT","Million US$, purchasing power parity","FIN","Finland","2019","2019",108.5,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOPPMT","Million US$, purchasing power parity","FIN","Finland","2020","2020",114,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOPPMT","Million US$, purchasing power parity","FIN","Finland","2021","2021",109.2,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","TCPPERMT","/capita, US$ exchange rate","FIN","Finland","2010","2010",23.6,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","TCPPERMT","/capita, US$ exchange rate","FIN","Finland","2011","2011",24.2,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","TCPPERMT","/capita, US$ exchange rate","FIN","Finland","2012","2012",22.8,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","TCPPERMT","/capita, US$ exchange rate","FIN","Finland","2013","2013",22.6,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","TCPPERMT","/capita, US$ exchange rate","FIN","Finland","2014","2014",22.1,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","TCPPERMT","/capita, US$ exchange rate","FIN","Finland","2015","2015",17.7,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","TCPPERMT","/capita, US$ exchange rate","FIN","Finland","2016","2016",18.2,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","TCPPERMT","/capita, US$ exchange rate","FIN","Finland","2017","2017",19,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","TCPPERMT","/capita, US$ exchange rate","FIN","Finland","2018","2018",20,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","TCPPERMT","/capita, US$ exchange rate","FIN","Finland","2019","2019",18.4,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","TCPPERMT","/capita, US$ exchange rate","FIN","Finland","2020","2020",19.4,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","TCPPERMT","/capita, US$ exchange rate","FIN","Finland","2021","2021",19.3,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2010","2010",19.8,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2011","2011",19.4,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2012","2012",19.5,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2013","2013",18.8,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2014","2014",18.3,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2015","2015",17.6,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2016","2016",18.7,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2017","2017",19.4,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2018","2018",19.9,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2019","2019",19.7,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2020","2020",20.6,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2021","2021",19.7,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","ATCPTTMT","% of total sales","FIN","Finland","2010","2010",5.1,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","ATCPTTMT","% of total sales","FIN","Finland","2011","2011",4.9,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","ATCPTTMT","% of total sales","FIN","Finland","2012","2012",4.9,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","ATCPTTMT","% of total sales","FIN","Finland","2013","2013",4.6,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","ATCPTTMT","% of total sales","FIN","Finland","2014","2014",4.3,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","ATCPTTMT","% of total sales","FIN","Finland","2015","2015",4,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","ATCPTTMT","% of total sales","FIN","Finland","2016","2016",4,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","ATCPTTMT","% of total sales","FIN","Finland","2017","2017",4,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","ATCPTTMT","% of total sales","FIN","Finland","2018","2018",3.7,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","ATCPTTMT","% of total sales","FIN","Finland","2019","2019",3.4,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","ATCPTTMT","% of total sales","FIN","Finland","2020","2020",3.5,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","ATCPTTMT","% of total sales","FIN","Finland","2021","2021",3.2,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MLLNCUMT","Million of national currency units","DEU","Germany","2010","2010",1723,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MLLNCUMT","Million of national currency units","DEU","Germany","2011","2011",1670.5,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MLLNCUMT","Million of national currency units","DEU","Germany","2012","2012",1625.7,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MLLNCUMT","Million of national currency units","DEU","Germany","2013","2013",1687.6,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MLLNCUMT","Million of national currency units","DEU","Germany","2014","2014",1708.8,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MLLNCUMT","Million of national currency units","DEU","Germany","2015","2015",1697.3,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MLLNCUMT","Million of national currency units","DEU","Germany","2016","2016",1743.1,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MLLNCUMT","Million of national currency units","DEU","Germany","2017","2017",1776.3,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MLLNCUMT","Million of national currency units","DEU","Germany","2018","2018",1903.7,"B; D","Break; Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MLLNCUMT","Million of national currency units","DEU","Germany","2019","2019",2018.7,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MLLNCUMT","Million of national currency units","DEU","Germany","2020","2020",2103.3,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MLLNCUMT","Million of national currency units","DEU","Germany","2021","2021",2181.3,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOTCMT","Million US$ at exchange rate","DEU","Germany","2010","2010",2284.2,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOTCMT","Million US$ at exchange rate","DEU","Germany","2011","2011",2325.3,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOTCMT","Million US$ at exchange rate","DEU","Germany","2012","2012",2088.7,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOTCMT","Million US$ at exchange rate","DEU","Germany","2013","2013",2241.3,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOTCMT","Million US$ at exchange rate","DEU","Germany","2014","2014",2270.1,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOTCMT","Million US$ at exchange rate","DEU","Germany","2015","2015",1883.2,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOTCMT","Million US$ at exchange rate","DEU","Germany","2016","2016",1929.4,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOTCMT","Million US$ at exchange rate","DEU","Germany","2017","2017",2006.7,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOTCMT","Million US$ at exchange rate","DEU","Germany","2018","2018",2248.2,"B; D","Break; Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOTCMT","Million US$ at exchange rate","DEU","Germany","2019","2019",2259.9,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOTCMT","Million US$ at exchange rate","DEU","Germany","2020","2020",2402.4,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOTCMT","Million US$ at exchange rate","DEU","Germany","2021","2021",2579.9,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOPPMT","Million US$, purchasing power parity","DEU","Germany","2010","2010",2140.2,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOPPMT","Million US$, purchasing power parity","DEU","Germany","2011","2011",2117.9,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOPPMT","Million US$, purchasing power parity","DEU","Germany","2012","2012",2065,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOPPMT","Million US$, purchasing power parity","DEU","Germany","2013","2013",2178.2,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOPPMT","Million US$, purchasing power parity","DEU","Germany","2014","2014",2222.3,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOPPMT","Million US$, purchasing power parity","DEU","Germany","2015","2015",2181.3,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOPPMT","Million US$, purchasing power parity","DEU","Germany","2016","2016",2316.1,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOPPMT","Million US$, purchasing power parity","DEU","Germany","2017","2017",2385,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOPPMT","Million US$, purchasing power parity","DEU","Germany","2018","2018",2588.5,"B; D","Break; Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOPPMT","Million US$, purchasing power parity","DEU","Germany","2019","2019",2772,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOPPMT","Million US$, purchasing power parity","DEU","Germany","2020","2020",2901.1,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOPPMT","Million US$, purchasing power parity","DEU","Germany","2021","2021",2962.6,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","TCPPERMT","/capita, US$ exchange rate","DEU","Germany","2010","2010",27.9,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","TCPPERMT","/capita, US$ exchange rate","DEU","Germany","2011","2011",29,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","TCPPERMT","/capita, US$ exchange rate","DEU","Germany","2012","2012",26,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","TCPPERMT","/capita, US$ exchange rate","DEU","Germany","2013","2013",27.8,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","TCPPERMT","/capita, US$ exchange rate","DEU","Germany","2014","2014",28,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","TCPPERMT","/capita, US$ exchange rate","DEU","Germany","2015","2015",23.1,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","TCPPERMT","/capita, US$ exchange rate","DEU","Germany","2016","2016",23.4,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","TCPPERMT","/capita, US$ exchange rate","DEU","Germany","2017","2017",24.3,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","TCPPERMT","/capita, US$ exchange rate","DEU","Germany","2018","2018",27.1,"B; D","Break; Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","TCPPERMT","/capita, US$ exchange rate","DEU","Germany","2019","2019",27.2,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","TCPPERMT","/capita, US$ exchange rate","DEU","Germany","2020","2020",28.9,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","TCPPERMT","/capita, US$ exchange rate","DEU","Germany","2021","2021",31,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2010","2010",26.2,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2011","2011",26.4,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2012","2012",25.7,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2013","2013",27,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2014","2014",27.4,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2015","2015",26.7,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2016","2016",28.1,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2017","2017",28.9,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2018","2018",31.2,"B; D","Break; Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2019","2019",33.4,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2020","2020",34.9,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2021","2021",35.6,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","ATCPTTMT","% of total sales","DEU","Germany","2010","2010",5.8,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","ATCPTTMT","% of total sales","DEU","Germany","2011","2011",5.6,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","ATCPTTMT","% of total sales","DEU","Germany","2012","2012",5.3,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","ATCPTTMT","% of total sales","DEU","Germany","2013","2013",5.4,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","ATCPTTMT","% of total sales","DEU","Germany","2014","2014",5.1,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","ATCPTTMT","% of total sales","DEU","Germany","2015","2015",4.8,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","ATCPTTMT","% of total sales","DEU","Germany","2016","2016",4.8,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","ATCPTTMT","% of total sales","DEU","Germany","2017","2017",4.8,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","ATCPTTMT","% of total sales","DEU","Germany","2018","2018",4.3,"B; D","Break; Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","ATCPTTMT","% of total sales","DEU","Germany","2019","2019",4.3,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","ATCPTTMT","% of total sales","DEU","Germany","2020","2020",4.3,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","ATCPTTMT","% of total sales","DEU","Germany","2021","2021",4.1,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MLLNCUMT","Million of national currency units","GRC","Greece","2010","2010",322.2,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MLLNCUMT","Million of national currency units","GRC","Greece","2011","2011",315,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MLLNCUMT","Million of national currency units","GRC","Greece","2012","2012",277.8,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MLLNCUMT","Million of national currency units","GRC","Greece","2013","2013",247.3,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MLLNCUMT","Million of national currency units","GRC","Greece","2014","2014",247.3,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MLLNCUMT","Million of national currency units","GRC","Greece","2015","2015",211.5,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MLLNCUMT","Million of national currency units","GRC","Greece","2016","2016",260.3,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MLLNCUMT","Million of national currency units","GRC","Greece","2017","2017",267.2,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MLLNCUMT","Million of national currency units","GRC","Greece","2018","2018",279.6,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MLLNCUMT","Million of national currency units","GRC","Greece","2019","2019",284.9,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MLLNCUMT","Million of national currency units","GRC","Greece","2020","2020",295.1,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MLLNCUMT","Million of national currency units","GRC","Greece","2021","2021",298.6,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MLLNCUMT","Million of national currency units","GRC","Greece","2022","2022",282.2,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOTCMT","Million US$ at exchange rate","GRC","Greece","2010","2010",427.1,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOTCMT","Million US$ at exchange rate","GRC","Greece","2011","2011",438.4,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOTCMT","Million US$ at exchange rate","GRC","Greece","2012","2012",356.9,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOTCMT","Million US$ at exchange rate","GRC","Greece","2013","2013",328.4,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOTCMT","Million US$ at exchange rate","GRC","Greece","2014","2014",328.5,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOTCMT","Million US$ at exchange rate","GRC","Greece","2015","2015",234.7,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOTCMT","Million US$ at exchange rate","GRC","Greece","2016","2016",288.1,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOTCMT","Million US$ at exchange rate","GRC","Greece","2017","2017",301.8,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOTCMT","Million US$ at exchange rate","GRC","Greece","2018","2018",330.2,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOTCMT","Million US$ at exchange rate","GRC","Greece","2019","2019",318.9,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOTCMT","Million US$ at exchange rate","GRC","Greece","2020","2020",337.1,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOTCMT","Million US$ at exchange rate","GRC","Greece","2021","2021",353.1,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOTCMT","Million US$ at exchange rate","GRC","Greece","2022","2022",297.2,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOPPMT","Million US$, purchasing power parity","GRC","Greece","2010","2010",446.2,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOPPMT","Million US$, purchasing power parity","GRC","Greece","2011","2011",441.7,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOPPMT","Million US$, purchasing power parity","GRC","Greece","2012","2012",405.7,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOPPMT","Million US$, purchasing power parity","GRC","Greece","2013","2013",391.7,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOPPMT","Million US$, purchasing power parity","GRC","Greece","2014","2014",404.6,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOPPMT","Million US$, purchasing power parity","GRC","Greece","2015","2015",347.3,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOPPMT","Million US$, purchasing power parity","GRC","Greece","2016","2016",442.2,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOPPMT","Million US$, purchasing power parity","GRC","Greece","2017","2017",464.6,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOPPMT","Million US$, purchasing power parity","GRC","Greece","2018","2018",495,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOPPMT","Million US$, purchasing power parity","GRC","Greece","2019","2019",519,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOPPMT","Million US$, purchasing power parity","GRC","Greece","2020","2020",542.5,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOPPMT","Million US$, purchasing power parity","GRC","Greece","2021","2021",547.3,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOPPMT","Million US$, purchasing power parity","GRC","Greece","2022","2022",534,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","TCPPERMT","/capita, US$ exchange rate","GRC","Greece","2010","2010",38.4,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","TCPPERMT","/capita, US$ exchange rate","GRC","Greece","2011","2011",39.5,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","TCPPERMT","/capita, US$ exchange rate","GRC","Greece","2012","2012",32.3,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","TCPPERMT","/capita, US$ exchange rate","GRC","Greece","2013","2013",29.9,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","TCPPERMT","/capita, US$ exchange rate","GRC","Greece","2014","2014",30.2,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","TCPPERMT","/capita, US$ exchange rate","GRC","Greece","2015","2015",21.7,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","TCPPERMT","/capita, US$ exchange rate","GRC","Greece","2016","2016",26.7,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","TCPPERMT","/capita, US$ exchange rate","GRC","Greece","2017","2017",28.1,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","TCPPERMT","/capita, US$ exchange rate","GRC","Greece","2018","2018",30.8,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","TCPPERMT","/capita, US$ exchange rate","GRC","Greece","2019","2019",29.7,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","TCPPERMT","/capita, US$ exchange rate","GRC","Greece","2020","2020",31.5,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","TCPPERMT","/capita, US$ exchange rate","GRC","Greece","2021","2021",33.4,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","TCPPERMT","/capita, US$ exchange rate","GRC","Greece","2022","2022",28.4,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2010","2010",40.1,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2011","2011",39.8,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2012","2012",36.7,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2013","2013",35.7,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2014","2014",37.1,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2015","2015",32.1,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2016","2016",41,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2017","2017",43.2,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2018","2018",46.1,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2019","2019",48.4,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2020","2020",50.7,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2021","2021",51.8,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2022","2022",51.1,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MLLNCUMT","Million of national currency units","HUN","Hungary","2010","2010",27620.8,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MLLNCUMT","Million of national currency units","HUN","Hungary","2011","2011",29340.5,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MLLNCUMT","Million of national currency units","HUN","Hungary","2012","2012",28440.2,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MLLNCUMT","Million of national currency units","HUN","Hungary","2013","2013",29536.7,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MLLNCUMT","Million of national currency units","HUN","Hungary","2014","2014",29679.1,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MLLNCUMT","Million of national currency units","HUN","Hungary","2015","2015",28986.7,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MLLNCUMT","Million of national currency units","HUN","Hungary","2016","2016",29620.8,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MLLNCUMT","Million of national currency units","HUN","Hungary","2017","2017",29875.7,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MLLNCUMT","Million of national currency units","HUN","Hungary","2018","2018",30450.4,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MLLNCUMT","Million of national currency units","HUN","Hungary","2019","2019",31314.2,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MLLNCUMT","Million of national currency units","HUN","Hungary","2020","2020",33090.3,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MLLNCUMT","Million of national currency units","HUN","Hungary","2021","2021",31572.3,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MLLNCUMT","Million of national currency units","HUN","Hungary","2022","2022",32216.4,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOTCMT","Million US$ at exchange rate","HUN","Hungary","2010","2010",132.8,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOTCMT","Million US$ at exchange rate","HUN","Hungary","2011","2011",145.9,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOTCMT","Million US$ at exchange rate","HUN","Hungary","2012","2012",126.3,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOTCMT","Million US$ at exchange rate","HUN","Hungary","2013","2013",132,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOTCMT","Million US$ at exchange rate","HUN","Hungary","2014","2014",127.6,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOTCMT","Million US$ at exchange rate","HUN","Hungary","2015","2015",103.8,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOTCMT","Million US$ at exchange rate","HUN","Hungary","2016","2016",105.2,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOTCMT","Million US$ at exchange rate","HUN","Hungary","2017","2017",108.9,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOTCMT","Million US$ at exchange rate","HUN","Hungary","2018","2018",112.7,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOTCMT","Million US$ at exchange rate","HUN","Hungary","2019","2019",107.7,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOTCMT","Million US$ at exchange rate","HUN","Hungary","2020","2020",107.4,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOTCMT","Million US$ at exchange rate","HUN","Hungary","2021","2021",104.2,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOTCMT","Million US$ at exchange rate","HUN","Hungary","2022","2022",86.5,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOPPMT","Million US$, purchasing power parity","HUN","Hungary","2010","2010",218.5,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOPPMT","Million US$, purchasing power parity","HUN","Hungary","2011","2011",236.1,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOPPMT","Million US$, purchasing power parity","HUN","Hungary","2012","2012",226.4,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOPPMT","Million US$, purchasing power parity","HUN","Hungary","2013","2013",236.3,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOPPMT","Million US$, purchasing power parity","HUN","Hungary","2014","2014",229.3,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOPPMT","Million US$, purchasing power parity","HUN","Hungary","2015","2015",218.7,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOPPMT","Million US$, purchasing power parity","HUN","Hungary","2016","2016",224.3,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOPPMT","Million US$, purchasing power parity","HUN","Hungary","2017","2017",219.6,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOPPMT","Million US$, purchasing power parity","HUN","Hungary","2018","2018",218.9,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOPPMT","Million US$, purchasing power parity","HUN","Hungary","2019","2019",222.4,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOPPMT","Million US$, purchasing power parity","HUN","Hungary","2020","2020",227.7,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOPPMT","Million US$, purchasing power parity","HUN","Hungary","2021","2021",204,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOPPMT","Million US$, purchasing power parity","HUN","Hungary","2022","2022",199.8,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","TCPPERMT","/capita, US$ exchange rate","HUN","Hungary","2010","2010",13.3,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","TCPPERMT","/capita, US$ exchange rate","HUN","Hungary","2011","2011",14.6,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","TCPPERMT","/capita, US$ exchange rate","HUN","Hungary","2012","2012",12.7,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","TCPPERMT","/capita, US$ exchange rate","HUN","Hungary","2013","2013",13.3,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","TCPPERMT","/capita, US$ exchange rate","HUN","Hungary","2014","2014",12.9,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","TCPPERMT","/capita, US$ exchange rate","HUN","Hungary","2015","2015",10.5,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","TCPPERMT","/capita, US$ exchange rate","HUN","Hungary","2016","2016",10.7,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","TCPPERMT","/capita, US$ exchange rate","HUN","Hungary","2017","2017",11.1,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","TCPPERMT","/capita, US$ exchange rate","HUN","Hungary","2018","2018",11.5,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","TCPPERMT","/capita, US$ exchange rate","HUN","Hungary","2019","2019",11,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","TCPPERMT","/capita, US$ exchange rate","HUN","Hungary","2020","2020",11,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","TCPPERMT","/capita, US$ exchange rate","HUN","Hungary","2021","2021",10.7,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","TCPPERMT","/capita, US$ exchange rate","HUN","Hungary","2022","2022",8.9,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2010","2010",21.8,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2011","2011",23.7,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2012","2012",22.8,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2013","2013",23.9,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2014","2014",23.2,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2015","2015",22.2,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2016","2016",22.9,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2017","2017",22.4,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2018","2018",22.4,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2019","2019",22.8,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2020","2020",23.3,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2021","2021",21,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2022","2022",20.6,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","ATCPTTMT","% of total sales","HUN","Hungary","2010","2010",5.5,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","ATCPTTMT","% of total sales","HUN","Hungary","2011","2011",5.7,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","ATCPTTMT","% of total sales","HUN","Hungary","2012","2012",6.4,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","ATCPTTMT","% of total sales","HUN","Hungary","2013","2013",6.9,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","ATCPTTMT","% of total sales","HUN","Hungary","2014","2014",6.7,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","ATCPTTMT","% of total sales","HUN","Hungary","2015","2015",6.2,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","ATCPTTMT","% of total sales","HUN","Hungary","2016","2016",5.9,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","ATCPTTMT","% of total sales","HUN","Hungary","2017","2017",6.1,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","ATCPTTMT","% of total sales","HUN","Hungary","2018","2018",6.1,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","ATCPTTMT","% of total sales","HUN","Hungary","2019","2019",5.9,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","ATCPTTMT","% of total sales","HUN","Hungary","2020","2020",5.9,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","ATCPTTMT","% of total sales","HUN","Hungary","2021","2021",5.6,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","ATCPTTMT","% of total sales","HUN","Hungary","2022","2022",5.4,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MLLNCUMT","Million of national currency units","ISL","Iceland","2010","2010",1114.5,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MLLNCUMT","Million of national currency units","ISL","Iceland","2011","2011",1180.2,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MLLNCUMT","Million of national currency units","ISL","Iceland","2012","2012",1196.5,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MLLNCUMT","Million of national currency units","ISL","Iceland","2013","2013",1215.5,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MLLNCUMT","Million of national currency units","ISL","Iceland","2014","2014",1164.2,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MLLNCUMT","Million of national currency units","ISL","Iceland","2015","2015",1085.7,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MLLNCUMT","Million of national currency units","ISL","Iceland","2016","2016",1141.2,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MLLNCUMT","Million of national currency units","ISL","Iceland","2017","2017",1136.8,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MLLNCUMT","Million of national currency units","ISL","Iceland","2018","2018",1285.3,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MLLNCUMT","Million of national currency units","ISL","Iceland","2019","2019",1458.7,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MLLNCUMT","Million of national currency units","ISL","Iceland","2020","2020",1710.2,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MLLNCUMT","Million of national currency units","ISL","Iceland","2021","2021",1809.2,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOTCMT","Million US$ at exchange rate","ISL","Iceland","2010","2010",9.1,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOTCMT","Million US$ at exchange rate","ISL","Iceland","2011","2011",10.2,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOTCMT","Million US$ at exchange rate","ISL","Iceland","2012","2012",9.6,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOTCMT","Million US$ at exchange rate","ISL","Iceland","2013","2013",9.9,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOTCMT","Million US$ at exchange rate","ISL","Iceland","2014","2014",10,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOTCMT","Million US$ at exchange rate","ISL","Iceland","2015","2015",8.2,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOTCMT","Million US$ at exchange rate","ISL","Iceland","2016","2016",9.4,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOTCMT","Million US$ at exchange rate","ISL","Iceland","2017","2017",10.6,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOTCMT","Million US$ at exchange rate","ISL","Iceland","2018","2018",11.9,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOTCMT","Million US$ at exchange rate","ISL","Iceland","2019","2019",11.9,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOTCMT","Million US$ at exchange rate","ISL","Iceland","2020","2020",12.6,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOTCMT","Million US$ at exchange rate","ISL","Iceland","2021","2021",14.2,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOPPMT","Million US$, purchasing power parity","ISL","Iceland","2010","2010",8.4,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOPPMT","Million US$, purchasing power parity","ISL","Iceland","2011","2011",8.7,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOPPMT","Million US$, purchasing power parity","ISL","Iceland","2012","2012",8.7,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOPPMT","Million US$, purchasing power parity","ISL","Iceland","2013","2013",8.9,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOPPMT","Million US$, purchasing power parity","ISL","Iceland","2014","2014",8.4,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOPPMT","Million US$, purchasing power parity","ISL","Iceland","2015","2015",7.6,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOPPMT","Million US$, purchasing power parity","ISL","Iceland","2016","2016",8.1,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOPPMT","Million US$, purchasing power parity","ISL","Iceland","2017","2017",8.2,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOPPMT","Million US$, purchasing power parity","ISL","Iceland","2018","2018",9.1,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOPPMT","Million US$, purchasing power parity","ISL","Iceland","2019","2019",10.4,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOPPMT","Million US$, purchasing power parity","ISL","Iceland","2020","2020",11.7,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOPPMT","Million US$, purchasing power parity","ISL","Iceland","2021","2021",12.1,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","TCPPERMT","/capita, US$ exchange rate","ISL","Iceland","2010","2010",28.7,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","TCPPERMT","/capita, US$ exchange rate","ISL","Iceland","2011","2011",31.9,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","TCPPERMT","/capita, US$ exchange rate","ISL","Iceland","2012","2012",29.8,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","TCPPERMT","/capita, US$ exchange rate","ISL","Iceland","2013","2013",30.7,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","TCPPERMT","/capita, US$ exchange rate","ISL","Iceland","2014","2014",30.5,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","TCPPERMT","/capita, US$ exchange rate","ISL","Iceland","2015","2015",24.9,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","TCPPERMT","/capita, US$ exchange rate","ISL","Iceland","2016","2016",28.2,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","TCPPERMT","/capita, US$ exchange rate","ISL","Iceland","2017","2017",31,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","TCPPERMT","/capita, US$ exchange rate","ISL","Iceland","2018","2018",33.6,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","TCPPERMT","/capita, US$ exchange rate","ISL","Iceland","2019","2019",33,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","TCPPERMT","/capita, US$ exchange rate","ISL","Iceland","2020","2020",34.5,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","TCPPERMT","/capita, US$ exchange rate","ISL","Iceland","2021","2021",38.2,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2010","2010",26.4,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2011","2011",27.4,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2012","2012",27.2,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2013","2013",27.4,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2014","2014",25.7,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2015","2015",23.1,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2016","2016",24.3,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2017","2017",23.9,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2018","2018",25.8,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2019","2019",28.8,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2020","2020",31.8,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2021","2021",32.4,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","ATCPTTMT","% of total sales","ISL","Iceland","2010","2010",4.5,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","ATCPTTMT","% of total sales","ISL","Iceland","2011","2011",4.5,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","ATCPTTMT","% of total sales","ISL","Iceland","2012","2012",4.9,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","ATCPTTMT","% of total sales","ISL","Iceland","2013","2013",4.7,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","ATCPTTMT","% of total sales","ISL","Iceland","2014","2014",4.9,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","ATCPTTMT","% of total sales","ISL","Iceland","2015","2015",4.4,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","ATCPTTMT","% of total sales","ISL","Iceland","2016","2016",4.5,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","ATCPTTMT","% of total sales","ISL","Iceland","2017","2017",4.3,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","ATCPTTMT","% of total sales","ISL","Iceland","2018","2018",4.3,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","ATCPTTMT","% of total sales","ISL","Iceland","2019","2019",4.3,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","ATCPTTMT","% of total sales","ISL","Iceland","2020","2020",4.3,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","ATCPTTMT","% of total sales","ISL","Iceland","2021","2021",4,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MLLNCUMT","Million of national currency units","IRL","Ireland","2010","2010",134.6,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MLLNCUMT","Million of national currency units","IRL","Ireland","2011","2011",129.2,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MLLNCUMT","Million of national currency units","IRL","Ireland","2012","2012",132.5,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MLLNCUMT","Million of national currency units","IRL","Ireland","2013","2013",119,"B; D","Break; Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MLLNCUMT","Million of national currency units","IRL","Ireland","2014","2014",113.5,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MLLNCUMT","Million of national currency units","IRL","Ireland","2015","2015",115.4,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MLLNCUMT","Million of national currency units","IRL","Ireland","2016","2016",111.3,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MLLNCUMT","Million of national currency units","IRL","Ireland","2017","2017",102.8,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MLLNCUMT","Million of national currency units","IRL","Ireland","2018","2018",101.8,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MLLNCUMT","Million of national currency units","IRL","Ireland","2019","2019",102.5,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MLLNCUMT","Million of national currency units","IRL","Ireland","2020","2020",108.2,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MLLNCUMT","Million of national currency units","IRL","Ireland","2021","2021",106.3,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOTCMT","Million US$ at exchange rate","IRL","Ireland","2010","2010",178.5,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOTCMT","Million US$ at exchange rate","IRL","Ireland","2011","2011",179.8,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOTCMT","Million US$ at exchange rate","IRL","Ireland","2012","2012",170.2,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOTCMT","Million US$ at exchange rate","IRL","Ireland","2013","2013",158.1,"B; D","Break; Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOTCMT","Million US$ at exchange rate","IRL","Ireland","2014","2014",150.7,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOTCMT","Million US$ at exchange rate","IRL","Ireland","2015","2015",128,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOTCMT","Million US$ at exchange rate","IRL","Ireland","2016","2016",123.2,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOTCMT","Million US$ at exchange rate","IRL","Ireland","2017","2017",116.1,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOTCMT","Million US$ at exchange rate","IRL","Ireland","2018","2018",120.2,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOTCMT","Million US$ at exchange rate","IRL","Ireland","2019","2019",114.7,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOTCMT","Million US$ at exchange rate","IRL","Ireland","2020","2020",123.6,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOTCMT","Million US$ at exchange rate","IRL","Ireland","2021","2021",125.8,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOPPMT","Million US$, purchasing power parity","IRL","Ireland","2010","2010",158.5,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOPPMT","Million US$, purchasing power parity","IRL","Ireland","2011","2011",155.4,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOPPMT","Million US$, purchasing power parity","IRL","Ireland","2012","2012",161,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOPPMT","Million US$, purchasing power parity","IRL","Ireland","2013","2013",146.7,"B; D","Break; Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOPPMT","Million US$, purchasing power parity","IRL","Ireland","2014","2014",138.5,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOPPMT","Million US$, purchasing power parity","IRL","Ireland","2015","2015",142.5,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOPPMT","Million US$, purchasing power parity","IRL","Ireland","2016","2016",140.2,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOPPMT","Million US$, purchasing power parity","IRL","Ireland","2017","2017",129.4,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOPPMT","Million US$, purchasing power parity","IRL","Ireland","2018","2018",128.5,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOPPMT","Million US$, purchasing power parity","IRL","Ireland","2019","2019",127.2,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOPPMT","Million US$, purchasing power parity","IRL","Ireland","2020","2020",135.9,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOPPMT","Million US$, purchasing power parity","IRL","Ireland","2021","2021",133.8,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","TCPPERMT","/capita, US$ exchange rate","IRL","Ireland","2010","2010",39.1,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","TCPPERMT","/capita, US$ exchange rate","IRL","Ireland","2011","2011",39.3,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","TCPPERMT","/capita, US$ exchange rate","IRL","Ireland","2012","2012",37,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","TCPPERMT","/capita, US$ exchange rate","IRL","Ireland","2013","2013",34.2,"B; D","Break; Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","TCPPERMT","/capita, US$ exchange rate","IRL","Ireland","2014","2014",32.4,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","TCPPERMT","/capita, US$ exchange rate","IRL","Ireland","2015","2015",27.2,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","TCPPERMT","/capita, US$ exchange rate","IRL","Ireland","2016","2016",25.9,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","TCPPERMT","/capita, US$ exchange rate","IRL","Ireland","2017","2017",24.2,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","TCPPERMT","/capita, US$ exchange rate","IRL","Ireland","2018","2018",24.7,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","TCPPERMT","/capita, US$ exchange rate","IRL","Ireland","2019","2019",23.2,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","TCPPERMT","/capita, US$ exchange rate","IRL","Ireland","2020","2020",24.8,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","TCPPERMT","/capita, US$ exchange rate","IRL","Ireland","2021","2021",25,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2010","2010",34.8,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2011","2011",33.9,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2012","2012",35,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2013","2013",31.7,"B; D","Break; Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2014","2014",29.7,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2015","2015",30.3,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2016","2016",29.5,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2017","2017",26.9,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2018","2018",26.4,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2019","2019",25.8,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2020","2020",27.3,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2021","2021",26.6,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","ATCPTTMT","% of total sales","IRL","Ireland","2010","2010",6.6,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","ATCPTTMT","% of total sales","IRL","Ireland","2011","2011",6.6,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","ATCPTTMT","% of total sales","IRL","Ireland","2012","2012",6.5,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","ATCPTTMT","% of total sales","IRL","Ireland","2013","2013",6.1,"B; D","Break; Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","ATCPTTMT","% of total sales","IRL","Ireland","2014","2014",5.9,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","ATCPTTMT","% of total sales","IRL","Ireland","2015","2015",5.8,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","ATCPTTMT","% of total sales","IRL","Ireland","2016","2016",5.4,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","ATCPTTMT","% of total sales","IRL","Ireland","2017","2017",4.8,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","ATCPTTMT","% of total sales","IRL","Ireland","2018","2018",4.5,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","ATCPTTMT","% of total sales","IRL","Ireland","2019","2019",4.3,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","ATCPTTMT","% of total sales","IRL","Ireland","2020","2020",4.4,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","ATCPTTMT","% of total sales","IRL","Ireland","2021","2021",4.1,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MLLNCUMT","Million of national currency units","ITA","Italy","2011","2011",1030.5,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MLLNCUMT","Million of national currency units","ITA","Italy","2012","2012",1008.3,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MLLNCUMT","Million of national currency units","ITA","Italy","2013","2013",986.1,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MLLNCUMT","Million of national currency units","ITA","Italy","2014","2014",1009.2,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MLLNCUMT","Million of national currency units","ITA","Italy","2015","2015",1020.1,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MLLNCUMT","Million of national currency units","ITA","Italy","2016","2016",991.3,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MLLNCUMT","Million of national currency units","ITA","Italy","2017","2017",988.2,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MLLNCUMT","Million of national currency units","ITA","Italy","2018","2018",1001.4,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MLLNCUMT","Million of national currency units","ITA","Italy","2019","2019",1055.5,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MLLNCUMT","Million of national currency units","ITA","Italy","2020","2020",1084.3,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MLLNCUMT","Million of national currency units","ITA","Italy","2021","2021",1029.6,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MLLNCUMT","Million of national currency units","ITA","Italy","2022","2022",1020.3,"E","Estimated value"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOTCMT","Million US$ at exchange rate","ITA","Italy","2011","2011",1434.4,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOTCMT","Million US$ at exchange rate","ITA","Italy","2012","2012",1295.5,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOTCMT","Million US$ at exchange rate","ITA","Italy","2013","2013",1309.6,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOTCMT","Million US$ at exchange rate","ITA","Italy","2014","2014",1340.7,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOTCMT","Million US$ at exchange rate","ITA","Italy","2015","2015",1131.8,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOTCMT","Million US$ at exchange rate","ITA","Italy","2016","2016",1097.3,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOTCMT","Million US$ at exchange rate","ITA","Italy","2017","2017",1116.4,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOTCMT","Million US$ at exchange rate","ITA","Italy","2018","2018",1182.6,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOTCMT","Million US$ at exchange rate","ITA","Italy","2019","2019",1181.6,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOTCMT","Million US$ at exchange rate","ITA","Italy","2020","2020",1238.5,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOTCMT","Million US$ at exchange rate","ITA","Italy","2021","2021",1217.8,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOTCMT","Million US$ at exchange rate","ITA","Italy","2022","2022",1074.5,"E","Estimated value"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOPPMT","Million US$, purchasing power parity","ITA","Italy","2011","2011",1358.2,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOPPMT","Million US$, purchasing power parity","ITA","Italy","2012","2012",1348.5,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOPPMT","Million US$, purchasing power parity","ITA","Italy","2013","2013",1337.4,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOPPMT","Million US$, purchasing power parity","ITA","Italy","2014","2014",1364.4,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOPPMT","Million US$, purchasing power parity","ITA","Italy","2015","2015",1380.9,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOPPMT","Million US$, purchasing power parity","ITA","Italy","2016","2016",1415.1,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOPPMT","Million US$, purchasing power parity","ITA","Italy","2017","2017",1432.4,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOPPMT","Million US$, purchasing power parity","ITA","Italy","2018","2018",1470,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOPPMT","Million US$, purchasing power parity","ITA","Italy","2019","2019",1607.1,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOPPMT","Million US$, purchasing power parity","ITA","Italy","2020","2020",1674,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOPPMT","Million US$, purchasing power parity","ITA","Italy","2021","2021",1590,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOPPMT","Million US$, purchasing power parity","ITA","Italy","2022","2022",1652.6,"E","Estimated value"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","TCPPERMT","/capita, US$ exchange rate","ITA","Italy","2011","2011",24.2,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","TCPPERMT","/capita, US$ exchange rate","ITA","Italy","2012","2012",21.8,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","TCPPERMT","/capita, US$ exchange rate","ITA","Italy","2013","2013",21.7,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","TCPPERMT","/capita, US$ exchange rate","ITA","Italy","2014","2014",22.1,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","TCPPERMT","/capita, US$ exchange rate","ITA","Italy","2015","2015",18.6,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","TCPPERMT","/capita, US$ exchange rate","ITA","Italy","2016","2016",18.1,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","TCPPERMT","/capita, US$ exchange rate","ITA","Italy","2017","2017",18.4,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","TCPPERMT","/capita, US$ exchange rate","ITA","Italy","2018","2018",19.6,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","TCPPERMT","/capita, US$ exchange rate","ITA","Italy","2019","2019",19.8,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","TCPPERMT","/capita, US$ exchange rate","ITA","Italy","2020","2020",20.8,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","TCPPERMT","/capita, US$ exchange rate","ITA","Italy","2021","2021",20.6,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","TCPPERMT","/capita, US$ exchange rate","ITA","Italy","2022","2022",18.2,"E","Estimated value"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2011","2011",22.9,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2012","2012",22.6,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2013","2013",22.2,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2014","2014",22.4,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2015","2015",22.7,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2016","2016",23.3,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2017","2017",23.7,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2018","2018",24.3,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2019","2019",26.9,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2020","2020",28.2,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2021","2021",26.9,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2022","2022",28,"E","Estimated value"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","ATCPTTMT","% of total sales","ITA","Italy","2011","2011",5.3,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","ATCPTTMT","% of total sales","ITA","Italy","2012","2012",5.3,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","ATCPTTMT","% of total sales","ITA","Italy","2013","2013",5.1,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","ATCPTTMT","% of total sales","ITA","Italy","2014","2014",5.1,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","ATCPTTMT","% of total sales","ITA","Italy","2015","2015",4.5,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","ATCPTTMT","% of total sales","ITA","Italy","2016","2016",4.4,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","ATCPTTMT","% of total sales","ITA","Italy","2017","2017",4.4,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","ATCPTTMT","% of total sales","ITA","Italy","2018","2018",4.5,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","ATCPTTMT","% of total sales","ITA","Italy","2019","2019",4.6,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","ATCPTTMT","% of total sales","ITA","Italy","2020","2020",4.7,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","ATCPTTMT","% of total sales","ITA","Italy","2021","2021",4.3,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","ATCPTTMT","% of total sales","ITA","Italy","2022","2022",4.1,"E","Estimated value"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MLLNCUMT","Million of national currency units","KOR","Korea","2010","2010",273823,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MLLNCUMT","Million of national currency units","KOR","Korea","2011","2011",307833.9,"B","Break"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MLLNCUMT","Million of national currency units","KOR","Korea","2012","2012",293533.2,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MLLNCUMT","Million of national currency units","KOR","Korea","2013","2013",287375.9,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MLLNCUMT","Million of national currency units","KOR","Korea","2014","2014",305537.9,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MLLNCUMT","Million of national currency units","KOR","Korea","2015","2015",314131.8,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MLLNCUMT","Million of national currency units","KOR","Korea","2016","2016",311925.5,"B","Break"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MLLNCUMT","Million of national currency units","KOR","Korea","2017","2017",311635,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MLLNCUMT","Million of national currency units","KOR","Korea","2018","2018",349710.7,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MLLNCUMT","Million of national currency units","KOR","Korea","2019","2019",368692.5,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MLLNCUMT","Million of national currency units","KOR","Korea","2020","2020",346455.7,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MLLNCUMT","Million of national currency units","KOR","Korea","2021","2021",346440.3,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOTCMT","Million US$ at exchange rate","KOR","Korea","2010","2010",236.8,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOTCMT","Million US$ at exchange rate","KOR","Korea","2011","2011",277.8,"B","Break"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOTCMT","Million US$ at exchange rate","KOR","Korea","2012","2012",260.5,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOTCMT","Million US$ at exchange rate","KOR","Korea","2013","2013",262.4,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOTCMT","Million US$ at exchange rate","KOR","Korea","2014","2014",290.2,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOTCMT","Million US$ at exchange rate","KOR","Korea","2015","2015",277.8,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOTCMT","Million US$ at exchange rate","KOR","Korea","2016","2016",268.7,"B","Break"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOTCMT","Million US$ at exchange rate","KOR","Korea","2017","2017",275.5,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOTCMT","Million US$ at exchange rate","KOR","Korea","2018","2018",317.9,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOTCMT","Million US$ at exchange rate","KOR","Korea","2019","2019",316.4,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOTCMT","Million US$ at exchange rate","KOR","Korea","2020","2020",293.5,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOTCMT","Million US$ at exchange rate","KOR","Korea","2021","2021",302.8,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOPPMT","Million US$, purchasing power parity","KOR","Korea","2010","2010",325.6,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOPPMT","Million US$, purchasing power parity","KOR","Korea","2011","2011",360.2,"B","Break"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOPPMT","Million US$, purchasing power parity","KOR","Korea","2012","2012",343.4,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOPPMT","Million US$, purchasing power parity","KOR","Korea","2013","2013",330.7,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOPPMT","Million US$, purchasing power parity","KOR","Korea","2014","2014",350.4,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOPPMT","Million US$, purchasing power parity","KOR","Korea","2015","2015",366.3,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOPPMT","Million US$, purchasing power parity","KOR","Korea","2016","2016",363.2,"B","Break"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOPPMT","Million US$, purchasing power parity","KOR","Korea","2017","2017",357.1,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOPPMT","Million US$, purchasing power parity","KOR","Korea","2018","2018",409.1,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOPPMT","Million US$, purchasing power parity","KOR","Korea","2019","2019",430.5,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOPPMT","Million US$, purchasing power parity","KOR","Korea","2020","2020",413.6,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOPPMT","Million US$, purchasing power parity","KOR","Korea","2021","2021",405.6,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","TCPPERMT","/capita, US$ exchange rate","KOR","Korea","2010","2010",4.8,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","TCPPERMT","/capita, US$ exchange rate","KOR","Korea","2011","2011",5.6,"B","Break"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","TCPPERMT","/capita, US$ exchange rate","KOR","Korea","2012","2012",5.2,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","TCPPERMT","/capita, US$ exchange rate","KOR","Korea","2013","2013",5.2,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","TCPPERMT","/capita, US$ exchange rate","KOR","Korea","2014","2014",5.7,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","TCPPERMT","/capita, US$ exchange rate","KOR","Korea","2015","2015",5.4,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","TCPPERMT","/capita, US$ exchange rate","KOR","Korea","2016","2016",5.2,"B","Break"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","TCPPERMT","/capita, US$ exchange rate","KOR","Korea","2017","2017",5.4,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","TCPPERMT","/capita, US$ exchange rate","KOR","Korea","2018","2018",6.2,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","TCPPERMT","/capita, US$ exchange rate","KOR","Korea","2019","2019",6.1,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","TCPPERMT","/capita, US$ exchange rate","KOR","Korea","2020","2020",5.7,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","TCPPERMT","/capita, US$ exchange rate","KOR","Korea","2021","2021",5.9,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2010","2010",6.6,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2011","2011",7.2,"B","Break"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2012","2012",6.8,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2013","2013",6.6,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2014","2014",6.9,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2015","2015",7.2,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2016","2016",7.1,"B","Break"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2017","2017",7,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2018","2018",7.9,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2019","2019",8.3,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2020","2020",8,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2021","2021",7.8,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","ATCPTTMT","% of total sales","KOR","Korea","2010","2010",1.3,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","ATCPTTMT","% of total sales","KOR","Korea","2011","2011",1.4,"B","Break"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","ATCPTTMT","% of total sales","KOR","Korea","2012","2012",1.4,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","ATCPTTMT","% of total sales","KOR","Korea","2013","2013",1.3,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","ATCPTTMT","% of total sales","KOR","Korea","2014","2014",1.3,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","ATCPTTMT","% of total sales","KOR","Korea","2015","2015",1.3,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","ATCPTTMT","% of total sales","KOR","Korea","2016","2016",1.2,"B","Break"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","ATCPTTMT","% of total sales","KOR","Korea","2017","2017",1.2,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","ATCPTTMT","% of total sales","KOR","Korea","2018","2018",1.2,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","ATCPTTMT","% of total sales","KOR","Korea","2019","2019",1.2,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","ATCPTTMT","% of total sales","KOR","Korea","2020","2020",1.1,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","ATCPTTMT","% of total sales","KOR","Korea","2021","2021",1,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MLLNCUMT","Million of national currency units","LUX","Luxembourg","2010","2010",10.7,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MLLNCUMT","Million of national currency units","LUX","Luxembourg","2011","2011",11,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MLLNCUMT","Million of national currency units","LUX","Luxembourg","2012","2012",11.2,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MLLNCUMT","Million of national currency units","LUX","Luxembourg","2013","2013",11.4,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MLLNCUMT","Million of national currency units","LUX","Luxembourg","2014","2014",10.6,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MLLNCUMT","Million of national currency units","LUX","Luxembourg","2015","2015",10.5,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MLLNCUMT","Million of national currency units","LUX","Luxembourg","2016","2016",10,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MLLNCUMT","Million of national currency units","LUX","Luxembourg","2017","2017",9.4,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MLLNCUMT","Million of national currency units","LUX","Luxembourg","2018","2018",9.7,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MLLNCUMT","Million of national currency units","LUX","Luxembourg","2019","2019",9.7,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MLLNCUMT","Million of national currency units","LUX","Luxembourg","2020","2020",10.1,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MLLNCUMT","Million of national currency units","LUX","Luxembourg","2021","2021",11.1,"B; D; P","Break; Difference in methodology; Provisional value"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MLLNCUMT","Million of national currency units","LUX","Luxembourg","2022","2022",11.4,"D; P","Difference in methodology; Provisional value"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOTCMT","Million US$ at exchange rate","LUX","Luxembourg","2010","2010",14.1,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOTCMT","Million US$ at exchange rate","LUX","Luxembourg","2011","2011",15.2,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOTCMT","Million US$ at exchange rate","LUX","Luxembourg","2012","2012",14.4,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOTCMT","Million US$ at exchange rate","LUX","Luxembourg","2013","2013",15.2,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOTCMT","Million US$ at exchange rate","LUX","Luxembourg","2014","2014",14.1,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOTCMT","Million US$ at exchange rate","LUX","Luxembourg","2015","2015",11.6,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOTCMT","Million US$ at exchange rate","LUX","Luxembourg","2016","2016",11,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOTCMT","Million US$ at exchange rate","LUX","Luxembourg","2017","2017",10.6,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOTCMT","Million US$ at exchange rate","LUX","Luxembourg","2018","2018",11.4,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOTCMT","Million US$ at exchange rate","LUX","Luxembourg","2019","2019",10.9,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOTCMT","Million US$ at exchange rate","LUX","Luxembourg","2020","2020",11.5,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOTCMT","Million US$ at exchange rate","LUX","Luxembourg","2021","2021",13.2,"B; D; P","Break; Difference in methodology; Provisional value"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOTCMT","Million US$ at exchange rate","LUX","Luxembourg","2022","2022",12,"D; P","Difference in methodology; Provisional value"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOPPMT","Million US$, purchasing power parity","LUX","Luxembourg","2010","2010",11.5,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOPPMT","Million US$, purchasing power parity","LUX","Luxembourg","2011","2011",12.1,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOPPMT","Million US$, purchasing power parity","LUX","Luxembourg","2012","2012",12.3,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOPPMT","Million US$, purchasing power parity","LUX","Luxembourg","2013","2013",12.7,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOPPMT","Million US$, purchasing power parity","LUX","Luxembourg","2014","2014",12,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOPPMT","Million US$, purchasing power parity","LUX","Luxembourg","2015","2015",11.9,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOPPMT","Million US$, purchasing power parity","LUX","Luxembourg","2016","2016",11.7,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOPPMT","Million US$, purchasing power parity","LUX","Luxembourg","2017","2017",11.1,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOPPMT","Million US$, purchasing power parity","LUX","Luxembourg","2018","2018",11.4,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOPPMT","Million US$, purchasing power parity","LUX","Luxembourg","2019","2019",11.5,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOPPMT","Million US$, purchasing power parity","LUX","Luxembourg","2020","2020",11.8,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOPPMT","Million US$, purchasing power parity","LUX","Luxembourg","2021","2021",13,"B; D; P","Break; Difference in methodology; Provisional value"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOPPMT","Million US$, purchasing power parity","LUX","Luxembourg","2022","2022",13.6,"D; P","Difference in methodology; Provisional value"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","TCPPERMT","/capita, US$ exchange rate","LUX","Luxembourg","2010","2010",29.8,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","TCPPERMT","/capita, US$ exchange rate","LUX","Luxembourg","2011","2011",31.6,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","TCPPERMT","/capita, US$ exchange rate","LUX","Luxembourg","2012","2012",29.2,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","TCPPERMT","/capita, US$ exchange rate","LUX","Luxembourg","2013","2013",30.2,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","TCPPERMT","/capita, US$ exchange rate","LUX","Luxembourg","2014","2014",27.5,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","TCPPERMT","/capita, US$ exchange rate","LUX","Luxembourg","2015","2015",22.4,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","TCPPERMT","/capita, US$ exchange rate","LUX","Luxembourg","2016","2016",20.9,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","TCPPERMT","/capita, US$ exchange rate","LUX","Luxembourg","2017","2017",19.9,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","TCPPERMT","/capita, US$ exchange rate","LUX","Luxembourg","2018","2018",20.9,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","TCPPERMT","/capita, US$ exchange rate","LUX","Luxembourg","2019","2019",19.5,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","TCPPERMT","/capita, US$ exchange rate","LUX","Luxembourg","2020","2020",20.3,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","TCPPERMT","/capita, US$ exchange rate","LUX","Luxembourg","2021","2021",22.9,"B; D; P","Break; Difference in methodology; Provisional value"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","TCPPERMT","/capita, US$ exchange rate","LUX","Luxembourg","2022","2022",20.4,"D; P","Difference in methodology; Provisional value"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2010","2010",24.3,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2011","2011",25.1,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2012","2012",25,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2013","2013",25.4,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2014","2014",23.5,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2015","2015",22.9,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2016","2016",22.2,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2017","2017",20.7,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2018","2018",20.9,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2019","2019",20.7,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2020","2020",20.8,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2021","2021",22.5,"B; D; P","Break; Difference in methodology; Provisional value"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2022","2022",23.3,"D; P","Difference in methodology; Provisional value"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","ATCPTTMT","% of total sales","LUX","Luxembourg","2010","2010",5.6,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","ATCPTTMT","% of total sales","LUX","Luxembourg","2011","2011",5.8,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","ATCPTTMT","% of total sales","LUX","Luxembourg","2012","2012",5.7,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","ATCPTTMT","% of total sales","LUX","Luxembourg","2013","2013",5.9,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","ATCPTTMT","% of total sales","LUX","Luxembourg","2014","2014",5.5,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","ATCPTTMT","% of total sales","LUX","Luxembourg","2015","2015",5.4,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","ATCPTTMT","% of total sales","LUX","Luxembourg","2016","2016",5.1,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","ATCPTTMT","% of total sales","LUX","Luxembourg","2017","2017",4.9,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","ATCPTTMT","% of total sales","LUX","Luxembourg","2018","2018",4.9,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","ATCPTTMT","% of total sales","LUX","Luxembourg","2019","2019",4.7,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","ATCPTTMT","% of total sales","LUX","Luxembourg","2020","2020",4.8,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","ATCPTTMT","% of total sales","LUX","Luxembourg","2021","2021",4.6,"B; D; P","Break; Difference in methodology; Provisional value"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","ATCPTTMT","% of total sales","LUX","Luxembourg","2022","2022",4.4,"D; P","Difference in methodology; Provisional value"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MLLNCUMT","Million of national currency units","NLD","Netherlands","2010","2010",436,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MLLNCUMT","Million of national currency units","NLD","Netherlands","2011","2011",457.1,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MLLNCUMT","Million of national currency units","NLD","Netherlands","2012","2012",445.4,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MLLNCUMT","Million of national currency units","NLD","Netherlands","2013","2013",430.1,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MLLNCUMT","Million of national currency units","NLD","Netherlands","2014","2014",414.1,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOTCMT","Million US$ at exchange rate","NLD","Netherlands","2010","2010",578,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOTCMT","Million US$ at exchange rate","NLD","Netherlands","2011","2011",636.3,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOTCMT","Million US$ at exchange rate","NLD","Netherlands","2012","2012",572.2,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOTCMT","Million US$ at exchange rate","NLD","Netherlands","2013","2013",571.3,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOTCMT","Million US$ at exchange rate","NLD","Netherlands","2014","2014",550.2,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOPPMT","Million US$, purchasing power parity","NLD","Netherlands","2010","2010",510.5,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOPPMT","Million US$, purchasing power parity","NLD","Netherlands","2011","2011",546.7,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOPPMT","Million US$, purchasing power parity","NLD","Netherlands","2012","2012",540.2,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOPPMT","Million US$, purchasing power parity","NLD","Netherlands","2013","2013",538.9,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOPPMT","Million US$, purchasing power parity","NLD","Netherlands","2014","2014",512,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","TCPPERMT","/capita, US$ exchange rate","NLD","Netherlands","2010","2010",34.8,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","TCPPERMT","/capita, US$ exchange rate","NLD","Netherlands","2011","2011",38.1,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","TCPPERMT","/capita, US$ exchange rate","NLD","Netherlands","2012","2012",34.2,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","TCPPERMT","/capita, US$ exchange rate","NLD","Netherlands","2013","2013",34,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","TCPPERMT","/capita, US$ exchange rate","NLD","Netherlands","2014","2014",32.6,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","NLD","Netherlands","2010","2010",30.7,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","NLD","Netherlands","2011","2011",32.8,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","NLD","Netherlands","2012","2012",32.2,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","NLD","Netherlands","2013","2013",32.1,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","NLD","Netherlands","2014","2014",30.4,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","ATCPTTMT","% of total sales","NLD","Netherlands","2010","2010",8.4,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","ATCPTTMT","% of total sales","NLD","Netherlands","2011","2011",8.8,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","ATCPTTMT","% of total sales","NLD","Netherlands","2012","2012",9.7,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","ATCPTTMT","% of total sales","NLD","Netherlands","2013","2013",10,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","ATCPTTMT","% of total sales","NLD","Netherlands","2014","2014",9.6,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MLLNCUMT","Million of national currency units","NZL","New Zealand","2010","2010",68.3,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MLLNCUMT","Million of national currency units","NZL","New Zealand","2011","2011",73.3,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MLLNCUMT","Million of national currency units","NZL","New Zealand","2012","2012",77.2,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MLLNCUMT","Million of national currency units","NZL","New Zealand","2013","2013",79.6,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MLLNCUMT","Million of national currency units","NZL","New Zealand","2014","2014",84.7,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MLLNCUMT","Million of national currency units","NZL","New Zealand","2015","2015",90.5,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MLLNCUMT","Million of national currency units","NZL","New Zealand","2016","2016",92.7,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MLLNCUMT","Million of national currency units","NZL","New Zealand","2017","2017",89.1,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MLLNCUMT","Million of national currency units","NZL","New Zealand","2018","2018",100.6,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MLLNCUMT","Million of national currency units","NZL","New Zealand","2019","2019",102,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MLLNCUMT","Million of national currency units","NZL","New Zealand","2020","2020",112.4,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MLLNCUMT","Million of national currency units","NZL","New Zealand","2021","2021",116.3,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MLLNCUMT","Million of national currency units","NZL","New Zealand","2022","2022",135.3,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOTCMT","Million US$ at exchange rate","NZL","New Zealand","2010","2010",49.2,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOTCMT","Million US$ at exchange rate","NZL","New Zealand","2011","2011",57.9,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOTCMT","Million US$ at exchange rate","NZL","New Zealand","2012","2012",62.5,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOTCMT","Million US$ at exchange rate","NZL","New Zealand","2013","2013",65.2,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOTCMT","Million US$ at exchange rate","NZL","New Zealand","2014","2014",70.3,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOTCMT","Million US$ at exchange rate","NZL","New Zealand","2015","2015",63.1,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOTCMT","Million US$ at exchange rate","NZL","New Zealand","2016","2016",64.6,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOTCMT","Million US$ at exchange rate","NZL","New Zealand","2017","2017",63.3,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOTCMT","Million US$ at exchange rate","NZL","New Zealand","2018","2018",69.6,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOTCMT","Million US$ at exchange rate","NZL","New Zealand","2019","2019",67.2,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOTCMT","Million US$ at exchange rate","NZL","New Zealand","2020","2020",72.9,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOTCMT","Million US$ at exchange rate","NZL","New Zealand","2021","2021",82.3,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOTCMT","Million US$ at exchange rate","NZL","New Zealand","2022","2022",85.8,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOPPMT","Million US$, purchasing power parity","NZL","New Zealand","2010","2010",45.6,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOPPMT","Million US$, purchasing power parity","NZL","New Zealand","2011","2011",49.4,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOPPMT","Million US$, purchasing power parity","NZL","New Zealand","2012","2012",51.6,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOPPMT","Million US$, purchasing power parity","NZL","New Zealand","2013","2013",55,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOPPMT","Million US$, purchasing power parity","NZL","New Zealand","2014","2014",58.8,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOPPMT","Million US$, purchasing power parity","NZL","New Zealand","2015","2015",61.2,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOPPMT","Million US$, purchasing power parity","NZL","New Zealand","2016","2016",64.4,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOPPMT","Million US$, purchasing power parity","NZL","New Zealand","2017","2017",62.2,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOPPMT","Million US$, purchasing power parity","NZL","New Zealand","2018","2018",68.4,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOPPMT","Million US$, purchasing power parity","NZL","New Zealand","2019","2019",72,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOPPMT","Million US$, purchasing power parity","NZL","New Zealand","2020","2020",79.5,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOPPMT","Million US$, purchasing power parity","NZL","New Zealand","2021","2021",79.7,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOPPMT","Million US$, purchasing power parity","NZL","New Zealand","2022","2022",93.8,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","TCPPERMT","/capita, US$ exchange rate","NZL","New Zealand","2010","2010",11.3,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","TCPPERMT","/capita, US$ exchange rate","NZL","New Zealand","2011","2011",13.2,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","TCPPERMT","/capita, US$ exchange rate","NZL","New Zealand","2012","2012",14.2,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","TCPPERMT","/capita, US$ exchange rate","NZL","New Zealand","2013","2013",14.7,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","TCPPERMT","/capita, US$ exchange rate","NZL","New Zealand","2014","2014",15.6,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","TCPPERMT","/capita, US$ exchange rate","NZL","New Zealand","2015","2015",13.7,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","TCPPERMT","/capita, US$ exchange rate","NZL","New Zealand","2016","2016",13.7,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","TCPPERMT","/capita, US$ exchange rate","NZL","New Zealand","2017","2017",13.1,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","TCPPERMT","/capita, US$ exchange rate","NZL","New Zealand","2018","2018",14.2,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","TCPPERMT","/capita, US$ exchange rate","NZL","New Zealand","2019","2019",13.5,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","TCPPERMT","/capita, US$ exchange rate","NZL","New Zealand","2020","2020",14.3,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","TCPPERMT","/capita, US$ exchange rate","NZL","New Zealand","2021","2021",16.1,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","TCPPERMT","/capita, US$ exchange rate","NZL","New Zealand","2022","2022",16.7,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2010","2010",10.5,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2011","2011",11.3,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2012","2012",11.7,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2013","2013",12.4,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2014","2014",13,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2015","2015",13.3,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2016","2016",13.7,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2017","2017",12.9,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2018","2018",14,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2019","2019",14.5,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2020","2020",15.6,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2021","2021",15.6,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2022","2022",18.3,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","ATCPTTMT","% of total sales","NZL","New Zealand","2010","2010",9.1,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","ATCPTTMT","% of total sales","NZL","New Zealand","2011","2011",9,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","ATCPTTMT","% of total sales","NZL","New Zealand","2012","2012",8.3,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","ATCPTTMT","% of total sales","NZL","New Zealand","2013","2013",8.6,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","ATCPTTMT","% of total sales","NZL","New Zealand","2014","2014",8.8,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","ATCPTTMT","% of total sales","NZL","New Zealand","2015","2015",9.2,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","ATCPTTMT","% of total sales","NZL","New Zealand","2016","2016",8.7,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","ATCPTTMT","% of total sales","NZL","New Zealand","2017","2017",7.1,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","ATCPTTMT","% of total sales","NZL","New Zealand","2018","2018",7.6,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","ATCPTTMT","% of total sales","NZL","New Zealand","2019","2019",6.8,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","ATCPTTMT","% of total sales","NZL","New Zealand","2020","2020",6.8,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","ATCPTTMT","% of total sales","NZL","New Zealand","2021","2021",6.5,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","ATCPTTMT","% of total sales","NZL","New Zealand","2022","2022",7.1,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MLLNCUMT","Million of national currency units","NOR","Norway","2010","2010",1156,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MLLNCUMT","Million of national currency units","NOR","Norway","2011","2011",1136,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MLLNCUMT","Million of national currency units","NOR","Norway","2012","2012",1119,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MLLNCUMT","Million of national currency units","NOR","Norway","2013","2013",1045,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MLLNCUMT","Million of national currency units","NOR","Norway","2014","2014",1098,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MLLNCUMT","Million of national currency units","NOR","Norway","2015","2015",1108,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MLLNCUMT","Million of national currency units","NOR","Norway","2016","2016",1186,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MLLNCUMT","Million of national currency units","NOR","Norway","2017","2017",1214,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MLLNCUMT","Million of national currency units","NOR","Norway","2018","2018",1212,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MLLNCUMT","Million of national currency units","NOR","Norway","2019","2019",1257,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MLLNCUMT","Million of national currency units","NOR","Norway","2020","2020",1347,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MLLNCUMT","Million of national currency units","NOR","Norway","2021","2021",1427,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MLLNCUMT","Million of national currency units","NOR","Norway","2022","2022",1490,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOTCMT","Million US$ at exchange rate","NOR","Norway","2010","2010",191.3,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOTCMT","Million US$ at exchange rate","NOR","Norway","2011","2011",202.7,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOTCMT","Million US$ at exchange rate","NOR","Norway","2012","2012",192.4,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOTCMT","Million US$ at exchange rate","NOR","Norway","2013","2013",177.9,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOTCMT","Million US$ at exchange rate","NOR","Norway","2014","2014",174.2,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOTCMT","Million US$ at exchange rate","NOR","Norway","2015","2015",137.4,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOTCMT","Million US$ at exchange rate","NOR","Norway","2016","2016",141.2,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOTCMT","Million US$ at exchange rate","NOR","Norway","2017","2017",146.8,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOTCMT","Million US$ at exchange rate","NOR","Norway","2018","2018",149,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOTCMT","Million US$ at exchange rate","NOR","Norway","2019","2019",142.8,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOTCMT","Million US$ at exchange rate","NOR","Norway","2020","2020",143.1,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOTCMT","Million US$ at exchange rate","NOR","Norway","2021","2021",166.1,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOTCMT","Million US$ at exchange rate","NOR","Norway","2022","2022",155,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOPPMT","Million US$, purchasing power parity","NOR","Norway","2010","2010",126.3,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOPPMT","Million US$, purchasing power parity","NOR","Norway","2011","2011",125.1,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOPPMT","Million US$, purchasing power parity","NOR","Norway","2012","2012",123.8,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOPPMT","Million US$, purchasing power parity","NOR","Norway","2013","2013",115.7,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOPPMT","Million US$, purchasing power parity","NOR","Norway","2014","2014",118.3,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOPPMT","Million US$, purchasing power parity","NOR","Norway","2015","2015",111.6,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOPPMT","Million US$, purchasing power parity","NOR","Norway","2016","2016",118.1,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOPPMT","Million US$, purchasing power parity","NOR","Norway","2017","2017",124.5,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOPPMT","Million US$, purchasing power parity","NOR","Norway","2018","2018",126.5,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOPPMT","Million US$, purchasing power parity","NOR","Norway","2019","2019",130.7,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOPPMT","Million US$, purchasing power parity","NOR","Norway","2020","2020",136.3,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOPPMT","Million US$, purchasing power parity","NOR","Norway","2021","2021",150,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOPPMT","Million US$, purchasing power parity","NOR","Norway","2022","2022",138.7,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","TCPPERMT","/capita, US$ exchange rate","NOR","Norway","2010","2010",39.1,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","TCPPERMT","/capita, US$ exchange rate","NOR","Norway","2011","2011",40.9,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","TCPPERMT","/capita, US$ exchange rate","NOR","Norway","2012","2012",38.3,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","TCPPERMT","/capita, US$ exchange rate","NOR","Norway","2013","2013",35,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","TCPPERMT","/capita, US$ exchange rate","NOR","Norway","2014","2014",33.9,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","TCPPERMT","/capita, US$ exchange rate","NOR","Norway","2015","2015",26.5,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","TCPPERMT","/capita, US$ exchange rate","NOR","Norway","2016","2016",27,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","TCPPERMT","/capita, US$ exchange rate","NOR","Norway","2017","2017",27.8,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","TCPPERMT","/capita, US$ exchange rate","NOR","Norway","2018","2018",28.1,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","TCPPERMT","/capita, US$ exchange rate","NOR","Norway","2019","2019",26.7,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","TCPPERMT","/capita, US$ exchange rate","NOR","Norway","2020","2020",26.6,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","TCPPERMT","/capita, US$ exchange rate","NOR","Norway","2021","2021",30.7,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","TCPPERMT","/capita, US$ exchange rate","NOR","Norway","2022","2022",28.6,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2010","2010",25.8,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2011","2011",25.3,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2012","2012",24.7,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2013","2013",22.8,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2014","2014",23,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2015","2015",21.5,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2016","2016",22.6,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2017","2017",23.6,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2018","2018",23.8,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2019","2019",24.4,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2020","2020",25.3,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2021","2021",27.7,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2022","2022",25.6,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","ATCPTTMT","% of total sales","NOR","Norway","2010","2010",6.5,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","ATCPTTMT","% of total sales","NOR","Norway","2011","2011",6.2,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","ATCPTTMT","% of total sales","NOR","Norway","2012","2012",6,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","ATCPTTMT","% of total sales","NOR","Norway","2013","2013",5.4,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","ATCPTTMT","% of total sales","NOR","Norway","2014","2014",5.2,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","ATCPTTMT","% of total sales","NOR","Norway","2015","2015",4.9,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","ATCPTTMT","% of total sales","NOR","Norway","2016","2016",4.8,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","ATCPTTMT","% of total sales","NOR","Norway","2017","2017",4.6,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","ATCPTTMT","% of total sales","NOR","Norway","2018","2018",4.4,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","ATCPTTMT","% of total sales","NOR","Norway","2019","2019",4.4,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","ATCPTTMT","% of total sales","NOR","Norway","2020","2020",4.5,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","ATCPTTMT","% of total sales","NOR","Norway","2021","2021",4.3,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","ATCPTTMT","% of total sales","NOR","Norway","2022","2022",4.1,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MLLNCUMT","Million of national currency units","PRT","Portugal","2010","2010",131.5,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MLLNCUMT","Million of national currency units","PRT","Portugal","2011","2011",132.1,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MLLNCUMT","Million of national currency units","PRT","Portugal","2012","2012",130.7,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MLLNCUMT","Million of national currency units","PRT","Portugal","2013","2013",124.3,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MLLNCUMT","Million of national currency units","PRT","Portugal","2014","2014",117.1,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MLLNCUMT","Million of national currency units","PRT","Portugal","2015","2015",124.4,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MLLNCUMT","Million of national currency units","PRT","Portugal","2016","2016",130.7,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MLLNCUMT","Million of national currency units","PRT","Portugal","2017","2017",131.8,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MLLNCUMT","Million of national currency units","PRT","Portugal","2018","2018",135.1,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MLLNCUMT","Million of national currency units","PRT","Portugal","2019","2019",143.1,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MLLNCUMT","Million of national currency units","PRT","Portugal","2020","2020",147.8,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MLLNCUMT","Million of national currency units","PRT","Portugal","2021","2021",141.5,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MLLNCUMT","Million of national currency units","PRT","Portugal","2022","2022",152.6,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOTCMT","Million US$ at exchange rate","PRT","Portugal","2010","2010",174.3,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOTCMT","Million US$ at exchange rate","PRT","Portugal","2011","2011",183.9,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOTCMT","Million US$ at exchange rate","PRT","Portugal","2012","2012",167.9,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOTCMT","Million US$ at exchange rate","PRT","Portugal","2013","2013",165.1,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOTCMT","Million US$ at exchange rate","PRT","Portugal","2014","2014",155.6,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOTCMT","Million US$ at exchange rate","PRT","Portugal","2015","2015",138,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOTCMT","Million US$ at exchange rate","PRT","Portugal","2016","2016",144.6,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOTCMT","Million US$ at exchange rate","PRT","Portugal","2017","2017",148.9,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOTCMT","Million US$ at exchange rate","PRT","Portugal","2018","2018",159.5,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOTCMT","Million US$ at exchange rate","PRT","Portugal","2019","2019",160.2,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOTCMT","Million US$ at exchange rate","PRT","Portugal","2020","2020",168.8,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOTCMT","Million US$ at exchange rate","PRT","Portugal","2021","2021",167.4,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOTCMT","Million US$ at exchange rate","PRT","Portugal","2022","2022",160.7,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOPPMT","Million US$, purchasing power parity","PRT","Portugal","2010","2010",211,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOPPMT","Million US$, purchasing power parity","PRT","Portugal","2011","2011",212,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOPPMT","Million US$, purchasing power parity","PRT","Portugal","2012","2012",215.9,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOPPMT","Million US$, purchasing power parity","PRT","Portugal","2013","2013",212.9,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOPPMT","Million US$, purchasing power parity","PRT","Portugal","2014","2014",202.3,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOPPMT","Million US$, purchasing power parity","PRT","Portugal","2015","2015",212.7,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOPPMT","Million US$, purchasing power parity","PRT","Portugal","2016","2016",228.7,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOPPMT","Million US$, purchasing power parity","PRT","Portugal","2017","2017",228.9,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOPPMT","Million US$, purchasing power parity","PRT","Portugal","2018","2018",236.4,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOPPMT","Million US$, purchasing power parity","PRT","Portugal","2019","2019",256.1,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOPPMT","Million US$, purchasing power parity","PRT","Portugal","2020","2020",265.3,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOPPMT","Million US$, purchasing power parity","PRT","Portugal","2021","2021",249.3,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOPPMT","Million US$, purchasing power parity","PRT","Portugal","2022","2022",277.6,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","TCPPERMT","/capita, US$ exchange rate","PRT","Portugal","2010","2010",16.5,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","TCPPERMT","/capita, US$ exchange rate","PRT","Portugal","2011","2011",17.4,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","TCPPERMT","/capita, US$ exchange rate","PRT","Portugal","2012","2012",16,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","TCPPERMT","/capita, US$ exchange rate","PRT","Portugal","2013","2013",15.8,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","TCPPERMT","/capita, US$ exchange rate","PRT","Portugal","2014","2014",15,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","TCPPERMT","/capita, US$ exchange rate","PRT","Portugal","2015","2015",13.3,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","TCPPERMT","/capita, US$ exchange rate","PRT","Portugal","2016","2016",14,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","TCPPERMT","/capita, US$ exchange rate","PRT","Portugal","2017","2017",14.5,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","TCPPERMT","/capita, US$ exchange rate","PRT","Portugal","2018","2018",15.5,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","TCPPERMT","/capita, US$ exchange rate","PRT","Portugal","2019","2019",15.6,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","TCPPERMT","/capita, US$ exchange rate","PRT","Portugal","2020","2020",16.4,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","TCPPERMT","/capita, US$ exchange rate","PRT","Portugal","2021","2021",16.2,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","TCPPERMT","/capita, US$ exchange rate","PRT","Portugal","2022","2022",15.5,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2010","2010",20,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2011","2011",20.1,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2012","2012",20.5,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2013","2013",20.4,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2014","2014",19.4,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2015","2015",20.5,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2016","2016",22.1,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2017","2017",22.2,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2018","2018",23,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2019","2019",24.9,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2020","2020",25.8,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2021","2021",24.1,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2022","2022",26.8,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","ATCPTTMT","% of total sales","PRT","Portugal","2010","2010",4.1,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","ATCPTTMT","% of total sales","PRT","Portugal","2011","2011",4.5,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","ATCPTTMT","% of total sales","PRT","Portugal","2012","2012",5,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","ATCPTTMT","% of total sales","PRT","Portugal","2013","2013",5.2,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","ATCPTTMT","% of total sales","PRT","Portugal","2014","2014",4.9,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","ATCPTTMT","% of total sales","PRT","Portugal","2015","2015",5,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","ATCPTTMT","% of total sales","PRT","Portugal","2016","2016",5.2,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","ATCPTTMT","% of total sales","PRT","Portugal","2017","2017",5.2,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","ATCPTTMT","% of total sales","PRT","Portugal","2018","2018",5.1,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","ATCPTTMT","% of total sales","PRT","Portugal","2019","2019",5.1,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","ATCPTTMT","% of total sales","PRT","Portugal","2020","2020",5.3,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","ATCPTTMT","% of total sales","PRT","Portugal","2021","2021",4.8,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","ATCPTTMT","% of total sales","PRT","Portugal","2022","2022",4.8,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MLLNCUMT","Million of national currency units","SVK","Slovak Republic","2010","2010",34.2,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MLLNCUMT","Million of national currency units","SVK","Slovak Republic","2011","2011",36.9,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MLLNCUMT","Million of national currency units","SVK","Slovak Republic","2012","2012",34,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MLLNCUMT","Million of national currency units","SVK","Slovak Republic","2013","2013",38.8,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MLLNCUMT","Million of national currency units","SVK","Slovak Republic","2014","2014",41.5,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MLLNCUMT","Million of national currency units","SVK","Slovak Republic","2015","2015",42.8,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MLLNCUMT","Million of national currency units","SVK","Slovak Republic","2016","2016",49.8,"B","Break"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MLLNCUMT","Million of national currency units","SVK","Slovak Republic","2017","2017",48.2,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MLLNCUMT","Million of national currency units","SVK","Slovak Republic","2018","2018",43.4,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MLLNCUMT","Million of national currency units","SVK","Slovak Republic","2019","2019",44.1,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MLLNCUMT","Million of national currency units","SVK","Slovak Republic","2020","2020",42.6,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MLLNCUMT","Million of national currency units","SVK","Slovak Republic","2021","2021",41.3,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOTCMT","Million US$ at exchange rate","SVK","Slovak Republic","2010","2010",45.4,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOTCMT","Million US$ at exchange rate","SVK","Slovak Republic","2011","2011",51.4,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOTCMT","Million US$ at exchange rate","SVK","Slovak Republic","2012","2012",43.7,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOTCMT","Million US$ at exchange rate","SVK","Slovak Republic","2013","2013",51.5,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOTCMT","Million US$ at exchange rate","SVK","Slovak Republic","2014","2014",55.1,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOTCMT","Million US$ at exchange rate","SVK","Slovak Republic","2015","2015",47.5,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOTCMT","Million US$ at exchange rate","SVK","Slovak Republic","2016","2016",55.1,"B","Break"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOTCMT","Million US$ at exchange rate","SVK","Slovak Republic","2017","2017",54.5,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOTCMT","Million US$ at exchange rate","SVK","Slovak Republic","2018","2018",51.2,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOTCMT","Million US$ at exchange rate","SVK","Slovak Republic","2019","2019",49.4,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOTCMT","Million US$ at exchange rate","SVK","Slovak Republic","2020","2020",48.6,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOTCMT","Million US$ at exchange rate","SVK","Slovak Republic","2021","2021",48.9,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOPPMT","Million US$, purchasing power parity","SVK","Slovak Republic","2010","2010",68.2,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOPPMT","Million US$, purchasing power parity","SVK","Slovak Republic","2011","2011",72.9,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOPPMT","Million US$, purchasing power parity","SVK","Slovak Republic","2012","2012",67.5,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOPPMT","Million US$, purchasing power parity","SVK","Slovak Republic","2013","2013",78.9,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOPPMT","Million US$, purchasing power parity","SVK","Slovak Republic","2014","2014",85.5,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOPPMT","Million US$, purchasing power parity","SVK","Slovak Republic","2015","2015",87.1,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOPPMT","Million US$, purchasing power parity","SVK","Slovak Republic","2016","2016",99,"B","Break"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOPPMT","Million US$, purchasing power parity","SVK","Slovak Republic","2017","2017",93.4,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOPPMT","Million US$, purchasing power parity","SVK","Slovak Republic","2018","2018",82.4,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOPPMT","Million US$, purchasing power parity","SVK","Slovak Republic","2019","2019",85.3,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOPPMT","Million US$, purchasing power parity","SVK","Slovak Republic","2020","2020",81.9,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOPPMT","Million US$, purchasing power parity","SVK","Slovak Republic","2021","2021",77.5,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","TCPPERMT","/capita, US$ exchange rate","SVK","Slovak Republic","2010","2010",8.4,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","TCPPERMT","/capita, US$ exchange rate","SVK","Slovak Republic","2011","2011",9.5,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","TCPPERMT","/capita, US$ exchange rate","SVK","Slovak Republic","2012","2012",8.1,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","TCPPERMT","/capita, US$ exchange rate","SVK","Slovak Republic","2013","2013",9.5,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","TCPPERMT","/capita, US$ exchange rate","SVK","Slovak Republic","2014","2014",10.2,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","TCPPERMT","/capita, US$ exchange rate","SVK","Slovak Republic","2015","2015",8.8,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","TCPPERMT","/capita, US$ exchange rate","SVK","Slovak Republic","2016","2016",10.2,"B","Break"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","TCPPERMT","/capita, US$ exchange rate","SVK","Slovak Republic","2017","2017",10,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","TCPPERMT","/capita, US$ exchange rate","SVK","Slovak Republic","2018","2018",9.4,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","TCPPERMT","/capita, US$ exchange rate","SVK","Slovak Republic","2019","2019",9.1,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","TCPPERMT","/capita, US$ exchange rate","SVK","Slovak Republic","2020","2020",8.9,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","TCPPERMT","/capita, US$ exchange rate","SVK","Slovak Republic","2021","2021",9,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2010","2010",12.6,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2011","2011",13.5,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2012","2012",12.5,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2013","2013",14.6,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2014","2014",15.8,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2015","2015",16.1,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2016","2016",18.2,"B","Break"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2017","2017",17.2,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2018","2018",15.1,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2019","2019",15.6,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2020","2020",15,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2021","2021",14.2,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","ATCPTTMT","% of total sales","SVK","Slovak Republic","2010","2010",3.1,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","ATCPTTMT","% of total sales","SVK","Slovak Republic","2011","2011",3.3,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","ATCPTTMT","% of total sales","SVK","Slovak Republic","2012","2012",3.1,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","ATCPTTMT","% of total sales","SVK","Slovak Republic","2013","2013",3.2,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","ATCPTTMT","% of total sales","SVK","Slovak Republic","2014","2014",3.2,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","ATCPTTMT","% of total sales","SVK","Slovak Republic","2015","2015",3.1,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","ATCPTTMT","% of total sales","SVK","Slovak Republic","2016","2016",3.2,"B","Break"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","ATCPTTMT","% of total sales","SVK","Slovak Republic","2017","2017",3.1,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","ATCPTTMT","% of total sales","SVK","Slovak Republic","2018","2018",2.7,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","ATCPTTMT","% of total sales","SVK","Slovak Republic","2019","2019",2.6,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","ATCPTTMT","% of total sales","SVK","Slovak Republic","2020","2020",2.6,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","ATCPTTMT","% of total sales","SVK","Slovak Republic","2021","2021",2.3,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MLLNCUMT","Million of national currency units","ESP","Spain","2010","2010",1043.8,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MLLNCUMT","Million of national currency units","ESP","Spain","2011","2011",1063,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MLLNCUMT","Million of national currency units","ESP","Spain","2012","2012",1009,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MLLNCUMT","Million of national currency units","ESP","Spain","2013","2013",945,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MLLNCUMT","Million of national currency units","ESP","Spain","2014","2014",985.8,"B; D","Break; Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MLLNCUMT","Million of national currency units","ESP","Spain","2015","2015",1007.5,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MLLNCUMT","Million of national currency units","ESP","Spain","2016","2016",981.7,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MLLNCUMT","Million of national currency units","ESP","Spain","2017","2017",961.2,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MLLNCUMT","Million of national currency units","ESP","Spain","2018","2018",1143.7,"B","Break"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MLLNCUMT","Million of national currency units","ESP","Spain","2019","2019",1176.9,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MLLNCUMT","Million of national currency units","ESP","Spain","2020","2020",1191.6,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MLLNCUMT","Million of national currency units","ESP","Spain","2021","2021",1189.2,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MLLNCUMT","Million of national currency units","ESP","Spain","2022","2022",1243.9,"P","Provisional value"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOTCMT","Million US$ at exchange rate","ESP","Spain","2010","2010",1383.8,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOTCMT","Million US$ at exchange rate","ESP","Spain","2011","2011",1479.7,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOTCMT","Million US$ at exchange rate","ESP","Spain","2012","2012",1296.3,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOTCMT","Million US$ at exchange rate","ESP","Spain","2013","2013",1255.1,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOTCMT","Million US$ at exchange rate","ESP","Spain","2014","2014",1309.6,"B; D","Break; Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOTCMT","Million US$ at exchange rate","ESP","Spain","2015","2015",1117.9,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOTCMT","Million US$ at exchange rate","ESP","Spain","2016","2016",1086.6,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOTCMT","Million US$ at exchange rate","ESP","Spain","2017","2017",1085.8,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOTCMT","Million US$ at exchange rate","ESP","Spain","2018","2018",1350.7,"B","Break"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOTCMT","Million US$ at exchange rate","ESP","Spain","2019","2019",1317.5,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOTCMT","Million US$ at exchange rate","ESP","Spain","2020","2020",1361,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOTCMT","Million US$ at exchange rate","ESP","Spain","2021","2021",1406.5,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOTCMT","Million US$ at exchange rate","ESP","Spain","2022","2022",1309.9,"P","Provisional value"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOPPMT","Million US$, purchasing power parity","ESP","Spain","2010","2010",1435.9,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOPPMT","Million US$, purchasing power parity","ESP","Spain","2011","2011",1488.5,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOPPMT","Million US$, purchasing power parity","ESP","Spain","2012","2012",1451.8,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOPPMT","Million US$, purchasing power parity","ESP","Spain","2013","2013",1400.5,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOPPMT","Million US$, purchasing power parity","ESP","Spain","2014","2014",1488.3,"B; D","Break; Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOPPMT","Million US$, purchasing power parity","ESP","Spain","2015","2015",1515.7,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOPPMT","Million US$, purchasing power parity","ESP","Spain","2016","2016",1527.5,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOPPMT","Million US$, purchasing power parity","ESP","Spain","2017","2017",1523.6,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOPPMT","Million US$, purchasing power parity","ESP","Spain","2018","2018",1810.3,"B","Break"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOPPMT","Million US$, purchasing power parity","ESP","Spain","2019","2019",1919.9,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOPPMT","Million US$, purchasing power parity","ESP","Spain","2020","2020",1917.8,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOPPMT","Million US$, purchasing power parity","ESP","Spain","2021","2021",1899.8,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOPPMT","Million US$, purchasing power parity","ESP","Spain","2022","2022",2086.3,"P","Provisional value"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","TCPPERMT","/capita, US$ exchange rate","ESP","Spain","2010","2010",29.7,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","TCPPERMT","/capita, US$ exchange rate","ESP","Spain","2011","2011",31.7,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","TCPPERMT","/capita, US$ exchange rate","ESP","Spain","2012","2012",27.7,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","TCPPERMT","/capita, US$ exchange rate","ESP","Spain","2013","2013",26.9,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","TCPPERMT","/capita, US$ exchange rate","ESP","Spain","2014","2014",28.2,"B; D","Break; Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","TCPPERMT","/capita, US$ exchange rate","ESP","Spain","2015","2015",24.1,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","TCPPERMT","/capita, US$ exchange rate","ESP","Spain","2016","2016",23.4,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","TCPPERMT","/capita, US$ exchange rate","ESP","Spain","2017","2017",23.3,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","TCPPERMT","/capita, US$ exchange rate","ESP","Spain","2018","2018",28.9,"B","Break"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","TCPPERMT","/capita, US$ exchange rate","ESP","Spain","2019","2019",28,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","TCPPERMT","/capita, US$ exchange rate","ESP","Spain","2020","2020",28.7,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","TCPPERMT","/capita, US$ exchange rate","ESP","Spain","2021","2021",29.7,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","TCPPERMT","/capita, US$ exchange rate","ESP","Spain","2022","2022",27.6,"P","Provisional value"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2010","2010",30.8,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2011","2011",31.8,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2012","2012",31,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2013","2013",30,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2014","2014",32,"B; D","Break; Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2015","2015",32.6,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2016","2016",32.9,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2017","2017",32.7,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2018","2018",38.7,"B","Break"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2019","2019",40.7,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2020","2020",40.5,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2021","2021",40.1,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2022","2022",44,"P","Provisional value"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","ATCPTTMT","% of total sales","ESP","Spain","2010","2010",7.9,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","ATCPTTMT","% of total sales","ESP","Spain","2011","2011",8.6,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","ATCPTTMT","% of total sales","ESP","Spain","2012","2012",9.1,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","ATCPTTMT","% of total sales","ESP","Spain","2013","2013",8.9,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","ATCPTTMT","% of total sales","ESP","Spain","2014","2014",8.7,"B; D","Break; Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","ATCPTTMT","% of total sales","ESP","Spain","2015","2015",8.8,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","ATCPTTMT","% of total sales","ESP","Spain","2016","2016",8.3,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","ATCPTTMT","% of total sales","ESP","Spain","2017","2017",8,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","ATCPTTMT","% of total sales","ESP","Spain","2018","2018",6,"B","Break"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","ATCPTTMT","% of total sales","ESP","Spain","2019","2019",5.9,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","ATCPTTMT","% of total sales","ESP","Spain","2020","2020",5.7,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","ATCPTTMT","% of total sales","ESP","Spain","2021","2021",5.4,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","ATCPTTMT","% of total sales","ESP","Spain","2022","2022",5.4,"P","Provisional value"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MLLNCUMT","Million of national currency units","SWE","Sweden","2010","2010",1932.4,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MLLNCUMT","Million of national currency units","SWE","Sweden","2011","2011",1999.8,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MLLNCUMT","Million of national currency units","SWE","Sweden","2012","2012",2058.9,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MLLNCUMT","Million of national currency units","SWE","Sweden","2013","2013",2029.1,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MLLNCUMT","Million of national currency units","SWE","Sweden","2014","2014",1982.6,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MLLNCUMT","Million of national currency units","SWE","Sweden","2015","2015",1702.5,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MLLNCUMT","Million of national currency units","SWE","Sweden","2016","2016",1741.7,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MLLNCUMT","Million of national currency units","SWE","Sweden","2017","2017",1731.2,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MLLNCUMT","Million of national currency units","SWE","Sweden","2018","2018",1807.8,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MLLNCUMT","Million of national currency units","SWE","Sweden","2019","2019",1920.7,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MLLNCUMT","Million of national currency units","SWE","Sweden","2020","2020",2097.9,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MLLNCUMT","Million of national currency units","SWE","Sweden","2021","2021",2019.2,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MLLNCUMT","Million of national currency units","SWE","Sweden","2022","2022",2124.5,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOTCMT","Million US$ at exchange rate","SWE","Sweden","2010","2010",268.1,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOTCMT","Million US$ at exchange rate","SWE","Sweden","2011","2011",308,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOTCMT","Million US$ at exchange rate","SWE","Sweden","2012","2012",303.9,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOTCMT","Million US$ at exchange rate","SWE","Sweden","2013","2013",311.5,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOTCMT","Million US$ at exchange rate","SWE","Sweden","2014","2014",289,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOTCMT","Million US$ at exchange rate","SWE","Sweden","2015","2015",201.8,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOTCMT","Million US$ at exchange rate","SWE","Sweden","2016","2016",203.4,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOTCMT","Million US$ at exchange rate","SWE","Sweden","2017","2017",202.5,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOTCMT","Million US$ at exchange rate","SWE","Sweden","2018","2018",208,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOTCMT","Million US$ at exchange rate","SWE","Sweden","2019","2019",203.1,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOTCMT","Million US$ at exchange rate","SWE","Sweden","2020","2020",227.8,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOTCMT","Million US$ at exchange rate","SWE","Sweden","2021","2021",235.4,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOTCMT","Million US$ at exchange rate","SWE","Sweden","2022","2022",210,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOPPMT","Million US$, purchasing power parity","SWE","Sweden","2010","2010",214.1,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOPPMT","Million US$, purchasing power parity","SWE","Sweden","2011","2011",226.1,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOPPMT","Million US$, purchasing power parity","SWE","Sweden","2012","2012",237.9,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOPPMT","Million US$, purchasing power parity","SWE","Sweden","2013","2013",236,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOPPMT","Million US$, purchasing power parity","SWE","Sweden","2014","2014",227.2,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOPPMT","Million US$, purchasing power parity","SWE","Sweden","2015","2015",192.3,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOPPMT","Million US$, purchasing power parity","SWE","Sweden","2016","2016",197.4,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOPPMT","Million US$, purchasing power parity","SWE","Sweden","2017","2017",195.6,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOPPMT","Million US$, purchasing power parity","SWE","Sweden","2018","2018",203.9,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOPPMT","Million US$, purchasing power parity","SWE","Sweden","2019","2019",220.5,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOPPMT","Million US$, purchasing power parity","SWE","Sweden","2020","2020",242,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOPPMT","Million US$, purchasing power parity","SWE","Sweden","2021","2021",231.5,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOPPMT","Million US$, purchasing power parity","SWE","Sweden","2022","2022",245.1,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","TCPPERMT","/capita, US$ exchange rate","SWE","Sweden","2010","2010",28.6,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","TCPPERMT","/capita, US$ exchange rate","SWE","Sweden","2011","2011",32.6,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","TCPPERMT","/capita, US$ exchange rate","SWE","Sweden","2012","2012",31.9,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","TCPPERMT","/capita, US$ exchange rate","SWE","Sweden","2013","2013",32.4,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","TCPPERMT","/capita, US$ exchange rate","SWE","Sweden","2014","2014",29.8,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","TCPPERMT","/capita, US$ exchange rate","SWE","Sweden","2015","2015",20.6,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","TCPPERMT","/capita, US$ exchange rate","SWE","Sweden","2016","2016",20.5,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","TCPPERMT","/capita, US$ exchange rate","SWE","Sweden","2017","2017",20.1,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","TCPPERMT","/capita, US$ exchange rate","SWE","Sweden","2018","2018",20.4,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","TCPPERMT","/capita, US$ exchange rate","SWE","Sweden","2019","2019",19.8,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","TCPPERMT","/capita, US$ exchange rate","SWE","Sweden","2020","2020",22,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","TCPPERMT","/capita, US$ exchange rate","SWE","Sweden","2021","2021",22.6,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","TCPPERMT","/capita, US$ exchange rate","SWE","Sweden","2022","2022",20.1,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2010","2010",22.8,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2011","2011",23.9,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2012","2012",25,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2013","2013",24.6,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2014","2014",23.4,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2015","2015",19.6,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2016","2016",19.9,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2017","2017",19.4,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2018","2018",20,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2019","2019",21.5,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2020","2020",23.4,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2021","2021",22.2,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2022","2022",23.5,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","ATCPTTMT","% of total sales","SWE","Sweden","2010","2010",5.4,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","ATCPTTMT","% of total sales","SWE","Sweden","2011","2011",5.4,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","ATCPTTMT","% of total sales","SWE","Sweden","2012","2012",5.7,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","ATCPTTMT","% of total sales","SWE","Sweden","2013","2013",5.6,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","ATCPTTMT","% of total sales","SWE","Sweden","2014","2014",5.2,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","ATCPTTMT","% of total sales","SWE","Sweden","2015","2015",4.2,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","ATCPTTMT","% of total sales","SWE","Sweden","2016","2016",4.1,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","ATCPTTMT","% of total sales","SWE","Sweden","2017","2017",4,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","ATCPTTMT","% of total sales","SWE","Sweden","2018","2018",3.8,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","ATCPTTMT","% of total sales","SWE","Sweden","2019","2019",3.8,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","ATCPTTMT","% of total sales","SWE","Sweden","2020","2020",4,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","ATCPTTMT","% of total sales","SWE","Sweden","2021","2021",3.7,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","ATCPTTMT","% of total sales","SWE","Sweden","2022","2022",3.7,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MLLNCUMT","Million of national currency units","TUR","Türkiye","2010","2010",899,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MLLNCUMT","Million of national currency units","TUR","Türkiye","2011","2011",860,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MLLNCUMT","Million of national currency units","TUR","Türkiye","2012","2012",707.2,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MLLNCUMT","Million of national currency units","TUR","Türkiye","2013","2013",727.2,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MLLNCUMT","Million of national currency units","TUR","Türkiye","2014","2014",777,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MLLNCUMT","Million of national currency units","TUR","Türkiye","2015","2015",857.2,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MLLNCUMT","Million of national currency units","TUR","Türkiye","2016","2016",973.9,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MLLNCUMT","Million of national currency units","TUR","Türkiye","2017","2017",1171.1,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MLLNCUMT","Million of national currency units","TUR","Türkiye","2018","2018",1451.1,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MLLNCUMT","Million of national currency units","TUR","Türkiye","2019","2019",1853,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MLLNCUMT","Million of national currency units","TUR","Türkiye","2020","2020",2231.6,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MLLNCUMT","Million of national currency units","TUR","Türkiye","2021","2021",2679.8,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOTCMT","Million US$ at exchange rate","TUR","Türkiye","2010","2010",598.2,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOTCMT","Million US$ at exchange rate","TUR","Türkiye","2011","2011",513.5,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOTCMT","Million US$ at exchange rate","TUR","Türkiye","2012","2012",393.8,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOTCMT","Million US$ at exchange rate","TUR","Türkiye","2013","2013",382,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOTCMT","Million US$ at exchange rate","TUR","Türkiye","2014","2014",355,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOTCMT","Million US$ at exchange rate","TUR","Türkiye","2015","2015",315.2,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOTCMT","Million US$ at exchange rate","TUR","Türkiye","2016","2016",322.5,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOTCMT","Million US$ at exchange rate","TUR","Türkiye","2017","2017",321,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOTCMT","Million US$ at exchange rate","TUR","Türkiye","2018","2018",300.5,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOTCMT","Million US$ at exchange rate","TUR","Türkiye","2019","2019",326.6,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOTCMT","Million US$ at exchange rate","TUR","Türkiye","2020","2020",318.4,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOTCMT","Million US$ at exchange rate","TUR","Türkiye","2021","2021",302.8,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOPPMT","Million US$, purchasing power parity","TUR","Türkiye","2010","2010",976.8,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOPPMT","Million US$, purchasing power parity","TUR","Türkiye","2011","2011",890.1,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOPPMT","Million US$, purchasing power parity","TUR","Türkiye","2012","2012",693.4,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOPPMT","Million US$, purchasing power parity","TUR","Türkiye","2013","2013",679.4,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOPPMT","Million US$, purchasing power parity","TUR","Türkiye","2014","2014",703.5,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOPPMT","Million US$, purchasing power parity","TUR","Türkiye","2015","2015",737.4,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOPPMT","Million US$, purchasing power parity","TUR","Türkiye","2016","2016",784.7,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOPPMT","Million US$, purchasing power parity","TUR","Türkiye","2017","2017",846.2,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOPPMT","Million US$, purchasing power parity","TUR","Türkiye","2018","2018",888.8,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOPPMT","Million US$, purchasing power parity","TUR","Türkiye","2019","2019",994.1,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOPPMT","Million US$, purchasing power parity","TUR","Türkiye","2020","2020",1031.2,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOPPMT","Million US$, purchasing power parity","TUR","Türkiye","2021","2021",954.4,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","TCPPERMT","/capita, US$ exchange rate","TUR","Türkiye","2010","2010",8.2,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","TCPPERMT","/capita, US$ exchange rate","TUR","Türkiye","2011","2011",6.9,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","TCPPERMT","/capita, US$ exchange rate","TUR","Türkiye","2012","2012",5.2,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","TCPPERMT","/capita, US$ exchange rate","TUR","Türkiye","2013","2013",5,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","TCPPERMT","/capita, US$ exchange rate","TUR","Türkiye","2014","2014",4.6,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","TCPPERMT","/capita, US$ exchange rate","TUR","Türkiye","2015","2015",4,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","TCPPERMT","/capita, US$ exchange rate","TUR","Türkiye","2016","2016",4.1,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","TCPPERMT","/capita, US$ exchange rate","TUR","Türkiye","2017","2017",4,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","TCPPERMT","/capita, US$ exchange rate","TUR","Türkiye","2018","2018",3.7,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","TCPPERMT","/capita, US$ exchange rate","TUR","Türkiye","2019","2019",4,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","TCPPERMT","/capita, US$ exchange rate","TUR","Türkiye","2020","2020",3.8,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","TCPPERMT","/capita, US$ exchange rate","TUR","Türkiye","2021","2021",3.6,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2010","2010",13.4,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2011","2011",12,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2012","2012",9.2,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2013","2013",8.9,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2014","2014",9.1,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2015","2015",9.4,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2016","2016",9.9,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2017","2017",10.5,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2018","2018",10.9,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2019","2019",12,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2020","2020",12.4,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2021","2021",11.3,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","ATCPTTMT","% of total sales","TUR","Türkiye","2010","2010",5.8,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","ATCPTTMT","% of total sales","TUR","Türkiye","2011","2011",6.1,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","ATCPTTMT","% of total sales","TUR","Türkiye","2012","2012",5.2,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","ATCPTTMT","% of total sales","TUR","Türkiye","2013","2013",5.1,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","ATCPTTMT","% of total sales","TUR","Türkiye","2014","2014",4.9,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","ATCPTTMT","% of total sales","TUR","Türkiye","2015","2015",4.7,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","ATCPTTMT","% of total sales","TUR","Türkiye","2016","2016",4.4,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","ATCPTTMT","% of total sales","TUR","Türkiye","2017","2017",4.6,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","ATCPTTMT","% of total sales","TUR","Türkiye","2018","2018",4.5,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","ATCPTTMT","% of total sales","TUR","Türkiye","2019","2019",4.4,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","ATCPTTMT","% of total sales","TUR","Türkiye","2020","2020",4.5,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","ATCPTTMT","% of total sales","TUR","Türkiye","2021","2021",4.1,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MLLNCUMT","Million of national currency units","CHL","Chile","2010","2010",15206.7,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MLLNCUMT","Million of national currency units","CHL","Chile","2011","2011",26263.5,"B","Break"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MLLNCUMT","Million of national currency units","CHL","Chile","2012","2012",29207.1,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MLLNCUMT","Million of national currency units","CHL","Chile","2013","2013",30901.9,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MLLNCUMT","Million of national currency units","CHL","Chile","2014","2014",37615.6,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MLLNCUMT","Million of national currency units","CHL","Chile","2015","2015",46814.6,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MLLNCUMT","Million of national currency units","CHL","Chile","2016","2016",52879.3,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MLLNCUMT","Million of national currency units","CHL","Chile","2017","2017",56041,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MLLNCUMT","Million of national currency units","CHL","Chile","2018","2018",59206.9,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MLLNCUMT","Million of national currency units","CHL","Chile","2019","2019",57730.3,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MLLNCUMT","Million of national currency units","CHL","Chile","2020","2020",63661.9,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MLLNCUMT","Million of national currency units","CHL","Chile","2021","2021",80618.1,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MLLNCUMT","Million of national currency units","CHL","Chile","2022","2022",88464,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOTCMT","Million US$ at exchange rate","CHL","Chile","2010","2010",29.8,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOTCMT","Million US$ at exchange rate","CHL","Chile","2011","2011",54.3,"B","Break"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOTCMT","Million US$ at exchange rate","CHL","Chile","2012","2012",60,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOTCMT","Million US$ at exchange rate","CHL","Chile","2013","2013",62.4,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOTCMT","Million US$ at exchange rate","CHL","Chile","2014","2014",66,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOTCMT","Million US$ at exchange rate","CHL","Chile","2015","2015",71.6,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOTCMT","Million US$ at exchange rate","CHL","Chile","2016","2016",78.1,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOTCMT","Million US$ at exchange rate","CHL","Chile","2017","2017",86.4,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOTCMT","Million US$ at exchange rate","CHL","Chile","2018","2018",92.3,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOTCMT","Million US$ at exchange rate","CHL","Chile","2019","2019",82.1,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOTCMT","Million US$ at exchange rate","CHL","Chile","2020","2020",80.3,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOTCMT","Million US$ at exchange rate","CHL","Chile","2021","2021",106.2,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOTCMT","Million US$ at exchange rate","CHL","Chile","2022","2022",101.3,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOPPMT","Million US$, purchasing power parity","CHL","Chile","2010","2010",42.3,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOPPMT","Million US$, purchasing power parity","CHL","Chile","2011","2011",75.5,"B","Break"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOPPMT","Million US$, purchasing power parity","CHL","Chile","2012","2012",84.1,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOPPMT","Million US$, purchasing power parity","CHL","Chile","2013","2013",88.4,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOPPMT","Million US$, purchasing power parity","CHL","Chile","2014","2014",102.4,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOPPMT","Million US$, purchasing power parity","CHL","Chile","2015","2015",119.7,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOPPMT","Million US$, purchasing power parity","CHL","Chile","2016","2016",133.1,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOPPMT","Million US$, purchasing power parity","CHL","Chile","2017","2017",140.9,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOPPMT","Million US$, purchasing power parity","CHL","Chile","2018","2018",149.4,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOPPMT","Million US$, purchasing power parity","CHL","Chile","2019","2019",143.7,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOPPMT","Million US$, purchasing power parity","CHL","Chile","2020","2020",152.1,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOPPMT","Million US$, purchasing power parity","CHL","Chile","2021","2021",185.3,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOPPMT","Million US$, purchasing power parity","CHL","Chile","2022","2022",202.2,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","TCPPERMT","/capita, US$ exchange rate","CHL","Chile","2010","2010",1.7,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","TCPPERMT","/capita, US$ exchange rate","CHL","Chile","2011","2011",3.1,"B","Break"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","TCPPERMT","/capita, US$ exchange rate","CHL","Chile","2012","2012",3.4,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","TCPPERMT","/capita, US$ exchange rate","CHL","Chile","2013","2013",3.5,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","TCPPERMT","/capita, US$ exchange rate","CHL","Chile","2014","2014",3.7,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","TCPPERMT","/capita, US$ exchange rate","CHL","Chile","2015","2015",4,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","TCPPERMT","/capita, US$ exchange rate","CHL","Chile","2016","2016",4.3,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","TCPPERMT","/capita, US$ exchange rate","CHL","Chile","2017","2017",4.7,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","TCPPERMT","/capita, US$ exchange rate","CHL","Chile","2018","2018",4.9,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","TCPPERMT","/capita, US$ exchange rate","CHL","Chile","2019","2019",4.3,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","TCPPERMT","/capita, US$ exchange rate","CHL","Chile","2020","2020",4.1,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","TCPPERMT","/capita, US$ exchange rate","CHL","Chile","2021","2021",5.4,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","TCPPERMT","/capita, US$ exchange rate","CHL","Chile","2022","2022",5.1,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2010","2010",2.5,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2011","2011",4.4,"B","Break"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2012","2012",4.8,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2013","2013",5,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2014","2014",5.8,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2015","2015",6.7,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2016","2016",7.3,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2017","2017",7.7,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2018","2018",8,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2019","2019",7.5,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2020","2020",7.8,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2021","2021",9.4,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2022","2022",10.2,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","ATCPTTMT","% of total sales","CHL","Chile","2010","2010",1.8,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","ATCPTTMT","% of total sales","CHL","Chile","2011","2011",2.2,"B","Break"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","ATCPTTMT","% of total sales","CHL","Chile","2012","2012",2.3,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","ATCPTTMT","% of total sales","CHL","Chile","2013","2013",2.1,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","ATCPTTMT","% of total sales","CHL","Chile","2014","2014",2.4,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","ATCPTTMT","% of total sales","CHL","Chile","2015","2015",2.6,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","ATCPTTMT","% of total sales","CHL","Chile","2016","2016",2.6,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","ATCPTTMT","% of total sales","CHL","Chile","2017","2017",2.7,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","ATCPTTMT","% of total sales","CHL","Chile","2018","2018",2.6,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","ATCPTTMT","% of total sales","CHL","Chile","2019","2019",2.3,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","ATCPTTMT","% of total sales","CHL","Chile","2020","2020",2.4,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","ATCPTTMT","% of total sales","CHL","Chile","2021","2021",2.9,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","ATCPTTMT","% of total sales","CHL","Chile","2022","2022",3.1,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MLLNCUMT","Million of national currency units","EST","Estonia","2010","2010",6.4,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MLLNCUMT","Million of national currency units","EST","Estonia","2011","2011",6.7,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MLLNCUMT","Million of national currency units","EST","Estonia","2012","2012",7.4,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MLLNCUMT","Million of national currency units","EST","Estonia","2013","2013",8.3,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MLLNCUMT","Million of national currency units","EST","Estonia","2014","2014",8.7,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MLLNCUMT","Million of national currency units","EST","Estonia","2015","2015",8.6,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MLLNCUMT","Million of national currency units","EST","Estonia","2016","2016",8.9,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MLLNCUMT","Million of national currency units","EST","Estonia","2017","2017",9.2,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MLLNCUMT","Million of national currency units","EST","Estonia","2018","2018",10.2,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MLLNCUMT","Million of national currency units","EST","Estonia","2019","2019",10.5,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MLLNCUMT","Million of national currency units","EST","Estonia","2020","2020",11.1,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MLLNCUMT","Million of national currency units","EST","Estonia","2021","2021",11.3,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MLLNCUMT","Million of national currency units","EST","Estonia","2022","2022",11.6,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOTCMT","Million US$ at exchange rate","EST","Estonia","2010","2010",8.5,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOTCMT","Million US$ at exchange rate","EST","Estonia","2011","2011",9.3,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOTCMT","Million US$ at exchange rate","EST","Estonia","2012","2012",9.5,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOTCMT","Million US$ at exchange rate","EST","Estonia","2013","2013",11.1,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOTCMT","Million US$ at exchange rate","EST","Estonia","2014","2014",11.6,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOTCMT","Million US$ at exchange rate","EST","Estonia","2015","2015",9.6,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOTCMT","Million US$ at exchange rate","EST","Estonia","2016","2016",9.8,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOTCMT","Million US$ at exchange rate","EST","Estonia","2017","2017",10.4,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOTCMT","Million US$ at exchange rate","EST","Estonia","2018","2018",12,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOTCMT","Million US$ at exchange rate","EST","Estonia","2019","2019",11.7,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOTCMT","Million US$ at exchange rate","EST","Estonia","2020","2020",12.6,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOTCMT","Million US$ at exchange rate","EST","Estonia","2021","2021",13.4,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOTCMT","Million US$ at exchange rate","EST","Estonia","2022","2022",12.2,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOPPMT","Million US$, purchasing power parity","EST","Estonia","2010","2010",12.5,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOPPMT","Million US$, purchasing power parity","EST","Estonia","2011","2011",13.1,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOPPMT","Million US$, purchasing power parity","EST","Estonia","2012","2012",14.2,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOPPMT","Million US$, purchasing power parity","EST","Estonia","2013","2013",16,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOPPMT","Million US$, purchasing power parity","EST","Estonia","2014","2014",16.6,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOPPMT","Million US$, purchasing power parity","EST","Estonia","2015","2015",16,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOPPMT","Million US$, purchasing power parity","EST","Estonia","2016","2016",16.8,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOPPMT","Million US$, purchasing power parity","EST","Estonia","2017","2017",17.2,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOPPMT","Million US$, purchasing power parity","EST","Estonia","2018","2018",18.9,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOPPMT","Million US$, purchasing power parity","EST","Estonia","2019","2019",19.6,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOPPMT","Million US$, purchasing power parity","EST","Estonia","2020","2020",21.1,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOPPMT","Million US$, purchasing power parity","EST","Estonia","2021","2021",20.9,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOPPMT","Million US$, purchasing power parity","EST","Estonia","2022","2022",20.4,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","TCPPERMT","/capita, US$ exchange rate","EST","Estonia","2010","2010",6.4,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","TCPPERMT","/capita, US$ exchange rate","EST","Estonia","2011","2011",7,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","TCPPERMT","/capita, US$ exchange rate","EST","Estonia","2012","2012",7.2,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","TCPPERMT","/capita, US$ exchange rate","EST","Estonia","2013","2013",8.4,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","TCPPERMT","/capita, US$ exchange rate","EST","Estonia","2014","2014",8.8,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","TCPPERMT","/capita, US$ exchange rate","EST","Estonia","2015","2015",7.3,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","TCPPERMT","/capita, US$ exchange rate","EST","Estonia","2016","2016",7.5,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","TCPPERMT","/capita, US$ exchange rate","EST","Estonia","2017","2017",7.9,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","TCPPERMT","/capita, US$ exchange rate","EST","Estonia","2018","2018",9.1,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","TCPPERMT","/capita, US$ exchange rate","EST","Estonia","2019","2019",8.8,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","TCPPERMT","/capita, US$ exchange rate","EST","Estonia","2020","2020",9.5,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","TCPPERMT","/capita, US$ exchange rate","EST","Estonia","2021","2021",10.1,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","TCPPERMT","/capita, US$ exchange rate","EST","Estonia","2022","2022",9.2,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2010","2010",9.4,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2011","2011",9.8,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2012","2012",10.7,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2013","2013",12.1,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2014","2014",12.6,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2015","2015",12.2,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2016","2016",12.8,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2017","2017",13.1,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2018","2018",14.3,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2019","2019",14.7,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2020","2020",15.9,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2021","2021",15.7,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2022","2022",15.3,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","ATCPTTMT","% of total sales","EST","Estonia","2010","2010",3.3,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","ATCPTTMT","% of total sales","EST","Estonia","2011","2011",3.3,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","ATCPTTMT","% of total sales","EST","Estonia","2012","2012",3.3,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","ATCPTTMT","% of total sales","EST","Estonia","2013","2013",3.6,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","ATCPTTMT","% of total sales","EST","Estonia","2014","2014",3.5,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","ATCPTTMT","% of total sales","EST","Estonia","2015","2015",3.3,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","ATCPTTMT","% of total sales","EST","Estonia","2016","2016",3.1,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","ATCPTTMT","% of total sales","EST","Estonia","2017","2017",3.1,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","ATCPTTMT","% of total sales","EST","Estonia","2018","2018",3.1,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","ATCPTTMT","% of total sales","EST","Estonia","2019","2019",3,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","ATCPTTMT","% of total sales","EST","Estonia","2020","2020",3.1,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","ATCPTTMT","% of total sales","EST","Estonia","2021","2021",2.8,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","ATCPTTMT","% of total sales","EST","Estonia","2022","2022",2.7,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MLLNCUMT","Million of national currency units","SVN","Slovenia","2010","2010",23,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MLLNCUMT","Million of national currency units","SVN","Slovenia","2011","2011",23,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MLLNCUMT","Million of national currency units","SVN","Slovenia","2012","2012",22.8,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MLLNCUMT","Million of national currency units","SVN","Slovenia","2013","2013",22.1,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MLLNCUMT","Million of national currency units","SVN","Slovenia","2014","2014",21.3,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MLLNCUMT","Million of national currency units","SVN","Slovenia","2015","2015",21.3,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MLLNCUMT","Million of national currency units","SVN","Slovenia","2016","2016",22.2,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MLLNCUMT","Million of national currency units","SVN","Slovenia","2017","2017",20.6,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MLLNCUMT","Million of national currency units","SVN","Slovenia","2018","2018",18.9,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MLLNCUMT","Million of national currency units","SVN","Slovenia","2019","2019",20.3,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MLLNCUMT","Million of national currency units","SVN","Slovenia","2020","2020",21.7,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MLLNCUMT","Million of national currency units","SVN","Slovenia","2021","2021",23,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MLLNCUMT","Million of national currency units","SVN","Slovenia","2022","2022",24.1,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOTCMT","Million US$ at exchange rate","SVN","Slovenia","2010","2010",30.5,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOTCMT","Million US$ at exchange rate","SVN","Slovenia","2011","2011",32,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOTCMT","Million US$ at exchange rate","SVN","Slovenia","2012","2012",29.3,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOTCMT","Million US$ at exchange rate","SVN","Slovenia","2013","2013",29.3,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOTCMT","Million US$ at exchange rate","SVN","Slovenia","2014","2014",28.3,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOTCMT","Million US$ at exchange rate","SVN","Slovenia","2015","2015",23.6,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOTCMT","Million US$ at exchange rate","SVN","Slovenia","2016","2016",24.6,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOTCMT","Million US$ at exchange rate","SVN","Slovenia","2017","2017",23.3,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOTCMT","Million US$ at exchange rate","SVN","Slovenia","2018","2018",22.3,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOTCMT","Million US$ at exchange rate","SVN","Slovenia","2019","2019",22.8,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOTCMT","Million US$ at exchange rate","SVN","Slovenia","2020","2020",24.7,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOTCMT","Million US$ at exchange rate","SVN","Slovenia","2021","2021",27.2,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOTCMT","Million US$ at exchange rate","SVN","Slovenia","2022","2022",25.4,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOPPMT","Million US$, purchasing power parity","SVN","Slovenia","2010","2010",36,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOPPMT","Million US$, purchasing power parity","SVN","Slovenia","2011","2011",36.9,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOPPMT","Million US$, purchasing power parity","SVN","Slovenia","2012","2012",37.6,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOPPMT","Million US$, purchasing power parity","SVN","Slovenia","2013","2013",37.4,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOPPMT","Million US$, purchasing power parity","SVN","Slovenia","2014","2014",36.1,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOPPMT","Million US$, purchasing power parity","SVN","Slovenia","2015","2015",35.8,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOPPMT","Million US$, purchasing power parity","SVN","Slovenia","2016","2016",38.5,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOPPMT","Million US$, purchasing power parity","SVN","Slovenia","2017","2017",36.2,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOPPMT","Million US$, purchasing power parity","SVN","Slovenia","2018","2018",33.3,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOPPMT","Million US$, purchasing power parity","SVN","Slovenia","2019","2019",36.8,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOPPMT","Million US$, purchasing power parity","SVN","Slovenia","2020","2020",39.6,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOPPMT","Million US$, purchasing power parity","SVN","Slovenia","2021","2021",40.8,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOPPMT","Million US$, purchasing power parity","SVN","Slovenia","2022","2022",43.8,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","TCPPERMT","/capita, US$ exchange rate","SVN","Slovenia","2010","2010",14.9,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","TCPPERMT","/capita, US$ exchange rate","SVN","Slovenia","2011","2011",15.6,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","TCPPERMT","/capita, US$ exchange rate","SVN","Slovenia","2012","2012",14.3,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","TCPPERMT","/capita, US$ exchange rate","SVN","Slovenia","2013","2013",14.2,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","TCPPERMT","/capita, US$ exchange rate","SVN","Slovenia","2014","2014",13.7,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","TCPPERMT","/capita, US$ exchange rate","SVN","Slovenia","2015","2015",11.5,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","TCPPERMT","/capita, US$ exchange rate","SVN","Slovenia","2016","2016",11.9,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","TCPPERMT","/capita, US$ exchange rate","SVN","Slovenia","2017","2017",11.3,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","TCPPERMT","/capita, US$ exchange rate","SVN","Slovenia","2018","2018",10.8,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","TCPPERMT","/capita, US$ exchange rate","SVN","Slovenia","2019","2019",10.9,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","TCPPERMT","/capita, US$ exchange rate","SVN","Slovenia","2020","2020",11.8,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","TCPPERMT","/capita, US$ exchange rate","SVN","Slovenia","2021","2021",12.9,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","TCPPERMT","/capita, US$ exchange rate","SVN","Slovenia","2022","2022",12.1,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2010","2010",17.6,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2011","2011",18,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2012","2012",18.3,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2013","2013",18.2,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2014","2014",17.5,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2015","2015",17.3,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2016","2016",18.6,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2017","2017",17.5,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2018","2018",16,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2019","2019",17.6,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2020","2020",18.8,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2021","2021",19.3,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2022","2022",20.8,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","ATCPTTMT","% of total sales","SVN","Slovenia","2010","2010",4.8,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","ATCPTTMT","% of total sales","SVN","Slovenia","2011","2011",4.9,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","ATCPTTMT","% of total sales","SVN","Slovenia","2012","2012",5,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","ATCPTTMT","% of total sales","SVN","Slovenia","2013","2013",4.9,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","ATCPTTMT","% of total sales","SVN","Slovenia","2014","2014",4.9,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","ATCPTTMT","% of total sales","SVN","Slovenia","2015","2015",4.8,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","ATCPTTMT","% of total sales","SVN","Slovenia","2016","2016",4.8,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","ATCPTTMT","% of total sales","SVN","Slovenia","2017","2017",4.3,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","ATCPTTMT","% of total sales","SVN","Slovenia","2018","2018",3.7,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","ATCPTTMT","% of total sales","SVN","Slovenia","2019","2019",3.8,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","ATCPTTMT","% of total sales","SVN","Slovenia","2020","2020",3.8,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","ATCPTTMT","% of total sales","SVN","Slovenia","2021","2021",3.7,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","ATCPTTMT","% of total sales","SVN","Slovenia","2022","2022",3.6,"D","Difference in methodology"
+"PATCOTHR","Products not elsewhere classified","MLLNCUMT","Million of national currency units","AUS","Australia","2010","2010",2266,"D","Difference in methodology"
+"PATCOTHR","Products not elsewhere classified","MLLNCUMT","Million of national currency units","AUS","Australia","2011","2011",2515,"D","Difference in methodology"
+"PATCOTHR","Products not elsewhere classified","MLLNCUMT","Million of national currency units","AUS","Australia","2012","2012",2822,"D","Difference in methodology"
+"PATCOTHR","Products not elsewhere classified","MLLNCUMT","Million of national currency units","AUS","Australia","2013","2013",3239,"B; D","Break; Difference in methodology"
+"PATCOTHR","Products not elsewhere classified","MLLNCUMT","Million of national currency units","AUS","Australia","2014","2014",3616,"D","Difference in methodology"
+"PATCOTHR","Products not elsewhere classified","MLLNCUMT","Million of national currency units","AUS","Australia","2015","2015",3987,"D","Difference in methodology"
+"PATCOTHR","Products not elsewhere classified","MLLNCUMT","Million of national currency units","AUS","Australia","2016","2016",4356,"D","Difference in methodology"
+"PATCOTHR","Products not elsewhere classified","MLLNCUMT","Million of national currency units","AUS","Australia","2017","2017",4587,"D","Difference in methodology"
+"PATCOTHR","Products not elsewhere classified","MLLNCUMT","Million of national currency units","AUS","Australia","2018","2018",5280,"D","Difference in methodology"
+"PATCOTHR","Products not elsewhere classified","MLLNCUMT","Million of national currency units","AUS","Australia","2019","2019",5999,"D","Difference in methodology"
+"PATCOTHR","Products not elsewhere classified","MLLNCUMT","Million of national currency units","AUS","Australia","2020","2020",6768,"D","Difference in methodology"
+"PATCOTHR","Products not elsewhere classified","MLLNCUMT","Million of national currency units","AUS","Australia","2021","2021",7354,"D","Difference in methodology"
+"PATCOTHR","Products not elsewhere classified","MTMOTCMT","Million US$ at exchange rate","AUS","Australia","2010","2010",2078.6,"D","Difference in methodology"
+"PATCOTHR","Products not elsewhere classified","MTMOTCMT","Million US$ at exchange rate","AUS","Australia","2011","2011",2594.2,"D","Difference in methodology"
+"PATCOTHR","Products not elsewhere classified","MTMOTCMT","Million US$ at exchange rate","AUS","Australia","2012","2012",2921.9,"D","Difference in methodology"
+"PATCOTHR","Products not elsewhere classified","MTMOTCMT","Million US$ at exchange rate","AUS","Australia","2013","2013",3126.9,"B; D","Break; Difference in methodology"
+"PATCOTHR","Products not elsewhere classified","MTMOTCMT","Million US$ at exchange rate","AUS","Australia","2014","2014",3259.5,"D","Difference in methodology"
+"PATCOTHR","Products not elsewhere classified","MTMOTCMT","Million US$ at exchange rate","AUS","Australia","2015","2015",2995.3,"D","Difference in methodology"
+"PATCOTHR","Products not elsewhere classified","MTMOTCMT","Million US$ at exchange rate","AUS","Australia","2016","2016",3238.1,"D","Difference in methodology"
+"PATCOTHR","Products not elsewhere classified","MTMOTCMT","Million US$ at exchange rate","AUS","Australia","2017","2017",3515.6,"D","Difference in methodology"
+"PATCOTHR","Products not elsewhere classified","MTMOTCMT","Million US$ at exchange rate","AUS","Australia","2018","2018",3945,"D","Difference in methodology"
+"PATCOTHR","Products not elsewhere classified","MTMOTCMT","Million US$ at exchange rate","AUS","Australia","2019","2019",4170.3,"D","Difference in methodology"
+"PATCOTHR","Products not elsewhere classified","MTMOTCMT","Million US$ at exchange rate","AUS","Australia","2020","2020",4657.7,"D","Difference in methodology"
+"PATCOTHR","Products not elsewhere classified","MTMOTCMT","Million US$ at exchange rate","AUS","Australia","2021","2021",5524.2,"D","Difference in methodology"
+"PATCOTHR","Products not elsewhere classified","MTMOPPMT","Million US$, purchasing power parity","AUS","Australia","2010","2010",1507,"D","Difference in methodology"
+"PATCOTHR","Products not elsewhere classified","MTMOPPMT","Million US$, purchasing power parity","AUS","Australia","2011","2011",1664.4,"D","Difference in methodology"
+"PATCOTHR","Products not elsewhere classified","MTMOPPMT","Million US$, purchasing power parity","AUS","Australia","2012","2012",1832.3,"D","Difference in methodology"
+"PATCOTHR","Products not elsewhere classified","MTMOPPMT","Million US$, purchasing power parity","AUS","Australia","2013","2013",2238.2,"B; D","Break; Difference in methodology"
+"PATCOTHR","Products not elsewhere classified","MTMOPPMT","Million US$, purchasing power parity","AUS","Australia","2014","2014",2489.5,"D","Difference in methodology"
+"PATCOTHR","Products not elsewhere classified","MTMOPPMT","Million US$, purchasing power parity","AUS","Australia","2015","2015",2705.5,"D","Difference in methodology"
+"PATCOTHR","Products not elsewhere classified","MTMOPPMT","Million US$, purchasing power parity","AUS","Australia","2016","2016",3003.8,"D","Difference in methodology"
+"PATCOTHR","Products not elsewhere classified","MTMOPPMT","Million US$, purchasing power parity","AUS","Australia","2017","2017",3104.5,"D","Difference in methodology"
+"PATCOTHR","Products not elsewhere classified","MTMOPPMT","Million US$, purchasing power parity","AUS","Australia","2018","2018",3590.9,"D","Difference in methodology"
+"PATCOTHR","Products not elsewhere classified","MTMOPPMT","Million US$, purchasing power parity","AUS","Australia","2019","2019",4053.7,"D","Difference in methodology"
+"PATCOTHR","Products not elsewhere classified","MTMOPPMT","Million US$, purchasing power parity","AUS","Australia","2020","2020",4654.9,"D","Difference in methodology"
+"PATCOTHR","Products not elsewhere classified","MTMOPPMT","Million US$, purchasing power parity","AUS","Australia","2021","2021",5080.2,"D","Difference in methodology"
+"PATCOTHR","Products not elsewhere classified","TCPPERMT","/capita, US$ exchange rate","AUS","Australia","2010","2010",94.3,"D","Difference in methodology"
+"PATCOTHR","Products not elsewhere classified","TCPPERMT","/capita, US$ exchange rate","AUS","Australia","2011","2011",116.1,"D","Difference in methodology"
+"PATCOTHR","Products not elsewhere classified","TCPPERMT","/capita, US$ exchange rate","AUS","Australia","2012","2012",128.5,"D","Difference in methodology"
+"PATCOTHR","Products not elsewhere classified","TCPPERMT","/capita, US$ exchange rate","AUS","Australia","2013","2013",135.2,"B; D","Break; Difference in methodology"
+"PATCOTHR","Products not elsewhere classified","TCPPERMT","/capita, US$ exchange rate","AUS","Australia","2014","2014",138.8,"D","Difference in methodology"
+"PATCOTHR","Products not elsewhere classified","TCPPERMT","/capita, US$ exchange rate","AUS","Australia","2015","2015",125.8,"D","Difference in methodology"
+"PATCOTHR","Products not elsewhere classified","TCPPERMT","/capita, US$ exchange rate","AUS","Australia","2016","2016",133.9,"D","Difference in methodology"
+"PATCOTHR","Products not elsewhere classified","TCPPERMT","/capita, US$ exchange rate","AUS","Australia","2017","2017",142.9,"D","Difference in methodology"
+"PATCOTHR","Products not elsewhere classified","TCPPERMT","/capita, US$ exchange rate","AUS","Australia","2018","2018",158,"D","Difference in methodology"
+"PATCOTHR","Products not elsewhere classified","TCPPERMT","/capita, US$ exchange rate","AUS","Australia","2019","2019",164.6,"D","Difference in methodology"
+"PATCOTHR","Products not elsewhere classified","TCPPERMT","/capita, US$ exchange rate","AUS","Australia","2020","2020",181.5,"D","Difference in methodology"
+"PATCOTHR","Products not elsewhere classified","TCPPERMT","/capita, US$ exchange rate","AUS","Australia","2021","2021",215.1,"D","Difference in methodology"
+"PATCOTHR","Products not elsewhere classified","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2010","2010",68.4,"D","Difference in methodology"
+"PATCOTHR","Products not elsewhere classified","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2011","2011",74.5,"D","Difference in methodology"
+"PATCOTHR","Products not elsewhere classified","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2012","2012",80.6,"D","Difference in methodology"
+"PATCOTHR","Products not elsewhere classified","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2013","2013",96.8,"B; D","Break; Difference in methodology"
+"PATCOTHR","Products not elsewhere classified","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2014","2014",106,"D","Difference in methodology"
+"PATCOTHR","Products not elsewhere classified","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2015","2015",113.6,"D","Difference in methodology"
+"PATCOTHR","Products not elsewhere classified","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2016","2016",124.2,"D","Difference in methodology"
+"PATCOTHR","Products not elsewhere classified","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2017","2017",126.2,"D","Difference in methodology"
+"PATCOTHR","Products not elsewhere classified","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2018","2018",143.8,"D","Difference in methodology"
+"PATCOTHR","Products not elsewhere classified","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2019","2019",160,"D","Difference in methodology"
+"PATCOTHR","Products not elsewhere classified","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2020","2020",181.4,"D","Difference in methodology"
+"PATCOTHR","Products not elsewhere classified","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2021","2021",197.8,"D","Difference in methodology"
+"PATCOTHR","Products not elsewhere classified","ATCPTTMT","% of total sales","AUS","Australia","2010","2010",23.1,"D","Difference in methodology"
+"PATCOTHR","Products not elsewhere classified","ATCPTTMT","% of total sales","AUS","Australia","2011","2011",24.5,"D","Difference in methodology"
+"PATCOTHR","Products not elsewhere classified","ATCPTTMT","% of total sales","AUS","Australia","2012","2012",27.3,"D","Difference in methodology"
+"PATCOTHR","Products not elsewhere classified","ATCPTTMT","% of total sales","AUS","Australia","2013","2013",27.4,"B; D","Break; Difference in methodology"
+"PATCOTHR","Products not elsewhere classified","ATCPTTMT","% of total sales","AUS","Australia","2014","2014",30.4,"D","Difference in methodology"
+"PATCOTHR","Products not elsewhere classified","ATCPTTMT","% of total sales","AUS","Australia","2015","2015",32.5,"D","Difference in methodology"
+"PATCOTHR","Products not elsewhere classified","ATCPTTMT","% of total sales","AUS","Australia","2016","2016",28.5,"D","Difference in methodology"
+"PATCOTHR","Products not elsewhere classified","ATCPTTMT","% of total sales","AUS","Australia","2017","2017",31,"D","Difference in methodology"
+"PATCOTHR","Products not elsewhere classified","ATCPTTMT","% of total sales","AUS","Australia","2018","2018",35.4,"D","Difference in methodology"
+"PATCOTHR","Products not elsewhere classified","ATCPTTMT","% of total sales","AUS","Australia","2019","2019",38.6,"D","Difference in methodology"
+"PATCOTHR","Products not elsewhere classified","ATCPTTMT","% of total sales","AUS","Australia","2020","2020",40.7,"D","Difference in methodology"
+"PATCOTHR","Products not elsewhere classified","ATCPTTMT","% of total sales","AUS","Australia","2021","2021",41.9,"D","Difference in methodology"
+"PATCOTHR","Products not elsewhere classified","MLLNCUMT","Million of national currency units","AUT","Austria","2010","2010",583.6,"D","Difference in methodology"
+"PATCOTHR","Products not elsewhere classified","MLLNCUMT","Million of national currency units","AUT","Austria","2011","2011",617.8,"D","Difference in methodology"
+"PATCOTHR","Products not elsewhere classified","MLLNCUMT","Million of national currency units","AUT","Austria","2012","2012",664.5,"D","Difference in methodology"
+"PATCOTHR","Products not elsewhere classified","MLLNCUMT","Million of national currency units","AUT","Austria","2013","2013",712.5,"D","Difference in methodology"
+"PATCOTHR","Products not elsewhere classified","MLLNCUMT","Million of national currency units","AUT","Austria","2014","2014",767.7,"D","Difference in methodology"
+"PATCOTHR","Products not elsewhere classified","MLLNCUMT","Million of national currency units","AUT","Austria","2015","2015",832.2,"D","Difference in methodology"
+"PATCOTHR","Products not elsewhere classified","MLLNCUMT","Million of national currency units","AUT","Austria","2016","2016",920.3,"D","Difference in methodology"
+"PATCOTHR","Products not elsewhere classified","MLLNCUMT","Million of national currency units","AUT","Austria","2017","2017",987.4,"D","Difference in methodology"
+"PATCOTHR","Products not elsewhere classified","MLLNCUMT","Million of national currency units","AUT","Austria","2018","2018",1066,"D","Difference in methodology"
+"PATCOTHR","Products not elsewhere classified","MLLNCUMT","Million of national currency units","AUT","Austria","2019","2019",1155.9,"D","Difference in methodology"
+"PATCOTHR","Products not elsewhere classified","MLLNCUMT","Million of national currency units","AUT","Austria","2020","2020",1262,"D","Difference in methodology"
+"PATCOTHR","Products not elsewhere classified","MLLNCUMT","Million of national currency units","AUT","Austria","2021","2021",1380.2,"D","Difference in methodology"
+"PATCOTHR","Products not elsewhere classified","MTMOTCMT","Million US$ at exchange rate","AUT","Austria","2010","2010",773.7,"D","Difference in methodology"
+"PATCOTHR","Products not elsewhere classified","MTMOTCMT","Million US$ at exchange rate","AUT","Austria","2011","2011",859.9,"D","Difference in methodology"
+"PATCOTHR","Products not elsewhere classified","MTMOTCMT","Million US$ at exchange rate","AUT","Austria","2012","2012",853.7,"D","Difference in methodology"
+"PATCOTHR","Products not elsewhere classified","MTMOTCMT","Million US$ at exchange rate","AUT","Austria","2013","2013",946.3,"D","Difference in methodology"
+"PATCOTHR","Products not elsewhere classified","MTMOTCMT","Million US$ at exchange rate","AUT","Austria","2014","2014",1020,"D","Difference in methodology"
+"PATCOTHR","Products not elsewhere classified","MTMOTCMT","Million US$ at exchange rate","AUT","Austria","2015","2015",923.3,"D","Difference in methodology"
+"PATCOTHR","Products not elsewhere classified","MTMOTCMT","Million US$ at exchange rate","AUT","Austria","2016","2016",1018.7,"D","Difference in methodology"
+"PATCOTHR","Products not elsewhere classified","MTMOTCMT","Million US$ at exchange rate","AUT","Austria","2017","2017",1115.5,"D","Difference in methodology"
+"PATCOTHR","Products not elsewhere classified","MTMOTCMT","Million US$ at exchange rate","AUT","Austria","2018","2018",1258.9,"D","Difference in methodology"
+"PATCOTHR","Products not elsewhere classified","MTMOTCMT","Million US$ at exchange rate","AUT","Austria","2019","2019",1294,"D","Difference in methodology"
+"PATCOTHR","Products not elsewhere classified","MTMOTCMT","Million US$ at exchange rate","AUT","Austria","2020","2020",1441.5,"D","Difference in methodology"
+"PATCOTHR","Products not elsewhere classified","MTMOTCMT","Million US$ at exchange rate","AUT","Austria","2021","2021",1632.4,"D","Difference in methodology"
+"PATCOTHR","Products not elsewhere classified","MTMOPPMT","Million US$, purchasing power parity","AUT","Austria","2010","2010",693,"D","Difference in methodology"
+"PATCOTHR","Products not elsewhere classified","MTMOPPMT","Million US$, purchasing power parity","AUT","Austria","2011","2011",743.1,"D","Difference in methodology"
+"PATCOTHR","Products not elsewhere classified","MTMOPPMT","Million US$, purchasing power parity","AUT","Austria","2012","2012",816.7,"D","Difference in methodology"
+"PATCOTHR","Products not elsewhere classified","MTMOPPMT","Million US$, purchasing power parity","AUT","Austria","2013","2013",893.9,"D","Difference in methodology"
+"PATCOTHR","Products not elsewhere classified","MTMOPPMT","Million US$, purchasing power parity","AUT","Austria","2014","2014",961.1,"D","Difference in methodology"
+"PATCOTHR","Products not elsewhere classified","MTMOPPMT","Million US$, purchasing power parity","AUT","Austria","2015","2015",1041.8,"D","Difference in methodology"
+"PATCOTHR","Products not elsewhere classified","MTMOPPMT","Million US$, purchasing power parity","AUT","Austria","2016","2016",1184.5,"D","Difference in methodology"
+"PATCOTHR","Products not elsewhere classified","MTMOPPMT","Million US$, purchasing power parity","AUT","Austria","2017","2017",1274.1,"D","Difference in methodology"
+"PATCOTHR","Products not elsewhere classified","MTMOPPMT","Million US$, purchasing power parity","AUT","Austria","2018","2018",1392.7,"D","Difference in methodology"
+"PATCOTHR","Products not elsewhere classified","MTMOPPMT","Million US$, purchasing power parity","AUT","Austria","2019","2019",1543,"D","Difference in methodology"
+"PATCOTHR","Products not elsewhere classified","MTMOPPMT","Million US$, purchasing power parity","AUT","Austria","2020","2020",1691,"D","Difference in methodology"
+"PATCOTHR","Products not elsewhere classified","MTMOPPMT","Million US$, purchasing power parity","AUT","Austria","2021","2021",1824.9,"D","Difference in methodology"
+"PATCOTHR","Products not elsewhere classified","TCPPERMT","/capita, US$ exchange rate","AUT","Austria","2010","2010",92.5,"D","Difference in methodology"
+"PATCOTHR","Products not elsewhere classified","TCPPERMT","/capita, US$ exchange rate","AUT","Austria","2011","2011",102.5,"D","Difference in methodology"
+"PATCOTHR","Products not elsewhere classified","TCPPERMT","/capita, US$ exchange rate","AUT","Austria","2012","2012",101.3,"D","Difference in methodology"
+"PATCOTHR","Products not elsewhere classified","TCPPERMT","/capita, US$ exchange rate","AUT","Austria","2013","2013",111.6,"D","Difference in methodology"
+"PATCOTHR","Products not elsewhere classified","TCPPERMT","/capita, US$ exchange rate","AUT","Austria","2014","2014",119.3,"D","Difference in methodology"
+"PATCOTHR","Products not elsewhere classified","TCPPERMT","/capita, US$ exchange rate","AUT","Austria","2015","2015",106.8,"D","Difference in methodology"
+"PATCOTHR","Products not elsewhere classified","TCPPERMT","/capita, US$ exchange rate","AUT","Austria","2016","2016",116.6,"D","Difference in methodology"
+"PATCOTHR","Products not elsewhere classified","TCPPERMT","/capita, US$ exchange rate","AUT","Austria","2017","2017",126.8,"D","Difference in methodology"
+"PATCOTHR","Products not elsewhere classified","TCPPERMT","/capita, US$ exchange rate","AUT","Austria","2018","2018",142.4,"D","Difference in methodology"
+"PATCOTHR","Products not elsewhere classified","TCPPERMT","/capita, US$ exchange rate","AUT","Austria","2019","2019",145.7,"D","Difference in methodology"
+"PATCOTHR","Products not elsewhere classified","TCPPERMT","/capita, US$ exchange rate","AUT","Austria","2020","2020",161.7,"D","Difference in methodology"
+"PATCOTHR","Products not elsewhere classified","TCPPERMT","/capita, US$ exchange rate","AUT","Austria","2021","2021",182.3,"D","Difference in methodology"
+"PATCOTHR","Products not elsewhere classified","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2010","2010",82.9,"D","Difference in methodology"
+"PATCOTHR","Products not elsewhere classified","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2011","2011",88.6,"D","Difference in methodology"
+"PATCOTHR","Products not elsewhere classified","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2012","2012",96.9,"D","Difference in methodology"
+"PATCOTHR","Products not elsewhere classified","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2013","2013",105.4,"D","Difference in methodology"
+"PATCOTHR","Products not elsewhere classified","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2014","2014",112.5,"D","Difference in methodology"
+"PATCOTHR","Products not elsewhere classified","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2015","2015",120.5,"D","Difference in methodology"
+"PATCOTHR","Products not elsewhere classified","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2016","2016",135.6,"D","Difference in methodology"
+"PATCOTHR","Products not elsewhere classified","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2017","2017",144.8,"D","Difference in methodology"
+"PATCOTHR","Products not elsewhere classified","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2018","2018",157.5,"D","Difference in methodology"
+"PATCOTHR","Products not elsewhere classified","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2019","2019",173.8,"D","Difference in methodology"
+"PATCOTHR","Products not elsewhere classified","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2020","2020",189.6,"D","Difference in methodology"
+"PATCOTHR","Products not elsewhere classified","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2021","2021",203.8,"D","Difference in methodology"
+"PATCOTHR","Products not elsewhere classified","ATCPTTMT","% of total sales","AUT","Austria","2010","2010",23.4,"D","Difference in methodology"
+"PATCOTHR","Products not elsewhere classified","ATCPTTMT","% of total sales","AUT","Austria","2011","2011",24.2,"D","Difference in methodology"
+"PATCOTHR","Products not elsewhere classified","ATCPTTMT","% of total sales","AUT","Austria","2012","2012",25.4,"D","Difference in methodology"
+"PATCOTHR","Products not elsewhere classified","ATCPTTMT","% of total sales","AUT","Austria","2013","2013",27,"D","Difference in methodology"
+"PATCOTHR","Products not elsewhere classified","ATCPTTMT","% of total sales","AUT","Austria","2014","2014",27.5,"D","Difference in methodology"
+"PATCOTHR","Products not elsewhere classified","ATCPTTMT","% of total sales","AUT","Austria","2015","2015",28.4,"D","Difference in methodology"
+"PATCOTHR","Products not elsewhere classified","ATCPTTMT","% of total sales","AUT","Austria","2016","2016",30.6,"D","Difference in methodology"
+"PATCOTHR","Products not elsewhere classified","ATCPTTMT","% of total sales","AUT","Austria","2017","2017",31.6,"D","Difference in methodology"
+"PATCOTHR","Products not elsewhere classified","ATCPTTMT","% of total sales","AUT","Austria","2018","2018",33.2,"D","Difference in methodology"
+"PATCOTHR","Products not elsewhere classified","ATCPTTMT","% of total sales","AUT","Austria","2019","2019",34.9,"D","Difference in methodology"
+"PATCOTHR","Products not elsewhere classified","ATCPTTMT","% of total sales","AUT","Austria","2020","2020",36.3,"D","Difference in methodology"
+"PATCOTHR","Products not elsewhere classified","ATCPTTMT","% of total sales","AUT","Austria","2021","2021",37.2,"D","Difference in methodology"
+"PATCOTHR","Products not elsewhere classified","MLLNCUMT","Million of national currency units","BEL","Belgium","2010","2010",1195.5,,
+"PATCOTHR","Products not elsewhere classified","MLLNCUMT","Million of national currency units","BEL","Belgium","2011","2011",1234.9,,
+"PATCOTHR","Products not elsewhere classified","MLLNCUMT","Million of national currency units","BEL","Belgium","2012","2012",1284.3,,
+"PATCOTHR","Products not elsewhere classified","MLLNCUMT","Million of national currency units","BEL","Belgium","2013","2013",1324.7,,
+"PATCOTHR","Products not elsewhere classified","MLLNCUMT","Million of national currency units","BEL","Belgium","2014","2014",1443.5,,
+"PATCOTHR","Products not elsewhere classified","MLLNCUMT","Million of national currency units","BEL","Belgium","2015","2015",1560.4,,
+"PATCOTHR","Products not elsewhere classified","MLLNCUMT","Million of national currency units","BEL","Belgium","2016","2016",1656.3,,
+"PATCOTHR","Products not elsewhere classified","MLLNCUMT","Million of national currency units","BEL","Belgium","2017","2017",1910.8,,
+"PATCOTHR","Products not elsewhere classified","MLLNCUMT","Million of national currency units","BEL","Belgium","2018","2018",2183.4,,
+"PATCOTHR","Products not elsewhere classified","MLLNCUMT","Million of national currency units","BEL","Belgium","2019","2019",2606.7,,
+"PATCOTHR","Products not elsewhere classified","MLLNCUMT","Million of national currency units","BEL","Belgium","2020","2020",2990.6,,
+"PATCOTHR","Products not elsewhere classified","MLLNCUMT","Million of national currency units","BEL","Belgium","2021","2021",3268.6,,
+"PATCOTHR","Products not elsewhere classified","MLLNCUMT","Million of national currency units","BEL","Belgium","2022","2022",3650.4,"E","Estimated value"
+"PATCOTHR","Products not elsewhere classified","MTMOTCMT","Million US$ at exchange rate","BEL","Belgium","2010","2010",1584.9,,
+"PATCOTHR","Products not elsewhere classified","MTMOTCMT","Million US$ at exchange rate","BEL","Belgium","2011","2011",1719,,
+"PATCOTHR","Products not elsewhere classified","MTMOTCMT","Million US$ at exchange rate","BEL","Belgium","2012","2012",1650.1,,
+"PATCOTHR","Products not elsewhere classified","MTMOTCMT","Million US$ at exchange rate","BEL","Belgium","2013","2013",1759.4,,
+"PATCOTHR","Products not elsewhere classified","MTMOTCMT","Million US$ at exchange rate","BEL","Belgium","2014","2014",1917.7,,
+"PATCOTHR","Products not elsewhere classified","MTMOTCMT","Million US$ at exchange rate","BEL","Belgium","2015","2015",1731.3,,
+"PATCOTHR","Products not elsewhere classified","MTMOTCMT","Million US$ at exchange rate","BEL","Belgium","2016","2016",1833.4,,
+"PATCOTHR","Products not elsewhere classified","MTMOTCMT","Million US$ at exchange rate","BEL","Belgium","2017","2017",2158.6,,
+"PATCOTHR","Products not elsewhere classified","MTMOTCMT","Million US$ at exchange rate","BEL","Belgium","2018","2018",2578.4,,
+"PATCOTHR","Products not elsewhere classified","MTMOTCMT","Million US$ at exchange rate","BEL","Belgium","2019","2019",2918.2,,
+"PATCOTHR","Products not elsewhere classified","MTMOTCMT","Million US$ at exchange rate","BEL","Belgium","2020","2020",3415.8,,
+"PATCOTHR","Products not elsewhere classified","MTMOTCMT","Million US$ at exchange rate","BEL","Belgium","2021","2021",3865.9,,
+"PATCOTHR","Products not elsewhere classified","MTMOTCMT","Million US$ at exchange rate","BEL","Belgium","2022","2022",3844.1,"E","Estimated value"
+"PATCOTHR","Products not elsewhere classified","MTMOPPMT","Million US$, purchasing power parity","BEL","Belgium","2010","2010",1428.9,,
+"PATCOTHR","Products not elsewhere classified","MTMOPPMT","Million US$, purchasing power parity","BEL","Belgium","2011","2011",1484.5,,
+"PATCOTHR","Products not elsewhere classified","MTMOPPMT","Million US$, purchasing power parity","BEL","Belgium","2012","2012",1562.2,,
+"PATCOTHR","Products not elsewhere classified","MTMOPPMT","Million US$, purchasing power parity","BEL","Belgium","2013","2013",1643.2,,
+"PATCOTHR","Products not elsewhere classified","MTMOPPMT","Million US$, purchasing power parity","BEL","Belgium","2014","2014",1803.9,,
+"PATCOTHR","Products not elsewhere classified","MTMOPPMT","Million US$, purchasing power parity","BEL","Belgium","2015","2015",1950.5,,
+"PATCOTHR","Products not elsewhere classified","MTMOPPMT","Million US$, purchasing power parity","BEL","Belgium","2016","2016",2120.7,,
+"PATCOTHR","Products not elsewhere classified","MTMOPPMT","Million US$, purchasing power parity","BEL","Belgium","2017","2017",2463.6,,
+"PATCOTHR","Products not elsewhere classified","MTMOPPMT","Million US$, purchasing power parity","BEL","Belgium","2018","2018",2848.8,,
+"PATCOTHR","Products not elsewhere classified","MTMOPPMT","Million US$, purchasing power parity","BEL","Belgium","2019","2019",3491.4,,
+"PATCOTHR","Products not elsewhere classified","MTMOPPMT","Million US$, purchasing power parity","BEL","Belgium","2020","2020",4095.1,,
+"PATCOTHR","Products not elsewhere classified","MTMOPPMT","Million US$, purchasing power parity","BEL","Belgium","2021","2021",4436.9,,
+"PATCOTHR","Products not elsewhere classified","MTMOPPMT","Million US$, purchasing power parity","BEL","Belgium","2022","2022",5113.1,"E","Estimated value"
+"PATCOTHR","Products not elsewhere classified","TCPPERMT","/capita, US$ exchange rate","BEL","Belgium","2010","2010",145.5,,
+"PATCOTHR","Products not elsewhere classified","TCPPERMT","/capita, US$ exchange rate","BEL","Belgium","2011","2011",155.7,,
+"PATCOTHR","Products not elsewhere classified","TCPPERMT","/capita, US$ exchange rate","BEL","Belgium","2012","2012",148.6,,
+"PATCOTHR","Products not elsewhere classified","TCPPERMT","/capita, US$ exchange rate","BEL","Belgium","2013","2013",157.7,,
+"PATCOTHR","Products not elsewhere classified","TCPPERMT","/capita, US$ exchange rate","BEL","Belgium","2014","2014",171.1,,
+"PATCOTHR","Products not elsewhere classified","TCPPERMT","/capita, US$ exchange rate","BEL","Belgium","2015","2015",153.6,,
+"PATCOTHR","Products not elsewhere classified","TCPPERMT","/capita, US$ exchange rate","BEL","Belgium","2016","2016",161.8,,
+"PATCOTHR","Products not elsewhere classified","TCPPERMT","/capita, US$ exchange rate","BEL","Belgium","2017","2017",189.8,,
+"PATCOTHR","Products not elsewhere classified","TCPPERMT","/capita, US$ exchange rate","BEL","Belgium","2018","2018",225.6,,
+"PATCOTHR","Products not elsewhere classified","TCPPERMT","/capita, US$ exchange rate","BEL","Belgium","2019","2019",254,,
+"PATCOTHR","Products not elsewhere classified","TCPPERMT","/capita, US$ exchange rate","BEL","Belgium","2020","2020",296,,
+"PATCOTHR","Products not elsewhere classified","TCPPERMT","/capita, US$ exchange rate","BEL","Belgium","2021","2021",333.7,,
+"PATCOTHR","Products not elsewhere classified","TCPPERMT","/capita, US$ exchange rate","BEL","Belgium","2022","2022",330.9,"E","Estimated value"
+"PATCOTHR","Products not elsewhere classified","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2010","2010",131.1,,
+"PATCOTHR","Products not elsewhere classified","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2011","2011",134.5,,
+"PATCOTHR","Products not elsewhere classified","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2012","2012",140.7,,
+"PATCOTHR","Products not elsewhere classified","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2013","2013",147.2,,
+"PATCOTHR","Products not elsewhere classified","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2014","2014",160.9,,
+"PATCOTHR","Products not elsewhere classified","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2015","2015",173,,
+"PATCOTHR","Products not elsewhere classified","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2016","2016",187.2,,
+"PATCOTHR","Products not elsewhere classified","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2017","2017",216.6,,
+"PATCOTHR","Products not elsewhere classified","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2018","2018",249.3,,
+"PATCOTHR","Products not elsewhere classified","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2019","2019",303.9,,
+"PATCOTHR","Products not elsewhere classified","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2020","2020",354.9,,
+"PATCOTHR","Products not elsewhere classified","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2021","2021",382.9,,
+"PATCOTHR","Products not elsewhere classified","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2022","2022",440.1,"E","Estimated value"
+"PATCOTHR","Products not elsewhere classified","ATCPTTMT","% of total sales","BEL","Belgium","2010","2010",20.3,,
+"PATCOTHR","Products not elsewhere classified","ATCPTTMT","% of total sales","BEL","Belgium","2011","2011",20.6,,
+"PATCOTHR","Products not elsewhere classified","ATCPTTMT","% of total sales","BEL","Belgium","2012","2012",21.6,,
+"PATCOTHR","Products not elsewhere classified","ATCPTTMT","% of total sales","BEL","Belgium","2013","2013",22.3,,
+"PATCOTHR","Products not elsewhere classified","ATCPTTMT","% of total sales","BEL","Belgium","2014","2014",24.3,,
+"PATCOTHR","Products not elsewhere classified","ATCPTTMT","% of total sales","BEL","Belgium","2015","2015",25.2,,
+"PATCOTHR","Products not elsewhere classified","ATCPTTMT","% of total sales","BEL","Belgium","2016","2016",26.5,,
+"PATCOTHR","Products not elsewhere classified","ATCPTTMT","% of total sales","BEL","Belgium","2017","2017",29.2,,
+"PATCOTHR","Products not elsewhere classified","ATCPTTMT","% of total sales","BEL","Belgium","2018","2018",32.7,,
+"PATCOTHR","Products not elsewhere classified","ATCPTTMT","% of total sales","BEL","Belgium","2019","2019",35.4,,
+"PATCOTHR","Products not elsewhere classified","ATCPTTMT","% of total sales","BEL","Belgium","2020","2020",39,,
+"PATCOTHR","Products not elsewhere classified","ATCPTTMT","% of total sales","BEL","Belgium","2021","2021",40.6,,
+"PATCOTHR","Products not elsewhere classified","ATCPTTMT","% of total sales","BEL","Belgium","2022","2022",40.5,"E","Estimated value"
+"PATCOTHR","Products not elsewhere classified","MLLNCUMT","Million of national currency units","CAN","Canada","2012","2012",4584,"D","Difference in methodology"
+"PATCOTHR","Products not elsewhere classified","MLLNCUMT","Million of national currency units","CAN","Canada","2013","2013",5143,"D","Difference in methodology"
+"PATCOTHR","Products not elsewhere classified","MLLNCUMT","Million of national currency units","CAN","Canada","2014","2014",5547,"D","Difference in methodology"
+"PATCOTHR","Products not elsewhere classified","MLLNCUMT","Million of national currency units","CAN","Canada","2015","2015",6123.2,"D","Difference in methodology"
+"PATCOTHR","Products not elsewhere classified","MLLNCUMT","Million of national currency units","CAN","Canada","2016","2016",6771.3,"D","Difference in methodology"
+"PATCOTHR","Products not elsewhere classified","MLLNCUMT","Million of national currency units","CAN","Canada","2017","2017",7576.5,"D","Difference in methodology"
+"PATCOTHR","Products not elsewhere classified","MLLNCUMT","Million of national currency units","CAN","Canada","2018","2018",8470,"E; B; D","Estimated value; Break; Difference in methodology"
+"PATCOTHR","Products not elsewhere classified","MLLNCUMT","Million of national currency units","CAN","Canada","2019","2019",9393.8,"E; D","Estimated value; Difference in methodology"
+"PATCOTHR","Products not elsewhere classified","MLLNCUMT","Million of national currency units","CAN","Canada","2020","2020",10533.4,"E; D","Estimated value; Difference in methodology"
+"PATCOTHR","Products not elsewhere classified","MLLNCUMT","Million of national currency units","CAN","Canada","2021","2021",11654.6,"E; D","Estimated value; Difference in methodology"
+"PATCOTHR","Products not elsewhere classified","MLLNCUMT","Million of national currency units","CAN","Canada","2022","2022",12657.3,"E; D","Estimated value; Difference in methodology"
+"PATCOTHR","Products not elsewhere classified","MTMOTCMT","Million US$ at exchange rate","CAN","Canada","2012","2012",4586.9,"D","Difference in methodology"
+"PATCOTHR","Products not elsewhere classified","MTMOTCMT","Million US$ at exchange rate","CAN","Canada","2013","2013",4992.5,"D","Difference in methodology"
+"PATCOTHR","Products not elsewhere classified","MTMOTCMT","Million US$ at exchange rate","CAN","Canada","2014","2014",5021.1,"D","Difference in methodology"
+"PATCOTHR","Products not elsewhere classified","MTMOTCMT","Million US$ at exchange rate","CAN","Canada","2015","2015",4788.3,"D","Difference in methodology"
+"PATCOTHR","Products not elsewhere classified","MTMOTCMT","Million US$ at exchange rate","CAN","Canada","2016","2016",5108,"D","Difference in methodology"
+"PATCOTHR","Products not elsewhere classified","MTMOTCMT","Million US$ at exchange rate","CAN","Canada","2017","2017",5837.3,"D","Difference in methodology"
+"PATCOTHR","Products not elsewhere classified","MTMOTCMT","Million US$ at exchange rate","CAN","Canada","2018","2018",6536.4,"E; B; D","Estimated value; Break; Difference in methodology"
+"PATCOTHR","Products not elsewhere classified","MTMOTCMT","Million US$ at exchange rate","CAN","Canada","2019","2019",7080.1,"E; D","Estimated value; Difference in methodology"
+"PATCOTHR","Products not elsewhere classified","MTMOTCMT","Million US$ at exchange rate","CAN","Canada","2020","2020",7854,"E; D","Estimated value; Difference in methodology"
+"PATCOTHR","Products not elsewhere classified","MTMOTCMT","Million US$ at exchange rate","CAN","Canada","2021","2021",9294.8,"E; D","Estimated value; Difference in methodology"
+"PATCOTHR","Products not elsewhere classified","MTMOTCMT","Million US$ at exchange rate","CAN","Canada","2022","2022",9724.8,"E; D","Estimated value; Difference in methodology"
+"PATCOTHR","Products not elsewhere classified","MTMOPPMT","Million US$, purchasing power parity","CAN","Canada","2012","2012",3683.1,"D","Difference in methodology"
+"PATCOTHR","Products not elsewhere classified","MTMOPPMT","Million US$, purchasing power parity","CAN","Canada","2013","2013",4201.8,"D","Difference in methodology"
+"PATCOTHR","Products not elsewhere classified","MTMOPPMT","Million US$, purchasing power parity","CAN","Canada","2014","2014",4508.4,"D","Difference in methodology"
+"PATCOTHR","Products not elsewhere classified","MTMOPPMT","Million US$, purchasing power parity","CAN","Canada","2015","2015",4906.2,"D","Difference in methodology"
+"PATCOTHR","Products not elsewhere classified","MTMOPPMT","Million US$, purchasing power parity","CAN","Canada","2016","2016",5609.8,"D","Difference in methodology"
+"PATCOTHR","Products not elsewhere classified","MTMOPPMT","Million US$, purchasing power parity","CAN","Canada","2017","2017",6249.7,"D","Difference in methodology"
+"PATCOTHR","Products not elsewhere classified","MTMOPPMT","Million US$, purchasing power parity","CAN","Canada","2018","2018",7020.2,"E; B; D","Estimated value; Break; Difference in methodology"
+"PATCOTHR","Products not elsewhere classified","MTMOPPMT","Million US$, purchasing power parity","CAN","Canada","2019","2019",7608.1,"E; D","Estimated value; Difference in methodology"
+"PATCOTHR","Products not elsewhere classified","MTMOPPMT","Million US$, purchasing power parity","CAN","Canada","2020","2020",8556.3,"E; D","Estimated value; Difference in methodology"
+"PATCOTHR","Products not elsewhere classified","MTMOPPMT","Million US$, purchasing power parity","CAN","Canada","2021","2021",9412.8,"E; D","Estimated value; Difference in methodology"
+"PATCOTHR","Products not elsewhere classified","MTMOPPMT","Million US$, purchasing power parity","CAN","Canada","2022","2022",10094.9,"E; D","Estimated value; Difference in methodology"
+"PATCOTHR","Products not elsewhere classified","TCPPERMT","/capita, US$ exchange rate","CAN","Canada","2012","2012",132.1,"D","Difference in methodology"
+"PATCOTHR","Products not elsewhere classified","TCPPERMT","/capita, US$ exchange rate","CAN","Canada","2013","2013",142.3,"D","Difference in methodology"
+"PATCOTHR","Products not elsewhere classified","TCPPERMT","/capita, US$ exchange rate","CAN","Canada","2014","2014",141.7,"D","Difference in methodology"
+"PATCOTHR","Products not elsewhere classified","TCPPERMT","/capita, US$ exchange rate","CAN","Canada","2015","2015",134.1,"D","Difference in methodology"
+"PATCOTHR","Products not elsewhere classified","TCPPERMT","/capita, US$ exchange rate","CAN","Canada","2016","2016",141.5,"D","Difference in methodology"
+"PATCOTHR","Products not elsewhere classified","TCPPERMT","/capita, US$ exchange rate","CAN","Canada","2017","2017",159.7,"D","Difference in methodology"
+"PATCOTHR","Products not elsewhere classified","TCPPERMT","/capita, US$ exchange rate","CAN","Canada","2018","2018",176.3,"E; B; D","Estimated value; Break; Difference in methodology"
+"PATCOTHR","Products not elsewhere classified","TCPPERMT","/capita, US$ exchange rate","CAN","Canada","2019","2019",188.3,"E; D","Estimated value; Difference in methodology"
+"PATCOTHR","Products not elsewhere classified","TCPPERMT","/capita, US$ exchange rate","CAN","Canada","2020","2020",206.5,"E; D","Estimated value; Difference in methodology"
+"PATCOTHR","Products not elsewhere classified","TCPPERMT","/capita, US$ exchange rate","CAN","Canada","2021","2021",243,"E; D","Estimated value; Difference in methodology"
+"PATCOTHR","Products not elsewhere classified","TCPPERMT","/capita, US$ exchange rate","CAN","Canada","2022","2022",250.1,"E; D","Estimated value; Difference in methodology"
+"PATCOTHR","Products not elsewhere classified","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2012","2012",106.1,"D","Difference in methodology"
+"PATCOTHR","Products not elsewhere classified","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2013","2013",119.8,"D","Difference in methodology"
+"PATCOTHR","Products not elsewhere classified","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2014","2014",127.2,"D","Difference in methodology"
+"PATCOTHR","Products not elsewhere classified","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2015","2015",137.4,"D","Difference in methodology"
+"PATCOTHR","Products not elsewhere classified","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2016","2016",155.4,"D","Difference in methodology"
+"PATCOTHR","Products not elsewhere classified","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2017","2017",171,"D","Difference in methodology"
+"PATCOTHR","Products not elsewhere classified","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2018","2018",189.4,"E; B; D","Estimated value; Break; Difference in methodology"
+"PATCOTHR","Products not elsewhere classified","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2019","2019",202.3,"E; D","Estimated value; Difference in methodology"
+"PATCOTHR","Products not elsewhere classified","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2020","2020",224.9,"E; D","Estimated value; Difference in methodology"
+"PATCOTHR","Products not elsewhere classified","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2021","2021",246.1,"E; D","Estimated value; Difference in methodology"
+"PATCOTHR","Products not elsewhere classified","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2022","2022",259.6,"E; D","Estimated value; Difference in methodology"
+"PATCOTHR","Products not elsewhere classified","ATCPTTMT","% of total sales","CAN","Canada","2012","2012",18.9,"D","Difference in methodology"
+"PATCOTHR","Products not elsewhere classified","ATCPTTMT","% of total sales","CAN","Canada","2013","2013",20.9,"D","Difference in methodology"
+"PATCOTHR","Products not elsewhere classified","ATCPTTMT","% of total sales","CAN","Canada","2014","2014",21.7,"D","Difference in methodology"
+"PATCOTHR","Products not elsewhere classified","ATCPTTMT","% of total sales","CAN","Canada","2015","2015",22.6,"D","Difference in methodology"
+"PATCOTHR","Products not elsewhere classified","ATCPTTMT","% of total sales","CAN","Canada","2016","2016",23.9,"D","Difference in methodology"
+"PATCOTHR","Products not elsewhere classified","ATCPTTMT","% of total sales","CAN","Canada","2017","2017",25.4,"D","Difference in methodology"
+"PATCOTHR","Products not elsewhere classified","ATCPTTMT","% of total sales","CAN","Canada","2018","2018",27.7,"E; B; D","Estimated value; Break; Difference in methodology"
+"PATCOTHR","Products not elsewhere classified","ATCPTTMT","% of total sales","CAN","Canada","2019","2019",29.5,"E; D","Estimated value; Difference in methodology"
+"PATCOTHR","Products not elsewhere classified","ATCPTTMT","% of total sales","CAN","Canada","2020","2020",30.7,"E; D","Estimated value; Difference in methodology"
+"PATCOTHR","Products not elsewhere classified","ATCPTTMT","% of total sales","CAN","Canada","2021","2021",31.6,"E; D","Estimated value; Difference in methodology"
+"PATCOTHR","Products not elsewhere classified","ATCPTTMT","% of total sales","CAN","Canada","2022","2022",31.7,"E; D","Estimated value; Difference in methodology"
+"PATCOTHR","Products not elsewhere classified","MLLNCUMT","Million of national currency units","CZE","Czech Republic","2010","2010",20004.5,,
+"PATCOTHR","Products not elsewhere classified","MLLNCUMT","Million of national currency units","CZE","Czech Republic","2011","2011",19111.1,,
+"PATCOTHR","Products not elsewhere classified","MLLNCUMT","Million of national currency units","CZE","Czech Republic","2012","2012",20008.4,,
+"PATCOTHR","Products not elsewhere classified","MLLNCUMT","Million of national currency units","CZE","Czech Republic","2013","2013",19385.6,,
+"PATCOTHR","Products not elsewhere classified","MLLNCUMT","Million of national currency units","CZE","Czech Republic","2014","2014",20371.8,,
+"PATCOTHR","Products not elsewhere classified","MLLNCUMT","Million of national currency units","CZE","Czech Republic","2015","2015",22839.7,,
+"PATCOTHR","Products not elsewhere classified","MLLNCUMT","Million of national currency units","CZE","Czech Republic","2016","2016",23953.9,,
+"PATCOTHR","Products not elsewhere classified","MLLNCUMT","Million of national currency units","CZE","Czech Republic","2017","2017",25531,,
+"PATCOTHR","Products not elsewhere classified","MLLNCUMT","Million of national currency units","CZE","Czech Republic","2018","2018",27722.5,,
+"PATCOTHR","Products not elsewhere classified","MLLNCUMT","Million of national currency units","CZE","Czech Republic","2019","2019",30142.3,,
+"PATCOTHR","Products not elsewhere classified","MLLNCUMT","Million of national currency units","CZE","Czech Republic","2020","2020",29470.5,"B","Break"
+"PATCOTHR","Products not elsewhere classified","MLLNCUMT","Million of national currency units","CZE","Czech Republic","2021","2021",31813.4,,
+"PATCOTHR","Products not elsewhere classified","MTMOTCMT","Million US$ at exchange rate","CZE","Czech Republic","2010","2010",1047.5,,
+"PATCOTHR","Products not elsewhere classified","MTMOTCMT","Million US$ at exchange rate","CZE","Czech Republic","2011","2011",1080,,
+"PATCOTHR","Products not elsewhere classified","MTMOTCMT","Million US$ at exchange rate","CZE","Czech Republic","2012","2012",1022,,
+"PATCOTHR","Products not elsewhere classified","MTMOTCMT","Million US$ at exchange rate","CZE","Czech Republic","2013","2013",990.5,,
+"PATCOTHR","Products not elsewhere classified","MTMOTCMT","Million US$ at exchange rate","CZE","Czech Republic","2014","2014",981.4,,
+"PATCOTHR","Products not elsewhere classified","MTMOTCMT","Million US$ at exchange rate","CZE","Czech Republic","2015","2015",928.5,,
+"PATCOTHR","Products not elsewhere classified","MTMOTCMT","Million US$ at exchange rate","CZE","Czech Republic","2016","2016",980.1,,
+"PATCOTHR","Products not elsewhere classified","MTMOTCMT","Million US$ at exchange rate","CZE","Czech Republic","2017","2017",1092.2,,
+"PATCOTHR","Products not elsewhere classified","MTMOTCMT","Million US$ at exchange rate","CZE","Czech Republic","2018","2018",1275.8,,
+"PATCOTHR","Products not elsewhere classified","MTMOTCMT","Million US$ at exchange rate","CZE","Czech Republic","2019","2019",1314.4,,
+"PATCOTHR","Products not elsewhere classified","MTMOTCMT","Million US$ at exchange rate","CZE","Czech Republic","2020","2020",1269.7,"B","Break"
+"PATCOTHR","Products not elsewhere classified","MTMOTCMT","Million US$ at exchange rate","CZE","Czech Republic","2021","2021",1467.5,,
+"PATCOTHR","Products not elsewhere classified","MTMOPPMT","Million US$, purchasing power parity","CZE","Czech Republic","2010","2010",1463.1,,
+"PATCOTHR","Products not elsewhere classified","MTMOPPMT","Million US$, purchasing power parity","CZE","Czech Republic","2011","2011",1432,,
+"PATCOTHR","Products not elsewhere classified","MTMOPPMT","Million US$, purchasing power parity","CZE","Czech Republic","2012","2012",1504.7,,
+"PATCOTHR","Products not elsewhere classified","MTMOPPMT","Million US$, purchasing power parity","CZE","Czech Republic","2013","2013",1516.2,,
+"PATCOTHR","Products not elsewhere classified","MTMOPPMT","Million US$, purchasing power parity","CZE","Czech Republic","2014","2014",1603.7,,
+"PATCOTHR","Products not elsewhere classified","MTMOPPMT","Million US$, purchasing power parity","CZE","Czech Republic","2015","2015",1765.3,,
+"PATCOTHR","Products not elsewhere classified","MTMOPPMT","Million US$, purchasing power parity","CZE","Czech Republic","2016","2016",1904.7,,
+"PATCOTHR","Products not elsewhere classified","MTMOPPMT","Million US$, purchasing power parity","CZE","Czech Republic","2017","2017",2054.8,,
+"PATCOTHR","Products not elsewhere classified","MTMOPPMT","Million US$, purchasing power parity","CZE","Czech Republic","2018","2018",2240.8,,
+"PATCOTHR","Products not elsewhere classified","MTMOPPMT","Million US$, purchasing power parity","CZE","Czech Republic","2019","2019",2455.7,,
+"PATCOTHR","Products not elsewhere classified","MTMOPPMT","Million US$, purchasing power parity","CZE","Czech Republic","2020","2020",2365,"B","Break"
+"PATCOTHR","Products not elsewhere classified","MTMOPPMT","Million US$, purchasing power parity","CZE","Czech Republic","2021","2021",2496.5,,
+"PATCOTHR","Products not elsewhere classified","TCPPERMT","/capita, US$ exchange rate","CZE","Czech Republic","2010","2010",100,,
+"PATCOTHR","Products not elsewhere classified","TCPPERMT","/capita, US$ exchange rate","CZE","Czech Republic","2011","2011",102.9,,
+"PATCOTHR","Products not elsewhere classified","TCPPERMT","/capita, US$ exchange rate","CZE","Czech Republic","2012","2012",97.2,,
+"PATCOTHR","Products not elsewhere classified","TCPPERMT","/capita, US$ exchange rate","CZE","Czech Republic","2013","2013",94.2,,
+"PATCOTHR","Products not elsewhere classified","TCPPERMT","/capita, US$ exchange rate","CZE","Czech Republic","2014","2014",93.2,,
+"PATCOTHR","Products not elsewhere classified","TCPPERMT","/capita, US$ exchange rate","CZE","Czech Republic","2015","2015",88,,
+"PATCOTHR","Products not elsewhere classified","TCPPERMT","/capita, US$ exchange rate","CZE","Czech Republic","2016","2016",92.8,,
+"PATCOTHR","Products not elsewhere classified","TCPPERMT","/capita, US$ exchange rate","CZE","Czech Republic","2017","2017",103.1,,
+"PATCOTHR","Products not elsewhere classified","TCPPERMT","/capita, US$ exchange rate","CZE","Czech Republic","2018","2018",120,,
+"PATCOTHR","Products not elsewhere classified","TCPPERMT","/capita, US$ exchange rate","CZE","Czech Republic","2019","2019",123.2,,
+"PATCOTHR","Products not elsewhere classified","TCPPERMT","/capita, US$ exchange rate","CZE","Czech Republic","2020","2020",118.7,"B","Break"
+"PATCOTHR","Products not elsewhere classified","TCPPERMT","/capita, US$ exchange rate","CZE","Czech Republic","2021","2021",139.7,,
+"PATCOTHR","Products not elsewhere classified","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czech Republic","2010","2010",139.7,,
+"PATCOTHR","Products not elsewhere classified","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czech Republic","2011","2011",136.4,,
+"PATCOTHR","Products not elsewhere classified","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czech Republic","2012","2012",143.2,,
+"PATCOTHR","Products not elsewhere classified","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czech Republic","2013","2013",144.2,,
+"PATCOTHR","Products not elsewhere classified","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czech Republic","2014","2014",152.4,,
+"PATCOTHR","Products not elsewhere classified","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czech Republic","2015","2015",167.4,,
+"PATCOTHR","Products not elsewhere classified","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czech Republic","2016","2016",180.3,,
+"PATCOTHR","Products not elsewhere classified","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czech Republic","2017","2017",194,,
+"PATCOTHR","Products not elsewhere classified","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czech Republic","2018","2018",210.8,,
+"PATCOTHR","Products not elsewhere classified","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czech Republic","2019","2019",230.1,,
+"PATCOTHR","Products not elsewhere classified","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czech Republic","2020","2020",221.1,"B","Break"
+"PATCOTHR","Products not elsewhere classified","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czech Republic","2021","2021",237.6,,
+"PATCOTHR","Products not elsewhere classified","ATCPTTMT","% of total sales","CZE","Czech Republic","2010","2010",24.6,,
+"PATCOTHR","Products not elsewhere classified","ATCPTTMT","% of total sales","CZE","Czech Republic","2011","2011",23.6,,
+"PATCOTHR","Products not elsewhere classified","ATCPTTMT","% of total sales","CZE","Czech Republic","2012","2012",23.9,,
+"PATCOTHR","Products not elsewhere classified","ATCPTTMT","% of total sales","CZE","Czech Republic","2013","2013",24.3,,
+"PATCOTHR","Products not elsewhere classified","ATCPTTMT","% of total sales","CZE","Czech Republic","2014","2014",25.1,,
+"PATCOTHR","Products not elsewhere classified","ATCPTTMT","% of total sales","CZE","Czech Republic","2015","2015",27,,
+"PATCOTHR","Products not elsewhere classified","ATCPTTMT","% of total sales","CZE","Czech Republic","2016","2016",27.4,,
+"PATCOTHR","Products not elsewhere classified","ATCPTTMT","% of total sales","CZE","Czech Republic","2017","2017",27.7,,
+"PATCOTHR","Products not elsewhere classified","ATCPTTMT","% of total sales","CZE","Czech Republic","2018","2018",28.3,,
+"PATCOTHR","Products not elsewhere classified","ATCPTTMT","% of total sales","CZE","Czech Republic","2019","2019",29.2,,
+"PATCOTHR","Products not elsewhere classified","ATCPTTMT","% of total sales","CZE","Czech Republic","2020","2020",33.6,"B","Break"
+"PATCOTHR","Products not elsewhere classified","ATCPTTMT","% of total sales","CZE","Czech Republic","2021","2021",34.2,,
+"PATCOTHR","Products not elsewhere classified","MLLNCUMT","Million of national currency units","DNK","Denmark","2010","2010",5687.4,,
+"PATCOTHR","Products not elsewhere classified","MLLNCUMT","Million of national currency units","DNK","Denmark","2011","2011",5610,,
+"PATCOTHR","Products not elsewhere classified","MLLNCUMT","Million of national currency units","DNK","Denmark","2012","2012",5976.8,,
+"PATCOTHR","Products not elsewhere classified","MLLNCUMT","Million of national currency units","DNK","Denmark","2013","2013",6538.7,,
+"PATCOTHR","Products not elsewhere classified","MLLNCUMT","Million of national currency units","DNK","Denmark","2014","2014",7193,,
+"PATCOTHR","Products not elsewhere classified","MLLNCUMT","Million of national currency units","DNK","Denmark","2015","2015",7278.8,,
+"PATCOTHR","Products not elsewhere classified","MLLNCUMT","Million of national currency units","DNK","Denmark","2016","2016",7562.7,,
+"PATCOTHR","Products not elsewhere classified","MLLNCUMT","Million of national currency units","DNK","Denmark","2017","2017",8416.3,,
+"PATCOTHR","Products not elsewhere classified","MLLNCUMT","Million of national currency units","DNK","Denmark","2018","2018",8988.3,,
+"PATCOTHR","Products not elsewhere classified","MLLNCUMT","Million of national currency units","DNK","Denmark","2019","2019",8869.5,,
+"PATCOTHR","Products not elsewhere classified","MLLNCUMT","Million of national currency units","DNK","Denmark","2020","2020",9157.9,,
+"PATCOTHR","Products not elsewhere classified","MLLNCUMT","Million of national currency units","DNK","Denmark","2021","2021",9298,,
+"PATCOTHR","Products not elsewhere classified","MTMOTCMT","Million US$ at exchange rate","DNK","Denmark","2010","2010",1011.3,,
+"PATCOTHR","Products not elsewhere classified","MTMOTCMT","Million US$ at exchange rate","DNK","Denmark","2011","2011",1044.9,,
+"PATCOTHR","Products not elsewhere classified","MTMOTCMT","Million US$ at exchange rate","DNK","Denmark","2012","2012",1031.8,,
+"PATCOTHR","Products not elsewhere classified","MTMOTCMT","Million US$ at exchange rate","DNK","Denmark","2013","2013",1164.2,,
+"PATCOTHR","Products not elsewhere classified","MTMOTCMT","Million US$ at exchange rate","DNK","Denmark","2014","2014",1281.6,,
+"PATCOTHR","Products not elsewhere classified","MTMOTCMT","Million US$ at exchange rate","DNK","Denmark","2015","2015",1081.9,,
+"PATCOTHR","Products not elsewhere classified","MTMOTCMT","Million US$ at exchange rate","DNK","Denmark","2016","2016",1123.4,,
+"PATCOTHR","Products not elsewhere classified","MTMOTCMT","Million US$ at exchange rate","DNK","Denmark","2017","2017",1274.6,,
+"PATCOTHR","Products not elsewhere classified","MTMOTCMT","Million US$ at exchange rate","DNK","Denmark","2018","2018",1423.4,,
+"PATCOTHR","Products not elsewhere classified","MTMOTCMT","Million US$ at exchange rate","DNK","Denmark","2019","2019",1329.9,,
+"PATCOTHR","Products not elsewhere classified","MTMOTCMT","Million US$ at exchange rate","DNK","Denmark","2020","2020",1399.8,,
+"PATCOTHR","Products not elsewhere classified","MTMOTCMT","Million US$ at exchange rate","DNK","Denmark","2021","2021",1478.9,,
+"PATCOTHR","Products not elsewhere classified","MTMOPPMT","Million US$, purchasing power parity","DNK","Denmark","2010","2010",749.2,,
+"PATCOTHR","Products not elsewhere classified","MTMOPPMT","Million US$, purchasing power parity","DNK","Denmark","2011","2011",751.4,,
+"PATCOTHR","Products not elsewhere classified","MTMOPPMT","Million US$, purchasing power parity","DNK","Denmark","2012","2012",790.2,,
+"PATCOTHR","Products not elsewhere classified","MTMOPPMT","Million US$, purchasing power parity","DNK","Denmark","2013","2013",889,,
+"PATCOTHR","Products not elsewhere classified","MTMOPPMT","Million US$, purchasing power parity","DNK","Denmark","2014","2014",981.5,,
+"PATCOTHR","Products not elsewhere classified","MTMOPPMT","Million US$, purchasing power parity","DNK","Denmark","2015","2015",996.4,,
+"PATCOTHR","Products not elsewhere classified","MTMOPPMT","Million US$, purchasing power parity","DNK","Denmark","2016","2016",1068.2,,
+"PATCOTHR","Products not elsewhere classified","MTMOPPMT","Million US$, purchasing power parity","DNK","Denmark","2017","2017",1224.8,,
+"PATCOTHR","Products not elsewhere classified","MTMOPPMT","Million US$, purchasing power parity","DNK","Denmark","2018","2018",1328.5,,
+"PATCOTHR","Products not elsewhere classified","MTMOPPMT","Million US$, purchasing power parity","DNK","Denmark","2019","2019",1337,,
+"PATCOTHR","Products not elsewhere classified","MTMOPPMT","Million US$, purchasing power parity","DNK","Denmark","2020","2020",1397.9,,
+"PATCOTHR","Products not elsewhere classified","MTMOPPMT","Million US$, purchasing power parity","DNK","Denmark","2021","2021",1411,,
+"PATCOTHR","Products not elsewhere classified","TCPPERMT","/capita, US$ exchange rate","DNK","Denmark","2010","2010",182.3,,
+"PATCOTHR","Products not elsewhere classified","TCPPERMT","/capita, US$ exchange rate","DNK","Denmark","2011","2011",187.6,,
+"PATCOTHR","Products not elsewhere classified","TCPPERMT","/capita, US$ exchange rate","DNK","Denmark","2012","2012",184.5,,
+"PATCOTHR","Products not elsewhere classified","TCPPERMT","/capita, US$ exchange rate","DNK","Denmark","2013","2013",207.3,,
+"PATCOTHR","Products not elsewhere classified","TCPPERMT","/capita, US$ exchange rate","DNK","Denmark","2014","2014",227.1,,
+"PATCOTHR","Products not elsewhere classified","TCPPERMT","/capita, US$ exchange rate","DNK","Denmark","2015","2015",190.4,,
+"PATCOTHR","Products not elsewhere classified","TCPPERMT","/capita, US$ exchange rate","DNK","Denmark","2016","2016",196.1,,
+"PATCOTHR","Products not elsewhere classified","TCPPERMT","/capita, US$ exchange rate","DNK","Denmark","2017","2017",221.1,,
+"PATCOTHR","Products not elsewhere classified","TCPPERMT","/capita, US$ exchange rate","DNK","Denmark","2018","2018",245.7,,
+"PATCOTHR","Products not elsewhere classified","TCPPERMT","/capita, US$ exchange rate","DNK","Denmark","2019","2019",228.7,,
+"PATCOTHR","Products not elsewhere classified","TCPPERMT","/capita, US$ exchange rate","DNK","Denmark","2020","2020",240.1,,
+"PATCOTHR","Products not elsewhere classified","TCPPERMT","/capita, US$ exchange rate","DNK","Denmark","2021","2021",252.5,,
+"PATCOTHR","Products not elsewhere classified","PPPPERMT","/capita, US$ purchasing power parity","DNK","Denmark","2010","2010",135,,
+"PATCOTHR","Products not elsewhere classified","PPPPERMT","/capita, US$ purchasing power parity","DNK","Denmark","2011","2011",134.9,,
+"PATCOTHR","Products not elsewhere classified","PPPPERMT","/capita, US$ purchasing power parity","DNK","Denmark","2012","2012",141.3,,
+"PATCOTHR","Products not elsewhere classified","PPPPERMT","/capita, US$ purchasing power parity","DNK","Denmark","2013","2013",158.3,,
+"PATCOTHR","Products not elsewhere classified","PPPPERMT","/capita, US$ purchasing power parity","DNK","Denmark","2014","2014",173.9,,
+"PATCOTHR","Products not elsewhere classified","PPPPERMT","/capita, US$ purchasing power parity","DNK","Denmark","2015","2015",175.3,,
+"PATCOTHR","Products not elsewhere classified","PPPPERMT","/capita, US$ purchasing power parity","DNK","Denmark","2016","2016",186.5,,
+"PATCOTHR","Products not elsewhere classified","PPPPERMT","/capita, US$ purchasing power parity","DNK","Denmark","2017","2017",212.5,,
+"PATCOTHR","Products not elsewhere classified","PPPPERMT","/capita, US$ purchasing power parity","DNK","Denmark","2018","2018",229.3,,
+"PATCOTHR","Products not elsewhere classified","PPPPERMT","/capita, US$ purchasing power parity","DNK","Denmark","2019","2019",229.9,,
+"PATCOTHR","Products not elsewhere classified","PPPPERMT","/capita, US$ purchasing power parity","DNK","Denmark","2020","2020",239.7,,
+"PATCOTHR","Products not elsewhere classified","PPPPERMT","/capita, US$ purchasing power parity","DNK","Denmark","2021","2021",240.9,,
+"PATCOTHR","Products not elsewhere classified","ATCPTTMT","% of total sales","DNK","Denmark","2010","2010",26.9,,
+"PATCOTHR","Products not elsewhere classified","ATCPTTMT","% of total sales","DNK","Denmark","2011","2011",27.3,,
+"PATCOTHR","Products not elsewhere classified","ATCPTTMT","% of total sales","DNK","Denmark","2012","2012",29.2,,
+"PATCOTHR","Products not elsewhere classified","ATCPTTMT","% of total sales","DNK","Denmark","2013","2013",32,,
+"PATCOTHR","Products not elsewhere classified","ATCPTTMT","% of total sales","DNK","Denmark","2014","2014",33.6,,
+"PATCOTHR","Products not elsewhere classified","ATCPTTMT","% of total sales","DNK","Denmark","2015","2015",33.2,,
+"PATCOTHR","Products not elsewhere classified","ATCPTTMT","% of total sales","DNK","Denmark","2016","2016",34.2,,
+"PATCOTHR","Products not elsewhere classified","ATCPTTMT","% of total sales","DNK","Denmark","2017","2017",36.7,,
+"PATCOTHR","Products not elsewhere classified","ATCPTTMT","% of total sales","DNK","Denmark","2018","2018",37.7,,
+"PATCOTHR","Products not elsewhere classified","ATCPTTMT","% of total sales","DNK","Denmark","2019","2019",36.1,,
+"PATCOTHR","Products not elsewhere classified","ATCPTTMT","% of total sales","DNK","Denmark","2020","2020",36.2,,
+"PATCOTHR","Products not elsewhere classified","ATCPTTMT","% of total sales","DNK","Denmark","2021","2021",36.4,,
+"PATCOTHR","Products not elsewhere classified","MLLNCUMT","Million of national currency units","DEU","Germany","2010","2010",6585.2,"D","Difference in methodology"
+"PATCOTHR","Products not elsewhere classified","MLLNCUMT","Million of national currency units","DEU","Germany","2011","2011",6791.6,"D","Difference in methodology"
+"PATCOTHR","Products not elsewhere classified","MLLNCUMT","Million of national currency units","DEU","Germany","2012","2012",7344.1,"D","Difference in methodology"
+"PATCOTHR","Products not elsewhere classified","MLLNCUMT","Million of national currency units","DEU","Germany","2013","2013",8022.7,"D","Difference in methodology"
+"PATCOTHR","Products not elsewhere classified","MLLNCUMT","Million of national currency units","DEU","Germany","2014","2014",8741.3,"D","Difference in methodology"
+"PATCOTHR","Products not elsewhere classified","MLLNCUMT","Million of national currency units","DEU","Germany","2015","2015",9719.6,"D","Difference in methodology"
+"PATCOTHR","Products not elsewhere classified","MLLNCUMT","Million of national currency units","DEU","Germany","2016","2016",10572.5,"D","Difference in methodology"
+"PATCOTHR","Products not elsewhere classified","MLLNCUMT","Million of national currency units","DEU","Germany","2017","2017",11759.2,"D","Difference in methodology"
+"PATCOTHR","Products not elsewhere classified","MLLNCUMT","Million of national currency units","DEU","Germany","2018","2018",17675.4,"B; D","Break; Difference in methodology"
+"PATCOTHR","Products not elsewhere classified","MLLNCUMT","Million of national currency units","DEU","Germany","2019","2019",19221.7,"D","Difference in methodology"
+"PATCOTHR","Products not elsewhere classified","MLLNCUMT","Million of national currency units","DEU","Germany","2020","2020",20725.2,"D","Difference in methodology"
+"PATCOTHR","Products not elsewhere classified","MLLNCUMT","Million of national currency units","DEU","Germany","2021","2021",22734.2,"D","Difference in methodology"
+"PATCOTHR","Products not elsewhere classified","MTMOTCMT","Million US$ at exchange rate","DEU","Germany","2010","2010",8730.1,"D","Difference in methodology"
+"PATCOTHR","Products not elsewhere classified","MTMOTCMT","Million US$ at exchange rate","DEU","Germany","2011","2011",9453.6,"D","Difference in methodology"
+"PATCOTHR","Products not elsewhere classified","MTMOTCMT","Million US$ at exchange rate","DEU","Germany","2012","2012",9435.6,"D","Difference in methodology"
+"PATCOTHR","Products not elsewhere classified","MTMOTCMT","Million US$ at exchange rate","DEU","Germany","2013","2013",10655.1,"D","Difference in methodology"
+"PATCOTHR","Products not elsewhere classified","MTMOTCMT","Million US$ at exchange rate","DEU","Germany","2014","2014",11612.8,"D","Difference in methodology"
+"PATCOTHR","Products not elsewhere classified","MTMOTCMT","Million US$ at exchange rate","DEU","Germany","2015","2015",10784,"D","Difference in methodology"
+"PATCOTHR","Products not elsewhere classified","MTMOTCMT","Million US$ at exchange rate","DEU","Germany","2016","2016",11702.7,"D","Difference in methodology"
+"PATCOTHR","Products not elsewhere classified","MTMOTCMT","Million US$ at exchange rate","DEU","Germany","2017","2017",13284.1,"D","Difference in methodology"
+"PATCOTHR","Products not elsewhere classified","MTMOTCMT","Million US$ at exchange rate","DEU","Germany","2018","2018",20873.8,"B; D","Break; Difference in methodology"
+"PATCOTHR","Products not elsewhere classified","MTMOTCMT","Million US$ at exchange rate","DEU","Germany","2019","2019",21518.2,"D","Difference in methodology"
+"PATCOTHR","Products not elsewhere classified","MTMOTCMT","Million US$ at exchange rate","DEU","Germany","2020","2020",23672.3,"D","Difference in methodology"
+"PATCOTHR","Products not elsewhere classified","MTMOTCMT","Million US$ at exchange rate","DEU","Germany","2021","2021",26888.7,"D","Difference in methodology"
+"PATCOTHR","Products not elsewhere classified","MTMOPPMT","Million US$, purchasing power parity","DEU","Germany","2010","2010",8179.5,"D","Difference in methodology"
+"PATCOTHR","Products not elsewhere classified","MTMOPPMT","Million US$, purchasing power parity","DEU","Germany","2011","2011",8610.7,"D","Difference in methodology"
+"PATCOTHR","Products not elsewhere classified","MTMOPPMT","Million US$, purchasing power parity","DEU","Germany","2012","2012",9328.9,"D","Difference in methodology"
+"PATCOTHR","Products not elsewhere classified","MTMOPPMT","Million US$, purchasing power parity","DEU","Germany","2013","2013",10354.8,"D","Difference in methodology"
+"PATCOTHR","Products not elsewhere classified","MTMOPPMT","Million US$, purchasing power parity","DEU","Germany","2014","2014",11368,"D","Difference in methodology"
+"PATCOTHR","Products not elsewhere classified","MTMOPPMT","Million US$, purchasing power parity","DEU","Germany","2015","2015",12491.1,"D","Difference in methodology"
+"PATCOTHR","Products not elsewhere classified","MTMOPPMT","Million US$, purchasing power parity","DEU","Germany","2016","2016",14047.8,"D","Difference in methodology"
+"PATCOTHR","Products not elsewhere classified","MTMOPPMT","Million US$, purchasing power parity","DEU","Germany","2017","2017",15788.8,"D","Difference in methodology"
+"PATCOTHR","Products not elsewhere classified","MTMOPPMT","Million US$, purchasing power parity","DEU","Germany","2018","2018",24033.5,"B; D","Break; Difference in methodology"
+"PATCOTHR","Products not elsewhere classified","MTMOPPMT","Million US$, purchasing power parity","DEU","Germany","2019","2019",26394.4,"D","Difference in methodology"
+"PATCOTHR","Products not elsewhere classified","MTMOPPMT","Million US$, purchasing power parity","DEU","Germany","2020","2020",28586.4,"D","Difference in methodology"
+"PATCOTHR","Products not elsewhere classified","MTMOPPMT","Million US$, purchasing power parity","DEU","Germany","2021","2021",30877.2,"D","Difference in methodology"
+"PATCOTHR","Products not elsewhere classified","TCPPERMT","/capita, US$ exchange rate","DEU","Germany","2010","2010",106.8,"D","Difference in methodology"
+"PATCOTHR","Products not elsewhere classified","TCPPERMT","/capita, US$ exchange rate","DEU","Germany","2011","2011",117.8,"D","Difference in methodology"
+"PATCOTHR","Products not elsewhere classified","TCPPERMT","/capita, US$ exchange rate","DEU","Germany","2012","2012",117.3,"D","Difference in methodology"
+"PATCOTHR","Products not elsewhere classified","TCPPERMT","/capita, US$ exchange rate","DEU","Germany","2013","2013",132.1,"D","Difference in methodology"
+"PATCOTHR","Products not elsewhere classified","TCPPERMT","/capita, US$ exchange rate","DEU","Germany","2014","2014",143.4,"D","Difference in methodology"
+"PATCOTHR","Products not elsewhere classified","TCPPERMT","/capita, US$ exchange rate","DEU","Germany","2015","2015",132,"D","Difference in methodology"
+"PATCOTHR","Products not elsewhere classified","TCPPERMT","/capita, US$ exchange rate","DEU","Germany","2016","2016",142.1,"D","Difference in methodology"
+"PATCOTHR","Products not elsewhere classified","TCPPERMT","/capita, US$ exchange rate","DEU","Germany","2017","2017",160.7,"D","Difference in methodology"
+"PATCOTHR","Products not elsewhere classified","TCPPERMT","/capita, US$ exchange rate","DEU","Germany","2018","2018",251.8,"B; D","Break; Difference in methodology"
+"PATCOTHR","Products not elsewhere classified","TCPPERMT","/capita, US$ exchange rate","DEU","Germany","2019","2019",259,"D","Difference in methodology"
+"PATCOTHR","Products not elsewhere classified","TCPPERMT","/capita, US$ exchange rate","DEU","Germany","2020","2020",284.7,"D","Difference in methodology"
+"PATCOTHR","Products not elsewhere classified","TCPPERMT","/capita, US$ exchange rate","DEU","Germany","2021","2021",323.2,"D","Difference in methodology"
+"PATCOTHR","Products not elsewhere classified","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2010","2010",100,"D","Difference in methodology"
+"PATCOTHR","Products not elsewhere classified","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2011","2011",107.3,"D","Difference in methodology"
+"PATCOTHR","Products not elsewhere classified","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2012","2012",116,"D","Difference in methodology"
+"PATCOTHR","Products not elsewhere classified","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2013","2013",128.4,"D","Difference in methodology"
+"PATCOTHR","Products not elsewhere classified","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2014","2014",140.4,"D","Difference in methodology"
+"PATCOTHR","Products not elsewhere classified","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2015","2015",152.9,"D","Difference in methodology"
+"PATCOTHR","Products not elsewhere classified","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2016","2016",170.6,"D","Difference in methodology"
+"PATCOTHR","Products not elsewhere classified","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2017","2017",191,"D","Difference in methodology"
+"PATCOTHR","Products not elsewhere classified","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2018","2018",289.9,"B; D","Break; Difference in methodology"
+"PATCOTHR","Products not elsewhere classified","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2019","2019",317.6,"D","Difference in methodology"
+"PATCOTHR","Products not elsewhere classified","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2020","2020",343.7,"D","Difference in methodology"
+"PATCOTHR","Products not elsewhere classified","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2021","2021",371.1,"D","Difference in methodology"
+"PATCOTHR","Products not elsewhere classified","ATCPTTMT","% of total sales","DEU","Germany","2010","2010",22.2,"D","Difference in methodology"
+"PATCOTHR","Products not elsewhere classified","ATCPTTMT","% of total sales","DEU","Germany","2011","2011",22.9,"D","Difference in methodology"
+"PATCOTHR","Products not elsewhere classified","ATCPTTMT","% of total sales","DEU","Germany","2012","2012",24.1,"D","Difference in methodology"
+"PATCOTHR","Products not elsewhere classified","ATCPTTMT","% of total sales","DEU","Germany","2013","2013",25.4,"D","Difference in methodology"
+"PATCOTHR","Products not elsewhere classified","ATCPTTMT","% of total sales","DEU","Germany","2014","2014",26,"D","Difference in methodology"
+"PATCOTHR","Products not elsewhere classified","ATCPTTMT","% of total sales","DEU","Germany","2015","2015",27.5,"D","Difference in methodology"
+"PATCOTHR","Products not elsewhere classified","ATCPTTMT","% of total sales","DEU","Germany","2016","2016",29.3,"D","Difference in methodology"
+"PATCOTHR","Products not elsewhere classified","ATCPTTMT","% of total sales","DEU","Germany","2017","2017",31.6,"D","Difference in methodology"
+"PATCOTHR","Products not elsewhere classified","ATCPTTMT","% of total sales","DEU","Germany","2018","2018",40,"B; D","Break; Difference in methodology"
+"PATCOTHR","Products not elsewhere classified","ATCPTTMT","% of total sales","DEU","Germany","2019","2019",41,"D","Difference in methodology"
+"PATCOTHR","Products not elsewhere classified","ATCPTTMT","% of total sales","DEU","Germany","2020","2020",42.2,"D","Difference in methodology"
+"PATCOTHR","Products not elsewhere classified","ATCPTTMT","% of total sales","DEU","Germany","2021","2021",42.7,"D","Difference in methodology"
+"PATCOTHR","Products not elsewhere classified","MLLNCUMT","Million of national currency units","ISL","Iceland","2010","2010",5683.3,,
+"PATCOTHR","Products not elsewhere classified","MLLNCUMT","Million of national currency units","ISL","Iceland","2011","2011",8260.8,,
+"PATCOTHR","Products not elsewhere classified","MLLNCUMT","Million of national currency units","ISL","Iceland","2012","2012",6983.5,,
+"PATCOTHR","Products not elsewhere classified","MLLNCUMT","Million of national currency units","ISL","Iceland","2013","2013",6524.4,,
+"PATCOTHR","Products not elsewhere classified","MLLNCUMT","Million of national currency units","ISL","Iceland","2014","2014",6288.7,,
+"PATCOTHR","Products not elsewhere classified","MLLNCUMT","Million of national currency units","ISL","Iceland","2015","2015",6869.4,,
+"PATCOTHR","Products not elsewhere classified","MLLNCUMT","Million of national currency units","ISL","Iceland","2016","2016",7341.2,,
+"PATCOTHR","Products not elsewhere classified","MLLNCUMT","Million of national currency units","ISL","Iceland","2017","2017",8027.6,,
+"PATCOTHR","Products not elsewhere classified","MLLNCUMT","Million of national currency units","ISL","Iceland","2018","2018",10229.8,,
+"PATCOTHR","Products not elsewhere classified","MLLNCUMT","Million of national currency units","ISL","Iceland","2019","2019",10845.4,,
+"PATCOTHR","Products not elsewhere classified","MLLNCUMT","Million of national currency units","ISL","Iceland","2020","2020",13383.4,,
+"PATCOTHR","Products not elsewhere classified","MLLNCUMT","Million of national currency units","ISL","Iceland","2021","2021",15274.6,,
+"PATCOTHR","Products not elsewhere classified","MTMOTCMT","Million US$ at exchange rate","ISL","Iceland","2010","2010",46.5,,
+"PATCOTHR","Products not elsewhere classified","MTMOTCMT","Million US$ at exchange rate","ISL","Iceland","2011","2011",71.2,,
+"PATCOTHR","Products not elsewhere classified","MTMOTCMT","Million US$ at exchange rate","ISL","Iceland","2012","2012",55.8,,
+"PATCOTHR","Products not elsewhere classified","MTMOTCMT","Million US$ at exchange rate","ISL","Iceland","2013","2013",53.4,,
+"PATCOTHR","Products not elsewhere classified","MTMOTCMT","Million US$ at exchange rate","ISL","Iceland","2014","2014",53.9,,
+"PATCOTHR","Products not elsewhere classified","MTMOTCMT","Million US$ at exchange rate","ISL","Iceland","2015","2015",52.1,,
+"PATCOTHR","Products not elsewhere classified","MTMOTCMT","Million US$ at exchange rate","ISL","Iceland","2016","2016",60.8,,
+"PATCOTHR","Products not elsewhere classified","MTMOTCMT","Million US$ at exchange rate","ISL","Iceland","2017","2017",75.1,,
+"PATCOTHR","Products not elsewhere classified","MTMOTCMT","Million US$ at exchange rate","ISL","Iceland","2018","2018",94.5,,
+"PATCOTHR","Products not elsewhere classified","MTMOTCMT","Million US$ at exchange rate","ISL","Iceland","2019","2019",88.5,,
+"PATCOTHR","Products not elsewhere classified","MTMOTCMT","Million US$ at exchange rate","ISL","Iceland","2020","2020",98.8,,
+"PATCOTHR","Products not elsewhere classified","MTMOTCMT","Million US$ at exchange rate","ISL","Iceland","2021","2021",120.3,,
+"PATCOTHR","Products not elsewhere classified","MTMOPPMT","Million US$, purchasing power parity","ISL","Iceland","2010","2010",42.8,,
+"PATCOTHR","Products not elsewhere classified","MTMOPPMT","Million US$, purchasing power parity","ISL","Iceland","2011","2011",61.1,,
+"PATCOTHR","Products not elsewhere classified","MTMOPPMT","Million US$, purchasing power parity","ISL","Iceland","2012","2012",51,,
+"PATCOTHR","Products not elsewhere classified","MTMOPPMT","Million US$, purchasing power parity","ISL","Iceland","2013","2013",47.6,,
+"PATCOTHR","Products not elsewhere classified","MTMOPPMT","Million US$, purchasing power parity","ISL","Iceland","2014","2014",45.4,,
+"PATCOTHR","Products not elsewhere classified","MTMOPPMT","Million US$, purchasing power parity","ISL","Iceland","2015","2015",48.4,,
+"PATCOTHR","Products not elsewhere classified","MTMOPPMT","Million US$, purchasing power parity","ISL","Iceland","2016","2016",52.4,,
+"PATCOTHR","Products not elsewhere classified","MTMOPPMT","Million US$, purchasing power parity","ISL","Iceland","2017","2017",58.1,,
+"PATCOTHR","Products not elsewhere classified","MTMOPPMT","Million US$, purchasing power parity","ISL","Iceland","2018","2018",72.6,,
+"PATCOTHR","Products not elsewhere classified","MTMOPPMT","Million US$, purchasing power parity","ISL","Iceland","2019","2019",77.1,,
+"PATCOTHR","Products not elsewhere classified","MTMOPPMT","Million US$, purchasing power parity","ISL","Iceland","2020","2020",91.2,,
+"PATCOTHR","Products not elsewhere classified","MTMOPPMT","Million US$, purchasing power parity","ISL","Iceland","2021","2021",102,,
+"PATCOTHR","Products not elsewhere classified","TCPPERMT","/capita, US$ exchange rate","ISL","Iceland","2010","2010",146.2,,
+"PATCOTHR","Products not elsewhere classified","TCPPERMT","/capita, US$ exchange rate","ISL","Iceland","2011","2011",223.3,,
+"PATCOTHR","Products not elsewhere classified","TCPPERMT","/capita, US$ exchange rate","ISL","Iceland","2012","2012",174.1,,
+"PATCOTHR","Products not elsewhere classified","TCPPERMT","/capita, US$ exchange rate","ISL","Iceland","2013","2013",164.9,,
+"PATCOTHR","Products not elsewhere classified","TCPPERMT","/capita, US$ exchange rate","ISL","Iceland","2014","2014",164.5,,
+"PATCOTHR","Products not elsewhere classified","TCPPERMT","/capita, US$ exchange rate","ISL","Iceland","2015","2015",157.4,,
+"PATCOTHR","Products not elsewhere classified","TCPPERMT","/capita, US$ exchange rate","ISL","Iceland","2016","2016",181.2,,
+"PATCOTHR","Products not elsewhere classified","TCPPERMT","/capita, US$ exchange rate","ISL","Iceland","2017","2017",218.8,,
+"PATCOTHR","Products not elsewhere classified","TCPPERMT","/capita, US$ exchange rate","ISL","Iceland","2018","2018",267.8,,
+"PATCOTHR","Products not elsewhere classified","TCPPERMT","/capita, US$ exchange rate","ISL","Iceland","2019","2019",245.3,,
+"PATCOTHR","Products not elsewhere classified","TCPPERMT","/capita, US$ exchange rate","ISL","Iceland","2020","2020",269.7,,
+"PATCOTHR","Products not elsewhere classified","TCPPERMT","/capita, US$ exchange rate","ISL","Iceland","2021","2021",322.9,,
+"PATCOTHR","Products not elsewhere classified","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2010","2010",134.5,,
+"PATCOTHR","Products not elsewhere classified","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2011","2011",191.6,,
+"PATCOTHR","Products not elsewhere classified","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2012","2012",159,,
+"PATCOTHR","Products not elsewhere classified","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2013","2013",147.1,,
+"PATCOTHR","Products not elsewhere classified","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2014","2014",138.6,,
+"PATCOTHR","Products not elsewhere classified","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2015","2015",146.3,,
+"PATCOTHR","Products not elsewhere classified","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2016","2016",156.3,,
+"PATCOTHR","Products not elsewhere classified","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2017","2017",169.1,,
+"PATCOTHR","Products not elsewhere classified","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2018","2018",205.7,,
+"PATCOTHR","Products not elsewhere classified","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2019","2019",213.8,,
+"PATCOTHR","Products not elsewhere classified","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2020","2020",249,,
+"PATCOTHR","Products not elsewhere classified","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2021","2021",273.9,,
+"PATCOTHR","Products not elsewhere classified","ATCPTTMT","% of total sales","ISL","Iceland","2010","2010",22.7,,
+"PATCOTHR","Products not elsewhere classified","ATCPTTMT","% of total sales","ISL","Iceland","2011","2011",31.7,,
+"PATCOTHR","Products not elsewhere classified","ATCPTTMT","% of total sales","ISL","Iceland","2012","2012",28.8,,
+"PATCOTHR","Products not elsewhere classified","ATCPTTMT","% of total sales","ISL","Iceland","2013","2013",25.1,,
+"PATCOTHR","Products not elsewhere classified","ATCPTTMT","% of total sales","ISL","Iceland","2014","2014",26.5,,
+"PATCOTHR","Products not elsewhere classified","ATCPTTMT","% of total sales","ISL","Iceland","2015","2015",28.1,,
+"PATCOTHR","Products not elsewhere classified","ATCPTTMT","% of total sales","ISL","Iceland","2016","2016",28.9,,
+"PATCOTHR","Products not elsewhere classified","ATCPTTMT","% of total sales","ISL","Iceland","2017","2017",30.3,,
+"PATCOTHR","Products not elsewhere classified","ATCPTTMT","% of total sales","ISL","Iceland","2018","2018",33.9,,
+"PATCOTHR","Products not elsewhere classified","ATCPTTMT","% of total sales","ISL","Iceland","2019","2019",32.2,,
+"PATCOTHR","Products not elsewhere classified","ATCPTTMT","% of total sales","ISL","Iceland","2020","2020",33.6,,
+"PATCOTHR","Products not elsewhere classified","ATCPTTMT","% of total sales","ISL","Iceland","2021","2021",33.9,,
+"PATCOTHR","Products not elsewhere classified","MLLNCUMT","Million of national currency units","IRL","Ireland","2010","2010",507.7,"D","Difference in methodology"
+"PATCOTHR","Products not elsewhere classified","MLLNCUMT","Million of national currency units","IRL","Ireland","2011","2011",514.8,"D","Difference in methodology"
+"PATCOTHR","Products not elsewhere classified","MLLNCUMT","Million of national currency units","IRL","Ireland","2012","2012",544.1,"D","Difference in methodology"
+"PATCOTHR","Products not elsewhere classified","MLLNCUMT","Million of national currency units","IRL","Ireland","2013","2013",565.6,"B; D","Break; Difference in methodology"
+"PATCOTHR","Products not elsewhere classified","MLLNCUMT","Million of national currency units","IRL","Ireland","2014","2014",604.7,"D","Difference in methodology"
+"PATCOTHR","Products not elsewhere classified","MLLNCUMT","Million of national currency units","IRL","Ireland","2015","2015",663.8,"D","Difference in methodology"
+"PATCOTHR","Products not elsewhere classified","MLLNCUMT","Million of national currency units","IRL","Ireland","2016","2016",733.3,"D","Difference in methodology"
+"PATCOTHR","Products not elsewhere classified","MLLNCUMT","Million of national currency units","IRL","Ireland","2017","2017",783.7,"D","Difference in methodology"
+"PATCOTHR","Products not elsewhere classified","MLLNCUMT","Million of national currency units","IRL","Ireland","2018","2018",870.5,"D","Difference in methodology"
+"PATCOTHR","Products not elsewhere classified","MLLNCUMT","Million of national currency units","IRL","Ireland","2019","2019",1040.8,"D","Difference in methodology"
+"PATCOTHR","Products not elsewhere classified","MLLNCUMT","Million of national currency units","IRL","Ireland","2020","2020",1067.7,"D","Difference in methodology"
+"PATCOTHR","Products not elsewhere classified","MLLNCUMT","Million of national currency units","IRL","Ireland","2021","2021",1177.2,"D","Difference in methodology"
+"PATCOTHR","Products not elsewhere classified","MTMOTCMT","Million US$ at exchange rate","IRL","Ireland","2010","2010",673.1,"D","Difference in methodology"
+"PATCOTHR","Products not elsewhere classified","MTMOTCMT","Million US$ at exchange rate","IRL","Ireland","2011","2011",716.6,"D","Difference in methodology"
+"PATCOTHR","Products not elsewhere classified","MTMOTCMT","Million US$ at exchange rate","IRL","Ireland","2012","2012",699.1,"D","Difference in methodology"
+"PATCOTHR","Products not elsewhere classified","MTMOTCMT","Million US$ at exchange rate","IRL","Ireland","2013","2013",751.2,"B; D","Break; Difference in methodology"
+"PATCOTHR","Products not elsewhere classified","MTMOTCMT","Million US$ at exchange rate","IRL","Ireland","2014","2014",803.3,"D","Difference in methodology"
+"PATCOTHR","Products not elsewhere classified","MTMOTCMT","Million US$ at exchange rate","IRL","Ireland","2015","2015",736.5,"D","Difference in methodology"
+"PATCOTHR","Products not elsewhere classified","MTMOTCMT","Million US$ at exchange rate","IRL","Ireland","2016","2016",811.7,"D","Difference in methodology"
+"PATCOTHR","Products not elsewhere classified","MTMOTCMT","Million US$ at exchange rate","IRL","Ireland","2017","2017",885.3,"D","Difference in methodology"
+"PATCOTHR","Products not elsewhere classified","MTMOTCMT","Million US$ at exchange rate","IRL","Ireland","2018","2018",1028,"D","Difference in methodology"
+"PATCOTHR","Products not elsewhere classified","MTMOTCMT","Million US$ at exchange rate","IRL","Ireland","2019","2019",1165.1,"D","Difference in methodology"
+"PATCOTHR","Products not elsewhere classified","MTMOTCMT","Million US$ at exchange rate","IRL","Ireland","2020","2020",1219.5,"D","Difference in methodology"
+"PATCOTHR","Products not elsewhere classified","MTMOTCMT","Million US$ at exchange rate","IRL","Ireland","2021","2021",1392.4,"D","Difference in methodology"
+"PATCOTHR","Products not elsewhere classified","MTMOPPMT","Million US$, purchasing power parity","IRL","Ireland","2010","2010",597.6,"D","Difference in methodology"
+"PATCOTHR","Products not elsewhere classified","MTMOPPMT","Million US$, purchasing power parity","IRL","Ireland","2011","2011",619.1,"D","Difference in methodology"
+"PATCOTHR","Products not elsewhere classified","MTMOPPMT","Million US$, purchasing power parity","IRL","Ireland","2012","2012",661.1,"D","Difference in methodology"
+"PATCOTHR","Products not elsewhere classified","MTMOPPMT","Million US$, purchasing power parity","IRL","Ireland","2013","2013",697.2,"B; D","Break; Difference in methodology"
+"PATCOTHR","Products not elsewhere classified","MTMOPPMT","Million US$, purchasing power parity","IRL","Ireland","2014","2014",738.3,"D","Difference in methodology"
+"PATCOTHR","Products not elsewhere classified","MTMOPPMT","Million US$, purchasing power parity","IRL","Ireland","2015","2015",819.8,"D","Difference in methodology"
+"PATCOTHR","Products not elsewhere classified","MTMOPPMT","Million US$, purchasing power parity","IRL","Ireland","2016","2016",923.2,"D","Difference in methodology"
+"PATCOTHR","Products not elsewhere classified","MTMOPPMT","Million US$, purchasing power parity","IRL","Ireland","2017","2017",986.5,"D","Difference in methodology"
+"PATCOTHR","Products not elsewhere classified","MTMOPPMT","Million US$, purchasing power parity","IRL","Ireland","2018","2018",1098.8,"D","Difference in methodology"
+"PATCOTHR","Products not elsewhere classified","MTMOPPMT","Million US$, purchasing power parity","IRL","Ireland","2019","2019",1291.7,"D","Difference in methodology"
+"PATCOTHR","Products not elsewhere classified","MTMOPPMT","Million US$, purchasing power parity","IRL","Ireland","2020","2020",1341.1,"D","Difference in methodology"
+"PATCOTHR","Products not elsewhere classified","MTMOPPMT","Million US$, purchasing power parity","IRL","Ireland","2021","2021",1481.3,"D","Difference in methodology"
+"PATCOTHR","Products not elsewhere classified","TCPPERMT","/capita, US$ exchange rate","IRL","Ireland","2010","2010",147.6,"D","Difference in methodology"
+"PATCOTHR","Products not elsewhere classified","TCPPERMT","/capita, US$ exchange rate","IRL","Ireland","2011","2011",156.4,"D","Difference in methodology"
+"PATCOTHR","Products not elsewhere classified","TCPPERMT","/capita, US$ exchange rate","IRL","Ireland","2012","2012",152,"D","Difference in methodology"
+"PATCOTHR","Products not elsewhere classified","TCPPERMT","/capita, US$ exchange rate","IRL","Ireland","2013","2013",162.5,"B; D","Break; Difference in methodology"
+"PATCOTHR","Products not elsewhere classified","TCPPERMT","/capita, US$ exchange rate","IRL","Ireland","2014","2014",172.5,"D","Difference in methodology"
+"PATCOTHR","Products not elsewhere classified","TCPPERMT","/capita, US$ exchange rate","IRL","Ireland","2015","2015",156.6,"D","Difference in methodology"
+"PATCOTHR","Products not elsewhere classified","TCPPERMT","/capita, US$ exchange rate","IRL","Ireland","2016","2016",170.7,"D","Difference in methodology"
+"PATCOTHR","Products not elsewhere classified","TCPPERMT","/capita, US$ exchange rate","IRL","Ireland","2017","2017",184.2,"D","Difference in methodology"
+"PATCOTHR","Products not elsewhere classified","TCPPERMT","/capita, US$ exchange rate","IRL","Ireland","2018","2018",211.2,"D","Difference in methodology"
+"PATCOTHR","Products not elsewhere classified","TCPPERMT","/capita, US$ exchange rate","IRL","Ireland","2019","2019",236.1,"D","Difference in methodology"
+"PATCOTHR","Products not elsewhere classified","TCPPERMT","/capita, US$ exchange rate","IRL","Ireland","2020","2020",244.6,"D","Difference in methodology"
+"PATCOTHR","Products not elsewhere classified","TCPPERMT","/capita, US$ exchange rate","IRL","Ireland","2021","2021",276.6,"D","Difference in methodology"
+"PATCOTHR","Products not elsewhere classified","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2010","2010",131.1,"D","Difference in methodology"
+"PATCOTHR","Products not elsewhere classified","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2011","2011",135.2,"D","Difference in methodology"
+"PATCOTHR","Products not elsewhere classified","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2012","2012",143.7,"D","Difference in methodology"
+"PATCOTHR","Products not elsewhere classified","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2013","2013",150.8,"B; D","Break; Difference in methodology"
+"PATCOTHR","Products not elsewhere classified","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2014","2014",158.5,"D","Difference in methodology"
+"PATCOTHR","Products not elsewhere classified","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2015","2015",174.4,"D","Difference in methodology"
+"PATCOTHR","Products not elsewhere classified","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2016","2016",194.1,"D","Difference in methodology"
+"PATCOTHR","Products not elsewhere classified","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2017","2017",205.2,"D","Difference in methodology"
+"PATCOTHR","Products not elsewhere classified","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2018","2018",225.8,"D","Difference in methodology"
+"PATCOTHR","Products not elsewhere classified","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2019","2019",261.8,"D","Difference in methodology"
+"PATCOTHR","Products not elsewhere classified","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2020","2020",269,"D","Difference in methodology"
+"PATCOTHR","Products not elsewhere classified","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2021","2021",294.3,"D","Difference in methodology"
+"PATCOTHR","Products not elsewhere classified","ATCPTTMT","% of total sales","IRL","Ireland","2010","2010",24.8,"D","Difference in methodology"
+"PATCOTHR","Products not elsewhere classified","ATCPTTMT","% of total sales","IRL","Ireland","2011","2011",26.3,"D","Difference in methodology"
+"PATCOTHR","Products not elsewhere classified","ATCPTTMT","% of total sales","IRL","Ireland","2012","2012",26.6,"D","Difference in methodology"
+"PATCOTHR","Products not elsewhere classified","ATCPTTMT","% of total sales","IRL","Ireland","2013","2013",28.9,"B; D","Break; Difference in methodology"
+"PATCOTHR","Products not elsewhere classified","ATCPTTMT","% of total sales","IRL","Ireland","2014","2014",31.6,"D","Difference in methodology"
+"PATCOTHR","Products not elsewhere classified","ATCPTTMT","% of total sales","IRL","Ireland","2015","2015",33.4,"D","Difference in methodology"
+"PATCOTHR","Products not elsewhere classified","ATCPTTMT","% of total sales","IRL","Ireland","2016","2016",35.3,"D","Difference in methodology"
+"PATCOTHR","Products not elsewhere classified","ATCPTTMT","% of total sales","IRL","Ireland","2017","2017",36.9,"D","Difference in methodology"
+"PATCOTHR","Products not elsewhere classified","ATCPTTMT","% of total sales","IRL","Ireland","2018","2018",38.4,"D","Difference in methodology"
+"PATCOTHR","Products not elsewhere classified","ATCPTTMT","% of total sales","IRL","Ireland","2019","2019",43.3,"D","Difference in methodology"
+"PATCOTHR","Products not elsewhere classified","ATCPTTMT","% of total sales","IRL","Ireland","2020","2020",43.4,"D","Difference in methodology"
+"PATCOTHR","Products not elsewhere classified","ATCPTTMT","% of total sales","IRL","Ireland","2021","2021",44.9,"D","Difference in methodology"
+"PATCOTHR","Products not elsewhere classified","MLLNCUMT","Million of national currency units","JPN","Japan","2010","2010",2899512,"D","Difference in methodology"
+"PATCOTHR","Products not elsewhere classified","MLLNCUMT","Million of national currency units","JPN","Japan","2011","2011",3029486,"D","Difference in methodology"
+"PATCOTHR","Products not elsewhere classified","MLLNCUMT","Million of national currency units","JPN","Japan","2012","2012",3003413,"D","Difference in methodology"
+"PATCOTHR","Products not elsewhere classified","MLLNCUMT","Million of national currency units","JPN","Japan","2013","2013",3090356,"D","Difference in methodology"
+"PATCOTHR","Products not elsewhere classified","MLLNCUMT","Million of national currency units","JPN","Japan","2014","2014",3032529,"D","Difference in methodology"
+"PATCOTHR","Products not elsewhere classified","MLLNCUMT","Million of national currency units","JPN","Japan","2015","2015",3250399,"D","Difference in methodology"
+"PATCOTHR","Products not elsewhere classified","MLLNCUMT","Million of national currency units","JPN","Japan","2016","2016",3337024,"D","Difference in methodology"
+"PATCOTHR","Products not elsewhere classified","MLLNCUMT","Million of national currency units","JPN","Japan","2017","2017",3541392,"D","Difference in methodology"
+"PATCOTHR","Products not elsewhere classified","MLLNCUMT","Million of national currency units","JPN","Japan","2018","2018",3902278,"D","Difference in methodology"
+"PATCOTHR","Products not elsewhere classified","MLLNCUMT","Million of national currency units","JPN","Japan","2019","2019",5374795,"B; D","Break; Difference in methodology"
+"PATCOTHR","Products not elsewhere classified","MLLNCUMT","Million of national currency units","JPN","Japan","2020","2020",5321541,"D","Difference in methodology"
+"PATCOTHR","Products not elsewhere classified","MLLNCUMT","Million of national currency units","JPN","Japan","2021","2021",5505328,"D","Difference in methodology"
+"PATCOTHR","Products not elsewhere classified","MTMOTCMT","Million US$ at exchange rate","JPN","Japan","2010","2010",33031.6,"D","Difference in methodology"
+"PATCOTHR","Products not elsewhere classified","MTMOTCMT","Million US$ at exchange rate","JPN","Japan","2011","2011",37960.1,"D","Difference in methodology"
+"PATCOTHR","Products not elsewhere classified","MTMOTCMT","Million US$ at exchange rate","JPN","Japan","2012","2012",37641.3,"D","Difference in methodology"
+"PATCOTHR","Products not elsewhere classified","MTMOTCMT","Million US$ at exchange rate","JPN","Japan","2013","2013",31664.9,"D","Difference in methodology"
+"PATCOTHR","Products not elsewhere classified","MTMOTCMT","Million US$ at exchange rate","JPN","Japan","2014","2014",28623.7,"D","Difference in methodology"
+"PATCOTHR","Products not elsewhere classified","MTMOTCMT","Million US$ at exchange rate","JPN","Japan","2015","2015",26853,"D","Difference in methodology"
+"PATCOTHR","Products not elsewhere classified","MTMOTCMT","Million US$ at exchange rate","JPN","Japan","2016","2016",30673.2,"D","Difference in methodology"
+"PATCOTHR","Products not elsewhere classified","MTMOTCMT","Million US$ at exchange rate","JPN","Japan","2017","2017",31572.7,"D","Difference in methodology"
+"PATCOTHR","Products not elsewhere classified","MTMOTCMT","Million US$ at exchange rate","JPN","Japan","2018","2018",35339.3,"D","Difference in methodology"
+"PATCOTHR","Products not elsewhere classified","MTMOTCMT","Million US$ at exchange rate","JPN","Japan","2019","2019",49305.7,"B; D","Break; Difference in methodology"
+"PATCOTHR","Products not elsewhere classified","MTMOTCMT","Million US$ at exchange rate","JPN","Japan","2020","2020",49839,"D","Difference in methodology"
+"PATCOTHR","Products not elsewhere classified","MTMOTCMT","Million US$ at exchange rate","JPN","Japan","2021","2021",50160.5,"D","Difference in methodology"
+"PATCOTHR","Products not elsewhere classified","MTMOPPMT","Million US$, purchasing power parity","JPN","Japan","2010","2010",25955.8,"D","Difference in methodology"
+"PATCOTHR","Products not elsewhere classified","MTMOPPMT","Million US$, purchasing power parity","JPN","Japan","2011","2011",28193.3,"D","Difference in methodology"
+"PATCOTHR","Products not elsewhere classified","MTMOPPMT","Million US$, purchasing power parity","JPN","Japan","2012","2012",28803.1,"D","Difference in methodology"
+"PATCOTHR","Products not elsewhere classified","MTMOPPMT","Million US$, purchasing power parity","JPN","Japan","2013","2013",30506.2,"D","Difference in methodology"
+"PATCOTHR","Products not elsewhere classified","MTMOPPMT","Million US$, purchasing power parity","JPN","Japan","2014","2014",29427.2,"D","Difference in methodology"
+"PATCOTHR","Products not elsewhere classified","MTMOPPMT","Million US$, purchasing power parity","JPN","Japan","2015","2015",31414.1,"D","Difference in methodology"
+"PATCOTHR","Products not elsewhere classified","MTMOPPMT","Million US$, purchasing power parity","JPN","Japan","2016","2016",31624.7,"D","Difference in methodology"
+"PATCOTHR","Products not elsewhere classified","MTMOPPMT","Million US$, purchasing power parity","JPN","Japan","2017","2017",33694.8,"D","Difference in methodology"
+"PATCOTHR","Products not elsewhere classified","MTMOPPMT","Million US$, purchasing power parity","JPN","Japan","2018","2018",37464.8,"D","Difference in methodology"
+"PATCOTHR","Products not elsewhere classified","MTMOPPMT","Million US$, purchasing power parity","JPN","Japan","2019","2019",51568.7,"B; D","Break; Difference in methodology"
+"PATCOTHR","Products not elsewhere classified","MTMOPPMT","Million US$, purchasing power parity","JPN","Japan","2020","2020",51954.1,"D","Difference in methodology"
+"PATCOTHR","Products not elsewhere classified","MTMOPPMT","Million US$, purchasing power parity","JPN","Japan","2021","2021",53947.3,"D","Difference in methodology"
+"PATCOTHR","Products not elsewhere classified","TCPPERMT","/capita, US$ exchange rate","JPN","Japan","2010","2010",257.9,"D","Difference in methodology"
+"PATCOTHR","Products not elsewhere classified","TCPPERMT","/capita, US$ exchange rate","JPN","Japan","2011","2011",296.9,"D","Difference in methodology"
+"PATCOTHR","Products not elsewhere classified","TCPPERMT","/capita, US$ exchange rate","JPN","Japan","2012","2012",295,"D","Difference in methodology"
+"PATCOTHR","Products not elsewhere classified","TCPPERMT","/capita, US$ exchange rate","JPN","Japan","2013","2013",248.5,"D","Difference in methodology"
+"PATCOTHR","Products not elsewhere classified","TCPPERMT","/capita, US$ exchange rate","JPN","Japan","2014","2014",225,"D","Difference in methodology"
+"PATCOTHR","Products not elsewhere classified","TCPPERMT","/capita, US$ exchange rate","JPN","Japan","2015","2015",211.3,"D","Difference in methodology"
+"PATCOTHR","Products not elsewhere classified","TCPPERMT","/capita, US$ exchange rate","JPN","Japan","2016","2016",241.6,"D","Difference in methodology"
+"PATCOTHR","Products not elsewhere classified","TCPPERMT","/capita, US$ exchange rate","JPN","Japan","2017","2017",249.2,"D","Difference in methodology"
+"PATCOTHR","Products not elsewhere classified","TCPPERMT","/capita, US$ exchange rate","JPN","Japan","2018","2018",279.5,"D","Difference in methodology"
+"PATCOTHR","Products not elsewhere classified","TCPPERMT","/capita, US$ exchange rate","JPN","Japan","2019","2019",390.8,"B; D","Break; Difference in methodology"
+"PATCOTHR","Products not elsewhere classified","TCPPERMT","/capita, US$ exchange rate","JPN","Japan","2020","2020",395.1,"D","Difference in methodology"
+"PATCOTHR","Products not elsewhere classified","TCPPERMT","/capita, US$ exchange rate","JPN","Japan","2021","2021",399.7,"D","Difference in methodology"
+"PATCOTHR","Products not elsewhere classified","PPPPERMT","/capita, US$ purchasing power parity","JPN","Japan","2010","2010",202.7,"D","Difference in methodology"
+"PATCOTHR","Products not elsewhere classified","PPPPERMT","/capita, US$ purchasing power parity","JPN","Japan","2011","2011",220.5,"D","Difference in methodology"
+"PATCOTHR","Products not elsewhere classified","PPPPERMT","/capita, US$ purchasing power parity","JPN","Japan","2012","2012",225.7,"D","Difference in methodology"
+"PATCOTHR","Products not elsewhere classified","PPPPERMT","/capita, US$ purchasing power parity","JPN","Japan","2013","2013",239.4,"D","Difference in methodology"
+"PATCOTHR","Products not elsewhere classified","PPPPERMT","/capita, US$ purchasing power parity","JPN","Japan","2014","2014",231.3,"D","Difference in methodology"
+"PATCOTHR","Products not elsewhere classified","PPPPERMT","/capita, US$ purchasing power parity","JPN","Japan","2015","2015",247.2,"D","Difference in methodology"
+"PATCOTHR","Products not elsewhere classified","PPPPERMT","/capita, US$ purchasing power parity","JPN","Japan","2016","2016",249.1,"D","Difference in methodology"
+"PATCOTHR","Products not elsewhere classified","PPPPERMT","/capita, US$ purchasing power parity","JPN","Japan","2017","2017",265.9,"D","Difference in methodology"
+"PATCOTHR","Products not elsewhere classified","PPPPERMT","/capita, US$ purchasing power parity","JPN","Japan","2018","2018",296.3,"D","Difference in methodology"
+"PATCOTHR","Products not elsewhere classified","PPPPERMT","/capita, US$ purchasing power parity","JPN","Japan","2019","2019",408.7,"B; D","Break; Difference in methodology"
+"PATCOTHR","Products not elsewhere classified","PPPPERMT","/capita, US$ purchasing power parity","JPN","Japan","2020","2020",411.9,"D","Difference in methodology"
+"PATCOTHR","Products not elsewhere classified","PPPPERMT","/capita, US$ purchasing power parity","JPN","Japan","2021","2021",429.9,"D","Difference in methodology"
+"PATCOTHR","Products not elsewhere classified","ATCPTTMT","% of total sales","JPN","Japan","2010","2010",42.8,"D","Difference in methodology"
+"PATCOTHR","Products not elsewhere classified","ATCPTTMT","% of total sales","JPN","Japan","2011","2011",43.4,"D","Difference in methodology"
+"PATCOTHR","Products not elsewhere classified","ATCPTTMT","% of total sales","JPN","Japan","2012","2012",43,"D","Difference in methodology"
+"PATCOTHR","Products not elsewhere classified","ATCPTTMT","% of total sales","JPN","Japan","2013","2013",44.8,"D","Difference in methodology"
+"PATCOTHR","Products not elsewhere classified","ATCPTTMT","% of total sales","JPN","Japan","2014","2014",46,"D","Difference in methodology"
+"PATCOTHR","Products not elsewhere classified","ATCPTTMT","% of total sales","JPN","Japan","2015","2015",48.2,"D","Difference in methodology"
+"PATCOTHR","Products not elsewhere classified","ATCPTTMT","% of total sales","JPN","Japan","2016","2016",50.4,"D","Difference in methodology"
+"PATCOTHR","Products not elsewhere classified","ATCPTTMT","% of total sales","JPN","Japan","2017","2017",52.7,"D","Difference in methodology"
+"PATCOTHR","Products not elsewhere classified","ATCPTTMT","% of total sales","JPN","Japan","2018","2018",56.5,"D","Difference in methodology"
+"PATCOTHR","Products not elsewhere classified","ATCPTTMT","% of total sales","JPN","Japan","2019","2019",56.6,"B; D","Break; Difference in methodology"
+"PATCOTHR","Products not elsewhere classified","ATCPTTMT","% of total sales","JPN","Japan","2020","2020",57.4,"D","Difference in methodology"
+"PATCOTHR","Products not elsewhere classified","ATCPTTMT","% of total sales","JPN","Japan","2021","2021",60,"D","Difference in methodology"
+"PATCOTHR","Products not elsewhere classified","MLLNCUMT","Million of national currency units","KOR","Korea","2010","2010",5595610,,
+"PATCOTHR","Products not elsewhere classified","MLLNCUMT","Million of national currency units","KOR","Korea","2011","2011",5991080.2,"B","Break"
+"PATCOTHR","Products not elsewhere classified","MLLNCUMT","Million of national currency units","KOR","Korea","2012","2012",6275160,,
+"PATCOTHR","Products not elsewhere classified","MLLNCUMT","Million of national currency units","KOR","Korea","2013","2013",6613982.4,,
+"PATCOTHR","Products not elsewhere classified","MLLNCUMT","Million of national currency units","KOR","Korea","2014","2014",7047389.1,,
+"PATCOTHR","Products not elsewhere classified","MLLNCUMT","Million of national currency units","KOR","Korea","2015","2015",7318854.6,,
+"PATCOTHR","Products not elsewhere classified","MLLNCUMT","Million of national currency units","KOR","Korea","2016","2016",7816107.1,"B","Break"
+"PATCOTHR","Products not elsewhere classified","MLLNCUMT","Million of national currency units","KOR","Korea","2017","2017",8367494.7,,
+"PATCOTHR","Products not elsewhere classified","MLLNCUMT","Million of national currency units","KOR","Korea","2018","2018",9096656.8,,
+"PATCOTHR","Products not elsewhere classified","MLLNCUMT","Million of national currency units","KOR","Korea","2019","2019",9936708.2,,
+"PATCOTHR","Products not elsewhere classified","MLLNCUMT","Million of national currency units","KOR","Korea","2020","2020",10252126.7,,
+"PATCOTHR","Products not elsewhere classified","MLLNCUMT","Million of national currency units","KOR","Korea","2021","2021",11116136.7,,
+"PATCOTHR","Products not elsewhere classified","MTMOTCMT","Million US$ at exchange rate","KOR","Korea","2010","2010",4838.6,,
+"PATCOTHR","Products not elsewhere classified","MTMOTCMT","Million US$ at exchange rate","KOR","Korea","2011","2011",5406,"B","Break"
+"PATCOTHR","Products not elsewhere classified","MTMOTCMT","Million US$ at exchange rate","KOR","Korea","2012","2012",5569,,
+"PATCOTHR","Products not elsewhere classified","MTMOTCMT","Million US$ at exchange rate","KOR","Korea","2013","2013",6040.3,,
+"PATCOTHR","Products not elsewhere classified","MTMOTCMT","Million US$ at exchange rate","KOR","Korea","2014","2014",6693.7,,
+"PATCOTHR","Products not elsewhere classified","MTMOTCMT","Million US$ at exchange rate","KOR","Korea","2015","2015",6471.4,,
+"PATCOTHR","Products not elsewhere classified","MTMOTCMT","Million US$ at exchange rate","KOR","Korea","2016","2016",6733.6,"B","Break"
+"PATCOTHR","Products not elsewhere classified","MTMOTCMT","Million US$ at exchange rate","KOR","Korea","2017","2017",7398.3,,
+"PATCOTHR","Products not elsewhere classified","MTMOTCMT","Million US$ at exchange rate","KOR","Korea","2018","2018",8268.5,,
+"PATCOTHR","Products not elsewhere classified","MTMOTCMT","Million US$ at exchange rate","KOR","Korea","2019","2019",8526.7,,
+"PATCOTHR","Products not elsewhere classified","MTMOTCMT","Million US$ at exchange rate","KOR","Korea","2020","2020",8686.3,,
+"PATCOTHR","Products not elsewhere classified","MTMOTCMT","Million US$ at exchange rate","KOR","Korea","2021","2021",9717.3,,
+"PATCOTHR","Products not elsewhere classified","MTMOPPMT","Million US$, purchasing power parity","KOR","Korea","2010","2010",6653.6,,
+"PATCOTHR","Products not elsewhere classified","MTMOPPMT","Million US$, purchasing power parity","KOR","Korea","2011","2011",7010.5,"B","Break"
+"PATCOTHR","Products not elsewhere classified","MTMOPPMT","Million US$, purchasing power parity","KOR","Korea","2012","2012",7340.3,,
+"PATCOTHR","Products not elsewhere classified","MTMOPPMT","Million US$, purchasing power parity","KOR","Korea","2013","2013",7610.3,,
+"PATCOTHR","Products not elsewhere classified","MTMOPPMT","Million US$, purchasing power parity","KOR","Korea","2014","2014",8083,,
+"PATCOTHR","Products not elsewhere classified","MTMOPPMT","Million US$, purchasing power parity","KOR","Korea","2015","2015",8535.3,,
+"PATCOTHR","Products not elsewhere classified","MTMOPPMT","Million US$, purchasing power parity","KOR","Korea","2016","2016",9101.1,"B","Break"
+"PATCOTHR","Products not elsewhere classified","MTMOPPMT","Million US$, purchasing power parity","KOR","Korea","2017","2017",9588.9,,
+"PATCOTHR","Products not elsewhere classified","MTMOPPMT","Million US$, purchasing power parity","KOR","Korea","2018","2018",10641,,
+"PATCOTHR","Products not elsewhere classified","MTMOPPMT","Million US$, purchasing power parity","KOR","Korea","2019","2019",11602.5,,
+"PATCOTHR","Products not elsewhere classified","MTMOPPMT","Million US$, purchasing power parity","KOR","Korea","2020","2020",12238.8,,
+"PATCOTHR","Products not elsewhere classified","MTMOPPMT","Million US$, purchasing power parity","KOR","Korea","2021","2021",13015.1,,
+"PATCOTHR","Products not elsewhere classified","TCPPERMT","/capita, US$ exchange rate","KOR","Korea","2010","2010",97.6,,
+"PATCOTHR","Products not elsewhere classified","TCPPERMT","/capita, US$ exchange rate","KOR","Korea","2011","2011",108.3,"B","Break"
+"PATCOTHR","Products not elsewhere classified","TCPPERMT","/capita, US$ exchange rate","KOR","Korea","2012","2012",110.9,,
+"PATCOTHR","Products not elsewhere classified","TCPPERMT","/capita, US$ exchange rate","KOR","Korea","2013","2013",119.8,,
+"PATCOTHR","Products not elsewhere classified","TCPPERMT","/capita, US$ exchange rate","KOR","Korea","2014","2014",131.9,,
+"PATCOTHR","Products not elsewhere classified","TCPPERMT","/capita, US$ exchange rate","KOR","Korea","2015","2015",126.9,,
+"PATCOTHR","Products not elsewhere classified","TCPPERMT","/capita, US$ exchange rate","KOR","Korea","2016","2016",131.5,"B","Break"
+"PATCOTHR","Products not elsewhere classified","TCPPERMT","/capita, US$ exchange rate","KOR","Korea","2017","2017",144,,
+"PATCOTHR","Products not elsewhere classified","TCPPERMT","/capita, US$ exchange rate","KOR","Korea","2018","2018",160.3,,
+"PATCOTHR","Products not elsewhere classified","TCPPERMT","/capita, US$ exchange rate","KOR","Korea","2019","2019",164.7,,
+"PATCOTHR","Products not elsewhere classified","TCPPERMT","/capita, US$ exchange rate","KOR","Korea","2020","2020",167.6,,
+"PATCOTHR","Products not elsewhere classified","TCPPERMT","/capita, US$ exchange rate","KOR","Korea","2021","2021",187.8,,
+"PATCOTHR","Products not elsewhere classified","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2010","2010",134.3,,
+"PATCOTHR","Products not elsewhere classified","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2011","2011",140.4,"B","Break"
+"PATCOTHR","Products not elsewhere classified","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2012","2012",146.2,,
+"PATCOTHR","Products not elsewhere classified","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2013","2013",150.9,,
+"PATCOTHR","Products not elsewhere classified","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2014","2014",159.3,,
+"PATCOTHR","Products not elsewhere classified","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2015","2015",167.3,,
+"PATCOTHR","Products not elsewhere classified","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2016","2016",177.7,"B","Break"
+"PATCOTHR","Products not elsewhere classified","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2017","2017",186.7,,
+"PATCOTHR","Products not elsewhere classified","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2018","2018",206.3,,
+"PATCOTHR","Products not elsewhere classified","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2019","2019",224.1,,
+"PATCOTHR","Products not elsewhere classified","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2020","2020",236.1,,
+"PATCOTHR","Products not elsewhere classified","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2021","2021",251.5,,
+"PATCOTHR","Products not elsewhere classified","ATCPTTMT","% of total sales","KOR","Korea","2010","2010",27.5,,
+"PATCOTHR","Products not elsewhere classified","ATCPTTMT","% of total sales","KOR","Korea","2011","2011",27.2,"B","Break"
+"PATCOTHR","Products not elsewhere classified","ATCPTTMT","% of total sales","KOR","Korea","2012","2012",28.9,,
+"PATCOTHR","Products not elsewhere classified","ATCPTTMT","% of total sales","KOR","Korea","2013","2013",29.3,,
+"PATCOTHR","Products not elsewhere classified","ATCPTTMT","% of total sales","KOR","Korea","2014","2014",29.8,,
+"PATCOTHR","Products not elsewhere classified","ATCPTTMT","% of total sales","KOR","Korea","2015","2015",29.7,,
+"PATCOTHR","Products not elsewhere classified","ATCPTTMT","% of total sales","KOR","Korea","2016","2016",30.8,"B","Break"
+"PATCOTHR","Products not elsewhere classified","ATCPTTMT","% of total sales","KOR","Korea","2017","2017",31,,
+"PATCOTHR","Products not elsewhere classified","ATCPTTMT","% of total sales","KOR","Korea","2018","2018",31.5,,
+"PATCOTHR","Products not elsewhere classified","ATCPTTMT","% of total sales","KOR","Korea","2019","2019",32,,
+"PATCOTHR","Products not elsewhere classified","ATCPTTMT","% of total sales","KOR","Korea","2020","2020",31.5,,
+"PATCOTHR","Products not elsewhere classified","ATCPTTMT","% of total sales","KOR","Korea","2021","2021",32,,
+"PATCOTHR","Products not elsewhere classified","MLLNCUMT","Million of national currency units","LUX","Luxembourg","2019","2019",40,"D","Difference in methodology"
+"PATCOTHR","Products not elsewhere classified","MLLNCUMT","Million of national currency units","LUX","Luxembourg","2020","2020",42.9,"D","Difference in methodology"
+"PATCOTHR","Products not elsewhere classified","MLLNCUMT","Million of national currency units","LUX","Luxembourg","2021","2021",55,"B; D; P","Break; Difference in methodology; Provisional value"
+"PATCOTHR","Products not elsewhere classified","MLLNCUMT","Million of national currency units","LUX","Luxembourg","2022","2022",68.6,"D; P","Difference in methodology; Provisional value"
+"PATCOTHR","Products not elsewhere classified","MTMOTCMT","Million US$ at exchange rate","LUX","Luxembourg","2019","2019",44.8,"D","Difference in methodology"
+"PATCOTHR","Products not elsewhere classified","MTMOTCMT","Million US$ at exchange rate","LUX","Luxembourg","2020","2020",49,"D","Difference in methodology"
+"PATCOTHR","Products not elsewhere classified","MTMOTCMT","Million US$ at exchange rate","LUX","Luxembourg","2021","2021",65,"B; D; P","Break; Difference in methodology; Provisional value"
+"PATCOTHR","Products not elsewhere classified","MTMOTCMT","Million US$ at exchange rate","LUX","Luxembourg","2022","2022",72.2,"D; P","Difference in methodology; Provisional value"
+"PATCOTHR","Products not elsewhere classified","MTMOPPMT","Million US$, purchasing power parity","LUX","Luxembourg","2019","2019",47.5,"D","Difference in methodology"
+"PATCOTHR","Products not elsewhere classified","MTMOPPMT","Million US$, purchasing power parity","LUX","Luxembourg","2020","2020",50.1,"D","Difference in methodology"
+"PATCOTHR","Products not elsewhere classified","MTMOPPMT","Million US$, purchasing power parity","LUX","Luxembourg","2021","2021",64,"B; D; P","Break; Difference in methodology; Provisional value"
+"PATCOTHR","Products not elsewhere classified","MTMOPPMT","Million US$, purchasing power parity","LUX","Luxembourg","2022","2022",82.5,"D; P","Difference in methodology; Provisional value"
+"PATCOTHR","Products not elsewhere classified","TCPPERMT","/capita, US$ exchange rate","LUX","Luxembourg","2019","2019",80.5,"D","Difference in methodology"
+"PATCOTHR","Products not elsewhere classified","TCPPERMT","/capita, US$ exchange rate","LUX","Luxembourg","2020","2020",86.3,"D","Difference in methodology"
+"PATCOTHR","Products not elsewhere classified","TCPPERMT","/capita, US$ exchange rate","LUX","Luxembourg","2021","2021",113,"B; D; P","Break; Difference in methodology; Provisional value"
+"PATCOTHR","Products not elsewhere classified","TCPPERMT","/capita, US$ exchange rate","LUX","Luxembourg","2022","2022",123.1,"D; P","Difference in methodology; Provisional value"
+"PATCOTHR","Products not elsewhere classified","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2019","2019",85.4,"D","Difference in methodology"
+"PATCOTHR","Products not elsewhere classified","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2020","2020",88.3,"D","Difference in methodology"
+"PATCOTHR","Products not elsewhere classified","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2021","2021",111.3,"B; D; P","Break; Difference in methodology; Provisional value"
+"PATCOTHR","Products not elsewhere classified","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2022","2022",140.6,"D; P","Difference in methodology; Provisional value"
+"PATCOTHR","Products not elsewhere classified","ATCPTTMT","% of total sales","LUX","Luxembourg","2019","2019",19.6,"D","Difference in methodology"
+"PATCOTHR","Products not elsewhere classified","ATCPTTMT","% of total sales","LUX","Luxembourg","2020","2020",20.5,"D","Difference in methodology"
+"PATCOTHR","Products not elsewhere classified","ATCPTTMT","% of total sales","LUX","Luxembourg","2021","2021",22.9,"B; D; P","Break; Difference in methodology; Provisional value"
+"PATCOTHR","Products not elsewhere classified","ATCPTTMT","% of total sales","LUX","Luxembourg","2022","2022",26.7,"D; P","Difference in methodology; Provisional value"
+"PATCOTHR","Products not elsewhere classified","MLLNCUMT","Million of national currency units","MEX","Mexico","2010","2010",17216,,
+"PATCOTHR","Products not elsewhere classified","MLLNCUMT","Million of national currency units","MEX","Mexico","2011","2011",17014,,
+"PATCOTHR","Products not elsewhere classified","MLLNCUMT","Million of national currency units","MEX","Mexico","2012","2012",15972,,
+"PATCOTHR","Products not elsewhere classified","MLLNCUMT","Million of national currency units","MEX","Mexico","2013","2013",17807.7,,
+"PATCOTHR","Products not elsewhere classified","MLLNCUMT","Million of national currency units","MEX","Mexico","2014","2014",17108.4,,
+"PATCOTHR","Products not elsewhere classified","MLLNCUMT","Million of national currency units","MEX","Mexico","2015","2015",17559.7,,
+"PATCOTHR","Products not elsewhere classified","MLLNCUMT","Million of national currency units","MEX","Mexico","2016","2016",19174.5,,
+"PATCOTHR","Products not elsewhere classified","MLLNCUMT","Million of national currency units","MEX","Mexico","2017","2017",19800.8,,
+"PATCOTHR","Products not elsewhere classified","MLLNCUMT","Million of national currency units","MEX","Mexico","2018","2018",19951.1,,
+"PATCOTHR","Products not elsewhere classified","MLLNCUMT","Million of national currency units","MEX","Mexico","2019","2019",20779.4,,
+"PATCOTHR","Products not elsewhere classified","MLLNCUMT","Million of national currency units","MEX","Mexico","2020","2020",20184.1,,
+"PATCOTHR","Products not elsewhere classified","MLLNCUMT","Million of national currency units","MEX","Mexico","2021","2021",21170.2,,
+"PATCOTHR","Products not elsewhere classified","MLLNCUMT","Million of national currency units","MEX","Mexico","2022","2022",24535.8,"E","Estimated value"
+"PATCOTHR","Products not elsewhere classified","MTMOTCMT","Million US$ at exchange rate","MEX","Mexico","2010","2010",1362.5,,
+"PATCOTHR","Products not elsewhere classified","MTMOTCMT","Million US$ at exchange rate","MEX","Mexico","2011","2011",1369.5,,
+"PATCOTHR","Products not elsewhere classified","MTMOTCMT","Million US$ at exchange rate","MEX","Mexico","2012","2012",1212.8,,
+"PATCOTHR","Products not elsewhere classified","MTMOTCMT","Million US$ at exchange rate","MEX","Mexico","2013","2013",1394.3,,
+"PATCOTHR","Products not elsewhere classified","MTMOTCMT","Million US$ at exchange rate","MEX","Mexico","2014","2014",1287.1,,
+"PATCOTHR","Products not elsewhere classified","MTMOTCMT","Million US$ at exchange rate","MEX","Mexico","2015","2015",1108,,
+"PATCOTHR","Products not elsewhere classified","MTMOTCMT","Million US$ at exchange rate","MEX","Mexico","2016","2016",1027.3,,
+"PATCOTHR","Products not elsewhere classified","MTMOTCMT","Million US$ at exchange rate","MEX","Mexico","2017","2017",1046.2,,
+"PATCOTHR","Products not elsewhere classified","MTMOTCMT","Million US$ at exchange rate","MEX","Mexico","2018","2018",1036.7,,
+"PATCOTHR","Products not elsewhere classified","MTMOTCMT","Million US$ at exchange rate","MEX","Mexico","2019","2019",1078.7,,
+"PATCOTHR","Products not elsewhere classified","MTMOTCMT","Million US$ at exchange rate","MEX","Mexico","2020","2020",939.4,,
+"PATCOTHR","Products not elsewhere classified","MTMOTCMT","Million US$ at exchange rate","MEX","Mexico","2021","2021",1044.3,,
+"PATCOTHR","Products not elsewhere classified","MTMOTCMT","Million US$ at exchange rate","MEX","Mexico","2022","2022",1219,"E","Estimated value"
+"PATCOTHR","Products not elsewhere classified","MTMOPPMT","Million US$, purchasing power parity","MEX","Mexico","2010","2010",2241.8,,
+"PATCOTHR","Products not elsewhere classified","MTMOPPMT","Million US$, purchasing power parity","MEX","Mexico","2011","2011",2217.4,,
+"PATCOTHR","Products not elsewhere classified","MTMOPPMT","Million US$, purchasing power parity","MEX","Mexico","2012","2012",2032.4,,
+"PATCOTHR","Products not elsewhere classified","MTMOPPMT","Million US$, purchasing power parity","MEX","Mexico","2013","2013",2258.6,,
+"PATCOTHR","Products not elsewhere classified","MTMOPPMT","Million US$, purchasing power parity","MEX","Mexico","2014","2014",2126.5,,
+"PATCOTHR","Products not elsewhere classified","MTMOPPMT","Million US$, purchasing power parity","MEX","Mexico","2015","2015",2108.6,,
+"PATCOTHR","Products not elsewhere classified","MTMOPPMT","Million US$, purchasing power parity","MEX","Mexico","2016","2016",2270.2,,
+"PATCOTHR","Products not elsewhere classified","MTMOPPMT","Million US$, purchasing power parity","MEX","Mexico","2017","2017",2221.4,,
+"PATCOTHR","Products not elsewhere classified","MTMOPPMT","Million US$, purchasing power parity","MEX","Mexico","2018","2018",2150.7,,
+"PATCOTHR","Products not elsewhere classified","MTMOPPMT","Million US$, purchasing power parity","MEX","Mexico","2019","2019",2150.4,,
+"PATCOTHR","Products not elsewhere classified","MTMOPPMT","Million US$, purchasing power parity","MEX","Mexico","2020","2020",2010.4,,
+"PATCOTHR","Products not elsewhere classified","MTMOPPMT","Million US$, purchasing power parity","MEX","Mexico","2021","2021",2035.3,,
+"PATCOTHR","Products not elsewhere classified","MTMOPPMT","Million US$, purchasing power parity","MEX","Mexico","2022","2022",2319.9,"E","Estimated value"
+"PATCOTHR","Products not elsewhere classified","TCPPERMT","/capita, US$ exchange rate","MEX","Mexico","2010","2010",12,,
+"PATCOTHR","Products not elsewhere classified","TCPPERMT","/capita, US$ exchange rate","MEX","Mexico","2011","2011",11.9,,
+"PATCOTHR","Products not elsewhere classified","TCPPERMT","/capita, US$ exchange rate","MEX","Mexico","2012","2012",10.4,,
+"PATCOTHR","Products not elsewhere classified","TCPPERMT","/capita, US$ exchange rate","MEX","Mexico","2013","2013",11.8,,
+"PATCOTHR","Products not elsewhere classified","TCPPERMT","/capita, US$ exchange rate","MEX","Mexico","2014","2014",10.7,,
+"PATCOTHR","Products not elsewhere classified","TCPPERMT","/capita, US$ exchange rate","MEX","Mexico","2015","2015",9.1,,
+"PATCOTHR","Products not elsewhere classified","TCPPERMT","/capita, US$ exchange rate","MEX","Mexico","2016","2016",8.4,,
+"PATCOTHR","Products not elsewhere classified","TCPPERMT","/capita, US$ exchange rate","MEX","Mexico","2017","2017",8.4,,
+"PATCOTHR","Products not elsewhere classified","TCPPERMT","/capita, US$ exchange rate","MEX","Mexico","2018","2018",8.3,,
+"PATCOTHR","Products not elsewhere classified","TCPPERMT","/capita, US$ exchange rate","MEX","Mexico","2019","2019",8.5,,
+"PATCOTHR","Products not elsewhere classified","TCPPERMT","/capita, US$ exchange rate","MEX","Mexico","2020","2020",7.4,,
+"PATCOTHR","Products not elsewhere classified","TCPPERMT","/capita, US$ exchange rate","MEX","Mexico","2021","2021",8.1,,
+"PATCOTHR","Products not elsewhere classified","TCPPERMT","/capita, US$ exchange rate","MEX","Mexico","2022","2022",9.4,"E","Estimated value"
+"PATCOTHR","Products not elsewhere classified","PPPPERMT","/capita, US$ purchasing power parity","MEX","Mexico","2010","2010",19.7,,
+"PATCOTHR","Products not elsewhere classified","PPPPERMT","/capita, US$ purchasing power parity","MEX","Mexico","2011","2011",19.2,,
+"PATCOTHR","Products not elsewhere classified","PPPPERMT","/capita, US$ purchasing power parity","MEX","Mexico","2012","2012",17.4,,
+"PATCOTHR","Products not elsewhere classified","PPPPERMT","/capita, US$ purchasing power parity","MEX","Mexico","2013","2013",19.1,,
+"PATCOTHR","Products not elsewhere classified","PPPPERMT","/capita, US$ purchasing power parity","MEX","Mexico","2014","2014",17.7,,
+"PATCOTHR","Products not elsewhere classified","PPPPERMT","/capita, US$ purchasing power parity","MEX","Mexico","2015","2015",17.4,,
+"PATCOTHR","Products not elsewhere classified","PPPPERMT","/capita, US$ purchasing power parity","MEX","Mexico","2016","2016",18.5,,
+"PATCOTHR","Products not elsewhere classified","PPPPERMT","/capita, US$ purchasing power parity","MEX","Mexico","2017","2017",17.9,,
+"PATCOTHR","Products not elsewhere classified","PPPPERMT","/capita, US$ purchasing power parity","MEX","Mexico","2018","2018",17.2,,
+"PATCOTHR","Products not elsewhere classified","PPPPERMT","/capita, US$ purchasing power parity","MEX","Mexico","2019","2019",17,,
+"PATCOTHR","Products not elsewhere classified","PPPPERMT","/capita, US$ purchasing power parity","MEX","Mexico","2020","2020",15.7,,
+"PATCOTHR","Products not elsewhere classified","PPPPERMT","/capita, US$ purchasing power parity","MEX","Mexico","2021","2021",15.8,,
+"PATCOTHR","Products not elsewhere classified","PPPPERMT","/capita, US$ purchasing power parity","MEX","Mexico","2022","2022",17.8,"E","Estimated value"
+"PATCOTHR","Products not elsewhere classified","ATCPTTMT","% of total sales","MEX","Mexico","2013","2013",12.6,,
+"PATCOTHR","Products not elsewhere classified","ATCPTTMT","% of total sales","MEX","Mexico","2018","2018",8.7,,
+"PATCOTHR","Products not elsewhere classified","MLLNCUMT","Million of national currency units","NZL","New Zealand","2010","2010",186.3,"D","Difference in methodology"
+"PATCOTHR","Products not elsewhere classified","MLLNCUMT","Million of national currency units","NZL","New Zealand","2011","2011",202.6,"D","Difference in methodology"
+"PATCOTHR","Products not elsewhere classified","MLLNCUMT","Million of national currency units","NZL","New Zealand","2012","2012",290,"D","Difference in methodology"
+"PATCOTHR","Products not elsewhere classified","MLLNCUMT","Million of national currency units","NZL","New Zealand","2013","2013",311.2,"D","Difference in methodology"
+"PATCOTHR","Products not elsewhere classified","MLLNCUMT","Million of national currency units","NZL","New Zealand","2014","2014",323.1,"D","Difference in methodology"
+"PATCOTHR","Products not elsewhere classified","MLLNCUMT","Million of national currency units","NZL","New Zealand","2015","2015",343.1,"D","Difference in methodology"
+"PATCOTHR","Products not elsewhere classified","MLLNCUMT","Million of national currency units","NZL","New Zealand","2016","2016",383.6,"D","Difference in methodology"
+"PATCOTHR","Products not elsewhere classified","MLLNCUMT","Million of national currency units","NZL","New Zealand","2017","2017",653.2,"D","Difference in methodology"
+"PATCOTHR","Products not elsewhere classified","MLLNCUMT","Million of national currency units","NZL","New Zealand","2018","2018",614.3,"D","Difference in methodology"
+"PATCOTHR","Products not elsewhere classified","MLLNCUMT","Million of national currency units","NZL","New Zealand","2019","2019",758.8,"D","Difference in methodology"
+"PATCOTHR","Products not elsewhere classified","MLLNCUMT","Million of national currency units","NZL","New Zealand","2020","2020",904.8,"D","Difference in methodology"
+"PATCOTHR","Products not elsewhere classified","MLLNCUMT","Million of national currency units","NZL","New Zealand","2021","2021",968.8,"D","Difference in methodology"
+"PATCOTHR","Products not elsewhere classified","MLLNCUMT","Million of national currency units","NZL","New Zealand","2022","2022",1012.4,"D","Difference in methodology"
+"PATCOTHR","Products not elsewhere classified","MTMOTCMT","Million US$ at exchange rate","NZL","New Zealand","2010","2010",134.3,"D","Difference in methodology"
+"PATCOTHR","Products not elsewhere classified","MTMOTCMT","Million US$ at exchange rate","NZL","New Zealand","2011","2011",160,"D","Difference in methodology"
+"PATCOTHR","Products not elsewhere classified","MTMOTCMT","Million US$ at exchange rate","NZL","New Zealand","2012","2012",234.9,"D","Difference in methodology"
+"PATCOTHR","Products not elsewhere classified","MTMOTCMT","Million US$ at exchange rate","NZL","New Zealand","2013","2013",255.2,"D","Difference in methodology"
+"PATCOTHR","Products not elsewhere classified","MTMOTCMT","Million US$ at exchange rate","NZL","New Zealand","2014","2014",268,"D","Difference in methodology"
+"PATCOTHR","Products not elsewhere classified","MTMOTCMT","Million US$ at exchange rate","NZL","New Zealand","2015","2015",239.3,"D","Difference in methodology"
+"PATCOTHR","Products not elsewhere classified","MTMOTCMT","Million US$ at exchange rate","NZL","New Zealand","2016","2016",267,"D","Difference in methodology"
+"PATCOTHR","Products not elsewhere classified","MTMOTCMT","Million US$ at exchange rate","NZL","New Zealand","2017","2017",464.1,"D","Difference in methodology"
+"PATCOTHR","Products not elsewhere classified","MTMOTCMT","Million US$ at exchange rate","NZL","New Zealand","2018","2018",425,"D","Difference in methodology"
+"PATCOTHR","Products not elsewhere classified","MTMOTCMT","Million US$ at exchange rate","NZL","New Zealand","2019","2019",499.9,"D","Difference in methodology"
+"PATCOTHR","Products not elsewhere classified","MTMOTCMT","Million US$ at exchange rate","NZL","New Zealand","2020","2020",586.7,"D","Difference in methodology"
+"PATCOTHR","Products not elsewhere classified","MTMOTCMT","Million US$ at exchange rate","NZL","New Zealand","2021","2021",685.2,"D","Difference in methodology"
+"PATCOTHR","Products not elsewhere classified","MTMOTCMT","Million US$ at exchange rate","NZL","New Zealand","2022","2022",641.9,"D","Difference in methodology"
+"PATCOTHR","Products not elsewhere classified","MTMOPPMT","Million US$, purchasing power parity","NZL","New Zealand","2010","2010",124.5,"D","Difference in methodology"
+"PATCOTHR","Products not elsewhere classified","MTMOPPMT","Million US$, purchasing power parity","NZL","New Zealand","2011","2011",136.3,"D","Difference in methodology"
+"PATCOTHR","Products not elsewhere classified","MTMOPPMT","Million US$, purchasing power parity","NZL","New Zealand","2012","2012",193.9,"D","Difference in methodology"
+"PATCOTHR","Products not elsewhere classified","MTMOPPMT","Million US$, purchasing power parity","NZL","New Zealand","2013","2013",215.2,"D","Difference in methodology"
+"PATCOTHR","Products not elsewhere classified","MTMOPPMT","Million US$, purchasing power parity","NZL","New Zealand","2014","2014",224.3,"D","Difference in methodology"
+"PATCOTHR","Products not elsewhere classified","MTMOPPMT","Million US$, purchasing power parity","NZL","New Zealand","2015","2015",232.1,"D","Difference in methodology"
+"PATCOTHR","Products not elsewhere classified","MTMOPPMT","Million US$, purchasing power parity","NZL","New Zealand","2016","2016",266.2,"D","Difference in methodology"
+"PATCOTHR","Products not elsewhere classified","MTMOPPMT","Million US$, purchasing power parity","NZL","New Zealand","2017","2017",456.5,"D","Difference in methodology"
+"PATCOTHR","Products not elsewhere classified","MTMOPPMT","Million US$, purchasing power parity","NZL","New Zealand","2018","2018",417.9,"D","Difference in methodology"
+"PATCOTHR","Products not elsewhere classified","MTMOPPMT","Million US$, purchasing power parity","NZL","New Zealand","2019","2019",535.6,"D","Difference in methodology"
+"PATCOTHR","Products not elsewhere classified","MTMOPPMT","Million US$, purchasing power parity","NZL","New Zealand","2020","2020",640.1,"D","Difference in methodology"
+"PATCOTHR","Products not elsewhere classified","MTMOPPMT","Million US$, purchasing power parity","NZL","New Zealand","2021","2021",664,"D","Difference in methodology"
+"PATCOTHR","Products not elsewhere classified","MTMOPPMT","Million US$, purchasing power parity","NZL","New Zealand","2022","2022",701.9,"D","Difference in methodology"
+"PATCOTHR","Products not elsewhere classified","TCPPERMT","/capita, US$ exchange rate","NZL","New Zealand","2010","2010",30.9,"D","Difference in methodology"
+"PATCOTHR","Products not elsewhere classified","TCPPERMT","/capita, US$ exchange rate","NZL","New Zealand","2011","2011",36.5,"D","Difference in methodology"
+"PATCOTHR","Products not elsewhere classified","TCPPERMT","/capita, US$ exchange rate","NZL","New Zealand","2012","2012",53.3,"D","Difference in methodology"
+"PATCOTHR","Products not elsewhere classified","TCPPERMT","/capita, US$ exchange rate","NZL","New Zealand","2013","2013",57.5,"D","Difference in methodology"
+"PATCOTHR","Products not elsewhere classified","TCPPERMT","/capita, US$ exchange rate","NZL","New Zealand","2014","2014",59.3,"D","Difference in methodology"
+"PATCOTHR","Products not elsewhere classified","TCPPERMT","/capita, US$ exchange rate","NZL","New Zealand","2015","2015",51.9,"D","Difference in methodology"
+"PATCOTHR","Products not elsewhere classified","TCPPERMT","/capita, US$ exchange rate","NZL","New Zealand","2016","2016",56.6,"D","Difference in methodology"
+"PATCOTHR","Products not elsewhere classified","TCPPERMT","/capita, US$ exchange rate","NZL","New Zealand","2017","2017",96.4,"D","Difference in methodology"
+"PATCOTHR","Products not elsewhere classified","TCPPERMT","/capita, US$ exchange rate","NZL","New Zealand","2018","2018",86.7,"D","Difference in methodology"
+"PATCOTHR","Products not elsewhere classified","TCPPERMT","/capita, US$ exchange rate","NZL","New Zealand","2019","2019",100.4,"D","Difference in methodology"
+"PATCOTHR","Products not elsewhere classified","TCPPERMT","/capita, US$ exchange rate","NZL","New Zealand","2020","2020",115.3,"D","Difference in methodology"
+"PATCOTHR","Products not elsewhere classified","TCPPERMT","/capita, US$ exchange rate","NZL","New Zealand","2021","2021",134.1,"D","Difference in methodology"
+"PATCOTHR","Products not elsewhere classified","TCPPERMT","/capita, US$ exchange rate","NZL","New Zealand","2022","2022",125.3,"D","Difference in methodology"
+"PATCOTHR","Products not elsewhere classified","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2010","2010",28.6,"D","Difference in methodology"
+"PATCOTHR","Products not elsewhere classified","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2011","2011",31.1,"D","Difference in methodology"
+"PATCOTHR","Products not elsewhere classified","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2012","2012",44,"D","Difference in methodology"
+"PATCOTHR","Products not elsewhere classified","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2013","2013",48.5,"D","Difference in methodology"
+"PATCOTHR","Products not elsewhere classified","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2014","2014",49.7,"D","Difference in methodology"
+"PATCOTHR","Products not elsewhere classified","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2015","2015",50.4,"D","Difference in methodology"
+"PATCOTHR","Products not elsewhere classified","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2016","2016",56.5,"D","Difference in methodology"
+"PATCOTHR","Products not elsewhere classified","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2017","2017",94.8,"D","Difference in methodology"
+"PATCOTHR","Products not elsewhere classified","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2018","2018",85.3,"D","Difference in methodology"
+"PATCOTHR","Products not elsewhere classified","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2019","2019",107.6,"D","Difference in methodology"
+"PATCOTHR","Products not elsewhere classified","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2020","2020",125.7,"D","Difference in methodology"
+"PATCOTHR","Products not elsewhere classified","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2021","2021",129.9,"D","Difference in methodology"
+"PATCOTHR","Products not elsewhere classified","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2022","2022",137,"D","Difference in methodology"
+"PATCOTHR","Products not elsewhere classified","ATCPTTMT","% of total sales","NZL","New Zealand","2010","2010",24.9,"D","Difference in methodology"
+"PATCOTHR","Products not elsewhere classified","ATCPTTMT","% of total sales","NZL","New Zealand","2011","2011",24.8,"D","Difference in methodology"
+"PATCOTHR","Products not elsewhere classified","ATCPTTMT","% of total sales","NZL","New Zealand","2012","2012",31.4,"D","Difference in methodology"
+"PATCOTHR","Products not elsewhere classified","ATCPTTMT","% of total sales","NZL","New Zealand","2013","2013",33.7,"D","Difference in methodology"
+"PATCOTHR","Products not elsewhere classified","ATCPTTMT","% of total sales","NZL","New Zealand","2014","2014",33.7,"D","Difference in methodology"
+"PATCOTHR","Products not elsewhere classified","ATCPTTMT","% of total sales","NZL","New Zealand","2015","2015",34.7,"D","Difference in methodology"
+"PATCOTHR","Products not elsewhere classified","ATCPTTMT","% of total sales","NZL","New Zealand","2016","2016",35.8,"D","Difference in methodology"
+"PATCOTHR","Products not elsewhere classified","ATCPTTMT","% of total sales","NZL","New Zealand","2017","2017",51.7,"D","Difference in methodology"
+"PATCOTHR","Products not elsewhere classified","ATCPTTMT","% of total sales","NZL","New Zealand","2018","2018",46.5,"D","Difference in methodology"
+"PATCOTHR","Products not elsewhere classified","ATCPTTMT","% of total sales","NZL","New Zealand","2019","2019",50.9,"D","Difference in methodology"
+"PATCOTHR","Products not elsewhere classified","ATCPTTMT","% of total sales","NZL","New Zealand","2020","2020",54.8,"D","Difference in methodology"
+"PATCOTHR","Products not elsewhere classified","ATCPTTMT","% of total sales","NZL","New Zealand","2021","2021",54.5,"D","Difference in methodology"
+"PATCOTHR","Products not elsewhere classified","ATCPTTMT","% of total sales","NZL","New Zealand","2022","2022",53.2,"D","Difference in methodology"
+"PATCOTHR","Products not elsewhere classified","MLLNCUMT","Million of national currency units","NOR","Norway","2010","2010",4403,,
+"PATCOTHR","Products not elsewhere classified","MLLNCUMT","Million of national currency units","NOR","Norway","2011","2011",4498,,
+"PATCOTHR","Products not elsewhere classified","MLLNCUMT","Million of national currency units","NOR","Norway","2012","2012",4842,,
+"PATCOTHR","Products not elsewhere classified","MLLNCUMT","Million of national currency units","NOR","Norway","2013","2013",5243,,
+"PATCOTHR","Products not elsewhere classified","MLLNCUMT","Million of national currency units","NOR","Norway","2014","2014",6014,,
+"PATCOTHR","Products not elsewhere classified","MLLNCUMT","Million of national currency units","NOR","Norway","2015","2015",6491,,
+"PATCOTHR","Products not elsewhere classified","MLLNCUMT","Million of national currency units","NOR","Norway","2016","2016",7112,,
+"PATCOTHR","Products not elsewhere classified","MLLNCUMT","Million of national currency units","NOR","Norway","2017","2017",8018,,
+"PATCOTHR","Products not elsewhere classified","MLLNCUMT","Million of national currency units","NOR","Norway","2018","2018",8422,,
+"PATCOTHR","Products not elsewhere classified","MLLNCUMT","Million of national currency units","NOR","Norway","2019","2019",8490,,
+"PATCOTHR","Products not elsewhere classified","MLLNCUMT","Million of national currency units","NOR","Norway","2020","2020",9002,,
+"PATCOTHR","Products not elsewhere classified","MLLNCUMT","Million of national currency units","NOR","Norway","2021","2021",9822,,
+"PATCOTHR","Products not elsewhere classified","MLLNCUMT","Million of national currency units","NOR","Norway","2022","2022",9826,,
+"PATCOTHR","Products not elsewhere classified","MTMOTCMT","Million US$ at exchange rate","NOR","Norway","2010","2010",728.5,,
+"PATCOTHR","Products not elsewhere classified","MTMOTCMT","Million US$ at exchange rate","NOR","Norway","2011","2011",802.6,,
+"PATCOTHR","Products not elsewhere classified","MTMOTCMT","Million US$ at exchange rate","NOR","Norway","2012","2012",832.3,,
+"PATCOTHR","Products not elsewhere classified","MTMOTCMT","Million US$ at exchange rate","NOR","Norway","2013","2013",892.4,,
+"PATCOTHR","Products not elsewhere classified","MTMOTCMT","Million US$ at exchange rate","NOR","Norway","2014","2014",954.4,,
+"PATCOTHR","Products not elsewhere classified","MTMOTCMT","Million US$ at exchange rate","NOR","Norway","2015","2015",804.9,,
+"PATCOTHR","Products not elsewhere classified","MTMOTCMT","Million US$ at exchange rate","NOR","Norway","2016","2016",846.7,,
+"PATCOTHR","Products not elsewhere classified","MTMOTCMT","Million US$ at exchange rate","NOR","Norway","2017","2017",969.3,,
+"PATCOTHR","Products not elsewhere classified","MTMOTCMT","Million US$ at exchange rate","NOR","Norway","2018","2018",1035.6,,
+"PATCOTHR","Products not elsewhere classified","MTMOTCMT","Million US$ at exchange rate","NOR","Norway","2019","2019",964.8,,
+"PATCOTHR","Products not elsewhere classified","MTMOTCMT","Million US$ at exchange rate","NOR","Norway","2020","2020",956,,
+"PATCOTHR","Products not elsewhere classified","MTMOTCMT","Million US$ at exchange rate","NOR","Norway","2021","2021",1143.4,,
+"PATCOTHR","Products not elsewhere classified","MTMOTCMT","Million US$ at exchange rate","NOR","Norway","2022","2022",1022,,
+"PATCOTHR","Products not elsewhere classified","MTMOPPMT","Million US$, purchasing power parity","NOR","Norway","2010","2010",481.1,,
+"PATCOTHR","Products not elsewhere classified","MTMOPPMT","Million US$, purchasing power parity","NOR","Norway","2011","2011",495.2,,
+"PATCOTHR","Products not elsewhere classified","MTMOPPMT","Million US$, purchasing power parity","NOR","Norway","2012","2012",535.8,,
+"PATCOTHR","Products not elsewhere classified","MTMOPPMT","Million US$, purchasing power parity","NOR","Norway","2013","2013",580.7,,
+"PATCOTHR","Products not elsewhere classified","MTMOPPMT","Million US$, purchasing power parity","NOR","Norway","2014","2014",648.2,,
+"PATCOTHR","Products not elsewhere classified","MTMOPPMT","Million US$, purchasing power parity","NOR","Norway","2015","2015",653.5,,
+"PATCOTHR","Products not elsewhere classified","MTMOPPMT","Million US$, purchasing power parity","NOR","Norway","2016","2016",708.2,,
+"PATCOTHR","Products not elsewhere classified","MTMOPPMT","Million US$, purchasing power parity","NOR","Norway","2017","2017",822.4,,
+"PATCOTHR","Products not elsewhere classified","MTMOPPMT","Million US$, purchasing power parity","NOR","Norway","2018","2018",878.8,,
+"PATCOTHR","Products not elsewhere classified","MTMOPPMT","Million US$, purchasing power parity","NOR","Norway","2019","2019",882.5,,
+"PATCOTHR","Products not elsewhere classified","MTMOPPMT","Million US$, purchasing power parity","NOR","Norway","2020","2020",911.1,,
+"PATCOTHR","Products not elsewhere classified","MTMOPPMT","Million US$, purchasing power parity","NOR","Norway","2021","2021",1032.6,,
+"PATCOTHR","Products not elsewhere classified","MTMOPPMT","Million US$, purchasing power parity","NOR","Norway","2022","2022",914.9,,
+"PATCOTHR","Products not elsewhere classified","TCPPERMT","/capita, US$ exchange rate","NOR","Norway","2010","2010",149,,
+"PATCOTHR","Products not elsewhere classified","TCPPERMT","/capita, US$ exchange rate","NOR","Norway","2011","2011",162,,
+"PATCOTHR","Products not elsewhere classified","TCPPERMT","/capita, US$ exchange rate","NOR","Norway","2012","2012",165.8,,
+"PATCOTHR","Products not elsewhere classified","TCPPERMT","/capita, US$ exchange rate","NOR","Norway","2013","2013",175.7,,
+"PATCOTHR","Products not elsewhere classified","TCPPERMT","/capita, US$ exchange rate","NOR","Norway","2014","2014",185.8,,
+"PATCOTHR","Products not elsewhere classified","TCPPERMT","/capita, US$ exchange rate","NOR","Norway","2015","2015",155.1,,
+"PATCOTHR","Products not elsewhere classified","TCPPERMT","/capita, US$ exchange rate","NOR","Norway","2016","2016",161.7,,
+"PATCOTHR","Products not elsewhere classified","TCPPERMT","/capita, US$ exchange rate","NOR","Norway","2017","2017",183.7,,
+"PATCOTHR","Products not elsewhere classified","TCPPERMT","/capita, US$ exchange rate","NOR","Norway","2018","2018",195,,
+"PATCOTHR","Products not elsewhere classified","TCPPERMT","/capita, US$ exchange rate","NOR","Norway","2019","2019",180.4,,
+"PATCOTHR","Products not elsewhere classified","TCPPERMT","/capita, US$ exchange rate","NOR","Norway","2020","2020",177.7,,
+"PATCOTHR","Products not elsewhere classified","TCPPERMT","/capita, US$ exchange rate","NOR","Norway","2021","2021",211.4,,
+"PATCOTHR","Products not elsewhere classified","TCPPERMT","/capita, US$ exchange rate","NOR","Norway","2022","2022",188.4,,
+"PATCOTHR","Products not elsewhere classified","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2010","2010",98.4,,
+"PATCOTHR","Products not elsewhere classified","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2011","2011",100,,
+"PATCOTHR","Products not elsewhere classified","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2012","2012",106.8,,
+"PATCOTHR","Products not elsewhere classified","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2013","2013",114.3,,
+"PATCOTHR","Products not elsewhere classified","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2014","2014",126.2,,
+"PATCOTHR","Products not elsewhere classified","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2015","2015",126,,
+"PATCOTHR","Products not elsewhere classified","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2016","2016",135.3,,
+"PATCOTHR","Products not elsewhere classified","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2017","2017",155.8,,
+"PATCOTHR","Products not elsewhere classified","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2018","2018",165.4,,
+"PATCOTHR","Products not elsewhere classified","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2019","2019",165,,
+"PATCOTHR","Products not elsewhere classified","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2020","2020",169.4,,
+"PATCOTHR","Products not elsewhere classified","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2021","2021",190.9,,
+"PATCOTHR","Products not elsewhere classified","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2022","2022",168.6,,
+"PATCOTHR","Products not elsewhere classified","ATCPTTMT","% of total sales","NOR","Norway","2010","2010",24.6,,
+"PATCOTHR","Products not elsewhere classified","ATCPTTMT","% of total sales","NOR","Norway","2011","2011",24.7,,
+"PATCOTHR","Products not elsewhere classified","ATCPTTMT","% of total sales","NOR","Norway","2012","2012",25.8,,
+"PATCOTHR","Products not elsewhere classified","ATCPTTMT","% of total sales","NOR","Norway","2013","2013",27.2,,
+"PATCOTHR","Products not elsewhere classified","ATCPTTMT","% of total sales","NOR","Norway","2014","2014",28.5,,
+"PATCOTHR","Products not elsewhere classified","ATCPTTMT","% of total sales","NOR","Norway","2015","2015",28.5,,
+"PATCOTHR","Products not elsewhere classified","ATCPTTMT","% of total sales","NOR","Norway","2016","2016",28.7,,
+"PATCOTHR","Products not elsewhere classified","ATCPTTMT","% of total sales","NOR","Norway","2017","2017",30.1,,
+"PATCOTHR","Products not elsewhere classified","ATCPTTMT","% of total sales","NOR","Norway","2018","2018",30.6,,
+"PATCOTHR","Products not elsewhere classified","ATCPTTMT","% of total sales","NOR","Norway","2019","2019",29.9,,
+"PATCOTHR","Products not elsewhere classified","ATCPTTMT","% of total sales","NOR","Norway","2020","2020",30.3,,
+"PATCOTHR","Products not elsewhere classified","ATCPTTMT","% of total sales","NOR","Norway","2021","2021",29.3,,
+"PATCOTHR","Products not elsewhere classified","ATCPTTMT","% of total sales","NOR","Norway","2022","2022",27.3,,
+"PATCOTHR","Products not elsewhere classified","MLLNCUMT","Million of national currency units","PRT","Portugal","2010","2010",0,"D","Difference in methodology"
+"PATCOTHR","Products not elsewhere classified","MLLNCUMT","Million of national currency units","PRT","Portugal","2011","2011",0,"D","Difference in methodology"
+"PATCOTHR","Products not elsewhere classified","MLLNCUMT","Million of national currency units","PRT","Portugal","2012","2012",0,"D","Difference in methodology"
+"PATCOTHR","Products not elsewhere classified","MLLNCUMT","Million of national currency units","PRT","Portugal","2013","2013",0,"D","Difference in methodology"
+"PATCOTHR","Products not elsewhere classified","MLLNCUMT","Million of national currency units","PRT","Portugal","2014","2014",0,"D","Difference in methodology"
+"PATCOTHR","Products not elsewhere classified","MLLNCUMT","Million of national currency units","PRT","Portugal","2015","2015",0,"D","Difference in methodology"
+"PATCOTHR","Products not elsewhere classified","MLLNCUMT","Million of national currency units","PRT","Portugal","2016","2016",0,"D","Difference in methodology"
+"PATCOTHR","Products not elsewhere classified","MLLNCUMT","Million of national currency units","PRT","Portugal","2017","2017",0,"D","Difference in methodology"
+"PATCOTHR","Products not elsewhere classified","MLLNCUMT","Million of national currency units","PRT","Portugal","2018","2018",0,"D","Difference in methodology"
+"PATCOTHR","Products not elsewhere classified","MLLNCUMT","Million of national currency units","PRT","Portugal","2019","2019",0,"D","Difference in methodology"
+"PATCOTHR","Products not elsewhere classified","MLLNCUMT","Million of national currency units","PRT","Portugal","2020","2020",0,"D","Difference in methodology"
+"PATCOTHR","Products not elsewhere classified","MLLNCUMT","Million of national currency units","PRT","Portugal","2021","2021",0,"D","Difference in methodology"
+"PATCOTHR","Products not elsewhere classified","MLLNCUMT","Million of national currency units","PRT","Portugal","2022","2022",0,"D","Difference in methodology"
+"PATCOTHR","Products not elsewhere classified","MTMOTCMT","Million US$ at exchange rate","PRT","Portugal","2010","2010",0,"D","Difference in methodology"
+"PATCOTHR","Products not elsewhere classified","MTMOTCMT","Million US$ at exchange rate","PRT","Portugal","2011","2011",0,"D","Difference in methodology"
+"PATCOTHR","Products not elsewhere classified","MTMOTCMT","Million US$ at exchange rate","PRT","Portugal","2012","2012",0,"D","Difference in methodology"
+"PATCOTHR","Products not elsewhere classified","MTMOTCMT","Million US$ at exchange rate","PRT","Portugal","2013","2013",0,"D","Difference in methodology"
+"PATCOTHR","Products not elsewhere classified","MTMOTCMT","Million US$ at exchange rate","PRT","Portugal","2014","2014",0,"D","Difference in methodology"
+"PATCOTHR","Products not elsewhere classified","MTMOTCMT","Million US$ at exchange rate","PRT","Portugal","2015","2015",0,"D","Difference in methodology"
+"PATCOTHR","Products not elsewhere classified","MTMOTCMT","Million US$ at exchange rate","PRT","Portugal","2016","2016",0,"D","Difference in methodology"
+"PATCOTHR","Products not elsewhere classified","MTMOTCMT","Million US$ at exchange rate","PRT","Portugal","2017","2017",0,"D","Difference in methodology"
+"PATCOTHR","Products not elsewhere classified","MTMOTCMT","Million US$ at exchange rate","PRT","Portugal","2018","2018",0,"D","Difference in methodology"
+"PATCOTHR","Products not elsewhere classified","MTMOTCMT","Million US$ at exchange rate","PRT","Portugal","2019","2019",0,"D","Difference in methodology"
+"PATCOTHR","Products not elsewhere classified","MTMOTCMT","Million US$ at exchange rate","PRT","Portugal","2020","2020",0,"D","Difference in methodology"
+"PATCOTHR","Products not elsewhere classified","MTMOTCMT","Million US$ at exchange rate","PRT","Portugal","2021","2021",0,"D","Difference in methodology"
+"PATCOTHR","Products not elsewhere classified","MTMOTCMT","Million US$ at exchange rate","PRT","Portugal","2022","2022",0,"D","Difference in methodology"
+"PATCOTHR","Products not elsewhere classified","MTMOPPMT","Million US$, purchasing power parity","PRT","Portugal","2010","2010",0,"D","Difference in methodology"
+"PATCOTHR","Products not elsewhere classified","MTMOPPMT","Million US$, purchasing power parity","PRT","Portugal","2011","2011",0,"D","Difference in methodology"
+"PATCOTHR","Products not elsewhere classified","MTMOPPMT","Million US$, purchasing power parity","PRT","Portugal","2012","2012",0,"D","Difference in methodology"
+"PATCOTHR","Products not elsewhere classified","MTMOPPMT","Million US$, purchasing power parity","PRT","Portugal","2013","2013",0,"D","Difference in methodology"
+"PATCOTHR","Products not elsewhere classified","MTMOPPMT","Million US$, purchasing power parity","PRT","Portugal","2014","2014",0,"D","Difference in methodology"
+"PATCOTHR","Products not elsewhere classified","MTMOPPMT","Million US$, purchasing power parity","PRT","Portugal","2015","2015",0,"D","Difference in methodology"
+"PATCOTHR","Products not elsewhere classified","MTMOPPMT","Million US$, purchasing power parity","PRT","Portugal","2016","2016",0,"D","Difference in methodology"
+"PATCOTHR","Products not elsewhere classified","MTMOPPMT","Million US$, purchasing power parity","PRT","Portugal","2017","2017",0,"D","Difference in methodology"
+"PATCOTHR","Products not elsewhere classified","MTMOPPMT","Million US$, purchasing power parity","PRT","Portugal","2018","2018",0,"D","Difference in methodology"
+"PATCOTHR","Products not elsewhere classified","MTMOPPMT","Million US$, purchasing power parity","PRT","Portugal","2019","2019",0,"D","Difference in methodology"
+"PATCOTHR","Products not elsewhere classified","MTMOPPMT","Million US$, purchasing power parity","PRT","Portugal","2020","2020",0,"D","Difference in methodology"
+"PATCOTHR","Products not elsewhere classified","MTMOPPMT","Million US$, purchasing power parity","PRT","Portugal","2021","2021",0,"D","Difference in methodology"
+"PATCOTHR","Products not elsewhere classified","MTMOPPMT","Million US$, purchasing power parity","PRT","Portugal","2022","2022",0,"D","Difference in methodology"
+"PATCOTHR","Products not elsewhere classified","TCPPERMT","/capita, US$ exchange rate","PRT","Portugal","2010","2010",0,"D","Difference in methodology"
+"PATCOTHR","Products not elsewhere classified","TCPPERMT","/capita, US$ exchange rate","PRT","Portugal","2011","2011",0,"D","Difference in methodology"
+"PATCOTHR","Products not elsewhere classified","TCPPERMT","/capita, US$ exchange rate","PRT","Portugal","2012","2012",0,"D","Difference in methodology"
+"PATCOTHR","Products not elsewhere classified","TCPPERMT","/capita, US$ exchange rate","PRT","Portugal","2013","2013",0,"D","Difference in methodology"
+"PATCOTHR","Products not elsewhere classified","TCPPERMT","/capita, US$ exchange rate","PRT","Portugal","2014","2014",0,"D","Difference in methodology"
+"PATCOTHR","Products not elsewhere classified","TCPPERMT","/capita, US$ exchange rate","PRT","Portugal","2015","2015",0,"D","Difference in methodology"
+"PATCOTHR","Products not elsewhere classified","TCPPERMT","/capita, US$ exchange rate","PRT","Portugal","2016","2016",0,"D","Difference in methodology"
+"PATCOTHR","Products not elsewhere classified","TCPPERMT","/capita, US$ exchange rate","PRT","Portugal","2017","2017",0,"D","Difference in methodology"
+"PATCOTHR","Products not elsewhere classified","TCPPERMT","/capita, US$ exchange rate","PRT","Portugal","2018","2018",0,"D","Difference in methodology"
+"PATCOTHR","Products not elsewhere classified","TCPPERMT","/capita, US$ exchange rate","PRT","Portugal","2019","2019",0,"D","Difference in methodology"
+"PATCOTHR","Products not elsewhere classified","TCPPERMT","/capita, US$ exchange rate","PRT","Portugal","2020","2020",0,"D","Difference in methodology"
+"PATCOTHR","Products not elsewhere classified","TCPPERMT","/capita, US$ exchange rate","PRT","Portugal","2021","2021",0,"D","Difference in methodology"
+"PATCOTHR","Products not elsewhere classified","TCPPERMT","/capita, US$ exchange rate","PRT","Portugal","2022","2022",0,"D","Difference in methodology"
+"PATCOTHR","Products not elsewhere classified","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2010","2010",0,"D","Difference in methodology"
+"PATCOTHR","Products not elsewhere classified","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2011","2011",0,"D","Difference in methodology"
+"PATCOTHR","Products not elsewhere classified","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2012","2012",0,"D","Difference in methodology"
+"PATCOTHR","Products not elsewhere classified","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2013","2013",0,"D","Difference in methodology"
+"PATCOTHR","Products not elsewhere classified","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2014","2014",0,"D","Difference in methodology"
+"PATCOTHR","Products not elsewhere classified","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2015","2015",0,"D","Difference in methodology"
+"PATCOTHR","Products not elsewhere classified","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2016","2016",0,"D","Difference in methodology"
+"PATCOTHR","Products not elsewhere classified","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2017","2017",0,"D","Difference in methodology"
+"PATCOTHR","Products not elsewhere classified","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2018","2018",0,"D","Difference in methodology"
+"PATCOTHR","Products not elsewhere classified","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2019","2019",0,"D","Difference in methodology"
+"PATCOTHR","Products not elsewhere classified","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2020","2020",0,"D","Difference in methodology"
+"PATCOTHR","Products not elsewhere classified","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2021","2021",0,"D","Difference in methodology"
+"PATCOTHR","Products not elsewhere classified","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2022","2022",0,"D","Difference in methodology"
+"PATCOTHR","Products not elsewhere classified","ATCPTTMT","% of total sales","PRT","Portugal","2010","2010",0,"D","Difference in methodology"
+"PATCOTHR","Products not elsewhere classified","ATCPTTMT","% of total sales","PRT","Portugal","2011","2011",0,"D","Difference in methodology"
+"PATCOTHR","Products not elsewhere classified","ATCPTTMT","% of total sales","PRT","Portugal","2012","2012",0,"D","Difference in methodology"
+"PATCOTHR","Products not elsewhere classified","ATCPTTMT","% of total sales","PRT","Portugal","2013","2013",0,"D","Difference in methodology"
+"PATCOTHR","Products not elsewhere classified","ATCPTTMT","% of total sales","PRT","Portugal","2014","2014",0,"D","Difference in methodology"
+"PATCOTHR","Products not elsewhere classified","ATCPTTMT","% of total sales","PRT","Portugal","2015","2015",0,"D","Difference in methodology"
+"PATCOTHR","Products not elsewhere classified","ATCPTTMT","% of total sales","PRT","Portugal","2016","2016",0,"D","Difference in methodology"
+"PATCOTHR","Products not elsewhere classified","ATCPTTMT","% of total sales","PRT","Portugal","2017","2017",0,"D","Difference in methodology"
+"PATCOTHR","Products not elsewhere classified","ATCPTTMT","% of total sales","PRT","Portugal","2018","2018",0,"D","Difference in methodology"
+"PATCOTHR","Products not elsewhere classified","ATCPTTMT","% of total sales","PRT","Portugal","2019","2019",0,"D","Difference in methodology"
+"PATCOTHR","Products not elsewhere classified","ATCPTTMT","% of total sales","PRT","Portugal","2020","2020",0,"D","Difference in methodology"
+"PATCOTHR","Products not elsewhere classified","ATCPTTMT","% of total sales","PRT","Portugal","2021","2021",0,"D","Difference in methodology"
+"PATCOTHR","Products not elsewhere classified","ATCPTTMT","% of total sales","PRT","Portugal","2022","2022",0,"D","Difference in methodology"
+"PATCOTHR","Products not elsewhere classified","MLLNCUMT","Million of national currency units","SVK","Slovak Republic","2010","2010",262.6,,
+"PATCOTHR","Products not elsewhere classified","MLLNCUMT","Million of national currency units","SVK","Slovak Republic","2011","2011",257.4,,
+"PATCOTHR","Products not elsewhere classified","MLLNCUMT","Million of national currency units","SVK","Slovak Republic","2012","2012",275.2,,
+"PATCOTHR","Products not elsewhere classified","MLLNCUMT","Million of national currency units","SVK","Slovak Republic","2013","2013",352,,
+"PATCOTHR","Products not elsewhere classified","MLLNCUMT","Million of national currency units","SVK","Slovak Republic","2014","2014",390,,
+"PATCOTHR","Products not elsewhere classified","MLLNCUMT","Million of national currency units","SVK","Slovak Republic","2015","2015",415.8,,
+"PATCOTHR","Products not elsewhere classified","MLLNCUMT","Million of national currency units","SVK","Slovak Republic","2016","2016",466.6,"B","Break"
+"PATCOTHR","Products not elsewhere classified","MLLNCUMT","Million of national currency units","SVK","Slovak Republic","2017","2017",460.7,,
+"PATCOTHR","Products not elsewhere classified","MLLNCUMT","Million of national currency units","SVK","Slovak Republic","2018","2018",489.5,,
+"PATCOTHR","Products not elsewhere classified","MLLNCUMT","Million of national currency units","SVK","Slovak Republic","2019","2019",548.9,,
+"PATCOTHR","Products not elsewhere classified","MLLNCUMT","Million of national currency units","SVK","Slovak Republic","2020","2020",505.1,,
+"PATCOTHR","Products not elsewhere classified","MLLNCUMT","Million of national currency units","SVK","Slovak Republic","2021","2021",556.5,,
+"PATCOTHR","Products not elsewhere classified","MTMOTCMT","Million US$ at exchange rate","SVK","Slovak Republic","2010","2010",348.1,,
+"PATCOTHR","Products not elsewhere classified","MTMOTCMT","Million US$ at exchange rate","SVK","Slovak Republic","2011","2011",358.3,,
+"PATCOTHR","Products not elsewhere classified","MTMOTCMT","Million US$ at exchange rate","SVK","Slovak Republic","2012","2012",353.6,,
+"PATCOTHR","Products not elsewhere classified","MTMOTCMT","Million US$ at exchange rate","SVK","Slovak Republic","2013","2013",467.5,,
+"PATCOTHR","Products not elsewhere classified","MTMOTCMT","Million US$ at exchange rate","SVK","Slovak Republic","2014","2014",518.1,,
+"PATCOTHR","Products not elsewhere classified","MTMOTCMT","Million US$ at exchange rate","SVK","Slovak Republic","2015","2015",461.3,,
+"PATCOTHR","Products not elsewhere classified","MTMOTCMT","Million US$ at exchange rate","SVK","Slovak Republic","2016","2016",516.4,"B","Break"
+"PATCOTHR","Products not elsewhere classified","MTMOTCMT","Million US$ at exchange rate","SVK","Slovak Republic","2017","2017",520.4,,
+"PATCOTHR","Products not elsewhere classified","MTMOTCMT","Million US$ at exchange rate","SVK","Slovak Republic","2018","2018",578.1,,
+"PATCOTHR","Products not elsewhere classified","MTMOTCMT","Million US$ at exchange rate","SVK","Slovak Republic","2019","2019",614.5,,
+"PATCOTHR","Products not elsewhere classified","MTMOTCMT","Million US$ at exchange rate","SVK","Slovak Republic","2020","2020",576.9,,
+"PATCOTHR","Products not elsewhere classified","MTMOTCMT","Million US$ at exchange rate","SVK","Slovak Republic","2021","2021",658.2,,
+"PATCOTHR","Products not elsewhere classified","MTMOPPMT","Million US$, purchasing power parity","SVK","Slovak Republic","2010","2010",523,,
+"PATCOTHR","Products not elsewhere classified","MTMOPPMT","Million US$, purchasing power parity","SVK","Slovak Republic","2011","2011",508.3,,
+"PATCOTHR","Products not elsewhere classified","MTMOPPMT","Million US$, purchasing power parity","SVK","Slovak Republic","2012","2012",545.4,,
+"PATCOTHR","Products not elsewhere classified","MTMOPPMT","Million US$, purchasing power parity","SVK","Slovak Republic","2013","2013",716.7,,
+"PATCOTHR","Products not elsewhere classified","MTMOPPMT","Million US$, purchasing power parity","SVK","Slovak Republic","2014","2014",803.4,,
+"PATCOTHR","Products not elsewhere classified","MTMOPPMT","Million US$, purchasing power parity","SVK","Slovak Republic","2015","2015",845.9,,
+"PATCOTHR","Products not elsewhere classified","MTMOPPMT","Million US$, purchasing power parity","SVK","Slovak Republic","2016","2016",927.2,"B","Break"
+"PATCOTHR","Products not elsewhere classified","MTMOPPMT","Million US$, purchasing power parity","SVK","Slovak Republic","2017","2017",892,,
+"PATCOTHR","Products not elsewhere classified","MTMOPPMT","Million US$, purchasing power parity","SVK","Slovak Republic","2018","2018",930.7,,
+"PATCOTHR","Products not elsewhere classified","MTMOPPMT","Million US$, purchasing power parity","SVK","Slovak Republic","2019","2019",1060.6,,
+"PATCOTHR","Products not elsewhere classified","MTMOPPMT","Million US$, purchasing power parity","SVK","Slovak Republic","2020","2020",971.5,,
+"PATCOTHR","Products not elsewhere classified","MTMOPPMT","Million US$, purchasing power parity","SVK","Slovak Republic","2021","2021",1043.3,,
+"PATCOTHR","Products not elsewhere classified","TCPPERMT","/capita, US$ exchange rate","SVK","Slovak Republic","2010","2010",64.6,,
+"PATCOTHR","Products not elsewhere classified","TCPPERMT","/capita, US$ exchange rate","SVK","Slovak Republic","2011","2011",66.4,,
+"PATCOTHR","Products not elsewhere classified","TCPPERMT","/capita, US$ exchange rate","SVK","Slovak Republic","2012","2012",65.4,,
+"PATCOTHR","Products not elsewhere classified","TCPPERMT","/capita, US$ exchange rate","SVK","Slovak Republic","2013","2013",86.4,,
+"PATCOTHR","Products not elsewhere classified","TCPPERMT","/capita, US$ exchange rate","SVK","Slovak Republic","2014","2014",95.6,,
+"PATCOTHR","Products not elsewhere classified","TCPPERMT","/capita, US$ exchange rate","SVK","Slovak Republic","2015","2015",85.1,,
+"PATCOTHR","Products not elsewhere classified","TCPPERMT","/capita, US$ exchange rate","SVK","Slovak Republic","2016","2016",95.1,"B","Break"
+"PATCOTHR","Products not elsewhere classified","TCPPERMT","/capita, US$ exchange rate","SVK","Slovak Republic","2017","2017",95.7,,
+"PATCOTHR","Products not elsewhere classified","TCPPERMT","/capita, US$ exchange rate","SVK","Slovak Republic","2018","2018",106.1,,
+"PATCOTHR","Products not elsewhere classified","TCPPERMT","/capita, US$ exchange rate","SVK","Slovak Republic","2019","2019",112.7,,
+"PATCOTHR","Products not elsewhere classified","TCPPERMT","/capita, US$ exchange rate","SVK","Slovak Republic","2020","2020",105.7,,
+"PATCOTHR","Products not elsewhere classified","TCPPERMT","/capita, US$ exchange rate","SVK","Slovak Republic","2021","2021",120.8,,
+"PATCOTHR","Products not elsewhere classified","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2010","2010",97,,
+"PATCOTHR","Products not elsewhere classified","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2011","2011",94.2,,
+"PATCOTHR","Products not elsewhere classified","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2012","2012",100.9,,
+"PATCOTHR","Products not elsewhere classified","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2013","2013",132.4,,
+"PATCOTHR","Products not elsewhere classified","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2014","2014",148.3,,
+"PATCOTHR","Products not elsewhere classified","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2015","2015",156,,
+"PATCOTHR","Products not elsewhere classified","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2016","2016",170.7,"B","Break"
+"PATCOTHR","Products not elsewhere classified","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2017","2017",164,,
+"PATCOTHR","Products not elsewhere classified","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2018","2018",170.9,,
+"PATCOTHR","Products not elsewhere classified","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2019","2019",194.5,,
+"PATCOTHR","Products not elsewhere classified","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2020","2020",178,,
+"PATCOTHR","Products not elsewhere classified","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2021","2021",191.5,,
+"PATCOTHR","Products not elsewhere classified","ATCPTTMT","% of total sales","SVK","Slovak Republic","2010","2010",23.5,"D","Difference in methodology"
+"PATCOTHR","Products not elsewhere classified","ATCPTTMT","% of total sales","SVK","Slovak Republic","2011","2011",22.8,"D","Difference in methodology"
+"PATCOTHR","Products not elsewhere classified","ATCPTTMT","% of total sales","SVK","Slovak Republic","2012","2012",24.9,"D","Difference in methodology"
+"PATCOTHR","Products not elsewhere classified","ATCPTTMT","% of total sales","SVK","Slovak Republic","2013","2013",28.6,"D","Difference in methodology"
+"PATCOTHR","Products not elsewhere classified","ATCPTTMT","% of total sales","SVK","Slovak Republic","2014","2014",29.6,"D","Difference in methodology"
+"PATCOTHR","Products not elsewhere classified","ATCPTTMT","% of total sales","SVK","Slovak Republic","2015","2015",30,"D","Difference in methodology"
+"PATCOTHR","Products not elsewhere classified","ATCPTTMT","% of total sales","SVK","Slovak Republic","2016","2016",29.7,"B","Break"
+"PATCOTHR","Products not elsewhere classified","ATCPTTMT","% of total sales","SVK","Slovak Republic","2017","2017",29.5,,
+"PATCOTHR","Products not elsewhere classified","ATCPTTMT","% of total sales","SVK","Slovak Republic","2018","2018",30,,
+"PATCOTHR","Products not elsewhere classified","ATCPTTMT","% of total sales","SVK","Slovak Republic","2019","2019",31.7,,
+"PATCOTHR","Products not elsewhere classified","ATCPTTMT","% of total sales","SVK","Slovak Republic","2020","2020",30.4,,
+"PATCOTHR","Products not elsewhere classified","ATCPTTMT","% of total sales","SVK","Slovak Republic","2021","2021",31.1,,
+"PATCOTHR","Products not elsewhere classified","MLLNCUMT","Million of national currency units","CHE","Switzerland","2010","2010",980.6,"D","Difference in methodology"
+"PATCOTHR","Products not elsewhere classified","MLLNCUMT","Million of national currency units","CHE","Switzerland","2011","2011",1030,"D","Difference in methodology"
+"PATCOTHR","Products not elsewhere classified","MLLNCUMT","Million of national currency units","CHE","Switzerland","2012","2012",1180,"D","Difference in methodology"
+"PATCOTHR","Products not elsewhere classified","MLLNCUMT","Million of national currency units","CHE","Switzerland","2013","2013",1238,"D","Difference in methodology"
+"PATCOTHR","Products not elsewhere classified","MLLNCUMT","Million of national currency units","CHE","Switzerland","2014","2014",1258,"D","Difference in methodology"
+"PATCOTHR","Products not elsewhere classified","MLLNCUMT","Million of national currency units","CHE","Switzerland","2015","2015",1291,"D","Difference in methodology"
+"PATCOTHR","Products not elsewhere classified","MLLNCUMT","Million of national currency units","CHE","Switzerland","2016","2016",1218,"B; D","Break; Difference in methodology"
+"PATCOTHR","Products not elsewhere classified","MLLNCUMT","Million of national currency units","CHE","Switzerland","2017","2017",1298,"D","Difference in methodology"
+"PATCOTHR","Products not elsewhere classified","MLLNCUMT","Million of national currency units","CHE","Switzerland","2018","2018",1377,"D","Difference in methodology"
+"PATCOTHR","Products not elsewhere classified","MLLNCUMT","Million of national currency units","CHE","Switzerland","2019","2019",1454,"D","Difference in methodology"
+"PATCOTHR","Products not elsewhere classified","MLLNCUMT","Million of national currency units","CHE","Switzerland","2020","2020",1631,"D","Difference in methodology"
+"PATCOTHR","Products not elsewhere classified","MLLNCUMT","Million of national currency units","CHE","Switzerland","2021","2021",1772,"D","Difference in methodology"
+"PATCOTHR","Products not elsewhere classified","MLLNCUMT","Million of national currency units","CHE","Switzerland","2022","2022",1931,"D","Difference in methodology"
+"PATCOTHR","Products not elsewhere classified","MTMOTCMT","Million US$ at exchange rate","CHE","Switzerland","2010","2010",940.2,"D","Difference in methodology"
+"PATCOTHR","Products not elsewhere classified","MTMOTCMT","Million US$ at exchange rate","CHE","Switzerland","2011","2011",1159.9,"D","Difference in methodology"
+"PATCOTHR","Products not elsewhere classified","MTMOTCMT","Million US$ at exchange rate","CHE","Switzerland","2012","2012",1258.4,"D","Difference in methodology"
+"PATCOTHR","Products not elsewhere classified","MTMOTCMT","Million US$ at exchange rate","CHE","Switzerland","2013","2013",1335.6,"D","Difference in methodology"
+"PATCOTHR","Products not elsewhere classified","MTMOTCMT","Million US$ at exchange rate","CHE","Switzerland","2014","2014",1373.1,"D","Difference in methodology"
+"PATCOTHR","Products not elsewhere classified","MTMOTCMT","Million US$ at exchange rate","CHE","Switzerland","2015","2015",1341.5,"D","Difference in methodology"
+"PATCOTHR","Products not elsewhere classified","MTMOTCMT","Million US$ at exchange rate","CHE","Switzerland","2016","2016",1236.1,"B; D","Break; Difference in methodology"
+"PATCOTHR","Products not elsewhere classified","MTMOTCMT","Million US$ at exchange rate","CHE","Switzerland","2017","2017",1318.2,"D","Difference in methodology"
+"PATCOTHR","Products not elsewhere classified","MTMOTCMT","Million US$ at exchange rate","CHE","Switzerland","2018","2018",1408.1,"D","Difference in methodology"
+"PATCOTHR","Products not elsewhere classified","MTMOTCMT","Million US$ at exchange rate","CHE","Switzerland","2019","2019",1463.2,"D","Difference in methodology"
+"PATCOTHR","Products not elsewhere classified","MTMOTCMT","Million US$ at exchange rate","CHE","Switzerland","2020","2020",1737,"D","Difference in methodology"
+"PATCOTHR","Products not elsewhere classified","MTMOTCMT","Million US$ at exchange rate","CHE","Switzerland","2021","2021",1939.1,"D","Difference in methodology"
+"PATCOTHR","Products not elsewhere classified","MTMOTCMT","Million US$ at exchange rate","CHE","Switzerland","2022","2022",2022.3,"D","Difference in methodology"
+"PATCOTHR","Products not elsewhere classified","MTMOPPMT","Million US$, purchasing power parity","CHE","Switzerland","2010","2010",668.8,"D","Difference in methodology"
+"PATCOTHR","Products not elsewhere classified","MTMOPPMT","Million US$, purchasing power parity","CHE","Switzerland","2011","2011",737,"D","Difference in methodology"
+"PATCOTHR","Products not elsewhere classified","MTMOPPMT","Million US$, purchasing power parity","CHE","Switzerland","2012","2012",871.4,"D","Difference in methodology"
+"PATCOTHR","Products not elsewhere classified","MTMOPPMT","Million US$, purchasing power parity","CHE","Switzerland","2013","2013",943.3,"D","Difference in methodology"
+"PATCOTHR","Products not elsewhere classified","MTMOPPMT","Million US$, purchasing power parity","CHE","Switzerland","2014","2014",981.5,"D","Difference in methodology"
+"PATCOTHR","Products not elsewhere classified","MTMOPPMT","Million US$, purchasing power parity","CHE","Switzerland","2015","2015",1044.7,"D","Difference in methodology"
+"PATCOTHR","Products not elsewhere classified","MTMOPPMT","Million US$, purchasing power parity","CHE","Switzerland","2016","2016",1013.3,"B; D","Break; Difference in methodology"
+"PATCOTHR","Products not elsewhere classified","MTMOPPMT","Million US$, purchasing power parity","CHE","Switzerland","2017","2017",1092.8,"D","Difference in methodology"
+"PATCOTHR","Products not elsewhere classified","MTMOPPMT","Million US$, purchasing power parity","CHE","Switzerland","2018","2018",1168.1,"D","Difference in methodology"
+"PATCOTHR","Products not elsewhere classified","MTMOPPMT","Million US$, purchasing power parity","CHE","Switzerland","2019","2019",1263.9,"D","Difference in methodology"
+"PATCOTHR","Products not elsewhere classified","MTMOPPMT","Million US$, purchasing power parity","CHE","Switzerland","2020","2020",1436.2,"D","Difference in methodology"
+"PATCOTHR","Products not elsewhere classified","MTMOPPMT","Million US$, purchasing power parity","CHE","Switzerland","2021","2021",1601.6,"D","Difference in methodology"
+"PATCOTHR","Products not elsewhere classified","MTMOPPMT","Million US$, purchasing power parity","CHE","Switzerland","2022","2022",1811.6,"D","Difference in methodology"
+"PATCOTHR","Products not elsewhere classified","TCPPERMT","/capita, US$ exchange rate","CHE","Switzerland","2010","2010",120.2,"D","Difference in methodology"
+"PATCOTHR","Products not elsewhere classified","TCPPERMT","/capita, US$ exchange rate","CHE","Switzerland","2011","2011",146.6,"D","Difference in methodology"
+"PATCOTHR","Products not elsewhere classified","TCPPERMT","/capita, US$ exchange rate","CHE","Switzerland","2012","2012",157.4,"D","Difference in methodology"
+"PATCOTHR","Products not elsewhere classified","TCPPERMT","/capita, US$ exchange rate","CHE","Switzerland","2013","2013",165.1,"D","Difference in methodology"
+"PATCOTHR","Products not elsewhere classified","TCPPERMT","/capita, US$ exchange rate","CHE","Switzerland","2014","2014",167.7,"D","Difference in methodology"
+"PATCOTHR","Products not elsewhere classified","TCPPERMT","/capita, US$ exchange rate","CHE","Switzerland","2015","2015",162,"D","Difference in methodology"
+"PATCOTHR","Products not elsewhere classified","TCPPERMT","/capita, US$ exchange rate","CHE","Switzerland","2016","2016",147.6,"B; D","Break; Difference in methodology"
+"PATCOTHR","Products not elsewhere classified","TCPPERMT","/capita, US$ exchange rate","CHE","Switzerland","2017","2017",156,"D","Difference in methodology"
+"PATCOTHR","Products not elsewhere classified","TCPPERMT","/capita, US$ exchange rate","CHE","Switzerland","2018","2018",165.4,"D","Difference in methodology"
+"PATCOTHR","Products not elsewhere classified","TCPPERMT","/capita, US$ exchange rate","CHE","Switzerland","2019","2019",170.6,"D","Difference in methodology"
+"PATCOTHR","Products not elsewhere classified","TCPPERMT","/capita, US$ exchange rate","CHE","Switzerland","2020","2020",201.1,"D","Difference in methodology"
+"PATCOTHR","Products not elsewhere classified","TCPPERMT","/capita, US$ exchange rate","CHE","Switzerland","2021","2021",222.8,"D","Difference in methodology"
+"PATCOTHR","Products not elsewhere classified","TCPPERMT","/capita, US$ exchange rate","CHE","Switzerland","2022","2022",231.4,"D","Difference in methodology"
+"PATCOTHR","Products not elsewhere classified","PPPPERMT","/capita, US$ purchasing power parity","CHE","Switzerland","2010","2010",85.5,"D","Difference in methodology"
+"PATCOTHR","Products not elsewhere classified","PPPPERMT","/capita, US$ purchasing power parity","CHE","Switzerland","2011","2011",93.1,"D","Difference in methodology"
+"PATCOTHR","Products not elsewhere classified","PPPPERMT","/capita, US$ purchasing power parity","CHE","Switzerland","2012","2012",109,"D","Difference in methodology"
+"PATCOTHR","Products not elsewhere classified","PPPPERMT","/capita, US$ purchasing power parity","CHE","Switzerland","2013","2013",116.6,"D","Difference in methodology"
+"PATCOTHR","Products not elsewhere classified","PPPPERMT","/capita, US$ purchasing power parity","CHE","Switzerland","2014","2014",119.9,"D","Difference in methodology"
+"PATCOTHR","Products not elsewhere classified","PPPPERMT","/capita, US$ purchasing power parity","CHE","Switzerland","2015","2015",126.1,"D","Difference in methodology"
+"PATCOTHR","Products not elsewhere classified","PPPPERMT","/capita, US$ purchasing power parity","CHE","Switzerland","2016","2016",121,"B; D","Break; Difference in methodology"
+"PATCOTHR","Products not elsewhere classified","PPPPERMT","/capita, US$ purchasing power parity","CHE","Switzerland","2017","2017",129.3,"D","Difference in methodology"
+"PATCOTHR","Products not elsewhere classified","PPPPERMT","/capita, US$ purchasing power parity","CHE","Switzerland","2018","2018",137.2,"D","Difference in methodology"
+"PATCOTHR","Products not elsewhere classified","PPPPERMT","/capita, US$ purchasing power parity","CHE","Switzerland","2019","2019",147.4,"D","Difference in methodology"
+"PATCOTHR","Products not elsewhere classified","PPPPERMT","/capita, US$ purchasing power parity","CHE","Switzerland","2020","2020",166.3,"D","Difference in methodology"
+"PATCOTHR","Products not elsewhere classified","PPPPERMT","/capita, US$ purchasing power parity","CHE","Switzerland","2021","2021",184,"D","Difference in methodology"
+"PATCOTHR","Products not elsewhere classified","PPPPERMT","/capita, US$ purchasing power parity","CHE","Switzerland","2022","2022",207.3,"D","Difference in methodology"
+"PATCOTHR","Products not elsewhere classified","ATCPTTMT","% of total sales","CHE","Switzerland","2010","2010",17.1,"D","Difference in methodology"
+"PATCOTHR","Products not elsewhere classified","ATCPTTMT","% of total sales","CHE","Switzerland","2011","2011",17.8,"D","Difference in methodology"
+"PATCOTHR","Products not elsewhere classified","ATCPTTMT","% of total sales","CHE","Switzerland","2012","2012",19.9,"D","Difference in methodology"
+"PATCOTHR","Products not elsewhere classified","ATCPTTMT","% of total sales","CHE","Switzerland","2013","2013",20.9,"D","Difference in methodology"
+"PATCOTHR","Products not elsewhere classified","ATCPTTMT","% of total sales","CHE","Switzerland","2014","2014",21.2,"D","Difference in methodology"
+"PATCOTHR","Products not elsewhere classified","ATCPTTMT","% of total sales","CHE","Switzerland","2015","2015",20.9,"D","Difference in methodology"
+"PATCOTHR","Products not elsewhere classified","ATCPTTMT","% of total sales","CHE","Switzerland","2016","2016",19.1,"B; D","Break; Difference in methodology"
+"PATCOTHR","Products not elsewhere classified","ATCPTTMT","% of total sales","CHE","Switzerland","2017","2017",19.9,"D","Difference in methodology"
+"PATCOTHR","Products not elsewhere classified","ATCPTTMT","% of total sales","CHE","Switzerland","2018","2018",20.8,"D","Difference in methodology"
+"PATCOTHR","Products not elsewhere classified","ATCPTTMT","% of total sales","CHE","Switzerland","2019","2019",21.7,"D","Difference in methodology"
+"PATCOTHR","Products not elsewhere classified","ATCPTTMT","% of total sales","CHE","Switzerland","2020","2020",23.9,"D","Difference in methodology"
+"PATCOTHR","Products not elsewhere classified","ATCPTTMT","% of total sales","CHE","Switzerland","2021","2021",24.9,"D","Difference in methodology"
+"PATCOTHR","Products not elsewhere classified","ATCPTTMT","% of total sales","CHE","Switzerland","2022","2022",25.4,"D","Difference in methodology"
+"PATCOTHR","Products not elsewhere classified","MLLNCUMT","Million of national currency units","TUR","Türkiye","2010","2010",2757.9,,
+"PATCOTHR","Products not elsewhere classified","MLLNCUMT","Million of national currency units","TUR","Türkiye","2011","2011",2753.9,,
+"PATCOTHR","Products not elsewhere classified","MLLNCUMT","Million of national currency units","TUR","Türkiye","2012","2012",2842.6,,
+"PATCOTHR","Products not elsewhere classified","MLLNCUMT","Million of national currency units","TUR","Türkiye","2013","2013",3163,,
+"PATCOTHR","Products not elsewhere classified","MLLNCUMT","Million of national currency units","TUR","Türkiye","2014","2014",3698.5,,
+"PATCOTHR","Products not elsewhere classified","MLLNCUMT","Million of national currency units","TUR","Türkiye","2015","2015",4528.2,,
+"PATCOTHR","Products not elsewhere classified","MLLNCUMT","Million of national currency units","TUR","Türkiye","2016","2016",5484.2,,
+"PATCOTHR","Products not elsewhere classified","MLLNCUMT","Million of national currency units","TUR","Türkiye","2017","2017",5689.7,,
+"PATCOTHR","Products not elsewhere classified","MLLNCUMT","Million of national currency units","TUR","Türkiye","2018","2018",7358.3,,
+"PATCOTHR","Products not elsewhere classified","MLLNCUMT","Million of national currency units","TUR","Türkiye","2019","2019",9709.8,,
+"PATCOTHR","Products not elsewhere classified","MLLNCUMT","Million of national currency units","TUR","Türkiye","2020","2020",11913.6,,
+"PATCOTHR","Products not elsewhere classified","MLLNCUMT","Million of national currency units","TUR","Türkiye","2021","2021",15726.2,,
+"PATCOTHR","Products not elsewhere classified","MTMOTCMT","Million US$ at exchange rate","TUR","Türkiye","2010","2010",1835.1,,
+"PATCOTHR","Products not elsewhere classified","MTMOTCMT","Million US$ at exchange rate","TUR","Türkiye","2011","2011",1644.2,,
+"PATCOTHR","Products not elsewhere classified","MTMOTCMT","Million US$ at exchange rate","TUR","Türkiye","2012","2012",1582.8,,
+"PATCOTHR","Products not elsewhere classified","MTMOTCMT","Million US$ at exchange rate","TUR","Türkiye","2013","2013",1661.4,,
+"PATCOTHR","Products not elsewhere classified","MTMOTCMT","Million US$ at exchange rate","TUR","Türkiye","2014","2014",1689.9,,
+"PATCOTHR","Products not elsewhere classified","MTMOTCMT","Million US$ at exchange rate","TUR","Türkiye","2015","2015",1664.8,,
+"PATCOTHR","Products not elsewhere classified","MTMOTCMT","Million US$ at exchange rate","TUR","Türkiye","2016","2016",1815.9,,
+"PATCOTHR","Products not elsewhere classified","MTMOTCMT","Million US$ at exchange rate","TUR","Türkiye","2017","2017",1559.6,,
+"PATCOTHR","Products not elsewhere classified","MTMOTCMT","Million US$ at exchange rate","TUR","Türkiye","2018","2018",1524,,
+"PATCOTHR","Products not elsewhere classified","MTMOTCMT","Million US$ at exchange rate","TUR","Türkiye","2019","2019",1711.3,,
+"PATCOTHR","Products not elsewhere classified","MTMOTCMT","Million US$ at exchange rate","TUR","Türkiye","2020","2020",1699.9,,
+"PATCOTHR","Products not elsewhere classified","MTMOTCMT","Million US$ at exchange rate","TUR","Türkiye","2021","2021",1776.9,,
+"PATCOTHR","Products not elsewhere classified","MTMOPPMT","Million US$, purchasing power parity","TUR","Türkiye","2010","2010",2996.6,,
+"PATCOTHR","Products not elsewhere classified","MTMOPPMT","Million US$, purchasing power parity","TUR","Türkiye","2011","2011",2850.3,,
+"PATCOTHR","Products not elsewhere classified","MTMOPPMT","Million US$, purchasing power parity","TUR","Türkiye","2012","2012",2787.3,,
+"PATCOTHR","Products not elsewhere classified","MTMOPPMT","Million US$, purchasing power parity","TUR","Türkiye","2013","2013",2955.2,,
+"PATCOTHR","Products not elsewhere classified","MTMOPPMT","Million US$, purchasing power parity","TUR","Türkiye","2014","2014",3348.5,,
+"PATCOTHR","Products not elsewhere classified","MTMOPPMT","Million US$, purchasing power parity","TUR","Türkiye","2015","2015",3895.4,,
+"PATCOTHR","Products not elsewhere classified","MTMOPPMT","Million US$, purchasing power parity","TUR","Türkiye","2016","2016",4419,,
+"PATCOTHR","Products not elsewhere classified","MTMOPPMT","Million US$, purchasing power parity","TUR","Türkiye","2017","2017",4111.1,,
+"PATCOTHR","Products not elsewhere classified","MTMOPPMT","Million US$, purchasing power parity","TUR","Türkiye","2018","2018",4507.1,,
+"PATCOTHR","Products not elsewhere classified","MTMOPPMT","Million US$, purchasing power parity","TUR","Türkiye","2019","2019",5209.1,,
+"PATCOTHR","Products not elsewhere classified","MTMOPPMT","Million US$, purchasing power parity","TUR","Türkiye","2020","2020",5504.9,,
+"PATCOTHR","Products not elsewhere classified","MTMOPPMT","Million US$, purchasing power parity","TUR","Türkiye","2021","2021",5600.7,,
+"PATCOTHR","Products not elsewhere classified","TCPPERMT","/capita, US$ exchange rate","TUR","Türkiye","2010","2010",25.1,,
+"PATCOTHR","Products not elsewhere classified","TCPPERMT","/capita, US$ exchange rate","TUR","Türkiye","2011","2011",22.2,,
+"PATCOTHR","Products not elsewhere classified","TCPPERMT","/capita, US$ exchange rate","TUR","Türkiye","2012","2012",21.1,,
+"PATCOTHR","Products not elsewhere classified","TCPPERMT","/capita, US$ exchange rate","TUR","Türkiye","2013","2013",21.8,,
+"PATCOTHR","Products not elsewhere classified","TCPPERMT","/capita, US$ exchange rate","TUR","Türkiye","2014","2014",21.9,,
+"PATCOTHR","Products not elsewhere classified","TCPPERMT","/capita, US$ exchange rate","TUR","Türkiye","2015","2015",21.3,,
+"PATCOTHR","Products not elsewhere classified","TCPPERMT","/capita, US$ exchange rate","TUR","Türkiye","2016","2016",22.9,,
+"PATCOTHR","Products not elsewhere classified","TCPPERMT","/capita, US$ exchange rate","TUR","Türkiye","2017","2017",19.4,,
+"PATCOTHR","Products not elsewhere classified","TCPPERMT","/capita, US$ exchange rate","TUR","Türkiye","2018","2018",18.7,,
+"PATCOTHR","Products not elsewhere classified","TCPPERMT","/capita, US$ exchange rate","TUR","Türkiye","2019","2019",20.7,,
+"PATCOTHR","Products not elsewhere classified","TCPPERMT","/capita, US$ exchange rate","TUR","Türkiye","2020","2020",20.4,,
+"PATCOTHR","Products not elsewhere classified","TCPPERMT","/capita, US$ exchange rate","TUR","Türkiye","2021","2021",21.1,,
+"PATCOTHR","Products not elsewhere classified","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2010","2010",41,,
+"PATCOTHR","Products not elsewhere classified","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2011","2011",38.4,,
+"PATCOTHR","Products not elsewhere classified","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2012","2012",37.1,,
+"PATCOTHR","Products not elsewhere classified","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2013","2013",38.8,,
+"PATCOTHR","Products not elsewhere classified","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2014","2014",43.4,,
+"PATCOTHR","Products not elsewhere classified","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2015","2015",49.8,,
+"PATCOTHR","Products not elsewhere classified","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2016","2016",55.7,,
+"PATCOTHR","Products not elsewhere classified","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2017","2017",51.2,,
+"PATCOTHR","Products not elsewhere classified","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2018","2018",55.4,,
+"PATCOTHR","Products not elsewhere classified","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2019","2019",63.1,,
+"PATCOTHR","Products not elsewhere classified","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2020","2020",66,,
+"PATCOTHR","Products not elsewhere classified","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2021","2021",66.6,,
+"PATCOTHR","Products not elsewhere classified","ATCPTTMT","% of total sales","TUR","Türkiye","2010","2010",17.7,,
+"PATCOTHR","Products not elsewhere classified","ATCPTTMT","% of total sales","TUR","Türkiye","2011","2011",19.4,,
+"PATCOTHR","Products not elsewhere classified","ATCPTTMT","% of total sales","TUR","Türkiye","2012","2012",21,,
+"PATCOTHR","Products not elsewhere classified","ATCPTTMT","% of total sales","TUR","Türkiye","2013","2013",22.1,,
+"PATCOTHR","Products not elsewhere classified","ATCPTTMT","% of total sales","TUR","Türkiye","2014","2014",23.6,,
+"PATCOTHR","Products not elsewhere classified","ATCPTTMT","% of total sales","TUR","Türkiye","2015","2015",24.7,,
+"PATCOTHR","Products not elsewhere classified","ATCPTTMT","% of total sales","TUR","Türkiye","2016","2016",25,,
+"PATCOTHR","Products not elsewhere classified","ATCPTTMT","% of total sales","TUR","Türkiye","2017","2017",22.4,,
+"PATCOTHR","Products not elsewhere classified","ATCPTTMT","% of total sales","TUR","Türkiye","2018","2018",23,,
+"PATCOTHR","Products not elsewhere classified","ATCPTTMT","% of total sales","TUR","Türkiye","2019","2019",23.1,,
+"PATCOTHR","Products not elsewhere classified","ATCPTTMT","% of total sales","TUR","Türkiye","2020","2020",23.8,,
+"PATCOTHR","Products not elsewhere classified","ATCPTTMT","% of total sales","TUR","Türkiye","2021","2021",24.3,,
+"PATCOTHR","Products not elsewhere classified","MLLNCUMT","Million of national currency units","CHL","Chile","2010","2010",95614.1,,
+"PATCOTHR","Products not elsewhere classified","MLLNCUMT","Million of national currency units","CHL","Chile","2011","2011",166797.1,"B","Break"
+"PATCOTHR","Products not elsewhere classified","MLLNCUMT","Million of national currency units","CHL","Chile","2012","2012",169953.3,,
+"PATCOTHR","Products not elsewhere classified","MLLNCUMT","Million of national currency units","CHL","Chile","2013","2013",235364.6,,
+"PATCOTHR","Products not elsewhere classified","MLLNCUMT","Million of national currency units","CHL","Chile","2014","2014",218422.5,,
+"PATCOTHR","Products not elsewhere classified","MLLNCUMT","Million of national currency units","CHL","Chile","2015","2015",241259,,
+"PATCOTHR","Products not elsewhere classified","MLLNCUMT","Million of national currency units","CHL","Chile","2016","2016",272690.5,,
+"PATCOTHR","Products not elsewhere classified","MLLNCUMT","Million of national currency units","CHL","Chile","2017","2017",326087.2,,
+"PATCOTHR","Products not elsewhere classified","MLLNCUMT","Million of national currency units","CHL","Chile","2018","2018",374177.7,,
+"PATCOTHR","Products not elsewhere classified","MLLNCUMT","Million of national currency units","CHL","Chile","2019","2019",484298.5,,
+"PATCOTHR","Products not elsewhere classified","MLLNCUMT","Million of national currency units","CHL","Chile","2020","2020",497444.1,,
+"PATCOTHR","Products not elsewhere classified","MLLNCUMT","Million of national currency units","CHL","Chile","2021","2021",484621.8,,
+"PATCOTHR","Products not elsewhere classified","MLLNCUMT","Million of national currency units","CHL","Chile","2022","2022",444493.4,,
+"PATCOTHR","Products not elsewhere classified","MTMOTCMT","Million US$ at exchange rate","CHL","Chile","2010","2010",187.4,,
+"PATCOTHR","Products not elsewhere classified","MTMOTCMT","Million US$ at exchange rate","CHL","Chile","2011","2011",344.9,"B","Break"
+"PATCOTHR","Products not elsewhere classified","MTMOTCMT","Million US$ at exchange rate","CHL","Chile","2012","2012",349.4,,
+"PATCOTHR","Products not elsewhere classified","MTMOTCMT","Million US$ at exchange rate","CHL","Chile","2013","2013",475.2,,
+"PATCOTHR","Products not elsewhere classified","MTMOTCMT","Million US$ at exchange rate","CHL","Chile","2014","2014",383,,
+"PATCOTHR","Products not elsewhere classified","MTMOTCMT","Million US$ at exchange rate","CHL","Chile","2015","2015",368.8,,
+"PATCOTHR","Products not elsewhere classified","MTMOTCMT","Million US$ at exchange rate","CHL","Chile","2016","2016",402.8,,
+"PATCOTHR","Products not elsewhere classified","MTMOTCMT","Million US$ at exchange rate","CHL","Chile","2017","2017",502.6,,
+"PATCOTHR","Products not elsewhere classified","MTMOTCMT","Million US$ at exchange rate","CHL","Chile","2018","2018",583.5,,
+"PATCOTHR","Products not elsewhere classified","MTMOTCMT","Million US$ at exchange rate","CHL","Chile","2019","2019",689,,
+"PATCOTHR","Products not elsewhere classified","MTMOTCMT","Million US$ at exchange rate","CHL","Chile","2020","2020",627.5,,
+"PATCOTHR","Products not elsewhere classified","MTMOTCMT","Million US$ at exchange rate","CHL","Chile","2021","2021",638.5,,
+"PATCOTHR","Products not elsewhere classified","MTMOTCMT","Million US$ at exchange rate","CHL","Chile","2022","2022",509,,
+"PATCOTHR","Products not elsewhere classified","MTMOPPMT","Million US$, purchasing power parity","CHL","Chile","2010","2010",265.7,,
+"PATCOTHR","Products not elsewhere classified","MTMOPPMT","Million US$, purchasing power parity","CHL","Chile","2011","2011",479.3,"B","Break"
+"PATCOTHR","Products not elsewhere classified","MTMOPPMT","Million US$, purchasing power parity","CHL","Chile","2012","2012",489.5,,
+"PATCOTHR","Products not elsewhere classified","MTMOPPMT","Million US$, purchasing power parity","CHL","Chile","2013","2013",673.1,,
+"PATCOTHR","Products not elsewhere classified","MTMOPPMT","Million US$, purchasing power parity","CHL","Chile","2014","2014",594.8,,
+"PATCOTHR","Products not elsewhere classified","MTMOPPMT","Million US$, purchasing power parity","CHL","Chile","2015","2015",616.7,,
+"PATCOTHR","Products not elsewhere classified","MTMOPPMT","Million US$, purchasing power parity","CHL","Chile","2016","2016",686.4,,
+"PATCOTHR","Products not elsewhere classified","MTMOPPMT","Million US$, purchasing power parity","CHL","Chile","2017","2017",820,,
+"PATCOTHR","Products not elsewhere classified","MTMOPPMT","Million US$, purchasing power parity","CHL","Chile","2018","2018",944.3,,
+"PATCOTHR","Products not elsewhere classified","MTMOPPMT","Million US$, purchasing power parity","CHL","Chile","2019","2019",1205.9,,
+"PATCOTHR","Products not elsewhere classified","MTMOPPMT","Million US$, purchasing power parity","CHL","Chile","2020","2020",1188.8,,
+"PATCOTHR","Products not elsewhere classified","MTMOPPMT","Million US$, purchasing power parity","CHL","Chile","2021","2021",1113.7,,
+"PATCOTHR","Products not elsewhere classified","MTMOPPMT","Million US$, purchasing power parity","CHL","Chile","2022","2022",1015.8,,
+"PATCOTHR","Products not elsewhere classified","TCPPERMT","/capita, US$ exchange rate","CHL","Chile","2010","2010",11,,
+"PATCOTHR","Products not elsewhere classified","TCPPERMT","/capita, US$ exchange rate","CHL","Chile","2011","2011",20,"B","Break"
+"PATCOTHR","Products not elsewhere classified","TCPPERMT","/capita, US$ exchange rate","CHL","Chile","2012","2012",20,,
+"PATCOTHR","Products not elsewhere classified","TCPPERMT","/capita, US$ exchange rate","CHL","Chile","2013","2013",27,,
+"PATCOTHR","Products not elsewhere classified","TCPPERMT","/capita, US$ exchange rate","CHL","Chile","2014","2014",21.5,,
+"PATCOTHR","Products not elsewhere classified","TCPPERMT","/capita, US$ exchange rate","CHL","Chile","2015","2015",20.5,,
+"PATCOTHR","Products not elsewhere classified","TCPPERMT","/capita, US$ exchange rate","CHL","Chile","2016","2016",22.2,,
+"PATCOTHR","Products not elsewhere classified","TCPPERMT","/capita, US$ exchange rate","CHL","Chile","2017","2017",27.3,,
+"PATCOTHR","Products not elsewhere classified","TCPPERMT","/capita, US$ exchange rate","CHL","Chile","2018","2018",31.1,,
+"PATCOTHR","Products not elsewhere classified","TCPPERMT","/capita, US$ exchange rate","CHL","Chile","2019","2019",36.1,,
+"PATCOTHR","Products not elsewhere classified","TCPPERMT","/capita, US$ exchange rate","CHL","Chile","2020","2020",32.2,,
+"PATCOTHR","Products not elsewhere classified","TCPPERMT","/capita, US$ exchange rate","CHL","Chile","2021","2021",32.4,,
+"PATCOTHR","Products not elsewhere classified","TCPPERMT","/capita, US$ exchange rate","CHL","Chile","2022","2022",25.7,,
+"PATCOTHR","Products not elsewhere classified","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2010","2010",15.6,,
+"PATCOTHR","Products not elsewhere classified","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2011","2011",27.8,"B","Break"
+"PATCOTHR","Products not elsewhere classified","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2012","2012",28.1,,
+"PATCOTHR","Products not elsewhere classified","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2013","2013",38.2,,
+"PATCOTHR","Products not elsewhere classified","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2014","2014",33.4,,
+"PATCOTHR","Products not elsewhere classified","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2015","2015",34.3,,
+"PATCOTHR","Products not elsewhere classified","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2016","2016",37.8,,
+"PATCOTHR","Products not elsewhere classified","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2017","2017",44.5,,
+"PATCOTHR","Products not elsewhere classified","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2018","2018",50.4,,
+"PATCOTHR","Products not elsewhere classified","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2019","2019",63.1,,
+"PATCOTHR","Products not elsewhere classified","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2020","2020",61.1,,
+"PATCOTHR","Products not elsewhere classified","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2021","2021",56.6,,
+"PATCOTHR","Products not elsewhere classified","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2022","2022",51.2,,
+"PATCOTHR","Products not elsewhere classified","ATCPTTMT","% of total sales","CHL","Chile","2010","2010",11.6,,
+"PATCOTHR","Products not elsewhere classified","ATCPTTMT","% of total sales","CHL","Chile","2011","2011",14.1,"B","Break"
+"PATCOTHR","Products not elsewhere classified","ATCPTTMT","% of total sales","CHL","Chile","2012","2012",13.6,,
+"PATCOTHR","Products not elsewhere classified","ATCPTTMT","% of total sales","CHL","Chile","2013","2013",16.3,,
+"PATCOTHR","Products not elsewhere classified","ATCPTTMT","% of total sales","CHL","Chile","2014","2014",14.1,,
+"PATCOTHR","Products not elsewhere classified","ATCPTTMT","% of total sales","CHL","Chile","2015","2015",13.2,,
+"PATCOTHR","Products not elsewhere classified","ATCPTTMT","% of total sales","CHL","Chile","2016","2016",13.5,,
+"PATCOTHR","Products not elsewhere classified","ATCPTTMT","% of total sales","CHL","Chile","2017","2017",15.8,,
+"PATCOTHR","Products not elsewhere classified","ATCPTTMT","% of total sales","CHL","Chile","2018","2018",16.3,,
+"PATCOTHR","Products not elsewhere classified","ATCPTTMT","% of total sales","CHL","Chile","2019","2019",19.2,,
+"PATCOTHR","Products not elsewhere classified","ATCPTTMT","% of total sales","CHL","Chile","2020","2020",18.5,,
+"PATCOTHR","Products not elsewhere classified","ATCPTTMT","% of total sales","CHL","Chile","2021","2021",17.2,,
+"PATCOTHR","Products not elsewhere classified","ATCPTTMT","% of total sales","CHL","Chile","2022","2022",15.8,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","ATCPTTMT","% of total sales","LVA","Latvia","2010","2010",0.1,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","ATCPTTMT","% of total sales","LVA","Latvia","2011","2011",0.2,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","ATCPTTMT","% of total sales","LVA","Latvia","2012","2012",0.2,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","ATCPTTMT","% of total sales","LVA","Latvia","2013","2013",0.2,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","ATCPTTMT","% of total sales","LVA","Latvia","2014","2014",0.2,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","ATCPTTMT","% of total sales","LVA","Latvia","2015","2015",0.2,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","ATCPTTMT","% of total sales","LVA","Latvia","2016","2016",0.2,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","ATCPTTMT","% of total sales","LVA","Latvia","2017","2017",0.2,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","ATCPTTMT","% of total sales","LVA","Latvia","2018","2018",0.2,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","ATCPTTMT","% of total sales","LVA","Latvia","2019","2019",0.2,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","ATCPTTMT","% of total sales","LVA","Latvia","2020","2020",0.2,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","ATCPTTMT","% of total sales","LVA","Latvia","2021","2021",0.2,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","ATCPTTMT","% of total sales","LVA","Latvia","2022","2022",0.3,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","ATCPTTMT","% of total sales","LVA","Latvia","2010","2010",0.9,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","ATCPTTMT","% of total sales","LVA","Latvia","2011","2011",0.9,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","ATCPTTMT","% of total sales","LVA","Latvia","2012","2012",0.8,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","ATCPTTMT","% of total sales","LVA","Latvia","2013","2013",0.8,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","ATCPTTMT","% of total sales","LVA","Latvia","2014","2014",0.9,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","ATCPTTMT","% of total sales","LVA","Latvia","2015","2015",0.9,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","ATCPTTMT","% of total sales","LVA","Latvia","2016","2016",0.8,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","ATCPTTMT","% of total sales","LVA","Latvia","2017","2017",0.8,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","ATCPTTMT","% of total sales","LVA","Latvia","2018","2018",0.8,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","ATCPTTMT","% of total sales","LVA","Latvia","2019","2019",0.8,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","ATCPTTMT","% of total sales","LVA","Latvia","2020","2020",0.9,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","ATCPTTMT","% of total sales","LVA","Latvia","2021","2021",1,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","ATCPTTMT","% of total sales","LVA","Latvia","2022","2022",0.9,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","ATCPTTMT","% of total sales","LVA","Latvia","2010","2010",3.4,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","ATCPTTMT","% of total sales","LVA","Latvia","2011","2011",3.3,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","ATCPTTMT","% of total sales","LVA","Latvia","2012","2012",3.2,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","ATCPTTMT","% of total sales","LVA","Latvia","2013","2013",3.1,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","ATCPTTMT","% of total sales","LVA","Latvia","2014","2014",3.1,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","ATCPTTMT","% of total sales","LVA","Latvia","2015","2015",3,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","ATCPTTMT","% of total sales","LVA","Latvia","2016","2016",2.7,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","ATCPTTMT","% of total sales","LVA","Latvia","2017","2017",2.7,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","ATCPTTMT","% of total sales","LVA","Latvia","2018","2018",2.5,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","ATCPTTMT","% of total sales","LVA","Latvia","2019","2019",2.5,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","ATCPTTMT","% of total sales","LVA","Latvia","2020","2020",2.2,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","ATCPTTMT","% of total sales","LVA","Latvia","2021","2021",2.1,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","ATCPTTMT","% of total sales","LVA","Latvia","2022","2022",2.1,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","ATCPTTMT","% of total sales","LVA","Latvia","2010","2010",6.8,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","ATCPTTMT","% of total sales","LVA","Latvia","2011","2011",6.5,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","ATCPTTMT","% of total sales","LVA","Latvia","2012","2012",6.6,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","ATCPTTMT","% of total sales","LVA","Latvia","2013","2013",6.7,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","ATCPTTMT","% of total sales","LVA","Latvia","2014","2014",7,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","ATCPTTMT","% of total sales","LVA","Latvia","2015","2015",7,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","ATCPTTMT","% of total sales","LVA","Latvia","2016","2016",6.7,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","ATCPTTMT","% of total sales","LVA","Latvia","2017","2017",7.2,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","ATCPTTMT","% of total sales","LVA","Latvia","2018","2018",7.7,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","ATCPTTMT","% of total sales","LVA","Latvia","2019","2019",9,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","ATCPTTMT","% of total sales","LVA","Latvia","2020","2020",8.9,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","ATCPTTMT","% of total sales","LVA","Latvia","2021","2021",9.4,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","ATCPTTMT","% of total sales","LVA","Latvia","2022","2022",8.8,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","ATCPTTMT","% of total sales","LVA","Latvia","2010","2010",3.1,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","ATCPTTMT","% of total sales","LVA","Latvia","2011","2011",3.1,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","ATCPTTMT","% of total sales","LVA","Latvia","2012","2012",3.1,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","ATCPTTMT","% of total sales","LVA","Latvia","2013","2013",3,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","ATCPTTMT","% of total sales","LVA","Latvia","2014","2014",3,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","ATCPTTMT","% of total sales","LVA","Latvia","2015","2015",2.8,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","ATCPTTMT","% of total sales","LVA","Latvia","2016","2016",2.5,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","ATCPTTMT","% of total sales","LVA","Latvia","2017","2017",2.5,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","ATCPTTMT","% of total sales","LVA","Latvia","2018","2018",2.3,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","ATCPTTMT","% of total sales","LVA","Latvia","2019","2019",2.3,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","ATCPTTMT","% of total sales","LVA","Latvia","2020","2020",2.2,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","ATCPTTMT","% of total sales","LVA","Latvia","2021","2021",2.1,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","ATCPTTMT","% of total sales","LVA","Latvia","2022","2022",2,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","ATCPTTMT","% of total sales","LVA","Latvia","2010","2010",12,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","ATCPTTMT","% of total sales","LVA","Latvia","2011","2011",11.6,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","ATCPTTMT","% of total sales","LVA","Latvia","2012","2012",11.3,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","ATCPTTMT","% of total sales","LVA","Latvia","2013","2013",10.8,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","ATCPTTMT","% of total sales","LVA","Latvia","2014","2014",10.7,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","ATCPTTMT","% of total sales","LVA","Latvia","2015","2015",10.5,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","ATCPTTMT","% of total sales","LVA","Latvia","2016","2016",9.6,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","ATCPTTMT","% of total sales","LVA","Latvia","2017","2017",9.5,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","ATCPTTMT","% of total sales","LVA","Latvia","2018","2018",9.5,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","ATCPTTMT","% of total sales","LVA","Latvia","2019","2019",9.7,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","ATCPTTMT","% of total sales","LVA","Latvia","2020","2020",9.8,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","ATCPTTMT","% of total sales","LVA","Latvia","2021","2021",10,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","ATCPTTMT","% of total sales","LVA","Latvia","2022","2022",10.1,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","ATCPTTMT","% of total sales","LVA","Latvia","2010","2010",2.1,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","ATCPTTMT","% of total sales","LVA","Latvia","2011","2011",2,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","ATCPTTMT","% of total sales","LVA","Latvia","2012","2012",2,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","ATCPTTMT","% of total sales","LVA","Latvia","2013","2013",2,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","ATCPTTMT","% of total sales","LVA","Latvia","2014","2014",2,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","ATCPTTMT","% of total sales","LVA","Latvia","2015","2015",1.9,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","ATCPTTMT","% of total sales","LVA","Latvia","2016","2016",1.7,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","ATCPTTMT","% of total sales","LVA","Latvia","2017","2017",1.7,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","ATCPTTMT","% of total sales","LVA","Latvia","2018","2018",1.6,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","ATCPTTMT","% of total sales","LVA","Latvia","2019","2019",1.7,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","ATCPTTMT","% of total sales","LVA","Latvia","2020","2020",1.5,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","ATCPTTMT","% of total sales","LVA","Latvia","2021","2021",1.5,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","ATCPTTMT","% of total sales","LVA","Latvia","2022","2022",1.5,"D","Difference in methodology"
+"PATCACID","A02A-Antacids","ATCPTTMT","% of total sales","LVA","Latvia","2010","2010",0.1,"D","Difference in methodology"
+"PATCACID","A02A-Antacids","ATCPTTMT","% of total sales","LVA","Latvia","2011","2011",0.1,"D","Difference in methodology"
+"PATCACID","A02A-Antacids","ATCPTTMT","% of total sales","LVA","Latvia","2012","2012",0.1,"D","Difference in methodology"
+"PATCACID","A02A-Antacids","ATCPTTMT","% of total sales","LVA","Latvia","2013","2013",0.1,"D","Difference in methodology"
+"PATCACID","A02A-Antacids","ATCPTTMT","% of total sales","LVA","Latvia","2014","2014",0.1,"D","Difference in methodology"
+"PATCACID","A02A-Antacids","ATCPTTMT","% of total sales","LVA","Latvia","2015","2015",0.1,"D","Difference in methodology"
+"PATCACID","A02A-Antacids","ATCPTTMT","% of total sales","LVA","Latvia","2016","2016",0.1,"D","Difference in methodology"
+"PATCACID","A02A-Antacids","ATCPTTMT","% of total sales","LVA","Latvia","2017","2017",0.1,"D","Difference in methodology"
+"PATCACID","A02A-Antacids","ATCPTTMT","% of total sales","LVA","Latvia","2018","2018",0.1,"D","Difference in methodology"
+"PATCACID","A02A-Antacids","ATCPTTMT","% of total sales","LVA","Latvia","2019","2019",0.1,"D","Difference in methodology"
+"PATCACID","A02A-Antacids","ATCPTTMT","% of total sales","LVA","Latvia","2020","2020",0.1,"D","Difference in methodology"
+"PATCACID","A02A-Antacids","ATCPTTMT","% of total sales","LVA","Latvia","2021","2021",0.1,"D","Difference in methodology"
+"PATCACID","A02A-Antacids","ATCPTTMT","% of total sales","LVA","Latvia","2022","2022",0.1,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","ATCPTTMT","% of total sales","LVA","Latvia","2010","2010",2.6,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","ATCPTTMT","% of total sales","LVA","Latvia","2011","2011",2.7,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","ATCPTTMT","% of total sales","LVA","Latvia","2012","2012",2.6,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","ATCPTTMT","% of total sales","LVA","Latvia","2013","2013",2.2,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","ATCPTTMT","% of total sales","LVA","Latvia","2014","2014",1.8,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","ATCPTTMT","% of total sales","LVA","Latvia","2015","2015",1.6,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","ATCPTTMT","% of total sales","LVA","Latvia","2016","2016",1.5,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","ATCPTTMT","% of total sales","LVA","Latvia","2017","2017",1.6,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","ATCPTTMT","% of total sales","LVA","Latvia","2018","2018",1.6,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","ATCPTTMT","% of total sales","LVA","Latvia","2019","2019",1.9,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","ATCPTTMT","% of total sales","LVA","Latvia","2020","2020",1.9,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","ATCPTTMT","% of total sales","LVA","Latvia","2021","2021",2,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","ATCPTTMT","% of total sales","LVA","Latvia","2022","2022",2,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","ATCPTTMT","% of total sales","LVA","Latvia","2010","2010",2.6,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","ATCPTTMT","% of total sales","LVA","Latvia","2011","2011",2.6,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","ATCPTTMT","% of total sales","LVA","Latvia","2012","2012",2.5,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","ATCPTTMT","% of total sales","LVA","Latvia","2013","2013",2.4,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","ATCPTTMT","% of total sales","LVA","Latvia","2014","2014",2.3,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","ATCPTTMT","% of total sales","LVA","Latvia","2015","2015",2.3,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","ATCPTTMT","% of total sales","LVA","Latvia","2016","2016",2.1,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","ATCPTTMT","% of total sales","LVA","Latvia","2017","2017",2.1,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","ATCPTTMT","% of total sales","LVA","Latvia","2018","2018",2.1,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","ATCPTTMT","% of total sales","LVA","Latvia","2019","2019",2.2,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","ATCPTTMT","% of total sales","LVA","Latvia","2020","2020",2.3,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","ATCPTTMT","% of total sales","LVA","Latvia","2021","2021",2.8,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","ATCPTTMT","% of total sales","LVA","Latvia","2022","2022",3.1,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","ATCPTTMT","% of total sales","LVA","Latvia","2010","2010",1.7,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","ATCPTTMT","% of total sales","LVA","Latvia","2011","2011",1.7,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","ATCPTTMT","% of total sales","LVA","Latvia","2012","2012",1.9,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","ATCPTTMT","% of total sales","LVA","Latvia","2013","2013",2,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","ATCPTTMT","% of total sales","LVA","Latvia","2014","2014",1.8,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","ATCPTTMT","% of total sales","LVA","Latvia","2015","2015",1.8,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","ATCPTTMT","% of total sales","LVA","Latvia","2016","2016",1.6,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","ATCPTTMT","% of total sales","LVA","Latvia","2017","2017",1.6,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","ATCPTTMT","% of total sales","LVA","Latvia","2018","2018",1.5,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","ATCPTTMT","% of total sales","LVA","Latvia","2019","2019",1.5,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","ATCPTTMT","% of total sales","LVA","Latvia","2020","2020",1.4,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","ATCPTTMT","% of total sales","LVA","Latvia","2021","2021",1.4,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","ATCPTTMT","% of total sales","LVA","Latvia","2022","2022",1.2,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","ATCPTTMT","% of total sales","LVA","Latvia","2010","2010",1.5,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","ATCPTTMT","% of total sales","LVA","Latvia","2011","2011",1.5,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","ATCPTTMT","% of total sales","LVA","Latvia","2012","2012",1.6,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","ATCPTTMT","% of total sales","LVA","Latvia","2013","2013",1.5,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","ATCPTTMT","% of total sales","LVA","Latvia","2014","2014",1.5,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","ATCPTTMT","% of total sales","LVA","Latvia","2015","2015",1.5,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","ATCPTTMT","% of total sales","LVA","Latvia","2016","2016",1.4,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","ATCPTTMT","% of total sales","LVA","Latvia","2017","2017",1.3,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","ATCPTTMT","% of total sales","LVA","Latvia","2018","2018",1.3,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","ATCPTTMT","% of total sales","LVA","Latvia","2019","2019",1.4,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","ATCPTTMT","% of total sales","LVA","Latvia","2020","2020",1.5,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","ATCPTTMT","% of total sales","LVA","Latvia","2021","2021",1.5,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","ATCPTTMT","% of total sales","LVA","Latvia","2022","2022",1.4,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","ATCPTTMT","% of total sales","LVA","Latvia","2010","2010",2.4,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","ATCPTTMT","% of total sales","LVA","Latvia","2011","2011",2.4,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","ATCPTTMT","% of total sales","LVA","Latvia","2012","2012",2.4,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","ATCPTTMT","% of total sales","LVA","Latvia","2013","2013",2.4,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","ATCPTTMT","% of total sales","LVA","Latvia","2014","2014",2.4,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","ATCPTTMT","% of total sales","LVA","Latvia","2015","2015",2.3,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","ATCPTTMT","% of total sales","LVA","Latvia","2016","2016",2.1,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","ATCPTTMT","% of total sales","LVA","Latvia","2017","2017",2,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","ATCPTTMT","% of total sales","LVA","Latvia","2018","2018",1.8,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","ATCPTTMT","% of total sales","LVA","Latvia","2019","2019",1.7,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","ATCPTTMT","% of total sales","LVA","Latvia","2020","2020",1.4,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","ATCPTTMT","% of total sales","LVA","Latvia","2021","2021",1.4,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","ATCPTTMT","% of total sales","LVA","Latvia","2022","2022",1.2,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","ATCPTTMT","% of total sales","LVA","Latvia","2010","2010",0.8,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","ATCPTTMT","% of total sales","LVA","Latvia","2011","2011",0.8,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","ATCPTTMT","% of total sales","LVA","Latvia","2012","2012",0.8,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","ATCPTTMT","% of total sales","LVA","Latvia","2013","2013",0.7,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","ATCPTTMT","% of total sales","LVA","Latvia","2014","2014",0.7,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","ATCPTTMT","% of total sales","LVA","Latvia","2015","2015",0.8,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","ATCPTTMT","% of total sales","LVA","Latvia","2016","2016",0.7,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","ATCPTTMT","% of total sales","LVA","Latvia","2017","2017",0.7,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","ATCPTTMT","% of total sales","LVA","Latvia","2018","2018",0.7,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","ATCPTTMT","% of total sales","LVA","Latvia","2019","2019",0.7,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","ATCPTTMT","% of total sales","LVA","Latvia","2020","2020",0.7,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","ATCPTTMT","% of total sales","LVA","Latvia","2021","2021",0.7,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","ATCPTTMT","% of total sales","LVA","Latvia","2022","2022",0.8,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","ATCPTTMT","% of total sales","LVA","Latvia","2010","2010",6.6,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","ATCPTTMT","% of total sales","LVA","Latvia","2011","2011",6.6,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","ATCPTTMT","% of total sales","LVA","Latvia","2012","2012",6.6,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","ATCPTTMT","% of total sales","LVA","Latvia","2013","2013",6.5,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","ATCPTTMT","% of total sales","LVA","Latvia","2014","2014",6.6,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","ATCPTTMT","% of total sales","LVA","Latvia","2015","2015",6.6,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","ATCPTTMT","% of total sales","LVA","Latvia","2016","2016",6.2,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","ATCPTTMT","% of total sales","LVA","Latvia","2017","2017",6.3,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","ATCPTTMT","% of total sales","LVA","Latvia","2018","2018",6.2,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","ATCPTTMT","% of total sales","LVA","Latvia","2019","2019",6.8,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","ATCPTTMT","% of total sales","LVA","Latvia","2020","2020",6.5,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","ATCPTTMT","% of total sales","LVA","Latvia","2021","2021",6.8,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","ATCPTTMT","% of total sales","LVA","Latvia","2022","2022",6.8,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","ATCPTTMT","% of total sales","LVA","Latvia","2010","2010",18.9,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","ATCPTTMT","% of total sales","LVA","Latvia","2011","2011",18.6,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","ATCPTTMT","% of total sales","LVA","Latvia","2012","2012",18.6,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","ATCPTTMT","% of total sales","LVA","Latvia","2013","2013",18,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","ATCPTTMT","% of total sales","LVA","Latvia","2014","2014",17.2,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","ATCPTTMT","% of total sales","LVA","Latvia","2015","2015",16.2,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","ATCPTTMT","% of total sales","LVA","Latvia","2016","2016",14.9,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","ATCPTTMT","% of total sales","LVA","Latvia","2017","2017",14.5,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","ATCPTTMT","% of total sales","LVA","Latvia","2018","2018",13.8,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","ATCPTTMT","% of total sales","LVA","Latvia","2019","2019",13.9,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","ATCPTTMT","% of total sales","LVA","Latvia","2020","2020",12.9,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","ATCPTTMT","% of total sales","LVA","Latvia","2021","2021",12.6,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","ATCPTTMT","% of total sales","LVA","Latvia","2022","2022",11.5,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","ATCPTTMT","% of total sales","LVA","Latvia","2010","2010",1.5,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","ATCPTTMT","% of total sales","LVA","Latvia","2011","2011",1.3,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","ATCPTTMT","% of total sales","LVA","Latvia","2012","2012",1.2,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","ATCPTTMT","% of total sales","LVA","Latvia","2013","2013",1.1,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","ATCPTTMT","% of total sales","LVA","Latvia","2014","2014",1,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","ATCPTTMT","% of total sales","LVA","Latvia","2015","2015",0.9,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","ATCPTTMT","% of total sales","LVA","Latvia","2016","2016",0.7,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","ATCPTTMT","% of total sales","LVA","Latvia","2017","2017",0.6,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","ATCPTTMT","% of total sales","LVA","Latvia","2018","2018",0.5,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","ATCPTTMT","% of total sales","LVA","Latvia","2019","2019",0.5,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","ATCPTTMT","% of total sales","LVA","Latvia","2020","2020",0.4,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","ATCPTTMT","% of total sales","LVA","Latvia","2021","2021",0.4,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","ATCPTTMT","% of total sales","LVA","Latvia","2022","2022",0.3,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","ATCPTTMT","% of total sales","LVA","Latvia","2010","2010",0.9,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","ATCPTTMT","% of total sales","LVA","Latvia","2011","2011",1,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","ATCPTTMT","% of total sales","LVA","Latvia","2012","2012",1,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","ATCPTTMT","% of total sales","LVA","Latvia","2013","2013",1,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","ATCPTTMT","% of total sales","LVA","Latvia","2014","2014",1,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","ATCPTTMT","% of total sales","LVA","Latvia","2015","2015",1,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","ATCPTTMT","% of total sales","LVA","Latvia","2016","2016",1,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","ATCPTTMT","% of total sales","LVA","Latvia","2017","2017",1,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","ATCPTTMT","% of total sales","LVA","Latvia","2018","2018",0.9,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","ATCPTTMT","% of total sales","LVA","Latvia","2019","2019",0.9,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","ATCPTTMT","% of total sales","LVA","Latvia","2020","2020",0.8,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","ATCPTTMT","% of total sales","LVA","Latvia","2021","2021",0.7,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","ATCPTTMT","% of total sales","LVA","Latvia","2022","2022",0.6,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","ATCPTTMT","% of total sales","LVA","Latvia","2010","2010",4.5,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","ATCPTTMT","% of total sales","LVA","Latvia","2011","2011",4.5,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","ATCPTTMT","% of total sales","LVA","Latvia","2012","2012",4.4,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","ATCPTTMT","% of total sales","LVA","Latvia","2013","2013",4.5,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","ATCPTTMT","% of total sales","LVA","Latvia","2014","2014",4.5,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","ATCPTTMT","% of total sales","LVA","Latvia","2015","2015",4.3,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","ATCPTTMT","% of total sales","LVA","Latvia","2016","2016",3.8,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","ATCPTTMT","% of total sales","LVA","Latvia","2017","2017",3.8,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","ATCPTTMT","% of total sales","LVA","Latvia","2018","2018",3.6,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","ATCPTTMT","% of total sales","LVA","Latvia","2019","2019",3.6,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","ATCPTTMT","% of total sales","LVA","Latvia","2020","2020",3.2,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","ATCPTTMT","% of total sales","LVA","Latvia","2021","2021",3.2,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","ATCPTTMT","% of total sales","LVA","Latvia","2022","2022",3.1,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","ATCPTTMT","% of total sales","LVA","Latvia","2010","2010",9.3,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","ATCPTTMT","% of total sales","LVA","Latvia","2011","2011",9.2,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","ATCPTTMT","% of total sales","LVA","Latvia","2012","2012",9.9,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","ATCPTTMT","% of total sales","LVA","Latvia","2013","2013",10.4,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","ATCPTTMT","% of total sales","LVA","Latvia","2014","2014",9.9,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","ATCPTTMT","% of total sales","LVA","Latvia","2015","2015",10.6,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","ATCPTTMT","% of total sales","LVA","Latvia","2016","2016",15,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","ATCPTTMT","% of total sales","LVA","Latvia","2017","2017",15.4,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","ATCPTTMT","% of total sales","LVA","Latvia","2018","2018",15.8,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","ATCPTTMT","% of total sales","LVA","Latvia","2019","2019",13,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","ATCPTTMT","% of total sales","LVA","Latvia","2020","2020",13.9,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","ATCPTTMT","% of total sales","LVA","Latvia","2021","2021",11.2,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","ATCPTTMT","% of total sales","LVA","Latvia","2022","2022",10.9,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","ATCPTTMT","% of total sales","LVA","Latvia","2010","2010",5.5,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","ATCPTTMT","% of total sales","LVA","Latvia","2011","2011",5.8,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","ATCPTTMT","% of total sales","LVA","Latvia","2012","2012",5.7,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","ATCPTTMT","% of total sales","LVA","Latvia","2013","2013",5.6,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","ATCPTTMT","% of total sales","LVA","Latvia","2014","2014",5.7,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","ATCPTTMT","% of total sales","LVA","Latvia","2015","2015",6,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","ATCPTTMT","% of total sales","LVA","Latvia","2016","2016",5.7,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","ATCPTTMT","% of total sales","LVA","Latvia","2017","2017",5.7,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","ATCPTTMT","% of total sales","LVA","Latvia","2018","2018",5.5,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","ATCPTTMT","% of total sales","LVA","Latvia","2019","2019",5.7,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","ATCPTTMT","% of total sales","LVA","Latvia","2020","2020",6,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","ATCPTTMT","% of total sales","LVA","Latvia","2021","2021",6.4,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","ATCPTTMT","% of total sales","LVA","Latvia","2022","2022",6.5,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","ATCPTTMT","% of total sales","LVA","Latvia","2010","2010",0.8,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","ATCPTTMT","% of total sales","LVA","Latvia","2011","2011",0.7,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","ATCPTTMT","% of total sales","LVA","Latvia","2012","2012",0.7,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","ATCPTTMT","% of total sales","LVA","Latvia","2013","2013",0.7,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","ATCPTTMT","% of total sales","LVA","Latvia","2014","2014",0.7,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","ATCPTTMT","% of total sales","LVA","Latvia","2015","2015",0.7,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","ATCPTTMT","% of total sales","LVA","Latvia","2016","2016",0.6,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","ATCPTTMT","% of total sales","LVA","Latvia","2017","2017",0.6,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","ATCPTTMT","% of total sales","LVA","Latvia","2018","2018",0.6,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","ATCPTTMT","% of total sales","LVA","Latvia","2019","2019",0.7,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","ATCPTTMT","% of total sales","LVA","Latvia","2020","2020",0.7,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","ATCPTTMT","% of total sales","LVA","Latvia","2021","2021",0.7,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","ATCPTTMT","% of total sales","LVA","Latvia","2022","2022",0.6,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","ATCPTTMT","% of total sales","LVA","Latvia","2010","2010",7.4,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","ATCPTTMT","% of total sales","LVA","Latvia","2011","2011",7.4,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","ATCPTTMT","% of total sales","LVA","Latvia","2012","2012",7.6,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","ATCPTTMT","% of total sales","LVA","Latvia","2013","2013",7.6,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","ATCPTTMT","% of total sales","LVA","Latvia","2014","2014",7.6,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","ATCPTTMT","% of total sales","LVA","Latvia","2015","2015",7.3,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","ATCPTTMT","% of total sales","LVA","Latvia","2016","2016",7,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","ATCPTTMT","% of total sales","LVA","Latvia","2017","2017",7.1,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","ATCPTTMT","% of total sales","LVA","Latvia","2018","2018",7,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","ATCPTTMT","% of total sales","LVA","Latvia","2019","2019",7,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","ATCPTTMT","% of total sales","LVA","Latvia","2020","2020",6.1,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","ATCPTTMT","% of total sales","LVA","Latvia","2021","2021",6.2,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","ATCPTTMT","% of total sales","LVA","Latvia","2022","2022",8.4,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","ATCPTTMT","% of total sales","LVA","Latvia","2010","2010",3.7,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","ATCPTTMT","% of total sales","LVA","Latvia","2011","2011",3.9,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","ATCPTTMT","% of total sales","LVA","Latvia","2012","2012",3.9,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","ATCPTTMT","% of total sales","LVA","Latvia","2013","2013",4,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","ATCPTTMT","% of total sales","LVA","Latvia","2014","2014",4.1,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","ATCPTTMT","% of total sales","LVA","Latvia","2015","2015",4.2,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","ATCPTTMT","% of total sales","LVA","Latvia","2016","2016",4,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","ATCPTTMT","% of total sales","LVA","Latvia","2017","2017",3.9,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","ATCPTTMT","% of total sales","LVA","Latvia","2018","2018",3.9,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","ATCPTTMT","% of total sales","LVA","Latvia","2019","2019",3.8,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","ATCPTTMT","% of total sales","LVA","Latvia","2020","2020",3.6,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","ATCPTTMT","% of total sales","LVA","Latvia","2021","2021",3.7,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","ATCPTTMT","% of total sales","LVA","Latvia","2022","2022",3.8,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","ATCPTTMT","% of total sales","LVA","Latvia","2010","2010",13,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","ATCPTTMT","% of total sales","LVA","Latvia","2011","2011",13.1,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","ATCPTTMT","% of total sales","LVA","Latvia","2012","2012",13.2,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","ATCPTTMT","% of total sales","LVA","Latvia","2013","2013",13.2,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","ATCPTTMT","% of total sales","LVA","Latvia","2014","2014",13.5,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","ATCPTTMT","% of total sales","LVA","Latvia","2015","2015",13.7,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","ATCPTTMT","% of total sales","LVA","Latvia","2016","2016",13.3,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","ATCPTTMT","% of total sales","LVA","Latvia","2017","2017",12.8,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","ATCPTTMT","% of total sales","LVA","Latvia","2018","2018",12.6,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","ATCPTTMT","% of total sales","LVA","Latvia","2019","2019",13.1,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","ATCPTTMT","% of total sales","LVA","Latvia","2020","2020",13.5,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","ATCPTTMT","% of total sales","LVA","Latvia","2021","2021",14.3,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","ATCPTTMT","% of total sales","LVA","Latvia","2022","2022",14.4,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","ATCPTTMT","% of total sales","LVA","Latvia","2010","2010",0,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","ATCPTTMT","% of total sales","LVA","Latvia","2011","2011",0,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","ATCPTTMT","% of total sales","LVA","Latvia","2012","2012",0,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","ATCPTTMT","% of total sales","LVA","Latvia","2013","2013",0,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","ATCPTTMT","% of total sales","LVA","Latvia","2014","2014",0,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","ATCPTTMT","% of total sales","LVA","Latvia","2015","2015",0,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","ATCPTTMT","% of total sales","LVA","Latvia","2016","2016",0,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","ATCPTTMT","% of total sales","LVA","Latvia","2017","2017",0,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","ATCPTTMT","% of total sales","LVA","Latvia","2018","2018",0,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","ATCPTTMT","% of total sales","LVA","Latvia","2019","2019",0,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","ATCPTTMT","% of total sales","LVA","Latvia","2020","2020",0,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","ATCPTTMT","% of total sales","LVA","Latvia","2021","2021",0,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","ATCPTTMT","% of total sales","LVA","Latvia","2022","2022",0,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","ATCPTTMT","% of total sales","LVA","Latvia","2010","2010",6.5,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","ATCPTTMT","% of total sales","LVA","Latvia","2011","2011",6.3,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","ATCPTTMT","% of total sales","LVA","Latvia","2012","2012",6.4,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","ATCPTTMT","% of total sales","LVA","Latvia","2013","2013",6.3,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","ATCPTTMT","% of total sales","LVA","Latvia","2014","2014",6.1,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","ATCPTTMT","% of total sales","LVA","Latvia","2015","2015",5.6,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","ATCPTTMT","% of total sales","LVA","Latvia","2016","2016",5.1,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","ATCPTTMT","% of total sales","LVA","Latvia","2017","2017",5,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","ATCPTTMT","% of total sales","LVA","Latvia","2018","2018",4.9,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","ATCPTTMT","% of total sales","LVA","Latvia","2019","2019",4.8,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","ATCPTTMT","% of total sales","LVA","Latvia","2020","2020",4.4,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","ATCPTTMT","% of total sales","LVA","Latvia","2021","2021",4.1,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","ATCPTTMT","% of total sales","LVA","Latvia","2022","2022",3.5,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","ATCPTTMT","% of total sales","LVA","Latvia","2010","2010",0.8,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","ATCPTTMT","% of total sales","LVA","Latvia","2011","2011",0.8,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","ATCPTTMT","% of total sales","LVA","Latvia","2012","2012",0.8,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","ATCPTTMT","% of total sales","LVA","Latvia","2013","2013",0.8,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","ATCPTTMT","% of total sales","LVA","Latvia","2014","2014",0.8,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","ATCPTTMT","% of total sales","LVA","Latvia","2015","2015",0.8,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","ATCPTTMT","% of total sales","LVA","Latvia","2016","2016",0.8,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","ATCPTTMT","% of total sales","LVA","Latvia","2017","2017",0.7,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","ATCPTTMT","% of total sales","LVA","Latvia","2018","2018",0.7,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","ATCPTTMT","% of total sales","LVA","Latvia","2019","2019",0.7,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","ATCPTTMT","% of total sales","LVA","Latvia","2020","2020",0.7,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","ATCPTTMT","% of total sales","LVA","Latvia","2021","2021",0.6,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","ATCPTTMT","% of total sales","LVA","Latvia","2022","2022",0.5,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","MLLNCUMT","Million of national currency units","LVA","Latvia","2010","2010",276.2,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","MLLNCUMT","Million of national currency units","LVA","Latvia","2011","2011",289.9,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","MLLNCUMT","Million of national currency units","LVA","Latvia","2012","2012",295.4,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","MLLNCUMT","Million of national currency units","LVA","Latvia","2013","2013",307.6,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","MLLNCUMT","Million of national currency units","LVA","Latvia","2014","2014",315.9,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","MLLNCUMT","Million of national currency units","LVA","Latvia","2015","2015",331.6,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","MLLNCUMT","Million of national currency units","LVA","Latvia","2016","2016",369.2,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","MLLNCUMT","Million of national currency units","LVA","Latvia","2017","2017",392.8,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","MLLNCUMT","Million of national currency units","LVA","Latvia","2018","2018",411.3,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","MLLNCUMT","Million of national currency units","LVA","Latvia","2019","2019",426.6,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","MLLNCUMT","Million of national currency units","LVA","Latvia","2020","2020",447.5,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","MLLNCUMT","Million of national currency units","LVA","Latvia","2021","2021",458.9,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","MLLNCUMT","Million of national currency units","LVA","Latvia","2022","2022",521.9,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","MLLNCUMT","Million of national currency units","LVA","Latvia","2010","2010",35.8,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","MLLNCUMT","Million of national currency units","LVA","Latvia","2011","2011",38.1,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","MLLNCUMT","Million of national currency units","LVA","Latvia","2012","2012",38.9,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","MLLNCUMT","Million of national currency units","LVA","Latvia","2013","2013",40.5,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","MLLNCUMT","Million of national currency units","LVA","Latvia","2014","2014",42.6,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","MLLNCUMT","Million of national currency units","LVA","Latvia","2015","2015",45.6,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","MLLNCUMT","Million of national currency units","LVA","Latvia","2016","2016",49.1,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","MLLNCUMT","Million of national currency units","LVA","Latvia","2017","2017",50.4,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","MLLNCUMT","Million of national currency units","LVA","Latvia","2018","2018",52,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","MLLNCUMT","Million of national currency units","LVA","Latvia","2019","2019",56,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","MLLNCUMT","Million of national currency units","LVA","Latvia","2020","2020",60.2,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","MLLNCUMT","Million of national currency units","LVA","Latvia","2021","2021",65.5,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","MLLNCUMT","Million of national currency units","LVA","Latvia","2022","2022",75.2,"D","Difference in methodology"
+"PATCACID","A02A-Antacids","MLLNCUMT","Million of national currency units","LVA","Latvia","2010","2010",0.4,"D","Difference in methodology"
+"PATCACID","A02A-Antacids","MLLNCUMT","Million of national currency units","LVA","Latvia","2011","2011",0.4,"D","Difference in methodology"
+"PATCACID","A02A-Antacids","MLLNCUMT","Million of national currency units","LVA","Latvia","2012","2012",0.4,"D","Difference in methodology"
+"PATCACID","A02A-Antacids","MLLNCUMT","Million of national currency units","LVA","Latvia","2013","2013",0.4,"D","Difference in methodology"
+"PATCACID","A02A-Antacids","MLLNCUMT","Million of national currency units","LVA","Latvia","2014","2014",0.4,"D","Difference in methodology"
+"PATCACID","A02A-Antacids","MLLNCUMT","Million of national currency units","LVA","Latvia","2015","2015",0.4,"D","Difference in methodology"
+"PATCACID","A02A-Antacids","MLLNCUMT","Million of national currency units","LVA","Latvia","2016","2016",0.4,"D","Difference in methodology"
+"PATCACID","A02A-Antacids","MLLNCUMT","Million of national currency units","LVA","Latvia","2017","2017",0.4,"D","Difference in methodology"
+"PATCACID","A02A-Antacids","MLLNCUMT","Million of national currency units","LVA","Latvia","2018","2018",0.5,"D","Difference in methodology"
+"PATCACID","A02A-Antacids","MLLNCUMT","Million of national currency units","LVA","Latvia","2019","2019",0.5,"D","Difference in methodology"
+"PATCACID","A02A-Antacids","MLLNCUMT","Million of national currency units","LVA","Latvia","2020","2020",0.6,"D","Difference in methodology"
+"PATCACID","A02A-Antacids","MLLNCUMT","Million of national currency units","LVA","Latvia","2021","2021",0.6,"D","Difference in methodology"
+"PATCACID","A02A-Antacids","MLLNCUMT","Million of national currency units","LVA","Latvia","2022","2022",0.7,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MLLNCUMT","Million of national currency units","LVA","Latvia","2010","2010",4.2,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MLLNCUMT","Million of national currency units","LVA","Latvia","2011","2011",4.4,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MLLNCUMT","Million of national currency units","LVA","Latvia","2012","2012",4.6,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MLLNCUMT","Million of national currency units","LVA","Latvia","2013","2013",4.7,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MLLNCUMT","Million of national currency units","LVA","Latvia","2014","2014",4.9,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MLLNCUMT","Million of national currency units","LVA","Latvia","2015","2015",4.9,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MLLNCUMT","Million of national currency units","LVA","Latvia","2016","2016",5.1,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MLLNCUMT","Million of national currency units","LVA","Latvia","2017","2017",5.2,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MLLNCUMT","Million of national currency units","LVA","Latvia","2018","2018",5.3,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MLLNCUMT","Million of national currency units","LVA","Latvia","2019","2019",6.1,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MLLNCUMT","Million of national currency units","LVA","Latvia","2020","2020",6.6,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MLLNCUMT","Million of national currency units","LVA","Latvia","2021","2021",6.8,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MLLNCUMT","Million of national currency units","LVA","Latvia","2022","2022",7.2,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","MLLNCUMT","Million of national currency units","LVA","Latvia","2010","2010",15.2,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","MLLNCUMT","Million of national currency units","LVA","Latvia","2011","2011",16.8,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","MLLNCUMT","Million of national currency units","LVA","Latvia","2012","2012",16.7,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","MLLNCUMT","Million of national currency units","LVA","Latvia","2013","2013",17.2,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","MLLNCUMT","Million of national currency units","LVA","Latvia","2014","2014",18.1,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","MLLNCUMT","Million of national currency units","LVA","Latvia","2015","2015",19.8,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","MLLNCUMT","Million of national currency units","LVA","Latvia","2016","2016",21.1,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","MLLNCUMT","Million of national currency units","LVA","Latvia","2017","2017",22.4,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","MLLNCUMT","Million of national currency units","LVA","Latvia","2018","2018",22.6,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","MLLNCUMT","Million of national currency units","LVA","Latvia","2019","2019",24.3,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","MLLNCUMT","Million of national currency units","LVA","Latvia","2020","2020",27,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","MLLNCUMT","Million of national currency units","LVA","Latvia","2021","2021",29.2,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","MLLNCUMT","Million of national currency units","LVA","Latvia","2022","2022",34,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","MLLNCUMT","Million of national currency units","LVA","Latvia","2010","2010",18.7,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","MLLNCUMT","Million of national currency units","LVA","Latvia","2011","2011",18.9,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","MLLNCUMT","Million of national currency units","LVA","Latvia","2012","2012",19.5,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","MLLNCUMT","Million of national currency units","LVA","Latvia","2013","2013",20.5,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","MLLNCUMT","Million of national currency units","LVA","Latvia","2014","2014",22.1,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","MLLNCUMT","Million of national currency units","LVA","Latvia","2015","2015",23.1,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","MLLNCUMT","Million of national currency units","LVA","Latvia","2016","2016",24.6,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","MLLNCUMT","Million of national currency units","LVA","Latvia","2017","2017",28.3,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","MLLNCUMT","Million of national currency units","LVA","Latvia","2018","2018",31.6,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","MLLNCUMT","Million of national currency units","LVA","Latvia","2019","2019",38.3,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","MLLNCUMT","Million of national currency units","LVA","Latvia","2020","2020",40,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","MLLNCUMT","Million of national currency units","LVA","Latvia","2021","2021",43.3,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","MLLNCUMT","Million of national currency units","LVA","Latvia","2022","2022",45.9,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","MLLNCUMT","Million of national currency units","LVA","Latvia","2010","2010",52.3,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","MLLNCUMT","Million of national currency units","LVA","Latvia","2011","2011",53.9,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","MLLNCUMT","Million of national currency units","LVA","Latvia","2012","2012",55.1,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","MLLNCUMT","Million of national currency units","LVA","Latvia","2013","2013",55.2,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","MLLNCUMT","Million of national currency units","LVA","Latvia","2014","2014",54.2,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","MLLNCUMT","Million of national currency units","LVA","Latvia","2015","2015",53.6,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","MLLNCUMT","Million of national currency units","LVA","Latvia","2016","2016",54.9,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","MLLNCUMT","Million of national currency units","LVA","Latvia","2017","2017",56.8,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","MLLNCUMT","Million of national currency units","LVA","Latvia","2018","2018",56.9,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","MLLNCUMT","Million of national currency units","LVA","Latvia","2019","2019",59.2,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","MLLNCUMT","Million of national currency units","LVA","Latvia","2020","2020",57.6,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","MLLNCUMT","Million of national currency units","LVA","Latvia","2021","2021",58,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","MLLNCUMT","Million of national currency units","LVA","Latvia","2022","2022",60.1,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","MLLNCUMT","Million of national currency units","LVA","Latvia","2010","2010",0.1,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","MLLNCUMT","Million of national currency units","LVA","Latvia","2011","2011",0.1,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","MLLNCUMT","Million of national currency units","LVA","Latvia","2012","2012",0.1,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","MLLNCUMT","Million of national currency units","LVA","Latvia","2013","2013",0.1,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","MLLNCUMT","Million of national currency units","LVA","Latvia","2014","2014",0.1,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","MLLNCUMT","Million of national currency units","LVA","Latvia","2015","2015",0.1,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","MLLNCUMT","Million of national currency units","LVA","Latvia","2016","2016",0.1,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","MLLNCUMT","Million of national currency units","LVA","Latvia","2017","2017",0.1,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","MLLNCUMT","Million of national currency units","LVA","Latvia","2018","2018",0.1,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","MLLNCUMT","Million of national currency units","LVA","Latvia","2019","2019",0.1,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","MLLNCUMT","Million of national currency units","LVA","Latvia","2020","2020",0.1,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","MLLNCUMT","Million of national currency units","LVA","Latvia","2021","2021",0.1,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","MLLNCUMT","Million of national currency units","LVA","Latvia","2022","2022",0.1,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MLLNCUMT","Million of national currency units","LVA","Latvia","2010","2010",0.4,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MLLNCUMT","Million of national currency units","LVA","Latvia","2011","2011",0.5,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MLLNCUMT","Million of national currency units","LVA","Latvia","2012","2012",0.5,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MLLNCUMT","Million of national currency units","LVA","Latvia","2013","2013",0.6,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MLLNCUMT","Million of national currency units","LVA","Latvia","2014","2014",0.6,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MLLNCUMT","Million of national currency units","LVA","Latvia","2015","2015",0.7,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MLLNCUMT","Million of national currency units","LVA","Latvia","2016","2016",0.8,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MLLNCUMT","Million of national currency units","LVA","Latvia","2017","2017",0.8,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MLLNCUMT","Million of national currency units","LVA","Latvia","2018","2018",0.9,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MLLNCUMT","Million of national currency units","LVA","Latvia","2019","2019",1,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MLLNCUMT","Million of national currency units","LVA","Latvia","2020","2020",1.1,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MLLNCUMT","Million of national currency units","LVA","Latvia","2021","2021",1.1,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MLLNCUMT","Million of national currency units","LVA","Latvia","2022","2022",1.6,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","MLLNCUMT","Million of national currency units","LVA","Latvia","2010","2010",2.6,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","MLLNCUMT","Million of national currency units","LVA","Latvia","2011","2011",2.9,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","MLLNCUMT","Million of national currency units","LVA","Latvia","2012","2012",3,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","MLLNCUMT","Million of national currency units","LVA","Latvia","2013","2013",3,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","MLLNCUMT","Million of national currency units","LVA","Latvia","2014","2014",3.1,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","MLLNCUMT","Million of national currency units","LVA","Latvia","2015","2015",3.3,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","MLLNCUMT","Million of national currency units","LVA","Latvia","2016","2016",3.6,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","MLLNCUMT","Million of national currency units","LVA","Latvia","2017","2017",3.8,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","MLLNCUMT","Million of national currency units","LVA","Latvia","2018","2018",3.9,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","MLLNCUMT","Million of national currency units","LVA","Latvia","2019","2019",3.7,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","MLLNCUMT","Million of national currency units","LVA","Latvia","2020","2020",3.7,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","MLLNCUMT","Million of national currency units","LVA","Latvia","2021","2021",3.1,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","MLLNCUMT","Million of national currency units","LVA","Latvia","2022","2022",3,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","MLLNCUMT","Million of national currency units","LVA","Latvia","2010","2010",2.1,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","MLLNCUMT","Million of national currency units","LVA","Latvia","2011","2011",2.1,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","MLLNCUMT","Million of national currency units","LVA","Latvia","2012","2012",2.2,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","MLLNCUMT","Million of national currency units","LVA","Latvia","2013","2013",2.2,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","MLLNCUMT","Million of national currency units","LVA","Latvia","2014","2014",2.2,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","MLLNCUMT","Million of national currency units","LVA","Latvia","2015","2015",2.2,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","MLLNCUMT","Million of national currency units","LVA","Latvia","2016","2016",2.3,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","MLLNCUMT","Million of national currency units","LVA","Latvia","2017","2017",2.5,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","MLLNCUMT","Million of national currency units","LVA","Latvia","2018","2018",2.6,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","MLLNCUMT","Million of national currency units","LVA","Latvia","2019","2019",2.9,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","MLLNCUMT","Million of national currency units","LVA","Latvia","2020","2020",3,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","MLLNCUMT","Million of national currency units","LVA","Latvia","2021","2021",3.1,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","MLLNCUMT","Million of national currency units","LVA","Latvia","2022","2022",3.1,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","MLLNCUMT","Million of national currency units","LVA","Latvia","2010","2010",6.5,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","MLLNCUMT","Million of national currency units","LVA","Latvia","2011","2011",6.9,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","MLLNCUMT","Million of national currency units","LVA","Latvia","2012","2012",7,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","MLLNCUMT","Million of national currency units","LVA","Latvia","2013","2013",7.2,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","MLLNCUMT","Million of national currency units","LVA","Latvia","2014","2014",7.5,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","MLLNCUMT","Million of national currency units","LVA","Latvia","2015","2015",7.6,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","MLLNCUMT","Million of national currency units","LVA","Latvia","2016","2016",7.9,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","MLLNCUMT","Million of national currency units","LVA","Latvia","2017","2017",7.9,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","MLLNCUMT","Million of national currency units","LVA","Latvia","2018","2018",7.2,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","MLLNCUMT","Million of national currency units","LVA","Latvia","2019","2019",7.1,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","MLLNCUMT","Million of national currency units","LVA","Latvia","2020","2020",6.4,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","MLLNCUMT","Million of national currency units","LVA","Latvia","2021","2021",6.3,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","MLLNCUMT","Million of national currency units","LVA","Latvia","2022","2022",6.2,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","MLLNCUMT","Million of national currency units","LVA","Latvia","2010","2010",4,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","MLLNCUMT","Million of national currency units","LVA","Latvia","2011","2011",3.9,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","MLLNCUMT","Million of national currency units","LVA","Latvia","2012","2012",3.7,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","MLLNCUMT","Million of national currency units","LVA","Latvia","2013","2013",3.4,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","MLLNCUMT","Million of national currency units","LVA","Latvia","2014","2014",3.2,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","MLLNCUMT","Million of national currency units","LVA","Latvia","2015","2015",2.9,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","MLLNCUMT","Million of national currency units","LVA","Latvia","2016","2016",2.6,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","MLLNCUMT","Million of national currency units","LVA","Latvia","2017","2017",2.4,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","MLLNCUMT","Million of national currency units","LVA","Latvia","2018","2018",2.2,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","MLLNCUMT","Million of national currency units","LVA","Latvia","2019","2019",2.1,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","MLLNCUMT","Million of national currency units","LVA","Latvia","2020","2020",1.9,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","MLLNCUMT","Million of national currency units","LVA","Latvia","2021","2021",1.7,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","MLLNCUMT","Million of national currency units","LVA","Latvia","2022","2022",1.6,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MLLNCUMT","Million of national currency units","LVA","Latvia","2010","2010",18,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MLLNCUMT","Million of national currency units","LVA","Latvia","2011","2011",18.4,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MLLNCUMT","Million of national currency units","LVA","Latvia","2012","2012",19,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MLLNCUMT","Million of national currency units","LVA","Latvia","2013","2013",19.5,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MLLNCUMT","Million of national currency units","LVA","Latvia","2014","2014",19.1,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MLLNCUMT","Million of national currency units","LVA","Latvia","2015","2015",18.7,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MLLNCUMT","Million of national currency units","LVA","Latvia","2016","2016",18.8,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MLLNCUMT","Million of national currency units","LVA","Latvia","2017","2017",19.8,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MLLNCUMT","Million of national currency units","LVA","Latvia","2018","2018",20.1,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MLLNCUMT","Million of national currency units","LVA","Latvia","2019","2019",20.6,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MLLNCUMT","Million of national currency units","LVA","Latvia","2020","2020",19.7,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MLLNCUMT","Million of national currency units","LVA","Latvia","2021","2021",18.8,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MLLNCUMT","Million of national currency units","LVA","Latvia","2022","2022",18.3,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","MLLNCUMT","Million of national currency units","LVA","Latvia","2010","2010",7.3,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","MLLNCUMT","Million of national currency units","LVA","Latvia","2011","2011",7.7,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","MLLNCUMT","Million of national currency units","LVA","Latvia","2012","2012",7.6,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","MLLNCUMT","Million of national currency units","LVA","Latvia","2013","2013",6.9,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","MLLNCUMT","Million of national currency units","LVA","Latvia","2014","2014",5.6,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","MLLNCUMT","Million of national currency units","LVA","Latvia","2015","2015",5.3,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","MLLNCUMT","Million of national currency units","LVA","Latvia","2016","2016",5.6,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","MLLNCUMT","Million of national currency units","LVA","Latvia","2017","2017",6.2,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","MLLNCUMT","Million of national currency units","LVA","Latvia","2018","2018",6.6,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","MLLNCUMT","Million of national currency units","LVA","Latvia","2019","2019",7.9,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","MLLNCUMT","Million of national currency units","LVA","Latvia","2020","2020",8.5,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","MLLNCUMT","Million of national currency units","LVA","Latvia","2021","2021",9.4,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","MLLNCUMT","Million of national currency units","LVA","Latvia","2022","2022",10.6,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","MLLNCUMT","Million of national currency units","LVA","Latvia","2010","2010",12.4,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","MLLNCUMT","Million of national currency units","LVA","Latvia","2011","2011",13,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","MLLNCUMT","Million of national currency units","LVA","Latvia","2012","2012",13.1,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","MLLNCUMT","Million of national currency units","LVA","Latvia","2013","2013",13.8,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","MLLNCUMT","Million of national currency units","LVA","Latvia","2014","2014",14.3,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","MLLNCUMT","Million of national currency units","LVA","Latvia","2015","2015",14.2,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","MLLNCUMT","Million of national currency units","LVA","Latvia","2016","2016",14.2,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","MLLNCUMT","Million of national currency units","LVA","Latvia","2017","2017",14.9,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","MLLNCUMT","Million of national currency units","LVA","Latvia","2018","2018",14.7,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","MLLNCUMT","Million of national currency units","LVA","Latvia","2019","2019",15.2,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","MLLNCUMT","Million of national currency units","LVA","Latvia","2020","2020",14.3,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","MLLNCUMT","Million of national currency units","LVA","Latvia","2021","2021",14.5,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","MLLNCUMT","Million of national currency units","LVA","Latvia","2022","2022",16.3,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MLLNCUMT","Million of national currency units","LVA","Latvia","2010","2010",5.7,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MLLNCUMT","Million of national currency units","LVA","Latvia","2011","2011",5.9,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MLLNCUMT","Million of national currency units","LVA","Latvia","2012","2012",5.9,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MLLNCUMT","Million of national currency units","LVA","Latvia","2013","2013",6.1,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MLLNCUMT","Million of national currency units","LVA","Latvia","2014","2014",6.2,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MLLNCUMT","Million of national currency units","LVA","Latvia","2015","2015",6.2,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MLLNCUMT","Million of national currency units","LVA","Latvia","2016","2016",6.3,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MLLNCUMT","Million of national currency units","LVA","Latvia","2017","2017",6.5,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MLLNCUMT","Million of national currency units","LVA","Latvia","2018","2018",6.6,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MLLNCUMT","Million of national currency units","LVA","Latvia","2019","2019",7.1,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MLLNCUMT","Million of national currency units","LVA","Latvia","2020","2020",6.6,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MLLNCUMT","Million of national currency units","LVA","Latvia","2021","2021",6.8,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MLLNCUMT","Million of national currency units","LVA","Latvia","2022","2022",8.1,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MLLNCUMT","Million of national currency units","LVA","Latvia","2010","2010",4.6,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MLLNCUMT","Million of national currency units","LVA","Latvia","2011","2011",5,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MLLNCUMT","Million of national currency units","LVA","Latvia","2012","2012",5.5,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MLLNCUMT","Million of national currency units","LVA","Latvia","2013","2013",6.1,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MLLNCUMT","Million of national currency units","LVA","Latvia","2014","2014",5.7,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MLLNCUMT","Million of national currency units","LVA","Latvia","2015","2015",5.9,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MLLNCUMT","Million of national currency units","LVA","Latvia","2016","2016",6,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MLLNCUMT","Million of national currency units","LVA","Latvia","2017","2017",6.1,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MLLNCUMT","Million of national currency units","LVA","Latvia","2018","2018",6.3,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MLLNCUMT","Million of national currency units","LVA","Latvia","2019","2019",6.5,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MLLNCUMT","Million of national currency units","LVA","Latvia","2020","2020",6.4,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MLLNCUMT","Million of national currency units","LVA","Latvia","2021","2021",6.5,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MLLNCUMT","Million of national currency units","LVA","Latvia","2022","2022",6.2,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","MLLNCUMT","Million of national currency units","LVA","Latvia","2010","2010",25.6,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","MLLNCUMT","Million of national currency units","LVA","Latvia","2011","2011",26.8,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","MLLNCUMT","Million of national currency units","LVA","Latvia","2012","2012",29.3,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","MLLNCUMT","Million of national currency units","LVA","Latvia","2013","2013",32,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","MLLNCUMT","Million of national currency units","LVA","Latvia","2014","2014",31.1,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","MLLNCUMT","Million of national currency units","LVA","Latvia","2015","2015",35.3,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","MLLNCUMT","Million of national currency units","LVA","Latvia","2016","2016",55.5,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","MLLNCUMT","Million of national currency units","LVA","Latvia","2017","2017",60.5,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","MLLNCUMT","Million of national currency units","LVA","Latvia","2018","2018",65.2,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","MLLNCUMT","Million of national currency units","LVA","Latvia","2019","2019",55.4,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","MLLNCUMT","Million of national currency units","LVA","Latvia","2020","2020",62.3,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","MLLNCUMT","Million of national currency units","LVA","Latvia","2021","2021",51.2,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","MLLNCUMT","Million of national currency units","LVA","Latvia","2022","2022",57.1,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","MLLNCUMT","Million of national currency units","LVA","Latvia","2010","2010",9.4,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","MLLNCUMT","Million of national currency units","LVA","Latvia","2011","2011",9.6,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","MLLNCUMT","Million of national currency units","LVA","Latvia","2012","2012",9.5,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","MLLNCUMT","Million of national currency units","LVA","Latvia","2013","2013",9.5,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","MLLNCUMT","Million of national currency units","LVA","Latvia","2014","2014",9.8,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","MLLNCUMT","Million of national currency units","LVA","Latvia","2015","2015",9.9,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","MLLNCUMT","Million of national currency units","LVA","Latvia","2016","2016",10.1,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","MLLNCUMT","Million of national currency units","LVA","Latvia","2017","2017",10.6,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","MLLNCUMT","Million of national currency units","LVA","Latvia","2018","2018",10.3,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","MLLNCUMT","Million of national currency units","LVA","Latvia","2019","2019",10.6,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","MLLNCUMT","Million of national currency units","LVA","Latvia","2020","2020",9.8,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","MLLNCUMT","Million of national currency units","LVA","Latvia","2021","2021",9.7,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","MLLNCUMT","Million of national currency units","LVA","Latvia","2022","2022",10.7,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","MLLNCUMT","Million of national currency units","LVA","Latvia","2010","2010",18.2,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","MLLNCUMT","Million of national currency units","LVA","Latvia","2011","2011",19.1,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","MLLNCUMT","Million of national currency units","LVA","Latvia","2012","2012",19.4,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","MLLNCUMT","Million of national currency units","LVA","Latvia","2013","2013",20.1,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","MLLNCUMT","Million of national currency units","LVA","Latvia","2014","2014",20.8,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","MLLNCUMT","Million of national currency units","LVA","Latvia","2015","2015",21.7,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","MLLNCUMT","Million of national currency units","LVA","Latvia","2016","2016",22.8,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","MLLNCUMT","Million of national currency units","LVA","Latvia","2017","2017",24.6,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","MLLNCUMT","Million of national currency units","LVA","Latvia","2018","2018",25.6,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","MLLNCUMT","Million of national currency units","LVA","Latvia","2019","2019",28.9,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","MLLNCUMT","Million of national currency units","LVA","Latvia","2020","2020",29.1,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","MLLNCUMT","Million of national currency units","LVA","Latvia","2021","2021",31.1,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","MLLNCUMT","Million of national currency units","LVA","Latvia","2022","2022",35.7,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MLLNCUMT","Million of national currency units","LVA","Latvia","2010","2010",10.3,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MLLNCUMT","Million of national currency units","LVA","Latvia","2011","2011",11.2,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MLLNCUMT","Million of national currency units","LVA","Latvia","2012","2012",11.6,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MLLNCUMT","Million of national currency units","LVA","Latvia","2013","2013",12.3,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MLLNCUMT","Million of national currency units","LVA","Latvia","2014","2014",13,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MLLNCUMT","Million of national currency units","LVA","Latvia","2015","2015",13.9,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MLLNCUMT","Million of national currency units","LVA","Latvia","2016","2016",14.9,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MLLNCUMT","Million of national currency units","LVA","Latvia","2017","2017",15.4,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MLLNCUMT","Million of national currency units","LVA","Latvia","2018","2018",15.8,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MLLNCUMT","Million of national currency units","LVA","Latvia","2019","2019",16.3,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MLLNCUMT","Million of national currency units","LVA","Latvia","2020","2020",16.2,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MLLNCUMT","Million of national currency units","LVA","Latvia","2021","2021",16.8,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MLLNCUMT","Million of national currency units","LVA","Latvia","2022","2022",19.6,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","MLLNCUMT","Million of national currency units","LVA","Latvia","2010","2010",33.1,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","MLLNCUMT","Million of national currency units","LVA","Latvia","2011","2011",33.5,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","MLLNCUMT","Million of national currency units","LVA","Latvia","2012","2012",33.5,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","MLLNCUMT","Million of national currency units","LVA","Latvia","2013","2013",33.3,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","MLLNCUMT","Million of national currency units","LVA","Latvia","2014","2014",33.7,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","MLLNCUMT","Million of national currency units","LVA","Latvia","2015","2015",34.7,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","MLLNCUMT","Million of national currency units","LVA","Latvia","2016","2016",35.3,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","MLLNCUMT","Million of national currency units","LVA","Latvia","2017","2017",37.4,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","MLLNCUMT","Million of national currency units","LVA","Latvia","2018","2018",39,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","MLLNCUMT","Million of national currency units","LVA","Latvia","2019","2019",41.5,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","MLLNCUMT","Million of national currency units","LVA","Latvia","2020","2020",43.9,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","MLLNCUMT","Million of national currency units","LVA","Latvia","2021","2021",46,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","MLLNCUMT","Million of national currency units","LVA","Latvia","2022","2022",52.8,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","MLLNCUMT","Million of national currency units","LVA","Latvia","2010","2010",7.2,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","MLLNCUMT","Million of national currency units","LVA","Latvia","2011","2011",7.4,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","MLLNCUMT","Million of national currency units","LVA","Latvia","2012","2012",7.3,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","MLLNCUMT","Million of national currency units","LVA","Latvia","2013","2013",7.4,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","MLLNCUMT","Million of national currency units","LVA","Latvia","2014","2014",7.4,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","MLLNCUMT","Million of national currency units","LVA","Latvia","2015","2015",7.7,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","MLLNCUMT","Million of national currency units","LVA","Latvia","2016","2016",7.9,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","MLLNCUMT","Million of national currency units","LVA","Latvia","2017","2017",8.3,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","MLLNCUMT","Million of national currency units","LVA","Latvia","2018","2018",8.8,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","MLLNCUMT","Million of national currency units","LVA","Latvia","2019","2019",9.5,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","MLLNCUMT","Million of national currency units","LVA","Latvia","2020","2020",10.2,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","MLLNCUMT","Million of national currency units","LVA","Latvia","2021","2021",12.9,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","MLLNCUMT","Million of national currency units","LVA","Latvia","2022","2022",16.3,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","MLLNCUMT","Million of national currency units","LVA","Latvia","2010","2010",2.1,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","MLLNCUMT","Million of national currency units","LVA","Latvia","2011","2011",2.2,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","MLLNCUMT","Million of national currency units","LVA","Latvia","2012","2012",2.4,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","MLLNCUMT","Million of national currency units","LVA","Latvia","2013","2013",2.4,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","MLLNCUMT","Million of national currency units","LVA","Latvia","2014","2014",2.6,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","MLLNCUMT","Million of national currency units","LVA","Latvia","2015","2015",2.7,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","MLLNCUMT","Million of national currency units","LVA","Latvia","2016","2016",2.8,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","MLLNCUMT","Million of national currency units","LVA","Latvia","2017","2017",2.9,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","MLLNCUMT","Million of national currency units","LVA","Latvia","2018","2018",2.9,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","MLLNCUMT","Million of national currency units","LVA","Latvia","2019","2019",3.1,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","MLLNCUMT","Million of national currency units","LVA","Latvia","2020","2020",3.3,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","MLLNCUMT","Million of national currency units","LVA","Latvia","2021","2021",2.5,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","MLLNCUMT","Million of national currency units","LVA","Latvia","2022","2022",2.7,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","MLLNCUMT","Million of national currency units","LVA","Latvia","2010","2010",2.4,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","MLLNCUMT","Million of national currency units","LVA","Latvia","2011","2011",2.5,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","MLLNCUMT","Million of national currency units","LVA","Latvia","2012","2012",2.5,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","MLLNCUMT","Million of national currency units","LVA","Latvia","2013","2013",2.6,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","MLLNCUMT","Million of national currency units","LVA","Latvia","2014","2014",2.7,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","MLLNCUMT","Million of national currency units","LVA","Latvia","2015","2015",2.8,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","MLLNCUMT","Million of national currency units","LVA","Latvia","2016","2016",3,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","MLLNCUMT","Million of national currency units","LVA","Latvia","2017","2017",3.1,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","MLLNCUMT","Million of national currency units","LVA","Latvia","2018","2018",3.2,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","MLLNCUMT","Million of national currency units","LVA","Latvia","2019","2019",3.5,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","MLLNCUMT","Million of national currency units","LVA","Latvia","2020","2020",4,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","MLLNCUMT","Million of national currency units","LVA","Latvia","2021","2021",4.7,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","MLLNCUMT","Million of national currency units","LVA","Latvia","2022","2022",4.9,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","MLLNCUMT","Million of national currency units","LVA","Latvia","2010","2010",2.3,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","MLLNCUMT","Million of national currency units","LVA","Latvia","2011","2011",2.3,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","MLLNCUMT","Million of national currency units","LVA","Latvia","2012","2012",2.3,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","MLLNCUMT","Million of national currency units","LVA","Latvia","2013","2013",2.2,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","MLLNCUMT","Million of national currency units","LVA","Latvia","2014","2014",2.3,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","MLLNCUMT","Million of national currency units","LVA","Latvia","2015","2015",2.5,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","MLLNCUMT","Million of national currency units","LVA","Latvia","2016","2016",2.6,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","MLLNCUMT","Million of national currency units","LVA","Latvia","2017","2017",2.8,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","MLLNCUMT","Million of national currency units","LVA","Latvia","2018","2018",2.8,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","MLLNCUMT","Million of national currency units","LVA","Latvia","2019","2019",3,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","MLLNCUMT","Million of national currency units","LVA","Latvia","2020","2020",3.2,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","MLLNCUMT","Million of national currency units","LVA","Latvia","2021","2021",3.4,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","MLLNCUMT","Million of national currency units","LVA","Latvia","2022","2022",4.1,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","MLLNCUMT","Million of national currency units","LVA","Latvia","2010","2010",20.6,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","MLLNCUMT","Million of national currency units","LVA","Latvia","2011","2011",21.4,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","MLLNCUMT","Million of national currency units","LVA","Latvia","2012","2012",22.3,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","MLLNCUMT","Million of national currency units","LVA","Latvia","2013","2013",23.3,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","MLLNCUMT","Million of national currency units","LVA","Latvia","2014","2014",24,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","MLLNCUMT","Million of national currency units","LVA","Latvia","2015","2015",24.3,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","MLLNCUMT","Million of national currency units","LVA","Latvia","2016","2016",25.7,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","MLLNCUMT","Million of national currency units","LVA","Latvia","2017","2017",27.7,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","MLLNCUMT","Million of national currency units","LVA","Latvia","2018","2018",28.8,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","MLLNCUMT","Million of national currency units","LVA","Latvia","2019","2019",29.9,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","MLLNCUMT","Million of national currency units","LVA","Latvia","2020","2020",27.3,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","MLLNCUMT","Million of national currency units","LVA","Latvia","2021","2021",28.5,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","MLLNCUMT","Million of national currency units","LVA","Latvia","2022","2022",43.7,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MLLNCUMT","Million of national currency units","LVA","Latvia","2010","2010",8.4,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MLLNCUMT","Million of national currency units","LVA","Latvia","2011","2011",8.9,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MLLNCUMT","Million of national currency units","LVA","Latvia","2012","2012",9.1,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MLLNCUMT","Million of national currency units","LVA","Latvia","2013","2013",9.3,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MLLNCUMT","Million of national currency units","LVA","Latvia","2014","2014",9.6,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MLLNCUMT","Million of national currency units","LVA","Latvia","2015","2015",9.2,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MLLNCUMT","Million of national currency units","LVA","Latvia","2016","2016",9.3,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MLLNCUMT","Million of national currency units","LVA","Latvia","2017","2017",9.8,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MLLNCUMT","Million of national currency units","LVA","Latvia","2018","2018",9.5,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MLLNCUMT","Million of national currency units","LVA","Latvia","2019","2019",9.7,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MLLNCUMT","Million of national currency units","LVA","Latvia","2020","2020",9.6,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MLLNCUMT","Million of national currency units","LVA","Latvia","2021","2021",9.6,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MLLNCUMT","Million of national currency units","LVA","Latvia","2022","2022",10.7,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","MTMOTCMT","Million US$ at exchange rate","LVA","Latvia","2010","2010",365.9,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","MTMOTCMT","Million US$ at exchange rate","LVA","Latvia","2011","2011",406.4,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","MTMOTCMT","Million US$ at exchange rate","LVA","Latvia","2012","2012",379.6,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","MTMOTCMT","Million US$ at exchange rate","LVA","Latvia","2013","2013",408.3,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","MTMOTCMT","Million US$ at exchange rate","LVA","Latvia","2014","2014",419.7,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","MTMOTCMT","Million US$ at exchange rate","LVA","Latvia","2015","2015",367.9,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","MTMOTCMT","Million US$ at exchange rate","LVA","Latvia","2016","2016",408.7,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","MTMOTCMT","Million US$ at exchange rate","LVA","Latvia","2017","2017",443.7,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","MTMOTCMT","Million US$ at exchange rate","LVA","Latvia","2018","2018",485.8,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","MTMOTCMT","Million US$ at exchange rate","LVA","Latvia","2019","2019",477.6,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","MTMOTCMT","Million US$ at exchange rate","LVA","Latvia","2020","2020",511.1,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","MTMOTCMT","Million US$ at exchange rate","LVA","Latvia","2021","2021",542.7,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","MTMOTCMT","Million US$ at exchange rate","LVA","Latvia","2022","2022",549.6,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","MTMOTCMT","Million US$ at exchange rate","LVA","Latvia","2010","2010",47.4,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","MTMOTCMT","Million US$ at exchange rate","LVA","Latvia","2011","2011",53.4,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","MTMOTCMT","Million US$ at exchange rate","LVA","Latvia","2012","2012",49.9,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","MTMOTCMT","Million US$ at exchange rate","LVA","Latvia","2013","2013",53.8,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","MTMOTCMT","Million US$ at exchange rate","LVA","Latvia","2014","2014",56.6,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","MTMOTCMT","Million US$ at exchange rate","LVA","Latvia","2015","2015",50.6,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","MTMOTCMT","Million US$ at exchange rate","LVA","Latvia","2016","2016",54.4,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","MTMOTCMT","Million US$ at exchange rate","LVA","Latvia","2017","2017",57,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","MTMOTCMT","Million US$ at exchange rate","LVA","Latvia","2018","2018",61.4,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","MTMOTCMT","Million US$ at exchange rate","LVA","Latvia","2019","2019",62.6,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","MTMOTCMT","Million US$ at exchange rate","LVA","Latvia","2020","2020",68.8,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","MTMOTCMT","Million US$ at exchange rate","LVA","Latvia","2021","2021",77.5,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","MTMOTCMT","Million US$ at exchange rate","LVA","Latvia","2022","2022",79.2,"D","Difference in methodology"
+"PATCACID","A02A-Antacids","MTMOTCMT","Million US$ at exchange rate","LVA","Latvia","2010","2010",0.5,"D","Difference in methodology"
+"PATCACID","A02A-Antacids","MTMOTCMT","Million US$ at exchange rate","LVA","Latvia","2011","2011",0.5,"D","Difference in methodology"
+"PATCACID","A02A-Antacids","MTMOTCMT","Million US$ at exchange rate","LVA","Latvia","2012","2012",0.5,"D","Difference in methodology"
+"PATCACID","A02A-Antacids","MTMOTCMT","Million US$ at exchange rate","LVA","Latvia","2013","2013",0.5,"D","Difference in methodology"
+"PATCACID","A02A-Antacids","MTMOTCMT","Million US$ at exchange rate","LVA","Latvia","2014","2014",0.5,"D","Difference in methodology"
+"PATCACID","A02A-Antacids","MTMOTCMT","Million US$ at exchange rate","LVA","Latvia","2015","2015",0.5,"D","Difference in methodology"
+"PATCACID","A02A-Antacids","MTMOTCMT","Million US$ at exchange rate","LVA","Latvia","2016","2016",0.5,"D","Difference in methodology"
+"PATCACID","A02A-Antacids","MTMOTCMT","Million US$ at exchange rate","LVA","Latvia","2017","2017",0.5,"D","Difference in methodology"
+"PATCACID","A02A-Antacids","MTMOTCMT","Million US$ at exchange rate","LVA","Latvia","2018","2018",0.5,"D","Difference in methodology"
+"PATCACID","A02A-Antacids","MTMOTCMT","Million US$ at exchange rate","LVA","Latvia","2019","2019",0.6,"D","Difference in methodology"
+"PATCACID","A02A-Antacids","MTMOTCMT","Million US$ at exchange rate","LVA","Latvia","2020","2020",0.7,"D","Difference in methodology"
+"PATCACID","A02A-Antacids","MTMOTCMT","Million US$ at exchange rate","LVA","Latvia","2021","2021",0.8,"D","Difference in methodology"
+"PATCACID","A02A-Antacids","MTMOTCMT","Million US$ at exchange rate","LVA","Latvia","2022","2022",0.7,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOTCMT","Million US$ at exchange rate","LVA","Latvia","2010","2010",5.6,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOTCMT","Million US$ at exchange rate","LVA","Latvia","2011","2011",6.2,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOTCMT","Million US$ at exchange rate","LVA","Latvia","2012","2012",5.9,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOTCMT","Million US$ at exchange rate","LVA","Latvia","2013","2013",6.2,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOTCMT","Million US$ at exchange rate","LVA","Latvia","2014","2014",6.4,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOTCMT","Million US$ at exchange rate","LVA","Latvia","2015","2015",5.5,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOTCMT","Million US$ at exchange rate","LVA","Latvia","2016","2016",5.6,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOTCMT","Million US$ at exchange rate","LVA","Latvia","2017","2017",5.9,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOTCMT","Million US$ at exchange rate","LVA","Latvia","2018","2018",6.2,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOTCMT","Million US$ at exchange rate","LVA","Latvia","2019","2019",6.8,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOTCMT","Million US$ at exchange rate","LVA","Latvia","2020","2020",7.5,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOTCMT","Million US$ at exchange rate","LVA","Latvia","2021","2021",8,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOTCMT","Million US$ at exchange rate","LVA","Latvia","2022","2022",7.6,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","MTMOTCMT","Million US$ at exchange rate","LVA","Latvia","2010","2010",20.1,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","MTMOTCMT","Million US$ at exchange rate","LVA","Latvia","2011","2011",23.5,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","MTMOTCMT","Million US$ at exchange rate","LVA","Latvia","2012","2012",21.5,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","MTMOTCMT","Million US$ at exchange rate","LVA","Latvia","2013","2013",22.9,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","MTMOTCMT","Million US$ at exchange rate","LVA","Latvia","2014","2014",24,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","MTMOTCMT","Million US$ at exchange rate","LVA","Latvia","2015","2015",22,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","MTMOTCMT","Million US$ at exchange rate","LVA","Latvia","2016","2016",23.4,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","MTMOTCMT","Million US$ at exchange rate","LVA","Latvia","2017","2017",25.3,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","MTMOTCMT","Million US$ at exchange rate","LVA","Latvia","2018","2018",26.7,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","MTMOTCMT","Million US$ at exchange rate","LVA","Latvia","2019","2019",27.1,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","MTMOTCMT","Million US$ at exchange rate","LVA","Latvia","2020","2020",30.9,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","MTMOTCMT","Million US$ at exchange rate","LVA","Latvia","2021","2021",34.6,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","MTMOTCMT","Million US$ at exchange rate","LVA","Latvia","2022","2022",35.8,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","MTMOTCMT","Million US$ at exchange rate","LVA","Latvia","2010","2010",24.8,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","MTMOTCMT","Million US$ at exchange rate","LVA","Latvia","2011","2011",26.6,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","MTMOTCMT","Million US$ at exchange rate","LVA","Latvia","2012","2012",25.1,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","MTMOTCMT","Million US$ at exchange rate","LVA","Latvia","2013","2013",27.2,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","MTMOTCMT","Million US$ at exchange rate","LVA","Latvia","2014","2014",29.3,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","MTMOTCMT","Million US$ at exchange rate","LVA","Latvia","2015","2015",25.7,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","MTMOTCMT","Million US$ at exchange rate","LVA","Latvia","2016","2016",27.3,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","MTMOTCMT","Million US$ at exchange rate","LVA","Latvia","2017","2017",32,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","MTMOTCMT","Million US$ at exchange rate","LVA","Latvia","2018","2018",37.3,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","MTMOTCMT","Million US$ at exchange rate","LVA","Latvia","2019","2019",42.8,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","MTMOTCMT","Million US$ at exchange rate","LVA","Latvia","2020","2020",45.7,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","MTMOTCMT","Million US$ at exchange rate","LVA","Latvia","2021","2021",51.2,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","MTMOTCMT","Million US$ at exchange rate","LVA","Latvia","2022","2022",48.3,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","MTMOTCMT","Million US$ at exchange rate","LVA","Latvia","2010","2010",69.2,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","MTMOTCMT","Million US$ at exchange rate","LVA","Latvia","2011","2011",75.6,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","MTMOTCMT","Million US$ at exchange rate","LVA","Latvia","2012","2012",70.8,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","MTMOTCMT","Million US$ at exchange rate","LVA","Latvia","2013","2013",73.3,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","MTMOTCMT","Million US$ at exchange rate","LVA","Latvia","2014","2014",72,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","MTMOTCMT","Million US$ at exchange rate","LVA","Latvia","2015","2015",59.5,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","MTMOTCMT","Million US$ at exchange rate","LVA","Latvia","2016","2016",60.8,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","MTMOTCMT","Million US$ at exchange rate","LVA","Latvia","2017","2017",64.2,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","MTMOTCMT","Million US$ at exchange rate","LVA","Latvia","2018","2018",67.2,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","MTMOTCMT","Million US$ at exchange rate","LVA","Latvia","2019","2019",66.3,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","MTMOTCMT","Million US$ at exchange rate","LVA","Latvia","2020","2020",65.8,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","MTMOTCMT","Million US$ at exchange rate","LVA","Latvia","2021","2021",68.6,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","MTMOTCMT","Million US$ at exchange rate","LVA","Latvia","2022","2022",63.3,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","MTMOTCMT","Million US$ at exchange rate","LVA","Latvia","2010","2010",0.1,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","MTMOTCMT","Million US$ at exchange rate","LVA","Latvia","2011","2011",0.1,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","MTMOTCMT","Million US$ at exchange rate","LVA","Latvia","2012","2012",0.1,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","MTMOTCMT","Million US$ at exchange rate","LVA","Latvia","2013","2013",0.1,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","MTMOTCMT","Million US$ at exchange rate","LVA","Latvia","2014","2014",0.1,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","MTMOTCMT","Million US$ at exchange rate","LVA","Latvia","2015","2015",0.1,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","MTMOTCMT","Million US$ at exchange rate","LVA","Latvia","2016","2016",0.1,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","MTMOTCMT","Million US$ at exchange rate","LVA","Latvia","2017","2017",0.1,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","MTMOTCMT","Million US$ at exchange rate","LVA","Latvia","2018","2018",0.1,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","MTMOTCMT","Million US$ at exchange rate","LVA","Latvia","2019","2019",0.1,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","MTMOTCMT","Million US$ at exchange rate","LVA","Latvia","2020","2020",0.1,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","MTMOTCMT","Million US$ at exchange rate","LVA","Latvia","2021","2021",0.1,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","MTMOTCMT","Million US$ at exchange rate","LVA","Latvia","2022","2022",0.1,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOTCMT","Million US$ at exchange rate","LVA","Latvia","2010","2010",0.5,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOTCMT","Million US$ at exchange rate","LVA","Latvia","2011","2011",0.6,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOTCMT","Million US$ at exchange rate","LVA","Latvia","2012","2012",0.7,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOTCMT","Million US$ at exchange rate","LVA","Latvia","2013","2013",0.8,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOTCMT","Million US$ at exchange rate","LVA","Latvia","2014","2014",0.9,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOTCMT","Million US$ at exchange rate","LVA","Latvia","2015","2015",0.8,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOTCMT","Million US$ at exchange rate","LVA","Latvia","2016","2016",0.8,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOTCMT","Million US$ at exchange rate","LVA","Latvia","2017","2017",0.9,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOTCMT","Million US$ at exchange rate","LVA","Latvia","2018","2018",1.1,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOTCMT","Million US$ at exchange rate","LVA","Latvia","2019","2019",1.1,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOTCMT","Million US$ at exchange rate","LVA","Latvia","2020","2020",1.2,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOTCMT","Million US$ at exchange rate","LVA","Latvia","2021","2021",1.3,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOTCMT","Million US$ at exchange rate","LVA","Latvia","2022","2022",1.7,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","MTMOTCMT","Million US$ at exchange rate","LVA","Latvia","2010","2010",3.4,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","MTMOTCMT","Million US$ at exchange rate","LVA","Latvia","2011","2011",4,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","MTMOTCMT","Million US$ at exchange rate","LVA","Latvia","2012","2012",3.8,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","MTMOTCMT","Million US$ at exchange rate","LVA","Latvia","2013","2013",4,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","MTMOTCMT","Million US$ at exchange rate","LVA","Latvia","2014","2014",4.2,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","MTMOTCMT","Million US$ at exchange rate","LVA","Latvia","2015","2015",3.6,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","MTMOTCMT","Million US$ at exchange rate","LVA","Latvia","2016","2016",3.9,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","MTMOTCMT","Million US$ at exchange rate","LVA","Latvia","2017","2017",4.2,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","MTMOTCMT","Million US$ at exchange rate","LVA","Latvia","2018","2018",4.6,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","MTMOTCMT","Million US$ at exchange rate","LVA","Latvia","2019","2019",4.2,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","MTMOTCMT","Million US$ at exchange rate","LVA","Latvia","2020","2020",4.2,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","MTMOTCMT","Million US$ at exchange rate","LVA","Latvia","2021","2021",3.7,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","MTMOTCMT","Million US$ at exchange rate","LVA","Latvia","2022","2022",3.1,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","MTMOTCMT","Million US$ at exchange rate","LVA","Latvia","2010","2010",2.8,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","MTMOTCMT","Million US$ at exchange rate","LVA","Latvia","2011","2011",3,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","MTMOTCMT","Million US$ at exchange rate","LVA","Latvia","2012","2012",2.8,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","MTMOTCMT","Million US$ at exchange rate","LVA","Latvia","2013","2013",2.9,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","MTMOTCMT","Million US$ at exchange rate","LVA","Latvia","2014","2014",2.9,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","MTMOTCMT","Million US$ at exchange rate","LVA","Latvia","2015","2015",2.4,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","MTMOTCMT","Million US$ at exchange rate","LVA","Latvia","2016","2016",2.6,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","MTMOTCMT","Million US$ at exchange rate","LVA","Latvia","2017","2017",2.8,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","MTMOTCMT","Million US$ at exchange rate","LVA","Latvia","2018","2018",3.1,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","MTMOTCMT","Million US$ at exchange rate","LVA","Latvia","2019","2019",3.2,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","MTMOTCMT","Million US$ at exchange rate","LVA","Latvia","2020","2020",3.4,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","MTMOTCMT","Million US$ at exchange rate","LVA","Latvia","2021","2021",3.6,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","MTMOTCMT","Million US$ at exchange rate","LVA","Latvia","2022","2022",3.3,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","MTMOTCMT","Million US$ at exchange rate","LVA","Latvia","2010","2010",8.7,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","MTMOTCMT","Million US$ at exchange rate","LVA","Latvia","2011","2011",9.7,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","MTMOTCMT","Million US$ at exchange rate","LVA","Latvia","2012","2012",9,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","MTMOTCMT","Million US$ at exchange rate","LVA","Latvia","2013","2013",9.6,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","MTMOTCMT","Million US$ at exchange rate","LVA","Latvia","2014","2014",10,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","MTMOTCMT","Million US$ at exchange rate","LVA","Latvia","2015","2015",8.4,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","MTMOTCMT","Million US$ at exchange rate","LVA","Latvia","2016","2016",8.7,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","MTMOTCMT","Million US$ at exchange rate","LVA","Latvia","2017","2017",8.9,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","MTMOTCMT","Million US$ at exchange rate","LVA","Latvia","2018","2018",8.5,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","MTMOTCMT","Million US$ at exchange rate","LVA","Latvia","2019","2019",8,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","MTMOTCMT","Million US$ at exchange rate","LVA","Latvia","2020","2020",7.3,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","MTMOTCMT","Million US$ at exchange rate","LVA","Latvia","2021","2021",7.4,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","MTMOTCMT","Million US$ at exchange rate","LVA","Latvia","2022","2022",6.5,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","MTMOTCMT","Million US$ at exchange rate","LVA","Latvia","2010","2010",5.4,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","MTMOTCMT","Million US$ at exchange rate","LVA","Latvia","2011","2011",5.4,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","MTMOTCMT","Million US$ at exchange rate","LVA","Latvia","2012","2012",4.7,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","MTMOTCMT","Million US$ at exchange rate","LVA","Latvia","2013","2013",4.6,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","MTMOTCMT","Million US$ at exchange rate","LVA","Latvia","2014","2014",4.2,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","MTMOTCMT","Million US$ at exchange rate","LVA","Latvia","2015","2015",3.2,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","MTMOTCMT","Million US$ at exchange rate","LVA","Latvia","2016","2016",2.9,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","MTMOTCMT","Million US$ at exchange rate","LVA","Latvia","2017","2017",2.7,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","MTMOTCMT","Million US$ at exchange rate","LVA","Latvia","2018","2018",2.6,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","MTMOTCMT","Million US$ at exchange rate","LVA","Latvia","2019","2019",2.3,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","MTMOTCMT","Million US$ at exchange rate","LVA","Latvia","2020","2020",2.2,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","MTMOTCMT","Million US$ at exchange rate","LVA","Latvia","2021","2021",2,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","MTMOTCMT","Million US$ at exchange rate","LVA","Latvia","2022","2022",1.7,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOTCMT","Million US$ at exchange rate","LVA","Latvia","2010","2010",23.8,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOTCMT","Million US$ at exchange rate","LVA","Latvia","2011","2011",25.7,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOTCMT","Million US$ at exchange rate","LVA","Latvia","2012","2012",24.5,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOTCMT","Million US$ at exchange rate","LVA","Latvia","2013","2013",25.8,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOTCMT","Million US$ at exchange rate","LVA","Latvia","2014","2014",25.4,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOTCMT","Million US$ at exchange rate","LVA","Latvia","2015","2015",20.7,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOTCMT","Million US$ at exchange rate","LVA","Latvia","2016","2016",20.8,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOTCMT","Million US$ at exchange rate","LVA","Latvia","2017","2017",22.4,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOTCMT","Million US$ at exchange rate","LVA","Latvia","2018","2018",23.7,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOTCMT","Million US$ at exchange rate","LVA","Latvia","2019","2019",23,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOTCMT","Million US$ at exchange rate","LVA","Latvia","2020","2020",22.5,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOTCMT","Million US$ at exchange rate","LVA","Latvia","2021","2021",22.2,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOTCMT","Million US$ at exchange rate","LVA","Latvia","2022","2022",19.3,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","MTMOTCMT","Million US$ at exchange rate","LVA","Latvia","2010","2010",9.6,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","MTMOTCMT","Million US$ at exchange rate","LVA","Latvia","2011","2011",10.8,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","MTMOTCMT","Million US$ at exchange rate","LVA","Latvia","2012","2012",9.8,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","MTMOTCMT","Million US$ at exchange rate","LVA","Latvia","2013","2013",9.1,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","MTMOTCMT","Million US$ at exchange rate","LVA","Latvia","2014","2014",7.5,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","MTMOTCMT","Million US$ at exchange rate","LVA","Latvia","2015","2015",5.9,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","MTMOTCMT","Million US$ at exchange rate","LVA","Latvia","2016","2016",6.2,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","MTMOTCMT","Million US$ at exchange rate","LVA","Latvia","2017","2017",7,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","MTMOTCMT","Million US$ at exchange rate","LVA","Latvia","2018","2018",7.8,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","MTMOTCMT","Million US$ at exchange rate","LVA","Latvia","2019","2019",8.9,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","MTMOTCMT","Million US$ at exchange rate","LVA","Latvia","2020","2020",9.7,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","MTMOTCMT","Million US$ at exchange rate","LVA","Latvia","2021","2021",11.1,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","MTMOTCMT","Million US$ at exchange rate","LVA","Latvia","2022","2022",11.2,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","MTMOTCMT","Million US$ at exchange rate","LVA","Latvia","2010","2010",16.5,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","MTMOTCMT","Million US$ at exchange rate","LVA","Latvia","2011","2011",18.2,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","MTMOTCMT","Million US$ at exchange rate","LVA","Latvia","2012","2012",16.9,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","MTMOTCMT","Million US$ at exchange rate","LVA","Latvia","2013","2013",18.4,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","MTMOTCMT","Million US$ at exchange rate","LVA","Latvia","2014","2014",19,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","MTMOTCMT","Million US$ at exchange rate","LVA","Latvia","2015","2015",15.7,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","MTMOTCMT","Million US$ at exchange rate","LVA","Latvia","2016","2016",15.7,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","MTMOTCMT","Million US$ at exchange rate","LVA","Latvia","2017","2017",16.9,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","MTMOTCMT","Million US$ at exchange rate","LVA","Latvia","2018","2018",17.4,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","MTMOTCMT","Million US$ at exchange rate","LVA","Latvia","2019","2019",17,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","MTMOTCMT","Million US$ at exchange rate","LVA","Latvia","2020","2020",16.3,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","MTMOTCMT","Million US$ at exchange rate","LVA","Latvia","2021","2021",17.2,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","MTMOTCMT","Million US$ at exchange rate","LVA","Latvia","2022","2022",17.2,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOTCMT","Million US$ at exchange rate","LVA","Latvia","2010","2010",7.6,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOTCMT","Million US$ at exchange rate","LVA","Latvia","2011","2011",8.2,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOTCMT","Million US$ at exchange rate","LVA","Latvia","2012","2012",7.5,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOTCMT","Million US$ at exchange rate","LVA","Latvia","2013","2013",8.1,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOTCMT","Million US$ at exchange rate","LVA","Latvia","2014","2014",8.3,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOTCMT","Million US$ at exchange rate","LVA","Latvia","2015","2015",6.9,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOTCMT","Million US$ at exchange rate","LVA","Latvia","2016","2016",6.9,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOTCMT","Million US$ at exchange rate","LVA","Latvia","2017","2017",7.4,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOTCMT","Million US$ at exchange rate","LVA","Latvia","2018","2018",7.8,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOTCMT","Million US$ at exchange rate","LVA","Latvia","2019","2019",8,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOTCMT","Million US$ at exchange rate","LVA","Latvia","2020","2020",7.6,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOTCMT","Million US$ at exchange rate","LVA","Latvia","2021","2021",8.1,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOTCMT","Million US$ at exchange rate","LVA","Latvia","2022","2022",8.5,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOTCMT","Million US$ at exchange rate","LVA","Latvia","2010","2010",6,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOTCMT","Million US$ at exchange rate","LVA","Latvia","2011","2011",7,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOTCMT","Million US$ at exchange rate","LVA","Latvia","2012","2012",7,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOTCMT","Million US$ at exchange rate","LVA","Latvia","2013","2013",8.1,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOTCMT","Million US$ at exchange rate","LVA","Latvia","2014","2014",7.6,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOTCMT","Million US$ at exchange rate","LVA","Latvia","2015","2015",6.5,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOTCMT","Million US$ at exchange rate","LVA","Latvia","2016","2016",6.7,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOTCMT","Million US$ at exchange rate","LVA","Latvia","2017","2017",6.9,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOTCMT","Million US$ at exchange rate","LVA","Latvia","2018","2018",7.5,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOTCMT","Million US$ at exchange rate","LVA","Latvia","2019","2019",7.2,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOTCMT","Million US$ at exchange rate","LVA","Latvia","2020","2020",7.3,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOTCMT","Million US$ at exchange rate","LVA","Latvia","2021","2021",7.7,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOTCMT","Million US$ at exchange rate","LVA","Latvia","2022","2022",6.6,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","MTMOTCMT","Million US$ at exchange rate","LVA","Latvia","2010","2010",33.9,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","MTMOTCMT","Million US$ at exchange rate","LVA","Latvia","2011","2011",37.5,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","MTMOTCMT","Million US$ at exchange rate","LVA","Latvia","2012","2012",37.6,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","MTMOTCMT","Million US$ at exchange rate","LVA","Latvia","2013","2013",42.4,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","MTMOTCMT","Million US$ at exchange rate","LVA","Latvia","2014","2014",41.4,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","MTMOTCMT","Million US$ at exchange rate","LVA","Latvia","2015","2015",39.1,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","MTMOTCMT","Million US$ at exchange rate","LVA","Latvia","2016","2016",61.5,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","MTMOTCMT","Million US$ at exchange rate","LVA","Latvia","2017","2017",68.4,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","MTMOTCMT","Million US$ at exchange rate","LVA","Latvia","2018","2018",77,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","MTMOTCMT","Million US$ at exchange rate","LVA","Latvia","2019","2019",62.1,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","MTMOTCMT","Million US$ at exchange rate","LVA","Latvia","2020","2020",71.1,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","MTMOTCMT","Million US$ at exchange rate","LVA","Latvia","2021","2021",60.6,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","MTMOTCMT","Million US$ at exchange rate","LVA","Latvia","2022","2022",60.1,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","MTMOTCMT","Million US$ at exchange rate","LVA","Latvia","2010","2010",12.4,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","MTMOTCMT","Million US$ at exchange rate","LVA","Latvia","2011","2011",13.4,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","MTMOTCMT","Million US$ at exchange rate","LVA","Latvia","2012","2012",12.2,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","MTMOTCMT","Million US$ at exchange rate","LVA","Latvia","2013","2013",12.7,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","MTMOTCMT","Million US$ at exchange rate","LVA","Latvia","2014","2014",13,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","MTMOTCMT","Million US$ at exchange rate","LVA","Latvia","2015","2015",11,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","MTMOTCMT","Million US$ at exchange rate","LVA","Latvia","2016","2016",11.1,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","MTMOTCMT","Million US$ at exchange rate","LVA","Latvia","2017","2017",12,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","MTMOTCMT","Million US$ at exchange rate","LVA","Latvia","2018","2018",12.2,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","MTMOTCMT","Million US$ at exchange rate","LVA","Latvia","2019","2019",11.9,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","MTMOTCMT","Million US$ at exchange rate","LVA","Latvia","2020","2020",11.2,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","MTMOTCMT","Million US$ at exchange rate","LVA","Latvia","2021","2021",11.4,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","MTMOTCMT","Million US$ at exchange rate","LVA","Latvia","2022","2022",11.3,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","MTMOTCMT","Million US$ at exchange rate","LVA","Latvia","2010","2010",24.1,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","MTMOTCMT","Million US$ at exchange rate","LVA","Latvia","2011","2011",26.8,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","MTMOTCMT","Million US$ at exchange rate","LVA","Latvia","2012","2012",24.9,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","MTMOTCMT","Million US$ at exchange rate","LVA","Latvia","2013","2013",26.7,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","MTMOTCMT","Million US$ at exchange rate","LVA","Latvia","2014","2014",27.6,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","MTMOTCMT","Million US$ at exchange rate","LVA","Latvia","2015","2015",24.1,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","MTMOTCMT","Million US$ at exchange rate","LVA","Latvia","2016","2016",25.3,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","MTMOTCMT","Million US$ at exchange rate","LVA","Latvia","2017","2017",27.7,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","MTMOTCMT","Million US$ at exchange rate","LVA","Latvia","2018","2018",30.3,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","MTMOTCMT","Million US$ at exchange rate","LVA","Latvia","2019","2019",32.3,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","MTMOTCMT","Million US$ at exchange rate","LVA","Latvia","2020","2020",33.3,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","MTMOTCMT","Million US$ at exchange rate","LVA","Latvia","2021","2021",36.8,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","MTMOTCMT","Million US$ at exchange rate","LVA","Latvia","2022","2022",37.6,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOTCMT","Million US$ at exchange rate","LVA","Latvia","2010","2010",13.7,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOTCMT","Million US$ at exchange rate","LVA","Latvia","2011","2011",15.8,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOTCMT","Million US$ at exchange rate","LVA","Latvia","2012","2012",14.8,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOTCMT","Million US$ at exchange rate","LVA","Latvia","2013","2013",16.4,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOTCMT","Million US$ at exchange rate","LVA","Latvia","2014","2014",17.3,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOTCMT","Million US$ at exchange rate","LVA","Latvia","2015","2015",15.5,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOTCMT","Million US$ at exchange rate","LVA","Latvia","2016","2016",16.4,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOTCMT","Million US$ at exchange rate","LVA","Latvia","2017","2017",17.4,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOTCMT","Million US$ at exchange rate","LVA","Latvia","2018","2018",18.7,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOTCMT","Million US$ at exchange rate","LVA","Latvia","2019","2019",18.2,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOTCMT","Million US$ at exchange rate","LVA","Latvia","2020","2020",18.5,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOTCMT","Million US$ at exchange rate","LVA","Latvia","2021","2021",19.9,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOTCMT","Million US$ at exchange rate","LVA","Latvia","2022","2022",20.7,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","MTMOTCMT","Million US$ at exchange rate","LVA","Latvia","2010","2010",43.8,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","MTMOTCMT","Million US$ at exchange rate","LVA","Latvia","2011","2011",47,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","MTMOTCMT","Million US$ at exchange rate","LVA","Latvia","2012","2012",43,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","MTMOTCMT","Million US$ at exchange rate","LVA","Latvia","2013","2013",44.2,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","MTMOTCMT","Million US$ at exchange rate","LVA","Latvia","2014","2014",44.8,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","MTMOTCMT","Million US$ at exchange rate","LVA","Latvia","2015","2015",38.5,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","MTMOTCMT","Million US$ at exchange rate","LVA","Latvia","2016","2016",39.1,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","MTMOTCMT","Million US$ at exchange rate","LVA","Latvia","2017","2017",42.2,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","MTMOTCMT","Million US$ at exchange rate","LVA","Latvia","2018","2018",46.1,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","MTMOTCMT","Million US$ at exchange rate","LVA","Latvia","2019","2019",46.5,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","MTMOTCMT","Million US$ at exchange rate","LVA","Latvia","2020","2020",50.1,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","MTMOTCMT","Million US$ at exchange rate","LVA","Latvia","2021","2021",54.5,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","MTMOTCMT","Million US$ at exchange rate","LVA","Latvia","2022","2022",55.6,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","MTMOTCMT","Million US$ at exchange rate","LVA","Latvia","2010","2010",9.5,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","MTMOTCMT","Million US$ at exchange rate","LVA","Latvia","2011","2011",10.4,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","MTMOTCMT","Million US$ at exchange rate","LVA","Latvia","2012","2012",9.4,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","MTMOTCMT","Million US$ at exchange rate","LVA","Latvia","2013","2013",9.9,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","MTMOTCMT","Million US$ at exchange rate","LVA","Latvia","2014","2014",9.8,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","MTMOTCMT","Million US$ at exchange rate","LVA","Latvia","2015","2015",8.5,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","MTMOTCMT","Million US$ at exchange rate","LVA","Latvia","2016","2016",8.8,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","MTMOTCMT","Million US$ at exchange rate","LVA","Latvia","2017","2017",9.4,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","MTMOTCMT","Million US$ at exchange rate","LVA","Latvia","2018","2018",10.4,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","MTMOTCMT","Million US$ at exchange rate","LVA","Latvia","2019","2019",10.7,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","MTMOTCMT","Million US$ at exchange rate","LVA","Latvia","2020","2020",11.7,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","MTMOTCMT","Million US$ at exchange rate","LVA","Latvia","2021","2021",15.3,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","MTMOTCMT","Million US$ at exchange rate","LVA","Latvia","2022","2022",17.1,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","MTMOTCMT","Million US$ at exchange rate","LVA","Latvia","2010","2010",2.8,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","MTMOTCMT","Million US$ at exchange rate","LVA","Latvia","2011","2011",3.1,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","MTMOTCMT","Million US$ at exchange rate","LVA","Latvia","2012","2012",3,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","MTMOTCMT","Million US$ at exchange rate","LVA","Latvia","2013","2013",3.2,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","MTMOTCMT","Million US$ at exchange rate","LVA","Latvia","2014","2014",3.4,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","MTMOTCMT","Million US$ at exchange rate","LVA","Latvia","2015","2015",3,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","MTMOTCMT","Million US$ at exchange rate","LVA","Latvia","2016","2016",3.1,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","MTMOTCMT","Million US$ at exchange rate","LVA","Latvia","2017","2017",3.3,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","MTMOTCMT","Million US$ at exchange rate","LVA","Latvia","2018","2018",3.4,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","MTMOTCMT","Million US$ at exchange rate","LVA","Latvia","2019","2019",3.5,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","MTMOTCMT","Million US$ at exchange rate","LVA","Latvia","2020","2020",3.8,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","MTMOTCMT","Million US$ at exchange rate","LVA","Latvia","2021","2021",3,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","MTMOTCMT","Million US$ at exchange rate","LVA","Latvia","2022","2022",2.8,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","MTMOTCMT","Million US$ at exchange rate","LVA","Latvia","2010","2010",3.2,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","MTMOTCMT","Million US$ at exchange rate","LVA","Latvia","2011","2011",3.5,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","MTMOTCMT","Million US$ at exchange rate","LVA","Latvia","2012","2012",3.2,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","MTMOTCMT","Million US$ at exchange rate","LVA","Latvia","2013","2013",3.5,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","MTMOTCMT","Million US$ at exchange rate","LVA","Latvia","2014","2014",3.6,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","MTMOTCMT","Million US$ at exchange rate","LVA","Latvia","2015","2015",3.2,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","MTMOTCMT","Million US$ at exchange rate","LVA","Latvia","2016","2016",3.3,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","MTMOTCMT","Million US$ at exchange rate","LVA","Latvia","2017","2017",3.5,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","MTMOTCMT","Million US$ at exchange rate","LVA","Latvia","2018","2018",3.7,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","MTMOTCMT","Million US$ at exchange rate","LVA","Latvia","2019","2019",4,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","MTMOTCMT","Million US$ at exchange rate","LVA","Latvia","2020","2020",4.5,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","MTMOTCMT","Million US$ at exchange rate","LVA","Latvia","2021","2021",5.5,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","MTMOTCMT","Million US$ at exchange rate","LVA","Latvia","2022","2022",5.1,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","MTMOTCMT","Million US$ at exchange rate","LVA","Latvia","2010","2010",3,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","MTMOTCMT","Million US$ at exchange rate","LVA","Latvia","2011","2011",3.2,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","MTMOTCMT","Million US$ at exchange rate","LVA","Latvia","2012","2012",2.9,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","MTMOTCMT","Million US$ at exchange rate","LVA","Latvia","2013","2013",3,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","MTMOTCMT","Million US$ at exchange rate","LVA","Latvia","2014","2014",3,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","MTMOTCMT","Million US$ at exchange rate","LVA","Latvia","2015","2015",2.8,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","MTMOTCMT","Million US$ at exchange rate","LVA","Latvia","2016","2016",2.9,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","MTMOTCMT","Million US$ at exchange rate","LVA","Latvia","2017","2017",3.2,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","MTMOTCMT","Million US$ at exchange rate","LVA","Latvia","2018","2018",3.3,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","MTMOTCMT","Million US$ at exchange rate","LVA","Latvia","2019","2019",3.4,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","MTMOTCMT","Million US$ at exchange rate","LVA","Latvia","2020","2020",3.7,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","MTMOTCMT","Million US$ at exchange rate","LVA","Latvia","2021","2021",4,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","MTMOTCMT","Million US$ at exchange rate","LVA","Latvia","2022","2022",4.3,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","MTMOTCMT","Million US$ at exchange rate","LVA","Latvia","2010","2010",27.3,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","MTMOTCMT","Million US$ at exchange rate","LVA","Latvia","2011","2011",30,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","MTMOTCMT","Million US$ at exchange rate","LVA","Latvia","2012","2012",28.7,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","MTMOTCMT","Million US$ at exchange rate","LVA","Latvia","2013","2013",30.9,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","MTMOTCMT","Million US$ at exchange rate","LVA","Latvia","2014","2014",31.8,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","MTMOTCMT","Million US$ at exchange rate","LVA","Latvia","2015","2015",26.9,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","MTMOTCMT","Million US$ at exchange rate","LVA","Latvia","2016","2016",28.4,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","MTMOTCMT","Million US$ at exchange rate","LVA","Latvia","2017","2017",31.3,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","MTMOTCMT","Million US$ at exchange rate","LVA","Latvia","2018","2018",34.1,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","MTMOTCMT","Million US$ at exchange rate","LVA","Latvia","2019","2019",33.4,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","MTMOTCMT","Million US$ at exchange rate","LVA","Latvia","2020","2020",31.2,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","MTMOTCMT","Million US$ at exchange rate","LVA","Latvia","2021","2021",33.7,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","MTMOTCMT","Million US$ at exchange rate","LVA","Latvia","2022","2022",46,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOTCMT","Million US$ at exchange rate","LVA","Latvia","2010","2010",11.2,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOTCMT","Million US$ at exchange rate","LVA","Latvia","2011","2011",12.5,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOTCMT","Million US$ at exchange rate","LVA","Latvia","2012","2012",11.7,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOTCMT","Million US$ at exchange rate","LVA","Latvia","2013","2013",12.4,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOTCMT","Million US$ at exchange rate","LVA","Latvia","2014","2014",12.7,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOTCMT","Million US$ at exchange rate","LVA","Latvia","2015","2015",10.2,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOTCMT","Million US$ at exchange rate","LVA","Latvia","2016","2016",10.3,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOTCMT","Million US$ at exchange rate","LVA","Latvia","2017","2017",11,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOTCMT","Million US$ at exchange rate","LVA","Latvia","2018","2018",11.2,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOTCMT","Million US$ at exchange rate","LVA","Latvia","2019","2019",10.8,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOTCMT","Million US$ at exchange rate","LVA","Latvia","2020","2020",11,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOTCMT","Million US$ at exchange rate","LVA","Latvia","2021","2021",11.3,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOTCMT","Million US$ at exchange rate","LVA","Latvia","2022","2022",11.2,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","MTMOPPMT","Million US$, purchasing power parity","LVA","Latvia","2010","2010",567.2,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","MTMOPPMT","Million US$, purchasing power parity","LVA","Latvia","2011","2011",581.5,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","MTMOPPMT","Million US$, purchasing power parity","LVA","Latvia","2012","2012",583.5,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","MTMOPPMT","Million US$, purchasing power parity","LVA","Latvia","2013","2013",616,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","MTMOPPMT","Million US$, purchasing power parity","LVA","Latvia","2014","2014",634.9,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","MTMOPPMT","Million US$, purchasing power parity","LVA","Latvia","2015","2015",666.4,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","MTMOPPMT","Million US$, purchasing power parity","LVA","Latvia","2016","2016",762,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","MTMOPPMT","Million US$, purchasing power parity","LVA","Latvia","2017","2017",810.6,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","MTMOPPMT","Million US$, purchasing power parity","LVA","Latvia","2018","2018",839.6,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","MTMOPPMT","Million US$, purchasing power parity","LVA","Latvia","2019","2019",876.3,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","MTMOPPMT","Million US$, purchasing power parity","LVA","Latvia","2020","2020",926.9,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","MTMOPPMT","Million US$, purchasing power parity","LVA","Latvia","2021","2021",901.6,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","MTMOPPMT","Million US$, purchasing power parity","LVA","Latvia","2022","2022",1024.8,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","MTMOPPMT","Million US$, purchasing power parity","LVA","Latvia","2010","2010",73.5,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","MTMOPPMT","Million US$, purchasing power parity","LVA","Latvia","2011","2011",76.4,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","MTMOPPMT","Million US$, purchasing power parity","LVA","Latvia","2012","2012",76.8,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","MTMOPPMT","Million US$, purchasing power parity","LVA","Latvia","2013","2013",81.2,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","MTMOPPMT","Million US$, purchasing power parity","LVA","Latvia","2014","2014",85.7,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","MTMOPPMT","Million US$, purchasing power parity","LVA","Latvia","2015","2015",91.6,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","MTMOPPMT","Million US$, purchasing power parity","LVA","Latvia","2016","2016",101.3,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","MTMOPPMT","Million US$, purchasing power parity","LVA","Latvia","2017","2017",104,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","MTMOPPMT","Million US$, purchasing power parity","LVA","Latvia","2018","2018",106.1,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","MTMOPPMT","Million US$, purchasing power parity","LVA","Latvia","2019","2019",114.9,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","MTMOPPMT","Million US$, purchasing power parity","LVA","Latvia","2020","2020",124.7,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","MTMOPPMT","Million US$, purchasing power parity","LVA","Latvia","2021","2021",128.8,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","MTMOPPMT","Million US$, purchasing power parity","LVA","Latvia","2022","2022",147.8,"D","Difference in methodology"
+"PATCACID","A02A-Antacids","MTMOPPMT","Million US$, purchasing power parity","LVA","Latvia","2010","2010",0.8,"D","Difference in methodology"
+"PATCACID","A02A-Antacids","MTMOPPMT","Million US$, purchasing power parity","LVA","Latvia","2011","2011",0.8,"D","Difference in methodology"
+"PATCACID","A02A-Antacids","MTMOPPMT","Million US$, purchasing power parity","LVA","Latvia","2012","2012",0.8,"D","Difference in methodology"
+"PATCACID","A02A-Antacids","MTMOPPMT","Million US$, purchasing power parity","LVA","Latvia","2013","2013",0.8,"D","Difference in methodology"
+"PATCACID","A02A-Antacids","MTMOPPMT","Million US$, purchasing power parity","LVA","Latvia","2014","2014",0.8,"D","Difference in methodology"
+"PATCACID","A02A-Antacids","MTMOPPMT","Million US$, purchasing power parity","LVA","Latvia","2015","2015",0.8,"D","Difference in methodology"
+"PATCACID","A02A-Antacids","MTMOPPMT","Million US$, purchasing power parity","LVA","Latvia","2016","2016",0.8,"D","Difference in methodology"
+"PATCACID","A02A-Antacids","MTMOPPMT","Million US$, purchasing power parity","LVA","Latvia","2017","2017",0.9,"D","Difference in methodology"
+"PATCACID","A02A-Antacids","MTMOPPMT","Million US$, purchasing power parity","LVA","Latvia","2018","2018",0.9,"D","Difference in methodology"
+"PATCACID","A02A-Antacids","MTMOPPMT","Million US$, purchasing power parity","LVA","Latvia","2019","2019",1.1,"D","Difference in methodology"
+"PATCACID","A02A-Antacids","MTMOPPMT","Million US$, purchasing power parity","LVA","Latvia","2020","2020",1.3,"D","Difference in methodology"
+"PATCACID","A02A-Antacids","MTMOPPMT","Million US$, purchasing power parity","LVA","Latvia","2021","2021",1.3,"D","Difference in methodology"
+"PATCACID","A02A-Antacids","MTMOPPMT","Million US$, purchasing power parity","LVA","Latvia","2022","2022",1.4,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOPPMT","Million US$, purchasing power parity","LVA","Latvia","2010","2010",8.7,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOPPMT","Million US$, purchasing power parity","LVA","Latvia","2011","2011",8.8,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOPPMT","Million US$, purchasing power parity","LVA","Latvia","2012","2012",9.1,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOPPMT","Million US$, purchasing power parity","LVA","Latvia","2013","2013",9.3,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOPPMT","Million US$, purchasing power parity","LVA","Latvia","2014","2014",9.8,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOPPMT","Million US$, purchasing power parity","LVA","Latvia","2015","2015",9.9,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOPPMT","Million US$, purchasing power parity","LVA","Latvia","2016","2016",10.5,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOPPMT","Million US$, purchasing power parity","LVA","Latvia","2017","2017",10.7,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOPPMT","Million US$, purchasing power parity","LVA","Latvia","2018","2018",10.8,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOPPMT","Million US$, purchasing power parity","LVA","Latvia","2019","2019",12.5,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOPPMT","Million US$, purchasing power parity","LVA","Latvia","2020","2020",13.6,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOPPMT","Million US$, purchasing power parity","LVA","Latvia","2021","2021",13.3,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOPPMT","Million US$, purchasing power parity","LVA","Latvia","2022","2022",14.2,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","MTMOPPMT","Million US$, purchasing power parity","LVA","Latvia","2010","2010",31.2,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","MTMOPPMT","Million US$, purchasing power parity","LVA","Latvia","2011","2011",33.7,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","MTMOPPMT","Million US$, purchasing power parity","LVA","Latvia","2012","2012",33,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","MTMOPPMT","Million US$, purchasing power parity","LVA","Latvia","2013","2013",34.5,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","MTMOPPMT","Million US$, purchasing power parity","LVA","Latvia","2014","2014",36.3,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","MTMOPPMT","Million US$, purchasing power parity","LVA","Latvia","2015","2015",39.8,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","MTMOPPMT","Million US$, purchasing power parity","LVA","Latvia","2016","2016",43.6,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","MTMOPPMT","Million US$, purchasing power parity","LVA","Latvia","2017","2017",46.1,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","MTMOPPMT","Million US$, purchasing power parity","LVA","Latvia","2018","2018",46.2,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","MTMOPPMT","Million US$, purchasing power parity","LVA","Latvia","2019","2019",49.8,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","MTMOPPMT","Million US$, purchasing power parity","LVA","Latvia","2020","2020",56,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","MTMOPPMT","Million US$, purchasing power parity","LVA","Latvia","2021","2021",57.5,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","MTMOPPMT","Million US$, purchasing power parity","LVA","Latvia","2022","2022",66.8,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","MTMOPPMT","Million US$, purchasing power parity","LVA","Latvia","2010","2010",38.5,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","MTMOPPMT","Million US$, purchasing power parity","LVA","Latvia","2011","2011",38,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","MTMOPPMT","Million US$, purchasing power parity","LVA","Latvia","2012","2012",38.6,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","MTMOPPMT","Million US$, purchasing power parity","LVA","Latvia","2013","2013",41.1,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","MTMOPPMT","Million US$, purchasing power parity","LVA","Latvia","2014","2014",44.4,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","MTMOPPMT","Million US$, purchasing power parity","LVA","Latvia","2015","2015",46.5,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","MTMOPPMT","Million US$, purchasing power parity","LVA","Latvia","2016","2016",50.9,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","MTMOPPMT","Million US$, purchasing power parity","LVA","Latvia","2017","2017",58.4,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","MTMOPPMT","Million US$, purchasing power parity","LVA","Latvia","2018","2018",64.4,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","MTMOPPMT","Million US$, purchasing power parity","LVA","Latvia","2019","2019",78.6,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","MTMOPPMT","Million US$, purchasing power parity","LVA","Latvia","2020","2020",82.9,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","MTMOPPMT","Million US$, purchasing power parity","LVA","Latvia","2021","2021",85.1,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","MTMOPPMT","Million US$, purchasing power parity","LVA","Latvia","2022","2022",90.1,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","MTMOPPMT","Million US$, purchasing power parity","LVA","Latvia","2010","2010",107.3,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","MTMOPPMT","Million US$, purchasing power parity","LVA","Latvia","2011","2011",108.2,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","MTMOPPMT","Million US$, purchasing power parity","LVA","Latvia","2012","2012",108.8,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","MTMOPPMT","Million US$, purchasing power parity","LVA","Latvia","2013","2013",110.6,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","MTMOPPMT","Million US$, purchasing power parity","LVA","Latvia","2014","2014",108.9,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","MTMOPPMT","Million US$, purchasing power parity","LVA","Latvia","2015","2015",107.7,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","MTMOPPMT","Million US$, purchasing power parity","LVA","Latvia","2016","2016",113.4,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","MTMOPPMT","Million US$, purchasing power parity","LVA","Latvia","2017","2017",117.2,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","MTMOPPMT","Million US$, purchasing power parity","LVA","Latvia","2018","2018",116.2,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","MTMOPPMT","Million US$, purchasing power parity","LVA","Latvia","2019","2019",121.6,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","MTMOPPMT","Million US$, purchasing power parity","LVA","Latvia","2020","2020",119.3,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","MTMOPPMT","Million US$, purchasing power parity","LVA","Latvia","2021","2021",113.9,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","MTMOPPMT","Million US$, purchasing power parity","LVA","Latvia","2022","2022",118.1,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","MTMOPPMT","Million US$, purchasing power parity","LVA","Latvia","2010","2010",0.2,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","MTMOPPMT","Million US$, purchasing power parity","LVA","Latvia","2011","2011",0.2,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","MTMOPPMT","Million US$, purchasing power parity","LVA","Latvia","2012","2012",0.2,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","MTMOPPMT","Million US$, purchasing power parity","LVA","Latvia","2013","2013",0.2,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","MTMOPPMT","Million US$, purchasing power parity","LVA","Latvia","2014","2014",0.2,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","MTMOPPMT","Million US$, purchasing power parity","LVA","Latvia","2015","2015",0.2,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","MTMOPPMT","Million US$, purchasing power parity","LVA","Latvia","2016","2016",0.2,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","MTMOPPMT","Million US$, purchasing power parity","LVA","Latvia","2017","2017",0.2,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","MTMOPPMT","Million US$, purchasing power parity","LVA","Latvia","2018","2018",0.2,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","MTMOPPMT","Million US$, purchasing power parity","LVA","Latvia","2019","2019",0.2,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","MTMOPPMT","Million US$, purchasing power parity","LVA","Latvia","2020","2020",0.2,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","MTMOPPMT","Million US$, purchasing power parity","LVA","Latvia","2021","2021",0.2,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","MTMOPPMT","Million US$, purchasing power parity","LVA","Latvia","2022","2022",0.2,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOPPMT","Million US$, purchasing power parity","LVA","Latvia","2010","2010",0.8,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOPPMT","Million US$, purchasing power parity","LVA","Latvia","2011","2011",0.9,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOPPMT","Million US$, purchasing power parity","LVA","Latvia","2012","2012",1,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOPPMT","Million US$, purchasing power parity","LVA","Latvia","2013","2013",1.2,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOPPMT","Million US$, purchasing power parity","LVA","Latvia","2014","2014",1.3,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOPPMT","Million US$, purchasing power parity","LVA","Latvia","2015","2015",1.4,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOPPMT","Million US$, purchasing power parity","LVA","Latvia","2016","2016",1.6,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOPPMT","Million US$, purchasing power parity","LVA","Latvia","2017","2017",1.7,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOPPMT","Million US$, purchasing power parity","LVA","Latvia","2018","2018",1.8,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOPPMT","Million US$, purchasing power parity","LVA","Latvia","2019","2019",2.1,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOPPMT","Million US$, purchasing power parity","LVA","Latvia","2020","2020",2.2,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOPPMT","Million US$, purchasing power parity","LVA","Latvia","2021","2021",2.2,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOPPMT","Million US$, purchasing power parity","LVA","Latvia","2022","2022",3.1,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","MTMOPPMT","Million US$, purchasing power parity","LVA","Latvia","2010","2010",5.3,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","MTMOPPMT","Million US$, purchasing power parity","LVA","Latvia","2011","2011",5.7,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","MTMOPPMT","Million US$, purchasing power parity","LVA","Latvia","2012","2012",5.8,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","MTMOPPMT","Million US$, purchasing power parity","LVA","Latvia","2013","2013",6.1,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","MTMOPPMT","Million US$, purchasing power parity","LVA","Latvia","2014","2014",6.3,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","MTMOPPMT","Million US$, purchasing power parity","LVA","Latvia","2015","2015",6.6,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","MTMOPPMT","Million US$, purchasing power parity","LVA","Latvia","2016","2016",7.3,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","MTMOPPMT","Million US$, purchasing power parity","LVA","Latvia","2017","2017",7.7,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","MTMOPPMT","Million US$, purchasing power parity","LVA","Latvia","2018","2018",7.9,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","MTMOPPMT","Million US$, purchasing power parity","LVA","Latvia","2019","2019",7.7,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","MTMOPPMT","Million US$, purchasing power parity","LVA","Latvia","2020","2020",7.6,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","MTMOPPMT","Million US$, purchasing power parity","LVA","Latvia","2021","2021",6.1,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","MTMOPPMT","Million US$, purchasing power parity","LVA","Latvia","2022","2022",5.8,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","MTMOPPMT","Million US$, purchasing power parity","LVA","Latvia","2010","2010",4.4,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","MTMOPPMT","Million US$, purchasing power parity","LVA","Latvia","2011","2011",4.2,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","MTMOPPMT","Million US$, purchasing power parity","LVA","Latvia","2012","2012",4.3,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","MTMOPPMT","Million US$, purchasing power parity","LVA","Latvia","2013","2013",4.4,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","MTMOPPMT","Million US$, purchasing power parity","LVA","Latvia","2014","2014",4.4,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","MTMOPPMT","Million US$, purchasing power parity","LVA","Latvia","2015","2015",4.4,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","MTMOPPMT","Million US$, purchasing power parity","LVA","Latvia","2016","2016",4.8,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","MTMOPPMT","Million US$, purchasing power parity","LVA","Latvia","2017","2017",5.1,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","MTMOPPMT","Million US$, purchasing power parity","LVA","Latvia","2018","2018",5.3,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","MTMOPPMT","Million US$, purchasing power parity","LVA","Latvia","2019","2019",5.9,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","MTMOPPMT","Million US$, purchasing power parity","LVA","Latvia","2020","2020",6.2,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","MTMOPPMT","Million US$, purchasing power parity","LVA","Latvia","2021","2021",6,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","MTMOPPMT","Million US$, purchasing power parity","LVA","Latvia","2022","2022",6.2,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","MTMOPPMT","Million US$, purchasing power parity","LVA","Latvia","2010","2010",13.4,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","MTMOPPMT","Million US$, purchasing power parity","LVA","Latvia","2011","2011",13.9,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","MTMOPPMT","Million US$, purchasing power parity","LVA","Latvia","2012","2012",13.9,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","MTMOPPMT","Million US$, purchasing power parity","LVA","Latvia","2013","2013",14.5,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","MTMOPPMT","Million US$, purchasing power parity","LVA","Latvia","2014","2014",15.1,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","MTMOPPMT","Million US$, purchasing power parity","LVA","Latvia","2015","2015",15.3,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","MTMOPPMT","Million US$, purchasing power parity","LVA","Latvia","2016","2016",16.3,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","MTMOPPMT","Million US$, purchasing power parity","LVA","Latvia","2017","2017",16.2,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","MTMOPPMT","Million US$, purchasing power parity","LVA","Latvia","2018","2018",14.7,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","MTMOPPMT","Million US$, purchasing power parity","LVA","Latvia","2019","2019",14.6,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","MTMOPPMT","Million US$, purchasing power parity","LVA","Latvia","2020","2020",13.2,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","MTMOPPMT","Million US$, purchasing power parity","LVA","Latvia","2021","2021",12.3,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","MTMOPPMT","Million US$, purchasing power parity","LVA","Latvia","2022","2022",12.2,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","MTMOPPMT","Million US$, purchasing power parity","LVA","Latvia","2010","2010",8.3,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","MTMOPPMT","Million US$, purchasing power parity","LVA","Latvia","2011","2011",7.7,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","MTMOPPMT","Million US$, purchasing power parity","LVA","Latvia","2012","2012",7.3,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","MTMOPPMT","Million US$, purchasing power parity","LVA","Latvia","2013","2013",6.9,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","MTMOPPMT","Million US$, purchasing power parity","LVA","Latvia","2014","2014",6.4,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","MTMOPPMT","Million US$, purchasing power parity","LVA","Latvia","2015","2015",5.8,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","MTMOPPMT","Million US$, purchasing power parity","LVA","Latvia","2016","2016",5.3,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","MTMOPPMT","Million US$, purchasing power parity","LVA","Latvia","2017","2017",5,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","MTMOPPMT","Million US$, purchasing power parity","LVA","Latvia","2018","2018",4.6,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","MTMOPPMT","Million US$, purchasing power parity","LVA","Latvia","2019","2019",4.3,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","MTMOPPMT","Million US$, purchasing power parity","LVA","Latvia","2020","2020",4,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","MTMOPPMT","Million US$, purchasing power parity","LVA","Latvia","2021","2021",3.3,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","MTMOPPMT","Million US$, purchasing power parity","LVA","Latvia","2022","2022",3.1,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOPPMT","Million US$, purchasing power parity","LVA","Latvia","2010","2010",36.9,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOPPMT","Million US$, purchasing power parity","LVA","Latvia","2011","2011",36.8,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOPPMT","Million US$, purchasing power parity","LVA","Latvia","2012","2012",37.6,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOPPMT","Million US$, purchasing power parity","LVA","Latvia","2013","2013",39,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOPPMT","Million US$, purchasing power parity","LVA","Latvia","2014","2014",38.4,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOPPMT","Million US$, purchasing power parity","LVA","Latvia","2015","2015",37.6,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOPPMT","Million US$, purchasing power parity","LVA","Latvia","2016","2016",38.9,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOPPMT","Million US$, purchasing power parity","LVA","Latvia","2017","2017",40.9,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOPPMT","Million US$, purchasing power parity","LVA","Latvia","2018","2018",40.9,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOPPMT","Million US$, purchasing power parity","LVA","Latvia","2019","2019",42.2,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOPPMT","Million US$, purchasing power parity","LVA","Latvia","2020","2020",40.7,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOPPMT","Million US$, purchasing power parity","LVA","Latvia","2021","2021",36.9,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOPPMT","Million US$, purchasing power parity","LVA","Latvia","2022","2022",36,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","MTMOPPMT","Million US$, purchasing power parity","LVA","Latvia","2010","2010",14.9,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","MTMOPPMT","Million US$, purchasing power parity","LVA","Latvia","2011","2011",15.4,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","MTMOPPMT","Million US$, purchasing power parity","LVA","Latvia","2012","2012",15,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","MTMOPPMT","Million US$, purchasing power parity","LVA","Latvia","2013","2013",13.7,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","MTMOPPMT","Million US$, purchasing power parity","LVA","Latvia","2014","2014",11.3,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","MTMOPPMT","Million US$, purchasing power parity","LVA","Latvia","2015","2015",10.7,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","MTMOPPMT","Million US$, purchasing power parity","LVA","Latvia","2016","2016",11.5,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","MTMOPPMT","Million US$, purchasing power parity","LVA","Latvia","2017","2017",12.9,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","MTMOPPMT","Million US$, purchasing power parity","LVA","Latvia","2018","2018",13.5,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","MTMOPPMT","Million US$, purchasing power parity","LVA","Latvia","2019","2019",16.3,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","MTMOPPMT","Million US$, purchasing power parity","LVA","Latvia","2020","2020",17.7,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","MTMOPPMT","Million US$, purchasing power parity","LVA","Latvia","2021","2021",18.4,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","MTMOPPMT","Million US$, purchasing power parity","LVA","Latvia","2022","2022",20.9,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","MTMOPPMT","Million US$, purchasing power parity","LVA","Latvia","2010","2010",25.5,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","MTMOPPMT","Million US$, purchasing power parity","LVA","Latvia","2011","2011",26.1,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","MTMOPPMT","Million US$, purchasing power parity","LVA","Latvia","2012","2012",25.9,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","MTMOPPMT","Million US$, purchasing power parity","LVA","Latvia","2013","2013",27.7,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","MTMOPPMT","Million US$, purchasing power parity","LVA","Latvia","2014","2014",28.7,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","MTMOPPMT","Million US$, purchasing power parity","LVA","Latvia","2015","2015",28.4,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","MTMOPPMT","Million US$, purchasing power parity","LVA","Latvia","2016","2016",29.2,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","MTMOPPMT","Million US$, purchasing power parity","LVA","Latvia","2017","2017",30.8,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","MTMOPPMT","Million US$, purchasing power parity","LVA","Latvia","2018","2018",30.1,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","MTMOPPMT","Million US$, purchasing power parity","LVA","Latvia","2019","2019",31.2,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","MTMOPPMT","Million US$, purchasing power parity","LVA","Latvia","2020","2020",29.6,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","MTMOPPMT","Million US$, purchasing power parity","LVA","Latvia","2021","2021",28.5,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","MTMOPPMT","Million US$, purchasing power parity","LVA","Latvia","2022","2022",32,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOPPMT","Million US$, purchasing power parity","LVA","Latvia","2010","2010",11.7,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOPPMT","Million US$, purchasing power parity","LVA","Latvia","2011","2011",11.8,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOPPMT","Million US$, purchasing power parity","LVA","Latvia","2012","2012",11.6,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOPPMT","Million US$, purchasing power parity","LVA","Latvia","2013","2013",12.2,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOPPMT","Million US$, purchasing power parity","LVA","Latvia","2014","2014",12.5,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOPPMT","Million US$, purchasing power parity","LVA","Latvia","2015","2015",12.5,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOPPMT","Million US$, purchasing power parity","LVA","Latvia","2016","2016",12.9,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOPPMT","Million US$, purchasing power parity","LVA","Latvia","2017","2017",13.5,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOPPMT","Million US$, purchasing power parity","LVA","Latvia","2018","2018",13.4,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOPPMT","Million US$, purchasing power parity","LVA","Latvia","2019","2019",14.6,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOPPMT","Million US$, purchasing power parity","LVA","Latvia","2020","2020",13.7,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOPPMT","Million US$, purchasing power parity","LVA","Latvia","2021","2021",13.4,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOPPMT","Million US$, purchasing power parity","LVA","Latvia","2022","2022",15.9,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOPPMT","Million US$, purchasing power parity","LVA","Latvia","2010","2010",9.4,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOPPMT","Million US$, purchasing power parity","LVA","Latvia","2011","2011",10,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOPPMT","Million US$, purchasing power parity","LVA","Latvia","2012","2012",10.8,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOPPMT","Million US$, purchasing power parity","LVA","Latvia","2013","2013",12.3,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOPPMT","Million US$, purchasing power parity","LVA","Latvia","2014","2014",11.5,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOPPMT","Million US$, purchasing power parity","LVA","Latvia","2015","2015",11.8,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOPPMT","Million US$, purchasing power parity","LVA","Latvia","2016","2016",12.5,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOPPMT","Million US$, purchasing power parity","LVA","Latvia","2017","2017",12.6,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOPPMT","Million US$, purchasing power parity","LVA","Latvia","2018","2018",13,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOPPMT","Million US$, purchasing power parity","LVA","Latvia","2019","2019",13.2,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOPPMT","Million US$, purchasing power parity","LVA","Latvia","2020","2020",13.3,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOPPMT","Million US$, purchasing power parity","LVA","Latvia","2021","2021",12.8,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOPPMT","Million US$, purchasing power parity","LVA","Latvia","2022","2022",12.2,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","MTMOPPMT","Million US$, purchasing power parity","LVA","Latvia","2010","2010",52.5,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","MTMOPPMT","Million US$, purchasing power parity","LVA","Latvia","2011","2011",53.7,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","MTMOPPMT","Million US$, purchasing power parity","LVA","Latvia","2012","2012",57.8,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","MTMOPPMT","Million US$, purchasing power parity","LVA","Latvia","2013","2013",64,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","MTMOPPMT","Million US$, purchasing power parity","LVA","Latvia","2014","2014",62.6,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","MTMOPPMT","Million US$, purchasing power parity","LVA","Latvia","2015","2015",70.9,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","MTMOPPMT","Million US$, purchasing power parity","LVA","Latvia","2016","2016",114.6,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","MTMOPPMT","Million US$, purchasing power parity","LVA","Latvia","2017","2017",124.9,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","MTMOPPMT","Million US$, purchasing power parity","LVA","Latvia","2018","2018",133,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","MTMOPPMT","Million US$, purchasing power parity","LVA","Latvia","2019","2019",113.9,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","MTMOPPMT","Million US$, purchasing power parity","LVA","Latvia","2020","2020",129,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","MTMOPPMT","Million US$, purchasing power parity","LVA","Latvia","2021","2021",100.6,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","MTMOPPMT","Million US$, purchasing power parity","LVA","Latvia","2022","2022",112.2,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","MTMOPPMT","Million US$, purchasing power parity","LVA","Latvia","2010","2010",19.2,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","MTMOPPMT","Million US$, purchasing power parity","LVA","Latvia","2011","2011",19.2,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","MTMOPPMT","Million US$, purchasing power parity","LVA","Latvia","2012","2012",18.8,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","MTMOPPMT","Million US$, purchasing power parity","LVA","Latvia","2013","2013",19.1,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","MTMOPPMT","Million US$, purchasing power parity","LVA","Latvia","2014","2014",19.7,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","MTMOPPMT","Million US$, purchasing power parity","LVA","Latvia","2015","2015",19.9,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","MTMOPPMT","Million US$, purchasing power parity","LVA","Latvia","2016","2016",20.8,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","MTMOPPMT","Million US$, purchasing power parity","LVA","Latvia","2017","2017",21.9,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","MTMOPPMT","Million US$, purchasing power parity","LVA","Latvia","2018","2018",21.1,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","MTMOPPMT","Million US$, purchasing power parity","LVA","Latvia","2019","2019",21.8,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","MTMOPPMT","Million US$, purchasing power parity","LVA","Latvia","2020","2020",20.3,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","MTMOPPMT","Million US$, purchasing power parity","LVA","Latvia","2021","2021",19,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","MTMOPPMT","Million US$, purchasing power parity","LVA","Latvia","2022","2022",21,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","MTMOPPMT","Million US$, purchasing power parity","LVA","Latvia","2010","2010",37.4,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","MTMOPPMT","Million US$, purchasing power parity","LVA","Latvia","2011","2011",38.3,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","MTMOPPMT","Million US$, purchasing power parity","LVA","Latvia","2012","2012",38.3,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","MTMOPPMT","Million US$, purchasing power parity","LVA","Latvia","2013","2013",40.2,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","MTMOPPMT","Million US$, purchasing power parity","LVA","Latvia","2014","2014",41.8,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","MTMOPPMT","Million US$, purchasing power parity","LVA","Latvia","2015","2015",43.7,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","MTMOPPMT","Million US$, purchasing power parity","LVA","Latvia","2016","2016",47.1,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","MTMOPPMT","Million US$, purchasing power parity","LVA","Latvia","2017","2017",50.7,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","MTMOPPMT","Million US$, purchasing power parity","LVA","Latvia","2018","2018",52.3,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","MTMOPPMT","Million US$, purchasing power parity","LVA","Latvia","2019","2019",59.3,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","MTMOPPMT","Million US$, purchasing power parity","LVA","Latvia","2020","2020",60.4,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","MTMOPPMT","Million US$, purchasing power parity","LVA","Latvia","2021","2021",61.2,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","MTMOPPMT","Million US$, purchasing power parity","LVA","Latvia","2022","2022",70.1,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOPPMT","Million US$, purchasing power parity","LVA","Latvia","2010","2010",21.2,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOPPMT","Million US$, purchasing power parity","LVA","Latvia","2011","2011",22.5,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOPPMT","Million US$, purchasing power parity","LVA","Latvia","2012","2012",22.8,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOPPMT","Million US$, purchasing power parity","LVA","Latvia","2013","2013",24.7,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOPPMT","Million US$, purchasing power parity","LVA","Latvia","2014","2014",26.1,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOPPMT","Million US$, purchasing power parity","LVA","Latvia","2015","2015",28,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOPPMT","Million US$, purchasing power parity","LVA","Latvia","2016","2016",30.7,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOPPMT","Million US$, purchasing power parity","LVA","Latvia","2017","2017",31.8,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOPPMT","Million US$, purchasing power parity","LVA","Latvia","2018","2018",32.3,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOPPMT","Million US$, purchasing power parity","LVA","Latvia","2019","2019",33.4,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOPPMT","Million US$, purchasing power parity","LVA","Latvia","2020","2020",33.6,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOPPMT","Million US$, purchasing power parity","LVA","Latvia","2021","2021",33,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOPPMT","Million US$, purchasing power parity","LVA","Latvia","2022","2022",38.5,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","MTMOPPMT","Million US$, purchasing power parity","LVA","Latvia","2010","2010",67.9,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","MTMOPPMT","Million US$, purchasing power parity","LVA","Latvia","2011","2011",67.3,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","MTMOPPMT","Million US$, purchasing power parity","LVA","Latvia","2012","2012",66.2,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","MTMOPPMT","Million US$, purchasing power parity","LVA","Latvia","2013","2013",66.7,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","MTMOPPMT","Million US$, purchasing power parity","LVA","Latvia","2014","2014",67.7,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","MTMOPPMT","Million US$, purchasing power parity","LVA","Latvia","2015","2015",69.8,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","MTMOPPMT","Million US$, purchasing power parity","LVA","Latvia","2016","2016",72.8,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","MTMOPPMT","Million US$, purchasing power parity","LVA","Latvia","2017","2017",77.1,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","MTMOPPMT","Million US$, purchasing power parity","LVA","Latvia","2018","2018",79.6,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","MTMOPPMT","Million US$, purchasing power parity","LVA","Latvia","2019","2019",85.3,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","MTMOPPMT","Million US$, purchasing power parity","LVA","Latvia","2020","2020",90.9,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","MTMOPPMT","Million US$, purchasing power parity","LVA","Latvia","2021","2021",90.5,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","MTMOPPMT","Million US$, purchasing power parity","LVA","Latvia","2022","2022",103.7,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","MTMOPPMT","Million US$, purchasing power parity","LVA","Latvia","2010","2010",14.7,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","MTMOPPMT","Million US$, purchasing power parity","LVA","Latvia","2011","2011",14.8,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","MTMOPPMT","Million US$, purchasing power parity","LVA","Latvia","2012","2012",14.5,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","MTMOPPMT","Million US$, purchasing power parity","LVA","Latvia","2013","2013",14.9,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","MTMOPPMT","Million US$, purchasing power parity","LVA","Latvia","2014","2014",14.9,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","MTMOPPMT","Million US$, purchasing power parity","LVA","Latvia","2015","2015",15.4,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","MTMOPPMT","Million US$, purchasing power parity","LVA","Latvia","2016","2016",16.4,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","MTMOPPMT","Million US$, purchasing power parity","LVA","Latvia","2017","2017",17.2,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","MTMOPPMT","Million US$, purchasing power parity","LVA","Latvia","2018","2018",18,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","MTMOPPMT","Million US$, purchasing power parity","LVA","Latvia","2019","2019",19.6,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","MTMOPPMT","Million US$, purchasing power parity","LVA","Latvia","2020","2020",21.2,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","MTMOPPMT","Million US$, purchasing power parity","LVA","Latvia","2021","2021",25.4,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","MTMOPPMT","Million US$, purchasing power parity","LVA","Latvia","2022","2022",32,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","MTMOPPMT","Million US$, purchasing power parity","LVA","Latvia","2010","2010",4.3,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","MTMOPPMT","Million US$, purchasing power parity","LVA","Latvia","2011","2011",4.5,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","MTMOPPMT","Million US$, purchasing power parity","LVA","Latvia","2012","2012",4.7,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","MTMOPPMT","Million US$, purchasing power parity","LVA","Latvia","2013","2013",4.9,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","MTMOPPMT","Million US$, purchasing power parity","LVA","Latvia","2014","2014",5.2,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","MTMOPPMT","Million US$, purchasing power parity","LVA","Latvia","2015","2015",5.5,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","MTMOPPMT","Million US$, purchasing power parity","LVA","Latvia","2016","2016",5.8,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","MTMOPPMT","Million US$, purchasing power parity","LVA","Latvia","2017","2017",6,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","MTMOPPMT","Million US$, purchasing power parity","LVA","Latvia","2018","2018",5.9,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","MTMOPPMT","Million US$, purchasing power parity","LVA","Latvia","2019","2019",6.4,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","MTMOPPMT","Million US$, purchasing power parity","LVA","Latvia","2020","2020",6.9,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","MTMOPPMT","Million US$, purchasing power parity","LVA","Latvia","2021","2021",5,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","MTMOPPMT","Million US$, purchasing power parity","LVA","Latvia","2022","2022",5.3,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","MTMOPPMT","Million US$, purchasing power parity","LVA","Latvia","2010","2010",5,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","MTMOPPMT","Million US$, purchasing power parity","LVA","Latvia","2011","2011",5,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","MTMOPPMT","Million US$, purchasing power parity","LVA","Latvia","2012","2012",4.9,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","MTMOPPMT","Million US$, purchasing power parity","LVA","Latvia","2013","2013",5.2,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","MTMOPPMT","Million US$, purchasing power parity","LVA","Latvia","2014","2014",5.5,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","MTMOPPMT","Million US$, purchasing power parity","LVA","Latvia","2015","2015",5.7,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","MTMOPPMT","Million US$, purchasing power parity","LVA","Latvia","2016","2016",6.2,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","MTMOPPMT","Million US$, purchasing power parity","LVA","Latvia","2017","2017",6.4,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","MTMOPPMT","Million US$, purchasing power parity","LVA","Latvia","2018","2018",6.4,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","MTMOPPMT","Million US$, purchasing power parity","LVA","Latvia","2019","2019",7.3,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","MTMOPPMT","Million US$, purchasing power parity","LVA","Latvia","2020","2020",8.2,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","MTMOPPMT","Million US$, purchasing power parity","LVA","Latvia","2021","2021",9.2,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","MTMOPPMT","Million US$, purchasing power parity","LVA","Latvia","2022","2022",9.6,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","MTMOPPMT","Million US$, purchasing power parity","LVA","Latvia","2010","2010",4.7,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","MTMOPPMT","Million US$, purchasing power parity","LVA","Latvia","2011","2011",4.6,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","MTMOPPMT","Million US$, purchasing power parity","LVA","Latvia","2012","2012",4.5,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","MTMOPPMT","Million US$, purchasing power parity","LVA","Latvia","2013","2013",4.5,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","MTMOPPMT","Million US$, purchasing power parity","LVA","Latvia","2014","2014",4.6,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","MTMOPPMT","Million US$, purchasing power parity","LVA","Latvia","2015","2015",5,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","MTMOPPMT","Million US$, purchasing power parity","LVA","Latvia","2016","2016",5.4,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","MTMOPPMT","Million US$, purchasing power parity","LVA","Latvia","2017","2017",5.9,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","MTMOPPMT","Million US$, purchasing power parity","LVA","Latvia","2018","2018",5.7,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","MTMOPPMT","Million US$, purchasing power parity","LVA","Latvia","2019","2019",6.2,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","MTMOPPMT","Million US$, purchasing power parity","LVA","Latvia","2020","2020",6.6,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","MTMOPPMT","Million US$, purchasing power parity","LVA","Latvia","2021","2021",6.7,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","MTMOPPMT","Million US$, purchasing power parity","LVA","Latvia","2022","2022",8,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","MTMOPPMT","Million US$, purchasing power parity","LVA","Latvia","2010","2010",42.3,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","MTMOPPMT","Million US$, purchasing power parity","LVA","Latvia","2011","2011",43,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","MTMOPPMT","Million US$, purchasing power parity","LVA","Latvia","2012","2012",44.1,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","MTMOPPMT","Million US$, purchasing power parity","LVA","Latvia","2013","2013",46.6,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","MTMOPPMT","Million US$, purchasing power parity","LVA","Latvia","2014","2014",48.2,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","MTMOPPMT","Million US$, purchasing power parity","LVA","Latvia","2015","2015",48.8,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","MTMOPPMT","Million US$, purchasing power parity","LVA","Latvia","2016","2016",53,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","MTMOPPMT","Million US$, purchasing power parity","LVA","Latvia","2017","2017",57.2,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","MTMOPPMT","Million US$, purchasing power parity","LVA","Latvia","2018","2018",58.9,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","MTMOPPMT","Million US$, purchasing power parity","LVA","Latvia","2019","2019",61.3,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","MTMOPPMT","Million US$, purchasing power parity","LVA","Latvia","2020","2020",56.5,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","MTMOPPMT","Million US$, purchasing power parity","LVA","Latvia","2021","2021",55.9,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","MTMOPPMT","Million US$, purchasing power parity","LVA","Latvia","2022","2022",85.8,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOPPMT","Million US$, purchasing power parity","LVA","Latvia","2010","2010",17.3,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOPPMT","Million US$, purchasing power parity","LVA","Latvia","2011","2011",17.9,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOPPMT","Million US$, purchasing power parity","LVA","Latvia","2012","2012",18,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOPPMT","Million US$, purchasing power parity","LVA","Latvia","2013","2013",18.7,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOPPMT","Million US$, purchasing power parity","LVA","Latvia","2014","2014",19.2,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOPPMT","Million US$, purchasing power parity","LVA","Latvia","2015","2015",18.4,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOPPMT","Million US$, purchasing power parity","LVA","Latvia","2016","2016",19.1,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOPPMT","Million US$, purchasing power parity","LVA","Latvia","2017","2017",20.1,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOPPMT","Million US$, purchasing power parity","LVA","Latvia","2018","2018",19.3,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOPPMT","Million US$, purchasing power parity","LVA","Latvia","2019","2019",19.8,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOPPMT","Million US$, purchasing power parity","LVA","Latvia","2020","2020",19.9,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOPPMT","Million US$, purchasing power parity","LVA","Latvia","2021","2021",18.8,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOPPMT","Million US$, purchasing power parity","LVA","Latvia","2022","2022",21,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","TCPPERMT","/capita, US$ exchange rate","LVA","Latvia","2010","2010",174.5,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","TCPPERMT","/capita, US$ exchange rate","LVA","Latvia","2011","2011",197.3,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","TCPPERMT","/capita, US$ exchange rate","LVA","Latvia","2012","2012",186.6,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","TCPPERMT","/capita, US$ exchange rate","LVA","Latvia","2013","2013",202.9,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","TCPPERMT","/capita, US$ exchange rate","LVA","Latvia","2014","2014",210.5,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","TCPPERMT","/capita, US$ exchange rate","LVA","Latvia","2015","2015",186,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","TCPPERMT","/capita, US$ exchange rate","LVA","Latvia","2016","2016",208.6,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","TCPPERMT","/capita, US$ exchange rate","LVA","Latvia","2017","2017",228.5,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","TCPPERMT","/capita, US$ exchange rate","LVA","Latvia","2018","2018",252.1,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","TCPPERMT","/capita, US$ exchange rate","LVA","Latvia","2019","2019",249.6,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","TCPPERMT","/capita, US$ exchange rate","LVA","Latvia","2020","2020",268.9,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","TCPPERMT","/capita, US$ exchange rate","LVA","Latvia","2021","2021",288,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","TCPPERMT","/capita, US$ exchange rate","LVA","Latvia","2022","2022",293,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","TCPPERMT","/capita, US$ exchange rate","LVA","Latvia","2010","2010",22.6,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","TCPPERMT","/capita, US$ exchange rate","LVA","Latvia","2011","2011",25.9,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","TCPPERMT","/capita, US$ exchange rate","LVA","Latvia","2012","2012",24.6,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","TCPPERMT","/capita, US$ exchange rate","LVA","Latvia","2013","2013",26.7,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","TCPPERMT","/capita, US$ exchange rate","LVA","Latvia","2014","2014",28.4,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","TCPPERMT","/capita, US$ exchange rate","LVA","Latvia","2015","2015",25.6,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","TCPPERMT","/capita, US$ exchange rate","LVA","Latvia","2016","2016",27.7,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","TCPPERMT","/capita, US$ exchange rate","LVA","Latvia","2017","2017",29.3,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","TCPPERMT","/capita, US$ exchange rate","LVA","Latvia","2018","2018",31.8,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","TCPPERMT","/capita, US$ exchange rate","LVA","Latvia","2019","2019",32.7,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","TCPPERMT","/capita, US$ exchange rate","LVA","Latvia","2020","2020",36.2,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","TCPPERMT","/capita, US$ exchange rate","LVA","Latvia","2021","2021",41.1,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","TCPPERMT","/capita, US$ exchange rate","LVA","Latvia","2022","2022",42.2,"D","Difference in methodology"
+"PATCACID","A02A-Antacids","TCPPERMT","/capita, US$ exchange rate","LVA","Latvia","2010","2010",0.2,"D","Difference in methodology"
+"PATCACID","A02A-Antacids","TCPPERMT","/capita, US$ exchange rate","LVA","Latvia","2011","2011",0.3,"D","Difference in methodology"
+"PATCACID","A02A-Antacids","TCPPERMT","/capita, US$ exchange rate","LVA","Latvia","2012","2012",0.3,"D","Difference in methodology"
+"PATCACID","A02A-Antacids","TCPPERMT","/capita, US$ exchange rate","LVA","Latvia","2013","2013",0.3,"D","Difference in methodology"
+"PATCACID","A02A-Antacids","TCPPERMT","/capita, US$ exchange rate","LVA","Latvia","2014","2014",0.3,"D","Difference in methodology"
+"PATCACID","A02A-Antacids","TCPPERMT","/capita, US$ exchange rate","LVA","Latvia","2015","2015",0.2,"D","Difference in methodology"
+"PATCACID","A02A-Antacids","TCPPERMT","/capita, US$ exchange rate","LVA","Latvia","2016","2016",0.2,"D","Difference in methodology"
+"PATCACID","A02A-Antacids","TCPPERMT","/capita, US$ exchange rate","LVA","Latvia","2017","2017",0.3,"D","Difference in methodology"
+"PATCACID","A02A-Antacids","TCPPERMT","/capita, US$ exchange rate","LVA","Latvia","2018","2018",0.3,"D","Difference in methodology"
+"PATCACID","A02A-Antacids","TCPPERMT","/capita, US$ exchange rate","LVA","Latvia","2019","2019",0.3,"D","Difference in methodology"
+"PATCACID","A02A-Antacids","TCPPERMT","/capita, US$ exchange rate","LVA","Latvia","2020","2020",0.4,"D","Difference in methodology"
+"PATCACID","A02A-Antacids","TCPPERMT","/capita, US$ exchange rate","LVA","Latvia","2021","2021",0.4,"D","Difference in methodology"
+"PATCACID","A02A-Antacids","TCPPERMT","/capita, US$ exchange rate","LVA","Latvia","2022","2022",0.4,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","TCPPERMT","/capita, US$ exchange rate","LVA","Latvia","2010","2010",2.7,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","TCPPERMT","/capita, US$ exchange rate","LVA","Latvia","2011","2011",3,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","TCPPERMT","/capita, US$ exchange rate","LVA","Latvia","2012","2012",2.9,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","TCPPERMT","/capita, US$ exchange rate","LVA","Latvia","2013","2013",3.1,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","TCPPERMT","/capita, US$ exchange rate","LVA","Latvia","2014","2014",3.2,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","TCPPERMT","/capita, US$ exchange rate","LVA","Latvia","2015","2015",2.8,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","TCPPERMT","/capita, US$ exchange rate","LVA","Latvia","2016","2016",2.9,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","TCPPERMT","/capita, US$ exchange rate","LVA","Latvia","2017","2017",3,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","TCPPERMT","/capita, US$ exchange rate","LVA","Latvia","2018","2018",3.2,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","TCPPERMT","/capita, US$ exchange rate","LVA","Latvia","2019","2019",3.6,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","TCPPERMT","/capita, US$ exchange rate","LVA","Latvia","2020","2020",4,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","TCPPERMT","/capita, US$ exchange rate","LVA","Latvia","2021","2021",4.2,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","TCPPERMT","/capita, US$ exchange rate","LVA","Latvia","2022","2022",4.1,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","TCPPERMT","/capita, US$ exchange rate","LVA","Latvia","2010","2010",9.6,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","TCPPERMT","/capita, US$ exchange rate","LVA","Latvia","2011","2011",11.4,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","TCPPERMT","/capita, US$ exchange rate","LVA","Latvia","2012","2012",10.6,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","TCPPERMT","/capita, US$ exchange rate","LVA","Latvia","2013","2013",11.4,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","TCPPERMT","/capita, US$ exchange rate","LVA","Latvia","2014","2014",12,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","TCPPERMT","/capita, US$ exchange rate","LVA","Latvia","2015","2015",11.1,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","TCPPERMT","/capita, US$ exchange rate","LVA","Latvia","2016","2016",11.9,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","TCPPERMT","/capita, US$ exchange rate","LVA","Latvia","2017","2017",13,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","TCPPERMT","/capita, US$ exchange rate","LVA","Latvia","2018","2018",13.9,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","TCPPERMT","/capita, US$ exchange rate","LVA","Latvia","2019","2019",14.2,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","TCPPERMT","/capita, US$ exchange rate","LVA","Latvia","2020","2020",16.2,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","TCPPERMT","/capita, US$ exchange rate","LVA","Latvia","2021","2021",18.4,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","TCPPERMT","/capita, US$ exchange rate","LVA","Latvia","2022","2022",19.1,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","TCPPERMT","/capita, US$ exchange rate","LVA","Latvia","2010","2010",11.8,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","TCPPERMT","/capita, US$ exchange rate","LVA","Latvia","2011","2011",12.9,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","TCPPERMT","/capita, US$ exchange rate","LVA","Latvia","2012","2012",12.3,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","TCPPERMT","/capita, US$ exchange rate","LVA","Latvia","2013","2013",13.5,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","TCPPERMT","/capita, US$ exchange rate","LVA","Latvia","2014","2014",14.7,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","TCPPERMT","/capita, US$ exchange rate","LVA","Latvia","2015","2015",13,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","TCPPERMT","/capita, US$ exchange rate","LVA","Latvia","2016","2016",13.9,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","TCPPERMT","/capita, US$ exchange rate","LVA","Latvia","2017","2017",16.5,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","TCPPERMT","/capita, US$ exchange rate","LVA","Latvia","2018","2018",19.3,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","TCPPERMT","/capita, US$ exchange rate","LVA","Latvia","2019","2019",22.4,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","TCPPERMT","/capita, US$ exchange rate","LVA","Latvia","2020","2020",24,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","TCPPERMT","/capita, US$ exchange rate","LVA","Latvia","2021","2021",27.2,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","TCPPERMT","/capita, US$ exchange rate","LVA","Latvia","2022","2022",25.8,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","TCPPERMT","/capita, US$ exchange rate","LVA","Latvia","2010","2010",33,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","TCPPERMT","/capita, US$ exchange rate","LVA","Latvia","2011","2011",36.7,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","TCPPERMT","/capita, US$ exchange rate","LVA","Latvia","2012","2012",34.8,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","TCPPERMT","/capita, US$ exchange rate","LVA","Latvia","2013","2013",36.4,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","TCPPERMT","/capita, US$ exchange rate","LVA","Latvia","2014","2014",36.1,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","TCPPERMT","/capita, US$ exchange rate","LVA","Latvia","2015","2015",30.1,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","TCPPERMT","/capita, US$ exchange rate","LVA","Latvia","2016","2016",31,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","TCPPERMT","/capita, US$ exchange rate","LVA","Latvia","2017","2017",33,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","TCPPERMT","/capita, US$ exchange rate","LVA","Latvia","2018","2018",34.9,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","TCPPERMT","/capita, US$ exchange rate","LVA","Latvia","2019","2019",34.6,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","TCPPERMT","/capita, US$ exchange rate","LVA","Latvia","2020","2020",34.6,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","TCPPERMT","/capita, US$ exchange rate","LVA","Latvia","2021","2021",36.4,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","TCPPERMT","/capita, US$ exchange rate","LVA","Latvia","2022","2022",33.8,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","TCPPERMT","/capita, US$ exchange rate","LVA","Latvia","2010","2010",0.1,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","TCPPERMT","/capita, US$ exchange rate","LVA","Latvia","2011","2011",0.1,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","TCPPERMT","/capita, US$ exchange rate","LVA","Latvia","2012","2012",0.1,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","TCPPERMT","/capita, US$ exchange rate","LVA","Latvia","2013","2013",0.1,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","TCPPERMT","/capita, US$ exchange rate","LVA","Latvia","2014","2014",0.1,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","TCPPERMT","/capita, US$ exchange rate","LVA","Latvia","2015","2015",0.1,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","TCPPERMT","/capita, US$ exchange rate","LVA","Latvia","2016","2016",0.1,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","TCPPERMT","/capita, US$ exchange rate","LVA","Latvia","2017","2017",0.1,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","TCPPERMT","/capita, US$ exchange rate","LVA","Latvia","2018","2018",0.1,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","TCPPERMT","/capita, US$ exchange rate","LVA","Latvia","2019","2019",0.1,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","TCPPERMT","/capita, US$ exchange rate","LVA","Latvia","2020","2020",0.1,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","TCPPERMT","/capita, US$ exchange rate","LVA","Latvia","2021","2021",0.1,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","TCPPERMT","/capita, US$ exchange rate","LVA","Latvia","2022","2022",0.1,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","TCPPERMT","/capita, US$ exchange rate","LVA","Latvia","2010","2010",0.3,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","TCPPERMT","/capita, US$ exchange rate","LVA","Latvia","2011","2011",0.3,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","TCPPERMT","/capita, US$ exchange rate","LVA","Latvia","2012","2012",0.3,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","TCPPERMT","/capita, US$ exchange rate","LVA","Latvia","2013","2013",0.4,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","TCPPERMT","/capita, US$ exchange rate","LVA","Latvia","2014","2014",0.4,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","TCPPERMT","/capita, US$ exchange rate","LVA","Latvia","2015","2015",0.4,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","TCPPERMT","/capita, US$ exchange rate","LVA","Latvia","2016","2016",0.4,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","TCPPERMT","/capita, US$ exchange rate","LVA","Latvia","2017","2017",0.5,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","TCPPERMT","/capita, US$ exchange rate","LVA","Latvia","2018","2018",0.6,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","TCPPERMT","/capita, US$ exchange rate","LVA","Latvia","2019","2019",0.6,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","TCPPERMT","/capita, US$ exchange rate","LVA","Latvia","2020","2020",0.6,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","TCPPERMT","/capita, US$ exchange rate","LVA","Latvia","2021","2021",0.7,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","TCPPERMT","/capita, US$ exchange rate","LVA","Latvia","2022","2022",0.9,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","TCPPERMT","/capita, US$ exchange rate","LVA","Latvia","2010","2010",1.6,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","TCPPERMT","/capita, US$ exchange rate","LVA","Latvia","2011","2011",1.9,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","TCPPERMT","/capita, US$ exchange rate","LVA","Latvia","2012","2012",1.9,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","TCPPERMT","/capita, US$ exchange rate","LVA","Latvia","2013","2013",2,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","TCPPERMT","/capita, US$ exchange rate","LVA","Latvia","2014","2014",2.1,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","TCPPERMT","/capita, US$ exchange rate","LVA","Latvia","2015","2015",1.8,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","TCPPERMT","/capita, US$ exchange rate","LVA","Latvia","2016","2016",2,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","TCPPERMT","/capita, US$ exchange rate","LVA","Latvia","2017","2017",2.2,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","TCPPERMT","/capita, US$ exchange rate","LVA","Latvia","2018","2018",2.4,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","TCPPERMT","/capita, US$ exchange rate","LVA","Latvia","2019","2019",2.2,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","TCPPERMT","/capita, US$ exchange rate","LVA","Latvia","2020","2020",2.2,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","TCPPERMT","/capita, US$ exchange rate","LVA","Latvia","2021","2021",1.9,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","TCPPERMT","/capita, US$ exchange rate","LVA","Latvia","2022","2022",1.7,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","TCPPERMT","/capita, US$ exchange rate","LVA","Latvia","2010","2010",1.3,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","TCPPERMT","/capita, US$ exchange rate","LVA","Latvia","2011","2011",1.4,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","TCPPERMT","/capita, US$ exchange rate","LVA","Latvia","2012","2012",1.4,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","TCPPERMT","/capita, US$ exchange rate","LVA","Latvia","2013","2013",1.4,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","TCPPERMT","/capita, US$ exchange rate","LVA","Latvia","2014","2014",1.5,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","TCPPERMT","/capita, US$ exchange rate","LVA","Latvia","2015","2015",1.2,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","TCPPERMT","/capita, US$ exchange rate","LVA","Latvia","2016","2016",1.3,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","TCPPERMT","/capita, US$ exchange rate","LVA","Latvia","2017","2017",1.4,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","TCPPERMT","/capita, US$ exchange rate","LVA","Latvia","2018","2018",1.6,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","TCPPERMT","/capita, US$ exchange rate","LVA","Latvia","2019","2019",1.7,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","TCPPERMT","/capita, US$ exchange rate","LVA","Latvia","2020","2020",1.8,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","TCPPERMT","/capita, US$ exchange rate","LVA","Latvia","2021","2021",1.9,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","TCPPERMT","/capita, US$ exchange rate","LVA","Latvia","2022","2022",1.8,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","TCPPERMT","/capita, US$ exchange rate","LVA","Latvia","2010","2010",4.1,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","TCPPERMT","/capita, US$ exchange rate","LVA","Latvia","2011","2011",4.7,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","TCPPERMT","/capita, US$ exchange rate","LVA","Latvia","2012","2012",4.4,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","TCPPERMT","/capita, US$ exchange rate","LVA","Latvia","2013","2013",4.8,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","TCPPERMT","/capita, US$ exchange rate","LVA","Latvia","2014","2014",5,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","TCPPERMT","/capita, US$ exchange rate","LVA","Latvia","2015","2015",4.3,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","TCPPERMT","/capita, US$ exchange rate","LVA","Latvia","2016","2016",4.5,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","TCPPERMT","/capita, US$ exchange rate","LVA","Latvia","2017","2017",4.6,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","TCPPERMT","/capita, US$ exchange rate","LVA","Latvia","2018","2018",4.4,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","TCPPERMT","/capita, US$ exchange rate","LVA","Latvia","2019","2019",4.2,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","TCPPERMT","/capita, US$ exchange rate","LVA","Latvia","2020","2020",3.8,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","TCPPERMT","/capita, US$ exchange rate","LVA","Latvia","2021","2021",3.9,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","TCPPERMT","/capita, US$ exchange rate","LVA","Latvia","2022","2022",3.5,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","TCPPERMT","/capita, US$ exchange rate","LVA","Latvia","2010","2010",2.6,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","TCPPERMT","/capita, US$ exchange rate","LVA","Latvia","2011","2011",2.6,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","TCPPERMT","/capita, US$ exchange rate","LVA","Latvia","2012","2012",2.3,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","TCPPERMT","/capita, US$ exchange rate","LVA","Latvia","2013","2013",2.3,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","TCPPERMT","/capita, US$ exchange rate","LVA","Latvia","2014","2014",2.1,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","TCPPERMT","/capita, US$ exchange rate","LVA","Latvia","2015","2015",1.6,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","TCPPERMT","/capita, US$ exchange rate","LVA","Latvia","2016","2016",1.5,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","TCPPERMT","/capita, US$ exchange rate","LVA","Latvia","2017","2017",1.4,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","TCPPERMT","/capita, US$ exchange rate","LVA","Latvia","2018","2018",1.4,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","TCPPERMT","/capita, US$ exchange rate","LVA","Latvia","2019","2019",1.2,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","TCPPERMT","/capita, US$ exchange rate","LVA","Latvia","2020","2020",1.2,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","TCPPERMT","/capita, US$ exchange rate","LVA","Latvia","2021","2021",1,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","TCPPERMT","/capita, US$ exchange rate","LVA","Latvia","2022","2022",0.9,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","TCPPERMT","/capita, US$ exchange rate","LVA","Latvia","2010","2010",11.4,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","TCPPERMT","/capita, US$ exchange rate","LVA","Latvia","2011","2011",12.5,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","TCPPERMT","/capita, US$ exchange rate","LVA","Latvia","2012","2012",12,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","TCPPERMT","/capita, US$ exchange rate","LVA","Latvia","2013","2013",12.8,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","TCPPERMT","/capita, US$ exchange rate","LVA","Latvia","2014","2014",12.7,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","TCPPERMT","/capita, US$ exchange rate","LVA","Latvia","2015","2015",10.5,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","TCPPERMT","/capita, US$ exchange rate","LVA","Latvia","2016","2016",10.6,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","TCPPERMT","/capita, US$ exchange rate","LVA","Latvia","2017","2017",11.5,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","TCPPERMT","/capita, US$ exchange rate","LVA","Latvia","2018","2018",12.3,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","TCPPERMT","/capita, US$ exchange rate","LVA","Latvia","2019","2019",12,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","TCPPERMT","/capita, US$ exchange rate","LVA","Latvia","2020","2020",11.8,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","TCPPERMT","/capita, US$ exchange rate","LVA","Latvia","2021","2021",11.8,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","TCPPERMT","/capita, US$ exchange rate","LVA","Latvia","2022","2022",10.3,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","TCPPERMT","/capita, US$ exchange rate","LVA","Latvia","2010","2010",4.6,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","TCPPERMT","/capita, US$ exchange rate","LVA","Latvia","2011","2011",5.2,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","TCPPERMT","/capita, US$ exchange rate","LVA","Latvia","2012","2012",4.8,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","TCPPERMT","/capita, US$ exchange rate","LVA","Latvia","2013","2013",4.5,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","TCPPERMT","/capita, US$ exchange rate","LVA","Latvia","2014","2014",3.7,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","TCPPERMT","/capita, US$ exchange rate","LVA","Latvia","2015","2015",3,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","TCPPERMT","/capita, US$ exchange rate","LVA","Latvia","2016","2016",3.1,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","TCPPERMT","/capita, US$ exchange rate","LVA","Latvia","2017","2017",3.6,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","TCPPERMT","/capita, US$ exchange rate","LVA","Latvia","2018","2018",4,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","TCPPERMT","/capita, US$ exchange rate","LVA","Latvia","2019","2019",4.6,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","TCPPERMT","/capita, US$ exchange rate","LVA","Latvia","2020","2020",5.1,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","TCPPERMT","/capita, US$ exchange rate","LVA","Latvia","2021","2021",5.9,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","TCPPERMT","/capita, US$ exchange rate","LVA","Latvia","2022","2022",6,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","TCPPERMT","/capita, US$ exchange rate","LVA","Latvia","2010","2010",7.8,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","TCPPERMT","/capita, US$ exchange rate","LVA","Latvia","2011","2011",8.8,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","TCPPERMT","/capita, US$ exchange rate","LVA","Latvia","2012","2012",8.3,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","TCPPERMT","/capita, US$ exchange rate","LVA","Latvia","2013","2013",9.1,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","TCPPERMT","/capita, US$ exchange rate","LVA","Latvia","2014","2014",9.5,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","TCPPERMT","/capita, US$ exchange rate","LVA","Latvia","2015","2015",7.9,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","TCPPERMT","/capita, US$ exchange rate","LVA","Latvia","2016","2016",8,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","TCPPERMT","/capita, US$ exchange rate","LVA","Latvia","2017","2017",8.7,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","TCPPERMT","/capita, US$ exchange rate","LVA","Latvia","2018","2018",9,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","TCPPERMT","/capita, US$ exchange rate","LVA","Latvia","2019","2019",8.9,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","TCPPERMT","/capita, US$ exchange rate","LVA","Latvia","2020","2020",8.6,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","TCPPERMT","/capita, US$ exchange rate","LVA","Latvia","2021","2021",9.1,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","TCPPERMT","/capita, US$ exchange rate","LVA","Latvia","2022","2022",9.1,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","TCPPERMT","/capita, US$ exchange rate","LVA","Latvia","2010","2010",3.6,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","TCPPERMT","/capita, US$ exchange rate","LVA","Latvia","2011","2011",4,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","TCPPERMT","/capita, US$ exchange rate","LVA","Latvia","2012","2012",3.7,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","TCPPERMT","/capita, US$ exchange rate","LVA","Latvia","2013","2013",4,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","TCPPERMT","/capita, US$ exchange rate","LVA","Latvia","2014","2014",4.1,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","TCPPERMT","/capita, US$ exchange rate","LVA","Latvia","2015","2015",3.5,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","TCPPERMT","/capita, US$ exchange rate","LVA","Latvia","2016","2016",3.5,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","TCPPERMT","/capita, US$ exchange rate","LVA","Latvia","2017","2017",3.8,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","TCPPERMT","/capita, US$ exchange rate","LVA","Latvia","2018","2018",4,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","TCPPERMT","/capita, US$ exchange rate","LVA","Latvia","2019","2019",4.2,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","TCPPERMT","/capita, US$ exchange rate","LVA","Latvia","2020","2020",4,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","TCPPERMT","/capita, US$ exchange rate","LVA","Latvia","2021","2021",4.3,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","TCPPERMT","/capita, US$ exchange rate","LVA","Latvia","2022","2022",4.5,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","TCPPERMT","/capita, US$ exchange rate","LVA","Latvia","2010","2010",2.9,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","TCPPERMT","/capita, US$ exchange rate","LVA","Latvia","2011","2011",3.4,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","TCPPERMT","/capita, US$ exchange rate","LVA","Latvia","2012","2012",3.5,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","TCPPERMT","/capita, US$ exchange rate","LVA","Latvia","2013","2013",4,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","TCPPERMT","/capita, US$ exchange rate","LVA","Latvia","2014","2014",3.8,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","TCPPERMT","/capita, US$ exchange rate","LVA","Latvia","2015","2015",3.3,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","TCPPERMT","/capita, US$ exchange rate","LVA","Latvia","2016","2016",3.4,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","TCPPERMT","/capita, US$ exchange rate","LVA","Latvia","2017","2017",3.5,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","TCPPERMT","/capita, US$ exchange rate","LVA","Latvia","2018","2018",3.9,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","TCPPERMT","/capita, US$ exchange rate","LVA","Latvia","2019","2019",3.8,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","TCPPERMT","/capita, US$ exchange rate","LVA","Latvia","2020","2020",3.9,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","TCPPERMT","/capita, US$ exchange rate","LVA","Latvia","2021","2021",4.1,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","TCPPERMT","/capita, US$ exchange rate","LVA","Latvia","2022","2022",3.5,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","TCPPERMT","/capita, US$ exchange rate","LVA","Latvia","2010","2010",16.2,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","TCPPERMT","/capita, US$ exchange rate","LVA","Latvia","2011","2011",18.2,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","TCPPERMT","/capita, US$ exchange rate","LVA","Latvia","2012","2012",18.5,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","TCPPERMT","/capita, US$ exchange rate","LVA","Latvia","2013","2013",21.1,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","TCPPERMT","/capita, US$ exchange rate","LVA","Latvia","2014","2014",20.7,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","TCPPERMT","/capita, US$ exchange rate","LVA","Latvia","2015","2015",19.8,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","TCPPERMT","/capita, US$ exchange rate","LVA","Latvia","2016","2016",31.4,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","TCPPERMT","/capita, US$ exchange rate","LVA","Latvia","2017","2017",35.2,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","TCPPERMT","/capita, US$ exchange rate","LVA","Latvia","2018","2018",39.9,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","TCPPERMT","/capita, US$ exchange rate","LVA","Latvia","2019","2019",32.4,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","TCPPERMT","/capita, US$ exchange rate","LVA","Latvia","2020","2020",37.4,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","TCPPERMT","/capita, US$ exchange rate","LVA","Latvia","2021","2021",32.1,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","TCPPERMT","/capita, US$ exchange rate","LVA","Latvia","2022","2022",32.1,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","TCPPERMT","/capita, US$ exchange rate","LVA","Latvia","2010","2010",5.9,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","TCPPERMT","/capita, US$ exchange rate","LVA","Latvia","2011","2011",6.5,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","TCPPERMT","/capita, US$ exchange rate","LVA","Latvia","2012","2012",6,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","TCPPERMT","/capita, US$ exchange rate","LVA","Latvia","2013","2013",6.3,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","TCPPERMT","/capita, US$ exchange rate","LVA","Latvia","2014","2014",6.5,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","TCPPERMT","/capita, US$ exchange rate","LVA","Latvia","2015","2015",5.6,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","TCPPERMT","/capita, US$ exchange rate","LVA","Latvia","2016","2016",5.7,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","TCPPERMT","/capita, US$ exchange rate","LVA","Latvia","2017","2017",6.2,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","TCPPERMT","/capita, US$ exchange rate","LVA","Latvia","2018","2018",6.3,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","TCPPERMT","/capita, US$ exchange rate","LVA","Latvia","2019","2019",6.2,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","TCPPERMT","/capita, US$ exchange rate","LVA","Latvia","2020","2020",5.9,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","TCPPERMT","/capita, US$ exchange rate","LVA","Latvia","2021","2021",6.1,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","TCPPERMT","/capita, US$ exchange rate","LVA","Latvia","2022","2022",6,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","TCPPERMT","/capita, US$ exchange rate","LVA","Latvia","2010","2010",11.5,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","TCPPERMT","/capita, US$ exchange rate","LVA","Latvia","2011","2011",13,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","TCPPERMT","/capita, US$ exchange rate","LVA","Latvia","2012","2012",12.2,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","TCPPERMT","/capita, US$ exchange rate","LVA","Latvia","2013","2013",13.2,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","TCPPERMT","/capita, US$ exchange rate","LVA","Latvia","2014","2014",13.9,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","TCPPERMT","/capita, US$ exchange rate","LVA","Latvia","2015","2015",12.2,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","TCPPERMT","/capita, US$ exchange rate","LVA","Latvia","2016","2016",12.9,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","TCPPERMT","/capita, US$ exchange rate","LVA","Latvia","2017","2017",14.3,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","TCPPERMT","/capita, US$ exchange rate","LVA","Latvia","2018","2018",15.7,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","TCPPERMT","/capita, US$ exchange rate","LVA","Latvia","2019","2019",16.9,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","TCPPERMT","/capita, US$ exchange rate","LVA","Latvia","2020","2020",17.5,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","TCPPERMT","/capita, US$ exchange rate","LVA","Latvia","2021","2021",19.5,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","TCPPERMT","/capita, US$ exchange rate","LVA","Latvia","2022","2022",20,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","TCPPERMT","/capita, US$ exchange rate","LVA","Latvia","2010","2010",6.5,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","TCPPERMT","/capita, US$ exchange rate","LVA","Latvia","2011","2011",7.7,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","TCPPERMT","/capita, US$ exchange rate","LVA","Latvia","2012","2012",7.3,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","TCPPERMT","/capita, US$ exchange rate","LVA","Latvia","2013","2013",8.1,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","TCPPERMT","/capita, US$ exchange rate","LVA","Latvia","2014","2014",8.7,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","TCPPERMT","/capita, US$ exchange rate","LVA","Latvia","2015","2015",7.8,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","TCPPERMT","/capita, US$ exchange rate","LVA","Latvia","2016","2016",8.4,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","TCPPERMT","/capita, US$ exchange rate","LVA","Latvia","2017","2017",9,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","TCPPERMT","/capita, US$ exchange rate","LVA","Latvia","2018","2018",9.7,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","TCPPERMT","/capita, US$ exchange rate","LVA","Latvia","2019","2019",9.5,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","TCPPERMT","/capita, US$ exchange rate","LVA","Latvia","2020","2020",9.8,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","TCPPERMT","/capita, US$ exchange rate","LVA","Latvia","2021","2021",10.5,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","TCPPERMT","/capita, US$ exchange rate","LVA","Latvia","2022","2022",11,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","TCPPERMT","/capita, US$ exchange rate","LVA","Latvia","2010","2010",20.9,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","TCPPERMT","/capita, US$ exchange rate","LVA","Latvia","2011","2011",22.8,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","TCPPERMT","/capita, US$ exchange rate","LVA","Latvia","2012","2012",21.2,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","TCPPERMT","/capita, US$ exchange rate","LVA","Latvia","2013","2013",22,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","TCPPERMT","/capita, US$ exchange rate","LVA","Latvia","2014","2014",22.5,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","TCPPERMT","/capita, US$ exchange rate","LVA","Latvia","2015","2015",19.5,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","TCPPERMT","/capita, US$ exchange rate","LVA","Latvia","2016","2016",19.9,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","TCPPERMT","/capita, US$ exchange rate","LVA","Latvia","2017","2017",21.7,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","TCPPERMT","/capita, US$ exchange rate","LVA","Latvia","2018","2018",23.9,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","TCPPERMT","/capita, US$ exchange rate","LVA","Latvia","2019","2019",24.3,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","TCPPERMT","/capita, US$ exchange rate","LVA","Latvia","2020","2020",26.4,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","TCPPERMT","/capita, US$ exchange rate","LVA","Latvia","2021","2021",28.9,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","TCPPERMT","/capita, US$ exchange rate","LVA","Latvia","2022","2022",29.7,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","TCPPERMT","/capita, US$ exchange rate","LVA","Latvia","2010","2010",4.5,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","TCPPERMT","/capita, US$ exchange rate","LVA","Latvia","2011","2011",5,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","TCPPERMT","/capita, US$ exchange rate","LVA","Latvia","2012","2012",4.6,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","TCPPERMT","/capita, US$ exchange rate","LVA","Latvia","2013","2013",4.9,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","TCPPERMT","/capita, US$ exchange rate","LVA","Latvia","2014","2014",4.9,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","TCPPERMT","/capita, US$ exchange rate","LVA","Latvia","2015","2015",4.3,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","TCPPERMT","/capita, US$ exchange rate","LVA","Latvia","2016","2016",4.5,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","TCPPERMT","/capita, US$ exchange rate","LVA","Latvia","2017","2017",4.9,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","TCPPERMT","/capita, US$ exchange rate","LVA","Latvia","2018","2018",5.4,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","TCPPERMT","/capita, US$ exchange rate","LVA","Latvia","2019","2019",5.6,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","TCPPERMT","/capita, US$ exchange rate","LVA","Latvia","2020","2020",6.2,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","TCPPERMT","/capita, US$ exchange rate","LVA","Latvia","2021","2021",8.1,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","TCPPERMT","/capita, US$ exchange rate","LVA","Latvia","2022","2022",9.1,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","TCPPERMT","/capita, US$ exchange rate","LVA","Latvia","2010","2010",1.3,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","TCPPERMT","/capita, US$ exchange rate","LVA","Latvia","2011","2011",1.5,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","TCPPERMT","/capita, US$ exchange rate","LVA","Latvia","2012","2012",1.5,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","TCPPERMT","/capita, US$ exchange rate","LVA","Latvia","2013","2013",1.6,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","TCPPERMT","/capita, US$ exchange rate","LVA","Latvia","2014","2014",1.7,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","TCPPERMT","/capita, US$ exchange rate","LVA","Latvia","2015","2015",1.5,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","TCPPERMT","/capita, US$ exchange rate","LVA","Latvia","2016","2016",1.6,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","TCPPERMT","/capita, US$ exchange rate","LVA","Latvia","2017","2017",1.7,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","TCPPERMT","/capita, US$ exchange rate","LVA","Latvia","2018","2018",1.8,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","TCPPERMT","/capita, US$ exchange rate","LVA","Latvia","2019","2019",1.8,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","TCPPERMT","/capita, US$ exchange rate","LVA","Latvia","2020","2020",2,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","TCPPERMT","/capita, US$ exchange rate","LVA","Latvia","2021","2021",1.6,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","TCPPERMT","/capita, US$ exchange rate","LVA","Latvia","2022","2022",1.5,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","TCPPERMT","/capita, US$ exchange rate","LVA","Latvia","2010","2010",1.5,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","TCPPERMT","/capita, US$ exchange rate","LVA","Latvia","2011","2011",1.7,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","TCPPERMT","/capita, US$ exchange rate","LVA","Latvia","2012","2012",1.6,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","TCPPERMT","/capita, US$ exchange rate","LVA","Latvia","2013","2013",1.7,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","TCPPERMT","/capita, US$ exchange rate","LVA","Latvia","2014","2014",1.8,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","TCPPERMT","/capita, US$ exchange rate","LVA","Latvia","2015","2015",1.6,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","TCPPERMT","/capita, US$ exchange rate","LVA","Latvia","2016","2016",1.7,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","TCPPERMT","/capita, US$ exchange rate","LVA","Latvia","2017","2017",1.8,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","TCPPERMT","/capita, US$ exchange rate","LVA","Latvia","2018","2018",1.9,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","TCPPERMT","/capita, US$ exchange rate","LVA","Latvia","2019","2019",2.1,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","TCPPERMT","/capita, US$ exchange rate","LVA","Latvia","2020","2020",2.4,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","TCPPERMT","/capita, US$ exchange rate","LVA","Latvia","2021","2021",2.9,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","TCPPERMT","/capita, US$ exchange rate","LVA","Latvia","2022","2022",2.7,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","TCPPERMT","/capita, US$ exchange rate","LVA","Latvia","2010","2010",1.4,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","TCPPERMT","/capita, US$ exchange rate","LVA","Latvia","2011","2011",1.6,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","TCPPERMT","/capita, US$ exchange rate","LVA","Latvia","2012","2012",1.4,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","TCPPERMT","/capita, US$ exchange rate","LVA","Latvia","2013","2013",1.5,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","TCPPERMT","/capita, US$ exchange rate","LVA","Latvia","2014","2014",1.5,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","TCPPERMT","/capita, US$ exchange rate","LVA","Latvia","2015","2015",1.4,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","TCPPERMT","/capita, US$ exchange rate","LVA","Latvia","2016","2016",1.5,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","TCPPERMT","/capita, US$ exchange rate","LVA","Latvia","2017","2017",1.7,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","TCPPERMT","/capita, US$ exchange rate","LVA","Latvia","2018","2018",1.7,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","TCPPERMT","/capita, US$ exchange rate","LVA","Latvia","2019","2019",1.8,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","TCPPERMT","/capita, US$ exchange rate","LVA","Latvia","2020","2020",1.9,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","TCPPERMT","/capita, US$ exchange rate","LVA","Latvia","2021","2021",2.1,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","TCPPERMT","/capita, US$ exchange rate","LVA","Latvia","2022","2022",2.3,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","TCPPERMT","/capita, US$ exchange rate","LVA","Latvia","2010","2010",13,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","TCPPERMT","/capita, US$ exchange rate","LVA","Latvia","2011","2011",14.6,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","TCPPERMT","/capita, US$ exchange rate","LVA","Latvia","2012","2012",14.1,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","TCPPERMT","/capita, US$ exchange rate","LVA","Latvia","2013","2013",15.3,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","TCPPERMT","/capita, US$ exchange rate","LVA","Latvia","2014","2014",16,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","TCPPERMT","/capita, US$ exchange rate","LVA","Latvia","2015","2015",13.6,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","TCPPERMT","/capita, US$ exchange rate","LVA","Latvia","2016","2016",14.5,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","TCPPERMT","/capita, US$ exchange rate","LVA","Latvia","2017","2017",16.1,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","TCPPERMT","/capita, US$ exchange rate","LVA","Latvia","2018","2018",17.7,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","TCPPERMT","/capita, US$ exchange rate","LVA","Latvia","2019","2019",17.5,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","TCPPERMT","/capita, US$ exchange rate","LVA","Latvia","2020","2020",16.4,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","TCPPERMT","/capita, US$ exchange rate","LVA","Latvia","2021","2021",17.9,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","TCPPERMT","/capita, US$ exchange rate","LVA","Latvia","2022","2022",24.5,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","TCPPERMT","/capita, US$ exchange rate","LVA","Latvia","2010","2010",5.3,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","TCPPERMT","/capita, US$ exchange rate","LVA","Latvia","2011","2011",6.1,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","TCPPERMT","/capita, US$ exchange rate","LVA","Latvia","2012","2012",5.7,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","TCPPERMT","/capita, US$ exchange rate","LVA","Latvia","2013","2013",6.2,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","TCPPERMT","/capita, US$ exchange rate","LVA","Latvia","2014","2014",6.4,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","TCPPERMT","/capita, US$ exchange rate","LVA","Latvia","2015","2015",5.1,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","TCPPERMT","/capita, US$ exchange rate","LVA","Latvia","2016","2016",5.2,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","TCPPERMT","/capita, US$ exchange rate","LVA","Latvia","2017","2017",5.7,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","TCPPERMT","/capita, US$ exchange rate","LVA","Latvia","2018","2018",5.8,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","TCPPERMT","/capita, US$ exchange rate","LVA","Latvia","2019","2019",5.6,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","TCPPERMT","/capita, US$ exchange rate","LVA","Latvia","2020","2020",5.8,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","TCPPERMT","/capita, US$ exchange rate","LVA","Latvia","2021","2021",6,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","TCPPERMT","/capita, US$ exchange rate","LVA","Latvia","2022","2022",6,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2010","2010",270.4,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2011","2011",282.3,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2012","2012",286.8,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2013","2013",306.1,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2014","2014",318.5,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2015","2015",337,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2016","2016",388.9,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2017","2017",417.4,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2018","2018",435.6,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2019","2019",457.9,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2020","2020",487.7,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2021","2021",478.4,"D","Difference in methodology"
+"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2022","2022",546.3,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2010","2010",35,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2011","2011",37.1,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2012","2012",37.7,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2013","2013",40.3,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2014","2014",43,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2015","2015",46.3,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2016","2016",51.7,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2017","2017",53.6,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2018","2018",55,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2019","2019",60.1,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2020","2020",65.6,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2021","2021",68.3,"D","Difference in methodology"
+"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2022","2022",78.8,"D","Difference in methodology"
+"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2010","2010",0.4,"D","Difference in methodology"
+"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2011","2011",0.4,"D","Difference in methodology"
+"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2012","2012",0.4,"D","Difference in methodology"
+"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2013","2013",0.4,"D","Difference in methodology"
+"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2014","2014",0.4,"D","Difference in methodology"
+"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2015","2015",0.4,"D","Difference in methodology"
+"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2016","2016",0.4,"D","Difference in methodology"
+"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2017","2017",0.5,"D","Difference in methodology"
+"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2018","2018",0.5,"D","Difference in methodology"
+"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2019","2019",0.6,"D","Difference in methodology"
+"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2020","2020",0.7,"D","Difference in methodology"
+"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2021","2021",0.7,"D","Difference in methodology"
+"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2022","2022",0.7,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2010","2010",4.1,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2011","2011",4.3,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2012","2012",4.5,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2013","2013",4.6,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2014","2014",4.9,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2015","2015",5,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2016","2016",5.4,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2017","2017",5.5,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2018","2018",5.6,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2019","2019",6.5,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2020","2020",7.2,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2021","2021",7.1,"D","Difference in methodology"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2022","2022",7.6,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2010","2010",14.9,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2011","2011",16.4,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2012","2012",16.2,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2013","2013",17.2,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2014","2014",18.2,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2015","2015",20.1,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2016","2016",22.2,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2017","2017",23.8,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2018","2018",24,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2019","2019",26,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2020","2020",29.5,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2021","2021",30.5,"D","Difference in methodology"
+"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2022","2022",35.6,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2010","2010",18.3,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2011","2011",18.5,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2012","2012",19,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2013","2013",20.4,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2014","2014",22.3,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2015","2015",23.5,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2016","2016",26,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2017","2017",30.1,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2018","2018",33.4,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2019","2019",41.1,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2020","2020",43.6,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2021","2021",45.1,"D","Difference in methodology"
+"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2022","2022",48,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2010","2010",51.2,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2011","2011",52.5,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2012","2012",53.5,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2013","2013",55,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2014","2014",54.6,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2015","2015",54.5,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2016","2016",57.9,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2017","2017",60.3,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2018","2018",60.3,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2019","2019",63.5,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2020","2020",62.8,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2021","2021",60.5,"D","Difference in methodology"
+"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2022","2022",63,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2010","2010",0.1,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2011","2011",0.1,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2012","2012",0.1,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2013","2013",0.1,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2014","2014",0.1,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2015","2015",0.1,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2016","2016",0.1,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2017","2017",0.1,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2018","2018",0.1,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2019","2019",0.1,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2020","2020",0.1,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2021","2021",0.1,"D","Difference in methodology"
+"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2022","2022",0.1,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2010","2010",0.4,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2011","2011",0.4,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2012","2012",0.5,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2013","2013",0.6,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2014","2014",0.6,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2015","2015",0.7,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2016","2016",0.8,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2017","2017",0.9,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2018","2018",1,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2019","2019",1.1,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2020","2020",1.2,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2021","2021",1.2,"D","Difference in methodology"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2022","2022",1.7,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2010","2010",2.5,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2011","2011",2.8,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2012","2012",2.9,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2013","2013",3,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2014","2014",3.2,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2015","2015",3.3,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2016","2016",3.7,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2017","2017",4,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2018","2018",4.1,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2019","2019",4,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2020","2020",4,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2021","2021",3.2,"D","Difference in methodology"
+"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2022","2022",3.1,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2010","2010",2.1,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2011","2011",2.1,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2012","2012",2.1,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2013","2013",2.2,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2014","2014",2.2,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2015","2015",2.2,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2016","2016",2.4,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2017","2017",2.6,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2018","2018",2.7,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2019","2019",3.1,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2020","2020",3.3,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2021","2021",3.2,"D","Difference in methodology"
+"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2022","2022",3.3,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2010","2010",6.4,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2011","2011",6.7,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2012","2012",6.8,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2013","2013",7.2,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2014","2014",7.6,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2015","2015",7.7,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2016","2016",8.3,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2017","2017",8.3,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2018","2018",7.7,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2019","2019",7.6,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2020","2020",7,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2021","2021",6.5,"D","Difference in methodology"
+"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2022","2022",6.5,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2010","2010",4,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2011","2011",3.8,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2012","2012",3.6,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2013","2013",3.4,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2014","2014",3.2,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2015","2015",2.9,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2016","2016",2.7,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2017","2017",2.5,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2018","2018",2.4,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2019","2019",2.2,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2020","2020",2.1,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2021","2021",1.7,"D","Difference in methodology"
+"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2022","2022",1.7,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2010","2010",17.6,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2011","2011",17.9,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2012","2012",18.5,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2013","2013",19.4,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2014","2014",19.3,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2015","2015",19,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2016","2016",19.8,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2017","2017",21.1,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2018","2018",21.2,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2019","2019",22.1,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2020","2020",21.4,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2021","2021",19.6,"D","Difference in methodology"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2022","2022",19.2,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2010","2010",7.1,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2011","2011",7.5,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2012","2012",7.4,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2013","2013",6.8,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2014","2014",5.7,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2015","2015",5.4,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2016","2016",5.9,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2017","2017",6.6,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2018","2018",7,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2019","2019",8.5,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2020","2020",9.3,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2021","2021",9.8,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2022","2022",11.1,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2010","2010",12.2,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2011","2011",12.7,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2012","2012",12.8,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2013","2013",13.8,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2014","2014",14.4,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2015","2015",14.4,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2016","2016",14.9,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2017","2017",15.9,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2018","2018",15.6,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2019","2019",16.3,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2020","2020",15.6,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2021","2021",15.1,"D","Difference in methodology"
+"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2022","2022",17.1,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2010","2010",5.6,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2011","2011",5.7,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2012","2012",5.7,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2013","2013",6.1,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2014","2014",6.3,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2015","2015",6.3,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2016","2016",6.6,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2017","2017",6.9,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2018","2018",7,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2019","2019",7.6,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2020","2020",7.2,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2021","2021",7.1,"D","Difference in methodology"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2022","2022",8.5,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2010","2010",4.5,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2011","2011",4.9,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2012","2012",5.3,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2013","2013",6.1,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2014","2014",5.8,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2015","2015",6,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2016","2016",6.4,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2017","2017",6.5,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2018","2018",6.7,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2019","2019",6.9,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2020","2020",7,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2021","2021",6.8,"D","Difference in methodology"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2022","2022",6.5,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2010","2010",25,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2011","2011",26.1,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2012","2012",28.4,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2013","2013",31.8,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2014","2014",31.4,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2015","2015",35.9,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2016","2016",58.5,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2017","2017",64.3,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2018","2018",69,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2019","2019",59.5,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2020","2020",67.9,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2021","2021",53.4,"D","Difference in methodology"
+"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2022","2022",59.8,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2010","2010",9.2,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2011","2011",9.3,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2012","2012",9.2,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2013","2013",9.5,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2014","2014",9.9,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2015","2015",10.1,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2016","2016",10.6,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2017","2017",11.3,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2018","2018",10.9,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2019","2019",11.4,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2020","2020",10.7,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2021","2021",10.1,"D","Difference in methodology"
+"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2022","2022",11.2,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2010","2010",17.8,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2011","2011",18.6,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2012","2012",18.8,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2013","2013",20,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2014","2014",21,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2015","2015",22.1,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2016","2016",24,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2017","2017",26.1,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2018","2018",27.1,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2019","2019",31,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2020","2020",31.8,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2021","2021",32.5,"D","Difference in methodology"
+"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2022","2022",37.4,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2010","2010",10.1,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2011","2011",10.9,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2012","2012",11.2,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2013","2013",12.3,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2014","2014",13.1,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2015","2015",14.2,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2016","2016",15.7,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2017","2017",16.4,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2018","2018",16.8,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2019","2019",17.5,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2020","2020",17.7,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2021","2021",17.5,"D","Difference in methodology"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2022","2022",20.5,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2010","2010",32.4,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2011","2011",32.7,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2012","2012",32.5,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2013","2013",33.1,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2014","2014",34,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2015","2015",35.3,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2016","2016",37.2,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2017","2017",39.7,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2018","2018",41.3,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2019","2019",44.6,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2020","2020",47.9,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2021","2021",48,"D","Difference in methodology"
+"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2022","2022",55.3,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2010","2010",7,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2011","2011",7.2,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2012","2012",7.1,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2013","2013",7.4,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2014","2014",7.4,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2015","2015",7.8,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2016","2016",8.4,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2017","2017",8.9,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2018","2018",9.3,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2019","2019",10.2,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2020","2020",11.2,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2021","2021",13.5,"D","Difference in methodology"
+"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2022","2022",17,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2010","2010",2,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2011","2011",2.2,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2012","2012",2.3,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2013","2013",2.4,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2014","2014",2.6,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2015","2015",2.8,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2016","2016",2.9,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2017","2017",3.1,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2018","2018",3.1,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2019","2019",3.4,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2020","2020",3.7,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2021","2021",2.6,"D","Difference in methodology"
+"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2022","2022",2.8,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2010","2010",2.4,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2011","2011",2.4,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2012","2012",2.4,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2013","2013",2.6,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2014","2014",2.8,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2015","2015",2.9,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2016","2016",3.2,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2017","2017",3.3,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2018","2018",3.3,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2019","2019",3.8,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2020","2020",4.3,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2021","2021",4.9,"D","Difference in methodology"
+"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2022","2022",5.1,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2010","2010",2.2,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2011","2011",2.2,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2012","2012",2.2,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2013","2013",2.2,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2014","2014",2.3,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2015","2015",2.5,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2016","2016",2.7,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2017","2017",3,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2018","2018",3,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2019","2019",3.2,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2020","2020",3.5,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2021","2021",3.6,"D","Difference in methodology"
+"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2022","2022",4.2,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2010","2010",20.1,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2011","2011",20.9,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2012","2012",21.7,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2013","2013",23.2,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2014","2014",24.2,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2015","2015",24.7,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2016","2016",27,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2017","2017",29.4,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2018","2018",30.5,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2019","2019",32.1,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2020","2020",29.7,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2021","2021",29.7,"D","Difference in methodology"
+"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2022","2022",45.8,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2010","2010",8.3,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2011","2011",8.7,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2012","2012",8.8,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2013","2013",9.3,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2014","2014",9.6,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2015","2015",9.3,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2016","2016",9.8,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2017","2017",10.4,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2018","2018",10,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2019","2019",10.4,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2020","2020",10.5,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2021","2021",10,"D","Difference in methodology"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2022","2022",11.2,"D","Difference in methodology"
+"PATCCHLS","C10-Lipid modifying agents","MTMOTCMT","Million US$ at exchange rate","CRI","Costa Rica","2010","2010",3.6,,
+"PATCCHLS","C10-Lipid modifying agents","MTMOTCMT","Million US$ at exchange rate","CRI","Costa Rica","2011","2011",3.9,,
+"PATCCHLS","C10-Lipid modifying agents","MTMOTCMT","Million US$ at exchange rate","CRI","Costa Rica","2012","2012",4.2,,
+"PATCCHLS","C10-Lipid modifying agents","MTMOTCMT","Million US$ at exchange rate","CRI","Costa Rica","2013","2013",3.9,,
+"PATCCHLS","C10-Lipid modifying agents","MTMOTCMT","Million US$ at exchange rate","CRI","Costa Rica","2014","2014",5.5,"B","Break"
+"PATCCHLS","C10-Lipid modifying agents","MTMOTCMT","Million US$ at exchange rate","CRI","Costa Rica","2015","2015",3.2,,
+"PATCCHLS","C10-Lipid modifying agents","MTMOTCMT","Million US$ at exchange rate","CRI","Costa Rica","2016","2016",3.1,,
+"PATCCHLS","C10-Lipid modifying agents","MTMOTCMT","Million US$ at exchange rate","CRI","Costa Rica","2017","2017",3.4,,
+"PATCCHLS","C10-Lipid modifying agents","MTMOTCMT","Million US$ at exchange rate","CRI","Costa Rica","2018","2018",4.1,,
+"PATCCHLS","C10-Lipid modifying agents","MTMOTCMT","Million US$ at exchange rate","CRI","Costa Rica","2019","2019",4.6,,
+"PATCCHLS","C10-Lipid modifying agents","MTMOTCMT","Million US$ at exchange rate","CRI","Costa Rica","2020","2020",4.1,,
+"PATCCHLS","C10-Lipid modifying agents","MTMOTCMT","Million US$ at exchange rate","CRI","Costa Rica","2021","2021",4.7,,
+"PATCCHLS","C10-Lipid modifying agents","MTMOTCMT","Million US$ at exchange rate","CRI","Costa Rica","2022","2022",3.2,,
+"PATCBLOO","B-Blood and blood forming organs","TCPPERMT","/capita, US$ exchange rate","CRI","Costa Rica","2010","2010",4.8,,
+"PATCBLOO","B-Blood and blood forming organs","TCPPERMT","/capita, US$ exchange rate","CRI","Costa Rica","2011","2011",5.1,,
+"PATCBLOO","B-Blood and blood forming organs","TCPPERMT","/capita, US$ exchange rate","CRI","Costa Rica","2012","2012",5.2,,
+"PATCBLOO","B-Blood and blood forming organs","TCPPERMT","/capita, US$ exchange rate","CRI","Costa Rica","2013","2013",6.3,,
+"PATCBLOO","B-Blood and blood forming organs","TCPPERMT","/capita, US$ exchange rate","CRI","Costa Rica","2014","2014",7.2,"B","Break"
+"PATCBLOO","B-Blood and blood forming organs","TCPPERMT","/capita, US$ exchange rate","CRI","Costa Rica","2015","2015",6.5,,
+"PATCBLOO","B-Blood and blood forming organs","TCPPERMT","/capita, US$ exchange rate","CRI","Costa Rica","2016","2016",6,,
+"PATCBLOO","B-Blood and blood forming organs","TCPPERMT","/capita, US$ exchange rate","CRI","Costa Rica","2017","2017",5.5,,
+"PATCBLOO","B-Blood and blood forming organs","TCPPERMT","/capita, US$ exchange rate","CRI","Costa Rica","2018","2018",6.1,,
+"PATCBLOO","B-Blood and blood forming organs","TCPPERMT","/capita, US$ exchange rate","CRI","Costa Rica","2019","2019",6.8,,
+"PATCBLOO","B-Blood and blood forming organs","TCPPERMT","/capita, US$ exchange rate","CRI","Costa Rica","2020","2020",5.4,,
+"PATCBLOO","B-Blood and blood forming organs","TCPPERMT","/capita, US$ exchange rate","CRI","Costa Rica","2021","2021",6.3,,
+"PATCBLOO","B-Blood and blood forming organs","TCPPERMT","/capita, US$ exchange rate","CRI","Costa Rica","2022","2022",5.7,,
+"PATCHYPN","N05C-Hypnotics and sedatives","TCPPERMT","/capita, US$ exchange rate","CRI","Costa Rica","2010","2010",0.1,,
+"PATCHYPN","N05C-Hypnotics and sedatives","TCPPERMT","/capita, US$ exchange rate","CRI","Costa Rica","2011","2011",0.1,,
+"PATCHYPN","N05C-Hypnotics and sedatives","TCPPERMT","/capita, US$ exchange rate","CRI","Costa Rica","2012","2012",0.1,,
+"PATCHYPN","N05C-Hypnotics and sedatives","TCPPERMT","/capita, US$ exchange rate","CRI","Costa Rica","2013","2013",0.1,,
+"PATCHYPN","N05C-Hypnotics and sedatives","TCPPERMT","/capita, US$ exchange rate","CRI","Costa Rica","2014","2014",0.1,"B","Break"
+"PATCHYPN","N05C-Hypnotics and sedatives","TCPPERMT","/capita, US$ exchange rate","CRI","Costa Rica","2015","2015",0.1,,
+"PATCHYPN","N05C-Hypnotics and sedatives","TCPPERMT","/capita, US$ exchange rate","CRI","Costa Rica","2016","2016",0.1,,
+"PATCHYPN","N05C-Hypnotics and sedatives","TCPPERMT","/capita, US$ exchange rate","CRI","Costa Rica","2017","2017",0.1,,
+"PATCHYPN","N05C-Hypnotics and sedatives","TCPPERMT","/capita, US$ exchange rate","CRI","Costa Rica","2018","2018",0.1,,
+"PATCHYPN","N05C-Hypnotics and sedatives","TCPPERMT","/capita, US$ exchange rate","CRI","Costa Rica","2019","2019",0.1,,
+"PATCHYPN","N05C-Hypnotics and sedatives","TCPPERMT","/capita, US$ exchange rate","CRI","Costa Rica","2020","2020",0,,
+"PATCHYPN","N05C-Hypnotics and sedatives","TCPPERMT","/capita, US$ exchange rate","CRI","Costa Rica","2021","2021",0.1,,
+"PATCHYPN","N05C-Hypnotics and sedatives","TCPPERMT","/capita, US$ exchange rate","CRI","Costa Rica","2022","2022",0,,
+"PATCACID","A02A-Antacids","TCPPERMT","/capita, US$ exchange rate","CRI","Costa Rica","2010","2010",0.3,,
+"PATCACID","A02A-Antacids","TCPPERMT","/capita, US$ exchange rate","CRI","Costa Rica","2011","2011",0.3,,
+"PATCACID","A02A-Antacids","TCPPERMT","/capita, US$ exchange rate","CRI","Costa Rica","2012","2012",0.3,,
+"PATCACID","A02A-Antacids","TCPPERMT","/capita, US$ exchange rate","CRI","Costa Rica","2013","2013",0.4,,
+"PATCACID","A02A-Antacids","TCPPERMT","/capita, US$ exchange rate","CRI","Costa Rica","2014","2014",0.3,"B","Break"
+"PATCACID","A02A-Antacids","TCPPERMT","/capita, US$ exchange rate","CRI","Costa Rica","2015","2015",0.3,,
+"PATCACID","A02A-Antacids","TCPPERMT","/capita, US$ exchange rate","CRI","Costa Rica","2016","2016",0.3,,
+"PATCACID","A02A-Antacids","TCPPERMT","/capita, US$ exchange rate","CRI","Costa Rica","2017","2017",0.4,,
+"PATCACID","A02A-Antacids","TCPPERMT","/capita, US$ exchange rate","CRI","Costa Rica","2018","2018",0.4,,
+"PATCACID","A02A-Antacids","TCPPERMT","/capita, US$ exchange rate","CRI","Costa Rica","2019","2019",0.5,,
+"PATCACID","A02A-Antacids","TCPPERMT","/capita, US$ exchange rate","CRI","Costa Rica","2020","2020",0.5,,
+"PATCACID","A02A-Antacids","TCPPERMT","/capita, US$ exchange rate","CRI","Costa Rica","2021","2021",0.6,,
+"PATCACID","A02A-Antacids","TCPPERMT","/capita, US$ exchange rate","CRI","Costa Rica","2022","2022",0.4,,
+"PATCBETA","C07-Beta blocking agents","MLLNCUMT","Million of national currency units","CRI","Costa Rica","2010","2010",314.6,,
+"PATCBETA","C07-Beta blocking agents","MLLNCUMT","Million of national currency units","CRI","Costa Rica","2011","2011",501.3,,
+"PATCBETA","C07-Beta blocking agents","MLLNCUMT","Million of national currency units","CRI","Costa Rica","2012","2012",591.5,,
+"PATCBETA","C07-Beta blocking agents","MLLNCUMT","Million of national currency units","CRI","Costa Rica","2013","2013",622.3,,
+"PATCBETA","C07-Beta blocking agents","MLLNCUMT","Million of national currency units","CRI","Costa Rica","2014","2014",656.4,"B","Break"
+"PATCBETA","C07-Beta blocking agents","MLLNCUMT","Million of national currency units","CRI","Costa Rica","2015","2015",830.8,,
+"PATCBETA","C07-Beta blocking agents","MLLNCUMT","Million of national currency units","CRI","Costa Rica","2016","2016",868.6,,
+"PATCBETA","C07-Beta blocking agents","MLLNCUMT","Million of national currency units","CRI","Costa Rica","2017","2017",941,,
+"PATCBETA","C07-Beta blocking agents","MLLNCUMT","Million of national currency units","CRI","Costa Rica","2018","2018",809.4,,
+"PATCBETA","C07-Beta blocking agents","MLLNCUMT","Million of national currency units","CRI","Costa Rica","2019","2019",624.8,,
+"PATCBETA","C07-Beta blocking agents","MLLNCUMT","Million of national currency units","CRI","Costa Rica","2020","2020",555.8,,
+"PATCBETA","C07-Beta blocking agents","MLLNCUMT","Million of national currency units","CRI","Costa Rica","2021","2021",827.2,,
+"PATCBETA","C07-Beta blocking agents","MLLNCUMT","Million of national currency units","CRI","Costa Rica","2022","2022",786.5,,
+"PATCCARV","C-Cardiovascular system","MTMOPPMT","Million US$, purchasing power parity","CRI","Costa Rica","2010","2010",14.8,,
+"PATCCARV","C-Cardiovascular system","MTMOPPMT","Million US$, purchasing power parity","CRI","Costa Rica","2011","2011",14.5,,
+"PATCCARV","C-Cardiovascular system","MTMOPPMT","Million US$, purchasing power parity","CRI","Costa Rica","2012","2012",14.7,,
+"PATCCARV","C-Cardiovascular system","MTMOPPMT","Million US$, purchasing power parity","CRI","Costa Rica","2013","2013",15.4,,
+"PATCCARV","C-Cardiovascular system","MTMOPPMT","Million US$, purchasing power parity","CRI","Costa Rica","2014","2014",19.2,"B","Break"
+"PATCCARV","C-Cardiovascular system","MTMOPPMT","Million US$, purchasing power parity","CRI","Costa Rica","2015","2015",16.2,,
+"PATCCARV","C-Cardiovascular system","MTMOPPMT","Million US$, purchasing power parity","CRI","Costa Rica","2016","2016",16,,
+"PATCCARV","C-Cardiovascular system","MTMOPPMT","Million US$, purchasing power parity","CRI","Costa Rica","2017","2017",19,,
+"PATCCARV","C-Cardiovascular system","MTMOPPMT","Million US$, purchasing power parity","CRI","Costa Rica","2018","2018",21.8,,
+"PATCCARV","C-Cardiovascular system","MTMOPPMT","Million US$, purchasing power parity","CRI","Costa Rica","2019","2019",28.5,,
+"PATCCARV","C-Cardiovascular system","MTMOPPMT","Million US$, purchasing power parity","CRI","Costa Rica","2020","2020",26.2,,
+"PATCCARV","C-Cardiovascular system","MTMOPPMT","Million US$, purchasing power parity","CRI","Costa Rica","2021","2021",29.7,,
+"PATCCARV","C-Cardiovascular system","MTMOPPMT","Million US$, purchasing power parity","CRI","Costa Rica","2022","2022",24.5,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2010","2010",1.6,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2011","2011",1.4,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2012","2012",1.4,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2013","2013",1.5,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2014","2014",1.6,"B","Break"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2015","2015",1.3,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2016","2016",1.4,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2017","2017",1.5,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2018","2018",1.6,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2019","2019",1.8,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2020","2020",1.6,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2021","2021",3.1,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2022","2022",2.8,,
+"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2010","2010",0.2,,
+"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2011","2011",0.2,,
+"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2012","2012",0.2,,
+"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2013","2013",0.2,,
+"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2014","2014",0.2,"B","Break"
+"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2015","2015",0.2,,
+"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2016","2016",0.2,,
+"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2017","2017",0.2,,
+"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2018","2018",0.3,,
+"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2019","2019",0.4,,
+"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2020","2020",0.3,,
+"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2021","2021",0.2,,
+"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2022","2022",0.2,,
+"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2010","2010",1.8,,
+"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2011","2011",1.8,,
+"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2012","2012",2.1,,
+"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2013","2013",2.2,,
+"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2014","2014",2.5,"B","Break"
+"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2015","2015",2.3,,
+"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2016","2016",2.6,,
+"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2017","2017",2.7,,
+"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2018","2018",2.8,,
+"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2019","2019",3.2,,
+"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2020","2020",3.4,,
+"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2021","2021",3.5,,
+"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2022","2022",3.1,,
+"PATCCHLS","C10-Lipid modifying agents","MLLNCUMT","Million of national currency units","CRI","Costa Rica","2010","2010",1900.8,,
+"PATCCHLS","C10-Lipid modifying agents","MLLNCUMT","Million of national currency units","CRI","Costa Rica","2011","2011",1973.1,,
+"PATCCHLS","C10-Lipid modifying agents","MLLNCUMT","Million of national currency units","CRI","Costa Rica","2012","2012",2104.9,,
+"PATCCHLS","C10-Lipid modifying agents","MLLNCUMT","Million of national currency units","CRI","Costa Rica","2013","2013",1969.3,,
+"PATCCHLS","C10-Lipid modifying agents","MLLNCUMT","Million of national currency units","CRI","Costa Rica","2014","2014",2949.9,"B","Break"
+"PATCCHLS","C10-Lipid modifying agents","MLLNCUMT","Million of national currency units","CRI","Costa Rica","2015","2015",1710.2,,
+"PATCCHLS","C10-Lipid modifying agents","MLLNCUMT","Million of national currency units","CRI","Costa Rica","2016","2016",1683.6,,
+"PATCCHLS","C10-Lipid modifying agents","MLLNCUMT","Million of national currency units","CRI","Costa Rica","2017","2017",1908.2,,
+"PATCCHLS","C10-Lipid modifying agents","MLLNCUMT","Million of national currency units","CRI","Costa Rica","2018","2018",2382.3,,
+"PATCCHLS","C10-Lipid modifying agents","MLLNCUMT","Million of national currency units","CRI","Costa Rica","2019","2019",2725.5,,
+"PATCCHLS","C10-Lipid modifying agents","MLLNCUMT","Million of national currency units","CRI","Costa Rica","2020","2020",2369.5,,
+"PATCCHLS","C10-Lipid modifying agents","MLLNCUMT","Million of national currency units","CRI","Costa Rica","2021","2021",2916.5,,
+"PATCCHLS","C10-Lipid modifying agents","MLLNCUMT","Million of national currency units","CRI","Costa Rica","2022","2022",2082.6,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MLLNCUMT","Million of national currency units","CRI","Costa Rica","2010","2010",2333.6,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MLLNCUMT","Million of national currency units","CRI","Costa Rica","2011","2011",2218.4,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MLLNCUMT","Million of national currency units","CRI","Costa Rica","2012","2012",2194.5,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MLLNCUMT","Million of national currency units","CRI","Costa Rica","2013","2013",2416.6,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MLLNCUMT","Million of national currency units","CRI","Costa Rica","2014","2014",2700.8,"B","Break"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MLLNCUMT","Million of national currency units","CRI","Costa Rica","2015","2015",2298.6,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MLLNCUMT","Million of national currency units","CRI","Costa Rica","2016","2016",2333.1,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MLLNCUMT","Million of national currency units","CRI","Costa Rica","2017","2017",2446.5,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MLLNCUMT","Million of national currency units","CRI","Costa Rica","2018","2018",2655.8,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MLLNCUMT","Million of national currency units","CRI","Costa Rica","2019","2019",2947,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MLLNCUMT","Million of national currency units","CRI","Costa Rica","2020","2020",2647.7,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MLLNCUMT","Million of national currency units","CRI","Costa Rica","2021","2021",5575.2,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MLLNCUMT","Million of national currency units","CRI","Costa Rica","2022","2022",5031.4,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOPPMT","Million US$, purchasing power parity","CRI","Costa Rica","2010","2010",4.4,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOPPMT","Million US$, purchasing power parity","CRI","Costa Rica","2011","2011",3,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOPPMT","Million US$, purchasing power parity","CRI","Costa Rica","2012","2012",3.5,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOPPMT","Million US$, purchasing power parity","CRI","Costa Rica","2013","2013",4.1,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOPPMT","Million US$, purchasing power parity","CRI","Costa Rica","2014","2014",4.6,"B","Break"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOPPMT","Million US$, purchasing power parity","CRI","Costa Rica","2015","2015",4.5,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOPPMT","Million US$, purchasing power parity","CRI","Costa Rica","2016","2016",4,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOPPMT","Million US$, purchasing power parity","CRI","Costa Rica","2017","2017",5.7,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOPPMT","Million US$, purchasing power parity","CRI","Costa Rica","2018","2018",7,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOPPMT","Million US$, purchasing power parity","CRI","Costa Rica","2019","2019",12.5,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOPPMT","Million US$, purchasing power parity","CRI","Costa Rica","2020","2020",11.2,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOPPMT","Million US$, purchasing power parity","CRI","Costa Rica","2021","2021",10.8,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOPPMT","Million US$, purchasing power parity","CRI","Costa Rica","2022","2022",9.9,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOTCMT","Million US$ at exchange rate","CRI","Costa Rica","2010","2010",4.4,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOTCMT","Million US$ at exchange rate","CRI","Costa Rica","2011","2011",4.4,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOTCMT","Million US$ at exchange rate","CRI","Costa Rica","2012","2012",4.4,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOTCMT","Million US$ at exchange rate","CRI","Costa Rica","2013","2013",4.8,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOTCMT","Million US$ at exchange rate","CRI","Costa Rica","2014","2014",5,"B","Break"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOTCMT","Million US$ at exchange rate","CRI","Costa Rica","2015","2015",4.3,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOTCMT","Million US$ at exchange rate","CRI","Costa Rica","2016","2016",4.3,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOTCMT","Million US$ at exchange rate","CRI","Costa Rica","2017","2017",4.3,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOTCMT","Million US$ at exchange rate","CRI","Costa Rica","2018","2018",4.6,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOTCMT","Million US$ at exchange rate","CRI","Costa Rica","2019","2019",5,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOTCMT","Million US$ at exchange rate","CRI","Costa Rica","2020","2020",4.5,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOTCMT","Million US$ at exchange rate","CRI","Costa Rica","2021","2021",9,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOTCMT","Million US$ at exchange rate","CRI","Costa Rica","2022","2022",7.8,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","TCPPERMT","/capita, US$ exchange rate","CRI","Costa Rica","2010","2010",1.4,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","TCPPERMT","/capita, US$ exchange rate","CRI","Costa Rica","2011","2011",1.3,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","TCPPERMT","/capita, US$ exchange rate","CRI","Costa Rica","2012","2012",1.4,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","TCPPERMT","/capita, US$ exchange rate","CRI","Costa Rica","2013","2013",1.6,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","TCPPERMT","/capita, US$ exchange rate","CRI","Costa Rica","2014","2014",1.7,"B","Break"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","TCPPERMT","/capita, US$ exchange rate","CRI","Costa Rica","2015","2015",1.4,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","TCPPERMT","/capita, US$ exchange rate","CRI","Costa Rica","2016","2016",1.2,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","TCPPERMT","/capita, US$ exchange rate","CRI","Costa Rica","2017","2017",1.1,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","TCPPERMT","/capita, US$ exchange rate","CRI","Costa Rica","2018","2018",1,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","TCPPERMT","/capita, US$ exchange rate","CRI","Costa Rica","2019","2019",1.2,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","TCPPERMT","/capita, US$ exchange rate","CRI","Costa Rica","2020","2020",1.4,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","TCPPERMT","/capita, US$ exchange rate","CRI","Costa Rica","2021","2021",1.6,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","TCPPERMT","/capita, US$ exchange rate","CRI","Costa Rica","2022","2022",1.4,,
+"PATCDIAB","A10-Drugs used in diabetes","MTMOTCMT","Million US$ at exchange rate","CRI","Costa Rica","2010","2010",5.2,,
+"PATCDIAB","A10-Drugs used in diabetes","MTMOTCMT","Million US$ at exchange rate","CRI","Costa Rica","2011","2011",5.6,,
+"PATCDIAB","A10-Drugs used in diabetes","MTMOTCMT","Million US$ at exchange rate","CRI","Costa Rica","2012","2012",6.6,,
+"PATCDIAB","A10-Drugs used in diabetes","MTMOTCMT","Million US$ at exchange rate","CRI","Costa Rica","2013","2013",7.1,,
+"PATCDIAB","A10-Drugs used in diabetes","MTMOTCMT","Million US$ at exchange rate","CRI","Costa Rica","2014","2014",7.9,"B","Break"
+"PATCDIAB","A10-Drugs used in diabetes","MTMOTCMT","Million US$ at exchange rate","CRI","Costa Rica","2015","2015",7.5,,
+"PATCDIAB","A10-Drugs used in diabetes","MTMOTCMT","Million US$ at exchange rate","CRI","Costa Rica","2016","2016",7.9,,
+"PATCDIAB","A10-Drugs used in diabetes","MTMOTCMT","Million US$ at exchange rate","CRI","Costa Rica","2017","2017",8.1,,
+"PATCDIAB","A10-Drugs used in diabetes","MTMOTCMT","Million US$ at exchange rate","CRI","Costa Rica","2018","2018",8.3,,
+"PATCDIAB","A10-Drugs used in diabetes","MTMOTCMT","Million US$ at exchange rate","CRI","Costa Rica","2019","2019",9.1,,
+"PATCDIAB","A10-Drugs used in diabetes","MTMOTCMT","Million US$ at exchange rate","CRI","Costa Rica","2020","2020",9.8,,
+"PATCDIAB","A10-Drugs used in diabetes","MTMOTCMT","Million US$ at exchange rate","CRI","Costa Rica","2021","2021",10.1,,
+"PATCDIAB","A10-Drugs used in diabetes","MTMOTCMT","Million US$ at exchange rate","CRI","Costa Rica","2022","2022",8.6,,
+"PATCCCBR","C08-Calcium channel blockers","TCPPERMT","/capita, US$ exchange rate","CRI","Costa Rica","2010","2010",0.1,,
+"PATCCCBR","C08-Calcium channel blockers","TCPPERMT","/capita, US$ exchange rate","CRI","Costa Rica","2011","2011",0.1,,
+"PATCCCBR","C08-Calcium channel blockers","TCPPERMT","/capita, US$ exchange rate","CRI","Costa Rica","2012","2012",0.1,,
+"PATCCCBR","C08-Calcium channel blockers","TCPPERMT","/capita, US$ exchange rate","CRI","Costa Rica","2013","2013",0.1,,
+"PATCCCBR","C08-Calcium channel blockers","TCPPERMT","/capita, US$ exchange rate","CRI","Costa Rica","2014","2014",0.1,"B","Break"
+"PATCCCBR","C08-Calcium channel blockers","TCPPERMT","/capita, US$ exchange rate","CRI","Costa Rica","2015","2015",0.1,,
+"PATCCCBR","C08-Calcium channel blockers","TCPPERMT","/capita, US$ exchange rate","CRI","Costa Rica","2016","2016",0.1,,
+"PATCCCBR","C08-Calcium channel blockers","TCPPERMT","/capita, US$ exchange rate","CRI","Costa Rica","2017","2017",0.1,,
+"PATCCCBR","C08-Calcium channel blockers","TCPPERMT","/capita, US$ exchange rate","CRI","Costa Rica","2018","2018",0.1,,
+"PATCCCBR","C08-Calcium channel blockers","TCPPERMT","/capita, US$ exchange rate","CRI","Costa Rica","2019","2019",0.1,,
+"PATCCCBR","C08-Calcium channel blockers","TCPPERMT","/capita, US$ exchange rate","CRI","Costa Rica","2020","2020",0.2,,
+"PATCCCBR","C08-Calcium channel blockers","TCPPERMT","/capita, US$ exchange rate","CRI","Costa Rica","2021","2021",0.2,,
+"PATCCCBR","C08-Calcium channel blockers","TCPPERMT","/capita, US$ exchange rate","CRI","Costa Rica","2022","2022",0.1,,
+"PATCBIOT","J01-Antibacterials for systemic use","MTMOPPMT","Million US$, purchasing power parity","CRI","Costa Rica","2010","2010",18.5,,
+"PATCBIOT","J01-Antibacterials for systemic use","MTMOPPMT","Million US$, purchasing power parity","CRI","Costa Rica","2011","2011",16.5,,
+"PATCBIOT","J01-Antibacterials for systemic use","MTMOPPMT","Million US$, purchasing power parity","CRI","Costa Rica","2012","2012",14.1,,
+"PATCBIOT","J01-Antibacterials for systemic use","MTMOPPMT","Million US$, purchasing power parity","CRI","Costa Rica","2013","2013",14.6,,
+"PATCBIOT","J01-Antibacterials for systemic use","MTMOPPMT","Million US$, purchasing power parity","CRI","Costa Rica","2014","2014",16.3,"B","Break"
+"PATCBIOT","J01-Antibacterials for systemic use","MTMOPPMT","Million US$, purchasing power parity","CRI","Costa Rica","2015","2015",13.9,,
+"PATCBIOT","J01-Antibacterials for systemic use","MTMOPPMT","Million US$, purchasing power parity","CRI","Costa Rica","2016","2016",14.9,,
+"PATCBIOT","J01-Antibacterials for systemic use","MTMOPPMT","Million US$, purchasing power parity","CRI","Costa Rica","2017","2017",12.9,,
+"PATCBIOT","J01-Antibacterials for systemic use","MTMOPPMT","Million US$, purchasing power parity","CRI","Costa Rica","2018","2018",11.3,,
+"PATCBIOT","J01-Antibacterials for systemic use","MTMOPPMT","Million US$, purchasing power parity","CRI","Costa Rica","2019","2019",12.1,,
+"PATCBIOT","J01-Antibacterials for systemic use","MTMOPPMT","Million US$, purchasing power parity","CRI","Costa Rica","2020","2020",9.2,,
+"PATCBIOT","J01-Antibacterials for systemic use","MTMOPPMT","Million US$, purchasing power parity","CRI","Costa Rica","2021","2021",10.7,,
+"PATCBIOT","J01-Antibacterials for systemic use","MTMOPPMT","Million US$, purchasing power parity","CRI","Costa Rica","2022","2022",8.8,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOPPMT","Million US$, purchasing power parity","CRI","Costa Rica","2010","2010",4.5,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOPPMT","Million US$, purchasing power parity","CRI","Costa Rica","2011","2011",5,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOPPMT","Million US$, purchasing power parity","CRI","Costa Rica","2012","2012",4.6,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOPPMT","Million US$, purchasing power parity","CRI","Costa Rica","2013","2013",4.8,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOPPMT","Million US$, purchasing power parity","CRI","Costa Rica","2014","2014",5,"B","Break"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOPPMT","Million US$, purchasing power parity","CRI","Costa Rica","2015","2015",5,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOPPMT","Million US$, purchasing power parity","CRI","Costa Rica","2016","2016",5.3,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOPPMT","Million US$, purchasing power parity","CRI","Costa Rica","2017","2017",6,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOPPMT","Million US$, purchasing power parity","CRI","Costa Rica","2018","2018",7.5,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOPPMT","Million US$, purchasing power parity","CRI","Costa Rica","2019","2019",9.3,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOPPMT","Million US$, purchasing power parity","CRI","Costa Rica","2020","2020",8.3,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOPPMT","Million US$, purchasing power parity","CRI","Costa Rica","2021","2021",9.2,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOPPMT","Million US$, purchasing power parity","CRI","Costa Rica","2022","2022",8,,
+"PATCANXO","N05B-Anxiolytics","MLLNCUMT","Million of national currency units","CRI","Costa Rica","2010","2010",272.4,,
+"PATCANXO","N05B-Anxiolytics","MLLNCUMT","Million of national currency units","CRI","Costa Rica","2011","2011",277.6,,
+"PATCANXO","N05B-Anxiolytics","MLLNCUMT","Million of national currency units","CRI","Costa Rica","2012","2012",282.2,,
+"PATCANXO","N05B-Anxiolytics","MLLNCUMT","Million of national currency units","CRI","Costa Rica","2013","2013",314,,
+"PATCANXO","N05B-Anxiolytics","MLLNCUMT","Million of national currency units","CRI","Costa Rica","2014","2014",351.2,"B","Break"
+"PATCANXO","N05B-Anxiolytics","MLLNCUMT","Million of national currency units","CRI","Costa Rica","2015","2015",348.3,,
+"PATCANXO","N05B-Anxiolytics","MLLNCUMT","Million of national currency units","CRI","Costa Rica","2016","2016",355.5,,
+"PATCANXO","N05B-Anxiolytics","MLLNCUMT","Million of national currency units","CRI","Costa Rica","2017","2017",399.9,,
+"PATCANXO","N05B-Anxiolytics","MLLNCUMT","Million of national currency units","CRI","Costa Rica","2018","2018",477.9,,
+"PATCANXO","N05B-Anxiolytics","MLLNCUMT","Million of national currency units","CRI","Costa Rica","2019","2019",602.8,,
+"PATCANXO","N05B-Anxiolytics","MLLNCUMT","Million of national currency units","CRI","Costa Rica","2020","2020",557.9,,
+"PATCANXO","N05B-Anxiolytics","MLLNCUMT","Million of national currency units","CRI","Costa Rica","2021","2021",418.6,,
+"PATCANXO","N05B-Anxiolytics","MLLNCUMT","Million of national currency units","CRI","Costa Rica","2022","2022",394.8,,
+"PATCDIAB","A10-Drugs used in diabetes","MLLNCUMT","Million of national currency units","CRI","Costa Rica","2010","2010",2715.6,,
+"PATCDIAB","A10-Drugs used in diabetes","MLLNCUMT","Million of national currency units","CRI","Costa Rica","2011","2011",2834,,
+"PATCDIAB","A10-Drugs used in diabetes","MLLNCUMT","Million of national currency units","CRI","Costa Rica","2012","2012",3318.6,,
+"PATCDIAB","A10-Drugs used in diabetes","MLLNCUMT","Million of national currency units","CRI","Costa Rica","2013","2013",3557.3,,
+"PATCDIAB","A10-Drugs used in diabetes","MLLNCUMT","Million of national currency units","CRI","Costa Rica","2014","2014",4269.6,"B","Break"
+"PATCDIAB","A10-Drugs used in diabetes","MLLNCUMT","Million of national currency units","CRI","Costa Rica","2015","2015",4018,,
+"PATCDIAB","A10-Drugs used in diabetes","MLLNCUMT","Million of national currency units","CRI","Costa Rica","2016","2016",4281.7,,
+"PATCDIAB","A10-Drugs used in diabetes","MLLNCUMT","Million of national currency units","CRI","Costa Rica","2017","2017",4591,,
+"PATCDIAB","A10-Drugs used in diabetes","MLLNCUMT","Million of national currency units","CRI","Costa Rica","2018","2018",4795,,
+"PATCDIAB","A10-Drugs used in diabetes","MLLNCUMT","Million of national currency units","CRI","Costa Rica","2019","2019",5364.2,,
+"PATCDIAB","A10-Drugs used in diabetes","MLLNCUMT","Million of national currency units","CRI","Costa Rica","2020","2020",5744.4,,
+"PATCDIAB","A10-Drugs used in diabetes","MLLNCUMT","Million of national currency units","CRI","Costa Rica","2021","2021",6260.3,,
+"PATCDIAB","A10-Drugs used in diabetes","MLLNCUMT","Million of national currency units","CRI","Costa Rica","2022","2022",5540.8,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOPPMT","Million US$, purchasing power parity","CRI","Costa Rica","2010","2010",2.8,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOPPMT","Million US$, purchasing power parity","CRI","Costa Rica","2011","2011",2.6,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOPPMT","Million US$, purchasing power parity","CRI","Costa Rica","2012","2012",2.9,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOPPMT","Million US$, purchasing power parity","CRI","Costa Rica","2013","2013",4,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOPPMT","Million US$, purchasing power parity","CRI","Costa Rica","2014","2014",4.9,"B","Break"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOPPMT","Million US$, purchasing power parity","CRI","Costa Rica","2015","2015",4.7,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOPPMT","Million US$, purchasing power parity","CRI","Costa Rica","2016","2016",4.9,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOPPMT","Million US$, purchasing power parity","CRI","Costa Rica","2017","2017",5.4,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOPPMT","Million US$, purchasing power parity","CRI","Costa Rica","2018","2018",4.7,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOPPMT","Million US$, purchasing power parity","CRI","Costa Rica","2019","2019",4.2,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOPPMT","Million US$, purchasing power parity","CRI","Costa Rica","2020","2020",3.8,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOPPMT","Million US$, purchasing power parity","CRI","Costa Rica","2021","2021",4,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOPPMT","Million US$, purchasing power parity","CRI","Costa Rica","2022","2022",3.4,,
+"PATCDEPR","N06A-Antidepressants","MTMOPPMT","Million US$, purchasing power parity","CRI","Costa Rica","2010","2010",4.9,,
+"PATCDEPR","N06A-Antidepressants","MTMOPPMT","Million US$, purchasing power parity","CRI","Costa Rica","2011","2011",4.3,,
+"PATCDEPR","N06A-Antidepressants","MTMOPPMT","Million US$, purchasing power parity","CRI","Costa Rica","2012","2012",2.7,,
+"PATCDEPR","N06A-Antidepressants","MTMOPPMT","Million US$, purchasing power parity","CRI","Costa Rica","2013","2013",3,,
+"PATCDEPR","N06A-Antidepressants","MTMOPPMT","Million US$, purchasing power parity","CRI","Costa Rica","2014","2014",3.2,"B","Break"
+"PATCDEPR","N06A-Antidepressants","MTMOPPMT","Million US$, purchasing power parity","CRI","Costa Rica","2015","2015",3.6,,
+"PATCDEPR","N06A-Antidepressants","MTMOPPMT","Million US$, purchasing power parity","CRI","Costa Rica","2016","2016",4.4,,
+"PATCDEPR","N06A-Antidepressants","MTMOPPMT","Million US$, purchasing power parity","CRI","Costa Rica","2017","2017",4.2,,
+"PATCDEPR","N06A-Antidepressants","MTMOPPMT","Million US$, purchasing power parity","CRI","Costa Rica","2018","2018",4.2,,
+"PATCDEPR","N06A-Antidepressants","MTMOPPMT","Million US$, purchasing power parity","CRI","Costa Rica","2019","2019",4.8,,
+"PATCDEPR","N06A-Antidepressants","MTMOPPMT","Million US$, purchasing power parity","CRI","Costa Rica","2020","2020",4.3,,
+"PATCDEPR","N06A-Antidepressants","MTMOPPMT","Million US$, purchasing power parity","CRI","Costa Rica","2021","2021",4.1,,
+"PATCDEPR","N06A-Antidepressants","MTMOPPMT","Million US$, purchasing power parity","CRI","Costa Rica","2022","2022",3.7,,
+"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2010","2010",1.3,,
+"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2011","2011",1.3,,
+"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2012","2012",1.3,,
+"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2013","2013",1.2,,
+"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2014","2014",1.7,"B","Break"
+"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2015","2015",1,,
+"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2016","2016",1,,
+"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2017","2017",1.1,,
+"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2018","2018",1.4,,
+"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2019","2019",1.6,,
+"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2020","2020",1.4,,
+"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2021","2021",1.6,,
+"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2022","2022",1.2,,
+"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2010","2010",0.2,,
+"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2011","2011",0.3,,
+"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2012","2012",0.4,,
+"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2013","2013",0.4,,
+"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2014","2014",0.4,"B","Break"
+"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2015","2015",0.5,,
+"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2016","2016",0.5,,
+"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2017","2017",0.6,,
+"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2018","2018",0.5,,
+"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2019","2019",0.4,,
+"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2020","2020",0.3,,
+"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2021","2021",0.5,,
+"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2022","2022",0.4,,
+"PATCINFC","J-Antiinfectives for systemic use","TCPPERMT","/capita, US$ exchange rate","CRI","Costa Rica","2010","2010",7.2,,
+"PATCINFC","J-Antiinfectives for systemic use","TCPPERMT","/capita, US$ exchange rate","CRI","Costa Rica","2011","2011",6.4,,
+"PATCINFC","J-Antiinfectives for systemic use","TCPPERMT","/capita, US$ exchange rate","CRI","Costa Rica","2012","2012",6,,
+"PATCINFC","J-Antiinfectives for systemic use","TCPPERMT","/capita, US$ exchange rate","CRI","Costa Rica","2013","2013",6,,
+"PATCINFC","J-Antiinfectives for systemic use","TCPPERMT","/capita, US$ exchange rate","CRI","Costa Rica","2014","2014",6.6,"B","Break"
+"PATCINFC","J-Antiinfectives for systemic use","TCPPERMT","/capita, US$ exchange rate","CRI","Costa Rica","2015","2015",6.7,,
+"PATCINFC","J-Antiinfectives for systemic use","TCPPERMT","/capita, US$ exchange rate","CRI","Costa Rica","2016","2016",7.1,,
+"PATCINFC","J-Antiinfectives for systemic use","TCPPERMT","/capita, US$ exchange rate","CRI","Costa Rica","2017","2017",7,,
+"PATCINFC","J-Antiinfectives for systemic use","TCPPERMT","/capita, US$ exchange rate","CRI","Costa Rica","2018","2018",7.3,,
+"PATCINFC","J-Antiinfectives for systemic use","TCPPERMT","/capita, US$ exchange rate","CRI","Costa Rica","2019","2019",7.5,,
+"PATCINFC","J-Antiinfectives for systemic use","TCPPERMT","/capita, US$ exchange rate","CRI","Costa Rica","2020","2020",7.4,,
+"PATCINFC","J-Antiinfectives for systemic use","TCPPERMT","/capita, US$ exchange rate","CRI","Costa Rica","2021","2021",7.9,,
+"PATCINFC","J-Antiinfectives for systemic use","TCPPERMT","/capita, US$ exchange rate","CRI","Costa Rica","2022","2022",6.8,,
+"PATCGLYC","C01A-Cardiac glycosides","MTMOTCMT","Million US$ at exchange rate","CRI","Costa Rica","2010","2010",0.3,,
+"PATCGLYC","C01A-Cardiac glycosides","MTMOTCMT","Million US$ at exchange rate","CRI","Costa Rica","2011","2011",0.3,,
+"PATCGLYC","C01A-Cardiac glycosides","MTMOTCMT","Million US$ at exchange rate","CRI","Costa Rica","2012","2012",0.3,,
+"PATCGLYC","C01A-Cardiac glycosides","MTMOTCMT","Million US$ at exchange rate","CRI","Costa Rica","2013","2013",0.3,,
+"PATCGLYC","C01A-Cardiac glycosides","MTMOTCMT","Million US$ at exchange rate","CRI","Costa Rica","2014","2014",0.4,"B","Break"
+"PATCGLYC","C01A-Cardiac glycosides","MTMOTCMT","Million US$ at exchange rate","CRI","Costa Rica","2015","2015",0.4,,
+"PATCGLYC","C01A-Cardiac glycosides","MTMOTCMT","Million US$ at exchange rate","CRI","Costa Rica","2016","2016",0.4,,
+"PATCGLYC","C01A-Cardiac glycosides","MTMOTCMT","Million US$ at exchange rate","CRI","Costa Rica","2017","2017",0.3,,
+"PATCGLYC","C01A-Cardiac glycosides","MTMOTCMT","Million US$ at exchange rate","CRI","Costa Rica","2018","2018",0.2,,
+"PATCGLYC","C01A-Cardiac glycosides","MTMOTCMT","Million US$ at exchange rate","CRI","Costa Rica","2019","2019",0.2,,
+"PATCGLYC","C01A-Cardiac glycosides","MTMOTCMT","Million US$ at exchange rate","CRI","Costa Rica","2020","2020",0.2,,
+"PATCGLYC","C01A-Cardiac glycosides","MTMOTCMT","Million US$ at exchange rate","CRI","Costa Rica","2021","2021",0.2,,
+"PATCGLYC","C01A-Cardiac glycosides","MTMOTCMT","Million US$ at exchange rate","CRI","Costa Rica","2022","2022",0.1,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOTCMT","Million US$ at exchange rate","CRI","Costa Rica","2010","2010",0.1,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOTCMT","Million US$ at exchange rate","CRI","Costa Rica","2011","2011",0.1,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOTCMT","Million US$ at exchange rate","CRI","Costa Rica","2012","2012",0.1,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOTCMT","Million US$ at exchange rate","CRI","Costa Rica","2013","2013",0.2,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOTCMT","Million US$ at exchange rate","CRI","Costa Rica","2014","2014",0.1,"B","Break"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOTCMT","Million US$ at exchange rate","CRI","Costa Rica","2015","2015",0.1,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOTCMT","Million US$ at exchange rate","CRI","Costa Rica","2016","2016",0.1,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOTCMT","Million US$ at exchange rate","CRI","Costa Rica","2017","2017",0.1,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOTCMT","Million US$ at exchange rate","CRI","Costa Rica","2018","2018",0.2,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOTCMT","Million US$ at exchange rate","CRI","Costa Rica","2019","2019",0.2,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOTCMT","Million US$ at exchange rate","CRI","Costa Rica","2020","2020",0.2,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOTCMT","Million US$ at exchange rate","CRI","Costa Rica","2021","2021",0.2,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOTCMT","Million US$ at exchange rate","CRI","Costa Rica","2022","2022",0.2,,
+"PATCBIOT","J01-Antibacterials for systemic use","TCPPERMT","/capita, US$ exchange rate","CRI","Costa Rica","2010","2010",2.5,,
+"PATCBIOT","J01-Antibacterials for systemic use","TCPPERMT","/capita, US$ exchange rate","CRI","Costa Rica","2011","2011",2.4,,
+"PATCBIOT","J01-Antibacterials for systemic use","TCPPERMT","/capita, US$ exchange rate","CRI","Costa Rica","2012","2012",2.1,,
+"PATCBIOT","J01-Antibacterials for systemic use","TCPPERMT","/capita, US$ exchange rate","CRI","Costa Rica","2013","2013",2.2,,
+"PATCBIOT","J01-Antibacterials for systemic use","TCPPERMT","/capita, US$ exchange rate","CRI","Costa Rica","2014","2014",2.2,"B","Break"
+"PATCBIOT","J01-Antibacterials for systemic use","TCPPERMT","/capita, US$ exchange rate","CRI","Costa Rica","2015","2015",1.9,,
+"PATCBIOT","J01-Antibacterials for systemic use","TCPPERMT","/capita, US$ exchange rate","CRI","Costa Rica","2016","2016",1.9,,
+"PATCBIOT","J01-Antibacterials for systemic use","TCPPERMT","/capita, US$ exchange rate","CRI","Costa Rica","2017","2017",1.6,,
+"PATCBIOT","J01-Antibacterials for systemic use","TCPPERMT","/capita, US$ exchange rate","CRI","Costa Rica","2018","2018",1.3,,
+"PATCBIOT","J01-Antibacterials for systemic use","TCPPERMT","/capita, US$ exchange rate","CRI","Costa Rica","2019","2019",1.3,,
+"PATCBIOT","J01-Antibacterials for systemic use","TCPPERMT","/capita, US$ exchange rate","CRI","Costa Rica","2020","2020",1,,
+"PATCBIOT","J01-Antibacterials for systemic use","TCPPERMT","/capita, US$ exchange rate","CRI","Costa Rica","2021","2021",1.1,,
+"PATCBIOT","J01-Antibacterials for systemic use","TCPPERMT","/capita, US$ exchange rate","CRI","Costa Rica","2022","2022",0.9,,
+"PATCACID","A02A-Antacids","MLLNCUMT","Million of national currency units","CRI","Costa Rica","2010","2010",649.4,,
+"PATCACID","A02A-Antacids","MLLNCUMT","Million of national currency units","CRI","Costa Rica","2011","2011",749.2,,
+"PATCACID","A02A-Antacids","MLLNCUMT","Million of national currency units","CRI","Costa Rica","2012","2012",765.2,,
+"PATCACID","A02A-Antacids","MLLNCUMT","Million of national currency units","CRI","Costa Rica","2013","2013",975.1,,
+"PATCACID","A02A-Antacids","MLLNCUMT","Million of national currency units","CRI","Costa Rica","2014","2014",864,"B","Break"
+"PATCACID","A02A-Antacids","MLLNCUMT","Million of national currency units","CRI","Costa Rica","2015","2015",882.4,,
+"PATCACID","A02A-Antacids","MLLNCUMT","Million of national currency units","CRI","Costa Rica","2016","2016",927.7,,
+"PATCACID","A02A-Antacids","MLLNCUMT","Million of national currency units","CRI","Costa Rica","2017","2017",1006.5,,
+"PATCACID","A02A-Antacids","MLLNCUMT","Million of national currency units","CRI","Costa Rica","2018","2018",1082.3,,
+"PATCACID","A02A-Antacids","MLLNCUMT","Million of national currency units","CRI","Costa Rica","2019","2019",1422.8,,
+"PATCACID","A02A-Antacids","MLLNCUMT","Million of national currency units","CRI","Costa Rica","2020","2020",1514.7,,
+"PATCACID","A02A-Antacids","MLLNCUMT","Million of national currency units","CRI","Costa Rica","2021","2021",1764.4,,
+"PATCACID","A02A-Antacids","MLLNCUMT","Million of national currency units","CRI","Costa Rica","2022","2022",1483.9,,
+"PATCBLOO","B-Blood and blood forming organs","MLLNCUMT","Million of national currency units","CRI","Costa Rica","2010","2010",11435.7,,
+"PATCBLOO","B-Blood and blood forming organs","MLLNCUMT","Million of national currency units","CRI","Costa Rica","2011","2011",11848,,
+"PATCBLOO","B-Blood and blood forming organs","MLLNCUMT","Million of national currency units","CRI","Costa Rica","2012","2012",12208.2,,
+"PATCBLOO","B-Blood and blood forming organs","MLLNCUMT","Million of national currency units","CRI","Costa Rica","2013","2013",14811.2,,
+"PATCBLOO","B-Blood and blood forming organs","MLLNCUMT","Million of national currency units","CRI","Costa Rica","2014","2014",18566,"B","Break"
+"PATCBLOO","B-Blood and blood forming organs","MLLNCUMT","Million of national currency units","CRI","Costa Rica","2015","2015",16694.8,,
+"PATCBLOO","B-Blood and blood forming organs","MLLNCUMT","Million of national currency units","CRI","Costa Rica","2016","2016",15990.6,,
+"PATCBLOO","B-Blood and blood forming organs","MLLNCUMT","Million of national currency units","CRI","Costa Rica","2017","2017",15352.6,,
+"PATCBLOO","B-Blood and blood forming organs","MLLNCUMT","Million of national currency units","CRI","Costa Rica","2018","2018",17700.7,,
+"PATCBLOO","B-Blood and blood forming organs","MLLNCUMT","Million of national currency units","CRI","Costa Rica","2019","2019",20126.6,,
+"PATCBLOO","B-Blood and blood forming organs","MLLNCUMT","Million of national currency units","CRI","Costa Rica","2020","2020",16108.2,,
+"PATCBLOO","B-Blood and blood forming organs","MLLNCUMT","Million of national currency units","CRI","Costa Rica","2021","2021",20289.6,,
+"PATCBLOO","B-Blood and blood forming organs","MLLNCUMT","Million of national currency units","CRI","Costa Rica","2022","2022",19316.5,,
+"PATCBETA","C07-Beta blocking agents","MTMOTCMT","Million US$ at exchange rate","CRI","Costa Rica","2010","2010",0.6,,
+"PATCBETA","C07-Beta blocking agents","MTMOTCMT","Million US$ at exchange rate","CRI","Costa Rica","2011","2011",1,,
+"PATCBETA","C07-Beta blocking agents","MTMOTCMT","Million US$ at exchange rate","CRI","Costa Rica","2012","2012",1.2,,
+"PATCBETA","C07-Beta blocking agents","MTMOTCMT","Million US$ at exchange rate","CRI","Costa Rica","2013","2013",1.2,,
+"PATCBETA","C07-Beta blocking agents","MTMOTCMT","Million US$ at exchange rate","CRI","Costa Rica","2014","2014",1.2,"B","Break"
+"PATCBETA","C07-Beta blocking agents","MTMOTCMT","Million US$ at exchange rate","CRI","Costa Rica","2015","2015",1.6,,
+"PATCBETA","C07-Beta blocking agents","MTMOTCMT","Million US$ at exchange rate","CRI","Costa Rica","2016","2016",1.6,,
+"PATCBETA","C07-Beta blocking agents","MTMOTCMT","Million US$ at exchange rate","CRI","Costa Rica","2017","2017",1.7,,
+"PATCBETA","C07-Beta blocking agents","MTMOTCMT","Million US$ at exchange rate","CRI","Costa Rica","2018","2018",1.4,,
+"PATCBETA","C07-Beta blocking agents","MTMOTCMT","Million US$ at exchange rate","CRI","Costa Rica","2019","2019",1.1,,
+"PATCBETA","C07-Beta blocking agents","MTMOTCMT","Million US$ at exchange rate","CRI","Costa Rica","2020","2020",1,,
+"PATCBETA","C07-Beta blocking agents","MTMOTCMT","Million US$ at exchange rate","CRI","Costa Rica","2021","2021",1.3,,
+"PATCBETA","C07-Beta blocking agents","MTMOTCMT","Million US$ at exchange rate","CRI","Costa Rica","2022","2022",1.2,,
+"PATCACID","A02A-Antacids","MTMOTCMT","Million US$ at exchange rate","CRI","Costa Rica","2010","2010",1.2,,
+"PATCACID","A02A-Antacids","MTMOTCMT","Million US$ at exchange rate","CRI","Costa Rica","2011","2011",1.5,,
+"PATCACID","A02A-Antacids","MTMOTCMT","Million US$ at exchange rate","CRI","Costa Rica","2012","2012",1.5,,
+"PATCACID","A02A-Antacids","MTMOTCMT","Million US$ at exchange rate","CRI","Costa Rica","2013","2013",2,,
+"PATCACID","A02A-Antacids","MTMOTCMT","Million US$ at exchange rate","CRI","Costa Rica","2014","2014",1.6,"B","Break"
+"PATCACID","A02A-Antacids","MTMOTCMT","Million US$ at exchange rate","CRI","Costa Rica","2015","2015",1.7,,
+"PATCACID","A02A-Antacids","MTMOTCMT","Million US$ at exchange rate","CRI","Costa Rica","2016","2016",1.7,,
+"PATCACID","A02A-Antacids","MTMOTCMT","Million US$ at exchange rate","CRI","Costa Rica","2017","2017",1.8,,
+"PATCACID","A02A-Antacids","MTMOTCMT","Million US$ at exchange rate","CRI","Costa Rica","2018","2018",1.9,,
+"PATCACID","A02A-Antacids","MTMOTCMT","Million US$ at exchange rate","CRI","Costa Rica","2019","2019",2.4,,
+"PATCACID","A02A-Antacids","MTMOTCMT","Million US$ at exchange rate","CRI","Costa Rica","2020","2020",2.6,,
+"PATCACID","A02A-Antacids","MTMOTCMT","Million US$ at exchange rate","CRI","Costa Rica","2021","2021",2.8,,
+"PATCACID","A02A-Antacids","MTMOTCMT","Million US$ at exchange rate","CRI","Costa Rica","2022","2022",2.3,,
+"PATCBLOO","B-Blood and blood forming organs","MTMOTCMT","Million US$ at exchange rate","CRI","Costa Rica","2010","2010",21.7,,
+"PATCBLOO","B-Blood and blood forming organs","MTMOTCMT","Million US$ at exchange rate","CRI","Costa Rica","2011","2011",23.4,,
+"PATCBLOO","B-Blood and blood forming organs","MTMOTCMT","Million US$ at exchange rate","CRI","Costa Rica","2012","2012",24.3,,
+"PATCBLOO","B-Blood and blood forming organs","MTMOTCMT","Million US$ at exchange rate","CRI","Costa Rica","2013","2013",29.6,,
+"PATCBLOO","B-Blood and blood forming organs","MTMOTCMT","Million US$ at exchange rate","CRI","Costa Rica","2014","2014",34.5,"B","Break"
+"PATCBLOO","B-Blood and blood forming organs","MTMOTCMT","Million US$ at exchange rate","CRI","Costa Rica","2015","2015",31.2,,
+"PATCBLOO","B-Blood and blood forming organs","MTMOTCMT","Million US$ at exchange rate","CRI","Costa Rica","2016","2016",29.4,,
+"PATCBLOO","B-Blood and blood forming organs","MTMOTCMT","Million US$ at exchange rate","CRI","Costa Rica","2017","2017",27.1,,
+"PATCBLOO","B-Blood and blood forming organs","MTMOTCMT","Million US$ at exchange rate","CRI","Costa Rica","2018","2018",30.7,,
+"PATCBLOO","B-Blood and blood forming organs","MTMOTCMT","Million US$ at exchange rate","CRI","Costa Rica","2019","2019",34.3,,
+"PATCBLOO","B-Blood and blood forming organs","MTMOTCMT","Million US$ at exchange rate","CRI","Costa Rica","2020","2020",27.5,,
+"PATCBLOO","B-Blood and blood forming organs","MTMOTCMT","Million US$ at exchange rate","CRI","Costa Rica","2021","2021",32.7,,
+"PATCBLOO","B-Blood and blood forming organs","MTMOTCMT","Million US$ at exchange rate","CRI","Costa Rica","2022","2022",29.8,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","TCPPERMT","/capita, US$ exchange rate","CRI","Costa Rica","2010","2010",0.6,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","TCPPERMT","/capita, US$ exchange rate","CRI","Costa Rica","2011","2011",0.7,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","TCPPERMT","/capita, US$ exchange rate","CRI","Costa Rica","2012","2012",0.7,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","TCPPERMT","/capita, US$ exchange rate","CRI","Costa Rica","2013","2013",0.7,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","TCPPERMT","/capita, US$ exchange rate","CRI","Costa Rica","2014","2014",0.7,"B","Break"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","TCPPERMT","/capita, US$ exchange rate","CRI","Costa Rica","2015","2015",0.7,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","TCPPERMT","/capita, US$ exchange rate","CRI","Costa Rica","2016","2016",0.7,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","TCPPERMT","/capita, US$ exchange rate","CRI","Costa Rica","2017","2017",0.7,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","TCPPERMT","/capita, US$ exchange rate","CRI","Costa Rica","2018","2018",0.9,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","TCPPERMT","/capita, US$ exchange rate","CRI","Costa Rica","2019","2019",1,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","TCPPERMT","/capita, US$ exchange rate","CRI","Costa Rica","2020","2020",0.9,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","TCPPERMT","/capita, US$ exchange rate","CRI","Costa Rica","2021","2021",1,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","TCPPERMT","/capita, US$ exchange rate","CRI","Costa Rica","2022","2022",0.8,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","TCPPERMT","/capita, US$ exchange rate","CRI","Costa Rica","2010","2010",0.6,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","TCPPERMT","/capita, US$ exchange rate","CRI","Costa Rica","2011","2011",0.4,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","TCPPERMT","/capita, US$ exchange rate","CRI","Costa Rica","2012","2012",0.5,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","TCPPERMT","/capita, US$ exchange rate","CRI","Costa Rica","2013","2013",0.6,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","TCPPERMT","/capita, US$ exchange rate","CRI","Costa Rica","2014","2014",0.6,"B","Break"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","TCPPERMT","/capita, US$ exchange rate","CRI","Costa Rica","2015","2015",0.6,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","TCPPERMT","/capita, US$ exchange rate","CRI","Costa Rica","2016","2016",0.5,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","TCPPERMT","/capita, US$ exchange rate","CRI","Costa Rica","2017","2017",0.7,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","TCPPERMT","/capita, US$ exchange rate","CRI","Costa Rica","2018","2018",0.8,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","TCPPERMT","/capita, US$ exchange rate","CRI","Costa Rica","2019","2019",1.4,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","TCPPERMT","/capita, US$ exchange rate","CRI","Costa Rica","2020","2020",1.2,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","TCPPERMT","/capita, US$ exchange rate","CRI","Costa Rica","2021","2021",1.2,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","TCPPERMT","/capita, US$ exchange rate","CRI","Costa Rica","2022","2022",1,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MLLNCUMT","Million of national currency units","CRI","Costa Rica","2010","2010",55.7,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MLLNCUMT","Million of national currency units","CRI","Costa Rica","2011","2011",73.6,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MLLNCUMT","Million of national currency units","CRI","Costa Rica","2012","2012",74.5,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MLLNCUMT","Million of national currency units","CRI","Costa Rica","2013","2013",114,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MLLNCUMT","Million of national currency units","CRI","Costa Rica","2014","2014",71.7,"B","Break"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MLLNCUMT","Million of national currency units","CRI","Costa Rica","2015","2015",64.5,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MLLNCUMT","Million of national currency units","CRI","Costa Rica","2016","2016",75.6,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MLLNCUMT","Million of national currency units","CRI","Costa Rica","2017","2017",76.7,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MLLNCUMT","Million of national currency units","CRI","Costa Rica","2018","2018",91,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MLLNCUMT","Million of national currency units","CRI","Costa Rica","2019","2019",131,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MLLNCUMT","Million of national currency units","CRI","Costa Rica","2020","2020",136.9,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MLLNCUMT","Million of national currency units","CRI","Costa Rica","2021","2021",154.4,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MLLNCUMT","Million of national currency units","CRI","Costa Rica","2022","2022",121.8,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MLLNCUMT","Million of national currency units","CRI","Costa Rica","2010","2010",3327.3,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MLLNCUMT","Million of national currency units","CRI","Costa Rica","2011","2011",3103.4,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MLLNCUMT","Million of national currency units","CRI","Costa Rica","2012","2012",3202.7,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MLLNCUMT","Million of national currency units","CRI","Costa Rica","2013","2013",3657.2,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MLLNCUMT","Million of national currency units","CRI","Costa Rica","2014","2014",4275.6,"B","Break"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MLLNCUMT","Million of national currency units","CRI","Costa Rica","2015","2015",3675.4,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MLLNCUMT","Million of national currency units","CRI","Costa Rica","2016","2016",3104.4,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MLLNCUMT","Million of national currency units","CRI","Costa Rica","2017","2017",3015.6,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MLLNCUMT","Million of national currency units","CRI","Costa Rica","2018","2018",2987.9,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MLLNCUMT","Million of national currency units","CRI","Costa Rica","2019","2019",3517.5,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MLLNCUMT","Million of national currency units","CRI","Costa Rica","2020","2020",4240,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MLLNCUMT","Million of national currency units","CRI","Costa Rica","2021","2021",5193.3,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MLLNCUMT","Million of national currency units","CRI","Costa Rica","2022","2022",4805.5,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2010","2010",1,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2011","2011",1.1,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2012","2012",1.1,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2013","2013",1.2,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2014","2014",1,"B","Break"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2015","2015",1.1,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2016","2016",1.1,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2017","2017",1.1,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2018","2018",1,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2019","2019",0.9,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2020","2020",0.8,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2021","2021",0.9,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2022","2022",0.8,,
+"PATCDIUR","C03-Diuretics","MTMOPPMT","Million US$, purchasing power parity","CRI","Costa Rica","2010","2010",1.5,,
+"PATCDIUR","C03-Diuretics","MTMOPPMT","Million US$, purchasing power parity","CRI","Costa Rica","2011","2011",2,,
+"PATCDIUR","C03-Diuretics","MTMOPPMT","Million US$, purchasing power parity","CRI","Costa Rica","2012","2012",1.1,,
+"PATCDIUR","C03-Diuretics","MTMOPPMT","Million US$, purchasing power parity","CRI","Costa Rica","2013","2013",1.2,,
+"PATCDIUR","C03-Diuretics","MTMOPPMT","Million US$, purchasing power parity","CRI","Costa Rica","2014","2014",1.2,"B","Break"
+"PATCDIUR","C03-Diuretics","MTMOPPMT","Million US$, purchasing power parity","CRI","Costa Rica","2015","2015",1.2,,
+"PATCDIUR","C03-Diuretics","MTMOPPMT","Million US$, purchasing power parity","CRI","Costa Rica","2016","2016",1.2,,
+"PATCDIUR","C03-Diuretics","MTMOPPMT","Million US$, purchasing power parity","CRI","Costa Rica","2017","2017",1.2,,
+"PATCDIUR","C03-Diuretics","MTMOPPMT","Million US$, purchasing power parity","CRI","Costa Rica","2018","2018",1.3,,
+"PATCDIUR","C03-Diuretics","MTMOPPMT","Million US$, purchasing power parity","CRI","Costa Rica","2019","2019",1.4,,
+"PATCDIUR","C03-Diuretics","MTMOPPMT","Million US$, purchasing power parity","CRI","Costa Rica","2020","2020",1.4,,
+"PATCDIUR","C03-Diuretics","MTMOPPMT","Million US$, purchasing power parity","CRI","Costa Rica","2021","2021",1.5,,
+"PATCDIUR","C03-Diuretics","MTMOPPMT","Million US$, purchasing power parity","CRI","Costa Rica","2022","2022",1.3,,
+"PATCGLYC","C01A-Cardiac glycosides","MTMOPPMT","Million US$, purchasing power parity","CRI","Costa Rica","2010","2010",0.5,,
+"PATCGLYC","C01A-Cardiac glycosides","MTMOPPMT","Million US$, purchasing power parity","CRI","Costa Rica","2011","2011",0.4,,
+"PATCGLYC","C01A-Cardiac glycosides","MTMOPPMT","Million US$, purchasing power parity","CRI","Costa Rica","2012","2012",0.4,,
+"PATCGLYC","C01A-Cardiac glycosides","MTMOPPMT","Million US$, purchasing power parity","CRI","Costa Rica","2013","2013",0.4,,
+"PATCGLYC","C01A-Cardiac glycosides","MTMOPPMT","Million US$, purchasing power parity","CRI","Costa Rica","2014","2014",0.6,"B","Break"
+"PATCGLYC","C01A-Cardiac glycosides","MTMOPPMT","Million US$, purchasing power parity","CRI","Costa Rica","2015","2015",0.6,,
+"PATCGLYC","C01A-Cardiac glycosides","MTMOPPMT","Million US$, purchasing power parity","CRI","Costa Rica","2016","2016",0.6,,
+"PATCGLYC","C01A-Cardiac glycosides","MTMOPPMT","Million US$, purchasing power parity","CRI","Costa Rica","2017","2017",0.5,,
+"PATCGLYC","C01A-Cardiac glycosides","MTMOPPMT","Million US$, purchasing power parity","CRI","Costa Rica","2018","2018",0.4,,
+"PATCGLYC","C01A-Cardiac glycosides","MTMOPPMT","Million US$, purchasing power parity","CRI","Costa Rica","2019","2019",0.3,,
+"PATCGLYC","C01A-Cardiac glycosides","MTMOPPMT","Million US$, purchasing power parity","CRI","Costa Rica","2020","2020",0.3,,
+"PATCGLYC","C01A-Cardiac glycosides","MTMOPPMT","Million US$, purchasing power parity","CRI","Costa Rica","2021","2021",0.3,,
+"PATCGLYC","C01A-Cardiac glycosides","MTMOPPMT","Million US$, purchasing power parity","CRI","Costa Rica","2022","2022",0.3,,
+"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2010","2010",0.1,,
+"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2011","2011",0.1,,
+"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2012","2012",0.1,,
+"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2013","2013",0.2,,
+"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2014","2014",0.2,"B","Break"
+"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2015","2015",0.2,,
+"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2016","2016",0.2,,
+"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2017","2017",0.2,,
+"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2018","2018",0.3,,
+"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2019","2019",0.3,,
+"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2020","2020",0.3,,
+"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2021","2021",0.3,,
+"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2022","2022",0.2,,
+"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2010","2010",11.6,,
+"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2011","2011",9.6,,
+"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2012","2012",8.7,,
+"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2013","2013",8.6,,
+"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2014","2014",10,"B","Break"
+"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2015","2015",10.1,,
+"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2016","2016",11.4,,
+"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2017","2017",11.6,,
+"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2018","2018",12.4,,
+"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2019","2019",13.4,,
+"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2020","2020",13.2,,
+"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2021","2021",14.3,,
+"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2022","2022",12.7,,
+"PATCDIAB","A10-Drugs used in diabetes","MTMOPPMT","Million US$, purchasing power parity","CRI","Costa Rica","2010","2010",8.3,,
+"PATCDIAB","A10-Drugs used in diabetes","MTMOPPMT","Million US$, purchasing power parity","CRI","Costa Rica","2011","2011",8.5,,
+"PATCDIAB","A10-Drugs used in diabetes","MTMOPPMT","Million US$, purchasing power parity","CRI","Costa Rica","2012","2012",9.7,,
+"PATCDIAB","A10-Drugs used in diabetes","MTMOPPMT","Million US$, purchasing power parity","CRI","Costa Rica","2013","2013",10.2,,
+"PATCDIAB","A10-Drugs used in diabetes","MTMOPPMT","Million US$, purchasing power parity","CRI","Costa Rica","2014","2014",12.1,"B","Break"
+"PATCDIAB","A10-Drugs used in diabetes","MTMOPPMT","Million US$, purchasing power parity","CRI","Costa Rica","2015","2015",11.4,,
+"PATCDIAB","A10-Drugs used in diabetes","MTMOPPMT","Million US$, purchasing power parity","CRI","Costa Rica","2016","2016",12.5,,
+"PATCDIAB","A10-Drugs used in diabetes","MTMOPPMT","Million US$, purchasing power parity","CRI","Costa Rica","2017","2017",13.5,,
+"PATCDIAB","A10-Drugs used in diabetes","MTMOPPMT","Million US$, purchasing power parity","CRI","Costa Rica","2018","2018",14.2,,
+"PATCDIAB","A10-Drugs used in diabetes","MTMOPPMT","Million US$, purchasing power parity","CRI","Costa Rica","2019","2019",16.3,,
+"PATCDIAB","A10-Drugs used in diabetes","MTMOPPMT","Million US$, purchasing power parity","CRI","Costa Rica","2020","2020",17.5,,
+"PATCDIAB","A10-Drugs used in diabetes","MTMOPPMT","Million US$, purchasing power parity","CRI","Costa Rica","2021","2021",18.2,,
+"PATCDIAB","A10-Drugs used in diabetes","MTMOPPMT","Million US$, purchasing power parity","CRI","Costa Rica","2022","2022",16,,
+"PATCANXO","N05B-Anxiolytics","MTMOTCMT","Million US$ at exchange rate","CRI","Costa Rica","2010","2010",0.5,,
+"PATCANXO","N05B-Anxiolytics","MTMOTCMT","Million US$ at exchange rate","CRI","Costa Rica","2011","2011",0.5,,
+"PATCANXO","N05B-Anxiolytics","MTMOTCMT","Million US$ at exchange rate","CRI","Costa Rica","2012","2012",0.6,,
+"PATCANXO","N05B-Anxiolytics","MTMOTCMT","Million US$ at exchange rate","CRI","Costa Rica","2013","2013",0.6,,
+"PATCANXO","N05B-Anxiolytics","MTMOTCMT","Million US$ at exchange rate","CRI","Costa Rica","2014","2014",0.7,"B","Break"
+"PATCANXO","N05B-Anxiolytics","MTMOTCMT","Million US$ at exchange rate","CRI","Costa Rica","2015","2015",0.7,,
+"PATCANXO","N05B-Anxiolytics","MTMOTCMT","Million US$ at exchange rate","CRI","Costa Rica","2016","2016",0.7,,
+"PATCANXO","N05B-Anxiolytics","MTMOTCMT","Million US$ at exchange rate","CRI","Costa Rica","2017","2017",0.7,,
+"PATCANXO","N05B-Anxiolytics","MTMOTCMT","Million US$ at exchange rate","CRI","Costa Rica","2018","2018",0.8,,
+"PATCANXO","N05B-Anxiolytics","MTMOTCMT","Million US$ at exchange rate","CRI","Costa Rica","2019","2019",1,,
+"PATCANXO","N05B-Anxiolytics","MTMOTCMT","Million US$ at exchange rate","CRI","Costa Rica","2020","2020",1,,
+"PATCANXO","N05B-Anxiolytics","MTMOTCMT","Million US$ at exchange rate","CRI","Costa Rica","2021","2021",0.7,,
+"PATCANXO","N05B-Anxiolytics","MTMOTCMT","Million US$ at exchange rate","CRI","Costa Rica","2022","2022",0.6,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOTCMT","Million US$ at exchange rate","CRI","Costa Rica","2010","2010",2.9,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOTCMT","Million US$ at exchange rate","CRI","Costa Rica","2011","2011",3.3,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOTCMT","Million US$ at exchange rate","CRI","Costa Rica","2012","2012",3.5,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOTCMT","Million US$ at exchange rate","CRI","Costa Rica","2013","2013",3.8,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOTCMT","Million US$ at exchange rate","CRI","Costa Rica","2014","2014",3.1,"B","Break"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOTCMT","Million US$ at exchange rate","CRI","Costa Rica","2015","2015",3.5,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOTCMT","Million US$ at exchange rate","CRI","Costa Rica","2016","2016",3.4,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOTCMT","Million US$ at exchange rate","CRI","Costa Rica","2017","2017",3.4,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOTCMT","Million US$ at exchange rate","CRI","Costa Rica","2018","2018",3,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOTCMT","Million US$ at exchange rate","CRI","Costa Rica","2019","2019",2.6,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOTCMT","Million US$ at exchange rate","CRI","Costa Rica","2020","2020",2.3,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOTCMT","Million US$ at exchange rate","CRI","Costa Rica","2021","2021",2.7,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOTCMT","Million US$ at exchange rate","CRI","Costa Rica","2022","2022",2.3,,
+"PATCHYPO","C02-Antihypertensives","TCPPERMT","/capita, US$ exchange rate","CRI","Costa Rica","2010","2010",0.1,,
+"PATCHYPO","C02-Antihypertensives","TCPPERMT","/capita, US$ exchange rate","CRI","Costa Rica","2011","2011",0.1,,
+"PATCHYPO","C02-Antihypertensives","TCPPERMT","/capita, US$ exchange rate","CRI","Costa Rica","2012","2012",0.2,,
+"PATCHYPO","C02-Antihypertensives","TCPPERMT","/capita, US$ exchange rate","CRI","Costa Rica","2013","2013",0.2,,
+"PATCHYPO","C02-Antihypertensives","TCPPERMT","/capita, US$ exchange rate","CRI","Costa Rica","2014","2014",0.2,"B","Break"
+"PATCHYPO","C02-Antihypertensives","TCPPERMT","/capita, US$ exchange rate","CRI","Costa Rica","2015","2015",0.2,,
+"PATCHYPO","C02-Antihypertensives","TCPPERMT","/capita, US$ exchange rate","CRI","Costa Rica","2016","2016",0.2,,
+"PATCHYPO","C02-Antihypertensives","TCPPERMT","/capita, US$ exchange rate","CRI","Costa Rica","2017","2017",0.2,,
+"PATCHYPO","C02-Antihypertensives","TCPPERMT","/capita, US$ exchange rate","CRI","Costa Rica","2018","2018",0.2,,
+"PATCHYPO","C02-Antihypertensives","TCPPERMT","/capita, US$ exchange rate","CRI","Costa Rica","2019","2019",0.3,,
+"PATCHYPO","C02-Antihypertensives","TCPPERMT","/capita, US$ exchange rate","CRI","Costa Rica","2020","2020",0.3,,
+"PATCHYPO","C02-Antihypertensives","TCPPERMT","/capita, US$ exchange rate","CRI","Costa Rica","2021","2021",0.3,,
+"PATCHYPO","C02-Antihypertensives","TCPPERMT","/capita, US$ exchange rate","CRI","Costa Rica","2022","2022",0.2,,
+"PATCCARV","C-Cardiovascular system","TCPPERMT","/capita, US$ exchange rate","CRI","Costa Rica","2010","2010",2,,
+"PATCCARV","C-Cardiovascular system","TCPPERMT","/capita, US$ exchange rate","CRI","Costa Rica","2011","2011",2.1,,
+"PATCCARV","C-Cardiovascular system","TCPPERMT","/capita, US$ exchange rate","CRI","Costa Rica","2012","2012",2.2,,
+"PATCCARV","C-Cardiovascular system","TCPPERMT","/capita, US$ exchange rate","CRI","Costa Rica","2013","2013",2.3,,
+"PATCCARV","C-Cardiovascular system","TCPPERMT","/capita, US$ exchange rate","CRI","Costa Rica","2014","2014",2.6,"B","Break"
+"PATCCARV","C-Cardiovascular system","TCPPERMT","/capita, US$ exchange rate","CRI","Costa Rica","2015","2015",2.2,,
+"PATCCARV","C-Cardiovascular system","TCPPERMT","/capita, US$ exchange rate","CRI","Costa Rica","2016","2016",2.1,,
+"PATCCARV","C-Cardiovascular system","TCPPERMT","/capita, US$ exchange rate","CRI","Costa Rica","2017","2017",2.3,,
+"PATCCARV","C-Cardiovascular system","TCPPERMT","/capita, US$ exchange rate","CRI","Costa Rica","2018","2018",2.6,,
+"PATCCARV","C-Cardiovascular system","TCPPERMT","/capita, US$ exchange rate","CRI","Costa Rica","2019","2019",3.2,,
+"PATCCARV","C-Cardiovascular system","TCPPERMT","/capita, US$ exchange rate","CRI","Costa Rica","2020","2020",2.9,,
+"PATCCARV","C-Cardiovascular system","TCPPERMT","/capita, US$ exchange rate","CRI","Costa Rica","2021","2021",3.2,,
+"PATCCARV","C-Cardiovascular system","TCPPERMT","/capita, US$ exchange rate","CRI","Costa Rica","2022","2022",2.5,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","TCPPERMT","/capita, US$ exchange rate","CRI","Costa Rica","2010","2010",0.4,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","TCPPERMT","/capita, US$ exchange rate","CRI","Costa Rica","2011","2011",0.4,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","TCPPERMT","/capita, US$ exchange rate","CRI","Costa Rica","2012","2012",0.4,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","TCPPERMT","/capita, US$ exchange rate","CRI","Costa Rica","2013","2013",0.6,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","TCPPERMT","/capita, US$ exchange rate","CRI","Costa Rica","2014","2014",0.7,"B","Break"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","TCPPERMT","/capita, US$ exchange rate","CRI","Costa Rica","2015","2015",0.6,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","TCPPERMT","/capita, US$ exchange rate","CRI","Costa Rica","2016","2016",0.6,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","TCPPERMT","/capita, US$ exchange rate","CRI","Costa Rica","2017","2017",0.7,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","TCPPERMT","/capita, US$ exchange rate","CRI","Costa Rica","2018","2018",0.6,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","TCPPERMT","/capita, US$ exchange rate","CRI","Costa Rica","2019","2019",0.5,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","TCPPERMT","/capita, US$ exchange rate","CRI","Costa Rica","2020","2020",0.4,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","TCPPERMT","/capita, US$ exchange rate","CRI","Costa Rica","2021","2021",0.4,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","TCPPERMT","/capita, US$ exchange rate","CRI","Costa Rica","2022","2022",0.3,,
+"PATCINFC","J-Antiinfectives for systemic use","MLLNCUMT","Million of national currency units","CRI","Costa Rica","2010","2010",17239.8,,
+"PATCINFC","J-Antiinfectives for systemic use","MLLNCUMT","Million of national currency units","CRI","Costa Rica","2011","2011",14773.7,,
+"PATCINFC","J-Antiinfectives for systemic use","MLLNCUMT","Million of national currency units","CRI","Costa Rica","2012","2012",13948.3,,
+"PATCINFC","J-Antiinfectives for systemic use","MLLNCUMT","Million of national currency units","CRI","Costa Rica","2013","2013",14080.5,,
+"PATCINFC","J-Antiinfectives for systemic use","MLLNCUMT","Million of national currency units","CRI","Costa Rica","2014","2014",16847.2,"B","Break"
+"PATCINFC","J-Antiinfectives for systemic use","MLLNCUMT","Million of national currency units","CRI","Costa Rica","2015","2015",17281.8,,
+"PATCINFC","J-Antiinfectives for systemic use","MLLNCUMT","Million of national currency units","CRI","Costa Rica","2016","2016",19042.5,,
+"PATCINFC","J-Antiinfectives for systemic use","MLLNCUMT","Million of national currency units","CRI","Costa Rica","2017","2017",19558.1,,
+"PATCINFC","J-Antiinfectives for systemic use","MLLNCUMT","Million of national currency units","CRI","Costa Rica","2018","2018",20937.1,,
+"PATCINFC","J-Antiinfectives for systemic use","MLLNCUMT","Million of national currency units","CRI","Costa Rica","2019","2019",22322,,
+"PATCINFC","J-Antiinfectives for systemic use","MLLNCUMT","Million of national currency units","CRI","Costa Rica","2020","2020",22117.7,,
+"PATCINFC","J-Antiinfectives for systemic use","MLLNCUMT","Million of national currency units","CRI","Costa Rica","2021","2021",25408.9,,
+"PATCINFC","J-Antiinfectives for systemic use","MLLNCUMT","Million of national currency units","CRI","Costa Rica","2022","2022",22871,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MLLNCUMT","Million of national currency units","CRI","Costa Rica","2010","2010",1530.3,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MLLNCUMT","Million of national currency units","CRI","Costa Rica","2011","2011",1662.2,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MLLNCUMT","Million of national currency units","CRI","Costa Rica","2012","2012",1763.9,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MLLNCUMT","Million of national currency units","CRI","Costa Rica","2013","2013",1915.9,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MLLNCUMT","Million of national currency units","CRI","Costa Rica","2014","2014",1674.9,"B","Break"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MLLNCUMT","Million of national currency units","CRI","Costa Rica","2015","2015",1858.9,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MLLNCUMT","Million of national currency units","CRI","Costa Rica","2016","2016",1877.2,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MLLNCUMT","Million of national currency units","CRI","Costa Rica","2017","2017",1901.9,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MLLNCUMT","Million of national currency units","CRI","Costa Rica","2018","2018",1715.3,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MLLNCUMT","Million of national currency units","CRI","Costa Rica","2019","2019",1506.2,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MLLNCUMT","Million of national currency units","CRI","Costa Rica","2020","2020",1339.5,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MLLNCUMT","Million of national currency units","CRI","Costa Rica","2021","2021",1681,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MLLNCUMT","Million of national currency units","CRI","Costa Rica","2022","2022",1475.4,,
+"PATCINFC","J-Antiinfectives for systemic use","MTMOTCMT","Million US$ at exchange rate","CRI","Costa Rica","2010","2010",32.8,,
+"PATCINFC","J-Antiinfectives for systemic use","MTMOTCMT","Million US$ at exchange rate","CRI","Costa Rica","2011","2011",29.2,,
+"PATCINFC","J-Antiinfectives for systemic use","MTMOTCMT","Million US$ at exchange rate","CRI","Costa Rica","2012","2012",27.7,,
+"PATCINFC","J-Antiinfectives for systemic use","MTMOTCMT","Million US$ at exchange rate","CRI","Costa Rica","2013","2013",28.2,,
+"PATCINFC","J-Antiinfectives for systemic use","MTMOTCMT","Million US$ at exchange rate","CRI","Costa Rica","2014","2014",31.3,"B","Break"
+"PATCINFC","J-Antiinfectives for systemic use","MTMOTCMT","Million US$ at exchange rate","CRI","Costa Rica","2015","2015",32.3,,
+"PATCINFC","J-Antiinfectives for systemic use","MTMOTCMT","Million US$ at exchange rate","CRI","Costa Rica","2016","2016",35,,
+"PATCINFC","J-Antiinfectives for systemic use","MTMOTCMT","Million US$ at exchange rate","CRI","Costa Rica","2017","2017",34.5,,
+"PATCINFC","J-Antiinfectives for systemic use","MTMOTCMT","Million US$ at exchange rate","CRI","Costa Rica","2018","2018",36.3,,
+"PATCINFC","J-Antiinfectives for systemic use","MTMOTCMT","Million US$ at exchange rate","CRI","Costa Rica","2019","2019",38,,
+"PATCINFC","J-Antiinfectives for systemic use","MTMOTCMT","Million US$ at exchange rate","CRI","Costa Rica","2020","2020",37.8,,
+"PATCINFC","J-Antiinfectives for systemic use","MTMOTCMT","Million US$ at exchange rate","CRI","Costa Rica","2021","2021",40.9,,
+"PATCINFC","J-Antiinfectives for systemic use","MTMOTCMT","Million US$ at exchange rate","CRI","Costa Rica","2022","2022",35.3,,
+"PATCANAL","N02-Analgesics","MTMOPPMT","Million US$, purchasing power parity","CRI","Costa Rica","2010","2010",4.4,,
+"PATCANAL","N02-Analgesics","MTMOPPMT","Million US$, purchasing power parity","CRI","Costa Rica","2011","2011",4.6,,
+"PATCANAL","N02-Analgesics","MTMOPPMT","Million US$, purchasing power parity","CRI","Costa Rica","2012","2012",4.9,,
+"PATCANAL","N02-Analgesics","MTMOPPMT","Million US$, purchasing power parity","CRI","Costa Rica","2013","2013",5.5,,
+"PATCANAL","N02-Analgesics","MTMOPPMT","Million US$, purchasing power parity","CRI","Costa Rica","2014","2014",8,"B","Break"
+"PATCANAL","N02-Analgesics","MTMOPPMT","Million US$, purchasing power parity","CRI","Costa Rica","2015","2015",7.4,,
+"PATCANAL","N02-Analgesics","MTMOPPMT","Million US$, purchasing power parity","CRI","Costa Rica","2016","2016",7.7,,
+"PATCANAL","N02-Analgesics","MTMOPPMT","Million US$, purchasing power parity","CRI","Costa Rica","2017","2017",8.2,,
+"PATCANAL","N02-Analgesics","MTMOPPMT","Million US$, purchasing power parity","CRI","Costa Rica","2018","2018",9.8,,
+"PATCANAL","N02-Analgesics","MTMOPPMT","Million US$, purchasing power parity","CRI","Costa Rica","2019","2019",14.3,,
+"PATCANAL","N02-Analgesics","MTMOPPMT","Million US$, purchasing power parity","CRI","Costa Rica","2020","2020",14.1,,
+"PATCANAL","N02-Analgesics","MTMOPPMT","Million US$, purchasing power parity","CRI","Costa Rica","2021","2021",14.7,,
+"PATCANAL","N02-Analgesics","MTMOPPMT","Million US$, purchasing power parity","CRI","Costa Rica","2022","2022",15,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2010","2010",2.2,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2011","2011",2,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2012","2012",2,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2013","2013",2.2,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2014","2014",2.5,"B","Break"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2015","2015",2.1,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2016","2016",1.9,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2017","2017",1.8,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2018","2018",1.8,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2019","2019",2.1,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2020","2020",2.5,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2021","2021",2.9,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2022","2022",2.7,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2010","2010",0,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2011","2011",0,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2012","2012",0,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2013","2013",0.1,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2014","2014",0,"B","Break"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2015","2015",0,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2016","2016",0,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2017","2017",0,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2018","2018",0.1,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2019","2019",0.1,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2020","2020",0.1,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2021","2021",0.1,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2022","2022",0.1,,
+"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2010","2010",0.4,,
+"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2011","2011",0.5,,
+"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2012","2012",0.5,,
+"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2013","2013",0.6,,
+"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2014","2014",0.5,"B","Break"
+"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2015","2015",0.5,,
+"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2016","2016",0.6,,
+"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2017","2017",0.6,,
+"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2018","2018",0.6,,
+"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2019","2019",0.9,,
+"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2020","2020",0.9,,
+"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2021","2021",1,,
+"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2022","2022",0.8,,
+"PATCCHLS","C10-Lipid modifying agents","MTMOPPMT","Million US$, purchasing power parity","CRI","Costa Rica","2010","2010",5.8,,
+"PATCCHLS","C10-Lipid modifying agents","MTMOPPMT","Million US$, purchasing power parity","CRI","Costa Rica","2011","2011",5.9,,
+"PATCCHLS","C10-Lipid modifying agents","MTMOPPMT","Million US$, purchasing power parity","CRI","Costa Rica","2012","2012",6.1,,
+"PATCCHLS","C10-Lipid modifying agents","MTMOPPMT","Million US$, purchasing power parity","CRI","Costa Rica","2013","2013",5.7,,
+"PATCCHLS","C10-Lipid modifying agents","MTMOPPMT","Million US$, purchasing power parity","CRI","Costa Rica","2014","2014",8.4,"B","Break"
+"PATCCHLS","C10-Lipid modifying agents","MTMOPPMT","Million US$, purchasing power parity","CRI","Costa Rica","2015","2015",4.8,,
+"PATCCHLS","C10-Lipid modifying agents","MTMOPPMT","Million US$, purchasing power parity","CRI","Costa Rica","2016","2016",4.9,,
+"PATCCHLS","C10-Lipid modifying agents","MTMOPPMT","Million US$, purchasing power parity","CRI","Costa Rica","2017","2017",5.6,,
+"PATCCHLS","C10-Lipid modifying agents","MTMOPPMT","Million US$, purchasing power parity","CRI","Costa Rica","2018","2018",7.1,,
+"PATCCHLS","C10-Lipid modifying agents","MTMOPPMT","Million US$, purchasing power parity","CRI","Costa Rica","2019","2019",8.3,,
+"PATCCHLS","C10-Lipid modifying agents","MTMOPPMT","Million US$, purchasing power parity","CRI","Costa Rica","2020","2020",7.2,,
+"PATCCHLS","C10-Lipid modifying agents","MTMOPPMT","Million US$, purchasing power parity","CRI","Costa Rica","2021","2021",8.5,,
+"PATCCHLS","C10-Lipid modifying agents","MTMOPPMT","Million US$, purchasing power parity","CRI","Costa Rica","2022","2022",6,,
+"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2010","2010",7.7,,
+"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2011","2011",7.7,,
+"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2012","2012",7.6,,
+"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2013","2013",9,,
+"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2014","2014",11,"B","Break"
+"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2015","2015",9.8,,
+"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2016","2016",9.5,,
+"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2017","2017",9.1,,
+"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2018","2018",10.5,,
+"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2019","2019",12.1,,
+"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2020","2020",9.6,,
+"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2021","2021",11.4,,
+"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2022","2022",10.7,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOPPMT","Million US$, purchasing power parity","CRI","Costa Rica","2010","2010",7.1,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOPPMT","Million US$, purchasing power parity","CRI","Costa Rica","2011","2011",6.6,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOPPMT","Million US$, purchasing power parity","CRI","Costa Rica","2012","2012",6.4,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOPPMT","Million US$, purchasing power parity","CRI","Costa Rica","2013","2013",6.9,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOPPMT","Million US$, purchasing power parity","CRI","Costa Rica","2014","2014",7.6,"B","Break"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOPPMT","Million US$, purchasing power parity","CRI","Costa Rica","2015","2015",6.5,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOPPMT","Million US$, purchasing power parity","CRI","Costa Rica","2016","2016",6.8,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOPPMT","Million US$, purchasing power parity","CRI","Costa Rica","2017","2017",7.2,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOPPMT","Million US$, purchasing power parity","CRI","Costa Rica","2018","2018",7.9,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOPPMT","Million US$, purchasing power parity","CRI","Costa Rica","2019","2019",9,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOPPMT","Million US$, purchasing power parity","CRI","Costa Rica","2020","2020",8.1,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOPPMT","Million US$, purchasing power parity","CRI","Costa Rica","2021","2021",16.2,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOPPMT","Million US$, purchasing power parity","CRI","Costa Rica","2022","2022",14.5,,
+"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2010","2010",1.1,,
+"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2011","2011",0.9,,
+"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2012","2012",0.6,,
+"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2013","2013",0.6,,
+"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2014","2014",0.7,"B","Break"
+"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2015","2015",0.7,,
+"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2016","2016",0.9,,
+"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2017","2017",0.8,,
+"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2018","2018",0.8,,
+"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2019","2019",0.9,,
+"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2020","2020",0.8,,
+"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2021","2021",0.8,,
+"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2022","2022",0.7,,
+"PATCHYPO","C02-Antihypertensives","MTMOPPMT","Million US$, purchasing power parity","CRI","Costa Rica","2010","2010",0.9,,
+"PATCHYPO","C02-Antihypertensives","MTMOPPMT","Million US$, purchasing power parity","CRI","Costa Rica","2011","2011",1,,
+"PATCHYPO","C02-Antihypertensives","MTMOPPMT","Million US$, purchasing power parity","CRI","Costa Rica","2012","2012",1.1,,
+"PATCHYPO","C02-Antihypertensives","MTMOPPMT","Million US$, purchasing power parity","CRI","Costa Rica","2013","2013",1.1,,
+"PATCHYPO","C02-Antihypertensives","MTMOPPMT","Million US$, purchasing power parity","CRI","Costa Rica","2014","2014",1.4,"B","Break"
+"PATCHYPO","C02-Antihypertensives","MTMOPPMT","Million US$, purchasing power parity","CRI","Costa Rica","2015","2015",1.5,,
+"PATCHYPO","C02-Antihypertensives","MTMOPPMT","Million US$, purchasing power parity","CRI","Costa Rica","2016","2016",1.6,,
+"PATCHYPO","C02-Antihypertensives","MTMOPPMT","Million US$, purchasing power parity","CRI","Costa Rica","2017","2017",1.8,,
+"PATCHYPO","C02-Antihypertensives","MTMOPPMT","Million US$, purchasing power parity","CRI","Costa Rica","2018","2018",2.1,,
+"PATCHYPO","C02-Antihypertensives","MTMOPPMT","Million US$, purchasing power parity","CRI","Costa Rica","2019","2019",2.3,,
+"PATCHYPO","C02-Antihypertensives","MTMOPPMT","Million US$, purchasing power parity","CRI","Costa Rica","2020","2020",2.6,,
+"PATCHYPO","C02-Antihypertensives","MTMOPPMT","Million US$, purchasing power parity","CRI","Costa Rica","2021","2021",2.8,,
+"PATCHYPO","C02-Antihypertensives","MTMOPPMT","Million US$, purchasing power parity","CRI","Costa Rica","2022","2022",2.4,,
+"PATCCCBR","C08-Calcium channel blockers","MTMOPPMT","Million US$, purchasing power parity","CRI","Costa Rica","2010","2010",0.5,,
+"PATCCCBR","C08-Calcium channel blockers","MTMOPPMT","Million US$, purchasing power parity","CRI","Costa Rica","2011","2011",0.5,,
+"PATCCCBR","C08-Calcium channel blockers","MTMOPPMT","Million US$, purchasing power parity","CRI","Costa Rica","2012","2012",0.6,,
+"PATCCCBR","C08-Calcium channel blockers","MTMOPPMT","Million US$, purchasing power parity","CRI","Costa Rica","2013","2013",0.8,,
+"PATCCCBR","C08-Calcium channel blockers","MTMOPPMT","Million US$, purchasing power parity","CRI","Costa Rica","2014","2014",0.9,"B","Break"
+"PATCCCBR","C08-Calcium channel blockers","MTMOPPMT","Million US$, purchasing power parity","CRI","Costa Rica","2015","2015",1,,
+"PATCCCBR","C08-Calcium channel blockers","MTMOPPMT","Million US$, purchasing power parity","CRI","Costa Rica","2016","2016",0.9,,
+"PATCCCBR","C08-Calcium channel blockers","MTMOPPMT","Million US$, purchasing power parity","CRI","Costa Rica","2017","2017",1.1,,
+"PATCCCBR","C08-Calcium channel blockers","MTMOPPMT","Million US$, purchasing power parity","CRI","Costa Rica","2018","2018",1.3,,
+"PATCCCBR","C08-Calcium channel blockers","MTMOPPMT","Million US$, purchasing power parity","CRI","Costa Rica","2019","2019",1.3,,
+"PATCCCBR","C08-Calcium channel blockers","MTMOPPMT","Million US$, purchasing power parity","CRI","Costa Rica","2020","2020",1.4,,
+"PATCCCBR","C08-Calcium channel blockers","MTMOPPMT","Million US$, purchasing power parity","CRI","Costa Rica","2021","2021",1.5,,
+"PATCCCBR","C08-Calcium channel blockers","MTMOPPMT","Million US$, purchasing power parity","CRI","Costa Rica","2022","2022",1.3,,
+"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2010","2010",1,,
+"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2011","2011",1,,
+"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2012","2012",1.1,,
+"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2013","2013",1.2,,
+"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2014","2014",1.7,"B","Break"
+"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2015","2015",1.5,,
+"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2016","2016",1.6,,
+"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2017","2017",1.7,,
+"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2018","2018",2,,
+"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2019","2019",2.8,,
+"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2020","2020",2.8,,
+"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2021","2021",2.8,,
+"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2022","2022",2.9,,
+"PATCCHLS","C10-Lipid modifying agents","TCPPERMT","/capita, US$ exchange rate","CRI","Costa Rica","2010","2010",0.8,,
+"PATCCHLS","C10-Lipid modifying agents","TCPPERMT","/capita, US$ exchange rate","CRI","Costa Rica","2011","2011",0.8,,
+"PATCCHLS","C10-Lipid modifying agents","TCPPERMT","/capita, US$ exchange rate","CRI","Costa Rica","2012","2012",0.9,,
+"PATCCHLS","C10-Lipid modifying agents","TCPPERMT","/capita, US$ exchange rate","CRI","Costa Rica","2013","2013",0.8,,
+"PATCCHLS","C10-Lipid modifying agents","TCPPERMT","/capita, US$ exchange rate","CRI","Costa Rica","2014","2014",1.1,"B","Break"
+"PATCCHLS","C10-Lipid modifying agents","TCPPERMT","/capita, US$ exchange rate","CRI","Costa Rica","2015","2015",0.7,,
+"PATCCHLS","C10-Lipid modifying agents","TCPPERMT","/capita, US$ exchange rate","CRI","Costa Rica","2016","2016",0.6,,
+"PATCCHLS","C10-Lipid modifying agents","TCPPERMT","/capita, US$ exchange rate","CRI","Costa Rica","2017","2017",0.7,,
+"PATCCHLS","C10-Lipid modifying agents","TCPPERMT","/capita, US$ exchange rate","CRI","Costa Rica","2018","2018",0.8,,
+"PATCCHLS","C10-Lipid modifying agents","TCPPERMT","/capita, US$ exchange rate","CRI","Costa Rica","2019","2019",0.9,,
+"PATCCHLS","C10-Lipid modifying agents","TCPPERMT","/capita, US$ exchange rate","CRI","Costa Rica","2020","2020",0.8,,
+"PATCCHLS","C10-Lipid modifying agents","TCPPERMT","/capita, US$ exchange rate","CRI","Costa Rica","2021","2021",0.9,,
+"PATCCHLS","C10-Lipid modifying agents","TCPPERMT","/capita, US$ exchange rate","CRI","Costa Rica","2022","2022",0.6,,
+"PATCDEPR","N06A-Antidepressants","MTMOTCMT","Million US$ at exchange rate","CRI","Costa Rica","2010","2010",3.1,,
+"PATCDEPR","N06A-Antidepressants","MTMOTCMT","Million US$ at exchange rate","CRI","Costa Rica","2011","2011",2.8,,
+"PATCDEPR","N06A-Antidepressants","MTMOTCMT","Million US$ at exchange rate","CRI","Costa Rica","2012","2012",1.9,,
+"PATCDEPR","N06A-Antidepressants","MTMOTCMT","Million US$ at exchange rate","CRI","Costa Rica","2013","2013",2.1,,
+"PATCDEPR","N06A-Antidepressants","MTMOTCMT","Million US$ at exchange rate","CRI","Costa Rica","2014","2014",2.1,"B","Break"
+"PATCDEPR","N06A-Antidepressants","MTMOTCMT","Million US$ at exchange rate","CRI","Costa Rica","2015","2015",2.4,,
+"PATCDEPR","N06A-Antidepressants","MTMOTCMT","Million US$ at exchange rate","CRI","Costa Rica","2016","2016",2.7,,
+"PATCDEPR","N06A-Antidepressants","MTMOTCMT","Million US$ at exchange rate","CRI","Costa Rica","2017","2017",2.5,,
+"PATCDEPR","N06A-Antidepressants","MTMOTCMT","Million US$ at exchange rate","CRI","Costa Rica","2018","2018",2.5,,
+"PATCDEPR","N06A-Antidepressants","MTMOTCMT","Million US$ at exchange rate","CRI","Costa Rica","2019","2019",2.7,,
+"PATCDEPR","N06A-Antidepressants","MTMOTCMT","Million US$ at exchange rate","CRI","Costa Rica","2020","2020",2.4,,
+"PATCDEPR","N06A-Antidepressants","MTMOTCMT","Million US$ at exchange rate","CRI","Costa Rica","2021","2021",2.3,,
+"PATCDEPR","N06A-Antidepressants","MTMOTCMT","Million US$ at exchange rate","CRI","Costa Rica","2022","2022",2,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOTCMT","Million US$ at exchange rate","CRI","Costa Rica","2010","2010",1.8,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOTCMT","Million US$ at exchange rate","CRI","Costa Rica","2011","2011",1.8,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOTCMT","Million US$ at exchange rate","CRI","Costa Rica","2012","2012",2,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOTCMT","Million US$ at exchange rate","CRI","Costa Rica","2013","2013",2.8,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOTCMT","Million US$ at exchange rate","CRI","Costa Rica","2014","2014",3.2,"B","Break"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOTCMT","Million US$ at exchange rate","CRI","Costa Rica","2015","2015",3.1,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOTCMT","Million US$ at exchange rate","CRI","Costa Rica","2016","2016",3.1,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOTCMT","Million US$ at exchange rate","CRI","Costa Rica","2017","2017",3.2,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOTCMT","Million US$ at exchange rate","CRI","Costa Rica","2018","2018",2.8,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOTCMT","Million US$ at exchange rate","CRI","Costa Rica","2019","2019",2.4,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOTCMT","Million US$ at exchange rate","CRI","Costa Rica","2020","2020",2.1,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOTCMT","Million US$ at exchange rate","CRI","Costa Rica","2021","2021",2.2,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOTCMT","Million US$ at exchange rate","CRI","Costa Rica","2022","2022",1.8,,
+"PATCANAL","N02-Analgesics","MLLNCUMT","Million of national currency units","CRI","Costa Rica","2010","2010",1450,,
+"PATCANAL","N02-Analgesics","MLLNCUMT","Million of national currency units","CRI","Costa Rica","2011","2011",1540.2,,
+"PATCANAL","N02-Analgesics","MLLNCUMT","Million of national currency units","CRI","Costa Rica","2012","2012",1696.3,,
+"PATCANAL","N02-Analgesics","MLLNCUMT","Million of national currency units","CRI","Costa Rica","2013","2013",1924,,
+"PATCANAL","N02-Analgesics","MLLNCUMT","Million of national currency units","CRI","Costa Rica","2014","2014",2811.6,"B","Break"
+"PATCANAL","N02-Analgesics","MLLNCUMT","Million of national currency units","CRI","Costa Rica","2015","2015",2634.7,,
+"PATCANAL","N02-Analgesics","MLLNCUMT","Million of national currency units","CRI","Costa Rica","2016","2016",2631.2,,
+"PATCANAL","N02-Analgesics","MLLNCUMT","Million of national currency units","CRI","Costa Rica","2017","2017",2796.1,,
+"PATCANAL","N02-Analgesics","MLLNCUMT","Million of national currency units","CRI","Costa Rica","2018","2018",3307.8,,
+"PATCANAL","N02-Analgesics","MLLNCUMT","Million of national currency units","CRI","Costa Rica","2019","2019",4698.6,,
+"PATCANAL","N02-Analgesics","MLLNCUMT","Million of national currency units","CRI","Costa Rica","2020","2020",4616,,
+"PATCANAL","N02-Analgesics","MLLNCUMT","Million of national currency units","CRI","Costa Rica","2021","2021",5044.9,,
+"PATCANAL","N02-Analgesics","MLLNCUMT","Million of national currency units","CRI","Costa Rica","2022","2022",5191.4,,
+"PATCBETA","C07-Beta blocking agents","TCPPERMT","/capita, US$ exchange rate","CRI","Costa Rica","2010","2010",0.1,,
+"PATCBETA","C07-Beta blocking agents","TCPPERMT","/capita, US$ exchange rate","CRI","Costa Rica","2011","2011",0.2,,
+"PATCBETA","C07-Beta blocking agents","TCPPERMT","/capita, US$ exchange rate","CRI","Costa Rica","2012","2012",0.3,,
+"PATCBETA","C07-Beta blocking agents","TCPPERMT","/capita, US$ exchange rate","CRI","Costa Rica","2013","2013",0.3,,
+"PATCBETA","C07-Beta blocking agents","TCPPERMT","/capita, US$ exchange rate","CRI","Costa Rica","2014","2014",0.3,"B","Break"
+"PATCBETA","C07-Beta blocking agents","TCPPERMT","/capita, US$ exchange rate","CRI","Costa Rica","2015","2015",0.3,,
+"PATCBETA","C07-Beta blocking agents","TCPPERMT","/capita, US$ exchange rate","CRI","Costa Rica","2016","2016",0.3,,
+"PATCBETA","C07-Beta blocking agents","TCPPERMT","/capita, US$ exchange rate","CRI","Costa Rica","2017","2017",0.3,,
+"PATCBETA","C07-Beta blocking agents","TCPPERMT","/capita, US$ exchange rate","CRI","Costa Rica","2018","2018",0.3,,
+"PATCBETA","C07-Beta blocking agents","TCPPERMT","/capita, US$ exchange rate","CRI","Costa Rica","2019","2019",0.2,,
+"PATCBETA","C07-Beta blocking agents","TCPPERMT","/capita, US$ exchange rate","CRI","Costa Rica","2020","2020",0.2,,
+"PATCBETA","C07-Beta blocking agents","TCPPERMT","/capita, US$ exchange rate","CRI","Costa Rica","2021","2021",0.3,,
+"PATCBETA","C07-Beta blocking agents","TCPPERMT","/capita, US$ exchange rate","CRI","Costa Rica","2022","2022",0.2,,
+"PATCDEPR","N06A-Antidepressants","MLLNCUMT","Million of national currency units","CRI","Costa Rica","2010","2010",1617.5,,
+"PATCDEPR","N06A-Antidepressants","MLLNCUMT","Million of national currency units","CRI","Costa Rica","2011","2011",1440.9,,
+"PATCDEPR","N06A-Antidepressants","MLLNCUMT","Million of national currency units","CRI","Costa Rica","2012","2012",933.3,,
+"PATCDEPR","N06A-Antidepressants","MLLNCUMT","Million of national currency units","CRI","Costa Rica","2013","2013",1043,,
+"PATCDEPR","N06A-Antidepressants","MLLNCUMT","Million of national currency units","CRI","Costa Rica","2014","2014",1118.1,"B","Break"
+"PATCDEPR","N06A-Antidepressants","MLLNCUMT","Million of national currency units","CRI","Costa Rica","2015","2015",1278.7,,
+"PATCDEPR","N06A-Antidepressants","MLLNCUMT","Million of national currency units","CRI","Costa Rica","2016","2016",1494.7,,
+"PATCDEPR","N06A-Antidepressants","MLLNCUMT","Million of national currency units","CRI","Costa Rica","2017","2017",1423.3,,
+"PATCDEPR","N06A-Antidepressants","MLLNCUMT","Million of national currency units","CRI","Costa Rica","2018","2018",1429.4,,
+"PATCDEPR","N06A-Antidepressants","MLLNCUMT","Million of national currency units","CRI","Costa Rica","2019","2019",1564.6,,
+"PATCDEPR","N06A-Antidepressants","MLLNCUMT","Million of national currency units","CRI","Costa Rica","2020","2020",1400.7,,
+"PATCDEPR","N06A-Antidepressants","MLLNCUMT","Million of national currency units","CRI","Costa Rica","2021","2021",1403.9,,
+"PATCDEPR","N06A-Antidepressants","MLLNCUMT","Million of national currency units","CRI","Costa Rica","2022","2022",1269.3,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","TCPPERMT","/capita, US$ exchange rate","CRI","Costa Rica","2010","2010",0,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","TCPPERMT","/capita, US$ exchange rate","CRI","Costa Rica","2011","2011",0,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","TCPPERMT","/capita, US$ exchange rate","CRI","Costa Rica","2012","2012",0,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","TCPPERMT","/capita, US$ exchange rate","CRI","Costa Rica","2013","2013",0,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","TCPPERMT","/capita, US$ exchange rate","CRI","Costa Rica","2014","2014",0,"B","Break"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","TCPPERMT","/capita, US$ exchange rate","CRI","Costa Rica","2015","2015",0,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","TCPPERMT","/capita, US$ exchange rate","CRI","Costa Rica","2016","2016",0,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","TCPPERMT","/capita, US$ exchange rate","CRI","Costa Rica","2017","2017",0,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","TCPPERMT","/capita, US$ exchange rate","CRI","Costa Rica","2018","2018",0,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","TCPPERMT","/capita, US$ exchange rate","CRI","Costa Rica","2019","2019",0,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","TCPPERMT","/capita, US$ exchange rate","CRI","Costa Rica","2020","2020",0,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","TCPPERMT","/capita, US$ exchange rate","CRI","Costa Rica","2021","2021",0,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","TCPPERMT","/capita, US$ exchange rate","CRI","Costa Rica","2022","2022",0,,
+"PATCANAL","N02-Analgesics","MTMOTCMT","Million US$ at exchange rate","CRI","Costa Rica","2010","2010",2.8,,
+"PATCANAL","N02-Analgesics","MTMOTCMT","Million US$ at exchange rate","CRI","Costa Rica","2011","2011",3,,
+"PATCANAL","N02-Analgesics","MTMOTCMT","Million US$ at exchange rate","CRI","Costa Rica","2012","2012",3.4,,
+"PATCANAL","N02-Analgesics","MTMOTCMT","Million US$ at exchange rate","CRI","Costa Rica","2013","2013",3.8,,
+"PATCANAL","N02-Analgesics","MTMOTCMT","Million US$ at exchange rate","CRI","Costa Rica","2014","2014",5.2,"B","Break"
+"PATCANAL","N02-Analgesics","MTMOTCMT","Million US$ at exchange rate","CRI","Costa Rica","2015","2015",4.9,,
+"PATCANAL","N02-Analgesics","MTMOTCMT","Million US$ at exchange rate","CRI","Costa Rica","2016","2016",4.8,,
+"PATCANAL","N02-Analgesics","MTMOTCMT","Million US$ at exchange rate","CRI","Costa Rica","2017","2017",4.9,,
+"PATCANAL","N02-Analgesics","MTMOTCMT","Million US$ at exchange rate","CRI","Costa Rica","2018","2018",5.7,,
+"PATCANAL","N02-Analgesics","MTMOTCMT","Million US$ at exchange rate","CRI","Costa Rica","2019","2019",8,,
+"PATCANAL","N02-Analgesics","MTMOTCMT","Million US$ at exchange rate","CRI","Costa Rica","2020","2020",7.9,,
+"PATCANAL","N02-Analgesics","MTMOTCMT","Million US$ at exchange rate","CRI","Costa Rica","2021","2021",8.1,,
+"PATCANAL","N02-Analgesics","MTMOTCMT","Million US$ at exchange rate","CRI","Costa Rica","2022","2022",8,,
+"PATCHYPN","N05C-Hypnotics and sedatives","MTMOPPMT","Million US$, purchasing power parity","CRI","Costa Rica","2010","2010",0.5,,
+"PATCHYPN","N05C-Hypnotics and sedatives","MTMOPPMT","Million US$, purchasing power parity","CRI","Costa Rica","2011","2011",0.4,,
+"PATCHYPN","N05C-Hypnotics and sedatives","MTMOPPMT","Million US$, purchasing power parity","CRI","Costa Rica","2012","2012",0.4,,
+"PATCHYPN","N05C-Hypnotics and sedatives","MTMOPPMT","Million US$, purchasing power parity","CRI","Costa Rica","2013","2013",0.4,,
+"PATCHYPN","N05C-Hypnotics and sedatives","MTMOPPMT","Million US$, purchasing power parity","CRI","Costa Rica","2014","2014",0.5,"B","Break"
+"PATCHYPN","N05C-Hypnotics and sedatives","MTMOPPMT","Million US$, purchasing power parity","CRI","Costa Rica","2015","2015",0.6,,
+"PATCHYPN","N05C-Hypnotics and sedatives","MTMOPPMT","Million US$, purchasing power parity","CRI","Costa Rica","2016","2016",0.6,,
+"PATCHYPN","N05C-Hypnotics and sedatives","MTMOPPMT","Million US$, purchasing power parity","CRI","Costa Rica","2017","2017",0.6,,
+"PATCHYPN","N05C-Hypnotics and sedatives","MTMOPPMT","Million US$, purchasing power parity","CRI","Costa Rica","2018","2018",0.6,,
+"PATCHYPN","N05C-Hypnotics and sedatives","MTMOPPMT","Million US$, purchasing power parity","CRI","Costa Rica","2019","2019",0.6,,
+"PATCHYPN","N05C-Hypnotics and sedatives","MTMOPPMT","Million US$, purchasing power parity","CRI","Costa Rica","2020","2020",0.4,,
+"PATCHYPN","N05C-Hypnotics and sedatives","MTMOPPMT","Million US$, purchasing power parity","CRI","Costa Rica","2021","2021",0.9,,
+"PATCHYPN","N05C-Hypnotics and sedatives","MTMOPPMT","Million US$, purchasing power parity","CRI","Costa Rica","2022","2022",0.4,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOPPMT","Million US$, purchasing power parity","CRI","Costa Rica","2010","2010",10.2,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOPPMT","Million US$, purchasing power parity","CRI","Costa Rica","2011","2011",9.3,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOPPMT","Million US$, purchasing power parity","CRI","Costa Rica","2012","2012",9.3,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOPPMT","Million US$, purchasing power parity","CRI","Costa Rica","2013","2013",10.5,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOPPMT","Million US$, purchasing power parity","CRI","Costa Rica","2014","2014",12.1,"B","Break"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOPPMT","Million US$, purchasing power parity","CRI","Costa Rica","2015","2015",10.4,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOPPMT","Million US$, purchasing power parity","CRI","Costa Rica","2016","2016",9.1,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOPPMT","Million US$, purchasing power parity","CRI","Costa Rica","2017","2017",8.8,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOPPMT","Million US$, purchasing power parity","CRI","Costa Rica","2018","2018",8.8,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOPPMT","Million US$, purchasing power parity","CRI","Costa Rica","2019","2019",10.7,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOPPMT","Million US$, purchasing power parity","CRI","Costa Rica","2020","2020",12.9,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOPPMT","Million US$, purchasing power parity","CRI","Costa Rica","2021","2021",15.1,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOPPMT","Million US$, purchasing power parity","CRI","Costa Rica","2022","2022",13.9,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2010","2010",1,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2011","2011",0.6,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2012","2012",0.8,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2013","2013",0.9,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2014","2014",1,"B","Break"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2015","2015",0.9,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2016","2016",0.8,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2017","2017",1.2,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2018","2018",1.4,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2019","2019",2.5,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2020","2020",2.2,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2021","2021",2.1,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2022","2022",1.9,,
+"PATCACID","A02A-Antacids","MTMOPPMT","Million US$, purchasing power parity","CRI","Costa Rica","2010","2010",2,,
+"PATCACID","A02A-Antacids","MTMOPPMT","Million US$, purchasing power parity","CRI","Costa Rica","2011","2011",2.2,,
+"PATCACID","A02A-Antacids","MTMOPPMT","Million US$, purchasing power parity","CRI","Costa Rica","2012","2012",2.2,,
+"PATCACID","A02A-Antacids","MTMOPPMT","Million US$, purchasing power parity","CRI","Costa Rica","2013","2013",2.8,,
+"PATCACID","A02A-Antacids","MTMOPPMT","Million US$, purchasing power parity","CRI","Costa Rica","2014","2014",2.4,"B","Break"
+"PATCACID","A02A-Antacids","MTMOPPMT","Million US$, purchasing power parity","CRI","Costa Rica","2015","2015",2.5,,
+"PATCACID","A02A-Antacids","MTMOPPMT","Million US$, purchasing power parity","CRI","Costa Rica","2016","2016",2.7,,
+"PATCACID","A02A-Antacids","MTMOPPMT","Million US$, purchasing power parity","CRI","Costa Rica","2017","2017",3,,
+"PATCACID","A02A-Antacids","MTMOPPMT","Million US$, purchasing power parity","CRI","Costa Rica","2018","2018",3.2,,
+"PATCACID","A02A-Antacids","MTMOPPMT","Million US$, purchasing power parity","CRI","Costa Rica","2019","2019",4.3,,
+"PATCACID","A02A-Antacids","MTMOPPMT","Million US$, purchasing power parity","CRI","Costa Rica","2020","2020",4.6,,
+"PATCACID","A02A-Antacids","MTMOPPMT","Million US$, purchasing power parity","CRI","Costa Rica","2021","2021",5.1,,
+"PATCACID","A02A-Antacids","MTMOPPMT","Million US$, purchasing power parity","CRI","Costa Rica","2022","2022",4.3,,
+"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2010","2010",0.3,,
+"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2011","2011",0.4,,
+"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2012","2012",0.2,,
+"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2013","2013",0.2,,
+"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2014","2014",0.3,"B","Break"
+"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2015","2015",0.2,,
+"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2016","2016",0.3,,
+"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2017","2017",0.2,,
+"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2018","2018",0.3,,
+"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2019","2019",0.3,,
+"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2020","2020",0.3,,
+"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2021","2021",0.3,,
+"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2022","2022",0.3,,
+"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2010","2010",0.1,,
+"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2011","2011",0.1,,
+"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2012","2012",0.1,,
+"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2013","2013",0.1,,
+"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2014","2014",0.1,"B","Break"
+"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2015","2015",0.1,,
+"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2016","2016",0.1,,
+"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2017","2017",0.1,,
+"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2018","2018",0.1,,
+"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2019","2019",0.1,,
+"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2020","2020",0.1,,
+"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2021","2021",0.1,,
+"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2022","2022",0.1,,
+"PATCGLYC","C01A-Cardiac glycosides","MLLNCUMT","Million of national currency units","CRI","Costa Rica","2010","2010",157,,
+"PATCGLYC","C01A-Cardiac glycosides","MLLNCUMT","Million of national currency units","CRI","Costa Rica","2011","2011",132.1,,
+"PATCGLYC","C01A-Cardiac glycosides","MLLNCUMT","Million of national currency units","CRI","Costa Rica","2012","2012",126.1,,
+"PATCGLYC","C01A-Cardiac glycosides","MLLNCUMT","Million of national currency units","CRI","Costa Rica","2013","2013",137.7,,
+"PATCGLYC","C01A-Cardiac glycosides","MLLNCUMT","Million of national currency units","CRI","Costa Rica","2014","2014",227.2,"B","Break"
+"PATCGLYC","C01A-Cardiac glycosides","MLLNCUMT","Million of national currency units","CRI","Costa Rica","2015","2015",200.6,,
+"PATCGLYC","C01A-Cardiac glycosides","MLLNCUMT","Million of national currency units","CRI","Costa Rica","2016","2016",201.9,,
+"PATCGLYC","C01A-Cardiac glycosides","MLLNCUMT","Million of national currency units","CRI","Costa Rica","2017","2017",185.4,,
+"PATCGLYC","C01A-Cardiac glycosides","MLLNCUMT","Million of national currency units","CRI","Costa Rica","2018","2018",131.8,,
+"PATCGLYC","C01A-Cardiac glycosides","MLLNCUMT","Million of national currency units","CRI","Costa Rica","2019","2019",110.4,,
+"PATCGLYC","C01A-Cardiac glycosides","MLLNCUMT","Million of national currency units","CRI","Costa Rica","2020","2020",96.3,,
+"PATCGLYC","C01A-Cardiac glycosides","MLLNCUMT","Million of national currency units","CRI","Costa Rica","2021","2021",114.7,,
+"PATCGLYC","C01A-Cardiac glycosides","MLLNCUMT","Million of national currency units","CRI","Costa Rica","2022","2022",90.6,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOTCMT","Million US$ at exchange rate","CRI","Costa Rica","2010","2010",2.8,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOTCMT","Million US$ at exchange rate","CRI","Costa Rica","2011","2011",3.3,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOTCMT","Million US$ at exchange rate","CRI","Costa Rica","2012","2012",3.2,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOTCMT","Million US$ at exchange rate","CRI","Costa Rica","2013","2013",3.4,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOTCMT","Million US$ at exchange rate","CRI","Costa Rica","2014","2014",3.3,"B","Break"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOTCMT","Million US$ at exchange rate","CRI","Costa Rica","2015","2015",3.3,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOTCMT","Million US$ at exchange rate","CRI","Costa Rica","2016","2016",3.3,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOTCMT","Million US$ at exchange rate","CRI","Costa Rica","2017","2017",3.6,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOTCMT","Million US$ at exchange rate","CRI","Costa Rica","2018","2018",4.4,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOTCMT","Million US$ at exchange rate","CRI","Costa Rica","2019","2019",5.2,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOTCMT","Million US$ at exchange rate","CRI","Costa Rica","2020","2020",4.7,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOTCMT","Million US$ at exchange rate","CRI","Costa Rica","2021","2021",5.1,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOTCMT","Million US$ at exchange rate","CRI","Costa Rica","2022","2022",4.3,,
+"PATCDIUR","C03-Diuretics","MLLNCUMT","Million of national currency units","CRI","Costa Rica","2010","2010",488,,
+"PATCDIUR","C03-Diuretics","MLLNCUMT","Million of national currency units","CRI","Costa Rica","2011","2011",671.9,,
+"PATCDIUR","C03-Diuretics","MLLNCUMT","Million of national currency units","CRI","Costa Rica","2012","2012",364.4,,
+"PATCDIUR","C03-Diuretics","MLLNCUMT","Million of national currency units","CRI","Costa Rica","2013","2013",406.6,,
+"PATCDIUR","C03-Diuretics","MLLNCUMT","Million of national currency units","CRI","Costa Rica","2014","2014",427.6,"B","Break"
+"PATCDIUR","C03-Diuretics","MLLNCUMT","Million of national currency units","CRI","Costa Rica","2015","2015",413.6,,
+"PATCDIUR","C03-Diuretics","MLLNCUMT","Million of national currency units","CRI","Costa Rica","2016","2016",427.5,,
+"PATCDIUR","C03-Diuretics","MLLNCUMT","Million of national currency units","CRI","Costa Rica","2017","2017",405,,
+"PATCDIUR","C03-Diuretics","MLLNCUMT","Million of national currency units","CRI","Costa Rica","2018","2018",426.4,,
+"PATCDIUR","C03-Diuretics","MLLNCUMT","Million of national currency units","CRI","Costa Rica","2019","2019",470.3,,
+"PATCDIUR","C03-Diuretics","MLLNCUMT","Million of national currency units","CRI","Costa Rica","2020","2020",474.1,,
+"PATCDIUR","C03-Diuretics","MLLNCUMT","Million of national currency units","CRI","Costa Rica","2021","2021",516.7,,
+"PATCDIUR","C03-Diuretics","MLLNCUMT","Million of national currency units","CRI","Costa Rica","2022","2022",461.1,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOTCMT","Million US$ at exchange rate","CRI","Costa Rica","2010","2010",2.7,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOTCMT","Million US$ at exchange rate","CRI","Costa Rica","2011","2011",2,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOTCMT","Million US$ at exchange rate","CRI","Costa Rica","2012","2012",2.4,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOTCMT","Million US$ at exchange rate","CRI","Costa Rica","2013","2013",2.9,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOTCMT","Million US$ at exchange rate","CRI","Costa Rica","2014","2014",3,"B","Break"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOTCMT","Million US$ at exchange rate","CRI","Costa Rica","2015","2015",3,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOTCMT","Million US$ at exchange rate","CRI","Costa Rica","2016","2016",2.5,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOTCMT","Million US$ at exchange rate","CRI","Costa Rica","2017","2017",3.4,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOTCMT","Million US$ at exchange rate","CRI","Costa Rica","2018","2018",4.1,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOTCMT","Million US$ at exchange rate","CRI","Costa Rica","2019","2019",7,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOTCMT","Million US$ at exchange rate","CRI","Costa Rica","2020","2020",6.3,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOTCMT","Million US$ at exchange rate","CRI","Costa Rica","2021","2021",6,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOTCMT","Million US$ at exchange rate","CRI","Costa Rica","2022","2022",5.3,,
+"PATCANXO","N05B-Anxiolytics","TCPPERMT","/capita, US$ exchange rate","CRI","Costa Rica","2010","2010",0.1,,
+"PATCANXO","N05B-Anxiolytics","TCPPERMT","/capita, US$ exchange rate","CRI","Costa Rica","2011","2011",0.1,,
+"PATCANXO","N05B-Anxiolytics","TCPPERMT","/capita, US$ exchange rate","CRI","Costa Rica","2012","2012",0.1,,
+"PATCANXO","N05B-Anxiolytics","TCPPERMT","/capita, US$ exchange rate","CRI","Costa Rica","2013","2013",0.1,,
+"PATCANXO","N05B-Anxiolytics","TCPPERMT","/capita, US$ exchange rate","CRI","Costa Rica","2014","2014",0.1,"B","Break"
+"PATCANXO","N05B-Anxiolytics","TCPPERMT","/capita, US$ exchange rate","CRI","Costa Rica","2015","2015",0.1,,
+"PATCANXO","N05B-Anxiolytics","TCPPERMT","/capita, US$ exchange rate","CRI","Costa Rica","2016","2016",0.1,,
+"PATCANXO","N05B-Anxiolytics","TCPPERMT","/capita, US$ exchange rate","CRI","Costa Rica","2017","2017",0.1,,
+"PATCANXO","N05B-Anxiolytics","TCPPERMT","/capita, US$ exchange rate","CRI","Costa Rica","2018","2018",0.2,,
+"PATCANXO","N05B-Anxiolytics","TCPPERMT","/capita, US$ exchange rate","CRI","Costa Rica","2019","2019",0.2,,
+"PATCANXO","N05B-Anxiolytics","TCPPERMT","/capita, US$ exchange rate","CRI","Costa Rica","2020","2020",0.2,,
+"PATCANXO","N05B-Anxiolytics","TCPPERMT","/capita, US$ exchange rate","CRI","Costa Rica","2021","2021",0.1,,
+"PATCANXO","N05B-Anxiolytics","TCPPERMT","/capita, US$ exchange rate","CRI","Costa Rica","2022","2022",0.1,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MLLNCUMT","Million of national currency units","CRI","Costa Rica","2010","2010",1443.7,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MLLNCUMT","Million of national currency units","CRI","Costa Rica","2011","2011",996.1,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MLLNCUMT","Million of national currency units","CRI","Costa Rica","2012","2012",1212.1,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MLLNCUMT","Million of national currency units","CRI","Costa Rica","2013","2013",1436,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MLLNCUMT","Million of national currency units","CRI","Costa Rica","2014","2014",1623.3,"B","Break"
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MLLNCUMT","Million of national currency units","CRI","Costa Rica","2015","2015",1579.9,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MLLNCUMT","Million of national currency units","CRI","Costa Rica","2016","2016",1357.8,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MLLNCUMT","Million of national currency units","CRI","Costa Rica","2017","2017",1954.6,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MLLNCUMT","Million of national currency units","CRI","Costa Rica","2018","2018",2352.6,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MLLNCUMT","Million of national currency units","CRI","Costa Rica","2019","2019",4129.4,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MLLNCUMT","Million of national currency units","CRI","Costa Rica","2020","2020",3669.2,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MLLNCUMT","Million of national currency units","CRI","Costa Rica","2021","2021",3703.3,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MLLNCUMT","Million of national currency units","CRI","Costa Rica","2022","2022",3442.2,,
+"PATCDIUR","C03-Diuretics","MTMOTCMT","Million US$ at exchange rate","CRI","Costa Rica","2010","2010",0.9,,
+"PATCDIUR","C03-Diuretics","MTMOTCMT","Million US$ at exchange rate","CRI","Costa Rica","2011","2011",1.3,,
+"PATCDIUR","C03-Diuretics","MTMOTCMT","Million US$ at exchange rate","CRI","Costa Rica","2012","2012",0.7,,
+"PATCDIUR","C03-Diuretics","MTMOTCMT","Million US$ at exchange rate","CRI","Costa Rica","2013","2013",0.8,,
+"PATCDIUR","C03-Diuretics","MTMOTCMT","Million US$ at exchange rate","CRI","Costa Rica","2014","2014",0.8,"B","Break"
+"PATCDIUR","C03-Diuretics","MTMOTCMT","Million US$ at exchange rate","CRI","Costa Rica","2015","2015",0.8,,
+"PATCDIUR","C03-Diuretics","MTMOTCMT","Million US$ at exchange rate","CRI","Costa Rica","2016","2016",0.8,,
+"PATCDIUR","C03-Diuretics","MTMOTCMT","Million US$ at exchange rate","CRI","Costa Rica","2017","2017",0.7,,
+"PATCDIUR","C03-Diuretics","MTMOTCMT","Million US$ at exchange rate","CRI","Costa Rica","2018","2018",0.7,,
+"PATCDIUR","C03-Diuretics","MTMOTCMT","Million US$ at exchange rate","CRI","Costa Rica","2019","2019",0.8,,
+"PATCDIUR","C03-Diuretics","MTMOTCMT","Million US$ at exchange rate","CRI","Costa Rica","2020","2020",0.8,,
+"PATCDIUR","C03-Diuretics","MTMOTCMT","Million US$ at exchange rate","CRI","Costa Rica","2021","2021",0.8,,
+"PATCDIUR","C03-Diuretics","MTMOTCMT","Million US$ at exchange rate","CRI","Costa Rica","2022","2022",0.7,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MLLNCUMT","Million of national currency units","CRI","Costa Rica","2010","2010",1471.6,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MLLNCUMT","Million of national currency units","CRI","Costa Rica","2011","2011",1661.5,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MLLNCUMT","Million of national currency units","CRI","Costa Rica","2012","2012",1597.4,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MLLNCUMT","Million of national currency units","CRI","Costa Rica","2013","2013",1682.6,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MLLNCUMT","Million of national currency units","CRI","Costa Rica","2014","2014",1766.7,"B","Break"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MLLNCUMT","Million of national currency units","CRI","Costa Rica","2015","2015",1760.3,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MLLNCUMT","Million of national currency units","CRI","Costa Rica","2016","2016",1812.8,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MLLNCUMT","Million of national currency units","CRI","Costa Rica","2017","2017",2033.8,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MLLNCUMT","Million of national currency units","CRI","Costa Rica","2018","2018",2534.4,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MLLNCUMT","Million of national currency units","CRI","Costa Rica","2019","2019",3072.6,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MLLNCUMT","Million of national currency units","CRI","Costa Rica","2020","2020",2721.8,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MLLNCUMT","Million of national currency units","CRI","Costa Rica","2021","2021",3171,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MLLNCUMT","Million of national currency units","CRI","Costa Rica","2022","2022",2788.1,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","TCPPERMT","/capita, US$ exchange rate","CRI","Costa Rica","2010","2010",0.6,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","TCPPERMT","/capita, US$ exchange rate","CRI","Costa Rica","2011","2011",0.7,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","TCPPERMT","/capita, US$ exchange rate","CRI","Costa Rica","2012","2012",0.8,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","TCPPERMT","/capita, US$ exchange rate","CRI","Costa Rica","2013","2013",0.8,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","TCPPERMT","/capita, US$ exchange rate","CRI","Costa Rica","2014","2014",0.7,"B","Break"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","TCPPERMT","/capita, US$ exchange rate","CRI","Costa Rica","2015","2015",0.7,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","TCPPERMT","/capita, US$ exchange rate","CRI","Costa Rica","2016","2016",0.7,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","TCPPERMT","/capita, US$ exchange rate","CRI","Costa Rica","2017","2017",0.7,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","TCPPERMT","/capita, US$ exchange rate","CRI","Costa Rica","2018","2018",0.6,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","TCPPERMT","/capita, US$ exchange rate","CRI","Costa Rica","2019","2019",0.5,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","TCPPERMT","/capita, US$ exchange rate","CRI","Costa Rica","2020","2020",0.4,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","TCPPERMT","/capita, US$ exchange rate","CRI","Costa Rica","2021","2021",0.5,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","TCPPERMT","/capita, US$ exchange rate","CRI","Costa Rica","2022","2022",0.4,,
+"PATCBIOT","J01-Antibacterials for systemic use","MLLNCUMT","Million of national currency units","CRI","Costa Rica","2010","2010",6059.1,,
+"PATCBIOT","J01-Antibacterials for systemic use","MLLNCUMT","Million of national currency units","CRI","Costa Rica","2011","2011",5512.1,,
+"PATCBIOT","J01-Antibacterials for systemic use","MLLNCUMT","Million of national currency units","CRI","Costa Rica","2012","2012",4854,,
+"PATCBIOT","J01-Antibacterials for systemic use","MLLNCUMT","Million of national currency units","CRI","Costa Rica","2013","2013",5081.9,,
+"PATCBIOT","J01-Antibacterials for systemic use","MLLNCUMT","Million of national currency units","CRI","Costa Rica","2014","2014",5751.6,"B","Break"
+"PATCBIOT","J01-Antibacterials for systemic use","MLLNCUMT","Million of national currency units","CRI","Costa Rica","2015","2015",4904.9,,
+"PATCBIOT","J01-Antibacterials for systemic use","MLLNCUMT","Million of national currency units","CRI","Costa Rica","2016","2016",5106.3,,
+"PATCBIOT","J01-Antibacterials for systemic use","MLLNCUMT","Million of national currency units","CRI","Costa Rica","2017","2017",4383.7,,
+"PATCBIOT","J01-Antibacterials for systemic use","MLLNCUMT","Million of national currency units","CRI","Costa Rica","2018","2018",3832.7,,
+"PATCBIOT","J01-Antibacterials for systemic use","MLLNCUMT","Million of national currency units","CRI","Costa Rica","2019","2019",3984.9,,
+"PATCBIOT","J01-Antibacterials for systemic use","MLLNCUMT","Million of national currency units","CRI","Costa Rica","2020","2020",3027.8,,
+"PATCBIOT","J01-Antibacterials for systemic use","MLLNCUMT","Million of national currency units","CRI","Costa Rica","2021","2021",3675.9,,
+"PATCBIOT","J01-Antibacterials for systemic use","MLLNCUMT","Million of national currency units","CRI","Costa Rica","2022","2022",3049.6,,
+"PATCINFC","J-Antiinfectives for systemic use","MTMOPPMT","Million US$, purchasing power parity","CRI","Costa Rica","2010","2010",52.7,,
+"PATCINFC","J-Antiinfectives for systemic use","MTMOPPMT","Million US$, purchasing power parity","CRI","Costa Rica","2011","2011",44.1,,
+"PATCINFC","J-Antiinfectives for systemic use","MTMOPPMT","Million US$, purchasing power parity","CRI","Costa Rica","2012","2012",40.6,,
+"PATCINFC","J-Antiinfectives for systemic use","MTMOPPMT","Million US$, purchasing power parity","CRI","Costa Rica","2013","2013",40.5,,
+"PATCINFC","J-Antiinfectives for systemic use","MTMOPPMT","Million US$, purchasing power parity","CRI","Costa Rica","2014","2014",47.7,"B","Break"
+"PATCINFC","J-Antiinfectives for systemic use","MTMOPPMT","Million US$, purchasing power parity","CRI","Costa Rica","2015","2015",48.8,,
+"PATCINFC","J-Antiinfectives for systemic use","MTMOPPMT","Million US$, purchasing power parity","CRI","Costa Rica","2016","2016",55.5,,
+"PATCINFC","J-Antiinfectives for systemic use","MTMOPPMT","Million US$, purchasing power parity","CRI","Costa Rica","2017","2017",57.4,,
+"PATCINFC","J-Antiinfectives for systemic use","MTMOPPMT","Million US$, purchasing power parity","CRI","Costa Rica","2018","2018",62,,
+"PATCINFC","J-Antiinfectives for systemic use","MTMOPPMT","Million US$, purchasing power parity","CRI","Costa Rica","2019","2019",67.8,,
+"PATCINFC","J-Antiinfectives for systemic use","MTMOPPMT","Million US$, purchasing power parity","CRI","Costa Rica","2020","2020",67.4,,
+"PATCINFC","J-Antiinfectives for systemic use","MTMOPPMT","Million US$, purchasing power parity","CRI","Costa Rica","2021","2021",73.9,,
+"PATCINFC","J-Antiinfectives for systemic use","MTMOPPMT","Million US$, purchasing power parity","CRI","Costa Rica","2022","2022",66,,
+"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2010","2010",0.2,,
+"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2011","2011",0.2,,
+"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2012","2012",0.2,,
+"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2013","2013",0.2,,
+"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2014","2014",0.3,"B","Break"
+"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2015","2015",0.3,,
+"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2016","2016",0.3,,
+"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2017","2017",0.4,,
+"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2018","2018",0.4,,
+"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2019","2019",0.5,,
+"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2020","2020",0.5,,
+"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2021","2021",0.5,,
+"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2022","2022",0.5,,
+"PATCHYPN","N05C-Hypnotics and sedatives","MLLNCUMT","Million of national currency units","CRI","Costa Rica","2010","2010",166.7,,
+"PATCHYPN","N05C-Hypnotics and sedatives","MLLNCUMT","Million of national currency units","CRI","Costa Rica","2011","2011",129.2,,
+"PATCHYPN","N05C-Hypnotics and sedatives","MLLNCUMT","Million of national currency units","CRI","Costa Rica","2012","2012",141.2,,
+"PATCHYPN","N05C-Hypnotics and sedatives","MLLNCUMT","Million of national currency units","CRI","Costa Rica","2013","2013",138.7,,
+"PATCHYPN","N05C-Hypnotics and sedatives","MLLNCUMT","Million of national currency units","CRI","Costa Rica","2014","2014",176.3,"B","Break"
+"PATCHYPN","N05C-Hypnotics and sedatives","MLLNCUMT","Million of national currency units","CRI","Costa Rica","2015","2015",195.8,,
+"PATCHYPN","N05C-Hypnotics and sedatives","MLLNCUMT","Million of national currency units","CRI","Costa Rica","2016","2016",213,,
+"PATCHYPN","N05C-Hypnotics and sedatives","MLLNCUMT","Million of national currency units","CRI","Costa Rica","2017","2017",212,,
+"PATCHYPN","N05C-Hypnotics and sedatives","MLLNCUMT","Million of national currency units","CRI","Costa Rica","2018","2018",190.4,,
+"PATCHYPN","N05C-Hypnotics and sedatives","MLLNCUMT","Million of national currency units","CRI","Costa Rica","2019","2019",187,,
+"PATCHYPN","N05C-Hypnotics and sedatives","MLLNCUMT","Million of national currency units","CRI","Costa Rica","2020","2020",133.6,,
+"PATCHYPN","N05C-Hypnotics and sedatives","MLLNCUMT","Million of national currency units","CRI","Costa Rica","2021","2021",298,,
+"PATCHYPN","N05C-Hypnotics and sedatives","MLLNCUMT","Million of national currency units","CRI","Costa Rica","2022","2022",134.8,,
+"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2010","2010",3.3,,
+"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2011","2011",3.2,,
+"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2012","2012",3.2,,
+"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2013","2013",3.3,,
+"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2014","2014",4,"B","Break"
+"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2015","2015",3.3,,
+"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2016","2016",3.3,,
+"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2017","2017",3.8,,
+"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2018","2018",4.4,,
+"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2019","2019",5.6,,
+"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2020","2020",5.1,,
+"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2021","2021",5.7,,
+"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2022","2022",4.7,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOTCMT","Million US$ at exchange rate","CRI","Costa Rica","2010","2010",6.3,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOTCMT","Million US$ at exchange rate","CRI","Costa Rica","2011","2011",6.1,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOTCMT","Million US$ at exchange rate","CRI","Costa Rica","2012","2012",6.4,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOTCMT","Million US$ at exchange rate","CRI","Costa Rica","2013","2013",7.3,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOTCMT","Million US$ at exchange rate","CRI","Costa Rica","2014","2014",7.9,"B","Break"
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOTCMT","Million US$ at exchange rate","CRI","Costa Rica","2015","2015",6.9,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOTCMT","Million US$ at exchange rate","CRI","Costa Rica","2016","2016",5.7,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOTCMT","Million US$ at exchange rate","CRI","Costa Rica","2017","2017",5.3,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOTCMT","Million US$ at exchange rate","CRI","Costa Rica","2018","2018",5.2,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOTCMT","Million US$ at exchange rate","CRI","Costa Rica","2019","2019",6,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOTCMT","Million US$ at exchange rate","CRI","Costa Rica","2020","2020",7.2,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOTCMT","Million US$ at exchange rate","CRI","Costa Rica","2021","2021",8.4,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOTCMT","Million US$ at exchange rate","CRI","Costa Rica","2022","2022",7.4,,
+"PATCHYPN","N05C-Hypnotics and sedatives","MTMOTCMT","Million US$ at exchange rate","CRI","Costa Rica","2010","2010",0.3,,
+"PATCHYPN","N05C-Hypnotics and sedatives","MTMOTCMT","Million US$ at exchange rate","CRI","Costa Rica","2011","2011",0.3,,
+"PATCHYPN","N05C-Hypnotics and sedatives","MTMOTCMT","Million US$ at exchange rate","CRI","Costa Rica","2012","2012",0.3,,
+"PATCHYPN","N05C-Hypnotics and sedatives","MTMOTCMT","Million US$ at exchange rate","CRI","Costa Rica","2013","2013",0.3,,
+"PATCHYPN","N05C-Hypnotics and sedatives","MTMOTCMT","Million US$ at exchange rate","CRI","Costa Rica","2014","2014",0.3,"B","Break"
+"PATCHYPN","N05C-Hypnotics and sedatives","MTMOTCMT","Million US$ at exchange rate","CRI","Costa Rica","2015","2015",0.4,,
+"PATCHYPN","N05C-Hypnotics and sedatives","MTMOTCMT","Million US$ at exchange rate","CRI","Costa Rica","2016","2016",0.4,,
+"PATCHYPN","N05C-Hypnotics and sedatives","MTMOTCMT","Million US$ at exchange rate","CRI","Costa Rica","2017","2017",0.4,,
+"PATCHYPN","N05C-Hypnotics and sedatives","MTMOTCMT","Million US$ at exchange rate","CRI","Costa Rica","2018","2018",0.3,,
+"PATCHYPN","N05C-Hypnotics and sedatives","MTMOTCMT","Million US$ at exchange rate","CRI","Costa Rica","2019","2019",0.3,,
+"PATCHYPN","N05C-Hypnotics and sedatives","MTMOTCMT","Million US$ at exchange rate","CRI","Costa Rica","2020","2020",0.2,,
+"PATCHYPN","N05C-Hypnotics and sedatives","MTMOTCMT","Million US$ at exchange rate","CRI","Costa Rica","2021","2021",0.5,,
+"PATCHYPN","N05C-Hypnotics and sedatives","MTMOTCMT","Million US$ at exchange rate","CRI","Costa Rica","2022","2022",0.2,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2010","2010",0.6,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2011","2011",0.6,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2012","2012",0.6,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2013","2013",0.8,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2014","2014",1,"B","Break"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2015","2015",1,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2016","2016",1,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2017","2017",1.1,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2018","2018",0.9,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2019","2019",0.8,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2020","2020",0.7,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2021","2021",0.8,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2022","2022",0.6,,
+"PATCHYPO","C02-Antihypertensives","MTMOTCMT","Million US$ at exchange rate","CRI","Costa Rica","2010","2010",0.5,,
+"PATCHYPO","C02-Antihypertensives","MTMOTCMT","Million US$ at exchange rate","CRI","Costa Rica","2011","2011",0.7,,
+"PATCHYPO","C02-Antihypertensives","MTMOTCMT","Million US$ at exchange rate","CRI","Costa Rica","2012","2012",0.8,,
+"PATCHYPO","C02-Antihypertensives","MTMOTCMT","Million US$ at exchange rate","CRI","Costa Rica","2013","2013",0.8,,
+"PATCHYPO","C02-Antihypertensives","MTMOTCMT","Million US$ at exchange rate","CRI","Costa Rica","2014","2014",0.9,"B","Break"
+"PATCHYPO","C02-Antihypertensives","MTMOTCMT","Million US$ at exchange rate","CRI","Costa Rica","2015","2015",1,,
+"PATCHYPO","C02-Antihypertensives","MTMOTCMT","Million US$ at exchange rate","CRI","Costa Rica","2016","2016",1,,
+"PATCHYPO","C02-Antihypertensives","MTMOTCMT","Million US$ at exchange rate","CRI","Costa Rica","2017","2017",1.1,,
+"PATCHYPO","C02-Antihypertensives","MTMOTCMT","Million US$ at exchange rate","CRI","Costa Rica","2018","2018",1.2,,
+"PATCHYPO","C02-Antihypertensives","MTMOTCMT","Million US$ at exchange rate","CRI","Costa Rica","2019","2019",1.3,,
+"PATCHYPO","C02-Antihypertensives","MTMOTCMT","Million US$ at exchange rate","CRI","Costa Rica","2020","2020",1.4,,
+"PATCHYPO","C02-Antihypertensives","MTMOTCMT","Million US$ at exchange rate","CRI","Costa Rica","2021","2021",1.6,,
+"PATCHYPO","C02-Antihypertensives","MTMOTCMT","Million US$ at exchange rate","CRI","Costa Rica","2022","2022",1.3,,
+"PATCCARV","C-Cardiovascular system","MTMOTCMT","Million US$ at exchange rate","CRI","Costa Rica","2010","2010",9.2,,
+"PATCCARV","C-Cardiovascular system","MTMOTCMT","Million US$ at exchange rate","CRI","Costa Rica","2011","2011",9.6,,
+"PATCCARV","C-Cardiovascular system","MTMOTCMT","Million US$ at exchange rate","CRI","Costa Rica","2012","2012",10.1,,
+"PATCCARV","C-Cardiovascular system","MTMOTCMT","Million US$ at exchange rate","CRI","Costa Rica","2013","2013",10.7,,
+"PATCCARV","C-Cardiovascular system","MTMOTCMT","Million US$ at exchange rate","CRI","Costa Rica","2014","2014",12.6,"B","Break"
+"PATCCARV","C-Cardiovascular system","MTMOTCMT","Million US$ at exchange rate","CRI","Costa Rica","2015","2015",10.7,,
+"PATCCARV","C-Cardiovascular system","MTMOTCMT","Million US$ at exchange rate","CRI","Costa Rica","2016","2016",10.1,,
+"PATCCARV","C-Cardiovascular system","MTMOTCMT","Million US$ at exchange rate","CRI","Costa Rica","2017","2017",11.4,,
+"PATCCARV","C-Cardiovascular system","MTMOTCMT","Million US$ at exchange rate","CRI","Costa Rica","2018","2018",12.8,,
+"PATCCARV","C-Cardiovascular system","MTMOTCMT","Million US$ at exchange rate","CRI","Costa Rica","2019","2019",16,,
+"PATCCARV","C-Cardiovascular system","MTMOTCMT","Million US$ at exchange rate","CRI","Costa Rica","2020","2020",14.7,,
+"PATCCARV","C-Cardiovascular system","MTMOTCMT","Million US$ at exchange rate","CRI","Costa Rica","2021","2021",16.4,,
+"PATCCARV","C-Cardiovascular system","MTMOTCMT","Million US$ at exchange rate","CRI","Costa Rica","2022","2022",13.1,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","TCPPERMT","/capita, US$ exchange rate","CRI","Costa Rica","2010","2010",1,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","TCPPERMT","/capita, US$ exchange rate","CRI","Costa Rica","2011","2011",1,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","TCPPERMT","/capita, US$ exchange rate","CRI","Costa Rica","2012","2012",0.9,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","TCPPERMT","/capita, US$ exchange rate","CRI","Costa Rica","2013","2013",1,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","TCPPERMT","/capita, US$ exchange rate","CRI","Costa Rica","2014","2014",1.1,"B","Break"
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","TCPPERMT","/capita, US$ exchange rate","CRI","Costa Rica","2015","2015",0.9,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","TCPPERMT","/capita, US$ exchange rate","CRI","Costa Rica","2016","2016",0.9,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","TCPPERMT","/capita, US$ exchange rate","CRI","Costa Rica","2017","2017",0.9,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","TCPPERMT","/capita, US$ exchange rate","CRI","Costa Rica","2018","2018",0.9,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","TCPPERMT","/capita, US$ exchange rate","CRI","Costa Rica","2019","2019",1,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","TCPPERMT","/capita, US$ exchange rate","CRI","Costa Rica","2020","2020",0.9,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","TCPPERMT","/capita, US$ exchange rate","CRI","Costa Rica","2021","2021",1.7,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","TCPPERMT","/capita, US$ exchange rate","CRI","Costa Rica","2022","2022",1.5,,
+"PATCCARV","C-Cardiovascular system","MLLNCUMT","Million of national currency units","CRI","Costa Rica","2010","2010",4821.9,,
+"PATCCARV","C-Cardiovascular system","MLLNCUMT","Million of national currency units","CRI","Costa Rica","2011","2011",4872.5,,
+"PATCCARV","C-Cardiovascular system","MLLNCUMT","Million of national currency units","CRI","Costa Rica","2012","2012",5057.2,,
+"PATCCARV","C-Cardiovascular system","MLLNCUMT","Million of national currency units","CRI","Costa Rica","2013","2013",5356.4,,
+"PATCCARV","C-Cardiovascular system","MLLNCUMT","Million of national currency units","CRI","Costa Rica","2014","2014",6768.8,"B","Break"
+"PATCCARV","C-Cardiovascular system","MLLNCUMT","Million of national currency units","CRI","Costa Rica","2015","2015",5719.1,,
+"PATCCARV","C-Cardiovascular system","MLLNCUMT","Million of national currency units","CRI","Costa Rica","2016","2016",5484.2,,
+"PATCCARV","C-Cardiovascular system","MLLNCUMT","Million of national currency units","CRI","Costa Rica","2017","2017",6494.7,,
+"PATCCARV","C-Cardiovascular system","MLLNCUMT","Million of national currency units","CRI","Costa Rica","2018","2018",7363.9,,
+"PATCCARV","C-Cardiovascular system","MLLNCUMT","Million of national currency units","CRI","Costa Rica","2019","2019",9396,,
+"PATCCARV","C-Cardiovascular system","MLLNCUMT","Million of national currency units","CRI","Costa Rica","2020","2020",8609,,
+"PATCCARV","C-Cardiovascular system","MLLNCUMT","Million of national currency units","CRI","Costa Rica","2021","2021",10195,,
+"PATCCARV","C-Cardiovascular system","MLLNCUMT","Million of national currency units","CRI","Costa Rica","2022","2022",8505.5,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MLLNCUMT","Million of national currency units","CRI","Costa Rica","2010","2010",924.5,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MLLNCUMT","Million of national currency units","CRI","Costa Rica","2011","2011",886.3,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MLLNCUMT","Million of national currency units","CRI","Costa Rica","2012","2012",1000.3,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MLLNCUMT","Million of national currency units","CRI","Costa Rica","2013","2013",1381.1,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MLLNCUMT","Million of national currency units","CRI","Costa Rica","2014","2014",1732.8,"B","Break"
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MLLNCUMT","Million of national currency units","CRI","Costa Rica","2015","2015",1648.5,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MLLNCUMT","Million of national currency units","CRI","Costa Rica","2016","2016",1689.2,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MLLNCUMT","Million of national currency units","CRI","Costa Rica","2017","2017",1838.9,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MLLNCUMT","Million of national currency units","CRI","Costa Rica","2018","2018",1590.9,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MLLNCUMT","Million of national currency units","CRI","Costa Rica","2019","2019",1394.2,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MLLNCUMT","Million of national currency units","CRI","Costa Rica","2020","2020",1250.4,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MLLNCUMT","Million of national currency units","CRI","Costa Rica","2021","2021",1377.7,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MLLNCUMT","Million of national currency units","CRI","Costa Rica","2022","2022",1170.4,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOPPMT","Million US$, purchasing power parity","CRI","Costa Rica","2010","2010",4.7,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOPPMT","Million US$, purchasing power parity","CRI","Costa Rica","2011","2011",5,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOPPMT","Million US$, purchasing power parity","CRI","Costa Rica","2012","2012",5.1,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOPPMT","Million US$, purchasing power parity","CRI","Costa Rica","2013","2013",5.5,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOPPMT","Million US$, purchasing power parity","CRI","Costa Rica","2014","2014",4.7,"B","Break"
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOPPMT","Million US$, purchasing power parity","CRI","Costa Rica","2015","2015",5.3,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOPPMT","Million US$, purchasing power parity","CRI","Costa Rica","2016","2016",5.5,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOPPMT","Million US$, purchasing power parity","CRI","Costa Rica","2017","2017",5.6,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOPPMT","Million US$, purchasing power parity","CRI","Costa Rica","2018","2018",5.1,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOPPMT","Million US$, purchasing power parity","CRI","Costa Rica","2019","2019",4.6,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOPPMT","Million US$, purchasing power parity","CRI","Costa Rica","2020","2020",4.1,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOPPMT","Million US$, purchasing power parity","CRI","Costa Rica","2021","2021",4.9,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOPPMT","Million US$, purchasing power parity","CRI","Costa Rica","2022","2022",4.3,,
+"PATCANXO","N05B-Anxiolytics","MTMOPPMT","Million US$, purchasing power parity","CRI","Costa Rica","2010","2010",0.8,,
+"PATCANXO","N05B-Anxiolytics","MTMOPPMT","Million US$, purchasing power parity","CRI","Costa Rica","2011","2011",0.8,,
+"PATCANXO","N05B-Anxiolytics","MTMOPPMT","Million US$, purchasing power parity","CRI","Costa Rica","2012","2012",0.8,,
+"PATCANXO","N05B-Anxiolytics","MTMOPPMT","Million US$, purchasing power parity","CRI","Costa Rica","2013","2013",0.9,,
+"PATCANXO","N05B-Anxiolytics","MTMOPPMT","Million US$, purchasing power parity","CRI","Costa Rica","2014","2014",1,"B","Break"
+"PATCANXO","N05B-Anxiolytics","MTMOPPMT","Million US$, purchasing power parity","CRI","Costa Rica","2015","2015",1,,
+"PATCANXO","N05B-Anxiolytics","MTMOPPMT","Million US$, purchasing power parity","CRI","Costa Rica","2016","2016",1,,
+"PATCANXO","N05B-Anxiolytics","MTMOPPMT","Million US$, purchasing power parity","CRI","Costa Rica","2017","2017",1.2,,
+"PATCANXO","N05B-Anxiolytics","MTMOPPMT","Million US$, purchasing power parity","CRI","Costa Rica","2018","2018",1.4,,
+"PATCANXO","N05B-Anxiolytics","MTMOPPMT","Million US$, purchasing power parity","CRI","Costa Rica","2019","2019",1.8,,
+"PATCANXO","N05B-Anxiolytics","MTMOPPMT","Million US$, purchasing power parity","CRI","Costa Rica","2020","2020",1.7,,
+"PATCANXO","N05B-Anxiolytics","MTMOPPMT","Million US$, purchasing power parity","CRI","Costa Rica","2021","2021",1.2,,
+"PATCANXO","N05B-Anxiolytics","MTMOPPMT","Million US$, purchasing power parity","CRI","Costa Rica","2022","2022",1.1,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2010","2010",1,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2011","2011",1.1,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2012","2012",1,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2013","2013",1,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2014","2014",1,"B","Break"
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2015","2015",1,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2016","2016",1.1,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2017","2017",1.2,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2018","2018",1.5,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2019","2019",1.8,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2020","2020",1.6,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2021","2021",1.8,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2022","2022",1.5,,
+"PATCHYPO","C02-Antihypertensives","MLLNCUMT","Million of national currency units","CRI","Costa Rica","2010","2010",286.8,,
+"PATCHYPO","C02-Antihypertensives","MLLNCUMT","Million of national currency units","CRI","Costa Rica","2011","2011",347.1,,
+"PATCHYPO","C02-Antihypertensives","MLLNCUMT","Million of national currency units","CRI","Costa Rica","2012","2012",379.8,,
+"PATCHYPO","C02-Antihypertensives","MLLNCUMT","Million of national currency units","CRI","Costa Rica","2013","2013",394,,
+"PATCHYPO","C02-Antihypertensives","MLLNCUMT","Million of national currency units","CRI","Costa Rica","2014","2014",481.8,"B","Break"
+"PATCHYPO","C02-Antihypertensives","MLLNCUMT","Million of national currency units","CRI","Costa Rica","2015","2015",519.3,,
+"PATCHYPO","C02-Antihypertensives","MLLNCUMT","Million of national currency units","CRI","Costa Rica","2016","2016",539.3,,
+"PATCHYPO","C02-Antihypertensives","MLLNCUMT","Million of national currency units","CRI","Costa Rica","2017","2017",625.9,,
+"PATCHYPO","C02-Antihypertensives","MLLNCUMT","Million of national currency units","CRI","Costa Rica","2018","2018",703.5,,
+"PATCHYPO","C02-Antihypertensives","MLLNCUMT","Million of national currency units","CRI","Costa Rica","2019","2019",755,,
+"PATCHYPO","C02-Antihypertensives","MLLNCUMT","Million of national currency units","CRI","Costa Rica","2020","2020",837.9,,
+"PATCHYPO","C02-Antihypertensives","MLLNCUMT","Million of national currency units","CRI","Costa Rica","2021","2021",968.4,,
+"PATCHYPO","C02-Antihypertensives","MLLNCUMT","Million of national currency units","CRI","Costa Rica","2022","2022",833.5,,
+"PATCBLOO","B-Blood and blood forming organs","MTMOPPMT","Million US$, purchasing power parity","CRI","Costa Rica","2010","2010",35,,
+"PATCBLOO","B-Blood and blood forming organs","MTMOPPMT","Million US$, purchasing power parity","CRI","Costa Rica","2011","2011",35.4,,
+"PATCBLOO","B-Blood and blood forming organs","MTMOPPMT","Million US$, purchasing power parity","CRI","Costa Rica","2012","2012",35.5,,
+"PATCBLOO","B-Blood and blood forming organs","MTMOPPMT","Million US$, purchasing power parity","CRI","Costa Rica","2013","2013",42.6,,
+"PATCBLOO","B-Blood and blood forming organs","MTMOPPMT","Million US$, purchasing power parity","CRI","Costa Rica","2014","2014",52.6,"B","Break"
+"PATCBLOO","B-Blood and blood forming organs","MTMOPPMT","Million US$, purchasing power parity","CRI","Costa Rica","2015","2015",47.2,,
+"PATCBLOO","B-Blood and blood forming organs","MTMOPPMT","Million US$, purchasing power parity","CRI","Costa Rica","2016","2016",46.6,,
+"PATCBLOO","B-Blood and blood forming organs","MTMOPPMT","Million US$, purchasing power parity","CRI","Costa Rica","2017","2017",45,,
+"PATCBLOO","B-Blood and blood forming organs","MTMOPPMT","Million US$, purchasing power parity","CRI","Costa Rica","2018","2018",52.4,,
+"PATCBLOO","B-Blood and blood forming organs","MTMOPPMT","Million US$, purchasing power parity","CRI","Costa Rica","2019","2019",61.2,,
+"PATCBLOO","B-Blood and blood forming organs","MTMOPPMT","Million US$, purchasing power parity","CRI","Costa Rica","2020","2020",49.1,,
+"PATCBLOO","B-Blood and blood forming organs","MTMOPPMT","Million US$, purchasing power parity","CRI","Costa Rica","2021","2021",59,,
+"PATCBLOO","B-Blood and blood forming organs","MTMOPPMT","Million US$, purchasing power parity","CRI","Costa Rica","2022","2022",55.7,,
+"PATCCCBR","C08-Calcium channel blockers","MLLNCUMT","Million of national currency units","CRI","Costa Rica","2010","2010",175.2,,
+"PATCCCBR","C08-Calcium channel blockers","MLLNCUMT","Million of national currency units","CRI","Costa Rica","2011","2011",177.2,,
+"PATCCCBR","C08-Calcium channel blockers","MLLNCUMT","Million of national currency units","CRI","Costa Rica","2012","2012",204,,
+"PATCCCBR","C08-Calcium channel blockers","MLLNCUMT","Million of national currency units","CRI","Costa Rica","2013","2013",276.6,,
+"PATCCCBR","C08-Calcium channel blockers","MLLNCUMT","Million of national currency units","CRI","Costa Rica","2014","2014",319.1,"B","Break"
+"PATCCCBR","C08-Calcium channel blockers","MLLNCUMT","Million of national currency units","CRI","Costa Rica","2015","2015",362.9,,
+"PATCCCBR","C08-Calcium channel blockers","MLLNCUMT","Million of national currency units","CRI","Costa Rica","2016","2016",298.2,,
+"PATCCCBR","C08-Calcium channel blockers","MLLNCUMT","Million of national currency units","CRI","Costa Rica","2017","2017",364,,
+"PATCCCBR","C08-Calcium channel blockers","MLLNCUMT","Million of national currency units","CRI","Costa Rica","2018","2018",425,,
+"PATCCCBR","C08-Calcium channel blockers","MLLNCUMT","Million of national currency units","CRI","Costa Rica","2019","2019",424.5,,
+"PATCCCBR","C08-Calcium channel blockers","MLLNCUMT","Million of national currency units","CRI","Costa Rica","2020","2020",459.7,,
+"PATCCCBR","C08-Calcium channel blockers","MLLNCUMT","Million of national currency units","CRI","Costa Rica","2021","2021",513.3,,
+"PATCCCBR","C08-Calcium channel blockers","MLLNCUMT","Million of national currency units","CRI","Costa Rica","2022","2022",444.2,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOPPMT","Million US$, purchasing power parity","CRI","Costa Rica","2010","2010",0.2,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOPPMT","Million US$, purchasing power parity","CRI","Costa Rica","2011","2011",0.2,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOPPMT","Million US$, purchasing power parity","CRI","Costa Rica","2012","2012",0.2,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOPPMT","Million US$, purchasing power parity","CRI","Costa Rica","2013","2013",0.3,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOPPMT","Million US$, purchasing power parity","CRI","Costa Rica","2014","2014",0.2,"B","Break"
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOPPMT","Million US$, purchasing power parity","CRI","Costa Rica","2015","2015",0.2,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOPPMT","Million US$, purchasing power parity","CRI","Costa Rica","2016","2016",0.2,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOPPMT","Million US$, purchasing power parity","CRI","Costa Rica","2017","2017",0.2,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOPPMT","Million US$, purchasing power parity","CRI","Costa Rica","2018","2018",0.3,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOPPMT","Million US$, purchasing power parity","CRI","Costa Rica","2019","2019",0.4,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOPPMT","Million US$, purchasing power parity","CRI","Costa Rica","2020","2020",0.4,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOPPMT","Million US$, purchasing power parity","CRI","Costa Rica","2021","2021",0.4,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOPPMT","Million US$, purchasing power parity","CRI","Costa Rica","2022","2022",0.4,,
+"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2010","2010",4.1,,
+"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2011","2011",3.6,,
+"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2012","2012",3,,
+"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2013","2013",3.1,,
+"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2014","2014",3.4,"B","Break"
+"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2015","2015",2.9,,
+"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2016","2016",3,,
+"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2017","2017",2.6,,
+"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2018","2018",2.3,,
+"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2019","2019",2.4,,
+"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2020","2020",1.8,,
+"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2021","2021",2.1,,
+"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2022","2022",1.7,,
+"PATCCCBR","C08-Calcium channel blockers","MTMOTCMT","Million US$ at exchange rate","CRI","Costa Rica","2010","2010",0.3,,
+"PATCCCBR","C08-Calcium channel blockers","MTMOTCMT","Million US$ at exchange rate","CRI","Costa Rica","2011","2011",0.4,,
+"PATCCCBR","C08-Calcium channel blockers","MTMOTCMT","Million US$ at exchange rate","CRI","Costa Rica","2012","2012",0.4,,
+"PATCCCBR","C08-Calcium channel blockers","MTMOTCMT","Million US$ at exchange rate","CRI","Costa Rica","2013","2013",0.6,,
+"PATCCCBR","C08-Calcium channel blockers","MTMOTCMT","Million US$ at exchange rate","CRI","Costa Rica","2014","2014",0.6,"B","Break"
+"PATCCCBR","C08-Calcium channel blockers","MTMOTCMT","Million US$ at exchange rate","CRI","Costa Rica","2015","2015",0.7,,
+"PATCCCBR","C08-Calcium channel blockers","MTMOTCMT","Million US$ at exchange rate","CRI","Costa Rica","2016","2016",0.5,,
+"PATCCCBR","C08-Calcium channel blockers","MTMOTCMT","Million US$ at exchange rate","CRI","Costa Rica","2017","2017",0.6,,
+"PATCCCBR","C08-Calcium channel blockers","MTMOTCMT","Million US$ at exchange rate","CRI","Costa Rica","2018","2018",0.7,,
+"PATCCCBR","C08-Calcium channel blockers","MTMOTCMT","Million US$ at exchange rate","CRI","Costa Rica","2019","2019",0.7,,
+"PATCCCBR","C08-Calcium channel blockers","MTMOTCMT","Million US$ at exchange rate","CRI","Costa Rica","2020","2020",0.8,,
+"PATCCCBR","C08-Calcium channel blockers","MTMOTCMT","Million US$ at exchange rate","CRI","Costa Rica","2021","2021",0.8,,
+"PATCCCBR","C08-Calcium channel blockers","MTMOTCMT","Million US$ at exchange rate","CRI","Costa Rica","2022","2022",0.7,,
+"PATCDEPR","N06A-Antidepressants","TCPPERMT","/capita, US$ exchange rate","CRI","Costa Rica","2010","2010",0.7,,
+"PATCDEPR","N06A-Antidepressants","TCPPERMT","/capita, US$ exchange rate","CRI","Costa Rica","2011","2011",0.6,,
+"PATCDEPR","N06A-Antidepressants","TCPPERMT","/capita, US$ exchange rate","CRI","Costa Rica","2012","2012",0.4,,
+"PATCDEPR","N06A-Antidepressants","TCPPERMT","/capita, US$ exchange rate","CRI","Costa Rica","2013","2013",0.4,,
+"PATCDEPR","N06A-Antidepressants","TCPPERMT","/capita, US$ exchange rate","CRI","Costa Rica","2014","2014",0.4,"B","Break"
+"PATCDEPR","N06A-Antidepressants","TCPPERMT","/capita, US$ exchange rate","CRI","Costa Rica","2015","2015",0.5,,
+"PATCDEPR","N06A-Antidepressants","TCPPERMT","/capita, US$ exchange rate","CRI","Costa Rica","2016","2016",0.6,,
+"PATCDEPR","N06A-Antidepressants","TCPPERMT","/capita, US$ exchange rate","CRI","Costa Rica","2017","2017",0.5,,
+"PATCDEPR","N06A-Antidepressants","TCPPERMT","/capita, US$ exchange rate","CRI","Costa Rica","2018","2018",0.5,,
+"PATCDEPR","N06A-Antidepressants","TCPPERMT","/capita, US$ exchange rate","CRI","Costa Rica","2019","2019",0.5,,
+"PATCDEPR","N06A-Antidepressants","TCPPERMT","/capita, US$ exchange rate","CRI","Costa Rica","2020","2020",0.5,,
+"PATCDEPR","N06A-Antidepressants","TCPPERMT","/capita, US$ exchange rate","CRI","Costa Rica","2021","2021",0.4,,
+"PATCDEPR","N06A-Antidepressants","TCPPERMT","/capita, US$ exchange rate","CRI","Costa Rica","2022","2022",0.4,,
+"PATCANAL","N02-Analgesics","TCPPERMT","/capita, US$ exchange rate","CRI","Costa Rica","2010","2010",0.6,,
+"PATCANAL","N02-Analgesics","TCPPERMT","/capita, US$ exchange rate","CRI","Costa Rica","2011","2011",0.7,,
+"PATCANAL","N02-Analgesics","TCPPERMT","/capita, US$ exchange rate","CRI","Costa Rica","2012","2012",0.7,,
+"PATCANAL","N02-Analgesics","TCPPERMT","/capita, US$ exchange rate","CRI","Costa Rica","2013","2013",0.8,,
+"PATCANAL","N02-Analgesics","TCPPERMT","/capita, US$ exchange rate","CRI","Costa Rica","2014","2014",1.1,"B","Break"
+"PATCANAL","N02-Analgesics","TCPPERMT","/capita, US$ exchange rate","CRI","Costa Rica","2015","2015",1,,
+"PATCANAL","N02-Analgesics","TCPPERMT","/capita, US$ exchange rate","CRI","Costa Rica","2016","2016",1,,
+"PATCANAL","N02-Analgesics","TCPPERMT","/capita, US$ exchange rate","CRI","Costa Rica","2017","2017",1,,
+"PATCANAL","N02-Analgesics","TCPPERMT","/capita, US$ exchange rate","CRI","Costa Rica","2018","2018",1.1,,
+"PATCANAL","N02-Analgesics","TCPPERMT","/capita, US$ exchange rate","CRI","Costa Rica","2019","2019",1.6,,
+"PATCANAL","N02-Analgesics","TCPPERMT","/capita, US$ exchange rate","CRI","Costa Rica","2020","2020",1.5,,
+"PATCANAL","N02-Analgesics","TCPPERMT","/capita, US$ exchange rate","CRI","Costa Rica","2021","2021",1.6,,
+"PATCANAL","N02-Analgesics","TCPPERMT","/capita, US$ exchange rate","CRI","Costa Rica","2022","2022",1.5,,
+"PATCDIUR","C03-Diuretics","TCPPERMT","/capita, US$ exchange rate","CRI","Costa Rica","2010","2010",0.2,,
+"PATCDIUR","C03-Diuretics","TCPPERMT","/capita, US$ exchange rate","CRI","Costa Rica","2011","2011",0.3,,
+"PATCDIUR","C03-Diuretics","TCPPERMT","/capita, US$ exchange rate","CRI","Costa Rica","2012","2012",0.2,,
+"PATCDIUR","C03-Diuretics","TCPPERMT","/capita, US$ exchange rate","CRI","Costa Rica","2013","2013",0.2,,
+"PATCDIUR","C03-Diuretics","TCPPERMT","/capita, US$ exchange rate","CRI","Costa Rica","2014","2014",0.2,"B","Break"
+"PATCDIUR","C03-Diuretics","TCPPERMT","/capita, US$ exchange rate","CRI","Costa Rica","2015","2015",0.2,,
+"PATCDIUR","C03-Diuretics","TCPPERMT","/capita, US$ exchange rate","CRI","Costa Rica","2016","2016",0.2,,
+"PATCDIUR","C03-Diuretics","TCPPERMT","/capita, US$ exchange rate","CRI","Costa Rica","2017","2017",0.1,,
+"PATCDIUR","C03-Diuretics","TCPPERMT","/capita, US$ exchange rate","CRI","Costa Rica","2018","2018",0.1,,
+"PATCDIUR","C03-Diuretics","TCPPERMT","/capita, US$ exchange rate","CRI","Costa Rica","2019","2019",0.2,,
+"PATCDIUR","C03-Diuretics","TCPPERMT","/capita, US$ exchange rate","CRI","Costa Rica","2020","2020",0.2,,
+"PATCDIUR","C03-Diuretics","TCPPERMT","/capita, US$ exchange rate","CRI","Costa Rica","2021","2021",0.2,,
+"PATCDIUR","C03-Diuretics","TCPPERMT","/capita, US$ exchange rate","CRI","Costa Rica","2022","2022",0.1,,
+"PATCGLYC","C01A-Cardiac glycosides","TCPPERMT","/capita, US$ exchange rate","CRI","Costa Rica","2010","2010",0.1,,
+"PATCGLYC","C01A-Cardiac glycosides","TCPPERMT","/capita, US$ exchange rate","CRI","Costa Rica","2011","2011",0.1,,
+"PATCGLYC","C01A-Cardiac glycosides","TCPPERMT","/capita, US$ exchange rate","CRI","Costa Rica","2012","2012",0.1,,
+"PATCGLYC","C01A-Cardiac glycosides","TCPPERMT","/capita, US$ exchange rate","CRI","Costa Rica","2013","2013",0.1,,
+"PATCGLYC","C01A-Cardiac glycosides","TCPPERMT","/capita, US$ exchange rate","CRI","Costa Rica","2014","2014",0.1,"B","Break"
+"PATCGLYC","C01A-Cardiac glycosides","TCPPERMT","/capita, US$ exchange rate","CRI","Costa Rica","2015","2015",0.1,,
+"PATCGLYC","C01A-Cardiac glycosides","TCPPERMT","/capita, US$ exchange rate","CRI","Costa Rica","2016","2016",0.1,,
+"PATCGLYC","C01A-Cardiac glycosides","TCPPERMT","/capita, US$ exchange rate","CRI","Costa Rica","2017","2017",0.1,,
+"PATCGLYC","C01A-Cardiac glycosides","TCPPERMT","/capita, US$ exchange rate","CRI","Costa Rica","2018","2018",0,,
+"PATCGLYC","C01A-Cardiac glycosides","TCPPERMT","/capita, US$ exchange rate","CRI","Costa Rica","2019","2019",0,,
+"PATCGLYC","C01A-Cardiac glycosides","TCPPERMT","/capita, US$ exchange rate","CRI","Costa Rica","2020","2020",0,,
+"PATCGLYC","C01A-Cardiac glycosides","TCPPERMT","/capita, US$ exchange rate","CRI","Costa Rica","2021","2021",0,,
+"PATCGLYC","C01A-Cardiac glycosides","TCPPERMT","/capita, US$ exchange rate","CRI","Costa Rica","2022","2022",0,,
+"PATCDIAB","A10-Drugs used in diabetes","TCPPERMT","/capita, US$ exchange rate","CRI","Costa Rica","2010","2010",1.1,,
+"PATCDIAB","A10-Drugs used in diabetes","TCPPERMT","/capita, US$ exchange rate","CRI","Costa Rica","2011","2011",1.2,,
+"PATCDIAB","A10-Drugs used in diabetes","TCPPERMT","/capita, US$ exchange rate","CRI","Costa Rica","2012","2012",1.4,,
+"PATCDIAB","A10-Drugs used in diabetes","TCPPERMT","/capita, US$ exchange rate","CRI","Costa Rica","2013","2013",1.5,,
+"PATCDIAB","A10-Drugs used in diabetes","TCPPERMT","/capita, US$ exchange rate","CRI","Costa Rica","2014","2014",1.7,"B","Break"
+"PATCDIAB","A10-Drugs used in diabetes","TCPPERMT","/capita, US$ exchange rate","CRI","Costa Rica","2015","2015",1.6,,
+"PATCDIAB","A10-Drugs used in diabetes","TCPPERMT","/capita, US$ exchange rate","CRI","Costa Rica","2016","2016",1.6,,
+"PATCDIAB","A10-Drugs used in diabetes","TCPPERMT","/capita, US$ exchange rate","CRI","Costa Rica","2017","2017",1.6,,
+"PATCDIAB","A10-Drugs used in diabetes","TCPPERMT","/capita, US$ exchange rate","CRI","Costa Rica","2018","2018",1.7,,
+"PATCDIAB","A10-Drugs used in diabetes","TCPPERMT","/capita, US$ exchange rate","CRI","Costa Rica","2019","2019",1.8,,
+"PATCDIAB","A10-Drugs used in diabetes","TCPPERMT","/capita, US$ exchange rate","CRI","Costa Rica","2020","2020",1.9,,
+"PATCDIAB","A10-Drugs used in diabetes","TCPPERMT","/capita, US$ exchange rate","CRI","Costa Rica","2021","2021",2,,
+"PATCDIAB","A10-Drugs used in diabetes","TCPPERMT","/capita, US$ exchange rate","CRI","Costa Rica","2022","2022",1.6,,
+"PATCBIOT","J01-Antibacterials for systemic use","MTMOTCMT","Million US$ at exchange rate","CRI","Costa Rica","2010","2010",11.5,,
+"PATCBIOT","J01-Antibacterials for systemic use","MTMOTCMT","Million US$ at exchange rate","CRI","Costa Rica","2011","2011",10.9,,
+"PATCBIOT","J01-Antibacterials for systemic use","MTMOTCMT","Million US$ at exchange rate","CRI","Costa Rica","2012","2012",9.7,,
+"PATCBIOT","J01-Antibacterials for systemic use","MTMOTCMT","Million US$ at exchange rate","CRI","Costa Rica","2013","2013",10.2,,
+"PATCBIOT","J01-Antibacterials for systemic use","MTMOTCMT","Million US$ at exchange rate","CRI","Costa Rica","2014","2014",10.7,"B","Break"
+"PATCBIOT","J01-Antibacterials for systemic use","MTMOTCMT","Million US$ at exchange rate","CRI","Costa Rica","2015","2015",9.2,,
+"PATCBIOT","J01-Antibacterials for systemic use","MTMOTCMT","Million US$ at exchange rate","CRI","Costa Rica","2016","2016",9.4,,
+"PATCBIOT","J01-Antibacterials for systemic use","MTMOTCMT","Million US$ at exchange rate","CRI","Costa Rica","2017","2017",7.7,,
+"PATCBIOT","J01-Antibacterials for systemic use","MTMOTCMT","Million US$ at exchange rate","CRI","Costa Rica","2018","2018",6.6,,
+"PATCBIOT","J01-Antibacterials for systemic use","MTMOTCMT","Million US$ at exchange rate","CRI","Costa Rica","2019","2019",6.8,,
+"PATCBIOT","J01-Antibacterials for systemic use","MTMOTCMT","Million US$ at exchange rate","CRI","Costa Rica","2020","2020",5.2,,
+"PATCBIOT","J01-Antibacterials for systemic use","MTMOTCMT","Million US$ at exchange rate","CRI","Costa Rica","2021","2021",5.9,,
+"PATCBIOT","J01-Antibacterials for systemic use","MTMOTCMT","Million US$ at exchange rate","CRI","Costa Rica","2022","2022",4.7,,
+"PATCBETA","C07-Beta blocking agents","MTMOPPMT","Million US$, purchasing power parity","CRI","Costa Rica","2010","2010",1,,
+"PATCBETA","C07-Beta blocking agents","MTMOPPMT","Million US$, purchasing power parity","CRI","Costa Rica","2011","2011",1.5,,
+"PATCBETA","C07-Beta blocking agents","MTMOPPMT","Million US$, purchasing power parity","CRI","Costa Rica","2012","2012",1.7,,
+"PATCBETA","C07-Beta blocking agents","MTMOPPMT","Million US$, purchasing power parity","CRI","Costa Rica","2013","2013",1.8,,
+"PATCBETA","C07-Beta blocking agents","MTMOPPMT","Million US$, purchasing power parity","CRI","Costa Rica","2014","2014",1.9,"B","Break"
+"PATCBETA","C07-Beta blocking agents","MTMOPPMT","Million US$, purchasing power parity","CRI","Costa Rica","2015","2015",2.3,,
+"PATCBETA","C07-Beta blocking agents","MTMOPPMT","Million US$, purchasing power parity","CRI","Costa Rica","2016","2016",2.5,,
+"PATCBETA","C07-Beta blocking agents","MTMOPPMT","Million US$, purchasing power parity","CRI","Costa Rica","2017","2017",2.8,,
+"PATCBETA","C07-Beta blocking agents","MTMOPPMT","Million US$, purchasing power parity","CRI","Costa Rica","2018","2018",2.4,,
+"PATCBETA","C07-Beta blocking agents","MTMOPPMT","Million US$, purchasing power parity","CRI","Costa Rica","2019","2019",1.9,,
+"PATCBETA","C07-Beta blocking agents","MTMOPPMT","Million US$, purchasing power parity","CRI","Costa Rica","2020","2020",1.7,,
+"PATCBETA","C07-Beta blocking agents","MTMOPPMT","Million US$, purchasing power parity","CRI","Costa Rica","2021","2021",2.4,,
+"PATCBETA","C07-Beta blocking agents","MTMOPPMT","Million US$, purchasing power parity","CRI","Costa Rica","2022","2022",2.3,,
+"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2010","2010",0.1,,
+"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2011","2011",0.1,,
+"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2012","2012",0.1,,
+"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2013","2013",0.1,,
+"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2014","2014",0.1,"B","Break"
+"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2015","2015",0.1,,
+"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2016","2016",0.1,,
+"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2017","2017",0.1,,
+"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2018","2018",0.1,,
+"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2019","2019",0.1,,
+"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2020","2020",0.1,,
+"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2021","2021",0.2,,
+"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2022","2022",0.1,,
+"PATCGENU","G-Genito urinary system and sex hormones","ATCPTTMT","% of total sales","HRV","Croatia","2010","2010",3.4,,
+"PATCGENU","G-Genito urinary system and sex hormones","ATCPTTMT","% of total sales","HRV","Croatia","2011","2011",3.3,,
+"PATCGENU","G-Genito urinary system and sex hormones","ATCPTTMT","% of total sales","HRV","Croatia","2012","2012",3.2,,
+"PATCGENU","G-Genito urinary system and sex hormones","ATCPTTMT","% of total sales","HRV","Croatia","2013","2013",3.1,,
+"PATCGENU","G-Genito urinary system and sex hormones","ATCPTTMT","% of total sales","HRV","Croatia","2014","2014",3.2,,
+"PATCGENU","G-Genito urinary system and sex hormones","ATCPTTMT","% of total sales","HRV","Croatia","2015","2015",3.1,,
+"PATCGENU","G-Genito urinary system and sex hormones","ATCPTTMT","% of total sales","HRV","Croatia","2016","2016",3,,
+"PATCGENU","G-Genito urinary system and sex hormones","ATCPTTMT","% of total sales","HRV","Croatia","2017","2017",2.9,,
+"PATCGENU","G-Genito urinary system and sex hormones","ATCPTTMT","% of total sales","HRV","Croatia","2018","2018",2.8,,
+"PATCGENU","G-Genito urinary system and sex hormones","ATCPTTMT","% of total sales","HRV","Croatia","2019","2019",2.6,,
+"PATCGENU","G-Genito urinary system and sex hormones","ATCPTTMT","% of total sales","HRV","Croatia","2020","2020",2.3,,
+"PATCGENU","G-Genito urinary system and sex hormones","ATCPTTMT","% of total sales","HRV","Croatia","2021","2021",2,,
+"PATCBIOT","J01-Antibacterials for systemic use","ATCPTTMT","% of total sales","ROU","Romania","2022","2022",0,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","ATCPTTMT","% of total sales","ROU","Romania","2022","2022",0,,
+"PATCCCBR","C08-Calcium channel blockers","ATCPTTMT","% of total sales","HRV","Croatia","2010","2010",3,,
+"PATCCCBR","C08-Calcium channel blockers","ATCPTTMT","% of total sales","HRV","Croatia","2011","2011",2.9,,
+"PATCCCBR","C08-Calcium channel blockers","ATCPTTMT","% of total sales","HRV","Croatia","2012","2012",2.7,,
+"PATCCCBR","C08-Calcium channel blockers","ATCPTTMT","% of total sales","HRV","Croatia","2013","2013",2.4,,
+"PATCCCBR","C08-Calcium channel blockers","ATCPTTMT","% of total sales","HRV","Croatia","2014","2014",2.3,,
+"PATCCCBR","C08-Calcium channel blockers","ATCPTTMT","% of total sales","HRV","Croatia","2015","2015",1.9,,
+"PATCCCBR","C08-Calcium channel blockers","ATCPTTMT","% of total sales","HRV","Croatia","2016","2016",1.7,,
+"PATCCCBR","C08-Calcium channel blockers","ATCPTTMT","% of total sales","HRV","Croatia","2017","2017",1.4,,
+"PATCCCBR","C08-Calcium channel blockers","ATCPTTMT","% of total sales","HRV","Croatia","2018","2018",1.2,,
+"PATCCCBR","C08-Calcium channel blockers","ATCPTTMT","% of total sales","HRV","Croatia","2019","2019",0.9,,
+"PATCCCBR","C08-Calcium channel blockers","ATCPTTMT","% of total sales","HRV","Croatia","2020","2020",0.7,,
+"PATCCCBR","C08-Calcium channel blockers","ATCPTTMT","% of total sales","HRV","Croatia","2021","2021",0.6,,
+"PATCHYPO","C02-Antihypertensives","ATCPTTMT","% of total sales","HRV","Croatia","2010","2010",0.9,,
+"PATCHYPO","C02-Antihypertensives","ATCPTTMT","% of total sales","HRV","Croatia","2011","2011",0.9,,
+"PATCHYPO","C02-Antihypertensives","ATCPTTMT","% of total sales","HRV","Croatia","2012","2012",1,,
+"PATCHYPO","C02-Antihypertensives","ATCPTTMT","% of total sales","HRV","Croatia","2013","2013",1,,
+"PATCHYPO","C02-Antihypertensives","ATCPTTMT","% of total sales","HRV","Croatia","2014","2014",1,,
+"PATCHYPO","C02-Antihypertensives","ATCPTTMT","% of total sales","HRV","Croatia","2015","2015",0.9,,
+"PATCHYPO","C02-Antihypertensives","ATCPTTMT","% of total sales","HRV","Croatia","2016","2016",0.7,,
+"PATCHYPO","C02-Antihypertensives","ATCPTTMT","% of total sales","HRV","Croatia","2017","2017",0.8,,
+"PATCHYPO","C02-Antihypertensives","ATCPTTMT","% of total sales","HRV","Croatia","2018","2018",0.8,,
+"PATCHYPO","C02-Antihypertensives","ATCPTTMT","% of total sales","HRV","Croatia","2019","2019",0.8,,
+"PATCHYPO","C02-Antihypertensives","ATCPTTMT","% of total sales","HRV","Croatia","2020","2020",0.9,,
+"PATCHYPO","C02-Antihypertensives","ATCPTTMT","% of total sales","HRV","Croatia","2021","2021",0.7,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","ATCPTTMT","% of total sales","ROU","Romania","2022","2022",0,,
+"PATCBLOO","B-Blood and blood forming organs","ATCPTTMT","% of total sales","ROU","Romania","2022","2022",0.1,,
+"PATCALIM","A-Alimentary tract and metabolism","ATCPTTMT","% of total sales","HRV","Croatia","2010","2010",13.2,,
+"PATCALIM","A-Alimentary tract and metabolism","ATCPTTMT","% of total sales","HRV","Croatia","2011","2011",13.6,,
+"PATCALIM","A-Alimentary tract and metabolism","ATCPTTMT","% of total sales","HRV","Croatia","2012","2012",14,,
+"PATCALIM","A-Alimentary tract and metabolism","ATCPTTMT","% of total sales","HRV","Croatia","2013","2013",13.8,,
+"PATCALIM","A-Alimentary tract and metabolism","ATCPTTMT","% of total sales","HRV","Croatia","2014","2014",13.8,,
+"PATCALIM","A-Alimentary tract and metabolism","ATCPTTMT","% of total sales","HRV","Croatia","2015","2015",13.7,,
+"PATCALIM","A-Alimentary tract and metabolism","ATCPTTMT","% of total sales","HRV","Croatia","2016","2016",13.3,,
+"PATCALIM","A-Alimentary tract and metabolism","ATCPTTMT","% of total sales","HRV","Croatia","2017","2017",13,,
+"PATCALIM","A-Alimentary tract and metabolism","ATCPTTMT","% of total sales","HRV","Croatia","2018","2018",12.5,,
+"PATCALIM","A-Alimentary tract and metabolism","ATCPTTMT","% of total sales","HRV","Croatia","2019","2019",11.6,,
+"PATCALIM","A-Alimentary tract and metabolism","ATCPTTMT","% of total sales","HRV","Croatia","2020","2020",10.6,,
+"PATCALIM","A-Alimentary tract and metabolism","ATCPTTMT","% of total sales","HRV","Croatia","2021","2021",9.3,,
+"PATCACID","A02A-Antacids","ATCPTTMT","% of total sales","ROU","Romania","2022","2022",0,,
+"PATCCNSY","N-Nervous system","ATCPTTMT","% of total sales","ROU","Romania","2022","2022",0.1,,
+"PATCINFC","J-Antiinfectives for systemic use","ATCPTTMT","% of total sales","HRV","Croatia","2010","2010",9.8,,
+"PATCINFC","J-Antiinfectives for systemic use","ATCPTTMT","% of total sales","HRV","Croatia","2011","2011",9.1,,
+"PATCINFC","J-Antiinfectives for systemic use","ATCPTTMT","% of total sales","HRV","Croatia","2012","2012",8.4,,
+"PATCINFC","J-Antiinfectives for systemic use","ATCPTTMT","% of total sales","HRV","Croatia","2013","2013",8.3,,
+"PATCINFC","J-Antiinfectives for systemic use","ATCPTTMT","% of total sales","HRV","Croatia","2014","2014",8.2,,
+"PATCINFC","J-Antiinfectives for systemic use","ATCPTTMT","% of total sales","HRV","Croatia","2015","2015",7.8,,
+"PATCINFC","J-Antiinfectives for systemic use","ATCPTTMT","% of total sales","HRV","Croatia","2016","2016",8.4,,
+"PATCINFC","J-Antiinfectives for systemic use","ATCPTTMT","% of total sales","HRV","Croatia","2017","2017",9.9,,
+"PATCINFC","J-Antiinfectives for systemic use","ATCPTTMT","% of total sales","HRV","Croatia","2018","2018",9.1,,
+"PATCINFC","J-Antiinfectives for systemic use","ATCPTTMT","% of total sales","HRV","Croatia","2019","2019",9.3,,
+"PATCINFC","J-Antiinfectives for systemic use","ATCPTTMT","% of total sales","HRV","Croatia","2020","2020",8.5,,
+"PATCINFC","J-Antiinfectives for systemic use","ATCPTTMT","% of total sales","HRV","Croatia","2021","2021",14,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","ATCPTTMT","% of total sales","HRV","Croatia","2010","2010",2.3,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","ATCPTTMT","% of total sales","HRV","Croatia","2011","2011",2.2,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","ATCPTTMT","% of total sales","HRV","Croatia","2012","2012",2.2,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","ATCPTTMT","% of total sales","HRV","Croatia","2013","2013",2.3,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","ATCPTTMT","% of total sales","HRV","Croatia","2014","2014",2.5,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","ATCPTTMT","% of total sales","HRV","Croatia","2015","2015",2.4,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","ATCPTTMT","% of total sales","HRV","Croatia","2016","2016",2.3,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","ATCPTTMT","% of total sales","HRV","Croatia","2017","2017",2.3,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","ATCPTTMT","% of total sales","HRV","Croatia","2018","2018",2.3,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","ATCPTTMT","% of total sales","HRV","Croatia","2019","2019",2.1,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","ATCPTTMT","% of total sales","HRV","Croatia","2020","2020",2,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","ATCPTTMT","% of total sales","HRV","Croatia","2021","2021",1.3,,
+"PATCHYPN","N05C-Hypnotics and sedatives","ATCPTTMT","% of total sales","ROU","Romania","2022","2022",0,,
+"PATCCHLS","C10-Lipid modifying agents","ATCPTTMT","% of total sales","HRV","Croatia","2010","2010",5,,
+"PATCCHLS","C10-Lipid modifying agents","ATCPTTMT","% of total sales","HRV","Croatia","2011","2011",4.9,,
+"PATCCHLS","C10-Lipid modifying agents","ATCPTTMT","% of total sales","HRV","Croatia","2012","2012",4.9,,
+"PATCCHLS","C10-Lipid modifying agents","ATCPTTMT","% of total sales","HRV","Croatia","2013","2013",4.3,,
+"PATCCHLS","C10-Lipid modifying agents","ATCPTTMT","% of total sales","HRV","Croatia","2014","2014",3,,
+"PATCCHLS","C10-Lipid modifying agents","ATCPTTMT","% of total sales","HRV","Croatia","2015","2015",3.2,,
+"PATCCHLS","C10-Lipid modifying agents","ATCPTTMT","% of total sales","HRV","Croatia","2016","2016",2.5,,
+"PATCCHLS","C10-Lipid modifying agents","ATCPTTMT","% of total sales","HRV","Croatia","2017","2017",2.4,,
+"PATCCHLS","C10-Lipid modifying agents","ATCPTTMT","% of total sales","HRV","Croatia","2018","2018",2.3,,
+"PATCCHLS","C10-Lipid modifying agents","ATCPTTMT","% of total sales","HRV","Croatia","2019","2019",2.1,,
+"PATCCHLS","C10-Lipid modifying agents","ATCPTTMT","% of total sales","HRV","Croatia","2020","2020",2,,
+"PATCCHLS","C10-Lipid modifying agents","ATCPTTMT","% of total sales","HRV","Croatia","2021","2021",1.8,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","ATCPTTMT","% of total sales","HRV","Croatia","2010","2010",1.2,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","ATCPTTMT","% of total sales","HRV","Croatia","2011","2011",1.4,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","ATCPTTMT","% of total sales","HRV","Croatia","2012","2012",1.5,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","ATCPTTMT","% of total sales","HRV","Croatia","2013","2013",1.7,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","ATCPTTMT","% of total sales","HRV","Croatia","2014","2014",1.8,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","ATCPTTMT","% of total sales","HRV","Croatia","2015","2015",1.8,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","ATCPTTMT","% of total sales","HRV","Croatia","2016","2016",1.8,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","ATCPTTMT","% of total sales","HRV","Croatia","2017","2017",1.9,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","ATCPTTMT","% of total sales","HRV","Croatia","2018","2018",1.8,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","ATCPTTMT","% of total sales","HRV","Croatia","2019","2019",1.5,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","ATCPTTMT","% of total sales","HRV","Croatia","2020","2020",1.4,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","ATCPTTMT","% of total sales","HRV","Croatia","2021","2021",1.2,,
+"PATCCHLS","C10-Lipid modifying agents","ATCPTTMT","% of total sales","ROU","Romania","2022","2022",0,,
+"PATCBETA","C07-Beta blocking agents","ATCPTTMT","% of total sales","ROU","Romania","2022","2022",0,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","ATCPTTMT","% of total sales","ROU","Romania","2022","2022",0,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","ATCPTTMT","% of total sales","ROU","Romania","2022","2022",0,,
+"PATCSKEL","M-Musculo-skeletal system","ATCPTTMT","% of total sales","HRV","Croatia","2010","2010",4.4,,
+"PATCSKEL","M-Musculo-skeletal system","ATCPTTMT","% of total sales","HRV","Croatia","2011","2011",4.1,,
+"PATCSKEL","M-Musculo-skeletal system","ATCPTTMT","% of total sales","HRV","Croatia","2012","2012",4,,
+"PATCSKEL","M-Musculo-skeletal system","ATCPTTMT","% of total sales","HRV","Croatia","2013","2013",4,,
+"PATCSKEL","M-Musculo-skeletal system","ATCPTTMT","% of total sales","HRV","Croatia","2014","2014",4,,
+"PATCSKEL","M-Musculo-skeletal system","ATCPTTMT","% of total sales","HRV","Croatia","2015","2015",3.9,,
+"PATCSKEL","M-Musculo-skeletal system","ATCPTTMT","% of total sales","HRV","Croatia","2016","2016",3.7,,
+"PATCSKEL","M-Musculo-skeletal system","ATCPTTMT","% of total sales","HRV","Croatia","2017","2017",3.7,,
+"PATCSKEL","M-Musculo-skeletal system","ATCPTTMT","% of total sales","HRV","Croatia","2018","2018",4.9,,
+"PATCSKEL","M-Musculo-skeletal system","ATCPTTMT","% of total sales","HRV","Croatia","2019","2019",4.7,,
+"PATCSKEL","M-Musculo-skeletal system","ATCPTTMT","% of total sales","HRV","Croatia","2020","2020",4,,
+"PATCSKEL","M-Musculo-skeletal system","ATCPTTMT","% of total sales","HRV","Croatia","2021","2021",3.1,,
+"PATCSKEL","M-Musculo-skeletal system","ATCPTTMT","% of total sales","ROU","Romania","2022","2022",0,,
+"PATCDEPR","N06A-Antidepressants","ATCPTTMT","% of total sales","HRV","Croatia","2010","2010",1.8,,
+"PATCDEPR","N06A-Antidepressants","ATCPTTMT","% of total sales","HRV","Croatia","2011","2011",1.7,,
+"PATCDEPR","N06A-Antidepressants","ATCPTTMT","% of total sales","HRV","Croatia","2012","2012",1.7,,
+"PATCDEPR","N06A-Antidepressants","ATCPTTMT","% of total sales","HRV","Croatia","2013","2013",1.6,,
+"PATCDEPR","N06A-Antidepressants","ATCPTTMT","% of total sales","HRV","Croatia","2014","2014",1.6,,
+"PATCDEPR","N06A-Antidepressants","ATCPTTMT","% of total sales","HRV","Croatia","2015","2015",1.5,,
+"PATCDEPR","N06A-Antidepressants","ATCPTTMT","% of total sales","HRV","Croatia","2016","2016",1.4,,
+"PATCDEPR","N06A-Antidepressants","ATCPTTMT","% of total sales","HRV","Croatia","2017","2017",1.3,,
+"PATCDEPR","N06A-Antidepressants","ATCPTTMT","% of total sales","HRV","Croatia","2018","2018",1.2,,
+"PATCDEPR","N06A-Antidepressants","ATCPTTMT","% of total sales","HRV","Croatia","2019","2019",1,,
+"PATCDEPR","N06A-Antidepressants","ATCPTTMT","% of total sales","HRV","Croatia","2020","2020",0.9,,
+"PATCDEPR","N06A-Antidepressants","ATCPTTMT","% of total sales","HRV","Croatia","2021","2021",0.8,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","ATCPTTMT","% of total sales","ROU","Romania","2022","2022",0,,
+"PATCANAL","N02-Analgesics","ATCPTTMT","% of total sales","HRV","Croatia","2010","2010",3.8,,
+"PATCANAL","N02-Analgesics","ATCPTTMT","% of total sales","HRV","Croatia","2011","2011",3.8,,
+"PATCANAL","N02-Analgesics","ATCPTTMT","% of total sales","HRV","Croatia","2012","2012",3.8,,
+"PATCANAL","N02-Analgesics","ATCPTTMT","% of total sales","HRV","Croatia","2013","2013",3.6,,
+"PATCANAL","N02-Analgesics","ATCPTTMT","% of total sales","HRV","Croatia","2014","2014",3.7,,
+"PATCANAL","N02-Analgesics","ATCPTTMT","% of total sales","HRV","Croatia","2015","2015",3.6,,
+"PATCANAL","N02-Analgesics","ATCPTTMT","% of total sales","HRV","Croatia","2016","2016",3.2,,
+"PATCANAL","N02-Analgesics","ATCPTTMT","% of total sales","HRV","Croatia","2017","2017",3,,
+"PATCANAL","N02-Analgesics","ATCPTTMT","% of total sales","HRV","Croatia","2018","2018",3,,
+"PATCANAL","N02-Analgesics","ATCPTTMT","% of total sales","HRV","Croatia","2019","2019",2.8,,
+"PATCANAL","N02-Analgesics","ATCPTTMT","% of total sales","HRV","Croatia","2020","2020",2.8,,
+"PATCANAL","N02-Analgesics","ATCPTTMT","% of total sales","HRV","Croatia","2021","2021",2.4,,
+"PATCCARV","C-Cardiovascular system","ATCPTTMT","% of total sales","HRV","Croatia","2010","2010",20.2,,
+"PATCCARV","C-Cardiovascular system","ATCPTTMT","% of total sales","HRV","Croatia","2011","2011",19.4,,
+"PATCCARV","C-Cardiovascular system","ATCPTTMT","% of total sales","HRV","Croatia","2012","2012",19.8,,
+"PATCCARV","C-Cardiovascular system","ATCPTTMT","% of total sales","HRV","Croatia","2013","2013",18.3,,
+"PATCCARV","C-Cardiovascular system","ATCPTTMT","% of total sales","HRV","Croatia","2014","2014",15.5,,
+"PATCCARV","C-Cardiovascular system","ATCPTTMT","% of total sales","HRV","Croatia","2015","2015",14.8,,
+"PATCCARV","C-Cardiovascular system","ATCPTTMT","% of total sales","HRV","Croatia","2016","2016",13.4,,
+"PATCCARV","C-Cardiovascular system","ATCPTTMT","% of total sales","HRV","Croatia","2017","2017",12.8,,
+"PATCCARV","C-Cardiovascular system","ATCPTTMT","% of total sales","HRV","Croatia","2018","2018",12,,
+"PATCCARV","C-Cardiovascular system","ATCPTTMT","% of total sales","HRV","Croatia","2019","2019",10.7,,
+"PATCCARV","C-Cardiovascular system","ATCPTTMT","% of total sales","HRV","Croatia","2020","2020",10.3,,
+"PATCCARV","C-Cardiovascular system","ATCPTTMT","% of total sales","HRV","Croatia","2021","2021",8.9,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","ATCPTTMT","% of total sales","HRV","Croatia","2010","2010",4.1,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","ATCPTTMT","% of total sales","HRV","Croatia","2011","2011",3.9,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","ATCPTTMT","% of total sales","HRV","Croatia","2012","2012",4,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","ATCPTTMT","% of total sales","HRV","Croatia","2013","2013",3.1,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","ATCPTTMT","% of total sales","HRV","Croatia","2014","2014",2.5,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","ATCPTTMT","% of total sales","HRV","Croatia","2015","2015",2.2,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","ATCPTTMT","% of total sales","HRV","Croatia","2016","2016",1.9,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","ATCPTTMT","% of total sales","HRV","Croatia","2017","2017",1.9,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","ATCPTTMT","% of total sales","HRV","Croatia","2018","2018",1.8,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","ATCPTTMT","% of total sales","HRV","Croatia","2019","2019",1.7,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","ATCPTTMT","% of total sales","HRV","Croatia","2020","2020",1.4,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","ATCPTTMT","% of total sales","HRV","Croatia","2021","2021",1.3,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","ATCPTTMT","% of total sales","ROU","Romania","2022","2022",0,,
+"PATCDEPR","N06A-Antidepressants","ATCPTTMT","% of total sales","ROU","Romania","2022","2022",0,,
+"PATCCNSY","N-Nervous system","ATCPTTMT","% of total sales","HRV","Croatia","2010","2010",16.2,,
+"PATCCNSY","N-Nervous system","ATCPTTMT","% of total sales","HRV","Croatia","2011","2011",16,,
+"PATCCNSY","N-Nervous system","ATCPTTMT","% of total sales","HRV","Croatia","2012","2012",16.1,,
+"PATCCNSY","N-Nervous system","ATCPTTMT","% of total sales","HRV","Croatia","2013","2013",15.6,,
+"PATCCNSY","N-Nervous system","ATCPTTMT","% of total sales","HRV","Croatia","2014","2014",15.9,,
+"PATCCNSY","N-Nervous system","ATCPTTMT","% of total sales","HRV","Croatia","2015","2015",15.4,,
+"PATCCNSY","N-Nervous system","ATCPTTMT","% of total sales","HRV","Croatia","2016","2016",14.6,,
+"PATCCNSY","N-Nervous system","ATCPTTMT","% of total sales","HRV","Croatia","2017","2017",13.6,,
+"PATCCNSY","N-Nervous system","ATCPTTMT","% of total sales","HRV","Croatia","2018","2018",13,,
+"PATCCNSY","N-Nervous system","ATCPTTMT","% of total sales","HRV","Croatia","2019","2019",11.6,,
+"PATCCNSY","N-Nervous system","ATCPTTMT","% of total sales","HRV","Croatia","2020","2020",11,,
+"PATCCNSY","N-Nervous system","ATCPTTMT","% of total sales","HRV","Croatia","2021","2021",9.4,,
+"PATCHYPN","N05C-Hypnotics and sedatives","ATCPTTMT","% of total sales","HRV","Croatia","2010","2010",0.5,,
+"PATCHYPN","N05C-Hypnotics and sedatives","ATCPTTMT","% of total sales","HRV","Croatia","2011","2011",0.5,,
+"PATCHYPN","N05C-Hypnotics and sedatives","ATCPTTMT","% of total sales","HRV","Croatia","2012","2012",0.5,,
+"PATCHYPN","N05C-Hypnotics and sedatives","ATCPTTMT","% of total sales","HRV","Croatia","2013","2013",0.6,,
+"PATCHYPN","N05C-Hypnotics and sedatives","ATCPTTMT","% of total sales","HRV","Croatia","2014","2014",0.6,,
+"PATCHYPN","N05C-Hypnotics and sedatives","ATCPTTMT","% of total sales","HRV","Croatia","2015","2015",0.6,,
+"PATCHYPN","N05C-Hypnotics and sedatives","ATCPTTMT","% of total sales","HRV","Croatia","2016","2016",0.6,,
+"PATCHYPN","N05C-Hypnotics and sedatives","ATCPTTMT","% of total sales","HRV","Croatia","2017","2017",0.6,,
+"PATCHYPN","N05C-Hypnotics and sedatives","ATCPTTMT","% of total sales","HRV","Croatia","2018","2018",0.6,,
+"PATCHYPN","N05C-Hypnotics and sedatives","ATCPTTMT","% of total sales","HRV","Croatia","2019","2019",0.5,,
+"PATCHYPN","N05C-Hypnotics and sedatives","ATCPTTMT","% of total sales","HRV","Croatia","2020","2020",0.4,,
+"PATCHYPN","N05C-Hypnotics and sedatives","ATCPTTMT","% of total sales","HRV","Croatia","2021","2021",0.4,,
+"PATCOTHR","Products not elsewhere classified","ATCPTTMT","% of total sales","ROU","Romania","2022","2022",0.4,,
+"PATCCARV","C-Cardiovascular system","ATCPTTMT","% of total sales","ROU","Romania","2022","2022",0.1,,
+"PATCBIOT","J01-Antibacterials for systemic use","ATCPTTMT","% of total sales","HRV","Croatia","2010","2010",5.9,,
+"PATCBIOT","J01-Antibacterials for systemic use","ATCPTTMT","% of total sales","HRV","Croatia","2011","2011",5.7,,
+"PATCBIOT","J01-Antibacterials for systemic use","ATCPTTMT","% of total sales","HRV","Croatia","2012","2012",5.8,,
+"PATCBIOT","J01-Antibacterials for systemic use","ATCPTTMT","% of total sales","HRV","Croatia","2013","2013",5.7,,
+"PATCBIOT","J01-Antibacterials for systemic use","ATCPTTMT","% of total sales","HRV","Croatia","2014","2014",5.8,,
+"PATCBIOT","J01-Antibacterials for systemic use","ATCPTTMT","% of total sales","HRV","Croatia","2015","2015",5.6,,
+"PATCBIOT","J01-Antibacterials for systemic use","ATCPTTMT","% of total sales","HRV","Croatia","2016","2016",5.2,,
+"PATCBIOT","J01-Antibacterials for systemic use","ATCPTTMT","% of total sales","HRV","Croatia","2017","2017",5.1,,
+"PATCBIOT","J01-Antibacterials for systemic use","ATCPTTMT","% of total sales","HRV","Croatia","2018","2018",4.5,,
+"PATCBIOT","J01-Antibacterials for systemic use","ATCPTTMT","% of total sales","HRV","Croatia","2019","2019",3.6,,
+"PATCBIOT","J01-Antibacterials for systemic use","ATCPTTMT","% of total sales","HRV","Croatia","2020","2020",3.2,,
+"PATCBIOT","J01-Antibacterials for systemic use","ATCPTTMT","% of total sales","HRV","Croatia","2021","2021",3.1,,
+"PATCACID","A02A-Antacids","ATCPTTMT","% of total sales","HRV","Croatia","2010","2010",0.2,,
+"PATCACID","A02A-Antacids","ATCPTTMT","% of total sales","HRV","Croatia","2011","2011",0.2,,
+"PATCACID","A02A-Antacids","ATCPTTMT","% of total sales","HRV","Croatia","2012","2012",0.2,,
+"PATCACID","A02A-Antacids","ATCPTTMT","% of total sales","HRV","Croatia","2013","2013",0.2,,
+"PATCACID","A02A-Antacids","ATCPTTMT","% of total sales","HRV","Croatia","2014","2014",0.2,,
+"PATCACID","A02A-Antacids","ATCPTTMT","% of total sales","HRV","Croatia","2015","2015",0.2,,
+"PATCACID","A02A-Antacids","ATCPTTMT","% of total sales","HRV","Croatia","2016","2016",0.2,,
+"PATCACID","A02A-Antacids","ATCPTTMT","% of total sales","HRV","Croatia","2017","2017",0.1,,
+"PATCACID","A02A-Antacids","ATCPTTMT","% of total sales","HRV","Croatia","2018","2018",0.2,,
+"PATCACID","A02A-Antacids","ATCPTTMT","% of total sales","HRV","Croatia","2019","2019",0.1,,
+"PATCACID","A02A-Antacids","ATCPTTMT","% of total sales","HRV","Croatia","2020","2020",0.1,,
+"PATCACID","A02A-Antacids","ATCPTTMT","% of total sales","HRV","Croatia","2021","2021",0.1,,
+"PATCANAL","N02-Analgesics","ATCPTTMT","% of total sales","ROU","Romania","2022","2022",0,,
+"PATCHYPO","C02-Antihypertensives","ATCPTTMT","% of total sales","ROU","Romania","2022","2022",0,,
+"PATCBETA","C07-Beta blocking agents","ATCPTTMT","% of total sales","HRV","Croatia","2010","2010",1.9,,
+"PATCBETA","C07-Beta blocking agents","ATCPTTMT","% of total sales","HRV","Croatia","2011","2011",1.9,,
+"PATCBETA","C07-Beta blocking agents","ATCPTTMT","% of total sales","HRV","Croatia","2012","2012",1.9,,
+"PATCBETA","C07-Beta blocking agents","ATCPTTMT","% of total sales","HRV","Croatia","2013","2013",1.8,,
+"PATCBETA","C07-Beta blocking agents","ATCPTTMT","% of total sales","HRV","Croatia","2014","2014",1.8,,
+"PATCBETA","C07-Beta blocking agents","ATCPTTMT","% of total sales","HRV","Croatia","2015","2015",1.7,,
+"PATCBETA","C07-Beta blocking agents","ATCPTTMT","% of total sales","HRV","Croatia","2016","2016",1.5,,
+"PATCBETA","C07-Beta blocking agents","ATCPTTMT","% of total sales","HRV","Croatia","2017","2017",1.4,,
+"PATCBETA","C07-Beta blocking agents","ATCPTTMT","% of total sales","HRV","Croatia","2018","2018",1.4,,
+"PATCBETA","C07-Beta blocking agents","ATCPTTMT","% of total sales","HRV","Croatia","2019","2019",1.2,,
+"PATCBETA","C07-Beta blocking agents","ATCPTTMT","% of total sales","HRV","Croatia","2020","2020",1.1,,
+"PATCBETA","C07-Beta blocking agents","ATCPTTMT","% of total sales","HRV","Croatia","2021","2021",1,,
+"PATCGENU","G-Genito urinary system and sex hormones","ATCPTTMT","% of total sales","ROU","Romania","2022","2022",0,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","ATCPTTMT","% of total sales","HRV","Croatia","2010","2010",3.8,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","ATCPTTMT","% of total sales","HRV","Croatia","2011","2011",3.9,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","ATCPTTMT","% of total sales","HRV","Croatia","2012","2012",4,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","ATCPTTMT","% of total sales","HRV","Croatia","2013","2013",4,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","ATCPTTMT","% of total sales","HRV","Croatia","2014","2014",4.2,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","ATCPTTMT","% of total sales","HRV","Croatia","2015","2015",4.1,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","ATCPTTMT","% of total sales","HRV","Croatia","2016","2016",3.8,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","ATCPTTMT","% of total sales","HRV","Croatia","2017","2017",3.6,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","ATCPTTMT","% of total sales","HRV","Croatia","2018","2018",3.3,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","ATCPTTMT","% of total sales","HRV","Croatia","2019","2019",2.9,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","ATCPTTMT","% of total sales","HRV","Croatia","2020","2020",2.7,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","ATCPTTMT","% of total sales","HRV","Croatia","2021","2021",2.2,,
+"PATCCCBR","C08-Calcium channel blockers","ATCPTTMT","% of total sales","ROU","Romania","2022","2022",0,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","ATCPTTMT","% of total sales","HRV","Croatia","2010","2010",0.4,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","ATCPTTMT","% of total sales","HRV","Croatia","2011","2011",0.4,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","ATCPTTMT","% of total sales","HRV","Croatia","2012","2012",0.3,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","ATCPTTMT","% of total sales","HRV","Croatia","2013","2013",0.3,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","ATCPTTMT","% of total sales","HRV","Croatia","2014","2014",0.3,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","ATCPTTMT","% of total sales","HRV","Croatia","2015","2015",0.3,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","ATCPTTMT","% of total sales","HRV","Croatia","2016","2016",0.3,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","ATCPTTMT","% of total sales","HRV","Croatia","2017","2017",0.3,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","ATCPTTMT","% of total sales","HRV","Croatia","2018","2018",0.2,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","ATCPTTMT","% of total sales","HRV","Croatia","2019","2019",0.2,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","ATCPTTMT","% of total sales","HRV","Croatia","2020","2020",0.2,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","ATCPTTMT","% of total sales","HRV","Croatia","2021","2021",0.1,,
+"PATCBLOO","B-Blood and blood forming organs","ATCPTTMT","% of total sales","HRV","Croatia","2010","2010",5.5,,
+"PATCBLOO","B-Blood and blood forming organs","ATCPTTMT","% of total sales","HRV","Croatia","2011","2011",5.1,,
+"PATCBLOO","B-Blood and blood forming organs","ATCPTTMT","% of total sales","HRV","Croatia","2012","2012",5.6,,
+"PATCBLOO","B-Blood and blood forming organs","ATCPTTMT","% of total sales","HRV","Croatia","2013","2013",5.5,,
+"PATCBLOO","B-Blood and blood forming organs","ATCPTTMT","% of total sales","HRV","Croatia","2014","2014",6.1,,
+"PATCBLOO","B-Blood and blood forming organs","ATCPTTMT","% of total sales","HRV","Croatia","2015","2015",6.7,,
+"PATCBLOO","B-Blood and blood forming organs","ATCPTTMT","% of total sales","HRV","Croatia","2016","2016",7.7,,
+"PATCBLOO","B-Blood and blood forming organs","ATCPTTMT","% of total sales","HRV","Croatia","2017","2017",8.1,,
+"PATCBLOO","B-Blood and blood forming organs","ATCPTTMT","% of total sales","HRV","Croatia","2018","2018",7.8,,
+"PATCBLOO","B-Blood and blood forming organs","ATCPTTMT","% of total sales","HRV","Croatia","2019","2019",8.1,,
+"PATCBLOO","B-Blood and blood forming organs","ATCPTTMT","% of total sales","HRV","Croatia","2020","2020",8,,
+"PATCBLOO","B-Blood and blood forming organs","ATCPTTMT","% of total sales","HRV","Croatia","2021","2021",7.9,,
+"PATCINFC","J-Antiinfectives for systemic use","ATCPTTMT","% of total sales","ROU","Romania","2022","2022",0.1,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","ATCPTTMT","% of total sales","ROU","Romania","2022","2022",0,,
+"PATCRESS","R-Respiratory system","ATCPTTMT","% of total sales","HRV","Croatia","2010","2010",7,,
+"PATCRESS","R-Respiratory system","ATCPTTMT","% of total sales","HRV","Croatia","2011","2011",6.6,,
+"PATCRESS","R-Respiratory system","ATCPTTMT","% of total sales","HRV","Croatia","2012","2012",6.4,,
+"PATCRESS","R-Respiratory system","ATCPTTMT","% of total sales","HRV","Croatia","2013","2013",6.4,,
+"PATCRESS","R-Respiratory system","ATCPTTMT","% of total sales","HRV","Croatia","2014","2014",6.5,,
+"PATCRESS","R-Respiratory system","ATCPTTMT","% of total sales","HRV","Croatia","2015","2015",6.6,,
+"PATCRESS","R-Respiratory system","ATCPTTMT","% of total sales","HRV","Croatia","2016","2016",6.2,,
+"PATCRESS","R-Respiratory system","ATCPTTMT","% of total sales","HRV","Croatia","2017","2017",5.8,,
+"PATCRESS","R-Respiratory system","ATCPTTMT","% of total sales","HRV","Croatia","2018","2018",5.8,,
+"PATCRESS","R-Respiratory system","ATCPTTMT","% of total sales","HRV","Croatia","2019","2019",5.5,,
+"PATCRESS","R-Respiratory system","ATCPTTMT","% of total sales","HRV","Croatia","2020","2020",4.9,,
+"PATCRESS","R-Respiratory system","ATCPTTMT","% of total sales","HRV","Croatia","2021","2021",4.2,,
+"PATCDIUR","C03-Diuretics","ATCPTTMT","% of total sales","HRV","Croatia","2010","2010",0.8,,
+"PATCDIUR","C03-Diuretics","ATCPTTMT","% of total sales","HRV","Croatia","2011","2011",0.8,,
+"PATCDIUR","C03-Diuretics","ATCPTTMT","% of total sales","HRV","Croatia","2012","2012",0.8,,
+"PATCDIUR","C03-Diuretics","ATCPTTMT","% of total sales","HRV","Croatia","2013","2013",0.8,,
+"PATCDIUR","C03-Diuretics","ATCPTTMT","% of total sales","HRV","Croatia","2014","2014",0.9,,
+"PATCDIUR","C03-Diuretics","ATCPTTMT","% of total sales","HRV","Croatia","2015","2015",0.9,,
+"PATCDIUR","C03-Diuretics","ATCPTTMT","% of total sales","HRV","Croatia","2016","2016",0.9,,
+"PATCDIUR","C03-Diuretics","ATCPTTMT","% of total sales","HRV","Croatia","2017","2017",0.9,,
+"PATCDIUR","C03-Diuretics","ATCPTTMT","% of total sales","HRV","Croatia","2018","2018",0.8,,
+"PATCDIUR","C03-Diuretics","ATCPTTMT","% of total sales","HRV","Croatia","2019","2019",0.7,,
+"PATCDIUR","C03-Diuretics","ATCPTTMT","% of total sales","HRV","Croatia","2020","2020",0.7,,
+"PATCDIUR","C03-Diuretics","ATCPTTMT","% of total sales","HRV","Croatia","2021","2021",0.6,,
+"PATCALIM","A-Alimentary tract and metabolism","ATCPTTMT","% of total sales","ROU","Romania","2022","2022",0.2,,
+"PATCGLYC","C01A-Cardiac glycosides","ATCPTTMT","% of total sales","HRV","Croatia","2010","2010",0.1,,
+"PATCGLYC","C01A-Cardiac glycosides","ATCPTTMT","% of total sales","HRV","Croatia","2011","2011",0.1,,
+"PATCGLYC","C01A-Cardiac glycosides","ATCPTTMT","% of total sales","HRV","Croatia","2012","2012",0.1,,
+"PATCGLYC","C01A-Cardiac glycosides","ATCPTTMT","% of total sales","HRV","Croatia","2013","2013",0.1,,
+"PATCGLYC","C01A-Cardiac glycosides","ATCPTTMT","% of total sales","HRV","Croatia","2014","2014",0.1,,
+"PATCGLYC","C01A-Cardiac glycosides","ATCPTTMT","% of total sales","HRV","Croatia","2015","2015",0.1,,
+"PATCGLYC","C01A-Cardiac glycosides","ATCPTTMT","% of total sales","HRV","Croatia","2016","2016",0.1,,
+"PATCGLYC","C01A-Cardiac glycosides","ATCPTTMT","% of total sales","HRV","Croatia","2017","2017",0.1,,
+"PATCGLYC","C01A-Cardiac glycosides","ATCPTTMT","% of total sales","HRV","Croatia","2018","2018",0.1,,
+"PATCGLYC","C01A-Cardiac glycosides","ATCPTTMT","% of total sales","HRV","Croatia","2019","2019",0.1,,
+"PATCGLYC","C01A-Cardiac glycosides","ATCPTTMT","% of total sales","HRV","Croatia","2020","2020",0,,
+"PATCGLYC","C01A-Cardiac glycosides","ATCPTTMT","% of total sales","HRV","Croatia","2021","2021",0,,
+"PATCANXO","N05B-Anxiolytics","ATCPTTMT","% of total sales","HRV","Croatia","2010","2010",1.8,,
+"PATCANXO","N05B-Anxiolytics","ATCPTTMT","% of total sales","HRV","Croatia","2011","2011",1.7,,
+"PATCANXO","N05B-Anxiolytics","ATCPTTMT","% of total sales","HRV","Croatia","2012","2012",1.8,,
+"PATCANXO","N05B-Anxiolytics","ATCPTTMT","% of total sales","HRV","Croatia","2013","2013",1.7,,
+"PATCANXO","N05B-Anxiolytics","ATCPTTMT","% of total sales","HRV","Croatia","2014","2014",1.8,,
+"PATCANXO","N05B-Anxiolytics","ATCPTTMT","% of total sales","HRV","Croatia","2015","2015",1.7,,
+"PATCANXO","N05B-Anxiolytics","ATCPTTMT","% of total sales","HRV","Croatia","2016","2016",1.6,,
+"PATCANXO","N05B-Anxiolytics","ATCPTTMT","% of total sales","HRV","Croatia","2017","2017",1.5,,
+"PATCANXO","N05B-Anxiolytics","ATCPTTMT","% of total sales","HRV","Croatia","2018","2018",1.4,,
+"PATCANXO","N05B-Anxiolytics","ATCPTTMT","% of total sales","HRV","Croatia","2019","2019",1.2,,
+"PATCANXO","N05B-Anxiolytics","ATCPTTMT","% of total sales","HRV","Croatia","2020","2020",1.1,,
+"PATCANXO","N05B-Anxiolytics","ATCPTTMT","% of total sales","HRV","Croatia","2021","2021",0.9,,
+"PATCANXO","N05B-Anxiolytics","ATCPTTMT","% of total sales","ROU","Romania","2022","2022",0,,
+"PATCDIAB","A10-Drugs used in diabetes","ATCPTTMT","% of total sales","HRV","Croatia","2010","2010",5,,
+"PATCDIAB","A10-Drugs used in diabetes","ATCPTTMT","% of total sales","HRV","Croatia","2011","2011",5.1,,
+"PATCDIAB","A10-Drugs used in diabetes","ATCPTTMT","% of total sales","HRV","Croatia","2012","2012",5.5,,
+"PATCDIAB","A10-Drugs used in diabetes","ATCPTTMT","% of total sales","HRV","Croatia","2013","2013",5.8,,
+"PATCDIAB","A10-Drugs used in diabetes","ATCPTTMT","% of total sales","HRV","Croatia","2014","2014",6.3,,
+"PATCDIAB","A10-Drugs used in diabetes","ATCPTTMT","% of total sales","HRV","Croatia","2015","2015",6.5,,
+"PATCDIAB","A10-Drugs used in diabetes","ATCPTTMT","% of total sales","HRV","Croatia","2016","2016",6.7,,
+"PATCDIAB","A10-Drugs used in diabetes","ATCPTTMT","% of total sales","HRV","Croatia","2017","2017",6.7,,
+"PATCDIAB","A10-Drugs used in diabetes","ATCPTTMT","% of total sales","HRV","Croatia","2018","2018",6.3,,
+"PATCDIAB","A10-Drugs used in diabetes","ATCPTTMT","% of total sales","HRV","Croatia","2019","2019",5.6,,
+"PATCDIAB","A10-Drugs used in diabetes","ATCPTTMT","% of total sales","HRV","Croatia","2020","2020",5.4,,
+"PATCDIAB","A10-Drugs used in diabetes","ATCPTTMT","% of total sales","HRV","Croatia","2021","2021",4.9,,
+"PATCDIAB","A10-Drugs used in diabetes","ATCPTTMT","% of total sales","ROU","Romania","2022","2022",0.2,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","ATCPTTMT","% of total sales","HRV","Croatia","2010","2010",1.3,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","ATCPTTMT","% of total sales","HRV","Croatia","2011","2011",1.2,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","ATCPTTMT","% of total sales","HRV","Croatia","2012","2012",1.2,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","ATCPTTMT","% of total sales","HRV","Croatia","2013","2013",1.2,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","ATCPTTMT","% of total sales","HRV","Croatia","2014","2014",1.2,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","ATCPTTMT","% of total sales","HRV","Croatia","2015","2015",1.2,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","ATCPTTMT","% of total sales","HRV","Croatia","2016","2016",1.1,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","ATCPTTMT","% of total sales","HRV","Croatia","2017","2017",1,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","ATCPTTMT","% of total sales","HRV","Croatia","2018","2018",1,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","ATCPTTMT","% of total sales","HRV","Croatia","2019","2019",0.8,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","ATCPTTMT","% of total sales","HRV","Croatia","2020","2020",0.7,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","ATCPTTMT","% of total sales","HRV","Croatia","2021","2021",0.6,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","ATCPTTMT","% of total sales","HRV","Croatia","2010","2010",7,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","ATCPTTMT","% of total sales","HRV","Croatia","2011","2011",6.9,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","ATCPTTMT","% of total sales","HRV","Croatia","2012","2012",7.1,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","ATCPTTMT","% of total sales","HRV","Croatia","2013","2013",6.3,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","ATCPTTMT","% of total sales","HRV","Croatia","2014","2014",6.5,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","ATCPTTMT","% of total sales","HRV","Croatia","2015","2015",6,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","ATCPTTMT","% of total sales","HRV","Croatia","2016","2016",5.6,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","ATCPTTMT","% of total sales","HRV","Croatia","2017","2017",5.1,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","ATCPTTMT","% of total sales","HRV","Croatia","2018","2018",4.6,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","ATCPTTMT","% of total sales","HRV","Croatia","2019","2019",4,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","ATCPTTMT","% of total sales","HRV","Croatia","2020","2020",3.9,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","ATCPTTMT","% of total sales","HRV","Croatia","2021","2021",3.4,,
+"PATCDIUR","C03-Diuretics","ATCPTTMT","% of total sales","ROU","Romania","2022","2022",0,,
+"PATCRESS","R-Respiratory system","ATCPTTMT","% of total sales","ROU","Romania","2022","2022",0,,
+"PATCGLYC","C01A-Cardiac glycosides","ATCPTTMT","% of total sales","ROU","Romania","2022","2022",0,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","TCPPERMT","/capita, US$ exchange rate","ROU","Romania","2022","2022",3.2,,
+"PATCTOTT","Total pharmaceutical sales","MLLNCUMT","Million of national currency units","ROU","Romania","2022","2022",1338515.2,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2010","2010",83.8,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2011","2011",91.9,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2012","2012",96.8,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2013","2013",101.5,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2014","2014",105.9,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2015","2015",110.6,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2016","2016",116.9,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2017","2017",120.7,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2018","2018",122.9,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2019","2019",128.5,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2020","2020",133,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2021","2021",130,,
+"PATCBETA","C07-Beta blocking agents","MTMOTCMT","Million US$ at exchange rate","ROU","Romania","2022","2022",32.8,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","TCPPERMT","/capita, US$ exchange rate","ROU","Romania","2022","2022",0.2,,
+"PATCHYPN","N05C-Hypnotics and sedatives","TCPPERMT","/capita, US$ exchange rate","ROU","Romania","2022","2022",0.2,,
+"PATCCNSY","N-Nervous system","TCPPERMT","/capita, US$ exchange rate","ROU","Romania","2022","2022",13.7,,
+"PATCALIM","A-Alimentary tract and metabolism","TCPPERMT","/capita, US$ exchange rate","HRV","Croatia","2010","2010",204.1,,
+"PATCALIM","A-Alimentary tract and metabolism","TCPPERMT","/capita, US$ exchange rate","HRV","Croatia","2011","2011",227.1,,
+"PATCALIM","A-Alimentary tract and metabolism","TCPPERMT","/capita, US$ exchange rate","HRV","Croatia","2012","2012",213.6,,
+"PATCALIM","A-Alimentary tract and metabolism","TCPPERMT","/capita, US$ exchange rate","HRV","Croatia","2013","2013",221.3,,
+"PATCALIM","A-Alimentary tract and metabolism","TCPPERMT","/capita, US$ exchange rate","HRV","Croatia","2014","2014",214.1,,
+"PATCALIM","A-Alimentary tract and metabolism","TCPPERMT","/capita, US$ exchange rate","HRV","Croatia","2015","2015",188,,
+"PATCALIM","A-Alimentary tract and metabolism","TCPPERMT","/capita, US$ exchange rate","HRV","Croatia","2016","2016",205.4,,
+"PATCALIM","A-Alimentary tract and metabolism","TCPPERMT","/capita, US$ exchange rate","HRV","Croatia","2017","2017",220.1,,
+"PATCALIM","A-Alimentary tract and metabolism","TCPPERMT","/capita, US$ exchange rate","HRV","Croatia","2018","2018",242,,
+"PATCALIM","A-Alimentary tract and metabolism","TCPPERMT","/capita, US$ exchange rate","HRV","Croatia","2019","2019",248.7,,
+"PATCALIM","A-Alimentary tract and metabolism","TCPPERMT","/capita, US$ exchange rate","HRV","Croatia","2020","2020",250.8,,
+"PATCALIM","A-Alimentary tract and metabolism","TCPPERMT","/capita, US$ exchange rate","HRV","Croatia","2021","2021",275,,
+"PATCGLYC","C01A-Cardiac glycosides","MTMOTCMT","Million US$ at exchange rate","HRV","Croatia","2010","2010",6.9,,
+"PATCGLYC","C01A-Cardiac glycosides","MTMOTCMT","Million US$ at exchange rate","HRV","Croatia","2011","2011",5.6,,
+"PATCGLYC","C01A-Cardiac glycosides","MTMOTCMT","Million US$ at exchange rate","HRV","Croatia","2012","2012",6.4,,
+"PATCGLYC","C01A-Cardiac glycosides","MTMOTCMT","Million US$ at exchange rate","HRV","Croatia","2013","2013",5.3,,
+"PATCGLYC","C01A-Cardiac glycosides","MTMOTCMT","Million US$ at exchange rate","HRV","Croatia","2014","2014",6.6,,
+"PATCGLYC","C01A-Cardiac glycosides","MTMOTCMT","Million US$ at exchange rate","HRV","Croatia","2015","2015",5.5,,
+"PATCGLYC","C01A-Cardiac glycosides","MTMOTCMT","Million US$ at exchange rate","HRV","Croatia","2016","2016",5.5,,
+"PATCGLYC","C01A-Cardiac glycosides","MTMOTCMT","Million US$ at exchange rate","HRV","Croatia","2017","2017",5.7,,
+"PATCGLYC","C01A-Cardiac glycosides","MTMOTCMT","Million US$ at exchange rate","HRV","Croatia","2018","2018",6,,
+"PATCGLYC","C01A-Cardiac glycosides","MTMOTCMT","Million US$ at exchange rate","HRV","Croatia","2019","2019",5.7,,
+"PATCGLYC","C01A-Cardiac glycosides","MTMOTCMT","Million US$ at exchange rate","HRV","Croatia","2020","2020",4.6,,
+"PATCGLYC","C01A-Cardiac glycosides","MTMOTCMT","Million US$ at exchange rate","HRV","Croatia","2021","2021",3.6,,
+"PATCINFC","J-Antiinfectives for systemic use","MTMOPPMT","Million US$, purchasing power parity","ROU","Romania","2022","2022",609.1,,
+"PATCANAL","N02-Analgesics","MLLNCUMT","Million of national currency units","ROU","Romania","2022","2022",126.7,,
+"PATCINFC","J-Antiinfectives for systemic use","TCPPERMT","/capita, US$ exchange rate","HRV","Croatia","2010","2010",151.8,,
+"PATCINFC","J-Antiinfectives for systemic use","TCPPERMT","/capita, US$ exchange rate","HRV","Croatia","2011","2011",152.4,,
+"PATCINFC","J-Antiinfectives for systemic use","TCPPERMT","/capita, US$ exchange rate","HRV","Croatia","2012","2012",129.1,,
+"PATCINFC","J-Antiinfectives for systemic use","TCPPERMT","/capita, US$ exchange rate","HRV","Croatia","2013","2013",133.2,,
+"PATCINFC","J-Antiinfectives for systemic use","TCPPERMT","/capita, US$ exchange rate","HRV","Croatia","2014","2014",126.2,,
+"PATCINFC","J-Antiinfectives for systemic use","TCPPERMT","/capita, US$ exchange rate","HRV","Croatia","2015","2015",107.3,,
+"PATCINFC","J-Antiinfectives for systemic use","TCPPERMT","/capita, US$ exchange rate","HRV","Croatia","2016","2016",129.2,,
+"PATCINFC","J-Antiinfectives for systemic use","TCPPERMT","/capita, US$ exchange rate","HRV","Croatia","2017","2017",167.7,,
+"PATCINFC","J-Antiinfectives for systemic use","TCPPERMT","/capita, US$ exchange rate","HRV","Croatia","2018","2018",177.2,,
+"PATCINFC","J-Antiinfectives for systemic use","TCPPERMT","/capita, US$ exchange rate","HRV","Croatia","2019","2019",199.7,,
+"PATCINFC","J-Antiinfectives for systemic use","TCPPERMT","/capita, US$ exchange rate","HRV","Croatia","2020","2020",201,,
+"PATCINFC","J-Antiinfectives for systemic use","TCPPERMT","/capita, US$ exchange rate","HRV","Croatia","2021","2021",414.5,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOTCMT","Million US$ at exchange rate","HRV","Croatia","2010","2010",467.3,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOTCMT","Million US$ at exchange rate","HRV","Croatia","2011","2011",494.9,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOTCMT","Million US$ at exchange rate","HRV","Croatia","2012","2012",462.4,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOTCMT","Million US$ at exchange rate","HRV","Croatia","2013","2013",430.6,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOTCMT","Million US$ at exchange rate","HRV","Croatia","2014","2014",423.4,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOTCMT","Million US$ at exchange rate","HRV","Croatia","2015","2015",349.4,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOTCMT","Million US$ at exchange rate","HRV","Croatia","2016","2016",362,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOTCMT","Million US$ at exchange rate","HRV","Croatia","2017","2017",358.3,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOTCMT","Million US$ at exchange rate","HRV","Croatia","2018","2018",369.6,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOTCMT","Million US$ at exchange rate","HRV","Croatia","2019","2019",348.1,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOTCMT","Million US$ at exchange rate","HRV","Croatia","2020","2020",369.1,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOTCMT","Million US$ at exchange rate","HRV","Croatia","2021","2021",401.6,,
+"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2010","2010",120.9,,
+"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2011","2011",121.4,,
+"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2012","2012",135.8,,
+"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2013","2013",142.2,,
+"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2014","2014",152.1,,
+"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2015","2015",181,,
+"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2016","2016",238.1,,
+"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2017","2017",272.2,,
+"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2018","2018",287,,
+"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2019","2019",356.2,,
+"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2020","2020",396.1,,
+"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2021","2021",456,,
+"PATCBLOO","B-Blood and blood forming organs","TCPPERMT","/capita, US$ exchange rate","ROU","Romania","2022","2022",11.3,,
+"PATCCHLS","C10-Lipid modifying agents","MTMOTCMT","Million US$ at exchange rate","ROU","Romania","2022","2022",55.9,,
+"PATCCHLS","C10-Lipid modifying agents","MTMOPPMT","Million US$, purchasing power parity","HRV","Croatia","2010","2010",470.7,,
+"PATCCHLS","C10-Lipid modifying agents","MTMOPPMT","Million US$, purchasing power parity","HRV","Croatia","2011","2011",501.9,,
+"PATCCHLS","C10-Lipid modifying agents","MTMOPPMT","Million US$, purchasing power parity","HRV","Croatia","2012","2012",507.9,,
+"PATCCHLS","C10-Lipid modifying agents","MTMOPPMT","Million US$, purchasing power parity","HRV","Croatia","2013","2013",472.1,,
+"PATCCHLS","C10-Lipid modifying agents","MTMOPPMT","Million US$, purchasing power parity","HRV","Croatia","2014","2014",314.7,,
+"PATCCHLS","C10-Lipid modifying agents","MTMOPPMT","Million US$, purchasing power parity","HRV","Croatia","2015","2015",356.1,,
+"PATCCHLS","C10-Lipid modifying agents","MTMOPPMT","Million US$, purchasing power parity","HRV","Croatia","2016","2016",327.5,,
+"PATCCHLS","C10-Lipid modifying agents","MTMOPPMT","Million US$, purchasing power parity","HRV","Croatia","2017","2017",337.7,,
+"PATCCHLS","C10-Lipid modifying agents","MTMOPPMT","Million US$, purchasing power parity","HRV","Croatia","2018","2018",352.7,,
+"PATCCHLS","C10-Lipid modifying agents","MTMOPPMT","Million US$, purchasing power parity","HRV","Croatia","2019","2019",370.3,,
+"PATCCHLS","C10-Lipid modifying agents","MTMOPPMT","Million US$, purchasing power parity","HRV","Croatia","2020","2020",395.4,,
+"PATCCHLS","C10-Lipid modifying agents","MTMOPPMT","Million US$, purchasing power parity","HRV","Croatia","2021","2021",400.2,,
+"PATCDIAB","A10-Drugs used in diabetes","TCPPERMT","/capita, US$ exchange rate","HRV","Croatia","2010","2010",76.9,,
+"PATCDIAB","A10-Drugs used in diabetes","TCPPERMT","/capita, US$ exchange rate","HRV","Croatia","2011","2011",85.3,,
+"PATCDIAB","A10-Drugs used in diabetes","TCPPERMT","/capita, US$ exchange rate","HRV","Croatia","2012","2012",83.9,,
+"PATCDIAB","A10-Drugs used in diabetes","TCPPERMT","/capita, US$ exchange rate","HRV","Croatia","2013","2013",93.7,,
+"PATCDIAB","A10-Drugs used in diabetes","TCPPERMT","/capita, US$ exchange rate","HRV","Croatia","2014","2014",98.1,,
+"PATCDIAB","A10-Drugs used in diabetes","TCPPERMT","/capita, US$ exchange rate","HRV","Croatia","2015","2015",89.8,,
+"PATCDIAB","A10-Drugs used in diabetes","TCPPERMT","/capita, US$ exchange rate","HRV","Croatia","2016","2016",102.4,,
+"PATCDIAB","A10-Drugs used in diabetes","TCPPERMT","/capita, US$ exchange rate","HRV","Croatia","2017","2017",112.4,,
+"PATCDIAB","A10-Drugs used in diabetes","TCPPERMT","/capita, US$ exchange rate","HRV","Croatia","2018","2018",121.7,,
+"PATCDIAB","A10-Drugs used in diabetes","TCPPERMT","/capita, US$ exchange rate","HRV","Croatia","2019","2019",120.8,,
+"PATCDIAB","A10-Drugs used in diabetes","TCPPERMT","/capita, US$ exchange rate","HRV","Croatia","2020","2020",128.9,,
+"PATCDIAB","A10-Drugs used in diabetes","TCPPERMT","/capita, US$ exchange rate","HRV","Croatia","2021","2021",144.9,,
+"PATCDIUR","C03-Diuretics","MTMOTCMT","Million US$ at exchange rate","HRV","Croatia","2010","2010",53.4,,
+"PATCDIUR","C03-Diuretics","MTMOTCMT","Million US$ at exchange rate","HRV","Croatia","2011","2011",57.8,,
+"PATCDIUR","C03-Diuretics","MTMOTCMT","Million US$ at exchange rate","HRV","Croatia","2012","2012",55.4,,
+"PATCDIUR","C03-Diuretics","MTMOTCMT","Million US$ at exchange rate","HRV","Croatia","2013","2013",58.1,,
+"PATCDIUR","C03-Diuretics","MTMOTCMT","Million US$ at exchange rate","HRV","Croatia","2014","2014",59,,
+"PATCDIUR","C03-Diuretics","MTMOTCMT","Million US$ at exchange rate","HRV","Croatia","2015","2015",52.7,,
+"PATCDIUR","C03-Diuretics","MTMOTCMT","Million US$ at exchange rate","HRV","Croatia","2016","2016",57.6,,
+"PATCDIUR","C03-Diuretics","MTMOTCMT","Million US$ at exchange rate","HRV","Croatia","2017","2017",60.3,,
+"PATCDIUR","C03-Diuretics","MTMOTCMT","Million US$ at exchange rate","HRV","Croatia","2018","2018",66,,
+"PATCDIUR","C03-Diuretics","MTMOTCMT","Million US$ at exchange rate","HRV","Croatia","2019","2019",63.7,,
+"PATCDIUR","C03-Diuretics","MTMOTCMT","Million US$ at exchange rate","HRV","Croatia","2020","2020",71.8,,
+"PATCDIUR","C03-Diuretics","MTMOTCMT","Million US$ at exchange rate","HRV","Croatia","2021","2021",75.8,,
+"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2010","2010",4.1,,
+"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2011","2011",4.2,,
+"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2012","2012",3.9,,
+"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2013","2013",4.5,,
+"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2014","2014",5,,
+"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2015","2015",5.1,,
+"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2016","2016",5.3,,
+"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2017","2017",4.9,,
+"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2018","2018",5.6,,
+"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2019","2019",5.8,,
+"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2020","2020",5.9,,
+"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2021","2021",4.1,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOPPMT","Million US$, purchasing power parity","HRV","Croatia","2010","2010",116.7,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOPPMT","Million US$, purchasing power parity","HRV","Croatia","2011","2011",140.5,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOPPMT","Million US$, purchasing power parity","HRV","Croatia","2012","2012",154.2,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOPPMT","Million US$, purchasing power parity","HRV","Croatia","2013","2013",187.6,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOPPMT","Million US$, purchasing power parity","HRV","Croatia","2014","2014",191.4,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOPPMT","Million US$, purchasing power parity","HRV","Croatia","2015","2015",208.1,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOPPMT","Million US$, purchasing power parity","HRV","Croatia","2016","2016",233.9,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOPPMT","Million US$, purchasing power parity","HRV","Croatia","2017","2017",258.4,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOPPMT","Million US$, purchasing power parity","HRV","Croatia","2018","2018",268.5,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOPPMT","Million US$, purchasing power parity","HRV","Croatia","2019","2019",269.6,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOPPMT","Million US$, purchasing power parity","HRV","Croatia","2020","2020",273.9,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOPPMT","Million US$, purchasing power parity","HRV","Croatia","2021","2021",279.3,,
+"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","ROU","Romania","2022","2022",2.7,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOTCMT","Million US$ at exchange rate","ROU","Romania","2022","2022",35.2,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOPPMT","Million US$, purchasing power parity","ROU","Romania","2022","2022",63.1,,
+"PATCSKEL","M-Musculo-skeletal system","MLLNCUMT","Million of national currency units","ROU","Romania","2022","2022",378.3,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","TCPPERMT","/capita, US$ exchange rate","HRV","Croatia","2010","2010",35.4,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","TCPPERMT","/capita, US$ exchange rate","HRV","Croatia","2011","2011",36.2,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","TCPPERMT","/capita, US$ exchange rate","HRV","Croatia","2012","2012",34.1,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","TCPPERMT","/capita, US$ exchange rate","HRV","Croatia","2013","2013",36.6,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","TCPPERMT","/capita, US$ exchange rate","HRV","Croatia","2014","2014",39,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","TCPPERMT","/capita, US$ exchange rate","HRV","Croatia","2015","2015",33.7,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","TCPPERMT","/capita, US$ exchange rate","HRV","Croatia","2016","2016",35,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","TCPPERMT","/capita, US$ exchange rate","HRV","Croatia","2017","2017",38.3,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","TCPPERMT","/capita, US$ exchange rate","HRV","Croatia","2018","2018",44.6,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","TCPPERMT","/capita, US$ exchange rate","HRV","Croatia","2019","2019",45.6,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","TCPPERMT","/capita, US$ exchange rate","HRV","Croatia","2020","2020",47,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","TCPPERMT","/capita, US$ exchange rate","HRV","Croatia","2021","2021",39.9,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2010","2010",8.1,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2011","2011",8.9,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2012","2012",8.2,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2013","2013",8.9,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2014","2014",8,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2015","2015",8.7,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2016","2016",8.5,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2017","2017",8.8,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2018","2018",8.3,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2019","2019",8.1,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2020","2020",7.7,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2021","2021",7.6,,
+"PATCGENU","G-Genito urinary system and sex hormones","MLLNCUMT","Million of national currency units","HRV","Croatia","2010","2010",163,,
+"PATCGENU","G-Genito urinary system and sex hormones","MLLNCUMT","Million of national currency units","HRV","Croatia","2011","2011",166,,
+"PATCGENU","G-Genito urinary system and sex hormones","MLLNCUMT","Million of national currency units","HRV","Croatia","2012","2012",163,,
+"PATCGENU","G-Genito urinary system and sex hormones","MLLNCUMT","Million of national currency units","HRV","Croatia","2013","2013",161,,
+"PATCGENU","G-Genito urinary system and sex hormones","MLLNCUMT","Million of national currency units","HRV","Croatia","2014","2014",160,,
+"PATCGENU","G-Genito urinary system and sex hormones","MLLNCUMT","Million of national currency units","HRV","Croatia","2015","2015",165,,
+"PATCGENU","G-Genito urinary system and sex hormones","MLLNCUMT","Million of national currency units","HRV","Croatia","2016","2016",172,,
+"PATCGENU","G-Genito urinary system and sex hormones","MLLNCUMT","Million of national currency units","HRV","Croatia","2017","2017",179,,
+"PATCGENU","G-Genito urinary system and sex hormones","MLLNCUMT","Million of national currency units","HRV","Croatia","2018","2018",186,,
+"PATCGENU","G-Genito urinary system and sex hormones","MLLNCUMT","Million of national currency units","HRV","Croatia","2019","2019",196,,
+"PATCGENU","G-Genito urinary system and sex hormones","MLLNCUMT","Million of national currency units","HRV","Croatia","2020","2020",197,,
+"PATCGENU","G-Genito urinary system and sex hormones","MLLNCUMT","Million of national currency units","HRV","Croatia","2021","2021",199.9,,
+"PATCACID","A02A-Antacids","TCPPERMT","/capita, US$ exchange rate","ROU","Romania","2022","2022",0,,
+"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2010","2010",10.4,,
+"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2011","2011",11.3,,
+"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2012","2012",12.5,,
+"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2013","2013",14.4,,
+"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2014","2014",15.1,,
+"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2015","2015",15.8,,
+"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2016","2016",17.6,,
+"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2017","2017",19.2,,
+"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2018","2018",20.6,,
+"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2019","2019",20.2,,
+"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2020","2020",18.8,,
+"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2021","2021",24,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MLLNCUMT","Million of national currency units","ROU","Romania","2022","2022",175.5,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MLLNCUMT","Million of national currency units","ROU","Romania","2022","2022",165.1,,
+"PATCOTHR","Products not elsewhere classified","PPPPERMT","/capita, US$ purchasing power parity","ROU","Romania","2022","2022",143.2,,
+"PATCALIM","A-Alimentary tract and metabolism","MTMOPPMT","Million US$, purchasing power parity","ROU","Romania","2022","2022",1583.2,,
+"PATCANXO","N05B-Anxiolytics","TCPPERMT","/capita, US$ exchange rate","HRV","Croatia","2010","2010",27.4,,
+"PATCANXO","N05B-Anxiolytics","TCPPERMT","/capita, US$ exchange rate","HRV","Croatia","2011","2011",28.6,,
+"PATCANXO","N05B-Anxiolytics","TCPPERMT","/capita, US$ exchange rate","HRV","Croatia","2012","2012",26.8,,
+"PATCANXO","N05B-Anxiolytics","TCPPERMT","/capita, US$ exchange rate","HRV","Croatia","2013","2013",27.3,,
+"PATCANXO","N05B-Anxiolytics","TCPPERMT","/capita, US$ exchange rate","HRV","Croatia","2014","2014",27.8,,
+"PATCANXO","N05B-Anxiolytics","TCPPERMT","/capita, US$ exchange rate","HRV","Croatia","2015","2015",23.8,,
+"PATCANXO","N05B-Anxiolytics","TCPPERMT","/capita, US$ exchange rate","HRV","Croatia","2016","2016",24.4,,
+"PATCANXO","N05B-Anxiolytics","TCPPERMT","/capita, US$ exchange rate","HRV","Croatia","2017","2017",24.8,,
+"PATCANXO","N05B-Anxiolytics","TCPPERMT","/capita, US$ exchange rate","HRV","Croatia","2018","2018",26.7,,
+"PATCANXO","N05B-Anxiolytics","TCPPERMT","/capita, US$ exchange rate","HRV","Croatia","2019","2019",26,,
+"PATCANXO","N05B-Anxiolytics","TCPPERMT","/capita, US$ exchange rate","HRV","Croatia","2020","2020",26.5,,
+"PATCANXO","N05B-Anxiolytics","TCPPERMT","/capita, US$ exchange rate","HRV","Croatia","2021","2021",27.9,,
+"PATCCCBR","C08-Calcium channel blockers","MLLNCUMT","Million of national currency units","HRV","Croatia","2010","2010",146,,
+"PATCCCBR","C08-Calcium channel blockers","MLLNCUMT","Million of national currency units","HRV","Croatia","2011","2011",145,,
+"PATCCCBR","C08-Calcium channel blockers","MLLNCUMT","Million of national currency units","HRV","Croatia","2012","2012",137,,
+"PATCCCBR","C08-Calcium channel blockers","MLLNCUMT","Million of national currency units","HRV","Croatia","2013","2013",123,,
+"PATCCCBR","C08-Calcium channel blockers","MLLNCUMT","Million of national currency units","HRV","Croatia","2014","2014",114,,
+"PATCCCBR","C08-Calcium channel blockers","MLLNCUMT","Million of national currency units","HRV","Croatia","2015","2015",102,,
+"PATCCCBR","C08-Calcium channel blockers","MLLNCUMT","Million of national currency units","HRV","Croatia","2016","2016",98,,
+"PATCCCBR","C08-Calcium channel blockers","MLLNCUMT","Million of national currency units","HRV","Croatia","2017","2017",83,,
+"PATCCCBR","C08-Calcium channel blockers","MLLNCUMT","Million of national currency units","HRV","Croatia","2018","2018",79,,
+"PATCCCBR","C08-Calcium channel blockers","MLLNCUMT","Million of national currency units","HRV","Croatia","2019","2019",68,,
+"PATCCCBR","C08-Calcium channel blockers","MLLNCUMT","Million of national currency units","HRV","Croatia","2020","2020",63,,
+"PATCCCBR","C08-Calcium channel blockers","MLLNCUMT","Million of national currency units","HRV","Croatia","2021","2021",57,,
+"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","ROU","Romania","2022","2022",1.4,,
+"PATCANAL","N02-Analgesics","MTMOTCMT","Million US$ at exchange rate","ROU","Romania","2022","2022",27,,
+"PATCDIUR","C03-Diuretics","MTMOPPMT","Million US$, purchasing power parity","ROU","Romania","2022","2022",97.6,,
+"PATCDIUR","C03-Diuretics","TCPPERMT","/capita, US$ exchange rate","HRV","Croatia","2010","2010",12.4,,
+"PATCDIUR","C03-Diuretics","TCPPERMT","/capita, US$ exchange rate","HRV","Croatia","2011","2011",13.5,,
+"PATCDIUR","C03-Diuretics","TCPPERMT","/capita, US$ exchange rate","HRV","Croatia","2012","2012",13,,
+"PATCDIUR","C03-Diuretics","TCPPERMT","/capita, US$ exchange rate","HRV","Croatia","2013","2013",13.7,,
+"PATCDIUR","C03-Diuretics","TCPPERMT","/capita, US$ exchange rate","HRV","Croatia","2014","2014",13.9,,
+"PATCDIUR","C03-Diuretics","TCPPERMT","/capita, US$ exchange rate","HRV","Croatia","2015","2015",12.5,,
+"PATCDIUR","C03-Diuretics","TCPPERMT","/capita, US$ exchange rate","HRV","Croatia","2016","2016",13.8,,
+"PATCDIUR","C03-Diuretics","TCPPERMT","/capita, US$ exchange rate","HRV","Croatia","2017","2017",14.6,,
+"PATCDIUR","C03-Diuretics","TCPPERMT","/capita, US$ exchange rate","HRV","Croatia","2018","2018",16.1,,
+"PATCDIUR","C03-Diuretics","TCPPERMT","/capita, US$ exchange rate","HRV","Croatia","2019","2019",15.7,,
+"PATCDIUR","C03-Diuretics","TCPPERMT","/capita, US$ exchange rate","HRV","Croatia","2020","2020",17.7,,
+"PATCDIUR","C03-Diuretics","TCPPERMT","/capita, US$ exchange rate","HRV","Croatia","2021","2021",19.2,,
+"PATCANAL","N02-Analgesics","MTMOPPMT","Million US$, purchasing power parity","HRV","Croatia","2010","2010",361.8,,
+"PATCANAL","N02-Analgesics","MTMOPPMT","Million US$, purchasing power parity","HRV","Croatia","2011","2011",389.5,,
+"PATCANAL","N02-Analgesics","MTMOPPMT","Million US$, purchasing power parity","HRV","Croatia","2012","2012",392.7,,
+"PATCANAL","N02-Analgesics","MTMOPPMT","Million US$, purchasing power parity","HRV","Croatia","2013","2013",398.3,,
+"PATCANAL","N02-Analgesics","MTMOPPMT","Million US$, purchasing power parity","HRV","Croatia","2014","2014",393.4,,
+"PATCANAL","N02-Analgesics","MTMOPPMT","Million US$, purchasing power parity","HRV","Croatia","2015","2015",401.1,,
+"PATCANAL","N02-Analgesics","MTMOPPMT","Million US$, purchasing power parity","HRV","Croatia","2016","2016",409.9,,
+"PATCANAL","N02-Analgesics","MTMOPPMT","Million US$, purchasing power parity","HRV","Croatia","2017","2017",414.7,,
+"PATCANAL","N02-Analgesics","MTMOPPMT","Million US$, purchasing power parity","HRV","Croatia","2018","2018",452.8,,
+"PATCANAL","N02-Analgesics","MTMOPPMT","Million US$, purchasing power parity","HRV","Croatia","2019","2019",506.3,,
+"PATCANAL","N02-Analgesics","MTMOPPMT","Million US$, purchasing power parity","HRV","Croatia","2020","2020",564.5,,
+"PATCANAL","N02-Analgesics","MTMOPPMT","Million US$, purchasing power parity","HRV","Croatia","2021","2021",548.3,,
+"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","ROU","Romania","2022","2022",2.2,,
+"PATCCHLS","C10-Lipid modifying agents","MLLNCUMT","Million of national currency units","ROU","Romania","2022","2022",261.9,,
+"PATCRESS","R-Respiratory system","MTMOPPMT","Million US$, purchasing power parity","ROU","Romania","2022","2022",296,,
+"PATCCARV","C-Cardiovascular system","MTMOPPMT","Million US$, purchasing power parity","HRV","Croatia","2010","2010",1896.5,,
+"PATCCARV","C-Cardiovascular system","MTMOPPMT","Million US$, purchasing power parity","HRV","Croatia","2011","2011",1975.7,,
+"PATCCARV","C-Cardiovascular system","MTMOPPMT","Million US$, purchasing power parity","HRV","Croatia","2012","2012",2066.6,,
+"PATCCARV","C-Cardiovascular system","MTMOPPMT","Million US$, purchasing power parity","HRV","Croatia","2013","2013",1993.7,,
+"PATCCARV","C-Cardiovascular system","MTMOPPMT","Million US$, purchasing power parity","HRV","Croatia","2014","2014",1654.3,,
+"PATCCARV","C-Cardiovascular system","MTMOPPMT","Million US$, purchasing power parity","HRV","Croatia","2015","2015",1677.5,,
+"PATCCARV","C-Cardiovascular system","MTMOPPMT","Million US$, purchasing power parity","HRV","Croatia","2016","2016",1731,,
+"PATCCARV","C-Cardiovascular system","MTMOPPMT","Million US$, purchasing power parity","HRV","Croatia","2017","2017",1779,,
+"PATCCARV","C-Cardiovascular system","MTMOPPMT","Million US$, purchasing power parity","HRV","Croatia","2018","2018",1802.2,,
+"PATCCARV","C-Cardiovascular system","MTMOPPMT","Million US$, purchasing power parity","HRV","Croatia","2019","2019",1915,,
+"PATCCARV","C-Cardiovascular system","MTMOPPMT","Million US$, purchasing power parity","HRV","Croatia","2020","2020",2055.5,,
+"PATCCARV","C-Cardiovascular system","MTMOPPMT","Million US$, purchasing power parity","HRV","Croatia","2021","2021",2035.7,,
+"PATCBETA","C07-Beta blocking agents","TCPPERMT","/capita, US$ exchange rate","ROU","Romania","2022","2022",1.7,,
+"PATCBIOT","J01-Antibacterials for systemic use","MTMOTCMT","Million US$ at exchange rate","HRV","Croatia","2010","2010",389.2,,
+"PATCBIOT","J01-Antibacterials for systemic use","MTMOTCMT","Million US$ at exchange rate","HRV","Croatia","2011","2011",407.5,,
+"PATCBIOT","J01-Antibacterials for systemic use","MTMOTCMT","Million US$ at exchange rate","HRV","Croatia","2012","2012",377.4,,
+"PATCBIOT","J01-Antibacterials for systemic use","MTMOTCMT","Million US$ at exchange rate","HRV","Croatia","2013","2013",389.6,,
+"PATCBIOT","J01-Antibacterials for systemic use","MTMOTCMT","Million US$ at exchange rate","HRV","Croatia","2014","2014",377.5,,
+"PATCBIOT","J01-Antibacterials for systemic use","MTMOTCMT","Million US$ at exchange rate","HRV","Croatia","2015","2015",326.3,,
+"PATCBIOT","J01-Antibacterials for systemic use","MTMOTCMT","Million US$ at exchange rate","HRV","Croatia","2016","2016",333.2,,
+"PATCBIOT","J01-Antibacterials for systemic use","MTMOTCMT","Million US$ at exchange rate","HRV","Croatia","2017","2017",354.9,,
+"PATCBIOT","J01-Antibacterials for systemic use","MTMOTCMT","Million US$ at exchange rate","HRV","Croatia","2018","2018",358.8,,
+"PATCBIOT","J01-Antibacterials for systemic use","MTMOTCMT","Million US$ at exchange rate","HRV","Croatia","2019","2019",310.6,,
+"PATCBIOT","J01-Antibacterials for systemic use","MTMOTCMT","Million US$ at exchange rate","HRV","Croatia","2020","2020",304.2,,
+"PATCBIOT","J01-Antibacterials for systemic use","MTMOTCMT","Million US$ at exchange rate","HRV","Croatia","2021","2021",361.3,,
+"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2010","2010",41.7,,
+"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2011","2011",44.5,,
+"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2012","2012",46.7,,
+"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2013","2013",46.6,,
+"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2014","2014",45.7,,
+"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2015","2015",45.4,,
+"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2016","2016",45.4,,
+"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2017","2017",47.7,,
+"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2018","2018",50.1,,
+"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2019","2019",52.4,,
+"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2020","2020",55.3,,
+"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2021","2021",55.1,,
+"PATCANXO","N05B-Anxiolytics","MLLNCUMT","Million of national currency units","HRV","Croatia","2010","2010",86,,
+"PATCANXO","N05B-Anxiolytics","MLLNCUMT","Million of national currency units","HRV","Croatia","2011","2011",87,,
+"PATCANXO","N05B-Anxiolytics","MLLNCUMT","Million of national currency units","HRV","Croatia","2012","2012",89,,
+"PATCANXO","N05B-Anxiolytics","MLLNCUMT","Million of national currency units","HRV","Croatia","2013","2013",88,,
+"PATCANXO","N05B-Anxiolytics","MLLNCUMT","Million of national currency units","HRV","Croatia","2014","2014",90,,
+"PATCANXO","N05B-Anxiolytics","MLLNCUMT","Million of national currency units","HRV","Croatia","2015","2015",91,,
+"PATCANXO","N05B-Anxiolytics","MLLNCUMT","Million of national currency units","HRV","Croatia","2016","2016",92,,
+"PATCANXO","N05B-Anxiolytics","MLLNCUMT","Million of national currency units","HRV","Croatia","2017","2017",90,,
+"PATCANXO","N05B-Anxiolytics","MLLNCUMT","Million of national currency units","HRV","Croatia","2018","2018",91,,
+"PATCANXO","N05B-Anxiolytics","MLLNCUMT","Million of national currency units","HRV","Croatia","2019","2019",93,,
+"PATCANXO","N05B-Anxiolytics","MLLNCUMT","Million of national currency units","HRV","Croatia","2020","2020",94,,
+"PATCANXO","N05B-Anxiolytics","MLLNCUMT","Million of national currency units","HRV","Croatia","2021","2021",93,,
+"PATCBETA","C07-Beta blocking agents","MLLNCUMT","Million of national currency units","ROU","Romania","2022","2022",153.9,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOPPMT","Million US$, purchasing power parity","HRV","Croatia","2010","2010",383.2,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOPPMT","Million US$, purchasing power parity","HRV","Croatia","2011","2011",401.6,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOPPMT","Million US$, purchasing power parity","HRV","Croatia","2012","2012",413.3,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOPPMT","Million US$, purchasing power parity","HRV","Croatia","2013","2013",343.5,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOPPMT","Million US$, purchasing power parity","HRV","Croatia","2014","2014",267.9,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOPPMT","Million US$, purchasing power parity","HRV","Croatia","2015","2015",244.5,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOPPMT","Million US$, purchasing power parity","HRV","Croatia","2016","2016",249.5,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOPPMT","Million US$, purchasing power parity","HRV","Croatia","2017","2017",262.9,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOPPMT","Million US$, purchasing power parity","HRV","Croatia","2018","2018",277.6,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOPPMT","Million US$, purchasing power parity","HRV","Croatia","2019","2019",300,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOPPMT","Million US$, purchasing power parity","HRV","Croatia","2020","2020",285.8,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOPPMT","Million US$, purchasing power parity","HRV","Croatia","2021","2021",300.7,,
+"PATCDEPR","N06A-Antidepressants","MTMOTCMT","Million US$ at exchange rate","ROU","Romania","2022","2022",22.4,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2010","2010",27.2,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2011","2011",32.8,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2012","2012",36.1,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2013","2013",44.1,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2014","2014",45.2,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2015","2015",49.4,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2016","2016",56.1,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2017","2017",62.6,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2018","2018",65.6,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2019","2019",66.3,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2020","2020",67.7,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2021","2021",70.7,,
+"PATCGLYC","C01A-Cardiac glycosides","MTMOPPMT","Million US$, purchasing power parity","ROU","Romania","2022","2022",2.7,,
+"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","ROU","Romania","2022","2022",32,,
+"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2010","2010",109.6,,
+"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2011","2011",117.2,,
+"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2012","2012",119,,
+"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2013","2013",111,,
+"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2014","2014",74.3,,
+"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2015","2015",84.6,,
+"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2016","2016",78.5,,
+"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2017","2017",81.8,,
+"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2018","2018",86.2,,
+"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2019","2019",91.1,,
+"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2020","2020",97.7,,
+"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2021","2021",101.3,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MLLNCUMT","Million of national currency units","HRV","Croatia","2010","2010",111,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MLLNCUMT","Million of national currency units","HRV","Croatia","2011","2011",110,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MLLNCUMT","Million of national currency units","HRV","Croatia","2012","2012",113,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MLLNCUMT","Million of national currency units","HRV","Croatia","2013","2013",118,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MLLNCUMT","Million of national currency units","HRV","Croatia","2014","2014",126,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MLLNCUMT","Million of national currency units","HRV","Croatia","2015","2015",129,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MLLNCUMT","Million of national currency units","HRV","Croatia","2016","2016",132,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MLLNCUMT","Million of national currency units","HRV","Croatia","2017","2017",139,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MLLNCUMT","Million of national currency units","HRV","Croatia","2018","2018",152,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MLLNCUMT","Million of national currency units","HRV","Croatia","2019","2019",163,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MLLNCUMT","Million of national currency units","HRV","Croatia","2020","2020",167,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MLLNCUMT","Million of national currency units","HRV","Croatia","2021","2021",133,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","ROU","Romania","2022","2022",3.3,,
+"PATCANXO","N05B-Anxiolytics","MTMOPPMT","Million US$, purchasing power parity","ROU","Romania","2022","2022",6.9,,
+"PATCDIAB","A10-Drugs used in diabetes","MLLNCUMT","Million of national currency units","HRV","Croatia","2010","2010",241,,
+"PATCDIAB","A10-Drugs used in diabetes","MLLNCUMT","Million of national currency units","HRV","Croatia","2011","2011",259,,
+"PATCDIAB","A10-Drugs used in diabetes","MLLNCUMT","Million of national currency units","HRV","Croatia","2012","2012",278,,
+"PATCDIAB","A10-Drugs used in diabetes","MLLNCUMT","Million of national currency units","HRV","Croatia","2013","2013",302,,
+"PATCDIAB","A10-Drugs used in diabetes","MLLNCUMT","Million of national currency units","HRV","Croatia","2014","2014",317,,
+"PATCDIAB","A10-Drugs used in diabetes","MLLNCUMT","Million of national currency units","HRV","Croatia","2015","2015",344,,
+"PATCDIAB","A10-Drugs used in diabetes","MLLNCUMT","Million of national currency units","HRV","Croatia","2016","2016",386,,
+"PATCDIAB","A10-Drugs used in diabetes","MLLNCUMT","Million of national currency units","HRV","Croatia","2017","2017",408,,
+"PATCDIAB","A10-Drugs used in diabetes","MLLNCUMT","Million of national currency units","HRV","Croatia","2018","2018",415,,
+"PATCDIAB","A10-Drugs used in diabetes","MLLNCUMT","Million of national currency units","HRV","Croatia","2019","2019",432,,
+"PATCDIAB","A10-Drugs used in diabetes","MLLNCUMT","Million of national currency units","HRV","Croatia","2020","2020",458,,
+"PATCDIAB","A10-Drugs used in diabetes","MLLNCUMT","Million of national currency units","HRV","Croatia","2021","2021",483,,
+"PATCSKEL","M-Musculo-skeletal system","MTMOPPMT","Million US$, purchasing power parity","HRV","Croatia","2010","2010",410.4,,
+"PATCSKEL","M-Musculo-skeletal system","MTMOPPMT","Million US$, purchasing power parity","HRV","Croatia","2011","2011",417.6,,
+"PATCSKEL","M-Musculo-skeletal system","MTMOPPMT","Million US$, purchasing power parity","HRV","Croatia","2012","2012",421.5,,
+"PATCSKEL","M-Musculo-skeletal system","MTMOPPMT","Million US$, purchasing power parity","HRV","Croatia","2013","2013",438.4,,
+"PATCSKEL","M-Musculo-skeletal system","MTMOPPMT","Million US$, purchasing power parity","HRV","Croatia","2014","2014",423.1,,
+"PATCSKEL","M-Musculo-skeletal system","MTMOPPMT","Million US$, purchasing power parity","HRV","Croatia","2015","2015",437.6,,
+"PATCSKEL","M-Musculo-skeletal system","MTMOPPMT","Million US$, purchasing power parity","HRV","Croatia","2016","2016",483.4,,
+"PATCSKEL","M-Musculo-skeletal system","MTMOPPMT","Million US$, purchasing power parity","HRV","Croatia","2017","2017",516.7,,
+"PATCSKEL","M-Musculo-skeletal system","MTMOPPMT","Million US$, purchasing power parity","HRV","Croatia","2018","2018",735,,
+"PATCSKEL","M-Musculo-skeletal system","MTMOPPMT","Million US$, purchasing power parity","HRV","Croatia","2019","2019",846.2,,
+"PATCSKEL","M-Musculo-skeletal system","MTMOPPMT","Million US$, purchasing power parity","HRV","Croatia","2020","2020",807.4,,
+"PATCSKEL","M-Musculo-skeletal system","MTMOPPMT","Million US$, purchasing power parity","HRV","Croatia","2021","2021",718.4,,
+"PATCTOTT","Total pharmaceutical sales","MTMOTCMT","Million US$ at exchange rate","ROU","Romania","2022","2022",285490.5,,
+"PATCDIAB","A10-Drugs used in diabetes","MTMOPPMT","Million US$, purchasing power parity","ROU","Romania","2022","2022",1151.1,,
+"PATCINFC","J-Antiinfectives for systemic use","MLLNCUMT","Million of national currency units","HRV","Croatia","2010","2010",476,,
+"PATCINFC","J-Antiinfectives for systemic use","MLLNCUMT","Million of national currency units","HRV","Croatia","2011","2011",463,,
+"PATCINFC","J-Antiinfectives for systemic use","MLLNCUMT","Million of national currency units","HRV","Croatia","2012","2012",428,,
+"PATCINFC","J-Antiinfectives for systemic use","MLLNCUMT","Million of national currency units","HRV","Croatia","2013","2013",429,,
+"PATCINFC","J-Antiinfectives for systemic use","MLLNCUMT","Million of national currency units","HRV","Croatia","2014","2014",408,,
+"PATCINFC","J-Antiinfectives for systemic use","MLLNCUMT","Million of national currency units","HRV","Croatia","2015","2015",411,,
+"PATCINFC","J-Antiinfectives for systemic use","MLLNCUMT","Million of national currency units","HRV","Croatia","2016","2016",487,,
+"PATCINFC","J-Antiinfectives for systemic use","MLLNCUMT","Million of national currency units","HRV","Croatia","2017","2017",609,,
+"PATCINFC","J-Antiinfectives for systemic use","MLLNCUMT","Million of national currency units","HRV","Croatia","2018","2018",604,,
+"PATCINFC","J-Antiinfectives for systemic use","MLLNCUMT","Million of national currency units","HRV","Croatia","2019","2019",714,,
+"PATCINFC","J-Antiinfectives for systemic use","MLLNCUMT","Million of national currency units","HRV","Croatia","2020","2020",714,,
+"PATCINFC","J-Antiinfectives for systemic use","MLLNCUMT","Million of national currency units","HRV","Croatia","2021","2021",1382,,
+"PATCALIM","A-Alimentary tract and metabolism","MLLNCUMT","Million of national currency units","HRV","Croatia","2010","2010",640,,
+"PATCALIM","A-Alimentary tract and metabolism","MLLNCUMT","Million of national currency units","HRV","Croatia","2011","2011",690,,
+"PATCALIM","A-Alimentary tract and metabolism","MLLNCUMT","Million of national currency units","HRV","Croatia","2012","2012",708,,
+"PATCALIM","A-Alimentary tract and metabolism","MLLNCUMT","Million of national currency units","HRV","Croatia","2013","2013",713,,
+"PATCALIM","A-Alimentary tract and metabolism","MLLNCUMT","Million of national currency units","HRV","Croatia","2014","2014",692,,
+"PATCALIM","A-Alimentary tract and metabolism","MLLNCUMT","Million of national currency units","HRV","Croatia","2015","2015",720,,
+"PATCALIM","A-Alimentary tract and metabolism","MLLNCUMT","Million of national currency units","HRV","Croatia","2016","2016",774,,
+"PATCALIM","A-Alimentary tract and metabolism","MLLNCUMT","Million of national currency units","HRV","Croatia","2017","2017",799,,
+"PATCALIM","A-Alimentary tract and metabolism","MLLNCUMT","Million of national currency units","HRV","Croatia","2018","2018",825,,
+"PATCALIM","A-Alimentary tract and metabolism","MLLNCUMT","Million of national currency units","HRV","Croatia","2019","2019",889,,
+"PATCALIM","A-Alimentary tract and metabolism","MLLNCUMT","Million of national currency units","HRV","Croatia","2020","2020",891,,
+"PATCALIM","A-Alimentary tract and metabolism","MLLNCUMT","Million of national currency units","HRV","Croatia","2021","2021",916.8,,
+"PATCTOTT","Total pharmaceutical sales","MTMOPPMT","Million US$, purchasing power parity","HRV","Croatia","2010","2010",9408.5,,
+"PATCTOTT","Total pharmaceutical sales","MTMOPPMT","Million US$, purchasing power parity","HRV","Croatia","2011","2011",10175.5,,
+"PATCTOTT","Total pharmaceutical sales","MTMOPPMT","Million US$, purchasing power parity","HRV","Croatia","2012","2012",10435.6,,
+"PATCTOTT","Total pharmaceutical sales","MTMOPPMT","Million US$, purchasing power parity","HRV","Croatia","2013","2013",10923.1,,
+"PATCTOTT","Total pharmaceutical sales","MTMOPPMT","Million US$, purchasing power parity","HRV","Croatia","2014","2014",10644.2,,
+"PATCTOTT","Total pharmaceutical sales","MTMOPPMT","Million US$, purchasing power parity","HRV","Croatia","2015","2015",11298.4,,
+"PATCTOTT","Total pharmaceutical sales","MTMOPPMT","Million US$, purchasing power parity","HRV","Croatia","2016","2016",12928,,
+"PATCTOTT","Total pharmaceutical sales","MTMOPPMT","Million US$, purchasing power parity","HRV","Croatia","2017","2017",13896.6,,
+"PATCTOTT","Total pharmaceutical sales","MTMOPPMT","Million US$, purchasing power parity","HRV","Croatia","2018","2018",15077.8,,
+"PATCTOTT","Total pharmaceutical sales","MTMOPPMT","Million US$, purchasing power parity","HRV","Croatia","2019","2019",17931.5,,
+"PATCTOTT","Total pharmaceutical sales","MTMOPPMT","Million US$, purchasing power parity","HRV","Croatia","2020","2020",20028.5,,
+"PATCTOTT","Total pharmaceutical sales","MTMOPPMT","Million US$, purchasing power parity","HRV","Croatia","2021","2021",22848.7,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOTCMT","Million US$ at exchange rate","HRV","Croatia","2010","2010",85,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOTCMT","Million US$ at exchange rate","HRV","Croatia","2011","2011",84.6,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOTCMT","Million US$ at exchange rate","HRV","Croatia","2012","2012",81.1,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOTCMT","Million US$ at exchange rate","HRV","Croatia","2013","2013",81.9,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOTCMT","Million US$ at exchange rate","HRV","Croatia","2014","2014",80,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOTCMT","Million US$ at exchange rate","HRV","Croatia","2015","2015",69.2,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOTCMT","Million US$ at exchange rate","HRV","Croatia","2016","2016",67.5,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOTCMT","Million US$ at exchange rate","HRV","Croatia","2017","2017",70.5,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOTCMT","Million US$ at exchange rate","HRV","Croatia","2018","2018",76.8,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOTCMT","Million US$ at exchange rate","HRV","Croatia","2019","2019",74,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOTCMT","Million US$ at exchange rate","HRV","Croatia","2020","2020",68.3,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOTCMT","Million US$ at exchange rate","HRV","Croatia","2021","2021",74.6,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOTCMT","Million US$ at exchange rate","ROU","Romania","2022","2022",37.4,,
+"PATCGLYC","C01A-Cardiac glycosides","TCPPERMT","/capita, US$ exchange rate","HRV","Croatia","2010","2010",1.6,,
+"PATCGLYC","C01A-Cardiac glycosides","TCPPERMT","/capita, US$ exchange rate","HRV","Croatia","2011","2011",1.3,,
+"PATCGLYC","C01A-Cardiac glycosides","TCPPERMT","/capita, US$ exchange rate","HRV","Croatia","2012","2012",1.5,,
+"PATCGLYC","C01A-Cardiac glycosides","TCPPERMT","/capita, US$ exchange rate","HRV","Croatia","2013","2013",1.2,,
+"PATCGLYC","C01A-Cardiac glycosides","TCPPERMT","/capita, US$ exchange rate","HRV","Croatia","2014","2014",1.5,,
+"PATCGLYC","C01A-Cardiac glycosides","TCPPERMT","/capita, US$ exchange rate","HRV","Croatia","2015","2015",1.3,,
+"PATCGLYC","C01A-Cardiac glycosides","TCPPERMT","/capita, US$ exchange rate","HRV","Croatia","2016","2016",1.3,,
+"PATCGLYC","C01A-Cardiac glycosides","TCPPERMT","/capita, US$ exchange rate","HRV","Croatia","2017","2017",1.4,,
+"PATCGLYC","C01A-Cardiac glycosides","TCPPERMT","/capita, US$ exchange rate","HRV","Croatia","2018","2018",1.5,,
+"PATCGLYC","C01A-Cardiac glycosides","TCPPERMT","/capita, US$ exchange rate","HRV","Croatia","2019","2019",1.4,,
+"PATCGLYC","C01A-Cardiac glycosides","TCPPERMT","/capita, US$ exchange rate","HRV","Croatia","2020","2020",1.1,,
+"PATCGLYC","C01A-Cardiac glycosides","TCPPERMT","/capita, US$ exchange rate","HRV","Croatia","2021","2021",0.9,,
+"PATCDEPR","N06A-Antidepressants","MTMOPPMT","Million US$, purchasing power parity","HRV","Croatia","2010","2010",171.2,,
+"PATCDEPR","N06A-Antidepressants","MTMOPPMT","Million US$, purchasing power parity","HRV","Croatia","2011","2011",174.7,,
+"PATCDEPR","N06A-Antidepressants","MTMOPPMT","Million US$, purchasing power parity","HRV","Croatia","2012","2012",176.8,,
+"PATCDEPR","N06A-Antidepressants","MTMOPPMT","Million US$, purchasing power parity","HRV","Croatia","2013","2013",177,,
+"PATCDEPR","N06A-Antidepressants","MTMOPPMT","Million US$, purchasing power parity","HRV","Croatia","2014","2014",174.4,,
+"PATCDEPR","N06A-Antidepressants","MTMOPPMT","Million US$, purchasing power parity","HRV","Croatia","2015","2015",173.8,,
+"PATCDEPR","N06A-Antidepressants","MTMOPPMT","Million US$, purchasing power parity","HRV","Croatia","2016","2016",182.7,,
+"PATCDEPR","N06A-Antidepressants","MTMOPPMT","Million US$, purchasing power parity","HRV","Croatia","2017","2017",181.3,,
+"PATCDEPR","N06A-Antidepressants","MTMOPPMT","Million US$, purchasing power parity","HRV","Croatia","2018","2018",179.8,,
+"PATCDEPR","N06A-Antidepressants","MTMOPPMT","Million US$, purchasing power parity","HRV","Croatia","2019","2019",178.1,,
+"PATCDEPR","N06A-Antidepressants","MTMOPPMT","Million US$, purchasing power parity","HRV","Croatia","2020","2020",185.8,,
+"PATCDEPR","N06A-Antidepressants","MTMOPPMT","Million US$, purchasing power parity","HRV","Croatia","2021","2021",185.1,,
+"PATCRESS","R-Respiratory system","TCPPERMT","/capita, US$ exchange rate","HRV","Croatia","2010","2010",107.5,,
+"PATCRESS","R-Respiratory system","TCPPERMT","/capita, US$ exchange rate","HRV","Croatia","2011","2011",109.6,,
+"PATCRESS","R-Respiratory system","TCPPERMT","/capita, US$ exchange rate","HRV","Croatia","2012","2012",97.4,,
+"PATCRESS","R-Respiratory system","TCPPERMT","/capita, US$ exchange rate","HRV","Croatia","2013","2013",103.1,,
+"PATCRESS","R-Respiratory system","TCPPERMT","/capita, US$ exchange rate","HRV","Croatia","2014","2014",99.9,,
+"PATCRESS","R-Respiratory system","TCPPERMT","/capita, US$ exchange rate","HRV","Croatia","2015","2015",90.9,,
+"PATCRESS","R-Respiratory system","TCPPERMT","/capita, US$ exchange rate","HRV","Croatia","2016","2016",95.5,,
+"PATCRESS","R-Respiratory system","TCPPERMT","/capita, US$ exchange rate","HRV","Croatia","2017","2017",98.6,,
+"PATCRESS","R-Respiratory system","TCPPERMT","/capita, US$ exchange rate","HRV","Croatia","2018","2018",112.9,,
+"PATCRESS","R-Respiratory system","TCPPERMT","/capita, US$ exchange rate","HRV","Croatia","2019","2019",118,,
+"PATCRESS","R-Respiratory system","TCPPERMT","/capita, US$ exchange rate","HRV","Croatia","2020","2020",114.8,,
+"PATCRESS","R-Respiratory system","TCPPERMT","/capita, US$ exchange rate","HRV","Croatia","2021","2021",124.3,,
+"PATCCHLS","C10-Lipid modifying agents","TCPPERMT","/capita, US$ exchange rate","ROU","Romania","2022","2022",2.9,,
+"PATCSKEL","M-Musculo-skeletal system","MTMOTCMT","Million US$ at exchange rate","ROU","Romania","2022","2022",80.7,,
+"PATCGENU","G-Genito urinary system and sex hormones","MLLNCUMT","Million of national currency units","ROU","Romania","2022","2022",73.2,,
+"PATCRESS","R-Respiratory system","MLLNCUMT","Million of national currency units","HRV","Croatia","2010","2010",337,,
+"PATCRESS","R-Respiratory system","MLLNCUMT","Million of national currency units","HRV","Croatia","2011","2011",333,,
+"PATCRESS","R-Respiratory system","MLLNCUMT","Million of national currency units","HRV","Croatia","2012","2012",323,,
+"PATCRESS","R-Respiratory system","MLLNCUMT","Million of national currency units","HRV","Croatia","2013","2013",332,,
+"PATCRESS","R-Respiratory system","MLLNCUMT","Million of national currency units","HRV","Croatia","2014","2014",323,,
+"PATCRESS","R-Respiratory system","MLLNCUMT","Million of national currency units","HRV","Croatia","2015","2015",348,,
+"PATCRESS","R-Respiratory system","MLLNCUMT","Million of national currency units","HRV","Croatia","2016","2016",360,,
+"PATCRESS","R-Respiratory system","MLLNCUMT","Million of national currency units","HRV","Croatia","2017","2017",358,,
+"PATCRESS","R-Respiratory system","MLLNCUMT","Million of national currency units","HRV","Croatia","2018","2018",385,,
+"PATCRESS","R-Respiratory system","MLLNCUMT","Million of national currency units","HRV","Croatia","2019","2019",422,,
+"PATCRESS","R-Respiratory system","MLLNCUMT","Million of national currency units","HRV","Croatia","2020","2020",408,,
+"PATCRESS","R-Respiratory system","MLLNCUMT","Million of national currency units","HRV","Croatia","2021","2021",414.3,,
+"PATCDIUR","C03-Diuretics","MLLNCUMT","Million of national currency units","HRV","Croatia","2010","2010",39,,
+"PATCDIUR","C03-Diuretics","MLLNCUMT","Million of national currency units","HRV","Croatia","2011","2011",41,,
+"PATCDIUR","C03-Diuretics","MLLNCUMT","Million of national currency units","HRV","Croatia","2012","2012",43,,
+"PATCDIUR","C03-Diuretics","MLLNCUMT","Million of national currency units","HRV","Croatia","2013","2013",44,,
+"PATCDIUR","C03-Diuretics","MLLNCUMT","Million of national currency units","HRV","Croatia","2014","2014",45,,
+"PATCDIUR","C03-Diuretics","MLLNCUMT","Million of national currency units","HRV","Croatia","2015","2015",48,,
+"PATCDIUR","C03-Diuretics","MLLNCUMT","Million of national currency units","HRV","Croatia","2016","2016",52,,
+"PATCDIUR","C03-Diuretics","MLLNCUMT","Million of national currency units","HRV","Croatia","2017","2017",53,,
+"PATCDIUR","C03-Diuretics","MLLNCUMT","Million of national currency units","HRV","Croatia","2018","2018",55,,
+"PATCDIUR","C03-Diuretics","MLLNCUMT","Million of national currency units","HRV","Croatia","2019","2019",56,,
+"PATCDIUR","C03-Diuretics","MLLNCUMT","Million of national currency units","HRV","Croatia","2020","2020",63,,
+"PATCDIUR","C03-Diuretics","MLLNCUMT","Million of national currency units","HRV","Croatia","2021","2021",64,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2010","2010",154.4,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2011","2011",164.5,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2012","2012",172.9,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2013","2013",161.5,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2014","2014",162.1,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2015","2015",162.1,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2016","2016",174.6,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2017","2017",172.9,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2018","2018",171.3,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2019","2019",176.4,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2020","2020",190.7,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2021","2021",198.6,,
+"PATCCNSY","N-Nervous system","MTMOPPMT","Million US$, purchasing power parity","HRV","Croatia","2010","2010",1525,,
+"PATCCNSY","N-Nervous system","MTMOPPMT","Million US$, purchasing power parity","HRV","Croatia","2011","2011",1628.3,,
+"PATCCNSY","N-Nervous system","MTMOPPMT","Million US$, purchasing power parity","HRV","Croatia","2012","2012",1677.9,,
+"PATCCNSY","N-Nervous system","MTMOPPMT","Million US$, purchasing power parity","HRV","Croatia","2013","2013",1709.2,,
+"PATCCNSY","N-Nervous system","MTMOPPMT","Million US$, purchasing power parity","HRV","Croatia","2014","2014",1690.4,,
+"PATCCNSY","N-Nervous system","MTMOPPMT","Million US$, purchasing power parity","HRV","Croatia","2015","2015",1741.8,,
+"PATCCNSY","N-Nervous system","MTMOPPMT","Million US$, purchasing power parity","HRV","Croatia","2016","2016",1891.4,,
+"PATCCNSY","N-Nervous system","MTMOPPMT","Million US$, purchasing power parity","HRV","Croatia","2017","2017",1890,,
+"PATCCNSY","N-Nervous system","MTMOPPMT","Million US$, purchasing power parity","HRV","Croatia","2018","2018",1957,,
+"PATCCNSY","N-Nervous system","MTMOPPMT","Million US$, purchasing power parity","HRV","Croatia","2019","2019",2074.4,,
+"PATCCNSY","N-Nervous system","MTMOPPMT","Million US$, purchasing power parity","HRV","Croatia","2020","2020",2200.8,,
+"PATCCNSY","N-Nervous system","MTMOPPMT","Million US$, purchasing power parity","HRV","Croatia","2021","2021",2150.6,,
+"PATCCARV","C-Cardiovascular system","MTMOTCMT","Million US$ at exchange rate","ROU","Romania","2022","2022",300.3,,
+"PATCINFC","J-Antiinfectives for systemic use","MTMOTCMT","Million US$ at exchange rate","HRV","Croatia","2010","2010",652.3,,
+"PATCINFC","J-Antiinfectives for systemic use","MTMOTCMT","Million US$ at exchange rate","HRV","Croatia","2011","2011",652.8,,
+"PATCINFC","J-Antiinfectives for systemic use","MTMOTCMT","Million US$ at exchange rate","HRV","Croatia","2012","2012",551.2,,
+"PATCINFC","J-Antiinfectives for systemic use","MTMOTCMT","Million US$ at exchange rate","HRV","Croatia","2013","2013",566.6,,
+"PATCINFC","J-Antiinfectives for systemic use","MTMOTCMT","Million US$ at exchange rate","HRV","Croatia","2014","2014",534.8,,
+"PATCINFC","J-Antiinfectives for systemic use","MTMOTCMT","Million US$ at exchange rate","HRV","Croatia","2015","2015",451.5,,
+"PATCINFC","J-Antiinfectives for systemic use","MTMOTCMT","Million US$ at exchange rate","HRV","Croatia","2016","2016",539.1,,
+"PATCINFC","J-Antiinfectives for systemic use","MTMOTCMT","Million US$ at exchange rate","HRV","Croatia","2017","2017",692.7,,
+"PATCINFC","J-Antiinfectives for systemic use","MTMOTCMT","Million US$ at exchange rate","HRV","Croatia","2018","2018",724.8,,
+"PATCINFC","J-Antiinfectives for systemic use","MTMOTCMT","Million US$ at exchange rate","HRV","Croatia","2019","2019",812.3,,
+"PATCINFC","J-Antiinfectives for systemic use","MTMOTCMT","Million US$ at exchange rate","HRV","Croatia","2020","2020",813.4,,
+"PATCINFC","J-Antiinfectives for systemic use","MTMOTCMT","Million US$ at exchange rate","HRV","Croatia","2021","2021",1637.2,,
+"PATCHYPO","C02-Antihypertensives","MTMOTCMT","Million US$ at exchange rate","ROU","Romania","2022","2022",19.1,,
+"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2010","2010",17.7,,
+"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2011","2011",19.2,,
+"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2012","2012",20.7,,
+"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2013","2013",21.8,,
+"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2014","2014",22.6,,
+"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2015","2015",24.5,,
+"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2016","2016",27.8,,
+"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2017","2017",29.1,,
+"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2018","2018",30.6,,
+"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2019","2019",32.3,,
+"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2020","2020",37.1,,
+"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2021","2021",37.5,,
+"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","ROU","Romania","2022","2022",83.1,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOPPMT","Million US$, purchasing power parity","ROU","Romania","2022","2022",235.2,,
+"PATCCCBR","C08-Calcium channel blockers","MLLNCUMT","Million of national currency units","ROU","Romania","2022","2022",47.9,,
+"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","ROU","Romania","2022","2022",60.5,,
+"PATCGLYC","C01A-Cardiac glycosides","MLLNCUMT","Million of national currency units","HRV","Croatia","2010","2010",5,,
+"PATCGLYC","C01A-Cardiac glycosides","MLLNCUMT","Million of national currency units","HRV","Croatia","2011","2011",4,,
+"PATCGLYC","C01A-Cardiac glycosides","MLLNCUMT","Million of national currency units","HRV","Croatia","2012","2012",5,,
+"PATCGLYC","C01A-Cardiac glycosides","MLLNCUMT","Million of national currency units","HRV","Croatia","2013","2013",4,,
+"PATCGLYC","C01A-Cardiac glycosides","MLLNCUMT","Million of national currency units","HRV","Croatia","2014","2014",5,,
+"PATCGLYC","C01A-Cardiac glycosides","MLLNCUMT","Million of national currency units","HRV","Croatia","2015","2015",5,,
+"PATCGLYC","C01A-Cardiac glycosides","MLLNCUMT","Million of national currency units","HRV","Croatia","2016","2016",5,,
+"PATCGLYC","C01A-Cardiac glycosides","MLLNCUMT","Million of national currency units","HRV","Croatia","2017","2017",5,,
+"PATCGLYC","C01A-Cardiac glycosides","MLLNCUMT","Million of national currency units","HRV","Croatia","2018","2018",5,,
+"PATCGLYC","C01A-Cardiac glycosides","MLLNCUMT","Million of national currency units","HRV","Croatia","2019","2019",5,,
+"PATCGLYC","C01A-Cardiac glycosides","MLLNCUMT","Million of national currency units","HRV","Croatia","2020","2020",4,,
+"PATCGLYC","C01A-Cardiac glycosides","MLLNCUMT","Million of national currency units","HRV","Croatia","2021","2021",3,,
+"PATCBIOT","J01-Antibacterials for systemic use","MTMOPPMT","Million US$, purchasing power parity","HRV","Croatia","2010","2010",552.4,,
+"PATCBIOT","J01-Antibacterials for systemic use","MTMOPPMT","Million US$, purchasing power parity","HRV","Croatia","2011","2011",580.3,,
+"PATCBIOT","J01-Antibacterials for systemic use","MTMOPPMT","Million US$, purchasing power parity","HRV","Croatia","2012","2012",602.5,,
+"PATCBIOT","J01-Antibacterials for systemic use","MTMOPPMT","Million US$, purchasing power parity","HRV","Croatia","2013","2013",621.7,,
+"PATCBIOT","J01-Antibacterials for systemic use","MTMOPPMT","Million US$, purchasing power parity","HRV","Croatia","2014","2014",612.4,,
+"PATCBIOT","J01-Antibacterials for systemic use","MTMOPPMT","Million US$, purchasing power parity","HRV","Croatia","2015","2015",637.1,,
+"PATCBIOT","J01-Antibacterials for systemic use","MTMOPPMT","Million US$, purchasing power parity","HRV","Croatia","2016","2016",670.6,,
+"PATCBIOT","J01-Antibacterials for systemic use","MTMOPPMT","Million US$, purchasing power parity","HRV","Croatia","2017","2017",707.1,,
+"PATCBIOT","J01-Antibacterials for systemic use","MTMOPPMT","Million US$, purchasing power parity","HRV","Croatia","2018","2018",680.4,,
+"PATCBIOT","J01-Antibacterials for systemic use","MTMOPPMT","Million US$, purchasing power parity","HRV","Croatia","2019","2019",639.9,,
+"PATCBIOT","J01-Antibacterials for systemic use","MTMOPPMT","Million US$, purchasing power parity","HRV","Croatia","2020","2020",635.9,,
+"PATCBIOT","J01-Antibacterials for systemic use","MTMOPPMT","Million US$, purchasing power parity","HRV","Croatia","2021","2021",705.6,,
+"PATCACID","A02A-Antacids","MTMOPPMT","Million US$, purchasing power parity","HRV","Croatia","2010","2010",17.5,,
+"PATCACID","A02A-Antacids","MTMOPPMT","Million US$, purchasing power parity","HRV","Croatia","2011","2011",18.1,,
+"PATCACID","A02A-Antacids","MTMOPPMT","Million US$, purchasing power parity","HRV","Croatia","2012","2012",16.5,,
+"PATCACID","A02A-Antacids","MTMOPPMT","Million US$, purchasing power parity","HRV","Croatia","2013","2013",19,,
+"PATCACID","A02A-Antacids","MTMOPPMT","Million US$, purchasing power parity","HRV","Croatia","2014","2014",21.3,,
+"PATCACID","A02A-Antacids","MTMOPPMT","Million US$, purchasing power parity","HRV","Croatia","2015","2015",21.5,,
+"PATCACID","A02A-Antacids","MTMOPPMT","Million US$, purchasing power parity","HRV","Croatia","2016","2016",22.3,,
+"PATCACID","A02A-Antacids","MTMOPPMT","Million US$, purchasing power parity","HRV","Croatia","2017","2017",20.4,,
+"PATCACID","A02A-Antacids","MTMOPPMT","Million US$, purchasing power parity","HRV","Croatia","2018","2018",22.8,,
+"PATCACID","A02A-Antacids","MTMOPPMT","Million US$, purchasing power parity","HRV","Croatia","2019","2019",23.4,,
+"PATCACID","A02A-Antacids","MTMOPPMT","Million US$, purchasing power parity","HRV","Croatia","2020","2020",23.8,,
+"PATCACID","A02A-Antacids","MTMOPPMT","Million US$, purchasing power parity","HRV","Croatia","2021","2021",16.2,,
+"PATCOTHR","Products not elsewhere classified","MTMOTCMT","Million US$ at exchange rate","ROU","Romania","2022","2022",1018.5,,
+"PATCANAL","N02-Analgesics","TCPPERMT","/capita, US$ exchange rate","ROU","Romania","2022","2022",1.4,,
+"PATCCCBR","C08-Calcium channel blockers","MTMOTCMT","Million US$ at exchange rate","ROU","Romania","2022","2022",10.2,,
+"PATCCCBR","C08-Calcium channel blockers","MTMOTCMT","Million US$ at exchange rate","HRV","Croatia","2010","2010",200.1,,
+"PATCCCBR","C08-Calcium channel blockers","MTMOTCMT","Million US$ at exchange rate","HRV","Croatia","2011","2011",204.4,,
+"PATCCCBR","C08-Calcium channel blockers","MTMOTCMT","Million US$ at exchange rate","HRV","Croatia","2012","2012",176.4,,
+"PATCCCBR","C08-Calcium channel blockers","MTMOTCMT","Million US$ at exchange rate","HRV","Croatia","2013","2013",162.4,,
+"PATCCCBR","C08-Calcium channel blockers","MTMOTCMT","Million US$ at exchange rate","HRV","Croatia","2014","2014",149.4,,
+"PATCCCBR","C08-Calcium channel blockers","MTMOTCMT","Million US$ at exchange rate","HRV","Croatia","2015","2015",112.1,,
+"PATCCCBR","C08-Calcium channel blockers","MTMOTCMT","Million US$ at exchange rate","HRV","Croatia","2016","2016",108.5,,
+"PATCCCBR","C08-Calcium channel blockers","MTMOTCMT","Million US$ at exchange rate","HRV","Croatia","2017","2017",94.4,,
+"PATCCCBR","C08-Calcium channel blockers","MTMOTCMT","Million US$ at exchange rate","HRV","Croatia","2018","2018",94.8,,
+"PATCCCBR","C08-Calcium channel blockers","MTMOTCMT","Million US$ at exchange rate","HRV","Croatia","2019","2019",77.4,,
+"PATCCCBR","C08-Calcium channel blockers","MTMOTCMT","Million US$ at exchange rate","HRV","Croatia","2020","2020",71.8,,
+"PATCCCBR","C08-Calcium channel blockers","MTMOTCMT","Million US$ at exchange rate","HRV","Croatia","2021","2021",67.5,,
+"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","ROU","Romania","2022","2022",0.1,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","TCPPERMT","/capita, US$ exchange rate","HRV","Croatia","2010","2010",62.8,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","TCPPERMT","/capita, US$ exchange rate","HRV","Croatia","2011","2011",65.8,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","TCPPERMT","/capita, US$ exchange rate","HRV","Croatia","2012","2012",60.6,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","TCPPERMT","/capita, US$ exchange rate","HRV","Croatia","2013","2013",50.6,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","TCPPERMT","/capita, US$ exchange rate","HRV","Croatia","2014","2014",39,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","TCPPERMT","/capita, US$ exchange rate","HRV","Croatia","2015","2015",29.8,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","TCPPERMT","/capita, US$ exchange rate","HRV","Croatia","2016","2016",29.7,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","TCPPERMT","/capita, US$ exchange rate","HRV","Croatia","2017","2017",31.9,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","TCPPERMT","/capita, US$ exchange rate","HRV","Croatia","2018","2018",35.8,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","TCPPERMT","/capita, US$ exchange rate","HRV","Croatia","2019","2019",35.8,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","TCPPERMT","/capita, US$ exchange rate","HRV","Croatia","2020","2020",33.8,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","TCPPERMT","/capita, US$ exchange rate","HRV","Croatia","2021","2021",39,,
+"PATCSKEL","M-Musculo-skeletal system","TCPPERMT","/capita, US$ exchange rate","ROU","Romania","2022","2022",4.2,,
+"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","ROU","Romania","2022","2022",0.4,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","TCPPERMT","/capita, US$ exchange rate","ROU","Romania","2022","2022",2,,
+"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","ROU","Romania","2022","2022",15.5,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","TCPPERMT","/capita, US$ exchange rate","ROU","Romania","2022","2022",1.8,,
+"PATCCARV","C-Cardiovascular system","TCPPERMT","/capita, US$ exchange rate","HRV","Croatia","2010","2010",311,,
+"PATCCARV","C-Cardiovascular system","TCPPERMT","/capita, US$ exchange rate","HRV","Croatia","2011","2011",323.9,,
+"PATCCARV","C-Cardiovascular system","TCPPERMT","/capita, US$ exchange rate","HRV","Croatia","2012","2012",303.2,,
+"PATCCARV","C-Cardiovascular system","TCPPERMT","/capita, US$ exchange rate","HRV","Croatia","2013","2013",293.7,,
+"PATCCARV","C-Cardiovascular system","TCPPERMT","/capita, US$ exchange rate","HRV","Croatia","2014","2014",240.7,,
+"PATCCARV","C-Cardiovascular system","TCPPERMT","/capita, US$ exchange rate","HRV","Croatia","2015","2015",204.2,,
+"PATCCARV","C-Cardiovascular system","TCPPERMT","/capita, US$ exchange rate","HRV","Croatia","2016","2016",206.2,,
+"PATCCARV","C-Cardiovascular system","TCPPERMT","/capita, US$ exchange rate","HRV","Croatia","2017","2017",216.2,,
+"PATCCARV","C-Cardiovascular system","TCPPERMT","/capita, US$ exchange rate","HRV","Croatia","2018","2018",232.3,,
+"PATCCARV","C-Cardiovascular system","TCPPERMT","/capita, US$ exchange rate","HRV","Croatia","2019","2019",228.5,,
+"PATCCARV","C-Cardiovascular system","TCPPERMT","/capita, US$ exchange rate","HRV","Croatia","2020","2020",242.9,,
+"PATCCARV","C-Cardiovascular system","TCPPERMT","/capita, US$ exchange rate","HRV","Croatia","2021","2021",264,,
+"PATCINFC","J-Antiinfectives for systemic use","MLLNCUMT","Million of national currency units","ROU","Romania","2022","2022",1066.2,,
+"PATCANAL","N02-Analgesics","TCPPERMT","/capita, US$ exchange rate","HRV","Croatia","2010","2010",59.3,,
+"PATCANAL","N02-Analgesics","TCPPERMT","/capita, US$ exchange rate","HRV","Croatia","2011","2011",63.9,,
+"PATCANAL","N02-Analgesics","TCPPERMT","/capita, US$ exchange rate","HRV","Croatia","2012","2012",57.6,,
+"PATCANAL","N02-Analgesics","TCPPERMT","/capita, US$ exchange rate","HRV","Croatia","2013","2013",58.7,,
+"PATCANAL","N02-Analgesics","TCPPERMT","/capita, US$ exchange rate","HRV","Croatia","2014","2014",57.2,,
+"PATCANAL","N02-Analgesics","TCPPERMT","/capita, US$ exchange rate","HRV","Croatia","2015","2015",48.8,,
+"PATCANAL","N02-Analgesics","TCPPERMT","/capita, US$ exchange rate","HRV","Croatia","2016","2016",48.8,,
+"PATCANAL","N02-Analgesics","TCPPERMT","/capita, US$ exchange rate","HRV","Croatia","2017","2017",50.4,,
+"PATCANAL","N02-Analgesics","TCPPERMT","/capita, US$ exchange rate","HRV","Croatia","2018","2018",58.4,,
+"PATCANAL","N02-Analgesics","TCPPERMT","/capita, US$ exchange rate","HRV","Croatia","2019","2019",60.4,,
+"PATCANAL","N02-Analgesics","TCPPERMT","/capita, US$ exchange rate","HRV","Croatia","2020","2020",66.7,,
+"PATCANAL","N02-Analgesics","TCPPERMT","/capita, US$ exchange rate","HRV","Croatia","2021","2021",71.1,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOPPMT","Million US$, purchasing power parity","ROU","Romania","2022","2022",4.1,,
+"PATCTOTT","Total pharmaceutical sales","TCPPERMT","/capita, US$ exchange rate","ROU","Romania","2022","2022",14992.3,,
+"PATCDEPR","N06A-Antidepressants","TCPPERMT","/capita, US$ exchange rate","HRV","Croatia","2010","2010",28.1,,
+"PATCDEPR","N06A-Antidepressants","TCPPERMT","/capita, US$ exchange rate","HRV","Croatia","2011","2011",28.6,,
+"PATCDEPR","N06A-Antidepressants","TCPPERMT","/capita, US$ exchange rate","HRV","Croatia","2012","2012",25.9,,
+"PATCDEPR","N06A-Antidepressants","TCPPERMT","/capita, US$ exchange rate","HRV","Croatia","2013","2013",26.1,,
+"PATCDEPR","N06A-Antidepressants","TCPPERMT","/capita, US$ exchange rate","HRV","Croatia","2014","2014",25.4,,
+"PATCDEPR","N06A-Antidepressants","TCPPERMT","/capita, US$ exchange rate","HRV","Croatia","2015","2015",21.1,,
+"PATCDEPR","N06A-Antidepressants","TCPPERMT","/capita, US$ exchange rate","HRV","Croatia","2016","2016",21.8,,
+"PATCDEPR","N06A-Antidepressants","TCPPERMT","/capita, US$ exchange rate","HRV","Croatia","2017","2017",22,,
+"PATCDEPR","N06A-Antidepressants","TCPPERMT","/capita, US$ exchange rate","HRV","Croatia","2018","2018",23.2,,
+"PATCDEPR","N06A-Antidepressants","TCPPERMT","/capita, US$ exchange rate","HRV","Croatia","2019","2019",21.3,,
+"PATCDEPR","N06A-Antidepressants","TCPPERMT","/capita, US$ exchange rate","HRV","Croatia","2020","2020",22,,
+"PATCDEPR","N06A-Antidepressants","TCPPERMT","/capita, US$ exchange rate","HRV","Croatia","2021","2021",24,,
+"PATCGENU","G-Genito urinary system and sex hormones","MTMOTCMT","Million US$ at exchange rate","HRV","Croatia","2010","2010",223.4,,
+"PATCGENU","G-Genito urinary system and sex hormones","MTMOTCMT","Million US$ at exchange rate","HRV","Croatia","2011","2011",234,,
+"PATCGENU","G-Genito urinary system and sex hormones","MTMOTCMT","Million US$ at exchange rate","HRV","Croatia","2012","2012",209.9,,
+"PATCGENU","G-Genito urinary system and sex hormones","MTMOTCMT","Million US$ at exchange rate","HRV","Croatia","2013","2013",212.6,,
+"PATCGENU","G-Genito urinary system and sex hormones","MTMOTCMT","Million US$ at exchange rate","HRV","Croatia","2014","2014",209.7,,
+"PATCGENU","G-Genito urinary system and sex hormones","MTMOTCMT","Million US$ at exchange rate","HRV","Croatia","2015","2015",181.3,,
+"PATCGENU","G-Genito urinary system and sex hormones","MTMOTCMT","Million US$ at exchange rate","HRV","Croatia","2016","2016",190.4,,
+"PATCGENU","G-Genito urinary system and sex hormones","MTMOTCMT","Million US$ at exchange rate","HRV","Croatia","2017","2017",203.6,,
+"PATCGENU","G-Genito urinary system and sex hormones","MTMOTCMT","Million US$ at exchange rate","HRV","Croatia","2018","2018",223.2,,
+"PATCGENU","G-Genito urinary system and sex hormones","MTMOTCMT","Million US$ at exchange rate","HRV","Croatia","2019","2019",223,,
+"PATCGENU","G-Genito urinary system and sex hormones","MTMOTCMT","Million US$ at exchange rate","HRV","Croatia","2020","2020",224.4,,
+"PATCGENU","G-Genito urinary system and sex hormones","MTMOTCMT","Million US$ at exchange rate","HRV","Croatia","2021","2021",236.9,,
+"PATCHYPO","C02-Antihypertensives","TCPPERMT","/capita, US$ exchange rate","HRV","Croatia","2010","2010",13.7,,
+"PATCHYPO","C02-Antihypertensives","TCPPERMT","/capita, US$ exchange rate","HRV","Croatia","2011","2011",15.8,,
+"PATCHYPO","C02-Antihypertensives","TCPPERMT","/capita, US$ exchange rate","HRV","Croatia","2012","2012",15.4,,
+"PATCHYPO","C02-Antihypertensives","TCPPERMT","/capita, US$ exchange rate","HRV","Croatia","2013","2013",16.5,,
+"PATCHYPO","C02-Antihypertensives","TCPPERMT","/capita, US$ exchange rate","HRV","Croatia","2014","2014",16.1,,
+"PATCHYPO","C02-Antihypertensives","TCPPERMT","/capita, US$ exchange rate","HRV","Croatia","2015","2015",12.8,,
+"PATCHYPO","C02-Antihypertensives","TCPPERMT","/capita, US$ exchange rate","HRV","Croatia","2016","2016",11.4,,
+"PATCHYPO","C02-Antihypertensives","TCPPERMT","/capita, US$ exchange rate","HRV","Croatia","2017","2017",12.9,,
+"PATCHYPO","C02-Antihypertensives","TCPPERMT","/capita, US$ exchange rate","HRV","Croatia","2018","2018",15.5,,
+"PATCHYPO","C02-Antihypertensives","TCPPERMT","/capita, US$ exchange rate","HRV","Croatia","2019","2019",16.5,,
+"PATCHYPO","C02-Antihypertensives","TCPPERMT","/capita, US$ exchange rate","HRV","Croatia","2020","2020",20.3,,
+"PATCHYPO","C02-Antihypertensives","TCPPERMT","/capita, US$ exchange rate","HRV","Croatia","2021","2021",21.6,,
+"PATCDIAB","A10-Drugs used in diabetes","MTMOTCMT","Million US$ at exchange rate","HRV","Croatia","2010","2010",330.3,,
+"PATCDIAB","A10-Drugs used in diabetes","MTMOTCMT","Million US$ at exchange rate","HRV","Croatia","2011","2011",365.2,,
+"PATCDIAB","A10-Drugs used in diabetes","MTMOTCMT","Million US$ at exchange rate","HRV","Croatia","2012","2012",358,,
+"PATCDIAB","A10-Drugs used in diabetes","MTMOTCMT","Million US$ at exchange rate","HRV","Croatia","2013","2013",398.9,,
+"PATCDIAB","A10-Drugs used in diabetes","MTMOTCMT","Million US$ at exchange rate","HRV","Croatia","2014","2014",415.5,,
+"PATCDIAB","A10-Drugs used in diabetes","MTMOTCMT","Million US$ at exchange rate","HRV","Croatia","2015","2015",377.9,,
+"PATCDIAB","A10-Drugs used in diabetes","MTMOTCMT","Million US$ at exchange rate","HRV","Croatia","2016","2016",427.3,,
+"PATCDIAB","A10-Drugs used in diabetes","MTMOTCMT","Million US$ at exchange rate","HRV","Croatia","2017","2017",464.1,,
+"PATCDIAB","A10-Drugs used in diabetes","MTMOTCMT","Million US$ at exchange rate","HRV","Croatia","2018","2018",498,,
+"PATCDIAB","A10-Drugs used in diabetes","MTMOTCMT","Million US$ at exchange rate","HRV","Croatia","2019","2019",491.5,,
+"PATCDIAB","A10-Drugs used in diabetes","MTMOTCMT","Million US$ at exchange rate","HRV","Croatia","2020","2020",521.7,,
+"PATCDIAB","A10-Drugs used in diabetes","MTMOTCMT","Million US$ at exchange rate","HRV","Croatia","2021","2021",572.2,,
+"PATCOTHR","Products not elsewhere classified","TCPPERMT","/capita, US$ exchange rate","ROU","Romania","2022","2022",53.5,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOTCMT","Million US$ at exchange rate","HRV","Croatia","2010","2010",152.1,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOTCMT","Million US$ at exchange rate","HRV","Croatia","2011","2011",155.1,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOTCMT","Million US$ at exchange rate","HRV","Croatia","2012","2012",145.5,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOTCMT","Million US$ at exchange rate","HRV","Croatia","2013","2013",155.8,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOTCMT","Million US$ at exchange rate","HRV","Croatia","2014","2014",165.2,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOTCMT","Million US$ at exchange rate","HRV","Croatia","2015","2015",141.7,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOTCMT","Million US$ at exchange rate","HRV","Croatia","2016","2016",146.1,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOTCMT","Million US$ at exchange rate","HRV","Croatia","2017","2017",158.1,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOTCMT","Million US$ at exchange rate","HRV","Croatia","2018","2018",182.4,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOTCMT","Million US$ at exchange rate","HRV","Croatia","2019","2019",185.4,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOTCMT","Million US$ at exchange rate","HRV","Croatia","2020","2020",190.2,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOTCMT","Million US$ at exchange rate","HRV","Croatia","2021","2021",157.6,,
+"PATCDEPR","N06A-Antidepressants","TCPPERMT","/capita, US$ exchange rate","ROU","Romania","2022","2022",1.2,,
+"PATCOTHR","Products not elsewhere classified","MLLNCUMT","Million of national currency units","ROU","Romania","2022","2022",4775,,
+"PATCHYPN","N05C-Hypnotics and sedatives","MTMOPPMT","Million US$, purchasing power parity","HRV","Croatia","2010","2010",44.7,,
+"PATCHYPN","N05C-Hypnotics and sedatives","MTMOPPMT","Million US$, purchasing power parity","HRV","Croatia","2011","2011",48.2,,
+"PATCHYPN","N05C-Hypnotics and sedatives","MTMOPPMT","Million US$, purchasing power parity","HRV","Croatia","2012","2012",53.5,,
+"PATCHYPN","N05C-Hypnotics and sedatives","MTMOPPMT","Million US$, purchasing power parity","HRV","Croatia","2013","2013",61.1,,
+"PATCHYPN","N05C-Hypnotics and sedatives","MTMOPPMT","Million US$, purchasing power parity","HRV","Croatia","2014","2014",63.8,,
+"PATCHYPN","N05C-Hypnotics and sedatives","MTMOPPMT","Million US$, purchasing power parity","HRV","Croatia","2015","2015",66.5,,
+"PATCHYPN","N05C-Hypnotics and sedatives","MTMOPPMT","Million US$, purchasing power parity","HRV","Croatia","2016","2016",73.5,,
+"PATCHYPN","N05C-Hypnotics and sedatives","MTMOPPMT","Million US$, purchasing power parity","HRV","Croatia","2017","2017",79.3,,
+"PATCHYPN","N05C-Hypnotics and sedatives","MTMOPPMT","Million US$, purchasing power parity","HRV","Croatia","2018","2018",84.2,,
+"PATCHYPN","N05C-Hypnotics and sedatives","MTMOPPMT","Million US$, purchasing power parity","HRV","Croatia","2019","2019",82,,
+"PATCHYPN","N05C-Hypnotics and sedatives","MTMOPPMT","Million US$, purchasing power parity","HRV","Croatia","2020","2020",76.2,,
+"PATCHYPN","N05C-Hypnotics and sedatives","MTMOPPMT","Million US$, purchasing power parity","HRV","Croatia","2021","2021",94.8,,
+"PATCCCBR","C08-Calcium channel blockers","TCPPERMT","/capita, US$ exchange rate","HRV","Croatia","2010","2010",46.6,,
+"PATCCCBR","C08-Calcium channel blockers","TCPPERMT","/capita, US$ exchange rate","HRV","Croatia","2011","2011",47.7,,
+"PATCCCBR","C08-Calcium channel blockers","TCPPERMT","/capita, US$ exchange rate","HRV","Croatia","2012","2012",41.3,,
+"PATCCCBR","C08-Calcium channel blockers","TCPPERMT","/capita, US$ exchange rate","HRV","Croatia","2013","2013",38.2,,
+"PATCCCBR","C08-Calcium channel blockers","TCPPERMT","/capita, US$ exchange rate","HRV","Croatia","2014","2014",35.3,,
+"PATCCCBR","C08-Calcium channel blockers","TCPPERMT","/capita, US$ exchange rate","HRV","Croatia","2015","2015",26.6,,
+"PATCCCBR","C08-Calcium channel blockers","TCPPERMT","/capita, US$ exchange rate","HRV","Croatia","2016","2016",26,,
+"PATCCCBR","C08-Calcium channel blockers","TCPPERMT","/capita, US$ exchange rate","HRV","Croatia","2017","2017",22.9,,
+"PATCCCBR","C08-Calcium channel blockers","TCPPERMT","/capita, US$ exchange rate","HRV","Croatia","2018","2018",23.2,,
+"PATCCCBR","C08-Calcium channel blockers","TCPPERMT","/capita, US$ exchange rate","HRV","Croatia","2019","2019",19,,
+"PATCCCBR","C08-Calcium channel blockers","TCPPERMT","/capita, US$ exchange rate","HRV","Croatia","2020","2020",17.7,,
+"PATCCCBR","C08-Calcium channel blockers","TCPPERMT","/capita, US$ exchange rate","HRV","Croatia","2021","2021",17.1,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOPPMT","Million US$, purchasing power parity","HRV","Croatia","2010","2010",35,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOPPMT","Million US$, purchasing power parity","HRV","Croatia","2011","2011",38.1,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOPPMT","Million US$, purchasing power parity","HRV","Croatia","2012","2012",35,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOPPMT","Million US$, purchasing power parity","HRV","Croatia","2013","2013",37.9,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOPPMT","Million US$, purchasing power parity","HRV","Croatia","2014","2014",34,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOPPMT","Million US$, purchasing power parity","HRV","Croatia","2015","2015",36.5,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOPPMT","Million US$, purchasing power parity","HRV","Croatia","2016","2016",35.6,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOPPMT","Million US$, purchasing power parity","HRV","Croatia","2017","2017",36.3,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOPPMT","Million US$, purchasing power parity","HRV","Croatia","2018","2018",34.1,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOPPMT","Million US$, purchasing power parity","HRV","Croatia","2019","2019",32.8,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOPPMT","Million US$, purchasing power parity","HRV","Croatia","2020","2020",31,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOPPMT","Million US$, purchasing power parity","HRV","Croatia","2021","2021",30.1,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","ROU","Romania","2022","2022",0.2,,
+"PATCHYPO","C02-Antihypertensives","TCPPERMT","/capita, US$ exchange rate","ROU","Romania","2022","2022",1,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2010","2010",28.1,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2011","2011",28.1,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2012","2012",30.3,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2013","2013",30.7,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2014","2014",30.6,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2015","2015",32.1,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2016","2016",32.6,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2017","2017",34,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2018","2018",35.6,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2019","2019",37.5,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2020","2020",35.3,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2021","2021",36.9,,
+"PATCANXO","N05B-Anxiolytics","MTMOTCMT","Million US$ at exchange rate","HRV","Croatia","2010","2010",117.9,,
+"PATCANXO","N05B-Anxiolytics","MTMOTCMT","Million US$ at exchange rate","HRV","Croatia","2011","2011",122.7,,
+"PATCANXO","N05B-Anxiolytics","MTMOTCMT","Million US$ at exchange rate","HRV","Croatia","2012","2012",114.6,,
+"PATCANXO","N05B-Anxiolytics","MTMOTCMT","Million US$ at exchange rate","HRV","Croatia","2013","2013",116.2,,
+"PATCANXO","N05B-Anxiolytics","MTMOTCMT","Million US$ at exchange rate","HRV","Croatia","2014","2014",118,,
+"PATCANXO","N05B-Anxiolytics","MTMOTCMT","Million US$ at exchange rate","HRV","Croatia","2015","2015",100,,
+"PATCANXO","N05B-Anxiolytics","MTMOTCMT","Million US$ at exchange rate","HRV","Croatia","2016","2016",101.8,,
+"PATCANXO","N05B-Anxiolytics","MTMOTCMT","Million US$ at exchange rate","HRV","Croatia","2017","2017",102.4,,
+"PATCANXO","N05B-Anxiolytics","MTMOTCMT","Million US$ at exchange rate","HRV","Croatia","2018","2018",109.2,,
+"PATCANXO","N05B-Anxiolytics","MTMOTCMT","Million US$ at exchange rate","HRV","Croatia","2019","2019",105.8,,
+"PATCANXO","N05B-Anxiolytics","MTMOTCMT","Million US$ at exchange rate","HRV","Croatia","2020","2020",107.1,,
+"PATCANXO","N05B-Anxiolytics","MTMOTCMT","Million US$ at exchange rate","HRV","Croatia","2021","2021",110.2,,
+"PATCCNSY","N-Nervous system","MTMOPPMT","Million US$, purchasing power parity","ROU","Romania","2022","2022",699.5,,
+"PATCGENU","G-Genito urinary system and sex hormones","TCPPERMT","/capita, US$ exchange rate","HRV","Croatia","2010","2010",52,,
+"PATCGENU","G-Genito urinary system and sex hormones","TCPPERMT","/capita, US$ exchange rate","HRV","Croatia","2011","2011",54.6,,
+"PATCGENU","G-Genito urinary system and sex hormones","TCPPERMT","/capita, US$ exchange rate","HRV","Croatia","2012","2012",49.2,,
+"PATCGENU","G-Genito urinary system and sex hormones","TCPPERMT","/capita, US$ exchange rate","HRV","Croatia","2013","2013",50,,
+"PATCGENU","G-Genito urinary system and sex hormones","TCPPERMT","/capita, US$ exchange rate","HRV","Croatia","2014","2014",49.5,,
+"PATCGENU","G-Genito urinary system and sex hormones","TCPPERMT","/capita, US$ exchange rate","HRV","Croatia","2015","2015",43.1,,
+"PATCGENU","G-Genito urinary system and sex hormones","TCPPERMT","/capita, US$ exchange rate","HRV","Croatia","2016","2016",45.6,,
+"PATCGENU","G-Genito urinary system and sex hormones","TCPPERMT","/capita, US$ exchange rate","HRV","Croatia","2017","2017",49.3,,
+"PATCGENU","G-Genito urinary system and sex hormones","TCPPERMT","/capita, US$ exchange rate","HRV","Croatia","2018","2018",54.6,,
+"PATCGENU","G-Genito urinary system and sex hormones","TCPPERMT","/capita, US$ exchange rate","HRV","Croatia","2019","2019",54.8,,
+"PATCGENU","G-Genito urinary system and sex hormones","TCPPERMT","/capita, US$ exchange rate","HRV","Croatia","2020","2020",55.4,,
+"PATCGENU","G-Genito urinary system and sex hormones","TCPPERMT","/capita, US$ exchange rate","HRV","Croatia","2021","2021",60,,
+"PATCDEPR","N06A-Antidepressants","MLLNCUMT","Million of national currency units","ROU","Romania","2022","2022",104.9,,
+"PATCHYPO","C02-Antihypertensives","MLLNCUMT","Million of national currency units","ROU","Romania","2022","2022",89.5,,
+"PATCBLOO","B-Blood and blood forming organs","MTMOPPMT","Million US$, purchasing power parity","HRV","Croatia","2010","2010",519.3,,
+"PATCBLOO","B-Blood and blood forming organs","MTMOPPMT","Million US$, purchasing power parity","HRV","Croatia","2011","2011",520,,
+"PATCBLOO","B-Blood and blood forming organs","MTMOPPMT","Million US$, purchasing power parity","HRV","Croatia","2012","2012",579.9,,
+"PATCBLOO","B-Blood and blood forming organs","MTMOPPMT","Million US$, purchasing power parity","HRV","Croatia","2013","2013",604.8,,
+"PATCBLOO","B-Blood and blood forming organs","MTMOPPMT","Million US$, purchasing power parity","HRV","Croatia","2014","2014",644.3,,
+"PATCBLOO","B-Blood and blood forming organs","MTMOPPMT","Million US$, purchasing power parity","HRV","Croatia","2015","2015",761.5,,
+"PATCBLOO","B-Blood and blood forming organs","MTMOPPMT","Million US$, purchasing power parity","HRV","Croatia","2016","2016",993.6,,
+"PATCBLOO","B-Blood and blood forming organs","MTMOPPMT","Million US$, purchasing power parity","HRV","Croatia","2017","2017",1124.1,,
+"PATCBLOO","B-Blood and blood forming organs","MTMOPPMT","Million US$, purchasing power parity","HRV","Croatia","2018","2018",1174.2,,
+"PATCBLOO","B-Blood and blood forming organs","MTMOPPMT","Million US$, purchasing power parity","HRV","Croatia","2019","2019",1448.6,,
+"PATCBLOO","B-Blood and blood forming organs","MTMOPPMT","Million US$, purchasing power parity","HRV","Croatia","2020","2020",1602.9,,
+"PATCBLOO","B-Blood and blood forming organs","MTMOPPMT","Million US$, purchasing power parity","HRV","Croatia","2021","2021",1800.8,,
+"PATCCARV","C-Cardiovascular system","TCPPERMT","/capita, US$ exchange rate","ROU","Romania","2022","2022",15.8,,
+"PATCHYPN","N05C-Hypnotics and sedatives","MTMOPPMT","Million US$, purchasing power parity","ROU","Romania","2022","2022",8.4,,
+"PATCGENU","G-Genito urinary system and sex hormones","MTMOTCMT","Million US$ at exchange rate","ROU","Romania","2022","2022",15.6,,
+"PATCBIOT","J01-Antibacterials for systemic use","MLLNCUMT","Million of national currency units","HRV","Croatia","2010","2010",284,,
+"PATCBIOT","J01-Antibacterials for systemic use","MLLNCUMT","Million of national currency units","HRV","Croatia","2011","2011",289,,
+"PATCBIOT","J01-Antibacterials for systemic use","MLLNCUMT","Million of national currency units","HRV","Croatia","2012","2012",293,,
+"PATCBIOT","J01-Antibacterials for systemic use","MLLNCUMT","Million of national currency units","HRV","Croatia","2013","2013",295,,
+"PATCBIOT","J01-Antibacterials for systemic use","MLLNCUMT","Million of national currency units","HRV","Croatia","2014","2014",288,,
+"PATCBIOT","J01-Antibacterials for systemic use","MLLNCUMT","Million of national currency units","HRV","Croatia","2015","2015",297,,
+"PATCBIOT","J01-Antibacterials for systemic use","MLLNCUMT","Million of national currency units","HRV","Croatia","2016","2016",301,,
+"PATCBIOT","J01-Antibacterials for systemic use","MLLNCUMT","Million of national currency units","HRV","Croatia","2017","2017",312,,
+"PATCBIOT","J01-Antibacterials for systemic use","MLLNCUMT","Million of national currency units","HRV","Croatia","2018","2018",299,,
+"PATCBIOT","J01-Antibacterials for systemic use","MLLNCUMT","Million of national currency units","HRV","Croatia","2019","2019",273,,
+"PATCBIOT","J01-Antibacterials for systemic use","MLLNCUMT","Million of national currency units","HRV","Croatia","2020","2020",267,,
+"PATCBIOT","J01-Antibacterials for systemic use","MLLNCUMT","Million of national currency units","HRV","Croatia","2021","2021",305,,
+"PATCBIOT","J01-Antibacterials for systemic use","MTMOPPMT","Million US$, purchasing power parity","ROU","Romania","2022","2022",270,,
+"PATCBLOO","B-Blood and blood forming organs","MTMOPPMT","Million US$, purchasing power parity","ROU","Romania","2022","2022",574.1,,
+"PATCCARV","C-Cardiovascular system","MLLNCUMT","Million of national currency units","ROU","Romania","2022","2022",1408.2,,
+"PATCRESS","R-Respiratory system","MTMOTCMT","Million US$ at exchange rate","HRV","Croatia","2010","2010",461.8,,
+"PATCRESS","R-Respiratory system","MTMOTCMT","Million US$ at exchange rate","HRV","Croatia","2011","2011",469.5,,
+"PATCRESS","R-Respiratory system","MTMOTCMT","Million US$ at exchange rate","HRV","Croatia","2012","2012",416,,
+"PATCRESS","R-Respiratory system","MTMOTCMT","Million US$ at exchange rate","HRV","Croatia","2013","2013",438.5,,
+"PATCRESS","R-Respiratory system","MTMOTCMT","Million US$ at exchange rate","HRV","Croatia","2014","2014",423.4,,
+"PATCRESS","R-Respiratory system","MTMOTCMT","Million US$ at exchange rate","HRV","Croatia","2015","2015",382.3,,
+"PATCRESS","R-Respiratory system","MTMOTCMT","Million US$ at exchange rate","HRV","Croatia","2016","2016",398.5,,
+"PATCRESS","R-Respiratory system","MTMOTCMT","Million US$ at exchange rate","HRV","Croatia","2017","2017",407.2,,
+"PATCRESS","R-Respiratory system","MTMOTCMT","Million US$ at exchange rate","HRV","Croatia","2018","2018",462,,
+"PATCRESS","R-Respiratory system","MTMOTCMT","Million US$ at exchange rate","HRV","Croatia","2019","2019",480.1,,
+"PATCRESS","R-Respiratory system","MTMOTCMT","Million US$ at exchange rate","HRV","Croatia","2020","2020",464.8,,
+"PATCRESS","R-Respiratory system","MTMOTCMT","Million US$ at exchange rate","HRV","Croatia","2021","2021",490.9,,
+"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2010","2010",128.6,,
+"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2011","2011",135.5,,
+"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2012","2012",141.1,,
+"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2013","2013",146.1,,
+"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2014","2014",144.6,,
+"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2015","2015",151.4,,
+"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2016","2016",160.7,,
+"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2017","2017",171.2,,
+"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2018","2018",166.3,,
+"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2019","2019",157.3,,
+"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2020","2020",157.1,,
+"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2021","2021",178.7,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MLLNCUMT","Million of national currency units","HRV","Croatia","2010","2010",62,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MLLNCUMT","Million of national currency units","HRV","Croatia","2011","2011",60,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MLLNCUMT","Million of national currency units","HRV","Croatia","2012","2012",63,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MLLNCUMT","Million of national currency units","HRV","Croatia","2013","2013",62,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MLLNCUMT","Million of national currency units","HRV","Croatia","2014","2014",61,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MLLNCUMT","Million of national currency units","HRV","Croatia","2015","2015",63,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MLLNCUMT","Million of national currency units","HRV","Croatia","2016","2016",61,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MLLNCUMT","Million of national currency units","HRV","Croatia","2017","2017",62,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MLLNCUMT","Million of national currency units","HRV","Croatia","2018","2018",64,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MLLNCUMT","Million of national currency units","HRV","Croatia","2019","2019",65,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MLLNCUMT","Million of national currency units","HRV","Croatia","2020","2020",60,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MLLNCUMT","Million of national currency units","HRV","Croatia","2021","2021",63,,
+"PATCBETA","C07-Beta blocking agents","MTMOPPMT","Million US$, purchasing power parity","HRV","Croatia","2010","2010",179,,
+"PATCBETA","C07-Beta blocking agents","MTMOPPMT","Million US$, purchasing power parity","HRV","Croatia","2011","2011",190.7,,
+"PATCBETA","C07-Beta blocking agents","MTMOPPMT","Million US$, purchasing power parity","HRV","Croatia","2012","2012",199.5,,
+"PATCBETA","C07-Beta blocking agents","MTMOPPMT","Million US$, purchasing power parity","HRV","Croatia","2013","2013",198.1,,
+"PATCBETA","C07-Beta blocking agents","MTMOPPMT","Million US$, purchasing power parity","HRV","Croatia","2014","2014",193.5,,
+"PATCBETA","C07-Beta blocking agents","MTMOPPMT","Million US$, purchasing power parity","HRV","Croatia","2015","2015",190.9,,
+"PATCBETA","C07-Beta blocking agents","MTMOPPMT","Million US$, purchasing power parity","HRV","Croatia","2016","2016",189.4,,
+"PATCBETA","C07-Beta blocking agents","MTMOPPMT","Million US$, purchasing power parity","HRV","Croatia","2017","2017",197.2,,
+"PATCBETA","C07-Beta blocking agents","MTMOPPMT","Million US$, purchasing power parity","HRV","Croatia","2018","2018",204.8,,
+"PATCBETA","C07-Beta blocking agents","MTMOPPMT","Million US$, purchasing power parity","HRV","Croatia","2019","2019",213.3,,
+"PATCBETA","C07-Beta blocking agents","MTMOPPMT","Million US$, purchasing power parity","HRV","Croatia","2020","2020",223.9,,
+"PATCBETA","C07-Beta blocking agents","MTMOPPMT","Million US$, purchasing power parity","HRV","Croatia","2021","2021",217.5,,
+"PATCINFC","J-Antiinfectives for systemic use","MTMOTCMT","Million US$ at exchange rate","ROU","Romania","2022","2022",227.4,,
+"PATCALIM","A-Alimentary tract and metabolism","MTMOTCMT","Million US$ at exchange rate","HRV","Croatia","2010","2010",877.1,,
+"PATCALIM","A-Alimentary tract and metabolism","MTMOTCMT","Million US$ at exchange rate","HRV","Croatia","2011","2011",972.9,,
+"PATCALIM","A-Alimentary tract and metabolism","MTMOTCMT","Million US$ at exchange rate","HRV","Croatia","2012","2012",911.8,,
+"PATCALIM","A-Alimentary tract and metabolism","MTMOTCMT","Million US$ at exchange rate","HRV","Croatia","2013","2013",941.7,,
+"PATCALIM","A-Alimentary tract and metabolism","MTMOTCMT","Million US$ at exchange rate","HRV","Croatia","2014","2014",907,,
+"PATCALIM","A-Alimentary tract and metabolism","MTMOTCMT","Million US$ at exchange rate","HRV","Croatia","2015","2015",791,,
+"PATCALIM","A-Alimentary tract and metabolism","MTMOTCMT","Million US$ at exchange rate","HRV","Croatia","2016","2016",856.8,,
+"PATCALIM","A-Alimentary tract and metabolism","MTMOTCMT","Million US$ at exchange rate","HRV","Croatia","2017","2017",908.8,,
+"PATCALIM","A-Alimentary tract and metabolism","MTMOTCMT","Million US$ at exchange rate","HRV","Croatia","2018","2018",990,,
+"PATCALIM","A-Alimentary tract and metabolism","MTMOTCMT","Million US$ at exchange rate","HRV","Croatia","2019","2019",1011.4,,
+"PATCALIM","A-Alimentary tract and metabolism","MTMOTCMT","Million US$ at exchange rate","HRV","Croatia","2020","2020",1015,,
+"PATCALIM","A-Alimentary tract and metabolism","MTMOTCMT","Million US$ at exchange rate","HRV","Croatia","2021","2021",1086.1,,
+"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","ROU","Romania","2022","2022",5.1,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MLLNCUMT","Million of national currency units","HRV","Croatia","2010","2010",341,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MLLNCUMT","Million of national currency units","HRV","Croatia","2011","2011",351,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MLLNCUMT","Million of national currency units","HRV","Croatia","2012","2012",359,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MLLNCUMT","Million of national currency units","HRV","Croatia","2013","2013",326,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MLLNCUMT","Million of national currency units","HRV","Croatia","2014","2014",323,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MLLNCUMT","Million of national currency units","HRV","Croatia","2015","2015",318,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MLLNCUMT","Million of national currency units","HRV","Croatia","2016","2016",327,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MLLNCUMT","Million of national currency units","HRV","Croatia","2017","2017",315,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MLLNCUMT","Million of national currency units","HRV","Croatia","2018","2018",308,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MLLNCUMT","Million of national currency units","HRV","Croatia","2019","2019",306,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MLLNCUMT","Million of national currency units","HRV","Croatia","2020","2020",324,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MLLNCUMT","Million of national currency units","HRV","Croatia","2021","2021",339,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOPPMT","Million US$, purchasing power parity","HRV","Croatia","2010","2010",359.8,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOPPMT","Million US$, purchasing power parity","HRV","Croatia","2011","2011",393.5,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOPPMT","Million US$, purchasing power parity","HRV","Croatia","2012","2012",413.3,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOPPMT","Million US$, purchasing power parity","HRV","Croatia","2013","2013",432,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOPPMT","Million US$, purchasing power parity","HRV","Croatia","2014","2014",448.6,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOPPMT","Million US$, purchasing power parity","HRV","Croatia","2015","2015",465.5,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOPPMT","Million US$, purchasing power parity","HRV","Croatia","2016","2016",487.9,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOPPMT","Million US$, purchasing power parity","HRV","Croatia","2017","2017",498.6,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOPPMT","Million US$, purchasing power parity","HRV","Croatia","2018","2018",502.9,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOPPMT","Million US$, purchasing power parity","HRV","Croatia","2019","2019",522.7,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOPPMT","Million US$, purchasing power parity","HRV","Croatia","2020","2020",538.3,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOPPMT","Million US$, purchasing power parity","HRV","Croatia","2021","2021",513.6,,
+"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2010","2010",354.9,,
+"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2011","2011",380.2,,
+"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2012","2012",393,,
+"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2013","2013",401.7,,
+"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2014","2014",399,,
+"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2015","2015",413.9,,
+"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2016","2016",453.3,,
+"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2017","2017",457.7,,
+"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2018","2018",478.4,,
+"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2019","2019",510,,
+"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2020","2020",543.8,,
+"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2021","2021",544.5,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","ROU","Romania","2022","2022",12.3,,
+"PATCACID","A02A-Antacids","MTMOPPMT","Million US$, purchasing power parity","ROU","Romania","2022","2022",0.3,,
+"PATCSKEL","M-Musculo-skeletal system","MTMOTCMT","Million US$ at exchange rate","HRV","Croatia","2010","2010",289.2,,
+"PATCSKEL","M-Musculo-skeletal system","MTMOTCMT","Million US$ at exchange rate","HRV","Croatia","2011","2011",293.3,,
+"PATCSKEL","M-Musculo-skeletal system","MTMOTCMT","Million US$ at exchange rate","HRV","Croatia","2012","2012",264,,
+"PATCSKEL","M-Musculo-skeletal system","MTMOTCMT","Million US$ at exchange rate","HRV","Croatia","2013","2013",274.7,,
+"PATCSKEL","M-Musculo-skeletal system","MTMOTCMT","Million US$ at exchange rate","HRV","Croatia","2014","2014",260.8,,
+"PATCSKEL","M-Musculo-skeletal system","MTMOTCMT","Million US$ at exchange rate","HRV","Croatia","2015","2015",224.1,,
+"PATCSKEL","M-Musculo-skeletal system","MTMOTCMT","Million US$ at exchange rate","HRV","Croatia","2016","2016",240.2,,
+"PATCSKEL","M-Musculo-skeletal system","MTMOTCMT","Million US$ at exchange rate","HRV","Croatia","2017","2017",259.3,,
+"PATCSKEL","M-Musculo-skeletal system","MTMOTCMT","Million US$ at exchange rate","HRV","Croatia","2018","2018",387.6,,
+"PATCSKEL","M-Musculo-skeletal system","MTMOTCMT","Million US$ at exchange rate","HRV","Croatia","2019","2019",410.7,,
+"PATCSKEL","M-Musculo-skeletal system","MTMOTCMT","Million US$ at exchange rate","HRV","Croatia","2020","2020",386.2,,
+"PATCSKEL","M-Musculo-skeletal system","MTMOTCMT","Million US$ at exchange rate","HRV","Croatia","2021","2021",367.9,,
+"PATCGLYC","C01A-Cardiac glycosides","MTMOTCMT","Million US$ at exchange rate","ROU","Romania","2022","2022",1,,
+"PATCGLYC","C01A-Cardiac glycosides","MTMOPPMT","Million US$, purchasing power parity","HRV","Croatia","2010","2010",9.7,,
+"PATCGLYC","C01A-Cardiac glycosides","MTMOPPMT","Million US$, purchasing power parity","HRV","Croatia","2011","2011",8,,
+"PATCGLYC","C01A-Cardiac glycosides","MTMOPPMT","Million US$, purchasing power parity","HRV","Croatia","2012","2012",10.3,,
+"PATCGLYC","C01A-Cardiac glycosides","MTMOPPMT","Million US$, purchasing power parity","HRV","Croatia","2013","2013",8.4,,
+"PATCGLYC","C01A-Cardiac glycosides","MTMOPPMT","Million US$, purchasing power parity","HRV","Croatia","2014","2014",10.6,,
+"PATCGLYC","C01A-Cardiac glycosides","MTMOPPMT","Million US$, purchasing power parity","HRV","Croatia","2015","2015",10.7,,
+"PATCGLYC","C01A-Cardiac glycosides","MTMOPPMT","Million US$, purchasing power parity","HRV","Croatia","2016","2016",11.1,,
+"PATCGLYC","C01A-Cardiac glycosides","MTMOPPMT","Million US$, purchasing power parity","HRV","Croatia","2017","2017",11.3,,
+"PATCGLYC","C01A-Cardiac glycosides","MTMOPPMT","Million US$, purchasing power parity","HRV","Croatia","2018","2018",11.4,,
+"PATCGLYC","C01A-Cardiac glycosides","MTMOPPMT","Million US$, purchasing power parity","HRV","Croatia","2019","2019",11.7,,
+"PATCGLYC","C01A-Cardiac glycosides","MTMOPPMT","Million US$, purchasing power parity","HRV","Croatia","2020","2020",9.5,,
+"PATCGLYC","C01A-Cardiac glycosides","MTMOPPMT","Million US$, purchasing power parity","HRV","Croatia","2021","2021",6.9,,
+"PATCCCBR","C08-Calcium channel blockers","TCPPERMT","/capita, US$ exchange rate","ROU","Romania","2022","2022",0.5,,
+"PATCBETA","C07-Beta blocking agents","MTMOPPMT","Million US$, purchasing power parity","ROU","Romania","2022","2022",87.9,,
+"PATCBETA","C07-Beta blocking agents","TCPPERMT","/capita, US$ exchange rate","HRV","Croatia","2010","2010",29.3,,
+"PATCBETA","C07-Beta blocking agents","TCPPERMT","/capita, US$ exchange rate","HRV","Croatia","2011","2011",31.3,,
+"PATCBETA","C07-Beta blocking agents","TCPPERMT","/capita, US$ exchange rate","HRV","Croatia","2012","2012",29.3,,
+"PATCBETA","C07-Beta blocking agents","TCPPERMT","/capita, US$ exchange rate","HRV","Croatia","2013","2013",29.2,,
+"PATCBETA","C07-Beta blocking agents","TCPPERMT","/capita, US$ exchange rate","HRV","Croatia","2014","2014",28.2,,
+"PATCBETA","C07-Beta blocking agents","TCPPERMT","/capita, US$ exchange rate","HRV","Croatia","2015","2015",23.2,,
+"PATCBETA","C07-Beta blocking agents","TCPPERMT","/capita, US$ exchange rate","HRV","Croatia","2016","2016",22.6,,
+"PATCBETA","C07-Beta blocking agents","TCPPERMT","/capita, US$ exchange rate","HRV","Croatia","2017","2017",24,,
+"PATCBETA","C07-Beta blocking agents","TCPPERMT","/capita, US$ exchange rate","HRV","Croatia","2018","2018",26.4,,
+"PATCBETA","C07-Beta blocking agents","TCPPERMT","/capita, US$ exchange rate","HRV","Croatia","2019","2019",25.5,,
+"PATCBETA","C07-Beta blocking agents","TCPPERMT","/capita, US$ exchange rate","HRV","Croatia","2020","2020",26.5,,
+"PATCBETA","C07-Beta blocking agents","TCPPERMT","/capita, US$ exchange rate","HRV","Croatia","2021","2021",28.2,,
+"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","ROU","Romania","2022","2022",0,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MLLNCUMT","Million of national currency units","ROU","Romania","2022","2022",411.7,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOPPMT","Million US$, purchasing power parity","ROU","Romania","2022","2022",163,,
+"PATCHYPN","N05C-Hypnotics and sedatives","MLLNCUMT","Million of national currency units","HRV","Croatia","2010","2010",23,,
+"PATCHYPN","N05C-Hypnotics and sedatives","MLLNCUMT","Million of national currency units","HRV","Croatia","2011","2011",24,,
+"PATCHYPN","N05C-Hypnotics and sedatives","MLLNCUMT","Million of national currency units","HRV","Croatia","2012","2012",26,,
+"PATCHYPN","N05C-Hypnotics and sedatives","MLLNCUMT","Million of national currency units","HRV","Croatia","2013","2013",29,,
+"PATCHYPN","N05C-Hypnotics and sedatives","MLLNCUMT","Million of national currency units","HRV","Croatia","2014","2014",30,,
+"PATCHYPN","N05C-Hypnotics and sedatives","MLLNCUMT","Million of national currency units","HRV","Croatia","2015","2015",31,,
+"PATCHYPN","N05C-Hypnotics and sedatives","MLLNCUMT","Million of national currency units","HRV","Croatia","2016","2016",33,,
+"PATCHYPN","N05C-Hypnotics and sedatives","MLLNCUMT","Million of national currency units","HRV","Croatia","2017","2017",35,,
+"PATCHYPN","N05C-Hypnotics and sedatives","MLLNCUMT","Million of national currency units","HRV","Croatia","2018","2018",37,,
+"PATCHYPN","N05C-Hypnotics and sedatives","MLLNCUMT","Million of national currency units","HRV","Croatia","2019","2019",35,,
+"PATCHYPN","N05C-Hypnotics and sedatives","MLLNCUMT","Million of national currency units","HRV","Croatia","2020","2020",32,,
+"PATCHYPN","N05C-Hypnotics and sedatives","MLLNCUMT","Million of national currency units","HRV","Croatia","2021","2021",41,,
+"PATCANXO","N05B-Anxiolytics","MTMOTCMT","Million US$ at exchange rate","ROU","Romania","2022","2022",2.6,,
+"PATCANXO","N05B-Anxiolytics","MTMOPPMT","Million US$, purchasing power parity","HRV","Croatia","2010","2010",167.3,,
+"PATCANXO","N05B-Anxiolytics","MTMOPPMT","Million US$, purchasing power parity","HRV","Croatia","2011","2011",174.7,,
+"PATCANXO","N05B-Anxiolytics","MTMOPPMT","Million US$, purchasing power parity","HRV","Croatia","2012","2012",183,,
+"PATCANXO","N05B-Anxiolytics","MTMOPPMT","Million US$, purchasing power parity","HRV","Croatia","2013","2013",185.5,,
+"PATCANXO","N05B-Anxiolytics","MTMOPPMT","Million US$, purchasing power parity","HRV","Croatia","2014","2014",191.4,,
+"PATCANXO","N05B-Anxiolytics","MTMOPPMT","Million US$, purchasing power parity","HRV","Croatia","2015","2015",195.2,,
+"PATCANXO","N05B-Anxiolytics","MTMOPPMT","Million US$, purchasing power parity","HRV","Croatia","2016","2016",205,,
+"PATCANXO","N05B-Anxiolytics","MTMOPPMT","Million US$, purchasing power parity","HRV","Croatia","2017","2017",204,,
+"PATCANXO","N05B-Anxiolytics","MTMOPPMT","Million US$, purchasing power parity","HRV","Croatia","2018","2018",207.1,,
+"PATCANXO","N05B-Anxiolytics","MTMOPPMT","Million US$, purchasing power parity","HRV","Croatia","2019","2019",218,,
+"PATCANXO","N05B-Anxiolytics","MTMOPPMT","Million US$, purchasing power parity","HRV","Croatia","2020","2020",223.9,,
+"PATCANXO","N05B-Anxiolytics","MTMOPPMT","Million US$, purchasing power parity","HRV","Croatia","2021","2021",215.1,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOTCMT","Million US$ at exchange rate","HRV","Croatia","2010","2010",270,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOTCMT","Million US$ at exchange rate","HRV","Croatia","2011","2011",282,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOTCMT","Million US$ at exchange rate","HRV","Croatia","2012","2012",258.9,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOTCMT","Million US$ at exchange rate","HRV","Croatia","2013","2013",215.3,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOTCMT","Million US$ at exchange rate","HRV","Croatia","2014","2014",165.2,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOTCMT","Million US$ at exchange rate","HRV","Croatia","2015","2015",125.2,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOTCMT","Million US$ at exchange rate","HRV","Croatia","2016","2016",124,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOTCMT","Million US$ at exchange rate","HRV","Croatia","2017","2017",131.9,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOTCMT","Million US$ at exchange rate","HRV","Croatia","2018","2018",146.4,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOTCMT","Million US$ at exchange rate","HRV","Croatia","2019","2019",145.6,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOTCMT","Million US$ at exchange rate","HRV","Croatia","2020","2020",136.7,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOTCMT","Million US$ at exchange rate","HRV","Croatia","2021","2021",154,,
+"PATCRESS","R-Respiratory system","MTMOTCMT","Million US$ at exchange rate","ROU","Romania","2022","2022",110.5,,
+"PATCCHLS","C10-Lipid modifying agents","TCPPERMT","/capita, US$ exchange rate","HRV","Croatia","2010","2010",77.2,,
+"PATCCHLS","C10-Lipid modifying agents","TCPPERMT","/capita, US$ exchange rate","HRV","Croatia","2011","2011",82.3,,
+"PATCCHLS","C10-Lipid modifying agents","TCPPERMT","/capita, US$ exchange rate","HRV","Croatia","2012","2012",74.5,,
+"PATCCHLS","C10-Lipid modifying agents","TCPPERMT","/capita, US$ exchange rate","HRV","Croatia","2013","2013",69.5,,
+"PATCCHLS","C10-Lipid modifying agents","TCPPERMT","/capita, US$ exchange rate","HRV","Croatia","2014","2014",45.8,,
+"PATCCHLS","C10-Lipid modifying agents","TCPPERMT","/capita, US$ exchange rate","HRV","Croatia","2015","2015",43.3,,
+"PATCCHLS","C10-Lipid modifying agents","TCPPERMT","/capita, US$ exchange rate","HRV","Croatia","2016","2016",39,,
+"PATCCHLS","C10-Lipid modifying agents","TCPPERMT","/capita, US$ exchange rate","HRV","Croatia","2017","2017",41,,
+"PATCCHLS","C10-Lipid modifying agents","TCPPERMT","/capita, US$ exchange rate","HRV","Croatia","2018","2018",45.5,,
+"PATCCHLS","C10-Lipid modifying agents","TCPPERMT","/capita, US$ exchange rate","HRV","Croatia","2019","2019",44.2,,
+"PATCCHLS","C10-Lipid modifying agents","TCPPERMT","/capita, US$ exchange rate","HRV","Croatia","2020","2020",46.7,,
+"PATCCHLS","C10-Lipid modifying agents","TCPPERMT","/capita, US$ exchange rate","HRV","Croatia","2021","2021",51.9,,
+"PATCRESS","R-Respiratory system","MLLNCUMT","Million of national currency units","ROU","Romania","2022","2022",518.1,,
+"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","ROU","Romania","2022","2022",14.2,,
+"PATCDIUR","C03-Diuretics","MLLNCUMT","Million of national currency units","ROU","Romania","2022","2022",170.9,,
+"PATCCNSY","N-Nervous system","MLLNCUMT","Million of national currency units","HRV","Croatia","2010","2010",784,,
+"PATCCNSY","N-Nervous system","MLLNCUMT","Million of national currency units","HRV","Croatia","2011","2011",811,,
+"PATCCNSY","N-Nervous system","MLLNCUMT","Million of national currency units","HRV","Croatia","2012","2012",816,,
+"PATCCNSY","N-Nervous system","MLLNCUMT","Million of national currency units","HRV","Croatia","2013","2013",811,,
+"PATCCNSY","N-Nervous system","MLLNCUMT","Million of national currency units","HRV","Croatia","2014","2014",795,,
+"PATCCNSY","N-Nervous system","MLLNCUMT","Million of national currency units","HRV","Croatia","2015","2015",812,,
+"PATCCNSY","N-Nervous system","MLLNCUMT","Million of national currency units","HRV","Croatia","2016","2016",849,,
+"PATCCNSY","N-Nervous system","MLLNCUMT","Million of national currency units","HRV","Croatia","2017","2017",834,,
+"PATCCNSY","N-Nervous system","MLLNCUMT","Million of national currency units","HRV","Croatia","2018","2018",860,,
+"PATCCNSY","N-Nervous system","MLLNCUMT","Million of national currency units","HRV","Croatia","2019","2019",885,,
+"PATCCNSY","N-Nervous system","MLLNCUMT","Million of national currency units","HRV","Croatia","2020","2020",924,,
+"PATCCNSY","N-Nervous system","MLLNCUMT","Million of national currency units","HRV","Croatia","2021","2021",929.7,,
+"PATCBLOO","B-Blood and blood forming organs","MLLNCUMT","Million of national currency units","HRV","Croatia","2010","2010",267,,
+"PATCBLOO","B-Blood and blood forming organs","MLLNCUMT","Million of national currency units","HRV","Croatia","2011","2011",259,,
+"PATCBLOO","B-Blood and blood forming organs","MLLNCUMT","Million of national currency units","HRV","Croatia","2012","2012",282,,
+"PATCBLOO","B-Blood and blood forming organs","MLLNCUMT","Million of national currency units","HRV","Croatia","2013","2013",287,,
+"PATCBLOO","B-Blood and blood forming organs","MLLNCUMT","Million of national currency units","HRV","Croatia","2014","2014",303,,
+"PATCBLOO","B-Blood and blood forming organs","MLLNCUMT","Million of national currency units","HRV","Croatia","2015","2015",355,,
+"PATCBLOO","B-Blood and blood forming organs","MLLNCUMT","Million of national currency units","HRV","Croatia","2016","2016",446,,
+"PATCBLOO","B-Blood and blood forming organs","MLLNCUMT","Million of national currency units","HRV","Croatia","2017","2017",496,,
+"PATCBLOO","B-Blood and blood forming organs","MLLNCUMT","Million of national currency units","HRV","Croatia","2018","2018",516,,
+"PATCBLOO","B-Blood and blood forming organs","MLLNCUMT","Million of national currency units","HRV","Croatia","2019","2019",618,,
+"PATCBLOO","B-Blood and blood forming organs","MLLNCUMT","Million of national currency units","HRV","Croatia","2020","2020",673,,
+"PATCBLOO","B-Blood and blood forming organs","MLLNCUMT","Million of national currency units","HRV","Croatia","2021","2021",778.5,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOPPMT","Million US$, purchasing power parity","ROU","Romania","2022","2022",8,,
+"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2010","2010",73.8,,
+"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2011","2011",77.8,,
+"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2012","2012",78.5,,
+"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2013","2013",79.8,,
+"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2014","2014",80.3,,
+"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2015","2015",84.1,,
+"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2016","2016",91.8,,
+"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2017","2017",98.2,,
+"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2018","2018",103.5,,
+"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2019","2019",113,,
+"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2020","2020",115.9,,
+"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2021","2021",117.1,,
+"PATCANAL","N02-Analgesics","MTMOTCMT","Million US$ at exchange rate","HRV","Croatia","2010","2010",254.9,,
+"PATCANAL","N02-Analgesics","MTMOTCMT","Million US$ at exchange rate","HRV","Croatia","2011","2011",273.5,,
+"PATCANAL","N02-Analgesics","MTMOTCMT","Million US$ at exchange rate","HRV","Croatia","2012","2012",246,,
+"PATCANAL","N02-Analgesics","MTMOTCMT","Million US$ at exchange rate","HRV","Croatia","2013","2013",249.6,,
+"PATCANAL","N02-Analgesics","MTMOTCMT","Million US$ at exchange rate","HRV","Croatia","2014","2014",242.5,,
+"PATCANAL","N02-Analgesics","MTMOTCMT","Million US$ at exchange rate","HRV","Croatia","2015","2015",205.4,,
+"PATCANAL","N02-Analgesics","MTMOTCMT","Million US$ at exchange rate","HRV","Croatia","2016","2016",203.7,,
+"PATCANAL","N02-Analgesics","MTMOTCMT","Million US$ at exchange rate","HRV","Croatia","2017","2017",208.2,,
+"PATCANAL","N02-Analgesics","MTMOTCMT","Million US$ at exchange rate","HRV","Croatia","2018","2018",238.8,,
+"PATCANAL","N02-Analgesics","MTMOTCMT","Million US$ at exchange rate","HRV","Croatia","2019","2019",245.7,,
+"PATCANAL","N02-Analgesics","MTMOTCMT","Million US$ at exchange rate","HRV","Croatia","2020","2020",270,,
+"PATCANAL","N02-Analgesics","MTMOTCMT","Million US$ at exchange rate","HRV","Croatia","2021","2021",280.8,,
+"PATCDIAB","A10-Drugs used in diabetes","MTMOPPMT","Million US$, purchasing power parity","HRV","Croatia","2010","2010",468.8,,
+"PATCDIAB","A10-Drugs used in diabetes","MTMOPPMT","Million US$, purchasing power parity","HRV","Croatia","2011","2011",520,,
+"PATCDIAB","A10-Drugs used in diabetes","MTMOPPMT","Million US$, purchasing power parity","HRV","Croatia","2012","2012",571.6,,
+"PATCDIAB","A10-Drugs used in diabetes","MTMOPPMT","Million US$, purchasing power parity","HRV","Croatia","2013","2013",636.5,,
+"PATCDIAB","A10-Drugs used in diabetes","MTMOPPMT","Million US$, purchasing power parity","HRV","Croatia","2014","2014",674,,
+"PATCDIAB","A10-Drugs used in diabetes","MTMOPPMT","Million US$, purchasing power parity","HRV","Croatia","2015","2015",737.9,,
+"PATCDIAB","A10-Drugs used in diabetes","MTMOPPMT","Million US$, purchasing power parity","HRV","Croatia","2016","2016",859.9,,
+"PATCDIAB","A10-Drugs used in diabetes","MTMOPPMT","Million US$, purchasing power parity","HRV","Croatia","2017","2017",924.6,,
+"PATCDIAB","A10-Drugs used in diabetes","MTMOPPMT","Million US$, purchasing power parity","HRV","Croatia","2018","2018",944.4,,
+"PATCDIAB","A10-Drugs used in diabetes","MTMOPPMT","Million US$, purchasing power parity","HRV","Croatia","2019","2019",1012.6,,
+"PATCDIAB","A10-Drugs used in diabetes","MTMOPPMT","Million US$, purchasing power parity","HRV","Croatia","2020","2020",1090.9,,
+"PATCDIAB","A10-Drugs used in diabetes","MTMOPPMT","Million US$, purchasing power parity","HRV","Croatia","2021","2021",1117.3,,
+"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","ROU","Romania","2022","2022",36.7,,
+"PATCACID","A02A-Antacids","MLLNCUMT","Million of national currency units","HRV","Croatia","2010","2010",9,,
+"PATCACID","A02A-Antacids","MLLNCUMT","Million of national currency units","HRV","Croatia","2011","2011",9,,
+"PATCACID","A02A-Antacids","MLLNCUMT","Million of national currency units","HRV","Croatia","2012","2012",8,,
+"PATCACID","A02A-Antacids","MLLNCUMT","Million of national currency units","HRV","Croatia","2013","2013",9,,
+"PATCACID","A02A-Antacids","MLLNCUMT","Million of national currency units","HRV","Croatia","2014","2014",10,,
+"PATCACID","A02A-Antacids","MLLNCUMT","Million of national currency units","HRV","Croatia","2015","2015",10,,
+"PATCACID","A02A-Antacids","MLLNCUMT","Million of national currency units","HRV","Croatia","2016","2016",10,,
+"PATCACID","A02A-Antacids","MLLNCUMT","Million of national currency units","HRV","Croatia","2017","2017",9,,
+"PATCACID","A02A-Antacids","MLLNCUMT","Million of national currency units","HRV","Croatia","2018","2018",10,,
+"PATCACID","A02A-Antacids","MLLNCUMT","Million of national currency units","HRV","Croatia","2019","2019",10,,
+"PATCACID","A02A-Antacids","MLLNCUMT","Million of national currency units","HRV","Croatia","2020","2020",10,,
+"PATCACID","A02A-Antacids","MLLNCUMT","Million of national currency units","HRV","Croatia","2021","2021",7,,
+"PATCGLYC","C01A-Cardiac glycosides","MLLNCUMT","Million of national currency units","ROU","Romania","2022","2022",4.8,,
+"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2010","2010",215.5,,
+"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2011","2011",217.1,,
+"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2012","2012",206.2,,
+"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2013","2013",212.5,,
+"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2014","2014",204.8,,
+"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2015","2015",209.5,,
+"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2016","2016",260,,
+"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2017","2017",334.2,,
+"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2018","2018",336,,
+"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2019","2019",411.5,,
+"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2020","2020",420.2,,
+"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2021","2021",809.5,,
+"PATCALIM","A-Alimentary tract and metabolism","MTMOTCMT","Million US$ at exchange rate","ROU","Romania","2022","2022",591.1,,
+"PATCINFC","J-Antiinfectives for systemic use","TCPPERMT","/capita, US$ exchange rate","ROU","Romania","2022","2022",11.9,,
+"PATCDIAB","A10-Drugs used in diabetes","MTMOTCMT","Million US$ at exchange rate","ROU","Romania","2022","2022",429.8,,
+"PATCRESS","R-Respiratory system","MTMOPPMT","Million US$, purchasing power parity","HRV","Croatia","2010","2010",655.5,,
+"PATCRESS","R-Respiratory system","MTMOPPMT","Million US$, purchasing power parity","HRV","Croatia","2011","2011",668.6,,
+"PATCRESS","R-Respiratory system","MTMOPPMT","Million US$, purchasing power parity","HRV","Croatia","2012","2012",664.2,,
+"PATCRESS","R-Respiratory system","MTMOPPMT","Million US$, purchasing power parity","HRV","Croatia","2013","2013",699.7,,
+"PATCRESS","R-Respiratory system","MTMOPPMT","Million US$, purchasing power parity","HRV","Croatia","2014","2014",686.8,,
+"PATCRESS","R-Respiratory system","MTMOPPMT","Million US$, purchasing power parity","HRV","Croatia","2015","2015",746.5,,
+"PATCRESS","R-Respiratory system","MTMOPPMT","Million US$, purchasing power parity","HRV","Croatia","2016","2016",802,,
+"PATCRESS","R-Respiratory system","MTMOPPMT","Million US$, purchasing power parity","HRV","Croatia","2017","2017",811.3,,
+"PATCRESS","R-Respiratory system","MTMOPPMT","Million US$, purchasing power parity","HRV","Croatia","2018","2018",876.1,,
+"PATCRESS","R-Respiratory system","MTMOPPMT","Million US$, purchasing power parity","HRV","Croatia","2019","2019",989.2,,
+"PATCRESS","R-Respiratory system","MTMOPPMT","Million US$, purchasing power parity","HRV","Croatia","2020","2020",971.8,,
+"PATCRESS","R-Respiratory system","MTMOPPMT","Million US$, purchasing power parity","HRV","Croatia","2021","2021",958.5,,
+"PATCTOTT","Total pharmaceutical sales","MTMOTCMT","Million US$ at exchange rate","HRV","Croatia","2010","2010",6628.7,,
+"PATCTOTT","Total pharmaceutical sales","MTMOTCMT","Million US$ at exchange rate","HRV","Croatia","2011","2011",7145.5,,
+"PATCTOTT","Total pharmaceutical sales","MTMOTCMT","Million US$ at exchange rate","HRV","Croatia","2012","2012",6536,,
+"PATCTOTT","Total pharmaceutical sales","MTMOTCMT","Million US$ at exchange rate","HRV","Croatia","2013","2013",6845.2,,
+"PATCTOTT","Total pharmaceutical sales","MTMOTCMT","Million US$ at exchange rate","HRV","Croatia","2014","2014",6561.7,,
+"PATCTOTT","Total pharmaceutical sales","MTMOTCMT","Million US$ at exchange rate","HRV","Croatia","2015","2015",5786.3,,
+"PATCTOTT","Total pharmaceutical sales","MTMOTCMT","Million US$ at exchange rate","HRV","Croatia","2016","2016",6424.2,,
+"PATCTOTT","Total pharmaceutical sales","MTMOTCMT","Million US$ at exchange rate","HRV","Croatia","2017","2017",6975.1,,
+"PATCTOTT","Total pharmaceutical sales","MTMOTCMT","Million US$ at exchange rate","HRV","Croatia","2018","2018",7950.9,,
+"PATCTOTT","Total pharmaceutical sales","MTMOTCMT","Million US$ at exchange rate","HRV","Croatia","2019","2019",8703.4,,
+"PATCTOTT","Total pharmaceutical sales","MTMOTCMT","Million US$ at exchange rate","HRV","Croatia","2020","2020",9579.2,,
+"PATCTOTT","Total pharmaceutical sales","MTMOTCMT","Million US$ at exchange rate","HRV","Croatia","2021","2021",11700.8,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","TCPPERMT","/capita, US$ exchange rate","HRV","Croatia","2010","2010",59,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","TCPPERMT","/capita, US$ exchange rate","HRV","Croatia","2011","2011",64.5,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","TCPPERMT","/capita, US$ exchange rate","HRV","Croatia","2012","2012",60.6,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","TCPPERMT","/capita, US$ exchange rate","HRV","Croatia","2013","2013",63.6,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","TCPPERMT","/capita, US$ exchange rate","HRV","Croatia","2014","2014",65.3,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","TCPPERMT","/capita, US$ exchange rate","HRV","Croatia","2015","2015",56.7,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","TCPPERMT","/capita, US$ exchange rate","HRV","Croatia","2016","2016",58.1,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","TCPPERMT","/capita, US$ exchange rate","HRV","Croatia","2017","2017",60.6,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","TCPPERMT","/capita, US$ exchange rate","HRV","Croatia","2018","2018",64.8,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","TCPPERMT","/capita, US$ exchange rate","HRV","Croatia","2019","2019",62.4,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","TCPPERMT","/capita, US$ exchange rate","HRV","Croatia","2020","2020",63.6,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","TCPPERMT","/capita, US$ exchange rate","HRV","Croatia","2021","2021",66.6,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOTCMT","Million US$ at exchange rate","HRV","Croatia","2010","2010",82.2,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOTCMT","Million US$ at exchange rate","HRV","Croatia","2011","2011",98.7,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOTCMT","Million US$ at exchange rate","HRV","Croatia","2012","2012",96.6,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOTCMT","Million US$ at exchange rate","HRV","Croatia","2013","2013",117.5,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOTCMT","Million US$ at exchange rate","HRV","Croatia","2014","2014",118,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOTCMT","Million US$ at exchange rate","HRV","Croatia","2015","2015",106.6,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOTCMT","Million US$ at exchange rate","HRV","Croatia","2016","2016",116.2,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOTCMT","Million US$ at exchange rate","HRV","Croatia","2017","2017",129.7,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOTCMT","Million US$ at exchange rate","HRV","Croatia","2018","2018",141.6,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOTCMT","Million US$ at exchange rate","HRV","Croatia","2019","2019",130.8,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOTCMT","Million US$ at exchange rate","HRV","Croatia","2020","2020",131,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOTCMT","Million US$ at exchange rate","HRV","Croatia","2021","2021",143,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","TCPPERMT","/capita, US$ exchange rate","HRV","Croatia","2010","2010",5.7,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","TCPPERMT","/capita, US$ exchange rate","HRV","Croatia","2011","2011",6.3,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","TCPPERMT","/capita, US$ exchange rate","HRV","Croatia","2012","2012",5.1,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","TCPPERMT","/capita, US$ exchange rate","HRV","Croatia","2013","2013",5.6,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","TCPPERMT","/capita, US$ exchange rate","HRV","Croatia","2014","2014",5,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","TCPPERMT","/capita, US$ exchange rate","HRV","Croatia","2015","2015",4.4,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","TCPPERMT","/capita, US$ exchange rate","HRV","Croatia","2016","2016",4.2,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","TCPPERMT","/capita, US$ exchange rate","HRV","Croatia","2017","2017",4.4,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","TCPPERMT","/capita, US$ exchange rate","HRV","Croatia","2018","2018",4.4,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","TCPPERMT","/capita, US$ exchange rate","HRV","Croatia","2019","2019",3.9,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","TCPPERMT","/capita, US$ exchange rate","HRV","Croatia","2020","2020",3.7,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","TCPPERMT","/capita, US$ exchange rate","HRV","Croatia","2021","2021",3.9,,
+"PATCGENU","G-Genito urinary system and sex hormones","TCPPERMT","/capita, US$ exchange rate","ROU","Romania","2022","2022",0.8,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOTCMT","Million US$ at exchange rate","ROU","Romania","2022","2022",23.6,,
+"PATCBETA","C07-Beta blocking agents","MLLNCUMT","Million of national currency units","HRV","Croatia","2010","2010",92,,
+"PATCBETA","C07-Beta blocking agents","MLLNCUMT","Million of national currency units","HRV","Croatia","2011","2011",95,,
+"PATCBETA","C07-Beta blocking agents","MLLNCUMT","Million of national currency units","HRV","Croatia","2012","2012",97,,
+"PATCBETA","C07-Beta blocking agents","MLLNCUMT","Million of national currency units","HRV","Croatia","2013","2013",94,,
+"PATCBETA","C07-Beta blocking agents","MLLNCUMT","Million of national currency units","HRV","Croatia","2014","2014",91,,
+"PATCBETA","C07-Beta blocking agents","MLLNCUMT","Million of national currency units","HRV","Croatia","2015","2015",89,,
+"PATCBETA","C07-Beta blocking agents","MLLNCUMT","Million of national currency units","HRV","Croatia","2016","2016",85,,
+"PATCBETA","C07-Beta blocking agents","MLLNCUMT","Million of national currency units","HRV","Croatia","2017","2017",87,,
+"PATCBETA","C07-Beta blocking agents","MLLNCUMT","Million of national currency units","HRV","Croatia","2018","2018",90,,
+"PATCBETA","C07-Beta blocking agents","MLLNCUMT","Million of national currency units","HRV","Croatia","2019","2019",91,,
+"PATCBETA","C07-Beta blocking agents","MLLNCUMT","Million of national currency units","HRV","Croatia","2020","2020",94,,
+"PATCBETA","C07-Beta blocking agents","MLLNCUMT","Million of national currency units","HRV","Croatia","2021","2021",94,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MLLNCUMT","Million of national currency units","HRV","Croatia","2010","2010",18,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MLLNCUMT","Million of national currency units","HRV","Croatia","2011","2011",19,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MLLNCUMT","Million of national currency units","HRV","Croatia","2012","2012",17,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MLLNCUMT","Million of national currency units","HRV","Croatia","2013","2013",18,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MLLNCUMT","Million of national currency units","HRV","Croatia","2014","2014",16,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MLLNCUMT","Million of national currency units","HRV","Croatia","2015","2015",17,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MLLNCUMT","Million of national currency units","HRV","Croatia","2016","2016",16,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MLLNCUMT","Million of national currency units","HRV","Croatia","2017","2017",16,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MLLNCUMT","Million of national currency units","HRV","Croatia","2018","2018",15,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MLLNCUMT","Million of national currency units","HRV","Croatia","2019","2019",14,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MLLNCUMT","Million of national currency units","HRV","Croatia","2020","2020",13,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MLLNCUMT","Million of national currency units","HRV","Croatia","2021","2021",13,,
+"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2010","2010",152.6,,
+"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2011","2011",156.1,,
+"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2012","2012",155.6,,
+"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2013","2013",164.5,,
+"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2014","2014",162.1,,
+"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2015","2015",177.4,,
+"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2016","2016",192.2,,
+"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2017","2017",196.5,,
+"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2018","2018",214.2,,
+"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2019","2019",243.2,,
+"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2020","2020",240.1,,
+"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2021","2021",242.7,,
+"PATCANXO","N05B-Anxiolytics","TCPPERMT","/capita, US$ exchange rate","ROU","Romania","2022","2022",0.1,,
+"PATCDIUR","C03-Diuretics","MTMOTCMT","Million US$ at exchange rate","ROU","Romania","2022","2022",36.5,,
+"PATCHYPO","C02-Antihypertensives","MTMOTCMT","Million US$ at exchange rate","HRV","Croatia","2010","2010",58.9,,
+"PATCHYPO","C02-Antihypertensives","MTMOTCMT","Million US$ at exchange rate","HRV","Croatia","2011","2011",67.7,,
+"PATCHYPO","C02-Antihypertensives","MTMOTCMT","Million US$ at exchange rate","HRV","Croatia","2012","2012",65.7,,
+"PATCHYPO","C02-Antihypertensives","MTMOTCMT","Million US$ at exchange rate","HRV","Croatia","2013","2013",70,,
+"PATCHYPO","C02-Antihypertensives","MTMOTCMT","Million US$ at exchange rate","HRV","Croatia","2014","2014",68.2,,
+"PATCHYPO","C02-Antihypertensives","MTMOTCMT","Million US$ at exchange rate","HRV","Croatia","2015","2015",53.8,,
+"PATCHYPO","C02-Antihypertensives","MTMOTCMT","Million US$ at exchange rate","HRV","Croatia","2016","2016",47.6,,
+"PATCHYPO","C02-Antihypertensives","MTMOTCMT","Million US$ at exchange rate","HRV","Croatia","2017","2017",53.5,,
+"PATCHYPO","C02-Antihypertensives","MTMOTCMT","Million US$ at exchange rate","HRV","Croatia","2018","2018",63.6,,
+"PATCHYPO","C02-Antihypertensives","MTMOTCMT","Million US$ at exchange rate","HRV","Croatia","2019","2019",67.1,,
+"PATCHYPO","C02-Antihypertensives","MTMOTCMT","Million US$ at exchange rate","HRV","Croatia","2020","2020",82,,
+"PATCHYPO","C02-Antihypertensives","MTMOTCMT","Million US$ at exchange rate","HRV","Croatia","2021","2021",85.3,,
+"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2010","2010",289.8,,
+"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2011","2011",323.5,,
+"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2012","2012",341,,
+"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2013","2013",353.2,,
+"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2014","2014",347.3,,
+"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2015","2015",367,,
+"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2016","2016",413.3,,
+"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2017","2017",438.4,,
+"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2018","2018",458.9,,
+"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2019","2019",512.3,,
+"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2020","2020",524.4,,
+"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2021","2021",537,,
+"PATCTOTT","Total pharmaceutical sales","TCPPERMT","/capita, US$ exchange rate","HRV","Croatia","2010","2010",1542.9,,
+"PATCTOTT","Total pharmaceutical sales","TCPPERMT","/capita, US$ exchange rate","HRV","Croatia","2011","2011",1668.4,,
+"PATCTOTT","Total pharmaceutical sales","TCPPERMT","/capita, US$ exchange rate","HRV","Croatia","2012","2012",1531,,
+"PATCTOTT","Total pharmaceutical sales","TCPPERMT","/capita, US$ exchange rate","HRV","Croatia","2013","2013",1609,,
+"PATCTOTT","Total pharmaceutical sales","TCPPERMT","/capita, US$ exchange rate","HRV","Croatia","2014","2014",1549,,
+"PATCTOTT","Total pharmaceutical sales","TCPPERMT","/capita, US$ exchange rate","HRV","Croatia","2015","2015",1375.1,,
+"PATCTOTT","Total pharmaceutical sales","TCPPERMT","/capita, US$ exchange rate","HRV","Croatia","2016","2016",1539.7,,
+"PATCTOTT","Total pharmaceutical sales","TCPPERMT","/capita, US$ exchange rate","HRV","Croatia","2017","2017",1688.9,,
+"PATCTOTT","Total pharmaceutical sales","TCPPERMT","/capita, US$ exchange rate","HRV","Croatia","2018","2018",1943.6,,
+"PATCTOTT","Total pharmaceutical sales","TCPPERMT","/capita, US$ exchange rate","HRV","Croatia","2019","2019",2139.9,,
+"PATCTOTT","Total pharmaceutical sales","TCPPERMT","/capita, US$ exchange rate","HRV","Croatia","2020","2020",2366.8,,
+"PATCTOTT","Total pharmaceutical sales","TCPPERMT","/capita, US$ exchange rate","HRV","Croatia","2021","2021",2962.7,,
+"PATCCARV","C-Cardiovascular system","MTMOTCMT","Million US$ at exchange rate","HRV","Croatia","2010","2010",1336.1,,
+"PATCCARV","C-Cardiovascular system","MTMOTCMT","Million US$ at exchange rate","HRV","Croatia","2011","2011",1387.4,,
+"PATCCARV","C-Cardiovascular system","MTMOTCMT","Million US$ at exchange rate","HRV","Croatia","2012","2012",1294.3,,
+"PATCCARV","C-Cardiovascular system","MTMOTCMT","Million US$ at exchange rate","HRV","Croatia","2013","2013",1249.4,,
+"PATCCARV","C-Cardiovascular system","MTMOTCMT","Million US$ at exchange rate","HRV","Croatia","2014","2014",1019.8,,
+"PATCCARV","C-Cardiovascular system","MTMOTCMT","Million US$ at exchange rate","HRV","Croatia","2015","2015",859.1,,
+"PATCCARV","C-Cardiovascular system","MTMOTCMT","Million US$ at exchange rate","HRV","Croatia","2016","2016",860.2,,
+"PATCCARV","C-Cardiovascular system","MTMOTCMT","Million US$ at exchange rate","HRV","Croatia","2017","2017",892.9,,
+"PATCCARV","C-Cardiovascular system","MTMOTCMT","Million US$ at exchange rate","HRV","Croatia","2018","2018",950.4,,
+"PATCCARV","C-Cardiovascular system","MTMOTCMT","Million US$ at exchange rate","HRV","Croatia","2019","2019",929.5,,
+"PATCCARV","C-Cardiovascular system","MTMOTCMT","Million US$ at exchange rate","HRV","Croatia","2020","2020",983.1,,
+"PATCCARV","C-Cardiovascular system","MTMOTCMT","Million US$ at exchange rate","HRV","Croatia","2021","2021",1042.5,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOTCMT","Million US$ at exchange rate","ROU","Romania","2022","2022",87.8,,
+"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","ROU","Romania","2022","2022",30.2,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","TCPPERMT","/capita, US$ exchange rate","HRV","Croatia","2010","2010",19.1,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","TCPPERMT","/capita, US$ exchange rate","HRV","Croatia","2011","2011",23,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","TCPPERMT","/capita, US$ exchange rate","HRV","Croatia","2012","2012",22.6,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","TCPPERMT","/capita, US$ exchange rate","HRV","Croatia","2013","2013",27.6,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","TCPPERMT","/capita, US$ exchange rate","HRV","Croatia","2014","2014",27.8,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","TCPPERMT","/capita, US$ exchange rate","HRV","Croatia","2015","2015",25.3,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","TCPPERMT","/capita, US$ exchange rate","HRV","Croatia","2016","2016",27.9,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","TCPPERMT","/capita, US$ exchange rate","HRV","Croatia","2017","2017",31.4,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","TCPPERMT","/capita, US$ exchange rate","HRV","Croatia","2018","2018",34.6,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","TCPPERMT","/capita, US$ exchange rate","HRV","Croatia","2019","2019",32.2,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","TCPPERMT","/capita, US$ exchange rate","HRV","Croatia","2020","2020",32.4,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","TCPPERMT","/capita, US$ exchange rate","HRV","Croatia","2021","2021",36.2,,
+"PATCANXO","N05B-Anxiolytics","MLLNCUMT","Million of national currency units","ROU","Romania","2022","2022",12.1,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","TCPPERMT","/capita, US$ exchange rate","ROU","Romania","2022","2022",1.2,,
+"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2010","2010",109.1,,
+"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2011","2011",121.4,,
+"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2012","2012",133.9,,
+"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2013","2013",149.6,,
+"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2014","2014",159.1,,
+"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2015","2015",175.4,,
+"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2016","2016",206.1,,
+"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2017","2017",223.9,,
+"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2018","2018",230.8,,
+"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2019","2019",249,,
+"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2020","2020",269.5,,
+"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2021","2021",282.9,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2010","2010",50.3,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2011","2011",51.6,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2012","2012",54.4,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2013","2013",58.5,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2014","2014",63.2,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2015","2015",65.8,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2016","2016",70.5,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2017","2017",76.3,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2018","2018",84.6,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2019","2019",93.9,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2020","2020",98.3,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2021","2021",77.9,,
+"PATCSKEL","M-Musculo-skeletal system","MTMOPPMT","Million US$, purchasing power parity","ROU","Romania","2022","2022",216.1,,
+"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","ROU","Romania","2022","2022",0.4,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MLLNCUMT","Million of national currency units","ROU","Romania","2022","2022",110.5,,
+"PATCDEPR","N06A-Antidepressants","MTMOTCMT","Million US$ at exchange rate","HRV","Croatia","2010","2010",120.6,,
+"PATCDEPR","N06A-Antidepressants","MTMOTCMT","Million US$ at exchange rate","HRV","Croatia","2011","2011",122.7,,
+"PATCDEPR","N06A-Antidepressants","MTMOTCMT","Million US$ at exchange rate","HRV","Croatia","2012","2012",110.8,,
+"PATCDEPR","N06A-Antidepressants","MTMOTCMT","Million US$ at exchange rate","HRV","Croatia","2013","2013",110.9,,
+"PATCDEPR","N06A-Antidepressants","MTMOTCMT","Million US$ at exchange rate","HRV","Croatia","2014","2014",107.5,,
+"PATCDEPR","N06A-Antidepressants","MTMOTCMT","Million US$ at exchange rate","HRV","Croatia","2015","2015",89,,
+"PATCDEPR","N06A-Antidepressants","MTMOTCMT","Million US$ at exchange rate","HRV","Croatia","2016","2016",90.8,,
+"PATCDEPR","N06A-Antidepressants","MTMOTCMT","Million US$ at exchange rate","HRV","Croatia","2017","2017",91,,
+"PATCDEPR","N06A-Antidepressants","MTMOTCMT","Million US$ at exchange rate","HRV","Croatia","2018","2018",94.8,,
+"PATCDEPR","N06A-Antidepressants","MTMOTCMT","Million US$ at exchange rate","HRV","Croatia","2019","2019",86.5,,
+"PATCDEPR","N06A-Antidepressants","MTMOTCMT","Million US$ at exchange rate","HRV","Croatia","2020","2020",88.9,,
+"PATCDEPR","N06A-Antidepressants","MTMOTCMT","Million US$ at exchange rate","HRV","Croatia","2021","2021",94.8,,
+"PATCDIAB","A10-Drugs used in diabetes","TCPPERMT","/capita, US$ exchange rate","ROU","Romania","2022","2022",22.6,,
+"PATCSKEL","M-Musculo-skeletal system","TCPPERMT","/capita, US$ exchange rate","HRV","Croatia","2010","2010",67.3,,
+"PATCSKEL","M-Musculo-skeletal system","TCPPERMT","/capita, US$ exchange rate","HRV","Croatia","2011","2011",68.5,,
+"PATCSKEL","M-Musculo-skeletal system","TCPPERMT","/capita, US$ exchange rate","HRV","Croatia","2012","2012",61.8,,
+"PATCSKEL","M-Musculo-skeletal system","TCPPERMT","/capita, US$ exchange rate","HRV","Croatia","2013","2013",64.6,,
+"PATCSKEL","M-Musculo-skeletal system","TCPPERMT","/capita, US$ exchange rate","HRV","Croatia","2014","2014",61.6,,
+"PATCSKEL","M-Musculo-skeletal system","TCPPERMT","/capita, US$ exchange rate","HRV","Croatia","2015","2015",53.3,,
+"PATCSKEL","M-Musculo-skeletal system","TCPPERMT","/capita, US$ exchange rate","HRV","Croatia","2016","2016",57.6,,
+"PATCSKEL","M-Musculo-skeletal system","TCPPERMT","/capita, US$ exchange rate","HRV","Croatia","2017","2017",62.8,,
+"PATCSKEL","M-Musculo-skeletal system","TCPPERMT","/capita, US$ exchange rate","HRV","Croatia","2018","2018",94.7,,
+"PATCSKEL","M-Musculo-skeletal system","TCPPERMT","/capita, US$ exchange rate","HRV","Croatia","2019","2019",101,,
+"PATCSKEL","M-Musculo-skeletal system","TCPPERMT","/capita, US$ exchange rate","HRV","Croatia","2020","2020",95.4,,
+"PATCSKEL","M-Musculo-skeletal system","TCPPERMT","/capita, US$ exchange rate","HRV","Croatia","2021","2021",93.2,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOPPMT","Million US$, purchasing power parity","HRV","Croatia","2010","2010",120.6,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOPPMT","Million US$, purchasing power parity","HRV","Croatia","2011","2011",120.5,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOPPMT","Million US$, purchasing power parity","HRV","Croatia","2012","2012",129.5,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOPPMT","Million US$, purchasing power parity","HRV","Croatia","2013","2013",130.7,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOPPMT","Million US$, purchasing power parity","HRV","Croatia","2014","2014",129.7,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOPPMT","Million US$, purchasing power parity","HRV","Croatia","2015","2015",135.1,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOPPMT","Million US$, purchasing power parity","HRV","Croatia","2016","2016",135.9,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOPPMT","Million US$, purchasing power parity","HRV","Croatia","2017","2017",140.5,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOPPMT","Million US$, purchasing power parity","HRV","Croatia","2018","2018",145.6,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOPPMT","Million US$, purchasing power parity","HRV","Croatia","2019","2019",152.4,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOPPMT","Million US$, purchasing power parity","HRV","Croatia","2020","2020",142.9,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOPPMT","Million US$, purchasing power parity","HRV","Croatia","2021","2021",145.7,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","ROU","Romania","2022","2022",0.4,,
+"PATCCHLS","C10-Lipid modifying agents","MTMOPPMT","Million US$, purchasing power parity","ROU","Romania","2022","2022",149.6,,
+"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2010","2010",38.9,,
+"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2011","2011",40.8,,
+"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2012","2012",42.9,,
+"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2013","2013",43.6,,
+"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2014","2014",45.2,,
+"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2015","2015",46.4,,
+"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2016","2016",49.1,,
+"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2017","2017",49.4,,
+"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2018","2018",50.6,,
+"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2019","2019",53.6,,
+"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2020","2020",55.3,,
+"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2021","2021",54.5,,
+"PATCDIAB","A10-Drugs used in diabetes","MLLNCUMT","Million of national currency units","ROU","Romania","2022","2022",2015.1,,
+"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","ROU","Romania","2022","2022",4.6,,
+"PATCDIUR","C03-Diuretics","MTMOPPMT","Million US$, purchasing power parity","HRV","Croatia","2010","2010",75.9,,
+"PATCDIUR","C03-Diuretics","MTMOPPMT","Million US$, purchasing power parity","HRV","Croatia","2011","2011",82.3,,
+"PATCDIUR","C03-Diuretics","MTMOPPMT","Million US$, purchasing power parity","HRV","Croatia","2012","2012",88.4,,
+"PATCDIUR","C03-Diuretics","MTMOPPMT","Million US$, purchasing power parity","HRV","Croatia","2013","2013",92.7,,
+"PATCDIUR","C03-Diuretics","MTMOPPMT","Million US$, purchasing power parity","HRV","Croatia","2014","2014",95.7,,
+"PATCDIUR","C03-Diuretics","MTMOPPMT","Million US$, purchasing power parity","HRV","Croatia","2015","2015",103,,
+"PATCDIUR","C03-Diuretics","MTMOPPMT","Million US$, purchasing power parity","HRV","Croatia","2016","2016",115.8,,
+"PATCDIUR","C03-Diuretics","MTMOPPMT","Million US$, purchasing power parity","HRV","Croatia","2017","2017",120.1,,
+"PATCDIUR","C03-Diuretics","MTMOPPMT","Million US$, purchasing power parity","HRV","Croatia","2018","2018",125.2,,
+"PATCDIUR","C03-Diuretics","MTMOPPMT","Million US$, purchasing power parity","HRV","Croatia","2019","2019",131.3,,
+"PATCDIUR","C03-Diuretics","MTMOPPMT","Million US$, purchasing power parity","HRV","Croatia","2020","2020",150.1,,
+"PATCDIUR","C03-Diuretics","MTMOPPMT","Million US$, purchasing power parity","HRV","Croatia","2021","2021",148.1,,
+"PATCTOTT","Total pharmaceutical sales","MTMOPPMT","Million US$, purchasing power parity","ROU","Romania","2022","2022",764629.4,,
+"PATCCHLS","C10-Lipid modifying agents","MLLNCUMT","Million of national currency units","HRV","Croatia","2010","2010",242,,
+"PATCCHLS","C10-Lipid modifying agents","MLLNCUMT","Million of national currency units","HRV","Croatia","2011","2011",250,,
+"PATCCHLS","C10-Lipid modifying agents","MLLNCUMT","Million of national currency units","HRV","Croatia","2012","2012",247,,
+"PATCCHLS","C10-Lipid modifying agents","MLLNCUMT","Million of national currency units","HRV","Croatia","2013","2013",224,,
+"PATCCHLS","C10-Lipid modifying agents","MLLNCUMT","Million of national currency units","HRV","Croatia","2014","2014",148,,
+"PATCCHLS","C10-Lipid modifying agents","MLLNCUMT","Million of national currency units","HRV","Croatia","2015","2015",166,,
+"PATCCHLS","C10-Lipid modifying agents","MLLNCUMT","Million of national currency units","HRV","Croatia","2016","2016",147,,
+"PATCCHLS","C10-Lipid modifying agents","MLLNCUMT","Million of national currency units","HRV","Croatia","2017","2017",149,,
+"PATCCHLS","C10-Lipid modifying agents","MLLNCUMT","Million of national currency units","HRV","Croatia","2018","2018",155,,
+"PATCCHLS","C10-Lipid modifying agents","MLLNCUMT","Million of national currency units","HRV","Croatia","2019","2019",158,,
+"PATCCHLS","C10-Lipid modifying agents","MLLNCUMT","Million of national currency units","HRV","Croatia","2020","2020",166,,
+"PATCCHLS","C10-Lipid modifying agents","MLLNCUMT","Million of national currency units","HRV","Croatia","2021","2021",173,,
+"PATCALIM","A-Alimentary tract and metabolism","TCPPERMT","/capita, US$ exchange rate","ROU","Romania","2022","2022",31,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOPPMT","Million US$, purchasing power parity","HRV","Croatia","2010","2010",663.3,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOPPMT","Million US$, purchasing power parity","HRV","Croatia","2011","2011",704.7,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOPPMT","Million US$, purchasing power parity","HRV","Croatia","2012","2012",738.2,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOPPMT","Million US$, purchasing power parity","HRV","Croatia","2013","2013",687,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOPPMT","Million US$, purchasing power parity","HRV","Croatia","2014","2014",686.8,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOPPMT","Million US$, purchasing power parity","HRV","Croatia","2015","2015",682.2,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOPPMT","Million US$, purchasing power parity","HRV","Croatia","2016","2016",728.5,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOPPMT","Million US$, purchasing power parity","HRV","Croatia","2017","2017",713.9,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOPPMT","Million US$, purchasing power parity","HRV","Croatia","2018","2018",700.9,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOPPMT","Million US$, purchasing power parity","HRV","Croatia","2019","2019",717.3,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOPPMT","Million US$, purchasing power parity","HRV","Croatia","2020","2020",771.7,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","MTMOPPMT","Million US$, purchasing power parity","HRV","Croatia","2021","2021",784.2,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MTMOPPMT","Million US$, purchasing power parity","ROU","Romania","2022","2022",94.3,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","ROU","Romania","2022","2022",8.6,,
+"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2010","2010",2.3,,
+"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2011","2011",1.9,,
+"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2012","2012",2.4,,
+"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2013","2013",2,,
+"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2014","2014",2.5,,
+"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2015","2015",2.5,,
+"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2016","2016",2.7,,
+"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2017","2017",2.7,,
+"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2018","2018",2.8,,
+"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2019","2019",2.9,,
+"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2020","2020",2.4,,
+"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2021","2021",1.8,,
+"PATCALIM","A-Alimentary tract and metabolism","MLLNCUMT","Million of national currency units","ROU","Romania","2022","2022",2771.5,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MLLNCUMT","Million of national currency units","HRV","Croatia","2010","2010",185,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MLLNCUMT","Million of national currency units","HRV","Croatia","2011","2011",196,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MLLNCUMT","Million of national currency units","HRV","Croatia","2012","2012",201,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MLLNCUMT","Million of national currency units","HRV","Croatia","2013","2013",205,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MLLNCUMT","Million of national currency units","HRV","Croatia","2014","2014",211,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MLLNCUMT","Million of national currency units","HRV","Croatia","2015","2015",217,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MLLNCUMT","Million of national currency units","HRV","Croatia","2016","2016",219,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MLLNCUMT","Million of national currency units","HRV","Croatia","2017","2017",220,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MLLNCUMT","Million of national currency units","HRV","Croatia","2018","2018",221,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MLLNCUMT","Million of national currency units","HRV","Croatia","2019","2019",223,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MLLNCUMT","Million of national currency units","HRV","Croatia","2020","2020",226,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MLLNCUMT","Million of national currency units","HRV","Croatia","2021","2021",222,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","TCPPERMT","/capita, US$ exchange rate","ROU","Romania","2022","2022",4.6,,
+"PATCDEPR","N06A-Antidepressants","MTMOPPMT","Million US$, purchasing power parity","ROU","Romania","2022","2022",59.9,,
+"PATCCNSY","N-Nervous system","MTMOTCMT","Million US$ at exchange rate","ROU","Romania","2022","2022",261.2,,
+"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","ROU","Romania","2022","2022",7.9,,
+"PATCBLOO","B-Blood and blood forming organs","MTMOTCMT","Million US$ at exchange rate","HRV","Croatia","2010","2010",365.9,,
+"PATCBLOO","B-Blood and blood forming organs","MTMOTCMT","Million US$ at exchange rate","HRV","Croatia","2011","2011",365.2,,
+"PATCBLOO","B-Blood and blood forming organs","MTMOTCMT","Million US$ at exchange rate","HRV","Croatia","2012","2012",363.2,,
+"PATCBLOO","B-Blood and blood forming organs","MTMOTCMT","Million US$ at exchange rate","HRV","Croatia","2013","2013",379,,
+"PATCBLOO","B-Blood and blood forming organs","MTMOTCMT","Million US$ at exchange rate","HRV","Croatia","2014","2014",397.2,,
+"PATCBLOO","B-Blood and blood forming organs","MTMOTCMT","Million US$ at exchange rate","HRV","Croatia","2015","2015",390,,
+"PATCBLOO","B-Blood and blood forming organs","MTMOTCMT","Million US$ at exchange rate","HRV","Croatia","2016","2016",493.7,,
+"PATCBLOO","B-Blood and blood forming organs","MTMOTCMT","Million US$ at exchange rate","HRV","Croatia","2017","2017",564.2,,
+"PATCBLOO","B-Blood and blood forming organs","MTMOTCMT","Million US$ at exchange rate","HRV","Croatia","2018","2018",619.2,,
+"PATCBLOO","B-Blood and blood forming organs","MTMOTCMT","Million US$ at exchange rate","HRV","Croatia","2019","2019",703.1,,
+"PATCBLOO","B-Blood and blood forming organs","MTMOTCMT","Million US$ at exchange rate","HRV","Croatia","2020","2020",766.7,,
+"PATCBLOO","B-Blood and blood forming organs","MTMOTCMT","Million US$ at exchange rate","HRV","Croatia","2021","2021",922.2,,
+"PATCHYPO","C02-Antihypertensives","MTMOPPMT","Million US$, purchasing power parity","HRV","Croatia","2010","2010",83.6,,
+"PATCHYPO","C02-Antihypertensives","MTMOPPMT","Million US$, purchasing power parity","HRV","Croatia","2011","2011",96.4,,
+"PATCHYPO","C02-Antihypertensives","MTMOPPMT","Million US$, purchasing power parity","HRV","Croatia","2012","2012",104.9,,
+"PATCHYPO","C02-Antihypertensives","MTMOPPMT","Million US$, purchasing power parity","HRV","Croatia","2013","2013",111.7,,
+"PATCHYPO","C02-Antihypertensives","MTMOPPMT","Million US$, purchasing power parity","HRV","Croatia","2014","2014",110.6,,
+"PATCHYPO","C02-Antihypertensives","MTMOPPMT","Million US$, purchasing power parity","HRV","Croatia","2015","2015",105.1,,
+"PATCHYPO","C02-Antihypertensives","MTMOPPMT","Million US$, purchasing power parity","HRV","Croatia","2016","2016",95.8,,
+"PATCHYPO","C02-Antihypertensives","MTMOPPMT","Million US$, purchasing power parity","HRV","Croatia","2017","2017",106.5,,
+"PATCHYPO","C02-Antihypertensives","MTMOPPMT","Million US$, purchasing power parity","HRV","Croatia","2018","2018",120.6,,
+"PATCHYPO","C02-Antihypertensives","MTMOPPMT","Million US$, purchasing power parity","HRV","Croatia","2019","2019",138.3,,
+"PATCHYPO","C02-Antihypertensives","MTMOPPMT","Million US$, purchasing power parity","HRV","Croatia","2020","2020",171.5,,
+"PATCHYPO","C02-Antihypertensives","MTMOPPMT","Million US$, purchasing power parity","HRV","Croatia","2021","2021",166.6,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","ROU","Romania","2022","2022",5,,
+"PATCACID","A02A-Antacids","MTMOTCMT","Million US$ at exchange rate","HRV","Croatia","2010","2010",12.3,,
+"PATCACID","A02A-Antacids","MTMOTCMT","Million US$ at exchange rate","HRV","Croatia","2011","2011",12.7,,
+"PATCACID","A02A-Antacids","MTMOTCMT","Million US$ at exchange rate","HRV","Croatia","2012","2012",10.3,,
+"PATCACID","A02A-Antacids","MTMOTCMT","Million US$ at exchange rate","HRV","Croatia","2013","2013",11.9,,
+"PATCACID","A02A-Antacids","MTMOTCMT","Million US$ at exchange rate","HRV","Croatia","2014","2014",13.1,,
+"PATCACID","A02A-Antacids","MTMOTCMT","Million US$ at exchange rate","HRV","Croatia","2015","2015",11,,
+"PATCACID","A02A-Antacids","MTMOTCMT","Million US$ at exchange rate","HRV","Croatia","2016","2016",11.1,,
+"PATCACID","A02A-Antacids","MTMOTCMT","Million US$ at exchange rate","HRV","Croatia","2017","2017",10.2,,
+"PATCACID","A02A-Antacids","MTMOTCMT","Million US$ at exchange rate","HRV","Croatia","2018","2018",12,,
+"PATCACID","A02A-Antacids","MTMOTCMT","Million US$ at exchange rate","HRV","Croatia","2019","2019",11.4,,
+"PATCACID","A02A-Antacids","MTMOTCMT","Million US$ at exchange rate","HRV","Croatia","2020","2020",11.4,,
+"PATCACID","A02A-Antacids","MTMOTCMT","Million US$ at exchange rate","HRV","Croatia","2021","2021",8.3,,
+"PATCDIUR","C03-Diuretics","TCPPERMT","/capita, US$ exchange rate","ROU","Romania","2022","2022",1.9,,
+"PATCRESS","R-Respiratory system","TCPPERMT","/capita, US$ exchange rate","ROU","Romania","2022","2022",5.8,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MLLNCUMT","Million of national currency units","ROU","Romania","2022","2022",285.4,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","TCPPERMT","/capita, US$ exchange rate","HRV","Croatia","2010","2010",108.8,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","TCPPERMT","/capita, US$ exchange rate","HRV","Croatia","2011","2011",115.5,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","TCPPERMT","/capita, US$ exchange rate","HRV","Croatia","2012","2012",108.3,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","TCPPERMT","/capita, US$ exchange rate","HRV","Croatia","2013","2013",101.2,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","TCPPERMT","/capita, US$ exchange rate","HRV","Croatia","2014","2014",99.9,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","TCPPERMT","/capita, US$ exchange rate","HRV","Croatia","2015","2015",83,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","TCPPERMT","/capita, US$ exchange rate","HRV","Croatia","2016","2016",86.8,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","TCPPERMT","/capita, US$ exchange rate","HRV","Croatia","2017","2017",86.8,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","TCPPERMT","/capita, US$ exchange rate","HRV","Croatia","2018","2018",90.3,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","TCPPERMT","/capita, US$ exchange rate","HRV","Croatia","2019","2019",85.6,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","TCPPERMT","/capita, US$ exchange rate","HRV","Croatia","2020","2020",91.2,,
+"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","TCPPERMT","/capita, US$ exchange rate","HRV","Croatia","2021","2021",101.7,,
+"PATCCARV","C-Cardiovascular system","MTMOPPMT","Million US$, purchasing power parity","ROU","Romania","2022","2022",804.4,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOTCMT","Million US$ at exchange rate","HRV","Croatia","2010","2010",24.7,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOTCMT","Million US$ at exchange rate","HRV","Croatia","2011","2011",26.8,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOTCMT","Million US$ at exchange rate","HRV","Croatia","2012","2012",21.9,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOTCMT","Million US$ at exchange rate","HRV","Croatia","2013","2013",23.8,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOTCMT","Million US$ at exchange rate","HRV","Croatia","2014","2014",21,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOTCMT","Million US$ at exchange rate","HRV","Croatia","2015","2015",18.7,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOTCMT","Million US$ at exchange rate","HRV","Croatia","2016","2016",17.7,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOTCMT","Million US$ at exchange rate","HRV","Croatia","2017","2017",18.2,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOTCMT","Million US$ at exchange rate","HRV","Croatia","2018","2018",18,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOTCMT","Million US$ at exchange rate","HRV","Croatia","2019","2019",15.9,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOTCMT","Million US$ at exchange rate","HRV","Croatia","2020","2020",14.8,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOTCMT","Million US$ at exchange rate","HRV","Croatia","2021","2021",15.4,,
+"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2010","2010",2189.9,,
+"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2011","2011",2375.8,,
+"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2012","2012",2444.5,,
+"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2013","2013",2567.4,,
+"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2014","2014",2512.8,,
+"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2015","2015",2685,,
+"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2016","2016",3098.4,,
+"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2017","2017",3364.9,,
+"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2018","2018",3685.7,,
+"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2019","2019",4408.8,,
+"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2020","2020",4948.7,,
+"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2021","2021",5785.5,,
+"PATCHYPN","N05C-Hypnotics and sedatives","MTMOTCMT","Million US$ at exchange rate","HRV","Croatia","2010","2010",31.5,,
+"PATCHYPN","N05C-Hypnotics and sedatives","MTMOTCMT","Million US$ at exchange rate","HRV","Croatia","2011","2011",33.8,,
+"PATCHYPN","N05C-Hypnotics and sedatives","MTMOTCMT","Million US$ at exchange rate","HRV","Croatia","2012","2012",33.5,,
+"PATCHYPN","N05C-Hypnotics and sedatives","MTMOTCMT","Million US$ at exchange rate","HRV","Croatia","2013","2013",38.3,,
+"PATCHYPN","N05C-Hypnotics and sedatives","MTMOTCMT","Million US$ at exchange rate","HRV","Croatia","2014","2014",39.3,,
+"PATCHYPN","N05C-Hypnotics and sedatives","MTMOTCMT","Million US$ at exchange rate","HRV","Croatia","2015","2015",34.1,,
+"PATCHYPN","N05C-Hypnotics and sedatives","MTMOTCMT","Million US$ at exchange rate","HRV","Croatia","2016","2016",36.5,,
+"PATCHYPN","N05C-Hypnotics and sedatives","MTMOTCMT","Million US$ at exchange rate","HRV","Croatia","2017","2017",39.8,,
+"PATCHYPN","N05C-Hypnotics and sedatives","MTMOTCMT","Million US$ at exchange rate","HRV","Croatia","2018","2018",44.4,,
+"PATCHYPN","N05C-Hypnotics and sedatives","MTMOTCMT","Million US$ at exchange rate","HRV","Croatia","2019","2019",39.8,,
+"PATCHYPN","N05C-Hypnotics and sedatives","MTMOTCMT","Million US$ at exchange rate","HRV","Croatia","2020","2020",36.5,,
+"PATCHYPN","N05C-Hypnotics and sedatives","MTMOTCMT","Million US$ at exchange rate","HRV","Croatia","2021","2021",48.6,,
+"PATCANAL","N02-Analgesics","MTMOPPMT","Million US$, purchasing power parity","ROU","Romania","2022","2022",72.4,,
+"PATCGLYC","C01A-Cardiac glycosides","TCPPERMT","/capita, US$ exchange rate","ROU","Romania","2022","2022",0.1,,
+"PATCCNSY","N-Nervous system","MTMOTCMT","Million US$ at exchange rate","HRV","Croatia","2010","2010",1074.4,,
+"PATCCNSY","N-Nervous system","MTMOTCMT","Million US$ at exchange rate","HRV","Croatia","2011","2011",1143.5,,
+"PATCCNSY","N-Nervous system","MTMOTCMT","Million US$ at exchange rate","HRV","Croatia","2012","2012",1050.9,,
+"PATCCNSY","N-Nervous system","MTMOTCMT","Million US$ at exchange rate","HRV","Croatia","2013","2013",1071.1,,
+"PATCCNSY","N-Nervous system","MTMOTCMT","Million US$ at exchange rate","HRV","Croatia","2014","2014",1042.1,,
+"PATCCNSY","N-Nervous system","MTMOTCMT","Million US$ at exchange rate","HRV","Croatia","2015","2015",892.1,,
+"PATCCNSY","N-Nervous system","MTMOTCMT","Million US$ at exchange rate","HRV","Croatia","2016","2016",939.9,,
+"PATCCNSY","N-Nervous system","MTMOTCMT","Million US$ at exchange rate","HRV","Croatia","2017","2017",948.7,,
+"PATCCNSY","N-Nervous system","MTMOTCMT","Million US$ at exchange rate","HRV","Croatia","2018","2018",1032,,
+"PATCCNSY","N-Nervous system","MTMOTCMT","Million US$ at exchange rate","HRV","Croatia","2019","2019",1006.9,,
+"PATCCNSY","N-Nervous system","MTMOTCMT","Million US$ at exchange rate","HRV","Croatia","2020","2020",1052.6,,
+"PATCCNSY","N-Nervous system","MTMOTCMT","Million US$ at exchange rate","HRV","Croatia","2021","2021",1101.3,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","TCPPERMT","/capita, US$ exchange rate","HRV","Croatia","2010","2010",19.8,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","TCPPERMT","/capita, US$ exchange rate","HRV","Croatia","2011","2011",19.8,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","TCPPERMT","/capita, US$ exchange rate","HRV","Croatia","2012","2012",19,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","TCPPERMT","/capita, US$ exchange rate","HRV","Croatia","2013","2013",19.2,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","TCPPERMT","/capita, US$ exchange rate","HRV","Croatia","2014","2014",18.9,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","TCPPERMT","/capita, US$ exchange rate","HRV","Croatia","2015","2015",16.4,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","TCPPERMT","/capita, US$ exchange rate","HRV","Croatia","2016","2016",16.2,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","TCPPERMT","/capita, US$ exchange rate","HRV","Croatia","2017","2017",17.1,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","TCPPERMT","/capita, US$ exchange rate","HRV","Croatia","2018","2018",18.8,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","TCPPERMT","/capita, US$ exchange rate","HRV","Croatia","2019","2019",18.2,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","TCPPERMT","/capita, US$ exchange rate","HRV","Croatia","2020","2020",16.9,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","TCPPERMT","/capita, US$ exchange rate","HRV","Croatia","2021","2021",18.9,,
+"PATCHYPN","N05C-Hypnotics and sedatives","MLLNCUMT","Million of national currency units","ROU","Romania","2022","2022",14.8,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MLLNCUMT","Million of national currency units","ROU","Romania","2022","2022",14,,
+"PATCSKEL","M-Musculo-skeletal system","MLLNCUMT","Million of national currency units","HRV","Croatia","2010","2010",211,,
+"PATCSKEL","M-Musculo-skeletal system","MLLNCUMT","Million of national currency units","HRV","Croatia","2011","2011",208,,
+"PATCSKEL","M-Musculo-skeletal system","MLLNCUMT","Million of national currency units","HRV","Croatia","2012","2012",205,,
+"PATCSKEL","M-Musculo-skeletal system","MLLNCUMT","Million of national currency units","HRV","Croatia","2013","2013",208,,
+"PATCSKEL","M-Musculo-skeletal system","MLLNCUMT","Million of national currency units","HRV","Croatia","2014","2014",199,,
+"PATCSKEL","M-Musculo-skeletal system","MLLNCUMT","Million of national currency units","HRV","Croatia","2015","2015",204,,
+"PATCSKEL","M-Musculo-skeletal system","MLLNCUMT","Million of national currency units","HRV","Croatia","2016","2016",217,,
+"PATCSKEL","M-Musculo-skeletal system","MLLNCUMT","Million of national currency units","HRV","Croatia","2017","2017",228,,
+"PATCSKEL","M-Musculo-skeletal system","MLLNCUMT","Million of national currency units","HRV","Croatia","2018","2018",323,,
+"PATCSKEL","M-Musculo-skeletal system","MLLNCUMT","Million of national currency units","HRV","Croatia","2019","2019",361,,
+"PATCSKEL","M-Musculo-skeletal system","MLLNCUMT","Million of national currency units","HRV","Croatia","2020","2020",339,,
+"PATCSKEL","M-Musculo-skeletal system","MLLNCUMT","Million of national currency units","HRV","Croatia","2021","2021",310.5,,
+"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2010","2010",95.5,,
+"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2011","2011",97.5,,
+"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2012","2012",98.7,,
+"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2013","2013",103,,
+"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2014","2014",99.9,,
+"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2015","2015",104,,
+"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2016","2016",115.9,,
+"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2017","2017",125.1,,
+"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2018","2018",179.7,,
+"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2019","2019",208,,
+"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2020","2020",199.5,,
+"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2021","2021",181.9,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MTMOPPMT","Million US$, purchasing power parity","ROU","Romania","2022","2022",100.3,,
+"PATCCNSY","N-Nervous system","MLLNCUMT","Million of national currency units","ROU","Romania","2022","2022",1224.4,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOTCMT","Million US$ at exchange rate","HRV","Croatia","2010","2010",253.5,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOTCMT","Million US$ at exchange rate","HRV","Croatia","2011","2011",276.3,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOTCMT","Million US$ at exchange rate","HRV","Croatia","2012","2012",258.9,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOTCMT","Million US$ at exchange rate","HRV","Croatia","2013","2013",270.7,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOTCMT","Million US$ at exchange rate","HRV","Croatia","2014","2014",276.6,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOTCMT","Million US$ at exchange rate","HRV","Croatia","2015","2015",238.4,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOTCMT","Million US$ at exchange rate","HRV","Croatia","2016","2016",242.4,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOTCMT","Million US$ at exchange rate","HRV","Croatia","2017","2017",250.2,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOTCMT","Million US$ at exchange rate","HRV","Croatia","2018","2018",265.2,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOTCMT","Million US$ at exchange rate","HRV","Croatia","2019","2019",253.7,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOTCMT","Million US$ at exchange rate","HRV","Croatia","2020","2020",257.5,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOTCMT","Million US$ at exchange rate","HRV","Croatia","2021","2021",263,,
+"PATCBIOT","J01-Antibacterials for systemic use","TCPPERMT","/capita, US$ exchange rate","HRV","Croatia","2010","2010",90.6,,
+"PATCBIOT","J01-Antibacterials for systemic use","TCPPERMT","/capita, US$ exchange rate","HRV","Croatia","2011","2011",95.1,,
+"PATCBIOT","J01-Antibacterials for systemic use","TCPPERMT","/capita, US$ exchange rate","HRV","Croatia","2012","2012",88.4,,
+"PATCBIOT","J01-Antibacterials for systemic use","TCPPERMT","/capita, US$ exchange rate","HRV","Croatia","2013","2013",91.6,,
+"PATCBIOT","J01-Antibacterials for systemic use","TCPPERMT","/capita, US$ exchange rate","HRV","Croatia","2014","2014",89.1,,
+"PATCBIOT","J01-Antibacterials for systemic use","TCPPERMT","/capita, US$ exchange rate","HRV","Croatia","2015","2015",77.5,,
+"PATCBIOT","J01-Antibacterials for systemic use","TCPPERMT","/capita, US$ exchange rate","HRV","Croatia","2016","2016",79.9,,
+"PATCBIOT","J01-Antibacterials for systemic use","TCPPERMT","/capita, US$ exchange rate","HRV","Croatia","2017","2017",85.9,,
+"PATCBIOT","J01-Antibacterials for systemic use","TCPPERMT","/capita, US$ exchange rate","HRV","Croatia","2018","2018",87.7,,
+"PATCBIOT","J01-Antibacterials for systemic use","TCPPERMT","/capita, US$ exchange rate","HRV","Croatia","2019","2019",76.4,,
+"PATCBIOT","J01-Antibacterials for systemic use","TCPPERMT","/capita, US$ exchange rate","HRV","Croatia","2020","2020",75.2,,
+"PATCBIOT","J01-Antibacterials for systemic use","TCPPERMT","/capita, US$ exchange rate","HRV","Croatia","2021","2021",91.5,,
+"PATCACID","A02A-Antacids","MTMOTCMT","Million US$ at exchange rate","ROU","Romania","2022","2022",0.1,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MLLNCUMT","Million of national currency units","HRV","Croatia","2010","2010",60,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MLLNCUMT","Million of national currency units","HRV","Croatia","2011","2011",70,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MLLNCUMT","Million of national currency units","HRV","Croatia","2012","2012",75,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MLLNCUMT","Million of national currency units","HRV","Croatia","2013","2013",89,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MLLNCUMT","Million of national currency units","HRV","Croatia","2014","2014",90,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MLLNCUMT","Million of national currency units","HRV","Croatia","2015","2015",97,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MLLNCUMT","Million of national currency units","HRV","Croatia","2016","2016",105,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MLLNCUMT","Million of national currency units","HRV","Croatia","2017","2017",114,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MLLNCUMT","Million of national currency units","HRV","Croatia","2018","2018",118,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MLLNCUMT","Million of national currency units","HRV","Croatia","2019","2019",115,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MLLNCUMT","Million of national currency units","HRV","Croatia","2020","2020",115,,
+"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","MLLNCUMT","Million of national currency units","HRV","Croatia","2021","2021",120.7,,
+"PATCTOTT","Total pharmaceutical sales","MLLNCUMT","Million of national currency units","HRV","Croatia","2010","2010",4837,,
+"PATCTOTT","Total pharmaceutical sales","MLLNCUMT","Million of national currency units","HRV","Croatia","2011","2011",5068,,
+"PATCTOTT","Total pharmaceutical sales","MLLNCUMT","Million of national currency units","HRV","Croatia","2012","2012",5075,,
+"PATCTOTT","Total pharmaceutical sales","MLLNCUMT","Million of national currency units","HRV","Croatia","2013","2013",5183,,
+"PATCTOTT","Total pharmaceutical sales","MLLNCUMT","Million of national currency units","HRV","Croatia","2014","2014",5006,,
+"PATCTOTT","Total pharmaceutical sales","MLLNCUMT","Million of national currency units","HRV","Croatia","2015","2015",5267,,
+"PATCTOTT","Total pharmaceutical sales","MLLNCUMT","Million of national currency units","HRV","Croatia","2016","2016",5803,,
+"PATCTOTT","Total pharmaceutical sales","MLLNCUMT","Million of national currency units","HRV","Croatia","2017","2017",6132,,
+"PATCTOTT","Total pharmaceutical sales","MLLNCUMT","Million of national currency units","HRV","Croatia","2018","2018",6626,,
+"PATCTOTT","Total pharmaceutical sales","MLLNCUMT","Million of national currency units","HRV","Croatia","2019","2019",7650,,
+"PATCTOTT","Total pharmaceutical sales","MLLNCUMT","Million of national currency units","HRV","Croatia","2020","2020",8409,,
+"PATCTOTT","Total pharmaceutical sales","MLLNCUMT","Million of national currency units","HRV","Croatia","2021","2021",9877,,
+"PATCBLOO","B-Blood and blood forming organs","MLLNCUMT","Million of national currency units","ROU","Romania","2022","2022",1005,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2010","2010",89.2,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2011","2011",93.8,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2012","2012",96.8,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2013","2013",80.7,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2014","2014",63.2,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2015","2015",58.1,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2016","2016",59.8,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2017","2017",63.7,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2018","2018",67.9,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2019","2019",73.8,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2020","2020",70.6,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2021","2021",76.1,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MTMOTCMT","Million US$ at exchange rate","ROU","Romania","2022","2022",1.5,,
+"PATCBIOT","J01-Antibacterials for systemic use","MTMOTCMT","Million US$ at exchange rate","ROU","Romania","2022","2022",100.8,,
+"PATCACID","A02A-Antacids","MLLNCUMT","Million of national currency units","ROU","Romania","2022","2022",0.5,,
+"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2010","2010",84.2,,
+"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2011","2011",90.9,,
+"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2012","2012",92,,
+"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2013","2013",93.6,,
+"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2014","2014",92.9,,
+"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2015","2015",95.3,,
+"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2016","2016",98.2,,
+"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2017","2017",100.4,,
+"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2018","2018",110.7,,
+"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2019","2019",124.5,,
+"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2020","2020",139.5,,
+"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2021","2021",138.8,,
+"PATCCCBR","C08-Calcium channel blockers","MTMOPPMT","Million US$, purchasing power parity","HRV","Croatia","2010","2010",284,,
+"PATCCCBR","C08-Calcium channel blockers","MTMOPPMT","Million US$, purchasing power parity","HRV","Croatia","2011","2011",291.1,,
+"PATCCCBR","C08-Calcium channel blockers","MTMOPPMT","Million US$, purchasing power parity","HRV","Croatia","2012","2012",281.7,,
+"PATCCCBR","C08-Calcium channel blockers","MTMOPPMT","Million US$, purchasing power parity","HRV","Croatia","2013","2013",259.2,,
+"PATCCCBR","C08-Calcium channel blockers","MTMOPPMT","Million US$, purchasing power parity","HRV","Croatia","2014","2014",242.4,,
+"PATCCCBR","C08-Calcium channel blockers","MTMOPPMT","Million US$, purchasing power parity","HRV","Croatia","2015","2015",218.8,,
+"PATCCCBR","C08-Calcium channel blockers","MTMOPPMT","Million US$, purchasing power parity","HRV","Croatia","2016","2016",218.3,,
+"PATCCCBR","C08-Calcium channel blockers","MTMOPPMT","Million US$, purchasing power parity","HRV","Croatia","2017","2017",188.1,,
+"PATCCCBR","C08-Calcium channel blockers","MTMOPPMT","Million US$, purchasing power parity","HRV","Croatia","2018","2018",179.8,,
+"PATCCCBR","C08-Calcium channel blockers","MTMOPPMT","Million US$, purchasing power parity","HRV","Croatia","2019","2019",159.4,,
+"PATCCCBR","C08-Calcium channel blockers","MTMOPPMT","Million US$, purchasing power parity","HRV","Croatia","2020","2020",150.1,,
+"PATCCCBR","C08-Calcium channel blockers","MTMOPPMT","Million US$, purchasing power parity","HRV","Croatia","2021","2021",131.9,,
+"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","ROU","Romania","2022","2022",40153.9,,
+"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2010","2010",66.1,,
+"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2011","2011",68,,
+"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2012","2012",66,,
+"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2013","2013",60.9,,
+"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2014","2014",57.2,,
+"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2015","2015",52,,
+"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2016","2016",52.3,,
+"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2017","2017",45.5,,
+"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2018","2018",43.9,,
+"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2019","2019",39.2,,
+"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2020","2020",37.1,,
+"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2021","2021",33.4,,
+"PATCDEPR","N06A-Antidepressants","MLLNCUMT","Million of national currency units","HRV","Croatia","2010","2010",88,,
+"PATCDEPR","N06A-Antidepressants","MLLNCUMT","Million of national currency units","HRV","Croatia","2011","2011",87,,
+"PATCDEPR","N06A-Antidepressants","MLLNCUMT","Million of national currency units","HRV","Croatia","2012","2012",86,,
+"PATCDEPR","N06A-Antidepressants","MLLNCUMT","Million of national currency units","HRV","Croatia","2013","2013",84,,
+"PATCDEPR","N06A-Antidepressants","MLLNCUMT","Million of national currency units","HRV","Croatia","2014","2014",82,,
+"PATCDEPR","N06A-Antidepressants","MLLNCUMT","Million of national currency units","HRV","Croatia","2015","2015",81,,
+"PATCDEPR","N06A-Antidepressants","MLLNCUMT","Million of national currency units","HRV","Croatia","2016","2016",82,,
+"PATCDEPR","N06A-Antidepressants","MLLNCUMT","Million of national currency units","HRV","Croatia","2017","2017",80,,
+"PATCDEPR","N06A-Antidepressants","MLLNCUMT","Million of national currency units","HRV","Croatia","2018","2018",79,,
+"PATCDEPR","N06A-Antidepressants","MLLNCUMT","Million of national currency units","HRV","Croatia","2019","2019",76,,
+"PATCDEPR","N06A-Antidepressants","MLLNCUMT","Million of national currency units","HRV","Croatia","2020","2020",78,,
+"PATCDEPR","N06A-Antidepressants","MLLNCUMT","Million of national currency units","HRV","Croatia","2021","2021",80,,
+"PATCHYPN","N05C-Hypnotics and sedatives","MTMOTCMT","Million US$ at exchange rate","ROU","Romania","2022","2022",3.2,,
+"PATCHYPO","C02-Antihypertensives","MLLNCUMT","Million of national currency units","HRV","Croatia","2010","2010",43,,
+"PATCHYPO","C02-Antihypertensives","MLLNCUMT","Million of national currency units","HRV","Croatia","2011","2011",48,,
+"PATCHYPO","C02-Antihypertensives","MLLNCUMT","Million of national currency units","HRV","Croatia","2012","2012",51,,
+"PATCHYPO","C02-Antihypertensives","MLLNCUMT","Million of national currency units","HRV","Croatia","2013","2013",53,,
+"PATCHYPO","C02-Antihypertensives","MLLNCUMT","Million of national currency units","HRV","Croatia","2014","2014",52,,
+"PATCHYPO","C02-Antihypertensives","MLLNCUMT","Million of national currency units","HRV","Croatia","2015","2015",49,,
+"PATCHYPO","C02-Antihypertensives","MLLNCUMT","Million of national currency units","HRV","Croatia","2016","2016",43,,
+"PATCHYPO","C02-Antihypertensives","MLLNCUMT","Million of national currency units","HRV","Croatia","2017","2017",47,,
+"PATCHYPO","C02-Antihypertensives","MLLNCUMT","Million of national currency units","HRV","Croatia","2018","2018",53,,
+"PATCHYPO","C02-Antihypertensives","MLLNCUMT","Million of national currency units","HRV","Croatia","2019","2019",59,,
+"PATCHYPO","C02-Antihypertensives","MLLNCUMT","Million of national currency units","HRV","Croatia","2020","2020",72,,
+"PATCHYPO","C02-Antihypertensives","MLLNCUMT","Million of national currency units","HRV","Croatia","2021","2021",72,,
+"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2010","2010",39.8,,
+"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2011","2011",40.8,,
+"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2012","2012",41.4,,
+"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2013","2013",41.6,,
+"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2014","2014",41.2,,
+"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2015","2015",41.3,,
+"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2016","2016",43.8,,
+"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2017","2017",43.9,,
+"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2018","2018",43.9,,
+"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2019","2019",43.8,,
+"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2020","2020",45.9,,
+"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2021","2021",46.9,,
+"PATCCCBR","C08-Calcium channel blockers","MTMOPPMT","Million US$, purchasing power parity","ROU","Romania","2022","2022",27.3,,
+"PATCOTHR","Products not elsewhere classified","MTMOPPMT","Million US$, purchasing power parity","ROU","Romania","2022","2022",2727.7,,
+"PATCARIT","C01B-Antiarrhythmics, Class I and III","MTMOTCMT","Million US$ at exchange rate","ROU","Romania","2022","2022",3,,
+"PATCANAL","N02-Analgesics","MLLNCUMT","Million of national currency units","HRV","Croatia","2010","2010",186,,
+"PATCANAL","N02-Analgesics","MLLNCUMT","Million of national currency units","HRV","Croatia","2011","2011",194,,
+"PATCANAL","N02-Analgesics","MLLNCUMT","Million of national currency units","HRV","Croatia","2012","2012",191,,
+"PATCANAL","N02-Analgesics","MLLNCUMT","Million of national currency units","HRV","Croatia","2013","2013",189,,
+"PATCANAL","N02-Analgesics","MLLNCUMT","Million of national currency units","HRV","Croatia","2014","2014",185,,
+"PATCANAL","N02-Analgesics","MLLNCUMT","Million of national currency units","HRV","Croatia","2015","2015",187,,
+"PATCANAL","N02-Analgesics","MLLNCUMT","Million of national currency units","HRV","Croatia","2016","2016",184,,
+"PATCANAL","N02-Analgesics","MLLNCUMT","Million of national currency units","HRV","Croatia","2017","2017",183,,
+"PATCANAL","N02-Analgesics","MLLNCUMT","Million of national currency units","HRV","Croatia","2018","2018",199,,
+"PATCANAL","N02-Analgesics","MLLNCUMT","Million of national currency units","HRV","Croatia","2019","2019",216,,
+"PATCANAL","N02-Analgesics","MLLNCUMT","Million of national currency units","HRV","Croatia","2020","2020",237,,
+"PATCANAL","N02-Analgesics","MLLNCUMT","Million of national currency units","HRV","Croatia","2021","2021",237,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","ROU","Romania","2022","2022",5.3,,
+"PATCCARV","C-Cardiovascular system","MLLNCUMT","Million of national currency units","HRV","Croatia","2010","2010",975,,
+"PATCCARV","C-Cardiovascular system","MLLNCUMT","Million of national currency units","HRV","Croatia","2011","2011",984,,
+"PATCCARV","C-Cardiovascular system","MLLNCUMT","Million of national currency units","HRV","Croatia","2012","2012",1005,,
+"PATCCARV","C-Cardiovascular system","MLLNCUMT","Million of national currency units","HRV","Croatia","2013","2013",946,,
+"PATCCARV","C-Cardiovascular system","MLLNCUMT","Million of national currency units","HRV","Croatia","2014","2014",778,,
+"PATCCARV","C-Cardiovascular system","MLLNCUMT","Million of national currency units","HRV","Croatia","2015","2015",782,,
+"PATCCARV","C-Cardiovascular system","MLLNCUMT","Million of national currency units","HRV","Croatia","2016","2016",777,,
+"PATCCARV","C-Cardiovascular system","MLLNCUMT","Million of national currency units","HRV","Croatia","2017","2017",785,,
+"PATCCARV","C-Cardiovascular system","MLLNCUMT","Million of national currency units","HRV","Croatia","2018","2018",792,,
+"PATCCARV","C-Cardiovascular system","MLLNCUMT","Million of national currency units","HRV","Croatia","2019","2019",817,,
+"PATCCARV","C-Cardiovascular system","MLLNCUMT","Million of national currency units","HRV","Croatia","2020","2020",863,,
+"PATCCARV","C-Cardiovascular system","MLLNCUMT","Million of national currency units","HRV","Croatia","2021","2021",880,,
+"PATCINFC","J-Antiinfectives for systemic use","MTMOPPMT","Million US$, purchasing power parity","HRV","Croatia","2010","2010",925.9,,
+"PATCINFC","J-Antiinfectives for systemic use","MTMOPPMT","Million US$, purchasing power parity","HRV","Croatia","2011","2011",929.6,,
+"PATCINFC","J-Antiinfectives for systemic use","MTMOPPMT","Million US$, purchasing power parity","HRV","Croatia","2012","2012",880.1,,
+"PATCINFC","J-Antiinfectives for systemic use","MTMOPPMT","Million US$, purchasing power parity","HRV","Croatia","2013","2013",904.1,,
+"PATCINFC","J-Antiinfectives for systemic use","MTMOPPMT","Million US$, purchasing power parity","HRV","Croatia","2014","2014",867.5,,
+"PATCINFC","J-Antiinfectives for systemic use","MTMOPPMT","Million US$, purchasing power parity","HRV","Croatia","2015","2015",881.6,,
+"PATCINFC","J-Antiinfectives for systemic use","MTMOPPMT","Million US$, purchasing power parity","HRV","Croatia","2016","2016",1084.9,,
+"PATCINFC","J-Antiinfectives for systemic use","MTMOPPMT","Million US$, purchasing power parity","HRV","Croatia","2017","2017",1380.1,,
+"PATCINFC","J-Antiinfectives for systemic use","MTMOPPMT","Million US$, purchasing power parity","HRV","Croatia","2018","2018",1374.4,,
+"PATCINFC","J-Antiinfectives for systemic use","MTMOPPMT","Million US$, purchasing power parity","HRV","Croatia","2019","2019",1673.6,,
+"PATCINFC","J-Antiinfectives for systemic use","MTMOPPMT","Million US$, purchasing power parity","HRV","Croatia","2020","2020",1700.6,,
+"PATCINFC","J-Antiinfectives for systemic use","MTMOPPMT","Million US$, purchasing power parity","HRV","Croatia","2021","2021",3197,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOPPMT","Million US$, purchasing power parity","HRV","Croatia","2010","2010",215.9,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOPPMT","Million US$, purchasing power parity","HRV","Croatia","2011","2011",220.9,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOPPMT","Million US$, purchasing power parity","HRV","Croatia","2012","2012",232.4,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOPPMT","Million US$, purchasing power parity","HRV","Croatia","2013","2013",248.7,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOPPMT","Million US$, purchasing power parity","HRV","Croatia","2014","2014",267.9,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOPPMT","Million US$, purchasing power parity","HRV","Croatia","2015","2015",276.7,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOPPMT","Million US$, purchasing power parity","HRV","Croatia","2016","2016",294.1,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOPPMT","Million US$, purchasing power parity","HRV","Croatia","2017","2017",315,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOPPMT","Million US$, purchasing power parity","HRV","Croatia","2018","2018",345.9,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOPPMT","Million US$, purchasing power parity","HRV","Croatia","2019","2019",382.1,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOPPMT","Million US$, purchasing power parity","HRV","Croatia","2020","2020",397.8,,
+"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","MTMOPPMT","Million US$, purchasing power parity","HRV","Croatia","2021","2021",307.7,,
+"PATCOBAI","R03-Drugs for obstructive airway diseases","MTMOTCMT","Million US$ at exchange rate","ROU","Romania","2022","2022",60.9,,
+"PATCHYPO","C02-Antihypertensives","MTMOPPMT","Million US$, purchasing power parity","ROU","Romania","2022","2022",51.1,,
+"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","ROU","Romania","2022","2022",11.3,,
+"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","ROU","Romania","2022","2022",3.8,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MLLNCUMT","Million of national currency units","HRV","Croatia","2010","2010",197,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MLLNCUMT","Million of national currency units","HRV","Croatia","2011","2011",200,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MLLNCUMT","Million of national currency units","HRV","Croatia","2012","2012",201,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MLLNCUMT","Million of national currency units","HRV","Croatia","2013","2013",163,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MLLNCUMT","Million of national currency units","HRV","Croatia","2014","2014",126,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MLLNCUMT","Million of national currency units","HRV","Croatia","2015","2015",114,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MLLNCUMT","Million of national currency units","HRV","Croatia","2016","2016",112,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MLLNCUMT","Million of national currency units","HRV","Croatia","2017","2017",116,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MLLNCUMT","Million of national currency units","HRV","Croatia","2018","2018",122,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MLLNCUMT","Million of national currency units","HRV","Croatia","2019","2019",128,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MLLNCUMT","Million of national currency units","HRV","Croatia","2020","2020",120,,
+"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","MLLNCUMT","Million of national currency units","HRV","Croatia","2021","2021",130,,
+"PATCACID","A02A-Antacids","TCPPERMT","/capita, US$ exchange rate","HRV","Croatia","2010","2010",2.9,,
+"PATCACID","A02A-Antacids","TCPPERMT","/capita, US$ exchange rate","HRV","Croatia","2011","2011",3,,
+"PATCACID","A02A-Antacids","TCPPERMT","/capita, US$ exchange rate","HRV","Croatia","2012","2012",2.4,,
+"PATCACID","A02A-Antacids","TCPPERMT","/capita, US$ exchange rate","HRV","Croatia","2013","2013",2.8,,
+"PATCACID","A02A-Antacids","TCPPERMT","/capita, US$ exchange rate","HRV","Croatia","2014","2014",3.1,,
+"PATCACID","A02A-Antacids","TCPPERMT","/capita, US$ exchange rate","HRV","Croatia","2015","2015",2.6,,
+"PATCACID","A02A-Antacids","TCPPERMT","/capita, US$ exchange rate","HRV","Croatia","2016","2016",2.7,,
+"PATCACID","A02A-Antacids","TCPPERMT","/capita, US$ exchange rate","HRV","Croatia","2017","2017",2.5,,
+"PATCACID","A02A-Antacids","TCPPERMT","/capita, US$ exchange rate","HRV","Croatia","2018","2018",2.9,,
+"PATCACID","A02A-Antacids","TCPPERMT","/capita, US$ exchange rate","HRV","Croatia","2019","2019",2.8,,
+"PATCACID","A02A-Antacids","TCPPERMT","/capita, US$ exchange rate","HRV","Croatia","2020","2020",2.8,,
+"PATCACID","A02A-Antacids","TCPPERMT","/capita, US$ exchange rate","HRV","Croatia","2021","2021",2.1,,
+"PATCGENU","G-Genito urinary system and sex hormones","MTMOPPMT","Million US$, purchasing power parity","HRV","Croatia","2010","2010",317.1,,
+"PATCGENU","G-Genito urinary system and sex hormones","MTMOPPMT","Million US$, purchasing power parity","HRV","Croatia","2011","2011",333.3,,
+"PATCGENU","G-Genito urinary system and sex hormones","MTMOPPMT","Million US$, purchasing power parity","HRV","Croatia","2012","2012",335.2,,
+"PATCGENU","G-Genito urinary system and sex hormones","MTMOPPMT","Million US$, purchasing power parity","HRV","Croatia","2013","2013",339.3,,
+"PATCGENU","G-Genito urinary system and sex hormones","MTMOPPMT","Million US$, purchasing power parity","HRV","Croatia","2014","2014",340.2,,
+"PATCGENU","G-Genito urinary system and sex hormones","MTMOPPMT","Million US$, purchasing power parity","HRV","Croatia","2015","2015",353.9,,
+"PATCGENU","G-Genito urinary system and sex hormones","MTMOPPMT","Million US$, purchasing power parity","HRV","Croatia","2016","2016",383.2,,
+"PATCGENU","G-Genito urinary system and sex hormones","MTMOPPMT","Million US$, purchasing power parity","HRV","Croatia","2017","2017",405.7,,
+"PATCGENU","G-Genito urinary system and sex hormones","MTMOPPMT","Million US$, purchasing power parity","HRV","Croatia","2018","2018",423.3,,
+"PATCGENU","G-Genito urinary system and sex hormones","MTMOPPMT","Million US$, purchasing power parity","HRV","Croatia","2019","2019",459.4,,
+"PATCGENU","G-Genito urinary system and sex hormones","MTMOPPMT","Million US$, purchasing power parity","HRV","Croatia","2020","2020",469.2,,
+"PATCGENU","G-Genito urinary system and sex hormones","MTMOPPMT","Million US$, purchasing power parity","HRV","Croatia","2021","2021",462.5,,
+"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","ROU","Romania","2022","2022",42.2,,
+"PATCBIOT","J01-Antibacterials for systemic use","TCPPERMT","/capita, US$ exchange rate","ROU","Romania","2022","2022",5.3,,
+"PATCALIM","A-Alimentary tract and metabolism","MTMOPPMT","Million US$, purchasing power parity","HRV","Croatia","2010","2010",1244.9,,
+"PATCALIM","A-Alimentary tract and metabolism","MTMOPPMT","Million US$, purchasing power parity","HRV","Croatia","2011","2011",1385.4,,
+"PATCALIM","A-Alimentary tract and metabolism","MTMOPPMT","Million US$, purchasing power parity","HRV","Croatia","2012","2012",1455.8,,
+"PATCALIM","A-Alimentary tract and metabolism","MTMOPPMT","Million US$, purchasing power parity","HRV","Croatia","2013","2013",1502.6,,
+"PATCALIM","A-Alimentary tract and metabolism","MTMOPPMT","Million US$, purchasing power parity","HRV","Croatia","2014","2014",1471.4,,
+"PATCALIM","A-Alimentary tract and metabolism","MTMOPPMT","Million US$, purchasing power parity","HRV","Croatia","2015","2015",1544.5,,
+"PATCALIM","A-Alimentary tract and metabolism","MTMOPPMT","Million US$, purchasing power parity","HRV","Croatia","2016","2016",1724.3,,
+"PATCALIM","A-Alimentary tract and metabolism","MTMOPPMT","Million US$, purchasing power parity","HRV","Croatia","2017","2017",1810.7,,
+"PATCALIM","A-Alimentary tract and metabolism","MTMOPPMT","Million US$, purchasing power parity","HRV","Croatia","2018","2018",1877.3,,
+"PATCALIM","A-Alimentary tract and metabolism","MTMOPPMT","Million US$, purchasing power parity","HRV","Croatia","2019","2019",2083.8,,
+"PATCALIM","A-Alimentary tract and metabolism","MTMOPPMT","Million US$, purchasing power parity","HRV","Croatia","2020","2020",2122.2,,
+"PATCALIM","A-Alimentary tract and metabolism","MTMOPPMT","Million US$, purchasing power parity","HRV","Croatia","2021","2021",2120.9,,
+"PATCBLOO","B-Blood and blood forming organs","TCPPERMT","/capita, US$ exchange rate","HRV","Croatia","2010","2010",85.2,,
+"PATCBLOO","B-Blood and blood forming organs","TCPPERMT","/capita, US$ exchange rate","HRV","Croatia","2011","2011",85.3,,
+"PATCBLOO","B-Blood and blood forming organs","TCPPERMT","/capita, US$ exchange rate","HRV","Croatia","2012","2012",85.1,,
+"PATCBLOO","B-Blood and blood forming organs","TCPPERMT","/capita, US$ exchange rate","HRV","Croatia","2013","2013",89.1,,
+"PATCBLOO","B-Blood and blood forming organs","TCPPERMT","/capita, US$ exchange rate","HRV","Croatia","2014","2014",93.8,,
+"PATCBLOO","B-Blood and blood forming organs","TCPPERMT","/capita, US$ exchange rate","HRV","Croatia","2015","2015",92.7,,
+"PATCBLOO","B-Blood and blood forming organs","TCPPERMT","/capita, US$ exchange rate","HRV","Croatia","2016","2016",118.3,,
+"PATCBLOO","B-Blood and blood forming organs","TCPPERMT","/capita, US$ exchange rate","HRV","Croatia","2017","2017",136.6,,
+"PATCBLOO","B-Blood and blood forming organs","TCPPERMT","/capita, US$ exchange rate","HRV","Croatia","2018","2018",151.4,,
+"PATCBLOO","B-Blood and blood forming organs","TCPPERMT","/capita, US$ exchange rate","HRV","Croatia","2019","2019",172.9,,
+"PATCBLOO","B-Blood and blood forming organs","TCPPERMT","/capita, US$ exchange rate","HRV","Croatia","2020","2020",189.4,,
+"PATCBLOO","B-Blood and blood forming organs","TCPPERMT","/capita, US$ exchange rate","HRV","Croatia","2021","2021",233.5,,
+"PATCBETA","C07-Beta blocking agents","MTMOTCMT","Million US$ at exchange rate","HRV","Croatia","2010","2010",126.1,,
+"PATCBETA","C07-Beta blocking agents","MTMOTCMT","Million US$ at exchange rate","HRV","Croatia","2011","2011",133.9,,
+"PATCBETA","C07-Beta blocking agents","MTMOTCMT","Million US$ at exchange rate","HRV","Croatia","2012","2012",124.9,,
+"PATCBETA","C07-Beta blocking agents","MTMOTCMT","Million US$ at exchange rate","HRV","Croatia","2013","2013",124.1,,
+"PATCBETA","C07-Beta blocking agents","MTMOTCMT","Million US$ at exchange rate","HRV","Croatia","2014","2014",119.3,,
+"PATCBETA","C07-Beta blocking agents","MTMOTCMT","Million US$ at exchange rate","HRV","Croatia","2015","2015",97.8,,
+"PATCBETA","C07-Beta blocking agents","MTMOTCMT","Million US$ at exchange rate","HRV","Croatia","2016","2016",94.1,,
+"PATCBETA","C07-Beta blocking agents","MTMOTCMT","Million US$ at exchange rate","HRV","Croatia","2017","2017",99,,
+"PATCBETA","C07-Beta blocking agents","MTMOTCMT","Million US$ at exchange rate","HRV","Croatia","2018","2018",108,,
+"PATCBETA","C07-Beta blocking agents","MTMOTCMT","Million US$ at exchange rate","HRV","Croatia","2019","2019",103.5,,
+"PATCBETA","C07-Beta blocking agents","MTMOTCMT","Million US$ at exchange rate","HRV","Croatia","2020","2020",107.1,,
+"PATCBETA","C07-Beta blocking agents","MTMOTCMT","Million US$ at exchange rate","HRV","Croatia","2021","2021",111.4,,
+"PATCBIOT","J01-Antibacterials for systemic use","MLLNCUMT","Million of national currency units","ROU","Romania","2022","2022",472.7,,
+"PATCCNSY","N-Nervous system","TCPPERMT","/capita, US$ exchange rate","HRV","Croatia","2010","2010",250.1,,
+"PATCCNSY","N-Nervous system","TCPPERMT","/capita, US$ exchange rate","HRV","Croatia","2011","2011",267,,
+"PATCCNSY","N-Nervous system","TCPPERMT","/capita, US$ exchange rate","HRV","Croatia","2012","2012",246.2,,
+"PATCCNSY","N-Nervous system","TCPPERMT","/capita, US$ exchange rate","HRV","Croatia","2013","2013",251.8,,
+"PATCCNSY","N-Nervous system","TCPPERMT","/capita, US$ exchange rate","HRV","Croatia","2014","2014",246,,
+"PATCCNSY","N-Nervous system","TCPPERMT","/capita, US$ exchange rate","HRV","Croatia","2015","2015",212,,
+"PATCCNSY","N-Nervous system","TCPPERMT","/capita, US$ exchange rate","HRV","Croatia","2016","2016",225.3,,
+"PATCCNSY","N-Nervous system","TCPPERMT","/capita, US$ exchange rate","HRV","Croatia","2017","2017",229.7,,
+"PATCCNSY","N-Nervous system","TCPPERMT","/capita, US$ exchange rate","HRV","Croatia","2018","2018",252.3,,
+"PATCCNSY","N-Nervous system","TCPPERMT","/capita, US$ exchange rate","HRV","Croatia","2019","2019",247.6,,
+"PATCCNSY","N-Nervous system","TCPPERMT","/capita, US$ exchange rate","HRV","Croatia","2020","2020",260.1,,
+"PATCCNSY","N-Nervous system","TCPPERMT","/capita, US$ exchange rate","HRV","Croatia","2021","2021",278.9,,
+"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","ROU","Romania","2022","2022",3.1,,
+"PATCGENU","G-Genito urinary system and sex hormones","MTMOPPMT","Million US$, purchasing power parity","ROU","Romania","2022","2022",41.8,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","TCPPERMT","/capita, US$ exchange rate","ROU","Romania","2022","2022",0.1,,
+"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2010","2010",19.5,,
+"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2011","2011",22.5,,
+"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2012","2012",24.6,,
+"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2013","2013",26.3,,
+"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2014","2014",26.1,,
+"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2015","2015",25,,
+"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2016","2016",23,,
+"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2017","2017",25.8,,
+"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2018","2018",29.5,,
+"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2019","2019",34,,
+"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2020","2020",42.4,,
+"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2021","2021",42.2,,
+"PATCCHLS","C10-Lipid modifying agents","MTMOTCMT","Million US$ at exchange rate","HRV","Croatia","2010","2010",331.6,,
+"PATCCHLS","C10-Lipid modifying agents","MTMOTCMT","Million US$ at exchange rate","HRV","Croatia","2011","2011",352.5,,
+"PATCCHLS","C10-Lipid modifying agents","MTMOTCMT","Million US$ at exchange rate","HRV","Croatia","2012","2012",318.1,,
+"PATCCHLS","C10-Lipid modifying agents","MTMOTCMT","Million US$ at exchange rate","HRV","Croatia","2013","2013",295.8,,
+"PATCCHLS","C10-Lipid modifying agents","MTMOTCMT","Million US$ at exchange rate","HRV","Croatia","2014","2014",194,,
+"PATCCHLS","C10-Lipid modifying agents","MTMOTCMT","Million US$ at exchange rate","HRV","Croatia","2015","2015",182.4,,
+"PATCCHLS","C10-Lipid modifying agents","MTMOTCMT","Million US$ at exchange rate","HRV","Croatia","2016","2016",162.7,,
+"PATCCHLS","C10-Lipid modifying agents","MTMOTCMT","Million US$ at exchange rate","HRV","Croatia","2017","2017",169.5,,
+"PATCCHLS","C10-Lipid modifying agents","MTMOTCMT","Million US$ at exchange rate","HRV","Croatia","2018","2018",186,,
+"PATCCHLS","C10-Lipid modifying agents","MTMOTCMT","Million US$ at exchange rate","HRV","Croatia","2019","2019",179.8,,
+"PATCCHLS","C10-Lipid modifying agents","MTMOTCMT","Million US$ at exchange rate","HRV","Croatia","2020","2020",189.1,,
+"PATCCHLS","C10-Lipid modifying agents","MTMOTCMT","Million US$ at exchange rate","HRV","Croatia","2021","2021",204.9,,
+"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2010","2010",441.4,,
+"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2011","2011",461.3,,
+"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2012","2012",484.1,,
+"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2013","2013",468.6,,
+"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2014","2014",390.5,,
+"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2015","2015",398.6,,
+"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2016","2016",414.9,,
+"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2017","2017",430.8,,
+"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2018","2018",440.6,,
+"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2019","2019",470.8,,
+"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2020","2020",507.9,,
+"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2021","2021",515.5,,
+"PATCSHMG","G03-Sex hormones and modulators of the genital system","MLLNCUMT","Million of national currency units","ROU","Romania","2022","2022",7.1,,
+"PATCBLOO","B-Blood and blood forming organs","MTMOTCMT","Million US$ at exchange rate","ROU","Romania","2022","2022",214.4,,
+"PATCHYPN","N05C-Hypnotics and sedatives","TCPPERMT","/capita, US$ exchange rate","HRV","Croatia","2010","2010",7.3,,
+"PATCHYPN","N05C-Hypnotics and sedatives","TCPPERMT","/capita, US$ exchange rate","HRV","Croatia","2011","2011",7.9,,
+"PATCHYPN","N05C-Hypnotics and sedatives","TCPPERMT","/capita, US$ exchange rate","HRV","Croatia","2012","2012",7.8,,
+"PATCHYPN","N05C-Hypnotics and sedatives","TCPPERMT","/capita, US$ exchange rate","HRV","Croatia","2013","2013",9,,
+"PATCHYPN","N05C-Hypnotics and sedatives","TCPPERMT","/capita, US$ exchange rate","HRV","Croatia","2014","2014",9.3,,
+"PATCHYPN","N05C-Hypnotics and sedatives","TCPPERMT","/capita, US$ exchange rate","HRV","Croatia","2015","2015",8.1,,
+"PATCHYPN","N05C-Hypnotics and sedatives","TCPPERMT","/capita, US$ exchange rate","HRV","Croatia","2016","2016",8.8,,
+"PATCHYPN","N05C-Hypnotics and sedatives","TCPPERMT","/capita, US$ exchange rate","HRV","Croatia","2017","2017",9.6,,
+"PATCHYPN","N05C-Hypnotics and sedatives","TCPPERMT","/capita, US$ exchange rate","HRV","Croatia","2018","2018",10.9,,
+"PATCHYPN","N05C-Hypnotics and sedatives","TCPPERMT","/capita, US$ exchange rate","HRV","Croatia","2019","2019",9.8,,
+"PATCHYPN","N05C-Hypnotics and sedatives","TCPPERMT","/capita, US$ exchange rate","HRV","Croatia","2020","2020",9,,
+"PATCHYPN","N05C-Hypnotics and sedatives","TCPPERMT","/capita, US$ exchange rate","HRV","Croatia","2021","2021",12.3,,
diff --git a/exercicios/para-casa/exercicioCrisPereiraS11/maternal-mortality-who.csv b/exercicios/para-casa/exercicioCrisPereiraS11/maternal-mortality-who.csv
new file mode 100644
index 0000000..e7333d4
--- /dev/null
+++ b/exercicios/para-casa/exercicioCrisPereiraS11/maternal-mortality-who.csv
@@ -0,0 +1,3421 @@
+Entity,Code,Year,Indicator:Maternal mortality ratio (per 100 000 live births)
+Afghanistan,AFG,2000,1450
+Afghanistan,AFG,2001,1390
+Afghanistan,AFG,2002,1300
+Afghanistan,AFG,2003,1240
+Afghanistan,AFG,2004,1180
+Afghanistan,AFG,2005,1140
+Afghanistan,AFG,2006,1120
+Afghanistan,AFG,2007,1090
+Afghanistan,AFG,2008,1030
+Afghanistan,AFG,2009,993
+Afghanistan,AFG,2010,954
+Afghanistan,AFG,2011,905
+Afghanistan,AFG,2012,858
+Afghanistan,AFG,2013,810
+Afghanistan,AFG,2014,786
+Afghanistan,AFG,2015,701
+Afghanistan,AFG,2016,673
+Afghanistan,AFG,2017,638
+Africa,,2000,857
+Africa,,2001,837
+Africa,,2002,822
+Africa,,2003,801
+Africa,,2004,771
+Africa,,2005,735
+Africa,,2006,701
+Africa,,2007,673
+Africa,,2008,653
+Africa,,2009,634
+Africa,,2010,615
+Africa,,2011,599
+Africa,,2012,585
+Africa,,2013,572
+Africa,,2014,562
+Africa,,2015,548
+Africa,,2016,536
+Africa,,2017,525
+Albania,ALB,2000,23
+Albania,ALB,2001,23
+Albania,ALB,2002,21
+Albania,ALB,2003,21
+Albania,ALB,2004,18
+Albania,ALB,2005,22
+Albania,ALB,2006,18
+Albania,ALB,2007,19
+Albania,ALB,2008,20
+Albania,ALB,2009,20
+Albania,ALB,2010,21
+Albania,ALB,2011,22
+Albania,ALB,2012,17
+Albania,ALB,2013,16
+Albania,ALB,2014,16
+Albania,ALB,2015,15
+Albania,ALB,2016,16
+Albania,ALB,2017,15
+Algeria,DZA,2000,161
+Algeria,DZA,2001,155
+Algeria,DZA,2002,148
+Algeria,DZA,2003,145
+Algeria,DZA,2004,134
+Algeria,DZA,2005,127
+Algeria,DZA,2006,122
+Algeria,DZA,2007,119
+Algeria,DZA,2008,117
+Algeria,DZA,2009,117
+Algeria,DZA,2010,115
+Algeria,DZA,2011,116
+Algeria,DZA,2012,116
+Algeria,DZA,2013,115
+Algeria,DZA,2014,114
+Algeria,DZA,2015,114
+Algeria,DZA,2016,113
+Algeria,DZA,2017,112
+Americas,,2000,73
+Americas,,2001,72
+Americas,,2002,71
+Americas,,2003,70
+Americas,,2004,70
+Americas,,2005,68
+Americas,,2006,67
+Americas,,2007,66
+Americas,,2008,65
+Americas,,2009,66
+Americas,,2010,64
+Americas,,2011,62
+Americas,,2012,61
+Americas,,2013,60
+Americas,,2014,60
+Americas,,2015,59
+Americas,,2016,59
+Americas,,2017,57
+Angola,AGO,2000,827
+Angola,AGO,2001,766
+Angola,AGO,2002,690
+Angola,AGO,2003,628
+Angola,AGO,2004,574
+Angola,AGO,2005,519
+Angola,AGO,2006,473
+Angola,AGO,2007,431
+Angola,AGO,2008,395
+Angola,AGO,2009,359
+Angola,AGO,2010,326
+Angola,AGO,2011,300
+Angola,AGO,2012,281
+Angola,AGO,2013,269
+Angola,AGO,2014,258
+Angola,AGO,2015,251
+Angola,AGO,2016,246
+Angola,AGO,2017,241
+Antigua and Barbuda,ATG,2000,44
+Antigua and Barbuda,ATG,2001,44
+Antigua and Barbuda,ATG,2002,43
+Antigua and Barbuda,ATG,2003,44
+Antigua and Barbuda,ATG,2004,41
+Antigua and Barbuda,ATG,2005,40
+Antigua and Barbuda,ATG,2006,46
+Antigua and Barbuda,ATG,2007,48
+Antigua and Barbuda,ATG,2008,50
+Antigua and Barbuda,ATG,2009,45
+Antigua and Barbuda,ATG,2010,44
+Antigua and Barbuda,ATG,2011,43
+Antigua and Barbuda,ATG,2012,44
+Antigua and Barbuda,ATG,2013,43
+Antigua and Barbuda,ATG,2014,42
+Antigua and Barbuda,ATG,2015,43
+Antigua and Barbuda,ATG,2016,43
+Antigua and Barbuda,ATG,2017,42
+Argentina,ARG,2000,66
+Argentina,ARG,2001,67
+Argentina,ARG,2002,65
+Argentina,ARG,2003,65
+Argentina,ARG,2004,61
+Argentina,ARG,2005,59
+Argentina,ARG,2006,57
+Argentina,ARG,2007,56
+Argentina,ARG,2008,53
+Argentina,ARG,2009,56
+Argentina,ARG,2010,51
+Argentina,ARG,2011,48
+Argentina,ARG,2012,47
+Argentina,ARG,2013,44
+Argentina,ARG,2014,42
+Argentina,ARG,2015,41
+Argentina,ARG,2016,40
+Argentina,ARG,2017,39
+Armenia,ARM,2000,43
+Armenia,ARM,2001,42
+Armenia,ARM,2002,39
+Armenia,ARM,2003,38
+Armenia,ARM,2004,36
+Armenia,ARM,2005,35
+Armenia,ARM,2006,36
+Armenia,ARM,2007,32
+Armenia,ARM,2008,36
+Armenia,ARM,2009,32
+Armenia,ARM,2010,32
+Armenia,ARM,2011,30
+Armenia,ARM,2012,30
+Armenia,ARM,2013,26
+Armenia,ARM,2014,27
+Armenia,ARM,2015,28
+Armenia,ARM,2016,26
+Armenia,ARM,2017,26
+Australia,AUS,2000,7
+Australia,AUS,2001,6
+Australia,AUS,2002,6
+Australia,AUS,2003,6
+Australia,AUS,2004,5
+Australia,AUS,2005,5
+Australia,AUS,2006,5
+Australia,AUS,2007,5
+Australia,AUS,2008,5
+Australia,AUS,2009,5
+Australia,AUS,2010,5
+Australia,AUS,2011,6
+Australia,AUS,2012,6
+Australia,AUS,2013,6
+Australia,AUS,2014,6
+Australia,AUS,2015,6
+Australia,AUS,2016,6
+Australia,AUS,2017,6
+Austria,AUT,2000,6
+Austria,AUT,2001,6
+Austria,AUT,2002,6
+Austria,AUT,2003,6
+Austria,AUT,2004,5
+Austria,AUT,2005,6
+Austria,AUT,2006,5
+Austria,AUT,2007,5
+Austria,AUT,2008,5
+Austria,AUT,2009,5
+Austria,AUT,2010,5
+Austria,AUT,2011,5
+Austria,AUT,2012,5
+Austria,AUT,2013,5
+Austria,AUT,2014,5
+Austria,AUT,2015,5
+Austria,AUT,2016,5
+Austria,AUT,2017,5
+Azerbaijan,AZE,2000,47
+Azerbaijan,AZE,2001,44
+Azerbaijan,AZE,2002,43
+Azerbaijan,AZE,2003,44
+Azerbaijan,AZE,2004,39
+Azerbaijan,AZE,2005,42
+Azerbaijan,AZE,2006,35
+Azerbaijan,AZE,2007,34
+Azerbaijan,AZE,2008,32
+Azerbaijan,AZE,2009,32
+Azerbaijan,AZE,2010,31
+Azerbaijan,AZE,2011,30
+Azerbaijan,AZE,2012,29
+Azerbaijan,AZE,2013,28
+Azerbaijan,AZE,2014,28
+Azerbaijan,AZE,2015,27
+Azerbaijan,AZE,2016,26
+Azerbaijan,AZE,2017,26
+Bahamas,BHS,2000,75
+Bahamas,BHS,2001,76
+Bahamas,BHS,2002,78
+Bahamas,BHS,2003,79
+Bahamas,BHS,2004,78
+Bahamas,BHS,2005,77
+Bahamas,BHS,2006,78
+Bahamas,BHS,2007,77
+Bahamas,BHS,2008,77
+Bahamas,BHS,2009,78
+Bahamas,BHS,2010,78
+Bahamas,BHS,2011,78
+Bahamas,BHS,2012,78
+Bahamas,BHS,2013,78
+Bahamas,BHS,2014,77
+Bahamas,BHS,2015,74
+Bahamas,BHS,2016,72
+Bahamas,BHS,2017,70
+Bahrain,BHR,2000,27
+Bahrain,BHR,2001,19
+Bahrain,BHR,2002,25
+Bahrain,BHR,2003,21
+Bahrain,BHR,2004,21
+Bahrain,BHR,2005,19
+Bahrain,BHR,2006,24
+Bahrain,BHR,2007,16
+Bahrain,BHR,2008,18
+Bahrain,BHR,2009,19
+Bahrain,BHR,2010,18
+Bahrain,BHR,2011,15
+Bahrain,BHR,2012,18
+Bahrain,BHR,2013,17
+Bahrain,BHR,2014,15
+Bahrain,BHR,2015,15
+Bahrain,BHR,2016,15
+Bahrain,BHR,2017,14
+Bangladesh,BGD,2000,434
+Bangladesh,BGD,2001,423
+Bangladesh,BGD,2002,410
+Bangladesh,BGD,2003,395
+Bangladesh,BGD,2004,372
+Bangladesh,BGD,2005,343
+Bangladesh,BGD,2006,315
+Bangladesh,BGD,2007,297
+Bangladesh,BGD,2008,280
+Bangladesh,BGD,2009,269
+Bangladesh,BGD,2010,258
+Bangladesh,BGD,2011,248
+Bangladesh,BGD,2012,238
+Bangladesh,BGD,2013,227
+Bangladesh,BGD,2014,214
+Bangladesh,BGD,2015,200
+Bangladesh,BGD,2016,186
+Bangladesh,BGD,2017,173
+Barbados,BRB,2000,50
+Barbados,BRB,2001,48
+Barbados,BRB,2002,47
+Barbados,BRB,2003,45
+Barbados,BRB,2004,43
+Barbados,BRB,2005,42
+Barbados,BRB,2006,41
+Barbados,BRB,2007,40
+Barbados,BRB,2008,39
+Barbados,BRB,2009,38
+Barbados,BRB,2010,36
+Barbados,BRB,2011,35
+Barbados,BRB,2012,34
+Barbados,BRB,2013,32
+Barbados,BRB,2014,31
+Barbados,BRB,2015,31
+Barbados,BRB,2016,30
+Barbados,BRB,2017,27
+Belarus,BLR,2000,22
+Belarus,BLR,2001,19
+Belarus,BLR,2002,18
+Belarus,BLR,2003,15
+Belarus,BLR,2004,13
+Belarus,BLR,2005,11
+Belarus,BLR,2006,9
+Belarus,BLR,2007,7
+Belarus,BLR,2008,6
+Belarus,BLR,2009,6
+Belarus,BLR,2010,5
+Belarus,BLR,2011,5
+Belarus,BLR,2012,4
+Belarus,BLR,2013,3
+Belarus,BLR,2014,3
+Belarus,BLR,2015,3
+Belarus,BLR,2016,3
+Belarus,BLR,2017,2
+Belgium,BEL,2000,8
+Belgium,BEL,2001,8
+Belgium,BEL,2002,7
+Belgium,BEL,2003,7
+Belgium,BEL,2004,7
+Belgium,BEL,2005,7
+Belgium,BEL,2006,7
+Belgium,BEL,2007,7
+Belgium,BEL,2008,7
+Belgium,BEL,2009,6
+Belgium,BEL,2010,6
+Belgium,BEL,2011,6
+Belgium,BEL,2012,6
+Belgium,BEL,2013,6
+Belgium,BEL,2014,6
+Belgium,BEL,2015,5
+Belgium,BEL,2016,5
+Belgium,BEL,2017,5
+Belize,BLZ,2000,89
+Belize,BLZ,2001,88
+Belize,BLZ,2002,82
+Belize,BLZ,2003,80
+Belize,BLZ,2004,75
+Belize,BLZ,2005,70
+Belize,BLZ,2006,65
+Belize,BLZ,2007,61
+Belize,BLZ,2008,59
+Belize,BLZ,2009,57
+Belize,BLZ,2010,54
+Belize,BLZ,2011,52
+Belize,BLZ,2012,50
+Belize,BLZ,2013,48
+Belize,BLZ,2014,46
+Belize,BLZ,2015,43
+Belize,BLZ,2016,39
+Belize,BLZ,2017,36
+Benin,BEN,2000,520
+Benin,BEN,2001,516
+Benin,BEN,2002,511
+Benin,BEN,2003,510
+Benin,BEN,2004,505
+Benin,BEN,2005,500
+Benin,BEN,2006,493
+Benin,BEN,2007,486
+Benin,BEN,2008,480
+Benin,BEN,2009,471
+Benin,BEN,2010,464
+Benin,BEN,2011,458
+Benin,BEN,2012,450
+Benin,BEN,2013,441
+Benin,BEN,2014,432
+Benin,BEN,2015,421
+Benin,BEN,2016,408
+Benin,BEN,2017,397
+Bhutan,BTN,2000,423
+Bhutan,BTN,2001,384
+Bhutan,BTN,2002,365
+Bhutan,BTN,2003,348
+Bhutan,BTN,2004,332
+Bhutan,BTN,2005,310
+Bhutan,BTN,2006,291
+Bhutan,BTN,2007,275
+Bhutan,BTN,2008,264
+Bhutan,BTN,2009,255
+Bhutan,BTN,2010,247
+Bhutan,BTN,2011,239
+Bhutan,BTN,2012,231
+Bhutan,BTN,2013,223
+Bhutan,BTN,2014,214
+Bhutan,BTN,2015,203
+Bhutan,BTN,2016,193
+Bhutan,BTN,2017,183
+Bolivia,BOL,2000,331
+Bolivia,BOL,2001,320
+Bolivia,BOL,2002,309
+Bolivia,BOL,2003,297
+Bolivia,BOL,2004,283
+Bolivia,BOL,2005,271
+Bolivia,BOL,2006,258
+Bolivia,BOL,2007,246
+Bolivia,BOL,2008,234
+Bolivia,BOL,2009,222
+Bolivia,BOL,2010,212
+Bolivia,BOL,2011,202
+Bolivia,BOL,2012,192
+Bolivia,BOL,2013,184
+Bolivia,BOL,2014,175
+Bolivia,BOL,2015,168
+Bolivia,BOL,2016,161
+Bolivia,BOL,2017,155
+Bosnia and Herzegovina,BIH,2000,17
+Bosnia and Herzegovina,BIH,2001,16
+Bosnia and Herzegovina,BIH,2002,14
+Bosnia and Herzegovina,BIH,2003,14
+Bosnia and Herzegovina,BIH,2004,14
+Bosnia and Herzegovina,BIH,2005,13
+Bosnia and Herzegovina,BIH,2006,13
+Bosnia and Herzegovina,BIH,2007,13
+Bosnia and Herzegovina,BIH,2008,11
+Bosnia and Herzegovina,BIH,2009,11
+Bosnia and Herzegovina,BIH,2010,11
+Bosnia and Herzegovina,BIH,2011,10
+Bosnia and Herzegovina,BIH,2012,10
+Bosnia and Herzegovina,BIH,2013,10
+Bosnia and Herzegovina,BIH,2014,10
+Bosnia and Herzegovina,BIH,2015,10
+Bosnia and Herzegovina,BIH,2016,10
+Bosnia and Herzegovina,BIH,2017,10
+Botswana,BWA,2000,262
+Botswana,BWA,2001,271
+Botswana,BWA,2002,278
+Botswana,BWA,2003,278
+Botswana,BWA,2004,264
+Botswana,BWA,2005,239
+Botswana,BWA,2006,221
+Botswana,BWA,2007,209
+Botswana,BWA,2008,203
+Botswana,BWA,2009,189
+Botswana,BWA,2010,179
+Botswana,BWA,2011,176
+Botswana,BWA,2012,170
+Botswana,BWA,2013,164
+Botswana,BWA,2014,160
+Botswana,BWA,2015,156
+Botswana,BWA,2016,151
+Botswana,BWA,2017,144
+Brazil,BRA,2000,69
+Brazil,BRA,2001,68
+Brazil,BRA,2002,69
+Brazil,BRA,2003,70
+Brazil,BRA,2004,71
+Brazil,BRA,2005,71
+Brazil,BRA,2006,72
+Brazil,BRA,2007,71
+Brazil,BRA,2008,70
+Brazil,BRA,2009,69
+Brazil,BRA,2010,65
+Brazil,BRA,2011,61
+Brazil,BRA,2012,60
+Brazil,BRA,2013,61
+Brazil,BRA,2014,62
+Brazil,BRA,2015,63
+Brazil,BRA,2016,62
+Brazil,BRA,2017,60
+Brunei,BRN,2000,28
+Brunei,BRN,2001,28
+Brunei,BRN,2002,29
+Brunei,BRN,2003,30
+Brunei,BRN,2004,30
+Brunei,BRN,2005,29
+Brunei,BRN,2006,28
+Brunei,BRN,2007,27
+Brunei,BRN,2008,27
+Brunei,BRN,2009,27
+Brunei,BRN,2010,28
+Brunei,BRN,2011,28
+Brunei,BRN,2012,29
+Brunei,BRN,2013,28
+Brunei,BRN,2014,29
+Brunei,BRN,2015,30
+Brunei,BRN,2016,31
+Brunei,BRN,2017,31
+Bulgaria,BGR,2000,19
+Bulgaria,BGR,2001,18
+Bulgaria,BGR,2002,17
+Bulgaria,BGR,2003,16
+Bulgaria,BGR,2004,16
+Bulgaria,BGR,2005,15
+Bulgaria,BGR,2006,14
+Bulgaria,BGR,2007,13
+Bulgaria,BGR,2008,13
+Bulgaria,BGR,2009,12
+Bulgaria,BGR,2010,12
+Bulgaria,BGR,2011,12
+Bulgaria,BGR,2012,11
+Bulgaria,BGR,2013,10
+Bulgaria,BGR,2014,11
+Bulgaria,BGR,2015,10
+Bulgaria,BGR,2016,10
+Bulgaria,BGR,2017,10
+Burkina Faso,BFA,2000,516
+Burkina Faso,BFA,2001,501
+Burkina Faso,BFA,2002,486
+Burkina Faso,BFA,2003,471
+Burkina Faso,BFA,2004,454
+Burkina Faso,BFA,2005,437
+Burkina Faso,BFA,2006,422
+Burkina Faso,BFA,2007,410
+Burkina Faso,BFA,2008,401
+Burkina Faso,BFA,2009,393
+Burkina Faso,BFA,2010,385
+Burkina Faso,BFA,2011,377
+Burkina Faso,BFA,2012,369
+Burkina Faso,BFA,2013,362
+Burkina Faso,BFA,2014,353
+Burkina Faso,BFA,2015,343
+Burkina Faso,BFA,2016,331
+Burkina Faso,BFA,2017,320
+Burundi,BDI,2000,1010
+Burundi,BDI,2001,956
+Burundi,BDI,2002,925
+Burundi,BDI,2003,890
+Burundi,BDI,2004,844
+Burundi,BDI,2005,814
+Burundi,BDI,2006,785
+Burundi,BDI,2007,756
+Burundi,BDI,2008,733
+Burundi,BDI,2009,698
+Burundi,BDI,2010,665
+Burundi,BDI,2011,635
+Burundi,BDI,2012,608
+Burundi,BDI,2013,591
+Burundi,BDI,2014,576
+Burundi,BDI,2015,568
+Burundi,BDI,2016,558
+Burundi,BDI,2017,548
+Cambodia,KHM,2000,488
+Cambodia,KHM,2001,456
+Cambodia,KHM,2002,430
+Cambodia,KHM,2003,404
+Cambodia,KHM,2004,378
+Cambodia,KHM,2005,351
+Cambodia,KHM,2006,326
+Cambodia,KHM,2007,303
+Cambodia,KHM,2008,284
+Cambodia,KHM,2009,265
+Cambodia,KHM,2010,248
+Cambodia,KHM,2011,232
+Cambodia,KHM,2012,215
+Cambodia,KHM,2013,202
+Cambodia,KHM,2014,189
+Cambodia,KHM,2015,178
+Cambodia,KHM,2016,168
+Cambodia,KHM,2017,160
+Cameroon,CMR,2000,886
+Cameroon,CMR,2001,844
+Cameroon,CMR,2002,803
+Cameroon,CMR,2003,771
+Cameroon,CMR,2004,732
+Cameroon,CMR,2005,692
+Cameroon,CMR,2006,658
+Cameroon,CMR,2007,635
+Cameroon,CMR,2008,618
+Cameroon,CMR,2009,606
+Cameroon,CMR,2010,597
+Cameroon,CMR,2011,589
+Cameroon,CMR,2012,580
+Cameroon,CMR,2013,567
+Cameroon,CMR,2014,564
+Cameroon,CMR,2015,554
+Cameroon,CMR,2016,538
+Cameroon,CMR,2017,529
+Canada,CAN,2000,9
+Canada,CAN,2001,10
+Canada,CAN,2002,10
+Canada,CAN,2003,10
+Canada,CAN,2004,10
+Canada,CAN,2005,11
+Canada,CAN,2006,11
+Canada,CAN,2007,11
+Canada,CAN,2008,12
+Canada,CAN,2009,12
+Canada,CAN,2010,11
+Canada,CAN,2011,11
+Canada,CAN,2012,11
+Canada,CAN,2013,11
+Canada,CAN,2014,11
+Canada,CAN,2015,11
+Canada,CAN,2016,10
+Canada,CAN,2017,10
+Cape Verde,CPV,2000,118
+Cape Verde,CPV,2001,109
+Cape Verde,CPV,2002,101
+Cape Verde,CPV,2003,96
+Cape Verde,CPV,2004,91
+Cape Verde,CPV,2005,86
+Cape Verde,CPV,2006,82
+Cape Verde,CPV,2007,78
+Cape Verde,CPV,2008,75
+Cape Verde,CPV,2009,72
+Cape Verde,CPV,2010,70
+Cape Verde,CPV,2011,67
+Cape Verde,CPV,2012,65
+Cape Verde,CPV,2013,63
+Cape Verde,CPV,2014,62
+Cape Verde,CPV,2015,61
+Cape Verde,CPV,2016,59
+Cape Verde,CPV,2017,58
+Central African Republic,CAF,2000,1280
+Central African Republic,CAF,2001,1290
+Central African Republic,CAF,2002,1280
+Central African Republic,CAF,2003,1250
+Central African Republic,CAF,2004,1230
+Central African Republic,CAF,2005,1200
+Central African Republic,CAF,2006,1170
+Central African Republic,CAF,2007,1130
+Central African Republic,CAF,2008,1090
+Central African Republic,CAF,2009,1050
+Central African Republic,CAF,2010,1000
+Central African Republic,CAF,2011,981
+Central African Republic,CAF,2012,963
+Central African Republic,CAF,2013,1030
+Central African Republic,CAF,2014,961
+Central African Republic,CAF,2015,912
+Central African Republic,CAF,2016,890
+Central African Republic,CAF,2017,829
+Chad,TCD,2000,1420
+Chad,TCD,2001,1410
+Chad,TCD,2002,1400
+Chad,TCD,2003,1370
+Chad,TCD,2004,1350
+Chad,TCD,2005,1330
+Chad,TCD,2006,1340
+Chad,TCD,2007,1300
+Chad,TCD,2008,1310
+Chad,TCD,2009,1270
+Chad,TCD,2010,1240
+Chad,TCD,2011,1210
+Chad,TCD,2012,1190
+Chad,TCD,2013,1170
+Chad,TCD,2014,1170
+Chad,TCD,2015,1160
+Chad,TCD,2016,1140
+Chad,TCD,2017,1140
+Chile,CHL,2000,31
+Chile,CHL,2001,32
+Chile,CHL,2002,28
+Chile,CHL,2003,27
+Chile,CHL,2004,27
+Chile,CHL,2005,25
+Chile,CHL,2006,25
+Chile,CHL,2007,23
+Chile,CHL,2008,21
+Chile,CHL,2009,21
+Chile,CHL,2010,20
+Chile,CHL,2011,18
+Chile,CHL,2012,17
+Chile,CHL,2013,16
+Chile,CHL,2014,15
+Chile,CHL,2015,14
+Chile,CHL,2016,13
+Chile,CHL,2017,13
+China,CHN,2000,59
+China,CHN,2001,55
+China,CHN,2002,51
+China,CHN,2003,48
+China,CHN,2004,46
+China,CHN,2005,44
+China,CHN,2006,42
+China,CHN,2007,40
+China,CHN,2008,40
+China,CHN,2009,37
+China,CHN,2010,36
+China,CHN,2011,34
+China,CHN,2012,33
+China,CHN,2013,32
+China,CHN,2014,31
+China,CHN,2015,30
+China,CHN,2016,29
+China,CHN,2017,29
+Colombia,COL,2000,94
+Colombia,COL,2001,93
+Colombia,COL,2002,92
+Colombia,COL,2003,88
+Colombia,COL,2004,85
+Colombia,COL,2005,83
+Colombia,COL,2006,82
+Colombia,COL,2007,83
+Colombia,COL,2008,84
+Colombia,COL,2009,87
+Colombia,COL,2010,85
+Colombia,COL,2011,84
+Colombia,COL,2012,85
+Colombia,COL,2013,85
+Colombia,COL,2014,85
+Colombia,COL,2015,85
+Colombia,COL,2016,84
+Colombia,COL,2017,83
+Comoros,COM,2000,444
+Comoros,COM,2001,437
+Comoros,COM,2002,429
+Comoros,COM,2003,423
+Comoros,COM,2004,414
+Comoros,COM,2005,404
+Comoros,COM,2006,393
+Comoros,COM,2007,382
+Comoros,COM,2008,370
+Comoros,COM,2009,356
+Comoros,COM,2010,341
+Comoros,COM,2011,326
+Comoros,COM,2012,313
+Comoros,COM,2013,302
+Comoros,COM,2014,293
+Comoros,COM,2015,285
+Comoros,COM,2016,279
+Comoros,COM,2017,273
+Congo,COG,2000,739
+Congo,COG,2001,752
+Congo,COG,2002,769
+Congo,COG,2003,757
+Congo,COG,2004,724
+Congo,COG,2005,677
+Congo,COG,2006,623
+Congo,COG,2007,580
+Congo,COG,2008,552
+Congo,COG,2009,526
+Congo,COG,2010,506
+Congo,COG,2011,488
+Congo,COG,2012,468
+Congo,COG,2013,449
+Congo,COG,2014,433
+Congo,COG,2015,416
+Congo,COG,2016,397
+Congo,COG,2017,378
+Costa Rica,CRI,2000,40
+Costa Rica,CRI,2001,37
+Costa Rica,CRI,2002,38
+Costa Rica,CRI,2003,37
+Costa Rica,CRI,2004,36
+Costa Rica,CRI,2005,33
+Costa Rica,CRI,2006,35
+Costa Rica,CRI,2007,29
+Costa Rica,CRI,2008,29
+Costa Rica,CRI,2009,29
+Costa Rica,CRI,2010,32
+Costa Rica,CRI,2011,30
+Costa Rica,CRI,2012,29
+Costa Rica,CRI,2013,29
+Costa Rica,CRI,2014,29
+Costa Rica,CRI,2015,28
+Costa Rica,CRI,2016,28
+Costa Rica,CRI,2017,27
+Cote d'Ivoire,CIV,2000,704
+Cote d'Ivoire,CIV,2001,706
+Cote d'Ivoire,CIV,2002,713
+Cote d'Ivoire,CIV,2003,711
+Cote d'Ivoire,CIV,2004,709
+Cote d'Ivoire,CIV,2005,704
+Cote d'Ivoire,CIV,2006,699
+Cote d'Ivoire,CIV,2007,698
+Cote d'Ivoire,CIV,2008,694
+Cote d'Ivoire,CIV,2009,700
+Cote d'Ivoire,CIV,2010,701
+Cote d'Ivoire,CIV,2011,703
+Cote d'Ivoire,CIV,2012,702
+Cote d'Ivoire,CIV,2013,691
+Cote d'Ivoire,CIV,2014,676
+Cote d'Ivoire,CIV,2015,658
+Cote d'Ivoire,CIV,2016,636
+Cote d'Ivoire,CIV,2017,617
+Croatia,HRV,2000,11
+Croatia,HRV,2001,10
+Croatia,HRV,2002,10
+Croatia,HRV,2003,10
+Croatia,HRV,2004,10
+Croatia,HRV,2005,10
+Croatia,HRV,2006,9
+Croatia,HRV,2007,9
+Croatia,HRV,2008,9
+Croatia,HRV,2009,9
+Croatia,HRV,2010,9
+Croatia,HRV,2011,9
+Croatia,HRV,2012,8
+Croatia,HRV,2013,9
+Croatia,HRV,2014,8
+Croatia,HRV,2015,8
+Croatia,HRV,2016,7
+Croatia,HRV,2017,8
+Cuba,CUB,2000,46
+Cuba,CUB,2001,44
+Cuba,CUB,2002,41
+Cuba,CUB,2003,41
+Cuba,CUB,2004,40
+Cuba,CUB,2005,41
+Cuba,CUB,2006,38
+Cuba,CUB,2007,38
+Cuba,CUB,2008,40
+Cuba,CUB,2009,40
+Cuba,CUB,2010,41
+Cuba,CUB,2011,38
+Cuba,CUB,2012,39
+Cuba,CUB,2013,40
+Cuba,CUB,2014,39
+Cuba,CUB,2015,38
+Cuba,CUB,2016,37
+Cuba,CUB,2017,36
+Cyprus,CYP,2000,14
+Cyprus,CYP,2001,9
+Cyprus,CYP,2002,10
+Cyprus,CYP,2003,9
+Cyprus,CYP,2004,9
+Cyprus,CYP,2005,12
+Cyprus,CYP,2006,9
+Cyprus,CYP,2007,8
+Cyprus,CYP,2008,9
+Cyprus,CYP,2009,8
+Cyprus,CYP,2010,8
+Cyprus,CYP,2011,8
+Cyprus,CYP,2012,7
+Cyprus,CYP,2013,6
+Cyprus,CYP,2014,8
+Cyprus,CYP,2015,7
+Cyprus,CYP,2016,6
+Cyprus,CYP,2017,6
+Czechia,CZE,2000,7
+Czechia,CZE,2001,7
+Czechia,CZE,2002,6
+Czechia,CZE,2003,6
+Czechia,CZE,2004,5
+Czechia,CZE,2005,5
+Czechia,CZE,2006,5
+Czechia,CZE,2007,5
+Czechia,CZE,2008,5
+Czechia,CZE,2009,4
+Czechia,CZE,2010,4
+Czechia,CZE,2011,4
+Czechia,CZE,2012,4
+Czechia,CZE,2013,4
+Czechia,CZE,2014,4
+Czechia,CZE,2015,4
+Czechia,CZE,2016,4
+Czechia,CZE,2017,3
+Democratic Republic of Congo,COD,2000,760
+Democratic Republic of Congo,COD,2001,740
+Democratic Republic of Congo,COD,2002,734
+Democratic Republic of Congo,COD,2003,699
+Democratic Republic of Congo,COD,2004,661
+Democratic Republic of Congo,COD,2005,627
+Democratic Republic of Congo,COD,2006,598
+Democratic Republic of Congo,COD,2007,578
+Democratic Republic of Congo,COD,2008,565
+Democratic Republic of Congo,COD,2009,555
+Democratic Republic of Congo,COD,2010,542
+Democratic Republic of Congo,COD,2011,532
+Democratic Republic of Congo,COD,2012,524
+Democratic Republic of Congo,COD,2013,514
+Democratic Republic of Congo,COD,2014,500
+Democratic Republic of Congo,COD,2015,490
+Democratic Republic of Congo,COD,2016,481
+Democratic Republic of Congo,COD,2017,473
+Denmark,DNK,2000,8
+Denmark,DNK,2001,8
+Denmark,DNK,2002,8
+Denmark,DNK,2003,7
+Denmark,DNK,2004,7
+Denmark,DNK,2005,6
+Denmark,DNK,2006,6
+Denmark,DNK,2007,6
+Denmark,DNK,2008,6
+Denmark,DNK,2009,6
+Denmark,DNK,2010,5
+Denmark,DNK,2011,5
+Denmark,DNK,2012,5
+Denmark,DNK,2013,4
+Denmark,DNK,2014,4
+Denmark,DNK,2015,4
+Denmark,DNK,2016,4
+Denmark,DNK,2017,4
+Djibouti,DJI,2000,507
+Djibouti,DJI,2001,490
+Djibouti,DJI,2002,470
+Djibouti,DJI,2003,449
+Djibouti,DJI,2004,426
+Djibouti,DJI,2005,393
+Djibouti,DJI,2006,361
+Djibouti,DJI,2007,335
+Djibouti,DJI,2008,320
+Djibouti,DJI,2009,299
+Djibouti,DJI,2010,283
+Djibouti,DJI,2011,272
+Djibouti,DJI,2012,262
+Djibouti,DJI,2013,256
+Djibouti,DJI,2014,256
+Djibouti,DJI,2015,247
+Djibouti,DJI,2016,246
+Djibouti,DJI,2017,248
+Dominican Republic,DOM,2000,80
+Dominican Republic,DOM,2001,75
+Dominican Republic,DOM,2002,75
+Dominican Republic,DOM,2003,76
+Dominican Republic,DOM,2004,81
+Dominican Republic,DOM,2005,83
+Dominican Republic,DOM,2006,86
+Dominican Republic,DOM,2007,90
+Dominican Republic,DOM,2008,92
+Dominican Republic,DOM,2009,95
+Dominican Republic,DOM,2010,96
+Dominican Republic,DOM,2011,95
+Dominican Republic,DOM,2012,94
+Dominican Republic,DOM,2013,94
+Dominican Republic,DOM,2014,94
+Dominican Republic,DOM,2015,94
+Dominican Republic,DOM,2016,94
+Dominican Republic,DOM,2017,95
+East Timor,TLS,2000,745
+East Timor,TLS,2001,720
+East Timor,TLS,2002,668
+East Timor,TLS,2003,603
+East Timor,TLS,2004,507
+East Timor,TLS,2005,415
+East Timor,TLS,2006,348
+East Timor,TLS,2007,300
+East Timor,TLS,2008,269
+East Timor,TLS,2009,242
+East Timor,TLS,2010,219
+East Timor,TLS,2011,198
+East Timor,TLS,2012,185
+East Timor,TLS,2013,176
+East Timor,TLS,2014,168
+East Timor,TLS,2015,160
+East Timor,TLS,2016,152
+East Timor,TLS,2017,142
+Eastern Mediterranean,,2000,330
+Eastern Mediterranean,,2001,319
+Eastern Mediterranean,,2002,306
+Eastern Mediterranean,,2003,298
+Eastern Mediterranean,,2004,286
+Eastern Mediterranean,,2005,275
+Eastern Mediterranean,,2006,267
+Eastern Mediterranean,,2007,255
+Eastern Mediterranean,,2008,241
+Eastern Mediterranean,,2009,230
+Eastern Mediterranean,,2010,220
+Eastern Mediterranean,,2011,208
+Eastern Mediterranean,,2012,199
+Eastern Mediterranean,,2013,190
+Eastern Mediterranean,,2014,186
+Eastern Mediterranean,,2015,175
+Eastern Mediterranean,,2016,169
+Eastern Mediterranean,,2017,164
+Ecuador,ECU,2000,122
+Ecuador,ECU,2001,117
+Ecuador,ECU,2002,110
+Ecuador,ECU,2003,100
+Ecuador,ECU,2004,94
+Ecuador,ECU,2005,94
+Ecuador,ECU,2006,90
+Ecuador,ECU,2007,85
+Ecuador,ECU,2008,82
+Ecuador,ECU,2009,80
+Ecuador,ECU,2010,78
+Ecuador,ECU,2011,76
+Ecuador,ECU,2012,71
+Ecuador,ECU,2013,67
+Ecuador,ECU,2014,65
+Ecuador,ECU,2015,63
+Ecuador,ECU,2016,61
+Ecuador,ECU,2017,59
+Egypt,EGY,2000,64
+Egypt,EGY,2001,63
+Egypt,EGY,2002,60
+Egypt,EGY,2003,57
+Egypt,EGY,2004,54
+Egypt,EGY,2005,52
+Egypt,EGY,2006,50
+Egypt,EGY,2007,47
+Egypt,EGY,2008,45
+Egypt,EGY,2009,45
+Egypt,EGY,2010,45
+Egypt,EGY,2011,42
+Egypt,EGY,2012,42
+Egypt,EGY,2013,40
+Egypt,EGY,2014,39
+Egypt,EGY,2015,39
+Egypt,EGY,2016,38
+Egypt,EGY,2017,37
+El Salvador,SLV,2000,73
+El Salvador,SLV,2001,75
+El Salvador,SLV,2002,68
+El Salvador,SLV,2003,66
+El Salvador,SLV,2004,64
+El Salvador,SLV,2005,62
+El Salvador,SLV,2006,60
+El Salvador,SLV,2007,58
+El Salvador,SLV,2008,57
+El Salvador,SLV,2009,57
+El Salvador,SLV,2010,54
+El Salvador,SLV,2011,53
+El Salvador,SLV,2012,52
+El Salvador,SLV,2013,50
+El Salvador,SLV,2014,49
+El Salvador,SLV,2015,48
+El Salvador,SLV,2016,47
+El Salvador,SLV,2017,46
+Equatorial Guinea,GNQ,2000,454
+Equatorial Guinea,GNQ,2001,421
+Equatorial Guinea,GNQ,2002,392
+Equatorial Guinea,GNQ,2003,370
+Equatorial Guinea,GNQ,2004,357
+Equatorial Guinea,GNQ,2005,344
+Equatorial Guinea,GNQ,2006,331
+Equatorial Guinea,GNQ,2007,322
+Equatorial Guinea,GNQ,2008,314
+Equatorial Guinea,GNQ,2009,310
+Equatorial Guinea,GNQ,2010,308
+Equatorial Guinea,GNQ,2011,308
+Equatorial Guinea,GNQ,2012,305
+Equatorial Guinea,GNQ,2013,300
+Equatorial Guinea,GNQ,2014,295
+Equatorial Guinea,GNQ,2015,296
+Equatorial Guinea,GNQ,2016,301
+Equatorial Guinea,GNQ,2017,301
+Eritrea,ERI,2000,1280
+Eritrea,ERI,2001,1180
+Eritrea,ERI,2002,1130
+Eritrea,ERI,2003,1060
+Eritrea,ERI,2004,938
+Eritrea,ERI,2005,804
+Eritrea,ERI,2006,705
+Eritrea,ERI,2007,635
+Eritrea,ERI,2008,605
+Eritrea,ERI,2009,583
+Eritrea,ERI,2010,567
+Eritrea,ERI,2011,558
+Eritrea,ERI,2012,549
+Eritrea,ERI,2013,540
+Eritrea,ERI,2014,530
+Eritrea,ERI,2015,518
+Eritrea,ERI,2016,498
+Eritrea,ERI,2017,480
+Estonia,EST,2000,29
+Estonia,EST,2001,27
+Estonia,EST,2002,25
+Estonia,EST,2003,20
+Estonia,EST,2004,18
+Estonia,EST,2005,18
+Estonia,EST,2006,16
+Estonia,EST,2007,17
+Estonia,EST,2008,14
+Estonia,EST,2009,14
+Estonia,EST,2010,11
+Estonia,EST,2011,13
+Estonia,EST,2012,12
+Estonia,EST,2013,10
+Estonia,EST,2014,11
+Estonia,EST,2015,10
+Estonia,EST,2016,11
+Estonia,EST,2017,9
+Eswatini,SWZ,2000,521
+Eswatini,SWZ,2001,528
+Eswatini,SWZ,2002,534
+Eswatini,SWZ,2003,538
+Eswatini,SWZ,2004,539
+Eswatini,SWZ,2005,532
+Eswatini,SWZ,2006,518
+Eswatini,SWZ,2007,496
+Eswatini,SWZ,2008,474
+Eswatini,SWZ,2009,460
+Eswatini,SWZ,2010,450
+Eswatini,SWZ,2011,441
+Eswatini,SWZ,2012,435
+Eswatini,SWZ,2013,432
+Eswatini,SWZ,2014,434
+Eswatini,SWZ,2015,435
+Eswatini,SWZ,2016,436
+Eswatini,SWZ,2017,437
+Ethiopia,ETH,2000,1030
+Ethiopia,ETH,2001,988
+Ethiopia,ETH,2002,985
+Ethiopia,ETH,2003,972
+Ethiopia,ETH,2004,929
+Ethiopia,ETH,2005,865
+Ethiopia,ETH,2006,795
+Ethiopia,ETH,2007,731
+Ethiopia,ETH,2008,681
+Ethiopia,ETH,2009,638
+Ethiopia,ETH,2010,597
+Ethiopia,ETH,2011,558
+Ethiopia,ETH,2012,527
+Ethiopia,ETH,2013,498
+Ethiopia,ETH,2014,472
+Ethiopia,ETH,2015,446
+Ethiopia,ETH,2016,422
+Ethiopia,ETH,2017,401
+Europe,,2000,27
+Europe,,2001,26
+Europe,,2002,25
+Europe,,2003,24
+Europe,,2004,23
+Europe,,2005,22
+Europe,,2006,20
+Europe,,2007,19
+Europe,,2008,18
+Europe,,2009,17
+Europe,,2010,17
+Europe,,2011,16
+Europe,,2012,15
+Europe,,2013,15
+Europe,,2014,14
+Europe,,2015,14
+Europe,,2016,13
+Europe,,2017,13
+Fiji,FJI,2000,51
+Fiji,FJI,2001,49
+Fiji,FJI,2002,48
+Fiji,FJI,2003,48
+Fiji,FJI,2004,47
+Fiji,FJI,2005,46
+Fiji,FJI,2006,44
+Fiji,FJI,2007,43
+Fiji,FJI,2008,42
+Fiji,FJI,2009,40
+Fiji,FJI,2010,39
+Fiji,FJI,2011,38
+Fiji,FJI,2012,38
+Fiji,FJI,2013,37
+Fiji,FJI,2014,36
+Fiji,FJI,2015,35
+Fiji,FJI,2016,34
+Fiji,FJI,2017,34
+Finland,FIN,2000,6
+Finland,FIN,2001,5
+Finland,FIN,2002,5
+Finland,FIN,2003,5
+Finland,FIN,2004,5
+Finland,FIN,2005,5
+Finland,FIN,2006,4
+Finland,FIN,2007,4
+Finland,FIN,2008,4
+Finland,FIN,2009,4
+Finland,FIN,2010,4
+Finland,FIN,2011,4
+Finland,FIN,2012,4
+Finland,FIN,2013,4
+Finland,FIN,2014,3
+Finland,FIN,2015,3
+Finland,FIN,2016,3
+Finland,FIN,2017,3
+France,FRA,2000,10
+France,FRA,2001,10
+France,FRA,2002,10
+France,FRA,2003,9
+France,FRA,2004,9
+France,FRA,2005,9
+France,FRA,2006,9
+France,FRA,2007,9
+France,FRA,2008,9
+France,FRA,2009,9
+France,FRA,2010,9
+France,FRA,2011,9
+France,FRA,2012,9
+France,FRA,2013,9
+France,FRA,2014,8
+France,FRA,2015,8
+France,FRA,2016,8
+France,FRA,2017,8
+Gabon,GAB,2000,380
+Gabon,GAB,2001,370
+Gabon,GAB,2002,361
+Gabon,GAB,2003,356
+Gabon,GAB,2004,354
+Gabon,GAB,2005,348
+Gabon,GAB,2006,340
+Gabon,GAB,2007,336
+Gabon,GAB,2008,332
+Gabon,GAB,2009,324
+Gabon,GAB,2010,314
+Gabon,GAB,2011,304
+Gabon,GAB,2012,292
+Gabon,GAB,2013,277
+Gabon,GAB,2014,267
+Gabon,GAB,2015,261
+Gabon,GAB,2016,256
+Gabon,GAB,2017,252
+Gambia,GMB,2000,932
+Gambia,GMB,2001,905
+Gambia,GMB,2002,876
+Gambia,GMB,2003,843
+Gambia,GMB,2004,802
+Gambia,GMB,2005,756
+Gambia,GMB,2006,716
+Gambia,GMB,2007,690
+Gambia,GMB,2008,675
+Gambia,GMB,2009,668
+Gambia,GMB,2010,661
+Gambia,GMB,2011,656
+Gambia,GMB,2012,650
+Gambia,GMB,2013,644
+Gambia,GMB,2014,637
+Gambia,GMB,2015,625
+Gambia,GMB,2016,611
+Gambia,GMB,2017,597
+Georgia,GEO,2000,31
+Georgia,GEO,2001,33
+Georgia,GEO,2002,42
+Georgia,GEO,2003,37
+Georgia,GEO,2004,38
+Georgia,GEO,2005,39
+Georgia,GEO,2006,33
+Georgia,GEO,2007,36
+Georgia,GEO,2008,39
+Georgia,GEO,2009,43
+Georgia,GEO,2010,32
+Georgia,GEO,2011,32
+Georgia,GEO,2012,30
+Georgia,GEO,2013,30
+Georgia,GEO,2014,29
+Georgia,GEO,2015,27
+Georgia,GEO,2016,26
+Georgia,GEO,2017,25
+Germany,DEU,2000,7
+Germany,DEU,2001,7
+Germany,DEU,2002,7
+Germany,DEU,2003,6
+Germany,DEU,2004,6
+Germany,DEU,2005,6
+Germany,DEU,2006,6
+Germany,DEU,2007,6
+Germany,DEU,2008,6
+Germany,DEU,2009,6
+Germany,DEU,2010,6
+Germany,DEU,2011,6
+Germany,DEU,2012,5
+Germany,DEU,2013,5
+Germany,DEU,2014,5
+Germany,DEU,2015,5
+Germany,DEU,2016,5
+Germany,DEU,2017,7
+Ghana,GHA,2000,484
+Ghana,GHA,2001,445
+Ghana,GHA,2002,415
+Ghana,GHA,2003,398
+Ghana,GHA,2004,384
+Ghana,GHA,2005,371
+Ghana,GHA,2006,359
+Ghana,GHA,2007,349
+Ghana,GHA,2008,342
+Ghana,GHA,2009,339
+Ghana,GHA,2010,339
+Ghana,GHA,2011,339
+Ghana,GHA,2012,336
+Ghana,GHA,2013,331
+Ghana,GHA,2014,325
+Ghana,GHA,2015,320
+Ghana,GHA,2016,314
+Ghana,GHA,2017,308
+Greece,GRC,2000,3
+Greece,GRC,2001,3
+Greece,GRC,2002,3
+Greece,GRC,2003,3
+Greece,GRC,2004,3
+Greece,GRC,2005,3
+Greece,GRC,2006,3
+Greece,GRC,2007,3
+Greece,GRC,2008,3
+Greece,GRC,2009,3
+Greece,GRC,2010,3
+Greece,GRC,2011,3
+Greece,GRC,2012,3
+Greece,GRC,2013,3
+Greece,GRC,2014,3
+Greece,GRC,2015,3
+Greece,GRC,2016,3
+Greece,GRC,2017,3
+Grenada,GRD,2000,38
+Grenada,GRD,2001,36
+Grenada,GRD,2002,34
+Grenada,GRD,2003,34
+Grenada,GRD,2004,38
+Grenada,GRD,2005,33
+Grenada,GRD,2006,31
+Grenada,GRD,2007,31
+Grenada,GRD,2008,30
+Grenada,GRD,2009,30
+Grenada,GRD,2010,29
+Grenada,GRD,2011,28
+Grenada,GRD,2012,28
+Grenada,GRD,2013,27
+Grenada,GRD,2014,26
+Grenada,GRD,2015,25
+Grenada,GRD,2016,25
+Grenada,GRD,2017,25
+Guatemala,GTM,2000,161
+Guatemala,GTM,2001,147
+Guatemala,GTM,2002,145
+Guatemala,GTM,2003,137
+Guatemala,GTM,2004,137
+Guatemala,GTM,2005,142
+Guatemala,GTM,2006,137
+Guatemala,GTM,2007,132
+Guatemala,GTM,2008,125
+Guatemala,GTM,2009,131
+Guatemala,GTM,2010,129
+Guatemala,GTM,2011,122
+Guatemala,GTM,2012,118
+Guatemala,GTM,2013,113
+Guatemala,GTM,2014,107
+Guatemala,GTM,2015,103
+Guatemala,GTM,2016,98
+Guatemala,GTM,2017,95
+Guinea,GIN,2000,1020
+Guinea,GIN,2001,1070
+Guinea,GIN,2002,1090
+Guinea,GIN,2003,1080
+Guinea,GIN,2004,1020
+Guinea,GIN,2005,920
+Guinea,GIN,2006,831
+Guinea,GIN,2007,772
+Guinea,GIN,2008,754
+Guinea,GIN,2009,750
+Guinea,GIN,2010,747
+Guinea,GIN,2011,748
+Guinea,GIN,2012,744
+Guinea,GIN,2013,731
+Guinea,GIN,2014,767
+Guinea,GIN,2015,699
+Guinea,GIN,2016,621
+Guinea,GIN,2017,576
+Guinea-Bissau,GNB,2000,1210
+Guinea-Bissau,GNB,2001,1180
+Guinea-Bissau,GNB,2002,1150
+Guinea-Bissau,GNB,2003,1110
+Guinea-Bissau,GNB,2004,1050
+Guinea-Bissau,GNB,2005,979
+Guinea-Bissau,GNB,2006,912
+Guinea-Bissau,GNB,2007,860
+Guinea-Bissau,GNB,2008,827
+Guinea-Bissau,GNB,2009,800
+Guinea-Bissau,GNB,2010,779
+Guinea-Bissau,GNB,2011,762
+Guinea-Bissau,GNB,2012,744
+Guinea-Bissau,GNB,2013,726
+Guinea-Bissau,GNB,2014,711
+Guinea-Bissau,GNB,2015,694
+Guinea-Bissau,GNB,2016,679
+Guinea-Bissau,GNB,2017,667
+Guyana,GUY,2000,231
+Guyana,GUY,2001,216
+Guyana,GUY,2002,227
+Guyana,GUY,2003,226
+Guyana,GUY,2004,220
+Guyana,GUY,2005,223
+Guyana,GUY,2006,221
+Guyana,GUY,2007,208
+Guyana,GUY,2008,192
+Guyana,GUY,2009,185
+Guyana,GUY,2010,179
+Guyana,GUY,2011,180
+Guyana,GUY,2012,185
+Guyana,GUY,2013,175
+Guyana,GUY,2014,174
+Guyana,GUY,2015,172
+Guyana,GUY,2016,170
+Guyana,GUY,2017,169
+Haiti,HTI,2000,437
+Haiti,HTI,2001,437
+Haiti,HTI,2002,441
+Haiti,HTI,2003,446
+Haiti,HTI,2004,513
+Haiti,HTI,2005,459
+Haiti,HTI,2006,467
+Haiti,HTI,2007,473
+Haiti,HTI,2008,484
+Haiti,HTI,2009,484
+Haiti,HTI,2010,506
+Haiti,HTI,2011,496
+Haiti,HTI,2012,500
+Haiti,HTI,2013,496
+Haiti,HTI,2014,492
+Haiti,HTI,2015,488
+Haiti,HTI,2016,489
+Haiti,HTI,2017,480
+Honduras,HND,2000,85
+Honduras,HND,2001,83
+Honduras,HND,2002,80
+Honduras,HND,2003,78
+Honduras,HND,2004,77
+Honduras,HND,2005,77
+Honduras,HND,2006,77
+Honduras,HND,2007,77
+Honduras,HND,2008,76
+Honduras,HND,2009,75
+Honduras,HND,2010,74
+Honduras,HND,2011,72
+Honduras,HND,2012,70
+Honduras,HND,2013,69
+Honduras,HND,2014,68
+Honduras,HND,2015,67
+Honduras,HND,2016,65
+Honduras,HND,2017,65
+Hungary,HUN,2000,16
+Hungary,HUN,2001,15
+Hungary,HUN,2002,16
+Hungary,HUN,2003,15
+Hungary,HUN,2004,15
+Hungary,HUN,2005,15
+Hungary,HUN,2006,14
+Hungary,HUN,2007,15
+Hungary,HUN,2008,14
+Hungary,HUN,2009,13
+Hungary,HUN,2010,13
+Hungary,HUN,2011,13
+Hungary,HUN,2012,12
+Hungary,HUN,2013,12
+Hungary,HUN,2014,12
+Hungary,HUN,2015,12
+Hungary,HUN,2016,12
+Hungary,HUN,2017,12
+Iceland,ISL,2000,6
+Iceland,ISL,2001,6
+Iceland,ISL,2002,6
+Iceland,ISL,2003,6
+Iceland,ISL,2004,6
+Iceland,ISL,2005,5
+Iceland,ISL,2006,5
+Iceland,ISL,2007,5
+Iceland,ISL,2008,5
+Iceland,ISL,2009,5
+Iceland,ISL,2010,5
+Iceland,ISL,2011,5
+Iceland,ISL,2012,4
+Iceland,ISL,2013,4
+Iceland,ISL,2014,5
+Iceland,ISL,2015,4
+Iceland,ISL,2016,4
+Iceland,ISL,2017,4
+India,IND,2000,370
+India,IND,2001,354
+India,IND,2002,336
+India,IND,2003,319
+India,IND,2004,303
+India,IND,2005,286
+India,IND,2006,270
+India,IND,2007,255
+India,IND,2008,240
+India,IND,2009,225
+India,IND,2010,210
+India,IND,2011,197
+India,IND,2012,185
+India,IND,2013,175
+India,IND,2014,166
+India,IND,2015,158
+India,IND,2016,150
+India,IND,2017,145
+Indonesia,IDN,2000,272
+Indonesia,IDN,2001,269
+Indonesia,IDN,2002,265
+Indonesia,IDN,2003,261
+Indonesia,IDN,2004,264
+Indonesia,IDN,2005,252
+Indonesia,IDN,2006,249
+Indonesia,IDN,2007,243
+Indonesia,IDN,2008,239
+Indonesia,IDN,2009,234
+Indonesia,IDN,2010,228
+Indonesia,IDN,2011,221
+Indonesia,IDN,2012,214
+Indonesia,IDN,2013,207
+Indonesia,IDN,2014,199
+Indonesia,IDN,2015,192
+Indonesia,IDN,2016,184
+Indonesia,IDN,2017,177
+Iran,IRN,2000,48
+Iran,IRN,2001,44
+Iran,IRN,2002,41
+Iran,IRN,2003,39
+Iran,IRN,2004,36
+Iran,IRN,2005,34
+Iran,IRN,2006,32
+Iran,IRN,2007,30
+Iran,IRN,2008,28
+Iran,IRN,2009,25
+Iran,IRN,2010,22
+Iran,IRN,2011,19
+Iran,IRN,2012,18
+Iran,IRN,2013,17
+Iran,IRN,2014,17
+Iran,IRN,2015,17
+Iran,IRN,2016,16
+Iran,IRN,2017,16
+Iraq,IRQ,2000,79
+Iraq,IRQ,2001,76
+Iraq,IRQ,2002,74
+Iraq,IRQ,2003,136
+Iraq,IRQ,2004,122
+Iraq,IRQ,2005,127
+Iraq,IRQ,2006,158
+Iraq,IRQ,2007,138
+Iraq,IRQ,2008,90
+Iraq,IRQ,2009,75
+Iraq,IRQ,2010,70
+Iraq,IRQ,2011,67
+Iraq,IRQ,2012,66
+Iraq,IRQ,2013,75
+Iraq,IRQ,2014,92
+Iraq,IRQ,2015,83
+Iraq,IRQ,2016,78
+Iraq,IRQ,2017,79
+Ireland,IRL,2000,7
+Ireland,IRL,2001,7
+Ireland,IRL,2002,6
+Ireland,IRL,2003,6
+Ireland,IRL,2004,6
+Ireland,IRL,2005,7
+Ireland,IRL,2006,6
+Ireland,IRL,2007,6
+Ireland,IRL,2008,7
+Ireland,IRL,2009,7
+Ireland,IRL,2010,6
+Ireland,IRL,2011,7
+Ireland,IRL,2012,6
+Ireland,IRL,2013,6
+Ireland,IRL,2014,6
+Ireland,IRL,2015,6
+Ireland,IRL,2016,6
+Ireland,IRL,2017,5
+Israel,ISR,2000,7
+Israel,ISR,2001,7
+Israel,ISR,2002,7
+Israel,ISR,2003,6
+Israel,ISR,2004,6
+Israel,ISR,2005,5
+Israel,ISR,2006,5
+Israel,ISR,2007,5
+Israel,ISR,2008,4
+Israel,ISR,2009,4
+Israel,ISR,2010,4
+Israel,ISR,2011,4
+Israel,ISR,2012,4
+Israel,ISR,2013,4
+Israel,ISR,2014,4
+Israel,ISR,2015,3
+Israel,ISR,2016,3
+Israel,ISR,2017,3
+Italy,ITA,2000,4
+Italy,ITA,2001,3
+Italy,ITA,2002,3
+Italy,ITA,2003,3
+Italy,ITA,2004,3
+Italy,ITA,2005,3
+Italy,ITA,2006,2
+Italy,ITA,2007,2
+Italy,ITA,2008,2
+Italy,ITA,2009,2
+Italy,ITA,2010,2
+Italy,ITA,2011,2
+Italy,ITA,2012,2
+Italy,ITA,2013,2
+Italy,ITA,2014,2
+Italy,ITA,2015,2
+Italy,ITA,2016,2
+Italy,ITA,2017,2
+Jamaica,JAM,2000,77
+Jamaica,JAM,2001,79
+Jamaica,JAM,2002,78
+Jamaica,JAM,2003,79
+Jamaica,JAM,2004,80
+Jamaica,JAM,2005,80
+Jamaica,JAM,2006,79
+Jamaica,JAM,2007,79
+Jamaica,JAM,2008,79
+Jamaica,JAM,2009,79
+Jamaica,JAM,2010,79
+Jamaica,JAM,2011,79
+Jamaica,JAM,2012,79
+Jamaica,JAM,2013,79
+Jamaica,JAM,2014,78
+Jamaica,JAM,2015,78
+Jamaica,JAM,2016,80
+Jamaica,JAM,2017,80
+Japan,JPN,2000,9
+Japan,JPN,2001,8
+Japan,JPN,2002,8
+Japan,JPN,2003,7
+Japan,JPN,2004,7
+Japan,JPN,2005,7
+Japan,JPN,2006,7
+Japan,JPN,2007,6
+Japan,JPN,2008,6
+Japan,JPN,2009,6
+Japan,JPN,2010,6
+Japan,JPN,2011,6
+Japan,JPN,2012,5
+Japan,JPN,2013,5
+Japan,JPN,2014,5
+Japan,JPN,2015,5
+Japan,JPN,2016,5
+Japan,JPN,2017,5
+Jordan,JOR,2000,70
+Jordan,JOR,2001,68
+Jordan,JOR,2002,65
+Jordan,JOR,2003,63
+Jordan,JOR,2004,62
+Jordan,JOR,2005,62
+Jordan,JOR,2006,58
+Jordan,JOR,2007,56
+Jordan,JOR,2008,55
+Jordan,JOR,2009,54
+Jordan,JOR,2010,53
+Jordan,JOR,2011,52
+Jordan,JOR,2012,52
+Jordan,JOR,2013,51
+Jordan,JOR,2014,49
+Jordan,JOR,2015,48
+Jordan,JOR,2016,47
+Jordan,JOR,2017,46
+Kazakhstan,KAZ,2000,61
+Kazakhstan,KAZ,2001,57
+Kazakhstan,KAZ,2002,52
+Kazakhstan,KAZ,2003,49
+Kazakhstan,KAZ,2004,46
+Kazakhstan,KAZ,2005,43
+Kazakhstan,KAZ,2006,40
+Kazakhstan,KAZ,2007,36
+Kazakhstan,KAZ,2008,30
+Kazakhstan,KAZ,2009,24
+Kazakhstan,KAZ,2010,22
+Kazakhstan,KAZ,2011,19
+Kazakhstan,KAZ,2012,17
+Kazakhstan,KAZ,2013,14
+Kazakhstan,KAZ,2014,13
+Kazakhstan,KAZ,2015,12
+Kazakhstan,KAZ,2016,10
+Kazakhstan,KAZ,2017,10
+Kenya,KEN,2000,708
+Kenya,KEN,2001,702
+Kenya,KEN,2002,692
+Kenya,KEN,2003,678
+Kenya,KEN,2004,653
+Kenya,KEN,2005,618
+Kenya,KEN,2006,583
+Kenya,KEN,2007,545
+Kenya,KEN,2008,513
+Kenya,KEN,2009,472
+Kenya,KEN,2010,432
+Kenya,KEN,2011,398
+Kenya,KEN,2012,373
+Kenya,KEN,2013,364
+Kenya,KEN,2014,358
+Kenya,KEN,2015,353
+Kenya,KEN,2016,346
+Kenya,KEN,2017,342
+Kiribati,KIR,2000,136
+Kiribati,KIR,2001,131
+Kiribati,KIR,2002,127
+Kiribati,KIR,2003,124
+Kiribati,KIR,2004,121
+Kiribati,KIR,2005,119
+Kiribati,KIR,2006,117
+Kiribati,KIR,2007,115
+Kiribati,KIR,2008,115
+Kiribati,KIR,2009,113
+Kiribati,KIR,2010,112
+Kiribati,KIR,2011,110
+Kiribati,KIR,2012,107
+Kiribati,KIR,2013,104
+Kiribati,KIR,2014,100
+Kiribati,KIR,2015,97
+Kiribati,KIR,2016,94
+Kiribati,KIR,2017,92
+Kuwait,KWT,2000,10
+Kuwait,KWT,2001,10
+Kuwait,KWT,2002,10
+Kuwait,KWT,2003,10
+Kuwait,KWT,2004,10
+Kuwait,KWT,2005,10
+Kuwait,KWT,2006,10
+Kuwait,KWT,2007,10
+Kuwait,KWT,2008,10
+Kuwait,KWT,2009,10
+Kuwait,KWT,2010,10
+Kuwait,KWT,2011,10
+Kuwait,KWT,2012,11
+Kuwait,KWT,2013,11
+Kuwait,KWT,2014,11
+Kuwait,KWT,2015,11
+Kuwait,KWT,2016,12
+Kuwait,KWT,2017,12
+Kyrgyzstan,KGZ,2000,79
+Kyrgyzstan,KGZ,2001,76
+Kyrgyzstan,KGZ,2002,83
+Kyrgyzstan,KGZ,2003,82
+Kyrgyzstan,KGZ,2004,79
+Kyrgyzstan,KGZ,2005,82
+Kyrgyzstan,KGZ,2006,85
+Kyrgyzstan,KGZ,2007,84
+Kyrgyzstan,KGZ,2008,81
+Kyrgyzstan,KGZ,2009,80
+Kyrgyzstan,KGZ,2010,79
+Kyrgyzstan,KGZ,2011,79
+Kyrgyzstan,KGZ,2012,74
+Kyrgyzstan,KGZ,2013,70
+Kyrgyzstan,KGZ,2014,69
+Kyrgyzstan,KGZ,2015,66
+Kyrgyzstan,KGZ,2016,63
+Kyrgyzstan,KGZ,2017,60
+Laos,LAO,2000,544
+Laos,LAO,2001,517
+Laos,LAO,2002,491
+Laos,LAO,2003,465
+Laos,LAO,2004,437
+Laos,LAO,2005,410
+Laos,LAO,2006,385
+Laos,LAO,2007,360
+Laos,LAO,2008,336
+Laos,LAO,2009,314
+Laos,LAO,2010,292
+Laos,LAO,2011,272
+Laos,LAO,2012,254
+Laos,LAO,2013,238
+Laos,LAO,2014,223
+Laos,LAO,2015,209
+Laos,LAO,2016,196
+Laos,LAO,2017,185
+Latvia,LVA,2000,34
+Latvia,LVA,2001,35
+Latvia,LVA,2002,33
+Latvia,LVA,2003,34
+Latvia,LVA,2004,32
+Latvia,LVA,2005,30
+Latvia,LVA,2006,32
+Latvia,LVA,2007,32
+Latvia,LVA,2008,29
+Latvia,LVA,2009,28
+Latvia,LVA,2010,26
+Latvia,LVA,2011,26
+Latvia,LVA,2012,23
+Latvia,LVA,2013,27
+Latvia,LVA,2014,24
+Latvia,LVA,2015,23
+Latvia,LVA,2016,26
+Latvia,LVA,2017,19
+Lebanon,LBN,2000,28
+Lebanon,LBN,2001,27
+Lebanon,LBN,2002,26
+Lebanon,LBN,2003,25
+Lebanon,LBN,2004,24
+Lebanon,LBN,2005,24
+Lebanon,LBN,2006,24
+Lebanon,LBN,2007,23
+Lebanon,LBN,2008,23
+Lebanon,LBN,2009,23
+Lebanon,LBN,2010,23
+Lebanon,LBN,2011,25
+Lebanon,LBN,2012,25
+Lebanon,LBN,2013,27
+Lebanon,LBN,2014,28
+Lebanon,LBN,2015,29
+Lebanon,LBN,2016,29
+Lebanon,LBN,2017,29
+Lesotho,LSO,2000,614
+Lesotho,LSO,2001,633
+Lesotho,LSO,2002,653
+Lesotho,LSO,2003,671
+Lesotho,LSO,2004,680
+Lesotho,LSO,2005,679
+Lesotho,LSO,2006,668
+Lesotho,LSO,2007,652
+Lesotho,LSO,2008,623
+Lesotho,LSO,2009,607
+Lesotho,LSO,2010,594
+Lesotho,LSO,2011,585
+Lesotho,LSO,2012,586
+Lesotho,LSO,2013,583
+Lesotho,LSO,2014,579
+Lesotho,LSO,2015,574
+Lesotho,LSO,2016,559
+Lesotho,LSO,2017,544
+Liberia,LBR,2000,894
+Liberia,LBR,2001,913
+Liberia,LBR,2002,1010
+Liberia,LBR,2003,878
+Liberia,LBR,2004,837
+Liberia,LBR,2005,816
+Liberia,LBR,2006,782
+Liberia,LBR,2007,754
+Liberia,LBR,2008,738
+Liberia,LBR,2009,724
+Liberia,LBR,2010,708
+Liberia,LBR,2011,694
+Liberia,LBR,2012,683
+Liberia,LBR,2013,674
+Liberia,LBR,2014,688
+Liberia,LBR,2015,691
+Liberia,LBR,2016,661
+Liberia,LBR,2017,661
+Libya,LBY,2000,70
+Libya,LBY,2001,68
+Libya,LBY,2002,66
+Libya,LBY,2003,64
+Libya,LBY,2004,61
+Libya,LBY,2005,57
+Libya,LBY,2006,55
+Libya,LBY,2007,53
+Libya,LBY,2008,52
+Libya,LBY,2009,53
+Libya,LBY,2010,53
+Libya,LBY,2011,56
+Libya,LBY,2012,55
+Libya,LBY,2013,58
+Libya,LBY,2014,63
+Libya,LBY,2015,70
+Libya,LBY,2016,73
+Libya,LBY,2017,72
+Lithuania,LTU,2000,17
+Lithuania,LTU,2001,16
+Lithuania,LTU,2002,14
+Lithuania,LTU,2003,14
+Lithuania,LTU,2004,13
+Lithuania,LTU,2005,14
+Lithuania,LTU,2006,14
+Lithuania,LTU,2007,14
+Lithuania,LTU,2008,13
+Lithuania,LTU,2009,11
+Lithuania,LTU,2010,10
+Lithuania,LTU,2011,10
+Lithuania,LTU,2012,10
+Lithuania,LTU,2013,10
+Lithuania,LTU,2014,9
+Lithuania,LTU,2015,9
+Lithuania,LTU,2016,8
+Lithuania,LTU,2017,8
+Luxembourg,LUX,2000,10
+Luxembourg,LUX,2001,10
+Luxembourg,LUX,2002,9
+Luxembourg,LUX,2003,8
+Luxembourg,LUX,2004,8
+Luxembourg,LUX,2005,9
+Luxembourg,LUX,2006,9
+Luxembourg,LUX,2007,8
+Luxembourg,LUX,2008,6
+Luxembourg,LUX,2009,7
+Luxembourg,LUX,2010,8
+Luxembourg,LUX,2011,8
+Luxembourg,LUX,2012,7
+Luxembourg,LUX,2013,6
+Luxembourg,LUX,2014,6
+Luxembourg,LUX,2015,5
+Luxembourg,LUX,2016,5
+Luxembourg,LUX,2017,5
+Madagascar,MDG,2000,559
+Madagascar,MDG,2001,552
+Madagascar,MDG,2002,547
+Madagascar,MDG,2003,543
+Madagascar,MDG,2004,539
+Madagascar,MDG,2005,526
+Madagascar,MDG,2006,513
+Madagascar,MDG,2007,503
+Madagascar,MDG,2008,491
+Madagascar,MDG,2009,474
+Madagascar,MDG,2010,453
+Madagascar,MDG,2011,432
+Madagascar,MDG,2012,413
+Madagascar,MDG,2013,394
+Madagascar,MDG,2014,378
+Madagascar,MDG,2015,363
+Madagascar,MDG,2016,348
+Madagascar,MDG,2017,335
+Malawi,MWI,2000,749
+Malawi,MWI,2001,735
+Malawi,MWI,2002,714
+Malawi,MWI,2003,687
+Malawi,MWI,2004,654
+Malawi,MWI,2005,610
+Malawi,MWI,2006,566
+Malawi,MWI,2007,526
+Malawi,MWI,2008,493
+Malawi,MWI,2009,466
+Malawi,MWI,2010,444
+Malawi,MWI,2011,428
+Malawi,MWI,2012,413
+Malawi,MWI,2013,396
+Malawi,MWI,2014,381
+Malawi,MWI,2015,370
+Malawi,MWI,2016,358
+Malawi,MWI,2017,349
+Malaysia,MYS,2000,38
+Malaysia,MYS,2001,36
+Malaysia,MYS,2002,34
+Malaysia,MYS,2003,33
+Malaysia,MYS,2004,32
+Malaysia,MYS,2005,31
+Malaysia,MYS,2006,30
+Malaysia,MYS,2007,30
+Malaysia,MYS,2008,29
+Malaysia,MYS,2009,29
+Malaysia,MYS,2010,30
+Malaysia,MYS,2011,30
+Malaysia,MYS,2012,30
+Malaysia,MYS,2013,30
+Malaysia,MYS,2014,30
+Malaysia,MYS,2015,30
+Malaysia,MYS,2016,29
+Malaysia,MYS,2017,29
+Maldives,MDV,2000,125
+Maldives,MDV,2001,111
+Maldives,MDV,2002,105
+Maldives,MDV,2003,97
+Maldives,MDV,2004,89
+Maldives,MDV,2005,75
+Maldives,MDV,2006,71
+Maldives,MDV,2007,71
+Maldives,MDV,2008,72
+Maldives,MDV,2009,71
+Maldives,MDV,2010,67
+Maldives,MDV,2011,62
+Maldives,MDV,2012,60
+Maldives,MDV,2013,58
+Maldives,MDV,2014,56
+Maldives,MDV,2015,54
+Maldives,MDV,2016,54
+Maldives,MDV,2017,53
+Mali,MLI,2000,836
+Mali,MLI,2001,797
+Mali,MLI,2002,764
+Mali,MLI,2003,739
+Mali,MLI,2004,715
+Mali,MLI,2005,691
+Mali,MLI,2006,675
+Mali,MLI,2007,663
+Mali,MLI,2008,661
+Mali,MLI,2009,661
+Mali,MLI,2010,660
+Mali,MLI,2011,663
+Mali,MLI,2012,663
+Mali,MLI,2013,663
+Mali,MLI,2014,642
+Mali,MLI,2015,620
+Mali,MLI,2016,590
+Mali,MLI,2017,562
+Malta,MLT,2000,9
+Malta,MLT,2001,10
+Malta,MLT,2002,9
+Malta,MLT,2003,10
+Malta,MLT,2004,9
+Malta,MLT,2005,8
+Malta,MLT,2006,8
+Malta,MLT,2007,8
+Malta,MLT,2008,8
+Malta,MLT,2009,7
+Malta,MLT,2010,8
+Malta,MLT,2011,7
+Malta,MLT,2012,7
+Malta,MLT,2013,7
+Malta,MLT,2014,6
+Malta,MLT,2015,7
+Malta,MLT,2016,6
+Malta,MLT,2017,6
+Mauritania,MRT,2000,834
+Mauritania,MRT,2001,835
+Mauritania,MRT,2002,836
+Mauritania,MRT,2003,836
+Mauritania,MRT,2004,830
+Mauritania,MRT,2005,826
+Mauritania,MRT,2006,821
+Mauritania,MRT,2007,820
+Mauritania,MRT,2008,819
+Mauritania,MRT,2009,822
+Mauritania,MRT,2010,824
+Mauritania,MRT,2011,822
+Mauritania,MRT,2012,812
+Mauritania,MRT,2013,805
+Mauritania,MRT,2014,796
+Mauritania,MRT,2015,785
+Mauritania,MRT,2016,777
+Mauritania,MRT,2017,766
+Mauritius,MUS,2000,59
+Mauritius,MUS,2001,54
+Mauritius,MUS,2002,54
+Mauritius,MUS,2003,57
+Mauritius,MUS,2004,54
+Mauritius,MUS,2005,53
+Mauritius,MUS,2006,55
+Mauritius,MUS,2007,56
+Mauritius,MUS,2008,53
+Mauritius,MUS,2009,59
+Mauritius,MUS,2010,66
+Mauritius,MUS,2011,54
+Mauritius,MUS,2012,63
+Mauritius,MUS,2013,60
+Mauritius,MUS,2014,70
+Mauritius,MUS,2015,73
+Mauritius,MUS,2016,67
+Mauritius,MUS,2017,61
+Mexico,MEX,2000,55
+Mexico,MEX,2001,55
+Mexico,MEX,2002,56
+Mexico,MEX,2003,55
+Mexico,MEX,2004,54
+Mexico,MEX,2005,54
+Mexico,MEX,2006,51
+Mexico,MEX,2007,49
+Mexico,MEX,2008,49
+Mexico,MEX,2009,51
+Mexico,MEX,2010,46
+Mexico,MEX,2011,43
+Mexico,MEX,2012,41
+Mexico,MEX,2013,39
+Mexico,MEX,2014,38
+Mexico,MEX,2015,36
+Mexico,MEX,2016,34
+Mexico,MEX,2017,33
+Micronesia (country),FSM,2000,154
+Micronesia (country),FSM,2001,150
+Micronesia (country),FSM,2002,163
+Micronesia (country),FSM,2003,141
+Micronesia (country),FSM,2004,137
+Micronesia (country),FSM,2005,133
+Micronesia (country),FSM,2006,128
+Micronesia (country),FSM,2007,123
+Micronesia (country),FSM,2008,118
+Micronesia (country),FSM,2009,114
+Micronesia (country),FSM,2010,110
+Micronesia (country),FSM,2011,106
+Micronesia (country),FSM,2012,103
+Micronesia (country),FSM,2013,99
+Micronesia (country),FSM,2014,96
+Micronesia (country),FSM,2015,95
+Micronesia (country),FSM,2016,90
+Micronesia (country),FSM,2017,88
+Moldova,MDA,2000,44
+Moldova,MDA,2001,39
+Moldova,MDA,2002,38
+Moldova,MDA,2003,36
+Moldova,MDA,2004,32
+Moldova,MDA,2005,34
+Moldova,MDA,2006,31
+Moldova,MDA,2007,31
+Moldova,MDA,2008,29
+Moldova,MDA,2009,28
+Moldova,MDA,2010,29
+Moldova,MDA,2011,21
+Moldova,MDA,2012,22
+Moldova,MDA,2013,21
+Moldova,MDA,2014,23
+Moldova,MDA,2015,22
+Moldova,MDA,2016,20
+Moldova,MDA,2017,19
+Mongolia,MNG,2000,155
+Mongolia,MNG,2001,138
+Mongolia,MNG,2002,124
+Mongolia,MNG,2003,114
+Mongolia,MNG,2004,106
+Mongolia,MNG,2005,98
+Mongolia,MNG,2006,91
+Mongolia,MNG,2007,85
+Mongolia,MNG,2008,80
+Mongolia,MNG,2009,73
+Mongolia,MNG,2010,66
+Mongolia,MNG,2011,59
+Mongolia,MNG,2012,54
+Mongolia,MNG,2013,51
+Mongolia,MNG,2014,49
+Mongolia,MNG,2015,47
+Mongolia,MNG,2016,46
+Mongolia,MNG,2017,45
+Montenegro,MNE,2000,12
+Montenegro,MNE,2001,12
+Montenegro,MNE,2002,11
+Montenegro,MNE,2003,11
+Montenegro,MNE,2004,10
+Montenegro,MNE,2005,9
+Montenegro,MNE,2006,9
+Montenegro,MNE,2007,8
+Montenegro,MNE,2008,8
+Montenegro,MNE,2009,8
+Montenegro,MNE,2010,7
+Montenegro,MNE,2011,7
+Montenegro,MNE,2012,7
+Montenegro,MNE,2013,6
+Montenegro,MNE,2014,6
+Montenegro,MNE,2015,6
+Montenegro,MNE,2016,6
+Montenegro,MNE,2017,6
+Morocco,MAR,2000,188
+Morocco,MAR,2001,174
+Morocco,MAR,2002,162
+Morocco,MAR,2003,152
+Morocco,MAR,2004,142
+Morocco,MAR,2005,131
+Morocco,MAR,2006,121
+Morocco,MAR,2007,113
+Morocco,MAR,2008,106
+Morocco,MAR,2009,99
+Morocco,MAR,2010,92
+Morocco,MAR,2011,86
+Morocco,MAR,2012,81
+Morocco,MAR,2013,78
+Morocco,MAR,2014,76
+Morocco,MAR,2015,74
+Morocco,MAR,2016,72
+Morocco,MAR,2017,70
+Mozambique,MOZ,2000,798
+Mozambique,MOZ,2001,745
+Mozambique,MOZ,2002,700
+Mozambique,MOZ,2003,657
+Mozambique,MOZ,2004,615
+Mozambique,MOZ,2005,577
+Mozambique,MOZ,2006,539
+Mozambique,MOZ,2007,505
+Mozambique,MOZ,2008,471
+Mozambique,MOZ,2009,439
+Mozambique,MOZ,2010,412
+Mozambique,MOZ,2011,389
+Mozambique,MOZ,2012,371
+Mozambique,MOZ,2013,356
+Mozambique,MOZ,2014,339
+Mozambique,MOZ,2015,318
+Mozambique,MOZ,2016,301
+Mozambique,MOZ,2017,289
+Myanmar,MMR,2000,340
+Myanmar,MMR,2001,331
+Myanmar,MMR,2002,323
+Myanmar,MMR,2003,314
+Myanmar,MMR,2004,307
+Myanmar,MMR,2005,299
+Myanmar,MMR,2006,293
+Myanmar,MMR,2007,287
+Myanmar,MMR,2008,289
+Myanmar,MMR,2009,274
+Myanmar,MMR,2010,265
+Myanmar,MMR,2011,259
+Myanmar,MMR,2012,254
+Myanmar,MMR,2013,251
+Myanmar,MMR,2014,247
+Myanmar,MMR,2015,246
+Myanmar,MMR,2016,245
+Myanmar,MMR,2017,250
+Namibia,NAM,2000,348
+Namibia,NAM,2001,352
+Namibia,NAM,2002,356
+Namibia,NAM,2003,359
+Namibia,NAM,2004,358
+Namibia,NAM,2005,346
+Namibia,NAM,2006,328
+Namibia,NAM,2007,306
+Namibia,NAM,2008,284
+Namibia,NAM,2009,276
+Namibia,NAM,2010,266
+Namibia,NAM,2011,256
+Namibia,NAM,2012,240
+Namibia,NAM,2013,231
+Namibia,NAM,2014,223
+Namibia,NAM,2015,217
+Namibia,NAM,2016,207
+Namibia,NAM,2017,195
+Nepal,NPL,2000,553
+Nepal,NPL,2001,521
+Nepal,NPL,2002,520
+Nepal,NPL,2003,470
+Nepal,NPL,2004,447
+Nepal,NPL,2005,415
+Nepal,NPL,2006,386
+Nepal,NPL,2007,361
+Nepal,NPL,2008,342
+Nepal,NPL,2009,323
+Nepal,NPL,2010,305
+Nepal,NPL,2011,285
+Nepal,NPL,2012,266
+Nepal,NPL,2013,248
+Nepal,NPL,2014,231
+Nepal,NPL,2015,236
+Nepal,NPL,2016,200
+Nepal,NPL,2017,186
+Netherlands,NLD,2000,13
+Netherlands,NLD,2001,13
+Netherlands,NLD,2002,13
+Netherlands,NLD,2003,12
+Netherlands,NLD,2004,11
+Netherlands,NLD,2005,11
+Netherlands,NLD,2006,9
+Netherlands,NLD,2007,9
+Netherlands,NLD,2008,8
+Netherlands,NLD,2009,8
+Netherlands,NLD,2010,7
+Netherlands,NLD,2011,7
+Netherlands,NLD,2012,7
+Netherlands,NLD,2013,6
+Netherlands,NLD,2014,6
+Netherlands,NLD,2015,6
+Netherlands,NLD,2016,6
+Netherlands,NLD,2017,5
+New Zealand,NZL,2000,12
+New Zealand,NZL,2001,11
+New Zealand,NZL,2002,12
+New Zealand,NZL,2003,12
+New Zealand,NZL,2004,11
+New Zealand,NZL,2005,11
+New Zealand,NZL,2006,11
+New Zealand,NZL,2007,11
+New Zealand,NZL,2008,10
+New Zealand,NZL,2009,11
+New Zealand,NZL,2010,11
+New Zealand,NZL,2011,10
+New Zealand,NZL,2012,10
+New Zealand,NZL,2013,9
+New Zealand,NZL,2014,10
+New Zealand,NZL,2015,10
+New Zealand,NZL,2016,10
+New Zealand,NZL,2017,9
+Nicaragua,NIC,2000,162
+Nicaragua,NIC,2001,157
+Nicaragua,NIC,2002,151
+Nicaragua,NIC,2003,145
+Nicaragua,NIC,2004,138
+Nicaragua,NIC,2005,131
+Nicaragua,NIC,2006,124
+Nicaragua,NIC,2007,121
+Nicaragua,NIC,2008,116
+Nicaragua,NIC,2009,113
+Nicaragua,NIC,2010,112
+Nicaragua,NIC,2011,110
+Nicaragua,NIC,2012,108
+Nicaragua,NIC,2013,105
+Nicaragua,NIC,2014,103
+Nicaragua,NIC,2015,101
+Nicaragua,NIC,2016,100
+Nicaragua,NIC,2017,98
+Niger,NER,2000,813
+Niger,NER,2001,803
+Niger,NER,2002,795
+Niger,NER,2003,782
+Niger,NER,2004,770
+Niger,NER,2005,755
+Niger,NER,2006,739
+Niger,NER,2007,725
+Niger,NER,2008,709
+Niger,NER,2009,688
+Niger,NER,2010,663
+Niger,NER,2011,639
+Niger,NER,2012,616
+Niger,NER,2013,594
+Niger,NER,2014,573
+Niger,NER,2015,555
+Niger,NER,2016,530
+Niger,NER,2017,509
+Nigeria,NGA,2000,1200
+Nigeria,NGA,2001,1200
+Nigeria,NGA,2002,1180
+Nigeria,NGA,2003,1170
+Nigeria,NGA,2004,1130
+Nigeria,NGA,2005,1080
+Nigeria,NGA,2006,1040
+Nigeria,NGA,2007,1010
+Nigeria,NGA,2008,996
+Nigeria,NGA,2009,987
+Nigeria,NGA,2010,978
+Nigeria,NGA,2011,972
+Nigeria,NGA,2012,963
+Nigeria,NGA,2013,951
+Nigeria,NGA,2014,943
+Nigeria,NGA,2015,931
+Nigeria,NGA,2016,925
+Nigeria,NGA,2017,917
+North Korea,PRK,2000,139
+North Korea,PRK,2001,128
+North Korea,PRK,2002,122
+North Korea,PRK,2003,121
+North Korea,PRK,2004,120
+North Korea,PRK,2005,120
+North Korea,PRK,2006,120
+North Korea,PRK,2007,119
+North Korea,PRK,2008,118
+North Korea,PRK,2009,113
+North Korea,PRK,2010,106
+North Korea,PRK,2011,100
+North Korea,PRK,2012,96
+North Korea,PRK,2013,94
+North Korea,PRK,2014,93
+North Korea,PRK,2015,91
+North Korea,PRK,2016,90
+North Korea,PRK,2017,89
+North Macedonia,MKD,2000,13
+North Macedonia,MKD,2001,12
+North Macedonia,MKD,2002,12
+North Macedonia,MKD,2003,10
+North Macedonia,MKD,2004,11
+North Macedonia,MKD,2005,10
+North Macedonia,MKD,2006,10
+North Macedonia,MKD,2007,10
+North Macedonia,MKD,2008,8
+North Macedonia,MKD,2009,8
+North Macedonia,MKD,2010,8
+North Macedonia,MKD,2011,8
+North Macedonia,MKD,2012,8
+North Macedonia,MKD,2013,8
+North Macedonia,MKD,2014,8
+North Macedonia,MKD,2015,8
+North Macedonia,MKD,2016,8
+North Macedonia,MKD,2017,7
+Norway,NOR,2000,6
+Norway,NOR,2001,5
+Norway,NOR,2002,5
+Norway,NOR,2003,5
+Norway,NOR,2004,5
+Norway,NOR,2005,5
+Norway,NOR,2006,4
+Norway,NOR,2007,4
+Norway,NOR,2008,4
+Norway,NOR,2009,4
+Norway,NOR,2010,4
+Norway,NOR,2011,4
+Norway,NOR,2012,3
+Norway,NOR,2013,3
+Norway,NOR,2014,3
+Norway,NOR,2015,3
+Norway,NOR,2016,3
+Norway,NOR,2017,2
+Oman,OMN,2000,20
+Oman,OMN,2001,20
+Oman,OMN,2002,20
+Oman,OMN,2003,20
+Oman,OMN,2004,19
+Oman,OMN,2005,19
+Oman,OMN,2006,18
+Oman,OMN,2007,18
+Oman,OMN,2008,18
+Oman,OMN,2009,18
+Oman,OMN,2010,18
+Oman,OMN,2011,18
+Oman,OMN,2012,18
+Oman,OMN,2013,18
+Oman,OMN,2014,18
+Oman,OMN,2015,19
+Oman,OMN,2016,19
+Oman,OMN,2017,19
+Pakistan,PAK,2000,286
+Pakistan,PAK,2001,275
+Pakistan,PAK,2002,264
+Pakistan,PAK,2003,254
+Pakistan,PAK,2004,243
+Pakistan,PAK,2005,237
+Pakistan,PAK,2006,222
+Pakistan,PAK,2007,214
+Pakistan,PAK,2008,205
+Pakistan,PAK,2009,199
+Pakistan,PAK,2010,191
+Pakistan,PAK,2011,180
+Pakistan,PAK,2012,173
+Pakistan,PAK,2013,166
+Pakistan,PAK,2014,161
+Pakistan,PAK,2015,154
+Pakistan,PAK,2016,143
+Pakistan,PAK,2017,140
+Panama,PAN,2000,91
+Panama,PAN,2001,86
+Panama,PAN,2002,91
+Panama,PAN,2003,93
+Panama,PAN,2004,88
+Panama,PAN,2005,88
+Panama,PAN,2006,88
+Panama,PAN,2007,86
+Panama,PAN,2008,84
+Panama,PAN,2009,82
+Panama,PAN,2010,79
+Panama,PAN,2011,76
+Panama,PAN,2012,74
+Panama,PAN,2013,66
+Panama,PAN,2014,60
+Panama,PAN,2015,58
+Panama,PAN,2016,55
+Panama,PAN,2017,52
+Papua New Guinea,PNG,2000,249
+Papua New Guinea,PNG,2001,242
+Papua New Guinea,PNG,2002,234
+Papua New Guinea,PNG,2003,225
+Papua New Guinea,PNG,2004,213
+Papua New Guinea,PNG,2005,200
+Papua New Guinea,PNG,2006,187
+Papua New Guinea,PNG,2007,179
+Papua New Guinea,PNG,2008,173
+Papua New Guinea,PNG,2009,170
+Papua New Guinea,PNG,2010,168
+Papua New Guinea,PNG,2011,166
+Papua New Guinea,PNG,2012,164
+Papua New Guinea,PNG,2013,160
+Papua New Guinea,PNG,2014,155
+Papua New Guinea,PNG,2015,151
+Papua New Guinea,PNG,2016,148
+Papua New Guinea,PNG,2017,145
+Paraguay,PRY,2000,165
+Paraguay,PRY,2001,160
+Paraguay,PRY,2002,155
+Paraguay,PRY,2003,150
+Paraguay,PRY,2004,144
+Paraguay,PRY,2005,137
+Paraguay,PRY,2006,130
+Paraguay,PRY,2007,124
+Paraguay,PRY,2008,118
+Paraguay,PRY,2009,113
+Paraguay,PRY,2010,108
+Paraguay,PRY,2011,103
+Paraguay,PRY,2012,98
+Paraguay,PRY,2013,94
+Paraguay,PRY,2014,91
+Paraguay,PRY,2015,88
+Paraguay,PRY,2016,86
+Paraguay,PRY,2017,84
+Peru,PER,2000,144
+Peru,PER,2001,138
+Peru,PER,2002,132
+Peru,PER,2003,127
+Peru,PER,2004,122
+Peru,PER,2005,118
+Peru,PER,2006,114
+Peru,PER,2007,112
+Peru,PER,2008,108
+Peru,PER,2009,106
+Peru,PER,2010,104
+Peru,PER,2011,102
+Peru,PER,2012,100
+Peru,PER,2013,98
+Peru,PER,2014,96
+Peru,PER,2015,94
+Peru,PER,2016,91
+Peru,PER,2017,88
+Philippines,PHL,2000,160
+Philippines,PHL,2001,163
+Philippines,PHL,2002,160
+Philippines,PHL,2003,156
+Philippines,PHL,2004,156
+Philippines,PHL,2005,156
+Philippines,PHL,2006,156
+Philippines,PHL,2007,149
+Philippines,PHL,2008,148
+Philippines,PHL,2009,149
+Philippines,PHL,2010,144
+Philippines,PHL,2011,141
+Philippines,PHL,2012,139
+Philippines,PHL,2013,136
+Philippines,PHL,2014,131
+Philippines,PHL,2015,127
+Philippines,PHL,2016,124
+Philippines,PHL,2017,121
+Poland,POL,2000,7
+Poland,POL,2001,6
+Poland,POL,2002,5
+Poland,POL,2003,5
+Poland,POL,2004,5
+Poland,POL,2005,4
+Poland,POL,2006,4
+Poland,POL,2007,4
+Poland,POL,2008,4
+Poland,POL,2009,3
+Poland,POL,2010,3
+Poland,POL,2011,3
+Poland,POL,2012,3
+Poland,POL,2013,3
+Poland,POL,2014,2
+Poland,POL,2015,2
+Poland,POL,2016,2
+Poland,POL,2017,2
+Portugal,PRT,2000,10
+Portugal,PRT,2001,10
+Portugal,PRT,2002,10
+Portugal,PRT,2003,10
+Portugal,PRT,2004,10
+Portugal,PRT,2005,9
+Portugal,PRT,2006,9
+Portugal,PRT,2007,9
+Portugal,PRT,2008,9
+Portugal,PRT,2009,9
+Portugal,PRT,2010,9
+Portugal,PRT,2011,9
+Portugal,PRT,2012,9
+Portugal,PRT,2013,8
+Portugal,PRT,2014,8
+Portugal,PRT,2015,9
+Portugal,PRT,2016,9
+Portugal,PRT,2017,8
+Qatar,QAT,2000,14
+Qatar,QAT,2001,14
+Qatar,QAT,2002,13
+Qatar,QAT,2003,13
+Qatar,QAT,2004,13
+Qatar,QAT,2005,12
+Qatar,QAT,2006,11
+Qatar,QAT,2007,11
+Qatar,QAT,2008,11
+Qatar,QAT,2009,10
+Qatar,QAT,2010,10
+Qatar,QAT,2011,10
+Qatar,QAT,2012,10
+Qatar,QAT,2013,10
+Qatar,QAT,2014,10
+Qatar,QAT,2015,9
+Qatar,QAT,2016,9
+Qatar,QAT,2017,9
+Romania,ROU,2000,54
+Romania,ROU,2001,49
+Romania,ROU,2002,47
+Romania,ROU,2003,43
+Romania,ROU,2004,39
+Romania,ROU,2005,35
+Romania,ROU,2006,32
+Romania,ROU,2007,30
+Romania,ROU,2008,28
+Romania,ROU,2009,28
+Romania,ROU,2010,27
+Romania,ROU,2011,24
+Romania,ROU,2012,23
+Romania,ROU,2013,21
+Romania,ROU,2014,21
+Romania,ROU,2015,21
+Romania,ROU,2016,21
+Romania,ROU,2017,19
+Russia,RUS,2000,56
+Russia,RUS,2001,53
+Russia,RUS,2002,51
+Russia,RUS,2003,49
+Russia,RUS,2004,45
+Russia,RUS,2005,42
+Russia,RUS,2006,36
+Russia,RUS,2007,32
+Russia,RUS,2008,30
+Russia,RUS,2009,27
+Russia,RUS,2010,25
+Russia,RUS,2011,23
+Russia,RUS,2012,22
+Russia,RUS,2013,20
+Russia,RUS,2014,19
+Russia,RUS,2015,18
+Russia,RUS,2016,18
+Russia,RUS,2017,17
+Rwanda,RWA,2000,1160
+Rwanda,RWA,2001,1100
+Rwanda,RWA,2002,961
+Rwanda,RWA,2003,870
+Rwanda,RWA,2004,758
+Rwanda,RWA,2005,643
+Rwanda,RWA,2006,541
+Rwanda,RWA,2007,469
+Rwanda,RWA,2008,427
+Rwanda,RWA,2009,424
+Rwanda,RWA,2010,373
+Rwanda,RWA,2011,349
+Rwanda,RWA,2012,329
+Rwanda,RWA,2013,308
+Rwanda,RWA,2014,291
+Rwanda,RWA,2015,275
+Rwanda,RWA,2016,260
+Rwanda,RWA,2017,248
+Saint Lucia,LCA,2000,86
+Saint Lucia,LCA,2001,86
+Saint Lucia,LCA,2002,90
+Saint Lucia,LCA,2003,92
+Saint Lucia,LCA,2004,89
+Saint Lucia,LCA,2005,83
+Saint Lucia,LCA,2006,82
+Saint Lucia,LCA,2007,87
+Saint Lucia,LCA,2008,93
+Saint Lucia,LCA,2009,100
+Saint Lucia,LCA,2010,109
+Saint Lucia,LCA,2011,116
+Saint Lucia,LCA,2012,116
+Saint Lucia,LCA,2013,108
+Saint Lucia,LCA,2014,104
+Saint Lucia,LCA,2015,115
+Saint Lucia,LCA,2016,117
+Saint Lucia,LCA,2017,117
+Saint Vincent and the Grenadines,VCT,2000,80
+Saint Vincent and the Grenadines,VCT,2001,75
+Saint Vincent and the Grenadines,VCT,2002,72
+Saint Vincent and the Grenadines,VCT,2003,69
+Saint Vincent and the Grenadines,VCT,2004,64
+Saint Vincent and the Grenadines,VCT,2005,59
+Saint Vincent and the Grenadines,VCT,2006,62
+Saint Vincent and the Grenadines,VCT,2007,67
+Saint Vincent and the Grenadines,VCT,2008,70
+Saint Vincent and the Grenadines,VCT,2009,67
+Saint Vincent and the Grenadines,VCT,2010,63
+Saint Vincent and the Grenadines,VCT,2011,64
+Saint Vincent and the Grenadines,VCT,2012,71
+Saint Vincent and the Grenadines,VCT,2013,73
+Saint Vincent and the Grenadines,VCT,2014,69
+Saint Vincent and the Grenadines,VCT,2015,64
+Saint Vincent and the Grenadines,VCT,2016,67
+Saint Vincent and the Grenadines,VCT,2017,68
+Samoa,WSM,2000,88
+Samoa,WSM,2001,85
+Samoa,WSM,2002,84
+Samoa,WSM,2003,80
+Samoa,WSM,2004,74
+Samoa,WSM,2005,72
+Samoa,WSM,2006,66
+Samoa,WSM,2007,62
+Samoa,WSM,2008,60
+Samoa,WSM,2009,58
+Samoa,WSM,2010,58
+Samoa,WSM,2011,54
+Samoa,WSM,2012,52
+Samoa,WSM,2013,48
+Samoa,WSM,2014,47
+Samoa,WSM,2015,45
+Samoa,WSM,2016,44
+Samoa,WSM,2017,43
+Sao Tome and Principe,STP,2000,179
+Sao Tome and Principe,STP,2001,173
+Sao Tome and Principe,STP,2002,169
+Sao Tome and Principe,STP,2003,167
+Sao Tome and Principe,STP,2004,166
+Sao Tome and Principe,STP,2005,163
+Sao Tome and Principe,STP,2006,158
+Sao Tome and Principe,STP,2007,154
+Sao Tome and Principe,STP,2008,150
+Sao Tome and Principe,STP,2009,145
+Sao Tome and Principe,STP,2010,140
+Sao Tome and Principe,STP,2011,137
+Sao Tome and Principe,STP,2012,134
+Sao Tome and Principe,STP,2013,132
+Sao Tome and Principe,STP,2014,131
+Sao Tome and Principe,STP,2015,130
+Sao Tome and Principe,STP,2016,130
+Sao Tome and Principe,STP,2017,130
+Saudi Arabia,SAU,2000,24
+Saudi Arabia,SAU,2001,24
+Saudi Arabia,SAU,2002,23
+Saudi Arabia,SAU,2003,23
+Saudi Arabia,SAU,2004,22
+Saudi Arabia,SAU,2005,22
+Saudi Arabia,SAU,2006,21
+Saudi Arabia,SAU,2007,21
+Saudi Arabia,SAU,2008,20
+Saudi Arabia,SAU,2009,20
+Saudi Arabia,SAU,2010,19
+Saudi Arabia,SAU,2011,18
+Saudi Arabia,SAU,2012,18
+Saudi Arabia,SAU,2013,17
+Saudi Arabia,SAU,2014,17
+Saudi Arabia,SAU,2015,17
+Saudi Arabia,SAU,2016,17
+Saudi Arabia,SAU,2017,17
+Senegal,SEN,2000,553
+Senegal,SEN,2001,545
+Senegal,SEN,2002,537
+Senegal,SEN,2003,532
+Senegal,SEN,2004,526
+Senegal,SEN,2005,519
+Senegal,SEN,2006,514
+Senegal,SEN,2007,504
+Senegal,SEN,2008,492
+Senegal,SEN,2009,472
+Senegal,SEN,2010,447
+Senegal,SEN,2011,423
+Senegal,SEN,2012,400
+Senegal,SEN,2013,381
+Senegal,SEN,2014,364
+Senegal,SEN,2015,346
+Senegal,SEN,2016,330
+Senegal,SEN,2017,315
+Serbia,SRB,2000,13
+Serbia,SRB,2001,13
+Serbia,SRB,2002,13
+Serbia,SRB,2003,13
+Serbia,SRB,2004,13
+Serbia,SRB,2005,12
+Serbia,SRB,2006,12
+Serbia,SRB,2007,12
+Serbia,SRB,2008,12
+Serbia,SRB,2009,12
+Serbia,SRB,2010,12
+Serbia,SRB,2011,12
+Serbia,SRB,2012,12
+Serbia,SRB,2013,12
+Serbia,SRB,2014,12
+Serbia,SRB,2015,13
+Serbia,SRB,2016,12
+Serbia,SRB,2017,12
+Seychelles,SYC,2000,53
+Seychelles,SYC,2001,54
+Seychelles,SYC,2002,54
+Seychelles,SYC,2003,54
+Seychelles,SYC,2004,55
+Seychelles,SYC,2005,55
+Seychelles,SYC,2006,55
+Seychelles,SYC,2007,55
+Seychelles,SYC,2008,55
+Seychelles,SYC,2009,55
+Seychelles,SYC,2010,55
+Seychelles,SYC,2011,55
+Seychelles,SYC,2012,55
+Seychelles,SYC,2013,55
+Seychelles,SYC,2014,55
+Seychelles,SYC,2015,54
+Seychelles,SYC,2016,54
+Seychelles,SYC,2017,53
+Sierra Leone,SLE,2000,2480
+Sierra Leone,SLE,2001,2250
+Sierra Leone,SLE,2002,2080
+Sierra Leone,SLE,2003,1960
+Sierra Leone,SLE,2004,1850
+Sierra Leone,SLE,2005,1760
+Sierra Leone,SLE,2006,1680
+Sierra Leone,SLE,2007,1610
+Sierra Leone,SLE,2008,1530
+Sierra Leone,SLE,2009,1450
+Sierra Leone,SLE,2010,1360
+Sierra Leone,SLE,2011,1270
+Sierra Leone,SLE,2012,1210
+Sierra Leone,SLE,2013,1180
+Sierra Leone,SLE,2014,1190
+Sierra Leone,SLE,2015,1180
+Sierra Leone,SLE,2016,1120
+Sierra Leone,SLE,2017,1120
+Singapore,SGP,2000,13
+Singapore,SGP,2001,13
+Singapore,SGP,2002,14
+Singapore,SGP,2003,13
+Singapore,SGP,2004,14
+Singapore,SGP,2005,13
+Singapore,SGP,2006,13
+Singapore,SGP,2007,12
+Singapore,SGP,2008,11
+Singapore,SGP,2009,10
+Singapore,SGP,2010,10
+Singapore,SGP,2011,10
+Singapore,SGP,2012,10
+Singapore,SGP,2013,9
+Singapore,SGP,2014,8
+Singapore,SGP,2015,9
+Singapore,SGP,2016,8
+Singapore,SGP,2017,8
+Slovakia,SVK,2000,8
+Slovakia,SVK,2001,8
+Slovakia,SVK,2002,7
+Slovakia,SVK,2003,7
+Slovakia,SVK,2004,7
+Slovakia,SVK,2005,7
+Slovakia,SVK,2006,6
+Slovakia,SVK,2007,7
+Slovakia,SVK,2008,6
+Slovakia,SVK,2009,6
+Slovakia,SVK,2010,6
+Slovakia,SVK,2011,6
+Slovakia,SVK,2012,6
+Slovakia,SVK,2013,6
+Slovakia,SVK,2014,5
+Slovakia,SVK,2015,6
+Slovakia,SVK,2016,6
+Slovakia,SVK,2017,5
+Slovenia,SVN,2000,12
+Slovenia,SVN,2001,10
+Slovenia,SVN,2002,11
+Slovenia,SVN,2003,10
+Slovenia,SVN,2004,11
+Slovenia,SVN,2005,10
+Slovenia,SVN,2006,8
+Slovenia,SVN,2007,8
+Slovenia,SVN,2008,8
+Slovenia,SVN,2009,8
+Slovenia,SVN,2010,8
+Slovenia,SVN,2011,8
+Slovenia,SVN,2012,7
+Slovenia,SVN,2013,7
+Slovenia,SVN,2014,7
+Slovenia,SVN,2015,7
+Slovenia,SVN,2016,7
+Slovenia,SVN,2017,7
+Solomon Islands,SLB,2000,245
+Solomon Islands,SLB,2001,233
+Solomon Islands,SLB,2002,222
+Solomon Islands,SLB,2003,210
+Solomon Islands,SLB,2004,199
+Solomon Islands,SLB,2005,188
+Solomon Islands,SLB,2006,177
+Solomon Islands,SLB,2007,172
+Solomon Islands,SLB,2008,159
+Solomon Islands,SLB,2009,152
+Solomon Islands,SLB,2010,141
+Solomon Islands,SLB,2011,134
+Solomon Islands,SLB,2012,127
+Solomon Islands,SLB,2013,122
+Solomon Islands,SLB,2014,120
+Solomon Islands,SLB,2015,112
+Solomon Islands,SLB,2016,108
+Solomon Islands,SLB,2017,104
+Somalia,SOM,2000,1210
+Somalia,SOM,2001,1170
+Somalia,SOM,2002,1140
+Somalia,SOM,2003,1100
+Somalia,SOM,2004,1080
+Somalia,SOM,2005,1040
+Somalia,SOM,2006,1040
+Somalia,SOM,2007,1030
+Somalia,SOM,2008,1010
+Somalia,SOM,2009,994
+Somalia,SOM,2010,985
+Somalia,SOM,2011,955
+Somalia,SOM,2012,943
+Somalia,SOM,2013,893
+Somalia,SOM,2014,878
+Somalia,SOM,2015,855
+Somalia,SOM,2016,865
+Somalia,SOM,2017,829
+South Africa,ZAF,2000,160
+South Africa,ZAF,2001,168
+South Africa,ZAF,2002,177
+South Africa,ZAF,2003,186
+South Africa,ZAF,2004,195
+South Africa,ZAF,2005,201
+South Africa,ZAF,2006,201
+South Africa,ZAF,2007,199
+South Africa,ZAF,2008,191
+South Africa,ZAF,2009,179
+South Africa,ZAF,2010,171
+South Africa,ZAF,2011,161
+South Africa,ZAF,2012,143
+South Africa,ZAF,2013,133
+South Africa,ZAF,2014,128
+South Africa,ZAF,2015,125
+South Africa,ZAF,2016,122
+South Africa,ZAF,2017,119
+South Korea,KOR,2000,17
+South Korea,KOR,2001,15
+South Korea,KOR,2002,15
+South Korea,KOR,2003,16
+South Korea,KOR,2004,15
+South Korea,KOR,2005,15
+South Korea,KOR,2006,14
+South Korea,KOR,2007,15
+South Korea,KOR,2008,15
+South Korea,KOR,2009,16
+South Korea,KOR,2010,15
+South Korea,KOR,2011,14
+South Korea,KOR,2012,13
+South Korea,KOR,2013,13
+South Korea,KOR,2014,12
+South Korea,KOR,2015,12
+South Korea,KOR,2016,11
+South Korea,KOR,2017,11
+South Sudan,SSD,2000,1730
+South Sudan,SSD,2001,1690
+South Sudan,SSD,2002,1660
+South Sudan,SSD,2003,1610
+South Sudan,SSD,2004,1550
+South Sudan,SSD,2005,1480
+South Sudan,SSD,2006,1410
+South Sudan,SSD,2007,1330
+South Sudan,SSD,2008,1250
+South Sudan,SSD,2009,1170
+South Sudan,SSD,2010,1100
+South Sudan,SSD,2011,1070
+South Sudan,SSD,2012,1050
+South Sudan,SSD,2013,1090
+South Sudan,SSD,2014,1140
+South Sudan,SSD,2015,1110
+South Sudan,SSD,2016,1130
+South Sudan,SSD,2017,1150
+South-east Asia,,2000,355
+South-east Asia,,2001,341
+South-east Asia,,2002,326
+South-east Asia,,2003,311
+South-east Asia,,2004,297
+South-east Asia,,2005,280
+South-east Asia,,2006,266
+South-east Asia,,2007,252
+South-east Asia,,2008,239
+South-east Asia,,2009,226
+South-east Asia,,2010,214
+South-east Asia,,2011,202
+South-east Asia,,2012,191
+South-east Asia,,2013,182
+South-east Asia,,2014,173
+South-east Asia,,2015,165
+South-east Asia,,2016,157
+South-east Asia,,2017,152
+Spain,ESP,2000,5
+Spain,ESP,2001,5
+Spain,ESP,2002,5
+Spain,ESP,2003,5
+Spain,ESP,2004,5
+Spain,ESP,2005,5
+Spain,ESP,2006,4
+Spain,ESP,2007,4
+Spain,ESP,2008,4
+Spain,ESP,2009,4
+Spain,ESP,2010,4
+Spain,ESP,2011,4
+Spain,ESP,2012,4
+Spain,ESP,2013,4
+Spain,ESP,2014,4
+Spain,ESP,2015,4
+Spain,ESP,2016,4
+Spain,ESP,2017,4
+Sri Lanka,LKA,2000,56
+Sri Lanka,LKA,2001,53
+Sri Lanka,LKA,2002,50
+Sri Lanka,LKA,2003,50
+Sri Lanka,LKA,2004,48
+Sri Lanka,LKA,2005,45
+Sri Lanka,LKA,2006,47
+Sri Lanka,LKA,2007,43
+Sri Lanka,LKA,2008,42
+Sri Lanka,LKA,2009,41
+Sri Lanka,LKA,2010,38
+Sri Lanka,LKA,2011,38
+Sri Lanka,LKA,2012,37
+Sri Lanka,LKA,2013,37
+Sri Lanka,LKA,2014,36
+Sri Lanka,LKA,2015,36
+Sri Lanka,LKA,2016,36
+Sri Lanka,LKA,2017,36
+Sudan,SDN,2000,667
+Sudan,SDN,2001,645
+Sudan,SDN,2002,614
+Sudan,SDN,2003,598
+Sudan,SDN,2004,580
+Sudan,SDN,2005,529
+Sudan,SDN,2006,508
+Sudan,SDN,2007,479
+Sudan,SDN,2008,454
+Sudan,SDN,2009,433
+Sudan,SDN,2010,408
+Sudan,SDN,2011,390
+Sudan,SDN,2012,368
+Sudan,SDN,2013,349
+Sudan,SDN,2014,333
+Sudan,SDN,2015,320
+Sudan,SDN,2016,308
+Sudan,SDN,2017,295
+Suriname,SUR,2000,221
+Suriname,SUR,2001,218
+Suriname,SUR,2002,207
+Suriname,SUR,2003,189
+Suriname,SUR,2004,176
+Suriname,SUR,2005,164
+Suriname,SUR,2006,165
+Suriname,SUR,2007,167
+Suriname,SUR,2008,169
+Suriname,SUR,2009,159
+Suriname,SUR,2010,148
+Suriname,SUR,2011,139
+Suriname,SUR,2012,134
+Suriname,SUR,2013,129
+Suriname,SUR,2014,124
+Suriname,SUR,2015,122
+Suriname,SUR,2016,121
+Suriname,SUR,2017,120
+Sweden,SWE,2000,5
+Sweden,SWE,2001,5
+Sweden,SWE,2002,5
+Sweden,SWE,2003,5
+Sweden,SWE,2004,5
+Sweden,SWE,2005,5
+Sweden,SWE,2006,5
+Sweden,SWE,2007,5
+Sweden,SWE,2008,5
+Sweden,SWE,2009,5
+Sweden,SWE,2010,4
+Sweden,SWE,2011,5
+Sweden,SWE,2012,5
+Sweden,SWE,2013,5
+Sweden,SWE,2014,5
+Sweden,SWE,2015,4
+Sweden,SWE,2016,4
+Sweden,SWE,2017,4
+Switzerland,CHE,2000,7
+Switzerland,CHE,2001,7
+Switzerland,CHE,2002,7
+Switzerland,CHE,2003,7
+Switzerland,CHE,2004,7
+Switzerland,CHE,2005,7
+Switzerland,CHE,2006,7
+Switzerland,CHE,2007,6
+Switzerland,CHE,2008,6
+Switzerland,CHE,2009,6
+Switzerland,CHE,2010,6
+Switzerland,CHE,2011,6
+Switzerland,CHE,2012,6
+Switzerland,CHE,2013,6
+Switzerland,CHE,2014,5
+Switzerland,CHE,2015,5
+Switzerland,CHE,2016,5
+Switzerland,CHE,2017,5
+Syria,SYR,2000,26
+Syria,SYR,2001,26
+Syria,SYR,2002,26
+Syria,SYR,2003,25
+Syria,SYR,2004,26
+Syria,SYR,2005,25
+Syria,SYR,2006,26
+Syria,SYR,2007,26
+Syria,SYR,2008,26
+Syria,SYR,2009,26
+Syria,SYR,2010,27
+Syria,SYR,2011,28
+Syria,SYR,2012,28
+Syria,SYR,2013,29
+Syria,SYR,2014,30
+Syria,SYR,2015,30
+Syria,SYR,2016,30
+Syria,SYR,2017,31
+Tajikistan,TJK,2000,53
+Tajikistan,TJK,2001,52
+Tajikistan,TJK,2002,43
+Tajikistan,TJK,2003,35
+Tajikistan,TJK,2004,33
+Tajikistan,TJK,2005,32
+Tajikistan,TJK,2006,29
+Tajikistan,TJK,2007,27
+Tajikistan,TJK,2008,26
+Tajikistan,TJK,2009,26
+Tajikistan,TJK,2010,23
+Tajikistan,TJK,2011,22
+Tajikistan,TJK,2012,21
+Tajikistan,TJK,2013,20
+Tajikistan,TJK,2014,19
+Tajikistan,TJK,2015,18
+Tajikistan,TJK,2016,17
+Tajikistan,TJK,2017,17
+Tanzania,TZA,2000,854
+Tanzania,TZA,2001,819
+Tanzania,TZA,2002,788
+Tanzania,TZA,2003,763
+Tanzania,TZA,2004,741
+Tanzania,TZA,2005,721
+Tanzania,TZA,2006,703
+Tanzania,TZA,2007,685
+Tanzania,TZA,2008,666
+Tanzania,TZA,2009,656
+Tanzania,TZA,2010,644
+Tanzania,TZA,2011,628
+Tanzania,TZA,2012,615
+Tanzania,TZA,2013,593
+Tanzania,TZA,2014,574
+Tanzania,TZA,2015,556
+Tanzania,TZA,2016,539
+Tanzania,TZA,2017,524
+Thailand,THA,2000,43
+Thailand,THA,2001,43
+Thailand,THA,2002,44
+Thailand,THA,2003,44
+Thailand,THA,2004,46
+Thailand,THA,2005,43
+Thailand,THA,2006,42
+Thailand,THA,2007,42
+Thailand,THA,2008,43
+Thailand,THA,2009,43
+Thailand,THA,2010,42
+Thailand,THA,2011,41
+Thailand,THA,2012,39
+Thailand,THA,2013,39
+Thailand,THA,2014,38
+Thailand,THA,2015,38
+Thailand,THA,2016,37
+Thailand,THA,2017,37
+Togo,TGO,2000,489
+Togo,TGO,2001,489
+Togo,TGO,2002,489
+Togo,TGO,2003,489
+Togo,TGO,2004,488
+Togo,TGO,2005,492
+Togo,TGO,2006,482
+Togo,TGO,2007,480
+Togo,TGO,2008,473
+Togo,TGO,2009,458
+Togo,TGO,2010,440
+Togo,TGO,2011,422
+Togo,TGO,2012,410
+Togo,TGO,2013,404
+Togo,TGO,2014,401
+Togo,TGO,2015,398
+Togo,TGO,2016,395
+Togo,TGO,2017,396
+Tonga,TON,2000,77
+Tonga,TON,2001,73
+Tonga,TON,2002,71
+Tonga,TON,2003,69
+Tonga,TON,2004,67
+Tonga,TON,2005,66
+Tonga,TON,2006,64
+Tonga,TON,2007,62
+Tonga,TON,2008,60
+Tonga,TON,2009,61
+Tonga,TON,2010,57
+Tonga,TON,2011,56
+Tonga,TON,2012,56
+Tonga,TON,2013,56
+Tonga,TON,2014,55
+Tonga,TON,2015,54
+Tonga,TON,2016,53
+Tonga,TON,2017,52
+Trinidad and Tobago,TTO,2000,81
+Trinidad and Tobago,TTO,2001,78
+Trinidad and Tobago,TTO,2002,74
+Trinidad and Tobago,TTO,2003,75
+Trinidad and Tobago,TTO,2004,76
+Trinidad and Tobago,TTO,2005,76
+Trinidad and Tobago,TTO,2006,73
+Trinidad and Tobago,TTO,2007,65
+Trinidad and Tobago,TTO,2008,72
+Trinidad and Tobago,TTO,2009,74
+Trinidad and Tobago,TTO,2010,71
+Trinidad and Tobago,TTO,2011,72
+Trinidad and Tobago,TTO,2012,71
+Trinidad and Tobago,TTO,2013,70
+Trinidad and Tobago,TTO,2014,69
+Trinidad and Tobago,TTO,2015,68
+Trinidad and Tobago,TTO,2016,68
+Trinidad and Tobago,TTO,2017,67
+Tunisia,TUN,2000,66
+Tunisia,TUN,2001,63
+Tunisia,TUN,2002,60
+Tunisia,TUN,2003,57
+Tunisia,TUN,2004,54
+Tunisia,TUN,2005,51
+Tunisia,TUN,2006,49
+Tunisia,TUN,2007,47
+Tunisia,TUN,2008,47
+Tunisia,TUN,2009,46
+Tunisia,TUN,2010,46
+Tunisia,TUN,2011,46
+Tunisia,TUN,2012,46
+Tunisia,TUN,2013,46
+Tunisia,TUN,2014,46
+Tunisia,TUN,2015,46
+Tunisia,TUN,2016,45
+Tunisia,TUN,2017,43
+Turkey,TUR,2000,42
+Turkey,TUR,2001,41
+Turkey,TUR,2002,39
+Turkey,TUR,2003,38
+Turkey,TUR,2004,35
+Turkey,TUR,2005,33
+Turkey,TUR,2006,30
+Turkey,TUR,2007,28
+Turkey,TUR,2008,27
+Turkey,TUR,2009,25
+Turkey,TUR,2010,24
+Turkey,TUR,2011,23
+Turkey,TUR,2012,22
+Turkey,TUR,2013,20
+Turkey,TUR,2014,19
+Turkey,TUR,2015,19
+Turkey,TUR,2016,18
+Turkey,TUR,2017,17
+Turkmenistan,TKM,2000,29
+Turkmenistan,TKM,2001,27
+Turkmenistan,TKM,2002,25
+Turkmenistan,TKM,2003,21
+Turkmenistan,TKM,2004,20
+Turkmenistan,TKM,2005,18
+Turkmenistan,TKM,2006,18
+Turkmenistan,TKM,2007,15
+Turkmenistan,TKM,2008,13
+Turkmenistan,TKM,2009,12
+Turkmenistan,TKM,2010,10
+Turkmenistan,TKM,2011,10
+Turkmenistan,TKM,2012,9
+Turkmenistan,TKM,2013,9
+Turkmenistan,TKM,2014,8
+Turkmenistan,TKM,2015,8
+Turkmenistan,TKM,2016,8
+Turkmenistan,TKM,2017,7
+Uganda,UGA,2000,578
+Uganda,UGA,2001,550
+Uganda,UGA,2002,537
+Uganda,UGA,2003,520
+Uganda,UGA,2004,512
+Uganda,UGA,2005,491
+Uganda,UGA,2006,473
+Uganda,UGA,2007,465
+Uganda,UGA,2008,455
+Uganda,UGA,2009,442
+Uganda,UGA,2010,430
+Uganda,UGA,2011,419
+Uganda,UGA,2012,412
+Uganda,UGA,2013,401
+Uganda,UGA,2014,394
+Uganda,UGA,2015,387
+Uganda,UGA,2016,381
+Uganda,UGA,2017,375
+Ukraine,UKR,2000,35
+Ukraine,UKR,2001,33
+Ukraine,UKR,2002,33
+Ukraine,UKR,2003,32
+Ukraine,UKR,2004,33
+Ukraine,UKR,2005,33
+Ukraine,UKR,2006,31
+Ukraine,UKR,2007,33
+Ukraine,UKR,2008,33
+Ukraine,UKR,2009,27
+Ukraine,UKR,2010,25
+Ukraine,UKR,2011,23
+Ukraine,UKR,2012,24
+Ukraine,UKR,2013,23
+Ukraine,UKR,2014,24
+Ukraine,UKR,2015,21
+Ukraine,UKR,2016,20
+Ukraine,UKR,2017,19
+United Arab Emirates,ARE,2000,6
+United Arab Emirates,ARE,2001,6
+United Arab Emirates,ARE,2002,5
+United Arab Emirates,ARE,2003,5
+United Arab Emirates,ARE,2004,5
+United Arab Emirates,ARE,2005,5
+United Arab Emirates,ARE,2006,4
+United Arab Emirates,ARE,2007,4
+United Arab Emirates,ARE,2008,4
+United Arab Emirates,ARE,2009,4
+United Arab Emirates,ARE,2010,4
+United Arab Emirates,ARE,2011,4
+United Arab Emirates,ARE,2012,4
+United Arab Emirates,ARE,2013,3
+United Arab Emirates,ARE,2014,3
+United Arab Emirates,ARE,2015,3
+United Arab Emirates,ARE,2016,3
+United Arab Emirates,ARE,2017,3
+United Kingdom,GBR,2000,10
+United Kingdom,GBR,2001,11
+United Kingdom,GBR,2002,11
+United Kingdom,GBR,2003,11
+United Kingdom,GBR,2004,11
+United Kingdom,GBR,2005,11
+United Kingdom,GBR,2006,11
+United Kingdom,GBR,2007,11
+United Kingdom,GBR,2008,11
+United Kingdom,GBR,2009,10
+United Kingdom,GBR,2010,10
+United Kingdom,GBR,2011,9
+United Kingdom,GBR,2012,8
+United Kingdom,GBR,2013,8
+United Kingdom,GBR,2014,8
+United Kingdom,GBR,2015,8
+United Kingdom,GBR,2016,7
+United Kingdom,GBR,2017,7
+United States,USA,2000,12
+United States,USA,2001,13
+United States,USA,2002,13
+United States,USA,2003,13
+United States,USA,2004,13
+United States,USA,2005,13
+United States,USA,2006,14
+United States,USA,2007,14
+United States,USA,2008,14
+United States,USA,2009,15
+United States,USA,2010,15
+United States,USA,2011,15
+United States,USA,2012,16
+United States,USA,2013,16
+United States,USA,2014,16
+United States,USA,2015,18
+United States,USA,2016,19
+United States,USA,2017,19
+Uruguay,URY,2000,26
+Uruguay,URY,2001,25
+Uruguay,URY,2002,25
+Uruguay,URY,2003,23
+Uruguay,URY,2004,23
+Uruguay,URY,2005,22
+Uruguay,URY,2006,20
+Uruguay,URY,2007,20
+Uruguay,URY,2008,19
+Uruguay,URY,2009,19
+Uruguay,URY,2010,17
+Uruguay,URY,2011,17
+Uruguay,URY,2012,17
+Uruguay,URY,2013,18
+Uruguay,URY,2014,17
+Uruguay,URY,2015,18
+Uruguay,URY,2016,18
+Uruguay,URY,2017,17
+Uzbekistan,UZB,2000,41
+Uzbekistan,UZB,2001,41
+Uzbekistan,UZB,2002,41
+Uzbekistan,UZB,2003,39
+Uzbekistan,UZB,2004,37
+Uzbekistan,UZB,2005,38
+Uzbekistan,UZB,2006,37
+Uzbekistan,UZB,2007,35
+Uzbekistan,UZB,2008,34
+Uzbekistan,UZB,2009,32
+Uzbekistan,UZB,2010,31
+Uzbekistan,UZB,2011,32
+Uzbekistan,UZB,2012,32
+Uzbekistan,UZB,2013,31
+Uzbekistan,UZB,2014,30
+Uzbekistan,UZB,2015,30
+Uzbekistan,UZB,2016,29
+Uzbekistan,UZB,2017,29
+Vanuatu,VUT,2000,140
+Vanuatu,VUT,2001,135
+Vanuatu,VUT,2002,128
+Vanuatu,VUT,2003,123
+Vanuatu,VUT,2004,119
+Vanuatu,VUT,2005,113
+Vanuatu,VUT,2006,108
+Vanuatu,VUT,2007,103
+Vanuatu,VUT,2008,99
+Vanuatu,VUT,2009,96
+Vanuatu,VUT,2010,92
+Vanuatu,VUT,2011,88
+Vanuatu,VUT,2012,85
+Vanuatu,VUT,2013,82
+Vanuatu,VUT,2014,80
+Vanuatu,VUT,2015,76
+Vanuatu,VUT,2016,74
+Vanuatu,VUT,2017,72
+Venezuela,VEN,2000,119
+Venezuela,VEN,2001,123
+Venezuela,VEN,2002,135
+Venezuela,VEN,2003,127
+Venezuela,VEN,2004,119
+Venezuela,VEN,2005,113
+Venezuela,VEN,2006,114
+Venezuela,VEN,2007,114
+Venezuela,VEN,2008,116
+Venezuela,VEN,2009,119
+Venezuela,VEN,2010,117
+Venezuela,VEN,2011,116
+Venezuela,VEN,2012,116
+Venezuela,VEN,2013,115
+Venezuela,VEN,2014,113
+Venezuela,VEN,2015,115
+Venezuela,VEN,2016,121
+Venezuela,VEN,2017,125
+Vietnam,VNM,2000,68
+Vietnam,VNM,2001,65
+Vietnam,VNM,2002,62
+Vietnam,VNM,2003,59
+Vietnam,VNM,2004,57
+Vietnam,VNM,2005,54
+Vietnam,VNM,2006,51
+Vietnam,VNM,2007,49
+Vietnam,VNM,2008,49
+Vietnam,VNM,2009,48
+Vietnam,VNM,2010,47
+Vietnam,VNM,2011,47
+Vietnam,VNM,2012,46
+Vietnam,VNM,2013,46
+Vietnam,VNM,2014,45
+Vietnam,VNM,2015,45
+Vietnam,VNM,2016,44
+Vietnam,VNM,2017,43
+Western Pacific,,2000,75
+Western Pacific,,2001,72
+Western Pacific,,2002,69
+Western Pacific,,2003,66
+Western Pacific,,2004,63
+Western Pacific,,2005,61
+Western Pacific,,2006,59
+Western Pacific,,2007,56
+Western Pacific,,2008,55
+Western Pacific,,2009,53
+Western Pacific,,2010,51
+Western Pacific,,2011,49
+Western Pacific,,2012,47
+Western Pacific,,2013,46
+Western Pacific,,2014,44
+Western Pacific,,2015,43
+Western Pacific,,2016,42
+Western Pacific,,2017,41
+World,OWID_WRL,2000,342
+World,OWID_WRL,2001,335
+World,OWID_WRL,2002,328
+World,OWID_WRL,2003,319
+World,OWID_WRL,2004,309
+World,OWID_WRL,2005,296
+World,OWID_WRL,2006,284
+World,OWID_WRL,2007,274
+World,OWID_WRL,2008,265
+World,OWID_WRL,2009,257
+World,OWID_WRL,2010,248
+World,OWID_WRL,2011,241
+World,OWID_WRL,2012,234
+World,OWID_WRL,2013,229
+World,OWID_WRL,2014,224
+World,OWID_WRL,2015,219
+World,OWID_WRL,2016,214
+World,OWID_WRL,2017,211
+Yemen,YEM,2000,301
+Yemen,YEM,2001,290
+Yemen,YEM,2002,278
+Yemen,YEM,2003,266
+Yemen,YEM,2004,254
+Yemen,YEM,2005,242
+Yemen,YEM,2006,230
+Yemen,YEM,2007,219
+Yemen,YEM,2008,208
+Yemen,YEM,2009,200
+Yemen,YEM,2010,192
+Yemen,YEM,2011,187
+Yemen,YEM,2012,184
+Yemen,YEM,2013,175
+Yemen,YEM,2014,174
+Yemen,YEM,2015,169
+Yemen,YEM,2016,165
+Yemen,YEM,2017,164
+Zambia,ZMB,2000,528
+Zambia,ZMB,2001,491
+Zambia,ZMB,2002,465
+Zambia,ZMB,2003,453
+Zambia,ZMB,2004,437
+Zambia,ZMB,2005,421
+Zambia,ZMB,2006,406
+Zambia,ZMB,2007,387
+Zambia,ZMB,2008,356
+Zambia,ZMB,2009,329
+Zambia,ZMB,2010,305
+Zambia,ZMB,2011,283
+Zambia,ZMB,2012,267
+Zambia,ZMB,2013,254
+Zambia,ZMB,2014,242
+Zambia,ZMB,2015,232
+Zambia,ZMB,2016,222
+Zambia,ZMB,2017,213
+Zimbabwe,ZWE,2000,579
+Zimbabwe,ZWE,2001,629
+Zimbabwe,ZWE,2002,666
+Zimbabwe,ZWE,2003,680
+Zimbabwe,ZWE,2004,686
+Zimbabwe,ZWE,2005,685
+Zimbabwe,ZWE,2006,680
+Zimbabwe,ZWE,2007,671
+Zimbabwe,ZWE,2008,657
+Zimbabwe,ZWE,2009,632
+Zimbabwe,ZWE,2010,598
+Zimbabwe,ZWE,2011,557
+Zimbabwe,ZWE,2012,528
+Zimbabwe,ZWE,2013,509
+Zimbabwe,ZWE,2014,494
+Zimbabwe,ZWE,2015,480
+Zimbabwe,ZWE,2016,468
+Zimbabwe,ZWE,2017,458
\ No newline at end of file